PROTEIN DATA BANK LIST OF IDCODE, RESOLUTION, AND COMPOUND NAMES
Fri Apr 5 10:39:25 EDT 2024
IDCODE       RESOLUTION         COMPOUND
------  -    ---------- -       --------------------------------------
7RWG	;	0.97	;	""Crystal structure of human methionine adenosyltransferase 2A (MAT2A) in complex with SAM and allosteric inhibitor AGI-43192
2QPS	;	2.2	;	""Sugar tongs"" mutant Y380A in complex with acarbose
6F4G	;	1.9	;	'Crystal structure of the Drosophila melanogaster SNF/U2A'/U2-SL4 complex
7W7V	;	3.0	;	'late' E2P of SERCA2b
5NQ2	;	1.54	;	'Porcine (Sus scrofa) Major Histocompatibility Complex, class I, presenting IAYERMCNI
5NQ3	;	1.57	;	'Porcine (Sus scrofa) Major Histocompatibility Complex, class I, with human beta2 micro globulin, presenting EFEDLTFLA
2E5O	;		;	'Solution structure of the TRIP_4C domain of target of activating signal cointegrator 1
3RK1	;	2.3	;	'X-ray crystal Structure of the putative N-type ATP pyrophosphatase (PF0828) in complex with ATP from Pyrococcus furiosus, Northeast Structural Genomics Consortium Target PfR23
5L5V	;	2.7	;	'Yeast 20S proteasome with human beta5i (1-138; V31M) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 18
1N21	;	3.1	;	(+)-Bornyl Diphosphate Synthase: Cocrystal with Mg and 3-aza-2,3-dihydrogeranyl diphosphate
1N20	;	2.3	;	(+)-Bornyl Diphosphate Synthase: Complex with Mg and 3-aza-2,3-dihydrogeranyl diphosphate
1N24	;	2.3	;	(+)-Bornyl diphosphate synthase: Complex with Mg and product
1N1Z	;	2.3	;	(+)-Bornyl Diphosphate Synthase: Complex with Mg and pyrophosphate
1N23	;	2.4	;	(+)-Bornyl diphosphate synthase: Complex with Mg, pyrophosphate, and (1R,4S)-2-azabornane
1N22	;	2.4	;	(+)-Bornyl Diphosphate Synthase: Complex with Mg, pyrophosphate, and (4R)-7-aza-7,8-dihydrolimonene
1DSA	;		;	(+)-DUOCARMYCIN SA COVALENTLY LINKED TO DUPLEX DNA, NMR, 20 STRUCTURES
1DSM	;		;	(-)-duocarmycin SA covalently linked to duplex DNA
6OIA	;	1.777	;	(1S,3S)-3-amino-4-(perfluoropropan-2-ylidene)cyclopentane-1-carboxylic acid hydrochloride, a potent inhibitor of ornithine aminotransferase
8QML	;	1.4	;	(2R,4R)-MeTDA bound HydE structure (control experiment)
2AQY	;		;	(3+1) assembly of three human telomeric DNA repeats into an asymmetrical dimeric G-quadruplex
8PSE	;		;	(3+1) hybrid G-quadruplex from a G-rich sequence with five G-runs
8R4W	;		;	(3+1) hybrid-2 G-quadruplex with a -(llp) loop progression
2ET6	;	2.22	;	(3R)-Hydroxyacyl-CoA Dehydrogenase Domain of Candida tropicalis Peroxisomal Multifunctional Enzyme Type 2
1GZ6	;	2.38	;	(3R)-HYDROXYACYL-COA DEHYDROGENASE FRAGMENT OF RAT PEROXISOMAL MULTIFUNCTIONAL ENZYME TYPE 2
5KQF	;	1.98	;	(4~{S},6~{S})-4-[2,4-bis(fluoranyl)phenyl]-4-methyl-6-pyrimidin-5-yl-5,6-dihydro-1,3-thiazin-2-amine (compound 12) bound to BACE1
5KR8	;	2.118	;	(4~{S},6~{S})-4-[2,4-bis(fluoranyl)phenyl]-6-(3,5-dimethyl-1,2-oxazol-4-yl)-4-methyl-5,6-dihydro-1,3-thiazin-2-amine (compound 5) bound to BACE1
3FY4	;	2.7	;	(6-4) Photolyase Crystal Structure
4OYQ	;	1.7	;	(6-isothiocyanatohexyl)benzene inhibitor complexed with Macrophage Migration Inhibitory Factor
1H8E	;	2.0	;	(ADP.AlF4)2(ADP.SO4) bovine F1-ATPase (all three catalytic sites occupied)
1GBV	;	2.0	;	(ALPHA-OXY, BETA-(C112G)DEOXY) T-STATE HUMAN HEMOGLOBIN
2LJQ	;		;	(C9S, C14S)-leucocin A
1NP5	;		;	(GAC)3 parallel duplex
7O7P	;	4.6	;	(h-alpha2M)4 activated state
7O7L	;	4.5	;	(h-alpha2M)4 native I
7O7M	;	6.6	;	(h-alpha2M)4 native II
7O7R	;	3.9	;	(h-alpha2M)4 plasmin-activated I state
7O7S	;	4.3	;	(h-alpha2M)4 plasmin-activated II state
7O7N	;	7.3	;	(h-alpha2M)4 semiactivated I state
7O7O	;	4.8	;	(h-alpha2M)4 semiactivated II state
7O7Q	;	3.6	;	(h-alpha2M)4 trypsin-activated state
4IN6	;	2.7	;	(M)L214A mutant of the Rhodobacter sphaeroides Reaction Center
4IN5	;	2.2	;	(M)L214G mutant of the Rhodobacter sphaeroides Reaction Center
4IN7	;	2.85	;	(M)L214N mutant of the Rhodobacter sphaeroides Reaction Center
8RX0	;	3.7	;	(NEDD8)-CRL2VHL-MZ1-Brd4BD2-Ub(G76S, K48C)-UBE2R1(C93K, S138C, C191S, C223S)-Ub
4OIK	;	2.1	;	(Quasi-)Racemic X-ray crystal structure of glycosylated chemokine Ser-CCL1.
2RBS	;	1.557	;	(r)(+)-3-chloro-1-phenyl-1-propanol in complex with T4 lysozyme L99A/M102Q
3O3M	;	1.82	;	(R)-2-Hydroxyisocaproyl-CoA Dehydratase
3O3O	;	2.0	;	(R)-2-hydroxyisocaproyl-CoA dehydratase in complex with (R)-2-hydroxyisocaproate
3O3N	;	2.3	;	(R)-2-hydroxyisocaproyl-CoA dehydratase in complex with its substrate (R)-2-hydroxyisocaproyl-CoA
4YMJ	;	2.0	;	(R)-2-Phenylpyrrolidine Substitute Imidazopyridazines: a New Class of Potent and Selective Pan-TRK Inhibitors
4YNE	;	2.0229	;	(R)-2-Phenylpyrrolidine Substitute Imidazopyridazines: a New Class of Potent and Selective Pan-TRK Inhibitors
4YPS	;	2.1012	;	(R)-2-Phenylpyrrolidine Substitute Imidazopyridazines: a New Class of Potent and Selective Pan-TRK Inhibitors
3UKB	;	1.42	;	(R)-cEt-BNA decamer structure
1IQ6	;	1.5	;	(R)-HYDRATASE FROM A. CAVIAE INVOLVED IN PHA BIOSYNTHESIS
4CHI	;	1.27	;	(R)-selective amine transaminase from Aspergillus fumigatus at 1.27 A resolution
6SNL	;	3.129	;	(R)-selective amine transaminase from Exophiala sideris
6XU3	;	2.1	;	(R)-selective amine transaminase from Shinella sp.
2LBN	;		;	(Revised) Solution structure of the monomeric form of a mutant unliganded bovine neurophysin, 20 structures
3F80	;	1.6	;	(S)-2-amino-6-nitrohexanoic acid binds to human arginase I through multiple nitro-metal coordination interactions in the binuclear manganese cluster. Resolution 1.60 A.
6UXZ	;	2.8	;	(S)-4-Amino-5-phenoxypentanoate as a Selective Agonist of the Transcription Factor GabR
3UKC	;	1.54	;	(S)-cEt-BNA decamer structure
3UKE	;	1.68	;	(S)-cMOE-BNA decamer structure
3HTD	;	1.4	;	(Z)-Thiophene-2-carboxaldoxime in complex with T4 lysozyme L99A/M102Q
6WAZ	;	4.1	;	+1 extended HIV-1 reverse transcriptase initiation complex core (pre-translocation state)
6WB2	;	4.5	;	+3 extended HIV-1 reverse transcriptase initiation complex core (displaced state)
6WB1	;	4.7	;	+3 extended HIV-1 reverse transcriptase initiation complex core (intermediate state)
6WB0	;	4.2	;	+3 extended HIV-1 reverse transcriptase initiation complex core (pre-translocation state)
5LZN	;	1.4	;	-TIP microtubule-binding domain
3PSM	;	0.98	;	.98A crystal structure of a dimeric plant defensin SPE10
1HSS	;	2.06	;	0.19 ALPHA-AMYLASE INHIBITOR FROM WHEAT
1I0T	;	0.6	;	0.6 A STRUCTURE OF Z-DNA CGCGCG
7R2H	;	0.79	;	0.79A resolution structure of DMSO bound Cyclophilin D
3UI4	;	0.8	;	0.8 A resolution crystal structure of human Parvulin 14
2H5C	;	0.82	;	0.82A resolution crystal structure of alpha-lytic protease at pH 5
1SSX	;	0.83	;	0.83A resolution crystal structure of alpha-lytic protease at pH 8
1N55	;	0.83	;	0.83A resolution structure of the E65Q mutant of Leishmania mexicana triosephosphate isomerase complexed with 2-phosphoglycolate
1X8P	;	0.85	;	0.85 A Crystal Structure Of Nitrophorin 4 From Rhodnius Prolixus Complexed With Ammonia at pH 7.4
1X8Q	;	0.85	;	0.85 A Crystal Structure Of Nitrophorin 4 From Rhodnius Prolixus in Complex with Water at pH 5.6
1PJX	;	0.85	;	0.85 ANGSTROM STRUCTURE OF SQUID GANGLION DFPASE
4O8H	;	0.85	;	0.85A resolution structure of PEG 400 Bound Cyclophilin D
3UI6	;	0.89	;	0.89 A resolution crystal structure of human Parvulin 14 in complex with oxidized DTT
4OY5	;	0.89	;	0.89 Angstrom resolution crystal structure of (Gly-Pro-Hyp)10
4O6U	;	0.89	;	0.89A resolution structure of the hemophore HasA from Pseudomonas aeruginosa (H83A mutant)
1I1W	;	0.89	;	0.89A Ultra high resolution structure of a Thermostable Xylanase from Thermoascus Aurantiacus
1YWA	;	0.89	;	0.9 A Structure of NP4 from Rhodnius Prolixus complexed with CO at pH 5.6
1YWB	;	0.97	;	0.9 A Structure of NP4 from Rhodnius Prolixus complexed with NO at pH 5.6
3W7Y	;	0.92	;	0.92A structure of 2Zn human insulin at 100K
3M5Q	;	0.93	;	0.93 A Structure of Manganese-Bound Manganese Peroxidase
3NJ6	;	0.95	;	0.95 A resolution X-ray structure of (GGCAGCAGCC)2
4EGU	;	0.95	;	0.95A Resolution Structure of a Histidine Triad Protein from Clostridium difficile
4O6Q	;	0.95	;	0.95A resolution structure of the hemophore HasA from Pseudomonas aeruginosa (Y75A mutant)
2AT8	;	1.0	;	0.96 A Crystal Structure Of Nitrophorin 4 From Rhodnius Prolixus Containing Fe(III) 2,4 Dimethyl Deuteroporphyrin IX Complexed With Nitric Oxide at pH 5.6
1C75	;	0.97	;	0.97 A ""AB INITIO"" CRYSTAL STRUCTURE OF CYTOCHROME C-553 FROM BACILLUS PASTEURII
1TG0	;	0.97	;	0.97-A structure of the SH3 domain of bbc1
3C78	;	0.98	;	0.98 A crystal structure of nitrophorin 4 from Rhodnius prolixus containing FE(III) 2,4 dimethyl deuteroporphyrin ix complexed with ammonia at ph 7.5
6K9J	;	0.98	;	0.98 A three-dimensional structure of horse heart cytochrome C at 110K
2H5D	;	0.9	;	0.9A resolution crystal structure of alpha-lytic protease complexed with a transition state analogue, MeOSuc-Ala-Ala-Pro-Val boronic acid
6EH4	;	1.26	;	003 Human T-Cell Receptor specific for HIV GAG epitope SLYNTVATL carried by Human Leukocyte Antigen HLA-A*0201
6EH5	;	1.29	;	003 Human T-Cell Receptor specific for HIV GAG epitope SLYNTVATL carried by Human Leukocyte Antigen HLA-A*0201
6FR3	;	1.35	;	003 TCR Study of CDR Loop Flexibility
6FR4	;	1.28	;	003 TCR Study of CDR Loop Flexibility
4PRG	;	2.9	;	0072 PARTIAL AGONIST PPAR GAMMA COCRYSTAL
1EN8	;	0.985	;	1 A CRYSTAL STRUCTURES OF B-DNA REVEAL SEQUENCE-SPECIFIC BINDING AND GROOVE-SPECIFIC BENDING OF DNA BY MAGNESIUM AND CALCIUM
8GXU	;	2.5	;	1 ATP-bound V1EG of V/A-ATPase from Thermus thermophilus
8A6C	;	1.8	;	1 picosecond light activated crystal structure of bovine rhodopsin in Lipidic Cubic Phase
7CRI	;	1.85	;	1 ps Structure of Chloride ion pumping rhodopsin (ClR) with NTQ motif
8GXZ	;	3.1	;	1 sulfate and 1 ATP bound V1EG of V/A-ATPase from Thermus thermophilus.
6H9B	;	2.75	;	1,1-Diheterocyclic Ethylenes Derived from Quinaldine and Carbazole as New Tubulin Polymerization Inhibitors: Synthesis, Metabolism, and Biological Evaluation
5DPX	;	1.85	;	1,2,4-Triazole-3-thione compounds as inhibitors of L1, di-zinc metallo-beta-lactamases.
2OTY	;	1.83	;	1,2-dichlorobenzene in complex with T4 Lysozyme L99A
5I2A	;	2.1	;	1,2-propanediol Dehydration in Roseburia inulinivorans; Structural Basis for Substrate and Enantiomer Selectivity
5I2G	;	2.352	;	1,2-propanediol Dehydration in Roseburia inulinivorans; Structural Basis for Substrate and Enantiomer Selectivity
8QZG	;	1.73	;	1,3 L,D-transpeptidase from Gluconobacter oxydans
3DN6	;	1.8	;	1,3,5-trifluoro-2,4,6-trichlorobenzene binding in the hydrophobic cavity of T4 lysozyme L99A mutant
1H80	;	1.6	;	1,3-ALPHA-1,4-BETA-D-GALACTOSE-4-SULFATE- 3,6-ANHYDRO-D-GALACTOSE-2-SULFATE 4 GALACTOHYDROLASE
1DYP	;	1.54	;	1,3-ALPHA-1,4-BETA-D-GALACTOSE-4-SULFATE-3,6-ANHYDRO-D-GALACTOSE 4 GALACTOHYDROLASE
5CLM	;	2.61	;	1,4-Oxazine BACE1 inhibitors
8BRE	;	2.0	;	1,6-anhydro-n-actetylmuramic acid kinase (AnmK)
8CPB	;	1.7	;	1,6-anhydro-n-actetylmuramic acid kinase (AnmK) in complex with AMPPNP, and AnhMurNAc at 1.7 Angstroms resolution.
8C0U	;	2.112	;	1,6-anhydro-n-actetylmuramic acid kinase (AnmK) in complex with their natural substrates and products
8CP9	;	2.2	;	1,6-anhydro-n-actetylmuramic acid kinase (AnmK)in complex with non-hydrolyzable AMPPNP.
7KWR	;		;	1,N6-ethenoadnine (E) in dsDNA sequence (5'-CGCGEATTCGCG-3')
5MPJ	;	2.14	;	1-(2-chloro-[1,1'-biphenyl]-4-yl)-N-methylethanamine
1F2D	;	2.0	;	1-AMINOCYCLOPROPANE-1-CARBOXYLATE DEAMINASE
1B8G	;	2.37	;	1-AMINOCYCLOPROPANE-1-CARBOXYLATE SYNTHASE
1CP6	;	1.9	;	1-BUTANEBORONIC ACID BINDING TO AEROMONAS PROTEOLYTICA AMINOPEPTIDASE
1XCC	;	2.3	;	1-Cys peroxidoxin from Plasmodium Yoelli
3TB2	;	2.3	;	1-Cys peroxidoxin from Plasmodium Yoelli
6Q5V	;	2.747	;	1-Cys SiPrx, a Prx6-family 1-Cys peroxiredoxin of the thermoacidophilic archaeon Sulfolobus islandicus
7QP2	;	0.9	;	1-deazaguanosine modified-RNA Sarcin Ricin Loop
7S04	;	2.52	;	1-deoxy-D-xylulose 5-phosphate reductoisomerase (IspC) from Acinetobacter baumannii in complex with FR900098, NADPH, and a magnesium ion
5KQO	;	2.35	;	1-deoxy-D-xylulose 5-phosphate reductoisomerase from Vibrio vulnificus
5KRY	;	2.3	;	1-deoxy-D-xylulose 5-phosphate reductoisomerase from Vibrio vulnificus
5KS1	;	2.4	;	1-deoxy-D-xylulose 5-phosphate reductoisomerase from Vibrio vulnificus
5KRV	;	2.3	;	1-deoxy-D-xylulose 5-phosphate reductoisomerase from Vibrio vulnificus in complex Arginine
5KRR	;	2.5	;	1-deoxy-D-xylulose 5-phosphate reductoisomerase from Vibrio vulnificus in complex with Mn(2+)
5DUL	;	2.6	;	1-deoxy-D-xylulose 5-phosphate reductoisomerase from Yersinia pestis in complex with NADPH
3IIE	;	2.21	;	1-deoxy-D-xylulose 5-phosphate reductoisomerase from Yersinia pestis.
1R0L	;	2.7	;	1-deoxy-D-xylulose 5-phosphate reductoisomerase from zymomonas mobilis in complex with NADPH
6OUW	;	2.398	;	1-deoxy-D-xylulose 5-phosphate synthase (DXPS) from Deinococcus radiodurans with enamine intermediate bound
6OUV	;	1.937	;	1-deoxy-D-xylulose 5-phosphate synthase (DXPS) from Deinococcus radiodurans with methylacetylphosphonate (MAP) bound
2O1X	;	2.9	;	1-deoxy-D-xylulose 5-phosphate synthase (DXS) from Deinococcus radiodurans
2O1S	;	2.4	;	1-deoxy-D-xylulose 5-phosphate synthase (DXS) from Escherichia coli
8BZX	;	2.05	;	1-deoxy-D-xylulose 5-phosphate synthase from Klebsiella pneumoniae (kpDXPS),co-crystal with thiamine monophosphate analog
8A4D	;	2.2	;	1-deoxy-D-xylulose 5-phosphate synthase from Pseudomonas aeruginosa with a thiamine analog inhibitor
1K5H	;	2.5	;	1-deoxy-D-xylulose-5-phosphate reductoisomerase
2RBY	;	1.5	;	1-methyl-5-imidazolecarboxaldehyde in complex with Cytochrome C Peroxidase W191G
2OU0	;	1.94	;	1-methylpyrrole in complex with T4 Lysozyme L99A
8X6Z	;	2.95	;	1-naphthylamine GS from Pseudomonas sp. JS3066
8WWV	;	2.3	;	1-naphthylamine GS in complex with ADP and MetSox-P
8WWU	;	2.0	;	1-naphthylamine GS in complex with AMP PNP
6YSK	;	1.21	;	1-phenylpyrroles and 1-enylpyrrolidines as inhibitors of Notum
1QAS	;	2.4	;	1-PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE PHOSPHODIESTERASE DELTA 1
1QAT	;	3.0	;	1-PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE PHOSPHODIESTERASE DELTA COMPLEX WITH SAMARIUM (III) CHLORIDE
1UZB	;	1.4	;	1-PYRROLINE-5-CARBOXYLATE DEHYDROGENASE
2J40	;	2.1	;	1-pyrroline-5-carboxylate dehydrogenase from Thermus thermophilus with bound inhibitor L-proline and NAD.
2J5N	;	1.63	;	1-PYRROLINE-5-CARBOXYLATE DEHYDROGENASE FROM THERMUS THERMOPHIRUS WITH BOUND INHIBITOR GLYCINE AND NAD.
2IY6	;	1.8	;	1-PYRROLINE-5-CARBOXYLATE DEHYDROGENASE FROM THERMUS WITH BOUND CITRATE
1SY2	;	1.0	;	1.0 A Crystal Structure of D129A/L130A Mutant of Nitrophorin 4
1SXX	;	1.01	;	1.0 A Crystal Structure of D129A/L130A Mutant of Nitrophorin 4 Complexed with Nitric Oxide
1SY1	;	1.01	;	1.0 A Crystal Structure of T121V Mutant of Nitrophorin 4 Complexed with Nitric Oxide
2WYT	;	1.0	;	1.0 A resolution structure of L38V SOD1 mutant
2QCP	;	1.0	;	1.0 A Structure of CusF-Ag(I) residues 10-88 from Escherichia coli
3E6Z	;	1.0	;	1.0 A Structure of CusF-W44A-Cu(II) residues 10-88 from Escherichia coli
3CCD	;	1.0	;	1.0 A Structure of Post-Succinimide His15Asp HPr
5SV5	;	1.0	;	1.0 Angstrom Crystal Structure of pre-Peptidase C-terminal Domain of Collagenase from Bacillus anthracis.
6N59	;	1.02	;	1.0 Angstrom crystal structure of [FeFe]-hydrogenase
4GNR	;	1.0	;	1.0 Angstrom resolution crystal structure of the branched-chain amino acid transporter substrate binding protein LivJ from Streptococcus pneumoniae str. Canada MDR_19A in complex with Isoleucine
1SY3	;	1.0	;	1.00 A Crystal Structure of D30N Mutant of Nitrophorin 4 from Rhodnius Prolixus Complexed with Nitric Oxide
2AT3	;	1.0	;	1.00 A Crystal Structure Of L123V/L133V Mutant of Nitrophorin 4 From Rhodnius Prolixus Complexed With Imidazole at pH 5.6
2AT0	;	1.0	;	1.00 A Crystal Structure Of L133V Mutant of Nitrophorin 4 From Rhodnius Prolixus Complexed With Nitric Oxide at pH 5.6
2OFR	;	1.0	;	1.00 A Crystal Structure Of V36A/D129A/L130A Mutant of Nitrophorin 4 From Rhodnius Prolixus Complexed With Nitric Oxide at pH 5.6
4B4E	;	1.0	;	1.00 A Structure of Lysozyme Crystallized with (R)-2-methyl-2,4- pentanediol
1HJ8	;	1.0	;	1.00 AA Trypsin from Atlantic Salmon
1X8O	;	1.01	;	1.01 A Crystal Structure Of Nitrophorin 4 From Rhodnius Prolixus Complexed With Nitric Oxide at pH 5.6
6CLI	;	1.01	;	1.01 A MicroED structure of GSNQNNF at 0.17 e- / A^2
6CLC	;	1.01	;	1.01 A MicroED structure of GSNQNNF at 0.27 e- / A^2
6CLJ	;	1.01	;	1.01 A MicroED structure of GSNQNNF at 0.50 e- / A^2
6CLD	;	1.01	;	1.01 A MicroED structure of GSNQNNF at 0.81 e- / A^2
6CLK	;	1.01	;	1.01 A MicroED structure of GSNQNNF at 0.82 e- / A^2
6CLE	;	1.01	;	1.01 A MicroED structure of GSNQNNF at 1.3 e- / A^2
6CLM	;	1.01	;	1.01 A MicroED structure of GSNQNNF at 1.5 e- / A^2
6CLL	;	1.02	;	1.02 A MicroED structure of GSNQNNF at 1.2 e- / A^2
3NVS	;	1.021	;	1.02 Angstrom resolution crystal structure of 3-phosphoshikimate 1-carboxyvinyltransferase from Vibrio cholerae in complex with shikimate-3-phosphate (partially photolyzed) and glyphosate
1NH0	;	1.03	;	1.03 A structure of HIV-1 protease: inhibitor binding inside and outside the active site
3O1N	;	1.03	;	1.03 Angstrom Crystal Structure of Q236A Mutant Type I Dehydroquinate Dehydratase (aroD) from Salmonella typhimurium
1SXW	;	1.05	;	1.05 A Crystal Structure of D30A Mutant of Nitrophorin 4 from Rhodnius Prolixus Complexed with Nitric Oxide
3M8M	;	1.05	;	1.05 A Structure of Manganese-free Manganese Peroxidase
1I0M	;	1.05	;	1.05 A STRUCTURE OF THE A-DECAMER GCGTATACGC WITH A SINGLE 2'-O-FLUOROETHYL THYMINE IN PLACE OF T6, HIGH RB-SALT
1I0K	;	1.05	;	1.05 A STRUCTURE OF THE A-DECAMER GCGTATACGC WITH A SINGLE 2'-O-METHYL-[TRI(OXYETHYL)] THYMINE IN PLACE OF T6, MEDIUM CS-SALT
4I62	;	1.05	;	1.05 Angstrom crystal structure of an amino acid ABC transporter substrate-binding protein AbpA from Streptococcus pneumoniae Canada MDR_19A bound to L-arginine
5U4H	;	1.05	;	1.05 Angstrom Resolution Crystal Structure of UDP-N-acetylglucosamine 1-carboxyvinyltransferase from Acinetobacter baumannii in Covalently Bound Complex with (2R)-2-(phosphonooxy)propanoic Acid.
5IQX	;	1.05	;	1.05A resolution structure of Holo HasAp (R33A) from Pseudomonas aeruginosa
1I0J	;	1.06	;	1.06 A STRUCTURE OF THE A-DECAMER GCGTATACGC WITH A SINGLE 2'-O-METHYL-3'-METHYLENEPHOSPHONATE (T23) THYMINE IN PLACE OF T6, HIGH CS-SALT
1SFS	;	1.07	;	1.07 A crystal structure of an uncharacterized B. stearothermophilus protein
1SXY	;	1.07	;	1.07 A Crystal Structure of D30N Mutant of Nitrophorin 4 from Rhodnius Prolixus
3C76	;	1.07	;	1.07 A crystal structure of L133V mutant of nitrophorin 4 from Rhodnius prolixus complexed with ammonia at PH 7.5
1X8N	;	1.08	;	1.08 A Crystal Structure Of Nitrophorin 4 From Rhodnius Prolixus Complexed With Nitric Oxide at pH 7.4
3C77	;	1.08	;	1.08 A crystal structure of nitrophorin 4 from Rhodnius prolixus containing FE(III) deuteroporphyrin ix complexed with ammonia at ph 7.5
1JBE	;	1.08	;	1.08 A Structure of apo-Chey reveals meta-active conformation
1YWD	;	1.08	;	1.08 A Structure of Ferrous NP4 (aquo complex)
5DGJ	;	1.0	;	1.0A resolution structure of Norovirus 3CL protease in complex an oxadiazole-based, cell permeable macrocyclic (20-mer) inhibitor
2BV4	;	1.0	;	1.0A Structure of Chromobacterium Violaceum Lectin in Complex with alpha-methyl-mannoside
1A0M	;	1.1	;	1.1 ANGSTROM CRYSTAL STRUCTURE OF A-CONOTOXIN [TYR15]-EPI
4H4N	;	1.1	;	1.1 Angstrom Crystal Structure of Hypothetical Protein BA_2335 from Bacillus anthracis
3RPE	;	1.1	;	1.1 Angstrom Crystal Structure of Putative Modulator of Drug Activity (MdaB) from Yersinia pestis CO92.
1LU4	;	1.12	;	1.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF A SECRETED MYCOBACTERIUM TUBERCULOSIS DISULFIDE OXIDOREDUCTASE HOMOLOGOUS TO E. COLI DSBE: IMPLICATIONS FOR FUNCTIONS
6AT8	;	1.105	;	1.1 Angstrom Resolution Structure of Human Cellular Retinol-Binding Protein IV
1R0R	;	1.1	;	1.1 Angstrom Resolution Structure of the Complex Between the Protein Inhibitor, OMTKY3, and the Serine Protease, Subtilisin Carlsberg
4YL4	;	1.1	;	1.1 Angstrom resolution X-ray Crystallographic Structure of Psudoazurin
3U97	;	1.102	;	1.1 Angstrom-resolution crystal structure of the Brucella abortus ribonuclease toxin, BrnT
3BF7	;	1.1	;	1.1 resolution structure of ybfF, a new esterase from Escherichia coli: a unique substrate-binding crevice generated by domain arrangement
3BF8	;	1.68	;	1.1 resolution structure of ybfF, a new esterase from Escherichia coli: a unique substrate-binding crevice generated by domain arrangement
4LQT	;	1.1	;	1.10A resolution crystal structure of a superfolder green fluorescent protein (W57A) mutant
1I1X	;	1.11	;	1.11 A ATOMIC RESOLUTION STRUCTURE OF A THERMOSTABLE XYLANASE FROM THERMOASCUS AURANTIACUS
2OFM	;	1.11	;	1.11 A Crystal Structure of Apo Nitrophorin 4 From Rhodnius Prolixus
1D2U	;	1.15	;	1.15 A CRYSTAL STRUCTURE OF NITROPHORIN 4 FROM RHODNIUS PROLIXUS
1SY0	;	1.15	;	1.15 A Crystal Structure of T121V Mutant of Nitrophorin 4 from Rhodnius Prolixus
6CLN	;	1.15	;	1.15 A MicroED structure of GSNQNNF at 1.8 e- / A^2
6CLF	;	1.15	;	1.15 A MicroED structure of GSNQNNF at 1.9 e- / A^2
6CLO	;	1.15	;	1.15 A MicroED structure of GSNQNNF at 2.1 e- / A^2
6BID	;	1.15	;	1.15 A resolution structure of Norovirus 3CL protease in complex with a triazole-based macrocyclic inhibitor
7A6A	;	1.15	;	1.15 A structure of human apoferritin obtained from Titan Mono- BCOR microscope
3T3L	;	1.15	;	1.15 A structure of human frataxin variant Q153A
4B49	;	1.15	;	1.15 A Structure of Lysozyme Crystallized without 2-methyl-2,4- pentanediol
2W2E	;	1.15	;	1.15 Angstrom crystal structure of P.pastoris aquaporin, Aqy1, in a closed conformation at pH 3.5
2NSZ	;	1.15	;	1.15 Angstrom Crystal Structure of the MA3 domain of Pdcd4
1Z70	;	1.15	;	1.15A resolution structure of the formylglycine generating enzyme FGE
4O06	;	1.15	;	1.15A Resolution Structure of the Proteasome Assembly Chaperone Nas2 PDZ Domain
3W7Z	;	1.15	;	1.15A structure of human 2Zn insulin at 293K
6CLP	;	1.16	;	1.16 A MicroED structure of GSNQNNF at 2.5 e- / A^2
5Z0D	;	1.16	;	1.16 A-resolution crystal structure of the deoxy-form tyrosinase from Streptomyces castaneoglobisporus in complex with the caddie protein
6C4Q	;	1.16	;	1.16 Angstrom Resolution Crystal Structure of Acyl Carrier Protein Domain (residues 1-100) of Polyketide Synthase Pks13 from Mycobacterium tuberculosis
1R3G	;	1.16	;	1.16A X-ray structure of the synthetic DNA fragment with the incorporated 2'-O-[(2-Guanidinium)ethyl]-5-methyluridine residues
4NLM	;	1.18	;	1.18 Angstrom resolution crystal structure of uncharacterized protein lmo1340 from Listeria monocytogenes EGD-e
4JER	;	1.1	;	1.1A resolution Apo structure of the hemophore HasA from Yersinia pestis (Tetragonal Form)
2BOI	;	1.1	;	1.1A Structure of Chromobacterium Violaceum Lectin CV2L in Complex with alpha-methyl-fucoside
4PF4	;	1.13	;	1.1A X-RAY STRUCTURE OF THE APO CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE 1, aa 1-277
2CS7	;	1.2	;	1.2 A Crystal structure of the S. pneumoniae PhtA histidine triad domain a novel zinc binding fold
1QU9	;	1.2	;	1.2 A CRYSTAL STRUCTURE OF YJGF GENE PRODUCT FROM E. COLI
6GMC	;	1.2	;	1.2 A resolution structure of human hydroxyacid oxidase 1 bound with FMN and 4-carboxy-5-[(4-chlorophenyl)sulfanyl]-1,2,3-thiadiazole
367D	;	1.2	;	1.2 A STRUCTURE DETERMINATION OF THE D(CG(5-BRU)ACG)2/5-BROMO-9-AMINO-DACA COMPLEX
1G7A	;	1.2	;	1.2 A structure of T3R3 human insulin at 100 K
6COA	;	1.2	;	1.2 A Structure of Thaumatin Crystallized in Gel
3IR4	;	1.2	;	1.2 Angstrom Crystal Structure of the Glutaredoxin 2 (grxB) from Salmonella typhimurium in complex with Glutathione
6UOF	;	1.2	;	1.2 Angstrom Resolution Crystal Structure of CBS Domains of Transcriptional Regulator from Streptococcus pneumoniae
6DT3	;	1.2	;	1.2 Angstrom Resolution Crystal Structure of Nucleoside Triphosphatase NudI from Klebsiella pneumoniae in Complex with HEPES
1AMM	;	1.2	;	1.2 ANGSTROM STRUCTURE OF GAMMA-B CRYSTALLIN AT 150K
3G91	;	1.23	;	1.2 Angstrom structure of the exonuclease III homologue Mth0212
4HI9	;	1.203	;	1.2 structure of integrin-linked kinase ankyrin repeat domain in complex with PINCH1 LIM1 domain collected at wavelength 0.91974
3WNJ	;	1.2	;	1.20 A resolution crystal structure of dioxygen bound copper-containing nitrite reductase from Geobacillus thermodenitrificans
5E0G	;	1.2	;	1.20 A resolution structure of Norovirus 3CL protease in complex with a triazole-based macrocyclic (17-mer) inhibitor
5E0J	;	1.2	;	1.20 A resolution structure of Norovirus 3CL protease in complex with a triazole-based macrocyclic (21-mer) inhibitor
6E6Q	;	1.2	;	1.20 A resolution structure of the C-terminally truncated [2Fe-2S] ferredoxin (Bfd) from Pseudomonas aeruginosa
4B4I	;	1.2	;	1.20 A Structure of Lysozyme Crystallized with (S)-2-methyl-2,4- pentanediol
6CLQ	;	1.21	;	1.21 A MicroED structure of GSNQNNF at 2.8 e- / A^2
2AT5	;	1.22	;	1.22 A Crystal Structure Of Nitrophorin 4 From Rhodnius Prolixus Containing Fe(III) Deuteroporphyrin IX Complexed With Nitric Oxide at pH 5.6
2AT6	;	1.22	;	1.22 A Crystal Structure Of Nitrophorin 4 From Rhodnius Prolixus Containing Fe(III) Deuteroporphyrin IX Complexed With Water at pH 5.6
1MJU	;	1.22	;	1.22 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF ESTEROLYTIC ANTIBODY MS6-12
3GLP	;	1.23	;	1.23 A resolution X-ray structure of (GCUGCUGC)2
3T3K	;	1.24	;	1.24 A Structure of Friedreich's ataxia frataxin variant Q148R
3RM1	;	1.24	;	1.24 Angstrom X-ray structure of bovine TRTK12-Ca(2+)-S100B D63N
2C9U	;	1.24	;	1.24 Angstroms resolution structure of as-isolated Cu-Zn Human Superoxide dismutase
2C9S	;	1.24	;	1.24 Angstroms resolution structure of Zn-Zn Human Superoxide dismutase
5C5W	;	1.25	;	1.25 A resolution structure of an RNA 20-mer
6Z6U	;	1.25	;	1.25 A structure of human apoferritin obtained from Titan Mono-BCOR microscope
4B4J	;	1.25	;	1.25 A Structure of Lysozyme Crystallized with (RS)-2-methyl-2,4- pentanediol
6XXX	;	1.25	;	1.25 Angstrom crystal structure of Ca/CaM A102V:RyR2 peptide complex
5KZ6	;	1.252	;	1.25 Angstrom Crystal Structure of Chitinase from Bacillus anthracis.
3GIU	;	1.25	;	1.25 Angstrom Crystal Structure of Pyrrolidone-Carboxylate Peptidase (pcp) from Staphylococcus aureus
6E85	;	1.25	;	1.25 Angstrom Resolution Crystal Structure of 4-hydroxythreonine-4-phosphate Dehydrogenase from Klebsiella pneumoniae.
8QF3	;	1.25	;	1.25-A structure of anti-Arc nanobody H11
2DN3	;	1.25	;	1.25A resolution crystal structure of human hemoglobin in the carbonmonoxy form
2DN2	;	1.25	;	1.25A resolution crystal structure of human hemoglobin in the deoxy form
2DN1	;	1.25	;	1.25A resolution crystal structure of human hemoglobin in the oxy form
4HIL	;	1.25	;	1.25A Resolution Structure of Rat Type B Cytochrome b5
4O6T	;	1.25	;	1.25A resolution structure of the hemophore HasA from Pseudomonas aeruginosa (H83A mutant, pH 5.4)
1IKJ	;	1.27	;	1.27 A CRYSTAL STRUCTURE OF NITROPHORIN 4 FROM RHODNIUS PROLIXUS COMPLEXED WITH IMIDAZOLE
4QAS	;	1.25	;	1.27 A resolution structure of CT263-D161N (MTAN) from Chlamydia trachomatis
2CAK	;	1.27	;	1.27Angstrom Structure of Rusticyanin from Thiobacillus ferrooxidans
5OL4	;	1.28	;	1.28 A resolution of Sporosarcina pasteurii urease inhibited in the presence of NBPT
4QUS	;	1.28	;	1.28 Angstrom resolution crystal structure of predicted acyltransferase with acyl-CoA N-acyltransferase domain (ypeA) from Escherichia coli str. K-12 substr. MG1655
2F91	;	1.2	;	1.2A resolution structure of a crayfish trypsin complexed with a peptide inhibitor, SGTI
3HT1	;	1.2	;	1.2A structure of the polyketide cyclase RemF from Streptomyces resistomycificus
6XG7	;	1.3	;	1.3 A Resolution Structure of the of the NHL Repeat Region of D. melanogaster Thin
366D	;	1.3	;	1.3 A STRUCTURE DETERMINATION OF THE D(CG(5-BRU)ACG)2/6-BROMO-9-AMINO-DACA COMPLEX
6U4U	;	1.3	;	1.3 A structure of a pathogenic human Syt 1 C2B (I368T)
1G7B	;	1.3	;	1.3 A STRUCTURE OF T3R3 HUMAN INSULIN AT 100 K
1I0Q	;	1.3	;	1.3 A STRUCTURE OF THE A-DECAMER GCGTATACGC WITH A SINGLE 2'-O-METHYL-[TRI(OXYETHYL)] THYMINE IN PLACE OF T6, MEDIUM NA-SALT
1I0N	;	1.3	;	1.3 A STRUCTURE OF THE A-DECAMER GCGTATACGC WITH A SINGLE 2'-O-METHYL-[TRI(OXYETHYL)] THYMINE IN PLACE OF T6, MEDIUM RB-SALT
1I0P	;	1.3	;	1.3 A STRUCTURE OF THE A-DECAMER GCGTATACGC WITH A SINGLE 2'-O-METHYL-[TRI(OXYETHYL)], MEDIUM K-SALT
1JW8	;	1.3	;	1.3 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF P6 FORM OF MYOGLOBIN
7VBF	;	1.3	;	1.3 Angstrom Resolution Crystal Structure of SARS-CoV-2 Nucleocapsid dimerization domain, pH 8.5
6NKJ	;	1.3	;	1.3 Angstrom Resolution Crystal Structure of UDP-N-acetylglucosamine 1-carboxyvinyltransferase from Streptococcus pneumoniae in Complex with (2R)-2-(phosphonooxy)propanoic acid.
3DHC	;	1.3	;	1.3 Angstrom Structure of N-Acyl Homoserine Lactone Hydrolase with the Product N-Hexanoyl-L-Homocysteine Bound to The catalytic Metal Center
5UEJ	;	1.3	;	1.30 A crystal structure of DapE enzyme from Neisseria meningitidis MC58
6CLR	;	1.31	;	1.31 A MicroED structure of GSNQNNF at 3.1 e- / A^2
6RKG	;	1.32	;	1.32 A RESOLUTION OF SPOROSARCINA PASTEURII UREASE INHIBITED IN THE PRESENCE OF NBPTO AT pH 7.5
5HQH	;	1.32	;	1.32 Angstrom Crystal Structure of Ybbr like Domain of lmo2119 Protein from Listeria monocytogenes.
4O6S	;	1.32	;	1.32A resolution structure of the hemophore HasA from Pseudomonas aeruginosa (H83A mutant, Zinc Bound)
7A6B	;	1.33	;	1.33 A structure of human apoferritin obtained from Titan Mono- BCOR microscope
4DJC	;	1.35	;	1.35 A crystal structure of the NaV1.5 DIII-IV-Ca/CaM complex
6CLG	;	1.35	;	1.35 A MicroED structure of GSNQNNF at 2.4 e- / A^2
5I45	;	1.35	;	1.35 Angstrom Crystal Structure of C-terminal Domain of Glycosyl Transferase Group 1 Family Protein (LpcC) from Francisella tularensis.
5TKW	;	1.35	;	1.35 Angstrom Resolution Crystal Structure of a Pullulanase-specific Type II Secretion System Integral Cytoplasmic Membrane Protein GspL (N-terminal fragment; residues 1-237) from Klebsiella pneumoniae.
5SXO	;	1.35	;	1.35 angstrom resolution crystal structure of beta-ketoacyl-ACP synthase II (FabF) from Listeria monocytogenes
1ZGK	;	1.35	;	1.35 angstrom structure of the Kelch domain of Keap1
1LK2	;	1.35	;	1.35A crystal structure of H-2Kb complexed with the GNYSFYAL peptide
5VFB	;	1.36	;	1.36 Angstrom Resolution Crystal Structure of Malate Synthase G from Pseudomonas aeruginosa in Complex with Glycolic Acid.
6CLH	;	1.37	;	1.37 A MicroED structure of GSNQNNF at 2.9 e- / A^2
4MYD	;	1.374	;	1.37 Angstrom Crystal Structure of E. Coli 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate synthase (MenH) in complex with SHCHC
4EIV	;	1.37	;	1.37 Angstrom resolution crystal structure of apo-form of a putative deoxyribose-phosphate aldolase from Toxoplasma gondii ME49
3T3T	;	1.38	;	1.38 A structure of human frataxin variant Q148G
3C8Y	;	1.39	;	1.39 Angstrom crystal structure of Fe-only hydrogenase
1SXV	;	1.3	;	1.3A Crystal structure of rv3628, Mycobacterium tuberculosis inorganic pyrophosphatase (PPase) at pH5.0
3QGJ	;	1.3	;	1.3A Structure of alpha-Lytic Protease Bound to Ac-AlaAlaPro-Alanal
1SXU	;	1.4	;	1.4 A Crystal Structure of D30N Mutant of Nitrophorin 4 from Rhodnius Prolixus Complexed with Imidazole
1D3S	;	1.4	;	1.4 A crystal structure of nitrophorin 4 from Rhodnius prolixis at pH=5.6.
5KB3	;	1.399	;	1.4 A resolution structure of Helicobacter Pylori MTAN in complexed with p-ClPh-DADMe-ImmA
2TNF	;	1.4	;	1.4 A RESOLUTION STRUCTURE OF MOUSE TUMOR NECROSIS FACTOR, TOWARDS MODULATION OF ITS SELECTIVITY AND TRIMERISATION
6U4W	;	1.4	;	1.4 A structure of a pathogenic human Syt 1 C2B (D366E)
4MYS	;	1.423	;	1.4 Angstrom Crystal Structure of 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate synthase with SHCHC and Pyruvate
4EQ9	;	1.4	;	1.4 Angstrom Crystal Structure of ABC Transporter Glutathione-Binding Protein GshT from Streptococcus pneumoniae strain Canada MDR_19A in Complex with Glutathione
3I19	;	1.36	;	1.4 Angstrom Crystal Structure of Fluorescent Protein Cypet
2W1P	;	1.4	;	1.4 Angstrom crystal structure of P.pastoris aquaporin, Aqy1, in a closed conformation at pH 8.0
3M07	;	1.4	;	1.4 Angstrom Resolution Crystal Structure of Putative alpha Amylase from Salmonella typhimurium.
4GUC	;	1.4	;	1.4 Angstrom resolution crystal structure of uncharacterized protein BA_2500 from Bacillus anthracis str. Ames
3DHB	;	1.4	;	1.4 Angstrom Structure of N-Acyl Homoserine Lactone Hydrolase with the Product N-Hexanoyl-L-Homoserine Bound at The Catalytic Metal Center
1HMR	;	1.4	;	1.4 ANGSTROMS STRUCTURAL STUDIES ON HUMAN MUSCLE FATTY ACID BINDING PROTEIN: BINDING INTERACTIONS WITH THREE SATURATED AND UNSATURATED C18 FATTY ACIDS
1HMS	;	1.4	;	1.4 ANGSTROMS STRUCTURAL STUDIES ON HUMAN MUSCLE FATTY ACID BINDING PROTEIN: BINDING INTERACTIONS WITH THREE SATURATED AND UNSATURATED C18 FATTY ACIDS
1HMT	;	1.4	;	1.4 ANGSTROMS STRUCTURAL STUDIES ON HUMAN MUSCLE FATTY ACID BINDING PROTEIN: BINDING INTERACTIONS WITH THREE SATURATED AND UNSATURATED C18 FATTY ACIDS
5TG1	;	1.4	;	1.40 A resolution structure of Norovirus 3CL protease in complex with the a m-chlorophenyl substituted macrocyclic inhibitor (17-mer)
5LQ1	;	1.41	;	1.41 A resolution structure of PtxB from Trichodesmium erythraeum IMS101 in complex with methylphosphonate
4JB7	;	1.42	;	1.42 Angstrom resolution crystal structure of accessory colonization factor AcfC (acfC) in complex with D-aspartic acid
6PNV	;	1.42	;	1.42 Angstrom Resolution Crystal Structure of Translocation Protein TolB from Salmonella enterica
1CXU	;	1.42	;	1.42A RESOLUTION ASV INTEGRASE CORE DOMAIN FROM CITRATE
4M8I	;	1.43	;	1.43 Angstrom resolution crystal structure of cell division protein FtsZ (ftsZ) from Staphylococcus epidermidis RP62A in complex with GDP
4MVA	;	1.43	;	1.43 Angstrom Resolution Crystal Structure of Triosephosphate Isomerase (tpiA) from Escherichia coli in Complex with Acetyl Phosphate.
5WP2	;	1.439	;	1.44 Angstrom crystal structure of CYP121 from Mycobacterium tuberculosis in complex with substrate and CN
1DI6	;	1.45	;	1.45 A CRYSTAL STRUCTURE OF THE MOLYBDENUMM COFACTOR BIOSYNTHESIS PROTEIN MOGA FROM ESCHERICHIA COLI
6CLT	;	1.45	;	1.45 A MicroED structure of GSNQNNF at 3.8 e- / A^2
4MOV	;	1.4503	;	1.45 A Resolution Crystal Structure of Protein Phosphatase 1
6H8J	;	1.45	;	1.45 A resolution of Sporosarcina pasteurii urease inhibited in the presence of NBPTO
6NLF	;	1.45	;	1.45 A resolution structure of apo BfrB from Pseudomonas aeruginosa
4QAR	;	1.45	;	1.45 A resolution structure of CT263 (MTAN) from Chlamydia trachomatis bound to Adenine
6E6S	;	1.45	;	1.45 A resolution structure of the C-terminally truncated [2Fe-2S] ferredoxin (Bfd) R26E/K46Y mutant from Pseudomonas aeruginosa
1I0G	;	1.45	;	1.45 A STRUCTURE OF THE A-DECAMER GCGTATACGC WITH A SINGLE 2'-O-FLUOROETHYL THYMINE IN PLACE OF T6, MEDIUM NA-SALT
5EQV	;	1.45	;	1.45 Angstrom Crystal Structure of Bifunctional 2',3'-cyclic Nucleotide 2'-phosphodiesterase/3'-Nucleotidase Periplasmic Precursor Protein from Yersinia pestis with Phosphate bound to the Active site
3TNL	;	1.45	;	1.45 Angstrom Crystal Structure of Shikimate 5-dehydrogenase from Listeria monocytogenes in Complex with Shikimate and NAD.
4H48	;	1.45	;	1.45 angstrom CyPet Structure at pH7.0
6YUN	;	1.44	;	1.45 Angstrom Resolution Crystal Structure of C-terminal Dimerization Domain of Nucleocapsid Phosphoprotein from SARS-CoV-2
6BXG	;	1.45	;	1.45 Angstrom Resolution Crystal Structure of PDZ domain of Carboxy-Terminal Protease from Vibrio cholerae in Complex with Peptide.
3O8Q	;	1.45	;	1.45 Angstrom Resolution Crystal Structure of Shikimate 5-Dehydrogenase (aroE) from Vibrio cholerae
7KH6	;	1.45	;	1.45 Angstrom resolution internal aldimine crystal structure of the beta-Q114A mutant of TryptophanSynthase in complex with N-(4'-trifluoromethoxybenzenesulfonyl)-2-amino-1-ethylphosphate (F9F) at the enzyme alpha-site and cesium ion at the metal coordination site
4V4M	;	1.45	;	1.45 Angstrom Structure of STNV coat protein
4MXD	;	1.45	;	1.45 angstronm crystal structure of E.coli 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate synthase (MenH)
4XBD	;	1.45	;	1.45A resolution structure of Norovirus 3CL protease complex with a covalently bound dipeptidyl inhibitor (1R,2S)-2-({N-[(benzyloxy)carbonyl]-3-cyclohexyl-L-alanyl}amino)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid (Orthorhombic P Form)
4O8I	;	1.45	;	1.45A resolution structure of PEG 400 Bound Cyclophilin D
5C98	;	1.45	;	1.45A resolution structure of SRPN18 from Anopheles gambiae
6CLS	;	1.46	;	1.46 A MicroED structure of GSNQNNF at 3.4 e- / A^2
5LQ5	;	1.46	;	1.46 A resolution structure of PhnD1 from Prochlorococcus marinus (MIT 9301) in complex with phosphite
5TPI	;	1.47	;	1.47 Angstrom Crystal Structure of the C-terminal Substrate Binding Domain of LysR Family Transcriptional Regulator from Klebsiella pneumoniae.
6ZK0	;	1.47	;	1.47A human IMPase with ebselen
6YR3	;	1.48	;	1.48 Angstrom Resolution Crystal Structure of Transaldolase from Thermoplasma acidophilum in complex with D-fructose 6-phosphate Schiff-base intermediate
6RP1	;	1.49	;	1.49 A RESOLUTION OF SPOROSARCINA PASTEURII UREASE INHIBITED IN THE PRESENCE OF NBPTO AT pH 6.5
4X9C	;	1.4	;	1.4A crystal structure of Hfq from Methanococcus jannaschii
3LG3	;	1.4	;	1.4A Crystal Structure of Isocitrate Lyase from Yersinia pestis CO92
1O98	;	1.4	;	1.4A CRYSTAL STRUCTURE OF PHOSPHOGLYCERATE MUTASE FROM BACILLUS STEAROTHERMOPHILUS COMPLEXED WITH 2-PHOSPHOGLYCERATE
6VHC	;	1.4	;	1.4A damaged structure of GSNQNNF used to determine initial phases from radiation damage
6VHB	;	1.4	;	1.4A low-dose structure of GSNQNNF determined from initial phases generated using radiation damage
7N9I	;	1.4	;	1.4A Structure of Drosophila melanogaster Frataxin
1QTO	;	1.5	;	1.5 A CRYSTAL STRUCTURE OF A BLEOMYCIN RESISTANCE DETERMINANT FROM BLEOMYCIN-PRODUCING STREPTOMYCES VERTICILLUS
2GS5	;	1.5	;	1.5 A Crystal Structure of a Conserved Protein of Unknown Function from Corvnebacterium diphtheriae
1TP6	;	1.5	;	1.5 A Crystal Structure of a NTF-2 Like Protein of Unknown Function PA1314 from Pseudomonas aeruginosa
1TUA	;	1.5	;	1.5 A Crystal Structure of a Protein of Unknown Function APE0754 from Aeropyrum pernix
2GZ4	;	1.5	;	1.5 A Crystal Structure of a Protein of Unknown Function ATU1052 from Agrobacterium tumefaciens
1Z6N	;	1.5	;	1.5 A Crystal Structure of a Protein of Unknown Function PA1234 from Pseudomonas aeruginosa
2A35	;	1.5	;	1.5 A Crystal Structure of a Protein of Unknown Function PA4017 from Pseudomonas aeruginosa PAO1, Possible Epimerase
1SH8	;	1.5	;	1.5 A Crystal Structure of a Protein of Unknown Function PA5026 from Pseudomonas aeruginosa, Probable Thioesterase
5UR4	;	1.52	;	1.5 A Crystal structure of PYR1 bound to Pyrabactin
2B5H	;	1.5	;	1.5 A Resolution Crystal Structure of Recombinant R. Norvegicus Cysteine Dioxygenase
2GH2	;	1.5	;	1.5 A Resolution R. Norvegicus Cysteine Dioxygenase Structure Crystallized in the Presence of Cysteine
1PUY	;	1.5	;	1.5 A resolution structure of a synthetic DNA hairpin with a stilbenediether linker
1ZEQ	;	1.5	;	1.5 A Structure of apo-CusF residues 6-88 from Escherichia coli
2GRC	;	1.5	;	1.5 A structure of bromodomain from human BRG1 protein, a central ATPase of SWI/SNF remodeling complex
2OE5	;	1.51	;	1.5 A X-ray crystal structure of Apramycin complex with RNA fragment GGCGUCGCUAGUACCG/GGUACUAAAAGUCGCCC containing the human ribosomal decoding A site: RNA construct with 3'-overhang
4R52	;	1.53	;	1.5 angstrom crystal structure of 3-hydroxyanthranilate-3,4-dioxygenase from Cupriavidus metallidurans
4JGI	;	1.5	;	1.5 Angstrom crystal structure of a novel cobalamin-binding protein from Desulfitobacterium hafniense DCB-2
3HJB	;	1.5	;	1.5 Angstrom Crystal Structure of Glucose-6-phosphate Isomerase from Vibrio cholerae.
1WPA	;	1.5	;	1.5 Angstrom crystal structure of human occludin fragment 413-522
4NOH	;	1.502	;	1.5 Angstrom Crystal Structure of Putative Lipoprotein from Bacillus anthracis.
5DZS	;	1.5	;	1.5 Angstrom Crystal Structure of Shikimate Dehydrogenase 1 from Peptoclostridium difficile.
4EVM	;	1.506	;	1.5 Angstrom crystal structure of soluble domain of membrane-anchored thioredoxin family protein from Streptococcus pneumoniae strain Canada MDR_19A
4EQB	;	1.5	;	1.5 Angstrom Crystal Structure of Spermidine/Putrescine ABC Transporter Substrate-Binding Protein PotD from Streptococcus pneumoniae strain Canada MDR_19A in Complex with Calcium and HEPES
3RQT	;	1.5	;	1.5 Angstrom Crystal Structure of the Complex of Ligand Binding Component of ABC-type Import System from Staphylococcus aureus with Nickel and two Histidines
4GUF	;	1.5	;	1.5 Angstrom Crystal Structure of the Salmonella enterica 3-Dehydroquinate Dehydratase (aroD) E86A Mutant
1LMI	;	1.5	;	1.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF A SECRETED PROTEIN FROM MYCOBACTERIUM TUBERCULOSIS-MPT63
4IFA	;	1.5	;	1.5 Angstrom resolution crystal structure of an extracellular protein containing a SCP domain from Bacillus anthracis str. Ames
3TKF	;	1.5	;	1.5 Angstrom Resolution Crystal Structure of K135M Mutant of Transaldolase B (TalA) from Francisella tularensis in Complex with Sedoheptulose 7-phosphate.
5U4Q	;	1.5	;	1.5 Angstrom Resolution Crystal Structure of NAD-Dependent Epimerase from Klebsiella pneumoniae in Complex with NAD.
3UPB	;	1.5	;	1.5 Angstrom Resolution Crystal Structure of Transaldolase from Francisella tularensis in Covalent Complex with Arabinose-5-Phosphate
3RY4	;	1.5	;	1.5 Angstrom resolution structure of glycosylated fcgammariia (low-responder polymorphism)
3IQO	;	1.5	;	1.5 angstrom X-ray structure of bovine Ca(2+)-S100B
6ZNY	;	1.5	;	1.50 A resolution 3-methylcatechol (3-methylbenzene-1,2-diol) inhibited Sporosarcina pasteurii urease
5G4H	;	1.5	;	1.50 A resolution catechol (1,2-dihydroxybenzene) inhibited Sporosarcina pasteurii urease
3WNI	;	1.5	;	1.50 A resolution crystal structure of dioxygen bound copper-containing nitrite reductase from Geobacillus thermodenitrificans
6NLG	;	1.5	;	1.50 A resolution structure of BfrB (C89S/K96C) from Pseudomonas aeruginosa in complex with a small molecule fragment (analog 1)
7LKT	;	1.5	;	1.50 A resolution structure of SARS-CoV-2 3CL protease in complex with inhibitor 2k
6E6R	;	1.5	;	1.50 A resolution structure of the C-terminally truncated [2Fe-2S] ferredoxin (Bfd) R26E mutant from Pseudomonas aeruginosa
4BGU	;	1.487	;	1.50 A resolution structure of the malate dehydrogenase from Haloferax volcanii
7R7B	;	1.5	;	1.50 Angstroem Crystal Structure of FeoA from Bacteroides fragilis
5TW9	;	1.5	;	1.50 Angstrom Crystal Structure of C-terminal Fragment (residues 322-384) of Iron Uptake System Component EfeO from Yersinia pestis.
4GUJ	;	1.5	;	1.50 Angstrom Crystal Structure of the Salmonella enterica 3-Dehydroquinate Dehydratase (aroD) in Complex with Shikimate
6E5Y	;	1.5	;	1.50 Angstrom Resolution Crystal Structure of Argininosuccinate Synthase from Bordetella pertussis in Complex with AMP.
7KOS	;	1.5	;	1.50 Angstroms Resolution Crystal Structure of Putative Pterin Binding Protein PruR (Atu3496) from Agrobacterium fabrum str. C58
5D8X	;	1.5	;	1.50A resolution structure of BfrB (L68A E81A) from Pseudomonas aeruginosa
6AW4	;	1.5	;	1.50A resolution structure of catechol O-methyltransferase (COMT) from Nannospalax galili
5LQ8	;	1.52	;	1.52 A resolution structure of PhnD1 from Prochlorococcus marinus (MIT 9301) in complex with methylphosphonate
4QWO	;	1.52	;	1.52 Angstrom Crystal Structure of A42R Profilin-like Protein from Monkeypox Virus Zaire-96-I-16
5HSF	;	1.52	;	1.52 Angstrom Crystal Structure of Fc fragment of Human IgG1.
6WN5	;	1.52	;	1.52 Angstrom Resolution Crystal Structure of Transcriptional Regulator HdfR from Klebsiella pneumoniae
1K4V	;	1.53	;	1.53 A Crystal Structure of the Beta-Galactoside-alpha-1,3-galactosyltransferase in Complex with UDP
1WCF	;	1.54	;	1.54 A CRYSTAL STRUCTURE OF RV3628, MYCOBACTERIUM TUBERCULOSIS INORGANIC PYROPHOSPHATASE (PPASE) AT PH7.0
3QY1	;	1.54	;	1.54A Resolution Crystal Structure of a Beta-Carbonic Anhydrase from Salmonella enterica subsp. enterica serovar Typhimurium str. LT2
1MV8	;	1.55	;	1.55 A crystal structure of a ternary complex of GDP-mannose dehydrogenase from Psuedomonas aeruginosa
7OW0	;	1.55	;	1.55 A crystal structure of DNA/2'-O-methyl-RNA heteroduplex with overhangs solved by Zn-SAD.
4K9G	;	1.55	;	1.55 A Crystal Structure of Macrophage Migration Inhibitory Factor bound to ISO-66 and a related compound
1KQ1	;	1.55	;	1.55 A Crystal structure of the pleiotropic translational regulator, Hfq
4FOJ	;	1.55	;	1.55 A Crystal Structure of Xanthomonas citri FimX EAL domain in complex with c-diGMP
6ZO3	;	1.55	;	1.55 A resolution 3,6-dimethylcatechol (3,6-dimethylbenzene-1,2-diol) inhibited Sporosarcina pasteurii urease
6CR0	;	1.548	;	1.55 A resolution structure of (S)-6-hydroxynicotine oxidase from Shinella HZN7
5WKK	;	1.55	;	1.55 A resolution structure of MERS 3CL protease in complex with inhibitor GC813
7LKV	;	1.55	;	1.55 A resolution structure of SARS-CoV-2 3CL protease in complex with inhibitor 3c
6Z9E	;	1.55	;	1.55 A structure of human apoferritin obtained from data subset of Titan Mono-BCOR microscope
7QZJ	;	1.55	;	1.55 A X-ray crystallographic structure of SapH from Streptomyces sp. (HPH0547) involved in Pseudouridimycin biosynthesis
3GA7	;	1.55	;	1.55 Angstrom Crystal Structure of an Acetyl Esterase from Salmonella typhimurium
4RS2	;	1.55	;	1.55 Angstrom Crystal Structure of GNAT Family N-acetyltransferase (YhbS) from Escherichia coli in Complex with CoA
4S12	;	1.55	;	1.55 Angstrom Crystal Structure of N-acetylmuramic acid 6-phosphate Etherase from Yersinia enterocolitica.
4ERR	;	1.55	;	1.55 Angstrom Crystal Structure of the Four Helical Bundle Membrane Localization Domain (4HBM) of the Vibrio vulnificus MARTX Effector Domain DUF5
1F0L	;	1.55	;	1.55 ANGSTROM CRYSTAL STRUCTURE OF WILD TYPE DIPHTHERIA TOXIN
6NAU	;	1.55	;	1.55 Angstrom Resolution Crystal Structure of 6-phosphogluconolactonase from Klebsiella pneumoniae
5VDN	;	1.55	;	1.55 Angstrom Resolution Crystal Structure of Glutathione Reductase from Yersinia pestis in Complex with FAD
3IFE	;	1.55	;	1.55 Angstrom Resolution Crystal Structure of Peptidase T (pepT-1) from Bacillus anthracis str. 'Ames Ancestor'.
3R2K	;	1.55	;	1.55A resolution structure of As-Isolated FtnA from Pseudomonas aeruginosa (pH 7.5)
3NEP	;	1.551	;	1.55A resolution structure of malate dehydrogenase from Salinibacter ruber
7SNS	;	1.55	;	1.55A Resolution Structure of NanoLuc Luciferase
2Y3Q	;	1.55	;	1.55A structure of apo bacterioferritin from E. coli
6PUQ	;	1.56	;	1.56 A crystal structure of flavodoxin-like domain of Schizosaccharomyces japonicus putative tRNAPhe 4-demethylwyosine synthase Tyw1 in complex with FMN
6Z9F	;	1.56	;	1.56 A structure of human apoferritin obtained from data subset of Titan Mono-BCOR microscope
1HFC	;	1.5	;	1.56 ANGSTROM STRUCTURE OF MATURE TRUNCATED HUMAN FIBROBLAST COLLAGENASE
4D74	;	1.57	;	1.57 A crystal structure of erwinia amylovora tyrosine phosphatase amsI
3T3X	;	1.57	;	1.57 A structure of Friedreich's ataxia frataxin variant R165C
6E55	;	1.57	;	1.57 Angstroem Crystal Structure of FeoA from Klebsiella pneumoniae
4CEU	;	1.58	;	1.58 A resolution native Sporosarcina pasteurii urease
4QAQ	;	1.58	;	1.58 A resolution structure of CT263 (MTAN) from Chlamydia trachomatis
3GM7	;	1.58	;	1.58 A resolution X-ray structure of (CUG)6
7R5O	;	1.58	;	1.58 A STRUCTURE OF HUMAN APOFERRITIN OBTAINED FROM TITAN KRIOS 2 AT eBIC, DLS UNDER COMMISSIONING SESSION CM26464-2
4CEX	;	1.589	;	1.59 A resolution Fluoride inhibited Sporosarcina pasteurii urease
3L4E	;	1.5	;	1.5A Crystal Structure of a Putative Peptidase E Protein from Listeria monocytogenes EGD-e
1OZN	;	1.52	;	1.5A Crystal Structure of the Nogo Receptor Ligand Binding Domain Reveals a Convergent Recognition Scaffold Mediating Inhibition of Myelination
1SQE	;	1.5	;	1.5A Crystal Structure Of the protein PG130 from Staphylococcus aureus, Structural genomics
1ZKP	;	1.502	;	1.5A Resolution Crystal Structure of a Metallo Beta Lactamase Family Protein, the ELAC Homolgue of Bacillus anthracis, a Putative Ribonuclease
3UR6	;	1.5	;	1.5A resolution structure of apo Norwalk Virus Protease
1JKS	;	1.5	;	1.5A X-RAY STRUCTURE OF APO FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2AP3	;	1.6	;	1.6 A Crystal Structure of a Conserved Protein of Unknown Function from Staphylococcus aureus
1ZKE	;	1.6	;	1.6 A Crystal Structure of a Protein HP1531 of Unknown Function from Helicobacter pylori
3DMO	;	1.6	;	1.6 A crystal structure of cytidine deaminase from Burkholderia pseudomallei
5XB0	;	1.6	;	1.6 A crystal structure of peptidyl-prolyl cis-trans isomerase PPIase from Pseudomonas syringae pv. tomato str. DC3000 (PSPTO DC3000)
8EPU	;	1.6	;	1.6 A crystal structure of the lipocalin dog allergen Can f 1 with the C118S mutation
1HFE	;	1.6	;	1.6 A RESOLUTION STRUCTURE OF THE FE-ONLY HYDROGENASE FROM DESULFOVIBRIO DESULFURICANS
2WBZ	;	1.6	;	1.6 A Structure of Thaumatin Crystallized without Tartrate at 4 C
1I0F	;	1.6	;	1.6 A STRUCTURE OF THE A-DECAMER GCGTATACGC WITH A SINGLE 2'-O-AMINOOXYETHYL THYMINE IN PLACE OF T6, BA-FORM
1I0O	;	2.0	;	1.6 A STRUCTURE OF THE A-DECAMER GCGTATACGC WITH A SINGLE 2'-O-METHYL-3'-METHYLENEPHOSPHONATE THYMINE IN PLACE OF T6, HIGH K-SALT
3B9F	;	1.6	;	1.6 A structure of the PCI-thrombin-heparin complex
3GWA	;	1.6	;	1.6 Angstrom crystal structure of 3-oxoacyl-(acyl-carrier-protein) synthase III
2BL7	;	2.2	;	1.6 Angstrom crystal structure of EntA-im: a bacterial immunity protein conferring immunity to the antimicrobial activity of the pediocin-like bacteriocin, enterocin A
2BL8	;	1.6	;	1.6 Angstrom crystal structure of EntA-im: a bacterial immunity protein conferring immunity to the antimicrobial activity of the pediocin-like bacteriocin, enterocin A
3GEX	;	1.6	;	1.6 angstrom crystal structure of fluorescent protein Cypet
3LKM	;	1.6	;	1.6 Angstrom Crystal Structure of the Alpha-kinase Domain of Myosin Heavy Chain Kinase A Complex with AMP
1JLJ	;	1.6	;	1.6 Angstrom crystal structure of the human neuroreceptor anchoring and molybdenum cofactor biosynthesis protein gephyrin
6VC5	;	1.5	;	1.6 Angstrom Resolution Crystal Structure of endoglucanase from Komagataeibacter sucrofermentans
3PP9	;	1.6	;	1.6 Angstrom resolution crystal structure of putative streptothricin acetyltransferase from Bacillus anthracis str. Ames in complex with acetyl coenzyme A
7VBE	;	1.59	;	1.6 Angstrom Resolution Crystal Structure of SARS-CoV-2 Nucleocapsid dimerization domain, pH 5.0
2A7M	;	1.6	;	1.6 Angstrom Resolution Structure of the Quorum-Quenching N-Acyl Homoserine Lactone Hydrolase of Bacillus thuringiensis
1T4B	;	1.6	;	1.6 Angstrom structure of Esherichia coli aspartate-semialdehyde dehydrogenase.
2GIM	;	1.6	;	1.6 Angstrom structure of plastocyanin from Anabaena variabilis
1G4Y	;	1.6	;	1.60 A CRYSTAL STRUCTURE OF THE GATING DOMAIN FROM SMALL CONDUCTANCE POTASSIUM CHANNEL COMPLEXED WITH CALCIUM-CALMODULIN
4XBC	;	1.6	;	1.60 A resolution structure of Norovirus 3CL protease complex with a covalently bound dipeptidyl inhibitor (1R,2S)-2-({N-[(benzyloxy)carbonyl]-3-cyclohexyl-L-alanyl}amino)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid (Hexagonal Form)
7LKX	;	1.6	;	1.60 A resolution structure of SARS-CoV-2 3CL protease in complex with inhibitor 3e
6UBU	;	1.6	;	1.60 A resolution structure of the guanine riboswitch bound to guanine
6NLN	;	1.6	;	1.60 A resolution structure of WT BfrB from Pseudomonas aeruginosa in complex with a protein-protein interaction inhibitor (analog 16)
1DI7	;	1.6	;	1.60 ANGSTROM CRYSTAL STRUCTURE OF THE MOLYBDENUM COFACTOR BIOSYNTHESIS PROTEIN MOGA FROM ESCHERICHIA COLI
3U80	;	1.6	;	1.60 Angstrom Resolution Crystal Structure of a 3-Dehydroquinate Dehydratase-like Protein from Bifidobacterium longum
4PZJ	;	1.6	;	1.60 Angstrom resolution crystal structure of a transcriptional regulator of the LysR family from Eggerthella lenta DSM 2243
3V4G	;	1.6	;	1.60 Angstrom resolution crystal structure of an arginine repressor from Vibrio vulnificus CMCP6
7KBN	;	1.6	;	1.60 Angstrom resolution crystal structure of the beta-Q114A mutant of Tryptophan Synthase in complex with N-(4'-trifluoromethoxybenzenesulfonyl)-2-amino-1-ethylphosphate (F9F) at the enzyme alpha-site, cesium ion at the metal coordination site, and 2-aminophenol quinonoid at the enzyme beta site
7KA1	;	1.6	;	1.60 Angstrom resolution crystal structure of the beta-Q114A mutant Tryptophan Synthase in complex with inhibitor N-(4'-trifluoromethoxybenzenesulfonyl)-2-amino-1-ethylphosphate (F9F) at the alpha-site, aminoacrylate at the beta site, and cesium ion at the metal coordination site
4LQU	;	1.6	;	1.60A resolution crystal structure of a superfolder green fluorescent protein (W57G) mutant
6ZO1	;	1.61	;	1.61 A resolution 3,5-dimethylcatechol (3,5-dimethylbenzene-1,2-diol) inhibited Sporosarcina pasteurii urease
4GUG	;	1.62	;	1.62 Angstrom Crystal Structure of the Salmonella enterica 3-Dehydroquinate Dehydratase (aroD) E86A Mutant in Complex with Dehydroshikimate (Crystal Form #1)
7OKW	;	1.62	;	1.62A X-ray crystal structure of the conserved C-terminal (CCT) of human OSR1
8A18	;	1.63	;	1.63 A resolution hydroquinone inhibited Sporosarcina pasteurii urease
3UUW	;	1.63	;	1.63 Angstrom Resolution Crystal Structure of Dehydrogenase (MviM) from Clostridium difficile.
3RYK	;	1.631	;	1.63 Angstrom resolution crystal structure of dTDP-4-dehydrorhamnose 3,5-epimerase (rfbC) from Bacillus anthracis str. Ames with TDP and PPi bound
6ZO2	;	1.65	;	1.65 A resolution 4,5-dimethylcatechol (4,5-dimethylbenzene-1,2-diol) inhibited Sporosarcina pasteurii urease
6NLJ	;	1.65	;	1.65 A resolution structure of Apo BfrB from Pseudomonas aeruginosa in complex with a protein-protein interaction inhibitor (analog 12)
6W2A	;	1.65	;	1.65 A resolution structure of SARS-CoV 3CL protease in complex with inhibitor 7j
7K0F	;	1.65	;	1.65 A resolution structure of SARS-CoV-2 3CL protease in complex with a deuterated GC376 alpha-ketoamide analog (compound 5)
7LKR	;	1.65	;	1.65 A resolution structure of SARS-CoV-2 3CL protease in complex with inhibitor 2a
7LKU	;	1.65	;	1.65 A resolution structure of SARS-CoV-2 3CL protease in complex with inhibitor 3b (deuterated analog of inhibitor 2a)
7LKW	;	1.7	;	1.65 A resolution structure of SARS-CoV-2 3CL protease in complex with inhibitor 3d (deuterated analog of inhibitor 3c)
5A6T	;	1.65	;	1.65 A resolution Sulphite inhibited Sporosarcina pasteurii urease
1M93	;	1.65	;	1.65 A Structure of Cleaved Viral Serpin CRMA
1SDI	;	1.65	;	1.65 A structure of Escherichia coli ycfC gene product
4MBO	;	1.65	;	1.65 Angstrom Crystal Structure of Serine-rich Repeat Adhesion Glycoprotein (Srr1) from Streptococcus agalactiae
3D72	;	1.65	;	1.65 Angstrom crystal structure of the Cys71Val variant in the fungal photoreceptor VVD
6DAD	;	1.65	;	1.65 Angstrom crystal structure of the N97I Ca/CaM:CaV1.2 IQ domain complex
6U3A	;	1.65	;	1.65 Angstrom crystal structure of the N97S Ca-CaM:CaV1.2 IQ domain complex
5IBX	;	1.65	;	1.65 Angstrom Crystal Structure of Triosephosphate Isomerase (TIM) from Streptococcus pneumoniae
4QTO	;	1.65	;	1.65 Angstrom resolution crystal structure of betaine aldehyde dehydrogenase (betB) from Staphylococcus aureus with BME-modified Cys289 and PEG molecule in active site
5HOP	;	1.65	;	1.65 Angstrom resolution crystal structure of lmo0182 (residues 1-245) from Listeria monocytogenes EGD-e
3TNO	;	1.65	;	1.65 Angstrom Resolution Crystal Structure of Transaldolase B (TalA) from Francisella tularensis in Covalent Complex with Sedoheptulose-7-Phosphate
3LWZ	;	1.65	;	1.65 Angstrom Resolution Crystal Structure of Type II 3-Dehydroquinate Dehydratase (aroQ) from Yersinia pestis
1DHN	;	1.65	;	1.65 ANGSTROM RESOLUTION STRUCTURE OF 7,8-DIHYDRONEOPTERIN ALDOLASE FROM STAPHYLOCOCCUS AUREUS
2UZ1	;	1.65	;	1.65 Angstrom structure of Benzaldehyde Lyase complexed with 2-methyl- 2,4-pentanediol
5WOF	;	1.65	;	1.65 ANGSTROM STRUCTURE OF THE DYNEIN LIGHT CHAIN 1 FROM PLASMODIUM FALCIPARUM
6P4V	;	1.65	;	1.65 Angstrom ternary complex of Deoxyhypusine synthase with cofactor NAD and spermidine mimic inhibitor GC7
3DMS	;	1.65	;	1.65A crystal structure of isocitrate dehydrogenase from Burkholderia pseudomallei
4TOF	;	1.65	;	1.65A resolution structure of BfrB (C89S, K96C) crystal form 1 from Pseudomonas aeruginosa
3R2R	;	1.65	;	1.65A resolution structure of Iron Soaked FtnA from Pseudomonas aeruginosa (pH 6.0)
3UR9	;	1.65	;	1.65A resolution structure of Norwalk Virus Protease Containing a covalently bound dipeptidyl inhibitor
6UXC	;	1.65	;	1.65A resolution structure of the hypothetical protein CT253 from Chlamydia trachomatis
4MLO	;	1.65	;	1.65A resolution structure of ToxT from Vibrio cholerae (P21 Form)
4JBU	;	1.65	;	1.65A structure of the T3SS tip protein LcrV (G28-D322, C273S) from Yersinia pestis
1I2Y	;	1.66	;	1.66 A STRUCTURE OF A-DUPLEX WITH BULGED ADENOSINE, SPERMINE FORM
6MUQ	;	1.67	;	1.67 Angstrom Resolution Crystal Structure of Murein-DD-endopeptidase from Yersinia enterocolitica.
7ZRQ	;	1.68	;	1.68 Angstrom crystal structure of Ca/CaM-E140G:CaMKIIdelta peptide complex
5MKX	;	1.68	;	1.68A STRUCTURE PCAF BROMODOMAIN WITH 4-chloro-2-methyl-5-(methylamino)pyridazin-3(2H)-one
1LLN	;	1.6	;	1.6A CRYSTAL STRUCTURE OF POKEWEED ANTIVIRAL PROTEIN-III (PAP-III) WITH METHYLATED LYSINES
1YD9	;	1.6	;	1.6A Crystal Structure of the Non-Histone Domain of the Histone Variant MacroH2A1.1.
1RZ2	;	1.6	;	1.6A crystal structure of the protein BA4783/Q81L49 (similar to sortase B) from Bacillus anthracis.
4JES	;	1.6	;	1.6A resolution Apo structure of the hemophore HasA from Yersinia pestis (Hexagonal Form)
1JUX	;	1.6	;	1.6A Resolution Crystal Structures of the DNA Octamers d(IUATATAC) and d(ITITACAC):Binding of Two Distamycin Drugs Side-by-Side
2WCW	;	1.58	;	1.6A resolution structure of Archaeoglobus fulgidus Hjc, a Holliday junction resolvase from an archaeal hyperthermophile
2WCZ	;	1.65	;	1.6A resolution structure of Archaeoglobus fulgidus Hjc, a Holliday junction resolvase from an archaeal hyperthermophile
4DCD	;	1.69	;	1.6A resolution structure of PolioVirus 3C Protease Containing a covalently bound dipeptidyl inhibitor
3Q7R	;	1.6	;	1.6A resolution structure of the ChxR receiver domain from Chlamydia trachomatis
1JKL	;	1.62	;	1.6A X-RAY STRUCTURE OF BINARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE
1U17	;	1.7	;	1.7 A Crystal structure of H60C mutant of Nitrophorin I. Heme complexed with two molecules imidazole
3CXK	;	1.7	;	1.7 A Crystal structure of methionine-R-sulfoxide reductase from Burkholderia pseudomallei: crystallization in a microfluidic crystal card.
1Y7R	;	1.7	;	1.7 A Crystal Structure of Protein of Unknown Function SA2161 from Meticillin-Resistant Staphylococcus aureus, Probable Acetyltransferase
3R2H	;	1.7	;	1.7 A resolution structure of As-Isolated FtnA from Pseudomonas aeruginosa (pH 10.5)
4PD0	;	1.7	;	1.7 A resolution structure of gephyrin's E-domain
4UUU	;	1.71	;	1.7 A resolution structure of human cystathionine beta-synthase regulatory domain (del 516-525) in complex with SAM
1UWF	;	1.69	;	1.7 A resolution structure of the receptor binding domain of the FimH adhesin from uropathogenic E. coli
1QUS	;	1.7	;	1.7 A RESOLUTION STRUCTURE OF THE SOLUBLE LYTIC TRANSGLYCOSYLASE SLT35 FROM ESCHERICHIA COLI
4JCO	;	1.7	;	1.7 A resolution structure of wild type malate dehydrogenase from haloarcula marismortui
6XXF	;	1.7	;	1.7 Angstrom crystal structure of Ca/CaM:RyR2 peptide complex
3GVF	;	1.75	;	1.7 Angstrom crystal structure of inorganic pyrophosphatase from burkholderia pseudomallei bound with phosphate
1PXZ	;	1.7	;	1.7 Angstrom Crystal Structure of jun a 1, the major allergen from cedar pollen
4Q7G	;	1.7	;	1.7 Angstrom Crystal Structure of leukotoxin LukD from Staphylococcus aureus.
4S24	;	1.7	;	1.7 Angstrom Crystal Structure of of Putative Modulator of Drug Activity (apo- form) from Yersinia pestis CO92
1ZD7	;	1.7	;	1.7 Angstrom Crystal Structure Of Post-Splicing Form of a dnaE Intein from Synechocystis Sp. Pcc 6803
2PDR	;	1.7	;	1.7 Angstrom Crystal Structure of the Photo-excited Blue-light Photoreceptor Vivid
6U3B	;	1.7	;	1.7 Angstrom crystal structure of the Q135P Ca-CaM:CaV1.2 IQ domain complex
1Z9L	;	1.7	;	1.7 Angstrom Crystal Structure of the Rat VAP-A MSP Homology Domain
1EYE	;	1.7	;	1.7 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF 6-HYDROXYMETHYL-7,8-DIHYDROPTEROATE SYNTHASE (DHPS) FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH 6-HYDROXYMETHYLPTERIN MONOPHOSPHATE
3HJV	;	1.7	;	1.7 Angstrom resolution crystal structure of an acyl carrier protein S-malonyltransferase from Vibrio cholerae O1 biovar eltor str. N16961
6NFP	;	1.7	;	1.7 Angstrom Resolution Crystal Structure of Arginase from Bacillus subtilis subsp. subtilis str. 168
4MPB	;	1.7	;	1.7 Angstrom resolution crystal structure of betaine aldehyde dehydrogenase (betB) from Staphylococcus aureus
5BXI	;	1.7	;	1.7 Angstrom Resolution Crystal Structure of Putative Nucleoside Diphosphate Kinase from Toxoplasma gondii with Tyrosine of Tag Bound to Active Site
3SD7	;	1.7	;	1.7 Angstrom Resolution Crystal Structure of Putative Phosphatase from Clostridium difficile
3VAA	;	1.7	;	1.7 Angstrom Resolution Crystal Structure of Shikimate Kinase from Bacteroides thetaiotaomicron
4QPK	;	1.66	;	1.7 Angstrom Structure of a Bacterial Phosphotransferase
6U41	;	1.7	;	1.7 angstrom structure of a pathogenic human Syt 1 C2B (D304G)
2HRC	;	1.7	;	1.7 angstrom structure of human ferrochelatase variant R115L
1SBP	;	1.7	;	1.7 ANGSTROMS REFINED STRUCTURE OF SULFATE-BINDING PROTEIN INVOLVED IN ACTIVE TRANSPORT AND NOVEL MODE OF SULFATE BINDING
5B5Q	;	1.7	;	1.7 Angstroms structure of ChlaDub1 from Chlamydia Trachomatis
1I6K	;	1.72	;	1.7 HIGH RESOLUTION EXPERIMENTAL PHASES FOR TRYPTOPHANYL-TRNA SYNTHETASE COMPLEXED WITH TRYPTOPHANYL-5'AMP
1I6L	;	1.72	;	1.7 HIGH RESOLUTION EXPERIMENTAL PHASES FOR TRYPTOPHANYL-TRNA SYNTHETASE COMPLEXED WITH TRYPTOPHANYL-5'AMP
1I6M	;	1.72	;	1.7 HIGH RESOLUTION EXPERIMENTAL PHASES FOR TRYPTOPHANYL-TRNA SYNTHETASE COMPLEXED WITH TRYPTOPHANYL-5'AMP
6SJQ	;	1.604	;	1.7-A resolution crystal structure of the N-terminal domain of T. brucei BILBO1
1YR5	;	1.7	;	1.7-A structure of calmodulin bound to a peptide from DAP kinase
5KKI	;	1.7	;	1.7-Angstrom in situ Mylar structure of hen egg-white lysozyme (HEWL) at 100 K
5KKK	;	1.7	;	1.7-Angstrom In situ Mylar structure of sperm whale myoglobin (SWMb-CO) at 100 K
2KIM	;		;	1.7-mm microcryoprobe solution NMR structure of an O6-methylguanine DNA methyltransferase family protein from Vibrio parahaemolyticus. Northeast Structural Genomics Consortium target VpR247.
7EFC	;	1.7	;	1.70 A cryo-EM structure of streptavidin
7KPZ	;	1.703	;	1.70 A resolution crystal structure of Group A Streptococcus HupZ-V5-His6
7K0H	;	1.7	;	1.70 A resolution structure of SARS-CoV 3CL protease in complex with a deuterated GC376 alpha-ketoamide analog (compound 5)
7LKS	;	1.7	;	1.70 A resolution structure of SARS-CoV-2 3CL protease in complex with inhibitor 2f
6XMK	;	1.7	;	1.70 A resolution structure of SARS-CoV-2 3CL protease in complex with inhibitor 7j
4CL3	;	1.699	;	1.70 A resolution structure of the malate dehydrogenase from Chloroflexus aurantiacus
3T3J	;	1.7	;	1.70 A structure of Friedreich's ataxia frataxin variant N146K
4KI3	;	1.7	;	1.70 Angstrom resolution crystal structure of outer-membrane lipoprotein carrier protein (lolA) from Yersinia pestis CO92
6VJ4	;	1.7	;	1.70 Angstrom Resolution Crystal Structure of Peptidylprolyl Isomerase (PrsA) from Bacillus anthracis
3SLH	;	1.7	;	1.70 Angstrom resolution structure of 3-phosphoshikimate 1-carboxyvinyltransferase (AroA) from Coxiella burnetii in complex with shikimate-3-phosphate and glyphosate
4EAM	;	1.7	;	1.70A resolution structure of apo beta-glycosidase (W33G) from sulfolobus solfataricus
6AW6	;	1.7	;	1.70A resolution structure of catechol O-methyltransferase (COMT) L136M (rhombohedral form) from Nannospalax galili
7SNX	;	1.7	;	1.70A Resolution Structure of NanoBiT Complementation Reporter Complex of LgBit and SmBiT Subunits
6CL7	;	1.71	;	1.71 A MicroED structure of proteinase K at 0.86 e- / A^2
6AON	;	1.72	;	1.72 Angstrom Resolution Crystal Structure of 2-Oxoglutarate Dehydrogenase Complex Subunit Dihydrolipoamide Dehydrogenase from Bordetella pertussis in Complex with FAD
5EYU	;	1.72	;	1.72 Angstrom resolution crystal structure of betaine aldehyde dehydrogenase (betB) P449M point mutant from Staphylococcus aureus in complex with NAD+ and BME-modified Cys289
5VIS	;	1.73	;	1.73 Angstrom Resolution Crystal Structure of Dihydropteroate Synthase (folP-SMZ_B27) from Soil Uncultured Bacterium.
6B4O	;	1.73	;	1.73 Angstrom Resolution Crystal Structure of Glutathione Reductase from Enterococcus faecalis in Complex with FAD
5DGX	;	1.73	;	1.73 Angstrom resolution crystal structure of the ABC-ATPase domain (residues 357-609) of lipid A transport protein (msbA) from Francisella tularensis subsp. tularensis SCHU S4 in complex with ADP
7O86	;	1.73	;	1.73A X-ray crystal structure of the conserved C-terminal (CCT) of human SPAK
5FSD	;	1.75	;	1.75 A resolution 2,5-dihydroxybenzensulfonate inhibited Sporosarcina pasteurii urease
4QAT	;	1.75	;	1.75 A resolution structure of CT263-D161N (MTAN) from Chlamydia trachomatis bound to MTA
5TG2	;	1.75	;	1.75 A resolution structure of Norovirus 3CL protease in complex with the a n-pentyl substituted macrocyclic inhibitor (17-mer)
7K5E	;	1.75	;	1.75 A resolution structure of WT BfrB from Pseudomonas aeruginosa in complex with a protein-protein interaction inhibitor JAG-5-7
2ID7	;	1.75	;	1.75 A Structure of T87I Phosphono-CheY
5I4D	;	1.75	;	1.75 Angstrom Crystal Structure of Superantigen-like Protein, Exotoxin from Staphylococcus aureus, in Complex with Sialyl-LewisX.
6U3D	;	1.75	;	1.75 Angstrom crystal structure of the N53I Ca-CaM:CaV1.2 IQ domain complex
4GHJ	;	1.75	;	1.75 Angstrom Crystal Structure of Transcriptional Regulator ftom Vibrio vulnificus.
3OGA	;	1.75	;	1.75 Angstrom resolution crystal structure of a putative NTP pyrophosphohydrolase (yfaO) from Salmonella typhimurium LT2
3M3H	;	1.75	;	1.75 Angstrom resolution crystal structure of an orotate phosphoribosyltransferase from Bacillus anthracis str. 'Ames Ancestor'
6AZI	;	1.75	;	1.75 Angstrom Resolution Crystal Structure of D-alanyl-D-alanine Endopeptidase from Enterobacter cloacae in Complex with Covalently Bound Boronic Acid
5CXD	;	1.75	;	1.75 Angstrom resolution crystal structure of the apo-form acyl-carrier-protein synthase (AcpS) (acpS; purification tag off) from Staphylococcus aureus subsp. aureus COL in the I4 space group
6D7Y	;	1.75	;	1.75 Angstrom Resolution Crystal Structure of the Toxic C-Terminal Tip of CdiA from Pseudomonas aeruginosa in Complex with Immune Protein
4HVO	;	1.75	;	1.75 angstrom x-ray crystal structure of cufe reconstituted 3-hydroxyanthranilate-3,4-dioxygenase from cupriavidus metallidurans
5IXE	;	1.75	;	1.75A RESOLUTION STRUCTURE OF 5-Fluoroindole BOUND BETA-GLYCOSIDASE (W33G) FROM SULFOLOBUS SOLFATARICUS
4JBG	;	1.75	;	1.75A resolution structure of a thermostable alcohol dehydrogenase from Pyrobaculum aerophilum
4EAN	;	1.75	;	1.75A resolution structure of indole bound beta-glycosidase (W33G) from sulfolobus solfataricus
3PZF	;	1.75	;	1.75A resolution structure of Serpin-2 from Anopheles gambiae
5DN8	;	1.76	;	1.76 Angstrom Crystal Structure of GTP-binding Protein Der from Coxiella burnetii in Complex with GDP.
1UWL	;	1.76	;	1.76A Structure of Urocanate Hydratase from Pseudomonas putida
4DUN	;	1.76	;	1.76A X-ray Crystal Structure of a Putative Phenazine Biosynthesis PhzC/PhzF Protein from Clostridium difficile (strain 630)
7EFD	;	1.77	;	1.77 A cryo-EM structure of Streptavidin using first 40 frames (corresponding to about 40 e/A^2 total dose)
3LDV	;	1.77	;	1.77 Angstrom resolution crystal structure of orotidine 5'-phosphate decarboxylase from Vibrio cholerae O1 biovar eltor str. N16961
5V26	;	1.79	;	1.78 angstrom crystal structure of P97H 3-hydroxyanthranilate-3,4-dioxygenase from Cupriavidus metallidurans
4GUI	;	1.78	;	1.78 Angstrom Crystal Structure of the Salmonella enterica 3-Dehydroquinate Dehydratase (aroD) in Complex with Quinate
6N7M	;	1.78	;	1.78 Angstrom Resolution Crystal Structure of Hypothetical Protein CD630_05490 from Clostridioides difficile 630.
6B8D	;	1.78	;	1.78 Angstrom Resolution Crystal Structure of N-terminal Fragment (residues 1-405) of Elongation Factor G from Haemophilus influenzae
6D0G	;	1.78	;	1.78 Angstrom Resolution Crystal Structure of Quercetin 2,3-dioxygenase from Acinetobacter baumannii
1P99	;	1.7	;	1.7A crystal structure of protein PG110 from Staphylococcus aureus
3RIX	;	1.7	;	1.7A resolution structure of a firefly luciferase-Aspulvinone J inhibitor complex
6MAB	;	1.7	;	1.7A resolution structure of RsbU from Chlamydia trachomatis (periplasmic domain)
7CB7	;	1.69	;	1.7A resolution structure of SARS-CoV-2 main protease (Mpro) in complex with broad-spectrum coronavirus protease inhibitor GC376
3MHZ	;	1.7	;	1.7A structure of 2-fluorohistidine labeled Protective Antigen
4NAM	;	1.7	;	1.7A structure of 5-Fluoro Tryptophan Labeled Protective Antigen (W206Y)
3DGL	;	1.8	;	1.8 A Crystal Structure of a Non-biological Protein with Bound ATP in a Novel Bent Conformation
1S7I	;	1.8	;	1.8 A Crystal Structure of a Protein of Unknown Function PA1349 from Pseudomonas aeruginosa
1T8H	;	1.8	;	1.8 A CRYSTAL STRUCTURE OF AN UNCHARACTERIZED B. STEAROTHERMOPHILUS PROTEIN
1I6N	;	1.8	;	1.8 A Crystal structure of IOLI protein with a binding zinc atom
3FC0	;	1.76	;	1.8 A crystal structure of murine GITR ligand dimer expressed in Drosophila melanogaster S2 cells
4FOK	;	1.8	;	1.8 A Crystal structure of the FimX EAL domain in complex with c-diGMP
2Q3B	;	1.8	;	1.8 A Resolution Crystal Structure of O-Acetylserine Sulfhydrylase (OASS) Holoenzyme From MYCOBACTERIUM TUBERCULOSIS
4TNL	;	1.8	;	1.8 A resolution room temperature structure of Thermolysin recorded using an XFEL
1JUE	;	1.8	;	1.8 A resolution structure of native lactococcus lactis dihydroorotate dehydrogenase A
4BGV	;	1.811	;	1.8 A resolution structure of the malate dehydrogenase from Picrophilus torridus in its apo form
3S8F	;	1.8	;	1.8 A structure of ba3 cytochrome c oxidase from Thermus thermophilus in lipid environment
3S8G	;	1.8	;	1.8 A structure of ba3 cytochrome c oxidase mutant (A120F) from Thermus thermophilus in lipid environment
6DXO	;	1.8	;	1.8 A structure of RsbN-BldN complex.
4N6H	;	1.8	;	1.8 A Structure of the human delta opioid 7TM receptor (PSI Community Target)
2OE8	;	1.8	;	1.8 A X-ray crystal structure of Apramycin complex with RNA fragment GGGCGUCGCUAGUACC/CGGUACUAAAAGUCGCC containing the human ribosomal decoding A site: RNA construct with 5'-overhang
5EUM	;	1.8	;	1.8 Angstrom Crystal Structure of ATP-binding Component of Fused Lipid Transporter Subunits of ABC superfamily from Haemophilus influenzae.
1IMX	;	1.82	;	1.8 Angstrom crystal structure of IGF-1
4UAM	;	1.8	;	1.8 Angstrom crystal structure of IMP-1 metallo-beta-lactamase with a mixed iron-zinc center in the active site
5DO8	;	1.8	;	1.8 Angstrom crystal structure of Listeria monocytogenes Lmo0184 alpha-1,6-glucosidase
4NV4	;	1.8	;	1.8 Angstrom Crystal Structure of Signal Peptidase I from Bacillus anthracis.
5YS3	;	1.823	;	1.8 angstrom crystal structure of Succinate-Acetate Permease from Citrobacter koseri
4GFS	;	1.8	;	1.8 Angstrom Crystal Structure of the 3-Dehydroquinate Dehydratase (aroD) from Salmonella typhimurium LT2 with Nickel Bound at Active Site
2PD8	;	1.8	;	1.8 Angstrom Crystal Structure of the Cys71Ser mutant of Vivid
6AU8	;	1.8	;	1.8 angstrom crystal structure of the human Bag6-NLS & TRC35 complex
3HJI	;	1.8	;	1.8 Angstrom Crystal Structure of the I74V:I85V Variant of Vivid (VVD).
4ME3	;	1.794	;	1.8 Angstrom Crystal Structure of the N-terminal Domain of an Archaeal MCM
4RO3	;	1.8	;	1.8 Angstrom Crystal Structure of the N-terminal Domain of Protein with Unknown Function from Vibrio cholerae.
3BS6	;	1.8	;	1.8 Angstrom crystal structure of the periplasmic domain of the membrane insertase YidC
4IUO	;	1.8	;	1.8 Angstrom Crystal Structure of the Salmonella enterica 3-Dehydroquinate Dehydratase (aroD) K170M Mutant in Complex with Quinate
3LLP	;	1.8	;	1.8 Angstrom human fascin 1 crystal structure
3QYQ	;	1.8	;	1.8 Angstrom resolution crystal structure of a putative deoxyribose-phosphate aldolase from Toxoplasma gondii ME49
3LV8	;	1.8	;	1.8 Angstrom resolution crystal structure of a thymidylate kinase (tmk) from Vibrio cholerae O1 biovar eltor str. N16961 in complex with TMP, thymidine-5'-diphosphate and ADP
6DT4	;	1.8	;	1.8 Angstrom Resolution Crystal Structure of cAMP-Regulatory Protein from Yersinia pestis in Complex with cAMP
3IJ3	;	1.8	;	1.8 Angstrom Resolution Crystal Structure of Cytosol Aminopeptidase from Coxiella burnetii
3N2B	;	1.8	;	1.8 Angstrom Resolution Crystal Structure of Diaminopimelate Decarboxylase (lysA) from Vibrio cholerae.
3JZE	;	1.8	;	1.8 Angstrom resolution crystal structure of dihydroorotase (pyrC) from Salmonella enterica subsp. enterica serovar Typhimurium str. LT2
5TRO	;	1.8	;	1.8 Angstrom Resolution Crystal Structure of Dimerization and Transpeptidase domains (residues 39-608) of Penicillin-Binding Protein 1 from Staphylococcus aureus.
3KQF	;	1.8	;	1.8 Angstrom Resolution Crystal Structure of Enoyl-CoA Hydratase from Bacillus anthracis.
3TE9	;	1.8	;	1.8 Angstrom Resolution Crystal Structure of K135M Mutant of Transaldolase B (TalA) from Francisella tularensis in Complex with Fructose 6-phosphate
3RU6	;	1.8	;	1.8 Angstrom resolution crystal structure of orotidine 5'-phosphate decarboxylase (pyrF) from Campylobacter jejuni subsp. jejuni NCTC 11168
4E0C	;	1.8	;	1.8 Angstrom Resolution Crystal Structure of Transaldolase from Francisella tularensis (phosphate-free)
6X1Q	;	1.8	;	1.8 Angstrom resolution structure of b-galactosidase with a 200 kV cryoARM electron microscope
6P7L	;	1.8	;	1.8 Angstrom structure of Aln2 from Streptomyces sp. CM020
8F49	;	1.8	;	1.8 angstrom structure of apoferritin embedded in crystalline ice
3NE4	;	1.81	;	1.8 Angstrom structure of intact native wild-type alpha-1-antitrypsin
1MI3	;	1.8	;	1.8 Angstrom structure of xylose reductase from Candida tenuis in complex with NAD
1HXN	;	1.8	;	1.8 ANGSTROMS CRYSTAL STRUCTURE OF THE C-TERMINAL DOMAIN OF RABBIT SERUM HEMOPEXIN
1TPH	;	1.8	;	1.8 ANGSTROMS CRYSTAL STRUCTURE OF WILD TYPE CHICKEN TRIOSEPHOSPHATE ISOMERASE-PHOSPHOGLYCOLOHYDROXAMATE COMPLEX
1GLP	;	1.9	;	1.8 ANGSTROMS MOLECULAR STRUCTURE OF MOUSE LIVER CLASS PI GLUTATHIONE S-TRANSFERASE COMPLEXED WITH S-(P-NITROBENZYL)GLUTATHIONE AND OTHER INHIBITORS
1GLQ	;	1.8	;	1.8 ANGSTROMS MOLECULAR STRUCTURE OF MOUSE LIVER CLASS PI GLUTATHIONE S-TRANSFERASE COMPLEXED WITH S-(P-NITROBENZYL)GLUTATHIONE AND OTHER INHIBITORS
3O76	;	1.77	;	1.8 Angstroms molecular structure of mouse liver glutathione S-transferase mutant C47A complexed with S-(P-nitrobenzyl)glutathione
1THG	;	1.8	;	1.8 ANGSTROMS REFINED STRUCTURE OF THE LIPASE FROM GEOTRICHUM CANDIDUM
8CLM	;	1.8	;	1.80 A crystal structure of RNA/2'-O-methyl-RNA heteroduplex
7RT0	;	1.8	;	1.80 A resolution structure of MAO from P. nicotinovorans in complex with FAD
6NLL	;	1.8	;	1.80 A resolution structure of WT BfrB from Pseudomonas aeruginosa in complex with a protein-protein interaction inhibitor (analog 14)
3VCZ	;	1.8	;	1.80 Angstrom resolution crystal structure of a putative translation initiation inhibitor from Vibrio vulnificus CMCP6
6W4H	;	1.8	;	1.80 Angstrom Resolution Crystal Structure of NSP16 - NSP10 Complex from SARS-CoV-2
3UWQ	;	1.8	;	1.80 Angstrom resolution crystal structure of orotidine 5'-phosphate decarboxylase from Vibrio cholerae O1 biovar eltor str. N16961 in complex with uridine-5'-monophosphate (UMP)
4IG2	;	1.8	;	1.80 Angstroms X-ray crystal structure of R51A and R239A heterodimer 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase from Pseudomonas fluorescens
4TOG	;	1.8	;	1.80A resolution structure of BfrB (C89S, K96C) crystal form 2 from Pseudomonas aeruginosa
5W38	;	1.8	;	1.80A resolution structure of human IgG3 Fc (N392K)
7KNF	;	1.8	;	1.80A resolution structure of independent Phosphoglycerate mutase from C. elegans in complex with a macrocyclic peptide inhibitor (Ce-1 NHOH)
4TOH	;	1.8	;	1.80A resolution structure of Iron Bound BfrB (C89S, K96C) from Pseudomonas aeruginosa
7SNW	;	1.8	;	1.80A Resolution Structure of NanoLuc Luciferase with Bound Inhibitor PC 16026576
4JM7	;	1.824	;	1.82 Angstrom resolution crystal structure of holo-(acyl-carrier-protein) synthase (acpS) from Staphylococcus aureus
6BZ0	;	1.83	;	1.83 Angstrom Resolution Crystal Structure of Dihydrolipoyl Dehydrogenase from Acinetobacter baumannii in Complex with FAD.
6AWA	;	1.83	;	1.83 Angstrom Resolution Crystal Structure of Dihydrolipoyl Dehydrogenase from Pseudomonas putida in Complex with FAD and Adenosine-5'-monophosphate.
6BK7	;	1.83	;	1.83 Angstrom Resolution Crystal Structure of N-terminal Fragment (residues 1-404) of Elongation Factor G from Enterococcus faecalis
7KOU	;	1.83	;	1.83 Angstroms Resolution Crystal Structure of Putative Pterin Binding Protein PruR (Atu3496) from Agrobacterium fabrum str. C58
3OYT	;	1.84	;	1.84 Angstrom resolution crystal structure of 3-oxoacyl-(acyl carrier protein) synthase I (fabB) from Yersinia pestis CO92
5WKL	;	1.85	;	1.85 A resolution structure of MERS 3CL protease in complex with piperidine-based peptidomimetic inhibitor 17
6W5H	;	1.85	;	1.85 A resolution structure of Norovirus 3CL protease in complex with inhibitor 5d
6W5J	;	1.85	;	1.85 A resolution structure of Norovirus 3CL protease in complex with inhibitor 7d
7K0G	;	1.85	;	1.85 A resolution structure of SARS-CoV 3CL protease in complex with deuterated GC376
6NLK	;	1.85	;	1.85 A resolution structure of WT BfrB from Pseudomonas aeruginosa in complex with a protein-protein interaction inhibitor (analog 13)
1ODO	;	1.85	;	1.85 A structure of CYP154A1 from Streptomyces coelicolor A3(2)
2ID9	;	1.75	;	1.85 A Structure of T87I/Y106W Phosphono-CheY
4MWA	;	1.85	;	1.85 Angstrom Crystal Structure of GCPE Protein from Bacillus anthracis
4YF1	;	1.85	;	1.85 angstrom crystal structure of lmo0812 from Listeria monocytogenes EGD-e
4EGD	;	1.85	;	1.85 Angstrom crystal structure of native hypothetical protein SAOUHSC_02783 from Staphylococcus aureus
3GC2	;	1.85	;	1.85 Angstrom Crystal Structure of O-succinylbenzoate Synthase from Salmonella typhimurium in Complex with Succinic Acid
4IR8	;	1.85	;	1.85 Angstrom Crystal Structure of Putative Sedoheptulose-1,7 bisphosphatase from Toxoplasma gondii
3L2I	;	1.85	;	1.85 Angstrom Crystal Structure of the 3-Dehydroquinate Dehydratase (aroD) from Salmonella typhimurium LT2.
1U6E	;	1.85	;	1.85 Angstrom Crystal Structure of the C112A Mutant of Mycobacterium Tuberculosis Beta-Ketoacyl-Acyl Carrier Protein Synthase III (FabH)
4EDP	;	1.85	;	1.85 Angstrom resolution crystal structure of an ABC transporter from Clostridium perfringens ATCC 13124
4QJE	;	1.85	;	1.85 Angstrom resolution crystal structure of apo betaine aldehyde dehydrogenase (betB) G234S mutant from Staphylococcus aureus (IDP00699) with BME-free sulfinic acid form of Cys289
4MPY	;	1.85	;	1.85 Angstrom resolution crystal structure of betaine aldehyde dehydrogenase (betB) from Staphylococcus aureus (IDP00699) in complex with NAD+
6UE2	;	1.85	;	1.85 Angstrom Resolution Crystal Structure of Class D beta-lactamase from Clostridium difficile 630
3QM3	;	1.85	;	1.85 Angstrom Resolution Crystal Structure of Fructose-bisphosphate Aldolase (Fba) from Campylobacter jejuni
6VBF	;	1.85	;	1.85 Angstrom Resolution Crystal Structure of N-terminal Domain of Two-component System Response Regulator from Acinetobacter baumannii
4MGE	;	1.85	;	1.85 Angstrom Resolution Crystal Structure of PTS System Cellobiose-specific Transporter Subunit IIB from Bacillus anthracis.
3IGX	;	1.85	;	1.85 Angstrom Resolution Crystal Structure of Transaldolase B (talA) from Francisella tularensis.
4WKQ	;	1.85	;	1.85 angstrom structure of EGFR kinase domain with gefitinib
3R2L	;	1.85	;	1.85A resolution structure of Iron Soaked FtnA from Pseudomonas aeruginosa (pH 7.5)
4XBB	;	1.85	;	1.85A resolution structure of Norovirus 3CL protease complex with a covalently bound dipeptidyl inhibitor diethyl [(1R,2S)-2-[(N-{[(3-chlorobenzyl)oxy]carbonyl}-3-cyclohexyl-L-alanyl)amino]-1-hydroxy-3-(2-oxo-2H-pyrrol-3-yl)propyl]phosphonate
4UY4	;	1.862	;	1.86 A structure of human Spindlin-4 protein in complex with histone H3K4me3 peptide
5YL9	;	1.861	;	1.86 Angstrom crystal structure of human Coronavirus 229E fusion core
6BLB	;	1.88	;	1.88 Angstrom Resolution Crystal Structure Holliday Junction ATP-dependent DNA Helicase (RuvB) from Pseudomonas aeruginosa in Complex with ADP
5V36	;	1.88	;	1.88 Angstrom Resolution Crystal Structure of Glutathione Reductase from Streptococcus mutans UA159 in Complex with FAD
4R7K	;	1.88	;	1.88 Angstrom Resolution Crystal Structure of Hypothetical Protein jhp0584 from Helicobacter pylori.
6D0P	;	1.88	;	1.88 Angstrom Resolution Crystal Structure of Quercetin 2,3-dioxygenase from Acinetobacter baumannii
4HSJ	;	1.883	;	1.88 angstrom x-ray crystal structure of piconlinic-bound 3-hydroxyanthranilate-3,4-dioxygenase
8TFG	;	1.88	;	1.88A CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS TOPOISOMERASE I
6ZNZ	;	1.89	;	1.89 A resolution 4-methylcatechol (4-methylbenzene-1,2-diol) inhibited Sporosarcina pasteurii urease
1XFK	;	1.8	;	1.8A crystal structure of formiminoglutamase from Vibrio cholerae O1 biovar eltor str. N16961
3T5N	;	1.787	;	1.8A crystal structure of Lassa virus nucleoprotein in complex with ssRNA
2BWM	;	1.8	;	1.8A CRYSTAL STRUCTURE OF of Psathyrella velutina LECTIN IN COMPLEX WITH METHYL 2-ACETAMIDO-1,2-DIDEOXY-1-SELENO-BETA-D-GLUCOPYRANOSIDE
2C25	;	1.8	;	1.8A Crystal Structure of Psathyrella velutina lectin in complex with N-acetylneuraminic acid
1HUQ	;	1.8	;	1.8A CRYSTAL STRUCTURE OF THE MONOMERIC GTPASE RAB5C (MOUSE)
2PST	;	1.8	;	1.8A Crystal Structure of the PA2412 protein from Pseudomonas aeruginosa
3QH6	;	1.8	;	1.8A resolution structure of CT296 from Chlamydia trachomatis
3R2M	;	1.8	;	1.8A resolution structure of Doubly Soaked FtnA from Pseudomonas aeruginosa (pH 7.5)
1LJ5	;	1.8	;	1.8A Resolution Structure of Latent Plasminogen Activator Inhibitor-1(PAI-1)
1IG1	;	1.8	;	1.8A X-Ray structure of ternary complex of a catalytic domain of death-associated protein kinase with ATP analogue and Mn.
1Y7P	;	1.9	;	1.9 A Crystal Structure of a Protein of Unknown Function AF1403 from Archaeoglobus fulgidus, Probable Metabolic Regulator
1T06	;	1.9	;	1.9 A Crystal Structure of a Protein of Unknown Function from Bacillus cereus ATCC 14579
4HJZ	;	1.9	;	1.9 A Crystal structure of E. coli MltE-E64Q with bound chitopentaose
6PUP	;	1.89	;	1.9 A crystal structure of flavodoxin-like domain of Schizosaccharomyces japonicus putative tRNAPhe 4-demethylwyosine synthase Tyw1 in complex with FMN
1VTO	;	1.9	;	1.9 A RESOLUTION REFINED STRUCTURE OF TBP RECOGNIZING THE MINOR GROOVE OF TATAAAAG
3NJ7	;	1.904	;	1.9 A resolution X-ray structure of (GGCAGCAGCC)2
1C4W	;	1.84	;	1.9 A STRUCTURE OF A-THIOPHOSPHONATE MODIFIED CHEY D57C
5K2C	;	1.9	;	1.9 angstrom A2a adenosine receptor structure with sulfur SAD phasing and phase extension using XFEL data
4FCU	;	1.9	;	1.9 Angstrom Crystal Structure of 3-deoxy-manno-octulosonate Cytidylyltransferase (kdsB) from Acinetobacter baumannii without His-Tag Bound to the Active Site
1O0E	;	1.9	;	1.9 Angstrom Crystal Structure of a plant cysteine protease Ervatamin C
2YHF	;	1.9	;	1.9 Angstrom Crystal Structure of CLEC5A
7PVA	;	1.91	;	1.9 Angstrom crystal structure of dimeric PorX, co-crystallized in the presence of zinc
3G25	;	1.9	;	1.9 Angstrom Crystal Structure of Glycerol Kinase (glpK) from Staphylococcus aureus in Complex with Glycerol.
5IKM	;	1.9	;	1.9 Angstrom Crystal Structure of NS5 Methyl Transferase from Dengue Virus 1 in Complex with S-Adenosylmethionine and Beta-D-Fructopyranose.
3MJD	;	1.9	;	1.9 Angstrom Crystal Structure of Orotate Phosphoribosyltransferase (pyrE) Francisella tularensis.
5IQJ	;	1.9	;	1.9 Angstrom Crystal Structure of Protein with Unknown Function from Vibrio cholerae.
4RCO	;	1.9	;	1.9 Angstrom Crystal Structure of Superantigen-like Protein, Exotoxin from Staphylococcus aureus, in Complex with Sialyl-LewisX.
3EIF	;	1.9	;	1.9 angstrom crystal structure of the active form of the C5a peptidase from Streptococcus pyogenes (ScpA)
1Z9O	;	1.9	;	1.9 Angstrom Crystal Structure of the Rat VAP-A MSP Homology Domain in Complex with the Rat ORP1 FFAT Motif
2AFQ	;	1.93	;	1.9 angstrom crystal structure of wild-type human thrombin in the sodium free state
4H47	;	1.9	;	1.9 angstrom CyPet structure at pH5.2
3HMQ	;	1.9	;	1.9 Angstrom resolution crystal structure of a NAD synthetase (nadE) from Salmonella typhimurium LT2 in complex with NAD(+)
2PNS	;	1.9	;	1.9 Angstrom resolution crystal structure of a plant cysteine protease Ervatamin-C refinement with cDNA derived amino acid sequence
6C4V	;	1.9	;	1.9 Angstrom Resolution Crystal Structure of Acyl Carrier Protein Domain (residues 1350-1461) of Polyketide Synthase Pks13 from Mycobacterium tuberculosis
6B8W	;	1.9	;	1.9 Angstrom Resolution Crystal Structure of Cupin_2 Domain (pfam 07883) of XRE Family Transcriptional Regulator from Enterobacter cloacae.
5U9C	;	1.9	;	1.9 Angstrom Resolution Crystal Structure of dTDP-4-dehydrorhamnose Reductase from Yersinia enterocolitica
5TU0	;	1.9	;	1.9 Angstrom Resolution Crystal Structure of Maltose-Binding Periplasmic Protein MalE from Listeria monocytogenes in Complex with Maltose
4EG9	;	1.9	;	1.9 Angstrom resolution crystal structure of Se-methionine hypothetical protein SAOUHSC_02783 from Staphylococcus aureus
3V85	;	1.9	;	1.9 Angstrom resolution crystal structure of the protein Q9SIY3 from Arabidopsis thaliana
1EQ6	;	1.9	;	1.9 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE RAN-BINDING PROTEIN MOG1P
4KMQ	;	1.9	;	1.9 Angstrom resolution crystal structure of uncharacterized protein lmo2446 from Listeria monocytogenes EGD-e
4KWU	;	1.9	;	1.9 Angstrom resolution crystal structure of uncharacterized protein lmo2446 from Listeria monocytogenes EGD-e in complex with alpha-D-glucose, beta-D-glucose, magnesium and calcium
1FAS	;	1.8	;	1.9 ANGSTROM RESOLUTION STRUCTURE OF FASCICULIN 1, AN ANTI-ACETYLCHOLINESTERASE TOXIN FROM GREEN MAMBA SNAKE VENOM
1XW6	;	1.9	;	1.9 angstrom resolution structure of human glutathione S-transferase M1A-1A complexed with glutathione
4WRG	;	1.9	;	1.9 angstrom structure of EGFR kinase domain
3FZI	;	1.9	;	1.9 Angstrom structure of the thermophilic exonuclease III homologue Mth0212
5UE0	;	1.9	;	1.90 A resolution structure of CT622 C-terminal domain from Chlamydia trachomatis
4MPO	;	1.9	;	1.90 A resolution structure of CT771 from Chlamydia trachomatis Bound to Hydrolyzed Ap4A Products
5T6F	;	1.9	;	1.90 A resolution structure of Norovirus 3CL protease in complex with the dipeptidyl inhibitor 7l (orthorhombic P form)
7K0E	;	1.9	;	1.90 A resolution structure of SARS-CoV-2 3CL protease in complex with deuterated GC376
6NLI	;	1.9	;	1.90 A resolution structure of WT BfrB from Pseudomonas aeruginosa in complex with a protein-protein interaction inhibitor (analog 11)
6NLM	;	1.9	;	1.90 A resolution structure of WT BfrB from Pseudomonas aeruginosa in complex with a protein-protein interaction inhibitor (analog 15)
7K5F	;	1.95	;	1.90 A resolution structure of WT BfrB from Pseudomonas aeruginosa in complex with a protein-protein interaction inhibitor KM-5-50
7K5H	;	1.9	;	1.90 A resolution structure of WT BfrB from Pseudomonas aeruginosa in complex with a protein-protein interaction inhibitor KM-5-66
6VPW	;	1.9	;	1.90 Angstrom Resolution Crystal Structure Chemotaxis protein CheX from Vibrio vulnificus
4Q92	;	1.9	;	1.90 Angstrom resolution crystal structure of apo betaine aldehyde dehydrogenase (betB) G234S mutant from Staphylococcus aureus (IDP00699) with BME-modified Cys289
4NEA	;	1.9	;	1.90 Angstrom resolution crystal structure of betaine aldehyde dehydrogenase (betB) from Staphylococcus aureus in complex with NAD+ and BME-free Cys289
6N7F	;	1.9	;	1.90 Angstrom Resolution Crystal Structure of Glutathione Reductase from Streptococcus pyogenes in Complex with FAD.
3TI2	;	1.9	;	1.90 Angstrom resolution crystal structure of N-terminal domain 3-phosphoshikimate 1-carboxyvinyltransferase from Vibrio cholerae
6VPU	;	1.9	;	1.90 Angstrom Resolution Crystal Structure Phosphoadenosine Phosphosulfate Reductase (CysH) from Vibrio vulnificus
5D8O	;	1.9	;	1.90A resolution structure of BfrB (wild-type, C2221 form) from Pseudomonas aeruginosa
6AW5	;	1.9	;	1.90A resolution structure of catechol O-methyltransferase (COMT) L136M (hexagonal form) from Nannospalax galili
7TL7	;	1.9	;	1.90A resolution structure of independent phosphoglycerate mutase from C. elegans in complex with a macrocyclic peptide inhibitor (Sa-D2)
4ROA	;	1.9	;	1.90A resolution structure of SRPN2 (S358W) from Anopheles gambiae
7OXS	;	1.91	;	1.91 A crystal structure of DNA/2'-O-methyl-RNA heteroduplex
4PYW	;	1.91	;	1.92 angstrom crystal structure of A1AT:TTAI ternary complex
3TU3	;	1.92	;	1.92 Angstrom resolution crystal structure of the full-length SpcU in complex with full-length ExoU from the type III secretion system of Pseudomonas aeruginosa
7DY0	;	1.93	;	1.93 A cryo-EM structure of streptavidin
7P6F	;	1.93	;	1.93 A resolution X-ray crystal structure of the transcriptional regulator SrnR from Streptomyces griseus
4RFB	;	1.93	;	1.93 Angstrom Crystal Structure of Superantigen-like Protein from Staphylococcus aureus in Complex with Sialyl-Lewis X.
5HL8	;	1.93	;	1.93 Angstrom resolution crystal structure of a pullulanase-specific type II secretion system integral cytoplasmic membrane protein GspL (C-terminal fragment; residues 309-397) from Klebsiella pneumoniae subsp. pneumoniae NTUH-K2044
6MUK	;	1.93	;	1.93 Angstrom Resolution Crystal Structure of Peptidase M23 from Neisseria gonorrhoeae.
4NPI	;	1.94	;	1.94 Angstroms X-ray crystal structure of NAD- and intermediate- bound alpha-aminomuconate-epsilon-semialdehyde dehydrogenase from Pseudomonas fluorescens
1O6Z	;	1.95	;	1.95 A resolution structure of (R207S,R292S) mutant of malate dehydrogenase from the halophilic archaeon Haloarcula marismortui (holo form)
3R2O	;	1.95	;	1.95 A resolution structure of As-Isolated FtnA from Pseudomonas aeruginosa (pH 6.0)
6VH0	;	1.95	;	1.95 A resolution structure of MERS 3CL protease in complex with inhibitor 6g
5WEJ	;	1.95	;	1.95 A resolution structure of Norovirus 3CL protease in complex with a dipeptidyl oxazolidinone-based inhibitor
5E0H	;	1.95	;	1.95 A resolution structure of Norovirus 3CL protease in complex with a triazole-based macrocyclic (18-mer) inhibitor
6BIB	;	1.95	;	1.95 A resolution structure of Norovirus 3CL protease in complex with a triazole-based macrocyclic inhibitor
6W5K	;	1.95	;	1.95 A resolution structure of Norovirus 3CL protease in complex with inhibitor 5g
7K5G	;	1.95	;	1.95 A resolution structure of WT BfrB from Pseudomonas aeruginosa in complex with a protein-protein interaction inhibitor KM-5-28
1SUG	;	1.95	;	1.95 A structure of apo protein tyrosine phosphatase 1B
6MPQ	;	1.95	;	1.95 Ang crystal structure of OXA-24/40 beta-lactamase in complex the inhibitor ETX2514
3NVT	;	1.95	;	1.95 Angstrom crystal structure of a bifunctional 3-deoxy-7-phosphoheptulonate synthase/chorismate mutase (aroA) from Listeria monocytogenes EGD-e
3TFC	;	1.95	;	1.95 Angstrom crystal structure of a bifunctional 3-deoxy-7-phosphoheptulonate synthase/chorismate mutase (aroA) from Listeria monocytogenes EGD-e in complex with phosphoenolpyruvate
1ZDE	;	1.95	;	1.95 Angstrom Crystal Structure of a dnaE Intein Precursor from Synechocystis Sp. Pcc 6803
3III	;	1.95	;	1.95 Angstrom Crystal Structure of CocE/NonD family hydrolase (SACOL2612) from Staphylococcus aureus
3HVU	;	1.95	;	1.95 Angstrom Crystal Structure of Complex of Hypoxanthine-Guanine Phosphoribosyltransferase from Bacillus anthracis with 2-(N-morpholino)ethanesulfonic acid (MES)
4JBE	;	1.95	;	1.95 Angstrom Crystal Structure of Gamma-glutamyl phosphate Reductase from Saccharomonospora viridis.
4H3D	;	1.95	;	1.95 Angstrom Crystal Structure of of Type I 3-Dehydroquinate Dehydratase (aroD) from Clostridium difficile with Covalent Modified Comenic Acid.
5T8K	;	1.95	;	1.95 Angstrom Crystal Structure of S-adenosylhomocysteinase from Cryptosporidium parvum in Complex with Adenine and NAD
3T4E	;	1.95	;	1.95 Angstrom Crystal Structure of Shikimate 5-dehydrogenase (AroE) from Salmonella enterica subsp. enterica serovar Typhimurium in Complex with NAD
5JVA	;	1.95	;	1.95 angstrom crystal structure of TAGRFP-T
4GUH	;	1.95	;	1.95 Angstrom Crystal Structure of the Salmonella enterica 3-Dehydroquinate Dehydratase (aroD) E86A Mutant in Complex with Dehydroshikimate (Crystal Form #2)
3IJ5	;	1.95	;	1.95 Angstrom Resolution Crystal Structure of 3-deoxy-D-manno-octulosonate 8-phosphate phosphatase from Yersinia pestis
4QYI	;	1.95	;	1.95 Angstrom resolution crystal structure of a hypoxanthine-guanine phosphoribosyltransferase (hpt-2) from Bacillus anthracis str. 'Ames Ancestor' with HEPES molecule in the active site
6DXN	;	1.95	;	1.95 Angstrom Resolution Crystal Structure of DsbA Disulfide Interchange Protein from Klebsiella pneumoniae.
3T41	;	1.95	;	1.95 Angstrom Resolution Crystal Structure of Epidermin Leader Peptide Processing Serine Protease (EpiP) S393A Mutant from Staphylococcus aureus
5UH0	;	1.95	;	1.95 Angstrom Resolution Crystal Structure of Fragment (35-274) of Membrane-bound Lytic Murein Transglycosylase F from Yersinia pestis.
4DB3	;	1.95	;	1.95 Angstrom Resolution Crystal Structure of N-acetyl-D-glucosamine kinase from Vibrio vulnificus.
6W75	;	1.951	;	1.95 Angstrom Resolution Crystal Structure of NSP10 - NSP16 Complex from SARS-CoV-2
5U47	;	1.95	;	1.95 Angstrom Resolution Crystal Structure of Penicillin Binding Protein 2X from Streptococcus thermophilus
5TXU	;	1.95	;	1.95 Angstrom Resolution Crystal Structure of Stage II Sporulation Protein D (SpoIID) from Clostridium difficile in Apo Conformation
5IQW	;	1.95	;	1.95A resolution structure of Apo HasAp (R33A) from Pseudomonas aeruginosa
4TOB	;	1.95	;	1.95A resolution structure of BfrB (Q151L) from Pseudomonas aeruginosa
5KGN	;	1.95	;	1.95A resolution structure of independent phosphoglycerate mutase from C. elegans in complex with a macrocyclic peptide inhibitor (2d)
7TL8	;	1.95	;	1.95A resolution structure of independent phosphoglycerate mutase from S. aureus in complex with a macrocyclic peptide inhibitor (Sa-D3)
4TOA	;	1.95	;	1.95A resolution structure of Iron Bound BfrB (N148L) from Pseudomonas aeruginosa
5IBO	;	1.95	;	1.95A resolution structure of NanoLuc luciferase
3INO	;	1.95	;	1.95A Resolution Structure of Protective Antigen Domain 4
5JVB	;	1.95	;	1.95A resolution structure of PtxB from Trichodesmium erythraeum IMS101 in complex with phosphite
1U18	;	1.96	;	1.96 A Crystal structure of H60C mutant of nitrophorin complexed with histamine
1M5W	;	1.96	;	1.96 A Crystal Structure of Pyridoxine 5'-Phosphate Synthase in Complex with 1-deoxy-D-xylulose phosphate
7VD8	;	1.96	;	1.96 A structure of human apoferritin obtained from Talos Arctica microscope
2I5N	;	1.96	;	1.96 A X-ray structure of photosynthetic reaction center from Rhodopseudomonas viridis:Crystals grown by microfluidic technique
4I3P	;	1.961	;	1.96 angstrom x-ray crystal structure of 3-hydroxyanthranilate-3,4-dioxygenase bound with 3-aminosalicylic acid from cupriavidus metallidurans
7KQ2	;	1.981	;	1.98 A resolution crystal structure of Group A Streptococcus H111A HupZ-V5-His6
4Q7F	;	1.98	;	1.98 Angstrom Crystal Structure of Putative 5'-Nucleotidase from Staphylococcus aureus in complex with Adenosine.
3O7M	;	1.98	;	1.98 Angstrom resolution crystal structure of a hypoxanthine-guanine phosphoribosyltransferase (hpt-2) from Bacillus anthracis str. 'Ames Ancestor'
6WKQ	;	1.98	;	1.98 Angstrom Resolution Crystal Structure of NSP16-NSP10 Heterodimer from SARS-CoV-2 in Complex with Sinefungin
5IWI	;	1.98	;	1.98A structure of GSK945237 with S.aureus DNA gyrase and singly nicked DNA
5NPK	;	1.98	;	1.98A STRUCTURE OF THIOPHENE1 WITH S.AUREUS DNA GYRASE AND DNA
4QFB	;	1.986	;	1.99 A resolution structure of SeMet-CT263 (MTAN) from Chlamydia trachomatis
3IMF	;	1.99	;	1.99 Angstrom resolution crystal structure of a short chain dehydrogenase from Bacillus anthracis str. 'Ames Ancestor'
5K2D	;	1.9	;	1.9A angstrom A2a adenosine receptor structure with MR phasing using XFEL data
1YDP	;	1.9	;	1.9A crystal structure of HLA-G
1R4V	;	1.9	;	1.9A crystal structure of protein AQ328 from Aquifex aeolicus
1SFL	;	1.9	;	1.9A Crystal structure of Staphylococcus aureus type I 3-dehydroquinase, apo form
1G6L	;	1.9	;	1.9A CRYSTAL STRUCTURE OF TETHERED HIV-1 PROTEASE
6XAF	;	1.968	;	1.9A crystal structure of the GTPase domain of Parkinson's disease-associated protein LRRK2 carrying R1398H
1XBW	;	1.9	;	1.9A Crystal Structure of the protein isdG from Staphylococcus aureus aureus, Structural genomics, MCSG
3ENK	;	1.9	;	1.9A crystal structure of udp-glucose 4-epimerase from burkholderia pseudomallei
3D03	;	1.9	;	1.9A structure of Glycerophoshphodiesterase (GpdQ) from Enterobacter aerogenes
1CE1	;	1.9	;	1.9A STRUCTURE OF THE THERAPEUTIC ANTIBODY CAMPATH-1H FAB IN COMPLEX WITH A SYNTHETIC PEPTIDE ANTIGEN
2P1Y	;	2.42	;	1.B2.D9, a bispecific alpha/beta TCR
8PYQ	;	1.4	;	10 micrometer HEWL crystals solved at room-temperature using fixed-target serial crystallography.
7Z04	;	7.5	;	10 mM Rb+ soak of beryllium fluoride inhibited Na+,K+-ATPase, E2-BeFx (rigid body model)
8A6D	;	1.8	;	10 picosecond light activated crystal structure of bovine rhodopsin in Lipidic Cubic Phase
1K43	;		;	10 Structure Ensemble of the 14-residue peptide RG-KWTY-NG-ITYE-GR (MBH12)
7VG4	;	2.77	;	10,5-methenyltetrahydrofolate cyclohydrolase from Methylobacterium extorquens AM1 strain
7VG5	;	2.25	;	10,5-methenyltetrahydrofolate cyclohydrolase from Methylobacterium extorquens AM1 with tetrahydrofolate
7PG7	;	1.51	;	10-decarboxylase TamK from Streptomyces tsukubaensis
8PDP	;	2.9	;	10-mer ring of HMPV N-RNA bound to the C-terminal region of P
8PDL	;	3.1	;	10-mer ring of human metapneumovirus (HMPV) N-RNA
2GPN	;	1.99	;	100 K STRUCTURE OF GLYCOGEN PHOSPHORYLASE AT 2.0 ANGSTROMS RESOLUTION
8A6E	;	1.8	;	100 picosecond light activated crystal structure of bovine rhodopsin in Lipidic Cubic Phase (SACLA)
4PSY	;	0.85	;	100K crystal structure of Escherichia coli dihydrofolate reductase
7BKS	;	1.24	;	100K endothiapepsin structure obtained in presence of 40 mM DMSO
5A90	;	1.7	;	100K Neutron Ligand Free: Exploring the Mechanism of beta-Lactam Ring Protonation in the Class A beta-lactamase Acylation Mechanism Using Neutron and X-ray Crystallography
4GCB	;	1.8	;	100K X-ray diffraction study of a 6-fold molar excess of a cisplatin/carboplatin mixture binding to HEWL
4G4H	;	2.0	;	100K X-ray diffraction study of carboplatin binding to HEWL in DMSO media after 13 months of crystal storage
6KMP	;	1.31	;	100K X-ray structure of HIV-1 protease triple mutant (V32I,I47V,V82I) with tetrahedral intermediate mimic KVS-1
5LSP	;	2.605	;	107_A07 Fab in complex with fragment of the Met receptor
7SFX	;	3.1	;	10A1 Fab in complex with CD99 peptide
7QA9	;		;	10bp DNA/DNA duplex
3BEW	;	2.6	;	10mer Crystal Structure of chicken MHC class I haplotype B21
6XE9	;	4.3	;	10S myosin II (smooth muscle)
2JSI	;		;	11-23 obestatin fragment in DPC/SDS micellar solution
6NJ7	;	2.6	;	11-BETA DEHYDROGENASE ISOZYME 1 IN COMPLEX WITH COLLETOIC ACID
4NMH	;	2.9	;	11-beta-HSD1 in complex with a 3,3-Di-methyl-azetidin-2-one
1FYI	;		;	11-MER DNA DUPLEX CONTAINING A 2'-DEOXYARISTEROMYCIN 8-OXO-GUANINE BASE PAIR;
8PDQ	;	3.1	;	11-mer ring of HMPV N-RNA bound to the C-terminal region of P
8PDM	;	3.3	;	11-mer ring of human metapneumovirus (HMPV) N-RNA
7BXV	;	1.75	;	11A1 antibody-peptide complex
4C7J	;	2.16	;	11b-Hydroxysteroid Dehydrogenase Type I in complex with inhibitor
4C7K	;	1.91	;	11b-Hydroxysteroid Dehydrogenase Type I in complex with inhibitor
4YYZ	;	3.2	;	11B-HYDROXYSTEROID DEHYDROGENASE TYPE I IN COMPLEX WITH INHIBITOR
3BEV	;	2.1	;	11mer Structure of an MHC class I molecule from B21 chickens illustrate promiscuous peptide binding
5WXU	;	1.7	;	11S globulin from Wrightia tinctoria reveals auxin binding site
7W05	;	1.29	;	12 mutant Ribonuclease from Hericium erinaceus GMP binding form
5U5Q	;	3.8	;	12 Subunit RNA Polymerase II at Room Temperature collected using SFX
1Q45	;	2.0	;	12-0xo-phytodienoate reductase isoform 3
1BSO	;	2.23	;	12-BROMODODECANOIC ACID BINDS INSIDE THE CALYX OF BOVINE BETA-LACTOGLOBULIN
8CTZ	;	2.32	;	12-mer DNA structure of ExBIM & O6Me-G bound to RNase-H
8CTY	;	2.3	;	12-mer DNA structure of ExBIM bound to RNase-H
8CU0	;	1.74	;	12-mer DNA structure of ExBIM bound to RNaseH -modified DDD
1RSX	;		;	12-mer from site II calbindin D9K (DKNGDGEVSFEE) coordinating Cd(II)
1RT0	;		;	12-mer from site II calbindin D9K (DKNGDGEVSFEE) coordinating Zn(II)
1RSW	;		;	12-mer from site II calbindin D9K (DKNGDGEVSFEE) coordination Pb(II)
6MRT	;	2.8	;	12-meric ClyA pore complex
8AUE	;	1.82	;	12-oxophytodienoate reductase 3 (OPR3) from Solanum lycopersicum in complex with 2-methoxyethyl (Z)-2-(hydroxyimino)-3-oxobutanoate
8AUA	;	1.9	;	12-oxophytodienoate reductase 3 (OPR3) from Solanum lycopersicum in complex with ethyl (Z)-2-(hydroxyimino)-3-oxobutanoate
8AUB	;	1.62	;	12-oxophytodienoate reductase 3 (OPR3) from Solanum lycopersicum in complex with ethyl (Z)-2-(hydroxyimino)-3-oxopentanoate
2B8K	;	4.15	;	12-subunit RNA Polymerase II
3FKI	;	3.88	;	12-Subunit RNA Polymerase II Refined with Zn-SAD data
6KJ3	;	0.6	;	120kV MicroED structure of FUS (37-42) SYSGYS solved from merged datasets at 0.60 A
6KJ4	;	0.65	;	120kV MicroED structure of FUS (37-42) SYSGYS solved from single crystal at 0.65 A
7AS5	;	9.8	;	126 helix bundle DNA nanostructure
3RYG	;	1.75	;	128 hours neutron structure of perdeuterated rubredoxin
5X04	;	2.43	;	12:0-ACP thioesterase from Umbellularia californica
1ZJE	;	2.1	;	12mer-spd
1ZJF	;	2.2	;	12mer-spd-P4N
2IWO	;	1.7	;	12th PDZ domain of Multiple PDZ Domain Protein MPDZ
2IWP	;	2.15	;	12th PDZ domain of Multiple PDZ Domain Protein MPDZ
2OTJ	;	2.9	;	13-deoxytedanolide bound to the large subunit of Haloarcula marismortui
6MRU	;	3.2	;	13-meric ClyA pore complex
6E7B	;	3.5	;	13-pf 3-start GMPCPP-human alpha1B/beta3 microtubules
2HSS	;		;	13mer duplex DNA containg an abasic site with beta anomer, averaged structure
2HPX	;		;	13mer Duplex DNA containing a 4'-oxidized abasic site, averaged structure
2HSR	;		;	13mer duplex DNA containing an abasic site with beta anomer
1ZJG	;	3.0	;	13mer-co
7SJ9	;	3.8	;	13pf E254A microtubule from recombinant human tubulin decorated with EB3
7SJ8	;	3.6	;	13pf wildtype microtubule from recombinant human tubulin decorated with kinesin
8DGM	;	3.2	;	14-3-3 epsilon bound to phosphorylated PEAK1 (pT1165) peptide
8DGN	;	3.16	;	14-3-3 epsilon bound to phosphorylated PEAK2 (pS826) peptide
8DGP	;	2.7	;	14-3-3 epsilon bound to phosphorylated PEAK3 (pS69) peptide
8C2D	;	2.15	;	14-3-3 in complex with Pyrin pS208
8C2Y	;	1.46	;	14-3-3 in complex with Pyrinp pS242
8C28	;	1.6	;	14-3-3 in complex with PyrinpS208pS242
7ZIT	;	1.79	;	14-3-3 in complex with SARS-COV2 N phospho-peptide
4BG6	;	2.3	;	14-3-3 interaction with Rnd3 prenyl-phosphorylation motif
4IEA	;	1.7	;	14-3-3 isoform sigma in complex with a phosphorylated C-RAF peptide
4FJ3	;	1.95	;	14-3-3 isoform zeta in complex with a diphoyphorylated C-RAF peptide
2BQ0	;	2.5	;	14-3-3 Protein Beta (Human)
2C23	;	2.65	;	14-3-3 Protein Beta (Human) in complex with exoenzyme S peptide
2BR9	;	1.75	;	14-3-3 Protein Epsilon (Human) Complexed to Peptide
2C63	;	2.15	;	14-3-3 Protein Eta (Human) Complexed to Peptide
2C74	;	2.7	;	14-3-3 Protein Eta (Human) Complexed to Peptide
6KZH	;	2.645	;	14-3-3 protein in Complex with CIC S173 phosphorylated peptide
6KZG	;	2.0	;	14-3-3 protein in Complex with CIC S301 phosphorylated peptide
4JC3	;	2.05	;	14-3-3 protein interaction with Estrogen Receptor Alpha provides a novel drug target interface
4JDD	;	2.1	;	14-3-3 protein interaction with Estrogen Receptor Alpha provides a novel drug target interface
5IQP	;	2.602	;	14-3-3 PROTEIN TAU ISOFORM
2BTP	;	2.8	;	14-3-3 Protein Theta (Human) Complexed to Peptide
1A37	;	3.6	;	14-3-3 PROTEIN ZETA BOUND TO PS-RAF259 PEPTIDE
1A38	;	3.35	;	14-3-3 PROTEIN ZETA BOUND TO R18 PEPTIDE
2V7D	;	2.5	;	14-3-3 protein zeta in complex with Thr758 phosphorylated integrin beta2 peptide
1A4O	;	2.8	;	14-3-3 PROTEIN ZETA ISOFORM
7AEW	;	1.2	;	14-3-3 sigma bound to bis-phosphorylated aminopeptidase N (APN, CD13) via canonical and non-canonical binding motifs
6XWD	;	1.6	;	14-3-3 sigma bound to canonical mono-phosphorylated aminopeptidase N (APN, CD13) binding motif
6TWZ	;	2.8	;	14-3-3 sigma complexed with a phosphorylated 16E6 peptide
6QZS	;	1.9	;	14-3-3 sigma in complex with FOXO1 pS256 peptide
6QZR	;	2.3	;	14-3-3 sigma in complex with FOXO1 pT24 peptide
6YR6	;	1.75	;	14-3-3 sigma in complex with hDM2-186 peptide
6YR7	;	2.105	;	14-3-3 sigma in complex with hDMX-342+367 peptide
6YR5	;	2.25	;	14-3-3 sigma in complex with hDMX-367 peptide
6Y1J	;	1.127	;	14-3-3 sigma in complex with IkappaBalpha pS63 peptide
6Y3S	;	1.95	;	14-3-3 Sigma in complex with phosphorylated (pS210) Gab2 peptide
6Y3R	;	1.5	;	14-3-3 Sigma in complex with phosphorylated (Thr391) Gab2 peptide
6Y3M	;	1.5	;	14-3-3 Sigma in complex with phosphorylated ATPase peptide
6Y3V	;	1.499	;	14-3-3 Sigma in complex with phosphorylated c-Jun peptide
6Y3O	;	1.5	;	14-3-3 Sigma in complex with phosphorylated CAMKK2 peptide
6Y8A	;	1.5	;	14-3-3 Sigma in complex with phosphorylated camkk2{pS511} peptide
6Y8B	;	1.54	;	14-3-3 Sigma in complex with phosphorylated caspase{pS139} peptide
6Y8D	;	1.51	;	14-3-3 Sigma in complex with phosphorylated caspase{pS164} peptide
6ZVE	;	2.51	;	14-3-3 Sigma in complex with phosphorylated Gab2pT391 peptide - 1h incubation
6ZVB	;	2.51	;	14-3-3 Sigma in complex with phosphorylated Gab2pT391 peptide - 24h incubation
6ZVC	;	2.51	;	14-3-3 Sigma in complex with phosphorylated Gab2pT391 peptide - 48h incubation
6ZVD	;	2.5	;	14-3-3 Sigma in complex with phosphorylated Gab2pT391 peptide - 96h incubation
6Y8E	;	1.42	;	14-3-3 Sigma in complex with phosphorylated MLF1 peptide
6Y40	;	1.75	;	14-3-3 Sigma in complex with phosphorylated PLN peptide
6Y44	;	1.71	;	14-3-3 Sigma in complex with phosphorylated SOS1 peptide
7AOG	;	1.5	;	14-3-3 sigma in complex with Pin1 binding site pS72
7AXN	;	1.4	;	14-3-3 sigma in complex with Pin1 binding site pS72 and covalently bound TCF521-026
6YIA	;	1.3	;	14-3-3 sigma in complex with SMAD2 pS465 peptide
6YIB	;	1.7	;	14-3-3 sigma in complex with SMAD3 pS423 peptide
6YIC	;	1.6	;	14-3-3 sigma in complex with SMAD4 pS403 peptide
5N75	;	1.803	;	14-3-3 sigma in complex with TAZ pS89 peptide
5N5R	;	1.801	;	14-3-3 sigma in complex with TAZ pS89 peptide and fragment NV1
5N5T	;	1.8	;	14-3-3 sigma in complex with TAZ pS89 peptide and fragment NV2
5N5W	;	1.37	;	14-3-3 sigma in complex with TAZ pS89 peptide and fragment NV3
3MHR	;	1.15	;	14-3-3 sigma in complex with YAP pS127-peptide
8ANB	;	1.64	;	14-3-3 sigma sirtuin-1 phospho-peptide complex
8ANC	;	1.11	;	14-3-3 sigma sirtuin-3 phospho-peptide complex
7NIX	;	1.9	;	14-3-3 sigma with AS160 binding site pT642
7NSV	;	1.33	;	14-3-3 sigma with p65 (RelA) binding site pS45 and covalently bound PC2046
8C3C	;	1.6	;	14-3-3 sigma with Pin1 binding site pS72 and bound Fusicoccin A
8C2G	;	1.6	;	14-3-3 sigma with Pin1 binding site pS72 and covalently bound CV1040
7NRK	;	1.75	;	14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1002F1
7NJ6	;	1.59	;	14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1005
7NJA	;	1.75	;	14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1006
7NJ8	;	1.8	;	14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1007
7NIG	;	1.9	;	14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1008
7BDT	;	1.75	;	14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1009
7BGW	;	1.9	;	14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1011
7BGV	;	1.683	;	14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1012
7AZ1	;	1.15	;	14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1013
7AZ2	;	1.081	;	14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1014
7BGR	;	1.8	;	14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1016
7BDP	;	1.75	;	14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1017
7BGQ	;	1.75	;	14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1019
7NRL	;	1.8	;	14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1032
7BG3	;	1.4	;	14-3-3 sigma with Pin1 binding site pS72 and covalently bound PC2046
7BFW	;	1.8	;	14-3-3 sigma with Pin1 binding site pS72 and covalently bound PC2068A
7BDY	;	1.801	;	14-3-3 sigma with Pin1 binding site pS72 and covalently bound PC2068B
7NIF	;	1.71	;	14-3-3 sigma with Pin1 binding site pS72 and covalently bound TCF521-011
7AYF	;	1.752	;	14-3-3 sigma with Pin1 binding site pS72 and covalently bound TCF521-110
6QHM	;	1.25	;	14-3-3 sigma with RelA/p65 binding site pS281
6QHL	;	1.2	;	14-3-3 sigma with RelA/p65 binding site pS45
7NQP	;	1.24	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound LvD1009
6YOW	;	1.23	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521
6YP2	;	1.8	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-011
6YOY	;	1.8	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-025
6YOX	;	2.05	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-027
6YP3	;	1.8	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-028
6YP8	;	1.8	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-033
6YPL	;	1.8	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-037
7O3Q	;	1.8	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-041
7O3R	;	1.8	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-042
7O34	;	1.2	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-043
7BJB	;	1.8	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-044
7O3S	;	2.0	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-045
7O3A	;	1.2	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-046
7BJF	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-069
7NMH	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-070
7O6K	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-080
7O6J	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-083
7O6I	;	1.8	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-085
7O6O	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-096
7O6M	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-097
7NM9	;	1.7	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-110
7NR7	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-111
7O3P	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-116
7O3F	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-117
7NLE	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-118
7NLA	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-119
7NZV	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-120
7NZK	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-121
7NZG	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-122
6YPY	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-123
7NK5	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-124
7NZ6	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-125
7NM1	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-126
7NYG	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-127
7NK3	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-128
6YQ2	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-129
7NY4	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-130
7NYF	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-131
7NJB	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-132
7NJ9	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-133
7NYE	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-134
7NM3	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-135
7BJL	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-142
7BKH	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-153
7BJW	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-154
7O57	;	1.4	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-157
7O5A	;	1.8	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-158
7O5C	;	1.8	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-159
7O5D	;	1.8	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-160
7O5F	;	1.8	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-161
7O5G	;	1.8	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-164
7O5O	;	1.8	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-165
7O5P	;	1.8	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-166
7O5S	;	1.8	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-167
7O5U	;	1.8	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-168
7O5X	;	1.8	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-173
7BIY	;	1.8	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-175
7O6G	;	1.8	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-176
7O6F	;	2.0	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-178
7BI3	;	1.2	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-179
7BIQ	;	1.2	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-180
7NXY	;	1.2	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-181
7NXW	;	1.2	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-182
7NXT	;	1.2	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-183
7NXS	;	1.2	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-184
7NWS	;	1.2	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-185
7NVI	;	1.2	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-186
7BIW	;	1.2	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-187
7NV4	;	1.2	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-188
7O59	;	1.2	;	14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-192
6NV2	;	1.13	;	14-3-3 sigma with RelA/p65 binding site pS45 in complex with DP005
6EF5	;	2.44	;	14-3-3 with peptide
6ZFD	;	1.9	;	14-3-3 zeta bound to the phosphorylated 18E6 C-terminus
6ZFG	;	1.85	;	14-3-3 zeta chimera with 18E6 and fusicoccin
6F08	;	1.9	;	14-3-3 zeta in complex with the human Son of sevenless homolog 1 (SOS1)
1QJB	;	2.0	;	14-3-3 ZETA/PHOSPHOPEPTIDE COMPLEX (MODE 1)
1QJA	;	2.0	;	14-3-3 ZETA/PHOSPHOPEPTIDE COMPLEX (MODE 2)
4O46	;	2.9	;	14-3-3-gamma in complex with influenza NS1 C-terminal tail phosphorylated at S228
4HKC	;	2.2	;	14-3-3-zeta in complex with S1011 phosphorylated integrin alpha-4 peptide
5NWI	;	2.35	;	14-3-3c in complex with CPP
5NWK	;	3.3	;	14-3-3c in complex with CPP and fusicoccin
5NWJ	;	2.07	;	14-3-3c in complex with CPP7
4J6S	;	3.08	;	14-3-3gamma complexed with the N-terminal sequence of tyrosine hydroxylase (residues 1-43)
7ZMW	;	1.8	;	14-3-3s binding to non-natural peptide 2c
7ZMU	;	1.6	;	14-3-3s binding to non-natural peptide 2d
8C40	;	1.4	;	14-3-3sigma bound to PKA-responsive ERa phosphopeptide
8C3Z	;	1.4	;	14-3-3sigma bound to strep-tagged PKA-responsive ERa phosphopeptide
7O07	;	1.2	;	14-3-3sigma covalently bound to peptide (chloroacetamide-Cys interaction)
6G8Q	;	1.85	;	14-3-3sigma in complex with a A130beta3A and Q133beta3Q mutated YAP pS127 phosphopeptide
6G8J	;	1.47	;	14-3-3sigma in complex with a A130beta3A mutated YAP pS127 phosphopeptide
6G8L	;	1.37	;	14-3-3sigma in complex with a L132beta3L mutated YAP pS127 phosphopeptide
6G8P	;	1.9	;	14-3-3sigma in complex with a P129beta3P and L132beta3L mutated YAP pS127 phosphopeptide
6G6X	;	1.13	;	14-3-3sigma in complex with a P129beta3P mutated YAP pS127 phosphopeptide
6G8I	;	1.6	;	14-3-3sigma in complex with a R124beta3R mutated YAP pS127 phosphopeptide
6G8K	;	1.25	;	14-3-3sigma in complex with a S131beta3S mutated YAP pS127 phosphopeptide
6GHP	;	1.95	;	14-3-3sigma in complex with a TASK3 peptide stabilized by semi-synthetic natural product FC-NAc
6YLU	;	1.88	;	14-3-3sigma in complex with BLNKpT152 phosphopeptide crystal structure
7B13	;	1.37	;	14-3-3sigma in complex with SHN3pS542 phosphopeptide crystal structure
7B15	;	1.59	;	14-3-3sigma in complex with SHN3pT869 phosphopeptide crystal structure
6ZCJ	;	1.53	;	14-3-3sigma in complex with SLP76pS376 phosphopeptide crystal structure
6MRW	;	4.3	;	14-meric ClyA pore complex
6E7C	;	3.65	;	14-pf 3-start GMPCPP-human alpha1B/beta2B microtubules
4P5T	;	3.263	;	14.C6 TCR complexed with MHC class II I-Ab/3K peptide
8GH7	;	1.75	;	142D6 bound to BIR3-XIAP
1B4L	;	1.8	;	15 ATMOSPHERE OXYGEN YEAST CU/ZN SUPEROXIDE DISMUTASE ROOM TEMPERATURE (298K) STRUCTURE
7LAF	;	2.44	;	15-lipoxygenase-2 loop mutant bound to imidazole-based inhibitor
3BPP	;	2.3	;	1510-N membrane protease K138A mutant specific for a stomatin homolog from Pyrococcus horikoshii
2DEO	;	3.0	;	1510-N membrane protease specific for a stomatin homolog from Pyrococcus horikoshii
3VIV	;	2.25	;	1510-N membrane-bound stomatin-specific protease K138A mutant in complex with a substrate peptide
3WG5	;	2.4	;	1510-N membrane-bound stomatin-specific protease K138A mutant in complex with a substrate peptide under heat treatment
6M4B	;	2.25	;	1510-N membrane-bound stomatin-specific protease S97A mutant
5A91	;	1.2	;	15K X-ray ligand free: Exploring the Mechanism of beta-Lactam Ring Protonation in the Class A beta-lactamase Acylation Mechanism Using Neutron and X-ray Crystallography
5A92	;	1.05	;	15K X-ray structure with Cefotaxime: Exploring the Mechanism of beta- Lactam Ring Protonation in the Class A beta-lactamase Acylation Mechanism Using Neutron and X-ray Crystallography
7MWG	;	3.5	;	16-nm repeat microtubule doublet
8EVG	;	2.75	;	162bp CX3CR1 nucleosome (further classified with better nucleosome end)
6LER	;	3.0	;	169 bp nucleosome harboring non-identical cohesive DNA termini.
6LAB	;	3.2	;	169 bp nucleosome, harboring cohesive DNA termini, assembled with linker histone H1.0
8KAE	;	3.18	;	16d-bound human SPNS2
8FEP	;	1.55	;	16mer self-complementary duplex RNA with two continuous native U:U pairs
8FER	;	1.54	;	16mer self-complementary duplex RNA with two continuous s(2)U:s(2)U pairs
8FEO	;	1.52	;	16mer self-complementary duplex RNA with two separated native U:U pairs
8FEQ	;	1.5	;	16mer self-complementary duplex RNA with two separated s(2)U:s(2)U pairs
1AT0	;	1.9	;	17-kDA fragment of hedgehog C-terminal autoprocessing domain
7UR8	;	1.5	;	170_h_ob, a small beta-barrel de novo designed protein
8GJM	;	2.8	;	17b10 fab in complex with full-length SARS-CoV-2 Spike G614 trimer
8GJN	;	3.6	;	17B10 fab in complex with up-RBD of SARS-CoV-2 Spike G614 trimer
3KLP	;	2.5	;	17beta-HSD1 in complex with A-diol
3KLM	;	1.7	;	17beta-HSD1 in complex with DHT
4WDT	;	1.5	;	17beta-HSD5 in complex with 2-nitro-5-(phenylsulfonyl)phenol
4WDW	;	1.94	;	17beta-HSD5 in complex with 3,6-dihydropyridin-1(2H)-yl(5-methyl-1H-indol-2-yl)methanone
4XVE	;	1.55	;	17beta-HSD5 in complex with 3-pentyl-2-[(pyridin-2-ylmethyl)sulfanyl]-7-(pyrrolidin-1-ylcarbonyl)quinazolin-4(3H)-one
4WDU	;	1.7	;	17beta-HSD5 in complex with 4-chloro-N-(4-chlorobenzyl)-5-nitro-1H-pyrazole-3-carboxamide
4XVD	;	2.81	;	17beta-HSD5 in complex with 4-nitro-2-({4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}methyl)phenol
4WDX	;	1.64	;	17beta-HSD5 in complex with [4-(2-hydroxyethyl)piperidin-1-yl](5-methyl-1H-indol-2-yl)methanone
6HNO	;	1.68	;	17beta-hydroxysteroid dehydrogenase 14 variant S205 - mutant H93A
6FFB	;	1.65	;	17beta-hydroxysteroid dehydrogenase 14 variant S205 - mutant Q148A - in complex with a nonsteroidal inhibitor
5O6O	;	1.45	;	17beta-hydroxysteroid dehydrogenase 14 variant T205 in complex with a non-steroidal 2,6-pyridinketone inhibitor
5O42	;	1.76	;	17beta-hydroxysteroid dehydrogenase 14 variant T205 in complex with a non-steroidal 2,6-pyridinketone inhibitor.
5O43	;	1.5	;	17beta-hydroxysteroid dehydrogenase 14 variant T205 in complex with a non-steroidal 2,6-pyridinketone inhibitor.
5L7T	;	1.983	;	17beta-hydroxysteroid dehydrogenase 14 variant T205 in complex with a non-steroidal inhibitor.
5L7W	;	1.76	;	17beta-hydroxysteroid dehydrogenase 14 variant T205 in complex with a non-steroidal inhibitor.
5L7Y	;	1.912	;	17beta-hydroxysteroid dehydrogenase 14 variant T205 in complex with a non-steroidal inhibitor.
5O6X	;	1.35	;	17beta-hydroxysteroid dehydrogenase 14 variant T205 in complex with a non-steroidal quinoline based inhibitor
5O6Z	;	1.57	;	17beta-hydroxysteroid dehydrogenase 14 variant T205 in complex with a non-steroidal quinoline based inhibitor
5O72	;	1.91	;	17beta-hydroxysteroid dehydrogenase 14 variant T205 in complex with a non-steroidal quinoline based inhibitor
5O7C	;	1.6	;	17beta-hydroxysteroid dehydrogenase 14 variant T205 in complex with a non-steroidal quinoline based inhibitor
6GTB	;	1.619	;	17beta-hydroxysteroid dehydrogenase 14 variant T205 in complex with FB211
6QCK	;	1.68	;	17beta-hydroxysteroid dehydrogenase 14 variant T205 in complex with FB262
6GTU	;	2.25	;	17beta-hydroxysteroid dehydrogenase 14 variant T205 in complex with fragment J6
6EMM	;	2.47	;	17beta-hydroxysteroid dehydrogenase 14 variant T205 in complex with Salicylic acid
5ICM	;	1.68	;	17beta-hydroxysteroid dehydrogenase type 14 in complex with a non-steroidal inhibitor
6H0M	;	1.25	;	17beta-hydroxysteroid dehydrogenase type 14 mutant K158A in complex with Nicotinamide Adenine Dinucleotide
6G4L	;	1.444	;	17beta-hydroxysteroid Dehydrogenase Type 14 Mutant Y253A in Complex With a Non-steroidal Inhibitor
6GBT	;	2.1	;	17beta-hydroxysteroid dehydrogenase type 14 Mutant Y253A in complex with a non-steroidal inhibitor
6ZDI	;	2.13	;	17beta-hydroxysteroid dehydrogenase type 14 variant S205 in complex with 2-fluoro-5-nitrophenol
6ZRA	;	1.73	;	17beta-hydroxysteroid dehydrogenase type 14 variant S205 in complex with 2-fluoro-5-nitrophenol
6ZT2	;	1.95	;	17beta-hydroxysteroid dehydrogenase type 14 variant S205 in complex with 3-chloro-2,6-difluorophenol
6ZR6	;	1.5	;	17beta-hydroxysteroid dehydrogenase type 14 variant S205 in complex with non-steroidal inhibitor
6ZDE	;	1.87	;	17beta-hydroxysteroid dehydrogenase type 14 variant S205 in complex with pentafluorophenol
3HB4	;	2.21	;	17beta-hydroxysteroid dehydrogenase type1 complexed with E2B
3KM0	;	2.3	;	17betaHSD1 in complex with 3beta-diol
7UR7	;	1.21	;	17_bp_sh3, a small beta-barrel de novo designed protein
1GV8	;	1.95	;	18 kDa fragment of N-II domain of duck ovotransferrin
1ZNT	;		;	18 NMR structures of AcAMP2-Like Peptide with non Natural Fluoroaromatic Residue (AcAMP2F18Pff/Y20Pff) complex with N,N,N-triacetylchitotriose
1NP8	;	2.0	;	18-k C-terminally trunucated small subunit of calpain
7M20	;	3.84	;	18-mer HeLa-tubulin rings in complex with Cryptophycin 1
8AKQ	;	4.1	;	180 A SynPspA rod after incubation with ATP
1GVC	;	1.9	;	18kDa N-II domain fragment of duck ovotransferrin + NTA
8Q2M	;	3.21	;	18mer DNA mimic Foldamer with an Aliphatic linker in complex with Sac7d V26A/M29A protein
8CMN	;	2.65	;	18mer DNA mimic Foldamer with an aliphatic linker in complex with Sac7d wild protein
8QPC	;	3.24	;	18mer DNA mimic Foldamer with an Aromatic linker in complex with Sac7d V26A/M29A protein
1RUZ	;	2.9	;	1918 H1 Hemagglutinin
7NHA	;	2.91	;	1918 H1N1 Viral influenza polymerase heterotrimer - Endonuclease and priming loop ordered (Class2a)
7NHC	;	2.87	;	1918 H1N1 Viral influenza polymerase heterotrimer - Endonuclease ordered (Class2b)
7NHX	;	3.23	;	1918 H1N1 Viral influenza polymerase heterotrimer - full transcriptase (Class1)
7NI0	;	3.32	;	1918 H1N1 Viral influenza polymerase heterotrimer - Replicase (class 3)
7NIK	;	6.2	;	1918 H1N1 Viral influenza polymerase heterotrimer with Nb8189 core
7NIL	;	5.01	;	1918 H1N1 Viral influenza polymerase heterotrimer with Nb8190 core
7NIR	;	6.7	;	1918 H1N1 Viral influenza polymerase heterotrimer with Nb8191 core
7NIS	;	5.96	;	1918 H1N1 Viral influenza polymerase heterotrimer with Nb8192 core
7NJ3	;	4.48	;	1918 H1N1 Viral influenza polymerase heterotrimer with Nb8196 core
7NJ4	;	5.84	;	1918 H1N1 Viral influenza polymerase heterotrimer with Nb8198 core
7NJ5	;	4.63	;	1918 H1N1 Viral influenza polymerase heterotrimer with Nb8199 core
7NJ7	;	4.82	;	1918 H1N1 Viral influenza polymerase heterotrimer with Nb8200 core
7NK2	;	4.84	;	1918 H1N1 Viral influenza polymerase heterotrimer with Nb8202 core
7NK4	;	5.32	;	1918 H1N1 Viral influenza polymerase heterotrimer with Nb8203 core
7NK6	;	6.72	;	1918 H1N1 Viral influenza polymerase heterotrimer with Nb8204
7NK8	;	5.34	;	1918 H1N1 Viral influenza polymerase heterotrimer with Nb8205 core
7NKA	;	4.07	;	1918 H1N1 Viral influenza polymerase heterotrimer with Nb8206
7NKC	;	4.46	;	1918 H1N1 Viral influenza polymerase heterotrimer with Nb8207
7NKI	;	4.67	;	1918 H1N1 Viral influenza polymerase heterotrimer with Nb8209 core
7NKR	;	5.6	;	1918 H1N1 Viral influenza polymerase heterotrimer with Nb8210
8R60	;	3.23	;	1918 H1N1 Viral polymerase heterotrimer in complex with 4 repeat serine-5 phosphorylated PolII peptide
8R65	;	4.23	;	1918 H1N1 Viral polymerase heterotrimer in complex with 4 repeat serine-5 phosphorylated PolII peptide with ordered PB2 C-terminal domains
7NK1	;	4.22	;	1918 Influenza virus polymerase heterotirmer in complex with vRNA promoters and Nb8201
1RVT	;	2.5	;	1930 H1 Hemagglutinin in complex with LSTC
1RUY	;	2.7	;	1930 Swine H1 Hemagglutinin
1RV0	;	2.5	;	1930 Swine H1 Hemagglutinin complexed with LSTA
1RVX	;	2.2	;	1934 H1 Hemagglutinin in complex with LSTA
1RVZ	;	2.25	;	1934 H1 Hemagglutinin in complex with LSTC
1RU7	;	2.3	;	1934 Human H1 Hemagglutinin
7JO9	;	3.3	;	1:1 cGAS-nucleosome complex
1FYH	;	2.04	;	1:1 COMPLEX BETWEEN AN INTERFERON GAMMA SINGLE-CHAIN VARIANT AND ITS RECEPTOR
1HWH	;	2.9	;	1:1 COMPLEX OF HUMAN GROWTH HORMONE MUTANT G120R WITH ITS SOLUBLE BINDING PROTEIN
8S9P	;	3.8	;	1:1:1 agrin/LRP4/MuSK complex
1HWG	;	2.5	;	1:2 COMPLEX OF HUMAN GROWTH HORMONE WITH ITS SOLUBLE BINDING PROTEIN
1EN3	;	0.985	;	1A CRYSTAL STRUCTURES OF B-DNA REVEAL SEQUENCE-SPECIFIC BINDING AND GROOVE-SPECIFIC BENDING OF DNA BY MAGNESIUM AND CALCIUM
1EN9	;	0.985	;	1A CRYSTAL STRUCTURES OF B-DNA REVEAL SEQUENCE-SPECIFIC BINDING AND GROOVE-SPECIFIC BENDING OF DNA BY MAGNESIUM AND CALCIUM.
1ENE	;	0.985	;	1A CRYSTAL STRUCTURES OF B-DNA REVEAL SEQUENCE-SPECIFIC BINDING AND GROOVE-SPECIFIC BENDING OF DNA BY MAGNESIUM AND CALCIUM.
5MX7	;	1.98	;	1a,20S-dihydroxyvitamin D3 VDR complex
2B5R	;	1.65	;	1B Lactamase / B Lactamase Inhibitor
1S0W	;	2.3	;	1b Lactamse/ b Lactamase Inhibitor
6L9L	;	2.399	;	1D4 TCR recognition of H2-Ld a1a2 A5 Peptide Complexes
5HYJ	;	3.06	;	1E6 TCR in Complex with HLA-A02 carrying AQWGPDPAAA
5C0A	;	2.46	;	1E6 TCR in complex with HLA-A02 carrying MVW peptide
5C0B	;	2.03	;	1E6 TCR in complex with HLA-A02 carrying RQFGPDFPTI
5C0C	;	1.974	;	1E6 TCR in complex with HLA-A02 carrying RQFGPDWIVA
5C07	;	2.11	;	1E6 TCR in complex with HLA-A02 carrying YQFGPDFPIA
5C08	;	2.332	;	1E6 TCR in Complex with HLA-A0e carrying RQWGPDPAAV
3UTP	;	2.574	;	1E6 TCR specific for HLA-A*0201-ALWGPDPAAA
3UTS	;	2.712	;	1E6-A*0201-ALWGPDPAAA Complex, Monoclinic
3UTT	;	2.6	;	1E6-A*0201-ALWGPDPAAA Complex, Triclinic
3MFF	;	2.0	;	1F1E8hu TCR
8CT6	;	3.1	;	1F8 mAb in complex with the computationally optimized broadly reactive H1 influenza hemagglutinin P1
1SRL	;		;	1H AND 15N ASSIGNMENTS AND SECONDARY STRUCTURE OF THE SRC SH3 DOMAIN
1SRM	;		;	1H AND 15N ASSIGNMENTS AND SECONDARY STRUCTURE OF THE SRC SH3 DOMAIN
2LCN	;		;	1H and 15N assignments of WALP19-P10 peptide in SDS micelles
2LCO	;		;	1H and 15N assignments of WALP19-P8 peptide in SDS micelles
1DOX	;		;	1H AND 15N SEQUENTIAL ASSIGNMENT, SECONDARY STRUCTURE AND TERTIARY FOLD OF [2FE-2S] FERREDOXIN FROM SYNECHOCYSTIS SP. PCC 6803
1DOY	;		;	1H AND 15N SEQUENTIAL ASSIGNMENT, SECONDARY STRUCTURE AND TERTIARY FOLD OF [2FE-2S] FERREDOXIN FROM SYNECHOCYSTIS SP. PCC 6803
2L1J	;		;	1H assignments for ASIP(93-126, P103A, P105A, P111A, Q115Y, S124Y)
2LDJ	;		;	1H Chemical Shift Assignments and structure of Trp-Cage mini-protein with D-amino acid
2LR5	;		;	1H chemical shift assignments for micasin
2LS2	;		;	1H Chemical Shift Assignments for the first transmembrane domain from human copper transport 1
2LS3	;		;	1H Chemical Shift Assignments for the secondary transmembrane domain from human copper transport 1
2LS4	;		;	1H Chemical Shift Assignments for the third transmembrane domain from the human copper transport 1
1BJ6	;		;	1H NMR OF (12-53) NCP7/D(ACGCC) COMPLEX, 10 STRUCTURES
1DF6	;		;	1H NMR SOLUTION STRUCTURE OF CYCLOVIOLACIN O1
1Q3M	;		;	1H NMR structure bundle of bovine Ca2+-osteocalcin
1ORL	;		;	1H NMR structure determination of Viscotoxin C1
1Y9O	;		;	1H NMR Structure of Acylphosphatase from the hyperthermophile Sulfolobus Solfataricus
1MMC	;		;	1H NMR STUDY OF THE SOLUTION STRUCTURE OF AC-AMP2
2M74	;		;	1H, 13C and 15N assignments of the four N-terminal domains of human fibrillin-1
2KWA	;		;	1H, 13C and 15N backbone and side chain resonance assignments of the N-terminal domain of the histidine kinase inhibitor KipI from Bacillus subtilis
2N8A	;		;	1H, 13C and 15N chemical shift assignments and solution structure for PARP-1 F1F2 domains in complex with a DNA single-strand break
2M64	;		;	1H, 13C and 15N Chemical Shift Assignments for Phl p 5a
2MF4	;		;	1H, 13C, 15N chemical shift assignments of Streptomyces virginiae VirA acp5a
2MZY	;		;	1H, 13C, and 15N Chemical Shift Assignments and structure of Probable Fe(2+)-trafficking protein from Burkholderia pseudomallei 1710b.
2MUK	;		;	1H, 13C, and 15N Chemical Shift Assignments for AUX/IAA17
2N9K	;		;	1H, 13C, and 15N Chemical Shift Assignments for in vitro GB1
2N9L	;		;	1H, 13C, and 15N Chemical Shift Assignments for in-cell GB1
2KXC	;		;	1H, 13C, and 15N Chemical Shift Assignments for IRTKS-SH3 and EspFu-R47 complex
2RS2	;		;	1H, 13C, and 15N Chemical Shift Assignments for Musashi1 RBD1:r(GUAGU) complex
2MNQ	;		;	1H, 13C, and 15N Chemical Shift Assignments for Thymosin alpha 1
2LI6	;		;	1H, 13C, and 15N Chemical Shift Assignments for yeast protein
2L07	;		;	1H, 13C, and 15N chemical shifts and structure of brazzein-derived peptide CKR-PNG
2K0A	;		;	1H, 15N and 13C chemical shift assignments for Rds3 protein
1ESX	;		;	1H, 15N AND 13C STRUCTURE OF THE HIV-1 REGULATORY PROTEIN VPR : COMPARISON WITH THE N-AND C-TERMINAL DOMAIN STRUCTURE, (1-51)VPR AND (52-96)VPR
2KYQ	;		;	1H, 15N, 13C chemical shifts and structure of CKR-brazzein
2LX2	;		;	1H,13C,15N assignments for an isoform of the type III antifreeze protein from notched-fin eelpout
2LX3	;		;	1H,13C,15N assignments for an isoform of the type III antifreeze protein from notched-fin eelpout
2AIH	;		;	1H-NMR solution structure of a trypsin/chymotrypsin Bowman-Birk inhibitor from Lens culinaris.
1G47	;		;	1ST LIM DOMAIN OF PINCH PROTEIN
8THA	;	1.68	;	1TEL, non-compressed, double-helical crystal form
6RO5	;	1.68	;	1Yr-Y: Lysozyme with Re Cluster 1 year on shelf
2J9V	;	2.0	;	2 Angstrom X-ray structure of the yeast ESCRT-I Vps28 C-terminus
2J9U	;	2.0	;	2 Angstrom X-ray structure of the yeast ESCRT-I Vps28 C-terminus in complex with the NZF-N domain from ESCRT-II
3ETO	;	2.0	;	2 Angstrom Xray structure of the NOTCH1 Negative Regulatory Region (NRR)
8GXW	;	2.7	;	2 ATP-bound V1EG of V/A-ATPase from Thermus thermophilus
2W52	;	1.56	;	2 beta-glucans (6-O-glucosyl-laminaritriose) in both donor and acceptor sites of GH16 Laminarinase 16A from Phanerochaete chrysosporium.
5U52	;	1.942	;	2 helix minimized version of the B-domain from Protein A (Z34C0 bound to IgG1 Fc (monoclinic form)
6GKC	;	1.97	;	2 minute Fe2+ soak structure of SynFtn
7PFH	;	1.5	;	2 minute Fe2+ soak structure of SynFtn E141D
6SON	;	1.6	;	2 minute Fe2+ soak structure of SynFtn variant D137A
7PFB	;	1.7	;	2 minute Fe2+ soaked structure of SynFtn Variant D65A
7PFG	;	1.8	;	2 minute Fe2+ soaked structure of SynFtn Variant E141A
6SOQ	;	1.67	;	2 minute Fe2+ soaked structure of SynFtn variant E62A
8GXY	;	2.8	;	2 sulfate-bound V1EG of V/A-ATPase from Thermus thermophilus.
4A3H	;	1.65	;	2',4' DINITROPHENYL-2-DEOXY-2-FLURO-B-D-CELLOBIOSIDE COMPLEX OF THE ENDOGLUCANASE CEL5A FROM BACILLUS AGARADHAERENS AT 1.6 A RESOLUTION
1BHR	;		;	2'-DEOXY-ISOGUANOSINE BASE PAIRED TO THYMIDINE, NMR, MINIMIZED AVERAGE STRUCTURE
7KUN	;	1.58	;	2'-F modification at 3' end of RNA primer complex with guanosine dinucleotide ligand G(5')ppp(5')G
6TC8	;		;	2'-F-arabinoguanosine and 2'-F-riboguanosine modified hybrid type G-quadruplex with V-loop
6TCG	;		;	2'-F-riboguanosine and 2'-F-arabinoguanosine modified G-quadruplex with V-loop and all-syn G-tract
6YCV	;		;	2'-F-riboguanosine and LNA modified hybrid type G-quadruplex with V-loop
6RS3	;		;	2'-F-riboguanosine modified G-quadruplex with V-loop
6HUR	;	1.297	;	2'-fucosyllactose and 3-fucosyllactose binding protein from Bifidobacterium longum infantis, bound with 2'-fucosyllactose
6HUS	;	1.409	;	2'-fucosyllactose and 3-fucosyllactose binding protein from Bifidobacterium longum infantis, bound with 3-fucosyllactose
2DLJ	;	1.5	;	2'-Me-Se and Br Derivitation of A-DNA Octamer G(UMS)G(BRU)ACAC
2GPX	;	1.6	;	2'-Me-Se and Br Derivitation of A-DNA Octamer G(UMS)G(BRU)ACAC
1Z7I	;	1.28	;	2'-Me-Se Derivitation of A-DNA Octamer G(UMSe)GTACAC
7KUP	;	1.44	;	2'-OMe modification at 3' end of RNA primer complex with guanosine dinucleotide ligand G(5')ppp(5')G
2HC7	;	1.4	;	2'-selenium-T A-DNA [G(TSe)GTACAC]
3IFF	;	1.75	;	2'-SeMe-A modified DNA decamer
3IFI	;	1.2	;	2'-SeMe-dG modified octamer DNA
4NLF	;	1.0	;	2'-trifluoromethylthio-2'-deoxycytidine-modified SRL
4NMG	;	1.01	;	2'-Trifluoromethylthio-2'-deoxyuridine-modified SRL
4NXH	;	1.158	;	2'-Trifluoromethylthiouridine-modified E. coli 23S rRNA Sarcin Ricin Loop
5OV2	;		;	2'F-ANA-G modified quadruplex with a flipped tetrad
2M8A	;		;	2'F-ANA/2'F-RNA alternated sequences
5MJX	;		;	2'F-ANA/DNA Chimeric TBA Quadruplex structure
6F4Z	;		;	2'F-araG modified quadruplex with flipped G-tract and central tetrad
3P4A	;	1.2	;	2'Fluoro modified RNA octamer fA2U2
7A19	;	1.21	;	2,3-Dihydroxybenzoate Decarboxylase of Aspergillus oryzae
7A1A	;	1.53	;	2,3-Dihydroxybenzoate Decarboxylase of Aspergillus oryzae
1EIL	;	2.0	;	2,3-DIHYDROXYBIPHENYL-1,2-DIOXYGENASE
1EIQ	;	2.0	;	2,3-DIHYDROXYBIPHENYL-1,2-DIOXYGENASE
1EIR	;	2.0	;	2,3-DIHYDROXYBIPHENYL-1,2-DIOXYGENASE
4G5E	;	2.5	;	2,4,6-Trichlorophenol 4-monooxygenase
6P8C	;	2.07	;	2,5-diamino-6-(ribosylamino)-4(3H)-pyrimidinone 5'-phosphate reductase (MthRED) from Methanothermobacter thermautotrophicus
7CN3	;	2.2	;	2,5-dihydroxypridine Dioxygenase in complex with 2,5-dihydroxypridine and product N-formylmaleamic acid
4HUZ	;	2.6	;	2,6-Dichloro-p-hydroquinone 1,2-Dioxygenase
2RB0	;	1.84	;	2,6-difluorobenzylbromide complex with T4 lysozyme L99A
4JPG	;	2.33	;	2-((1H-benzo[d]imidazol-1-yl)methyl)-4H-pyrido[1,2-a]pyrimidin-4-ones as Novel PKM2 Activators
2R2M	;	2.1	;	2-(2-Chloro-6-Fluorophenyl)Acetamides as Potent Thrombin Inhibitors
4TPP	;	2.65	;	2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors
4W9S	;	1.8	;	2-(4-(1H-tetrazol-5-yl)phenyl)-5-hydroxypyrimidin-4(3H)-one bound to influenza 2009 H1N1 endonuclease
2RBP	;	1.467	;	2-(n-propylthio)ethanol in complex with T4 lysozyme L99A/M102Q
3BYZ	;	2.69	;	2-Amino-1,3-thiazol-4(5H)-ones as Potent and Selective 11-Hydroxysteroid Dehydrogenase Type 1 Inhibitors
1FC4	;	2.0	;	2-AMINO-3-KETOBUTYRATE COA LIGASE
7BXP	;	1.8	;	2-amino-3-ketobutyrate CoA ligase from Cupriavidus necator
7BXR	;	2.55	;	2-amino-3-ketobutyrate CoA ligase from Cupriavidus necator 3-Hydroxynorvaline binding form
7BXS	;	2.5	;	2-amino-3-ketobutyrate CoA ligase from Cupriavidus necator glycine binding form
7BXQ	;	2.49	;	2-amino-3-ketobutyrate CoA ligase from Cupriavidus necator L-Threonine binding form
7E7G	;	2.35	;	2-aminoethylphosphonate:pyruvate aminotransferase (AEPT) native
2KUZ	;		;	2-Aminopurine incorporation perturbs the dynamics and structure of DNA
2KV0	;		;	2-Aminopurine incorporation perturbs the dynamics and structure of DNA
3IO7	;	2.6	;	2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2
3IOK	;	2.1	;	2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2
7YEP	;	2.83	;	2-APB bound state of mTRPV2
4TWC	;	1.7	;	2-Benzamido-N-(1H-benzo[d]imidazol-2-yl)thiazole-4- carboxamide derivatives as potent inhibitors of CK1d/e
3GHZ	;	2.03	;	2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Salmonella typhimurium
1DXE	;	1.8	;	2-dehydro-3-deoxy-galactarate aldolase from Escherichia coli
1DXF	;	2.6	;	2-dehydro-3-deoxy-galactarate aldolase from Escherichia coli in complex with pyruvate
1E4I	;	2.0	;	2-deoxy-2-fluoro-beta-D-glucosyl/enzyme intermediate complex of the beta-glucosidase from Bacillus polymyxa
5A3H	;	1.82	;	2-DEOXY-2-FLURO-B-D-CELLOBIOSYL/ENZYME INTERMEDIATE COMPLEX OF THE ENDOGLUCANASE CEL5A FROM BACILLUS AGARADHEARANS AT 1.8 ANGSTROMS RESOLUTION
1H11	;	1.08	;	2-DEOXY-2-FLURO-B-D-CELLOTRIOSYL/ENZYME INTERMEDIATE COMPLEX OF THE ENDOGLUCANASE CEL5A FROM BACILLUS AGARADHEARANS AT 1.08 ANGSTROM RESOLUTION
6A3H	;	1.68	;	2-DEOXY-2-FLURO-B-D-CELLOTRIOSYL/ENZYME INTERMEDIATE COMPLEX OF THE ENDOGLUCANASE CEL5A FROM BACILLUS AGARADHEARANS AT 1.6 ANGSTROM RESOLUTION
6QUD	;	2.1	;	2-deoxy-galactose reaction intermediate of a Truncated beta-galactosidase III from Bifidobacterium bifidum
6X95	;	1.1	;	2-deoxy-glucose-bound structure of Marinomonas primoryensis PA14 carbohydrate-binding domain
4XBK	;	1.951	;	2-deoxyribose-5-phosphate aldolase from Lactobacillus brevis
4XBS	;	2.17	;	2-deoxyribose-5-phosphate aldolase mutant - E78K
6X9P	;	1.0	;	2-deoxyribose-bound structure of Marinomonas primoryensis PA14 carbohydrate-binding domain
6QAI	;	1.66	;	2-desoxiribosyltransferase from Leishmania mexicana
1DUB	;	2.5	;	2-ENOYL-COA HYDRATASE, DATA COLLECTED AT 100 K, PH 6.5
3HTG	;	1.26	;	2-ethoxy-3,4-dihydro-2h-pyran in complex with T4 lysozyme L99A/M102Q
2RB1	;	1.7	;	2-ethoxyphenol in complex with T4 lysozyme L99A
3HU8	;	1.8	;	2-ethoxyphenol in complex with T4 lysozyme L99A/M102Q
3HT7	;	1.7	;	2-ethylphenol in complex with T4 lysozyme L99A/M102Q
1E70	;	1.65	;	2-F-glucosylated MYROSINASE FROM SINAPIS ALBA
1E73	;	1.5	;	2-F-glucosylated MYROSINASE FROM SINAPIS ALBA with bound L-ascorbate
7DNH	;	3.64	;	2-fold subparticles refinement of human papillomavirus type 58 pseudovirus in complexed with the Fab fragment of 2H3
7DNK	;	6.41	;	2-fold subparticles refinement of human papillomavirus type 58 pseudovirus in complexed with the Fab fragment of 5G9
7DNL	;	4.19	;	2-fold subparticles refinement of human papillomavirus type 58 pseudovirus in complexed with the Fab fragment of A4B4
1C4X	;	2.4	;	2-HYDROXY-6-OXO-6-PHENYLHEXA-2,4-DIENOATE HYDROLASE (BPHD) FROM RHODOCOCCUS SP. STRAIN RHA1
2KH0	;		;	2-Hydroxy-7-nitrofluorene covalently linked into a 13mer DNA duplex - solution structure of the face-down orientation
2KH1	;		;	2-Hydroxy-7-nitrofluorene covalently linked into a 13mer DNA duplex - solution structure of the face-up orientation
4CY8	;	2.03	;	2-hydroxybiphenyl 3-monooxygenase (HbpA) in complex with FAD
2IME	;	1.7	;	2-Hydroxychromene-2-carboxylate Isomerase: a Kappa Class Glutathione-S-Transferase from Pseudomonas putida
2IMF	;	1.3	;	2-Hydroxychromene-2-carboxylate Isomerase: a Kappa Class Glutathione-S-Transferase from Pseudomonas putida
4YAR	;	1.75	;	2-Hydroxyethylphosphonate dioxygenase (HEPD) E176H
4UXD	;	2.5	;	2-keto 3-deoxygluconate aldolase from Picrophilus torridus
2Q18	;	2.1	;	2-keto-3-deoxy-D-arabinonate dehydratase
2Q19	;	3.0	;	2-keto-3-deoxy-D-arabinonate dehydratase apo form
2Q1C	;	2.8	;	2-keto-3-deoxy-D-arabinonate dehydratase complexed with calcium and 2-oxobutyrate
2Q1D	;	2.7	;	2-keto-3-deoxy-D-arabinonate dehydratase complexed with magnesium and 2,5-dioxopentanoate
2Q1A	;	2.5	;	2-keto-3-deoxy-D-arabinonate dehydratase complexed with magnesium and 2-oxobutyrate
4HGO	;	2.1	;	2-keto-3-deoxy-D-glycero-D-galactonononate-9-phosphate phosphohydrolase from Bacteroides thetaiotaomicron in complex with transition state mimic
2NUY	;	2.5	;	2-keto-3-deoxygluconate aldolase from Sulfolobus acidocaldarius in complex with pyruvate
2NUW	;	1.8	;	2-keto-3-deoxygluconate aldolase from Sulfolobus acidocaldarius, native structure at 1.8 A resolution
2NUX	;	2.5	;	2-keto-3-deoxygluconate aldolase from Sulfolobus acidocaldarius, native structure in p6522 at 2.5 A resolution
1V19	;	2.3	;	2-KETO-3-DEOXYGLUCONATE KINASE FROM THERMUS THERMOPHILUS
1V1S	;	3.2	;	2-KETO-3-DEOXYGLUCONATE KINASE FROM THERMUS THERMOPHILUS (CRYSTAL FORM 2)
1V1A	;	2.1	;	2-KETO-3-DEOXYGLUCONATE KINASE FROM THERMUS THERMOPHILUS WITH BOUND 2-KETO-3-DEOXYGLUCONATE AND ADP
1V1B	;	2.6	;	2-KETO-3-DEOXYGLUCONATE KINASE FROM THERMUS THERMOPHILUS WITH BOUND ATP
1W37	;	2.0	;	2-keto-3-deoxygluconate(KDG) aldolase of Sulfolobus solfataricus
3HT9	;	2.02	;	2-methoxyphenol in complex with T4 lysozyme L99A/M102Q
5HXI	;	1.5	;	2-Methyl-3-hydroxypyridine-5-carboxylic acid oxygenase, 5HN bound
3HT6	;	1.59	;	2-methylphenol in complex with T4 lysozyme L99A/M102Q
6QKG	;	2.2	;	2-Naphthoyl-CoA Reductase(NCR)
6QKR	;	2.2	;	2-Naphthoyl-CoA Reductase-2-Naphthoyl-CoA complex(NCR-NCoA-soaked complex)
6QKX	;	2.4	;	2-Naphthoyl-CoA Reductase-DiHydroNaphthoyl-CoA complex(NCR-DHNCoA co-crystallized complex)
2RBO	;	1.29	;	2-nitrothiophene in complex with T4 lysozyme L99A/M102Q
5B48	;	2.5	;	2-Oxoacid:Ferredoxin Oxidoreductase 1 from Sulfolobus tokodai
5B46	;	2.1	;	2-Oxoacid:Ferredoxin Oxidoreductase 2 from Sulfolobus tokodai - ligand free form
5B47	;	2.2	;	2-Oxoacid:Ferredoxin Oxidoreductase 2 from Sulfolobus tokodai - pyruvate complex
6N2O	;	2.824	;	2-oxoglutarate:ferredoxin oxidoreductase from Magnetococcus marinus with 2-oxoglutarate, coenzyme A and succinyl-CoA bound
1Z01	;	1.8	;	2-Oxoquinoline 8-Monooxygenase Component: Active site Modulation by Rieske-[2fe-2S] Center Oxidation/Reduction
1Z02	;	1.8	;	2-Oxoquinoline 8-Monooxygenase Component: Active site Modulation by Rieske-[2fe-2S] Center Oxidation/Reduction
1Z03	;	1.8	;	2-Oxoquinoline 8-Monooxygenase Component: Active site Modulation by Rieske-[2fe-2S] Center Oxidation/Reduction
2RBR	;	1.433	;	2-phenoxyethanol in complex with T4 lysozyme L99A/M102Q
3HTB	;	1.81	;	2-propylphenol in complex with T4 lysozyme L99A/M102Q
4Z4B	;	1.9652	;	2-Pyridyl Hoechst - a New Generation DNA-Binding Radioprotector
1EE0	;	2.05	;	2-PYRONE SYNTHASE COMPLEXED WITH ACETOACETYL-COA
5US2	;	1.9	;	2-Se-T2-DNA and native RNA hybrid in complex with RNase H catalytic domain D132N mutant
5W7N	;	1.8	;	2-Se-T2/4-DNA and native RNA hybrid in complex with RNase H catalytic domain D132N mutant
5W7O	;	1.75	;	2-Se-T4-DNA and native RNA hybrid in complex with RNase H catalytic domain D132N mutant
2ZL9	;	1.9	;	2-Substituted-16-ene-22-thia-1alpha,25-dihydroxy-26,27-dimethyl-19-norvitamin D3 analogs: Synthesis, biological evaluation and crystal structure
2ZLA	;	2.0	;	2-Substituted-16-ene-22-thia-1alpha,25-dihydroxy-26,27-dimethyl-19-norvitamin D3 analogs: Synthesis, biological evaluation and crystal structure
2ZLC	;	2.0	;	2-Substituted-16-ene-22-thia-1alpha,25-dihydroxy-26,27-dimethyl-19-norvitamin D3 analogs: Synthesis, biological evaluation and crystal structure
4YQH	;	2.308	;	2-[2-(4-Phenyl-1H-imidazol-2-yl)ethyl]quinoxaline (Sunovion Compound 14) co-crystallized with PDE10A
1R7L	;	2.0	;	2.0 A Crystal Structure of a Phage Protein from Bacillus cereus ATCC 14579
1TWU	;	2.0	;	2.0 A Crystal Structure of a YycE Protein of Unknown Function from Bacillus subtilis, Putative Glyoxalase/Fosfomycin Resistance Protein
1MUU	;	2.02	;	2.0 A crystal structure of GDP-mannose dehydrogenase
1NG5	;	2.0	;	2.0 A crystal structure of Staphylococcus aureus Sortase B
2BE6	;	2.0	;	2.0 A crystal structure of the CaV1.2 IQ domain-Ca/CaM complex
1DM1	;	1.99	;	2.0 A CRYSTAL STRUCTURE OF THE DOUBLE MUTANT H(E7)V, T(E10)R OF MYOGLOBIN FROM APLYSIA LIMACINA
4E6K	;	2.0	;	2.0 A resolution structure of Pseudomonas aeruginosa bacterioferritin (BfrB) in complex with bacterioferritin associated ferredoxin (Bfd)
2J5K	;	2.0	;	2.0 A resolution structure of the wild type malate dehydrogenase from Haloarcula marismortui (radiation damage series)
5DS7	;	2.0	;	2.0 A Structure of CPII, a nitrogen regulatory PII-like protein from Thiomonas intermedia K12, bound AMP
1NI9	;	2.0	;	2.0 A structure of glycerol metabolism protein from E. coli
1NIG	;	2.0	;	2.0 A Structure of Protein of Unknown Function from Thermoplasma acidophilum
1MI8	;	2.0	;	2.0 Angstrom crystal structure of a DnaB intein from Synechocystis sp. PCC 6803
3H0P	;	2.0	;	2.0 Angstrom Crystal Structure of an Acyl Carrier Protein S-malonyltransferase from Salmonella typhimurium.
6XY3	;	2.0	;	2.0 Angstrom crystal structure of Ca/CaM N53I:RyR2 peptide complex
3NZT	;	2.0	;	2.0 Angstrom Crystal structure of Glutamate--Cysteine Ligase (gshA) ftom Francisella tularensis in Complex with AMP
3UN6	;	2.01	;	2.0 Angstrom Crystal Structure of Ligand Binding Component of ABC-type Import System from Staphylococcus aureus with Zinc bound
2AYL	;	2.0	;	2.0 Angstrom Crystal Structure of Manganese Protoporphyrin IX-reconstituted Ovine Prostaglandin H2 Synthase-1 Complexed With Flurbiprofen
1Q4G	;	2.0	;	2.0 Angstrom Crystal Structure of Ovine Prostaglandin H2 Synthase-1, in complex with alpha-methyl-4-biphenylacetic acid
4RGT	;	2.0	;	2.0 Angstrom Crystal Structure of Superantigen-like Protein from Staphylococcus aureus in Complex with 3-N-Acetylneuraminyl-N-acetyllactosamine.
6DAE	;	2.0	;	2.0 Angstrom crystal structure of the D95V Ca/CaM:CaV1.2 IQ domain complex
2PD7	;	2.0	;	2.0 Angstrom Crystal Structure of the Fungal Blue-Light Photoreceptor Vivid
1APM	;	2.0	;	2.0 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PEPTIDE INHIBITOR AND DETERGENT
3IFS	;	2.004	;	2.0 Angstrom Resolution Crystal Structure of Glucose-6-phosphate Isomerase (pgi) from Bacillus anthracis.
6DB1	;	2.0	;	2.0 Angstrom Resolution Crystal Structure of N-Terminal Ligand-Binding Domain of Putative Methyl-Accepting Chemotaxis Protein from Salmonella enterica
6WJT	;	2.0	;	2.0 Angstrom Resolution Crystal Structure of Nsp16-Nsp10 Heterodimer from SARS-CoV-2 in Complex with S-Adenosyl-L-Homocysteine
4MFG	;	2.0	;	2.0 Angstrom Resolution Crystal Structure of Putative Carbonic Anhydrase from Clostridium difficile.
3TK7	;	2.0	;	2.0 Angstrom Resolution Crystal Structure of Transaldolase B (TalA) from Francisella tularensis in Covalent Complex with Fructose 6-Phosphate
5WI5	;	2.0	;	2.0 Angstrom Resolution Crystal Structure of UDP-N-acetylglucosamine 1-carboxyvinyltransferase from Streptococcus pneumoniae in Complex with Uridine-diphosphate-2(n-acetylglucosaminyl) butyric acid, (2R)-2-(phosphonooxy)propanoic acid and Magnesium.
7ATP	;	2.1	;	2.0 angstrom structure in complex with Ca of plant Extended Synaptotagmin 1, C2A domain
1N2Z	;	2.0	;	2.0 Angstrom structure of BtuF, the vitamin B12 binding protein of E. coli
1QLP	;	2.0	;	2.0 ANGSTROM STRUCTURE OF INTACT ALPHA-1-ANTITRYPSIN: A CANONICAL TEMPLATE FOR ACTIVE SERPINS
7AS6	;	2.0	;	2.0 angstrom structure of plant Extended Synaptotagmin 1, C2A domain
3HJK	;	2.0	;	2.0 Angstrom Structure of the Ile74Val Variant of Vivid (VVD).
3RLZ	;	2.01	;	2.0 Angstrom X-ray structure of bovine Ca(2+)-S100B D63N
2AFG	;	2.0	;	2.0 ANGSTROM X-RAY STRUCTURE OF HUMAN ACIDIC FIBROBLAST GROWTH FACTOR
4OFC	;	1.99	;	2.0 Angstroms X-ray crystal structure of human 2-amino-3-carboxymuconate-6-semialdehye decarboxylase
5KKJ	;	2.001	;	2.0-Angstrom In situ Mylar structure of hen egg-white lysozyme (HEWL) at 293 K
5WJK	;	2.0	;	2.0-Angstrom In situ Mylar structure of sperm whale myoglobin (SWMb) at 293 K
6CL8	;	2.0	;	2.00 A MicroED structure of proteinase K at 2.6 e- / A^2
2IDM	;	2.0	;	2.00 A Structure of T87I/Y106W Phosphono-CheY
3LXM	;	2.0	;	2.00 Angstrom resolution crystal structure of a catalytic subunit of an aspartate carbamoyltransferase (pyrB) from Yersinia pestis CO92
3PAJ	;	2.0	;	2.00 Angstrom resolution crystal structure of a quinolinate phosphoribosyltransferase from Vibrio cholerae O1 biovar eltor str. N16961
4ZV9	;	2.0	;	2.00 Angstrom resolution crystal structure of an uncharacterized protein from Escherichia coli O157:H7 str. Sakai
4HSL	;	2.0	;	2.00 angstrom x-ray crystal structure of substrate-bound E110A 3-hydroxyanthranilate-3,4-dioxygenase from Cupriavidus metallidurans
4OE2	;	2.0	;	2.00 Angstroms X-ray crystal structure of E268A 2-aminomuconate 6-semialdehyde dehydrogenase from Pseudomonas fluorescens
4I25	;	2.0	;	2.00 Angstroms X-ray crystal structure of NAD- and substrate-bound 2-aminomuconate 6-semialdehyde dehydrogenase from Pseudomonas fluorescens
4I1W	;	1.992	;	2.00 Angstroms X-ray crystal structure of NAD- bound 2-aminomuconate 6-semialdehyde dehydrogenase from Pseudomonas fluorescens
7SNR	;	2.0	;	2.00A Resolution Structure of NanoLuc Luciferase
3IMI	;	2.01	;	2.01 Angstrom resolution crystal structure of a HIT family protein from Bacillus anthracis str. 'Ames Ancestor'
2C3C	;	2.15	;	2.01 Angstrom X-ray crystal structure of a mixed disulfide between coenzyme M and NADPH-dependent oxidoreductase 2-ketopropyl coenzyme M carboxylase
7W9W	;	2.02	;	2.02 angstrom cryo-EM structure of the pump-like channelrhodopsin ChRmine
3FGP	;	2.05	;	2.05 a Crystal Structure of CysM from Mycobacterium Tuberculosis - Open and Closed Conformations
5EF4	;	2.05	;	2.05 A crystal structure of the Amb a 11 cysteine protease, a major ragweed pollen allergen, in its proform
5VXM	;	2.05	;	2.05 A resolution structure of IpaD from Shigella flexneri in complex with single-domain antibody 20ipaD
6VGY	;	2.05	;	2.05 A resolution structure of MERS 3CL protease in complex with inhibitor 6b
5WKJ	;	2.05	;	2.05 A resolution structure of MERS 3CL protease in complex with inhibitor GC376
6WB6	;	2.05	;	2.05 A resolution structure of transferrin 1 from Manduca sexta
3QFK	;	2.05	;	2.05 Angstrom Crystal Structure of Putative 5'-Nucleotidase from Staphylococcus aureus in complex with alpha-ketoglutarate
4NU7	;	2.05	;	2.05 Angstrom Crystal Structure of Ribulose-phosphate 3-epimerase from Toxoplasma gondii.
3IJR	;	2.05	;	2.05 Angstrom resolution crystal structure of a short chain dehydrogenase from Bacillus anthracis str. 'Ames Ancestor' in complex with NAD+
6OAD	;	2.05	;	2.05 Angstrom Resolution Crystal Structure of Aminopeptidase B from Escherichia coli str. K-12 substr. MG1655.
6WJI	;	2.052	;	2.05 Angstrom Resolution Crystal Structure of C-terminal Dimerization Domain of Nucleocapsid Phosphoprotein from SARS-CoV-2
5VRV	;	2.05	;	2.05 Angstrom Resolution Crystal Structure of C-terminal Domain (DUF2156) of Putative Lysylphosphatidylglycerol Synthetase from Agrobacterium fabrum.
3INP	;	2.05	;	2.05 Angstrom Resolution Crystal Structure of D-ribulose-phosphate 3-epimerase from Francisella tularensis.
3QFH	;	2.05	;	2.05 Angstrom Resolution Crystal Structure of Epidermin Leader Peptide Processing Serine Protease (EpiP) from Staphylococcus aureus.
6NBG	;	2.05	;	2.05 Angstrom Resolution Crystal Structure of Hypothetical Protein KP1_5497 from Klebsiella pneumoniae.
5TV7	;	2.05	;	2.05 Angstrom Resolution Crystal Structure of Peptidoglycan-Binding Protein from Clostridioides difficile in Complex with Glutamine Hydroxamate.
3GSD	;	2.05	;	2.05 Angstrom structure of a divalent-cation tolerance protein (CutA) from Yersinia pestis
2GEL	;	2.05	;	2.05A crystal structure of Salmonella typhimurium YeaZ, form B
4TOD	;	2.05	;	2.05A resolution structure of BfrB (D34F) from Pseudomonas aeruginosa
5D8Y	;	2.05	;	2.05A resolution structure of iron bound BfrB (L68A E81A) from Pseudomonas aeruginosa
6MV2	;	2.05	;	2.05A resolution structure of the CS-b5R domains of human Ncb5or (NADP+ form)
3I3O	;	2.06	;	2.06 Angstrom resolution crystal structure of a short chain dehydrogenase from Bacillus anthracis str. 'Ames Ancestor' in complex with NAD-acetone
4JJP	;	2.056	;	2.06 Angstrom resolution crystal structure of phosphomethylpyrimidine kinase (thiD)from Clostridium difficile 630
3H83	;	2.06	;	2.06 Angstrom resolution structure of a hypoxanthine-guanine phosphoribosyltransferase (hpt-1) from Bacillus anthracis str. 'Ames Ancestor'
5FSE	;	2.07	;	2.07 A resolution 1,4-Benzoquinone inhibited Sporosarcina pasteurii urease
6KML	;	2.095	;	2.09 Angstrom resolution crystal structure of tetrameric HigBA toxin-antitoxin complex from E.coli
3KB8	;	2.09	;	2.09 Angstrom resolution structure of a hypoxanthine-guanine phosphoribosyltransferase (hpt-1) from Bacillus anthracis str. 'Ames Ancestor' in complex with GMP
6WQA	;	2.0	;	2.0A angstrom A2a adenosine receptor structure using XFEL data collected in helium atmosphere.
4E77	;	2.0	;	2.0A Crystal Structure of a Glutamate-1-Semialdehyde Aminotransferase from Yersinia pestis CO92
3S5J	;	2.02	;	2.0A Crystal structure of human phosphoribosyl pyrophosphate synthetase 1
3EOL	;	2.0	;	2.0A crystal structure of isocitrate lyase from Brucella melitensis (P43212)
4O6I	;	2.0	;	2.0A crystal structure of Lymphocytic Choriomeningitis Virus Nucleoprotein C-terminal Domain
4TO9	;	2.0	;	2.0A resolution structure of BfrB (N148L) from Pseudomonas aeruginosa
4RO9	;	2.0	;	2.0A resolution structure of SRPN2 (S358E) from Anopheles gambiae
6UXD	;	2.0	;	2.0A resolution structure of the hypothetical protein CT021 from Chlamydia trachomatis
2QR8	;	2.0	;	2.0A X-ray structure of C-terminal kinase domain of p90 ribosomal S6 kinase 2 (RSK2)
2QR7	;	2.0	;	2.0A X-ray structure of C-terminal kinase domain of p90 ribosomal S6 kinase 2: Se-Met derivative
2F96	;	2.09	;	2.1 A crystal structure of Pseudomonas aeruginosa rnase T (Ribonuclease T)
1QQH	;	2.1	;	2.1 A CRYSTAL STRUCTURE OF THE HUMAN PAPILLOMAVIRUS TYPE 18 E2 ACTIVATION DOMAIN
2Q3C	;	2.1	;	2.1 A Resolution Crystal Structure of O-Acetylserine Sulfhydrylase (OASS) Holoenzyme From MYCOBACTERIUM TUBERCULOSIS in Complex with the Inhibitory Peptide DFSI
1QDR	;	2.1	;	2.1 A RESOLUTION STRUCTURE OF ESCHERICHIA COLI LYTIC TRANSGLYCOSYLASE SLT35
1QDT	;	2.1	;	2.1 A RESOLUTION STRUCTURE OF ESCHERICHIA COLI LYTIC TRANSGLYCOYSLASE SLT35 IN COMPLEX WITH CALCIUM
6DE6	;	2.1	;	2.1 A resolution structure of histamine dehydrogenase from Rhizobium sp. 4-9
6W5L	;	2.1	;	2.1 A resolution structure of Norovirus 3CL protease in complex with inhibitor 7g
6NTY	;	2.1	;	2.1 A resolution structure of the Musashi-2 (Msi2) RNA recognition motif 1 (RRM1) domain
3ETC	;	2.1	;	2.1 A structure of acyl-adenylate synthetase from Methanosarcina acetivorans containing a link between Lys256 and Cys298
3DKI	;	2.1	;	2.1 A X-ray structure of CysM (Rv1336) from Mycobacterium tuberculosis an O-phosphoserine dependent cysteine synthase
4ZRO	;	2.0566	;	2.1 A X-Ray Structure of FIPV-3CLpro bound to covalent inhibitor
2P04	;	2.11	;	2.1 Ang structure of the dimerized PAS domain of signal transduction histidine kinase from Nostoc punctiforme PCC 73102 with homology to the H-NOXA/H-NOBA domain of the soluble guanylyl cyclase
3GRP	;	2.09	;	2.1 Angstrom crystal structure of 3-ketoacyl-(acyl-carrier-protein) reductase from Bartonella henselae
3GWE	;	2.1	;	2.1 Angstrom crystal structure of 3-oxoacyl-(acyl-carrier-protein) synthase III
1QYR	;	2.1	;	2.1 Angstrom Crystal structure of KsgA: A Universally Conserved Adenosine Dimethyltransferase
3PP8	;	2.1	;	2.1 Angstrom Crystal Structure of Putative Oxidoreductase (ycdW) from Salmonella typhimurium
4RWR	;	2.1	;	2.1 Angstrom Crystal Structure of Stage II Sporulation Protein D from Bacillus anthracis
2A8T	;	2.1	;	2.1 Angstrom Crystal Structure of the Complex Between the Nuclear U8 snoRNA Decapping Nudix Hydrolase X29, Manganese and m7G-PPP-A
3TPZ	;	2.1	;	2.1 Angstrom crystal structure of the L114P mutant of E. Coli KsgA
1VF6	;	2.1	;	2.1 Angstrom crystal structure of the PALS-1-L27N and PATJ L27 heterodimer complex
6PO4	;	2.1	;	2.1 Angstrom Resolution Crystal Structure of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase (mtnN) from Haemophilus influenzae PittII.
6VC6	;	2.133	;	2.1 Angstrom Resolution Crystal Structure of 6-phospho-alpha-glucosidase from Gut Microorganisms in Complex with NAD and Mn2+
3N2L	;	2.1	;	2.1 Angstrom resolution crystal structure of an Orotate Phosphoribosyltransferase (pyrE) from Vibrio cholerae O1 biovar eltor str. N16961
3K96	;	2.1	;	2.1 Angstrom resolution crystal structure of glycerol-3-phosphate dehydrogenase (gpsA) from Coxiella burnetii
6BAL	;	2.1	;	2.1 Angstrom Resolution Crystal Structure of Malate Dehydrogenase from Haemophilus influenzae in Complex with L-Malate
5CQE	;	2.1	;	2.1 Angstrom resolution crystal structure of matrix protein 1 (M1; residues 1-164) from Influenza A virus (A/Puerto Rico/8/34(H1N1))
3R2U	;	2.1	;	2.1 Angstrom Resolution Crystal Structure of Metallo-beta-lactamase from Staphylococcus aureus subsp. aureus COL
4QVS	;	2.1	;	2.1 Angstrom resolution crystal structure of S-layer domain-containing protein (residues 221-444) from Clostridium thermocellum ATCC 27405
4GQO	;	2.1	;	2.1 Angstrom resolution crystal structure of uncharacterized protein lmo0859 from Listeria monocytogenes EGD-e
4QYB	;	2.1	;	2.1 Angstrom resolution crystal structure of uncharacterized protein, disulfide-bridged dimer, from Burkholderia cenocepacia J2315
2B5T	;	2.1	;	2.1 Angstrom structure of a nonproductive complex between antithrombin, synthetic heparin mimetic SR123781 and two S195A thrombin molecules
5BKA	;	2.11	;	2.1 Angstrom structure of ActVI-ORFA from Streptomyces Coelicolor
1G6N	;	2.1	;	2.1 ANGSTROM STRUCTURE OF CAP-CAMP
6OVL	;	2.1	;	2.1 Angstrom structure of wild type Glyoxylate/Hydroxypyruvate reductase A from Escherichia Coli in complex with glyoxylate and NADP
2A5H	;	2.1	;	2.1 Angstrom X-ray crystal structure of lysine-2,3-aminomutase from Clostridium subterminale SB4, with Michaelis analog (L-alpha-lysine external aldimine form of pyridoxal-5'-phosphate).
2WB0	;	1.95	;	2.1 resolution structure of the C-terminal domain of the human adenovirus 5 ssDNA binding protein
5KKH	;	2.125	;	2.1-Angstrom In situ Mylar structure of bacteriorhodopsin from Haloquadratum walsbyi (HwBR) at 100 K
5WKQ	;	2.1	;	2.10 A resolution structure of IpaB (residues 74-242) from Shigella flexneri
5T6D	;	2.1	;	2.10 A resolution structure of Norovirus 3CL protease in complex with the dipeptidyl inhibitor 7l (hexagonal form)
7KNG	;	2.1	;	2.10A resolution structure of independent Phosphoglycerate mutase from C. elegans in complex with a macrocyclic peptide inhibitor (Ce-2 Y7F)
7SNY	;	2.1	;	2.10A Resolution Structure of NanoBiT Complementation Reporter Large Subunit LgBiT
5EZ4	;	2.11	;	2.11 Angstrom resolution crystal structure of betaine aldehyde dehydrogenase (betB) P449M/Y450L double mutant from Staphylococcus aureus in complex with NAD+ and BME-modified Cys289
7O6E	;	2.1	;	2.12 A cryo-EM structure of Mycobacterium tuberculosis Ferritin
5LV1	;	2.12	;	2.12 A resolution structure of PtxB from Prochlorococcus marinus (MIT 9301) in complex with phosphite
4ILO	;	2.12	;	2.12A resolution structure of CT398 from Chlamydia trachomatis
4WBC	;	2.138	;	2.13 A STRUCTURE OF A KUNITZ-TYPE WINGED BEAN CHYMOTRYPSIN INHIBITOR PROTEIN
3KBO	;	2.14	;	2.14 Angstrom Crystal Structure of Putative Oxidoreductase (ycdW) from Salmonella typhimurium in Complex with NADP
2J5Q	;	2.15	;	2.15 A resolution structure of the wild type malate dehydrogenase from Haloarcula marismortui after first radiation burn (radiation damage series)
2C3D	;	2.15	;	2.15 Angstrom crystal structure of 2-ketopropyl coenzyme M oxidoreductase carboxylase with a coenzyme M disulfide bound at the active site
5T1Q	;	2.15	;	2.15 Angstrom Crystal Structure of N-acetylmuramoyl-L-alanine Amidase from Staphylococcus aureus.
5JPI	;	2.15	;	2.15 Angstrom Crystal Structure of S-adenosylhomocysteinase from Cryptosporidium parvum in Complex with D-Eritadenine and NAD
4K28	;	2.15	;	2.15 Angstrom resolution crystal structure of a shikimate dehydrogenase family protein from Pseudomonas putida KT2440 in complex with NAD+
5US8	;	2.15	;	2.15 Angstrom Resolution Crystal Structure of Argininosuccinate Synthase from Bordetella pertussis
6AOO	;	2.15	;	2.15 Angstrom Resolution Crystal Structure of Malate Dehydrogenase from Haemophilus influenzae
3H02	;	2.15	;	2.15 Angstrom Resolution Crystal Structure of Naphthoate Synthase from Salmonella typhimurium.
4I2R	;	2.15	;	2.15 Angstroms X-ray crystal structure of NAD- and alternative substrate-bound 2-aminomuconate 6-semialdehyde dehydrogenase from Pseudomonas fluorescens
3Q7T	;	2.15	;	2.15A resolution structure (I41 Form) of the ChxR receiver domain from Chlamydia trachomatis
6AW7	;	2.15	;	2.15A resolution structure of SAH bound catechol O-methyltransferase (COMT) from Nannospalax galili
6MV1	;	2.15	;	2.15A resolution structure of the CS-b5R domains of human Ncb5or (NAD+ form)
4NOI	;	2.17	;	2.17 Angstrom Crystal Structure of DNA-directed RNA Polymerase Subunit Alpha from Campylobacter jejuni.
4E0B	;	2.17	;	2.17 Angstrom resolution crystal structure of malate dehydrogenase from Vibrio vulnificus CMCP6
1H5W	;	2.1	;	2.1A Bacteriophage Phi-29 Connector
3ENN	;	2.1	;	2.1A crystal structure of glucose/ribitol dehydrogenase from brucella melitensis (p43212)
2GEM	;	2.1	;	2.1A crystal structure of Salmonella tyhpimurium YeaZ, a putative Gram-negative RPF, form-A
3SKY	;	2.1	;	2.1A crystal structure of the phosphate bound ATP binding domain of Archaeoglobus fulgidus COPB
3R2S	;	2.1	;	2.1A resolution structure of Doubly Soaked FtnA from Pseudomonas aeruginosa (pH 6.0)
3Q7S	;	2.1	;	2.1A resolution structure of the ChxR receiver domain containing I3C from Chlamydia trachomatis
1EK9	;	2.1	;	2.1A X-RAY STRUCTURE OF TOLC: AN INTEGRAL OUTER MEMBRANE PROTEIN AND EFFLUX PUMP COMPONENT FROM ESCHERICHIA COLI
2DXI	;	2.2	;	2.2 A crystal structure of glutamyl-tRNA synthetase from Thermus thermophilus complexed with tRNA(Glu), ATP, and L-glutamol
3D6B	;	2.21	;	2.2 A crystal structure of glutaryl-CoA dehydrogenase from Burkholderia pseudomallei
3D53	;	2.2	;	2.2 A crystal structure of inorganic pyrophosphatase from Rickettsia prowazekii
3EMJ	;	2.2	;	2.2 A crystal structure of inorganic pyrophosphatase from rickettsia prowazekii (p21 form)
8EPV	;	2.19	;	2.2 A crystal structure of the lipocalin cat allergen Fel d 7
5A1A	;	2.2	;	2.2 A resolution cryo-EM structure of beta-galactosidase in complex with a cell-permeant inhibitor
2Q3D	;	2.2	;	2.2 A Resolution Crystal Structure of O-Acetylserine Sulfhydrylase (OASS) From MYCOBACTERIUM TUBERCULOSIS in Complex with the Reaction Intermediate ALPHA-AMINOACRYLATE
2PZZ	;	2.2	;	2.2 A resolution crystal structure of UPF0201 protein from Methanococcus jannaschii
6NKL	;	2.2	;	2.2 A resolution structure of VapBC-1 from nontypeable Haemophilus influenzae
4ZAJ	;	2.22	;	2.2 Angstrom Crystal Structure of a Human Arginyl-tRNA Synthetase
5ISU	;	2.2	;	2.2 Angstrom Crystal Structure of ABC Transporter Substrate Binding Protein CtaP (Lmo0135) from Listeria monocytogenes.
3R2P	;	2.2045	;	2.2 Angstrom Crystal Structure of C Terminal Truncated Human Apolipoprotein A-I Reveals the Assembly of HDL by Dimerization.
4LES	;	2.2	;	2.2 Angstrom Crystal Structure of Conserved Hypothetical Protein from Bacillus anthracis.
4EG2	;	2.2	;	2.2 Angstrom Crystal Structure of Cytidine deaminase from Vibrio cholerae in Complex with Zinc and Uridine
3IAC	;	2.22	;	2.2 Angstrom Crystal Structure of Glucuronate Isomerase from Salmonella typhimurium.
3TOZ	;	2.2	;	2.2 Angstrom Crystal Structure of Shikimate 5-dehydrogenase from Listeria monocytogenes in Complex with NAD.
3PMA	;	2.2	;	2.2 Angstrom crystal structure of the complex between Bovine Thrombin and Sucrose Octasulfate
3DRM	;	2.2	;	2.2 Angstrom Crystal Structure of Thr114Phe Alpha1-Antitrypsin
1ATP	;	2.2	;	2.2 angstrom refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MNATP and a peptide inhibitor
3N3W	;	2.205	;	2.2 Angstrom Resolution Crystal Structure of Nuclease Domain of Ribonuclase III (rnc) from Campylobacter jejuni
6DLL	;	2.2	;	2.2 Angstrom Resolution Crystal Structure of P-Hydroxybenzoate Hydroxylase from Pseudomonas putida in Complex with FAD.
3OT5	;	2.2	;	2.2 Angstrom Resolution Crystal Structure of putative UDP-N-acetylglucosamine 2-epimerase from Listeria monocytogenes
3R2T	;	2.21	;	2.2 Angstrom Resolution Crystal Structure of Superantigen-like Protein from Staphylococcus aureus subsp. aureus NCTC 8325.
6CZP	;	2.24	;	2.2 Angstrom Resolution Crystal Structure Oxygen-Insensitive NAD(P)H-dependent Nitroreductase NfsB from Vibrio vulnificus in Complex with FMN
1DCC	;	2.2	;	2.2 ANGSTROM STRUCTURE OF OXYPEROXIDASE: A MODEL FOR THE ENZYME:PEROXIDE COMPLEX
3NA7	;	2.2	;	2.2 Angstrom Structure of the HP0958 Protein from Helicobacter pylori CCUG 17874
2QD1	;	2.2	;	2.2 Angstrom Structure of the human ferrochelatase variant E343K with substrate bound
1DR1	;	2.2	;	2.2 ANGSTROMS CRYSTAL STRUCTURE OF CHICKEN LIVER DIHYDROFOLATE REDUCTASE COMPLEXED WITH NADP+ AND BIOPTERIN
1LTA	;	2.2	;	2.2 ANGSTROMS CRYSTAL STRUCTURE OF E. COLI HEAT-LABILE ENTEROTOXIN (LT) WITH BOUND GALACTOSE
1WGC	;	2.2	;	2.2 ANGSTROMS RESOLUTION STRUCTURE ANALYSIS OF TWO REFINED N-ACETYLNEURAMINYLLACTOSE-WHEAT GERM AGGLUTININ ISOLECTIN COMPLEXES
2WGC	;	2.2	;	2.2 ANGSTROMS RESOLUTION STRUCTURE ANALYSIS OF TWO REFINED N-ACETYLNEURAMINYLLACTOSE-WHEAT GERM AGGLUTININ ISOLECTIN COMPLEXES
7WGA	;	2.0	;	2.2 ANGSTROMS RESOLUTION STRUCTURE ANALYSIS OF TWO REFINED N-ACETYLNEURAMINYLLACTOSE-WHEAT GERM AGGLUTININ ISOLECTIN COMPLEXES
9WGA	;	1.8	;	2.2 ANGSTROMS RESOLUTION STRUCTURE ANALYSIS OF TWO REFINED N-ACETYLNEURAMINYLLACTOSE-WHEAT GERM AGGLUTININ ISOLECTIN COMPLEXES
1HAR	;	2.2	;	2.2 ANGSTROMS RESOLUTION STRUCTURE OF THE AMINO-TERMINAL HALF OF HIV-1 REVERSE TRANSCRIPTASE (FINGERS AND PALM SUBDOMAINS)
5ITE	;	2.182	;	2.2-Angstrom in meso crystal structure of Haloquadratum Walsbyi Bacteriorhodopsin (HwBR) from Octylglucoside (OG) Detergent Micelles
5ITC	;	1.999	;	2.2-Angstrom in meso crystal structure of Haloquadratum Walsbyi Bacteriorhodopsin (HwBR) from Styrene Maleic Acid (SMA) Polymer Nanodiscs
6CL9	;	2.2	;	2.20 A MicroED structure of proteinase K at 4.3 e- / A^2
6VH3	;	2.2	;	2.20 A resolution structure of MERS 3CL protease in complex with inhibitor 7j
4ZOS	;	2.2	;	2.20 Angstrom resolution crystal structure of protein YE0340 of unidentified function from Yersinia enterocolitica subsp. enterocolitica 8081]
3ROI	;	2.2	;	2.20 Angstrom resolution structure of 3-phosphoshikimate 1-carboxyvinyltransferase (AroA) from Coxiella burnetii
4I26	;	2.204	;	2.20 Angstroms X-ray crystal structure of 2-aminomuconate 6-semialdehyde dehydrogenase from Pseudomonas fluorescens
5D8Q	;	2.2	;	2.20A resolution structure of BfrB (L68A) from Pseudomonas aeruginosa
4TOE	;	2.2	;	2.20A resolution structure of Iron Bound BfrB (D34F) from Pseudomonas aeruginosa
7SNT	;	2.2	;	2.20A Resolution Structure of NanoLuc Luciferase with Bound Substrate Analog 3-methoxy-furimazine
5TY0	;	2.22	;	2.22 Angstrom Crystal Structure of N-terminal Fragment (residues 1-419) of Elongation Factor G from Legionella pneumophila.
4NVR	;	2.22	;	2.22 Angstrom Resolution Crystal Structure of a Putative Acyltransferase from Salmonella enterica
5NPP	;	2.22	;	2.22A STRUCTURE OF THIOPHENE2 AND GSK945237 WITH S.AUREUS DNA GYRASE AND DNA
6ZO0	;	2.23	;	2.23 A resolution 3,4-dimethylcatechol (3,4-dimethylbenzene-1,2-diol) inhibited Sporosarcina pasteurii urease
3R38	;	2.23	;	2.23 Angstrom resolution crystal structure of UDP-N-acetylglucosamine 1-carboxyvinyltransferase (murA) from Listeria monocytogenes EGD-e
6VGZ	;	2.25	;	2.25 A resolution structure of MERS 3CL protease in complex with inhibitor 6d
5WKM	;	2.25	;	2.25 A resolution structure of MERS 3CL protease in complex with piperidine-based peptidomimetic inhibitor 21
6BIC	;	2.25	;	2.25 A resolution structure of Norovirus 3CL protease in complex with a triazole-based macrocyclic inhibitor
2J5R	;	2.25	;	2.25 A resolution structure of the wild type malate dehydrogenase from Haloarcula marismortui after second radiation burn (radiation damage series)
3QM2	;	2.25	;	2.25 Angstrom Crystal Structure of Phosphoserine Aminotransferase (SerC) from Salmonella enterica subsp. enterica serovar Typhimurium
5JXW	;	2.25	;	2.25 Angstrom Crystal Structure of S-adenosylhomocysteinase from Cryptosporidium parvum in Complex with Neplanocin-A and NAD
6DVV	;	2.25	;	2.25 Angstrom Resolution Crystal Structure of 6-phospho-alpha-glucosidase from Klebsiella pneumoniae in Complex with NAD and Mn2+.
6DUX	;	2.25	;	2.25 Angstrom Resolution Crystal Structure of 6-phospho-alpha-glucosidase from Klebsiella pneumoniae in Complex with NAD.
3N2I	;	2.25	;	2.25 Angstrom resolution crystal structure of a thymidylate kinase (tmk) from Vibrio cholerae O1 biovar eltor str. N16961 in complex with thymidine
8CZP	;	2.25	;	2.25 angstrom resolution crystal structure of as-isolated KatG from Mycobacterium tuberculosis with an MYW cofactor
5DIB	;	2.25	;	2.25 Angstrom resolution crystal structure of betaine aldehyde dehydrogenase (betB) Y450L point mutant from Staphylococcus aureus in complex with NAD+ and BME-modified Cys289
5ICR	;	2.25	;	2.25 Angstrom Resolution Crystal Structure of Fatty-Acid-CoA Ligase (FadD32) from Mycobacterium smegmatis in complex with Inhibitor 5'-O-[(11-phenoxyundecanoyl)sulfamoyl]adenosine.
5HM3	;	2.25	;	2.25 Angstrom Resolution Crystal Structure of Long-chain-fatty-acid-AMP Ligase FadD32 from Mycobacterium tuberculosis in complex with Inhibitor 5'-O-[(11-phenoxyundecanoyl)sulfamoyl]adenosine
4HV4	;	2.25	;	2.25 Angstrom resolution crystal structure of UDP-N-acetylmuramate--L-alanine ligase (murC) from Yersinia pestis CO92 in complex with AMP
4HW8	;	2.251	;	2.25 Angstrom Structure of the Extracellular Solute-binding Protein from Staphylococcus aureus in complex with Maltose.
6AW8	;	2.25	;	2.25A resolution domain swapped dimer structure of SAH bound catechol O-methyltransferase (COMT) from Nannospalax galili
4TOC	;	2.25	;	2.25A resolution structure of Iron Bound BfrB (Q151L) from Pseudomonas aeruginosa
4F49	;	2.25	;	2.25A resolution structure of Transmissible Gastroenteritis Virus Protease containing a covalently bound Dipeptidyl Inhibitor
6VH2	;	2.26	;	2.26 A resolution structure of MERS 3CL protease in complex with inhibitor 7i
7VDA	;	2.26	;	2.26 A structure of the glutamate dehydrogenase
4GIB	;	2.27	;	2.27 Angstrom Crystal Structure of beta-Phosphoglucomutase (pgmB) from Clostridium difficile
7P13	;	2.29	;	2.29 A Mycobacterium tuberculosis EspB.
7VD9	;	2.29	;	2.29 A structure of the human catalase
4DXB	;	2.29	;	2.29A structure of the engineered MBP TEM-1 fusion protein RG13 in complex with zinc, P1 space group
3GAF	;	2.2	;	2.2A Crystal Structure of 7-Alpha-Hydroxysteroid Dehydrogenase from Brucella Melitensis
6B86	;	2.2	;	2.2A Crystal Structure of Co-CAO1
4E5D	;	2.201	;	2.2A resolution structure of a firefly luciferase-benzothiazole inhibitor complex
4JBH	;	2.2	;	2.2A resolution structure of cobalt and zinc bound thermostable alcohol dehydrogenase from Pyrobaculum aerophilum
4JET	;	2.2	;	2.2A resolution structure of Holo hemophore HasA from Yersinia pestis
4FP7	;	2.2	;	2.2A resolution structure of Proteasome Assembly Chaperone Hsm3
3DAH	;	2.3	;	2.3 A crystal structure of ribose-phosphate pyrophosphokinase from Burkholderia pseudomallei
4ZWM	;	2.31	;	2.3 A resolution crystal structure of the ornithine aminotransferase from Toxoplasma gondii ME49
2G7U	;	2.3	;	2.3 A structure of putative catechol degradative operon regulator from Rhodococcus sp. RHA1
3POL	;	2.3	;	2.3 Angstrom Crystal Structure of 3-deoxy-manno-octulosonate Cytidylyltransferase (kdsB) from Acinetobacter baumannii.
3IS2	;	2.3	;	2.3 Angstrom Crystal Structure of a Cys71 Sulfenic Acid form of Vivid
4ECM	;	2.3	;	2.3 Angstrom Crystal Structure of a Glucose-1-phosphate Thymidylyltransferase from Bacillus anthracis in Complex with Thymidine-5-diphospho-alpha-D-glucose and Pyrophosphate
4QVR	;	2.3	;	2.3 Angstrom Crystal Structure of Hypothetical Protein FTT1539c from Francisella tularensis.
1Z7H	;	2.3	;	2.3 Angstrom crystal structure of tetanus neurotoxin light chain
5E31	;	2.3	;	2.3 Angstrom Crystal Structure of the Monomeric Form of Penicillin Binding Protein 2 Prime from Enterococcus faecium.
6CMZ	;	2.3	;	2.3 Angstrom Resolution Crystal Structure of Dihydrolipoamide Dehydrogenase from Burkholderia cenocepacia in Complex with FAD and NAD
5U1O	;	2.31	;	2.3 Angstrom Resolution Crystal Structure of Glutathione Reductase from Vibrio parahaemolyticus in Complex with FAD.
1XWK	;	2.3	;	2.3 angstrom resolution crystal structure of human glutathione S-transferase M1A-1A complexed with glutathionyl-S-dinitrobenzene
6KMQ	;	2.35	;	2.3 Angstrom resolution structure of dimeric HigBA toxin-antitoxin complex from E. coli
5DRK	;	2.38	;	2.3 Angstrom Structure of CPII, a nitrogen regulatory PII-like protein from Thiomonas intermedia K12, bound to ADP, AMP and bicarbonate.
6CNY	;	2.1	;	2.3 Angstrom Structure of Phosphodiesterase treated Vivid (complex with FMN)
1DR2	;	2.3	;	2.3 ANGSTROMS CRYSTAL STRUCTURE OF CHICKEN LIVER DIHYDROFOLATE REDUCTASE COMPLEXED WITH THIONADP+ AND BIOPTERIN
1DR3	;	2.3	;	2.3 ANGSTROMS CRYSTAL STRUCTURE OF CHICKEN LIVER DIHYDROFOLATE REDUCTASE COMPLEXED WITH THIONADP+ AND BIOPTERIN
1RPL	;	2.3	;	2.3 ANGSTROMS CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF DNA POLYMERASE BETA
6VH1	;	2.3	;	2.30 A resolution structure of MERS 3CL protease in complex with inhibitor 6h
4NU9	;	2.3	;	2.30 Angstrom resolution crystal structure of betaine aldehyde dehydrogenase (betB) from Staphylococcus aureus with BME-free Cys289
3HYK	;	2.31	;	2.31 Angstrom resolution crystal structure of a holo-(acyl-carrier-protein) synthase from Bacillus anthracis str. Ames in complex with CoA (3',5'-ADP)
6QTK	;	2.31	;	2.31A structure of gepotidacin with S.aureus DNA gyrase and doubly nicked DNA
4IGN	;	2.329	;	2.32 Angstrom X-ray Crystal structure of R47A mutant of human ACMSD
5TSE	;	2.35	;	2.35 Angstrom Crystal Structure Minor Lipoprotein from Acinetobacter baumannii.
4FBD	;	2.35	;	2.35 Angstrom Crystal Structure of Conserved Hypothetical Protein from Toxoplasma gondii ME49.
5V27	;	2.352	;	2.35 angstrom crystal structure of P97V 3-hydroxyanthranilate-3,4-dioxygenase from Cupriavidus metallidurans
3KY7	;	2.35	;	2.35 Angstrom resolution crystal structure of a putative tRNA (guanine-7-)-methyltransferase (trmD) from Staphylococcus aureus subsp. aureus MRSA252
4QRI	;	2.35	;	2.35 Angstrom resolution crystal structure of hypoxanthine-guanine-xanthine phosphoribosyltransferase from Leptospira interrogans serovar Copenhageni str. Fiocruz L1-130
4OC9	;	2.35	;	2.35 Angstrom resolution crystal structure of putative O-acetylhomoserine (thiol)-lyase (metY) from Campylobacter jejuni subsp. jejuni NCTC 11168 with N'-Pyridoxyl-Lysine-5'-Monophosphate at position 205
3DZC	;	2.35	;	2.35 Angstrom resolution structure of WecB (VC0917), a UDP-N-acetylglucosamine 2-epimerase from Vibrio cholerae.
6VW4	;	2.35	;	2.35 Angstrom structure of Caci_6494 from Catenulispora Acidiphila in complex with S-DNPA
5VRA	;	2.35	;	2.35-Angstrom In situ Mylar structure of human A2A adenosine receptor at 100 K
5D8P	;	2.35	;	2.35A resolution structure of iron bound BfrB (wild-type, C2221 form) from Pseudomonas aeruginosa
4JBI	;	2.35	;	2.35A resolution structure of NADPH bound thermostable alcohol dehydrogenase from Pyrobaculum aerophilum
5DG6	;	2.35	;	2.35A resolution structure of Norovirus 3CL protease in complex an oxadiazole-based, cell permeable macrocyclic (21-mer) inhibitor
3OO2	;	2.37	;	2.37 Angstrom resolution crystal structure of an alanine racemase (alr) from Staphylococcus aureus subsp. aureus COL
5BUF	;	2.37	;	2.37 Angstrom Structure of EPSP Synthase from acinetobacter baumannii
6QTP	;	2.37	;	2.37A structure of gepotidacin with S.aureus DNA gyrase and uncleaved DNA
4IGM	;	2.391	;	2.39 Angstrom X-ray Crystal structure of human ACMSD
6COM	;	2.3	;	2.3A crystal structure of E. coli phosphoenolpyruvate carboxykinase mutant Asp269Asn
1S6Y	;	2.31	;	2.3A crystal structure of phospho-beta-glucosidase
4HJY	;	2.4	;	2.4 A Crystal structure of E. coli MltE-E64Q with bound chitopentaose
3E5B	;	2.37	;	2.4 A crystal structure of isocitrate lyase from brucella melitensis
3EOM	;	2.398	;	2.4 A crystal structure of native glutaryl-coa dehydrogenase from Burkholderia pseudomallei
1EEP	;	2.4	;	2.4 A RESOLUTION CRYSTAL STRUCTURE OF BORRELIA BURGDORFERI INOSINE 5'-MONPHOSPHATE DEHYDROGENASE IN COMPLEX WITH A SULFATE ION
3DGM	;	2.4	;	2.4 A Structure of a Non-biological ATP binding protein with ADP bound
1I2X	;	2.4	;	2.4 A STRUCTURE OF A-DUPLEX WITH BULGED ADENOSINE, SPERMIDINE FORM
1IHH	;	2.4	;	2.4 ANGSTROM CRYSTAL STRUCTURE OF AN OXALIPLATIN 1,2-D(GPG) INTRASTRAND CROSS-LINK IN A DNA DODECAMER DUPLEX
7PPB	;	2.4	;	2.4 angstrom crystal structure of bone morphogenetic protein receptor type II (BMPRII) extracellular domain in complex with BMP10
3PNU	;	2.4	;	2.4 Angstrom Crystal Structure of Dihydroorotase (pyrC) from Campylobacter jejuni.
3MGA	;	2.4	;	2.4 Angstrom Crystal Structure of Ferric Enterobactin Esterase (fes) from Salmonella typhimurium
3GTD	;	2.4	;	2.4 Angstrom crystal structure of fumarate hydratase from Rickettsia prowazekii
2Q6S	;	2.4	;	2.4 angstrom crystal structure of PPAR gamma complexed to BVT.13 without co-activator peptides
5TLS	;	2.4	;	2.4 Angstrom Crystal Structure of S-adenosylhomocysteinase from Cryptosporidium parvum in Complex with DZ2002 and NAD
3HZZ	;	2.4	;	2.4 Angstrom Crystal Structure of Streptomyces collinus crotonyl CoA carboxylase/reductase
3V05	;	2.4	;	2.4 Angstrom Crystal Structure of Superantigen-like Protein from Staphylococcus aureus.
1LU5	;	2.4	;	2.4 Angstrom Crystal Structure of the Asymmetric Platinum Complex {Pt(ammine)(cyclohexylamine)}2+ Bound to a Dodecamer DNA Duplex
6U39	;	2.4	;	2.4 Angstrom crystal structure of the D129G Ca-CaM:CaV1.2 IQ domain complex
6DAF	;	2.4	;	2.4 Angstrom crystal structure of the F141L Ca/CaM:CaV1.2 IQ domain complex
4O0N	;	2.4	;	2.4 Angstrom Resolution Crystal Structure of Putative Nucleoside Diphosphate Kinase from Toxoplasma gondii.
4N3O	;	2.4	;	2.4 Angstrom Resolution Crystal Structure of Putative Sugar Kinase from Campylobacter jejuni.
3SEF	;	2.4	;	2.4 Angstrom resolution crystal structure of shikimate 5-dehydrogenase (aroE) from Vibrio cholerae O1 biovar eltor str. N16961 in complex with shikimate and NADPH
4IFR	;	2.391	;	2.40 Angstroms X-ray crystal structure of R239A 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase from Pseudomonas fluorescens
6CQI	;	2.42	;	2.42A Crystal structure of Mycobacterium tuberculosis Topoisomerase I in complex with an oligonucleotide MTS2-11
7P0Z	;	2.43	;	2.43 A Mycobacterium marinum EspB.
5T6G	;	2.45	;	2.45 A resolution structure of Norovirus 3CL protease in complex with the dipeptidyl inhibitor 7m (hexagonal form)
2A8R	;	2.45	;	2.45 Angstrom Crystal Structure of the Complex Between the Nuclear SnoRNA Decapping Nudix Hydrolase X29 and Manganese in the Presence of 7-methyl-GTP
2A8S	;	2.45	;	2.45 Angstrom Crystal Structure of the Complex Between the Nuclear SnoRNA Decapping Nudix Hydrolase X29, Manganese and GTP
5UJS	;	2.46	;	2.45 Angstrom Resolution Crystal Structure of UDP-N-acetylglucosamine 1-carboxyvinyltransferase from Campylobacter jejuni.
6BWT	;	2.45	;	2.45 Angstrom Resolution Crystal Structure Thioredoxin Reductase from Francisella tularensis.
5KGL	;	2.45	;	2.45A resolution structure of Apo independent phosphoglycerate mutase from C. elegans (orthorhombic form)
5CDP	;	2.45	;	2.45A structure of etoposide with S.aureus DNA gyrase and DNA
3PGJ	;	2.49	;	2.49 Angstrom resolution crystal structure of shikimate 5-dehydrogenase (aroE) from Vibrio cholerae O1 biovar eltor str. N16961 in complex with shikimate
1SFJ	;	2.4	;	2.4A Crystal structure of Staphylococcus aureus type I 3-dehydroquinase, with 3-dehydroquinate bound
4HIN	;	2.4	;	2.4A Resolution Structure of Bovine Cytochrome b5 (S71L)
6B6I	;	2.44	;	2.4A resolution structure of human Norovirus GII.4 protease
2OE6	;	2.4	;	2.4A X-ray crystal structure of unliganded RNA fragment GGGCGUCGCUAGUACC/CGGUACUAAAAGUCGCC containing the human ribosomal decoding A site: RNA construct with 5'-overhang
1JKK	;	2.4	;	2.4A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MG.
1X87	;	2.4	;	2.4A X-ray structure of Urocanase protein complexed with NAD
8PTU	;	2.52	;	2.5 A cryo-EM structure of the in vitro FimD-catalyzed assembly of type 1 pilus rod
3QH7	;	2.497	;	2.5 A resolution structure of Se-Met labeled CT296 from Chlamydia trachomatis
5K2B	;	2.5	;	2.5 angstrom A2a adenosine receptor structure with MR phasing using XFEL data
5K2A	;	2.5	;	2.5 angstrom A2a adenosine receptor structure with sulfur SAD phasing using XFEL data
5J7R	;	2.5	;	2.5 Angstrom Crystal Structure of Putative Lipoprotein from Clostridium perfringens
6DAH	;	2.502	;	2.5 Angstrom crystal structure of the N97S CaM mutant
3REH	;	2.5	;	2.5 Angstrom Crystal Structure of the Nucleosome Core Particle Assembled with a 145 bp Alpha-Satellite DNA (NCP145)
3OKF	;	2.5	;	2.5 Angstrom Resolution Crystal Structure of 3-Dehydroquinate Synthase (aroB) from Vibrio cholerae
4ECD	;	2.5	;	2.5 Angstrom Resolution Crystal Structure of Bifidobacterium longum Chorismate Synthase
5TR3	;	2.5	;	2.5 Angstrom Resolution Crystal Structure of Dihydrolipoyl Dehydrogenase from Pseudomonas putida in Complex with FAD.
2F9D	;	2.5	;	2.5 angstrom resolution structure of the spliceosomal protein p14 bound to region of SF3b155
1RC2	;	2.5	;	2.5 Angstrom Resolution X-ray Structure of Aquaporin Z
6P77	;	2.501	;	2.5 Angstrom structure of Caci_6494 from Catenulispora Acidiphila
6P35	;	2.495	;	2.5 Angstrom structure of wild type Glyoxylate/Hydroxypyruvate reductase A from Escherichia Coli in complex with 2-keto arginine and NADP
4IH3	;	2.493	;	2.5 Angstroms X-ray crystal structure of of human 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase in complex with dipicolinic acid
5Y2R	;	1.0	;	2.5 atm CO2-pressurized human carbonic anhydrase II
5VXJ	;	2.5	;	2.50 A resolution structure of IpaD from Shigella flexneri in complex with single-domain antibody JMK-E3
4EGR	;	2.5	;	2.50 angstrom resolution structure of 3-phosphoshikimate 1-carboxyvinyltransferase (AroA) from Coxiella burnetii in complex with phosphoenolpyruvate
4IFO	;	2.5	;	2.50 Angstroms X-ray crystal structure of R51A 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase from Pseudomonas fluorescens
5D8R	;	2.5	;	2.50A resolution structure of BfrB (E81A) from Pseudomonas aeruginosa
6WBT	;	2.52	;	2.52 Angstrom Resolution Crystal Structure of 6-phospho-alpha-glucosidase from Gut Microorganisms in Complex with NAD and Glucose-6-phosphate
4DXE	;	2.51	;	2.52 Angstrom resolution crystal structure of the acyl-carrier-protein synthase (AcpS)-acyl carrier protein (ACP) protein-protein complex from Staphylococcus aureus subsp. aureus COL
5VXK	;	2.55	;	2.55 A resolution structure of IpaD from Shigella flexneri in complex with single-domain antibody JMK-H2
3REJ	;	2.55	;	2.55 Angstrom Crystal Structure of the Nucleosome Core Particle Assembled with a 146 bp Alpha-Satellite DNA (NCP146b)
6BQ9	;	2.55	;	2.55 Angstrom Resolution Crystal Structure of N-terminal Fragment (residues 1-493) of DNA Topoisomerase IV Subunit A from Pseudomonas putida
6VJ6	;	2.553	;	2.55 Angstrom Resolution Crystal Structure of Peptidylprolyl Isomerase (PrsA) from Bacillus cereus
4ZND	;	2.55	;	2.55 Angstrom resolution structure of 3-phosphoshikimate 1-carboxyvinyltransferase (AroA) from Coxiella burnetii in complex with shikimate-3-phosphate, phosphate, and potassium
7CUB	;	2.55	;	2.55-Angstrom Cryo-EM structure of Cytochrome bo3 from Escherichia coli in Native Membrane
7CUQ	;	2.64	;	2.55-Angstrom Cryo-EM structure of Cytochrome bo3 from Escherichia coli in Native Membrane
3EON	;	2.55	;	2.55A crystal structure of native glutaryl-coa dehydrogenase from Burkholderia pseudomallei in complex with a small molecule
5D8S	;	2.55	;	2.55A resolution structure of BfrB (E85A) from Pseudomonas aeruginosa
6AW9	;	2.55	;	2.55A resolution structure of SAH bound catechol O-methyltransferase (COMT) L136M from Nannospalax galili
7VDF	;	2.56	;	2.56 A structure of influenza hemagglutinin (HA) trimer
3EMK	;	2.5	;	2.5A crystal structure of glucose/ribitol dehydrogenase from brucella melitensis
1TB6	;	2.5	;	2.5A Crystal Structure of the Antithrombin-Thrombin-Heparin Ternary Complex
1RD3	;	2.5	;	2.5A Structure of Anticoagulant Thrombin Variant E217K
5IWM	;	2.5	;	2.5A structure of GSK945237 with S.aureus DNA gyrase and DNA.
5A3E	;	2.501	;	2.5A structure of lysozyme determined by MicroED with data from a single crystal
3J6K	;	2.5	;	2.5A structure of lysozyme solved by MicroED
5CDM	;	2.5	;	2.5A structure of QPT-1 with S.aureus DNA gyrase and DNA
2AF5	;	2.5	;	2.5A X-ray Structure of Engineered OspA protein
1F66	;	2.6	;	2.6 A CRYSTAL STRUCTURE OF A NUCLEOSOME CORE PARTICLE CONTAINING THE VARIANT HISTONE H2A.Z
3DMP	;	2.6	;	2.6 A crystal structure of uracil phosphoribosyltransferase from Burkholderia pseudomallei
7SWY	;	2.6	;	2.6 A structure of a 40-601[TA-rich+1]-40 nucleosome
4ODI	;	2.6	;	2.6 Angstrom Crystal Structure of Putative Phosphoglycerate Mutase 1 from Toxoplasma gondii
4IIW	;	2.6	;	2.6 Angstrom Crystal Structure of Putative yceG-like Protein lmo1499 from Listeria monocytogenes
5TJ9	;	2.6	;	2.6 Angstrom Crystal Structure of S-adenosylhomocysteinase from Cryptosporidium parvum in Complex with Aristeromycin and NAD
2QO1	;	2.6	;	2.6 Angstrom Crystal Structure of the Complex Between 11-(decyldithiocarbonyloxy)-undecanoic acid and Mycobacterium Tuberculosis FabH.
2A8Q	;	2.6	;	2.6 Angstrom Crystal Structure of the Complex Between the Nuclear SnoRNA Decapping Nudix Hydrolase X29 and Manganese in the Presence of 7-methyl-GDP
3REK	;	2.6	;	2.6 Angstrom Crystal Structure of the Nucleosome Core Particle Assembled with a 146 bp Alpha-Satellite DNA (NCP146b) Derivatized with Oxaliplatin
3SG1	;	2.6	;	2.6 Angstrom Crystal Structure of UDP-N-acetylglucosamine 1-carboxyvinyltransferase 1 (MurA1) from Bacillus anthracis
6OV8	;	2.61	;	2.6 Angstrom Resolution Crystal Structure of Aminopeptidase B from Escherichia coli str. K-12 substr. MG1655
4QN2	;	2.6	;	2.6 Angstrom resolution crystal structure of betaine aldehyde dehydrogenase (betB) G234S mutant from Staphylococcus aureus (IDP00699) in complex with NAD+ and BME-free Cys289
5VH6	;	2.61	;	2.6 Angstrom Resolution Crystal Structure of N-terminal Fragment (residues 1-406) of Elongation Factor G from Bacillus subtilis.
5U2G	;	2.61	;	2.6 Angstrom Resolution Crystal Structure of Penicillin-Binding Protein 1A from Haemophilus influenzae
5I1T	;	2.6	;	2.6 Angstrom Resolution Crystal Structure of Stage II Sporulation Protein D (SpoIID) from Clostridium difficile in Complex with Triacetylchitotriose
4HS7	;	2.6	;	2.6 Angstrom Structure of the Extracellular Solute-binding Protein from Staphylococcus aureus in complex with PEG.
6OXN	;	2.61	;	2.6 Angstrom structure of W45F/H46S Glyoxylate/Hydroxypyruvate reductase A from Escherichia Coli in complex with glyoxylate and NADP
4DIR	;	2.6	;	2.6 Angstrom X-ray structure of human CA(2+)-S100A5
1LTB	;	2.6	;	2.6 ANGSTROMS CRYSTAL STRUCTURE OF PARTIALLY-ACTIVATED E. COLI HEAT-LABILE ENTEROTOXIN (LT)
4Q52	;	2.6	;	2.60 Angstrom resolution crystal structure of a conserved uncharacterized protein from Chitinophaga pinensis DSM 2588
4O96	;	2.6	;	2.60 Angstrom resolution crystal structure of a protein kinase domain of type III effector NleH2 (ECs1814) from Escherichia coli O157:H7 str. Sakai
4ZWL	;	2.6	;	2.60 Angstrom resolution crystal structure of betaine aldehyde dehydrogenase (betB) H448F/Y450L double mutant from Staphylococcus aureus in complex with NAD+ and BME-free Cys289
6N0I	;	2.6	;	2.60 Angstrom Resolution Crystal Structure of Elongation Factor G 2 from Pseudomonas putida.
6VBB	;	2.6	;	2.60 Angstrom Resolution Crystal Structure of Peptidase S41 from Acinetobacter baumannii
4NML	;	2.6	;	2.60 Angstrom resolution crystal structure of putative ribose 5-phosphate isomerase from Toxoplasma gondii ME49 in complex with DL-Malic acid
6FQV	;	2.6	;	2.60A BINARY COMPLEX OF S.AUREUS GYRASE with UNCLEAVED DNA
4ILQ	;	2.6	;	2.60A resolution structure of CT771 from Chlamydia trachomatis
7ZRP	;	2.65	;	2.65 Angstrom crystal structure of Ca/CaM:CaMKIIdelta peptide complex
3REI	;	2.65	;	2.65 Angstrom Crystal Structure of the Nucleosome Core Particle Assembled with a 145 bp Alpha-Satellite DNA (NCP145) Derivatized with Triamminechloroplatinum(II) Chloride
4RV4	;	2.65	;	2.65 Angstrom Resolution Crystal Structure of an orotate phosphoribosyltransferase from Bacillus anthracis str. 'Ames Ancestor' in complex with 5-phospho-alpha-D-ribosyl diphosphate (PRPP)
3SC6	;	2.65	;	2.65 Angstrom resolution crystal structure of dTDP-4-dehydrorhamnose reductase (rfbD) from Bacillus anthracis str. Ames in complex with NADP
4GFQ	;	2.65	;	2.65 Angstrom Resolution Crystal Structure of Ribosome Recycling Factor (frr) from Bacillus anthracis
5UTU	;	2.65	;	2.65 Angstrom Resolution Crystal Structure of S-adenosylhomocysteinase from Cryptosporidium parvum in Complex with SAH and NAD
5CDR	;	2.65	;	2.65 structure of S.aureus DNA gyrase and artificially nicked DNA
2C4D	;	2.6	;	2.6A Crystal Structure of Psathyrella velutina Lectin in Complex with N-acetylglucosamine
3R9I	;	2.6	;	2.6A resolution structure of MinD complexed with MinE (12-31) peptide
8PSV	;	2.7	;	2.7 A cryo-EM structure of in vitro assembled type 1 pilus rod
2GYS	;	2.7	;	2.7 A structure of the extracellular domains of the human beta common receptor involved in IL-3, IL-5, and GM-CSF signalling
5D6A	;	2.7	;	2.7 Angstrom Crystal Structure of ABC transporter ATPase from Vibrio vulnificus in Complex with Adenylyl-imidodiphosphate (AMP-PNP)
3V0A	;	2.703	;	2.7 angstrom crystal structure of BoNT/Ai in complex with NTNHA
3GE1	;	2.7	;	2.7 Angstrom Crystal Structure of Glycerol Kinase (glpK) from Staphylococcus aureus in Complex with ADP and Glycerol
2A8P	;	2.7	;	2.7 Angstrom Crystal Structure of the Complex Between the Nuclear SnoRNA Decapping Nudix Hydrolase X29 and Manganese
3REL	;	2.7	;	2.7 Angstrom Crystal Structure of the Nucleosome Core Particle Assembled with a 146 bp Alpha-Satellite DNA (NCP146b) Derivatized with Triamminechloroplatinum(II) Chloride
3PFI	;	2.695	;	2.7 Angstrom resolution crystal structure of a probable holliday junction DNA helicase (ruvB) from Campylobacter jejuni subsp. jejuni NCTC 11168 in complex with adenosine-5'-diphosphate
4GFP	;	2.7	;	2.7 Angstrom resolution structure of 3-phosphoshikimate 1-carboxyvinyltransferase (AroA) from Coxiella burnetii in a second conformational state
4QPJ	;	2.742	;	2.7 Angstrom Structure of a Phosphotransferase in Complex with a Receiver Domain
5EGW	;	2.7	;	2.70 A crystal structure of the Amb a 11 cysteine protease, a major ragweed pollen allergen, in its proform
4H44	;	2.7	;	2.70 A Cytochrome b6f Complex Structure From Nostoc PCC 7120
6WN8	;	2.7	;	2.70 Angstrom Resolution Crystal Structure of Uracil Phosphoribosyl Transferase from Klebsiella pneumoniae
5V28	;	2.724	;	2.72 angstrom crystal structure of P97A 3-hydroxyanthranilate-3,4-dioxygenase from Cupriavidus metallidurans
3OTR	;	2.75	;	2.75 Angstrom Crystal Structure of Enolase 1 from Toxoplasma gondii
6U7L	;	2.75	;	2.75 Angstrom Crystal Structure of Galactarate Dehydratase from Escherichia coli.
8OW4	;	2.75	;	2.75 angstrom crystal structure of human NFAT1 with bound DNA
4K15	;	2.75	;	2.75 Angstrom Crystal Structure of Hypothetical Protein lmo2686 from Listeria monocytogenes EGD-e
4O4A	;	2.75	;	2.75 Angstrom Crystal Structure of Putative Lipoprotein from Bacillus anthracis.
5UBU	;	2.75	;	2.75 Angstrom Resolution Crystal Structure of Acetamidase from Yersinia enterocolitica.
4MJZ	;	2.75	;	2.75 Angstrom Resolution Crystal Structure of Putative Orotidine-monophosphate-decarboxylase from Toxoplasma gondii.
4HHD	;	2.75	;	2.75 Angstrom resolution crystal structure of the A. thaliana LOV2 domain with an extended N-terminal A' helix (cryo dark structure)
6CN1	;	2.75	;	2.75 Angstrom Resolution Crystal Structure of UDP-N-acetylglucosamine 1-carboxyvinyltransferase from Pseudomonas putida in Complex with Uridine-diphosphate-2(n-acetylglucosaminyl) butyric acid, (2R)-2-(phosphonooxy)propanoic acid and Magnesium
5F2H	;	2.75	;	2.75 Angstrom resolution crystal structure of uncharacterized protein from Bacillus cereus ATCC 10987
4PUP	;	2.75	;	2.75 Angstrom resolution crystal structure of uncharacterized protein from Burkholderia cenocepacia J2315
2UUW	;	2.76	;	2.75 angstrom structure of the D347G D348G mutant structure of Sapporo Virus RdRp Polymerase
3HL3	;	2.76	;	2.76 Angstrom Crystal Structure of a Putative Glucose-1-Phosphate Thymidylyltransferase from Bacillus anthracis in Complex with a Sucrose.
2UXS	;	2.7	;	2.7A crystal structure of inorganic pyrophosphatase (Rv3628) from Mycobacterium tuberculosis at pH 7.5
6QX1	;	2.65	;	2.7A structure of benzoisoxazole 3 with S.aureus DNA gyrase and DNA.
6M0R	;	2.7	;	2.7A Yeast Vo state3
5BW8	;	2.8	;	2.8 A crystal structure of a Get3-Get4-Get5 intermediate complex from S.cerevisiae
6BDF	;	2.8	;	2.8 A resolution reconstruction of the Thermoplasma acidophilum 20S proteasome using cryo-electron microscopy
2X0J	;	2.786	;	2.8 A RESOLUTION STRUCTURE OF MALATE DEHYDROGENASE FROM ARCHAEOGLOBUS FULGIDUS IN COMPLEX WITH ETHENO-NAD
7R0W	;	2.8	;	2.8 Angstrom cryo-EM structure of the dimeric cytochrome b6f-PetP complex from Synechocystis sp. PCC 6803 with natively bound lipids and plastoquinone molecules
3JCS	;	2.8	;	2.8 Angstrom cryo-EM structure of the large ribosomal subunit from the eukaryotic parasite Leishmania
4ONX	;	2.8	;	2.8 Angstrom Crystal Structure of Sensor Domain of Histidine Kinase from Clostridium perfringens.
5YS8	;	2.798	;	2.8 angstrom crystal structure of Succinate-Acetate Permease from Citrobacter koseri
5TPM	;	2.8	;	2.8 Angstrom Crystal Structure of the C-terminal Dimerization Domain of Transcriptional Regulator PdhR from Escherichia coli.
4MH6	;	2.8	;	2.8 Angstrom Crystal Structure of Type III Secretion Protein YscO from Vibrio parahaemolyticus
4KQN	;	2.8	;	2.8 Angstrom Resolution Crystal Structure of D-Hydantoinase from Bacillus sp. AR9 in C2221 Space Group
1YSC	;	2.8	;	2.8 ANGSTROMS STRUCTURE OF YEAST SERINE CARBOXYPEPTIDASE
2AAT	;	2.8	;	2.8-ANGSTROMS-RESOLUTION CRYSTAL STRUCTURE OF AN ACTIVE-SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI
6CLA	;	2.8	;	2.80 A MicroED structure of proteinase K at 6.0 e- / A^2
5VXL	;	2.8	;	2.80 A resolution structure of IpaD from Shigella flexneri in complex with single-domain antibody JPS-G3
6Y7S	;	2.85	;	2.85 A cryo-EM structure of the in vivo assembled type 1 pilus rod
1IMV	;	2.85	;	2.85 A crystal structure of PEDF
7TIF	;	2.85	;	2.85 Angstroem crystal structure of Arginyltransferase 1 (ATE1) from Saccharomyces cerevisiae
5HM8	;	2.85	;	2.85 Angstrom Crystal Structure of S-adenosylhomocysteinase from Cryptosporidium parvum in Complex with Adenosine and NAD.
4ZXU	;	2.85	;	2.85 Angstrom resolution crystal structure of betaine aldehyde dehydrogenase (betB) H448F/P449M double mutant from Staphylococcus aureus in complex with NAD+ and BME-free Cys289
4MVJ	;	2.85	;	2.85 Angstrom Resolution Crystal Structure of Glyceraldehyde 3-phosphate Dehydrogenase A (gapA) from Escherichia coli Modified by Acetyl Phosphate.
4O6H	;	2.8	;	2.8A crystal structure of Lymphocytic Choriomeningitis Virus Nucleoprotein C-terminal Domain
5X3X	;	2.788	;	2.8A resolution structure of a cobalt energy-coupling factor transporter-CbiMQO
4ROB	;	2.8	;	2.8A resolution structure of SRPN2 (K198C) from Anopheles gambiae
5CDN	;	2.79	;	2.8A structure of etoposide with S.aureus DNA gyrase and DNA
8BP2	;	2.8	;	2.8A STRUCTURE OF ZOLIFLODACIN WITH S.AUREUS DNA GYRASE AND DNA
5NWY	;	2.9	;	2.9 A cryo-EM structure of VemP-stalled ribosome-nascent chain complex
1D2R	;	2.9	;	2.9 A CRYSTAL STRUCTURE OF LIGAND-FREE TRYPTOPHANYL-TRNA SYNTHETASE: DOMAIN MOVEMENTS FRAGMENT THE ADENINE NUCLEOTIDE BINDING SITE.
1NTA	;	2.9	;	2.9 A crystal structure of Streptomycin RNA-aptamer
1NTB	;	2.9	;	2.9 A crystal structure of Streptomycin RNA-aptamer complex
2X0I	;	2.91	;	2.9 A RESOLUTION STRUCTURE OF MALATE DEHYDROGENASE FROM ARCHAEOGLOBUS FULGIDUS IN COMPLEX WITH NADH
1C8O	;	2.9	;	2.9 A STRUCTURE OF CLEAVED VIRAL SERPIN CRMA
3PMB	;	2.9	;	2.9 Angstrom crystal structure of bovine thrombin in tetragonal spacegroup
1F5O	;	2.9	;	2.9 ANGSTROM CRYSTAL STRUCTURE OF DEOXYGENATED LAMPREY HEMOGLOBIN V IN THE SPACE GROUP P2(1)2(1)2(1)
1F5P	;	2.9	;	2.9 ANGSTROM CRYSTAL STRUCTURE OF LAMPREY HEMOGLOBIN THAT HAS BEEN EXPOSED TO CARBON MONOXIDE.
3UPD	;	2.91	;	2.9 Angstrom Crystal Structure of Ornithine Carbamoyltransferase (ArgF) from Vibrio vulnificus
4RH6	;	2.9	;	2.9 Angstrom Crystal Structure of Putative Exotoxin 3 from Staphylococcus aureus.
3JCI	;	2.9	;	2.9 Angstrom Resolution Cryo-EM 3-D Reconstruction of Close-packed PCV2 Virus-like Particles
6BI4	;	2.91	;	2.9 Angstrom Resolution Crystal Structure of dTDP-Glucose 4,6-dehydratase (rfbB) from Bacillus anthracis str. Ames in Complex with NAD.
6C43	;	2.9	;	2.9 Angstrom Resolution Crystal Structure of Gamma-Aminobutyraldehyde Dehydrogenase from Salmonella typhimurium.
2F8N	;	2.9	;	2.9 Angstrom X-ray structure of hybrid macroH2A nucleosomes
1BAF	;	2.9	;	2.9 ANGSTROMS RESOLUTION STRUCTURE OF AN ANTI-DINITROPHENYL-SPIN-LABEL MONOCLONAL ANTIBODY FAB FRAGMENT WITH BOUND HAPTEN
1VSG	;	2.9	;	2.9 ANGSTROMS RESOLUTION STRUCTURE OF THE N-TERMINAL DOMAIN OF A VARIANT SURFACE GLYCOPROTEIN FROM TRYPANOSOMA BRUCEI
7YQM	;	2.89	;	2.9-angstrom cryo-EM structure of Ecoli malate synthase G
6CN0	;	2.95	;	2.95 Angstrom Crystal Structure of 16S rRNA Methylase from Proteus mirabilis
5DVY	;	2.95	;	2.95 Angstrom Crystal Structure of the Dimeric Form of Penicillin Binding Protein 2 Prime from Enterococcus faecium
5KGM	;	2.95	;	2.95A resolution structure of Apo independent phosphoglycerate mutase from C. elegans (monoclinic form)
5CDQ	;	2.95	;	2.95A structure of Moxifloxacin with S.aureus DNA gyrase and DNA
3EOO	;	2.9	;	2.9A crystal structure of methyl-isocitrate lyase from Burkholderia pseudomallei
4RSQ	;	2.9	;	2.9A resolution structure of SRPN2 (K198C/E359C) from Anopheles gambiae
5AFI	;	2.9	;	2.9A Structure of E. coli ribosome-EF-TU complex by cs-corrected cryo-EM
5V56	;	2.9	;	2.9A XFEL structure of the multi-domain human smoothened receptor (with E194M mutation) in complex with TC114
5NGM	;	2.9	;	2.9S structure of the 70S ribosome composing the S. aureus 100S complex
2NDK	;		;	20 lowest energy ensemble of dermcidin (DCD1L) NMR structure
6GKA	;	1.76	;	20 minute Fe2+ soak structure of SynFtn
6SOO	;	1.57	;	20 minute Fe2+ soaked structure of SynFtn variant D137A
7PFI	;	1.7	;	20 minute Fe2+ soaked structure of SynFtn Variant D65A
7PFJ	;	1.65	;	20 minute Fe2+ soaked structure of SynFtn Variant E141A
7PFK	;	1.55	;	20 minute Fe2+ soaked structure of SynFtn variant E141D
6SOR	;	1.74	;	20 minute Fe2+ soaked structure of SynFtn variant E62A
8AKR	;	3.8	;	200 A SynPspA rod after incubation with ATP
5DES	;	2.05	;	2009 H1N1 PA endonuclease domain
5EGA	;	2.15	;	2009 H1N1 PA endonuclease domain in complex with an N-acylhydrazone inhibitor
5CCY	;	2.1	;	2009 H1N1 PA endonuclease in complex with dTMP
5CGV	;	2.17	;	2009 H1N1 PA endonuclease in complex with L-742,001
6YA5	;	2.0	;	2009 H1N1 PA Endonuclease in complex with LU2
5VPT	;	2.1	;	2009 H1N1 PA Endonuclease in complex with RO-7
5VRJ	;	2.302	;	2009 H1N1 PA Endonuclease in complex with RO-7 and Magnesium
5CL0	;	2.22	;	2009 H1N1 PA endonuclease in complex with rUMP
5CZN	;	1.98	;	2009 H1N1 PA endonuclease mutant E119D
5DBS	;	2.11	;	2009 H1N1 PA endonuclease mutant E119D in complex with dTMP
5D8U	;	2.29	;	2009 H1N1 PA endonuclease mutant E119D in complex with L-742,001
5DEB	;	2.14	;	2009 H1N1 PA endonuclease mutant E119D in complex with rUMP
5D2O	;	2.15	;	2009 H1N1 PA endonuclease mutant F105S
5D42	;	2.0	;	2009 H1N1 PA endonuclease mutant F105S in complex with dTMP
5D9J	;	1.85	;	2009 H1N1 PA endonuclease mutant F105S in complex with L-742,001
5D4G	;	2.08	;	2009 H1N1 PA endonuclease mutant F105S in complex with rUMP
6KJ1	;	0.65	;	200kV MicroED structure of FUS (37-42) SYSGYS solved from merged datasets at 0.65 A
6KJ2	;	0.67	;	200kV MicroED structure of FUS (37-42) SYSGYS solved from single crystal at 0.67 A
8CW6	;	1.65	;	200us Temperature-Jump (Dark1) XFEL structure of Lysozyme
8CWG	;	1.5	;	200us Temperature-Jump (Dark1) XFEL structure of Lysozyme Bound to N,N'-diacetylchitobiose
8CW7	;	1.57	;	200us Temperature-Jump (Dark2) XFEL structure of Lysozyme
8CWH	;	1.5	;	200us Temperature-Jump (Dark2) XFEL structure of Lysozyme Bound to N,N'-diacetylchitobiose
8CW5	;	1.57	;	200us Temperature-Jump (Light) XFEL structure of Lysozyme
8CWF	;	1.5	;	200us Temperature-Jump (Light) XFEL structure of Lysozyme Bound to N,N'-diacetylchitobiose
7SQS	;	3.1	;	201phi2-1 Chimallin C1 localized reconstruction
7SQQ	;	4.2	;	201Phi2-1 Chimallin Cubic (O, 24mer) assembly
7SQR	;	3.4	;	201phi2-1 Chimallin localized tetramer reconstruction
4YB1	;	2.081	;	20A Mutant c-di-GMP Vc2 Riboswitch bound with 3',3'-cGAMP
6C6D	;	5.5	;	20mer crystal structure of CC chemokine 5 (CCL5)
8CVV	;	1.57	;	20ns Temperature-Jump (Dark1) XFEL structure of Lysozyme
8CWD	;	1.48	;	20ns Temperature-Jump (Dark1) XFEL structure of Lysozyme Bound to N,N'-diacetylchitobiose
8CVW	;	1.57	;	20ns Temperature-Jump (Dark2) XFEL structure of Lysozyme
8CWE	;	1.48	;	20ns Temperature-Jump (Dark2) XFEL structure of Lysozyme Bound to N,N'-diacetylchitobiose
8CVU	;	1.57	;	20ns Temperature-Jump (Light) XFEL structure of Lysozyme
8CWC	;	1.48	;	20ns Temperature-Jump (Light) XFEL structure of Lysozyme Bound to N,N'-diacetylchitobiose
6HE5	;	4.12	;	20S core particle of PAN-proteasomes
6HE7	;	3.69	;	20S proteasome from Archaeoglobus fulgidus
1J2Q	;	2.83	;	20S proteasome in complex with calpain-Inhibitor I from archaeoglobus fulgidus
4FZC	;	2.8	;	20S yeast proteasome in complex with cepafungin I
4FZG	;	3.0	;	20S yeast proteasome in complex with glidobactin
7V5G	;	4.47	;	20S+monoUb-CyclinB1-NT (S1)
7V5M	;	3.88	;	20S+monoUb-CyclinB1-NT (S2)
8CW1	;	1.57	;	20us Temperature-Jump (Dark1) XFEL structure of Lysozyme
8CW3	;	1.57	;	20us Temperature-Jump (Dark2) XFEL structure of Lysozyme
8CW0	;	1.57	;	20us Temperature-Jump (Light) XFEL structure of Lysozyme
8AKS	;	3.9	;	215 A SynPspA rod after incubation with ATP
2FMJ	;	1.65	;	220-loop mutant of streptomyces griseus trypsin
1HCW	;		;	23-RESIDUE DESIGNED METAL-FREE PEPTIDE BASED ON THE ZINC FINGER DOMAINS, NMR, 35 STRUCTURES
8GOI	;	1.54	;	23-residues Heterotetramic Antiparallel Coiled-Coil Derived From LacI
8GOJ	;	1.38	;	23-residues Heterotetramic Antiparallel Coiled-Coil Derived From LacI
8AKT	;	4.4	;	235 A SynPspA rod after incubation with ATP
1GZ0	;	2.5	;	23S RIBOSOMAL RNA G2251 2'O-METHYLTRANSFERASE RLMB
7QSH	;	0.86	;	23S ribosomal RNA Sarcin Ricin Loop 27-nt fragment containing a Xanthosine residue at position 2648
1C2W	;	7.5	;	23S RRNA STRUCTURE FITTED TO A CRYO-ELECTRON MICROSCOPIC MAP AT 7.5 ANGSTROMS RESOLUTION
7L3R	;	1.01	;	23S Sarcin Ricin Loop with a 3-deazapurine A2670
1ZUV	;		;	24 NMR structures of AcAMP2-Like Peptide with Phenylalanine 18 mutated to Tryptophan
1RHT	;		;	24-MER RNA HAIRPIN COAT PROTEIN BINDING SITE FOR BACTERIOPHAGE R17 (NMR, MINIMIZED AVERAGE STRUCTURE)
8ORB	;	3.25	;	24-meric catalytic domain of dihydrolipoamide acetyltransferase (E2) of the E. coli pyruvate dehydrogenase complex.
7Y3J	;	2.6	;	24B3 antibody-peptide complex
8PYP	;	1.4	;	25 micrometer HEWL crystals solved at room-temperature using fixed-target serial crystallography.
1T0W	;		;	25 NMR structures of Truncated Hevein of 32 aa (Hevein-32) complex with N,N,N-triacetylglucosamina
8AKU	;	4.5	;	250 A SynPspA rod after incubation with ATP
1IGI	;	2.7	;	26-10 FAB:DIGOXIN COMPLEX-AFFINITY AND SPECIFICITY DUE TO SURFACE COMPLEMENTARITY
1IGJ	;	2.5	;	26-10 FAB:DIGOXIN COMPLEX-AFFINITY AND SPECIFICITY DUE TO SURFACE COMPLEMENTARITY
6YMC	;	2.0	;	26-mer stem-loop RNA
5MPB	;	7.8	;	26S proteasome in presence of AMP-PNP (s3)
5MP9	;	4.1	;	26S proteasome in presence of ATP (s1)
5MPD	;	4.1	;	26S proteasome in presence of ATP (s1)
5MPA	;	4.5	;	26S proteasome in presence of ATP (s2)
5MPE	;	4.5	;	26S proteasome in presence of ATP (s2)
5MPC	;	7.7	;	26S proteasome in presence of BeFx (s4)
7QO6	;	6.3	;	26S proteasome Rpt1-RK -Ubp6-UbVS complex in the s2 state
7QO5	;	6.0	;	26S proteasome Rpt1-RK -Ubp6-UbVS complex in the si state
7QO4	;	7.0	;	26S proteasome WT-Ubp6-UbVS complex in the si state (ATPases, Rpn1, Ubp6, and UbVS)
6FVT	;	4.1	;	26S proteasome, s1 state
6FVU	;	4.5	;	26S proteasome, s2 state
6FVV	;	5.4	;	26S proteasome, s3 state
6FVW	;	4.5	;	26S proteasome, s4 state
6FVX	;	4.9	;	26S proteasome, s5 state
6FVY	;	6.1	;	26S proteasome, s6 state
5MRX	;	0.851	;	27-nt SRL with a 5-hydroxymethyl cytidine modification
8AKV	;	4.4	;	270 A SynPspA rod after incubation with ATP
6KOU	;	2.43	;	277 K cryoEM structure of Sso-KARI in complex with magnesium ions
6KPA	;	2.75	;	277 K cryoEM structure of Sso-KARI in complex with Mg2+, NADH and CPD
4RGC	;	1.05	;	277K Crystal structure of Escherichia Coli dihydrofolate reductase
8AKW	;	5.4	;	280 A SynPspA rod after incubation with ATP
1OE7	;	1.8	;	28kDa glutathione S-transferase from Schistosoma haematobium
1OE8	;	1.65	;	28kDa glutathione S-transferase from Schistosoma haematobium (glutathione saturated)
8OIS	;	3.0	;	28S human mitochondrial small ribosomal subunit with mtRF1 and P-site tRNA
8OIP	;	3.6	;	28S mammalian mitochondrial small ribosomal subunit with mtRF1 and P-site tRNA
1D4R	;	2.0	;	29-mer fragment of human srp rna helix 6
8AKY	;	4.7	;	290 A SynPspA rod after incubation with ATP
5A93	;	2.2	;	293K Joint X-ray Neutron with Cefotaxime: EXPLORING THE MECHANISM OF BETA-LACTAM RING PROTONATION IN THE CLASS A BETA-LACTAMASE ACYLATION MECHANISM USING NEUTRON AND X-RAY CRYSTALLOGRAPHY
5A93	;	1.598	;	293K Joint X-ray Neutron with Cefotaxime: EXPLORING THE MECHANISM OF BETA-LACTAM RING PROTONATION IN THE CLASS A BETA-LACTAMASE ACYLATION MECHANISM USING NEUTRON AND X-RAY CRYSTALLOGRAPHY
6KPI	;	2.43	;	298 K cryoEM structure of Sso-KARI in complex with Mg2+
6KPJ	;	2.56	;	298 K cryoEM structure of Sso-KARI in complex with Mg2+, NADH and CPD
1A0Q	;	2.3	;	29G11 COMPLEXED WITH PHENYL [1-(1-N-SUCCINYLAMINO)PENTYL] PHOSPHONATE
7JOA	;	3.3	;	2:1 cGAS-nucleosome complex
1CD9	;	2.8	;	2:2 COMPLEX OF G-CSF WITH ITS RECEPTOR
1PGR	;	3.5	;	2:2 COMPLEX OF G-CSF WITH ITS RECEPTOR
1Z8R	;		;	2A cysteine proteinase from human coxsackievirus B4 (strain JVB / Benschoten / New York / 51)
2HRV	;	1.95	;	2A CYSTEINE PROTEINASE FROM HUMAN RHINOVIRUS 2
3MUS	;	2.0	;	2A Resolution Structure of Rat Type B Cytochrome b5
4HEI	;	1.6	;	2A X-RAY STRUCTURE OF HPF from VIBRIO CHOLERAE
5T0Y	;	3.011	;	2A10 Antibody FAB fragment
5SZF	;	2.52	;	2A10 FAB fragment 2.54 Angstoms
6BGA	;	2.307	;	2B4 I-Ek TCR-MHC complex with affinity-enhancing Velcro peptide
1JY8	;	2.5	;	2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase (IspF)
1W77	;	2.0	;	2C-methyl-D-erythritol 4-phosphate cytidylyltransferase (IspD) from Arabidopsis thaliana
1MWA	;	2.4	;	2C/H-2KBM3/DEV8 ALLOGENEIC COMPLEX
6FLC	;	2.0	;	2C8 Fab bound to EDIII of DenV 2
8B0H	;	3.3	;	2C9, C5b9-CD59 cryoEM structure
8B0G	;	3.3	;	2C9, C5b9-CD59 structure
7UTG	;	1.25	;	2D9 nanobody to BCL11A-exZF23 fragment
2DZI	;		;	2DZI/Solution Structure of the N-terminal Ubiquitin-like Domain in Human Ubiquitin-like Protein 4A (GDX)
2DZJ	;		;	2DZJ/Solution Structure of the N-terminal Ubiquitin-like Domain in Human Synaptic Glycoprotein SC2
12E8	;	1.9	;	2E8 FAB FRAGMENT
3LEX	;	1.97	;	2F5 Epitope scaffold elicited anti-HIV-1 monoclonal antibody 11F10 in complex with HIV-1 GP41
3LEY	;	1.99	;	2F5 Epitope scaffold elicited anti-HIV-1 monoclonal antibody 6a7 in complex with HIV-1 GP41
3LES	;	2.77	;	2F5 Epitope scaffold ES2
1DOI	;	1.9	;	2FE-2S FERREDOXIN FROM HALOARCULA MARISMORTUI
1OFF	;	1.8	;	2Fe-2S Ferredoxin from Synechocystis sp. PCC 6803
8E6K	;	3.1	;	2H08 Fab in complex with influenza virus neuraminidase from A/Brevig Mission/1/1918 (H1N1)
4KVC	;	2.306	;	2H2 Fab fragment of immature Dengue virus
3T5W	;	1.8	;	2ME modified human SOD1
2F9S	;	1.401	;	2nd Crystal Structure Of A Soluble Domain Of ResA In The Oxidised Form
2BYG	;	1.85	;	2nd PDZ Domain of Discs Large Homologue 2
3MLG	;	2.29	;	2ouf-2x, a designed knotted protein
3MLI	;	2.9	;	2ouf-ds, a disulfide-linked dimer of Helicobacter pylori protein HP0242
7CRK	;	1.85	;	2ps Structure of Chloride ion pumping rhodopsin (ClR) with NTQ motif
2QB1	;	2.61	;	2TEL crystallization module
7JKB	;	2.55	;	2xVH Fab
6RO3	;	1.03	;	2Yr-X: Lysozyme with Re Cluster 2 year on shelf
2FDN	;	0.94	;	2[4FE-4S] FERREDOXIN FROM CLOSTRIDIUM ACIDI-URICI
8AEY	;	3.05	;	3 A CRYO-EM STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS FERRITIN FROM TIMEPIX3 detector
8GXX	;	3.0	;	3 nucleotide-bound V1EG of V/A-ATPase from Thermus thermophilus.
1MFJ	;		;	3' Stem-Loop from Human U4 SNRNA
4YAZ	;	2.0	;	3',3'-cGAMP riboswitch bound with 3',3'-cGAMP
4YB0	;	2.121	;	3',3'-cGAMP riboswitch bound with c-di-GMP
2JC4	;	1.9	;	3'-5' exonuclease (NExo) from Neisseria Meningitidis
7LNF	;	1.652	;	3'-deoxy modification at 3' end of RNA primer complex with guanosine dinucleotide ligand G(5')ppp(5')G
398D	;	1.94	;	3'-DNA-RNA-5' JUNCTION FORMED DURING INITIATION OF MINUS-STRAND SYNTHESIS OF HIV REPLICATION
1ZBH	;	3.0	;	3'-end specific recognition of histone mRNA stem-loop by 3'-exonuclease
3Q61	;	1.56	;	3'-Fluoro Hexitol Nucleic Acid DNA Structure
1B99	;	2.7	;	3'-FLUORO-URIDINE DIPHOSPHATE BINDING TO NUCLEOSIDE DIPHOSPHATE KINASE
1BUX	;	2.8	;	3'-PHOSPHORYLATED NUCLEOTIDES BINDING TO NUCLEOSIDE DIPHOSPHATE KINASE
2J14	;	2.8	;	3,4,5-Trisubstituted Isoxazoles as Novel PPARdelta Agonists: Part2
3H0E	;	1.997	;	3,4-Dihydropyrimido(1,2-a)indol-10(2H)-ones as Potent Non-Peptidic Inhibitors of Caspase-3
1PVW	;	2.45	;	3,4-dihydroxy-2-butanone 4-phosphate synthase from M. jannaschii
1PVY	;	1.7	;	3,4-dihydroxy-2-butanone 4-phosphate synthase from M. jannaschii in complex with ribulose 5-phosphate
1SNN	;	1.55	;	3,4-dihydroxy-2-butanone 4-phosphate synthase from Methanococcus jannaschii
1B6Y	;		;	3,N4-ETHENO-2'-DEOXYCYTIDINE OPPOSITE ADENINE IN AN 11-MER DUPLEX, SOLUTION STRUCTURE FROM NMR AND MOLECULAR DYNAMICS, 2 STRUCTURES
1B60	;		;	3,N4-ETHENO-2'-DEOXYCYTIDINE OPPOSITE CYTIDINE IN AN 11-MER DUPLEX, SOLUTION STRUCTURE FROM NMR AND MOLECULAR DYNAMICS
1B6X	;		;	3,N4-ETHENO-2'-DEOXYCYTIDINE OPPOSITE GUANINE IN AN 11-MER DUPLEX, SOLUTION STRUCTURE FROM NMR AND MOLECULAR DYNAMICS, 4 STRUCTURES
1B5K	;		;	3,N4-ETHENO-2'-DEOXYCYTIDINE OPPOSITE THYMIDINE IN AN 11-MER DUPLEX, SOLUTION STRUCTURE FROM NMR AND MOLECULAR DYNAMICS
2BYH	;	1.9	;	3-(5-chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as Inhibitors of the Hsp90 Molecular Chaperone
2BYI	;	1.6	;	3-(5-chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as Inhibitors of the Hsp90 Molecular Chaperone
4MK2	;	1.85	;	3-(5-hydroxy-6-oxo-1,6-dihydropyridin-3-yl)benzonitrile bound to influenza 2009 pH1N1 endonuclease
6UOE	;	1.8	;	3-25 Fab germline-reversion variant bound to an HCMV gB-derived peptide
1LWI	;	2.7	;	3-ALPHA-HYDROXYSTEROID/DIHYDRODIOL DEHYDROGENASE FROM RATTUS NORVEGICUS
3L1S	;	2.9	;	3-Aryl-4-(arylhydrazono)-1H-pyrazol-5-ones: Highly ligand efficient and potent inhibitors of GSK3
2FEL	;	2.2	;	3-carboxy-cis,cis-muconate lactonizing enzyme from Agrobacterium radiobacter S2
2FEN	;	2.6	;	3-carboxy-cis,cis-muconate lactonizing enzyme from Agrobacterium radiobacter S2
1SYM	;		;	3-D SOLUTION STRUCTURE OF REDUCED APO-S100B FROM RAT, NMR, 20 STRUCTURES
1DZA	;	1.65	;	3-D structure of a HP-RNase
1GM6	;	2.13	;	3-D STRUCTURE OF A SALIVARY LIPOCALIN FROM BOAR
2DFS	;	24.0	;	3-D structure of Myosin-V inhibited state
2WYR	;	2.245	;	3-D structure of PhTET1-12s, dodecamer in the asymmetric unit
3HYX	;	2.9	;	3-D X-Ray structure of the sulfide:quinone oxidoreductase from Aquifex aeolicus in complex with Aurachin C
3HYV	;	2.3	;	3-D X-Ray structure of the sulfide:quinone oxidoreductase from the hyperthermophilic bacterium Aquifex aeolicus
3HYW	;	2.0	;	3-D X-Ray structure of the sulfide:quinone oxidoreductase of the hyperthermophilic bacterium Aquifex aeolicus in complex with decylubiquinone
2DHQ	;	2.0	;	3-DEHYDROQUINATE DEHYDRATASE FROM MYCOBACTERIUM TUBERCULOSIS
1H0S	;	1.7	;	3-dehydroquinate dehydratase from Mycobacterium tuberculosis in complex with 3-hydroxyimino-quinic acid
1H05	;	1.5	;	3-DEHYDROQUINATE DEHYDRATASE FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH SULPHATE
3QBD	;	2.47	;	3-Dehydroquinate Synthase (aroB) from Mycobacterium tuberculosis in complex with NAD
5EX4	;	2.25	;	3-deoxy-d-arabino-heptulosonate 7-phosphate synthase from Mycobacterium tuberculosis complexed with tryptophan in all three allosteric binding sites
5E2L	;	2.5	;	3-deoxy-D-arabino-heptulosonate 7-phosphate synthase from Mycobacterium tuberculosis in complex with D-phenylalanine
5E7Z	;	2.4	;	3-deoxy-D-arabino-heptulosonate 7-phosphate synthase from Mycobacterium tuberculosis in complex with D/L-tryptophan and D-phenylalanine
5E40	;	2.05	;	3-Deoxy-D-arabino-heptulosonate 7-phosphate synthase from Mycobacterium tuberculosis with D-tyrosine bound in the phenylalanine binding site
5E4N	;	2.05	;	3-Deoxy-D-arabino-heptulosonate 7-phosphate synthase from Mycobacterium tuberculosis with D-tyrosine bound in the tyrosine and phenylalanine binding sites
2YPP	;	2.3	;	3-deoxy-D-arabino-heptulosonate 7-phosphate synthase in complex with 3 tyrosine molecules
5E5G	;	1.95	;	3-deoxy-D-arabino-heptulosonate 7-phosphate synthase with D-tryptophan bound in the tryptophan and phenylalanine binding sites
2YPO	;	2.0	;	3-deoxy-D-arabino-heptulosonate 7-phosphate synthase with phenylalanine bound in only one site
2YPQ	;	2.76	;	3-deoxy-D-arabino-heptulosonate 7-phosphate synthase with tryptophan and tyrosine bound
3JTJ	;	2.18	;	3-deoxy-manno-octulosonate cytidylyltransferase from Yersinia pestis
1Q9H	;	2.35	;	3-Dimensional structure of native Cel7A from Talaromyces emersonii
6ZOB	;	2.8	;	3-Formylrifamycin SV binding to the access pocket of AcrB L protomer
6ZO7	;	2.85	;	3-Formylrifamycin SV binding to the access pocket of AcrB-G619P L and T protomer
6ZOH	;	2.8	;	3-Formylrifamycin SV binding to the access pocket of AcrB-G619P_G621P L and T protomers
3UDL	;	2.174	;	3-heterocyclyl quinolone bound to HCV NS5B
4I6Y	;	1.45	;	3-hydroxy-3-methyl (HMG) Coenzyme A Reductase bound to R-Mevalonate
4I6A	;	1.85	;	3-hydroxy-3-methylglutaryl (HMG) Coenzyme A reductase from Pseudomonas mevalonii complexed with HMG-CoA
4I6W	;	1.66	;	3-hydroxy-3-methylglutaryl (HMG) Coenzyme-A reductase complexed with thiomevalonate
4I64	;	1.75	;	3-hydroxy-3-methylglutaryl Coenzyme A reductase from Pseudomonas mevalonii, a high resolution native structure
3QAU	;	2.3	;	3-Hydroxy-3-MethylGlutaryl-Coenzyme A Reductase from Streptococcus pneumoniae
3QAE	;	2.3	;	3-hydroxy-3-methylglutaryl-coenzyme A reductase of Streptococcus pneumoniae
6NEM	;	1.95	;	3-hydroxy-5-[(naphthalen-1-yl)methyl]-6-[4-(1H-tetrazol-5-yl)phenyl]pyridin-2(1H)-one bound to influenza 2009 pH1N1 endonuclease
4M5O	;	2.0	;	3-HYDROXY-6-PHENYL-1,2-DIHYDROPYRIDIN-2-ONE bound to influenza 2009 H1N1 endonuclease
5HYM	;	2.3	;	3-Hydroxybenzoate 6-hydroxylase from Rhodococcus jostii in complex with phosphatidylinositol
1CNZ	;	1.76	;	3-ISOPROPYLMALATE DEHYDROGENASE (IPMDH) FROM SALMONELLA TYPHIMURIUM
1WAL	;	2.27	;	3-ISOPROPYLMALATE DEHYDROGENASE (IPMDH) MUTANT (M219A)FROM THERMUS THERMOPHILUS
1CM7	;	2.06	;	3-ISOPROPYLMALATE DEHYDROGENASE FROM ESCHERICHIA COLI
3VMK	;	1.48	;	3-isopropylmalate dehydrogenase from Shewanella benthica DB21 MT-2
3VMJ	;	1.56	;	3-isopropylmalate dehydrogenase from Shewanella oneidensis MR-1
3WZV	;	1.9	;	3-isopropylmalate dehydrogenase from Shewanella oneidensis MR-1 at 0.1MPa - complex with IPM and Mg
3VL2	;	2.06	;	3-isopropylmalate dehydrogenase from Shewanella oneidensis MR-1 at 160 MPa
3VL3	;	1.8	;	3-isopropylmalate dehydrogenase from Shewanella oneidensis MR-1 at 340 MPa
3VL4	;	1.88	;	3-isopropylmalate dehydrogenase from Shewanella oneidensis MR-1 at 410 MPa
3VL6	;	2.07	;	3-isopropylmalate dehydrogenase from Shewanella oneidensis MR-1 at 580 MPa
3WZW	;	1.8	;	3-isopropylmalate dehydrogenase from Shewanella oneidensis MR-1 at 580MPa - complex with IPM and Mg
3VL7	;	2.2	;	3-isopropylmalate dehydrogenase from Shewanella oneidensis MR-1 at 650 MPa
3VKZ	;	1.84	;	3-isopropylmalate dehydrogenase from Shewanella oneidensis MR-1 at atmospheric pressure
2AYQ	;	3.0	;	3-ISOPROPYLMALATE DEHYDROGENASE FROM THE MODERATE FACULTATIVE THERMOPHILE, BACILLUS COAGULANS
1IDM	;	2.2	;	3-ISOPROPYLMALATE DEHYDROGENASE, LOOP-DELETED CHIMERA
1XAA	;	2.1	;	3-ISOPROPYLMALATE DEHYDROGENASE, LOW TEMPERATURE (100K) STRUCTURE
1XAB	;	2.1	;	3-ISOPROPYLMALATE DEHYDROGENASE, LOW TEMPERATURE (150K) STRUCTURE
7VTR	;	1.93	;	3-ketoacyl-CoA thiolase Tfu_0875
1OKG	;	2.1	;	3-mercaptopyruvate sulfurtransferase from Leishmania major
1MPG	;	1.8	;	3-METHYLADENINE DNA GLYCOSYLASE II FROM ESCHERICHIA COLI
2JHJ	;	1.9	;	3-methyladenine dna-glycosylase from Archaeoglobus fulgidus
2JHN	;	1.8	;	3-methyladenine dna-glycosylase from Archaeoglobus fulgidus
1PVS	;	2.4	;	3-methyladenine Glcosylase II(AlkA) Hypoxanthine complex
2RBQ	;	1.633	;	3-methylbenzylazide in complex with T4 L99A/M102Q
2RB2	;	1.463	;	3-methylbenzylazide in complex with T4 lysozyme L99A
8F41	;	3.9	;	3-methylcrotonyl-CoA carboxylase in filament, alpha-subunit centered
8F3D	;	3.4	;	3-methylcrotonyl-CoA carboxylase in filament, beta-subunit centered
6X9M	;	1.0	;	3-O-methyl-glucose-bound structure of Marinomonas primoryensis PA14 carbohydrate-binding domain
1ISK	;		;	3-OXO-DELTA5-STEROID ISOMERASE, NMR, 20 STRUCTURES
7SUB	;	1.78	;	3-oxoacyl-ACP reductase FabG
2A4K	;	2.301	;	3-Oxoacyl-[acyl carrier protein] reductase from Thermus thermophilus TT0137
4DML	;	2.5	;	3-oxoacyl-[acyl-carrier-protein] reductase from Synechococcus elongatus PCC 7942
4DMM	;	2.38	;	3-oxoacyl-[acyl-carrier-protein] reductase from Synechococcus elongatus PCC 7942 in complex with NADP
1QPG	;	2.4	;	3-PHOSPHOGLYCERATE KINASE, MUTATION R65Q
5G55	;	2.45	;	3-Quinoline Carboxamides inhibitors of Pi3K
5AHS	;	2.3	;	3-Sulfinopropionyl-Coenzyme A (3SP-CoA) desulfinase from Advenella mimgardefordensis DPN7T: holo crystal structure with the substrate analog succinyl-CoA
5AF7	;	1.89	;	3-Sulfinopropionyl-coenzyme A (3SP-CoA) desulfinase from Advenella mimigardefordensis DPN7T: crystal structure and function of a desulfinase with an acyl-CoA dehydrogenase fold. Native crystal structure
3QGA	;	3.0	;	3.0 A Model of Iron Containing Urease UreA2B2 from Helicobacter mustelae
3QGK	;	3.0	;	3.0 A Model of Iron Containing Urease UreA2B2 from Helicobacter mustelae (refined w/ no ordered solvent)
2X0S	;	2.997	;	3.0 A RESOLUTION CRYSTAL STRUCTURE OF GLYCOSOMAL PYRUVATE PHOSPHATE DIKINASE FROM TRYPANOSOMA BRUCEI
7P30	;	3.0	;	3.0 A resolution structure of a DNA-loaded MCM double hexamer
364D	;	3.0	;	3.0 A STRUCTURE OF FRAGMENT I FROM E. COLI 5S RRNA
3RED	;	3.03	;	3.0 A structure of the Prunus mume hydroxynitrile lyase isozyme-1
2H1N	;	3.0	;	3.0 A X-ray structure of putative oligoendopeptidase F: crystals grown by vapor diffusion technique
5HVN	;	3.0	;	3.0 Angstrom Crystal Structure of 3-dehydroquinate Synthase (AroB) from Francisella tularensis in Complex with NAD.
2F9J	;	3.0	;	3.0 angstrom resolution structure of a Y22M mutant of the spliceosomal protein p14 bound to a region of SF3b155
4MLK	;	3.051	;	3.05A resolution structure of CT584 from Chlamydia trachomatis
6FQM	;	3.06	;	3.06A COMPLEX OF S.AUREUS GYRASE with imidazopyrazinone T1 AND DNA
5V57	;	3.0	;	3.0A SYN structure of the multi-domain human smoothened receptor in complex with TC114
4Q0C	;	3.1	;	3.1 A resolution crystal structure of the B. pertussis BvgS periplasmic domain
2H1J	;	3.1	;	3.1 A X-ray structure of putative Oligoendopeptidase F: Crystals grown by microfluidic seeding
7XR2	;	3.1	;	3.1 Angstrom cryoEM icosahedral reconstruction of mud crab reovirus
3IZX	;	3.1	;	3.1 Angstrom cryoEM structure of cytoplasmic polyhedrosis virus
1XQJ	;	3.1	;	3.10 A Crystal structure of maspin, space group I 4 2 2
1XQG	;	3.1	;	3.10 A crystal structure of maspin, Space group P 4 21 2
6VJ2	;	3.1	;	3.10 Angstrom Resolution Crystal Structure of Foldase Protein (PrsA) from Lactococcus lactis
6FQS	;	3.11	;	3.11A complex of S.Aureus gyrase with imidazopyrazinone T3 and DNA
7ZXY	;	3.15	;	3.15 Angstrom cryo-EM structure of the dimeric cytochrome b6f complex from Synechocystis sp. PCC 6803 with natively bound plastoquinone and lipid molecules.
5CDO	;	3.15	;	3.15A structure of QPT-1 with S.aureus DNA gyrase and DNA
5U9G	;	3.2	;	3.2 A cryo-EM ArfA-RF2 ribosome rescue complex (Structure I)
5U9F	;	3.2	;	3.2 A cryo-EM ArfA-RF2 ribosome rescue complex (Structure II)
7Y1B	;	3.23	;	3.2 angstrom cryo-EM structure of extracellular region of mouse Basigin-2 in complex with the Fab fragment of antibody 6E7F1
5WKT	;	3.2	;	3.2-Angstrom In situ Mylar structure of bovine opsin at 100 K
6CLB	;	3.2	;	3.20 A MicroED structure of proteinase K at 7.8 e- / A^2
7VDC	;	3.28	;	3.28 A structure of the rabbit muscle aldolase
6B3J	;	3.3	;	3.3 angstrom phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptor-Gs complex
5ZX5	;	3.28	;	3.3 angstrom structure of mouse TRPM7 with EDTA
6KE6	;	3.4	;	3.4 angstrom cryo-EM structure of yeast 90S small subunit preribosome
7XR3	;	3.7	;	3.4 Angstrom cryoEM D5 reconstruction of mud crab reovirus
6QX2	;	3.4	;	3.4A structure of benzoisoxazole 3 with S.aureus DNA gyrase and DNA
6ZS5	;	3.5	;	3.5 A cryo-EM structure of human uromodulin filament core
357D	;	3.5	;	3.5 A structure of fragment I from E. coli 5S RRNA
5T3Z	;	3.5	;	3.5 Angstrom Crystal Structure of a Fully and Natively Glycosylated BG505 SOSIP.664 HIV-1 Env Trimer in Complex with the Broadly Neutralizing Antibodies IOMA and 10-1074
5X41	;	3.47	;	3.5A resolution structure of a cobalt energy-coupling factor transporter using LCP method-CbiMQO
7VDE	;	3.6	;	3.6 A structure of the human hemoglobin
6RQF	;	3.58	;	3.6 Angstrom cryo-EM structure of the dimeric cytochrome b6f complex from Spinacia oleracea with natively bound thylakoid lipids and plastoquinone molecules
3J6J	;	3.64	;	3.6 Angstrom resolution MAVS filament generated from helical reconstruction
4MBR	;	3.65	;	3.65 Angstrom Crystal Structure of Serine-rich Repeat Protein (Srr2) from Streptococcus agalactiae
6PXK	;	3.647	;	3.65 Angstroms resolution structure of HslU with an axial-channel plug
6M0S	;	3.6	;	3.6A Yeast Vo state3 prime
6BWI	;	3.7	;	3.7 angstrom cryoEM structure of full length human TRPM4
6BWD	;	3.7	;	3.7 angstrom cryoEM structure of truncated mouse TRPM7
6PXL	;	3.741	;	3.74 Angstroms resolution structure of HlsU with an axial-channel plug
3CNF	;	3.88	;	3.88 Angstrom structure of cytoplasmic polyhedrosis virus by cryo-electron microscopy
5T3X	;	3.9	;	3.9 Angstrom Crystal Structure of a Fully and Natively Glycosylated BG505 SOSIP.664 HIV-1 Env Trimer in Complex with the Broadly Neutralizing Antibodies IOMA and 10-1074.
3V0B	;	3.9	;	3.9 angstrom crystal structure of BoNT/Ai in complex with NTNHA
6CXC	;	3.9	;	3.9A Cryo-EM structure of murine antibody bound at a novel epitope of respiratory syncytial virus fusion protein
1ZWU	;		;	30 NMR structures of AcAMP2-like peptide with non natural beta-(2-naphthyl)-alanine residue.
1L5I	;		;	30-CONFORMER NMR ENSEMBLE OF THE N-TERMINAL, DNA-BINDING DOMAIN OF THE REPLICATION INITIATION PROTEIN FROM A GEMINIVIRUS (TOMATO YELLOW LEAF CURL VIRUS-SARDINIA)
8AKX	;	6.6	;	305 A SynPspA rod after incubation with ATP
6KPK	;	2.3	;	309 K cryoEM structure of Sso-KARI in complex with Mg2+
6KQJ	;	2.54	;	309 K cryoEM structure of Sso-KARI in complex with Mg2+, NADH and CPD
3NQ4	;	3.5	;	30mer structure of Lumazine synthase from Salmonella typhimurium LT2
6O7K	;	4.2	;	30S initiation complex
4IYL	;	2.36	;	30S ribosomal protein S15 from Campylobacter jejuni
8AA8	;	1.71	;	30S ribosomal protein S24e from Thermococcus barophilus
8A8S	;	1.659	;	30S ribosomal protein S24e from Thermococcus kodakarensis
7OE1	;	3.05	;	30S ribosomal subunit from E. coli
2YKR	;	9.8	;	30S ribosomal subunit with RsgA bound in the presence of GMPPNP
4YY3	;	3.6	;	30S ribosomal subunit- HigB complex
2F4V	;	3.8	;	30S ribosome + designer antibiotic
6WUA	;	3.2	;	30S subunit (head) of 70S Ribosome Enterococcus faecalis MultiBody refinement
6WUB	;	3.2	;	30S subunit (head) of 70S Ribosome Enterococcus faecalis MultiBody refinement
6W6K	;	3.6	;	30S-Activated-high-Mg2+
6W77	;	3.6	;	30S-Inactivated-high-Mg2+ Class A
6W7M	;	3.8	;	30S-Inactive-high-Mg2+ + carbon layer
6W7N	;	3.4	;	30S-Inactive-low-Mg2+ Class A
6W7W	;	3.9	;	30S-Inactive-low-Mg2+ Class B
8EYT	;	2.8	;	30S_delta_ksgA+KsgA complex
8EYQ	;	3.3	;	30S_delta_ksgA_h44_inactive_conformation
4RBQ	;	1.05	;	32 base pair oligo(U) RNA
5AY6	;	1.839	;	32 kDa Fragment of the Flagellar hook protein FlgE from Caulobacter crescentus
8AKZ	;	6.9	;	320 A SynPspA rod after incubation with ATP
1U86	;		;	321-TW-322 insertion mutant of the third zinc finger of BKLF
6KQ4	;	2.3	;	323 K cryoEM structure of Sso-KARI in complex with Mg2+
6KQK	;	2.17	;	323 K cryoEM structure of Sso-KARI in complex with Mg2+, NADH and CPD
6KQ8	;	3.0	;	328 K cryoEM structure of Sso-KARI in complex with Mg2+
6KQO	;	2.52	;	328 K cryoEM structure of Sso-KARI in complex with Mg2+, NADH and CPD
8T8P	;	3.4	;	33-mer FliF MS-ring from Salmonella
6L9Z	;	2.5	;	338 bp di-nucleosome assembled with linker histone H1.X
6SCN	;	3.1	;	33mer structure of the Salmonella flagella MS-ring protein FliF
7D84	;	3.7	;	34-fold symmetry Salmonella S ring formed by full-length FliF
6LA2	;	3.89	;	343 bp di-nucleosome harboring cohesive DNA termini assembled with linker histone H1.0
6KPE	;	2.83	;	343 K cryoEM structure of Sso-KARI in complex with Mg2+
6KPH	;	2.41	;	343 K cryoEM structure of Sso-KARI in complex with Mg2+, NADH and CPD
6LA8	;	3.4	;	349 bp di-nucleosome harboring cohesive DNA termini assembled with linker histone H1.0
6LA9	;	3.7	;	349 bp di-nucleosome harboring cohesive DNA termini assembled with linker histone H1.0 (high cryoprotectant)
6SD3	;	3.3	;	34mer structure of the Salmonella flagella MS-ring protein FliF
3I77	;	2.1	;	35/99/170-loops of FXa in SGT
3I78	;	3.0	;	35/99/170/186/220-loops of FXa in SGT
7COW	;	2.86	;	353 bp di-nucleosome harboring cohesive DNA termini with linker histone H1.0
6M3V	;	4.6	;	355 bp di-nucleosome harboring cohesive DNA termini
6M44	;	3.81	;	355 bp di-nucleosome harboring cohesive DNA termini (high cryoprotectant)
8AL0	;	6.9	;	365 A SynPspA rod after incubation with ATP
6ATT	;	3.77	;	39S Fab bound to HER2 ecd
8OIT	;	2.9	;	39S human mitochondrial large ribosomal subunit with mtRF1 and P-site tRNA
4CE4	;	4.9	;	39S large subunit of the porcine mitochondrial ribosome
8OIQ	;	3.5	;	39S mammalian mitochondrial large ribosomal subunit with mtRF1 and P-site tRNA
7NSH	;	3.2	;	39S mammalian mitochondrial large ribosomal subunit with mtRRF (post) and mtEFG2
1FG9	;	2.9	;	3:1 COMPLEX OF INTERFERON-GAMMA RECEPTOR WITH INTERFERON-GAMMA DIMER
3T5Q	;	3.0	;	3A structure of Lassa virus nucleoprotein in complex with ssRNA
1N0Q	;	1.26	;	3ANK: A designed ankyrin repeat protein with three identical consensus repeats
2WNX	;	1.31	;	3b' carbohydrate-binding module from the Cel9V glycoside hydrolase from Clostridium thermocellum
2WO4	;	1.85	;	3b' carbohydrate-binding module from the Cel9V glycoside hydrolase from Clostridium thermocellum, in-house data
2WOB	;	2.0	;	3b' carbohydrate-binding module from the Cel9V glycoside hydrolase from Clostridium thermocellum. Orthorhombic structure
5CBA	;	2.5	;	3B4 in complex with CXCL13 - 3B4-CXCL13
2BHG	;	1.9	;	3C protease from type A10(61) foot-and-mouth disease virus
2J92	;	2.2	;	3C PROTEASE FROM TYPE A10(61) FOOT-AND-MOUTH DISEASE VIRUS - Crystal packing mutant (K51Q)
3ZV9	;	2.05	;	3C protease of Enterovirus 68 complexed with Michael receptor inhibitor 74
3ZVA	;	2.2	;	3C protease of Enterovirus 68 complexed with Michael receptor inhibitor 75
3ZVB	;	2.65	;	3C protease of Enterovirus 68 complexed with Michael receptor inhibitor 81
3ZVC	;	2.0	;	3C protease of Enterovirus 68 complexed with Michael receptor inhibitor 82
3ZVD	;	2.25	;	3C protease of Enterovirus 68 complexed with Michael receptor inhibitor 83
3ZVE	;	1.8	;	3C protease of Enterovirus 68 complexed with Michael receptor inhibitor 84
3ZVF	;	2.5	;	3C protease of Enterovirus 68 complexed with Michael receptor inhibitor 85
3ZVG	;	2.1	;	3C protease of Enterovirus 68 complexed with Michael receptor inhibitor 98
6T1Q	;	1.3	;	3C-like protease from Southampton norovirus.
6T2X	;	1.54	;	3C-like protease from Southampton virus complexed with FMOPL000004a.
6T4S	;	2.02	;	3C-like protease from Southampton virus complexed with FMOPL000013a.
6T5D	;	1.42	;	3C-like protease from Southampton virus complexed with FMOPL000014a.
6T5R	;	1.78	;	3C-like protease from Southampton virus complexed with FMOPL000091a.
6T2I	;	1.61	;	3C-like protease from Southampton virus complexed with FMOPL000157a.
6TAL	;	1.51	;	3C-like protease from Southampton virus complexed with FMOPL000227a.
6TC1	;	1.67	;	3C-like protease from Southampton virus complexed with FMOPL000283a.
6T3G	;	1.63	;	3C-like protease from Southampton virus complexed with FMOPL000324a.
6TBO	;	2.07	;	3C-like protease from Southampton virus complexed with FMOPL000363a.
6TAW	;	1.41	;	3C-like protease from Southampton virus complexed with FMOPL000411a.
6TBP	;	1.56	;	3C-like protease from Southampton virus complexed with FMOPL000490a.
6T82	;	1.46	;	3C-like protease from Southampton virus complexed with FMOPL000542a.
6T49	;	1.56	;	3C-like protease from Southampton virus complexed with FMOPL000582a.
6T8T	;	1.68	;	3C-like protease from Southampton virus complexed with FMOPL000603a.
6T8R	;	1.88	;	3C-like protease from Southampton virus complexed with FMOPL000605a.
6TGL	;	1.99	;	3c-like protease from Southampton virus complexed with FMOPL000644a.
6T71	;	1.52	;	3C-like protease from Southampton virus complexed with XST00000375b.
6TCF	;	1.79	;	3C-like protease from Southampton virus complexed with XST00000642b.
6T6W	;	1.8	;	3C-like protease from Southampton virus complexed with XST00000692b.
6XP6	;	2.4	;	3C11-DQ2-glia-a2 complex
5TV4	;	4.2	;	3D cryo-EM reconstruction of nucleotide-free MsbA in lipid nanodisc
5GTA	;	2.998	;	3D Crystal Structure of LsrB Bound to Furanosyl diester (R)-THMF, from Salmonella typhi
4M64	;	3.35	;	3D crystal structure of Na+/melibiose symporter of Salmonella typhimurium
6LES	;	2.004	;	3D domain-swapped dimer of the maltose-binding protein fused to a fragment of the focal adhesion kinase
6LF3	;	3.2	;	3D domain-swapped dimer of the maltose-binding protein fused to a fragment of the protein-tyrosine kinase 2-beta
1TIJ	;	3.03	;	3D Domain-swapped human cystatin C with amyloid-like intermolecular beta-sheets
6ZHB	;	3.25	;	3D electron diffraction structure of bovine insulin
8CPC	;	2.91	;	3D electron diffraction structure of Hen Egg-White Lysozyme from nano-crystals obtained by high pressure freezing and cryo-sectioning
6ZHN	;	2.76	;	3D electron diffraction structure of thaumatin from Thaumatococcus daniellii
6ZHJ	;	3.26	;	3D electron diffraction structure of thermolysin from Bacillus thermoproteolyticus
4D0A	;	6.0	;	3D EM map of the sodium proton antiporter MjNhaP1 from Methanocaldococcus jannaschii
7X7N	;	4.47	;	3D model of the 3-RBD up single trimeric spike protein of SARS-CoV2 in the presence of synthetic peptide SIH-5.
6R9Z	;		;	3D NMR solution structure of ligand peptide (Ac)EVNPPVP of Pro-Pro endopeptidase-1
2NAQ	;		;	3D NMR solution structure of NLRP3 PYD
2M9R	;		;	3D NMR structure of a complex between the amyloid beta peptide (1-40) and the polyphenol epsilon-viniferin glucoside
2M9S	;		;	3D NMR structure of a complex between the amyloid beta peptide (1-40) and the polyphenol epsilon-viniferin glucoside
2RMI	;		;	3D NMR structure of astressin
2K1M	;		;	3D NMR structure of domain cC0 of cardiac myosin binding protein C (MyBPC)
2JND	;		;	3D NMR structure of ECD1 of mCRF-R2b in complex with Astressin
2MOL	;		;	3D NMR structure of the cytoplasmic rhodanese domain of the full-length inner membrane protein YgaP from Escherichia coli
2MOI	;		;	3D NMR structure of the cytoplasmic rhodanese domain of the inner membrane protein YgaP from Escherichia coli
1U34	;		;	3D NMR structure of the first extracellular domain of CRFR-2beta, a type B1 G-protein coupled receptor
2MPN	;		;	3D NMR structure of the transmembrane domain of the full-length inner membrane protein YgaP from Escherichia coli
7ZHS	;	6.9	;	3D reconstruction of the cylindrical assembly of DnaJA2 delta G/F by imposing D5 symmetry
1J47	;		;	3D Solution NMR Structure of the M9I Mutant of the HMG-Box Domain of the Human Male Sex Determining Factor SRY Complexed to DNA
1J46	;		;	3D Solution NMR Structure of the Wild Type HMG-BOX Domain of the Human Male Sex Determining Factor Sry Complexed to DNA
2LG4	;		;	3D solution structure of antimicrobial peptide aurelin
2L37	;		;	3D solution structure of arginine/glutamate-rich polypeptide Luffin P1 from the seeds of sponge gourd (Luffa cylindrical)
2M6N	;		;	3D solution structure of EMI1 (Early Mitotic Inhibitor 1)
1AWZ	;		;	3D SOLUTION STRUCTURE OF HUMAN ANGIOGENIN DETERMINED BY 1H, 15N NMR SPECTROSCOPY, 30 STRUCTURES
2LJ7	;		;	3D solution structure of plant defensin Lc-def
2CXJ	;		;	3D Solution Structure of S100A13
1XJ1	;		;	3D solution structure of the C-terminal cysteine-rich domain of the VHv1.1 polydnaviral gene product
1X3Q	;		;	3D Solution Structure of the Chromo-2 Domain of cpSRP43
2HUG	;		;	3D Solution Structure of the Chromo-2 Domain of cpSRP43 complexed with cpSRP54 peptide
1X3P	;		;	3D solution structure of the Chromo-3 domain of cpSRP43
1YL8	;		;	3D Solution Structure of [Tyr3]Octreotate derivatives in DMSO
1YL9	;		;	3D Solution Structure of [Tyr3]Octreotate derivatives in DMSO
2JTC	;		;	3D structure and backbone dynamics of SPE B
2MTY	;		;	3D structure determination of STARP peptides implicated in P. falciparum Invasion of hepatic cells
2MU6	;		;	3D structure determination of STARP peptides implicated in P. falciparum Invasion of hepatic cells
3JCR	;	7.0	;	3D structure determination of the human*U4/U6.U5* tri-snRNP complex
3ZSE	;	1.78	;	3D Structure of a thermophilic family GH11 xylanase from Thermobifida fusca
2F9M	;	1.95	;	3D structure of active human Rab11b GTPase
2BEG	;		;	3D Structure of Alzheimer's Abeta(1-42) fibrils
2E8D	;		;	3D Structure of amyloid protofilaments of beta2-microglobulin fragment probed by solid-state NMR
2M0J	;		;	3D Structure of Calmodulin and Calmodulin binding domain of Olfactory cyclic nucleotide-gated ion channel complex
2M0K	;		;	3D Structure of Calmodulin and Calmodulin Binding Domain of Rat Olfactory Cyclic Nucleotide-Gated Ion Channel
2M02	;		;	3D structure of cap-gly domain of mammalian dynactin determined by magic angle spinning NMR spectroscopy
1W6L	;	2.0	;	3D structure of CotA incubated with CuCl2
1W8E	;	2.2	;	3D structure of CotA incubated with hydrogen peroxide
1W6W	;	2.2	;	3D structure of CotA incubated with sodium azide
2N9A	;		;	3D Structure of Decoralin-NH2 by Solution NMR
4ACK	;	2.15	;	3D Structure of DotU from Francisella novicida
4ACL	;	2.49	;	3D Structure of DotU from Francisella novicida
4AJ3	;	1.9	;	3D structure of E. coli Isocitrate Dehydrogenase in complex with Isocitrate, calcium(II) and NADP - The pseudo-Michaelis complex
4AJA	;	1.799	;	3D structure of E. coli Isocitrate Dehydrogenase in complex with Isocitrate, calcium(II) and thioNADP
4AJC	;	2.3	;	3D structure of E. coli Isocitrate Dehydrogenase K100M mutant in complex with alpha-ketoglutarate, calcium(II) and adenine nucleotide phosphate
4AJR	;	2.687	;	3D structure of E. coli Isocitrate Dehydrogenase K100M mutant in complex with alpha-ketoglutarate, magnesium(II) and NADPH - The product complex
4BNP	;	2.0	;	3D structure of E. coli Isocitrate Dehydrogenase K100M mutant in complex with isocitrate and magnesium(II)
4AJB	;	1.9	;	3D structure of E. coli Isocitrate Dehydrogenase K100M mutant in complex with Isocitrate, magnesium(II) and thioNADP
4AJS	;	1.802	;	3D structure of E. coli Isocitrate Dehydrogenase K100M mutant in complex with isocitrate, magnesium(II), Adenosine 2',5'-biphosphate and ribosylnicotinamide-5'-phosphate
3R0G	;	2.2	;	3D Structure of Ferric Methanosarcina Acetivorans Protoglobin I149F mutant in Aquomet form
3QZX	;	1.3	;	3D Structure of ferric methanosarcina acetivorans protoglobin Y61A mutant with unknown ligand
3QZZ	;	2.4	;	3D Structure of Ferric Methanosarcina Acetivorans Protoglobin Y61W mutant in Aquomet form
4CFI	;	1.3	;	3D structure of FliC from Burkholderia pseudomallei
4OIF	;	2.448	;	3D structure of Gan42B, a GH42 beta-galactosidase from G.
4V1W	;	4.7	;	3D structure of horse spleen apoferritin determined by electron cryomicroscopy
6RJH	;	2.1	;	3D structure of horse spleen apoferritin determined using multifunctional graphene supports for electron cryomicroscopy
2F9L	;	1.55	;	3D structure of inactive human Rab11b GTPase
1KCP	;		;	3D STRUCTURE OF K-CONOTOXIN PVIIA, A NOVEL POTASSIUM CHANNEL-BLOCKING TOXIN FROM CONE SNAILS, NMR, 22 STRUCTURES
2JFB	;	2.5	;	3D Structure of Lumazine Synthase from Candida albicans
2RQS	;		;	3D structure of Pin from the psychrophilic archeon Cenarcheaum symbiosum (CsPin)
2MQA	;		;	3D structure of RP domain of MiSp
3RX9	;	1.35	;	3D structure of SciN from an Escherichia coli Patotype
2WZN	;	1.9	;	3d structure of TET3 from Pyrococcus horikoshii
1IK6	;	2.0	;	3D structure of the E1beta subunit of pyruvate dehydrogenase from the archeon Pyrobaculum aerophilum
5DFA	;	2.5	;	3D structure of the E323A catalytic mutant of Gan42B, a GH42 beta-galactosidase from G. stearothermophilus
2C9O	;	2.2	;	3D Structure of the human RuvB-like helicase RuvBL1
6UT2	;		;	3D structure of the leiomodin/tropomyosin binding interface
2V1V	;		;	3D STRUCTURE OF THE M8L MUTANT OF SQUASH TRYPSIN INHIBITOR CMTI-I
3ZE6	;	1.5	;	3D structure of the Ni-Fe-Se hydrogenase from D. vulgaris Hildenborough in the as-isolated oxidized state at 1.50 Angstroms
3ZE7	;	1.95	;	3D structure of the Ni-Fe-Se hydrogenase from D. vulgaris Hildenborough in the reduced state at 1.95 Angstroms
3ZE8	;	1.801	;	3D structure of the Ni-Fe-Se hydrogenase from D. vulgaris Hildenborough in the reduced state at 1.95 Angstroms
3ZE9	;	1.33	;	3D structure of the NiFeSe hydrogenase from D. vulgaris Hildenborough in the oxidized as-isolated state at 1.33 Angstroms
3ZEA	;	1.82	;	3D structure of the NiFeSe hydrogenase from D. vulgaris Hildenborough in the reduced state at 1.82 Angstroms
2BHF	;	2.5	;	3D structure of the reduced form of CotA
2BAG	;	2.4	;	3D Structure of Torpedo californica acetylcholinesterase complexed with Ganstigmine
3I6M	;	2.26	;	3D Structure of Torpedo californica acetylcholinesterase complexed with N-piperidinopropyl-galanthamine
3I6Z	;	2.19	;	3D Structure of Torpedo californica acetylcholinesterase complexed with N-saccharinohexyl-galanthamine
2MN2	;		;	3D structure of YmoB, a modulator of biofilm formation
2WJ1	;	1.84	;	3D-crystal structure of humanized-rat fatty acid amide hydrolase (FAAH) conjugated with 7-phenyl-1-(4-(pyridin-2-yl)oxazol-2-yl)heptan- 1-one, an alpha-ketooxazole
2WJ2	;	2.55	;	3D-crystal structure of humanized-rat fatty acid amide hydrolase (FAAH) conjugated with 7-phenyl-1-(5-(pyridin-2-yl)oxazol-2-yl)heptan- 1-one, an alpha-ketooxazole
3LJ7	;	2.3	;	3D-crystal structure of humanized-rat fatty acid amide hydrolase (FAAH) conjugated with Carbamate inhibitor URB597
2WAP	;	2.8	;	3D-crystal structure of humanized-rat fatty acid amide hydrolase (FAAH) conjugated with the drug-like urea inhibitor PF-3845
3LJ6	;	2.42	;	3D-CRYSTAL STRUCTURE OF HUMANIZED-RAT FATTY ACID AMIDE HYDROLASE (FAAH) CONJUGATED WITH THE DRUG-LIKE UREA INHIBITOR PF-3845 at 2.42A RESOLUTION
2WW5	;	1.61	;	3D-structure of the modular autolysin LytC from Streptococcus pneumoniae at 1.6 A resolution
2WWD	;	2.25	;	3D-structure of the modular autolysin LytC from Streptococcus pneumoniae in complex with pneummococcal peptidoglycan fragment
2WWC	;	1.75	;	3D-structure of the modular autolysin LytC from Streptococcus pneumoniae in complex with synthetic peptidoglycan ligand
7Y8J	;	1.03	;	3D1 in complex with 6-mer HR1 peptide from SARS-CoV-2
5D99	;	0.97	;	3DW4 redetermined by direct methods starting from random phase angles
2VKR	;	2.01	;	3Fe-4S, 4Fe-4S plus Zn Acidianus ambivalens ferredoxin
8E6J	;	2.7	;	3H03 Fab in complex with influenza virus neuraminidase from A/Brevig Mission/1/1918 (H1N1)
7BH8	;	1.8	;	3H4-Fab HLA-E-VL9 co-complex
6FLA	;	2.9	;	3H5 Fab bound to EDIII of DenV 2 Xtal form 1
6FLB	;	2.2	;	3H5 Fab bound to EDIII of DenV 2 Xtal form 2
2RJM	;	2.0	;	3Ig structure of titin domains I67-I69 E-to-A mutated variant
2IWN	;	1.35	;	3rd PDZ domain of Multiple PDZ Domain Protein MPDZ
1ZRC	;	2.8	;	4 Crystal structures of CAP-DNA with all base-pair substitutions at position 6, CAP-ICAP38 DNA
1ZRD	;	2.8	;	4 crystal structures of CAP-DNA with all base-pair substitutions at position 6, CAP-[6A;17T]ICAP38 DNA
1ZRF	;	2.1	;	4 crystal structures of CAP-DNA with all base-pair substitutions at position 6, CAP-[6C;17G]ICAP38 DNA
1ZRE	;	2.8	;	4 crystal structures of CAP-DNA with all base-pair substitutions at position 6, CAP-[6G;17C]ICAP38 DNA
6QYF	;	1.4	;	4'-phosphopantetheinyl transferase PptAb from Mycobacterium abscessus at pH 4.6 with Mg2+ and CoA.
6QWU	;	1.4	;	4'-phosphopantetheinyl transferase PptAb from Mycobacterium abscessus at pH 5.5 with Mn2+ and CoA.
6QXQ	;	1.45	;	4'-phosphopantetheinyl transferase PptAb from Mycobacterium abscessus at pH 7 with Mn2+ and CoA.
6QYG	;	1.6	;	4'-phosphopantetheinyl transferase PptAb from Mycobacterium abscessus at pH 8.5 with Mg2+ and CoA.
6QXR	;	1.2	;	4'-phosphopantetheinyl transferase PptAb from Mycobacterium abscessus at pH 8.5 with Mn2+ and CoA.
4U89	;	1.4	;	4'-phosphopantetheinyl transferase PptT from Mycobacterium tuberculosis
2VKU	;	1.95	;	4,4'-Dihydroxybenzophenone Mimics Sterol Substrate in the Binding Site of Sterol 14alpha-Demethylase (CYP51) in the X-ray Structure of the Complex
4K26	;	2.21	;	4,4-Dioxo-5,6-dihydro-[1,4,3]oxathiazines, a novel class of 11 -HSD1 inhibitors for the treatment of diabetes
4K1L	;	1.96	;	4,4-Dioxo-5,6-dihydro-[1,4,3]oxathiazines, a novel class of 11 beta-HSD1 inhibitors for the treatment of diabetes
2VCI	;	2.0	;	4,5 Diaryl Isoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer
2VCJ	;	2.5	;	4,5 Diaryl Isoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer
3HUA	;	1.4	;	4,5,6,7-tetrahydroindole in complex with T4 lysozyme L99A/M102Q
4WOI	;	3.0	;	4,5-linked aminoglycoside antibiotics regulate the bacterial ribosome by targeting dynamic conformational processes within intersubunit bridge B2
5JBF	;	2.19	;	4,6-alpha-glucanotransferase GTFB (D1015N mutant) from Lactobacillus reuteri 121 complexed with maltopentaose
5JBD	;	1.8	;	4,6-alpha-glucanotransferase GTFB from Lactobacillus reuteri 121
5JBE	;	2.1	;	4,6-alpha-glucanotransferase GTFB from Lactobacillus reuteri 121 complexed with an isomalto-maltopentasaccharide
7P38	;	2.7	;	4,6-alpha-glucanotransferase GtfB from Limosilactobacillus reuteri NCC 2613
7P39	;	2.9	;	4,6-alpha-glucanotransferase GtfB from Limosilactobacillus reuteri NCC 2613 complexed with acarbose
7ZC0	;	2.25	;	4,6-alpha-glucanotransferase GtfC from Geobacillus 12AMOR1
7BHH	;	1.4	;	4-(2-(3-(4-iodophenyl)selenoureido)ethyl)benzenesulfonamide in complex with Carbonic Anhydrase II
7BFA	;	1.6	;	4-(2-(3-(4-iodophenyl)thioureido)ethyl)benzenesulfonamide in complex with Carbonic Anhydrase II
7BG5	;	1.428	;	4-(2-(3-(4-iodophenyl)ureido)ethyl)benzenesulfonamide in complex with Carbonic Anhydrase II
6NEL	;	2.0	;	4-(2-(4-fluorophenyl)-5-hydroxy-6-oxo-1,6-dihydropyridin-3-yl)benzoic acid bound to influenza 2009 pH1N1 endonuclease
4OSF	;	1.62	;	4-(2-isothiocyanatoethyl)phenol inhibitor complexed with Macrophage Migration Inhibitory Factor
3N3G	;	1.6	;	4-(3-Trifluoromethylphenyl)-pyrimidine-2-carbonitrile as cathepsin S inhibitors: N3, not N1 is critically important
2GDO	;	3.0	;	4-(Aminoalkylamino)-3-Benzimidazole-Quinolinones As Potent CHK1 Inhibitors
2RAZ	;	1.641	;	4-(methylthio)nitrobenzene in complex with T4 lysozyme L99A
1FLR	;	1.85	;	4-4-20 FAB FRAGMENT
1JXH	;	2.3	;	4-Amino-5-hydroxymethyl-2-methylpyrimidine Phosphate Kinase from Salmonella typhimurium
1JXI	;	2.64	;	4-Amino-5-hydroxymethyl-2-methylpyrimidine Phosphate Kinase from Salmonella typhimurium complexed with 4-Amino-5-hydroxymethyl-2-methylpyrimidine
1OHV	;	2.3	;	4-AMINOBUTYRATE-AMINOTRANSFERASE FROM PIG
1OHY	;	2.8	;	4-AMINOBUTYRATE-AMINOTRANSFERASE inactivated by gamma-ethynyl GABA
1OHW	;	2.3	;	4-AMINOBUTYRATE-AMINOTRANSFERASE inactivated by gamma-vinyl GABA
2CLX	;	1.8	;	4-Arylazo-3,5-diamino-1H-pyrazole CDK Inhibitors: SAR Study, Crystal Structure in Complex with CDK2, Selectivity, and Cellular Effects
3HTF	;	1.85	;	4-chloro-1h-pyrazole in complex with T4 lysozyme L99A/M102Q
6FJT	;	1.27	;	4-chloro-benzamidine in complex with thrombin
1NZY	;	1.8	;	4-CHLOROBENZOYL COENZYME A DEHALOGENASE FROM PSEUDOMONAS SP. STRAIN CBS-3
1T5D	;	2.206	;	4-Chlorobenzoyl-CoA Ligase/Synthetase bound to 4-chlorobenzoate
3CW9	;	2.0	;	4-Chlorobenzoyl-CoA Ligase/Synthetase in the Thioester-forming Conformation, bound to 4-chlorophenacyl-CoA
1T5H	;	2.002	;	4-Chlorobenzoyl-CoA Ligase/Synthetase unliganded, selenomethionine
3CW8	;	2.25	;	4-Chlorobenzoyl-CoA Ligase/Synthetase, bound to 4CBA-Adenylate
2QW0	;	2.56	;	4-Chlorobenzoyl-CoA Ligase/Synthetase, I303A mutation, bound to 3,4 Dichlorobenzoate
2QVZ	;	2.5	;	4-Chlorobenzoyl-CoA Ligase/Synthetase, I303A mutation, bound to 3-Chlorobenzoate
2QVY	;	2.76	;	4-Chlorobenzoyl-CoA Ligase/Synthetase, I303G mutation, bound to 3,4-Dichlorobenzoate
2QVX	;	2.7	;	4-Chlorobenzoyl-CoA Ligase/Synthetase, I303G mutation, bound to 3-Chlorobenzoate
3DLP	;	2.6	;	4-Chlorobenzoyl-CoA Ligase/Synthetase, Mutant D402P, bound to 4CB
3TSY	;	3.1	;	4-Coumaroyl-CoA Ligase::Stilbene Synthase fusion protein
7PBI	;	2.8	;	4-ethylphenol oxidase from Gulosibacter chungangensis: isoeugenol complex
7PBG	;	1.6	;	4-ethylphenol oxidase from Gulosibacter chungangensis: native structure
4WHS	;	1.35	;	4-fluorocatechol bound to Protocatechuate 3,4-dioxygenase (pseudomonas putida) at pH 8.5
6BDX	;	1.85	;	4-hydroxy tetrahydrodipicolinate reductase from Neisseria gonorrhoeae
8IUP	;	2.69	;	4-hydroxybutyryl-CoA Synthetase (ADP-forming) from Nitrosopumilus maritimus.
5GWR	;	2.2	;	4-hydroxyisoleucine dehydrogenase complexed with NADH
5GWS	;	2.35	;	4-hydroxyisoleucine dehydrogenase complexed with NADH and succinate
5GWT	;	1.9	;	4-hydroxyisoleucine dehydrogenase mutant complexed with NADH and succinate
1SP8	;	2.0	;	4-Hydroxyphenylpyruvate Dioxygenase
1SP9	;	3.0	;	4-Hydroxyphenylpyruvate Dioxygenase
3TSN	;	2.63	;	4-hydroxythreonine-4-phosphate dehydrogenase from Campylobacter jejuni
8VSW	;		;	4-MERCAPTOPHENOL-ALPHA3C
3OAW	;	2.75	;	4-Methylpteridineones as Orally Active and Selective PI3K/mTOR Dual Inhibitors
5D2F	;	1.738	;	4-oxalocrotonate decarboxylase from Pseudomonas putida G7 - apo form
5D2I	;	1.78	;	4-oxalocrotonate decarboxylase from Pseudomonas putida G7 - complexed with calcium and acetate
5D2G	;	1.897	;	4-oxalocrotonate decarboxylase from Pseudomonas putida G7 - complexed with magnesium
5D2K	;	1.571	;	4-oxalocrotonate decarboxylase from Pseudomonas putida G7 - complexed with magnesium and 2-oxoadipate
5D2J	;	1.718	;	4-oxalocrotonate decarboxylase from Pseudomonas putida G7 - complexed with magnesium and adipate
5D2H	;	1.936	;	4-oxalocrotonate decarboxylase from Pseudomonas putida G7 - complexed with magnesium and alpha-ketoglutarate
4OTA	;	2.75	;	4-OXALOCROTONATE TAUTOMERASE OBSERVED AS AN OCTODECAMER, ORTHORHOMBIC CRYSTAL FORM
4OTB	;	2.5	;	4-OXALOCROTONATE TAUTOMERASE OBSERVED AS AN OCTODECAMER, RHOMBOHEDRAL CRYSTAL FORM
4OTC	;	2.28	;	4-OXALOCROTONATE TAUTOMERASE OBSERVED AS AN OCTODECAMER, TRIGONAL CRYSTAL FORM
1OTF	;	1.9	;	4-OXALOCROTONATE TAUTOMERASE-TRICLINIC CRYSTAL FORM
2Q9M	;	2.05	;	4-Substituted Trinems as Broad Spectrum-Lactamase Inhibitors: Structure-based Design, Synthesis and Biological Activity
2Q9N	;	2.2	;	4-Substituted Trinems as Broad Spectrum-Lactamase Inhibitors: Structure-based Design, Synthesis and Biological Activity
6BWF	;	4.1	;	4.1 angstrom Mg2+-unbound structure of mouse TRPM7
6K9L	;	4.27	;	4.27 Angstrom resolution cryo-EM structure of human dimeric ATM kinase
3V0C	;	4.3	;	4.3 angstrom crystal structure of an inactive BoNT/A (E224Q/R363A/Y366F)
3R9J	;	4.3	;	4.3A resolution structure of a MinD-MinE(I24N) protein complex
2XEA	;	4.6	;	4.6 ANGSTROM CRYO-EM RECONSTRUCTION OF TOBACCO MOSAIC VIRUS FROM IMAGES RECORDED AT 300 KEV ON A 4KX4K CCD CAMERA
5ZCS	;	4.9	;	4.9 Angstrom Cryo-EM structure of human mTOR complex 2
2M4J	;		;	40-residue beta-amyloid fibril derived from Alzheimer's disease brain
2LNQ	;		;	40-residue D23N beta amyloid fibril
8G4S	;	3.14	;	40S ribosomal subunit of the 80S Giardia intestinalis assemblage A ribosome with Emetine bound in V2 conformation with mRNA and three tRNAs.
8FVY	;	2.94	;	40S subunit of the Giardia lamblia 80S ribosome
4UER	;	6.47	;	40S-eIF1-eIF1A-eIF3-eIF3j translation initiation complex from Lachancea kluyveri
2MXU	;		;	42-Residue Beta Amyloid Fibril
3TPU	;	3.1	;	42F3 p5E8/H2-Ld complex
4MVB	;	3.088	;	42F3 pCPB7/H-2Ld Complex
3TF7	;	2.75	;	42F3 QL9/H2-Ld complex
4N5E	;	3.059	;	42F3 TCR pCPA12/H-2Ld complex
4MS8	;	1.922	;	42F3 TCR pCPB9/H-2Ld Complex
4MXQ	;	2.596	;	42F3 TCR pCPC5/H-2Ld Complex
4N0C	;	2.9	;	42F3 TCR pCPE3/H-2Ld complex
3TJH	;	2.12	;	42F3-p3A1/H2-Ld complex
3TFK	;	2.753	;	42F3-p4B10/H2-Ld
7ASE	;	3.33	;	43S preinitiation complex from Trypanosoma cruzi with the kDDX60 helicase
7ASK	;	4.3	;	43S preinitiation complex from Trypanosoma cruzi with the kDDX60 helicase bound with ATP
7DBD	;	3.094	;	444 in complex with tubulin
7S9U	;	3.2	;	44SR3C ribosomal particle
7SAE	;	3.0	;	44SR70P Class1 ribosomal particle
6MKD	;	3.2	;	4699 TCR bound to I-Ab Padi4
6MNG	;	2.662	;	4738 TCR bound to IAb Padi4
7ART	;	10.0	;	48 helix bundle DNA origami brick
8G2Z	;	4.1	;	48-nm doublet microtubule from Tetrahymena thermophila strain CU428
8G3D	;	3.7	;	48-nm doublet microtubule from Tetrahymena thermophila strain K40R
7UNG	;	3.6	;	48-nm repeat of the human respiratory doublet microtubule
8OTZ	;	3.6	;	48-nm repeat of the native axonemal doublet microtubule from bovine sperm
8TO0	;	7.7	;	48-nm repeating structure of doublets from mouse sperm flagella
1GAF	;	1.95	;	48G7 HYBRIDOMA LINE FAB COMPLEXED WITH HAPTEN 5-(PARA-NITROPHENYL PHOSPHONATE)-PENTANOIC ACID
8P03	;	3.04	;	48S late-stage initiation complex with m6A mRNA
8P09	;	3.3	;	48S late-stage initiation complex with non methylated mRNA
1BP8	;		;	4:2:1 mithramycin:Mg++:d(ACCCGGGT)2 complex
1N0R	;	1.5	;	4ANK: A designed ankyrin repeat protein with four identical consensus repeats
4ODX	;	3.1	;	4E10 germline encoded precursor no.7 in complex with epitope scaffold T117
3CB8	;	2.77	;	4Fe-4S-Pyruvate formate-lyase activating enzyme in complex with AdoMet and a peptide substrate
3C8F	;	2.25	;	4Fe-4S-Pyruvate formate-lyase Activating Enzyme with partially disordered AdoMet
8VRR	;	2.36	;	4H11-scFv antibody
1X9Q	;	1.5	;	4m5.3 anti-fluorescein single chain antibody fragment (scFv)
6EQY	;		;	4th KOW domain of human hSpt5
1NYP	;		;	4th LIM domain of PINCH protein
3QSK	;	1.75	;	5 Histidine Variant of the anti-RNase A VHH in Complex with RNAse A
8PYO	;	1.54	;	5 micrometer HEWL crystals solved at room-temperature using fixed-target serial crystallography.
7R6L	;	2.85	;	5 prime exon-free pre-2S intermediate of the Tetrahymena group I intron, symmetry-expanded monomer from a synthetic dimeric construct
1NTS	;		;	5'(dCCPUPCPCPUPUP)3':3'(rAGGAGGAAA)5', where P=propynyl
1NTQ	;		;	5'(dCCUCCUU)3':3'(rAGGAGGAAA)5'
1NTT	;		;	5'(dCPCPUPCPCPUPUP)3':(rAGGAGGAAA)5', where P=propynyl
8EDB	;	1.55	;	5'-CGCGAATTCGCG-3' and an AT-specific binder (DB1884) complex
8EC1	;	1.63	;	5'-CGCGAATTCGCG-3' and benzimidazole diamidine (DB1476) comlpex with ligand orientation I
8ED6	;	1.63	;	5'-CGCGAATTCGCG-3' and benzimidazole diamidine (DB1476) complex with ligand orientation II
423D	;	1.6	;	5'-D(*AP*CP*CP*GP*AP*CP*GP*TP*CP*GP*GP*T)-3'
424D	;	2.7	;	5'-D(*AP*CP*CP*GP*AP*CP*GP*TP*CP*GP*GP*T)-3'
425D	;	2.8	;	5'-D(*AP*CP*CP*GP*GP*TP*AP*CP*CP*GP*GP*T)-3'
427D	;	1.1	;	5'-D(*CP*GP*CP*(CH2-DM1)GP*CP*G)-3'
403D	;	1.4	;	5'-D(*CP*GP*CP*(HYD)AP*AP*AP*TP*TP*TP*GP*CP*G)-3', 2'-(4-ETHOXYPHENYL)-5-(4-METHYL-1-PIPERAZINYL)-2,5'-BI-BENZIMIDAZOLE
447D	;	2.2	;	5'-D(*CP*GP*CP*GP*AP*AP*TP*TP*CP*GP*CP*G)-3'
442D	;	1.6	;	5'-D(*CP*GP*CP*GP*AP*AP*TP*TP*CP*GP*CP*G)-3', BENZIMIDAZOLE DERIVATIVE COMPLEX
444D	;	2.4	;	5'-D(*CP*GP*CP*GP*AP*AP*TP*TP*CP*GP*CP*G)-3', BENZIMIDAZOLE DERIVATIVE COMPLEX
445D	;	2.6	;	5'-D(*CP*GP*CP*GP*AP*AP*TP*TP*CP*GP*CP*G)-3', Benzimidazole derivative complex
448D	;	2.2	;	5'-D(*CP*GP*CP*GP*AP*AP*TP*TP*CP*GP*CP*G)-3', BENZIMIDAZOLE DERIVATIVE COMPLEX
449D	;	2.1	;	5'-D(*CP*GP*CP*GP*AP*AP*TP*TP*CP*GP*CP*G)-3', BENZIMIDAZOLE DERIVATIVE COMPLEX
453D	;	1.8	;	5'-D(*CP*GP*CP*GP*AP*AP*TP*TP*CP*GP*CP*G)-3'-BENZIMIDAZOLE COMPLEX
1FTD	;	2.0	;	5'-D(*CP*GP*CP*GP*AP*AP*TP*TP*CP*GP*CP*G)-3'-SYMMETRIC BIS-BENZIMIDAZOLE COMPLEX
443D	;	1.6	;	5'-D(*CP*GP*CP*GP*AP*AP*TP*TP*CP*GP*CP*G)-3'/ BENZIMIDAZOLE DERIVATIVE COMPLEX
2KBD	;		;	5'-D(*CP*TP*GP*GP*GP*GP*AP*CP*TP*TP*TP*CP*CP*AP*GP*G)-3', 5'-D(*CP*CP*TP*GP*GP*AP*AP*AP*GP*TP*CP*CP*CP*CP*AP*G)-3'
2B1D	;	2.5	;	5'-D(*GP*CP*AP*GP*AP*CP*GP*TP*CP*TP*GP*C)-3' Methionine Repressor binding site
2B1C	;	2.2	;	5'-D(*GP*CP*GP*TP*GP*GP*GP*AP*CP*C)-3' Zif268 binding site
2B1B	;	1.9	;	5'-D(*GP*CP*GP*TP*GP*GP*GP*CP*AP*C)-3' Zif268 binding site
1B3P	;		;	5'-D(*GP*GP*AP*GP*GP*AP*T)-3'
431D	;	1.15	;	5'-D(*GP*GP*CP*CP*AP*AP*TP*TP*GP*G)-3'
414D	;	1.9	;	5'-D(*GP*GP*GP*GP*CP*GP*CP*CP*CP*C)-3'
421D	;	1.8	;	5'-D(*TP*TP*CP*TP*TP*(BRO)CP*TP*TP*C)-3', 5'-R(*GP*AP*AP*GP*AP*AP*GP*AP*A)-3'
1JE1	;	1.8	;	5'-DEOXY-5'-METHYLTHIOADENOSINE PHOSPHORYLASE COMPLEX WITH GUANOSINE AND SULFATE
1JDS	;	1.8	;	5'-DEOXY-5'-METHYLTHIOADENOSINE PHOSPHORYLASE COMPLEX WITH PHOSPHATE (SPACE GROUP P21)
3T60	;	2.396	;	5'-Diphenyl Nucleoside Inhibitors of Plasmodium falciparum dUTPase
3T64	;	1.65	;	5'-Diphenyl Nucleoside Inhibitors of Plasmodium falciparum dUTPase
3T6Y	;	2.6	;	5'-Diphenyl Nucleoside Inhibitors of Plasmodium falciparum dUTPase
3T70	;	1.8	;	5'-Diphenyl Nucleoside Inhibitors of Plasmodium falciparum dUTPase
2H8G	;	1.5	;	5'-Methylthioadenosine Nucleosidase from Arabidopsis thaliana
5C7U	;	3.05	;	5'-monophosphate wt Guanine Riboswitch bound to hypoxanthine.
5C7W	;	3.22	;	5'-monophosphate Z:P Guanine Riboswitch bound to hypoxanthine.
1HPU	;	1.85	;	5'-NUCLEOTIDASE (CLOSED FORM), COMPLEX WITH AMPCP
1HO5	;	2.1	;	5'-NUCLEOTIDASE (E. COLI) IN COMPLEX WITH ADENOSINE AND PHOSPHATE
1OI8	;	2.1	;	5'-Nucleotidase (E. coli) with an Engineered Disulfide Bridge (P90C, L424C)
1OID	;	2.1	;	5'-Nucleotidase (E. coli) with an Engineered Disulfide Bridge (S228C, P513C)
1OIE	;	2.33	;	5'-Nucleotidase (E. coli) with an Engineered Disulfide Bridge (S228C, P513C)
1HP1	;	1.7	;	5'-NUCLEOTIDASE (OPEN FORM) COMPLEX WITH ATP
1USH	;	1.73	;	5'-NUCLEOTIDASE FROM E. COLI
2USH	;	2.22	;	5'-NUCLEOTIDASE FROM E. COLI
406D	;	1.8	;	5'-R(*CP*AP*CP*CP*GP*GP*AP*UP*GP*GP*UP*(BRO) UP*CP*GP*GP*UP*G)-3'
402D	;	2.3	;	5'-R(*CP*GP*CP*CP*AP*GP*CP*G)-3'
377D	;	1.76	;	5'-R(*CP*GP*UP*AP*CP*DG)-3'
439D	;	1.6	;	5'-R(*CP*UP*GP*GP*GP*CP*GP*G)-3', 5'-R(*CP*CP*GP*CP*CP*UP*GP*G)-3'
422D	;	2.6	;	5'-R(*GP*AP*UP*CP*AP*CP*UP*UP*CP*GP*GP*U)-3'
418D	;	2.4	;	5'-R(*GP*UP*GP*CP*AP*CP*A)-D(P*C)-3'
435D	;	1.4	;	5'-R(*UP*AP*GP*CP*CP*CP*C)-3', 5'-R(*GP*GP*GP*GP*CP*UP*A)-3'
434D	;	1.16	;	5'-R(*UP*AP*GP*CP*UP*CP*C)-3', 5'-R(*GP*GP*GP*GP*CP*UP*A)-3'
6Y50	;	4.1	;	5'domain of human 17S U2 snRNP
8QH3	;	2.81	;	5'vRNA-bound Hantaan virus polymerase in monomeric active state
8QGT	;	2.8	;	5'vRNA-bound Hantaan virus polymerase in monomeric intermediate state
1B0A	;	2.56	;	5,10, METHYLENE-TETRAHYDROPHOLATE DEHYDROGENASE/CYCLOHYDROLASE FROM E COLI.
1V93	;	1.9	;	5,10-Methylenetetrahydrofolate Reductase from Thermus thermophilus HB8
4LN7	;	1.73	;	5,6-bis(4-fluorophenyl)-3-hydroxy-2,5-dihydropyridin-2-one bound to influenza 2009 pH1N1 endonuclease
2C16	;	2.02	;	5-(4-Carboxy-2-oxo-butane-1-sulfinyl)-4-oxo-pentanoic acid acid bound to Porphobilinogen synthase from Pseudomonas aeruginosa
2C18	;	1.93	;	5-(4-Carboxy-2-oxo-butane-1-sulfonyl)-4-oxo-pentanoic acid bound to Porphobilinogen synthase from Pseudomonas aeruginosa
2C15	;	1.48	;	5-(4-Carboxy-2-oxo-butoxy)-4-oxo-pentanoic acid acid bound to Porphobilinogen synthase from Pseudomonas aeruginosa
2C14	;	1.9	;	5-(4-Carboxy-2-oxo-butylamino)-4-oxo-pentanoic acid acid bound to Porphobilinogen synthase from Pseudomonas aeruginosa
2C19	;	2.05	;	5-(4-Carboxy-2-oxo-butylsulfanyl)-4-oxo-pentanoic acid acid bound to Porphobilinogen synthase from Pseudomonas aeruginosa
4M5U	;	2.2	;	5-(4-FLUOROPHENYL)-3-HYDROXY-6-[4-(1H-1,2,3,4-TETRAZOL-5-YL)PHENYL]-1,2-DIHYDROPYRIDIN-2-ONE bound to influenza 2009 pH1N1 endonuclease
1AW5	;	2.3	;	5-AMINOLEVULINATE DEHYDRATASE FROM SACCHAROMYCES CEREVISIAE
2BWN	;	2.1	;	5-Aminolevulinate Synthase from Rhodobacter capsulatus
2BWP	;	2.7	;	5-Aminolevulinate Synthase from Rhodobacter capsulatus in complex with glycine
2BWO	;	2.8	;	5-Aminolevulinate Synthase from Rhodobacter capsulatus in complex with succinyl-CoA
7X98	;	2.05	;	5-Aminolevulinate synthase HemA from Rhodopseudomonas palustris
4AFJ	;	1.98	;	5-aryl-4-carboxamide-1,3-oxazoles: potent and selective GSK-3 inhibitors
4MK1	;	1.85	;	5-bromopyridine-2,3-diol bound to influenza 2009 pH1N1 endonuclease
1OTG	;	2.1	;	5-CARBOXYMETHYL-2-HYDROXYMUCONATE ISOMERASE
4LBH	;	1.75	;	5-chloro-2-hydroxyhydroquinone dehydrochlorinase (TftG) from Burkholderia phenoliruptrix AC1100: Apo-form
4LBP	;	1.87	;	5-chloro-2-hydroxyhydroquinone dehydrochlorinase (TftG) from Burkholderia phenoliruptrix AC1100: Complex with 2,5-dihydroxybenzoquinone
4LBI	;	2.21	;	5-chloro-2-hydroxyhydroquinone dehydrochlorinase (TftG) from Burkholderia phenoliruptrix AC1100: Selenomethionyl Apo-form
3HT8	;	1.6	;	5-chloro-2-methylphenol in complex with T4 lysozyme L99A/M102Q
5EAS	;	2.25	;	5-EPI-ARISTOLOCHENE SYNTHASE FROM NICOTIANA TABACUM
5EAU	;	2.15	;	5-EPI-ARISTOLOCHENE SYNTHASE FROM NICOTIANA TABACUM
5EAT	;	2.8	;	5-EPI-ARISTOLOCHENE SYNTHASE FROM NICOTIANA TABACUM WITH SUBSTRATE ANALOG FARNESYL HYDROXYPHOSPHONATE
3TAG	;	2.95	;	5-fluorocytosine paired with dAMP in RB69 gp43
3TAF	;	3.0	;	5-fluorocytosine paired with ddGMP in RB69 gp43
2ZNX	;	2.3	;	5-Fluorotryptophan Incorporated ScFv10 Complexed to Hen Egg Lysozyme
5OLY	;	2.0	;	5-fluorotryptophan labeled beta-phosphoglucomutase in a closed conformation, monoclinic crystal form
5OLX	;	1.38	;	5-fluorotryptophan labeled beta-phosphoglucomutase in a closed conformation, orthorhomic crystal form
5OLW	;	2.28	;	5-fluorotryptophan labeled beta-phosphoglucomutase in an open conformation
7LI9	;	3.9	;	5-HT bound serotonin transporter reconstituted in lipid nanodisc in KCl
7MGW	;	3.5	;	5-HT bound serotonin transporter reconstituted in lipid nanodisc in NaCl in occluded conformation
7LIA	;	3.3	;	5-HT bound serotonin transporter reconstituted in lipid nanodisc in presence of NaCl in outward facing conformation
8JT6	;	3.0	;	5-HT1A-Gi in complex with compound (R)-IHCH-7179
7RAN	;	3.45	;	5-HT2AR bound to a novel agonist in complex with a mini-Gq protein and an active-state stabilizing single-chain variable fragment (scFv16) obtained by cryo-electron microscopy (cryoEM)
7SRS	;	3.3	;	5-HT2B receptor bound to LSD in complex with beta-arrestin1 obtained by cryo-electron microscopy (cryoEM)
7SRR	;	2.9	;	5-HT2B receptor bound to LSD in complex with heterotrimeric mini-Gq protein obtained by cryo-electron microscopy (cryoEM)
7SRQ	;	2.7	;	5-HT2B receptor bound to LSD obtained by cryo-electron microscopy (cryoEM)
6Y5B	;	3.1	;	5-HT3A receptor in Salipro (apo, asymmetric)
6Y59	;	3.2	;	5-HT3A receptor in Salipro (apo, C5 symmetric)
2C13	;	2.15	;	5-hydroxy-levulinic acid bound to Porphobilinogen synthase from Pseudomonas aeruginosa
3TAE	;	2.71	;	5-hydroxycytosine paired with dAMP in RB69 gp43
3TAB	;	2.8	;	5-hydroxycytosine paired with dGMP in RB69 gp43
5SIW	;	2.13	;	5-methyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-8-(trifluoromethyl)-[1,2,4]triazolo[1,5-c]pyrimidine
5HVB	;	1.6	;	5-methyl-6-(1-naphthylthio)thieno[2,3-d]pyrimidine 2,4-diamine
5HVE	;	1.46	;	5-methyl-6-(3'-trifluromethoxyphenylthio)[2,3-d]pyrimidine 2,4-diamine
4GJU	;	1.412	;	5-Methylcytosine modified DNA oligomer
2E7F	;	2.2	;	5-methyltetrahydrofolate corrinoid/iron sulfur protein methyltransferase complexed with methyltetrahydrofolate to 2.2 Angsrom resolution
3ZZN	;	2.9	;	5-Mutant (R79W, R151A, E279A, E299A,E313A) Lactate-Dehydrogenase from Thermus thermophillus
3IJK	;	1.3	;	5-OMe modified DNA 8mer
3LTR	;	1.3	;	5-OMe-dU containing DNA 8mer
5USA	;	1.8	;	5-Se-T2-DNA and native RNA hybrid in complex with RNase H catalytic domain D132N mutant
5USG	;	1.7	;	5-Se-T2/4-DNA and native RNA hybrid in complex with RNase H catalytic domain D132N mutant
5USE	;	1.73	;	5-Se-T4-DNA and native RNA hybrid in complex with RNase H catalytic domain D132N mutant
3IJN	;	1.8	;	5-SeMe-Cytidine modified DNA 8mer
3LTU	;	1.4	;	5-SeMe-dU containing DNA 8mer
3IKI	;	1.38	;	5-SMe-dU containing DNA octamer
3KQ8	;	1.6	;	5-Te-uridine derivatized DNA-8mer
7Y1Q	;	5.03	;	5.0 angstrom cryo-EM structure of transmembrane regions of mouse Basigin/MCT1 in complex with antibody 6E7F1
7YZR	;	6.92	;	50 mM Rb+ soak of beryllium fluoride inhibited Na+,K+-ATPase, E2-BeFx (rigid body model)
7A0R	;	3.3	;	50S Deinococcus radiodurans ribosome bounded with mycinamicin I
7A0S	;	3.22	;	50S Deinococcus radiodurans ribosome bounded with mycinamicin I
7A18	;	3.4	;	50S Deinococcus radiodurans ribosome bounded with mycinamicin IV
6GC8	;	3.8	;	50S ribosomal subunit assembly intermediate - 50S rec*
6GC7	;	4.3	;	50S ribosomal subunit assembly intermediate state 1
6GC6	;	4.3	;	50S ribosomal subunit assembly intermediate state 2
6GC4	;	4.3	;	50S ribosomal subunit assembly intermediate state 3
6GC0	;	3.8	;	50S ribosomal subunit assembly intermediate state 4
6GBZ	;	3.8	;	50S ribosomal subunit assembly intermediate state 5
7TTU	;	3.0	;	50S ribosomal subunit from Staphylococcus aureus (Strain ATCC43300)
7TTW	;	2.9	;	50S ribosomal subunit from Staphylococcus aureus containing double mutation in uL3 imparting linezolid resistance
6WNT	;	3.1	;	50S ribosomal subunit without free 5S rRNA and perturbed PTC
6WU9	;	2.9	;	50S subunit of 70S Ribosome Enterococcus faecalis MultiBody refinement
2RDO	;	9.1	;	50S subunit with EF-G(GDPNP) and RRF bound
7BL6	;	4.0	;	50S-ObgE-GMPPNP particle
6MKR	;	3.355	;	5287 TCR bound to IAb Padi4
3NI3	;	1.34	;	54-Membered ring macrocyclic beta-sheet peptide
8OIR	;	3.1	;	55S human mitochondrial ribosome with mtRF1 and P-site tRNA
7NQL	;	3.4	;	55S mammalian mitochondrial ribosome with ICT1 and P site tRNAMet
6YDP	;	3.0	;	55S mammalian mitochondrial ribosome with mtEFG1 and P site fMet-tRNAMet (POST)
6YDW	;	4.2	;	55S mammalian mitochondrial ribosome with mtEFG1 and two tRNAMet (TI-POST)
8OIN	;	3.6	;	55S mammalian mitochondrial ribosome with mtRF1 and P-site tRNA
7NQH	;	3.5	;	55S mammalian mitochondrial ribosome with mtRF1a and P-site tRNAMet
7NSI	;	4.6	;	55S mammalian mitochondrial ribosome with mtRRF (pre) and tRNA(P/E)
7NSJ	;	3.9	;	55S mammalian mitochondrial ribosome with tRNA(P/P) and tRNA(E*)
6QB0	;		;	5675
6QB1	;		;	5676
6PRV	;	2.71	;	58nt RNA L11-binding domain from E. coli 23S rRNA
1AB4	;	2.8	;	59KDA FRAGMENT OF GYRASE A FROM E. COLI
5TZM	;	1.177	;	59th Ig domain of human obscurin (OBSCN Ig59)
4JPO	;	5.0	;	5A resolution structure of Proteasome Assembly Chaperone Hsm3 in complex with a C-terminal fragment of Rpt1
4OQ2	;	2.35	;	5hmC specific restriction endonuclease PvuRTs1I
5K8N	;	3.225	;	5NAA-bound 5-nitroanthranilate aminohydrolase
2GRZ	;	1.6	;	5ns Photoproduct of the M37V mutant of Scapharca HbI
1C2X	;	7.5	;	5S RRNA STRUCTURE FITTED TO A CRYO-ELECTRON MICROSCOPIC MAP AT 7.5 ANGSTROMS RESOLUTION
1IQ4	;	1.8	;	5S-RRNA BINDING RIBOSOMAL PROTEIN L5 FROM BACILLUS STEAROTHERMOPHILUS
8T2P	;	5.0	;	5TU-t1 - heterodimeric triplet polymerase ribozyme
1TEM	;	1.95	;	6 ALPHA HYDROXYMETHYL PENICILLOIC ACID ACYLATED ON THE TEM-1 BETA-LACTAMASE FROM ESCHERICHIA COLI
4MK5	;	1.9	;	6-(3-methoxyphenyl)pyridine-2,3-diol bound to influenza 2009 pH1N1 endonuclease
4M4Q	;	2.502	;	6-(4-fluorophenyl)-3-hydroxy-5-[4-(1H-1,2,3,4-tetrazol-5-yl)phenyl] -1,2-dihydropyridin-2-one bound to influenza 2009 H1N1 endonuclease
3Q3B	;	2.7	;	6-Amino-4-(pyrimidin-4-yl)pyridones: Novel Glycogen Synthase Kinase-3 Inhibitors
3VWQ	;	1.7	;	6-aminohexanoate-dimer hydrolase S112A/G181D/R187A/H266N/D370Y mutant complexd with 6-aminohexanoate
8IRN	;	2.7	;	6-BAP bound state of Arabidopsis AZG1
7M7E	;	3.2	;	6-Deoxyerythronolide B synthase (DEBS) hybrid module (M3/1) in complex with antibody fragment 1B2
7M7I	;	3.4	;	6-Deoxyerythronolide B synthase (DEBS) module 1 in complex with antibody fragment 1B2 (TE-free)
7M7J	;	4.3	;	6-Deoxyerythronolide B synthase (DEBS) module 1 in complex with antibody fragment 1B2: ""turnstile closed"" state (TE-free)
7M7F	;	3.2	;	6-Deoxyerythronolide B synthase (DEBS) module 1 in complex with antibody fragment 1B2: State 1
7M7H	;	4.1	;	6-Deoxyerythronolide B synthase (DEBS) module 1 in complex with antibody fragment 1B2: State 1'
7M7G	;	4.1	;	6-Deoxyerythronolide B synthase (DEBS) module 1 in complex with antibody fragment 1B2: State 2
6ZRY	;	1.652	;	6-dimethylallyl tryptophan synthase
1HKA	;	1.5	;	6-HYDROXYMETHYL-7,8-DIHYDROPTERIN PYROPHOSPHOKINASE
3N4C	;	1.9	;	6-Phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile as cathepsin S inhibitors
2PBG	;	2.5	;	6-PHOSPHO-BETA-D-GALACTOSIDASE FORM-B
3PBG	;	2.7	;	6-PHOSPHO-BETA-GALACTOSIDASE FORM-C
4PBG	;	2.5	;	6-PHOSPHO-BETA-GALACTOSIDASE FORM-CST
5FOO	;	2.1	;	6-phospho-beta-glucosidase
1BIF	;	2.0	;	6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE BIFUNCTIONAL ENZYME COMPLEXED WITH ATP-G-S AND PHOSPHATE
3BIF	;	2.3	;	6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE EMPTY 6-PF-2K ACTIVE SITE
2BIF	;	2.4	;	6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE H256A MUTANT WITH F6P IN PHOSPHATASE ACTIVE SITE
3E15	;	2.0	;	6-phosphogluconolactonase from Plasmodium vivax
6VYE	;	1.95	;	6-phosphogluconolactonase from Trypanosoma cruzi
1B66	;	1.9	;	6-PYRUVOYL TETRAHYDROPTERIN SYNTHASE
1B6Z	;	2.0	;	6-PYRUVOYL TETRAHYDROPTERIN SYNTHASE
1GTQ	;	2.3	;	6-PYRUVOYL TETRAHYDROPTERIN SYNTHASE
5HUI	;	1.46	;	6-substituted pyrido[3,2-d]pyrimidine--6-4'-trifluoromethoxyphenyl)
5HT4	;	1.6	;	6-substituted pyrrolo[2,3-d]pyrimidine 6-thieno-(4-methoxyphenyl)
5HT5	;	1.9	;	6-substituted pyrrolo[2,3-d]pyrimidine 6-thieno-(4-methoxyphenyl)
7WDT	;	1.65	;	6-sulfo-beta-D-N-acetylglucosaminidase from Bifidobacterium bifidum in complex with GlcNAc-6S
7WDU	;	2.23	;	6-sulfo-beta-D-N-acetylglucosaminidase from Bifidobacterium bifidum in complex with PUGNAc-6S
5BWK	;	6.0	;	6.0 A Crystal structure of a Get3-Get4-Get5 intermediate complex from S.cerevisiae
2I91	;	2.65	;	60kDa Ro autoantigen in complex with a fragment of misfolded RNA
4BXF	;	2.05	;	60S ribosomal protein L27A histidine hydroxylase (MINA53 Y209C) in complex with MN(II), 2-oxoglutarate (2OG) and 60S ribosomal protein L27A (RPL27A G37C) peptide fragment
4BU2	;	2.78	;	60S ribosomal protein L27A histidine hydroxylase (MINA53) in complex with Ni(II) and 2-oxoglutarate (2OG)
4CCN	;	2.23	;	60S ribosomal protein L8 histidine hydroxylase (NO66 L299C/C300S) in complex with Mn(II), N-oxalylglycine (NOG) and 60S ribosomal protein L8 (RPL8 G220C) peptide fragment (complex-2)
4CCO	;	2.3	;	60S ribosomal protein L8 histidine hydroxylase (NO66 S373C) in complex with Mn(II), N-oxalylglycine (NOG) and 60S ribosomal protein L8 (RPL8 G214C) peptide fragment (complex-3)
4CCJ	;	2.15	;	60S ribosomal protein L8 histidine hydroxylase (NO66) in apo form
4CCK	;	2.15	;	60S ribosomal protein L8 histidine hydroxylase (NO66) in complex with Mn(II) and N-oxalylglycine (NOG)
4CCM	;	2.51	;	60S ribosomal protein L8 histidine hydroxylase (NO66) in complex with Mn(II), N-oxalylglycine (NOG) and 60S ribosomal protein L8 (RPL8 G220C) peptide fragment (complex-1)
8OJ8	;	3.3	;	60S ribosomal subunit bound to the E3-UFM1 complex - state 1 (native)
8OJ0	;	3.3	;	60S ribosomal subunit bound to the E3-UFM1 complex - state 2 (native)
8OJ5	;	2.9	;	60S ribosomal subunit bound to the E3-UFM1 complex - state 3 (in-vitro reconstitution)
8OHD	;	3.1	;	60S ribosomal subunit bound to the E3-UFM1 complex - state 3 (native)
8FRU	;	2.49	;	60S subunit of the Giardia lamblia 80S ribosome
6VAR	;		;	61 nt human Hepatitis B virus epsilon pre-genomic RNA
7N4K	;	1.85	;	6218 TCR in complex with H2-Db PA 224
7N5P	;	2.09	;	6218 TCR in complex with H2-Db PA224-233 with a cysteine mutant
7N5C	;	1.87	;	6218 TCR in complex with H2Db PA with an engineered TCR-pMHC disulfide bond
6MNO	;	2.9	;	6235 TCR bound to I-Ab Padi4
6MNN	;	2.83	;	6236 TCR bound to I-Ab Padi4
6MNM	;	3.1	;	6256 TCR bound to I-Ab Padi4
1EHL	;	2.4	;	64M-2 ANTIBODY FAB COMPLEXED WITH D(5HT)(6-4)T
5IBU	;	1.71	;	6652 Fab (unbound)
4B03	;	6.0	;	6A Electron cryomicroscopy structure of immature Dengue virus serotype 1
1BUL	;	1.89	;	6ALPHA-(HYDROXYPROPYL)PENICILLANATE ACYLATED ON NMC-A BETA-LACTAMASE FROM ENTEROBACTER CLOACAE
5DZB	;	3.33	;	6beta1
2IZ1	;	2.3	;	6PDH complexed with PEX inhibitor synchrotron data
6ER0	;		;	6th KOW domain of human hSpt5
1AHH	;	2.3	;	7 ALPHA-HYDROXYSTEROID DEHYDROGENASE COMPLEXED WITH NAD+
1AHI	;	2.3	;	7 ALPHA-HYDROXYSTEROID DEHYDROGENASE COMPLEXED WITH NADH AND 7-OXO GLYCOCHENODEOXYCHOLIC ACID
1CBK	;	2.02	;	7,8-DIHYDRO-6-HYDROXYMETHYLPTERIN-PYROPHOSPHOKINASE FROM HAEMOPHILUS INFLUENZAE
1NBU	;	1.6	;	7,8-Dihydroneopterin Aldolase Complexed with Product From Mycobacterium Tuberculosis
1B9L	;	2.9	;	7,8-DIHYDRONEOPTERIN TRIPHOSPHATE EPIMERASE
4KIL	;	1.75	;	7-(4-fluorophenyl)-3-hydroxyquinolin-2(1H)-one bound to influenza 2009 H1N1 endonuclease
1FMC	;	1.8	;	7-ALPHA-HYDROXYSTEROID DEHYDROGENASE COMPLEX WITH NADH AND 7-OXO GLYCOCHENODEOXYCHOLIC ACID
3OPI	;	1.1	;	7-DEAZA-2'-DEOXYADENOSINE modification in B-FORM DNA
8SV3	;	1.51	;	7-Deazapurines and 5-Halogenpyrimidine DNA duplex
8SV4	;	2.3	;	7-Deazapurines and 5-Halogenpyrimidine DNA duplex
6FDR	;	1.4	;	7-FE FERREDOXIN FROM AZOTOBACTER VINELANDII AT 100K, NA DITHIONITE REDUCED AT PH 8.5, RESOLUTION 1.4 A
7FD1	;	1.3	;	7-FE FERREDOXIN FROM AZOTOBACTER VINELANDII AT PH 8.5, 100 K, 1.35 A
6FD1	;	1.35	;	7-FE FERREDOXIN FROM AZOTOBACTER VINELANDII LOW TEMPERATURE, 1.35 A
7FDR	;	1.4	;	7-FE FERREDOXIN FROM AZOTOBACTER VINELANDII, NA DITHIONITE REDUCED, PH 8.5, 1.4A RESOLUTION, 100 K
1BC6	;		;	7-FE FERREDOXIN FROM BACILLUS SCHLEGELII, NMR, 20 STRUCTURES
1BD6	;		;	7-FE FERREDOXIN FROM BACILLUS SCHLEGELII, NMR, MINIMIZED AVERAGE STRUCTURE
5Y2S	;	0.9	;	7.0 atm CO2-pressurized human carbonic anhydrase II
1KAY	;	1.7	;	70KD HEAT SHOCK COGNATE PROTEIN ATPASE DOMAIN, K71A MUTANT
1KAZ	;	1.7	;	70KD HEAT SHOCK COGNATE PROTEIN ATPASE DOMAIN, K71E MUTANT
1KAX	;	1.7	;	70KD HEAT SHOCK COGNATE PROTEIN ATPASE DOMAIN, K71M MUTANT
7ZP8	;	2.2	;	70S E. coli ribosome with a stalled filamin domain 5 nascent chain
7ZOD	;	2.56	;	70S E. coli ribosome with an extended uL23 loop from Candidatus marinimicrobia
7Z20	;	2.29	;	70S E. coli ribosome with an extended uL23 loop from Candidatus marinimicrobia and a stalled filamin domain 5 nascent chain
7ZQ5	;	2.7	;	70S E. coli ribosome with truncated uL23 and uL24 loops
7ZQ6	;	2.75	;	70S E. coli ribosome with truncated uL23 and uL24 loops and a stalled filamin domain 5 nascent chain
6O9J	;	3.9	;	70S Elongation Competent Ribosome
6O9K	;	4.0	;	70S initiation complex
6YEF	;	3.2	;	70S initiation complex with assigned rRNA modifications from Staphylococcus aureus
6VWM	;	3.4	;	70S ribosome bound to HIV frameshifting stem-loop (FSS) and P-site tRNA (non-rotated conformation, Structure I)
6VWN	;	3.4	;	70S ribosome bound to HIV frameshifting stem-loop (FSS) and P-site tRNA (non-rotated conformation, Structure II)
6VWL	;	3.1	;	70S ribosome bound to HIV frameshifting stem-loop (FSS) and P/E tRNA (rotated conformation)
5UYL	;	3.6	;	70S ribosome bound with cognate ternary complex base-paired to A site codon (Structure II)
5UYM	;	3.2	;	70S ribosome bound with cognate ternary complex base-paired to A site codon, closed 30S (Structure III)
5UYK	;	3.9	;	70S ribosome bound with cognate ternary complex not base-paired to A site codon (Structure I)
5UYQ	;	3.8	;	70S ribosome bound with near-cognate ternary complex base-paired to A site codon, closed 30S (Structure III-nc)
5UYP	;	3.9	;	70S ribosome bound with near-cognate ternary complex base-paired to A site codon, open 30S (Structure II-nc)
5UYN	;	4.0	;	70S ribosome bound with near-cognate ternary complex not base-paired to A site codon (Structure I-nc)
7UG7	;	2.58	;	70S ribosome complex in an intermediate state of translocation bound to EF-G(GDP) stalled by Argyrin B
5UQ8	;	3.2	;	70S ribosome complex with dnaX mRNA stem-loop and E-site tRNA (""out"" conformation)
5UQ7	;	3.5	;	70S ribosome complex with dnaX mRNA stemloop and E-site tRNA (""in"" conformation)
6QNR	;	3.1	;	70S ribosome elongation complex (EC) with experimentally assigned potassium ions
7JIL	;	2.8	;	70S ribosome Flavobacterium johnsoniae
5LI0	;	3.8	;	70S ribosome from Staphylococcus aureus
7NHM	;	3.1	;	70S ribosome from Staphylococcus aureus
6QNQ	;	3.5	;	70S ribosome initiation complex (IC) with experimentally assigned potassium ions
7JT2	;	3.5	;	70S ribosome stalled on long mRNA with ArfB bound in the A site
7JT1	;	3.3	;	70S ribosome stalled on long mRNA with ArfB-1 and ArfB-2 bound (+9-III)
4W29	;	3.8	;	70S ribosome translocation intermediate containing elongation factor EFG/GDP/fusidic acid, mRNA, and tRNAs trapped in the AP/AP pe/E chimeric hybrid state.
4V9L	;	3.5	;	70S Ribosome translocation intermediate FA-3.6A containing elongation factor EFG/FUSIDIC ACID/GDP, mRNA, and tRNA bound in the pe*/E state.
4V9M	;	4.0	;	70S Ribosome translocation intermediate FA-4.2A containing elongation factor EFG/FUSIDIC ACID/GDP, mRNA, and tRNA bound in the pe*/E state.
4V9K	;	3.5	;	70S ribosome translocation intermediate GDPNP-I containing elongation factor EFG/GDPNP, mRNA, and tRNA bound in the pe*/E state.
4V9J	;	3.86	;	70S ribosome translocation intermediate GDPNP-II containing elongation factor EFG/GDPNP, mRNA, and tRNA bound in the pe*/E state.
7PHC	;	9.9	;	70S ribosome with A*- and P/E-site tRNAs in chloramphenicol-treated Mycoplasma pneumoniae cells
7PAM	;	6.8	;	70S ribosome with A*- and P/E-site tRNAs in Mycoplasma pneumoniae cells
7PIR	;	12.1	;	70S ribosome with A*- and P/E-site tRNAs in pseudouridimycin-treated Mycoplasma pneumoniae cells
7PHB	;	4.9	;	70S ribosome with A- and P-site tRNAs in chloramphenicol-treated Mycoplasma pneumoniae cells
7PAL	;	4.7	;	70S ribosome with A- and P-site tRNAs in Mycoplasma pneumoniae cells
7PIQ	;	9.7	;	70S ribosome with A- and P-site tRNAs in pseudouridimycin-treated Mycoplasma pneumoniae cells
7PAN	;	9.7	;	70S ribosome with A/P- and P/E-site tRNAs in Mycoplasma pneumoniae cells
7PIA	;	13.6	;	70S ribosome with A/P- and P/E-site tRNAs in spectinomycin-treated Mycoplasma pneumoniae cells
7PAO	;	7.0	;	70S ribosome with EF-G, A*- and P/E-site tRNAs in Mycoplasma pneumoniae cells
7PIS	;	15.0	;	70S ribosome with EF-G, A*- and P/E-site tRNAs in pseudouridimycin-treated Mycoplasma pneumoniae cells
7PAQ	;	8.9	;	70S ribosome with EF-G, A/P- and P/E-site tRNAs in Mycoplasma pneumoniae cells
7PIT	;	5.7	;	70S ribosome with EF-G, A/P- and P/E-site tRNAs in pseudouridimycin-treated Mycoplasma pneumoniae cells
7PIB	;	4.7	;	70S ribosome with EF-G, A/P- and P/E-site tRNAs in spectinomycin-treated Mycoplasma pneumoniae cells
7PAR	;	8.2	;	70S ribosome with EF-G, ap/P- and pe/E-site tRNAs in Mycoplasma pneumoniae cells
7PHA	;	8.5	;	70S ribosome with EF-Tu-tRNA and P-site tRNA in chloramphenicol-treated Mycoplasma pneumoniae cells
7PAK	;	5.3	;	70S ribosome with EF-Tu-tRNA and P-site tRNA in Mycoplasma pneumoniae cells
7PIP	;	9.3	;	70S ribosome with EF-Tu-tRNA and P-site tRNA in pseudouridimycin-treated Mycoplasma pneumoniae cells
7PI9	;	6.3	;	70S ribosome with EF-Tu-tRNA and P-site tRNA in spectinomycin-treated Mycoplasma pneumoniae cells
7PAJ	;	7.3	;	70S ribosome with EF-Tu-tRNA, P- and E-site tRNAs in Mycoplasma pneumoniae cells
7PAH	;	9.5	;	70S ribosome with P- and E-site tRNAs in Mycoplasma pneumoniae cells
7PH9	;	8.7	;	70S ribosome with P-site tRNA in chloramphenicol-treated Mycoplasma pneumoniae cells
7PAI	;	6.7	;	70S ribosome with P-site tRNA in Mycoplasma pneumoniae cells
7PIO	;	9.5	;	70S ribosome with P-site tRNA in pseudouridimycin-treated Mycoplasma pneumoniae cells
7PI8	;	8.9	;	70S ribosome with P-site tRNA in spectinomycin-treated Mycoplasma pneumoniae cells
7PAS	;	16.0	;	70S ribosome with P/E-site tRNA in Mycoplasma pneumoniae cells
7PIC	;	9.1	;	70S ribosome with P/E-site tRNA in spectinomycin-treated Mycoplasma pneumoniae cells
6BU8	;	3.5	;	70S ribosome with S1 domains 1 and 2 (Class 1)
6WNV	;	3.5	;	70S ribosome without free 5S rRNA and with a perturbed PTC
5WDT	;	3.0	;	70S ribosome-EF-Tu H84A complex with GppNHp
5WE6	;	3.4	;	70S ribosome-EF-Tu H84A complex with GTP and cognate tRNA
5WF0	;	3.6	;	70S ribosome-EF-Tu H84A complex with GTP and near-cognate tRNA (Complex C2)
5WFK	;	3.4	;	70S ribosome-EF-Tu H84A complex with GTP and near-cognate tRNA (Complex C3)
5WFS	;	3.0	;	70S ribosome-EF-Tu H84A complex with GTP and near-cognate tRNA (Complex C4)
5WE4	;	3.1	;	70S ribosome-EF-Tu wt complex with GppNHp
5NP6	;	3.6	;	70S structure prior to bypassing
5CZP	;	3.29996	;	70S termination complex containing E. coli RF2
5DFE	;	3.09998	;	70S termination complex containing E. coli RF2
6OGI	;	3.4	;	70S termination complex with RF2 bound to the UAG codon. Rotated ribosome conformation (Structure V)
6OG7	;	3.3	;	70S termination complex with RF2 bound to the UGA codon. Non-rotated ribosome with RF2 bound (Structure II)
6OGF	;	3.9	;	70S termination complex with RF2 bound to the UGA codon. Partially rotated ribosome with RF2 bound (Structure III).
6OGG	;	4.2	;	70S termination complex with RF2 bound to the UGA codon. Rotated ribosome with RF2 bound (Structure IV).
4V4Z	;	4.51	;	70S Thermus thermophilous ribosome functional complex with mRNA and E- and P-site tRNAs at 4.5A.
7AZS	;	3.1	;	70S thermus thermophilus ribosome with bound antibiotic lead SEQ-569
7AZO	;	3.3	;	70S thermus thermophilus ribosome with bound antibiotic lead SEQ-977
4V74	;	17.0	;	70S-fMetVal-tRNAVal-tRNAfMet complex in hybrid pre-translocation state (pre5b)
8CD1	;	3.0	;	70S-PHIKZ014
4ZSN	;	3.6	;	70S-wild-type HigB toxin complex bound to a AAA lysine codon
6CTE	;	1.2	;	77Se-NMR probes the protein environment of selenomethionine
2IWQ	;	1.8	;	7th PDZ domain of Multiple PDZ Domain Protein MPDZ
6R5X	;	1.7	;	8-bladed beta-propeller formed by four 2-bladed fragments
6R5Y	;	2.15	;	8-bladed beta-propeller formed by two 4-bladed fragments
5ZND	;	3.0	;	8-mer nanotube derived from 24-mer rHuHF nanocage
7UN1	;	6.0	;	8-nm repeat of the human sperm tip singlet microtubule
3I4M	;	3.7	;	8-oxoguanine containing RNA polymerase II elongation complex D
3I4N	;	3.9	;	8-oxoguanine containing RNA polymerase II elongation complex E
4R5N	;	1.8	;	8-Tetrahydropyran-2-yl chromans: highly selective beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors
4RRN	;	1.8	;	8-Tetrahydropyran-2-yl chromans: highly selective beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors
4RRO	;	1.8	;	8-Tetrahydropyran-2-yl chromans: highly selective beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors
4RRS	;	1.8	;	8-Tetrahydropyran-2-yl chromans: highly selective beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors
2X5V	;	3.0	;	80 microsecond laue diffraction snapshot from crystals of a photosynthetic reaction centre 3 millisecond following photoactivation.
2X5U	;	3.0	;	80 microsecond Laue diffraction snapshot from crystals of a photosynthetic reaction centre without illumination.
7MDZ	;	3.2	;	80S rabbit ribosome stalled with benzamide-CHX
7LS2	;	3.1	;	80S ribosome from mouse bound to eEF2 (Class I)
7LS1	;	3.3	;	80S ribosome from mouse bound to eEF2 (Class II)
8CCS	;	1.97	;	80S S. cerevisiae ribosome with ligands in hybrid-1 pre-translocation (PRE-H1) complex
8CDL	;	2.72	;	80S S. cerevisiae ribosome with ligands in hybrid-2 pre-translocation (PRE-H2) complex
7UCK	;	2.8	;	80S translation initiation complex with ac4c(-1) mRNA and Harringtonine
7QDZ	;	3.6	;	80S-bound human SKI complex in the closed state
7QE0	;	6.5	;	80S-bound human SKI complex in the open state
7UYL	;	2.0	;	850 Fab
7UYM	;	2.2	;	850 Fab in complex with NANPNANPNANP peptide
5NMG	;	2.75	;	868 TCR in complex with HLA A02 presenting SLYFNTIAVL
5NMF	;	2.89	;	868 TCR in complex with HLA A02 presenting SLYNTIATL
5NME	;	2.94	;	868 TCR in complex with HLA A02 presenting SLYNTVATL
5NMD	;	2.07	;	868 TCR Specific for HLA A02 presenting HIV Epitope SLYNTVATL
8BPE	;	3.63	;	8:1 binding of FcMR on IgM pentameric core
1U45	;	2.01	;	8oxoguanine at the pre-insertion site of the polymerase active site
1DYL	;	9.0	;	9 ANGSTROM RESOLUTION CRYO-EM RECONSTRUCTION STRUCTURE OF SEMLIKI FOREST VIRUS (SFV) AND FITTING OF THE CAPSID PROTEIN STRUCTURE IN THE EM DENSITY
1FN2	;	1.6	;	9-AMINO-(N-(2-DIMETHYLAMINO)BUTYL)ACRIDINE-4-CARBOXAMIDE BOUND TO D(CGTACG)2
1RQY	;	1.55	;	9-amino-[N-(2-dimethylamino)proply]-acridine-4-carboxamide bound to d(CGTACG)2
6R5Z	;	1.75	;	9-bladed beta-propeller formed by three 3-bladed fragments
1S6R	;	2.24	;	908R class c beta-lactamase bound to iodo-acetamido-phenyl boronic acid
8GLV	;	3.1	;	96-nm repeat unit of doublet microtubules from Chlamydomonas reinhardtii flagella
8J07	;	4.1	;	96nm repeat of human respiratory doublet microtubule and associated axonemal complexes
8E8L	;	3.13	;	9H2 Fab-poliovirus 1 complex
8E8S	;	2.73	;	9H2 Fab-poliovirus 2 complex
8E8Z	;	3.15	;	9H2 Fab-Sabin poliovirus 1 complex
8E8Y	;	2.5	;	9H2 Fab-Sabin poliovirus 2 complex
8E8R	;	2.66	;	9H2 Fab-Sabin poliovirus 3 complex
8E8X	;	2.91	;	9H2 Fab-Sabin poliovirus 3 complex
460D	;	1.2	;	A ""HYDRAT-ION SPINE"" IN A B-DNA MINOR GROOVE
461D	;	1.5	;	A ""HYDRAT-ION SPINE"" IN A B-DNA MINOR GROOVE
397D	;	1.3	;	A 1.3 A RESOLUTION CRYSTAL STRUCTURE OF THE HIV-1 TRANS-ACTIVATION RESPONSE REGION RNA STEM REVEALS A METAL ION-DEPENDENT BULGE CONFORMATION
1TC1	;	1.41	;	A 1.4 ANGSTROM CRYSTAL STRUCTURE FOR THE HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE OF TRYPANOSOMA CRUZI
5KKO	;	1.55	;	A 1.55A X-Ray Structure from Vibrio cholerae O1 biovar El Tor of a Hypothetical Protein
7KQU	;	1.579	;	A 1.58-A resolution crystal structure of ferric-hydroperoxo intermediate of L-tyrosine hydroxylase in complex with 3-fluoro-L-tyrosine
7KQS	;	1.677	;	A 1.68-A resolution 3-fluoro-L-tyrosine bound crystal structure of heme-dependent tyrosine hydroxylase
7KQT	;	1.835	;	A 1.84-A resolution crystal structure of heme-dependent L-tyrosine hydroxylase in complex with 3-fluoro-L-tyrosine and cyanide
5TTA	;	1.85	;	A 1.85A X-Ray Structure from Peptoclostridium difficile 630 of a Hypothetical Protein
7KQR	;	1.89	;	A 1.89-A resolution substrate-bound crystal structure of heme-dependent tyrosine hydroxylase from S. sclerotialus
3WG7	;	1.9	;	A 1.9 angstrom radiation damage free X-ray structure of large (420KDa) protein by femtosecond crystallography
3NKB	;	1.916	;	A 1.9A crystal structure of the HDV ribozyme precleavage suggests both Lewis acid and general acid mechanisms contribute to phosphodiester cleavage
1OQM	;	2.1	;	A 1:1 complex between alpha-lactalbumin and beta1,4-galactosyltransferase in the presence of UDP-N-acetyl-galactosamine
5U4O	;	2.05	;	A 2.05A X-Ray Structureof A Bacterial Extracellular Solute-binding Protein, family 5 for Bacillus anthracis str. Ames
1HP7	;	2.1	;	A 2.1 ANGSTROM STRUCTURE OF AN UNCLEAVED ALPHA-1-ANTITRYPSIN SHOWS VARIABILITY OF THE REACTIVE CENTER AND OTHER LOOPS
4OU2	;	2.15	;	A 2.15 Angstroms X-ray crystal structure of E268A 2-aminomuconate 6-semialdehyde dehydrogenase catalytic intermediate from Pseudomonas fluorescens
4OUB	;	2.19	;	A 2.20 angstroms X-ray crystal structure of E268A 2-aminomucaonate 6-semialdehyde dehydrogenase catalytic intermediate from Pseudomonas fluorescens
3IGM	;	2.2	;	A 2.2A crystal structure of the AP2 domain of PF14_0633 from P. falciparum, bound as a domain-swapped dimer to its cognate DNA
1Y62	;	2.45	;	A 2.4 crystal structure of conkunitzin-S1, a novel Kunitz-fold cone snail neurotoxin.
6VN1	;	2.8	;	A 2.8 Angstrom Cryo-EM Structure of a Glycoprotein B-Neutralizing Antibody Complex Reveals a Critical Domain for Herpesvirus Fusion Initiation
7CPS	;		;	A 2:1 stoichiometric complex of anticancer drug 4'-Epiadriamycin bound to parallel G-quadruplex DNA [d-(TTGGGGT)]4.
7CSK	;		;	A 2:1 stoichiometric complex of anticancer drug Adriamycin bound to parallel G-quadruplex DNA [d-(TTGGGGT)]4.
3CQS	;	2.8	;	A 3'-OH, 2',5'-phosphodiester substitution in the hairpin ribozyme active site reveals similarities with protein ribonucleases
5OPQ	;	1.7	;	A 3,6-anhydro-D-galactosidase produced by Zobellia galactanivorans. This is an exo-lytic enzyme that hydrolyzes terminal 3,6-anhydro-D-galactose from the non-reducing end of carrageenan oligosaccharides.
2NWC	;	3.02	;	A 3.02 angstrom crystal structure of wild-type apo GroEL in a monoclinic space group
7KIP	;	3.39	;	A 3.4 Angstrom cryo-EM structure of the human coronavirus spike trimer computationally derived from vitrified NL63 virus particles
7B0N	;	3.7	;	A 3.7-angstrom structure of Yarrowia lipolytica complex I with an R121M mutation in NUCM.
1B37	;	1.9	;	A 30 ANGSTROM U-SHAPED CATALYTIC TUNNEL IN THE CRYSTAL STRUCTURE OF POLYAMINE OXIDASE
1B5Q	;	1.9	;	A 30 ANGSTROM U-SHAPED CATALYTIC TUNNEL IN THE CRYSTAL STRUCTURE OF POLYAMINE OXIDASE
2KQO	;		;	A 3D-structural model of unsulphated chondroitin from high-field NMR: 4-sulphation has little effect on backbone conformation
6KFU	;	2.2	;	A ACP-AMT Fusion Protein of Hybrid Polyketide/Non-Ribosomal Peptide Synthetase
3Q8W	;	3.64	;	A b-aminoacyl containing thiazolidine derivative and DPPIV complex
1NKE	;	1.8	;	A BACILLUS DNA POLYMERASE I PRODUCT COMPLEX BOUND TO A CYTOSINE-THYMINE MISMATCH AFTER A SINGLE ROUND OF PRIMER EXTENSION, FOLLOWING INCORPORATION OF DCTP.
1NK8	;	1.9	;	A BACILLUS DNA POLYMERASE I PRODUCT COMPLEX BOUND TO A GUANINE-THYMINE MISMATCH AFTER A SINGLE ROUND OF PRIMER EXTENSION, FOLLOWING INCORPORATION OF DCTP.
1NKC	;	1.8	;	A BACILLUS DNA POLYMERASE I PRODUCT COMPLEX BOUND TO A GUANINE-THYMINE MISMATCH AFTER FIVE ROUNDS OF PRIMER EXTENSION, FOLLOWING INCORPORATION OF DCTP, DGTP, DTTP, AND DATP.
1NKB	;	2.0	;	A BACILLUS DNA POLYMERASE I PRODUCT COMPLEX BOUND TO A GUANINE-THYMINE MISMATCH AFTER THREE ROUNDS OF PRIMER EXTENSION, FOLLOWING INCORPORATION OF DCTP, DGTP, AND DTTP.
1NK9	;	1.9	;	A BACILLUS DNA POLYMERASE I PRODUCT COMPLEX BOUND TO A GUANINE-THYMINE MISMATCH AFTER TWO ROUNDS OF PRIMER EXTENSION, FOLLOWING INCORPORATION OF DCTP AND DGTP.
2DYW	;	1.13	;	A Backbone binding DNA complex
7XVO	;	2.0	;	a bacteria protein complex
8HS8	;	2.7	;	a bacteria protein complex
8CZJ	;	2.751	;	A bacteria Zrt/Irt-like protein in the apo state
5AED	;	1.91	;	A bacterial protein structure in glycoside hydrolase family 31
5AEE	;	1.85	;	A bacterial protein structure in glycoside hydrolase family 31
5AEG	;	1.85	;	A bacterial protein structure in glycoside hydrolase family 31.
2MC5	;		;	A bacteriophage transcription regulator inhibits bacterial transcription initiation by -factor displacement
2MC6	;		;	A bacteriophage transcription regulator inhibits bacterial transcription initiation by sigma-factor displacement
7B4P	;	2.7	;	A Bacteroidetes bacterium CuZn-superoxide dismutase with CuZn metalation
7B4O	;	1.41	;	A Bacteroidetes bacterium CuZn-superoxide dismutase with ZnZn metalation
1FNZ	;	2.05	;	A bark lectin from robinia pseudoacacia in complex with N-acetylgalactosamine
6L92	;		;	A basket type G-quadruplex in WNT DNA promoter
8F1S	;	2.1	;	A benzimidazole (DB1476) sequence-specific recognition of 5'-CGCAAAAAAGCG-3' in A-orientation
8F1V	;	2.1	;	A benzimidazole (DB1476) sequence-specific recognition of 5'-CGCAAAAAAGCG-3' in B-orientation
4PDW	;	3.0	;	A benzonitrile analogue inhibits rhinovirus replication
3T8V	;	1.8	;	A bestatin-based chemical biology strategy reveals distinct roles for malaria M1- and M17-family aminopeptidases
3T8W	;	2.0	;	A bestatin-based chemical biology strategy reveals distinct roles for malaria M1- and M17-family aminopeptidases
1XBH	;		;	A BETA-HAIRPIN MIMIC FROM FCERI-ALPHA-CYCLO(L-262)
1C4B	;		;	A BETA-HAIRPIN MIMIC FROM FCERI-ALPHA-CYCLO(RD-262)
1HAA	;		;	A beta-Hairpin Structure in a 13-mer Peptide that Binds a-Bungarotoxin with High Affinity and Neutralizes its Toxicity
1HAJ	;		;	A beta-Hairpin Structure in a 13-mer Peptide that Binds a-Bungarotoxin with High Affinity and Neutralizes its Toxicity
3CWO	;	3.1	;	A beta/alpha-barrel built by the combination of fragments from different folds
2DND	;	2.2	;	A BIFURCATED HYDROGEN-BONDED CONFORMATION IN THE D(A.T) BASE PAIRS OF THE DNA DODECAMER D(CGCAAATTTGCG) AND ITS COMPLEX WITH DISTAMYCIN
3EM2	;	2.3	;	A bimolecular anti-parallel-stranded Oxytricha nova telomeric quadruplex in complex with a 3,6-disubstituted acridine BSU-6038
3EUI	;	2.2	;	A bimolecular anti-parallel-stranded Oxytricha nova telomeric quadruplex in complex with a 3,6-disubstituted acridine BSU-6042 in a large unit cell
3EQW	;	2.2	;	A bimolecular anti-parallel-stranded Oxytricha nova telomeric quadruplex in complex with a 3,6-disubstituted acridine BSU-6042 in small unit cell
3ERU	;	2.0	;	A bimolecular anti-parallel-stranded Oxytricha nova telomeric quadruplex in complex with a 3,6-disubstituted acridine BSU-6045
3ES0	;	2.2	;	A bimolecular anti-parallel-stranded Oxytricha nova telomeric quadruplex in complex with a 3,6-disubstituted acridine BSU-6048
3ET8	;	2.45	;	A bimolecular anti-parallel-stranded Oxytricha nova telomeric quadruplex in complex with a 3,6-disubstituted acridine BSU-6054
3EUM	;	1.78	;	A bimolecular anti-parallel-stranded Oxytricha nova telomeric quadruplex in complex with a 3,6-disubstituted acridine BSU-6066
3NYP	;	1.179	;	A bimolecular anti-parallel-stranded Oxytricha nova telomeric quadruplex in complex with a 3,6-disubstituted acridine ligand containing bis-3-fluoropyrrolidine end side chains
3NZ7	;	1.1	;	A bimolecular anti-parallel-stranded Oxytricha nova telomeric quadruplex in complex with a 3,6-disubstituted acridine ligand containing bis-3-fluoropyrrolidine end side chains
3CE5	;	2.5	;	A bimolecular parallel-stranded human telomeric quadruplex in complex with a 3,6,9-trisubstituted acridine molecule BRACO19
3VEQ	;	2.25	;	A binary complex betwwen bovine pancreatic trypsin and a engineered mutant trypsin inhibitor
1BKX	;	2.6	;	A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND ADENOSINE FURTHER DEFINES CONFORMATIONAL FLEXIBILITY
2L8I	;		;	A biocompatible backbone modification? - Structure and dynamics of a triazole-linked DNA duplex
7CC4	;	2.0	;	A biodegradable plastic-degrading cutinase-like enzyme from the phyllosphere yeast Pseudozyma antarctica
7MEU	;	1.91	;	A biphenyl inhibitor of eIF4E targeting an internal binding site enables the design of cell-permeable PROTAC-degraders
6RQM	;	3.0	;	A blocking anti-CTLA-4 Nanobody (KN044) complexed with CTLA-4
6PPS	;	2.8	;	A blue light illuminated LOV-PAS construct from the LOV-HK sensory protein from Brucella abortus (construct 15-273)
5XX3	;	1.12	;	A BPTI-[5,55] variant with C14GA38G mutations
5XX5	;	1.38	;	A BPTI-[5,55] variant with C14GA38I mutations
5XX4	;	1.67	;	A BPTI-[5,55] variant with C14GA38K mutations
5XX2	;	1.12	;	A BPTI-[5,55] variant with C14GA38L mutations
3GSJ	;	1.8	;	A Bulky Rhodium Complex Bound to an Adenosine-Adenosine DNA Mismatch
3GSK	;	1.6	;	A Bulky Rhodium Complex Bound to an Adenosine-Adenosine DNA Mismatch
5NYB	;	1.88	;	A C145A mutant of Nesterenkonia AN1 amidase bound to adipamide
5NY7	;	1.31	;	A C145A mutant of Nesterenkonia AN1 amidase bound to nicotinamide
5NYE	;	1.55	;	A C145A mutant of Nesterenkonia AN1 amidase bound to propionamide
5NYC	;	1.51	;	A C145A mutant of Nesterenkonia AN1 amidase bound to propionitrile
5NXZ	;	1.21	;	A C145A mutant of Nesterenkonia AN1 amidase from the nitrilase superfamily
5NY2	;	1.85	;	A C145A mutant of Nesterenkonia AN1 amidase from the nitrilase superfamily
5NZ5	;	1.47	;	A C145S mutant of Nesterenkonia AN1 amidase from the nitrilase superfamily
5DKA	;	1.55	;	A C2HC zinc finger is essential for the activity of the RING ubiquitin ligase RNF125
3ZUA	;		;	A C39-like domain
5IAU	;	1.781	;	A C69-family cysteine dipeptidase from Lactobacillus farciminis
5INR	;	1.652	;	A C69-family cysteine dipeptidase in complex with Ala-Pro from Lactobacillus farciminis
5INX	;	1.681	;	A C69-family cysteine dipeptidase in complex with Met and Ala from Lactobacillus farciminis
5LSW	;	2.15	;	A CAF40-binding motif facilitates recruitment of the CCR4-NOT complex to mRNAs targeted by Drosophila Roquin
8JIY	;	1.55	;	A carbohydrate binding domain of a putative chondroitinase
7NWP	;	2.163	;	A carbohydrate binding module family 9 (CBM9) from Caldicellulosiruptor kristjansonii in complex with cellobiose
7NWQ	;	2.231	;	A carbohydrate binding module family 9 (CBM9) from Caldicellulosiruptor kristjanssonii in complex with cellotriose
7NWO	;	2.7	;	A carbohydrate binding module family 9 (CBM9) from Caldicellulosiruptor kristjanssonii in complex with glucose
7NWN	;	1.97	;	A carbohydrate binding module family 9 (CBM9) from Caldicellulsiruptor kristjanssonii
7NN3	;	1.88948	;	A carbohydrate esterase family 15 (CE15) glucuronoyl esterase from Caldicellulosiruptor kristjansonii
8QEF	;	2.16	;	A carbohydrate esterase family 15 (CE15) glucuronoyl esterase from Phocaeicola ATCC 8482 bound to novel ligand.
8Q6S	;	1.99	;	A carbohydrate esterase family 15 (CE15) glucuronoyl esterase from Phocaeicola vulgatus ATCC 8482
8QCL	;	1.84	;	A carbohydrate esterase family 15 (CE15) glucuronoyl esterase from Phocaeicola vulgatus ATCC 8482
4R59	;	1.65	;	A Carbonic Anhydrase IX Mimic in Complex with a Carbohydrate-Based Sulfamate
4R5A	;	1.64	;	A Carbonic Anhydrase IX Mimic in Complex with a Carbohydrate-Based Sulfamate
4RIU	;	1.651	;	A Carbonic Anhydrase IX Mimic in Complex with a Saccharin-Based Inhibitor
4RIV	;	1.631	;	A Carbonic Anhydrase IX Mimic in Complex with Saccharin
1G49	;	1.9	;	A CARBOXYLIC ACID BASED INHIBITOR IN COMPLEX WITH MMP3
1HY7	;	1.5	;	A CARBOXYLIC ACID BASED INHIBITOR IN COMPLEX WITH MMP3
4UUI	;	1.79	;	A case study for twinned data analysis: multiple crystal forms of the enzyme N-acetyl-neuraminic lyase
1MBL	;	2.0	;	A catalytically-impaired class A beta-lactamase: 2 Angstroms crystal structure and kinetics of the Bacillus licheniformis E166A mutant
1CPD	;	2.2	;	A CATION BINDING MOTIF STABILIZES THE COMPOUND I RADICAL OF CYTOCHROME C PEROXIDASE
1CPE	;	2.2	;	A CATION BINDING MOTIF STABILIZES THE COMPOUND I RADICAL OF CYTOCHROME C PEROXIDASE
1CPF	;	2.2	;	A CATION BINDING MOTIF STABILIZES THE COMPOUND I RADICAL OF CYTOCHROME C PEROXIDASE
1CPG	;	2.2	;	A CATION BINDING MOTIF STABILIZES THE COMPOUND I RADICAL OF CYTOCHROME C PEROXIDASE
1L83	;	1.7	;	A CAVITY-CONTAINING MUTANT OF T4 LYSOZYME IS STABILIZED BY BURIED BENZENE
1L84	;	1.9	;	A CAVITY-CONTAINING MUTANT OF T4 LYSOZYME IS STABILIZED BY BURIED BENZENE
7X54	;	3.9	;	A CBg-ParM filament with ADP
7X56	;	3.5	;	A CBg-ParM filament with ADP
7X55	;	8.6	;	A CBg-ParM filament with GTP and a short incubation time
7X59	;	6.5	;	A CBg-ParM filament with GTP or GDPPi
5ZU6	;	1.4	;	A CBM32 derived from alginate lyase B (AlyB-OU02)
6HSW	;	2.14734	;	A CE15 glucuronoyl esterase from Teredinibacter turnerae T7901
1HBV	;	2.3	;	A CHECK ON RATIONAL DRUG DESIGN. CRYSTAL STRUCTURE OF A COMPLEX OF HIV-1 PROTEASE WITH A NOVEL GAMMA-TURN MIMETIC
1OSH	;	1.8	;	A Chemical, Genetic, and Structural Analysis of the nuclear bile acid receptor FXR
8P2L	;	2.68	;	A CHIMERA construct containing human SARM1 ARM and SAM domains and C. elegans TIR domain.
4EXK	;	1.28	;	A chimera protein containing MBP fused to the C-terminal domain of the uncharacterized protein STM14_2015 from Salmonella enterica
3O3Y	;	1.35	;	A chimeric alpha+alpha/beta peptide based on the CHR domain sequence of gp41
1UZH	;	2.2	;	A CHIMERIC CHLAMYDOMONAS, SYNECHOCOCCUS RUBISCO ENZYME
2WD2	;	1.49	;	A chimeric microtubule disruptor with efficacy on a taxane resistant cell line
6X0R	;	3.0	;	A Circular Permutant of the Tobacco Mosaic Virus (TMV) mutant Q101H
6X0Q	;	3.0	;	A Circular Permutant of the Tobacco Mosaic Virus (TMV) mutant Q101H coordinated with heme
5HPN	;	2.509	;	A circularly permuted PduA forming an icosahedral cage
5UBL	;	1.8	;	A circularly permuted version of PvdQ (cpPvdQ)
3IA3	;	3.2	;	A cis-proline in alpha-hemoglobin stabilizing Protein directs the structural reorganization of alpha-hemoglobin
6M5P	;	1.25	;	A class C beta-lactamase
6M5H	;	1.2	;	A class C beta-lactamase mutant - Y150F
6M5Q	;	1.3	;	A class C beta-lactamase mutant - Y150F
5LCK	;	1.89	;	A Clickable Covalent ERK 1/2 Inhibitor
6V4S	;	3.55	;	A Closed pore conformation of a Pentameic ligand-gated ion channel with additional N-terminal domain
1QRG	;	1.72	;	A CLOSER LOOK AND THE ACTIVE SITE OF GAMMA-CARBONIC ANHYDRASES: HIGH RESOLUTION CRYSTALLOGRAPHIC STUDIES OF THE CARBONIC ANHYDRASE FROM METHANOSARCINA THERMOPHILA
1QRM	;	1.95	;	A CLOSER LOOK AT THE ACTIVE SITE OF GAMMA-CARBONIC ANHYDRASES: HIGH RESOLUTION CRYSTAL STRUCTURES OF THE CARBONIC ANHYDRASE FROM METHANOSARCINA THERMOPHILA
1QRE	;	1.46	;	A CLOSER LOOK AT THE ACTIVE SITE OF GAMMA-CARBONIC ANHYDRASES: HIGH RESOLUTION CRYSTALLOGRAPHIC STUDIES OF THE CARBONIC ANHYDRASE FROM METHANOSARCINA THERMOPHILA
1QRF	;	1.55	;	A CLOSER LOOK AT THE ACTIVE SITE OF GAMMA-CARBONIC ANHYDRASES: HIGH RESOLUTION CRYSTALLOGRAPHIC STUDIES OF THE CARBONIC ANHYDRASE FROM METHANOSARCINA THERMOPHILA
1QRL	;	1.85	;	A CLOSER LOOK AT THE ACTIVE SITE OF GAMMA-CARBONIC ANHYDRASES: HIGH RESOLUTION CRYSTALLOGRAPHIC STUDIES OF THE CARBONIC ANHYDRASE FROM METHANOSARCINA THERMOPHILA
7A1T	;	1.42	;	A collapsed hexameric state of a de novo coiled-coil assembly: CC-Type2-(GgLaId)4-W19BrPhe.
3H8C	;	2.5	;	A combined crystallographic and molecular dynamics study of cathepsin-L retro-binding inhibitors (compound 14)
3H89	;	2.5	;	A combined crystallographic and molecular dynamics study of cathepsin-L retro-binding inhibitors(compound 4)
3H8B	;	1.8	;	A combined crystallographic and molecular dynamics study of cathepsin-L retro-binding inhibitors(compound 9)
1YXW	;	2.2	;	A common binding site for disialyllactose and a tri-peptide in the C-fragment of tetanus neurotoxin
1YYN	;	2.3	;	A common binding site for disialyllactose and a tri-peptide in the C-fragment of tetanus neurotoxin
2FSD	;	2.3	;	A Common Fold for the Receptor Binding Domains of Lactococcal Phages? The Crystal Structure of the Head Domain of Phage bIL170
1CEC	;	2.15	;	A COMMON PROTEIN FOLD AND SIMILAR ACTIVE SITE IN TWO DISTINCT FAMILIES OF BETA-GLYCANASES
1XYZ	;	1.4	;	A COMMON PROTEIN FOLD AND SIMILAR ACTIVE SITE IN TWO DISTINCT FAMILIES OF BETA-GLYCANASES
2C53	;	1.8	;	A comparative study of uracil DNA glycosylases from human and herpes simplex virus type 1
2C56	;	2.1	;	A comparative study of uracil DNA glycosylases from human and herpes simplex virus type 1
3GY2	;	1.57	;	A comparative study on the inhibition of bovine beta-trypsin by bis-benzamidines diminazene and pentamidine by X-ray crystallography and ITC
3GY3	;	1.7	;	A comparative study on the inhibition of bovine beta-trypsin by bis-benzamidines diminazene and pentamidine by X-ray crystallography and ITC
3GY4	;	1.55	;	A comparative study on the inhibition of bovine beta-trypsin by bis-benzamidines diminazene and pentamidine by X-ray crystallography and ITC
3GY5	;	1.57	;	A comparative study on the inhibition of bovine beta-trypsin by bis-benzamidines diminazene and pentamidine by X-ray crystallography and ITC
3GY7	;	1.55	;	A comparative study on the inhibition of bovine beta-trypsin by bis-benzamidines diminazene and pentamidine by X-ray crystallography and ITC
3GY8	;	1.75	;	A comparative study on the inhibition of bovine beta-trypsin by bis-benzamidines diminazene and pentamidine by X-ray crystallography and ITC
3GY6	;	1.7	;	A comparative study on the inhibition of bovine beta-trypsin by the bis-benzamidines diminazene and pentamidine
1KB7	;		;	A COMPARISON OF NMR SOLUTION STRUCTURES OF THE RECEPTOR BINDING DOMAINS OF PSEUDOMONAS AERUGINOSA PILI STRAINS PAO, KB7, AND PAK: IMPLICATIONS FOR RECEPTOR BINDING AND SYNTHETIC VACCINE DESIGN
1KB8	;		;	A COMPARISON OF NMR SOLUTION STRUCTURES OF THE RECEPTOR BINDING DOMAINS OF PSEUDOMONAS AERUGINOSA PILI STRAINS PAO, KB7, AND PAK: IMPLICATIONS FOR RECEPTOR BINDING AND SYNTHETIC VACCINE DESIGN
1NIL	;		;	A COMPARISON OF NMR SOLUTION STRUCTURES OF THE RECEPTOR BINDING DOMAINS OF PSEUDOMONAS AERUGINOSA PILI STRAINS PAO, KB7, AND PAK: IMPLICATIONS FOR RECEPTOR BINDING AND SYNTHETIC VACCINE DESIGN
1NIM	;		;	A COMPARISON OF NMR SOLUTION STRUCTURES OF THE RECEPTOR BINDING DOMAINS OF PSEUDOMONAS AERUGINOSA PILI STRAINS PAO, KB7, AND PAK: IMPLICATIONS FOR RECEPTOR BINDING AND SYNTHETIC VACCINE DESIGN
1PAN	;		;	A COMPARISON OF NMR SOLUTION STRUCTURES OF THE RECEPTOR BINDING DOMAINS OF PSEUDOMONAS AERUGINOSA PILI STRAINS PAO, KB7, AND PAK: IMPLICATIONS FOR RECEPTOR BINDING AND SYNTHETIC VACCINE DESIGN
1PAO	;		;	A COMPARISON OF NMR SOLUTION STRUCTURES OF THE RECEPTOR BINDING DOMAINS OF PSEUDOMONAS AERUGINOSA PILI STRAINS PAO, KB7, AND PAK: IMPLICATIONS FOR RECEPTOR BINDING AND SYNTHETIC VACCINE DESIGN
2HWB	;	3.0	;	A comparison of the anti-rhinoviral drug binding pocket in hrv14 and hrv1a
2HWC	;	3.0	;	A COMPARISON OF THE ANTI-RHINOVIRAL DRUG BINDING POCKET IN HRV14 AND HRV1A
2HWD	;	3.8	;	A COMPARISON OF THE ANTI-RHINOVIRAL DRUG BINDING POCKET IN HRV14 AND HRV1A
2HWE	;	3.8	;	A COMPARISON OF THE ANTI-RHINOVIRAL DRUG BINDING POCKET IN HRV14 AND HRV1A
2HWF	;	3.8	;	A COMPARISON OF THE ANTI-RHINOVIRAL DRUG BINDING POCKET IN HRV14 AND HRV1A
5I1B	;	2.1	;	A COMPARISON OF THE HIGH RESOLUTION STRUCTURES OF HUMAN AND MURINE INTERLEUKIN-1B
8I1B	;	2.4	;	A COMPARISON OF THE HIGH RESOLUTION STRUCTURES OF HUMAN AND MURINE INTERLEUKIN-1B
3LDH	;	3.0	;	A comparison of the structures of apo dogfish m4 lactate dehydrogenase and its ternary complexes
2SBT	;	2.8	;	A COMPARISON OF THE THREE-DIMENSIONAL STRUCTURES OF SUBTILISIN BPN AND SUBTILISIN NOVO
6UMM	;	3.7	;	A complete structure of the ESX-3 translocon complex
7FD4	;	2.4	;	A complete three-dimensional structure of the Lon protease translocating a protein substrate (conformation 1)
7FD5	;	2.4	;	A complete three-dimensional structure of the Lon protease translocating a protein substrate (conformation 2)
3BYT	;	2.3	;	A complex between a variant of staphylococcal enterotoxin C3 and the variable domain of the murine T cell receptor beta chain 8.2
1HKN	;	2.0	;	A complex between acidic fibroblast growth factor and 5-amino-2-naphthalenesulfonate
3ML6	;	3.5	;	a complex between Dishevelled2 and clathrin adaptor AP-2
6BCA	;	1.995	;	A Complex between PH Domain of LbcRhoGEF (AKAP-Lbc) and Activated RhoA Bound to a GTP Analog
6BCB	;	1.401	;	A Complex between PH Domain of p114RhoGEF and Activated RhoA Bound to a GTP Analog
6BC1	;	2.9	;	A Complex between PH Domain of p190RhoGEF and Activated Rac1 Bound to a GTP Analog
6BC0	;	2.198	;	A Complex between PH Domain of p190RhoGEF and Activated RhoA Bound to a GTP Analog
8CB2	;	2.7	;	A complex of cagX and cagY components of Helicobacter pylori type IV secretion system
1AHW	;	3.0	;	A COMPLEX OF EXTRACELLULAR DOMAIN OF TISSUE FACTOR WITH AN INHIBITORY FAB (5G9)
3ZEB	;	2.2	;	A complex of GlpG with isocoumarin inhibitor covalently bonded to serine 201 and histidine 150
5AIT	;	3.4	;	A complex of of RNF4-RING domain, UbeV2, Ubc13-Ub (isopeptide crosslink)
5AIU	;	2.21	;	A complex of RNF4-RING domain, Ubc13-Ub (isopeptide crosslink)
5TCY	;	1.9	;	A complex of the synthetic siderophore analogue Fe(III)-5-LICAM with CeuE (H227L variant), a periplasmic protein from Campylobacter jejuni.
5A5D	;	1.74	;	A complex of the synthetic siderophore analogue Fe(III)-5-LICAM with the CeuE periplasmic protein from Campylobacter jejuni
5A5V	;	2.04	;	A complex of the synthetic siderophore analogue Fe(III)-6-LICAM with the CeuE periplasmic protein from Campylobacter jejuni
5AD1	;	1.32	;	A complex of the synthetic siderophore analogue Fe(III)-8-LICAM with the CeuE periplasmic protein from Campylobacter jejuni
1UZX	;	1.85	;	A complex of the Vps23 UEV with ubiquitin
3STB	;	2.5	;	A complex of two editosome proteins and two nanobodies
2QCS	;	2.2	;	A complex structure between the Catalytic and Regulatory subunit of Protein Kinase A that represents the inhibited state
6PWC	;	4.9	;	A complex structure of arrestin-2 bound to neurotensin receptor 1
4AIS	;	2.0	;	A complex structure of BtGH84
4AIU	;	2.25	;	A complex structure of BtGH84
6ING	;	1.698	;	A complex structure of H25A mutant of glycosyltransferase with UDP
8IKW	;	1.94	;	A complex structure of PGIP-PG
6H5H	;		;	A computationally designed dRP lyase domain reconstructed from two heterologous fragments
8E15	;	2.41	;	A computationally stabilized hMPV F protein
5ZZK	;	2.64	;	A Con Artist: Phenylphenoxybenzamide is not a Glycosyltransferase Inhibitor
1IKF	;	2.5	;	A CONFORMATION OF CYCLOSPORIN A IN AQUEOUS ENVIRONMENT REVEALED BY THE X-RAY STRUCTURE OF A CYCLOSPORIN-FAB COMPLEX
3EY1	;	1.6	;	A Conformational Transition in the Structure of a 2'-Thiomethyl-Modified DNA Visualized at High Resolution
3EY2	;	1.04	;	A Conformational Transition in the Structure of a 2'-Thiomethyl-Modified DNA Visualized at High Resolution
3EY3	;	1.25	;	A Conformational Transition in the Structure of a 2'-Thiomethyl-Modified DNA Visualized at High Resolution
3DA7	;	2.25	;	A conformationally strained, circular permutant of barnase
6MJV	;		;	A consensus human beta defensin
6J4I	;		;	A conserved and buried edge-to-face aromatic interaction in SUMO is vital for the SUMO pathway
1Q8C	;	2.0	;	A conserved hypothetical protein from Mycoplasma genitalium shows structural homology to NusB proteins
3KXE	;	2.6	;	A conserved mode of protein recognition and binding in a ParD-ParE toxin-antitoxin complex
2AYS	;	1.86	;	A conserved non-metallic binding site in the C-terminal lobe of lactoferrin: Structure of the complex of C-terminal lobe of bovine lactoferrin with N-acetyl galactosamine at 1.86 A resolution
4PAM	;	2.101	;	A conserved phenylalanine as relay between the 5 helix and the GDP binding region of heterotrimeric G protein
4PAN	;	2.4	;	A conserved phenylalanine as relay between the 5 helix and the GDP binding region of heterotrimeric G protein
4PAO	;	2.003	;	A conserved phenylalanine as relay between the 5 helix and the GDP binding region of heterotrimeric G protein
4PAQ	;	2.0	;	A conserved phenylalanine as relay between the 5 helix and the GDP binding region of heterotrimeric G protein
4R0Z	;	2.005	;	A conserved phosphorylation switch controls the interaction between cadherin and beta-catenin in vitro and in vivo
4R10	;	2.3	;	A conserved phosphorylation switch controls the interaction between cadherin and beta-catenin in vitro and in vivo
4R11	;	2.789	;	A conserved phosphorylation switch controls the interaction between cadherin and beta-catenin in vitro and in vivo
1OK7	;	1.65	;	A Conserved protein binding-site on Bacterial Sliding Clamps
6EJ5	;	3.34	;	A conserved structural element in the RNA helicase UPF1 regulates its catalytic activity in an isoform-specific manner
282D	;	2.4	;	A CONTINOUS TRANSITION FROM A-DNA TO B-DNA IN THE 1:1 COMPLEX BETWEEN NOGALAMYCIN AND THE HEXAMER DCCCGGG
7OGL	;	3.4	;	A cooperative PNPase-Hfq-RNA carrier complex facilitates bacterial riboregulation. apo-PNPase
7OGK	;	3.4	;	A cooperative PNPase-Hfq-RNA carrier complex facilitates bacterial riboregulation. PNPase-3'ETS(leuZ)
7OGM	;	3.7	;	A cooperative PNPase-Hfq-RNA carrier complex facilitates bacterial riboregulation. PNPase-3'ETS(leuZ)-Hfq
1OPZ	;		;	A core mutation affecting the folding properties of a soluble domain of the ATPase protein CopA from Bacillus subtilis
1OQ3	;		;	A core mutation affecting the folding properties of a soluble domain of the ATPase protein CopA from Bacillus subtilis
2KN5	;		;	A Correspondence Between Solution-State Dynamics of an Individual Protein and the Sequence and Conformational Diversity of its Family
2K0E	;		;	A Coupled Equilibrium Shift Mechanism in Calmodulin-Mediated Signal Transduction
1QWH	;	1.36	;	a covalent dimer of transthyretin that affects the amyloid pathway
148L	;	1.9	;	A COVALENT ENZYME-SUBSTRATE INTERMEDIATE WITH SACCHARIDE DISTORTION IN A MUTANT T4 LYSOZYME
1LQT	;	1.05	;	A covalent modification of NADP+ revealed by the atomic resolution structure of FprA, a Mycobacterium tuberculosis oxidoreductase
2QK7	;	2.4	;	A covalent S-F heterodimer of staphylococcal gamma-hemolysin
7WKJ	;	1.5	;	A COVID-19 T-cell response detection method based on a newly identified human CD8+ T cell epitope from SARS-CoV-2-Hubei Province, 2021.
5ING	;	2.45	;	A crotonyl-CoA reductase-carboxylase independent pathway for assembly of unusual alkylmalonyl-CoA polyketide synthase extender unit
2RPN	;		;	A crucial role for high intrinsic specificity in the function of yeast SH3 domains
5B2K	;	2.75	;	A crucial role of Cys218 in the stabilization of an unprecedented auto-inhibition form of MAP2K7
5B2L	;	2.1	;	A crucial role of Cys218 in the stabilization of an unprecedented auto-inhibition form of MAP2K7
5B2M	;	3.06	;	A crucial role of Cys218 in the stabilization of an unprecedented auto-inhibition form of MAP2K7
8HIL	;	3.57	;	A cryo-EM structure of B. oleracea RNA polymerase V at 3.57 Angstrom
8HIM	;	2.8	;	A cryo-EM structure of B. oleracea RNA polymerase V elongation complex at 2.73 Angstrom
8HYJ	;	4.3	;	A cryo-EM structure of KTF1-bound polymerase V transcription elongation complex
5ZA0	;	2.0	;	A cryo-protectant induces the conformational change of glyceraldehyde-3-phosphate dehydrogenase
6ES4	;	2.2	;	A cryptic RNA-binding domain mediates Syncrip recognition and exosomal partitioning of miRNA targets
4K92	;	2.005	;	A Cryptic TOG Domain with a Distinct Architecture Underlies CLASP-Dependent Bipolar Spindle Formation
4RUB	;	2.7	;	A CRYSTAL FORM OF RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE(SLASH)OXYGENASE FROM NICOTIANA TABACUM IN THE ACTIVATED STATE
3SJ2	;	1.36	;	A Crystal Structure of a Model of the Repeating r(CGG) Transcript Found in Fragile X Syndrome
7F0S	;	2.6	;	A crystal structure of alphavirus nonstructural protein 4 (nsP4) reveals an intrinsically 1dynamic RNA-dependent RNA polymerase
7VB4	;	1.86	;	A crystal structure of alphavirus nonstructural protein 4 (nsP4) reveals an intrinsically dynamic RNA-dependent RNA polymerase
5X88	;	1.76	;	A crystal structure of cutinases from Malbranchea cinnamomea
6WAK	;	2.4	;	A crystal structure of EGFR(T790M/V948R) in complex with LN3754
6KK9	;	2.2	;	A Crystal structure of OspA mutant
6KWJ	;	1.94	;	A Crystal Structure of OspA mutant
6KWU	;	1.43	;	A Crystal Structure of OspA mutant
6KWV	;	1.37	;	A Crystal Structure of OspA mutant
6LJY	;	1.5	;	A Crystal Structure of OspA mutant
7FDD	;	2.9	;	A Crystal structure of OspA mutant
2P54	;	1.79	;	a crystal structure of PPAR alpha bound with SRC1 peptide and GW735
4GDF	;	2.8	;	A Crystal Structure of SV40 Large T Antigen
1SZP	;	3.25	;	A Crystal Structure of the Rad51 Filament
3OTJ	;	2.15	;	A Crystal Structure of Trypsin Complexed with BPTI (Bovine Pancreatic Trypsin Inhibitor) by X-ray/Neutron Joint Refinement
3OTJ	;	1.6	;	A Crystal Structure of Trypsin Complexed with BPTI (Bovine Pancreatic Trypsin Inhibitor) by X-ray/Neutron Joint Refinement
227D	;	2.2	;	A CRYSTALLOGRAPHIC AND SPECTROSCOPIC STUDY OF THE COMPLEX BETWEEN D(CGCGAATTCGCG)2 AND 2,5-BIS(4-GUANYLPHENYL)FURAN, AN ANALOGUE OF BERENIL. STRUCTURAL ORIGINS OF ENHANCED DNA-BINDING AFFINITY
1FX1	;	2.0	;	A CRYSTALLOGRAPHIC STRUCTURAL STUDY OF THE OXIDATION STATES OF DESULFOVIBRIO VULGARIS FLAVODOXIN
1HRS	;	2.6	;	A CRYSTALLOGRAPHIC STUDY OF HAEM BINDING TO FERRITIN
283D	;	2.3	;	A CURVED RNA HELIX INCORPORATING AN INTERNAL LOOP WITH G-A AND A-A NON-WATSON-CRICK BASE PAIRING
5H5O	;	2.122	;	A cyclic-GMP-dependent signalling pathway regulates bacterial phytopathogenesis
5ITI	;	1.95	;	A cynobacterial PP2C (tPphA) structure
3G8Q	;	2.4	;	A cytidine deaminase edits C-to-U in transfer RNAs in archaea
4YE1	;	1.39	;	A cytochrome c plus calixarene structure - alternative ligand binding mode
6NMY	;	3.301	;	A Cytokine-receptor complex
2GW0	;	1.55	;	A D(TGGGGT)- sodium and calcium complex.
3EHB	;	2.32	;	A D-Pathway Mutation Decouples the Paracoccus Denitrificans Cytochrome c Oxidase by Altering the side chain orientation of a distant, conserved Glutamate
4D1U	;	1.8	;	A D120A mutant of VIM-7 from Pseudomonas aeruginosa
7N2B	;	3.221	;	A DARPin semi-rigidly fused to the 3TEL crystallization chaperone
4DZM	;	1.94	;	A de novo designed Coiled Coil CC-Di
4DZN	;	1.59	;	A de novo designed Coiled Coil CC-pIL
4DZL	;	2.3	;	A de novo designed Coiled Coil CC-Tri
4DZK	;	1.79	;	A de novo designed Coiled Coil CC-Tri-N13
4PNA	;	2.1	;	A de novo designed heptameric coiled coil CC-Hept
5F2Y	;	2.1	;	A de novo designed heptameric coiled coil CC-Hept-homoCys-H-E
5EZ8	;	1.95	;	A de novo designed heptameric coiled coil CC-Hept-I-C-I
5EZ9	;	1.8	;	A de novo designed heptameric coiled coil CC-Hept-I-H-I
5EZE	;	1.8	;	A de novo designed heptameric coiled coil CC-Hept-I18betaMeCys-L22H-I25E
5EZA	;	1.76	;	A de novo designed heptameric coiled coil CC-Hept-I18C-L22H
5EZC	;	1.8	;	A de novo designed heptameric coiled coil CC-Hept-I18C-L22H-I25E
6EIK	;	1.52	;	A de novo designed heptameric coiled coil CC-Hept-I24E
7Q1T	;	1.68	;	A de novo designed hetero-dimeric antiparallel coiled coil apCC-Di-AB
7Q1S	;	1.99	;	A de novo designed hetero-dimeric antiparallel coiled coil apCC-Di-AB_var
4PN9	;	2.2	;	A de novo designed hexameric coiled coil CC-Hex2
6EIZ	;	1.85	;	A de novo designed hexameric coiled coil CC-Hex2 with farnesol bound in the channel.
4PNB	;	2.052	;	A de novo designed hexameric coiled coil CC-Hex3.
5EHB	;	3.19	;	A de novo designed hexameric coiled-coil peptide with iodotyrosine
7Q1R	;	1.08	;	A de novo designed homo-dimeric antiparallel coiled coil apCC-Di
7BIM	;	1.64	;	A de novo designed nonameric coiled coil, CC-Type2-(GgLaId)4
4PN8	;	2.0	;	A de novo designed pentameric coiled coil CC-Pent.
4PND	;	1.75	;	A de novo designed pentameric coiled coil CC-Pent_Variant
6M6Z	;	5.9	;	A de novo designed transmembrane nanopore, TMH4C4
6Z1L	;	2.29	;	A de novo Enzyme for the Morita-Baylis-Hillman Reaction BH32.12
6Z1K	;	1.48	;	A de novo Enzyme for the Morita-Baylis-Hillman Reaction BH32.6
7O1D	;	1.8	;	A de novo Enzyme for the Morita-Baylis-Hillman Reaction BH32.7
7BAU	;	1.42	;	A de novo pentameric coiled-coil assembly: CC-Type2-(TgIaId)4-W19BrPhe.
7BAS	;	1.1	;	A de novo pentameric coiled-coil assembly: CC-Type2-(TgLaId)4-W19BrPhe.
7BAV	;	1.3	;	A de novo pentameric coiled-coil assembly: CC-Type2-(TgLaId)4-W19BrPhe.
7DMF	;	2.201	;	A de novo protein that rigidly extends the structure of tVHS-like domain in tepsin with a new designed domain
6GJK	;	1.47	;	A degradation product of PD 404182 (P2742) bound to Histone Deacetylase-like Amidohydrolase
4ZBC	;	2.0	;	A dehydrated form of glucose isomerase collected at 100K.
4ZB0	;	2.0	;	A dehydrated form of glucose isomerase collected at room temperature.
2JAB	;	1.7	;	A designed ankyrin repeat protein evolved to picomolar affinity to Her2
6IWJ	;		;	A designed domain swapped dimer
4HB1	;	2.9	;	A DESIGNED FOUR HELIX BUNDLE PROTEIN.
6MCT	;	1.9	;	A designed pentameric membrane protein stabilized by van der Waals interaction
3R5K	;	2.86	;	A designed redox-controlled caspase-7
1IFH	;	2.8	;	A DETAILED ANALYSIS OF THE FREE AND BOUND CONFORMATION OF AN ANTIBODY: X-RAY STRUCTURES OF ANTI-PEPTIDE FAB 17(SLASH)9 AND THREE DIFFERENT FAB-PEPTIDE COMPLEXES
2SCU	;	2.3	;	A detailed description of the structure of Succinyl-COA synthetase from Escherichia coli
1SZR	;	2.15	;	A Dimer interface mutant of ornithine decarboxylase reveals structure of gem diamine intermediate
8BFE	;	2.1	;	A dimeric de novo coiled-coil assembly: PK-2 (CC-TypeN-LaUbUcLd)
6QK9	;	2.231	;	A dimeric ubiquitin formed by a single amino acid substitution
5DA1	;	2.75	;	A Dimerization-Dependent Mechanism Drives PRRSV NSP11 Functions As a Beta Interferon Antagonist and Endoribonuclease
1FS5	;	1.73	;	A DISCOVERY OF THREE ALTERNATE CONFORMATIONS IN THE ACTIVE SITE OF GLUCOSAMINE-6-PHOSPHATE ISOMERASE
2ND4	;		;	A distinct sortase SrtB anchors and processes a streptococcal adhesin AbpA with a novel structural property
5NZB	;	1.695	;	A disulfide switch determines proteolytic resistance in the birch pollen allergen Bet v 2
5NZC	;	1.999	;	A disulfide switch determines proteolytic resistance in the birch pollen allergen Bet v 2
2KJI	;		;	A divergent ins protein in c. elegans structurally resemble insulin and activates the human insulin receptor
6M7Z	;	2.5	;	A divergent kinase lacking the glycine-rich loop regulates membrane ultrastructure of the Toxoplasma parasitophorous vacuole
1N4L	;	2.0	;	A DNA analogue of the polypurine tract of HIV-1
3NAO	;	5.03	;	A DNA Crystal Designed to Contain Two Molecules per Asymmetric Unit Cell
309D	;	2.6	;	A DNA DECAMER WITH A STICKY END: THE CRYSTAL STRUCTURE OF D-CGACGATCGT
1D89	;	2.3	;	A DNA DODECAMER CONTAINING AN ADENINE TRACT CRYSTALLIZES IN A UNIQUE LATTICE AND EXHIBITS A NEW BEND
1SP6	;		;	A DNA duplex containing a cholesterol adduct (alpha-anomer)
1SSJ	;		;	A DNA DUPLEX CONTAINING A CHOLESTEROL ADDUCT (BETA-ANOMER)
6TZQ	;	2.29	;	A DNA G-quadruplex/i-motif hybrid
6TZR	;	2.4	;	A DNA G-quadruplex/i-motif hybrid
6TZS	;	2.6	;	A DNA i-motif/duplex hybrid
2VZB	;	2.3	;	A Dodecameric Thioferritin in the Bacterial Domain, Characterization of the Bacterioferritin-Related Protein from Bacteroides fragilis
3NUH	;	3.103	;	A domain insertion in E. coli GyrB adopts a novel fold that plays a critical role in gyrase function
3I8N	;	2.145	;	A domain of a conserved functionally known protein from Vibrio parahaemolyticus RIMD 2210633.
3I8O	;	2.638	;	A domain of a functionally unknown protein from Methanocaldococcus jannaschii DSM 2661.
1Q0P	;	1.8	;	A domain of Factor B
7W2H	;	3.796	;	A double cysteine variant of the sigma-1 receptor from Xenopus laevis complexed with S1RA
5G1L	;	1.7	;	A double mutant of DsbG engineered for denitrosylation
5C58	;	2.795	;	A double mutant of serratia marcescens hemophore receptor HasR in complex with its hemophore HasA and heme
4N4S	;	2.2	;	A Double Mutant Rat Erk2 in Complex With a Pyrazolo[3,4-d]pyrimidine Inhibitor
7BFI	;	2.44	;	A double-histidine mutant of HSP47 slows down client release at low pH
7TZC	;	2.45	;	A drug and ATP binding site in type 1 ryanodine receptor
3O2P	;	2.233	;	A Dual E3 Mechanism for Rub1 Ligation to Cdc53: Dcn1(P)-Cdc53(WHB)
3O6B	;	3.1	;	A Dual E3 Mechanism for Rub1 Ligation to Cdc53: Dcn1(P)-Cdc53(WHB) low resolution
7V1T	;	2.562	;	A dual Inhibitor Against Main Protease
1T31	;	1.9	;	A Dual Inhibitor of the Leukocyte Proteases Cathepsin G and Chymase with Therapeutic Efficacy in Animals Models of Inflammation
1T32	;	1.85	;	A Dual Inhibitor of the Leukocyte Proteases Cathepsin G and Chymase with Therapeutic Efficacy in Animals Models of Inflammation
7ED5	;	2.98	;	A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase
2FY1	;		;	A dual mode of RNA recognition by the RBMY protein
1SJK	;		;	A DUPLEX DNA WITH AN ABASIC SITE IN A DA TRACT, ALPHA FORM, NMR, MINIMIZED AVERAGE STRUCTURE
1SJL	;		;	A DUPLEX DNA WITH AN ABASIC SITE IN A DA TRACT, BETA FORM, NMR, MINIMIZED AVERAGE STRUCTURE
4D1V	;	1.7	;	A F218Y mutant of VIM-7 from Pseudomonas aeruginosa
6NOV	;	2.14	;	A Fab derived from ixekizumab
2WDB	;	2.03	;	A family 32 carbohydrate-binding module, from the Mu toxin produced by Clostridium perfringens, in complex with beta-D-glcNAc-beta(1,2) mannose
2W1U	;	2.0	;	A family 32 carbohydrate-binding module, from the Mu toxin produced by Clostridium perfringens, in complex with beta-D-glcNAc-beta(1,3) galNAc
7ZQU	;	1.75	;	A fast recovering full-length LOV protein (DsLOV) from the marine phototrophic bacterium Dinoroseobacter shibae (Dark state) - C72A mutant
6GBA	;	1.9	;	A fast recovering full-length LOV protein (DsLOV) from the marine phototrophic bacterium Dinoroseobacter shibae (Dark state) - M49A mutant
6GAY	;	1.86	;	A fast recovering full-length LOV protein (DsLOV) from the marine phototrophic bacterium Dinoroseobacter shibae (Dark state) - M49I mutant
6GB3	;	1.752	;	A fast recovering full-length LOV protein (DsLOV) from the marine phototrophic bacterium Dinoroseobacter shibae (Dark state) - M49S mutant
6GBV	;	1.63	;	A fast recovering full-length LOV protein (DsLOV) from the marine phototrophic bacterium Dinoroseobacter shibae (Dark state) - M49T mutant
7DMS	;	1.96	;	A Fe(II)-binding effector of Yersinia pseudotuberculosis
2P4Z	;	2.1	;	A Ferredoxin-like Metallo-beta-lactamase Superfamily Protein from Thermoanaerobacter tengcongensis
1BMW	;		;	A fibronectin type III fold in plant allergens: The solution structure of Phl PII from timothy grass pollen, NMR, 38 STRUCTURES
1ORO	;	2.4	;	A FLEXIBLE LOOP AT THE DIMER INTERFACE IS A PART OF THE ACTIVE SITE OF THE ADJACENT MONOMER OF ESCHERICHIA COLI OROTATE PHOSPHORIBOSYLTRANSFERASE
6F2D	;	4.2	;	A FliPQR complex forms the core of the Salmonella type III secretion system export apparatus.
1PX6	;	2.1	;	A folding mutant of human class pi glutathione transferase, created by mutating aspartate 153 of the wild-type protein to asparagine
1PX7	;	2.03	;	A folding mutant of human class pi glutathione transferase, created by mutating aspartate 153 of the wild-type protein to glutamate
1MD3	;	2.03	;	A folding mutant of human class pi glutathione transferase, created by mutating glycine 146 of the wild-type protein to alanine
1MD4	;	2.1	;	A folding mutant of human class pi glutathione transferase, created by mutating glycine 146 of the wild-type protein to valine
4ZB5	;	2.0	;	A form of glucose isomerase collected at 100K.
1GM0	;		;	A Form of the Pheromone-Binding Protein from Bombyx mori
1P8F	;	1.85	;	A four location model to explain the stereospecificity of proteins.
1PB1	;	1.7	;	A four location model to explain the stereospecificity of proteins.
1MKO	;	2.18	;	A Fourth Quaternary Structure of Human Hemoglobin A at 2.18 A Resolution
5T5S	;	2.202	;	A fragment of a human tRNA synthetase
5T76	;	2.0	;	A fragment of a human tRNA synthetase
5IMU	;	1.9	;	A fragment of conserved hypothetical protein Rv3899c (residues 184-410) from Mycobacterium tuberculosis
2XNY	;	7.5	;	A fragment of streptococcal M1 protein in complex with human fibrinogen
8RZW	;	2.02	;	A fragment-based inhibitor of SHP2
8RZY	;	1.91	;	A fragment-based inhibitor of SHP2
8S01	;	2.17	;	A fragment-based inhibitor of SHP2
8S04	;	1.89	;	A fragment-based inhibitor of SHP2
8S06	;	2.19	;	A fragment-based inhibitor of SHP2
8S07	;	1.83	;	A fragment-based inhibitor of SHP2
8S0H	;	1.99	;	A fragment-based inhibitor of SHP2
8S0I	;	1.929	;	A fragment-based inhibitor of SHP2
8S0J	;	1.89	;	A fragment-based inhibitor of SHP2
8S0K	;	1.84	;	A fragment-based inhibitor of SHP2
8S0O	;	1.834	;	A fragment-based inhibitor of SHP2
8S0P	;	2.0	;	A fragment-based inhibitor of SHP2
8S0Q	;	1.872	;	A fragment-based inhibitor of SHP2
8S0S	;	1.94	;	A fragment-based inhibitor of SHP2
5DQY	;	1.4	;	A fully oxidized human thioredoxin
2JTK	;		;	A functional domain of a Wnt signal protein
1G6R	;	2.8	;	A FUNCTIONAL HOT SPOT FOR ANTIGEN RECOGNITION IN A SUPERAGONIST TCR/MHC COMPLEX
7SHX	;		;	A functional SNP regulates E-cadherin expression by dynamically remodeling the 3D structure of a promoter-associated non-coding RNA transcript, NMR, minimized average structure
6M5X	;	2.05991	;	A fungal glyceraldehyde-3-phosphate dehydrogenase with self-resistance to inhibitor heptelidic acid
8H59	;	2.15	;	A fungal MAP kinase in complex with an inhibitor
3A1M	;	2.0	;	A fusion protein of a beta helix region of gene product 5 and the foldon region of bacteriophage T4
2KQG	;		;	A G-rich sequence within the c-kit oncogene promoter forms a parallel G-quadruplex having asymmetric G-tetrad dynamics
2KQH	;		;	A G-rich sequence within the c-kit oncogene promoter forms a parallel G-quadruplex having asymmetric G-tetrad dynamics
1K51	;	1.8	;	A G55A Mutation Induces 3D Domain Swapping in the B1 Domain of Protein L from Peptostreptococcus magnus
3QI2	;	2.797	;	A Galpha P-loop mutation prevents transition to the activated state: G42R bound to RGS14 GoLoco
3QE0	;	3.0	;	A Galpha-i1 P-loop mutation prevents transition to the activated state
1G0U	;	2.4	;	A GATED CHANNEL INTO THE PROTEASOME CORE PARTICLE
3UPA	;	1.8	;	A general strategy for the generation of human antibody variable domains with increased aggregation resistance
3UPC	;	2.8	;	A general strategy for the generation of human antibody variable domains with increased aggregation resistance
2DD7	;	1.9	;	A GFP-like protein from marine copepod, Chiridius poppei
7Z64	;	1.31	;	A GH18 from haloalkaliphilic bacterium unveils environment-dependent variations in the catalytic machinery of chitinases
7Z65	;	1.108	;	A GH18 from haloalkaliphilic bacterium unveils environment-dependent variations in the catalytic machinery of chitinases
5H7T	;	1.19	;	A GH19 chitinase domain from the Cryptomeria japnonica pollen (CJP-4) allergen
8BDP	;	1.47	;	A GH20 family sulfoglycosidase Bt4394 in complex with NAG-thiazoline and sulfite
5OHT	;	1.87	;	A GH31 family sulfoquinovosidase from E. coli in complex with aza-sugar inhibitor IFGSQ
6PNR	;	1.9	;	A GH31 family sulfoquinovosidase from E. rectale in complex with aza-sugar inhibitor IFGSQ
5OHY	;	1.77	;	A GH31 family sulfoquinovosidase in complex with aza-sugar inhibitor IFGSQ
5OHS	;	1.97	;	A GH31 family sulfoquinovosidase mutant D455N in complex with pNPSQ
5M77	;	1.46	;	a GH76 family enzyme structure
3MFQ	;	2.598	;	A Glance into the Metal Binding Specificity of TroA: Where Elaborate Behaviors Occur in the Active Center
7Q5I	;	1.8	;	A glucose-based molecular rotor probes the catalytic site of glycogen phosphorylase.
1HPG	;	1.5	;	A glutamic acid specific serine protease utilizes a novel histidine triad in substrate binding
3EXU	;	1.81	;	A glycoside hydrolase family 11 xylanase with an extended thumb region
7BWG	;	2.85	;	A Glycoside Hydrolase Family 20 beta-N-Acetylglucosaminidase
6IFE	;	1.804	;	A Glycoside Hydrolase Family 43 beta-Xylosidase
5HQB	;	1.8	;	A Glycoside Hydrolase Family 97 enzyme (E480Q) in complex with Panose from Pseudoalteromonas sp. strain K8
5HQ4	;	1.926	;	A Glycoside Hydrolase Family 97 enzyme from Pseudoalteromonas sp. strain K8
5HQA	;	1.747	;	A Glycoside Hydrolase Family 97 enzyme in complex with Acarbose from Pseudoalteromonas sp. strain K8
5HQC	;	2.001	;	A Glycoside Hydrolase Family 97 enzyme R171K variant from Pseudoalteromonas sp. strain K8
5L77	;	1.24	;	A glycoside hydrolase mutant with an unreacted activity based probe bound
6INF	;	1.69	;	a glycosyltransferase complex with UDP
6INI	;	1.7	;	a glycosyltransferase complex with UDP and the product
6INH	;	2.1	;	A glycosyltransferase with UDP and the substrate
4D1W	;	1.4	;	A H224Y mutant for VIM-7 from Pseudomonas aeruginosa
190L	;	2.0	;	A HELIX INITIATION SIGNAL IN T4 LYSOZYME IDENTIFIED BY POLYALANINE MUTAGENESIS
191L	;	1.95	;	A HELIX INITIATION SIGNAL IN T4 LYSOZYME IDENTIFIED BY POLYALANINE MUTAGENESIS
192L	;	1.9	;	A HELIX INITIATION SIGNAL IN T4 LYSOZYME IDENTIFIED BY POLYALANINE MUTAGENESIS
7BAW	;	1.71	;	A heptameric barrel state of a de novo coiled-coil assembly: CC-Type2-(GgIaId)4
7NFP	;	1.43	;	A heptameric barrel state of a de novo coiled-coil assembly: CC-Type2-(LaId)4-I17K
7NFN	;	1.45	;	A heptameric barrel state of a de novo coiled-coil assembly: CC-Type2-(LaId)4-L21N-I24N.
7NFJ	;	1.19	;	A heptameric barrel state of a de novo coiled-coil assembly: CC-Type2-(LaId)4-L28Y.
7NFH	;	1.62	;	A heptameric barrel state of a de novo coiled-coil assembly: CC-Type2-(MaId)4.
3CK4	;	1.7	;	A heterospecific leucine zipper tetramer
3CRP	;	1.7	;	A heterospecific leucine zipper tetramer
6F2R	;	3.9	;	A heterotetramer of human HspB2 and HspB3
8QP0	;	11.2	;	A hexamer pore in the S-layer of Sulfolobus acidocaldarius formed by SlaA protein
8B16	;	1.55	;	A hexameric barrel state of a de novo coiled-coil assembly: CC-Pent2-I17Q
7BAT	;	1.77	;	A hexameric barrel state of a de novo coiled-coil assembly: CC-Type2-(GgIaId)4
7NFO	;	1.37	;	A hexameric barrel state of a de novo coiled-coil assembly: CC-Type2-(LaId)4-I17C.
7NFG	;	1.09	;	A hexameric barrel state of a de novo coiled-coil assembly: CC-Type2-(LaId)4-L14A.
8A09	;	1.35	;	A hexameric barrel state of a de novo coiled-coil assembly: CC-Type2-(QgLaId)4
7BO8	;	1.84	;	A hexameric de novo coiled-coil assembly: CC-Type2-(VaYd)4-Y3F-W19(BrPhe)-Y24F.
7BO9	;	1.56	;	A hexameric de novo coiled-coil assembly: CC-Type2-(VaYd)4-Y3F-W19(BrPhe).
7BOA	;	1.65	;	A hexameric de novo coiled-coil assembly: CC-Type2-(YaFd)4-W19(BrPhe).
5JY4	;	2.11	;	A high magnesium structure of the isochorismate synthase, EntC
3D7D	;	1.69	;	A high resolution crystal structure of human glutamate carboxypeptidase II (GCPII) in a complex with DCFBD, a urea-based inhibitor
3D7H	;	1.55	;	A high resolution crystal structure of human glutamate carboxypeptidase II (GCPII) in a complex with DCIBzL, a urea-based inhibitor
3D7F	;	1.54	;	A high resolution crystal structure of human glutamate carboxypeptidase II (GCPII) in a complex with DCIT, a urea-based inhibitor
3D7G	;	1.75	;	A high resolution crystal structure of human glutamate carboxypeptidase II (GCPII) in a complex with DCMC, a urea-based inhibitor
2OR4	;	1.62	;	A high resolution crystal structure of human glutamate carboxypeptidase II in complex with quisqualic acid
1S2R	;	1.53	;	A High Resolution Crystal Structure of [d(CGCAAATTTGCG)]2
5IVB	;	1.389	;	A High Resolution Structure of a Linked KDM5A Jmj Domain with Alpha-Ketoglutarate
4JL5	;	1.24	;	A high resolution structure of Aquifex Adenylate kinase with 2 ADP's
4MCS	;	1.83	;	A high resolution structure of human glutamate carboxypeptidase II (GCPII) His475Tyr variant in complex with glutamic acid
2PVW	;	1.71	;	A high resolution structure of human glutamate carboxypeptidase II (GCPII) in complex with 2-(phosphonomethyl)pentanedioic acid (2-PMPA)
4MCP	;	1.65	;	A high resolution structure of human glutamate carboxypeptidase II (GCPII) in complex with folyl-gamma-L-glutamic acid (pteroyldi-gamma-L-glutamic acid)
4MCQ	;	2.0	;	A high resolution structure of human glutamate carboxypeptidase II (GCPII) in complex with folyldi-gamma-L-glutamic acid (pteroyltri-gamma-L-glutamic acid)
4MCR	;	1.65	;	A high resolution structure of human glutamate carboxypeptidase II (GCPII) in complex with folyltri-gamma-L-glutamic acid (pteroyltetra-gamma-L-glutamic acid)
2OOT	;	1.64	;	A High Resolution Structure of Ligand-free Human Glutamate Carboxypeptidase II
2IH9	;	2.0	;	A high-dose crystal structure of a recombinant Melanocarbus albomyces laccase
6NIY	;	3.34	;	A high-resolution cryo-electron microscopy structure of a calcitonin receptor-heterotrimeric Gs protein complex
6OJD	;	1.99	;	A high-resolution crystal structure of covalent complex of NocB thioesterase domain with fluorophosphonate nocardicin G analog
6OJC	;	1.94	;	A high-resolution crystal structure of NocB thioesterase domain from Nocardicin cluster
2KOD	;		;	A high-resolution NMR structure of the dimeric C-terminal domain of HIV-1 CA
6IUS	;	2.12	;	A higher kcat Rubisco
3HSS	;	1.9	;	A higher resolution structure of Rv0554 from Mycobacterium tuberculosis complexed with malonic acid
1Q1M	;	2.6	;	A Highly Efficient Approach to a Selective and Cell Active PTP1B inhibitors
7LMX	;	1.8	;	A HIGHLY SPECIFIC INHIBITOR OF INTEGRIN ALPHA-V BETA-6 WITH A DISULFIDE
8U20	;	1.9	;	A Highly Stable Variant of Corynactis Californica Green Fluorescent Protein, ccGFP 5
8U22	;	1.8	;	A Highly Stable Variant of Corynactis Californica Green Fluorescent Protein, ccGFP 7
8U23	;	1.78	;	A Highly Stable Variant of Corynactis Californica Green Fluorescent Protein, ccGFP 8
8U24	;	1.85	;	A Highly Stable Variant of Corynactis Californica Green Fluorescent Protein, ccGFP 9
8U21	;	1.96	;	A Highly Stable Variant of Corynactis Californica Green Fluorescent Protein, ccGFP E6
3TVB	;	1.08	;	A Highly Symmetric DNA G-4 Quadruplex/drug Complex
8FR7	;	3.39	;	A hinge glycan regulates spike bending and impacts coronavirus infectivity
5J8J	;	2.716	;	A histone deacetylase from Saccharomyces cerevisiae
5T0M	;	1.896	;	A histone H3K9M mutation traps histone methyltransferase Clr4 to prevent heterochromatin spreading
5Y2K	;	2.1	;	A human antibody AF4H1L1
5UHY	;	6.2	;	A Human Antibody Against Zika Virus Crosslinks the E Protein to Prevent Infection
8GV4	;	2.5	;	A human broadly neutralizing influenza A hemagglutinin stem-specific antibody PN-SIA28
1X0M	;	2.2	;	a Human Kynurenine Aminotransferase II Homologue from Pyrococcus horikoshii OT3
7VZT	;	3.41	;	A human neutralizing antibody targeting SARS-CoV-2 RBD
3NCC	;	2.5	;	A human Prolactin receptor antagonist in complex with the mutant extracellular domain H188A of the human prolactin receptor
6B4N	;	1.3	;	a hydroxymethyl functionality at the 4-position of the 2-phenyloxazole moiety of HIV-1 protease inhibitors involving the P2' ligands
6Q1S	;	2.3	;	A hypothetical aminotransferase from Mycobacterium tuberculosis, alpha-ketoglutarate and PMP bound form
6Q1Q	;	2.4	;	A hypothetical aminotransferase from Mycobacterium tuberculosis, apo form
6Q1R	;	2.702	;	A hypothetical aminotransferase from Mycobacterium tuberculosis, PLP-bound form
1VDW	;	1.3	;	A hypothetical protein PH1897 from Pyrococcus horikoshii with similarities for Inositol-1 monophosphatase
5VCQ	;	2.051	;	A Hyrdrogen Producing Hybrid Streptavidin-Diiron Catalyst
3L45	;	1.8	;	A Joint Neutron and X-ray structure of Oxidized Amicyanin
3L45	;	1.5	;	A Joint Neutron and X-ray structure of Oxidized Amicyanin
1A8W	;		;	A K+ CATION-INDUCED CONFORMATIONAL SWITCH WITHIN A LOOP SPANNING SEGMENT OF A DNA QUADRUPLEX CONTAINING G-G-G-C REPEATS, NMR, 8 STRUCTURES
2N91	;		;	A key amino acid in the control of different functional behavior within the triheme cytochrome family from Geobacter sulfurreducens
5YF4	;	1.897	;	A kinase complex MST4-MOB4
2JQC	;		;	A L-amino acid mutant of a D-amino acid containing conopeptide
2PHI	;	2.2	;	A LARGE CONFORMATIONAL CHANGE IS FOUND IN THE CRYSTAL STRUCTURE OF THE PORCINE PANCREATIC PHOSPHOLIPASE A2 POINT MUTANT F63V
7WX5	;	2.392	;	a Legionella acetyltransferase effector VipF
7WX6	;	2.273	;	A Legionella acetyltransferase VipF
7C0Q	;	2.6	;	a Legionella pneumophila effector Lpg2505
1LRV	;	2.6	;	A LEUCINE-RICH REPEAT VARIANT WITH A NOVEL REPETITIVE PROTEIN STRUCTURAL MOTIF
6YHT	;	2.15	;	A lid blocking mechanism of a cone snail toxin revealed at the atomic level
6YHY	;	1.55	;	A lid blocking mechanism of a cone snail toxin revealed at the atomic level
6ZOI	;	1.798	;	A lid blocking mechanism of a cone snail toxin revealed at the atomic level
5YXB	;	2.95	;	A ligand binding to FXR
5YXD	;	2.98	;	A ligand F binding to FXR
5YXL	;	2.24	;	A ligand M binding to FXR
1YTS	;	2.5	;	A LIGAND-INDUCED CONFORMATIONAL CHANGE IN THE YERSINIA PROTEIN TYROSINE PHOSPHATASE
7F7G	;	2.446	;	a linear Peptide Inhibitors in complex with GK domain
5E6H	;	2.238	;	A Linked Jumonji Domain of the KDM5A Lysine Demethylase
8X2K	;	3.03	;	a lipid receptor complex structure
6FPV	;	1.64	;	A llama-derived JBP1-targeting nanobody
6KQ9	;	2.251	;	A long chain secondary alcohol dehydrogenase of Micrococcus luteus
6KQB	;	2.261	;	A long chain secondary alcohol dehydrogenase of Micrococcus luteus
1BH7	;		;	A LOW ENERGY STRUCTURE FOR THE FINAL CYTOPLASMIC LOOP OF BAND 3, NMR, MINIMIZED AVERAGE STRUCTURE
5JXZ	;	1.88	;	A low magnesium structure of the isochorismate synthase, EntC
2IH8	;	2.0	;	A low-dose crystal structure of a recombinant Melanocarpus albomyces laccase
4JUO	;	6.53	;	A low-resolution three-gate structure of topoisomerase IV from Streptococcus pneumoniae in space group H32
6EQZ	;	2.293	;	A MamC-MIC insertion in MBP scaffold at position K170
8GW1	;	3.31	;	A mechanism for SARS-CoV-2 RNA capping and its inhibition by nucleotide analogue inhibitors
8GWF	;	3.39	;	A mechanism for SARS-CoV-2 RNA capping and its inhibition by nucleotide analogue inhibitors
8GWG	;	3.37	;	A mechanism for SARS-CoV-2 RNA capping and its inhibition by nucleotide analogue inhibitors
8GWI	;	3.18	;	A mechanism for SARS-CoV-2 RNA capping and its inhibition by nucleotide analogue inhibitors
8GWO	;	3.8	;	A mechanism for SARS-CoV-2 RNA capping and its inhibition by nucleotide analogue inhibitors
8GWN	;	3.38	;	A mechanism for SARS-CoV-2 RNA capping and its inhibitor of AT-527
6F5O	;	9.8	;	A mechanism for the activation of the influenza virus transcriptase
6F5P	;	4.14	;	A mechanism for the activation of the influenza virus transcriptase
2QJ2	;	1.81	;	A Mechanistic Basis for Converting a Receptor Tyrosine Kinase Agonist to an Antagonist
2QJ4	;	2.5	;	A Mechanistic Basis for Converting a Receptor Tyrosine Kinase Agonist to an Antagonist
8U1C	;	2.89	;	A mechanistic understanding of protective influenza B neuraminidase mAbs at the airway interface
8U1Q	;	3.36	;	A mechanistic understanding of protective influenza B neuraminidase mAbs at the airway interface
8U1S	;	3.21	;	A mechanistic understanding of protective influenza B neuraminidase mAbs at the airway interface
2Z3C	;	1.79	;	A Mechanistic view of Enzyme Inhibition and Peptide Hydrolysis in the Active Site of the SARS-CoV 3C-Like peptidase
2Z3D	;	2.1	;	A Mechanistic view of Enzyme Inhibition and Peptide Hydrolysis in the Active Site of the SARS-CoV 3C-Like peptidase
2Z3E	;	2.32	;	A Mechanistic view of Enzyme Inhibition and Peptide Hydrolysis in the Active Site of the SARS-CoV 3C-Like peptidase
4AMS	;	2.6	;	A Megaviridae ORFan gene encode a new nucleotidyl transferase
4AMQ	;	2.17	;	A Megaviridae Orfan gene encodes a new nucleotidyl transferase
5X5Y	;	3.465	;	A membrane protein complex
8Q4H	;	2.83	;	a membrane-bound menaquinol:organohalide oxidoreductase complex RDH complex
1XIS	;	1.6	;	A METAL-MEDIATED HYDRIDE SHIFT MECHANISM FOR XYLOSE ISOMERASE BASED ON THE 1.6 ANGSTROMS STREPTOMYCES RUBIGINOSUS STRUCTURES WITH XYLITOL AND D-XYLOSE
2XIS	;	1.71	;	A METAL-MEDIATED HYDRIDE SHIFT MECHANISM FOR XYLOSE ISOMERASE BASED ON THE 1.6 ANGSTROMS STREPTOMYCES RUBIGINOSUS STRUCTURES WITH XYLITOL AND D-XYLOSE
3XIS	;	1.6	;	A METAL-MEDIATED HYDRIDE SHIFT MECHANISM FOR XYLOSE ISOMERASE BASED ON THE 1.6 ANGSTROMS STREPTOMYCES RUBIGINOSUS STRUCTURES WITH XYLITOL AND D-XYLOSE
4XIS	;	1.6	;	A METAL-MEDIATED HYDRIDE SHIFT MECHANISM FOR XYLOSE ISOMERASE BASED ON THE 1.6 ANGSTROMS STREPTOMYCES RUBIGINOSUS STRUCTURES WITH XYLITOL AND D-XYLOSE
3NQW	;	2.9	;	A metazoan ortholog of SpoT hydrolyzes ppGpp and plays a role in starvation responses
3NR1	;	1.9	;	A metazoan ortholog of SpoT hydrolyzes ppGpp and plays a role in starvation responses
4X35	;	1.5	;	A micro-patterned silicon chip as sample holder for macromolecular crystallography experiments with minimal background scattering
4X3B	;	2.1	;	A micro-patterned silicon chip as sample holder for macromolecular crystallography experiments with minimal background scattering
2WXD	;	1.6	;	A MICROMOLAR O-SULFATED THIOHYDROXIMATE INHIBITOR BOUND TO PLANT MYROSINASE
1N09	;		;	A minimal beta-hairpin peptide scaffold for beta-turn display
3Q5U	;	2.5	;	A minimal NLS from human scramblase 4 complexed with importin alpha
2P7D	;	2.25	;	A Minimal, 'Hinged' Hairpin Ribozyme Construct Solved with Mimics of the Product Strands at 2.25 Angstroms Resolution
1DS7	;	2.06	;	A MINOR FMN-DEPENDENT NITROREDUCTASE FROM ESCHERICHIA COLI B
3WT5	;	1.9	;	A mixed population of antagonist and agonist binding conformers in a single crystal explains partial agonism against vitamin D receptor: Active vitamin D analogues with 22R-alkyl group
3WT6	;	2.0	;	A mixed population of antagonist and agonist binding conformers in a single crystal explains partial agonism against vitamin D receptor: Active vitamin D analogues with 22R-alkyl group
2AEW	;	2.7	;	A model for growth hormone receptor activation based on subunit rotation within a receptor dimer
5TGL	;	3.0	;	A MODEL FOR INTERFACIAL ACTIVATION IN LIPASES FROM THE STRUCTURE OF A FUNGAL LIPASE-INHIBITOR COMPLEX
6T63	;	3.8	;	A model of the EIAV CA-SP hexamer (C2) from Gag-deltaMA tubes assembled at pH6
6T61	;	3.7	;	A model of the EIAV CA-SP hexamer (C2) from Gag-deltaMA tubes assembled at pH8
6T64	;	3.7	;	A model of the EIAV CA-SP hexamer (C6) from Gag-deltaMA spheres assembled at pH6
1XS9	;		;	A MODEL OF THE TERNARY COMPLEX FORMED BETWEEN MARA, THE ALPHA-CTD OF RNA POLYMERASE AND DNA
5Y49	;	2.4	;	A moderator XD22 binding to bile acid receptor
5MTF	;	1.79	;	A modular route to novel potent and selective inhibitors of rhomboid intramembrane proteases
4ERS	;	2.637	;	A Molecular Basis for Negative Regulation of the Glucagon Receptor
4AXY	;	1.24	;	A molecular basis for the action of the collagen-specific chaperone Hsp47-SERPINH1 and its structure-specific client recognition.
3MAM	;	1.8	;	A molecular switch changes the low to the high affinity state in the substrate binding protein AfProX
2QA4	;	3.0	;	A more complete structure of the the L7/L12 stalk of the Haloarcula marismortui 50S large ribosomal subunit
5M3K	;	2.83	;	A multi-component acyltransferase PhlABC from Pseudomonas protegens
5MG5	;	3.44	;	A multi-component acyltransferase PhlABC from Pseudomonas protegens soaked with the monoacetylphloroglucinol (MAPG)
1LM3	;	2.7	;	A Multi-generation Analysis of Cytochrome b562 Redox Variants: Evolutionary Strategies for Modulating Redox Potential Revealed Using a Library Approach
6DML	;	1.5	;	A multiconformer ligand model of 3,5 dimethylisoxaxole bound to the bromodomain of human BRD4
6DMI	;	1.9	;	A multiconformer ligand model of 5T5 bound to BACE-1
6DMH	;	1.3	;	A multiconformer ligand model of acylenzyme intermediate of meropenem bound to an SFC-1 E166A mutant
6DMK	;	1.66	;	A multiconformer ligand model of an isoxazolyl-benzimidazole ligand bound to the bromodomain of human CREBBP
6DMG	;	2.2	;	A multiconformer ligand model of EK6 bound to ERK2
6DMJ	;	1.15	;	A multiconformer ligand model of inhibitor 53W bound to CREB binding protein bromodomain
6L2A	;	1.90045	;	A mutant form of M. tb toxin MazEF-mt1
3NCB	;	2.1	;	A mutant human Prolactin receptor antagonist H180A in complex with the extracellular domain of the human prolactin receptor
3N06	;	2.0	;	A mutant human Prolactin receptor antagonist H27A in complex with the extracellular domain of the human prolactin receptor
3NCE	;	2.0	;	A mutant human Prolactin receptor antagonist H27A in complex with the mutant extracellular domain H188A of the human prolactin receptor
3N0P	;	2.1	;	A mutant human Prolactin receptor antagonist H30A in complex with the extracellular domain of the human prolactin receptor
3NCF	;	2.8	;	A mutant human Prolactin receptor antagonist H30A in complex with the mutant extracellular domain H188A of the human prolactin receptor
7F5J	;	1.593	;	a mutant of an enzyme from Viola yedoensis
7F5P	;	1.9	;	a mutant of an enzyme from Viola yedoensis
4OAO	;	2.05	;	A mutant of Axe2 (R55A), and acetyl-xylooligosaccharide esterase from Geobacillus Stearmophilus
2DD9	;	2.3	;	A mutant of GFP-like protein from Chiridius poppei
7ES2	;	2.34	;	a mutant of glycosyktransferase in complex with UDP and Reb D
8I8Y	;	2.9	;	A mutant of the C-terminal complex of proteins 4.1G and NuMA
3HHT	;	1.16	;	A mutant of the nitrile hydratase from Geobacillus pallidus having enhanced thermostability
7QOM	;	1.45	;	A mutant of the nitrile hydratase from Geobacillus pallidus having enhanced thermostability
7QOP	;	1.8	;	A mutant of the nitrile hydratase from Geobacillus pallidus having enhanced thermostability
7QOU	;	1.3	;	A mutant of the nitrile hydratase from Geobacillus pallidus having enhanced thermostability
7QOY	;	1.45	;	A mutant of the nitrile hydratase from Geobacillus pallidus having enhanced thermostability
7Z0V	;	1.45	;	A mutant of the nitrile hydratase from Geobacillus pallidus having enhanced thermostability
1WCS	;	2.8	;	A mutant of Trypanosoma rangeli sialidase displaying trans-sialidase activity
2F7D	;	1.9	;	A mutant rabbit cathepsin K with a nitrile inhibitor
1KPD	;		;	A MUTANT RNA PSEUDOKNOT THAT PROMOTES RIBOSOMAL FRAMESHIFTING IN MOUSE MAMMARY TUMOR VIRUS, NMR, MINIMIZED AVERAGE STRUCTURE
1QOH	;	2.35	;	A MUTANT SHIGA-LIKE TOXIN IIE
2BOS	;	2.0	;	A MUTANT SHIGA-LIKE TOXIN IIE BOUND TO ITS RECEPTOR
2A9N	;	3.0	;	A Mutation Designed to Alter Crystal Packing Permits Structural Analysis of a Tight-binding Fluorescein-scFv complex
5X8Y	;	2.817	;	A Mutation identified in Neonatal Microcephaly Destabilizes Zika Virus NS1 Assembly in vitro
2LKW	;		;	A Myristoylated Polyproline Type II Helix Functions as a Novel Fusion Peptide During Cell-Cell Membrane Fusion Induced by the Baboon Reovirus p15 FAST Protein
4ZB2	;	2.0	;	A native form of glucose isomerase collected at room temperature.
5NRB	;	2.24	;	A Native Ternary Complex of Alpha-1,3-Galactosyltransferase (a-3GalT) Supports a Conserved Reaction Mechanism for Retaining Glycosyltransferases - alpha-3GalT in complex with Co2+, UDP-Gal and lactose - a3GalT-Co2+-UDP-Gal-LAT-1
5NRD	;	2.12	;	A Native Ternary Complex of Alpha-1,3-Galactosyltransferase (a-3GalT) Supports a Conserved Reaction Mechanism for Retaining Glycosyltransferases - alpha-3GalT in complex with Co2+, UDP-Gal and lactose - a3GalT-Co2+-UDP-Gal-LAT-2
5NRE	;	1.98	;	A Native Ternary Complex of Alpha-1,3-Galactosyltransferase (a3GalT) Supports a Conserved Reaction Mechanism for Retaining Glycosyltransferases - a3GalT in complex with lactose - a3GalT-LAT
5NR9	;	1.7	;	A Native Ternary Complex of Alpha-1,3-Galactosyltransferase (alpha-3GalT) Supports a Conserved Reaction Mechanism for Retaining Glycosyltransferases - Unliganded alpha-3GalT
2F8O	;	1.7	;	A Native to Amyloidogenic Transition Regulated by a Backbone Trigger
6LN1	;	2.699	;	A natural inhibitor of DYRK1A for treatment of diabetes mellitus
1N2R	;	1.7	;	A natural selected dimorphism in HLA B*44 alters self, peptide reportoire and T cell recognition.
4J3B	;	2.2	;	A naturally variable residue in the S1 subsite of M1-family aminopeptidases modulates catalytic properties and promotes functional specialization
7FGB	;	2.0	;	A naturally-occurring neuraminidase-inhibitors-resistant NA from asiatic toad influenza B-like virus
7FGC	;	1.9	;	A naturally-occurring neuraminidase-inhibitors-resistant NA from asiatic toad influenza B-like virus
7FGD	;	2.1	;	A naturally-occurring neuraminidase-inhibitors-resistant NA from asiatic toad influenza B-like virus
7FGE	;	2.8	;	A naturally-occurring neuraminidase-inhibitors-resistant NA from asiatic toad influenza B-like virus
8J1W	;	1.95	;	A near-infrared fluorescent protein of de novo backbone design
8J1X	;	2.25	;	A near-infrared fluorescent protein of de novo backbone design
8J98	;	2.9	;	A near-infrared fluorescent protein of de novo backbone design
8Y33	;	2.9	;	A near-infrared fluorescent protein of de novo backbone design
3TAX	;	1.88	;	A Neutral Diphosphate Mimic Crosslinks the Active Site of Human O-GlcNAc Transferase
1JJB	;	2.3	;	A neutral molecule in cation-binding site: Specific binding of PEG-SH to Acetylcholinesterase from Torpedo californica
7D6I	;	3.41	;	A neutralizing MAb targeting receptor-binding-domain of SARS-CoV-2
3FHP	;	2.0	;	A neutron crystallographic analysis of a porcine 2Zn insulin at 2.0 A resolution
6ITG	;	1.42	;	a new alginate lyase (PL6) from Vibrio splendidus OU02
6W35	;	1.98	;	A new Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis: A Clinical Candidate Discovered Using DNA-Encoded Chemistry
5IZU	;	2.494	;	A new binding site outside the canonical PDZ domain determines the specific interaction between Shank and SAPAP and their function
4UQG	;	2.0	;	A new bio-isosteric base pair based on reversible bonding
2JIM	;	2.45	;	A New Catalytic Mechanism of Periplasmic Nitrate Reductase from Desulfovibrio desulfuricans ATCC 27774 from Crystallographic and EPR Data and based on detailed analysis of the sixth ligand
2JIO	;	2.2	;	A New Catalytic Mechanism of Periplasmic Nitrate Reductase from Desulfovibrio desulfuricans ATCC 27774 from Crystallographic and EPR Data and based on detailed analysis of the sixth ligand
2JIP	;	2.3	;	A New Catalytic Mechanism of Periplasmic Nitrate Reductase from Desulfovibrio desulfuricans ATCC 27774 from Crystallographic and EPR Data and based on detailed analysis of the sixth ligand
2JIQ	;	2.44	;	A New Catalytic Mechanism of Periplasmic Nitrate Reductase from Desulfovibrio desulfuricans ATCC 27774 from Crystallographic and EPR Data and based on detailed analysis of the sixth ligand
2JIR	;	2.35	;	A New Catalytic Mechanism of Periplasmic Nitrate Reductase from Desulfovibrio desulfuricans ATCC 27774 from Crystallographic and EPR Data and based on detailed analysis of the sixth ligand
2V3V	;	1.99	;	A New Catalytic Mechanism of Periplasmic Nitrate Reductase from Desulfovibrio desulfuricans ATCC 27774 from Crystallographic and EPR Data and based on detailed analysis of the sixth ligand
2V45	;	2.4	;	A New Catalytic Mechanism of Periplasmic Nitrate Reductase from Desulfovibrio desulfuricans ATCC 27774 from Crystallographic and EPR Data and based on detailed analysis of the sixth ligand
3AID	;	2.5	;	A NEW CLASS OF HIV-1 PROTEASE INHIBITOR: THE CRYSTALLOGRAPHIC STRUCTURE, INHIBITION AND CHEMICAL SYNTHESIS OF AN AMINIMIDE PEPTIDE ISOSTERE
3E9S	;	2.5	;	A new class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication
4WHH	;	1.9	;	A New Class of Peptidomimetics Targeting the Polo-box Domain of Polo-like kinase 1
4WHK	;	1.8	;	A New Class of Peptidomimetics Targeting the Polo-box Domain of Polo-like kinase 1
4WHL	;	2.71	;	A New Class of Peptidomimetics Targeting the Polo-box Domain of Polo-like kinase 1
3SRK	;	2.65	;	A new class of suicide inhibitor blocks nucleotide binding to pyruvate kinase
2ZXM	;	3.01	;	A New Class of Vitamin D Receptor Ligands that Induce Structural Rearrangement of the Ligand-binding Pocket
2ZXN	;	2.1	;	A New Class of Vitamin D Receptor Ligands that Induce Structural Rearrangement of the Ligand-binding Pocket
5FNV	;	2.61	;	a new complex structure of tubulin with an alpha-beta unsaturated lactone
3WHE	;	4.0	;	A new conserved neutralizing epitope at the globular head of hemagglutinin in H3N2 influenza viruses
2QCA	;	1.33	;	A New Crystal Form of Bovine Pancreatic RNase A in Complex with 2'-Deoxyguanosine-5'-monophosphate
3M3J	;	1.6	;	A new crystal form of Lys48-linked diubiquitin
1GP9	;	2.5	;	A New Crystal Form of the Nk1 Splice Variant of Hgf/Sf Demonstrates Extensive Hinge Movement and Suggests that the Nk1 Dimer Originates by Domain Swapping
4ZFP	;	1.96	;	A new crystal structure for the adduct formed in the reaction between AuSac2, a cytotoxic homoleptic gold(I) compound with the saccharinate ligand, and the model protein hen egg white lysozyme
1EHV	;	1.8	;	A NEW CRYSTAL STRUCTURE FOR THE DODECAMER C-G-C-G-A-A-T-T-C-G-C-G: SYMMETRY EFFECTS ON SEQUENCE-DEPENDENT DNA STRUCTURE
3U7B	;	1.94	;	A new crystal structure of a Fusarium oxysporum GH10 xylanase reveals the presence of an extended loop on top of the catalytic cleft
3T7U	;	2.9	;	A NeW Crystal structure of APC-ARM
5A2R	;	1.85	;	A New Crystal Structure of the Drosophila melanogaster Angiotensin Converting Enzyme Homologue AnCE.
3ZBO	;	1.58	;	A new family of proteins related to the HEAT-like repeat DNA glycosylases with affinity for branched DNA structures
7RHA	;	1.8	;	A new fluorescent protein darkmRuby at pH 5.0
7RHB	;	2.51	;	A new fluorescent protein darkmRuby at pH 8.0
7RHC	;	2.8	;	A new fluorescent protein darkmRuby at pH 9.0
1Y75	;	2.3	;	A new form of catalytically inactive phospholipase A2 with an unusual disulphide bridge Cys 32- Cys 49 reveals recognition for N-acetylglucosmine
3EY0	;	2.52	;	A new form of DNA-drug interaction in the minor groove of a coiled coil
5V4A	;	1.75	;	A New Glycosyltransferase (DUF1792) from Streptococcus sanguinis
5BN0	;	2.8	;	A new HIV fusion peptide inhibitor
7BW5	;		;	a new lasso peptide koreensin
1O87	;	2.1	;	A new MgGDP complex of the Ffh NG domain
6SJJ	;	2.3	;	A new modulated crystal structure of ANS complex of St John's wort Hyp-1 protein with 36 protein molecules in the asymmetric unit of the supercell
3SMA	;	2.0	;	A new N-acetyltransferase fold in the structure and mechanism of the phosphonate biosynthetic enzyme FrbF
1CHZ	;	1.76	;	A NEW NEUROTOXIN FROM BUTHUS MARTENSII KARSCH
1NCF	;	2.25	;	A NEW PARADIGM FOR TUMOR NECROSIS FACTOR SIGNALLING
3MHY	;	1.4	;	A New PII Protein Structure
5Z9T	;	1.8	;	a new PL6 alginate lyase complex with trisaccharide
4KWN	;	1.8	;	A new stabilizing water structure at the substrate binding site in ribosome inactivating protein from Momordica balsamina at 1.80 A resolution
6TI5	;		;	A New Structural Model of Abeta(1-40) Fibrils
1ENU	;	1.95	;	A new target for shigellosis: Rational design and crystallographic studies of inhibitors of tRNA-guanine transglycosylase
1F3E	;	1.85	;	A NEW TARGET FOR SHIGELLOSIS: RATIONAL DESIGN AND CRYSTALLOGRAPHIC STUDIES OF INHIBITORS OF TRNA-GUANINE TRANSGLYCOSYLASE
3J4U	;	3.5	;	A new topology of the HK97-like fold revealed in Bordetella bacteriophage: non-covalent chainmail secured by jellyrolls
4ESV	;	3.2	;	A New Twist on the Translocation Mechanism of Helicases from the Structure of DnaB with its Substrates
6M1B	;	1.88	;	A new V27M variant of beta 2 microglobulin induced amyloidosis in a patient with long-term hemodialysis
7DQK	;	3.5	;	A nicotine MATE transporter, Nicotiana tabacum MATE2 (NtMATE2)
3DGN	;	2.7	;	A non-biological ATP binding protein crystallized in the presence of 100 mM ADP
3LT9	;	2.55	;	A non-biological ATP binding protein with a single point mutation (D65V), that contributes to optimized folding and ligand binding
3LT8	;	2.55	;	A non-biological ATP binding protein with a single point mutation (D65V), that contributes to optimized folding and ligand binding, crystallized in the presence of 100 mM ATP.
3DGO	;	2.5	;	A non-biological ATP binding protein with a Tyr-Phe mutation in the ligand binding domain
6RPJ	;	3.25	;	A Non-blocking anti-CTLA-4 Nanobody complexed with CTLA-4
4RTJ	;	1.99	;	A non-cognate complex of Escherichia coli DNA Adenine Methyltransferase (DAM) with DNA and Sinefungin
2V4E	;	2.4	;	A non-cytotoxic DsRed variant for whole-cell labeling
6M2A	;	2.23	;	A non-His-rich type of chimeric sirohydrochlorin nickelochelatase CfbA from M. jannaschii and M. barkeri
2OKW	;	1.9	;	A non-invasive GFP-based biosensor for mercury ions
2OKY	;	2.4	;	A non-invasive GFP-based biosensor for mercury ions
3OAY	;	1.95	;	A non-self sugar mimic of the HIV glycan shield shows enhanced antigenicity
3OAZ	;	1.75	;	A non-self sugar mimic of the HIV glycan shield shows enhanced antigenicity
3OB0	;	2.85	;	A non-self sugar mimic of the HIV glycan shield shows enhanced antigenicity
4LV4	;	2.08	;	A noncompetitive inhibitor for M. tuberculosis's class IIa fructose 1,6-bisphosphate aldolase
7W5S	;	1.76	;	A nonheme iron- and alpha-ketoglutarate- dependent halogenase that catalyzes nucleotide substrates
7W5T	;	1.74	;	A nonheme iron- and alpha-ketoglutarate- dependent halogenase that catalyzes nucleotide substrates
7W5V	;	1.81	;	A nonheme iron- and alpha-ketoglutarate- dependent halogenase that catalyzes nucleotide substrates
6LE0	;	2.51	;	A nonspecific heme-binding cyclase catalyzes [4 + 2] cycloaddition during neoabyssomicin biosynthesis
5WLO	;	1.27	;	a novel 13-ring macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands
2MDQ	;		;	A Novel 4/7-Conotoxin LvIA from Conus lividus that Selectively Blocks 3 2 vs. 6/3 2 3 Nicotinic Acetylcholine Receptors
1U8C	;	3.1	;	A novel adaptation of the integrin PSI domain revealed from its crystal structure
1UW1	;	1.94	;	A Novel ADP- and Zinc-binding fold from function-directed in vitro evolution
6KKB	;	1.7	;	A novel agonist of THRb
1HDA	;	2.2	;	A NOVEL ALLOSTERIC MECHANISM IN HAEMOGLOBIN. STRUCTURE OF BOVINE DEOXYHAEMOGLOBIN, ABSENCE OF SPECIFIC CHLORIDE-BINDING SITES AND ORIGIN OF THE CHLORIDE-LINKED BOHR EFFECT IN BOVINE AND HUMAN HAEMOGLOBIN
8JE0	;	2.9	;	A novel amidohydrolase
7N1R	;	2.03	;	A novel and unique ATP hydrolysis to AMP by a human Hsp70 BiP
2FVJ	;	1.99	;	A novel anti-adipogenic partial agonist of peroxisome proliferator-activated receptor-gamma (PPARG) recruits pparg-coactivator-1 alpha (PGC1A) but potentiates insulin signaling in vitro
6LS4	;	2.4	;	A novel anti-tumor agent S-40 in complex with tubulin
1EUJ	;	1.8	;	A NOVEL ANTI-TUMOR CYTOKINE CONTAINS A RNA-BINDING MOTIF PRESENT IN AMINOACYL-TRNA SYNTHETASES
5B64	;	2.7	;	A novel binding mode of MAGUK GK domain revealed by DLG GK domain in complex with KIF13B MBS domain
7WMG	;	2.93	;	A novel chemical derivative(52) of THRB agonist
7WLX	;	2.39	;	A novel chemical derivative(53) of THRB agonist
7WMH	;	1.97	;	A novel chemical derivative(56) of THRB agonist
7WMJ	;	2.81	;	A novel chemical derivative(71) of THRB agonist
7WML	;	2.67	;	A novel chemical derivative(85) of THRB agonist
7WMN	;	2.57	;	A novel chemical derivative(89) of THRB agonist
7WMO	;	2.56	;	A novel chemical derivative(92) of THRB agonist
3KCK	;	2.2	;	A Novel Chemotype of Kinase Inhibitors
1TNS	;		;	A NOVEL CLASS OF WINGED HELIX-TURN-HELIX PROTEIN: THE DNA-BINDING DOMAIN OF MU TRANSPOSASE
1TNT	;		;	A NOVEL CLASS OF WINGED HELIX-TURN-HELIX PROTEIN: THE DNA-BINDING DOMAIN OF MU TRANSPOSASE
7U2M	;	2.9	;	A novel compound mimics the structural and functional effects of the full agonist glycine on glycine channels-desenstized state
7U2O	;	3.1	;	A novel compound mimics the structural and functional effects of the full agonist glycine on glycine channels-Expanded-open state
7U2N	;	2.8	;	A novel compound mimics the structural and functional effects of the full agonist glycine on glycine channels-open state
2J9Q	;	2.65	;	A novel conformation for the TPR domain of pex5p
4HEX	;	2.001	;	A novel conformation of calmodulin
1WCT	;		;	A NOVEL CONOTOXIN FROM CONUS TEXTILE WITH UNUSUAL POST-TRANSLATIONAL MODIFICATIONS REDUCES PRESYNAPTIC CALCIUM INFLUX, NMR, 1 STRUCTURE, GLYCOSYLATED PROTEIN
3U4N	;	1.98	;	A novel covalently linked insulin dimer
5OAB	;	1.111	;	A novel crystal form of human RNase6 at atomic resolution
2CZQ	;	1.05	;	A novel cutinase-like protein from Cryptococcus sp.
4XKJ	;	3.148	;	a Novel D-lactate Dehydrogenase from Sporolactobacillus sp
2L60	;		;	A novel design concept: New Y-receptor agonists with increased membrane recruitment, Y2 affinity and selectivity
1HUL	;	2.4	;	A NOVEL DIMER CONFIGURATION REVEALED BY THE CRYSTAL STRUCTURE AT 2.4 ANGSTROMS RESOLUTION OF HUMAN INTERLEUKIN-5
2IBM	;	3.2	;	A novel dimer interface and conformational changes revealed by an X-ray structure of B. subtilis SecA
5Z16	;	3.0	;	A novel dimeric isocitrate dehydrogenase from Acinetobacter baumannii
1RAM	;	2.7	;	A NOVEL DNA RECOGNITION MODE BY NF-KB P65 HOMODIMER
2RAM	;	2.4	;	A NOVEL DNA RECOGNITION MODE BY NF-KB P65 HOMODIMER
5T3V	;	2.6	;	A Novel domain in human EXOG converts apoptotic endonuclease to DNA-repair enzyme
5T40	;	1.81	;	A Novel domain in human EXOG converts apoptotic endonuclease to DNA-repair enzyme
5T4I	;	2.389	;	A Novel domain in human EXOG converts apoptotic endonuclease to DNA-repair enzyme
5T5C	;	1.851	;	A Novel domain in human EXOG converts apoptotic endonuclease to DNA-repair enzyme
4LZF	;	1.72	;	A novel domain in the microcephaly protein CPAP suggests a role in centriole architecture
2JRA	;		;	A novel domain-swapped solution NMR structure of protein RPA2121 from Rhodopseudomonas palustris. Northeast Structural Genomics Target RpT6
1URR	;	1.5	;	A novel Drosophila Melanogaster Acylphosphatase (AcPDro2)
375D	;	2.4	;	A NOVEL END-TO-END BINDING OF TWO NETROPSINS TO THE DNA DECAMER D(CCCCCIIIII)2
474D	;	2.4	;	A NOVEL END-TO-END BINDING OF TWO NETROPSINS TO THE DNA DECAMER D(CCCCCIIIII)2
5BY3	;	2.44	;	A novel family GH115 4-O-Methyl-alpha-glucuronidase, BtGH115A, with specificity for decorated arabinogalactans
5U8M	;	2.105	;	A novel family of redox sensors in the streptococci evolved from two-component response regulators
3T3M	;	2.6	;	A Novel High Affinity Integrin alphaIIbbeta3 Receptor Antagonist That Unexpectedly Displaces Mg2+ from the beta3 MIDAS
3T3P	;	2.2	;	A Novel High Affinity Integrin alphaIIbbeta3 Receptor Antagonist That Unexpectedly Displaces Mg2+ from the beta3 MIDAS
6B72	;	3.2	;	A novel HIV-1 Nef dimer interface induced by a single octyl-glucoside molecule
5F8P	;	2.2	;	A Novel Inhibitor of the Obesity-Related Protein FTO
8D2J	;	2.1	;	A novel insecticidal protein from ferns IPD113_Cow.
3QYY	;	1.9	;	A Novel Interaction Mode between a Microbial GGDEF Domain and the Bis-(3, 5 )-cyclic di-GMP
1H21	;	2.5	;	A novel iron centre in the split-Soret cytochrome c from Desulfovibrio desulfuricans ATCC 27774
2JQW	;		;	A novel lectin-like peptide from Odorrana grahami
2NPQ	;	1.8	;	A Novel Lipid Binding Site in the p38 alpha MAP Kinase
6IK4	;	1.9	;	A Novel M23 Metalloprotease Pseudoalterin from Deep-sea
2BW7	;	2.3	;	A novel mechanism for adenylyl cyclase inhibition from the crystal structure of its complex with catechol estrogen
3RI6	;	2.2	;	A Novel Mechanism of Sulfur Transfer Catalyzed by O-Acetylhomoserine Sulfhydrylase in Methionine Biosynthetic Pathway of Wolinella succinogenes
6VPB	;	1.87	;	A novel membrane-bound 6-phosphogluconate dehydrogenase from the acetic acid bacteria Gluconacetobacter diazotrophicus (Gd6PGD)
6Z68	;	1.35	;	A novel metagenomic alpha/beta-fold esterase
6Z69	;	1.81	;	A novel metagenomic alpha/beta-fold esterase
1JAC	;	2.43	;	A NOVEL MODE OF CARBOHYDRATE RECOGNITION IN JACALIN, A MORACEAE PLANT LECTIN WITH A BETA-PRISM
1HL6	;	2.5	;	A novel mode of RBD-protein recognition in the Y14-mago complex
5Y44	;	2.35	;	A novel moderator XD4 for bile acid receptor
7Z3C	;		;	A novel molecular switch controls assembly of bacterial focal adhesions in response to changes in surface structure.
7ZOK	;		;	A novel molecular switch controls assembly of bacterial focal adhesions in response to changes in surface structure.
1S20	;	2.2	;	A novel NAD binding protein revealed by the crystal structure of E. Coli 2,3-diketogulonate reductase (YiaK) NORTHEAST STRUCTURAL GENOMICS CONSORTIUM TARGET ER82
1NXE	;	2.3	;	A Novel NADH Allosteric Regulator Site is Found on the Surface of the Hexameric Type II Phe383Ala Variant of Citrate Synthase
4LP8	;	2.46	;	A Novel Open-State Crystal Structure of the Prokaryotic Inward Rectifier KirBac3.1
5ACC	;	1.88	;	A Novel Oral Selective Estrogen Receptor Down-regulator, AZD9496, drives Tumour Growth Inhibition in Estrogen Receptor positive and ESR1 Mutant Models
3UT3	;	2.42	;	A novel PAI-I inhibitor and its structural mechanism
4QLI	;	1.45	;	A novel phospho-switch in the linker region of the snail zinc finger protein which regulates 14-3-3 association, DNA binding and epithelial-mesenchymal differentiation
5C77	;	2.5	;	A novel protein arginine methyltransferase
4TSH	;	2.0	;	A Novel Protein Fold Forms an Intramolecular Lock to Stabilize the Tertiary Structure of Streptococcus mutans Adhesin P1
1YZI	;	2.07	;	A novel quaternary structure of human carbonmonoxy hemoglobin
4BUP	;	2.166	;	A novel route to product specificity in the Suv4-20 family of histone H4K20 methyltransferases
3TGE	;	1.96	;	A novel series of potent and selective PDE5 inhibitor1
3TGG	;	1.91	;	A novel series of potent and selective PDE5 inhibitor2
1GHV	;	1.85	;	A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GHW	;	1.75	;	A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GHX	;	1.65	;	A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GHY	;	1.85	;	A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GHZ	;	1.39	;	A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI0	;	1.42	;	A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI1	;	1.42	;	A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI2	;	1.38	;	A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI3	;	1.44	;	A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI4	;	1.37	;	A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI5	;	1.6	;	A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI6	;	1.49	;	A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI7	;	1.79	;	A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI8	;	1.75	;	A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI9	;	1.8	;	A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
2XBP	;	1.2	;	A novel signal transduction protein PII variant from Synechococcus elongatus PCC7942 indicates a two-step process for NAGK PII complex formation
1MOA	;	1.9	;	A NOVEL SITE-DIRECTED MUTANT OF MYOGLOBIN WITH AN UNUSUALLY HIGH O2 AFFINITY AND LOW AUTOOXIDATION RATE
2SPL	;	1.7	;	A NOVEL SITE-DIRECTED MUTANT OF MYOGLOBIN WITH AN UNUSUALLY HIGH O2 AFFINITY AND LOW AUTOOXIDATION RATE
2SPM	;	1.7	;	A NOVEL SITE-DIRECTED MUTANT OF MYOGLOBIN WITH AN UNUSUALLY HIGH O2 AFFINITY AND LOW AUTOOXIDATION RATE
2SPN	;	1.7	;	A NOVEL SITE-DIRECTED MUTANT OF MYOGLOBIN WITH AN UNUSUALLY HIGH O2 AFFINITY AND LOW AUTOOXIDATION RATE
2SPO	;	1.7	;	A NOVEL SITE-DIRECTED MUTANT OF MYOGLOBIN WITH AN UNUSUALLY HIGH O2 AFFINITY AND LOW AUTOOXIDATION RATE
3ZH8	;	2.739	;	A novel small molecule aPKC inhibitor
2JYN	;		;	A novel solution NMR structure of protein yst0336 from Saccharomyces cerevisiae. Northeast Structural Genomics Consortium target YT51/Ontario Centre for Structural Proteomics target yst0336
4Q2J	;	2.603	;	A novel structure-based mechanism for DNA-binding of SATB1
1TFI	;		;	A NOVEL ZN FINGER MOTIF IN THE BASAL TRANSCRIPTIONAL MACHINERY: THREE-DIMENSIONAL NMR STUDIES OF THE NUCLEIC-ACID BINDING DOMAIN OF TRANSCRIPTIONAL ELONGATION FACTOR TFIIS
1GB1	;		;	A NOVEL, HIGHLY STABLE FOLD OF THE IMMUNOGLOBULIN BINDING DOMAIN OF STREPTOCOCCAL PROTEIN G
2GB1	;		;	A NOVEL, HIGHLY STABLE FOLD OF THE IMMUNOGLOBULIN BINDING DOMAIN OF STREPTOCOCCAL PROTEIN G
4REA	;	3.81	;	A Nuclease DNA complex
4REC	;	2.2	;	A nuclease-DNA complex form 3
4SKN	;	2.9	;	A NUCLEOTIDE-FLIPPING MECHANISM FROM THE STRUCTURE OF HUMAN URACIL-DNA GLYCOSYLASE BOUND TO DNA
6PLJ	;	1.59	;	A nucleotidyl transferase from Methanothermobacter thermautotroptrophicus (Mth528)
4JJR	;	2.4078	;	A P21 crystal form of mammalian casein kinase 1 delta
2IPZ	;	1.35	;	A Parallel Coiled-Coil Tetramer with Offset Helices
1R2L	;		;	A parallel stranded DNA duplex with an A-G mismatch base-pair
2HRI	;	2.09	;	A parallel stranded human telomeric quadruplex in complex with the porphyrin TMPyP4
2LFM	;		;	A partially folded structure of amyloid-beta(1 40) in an aqueous environment
8Q52	;	2.15	;	A PBP-like protein built from fragments of different folds
2G38	;	2.2	;	A PE/PPE Protein Complex from Mycobacterium tuberculosis
8B15	;	1.9	;	A pentameric barrel state of a de novo coiled-coil assembly: CC-Pent2-I10Q
4O2E	;	1.981	;	A peptide complexed with HLA-B*3901
4O2F	;	1.901	;	A peptide complexed with HLA-B*3901
7ELY	;		;	A peptide with high affinity for B-Cell lymphoma2(Bcl-2)
6INW	;	1.798	;	A Pericyclic Reaction enzyme
2KIE	;		;	A PH domain within OCRL bridges clathrin mediated membrane trafficking to phosphoinositide metabolis
2KIG	;		;	A PH domain within OCRL bridges clathrin mediated membrane trafficking to phosphoinositide metabolism
2GAR	;	1.8	;	A PH-DEPENDENT STABLIZATION OF AN ACTIVE SITE LOOP OBSERVED FROM LOW AND HIGH PH CRYSTAL STRUCTURES OF MUTANT MONOMERIC GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE
3GAR	;	1.9	;	A PH-DEPENDENT STABLIZATION OF AN ACTIVE SITE LOOP OBSERVED FROM LOW AND HIGH PH CRYSTAL STRUCTURES OF MUTANT MONOMERIC GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE
2CHW	;	2.6	;	A pharmacological map of the PI3-K family defines a role for p110 alpha in signaling: The structure of complex of phosphoinositide 3- kinase gamma with inhibitor PIK-39
2CHX	;	2.5	;	A pharmacological map of the PI3-K family defines a role for p110alpha in signaling: The structure of complex of phosphoinositide 3-kinase gamma with inhibitor PIK-90
2CHZ	;	2.6	;	A pharmacological map of the PI3-K family defines a role for p110alpha in signaling: The structure of complex of phosphoinositide 3-kinase gamma with inhibitor PIK-93
2JWO	;		;	A PHD finger motif in the C-terminus of RAG2 modulates recombination activity
6IUR	;	3.33	;	A phosphatase complex STRN3-PP2Aa
5J7C	;	2.535	;	A picomolar affinity FN3 domain in complex with hen egg-white lysozyme
2MDT	;		;	a PilT N-terminus domain protein SSO1118 from hyperthemophilic archaeon Sulfolobus solfataricus P2
1SOL	;		;	A PIP2 AND F-ACTIN-BINDING SITE OF GELSOLIN, RESIDUE 150-169 (NMR, AVERAGED STRUCTURE)
6H48	;	2.2	;	A polyamorous repressor: deciphering the evolutionary strategy used by the phage-inducible chromosomal islands to spread in nature.
6H49	;	1.8	;	A polyamorous repressor: deciphering the evolutionary strategy used by the phage-inducible chromosomal islands to spread in nature.
6H4B	;	2.902	;	A polyamorous repressor: deciphering the evolutionary strategy used by the phage-inducible chromosomal islands to spread in nature.
6H4C	;	2.52	;	A polyamorous repressor: deciphering the evolutionary strategy used by the phage-inducible chromosomal islands to spread in nature.
3GLJ	;	1.89	;	A polymorph of carboxypeptidase B zymogen structure
5V02	;	1.78	;	A positive allosteric modulator binding pocket in SK2 ion channels is shared by Riluzole and CyPPA
5V03	;	1.58	;	A positive allosteric modulator binding pocket in SK2 ion channels is shared by Riluzole and CyPPA
1GED	;	2.0	;	A positive charge route for the access of nadh to heme formed in the distal heme pocket of cytochrome p450nor
7EAR	;	2.2	;	A positively charged mutant Cry3Aa endotoxin
2BCH	;	1.1	;	A possible of Second calcium ion in interfacial binding: Atomic and Medium resolution crystal structures of the quadruple mutant of phospholipase A2
2BD1	;	1.9	;	A possible role of the second calcium ion in interfacial binding: Atomic and medium resolution crystal structures of the quadruple mutant of phospholipase A2
8K45	;	3.66	;	A potent and broad-spectrum neutralizing nanobody for SARS-CoV-2 viruses including all major Omicron strains
8K46	;	3.37	;	A potent and broad-spectrum neutralizing nanobody for SARS-CoV-2 viruses including all major Omicron strains
8K47	;	3.54	;	A potent and broad-spectrum neutralizing nanobody for SARS-CoV-2 viruses including all major Omicron strains
6TYS	;	3.5	;	A potent cross-neutralizing antibody targeting the fusion glycoprotein inhibits Nipah virus and Hendra virus infection
5MEM	;	1.78	;	A potent fluorescent inhibitor of glycogen phosphorylase as a catalytic site probe.
3DS9	;	1.758	;	A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformation than SNAP-25 substrate
3DSE	;	1.9	;	A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformation than SNAP-25 substrate
11BG	;	1.9	;	A POTENTIAL ALLOSTERIC SUBSITE GENERATED BY DOMAIN SWAPPING IN BOVINE SEMINAL RIBONUCLEASE
1VHH	;	1.7	;	A POTENTIAL CATALYTIC SITE WITHIN THE AMINO-TERMINAL SIGNALLING DOMAIN OF SONIC HEDGEHOG
6KQR	;	2.899	;	A pre-assembled molecular-helical Cascade backbone of Csy3 subunits from Zymomonas mobilis
1CL8	;	1.8	;	A PRE-TRANSITION STATE ECO RI ENDONUCLEASE/COGNATE DNA (TCGCGAPTTCGCG) COMPLEX WITH DNA BASE ANALOG PURINE (P)
1ADD	;	2.4	;	A PRE-TRANSITION STATE MIMIC OF AN ENZYME: X-RAY STRUCTURE OF ADENOSINE DEAMINASE WITH BOUND 1-DEAZA-ADENOSINE AND ZINC-ACTIVATED WATER
1GRZ	;	5.0	;	A PREORGANIZED ACTIVE SITE IN THE CRYSTAL STRUCTURE OF THE TETRAHYMENA RIBOZYME
1APB	;	1.76	;	A PRO TO GLY MUTATION IN THE HINGE OF THE ARABINOSE-BINDING PROTEIN ENHANCES BINDING AND ALTERS SPECIFICITY: SUGAR-BINDING AND CRYSTALLOGRAPHIC STUDIES
1BAP	;	1.75	;	A PRO TO GLY MUTATION IN THE HINGE OF THE ARABINOSE-BINDING PROTEIN ENHANCES BINDING AND ALTERS SPECIFICITY: SUGAR-BINDING AND CRYSTALLOGRAPHIC STUDIES
9ABP	;	1.97	;	A PRO TO GLY MUTATION IN THE HINGE OF THE ARABINOSE-BINDING PROTEIN ENHANCES BINDING AND ALTERS SPECIFICITY: SUGAR-BINDING AND CRYSTALLOGRAPHIC STUDIES
1AYP	;	2.57	;	A PROBE MOLECULE COMPOSED OF SEVENTEEN PERCENT OF TOTAL DIFFRACTING MATTER GIVES CORRECT SOLUTIONS IN MOLECULAR REPLACEMENT
2XD0	;	3.0	;	A processed non-coding RNA regulates a bacterial antiviral system
2XDB	;	2.55	;	A processed non-coding RNA regulates a bacterial antiviral system
2XDD	;	3.2	;	A processed non-coding RNA regulates a bacterial antiviral system
5WDK	;	2.36	;	A processive dipeptidyl aminopeptidase secreted from an established commensal bacterium P. distasonis
5WDL	;	2.625	;	A processive dipeptidyl aminopeptidase secreted from an established commensal bacterium P. distasonis
7D4G	;	3.9	;	A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2
5MQ5	;	1.6	;	A protease-resistant N24S Escherichia coli Asparaginase mutant with outstanding stability and enhanced anti-leukaemic activity
8WSQ	;	2.9	;	A protective human antibody against respiratory syncytial virus by targeting a prefusion epitope across sites IV and V of the viral fusion glycoprotein.
3ANW	;	2.65	;	A protein complex essential initiation of DNA replication
1OQU	;	2.0	;	A protein coordinated tri-nuclear Fe complex formed during soaking of crystals of the ribonucleotide reductase R2F protein from Corynebacterium Ammoniagenes
2L83	;		;	A protein from Haloferax volcanii
5L75	;	3.7	;	A protein structure
2J0N	;	2.1	;	A proteolytically truncated form of Shigella Flexneri IpaD
1EHJ	;		;	A PROTON-NMR INVESTIGATION OF THE FULLY REDUCED CYTOCHROME C7 FROM DESULFUROMONAS ACETOXIDANS
1F22	;		;	A PROTON-NMR INVESTIGATION OF THE FULLY REDUCED CYTOCHROME C7 FROM DESULFUROMONAS ACETOXIDANS. COMPARISON BETWEEN THE REDUCED AND THE OXIDIZED FORMS.
7WKC	;		;	A prototype protein nanocage minimized from carboxysomes with gated oxygen permeability
2CMN	;	2.3	;	A Proximal Arginine Residue in the Switching Mechanism of the FixL Oxygen Sensor
2DWP	;	2.7	;	A pseudo substrate complex of 6-phosphofructo-2-kinase of PFKFB
5AY7	;	2.15	;	A psychrophilic glycoside hydrolase family 10 endo-beta-1,4-xylanase
5D4Y	;	2.5	;	A psychrophilic glycoside hydrolase family 10 endo-beta-1,4-xylanase
2CGQ	;	1.83	;	a putative acyl carrier protein(Rv0033) from Mycobacterium tuberculosis
2FUJ	;	1.7	;	A putative acyl-CoA thioesterase from Xanthomonas campestris (XC229)
3MAH	;	2.31	;	A putative c-terminal regulatory domain of aspartate kinase from porphyromonas gingivalis w83.
3NQR	;	2.0	;	A putative CBS domain-containing protein from Salmonella typhimurium LT2
4WRR	;	2.16	;	A putative diacylglycerol kinase from Bacillus anthracis str. Sterne
3ELN	;	1.42	;	A Putative Fe2+-bound Persulfenate Intermediate in Cysteine Dioxygenase
3IV4	;	1.5	;	A putative oxidoreductase with a thioredoxin fold
2B78	;	2.0	;	A putative sam-dependent methyltransferase from Streptococcus mutans
3JRK	;	1.97	;	A putative tagatose 1,6-diphosphate aldolase from Streptococcus pyogenes
2M8K	;		;	A pyrimidine motif triple helix in the Kluyveromyces lactis telomerase RNA pseudoknot is essential for function in vivo
6R9K	;		;	A quadruplex hybrid structure with lpp loop orientation and 3 syn residues
6R9L	;		;	A quadruplex hybrid structure with lpp loop orientation and 5 syn residues
8R6G	;		;	A quadruplex-duplex hybrid with a three-layered chair G-quadruplex topology
8R6D	;		;	A quadruplex-duplex hybrid with a three-layered hybrid-2 G-quadruplex topology
8R6H	;		;	A quadruplex-duplex hybrid with a three-layered hybrid-2 G-quadruplex topology complexed with Phen-DC3
5LU5	;	1.55	;	A quantum half-site enzyme
6LII	;	2.3	;	A quinone oxidoreductase
2CGF	;	2.2	;	A RADICICOL ANALOGUE BOUND TO THE ATP BINDING SITE OF THE N-TERMINAL DOMAIN OF THE YEAST HSP90 CHAPERONE
5OCV	;	2.2	;	A Rare Lysozyme Crystal Form Solved Using High-Redundancy 3D Electron Diffraction Data from Micron-Sized Needle Shaped Crystals
3IGT	;	1.9	;	A rare nucleotide base tautomer in the structure of an asymmetric DNA junction
5ER1	;	2.0	;	A rational approach to the design of antihypertensives. X-ray studies of complexes between aspartic proteinases and aminoalcohol renin inhibitors
1VKQ	;	1.6	;	A re-determination of the structure of the triple mutant (K53,56,120M) of phospholipase A2 at 1.6A resolution using sulphur-SAS at 1.54A wavelength
2CHR	;	3.0	;	A RE-EVALUATION OF THE CRYSTAL STRUCTURE OF CHLOROMUCONATE CYCLOISOMERASE
5JZD	;	2.303	;	A re-refinement of the isochorismate synthase EntC
6M2H	;	3.1	;	A reaction intermediate of sirohydrochlorin nickelochelatase CfbA in complex with Ni2+ and sirohydrochlorin
1GSM	;	1.9	;	A reassessment of the MAdCAM-1 structure and its role in integrin recognition.
5BUO	;	2.31	;	A receptor molecule
7DY6	;	3.68	;	A refined cryo-EM structure of an Escherichia coli RNAP-promoter open complex (RPo) with SspA
3J1V	;	11.7	;	A refined model of the prototypical Salmonella typhimurium T3SS basal body reveals the molecular basis for its assembly
3J1W	;	11.7	;	A refined model of the prototypical Salmonella typhimurium T3SS basal body reveals the molecular basis for its assembly
3J1X	;	11.7	;	A refined model of the prototypical Salmonella typhimurium T3SS basal body reveals the molecular basis for its assembly
1DMZ	;		;	A REFINED NMR STRUCTURE OF A NEW PHOPHOPEPTIDE-BINDING DOMAIN CONTAINING THE FHA2 OF RAD53
1H6I	;	3.54	;	A REFINED STRUCTURE OF HUMAN AQUAPORIN 1
3CIQ	;	2.9	;	A regulatable switch mediates self-association in an immunoglobulin fold
4RAX	;	1.45	;	A regulatory domain of an ion channel
3BO2	;	3.31	;	A relaxed active site following exon ligation by a group I intron
3BO3	;	3.4	;	A relaxed active site following exon ligation by a group I intron
3BO4	;	3.33	;	A relaxed active site following exon ligation by a group I intron
3LFK	;	1.6	;	A reported archaeal mechanosensitive channel is a structural homolog of MarR-like transcriptional regulators
2B5B	;		;	A reptilian defensin with anti-bacterial and anti-viral activity
6ON1	;	1.982	;	A resting state structure of L-DOPA dioxygenase from Streptomyces sclerotialus
2I1A	;	2.3	;	A Retroviral Protease-Like Domain in the Eukaryotic Protein Ddi1
8INP	;	2.12	;	A reversible glycosyltransferase of tectorigenin - Bc7OUGT
8ITA	;	2.5	;	A reversible glycosyltransferase of tectorigenin - Bc7OUGT complexed with UDP and tectorigenin
4ZQX	;	1.46	;	A revised partiality model and post-refinement algorithm for X-ray free-electron laser data
6HN6	;	2.71	;	A revisited version of the apo structure of the ligand-binding domain of the human nuclear receptor RXR-ALPHA
7ES0	;	1.395	;	a rice glycosyltransferase in complex with UDP and REX
3HJH	;	1.95	;	A rigid N-terminal clamp restrains the motor domains of the bacterial transcription-repair coupling factor
3RTR	;	3.21	;	A RING E3-substrate complex poised for ubiquitin-like protein transfer: structural insights into cullin-RING ligases
3U3I	;	2.304	;	A RNA binding protein from Crimean-Congo hemorrhagic fever virus
3CM8	;	2.899	;	A RNA polymerase subunit structure from virus
2D09	;	1.8	;	A Role for Active Site Water Molecules and Hydroxyl Groups of Substrate for Oxygen Activation in Cytochrome P450 158A2
1MIH	;	2.7	;	A ROLE FOR CHEY GLU 89 IN CHEZ-MEDIATED DEPHOSPHORYLATION OF THE E. COLI CHEMOTAXIS RESPONSE REGULATOR CHEY
6M2M	;	2.85	;	A role for histone chaperone OsChz1 in histone recognition and deposition
2QV2	;	2.4	;	A role of the Lowe syndrome protein OCRL in early steps of the endocytic pathway
3MNN	;	2.5	;	A Ruthenium Antitumour Agent Forms Specific Histone Protein Adducts in the Nucleosome Core
7F0X	;	2.8	;	A SARS-CoV-2 neutralizing antibody
7F12	;	3.15	;	A SARS-CoV-2 neutralizing antibody
7F15	;	2.65	;	A SARS-CoV-2 neutralizing antibody
7PFM	;	2.0	;	A SARS-CoV2 major protease non-covalent ligand structure determined to 2.0 A resolution
1GHA	;	2.2	;	A SECOND ACTIVE SITE IN CHYMOTRYPSIN? THE X-RAY CRYSTAL STRUCTURE OF N-ACETYL-D-TRYPTOPHAN BOUND TO GAMMA-CHYMOTRYPSIN
1GHB	;	2.0	;	A SECOND ACTIVE SITE IN CHYMOTRYPSIN? THE X-RAY CRYSTAL STRUCTURE OF N-ACETYL-D-TRYPTOPHAN BOUND TO GAMMA-CHYMOTRYPSIN
4F04	;	2.3	;	A Second Allosteric site in E. coli Aspartate Transcarbamoylase: R-state ATCase with UTP bound
2FSZ	;	2.2	;	A second binding site for hydroxytamoxifen within the coactivator-binding groove of estrogen receptor beta
3NWK	;	2.09	;	A second C2221 form of concanavalin A (Canavalia ensiformis)
2WHX	;	2.2	;	A second conformation of the NS3 protease-helicase from dengue virus
1HD7	;	1.95	;	A Second Divalent Metal Ion in the Active Site of a New Crystal Form of Human Apurinic/Apyridinimic Endonuclease, Ape1, and its Implications for the Catalytic Mechanism
1E9N	;	2.2	;	A second divalent metal ion in the active site of a new crystal form of human apurinic/apyrimidinic endonuclease, Ape1, and its implications for the catalytic mechanism
2BN4	;	2.91	;	A second FMN-binding site in yeast NADPH-cytochrome P450 reductase suggests a novel mechanism of electron transfer by diflavin reductase
2BF4	;	3.0	;	A second FMN-binding site in yeast NADPH-cytochrome P450 reductase suggests a novel mechanism of electron transfer by diflavin reductases.
4PR6	;	2.3	;	A Second Look at the HDV Ribozyme Structure and Dynamics.
4PRF	;	2.395	;	A Second Look at the HDV Ribozyme Structure and Dynamics.
3EIU	;	3.43	;	A second transient position of ATP on its trail to the nucleotide-binding site of subunit B of the motor protein A1Ao ATP synthase
6Q40	;	2.412	;	A secreted LysM effector of the wheat pathogen Zymoseptoria tritici protects the fungal hyphae against chitinase hydrolysis through ligand-dependent polymerisation of LysM homodimers
5VY6	;	3.064	;	A self-assembling D-form DNA crystal lattice
6UAL	;	4.514	;	A Self-Assembling DNA Crystal Scaffold with Cavities Containing 3 Helical Turns per Edge
5VY7	;	3.0	;	A self-assembling L-form DNA crystal lattice
7OGV	;		;	A self-complementary DNA dodecamer duplex contaning 5-hydroxymethylcitosine
7OHE	;		;	A self-complementary DNA dodecamer duplex contaning 5-hydroxymethylcitosine
7OHJ	;		;	A self-complementary DNA dodecamer duplex contaning 5-hydroxymethylcitosine
7OHM	;		;	A self-complementary DNA dodecamer duplex contaning 5-hydroxymethylcitosine
1TGL	;	1.9	;	A SERINE PROTEASE TRIAD FORMS THE CATALYTIC CENTRE OF A TRIACYLGLYCEROL LIPASE
2AYR	;	1.9	;	A SERM Designed for the Treatment of Uterine Leiomyoma with Unique Tissue Specificity for Uterus and Ovaries in Rats
5HGC	;	2.43	;	A Serpin structure
6OX4	;	2.294	;	A SETD3 Mutant (N255A) in Complex with an Actin Peptide
6OX5	;	2.098	;	A SETD3 Mutant (N255A) in Complex with an Actin Peptide with His73 Replaced with Lysine
2HY6	;	1.25	;	A seven-helix coiled coil
1RMX	;		;	A SHORT LEXITROPSIN THAT RECOGNIZES THE DNA MINOR GROOVE AT 5'-ACTAGT-3': UNDERSTANDING THE ROLE OF ISOPROPYL-THIAZOLE
1RN9	;		;	A SHORT LEXITROPSIN THAT RECOGNIZES THE DNA MINOR GROOVE AT 5'-ACTAGT-3': UNDERSTANDING THE ROLE OF ISOPROPYL-THIAZOLE
1ULH	;	2.31	;	A short peptide insertion crucial for angiostatic activity of human tryptophanyl-tRNA synthetase
1INV	;	2.4	;	A SIALIC ACID DERIVED PHOSPHONATE ANALOG INHIBITS DIFFERENT STRAINS OF INFLUENZA VIRUS NEURAMINIDASE WITH DIFFERENT EFFICIENCIES
1INW	;	2.4	;	A SIALIC ACID DERIVED PHOSPHONATE ANALOG INHIBITS DIFFERENT STRAINS OF INFLUENZA VIRUS NEURAMINIDASE WITH DIFFERENT EFFICIENCIES
1INX	;	2.4	;	A SIALIC ACID DERIVED PHOSPHONATE ANALOG INHIBITS DIFFERENT STRAINS OF INFLUENZA VIRUS NEURAMINIDASE WITH DIFFERENT EFFICIENCIES
1INY	;	2.4	;	A SIALIC ACID DERIVED PHOSPHONATE ANALOG INHIBITS DIFFERENT STRAINS OF INFLUENZA VIRUS NEURAMINIDASE WITH DIFFERENT EFFICIENCIES
5JB4	;	1.99	;	A simplified BPTI variant containing 21 alanines out 58 of residues
5JB5	;	1.6	;	A simplified BPTI variant containing 22 alanines out of 58 residues
5JB6	;	1.9	;	A simplified BPTI variant containing 23 alanines out of 58 residues
5JB7	;	1.9	;	A simplified BPTI variant containing 24 alanines out of 58 residues
3AUB	;	1.0	;	A simplified BPTI variant stabilized by the A14G and A38V substitutions
3AUH	;	1.2	;	A simplified BPTI variant with poly Arg amino acid tag (C3R) at the C-terminus
3AUI	;	1.851	;	A simplified BPTI variant with poly Glu amino acid tag (C3E) at the C-terminus
3AUE	;	2.28	;	A simplified BPTI variant with poly His amino acid tag (C5H) at the C-terminus
3WNY	;	1.3	;	A simplified BPTI variant with poly Lys amino acid tag (C3K) at the C-terminus
3AUG	;	1.398	;	A simplified BPTI variant with poly Pro amino acid tag (C5P) at the C-terminus
3AUC	;	1.91	;	A simplified BPTI variant with poly SER (C5S) amino acid tag at the c-terminus
161D	;	1.9	;	A SINGLE 2'-HYDROXYL GROUP CONVERTS B-DNA TO A-DNA: CRYSTAL STRUCTURE OF THE DNA-RNA CHIMERIC DECAMER DUPLEX D(CCGGC)R(G)D(CCGG) WITH A NOVEL INTERMOLECULAR G.C BASE-PAIRED QUADRUPLET
2B83	;	2.25	;	A single amino acid substitution in the Clostridium beijerinckii alcohol dehydrogenase is critical for thermostabilization
4WGI	;	1.85	;	A Single Diastereomer of a Macrolactam Core Binds Specifically to Myeloid Cell Leukemia 1 (MCL1)
2LMS	;		;	A single GalNAc residue on Threonine-106 modifies the dynamics and the structure of Interferon alpha-2a around the glycosylation site
1SMI	;	2.0	;	A single mutation of P450 BM3 induces the conformational rearrangement seen upon substrate-binding in wild-type enzyme
6MTG	;	1.85	;	A Single Reactive Noncanonical Amino Acid is Able to Dramatically Stabilize Protein Structure
7NE9	;	2.1	;	A single sensor controls large variations in zinc quotas in a marine cyanobacterium
7ANA	;	2.3	;	A single sulfatase is required for metabolism of colonic mucin O-glycans and intestinal colonization by a symbiotic human gut bacterium (BT1622-S1_20)
7ANB	;	2.6	;	A single sulfatase is required for metabolism of colonic mucin O-glycans and intestinal colonization by a symbiotic human gut bacterium (BT1622-S1_20)
7AN1	;	1.5	;	A single sulfatase is required for metabolism of colonic mucin O-glycans and intestinal colonization by a symbiotic human gut bacterium (BT1636-S1_20)
7OQD	;	2.3	;	A single sulfatase is required for metabolism of colonic mucin O-glycans and intestinal colonization by a symbiotic human gut bacterium (BT1636-S1_20)
7ALL	;	1.63	;	A single sulfatase is required for metabolism of colonic mucin O-glycans and intestinal colonization by a symbiotic human gut bacterium (BT4683-S1_4)
3RGV	;	2.9	;	A single TCR bound to MHCI and MHC II reveals switchable TCR conformers
1BWM	;		;	A SINGLE-CHAIN T CELL RECEPTOR
1E3A	;	1.8	;	A slow processing precursor penicillin acylase from Escherichia coli
7P1Y	;	2.38	;	A small alarmone hydrolase TdActApo2 mutant - T78N
2E5L	;	3.3	;	A snapshot of the 30S ribosomal subunit capturing mRNA via the Shine- Dalgarno interaction
1U3N	;		;	A SOD-like protein from B. subtilis, unstructured in solution, becomes ordered in the crystal: implications for function and for fibrillogenesis
3EBN	;	2.4	;	A Special Dimerization of SARS-CoV Main Protease C-Terminal Domain Due to Domain-swapping
2YJY	;	2.598	;	A specific and modular binding code for cytosine recognition in PUF domains
4PQB	;	1.942	;	A sperm whale myoglobin double mutant L29E/F43H Mb with a non-native bis-His (His64/His93) coordination
4LPI	;	1.36	;	A sperm whale myoglobin double mutant L29H/F43Y Mb with a distal hydrogen-bonding network
5C6Y	;	1.793	;	A sperm whale myoglobin double mutant L29H/F43Y Mb with a Tyr-heme cross-link
4IT8	;	1.5	;	A sperm whale myoglobin mutant L29H Mb with two distal histidines
4PQC	;	1.503	;	A sperm whale myoglobin single mutant F43H Mb with native His93 coordination
4PQ6	;	1.45	;	A sperm whale myoglobin single mutant L29E Mb with native His93 coordination
4DKS	;	2.7	;	A spindle-shaped virus protein (chymotrypsin treated)
2G1T	;	1.8	;	A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain
2G2F	;	2.7	;	A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain
2G2H	;	2.0	;	A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain
2G2I	;	3.12	;	A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain
1LNA	;	1.9	;	A STRUCTURAL ANALYSIS OF METAL SUBSTITUTIONS IN THERMOLYSIN
1LNB	;	1.8	;	A STRUCTURAL ANALYSIS OF METAL SUBSTITUTIONS IN THERMOLYSIN
1LNC	;	1.8	;	A STRUCTURAL ANALYSIS OF METAL SUBSTITUTIONS IN THERMOLYSIN
1LND	;	1.7	;	A STRUCTURAL ANALYSIS OF METAL SUBSTITUTIONS IN THERMOLYSIN
1LNE	;	1.7	;	A STRUCTURAL ANALYSIS OF METAL SUBSTITUTIONS IN THERMOLYSIN
1LNF	;	1.7	;	A structural analysis of metal substitutions in thermolysin
4NSS	;	2.4	;	A structural and functional investigation of a novel protein from Mycobacterium smegmatis implicated in mycobacterial macrophage survivability
1OGA	;	1.4	;	A structural basis for immunodominant human T-cell receptor recognition.
2EYR	;	2.4	;	A structural basis for selection and cross-species reactivity of the semi-invariant NKT cell receptor in CD1d/glycolipid recognition
2EYS	;	2.21	;	A structural basis for selection and cross-species reactivity of the semi-invariant NKT cell receptor in CD1d/glycolipid recognition
2EYT	;	2.6	;	A structural basis for selection and cross-species reactivity of the semi-invariant NKT cell receptor in CD1d/glycolipid recognition
3C7A	;	2.1	;	A structural basis for substrate and stereo selectivity in octopine dehydrogenase (ODH-NADH)
3C7C	;	3.1	;	A structural basis for substrate and stereo selectivity in octopine dehydrogenase (ODH-NADH-L-Arginine)
3C7D	;	2.5	;	A structural basis for substrate and stereo selectivity in octopine dehydrogenase (ODH-NADH-Pyruvate)
3BEO	;	1.7	;	A Structural Basis for the allosteric regulation of non-hydrolyzing UDP-GlcNAc 2-epimerases
4DJB	;	2.053	;	A Structural Basis for the Assembly and Functions of a Viral Polymer that Inactivates Multiple Tumor Suppressors
1LPM	;	2.18	;	A STRUCTURAL BASIS FOR THE CHIRAL PREFERENCES OF LIPASES
1LPS	;	2.18	;	A STRUCTURAL BASIS FOR THE CHIRAL PREFERENCES OF LIPASES
1J7E	;	2.55	;	A Structural Basis for the Unique Binding Features of the Human Vitamin D-binding Protein
6VE6	;	2.446	;	A structural characterization of poly(aspartic acid) hydrolase-1 from Sphingomonas sp. KT-1.
4OTK	;	1.6	;	A structural characterization of the isoniazid Mycobacterium tuberculosis drug target, Rv2971, in its unliganded form
1EPL	;	2.0	;	A STRUCTURAL COMPARISON OF 21 INHIBITOR COMPLEXES OF THE ASPARTIC PROTEINASE FROM ENDOTHIA PARASITICA
1EPM	;	1.6	;	A STRUCTURAL COMPARISON OF 21 INHIBITOR COMPLEXES OF THE ASPARTIC PROTEINASE FROM ENDOTHIA PARASITICA
1EPN	;	1.6	;	A STRUCTURAL COMPARISON OF 21 INHIBITOR COMPLEXES OF THE ASPARTIC PROTEINASE FROM ENDOTHIA PARASITICA
3S0M	;	2.31	;	A Structural Element that Modulates Proton-Coupled Electron Transfer in Oxalate Decarboxylase
2ON3	;	3.0	;	A structural insight into the inhibition of human and Leishmania donovani ornithine decarboxylases by 3-aminooxy-1-aminopropane
2OO0	;	1.9	;	A structural insight into the inhibition of human and Leishmania donovani ornithine decarboxylases by 3-aminooxy-1-aminopropane
1SSA	;	2.0	;	A STRUCTURAL INVESTIGATION OF CATALYTICALLY MODIFIED F12OL AND F12OY SEMISYNTHETIC RIBONUCLEASES
1SSB	;	2.0	;	A STRUCTURAL INVESTIGATION OF CATALYTICALLY MODIFIED F12OL AND F12OY SEMISYNTHETIC RIBONUCLEASES
3LUT	;	2.9	;	A Structural Model for the Full-length Shaker Potassium Channel Kv1.2
1Z9I	;		;	A Structural Model for the Membrane-Bound Form of the Juxtamembrane Domain of the Epidermal Growth Factor Receptor
4BHP	;		;	A structural model of CAP mutant (T127L and S128I) in cGMP-bound state
4BH9	;		;	A structural model of CAP mutant (T127L and S128I) in the apo state
4UTQ	;	8.0	;	A structural model of the active ribosome-bound membrane protein insertase YidC
2VSG	;	2.7	;	A Structural Motif in the Variant Surface Glycoproteins of Trypanosoma Brucei
8EFJ	;	2.31	;	A structural study of selectivity mechanisms for JNK3 and p38 alpha with indazole scaffold probing compounds
2FVP	;	2.25	;	A Structural Study of the CA Dinucleotide Step in the Integrase Processing Site of Moloney Murine Leukemia Virus
2FVQ	;	2.3	;	A Structural Study of the CA Dinucleotide Step in the Integrase Processing Site of Moloney Murine Leukemia Virus
2FVR	;	2.2	;	A Structural Study of the CA Dinucleotide Step in the Integrase Processing Site of Moloney Murine Leukemia Virus
2FVS	;	2.35	;	A Structural Study of the CA Dinucleotide Step in the Integrase Processing Site of Moloney Murine Leukemia Virus
2VJ1	;	2.25	;	A Structural View of the Inactivation of the SARS-Coronavirus Main Proteinase by Benzotriazole Esters
5D8G	;	1.89	;	A structural view on the dissociation of E. coli Tryptophanase
3GE9	;	2.61	;	A Structurally Atypical ThyX from Corynebacterium glutamicum NCHU 87078 Is Not Required for Thymidylate Biosynthesis
6AZP	;	2.291	;	A Structurally Dynamic N-terminal Region Drives Function of the Staphylococcal Peroxidase Inhibitor (SPIN)
3KZ3	;	1.64	;	A structure of a lambda repressor fragment mutant
5Z12	;	2.75	;	A structure of FXR/RXR
5O33	;	1.64	;	A structure of the GEF Kalirin DH1 domain in complex with the small GTPase Rac1
8BK5	;	1.44	;	A structure of the truncated LpMIP with bound inhibitor JK095.
8BJE	;	1.49	;	A structure of the truncated LpMIP with bound inhibitor JK236.
1ZV7	;	1.7	;	A structure-based mechanism of SARS virus membrane fusion
1ZV8	;	1.94	;	A structure-based mechanism of SARS virus membrane fusion
1ZVA	;	1.5	;	A structure-based mechanism of SARS virus membrane fusion
1ZVB	;	1.7	;	A structure-based mechanism of SARS virus membrane fusion
5Y6L	;	2.9	;	A subcomplex crystal structure of human cytosolic aspartyl-tRNA synthetase and heterotetrameric glutathione transferase-homology domains in multi-tRNA synthetase complex
6ON3	;	2.31	;	A substrate bound structure of L-DOPA dioxygenase from Streptomyces sclerotialus
4GDJ	;	2.0	;	A subtype N10 neuraminidase-like protein of A/little yellow-shouldered bat/Guatemala/060/2010
4GDI	;	1.95	;	A subtype N10 neuraminidase-like protein of A/little yellow-shouldered bat/Guatemala/164/2009
2MR3	;		;	A subunit of 26S proteasome lid complex
485D	;	0.97	;	A SULFATE POCKET FORMED BY THREE GOU PAIRS IN THE STRUCTURE OF A NONAMERIC RNA
5XT6	;	3.5	;	A sulfur-transferring catalytic intermediate of SufS-SufU complex from Bacillus subtilis
4KUK	;	1.5	;	A superfast recovering full-length LOV protein from the marine phototrophic bacterium Dinoroseobacter shibae (Dark state)
4KUO	;	2.0	;	A superfast recovering full-length LOV protein from the marine phototrophic bacterium Dinoroseobacter shibae (Photoexcited state)
1ZI0	;	2.6	;	A Superhelical Spiral in Escherichia coli DNA Gyrase A C-terminal Domain Imparts Unidirectional Supercoiling Bias
1AGS	;	2.5	;	A SURFACE MUTANT (G82R) OF A HUMAN ALPHA-GLUTATHIONE S-TRANSFERASE SHOWS DECREASED THERMAL STABILITY AND A NEW MODE OF MOLECULAR ASSOCIATION IN THE CRYSTAL
2ONT	;	2.4	;	A swapped dimer of the HIV-1 capsid C-terminal domain
3NSU	;	2.0	;	A Systematic Screen for Protein-Lipid Interactions in Saccharomyces cerevisiae
5YXN	;	2.03	;	A T cell receptor in complex with HLA-A0201 restricted Hepatitis C virus NS3 peptide (KLVALGINAV)
3PJP	;	1.6	;	A Tandem SH2 Domain in Transcription Elongation Factor Spt6 Binds the Phosphorylated RNA Polymerase II C-terminal Repeat Domain(CTD)
2MOR	;		;	A tensor-free method for the structural and dynamical refinement of proteins using residual dipolar couplings
2VSU	;	1.9	;	A ternary complex of Hydroxycinnamoyl-CoA Hydratase-Lyase (HCHL) with acetyl-Coenzyme A and vanillin gives insights into substrate specificity and mechanism.
5HUQ	;	3.0	;	A tethered niacin-derived pincer complex with a nickel-carbon bond in lactate racemase
8EZI	;	1.99	;	A tethered niacin-derived pincer complex with a nickel-carbon bond in lactate racemase R98A/R100A variant modeled with separated sulfite and NPN
8EZH	;	1.99	;	A tethered niacin-derived pincer complex with a nickel-carbon bond in lactate racemase R98A/R100A variant modeled with sulfite-NPN adduct
6C1W	;	2.398	;	A tethered niacin-derived pincer complex with a nickel-carbon or sulfite-carbon bond in lactate racemase
8EZF	;	2.15	;	A tethered niacin-derived pincer complex with a nickel-carbon or sulfite-carbon bond in lactate racemase R98A/R100A variant
2DCK	;	2.1	;	A tetragonal-lattice structure of alkaliphilic XynJ from Bacillus sp. 41M-1
6QMU	;	1.98	;	A tetrahedral boronic acid diester formed by a non-natural amino acid in the ligand pocket of an engineered lipocalin
2MJJ	;		;	A tetrahelical DNA fold adopted by alternating GGG and GCG tracts
225D	;		;	A TETRAMERIC DNA STRUCTURE WITH PROTONATED CYTOSINE:CYTOSINE BASE PAIRS
3M79	;	2.1	;	A tetrameric Zn-bound cytochrome cb562 complex with covalently and non-covalently stabilized interfaces crystallized in the presence of Cu(II) and Zn(II)
4F5L	;	1.4	;	A Theoretical Optimized Mutant for the Conversion of Substrate Specificity and Activity of Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P7.
5MI0	;	2.35	;	A thermally stabilised version of Plasmodium falciparum RH5
3X2E	;	2.85	;	A thermophilic hydrolase
3X2F	;	2.04	;	A Thermophilic S-Adenosylhomocysteine Hydrolase
7Q4J	;	1.91	;	A thermostable lipase from Thermoanaerobacter thermohydrosulfuricus in complex a monoacylglycerol intermediate
7Q4H	;	2.00003	;	A thermostable lipase from Thermoanaerobacter thermohydrosulfuricus in complex with PMSF
4HVY	;	1.46	;	A thermostable variant of human NUDT18 NUDIX domain obtained by Hot Colony Filtration
3ZL1	;	1.551	;	A thiazolyl-mannoside bound to FimH, monoclinic space group
3ZL2	;	1.251	;	A thiazolyl-mannoside bound to FimH, orthorhombic space group
1VZK	;	1.77	;	A Thiophene Based Diamidine Forms a ""Super"" AT Binding Minor Groove Agent
1MP7	;		;	A Third Complex of Post-Activated Neocarzinostatin Chromophore with DNA. Bulge DNA Binding from the Minor Groove
6LQB	;	1.7	;	A third intermediate state of L,D-transpeptidase LdtMt2-ertapenem adduct
1BBB	;	1.7	;	A THIRD QUATERNARY STRUCTURE OF HUMAN HEMOGLOBIN A AT 1.7-ANGSTROMS RESOLUTION
5B6V	;	2.0	;	A three dimensional movie of structural changes in bacteriorhodopsin: resting state structure
5B6Z	;	2.1	;	A three dimensional movie of structural changes in bacteriorhodopsin: structure obtained 1.725 ms us after photoexcitation
5H2I	;	2.1	;	A three dimensional movie of structural changes in bacteriorhodopsin: structure obtained 110 ns after photoexcitation
5H2M	;	2.1	;	A three dimensional movie of structural changes in bacteriorhodopsin: structure obtained 13.8 us after photoexcitation
5B6W	;	2.1	;	A three dimensional movie of structural changes in bacteriorhodopsin: structure obtained 16 ns after photoexcitation
5H2K	;	2.1	;	A three dimensional movie of structural changes in bacteriorhodopsin: structure obtained 2 us after photoexcitation
5H2O	;	2.1	;	A three dimensional movie of structural changes in bacteriorhodopsin: structure obtained 250 us after photoexcitation
5H2J	;	2.1	;	A three dimensional movie of structural changes in bacteriorhodopsin: structure obtained 290 ns after photoexcitation
5B6Y	;	2.1	;	A three dimensional movie of structural changes in bacteriorhodopsin: structure obtained 36.2 us after photoexcitation
5H2H	;	2.1	;	A three dimensional movie of structural changes in bacteriorhodopsin: structure obtained 40 ns after photoexcitation
5H2L	;	2.1	;	A three dimensional movie of structural changes in bacteriorhodopsin: structure obtained 5.25 us after photoexcitation
5H2P	;	2.1	;	A three dimensional movie of structural changes in bacteriorhodopsin: structure obtained 657 us after photoexcitation
5B6X	;	2.1	;	A three dimensional movie of structural changes in bacteriorhodopsin: structure obtained 760 ns after photoexcitation
5H2N	;	2.1	;	A three dimensional movie of structural changes in bacteriorhodopsin: structure obtained 95.2 us after photoexcitation
1RMN	;		;	A THREE-DIMENSIONAL MODEL FOR THE HAMMERHEAD RIBOZYME BASED ON FLUORESCENCE MEASUREMENTS
4I3H	;	3.7	;	A three-gate structure of topoisomerase IV from Streptococcus pneumoniae
417D	;	1.5	;	A THYMINE-LIKE BASE ANALOGUE FORMS WOBBLE PAIRS WITH ADENINE
4FFB	;	2.882	;	A TOG:alpha/beta-tubulin Complex Structure Reveals Conformation-Based Mechanisms For a Microtubule Polymerase
2UZR	;	1.94	;	A transforming mutation in the pleckstrin homology domain of AKT1 in cancer (AKT1-PH_E17K)
2UZS	;	2.46	;	A transforming mutation in the pleckstrin homology domain of AKT1 in cancer (AKT1-PH_E17K)
2KZG	;		;	A Transient and Low Populated Protein Folding Intermediate at Atomic Resolution
1F51	;	3.0	;	A TRANSIENT INTERACTION BETWEEN TWO PHOSPHORELAY PROTEINS TRAPPED IN A CRYSTAL LATTICE REVEALS THE MECHANISM OF MOLECULAR RECOGNITION AND PHOSPHOTRANSFER IN SINGAL TRANSDUCTION
1DQ4	;	2.9	;	A transient unlocked concanavalin A structure with MN2+ bound in the transition metal ion binding site S1 and an empty calcium binding site S2
3H7Z	;	2.51	;	A transition from strong right-handed to canonical left-handed supercoiling in a conserved coiled coil segment of trimeric autotransporter adhesins - the M1 mutant structure
3LT7	;	1.5	;	A transition from strong right-handed to canonical left-handed supercoiling in a conserved coiled coil segment of trimeric autotransporter adhesins - the M3 mutant structure
3LT6	;	1.8	;	A transition from strong right-handed to canonical left-handed supercoiling in a conserved coiled coil segment of trimeric autotransporter adhesins - the Mutant 4 structure
3H7X	;	2.0	;	A transition from strong right-handed to canonical left-handed supercoiling in a conserved coiled coil segment of trimeric autotransporter adhesins - the wildtype structure
3FOP	;	3.0	;	A Triangular Cytochrome b562 Superstructure Mediated by Ni Coordination - Hexagonal Form
3FOO	;	2.4	;	A Triangular Cytochrome b562 Superstructure Mediated by Ni Coordination - Monoclinic Form
1GIS	;	1.7	;	A TRICHOSANTHIN(TCS) MUTANT(E85Q) COMPLEX STRUCTURE WITH 2'-DEOXY-ADENOSIN-5'-MONOPHOSPHATE
1GIU	;	1.8	;	A TRICHOSANTHIN(TCS) MUTANT(E85R) COMPLEX STRUCTURE WITH ADENINE
2WW4	;	2.0	;	a triclinic crystal form of E. coli 4-diphosphocytidyl-2C-methyl-D- erythritol kinase
1VLN	;	2.4	;	A TRICLINIC CRYSTAL FORM OF THE LECTIN CONCANAVALIN A
3R6Q	;	2.4	;	A triclinic-lattice structure of aspartase from Bacillus sp. YM55-1
198D	;	1.97	;	A TRIGONAL FORM OF THE IDARUBICIN-D(CGATCG) COMPLEX: CRYSTAL AND MOLECULAR STRUCTURE AT 2.0 ANGSTROMS RESOLUTION
7QDK	;	1.41	;	A trimeric de novo coiled-coil assembly: CC-TypeN-LaLd
3HFE	;	1.7	;	A trimeric form of the Kv7.1 A domain Tail
3HFC	;	2.45	;	A trimeric form of the Kv7.1 A domain Tail, L602M/L606M mutant Semet
5XRC	;	2.9	;	A Trimodular GH5_4 Subfamily Endoglucanase Structure with Large Unit Cell
1QIU	;	2.4	;	A triple beta-spiral in the adenovirus fibre shaft reveals a new structural motif for biological fibres
4RX2	;	2.315	;	A triple mutant in the omega-loop of TEM-1 beta-lactamase changes the substrate profile via a large conformational change and an altered general base for catalysis
4RX3	;	1.39	;	A triple mutant in the omega-loop of TEM-1 beta-lactamase changes the substrate profile via a large conformational change and an altered general base for catalysis
4RVA	;	1.4397	;	A triple mutant in the omega-loop of TEM-1 beta-lactamase changes the substrate profile via a large conformational change and an altered general base for deacylation
5G1K	;	1.96	;	A triple mutant of DsbG engineered for denitrosylation
3D17	;	2.8	;	A triply ligated crystal structure of relaxed state human hemoglobin
8BK6	;	2.263	;	A truncated structure of LpMIP with bound inhibitor JK095.
1FV7	;		;	A TWO B-Z JUNCTION CONTAINING DNA RESOLVES INTO AN ALL RIGHT HANDED DOUBLE HELIX
1BAH	;		;	A TWO DISULFIDE DERIVATIVE OF CHARYBDOTOXIN WITH DISULFIDE 13-33 REPLACED BY TWO ALPHA-AMINOBUTYRIC ACIDS, NMR, 30 STRUCTURES
2DCJ	;	2.24	;	A two-domain structure of alkaliphilic XynJ from Bacillus sp. 41M-1
5LQG	;		;	A two-quartet G-quadruplex formed by human telomere in KCl solution at neutral pH
5LQH	;		;	A two-quartet G-quadruplex formed by human telomere in KCl solution at pH 5.0
3ALE	;	2.5	;	A type III polyketide synthase that produces diarylheptanoid
4I6J	;	2.7	;	A ubiquitin ligase-substrate complex
6RA0	;	2.26	;	A ubiquitin-like dimerization domain controls protein kinase D activation by trans-autophosphorylation
5ZEW	;		;	A ubiquitin-like protein from the hyperthermophilic archaea Caldiarchaeum subterraneum
5ICK	;	2.47	;	A unique binding model of FXR LBD with feroline
4ZM6	;	2.8	;	A unique GCN5-related glucosamine N-acetyltransferase region exist in the fungal multi-domain GH3 beta-N-acetylglucosaminidase
4JMR	;	2.9	;	A unique spumavirus gag N-terminal domain with functional properties of orthoretroviral Matrix and Capsid
4JNH	;	2.402	;	A unique spumavirus gag N-terminal domain with functional properties of orthoretroviral Matrix and Capsid
6MEM	;	11.6	;	A unique supramolecular organization of photosystem I in the moss Physcomitrella patens
3R0Q	;	2.61	;	A Uniquely Open Conformation Revealed in the Crystal Structure of Arabidopsis Thaliana Protein Arginine Methyltransferase 10
6ALE	;	2.5	;	A V-to-F substitution in SK2 channels causes Ca2+ hypersensitivity and improves locomotion in a C. elegans ALS model
6CZQ	;	2.2	;	A V-to-F substitution in SK2 channels causes Ca2+ hypersensitivity and improves locomotion in a C. elegans ALS model
1K50	;	1.8	;	A V49A Mutation Induces 3D Domain Swapping in the B1 Domain of Protein L from Peptostreptococcus magnus
1SQ8	;		;	a variant 434 repressor DNA binding domain devoid of hydroxyl groups, NMR, 20 STRUCTURES
6K53	;	1.89	;	A variant of metagenome-derived GH6 cellobiohydrolase, HmCel6A (P88S/L230F/F414S)
6VLK	;	2.4529	;	A varicella-zoster virus glycoprotein
4JL8	;	1.79	;	A various kinds of ADP conformations in the Adenylate kinase active site
4I6E	;	2.7	;	A vertebrate cryptochrome
4I6G	;	2.2	;	a vertebrate cryptochrome with FAD
1CSH	;	1.65	;	A very short hydrogen bond provides only moderate stabilization of an enzyme: inhibitor complex of citrate synthase
1CSI	;	1.7	;	A very short hydrogen bond provides only moderate stabilization of an enzyme: inhibitor complex of citrate synthase
8G1R	;	3.4	;	A Vibrio cholerae viral satellite enables efficient horizontal transfer by using an external scaffold to assemble hijacked coat proteins into small capsids
6SCF	;	1.55	;	A viral anti-CRISPR subverts type III CRISPR immunity by rapid degradation of cyclic oligoadenylate
5LDN	;	2.7	;	A viral capsid:antibody complex
7PDY	;	2.54	;	A viral peptide from Marek's disease virus bound to chicken MHC-II molecule
2JBY	;	2.41	;	A viral protein unexpectedly mimics the structure and function of pro- survival Bcl-2
3J9X	;	3.8	;	A Virus that Infects a Hyperthermophile Encapsidates A-Form DNA
2XXP	;	1.692	;	A widespread family of bacterial cell wall assembly proteins
2XXQ	;	1.77	;	A widespread family of bacterial cell wall assembly proteins
2CE9	;	2.12	;	A WRPW peptide bound to the Groucho-TLE WD40 domain.
7BTT	;	1.86	;	A X-ray cocrystal structure of XMU-MP-5 bound to the ALK kinase domain
4IVZ	;	3.1	;	A Y37F mutant of C.Esp1396I bound to its highest affinity operator site OM
5C8J	;	3.502	;	A YidC-like protein in the archaeal plasma membrane
3LG2	;	2.6	;	A Ykr043C/ fructose-1,6-bisphosphate product complex following ligand soaking
1ZNM	;		;	A zinc finger with an artificial beta-turn, original sequence taken from the third zinc finger domain of the human transcriptional repressor protein YY1 (YING and YANG 1, a delta transcription factor), nmr, 34 structures
376D	;	2.1	;	A ZIPPER-LIKE DNA DUPLEX D(GCGAAAGCT)
3M15	;	2.6	;	A Zn-mediated asymmetric trimer of a cytochrome cb562 variant (D74A-RIDC1)
3M4B	;	2.5	;	A Zn-mediated tetrahedral protein lattice cage
3M4C	;	1.9	;	A Zn-mediated tetrahedral protein lattice cage encapsulating a microperoxidase
7E36	;	2.0	;	A [6+4]-cycloaddition adduct is the biosynthetic intermediate in streptoseomycin biosynthesis
413D	;	1.8	;	A'-FORM RNA DOUBLE HELIX IN THE SINGLE CRYSTAL STRUCTURE OF R(UGAGCUUCGGCUC)
8IMJ	;	2.59	;	A'1-A'2, A'3-A'4, B1-B2, C1-C2 cylinder in cyanobacterial phycobilisome from Anthocerotibacter panamensis (Cluster B)
1JJP	;		;	A(GGGG) Pentad-Containing Dimeric DNA Quadruplex Involving Stacked G(anti)G(anti)G(anti)G(syn) Tetrads
1EEG	;		;	A(GGGG)A HEXAD PAIRING ALIGMENT FOR THE D(G-G-A-G-G-A-G) SEQUENCE
1DNZ	;	1.6	;	A-DNA DECAMER ACCGGCCGGT WITH MAGNESIUM BINDING SITES
138D	;	1.8	;	A-DNA DECAMER D(GCGGGCCCGC)-HEXAGONAL CRYSTAL FORM
137D	;	1.7	;	A-DNA DECAMER D(GCGGGCCCGC)-ORTHORHOMBIC CRYSTAL FORM
1DPL	;	0.83	;	A-DNA DECAMER GCGTA(T23)TACGC WITH INCORPORATED 2'-METHOXY-3'-METHYLENEPHOSPHATE-THYMIDINE
1I5W	;	1.4	;	A-DNA DECAMER GCGTA(TLN)ACGC
1MA8	;	1.3	;	A-DNA decamer GCGTA(UMS)ACGC with incorporated 2'-methylseleno-uridine
1DNO	;	1.4	;	A-DNA/RNA DODECAMER R(GCG)D(TATACGC) MG BINDING SITES
1Y26	;	2.1	;	A-riboswitch-adenine complex
2F4S	;	2.8	;	A-site RNA in complex with neamine
1UUE	;	2.6	;	a-SPECTRIN SH3 DOMAIN (V44T, D48G MUTANT)
1E6H	;	2.01	;	A-SPECTRIN SH3 DOMAIN A11V, M25I, V44I, V58L MUTANTS
1E6G	;	2.3	;	A-SPECTRIN SH3 DOMAIN A11V, V23L, M25I, V53I, V58L MUTANT
1E7O	;	3.2	;	A-SPECTRIN SH3 DOMAIN A11V, V23L, M25V, V44I, V58L MUTATIONS
1H8K	;	2.7	;	A-SPECTRIN SH3 DOMAIN A11V, V23L, M25V, V53I, V58L MUTANT
1BK2	;	2.01	;	A-SPECTRIN SH3 DOMAIN D48G MUTANT
1HD3	;	1.98	;	A-SPECTRIN SH3 DOMAIN F52Y MUTANT
1NEV	;		;	A-tract decamer
1AL5	;		;	A-TRACT RNA DODECAMER, NMR, 12 STRUCTURES
5ZMB	;		;	A-ubiquitin like protein from the trypanosoma brucei
2IXA	;	2.3	;	A-zyme, N-acetylgalactosaminidase
5TVA	;	2.25	;	A. aeolicus BioW with AMP and CoA
5TV8	;	2.55	;	A. aeolicus BioW with AMP-CPP and pimelate
5TV6	;	2.456	;	A. aeolicus BioW with pimelate
1ZHA	;	1.74	;	A. aeolicus KDO8PS R106G mutant in complex with PEP and R5P
7UW1	;	2.21	;	A. baumannii 70S ribosome-Streptothricin-D complex
7UVX	;	2.35	;	A. baumannii 70S ribosome-Streptothricin-F complex
7MET	;	3.97	;	A. baumannii MsbA in complex with TBT1 decoupler
7M4U	;	2.71	;	A. baumannii Ribosome-Eravacycline complex: 30S
7M4V	;	2.54	;	A. baumannii Ribosome-Eravacycline complex: 50S
7M4Y	;	2.5	;	A. baumannii Ribosome-Eravacycline complex: E-site tRNA 70S
7M4W	;	2.55	;	A. baumannii Ribosome-Eravacycline complex: Empty 70S
7M4Z	;	2.92	;	A. baumannii Ribosome-Eravacycline complex: hpf-bound 70S
7M4X	;	2.66	;	A. baumannii Ribosome-Eravacycline complex: P-site tRNA 70S
7UVZ	;	2.21	;	A. baumannii ribosome-Streptothricin-D complex: 70S with E-site tRNA
7UVY	;	2.39	;	A. baumannii ribosome-Streptothricin-D complex: 70S with P-site tRNA
7UVV	;	2.5	;	A. baumannii ribosome-Streptothricin-F complex: 70S with P-site tRNA
7RYG	;	2.38	;	A. baumannii Ribosome-TP-6076 complex: E-site tRNA 70S
7RYH	;	2.43	;	A. baumannii Ribosome-TP-6076 complex: Empty 70S
7RYF	;	2.65	;	A. baumannii Ribosome-TP-6076 complex: P-site tRNA 70S
7UVW	;	2.37	;	A. baumannii ribosome: 70S with E-site tRNA
3T9Z	;	1.82	;	A. fulgidus GlnK3, ligand-free
3TA1	;	1.9	;	A. fulgidus GlnK3, MgADP complex
3TA0	;	2.3	;	A. fulgidus GlnK3, MgATP complex
3TA2	;	1.9	;	A. fulgidus GlnK3, MgATP/2-OG complex
4EB5	;	2.53	;	A. fulgidus IscS-IscU complex structure
4EB7	;	2.75	;	A. fulgidus IscS-IscU complex structure
2ZYI	;	2.3	;	A. Fulgidus lipase with fatty acid fragment and calcium
2ZYS	;	3.1	;	A. Fulgidus lipase with fatty acid fragment and chloride
2ZYR	;	1.77	;	A. Fulgidus lipase with fatty acid fragment and magnesium
2XVN	;	2.35	;	A. fumigatus chitinase A1 phenyl-methylguanylurea complex
4NZH	;	2.0	;	A. fumigatus flavin-dependent ornithine monooxygenase R279A mutant
4B64	;	2.28	;	A. fumigatus ornithine hydroxylase (SidA) bound to NADP and Lysine
4B63	;	1.9	;	A. fumigatus ornithine hydroxylase (SidA) bound to NADP and ornithine
4B69	;	2.3	;	A. fumigatus ornithine hydroxylase (SidA) bound to ornithine
4B68	;	2.29	;	A. fumigatus ornithine hydroxylase (SidA), re-oxidised state bound to NADP and Arg
4B67	;	2.75	;	A. fumigatus ornithine hydroxylase (SidA), re-oxidised state bound to NADP and ornithine
4B66	;	2.9	;	A. fumigatus ornithine hydroxylase (SidA), reduced state bound to NADP and Arg
4B65	;	2.32	;	A. fumigatus ornithine hydroxylase (SidA), reduced state bound to NADP(H)
2Y8U	;	1.99	;	A. nidulans chitin deacetylase
1U1H	;	2.55	;	A. thaliana cobalamine independent methionine synthase
1U1J	;	2.4	;	A. thaliana cobalamine independent methionine synthase
1U1U	;	2.95	;	A. thaliana cobalamine independent methionine synthase
1U22	;	2.65	;	A. thaliana cobalamine independent methionine synthase
5EKW	;	1.1	;	A. thaliana IGPD2 in complex with the racemate of the triazole-phosphonate inhibitor, C348
5ELW	;	1.4	;	A. thaliana IGPD2 in complex with the triazole-phosphonate inhibitor, (R)-C348, to 1.36A resolution
5EL9	;	1.1	;	A. thaliana IGPD2 in complex with the triazole-phosphonate inhibitor, (S)-C348, to 1.1A resolution
3LGS	;	2.2	;	A. thaliana MTA nucleosidase in complex with S-adenosylhomocysteine
6FL4	;	1.6	;	A. thaliana NUDT1 in complex with 8-oxo-dGTP
6SMN	;	1.63	;	A. thaliana serine hydroxymethyltransferase isoform 2 (AtSHMT2) in complex with methotrexate
6SMW	;	1.54	;	A. thaliana serine hydroxymethyltransferase isoform 2 (AtSHMT2) in complex with pemetrexed
6SMR	;	2.12	;	A. thaliana serine hydroxymethyltransferase isoform 4 (AtSHMT4) in complex with methotrexate
8BOQ	;	1.547	;	A. vinelandii Fe-nitrogenase FeFe protein
3U7Q	;	1.0	;	A. vinelandii nitrogenase MoFe protein at atomic resolution
6FEA	;	1.2	;	A. vinelandii vanadium nitrogenase, turnover state
4OZE	;	1.61	;	A.aolicus LpxC in complex with native product
8IWL	;	3.04	;	A.baumannii Uncharacterized sugar kinase ydjH
2B8H	;	2.2	;	A/NWS/whale/Maine/1/84 (H1N9) reassortant influenza virus neuraminidase
5W08	;	2.6	;	A/Texas/50/2012(H3N2) Influenza hemagglutinin in complex with K03.12 Fab
8GLC	;	3.12	;	A1 AncAla: Adenylation domain 1 core construct from ancestral reconstruction of glycopeptide antibiotic biosynthesis, alanine selection pocket
1AUQ	;	2.3	;	A1 DOMAIN OF VON WILLEBRAND FACTOR
8GJP	;	2.7	;	A1 Int graft: Adenylation domain 1 core construct from teicoplanin biosynthesis, intermediate selection pocket graft
8GKM	;	1.89	;	A1 Leu graft + Leu: Adenylation domain 1 core construct from teicoplanin biosynthesis, leucine selection pocket graft; leucine bound
8GIC	;	1.64	;	A1 Tei + Hpg: Adenylation domain 1 core construct from teicoplanin biosynthesis; 4-hydroxyphenylglycine bound
8GJ4	;	1.81	;	A1 Tei: Adenylation domain 1 core construct from teicoplanin biosynthesis
8IMI	;	2.59	;	A1-A2, A3-A4, B'1-B'2, C'1-C'2 cylinder in cyanobacterial phycobilisome from Anthocerotibacter panamensis (Cluster A)
6H0J	;		;	A1-type ACP domain from module 5 of MLSA1
4LID	;	3.0	;	A100, A DNA binding scaffold from Sulfolobus spindle-shape virus 1
2PQD	;	1.77	;	A100G CP4 EPSPS liganded with (R)-difluoromethyl tetrahedral reaction intermediate analog
4A6A	;	2.9	;	A115V variant of dCTP deaminase-dUTPase from Mycobacterium tuberculosis in complex with dTTP
4M9I	;	2.4	;	A125C NS2B-NS3 protease from dengue virus at pH 5.5
6E0X	;	1.974	;	A131E mutant of cyt P460 of Nitrosomonas sp. AL212
6E17	;	1.97	;	A131E mutant of cyt P460 of Nitrosomonas sp. AL212 with NO bound
6E0Z	;	2.3	;	A131Q mutant of cyt P460 of Nitrosomonas sp. AL212
6E0Y	;	2.257	;	A131Q mutant of cyt P460 of Nitrosomonas sp. AL212 with bound NH2OH
2JPX	;		;	A18H Vpu TM structure in lipid bilayers
1SZG	;	2.7	;	A198G:L230A flavocytochrome b2 with sulfite bound
1SZF	;	2.7	;	A198G:L230A mutant flavocytochrome b2 with pyruvate bound
7PBD	;	3.04	;	a1b3 GABA-A receptor + GABA
7PBZ	;	2.79	;	a1b3 GABA-A receptor + GABA + Zn2+
1C17	;		;	A1C12 SUBCOMPLEX OF F1FO ATP SYNTHASE
4JFO	;	2.11	;	A2 HLA complex with E1A heteroclitic variant of Melanoma peptide
4JFP	;	1.91	;	A2 HLA complex with G4A heteroclitic variant of Melanoma peptide
4JFQ	;	1.9	;	A2 HLA complex with L8A heteroclitic variant of Melanoma peptide
4GKN	;	2.753	;	A2-MHC Complex carrying FATGIGIITV
4GKS	;	2.346	;	A2-MHC Complex carrying FLTGIGIITV
8FIF	;	2.35	;	A2.3 Nanobody In Complex With Microcystin-LR
3ZJD	;	1.87	;	A20 OTU domain in reduced, active state at 1.87 A resolution
3ZJE	;	1.84	;	A20 OTU domain in reversibly oxidised (SOH) state
3ZJF	;	2.2	;	A20 OTU domain with irreversibly oxidised Cys103 from 270 min H2O2 soak.
3ZJG	;	1.92	;	A20 OTU domain with irreversibly oxidised Cys103 from 60 min H2O2 soak.
7ZKK	;	1.97	;	A216H variant of the CODH/ACS complex of C. hydrogenoformans
8CMW	;	2.6	;	A225L variant of the CODH/ACS complex of C. hydrogenoformans
8CJA	;	2.1	;	A225L/F231A variant of the CODH/ACS complex of C. hydrogenoformans
8EFU	;	3.2	;	a22L prion fibril
4LZ0	;	1.754	;	A236G Epi-isozizaene synthase: Complex with Mg, inorganic pyrophosphate and benzyl triethyl ammonium cation
6TXV	;	1.6	;	A25T Transthyretin structure in complex with Tolcalpone
8CJB	;	2.5	;	A268M variant of the CODH/ACS complex of C. hydrogenoformans
5NM2	;	1.948	;	A2A Adenosine receptor cryo structure
5NM4	;	1.7	;	A2A Adenosine receptor room-temperature structure determined by serial femtosecond crystallography
5NLX	;	2.14	;	A2A Adenosine receptor room-temperature structure determined by serial millisecond crystallography
6LPJ	;	1.8	;	A2AR crystallized in EROCOC17+4, LCP-SFX at 277 K
6LPK	;	1.8	;	A2AR crystallized in EROCOC17+4, LCP-SFX at 293 K
6LPL	;	2.0	;	A2AR crystallized in EROCOC17+4, SS-ROX at 100 K
1AO3	;	2.2	;	A3 DOMAIN OF VON WILLEBRAND FACTOR
1BH2	;	2.1	;	A326S MUTANT OF AN INHIBITORY ALPHA SUBUNIT
3AM3	;	2.5	;	A372M mutant of Enoyl-ACP Reductase from Plasmodium falciparum (PfENR) in complex with triclosan
3AM4	;	2.3	;	A372M mutant of Enoyl-ACP Reductase from Plasmodium falciparum (PfENR) in complex with triclosan variant T1
2YEO	;	1.08	;	A39L mutation of scorpion toxin lqh-alpha-it
1YKJ	;	2.0	;	A45G p-hydroxybenzoate hydroxylase with p-hydroxybenzoate bound
1UXM	;	1.9	;	A4V mutant of human SOD1
6Z4M	;	1.55	;	A4V mutant of human SOD1 bound with 2-(pyridin-3-ylmethyl)benzoisoselenazolone derivative 10 in P21 space group
6Z4L	;	1.6	;	A4V mutant of human SOD1 bound with 2-(pyridin-3-ylmethyl)benzoisoselenazolone derivative 9 in P21 space group
6Z4O	;	1.4	;	A4V mutant of human SOD1 bound with benzyl benzoisoselenazolone derivative 1 in P21 space group
6Z4H	;	1.95	;	A4V mutant of human SOD1 bound with benzyl benzoisoselenazolone derivative 2 in P21 space group
6Z4I	;	1.6	;	A4V mutant of human SOD1 bound with benzyl benzoisoselenazolone derivative 3 in P21 space group
6Z4J	;	1.55	;	A4V mutant of human SOD1 bound with benzyl benzoisoselenazolone derivative 5 in P21 space group
6Z4K	;	1.45	;	A4V mutant of human SOD1 bound with benzyl benzoisoselenazolone derivative 6 in P21 space group
6Z4G	;	1.45	;	A4V mutant of human SOD1 bound with ebselen in P21 space group
6Z3V	;	1.25	;	A4V mutant of human SOD1 bound with N-aryl benzoisoselenazolone derivative 13 in P21 space group
6SPJ	;	1.97	;	A4V MUTANT OF HUMAN SOD1 WITH EBSELEN DERIVATIVE 1
6SPI	;	2.8	;	A4V MUTANT OF HUMAN SOD1 WITH EBSELEN DERIVATIVE 4
6SPK	;	2.77	;	A4V MUTANT OF HUMAN SOD1 WITH EBSELEN DERIVATIVE 6
6SPA	;	1.65	;	A4V MUTANT OF HUMAN SUPEROXIDE DISMUTASE 1 IN C2 SPACE GROUP
6SPH	;	2.25	;	A4V MUTANT OF HUMAN SUPEROXIDE DISMUTASE 1 WITH EBSELEN BOND IN C2 SPACE GROUP
3AA5	;	2.1	;	A52F E.coli RNase HI
3AA2	;	1.9	;	A52I E. coli RNase HI
3AA3	;	2.2	;	A52L E. coli RNase HI
3AA4	;	1.79	;	A52V E.coli RNase HI
5T7R	;	1.55	;	A6-A11 trans-dicarba human insulin
455D	;	1.43	;	A6/A18 INTER-STRAND DITHIOBIS(PROPANE)-CROSSLINKED DODECAMER (CGCGAATTCGCG)2
7DZL	;	1.64	;	A69C-M71L mutant of Fabp protein
8JLR	;	3.0	;	A77636-bound hTAAR1-Gs protein complex
6S0N	;		;	A9 peptide derived from Herceptin fab binding region
5FTZ	;	1.38	;	AA10 lytic polysaccharide monooxygenase (LPMO) from Streptomyces lividans
4OPB	;	1.5	;	AA13 Lytic polysaccharide monooxygenase from Aspergillus oryzae
6TC4	;	2.0	;	AA13 Lytic polysaccharide monooxygenase from Aspergillus oryzae measured with SSX
6TBQ	;	1.72	;	AA13 Lytic polysaccharide monooxygenase from Aspergillus oryzae partially in Cu(II) state
7NTL	;	1.38	;	AA9 lytic polysaccharide monooxygenase (LPMO) from Malbranchea cinnamomea
3H4M	;	3.106	;	AAA ATPase domain of the proteasome- activating nucleotidase
5EXS	;	2.5	;	AAA+ ATPase FleQ from Pseudomonas aeruginosa bound to ATP-gamma-S
5EXX	;	3.311	;	AAA+ ATPase FleQ from Pseudomonas aeruginosa bound to c-di-GMP
6LSY	;	6.33	;	AAA+ ATPase, ClpL from Streptococcus pneumoniae - ATP bound
6LT4	;	4.5	;	AAA+ ATPase, ClpL from Streptococcus pneumoniae: ATPrS-bound
5EXP	;	1.8	;	AAA+ domain of FleQ from Pseudomonas aeruginosa
5EXT	;	2.4	;	AAA+ domain of FleQ from Pseudomonas aeruginosa bound to ADP
8OSF	;	4.0	;	AAA+ motor subunit ChlI of magnesium chelatase, hexamer conformation A
8OSG	;	3.8	;	AAA+ motor subunit ChlI of magnesium chelatase, hexamer conformation B
8OSH	;	4.9	;	AAA+ motor subunit ChlI of magnesium chelatase, pentamer spring-washer-like conformation
6HE4	;	4.85	;	AAA-ATPase ring of PAN-proteasomes
7MQM	;	1.6	;	AAC(3)-IIIa in complex with CoA and gentamicin
7MQL	;	1.6	;	AAC(3)-IIIa in complex with CoA and neomycin
7MQK	;	1.6	;	AAC(3)-IIIa in complex with CoA and sisomicin
6MB6	;	2.25	;	AAC-IIIb binary with CoASH
6MB5	;	2.2	;	AAC-IIIb binary with NEOMYCIN
6NP3	;	1.15	;	AAC-VIa bound to Gentamicin
6O5U	;	1.4	;	AAC-VIa bound to Kanamycin A
6NP5	;	1.353	;	AAC-VIa bound to Kanamycin B
6NP2	;	1.2	;	AAC-VIa bound to Sisomicin
6NP4	;	1.151	;	AAC-VIa bound to Tobramycin
5BK9	;	1.51	;	AAD-1 Bound to the Vanadyl Ion and Succinate
5LPA	;	1.4	;	AadA E87Q in complex with ATP, calcium and dihydrostreptomycin
5LUH	;	1.73	;	AadA E87Q in complex with ATP, calcium and streptomycin
5G4A	;	1.9	;	AadA in complex with ATP and magnesium
6FZB	;	2.05	;	AadA in complex with ATP, magnesium and streptomycin
4Y62	;	1.6	;	AAGlyB in complex with amino-acid analogues
4Y63	;	1.3	;	AAGlyB in complex with amino-acid analogues
4Y64	;	1.6	;	AAGlyB in complex with amino-acid analogues
7Z4T	;	3.3	;	AAL160 FAB IN COMPLEX WITH HUMAN INTERLEUKIN-1 BETA
7LTU	;	1.122	;	AALALL SEGMENT FROM THE NUCLEOPROTEIN OF SARS-COV-2, RESIDUES 217-222, CRYSTAL FORM 1
7LUX	;	1.303	;	AALALL segment from the Nucleoprotein of SARS-CoV-2, residues 217-222, crystal form 2
1FT7	;	2.2	;	AAP COMPLEXED WITH L-LEUCINEPHOSPHONIC ACID
6GIF	;		;	AapA1 V26A toxin from helicobacter pylori 26695
8OQ5	;	2.4	;	AApoAII amyloid fibril Morphology I (ex vivo)
8OQ4	;	2.6	;	AApoAII amyloid fibril Morphology II (ex vivo)
2I13	;	1.96	;	Aart, a six finger zinc finger designed to recognize ANN triplets
3C9U	;	1.48	;	AaThiL complexed with ADP and TPP
3C9S	;	2.2	;	AaThiL complexed with AMPPCP
3C9T	;	2.6	;	AaThiL complexed with AMPPCP and TMP
3C9R	;	2.3	;	AaThiL complexed with ATP
6JCQ	;	3.3	;	AAV1 in complex with AAVR
6JCR	;	3.07	;	AAV1 in neutral condition at 3.07 Ang
8FQ4	;	2.27	;	AAV1 VP3 Only Capsid
6JCS	;	3.18	;	AAV5 in complex with AAVR
6JCT	;	3.18	;	AAV5 in neutral condition at 3.18 Ang
6UBM	;	3.3	;	AAV8 Baculovirus-Sf9 produced, empty capsid
6U2V	;	3.6	;	AAV8 Baculovirus-Sf9 produced, full capsid
6U20	;	3.3	;	AAV8 human HEK293-produced, empty capsid
6PWA	;	3.3	;	AAV8 human HEK293-produced, full capsid
7RL1	;	2.71	;	AAVrh.10-7x capsid
6XTG	;	1.55	;	Ab 1116NS19.9 bound to CA19-9
6XUN	;	2.41	;	Ab 5b1 bound to CA19-9
6AC6	;	2.989	;	Ab initio crystal structure of Selenomethionine labelled Mycobacterium smegmatis Mfd
2YHG	;	1.08	;	Ab initio phasing of a nucleoside hydrolase-related hypothetical protein from Saccharophagus degradans that is associated with carbohydrate metabolism
1CKU	;	1.2	;	AB INITIO SOLUTION AND REFINEMENT OF TWO HIGH POTENTIAL IRON PROTEIN STRUCTURES AT ATOMIC RESOLUTION
7SKX	;	1.5	;	Ab initio structure of proteinase K from electron-counted MicroED data
7SKW	;	0.87	;	Ab initio structure of triclinic lysozyme from electron-counted MicroED data
8OTF	;	3.3	;	Ab typeII filament from Guam ALS/PDC
7MXE	;	3.7	;	Ab1245 Fab in complex with BG505 SOSIP.664 and 8ANC195 Fab
6FPD	;	2.5	;	AB21 protein from Agaricus bisporus
1W5I	;	2.3	;	ABA does not affect topology of pLI.
5MMQ	;	1.8	;	ABA RECEPTOR FROM CITRUS, CSPYL1
5MMX	;	2.882	;	ABA RECEPTOR FROM CITRUS, CSPYL1
5MN0	;	2.0	;	ABA RECEPTOR FROM CITRUS, CSPYL1
5MOA	;	1.65	;	ABA RECEPTOR FROM TOMATO, SlPYL1
5MOB	;	1.669	;	ABA RECEPTOR FROM TOMATO, SlPYL1
5VT7	;	2.624	;	ABA-mimicking ligand AMC1beta in complex with ABA receptor PYL2 and PP2C HAB1
5VR7	;	2.612	;	ABA-mimicking ligand AMF1alpha in complex with ABA receptor PYL2 and PP2C HAB1
5VRO	;	2.257	;	ABA-mimicking ligand AMF1beta in complex with ABA receptor PYL2 and PP2C HAB1
5VS5	;	2.8	;	ABA-mimicking ligand AMF2alpha in complex with ABA receptor PYL2 and PP2C HAB1
5VSQ	;	2.618	;	ABA-mimicking ligand AMF2beta in complex with ABA receptor PYL2 and PP2C HAB1
5VSR	;	2.618	;	ABA-mimicking ligand AMF4 in complex with ABA receptor PYL2 and PP2C HAB1
4LGB	;	3.15	;	ABA-mimicking ligand N-(1-METHYL-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-6-YL)-1-(4-METHYLPHENYL)METHANESULFONAMIDE in complex with ABA receptor PYL2 and PP2C HAB1
4LGA	;	2.7	;	ABA-mimicking ligand N-(2-OXO-1-PROPYL-1,2,3,4-TETRAHYDROQUINOLIN-6-YL)-1-PHENYLMETHANESULFONAMIDE in complex with ABA receptor PYL2 and PP2C HAB1
4LG5	;	2.88	;	ABA-mimicking ligand QUINABACTIN in complex with ABA receptor PYL2 and PP2C HAB1
2JUV	;		;	AbaA3-DKP-insulin
2OLK	;	2.1	;	ABC Protein ArtP in complex with ADP-beta-S
2OLJ	;	2.05	;	ABC Protein ArtP in complex with ADP/Mg2+
2Q0H	;	2.2	;	ABC Protein ArtP in complex with ADP/Mg2+, ATP-gamma-S hydrolyzed
3C41	;	2.25	;	ABC protein ArtP in complex with AMP-PNP/Mg2+
3C4J	;	2.33	;	ABC protein ArtP in complex with ATP-gamma-S
2OUK	;	2.15	;	ABC Protein ArtP in complex with Sulphate
5F7V	;	1.4	;	ABC substrate-binding protein Lmo0181 from Listeria monocytogenes in complex with cycloalternan
4Z9N	;	1.745	;	ABC transporter / periplasmic binding protein from Brucella ovis with glutathione bound
8BFY	;	1.55	;	ABC transporter binding protein CebE from Streptomyces scabiei in complex with cellotriose
8ART	;	3.17	;	ABC transporter binding protein MalE from Streptomyces scabiei in complex with maltose
7ZNQ	;	3.04	;	ABC transporter complex NosDFYL in GDN
7OSG	;	3.3	;	ABC Transporter complex NosDFYL, consensus refinement
7OSJ	;	3.8	;	ABC Transporter complex NosDFYL, membrane anchor
7OSF	;	3.8	;	ABC Transporter complex NosDFYL, R-domain 1
7OSH	;	3.8	;	ABC Transporter complex NosDFYL, R-domain 2
7OSI	;	3.8	;	ABC Transporter complex NosDFYL, R-domain 3
2ONK	;	3.1	;	ABC transporter ModBC in complex with its binding protein ModA
7O17	;	4.5	;	ABC transporter NosDFY E154Q, ATP-bound in lipid nanodisc
7O12	;	3.7	;	ABC transporter NosDFY, AMPPNP-bound in GDN
7O0Y	;	3.3	;	ABC transporter NosDFY, nucleotide-free in GDN
7O11	;	3.7	;	ABC transporter NosDFY, nucleotide-free in GDN, R-domain 1
7O10	;	3.6	;	ABC transporter NosDFY, nucleotide-free in GDN, R-domain 2
7O13	;	3.6	;	ABC transporter NosDFY, nucleotide-free in lipid nanodisc
7O14	;		;	ABC transporter NosDFY, nucleotide-free in lipid nanodisc, R-domain 1
7O15	;		;	ABC transporter NosDFY, nucleotide-free in lipid nanodisc, R-domain 2
7O16	;		;	ABC transporter NosDFY, nucleotide-free in lipid nanodisc, R-domain 3
7O0Z	;	3.7	;	ABC transporter NosFY, nucleotide-free in GDN
4PAG	;	1.901	;	ABC transporter solute binding protein from Sulfurospirillum deleyianum DSM 6946
4ZPJ	;	2.24	;	ABC transporter substrate-binding protein from Sphaerobacter thermophilus
4MLC	;	2.705	;	ABC Transporter Substrate-Binding Protein fromDesulfitobacterium hafniense
4P98	;	1.9	;	ABC transporter system solute-bindng protein from Conexibacter woesei DSM 14684
4KQC	;	1.62	;	ABC transporter, LacI family transcriptional regulator from Brachyspira murdochii
6PU3	;	1.8	;	ABC transporter-associated periplasmic binding protein DppA from Helicobacter pylori
6OFQ	;	1.45	;	ABC transporter-associated periplasmic binding protein DppA from Helicobacter pylori in complex with peptide STSA
2QI9	;	2.6	;	ABC-transporter BtuCD in complex with its periplasmic binding protein BtuF
2RIN	;	1.8	;	ABC-transporter choline binding protein in complex with acetylcholine
2REG	;	1.9	;	ABC-transporter choline binding protein in complex with choline
2REJ	;	2.6	;	ABC-transporter choline binding protein in unliganded semi-closed conformation
7ZK7	;	3.2	;	ABCB1 L335C mutant (mABCB1) in the inward facing state bound to AAC
8PEE	;	3.8	;	ABCB1 L335C mutant (mABCB1) in the inward facing state bound to AAC
7ZK6	;	3.1	;	ABCB1 L335C mutant (mABCB1) in the outward facing state bound to 2 molecules of AAC
7ZK5	;	2.6	;	ABCB1 L335C mutant (mABCB1) in the outward facing state bound to AAC
7ZK9	;	4.3	;	ABCB1 L971C mutant (mABCB1) in the inward facing state
7ZK8	;	3.0	;	ABCB1 L971C mutant (mABCB1) in the outward facing state bound to AAC
7ZKB	;	4.7	;	ABCB1 V978C mutant (mABCB1) in the inward facing state
7ZKA	;	2.9	;	ABCB1 V978C mutant (mABCB1) in the outward facing state bound to AAC
7OJ8	;	3.4	;	ABCG2 E1S turnover-2 state
7OJH	;	3.1	;	ABCG2 topotecan turnover-1 state
7OJI	;	3.4	;	ABCG2 topotecan turnover-2 state
8BHT	;	3.1	;	ABCG2 turnover-1 state with tariquidar bound
8BI0	;	3.2	;	ABCG2 turnover-2 state with tariquidar bound
8IWN	;	3.0	;	ABCG25 EQ mutant in ATP-bound state
8IWJ	;	3.0	;	ABCG25 Wild Type in Apo-state
8IWK	;	3.0	;	ABCG25 Wild Type purified with DDM plus CHS in ABA-bound state
8F37	;		;	AbdA Homeodomain NMR Solution Structure
8FOX	;	1.89	;	AbeH (Tryptophan-5-halogenase)
8FOV	;	1.86	;	AbeH (Tryptophan-5-halogenase) bound to FAD and Cl
7JQS	;	2.127	;	Abeta 16-36 beta-hairpin mimic with E22delta Osaka mutation
7JQR	;	2.07	;	Abeta 16-36 beta-hairpin mimic with E22G Arctic mutation
7JQU	;	2.611	;	Abeta 16-36 beta-hairpin mimic with E22G Arctic mutation
7JQT	;	2.08	;	Abeta 16-36 beta-hairpin mimic with E22K Italian mutation
6SHS	;	4.4	;	Abeta fibril (Morphology I)
1SO8	;	2.3	;	Abeta-bound human ABAD structure [also known as 3-hydroxyacyl-CoA dehydrogenase type II (Type II HADH), Endoplasmic reticulum-associated amyloid beta-peptide binding protein (ERAB)]
3S5A	;	1.7	;	ABH2 cross-linked to undamaged dsDNA-2 with cofactors
3S57	;	1.6	;	ABH2 cross-linked with undamaged dsDNA-1 containing cofactors
6Y8Q	;	1.83	;	AbiEi antitoxin from Streptococcus agalactiae
3S9V	;	2.3	;	abietadiene synthase from Abies grandis
6XR6	;		;	Abl 1b isoform active state
6XRG	;		;	Abl 1b isoform inactive2 state
6AMV	;		;	Abl 1b Regulatory Module 'inhibiting state'
6XR7	;		;	Abl isoform 1b inactive1 state
2HZ0	;	2.1	;	Abl kinase domain in complex with NVP-AEG082
2HZN	;	2.7	;	Abl kinase domain in complex with NVP-AFG210
2HZI	;	1.7	;	Abl kinase domain in complex with PD180970
2HZ4	;	2.8	;	Abl kinase domain unligated and in complex with tetrahydrostaurosporine
3MS9	;	1.8	;	ABL kinase in complex with imatinib and a fragment (FRAG1) in the myristate pocket
3MSS	;	1.95	;	Abl kinase in complex with imatinib and fragment (FRAG2) in the myristate site
8SSN	;	2.86	;	Abl kinase in complex with SKI and asciminib
6HD4	;	2.03	;	ABL1 IN COMPLEX WITH COMPOUND 7 AND IMATINIB (STI-571)
6HD6	;	2.3	;	ABL1 IN COMPLEX WITH COMPOUND6 AND IMATINIB (STI-571)
5MO4	;	2.17	;	ABL1 kinase (T334I_D382N) in complex with asciminib and nilotinib
5NP2	;	1.6	;	Abl1 SH3 pTyr89/134
6AMW	;		;	Abl1b Regulatory Module 'Activating' conformation
5NP3	;	2.0	;	Abl2 SH3
5NP5	;	1.4	;	Abl2 SH3 pTyr116/161
6XUK	;	1.42	;	AbLIFT design 15 of Ab 1116NS19.9
6GC2	;	2.55	;	AbLIFT: Antibody stability and affinity optimization by computational design of the variable light-heavy chain interface
6KE2	;	1.798	;	ABloop reengineered Ferritin Nanocage
6KE4	;	2.3	;	ABloop reengineered Ferritin Nanocage
8APP	;	1.82	;	AbLys1 endolysin from Acinetobacter baumannii phage AbTZA1
7R08	;	3.1	;	Abortive infection DNA polymerase Abi-P2
8OZ7	;	2.75	;	Abortive infection DNA polymerase AbiA from Lactococcus lactis
7R06	;	2.27	;	Abortive infection DNA polymerase AbiK from Lactococcus lactis
7R07	;	3.1	;	Abortive infection DNA polymerase AbiK from Lactococcus lactis
7Z0Z	;	2.68	;	Abortive infection DNA polymerase AbiK from Lactococcus lactis, Y44F variant
6W2M	;	1.998	;	Abortive ternary complex crystal structure of DNA polymerase Beta with 8OG-dC base pair at the primer terminus and flipped out dA
8DF0	;	2.1	;	Abp1D receptor binding domain
8DEZ	;	1.29	;	Abp2D Receptor Binding Domain ACICU
8DKA	;	1.9	;	Abp2D receptor binding domain R86E
1S22	;	1.6	;	Absolute Stereochemistry of Ulapualide A
4ILY	;	1.835	;	Abundantly secreted chitosanase from Streptomyces sp. SirexAA-E
5BY7	;	1.8	;	AbyA1 - tetronic acid condensing enzyme
4YWF	;	2.0	;	AbyA5
5NO5	;	2.5	;	AbyA5 Wildtype
5DYV	;	2.5	;	AbyU - wildtype
5DYQ	;	1.66	;	AbyU L73M L139M
3SIO	;	2.32	;	Ac-AChBP ligand binding domain (not including beta 9-10 linker) mutated to human alpha-7 nAChR
3SH1	;	2.9	;	Ac-AChBP ligand binding domain mutated to human alpha-7 nAChR
3T4M	;	3.0	;	Ac-AChBP ligand binding domain mutated to human alpha-7 nAChR (intermediate)
7C0G	;	2.4	;	Aca1 in complex with 14bp palindromic DNA target
7VJM	;	3.0	;	Aca1 in complex with 19bp palindromic DNA substrate
8PHE	;	3.1	;	ACAD9-WT in complex with ECSIT-CTER
4EFH	;	2.48	;	Acanthamoeba Actin complex with Spir domain D
7LES	;	2.65	;	Acanthamoeba castellanii CYP51 (AcCYP51)-Imidazole complex
1PRQ	;	2.5	;	ACANTHAMOEBA CASTELLANII PROFILIN IA
1ACF	;	2.0	;	ACANTHAMOEBA CASTELLANII PROFILIN IB
2ACG	;	2.5	;	ACANTHAMOEBA CASTELLANII PROFILIN II
6FWH	;	1.79	;	Acanthamoeba IGPD in complex with R-C348 to 1.7A resolution
2DRK	;	1.42	;	Acanthamoeba myosin I SH3 domain bound to Acan125
2DRM	;	1.35	;	Acanthamoeba myosin I SH3 domain bound to Acan125
1E3Z	;	1.93	;	Acarbose complex of chimaeric amylase from B. amyloliquefaciens and B. licheniformis at 1.93A
6WB7	;	2.44	;	Acarbose Kinase AcbK as a Complex with Acarbose and AMP-PNP
1XCW	;	2.0	;	Acarbose Rearrangement Mechanism Implied by the Kinetic and Structural Analysis of Human Pancreatic alpha-Amylase in Complex with Analogues and Their Elongated Counterparts
1XCX	;	1.9	;	Acarbose Rearrangement Mechanism Implied by the Kinetic and Structural Analysis of Human Pancreatic alpha-Amylase in Complex with Analogues and Their Elongated Counterparts
1XD0	;	2.0	;	Acarbose Rearrangement Mechanism Implied by the Kinetic and Structural Analysis of Human Pancreatic alpha-Amylase in Complex with Analogues and Their Elongated Counterparts
1XD1	;	2.2	;	Acarbose Rearrangement Mechanism Implied by the Kinetic and Structural Analysis of Human Pancreatic alpha-Amylase in Complex with Analogues and Their Elongated Counterparts
1J0D	;	2.2	;	ACC deaminase mutant complexed with ACC
1J0E	;	2.45	;	ACC deaminase mutant reacton intermediate
1J0C	;	2.75	;	ACC deaminase mutated to catalytic residue
1ZEZ	;	2.0	;	ACC Holliday Junction
5TCW	;	2.7	;	ACC oxidase complex with nickel and acetate
5TCV	;	2.6	;	ACC oxidase complex with substrate 1-aminocyclopropane-1-carboxylic acid
5MU2	;	2.7	;	ACC1 Fab fragment in complex with CII583-591 (CG10)
5MV3	;	2.95	;	ACC1 Fab fragment in complex with CII583-591 (CG10)
5MUB	;	3.1	;	ACC1 Fab fragment in complex with citrullinated C1 epitope of CII (CG05)
5MU0	;	2.7	;	ACC1 Fab fragment in complex with citrullinated C1 epitope of CII (IA03)
5MV4	;	2.9	;	ACC1 Fab fragment in complex with citrullinated CII616-639 epitope of collagen type II (ptm23)
1LTM	;	1.7	;	ACCELERATED X-RAY STRUCTURE ELUCIDATION OF A 36 KDA MURAMIDASE/TRANSGLYCOSYLASE USING WARP
1IKD	;		;	ACCEPTOR STEM, NMR, 30 STRUCTURES
1SJS	;	2.42	;	ACCESS TO PHOSPHORYLATION IN ISOCITRATE DEHYDROGENASE MAY OCCUR BY DOMAIN SHIFTING
5VL4	;	4.1	;	Accidental minimum contact crystal lattice formed by a redesigned protein oligomer
1STA	;	1.7	;	ACCOMMODATION OF INSERTION MUTATIONS ON THE SURFACE AND IN THE INTERIOR OF STAPHYLOCOCCAL NUCLEASE
1STB	;	2.0	;	ACCOMMODATION OF INSERTION MUTATIONS ON THE SURFACE AND IN THE INTERIOR OF STAPHYLOCOCCAL NUCLEASE
5IOO	;	2.521	;	Accommodation of massive sequence variation in Nanoarchaeota by the C-type lectin fold
2NU2	;	1.65	;	Accommodation of positively-charged residues in a hydrophobic specificity pocket: Crystal structures of SGPB in complex with OMTKY3 variants Lys18I and Arg18I
2NU3	;	1.8	;	Accommodation of positively-charged residues in a hydrophobic specificity pocket: Crystal structures of SGPB in complex with OMTKY3 variants Lys18I and Arg18I
2NU4	;	1.75	;	Accommodation of positively-charged residues in a hydrophobic specificity pocket: Crystal structures of SGPB in complex with OMTKY3 variants Lys18I and Arg18I
1S37	;		;	Accomodation of Mispair-Aligned N3T-Ethyl-N3T DNA Interstrand Crosslink
1PLC	;	1.33	;	ACCURACY AND PRECISION IN PROTEIN CRYSTAL STRUCTURE ANALYSIS: RESTRAINED LEAST-SQUARES REFINEMENT OF THE CRYSTAL STRUCTURE OF POPLAR PLASTOCYANIN AT 1.33 ANGSTROMS RESOLUTION
1PNC	;	1.6	;	ACCURACY AND PRECISION IN PROTEIN CRYSTAL STRUCTURE ANALYSIS: TWO INDEPENDENT REFINEMENTS OF THE STRUCTURE OF POPLAR PLASTOCYANIN AT 173K
1PND	;	1.6	;	ACCURACY AND PRECISION IN PROTEIN CRYSTAL STRUCTURE ANALYSIS: TWO INDEPENDENT REFINEMENTS OF THE STRUCTURE OF POPLAR PLASTOCYANIN AT 173K
8CUS	;	3.98	;	Accurate computational design of genetically encoded 3D protein crystals
8CUT	;	4.0	;	Accurate computational design of genetically encoded 3D protein crystals
8CUU	;	2.91	;	Accurate computational design of genetically encoded 3D protein crystals
8CUV	;	2.8	;	Accurate computational design of genetically encoded 3D protein crystals
8CUW	;	3.55	;	Accurate computational design of genetically encoded 3D protein crystals
8CUX	;	1.85	;	Accurate computational design of genetically encoded 3D protein crystals
8CWS	;	4.4	;	Accurate computational design of genetically encoded 3D protein crystals
8CWY	;	3.34	;	Accurate computational design of genetically encoded 3D protein crystals
8CWZ	;	5.53	;	Accurate computational design of genetically encoded 3D protein crystals
8FAR	;	3.66	;	Accurate computational design of genetically encoded 3D protein crystals
1KH0	;	1.9	;	Accurate Computer Base Design of a New Backbone Conformation in the Second Turn of Protein L
8RXA	;	1.751	;	ACDC domain of AP2-O5 from Plasmodium falciparum
8RXO	;	2.998	;	ACDC domain of Plasmodium falciparum AP2-I transcription factor
8RWU	;	3.152	;	ACDC domain of the AP2-I transcription factor from Plasmodium falciparum
7V61	;	3.2	;	ACE2 -Targeting Monoclonal Antibody as Potent and Broad-Spectrum Coronavirus Blocker
8B9P	;	2.11	;	ACE2 in complex with bicyclic peptide inhibitor
6M18	;	2.9	;	ACE2-B0AT1 complex
8I92	;	3.2	;	ACE2-B0AT1 complex bound with glutamine
8I93	;	3.1	;	ACE2-B0AT1 complex bound with methionine
6M1D	;	4.5	;	ACE2-B0AT1 complex, open conformation
8TOQ	;	2.3	;	ACE2-peptide 1 complex
8TOR	;	2.2	;	ACE2-peptide 2 complex
8TOU	;	3.1	;	ACE2-peptide 2 complex crystal form 3
8TOS	;	2.35	;	ACE2-peptide 6 complex
8TOT	;	2.8	;	ACE2-peptide2 complex crystal form 2
7KMB	;	3.39	;	ACE2-RBD Focused Refinement Using Symmetry Expansion of Applied C3 for Triple ACE2-bound SARS-CoV-2 Trimer Spike at pH 7.4
7VX4	;	3.9	;	ACE2-RBD in SARS-CoV-2 Beta variant S-ACE2 complex
7VX5	;	3.8	;	ACE2-RBD in SARS-CoV-2 Kappa variant S-ACE2 complex
8I91	;	3.3	;	ACE2-SIT1 complex bound with proline
4P69	;	3.3	;	Acek (D477A) ICDH complex
6ZGQ	;	1.9	;	AceL NrdHF class 3 split intein GSH linked splice inactive variant - C124A, N146A
1TUY	;	3.0	;	Acetate Kinase complexed with ADP, AlF3 and acetate
1TUU	;	2.5	;	Acetate Kinase crystallized with ATPgS
2IIR	;	3.3	;	Acetate kinase from a hypothermophile Thermotoga maritima
4Z3A	;	1.72	;	Acetate-free structure of the enzyme-product complex resulting from TDG action on a GU mismatch
8B73	;	2.24	;	Acetivibrio clariflavus beta-1,4-xylanase of Glycoside Hydrolase Family 10 (AcXyn10A).
4WD1	;	1.903	;	Acetoacetyl-CoA Synthetase from Streptomyces lividans
2B9V	;	2.0	;	Acetobacter turbidans alpha-amino acid ester hydrolase
2B4K	;	3.3	;	Acetobacter turbidans alpha-amino acid ester hydrolase complexed with phenylglycine
1NX9	;	2.2	;	Acetobacter turbidans alpha-amino acid ester hydrolase S205A mutant complexed with ampicillin
1RYY	;	2.8	;	Acetobacter turbidans alpha-amino acid ester hydrolase Y206A mutant
1YVE	;	1.65	;	ACETOHYDROXY ACID ISOMEROREDUCTASE COMPLEXED WITH NADPH, MAGNESIUM AND INHIBITOR IPOHA (N-HYDROXY-N-ISOPROPYLOXAMATE)
1QMG	;	1.6	;	Acetohydroxyacid isomeroreductase complexed with its reaction product dihydroxy-methylvalerate, manganese and ADP-ribose.
4BT3	;	1.1	;	acetolactate decarboxylase with a bound (2R,3R)-2,3-Dihydroxy-2- methylbutanoic acid
4BT5	;	1.1	;	acetolactate decarboxylase with a bound (2S,3R)-2,3-Dihydroxy-2- methylbutanoic acid
4BT4	;	1.6	;	acetolactate decarboxylase with a bound (2S,3S)-2,3-Dihydroxy-2- methylbutanoic acid
4BT2	;	1.1	;	acetolactate decarboxylase with a bound 1,2-ETHANEDIOL
4BT6	;	1.6	;	acetolactate decarboxylase with a bound glycerol
4BT7	;	1.1	;	acetolactate decarboxylase with a bound phosphate ion
4RJK	;	2.5	;	Acetolactate synthase from Bacillus subtilis bound to LThDP - crystal form II
4RJI	;	3.2	;	Acetolactate synthase from Bacillus subtilis bound to ThDP - crystal form I
4RJJ	;	2.34	;	Acetolactate synthase from Bacillus subtilis bound to ThDP - crystal form II
5WDG	;	2.12	;	Acetolactate Synthase from Klebsiella pneumoniae in Complex with a Reaction Intermediate
5D6R	;	2.276	;	Acetolactate Synthase from Klebsiella pneumoniae in Complex with Mechanism-Based Inhibitor
5DX6	;	1.75	;	Acetolactate Synthase from Klebsiella pneumoniae soaked with beta-fluoropyruvate
7EHE	;	2.28	;	Acetolactate Synthase from Trichoderma harzianum
7EGV	;	2.54	;	Acetolactate Synthase from Trichoderma harzianum with inhibitor harzianic acid
1PG3	;	2.3	;	Acetyl CoA Synthetase, Acetylated on Lys609
1PG4	;	1.75	;	Acetyl CoA Synthetase, Salmonella enterica
5X6S	;	1.9	;	Acetyl xylan esterase from Aspergillus awamori
2XLC	;	2.7	;	Acetyl xylan esterase from Bacillus pumilus CECT5072 bound to paraoxon
2XLB	;	1.9	;	Acetyl xylan esterase from Bacillus pumilus without ligands
6AGQ	;	2.1	;	Acetyl xylan esterase from Paenibacillus sp. R4
7CW4	;	1.56	;	Acetyl-CoA acetyltransferase from Bacillus cereus ATCC 14579
7CW5	;	2.0	;	Acetyl-CoA acetyltransferase from Bacillus cereus ATCC 14579
1OD2	;	2.7	;	Acetyl-CoA Carboxylase Carboxyltransferase Domain
1OD4	;	2.7	;	Acetyl-CoA Carboxylase Carboxyltransferase Domain
1UYT	;	2.5	;	Acetyl-CoA carboxylase carboxyltransferase domain
1UYR	;	2.5	;	Acetyl-CoA Carboxylase Carboxyltransferase Domain in complex with inhibitor Diclofop
1UYS	;	2.8	;	Acetyl-CoA carboxylase carboxyltransferase domain in complex with inhibitor haloxyfop
1UYV	;	2.6	;	Acetyl-CoA carboxylase carboxyltransferase domain L1705I/V1967I mutant
7W5U	;	2.34	;	Acetyl-CoA Carboxylase-AccB
2P2J	;	2.3	;	Acetyl-CoA Synthetase, K609A mutation
2P2M	;	2.11	;	Acetyl-CoA Synthetase, R194A mutation
2P20	;	2.22	;	Acetyl-CoA Synthetase, R584A mutation
2P2Q	;	2.42	;	Acetyl-CoA Synthetase, R584E mutation
2P2B	;	2.2	;	Acetyl-CoA Synthetase, V386A mutation
2P2F	;	2.58	;	Acetyl-CoA Synthetase, wild-type with acetate, AMP, and CoA bound
2X2C	;	2.41	;	acetyl-CypA:cyclosporine complex
2X2D	;	1.95	;	acetyl-CypA:HIV-1 N-term capsid domain complex
1DM3	;	2.0	;	ACETYLATED BIOSYNTHETIC THIOLASE FROM ZOOGLOEA RAMIGERA IN COMPLEX WITH ACETYL-COA
6O2Q	;	3.7	;	Acetylated Microtubules
6O2T	;	4.1	;	Acetylated Microtubules
8FNZ	;	3.88	;	Acetylated tau repeat 1 and 2 fragment (AcR1R2)
5ZS7	;	2.68	;	Acetylation of lysine 100 in Phosphoglycerate mutase 1
5ZS8	;	2.2	;	Acetylation of lysine 100 of Phosphoglycerate mutase 1 complexed with KH_ol
2XNT	;	3.21	;	Acetylcholine binding protein (AChBP) as template for hierarchical in silico screening procedures to identify structurally novel ligands for the nicotinic receptors
2XNU	;	2.55	;	Acetylcholine binding protein (AChBP) as template for hierarchical in silico screening procedures to identify structurally novel ligands for the nicotinic receptors
2XNV	;	2.44	;	Acetylcholine binding protein (AChBP) as template for hierarchical in silico screening procedures to identify structurally novel ligands for the nicotinic receptors
1EEA	;	4.5	;	Acetylcholinesterase
1FSS	;	3.0	;	ACETYLCHOLINESTERASE (E.C. 3.1.1.7) COMPLEXED WITH FASCICULIN-II
1VOT	;	2.5	;	ACETYLCHOLINESTERASE (E.C. 3.1.1.7) COMPLEXED WITH HUPERZINE A
1OCE	;	2.7	;	ACETYLCHOLINESTERASE (E.C. 3.1.1.7) COMPLEXED WITH MF268
1GQS	;	3.0	;	ACETYLCHOLINESTERASE (E.C. 3.1.1.7) COMPLEXED WITH NAP
1GQR	;	2.2	;	ACETYLCHOLINESTERASE (E.C. 3.1.1.7) COMPLEXED WITH RIVASTIGMINE
5BWB	;	2.57	;	ACETYLCHOLINESTERASE (E.C. 3.1.1.7) FROM TORPEDO CALIFORNICA IN COMPLEX WITH THE BIS-IMIDAZOLIUM OXIME 2BIM-7
5BWC	;	2.45	;	ACETYLCHOLINESTERASE (E.C. 3.1.1.7) FROM TORPEDO CALIFORNICA IN COMPLEX WITH THE BIS-PYRIDINIUM OXIME ORTHO-7
1QTI	;	2.5	;	Acetylcholinesterase (E.C.3.1.1.7)
1AX9	;	2.8	;	ACETYLCHOLINESTERASE COMPLEXED WITH EDROPHONIUM, LAUE DATA
2ACK	;	2.4	;	ACETYLCHOLINESTERASE COMPLEXED WITH EDROPHONIUM, MONOCHROMATIC DATA
5FOQ	;	2.3	;	Acetylcholinesterase in complex with C7653
5DLP	;	2.7	;	Acetylcholinesterase Methylene Blue no PEG
5E2I	;	2.65	;	Acetylcholinesterase Methylene Blue no PEG
5E4J	;	2.54	;	Acetylcholinesterase Methylene Blue no PEG
5E4T	;	2.43	;	Acetylcholinesterase Methylene Blue with PEG
5IH7	;	2.4	;	Acetylcholinesterase of Torpedo californica in complex with the N-methyl-indoxylacetate hydrolysis products
2E7Z	;	1.26	;	Acetylene Hydratase from Pelobacter acetylenicus
7YC4	;	2.1	;	Acetylesterase (LgEstI) F207A
7YC0	;	2.0	;	Acetylesterase (LgEstI) W.T.
2X2W	;	2.0	;	Acetylglutamate kinase from Escherichia coli bound to N-acetyl-L-glutamyl-5-phosphate
1OHB	;	1.9	;	Acetylglutamate kinase from Escherichia coli complexed with ADP and sulphate
1OHA	;	1.9	;	Acetylglutamate kinase from Escherichia coli complexed with MgADP and N-acetyl-L-glutamate
1OH9	;	1.91	;	Acetylglutamate kinase from Escherichia coli complexed with MgADP, N-acetyl-L-glutamate and the transition-state mimic AlF4-
2WXB	;	2.0	;	Acetylglutamate kinase from Escherichia coli free of substrates
2BTY	;	2.75	;	Acetylglutamate kinase from Thermotoga maritima complexed with its inhibitor arginine
1VEF	;	1.35	;	Acetylornithine aminotransferase from Thermus thermophilus HB8
1WKG	;	2.25	;	Acetylornithine aminotransferase from thermus thermophilus HB8
1WKH	;	2.25	;	Acetylornithine aminotransferase from thermus thermophilus HB8
7RSF	;	2.13	;	Acetylornithine deacetylase from Escherichia coli
2FBM	;	2.28	;	Acetyltransferase domain of CDY1
2OU2	;	2.3	;	Acetyltransferase domain of Human HIV-1 Tat interacting protein, 60kDa, isoform 3
4M98	;	1.67	;	Acetyltransferase domain of PglB from Neisseria gonorrhoeae FA1090
4M99	;	2.6	;	Acetyltransferase domain of PglB from Neisseria gonorrhoeae FA1090 in complex with acetyl coenzyme A
3IWG	;	2.3	;	Acetyltransferase from GNAT family from Colwellia psychrerythraea.
2ATR	;	2.01	;	Acetyltransferase, GNAT family protein SP0256 from Streptococcus pneumoniae TIGR4
7Q0Q	;	1.96	;	Acetyltrasferase(3) type IIIa in complex with 3-N-methyl-nemycin B
7Q10	;	1.82	;	Acetyltrasferase(3) type IIIa in complex with 3-N-methyl-nemycin B
7Q1D	;	1.43	;	Acetyltrasferase(3) type IIIa in complex with 3-N-methyl-nemycin B
7Q1X	;	1.45	;	Acetyltrasferase(3) type IIIa in complex with neomycin B
1G66	;	0.9	;	ACETYLXYLAN ESTERASE AT 0.90 ANGSTROM RESOLUTION
7FBW	;	1.9	;	Acetylxylan esterase from Caldanaerobacter subterraneus subsp. tengcongensis
7Y51	;	2.45	;	Acetylxylan esterase from Caldanaerobacter subterraneus subsp. tengcongensis TTE0866 delta100 mutant
1BS9	;	1.1	;	ACETYLXYLAN ESTERASE FROM P. PURPUROGENUM REFINED AT 1.10 ANGSTROMS
2UZ6	;	2.4	;	AChBP-targeted a-conotoxin correlates distinct binding orientations with nAChR subtype selectivity.
2W6C	;	2.69	;	ACHE IN COMPLEX WITH A BIS-(-)-NOR-MEPTAZINOL DERIVATIVE
1U65	;	2.61	;	Ache W. CPT-11
8EU6	;	3.0	;	Acheta domesticus segmented densovirus high buoyancy fraction 1 (HB1) empty capsid structure
8EU5	;	3.1	;	Acheta domesticus segmented densovirus high buoyancy fraction 2 empty capsid structure
8EU7	;	3.3	;	Acheta domesticus segmented densovirus VP-ORF1 virus-like particle
8ERK	;	2.5	;	Acheta domesticus segmented densovirus, high buoyancy (HB) capsid, a mixed population of empty and immature full particles
8ER8	;	2.3	;	Acheta domesticus segmented densovirus, mature virion capsid structure
3DPD	;	2.85	;	Achieving multi-isoform PI3K inhibition in a series of substituted 3,4-Dihydro-2H-benzo[1,4]oxazines
2IGX	;	1.7	;	Achiral, Cheap and Potent Inhibitors of Plasmepsins II
2IGY	;	2.6	;	Achiral, Cheap and Potent Inhibitors of Plasmepsins II
6GTI	;	1.5	;	Achromobacter cycloclastes copper nitrite reductase at pH 5.0
6GTK	;	1.5	;	Achromobacter cycloclastes copper nitrite reductase at pH 5.5
6GTL	;	1.5	;	Achromobacter cycloclastes copper nitrite reductase at pH 6.0
6GTN	;	1.5	;	Achromobacter cycloclastes copper nitrite reductase at pH 6.5
5ZUR	;	1.95	;	Achromobacter Dh1f Bacterioferritin
1YPP	;	2.4	;	ACID ANHYDRIDE HYDROLASE
5U84	;	2.34	;	Acid ceramidase (ASAH1, aCDase) from common minke whale, Cys143Ala, uncleaved
5U81	;	1.4	;	Acid ceramidase (ASAH1, aCDase) from naked mole rat, Cys143Ala, uncleaved
8GDL	;	1.75	;	Acid phosphatase pseudoenzyme from flea
1BXO	;	0.95	;	ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL CYCLO[(2S)-2-[[(1R)-1-(N-(L-N-(3-METHYLBUTANOYL)VALYL-L-ASPARTYL)AMINO)-3-METHYLBUT YL] HYDROXYPHOSPHINYLOXY]-3-(3-AMINOMETHYL) PHENYLPROPANOATE
2WEC	;	1.5	;	ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL(2S)-[1-(((N-(1-NAPHTHALENEACETYL))-L-VALYL)AMINOMETHYL)HYDROXY PHOSPHINYLOXY]-3-PHENYLPROPANOATE, SODIUM SALT
2WEB	;	1.5	;	ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL(2S)-[1-(((N-FORMYL)-L-VALYL)AMINO-2-(2-NAPHTHYL)ETHYL)HYDROXYPHOSPHINYLOXY]-3-PHENYLPROPANOATE, SODIUM SALT
2WEA	;	1.25	;	ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL[CYCLO-7[(2R)-((N-VALYL) AMINO)-2-(HYDROXYL-(1S)-1-METHYOXYCARBONYL-2-PHENYLETHOXY) PHOSPHINYLOXY-ETHYL]-1-NAPHTHALENEACETAMIDE], SODIUM SALT
2WED	;	1.5	;	ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE MACROCYCLIC INHIBITOR:METHYL[CYCLO-7[(2R)-((N-VALYL)AMINO)-2-(HYDROXYL-(1S)-1-METHYOXYCARBONYL-2-PHENYLETHOXY)PHOSPHINYLOXY-ETHYL]-1-NAPHTHALENEACETAMIDE], SODIUM SALT
1BXQ	;	1.41	;	ACID PROTEINASE (PENICILLOPEPSIN) COMPLEX WITH PHOSPHONATE INHIBITOR.
2NT0	;	1.79	;	Acid-beta-glucosidase low pH, glycerol bound
2V3F	;	1.95	;	acid-beta-glucosidase produced in carrot
2V3D	;	1.96	;	acid-beta-glucosidase with N-butyl-deoxynojirimycin
2V3E	;	2.0	;	acid-beta-glucosidase with N-nonyl-deoxynojirimycin
5Y00	;	1.6	;	Acid-tolerant monomeric GFP, Gamillus, fluorescence (ON) state
5Y01	;	2.65	;	Acid-tolerant monomeric GFP, Gamillus, non-fluorescence (OFF) state
3K1X	;	1.98	;	Acidic Fibroblast Growth Factor (FGF-1) complexed with dobesilate
3JUT	;	2.25	;	Acidic Fibroblast Growth Factor (FGF-1) complexed with gentisic acid
2K43	;		;	Acidic fibroblast growth factor solution structure in the FGF-1-C2A binary complex: key component in the fibroblast growthfactor non-classical pathway
3FXY	;	2.0	;	Acidic Mammalian Chinase, Catalytic Domain
7WG7	;	4.0	;	Acidic Omicron Spike Trimer
1PSJ	;	2.0	;	ACIDIC PHOSPHOLIPASE A2 FROM AGKISTRODON HALYS PALLAS
1GP7	;	2.6	;	Acidic Phospholipase A2 from venom of Ophiophagus Hannah
2HCT	;	1.95	;	Acidic residues at the active sites of CD38 and ADP-ribosyl cyclase determine NAAPD synthesis and hydrolysis activities
7DN2	;	2.7	;	Acidic stable capsid structure of Helicobacter pylori bacteriophage KHP30
8J2Y	;	2.3	;	Acidimicrobiaceae bacterium photocobilins protein, dark state
8DNA	;	2.77	;	Acidipropionibacterium acidipropionici encapsulin in a closed state at pH 3.0
8DN9	;	2.9	;	Acidipropionibacterium acidipropionici encapsulin in a closed state at pH 7.5
8DNL	;	3.32	;	Acidipropionibacterium acidipropionici encapsulin in an open state at pH 7.5
1H1O	;	2.13	;	Acidithiobacillus ferrooxidans cytochrome c4 structure supports a complex-induced tuning of electron transfer
1ECE	;	2.4	;	ACIDOTHERMUS CELLULOLYTICUS ENDOCELLULASE E1 CATALYTIC DOMAIN IN COMPLEX WITH A CELLOTETRAOSE
2WT9	;	1.65	;	Acinetobacter baumanii nicotinamidase pyrazinamidease
2WTA	;	1.7	;	Acinetobacter baumanii nicotinamidase pyrazinamidease
4WM9	;	2.4	;	Acinetobacter baumanii OXA-24 complex with Avibactam
8T6R	;	1.78	;	Acinetobacter baumannii 118362 family 2A cargo-loaded encapsulin shell
8GPM	;	1.7	;	Acinetobacter baumannii carbonic anhydrase
8GPP	;	2.09	;	Acinetobacter baumannii carbonic anhydrase PaaY
7UT5	;	1.4	;	Acinetobacter baumannii dihydroorotate dehydrogenase bound with inhibitor DSM186
7PQL	;	1.6	;	Acinetobacter baumannii DNA gyrase B 23kDa ATPase subdomain complexed with EBL2704
7PQM	;	1.55	;	Acinetobacter baumannii DNA gyrase B 23kDa ATPase subdomain complexed with EBL2888
7PQI	;	1.9	;	Acinetobacter baumannii DNA gyrase B 23kDa ATPase subdomain complexed with novobiocin
7CCH	;	2.848	;	Acinetobacter baumannii histidine kinase AdeS
8DA2	;	2.6	;	Acinetobacter baumannii L,D-transpeptidase
7ESJ	;	2.06	;	Acinetobacter baumannii membrane-bound lytic murein transglycosylase A
7B8Q	;	3.84	;	Acinetobacter baumannii multidrug transporter AdeB in L*OO state
7B8P	;	3.54	;	Acinetobacter baumannii multidrug transporter AdeB in OOO state
5ZC2	;	2.898	;	Acinetobacter baumannii p-hydroxyphenylacetate 3-hydroxylase (HPAH), reductase component (C1)
7CCI	;	1.65	;	Acinetobacter baumannii response regulator AdeR with disordered N terminus
3ZPC	;	2.2	;	Acinetobacter baumannii RibD, form 1
3ZPG	;	1.99	;	Acinetobacter baumannii RibD, form 2
6YPU	;	2.9	;	Acinetobacter baumannii ribosome-amikacin complex - 30S subunit body
6YS5	;	3.0	;	Acinetobacter baumannii ribosome-amikacin complex - 30S subunit head
6YHS	;	2.7	;	Acinetobacter baumannii ribosome-amikacin complex - 50S subunit
6YT9	;	2.7	;	Acinetobacter baumannii ribosome-tigecycline complex - 30S subunit body
6YTF	;	3.0	;	Acinetobacter baumannii ribosome-tigecycline complex - 30S subunit head
6YSI	;	2.5	;	Acinetobacter baumannii ribosome-tigecycline complex - 50S subunit
4W98	;	1.43	;	Acinetobacter baumannii SDF NDK
4WBF	;	2.64	;	Acinetobacter baumannii SDF NDK
7E52	;	1.9	;	Acinetobacter baumannii Thioredoxin reductase
6P8T	;	3.15	;	Acinetobacter baumannii tRNA synthetase in complex with compound 1
6SZG	;	1.84	;	Acinetobacter baumannii undecaprenyl pyrophosphate synthase (AB-UppS) in complex with GR839 and GSK513
6SZH	;	1.65	;	Acinetobacter baumannii undecaprenyl pyrophosphate synthase (AB-UppS) in complex with GW197
8UFG	;	3.1	;	Acinetobacter baylyi LptB2FG bound to Acinetobacter baylyi lipopolysaccharide
8UFH	;	3.2	;	Acinetobacter baylyi LptB2FG bound to Acinetobacter baylyi lipopolysaccharide and a macrocyclic peptide
8FRL	;	3.2	;	Acinetobacter baylyi LptB2FG bound to lipopolysaccharide and a macrocyclic peptide
8FRO	;	3.25	;	Acinetobacter baylyi LptB2FG bound to lipopolysaccharide and a macrocyclic peptide
8FRN	;	3.3	;	Acinetobacter baylyi LptB2FG bound to lipopolysaccharide and Zosurabalpin
8FRM	;	3.14	;	Acinetobacter baylyi LptB2FG bound to lipopolysaccharide.
8FRP	;	3.8	;	Acinetobacter baylyi LptB2FGC
8TOB	;	3.14	;	Acinetobacter GP16 Type IV pilus
7D0A	;	4.0	;	Acinetobacter MlaFEDB complex in ADP-vanadate trapped Vclose conformation
7D08	;	4.0	;	Acinetobacter MlaFEDB complex in ATP-bound Vtrans1 conformation
7D09	;	3.6	;	Acinetobacter MlaFEDB complex in ATP-bound Vtrans2 conformation
8TOC	;	3.11	;	Acinetobacter phage AP205
8TWC	;	3.0	;	Acinetobacter phage AP205 T=3 VLP
8TW2	;	3.39	;	Acinetobacter phage AP205 T=4 VLP
3WPA	;	1.79	;	Acinetobacter sp. Tol 5 AtaA C-terminal stalk_FL fused to GCN4 adaptors (CstalkFL)
3WP8	;	1.97	;	Acinetobacter sp. Tol 5 AtaA C-terminal Ylhead fused to GCN4 adaptors (Chead)
3WPR	;	1.899	;	Acinetobacter sp. Tol 5 AtaA N-terminal half of C-terminal stalk fused to GCN4 adaptors (CstalkN)
3WPO	;	2.397	;	Acinetobacter sp. Tol 5 AtaA YDD-DALL3 domains in C-terminal stalk fused to GCN4 adaptors (CstalkC1i)
3WQA	;	2.401	;	Acinetobacter sp. Tol 5 AtaA YDD-DALL3 domains in C-terminal stalk fused to GCN4 adaptors (CstalkC1ii)
3WPP	;	1.952	;	Acinetobacter sp. Tol 5 AtaA YDD-DALL3 domains in C-terminal stalk fused to GCN4 adaptors (CstalkC1iii)
8G9M	;	2.5	;	Acinetobacter_baumannii short-chain dehydrogenase
4QGM	;	2.97	;	Acireductone dioxygenase from Bacillus anthracis with cadmium ion in active center
4QGL	;	2.61	;	Acireductone dioxygenase from Bacillus anthracis with three cadmium ions
4ID7	;	3.0	;	ACK1 kinase in complex with the inhibitor cis-3-[8-amino-1-(4-phenoxyphenyl)imidazo[1,5-a]pyrazin-3-yl]cyclobutanol
7YVV	;	2.1	;	AcmP1, R-4-hydroxymandelate synthase
7K12	;	2.17	;	ACMSD in complex with diflunisal
7K13	;	1.83	;	ACMSD in complex with diflunisal derivative 14
1B0M	;	2.5	;	ACONITASE R644Q:FLUOROCITRATE COMPLEX
5F81	;	2.13	;	Acoustic injectors for drop-on-demand serial femtosecond crystallography
5HL4	;	2.2	;	Acoustic injectors for drop-on-demand serial femtosecond crystallography
5HQD	;	2.52	;	Acoustic injectors for drop-on-demand serial femtosecond crystallography
4P2E	;	1.6	;	Acoustic transfer of protein crystals from agar pedestals to micromeshes for high throughput screening of heavy atom derivatives
3RTO	;	1.8	;	Acoustically mounted porcine insulin microcrystals yield an X-ray SAD structure
7X5J	;	2.1	;	ACP-dependent oxoacyl reductase
8CUY	;	2.4	;	ACP1-KS-AT domains of mycobacterial Pks13
8CV1	;	2.6	;	ACP1-KS-AT domains of mycobacterial Pks13
6FIK	;	7.1	;	ACP2 crosslinked to the KS of the loading/condensing region of the CTB1 PKS
9ATX	;	2.11	;	AcpB protein from Bacillus anthracis, N-terminal part
6S2C	;	3.2	;	Acquired functional capsid structures in metazoan totivirus-like dsRNA virus.
7B5P	;	3.2	;	AcrB in cycloalkane amphipol
6ZOE	;	2.85	;	AcrB-F563A symmetric T protomer
452D	;	1.6	;	ACRIDINE BINDING TO DNA
7CHQ	;	1.33	;	AcrIE2
7XI1	;	2.53	;	AcrIF 24
7CHR	;	1.21	;	AcrIF9
8JFU	;	3.15	;	AcrIIA15 in complex with palindromic DNA substrate
7F7P	;	2.03	;	AcrIIC4
6PX2	;	2.4	;	Acropora millepora GAPDH
1C3H	;	2.1	;	ACRP30 CALCIUM COMPLEX
6A4L	;	2.8	;	AcrR from Mycobacterium tuberculosis
6A4W	;	2.587	;	AcrR from Mycobacterium tuberculosis
5GXF	;	2.288	;	Acryloyl-CoA reductase AcuI from Ruegeria pomeroyi DSS-3
7U5G	;	1.84	;	ACS122 Fab
1ZPV	;	1.9	;	ACT domain protein from Streptococcus pneumoniae
8TRM	;	2.5	;	Actin 1 from T. gondii in filaments bound to MgADP
8TRN	;	3.0	;	Actin 1 from T. gondii in filaments bound to MgADP and jasplakinolide
5BVR	;	1.46	;	Actin binding domain of alpha-actinin from Schizosaccharomyces pombe
1QAG	;	3.0	;	Actin binding region of the dystrophin homologue utrophin
4Z94	;	2.4	;	Actin Complex With a Chimera of Tropomodulin-1 and Leiomodin-1 Actin-Binding Site 2
3TU5	;	3.0	;	Actin complex with Gelsolin Segment 1 fused to Cobl segment
1RDW	;	2.3	;	Actin Crystal Dynamics: Structural Implications for F-actin Nucleation, Polymerization and Branching Mediated by the Anti-parallel Dimer
1RFQ	;	3.0	;	Actin Crystal Dynamics: Structural Implications for F-actin Nucleation, Polymerization and Branching Mediated by the Anti-parallel Dimer
2Q36	;	2.5	;	Actin Dimer Cross-linked between Residues 191 and 374 and complexed with Kabiramide C
2Q1N	;	2.7	;	Actin Dimer Cross-linked Between Residues 41 and 374
2Q31	;	2.7	;	Actin Dimer Cross-linked Between Residues 41 and 374 and proteolytically cleaved by subtilisin between residues 47 and 48.
3CJC	;	3.9	;	Actin dimer cross-linked by V. cholerae MARTX toxin and complexed with DNase I and Gelsolin-segment 1
3CJB	;	3.21	;	Actin dimer cross-linked by V. cholerae MARTX toxin and complexed with Gelsolin-segment 1
3B5U	;	9.5	;	Actin filament model from extended form of acromsomal bundle in the Limulus sperm
3B63	;	9.5	;	Actin filament model in the extended form of acromsomal bundle in the Limulus sperm
2Y83	;	22.9	;	Actin filament pointed end
6ABS	;	2.2	;	Actin interacting protein 5 (Aip5, mutant)
6ABR	;	2.002	;	Actin interacting protein 5 (Aip5, wild type)
6U96	;	3.8	;	Actin phalloidin at BeFx state
2A42	;	1.85	;	Actin-DNAse I Complex
1CJA	;	2.9	;	ACTIN-FRAGMIN KINASE, CATALYTIC DOMAIN FROM PHYSARUM POLYCEPHALUM
5AEY	;	4.3	;	actin-like ParM protein bound to AMPPNP
3P5U	;	1.5	;	Actinidin from Actinidia arguta planch (Sarusashi)
3P5V	;	1.9	;	Actinidin from Actinidia arguta planch (Sarusashi)
3P5W	;	2.2	;	Actinidin from Actinidia arguta planch (Sarusashi)
3P5X	;	2.2	;	Actinidin from Actinidia arguta planch (Sarusashi)
6C0A	;		;	Actinin-1 EF-Hand bound to the Cav1.2 IQ Motif
5APP	;	2.3	;	Actinobacillus actinomycetemcomitans OMP100 residues 133-198 fused to GCN4 adaptors
6DQX	;	1.76	;	Actinobacillus ureae class Id ribonucleotide reductase alpha subunit
3E35	;	2.2	;	Actinobacteria-specific protein of unknown function, SCO1997
7PT3	;	1.625	;	Actinobacterial 2-hydroxyacyl-CoA lyase (AcHACL) mutant E493A structure in complex with substrate 2-HIB-CoA and inactive cofactor 3-deaza-ThDP
7PT2	;	1.762	;	Actinobacterial 2-hydroxyacyl-CoA lyase (AcHACL) mutant E493Q structure in complex with substrate 2-HIB-CoA and inactive cofactor 3-deaza-ThDP
7PT4	;	1.64	;	Actinobacterial 2-hydroxyacyl-CoA lyase (AcHACL) structure in complex with a covalently bound reaction intermediate as well as products formyl-CoA and acetone
7PT1	;	1.553	;	Actinobacterial 2-hydroxyacyl-CoA lyase (AcHACL) structure in complex with substrate 2-HIB-CoA and inactive cofactor 3-deaza-ThDP
5AA5	;	2.497	;	Actinobacterial-type NiFe-hydrogenase from Ralstonia eutropha H16 at 2.85 Angstrom resolution
1MNV	;	2.6	;	Actinomycin D binding to ATGCTGCAT
1I3W	;	1.7	;	ACTINOMYCIN D BINDING TO CGATCGATCG
6JET	;	2.6	;	Actinonin bound crystal structure of class I type a peptide deformylase from Acinetobacter baumannii
6JF3	;	2.01	;	Actinonin bound crystal structure of class I type b peptide deformylase from Acinetobacter baumannii
6JFC	;	2.04	;	Actinonin bound crystal structure of class I type b peptide deformylase from Pseudomonas aeruginosa
2RHC	;	2.1	;	Actinorhodin ketordeuctase, actKR, with NADP+ and Inhibitor Emodin
2RH4	;	2.3	;	Actinorhodin ketoreductase, actKR, with NADPH and Inhibitor Emodin
3QRW	;	2.792	;	Actinorhodin Polyketide Ketoreductase Mutant P94L bound to NADPH
3CSD	;	2.29	;	Actinorhodin Polyketide Ketoreductase Mutant P94L bound to NADPH and the Inhibitor Emodin
3RI3	;	2.292	;	Actinorhodin Polyketide Ketoreductase Mutant P94L bound to NADPH and the Inhibitor Emodin
1XR3	;	2.71	;	Actinorhodin Polyketide Ketoreductase with NADP and the Inhibitor Isoniazid bound
1X7G	;	2.3	;	Actinorhodin Polyketide Ketoreductase, act KR, with NADP bound
1X7H	;	2.3	;	Actinorhodin Polyketide Ketoreductase, with NADPH bound
1AF8	;		;	ACTINORHODIN POLYKETIDE SYNTHASE ACYL CARRIER PROTEIN FROM STREPTOMYCES COELICOLOR A3(2), NMR, 24 STRUCTURES
2AF8	;		;	ACTINORHODIN POLYKETIDE SYNTHASE ACYL CARRIER PROTEIN FROM STREPTOMYCES COELICOLOR A3(2), NMR, MINIMIZED AVERAGE STRUCTURE
1ACX	;	2.0	;	ACTINOXANTHIN STRUCTURE AT THE ATOMIC LEVEL (RUSSIAN)
4Y5Q	;	2.0	;	Activated Calcium-Dependent Protein Kinase 1 from Cryptosporidium parvum (CpCDPK1) in complex with AMP
3NCG	;	2.49	;	Activated Calcium-Dependent Protein Kinase 1 from Cryptosporidium parvum (CpCDPK1) in complex with bumped kinase inhibitor NM-PP1
3MWU	;	1.98	;	Activated Calcium-Dependent Protein Kinase 1 from Cryptosporidium parvum (CpCDPK1) in complex with bumped kinase inhibitor RM-1-95
4A0Q	;	1.9	;	Activated Conformation of Integrin alpha1 I-Domain mutant
2WB4	;	2.8	;	activated diguanylate cyclase PleD in complex with c-di-GMP
8G33	;	2.49	;	Activated form of a CDCL long protein
7LZA	;	2.03	;	Activated form of VanR from S. coelicolor
5WEO	;	4.2	;	Activated GluA2 complex bound to glutamate, cyclothiazide, and STZ in digitonin
6ET7	;	2.852	;	Activated heterodimer of the bacteriophytochrome regulated diguanylyl cyclase variant - S505V A526V - from Idiomarina species A28L
6VXT	;	1.74	;	Activated Nitrogenase MoFe-protein from Azotobacter vinelandii
2FJU	;	2.2	;	Activated Rac1 bound to its effector phospholipase C beta 2
2V0N	;	2.71	;	ACTIVATED RESPONSE REGULATOR PLED IN COMPLEX WITH C-DIGMP AND GTP- ALPHA-S
1BWV	;	2.4	;	Activated Ribulose 1,5-Bisphosphate Carboxylase/Oxygenase (RUBISCO) Complexed with the Reaction Intermediate Analogue 2-Carboxyarabinitol 1,5-Bisphosphate
7SS5	;	2.7	;	Activated SgrAI endonuclease DNA-bound dimer with Ca2+ and intact primary site DNA
1UPM	;	2.3	;	ACTIVATED SPINACH RUBISCO COMPLEXED WITH 2-CARBOXYARABINITOL 2 BISPHOSPHAT AND CA2+.
8RUC	;	1.6	;	ACTIVATED SPINACH RUBISCO COMPLEXED WITH 2-CARBOXYARABINITOL BISPHOSPHATE
1RXO	;	2.2	;	ACTIVATED SPINACH RUBISCO IN COMPLEX WITH ITS SUBSTRATE RIBULOSE-1,5-BISPHOSPHATE AND CALCIUM
1AA1	;	2.2	;	ACTIVATED SPINACH RUBISCO IN COMPLEX WITH THE PRODUCT 3-PHOSPHOGLYCERATE
7T37	;	3.7	;	Activated state of 2-APB and CBD-bound wildtype rat TRPV2 in nanodiscs
7N0N	;	4.15	;	Activated state of 2-APB-bound wildtype rat TRPV2 in nanodiscs
5UX7	;	2.69	;	Activated state yeast Glycogen Synthase in complex with UDP-xylose
5UW0	;	2.73	;	Activated state yGsy2p in complex with UDP-2-fluoro-2-deoxy-glucose
5UW1	;	3.26	;	Activated state yGsy2p in complex with UDP-galactose
3F75	;	1.99	;	Activated Toxoplasma gondii cathepsin L (TgCPL) in complex with its propeptide
6IBL	;	2.7	;	ACTIVATED TURKEY BETA1 ADRENOCEPTOR WITH BOUND AGONIST FORMOTEROL AND NANOBODY Nb80
6H7J	;	2.8	;	ACTIVATED TURKEY BETA1 ADRENOCEPTOR WITH BOUND AGONIST ISOPRENALINE AND NANOBODY Nb80
6H7L	;	2.7	;	ACTIVATED TURKEY BETA1 ADRENOCEPTOR WITH BOUND PARTIAL AGONIST DOBUTAMINE AND NANOBODY Nb6B9
6H7M	;	2.76	;	ACTIVATED TURKEY BETA1 ADRENOCEPTOR WITH BOUND PARTIAL AGONIST SALBUTAMOL AND NANOBODY Nb6B9
6H7N	;	2.5	;	ACTIVATED TURKEY BETA1 ADRENOCEPTOR WITH BOUND PARTIAL AGONIST XAMOTEROL AND NANOBODY Nb6B9
6H7O	;	2.8	;	ACTIVATED TURKEY BETA1 ADRENOCEPTOR WITH BOUND WEAK PARTIAL AGONIST CYANOPINDOLOL AND NANOBODY Nb6B9
1AUS	;	2.2	;	ACTIVATED UNLIGANDED SPINACH RUBISCO
5UW4	;	2.98	;	Activated yeast Glycogen Synthase in complex with UDP glucosamine
1BJA	;	2.19	;	ACTIVATION DOMAIN OF THE PHAGE T4 TRANSCRIPTION FACTOR MOTA
1AVF	;	2.36	;	ACTIVATION INTERMEDIATE 2 OF HUMAN GASTRICSIN FROM HUMAN STOMACH
2W22	;	2.2	;	Activation Mechanism of Bacterial Thermoalkalophilic Lipases
8HQN	;	3.0	;	Activation mechanism of GPR132 by 9(S)-HODE
8HVI	;	3.04	;	Activation mechanism of GPR132 by compound NOX-6-7
8HQM	;	2.95	;	Activation mechanism of GPR132 by NPGLY
3MJI	;	2.5	;	Activation of catalytic cysteine without a base in a Mutant Penicillin Acylase Precursor
3J9Z	;	3.6	;	Activation of GTP Hydrolysis in mRNA-tRNA Translocation by Elongation Factor G
3JA1	;	3.6	;	Activation of GTP Hydrolysis in mRNA-tRNA Translocation by Elongation Factor G
2FNM	;	1.8	;	Activation of human carbonic anhdyrase II by exogenous proton donors
2FNK	;	1.8	;	Activation of Human Carbonic Anhydrase II by exogenous proton donors
2FNN	;	1.8	;	Activation of human carbonic anhydrase II by exogenous proton donors
5B3J	;	2.9	;	Activation of NMDA receptors and the mechanism of inhibition by ifenprodil
2VTX	;	2.5	;	ACTIVATION OF NUCLEOPLASMIN, AN OLIGOMERIC HISTONE CHAPERONE, CHALLENGES ITS STABILITY
1GQT	;	2.34	;	Activation of Ribokinase by Monovalent Cations
6EBR	;	1.816	;	Activation of RR02 bound to BeF3
3R8D	;	2.8	;	Activation of the Human Nuclear Xenobiotic Receptor PXR by the Reverse Transcriptase-Targeted Anti-HIV Drug PNU-142721
4EHT	;	1.95	;	Activator of the 2-Hydroxyisocaproyl-CoA dehydratase from Clostridium difficile with bound ADP
4EHU	;	1.6	;	Activator of the 2-Hydroxyisocaproyl-CoA Dehydratase from Clostridium difficile with bound ADPNP
4EIA	;	3.0	;	Activator of the 2-Hydroxyisocaproyl-CoA Dehydratase from Clostridium difficile without nucleotide
3GQY	;	1.85	;	Activator-Bound Structure of Human Pyruvate Kinase M2
3GR4	;	1.6	;	Activator-Bound Structure of Human Pyruvate Kinase M2
3H6O	;	2.0	;	Activator-Bound Structure of Human Pyruvate Kinase M2
3ME3	;	1.95	;	Activator-Bound Structure of Human Pyruvate Kinase M2
3U2Z	;	2.1	;	Activator-Bound Structure of Human Pyruvate Kinase M2
6WNW	;	3.2	;	Active 70S ribosome without free 5S rRNA and bound with A- and P- tRNA
5TV1	;	2.4	;	active arrestin-3 with inositol hexakisphosphate
4Z0Y	;	1.6	;	Active aurone synthase (polyphenol oxidase), copper B : sulfohistidine ~ 1.4 : 1
5TSU	;	2.2	;	Active conformation for Engineered human cystathionine gamma lyase (E59N, R119L, E339V) to depleting methionine
7KXZ	;	2.4	;	Active conformation of EGFR kinase in complex with BI-4020
1RQI	;	2.42	;	Active Conformation of Farnesyl Pyrophosphate Synthase Bound to Isopentyl Pyrophosphate and Dimethylallyl S-Thiolodiphosphate
1RQJ	;	1.95	;	Active Conformation of Farnesyl Pyrophosphate Synthase Bound to Isopentyl Pyrophosphate and Risedronate
6KUI	;	2.33	;	Active conformation of HslV from Staphylococcus aureus.
2QY0	;	2.6	;	Active dimeric structure of the catalytic domain of C1r reveals enzyme-product like contacts
6G0I	;	2.0	;	Active Fe-PP1
8DHB	;	3.53	;	Active FLCN GAP complex
5DU3	;	2.1	;	Active form of human C1-inhibitor
1DVM	;	2.4	;	ACTIVE FORM OF HUMAN PAI-1
4U7O	;	2.395	;	Active histidine kinase bound with ATP
5JUY	;	4.1	;	Active human apoptosome with procaspase-9
5DUQ	;	2.9	;	Active human c1-inhibitor in complex with dextran sulfate
7BW0	;	3.9	;	Active human TGR5 complex with a synthetic agonist 23H
1KYA	;	2.4	;	ACTIVE LACCASE FROM TRAMETES VERSICOLOR COMPLEXED WITH 2,5-XYLIDINE
7PIV	;	2.86	;	Active Melanocortin-4 receptor (MC4R)- Gs protein complex bound to agonist NDP-alpha-MSH at 2.86 A resolution.
1H9B	;	2.4	;	ACTIVE MUTANT (Q365->C) OF GLUCOSE 6-PHOSPHATE DEHYDROGENASE FROM LEUCONOSTOC MESENTEROIDES
1H93	;	2.2	;	ACTIVE MUTANT (S215->C) OF GLUCOSE 6-PHOSPHATE DEHYDROGENASE FROM LEUCONOSTOC MESENTEROIDES
5OEF	;	2.05	;	Active semisynthetic [FeFe]-hydrogenase CpI with aza-diselenato-bridged [2Fe] cofactor
4XDC	;	1.63	;	Active semisynthetic [FeFe]-hydrogenase CpI with aza-dithiolato-bridged [2Fe] cofactor
4Z40	;	2.35	;	Active site complex BamBC of Benzoyl Coenzyme A reductase as isolated
4Z3W	;	2.208	;	Active site complex BamBC of Benzoyl Coenzyme A reductase in complex with 1,5 Dienoyl-CoA
4Z3X	;	1.85	;	Active site complex BamBC of Benzoyl Coenzyme A reductase in complex with 1-Monoenoyl-CoA
4Z3Y	;	2.359	;	Active site complex BamBC of Benzoyl Coenzyme A reductase in complex with Benzoyl-CoA
4Z3Z	;	2.666	;	Active site complex BamBC of Benzoyl Coenzyme A reductase in complex with Zinc
1OAJ	;	1.73	;	Active site copper and zinc ions modulate the quaternary structure of prokaryotic Cu,Zn superoxide dismutase
1OAL	;	1.5	;	Active site copper and zinc ions modulate the quaternary structure of prokaryotic Cu,Zn superoxide dismutase
2D26	;	3.3	;	Active site distortion is sufficient for proteinase inhibit second crystal structure of covalent serpin-proteinase complex
2AUN	;	2.4	;	Active site His285Ala mutant of LD-carboxypeptidase
4DEF	;	1.64	;	Active site loop dynamics of a class IIa fructose 1,6-bisphosphate aldolase from M. tuberculosis
4DEL	;	1.58	;	Active site loop dynamics of a class IIa fructose 1,6-bisphosphate aldolase from M. tuberculosis
4A7Y	;	2.8	;	Active site metal depleted aldos-2-ulose dehydratase
1FPC	;	2.3	;	ACTIVE SITE MIMETIC INHIBITION OF THROMBIN
3HAT	;	2.5	;	ACTIVE SITE MIMETIC INHIBITION OF THROMBIN
1E7M	;	2.54	;	ACTIVE SITE MUTANT (D177->N) OF GLUCOSE 6-PHOSPHATE DEHYDROGENASE FROM LEUCONOSTOC MESENTEROIDES
1E7Y	;	2.48	;	ACTIVE SITE MUTANT (D177->N) OF GLUCOSE 6-PHOSPHATE DEHYDROGENASE FROM LEUCONOSTOC MESENTEROIDES COMPLEXED WITH SUBSTRATE AND NADPH
1SNM	;	1.74	;	ACTIVE SITE MUTANT GLU-43 (RIGHT ARROW) ASP IN STAPHYLOCOCCAL NUCLEASE DISPLAYS NONLOCAL STRUCTURAL CHANGES
2JCS	;	2.5	;	Active site mutant of dNK from D. melanogaster with dTTP bound
3IQM	;	3.4	;	Active site mutants of B. subtilis SecA
3IQY	;	3.3	;	Active site mutants of B. subtilis SecA
1HM2	;	2.0	;	ACTIVE SITE OF CHONDROITINASE AC LYASE REVEALED BY THE STRUCTURE OF ENZYME-OLIGOSACCHARIDE COMPLEXES AND MUTAGENESIS
1HM3	;	2.1	;	ACTIVE SITE OF CHONDROITINASE AC LYASE REVEALED BY THE STRUCTURE OF ENZYME-OLIGOSACCHARIDE COMPLEXES AND MUTAGENESIS
1HMU	;	2.0	;	ACTIVE SITE OF CHONDROITINASE AC LYASE REVEALED BY THE STRUCTURE OF ENZYME-OLIGOSACCHARIDE COMPLEXES AND MUTAGENESIS
1HMW	;	2.3	;	ACTIVE SITE OF CHONDROITINASE AC LYASE REVEALED BY THE STRUCTURE OF ENZYME-OLIGOSACCHARIDE COMPLEXES AND MUTAGENESIS
2UWX	;	2.39	;	Active site restructuring regulates ligand recognition in class A penicillin-binding proteins
2XD1	;	3.0	;	ACTIVE SITE RESTRUCTURING REGULATES LIGAND RECOGNITION IN CLASS A PENICILLIN-BINDING PROTEINS
2BG1	;	1.9	;	Active site restructuring regulates ligand recognition in classA Penicillin-binding proteins (PBPs)
1C0E	;	2.2	;	Active Site S19A Mutant of Bovine Heart Phosphotyrosyl Phosphatase
2AUM	;	2.4	;	Active site Ser115Ala mutant of LD-carboxypeptidase
1ORB	;	2.0	;	ACTIVE SITE STRUCTURAL FEATURES FOR CHEMICALLY MODIFIED FORMS OF RHODANESE
1JNW	;	2.07	;	Active Site Structure of E. coli pyridoxine 5'-phosphate Oxidase
1WAY	;	2.02	;	Active site thrombin inhibitors
1WBG	;	2.2	;	Active site thrombin inhibitors
7W2R	;	2.9	;	Active state CI from DQ-NADH dataset, Subclass 1
7W2U	;	2.6	;	Active state CI from DQ-NADH dataset, Subclass 2
7W2Y	;	2.7	;	Active state CI from DQ-NADH dataset, Subclass 3
7W4C	;	2.7	;	Active state CI from Q1-NADH dataset, Subclass 1
7W4D	;	3.0	;	Active state CI from Q1-NADH dataset, Subclass 2
7W4E	;	3.0	;	Active state CI from Q1-NADH dataset, Subclass 3
7W4F	;	2.7	;	Active state CI from Q1-NADH dataset, Subclass 4
7W4G	;	3.1	;	Active state CI from Q1-NADH dataset, Subclass 5
7VZV	;	3.2	;	Active state CI from Q10 dataset, Subclass 1
7VZW	;	3.2	;	Active state CI from Q10 dataset, Subclass 2
7W0R	;	2.8	;	Active state CI from Q10-NADH dataset, Subclass 1
7W0Y	;	3.4	;	Active state CI from Q10-NADH dataset, Subclass 2
7W1T	;	3.0	;	Active state CI from Rotenone dataset, Subclass 1
7W1U	;	3.2	;	Active state CI from Rotenone dataset, Subclass 2
7W1V	;	3.0	;	Active state CI from Rotenone-NADH dataset, Subclass 1
7W1Z	;	2.6	;	Active state CI from Rotenone-NADH dataset, Subclass 2
7W20	;	3.0	;	Active state CI from Rotenone-NADH dataset, Subclass 3
7V2H	;	2.5	;	Active state complex I from DQ-NADH dataset
7V2R	;	2.6	;	Active state complex I from Q1-NADH dataset
7V2C	;	2.9	;	Active state complex I from Q10 dataset
7V2E	;	2.8	;	Active state complex I from Q10-NADH dataset
7V31	;	2.9	;	Active state complex I from rotenone dataset
7V33	;	2.6	;	Active state complex I from rotenone-NADH dataset
7K6Q	;	3.1	;	Active state Dot1 bound to the H4K16ac nucleosome
7K6P	;	3.2	;	Active state Dot1 bound to the unacetylated H4 nucleosome
6NQA	;	3.54	;	Active state Dot1L bound to the H2B-Ubiquitinated nucleosome, 1-to-1 complex
6NJ9	;	2.96	;	Active state Dot1L bound to the H2B-Ubiquitinated nucleosome, 2-to-1 complex
7OCF	;	3.6	;	Active state GluA1/A2 AMPA receptor in complex with TARP gamma 8 and CNIH2 (LBD-TMD)
8C1P	;	2.9	;	Active state homomeric GluA1 AMPA receptor in complex with TARP gamma 3
7QHB	;	3.5	;	Active state of GluA1/2 in complex with TARP gamma 8, L-glutamate and CTZ
4G8L	;	2.8	;	Active state of intact sensor domain of human RNase L with 2-5A bound
6PAT	;	5.8	;	Active State of Manduca sexta soluble Guanylate Cyclase
5ZO5	;	2.297	;	active state of the nuclease
5MVF	;	3.268	;	Active structure of EHD4 complexed with ADP
5MTV	;	2.79	;	Active structure of EHD4 complexed with ATP-gamma-S
6Y86	;	3.4	;	Active YidC insertase crystal structure with the first transmembrane domain resolved
6HD2	;		;	Active-site conformational dynamics of carbonic anhydrase II under native conditions: An NMR perspective
1AXA	;	2.0	;	ACTIVE-SITE MOBILITY IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE AS DEMONSTRATED BY CRYSTAL STRUCTURE OF A28S MUTANT
4CEL	;	2.2	;	ACTIVE-SITE MUTANT D214N DETERMINED AT PH 6.0 WITH NO LIGAND BOUND IN THE ACTIVE SITE
3CEL	;	2.0	;	ACTIVE-SITE MUTANT E212Q DETERMINED AT PH 6.0 WITH CELLOBIOSE BOUND IN THE ACTIVE SITE
2CEL	;	2.0	;	ACTIVE-SITE MUTANT E212Q DETERMINED AT PH 6.0 WITH NO LIGAND BOUND IN THE ACTIVE SITE
4GZI	;	1.68	;	Active-site mutant of potato endo-1,3-beta-glucanase in complex with laminaratriose
4GZJ	;	1.55	;	Active-site mutant of potato endo-1,3-beta-glucanase in complex with laminaratriose and laminaratetrose
4WTR	;	2.27	;	Active-site mutant of Rhizomucor miehei beta-1,3-glucanosyltransferase in complex with laminaribiose
4WTS	;	2.3	;	Active-site mutant of Rhizomucor miehei beta-1,3-glucanosyltransferase in complex with laminaritriose
1TXX	;	2.2	;	ACTIVE-SITE VARIANT OF E.COLI THIOREDOXIN
2ARP	;	2.0	;	Activin A in complex with Fs12 fragment of follistatin
3T57	;	2.1	;	Activity and Crystal Structure of Arabidopsis UDP-N-acetylglucosamine acyltransferase
5F42	;	2.06	;	Activity and Crystal Structure of Francisella novicida UDP-N-Acetylglucosamine Acyltransferase
1ALD	;	2.0	;	ACTIVITY AND SPECIFICITY OF HUMAN ALDOLASES
3AAT	;	2.8	;	ACTIVITY AND STRUCTURE OF THE ACTIVE-SITE MUTANTS R386Y AND R386F OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE
4HEW	;	1.6984	;	Activity Enhancers of H64A Variant of Human Carbonic Anhydrase II Possess Multiple Binding Sites within and around the Enzyme Structure
4HEY	;	1.45	;	Activity Enhancers of H64A Variant of Human Carbonic Anhydrase II Possess Multiple Binding Sites within and around the Enzyme Structure
4HEZ	;	1.3446	;	Activity Enhancers of H64A Variant of Human Carbonic Anhydrase II Possess Multiple Binding Sites within and around the Enzyme Structure
4HF3	;	1.1476	;	Activity Enhancers of H64A Variant of Human Carbonic Anhydrase II Possess Multiple Binding Sites within and around the Enzyme Structure
7DGZ	;	3.8	;	Activity optimized complex I (closed form)
7DH0	;	4.2	;	Activity optimized complex I (open form)
7DGQ	;	5.0	;	Activity optimized supercomplex state1
7DGR	;	4.6	;	Activity optimized supercomplex state2
7DGS	;	7.8	;	Activity optimized supercomplex state3
7DKF	;	8.3	;	Activity optimized supercomplex state4
7RTX	;	1.65	;	Actophorin grown in microgravity
1BUD	;	1.9	;	ACUTOLYSIN A FROM SNAKE VENOM OF AGKISTRODON ACUTUS AT PH 5.0
1BSW	;	1.95	;	ACUTOLYSIN A FROM SNAKE VENOM OF AGKISTRODON ACUTUS AT PH 7.5
7Y4H	;	1.8	;	AcvX from Actinomadura viridis that exhibits deglycosylation activity on lobophorins
6P2I	;	1.63	;	Acyclic imino acid reductase (Bsp5) in complex with NADPH and D-Arg
6WC7	;	5.8	;	Acyl carrier protein (ACP) domain bound to dehydratase (DH) domain in fungal fatty acid synthase (FAS)
5DZ6	;	1.44	;	Acyl transferase from Bacillaene PKS
1WUT	;	2.26	;	Acyl Ureas as Human Liver Glycogen Phosphorylase Inhibitors for the Treatment of Type 2 Diabetes
8HSY	;	2.53	;	Acyl-ACP Synthetase structure
8I6M	;	2.59	;	Acyl-ACP synthetase structure bound to AMP-C18:1
8I51	;	2.76	;	Acyl-ACP synthetase structure bound to AMP-MC7
8I3I	;	2.68	;	Acyl-ACP synthetase structure bound to AMP-PNP in the presence of MgCl2
8I49	;	2.41	;	Acyl-ACP synthetase structure bound to ATP
8I8E	;	2.63	;	Acyl-ACP synthetase structure bound to C18:1-ACP
8I8D	;	2.51	;	Acyl-ACP synthetase structure bound to MC7-ACP
8I35	;	2.75	;	Acyl-ACP synthetase structure bound to oleic acid
8I22	;	2.15	;	Acyl-ACP synthetase structure bound to pimelic acid monoethyl ester
8HZX	;	2.68	;	Acyl-ACP synthetase structure-2
8QRT	;	2.0	;	Acyl-ACP thioesterase from Lemna paucicostata in complex with a spirolactam
8QS0	;	2.3	;	Acyl-ACP thioesterase from Lemna paucicostata in complex with a spirolactam
8P8K	;	2.8	;	Acyl-ACP thioesterase from Lemna paucicostata in complex with a thiazolopyridine
1HBK	;	2.0	;	Acyl-CoA binding protein from Plasmodium falciparum
1XNV	;	2.3	;	Acyl-CoA Carboxylase Beta Subunit from S. coelicolor (PccB), apo form #1
1XNW	;	2.6	;	Acyl-CoA Carboxylase Beta Subunit from S. coelicolor (PccB), apo form #2, mutant D422I
1XO6	;	2.2	;	Acyl-CoA Carboxylase Beta Subunit from S. coelicolor (PccB), apo form #3
7W0J	;	3.13	;	Acyl-CoA dehydrogenase, Tfu_1647
7DBL	;	1.84	;	Acyl-CoA hydrolase MpaH' mutant S139A in complex with MPA
5E7Q	;	2.23	;	Acyl-CoA synthetase PtmA2 from Streptomyces platensis
5UPQ	;	2.42	;	Acyl-CoA synthetase PtmA2 from Streptomyces platensis in complex with SBNP465 ligand
5UPT	;	1.92	;	Acyl-CoA synthetase PtmA2 from Streptomyces platensis in complex with SBNP468 ligand
5UPS	;	2.05	;	Acyl-CoA synthetase PtmA2 from Streptomyces platensis in complex with SBNP663 ligand
7DES	;	1.45	;	Acyl-Coenzyme A Binding Protein 103 (LMJF_17_0620) of Leishmania Major
7WFS	;	1.4	;	Acyl-Coenzyme A Binding Protein 103 (LMJF_17_0620) of Leishmania major in triclinic crystal form
7FC7	;	2.2	;	Acyl-Coenzyme A Binding Protein 96 (LMJ_17_0780) of Leishmania Major in complex with Coenzyme A
4MOB	;	2.401	;	Acyl-Coenzyme A thioesterase 12 in complex with ADP
8AKI	;	1.4	;	Acyl-enzyme complex of ampicillin bound to deacylation mutant KPC-2 (E166Q)
8AKJ	;	1.35	;	Acyl-enzyme complex of cephalothin bound to deacylation mutant KPC-2 (E166Q)
8AKM	;	1.25	;	Acyl-enzyme complex of ertapenem bound to deacylation mutant KPC-2 (E166Q)
8AKK	;	1.36	;	Acyl-enzyme complex of imipenem bound to deacylation mutant KPC-2 (E166Q)
8AKL	;	1.35	;	Acyl-enzyme complex of meropenem bound to deacylation mutant KPC-2 (E166Q)
2BU3	;	1.4	;	Acyl-enzyme intermediate between Alr0975 and glutathione at pH 3.4
7KHP	;	1.95	;	Acyl-enzyme intermediate structure of SARS-CoV-2 Mpro in complex with its C-terminal autoprocessing sequence.
2ACY	;	1.8	;	ACYL-PHOSPHATASE (COMMON TYPE) FROM BOVINE TESTIS
4RE5	;	1.9	;	Acylaminoacyl peptidase complexed with a chloromethylketone inhibitor
4RE6	;	2.55	;	Acylaminoacyl peptidase complexed with a chloromethylketone inhibitor
4HXF	;	1.601	;	Acylaminoacyl peptidase in complex with Z-Gly-Gly-Phe-chloromethyl ketone
6Z23	;	1.31	;	Acylenzyme complex of cefotaxime bound to deacylation mutant KPC-2 (E166Q)
6Z24	;	1.25	;	Acylenzyme complex of ceftazidime bound to deacylation mutant KPC-2 (E166Q)
6Z25	;	1.24	;	Acylenzyme complex of ceftazidime bound to deacylation mutant KPC-4 (E166Q)
6THO	;	1.09	;	Acylintermediate of glutathione and the mature primitive phytochelatin synthase Alr0975 from Nostoc PCC 7120 at atomic resolution.
8BV9	;	2.55	;	Acylphosphatase from E. coli
7CHX	;	1.49	;	acylphosphatase from Staphylococcus aureus
2BJE	;	1.9	;	Acylphosphatase from Sulfolobus solfataricus. Monclinic P21 space group
2W4D	;	2.4	;	Acylphosphatase variant G91A from Pyrococcus horikoshii
3TOQ	;	2.0	;	Acylphosphatase with mesophilic surface and thermophilic core
3TNV	;	1.6	;	Acylphosphatase with thermophilic surface and mesophilic core
7AHB	;	1.9	;	Acyltransferase domain of the polyketide synthase PpsC of Mycobacterium tuberculosis
7VT1	;	2.5	;	Acyltransferase from the 9th Module of Salinomycin Polyketide Synthase
3U0W	;	2.0	;	AD related murine antibody Fragment
2J12	;	1.5	;	Ad37 fibre head in complex with CAR D1
2WBW	;	1.55	;	Ad37 fibre head in complex with CAR D1 and sialic acid
4ATZ	;	1.95	;	Ad5 knob in complex with a designed ankyrin repeat protein
1SFE	;	2.1	;	ADA O6-METHYLGUANINE-DNA METHYLTRANSFERASE FROM ESCHERICHIA COLI
1A4L	;	2.6	;	ADA STRUCTURE COMPLEXED WITH DEOXYCOFORMYCIN AT PH 7.0
1A4M	;	1.95	;	ADA STRUCTURE COMPLEXED WITH PURINE RIBOSIDE AT PH 7.0
6CR1	;	1.521	;	adalimumab EFab
4DD8	;	2.1	;	ADAM-8 metalloproteinase domain with bound batimastat
2AO7	;	2.9	;	Adam10 Disintegrin and cysteine- rich domain
6BE6	;	2.8	;	ADAM10 Extracellular Domain
6BDZ	;	3.1	;	ADAM10 Extracellular Domain Bound by the 11G2 Fab
2AIG	;	2.6	;	ADAMALYSIN II WITH PEPTIDOMIMETIC INHIBITOR POL647
3AIG	;	2.8	;	ADAMALYSIN II WITH PEPTIDOMIMETIC INHIBITOR POL656
4AIG	;	2.0	;	ADAMALYSIN II WITH PHOSPHONATE INHIBITOR
3Q2G	;	2.3	;	Adamts1 in complex with a novel N-hydroxyformamide inhibitors
3Q2H	;	2.33	;	Adamts1 in complex with N-hydroxyformamide inhibitors of ADAM-TS4
7B01	;	2.8	;	ADAMTS13-CUB12
8TXN	;	1.75	;	Adaptive mechanism of collagen IV scaffold assembly in Drosophila: crystal structure of recombinant NC1 hexamer
8TYS	;	2.9	;	Adaptive mechanism of collagen IV scaffold assembly in Drosophila: crystal structure of tissue-extracted NC1 hexamer
8IMQ	;		;	Adaptive mutation is mediated by MsyB via its interaction with nucleoid-associated proteins HU and beta-clamp
3FCZ	;	2.804	;	Adaptive protein evolution grants organismal fitness by improving catalysis and flexibility
3U2A	;	1.7	;	Adaptor dependent degradation of a cell-cycle regulator reveals diversity in substrate architectures
8FQQ	;	1.48	;	ADC-162 in complex with boronic acid transition state inhibitor MB076
8FQS	;	1.21	;	ADC-212 in complex with boronic acid transition state inhibitor MB076
8FQU	;	1.49	;	ADC-219 in complex with boronic acid transition state inhibitor MB076
8FQW	;	1.59	;	ADC-30 in complex with boronic acid transition state inhibitor MB076
8FQO	;	1.83	;	ADC-33 in complex with boronic acid transition state inhibitor MB076
6PWM	;	2.4	;	ADC-7 in complex with Beta-lactam antibiotic ceftazidime
5WAC	;	2.061	;	ADC-7 in complex with boronic acid transition state inhibitor CR157
5WAD	;	2.09	;	ADC-7 in complex with boronic acid transition state inhibitor CR161
5WAE	;	1.804	;	ADC-7 in complex with boronic acid transition state inhibitor CR167
5WAF	;	2.03	;	ADC-7 in complex with boronic acid transition state inhibitor CR192
5W12	;	1.88	;	ADC-7 in complex with boronic acid transition state inhibitor EC04
6PWL	;	1.67	;	ADC-7 in complex with boronic acid transition state inhibitor LP06
8FQM	;	1.53	;	ADC-7 in complex with boronic acid transition state inhibitor MB076
6TZJ	;	1.8	;	ADC-7 in complex with boronic acid transition state inhibitor ME_096
6TZI	;	1.744	;	ADC-7 in complex with boronic acid transition state inhibitor PFC_001
5W14	;	1.88	;	ADC-7 in complex with boronic acid transition state inhibitor S03043
6TZH	;	2.04	;	ADC-7 in complex with boronic acid transition state inhibitor S06015
5WAG	;	1.931	;	ADC-7 in complex with boronic acid transition state inhibitor S06017
6TZF	;	1.96	;	ADC-7 in complex with boronic acid transition state inhibitor S17079
6TZG	;	1.816	;	ADC-7 in complex with boronic acid transition state inhibitor S17083
5W13	;	1.95	;	ADC-7 in complex with boronic acid transition state inhibitor SM23
2BIR	;	2.3	;	ADDITIVITY OF SUBSTRATE BINDING IN RIBONUCLEASE T1 (Y42A MUTANT)
8QB3	;	2.9	;	ADDobody zinc containing condition
6PL9	;	1.2	;	Adduct formed after 1 month in the reaction of dichlorido(1,3-dimethylbenzimidaz ol-2-ylidene)(eta5-pentamethylcyclopentadienyl)rhodium(III) with HEWL
6PLB	;	1.3	;	Adducts formed after 1 month in the reaction of dichlorido(1,3-dimethylbenzimida zol-2-ylidene)(eta5-pentamethylcyclopentadienyl)iridium(III) with HEWL
6PLA	;	1.25	;	Adducts formed after 1 month in the reaction of dichlorido(1,3-dimethylbenzimidazol-2-ylidene)(eta6-p-cymene)osmium(II) with HEWL
6BO2	;	1.48	;	Adducts formed after 1 month in the reaction of dichlorido(1,3-dimethylbenzimidazol-2-ylidene)(eta6-p-cymene)ruthenium(II) with HEWL
6WX5	;	1.3	;	Adducts formed after 3 weeks in the reaction of chlorido[chlorido(2,2'-((2-([2,2':6',2''-Terpyridin]-4'-yloxy)ethyl)azanediyl)bis(ethan-1-ol))platinum(II)] with HEWL
8DWE	;	2.2	;	Adenine glycosylase MutY variant E43Q in complex with DNA containing d(8-oxo-G) paired with substrate purine
8DWD	;	1.68	;	Adenine glycosylase MutY variant E43S in complex with DNA containing d(8-oxo-G) paired with an AP site generated by the enzyme acting on purine
5UZA	;	2.22	;	Adenine riboswitch aptamer domain labelled with iodo-uridine by position-selective labelling of RNA (PLOR)
1U49	;	2.15	;	Adenine-8oxoguanine mismatch at the polymerase active site
1NK5	;	2.1	;	ADENINE-ADENINE MISMATCH AT THE POLYMERASE ACTIVE SITE
6GZN	;		;	Adenine-driven structural switch from two- to three-quartet DNA G-quadruplex
1NK0	;	1.7	;	ADENINE-GUANINE MISMATCH AT THE POLYMERASE ACTIVE SITE
2ADM	;	2.6	;	ADENINE-N6-DNA-METHYLTRANSFERASE TAQI
7QW8	;	2.5	;	Adenine-specific DNA methyltransferase M.BseCI
7QW7	;	2.6	;	Adenine-specific DNA methyltransferase M.BseCI complexed with AdoHcy and cognate fully methylated DNA duplex
7QW6	;	2.4	;	Adenine-specific DNA methyltransferase M.BseCI complexed with AdoHcy and cognate hemimethylated DNA duplex
7QW5	;	2.3	;	Adenine-specific DNA methyltransferase M.BseCI complexed with AdoHcy and cognate unmethylated DNA duplex
1G38	;	2.0	;	ADENINE-SPECIFIC METHYLTRANSFERASE M. TAQ I/DNA COMPLEX
7KFR	;	1.56	;	Adeno-Associated Virus (AAV-DJ) - cryo-EM structure at 1.56 Angstrom Resolution
6IH9	;	2.8	;	Adeno-Associated Virus 2 at 2.8 ang
6IHB	;	2.84	;	Adeno-Associated Virus 2 in complex with AAVR
7JSH	;	4.4	;	Adeno-Associated Virus 2 Rep68 HD Heptamer-ssAAVS1 with ATPgS
7JSI	;	5.01	;	Adeno-Associated Virus 2 Rep68 HD Hexamer-ssDNA with ATPgS
7JSG	;	5.2	;	Adeno-Associated Virus 2 Rep68 HD-Heptamer-ssDNA with ATPgS
8SG7	;	2.4	;	Adeno-Associated Virus Bat origin capsid protein basic regions in complex with importin-alpha 2
7TI4	;	2.93	;	Adeno-associated Virus Go.1 at 2.9 Angstroms resolution, AAVGo.1 AAV-Go
7TI5	;	2.4	;	Adeno-associated virus Go.1 in Complex With Its Cellular Receptor AAVR at 2.4 Angstroms Resolution, AAVGo.1 AAVR
7JSF	;	6.7	;	Adeno-Associated Virus Helicase domain Heptamer with ssDNA
6XB8	;	3.3	;	Adeno-Associated Virus Origin Binding Domain in complex with ssDNA
7JSE	;	4.6	;	Adeno-Associated Virus Origin Binding Domain in complex with ssDNA
8FK3	;	2.6	;	Adeno-Associated Virus Porcine Origin capsid protein basic regions in complex with Importin-alpha 2
7KP3	;	2.1	;	Adeno-associated virus serotype 5 at 2.1 Angstroms resolution, AAV5
7KPN	;	2.5	;	Adeno-associated virus serotype 5 in complex with the cellular receptor AAVR at 2.5 Angstroms resolution, AAV5 AAVR
7WJX	;	3.23	;	Adeno-associated virus serotype 9 in complex with AAVR
7WQP	;	3.76	;	Adeno-associated virus serotype PHP.eB in complex with AAVR
7JOT	;	2.7	;	Adeno-associated virus strain AAV7 capsid icosahedral structure
6U95	;	2.56	;	Adeno-associated virus strain AAVhu.37 capsid icosahedral structure
7RWT	;	2.43	;	Adeno-associated virus type 2
1NDP	;	2.2	;	ADENOSINE 5'-DIPHOSPHATE BINDING AND THE ACTIVE SITE OF NUCLEOSIDE DIPHOSPHATE KINASE
2FJA	;	2.0	;	adenosine 5'-phosphosulfate reductase in complex with substrate
7EZC	;	3.8	;	Adenosine A2a receptor mutant-I92N
1VFL	;	1.8	;	Adenosine deaminase
1UIO	;	2.4	;	ADENOSINE DEAMINASE (HIS 238 ALA MUTANT)
1UIP	;	2.4	;	ADENOSINE DEAMINASE (HIS 238 GLU MUTANT)
4DC3	;	2.4	;	Adenosine kinase from Schistosoma mansoni in complex with 2-fluoroadenosine
3VAQ	;	2.44	;	Adenosine kinase from Schistosoma mansoni in complex with adenosine
3UQ6	;	2.3	;	Adenosine kinase from Schistosoma mansoni in complex with adenosine and AMP
3VAS	;	2.26	;	Adenosine kinase from Schistosoma mansoni in complex with adenosine in occluded loop conformation
3UQ9	;	2.343	;	Adenosine kinase from Schistosoma mansoni in complex with tubercidin
7XY7	;	3.26	;	Adenosine receptor bound to a non-selective agonist in complex with a G protein obtained by cryo-EM
7XY6	;	2.99	;	Adenosine receptor bound to an agonist in complex with G protein obtained by cryo-EM
4YB7	;	2.2	;	Adenosine triphosphate phosphoribosyltransferase from Campylobacter jejuni in complex with ATP
4YB5	;	2.24	;	Adenosine triphosphate phosphoribosyltransferase from Campylobacter jejuni in complex with the allosteric inhibitor histidine
4YB6	;	1.98	;	Adenosine triphosphate phosphoribosyltransferase from Campylobacter jejuni in complex with the inhibitors AMP and histidine
7DAM	;	2.7	;	Adenosine triphosphate phosphoribosyltransferase from Vibrio cholerae
7DAH	;	2.92	;	Adenosine triphosphate phosphoribosyltransferase from Vibrio cholerae in complex with ATP and PRPP
2FJB	;	1.7	;	Adenosine-5'-phosphosulfate reductase im complex with products
2FJD	;	1.84	;	adenosine-5-phosphosulfate reductase in complex with sulfite (covalent adduct)
2FJE	;	1.8	;	adenosine-5-phosphosulfate reductase oxidized state
8DB6	;	2.02	;	Adenosine/guanosine nucleoside hydrolase
8DB7	;	2.33	;	Adenosine/guanosine nucleoside hydrolase bound to a fragment inhibitor
8DB8	;	2.21	;	Adenosine/guanosine nucleoside hydrolase bound to ImH
8DB9	;	2.89	;	Adenosine/guanosine nucleoside hydrolase bound to inhibitor
8SA2	;	3.1	;	Adenosylcobalamin-bound riboswitch dimer, form 1
8SA3	;	3.0	;	Adenosylcobalamin-bound riboswitch dimer, form 2
8SA4	;	3.1	;	Adenosylcobalamin-bound riboswitch dimer, form 3
8SA5	;	3.5	;	Adenosylcobalamin-bound riboswitch dimer, form 4
1CBU	;	2.3	;	ADENOSYLCOBINAMIDE KINASE/ADENOSYLCOBINAMIDE PHOSPHATE GUANYLYLTRANSFERASE (COBU) FROM SALMONELLA TYPHIMURIUM
4WYD	;	1.35	;	Adenosylmethionine-8-amino-7-oxononanoate aminotransferase from Mycobacterium tuberculosis complexed with a fragment from DSF screening
6STW	;	1.37	;	Adenovirus 15 Fiber Knob protein
6STV	;	1.6	;	Adenovirus 29 Fiber Knob protein
6STT	;	1.54	;	Adenovirus 29 Fiber Knob protein in complex with Sialic acid
4WYJ	;	2.65	;	Adenovirus 3 head domain mutant V239D
6STU	;	2.39	;	Adenovirus 30 Fiber Knob protein
1ANV	;	2.7	;	ADENOVIRUS 5 DBP/URANYL FLUORIDE SOAK
1UXB	;	1.75	;	ADENOVIRUS AD19p FIBRE HEAD in complex with sialyl-lactose
1H7Z	;	1.6	;	Adenovirus Ad3 fibre head
2QLK	;	2.02	;	Adenovirus AD35 fibre head
1UXE	;	2.0	;	ADENOVIRUS AD37 FIBRE HEAD
1UXA	;	1.5	;	ADENOVIRUS AD37 FIBRE HEAD in complex with sialyl-lactose
1V1I	;	1.9	;	Adenovirus fibre shaft sequence N-terminally fused to the bacteriophage T4 fibritin foldon trimerisation motif with a long linker
1V1H	;	1.9	;	Adenovirus fibre shaft sequence N-terminally fused to the bacteriophage T4 fibritin foldon trimerisation motif with a short linker
6QPM	;	3.39	;	Adenovirus serotype 10 Fiber-Knob
6QU6	;	1.03	;	Adenovirus Serotype 26 (Ad26) in complex with sialic acid, pH4.0
6QU8	;	1.19	;	Adenovirus Serotype 26 (Ad26) in complex with sialic acid, pH8.0
6FJN	;	0.97	;	Adenovirus species 26 knob protein, 0.97A
6FJP	;	1.09	;	Adenovirus species 26 knob protein, high resolution, High pH
6FJO	;	1.17	;	Adenovirus species 26 knob protein, very high resolution
6FJQ	;	2.91	;	Adenovirus species 48, fiber knob protein
6QPN	;	2.74	;	Adenovirus species D serotype 49 Fiber-Knob
6QPO	;	2.45	;	Adenovirus species D serotype 49 Fiber-Knob KO1 mutant
6HCN	;	1.49	;	Adenovirus Type 5 Fiber Knob protein at 1.49A resolution
3N0Z	;	1.7	;	Adenylate cyclase class IV with active site ligand 3AT
3N0Y	;	1.7	;	Adenylate cyclase class IV with active site ligand APC
7RAH	;	2.6	;	Adenylate cyclase toxin RTX domain fragment bound to M1H5 Fab and M2B10 Fab
4AKE	;	2.2	;	ADENYLATE KINASE
6HAM	;	2.55	;	Adenylate kinase
6HAP	;	2.7	;	Adenylate kinase
1P3J	;	1.9	;	Adenylate Kinase from Bacillus subtilis
1ZAK	;	3.5	;	ADENYLATE KINASE FROM MAIZE IN COMPLEX WITH THE INHIBITOR P1,P5-BIS(ADENOSINE-5'-)PENTAPHOSPHATE (AP5A)
6PJW	;	2.4	;	Adenylate kinase from Methanococcus igneus - AMP bound form
6PSP	;	2.252	;	Adenylate kinase from Methanococcus igneus - AP5A bound form
6PK5	;	2.3	;	Adenylate kinase from Methanococcus igneus - apo form
1KI9	;	2.76	;	Adenylate kinase from Methanococcus thermolithotrophicus
1KHT	;	2.5	;	Adenylate kinase from Methanococcus voltae
1NKS	;	2.57	;	ADENYLATE KINASE FROM SULFOLOBUS ACIDOCALDARIUS
1AK2	;	1.92	;	ADENYLATE KINASE ISOENZYME-2
2AK2	;	2.1	;	ADENYLATE KINASE ISOENZYME-2
8BQF	;	2.05	;	Adenylate Kinase L107I MUTANT
1ZIN	;	1.6	;	ADENYLATE KINASE WITH BOUND AP5A
6ULY	;	2.3	;	Adenylation domain of a keto acid-selecting NRPS module bound to keto acyl adenylate space group P212121
6ULX	;	2.31	;	Adenylation domain of a keto acid-selecting NRPS module bound to keto acyl adenylate space group P43212
1ZAU	;	3.15	;	Adenylation domain of NAD+ dependent DNA ligase from M.tuberculosis
6ULZ	;	3.1	;	Adenylation domain of the initiation module of LgrA mutant P483M
8G95	;	2.2	;	Adenylation domain structure from NRPS-like Delta-Poly-L-Ornithine synthetase
8G97	;	2.51	;	Adenylation domain structure from NRPS-like Delta-Poly-L-Ornithine synthetase (D-Ornithine bound)
8G98	;	2.49	;	Adenylation domain structure from NRPS-like Delta-Poly-L-Ornithine synthetase (L-Lysine bound)
8G96	;	2.3	;	Adenylation domain structure from NRPS-like Delta-Poly-L-Ornithine synthetase (L-Ornithine bound)
6ULW	;	3.4	;	Adenylation, ketoreductase, and pseudo Asub multidomain structure of a keto acid-selecting NRPS module
5I34	;	1.53	;	Adenylosuccinate synthetase from Cryptococcus neoformans complexed with GDP and IMP
6ZXQ	;	1.4	;	Adenylosuccinate Synthetase from H. pylori in complex with HDA, GDP, IMO, Mg
7PVO	;	2.0	;	Adenylosuccinate Synthetase from H. pylori in complex with IMP
1SON	;	2.55	;	ADENYLOSUCCINATE SYNTHETASE IN COMPLEX WITH THE NATURAL FEEDBACK INHIBITOR AMP
1SOO	;	2.6	;	ADENYLOSUCCINATE SYNTHETASE INHIBITED BY HYDANTOCIDIN 5'-MONOPHOSPHATE
2FJT	;	1.901	;	Adenylyl cyclase class iv from Yersinia pestis
6CFD	;	2.57	;	ADEP4 bound to E. faecium ClpP
7QU8	;	3.37	;	ADGRG3/GPR97 Extracellular Region
8DJG	;	2.65	;	ADGRL3-lectin domain in complex with an activating synthetic antibody fragment
7WYB	;	2.97	;	ADGRL3/Gi complex
7WY5	;	2.83	;	ADGRL3/Gq complex
7WY8	;	2.83	;	ADGRL3/Gs complex
7X10	;	2.93	;	ADGRL3/miniG12 complex
7BVP	;	3.45	;	AdhE spirosome in extended conformation
5MY7	;	1.4	;	Adhesin Complex Protein from Neisseria meningitidis
6EVU	;	1.598	;	Adhesin domain of PrgB from Enterococcus faecalis
6GED	;	1.794	;	Adhesin domain of PrgB from Enterococcus faecalis bound to DNA
5LP2	;	2.6	;	Adhesin domain of the type 1 HopQ of Helicobacter pylori strain G27
6S3U	;	3.24	;	Adhesin P140 from Mycoplasma Genitalium
5A0O	;	2.73	;	adhiron raised against p300
4N6T	;	1.75	;	Adhiron: a stable and versatile peptide display scaffold - full length adhiron
4N6U	;	2.251	;	Adhiron: a stable and versatile peptide display scaffold - truncated adhiron
2ANS	;	2.5	;	ADIPOCYTE LIPID BINDING PROTEIN COMPLEXED WITH 1-ANILINO-8-NAPHTHALENE SULFONATE
1ADL	;	1.6	;	ADIPOCYTE LIPID BINDING PROTEIN COMPLEXED WITH ARACHIDONIC ACID: X-RAY CRYSTALLOGRAPHIC AND TITRATION CALORIMETRY STUDIES
3DFV	;	3.1	;	Adjacent GATA DNA binding
1K98	;	3.75	;	AdoMet complex of MetH C-terminal fragment
5H56	;	1.7	;	ADP and dTDP bound Crystal structure of thymidylate kinase (aq_969) from Aquifex Aeolicus VF5
1AMW	;	1.85	;	ADP BINDING SITE IN THE HSP90 MOLECULAR CHAPERONE
1XXI	;	4.1	;	ADP Bound E. coli Clamp Loader Complex
6NO0	;	2.209	;	ADP bound to ATP-grasp fold of Blastocystis hominis succinyl-CoA synthetase
6NO2	;	2.159	;	ADP bound to K114bD mutant ATP-grasp fold of Blastocystis hominis succinyl-CoA synthetase
6NO1	;	2.44	;	ADP bound to K46bE mutant ATP-grasp fold of Blastocystis hominis succinyl-CoA synthetase
6NO5	;	2.069	;	ADP bound to K46bE&K114bD mutant ATP-grasp fold of Blastocystis hominis succinyl-CoA synthetase
6NO4	;	2.24	;	ADP bound to L227bF mutant ATP-grasp fold of Blastocystis hominis succinyl-CoA synthetase
6NO3	;	1.939	;	ADP bound to V113bL mutant ATP-grasp fold of Blastocystis hominis succinyl-CoA synthetase
6VRF	;	1.5	;	ADP bound TTBK2 kinase domain
3IQX	;	3.5	;	ADP complex of C.therm. Get3 in closed form
1XJQ	;	2.06	;	ADP Complex OF HUMAN PAPS SYNTHETASE 1
3DSR	;	2.7	;	ADP in transition binding site in the subunit B of the energy converter A1Ao ATP synthase
1W0K	;	2.85	;	ADP inhibited bovine F1-ATPase
3X0J	;	0.92	;	ADP ribose pyrophosphatase from Thermus thermophilus HB8 in apo state at 0.92 angstrom resolution
3X0S	;	1.1	;	ADP ribose pyrophosphatase from Thermus thermophilus HB8 in E'-state at reaction time of 50 min
3X0K	;	0.97	;	ADP ribose pyrophosphatase from Thermus thermophilus HB8 in ES-state at 0.97 angstrom resolution
3X0L	;	1.0	;	ADP ribose pyrophosphatase from Thermus thermophilus HB8 in ES-state at 1.00 angstrom resolution
3X0M	;	1.15	;	ADP ribose pyrophosphatase from Thermus thermophilus HB8 in ESM-state at reaction time of 3 min
3X0N	;	1.12	;	ADP ribose pyrophosphatase from Thermus thermophilus HB8 in ESM-state at reaction time of 6 min
3X0O	;	1.09	;	ADP ribose pyrophosphatase from Thermus thermophilus HB8 in ESMM-state at reaction time of 10 min
3X0P	;	1.22	;	ADP ribose pyrophosphatase from Thermus thermophilus HB8 in ESMM-state at reaction time of 15 min
3X0Q	;	1.14	;	ADP ribose pyrophosphatase from Thermus thermophilus HB8 in ESMM-state at reaction time of 20 min
3X0I	;	0.91	;	ADP ribose pyrophosphatase in apo state at 0.91 angstrom resolution
7M9A	;	3.9	;	ADP-AlF3 bound TnsC structure from ShCAST system
7M9B	;	3.8	;	ADP-AlF3 bound TnsC structure in closed form
7M9C	;	4.2	;	ADP-AlF3 bound TnsC structure in open form
3ZQ6	;	2.107	;	ADP-ALF4 COMPLEX OF M. THERM. TRC40
2WOJ	;	1.994	;	ADP-AlF4 complex of S. cerevisiae GET3
7N46	;	2.21	;	ADP-binding state of the nucleotide-binding domain of Hsp70 DnaK
4AM7	;	3.25	;	ADP-BOUND C-TERMINAL DOMAIN OF ACTIN-RELATED PROTEIN ARP8 FROM S. CEREVISIAE
4GVA	;	1.83	;	ADP-bound form of the ERK2 kinase
6MRC	;	3.08	;	ADP-bound human mitochondrial Hsp60-Hsp10 football complex
6MRD	;	3.82	;	ADP-bound human mitochondrial Hsp60-Hsp10 half-football complex
3KJG	;	2.3	;	ADP-bound state of CooC1
5O0I	;	2.0	;	ADP-dependent glucokinase from Pyrococcus horikoshii
5O0J	;	1.81	;	ADP-dependent glucokinase from Pyrococcus horikoshii
6XIO	;	3.12	;	ADP-dependent kinase complex with fructose-6-phosphate and ADPbetaS
5XB3	;	1.77	;	ADP-dTMP bound Crystal structure of thymidylate kinase (aq_969) from Aquifex Aeolicus VF5
5XB2	;	2.161	;	ADP-Mg-F-dTMP bound Crystal structure of thymidylate kinase (aq_969) from Aquifex Aeolicus VF5
1MOZ	;	3.17	;	ADP-ribosylation factor-like 1 (ARL1) from Saccharomyces cerevisiae
2YZV	;	1.6	;	ADP-ribosylglycohydrolase-related protein complex
2YZW	;	1.7	;	ADP-ribosylglycohydrolase-related protein complex
6HH3	;	1.82	;	ADP-ribosylserine hydrolase ARH3 of Latimeria chalumnae in complex with ADP-HPD
6HH5	;	1.95	;	ADP-ribosylserine hydrolase ARH3 of Latimeria chalumnae in complex with ADP-HPM
6G1Q	;	2.1	;	ADP-ribosylserine hydrolase ARH3 of Latimeria chalumnae in complex with ADP-ribose
6HGZ	;	1.86	;	ADP-ribosylserine hydrolase ARH3 of Latimeria chalumnae in complex with ADP-ribose
6HH4	;	1.66	;	ADP-ribosylserine hydrolase ARH3 of Latimeria chalumnae in complex with ADP-ribosyl-L-arginine
7AQM	;	2.5	;	ADP-ribosylserine hydrolase ARH3 of Latimeria chalumnae in complex with alpha-1''-O-methyl-ADP-ribose (meADPr)
6HOZ	;	1.77	;	ADP-ribosylserine hydrolase ARH3 of Latimeria chalumnae in complex with inosine diphosphate ribose (IDPr)
8HE7	;	2.1	;	ADP-ribosyltransferase 1 (PARP1) catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitor
1R4B	;	1.85	;	ADP-ribosyltransferase C3bot2 from Clostridium botulinum, monoclinic form
1R45	;	1.57	;	ADP-ribosyltransferase C3bot2 from Clostridium botulinum, triclinic form
6DRE	;	1.8	;	ADP-ribosyltransferase toxin/immunity pair
6DRH	;	2.299	;	ADP-ribosyltransferase toxin/immunity pair
7B8B	;	2.03	;	ADPG2 - ENDOPOLYGALACTURONASE FROM ARABIDOPSIS THALIANA
2ADR	;		;	ADR1 DNA-BINDING DOMAIN FROM SACCHAROMYCES CEREVISIAE, NMR, 25 STRUCTURES
1CJE	;	2.5	;	ADRENODOXIN FROM BOVINE
1E1K	;	1.95	;	ADRENODOXIN REDUCTASE in complex with NADP+ obtained by a soaking experiment
1E1M	;	1.85	;	ADRENODOXIN REDUCTASE in complex with NADPH obtained by a soaking experiment
1E6E	;	2.3	;	ADRENODOXIN REDUCTASE/ADRENODOXIN COMPLEX OF MITOCHONDRIAL P450 SYSTEMS
2WLB	;	2.6	;	Adrenodoxin-like ferredoxin Etp1fd(516-618) of Schizosaccharomyces pombe mitochondria
6CO3	;	2.384	;	aducanumab abeta complex
6CNR	;	2.09	;	aducanumab apo Fab
3DZT	;	1.8	;	AeD7-leukotriene E4 complex
5FT3	;	1.431	;	Aedes aegypti GSTe2
1YIY	;	1.9	;	Aedes aegypti kynurenine aminotransferase
1YIZ	;	1.55	;	Aedes aegypti kynurenine aminotrasferase
2R5C	;	1.96	;	Aedes Kynurenine Aminotransferase in Complex with Cysteine
2R5E	;	1.84	;	Aedes kynurenine aminotransferase in complex with glutamine
4I3M	;	1.95	;	Aer2 poly-HAMP domains: L44H HAMP1 CW-lock mutant
4I44	;	2.88	;	Aer2 poly-HAMP domains: V33G HAMP1 inverted signaling mutant
6ZLF	;	1.8	;	Aerobic crystal structure of F420H2-Oxidase from Methanothermococcus thermolithotrophicus at 1.8A resolution under 125 bars of krypton
8C34	;	1.82	;	Aerobic light exposed 1.8 Angstrom crystal structure of cobalamin binding domain belonging to a light-dependent transcription regulator TtCarH
6ETB	;	1.905	;	Aerobic S262Y mutation of E. coli FLRD core
3P9O	;	1.45	;	Aerobic ternary complex of urate oxidase with azide and chloride
8SM6	;	1.39	;	Aerobic, Diiron(III)-metalated SfbO
4RJE	;	1.65	;	Aerococcus viridans L-lactate oxidase mutant
4YL2	;	1.9	;	Aerococcus viridans L-lactate oxidase Y191F mutant
5EBU	;	2.6	;	Aerococcus viridans L-lactate oxidase Y215F mutant
6I1X	;	3.7	;	Aeromonas hydrophila ExeD
6IF8	;	2.0	;	Aeromonas hydrophila MtaN-2 complexed with adenine
6K2Q	;	2.0	;	Aeromonas hydrophila MtaN-2 complexed with adenine
3WGC	;	2.5	;	Aeromonas jandaei L-allo-threonine aldolase H128Y/S292R double mutant
1IGB	;	2.3	;	AEROMONAS PROTEOLYTICA AMINOPEPTIDASE COMPLEXED WITH THE INHIBITOR PARA-IODO-D-PHENYLALANINE HYDROXAMATE
6B7L	;	2.3	;	Aeromonas veronii immune modulator A
7RC2	;	1.51	;	Aeronamide N-methyltransferase, AerE
7RC4	;	1.66	;	Aeronamide N-methyltransferase, AerE (D141A)
7RC5	;	1.88	;	Aeronamide N-methyltransferase, AerE (N231A)
7RC3	;	1.53	;	Aeronamide N-methyltransferase, AerE (Y137F)
7RC6	;	1.71	;	Aeronamide N-methyltransferase, AerE, bound to modified peptide substrate, AerA-DL,34
2QR5	;	2.2	;	Aeropyrum pernix acylaminoacyl peptidase, H367A mutant
4GQF	;	2.3	;	Aeropyrum pernix Peroxiredoxin Q Enzyme in the Locally Unfolded Conformation
7NVQ	;	2.05	;	Aerosol-soaked human cdk2 crystals with Staurosporine
8CJD	;	1.7	;	AetF, a single-component flavin-dependent tryptophan halogenase
8CJF	;	1.9	;	AetF, a single-component flavin-dependent tryptophan halogenase, in complex with 5-bromo-L-tryptophan
8CJG	;	2.3	;	AetF, a single-component flavin-dependent tryptophan halogenase, in complex with 7-bromo-L-tryptophan
8CJE	;	1.8	;	AetF, a single-component flavin-dependent tryptophan halogenase, in complex with L-tryptophan
5HJD	;	2.806	;	AF9 YEATS in complex with histone H3 Crotonylation at K18
5HJB	;	2.7	;	AF9 YEATS in complex with histone H3 Crotonylation at K9
1UT2	;	3.3	;	AfaE-3 adhesin from Escherichia Coli
5L88	;	1.88	;	AFAMIN ANTIBODY FRAGMENT, N14 FAB, L1- GLYCOSILATED, CRYSTAL FORM I, non-parsimonious model
5LGH	;	1.86	;	Afamin antibody fragment, N14 Fab, L1- glycosilated, crystal form II, same as 5L7X, but isomorphous setting indexed same as 5L88, 5L9D
5L9D	;	1.88	;	AFAMIN ANTIBODY FRAGMENT, N14 FAB, L1- GLYCOSYLATED, CRYSTAL FORM I, parsimonious model
5L7X	;	1.86	;	Afamin antibody fragment, N14 Fab, L1- glycosylated, crystal form II
8IF5	;		;	AFB1-AF26 APTAMER COMPLEX
4TX6	;	1.9	;	AfChiA1 in complex with compound 1
8IR0	;	2.89	;	AfFer mutant-P156F
8IQW	;	2.5	;	AfFer(Asterias forbesii ferritin) mutant-P156H
2JDG	;	2.0	;	Affilin based on HUMAN GAMMA-B CRYSTALLIN
6YXW	;	2.06	;	Affimer K3 - KRAS protein complex
6YR8	;	1.9	;	Affimer K6 - KRAS protein complex
7NY8	;	1.8	;	Affimer K69 - KRAS protein complex
6SWT	;	1.2	;	Affimer9 co-crystalised with the CH domains of alpha actinin 2.
6HJL	;	2.2	;	Affimer:BclxL
6HA5	;	1.87	;	AFGH61B L90V/D131S/M134L/A141W VARIANT
6H1Z	;	1.57	;	AFGH61B WILD-TYPE
6HAQ	;	1.37	;	AFGH61B WILD-TYPE COPPER LOADED
2VEZ	;	1.45	;	AfGNA1 crystal structure complexed with Acetyl-CoA and Glucose-6P gives new insights into catalysis
1GVE	;	1.38	;	Aflatoxin aldehyde reductase (AKR7A1) from Rat Liver
2KH4	;		;	Aflatoxin Formamidopyrimidine alpha anomer in single strand DNA
8C0O	;	3.9	;	African cichlid nackednavirus capsid at pH 5.5
8AAC	;	3.7	;	African cichlid nackednavirus capsid at pH 7.5
6LJO	;	2.28	;	African swine fever virus dUTPase
6L2T	;	4.1	;	African swine fever virus major capsid protein p72
2M2V	;		;	African Swine Fever Virus Pol X in the ternary complex with MgdGTP and DNA
5O51	;	2.01	;	AfRom2 CNH domain
8JKE	;	3.67	;	AfsR(T337A) transcription activation complex
7RXA	;	3.08	;	afTMEM16 DE/AA mutant in C14 lipid nanodiscs in the presence of Ca2+
7RX3	;	3.3	;	afTMEM16 in C14 lipid nanodiscs with MSP1E3 scaffold protein in the absence of Ca2+
7RXG	;	2.28	;	afTMEM16 in C18 lipid nanodiscs with MSP1E3 scaffold protein in the presence of Ca2+, full dimer
7RXH	;	2.3	;	afTMEM16 in C18 lipid nanodiscs with MSP1E3 scaffold protein in the presence of Ca2+, monomer with extra lipids
7RX2	;	2.7	;	afTMEM16 in C22 lipid nanodiscs with MSP1E3 scaffold protein in the presnece of Ca2+
7RWJ	;	3.5	;	afTMEM16 in C22 lipid nanodiscs with MSP2N2 scaffold protein in the presnece of Ca2+
7RXB	;	3.07	;	afTMEM16 lipid scramblase in C18 lipid nanodiscs in the absence of Ca2+
6DZ7	;	3.89	;	afTMEM16 reconstituted in nanodiscs in the absence of Ca2+
6E1O	;	3.59	;	afTMEM16 reconstituted in nanodiscs in the presence of Ca2+ and ceramide 24:0
6RVN	;	1.242	;	aFtsz-GDP-Wat
8GJF	;	2.0	;	afupcna bound with peptide mimetic
7BLM	;		;	AG repetition attached to a compact i-motif clip at 3'-end
7BMA	;		;	AG repetition attached to an extended i-motif clip at 3'-end
2MMS	;		;	AG(7-deaza)G FAPY modified duplex
1AQQ	;		;	AG-SUBSTITUTED METALLOTHIONEIN FROM SACCHAROMYCES CEREVISIAE, NMR, 10 STRUCTURES
1AOO	;		;	AG-SUBSTITUTED METALLOTHIONEIN FROM SACCHAROMYCES CEREVISIAE, NMR, MINIMIZED AVERAGE STRUCTURE
6PQ5	;	1.5	;	AGAAAA segment 113-118 from human prion
6PI0	;	2.09	;	AgaD472N-Linear Blood group B type 2 trisaccharide complex structure
2ERB	;	1.5	;	AgamOBP1, and odorant binding protein from Anopheles gambiae complexed with PEG
1RJO	;	1.67	;	AGAO + Xe
3KII	;	1.9	;	AGAO 5-phenoxy-2,3-pentadienylamine complex
3KN4	;	2.05	;	AGAO 6-phenyl-2,3-hexadienylamine complex
1W5Z	;	1.86	;	AGAO covalent complex with Benzylhydrazine
1W4N	;	1.65	;	AGAO covalent complex with Tranylcypromine
1W6G	;	1.55	;	AGAO holoenzyme at 1.55 angstroms
1W6C	;	2.2	;	AGAO holoenzyme in a small cell, at 2.2 angstroms
2BT3	;	1.73	;	AGAO in complex with Ruthenium-C4-wire at 1.73 angstroms
2CG1	;	1.67	;	AGAO in complex with wc11b (Ru-wire inhibitor, 11-carbon linker, data set b)
2CFG	;	1.55	;	AGAO in complex with wc4d3 (Ru-wire inhibitor, 4-carbon linker, delta enantiomer, data set 3)
2CFD	;	1.6	;	AGAO in complex with wc4l3 (Ru-wire inhibitor, 4-carbon linker, lambda enantiomer, data set 3)
2CFK	;	1.8	;	AGAO in complex with wc5 (Ru-wire inhibitor, 5-carbon linker)
2CFL	;	1.8	;	AGAO in complex with wc6b (Ru-wire inhibitor, 6-carbon linker, data set b)
2CFW	;	1.74	;	AGAO in complex with wc7a (Ru-wire inhibitor, 7-carbon linker, data set a)
2CG0	;	1.8	;	AGAO in complex with wc9a (Ru-wire inhibitor, 9-carbon linker, data set a)
1SIH	;	1.73	;	AGAO in covalent complex with the inhibitor MOBA (""4-(4-methylphenoxy)-2-butyn-1-amine"")
1SII	;	1.7	;	AGAO in covalent complex with the inhibitor NOBA (""4-(2-naphthyloxy)-2-butyn-1-amine"")
1ZFM	;	2.2	;	AGC Duplex B-DNA
2MMR	;		;	AGC FAPY modified duplex Major isomer
2WG0	;	2.2	;	AGED CONJUGATE OF TORPEDO CALIFORNICA ACETYLCHOLINESTERASE WITH SOMAN (OBTAINED BY IN CRYSTALLO AGING)
3DKK	;	2.31	;	Aged Form of Human Butyrylcholinesterase Inhibited by Tabun
2WIF	;	2.25	;	AGED FORM OF HUMAN BUTYRYLCHOLINESTERASE INHIBITED BY TABUN ANALOGUE TA1
2WSL	;	2.0	;	Aged Form of Human Butyrylcholinesterase Inhibited by Tabun Analogue TA4
2WIL	;	3.1	;	AGED FORM OF HUMAN BUTYRYLCHOLINESTERASE INHIBITED BY TABUN ANALOGUE TA5
2C0P	;	2.5	;	Aged form of mouse acetylcholinesterase inhibited by tabun
3DL7	;	2.5	;	Aged Form of Mouse Acetylcholinesterase Inhibited by Tabun- Update
8FDX	;	2.07	;	AGF271 and GAR in complex with human recombinant GARFTase, ligase, purine biosynthesis, transfers formyl group from 10-formyl tetrahydrofolate to glycinamide ribonucleotide (GAR) to form tetrahydrofolate and formyl GAR
2ZR1	;	2.6	;	Agglutinin from Abrus Precatorius
2Q3N	;	3.5	;	Agglutinin from Abrus Precatorius (APA-I)
1RZO	;	2.63	;	Agglutinin from Ricinus communis with galactoaza
1JLX	;	2.2	;	AGGLUTININ IN COMPLEX WITH T-DISACCHARIDE
1BJJ	;	2.8	;	AGKISTRODOTOXIN, A PHOSPHOLIPASE A2-TYPE PRESYNAPTIC NEUROTOXIN FROM AGKISTRODON HALYS PALLAS
1A2A	;	2.8	;	AGKISTROTOXIN, A PHOSPHOLIPASE A2-TYPE PRESYNAPTIC NEUROTOXIN FROM AGKISTRODON HALYS PALLAS
3S7G	;	3.13	;	Aglycosylated human igg1 fc fragment
3HVM	;	2.1	;	Agmatine Deiminase from Helicobacter pylori
2JER	;	1.65	;	Agmatine deiminase of Enterococcus faecalis catalyzing its reaction.
2X6T	;	2.36	;	AGME bound to ADP-B-mannose
2X86	;	2.8	;	AGME bound to ADP-B-mannose
5WF5	;	2.6	;	Agonist bound human A2a adenosine receptor with D52N mutation at 2.60 A resolution
5WF6	;	2.9	;	Agonist bound human A2a adenosine receptor with S91A mutation at 2.90 A resolution
3QAK	;	2.71	;	Agonist bound structure of the human adenosine A2a receptor
5I56	;	2.28	;	Agonist-bound GluN1/GluN2A agonist binding domains with TCN201
8J1H	;	3.88	;	Agonist1 and Ruthenium Red bound state of mTRPV4
1HYK	;		;	AGOUTI-RELATED PROTEIN (87-132) (AC-AGRP(87-132))
5W6J	;	1.78	;	Agrobacterium tumefaciens ADP-glucose pyrophosphorylase
5W5T	;	1.76	;	Agrobacterium tumefaciens ADP-Glucose Pyrophosphorylase bound to activator ethyl pyruvate
5W5R	;	1.754	;	Agrobacterium tumefaciens ADP-glucose pyrophosphorylase P96A mutant bound to activator pyruvate
6VR0	;	2.2	;	Agrobacterium Tumefaciens ADP-glucose pyrophosphorylase W106A
6V99	;	2.287	;	Agrobacterium tumefaciens ADP-Glucose pyrophosphorylase- S72D in the presence of sulfate
6V9A	;	2.3	;	Agrobacterium tumefaciens ADP-Glucose pyrophosphorylase-S72D
6V96	;	1.8	;	Agrobacterium tumefaciens ADP-Glucose pyrophosphorylase-S72E
4I7W	;	1.3	;	Agrobacterium tumefaciens DHDPS with lysine and pyruvate
4I7V	;	1.45	;	Agrobacterium tumefaciens DHDPS with pyruvate
8EXH	;	3.5	;	Agrobacterium tumefaciens Tpilus
1WW7	;	1.9	;	Agrocybe cylindracea galectin (Ligand-free)
1WW5	;	2.2	;	Agrocybe cylindracea galectin complexed with 3'-sulfonyl lactose
1WW6	;	2.2	;	Agrocybe cylindracea galectin complexed with lactose
1WW4	;	2.3	;	Agrocybe cylindracea galectin complexed with NeuAca2-3lactose
8GY0	;	1.988	;	Agrocybe pediades linalool sunthase (Ap.LS)
6I5S	;	1.73	;	AH, Bottromycin amidohydrolase
2JCC	;	2.5	;	AH3 recognition of mutant HLA-A2 W167A
8ES5	;	1.97	;	Aha1 domain protein from Pseudomonas aeruginosa
7VNI	;	1.997	;	AHR-ARNT PAS-B heterodimer
8JVM	;	3.86	;	AHS-CSF domains of phage lambda tail
8FUM	;	1.48	;	AibH1H2 metalated with Fe in the presence of Tris
7MGQ	;	2.67	;	AICAR transformylase/IMP cyclohydrolase (ATIC) is essential for de novo purine biosynthesis and infection by Cryptococcus neoformans
5LVC	;	4.2	;	Aichi virus 1: empty particle
5YWZ	;	2.2	;	AID-SUN tandem of SUN1
2KIV	;		;	AIDA-1 SAM domain tandem
4ZO2	;	1.09	;	AidC, a Dizinc Quorum-Quenching Lactonase
4ZO3	;	1.67	;	AidC, a Dizinc Quorum-Quenching Lactonase, in complex with a product N-hexnoyl-L-homoserine
3Q9J	;	2.55	;	AIIFL segment derived from Alzheimer's Amyloid-Beta displayed on 42-membered macrocycle scaffold
3T4G	;	1.7	;	AIIGLMV segment from Alzheimer's Amyloid-Beta displayed on 54-membered macrocycle scaffold
2MNF	;		;	AIK-18/51 DNA recognition sequence d(CGACTAGTCG)2
3FOD	;	1.4	;	AILSST segment from Islet Amyloid Polypeptide
4AIF	;	2.006	;	AIP TPR domain in complex with human Hsp90 peptide
4APO	;	1.895	;	AIP TPR domain in complex with human Tomm20 peptide
8SM8	;	2.0	;	Air-oxidized A. ca TruffO expressed from M9 minimal medium supplemented with Fe
8SM9	;	2.3	;	Air-oxidized C. fi TruffO expressed from M9 minimal medium supplemented with Fe
8SM7	;	2.2	;	Air-oxidized G. y4 TruffO expressed from M9 minimal medium supplemented with Fe
2W3G	;	1.4	;	Air-oxidized structure of the first GAF domain of Mycobacterium tuberculosis DosS
7DN0	;	3.5	;	AJ-GMPCPP-MT-non-seam
6A56	;	1.2	;	AJLec from the Sea Anemone Anthopleura japonica
2OM9	;	2.8	;	Ajulemic acid, a synthetic cannabinoid bound to PPAR gamma
8GQU	;	3.5	;	AK-42 inhibitor binding human ClC-2 TMD
4D0O	;	2.75	;	AKAP13 (AKAP-Lbc) DH domain
4D0N	;	2.1	;	AKAP13 (AKAP-Lbc) RhoGEF domain in complex with RhoA
2VFY	;	1.8	;	AKAP18 delta central domain
2VFK	;	1.5	;	AKAP18 delta central domain - AMP
2VFL	;	2.25	;	AKAP18 delta central domain - CMP
4ZP3	;	2.63	;	AKAP18:PKA-RIIalpha structure reveals crucial anchor points for recognition of regulatory subunits of PKA
7NHT	;	3.2	;	Akirin2 bound human proteasome
6F7R	;	0.92	;	AKR1B1 at 0.03 MGy radiation dose.
6F81	;	0.97	;	AKR1B1 at 0.75 MGy radiation dose.
6F82	;	1.03	;	AKR1B1 at 1.65 MGy radiation dose.
6F84	;	1.09	;	AKR1B1 at 2.55 MGy radiation dose.
6F8O	;	1.17	;	AKR1B1 at 3.45 MGy radiation dose.
6A7A	;	2.37	;	AKR1C1 complexed with new inhibitor with novel scaffold
4JTQ	;	1.6	;	AKR1C2 complex with flurbiprofen
4JTR	;	1.3	;	AKR1C2 complex with ibuprofen
4JQ4	;	1.52	;	AKR1C2 complex with indomethacin
4JQA	;	1.45	;	AKR1C2 complex with mefenamic acid
4JQ1	;	1.6	;	AKR1C2 complex with naproxen
4JQ2	;	1.75	;	AKR1C2 complex with sulindac
4JQ3	;	1.75	;	AKR1C2 complex with zomepirac
3R94	;	2.013	;	AKR1C3 complex with flurbiprofen
3R8G	;	1.799	;	AKR1C3 complex with ibuprofen
3UGR	;	1.65	;	AKR1C3 complex with indomethacin at pH 6.8
3UG8	;	1.73	;	AKR1C3 complex with indomethacin at pH 7.5
3R6I	;	1.95	;	AKR1C3 complex with meclofenamic acid
3R58	;	2.3	;	AKR1C3 complex with naproxen
3UFY	;	1.9	;	AKR1C3 complex with R-naproxen
3R7M	;	2.1	;	AKR1C3 complex with sulindac
3R8H	;	1.9	;	AKR1C3 complex with zomepirac
3UWE	;	1.68	;	AKR1C3 complexed with 3-phenoxybenzoic acid
4WRH	;	1.6	;	AKR1C3 complexed with breakdown product of N-(tert-butyl)-2-(2-chloro-4-(((3-mercapto-5-methyl-4H-1,2,4-triazol-4-yl)amino)methyl)-6-methoxyphenoxy)acetamide
3R43	;	2.0	;	AKR1C3 complexed with mefenamic acid
6A7B	;	2.37	;	AKR1C3 complexed with new inhibitor with novel scaffold
5EID	;	2.0	;	AKR2A ankyrin repeat domain
7F7M	;	2.47	;	AKR4C17 in complex with NADP+ and glyphosate
7T4X	;	2.8	;	AKT1 K+ channel from A. thaliana in MSP2N2 lipid nanodisc
3OCB	;	2.7	;	Akt1 kinase domain with pyrrolopyrimidine inhibitor
4EKK	;	2.8	;	Akt1 with AMP-PNP
4EKL	;	2.0	;	Akt1 with GDC0068
6IC3	;	3.3	;	AL amyloid fibril from a lambda 1 light chain
7NSL	;	3.1	;	AL amyloid fibril from a lambda 1 light chain
6Z1O	;	3.2	;	AL amyloid fibril from a lambda 3 light chain in conformation A
6Z1I	;	3.4	;	AL amyloid fibril from a lambda 3 light chain in conformation B
3CDY	;	2.43	;	AL-09 H87Y, immunoglobulin light chain variable domain
3U7A	;	2.0	;	AL-09 Y32F Y96F
3U79	;	1.62	;	AL-103 Y32F Y96F
7VOJ	;	3.0	;	Al-bound structure of the AtALMT1 mutant M60A
1SGP	;	1.4	;	ALA 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B
2FMO	;	2.25	;	Ala177Val mutant of E. coli Methylenetetrahydrofolate Reductase
2FMN	;	2.05	;	Ala177Val mutant of E. coli Methylenetetrahydrofolate Reductase complex with LY309887
2IFI	;		;	Ala6 Variant of ImI Conotoxin
1B6Q	;	1.8	;	ALANINE 31 PROLINE MUTANT OF ROP PROTEIN
1GMG	;	1.9	;	ALANINE 31 PROLINE MUTANT OF ROP PROTEIN, MONOCLINIC FORM
1XI9	;	2.33	;	Alanine aminotransferase from Pyrococcus furiosus Pfu-1397077-001
1OMO	;	2.32	;	alanine dehydrogenase dimer w/bound NAD (archaeal)
1SFT	;	1.9	;	ALANINE RACEMASE
1L6G	;	2.0	;	Alanine racemase bound with N-(5'-phosphopyridoxyl)-D-alanine
1L6F	;	2.0	;	Alanine racemase bound with N-(5'-phosphopyridoxyl)-L-alanine
1BD0	;	1.6	;	ALANINE RACEMASE COMPLEXED WITH ALANINE PHOSPHONATE
3HA1	;	1.95	;	Alanine racemase from Bacillus Anthracis (Ames)
7XLL	;	1.76	;	Alanine racemase from Lactobacillus sakei Uonuma-1.
5FAC	;	2.8	;	Alanine Racemase from Streptomyces coelicolor A3(2)
5FAJ	;	1.64	;	Alanine Racemase from Streptomyces coelicolor A3(2) in complex with D-Cycloserine
5FAG	;	1.51	;	Alanine Racemase from Streptomyces coelicolor A3(2) with Bound Propionate Inhibitor
1EPV	;	2.2	;	ALANINE RACEMASE WITH BOUND INHIBITOR DERIVED FROM D-CYCLOSERINE
1NIU	;	2.2	;	ALANINE RACEMASE WITH BOUND INHIBITOR DERIVED FROM L-CYCLOSERINE
2SFP	;	1.9	;	ALANINE RACEMASE WITH BOUND PROPIONATE INHIBITOR
4LUS	;	2.1	;	alanine racemase [Clostridium difficile 630]
4LUT	;	2.26	;	alanine racemase [Clostridium difficile 630] complex with cycloserine
4P2S	;	1.94	;	Alanine Scanning Mutagenesis Identifies an Asparagine-Arginine-Lysine Triad Essential to Assembly of the Shell of the Pdu Microcompartment
6PK3	;	2.18	;	Alanine-glyoxylate aminotransferase 1 (AGT1) from Arabidopsis thaliana
6PK1	;	2.1	;	Alanine-glyoxylate aminotransferase 1 (AGT1) from Arabidopsis thaliana in presence of serine
4KYO	;	2.2	;	Alanine-glyoxylate aminotransferase variant K390A in complex with the TPR domain of human Pex5p
4KXK	;	2.9	;	Alanine-glyoxylate aminotransferase variant K390A/K391A in complex with the TPR domain of human Pex5p
4I8A	;	2.9	;	Alanine-glyoxylate aminotransferase variant S187F
1V7O	;	2.62	;	Alanyl-tRNA synthetase editing domain homologue protein from Pyrococcus horikoshii
4Z9E	;	2.49	;	Alba from Thermoplasma volcanium
6H95	;	1.9	;	AlbA, albicidin resistance protein
6H96	;	1.55	;	AlbA-albicidin complex, albicidin resistance protein
6HAI	;	2.2	;	AlbAM131A mutant in complex with albicidin , albicidin resistance protein
6H97	;	2.598	;	AlbAT99V mutant , albicidin resistance protein
3OQV	;	1.9	;	AlbC, a cyclodipeptide synthase from Streptomyces noursei
7U6M	;	1.75	;	Albumin binding domain fused to a mutant of the Erwinia asparaginase
6XK0	;	2.4	;	Albumin-dexamethasone complex
2WKW	;	2.03	;	Alcaligenes esterase complexed with product analogue
1CDO	;	2.05	;	ALCOHOL DEHYDROGENASE (E.C.1.1.1.1) (EE ISOZYME) COMPLEXED WITH NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD), AND ZINC
2XAA	;	2.8	;	Alcohol dehydrogenase ADH-'A' from Rhodococcus ruber DSM 44541 at pH 8.5 in complex with NAD and butane-1,4-diol
4RQT	;	2.3	;	Alcohol Dehydrogenase Crystal Structure
4RQU	;	2.5	;	Alcohol Dehydrogenase crystal structure in complex with NAD
6QHE	;	1.83	;	Alcohol Dehydrogenase from Arthrobacter sp. TS-15 in complex with NAD+
6TQ3	;	2.0	;	Alcohol dehydrogenase from Candida magnoliae DSMZ 70638 (ADHA)
6TQ5	;	1.6	;	Alcohol dehydrogenase from Candida magnoliae DSMZ 70638 (ADHA): complex with NADP+
6TQ8	;	2.5	;	Alcohol dehydrogenase from Candida magnoliae DSMZ 70638 (ADHA): thermostable 10fold mutant
1JQB	;	1.97	;	Alcohol Dehydrogenase from Clostridium Beijerinckii: Crystal Structure of Mutant with Enhanced Thermal Stability
1A4U	;	1.92	;	ALCOHOL DEHYDROGENASE FROM DROSOPHILA LEBANONENSIS
1B14	;	2.4	;	Alcohol Dehydrogenase from Drosophila Lebanonensis Binary Complex with NAD+
1SBY	;	1.1	;	Alcohol dehydrogenase from Drosophila lebanonensis complexed with NAD+ and 2,2,2-trifluoroethanol at 1.1 A resolution
1B16	;	1.4	;	ALCOHOL DEHYDROGENASE FROM DROSOPHILA LEBANONENSIS TERNARY COMPLEX WITH NAD-3-PENTANONE
1B15	;	2.2	;	ALCOHOL DEHYDROGENASE FROM DROSOPHILA LEBANONENSIS TERNARY COMPLEX WITH NAD-ACETONE
1B2L	;	1.6	;	ALCOHOL DEHYDROGENASE FROM DROSOPHILA LEBANONENSIS: TERNARY COMPLEX WITH NAD-CYCLOHEXANONE
1Y9A	;	1.81	;	Alcohol Dehydrogenase from Entamoeba histolotica in complex with cacodylate
4FR2	;	3.2	;	Alcohol dehydrogenase from Oenococcus oeni
1R37	;	2.3	;	Alcohol dehydrogenase from sulfolobus solfataricus complexed with NAD(H) and 2-ethoxyethanol
7QUY	;	2.6	;	Alcohol Dehydrogenase from Thauera aromatica complexed with NADH
7QUL	;	1.8	;	Alcohol Dehydrogenase from Thauera aromatica K319A/K320A mutant
4Z6K	;	1.9	;	Alcohol dehydrogenase from the antarctic psychrophile Moraxella sp. TAE 123
1JVB	;	1.85	;	ALCOHOL DEHYDROGENASE FROM THE ARCHAEON SULFOLOBUS SOLFATARICUS
4CPD	;	2.74	;	Alcohol dehydrogenase TADH from Thermus sp. ATN1
5HSA	;	2.35	;	Alcohol Oxidase AOX1 from Pichia Pastoris
6H3G	;	2.6	;	Alcohol oxidase from Phanerochaete chrysosporium
6H3O	;	2.5	;	Alcohol oxidase from Phanerochaete chrysosporium mutant F101S
5I68	;	3.37	;	Alcohol oxidase from Pichia pastoris
8ENE	;	2.64	;	Aldehyde dehydrogenase 1 family member A1 from human liver
1AG8	;	2.65	;	ALDEHYDE DEHYDROGENASE FROM BOVINE MITOCHONDRIA
1A4Z	;	2.75	;	ALDEHYDE DEHYDROGENASE FROM BOVINE MITOCHONDRIA COMPLEX WITH NAD (REDUCED) AND SAMARIUM (III)
4C7Z	;	1.55	;	Aldehyde Oxidoreductase from Desulfovibrio gigas (MOP), activated with sodium dithionite and sodium sulfide
4US9	;	1.4	;	Aldehyde Oxidoreductase from Desulfovibrio gigas (MOP), soaked with 3- phenylpropionaldehyde
4US8	;	1.49	;	Aldehyde Oxidoreductase from Desulfovibrio gigas (MOP), soaked with benzaldehyde
4C80	;	1.5	;	Aldehyde Oxidoreductase from Desulfovibrio gigas (MOP), soaked with hydrogen peroxide
4C7Y	;	1.57	;	Aldehyde Oxidoreductase from Desulfovibrio gigas (MOP), soaked with sodium dithionite and sodium sulfide
4USA	;	1.13	;	Aldehyde Oxidoreductase from Desulfovibrio gigas (MOP), soaked with trans-cinnamaldehyde
2ALR	;	2.48	;	ALDEHYDE REDUCTASE
1AE4	;	2.4	;	ALDEHYDE REDUCTASE COMPLEXED WITH COFACTOR AND INHIBITOR, ALPHA CARBON ATOMS ONLY
6DUM	;	2.0	;	ALDH1A1 N121S in complex with 6-{[(3-fluorophenyl)methyl]sulfanyl}-2-(oxetan-3-yl)-5-phenyl-2,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (compound 13g)
6B5I	;	2.6	;	ALDH1A2 liganded with 1-(4-cyanophenyl)-N-(3-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole-4-carboxamide (compound CM121)
6B5G	;	2.2	;	ALDH1A2 liganded with NAD and (3-ethoxythiophen-2-yl){4-[4-nitro-3-(pyrrolidin-1-yl)phenyl]piperazin-1-yl}methanone (compound 6-118)
6B5H	;	2.3	;	ALDH1A2 liganded with NAD and 1-(4-cyanophenyl)-N-(3-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole-4-carboxamide (compound CM121)
6ALJ	;	1.89	;	ALDH1A2 liganded with NAD and compound WIN18,446
8OT8	;	2.4	;	Alditol oxidase from Actinomycetota bacterium in complex with D-xylulose
2VFU	;	1.9	;	Alditol Oxidase from Streptomyces coelicolor A3(2): Complex with Mannitol
2VFT	;	1.6	;	Alditol Oxidase from Streptomyces coelicolor A3(2): Complex with Sorbitol
2VFV	;	1.72	;	Alditol Oxidase from Streptomyces coelicolor A3(2): Complex with Sulphite
2VFS	;	1.6	;	Alditol Oxidase from Streptomyces coelicolor A3(2): Complex with Xylitol
2VFR	;	1.1	;	Alditol Oxidase from Streptomyces coelicolor A3(2): Native Enzyme
1YNP	;	1.25	;	aldo-keto reductase AKR11C1 from Bacillus halodurans (apo form)
1YNQ	;	1.3	;	aldo-keto reductase AKR11C1 from Bacillus halodurans (holo form)
8HWN	;	2.7	;	aldo-keto reductase DepB
8IKU	;	2.13	;	Aldo-keto reductase KmAKR - W297H
7K9X	;	3.8	;	Aldolase, rabbit muscle (beam-tilt refinement x1)
7KA2	;	3.6	;	Aldolase, rabbit muscle (beam-tilt refinement x2)
7KA3	;	3.3	;	Aldolase, rabbit muscle (beam-tilt refinement x3)
7KA4	;	2.8	;	Aldolase, rabbit muscle (beam-tilt refinement x4)
7K9L	;	4.9	;	Aldolase, rabbit muscle (no beam-tilt refinement)
3V35	;	1.9	;	Aldose reductase complexed with a nitro compound
3V36	;	2.0	;	Aldose reductase complexed with glceraldehyde
2IKG	;	1.43	;	Aldose reductase complexed with nitrophenyl-oxadiazol type inhibitor at 1.43 A
1AH3	;	2.3	;	ALDOSE REDUCTASE COMPLEXED WITH TOLRESTAT INHIBITOR
3DN5	;	1.45	;	Aldose Reductase in complex with novel biarylic inhibitor
3U2C	;	1.0	;	Aldose reductase in complex with NSAID-type inhibitor at 1.0 A resolution
2AGT	;	1.0	;	Aldose Reductase Mutant Leu 300 Pro complexed with Fidarestat
2F2K	;	1.94	;	Aldose reductase tertiary complex with NADPH and DEG
3G9E	;	2.3	;	Aleglitaar. a new. potent, and balanced dual ppara/g agonist for the treatment of type II diabetes
3G8I	;	2.2	;	Aleglitazar, a new, potent, and balanced PPAR alpha/gamma agonist for the treatment of type II diabetes
5MXC	;	1.14	;	Aleuria aurantia lectin (AAL) N224Q mutant in complex with alpha-methyl-L-fucoside
6GKE	;	1.08	;	Aleuria aurantia lectin AAL N224Q mutant in complex with Fucalpha1-6GlcNAc
6BQW	;	4.2	;	AlfA Filament bound to AMPPNP
6F95	;	3.44	;	AlfA from B. subtilis plasmid pLS32 filament structure at 3.4 A
2M7L	;		;	Alfa-actinin from parasite Entamoeba histolytica
6I2G	;	1.5	;	ALFA-tag binding nanobody (NbALFA) bound to ALFA-tag peptide.
1SUI	;	2.7	;	Alfalfa caffeoyl coenzyme A 3-O-methyltransferase
4NEI	;	1.85	;	Alg17c PL17 Family Alginate Lyase
3GZE	;	1.98	;	Algal prolyl 4-hydroxylase complexed with zinc and (Ser-Pro)5 peptide substrate
5IYU	;	2.7	;	AlgE_CIM
7VBO	;	1.5	;	Alginate binding domain CBM
4E1Y	;	2.1	;	Alginate lyase A1-III H192A apo form
4F10	;	2.2	;	Alginate lyase A1-III H192A complexed with tetrasaccharide
4F13	;	2.208	;	Alginate lyase A1-III Y246F complexed with tetrasaccharide
5ZQI	;	1.5	;	Alginate lyase AlgAT5 from Polysaccharide Lyase family 7
1J1T	;	2.0	;	Alginate lyase from Alteromonas sp.272
3F73	;	3.0	;	Alignment of guide-target seed duplex within an argonaute silencing complex
2UXY	;	1.25	;	Aliphatic amidase
3C3R	;	2.02	;	ALIX BRO1 CHMP4C complex
3C3O	;	2.15	;	ALIX Bro1-domain:CHMIP4A co-crystal structure
3C3Q	;	2.1	;	ALIX Bro1-domain:CHMIP4B co-crystal structure
4JJY	;	6.503	;	Alix V domain
3GXL	;	1.8	;	ALK-5 kinase complex with GW857175
5USQ	;	2.55	;	ALK-5 kinase inhibitor complex
7YRU	;	2.6	;	ALK2 antibody complex
2WOU	;	2.3	;	ALK5 IN COMPLEX WITH 4-((4-((2,6-dimethyl-3-pyridyl)oxy)-2-pyridyl) amino)benzenesulfonamide
2WOT	;	1.85	;	ALK5 IN COMPLEX WITH 4-((5,6-dimethyl-2-(2-pyridyl)-3-pyridyl)oxy)-N-(3,4,5-trimethoxyphenyl)pyridin-2-amine
5FRI	;	2.0	;	ALK5 in complex witha an N-(4-anilino-2-pyridyl)acetamide inhibitor.
7NWZ	;	4.17	;	ALK:ALKAL2 complex
3OH6	;	2.894	;	AlkA Undamaged DNA Complex: Interrogation of a C:G base pair
3OGD	;	2.8	;	AlkA Undamaged DNA Complex: Interrogation of a G*:C base pair
3OH9	;	2.802	;	AlkA Undamaged DNA Complex: Interrogation of a T:A base pair
2DIE	;	2.1	;	Alkaline alpha-amylase AmyK from Bacillus sp. KSM-1378
8JNX	;	3.2028	;	alkaline amylase Amy703 with truncated of N-terminus domain
1G01	;	1.9	;	ALKALINE CELLULASE K CATALYTIC DOMAIN
1G0C	;	1.9	;	ALKALINE CELLULASE K CATALYTIC DOMAIN-CELLOBIOSE COMPLEX
1WSD	;	1.5	;	Alkaline M-protease form I crystal structure
2ANH	;	2.4	;	ALKALINE PHOSPHATASE (D153H)
1ANI	;	2.5	;	ALKALINE PHOSPHATASE (D153H, K328H)
1URA	;	2.04	;	ALKALINE PHOSPHATASE (D51ZN)
1EW9	;	2.0	;	ALKALINE PHOSPHATASE (E.C. 3.1.3.1) COMPLEX WITH MERCAPTOMETHYL PHOSPHONATE
1EW8	;	2.2	;	ALKALINE PHOSPHATASE (E.C. 3.1.3.1) COMPLEX WITH PHOSPHONOACETIC ACID
1HQA	;	2.25	;	ALKALINE PHOSPHATASE (H412Q)
1ANJ	;	2.3	;	ALKALINE PHOSPHATASE (K328H)
1URB	;	2.14	;	ALKALINE PHOSPHATASE (N51MG)
1B8J	;	1.9	;	ALKALINE PHOSPHATASE COMPLEXED WITH VANADATE
1ZED	;	1.57	;	Alkaline phosphatase from human placenta in complex with p-nitrophenyl-phosphonate
1ALI	;	2.2	;	ALKALINE PHOSPHATASE MUTANT (H412N)
1ALJ	;	2.6	;	ALKALINE PHOSPHATASE MUTANT (H412N)
1HJK	;	2.3	;	ALKALINE PHOSPHATASE MUTANT H331Q
1AKL	;	2.0	;	ALKALINE PROTEASE FROM PSEUDOMONAS AERUGINOSA IFO3080
4MG2	;	2.3	;	ALKBH2 F102A cross-linked to undamaged dsDNA
4MGT	;	2.6	;	ALKBH2 R110A cross-linked to undamaged dsDNA
3Q3T	;	2.6	;	Alkyl Amine Renin Inhibitors: Filling S1 from S3
2UUV	;	1.99	;	alkyldihydroxyacetonephosphate synthase in P1
2UUU	;	1.95	;	alkyldihydroxyacetonephosphate synthase in P212121
5WX3	;	1.801	;	Alkyldiketide-CoA synthase from Evodia rutaecarpa
5WX7	;	1.904	;	Alkyldiketide-CoA synthase W332G mutant from Evodia rutaecarpa
5WX6	;	1.799	;	Alkyldiketide-CoA synthase W332Q mutant from Evodia rutaecarpa
4WHQ	;	1.78	;	Alkylperoxo reaction intermediate trapped in Protocatechuate 3,4-dioxygenase (pseudomonas putida) at pH 6.5
5CL3	;	1.971	;	Alkylpurine DNA glycosylase AlkD bound to DNA containing a 3-methyladenine analog (100% substrate at 4 hours)
5CLB	;	1.766	;	Alkylpurine DNA glycosylase AlkD bound to DNA containing a 3-methyladenine analog (9-mer A)
5CLC	;	1.729	;	Alkylpurine DNA glycosylase AlkD bound to DNA containing a 3-methyladenine analog (9-mer B)
5CL7	;	1.44	;	Alkylpurine DNA glycosylase AlkD bound to DNA containing a 3-methyladenine analog or DNA containing an abasic site and a free nucleobase (18% substrate/82% product at 96 hours)
5CL6	;	1.541	;	Alkylpurine DNA glycosylase AlkD bound to DNA containing a 3-methyladenine analog or DNA containing an abasic site and a free nucleobase (33% substrate/67% product at 72 hours)
5CL5	;	1.569	;	Alkylpurine DNA glycosylase AlkD bound to DNA containing a 3-methyladenine analog or DNA containing an abasic site and a free nucleobase (51% substrate/49% product at 48 hours)
5CL4	;	1.866	;	Alkylpurine DNA glycosylase AlkD bound to DNA containing a 3-methyladenine analog or DNA containing an abasic site and a free nucleobase (71% substrate/29% product at 24 hours)
5CL8	;	1.38	;	Alkylpurine DNA glycosylase AlkD bound to DNA containing an abasic site and a free nucleobase (100% product at 144 hours)
5CL9	;	1.538	;	Alkylpurine DNA glycosylase AlkD bound to DNA containing an abasic site and a free nucleobase (100% product at 240 hours)
5CLA	;	1.541	;	Alkylpurine DNA glycosylase AlkD bound to DNA containing an abasic site and a free nucleobase (100% product at 360 hours)
5CLE	;	1.73	;	Alkylpurine DNA glycosylase AlkD bound to DNA containing an abasic-site analog and a free 3-methyladenine nucleobase
5CLD	;	1.541	;	Alkylpurine DNA glycosylase AlkD bound to DNA containing an oxocarbenium-intermediate analog and a free 3-methyladenine nucleobase
5WX4	;	2.203	;	Alkylquinolone synthase from Evodia rutaecarpa
5WX5	;	3.058	;	Alkylquinolone synthase Y215V mutant from Evodia rutaecarpa
7TC6	;	1.85	;	All Phe-Azurin variant - F15W
7TC5	;	1.45	;	All Phe-Azurin variant - F15Y
5BPJ	;	1.756	;	All Three Ca(2+)-binding Loops of Light-sensitive Ctenophore Photoprotein Berovin Bind Magnesium Ions: The Spatial Structure of Mg(2+)-loaded Apo-berovin
1G1M	;	2.25	;	ALL-FERROUS NITROGENASE IRON PROTEIN FROM AZOTOBACTER VINELANDII
3QVJ	;	2.1	;	Allantoin racemase from Klebsiella pneumoniae
3QVK	;	1.999	;	Allantoin racemase from Klebsiella pneumoniae
3QVL	;	1.822	;	Allantoin racemase from Klebsiella pneumoniae
3DY5	;	3.51	;	Allene oxide synthase 8R-lipoxygenase from Plexaura homomalla
7B39	;	2.13	;	Allene-Based Design of a Noncalcemic Vitamin D Receptor Agonist
1W2Q	;		;	allergen arah6 from peanut (Arachis hypogaea)
1WHO	;	1.9	;	ALLERGEN PHL P 2
1WHP	;	3.0	;	ALLERGEN PHL P 2
2HOX	;	1.4	;	alliinase from allium sativum (garlic)
2JUU	;		;	allo-ThrA3 DKP-insulin
7UR5	;	2.6	;	allo-tRNAUTu1 in the A, P, and E sites of the E. coli ribosome
7URI	;	2.6	;	allo-tRNAUTu1A in the A site of the E. coli ribosome
7URM	;	3.0	;	allo-tRNAUTu1A in the P site of the E. coli ribosome
3MML	;	2.5	;	Allophanate Hydrolase Complex from Mycobacterium smegmatis, Msmeg0435-Msmeg0436
1ALL	;	2.3	;	ALLOPHYCOCYANIN
3DBJ	;	2.9	;	Allophycocyanin from Thermosynechococcus vulcanus
6X7T	;	1.0	;	Allose-bound structure of Marinomonas primoryensis PA14 carbohydrate-binding domain
6I44	;	1.36	;	Allosteric activation of human prekallikrein by apple domain disc rotation
6I58	;	2.6	;	Allosteric activation of human prekallikrein by apple domain disc rotation
2LXS	;		;	Allosteric communication in the KIX domain proceeds through dynamic re-packing of the hydrophobic core
2LXT	;		;	Allosteric communication in the KIX domain proceeds through dynamic re-packing of the hydrophobic core
4V9C	;	3.3	;	Allosteric control of the ribosome by small-molecule antibiotics
6UTJ	;	2.9	;	Allosteric couple between alpha rings of the 20S proteasome. 20S proteasome singly capped by PA26/E102A, C-terminus replaced by PAN C-terminus
6UTH	;	3.4	;	Allosteric coupling between alpha-rings of 20S proteasome, 20S proteasome singly capped with a PA26/E102A_PANc, together with LFP incubation
6UTI	;	3.4	;	Allosteric coupling between alpha-rings of 20S proteasome, 20S proteasome with singly capped PAN complex
6UTG	;	3.4	;	Allosteric coupling between alpha-rings of the 20S proteasome, 20S singly capped with a PA26/V230F
6UTF	;	3.4	;	Allosteric coupling between alpha-rings of the 20S proteasome, archaea 20S proteasome singly capped with a PAN complex
4R0X	;	1.2	;	Allosteric coupling of conformational transitions in the FK1 domain of FKBP51 near the site of steroid receptor interaction
6HHC	;	2.7	;	Allosteric Inhibition as a new mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated form of Coagulation Factor XI
2GPA	;	2.0	;	ALLOSTERIC INHIBITION OF GLYCOGEN PHOSPHORYLASE A BY A POTENTIAL ANTIDIABETIC DRUG
3AMV	;	2.1	;	ALLOSTERIC INHIBITION OF GLYCOGEN PHOSPHORYLASE A BY A POTENTIAL ANTIDIABETIC DRUG
5JYO	;	2.098	;	Allosteric inhibition of Kidney Isoform of Glutaminase
5JYP	;	2.74	;	Allosteric inhibition of Kidney Isoform of Glutaminase
1T48	;	2.2	;	Allosteric Inhibition of Protein Tyrosine Phosphatase 1B
1T49	;	1.9	;	Allosteric Inhibition of Protein Tyrosine Phosphatase 1B
1T4J	;	2.7	;	Allosteric Inhibition of Protein Tyrosine Phosphatase 1B
2I80	;	2.19	;	Allosteric inhibition of Staphylococcus aureus D-alanine:D-alanine ligase revealed by crystallographic studies
2I87	;	2.0	;	Allosteric inhibition of Staphylococcus aureus D-alanine:D-alanine ligase revealed by crystallographic studies
2I8C	;	2.46	;	Allosteric inhibition of Staphylococcus aureus D-alanine:D-alanine ligase revealed by crystallographic studies
4EHA	;	1.696	;	Allosteric Modulation of Caspase-3 through Mutagenesis
4EHD	;	1.581	;	Allosteric Modulation of Caspase-3 through Mutagenesis
4EHF	;	1.655	;	Allosteric Modulation of Caspase-3 through Mutagenesis
4EHH	;	1.78	;	Allosteric Modulation of Caspase-3 through Mutagenesis
4EHK	;	1.668	;	Allosteric Modulation of Caspase-3 through Mutagenesis
4EHL	;	1.799	;	Allosteric Modulation of Caspase-3 through Mutagenesis
4EHN	;	1.69	;	Allosteric Modulation of Caspase-3 through Mutagenesis
3I5E	;	0.98	;	Allosteric Modulation of DNA by Small Molecules
3I5L	;	1.18	;	Allosteric Modulation of DNA by Small Molecules
3K8Y	;	1.3	;	Allosteric modulation of H-Ras GTPase
3K9L	;	1.8	;	Allosteric modulation of H-Ras GTPase
3K9N	;	2.0	;	Allosteric modulation of H-Ras GTPase
7LJD	;	3.2	;	Allosteric modulator LY3154207 binding to dopamine-bound dopamine receptor 1 in complex with miniGs protein
7LJC	;	3.0	;	Allosteric modulator LY3154207 binding to SKF-81297-bound dopamine receptor 1 in complex with miniGs protein
7WV9	;	3.36	;	Allosteric modulator ZCZ011 binding to CP55940-bound cannabinoid receptor 1 in complex with Gi protein
4JN4	;	2.3	;	Allosteric opening of the polypeptide-binding site when an Hsp70 binds ATP
4JNE	;	1.96	;	Allosteric opening of the polypeptide-binding site when an Hsp70 binds ATP
4JNF	;	1.621	;	Allosteric opening of the polypeptide-binding site when an Hsp70 binds ATP
4EJF	;	2.6465	;	Allosteric peptides that bind to a caspase zymogen and mediate caspase tetramerization
4FGT	;	2.0	;	Allosteric peptidic inhibitor of human thymidylate synthase that stabilizes inactive conformation of the enzyme.
3Q1Y	;	2.03	;	Allosteric regulation by Lysine residue: A novel anion-hole formation in the ribokinase family
6Z0S	;	5.7	;	Allostery through DNA drives phenotype switching
7NBN	;	7.0	;	Allostery through DNA drives phenotype switching
3WNS	;	1.658	;	Allyl isothiocyanate inhibitor complexed with Macrophage Migration Inhibitory Factor
3GDN	;	1.67	;	Almond hydroxynitrile lyase in complex with benzaldehyde
4KBG	;	2.54	;	almost closed conformation of the helicase core of the RNA helicase Hera
4APW	;	19.7	;	Alp12 filament structure
6KXH	;	1.7804	;	Alp1U_Y247F mutant in complex with Fluostatin C
4X5T	;	3.5	;	alpha 1 glycine receptor transmembrane structure fused to the extracellular domain of GLIC
7AEL	;	1.76	;	alpha 1-antitrypsin (C232S) complexed with GSK716
7ALS	;	1.35	;	Alpha and beta Lactose isomer structure of Galectin 8, N-terminal domain
1XGB	;		;	ALPHA CONOTOXIN GI: 2-13;3-7 DISULFIDE BOND ISOMER NMR, 24 STRUCTURES
1XGC	;		;	ALPHA CONOTOXIN GI: 2-3;7-13 DISULFIDE BOND ISOMER, NMR, 25 STRUCTURES
1XGA	;		;	ALPHA CONOTOXIN GI: 2-7;3-13 (NATIVE) DISULFIDE BOND ISOMER, NMR, 35 STRUCTURES
5TWI	;		;	Alpha Helix Nucleation by a Simple Cyclic Tetrapeptide
5TWW	;		;	Alpha Helix Nucleation by a Simple Cyclic Tetrapeptide
2JUR	;		;	alpha RgIA, a Novel Conotoxin that Blocks the alpha9-alpha10 nAChR
2JUS	;		;	alpha RgIA, a Novel Conotoxin that Blocks the alpha9-alpha10 nAChR
2JUT	;		;	alpha RgIA, a Novel Conotoxin that Blocks the alpha9-alpha10 nAChR
1EA0	;	3.0	;	Alpha subunit of A. brasilense glutamate synthase
6CU7	;	3.5	;	Alpha Synuclein fibril formed by full length protein - Rod Polymorph
6CU8	;	3.6	;	Alpha Synuclein fibril formed by full length protein - Twister Polymorph
1OLP	;	2.5	;	Alpha Toxin from Clostridium Absonum
7R13	;	3.6	;	Alpha Variant SARS-CoV-2 Spike in Closed conformation
7R14	;	3.4	;	Alpha Variant SARS-CoV-2 Spike with 1 Erect RBD
7R15	;	4.1	;	Alpha Variant SARS-CoV-2 Spike with 2 Erect RBDs
1GWW	;	1.8	;	ALPHA-,1,3 GALACTOSYLTRANSFERASE - ALPHA-D-GLUCOSE COMPLEX
1GX0	;	1.8	;	ALPHA-,1,3 GALACTOSYLTRANSFERASE - BETA-D-GALACTOSE COMPLEX
1GWV	;	2.5	;	ALPHA-,1,3 GALACTOSYLTRANSFERASE - LACTOSE COMPLEX
1GX4	;	1.46	;	ALPHA-,1,3 GALACTOSYLTRANSFERASE - N-ACETYL LACTOSAMINE COMPLEX
7NPL	;	1.82	;	ALPHA-1 ANTITRYPSIN (C232S) COMPLEXED WITH cmpd 11
7NPK	;	1.83	;	ALPHA-1 ANTITRYPSIN C232S COMPLEXED WITH CMPD3
2M32	;		;	Alpha-1 integrin I-domain in complex with GLOGEN triple helical peptide
7FGA	;	3.2	;	Alpha-1,2-glucosyltransferase_UDP_sucrose_tll1591
7FG9	;	2.66	;	Alpha-1,2-glucosyltransferase_UDP_tll1591
1HCU	;	2.37	;	alpha-1,2-mannosidase from Trichoderma reesei
5VCS	;	2.799	;	Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase with Bound Acceptor
5VCM	;	1.599	;	Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase with bound UDP and Manganese
5VCR	;	1.992	;	Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase with bound uranium dioxide
6I7U	;	1.55	;	Alpha-1-antitrypsin (Ala250Met) in the native conformation
6ROD	;	1.85	;	Alpha-1-antitrypsin (Ser36Arg/Glu78Arg/Glu266Arg) in the native conformation
8P4J	;	1.91	;	Alpha-1-antitrypsin - Sydney variant (G192C)
8P4U	;	2.4	;	Alpha-1-antitrypsin - Sydney variant (G192C)
6I4V	;	1.78	;	Alpha-1-antitrypsin Queen's (K154N) variant
6IAY	;	1.9	;	Alpha-1-antitrypsin Queen's (Lys154Asn) variant
7KOO	;	3.0	;	Alpha-7 nicotinic acetylcholine receptor bound to alpha-bungarotoxin in a resting state
7KOX	;	2.7	;	Alpha-7 nicotinic acetylcholine receptor bound to epibatidine and PNU-120596 in the activated state
7KOQ	;	3.6	;	Alpha-7 nicotinic acetylcholine receptor bound to epibatidine in a desensitized state
6SL2	;	3.1	;	ALPHA-ACTININ FROM ENTAMOEBA HISTOLYTICA
6SL3	;	3.1	;	ALPHA-ACTININ FROM ENTAMOEBA HISTOLYTICA in orthorhombic space group
7AW8	;	1.5	;	Alpha-actinin in Rhodamnia argentea
1B9K	;	1.9	;	ALPHA-ADAPTIN APPENDAGE DOMAIN, FROM CLATHRIN ADAPTOR AP2
2VUM	;	3.4	;	Alpha-amanitin inhibited complete RNA polymerase II elongation complex
1MPX	;	1.9	;	ALPHA-AMINO ACID ESTER HYDROLASE LABELED WITH SELENOMETHIONINE
5M46	;	1.62	;	Alpha-amino epsilon-caprolactam racemase (ACLR) from Rhizobacterium freirei
5M4B	;	1.5	;	Alpha-amino epsilon-caprolactam racemase D210A mutant in complex with PLP and geminal diamine intermediate
5M49	;	1.51	;	Alpha-amino epsilon-caprolactam racemase in complex with PLP and D/L alpha amino epsilon-caprolactam (internal aldimine)
5M4D	;	1.93	;	Alpha-amino epsilon-caprolactam racemase K241A mutant in complex with D-ACL (external aldimine)
3BCF	;	2.3	;	Alpha-amylase B from Halothermothrix orenii
3BC9	;	1.35	;	Alpha-amylase B in complex with acarbose
3BCD	;	2.2	;	Alpha-amylase B in complex with maltotetraose and alpha-cyclodextrin
1AQH	;	2.0	;	ALPHA-AMYLASE FROM ALTEROMONAS HALOPLANCTIS
1B0I	;	2.4	;	ALPHA-AMYLASE FROM ALTEROMONAS HALOPLANCTIS
1AQM	;	1.85	;	ALPHA-AMYLASE FROM ALTEROMONAS HALOPLANCTIS COMPLEXED WITH TRIS
1BAG	;	2.5	;	ALPHA-AMYLASE FROM BACILLUS SUBTILIS COMPLEXED WITH MALTOPENTAOSE
1BVZ	;	2.6	;	ALPHA-AMYLASE II (TVAII) FROM THERMOACTINOMYCES VULGARIS R-47
6Z8L	;	1.4	;	Alpha-Amylase in complex with probe fragments
2KER	;		;	alpha-amylase inhibitor Parvulustat (Z-2685) from Streptomyces parvulus
6P64	;	3.05	;	Alpha-beta TCR Binding to Neoantigen KQWLVWLFL Presented by HLA-A206
1HC9	;	1.8	;	alpha-bungarotoxin complexed with high affinity peptide
1L7C	;	2.5	;	alpha-catenin fragment, residues 385-651
1H6G	;	2.2	;	alpha-catenin M-domain
5J4S	;	2.103	;	alpha-chymotrypsin from bovine pancreas in complex with a modified Bowman-Birk inhibitor from soybean
5J4Q	;	2.303	;	alpha-chymotrypsin from bovine pancreas in complex with Bowman-Birk inhibitor from soybean
1B45	;		;	ALPHA-CNIA CONOTOXIN FROM CONUS CONSORS, NMR, 43 STRUCTURES
1CNL	;		;	ALPHA-CONOTOXIN IMI
7N43	;	2.47	;	Alpha-conotoxin OmIA with unusual pharmacological properties at alpha7 nicotinic receptors
1PEN	;	1.1	;	ALPHA-CONOTOXIN PNI1
1AKG	;	1.1	;	ALPHA-CONOTOXIN PNIB FROM CONUS PENNACEUS
5LUM	;	2.6	;	Alpha-crystallin domain of human HSPB6 patched with its N-terminal peptide
1WVC	;	2.5	;	alpha-D-glucose-1-phosphate cytidylyltransferase complexed with CTP
1QZM	;	1.9	;	alpha-domain of ATPase
6UPV	;	3.2	;	Alpha-E-catenin ABD-F-actin complex
4E17	;	2.304	;	Alpha-E-catenin is an autoinhibited molecule that co-activates vinculin
4E18	;	2.403	;	Alpha-E-catenin is an autoinhibited molecule that co-activates vinculin
5TYP	;	1.88	;	alpha-esterase-7 in complex with (3-bromo-4-methylphenyl)boronic acid
5TYJ	;	1.75	;	alpha-esterase-7 in complex with (3-bromo-5-phenoxylphenyl)boronic acid
5TYK	;	1.65	;	alpha-esterase-7 in complex with 3-chloro-4-[(2-fluorophenyl)methoxy]phenylborinic acid
5TYL	;	1.75	;	alpha-esterase-7 in complex with naphthalen-2-ylboronic acid
5TYO	;	1.57	;	alpha-esterase-7 in complex with [3-(benzyloxy)-4-methylphenyl]borinic acid
5TYM	;	1.84	;	alpha-esterase-7 in complex with [3-bromo-5-(pyrrolidin-1-yl)phenyl]borinic acid
5TYN	;	1.531	;	alpha-esterase-7 in complex with [3-bromo-5-(pyrrolidin-1-yl)phenyl]borinic acid
1CSR	;	1.7	;	Alpha-fluoro acid and alpha-fluoro amide analogs of acetyl-coa as inhibitors of of citrate synthase: effect of pka matching on binding affinity and hydrogen bond length
1CSS	;	1.7	;	ALPHA-FLUORO ACID AND ALPHA-FLUORO AMIDE ANALOGS OF ACETYL-COA AS INHIBITORS OF OF CITRATE SYNTHASE: EFFECT OF PKA MATCHING ON BINDING AFFINITY AND HYDROGEN BOND LENGTH
6GVD	;	1.22	;	Alpha-galactosidase from Thermotoga maritima in complex with cyclohexene-based carbasugar mimic of galactose
6GWG	;	1.77	;	Alpha-galactosidase from Thermotoga maritima in complex with cyclohexene-based carbasugar mimic of galactose covalently linked to the nucleophile
6GX8	;	1.42	;	Alpha-galactosidase from Thermotoga maritima in complex with hydrolysed cyclohexene-based carbasugar mimic of galactose
6GTA	;	2.2	;	Alpha-galactosidase mutant D378A from Thermotoga maritima in complex with intact cyclohexene-based carbasugar mimic of galactose with 3,5 difluorophenyl leaving group
6GWF	;	1.72	;	Alpha-galactosidase mutant D387A from Thermotoga maritima in complex with intact cyclohexene-based carbasugar mimic of galactose with 2,4-dinitro leaving group
2J44	;	2.1	;	Alpha-glucan binding by a streptococcal virulence factor
2J73	;	1.4	;	alpha-glucan rcognition by a family 41 carbohydrate-binding module from Thermotoga maritima pullulanase PulA
2J71	;	1.69	;	alpha-glucan recognition by a family 41 carbohydrate-binding module from Thermotoga maritima pullulanase PulA
2J72	;	1.49	;	alpha-glucan recognition by a family 41 carbohydrate-binding module from Thermotoga maritima pullulanase PulA
2J43	;	1.6	;	Alpha-glucan recognition by family 41 carbohydrate-binding modules from streptococcal virulence factors
1OBB	;	1.9	;	alpha-glucosidase A, AglA, from Thermotoga maritima in complex with maltose and NAD+
7DCH	;	1.692	;	Alpha-glucosidase from Weissella cibaria BBK-1 bound with acarbose
7D9C	;	1.36	;	Alpha-glucosidase from Weissella cibaria BBK-1 bound with maltose
7DCG	;	1.53	;	Alpha-glucosidase from Weissella cibaria BBK-1 bound with maltotriose
2ZE0	;	2.0	;	Alpha-glucosidase GSJ
1XV5	;	1.73	;	alpha-glucosyltransferase (AGT) in complex with UDP
1YA6	;	2.4	;	alpha-glucosyltransferase in complex with UDP and a 13-mer DNA containing a central A:G mismatch
1Y8Z	;	1.9	;	alpha-glucosyltransferase in complex with UDP and a 13-mer DNA containing a HMU base at 1.9 A resolution
1Y6G	;	2.8	;	alpha-glucosyltransferase in complex with UDP and a 13_mer DNA containing a HMU base at 2.8 A resolution
1Y6F	;	2.4	;	alpha-glucosyltransferase in complex with UDP-glucose and DNA containing an abasic site
3LAY	;	2.7	;	Alpha-Helical barrel formed by the decamer of the zinc resistance-associated protein (STM4172) from Salmonella enterica subsp. enterica serovar Typhimurium str. LT2
7AHL	;	1.89	;	ALPHA-HEMOLYSIN FROM STAPHYLOCOCCUS AUREUS
7OC5	;	2.01	;	Alpha-humulene synthase AsR6 from Sarocladium schorii
7OC4	;	2.03	;	Alpha-humulene synthase AsR6 from Sarocladium schorii in complex with thiolodiphosphate and a cyclized reaction product.
3OKJ	;	2.7	;	Alpha-keto-aldehyde binding mechanism reveals a novel lead structure motif for proteasome inhibition
6YPV	;	2.1	;	Alpha-ketoglutarate-dependent dioxygenase AlkB in complex with Fe and AKG after oxygen exposure using FT-SSX methods
6Y0Q	;	1.75	;	Alpha-ketoglutarate-dependent dioxygenase AlkB in complex with Fe, AKG and methylated DNA under anaerobic environment using FT-SSX methods
4CWX	;	2.15	;	ALPHA-KETOGLUTARATE-DEPENDENT DIOXYGENASE COMPLEX1
5M0T	;	2.2	;	Alpha-ketoglutarate-dependent non-heme iron oxygenase EasH
3OJ8	;	1.9	;	Alpha-Ketoheterocycle Inhibitors of Fatty Acid Amide Hydrolase Containing Additional Conformational Contraints in the Acyl Side Chain
6VGS	;	1.8	;	Alpha-ketoisovalerate decarboxylase (KivD) from Lactococcus lactis, thermostable mutant
2ZWY	;	2.75	;	alpha-L-fucosidase
6OHE	;	3.14	;	Alpha-L-fucosidase AlfC D200A in complex with Fuca(1,6)GlcNAc
6O1C	;	2.6	;	Alpha-L-fucosidase AlfC D200A mutant in complex with 4-nitrophenyl-a-L-fucopyranoside substrate
6O1A	;	2.6	;	Alpha-L-fucosidase AlfC from Lactobacillus casei in complex with alpha-L-fucose product
6O1I	;	3.55	;	Alpha-L-fucosidase AlfC fucosyltransferase mutant E274A
6O1J	;	2.0	;	Alpha-L-fucosidase AlfC fucosyltransferase mutant N243A
2ZX9	;	2.62	;	alpha-L-fucosidase complexed with inhibitor, B4
2ZWZ	;	2.36	;	alpha-L-fucosidase complexed with inhibitor, Core1
2ZX5	;	2.65	;	alpha-L-fucosidase complexed with inhibitor, F10
2ZX6	;	2.42	;	alpha-L-fucosidase complexed with inhibitor, F10-1C
2ZX7	;	2.48	;	alpha-L-fucosidase complexed with inhibitor, F10-2C
2ZX8	;	2.33	;	alpha-L-fucosidase complexed with inhibitor, F10-2C-O
2ZXA	;	2.57	;	alpha-L-fucosidase complexed with inhibitor, FNJ-acetyl
2ZXD	;	2.15	;	alpha-L-fucosidase complexed with inhibitor, iso-6FNJ
2ZXB	;	2.61	;	alpha-L-fucosidase complexed with inhibitor, ph-6FNJ
6GN6	;	2.2	;	Alpha-L-fucosidase isoenzyme 1 from Paenibacillus thiaminolyticus
6TVK	;	2.1	;	Alpha-L-fucosidase isoenzyme 2 from Paenibacillus thiaminolyticus
1A4V	;	1.8	;	ALPHA-LACTALBUMIN
1HFX	;	1.9	;	ALPHA-LACTALBUMIN
1HFY	;	2.3	;	ALPHA-LACTALBUMIN
1HFZ	;	2.3	;	ALPHA-LACTALBUMIN
7PTX	;	4.03	;	Alpha-latrocrustotoxin monomer
1BMR	;		;	ALPHA-LIKE TOXIN LQH III FROM SCORPION LEIURUS QUINQUESTRIATUS HEBRAEUS, NMR, 25 STRUCTURES
1TAL	;	1.5	;	ALPHA-LYTIC PROTEASE AT 120 K (SINGLE STRUCTURE MODEL)
3PRO	;	1.8	;	ALPHA-LYTIC PROTEASE COMPLEXED WITH C-TERMINAL TRUNCATED PRO REGION
4PRO	;	2.4	;	ALPHA-LYTIC PROTEASE COMPLEXED WITH PRO REGION
6XHZ	;	1.25	;	Alpha-lytic protease homolog N4
1GBJ	;	2.0	;	ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA
1GBA	;	2.15	;	ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY ALA
1GBB	;	2.15	;	Alpha-lytic protease with met 190 replaced by ALA AND GLY 216 replaced by ALA complex with METHOXYSUCCINYL-ALA-ALA-PRO-ALANINE BORONIC ACID
1GBC	;	2.2	;	ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY ALA COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-LEUCINE BORONIC ACID
1GBD	;	2.2	;	ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY ALA COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-PHENYLALANINE BORONIC ACID
1GBE	;	2.3	;	ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY LEU
1GBF	;	2.15	;	ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY LEU COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-ALANINE BORONIC ACID
1GBH	;	2.2	;	ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY LEU COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-LEUCINE BORONIC ACID
1GBI	;	2.3	;	ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY LEU COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-PHENYLALANINE BORONIC ACID
1GBK	;	2.13	;	ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-ALANINE BORONIC ACID
1GBL	;	2.15	;	ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-LEUCINE BORONIC ACID
1GBM	;	2.28	;	ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-PHENYLALANINE BORONIC ACID
6XAQ	;	1.2	;	Alpha-methyl-glucose-bound structure of Marinomonas primoryensis PA14 carbohydrate-binding domain
8RP4	;	1.64	;	Alpha-Methylacyl-CoA racemase from Mycobacterium tuberculosis (D156A mutant)
8RP5	;	1.85	;	Alpha-Methylacyl-CoA racemase from Mycobacterium tuberculosis (E241A mutant)
8RP3	;	2.45	;	Alpha-Methylacyl-CoA racemase from Mycobacterium tuberculosis (H126A mutant)
1X74	;	1.79	;	Alpha-methylacyl-CoA racemase from Mycobacterium tuberculosis- mutational and structural characterization of the fold and active site
8RMW	;	1.65	;	Alpha-Methylacyl-CoA racemase from Mycobacterium tuberculosis.
5WZR	;	2.79	;	Alpha-N-acetylgalactosaminidase NagBb from Bifidobacterium bifidum - Gal-NHAc-DNJ complex
5WZN	;	2.1	;	Alpha-N-acetylgalactosaminidase NagBb from Bifidobacterium bifidum - GalNAc complex
5WZP	;	2.64	;	Alpha-N-acetylgalactosaminidase NagBb from Bifidobacterium bifidum - ligand free
5WZQ	;	1.9	;	Alpha-N-acetylgalactosaminidase NagBb from Bifidobacterium bifidum - quadruple mutant
3ASI	;	2.3	;	Alpha-Neurexin-1 ectodomain fragment; LNS5-EGF3-LNS6
2JUQ	;		;	alpha-RgIA, a Novel Conotoxin that Blocks the alpha9-alpha10 nAChR
1J2P	;	2.6	;	alpha-ring from the proteasome from archaeoglobus fulgidus
6IP1	;	3.9	;	alpha-SNAP-SNARE subcomplex in the whole 20S complex
2F2V	;	1.85	;	alpha-spectrin SH3 domain A56G mutant
2CDT	;	2.54	;	alpha-SPECTRIN SH3 DOMAIN A56S MUTANT
2F2W	;	1.7	;	alpha-spectrin SH3 domain R21A mutant
2F2X	;	1.6	;	alpha-spectrin SH3 domain R21G mutant
1G2B	;	1.12	;	ALPHA-SPECTRIN SRC HOMOLOGY 3 DOMAIN, CIRCULAR PERMUTANT, CUT AT N47-D48
1TUD	;	1.77	;	ALPHA-SPECTRIN SRC HOMOLOGY 3 DOMAIN, CIRCULAR PERMUTANT, CUT AT N47-D48
1TUC	;	2.02	;	ALPHA-SPECTRIN SRC HOMOLOGY 3 DOMAIN, CIRCULAR PERMUTANT, CUT AT S19-P20
1QKX	;	1.8	;	Alpha-spectrin Src Homology 3 domain, N47A mutant in the distal loop.
1QKW	;	2.0	;	Alpha-spectrin Src Homology 3 domain, N47G mutant in the distal loop.
1AEY	;		;	ALPHA-SPECTRIN SRC HOMOLOGY 3 DOMAIN, SOLUTION NMR, 15 STRUCTURES
8RRR	;	3.4	;	Alpha-synuclein amyloid fibril
8RQM	;	3.2	;	Alpha-synuclein amyloid fibrils
8CYR	;	4.2	;	Alpha-synuclein fibril from spontaneous control
7WMM	;	2.6	;	alpha-synuclein fibril-F0502B complex
7L7H	;	4.0	;	Alpha-synuclein fibrils
1ABZ	;		;	ALPHA-T-ALPHA, A DE NOVO DESIGNED PEPTIDE, NMR, 23 STRUCTURES
1UMA	;	2.0	;	ALPHA-THROMBIN (HIRUGEN) COMPLEXED WITH NA-(N,N-DIMETHYLCARBAMOYL)-ALPHA-AZALYSINE
1W7G	;	1.65	;	Alpha-thrombin complex with sulfated hirudin (residues 54-65) and L- Arginine template inhibitor CS107
1TOM	;	1.8	;	ALPHA-THROMBIN COMPLEXED WITH HIRUGEN
1BCU	;	2.0	;	ALPHA-THROMBIN COMPLEXED WITH HIRUGEN AND PROFLAVIN
1CA1	;	1.9	;	ALPHA-TOXIN FROM CLOSTRIDIUM PERFRINGENS
3FDM	;	2.26	;	alpha/beta foldamer in complex with Bcl-xL
6NY9	;	1.66	;	Alpha/beta hydrolase domain-containing protein 10 from mouse
4PW0	;	1.48	;	Alpha/beta hydrolase fold protein from Chitinophaga pinensis
4Y7D	;	1.68	;	Alpha/beta hydrolase fold protein from Nakamurella multipartita
2Q0X	;	2.2	;	Alpha/Beta hydrolase fold protein of unknown function
3C3H	;	2.2	;	alpha/beta-Peptide helix bundles: A GCN4-pLI analogue with an (alpha-alpha-beta) backbone and cyclic beta residues
3C3F	;	2.0	;	alpha/beta-Peptide helix bundles: The GCN4-pLI side chain sequence on an (alpha-alpha-alpha-beta) backbone
3C3G	;	1.8	;	alpha/beta-Peptide helix bundles: The GCN4-pLI side chain sequence on an (alpha-alpha-beta) backbone
3HF0	;	2.1	;	alpha/beta-Peptide helix crystallized from detergent solution: GCN4-pLI side chain sequence on an (alpha-alpha-beta-alpha-beta-alpha-beta) backbone with cyclic beta-residues
1QMN	;	2.27	;	Alpha1-antichymotrypsin serpin in the delta conformation (partial loop insertion)
1KCT	;	3.46	;	ALPHA1-ANTITRYPSIN
8FE1	;	3.0	;	Alpha1/BetaB Heteromeric Glycine Receptor in 1 mM Glycine 20 uM Ivermectin State
7TVI	;	3.2	;	Alpha1/BetaB Heteromeric Glycine Receptor in Glycine-Bound State
7TU9	;	3.0	;	Alpha1/BetaB Heteromeric Glycine Receptor in Strychnine-Bound State
8F4V	;		;	Alpha7 nicotinic acetylcholine receptor intracellular and transmembrane domains bound to ivermectin in a desensitized state
4HQP	;	3.51	;	Alpha7 nicotinic receptor chimera and its complex with Alpha bungarotoxin
5AFH	;	2.4	;	alpha7-AChBP in complex with lobeline
5AFJ	;	2.2	;	alpha7-AChBP in complex with lobeline and fragment 1
5AFK	;	2.381	;	alpha7-AChBP in complex with lobeline and fragment 2
5AFL	;	2.385	;	alpha7-AChBP in complex with lobeline and fragment 3
5AFM	;	2.85	;	alpha7-AChBP in complex with lobeline and fragment 4
5AFN	;	2.149	;	alpha7-AChBP in complex with lobeline and fragment 5
8UT1	;	2.3	;	Alpha7-nicotinic acetylcholine receptor bound to epibatidine
8V80	;	2.34	;	Alpha7-nicotinic acetylcholine receptor bound to epibatidine and (-)-TQS
8V88	;	2.3	;	Alpha7-nicotinic acetylcholine receptor bound to epibatidine and GAT107
8UZJ	;	2.3	;	Alpha7-nicotinic acetylcholine receptor bound to epibatidine and ivermectin
8UTB	;	2.3	;	Alpha7-nicotinic acetylcholine receptor bound to epibatidine and NS-1738
8V82	;	2.61	;	Alpha7-nicotinic acetylcholine receptor bound to epibatidine and PNU-120596
8V86	;	2.47	;	Alpha7-nicotinic acetylcholine receptor bound to GAT107
8V8C	;	3.29	;	Alpha7-nicotinic acetylcholine receptor time resolved bound to epibatidine and PNU-120596 asymmetric state 1
8V8D	;	3.31	;	Alpha7-nicotinic acetylcholine receptor time resolved bound to epibatidine and PNU-120596 asymmetric state 2
8V8A	;	2.19	;	Alpha7-nicotinic acetylcholine receptor time resolved bound to epibatidine and PNU-120596 desensitized intermediate state
8V89	;	2.53	;	Alpha7-nicotinic acetylcholine receptor time resolved resting state
4O02	;	3.605	;	AlphaVBeta3 integrin in complex with monoclonal antibody FAB fragment.
4GUA	;	2.854	;	Alphavirus P23pro-zbd
1HML	;	1.7	;	ALPHA_LACTALBUMIN POSSESSES A DISTINCT ZINC BINDING SITE
1AZ1	;	1.8	;	ALRESTATIN BOUND TO C298A/W219Y MUTANT HUMAN ALDOSE REDUCTASE
8CIK	;	2.22	;	Altai wapiti (Cervus elaphus sibiricus) chymosin at 2.2 A resolution
1MNI	;	2.07	;	ALTERATION OF AXIAL COORDINATION BY PROTEIN ENGINEERING IN MYOGLOBIN. BIS-IMIDAZOLE LIGATION IN THE HIS64-->VAL(SLASH)VAL68-->HIS DOUBLE MUTANT
2GIG	;	1.83	;	Alteration of sequence specificity of the type II restriction endonuclease HINCII through an indirect readout mechanism
1HJF	;	1.6	;	Alteration of the co-substrate selectivity of deacetoxycephalosporin C synthase: The role of arginine-258
1HJG	;	1.5	;	Alteration of the co-substrate selectivity of deacetoxycephalosporin C synthase: The role of arginine-258
2Q1E	;	2.55	;	Altered dimer interface decreases stability in an amyloidogenic kappa1 Bence Jones protein.
1H2G	;	2.0	;	Altered substrate specificity mutant of penicillin acylase
1JEA	;	2.0	;	ALTERED TOPOLOGY AND FLEXIBILITY IN ENGINEERED SUBTILISIN
3CCX	;	2.3	;	ALTERING SUBSTRATE SPECIFICITY AT THE HEME EDGE OF CYTOCHROME C PEROXIDASE
4CCX	;	1.9	;	ALTERING SUBSTRATE SPECIFICITY AT THE HEME EDGE OF CYTOCHROME C PEROXIDASE
1CCK	;	2.1	;	ALTERING SUBSTRATE SPECIFICITY OF CYTOCHROME C PEROXIDASE TOWARDS A SMALL MOLECULAR SUBSTRATE PEROXIDASE BY SUBSTITUTING TYROSINE FOR PHE 202
2RLA	;	3.0	;	ALTERING THE BINUCLEAR MANGANESE CLUSTER OF ARGINASE DIMINISHES THERMOSTABILITY AND CATALYTIC FUNCTION
3RLA	;	2.54	;	ALTERING THE BINUCLEAR MANGANESE CLUSTER OF ARGINASE DIMINISHES THERMOSTABILITY AND CATALYTIC FUNCTION
4RLA	;	2.94	;	ALTERING THE BINUCLEAR MANGANESE CLUSTER OF ARGINASE DIMINISHES THERMOSTABILITY AND CATALYTIC FUNCTION
5RLA	;	2.74	;	ALTERING THE BINUCLEAR MANGANESE CLUSTER OF ARGINASE DIMINISHES THERMOSTABILITY AND CATALYTIC FUNCTION
12CA	;	2.4	;	ALTERING THE MOUTH OF A HYDROPHOBIC POCKET. STRUCTURE AND KINETICS OF HUMAN CARBONIC ANHYDRASE II MUTANTS AT RESIDUE VAL-121
3K47	;	2.05	;	Alternate Binding Modes Observed for the E- and Z-Isomers of 2,4-Diaminofuro[2,3-d]pyrimidines as Ternary Complexes with NADPH and Mouse Dihydrofolate Reductase
3K45	;	1.6	;	Alternate Binding Modes Observed for the E- and Z-isomers of 2,4-Diaminofuro[2,3d]pyrimidines as Ternary Complexes with NADPH and Mouse Dihydrofolate Reductase
1C6X	;	2.5	;	ALTERNATE BINDING SITE FOR THE P1-P3 GROUP OF A CLASS OF POTENT HIV-1 PROTEASE INHIBITORS AS A RESULT OF CONCERTED STRUCTURAL CHANGE IN 80'S LOOP.
1C6Y	;	2.5	;	ALTERNATE BINDING SITE FOR THE P1-P3 GROUP OF A CLASS OF POTENT HIV-1 PROTEASE INHIBITORS AS A RESULT OF CONCERTED STRUCTURAL CHANGE IN 80'S LOOP.
1C6Z	;	2.5	;	ALTERNATE BINDING SITE FOR THE P1-P3 GROUP OF A CLASS OF POTENT HIV-1 PROTEASE INHIBITORS AS A RESULT OF CONCERTED STRUCTURAL CHANGE IN 80'S LOOP.
1C70	;	2.5	;	ALTERNATE BINDING SITE FOR THE P1-P3 GROUP OF A CLASS OF POTENT HIV-1 PROTEASE INHIBITORS AS A RESULT OF CONCERTED STRUCTURAL CHANGE IN 80'S LOOP.
7RRL	;	2.05	;	Alternate Crystal Form of Human Malate Dehydrogenase I
254D	;	1.9	;	ALTERNATING AND NON-ALTERNATING DG-DC HEXANUCLEOTIDES CRYSTALLIZE AS CANONICAL A-DNA
256D	;	2.2	;	ALTERNATING AND NON-ALTERNATING DG-DC HEXANUCLEOTIDES CRYSTALLIZE AS CANONICAL A-DNA
257D	;	2.3	;	ALTERNATING AND NON-ALTERNATING DG-DC HEXANUCLEOTIDES CRYSTALLIZE AS CANONICAL A-DNA
275D	;	2.0	;	ALTERNATING AND NON-ALTERNATING DG-DC HEXANUCLEOTIDES CRYSTALLIZE AS CANONICAL A-DNA
5ZNF	;		;	ALTERNATING ZINC FINGERS IN THE HUMAN MALE ASSOCIATED PROTEIN ZFY: 2D NMR STRUCTURE OF AN EVEN FINGER AND IMPLICATIONS FOR ""JUMPING-LINKER"" DNA RECOGNITION
7ZNF	;		;	ALTERNATING ZINC FINGERS IN THE HUMAN MALE ASSOCIATED PROTEIN ZFY: 2D NMR STRUCTURE OF AN EVEN FINGER AND IMPLICATIONS FOR ""JUMPING-LINKER"" DNA RECOGNITION
3P4B	;	1.45	;	Alternatingly modified 2'Fluoro RNA octamer f/rA2U2-P3
3P4C	;	1.15	;	Alternatingly modified 2'Fluoro RNA octamer f/rA2U2-R32
3P4D	;	1.85	;	Alternatingly modified 2'Fluoro RNA octamer f/rC4G4
1G00	;	2.3	;	ALTERNATION OF DNA AND SOLVENT LAYERS IN THE A FORM OF D(GGCGCC) OBTAINED BY ETHANOL CRYSTALLIZATION
3RUD	;	2.3	;	Alternative analogs as viable substrates of UDP-hexose 4-epimerases
3RUE	;	2.8	;	Alternative analogs as viable substrates of UDP-hexose 4-epimerases
3RUF	;	2.0	;	Alternative analogs as viable substrates of UDP-hexose 4-epimerases
3RUH	;	2.88	;	Alternative analogs as viable substrates of UDP-hexose 4-epimerases
3IMB	;	1.89	;	Alternative binding mode of restriction endonuclease BcnI to cognate DNA
4CLA	;	2.0	;	ALTERNATIVE BINDING MODES FOR CHLORAMPHENICOL AND 1-SUBSTITUTED CHLORAMPHENICOL ANALOGUES REVEALED BY SITE-DIRECTED MUTAGENESIS AND X-RAY CRYSTALLOGRAPHY OF CHLORAMPHENICOL ACETYLTRANSFERASE
6F0K	;	3.87	;	Alternative complex III
5IJO	;	21.4	;	Alternative composite structure of the inner ring of the human nuclear pore complex (16 copies of Nup188, 16 copies of Nup205)
2NNW	;	2.7	;	Alternative conformations of Nop56/58-fibrillarin complex and implication for induced-fit assenly of box C/D RNPs
3BJ5	;	2.2	;	Alternative conformations of the x region of human protein disulphide-isomerase modulate exposure of the substrate binding b' domain
7EJ9	;	2.6	;	Alternative crystal structure of mouse Cryptochrome 2 in complex with TH301 compound
5VGA	;	2.5	;	Alternative model for Fab 36-65
5HVQ	;	2.923	;	Alternative model of the MAGE-G1 NSE-1 complex
7UTI	;	4.8	;	ALTERNATIVE MODELING OF TROPOMYOSIN IN HUMAN CARDIAC THIN FILAMENT IN THE CALCIUM BOUND STATE
7UTL	;	6.6	;	ALTERNATIVE MODELING OF TROPOMYOSIN IN HUMAN CARDIAC THIN FILAMENT IN THE CALCIUM FREE STATE
2RIU	;	1.7	;	Alternative models for two crystal structures of Candida albicans 3,4-dihydroxy-2-butanone 4-phosphate synthase- alternate interpreation
1SIP	;	2.3	;	ALTERNATIVE NATIVE FLAP CONFORMATION REVEALED BY 2.3 ANGSTROMS RESOLUTION STRUCTURE OF SIV PROTEINASE
2FUN	;	3.0	;	alternative p35-caspase-8 complex
1RYF	;	1.75	;	Alternative Splicing of Rac1 Generates Rac1b, a Self-activating GTPase
1RYH	;	1.75	;	Alternative Splicing of Rac1 Generates Rac1b, a Self-activating GTPase
7ROQ	;	4.1	;	Alternative Structure of Human ABCA1
2RSU	;		;	Alternative structure of Ubiquitin
1D56	;	1.7	;	ALTERNATIVE STRUCTURES FOR ALTERNATING POLY(DA-DT) TRACTS: THE STRUCTURE OF THE B-DNA DECAMER C-G-A-T-A-T-A-T-C-G
1D57	;	2.0	;	ALTERNATIVE STRUCTURES FOR ALTERNATING POLY(DA-DT) TRACTS: THE STRUCTURE OF THE B-DNA DECAMER C-G-A-T-A-T-A-T-C-G
1JTM	;	1.9	;	Alternative Structures of a Sequence Extended T4 Lysozyme Show that the Highly Conserved Beta-Sheet has Weak Intrinsic Folding Propensity
1JTN	;	2.3	;	Alternative Structures of a Sequence Extended T4 Lysozyme Show that the Highly Conserved Beta-Sheet Region has weak intrinsic Folding Propensity
4N5V	;	1.9	;	Alternative substrates of Mycobacterium tuberculosis anthranilate phosphoribosyl transferase
4N8Q	;	2.08	;	Alternative substrates of Mycobacterium tuberculosis anthranilate phosphoribosyl transferase
4N93	;	2.03	;	Alternative substrates of Mycobacterium tuberculosis anthranilate phosphoribosyl transferase
1E8S	;	4.0	;	Alu domain of the mammalian SRP (potential Alu retroposition intermediate)
8BXB	;	3.9	;	Alvinella pompejana nicotinic acetylcholine receptor Alpo in apo state (dataset 2)
8BXF	;	3.4	;	Alvinella pompejana nicotinic acetylcholine receptor Alpo4 in apo state (Alpo4_apo, dataset 1)
8BXE	;	3.9	;	Alvinella pompejana nicotinic acetylcholine receptor Alpo4 in apo state (Alpo4_comb dataset 3)
8BXD	;	6.2	;	Alvinella pompejana nicotinic acetylcholine receptor Alpo4 in apo state (Alpo4_LMNG_Serotonin dataset 4)
8BX5	;	4.2	;	Alvinella pompejana nicotinic acetylcholine receptor Alpo4 in apo state (dataset 1)
8BYI	;	4.1	;	Alvinella pompejana nicotinic acetylcholine receptor Alpo4 in complex with CHAPS(Alpo4_CHAPS)
7XS3	;	1.9	;	AlXyn26A E243A-X3X4X
5ONP	;	1.34	;	Alzheimer's Amyloid-Beta Peptide Fragment 1-40 in Complex with Cd-substituted Thermolysin
5ONR	;	1.39	;	Alzheimer's Amyloid-Beta Peptide Fragment 1-40 in Complex with Thermolysin
5ONQ	;	1.17	;	Alzheimer's Amyloid-Beta Peptide Fragment 29-40 in Complex with Cd-substituted Thermolysin
6GHX	;	1.156	;	Alzheimer's Amyloid-Beta Peptide Fragment 31-35 in Complex with Cd-substituted Thermolysin
1HZ3	;		;	ALZHEIMER'S DISEASE AMYLOID-BETA PEPTIDE (RESIDUES 10-35)
8FUG	;	2.7	;	Alzheimer's disease paired-helical filament in complex with PET tracer GTP-1
7SCI	;	1.9	;	AM0627 metallopeptidase from Akkermansia muciniphila
1Z40	;	1.901	;	AMA1 from Plasmodium falciparum
8HBT	;	1.96	;	AmAT7-3 mutant A310G
2O9L	;		;	AMBER refined NMR Structure of the Sigma-54 RpoN Domain Bound to the-24 Promoter Element
8IQ7	;	2.1	;	Ambient Temperature Crystal Structure of Candida boidinii Formate Dehydrogenase
8HZ1	;	2.0	;	Ambient temperature crystal structure of Escherichia coli CyaY
7C8I	;	2.5	;	Ambient temperature structure of Bifidobacgterium longum phosphoketolase with thiamine diphosphate and phosphoenol pyuruvate
7C8H	;	2.5	;	Ambient temperature structure of Bifidobacterium longum phosphoketolase with thiamine diphosphate
5J9A	;	1.997	;	Ambient temperature transition state structure of arginine kinase - crystal 11/Form II
5J99	;	1.7	;	Ambient temperature transition state structure of arginine kinase - crystal 8/Form I
5BR8	;	3.4	;	Ambient-temperature crystal structure of 30S ribosomal subunit from Thermus thermophilus in complex with paromomycin
7CWB	;	1.9	;	Ambient-Temperature Serial Femtosecond X-ray Crystal structure of SARS-CoV-2 Main Protease at 1.9 A Resolution (C121)
7CWC	;	2.1	;	Ambient-Temperature Serial Femtosecond X-ray Crystal structure of SARS-CoV-2 Main Protease at 2.1 A Resolution (P212121)
6VO3	;	4.25	;	AMC009 SOSIP.v4.2 in complex with PGV04 Fab
7Z3A	;	3.95	;	AMC009 SOSIPv5.2 in complex with Fabs ACS101 and ACS124
7ZLK	;	3.99	;	AMC009 SOSIPv5.2 in complex with Fabs ACS101 and ACS124
6NC2	;	5.2	;	AMC011 v4.2 SOSIP Env trimer in complex with fusion peptide targeting antibody ACS202 fragment antigen binding
6NC3	;	4.5	;	AMC011 v4.2 SOSIP Env trimer in complex with fusion peptide targeting antibody VRC34 fragment antigen binding
7RSO	;	4.1	;	AMC016 SOSIP.v4.2 in complex with PGV04 Fab
7RSN	;	3.49	;	AMC018 SOSIP.v4.2 in complex with PGV04 Fab
3RM4	;	1.9	;	AMCase in complex with Compound 1
3RM8	;	1.8	;	AMCase in complex with Compound 2
3RM9	;	2.1	;	AMCase in complex with Compound 3
3RME	;	1.8	;	AMCase in complex with Compound 5
7ODM	;	2.6	;	AmGSTF1 Y118S variant
6SUI	;	1.6	;	AMICOUMACIN KINASE AMIN
6SUL	;	1.35	;	Amicoumacin kinase AmiN in complex with AMP-PNP, Mg2+ and Ami
6SV5	;	2.0	;	Amicoumacin kinase AmiN in complex with ATP
6SUN	;	1.35	;	Amicoumacin kinase hAmiN in complex with AMP-PNP, Ca2+ and Ami
6SUM	;	1.35	;	Amicoumacin kinase hAmiN in complex with AMP-PNP, MG2+ and Ami
1AAC	;	1.31	;	AMICYANIN OXIDIZED, 1.31 ANGSTROMS
1BXA	;	1.3	;	AMICYANIN REDUCED, PH 4.4, 1.3 ANGSTROMS
2RAC	;	1.3	;	AMICYANIN REDUCED, PH 7.7, 1.3 ANGSTROMS
2IH7	;		;	Amidated Pro6 Analogue of CMrVIA conotoxin
2IHA	;		;	Amidated variant of CMrVIA conotoxin
8PYY	;	2.9	;	Amide bond synthetase from Streptomyces hindustanus in open conformation
8PYX	;	2.02	;	Amide bond synthetase from Streptomyces hindustanus K492H mutant in complex with Adenosine
8PPP	;	2.57	;	Amide bond synthetase from Streptomyces hindustanus K492H mutant in complex with AMP-CPP
4O41	;	1.2	;	Amide linked RNA
1QO0	;	2.25	;	Amide receptor of the amidase operon of Pseudomonas aeruginosa (AmiC) complexed with the negative regulator AmiR.
1PEA	;	2.1	;	AMIDE RECEPTOR/NEGATIVE REGULATOR OF THE AMIDASE OPERON OF PSEUDOMONAS AERUGINOSA (AMIC) COMPLEXED WITH ACETAMIDE
1QNL	;	2.7	;	AMIDE RECEPTOR/NEGATIVE REGULATOR OF THE AMIDASE OPERON OF PSEUDOMONAS AERUGINOSA (AMIC) COMPLEXED WITH BUTYRAMIDE
6DXG	;	1.905	;	amidobenzimidazole (ABZI) STING agonists
1B4D	;	2.0	;	AMIDOCARBAMATE INHIBITOR OF GLYCOGEN PHOSPHORYLASE
6UVZ	;	2.898	;	Amidohydrolase 2 from Bifidobacterium longum subsp. infantis
6SJ0	;	1.75	;	Amidohydrolase, AHS
6SJ1	;	2.06	;	Amidohydrolase, AHS
6SJ2	;	1.25	;	Amidohydrolase, AHS with 3-HAA
6SJ3	;	1.17	;	Amidohydrolase, AHS with 3-HBA
6SJ4	;	1.81	;	Amidohydrolase, AHS with substrate analog
7QZN	;	1.64	;	Amine Dehydrogenase from Cystobacter fuscus (CfusAmDH) W145A mutant with NAD+
7QZL	;	1.5	;	Amine Dehydrogenase from Cystobacter fuscus (CfusAmDH) W145A mutant with NADP+ and pentylamine
6IAU	;	1.97	;	Amine Dehydrogenase from Cystobacter fuscus in complex with NADP+ and cyclohexylamine
6G1M	;	2.32	;	Amine Dehydrogenase from Petrotoga mobilis; open and closed form
6G1H	;	1.79	;	Amine Dehydrogenase from Petrotoga mobilis; open form
7ZBO	;	2.32	;	Amine Dehydrogenase MATOUAmDH2 in complex with NADP+
7R09	;	2.08	;	Amine Dehydrogenase MATOUAmDH2 in complex with NADP+ and Cyclohexylamine
5LH9	;	1.95	;	Amine transaminase crystal structure from an uncultivated Pseudomonas species in the PLP-bound (internal aldimine) form
5LHA	;	1.89	;	Amine transaminase crystal structure from an uncultivated Pseudomonas species in the PMP-bound form
1ND1	;	1.93	;	Amino acid sequence and crystal structure of BaP1, a metalloproteinase from Bothrops asper snake venom that exerts multiple tissue-damaging activities.
1HLM	;	2.9	;	AMINO ACID SEQUENCE OF A GLOBIN FROM THE SEA CUCUMBER CAUDINA (MOLPADIA) ARENICOLA
1R1O	;	2.8	;	Amino Acid Sulfonamides as Transition-State Analogue Inhibitors of Arginase
1ECL	;	1.9	;	AMINO TERMINAL 67KDA DOMAIN OF ESCHERICHIA COLI DNA TOPOISOMERASE I (RESIDUES 2-590 OF MATURE PROTEIN) CLONING ARTIFACT ADDS TWO RESIDUES TO THE AMINO-TERMINUS WHICH WERE NOT OBSERVED IN THE EXPERIMENTAL ELECTRON DENSITY (GLY-2, SER-1).
1VCC	;	1.6	;	AMINO TERMINAL 9KDA DOMAIN OF VACCINIA VIRUS DNA TOPOISOMERASE I RESIDUES 1-77, EXPERIMENTAL ELECTRON DENSITY FOR RESIDUES 1-77
1ZYM	;	2.5	;	AMINO TERMINAL DOMAIN OF ENZYME I FROM ESCHERICHIA COLI
1EZD	;		;	AMINO TERMINAL DOMAIN OF ENZYME I FROM ESCHERICHIA COLI NMR, 16 STRUCTURES
1EZA	;		;	AMINO TERMINAL DOMAIN OF ENZYME I FROM ESCHERICHIA COLI NMR, RESTRAINED REGULARIZED MEAN STRUCTURE
2EZB	;		;	AMINO TERMINAL DOMAIN OF ENZYME I FROM ESCHERICHIA COLI, NMR, 14 STRUCTURES
2EZC	;		;	AMINO TERMINAL DOMAIN OF ENZYME I FROM ESCHERICHIA COLI, NMR, 14 STRUCTURES
1EZB	;		;	AMINO TERMINAL DOMAIN OF ENZYME I FROM ESCHERICHIA COLI, NMR, 17 STRUCTURES
1EZC	;		;	AMINO TERMINAL DOMAIN OF ENZYME I FROM ESCHERICHIA COLI, NMR, 17 STRUCTURES
2EZA	;		;	AMINO TERMINAL DOMAIN OF ENZYME I FROM ESCHERICHIA COLI, NMR, RESTRAINED REGULARIZED MEAN STRUCTURE
1QDN	;	2.3	;	AMINO TERMINAL DOMAIN OF THE N-ETHYLMALEIMIDE SENSITIVE FUSION PROTEIN (NSF)
1SUH	;		;	AMINO-TERMINAL DOMAIN OF EPITHELIAL CADHERIN IN THE CALCIUM BOUND STATE, NMR, 20 STRUCTURES
2N3E	;		;	Amino-terminal domain of Latrodectus hesperus MaSp1 with neutralized acidic cluster
1A7I	;		;	AMINO-TERMINAL LIM DOMAIN FROM QUAIL CYSTEINE AND GLYCINE-RICH PROTEIN, NMR, MINIMIZED AVERAGE STRUCTURE
1ZFO	;		;	AMINO-TERMINAL LIM-DOMAIN PEPTIDE OF LASP-1, NMR
2H11	;	1.89	;	Amino-terminal Truncated Thiopurine S-Methyltransferase Complexed with S-Adenosyl-L-Homocysteine
6KFR	;	3.1	;	Amino-transferase (AMT) Domain - Arg Complex of Hybrid Polyketide/Non-Ribosomal Peptide Synthetase
6KFM	;	1.7	;	Amino-transferase (AMT) Domain of Hybrid Polyketide/Non-Ribosomal Peptide Synthetase
3CUL	;	2.8	;	Aminoacyl-tRNA synthetase ribozyme
3CUN	;	3.0	;	Aminoacyl-tRNA synthetase ribozyme
4BBE	;	1.9	;	Aminoalkylpyrimidine Inhibitor Complexes with JAK2
4BBF	;	2.0	;	Aminoalkylpyrimidine Inhibitor Complexes with JAK2
1I2K	;	1.79	;	AMINODEOXYCHORISMATE LYASE FROM ESCHERICHIA COLI
1UA0	;	2.1	;	Aminofluorene DNA adduct at the pre-insertion site of a DNA polymerase
1M44	;	1.6	;	Aminoglycoside 2'-N-acetyltransferase from Mycobacterium tuberculosis-APO Structure
1M4I	;	1.5	;	Aminoglycoside 2'-N-acetyltransferase from Mycobacterium tuberculosis-Complex with Coenzyme A and Kanamycin A
1M4G	;	1.8	;	Aminoglycoside 2'-N-acetyltransferase from Mycobacterium tuberculosis-Complex with Coenzyme A and Ribostamycin
1M4D	;	1.8	;	Aminoglycoside 2'-N-acetyltransferase from Mycobacterium tuberculosis-Complex with Coenzyme A and Tobramycin
7CRM	;	2.487	;	Aminoglycoside 2'-N-acetyltransferase from Mycolicibacterium smegmatis-APO Structure
7CSJ	;	2.168	;	Aminoglycoside 2'-N-acetyltransferase from Mycolicibacterium smegmatis-Complex with Coenzyme A and Gentamicin
7CS1	;	1.966	;	Aminoglycoside 2'-N-acetyltransferase from Mycolicibacterium smegmatis-Complex with Coenzyme A and Neomycin
7CS0	;	2.05	;	Aminoglycoside 2'-N-acetyltransferase from Mycolicibacterium smegmatis-Complex with Coenzyme A and Paromomycin
7CSI	;	1.89	;	Aminoglycoside 2'-N-acetyltransferase from Mycolicibacterium smegmatis-Complex with Coenzyme A and Sisomicin
6VR3	;	2.0	;	Aminoglycoside N-2'-Acetyltransferase-Ia [AAC(2')-Ia] in complex with acetylated-netilmicin and CoA
6VOU	;	1.95	;	Aminoglycoside N-2'-Acetyltransferase-Ia [AAC(2')-Ia] in complex with acetylated-plazomicin and CoA
6VR2	;	1.77	;	Aminoglycoside N-2'-Acetyltransferase-Ia [AAC(2')-Ia] in complex with acetylated-tobramycin and CoA
6VTA	;	1.42	;	Aminoglycoside N-2'-Acetyltransferase-Ia [AAC(2')-Ia] in complex with amikacin and acetyl-CoA
7JZS	;	1.3	;	Aminoglycoside N-2'-Acetyltransferase-Ia [AAC(2')-Ia] in complex with CoA
1S5K	;	2.4	;	Aminoglycoside N-Acetyltransferase AAC(6')-Iy in Complex with CoA and N-terminal His(6)-tag (crystal form 1)
1S60	;	3.0	;	Aminoglycoside N-Acetyltransferase AAC(6')-Iy in Complex with CoA and N-terminal His(6)-tag (crystal form 2)
1S3Z	;	2.0	;	Aminoglycoside N-Acetyltransferase AAC(6')-Iy in Complex with CoA and Ribostamycin
5IQG	;	2.5	;	Aminoglycoside Phosphotransferase (2'')-Ia (CTD of AAC(6')-Ie/APH(2'')-Ia) in complex with GDP, Magnesium, and Gentamicin C1
5BYL	;	2.15	;	Aminoglycoside Phosphotransferase (2'')-Ia (CTD of AAC(6')-Ie/APH(2'')-Ia) in complex with GMPPCP and Magnesium
5IQA	;	2.15	;	Aminoglycoside Phosphotransferase (2'')-Ia (CTD of AAC(6')-Ie/APH(2'')-Ia) in complex with GMPPNP and Magnesium
5IQC	;	2.3	;	Aminoglycoside Phosphotransferase (2'')-Ia (CTD of AAC(6')-Ie/APH(2'')-Ia) in complex with GMPPNP, Magnesium, and Gentamicin C1
5IQB	;	2.3	;	Aminoglycoside Phosphotransferase (2'')-Ia (CTD of AAC(6')-Ie/APH(2'')-Ia) in complex with GMPPNP, Magnesium, and Kanamycin A
5IQE	;	2.5	;	Aminoglycoside Phosphotransferase (2'')-Ia (CTD of AAC(6')-Ie/APH(2'')-Ia) in complex with GMPPNP, Magnesium, and Neomycin B
5IQD	;	2.2	;	Aminoglycoside Phosphotransferase (2'')-Ia (CTD of AAC(6')-Ie/APH(2'')-Ia) in complex with GMPPNP, Magnesium, and Ribostamycin
5IQH	;	2.25	;	Aminoglycoside Phosphotransferase (2'')-Ia (CTD of AAC(6')-Ie/APH(2'')-Ia) S214A mutant in complex with GMPPNP and Magnesium
5IQI	;	2.15	;	Aminoglycoside Phosphotransferase (2'')-Ia (CTD of AAC(6')-Ie/APH(2'')-Ia) Y237F mutant in complex with GMPPNP and Magnesium
5IQF	;	2.35	;	Aminoglycoside Phosphotransferase (2'')-Ia (CTD of APH(6')-Ie/APH(2'')-Ia) in complex with GDP and Magnesium
6CGD	;	2.2	;	Aminoglycoside Phosphotransferase (2'')-Ia in complex with GMPPNP, Magnesium, and Amikacin
6CGG	;	2.4	;	Aminoglycoside Phosphotransferase (2'')-Ia in complex with GMPPNP, Magnesium, and Arbekacin
6CAV	;	2.6	;	Aminoglycoside Phosphotransferase (2'')-Ia in complex with GMPPNP, Magnesium, and Dibekacin
6CEY	;	2.4	;	Aminoglycoside Phosphotransferase (2'')-Ia in complex with GMPPNP, Magnesium, and Lividomycin moieties
6C5U	;	2.41	;	Aminoglycoside Phosphotransferase (2'')-Ia in complex with GMPPNP, Magnesium, and Ribostamycin, Alternate form
6CH4	;	2.3	;	Aminoglycoside Phosphotransferase (2'')-Ia S376N mutant in complex with GMPPNP and Magnesium
7UY4	;	1.98	;	Aminoglycoside-modifying enzyme ANT-3,9 in complex with spectinomycin and AMP-PNP
4ACU	;	1.75	;	Aminoimidazoles as BACE-1 Inhibitors. X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 14
4ACX	;	2.0	;	Aminoimidazoles as BACE-1 Inhibitors. X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 23
4B70	;	1.6	;	Aminoimidazoles as BACE-1 Inhibitors: From De Novo Design to Ab- lowering in Brain
4B72	;	1.6	;	Aminoimidazoles as BACE-1 Inhibitors: From De Novo Design to Ab- lowering in Brain
4B77	;	1.8	;	Aminoimidazoles as BACE-1 Inhibitors: From De Novo Design to Ab- lowering in Brain
4B78	;	1.5	;	Aminoimidazoles as BACE-1 Inhibitors: From De Novo Design to Ab- lowering in Brain
5T1U	;	1.78	;	Aminomethyl-Derived Beta Secretase (BACE1) Inhibitors: Engaging Gly230 without an Anilide Functionality
5T1W	;	2.96	;	Aminomethyl-Derived Beta Secretase (BACE1) Inhibitors: Engaging Gly230 without an Anilide Functionality
4LC7	;	1.7	;	Aminooxazoline inhibitor of BACE-1
4WWV	;	3.006	;	Aminopeptidase APDkam598 from the archaeon Desulfurococcus kamchatkensis
2EK8	;	1.8	;	Aminopeptidase from Aneurinibacillus sp. strain AM-1
2EK9	;	1.97	;	Aminopeptidase from Aneurinibacillus sp. strain AM-1 with Bestatin
1CP7	;	1.58	;	AMINOPEPTIDASE FROM STREPTOMYCES GRISEUS
4FUK	;	1.75	;	Aminopeptidase from Trypanosoma brucei
5DLL	;	2.51	;	Aminopeptidase N (pepN) from Francisella tularensis subsp. tularensis SCHU S4
2ZXG	;	1.55	;	Aminopeptidase N complexed with the aminophosphinic inhibitor of PL250, a transition state analogue
1JAW	;	2.7	;	AMINOPEPTIDASE P FROM E. COLI LOW PH FORM
1A16	;	2.3	;	AMINOPEPTIDASE P FROM E. COLI WITH THE INHIBITOR PRO-LEU
1M35	;	2.4	;	Aminopeptidase P from Escherichia coli
1N51	;	2.3	;	Aminopeptidase P in complex with the inhibitor apstatin
1ZJC	;	1.8	;	Aminopeptidase S from S. aureus
2VVC	;	1.95	;	Aminopyrrolidine Factor Xa inhibitor
2VVU	;	2.3	;	Aminopyrrolidine Factor Xa inhibitor
2VWL	;	1.8	;	Aminopyrrolidine Factor Xa inhibitor
2VWM	;	1.96	;	Aminopyrrolidine Factor Xa inhibitor
2VWN	;	1.61	;	Aminopyrrolidine Factor Xa inhibitor
2VWO	;	1.6	;	Aminopyrrolidine Factor Xa inhibitor
2VVV	;	1.73	;	Aminopyrrolidine-related triazole Factor Xa inhibitor
2HXX	;	2.0	;	Aminotryptophan Barstar
7B3N	;	1.793	;	AmiP amidase-3 from Thermus parvatiensis
1H9D	;	2.6	;	Aml1/cbf-beta/dna complex
1E50	;	2.6	;	AML1/CBFbeta complex
5I32	;	1.18	;	Ammonia permeable aquaporin AtTIP2;1
7FZE	;	1.17	;	ammonium sulfate-based apo human FABP4, primitive orthorhombic form I
2B2H	;	1.54	;	Ammonium Transporter Amt-1 from A. fulgidus (AS)
2B2I	;	1.85	;	Ammonium Transporter Amt-1 from A. fulgidus (MA)
2B2J	;	1.85	;	Ammonium Transporter Amt-1 from A. fulgidus (Xe)
2B2F	;	1.72	;	Ammonium Transporter Amt-1 from A.fulgidus (Native)
8IH7	;	2.48	;	AmnG-AmnH complex
4GX6	;	2.5	;	AMP Complexes of Porcine Liver Fructose-1,6-bisphosphatase with Mutation E192Q
4GX4	;	2.5	;	AMP Complexes of Porcine Liver Fructose-1,6-bisphosphatase with mutation R22M
8HU6	;	2.33	;	AMP deaminase 2 in complex with AMP
8HUB	;	3.25	;	AMP deaminase 2 in complex with an inhibitor
1AM0	;		;	AMP RNA APTAMER COMPLEX, NMR, 8 STRUCTURES
6BX6	;	2.9	;	AMP-Activated protein kinase (AMPK) inhibition by SBI-0206965: alpha 2 kinase domain bound to SBI-0206965
6C9F	;	2.924	;	AMP-activated protein kinase bound to pharmacological activator R734
6C9J	;	3.05	;	AMP-activated protein kinase bound to pharmacological activator R734
6C9G	;	2.7	;	AMP-activated protein kinase bound to pharmacological activator R739
3S1Y	;	1.4	;	AMP-C BETA-LACTAMASE (PSEUDOMONAS AERUGINOSA) in complex with a beta-lactamase inhibitor
3S22	;	1.65	;	AMP-C BETA-LACTAMASE (PSEUDOMONAS AERUGINOSA) in complex with an inhibitor
4NK3	;	1.9	;	Amp-c beta-lactamase (pseudomonas aeruginosa) in complex with mk-7655
2WZX	;	1.4	;	AMP-C BETA-LACTAMASE (PSEUDOMONAS AERUGINOSA)IN COMPLEX WITH compound M-02
2WZZ	;	1.57	;	AMP-C BETA-LACTAMASE (PSEUDOMONAS AERUGINOSA)IN COMPLEX WITH compound M-03
7PH3	;	2.8	;	AMP-PNP bound nanodisc reconstituted MsbA with nanobodies, spin-labeled at position A60C
7PH4	;	2.8	;	AMP-PNP bound nanodisc reconstituted MsbA with nanobodies, spin-labeled at position T68C
5J5P	;	1.97	;	AMP-PNP-stabilized ATPase domain of topoisomerase IV from Streptococcus pneumoniae, complex type I
5J5Q	;	2.83	;	AMP-PNP-stabilized ATPase domain of topoisomerase IV from Streptococcus pneumoniae, complex type II
5N6P	;	2.8	;	AMPA receptor NTD mutant
5L1B	;	4.0	;	AMPA subtype ionotropic glutamate receptor GluA2 in Apo state
5L1G	;	4.507	;	AMPA subtype ionotropic glutamate receptor GluA2 in complex with GYKI-Br
5L1E	;	4.37	;	AMPA subtype ionotropic glutamate receptor GluA2 in complex with noncompetitive inhibitor CP465022
5L1H	;	3.801	;	AMPA subtype ionotropic glutamate receptor GluA2 in complex with noncompetitive inhibitor GYKI53655
5L1F	;	4.0	;	AMPA subtype ionotropic glutamate receptor GluA2 in complex with noncompetitive inhibitor Perampanel
3KG2	;	3.6	;	AMPA subtype ionotropic glutamate receptor in complex with competitive antagonist ZK 200775
2PU4	;	2.0	;	AmpC beta-lacamase with bound covalent oxadiazole inhibitor
1FSW	;	1.9	;	AMPC BETA-LACTAMASE FROM E. COLI COMPLEXED WITH INHIBITOR CEPHALOTHINBORONIC ACID
1FSY	;	1.75	;	AMPC BETA-LACTAMASE FROM E. COLI COMPLEXED WITH INHIBITOR CLOXACILLINBORONIC ACID
1C3B	;	2.25	;	AMPC BETA-LACTAMASE FROM E. COLI COMPLEXED WITH INHIBITOR, BENZO(B)THIOPHENE-2-BORONIC ACID (BZB)
2BLS	;	2.0	;	AMPC BETA-LACTAMASE FROM ESCHERICHIA COLI
3BLS	;	2.3	;	AMPC BETA-LACTAMASE FROM ESCHERICHIA COLI
2RCX	;	2.0	;	AmpC Beta-lactamase in complex with (1R)-1-(2-Thiophen-2-yl-acetylamino)-1-(3-(2-carboxyvinyl)-phenyl) methylboronic acid
4LV3	;	1.42	;	AmpC beta-lactamase in complex with (3,5-di-tert-butylphenyl) boronic acid
2HDU	;	1.49	;	AmpC beta-lactamase in complex with 2-acetamidothiophene-3-carboxylic acid
2HDQ	;	2.1	;	AmpC beta-lactamase in complex with 2-carboxythiophene
1XGI	;	1.96	;	AmpC beta-lactamase in complex with 3-(3-nitro-phenylsulfamoyl)-thiophene-2-carboxylic acid
1XGJ	;	1.97	;	AmpC beta-lactamase in complex with 3-(4-carboxy-2-hydroxy-phenylsulfamoyl)-thiophene-2-carboxylic acid
2HDR	;	2.2	;	AmpC beta-lactamase in complex with 4-Amino-3-hydroxybenzoic acid
2HDS	;	1.16	;	AmpC beta-lactamase in complex with 4-Methanesulfonylamino benzoic acid
2I72	;	2.2	;	AmpC beta-lactamase in complex with 5-diformylaminomethyl-benzo[b]thiophen-2-boronic acid
3BM6	;	2.1	;	AmpC beta-lactamase in complex with a p.carboxyphenylboronic acid
1MXO	;	1.83	;	AmpC beta-lactamase in complex with an m.carboxyphenylglycylboronic acid bearing the cephalothin R1 side chain
1MY8	;	1.72	;	AmpC beta-lactamase in complex with an M.carboxyphenylglycylboronic acid bearing the cephalothin R1 side chain
3GQZ	;	1.8	;	AmpC beta-lactamase in complex with Fragment-based Inhibitor
3GR2	;	1.8	;	AmpC beta-lactamase in complex with Fragment-based Inhibitor
3GRJ	;	2.49	;	AmpC beta-lactamase in complex with Fragment-based Inhibitor
3GSG	;	2.1	;	AmpC beta-lactamase in complex with Fragment-based Inhibitor
3GTC	;	1.9	;	AmpC beta-lactamase in complex with Fragment-based Inhibitor
3GV9	;	1.8	;	AmpC beta-lactamase in complex with Fragment-based Inhibitor
3GVB	;	1.8	;	AmpC beta-lactamase in complex with Fragment-based Inhibitor
4LV0	;	1.652	;	AmpC beta-lactamase in complex with m-aminophenyl boronic acid
4LV1	;	1.74	;	AmpC beta-lactamase in complex with [1-(3-chlorophenyl)-1H-pyrazol-4-yl] boronic acid
4LV2	;	1.65	;	AmpC beta-lactamase in complex with [1-(6-chloropyrimidin-4-yl)-1H-pyrazol-4-yl] boronic acid
2FFY	;	1.07	;	AmpC beta-lactamase N289A mutant in complex with a boronic acid deacylation transition state analog compound SM3
2PU2	;	1.86	;	AmpC beta-lactamase with bound Phthalamide inhibitor
2R9W	;	1.8	;	AmpC beta-lactamase with bound Phthalamide inhibitor
2R9X	;	1.9	;	AmpC beta-lactamase with bound Phthalamide inhibitor
3FKW	;	1.498	;	AmpC K67R mutant apo structure
3FKV	;	1.847	;	AmpC K67R mutant complexed with benzo(b)thiophene-2-boronic acid (bzb)
8JSO	;	3.4	;	AMPH-bound hTAAR1-Gs protein complex
3QQT	;	1.9	;	Amphiphilic nanotubes in the crystal structure of a biosurfactant protein hydrophobin HFBII
1URU	;	2.6	;	Amphiphysin BAR domain from Drosophila
5I22	;		;	Amphiphysin SH3 in complex with Chikungunya virus nsP3 peptide
7U4B	;	1.92	;	Ampicillin-CTX-M-15
5KQ5	;	3.41	;	AMPK bound to allosteric activator
5T5T	;	3.46	;	AMPK bound to allosteric activator
4S35	;	1.55	;	AMPPCP and TMP bound Crystal structure of thymidylate kinase (aq_969) from Aquifex Aeolicus VF5
5X8C	;	2.07	;	AMPPCP and TMP bound crystal structure of thymidylate kinase from thermus thermophilus HB8
4RH3	;	3.02	;	AMPPCP-bound structure of human platelet phosphofructokinase in an R-state, crystal form II
4W9M	;	2.7	;	AMPPNP bound Rad50 in complex with dsDNA
5ZMF	;	3.556	;	AMPPNP complex of C. reinhardtii ArsA1
3IQW	;	3.0	;	AMPPNP complex of C. therm. Get3
4WKM	;	2.15	;	AmpR effector binding domain from Citrobacter freundii bound to UDP-MurNAc-pentapeptide
1AVA	;	1.9	;	AMY2/BASI PROTEIN-PROTEIN COMPLEX FROM BARLEY SEED
7S8W	;	2.9	;	Amycolatopsis sp. T-1-60 N-succinylamino acid racemase/o-succinylbenzoate synthase R266Q mutant in complex with N-succinylphenylglycine
6GXV	;	2.07	;	Amylase in complex with acarbose
6GYA	;	2.95	;	Amylase in complex with branched ligand
8F2B	;	2.0	;	Amylin 3 Receptor in complex with Gs and Pramlintide analogue peptide San45
6O4J	;	1.402	;	Amyloid Beta KLVFFAENVGS 16-26 D23N Iowa mutation
7O1Q	;	3.4	;	Amyloid beta oligomer displayed on the alpha hemolysin scaffold
1QCM	;		;	AMYLOID BETA PEPTIDE (25-35), NMR, 20 STRUCTURES
3MOQ	;	2.054	;	Amyloid beta(18-41) peptide fusion with new antigen receptor variable domain from sharks
5ZMZ	;	1.4	;	Amyloid core of RIP1
7ZJ2	;	3.32	;	Amyloid fibril (in vitro) from full-length hnRNPA1 protein
7ZKY	;	2.56	;	Amyloid fibril from human systemic AA amyloidosis (vascular variant)
7QV6	;	3.5	;	Amyloid fibril from the antimicrobial peptide aurein 3.3
7QV5	;	3.0	;	Amyloid fibril from the antimicrobial peptide uperin 3.5
6ZCF	;	2.73	;	Amyloid fibril morphology i (in vitro) from murine SAA1.1 protein
6ZCH	;	3.5	;	Amyloid fibril morphology II (ex vivo) from murine SAA1.1 protein.
6ZCG	;	2.95	;	Amyloid fibril morphology ii (in vitro) from murine SAA1.1 protein
6Y1A	;	4.2	;	Amyloid fibril structure of islet amyloid polypeptide
6C3T	;	1.0	;	AMYLOID FORMING PEPTIDE AADTWE FROM TRANSTHYRETIN WITH ATTR-D38A MUTATION ASSOCIATED WITH A FAMILIAL FORM OF TRANSTHYRETIN AMYLOIDOSIS
6C3F	;	1.499	;	AMYLOID FORMING PEPTIDE IYKVEI FROM TRANSTHYRETIN
6C3G	;	1.601	;	AMYLOID FORMING PEPTIDE KALGIS FROM TRANSTHYRETIN
6C4O	;	1.79	;	AMYLOID FORMING PEPTIDE TIAALLS FROM TRANSTHYRETIN
6C3S	;	1.602	;	AMYLOID FORMING PEPTIDE YTIAAL FROM TRANSTHYRETIN
4RIK	;	1.854	;	Amyloid forming segment, AVVTGVTAV, from the NAC domain of Parkinson's disease protein alpha-synuclein, residues 69-77
6ZRF	;	3.6	;	amyloid structure of amylin (IAPP - islet amyloid polypeptide)
8FF2	;	2.87	;	Amyloid-beta (1-40) fibrils derived from a CAA patient
8FF3	;	3.09	;	Amyloid-beta (1-40) fibrils derived from familial Dutch-type CAA patient (population B)
6OIZ	;	1.1	;	Amyloid-Beta (20-34) wild type
6NB9	;	1.05	;	Amyloid-Beta (20-34) with L-isoaspartate 23
8QN7	;	2.7	;	Amyloid-beta 40 type 1 filament from the leptomeninges of individual with Alzheimer's disease and cerebral amyloid angiopathy
8QN6	;	2.4	;	Amyloid-beta 40 type 2 filament from the leptomeninges of individual with Alzheimer's disease and cerebral amyloid angiopathy
8BFZ	;	2.8	;	Amyloid-beta 42 filaments extracted from the human brain with Arctic mutation (E22G) of Alzheimer's disease | ABeta42
7Y8Q	;		;	Amyloid-beta assemblage on GM1-containing membranes
8BG0	;	1.99	;	Amyloid-beta tetrameric filaments with the Arctic mutation (E22G) from Alzheimer's disease brains | ABeta40
6W0O	;	2.77	;	Amyloid-beta(1-40) fibril derived from Alzheimer's disease cortical tissue
3SGO	;	2.557	;	Amyloid-related segment of alphaB-crystallin residues 90-100
3SGP	;	1.4016	;	Amyloid-related segment of alphaB-crystallin residues 90-100 mutant V91L
7ROJ	;	1.6	;	Amyloid-related segment of alphaB-crystallin residues 90-100 with G95W mutation
7ROL	;	1.996	;	Amyloid-related segment of alphaB-crystallin residues 90-100 with G95W mutation, bromo derivative
3SGS	;	1.703	;	Amyloid-related segment of alphaB-crystallin residues 95-100
1LYY	;	1.8	;	AMYLOIDOGENIC VARIANT (ASP67HIS) OF HUMAN LYSOZYME
1LOZ	;	1.8	;	AMYLOIDOGENIC VARIANT (I56T) VARIANT OF HUMAN LYSOZYME
6M6T	;	2.75	;	Amylomaltase from Streptococcus agalactiae in complex with acarbose
4S3Q	;	2.1	;	Amylomaltase MalQ from Escherichia coli in complex with maltose
4S3R	;	2.1	;	Amylomaltase MalQ from Escherichia coli in complex with the pseudo-heptasaccharide acarviosine-glucose-acarbose
4S3P	;	2.8	;	Amylomaltase MalQ from Escherichia coli, apo structure
1G5A	;	1.4	;	AMYLOSUCRASE FROM NEISSERIA POLYSACCHAREA
1MW0	;	2.01	;	Amylosucrase mutant E328Q co-crystallized with maltoheptaose then soaked with maltoheptaose.
1MVY	;	2.0	;	Amylosucrase mutant E328Q co-crystallized with maltoheptaose.
1ZS2	;	2.16	;	Amylosucrase Mutant E328Q in a ternary complex with sucrose and maltoheptaose
1MW2	;	2.1	;	Amylosucrase soaked with 100mM sucrose
1MW1	;	2.1	;	Amylosucrase soaked with 14mM sucrose.
1MW3	;	2.0	;	Amylosucrase soaked with 1M sucrose
1SPD	;	2.4	;	AMYOTROPHIC LATERAL SCLEROSIS AND STRUCTURAL DEFECTS IN CU,ZN SUPEROXIDE DISMUTASE
7WUD	;	1.9	;	An (R)-Selective Transaminase mutant
2LET	;		;	AN 1H NMR DETERMINATION OF THE THREE DIMENSIONAL STRUCTURES OF MIRROR IMAGE FORMS OF A LEU-5 VARIANT OF THE TRYPSIN INHIBITOR ECBALLIUM ELATERIUM (EETI-II)
4RO1	;	2.803	;	An 3'-5'-exoribonuclease that specifically recognizes RNAs.
4L4X	;	2.55	;	An A2-type ketoreductase from a modular polyketide synthase
6RW7	;	1.4	;	An AA10 LPMO from the shipworm symbiont Teredinibacter turnerae
7EXK	;	2.14	;	An AA9 LPMO of Ceriporiopsis subvermispora
3U37	;	2.1	;	An Acetyl Xylan Esterase (Est2A) from the Rumen Bacterium Butyrivibrio proteoclasticus.
4DEV	;	2.0	;	An Acetyl Xylan Esterase (Est2A) from the Rumen Bacterium Butyrivibrio proteoclasticus.
2GM4	;	3.5	;	An activated, tetrameric gamma-delta resolvase: Hin chimaera bound to cleaved DNA
2GM5	;	2.1	;	An activated, truncated gamma-delta resolvase tetramer
7F5Q	;	2.3	;	An active enzyme from the plant Viola yedoensis
1EFE	;		;	AN ACTIVE MINI-PROINSULIN, M2PI
1A72	;	2.6	;	AN ACTIVE-SITE DOUBLE MUTANT (PHE93->TRP, VAL203->ALA) OF HORSE LIVER ALCOHOL DEHYDROGENASE IN COMPLEX WITH THE ISOSTERIC NAD ANALOG CPAD
257L	;	1.9	;	AN ADAPTABLE METAL-BINDING SITE ENGINEERED INTO T4 LYSOZYME
258L	;	1.8	;	AN ADAPTABLE METAL-BINDING SITE ENGINEERED INTO T4 LYSOZYME
259L	;	1.92	;	AN ADAPTABLE METAL-BINDING SITE ENGINEERED INTO T4 LYSOZYME
260L	;	1.8	;	AN ADAPTABLE METAL-BINDING SITE ENGINEERED INTO T4 LYSOZYME
1H0T	;		;	An affibody in complex with a target protein: structure and coupled folding
5YXU	;	2.7	;	an affinity enhanced T cell receptor in complex with HLA-A0201 restricted HCV NS3 peptide KLVALGINAV
7V68	;	3.4	;	An Agonist and PAM-bound Class A GPCR with Gi protein complex structure
6PEX	;	1.581	;	An aldo keto reductase with 2-keto- L-gulonate reductase activity
1U0V	;	1.9	;	An Aldol Switch Discovered in Stilbene Synthases Mediates Cyclization of Specificity of Type III Polyketide Synthases: 18xCHS structure
1U0W	;	2.0	;	An Aldol Switch Discovered in Stilbene Synthases Mediates Cyclization Specificity of Type III Polyketide Synthases: 18xCHS+resveratrol Structure
1U0U	;	2.11	;	An Aldol Switch Discovered in Stilbene Synthases Mediates Cyclization Specificity of Type III Polyketide Synthases: Pine stilbene synthase structure
1DGD	;	2.8	;	AN ALKALI METAL ION SIZE-DEPENDENT SWITCH IN THE ACTIVE SITE STRUCTURE OF DIALKYLGLYCINE DECARBOXYLASE
1DGE	;	2.8	;	AN ALKALI METAL ION SIZE-DEPENDENT SWITCH IN THE ACTIVE SITE STRUCTURE OF DIALKYLGLYCINE DECARBOXYLASE
2F8Q	;	2.2	;	An alkali thermostable F/10 xylanase from alkalophilic Bacillus sp. NG-27
2FGL	;	2.2	;	An alkali thermostable F/10 xylanase from alkalophilic Bacillus sp. NG-27
3GS5	;	2.75	;	An all-RNA hairpin ribozyme A38N1dA variant with a product mimic substrate strand
3GS8	;	2.85	;	An all-RNA hairpin ribozyme A38N1dA38 variant with a transition-state mimic substrate strand
3GS1	;	2.85	;	An all-RNA Hairpin Ribozyme with mutation A38N1dA
1X9C	;	2.19	;	An all-RNA Hairpin Ribozyme with mutation U39C
1X9K	;	3.17	;	An all-RNA Hairpin Ribozyme with mutation U39C
1RD4	;	2.4	;	An allosteric inhibitor of LFA-1 bound to its I-domain
1NFD	;	2.8	;	AN ALPHA-BETA T CELL RECEPTOR (TCR) HETERODIMER IN COMPLEX WITH AN ANTI-TCR FAB FRAGMENT DERIVED FROM A MITOGENIC ANTIBODY
3F87	;	2.4	;	An alpha/beta-Peptide Helix Bundle with a Pure beta-Amino Acid Core and a Distinctive Quarternary Structure: GCN4pLI derivative with beta residues at a and d heptad positions - higher symmetry crystal
3F86	;	2.0	;	An alpha/beta-Peptide Helix Bundle with a Pure beta-Amino Acid Core and a Distinctive Quaternary Structure: GCN4pLI derivative with beta residues at a and d heptad positions
2OSN	;	2.5	;	An alternate description of a crystal structure of phospholipase A2 from Bungarus caeruleus
1MDG	;	1.5	;	An Alternating Antiparallel Octaplex in an RNA Crystal Structure
8EDA	;	1.63	;	An alternating AT dodecamer benzimidazole (DB1476) complex
2DD2	;		;	An alternating sheared AA pair in 5'GGUGAAGGCU/3'PCCGAAGCCG: I. The major conformation with A6/A15/A16 stack
2DD3	;		;	An alternating sheared AA pair in 5'GGUGAAGGCU/3'PCCGAAGCCG: II. The minor conformation with A6/A5/A16 stack
4ZV1	;	1.52	;	An ancestral arginine-binding protein bound to arginine
4ZV2	;	1.43	;	An ancestral arginine-binding protein bound to glutamine
1G99	;	2.5	;	AN ANCIENT ENZYME: ACETATE KINASE FROM METHANOSARCINA THERMOPHILA
2ACQ	;	1.76	;	AN ANION BINDING SITE IN HUMAN ALDOSE REDUCTASE: MECHANISTIC IMPLICATIONS FOR THE BINDING OF CITRATE, CACODYLATE, AND GLUCOSE-6-PHOSPHATE
2ACR	;	1.76	;	AN ANION BINDING SITE IN HUMAN ALDOSE REDUCTASE: MECHANISTIC IMPLICATIONS FOR THE BINDING OF CITRATE, CACODYLATE, AND GLUCOSE-6-PHOSPHATE
2ACS	;	1.76	;	AN ANION BINDING SITE IN HUMAN ALDOSE REDUCTASE: MECHANISTIC IMPLICATIONS FOR THE BINDING OF CITRATE, CACODYLATE, AND GLUCOSE-6-PHOSPHATE
2QTO	;	3.201	;	An anisotropic model for potassium channel KcsA
6JD6	;	2.2	;	An ankyrin-repeat protein complex guides cargos from inner envelope to thylakoid Tat pathway
5Z4E	;		;	An anthrahydroquino-Gama-pyrone synthase Txn09
5Z36	;		;	An anthrahydroquino-Gama-pyrone synthase Txn09 complexed with PDM
5Z4F	;		;	An anthrahydroquino-Gama-pyrone synthase Txn09 complexed with SUM
6C5V	;	4.8	;	An anti-gH/gL antibody that neutralizes dual-tropic infection defines a site of vulnerability on Epstein-Barr virus
1W5J	;	2.2	;	AN ANTI-PARALLEL FOUR HELIX BUNDLE
1W5K	;	1.92	;	AN ANTI-PARALLEL FOUR HELIX BUNDLE
1W5G	;	2.16	;	An anti-parallel four helix bundle (acetimide modification).
1W5H	;	2.5	;	An anti-parallel four helix bundle.
1W5L	;	2.17	;	An anti-parallel to parallel switch.
2FAT	;	1.77	;	An anti-urokinase plasminogen activator receptor (UPAR) antibody: Crystal structure and binding epitope
4K8R	;	3.22	;	An Antibody Against the C-terminal Domain of PCSK9 lowers LDL Cholesterol Levels in vivo
4LKC	;	2.2	;	An Antibody Against the C-terminal Domain of PCSK9 lowers LDL Cholesterol Levels in vivo
7UPY	;	3.1	;	An antibody from single human VH-rearranging mouse neutralizes all SARS-CoV-2 variants through BA.5 by inhibiting membrane fusion
4JN1	;	1.89	;	An Antidote for Dabigatran
4JN2	;	1.71	;	An Antidote for Dabigatran
5JQG	;	2.24	;	An apo tubulin-RB-TTL complex structure used for side-by-side comparison
8IKX	;	1.5	;	An Arabidopsis polygalacturonase PGLR
2O4V	;	1.94	;	An arginine ladder in OprP mediates phosphate specific transfer across the outer membrane
4K8W	;	1.67	;	An arm-swapped dimer of the S. pyogenes pilin specific assembly factor SipA
2MYU	;		;	An arsenate reductase in oxidized state
2MYN	;		;	An arsenate reductase in reduced state
2L19	;		;	An arsenate reductase in the intermediate state
2MYT	;		;	An arsenate reductase in the intermediate state
2L18	;		;	An arsenate reductase in the phosphate binding state
2MYP	;		;	An arsenate reductase in the phosphate binding state
2L17	;		;	An arsenate reductase in the reduced state
2KIK	;		;	An artificial di-iron oxo-protein with phenol oxidase activity
1SA3	;	1.95	;	An asymmetric complex of restriction endonuclease MspI on its palindromic DNA recognition site
8EAW	;	2.8	;	An asymmetric disk assembly formed by tandem dimers of the tobacco mosaic viral capsid protein (TMV)
1PZU	;	3.1	;	An asymmetric NFAT1-RHR homodimer on a pseudo-palindromic, Kappa-B site
3J32	;	4.5	;	An asymmetric unit map from electron cryo-microscopy of Haliotis diversicolor molluscan hemocyanin isoform 1 (HdH1)
8JE1	;	3.95	;	An asymmetry dimer of the Cul2-Rbx1-EloBC-FEM1B ubiquitin ligase complexed with BEX2
8FDQ	;	1.54	;	An AT-specific DNA 5-CGCAAATTTCGC-3' with benzimidazole (DB1476) complex
5L93	;	3.9	;	An atomic model of HIV-1 CA-SP1 reveals structures regulating assembly and maturation
5GJR	;	3.5	;	An atomic structure of the human 26S proteasome
5VKU	;	3.9	;	An atomic structure of the human cytomegalovirus (HCMV) capsid with its securing layer of pp150 tegument protein
3P9A	;	1.755	;	An atomic view of the nonameric small terminase subunit of Bacteriophage P22
8HAV	;	2.1	;	An auto-activation mechanism of plant non-specific phospholipase C
8HAW	;	2.1	;	An auto-activation mechanism of plant non-specific phospholipase C
4JHR	;	2.8	;	An auto-inhibited conformation of LGN reveals a distinct interaction mode between GoLoco motifs and TPR motifs
1CBV	;	2.66	;	AN AUTOANTIBODY TO SINGLE-STRANDED DNA: COMPARISON OF THE THREE-DIMENSIONAL STRUCTURES OF THE UNLIGANDED FAB AND A DEOXYNUCLEOTIDE-FAB COMPLEX
1NBV	;	2.0	;	AN AUTOANTIBODY TO SINGLE-STRANDED DNA: COMPARISON OF THE THREE-DIMENSIONAL STRUCTURES OF THE UNLIGANDED FAB AND A DEOXYNUCLEOTIDE-FAB COMPLEX
5BX0	;	2.93	;	An Automated Microscale Thermophoresis Screening Approach for Fragment-Based Lead Discovery
3AG7	;	1.8	;	An auxilin-like J-domain containing protein, JAC1 J-domain
1GSU	;	1.94	;	AN AVIAN CLASS-MU GLUTATHIONE S-TRANSFERASE, CGSTM1-1 AT 1.94 ANGSTROM RESOLUTION
5LUR	;	2.7	;	An avidin mutant
4OAP	;	1.93	;	An Axe2 mutant (W190I), an acetyl-xylooligosaccharide esterase from Geobacillus Stearmophilus
6B0D	;	1.5	;	An E. coli DPS protein from ferritin superfamily
5O2I	;	2.0	;	An efficient setup for fixed-target, time-resolved serial crystallography with optical excitation
2CE8	;	2.03	;	An EH1 peptide bound to the Groucho-TLE WD40 domain.
7Y9N	;	1.885	;	an engineered 5-helix bundle derived from SARS-CoV-2 S2 in complex with HR2P
4RA0	;	3.07	;	An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis
5VFW	;		;	An engineered cyclic peptide alleviates symptoms of inflammation in a murine model of inflammatory bowel disease
4GT7	;	2.61	;	An engineered disulfide bond reversibly traps the IgE-Fc3-4 in a closed, non-receptor binding conformation
7MWN	;	1.902	;	An engineered PYL2-based WIN 55,212-2 synthetic cannabinoid sensor with a stabilized HAB1 variant
4WVO	;	2.251	;	An engineered PYR1 mandipropamid receptor in complex with mandipropamid and HAB1
1PIO	;	2.8	;	AN ENGINEERED STAPHYLOCOCCUS AUREUS PC1 BETA-LACTAMASE THAT HYDROLYSES THIRD GENERATION CEPHALOSPORINS
1KL4	;	1.7	;	AN ENGINEERED STREPTAVIDIN WITH IMPROVED AFFINITY FOR THE STREP-TAG II PEPTIDE : apo-SAM2
1KL3	;	1.7	;	an engineered streptavidin with improved affinity for the strep-tag II peptide : SAm1-StrepII
1KL5	;	1.8	;	an engineered streptavidin with improved affinity for the strep-tag II peptide : SAm2-StrepII
1KFF	;	1.9	;	An engineered streptavidin with improved affinity for the strep-tag II peptide: apo-SAM1
1GKO	;	2.1	;	An Engineered Transthyretin Monomer that is Non-amyloidogenic - Unless Partially Denatured
3MI7	;	2.2	;	An Enhanced Repressor of Human Papillomavirus E2 Protein
6W3W	;	1.55	;	An enumerative algorithm for de novo design of proteins with diverse pocket structures
6W40	;	2.49	;	An enumerative algorithm for de novo design of proteins with diverse pocket structures
5W7G	;	4.5	;	An envelope of a filamentous hyperthermophilic virus carries lipids in a horseshoe conformation
7FA0	;	1.8	;	An enzyme mutant from Viola yedoensis
2AEP	;	2.1	;	An epidemiologically significant epitope of a 1998 influenza virus neuraminidase forms a highly hydrated interface in the NA-antibody complex.
2AEQ	;	3.0	;	An epidemiologically significant epitope of a 1998 influenza virus neuraminidase forms a highly hydrated interface in the NA-antibody complex.
2H6M	;	1.4	;	An episulfide cation (thiiranium ring) trapped in the active site of HAV 3C proteinase inactivated by peptide-based ketone inhibitors
2H9H	;	1.39	;	An episulfide cation (thiiranium ring) trapped in the active site of HAV 3C proteinase inactivated by peptide-based ketone inhibitors
2HAL	;	1.35	;	An episulfide cation (thiiranium ring) trapped in the active site of HAV 3C proteinase inactivated by peptide-based ketone inhibitors
4Y1M	;	3.0	;	An Escherichia coli yybP-ykoY Mn riboswitch in the Mn2+-free state
8DHR	;	1.75	;	An ester mutant of SfGFP
5A2G	;	1.899	;	An esterase from anaerobic Clostridium hathewayi can hydrolyze aliphatic aromatic polyesters
3QE4	;	2.3	;	An evolved aminoacyl-tRNA Synthetase with atypical polysubstrate specificity
4R9P	;	1.592	;	An Expansion to the Smad MH2-family: The structure of the N-MH2 expanded domain
5F67	;	1.76	;	An exquisitely specific PDZ/target recognition revealed by the structure of INAD PDZ3 in complex with TRP channel tail
2DMF	;		;	An extended conformation of the RWD domain of human Ring finger protein 25
1Q1H	;	2.9	;	An extended winged helix domain in general transcription factor E/IIE alpha
3LDY	;	1.97	;	An extraordinary mechanism of DNA perturbation exhibited by the rare-cutting HNH restriction endonuclease PacI
5NIP	;		;	An i-motif containing the neutral cytidine protonated analogue pseudoisocytidine
8BQY	;		;	An i-motif domain able to undergo pH-dependent conformational transitions (acidic structure)
8BV6	;		;	An i-motif domain able to undergo pH-dependent conformational transitions (neutral structure)
2KKK	;		;	An i-motif structure with intercalated T T pairs
1VCR	;	9.5	;	An icosahedral assembly of light-harvesting chlorophyll a/b protein complex from pea thylakoid membranes
4JE3	;	2.282	;	An Iml3-Chl4 heterodimer links the core centromere to factors required for accurate chromosome segregation
3PWV	;	2.696	;	An immmunodominant CTL epitope from rinderpest virus presented by cattle MHC class I molecule N*01801 (BoLA-A11)
3PWU	;	1.899	;	An immmunodominant CTL epitope from rinderpest virus presented by cattle MHC class I molecule N*01801(BoLA-A11)
3J2T	;	9.5	;	An improved model of the human apoptosome
5N29	;	2.1	;	An improved model of the Trypanosoma brucei CTP synthase glutaminase domain:acivicin complex.
5AGD	;	1.2	;	An inactive (D125N) variant of the catalytic domain, BcGH76, of Bacillus circulans Aman6 in complex with alpha-1,6-mannopentaose
6SHM	;	1.9	;	An inactive (D136A and D137A) variant of alpha-1,6-mannanase, GH76A of Salegentibacter sp. HEL1_6 in complex with alpha-1,6-mannotetrose
6Y8F	;	1.472	;	An inactive (D136N and D137N) variant of alpha-1,6-mannanase, GH76A of Salegentibacter sp. HEL1_6 in complex with alpha-1,6-mannotriose
4P2P	;	2.4	;	AN INDEPENDENT CRYSTALLOGRAPHIC REFINEMENT OF PORCINE PHOSPHOLIPASE A2 AT 2.4 ANGSTROMS RESOLUTION
3Q01	;	2.1	;	An induced fit mechanism regulates p53 DNA binding kinetics to confer sequence specificity
3Q05	;	2.4	;	An induced fit mechanism regulates p53 DNA binding kinetics to confer sequence specificity
3Q06	;	3.2	;	An induced fit mechanism regulates p53 DNA binding kinetics to confer sequence specificity
3MN3	;	2.38	;	An inhibited conformation for the protein kinase domain of the Saccharomyces cerevisiae AMPK homolog Snf1
8C37	;	2.15	;	An intermediate light exposed 2.15 Angstrom crystal structure of H132A variant of cobalamin binding domain belonging to a light-dependent transcription regulator TtCarH obtained under anaerobic conditions
4NEH	;	2.7505	;	An internal ligand-bound, metastable state of a leukocyte integrin, aXb2
4NEN	;	2.9012	;	An internal ligand-bound, metastable state of a leukocyte integrin, aXb2
4CN0	;	1.75	;	An intertwined homodimer of the PDZ homology domain of AHNAK2
4CMZ	;	2.7	;	An intertwined homodimer of the PDZ homology domain of periaxin
3V16	;	2.05	;	An intramolecular pi-cation latch in phosphatidylinositol-specific phospholipase C from S.aureus controls substrate access to the active site
1MYQ	;		;	An intramolecular quadruplex of (GGA)(4) triplet repeat DNA with a G:G:G:G tetrad and a G(:A):G(:A):G(:A):G heptad, and its dimeric interaction
3GDD	;	2.8	;	An inverted anthraquinone-DNA crystal structure
2TPK	;		;	AN INVESTIGATION OF THE STRUCTURE OF THE PSEUDOKNOT WITHIN THE GENE 32 MESSENGER RNA OF BACTERIOPHAGE T2 USING HETERONUCLEAR NMR METHODS
2NQ2	;	2.4	;	An inward-facing conformation of a putative metal-chelate type ABC transporter.
5JY8	;	2.942	;	An iron-bound structure of the isochorismate synthase EntC
5JY9	;	2.162	;	An iron-bound structure of the salicylate synthase Irp9
7POA	;	1.6	;	An Irreversible, Promiscuous and Highly Thermostable Claisen-Condensation Biocatalyst Drives the Synthesis of Substituted Pyrroles
7POB	;	2.0	;	An Irreversible, Promiscuous and Highly Thermostable Claisen-Condensation Biocatalyst Drives the Synthesis of Substituted Pyrroles
7POC	;	2.6	;	An Irreversible, Promiscuous and Highly Thermostable Claisen-Condensation Biocatalyst Drives the Synthesis of Substituted Pyrroles
4X6Q	;	2.52	;	An Isoform-specific Myristylation Switch Targets RIIb PKA Holoenzymes to Membranes
4X6R	;	2.4	;	An Isoform-specific Myristylation Switch Targets RIIb PKA Holoenzymes to Membranes
1M1U	;	2.3	;	AN ISOLEUCINE-BASED ALLOSTERIC SWITCH CONTROLS AFFINITY AND SHAPE SHIFTING IN INTEGRIN CD11B A-DOMAIN
1NHR	;	2.1	;	AN L40C MUTATION CONVERTS THE CYSTEINE-SULFENIC ACID REDOX CENTRE IN ENTEROCOCCAL NADH PEROXIDASE TO A DISULFIDE
1NHS	;	2.0	;	AN L40C MUTATION CONVERTS THE CYSTEINE-SULFENIC ACID REDOX CENTRE IN ENTEROCOCCAL NADH PEROXIDASE TO A DISULFIDE
4TXS	;	2.78	;	An Ligand-observed Mass Spectrometry-based Approach Integrated into the Fragment Based Lead Discovery Pipeline
4TY8	;	2.78	;	An Ligand-observed Mass Spectrometry-based Approach Integrated into the Fragment Based Lead Discovery Pipeline
4TY9	;	2.78	;	An Ligand-observed Mass Spectrometry-based Approach Integrated into the Fragment Based Lead Discovery Pipeline
4TYA	;	2.94	;	An Ligand-observed Mass Spectrometry-based Approach Integrated into the Fragment Based Lead Discovery Pipeline
4TYB	;	2.93	;	An Ligand-observed Mass Spectrometry-based Approach Integrated into the Fragment Based Lead Discovery Pipeline
3VVK	;	2.3	;	An M-like Reaction State of the azide-bound purple form of pharaonis halorhodopsin
1BDK	;		;	AN NMR, CD, MOLECULAR DYNAMICS, AND FLUOROMETRIC STUDY OF THE CONFORMATION OF THE BRADYKININ ANTAGONIST B-9340 IN WATER AND IN AQUEOUS MICELLAR SOLUTIONS
1PUT	;		;	AN NMR-DERIVED MODEL FOR THE SOLUTION STRUCTURE OF OXIDIZED PUTIDAREDOXIN, A 2FE, 2-S FERREDOXIN FROM PSEUDOMONAS
2N8V	;		;	An NMR/SAXS structure of the PKI domain of the honeybee dicistrovirus, Israeli acute paralysis virus (IAPV) IRES
4O2C	;	1.802	;	An Nt-acetylated peptide complexed with HLA-B*3901
7NFF	;	1.55	;	An octameric barrel state of a de novo coiled-coil assembly: CC-Type2-(LaId)4-I24A.
7NFL	;	1.44	;	An octameric barrel state of a de novo coiled-coil assembly: CC-Type2-(LaId)4-I24N.
7NFK	;	1.3	;	An octameric barrel state of a de novo coiled-coil assembly: CC-Type2-(LaId)4-I24S.
7NFM	;	1.45	;	An octameric barrel state of a de novo coiled-coil assembly: CC-Type2-(LaId)4-L21K.
7NFI	;	1.42	;	An octameric barrel state of a de novo coiled-coil assembly: CC-Type2-(LaId)4-L7Y.
1SN9	;	1.2	;	An Oligomeric Domain-Swapped Beta-Beta-Alpha Mini-Protein
1SNA	;	1.5	;	An Oligomeric Domain-Swapped Beta-Beta-Alpha Mini-Protein
1SNE	;	1.5	;	An Oligomeric Domain-Swapped Beta-Beta-Alpha Mini-Protein
5OXF	;	3.94	;	An oligomerised bacterial dynamin pair provides a mechanism for the long range sensing and tethering of membranes
5OWV	;	3.72	;	An oligomerised bacterial dynamin pair provides a mechanism for the long-range sensing and tethering of membranes
4UDE	;	2.25	;	An oligomerization domain confers pioneer properties to the LEAFY master floral regulator
7WZA	;	1.50029	;	An open conformation Form 1 of switch II for RhoA
7WZC	;	1.79945	;	An open conformation Form2 of switch II for RhoA GDP-bound state
6V4A	;	3.83	;	An open conformation of a Pentameic ligand-gated ion channel with additional N-terminal domain
2FMX	;	1.82	;	An open conformation of switch I revealed by Sar1-GDP crystal structure at low Mg(2+)
7W2E	;	3.557	;	An open-like conformation of the sigma-1 receptor from Xenopus laevis
7W2F	;	3.1	;	An open-like conformation of the sigma-1 receptor from Xenopus laevis complexed with PRE084 by co-crystallization
7W2G	;	2.851	;	An open-like conformation of the sigma-1 receptor from Xenopus laevis complexed with PRE084 by soaking
3EAM	;	2.9	;	An open-pore structure of a bacterial pentameric ligand-gated ion channel
3KXO	;	2.1	;	An orally active inhibitor bound at the active site of HPGDS
2PHB	;	2.3	;	An Orally Efficacious Factor Xa Inhibitor
1SBG	;	2.3	;	AN ORALLY-BIOAVAILABLE HIV-1 PROTEASE INHIBITOR CONTAINING AN IMIDAZOLE-DERIVED PEPTIDE BOND REPLACEMENT. CRYSTALLOGRAPHIC AND PHARMACOKINETIC ANALYSIS
6OSW	;		;	An order-to-disorder structural switch activates the FoxM1 transcription factor
4FKB	;	1.22	;	An Organic solvent tolerant lipase 42
6X94	;	1.45	;	An orthogonal seryl-tRNA synthetase/tRNA pair for noncanonical amino acid mutagenesis in Escherichia coli
2VOX	;	1.9	;	An oxidized tryptophan facilitates copper-binding in Methylococcus capsulatus secreted protein MopE. The structure of mercury soaked MopE to 1.9AA
2VOW	;	1.65	;	An oxidized tryptophan facilitates copper-binding in Methylococcus capsulatus secreted protein MopE. The structure of recombinant MopE to 1.65AA
2VOV	;	1.35	;	An oxidized tryptophan facilitates copper-binding in Methylococcus capsulatus secreted protein MopE. The structure of wild-type MopE to 1.35AA
3QJP	;	3.2986	;	An RAMP protein binding different RNA substrates
7RWR	;		;	An RNA aptamer that decreases flavin redox potential
6NOU	;	1.914	;	An scFv derived from ixekizumab
7K3Q	;	1.38	;	An ultra-potent human neutralizing antibody locks the SARS-CoV-2 spike in the closed conformation
5WDM	;	2.803	;	An ultra-stable single-chain insulin analog resists thermal inactivation and exhibits biological signaling duration equivalent to the native protein
3DHA	;	0.95	;	An Ultral High Resolution Structure of N-Acyl Homoserine Lactone Hydrolase with the Product N-Hexanoyl-L-Homoserine Bound at An Alternative Site
1HXI	;	1.6	;	AN UNEXPECTED EXTENDED CONFORMATION FOR THE THIRD TPR MOTIF OF THE PEROXIN PEX5 FROM TRYPANOSOMA BRUCEI
6NSO	;	1.6	;	An Unexpected Intermediate in the Reaction Catalyzed by Quinolinate Synthase
6OR8	;	1.65	;	An Unexpected Intermediate in the Reaction Catalyzed by Quinolinate Synthase
6ORA	;	2.2	;	An Unexpected Intermediate in the Reaction Catalyzed by Quinolinate Synthase
2N96	;		;	An unexpected mode of small molecule DNA binding provides the structural basis for DNA cleavage by the potent antiproliferative agent (-)-lomaiviticin A
2QPD	;	3.25	;	An unexpected outcome of surface-engineering an integral membrane protein: Improved crystallization of cytochrome ba3 oxidase from Thermus thermophilus
2QPE	;	2.9	;	An unexpected outcome of surface-engineering an integral membrane protein: Improved crystallization of cytochrome ba3 oxidase from Thermus thermophilus
7BI7	;	3.0	;	An Unexpected P-Cluster like Intermediate En Route to the Nitrogenase FeMo-co
6C62	;	1.95	;	An unexpected vestigial protein complex reveals the evolutionary origins of an s-triazine catabolic enzyme.
6C6G	;	2.1	;	An unexpected vestigial protein complex reveals the evolutionary origins of an s-triazine catabolic enzyme. Inhibitor bound complex.
1ADS	;	1.65	;	AN UNLIKELY SUGAR SUBSTRATE SITE IN THE 1.65 ANGSTROMS STRUCTURE OF THE HUMAN ALDOSE REDUCTASE HOLOENZYME IMPLICATED IN DIABETIC COMPLICATIONS
4D7E	;	2.4	;	An unprecedented NADPH domain conformation in Lysine Monooxygenase NbtG from Nocardia farcinica
1TIA	;	2.1	;	AN UNUSUAL BURIED POLAR CLUSTER IN A FAMILY OF FUNGAL LIPASES
1TFG	;	1.95	;	AN UNUSUAL FEATURE REVEALED BY THE CRYSTAL STRUCTURE AT 2.2 ANGSTROMS RESOLUTION OF HUMAN TRANSFORMING GROWTH FACTOR-BETA2
1WQC	;		;	An unusual fold for potassium channel blockers : NMR structure of three toxins from the scorpion Opisthacanthus madagascariensis
1WQD	;		;	An unusual fold for potassium channel blockers: NMR structure of three toxins from the scorpion Opisthacanthus madagascariensis
1WQE	;		;	An unusual fold for potassium channel blockers: NMR structure of three toxins from the scorpion Opisthacanthus madagascariensis
5G01	;	1.4	;	An unusual natural product primary sulfonamide: synthesis, carbonic anhydrase inhibition and protein x-ray structure of Psammaplin C
5G03	;	1.35	;	An unusual natural product primary sulfonamide: synthesis, carbonic anhydrase inhibition and protein x-ray structure of Psammaplin C
5G0B	;	1.55	;	An unusual natural product primary sulfonamide: synthesis, carbonic anhydrase inhibition and protein x-ray structure of Psammaplin C
5G0C	;	1.28	;	An unusual natural product primary sulfonamide: synthesis, carbonic anhydrase inhibition and protein x-ray structure of Psammaplin C
2NMR	;	2.1	;	An unusual twin-His arrangement in the pore of ammonia channels is essential for substrate conductance
2NOP	;	2.0	;	An unusual twin-His arrangement in the pore of ammonia channels is essential for substrate conductance
2NOW	;	2.2	;	An unusual twin-His arrangement in the pore of ammonia channels is essential for substrate conductance
2NPC	;	2.1	;	An unusual twin-His arrangement in the pore of ammonia channels is essential for substrate conductance
2NPD	;	2.1	;	An unusual twin-His arrangement in the pore of ammonia channels is essential for substrate conductance
2NPE	;	2.1	;	An unusual twin-His arrangement in the pore of ammonia channels is essential for substrate conductance
2NPG	;	2.0	;	An unusual twin-His arrangement in the pore of ammonia channels is essential for substrate conductance
2NPJ	;	2.0	;	An unusual twin-His arrangement in the pore of ammonia channels is essential for substrate conductance
2NPK	;	2.0	;	An unusual twin-His arrangement in the pore of ammonia channels is essential for substrate conductance
4EHI	;	2.28	;	An X-ray Crystal Structure of a putative Bifunctional Phosphoribosylaminoimidazolecarboxamide Formyltransferase/IMP Cyclohydrolase
4EHJ	;	2.71	;	An X-ray Structure of a Putative Phosphogylcerate Kinase from Francisella tularensis subsp. tularensis SCHU S4
4FEY	;	2.3	;	An X-ray Structure of a Putative Phosphogylcerate Kinase with Bound ADP from Francisella tularensis subsp. tularensis SCHU S4
6KRC	;	1.39	;	An X-ray structure of ferric F43Y/F46S sperm whale myoglobin
6KRF	;	1.86	;	An X-ray structure of ferric F43Y/F46S sperm whale myoglobin in complex with guaiacol
7CEN	;	2.35	;	an x-ray structure of ferric L29E Mb in complex with Mg(II)
7CEZ	;	1.57	;	An x-ray structure of G5K/Q8K/A19K/V21K Mb mutant with a positive charge
6JP1	;	1.99	;	An X-ray structure of met sperm whale F43Y/T67R myoglobin with Tyr-heme double cross-links
8LYZ	;	2.5	;	AN X-RAY STUDY OF THE STRUCTURE AND BINDING PROPERTIES OF IODINE-INACTIVATED LYSOZYME
7LNE	;	1.53	;	ANA modification at 3' end of RNA primer complex with guanosine dinucleotide ligand G(5')ppp(5')G
7UV2	;		;	Ana o 1 Leader Sequence Residues 82-132
6S5L	;	2.9	;	Anabaena Apo-C-Terminal Domain Homolog Of The Orange Carotenoid Protein In Native Conditions
6FEJ	;	2.75	;	Anabaena Apo-C-Terminal Domain Homolog Protein
2K2V	;		;	Anabaena CcbP in the calcium-bound form
1P78	;	2.25	;	Anabaena HU-DNA cocrystal structure (AHU2)
1P51	;	2.5	;	Anabaena HU-DNA cocrystal structure (AHU6)
1P71	;	1.9	;	Anabaena HU-DNA corcrystal structure (TR3)
1EWY	;	2.38	;	ANABAENA PCC7119 FERREDOXIN:FERREDOXIN-NADP+-REDUCTASE COMPLEX
1CZP	;	1.17	;	ANABAENA PCC7119 [2FE-2S] FERREDOXIN IN THE REDUCED AND OXIXIZED STATE AT 1.17 A
1XIO	;	2.0	;	Anabaena sensory rhodopsin
2II7	;	2.8	;	Anabaena sensory rhodopsin transducer
2II8	;	2.1	;	Anabaena sensory rhodopsin transducer
2II9	;	2.0	;	Anabaena sensory rhodopsin transducer
2IIA	;	1.8	;	Anabaena sensory rhodopsin transducer
4EV1	;	1.95	;	Anabaena Tic22 (protein transport)
7X99	;	2.2	;	Anabolic ornithine carbamoyltransferases (OTCs) from Psychrobacter sp. PAMC 21119
4DUL	;	3.0	;	ANAC019 NAC domain crystal form IV
3SWP	;	4.113	;	ANAC019 NAC domain in complex with DNA
2XWP	;	1.9	;	ANAEROBIC COBALT CHELATASE (CbiK) FROM SALMONELLA TYPHIMURIUM IN COMPLEX WITH METALATED TETRAPYRROLE
2XWS	;	1.6	;	ANAEROBIC COBALT CHELATASE (CbiX) FROM ARCHAEOGLOBUS FULGIDUS
2XWQ	;	2.01	;	Anaerobic cobalt chelatase from Archeaoglobus fulgidus (CbiX) in complex with metalated sirohydrochlorin product
1QGO	;	2.4	;	ANAEROBIC COBALT CHELATASE IN COBALAMIN BIOSYNTHESIS FROM SALMONELLA TYPHIMURIUM
3OBP	;	1.5	;	Anaerobic complex of urate oxidase with uric acid
2EI0	;	1.6	;	Anaerobic Crystal Structure Analysis of 1,2-dihydroxynaphthalene dioxygenase from Pseudomonas sp. strain C18 complexed with 3,4-dihydroxybiphenyl
2EHZ	;	1.35	;	Anaerobic Crystal Structure Analysis of 1,2-dihydroxynaphthalene dioxygenase from Pseudomonas sp. strain C18 complexed with 4-methylcatechol
2EI1	;	1.52	;	Anaerobic Crystal Structure Analysis of the 1,2-dihydroxynaphthalene dioxygeanse of Pseudomonas sp. strain C18 complexes to 1,2-dihydroxynaphthalene
2EI3	;	1.9	;	Anaerobic Crystal Structure Analysis of the 1,2-dihydroxynaphthalene dioxygenase from Pseudomonas sp. strain C18 complexes with 2,3-dihydroxybiphenyl
4QWT	;	2.002	;	Anaerobic crystal structure of delta413-417:GS LOX in complex with arachidonate
4IXK	;	2.1	;	Anaerobic crystal structure of iron soaked (2 h) ferritin from Pseudo-nitzschia multiseries
4ITW	;	2.0	;	Anaerobic crystal structure of iron soaked (75 min) ferritin from Pseudo-nitzschia multiseries
7VUA	;	2.695	;	Anaerobic hydroxyproline degradation involving C-N cleavage by a glycyl radical enzyme
8C33	;	2.25	;	Anaerobic light exposed 2.25 Angstrom crystal structure of cobalamin binding domain belonging to a light-dependent transcription regulator TtCarH
1QYO	;	1.8	;	Anaerobic precylization intermediate crystal structure for S65G Y66G GFP variant
4U3E	;	1.64	;	Anaerobic ribonucleotide reductase
1F1V	;	1.9	;	ANAEROBIC SUBSTRATE COMPLEX OF HOMOPROTOCATECHUATE 2,3-DIOXYGENASE FROM ARTHROBACTER GLOBIFORMIS. (COMPLEX WITH 3,4-DIHYDROXYPHENYLACETATE)
2PPA	;	1.69	;	Anaerobically manipulated wild type oxidized AfNiR bound to nitrous oxide
1DAU	;		;	Analog of dickerson-drew DNA dodecamer with 6'-alpha-methyl carbocyclic thymidines, NMR, minimized average structure
2LSQ	;		;	Analog of the fragment 197-221 of beta-1 adrenoreceptor
1ELA	;	2.0	;	Analogous inhibitors of elastase do not always bind analogously
1ELB	;	2.1	;	Analogous inhibitors of elastase do not always bind analogously
1ELC	;	1.75	;	Analogous inhibitors of elastase do not always bind analogously
1LPN	;	2.18	;	ANALOGS OF REACTION INTERMEDIATES IDENTIFY A UNIQUE SUBSTRATE BINDING SITE IN CANDIDA RUGOSA LIPASE
1LPO	;	2.18	;	ANALOGS OF REACTION INTERMEDIATES IDENTIFY A UNIQUE SUBSTRATE BINDING SITE IN CANDIDA RUGOSA LIPASE
1LPP	;	2.18	;	ANALOGS OF REACTION INTERMEDIATES IDENTIFY A UNIQUE SUBSTRATE BINDING SITE IN CANDIDA RUGOSA LIPASE
2IWU	;	2.8	;	Analogues of radicicol bound to the ATP-binding site of Hsp90
2IWX	;	1.5	;	Analogues of radicicol bound to the ATP-binding site of Hsp90.
1B95	;	2.05	;	ANALYSIS OF A MUTATIONAL HOT-SPOT IN THE ECORV RESTRICTION ENDONUCLEASE: A CATALYTIC ROLE FOR A MAIN CHAIN CARBONYL GROUP
1B96	;	2.3	;	ANALYSIS OF A MUTATIONAL HOT-SPOT IN THE ECORV RESTRICTION ENDONUCLEASE: A CATALYTIC ROLE FOR A MAIN CHAIN CARBONYL GROUP
1B97	;	1.9	;	ANALYSIS OF A MUTATIONAL HOT-SPOT IN THE ECORV RESTRICTION ENDONUCLEASE: A CATALYTIC ROLE FOR A MAIN CHAIN CARBONYL GROUP
3QT9	;	2.05	;	Analysis of a new family of widely distributed metal-independent alpha mannosidases provides unique insight into the processing of N-linked glycans, Clostridium perfringens CPE0426 complexed with alpha-1,6-linked 1-thio-alpha-mannobiose
3QRY	;	1.75	;	Analysis of a new family of widely distributed metal-independent alpha mannosidases provides unique insight into the processing of N-linked glycans, Streptococcus pneumoniae SP_2144 1-deoxymannojirimycin complex
3QSP	;	2.1	;	Analysis of a new family of widely distributed metal-independent alpha mannosidases provides unique insight into the processing of N-linked glycans, Streptococcus pneumoniae SP_2144 non-productive substrate complex with alpha-1,6-mannobiose
3QT3	;	2.35	;	Analysis of a New Family of Widely Distributed Metal-independent alpha-Mannosidases Provides Unique Insight into the Processing of N-linked Glycans, Clostridium perfringens CPE0426 apo-structure
3QPF	;	2.15	;	Analysis of a New Family of Widely Distributed Metal-independent alpha-Mannosidases Provides Unique Insight into the Processing of N-linked Glycans, Streptococcus pneumoniae SP_2144 apo-structure
7JY8	;	2.4	;	Analysis of a strand exchange reaction with a mini filament of 9-RecA, 27-mer ssDNA, partially-homologous 67 bp dsDNA and ATPgammaS
7JY6	;	2.5	;	Analysis of a strand exchange reaction with a mini filament of 9-RecA, oligo(dT)27 primary ssDNA, non-homologous 120 bp dsDNA and ATPgammaS
1I13	;	1.84	;	ANALYSIS OF AN INVARIANT ASPARTIC ACID IN HPRTS-ALANINE MUTANT
1I0L	;	1.72	;	ANALYSIS OF AN INVARIANT ASPARTIC ACID IN HPRTS-ASPARAGINE MUTANT
1I14	;	1.92	;	ANALYSIS OF AN INVARIANT ASPARTIC ACID IN HPRTS-GLUTAMIC ACID MUTANT
1I0I	;	2.06	;	ANALYSIS OF AN INVARIANT ASPARTIC ACID IN HPRTS-GLUTAMINE MUTANT
1LY3	;	1.9	;	ANALYSIS OF QUINAZOLINE AND PYRIDOPYRIMIDINE N9-C10 REVERSED BRIDGE ANTIFOLATES IN COMPLEX WITH NADP+ AND PNEUMOCYSTIS CARINII DIHYDROFOLATE REDUCTASE
1LY4	;	2.1	;	Analysis of quinazoline and PYRIDO[2,3D]PYRIMIDINE N9-C10 reversed bridge antifolates in complex with NADP+ and Pneumocystis carinii dihydrofolate reductase
2CRD	;		;	ANALYSIS OF SIDE-CHAIN ORGANIZATION ON A REFINED MODEL OF CHARYBDOTOXIN: STRUCTURAL AND FUNCTIONAL IMPLICATIONS
1YO5	;	2.0	;	Analysis of the 2.0A crystal structure of the protein-DNA complex of human PDEF Ets domain bound to the prostate specific antigen regulatory site
1HDB	;	2.2	;	ANALYSIS OF THE CRYSTAL STRUCTURE, MOLECULAR MODELING AND INFRARED SPECTROSCOPY OF THE DISTAL BETA-HEME POCKET VALINE67(E11)-THREONINE MUTATION OF HEMOGLOBIN
1L55	;	1.9	;	ANALYSIS OF THE INTERACTION BETWEEN CHARGED SIDE CHAINS AND THE ALPHA-HELIX DIPOLE USING DESIGNED THERMOSTABLE MUTANTS OF PHAGE T4 LYSOZYME
1L56	;	1.8	;	ANALYSIS OF THE INTERACTION BETWEEN CHARGED SIDE CHAINS AND THE ALPHA-HELIX DIPOLE USING DESIGNED THERMOSTABLE MUTANTS OF PHAGE T4 LYSOZYME
1L57	;	1.9	;	ANALYSIS OF THE INTERACTION BETWEEN CHARGED SIDE CHAINS AND THE ALPHA-HELIX DIPOLE USING DESIGNED THERMOSTABLE MUTANTS OF PHAGE T4 LYSOZYME
1L58	;	1.65	;	ANALYSIS OF THE INTERACTION BETWEEN CHARGED SIDE CHAINS AND THE ALPHA-HELIX DIPOLE USING DESIGNED THERMOSTABLE MUTANTS OF PHAGE T4 LYSOZYME
1L59	;	1.75	;	ANALYSIS OF THE INTERACTION BETWEEN CHARGED SIDE CHAINS AND THE ALPHA-HELIX DIPOLE USING DESIGNED THERMOSTABLE MUTANTS OF PHAGE T4 LYSOZYME
1L60	;	1.7	;	ANALYSIS OF THE INTERACTION BETWEEN CHARGED SIDE CHAINS AND THE ALPHA-HELIX DIPOLE USING DESIGNED THERMOSTABLE MUTANTS OF PHAGE T4 LYSOZYME
1L61	;	1.8	;	ANALYSIS OF THE INTERACTION BETWEEN CHARGED SIDE CHAINS AND THE ALPHA-HELIX DIPOLE USING DESIGNED THERMOSTABLE MUTANTS OF PHAGE T4 LYSOZYME
1L62	;	1.7	;	ANALYSIS OF THE INTERACTION BETWEEN CHARGED SIDE CHAINS AND THE ALPHA-HELIX DIPOLE USING DESIGNED THERMOSTABLE MUTANTS OF PHAGE T4 LYSOZYME
1L63	;	1.75	;	ANALYSIS OF THE INTERACTION BETWEEN CHARGED SIDE CHAINS AND THE ALPHA-HELIX DIPOLE USING DESIGNED THERMOSTABLE MUTANTS OF PHAGE T4 LYSOZYME
1ITM	;		;	ANALYSIS OF THE SOLUTION STRUCTURE OF HUMAN INTERLEUKIN 4 DETERMINED BY HETERONUCLEAR THREE-DIMENSIONAL NUCLEAR MAGNETIC RESONANCE TECHNIQUES
1KXW	;	1.96	;	ANALYSIS OF THE STABILIZATION OF HEN LYSOZYME WITH THE HELIX DIPOLE AND CHARGED SIDE CHAINS
1KXX	;	1.71	;	ANALYSIS OF THE STABILIZATION OF HEN LYSOZYME WITH THE HELIX DIPOLE AND CHARGED SIDE CHAINS
1KXY	;	1.79	;	ANALYSIS OF THE STABILIZATION OF HEN LYSOZYME WITH THE HELIX DIPOLE AND CHARGED SIDE CHAINS
1RFP	;	1.75	;	ANALYSIS OF THE STABILIZATION OF HEN LYSOZYME WITH THE HELIX DIPOLE AND CHARGED SIDE CHAINS
1UIA	;	1.76	;	ANALYSIS OF THE STABILIZATION OF HEN LYSOZYME WITH THE HELIX DIPOLE AND CHARGED SIDE CHAINS
1UIB	;	1.76	;	ANALYSIS OF THE STABILIZATION OF HEN LYSOZYME WITH THE HELIX DIPOLE AND CHARGED SIDE CHAINS
1UIC	;	1.95	;	ANALYSIS OF THE STABILIZATION OF HEN LYSOZYME WITH THE HELIX DIPOLE AND CHARGED SIDE CHAINS
1UID	;	1.95	;	ANALYSIS OF THE STABILIZATION OF HEN LYSOZYME WITH THE HELIX DIPOLE AND CHARGED SIDE CHAINS
1UIE	;	1.95	;	ANALYSIS OF THE STABILIZATION OF HEN LYSOZYME WITH THE HELIX DIPOLE AND CHARGED SIDE CHAINS
1UIF	;	1.85	;	ANALYSIS OF THE STABILIZATION OF HEN LYSOZYME WITH THE HELIX DIPOLE AND CHARGED SIDE CHAINS
1UIG	;	1.95	;	ANALYSIS OF THE STABILIZATION OF HEN LYSOZYME WITH THE HELIX DIPOLE AND CHARGED SIDE CHAINS
1UIH	;	1.75	;	ANALYSIS OF THE STABILIZATION OF HEN LYSOZYME WITH THE HELIX DIPOLE AND CHARGED SIDE CHAINS
2M4X	;		;	Analysis of the structural and molecular basis of voltage-sensitive sodium channel inhibition by the spider toxin, Huwentoxin-IV (-TRTX-Hh2a).
2M4Z	;		;	Analysis of the structural and molecular basis of voltage-sensitive sodium channel inhibition by the spider toxin, Huwentoxin-IV (-TRTX-Hh2a).
2M50	;		;	Analysis of the structural and molecular basis of voltage-sensitive sodium channel inhibition by the spider toxin, Huwentoxin-IV (-TRTX-Hh2a).
3FM9	;	2.7	;	Analysis of the Structural Determinants Underlying Discrimination between Substrate and Solvent in beta-Phosphoglucomutase Catalysis
1PD8	;	2.1	;	Analysis of Three Crystal Structure Determinations of a 5-Methyl-6-N-Methylanilino Pyridopyrimidine Antifolate Complex with Human Dihydrofolate Reductase
1PD9	;	2.2	;	Analysis of Three Crystal Structure Determinations of a 5-Methyl-6-N-Methylanilino Pyridopyrimidine antifolate Complex with Human Dihydrofolate Reductase
1PDB	;	2.2	;	Analysis of Three Crystal Structure Determinations of a 5-Methyl-6-N-Methylanilino Pyridopyrimidine Antifolate Complex with Human Dihydrofolate Reductase
1MVS	;	1.9	;	Analysis of Two Polymorphic Forms of a Pyrido[2,3-d]pyrimidine N9-C10 Reverse-Bridge Antifolate Binary Complex with Human Dihydrofolate Reductase
1MVT	;	1.8	;	Analysis of Two Polymorphic Forms of a Pyrido[2,3-d]pyrimidine N9-C10 Reverse-Bridge Antifolate Binary Complex with Human Dihydrofolate Reductase
4IPX	;	1.7	;	Analyzing the visible conformational substates of the FK506 binding protein FKBP12
7AX5	;	1.756	;	Anammox-specific acyl carrier protein from Kuenenia stuttgartiensis; ensemble refinement
7AUF	;	1.76	;	anammox-specific acyl carrier protein from Kuenenia stuttgartiensis; normal refinement
8AYB	;	1.8	;	anammox-specific FabZ from Scalindua brodae
8AYD	;	2.8	;	Anammox-specific FabZ from the annamox bacterium Kuenenia stuttgartiensis
5IMX	;	2.12	;	Anaplastic lymphoma kinase (ALK) catalytic domain complexed with novel inhibitor 3-sulfonylpyrazol-4-amino pyrimidine
7N00	;	2.27	;	Anaplastic lymphoma kinase (ALK) extracellular fragment of ligand binding region 648-1025 in complex with AUG-alpha
7MZY	;	1.5	;	Anaplastic lymphoma kinase (ALK) extracellular fragment of ligand binding region 673-986
7MZW	;		;	Anaplastic lymphoma kinase (ALK) extracellular ligand binding region 673-1025
4Z55	;	1.55	;	Anaplastic lymphoma kinase catalytic domain complexed with pyrazolopyrimidine derivative of LDK378
8ARJ	;	1.645	;	Anaplastic Lymphoma Kinase with a novel carboline inhibitor
1Q38	;		;	Anastellin
1GES	;	1.74	;	ANATOMY OF AN ENGINEERED NAD-BINDING SITE
1GET	;	2.0	;	ANATOMY OF AN ENGINEERED NAD-BINDING SITE
1GEU	;	2.2	;	ANATOMY OF AN ENGINEERED NAD-BINDING SITE
1OJI	;	2.15	;	Anatomy of glycosynthesis: Structure and kinetics of the Humicola insolens Cel7B E197A and E197S glycosynthase mutants
1OJJ	;	1.4	;	Anatomy of glycosynthesis: Structure and kinetics of the Humicola insolens Cel7BE197A and E197S glycosynthase mutants
1OJK	;	1.5	;	Anatomy of glycosynthesis: Structure and kinetics of the Humicola insolens Cel7BE197A and E197S glycosynthase mutants
5NYW	;	2.501	;	Anbu (ancestral beta-subunit) from Yersinia bercovieri
5NYG	;	2.4	;	Anbu (Gly-1) mutant from Hyphomicrobium sp. strain MC1 - SG P2(1)2(1)2(1)
5NYQ	;	1.95	;	Anbu (Gly-1) mutant from Hyphomicrobium sp. strain MC1 - SG:R32
5NYJ	;	3.2	;	Anbu from Hyphomicrobium sp. strain MC1 - SG: C2
5NYP	;	1.9	;	Anbu from Hyphomicrobium sp. strain MC1 - SG: R32
5NYR	;	2.0	;	Anbu from Hyphomicrobium sp. strain MC1 -SG: R3
7RAE	;	2.098	;	AncAR1 - progesterone - Tif2
7RAF	;	1.551	;	AncAR1-Rev - progesterone - Tif2
8JKU	;	2.57	;	Ancestal imine reductase
3ZDJ	;	2.4	;	Ancestral (ENCA) beta-lactamase class A
4B88	;	2.05	;	Ancestral (GNCA) Beta-lactamase class A
7XPM	;	2.35	;	Ancestral ADH WT
6PPM	;	2.61	;	Ancestral Caspase 6
5TUJ	;	3.352	;	Ancestral Cationic Amino Acid Solute Binding Protein (AncCDT-1)
2Q3Y	;	2.4	;	Ancestral Corticiod Receptor in Complex with DOC
2Q1H	;	1.9	;	Ancestral Corticoid Receptor in Complex with Aldosterone
2Q1V	;	1.95	;	Ancestral corticoid receptor in complex with cortisol
6PDQ	;	1.83	;	Ancestral Effector Caspase 3/6/7
6GJF	;	1.45	;	Ancestral endocellulase Cel5A
7AL4	;	3.0	;	Ancestral Flavin-containing monooxygenase (FMO) 1 (mammalian)
6Z1H	;	2.5	;	Ancestral glycosidase (family 1)
8JYT	;	1.79	;	Ancestral imine reducatase N560
8HWY	;	2.32	;	Ancestral imine reductase mutant N559_M6
4LTW	;	2.045	;	Ancestral Ketosteroid Receptor-Progesterone-Mifepristone Complex
7C4N	;	2.2	;	Ancestral L-amino acid oxidase (AncLAAO-N5) L-Phe binding form
7C4M	;	2.4	;	Ancestral L-amino acid oxidase (AncLAAO-N5) L-Trp binding form
7C4K	;	2.4	;	Ancestral L-amino acid oxidase (AncLAAO-N5) ligand free form
7X7K	;	1.6	;	Ancestral L-Lys oxidase (AncLLysO-2) L-Arg binding form
7X7J	;	1.4	;	Ancestral L-Lys oxidase (AncLLysO-2) L-Lys binding form
7X7I	;	1.55	;	Ancestral L-Lys oxidase (AncLLysO-2) ligand free form
7EIH	;	2.2	;	Ancestral L-Lys oxidase (ligand free form)
7EIJ	;	2.2	;	Ancestral L-Lys oxidase K387A variant (L-Arg binding form)
7EII	;	2.4	;	Ancestral L-Lys oxidase K387A variant (L-Lys binding form)
6K4D	;	1.7	;	Ancestral luciferase AncLamp in complex with ATP and D-luciferin
6K4C	;	2.1	;	Ancestral luciferase AncLamp in complex with DLSA
7DDT	;	2.9	;	Ancestral myoglobin aMbSe of Enaliarctos relative (imidazol ligand)
7DDS	;	2.3	;	Ancestral myoglobin aMbSp of Puijila Darwini relative
7DDR	;	1.5	;	Ancestral myoglobin aMbSp of Puijila Darwini relative (imidazol ligand)
5YCH	;	1.354	;	Ancestral myoglobin aMbWb of Basilosaurus relative (monophyly)
5YCI	;	1.97	;	Ancestral myoglobin aMbWb' of Basilosaurus relative (polyphyly)
5YCJ	;	1.58	;	Ancestral myoglobin aMbWb' of Basilosaurus relative (polyphyly) imidazole-ligand
5YCG	;	2.4	;	Ancestral myoglobin aMbWp of Pakicetus relative
8ETY	;	1.54	;	Ancestral PETase 35_442
8ETZ	;	1.68	;	Ancestral PETase 35_442 Mutant E13D
8EU0	;	2.06	;	Ancestral PETase 35_442 Mutant E27Q
8EU1	;	2.23	;	Ancestral PETase 35_442 Mutant F93L
8ETX	;	1.75	;	Ancestral PETase 55_547
4C6Y	;	1.799	;	Ancestral PNCA (last common ancestors of Gram-positive and Gram- negative bacteria) beta-lactamase class A
7R8Z	;	2.3	;	Ancestral protein AncEn of Phosphomethylpyrimidine kinases family
8G1H	;	2.7	;	Ancestral protein AncTh of Phosphomethylpirimidine kinases family
7R8Y	;	3.2	;	Ancestral protein AncThEn of Phosphomethylpyrimidine kinases family
7UKB	;	1.95	;	Ancestral reconstruction of a plant alpha/beta-hydrolase
4LY7	;	1.36	;	Ancestral RNase H
4OLN	;	1.7	;	Ancestral Steroid Receptor 1 in complex with estrogen response element DNA
4OND	;	2.253	;	Ancestral Steroid Receptor 2 DBD helix mutant - ERE DNA complex
4OV7	;	2.701	;	Ancestral Steroid Receptor 2 DBD helix mutant - SRE DNA complex
4OOR	;	2.701	;	Ancestral Steroid Receptor 2 DNA binding domain in complex with a steroid response element
5CBX	;	2.0	;	AncGR DNA Binding Domain - (+)GRE Complex
5CBY	;	1.997	;	AncGR2 DNA Binding Domain - (+)GRE Complex
3SE7	;	3.07	;	ancient VanA
5CBZ	;	2.2	;	AncMR DNA Binding Domain - (+)GRE Complex
5CC0	;	2.405	;	AncSR2 - TSLP nGRE complex
3RF4	;	1.8	;	Ancylostoma ceylanicum mif in complex with furosemide
3RF5	;	2.1	;	Ancylostoma ceylanicum mif in complex with n-(2,3,4,5,6-pentafluoro-benzyl)-4-sulfamoyl-benzamide
3S6S	;	2.4	;	Ancylostoma-secreted protein Ac-ASP-7
7WPY	;	2.25	;	AndA_M119A_N121V variant
6Q99	;	2.951	;	Ande virus L protein N-terminus mutant K124A
4C46	;	1.95	;	ANDREI-N-LVPAS fused to GCN4 adaptors
2LMU	;		;	Androcam at high calcium
2LMV	;		;	Androcam at high calcium with three explicit Ca2+
2PIO	;	2.03	;	Androgen receptor LBD with small molecule
2PIP	;	1.8	;	Androgen receptor LBD with small molecule
2PIQ	;	2.4	;	androgen receptor LBD with small molecule
2PIR	;	2.1	;	Androgen receptor LBD with small molecule
2PIT	;	1.76	;	Androgen receptor LBD with small molecule
2PIU	;	2.12	;	Androgen receptor LBD with small molecule
2PKL	;	2.49	;	Androgen receptor LBD with small molecule
2PIV	;	1.95	;	Androgen receptor with small molecule
2PIW	;	2.58	;	Androgen receptor with small molecule
7CL9	;	1.95	;	Androstenedione-bound structure of CYP154C2 from Streptomyces avermitilis in an open conformation
3CFA	;	1.75	;	Anemonia sulcata red fluorescent protein asRFP
1Q0C	;	2.1	;	Anerobic Substrate Complex of Homoprotocatechuate 2,3-Dioxygenase from Brevibacterium fuscum. (Complex with 3,4-Dihydroxyphenylacetate)
4EPU	;	2.098	;	Ang1 fibrinogen-related domain (FReD)
4JZC	;	1.9	;	Angiopoietin-2 fibrinogen domain TAG mutant
1Z3S	;	2.35	;	Angiopoietin-2 Receptor Binding Domain
2GY7	;	3.7	;	Angiopoietin-2/Tie2 Complex Crystal Structure
2JP8	;		;	Angiotensin 1-7
3NXQ	;	1.99	;	Angiotensin Converting Enzyme N domain glycsoylation mutant (Ndom389) in complex with RXP407
6JOD	;	3.2	;	Angiotensin II type 2 receptor with ligand
4MWJ	;	1.8	;	Anhui N9
4MWU	;	1.799	;	Anhui N9-laninamivir
4MWQ	;	2.0	;	Anhui N9-oseltamivir carboxylate
4MWV	;	2.0	;	Anhui N9-peramivir
4MWR	;	1.797	;	Anhui N9-zanamivir
4WHR	;	1.58	;	Anhydride reaction intermediate trapped in Protocatechuate 3,4-dioxygenase (pseudomonas putida) at pH 8.5
7VGV	;	2.3	;	Anion free form of light-driven chloride ion-pumping rhodopsin, NM-R3, structure determined by serial femtosecond crystallography at SACLA
3QBG	;	1.8	;	Anion-free blue form of pharaonis halorhodopsin
1S8L	;	2.3	;	Anion-free form of the D85S mutant of bacteriorhodopsin from crystals grown in the presence of halide
1E54	;	2.1	;	Anion-selective porin from Comamonas acidovorans
3F49	;	1.7	;	Anion-triggered Engineered Subtilisin SUBT_BACAM
2STA	;	1.8	;	ANIONIC SALMON TRYPSIN IN COMPLEX WITH SQUASH SEED INHIBITOR (CUCURBITA MAXIMA TRYPSIN INHIBITOR I)
2STB	;	1.8	;	ANIONIC SALMON TRYPSIN IN COMPLEX WITH SQUASH SEED INHIBITOR (CUCURBITA PEPO TRYPSIN INHIBITOR II)
1MBQ	;	1.8	;	Anionic Trypsin from Pacific Chum Salmon
3FP6	;	1.49	;	Anionic trypsin in complex with bovine pancreatic trypsin inhibitor (BPTI) determined to the 1.49 A resolution limit
1AND	;	2.3	;	ANIONIC TRYPSIN MUTANT WITH ARG 96 REPLACED BY HIS
1ANB	;	2.8	;	ANIONIC TRYPSIN MUTANT WITH SER 214 REPLACED BY GLU
1ANC	;	2.2	;	ANIONIC TRYPSIN MUTANT WITH SER 214 REPLACED BY LYS
3FP7	;	1.46	;	Anionic trypsin variant S195A in complex with bovine pancreatic trypsin inhibitor (BPTI) cleaved at the scissile bond (LYS15-ALA16) determined to the 1.46 A resolution limit
3FP8	;	1.46	;	Anionic trypsin variant S195A in complex with bovine pancreatic trypsin inhibitor (BPTI) determined to the 1.46 A resolution limit
1ANE	;	2.2	;	ANIONIC TRYPSIN WILD TYPE
3LSW	;	1.752	;	Aniracetam bound to the ligand binding domain of GluA3
6J1M	;	2.001	;	Anisodus acutangulus type III polyketide sythase AaPKS2 in complex with 4-carboxy-3-oxobutanoyl covalent to C166
6J1N	;	2.532	;	Anisodus acutangulus type III polyketide sythase AaPKS2 in complex with 4-carboxy-3-oxobutanoyl-CoA
2BF9	;	0.99	;	Anisotropic refinement of avian (turkey) pancreatic polypeptide at 0. 99 Angstroms resolution.
2IGD	;	1.1	;	ANISOTROPIC STRUCTURE OF PROTEIN G IGG-BINDING DOMAIN III AT 1.1 ANGSTROM RESOLUTION
7BNA	;	1.9	;	ANISOTROPIC THERMAL-PARAMETER REFINEMENT OF THE DNA DODECAMER CGCGAATTCGCG BY THE SEGMENTED RIGID-BODY METHOD
2PFD	;	3.42	;	Anisotropically refined structure of FTCD
8DEH	;	1.815	;	Ankyrin domain of SKD3
8FDS	;	1.65	;	Ankyrin domain of SKD3 isoform 2
3ZNG	;	2.85	;	Ankyrin repeat and SOCS-box protein 9 (ASB9) in complex with ElonginB and ElonginC
6V9H	;	4.1	;	Ankyrin repeat and SOCS-box protein 9 (ASB9), ElonginB (ELOB), and ElonginC (ELOC) bound to its substrate Brain-type Creatine Kinase (CKB)
3LJN	;	2.9	;	Ankyrin repeat protein from Leishmania major
7UZU	;	2.3	;	Ankyrin-1 (N-terminal region of membrane binding domain, local refinement from consensus reconstruction; bound to N-terminal peptide from band 3)
7C4L	;	2.6	;	Anncestral L-amino acid oxidase (AncLAAO-N5) L-Gln binding form
7TII	;	2.45	;	Annealed structure of oxidized bovine cytochrome c oxidase with reduced metal centers induced by synchrotron X-ray exposure
6B3I	;	2.6	;	Annexin A13a
1W7B	;	1.52	;	Annexin A2: Does it induce membrane aggregation by a new multimeric state of the protein.
8H0J	;	2.23	;	Annexin A5 mutant
8GYC	;	1.8	;	Annexin A5 protein dimer mutant
8H9Z	;	1.42	;	Annexin A5 protein mutant
1N00	;	2.1	;	Annexin Gh1 from cotton
1AII	;	1.95	;	ANNEXIN III
1ANN	;	2.3	;	ANNEXIN IV
1AOW	;	3.0	;	ANNEXIN IV
1G5N	;	1.9	;	ANNEXIN V COMPLEX WITH HEPARIN OLIGOSACCHARIDES
2IE7	;	1.75	;	Annexin V under 2.0 MPa pressure of nitrous oxide
2IE6	;	1.83	;	Annexin V under 2.0 MPa pressure of xenon
1DM5	;	1.93	;	ANNEXIN XII E105K HOMOHEXAMER CRYSTAL STRUCTURE
7O8Z	;	1.8	;	Anomalous bromide substructure of NmHR under continuous illumination determined at 13.7 keV with serial crystallography
7O8Y	;	1.75	;	Anomalous bromide substructure of NmHR under dark state conditions determined at 13.7 keV with serial crystallography
6W2B	;	4.7	;	Anomalous bromine signal reveals the position of Br-paroxetine complexed with the serotonin transporter at the central site
6AWQ	;	4.046	;	Anomalous chloride signal reveals the position of sertraline complexed with the serotonin transporter at the central site
5SVT	;	3.794	;	Anomalous Cs+ signal reveals the site of Na+ ion entry to the channel pore of the human P2X3 ion channel through the extracellular fenestrations
6W2C	;	6.3	;	Anomalous iodine signal reveals the position of I-paroxetine complexed with the serotonin transporter at the central site
5SVS	;	4.025	;	Anomalous Mn2+ signal reveals a divalent cation-binding site in the head domain of the ATP-gated human P2X3 ion channel
5AI2	;	1.75	;	Anomalous Neutron phased crystal structure of 113Cd-substituted Perdeuterated Pyrococcus furiosus rubredoxin to 1.75A resolution at 295K
1LZ9	;	1.7	;	ANOMALOUS SIGNAL OF SOLVENT BROMINES USED FOR PHASING OF LYSOZYME
2G4X	;	1.95	;	Anomalous substructure od ribonuclease A (P3221)
2G4O	;	2.0	;	anomalous substructure of 3-ISOPROPYLMALATE DEHYDROGENASE
2G4N	;	2.3	;	Anomalous substructure of alpha-lactalbumin
2G4H	;	2.0	;	Anomalous substructure of apoferritin
2G4I	;	2.4	;	Anomalous substructure of Concanavalin A
2G4J	;	1.85	;	Anomalous substructure of Glucose isomerase
2G4K	;	1.82	;	Anomalous substructure of human ADP-ribosylhydrolase 3
2G4L	;	1.84	;	Anomalous substructure of hydroxynitrile lyase
2G4P	;	1.84	;	Anomalous substructure of lysozyme at pH 4.5
2G4Q	;	1.84	;	Anomalous substructure of lysozyme at pH 8.0
2G4R	;	1.92	;	anomalous substructure of MogA
2G4S	;	2.15	;	Anomalous substructure of NBR1PB1
2G4U	;	1.84	;	Anomalous substructure of porcine pancreatic elastaase (Ca)
2G4T	;	2.15	;	anomalous substructure of porcine pancreatic elastase (Na)
2G4V	;	2.14	;	anomalous substructure of proteinase K
2G4W	;	1.84	;	anomalous substructure of ribonuclease A (C2)
2G4Z	;	1.98	;	anomalous substructure of thermolysin
2ILL	;	2.2	;	Anomalous substructure of Titin-A168169
2G51	;	1.84	;	anomalous substructure of trypsin (p1)
2G52	;	1.84	;	Anomalous substructure of trypsin (P21)
2G55	;	1.82	;	Anomalous substructure of trypsin (P3121)
5SVP	;	3.298	;	Anomalous sulfur signal reveals the position of agonist 2-methylthio-ATP bound to the ATP-gated human P2X3 ion channel in the desensitized state
1JLV	;	1.75	;	Anopheles dirus species B glutathione S-transferases 1-3
1JLW	;	2.45	;	Anopheles dirus species B glutathione S-transferases 1-4
3ZMK	;	2.2	;	Anopheles funestus glutathione-s-transferase epsilon 2 (GSTe2) protein structure from different alelles: A single amino acid change confers high level of DDT resistance and cross resistance to permethrin in a major malaria vector in Africa
3ZML	;	1.639	;	Anopheles funestus glutathione-s-transferase epsilon 2 (GSTe2) protein structure from different alelles: A single amino acid change confers high level of DDT resistance and cross resistance to permethrin in a major malaria vector in Africa
4E05	;	2.304	;	Anophelin from the malaria vector inhibits thrombin through a novel reverse-binding mechanism
4E06	;	3.196	;	Anophelin from the malaria vector inhibits thrombin through a novel reverse-binding mechanism
2MJT	;		;	Anoplin R5F T8W in DPC micelles
2MJS	;		;	Anoplin R5K T8W in DPC micelles
2MJR	;		;	Anoplin R5W structure in DPC micelles
4N81	;	1.901	;	Another flexible region at the active site of an inositol monophosphatase from Zymomonas mobilis
4XOS	;	1.559	;	ANP32A LRR domain
8CLD	;	3.2	;	Ansamitocin P3 bound to tubulin (T2R-TTL) complex
1AGD	;	2.05	;	ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYKL-INDEX PEPTIDE)
1AGC	;	2.1	;	ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYQL-7Q MUTATION)
1AGE	;	2.3	;	ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYRL-7R MUTATION)
1AGF	;	2.2	;	ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKRYKL-5R MUTATION)
1AGB	;	2.2	;	ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGRKKYKL-3R MUTATION)
6Q6P	;	3.0	;	Antarctic fish cytoglobin 1 from D.mawsoni
6SMO	;	2.7	;	AntDE:AntF (apo): type II PKS acyl-carrier protein in complex with its ketosynthase bound to the hexaketide
6SMP	;	2.9	;	AntDE:AntF (holo): type II PKS acyl-carrier protein in complex with its ketosynthase bound to the hexaketide
1KX8	;	2.8	;	Antennal Chemosensory Protein A6 from Mamestra brassicae, tetragonal form
1KX9	;	1.65	;	ANTENNAL CHEMOSENSORY PROTEIN A6 FROM THE MOTH MAMESTRA BRASSICAE
9ANT	;	2.4	;	ANTENNAPEDIA HOMEODOMAIN-DNA COMPLEX
6SM4	;	1.85	;	AntF (apo): type II PKS acyl-carrier protein
6SM6	;	2.4	;	AntF (holo): type II PKS acyl-carrier protein
7JXV	;	2.35	;	ANTH domain of CALM (clathrin-assembly lymphoid myeloid leukemia protein) bound to ubiquitin
1GP4	;	2.1	;	Anthocyanidin synthase from Arabidopsis thaliana (selenomethionine substituted)
2BRT	;	2.2	;	ANTHOCYANIDIN SYNTHASE FROM ARABIDOPSIS THALIANA COMPLEXED with naringenin
1GP5	;	2.2	;	Anthocyanidin synthase from Arabidopsis thaliana complexed with trans-dihydroquercetin
1GP6	;	1.75	;	Anthocyanidin synthase from Arabidopsis thaliana complexed with trans-dihydroquercetin (with 30 min exposure to O2)
1AHL	;		;	ANTHOPLEURIN-A,NMR, 20 STRUCTURES
1APF	;		;	ANTHOPLEURIN-B, NMR, 20 STRUCTURES
1D54	;	1.4	;	ANTHRACYCLINE BINDING TO DNA: HIGH RESOLUTION STRUCTURE OF D(TGTACA) COMPLEXED WITH 4'-EPIADRIAMYCIN
110D	;	1.9	;	ANTHRACYCLINE-DNA INTERACTIONS AT UNFAVOURABLE BASE BASE-PAIR TRIPLET-BINDING SITES: STRUCTURES OF D(CGGCCG)/DAUNOMYCIN AND D(TGGCCA)/ADRIAMYCIN COMPL
1DA9	;	1.7	;	ANTHRACYCLINE-DNA INTERACTIONS AT UNFAVOURABLE BASE BASE-PAIR TRIPLET-BINDING SITES: STRUCTURES OF D(CGGCCG)/DAUNOMYCIN AND D(TGGCCA)/ADRIAMYCIN COMPL
4YI7	;	1.853	;	Anthranilate bound at active site of anthranilate phosphoribosyl transferase from Acinetobacter (AnPRT; TrpD)
4OWM	;	1.99	;	Anthranilate phosphoribosyl transferase from Mycobacterium tuberculosis in complex with 3-fluoroanthranilate, PRPP and Magnesium
4OWQ	;	1.89	;	Anthranilate phosphoribosyl transferase from Mycobacterium tuberculosis in complex with 3-methylanthranilate, PRPP and Magnesium
4OWS	;	2.43	;	Anthranilate phosphoribosyl transferase from Mycobacterium tuberculosis in complex with 4-methylanthranilate, PRPP and Magnesium
4OWN	;	2.11	;	Anthranilate phosphoribosyl transferase from Mycobacterium tuberculosis in complex with 5-fluoroanthranilate, PRPP and Magnesium
4OWU	;	1.89	;	Anthranilate phosphoribosyl transferase from Mycobacterium tuberculosis in complex with 5-methylanthranilate, PRPP and Magnesium
4OWO	;	1.99	;	Anthranilate phosphoribosyl transferase from Mycobacterium tuberculosis in complex with 6-fluoroanthranilate, PRPP and Magnesium
4OWV	;	1.9	;	Anthranilate phosphoribosyl transferase from Mycobacterium tuberculosis in complex with anthranilate
4X58	;	1.75	;	Anthranilate phosphoribosyl transferase variant N138A from Mycobacterium tuberculosis in complex with PRPP and Mg
1O17	;	2.05	;	ANTHRANILATE PHOSPHORIBOSYL-TRANSFERASE (TRPD)
3GBR	;	2.25	;	Anthranilate phosphoribosyl-transferase (TRPD) double mutant D83G F149S from S. solfataricus
2GVQ	;	2.43	;	Anthranilate phosphoribosyl-transferase (TRPD) from S. solfataricus in complex with anthranilate
2BPQ	;	1.9	;	Anthranilate phosphoribosyltransferase (TrpD) from Mycobacterium tuberculosis (Apo structure)
3QR9	;	1.87	;	Anthranilate phosphoribosyltransferase (trpD) from Mycobacterium tuberculosis (apo structure)
3UU1	;	1.82	;	Anthranilate phosphoribosyltransferase (trpD) from Mycobacterium tuberculosis (complex with inhibitor ACS142)
3R88	;	1.73	;	Anthranilate phosphoribosyltransferase (trpD) from Mycobacterium tuberculosis (complex with inhibitor ACS145)
3QQS	;	1.97	;	Anthranilate phosphoribosyltransferase (TRPD) from Mycobacterium tuberculosis (complex with inhibitor ACS172)
3QS8	;	2.0	;	Anthranilate phosphoribosyltransferase (trpD) from Mycobacterium tuberculosis (complex with inhibitor ACS174)
3R6C	;	1.83	;	Anthranilate phosphoribosyltransferase (trpD) from Mycobacterium tuberculosis (complex with inhibitor ACS179)
3QSA	;	2.18	;	Anthranilate phosphoribosyltransferase (trpD) from Mycobacterium tuberculosis (complex with inhibitor TAMU-A7)
7DSM	;	2.39	;	Anthranilate phosphoribosyltransferase from Saccharomyces cerevisiae
7DSO	;	2.34	;	Anthranilate phosphoribosyltransferase from Saccharomyces cerevisiae in complex with 4-fluoroanthranilate
7DSJ	;	2.44	;	Anthranilate phosphoribosyltransferase from Saccharomyces cerevisiae in complex with PRPP and Mg
1ZXY	;	2.56	;	Anthranilate Phosphoribosyltransferase from Sulfolobus solfataricus in complex with PRPP and Magnesium
5NOE	;	1.91	;	Anthranilate phosphoribosyltransferase from Thermococcus kodakaraensis
5NOF	;	2.42	;	Anthranilate phosphoribosyltransferase from Thermococcus kodakaraensis
1ZYK	;	2.4	;	Anthranilate Phosphoribosyltransferase in complex with PRPP, anthranilate and magnesium
1GXB	;	2.65	;	ANTHRANILATE PHOSPHORIBOSYLTRANSFERASE IN COMPLEX WITH PYROPHOSPHATE AND MAGNESIUM
7DSR	;	2.5	;	Anthranilate phosphoribosyltransferase variant Gly141Asn from Saccharomyces cerevisiae in complex with 4-fluoroanthranilate
4X59	;	1.8	;	Anthranilate phosphoribosyltransferase variant P180A from Mycobacterium tuberculosis in complex with PRPP and Mg
4X5A	;	1.93	;	Anthranilate phosphoribosyltransferase variant R193A from Mycobacterium tuberculosis remains ligand-free when co-crystallised with PRPP and Mg
4X5D	;	2.3	;	Anthranilate phosphoribosyltransferase variant R193A from Mycobacterium tuberculosis with anthranilate bound
4X5B	;	2.47	;	Anthranilate phosphoribosyltransferase variant R193L from Mycobacterium tuberculosis in complex with PRPP and Mg
4X5C	;	2.33	;	Anthranilate phosphoribosyltransferase variant R193L from Mycobacterium tuberculosis with pyrophosphate/PRPP and Mg2+ bound
4X5E	;	1.77	;	Anthranilate phosphoribosyltransferase variant R194A from Mycobacterium tuberculosis with pyrophosphate, Mg2+ and anthranilate bound
7DSP	;	1.95	;	Anthranilate phosphoribosyltransferase variant Ser121Ala from Saccharomyces cerevisiae with Mg bound
7BVD	;	1.7	;	Anthranilate synthase component I (TrpE)[Mycolicibacterium smegmatis]
1I7Q	;	1.95	;	ANTHRANILATE SYNTHASE FROM S. MARCESCENS
1I7S	;	2.4	;	ANTHRANILATE SYNTHASE FROM SERRATIA MARCESCENS IN COMPLEX WITH ITS END PRODUCT INHIBITOR L-TRYPTOPHAN
4DV8	;	1.632	;	Anthrax Lethal Factor metalloproteinase in complex with the Hydroxamic acid based small molecule PT8421
6VRA	;	3.3	;	Anthrax octamer prechannel bound to full-length edema factor
6WJJ	;	3.8	;	Anthrax octamer prechannel bound to full-length lethal factor
1ACC	;	2.1	;	ANTHRAX PROTECTIVE ANTIGEN
1J7N	;	2.3	;	Anthrax Toxin Lethal factor
4PKR	;	2.2	;	Anthrax toxin lethal factor with bound small molecule inhibitor 10
4PKS	;	2.3	;	Anthrax toxin lethal factor with bound small molecule inhibitor 11
4PKT	;	2.4	;	Anthrax toxin lethal factor with bound small molecule inhibitor 13
4PKU	;	2.4	;	Anthrax toxin lethal factor with bound small molecule inhibitor 15
4PKV	;	2.5	;	Anthrax toxin lethal factor with bound small molecule inhibitor 16
4PKW	;	1.75	;	Anthrax toxin lethal factor with bound small molecule inhibitor GM6001
4WF6	;	2.6521	;	Anthrax toxin lethal factor with bound small molecule inhibitor MK-31
4PKQ	;	2.2	;	Anthrax toxin lethal factor with bound zinc
5D1S	;	2.1	;	Anthrax toxin lethal factor with hydroxamic acid inhibitor
5D1T	;	2.2	;	Anthrax toxin lethal factor with hydroxamic acid inhibitor
5D1U	;	2.8503	;	Anthrax toxin lethal factor with hydroxamic acid inhibitor
4XM6	;	2.352	;	Anthrax toxin lethal factor with ligand-induced binding pocket
4XM7	;	2.7	;	Anthrax toxin lethal factor with ligand-induced binding pocket
4XM8	;	2.7	;	Anthrax toxin lethal factor with ligand-induced binding pocket
7O85	;	3.3	;	Anthrax toxin prepore in complex with the neutralizing Fab cAb29
6UZB	;	3.2	;	Anthrax toxin protective antigen channels bound to edema factor
6UZD	;	3.4	;	Anthrax toxin protective antigen channels bound to edema factor
6UZE	;	3.4	;	Anthrax toxin protective antigen channels bound to edema factor
6PSN	;	4.6	;	Anthrax toxin protective antigen channels bound to lethal factor
6ADM	;	2.84	;	Anthrax Toxin Receptor 1-bound full particles of Seneca Valley Virus in acidic conditions
6ADL	;	3.08	;	Anthrax Toxin Receptor 1-bound spent particles of Seneca Valley Virus in acidic conditions
6ADR	;	3.38	;	Anthrax Toxin Receptor 1-bound the Seneca Valley Virus in neutral conditions
4LCI	;	1.9	;	Anti canine CD28 antibody, 1C6
4R90	;	1.746	;	Anti CD70 Llama glama Fab 27B3
2W60	;	1.5	;	Anti citrullinated Collagen type 2 antibody acc4
2W65	;	2.21	;	Anti citrullinated Collagen type 2 antibody acc4 in complex with a citrullinated peptide
4LRI	;	1.65	;	Anti CMV Fab Fragment
6HXA	;	1.85	;	AntI from P. luminescens catalyses terminal polyketide shortening in the biosynthesis of anthraquinones
6CJK	;	1.795	;	Anti HIV Fab 10A
8D54	;	1.4	;	anti HIV gp120/CD4 complex antibody CG10 Fab
1CL7	;	3.0	;	ANTI HIV1 PROTEASE FAB
1MF2	;	2.6	;	ANTI HIV1 PROTEASE FAB COMPLEX
8QBI	;	1.55	;	AntI in closed state
8QBH	;	2.05	;	AntI in complex with 1-Naphthol
3IU4	;	1.75	;	anti NeuGcGM3 ganglioside chimeric antibody chP3
6DSI	;	2.49	;	Anti recombinant prolactin receptor scFv
4HFW	;	2.601	;	Anti Rotavirus Antibody
8QD6	;	1.7	;	AntI Ser245DHA (PMSF)
8QD5	;	1.8	;	AntI Ser245DHA (PSF)
1AY1	;	2.2	;	ANTI TAQ FAB TP7
2VQ1	;	2.5	;	anti trimeric Lewis X Fab54-5C10-A
1GHF	;	2.7	;	ANTI-ANTI-IDIOTYPE GH1002 FAB FRAGMENT
2CK0	;	2.2	;	ANTI-ANTI-IDIOTYPIC ANTIBODY AGAINST HUMAN ANGIOTENSIN II, COMPLEX WITH A SYNTHETIC CYCLIC PEPTIDE
3CK0	;	3.0	;	ANTI-ANTI-IDIOTYPIC ANTIBODY AGAINST HUMAN ANGIOTENSIN II, COMPLEX WITH HUMAN ANGIOTENSIN II
1CK0	;	2.5	;	ANTI-ANTI-IDIOTYPIC ANTIBODY AGAINST HUMAN ANGIOTENSIN II, UNLIGANDED FORM
7YB7	;	2.2	;	anti-apoptotic protein BCL-2-M12
7R20	;	1.42	;	Anti-Arc nanobody E5
5CMA	;	2.5	;	Anti-B7-H3 monoclonal antibody ch8H9 Fab fragment
3O11	;	2.8	;	Anti-beta-amyloid antibody c706 fab in space group c2
3MCL	;	1.7	;	Anti-beta-amyloid antibody c706 fab in space group P21
4OUO	;	1.8	;	anti-Bla g 1 scFv
1JV5	;	2.2	;	Anti-blood group A Fv
8F6O	;	2.31	;	anti-BTLA monoclonal antibody h22B3 in complex with BTLA
8F6L	;	1.85	;	anti-BTLA monoclonal antibody h25F7 in complex with BTLA
8F60	;	1.64	;	anti-BTLA monoclonal antibody r23C8 in complex with BTLA
4R0L	;	3.3	;	Anti-canine CD28 antibody, 1C6, bound canine CD28
1CLO	;	2.1	;	ANTI-CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY A5B7
7KX4	;	2.6	;	Anti-CCHFV ADI-36121 Fab
5IW3	;	2.05	;	anti-CD20 monoclonal antibody Fc fragment
5IW6	;	2.34	;	anti-CD20 monoclonal antibody Fc fragment
6O89	;	2.09	;	Anti-CD28xCD3 CODV Fab
6O8D	;	3.547	;	Anti-CD28xCD3 CODV Fab bound to CD28
2A1W	;	2.7	;	Anti-cocaine antibody 7.5.21, crystal form I
2A77	;	1.8	;	Anti-Cocaine Antibody 7.5.21, Crystal Form II
2AI0	;	2.2	;	Anti-Cocaine Antibody 7.5.21, Crystal Form III
1RFD	;	2.09	;	ANTI-COCAINE ANTIBODY M82G2
1QYG	;	1.81	;	ANTI-COCAINE ANTIBODY M82G2 COMPLEXED WITH BENZOYLECGONINE
1Q72	;	1.7	;	Anti-Cocaine Antibody M82G2 Complexed with Cocaine
1RIV	;	2.2	;	Anti-Cocaine Antibody M82G2 Complexed With meta-Oxybenzoylecgonine
1RIU	;	2.0	;	Anti-Cocaine Antibody M82G2 Complexed With Norbenzoylecgonine
7VZM	;		;	Anti-CRISPR AcrIE4-F7
6EYY	;	2.5	;	Anti-CRISPR AcrIIa6 cubic form
6EYX	;	1.96	;	Anti-CRISPR AcrIIa6 tetragonal form
7B5J	;	1.34	;	Anti-CRISPR associated (Aca) protein, Aca2
7YHR	;	1.45	;	Anti-CRISPR protein AcrIC5
8HJJ	;	2.4	;	Anti-CRISPR protein AcrIC9
5XN4	;		;	Anti-CRISPR protein AcrIIA4
8F3K	;	2.1	;	Anti-CRISPR protein AcrIIC5 inhibits CRISPR-Cas9 by acting as a DNA mimic
5XLP	;	4.2	;	Anti-CRISPR proteins AcrF1/2 bound to Csy surveillance complex with a 20nt spacer crRNA backbone region
5XLO	;	3.8	;	Anti-CRISPR proteins AcrF1/2 bound to Csy surveillance complex with a 32nt spacer crRNA backbone region
7XI5	;	1.76	;	Anti-CRISPR-associated Aca10
7EZY	;	1.92	;	anti-CRISPR-associated Aca2
5C2B	;	1.4049	;	anti-CXCL13 parental scFv - 3B4
5C6W	;	1.54	;	anti-CXCL13 scFv - E10
2OJZ	;	2.73	;	Anti-DNA antibody ED10
7OM5	;	1.48	;	Anti-EGFR nanobody EgB4
3P0V	;	2.85	;	anti-EGFR/HER3 Fab DL11 alone
3P0Y	;	1.8	;	anti-EGFR/HER3 Fab DL11 in complex with domain III of EGFR extracellular region
3P11	;	3.7	;	anti-EGFR/HER3 Fab DL11 in complex with domains I-III of the HER3 extracellular region
7OOI	;	2.28	;	Anti-EphA1 JD1 VH domain
7OMN	;	1.7	;	Anti-EphA1 JD1-1 VH domain
8OL9	;	2.6	;	Anti-FIXa Fab in complex with human des-(Gla-EGF1) FIXa
7AHV	;	3.11	;	Anti-FIXa Fab of mim8 in complex with human FIXa
7AHU	;	2.6	;	Anti-FX Fab of mim8 in complex with human FXa
2KK9	;		;	Anti-group A streptococcal vaccine epitope: structure, stability and its ability to interact with HLA class II molecules
1YMH	;	2.6	;	anti-HCV Fab 19D9D6 complexed with protein L (PpL) mutant A66W
7RYU	;	1.51	;	Anti-HIV neutralizing antibody Ab1303 Fab isolated from sequentially immunized mcaques
7RYV	;	2.5	;	Anti-HIV neutralizing antibody Ab1573 Fab isolated from sequentially immunized macaques
7EKK	;	1.7	;	Anti-HIV-1 broadly neutralizing antibody delta-loop 4E10 modified with pyrene acetamide
6N35	;	1.747	;	Anti-HIV-1 Fab 2G12 + Man1-2 re-refinement
6MUB	;	2.503	;	Anti-HIV-1 Fab 2G12 + Man5 re-refinement
6MU3	;	2.327	;	Anti-HIV-1 Fab 2G12 + Man7 re-refinement
6MNF	;	2.758	;	Anti-HIV-1 Fab 2G12 + Man8 re-refinement
6N2X	;	3.0	;	Anti-HIV-1 Fab 2G12 + Man9 re-refinement
6CXL	;	3.586	;	anti-HIV-1 Fab 2G12 in complex with glycopeptide 10F5
6CXG	;	2.298	;	anti-HIV-1 Fab 2G12 in complex with glycopeptide 10V1S
6N32	;	2.2	;	Anti-HIV-1 Fab 2G12 re-refinement
6MSY	;	1.999	;	Anti-HIV-1 Fab Fab 2G12 + Man4 re-refinement
8D5C	;	3.9	;	anti-HIV-1 gp120-sCD4 complex antibody CG10 Fab in complex with B41-sCD4
7SJM	;	1.8	;	anti-HtrA1 Fab15H6.v4
7SJP	;	2.1	;	anti-HtrA1 Fab15H6.v4 bound to HtrA1-LoopA peptide
8EW6	;	1.904	;	Anti-human CD8 VHH complex with CD8 alpha
4HH9	;	1.7	;	Anti-Human Cytomegalovirus (HCMV) Fab KE5
4HHA	;	1.6	;	Anti-Human Cytomegalovirus (HCMV) Fab KE5 with epitope peptide AD-2S1
1AIF	;	2.9	;	ANTI-IDIOTYPIC FAB 409.5.3 (IGG2A) FAB FROM MOUSE
3OJD	;	2.0	;	Anti-Indolicidin monoclonal antibody V2D2 (Fab fragment)
1UZ8	;	1.8	;	anti-Lewis X Fab fragment in complex with Lewis X
1UZ6	;	2.05	;	anti-Lewis X Fab fragment uncomplexed
3EYV	;	2.5	;	Anti-Lewis Y Fab fragment with Lewis Y antigen in the presence of zinc ions
1LQQ	;		;	ANTI-MAMMAL AND ANTI-INSECT LQQIII SCORPION TOXIN, NMR, 15 STRUCTURES
6APO	;	1.168	;	Anti-Marburgvirus Nucleoprotein Single Domain Antibody A
6APP	;	1.75	;	Anti-Marburgvirus Nucleoprotein Single Domain Antibody A Complexed with Nucleoprotein C-terminal domain
6APQ	;	1.9	;	Anti-Marburgvirus Nucleoprotein Single Domain Antibody B
4W2O	;	3.2	;	Anti-Marburgvirus Nucleoprotein Single Domain Antibody B Complexed with Nucleoprotein C-terminal domain
4W2P	;	1.77	;	Anti-Marburgvirus Nucleoprotein Single Domain Antibody C
4W2Q	;	2.7	;	Anti-Marburgvirus Nucleoprotein Single Domain Antibody C Complexed with Nucleoprotein C-terminal domain
3GM0	;	2.4	;	Anti-methamphetamine single chain Fv in complex with MDMA
1Q0Y	;	2.0	;	Anti-Morphine Antibody 9B1 Complexed with Morphine
1Q0X	;	1.6	;	Anti-morphine Antibody 9B1 Unliganded Form
4OUU	;	2.6	;	anti-MT1-MMP monoclonal antibody
1BLN	;	2.8	;	ANTI-P-GLYCOPROTEIN FAB MRK-16
1CFQ	;	2.8	;	ANTI-P24 (HIV-1) FAB FRAGMENT CB41
1HH6	;	2.6	;	ANTI-P24 (HIV-1) FAB FRAGMENT CB41 COMPLEXED WITH A PEPTIDE
1HH9	;	2.7	;	ANTI-P24 (HIV-1) FAB FRAGMENT CB41 COMPLEXED WITH A PEPTIDE
1HI6	;	2.55	;	ANTI-P24 (HIV-1) FAB FRAGMENT CB41 COMPLEXED WITH A PEPTIDE
1BOG	;	2.6	;	ANTI-P24 (HIV-1) FAB FRAGMENT CB41 COMPLEXED WITH AN EPITOPE-HOMOLOGOUS PEPTIDE
1CFN	;	2.65	;	ANTI-P24 (HIV-1) FAB FRAGMENT CB41 COMPLEXED WITH AN EPITOPE-RELATED PEPTIDE
1CFT	;	2.8	;	ANTI-P24 (HIV-1) FAB FRAGMENT CB41 COMPLEXED WITH AN EPITOPE-UNRELATED D-PEPTIDE
1CFS	;	2.75	;	ANTI-P24 (HIV-1) FAB FRAGMENT CB41 COMPLEXED WITH AN EPITOPE-UNRELATED PEPTIDE
3U1C	;	1.8	;	Anti-parallel dimer of N-terminal 98-aa fragment of smooth muscle tropomyosin alpha
4NQT	;	2.1	;	anti-parallel Fc-hole(T366S/L368A/Y407V) homodimer
4NQU	;	2.5	;	anti-parallel Fc-knob (T366W) homodimer
6E4Z	;	2.202	;	Anti-PCSK9 fab 6E2 bound to the modified N-terminal peptide from PCSK9
6MV5	;	2.1	;	Anti-PCSK9 fab 6E2 bound to the N-terminal peptide from PCSK9 (E32K)
6E4Y	;	2.24	;	Anti-PCSK9 fab 6E2 bound to the N-terminal peptide from PCSK9, unmodified
6VL8	;	2.42	;	Anti-PEG antibody 6-3 Fab fragment in complex with PEG
6VL9	;	2.63	;	Anti-PEG antibody 6-3 Fab fragment in complex with PEG
6DF1	;	2.3	;	Anti-phosphotyrosine antibody 4G10-4D5 Fab complexed with phosphotyrosine peptide
6DF0	;	2.3	;	anti-phosphotyrosine antibody 4G10-4D5 Fab complexed with sulfate
6DEZ	;	3.2	;	Anti-phosphotyrosine antibody PY20-4D5 Fab complexed with sulfate
7KQK	;	2.6	;	anti-pTau C21-ABS Fab in complex with pTau peptide
5SV4	;	2.7	;	Anti-Ricin A-chain Single Domain Antibody A3C8
6CWK	;	1.256	;	Anti-RTA VHH antibody
6QE7	;	2.06	;	anti-sigma factor domain-containing protein
6QDI	;	1.13	;	anti-sigma factor domain-containing protein from Clostridium clariflavum
8IH8	;	2.0	;	anti-sigmaF factor and Anti-sigmaF factor antagonist complex(usfx-RsfB)
4HIE	;	1.9	;	Anti-Streptococcus pneumoniae 23F Fab 023.102
4HIJ	;	2.1	;	Anti-Streptococcus pneumoniae 23F Fab 023.102 with bound L-rhamnose-(1-2)-alpha-D-galactose-(3-O)-phosphate-2-glycerol
4HII	;	2.3	;	Anti-Streptococcus pneumoniae 23F Fab 023.102 with bound rhamnose-galactose
4HIH	;	2.0	;	Anti-Streptococcus pneumoniae 23F Fab 023.102 with bound rhamnose.
6U50	;	1.6	;	Anti-Sudan ebolavirus Nucleoprotein Single Domain Antibody Sudan B (SB)
6U51	;	2.52	;	Anti-Sudan ebolavirus Nucleoprotein Single Domain Antibody Sudan B (SB) Complexed with Sudan ebolavirus Nucleoprotein C-terminal Domain 610-738
6U52	;	1.9	;	Anti-Sudan ebolavirus Nucleoprotein Single Domain Antibody Sudan B (SB) Complexed with Sudan ebolavirus Nucleoprotein C-terminal Domain 634-738
3O6L	;	2.1	;	Anti-Tat HIV 11H6H1 Fab' complexed with a 15-mer Tat peptide
3O6M	;	2.4	;	Anti-Tat HIV 11H6H1 Fab' complexed with a 9-mer Tat peptide
5E2V	;	1.64	;	Anti-TAU AT8 FAB with doubly phosphorylated TAU peptide
5E2W	;	1.5	;	Anti-TAU AT8 FAB with triply phosphorylated TAU peptide
6PXR	;	1.556	;	Anti-TAU BIIB092 FAB with TAU peptide
3LS5	;	1.9	;	Anti-tetrahydrocannabinol Fab Fragment, Free Form
7KQL	;	1.49	;	Anti-Tim3 antibody Fab complex
5W05	;	1.64	;	ANTI-TISSUE FACTOR ANTIBODY M59, A HUMANIZED VERSION OF 10H10
6VVU	;	3.0	;	Anti-Tryptase fab E104.v1 bound to tryptase
7YHN	;	2.6	;	ANTI-TUMOR AGENT Y48 IN COMPLEX WITH TUBULIN
6S2I	;	2.285	;	Anti-tumor antibody 14F7-derived scFv in complex with NeuGc Gm3
6FFJ	;	2.2	;	Anti-tumor antibody 14F7-derived single chain fragment variable (scFv)
8IJZ	;	2.1	;	anti-VEGF mutant
8IIU	;	1.27	;	anti-VEGF nanobody
8IJS	;	1.752	;	anti-VEGF nanobody mutant
6U53	;	1.49	;	Anti-Zaire ebolavirus Nucleoprotein Single Domain Antibody Zaire C (ZC)
6U54	;	1.6	;	Anti-Zaire ebolavirus Nucleoprotein Single Domain Antibody Zaire C (ZC) Complexed with Zaire ebolavirus Nucleoprotein C-terminal Domain 634-739
6U55	;	1.93	;	Anti-Zaire ebolavirus Nucleoprotein Single Domain Antibody Zaire E (ZE) Complexed with Sudan ebolavirus Nucleoprotein C-terminal Domain 634-738
4Z8D	;	2.0	;	Antibacterial FabH Inhibitors with Validated Mode of Action in Haemophilus Influenzae by in vitro resistance mutation mapping
5EG1	;	3.42	;	Antibacterial peptide ABC transporter McjD with a resolved lipid
2JR3	;		;	Antibacterial Peptide from Eggshell Matrix: Structure and Self-assembly of beta-defensin Like Peptide from the Chinese Soft-shelled Turtle Eggshell
6IHA	;		;	antibacterial peptide SibaCec-A
8GXT	;		;	Antibacterial peptide, mehamycin
1T51	;		;	Antibiotic Activity and Structural Analysis of a Scorpion-derived Antimicrobial peptide IsCT and Its Analogs
1T52	;		;	Antibiotic Activity and Structural Analysis of a Scorpion-derived Antimicrobial peptide IsCT and Its Analogs
1T54	;		;	Antibiotic Activity and Structural Analysis of a Scorpion-derived Antimicrobial peptide IsCT and Its Analogs
1T55	;		;	Antibiotic Activity and Structural Analysis of a Scorpion-derived Antimicrobial peptide IsCT and Its Analogs
1NY9	;		;	Antibiotic binding domain of a TipA-class multidrug resistance transcriptional regulator
6BOH	;	3.4	;	Antibiotic blasticidin S and E. coli release factor 1 (containing deletion 302-304) bound to the 70S ribosome
6B4V	;	3.4	;	Antibiotic blasticidin S and E. coli release factor 1 bound to the 70S ribosome
3G5V	;	2.001	;	Antibodies Specifically Targeting a Locally Misfolded Region of Tumor Associated EGFR
3G5X	;	2.3	;	Antibodies Specifically Targeting a Locally Misfolded Region of Tumor Associated EGFR
3G5Y	;	1.59	;	Antibodies Specifically Targeting a Locally Misfolded Region of Tumor Associated EGFR
3G5Z	;	2.6	;	Antibodies Specifically Targeting a Locally Misfolded Region of Tumor Associated EGFR
7KQG	;	2.6	;	Antibodies that engage the hemagglutinin receptor-binding site of influenza B viruses
7KQH	;	3.5	;	Antibodies that engage the hemagglutinin receptor-binding site of influenza B viruses
7KQI	;	4.2	;	Antibodies that engage the hemagglutinin receptor-binding site of influenza B viruses
7M7W	;	2.65	;	Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape
7RM0	;	2.71	;	Antibody 2E10.E9 in complex with P. vivax CSP peptide ANGAGNQPGANGAGNQPG
7RM3	;	2.68	;	Antibody 2E10.E9 in complex with P. vivax CSP peptide ANGAGNQPGANGAGNQPGANGAGGQAA
7RLY	;	2.67	;	Antibody 2F2 in complex with P. vivax CSP peptide DRAAGQPAGDRADGQPA
7RM1	;	3.19	;	Antibody 2F2 in complex with P. vivax CSP peptide EDGAGNQPGANGAGNQPGANGAGNQPG
7RLW	;	2.54	;	Antibody 2F2 in complex with P. vivax CSP peptide GDRAAGQPAGDRAAGQPA
7RLZ	;	2.27	;	Antibody 2F2 in complex with P. vivax CSP peptide GDRAAGQPAGNGAGGQAA
7RLX	;	1.97	;	Antibody 2F2 in complex with P. vivax CSP peptide GDRADGQPAGDRAAGQPA
7RLV	;	2.2	;	Antibody 2F2 in complex with P. vivax CSP peptide GDRADGQPAGDRADGQPA
3OAU	;	1.9	;	Antibody 2G12 Recognizes Di-Mannose Equivalently in Domain- and Non-Domain-Exchanged Forms, but only binds the HIV-1 Glycan Shield if Domain-Exchanged
1KEG	;	2.4	;	Antibody 64M-2 Fab complexed with dTT(6-4)TT
3VW3	;	2.5	;	Antibody 64M-5 Fab in complex with a double-stranded DNA (6-4) photoproduct
6IDG	;	2.0	;	antibody 64M-5 Fab in complex with dT(6-4)T
6IDH	;	2.5	;	Antibody 64M-5 Fab in ligand-free form
6KDI	;	2.7	;	Antibody 64M-5 Fab including isoAsp in complex with dT(6-4)T
6KDH	;	2.47	;	Antibody 64M-5 Fab including isoAsp in ligand-free form
7SJ0	;	3.36	;	Antibody A7V3 bound to N-terminal domain of the spike
7K78	;	3.1	;	antibody and nucleosome complex
5W3P	;	1.92	;	ANTIBODY C706 IN COMPLEX WTH BETA-AMYLOID PEPTIDE 1-16
1MEX	;	1.25	;	Antibody Catalysis of a Bimolecular Cycloaddition Reaction
6FA1	;	1.97	;	Antibody derived (Abd-4) small molecule binding to KRAS.
6FA2	;	2.6	;	Antibody derived (Abd-5) small molecule binding to KRAS.
6FA3	;	1.82	;	Antibody derived (Abd-6) small molecule binding to KRAS.
6FA4	;	2.02	;	Antibody derived (Abd-7) small molecule binding to KRAS.
6F76	;	2.2	;	Antibody derived (Abd-8) small molecule binding to KRAS.
8DKF	;	1.79	;	Antibody DH1030.1 Fab fragment
7TOW	;	2.15	;	Antibody DH1058 Fab fragment bound to SARS-CoV-2 fusion peptide
7KFG	;	3.002	;	Antibody Fab BDBV-289
2PCP	;	2.2	;	ANTIBODY FAB COMPLEXED WITH PHENCYCLIDINE
8F2T	;	2.12	;	Antibody Fab directed against SARS-CoV-2 Spike Protein Receptor Binding Domain (RBD)
8F2V	;	3.5	;	Antibody Fab directed against SARS-CoV-2 Spike Protein Receptor Binding Domain (RBD)
3VG0	;	2.27	;	Antibody Fab fragment
5JQD	;	2.591	;	Antibody Fab Fragment
3C2A	;	2.1	;	Antibody Fab fragment 447-52D in complex with UG1033 peptide
5JO4	;	2.53	;	Antibody Fab Fragment Complex
6QNK	;	1.9	;	Antibody FAB fragment targeting Gi protein heterotrimer
7QT0	;	2.07	;	Antibody FenAb136 - fentanyl complex
7QT2	;	1.92	;	Antibody FenAb208 - fentanyl complex
7QT3	;	1.7	;	Antibody FenAb609 - fentanyl complex
7QT4	;	2.32	;	Antibody FenAb709 - fentanyl complex
1I7Z	;	2.3	;	ANTIBODY GNC92H2 BOUND TO LIGAND
6Q1J	;	2.703	;	Antibody H2227 from the human antibody lineage 652
4XNQ	;	2.001	;	Antibody hemagglutinin Complexes
4XRC	;	2.74	;	Antibody hemagglutinin Complexes
4XNM	;	2.51	;	Antibody Influenza H5 Complex
1OAY	;	2.66	;	Antibody multispecificity mediated by conformational diversity
8TMA	;	3.2	;	Antibody N3-1 bound to RBD in the up conformation
8TM1	;	2.79	;	Antibody N3-1 bound to RBDs in the up and down conformations
6PK8	;	2.91	;	Antibody scFv-M204 dimeric state
6PIL	;	2.2	;	Antibody scFv-M204 monomeric state
6PSC	;	3.6	;	Antibody scFv-M204 trimeric state
3ZL4	;	1.95	;	Antibody structural organization: Role of kappa - lambda chain constant domain switch in catalytic functionality
3I75	;	1.95	;	Antibody Structure
1BEY	;	3.25	;	ANTIBODY TO CAMPATH-1H HUMANIZED FAB
8FR6	;	2.5	;	Antibody vFP53.02 in complex with HIV-1 envelope trimer BG505 DS-SOSIP
6SXI	;	1.85	;	Antibody-anti-idiotype complex: AP33 Fab (hepatitis C virus E2 antibody) - B2.1A scFv (anti-idiotype)
5E94	;	2.0	;	Antibody-bound Glucagon-like Peptide-1 receptor extracellular domain
1LNM	;	1.9	;	ANTICALIN DIGA16 IN COMPLEX WITH DIGITOXIGENIN
5KJ9	;	1.2	;	Anticancer activity of Ru- and Os(arene) compounds of a maleimide-functionalized bioactive pyridinecarbothioamide ligand
3DLW	;	2.7	;	Antichymotrypsin
1VIP	;	2.2	;	ANTICOAGULANT CLASS II PHOSPHOLIPASE A2 FROM THE VENOM OF VIPERA RUSSELLI RUSSELLI
1COU	;		;	ANTICOAGULANT PROTEIN FROM THE NEMATODE ANCYLOSTOMA CANINUM
1G6E	;		;	ANTIFUNGAL PROTEIN FROM STREPTOMYCES TENDAE TU901, 30-CONFORMERS ENSEMBLE
1GH5	;		;	ANTIFUNGAL PROTEIN FROM STREPTOMYCES TENDAE TU901, NMR AVERAGE STRUCTURE
1VA5	;	2.02	;	Antigen 85C with octylthioglucoside in active site
4QXG	;	2.3	;	Antigen binding fragment of an anti IFNAR1 antibody
6WLA	;	2.6	;	Antigen binding fragment of ch128.1
6WX1	;	2.0	;	Antigen Binding Fragment of OKT9
6DG2	;	1.96	;	Antigen Binding Fragment of the Pan-ebolavirus Monoclonal Antibody 6D6
5J1A	;	1.86	;	Antigen presenting molecule
3GIV	;	2.0	;	Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance
2HRP	;	2.2	;	ANTIGEN-ANTIBODY COMPLEX
1JFQ	;	1.9	;	ANTIGEN-BINDING FRAGMENT OF THE MURINE ANTI-PHENYLARSONATE ANTIBODY 36-71, ""FAB 36-71""
8SVB	;		;	Antimicrobial lasso peptide achromonodin-1
6MW6	;		;	Antimicrobial lasso peptide citrocin
8DYN	;		;	Antimicrobial lasso peptide cloacaenodin
6POR	;		;	Antimicrobial lasso peptide ubonodin
2L24	;		;	Antimicrobial peptide
5YKK	;		;	Antimicrobial peptide Andersonin-Y1 (AY1)
5YKL	;		;	Antimicrobial peptide AY1C designed from the skin secretion of Chinese Odorous frogs
7ALD	;		;	Antimicrobial peptide Capitellacin from polychaeta Capitella teleta
8B4S	;		;	Antimicrobial peptide capitellacin from polychaeta Capitella teleta in DPC (dodecylphosphocholine) micelles, dimeric form
8B4R	;		;	Antimicrobial peptide capitellacin from polychaeta Capitella teleta in DPC (dodecylphosphocholine) micelles, monomeric form
2NC7	;		;	Antimicrobial peptide protegrin PG-5
7WKF	;		;	Antimicrobial peptide-LaIT2
2JSO	;		;	Antimicrobial resistance protein
6GFT	;		;	Antinociceptive evaluation of cyriotoxin-1a, the first toxin purified from Cyriopagopus schioedtei spider venom
6ZX7	;		;	Antiparallel basket-type G-quadruplex DNA structure formed in human Bcl-2 promoter
6ZX6	;		;	Antiparallel basket-type G-quadruplex DNA structure formed in human Bcl-2 promoter containing 8-oxoG
5W0J	;	2.201	;	Antiparallel coiled coil hexamer formed by de novo peptides (ACC-Hex2).
2CCF	;	1.7	;	Antiparallel Configuration of pLI E20S
2B1F	;	1.5	;	Antiparallel four-stranded coiled coil specified by a 3-3-1 hydrophobic heptad repeat
2B22	;	2.0	;	Antiparallel four-stranded coiled coil specified by a 3-3-1 hydrophobic heptad repeat
5NFD	;	2.18	;	Antiparallel monomeric coiled coil of Kif21A
1RB4	;	1.9	;	ANTIPARALLEL TRIMER OF GCN4-LEUCINE ZIPPER CORE MUTANT AS N16A TETRAGONAL AUTOMATIC SOLUTION
1RB6	;	1.9	;	ANTIPARALLEL TRIMER OF GCN4-LEUCINE ZIPPER CORE MUTANT AS N16A TETRAGONAL FORM
1RB5	;	1.9	;	ANTIPARALLEL TRIMER OF GCN4-LEUCINE ZIPPER CORE MUTANT AS N16A TRIGONAL FORM
1CX5	;		;	ANTISENSE DNA/RNA HYBRID CONTAINING MODIFIED BACKBONE
7UZ0	;	3.03	;	AntiT-tRNA flip UCCA
1SR5	;	3.1	;	ANTITHROMBIN-ANHYDROTHROMBIN-HEPARIN TERNARY COMPLEX STRUCTURE
1AZX	;	2.9	;	ANTITHROMBIN/PENTASACCHARIDE COMPLEX
6F8H	;	2.002	;	antitoxin GraA
6FIX	;	3.8	;	antitoxin GraA in complex with its operator
4P7D	;	2.781	;	Antitoxin HicB3 crystal structure
4ZM0	;	3.17	;	Antitoxin Phd from phage P1 in complex with its operator DNA inverted repeat
4ZM2	;	3.88	;	Antitoxin Phd from phage P1 in complex with its operator DNA inverted repeat in a monoclinic space group
4XIC	;	2.69	;	ANTPHD WITH 15BP di-thioate modified DNA DUPLEX
4XID	;	2.701	;	AntpHD with 15bp DNA duplex
5JLW	;	2.088	;	AntpHD with 15bp DNA duplex R-monothioated at Cytidine-8
5JLX	;	2.748	;	AntpHD with 15bp DNA duplex S-monothioated at Cytidine-8
8AVQ	;	2.0	;	AO75L in Complex with UDP-Xylose
8D9U	;	20.0	;	AP-1, Arf1, Nef lattice on MHC-I lipopeptide incorporated narrow membrane tubes, centered on beta-Arf1
8D9T	;	20.0	;	AP-1, Arf1, Nef lattice on MHC-I lipopeptide incorporated narrow membrane tubes, centered on gamma-Arf1
8D9S	;	20.0	;	AP-1, Arf1, Nef lattice on MHC-I lipopeptide incorporated wide membrane tubes, centered on beta-Arf1
8D9R	;	20.0	;	AP-1, Arf1, Nef lattice on MHC-I lipopeptide incorporated wide membrane tubes, centered on gamma-Arf1
1KYF	;	1.22	;	AP-2 CLATHRIN ADAPTOR ALPHA-APPENDAGE IN COMPLEX WITH EPS15 DPF PEPTIDE
1KYU	;	1.8	;	AP-2 CLATHRIN ADAPTOR ALPHA-APPENDAGE IN COMPLEX WITH EPS15 DPF PEPTIDE
1KY6	;	2.0	;	AP-2 CLATHRIN ADAPTOR ALPHA-APPENDAGE IN COMPLEX WITH EPSIN DPW PEPTIDE
1KYD	;	2.0	;	AP-2 CLATHRIN ADAPTOR ALPHA-APPENDAGE IN COMPLEX WITH EPSIN DPW PEPTIDE
6Y76	;	1.98	;	AP01 - a redesigned transferrin receptor apical domain
8P0Z	;	1.88	;	AP01-S2.3 - a variant of a redesigned transferrin receptor apical domain
1W63	;	4.0	;	AP1 clathrin adaptor core
7RWA	;	4.7	;	AP2 bound to heparin and Tgn38 tyrosine cargo peptide
7RW9	;	3.9	;	AP2 bound to heparin in the bowl conformation
7RW8	;	3.5	;	AP2 bound to heparin in the closed conformation
8T1O	;	3.3	;	AP2 bound to MSP2N2 nanodisc with Tgn38 cargo peptide; composite map
7RWC	;	3.8	;	AP2 bound to the APA domain of SGIP and heparin; partial signal subtraction and symmetry expansion
7RWB	;	3.9	;	AP2 bound to the APA domain of SGIP in the presence of heparin
2VGL	;	2.6	;	AP2 CLATHRIN ADAPTOR CORE
2XA7	;	3.1	;	AP2 clathrin adaptor core in active complex with cargo peptides
7OG1	;	3.25	;	AP2 clathrin adaptor core in complex with cargo peptide and FCHO2
2JKT	;	3.4	;	AP2 CLATHRIN ADAPTOR CORE with CD4 Dileucine peptide RM(phosphoS) EIKRLLSE Q to E mutant
2JKR	;	2.98	;	AP2 CLATHRIN ADAPTOR CORE with Dileucine peptide RM(phosphoS)QIKRLLSE
6QH6	;	5.0	;	AP2 clathrin adaptor core with two cargo peptides in open+ conformation
6QH5	;	2.56	;	AP2 clathrin adaptor mu2T156-phosphorylated core in closed conformation
6QH7	;	3.4	;	AP2 clathrin adaptor mu2T156-phosphorylated core with two cargo peptides in open+ conformation
4UQI	;	2.79	;	AP2 controls clathrin polymerization with a membrane-activated switch
6YAE	;	3.9	;	AP2 core in physiological buffer
6YAH	;	10.2	;	AP2 in clathrin coats assembled on a membrane containing dileucine- and tyrosine-based cargo peptides
5C7Z	;	2.77	;	AP2 Mu2 adaptin C-terminal domain complexed with integrin alpha-4 peptide
6YAF	;	9.1	;	AP2 on a membrane containing tyrosine-based cargo peptide
3IK3	;	1.9	;	AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
3YGS	;	2.5	;	APAF-1 CARD IN COMPLEX WITH PRODOMAIN OF PROCASPASE-9
5WVE	;	4.4	;	Apaf-1-Caspase-9 holoenzyme
5HDW	;	2.0	;	ApaG Domain of FBxo3
5Z8H	;	1.79	;	APC with an inhibitor
7F7O	;	2.8	;	APC-Asef FP assay tracer
8GSJ	;	2.1	;	APC-Asef tripeptide inhibitor
8TAU	;	3.5	;	APC/C-CDH1-UBE2C-UBE2S-Ubiquitin-CyclinB
8TAR	;	4.0	;	APC/C-CDH1-UBE2C-Ubiquitin-CyclinB-NTD
1GQP	;	2.2	;	APC10/DOC1 SUBUNIT OF S. cerevisiae
5JG6	;	2.0013	;	APC11-Ubv shows role of noncovalent RING-Ubiquitin interactions in processive multiubiquitination and Ubiquitin chain elongation by APC/C
6W43	;	1.99	;	APE1 AP-endonuclease product complex R237C
7U50	;	3.4	;	APE1 bound to a nucleosome core particle with AP-site at SHL-6
6W0Q	;	1.89	;	APE1 endonuclease product complex D148E
6W2P	;	1.94	;	APE1 endonuclease product complex L104R
5WN1	;	2.3	;	APE1 exonuclease product complex
6W3N	;	2.69	;	APE1 exonuclease substrate complex D148E
6W3Q	;	2.49	;	APE1 exonuclease substrate complex L104R
6W3U	;	2.4	;	APE1 exonuclease substrate complex R237C
6W3L	;	2.59	;	APE1 exonuclease substrate complex wild-type
7SUV	;	1.99	;	APE1 exonuclease substrate complex with 8oxoG opposite A
7SVB	;	2.24	;	APE1 exonuclease substrate complex with 8oxoG opposite C
5WN0	;	2.6	;	APE1 exonuclease substrate complex with a C/G match
5WN4	;	2.1	;	APE1 exonuclease substrate complex with a C/T mismatch
5WN5	;	2.2	;	APE1 exonuclease substrate complex with a C/T mismatch and Mn2+
5WN2	;	2.288	;	APE1 exonuclease substrate complex with phosphoglycolate
5WN3	;	2.0	;	APE1 F266A exonuclease substrate complex with a C/T mismatch
7LPJ	;	2.56	;	APE1 Mn-bound phosphorothioate substrate complex with abasic ribonucleotide DNA
7LPH	;	1.99	;	APE1 Mn-bound product complex with abasic ribonucleotide DNA
7LPI	;	2.05	;	APE1 phosphorothioate substrate complex with abasic ribonucleotide DNA
7LPG	;	2.08	;	APE1 product complex with abasic ribonucleotide DNA
7TR7	;	2.0	;	APE1 product complex with abasic ssDNA
6W4T	;	2.77	;	APE1 Y269A phosphorothioate substrate complex with abasic DNA
6W4I	;	2.2	;	APE1 Y269A product complex with abasic DNA
6KNM	;	3.2	;	Apelin receptor in complex with single domain antibody
7T9A	;	3.54	;	ApexGT2 in complex with GT2-d42.16 and RM20A3 Fabs
7T9B	;	3.72	;	ApexGT5 in complex with GT5-d42.16 and RM20A3 Fabs
5C4K	;	3.05	;	APH(2"")-IVa in complex with GET (G418) at room temperature
1WCG	;	1.1	;	Aphid myrosinase
5CDJ	;	1.75	;	apical domain of chloroplast chaperonin 60a
5CDK	;	1.5	;	Apical domain of chloroplast chaperonin 60b1
1ASS	;	2.3	;	APICAL DOMAIN OF THE CHAPERONIN FROM THERMOPLASMA ACIDOPHILUM
1ASX	;	2.8	;	APICAL DOMAIN OF THE CHAPERONIN FROM THERMOPLASMA ACIDOPHILUM
3S0G	;	1.85	;	Apis mellifera OBP 14 double mutant Gln44Cys, His97Cys
3S0D	;	1.24	;	Apis mellifera OBP 14 in complex with the citrus odorant citralva (3,7-dimethylocta-2,6-dienenitrile)
3RZS	;	1.88	;	Apis mellifera OBP14 in complex with Ta6Br14
3S0B	;	1.22	;	Apis mellifera OBP14 in complex with the fluorescent probe 1-N-phenylnaphthylamine (NPN)
3S0E	;	1.6	;	Apis mellifera OBP14 in complex with the odorant eugenol (2-methoxy-4(2-propenyl)-phenol)
3S0F	;	2.03	;	Apis mellifera OBP14 native apo, crystal form 2
3S0A	;	1.15	;	Apis mellifera OBP14, native apo-protein
3R72	;	1.15	;	Apis mellifera odorant binding protein 5
5E50	;	1.376	;	APLF/XRCC4 complex
1LBE	;	2.4	;	APLYSIA ADP RIBOSYL CYCLASE
1R15	;	2.4	;	Aplysia ADP ribosyl cyclase with bound nicotinamide and R5P
1R16	;	2.0	;	Aplysia ADP ribosyl cyclase with bound pyridylcarbinol and R5P
8Q1M	;	2.0	;	Aplysia californica acetylcholine-binding protein in complex with Spiroimine (+)-4 R
8QTL	;	1.85	;	Aplysia californica acetylcholine-binding protein in complex with Spiroimine (-)-4 S
8QX2	;	2.1	;	Aplysia californica acetylcholine-binding protein in complex with with racemic spiroimine (+)/(-)-4
2W8F	;	2.7	;	Aplysia californica AChBP bound to in silico compound 31
2W8G	;	2.6	;	Aplysia californica AChBP bound to in silico compound 35
2Y7Y	;	1.895	;	APLYSIA CALIFORNICA ACHBP IN APO STATE
6QKK	;	2.2	;	Aplysia californica AChBP in complex with 2-Fluoro-(carbamoylpyridinyl)deschloroepibatidine analogue (1)
6QQP	;	2.4	;	Aplysia californica AChBP in complex with 2-Fluoro-(carbamoylpyridinyl)deschloroepibatidine analogue (2)
6QQO	;	2.5	;	Aplysia californica AChBP in complex with 2-Fluoro-(carbamoylpyridinyl)deschloroepibatidine analogue (3)
6T9R	;	1.72	;	Aplysia californica AChBP in complex with a cytisine derivative
4BQT	;	2.88	;	Aplysia californica AChBP in complex with Cytisine
4AFT	;	3.2	;	Aplysia californica AChBP in complex with Varenicline
7YVC	;	3.0	;	Aplysia californica FaNaC in apo state
7YVB	;	3.0	;	Aplysia californica FaNaC in ligand bound state
4DBM	;	2.3	;	Aplysia californica-AChBP in complex with triazole 18
1MBA	;	1.6	;	APLYSIA LIMACINA MYOGLOBIN. CRYSTALLOGRAPHIC ANALYSIS AT 1.6 ANGSTROMS RESOLUTION
3MBA	;	2.0	;	APLYSIA LIMACINA MYOGLOBIN. CRYSTALLOGRAPHIC ANALYSIS AT 1.6 ANGSTROMS RESOLUTION
4MBA	;	2.0	;	APLYSIA LIMACINA MYOGLOBIN. CRYSTALLOGRAPHIC ANALYSIS AT 1.6 ANGSTROMS RESOLUTION
7RJT	;	2.93	;	Aplysia Slo1 with Barium
7RK6	;	2.91	;	Aplysia Slo1 with Barium
4WZ9	;	2.65	;	APN1 from Anopheles gambiae
2J16	;	2.7	;	Apo & Sulphate bound forms of SDP-1
3DHZ	;	1.63	;	Apo (iron free) structure of C. ammoniagenes R2 protein
6HRJ	;	1.7	;	Apo - YndL
8A29	;	2.1	;	Apo 1-deoxy-D-xylulose 5-phosphate synthase from Pseudomonas aeruginosa
5K8M	;	2.75	;	Apo 5-nitroanthranilate aminohydrolase
6XUD	;	1.51	;	Apo Ab 1116NS19.9
6XUL	;	2.41	;	Apo Ab 5b1
8FQP	;	1.419	;	apo ADC-162 beta-lactamase
8FQR	;	1.24	;	Apo ADC-212 beta-lactamase
8FQT	;	1.89	;	Apo ADC-219 beta-lactamase
8FQV	;	1.48	;	apo ADC-30 beta-lactamase
8FQN	;	1.256	;	apo ADC-33 beta-lactamase
2BGQ	;	2.5	;	apo aldose reductase from barley
1WLR	;	2.1	;	Apo aminopeptidase P from E. coli
1PIW	;	3.0	;	APO AND HOLO STRUCTURES OF AN NADP(H)-DEPENDENT CINNAMYL ALCOHOL DEHYDROGENASE FROM SACCHAROMYCES CEREVISIAE
1Q1N	;	3.15	;	APO AND HOLO STRUCTURES OF AN NADP(H)-DEPENDENT CINNAMYL ALCOHOL DEHYDROGENASE FROM SACCHAROMYCES CEREVISIAE
3T8S	;	3.77	;	Apo and InsP3-bound Crystal Structures of the Ligand-Binding Domain of an InsP3 Receptor
3K6W	;	2.45	;	Apo and ligand bound structures of ModA from the archaeon Methanosarcina acetivorans
3C6Q	;	2.3	;	Apo and ligand-bound form of a thermophilic glucose/xylose binding protein
3N4T	;	2.2	;	apo APH(2"")-IVa form I
3N4V	;	2.4	;	apo APH(2"")-IVa form III
6WLK	;	10.0	;	Apo ATP-TTR-3 models, 10.0 Angstrom resolution
8DRJ	;	2.4	;	Apo B2 dimer (H60/H100/H104) formed in the presence of Cu(II)
6XAG	;	3.3	;	Apo BRAF dimer bound to 14-3-3
3BKU	;	2.1	;	Apo C-terminal Domain of NikR
7TR2	;	3.0	;	Apo CaKip3[2-436]-L2-mutant(HsKHC) in complex with a microtubule
7TQZ	;	2.7	;	Apo CaKip3[2-482] in complex with a microtubule
8T64	;	2.25	;	Apo Cam1(42-206)
3PXR	;	2.0	;	Apo CDK2 crystallized from Jeffamine
6MVI	;	1.89	;	Apo Cel45A from Neurospora crassa OR74A
2V5J	;	1.6	;	Apo Class II aldolase HpcH
6QRQ	;	2.562	;	Apo conformation of chemotaxis sensor ODP
6IBU	;	2.25	;	Apo Crh5 transglycosylase
4I1U	;	2.05	;	Apo crystal structure of a dephospho-CoA kinase from Burkholderia vietnamiensis
7QG4	;	2.08	;	Apo crystal structure of a mutant of SN243 (D415N)
6IA8	;	1.9	;	Apo crystal structure of archaeal Methanocaldococcus infernus Elp3 (del1-19)
6IAD	;	2.05	;	Apo crystal structure of archaeal Methanocaldococcus infernus Elp3 (del1-54)
8FWX	;	2.12	;	Apo crystal structure of beluga whale Gammacoronavirus SW1 Mpro
7ZEQ	;	1.89	;	Apo crystal structure of beta-xylosidase from Thermotoga maritima
4RGJ	;	2.303	;	Apo crystal structure of CDPK4 from Plasmodium falciparum, PF3D7_0717500
6JER	;	2.4	;	Apo crystal structure of class I type a peptide deformylase from Acinetobacter baumannii
6JES	;	1.75	;	Apo crystal structure of class I type b peptide deformylase from Acinetobacter baumannii
6JF9	;	1.7	;	Apo crystal structure of class I type b peptide deformylase from Pseudomonas aeruginosa
4E76	;	2.5	;	Apo crystal structure of HCV NS5B genotype 2A JFH-1 isolate with beta hairpin loop deletion
4WT9	;	2.5	;	APO CRYSTAL STRUCTURE OF HCV NS5B GENOTYPE 2A JFH-1 ISOLATE WITH E86Q E87Q S15G C223H V321I AND DELTA8 MUTATIONS
3HQN	;	2.0	;	Apo crystal structure of Leishmania mexicana(LmPYK)pyruvate kinase
1ZM8	;	1.9	;	Apo Crystal structure of Nuclease A from Anabaena sp.
7DTQ	;	1.75	;	Apo Crystal Structure of Octaketide Synthase from A. arborescens
8PQK	;	2.0	;	APO crystal structure of PDGFRA-T674I kinase domain
3ILY	;	2.2	;	Apo crystal structure of protein tyrosine phosphatase from Entamoeba histolytica featuring a disordered active site
4KRZ	;	2.5	;	Apo crystal structure of pyruvate kinase (PYK) from Trypanosoma cruzi
6C3K	;	1.6	;	Apo crystal structure of S. aureus penicillin binding protein 4 (PBP4) mutant (E183A, F241R)
6D34	;	2.1	;	Apo Crystal Structure of TerC, a Terfestatin Biosynthesis Enzyme
6E0V	;	1.75	;	Apo crystal structure of the colanidase tailspike protein gp150 of Phage Phi92
1EVX	;	2.0	;	APO CRYSTAL STRUCTURE OF THE HOMING ENDONUCLEASE, I-PPOI
7AB0	;	1.74	;	Apo crystal structure of the MerTK kinase domain
6EH0	;	1.49	;	Apo crystal structure of the Protein-Kinase A catalytic subunit from Criteculus
5ZHI	;	2.2	;	Apo crystal structure of TrmD from Mycobacterium tuberculosis
6C39	;	1.69	;	Apo crystal structure of wild-type S. aureus penicillin binding protein 4 (PBP4)
5BJS	;	2.189	;	Apo ctPRC2 in an autoinhibited state
5VK3	;	2.114	;	Apo ctPRC2 with E840A and K852D mutations in Ezh2
5K71	;	2.57	;	apo Dbr1
7EQ3	;	2.87	;	Apo diabody form of CRH2-directed antibody 9F8
5U7E	;	1.942	;	Apo dihydroneopterin triphosphate pyrophosphohydrolase from E. coli
1AOV	;	4.0	;	APO DUCK OVOTRANSFERRIN
5WXJ	;	1.85	;	Apo EarP
8F35	;	3.17	;	Apo ELIC in spMSP1D1 nanodiscs with 2:1:1 POPC:POPE:POPG
5CB1	;	3.3	;	Apo enzyme of human Polymerase lambda
4Q13	;	2.24	;	Apo Estrogen Receptor Alpha Ligand Binding Domain D538G Mutant with a glucocorticoid receptor-interacting protein 1 NR box II peptide
6WLL	;	10.0	;	Apo F. nucleatum glycine riboswitch models, 10.0 Angstrom resolution
8TFR	;	2.99	;	Apo Fab from C10-S66K antibody
6DC7	;	1.901	;	Apo Fab structure of mouse monoclonal antibody 8B2
7PPS	;	1.3	;	apo FabB from Pseudomonas aeruginosa with single point mutation C161A
5BXF	;	2.851	;	Apo FcRn Structure at pH 4.5
5KTA	;	1.89	;	Apo FdhC- a nucleotide-linked sugar GNAT
8CY8	;	2.94	;	apo form Cryo-EM structure of Campylobacter jejune ketol-acid reductoisommerase crosslinked by Glutaraldehyde
5WY9	;	1.45	;	Apo form crystal structure of human Lipocalin PGDS .
1ZCV	;	1.98	;	apo form of a mutant of glycogenin in which Asp159 is replaced by Asn
1ZCY	;	1.99	;	apo form of a mutant of glycogenin in which Asp159 is replaced by Ser
1EUH	;	1.82	;	APO FORM OF A NADP DEPENDENT ALDEHYDE DEHYDROGENASE FROM STREPTOCOCCUS MUTANS
6K1O	;	2.033	;	Apo form of a putative cystathionine gamma-lyase
4BG8	;	1.96	;	Apo form of a putative sugar kinase MK0840 from Methanopyrus kandleri (monoclinic space group)
4BG9	;	1.902	;	Apo form of a putative sugar kinase MK0840 from Methanopyrus kandleri (orthorhombic space group)
4L63	;	1.8	;	Apo form of AB5 holotoxin
8SA6	;	5.3	;	apo form of adenosylcobalamin riboswitch dimer
6G1P	;	1.55	;	Apo form of ADP-ribosylserine hydrolase ARH3 of Latimeria chalumnae
6Q3A	;	3.1	;	Apo form of Apolipoprotein N-acyltransferase (Lnt)
3APZ	;	2.6	;	Apo form of Arabidopsis medium/long-chain length prenyl pyrophosphate synthase
4P04	;	1.95	;	Apo form of bacterial arylsulfate sulfotransferase (ASST) H436N mutant with MPO in the active site
4CBB	;	1.8	;	APO FORM OF BETAINE ALDEHYDE DEHYDROGENASE FROM Pseudomonas aeruginosa
6T5S	;	1.5	;	Apo form of C-type lysozyme from the upper gastrointestinal tract of Opisthocomus hoatzin
2N8Z	;		;	Apo form of Calmodulin-Like Domain of Human Non-Muscle alpha-actinin 1
3TEO	;	2.4	;	APO Form of carbon disulfide hydrolase (selenomethionine form)
6QER	;	2.465	;	Apo Form Of ComR From S. Thermophilus in space group C2
8EVV	;	2.05	;	Apo form of DdlA from Pseudomonas aeruginosa PAO1
2ARA	;	2.8	;	APO FORM OF ESCHERICHIA COLI REGULATORY PROTEIN ARAC
5H3S	;	3.0	;	apo form of GEMIN5-WD
3ZSS	;	1.8	;	Apo form of GlgE isoform 1 from Streptomyces coelicolor
1O05	;	2.25	;	Apo form of human mitochondrial aldehyde dehydrogenase
5A9R	;	1.55	;	Apo form of Imine reductase from Amycolatopsis orientalis
4ZQQ	;	1.8	;	Apo form of influenza strain H1N1 polymerase acidic subunit N-terminal region
5JHV	;	2.749	;	Apo form of influenza strain H1N1 polymerase acidic subunit N-terminal region crystallized with polyethylene glycol 8000
5JHT	;	1.751	;	Apo form of influenza strain H1N1 polymerase acidic subunit N-terminal region crystallized with potassium sodium tartrate
2GCA	;	2.4	;	apo form of L. casei FPGS
6E2S	;	1.791	;	apo form of MDDEF with buffer exchange
7DCY	;	1.972	;	Apo form of Mycoplasma genitalium RNase R
6HR4	;	1.19	;	Apo form of penicillin-binding protein 3 from P. aeruginosa
6XI2	;	2.57	;	Apo form of POMGNT2
2PRY	;	2.35	;	Apo form of S. cerevisiae orotate phosphoribosyltransferase
1ZCU	;	2.0	;	apo form of the 162S mutant of glycogenin
5WH1	;	3.39	;	Apo form of the C-terminal region of human Transcription Factor IIB
2JCG	;	2.6	;	Apo form of the catabolite control protein A (ccpA) from bacillus megaterium, with the DNA binding domain
6HU8	;	1.894	;	Apo form of the competence regulator ComR from Streptococcus vestibularis
6BJP	;	2.102	;	Apo form of the E124S mutant of betaine aldehyde dehydrogenase from Pseudomonas aeruginosa
7ERY	;	1.77	;	apo form of the glycosyltransferase
3NSF	;	2.0	;	Apo form of the multicopper oxidase CueO
5ZO3	;	1.493	;	apo form of the nuclease
5DBK	;	3.241	;	apo form of the quorum sensor NprR from B. thuringiensis
6SF4	;	1.7	;	Apo form of the ribonucleotide reductase NrdB protein from Leeuwenhoekiella blandensis
5MIN	;	1.76	;	Apo form of the soluble PQQ-dependent Glucose Dehydrogenase from Acinetobacter calcoaceticus
2C0M	;	2.5	;	apo form of the TPR domain of the pex5p receptor
1XJA	;	2.4	;	Apo form of the Y31V mutant dimerization domain fragment of Escherichia coli regulatory protein AraC
7BFN	;	1.7	;	Apo form of Thermogutta terrifontis esterase 2
5EEB	;	3.038	;	Apo form of thermostable aldehyde dehydrogenase from Pyrobaculum sp. 1860
6U1C	;	2.2	;	Apo form of Thermus thermophilus D-alanine-D-alanine ligase
3AEY	;	1.92	;	Apo form of threonine synthase from Thermus thermophilus HB8
6FN4	;	4.14	;	Apo form of UIC2 Fab complex of human-mouse chimeric ABCB1 (ABCB1HM)
7UK8	;	1.85	;	Apo form of YgiC from Escherichia coli K-12
7UK6	;	1.9	;	Apo form of YjfC from Escherichia coli K-12
6XLB	;	3.8	;	Apo full-length Hsc82 in complex with Aha1
6U84	;	3.7	;	Apo full-length rat TRPV2 in nanodiscs, state 1
6U86	;	4.0	;	Apo full-length rat TRPV2 in nanodiscs, state 2
2VOZ	;	1.7	;	Apo FutA2 from Synechocystis PCC6803
5F82	;	0.96	;	Apo GES-5 C69G mutant
2YNU	;	2.06	;	Apo GIM-1 with 2Mol. Crystal structures of Pseudomonas aeruginosa GIM-1: active site plasticity in metallo-beta-lactamases
3I69	;	2.38	;	Apo Glutathione Transferase A1-1 GIMF-helix mutant
4BYY	;	2.48	;	Apo GlxR
7CQL	;	2.801	;	Apo GmaS without ligand
8D97	;	3.8	;	Apo gRAMP
4LO4	;	2.871	;	Apo HA-70
4LO0	;	2.055	;	Apo HA17-HA33
8C4S	;	3.27	;	Apo Hantaan virus polymerase core
8QGU	;	3.03	;	Apo Hantaan virus polymerase in dimeric state
8QE5	;	2.6	;	Apo Hantaan virus polymerase in monomeric state
5O4N	;	2.05	;	Apo HcgC from Methanococcus maripaludis soaked with SAH and pyridinol
7RE4	;	1.87	;	Apo Hemophilin from A. baumannii
7REA	;	1.49	;	Apo Hemophilin from A. baumannii
2AXQ	;	1.7	;	Apo histidine-tagged saccharopine dehydrogenase (L-Glu forming) from Saccharomyces cerevisiae
4EJ8	;	2.347	;	Apo HIV Protease (PR) dimer in closed form with fragment 1F1 in the outside/top of flap
4EJL	;	2.445	;	Apo HIV Protease (PR) dimer in closed form with fragment 1F1-N in the outside/top of flap
7ULI	;	1.9	;	Apo HMG-CoA Reductase from Arabidopsis thaliana (HMG1)
7PN1	;	3.9	;	Apo HsPepT1 in the outward facing open conformation
8ELM	;	2.19	;	Apo human biliverdin reductase beta (293K)
8ELL	;	1.52	;	Apo human biliverdin reductase beta (cryogenic)
6QP5	;	1.9	;	Apo Human Calcium/Calmodulin-dependent kinase type 1D
3D93	;	1.1	;	Apo Human carbonic anhydrase II bound with substrate carbon dioxide
7PQT	;	2.65	;	Apo human Kv3.1 cryo-EM structure
7WFW	;	3.1	;	Apo human Nav1.8
7AST	;	4.0	;	Apo Human RNA Polymerase III
8D0J	;	1.94	;	Apo Human SARM1 TIR domain
7QDR	;	3.7	;	Apo human SKI complex in the closed state
7QDS	;	3.8	;	Apo human SKI complex in the open state
7YUF	;	3.29	;	apo human SPNS2
3SPJ	;	3.307	;	Apo inward rectifier potassium channel Kir2.2 I223L mutant
4P3J	;	3.5	;	Apo inward-facing state of the glutamate transporter homologue GltPh in alkali-free conditions
2O8Y	;	2.4	;	Apo IRAK4 Kinase Domain
3VUA	;	1.85	;	Apo IsdH-NEAT3 in space group P3121 at a resolution of 1.85 A
6WWT	;	3.2	;	Apo KIF14[391-735] in complex with a microtubule
6WWP	;	3.1	;	Apo KIF14[391-743] in complex with a microtubule
6WWI	;	3.6	;	Apo KIF14[391-755] in complex with a microtubule
6WWE	;	3.9	;	Apo KIF14[391-772] in complex with a microtubule
8F1A	;	3.1	;	Apo KIF20A[1-565] class-1 in complex with a microtubule
8F18	;	3.2	;	Apo KIF20A[1-565] class-2 in complex with a microtubule
8BJS	;	2.73	;	Apo KIF20A[55-510] crystal structure
6B0I	;	3.78	;	Apo KLP10A in complex with a microtubule
5UL8	;	1.15	;	Apo KPC-2 beta-lactamase crystal structure at 1.15 Angstrom resolution
6XD5	;	1.2	;	Apo KPC-2 N170A mutant at 1.20 A
7EZ0	;	3.14	;	Apo L-21 ScaI Tetrahymena ribozyme
2V65	;	2.35	;	Apo LDH from the psychrophile C. gunnari
7ZB2	;	1.94	;	apo macrocyclase OphP
8ON8	;	2.7	;	Apo Malacoceros FaNaC1 in lipid nanodiscs
4U3Z	;	2.09	;	APO MAP4K4 T181E Phosphomimetic Mutant
6UKP	;	3.81	;	Apo mBcs1
6QB3	;	1.9	;	Apo Mcl1 in a complex with a scFv
4U3Y	;	1.45	;	Apo Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4)
8FG5	;	1.3	;	Apo mouse acidic mammalian chitinase, catalytic domain at 100 K
8FG7	;	1.64	;	Apo mouse acidic mammalian chitinase, catalytic domain at 277 K
4HNY	;	2.249	;	Apo N-terminal acetyltransferase complex A
3SPU	;	2.1	;	apo NDM-1 Crystal Structure
6NL2	;	1.92	;	Apo NIS synthetase DesD variant R306Q
6XRC	;	2.45	;	Apo NIS synthetase DesD variant R306Q
7EVG	;	2.48	;	Apo Odinarchaeota tubulin (OdinTubulin) H393D mutant, in a psuedo-protofilament arrangement
2FW0	;	1.55	;	Apo Open Form of Glucose/Galactose Binding Protein
1AIV	;	3.0	;	APO OVOTRANSFERRIN
6P17	;	1.851	;	Apo PCuAC domain from PmoF1
5OVA	;	2.3	;	Apo PDZ domain from rat Shank3
4P71	;	2.79	;	Apo PheRS from P. aeuriginosa
6P1F	;	1.654	;	apo PmoF2 PCuAC domain
6VUH	;	1.999	;	APO PreQ1 riboswitch aptamer grown in Mn2+
5F1E	;	2.7	;	Apo protein of Sandercyanin
8U1E	;	1.43	;	Apo protein tyrosine phosphatase 1B (PTP1B) at high resolution (1.43 A) in space group P43212 with two distinctly ordered chains
8CN8	;	1.8	;	apo Pseudomonas aeruginosa FabF C164A mutant
6UED	;	1.55	;	Apo Pseudomonas aeruginosa LpxD Structure
7RIN	;	1.85	;	Apo PTP1B by Native S-SAD at Room Temperature
1XGD	;	2.1	;	Apo R268A human aldose reductase
8EKP	;	2.75	;	Apo rat TRPV2 in nanodiscs, state 1
8EKQ	;	2.6	;	Apo rat TRPV2 in nanodiscs, state 2
8EKR	;	3.0	;	Apo rat TRPV2 in nanodiscs, state 3
2OAM	;	2.3	;	Apo RebH from Lechevalieria aerocolonigenes
4TVY	;	2.151	;	Apo resorufin ligase
7UEZ	;	1.08	;	Apo RibB from Vibrio cholera
6EU3	;	3.3	;	Apo RNA Polymerase III - closed conformation (cPOL3)
6EU2	;	3.4	;	Apo RNA Polymerase III - open conformation (oPOL3)
7LQ2	;	1.85	;	Apo Rr RsiG- crystal form 1
1FF9	;	2.0	;	APO SACCHAROPINE REDUCTASE
1E5L	;	2.4	;	Apo saccharopine reductase from Magnaporthe grisea
6UES	;	3.7	;	Apo SAM-IV Riboswitch
6WLQ	;	4.7	;	Apo SAM-IV riboswitch models, 4.7 Angstrom resolution
7E2X	;	3.0	;	Apo serotonin 1A (5-HT1A) receptor-Gi protein complex
7LI8	;	3.9	;	apo serotonin transporter reconstituted in lipid nanodisc in presence of NaCl in inward open conformation
7LI7	;	4.1	;	apo serotonin transporter reconstituted in lipid nanodisc in presence of NaCl in occluded conformation
7LI6	;	3.5	;	apo SERT reconstituted in lipid nanodisc in KCl
2NC9	;		;	Apo solution structure of Hop TPR2A
8UF2	;	1.6	;	Apo SOS2 crystal structure in P1 space group
7DZW	;	3.45	;	Apo spike protein from SARS-CoV2
8IRL	;	2.7	;	Apo state of Arabidopsis AZG1 at pH 7.4
8WO7	;	2.9	;	Apo state of Arabidopsis AZG1 T440Y
7WKS	;	3.0	;	Apo state of AtPIN3
6QNM	;	2.1	;	Apo state of chemotaxis sensor ODP from T. denticola
7DGD	;	3.96	;	apo state of class C GPCR
5JWH	;	1.4	;	Apo structure
8FCH	;	1.956	;	Apo Structure of (N1G37) Methyltransferase from Mycobacterium avium
8TXA	;	1.591	;	Apo Structure of (N1G37) tRNA Methyltransferase from Mycobacterium marinum
4CY6	;	2.76	;	apo structure of 2-hydroxybiphenyl 3-monooxygenase HbpA
5TEK	;	2.01	;	Apo Structure of 4-Hydroxy-tetrahydrodipicolinate Reductase from Mycobacterium tuberculosis
4CKK	;	1.9	;	Apo structure of 55 kDa N-terminal domain of E. coli DNA gyrase A subunit
6IER	;	2.246	;	Apo structure of a beta-glucosidase 1317
6Z3N	;	1.58	;	Apo Structure of a Hydrolase from Pseudomonas aeruginosa PAO1
2WYL	;	2.59	;	Apo structure of a metallo-b-lactamase
4O0Q	;	1.92	;	Apo structure of a methyltransferase component involved in O-demethylation
7JT8	;	1.84	;	Apo structure of a pseudomurein peptide ligase type E from Methanothermus fervidus
4GMF	;	1.85	;	Apo Structure of a Thiazolinyl Imine Reductase from Yersinia enterocolitica (Irp3)
4OD4	;	3.301	;	Apo structure of a UbiA homolog from Aeropyrum pernix K1
6MB8	;	1.6	;	Apo structure of AAC-IIIb
5GT6	;	2.6	;	Apo structure of Aldehyde Dehydrogenase from Bacillus cereus
5Y4G	;	2.0	;	Apo Structure of AmbP3
6JIZ	;	1.763	;	Apo structure of an imine reductase at 1.76 Angstrom resolution
6JZ1	;	1.73	;	Apo structure of b-glucuronidase from Ruminococcus gnavus at 1.7 Angstrom resolution
1SXH	;	2.75	;	apo structure of B. megaterium transcription regulator
1W50	;	1.75	;	Apo Structure of BACE (Beta Secretase)
3TPJ	;	1.61	;	APO structure of BACE1
3TPL	;	2.5	;	APO Structure of BACE1
5EN5	;	2.3	;	Apo structure of bacterial efflux pump.
6D1N	;	2.2	;	Apo structure of Bacteroides uniformis Beta-glucuronidase 1
6D1P	;	2.35	;	Apo structure of Bacteroides uniformis beta-glucuronidase 3
5XD0	;	1.79	;	Apo Structure of Beta-1,3-1,4-glucanase from Paenibacillus sp.X4
3FJP	;	2.3	;	Apo structure of Biotin protein ligase from Aquifex aeolicus
7QGJ	;	1.3	;	Apo structure of BIR2 Domain of BIRC2
5HOQ	;	1.793	;	Apo structure of CalS11, TDP-rhamnose 3'-o-methyltransferase, an enzyme in Calicheamicin biosynthesis
2YG1	;	1.9	;	APO STRUCTURE OF CELLOBIOHYDROLASE 1 (CEL7A) FROM HETEROBASIDION ANNOSUM
2ZQ7	;	0.94	;	Apo structure of Class A beta-lactamase Toho-1 E166A/R274N/R276N triple mutant
2ZQ8	;	1.03	;	Apo structure of class a beta-lactamase Toho-1 R274N/R276N double mutant
8SJF	;	2.3	;	Apo Structure of Computationally Designed Homotrimer Tet4
8SJI	;	1.5	;	Apo Structure of Computationally Designed Homotrimer TP1
5B7S	;	2.58	;	Apo structure of Cysteine Desulfurase from Thermococcus onnurineus NA1
5B7U	;	1.9	;	Apo Structure of Cysteine Desulfurase from Thermococcus onnurineus NA1 at 1.89A
7CS2	;	2.688	;	Apo structure of dimeric IiPLR1
6KI9	;	1.64	;	Apo structure of FabMG, novel types of Enoyl-acyl carrier protein reductase
5GK5	;	1.9	;	Apo structure of fructose 1,6-bisphosphate aldolase from Escherichia coli at 1.9 angstrom resolution
8IXP	;	2.45	;	Apo structure of glycosyltransferase LmbT wild type
1ZMO	;	2.0	;	Apo structure of haloalcohol dehalogenase HheA of Arthrobacter sp. AD2
8HOE	;	2.2	;	Apo structure of HopBF1 kinase from Ewingella americana
1PW2	;	1.95	;	APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2
2MNG	;		;	Apo Structure of human HCN4 CNBD solved by NMR
5FWQ	;	2.047	;	Apo structure of human Leukotriene A4 hydrolase
5H7Z	;	3.057	;	Apo structure of immunity protein TplEi of T6SS from Pseudomonas aeruginosa
7LNV	;	2.2	;	Apo Structure of Isopentenyl Phosphate Kinase from Candidatus methanomethylophilus alvus
4XEH	;	1.391	;	Apo structure of KARI from Ignisphaera aggregans
7P1B	;	1.45	;	Apo structure of KDNase from Aspergillus Terrerus
7P1V	;	1.47	;	Apo structure of KDNase from Trichophyton Rubrum
5NSK	;	2.6	;	apo Structure of Leucyl aminopeptidase from Trypanosoma brucei
5NTF	;	2.3	;	apo Structure of Leucyl aminopeptidase from Trypanosoma cruzi
5G1W	;	1.76	;	Apo Structure of Linalool Dehydratase-Isomerase
7XGW	;	2.25	;	Apo structure of LW domain from Trypanosoma brucei
7OFP	;	1.92	;	Apo Structure of Mu2 Adaptin Subunit (Ap50) Of AP2 Clathrin Adaptor
6IXO	;	1.901	;	Apo structure of Myo2-GTD
4RS8	;	2.29	;	Apo structure of novel pNOB8 plasmid centromere binding protein
6K9B	;	2.45	;	Apo structure of NrS-1 N terminal domain N305
5IKY	;	2.5	;	Apo structure of Obc1, a bifunctional enzyme for quorum sensing-dependent oxalogenesis
4NNA	;	2.103	;	Apo structure of ObcA
5NBT	;	2.4	;	Apo structure of p60N/p80C katanin
6H2O	;	1.9	;	APO structure of Phenylalanine ammonia-lyase from Petroselinum crispum
4JFY	;	2.63	;	Apo structure of phosphotyrosine (pYAb) scaffold
5BNF	;	2.3	;	Apo structure of porcine CD38
3HGW	;	2.25	;	Apo Structure of Pseudomonas aeruginosa Isochorismate-Pyruvate Lyase I87T mutant
5M2E	;	2.7	;	Apo structure of Pseudomonas aeruginosa Isocitrate Dehydrogenase, ICD.
6HZR	;	1.19	;	Apo structure of Pseudomonas aeruginosa Penicillin-Binding Protein 3
6R40	;	2.2	;	Apo structure of R504C mutant of Pseudomonas aeruginosa Penicillin-Binding Protein 3 (PBP3)
3V7L	;	2.66	;	Apo Structure of Rat DNA polymerase beta K72E variant
4BMN	;	1.5	;	apo structure of short-chain alcohol dehydrogenase from Ralstonia sp. DSM 6428
2CEY	;	1.7	;	Apo Structure of SiaP
4OCH	;	1.4001	;	Apo structure of Smr domain of MutS2 from Deinococcus radiodurans
7V1K	;	3.287	;	Apo structure of sNASP core
5AHX	;	2.0	;	Apo structure of soluble epoxide hydrolase
7PF7	;	1.7	;	Apo structure of SynFtn variant D65A
6D2V	;	1.901	;	Apo Structure of TerB, an NADP Dependent Oxidoreductase in the Terfestatin Biosynthesis Pathway
5ZTC	;	1.7	;	Apo structure of TetR family transcription regulator Lmo2088 of Listeria monocytogenes EGDe
4UBW	;	2.7	;	Apo structure of the 3-ketoacyl-CoA thiolase FadA5 from M. tuberculosis
6NEW	;	2.5	;	Apo structure of the activated truncation of Vav1
2X0O	;	2.4	;	Apo structure of the Alcaligin biosynthesis protein C (AlcC) from Bordetella bronchiseptica
6T6H	;	1.18	;	Apo structure of the Bottromycin epimerase BotH
4NTS	;	2.9	;	Apo structure of the catalytic subunit of cAMP-dependent protein kinase
2V28	;	1.95	;	Apo structure of the cold active phenylalanine hydroxylase from Colwellia psychrerythraea 34H
6V67	;	1.07	;	Apo Structure of the De Novo PD-1 Binding Miniprotein GR918.2
6P01	;	1.89	;	Apo structure of the E52D mutant of ANT-4
6TWJ	;	2.15	;	Apo structure of the Ectoine utilization protein EutD (DoeA) from Halomonas elongata
6TWL	;	2.0	;	Apo structure of the Ectoine utilization protein EutE (DoeB) from Ruegeria pomeroyi
6WJS	;	3.8	;	Apo structure of the FMN riboswitch aptamer domain in the presence of phosphate
6WJR	;	2.7	;	Apo structure of the FMN riboswitch aptamer domain in the presence of sulfate
4WWQ	;	1.8	;	Apo structure of the Grb7 SH2 domain
2P6U	;	3.14	;	Apo structure of the Hel308 superfamily 2 helicase
7LNY	;	2.1	;	Apo structure of the Histone chaperone ASF1A residues 1-155
6A2E	;	1.939	;	Apo structure of the Kdo hydroxylase KdoO, a non-heme Fe(II) alphaketoglutarate dependent dioxygenase
7QH0	;	2.15	;	Apo structure of the Leishmania mexicana triose-phosphate isomerase (LmTIM), N11A-E65Q variant, open conformation
6EAZ	;	2.504	;	Apo structure of the mitochondrial calcium uniporter protein MICU2
7EBJ	;	1.8	;	Apo structure of the mouse Trim66 PHD-Bromo dual domain
4FN7	;	1.25	;	Apo Structure of the Mtb enoyol CoA isomerase (Rv0632c)
6IJM	;	2.016	;	Apo structure of the N6-methyl-AMP Deaminase from Arabidopsis thaliana
2MR7	;		;	apo structure of the Peptidyl Carrier Protein Domain 7 of the teicoplanin producing Non-ribosomal peptide synthetase
3LF1	;	2.315	;	Apo structure of The Short Chain Oxidoreductase Q9HYA2 from Pseudomonas aeruginosa PAO1 Containing an Atypical Catalytic Center
8BXJ	;		;	apo structure of the specific silver chaperone needed for bacterial silver resistance
6NLT	;	1.9	;	Apo structure of the T130K mutant of ANT-4
7KD1	;	1.9	;	Apo structure of the THF riboswitch aptamer domain
8F4O	;	3.1	;	Apo structure of the TPP riboswitch aptamer domain
6HZI	;	2.29	;	Apo structure of TP domain from Burkholderia pseudomallei penicillin-binding protein 3
6HZH	;	1.83	;	Apo structure of TP domain from Chlamydia trachomatis penicillin-binding protein 3
6HZJ	;	1.43	;	Apo structure of TP domain from clinical penicillin-resistant mutant Neisseria gonorrhoea strain 6140 Penicillin-Binding Protein 2 (PBP2)
6HZQ	;	1.95	;	Apo structure of TP domain from Escherichia coli Penicillin-Binding Protein 3
6HZO	;	2.44	;	Apo structure of TP domain from Haemophilus influenzae Penicillin-Binding Protein 3
5BS6	;	2.35	;	Apo structure of transcriptional factor AraR from Bacteroides thetaiotaomicron VPI
5DD4	;	2.56	;	Apo structure of transcriptional factor AraR from Bacteroides thetaiotaomicron VPI
7LWZ	;	2.32	;	Apo Structure of Vibrio cholerae dGTPase protein VC1979
7DUP	;	1.62	;	Apo structure of wild type Bt4394, a GH20 family sulfoglycosidase
2X0D	;	2.28	;	APO structure of WsaF
6OAU	;	2.48	;	Apo Structure of WT Lipoprotein Lipase in Complex with GPIHBP1 Mutant N78D N82D produced in GnTI-deficient HEK293-F cells
6OAZ	;	3.04	;	Apo Structure of WT Lipoprotein Lipase in Complex with GPIHBP1 Mutant N78D N82D produced in HEK293-F cells
6DTT	;	1.9	;	Apo T. maritima MalE2
6DTR	;	2.301	;	Apo T. maritima MalE3
3EQQ	;	3.2	;	Apo Toluene 2,3-Dioxygenase
4C7V	;	2.2	;	Apo Transketolase from Lactobacillus salivarius at 2.2A resolution
4UUM	;	1.368	;	Apo trichomonas vaginalis lactate dehydrogenase
4UUL	;	1.28	;	Apo trichomonas vaginalis lactate dehydrogenase L91R
4UUO	;	2.842	;	Apo Trichomonas vaginalis malate dehydrogenase
7ADN	;	1.92	;	apo tRNA-guanine transglycosylase C158S/C281S/Y330C/H333A mutant
7EQM	;	2.50002	;	Apo Truncated VhChiP (Delta 1-19)
7X5Q	;	2.7	;	Apo Truncated VhChiP (Delta 1-19) in complex with peptide (DGANSDAAK)
2EZ2	;	1.85	;	Apo tyrosine phenol-lyase from Citrobacter freundii at pH 8.0
6WLT	;	4.8	;	Apo V. cholerae glycine riboswitch models, 4.8 Angstrom resolution
2PC0	;	1.4	;	Apo Wild-type HIV Protease in the open conformation
4Q84	;	2.64	;	Apo YcaO
4WEP	;	1.5	;	Apo YehZ from Escerichia coli
6Q1C	;	1.76	;	Apo YfeA extracted from the E. coli periplasm
6B2X	;	2.199	;	Apo YiuA Crystal Form 1
6B2Y	;	1.77	;	Apo YiuA Crystal Form 2
4XDD	;	1.599	;	Apo [FeFe]-Hydrogenase CpI
6GL6	;	1.8	;	apo [FeFe]-hydrogenase HydA1 from Chlamydomonas reinhardtii, variant C377H
6LUU	;	1.2	;	apo- Carbonic Anhydrase II pH 7.8 0 atm CO2
6LUV	;	1.2	;	apo- Carbonic Anhydrase II pH 7.8 20 atm CO2
2RG7	;	2.05	;	Apo- Crystal Structure of a Periplasmic Heme Binding Protein from Shigella dysenteriae
5H9G	;	2.6	;	apo-ACP from Helicobacter pylori
6J9K	;	2.234	;	Apo-AcrIIC2
7YP7	;	3.1	;	apo-ADGRG2 coupled to Gs
8GF6	;	3.1	;	Apo-apo MCR assembly intermediate
7XWD	;	2.396	;	Apo-AtPRT6 UBR box
6L1L	;	1.9	;	Apo-BacF structure from Bacillus subtillis
6N7U	;	2.03	;	apo-BDBV223 Fab
8QX7	;	1.95	;	Apo-C-Terminal Domain Homolog of the Orange Carotenoid Protein from Anabaena at a resolution of 1.95 Angstroms
6CTB	;		;	Apo-Calmodulin Bound to Calcium Voltage Gated Channel 1.2 IQ-Motif
7Y2L	;	1.25	;	apo-Carbonic Anhydrase II soaked in 3NPA after UV at 120 K
7Y2M	;	1.25	;	apo-Carbonic Anhydrase II soaked in 3NPA after UV at 140 K
7Y2N	;	1.25	;	apo-Carbonic Anhydrase II soaked in 3NPA after UV at 160 K
7Y2O	;	1.25	;	apo-Carbonic Anhydrase II soaked in 3NPA after UV at 180 K
7Y2Q	;	1.35	;	apo-Carbonic Anhydrase II soaked in 3NPA after UV at 200 K
7Y2K	;	1.25	;	apo-Carbonic Anhydrase II soaked in 3NPA after UV at 90 K
7Y2J	;	1.25	;	apo-Carbonic Anhydrase II soaked in 3NPA before UV at 90 K
1CBI	;	2.7	;	APO-CELLULAR RETINOIC ACID BINDING PROTEIN I
1XCA	;	2.3	;	APO-CELLULAR RETINOIC ACID BINDING PROTEIN II
7SHS	;	4.1	;	Apo-ChRmine in MSP1E3D1 lipid nanodisc
7DCN	;	1.695	;	Apo-citrate lyase phosphoribosyl-dephospho-CoA transferase
1SWA	;	1.9	;	APO-CORE-STREPTAVIDIN AT PH 4.5
1SWC	;	1.8	;	APO-CORE-STREPTAVIDIN AT PH 4.5
1SWB	;	1.85	;	APO-CORE-STREPTAVIDIN AT PH 7.5
1SWD	;	1.9	;	APO-CORE-STREPTAVIDIN IN COMPLEX WITH BIOTIN (TWO UNOCCUPIED BINDING SITES) AT PH 4.5
1SWE	;	2.06	;	APO-CORE-STREPTAVIDIN IN COMPLEX WITH BIOTIN AT PH 4.5
8CI7	;	2.4	;	Apo-crystal structure of a wild-type South African HIV-1 subtype C protease at 2.4 angstrom
4QVK	;	1.97	;	Apo-crystal structure of Podospora anserina methyltransferase PaMTH1
5FJD	;	1.5	;	APO-CSP1 (COPPER STORAGE PROTEIN 1) FROM METHYLOSINUS TRICHOSPORIUM OB3B
5FIG	;	1.7	;	APO-CSP3 (COPPER STORAGE PROTEIN 3) FROM BACILLUS SUBTILIS
5ARM	;	1.194	;	APO-CSP3 (COPPER STORAGE PROTEIN 3) FROM METHYLOSINUS
7U57	;	2.37	;	apo-CTX-M-15
4OOQ	;	2.004	;	apo-dUTPase from Arabidopsis thaliana
7D48	;	2.15	;	apo-form cyclic trinucleotide synthase CdnD
7D4S	;	1.93	;	apo-form cyclic trinucleotide synthase CdnD
6UAM	;	2.802	;	Apo-form Dimer of Y77A Mutant Putative Ryanodine Receptor from Bacteroides thetaiotaomicron VPI-5482
2ZYG	;	2.1	;	Apo-form of dimeric 6-phosphogluconate dehydrogenase
7UI3	;	3.18	;	Apo-form of Human Tryptophan 2,3-Dioxygenase Induced by NADH Binding
3FN4	;	1.96	;	Apo-form of NAD-dependent formate dehydrogenase from bacterium Moraxella sp.C-1 in closed conformation
3NAQ	;	1.7	;	Apo-form of NAD-dependent formate dehydrogenase from higher-plant Arabidopsis thaliana
8HK9	;	2.0	;	Apo-form of Periplasmic terephthalate binding protein (TBP) from Ideonella sakaiensis
6HQJ	;	1.802	;	apo-form of polyphenol oxidase from Solanum lycopersicum
5EFY	;	2.7	;	Apo-form of SCO3201
3FUT	;	1.52	;	Apo-form of T. thermophilus 16S rRNA A1518 and A1519 methyltransferase (KsgA) in space group P21212
3FUV	;	1.95	;	Apo-form of T. thermophilus 16S rRNA A1518 and A1519 methyltransferase (KsgA) in space group P43212
2NXC	;	1.59	;	Apo-form of T. thermophilus ribosomal protein L11 methyltransferase (PrmA)
5AHL	;	1.951	;	Apo-form of the DeltaCBS mutant of IMPDH from Pseudomonas aeruginosa
2KLS	;		;	Apo-form of the second Ca2+ binding domain of NCX1.4
5ZW0	;	2.54	;	Apo-form PigA
6M5N	;	1.84	;	Apo-Form Structure of Borneol Dehydrogenase
6IIP	;	0.951	;	Apo-form structure of the HRP3 PWWP domain
3H7G	;	1.65	;	Apo-FR with AU ions
2Z5R	;	2.5	;	Apo-Fr with high content of Pd ions
2Z5Q	;	2.1	;	Apo-Fr with intermediate content of Pd ion
2Z5P	;	1.65	;	Apo-Fr with low content of Pd ions
3KDS	;	2.601	;	apo-FtsH crystal structure
4Y2M	;	1.4	;	apo-GolB protein
3FI6	;	1.8	;	apo-H49AFr with high content of Pd ions
2C9R	;	2.0	;	apo-H91F CopC
3GZ0	;	1.26	;	Apo-human carbonic anhydrase II revisited: Implications of the loss of a metal in protein structure, stability and solvent network
2HAV	;	2.7	;	Apo-Human Serum Transferrin (Glycosylated)
2HAU	;	2.7	;	Apo-Human Serum Transferrin (Non-Glycosylated)
8CP3	;	2.35	;	Apo-LarE in complex with AMP-PNP
6O00	;	4.18	;	apo-LRRC8A in MSP2N2 nanodisc constricted state
1BV4	;	1.85	;	APO-MANNOSE-BINDING PROTEIN-C
7CED	;	1.9	;	Apo-methanol dehydrogenase (MDH) from Methylococcus capsulatus (Bath)
1Q5V	;	2.3	;	Apo-NikR
2CA9	;	2.05	;	apo-NIKR from helicobacter pylori in closed trans-conformation
5K3V	;	1.9	;	apo-PDX1.3 (Arabidopsis)
1PZC	;	1.85	;	APO-PSEUDOAZURIN (METAL FREE PROTEIN)
6TI3	;	1.96	;	Apo-SHMT from Streptococcus thermophilus Tyr55Ser variant in complex with D-Threonine
6JSH	;	5.1	;	Apo-state Fatty Acid Synthase
6J6K	;	3.3	;	Apo-state streptavidin
7AGX	;	3.6	;	Apo-state type 3 secretion system export apparatus complex from Salmonella enterica typhimurium
4A10	;	2.25	;	Apo-structure of 2-octenoyl-CoA carboxylase reductase CinF from streptomyces sp.
4V2U	;	2.71	;	Apo-structure of alpha2,3-sialyltransferase from Pasteurella dagmatis
4V38	;	1.96	;	Apo-structure of alpha2,3-sialyltransferase variant 1 from Pasteurella dagmatis
4V39	;	2.6	;	Apo-structure of alpha2,3-sialyltransferase variant 2 from Pasteurella dagmatis
5LB4	;	1.98	;	Apo-structure of humanised RadA-mutant humRadA14
5LB2	;	2.1	;	Apo-structure of humanised RadA-mutant humRadA2
5KDD	;	1.99	;	Apo-structure of humanised RadA-mutant humRadA22
5J4L	;	1.13	;	Apo-structure of humanised RadA-mutant humRadA22F
5JEE	;	1.49	;	Apo-structure of humanised RadA-mutant humRadA26F
5JED	;	1.332	;	Apo-structure of humanised RadA-mutant humRadA28
5LBI	;	1.43	;	Apo-structure of humanised RadA-mutant humRadA3
5JEC	;	2.34	;	Apo-structure of humanised RadA-mutant humRadA33F
5L8V	;	1.5	;	Apo-structure of humanised RadA-mutant humRadA4
6GJV	;	2.11	;	apo-structure of IMPDH from Pseudomonas aeruginosa
7OE7	;	3.73	;	Apo-structure of Lassa virus L protein (well-resolved alpha ribbon) [APO-RIBBON]
7OE3	;	3.35	;	Apo-structure of Lassa virus L protein (well-resolved endonuclease) [APO-ENDO]
7OCH	;	3.14	;	Apo-structure of Lassa virus L protein (well-resolved polymerase core) [APO-CORE]
5UHM	;	1.9	;	Apo-Structure of Mature Growth Differentiation Factor 11
5A0P	;	1.398	;	Apo-structure of metalloprotease Zmp1 from Clostridium difficile
5A0S	;	2.56	;	Apo-structure of metalloprotease Zmp1 variant E143A from Clostridium difficile
3ZGY	;	2.71	;	Apo-structure of R-selective imine reductase from Streptomyces kanamyceticus
7QCW	;	2.81	;	Apo-structure of serine hydroxymethyltransferase (PbzB) involved in benzobactin biosynthesis in P. chlororaphis subsp. piscium DSM 21509
6G56	;	2.15	;	Apo-structure of the alanine racemase from Staphylococcus aureus
2BLL	;	2.3	;	Apo-structure of the C-terminal decarboxylase domain of ArnA
4W99	;	2.0	;	Apo-structure of the Y79F,W322E-double mutant of Etr1p
5EIP	;	1.49	;	apo-structure of YTH domain of SpMmi1
4Z9J	;	1.78	;	Apo-Tar from E. coli
6ZJ4	;	2.1	;	apo-Trehalose transferase (apo-TreT) from Thermoproteus uzoniensis
8FIK	;	1.912	;	APOBEC3A E72A inactive mutant in complex with ATTC-hairpin DNA substrate
7KM6	;	1.67	;	APOBEC3B antibody 5G7 Fv-clasp
5W2M	;	3.7	;	APOBEC3F Catalytic Domain Complex with a Single-Stranded DNA
5HX5	;	2.33	;	APOBEC3F Catalytic Domain Crystal Structure
5ZVA	;	2.3	;	APOBEC3F Chimeric Catalytic Domain in Complex with DNA(dC9)
5ZVB	;	2.0	;	APOBEC3F Chimeric Catalytic Domain in Complex with DNA(dT9)
1OBQ	;	1.85	;	Apocrustacyanin C1 crystals grown in space and earth using vapour diffusion geometry
1OBU	;	2.0	;	Apocrustacyanin C1 crystals grown in space and earth using vapour diffusion geometry
1IEU	;		;	APOCYTOCHROME B5, PH 6.2, 298 K, NMR, 10 STRUCTURES
1IET	;		;	APOCYTOCHROME B5, PH 6.2, 298 K, NMR, MINIMIZED AVERAGE STRUCTURE
8GRX	;	3.0	;	APOE4 receptor in complex with APOE4 NTD
2H34	;	2.8	;	Apoenzyme crystal structure of the tuberculosis serine/threonine kinase, PknE
3KAJ	;	2.0	;	Apoenzyme structure of homoglutathione synthetase from Glycine max in open conformation
6S61	;	1.84	;	Apoferritin from mouse at 1.84 angstrom resolution
7RRP	;	1.27	;	Apoferritin structure at 1.27 angstrom resolution determined from a 300 kV Titan Krios G3i electron microscope with Falcon4 detector
7K3V	;	1.34	;	Apoferritin structure at 1.34 angstrom resolution determined from a 300 kV Titan Krios G3i electron microscope with K3 detector
7K3W	;	1.36	;	Apoferritin structure at 1.36 angstrom resolution determined from a 300 kV Titan Krios G3i electron microscope with Falcon4 detector
3F34	;	1.68	;	Apoferritin: complex with 2,6-diethylphenol
3F35	;	1.92	;	Apoferritin: complex with 2,6-diethylphenol
3F37	;	1.54	;	Apoferritin: complex with 2,6-dimethylphenol
3F38	;	1.75	;	Apoferritin: complex with 2,6-dimethylphenol
3F36	;	1.7	;	Apoferritin: complex with 2-isopropylphenol
3F39	;	1.85	;	Apoferritin: complex with phenol
3F33	;	1.7	;	Apoferritin: complex with propofol
3U90	;	1.9	;	apoferritin: complex with SDS
2BMV	;	2.11	;	Apoflavodoxin from Helicobacter pylori
7R4U	;	1.23	;	Apoform of FtrA/P19 from Rubrivivax gelatinosus
7R3P	;	1.4	;	Apoform of the periplasmic FtrA/P19 protein from Rubrivivax gelatinosus (His-tag)
7L6K	;		;	ApoL1 N-terminal domain
1NFO	;	2.0	;	APOLIPOPROTEIN E2 (APOE2, D154A MUTATION)
1BZ4	;	1.85	;	APOLIPOPROTEIN E3 (APO-E3), TRUNCATION MUTANT 165
1NFN	;	1.8	;	APOLIPOPROTEIN E3 (APOE3)
1OR2	;	2.5	;	APOLIPOPROTEIN E3 (APOE3) TRUNCATION MUTANT 165
1OR3	;	1.73	;	APOLIPOPROTEIN E3 (APOE3), TRIGONAL TRUNCATION MUTANT 165
1H7I	;	1.9	;	Apolipoprotein E3 22kD fragment LYS146GLN mutant
1EA8	;	1.95	;	Apolipoprotein E3 22kD fragment LYS146GLU mutant
1B68	;	2.0	;	APOLIPOPROTEIN E4 (APOE4), 22K FRAGMENT
1GS9	;	1.7	;	Apolipoprotein E4, 22k domain
5XHQ	;	2.587	;	Apolipoprotein N-acyl Transferase
5VRH	;	2.137	;	Apolipoprotein N-acyltransferase C387S active site mutant
7Y69	;	3.21	;	ApoSIDT2-pH5.5
7Y63	;	3.16	;	ApoSIDT2-pH7.4
7VHR	;	2.756	;	Apostichopus japonicus ferritin
7Y74	;	1.98	;	Apostichopus japonicus ferritin mutant-D129A/E132A
2IZC	;	1.4	;	APOSTREPTAVIDIN PH 2.0 I222 COMPLEX
2IZA	;	1.46	;	APOSTREPTAVIDIN PH 2.00 I4122 STRUCTURE
2IZD	;	1.6	;	APOSTREPTAVIDIN pH 3.0 I222 COMPLEX
2IZE	;	1.57	;	APOSTREPTAVIDIN PH 3.08 I222 COMPLEX
2IZB	;	1.2	;	APOSTREPTAVIDIN PH 3.12 I4122 STRUCTURE
2RTA	;	1.39	;	APOSTREPTAVIDIN, PH 2.97, SPACE GROUP I4122
2RTB	;	1.5	;	APOSTREPTAVIDIN, PH 3.32, SPACE GROUP I222
2RTC	;	1.5	;	APOSTREPTAVIDIN, PH 3.60, SPACE GROUP I222
1SLF	;	1.76	;	APOSTREPTAVIDIN, PH 5.6, TWO MOLECULES OF (SO4)2 BOUND AT THE BIOTIN BINDING SITE
5M0U	;	1.667	;	Apostructure structure of cAMP-dependent Protein Kinase (PKA) from CHO cells with a peptidic inhibitor fragment
2M6R	;		;	apo_YqcA
3N4U	;	2.2	;	app APH(2"")-IVa form II
1R4M	;	3.0	;	APPBP1-UBA3-NEDD8, an E1-ubiquitin-like protein complex
1R4N	;	3.6	;	APPBP1-UBA3-NEDD8, an E1-ubiquitin-like protein complex with ATP
3IUR	;	2.05	;	apPEP_D266Nx+H2H3 opened state
3IUN	;	2.4	;	apPEP_D622N opened state
3IUQ	;	2.1	;	apPEP_D622N+PP closed state
3MUN	;	2.1	;	APPEP_PEPCLOSE closed state
3MUO	;	1.95	;	APPEP_PEPCLOSE+PP closed state
3IVM	;	2.05	;	apPEP_WT+PP closed state
3IUL	;	1.95	;	apPEP_WT1 opened state
3IUJ	;	1.8	;	apPEP_WT2 opened state
3IUM	;	2.25	;	apPEP_WTX opened state
1CRY	;	3.0	;	APPLICATION OF AN AUTOMATIC MOLECULAR REPLACEMENT PROCEDURE TO CRYSTAL STRUCTURE OF CYTOCHROME C2 FROM RHODOPSEUDOMONAS VIRIDIS
6K64	;	1.933	;	Application of anti-helix antibodies in protein structure determination (8188-3LRH)
6K6A	;	1.94	;	Application of anti-helix antibodies in protein structure determination (8188cys-3LRHcys)
6K3M	;	1.8	;	Application of anti-helix antibodies in protein structure determination (8189-3LRH)
6K68	;	3.2	;	Application of anti-helix antibodies in protein structure determination (8420-3MNZ)
6K6B	;	2.06	;	Application of anti-helix antibodies in protein structure determination (8496-3LRH)
6K67	;	1.95	;	Application of anti-helix antibodies in protein structure determination (9011-3LRH)
6K65	;	1.65	;	Application of anti-helix antibodies in protein structure determination (9014-1P4B)
6K69	;	2.401	;	Application of anti-helix antibodies in protein structure determination (9213-3LRH)
1ULA	;	2.75	;	APPLICATION OF CRYSTALLOGRAPHIC AND MODELING METHODS IN THE DESIGN OF PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITORS
1ULB	;	2.75	;	APPLICATION OF CRYSTALLOGRAPHIC AND MODELING METHODS IN THE DESIGN OF PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITORS
5M4E	;	1.9	;	Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase
5M4H	;	2.0	;	Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase
5M4K	;	2.6	;	Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase
5M4M	;	2.4	;	Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase
5M4N	;	2.6	;	Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase
5M4P	;	2.3	;	Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase
3ED8	;	2.7	;	Application of the superfolder YFP bimolecular fluorescence complementation for studying protein-protein interactions in vitro
4NYI	;	2.9612	;	Approach for Targeting Ras with Small Molecules that Activate SOS-Mediated Nucleotide Exchange
4NYJ	;	2.8522	;	Approach for Targeting Ras with Small Molecules that Activate SOS-Mediated Nucleotide Exchange
4NYM	;	3.5529	;	Approach for Targeting Ras with Small Molecules that Activate SOS-Mediated Nucleotide Exchange
5A5Z	;	2.6	;	Approved Drugs Containing Thiols as Inhibitors of Metallo-beta- lactamases: Strategy To Combat Multidrug-Resistant Bacteria
6B3A	;	1.784	;	AprA Methyltransferase 1 - GNAT didomain in complex with Mn2+ and SAM
7UCH	;	2.18	;	AprA Methyltransferase 1 - GNAT in complex with Mn2+ , SAM, and Di-methyl-malonate
6B3B	;	1.85	;	AprA Methyltransferase 1 - GNAT in complex with Mn2+ , SAM, and Malonate
6B39	;	2.392	;	AprA Methyltransferase 1 - GNAT in complex with SAH
6D6Y	;	2.246	;	AprA Methyltransferase 2 - GNAT didomain in complex with SAH
8CGR	;	2.12	;	Apramycin bound to the 30S body
3KT9	;	1.65	;	Aprataxin FHA Domain
3U1J	;	1.8	;	Aprotinin bound to Dengue virus protease
1XNJ	;	1.98	;	APS complex of human PAPS synthetase 1
8A8H	;	1.77	;	APS kinase from Methanothermococcus thermolithotrophicus refined to 1.77 A
7E5P	;		;	Aptamer enhancing peroxidase activity of myoglobin
2JC5	;	1.5	;	Apurinic Apyrimidinic (AP) endonuclease (NApe) from Neisseria Meningitidis
1A9G	;		;	APURINIC DNA WITH BOUND WATER AT THE DAMAGED SITE AND N3 OF CYTOSINE, BETA FORM, NMR, 1 STRUCTURE
1A9H	;		;	APURINIC DNA WITH BOUND WATER AT THE DAMAGED SITE AND O2 OF CYTOSINE, BETA FORM, NMR, 1 STRUCTURE
1A9I	;		;	APYRIMIDINIC DNA WITH BOUND WATER AT THE DAMAGED SITE, ALPHA FORM, NMR, 1 STRUCTURE
1A9J	;		;	APYRIMIDINIC DNA WITH BOUND WATER AT THE DAMAGED SITE, BETA FORM, NMR, 1 STRUCTURE
8H0U	;		;	AQEE-30 in a DPC solution
8H0G	;		;	AQEE-30 in a HFIP solution
7STC	;	2.25	;	AQP5 T41H with Ni2+
8AMW	;	3.0	;	AQP7 dimer of tetramers_C1
8AMX	;	2.55	;	AQP7 dimer of tetramers_D4
8C9H	;	3.2	;	AQP7_inhibitor
4DZT	;	1.95	;	Aqualysin I: the crystal structure of a serine protease from an extreme thermophile, Thermus aquaticus YT-1
3LLQ	;	2.01	;	Aquaporin structure from plant pathogen Agrobacterium Tumerfaciens
1SOR	;	3.0	;	Aquaporin-0 membrane junctions reveal the structure of a closed water pore
1Z0Q	;		;	Aqueous Solution Structure of the Alzheimer's Disease Abeta Peptide (1-42)
1TZ7	;	2.15	;	Aquifex aeolicus amylomaltase
2R6R	;	1.7	;	Aquifex aeolicus FtsZ
2R75	;	1.402	;	Aquifex aeolicus FtsZ with 8-morpholino-GTP
2VF3	;	2.2	;	Aquifex aeolicus IspE in complex with ligand
1FX6	;	2.06	;	AQUIFEX AEOLICUS KDO8P SYNTHASE
1LRN	;	2.1	;	Aquifex aeolicus KDO8P synthase H185G mutant in complex with Cadmium
1LRO	;	1.8	;	Aquifex aeolicus KDO8P synthase H185G mutant in complex with PEP and Cadmium
1LRQ	;	1.8	;	Aquifex aeolicus KDO8P synthase H185G mutant in complex with PEP, A5P and Cadmium
1JCX	;	1.8	;	Aquifex aeolicus KDO8P synthase in complex with API and Cadmium
1FXP	;	1.8	;	AQUIFEX AEOLICUS KDO8P SYNTHASE IN COMPLEX WITH CADMIUM
1FY6	;	1.89	;	AQUIFEX AEOLICUS KDO8P SYNTHASE IN COMPLEX WITH CADMIUM AND A5P
1FWN	;	1.94	;	AQUIFEX AEOLICUS KDO8P SYNTHASE IN COMPLEX WITH PEP
1FXQ	;	1.8	;	AQUIFEX AEOLICUS KDO8P SYNTHASE IN COMPLEX WITH PEP AND A5P
1FWS	;	1.9	;	AQUIFEX AEOLICUS KDO8P SYNTHASE IN COMPLEX WITH PEP AND CADMIUM
1FWW	;	1.85	;	AQUIFEX AEOLICUS KDO8P SYNTHASE IN COMPLEX WITH PEP, A5P AND CADMIUM
1FWT	;	1.9	;	AQUIFEX AEOLICUS KDO8P SYNTHASE IN COMPLEX WITH PEP, E4P AND CADMIUM
1JCY	;	1.9	;	Aquifex aeolicus KDO8P synthase in complex with R5P, PEP and Cadmium
1PE1	;	1.74	;	Aquifex aeolicus KDO8PS in complex with cadmium and 2-PGA
1PCW	;	1.85	;	Aquifex aeolicus KDO8PS in complex with cadmium and APP, a bisubstrate inhibitor
2A2I	;	1.95	;	Aquifex aeolicus KDO8PS in complex with PEP, A5P, Zn2+
2A21	;	1.8	;	Aquifex aeolicus KDO8PS in complex with PEP, PO4, and Zn2+
1PCK	;	1.8	;	Aquifex aeolicus KDO8PS in complex with Z-methyl-PEP
1ZJI	;	2.25	;	Aquifex aeolicus KDO8PS R106G mutant in complex with 2PGA and R5P
6IH0	;	1.21	;	Aquifex aeolicus LpxC complex with ACHN-975
7A4F	;	3.5	;	Aquifex aeolicus lumazine synthase-derived nucleocapsid variant NC-1 (120-mer)
7A4G	;	4.2	;	Aquifex aeolicus lumazine synthase-derived nucleocapsid variant NC-1 (180-mer)
7A4H	;	4.5	;	Aquifex aeolicus lumazine synthase-derived nucleocapsid variant NC-2 (180-mer)
7A4I	;	7.04	;	Aquifex aeolicus lumazine synthase-derived nucleocapsid variant NC-3
7A4J	;	3.04	;	Aquifex aeolicus lumazine synthase-derived nucleocapsid variant NC-4
3SWG	;	1.81	;	AQUIFEX AEOLICUS MurA in complex with UDP-N-acetylmuramic acid and covalent adduct of PEP with Cys124
6LZI	;	1.69106	;	Aquifex aeolicus MutL ATPase domain complexed with ADP
6LZJ	;	1.72836	;	Aquifex aeolicus MutL ATPase domain complexed with AMPPCP
6LZK	;	3.1595	;	Aquifex aeolicus MutL ATPase domain with K252N mutation
8H1E	;	1.22	;	Aquifex aeolicus MutL endonuclease domain complexed with manganese ions
8H1F	;	1.22	;	Aquifex aeolicus MutL endonuclease domain complexed with zinc ions after soaking
5Z41	;	1.7	;	Aquifex aeolicus MutL endonuclease domain with a single zinc ion.
5Z42	;	1.3	;	Aquifex aeolicus MutL endonuclease domain with three zinc ions.
4NMN	;	3.301	;	Aquifex aeolicus replicative helicase (DnaB) complexed with ADP, at 3.3 resolution
8IEY	;	2.0	;	Aquifex aeolicus TsaD-TsaB
8IFX	;	2.0	;	Aquifex aeolicus TsaD-TsaB in complex with ADP
3NO0	;	1.3004	;	Aquifex aeolicus type IIA topoisomerase C-terminal domain
2XKI	;	1.3	;	Aquo-met structure of C.lacteus mini-Hb
4FWZ	;	1.9	;	Aquoferric CuB myoglobin (L29H F43H sperm whale myoglobin)
4FWX	;	1.9	;	Aquoferric F33Y CuB myoglobin (F33Y L29H F43H sperm whale myoglobin)
4F6B	;	1.64	;	Aquomet structure of His100Phe Cerebratulus lacteus mini-hemoglobin
4F6G	;	1.64	;	Aquomet Structure of His100Trp Cerebratulus lacteus mini-hemoglobin
1A6K	;	1.1	;	AQUOMET-MYOGLOBIN, ATOMIC RESOLUTION
2PIX	;	2.4	;	AR LBD with small molecule
2QPY	;	2.5	;	AR LBD with small molecule
3BTR	;	2.6	;	AR-NLS:Importin-alpha complex
2LOU	;		;	AR55 solubilised in DPC micelles
2LOV	;		;	AR55 solubilised in LPPG micelles
2LOT	;		;	AR55 solubilised in SDS micelles
7LXK	;		;	Ara h 1 leader sequence, Ara h 1.0101 (25-83) A25G
6AWV	;	2.55	;	Ara h 8.01 in complex with epicatechin
4G01	;	2.2	;	ARA7-GDP-Ca2+/VPS9a
2EFC	;	2.09	;	Ara7-GDP/AtVps9a
2EFH	;	2.1	;	Ara7-GDP/AtVps9a(D185N)
2EFE	;	2.08	;	Ara7-GDPNH2/AtVps9a
2EFD	;	3.0	;	Ara7/AtVps9a
8KA5	;	2.8	;	Arabidopsis AP endonuclease ARP complex with 20bp THF-containing DNA
8KA4	;	2.3	;	Arabidopsis AP endonuclease ARP complex with 21bp THF-containing DNA
8KA3	;	3.0	;	Arabidopsis AP endonuclease ARP complex with 22bp THF-containing DNA
6YPO	;	1.67	;	Arabidopsis aspartate transcarbamoylase bound to UMP
6YVB	;	1.826	;	Arabidopsis aspartate transcarbamoylase complex with carbamoyl phosphate
6YS6	;	1.55	;	Arabidopsis aspartate transcarbamoylase complex with PALA
6YSP	;	1.38	;	Arabidopsis aspartate transcarbamoylase complex with PALA and carbamoyl phosphate
6YY1	;	3.06	;	Arabidopsis aspartate transcarbamoylase in apo state
6YW9	;	1.68	;	Arabidopsis aspartate transcarbamoylase mutant F161A complex with PALA
6YWJ	;	2.4	;	Arabidopsis aspartate transcarbamoylase mutant F161A complex with UMP
7UX9	;	3.2	;	Arabidopsis DDM1 bound to nucleosome (H2A.W, H2B, H3.3, H4, with 147 bp DNA)
6J9B	;	1.9	;	Arabidopsis FUS3-DNA complex
7X8K	;	3.0	;	Arabidopsis GDP-D-mannose pyrophosphorylase (VTC1) structure (product-bound)
7X8J	;	2.798	;	Arabidopsis GDP-D-mannose pyrophosphorylase (VTC1) structure (unliganded)
6OMS	;	1.942	;	Arabidopsis GH3.12 with Chorismate
2EBI	;		;	Arabidopsis GT-1 DNA-binding domain with T133D phosphomimetic mutation
4QS9	;	2.103	;	Arabidopsis Hexokinase 1 (AtHXK1) mutant S177A structure in glucose-bound form
4QS7	;	2.001	;	Arabidopsis Hexokinase 1 (AtHXK1) structure in glucose-bound form
4QS8	;	1.798	;	Arabidopsis Hexokinase 1 (AtHXK1) structure in ligand-free form
3T4O	;	1.75	;	Arabidopsis histidine kinase 4 sensor domain in complex with dihydrozeatin
3T4S	;	1.6	;	Arabidopsis histidine kinase 4 sensor domain in complex with kinetin
3T4K	;	1.77	;	Arabidopsis histidine kinase 4 sensor domain in complex with N-benzyladenine
3T4J	;	1.65	;	Arabidopsis histidine kinase 4 sensor domain in complex with N-isopentenyl adenine
3T4T	;	1.7	;	Arabidopsis histidine kinase 4 sensor domain in complex with thiadiazuron
3T4L	;	1.53	;	Arabidopsis histidine kinase 4 sensor domain in complex with trans-zeatin
3T4Q	;	2.3	;	Arabidopsis histidine kinase 4 sensor domain in complex with trans-zeatin riboside (hydrolysed)
4FRZ	;	2.4	;	Arabidopsis KCBP motor domain dimerized via regulatory domain
6R2V	;	2.503	;	Arabidopsis NF-Y/CCAAT-box complex
6HPG	;	2.0	;	Arabidopsis OM64 TPR domain
6Q3Q	;	2.0	;	Arabidopsis OM64 TPR domain
7RQS	;	3.57	;	Arabidopsis RNA-dependent RNA polymerase 2
5Z9X	;	2.8	;	Arabidopsis SMALL RNA DEGRADING NUCLEASE 1 in complex with an RNA substrate
6U9H	;	3.8	;	Arabidopsis thaliana acetohydroxyacid synthase complex
6VZ8	;	3.45	;	Arabidopsis thaliana acetohydroxyacid synthase complex with valine bound
3E9Y	;	3.0	;	Arabidopsis thaliana acetohydroxyacid synthase in complex with monosulfuron
3EA4	;	2.8	;	Arabidopsis thaliana acetohydroxyacid synthase in complex with monosulfuron-ester
1W07	;	2.0	;	Arabidopsis thaliana acyl-CoA oxidase 1
8DAE	;	2.0	;	Arabidopsis thaliana bifunctional dihydrofolate reductase-thymidylate synthase
6XX6	;	1.8492	;	Arabidopsis thaliana Casein Kinase 2 (CK2) alpha-1 crystal form I
6XX8	;	1.8	;	Arabidopsis thaliana Casein Kinase 2 (CK2) alpha-1 crystal form II
6XX9	;	1.84	;	Arabidopsis thaliana Casein Kinase 2 (CK2) alpha-1 crystal form III
6XX7	;	2.4	;	Arabidopsis thaliana Casein Kinase 2 (CK2) alpha-1 crystal in complex with ANP
4BQE	;	1.7	;	Arabidopsis thaliana Cytosolic Alpha-1,4-glucan Phosphorylase (PHS2)
4BQF	;	2.35	;	Arabidopsis thaliana cytosolic alpha-1,4-glucan phosphorylase (PHS2) in complex with acarbose
4BQI	;	1.9	;	ARABIDOPSIS THALIANA cytosolic alpha-1,4-glucan phosphorylase (PHS2) in complex with maltotriose
6GIR	;	2.343	;	Arabidopsis thaliana cytosolic seryl-tRNA synthetase
6VVI	;	2.145	;	Arabidopsis thaliana dihydrodipicolinate synthase isoform 1 (DHDPS1)
6VVH	;	1.792	;	Arabidopsis thaliana dihydrodipicolinate synthase isoform 1 (DHDPS1) in complex with lysine
4OOP	;	1.5	;	Arabidopsis thaliana dUTPase with with magnesium and alpha,beta-imido-dUTP
3T34	;	2.405	;	Arabidopsis thaliana dynamin-related protein 1A (AtDRP1A) in prefission state
3T35	;	3.592	;	Arabidopsis thaliana dynamin-related protein 1A in postfission state
5KOR	;	2.2	;	Arabidopsis thaliana fucosyltransferase 1 (FUT1) in complex with GDP and a xylo-oligossacharide
5KOP	;	2.1	;	Arabidopsis thaliana fucosyltransferase 1 (FUT1) in its apo-form
7F3A	;	1.7	;	Arabidopsis thaliana GH1 beta-glucosidase AtBGlu42
6YEH	;	2.59	;	Arabidopsis thaliana glutamate dehydrogenase isoform 1 in apo form
6YEI	;	2.02	;	Arabidopsis thaliana glutamate dehydrogenase isoform 1 in complex with NAD
6EZY	;	2.35	;	ARABIDOPSIS THALIANA GSTF9, GSH AND GSOH BOUND
6F01	;	2.5	;	ARABIDOPSIS THALIANA GSTF9, GSO3 AND GSOH BOUND
6F05	;	2.2	;	ARABIDOPSIS THALIANA GSTF9, GSO3 BOUND
6EP7	;	1.947	;	ARABIDOPSIS THALIANA GSTU23, GSH bound
6EP6	;	1.592	;	ARABIDOPSIS THALIANA GSTU23, reduced
4NAI	;	1.5	;	Arabidopsis thaliana IspD apo
5MRQ	;	2.2	;	Arabidopsis thaliana IspD Asp262Ala Mutant
5MRN	;	2.0	;	Arabidopsis thaliana IspD Glu258Ala Mutant
5MRO	;	1.8	;	Arabidopsis thaliana IspD Glu258Ala mutant in complex with Azolopyrimidine (1)
5MRP	;	1.9	;	Arabidopsis thaliana IspD Glu258Ala mutant in complex with Azolopyrimidine (2)
5MRM	;	1.8	;	Arabidopsis thaliana IspD in complex with Isoxazole (4)
4NAK	;	1.8	;	Arabidopsis thaliana IspD in complex with pentabromo-pseudilin
4NAN	;	1.8	;	Arabidopsis thaliana IspD in complex with tetrabromo-pseudilin
4NAL	;	1.8	;	Arabidopsis thaliana IspD in complex with tribromodichloro-pseudilin
2IX4	;	1.95	;	Arabidopsis thaliana mitochondrial beta-ketoacyl ACP synthase hexanoic acid complex
1W0I	;	2.1	;	Arabidopsis thaliana Mitochondrial KAS
2WTB	;	2.5	;	Arabidopsis thaliana multifuctional protein, MFP2
6YZZ	;	1.79	;	Arabidopsis thaliana Naa50 in complex with AcCoA
6Z00	;	1.42	;	Arabidopsis thaliana Naa50 in complex with bisubstrate analogue CoA-Ac-MVNAL
5FT9	;	3.05	;	Arabidopsis thaliana nuclear protein-only RNase P 2 (PRORP2)
1PA2	;	1.45	;	ARABIDOPSIS THALIANA PEROXIDASE A2
1QO4	;	3.0	;	ARABIDOPSIS THALIANA PEROXIDASE A2 AT ROOM TEMPERATURE
1QGJ	;	1.9	;	ARABIDOPSIS THALIANA PEROXIDASE N
8OJZ	;	3.24781	;	Arabidopsis thaliana Phosphoenolpyruvate carboxylase 1 (PPC1) G678S mutant
8CJ5	;	3.00135	;	Arabidopsis thaliana Phosphoenolpyruvate carboxylase PPC1 A651V mutant with bound phosphate
8OJ9	;	3.24638	;	Arabidopsis thaliana Phosphoenolpyruvate carboxylase PPC1 free form
8OJE	;	3.1424	;	Arabidopsis thaliana Phosphoenolpyruvate carboxylase PPC1 in complex with L-malate
8CJ8	;	3.48992	;	Arabidopsis thaliana Phosphoenolpyruvate carboxylase PPC1 mutant A651V in complex with L-malate
8OJY	;	3.09894	;	Arabidopsis thaliana Phosphoenolpyruvate carboxylase PPC1 T778 mutant with bound malate
8OJQ	;	3.04938	;	Arabidopsis thaliana Phosphoenolpyruvate carboxylase PPC1 T778 mutant with bound phosphate
8OJF	;	3.03684	;	Arabidopsis thaliana Phosphoenolpyruvate carboxylase PPC1 with bound phosphate
5WP4	;	1.341	;	Arabidopsis thaliana phosphoethanolamine N-methyltransferase 1 (AtPMT1, XIOPTL) in complex with SAH and phosphocholine
5WP5	;	1.5	;	Arabidopsis thaliana phosphoethanolamine N-methyltransferase 2 (AtPMT2) in complex with SAH
5WMH	;	3.0	;	Arabidopsis thaliana prephenate aminotransferase
5WMK	;	1.398	;	Arabidopsis thaliana Prephenate Aminotransferase double mutant- T84V K169V
5WML	;	2.103	;	Arabidopsis thaliana Prephenate Aminotransferase mutant- K306A
5WMI	;	2.0	;	Arabidopsis thaliana Prephenate Aminotransferase mutant- T84V
7F2I	;	2.35	;	Arabidopsis thaliana protease-associated domain of vacuolar-sorting receptor 1 in complex with cruciferin 1 C-terminal pentapeptide RVAAA (pH6.5)
7F2D	;	2.45	;	Arabidopsis thaliana protease-associated domain of vacuolar-sorting receptor 1 in complex with cruciferin 1 C-terminal pentapeptide RVAAA (pH9)
5VJW	;	1.8	;	Arabidopsis thaliana Rhizobiales-like phosphatase 2 complexed with tungstate
1VOK	;	2.1	;	ARABIDOPSIS THALIANA TBP (DIMER)
6XZL	;	1.39	;	Arabidopsis UV-B photoreceptor UVR8 mutant D96N D107N
6XZM	;	2.10009	;	Arabidopsis UV-B photoreceptor UVR8 mutant D96N D107N W285A
6XZN	;	1.75	;	Arabidopsis UV-B photoreceptor UVR8 mutant G101S W285A
6X8D	;	1.0	;	Arabinose-bound structure of Marinomonas primoryensis PA14 carbohydrate-binding domain
8IF8	;	3.1	;	Arabinosyltransferase AftA
8IFE	;	2.57	;	Arbekacin-added human 80S ribosome
8IFC	;	2.9	;	Arbekacin-bound E.coli 70S ribosome in the PURE system
6HP3	;	2.7	;	ARBITRIUM PEPTIDE RECEPTOR FROM SPBETA PHAGE
6HP5	;	2.28	;	ARBITRIUM PEPTIDE RECEPTOR FROM SPBETA PHAGE
6HP7	;	2.2	;	ARBITRIUM PEPTIDE RECEPTOR FROM SPBETA PHAGE in complex with 43 mer DNA
6S7I	;	2.4	;	Arbitrium receptor from a Bacillus subtilis Katmira33 phage
6S7L	;	2.6	;	Arbitrium receptor from a Bacillus subtilis Katmira33 phage
7Q0N	;	2.5	;	Arbitrium receptor from Katmira phage
1BDV	;	2.8	;	ARC FV10 COCRYSTAL
1BAZ	;	1.9	;	ARC REPRESSOR MUTANT PHE10VAL
1B28	;		;	ARC REPRESSOR MYL MUTANT FROM SALMONELLA BACTERIOPHAGE P22
5LY5	;	2.0	;	Arcadin-1 from Pyrobaculum calidifontis
2LX0	;		;	Arced helix (ArcH) NMR structure of the reovirus p14 fusion-associated small transmembrane (FAST) protein transmembrane domain (TMD) in dodecyl phosphocholine (DPC) micelles
1AVB	;	1.9	;	ARCELIN-1 FROM PHASEOLUS VULGARIS L
1IOA	;	2.7	;	ARCELIN-5, A LECTIN-LIKE DEFENSE PROTEIN FROM PHASEOLUS VULGARIS
4LX9	;	1.98	;	Archaeal amino-terminal acetyltransferase (NAT) bound to acetyl coenzyme A
5D1O	;	2.648	;	Archaeal ATP-dependent RNA ligase - form 1
5D1P	;	2.199	;	Archaeal ATP-dependent RNA ligase - form 2
5MQZ	;	2.1	;	Archaeal branched-chain amino acid aminotransferase from Archaeoglobus fulgidus; holoform
2OX1	;	2.33	;	Archaeal Dehydroquinase
2ZJ2	;	2.4	;	Archaeal DNA helicase Hjm apo state in form 1
2ZJ8	;	2.0	;	Archaeal DNA helicase Hjm apo state in form 2
2ZJ5	;	2.4	;	Archaeal DNA helicase Hjm complexed with ADP in form 1
2ZJA	;	2.7	;	Archaeal DNA helicase Hjm complexed with AMPPCP in form 2
7RPW	;	4.38	;	Archaeal DNA ligase and heterotrimeric PCNA in complex with adenylated DNA
7RPX	;	4.2	;	Archaeal DNA ligase and heterotrimeric PCNA in complex with end-joined DNA
7RPO	;	4.16	;	Archaeal DNA ligase and heterotrimeric PCNA in complex with non-ligatable DNA
5N41	;	1.351	;	Archaeal DNA polymerase holoenzyme - SSO6202 at 1.35 Ang resolution
4BA1	;	1.8	;	Archaeal exosome (Rrp4-Rrp41(D182A)-Rrp42) bound to inorganic phosphate
4BA2	;	2.501	;	Archaeal exosome (Rrp4-Rrp41(D182A)-Rrp42) bound to inorganic phosphate
2BA0	;	2.7	;	Archaeal exosome core
2BA1	;	2.7	;	Archaeal exosome core
1OK4	;	2.1	;	Archaeal fructose 1,6-bisphosphate aldolase covalently bound to the substrate dihydroxyacetone phosphate
1JT8	;		;	ARCHAEAL INITIATION FACTOR-1A, AIF-1A
3E54	;	2.5	;	Archaeal Intron-encoded Homing Endonuclease I-Vdi141I Complexed With DNA
3AII	;	1.65	;	Archaeal non-discriminating glutamyl-tRNA synthetase from Methanothermobacter thermautotrophicus
7FI3	;	2.3	;	Archaeal oligopeptide permease A (OppA) from Thermococcus kodakaraensis in complex with an endogenous pentapeptide
7E9S	;	2.7	;	Archaeal oligosaccharyltransferase AglB from Archaeoglobus fulgidus in complex with an inhibitory peptide and a dolichol-phosphate
3VMF	;	2.3	;	Archaeal protein
2PMZ	;	3.4	;	Archaeal RNA polymerase from Sulfolobus solfataricus
4V8S	;	4.323	;	Archaeal RNAP-DNA binary complex at 4.32Ang
8HNP	;	3.39	;	Archaeal transcription factor Mutant
8HNO	;	2.84	;	Archaeal transcription factor Wild type
3ODM	;	2.95	;	Archaeal-type phosphoenolpyruvate carboxylase
5F4H	;	2.699	;	Archael RuvB-like Holiday junction helicase
5YWW	;	2.33	;	Archael RuvB-like Holiday junction helicase
4II7	;	3.59	;	Archaellum Assembly ATPase FlaI
4IHQ	;	2.0	;	Archaellum Assembly ATPase FlaI bound to ADP
5TUG	;	2.47	;	Archaellum periplasmic stator protein complex FlaF and FlaG from Sulfolobus acidocaldarius
6PBK	;	2.805	;	Archaellum periplasmic stator protein complex FlaF and FlaG from Sulfolobus acidocaldarius
5TUH	;	1.929	;	Archaellum periplasmic stator protein FlaG from Sulfolobus acidocaldarius
8QG0	;	3.43	;	Archaeoglobus fulgidus AfAgo complex with AfAgo-N protein (fAfAgo) bound with 17 nt RNA guide and 17 nt DNA target
8PVV	;	2.81	;	Archaeoglobus fulgidus AfAgo complex with AfAgo-N protein (fAfAgo) bound with 30 nt RNA guide and 51 nt DNA target
3NE2	;	3.0	;	Archaeoglobus fulgidus aquaporin
6XU0	;	1.9	;	Archaeoglobus fulgidus Argonaute protein with DNA oligoduplex 5'-pATCGTGGCCACGAT
6XUP	;	1.9	;	Archaeoglobus fulgidus Argonaute protein with DNA oligoduplex 5'-pATCGTGGCCACGAT
3M7N	;	2.4	;	archaeoglobus fulgidus exosome with RNA bound to the active site
3M85	;	3.0	;	Archaeoglobus fulgidus exosome y70a with RNA bound to the active site
1I0S	;	1.65	;	ARCHAEOGLOBUS FULGIDUS FERRIC REDUCTASE COMPLEX WITH NADP+
3O8W	;	2.28	;	Archaeoglobus fulgidus GlnK1
1GL9	;	3.2	;	Archaeoglobus fulgidus reverse gyrase complexed with ADPNP
4XHM	;	1.95	;	Archaeoglobus fulgidus thioredoxin 3 M60H
7BGS	;	2.5	;	Archeal holliday junction resolvase from Thermus thermophilus phage 15-6
7BNX	;	2.551	;	Archeal holliday junction resolvase from Thermus thermophilus phage 15-6
4AF1	;	2.0	;	Archeal Release Factor aRF1
7Q1V	;	6.18	;	Arches protomer (trimer of TrwG/VirB8peri) structure from the fully-assembled R388 type IV secretion system determined by cryo-EM.
4YX6	;	1.86	;	Architectural hierarchy of trans-acting enoyl reductases from polyunsaturated fatty acid and trans-AT polyketide synthases
3JC9	;		;	Architectural model of the type IVa pilus machine in a non-piliated state
3JC8	;		;	Architectural model of the type IVa pilus machine in a piliated state
6O1L	;	3.37	;	Architectural principles for Hfq/Crc-mediated regulation of gene expression Hfq-Crc-amiE 2:3:2 complex
6O1K	;	3.13	;	Architectural principles for Hfq/Crc-mediated regulation of gene expression. Hfq-Crc-amiE 2:2:2 complex (core complex)
6O1M	;	3.15	;	Architectural principles for Hfq/Crc-mediated regulation of gene expression. Hfq-Crc-amiE 2:4:2 complex
6A2H	;	2.3	;	Architectural roles of Cren7 in folding crenarchaeal chromatin filament
6A2I	;	2.4	;	Architectural roles of Cren7 in folding crenarchaeal chromatin filament
4BXO	;	2.15	;	Architecture and DNA recognition elements of the Fanconi anemia FANCM- FAAP24 complex
6NJL	;	6.7	;	Architecture and subunit arrangement of native AMPA receptors
6NJM	;	6.5	;	Architecture and subunit arrangement of native AMPA receptors
6NJN	;	6.5	;	Architecture and subunit arrangement of native AMPA receptors
3BG0	;	3.15	;	Architecture of a Coat for the Nuclear Pore Membrane
3BG1	;	3.0	;	Architecture of a Coat for the Nuclear Pore Membrane
8CJH	;	2.982	;	Architecture of a PKS-NRPS hybrid megaenzyme involved in the biosynthesis of the genotoxin colibactin
7CXM	;	2.9	;	Architecture of a SARS-CoV-2 mini replication and transcription complex
7CXN	;	3.84	;	Architecture of a SARS-CoV-2 mini replication and transcription complex
7BRM	;	3.6	;	Architecture of curli complex
5KK2	;	7.3	;	Architecture of fully occupied GluA2 AMPA receptor - TARP complex elucidated by single particle cryo-electron microscopy
6B19	;	4.5	;	Architecture of HIV-1 reverse transcriptase initiation complex core
5FLC	;	5.9	;	Architecture of human mTOR Complex 1 - 5.9 Angstrom reconstruction
5J7Y	;	6.7	;	Architecture of loose respirasome
2CF2	;	4.3	;	Architecture of mammalian fatty acid synthase
5GPN	;	5.4	;	Architecture of mammalian respirasome
5J8K	;	7.8	;	Architecture of supercomplex I-III2
8AFZ	;	10.0	;	Architecture of the ESCPE-1 membrane coat
3SOH	;	3.5	;	Architecture of the Flagellar Rotor
5KZ5	;	14.3	;	Architecture of the Human Mitochondrial Iron-Sulfur Cluster Assembly Machinery: the Complex Formed by the Iron Donor, the Sulfur Donor, and the Scaffold
7WJI	;	4.5	;	Architecture of the human NALCN channelosome
3RJ1	;	4.3	;	Architecture of the Mediator Head module
8F5D	;	2.56	;	Architecture of the MurE-MurF ligase bacterial cell wall biosynthesis complex
1S5L	;	3.5	;	Architecture of the photosynthetic oxygen evolving center
4V1M	;	6.6	;	Architecture of the RNA polymerase II-Mediator core transcription initiation complex
4V1N	;	7.8	;	Architecture of the RNA polymerase II-Mediator core transcription initiation complex
4V1O	;	9.7	;	Architecture of the RNA polymerase II-Mediator core transcription initiation complex
2CDH	;	4.2	;	ARCHITECTURE OF THE THERMOMYCES LANUGINOSUS FUNGAL FATTY ACID SYNTHASE AT 5 ANGSTROM RESOLUTION.
5T0V	;	17.5	;	Architecture of the Yeast Mitochondrial Iron-Sulfur Cluster Assembly Machinery: the Sub-Complex Formed by the Iron Donor, Yfh1, and the Scaffold, Isu1
5TZS	;	5.1	;	Architecture of the yeast small subunit processome
5J4Z	;	5.8	;	Architecture of tight respirasome
4B6W	;	2.35	;	Architecture of Trypanosoma brucei Tubulin-Binding cofactor B
1GLN	;	2.5	;	ARCHITECTURES OF CLASS-DEFINING AND SPECIFIC DOMAINS OF GLUTAMYL-TRNA SYNTHETASE
5JHQ	;	3.2	;	ARCs 1-3 of human Tankyrase-1 bound to a peptide derived from IRAP
2WJ9	;	1.62	;	ArdB
1JQU	;	2.6	;	Are Carboxy Terminii of Helices Coded by the Local Sequence or by Tertiary Structure Contacts
1LLH	;	1.8	;	ARE CARBOXY TERMINII OF HELICES CODED BY THE LOCAL SEQUENCE OR BY TERTIARY STRUCTURE CONTACTS
8BUU	;	2.9	;	ARE-ABCF VmlR2 bound to a 70S ribosome
4C0A	;	3.3	;	Arf1(Delta1-17)in complex with BRAG2 Sec7-PH domain
1S9D	;	1.8	;	ARF1[DELTA 1-17]-GDP-MG IN COMPLEX WITH BREFELDIN A AND A SEC7 DOMAIN
1R8S	;	1.46	;	ARF1[DELTA1-17]-GDP IN COMPLEX WITH A SEC7 DOMAIN CARRYING THE MUTATION OF THE CATALYTIC GLUTAMATE TO LYSINE
6L5K	;	2.91	;	ARF5 Aux/IAA17 Complex
7JSS	;	3.7	;	ArfB Rescue of a 70S Ribosome stalled on truncated mRNA with a partial A-site codon (+2-II)
7JSW	;	3.8	;	ArfB Rescue of a 70S Ribosome stalled on truncated mRNA with a partial A-site codon (+2-III)
7JSZ	;	3.7	;	ArfB Rescue of a 70S Ribosome stalled on truncated mRNA with a partial A-site codon (+2-IV)
2OLM	;	1.48	;	ArfGap domain of HIV-1 Rev binding protein
1ARJ	;		;	ARG-BOUND TAR RNA, NMR
2PLZ	;	1.36	;	Arg-modified human beta-defensin 1 (HBD1)
1U85	;		;	ARG326-TRP mutant of the third zinc finger of BKLF
2ONN	;	2.75	;	Arg475Gln Mutant of Human Mitochondrial Aldehyde Dehydrogenase, Apo form
2ONP	;	2.0	;	Arg475Gln Mutant of Human Mitochondrial Aldehyde Dehydrogenase, complexed with NAD+
2ONO	;	2.15	;	Arg475Gln Mutant of Mitochondrial Aldehyde Dehydrogenase, apo form, pseudo-merohedrally twinned
6CRT	;	1.995	;	Arg65Gln Mutagenic E.coli PCK
1G3Y	;	2.8	;	ARG80ALA DTXR
3ZOP	;	1.61	;	Arg90Cit chorismate mutase of Bacillus subtilis at 1.6 A resolution
3ZP4	;	1.798	;	Arg90Cit chorismate mutase of Bacillus subtilis in complex with a transition state analog
3ZP7	;	1.698	;	Arg90Cit chorismate mutase of Bacillus subtilis in complex with chorismate and prephenate
5YGE	;	2.039	;	ArgA complexed with AceCoA and glutamate
8D27	;	2.25	;	Arginase Domain of Ornithine Decarboxylase/Arginase from Fusobacterium nucleatum
6VSU	;	2.25	;	Arginase from Arabidopsis thaliana in Complex with Ornithine
3CEV	;	2.4	;	ARGINASE FROM BACILLUS CALDEVELOX, COMPLEXED WITH L-ARGININE
5CEV	;	2.5	;	ARGINASE FROM BACILLUS CALDEVELOX, L-LYSINE COMPLEX
4CEV	;	2.7	;	ARGINASE FROM BACILLUS CALDEVELOX, L-ORNITHINE COMPLEX
2CEV	;	2.15	;	ARGINASE FROM BACILLUS CALDEVELOX, NATIVE STRUCTURE AT PH 8.5
1CEV	;	2.4	;	ARGINASE FROM BACILLUS CALDOVELOX, NATIVE STRUCTURE AT PH 5.6
6VSS	;	1.93	;	Arginase from Medicago truncatula
6VST	;	2.12	;	Arginase from Medicago truncatula in complex with ornithine
2ZAV	;	1.7	;	Arginase I (homo sapiens): native and unliganded structure at 1.70 A resolution
1ZPE	;	1.7	;	Arginase I covalently modified with butylamine at Q19C
1ZPG	;	1.9	;	Arginase I covalently modified with propylamine at Q19C
1T5F	;	2.2	;	arginase I-AOH complex
2A0M	;	1.603	;	Arginase superfamily protein from Trypanosoma cruzi
1T4P	;	2.6	;	Arginase-dehydro-ABH complex
1T4R	;	2.6	;	arginase-descarboxy-nor-NOHA complex
1T4T	;	2.2	;	arginase-dinor-NOHA complex
1T5G	;	2.4	;	Arginase-F2-L-Arginine complex
1T4S	;	2.8	;	arginase-L-valine complex
1NND	;	2.3	;	Arginine 116 is Essential for Nucleic Acid Recognition by the Fingers Domain of Moloney Murine Leukemia Virus Reverse Transcriptase
1ACM	;	2.8	;	ARGININE 54 IN THE ACTIVE SITE OF ESCHERICHIA COLI ASPARTATE TRANSCARBAMOYLASE IS CRITICAL FOR CATALYSIS: A SITE-SPECIFIC MUTAGENESIS, NMR AND X-RAY CRYSTALLOGRAPHY STUDY
6OWD	;	1.5	;	Arginine Containing Reengineered Coiled-Coiled Dimer to Examine the Impact of Proximal Cation Identity on Hydrophobically-Driven Assembly
2BUF	;	2.95	;	Arginine Feed-Back Inhibitable Acetylglutamate Kinase
6Y12	;	1.7	;	Arginine hydroxylase VioC in complex with (3S)-OH-Arg, succinate and Fe after oxygen exposure using FT-SSX methods
6Y0N	;	1.86	;	Arginine hydroxylase VioC in complex with Arg, 2OG and Fe under anaerobic environment using FT-SSX methods
7VCJ	;	1.75	;	Arginine kinase H227A from Daphnia magna
1XIM	;	2.2	;	ARGININE RESIDUES AS STABILIZING ELEMENTS IN PROTEINS
2XIM	;	2.3	;	ARGININE RESIDUES AS STABILIZING ELEMENTS IN PROTEINS
3XIM	;	2.3	;	ARGININE RESIDUES AS STABILIZING ELEMENTS IN PROTEINS
5I2C	;	1.801	;	Arginine-bound CASTOR1 from Homo sapiens
4IFK	;	2.012	;	Arginines 51 and 239* from a Neighboring Subunit are Essential for Catalysis in a Zinc-dependent Decarboxylase
6IEM	;	2.2	;	Argininosuccinate lyase from Mycobacterium tuberculosis
5T7B	;	2.529	;	Argonaute-2 - 5'-(E)-vinylphosphonate 2'-O-methyl-uridine modified mrTTR guide RNA complex
3VPC	;	1.87	;	ArgX from Sulfolobus tokodaii complexed with ADP
3VPB	;	1.8	;	ArgX from Sulfolobus tokodaii complexed with LysW/Glu/ADP/Mg/Zn/Sulfate
7P6D	;	3.3	;	Argyrophilic grain disease type 1 tau filament
7P6E	;	3.4	;	Argyrophilic grain disease type 2 tau filament
1GV7	;	2.1	;	ARH-I, an angiogenin/RNase A chimera
1UN5	;	2.6	;	ARH-II, AN ANGIOGENIN/RNASE A CHIMERA
2P0H	;	1.9	;	ArhGAP9 PH domain in complex with Ins(1,3,4)P3
2P0F	;	1.91	;	ArhGAP9 PH domain in complex with Ins(1,3,5)P3
2P0D	;	1.811	;	ArhGAP9 PH domain in complex with Ins(1,4,5)P3
7G99	;	1.78	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102102-001
7G9A	;	2.583	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102113-001
7G9B	;	2.553	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102116-001
7G9C	;	2.686	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102141-001
7G9D	;	2.659	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102179-001
7G9E	;	2.151	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102197-001
7G9F	;	1.935	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102209-001
7G9G	;	2.079	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102236-001
7G9H	;	2.746	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102245-001
7G9I	;	2.202	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102253-001
7G9J	;	1.97	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102281-001
7G8A	;	1.5	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z100642432
7G8B	;	1.42	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z100643660
7G8C	;	2.176	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1037511924
7G80	;	1.671	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1041785508
7G8D	;	1.937	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z104474228
7G81	;	1.51	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z104474512
7G8E	;	1.79	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z104479710
7G8F	;	1.42	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1079168976
7G82	;	1.409	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1079512010
7G83	;	1.31	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z108545814
7G84	;	1.811	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1102357527
7G85	;	1.735	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z111529496
7G8G	;	1.92	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z111529496
7G86	;	1.699	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1137725943
7G87	;	2.053	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1148165337
7G88	;	1.869	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1148747945
7G89	;	1.901	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1192341021
7G8H	;	1.67	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1198180782
7G8I	;	2.468	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1198316457
7G96	;	2.3	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1203730981
7G8J	;	1.986	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1216861874
7G8K	;	1.491	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1217131798
7G8L	;	1.6	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1251207602
7G8M	;	2.029	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1255459547
7G8N	;	2.32	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1262549981
7G8O	;	1.579	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1267800292
7G8P	;	2.209	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1269184613
7G8Q	;	1.561	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1269220427
7G8R	;	1.44	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1270087714
7G8S	;	1.6	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1270393711
7G8T	;	1.385	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1273312142
7G8U	;	2.44	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z131833926
7G8V	;	1.451	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z133716556
7G8W	;	1.939	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1416193393
7G8X	;	1.711	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1416571195
7G8Y	;	1.75	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1449748885
7G8Z	;	1.509	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1493056027
7G90	;	1.911	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1509195674
7G91	;	2.292	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1509257513
7G92	;	1.872	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1545313172
7G93	;	1.693	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1565771450
7G94	;	1.47	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1575337975
7G95	;	1.551	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z165170770
7G98	;	2.878	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z4605084898
7G97	;	2.3	;	ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z57899718
7E2Z	;	3.1	;	Aripiprazole-bound serotonin 1A (5-HT1A) receptor-Gi protein complex
1DGP	;	2.8	;	ARISTOLOCHENE SYNTHASE FARNESOL COMPLEX
2OA6	;	2.15	;	Aristolochene synthase from Aspergillus terreus complexed with pyrophosphate
7BDX	;	2.6	;	Armadillo domain of HSF2BP in complex with BRCA2 peptide
7TD6	;	3.0	;	aRML prion fibril
4LPZ	;	3.15	;	ARNT transcription factor/coactivator complex
4PKY	;	3.2	;	ARNT/HIF transcription factor/coactivator complex
5EWP	;	1.8	;	ARO (armadillo repeats only protein) from Plasmodium falciparum
1AY8	;	2.3	;	AROMATIC AMINO ACID AMINOTRANSFERASE COMPLEX WITH 3-PHENYLPROPIONATE
1AY5	;	2.5	;	AROMATIC AMINO ACID AMINOTRANSFERASE COMPLEX WITH MALEATE
2AY3	;	2.4	;	AROMATIC AMINO ACID AMINOTRANSFERASE WITH 3-(3,4-DIMETHOXYPHENYL)PROPIONIC ACID
2AY4	;	2.2	;	AROMATIC AMINO ACID AMINOTRANSFERASE WITH 3-(P-TOLYL)PROPIONIC ACID
2AY6	;	2.2	;	AROMATIC AMINO ACID AMINOTRANSFERASE WITH 3-INDOLEBUTYRIC ACID
2AY5	;	2.4	;	AROMATIC AMINO ACID AMINOTRANSFERASE WITH 3-INDOLEPROPIONIC ACID
2AY8	;	2.2	;	AROMATIC AMINO ACID AMINOTRANSFERASE WITH 4-(2-THIENYL)BUTYRIC ACID
2AY1	;	2.2	;	AROMATIC AMINO ACID AMINOTRANSFERASE WITH 4-AMINOHYDROCINNAMIC ACID
2AY7	;	2.4	;	AROMATIC AMINO ACID AMINOTRANSFERASE WITH 4-PHENYLBUTYRIC ACID
2AY9	;	2.5	;	AROMATIC AMINO ACID AMINOTRANSFERASE WITH 5-PHENYLVALERIC ACID
2AY2	;	2.4	;	AROMATIC AMINO ACID AMINOTRANSFERASE WITH CYCLOHEXANE PROPIONIC ACID
1AY4	;	2.33	;	AROMATIC AMINO ACID AMINOTRANSFERASE WITHOUT SUBSTRATE
6S8W	;	2.4	;	Aromatic aminotransferase AroH (Aro8) form Aspergillus fumigatus in complex with PLP (internal aldimine)
6M78	;		;	Aromatic interactions drive the coupled folding and binding of the intrinsically disordered Sesbania mosaic virus VPg protein
6LXF	;		;	Aromatic interactions drive the coupled folding and binding of the intrinsically disordered Sesbania mosaic virus VPg protein.
4BTL	;	2.5	;	Aromatic interactions in acetylcholinesterase-inhibitor complexes
8UXW	;	2.7	;	Arp2/3 branch junction complex, ADP state
8UXX	;	3.2	;	Arp2/3 branch junction complex, BeFx state
3A4J	;	1.25	;	arPTE (K185R/D208G/N265D/T274N)
6Z5J	;	8.0	;	Arrangement of the matrix protein M1 in influenza A/Hong Kong/1/1968 VLPs (HA,NA,M1,M2)
3PO2	;	3.3	;	Arrested RNA Polymerase II elongation complex
3PO3	;	3.3	;	Arrested RNA Polymerase II reactivation intermediate
4BXX	;	3.28	;	Arrested RNA polymerase II-Bye1 complex
1AYR	;	3.3	;	ARRESTIN FROM BOVINE ROD OUTER SEGMENTS
1CF1	;	2.8	;	ARRESTIN FROM BOVINE ROD OUTER SEGMENTS
1VQX	;		;	ARRESTIN-BOUND NMR STRUCTURES OF THE PHOSPHORYLATED CARBOXY-TERMINAL DOMAIN OF RHODOPSIN, REFINED
1RXE	;	1.7	;	ArsC complexed with MNB
2FXI	;	1.8	;	Arsenate reductase (ArsC from pI258) C10S/C15A double mutant with sulfate in its active site
8P6M	;	1.65	;	Arsenate reductase (ArsC2) from Deinococcus indicus
8P5N	;	1.5	;	Arsenate reductase (ArsC2) from Deinococcus indicus, co-crystallized with arsenate
1JZW	;	1.76	;	Arsenate Reductase + Sodium Arsenate From E. coli
1SD9	;	1.65	;	ARSENATE REDUCTASE C12S MUTANT +0.4M ARSENATE FROM E. COLI
1S3C	;	1.25	;	ARSENATE REDUCTASE C12S MUTANT FROM E. COLI
1I9D	;	1.65	;	ARSENATE REDUCTASE FROM E. COLI
3F0I	;	1.88	;	Arsenate reductase from Vibrio cholerae.
1SK2	;	1.54	;	ARSENATE REDUCTASE R60A MUTANT +0.4M ARSENATE FROM E. COLI
1SK0	;	1.8	;	ARSENATE REDUCTASE R60A MUTANT +0.4M ARSENITE FROM E. COLI
1S3D	;	1.54	;	ARSENATE REDUCTASE R60A MUTANT FROM E. COLI
1SK1	;	1.55	;	ARSENATE REDUCTASE R60K MUTANT +0.4M ARSENATE FROM E. COLI
1SJZ	;	1.8	;	ARSENATE REDUCTASE R60K MUTANT +0.4M ARSENITE FROM E. COLI
1SD8	;	1.59	;	ARSENATE REDUCTASE R60K MUTANT FROM E. COLI
1J9B	;	1.26	;	ARSENATE REDUCTASE+0.4M ARSENITE FROM E. COLI
7DHY	;	2.15	;	Arsenic-bound p53 DNA-binding domain mutant G245S
7DHZ	;	1.74	;	Arsenic-bound p53 DNA-binding domain mutant R249S
7V97	;	2.02	;	Arsenic-bound p53 DNA-binding domain mutant V272M
5NQD	;	2.2	;	Arsenite oxidase AioAB from Rhizobium sp. str. NT-26 mutant AioBF108A
3ENZ	;	2.03	;	Arsenolytic structure of Plasmodium falciparum purine nucleoside phosphorylase with hypoxanthine, ribose and arsenate ion
7PLE	;	2.6	;	ArsH of Paracoccus denitrificans
4FSD	;	1.75	;	ArsM arsenic(III) S-adenosylmethionine methyltransferase with As(III)
4FR0	;	2.75	;	ArsM arsenic(III) S-adenosylmethionine methyltransferase with SAM
4RSR	;	2.25	;	ArsM arsenic(III) S-adenosylmethionine methyltransferase with trivalent phenyl arsencial derivative-Roxarsone
2K4J	;		;	ArsR DNA Binding Domain
2OQG	;	1.54	;	ArsR-like Transcriptional Regulator from Rhodococcus sp. RHA1
5AWP	;	2.0	;	Arthrobacter globiformis T6 isomalto-dextranase complexed with isomaltose
5AWO	;	1.44	;	Arthrobacter globiformis T6 isomalto-dextranse
5AWQ	;	1.48	;	Arthrobacter globiformis T6 isomalto-dextranse complexed with panose
8ECI	;	4.0	;	Arthrobacter phage Bridgette
1BQX	;		;	ARTIFICIAL FE8S8 FERREDOXIN: THE D13C VARIANT OF BACILLUS SCHLEGELII FE7S8 FERREDOXIN
1BWE	;		;	ARTIFICIAL FE8S8 FERREDOXIN: THE D13C VARIANT OF BACILLUS SCHLEGELII FE7S8 FERREDOXIN
6S9A	;	1.86	;	Artificial GTPase-BSE dimer of human Dynamin1
5CMU	;	2.113	;	Artificial HIV fusion inhibitor AP1 fused to the C-terminus of gp41 NHR
5CN0	;	1.901	;	Artificial HIV fusion inhibitor AP2 fused to the C-terminus of gp41 NHR
5CMZ	;	2.574	;	Artificial HIV fusion inhibitor AP3 fused to the C-terminus of gp41 NHR
6ESS	;	1.91	;	Artificial imine reductase mutant S112A-N118P-K121A-S122M
6ESU	;	1.78	;	Artificial imine reductase mutant S112A-N118P-K121A-S122M
6UI0	;	1.4	;	Artificial Iron Proteins: Modelling the Active Sites in Non-Heme Dioxygenases
6UIU	;	1.35	;	Artificial Iron Proteins: Modelling the Active Sites in Non-Heme Dioxygenases
6UIY	;	1.47	;	Artificial Iron Proteins: Modelling the Active Sites in Non-Heme Dioxygenases
6UIZ	;	1.85	;	Artificial Iron Proteins: Modelling the Active Sites in Non-Heme Dioxygenases
6US6	;	1.5	;	Artificial Iron Proteins: Modelling the Active Sites in Non-Heme Dioxygenases
5Z75	;	2.1	;	Artificial L-threonine 3-dehydrogenase designed by ancestral sequence reconstruction.
5Z76	;	2.8	;	Artificial L-threonine 3-dehydrogenase designed by full consensus design
6AUO	;	1.7	;	Artificial Metalloproteins Containing a Co4O4 Active Site - 2xm-S112F
6AUH	;	1.6	;	Artificial Metalloproteins Containing a Co4O4 Active Site - 2xm-S112Y-a
6AUE	;	1.36	;	Artificial Metalloproteins Containing a Co4O4 Active Site - 2xm-S112Y-b
6AUL	;	1.36	;	Artificial Metalloproteins Containing a Co4O4 Active Site - 2xm-S112Y-b
6AUC	;	1.46	;	Artificial metalloproteins containing a Co4O4 active site - 2xm-Sav
6VO9	;	1.5	;	Artificial Metalloproteins with Dinuclear Iron Centers
6VOB	;	1.7	;	Artificial Metalloproteins with Dinuclear Iron Centers
6VOZ	;	1.3	;	Artificial Metalloproteins with Dinuclear Iron Centers
6VP1	;	1.45	;	Artificial Metalloproteins with Dinuclear Iron Centers
6VP2	;	1.8	;	Artificial Metalloproteins with Dinuclear Iron Centers
6VP3	;	1.65	;	Artificial Metalloproteins with Dinuclear Iron Centers
7KBY	;	1.7	;	Artificial Metalloproteins with Dinuclear Iron Centers
7KBZ	;	1.9	;	Artificial Metalloproteins with Dinuclear Iron Centers
7KNL	;	1.35	;	Artificial Metalloproteins with Dinuclear Iron Centers
1A3O	;	1.8	;	ARTIFICIAL MUTANT (ALPHA Y42H) OF DEOXY HEMOGLOBIN
8P5Y	;	1.88	;	Artificial transfer hydrogenase with a Mn-12 cofactor and Streptavidin S112Y-K121M mutant
8P5Z	;	1.56	;	Artificial transfer hydrogenase with a Mn-5 cofactor and Streptavidin S112Y-K121M mutant
3PK2	;	1.9	;	Artificial Transfer Hydrogenases for the Enantioselective Reduction of Cyclic Imines
7ZNW	;	2.09	;	Artificial Unspecific Peroxygenase expressed in Escherichia coli at 2.09 Angstrom resolution
7ZNV	;	1.21	;	Artificial Unspecific Peroxygenase expressed in Pichia pastoris at 1.21 Angstrom resolution
7ZNM	;	2.01	;	Artificial Unspecific Peroxygenase expressed in Pichia pastoris at 2.01 Angstrom resolution
6ZVL	;	1.3	;	ARUK3000263 complex with Notum
7QVZ	;	1.47	;	ARUK3001043_Notum
4V7F	;	8.7	;	Arx1 pre-60S particle.
1N95	;	2.3	;	Aryl Tetrahydrophyridine Inhbitors of Farnesyltranferase: Glycine, Phenylalanine and Histidine Derivatives
1N94	;	3.5	;	Aryl Tetrahydropyridine Inhbitors of Farnesyltransferase: Glycine, Phenylalanine and Histidine Derivates
1E2T	;	2.8	;	Arylamine N-acetyltransferase (NAT) from Salmonella typhimurium
1W6F	;	2.1	;	Arylamine N-acetyltransferase from Mycobacterium smegmatis with the anti-tubercular drug isoniazid bound in the active site.
1HDH	;	1.3	;	Arylsulfatase from Pseudomonas aeruginosa
5EG5	;	1.97	;	As (III) S-adenosylmethyltransferase cysteine mutant C72A bound Phenylarsine oxide (PhAs(III) in the arsenic binding site
4TZP	;	8.503	;	As Grown, Untreated Co-crystals of the Ternary Complex Containing a T-box Stem I RNA, its cognate tRNAGly, and B. subtilis YbxF protein
7QXK	;	1.35	;	As isolated MSOX movie series dataset 1 (0.4 MGy) of the copper nitrite reductase from Bradyrhizobium sp. ORS 375 (two-domain)
7QYC	;	1.35	;	As isolated MSOX movie series dataset 20 (8 MGy) of the copper nitrite reductase from Bradyrhizobium sp. ORS 375 (two-domain)
7QY4	;	1.35	;	As isolated MSOX movie series dataset 5 (2 MGy) of the copper nitrite reductase from Bradyrhizobium sp. ORS 375 (two-domain)
6ZAR	;	1.1	;	As-isolated copper nitrite reductase from Bradyrhizobium sp. ORS 375 (two-domain) at 1.1 A resolution (unrestrained, full matrix refinement by SHELX)
5K73	;	2.08	;	as-isolated Dbr1 with Fe(II) and Zn(II)
1W9M	;	1.35	;	AS-isolated hybrid cluster protein from Desulfovibrio vulgaris X-ray structure at 1.35A resolution using iron anomalous signal
6T7J	;	2.43	;	As-isolated Ni-free crystal structure of carbon monoxide dehydrogenase from Thermococcus sp. AM4 produced without CooC maturase
5ONY	;	1.6	;	As-isolated resting state copper nitrite reductase from Achromobacter xylosoxidans
3KM2	;	3.1	;	As-isolated TOMATO CHLOROPLAST SUPEROXIDE DISMUTASE
6I8X	;	2.3	;	As-p18, an extracellular fatty acid binding protein
1VPT	;	1.8	;	AS11 VARIANT OF VACCINIA VIRUS PROTEIN VP39 IN COMPLEX WITH S-ADENOSYL-L-METHIONINE
7N2S	;	2.37	;	AS3.1-PRPF3-HLA*B27
7N2O	;	2.3	;	AS4.2-YEIH-HLA*B27
7N2R	;	2.28	;	AS4.3-PRPF3-HLA*B27
7N2P	;	2.5	;	AS4.3-RNASEH2b-HLA*B27
7N2Q	;	2.7	;	AS4.3-YEIH-HLA*B27
2X3B	;	2.28	;	AsaP1 inactive mutant E294A, an extracellular toxic zinc metalloendopeptidase
2X3A	;	2.0	;	AsaP1 inactive mutant E294Q, an extracellular toxic zinc metalloendopeptidase
2X3C	;	1.99	;	AsaP1 inactive mutant E294Q, an extracellular toxic zinc metalloendopeptidase
3FJU	;	1.6	;	Ascaris suum carboxypeptidase inhibitor in complex with human carboxypeptidase A1
1OAF	;	1.4	;	Ascobate peroxidase from soybean cytosol in complex with ascorbate
1V0H	;	1.46	;	ASCOBATE PEROXIDASE FROM SOYBEAN CYTOSOL IN COMPLEX WITH SALICYLHYDROXAMIC ACID
2YDG	;	2.0	;	Ascorbate co-crystallized HEWL.
2WD4	;	1.4	;	Ascorbate Peroxidase as a heme oxygenase: w41A variant product with t-butyl peroxide
1OAG	;	1.75	;	Ascorbate peroxidase from soybean cytosol
2CL4	;	1.8	;	Ascorbate Peroxidase R172A mutant
2Y6A	;	2.0	;	Ascorbate Peroxidase R38A mutant
2Y6B	;	1.9	;	Ascorbate Peroxidase R38K mutant
3ZCG	;	1.491	;	Ascorbate peroxidase W41A-H42C mutant
3ZCH	;	2.0	;	Ascorbate peroxidase W41A-H42M mutant
3ZCY	;	2.0	;	Ascorbate peroxidase W41A-H42Y mutant
5KK5	;	3.289	;	AsCpf1(E993A)-crRNA-DNA ternary complex
7BCT	;	3.37	;	ASCT2 in the presence of the inhibitor ERA-21 in the outward-open conformation.
7BCS	;	3.43	;	ASCT2 in the presence of the inhibitor Lc-BPE (position ""down"") in the outward-open conformation.
7BCQ	;	3.43	;	ASCT2 in the presence of the inhibitor Lc-BPE (position ""up"") in the outward-open conformation.
6LNL	;	1.9286	;	ASFV core shell protein p15
6LIS	;	1.998	;	ASFV dUTPase in complex with dUMP
6LMJ	;	2.8	;	ASFV pA104R in complex with double-strand DNA
2M2T	;		;	ASFV Pol X structure
8J87	;	3.42	;	Asfv topoisomerase 2 - apo conformer Ia
8J88	;	3.49	;	Asfv topoisomerase 2 - apo conformer Ib
8JA2	;	1.73	;	ASFV Topoisomerase ATPase domain in complex with AMP-PNP and Mg2+
8JA1	;	1.14	;	ASFV Topoisomerase ATPase domain in complex with AMP-PNP and Mg2+ (oxidized form)
6FVI	;	1.0	;	ASH / PapD-like domain of human CEP192 (PapD-like domain 7)
4YPE	;	2.2	;	ASH1L SET domain H2193F mutant in complex with S-adenosyl methionine (SAM)
6WZW	;	1.69	;	Ash1L SET domain in complex with AS-85
4YPU	;	2.6	;	ASH1L SET domain K2264L mutant in complex with S-adenosyl methionine (SAM)
6X0P	;	1.69	;	Ash1L SET domain Q2265A mutant in complex with AS-5
4YPA	;	2.3	;	ASH1L SET domain Q2265A mutant in complex with S-adenosyl methionine (SAM)
4YNP	;	2.9	;	ASH1L SET domain S2259M mutant in complex with S-adenosyl methionine (SAM)
4YNM	;	2.19	;	ASH1L wild-type SET domain in complex with S-adenosyl methionine (SAM)
2L7P	;		;	ASHH2 a CW domain
2F4T	;	3.0	;	Asite RNA + designer antibiotic
2F4U	;	2.6	;	Asite RNA + designer antibiotic
7MU7	;	2.298	;	Ask1 bound to compound 3
6E2M	;	2.253	;	ASK1 kinase domain complex with inhibitor
6E2N	;	2.098	;	ASK1 kinase domain complex with inhibitor
6E2O	;	2.389	;	ASK1 kinase domain complex with inhibitor
6OYW	;	2.603	;	ASK1 kinase domain in complex with Compound 11
6OYT	;	2.824	;	ASK1 kinase domain in complex with GS-4997
5WCV	;		;	AsK132958: A minimal homologue of ShK identified in the transcriptome of Anemonia sulcata
6DJ0	;	1.3	;	ASLTVS segment from Human Immunoglobulin Light-Chain Variable Domain, Residues 73-78, assembled as an amyloid fibril
1XNL	;		;	ASLV fusion peptide
5I81	;	2.25	;	aSMase with zinc
5I8R	;	3.646	;	aSMase with zinc
5I85	;	2.5	;	aSMase with zinc and phosphocholine
1SGN	;	1.8	;	ASN 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B
2ZGD	;	1.9	;	Asn-hydroxylation stabilises the ankyrin repeat domain fold
2ZGG	;	2.0	;	Asn-hydroxylation stabilises the ankyrin repeat domain fold
2OGY	;	2.3	;	Asn199Ala Mutant of the 5-methyltetrahydrofolate corrinoid/iron sulfur protein methyltransferase complexed with methyltetrahydrofolate to 2.3 Angstrom resolution
2SGD	;	1.8	;	ASP 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 10.7
1SGD	;	1.8	;	ASP 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 6.5
7UGD	;	2.95	;	Asp-bound GltPh RSMR mutant in IFS-A1 state
7UGV	;	2.94	;	Asp-bound GltPh RSMR mutant in IFS-A2 state
7UGX	;	2.96	;	Asp-bound GltPh RSMR mutant in IFS-B1 state
7UH6	;	3.44	;	Asp-bound GltPh RSMR mutant in IFS-B2 state
7UH3	;	2.99	;	Asp-bound GltPh RSMR mutant in iOFS state
4Z9H	;	1.452	;	Asp-Tar from E. coli
4Z9I	;	1.57	;	Asp-TarS from E. coli
8E1J	;	1.6	;	Asp1 kinase in complex with 1,5-IP8
8E1H	;	1.9	;	Asp1 kinase in complex with ADP Mg 5-IP7
8E1V	;	1.9	;	Asp1 kinase in complex with ADPNP Mg IP6
8E1T	;	1.71	;	Asp1 kinase in complex with ADPNP Mg IP7
8E1S	;	1.72	;	Asp1 kinase in complex with ADPNP Mn IP6
8E1I	;	2.0	;	Asp1 kinase in complex with ATP Mg 5-IP7
1EKS	;	2.5	;	ASP128ALA VARIANT OF MOAC PROTEIN FROM E. COLI
3S1F	;	2.0	;	Asp169Glu mutant of maize cytokinin oxidase/dehydrogenase complexed with N6-isopentenyladenine
1DZN	;	2.8	;	Asp170Ser mutant of vanillyl-alcohol oxidase
2BWT	;	2.9	;	Asp260Ala Escherichia coli Aminopeptidase P
2BWU	;	2.2	;	Asp271Ala Escherichia coli Aminopeptidase P
3PGR	;	2.6	;	Asp348Arg mutant of EcFadL
1C99	;		;	ASP61 DEPROTONATED FORM OF SUBUNIT C OF THE F1FO ATP SYNTHASE OF ESCHERICHIA COLI
2CF7	;	1.5	;	Asp74Ala mutant crystal structure for Dps-like peroxide resistance protein Dpr from Streptococcus suis.
1YNV	;	1.2	;	Asp79 makes a large, unfavorable contribution to the stability of RNase Sa
2E2A	;	2.1	;	ASP81LEU ENZYME IIA FROM THE LACTOSE SPECIFIC PTS FROM LACTOCOCCUS LACTIS
5K5R	;	3.09	;	AspA-32mer DNA,crystal form 2
4ECA	;	2.2	;	ASPARAGINASE FROM E. COLI, MUTANT T89V WITH COVALENTLY BOUND ASPARTATE
1HFJ	;	2.4	;	Asparaginase from Erwinia chrysanthemi, hexagonal form with sulfate
1HFK	;	2.17	;	Asparaginase from Erwinia chrysanthemi, hexagonal form with weak sulfate
6UOD	;	2.4	;	Asparaginase II from Escherichia coli
6UOG	;	2.29	;	Asparaginase II from Escherichia coli
6UOH	;	2.1	;	Asparaginase II from Escherichia coli
11AS	;	2.5	;	ASPARAGINE SYNTHETASE MUTANT C51A, C315A COMPLEXED WITH L-ASPARAGINE
12AS	;	2.2	;	ASPARAGINE SYNTHETASE MUTANT C51A, C315A COMPLEXED WITH L-ASPARAGINE AND AMP
6AZT	;	1.8	;	Asparaginyl endopeptidase 1 bound to AAN peptide, a tetrahedral intermediate
2XTI	;	2.4	;	Asparaginyl-tRNA synthetase from Brugia malayi complexed with ATP:Mg and L-Asp-beta-NOH adenylate:PPi:Mg
2XGT	;	1.9	;	Asparaginyl-tRNA synthetase from Brugia malayi complexed with the sulphamoyl analogue of asparaginyl-adenylate
1CQ7	;	2.4	;	ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C5-PYRIDOXAL-5P-PHOSPHATE
1CQ8	;	2.4	;	ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C6-PYRIDOXAL-5P-PHOSPHATE
1G4X	;	2.2	;	ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L
1G7X	;	2.2	;	ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L/R386L
1G7W	;	2.2	;	ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R386L
1G4V	;	2.0	;	ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/Y225F
1IX6	;	2.2	;	Aspartate Aminotransferase Active Site Mutant V39F
1IX7	;	2.2	;	Aspartate Aminotransferase Active Site Mutant V39F maleate complex
1IX8	;	2.2	;	Aspartate Aminotransferase Active Site Mutant V39F/N194A
1CQ6	;	2.7	;	ASPARTATE AMINOTRANSFERASE COMPLEX WITH C4-PYRIDOXAL-5P-PHOSPHATE
1C9C	;	2.4	;	ASPARTATE AMINOTRANSFERASE COMPLEXED WITH C3-PYRIDOXAL-5'-PHOSPHATE
5EAA	;	2.4	;	ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION
1B4X	;	2.45	;	ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION, WITH BOUND MALEATE
1QIS	;	1.9	;	ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191F MUTATION, WITH BOUND MALEATE
1QIT	;	1.9	;	ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191W MUTATION, WITH BOUND MALEATE
1QIR	;	2.2	;	ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191Y MUTATION, WITH BOUND MALEATE
1J32	;	2.1	;	Aspartate Aminotransferase from Phormidium lapideum
1YAA	;	2.05	;	ASPARTATE AMINOTRANSFERASE FROM SACCHAROMYCES CEREVISIAE CYTOPLASM
1BJW	;	1.8	;	ASPARTATE AMINOTRANSFERASE FROM THERMUS THERMOPHILUS
1BKG	;	2.6	;	ASPARTATE AMINOTRANSFERASE FROM THERMUS THERMOPHILUS WITH MALEATE
1AHE	;	2.3	;	ASPARTATE AMINOTRANSFERASE HEXAMUTANT
1AHF	;	2.3	;	ASPARTATE AMINOTRANSFERASE HEXAMUTANT
1AHG	;	2.5	;	ASPARTATE AMINOTRANSFERASE HEXAMUTANT
1AHX	;	2.0	;	ASPARTATE AMINOTRANSFERASE HEXAMUTANT
1AHY	;	2.3	;	ASPARTATE AMINOTRANSFERASE HEXAMUTANT
1YOO	;	2.4	;	ASPARTATE AMINOTRANSFERASE MUTANT ATB17 WITH ISOVALERIC ACID
1CZC	;	2.5	;	ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH GLUTARIC ACID
1CZE	;	2.4	;	ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH SUCCINIC ACID
2D7Y	;	2.66	;	Aspartate Aminotransferase Mutant MA
2D63	;	2.05	;	Aspartate Aminotransferase Mutant MA With Isovaleric Acid
2D61	;	2.01	;	Aspartate Aminotransferase Mutant MA With Maleic Acid
2D66	;	2.18	;	Aspartate Aminotransferase Mutant MAB
2D7Z	;	2.65	;	Aspartate Aminotransferase Mutant MAB Complexed with Maleic Acid
2D65	;	2.3	;	Aspartate Aminotransferase Mutant MABC
2D64	;	2.05	;	Aspartate Aminotransferase Mutant MABC With Isovaleric Acid
2D5Y	;	1.98	;	Aspartate Aminotransferase Mutant MC With Isovaleric Acid
3K7Y	;	2.8	;	Aspartate Aminotransferase of Plasmodium falciparum
1BQD	;	2.1	;	ASPARTATE AMINOTRANSFERASE P138A/P195A DOUBLE MUTANT
1BQA	;	2.1	;	ASPARTATE AMINOTRANSFERASE P195A MUTANT
5VK7	;	1.9	;	aspartate aminotransferase pH 4.0
1OXP	;	2.5	;	ASPARTATE AMINOTRANSFERASE, H-ASP COMPLEX, CLOSED CONFORMATION
1OXO	;	2.3	;	ASPARTATE AMINOTRANSFERASE, H-ASP COMPLEX, OPEN CONFORMATION
1ARG	;	2.2	;	Aspartate aminotransferase, phospho-5'-pyridoxyl aspartate complex
1ARI	;	2.3	;	Aspartate aminotransferase, W140H mutant, maleate complex
1ARH	;	2.3	;	ASPARTATE AMINOTRANSFERASE, Y225R/R386A MUTANT
1BRM	;	2.5	;	ASPARTATE BETA-SEMIALDEHYDE DEHYDROGENASE FROM ESCHERICHIA COLI
1GL3	;	2.6	;	ASPARTATE BETA-SEMIALDEHYDE DEHYDROGENASE IN COMPLEX WITH NADP AND SUBSTRATE ANALOGUE S-METHYL CYSTEINE SULFOXIDE
4WOJ	;	2.45	;	Aspartate Semialdehyde Dehydrogenase from Francisella tularensis
1TU0	;	2.55	;	Aspartate Transcarbamoylase Catalytic Chain Mutant E50A Complex with Phosphonoacetamide
1TUG	;	2.1	;	Aspartate Transcarbamoylase Catalytic Chain Mutant E50A Complex with Phosphonoacetamide, Malonate, and Cytidine-5-Prime-Triphosphate (CTP)
1TTH	;	2.8	;	Aspartate Transcarbamoylase Catalytic Chain Mutant Glu50Ala Complexed with N-(Phosphonacetyl-L-Aspartate) (PALA)
4FYV	;	2.0976	;	Aspartate Transcarbamoylase Complexed with dCTP
1D09	;	2.1	;	ASPARTATE TRANSCARBAMOYLASE COMPLEXED WITH N-PHOSPHONACETYL-L-ASPARTATE (PALA)
5G1P	;	3.19	;	Aspartate transcarbamoylase domain of human CAD bound to carbamoyl phosphate
5G1N	;	2.1	;	Aspartate transcarbamoylase domain of human CAD bound to PALA
5G1O	;	2.1	;	Aspartate transcarbamoylase domain of human CAD in apo form
5NNN	;	2.26	;	Aspartate transcarbamoylase from Chaetomium thermophilum CAD-like
5NNQ	;	2.26	;	Aspartate transcarbamoylase from Chaetomium thermophilum CAD-like bound to carbamoyl phosphate
8BPL	;	1.58	;	Aspartate transcarbamoylase mutant (N2045C, R2238C) from Chaetomium thermophilum CAD-like bound to carbamoyl phosphate
8BPS	;	2.03	;	Aspartate transcarbamoylase mutant (N2045C, R2238C) from Chaetomium thermophilum CAD-like in apo form
1NBE	;	2.6	;	ASPARTATE TRANSCARBAMOYLASE REGULATORY CHAIN MUTANT (T82A)
1Q95	;	2.46	;	Aspartate Transcarbamylase (ATCase) of Escherichia coli: A New Crystalline R State Bound to PALA, or to Product Analogues Phosphate and Citrate
1R0B	;	2.9	;	Aspartate Transcarbamylase (ATCase) of Escherichia coli: A New Crystalline R State Bound to PALA, or to Product Analogues Phosphate and Citrate
2ASI	;	2.15	;	ASPARTIC PROTEINASE
4Y9W	;	0.83	;	Aspartic Proteinase Sapp2 Secreted from Candida Parapsilosis at 0.82 A Resolution.
4YBF	;	1.24	;	Aspartic Proteinase Sapp2 Secreted from Candida Parapsilosis at 1.25 A Resolution
8DYM	;		;	Aspartimidylated Graspetide Amycolimiditide
7LCW	;		;	Aspartimidylated Lasso Peptide Lihuanodin
7LIF	;		;	Aspartimidylated omega ester peptide fuscimiditide
1FY2	;	1.2	;	Aspartyl Dipeptidase
1FYE	;	1.2	;	Aspartyl Dipeptidase (Anisotropic B-Factor Refinement)
3I7F	;	2.8	;	Aspartyl tRNA synthetase from Entamoeba histolytica
1G51	;	2.4	;	ASPARTYL TRNA SYNTHETASE FROM THERMUS THERMOPHILUS AT 2.4 A RESOLUTION
1B8A	;	1.9	;	ASPARTYL-TRNA SYNTHETASE
3NEL	;	1.954	;	Aspartyl-tRNA synthetase complexed with aspartic acid
3NEM	;	1.89	;	Aspartyl-tRNA synthetase complexed with aspartyl adenylate
1L0W	;	2.01	;	Aspartyl-tRNA synthetase-1 from space-grown crystals
6Q9I	;	1.852	;	Aspartyl/Asparaginyl beta-hydroxylase (AspH) H679A in complex with Factor X peptide fragment (39mer-4Ser)
6Q9F	;	1.63	;	Aspartyl/Asparaginyl beta-hydroxylase (AspH) H679A in complex with Mn, NOG and Factor X peptide fragment (39mer-4Ser)
6QA5	;	2.655	;	Aspartyl/Asparaginyl beta-hydroxylase (AspH) H679A in the apo form
7E6J	;	1.9	;	Aspartyl/Asparaginyl beta-hydroxylase (AspH) H725A in complex with Factor X peptide fragment (39mer-4Ser)
7YBC	;	1.84	;	Aspartyl/Asparaginyl beta-hydroxylase (AspH) oxygenase and TPR domains in complex with (S)-4-hydroxy-4-methyl-2-oxoglutarate and factor X-derived peptide (39mer-4Ser)
7YB8	;	1.98	;	Aspartyl/Asparaginyl beta-hydroxylase (AspH) oxygenase and TPR domains in complex with D-2-hydroxyglutarate and factor X-derived peptide (39mer-4Ser)
7YBA	;	1.86	;	Aspartyl/Asparaginyl beta-hydroxylase (AspH) oxygenase and TPR domains in complex with D-4-hydroxy-2-oxoglutarate
7YBB	;	1.68	;	Aspartyl/Asparaginyl beta-hydroxylase (AspH) oxygenase and TPR domains in complex with D-4-hydroxy-2-oxoglutarate and factor X-derived peptide (39mer-4Ser)
7YB9	;	1.54	;	Aspartyl/Asparaginyl beta-hydroxylase (AspH) oxygenase and TPR domains in complex with L-2-hydroxyglutarate and factor X-derived peptide (39mer-4Ser)
6YYU	;	2.11	;	Aspartyl/Asparaginyl beta-hydroxylase (AspH) oxygenase and TPR domains in complex with manganese and 2-oxoglutarate
6YYV	;	1.77	;	Aspartyl/Asparaginyl beta-hydroxylase (AspH) oxygenase and TPR domains in complex with manganese and 3-methyl-2-oxoglutarate
6YYW	;	2.27	;	Aspartyl/Asparaginyl beta-hydroxylase (AspH) oxygenase and TPR domains in complex with manganese, 2-oxoglutarate, and factor X substrate peptide fragment(39mer-4Ser)
6Z6Q	;	1.81	;	Aspartyl/Asparaginyl beta-hydroxylase (AspH) oxygenase and TPR domains in complex with manganese, 3-ethyl-2-oxoglutarate, and factor X substrate peptide fragment(39mer-4Ser)
7BMI	;	1.66	;	Aspartyl/Asparaginyl beta-hydroxylase (AspH) oxygenase and TPR domains in complex with manganese, 3-fluoropyridine-2,4-dicarboxylic acid, and factor X substrate peptide fragment (39mer-4Ser)
6YYX	;	1.53	;	Aspartyl/Asparaginyl beta-hydroxylase (AspH) oxygenase and TPR domains in complex with manganese, 3-methyl-2-oxoglutarate, and factor X substrate peptide fragment(39mer-4Ser)
6YYY	;	2.29	;	Aspartyl/Asparaginyl beta-hydroxylase (AspH) oxygenase and TPR domains in complex with manganese, 4,4-dimethyl-2-oxoglutarate, and factor X substrate peptide fragment(39mer-4Ser)
7BMJ	;	1.75	;	Aspartyl/Asparaginyl beta-hydroxylase (AspH) oxygenase and TPR domains in complex with manganese, 5-fluoropyridine-2,4-dicarboxylic acid, and factor X substrate peptide fragment (39mer-4Ser)
6Z6R	;	2.13	;	Aspartyl/Asparaginyl beta-hydroxylase (AspH) oxygenase and TPR domains in complex with manganese, N-oxalyl-alpha-methylalanine, and factor X substrate peptide fragment(39mer-4Ser)
5JZ6	;	2.354	;	Aspartyl/Asparaginyl beta-hydroxylase (AspH)oxygenase and TPR domains in complex with manganese and L-malate
5JZA	;	2.14	;	Aspartyl/Asparaginyl beta-hydroxylase (AspH)oxygenase and TPR domains in complex with manganese and N-oxalylglycine
5JTC	;	2.24	;	Aspartyl/Asparaginyl beta-hydroxylase (AspH)oxygenase and TPR domains in complex with manganese, 2,4-pyridine dicarboxylate and factor X substrate peptide fragment(39mer-4Ser)
6RK9	;	2.292	;	Aspartyl/Asparaginyl beta-hydroxylase (AspH)oxygenase and TPR domains in complex with manganese, N-oxalylglycine and cyclic peptide substrate mimic of factor X
5JZU	;	2.5	;	Aspartyl/Asparaginyl beta-hydroxylase (AspH)oxygenase and TPR domains in complex with manganese, N-oxalylglycine and factor X substrate peptide fragment (26mer)
5JQY	;	1.99	;	Aspartyl/Asparaginyl beta-hydroxylase (AspH)oxygenase and TPR domains in complex with manganese, N-oxalylglycine and factor X substrate peptide fragment(39mer-4Ser)
5JZ8	;	2.095	;	Aspartyl/Asparaginyl beta-hydroxylase (AspH)oxygenase and TPR domains in complex with manganese, N-oxalylglycine, and factor X substrate peptide fragment (39mer)
6DEY	;	1.63	;	Aspartylglucosaminuria mutant structure and function
1CYL	;		;	ASPECTS OF RECEPTOR BINDING AND SIGNALLING OF INTERLEUKIN-4 INVESTIGATED BY SITE-DIRECTED MUTAGENESIS AND NMR SPECTROSCOPY
2CYK	;		;	ASPECTS OF RECEPTOR BINDING AND SIGNALLING OF INTERLEUKIN-4 INVESTIGATED BY SITE-DIRECTED MUTAGENESIS AND NMR SPECTROSCOPY
8H4Q	;	2.22	;	Aspergillomarasmine A biosynthese complex with OPS
1IBQ	;	2.14	;	ASPERGILLOPEPSIN FROM ASPERGILLUS PHOENICIS
6Q3R	;	2.69	;	ASPERGILLUS ACULEATUS GALACTANASE
7Z6T	;	1.51	;	Aspergillus clavatus M36 protease without the propeptide
6AGY	;	1.8	;	Aspergillus fumigatus Af293 NDK
6ARE	;	1.75	;	Aspergillus fumigatus Cytosolic Thiolase in complex with two tetrahedral reaction intermediates and ammonium ions
6AQP	;	1.8	;	Aspergillus fumigatus Cytosolic Thiolase: Acetylated enzyme in complex with CoA and potassium ions
6ARR	;	1.822	;	Aspergillus fumigatus Cytosolic Thiolase: Apo enzyme in complex with cesium ions
6ART	;	2.25	;	Aspergillus fumigatus Cytosolic Thiolase: Apo enzyme in complex with cesium ions
6ARF	;	1.702	;	Aspergillus fumigatus Cytosolic Thiolase: Apo enzyme in complex with potassium ions
6ARG	;	1.782	;	Aspergillus fumigatus Cytosolic Thiolase: Apo enzyme in complex with rubidium ions
6ARL	;	1.9	;	Aspergillus fumigatus Cytosolic Thiolase: Apo enzyme in complex with rubidium ions
7RHV	;	2.0	;	Aspergillus fumigatus Enolase
7RHW	;	1.9	;	Aspergillus fumigatus Enolase Bound to 2-Phosphoglycerate
7RI0	;	2.3	;	Aspergillus fumigatus Enolase Bound to Phosphoenolpyruvate and 2-Phosphoglycerate
5HWB	;	2.306	;	Aspergillus fumigatus FKBP12 apo protein in P212121 space group
5HWC	;	2.05	;	Aspergillus fumigatus FKBP12 P90G protein bound with FK506 in P212121 space group
6VCV	;	1.6	;	Aspergillus fumigatus FKBP12 protein bound with APX879 in P1 space group
4LNG	;	1.905	;	Aspergillus fumigatus protein farnesyltransferase complex with farnesyldiphosphate and tipifarnib
4LNB	;	1.752	;	Aspergillus fumigatus protein farnesyltransferase ternary complex with farnesyldiphosphate and ethylenediamine scaffold inhibitor 5
5ZVP	;	1.42	;	Aspergillus fumigatus Rho1 F25N
6JIK	;	2.35	;	Aspergillus fumigatus Rho1 GsGTP
6BPY	;	3.201	;	Aspergillus fumigatus Thioredoxin Reductase
5XH9	;	2.3	;	Aspergillus kawachii beta-fructofuranosidase
5XHA	;	2.1	;	Aspergillus kawachii beta-fructofuranosidase complexed with fructose
5XH8	;	2.1	;	Aspergillus kawachii beta-fructofuranosidase complexed with glycerol
2Z8G	;	1.7	;	Aspergillus niger ATCC9642 isopullulanase complexed with isopanose
6R3O	;	1.13	;	Aspergillus niger ferric acid decarboxylase (Fdc) L439G variant in complex with prFMN (purified in the radical form) and phenylpropiolic acid
6R32	;	1.21	;	Aspergillus niger ferrulic acid decarboxylase (Fdc) in complex with the covalent adduct formed between prFMN cofactor and phenylpropiolic acid (Int1')
8OEH	;	1.77	;	Aspergillus niger ferulic acid decarboxylase (Fdc) C122-S261C (DB3) variant in complex with prenylated flavin
6R3G	;	1.13	;	Aspergillus niger ferulic acid decarboxylase (Fdc) E282Q variant in complex with the covalent adduct formed between prFMN cofactor and alphafluoro-cinnamic acid (Int2)
6R3F	;	1.25	;	Aspergillus niger ferulic acid decarboxylase (Fdc) E282Q variant in complex with the covalent adduct formed between prFMN cofactor and cinnamic acid (Int2)
6R3I	;	1.14	;	Aspergillus niger ferulic acid decarboxylase (Fdc) E282Q variant in complex with the covalent adduct formed between prFMN cofactor and pentafluorocinnamic acid (Int2)
6R2Z	;	1.08	;	Aspergillus niger ferulic acid decarboxylase (Fdc) F437L variant in complex with the covalent adduct formed between prFMN cofactor and phenylpropiolic acid (Int1')
6R2P	;	1.26	;	Aspergillus niger ferulic acid decarboxylase (Fdc) in complex with FMN and cinnamic acid
6R2R	;	1.13	;	Aspergillus niger ferulic acid decarboxylase (Fdc) in complex with prFMN (purified in dark) and alphafluorocinnamic acid
6R2T	;	1.29	;	Aspergillus niger ferulic acid decarboxylase (Fdc) in complex with prFMN (purified in the radical form) and phenylpropiolic acid
6R3N	;	1.02	;	Aspergillus niger ferulic acid decarboxylase (Fdc) in complex with the covalent adduct formed between prFMN cofactor and butynoic acid (Int1')
6R3L	;	1.24	;	Aspergillus niger ferulic acid decarboxylase (Fdc) in complex with the covalent adduct formed between prFMN cofactor and cinnamic acid following decarboxylation (Int3)
6R3J	;	1.39	;	Aspergillus niger ferulic acid decarboxylase (Fdc) in complex with the covalent adduct formed between prFMN cofactor and crotonic acid following decarboxylation (Int3)
6R34	;	1.1	;	Aspergillus niger ferulic acid decarboxylase (Fdc) in complex with the covalent adduct formed between prFMN cofactor and phenyl acetylene (Int3')
6R30	;	1.12	;	Aspergillus niger ferulic acid decarboxylase (Fdc) L439G variant in complex with the covalent adduct formed between prFMN cofactor and phenylpropiolic acid (Int1')
8OED	;	1.37	;	Aspergillus niger ferulic acid decarboxylase (Fdc) S145C-P289C (DB2) variant in complex with prenylated flavin hydroxylated at the C1 prime position
8CRD	;	1.35	;	Aspergillus niger ferulic acid decarboxylase (Fdc) T40C-S315C (DB1) variant in complex with prenylated flavin hydroxylated at the C1 prime position
8OEO	;	1.3	;	Aspergillus niger ferulic acid decarboxylase (Fdc) V186C-A296C (DB4) variant in complex with prenylated flavin
6R33	;	1.01	;	Aspergillus niger ferulic acid decarboxylase (Fdc)in complex with the covalent adduct formed between prFMN cofactor and phenylpropiolic acid, following decarboxylation (Int3')
3K4P	;	2.4	;	Aspergillus niger Phytase
3K4Q	;	2.2	;	Aspergillus niger Phytase in complex with myo-inositol hexakis sulfate
8IWD	;	2.81	;	Aspergillus niger Rha-2
8IWF	;	2.86	;	Aspergillus niger Rha-2 and pNPR
6JU8	;	1.27	;	Aspergillus oryzae active-tyrosinase copper-bound C92A mutant
6JU9	;	1.42	;	Aspergillus oryzae active-tyrosinase copper-bound C92A mutant complexed with L-tyrosine
6JU6	;	1.5	;	Aspergillus oryzae active-tyrosinase copper-depleted C92A mutant
6JU7	;	1.42	;	Aspergillus oryzae active-tyrosinase copper-depleted C92A mutant complexed with L-tyrosine
6ZEQ	;	1.97	;	Aspergillus oryzae Leucine Aminopeptidase A mature enzyme
6JU5	;	1.34	;	Aspergillus oryzae pro-tyrosinase C92A/F513Y mutant
6JU4	;	1.35	;	Aspergillus oryzae pro-tyrosinase F513Y mutant
6JUA	;	1.45	;	Aspergillus oryzae pro-tyrosinase oxygen-bound C92A mutant
6JUC	;	1.44	;	Aspergillus oryzae pro-tyrosinase oxygen-bound C92A/H103F mutant
7XOI	;	2.3	;	Aspergillus sojae alpha-glucosidase AsojAgdL in complex with trehalose
1OXR	;	1.93	;	Aspirin induces its Anti-inflammatory effects through its specific binding to Phospholipase A2: Crystal structure of the complex formed between Phospholipase A2 and Aspirin at 1.9A resolution
6T1P	;	3.5	;	ASR Alternansucrase in complex with isomaltononaose
6SZI	;	3.0	;	ASR Alternansucrase in complex with isomaltose
6SYQ	;	3.0	;	ASR Alternansucrase in complex with isomaltotriose
6T18	;	3.15	;	ASR Alternansucrase in complex with oligoalternan
6T16	;	3.1	;	ASR Alternansucrase in complex with panose
3TOK	;	1.74	;	Assaying the energies of biological halogen bonds.
4YNW	;	2.95	;	Assembly Chaperone of RpL4 (Acl4) (Residues 1-338)
4YNV	;	2.95	;	Assembly Chaperone of RpL4 (Acl4) (Residues 28-338)
1VDF	;	2.05	;	ASSEMBLY DOMAIN OF CARTILAGE OLIGOMERIC MATRIX PROTEIN
1FBM	;	2.7	;	ASSEMBLY DOMAIN OF CARTILAGE OLIGOMERIC MATRIX PROTEIN IN COMPLEX WITH ALL-TRANS RETINOL
7PO4	;	2.56	;	Assembly intermediate of human mitochondrial ribosome large subunit (largely unfolded rRNA with MALSU1, L0R8F8 and ACP)
7PO0	;	2.9	;	Assembly intermediate of human mitochondrial ribosome small subunit without mS37 in complex with RBFA and IF3
7PNX	;	2.76	;	Assembly intermediate of human mitochondrial ribosome small subunit without mS37 in complex with RBFA and METTL15 conformation a
7PNY	;	3.06	;	Assembly intermediate of human mitochondrial ribosome small subunit without mS37 in complex with RBFA and METTL15 conformation b
7PNZ	;	3.09	;	Assembly intermediate of human mitochondrial ribosome small subunit without mS37 in complex with RBFA and METTL15 conformation c
7PNV	;	3.06	;	Assembly intermediate of mouse mitochondrial ribosome small subunit without mS37 in complex with RbfA and Mettl15
7PNT	;	3.19	;	Assembly intermediate of mouse mitochondrial ribosome small subunit without mS37 in complex with RbfA and Tfb1m
7PNU	;	3.06	;	Assembly intermediate of mouse mitochondrial ribosome small subunit without mS37 in complex with RbfA inward conformation
7A24	;	3.8	;	Assembly intermediate of the plant mitochondrial complex I
6ZTS	;		;	Assembly intermediates of orthoreovirus captured in the cell
6ZTY	;		;	Assembly intermediates of orthoreovirus captured in the cell
6ZTZ	;		;	Assembly intermediates of orthoreovirus captured in the cell
4BFQ	;	2.4	;	Assembly of a triple pi-stack of ligands in the binding site of Aplysia californica acetylcholine binding protein (AChBP)
5AFW	;	1.6	;	Assembly of methylated LSD1 and CHD1 drives AR-dependent transcription and translocation
6PYQ	;	1.79	;	Assembly of VIQKI D455(beta-L-homoaspartic acid)with human parainfluenza virus type 3 (HPIV3) fusion glycoprotein N-terminal heptad repeat domain
6VAS	;	1.49	;	Assembly of VIQKI I454(beta-L-homoisoleucine)with human parainfluenza virus type 3 (HPIV3) fusion glycoprotein N-terminal heptad repeat domain
6V3V	;	2.17	;	Assembly of VIQKI I456(beta-L-homoisoleucine)with human parainfluenza virus type 3 (HPIV3) fusion glycoprotein N-terminal heptad repeat domain
6PRL	;	1.87	;	Assembly of VIQKI P5(beta-L-homoproline) with human parainfluenza virus type 3 (HPIV3) fusion glycoprotein N-terminal heptad repeat domain
4UPF	;	7.5	;	Assembly principles of the unique cage formed by the ATPase RavA hexamer and the lysine decarboxylase LdcI decamer
6QEB	;		;	Assessment of a large enzyme-drug complex by proton-detected solid-state NMR without deuteration
8ON9	;	2.4	;	ASSFVRIa-bound Malacoceros FaNaC1 in lipid nanodiscs
4MET	;	2.095	;	Assigning the EPR Fine Structure Parameters of the Mn(II) Centers in Bacillus subtilis Oxalate Decarboxylase by Site-Directed Mutagenesis and DFT/MM Calculations
2LRM	;		;	Assignment and structure of E coli periplasmic protein YmgD
2LRV	;		;	Assignment of E coli periplasmic protein YmgD
2JUA	;		;	Assignment, structure, and dynamics of de novo designed protein S836
1CEY	;		;	ASSIGNMENTS, SECONDARY STRUCTURE, GLOBAL FOLD, AND DYNAMICS OF CHEMOTAXIS Y PROTEIN USING THREE-AND FOUR-DIMENSIONAL HETERONUCLEAR (13C,15N) NMR SPECTROSCOPY
3VM1	;	1.5	;	assimilatory nitrite reductase (Nii3) - N226K mutant - HCO3 complex from tobacco leaf
3VLX	;	1.35	;	Assimilatory nitrite reductase (Nii3) - N226K mutant - ligand free form from tobacco leaf
3VM0	;	1.695	;	Assimilatory nitrite reductase (Nii3) - N226K mutant - NO2 complex from tobacco leaf
3VLZ	;	2.07	;	Assimilatory nitrite reductase (Nii3) - N226K mutant - SO3 full complex from tobacco leaf
3VLY	;	1.55	;	Assimilatory nitrite reductase (Nii3) - N226K mutant - SO3 partial complex from tobacco leaf
3VKT	;	1.3	;	Assimilatory nitrite reductase (Nii3) - NH2OH complex from tobbaco leaf
3VKS	;	1.4	;	Assimilatory nitrite reductase (Nii3) - NO complex from tobbaco leaf
3VKR	;	1.6	;	Assimilatory nitrite reductase (Nii3) - NO2 complex from tobbaco leaf analysed with high X-ray dose
3VKP	;	1.4	;	Assimilatory nitrite reductase (Nii3) - NO2 complex from tobbaco leaf analysed with low X-ray dose
3VKQ	;	1.6	;	Assimilatory nitrite reductase (Nii3) - NO2 complex from tobbaco leaf analysed with middle X-ray dose
3B0G	;	1.25	;	Assimilatory nitrite reductase (Nii3) from tobbaco leaf
3B0H	;	2.306	;	Assimilatory nitrite reductase (Nii4) from tobbaco root
5G4V	;	2.87	;	Association of four two-k-turn units based on Kt-7 3bG,3nC, forming a square-shaped structure
2K88	;		;	Association of subunit d (Vma6p) and E (Vma4p) with G (Vma10p) and the NMR solution structure of subunit G (G1-59) of the Saccharomyces cerevisiae V1VO ATPase
3IYA	;	22.0	;	Association of the pr peptides with dengue virus blocks membrane fusion at acidic pH
6ZDG	;	4.7	;	Association of three complexes of largely structurally disordered Spike ectodomain with bound EY6A Fab
5G4U	;	2.65	;	Association of three two-k-turn units based on Kt-7 3bU,3nU, forming a triangular-shaped structure
6ZFO	;	4.4	;	Association of two complexes of largely structurally disordered Spike ectodomain with bound EY6A Fab
8CYL	;	1.888	;	Ast89 P domain
8IQV	;	1.91	;	Asterias forbesii ferritin
8IQZ	;	4.19	;	Asterias forbesii ferritin mutant-P156F
8IQY	;	2.1	;	Asterias forbesii ferritin mutant-P156H
2RMD	;		;	Astressin-B
2RM9	;		;	Astressin2B
1VSK	;	2.2	;	ASV INTEGRASE CORE DOMAIN D64N MUTATION IN CITRATE BUFFER PH 6.0
1VSL	;	2.2	;	ASV INTEGRASE CORE DOMAIN D64N MUTATION WITH ZINC CATION
1VSM	;	2.15	;	ASV INTEGRASE CORE DOMAIN IN CITRATE BUFFER PH 5.0
1VSI	;	2.2	;	ASV INTEGRASE CORE DOMAIN WITH CA(II) COFACTOR
1VSJ	;	2.1	;	ASV INTEGRASE CORE DOMAIN WITH CD(II) COFACTORS
1A5W	;	2.0	;	ASV INTEGRASE CORE DOMAIN WITH HIV-1 INTEGRASE INHIBITOR Y3
1A5X	;	1.9	;	ASV INTEGRASE CORE DOMAIN WITH HIV-1 INTEGRASE INHIBITOR Y3
1A5V	;	1.9	;	ASV INTEGRASE CORE DOMAIN WITH HIV-1 INTEGRASE INHIBITOR Y3 AND MN CATION
1VSD	;	1.7	;	ASV INTEGRASE CORE DOMAIN WITH MG(II) COFACTOR AND HEPES LIGAND, HIGH MG CONCENTRATION FORM
1VSE	;	2.2	;	ASV INTEGRASE CORE DOMAIN WITH MG(II) COFACTOR AND HEPES LIGAND, LOW MG CONCENTRATION FORM
1VSF	;	2.05	;	ASV INTEGRASE CORE DOMAIN WITH MN(II) COFACTOR AND HEPES LIGAND, HIGH MG CONCENTRATION FORM
1VSH	;	1.95	;	ASV INTEGRASE CORE DOMAIN WITH ZN(II) COFACTORS
3G6W	;	2.9	;	Asymetric GTP bound structure of UPRTase from Sulfolobus solfataricus containing PRPP-mg2+ in half of the active sites and R5P and PPi in the other half
8QQU	;	2.9	;	Asymetric subunit of E. coli DNA gyrase bound to a linear part of a DNA minicircle
5O66	;	5.9	;	Asymmetric AcrABZ-TolC
7M3E	;	3.2	;	Asymmetric Activation of the Calcium Sensing Receptor Homodimer
7M3F	;	2.8	;	Asymmetric Activation of the Calcium Sensing Receptor Homodimer
7M3G	;	2.5	;	Asymmetric Activation of the Calcium Sensing Receptor Homodimer
7M3J	;	4.1	;	Asymmetric Activation of the Calcium Sensing Receptor Homodimer
6R60	;	1.75	;	asymmetric antiparallel assembly of two 5-bladed beta-propeller fragments
3QFQ	;	2.9001	;	Asymmetric Assembly of Merkel Cell Polyomavirus Large T-antigen Origin Binding Domains at the Viral Origin
1OFH	;	2.5	;	Asymmetric complex between HslV and I-domain deleted HslU (H. influenzae)
1OFI	;	3.2	;	Asymmetric complex between HslV and I-domain deleted HslU (H. influenzae)
6SZW	;	3.14	;	Asymmetric complex of Factor XII and kininogen with gC1qR/C1QBP/P32 is governed by allostery
3UCC	;	1.5	;	Asymmetric complex of human neuron specific enolase-1-PGA/PEP
3UCD	;	1.41	;	Asymmetric complex of human neuron specific enolase-2-PGA/PEP
3UJE	;	1.55	;	Asymmetric complex of human neuron specific enolase-3-PGA/PEP
3UJF	;	2.1	;	Asymmetric complex of human neuron specific enolase-4-PGA/PEP
3UJR	;	1.4	;	Asymmetric complex of human neuron specific enolase-5-PGA/PEP
3UJS	;	1.65	;	Asymmetric complex of human neuron specific enolase-6-PGA/PEP
1H6S	;	3.0	;	Asymmetric conductivity of engineered proteins
4A8A	;	14.2	;	Asymmetric cryo-EM reconstruction of E. coli DegQ 12-mer in complex with lysozyme
8FK0	;	4.0	;	Asymmetric cryo-EM structure of a curved Saccharolobus solfataricus type IV pilus
8SP3	;	3.52	;	Asymmetric dimer of MapSPARTA bound with gRNA/tDNA hybrid
8CEF	;	2.486	;	Asymmetric Dimerization in a Transcription Factor Superfamily is Promoted by Allosteric Interactions with DNA
4CRX	;	2.2	;	ASYMMETRIC DNA-BENDING IN THE CRE-LOXP SITE-SPECIFIC RECOMBINATION SYNAPSE
5CRX	;	2.7	;	ASYMMETRIC DNA-BENDING IN THE CRE-LOXP SITE-SPECIFIC RECOMBINATION SYNAPSE
8D4W	;	1.35	;	Asymmetric ene-reduction of alpha,beta-unsaturated compounds using MSMEG_2850
6OUC	;	2.8	;	Asymmetric focsued reconstruction of human norovirus GII.2 Snow Mountain Virus strain VLP asymmetric unit in T=1 symmetry
6OUT	;	2.6	;	Asymmetric focused reconstruction of human norovirus GI.1 Norwalk strain VLP asymmetric unit in T=3 symmetry
6OU9	;	3.2	;	Asymmetric focused reconstruction of human norovirus GI.7 Houston strain VLP asymmetric unit in T=3 symmetry
6PGI	;	3.5	;	Asymmetric functions of a binuclear metal cluster within the transport pathway of the ZIP transition metal transporters
6OOY	;	2.5	;	Asymmetric hTNF-alpha
6OOZ	;	2.8	;	Asymmetric hTNF-alpha
6OP0	;	2.55	;	Asymmetric hTNF-alpha
7KP9	;	2.15	;	asymmetric hTNF-alpha
7KPA	;	2.3	;	asymmetric hTNF-alpha
6XLH	;	2.83	;	Asymmetric hydrolysis state of Hsc82 in complex with Aha1 bound with ADP and ATPgammaS
8JWT	;	3.4	;	Asymmetric middle segment of the bacteriophage M13 mini variant
6OPP	;	3.7	;	Asymmetric model of CD4- and 17-bound B41 HIV-1 Env SOSIP in complex with DDM
6X5C	;	4.04	;	Asymmetric model of CD4-bound B41 HIV-1 Env SOSIP in complex with small molecule GO52
7KP7	;	2.65	;	asymmetric mTNF-alpha hTNFR1 complex
7KP8	;	3.15	;	asymmetric mTNF-alpha hTNFR1 complex
4WZA	;	1.8995	;	Asymmetric Nucleotide Binding in the Nitrogenase Complex
8CKB	;	4.39	;	Asymmetric reconstruction of the crAss001 virion
4BP7	;	39.0	;	Asymmetric structure of a virus-receptor complex
8FAD	;	4.0	;	Asymmetric structure of cleaved HIV-1 AD8 envelope glycoprotein trimer in styrene-maleic acid lipid nanoparticles
8FAE	;	3.8	;	Asymmetric structure of cleaved HIV-1 AE2 envelope glycoprotein trimer in styrene-maleic acid lipid nanoparticles (AE2.1)
8QO0	;	10.62	;	Asymmetric structure of the Borrelia bacteriophage BB1 procapsid, 3D class 2
8QO1	;	9.76	;	Asymmetric structure of the Borrelia bacteriophage BB1 procapsid, 3D class 3
8PHU	;	7.41	;	Asymmetric structure of the portal-containing cap of the Borrelia bacteriophage BB1 procapsid
2GIF	;	2.9	;	Asymmetric structure of trimeric AcrB from Escherichia coli
2HRT	;	3.0	;	Asymmetric structure of trimeric AcrB from Escherichia coli
5IKD	;	1.109	;	Asymmetric sulfoxidation by engineering the heme pocket of a dye-decolorizing peroxidase
5IKG	;	1.95	;	Asymmetric sulfoxidation by engineering the heme pocket of a dye-decolorizing peroxidase
2WX4	;	2.8	;	Asymmetric trimer of the Drosophila melanogaster DCP1 C-terminal domain
2WX3	;	2.31	;	Asymmetric trimer of the human DCP1a C-terminal domain
7LGG	;	6.2	;	Asymmetric unit for phage Qbeta oblate particle
7LGF	;	6.1	;	Asymmetric unit for phage Qbeta prolate particle
7LGH	;	8.9	;	Asymmetric unit for phage Qbeta small prolate particle
7LGE	;	5.6	;	Asymmetric unit for phage Qbeta T=4 particle
5KIP	;	3.7	;	Asymmetric unit for the coat proteins of phage Qbeta
5VLY	;	3.3	;	Asymmetric unit for the coat proteins of phage Qbeta
7UX3	;	9.6	;	Asymmetric unit of AP-1, Arf1, Nef lattice on MHC-I lipopeptide incorporated narrow membrane tubes
8D4E	;	9.2	;	Asymmetric unit of AP-1, Arf1, Nef lattice on MHC-I lipopeptide incorporated wide(r) membrane tubes
7VIK	;	3.76	;	Asymmetric unit of cryoEM structure of bacteriophage lambda capsid at 3.76 Angstrom
8FQK	;	3.5	;	Asymmetric unit of HK97 phage prohead I
6F9B	;	13.3	;	Asymmetric unit of Rift Valley fever virus glycoprotein shell
8PSF	;	2.8	;	Asymmetric unit of the yeast fatty acid synthase in non-rotated state with ACP at the acetyl transferase domain (FASx sample)
8PSP	;	2.9	;	Asymmetric unit of the yeast fatty acid synthase in rotated state with ACP at the acetyl transferase domain (FASx sample)
8PRV	;	2.9	;	Asymmetric unit of the yeast fatty acid synthase in the non-rotated state with ACP at the ketosreductase domain (FASamn sample)
8PS9	;	2.9	;	Asymmetric unit of the yeast fatty acid synthase in the non-rotated state with ACP at the ketosynthase domain (FASam sample)
8PS1	;	2.8	;	Asymmetric unit of the yeast fatty acid synthase in the non-rotated state with ACP at the ketosynthase domain (FASamn sample)
8PSK	;	2.8	;	Asymmetric unit of the yeast fatty acid synthase in the non-rotated state with ACP at the ketosynthase domain (FASx sample)
8PSM	;	3.1	;	Asymmetric unit of the yeast fatty acid synthase in the non-rotated state with ACP at the malonyl/palmitoyl transferase domain (FASx sample)
8PSG	;	3.7	;	Asymmetric unit of the yeast fatty acid synthase in the semi non-rotated state with ACP at the acetyl transferase domain (FASx sample)
8PS8	;	4.0	;	Asymmetric unit of the yeast fatty acid synthase in the semi non-rotated state with ACP at the enoyl reductase domain (FASam sample)
8PSA	;	3.6	;	Asymmetric unit of the yeast fatty acid synthase in the semi non-rotated state with ACP at the ketosynthase domain (FASam sample)
8PSL	;	3.7	;	Asymmetric unit of the yeast fatty acid synthase in the semi non-rotated state with ACP at the ketosynthase domain (FASx sample)
8PSJ	;	3.4	;	Asymmetric unit of the yeast fatty acid synthase in the semi rotated state with ACP at the acetyl transferase domain (FASx sample)
8PS2	;	2.9	;	Asymmetric unit of the yeast fatty acid synthase with ACP at the enoyl reductase domain (FASam sample)
8DEE	;	3.4	;	Asymmetric Unit of Western Equine Encephalitis Virus
6WCJ	;	6.3	;	Asymmetric vertex of the clathrin minicoat cage
2ONE	;	2.0	;	ASYMMETRIC YEAST ENOLASE DIMER COMPLEXED WITH RESOLVED 2'-PHOSPHOGLYCERATE AND PHOSPHOENOLPYRUVATE
6YKA	;	2.1	;	Asymmetric [Fe]-hydrogenase from Methanolacinia paynteri apo and in complex with FeGP at 2.1-A resolution
7MI5	;	3.57	;	Asymmetrical PAM-Non PAM prespacer bound Cas4/Cas1/Cas2 complex
6U0L	;	3.3	;	Asymmetrically open conformational state (Class I) of HIV-1 Env trimer BG505 SOSIP.664 in complex with sCD4 and E51 Fab
6U0N	;	3.5	;	Asymmetrically open conformational state (Class II) of HIV-1 Env trimer BG505 SOSIP.664 in complex with sCD4 and E51 Fab
5ID2	;	2.43	;	Asymmetry in the active site of Mycobacterium tuberculosis AhpE upon exposure to Mycothiol
1VTW	;	1.2	;	AT Base Pairs Are Less Stable than GC Base Pairs in Z-DNA: The Crystal Structure of D(M(5)CGTAM(5)CG)
8CZC	;	2.86	;	AT from first module of the pikromycin synthase
5M68	;	2.64	;	AT-rich DNA dodecamer with extra helical guanine-nickel coordination
7M98	;	1.6	;	ATAD2 bromodomain complexed with histone H4K5ac (res 1-10) ligand
7PX5	;	2.18	;	ATAD2 in complex with 1-Methyl-2-quinolone
7Z9U	;	1.76	;	ATAD2 in complex with Acetyl-Lys
7QUK	;	1.47	;	ATAD2 in complex with FragLite1
7QXT	;	1.51	;	ATAD2 in complex with FragLite10
7QU7	;	2.13	;	ATAD2 in complex with FragLite16
7QYK	;	1.43	;	ATAD2 in complex with FragLite18
7QUM	;	1.5	;	ATAD2 in complex with FragLite2
7QYL	;	1.44	;	ATAD2 in complex with FragLite23
7QZM	;	1.45	;	ATAD2 in complex with FragLite28
7QZY	;	1.93	;	ATAD2 in complex with FragLite29
7PPX	;	1.35	;	ATAD2 in complex with FragLite3
7QZZ	;	2.52	;	ATAD2 in complex with FragLite31
7R00	;	1.48	;	ATAD2 in complex with FragLite33
7QWO	;	1.5	;	ATAD2 in complex with FragLite6
7QX1	;	1.49	;	ATAD2 in complex with FragLite7
7Z9I	;	1.5	;	ATAD2 in complex with PepLite-Ala
7Z9S	;	1.5	;	ATAD2 in complex with PepLite-Arg
7Z9H	;	1.34	;	ATAD2 in complex with PepLite-Asp
7R0Y	;	1.43	;	ATAD2 in complex with PepLite-Glu
7Z9J	;	1.9	;	ATAD2 in complex with PepLite-Gly
7R05	;	1.53	;	ATAD2 in complex with PepLite-Ile
7Z9O	;	1.47	;	ATAD2 in complex with PepLite-Tyr
7Z9N	;	1.34	;	ATAD2 in complex with PepLite-Val
6VEO	;	2.4	;	ATAD2B bromodomain in complex with 4-({[(3R,4R)-4-{[3-methyl-5-(5-methylpyridin-3-yl)-2-oxo-1,2-dihydro-1,7-naphthyridin-8-yl]amino}piperidin-3-yl]oxy}methyl)-1lambda~6~-thiane-1,1-dione (compound 38)
8HIW	;	3.34	;	AtALMT9 in the apo state
8HIY	;	3.8	;	AtALMT9 plus malate
7CHD	;	3.804	;	AtaT complexed with acetyl-methionyl-tRNAfMet
4WTH	;	2.25	;	Ataxin-3 Carboxy Terminal Region - Crystal C2 (triclinic)
4YS9	;	2.0	;	Ataxin-3 Carboxy-Terminal Region - Crystal C1 (tetragonal)
4UD8	;	2.088	;	AtBBE15
1ZFC	;	2.0	;	ATC Duplex B-DNA
1ZF3	;	1.84	;	ATC Four-stranded DNA Holliday Junction
1ZF4	;	1.65	;	ATC Four-stranded DNA Holliday Junction
9ATC	;	2.4	;	ATCASE Y165F MUTANT
3S2R	;	1.14	;	ATChloroNEET (H87C mutant)
7D34	;	2.007	;	AtClpS1-peptide complex
6KWA	;	2.09429	;	AtDAO1(dioxygenase for auxin oxidation 1 from Arabidopsis thaliana)
6KWB	;	2.51839	;	AtDAO1(dioxygenase for auxin oxidation 1 from Arabidopsis thaliana) - 2-oxoglutarate binray complex
1SAA	;		;	ATF-2 RECOGNITION SITE, NMR, 10 STRUCTURES
6J2Z	;	2.4	;	AtFKBP53 N-terminal Nucleoplasmin Domain
4J2G	;	2.29	;	Atg13 HORMA domain
3T7E	;	2.25	;	Atg8 transfer from Atg7 to Atg3: a distinctive E1-E2 architecture and mechanism in the autophagy pathway
3T7F	;	1.89	;	Atg8 transfer from Atg7 to Atg3: a distinctive E1-E2 architecture and mechanism in the autophagy pathway
3T7G	;	2.08	;	Atg8 transfer from Atg7 to Atg3: a distinctive E1-E2 architecture and mechanism in the autophagy pathway
3T7H	;	1.6	;	Atg8 transfer from Atg7 to Atg3: a distinctive E1-E2 architecture and mechanism in the autophagy pathway
6E1Q	;	2.148	;	AtGH3.15 acyl acid amido synthetase in complex with 2,4-DB
5A5K	;	2.77	;	AtGSTF2 from Arabidopsis thaliana in complex with camalexin
5A4U	;	2.0	;	AtGSTF2 from Arabidopsis thaliana in complex with indole-3-aldehyde
5A4V	;	2.38	;	AtGSTF2 from Arabidopsis thaliana in complex with quercetin
5A4W	;	2.25	;	AtGSTF2 from Arabidopsis thaliana in complex with quercetrin
6COD	;	1.8	;	AtHNL enantioselectivity mutant At-A9-H7 Apo Y13C,Y121L,P126F,L128W,C131T,F179L,A209I with benzaldehyde
6COE	;	1.844	;	AtHNL enantioselectivity mutant At-A9-H7 Apo Y13C,Y121L,P126F,L128W,C131T,F179L,A209I with benzaldehyde, MANDELIC ACID NITRILE
6COF	;	1.52	;	AtHNL enantioselectivity mutant At-A9-H7 Apo, Y13C,Y121L,P126F,L128W,C131T,A209I
6COG	;	1.8	;	AtHNL enantioselectivity mutant At-A9-H7 Apo, Y13C,Y121L,P126F,L128W,C131T,A209I with benzaldehyde
6COH	;	2.367	;	AtHNL enantioselectivity mutant At-A9-H7 Apo, Y13C,Y121L,P126F,L128W,C131T,A209I with benzaldehyde, MANDELIC ACID NITRILE
6COI	;	2.024	;	AtHNL enantioselectivity mutant At-A9-H7 Apo, Y13C,Y121L,P126F,L128W,C131T,A209I with CYANIDE, benzaldehyde, MANDELIC ACID NITRILE
6COB	;	1.82	;	AtHNL enantioselectivity mutant At-A9-H7 Apo, Y13C,Y121L,P126F,L128W,C131T,F179L,A209I
6COC	;	1.93	;	AtHNL enantioselectivity mutant At-A9-H7 Apo, Y13C,Y121L,P126F,L128W,C131T,F179L,A209I with benzaldehyde
6RJ0	;	3.7	;	Atlantic Cod Nervous Necrosis Virus-Like Particle produced in Nicotiana benthamiana
8OXM	;	3.3	;	ATM(Q2971A) activated by oxidative stress in complex with Mg AMP-PNP and p53 peptide
8OXO	;	3.0	;	ATM(Q2971A) dimeric C-terminal region activated by oxidative stress in complex with Mg AMP-PNP and p53 peptide
8OXQ	;	2.5	;	ATM(Q2971A) dimeric C-terminal region in complex with Mg AMP-PNP
8OXP	;	2.6	;	ATM(Q2971A) in complex with Mg AMP-PNP
6UV6	;	2.72	;	AtmM with bound rebeccamycin analogue
6TGS	;	1.53	;	AtNBR1-PB1 domain
1SBT	;	2.5	;	ATOMIC COORDINATES FOR SUBTILISIN BPN (OR NOVO)
3IYL	;	3.3	;	Atomic CryoEM Structure of a Nonenveloped Virus Suggests How Membrane Penetration Protein is Primed for Cell Entry
5FWK	;	3.9	;	Atomic cryoEM structure of Hsp90-Cdc37-Cdk4 complex
5FWL	;	9.0	;	Atomic cryoEM structure of Hsp90-Cdc37-Cdk4 complex
5FWM	;	8.0	;	Atomic cryoEM structure of Hsp90-Cdc37-Cdk4 complex
5FWP	;	7.2	;	Atomic cryoEM structure of Hsp90-Cdc37-Cdk4 complex
7KW7	;	3.57	;	Atomic cryoEM structure of Hsp90-Hsp70-Hop-GR
2BTV	;	3.5	;	ATOMIC MODEL FOR BLUETONGUE VIRUS (BTV) CORE
5TJ5	;	3.9	;	Atomic model for the membrane-embedded motor of a eukaryotic V-ATPase
2YPW	;	12.4	;	Atomic model for the N-terminus of TraO fitted in the full-length structure of the bacterial pKM101 type IV secretion system core complex
6T34	;	5.2	;	Atomic model for Turnip mosaic virus (TuMV)
3JAW	;	3.9	;	Atomic model of a microtubule seam based on a cryo-EM reconstruction of the EB3-bound microtubule (merged dataset containing tubulin bound to GTPgammaS, GMPCPP, and GDP)
1VAS	;	2.75	;	ATOMIC MODEL OF A PYRIMIDINE DIMER SPECIFIC EXCISION REPAIR ENZYME COMPLEXED WITH A DNA SUBSTRATE: STRUCTURAL BASIS FOR DAMAGED DNA RECOGNITION
4V7Q	;	3.8	;	Atomic model of an infectious rotavirus particle
6ZJM	;	11.4	;	Atomic model of Andes virus glycoprotein spike tetramer generated by fitting into a Tula virus reconstruction
3KTT	;	4.0	;	Atomic model of bovine TRiC CCT2(beta) subunit derived from a 4.0 Angstrom cryo-EM map
2BZX	;	2.8	;	Atomic model of CrkL-SH3C monomer
3JAZ	;	3.1	;	Atomic model of cytoplasmic polyhedrosis virus with ATP
3JB0	;	2.9	;	Atomic model of cytoplasmic polyhedrosis virus with GTP
3JB1	;	3.1	;	Atomic model of cytoplasmic polyhedrosis virus with SAM
3JB2	;	3.1	;	Atomic model of cytoplasmic polyhedrosis virus with SAM and GTP
3JB3	;	3.1	;	Atomic model of cytoplasmic polyhedrosis virus with SAM, GTP and ATP
3MFP	;	6.6	;	Atomic model of F-actin based on a 6.6 angstrom resolution cryoEM map
3LOS	;	4.3	;	Atomic Model of Mm-cpn in the Closed State
6WGF	;	7.7	;	Atomic model of mutant Mcm2-7 hexamer with Mcm6 WHD truncation
6WGG	;	8.1	;	Atomic model of pre-insertion mutant OCCM-DNA complex(ORC-Cdc6-Cdt1-Mcm2-7 with Mcm6 WHD truncation)
7SUN	;	3.6	;	Atomic model of prestin from gerbil (Meriones unguiculatus)
3J1P	;	6.5	;	Atomic model of rabbit hemorrhagic disease virus
7TFL	;	3.33	;	Atomic model of S. cerevisiae clamp loader RFC bound to DNA
7TFK	;	3.25	;	Atomic model of S. cerevisiae clamp loader RFC bound to two DNA molecules, one at the 5'-recessed end and the other at the 3'-recessed end
7TFJ	;	3.3	;	Atomic model of S. cerevisiae clamp-clamp loader complex PCNA-RFC bound to DNA with a closed clamp ring
8SNB	;	3.3	;	atomic model of sea urchin sperm doublet microtubule (48-nm periodicity)
6WGC	;	4.3	;	Atomic model of semi-attached mutant OCCM-DNA complex (ORC-Cdc6-Cdt1-Mcm2-7 with Mcm6 WHD truncation)
2MPZ	;		;	Atomic model of the Abeta D23N ""Iowa"" mutant using solid-state NMR, EM and Rosetta modeling
2BGZ	;	9.0	;	ATOMIC MODEL OF THE BACTERIAL FLAGELLAR BASED ON DOCKING AN X-RAY DERIVED HOOK STRUCTURE INTO AN EM MAP.
3A69	;	7.1	;	Atomic model of the bacterial flagellar hook based on docking an X-ray derived structure and terminal two alpha-helices into an 7.1 angstrom resolution cryoEM map
8EYI	;	2.7	;	Atomic model of the core modifying region of human fatty acid synthase
8EYK	;	2.7	;	Atomic model of the core modifying region of human fatty acid synthase in complex with TVB-2640
8GKC	;	2.45	;	Atomic model of the core modifying region of human fatty acid synthase in complex with TVB-2640 - C2 refinement
2Y7H	;	18.0	;	Atomic model of the DNA-bound methylase complex from the Type I restriction-modification enzyme EcoKI (M2S1). Based on fitting into EM map 1534.
6ZVP	;	4.0	;	Atomic model of the EM-based structure of the full-length tyrosine hydroxylase in complex with dopamine (residues 40-497) in which the regulatory domain (residues 40-165) has been included only with the backbone atoms
3J3V	;	13.3	;	Atomic model of the immature 50S subunit from Bacillus subtilis (state I-a)
3J3W	;	10.7	;	Atomic model of the immature 50S subunit from Bacillus subtilis (state II-a)
3IYF	;	8.0	;	Atomic Model of the Lidless Mm-cpn in the Open State
6W1S	;	4.02	;	Atomic model of the mammalian Mediator complex
6WGI	;	10.0	;	Atomic model of the mutant OCCM (ORC-Cdc6-Cdt1-Mcm2-7 with Mcm6 WHD truncation) loaded on DNA at 10.5 A resolution
2Y7C	;	18.0	;	Atomic model of the Ocr-bound methylase complex from the Type I restriction-modification enzyme EcoKI (M2S1). Based on fitting into EM map 1534.
7UWS	;	3.47	;	Atomic model of the partial VSV nucleocapsid
7TFI	;	3.41	;	Atomic model of the S. cerevisiae clamp-clamp loader complex PCNA-RFC bound to DNA with an open clamp
7TFH	;	3.09	;	Atomic model of the S. cerevisiae clamp-clamp loader complex PCNA-RFC bound to two DNA molecules, one at the 5'-recessed end and the other at the 3'-recessed end
5TCR	;	6.3	;	Atomic model of the Salmonella SPI-1 type III secretion injectisome basal body proteins InvG, PrgH, and PrgK
2XKV	;	13.5	;	Atomic Model of the SRP-FtsY Early Conformation
2LPZ	;		;	Atomic model of the Type-III Secretion System Needle
3J9G	;	3.5	;	Atomic model of the VipA/VipB, the type six secretion system contractile sheath of Vibrio cholerae from cryo-EM
5MXN	;	3.7	;	Atomic model of the VipA/VipB/Hcp, the type six secretion system non-contractile sheath-tube of Vibrio cholerae from cryo-EM
3JAY	;	3.0	;	Atomic model of transcribing cytoplasmic polyhedrosis virus
1HRB	;	5.5	;	ATOMIC MODELS FOR THE POLYPEPTIDE BACKBONES OF MYOHEMERYTHRIN AND HEMERYTHRIN
6HY0	;	3.5	;	Atomic models of P1, P4 C-terminal fragment and P8 fitted in the bacteriophage phi6 nucleocapsid reconstructed with icosahedral symmetry
1CBN	;	0.83	;	ATOMIC RESOLUTION (0.83 ANGSTROMS) CRYSTAL STRUCTURE OF THE HYDROPHOBIC PROTEIN CRAMBIN AT 130 K
2VHK	;	0.94	;	Atomic resolution (0.94 A) structure of purified thaumatin I grown in sodium L-tartrate at 22C
2VU6	;	0.95	;	Atomic resolution (0.95 A) structure of purified Thaumatin I grown in sodium meso-tartrate at 19 C.
2VHR	;	0.95	;	Atomic resolution (0.95A) structure of purified thaumatin I grown in sodium L-tartrate at 4 C
1VL9	;	0.97	;	Atomic resolution (0.97A) structure of the triple mutant (K53,56,121M) of bovine pancreatic phospholipase A2
2VI3	;	0.98	;	Atomic resolution (0.98 A) structure of purified thaumatin I grown in sodium DL-tartrate at 20 C
1GQV	;	0.98	;	Atomic Resolution (0.98A) Structure of Eosinophil-Derived Neurotoxin
2VI1	;	1.04	;	Atomic resolution (1.04 A) structure of purified thaumatin I grown in sodium D-tartrate at 22 C.
2VI2	;	1.08	;	Atomic resolution (1.05 A) structure of purified Thaumatin I grown in sodium D-tartrate at 4C
1NKD	;	1.09	;	ATOMIC RESOLUTION (1.07 ANGSTROMS) STRUCTURE OF THE ROP MUTANT <2AA>
2VU7	;	1.08	;	Atomic resolution (1.08 A) structure of purified thaumatin I grown in sodium meso-tartrate at 4 C
2VI4	;	1.1	;	Atomic resolution (1.10 A) structure of purified thaumatin I grown in sodium DL-tartrate at 6 C.
1Q0E	;	1.15	;	Atomic resolution (1.15 ) crystal structure of bovine copper, zinc superoxide dismutase
1CZ9	;	1.2	;	ATOMIC RESOLUTION ASV INTEGRASE CORE DOMAIN (D64N) FROM CITRATE
1CXQ	;	1.02	;	ATOMIC RESOLUTION ASV INTEGRASE CORE DOMAIN FROM AMMONIUM SULFATE
1CZB	;	1.06	;	ATOMIC RESOLUTION ASV INTEGRASE CORE DOMAIN FROM HEPES
6CVM	;	1.9	;	Atomic resolution cryo-EM structure of beta-galactosidase
1BZP	;	1.15	;	ATOMIC RESOLUTION CRYSTAL STRUCTURE ANALYSIS OF NATIVE DEOXY AND CO MYOGLOBIN FROM SPERM WHALE AT ROOM TEMPERATURE
1BZR	;	1.15	;	ATOMIC RESOLUTION CRYSTAL STRUCTURE ANALYSIS OF NATIVE DEOXY AND CO MYOGLOBIN FROM SPERM WHALE AT ROOM TEMPERATURE
1BZ6	;	1.2	;	ATOMIC RESOLUTION CRYSTAL STRUCTURE AQUOMET-MYOGLOBIN FROM SPERM WHALE AT ROOM TEMPERATURE
6Q41	;	1.03	;	Atomic resolution crystal structure of a BAA collagen heterotrimer
4N0K	;	1.05	;	Atomic resolution crystal structure of a cytochrome c-calixarene complex
1L2X	;	1.25	;	Atomic Resolution Crystal Structure of a Viral RNA Pseudoknot
6Q3P	;	1.03	;	Atomic resolution crystal structure of an AAB collagen heterotrimer
6Q43	;	1.16	;	Atomic resolution crystal structure of an ABA collagen heterotrimer
5DA6	;	1.05	;	Atomic resolution crystal structure of double-stranded RNA 32 base pairs long determined from random starting phases angles in the presence of pseudo translational symmetry using the direct methods program SIR2014.
2O90	;	1.07	;	Atomic resolution crystal structure of E.coli dihydroneopterin aldolase in complex with neopterin
2V0A	;	1.15	;	Atomic resolution crystal structure of Human Superoxide Dismutase
4U2W	;	1.0	;	Atomic resolution crystal structure of HV-BBI protease inhibitor from amphibian skin in complex with bovine trypsin
4KEL	;	1.148	;	Atomic resolution crystal structure of Kallikrein-Related Peptidase 4 complexed with a modified SFTI inhibitor FCQR(N)
3U23	;	1.11	;	Atomic resolution crystal structure of the 2nd SH3 domain from human CD2AP (CMS) in complex with a proline-rich peptide from human RIN3
2FWH	;	0.99	;	atomic resolution crystal structure of the C-terminal domain of the electron transfer catalyst DsbD (reduced form at pH7)
2WFI	;	0.75	;	Atomic resolution crystal structure of the PPIase domain of human cyclophilin G
2WFJ	;	0.75	;	Atomic resolution crystal structure of the PPIase domain of human cyclophilin G in complex with cyclosporin A.
4K1E	;	1.3	;	Atomic resolution crystal structures of Kallikrein-Related Peptidase 4 complexed with a modified SFTI inhibitor FCQR
4K8Y	;	1.0	;	Atomic resolution crystal structures of Kallikrein-Related Peptidase 4 complexed with Sunflower Trypsin Inhibitor (SFTI-1)
3EA6	;	0.92	;	Atomic resolution of crystal structure of SEK
2KQ4	;		;	Atomic resolution protein structure determination by three-dimensional transferred echo double resonance solid-state nuclear magnetic resonance spectroscopy
2LGI	;		;	Atomic Resolution Protein Structures using NMR Chemical Shift Tensors
4LZT	;	0.95	;	ATOMIC RESOLUTION REFINEMENT OF TRICLINIC HEW LYSOZYME AT 295K
2ZL5	;	1.47	;	Atomic resolution structural characterization of recognition of histo-blood group antigen by Norwalk virus
2ZL6	;	1.43	;	Atomic resolution structural characterization of recognition of histo-blood group antigens by Norwalk virus
2ZL7	;	1.35	;	Atomic resolution structural characterization of recognition of histo-blood group antigens by Norwalk virus
1OE3	;	1.15	;	Atomic resolution structure of 'Half Apo' NiR
1M69	;	1.1	;	Atomic Resolution Structure of 5Br-9amino-DACA with d[CGTACG]2
2NAO	;		;	Atomic resolution structure of a disease-relevant Abeta(1-42) amyloid fibril
2BWD	;	1.15	;	Atomic Resolution Structure of Achromobacter cycloclastes Cu Nitrite Reductase with Endogenously bound Nitrite and NO
1KWF	;	0.94	;	Atomic Resolution Structure of an Inverting Glycosidase in Complex with Substrate
2HEU	;	1.04	;	Atomic resolution structure of apo-form of RafE from Streptococcus pneumoniae
1VB0	;	0.92	;	Atomic resolution structure of atratoxin-b, one short-chain neurotoxin from Naja atra
5NB4	;	1.14	;	Atomic resolution structure of C-phycoerythrin from marine cyanobacterium Phormidium sp. A09DM at pH 7.5
1MXT	;	0.95	;	Atomic resolution structure of Cholesterol oxidase (Streptomyces sp. SA-COO)
1N4W	;	0.92	;	ATOMIC RESOLUTION STRUCTURE OF CHOLESTEROL OXIDASE @ pH 7.3 (STREPTOMYCES SP. SA-COO)
1N1P	;	0.95	;	ATOMIC RESOLUTION STRUCTURE OF CHOLESTEROL OXIDASE @ pH 7.4 (STREPTOMYCES SP. SA-COO)
2GEW	;	0.97	;	Atomic resolution structure of cholesterol oxidase @ pH 9.0 (Streptomyces sp. SA-COO)
1N4V	;	1.0	;	ATOMIC RESOLUTION STRUCTURE OF CHOLESTEROL OXIDASE @pH 5.8 (STREPTOMYCES SP. SA-COO)
1YLT	;	1.1	;	Atomic resolution structure of CTX-M-14 beta-lactamase
1YLP	;	1.2	;	Atomic resolution structure of CTX-M-27 beta-lactamase
1YLJ	;	0.98	;	Atomic resolution structure of CTX-M-9 beta-lactamase
2C9V	;	1.07	;	Atomic resolution structure of Cu-Zn Human Superoxide dismutase
3BWH	;	1.0	;	Atomic resolution structure of cucurmosin, a novel type 1 RIP from the sarcocarp of Cucurbita moschata
5SYA	;	1.1	;	Atomic resolution structure of D24N mutant human DJ-1
1OE2	;	1.12	;	Atomic Resolution Structure of D92E Mutant of Alcaligenes xylosoxidans Nitrite Reductase
1EUW	;	1.05	;	ATOMIC RESOLUTION STRUCTURE OF E. COLI DUTPASE
5SY9	;	1.1	;	Atomic resolution structure of E15Q mutant human DJ-1
1OEX	;	1.1	;	Atomic Resolution Structure of Endothiapepsin in Complex with a Hydroxyethylene Transition State Analogue Inhibitor H261
1O7J	;	1.0	;	Atomic resolution structure of Erwinia chrysanthemi L-asparaginase
4IAU	;	0.99	;	Atomic resolution structure of Geodin, a beta-gamma crystallin from Geodia cydonium
2WUR	;	0.9	;	Atomic resolution structure of GFP measured on a rotating anode
1A7S	;	1.12	;	ATOMIC RESOLUTION STRUCTURE OF HBP
6BWX	;	2.84	;	Atomic resolution structure of human bufavirus 1
6BX0	;	3.79	;	Atomic resolution structure of human bufavirus 2
6BX1	;	3.25	;	Atomic resolution structure of human bufavirus 3
6SFQ	;	1.0	;	Atomic resolution structure of human Carbonic Anhydrase II in complex with (R)-5-phenyloxazolidine-2,4-dione
6SG0	;	1.13	;	Atomic resolution structure of Human Carbonic Anhydrase II in complex with furosemide
5SY6	;	1.15	;	Atomic resolution structure of human DJ-1, DTT bound
6ENP	;	1.042	;	Atomic resolution structure of human RNase 6 in the presence of phosphate anions in P21 space group.
5NMN	;	0.95	;	Atomic resolution structure of LL-37 in a monomeric state
1GWE	;	0.88	;	Atomic resolution structure of Micrococcus Lysodeikticus catalase
1GWH	;	1.74	;	Atomic resolution structure of Micrococcus Lysodeikticus catalase complexed with NADPH
2V8U	;	1.05	;	Atomic resolution structure of Mn catalase from Thermus Thermophilus
5KK3	;		;	Atomic Resolution Structure of Monomorphic AB42 Amyloid Fibrils
1OEW	;	0.9	;	ATOMIC RESOLUTION STRUCTURE OF NATIVE ENDOTHIAPEPSIN
2BWI	;	1.1	;	Atomic Resolution Structure of Nitrite -soaked Achromobacter cycloclastes Cu Nitrite Reductase
5AKR	;	0.87	;	ATOMIC RESOLUTION STRUCTURE OF NITRITE BOUND STATE OF THE ACHROMOBACTER CYCLOCLASTES CU NITRITE REDUCTASE AT 0.87 A RESOLUTION
2BW5	;	1.12	;	Atomic Resolution Structure of NO-bound Achromobacter cycloclastes Cu Nitrite Reductase
1QV0	;	1.1	;	Atomic resolution structure of obelin from Obelia longissima
1QV1	;	1.1	;	Atomic resolution structure of obelin from Obelia longissima
3W07	;	1.03	;	Atomic resolution structure of orotidine 5'-monophosphate decarboxylase from Methanothermobacter thermoautotrophicus bound with UMP.
4MZC	;	0.949	;	Atomic Resolution Structure of PfGrx1
5SY4	;	0.98	;	Atomic resolution structure of reduced E. coli YajL
2BW4	;	0.9	;	Atomic Resolution Structure of Resting State of the Achromobacter cycloclastes Cu Nitrite Reductase
6ETK	;	0.85	;	Atomic resolution structure of RNase A (data collection 1)
6ETL	;	0.85	;	Atomic resolution structure of RNase A (data collection 2)
6ETM	;	0.92	;	Atomic resolution structure of RNase A (data collection 3)
6ETN	;	0.92	;	Atomic resolution structure of RNase A (data collection 4)
6ETO	;	1.02	;	Atomic resolution structure of RNase A (data collection 5)
6ETP	;	1.02	;	Atomic resolution structure of RNase A (data collection 6)
6ETQ	;	1.08	;	Atomic resolution structure of RNase A (data collection 7)
6ETR	;	1.17	;	Atomic resolution structure of RNase A (data collection 8)
1KF2	;	1.1	;	Atomic Resolution Structure of RNase A at pH 5.2
1KF3	;	1.05	;	Atomic Resolution Structure of RNase A at pH 5.9
1KF4	;	1.1	;	Atomic Resolution Structure of RNase A at pH 6.3
1KF5	;	1.15	;	Atomic Resolution Structure of RNase A at pH 7.1
1KF7	;	1.15	;	Atomic Resolution Structure of RNase A at pH 8.0
1KF8	;	1.15	;	Atomic resolution structure of RNase A at pH 8.8
2CNQ	;	1.0	;	Atomic resolution structure of SAICAR-synthase from Saccharomyces cerevisiae complexed with ADP, AICAR, succinate
2CNU	;	1.05	;	Atomic resolution structure of SAICAR-synthase from Saccharomyces cerevisiae complexed with aspartic acid
1DJT	;	1.2	;	ATOMIC RESOLUTION STRUCTURE OF SCORPION ALPHA-LIKE TOXIN BMK M1 IN A NEW CRYSTAL FORM
5MM8	;	1.75	;	Atomic resolution structure of SplE protease from Staphylococcus aureus
6SF7	;	1.7	;	Atomic resolution structure of SplF protease from Staphylococcus aureus
1LU0	;	1.03	;	Atomic Resolution Structure of Squash Trypsin Inhibitor: Unexpected Metal Coordination
2BF6	;	0.97	;	Atomic Resolution Structure of the bacterial sialidase NanI from Clostridium perfringens in complex with alpha-Sialic Acid (Neu5Ac).
2VZP	;	1.05	;	Atomic Resolution Structure of the C-terminal CBM35 from Amycolatopsis orientalis exo-chitosanase CsxA
2JLI	;	1.13	;	Atomic resolution structure of the cytoplasmic domain of Yersinia pestis YscU, a regulatory switch involved in type III secretion
2BAX	;	1.1	;	Atomic Resolution Structure of the Double Mutant (K53,56M) of Bovine Pancreatic Phospholipase A2
4Q2L	;	1.071	;	Atomic Resolution Structure of the E. coli YajR Transporter YAM Domain
1R2M	;	1.0	;	Atomic resolution structure of the HFBII hydrophobin: a self-assembling amphiphile
1H1N	;	1.12	;	Atomic resolution structure of the major endoglucanase from Thermoascus aurantiacus
1OE1	;	1.04	;	Atomic Resolution Structure of the Wildtype Native Nitrite Reductase from Alcaligenes xylosoxidans
3PUC	;	0.96	;	Atomic resolution structure of titin domain M7
2XOM	;	0.95	;	Atomic resolution structure of TmCBM61 in complex with beta-1,4- galactotriose
3D1P	;	0.98	;	Atomic resolution structure of uncharacterized protein from Saccharomyces cerevisiae
3CUX	;	1.7	;	Atomic Resolution Structures of Escherichia coli and Bacillis anthracis Malate Synthase A: Comparison with Isoform G and Implications for Structure Based Drug Design
3CUZ	;	1.04	;	Atomic Resolution Structures of Escherichia coli and Bacillis anthracis Malate Synthase A: Comparison with Isoform G and Implications for Structure Based Drug Design
3CV1	;	1.68	;	Atomic Resolution Structures of Escherichia coli and Bacillis anthracis Malate Synthase A: Comparison with Isoform G and Implications for Structure Based Drug Design
3CV2	;	1.4	;	Atomic Resolution Structures of Escherichia coli and Bacillis anthracis Malate Synthase A: Comparison with Isoform G and Implications for Structure Based Drug Design
1HJ9	;	0.95	;	Atomic resolution structures of trypsin provide insight into structural radiation damage
4XXR	;	1.18	;	Atomic Resolution X-Ray Crystal Structure of a Ruthenocene Conjugated Beta-Lactam Antibiotic in Complex with CTX-M-14 E166A Beta-Lactamase
5TOP	;	1.18	;	Atomic Resolution X-Ray Crystal Structure of a Ruthenocene Conjugated Beta-Lactam Antibiotic in Complex with CTX-M-14 S70G Beta-Lactamase
5LXW	;	1.0	;	Atomic resolution X-ray crystal structure of cisplatin bound to hen egg white lysozyme stored for 5 years on the shelf
6Z9Z	;	1.04	;	Atomic resolution X-ray structure of the Uridine phosphorylase from Vibrio cholerae on crystals grown under microgravity
8PWH	;	3.17	;	Atomic structure and conformational variability of the HER2-Trastuzumab-Pertuzumab complex
8Q6J	;	3.3	;	Atomic structure and conformational variability of the HER2-Trastuzumab-Pertuzumab complex
5MUV	;	9.1	;	Atomic structure fitted into a localized reconstruction of bacteriophage phi6 packaging hexamer P4
1BBH	;	1.8	;	ATOMIC STRUCTURE OF A CYTOCHROME C' WITH AN UNUSUAL LIGAND-CONTROLLED DIMER DISSOCIATION AT 1.8 ANGSTROMS RESOLUTION
6NIZ	;	0.93	;	Atomic structure of a fluorescent Ag8 cluster templated by a multistranded DNA scaffold
3J9D	;	3.3	;	Atomic structure of a non-enveloped virus reveals pH sensors for a coordinated process of cell entry
3J9E	;	3.3	;	Atomic structure of a non-enveloped virus reveals pH sensors for a coordinated process of cell entry
1T8Z	;	1.45	;	Atomic Structure of A Novel Tryptophan-Zipper Pentamer
1S9U	;	1.38	;	Atomic structure of a putative anaerobic dehydrogenase component
6CBE	;	2.78	;	Atomic structure of a rationally engineered gene delivery vector, AAV2.5
1SZT	;	2.4	;	ATOMIC STRUCTURE OF A THERMOSTABLE SUBDOMAIN OF HIV-1 GP41
2ADA	;	2.4	;	ATOMIC STRUCTURE OF ADENOSINE DEAMINASE COMPLEXED WITH A TRANSITION-STATE ANALOG: UNDERSTANDING CATALYSIS AND IMMUNODEFICIENCY MUTATIONS
4K6B	;	1.101	;	Atomic structure of bacteriophage HS1 tail needle knob
3RWN	;	1.0	;	Atomic structure of bacteriophage sf6 tail needle knob
7MIZ	;	3.4	;	Atomic structure of cortical microtubule from Toxoplasma gondii
1N40	;	1.06	;	Atomic structure of CYP121, a mycobacterial P450
4HRF	;	1.68	;	Atomic structure of DUSP26
1FKF	;	1.7	;	ATOMIC STRUCTURE OF FKBP-FK506, AN IMMUNOPHILIN-IMMUNOSUPPRESSANT COMPLEX
1FKK	;	2.2	;	ATOMIC STRUCTURE OF FKBP12, AN IMMUNOPHILIN BINDING PROTEIN
1FKJ	;	1.7	;	ATOMIC STRUCTURE OF FKBP12-FK506, AN IMMUNOPHILIN IMMUNOSUPPRESSANT COMPLEX
1FKL	;	1.7	;	ATOMIC STRUCTURE OF FKBP12-RAPAYMYCIN, AN IMMUNOPHILIN-IMMUNOSUPPRESSANT COMPLEX
1MNZ	;	0.99	;	Atomic structure of Glucose isomerase
6E3D	;	1.271	;	Atomic structure of Mycobacterium tuberculosis DppA
6E4D	;	1.252	;	Atomic structure of Mycobacterium tuberculosis DppA
6N9Y	;	4.0	;	Atomic structure of Non-Structural protein 1 of bluetongue virus
5MUW	;	9.1	;	Atomic structure of P4 packaging enzyme fitted into a localized reconstruction of bacteriophage phi6 vertex
6R7G	;	2.2	;	Atomic structure of potato virus X, the prototype of the Alphaflexiviridae family
8UEE	;	3.2	;	Atomic structure of Salmonella SipA/F-actin complex by cryo-EM
2BPA	;	3.0	;	ATOMIC STRUCTURE OF SINGLE-STRANDED DNA BACTERIOPHAGE PHIX174 AND ITS FUNCTIONAL IMPLICATIONS
1ATN	;	2.8	;	Atomic structure of the actin:DNASE I complex
3JBT	;	3.8	;	Atomic structure of the Apaf-1 apoptosome
8B8F	;	1.0	;	Atomic structure of the beta-trefoil domain of the Laccaria bicolor lectin LBL in complex with lactose
1ECM	;	2.2	;	ATOMIC STRUCTURE OF THE BURIED CATALYTIC POCKET OF ESCHERICHIA COLI CHORISMATE MUTASE
1EAA	;	2.6	;	ATOMIC STRUCTURE OF THE CUBIC CORE OF THE PYRUVATE DEHYDROGENASE MULTIENZYME COMPLEX
1EAB	;	2.6	;	ATOMIC STRUCTURE OF THE CUBIC CORE OF THE PYRUVATE DEHYDROGENASE MULTIENZYME COMPLEX
1EAC	;	2.6	;	ATOMIC STRUCTURE OF THE CUBIC CORE OF THE PYRUVATE DEHYDROGENASE MULTIENZYME COMPLEX
1EAD	;	2.6	;	ATOMIC STRUCTURE OF THE CUBIC CORE OF THE PYRUVATE DEHYDROGENASE MULTIENZYME COMPLEX
1EAE	;	2.6	;	ATOMIC STRUCTURE OF THE CUBIC CORE OF THE PYRUVATE DEHYDROGENASE MULTIENZYME COMPLEX
1EAF	;	2.6	;	ATOMIC STRUCTURE OF THE CUBIC CORE OF THE PYRUVATE DEHYDROGENASE MULTIENZYME COMPLEX
2N3D	;		;	Atomic structure of the cytoskeletal bactofilin BacA revealed by solid-state NMR
6CT0	;	3.1	;	Atomic Structure of the E2 Inner Core of Human Pyruvate Dehydrogenase Complex
1ENV	;	2.6	;	ATOMIC STRUCTURE OF THE ECTODOMAIN FROM HIV-1 GP41
6RVR	;	3.46	;	Atomic structure of the Epstein-Barr portal, structure I
6RVS	;	3.59	;	Atomic structure of the Epstein-Barr portal, structure II
5V7P	;	2.3	;	Atomic structure of the eukaryotic intramembrane Ras methyltransferase ICMT (isoprenylcysteine carboxyl methyltransferase), in complex with a monobody
2IJ2	;	1.2	;	Atomic structure of the heme domain of flavocytochrome P450-BM3
5ZAP	;	3.1	;	Atomic structure of the herpes simplex virus type 2 B-capsid
4UI9	;	3.6	;	Atomic structure of the human Anaphase-Promoting Complex
6Q1F	;	9.0	;	Atomic structure of the Human Herpesvirus 6B Capsid and Capsid-Associated Tegument Complexes
7TFM	;	1.055	;	Atomic Structure of the Leishmania spp. Hsp100 N-Domain
5OR7	;	2.046	;	Atomic structure of the murine norovirus protruding domain and sCD300lf receptor complex
2ESW	;	2.01	;	Atomic structure of the N-terminal SH3 domain of mouse beta PIX,p21-activated kinase (PAK)-interacting exchange factor
7AP8	;	3.15	;	Atomic structure of the poxvirus initially transcribing complex in conformation 2
7AP9	;	3.01	;	Atomic structure of the poxvirus initially transcribing complex in conformation 3
7AOH	;	2.7	;	Atomic structure of the poxvirus late initially transcribing complex
7AOZ	;	2.85	;	Atomic structure of the poxvirus transcription initiation complex in conformation 1
7AOF	;	2.98	;	Atomic structure of the poxvirus transcription late pre-initiation complex
7AMV	;	2.8	;	Atomic structure of the poxvirus transcription pre-initiation complex in the initially melted state
1FKB	;	1.7	;	ATOMIC STRUCTURE OF THE RAPAMYCIN HUMAN IMMUNOPHILIN FKBP-12 COMPLEX
1HJR	;	2.5	;	ATOMIC STRUCTURE OF THE RUVC RESOLVASE: A HOLLIDAY JUNCTION-SPECIFIC ENDONUCLEASE FROM E. COLI
1TPS	;	1.9	;	ATOMIC STRUCTURE OF THE TRYPSIN-A90720A COMPLEX: A UNIFIED APPROACH TO STRUCTURE AND FUNCTION
1TYN	;	2.0	;	ATOMIC STRUCTURE OF THE TRYPSIN-CYCLOTHEONAMIDE A COMPLEX: LESSONS FOR THE DESIGN OF SERINE PROTEASE INHIBITORS
3OV5	;	1.04	;	Atomic structure of the Xanthomonas citri VirB7 globular domain.
2NXU	;		;	Atomic structure of translation initiation factor aIF2 beta-subunit from Archaebacteria sulfolobus solfataricus: high resolution NMR in solution
4QLP	;	1.1	;	Atomic structure of tuberculosis necrotizing toxin (TNT) complexed with its immunity factor IFT
8JIV	;	2.84	;	Atomic structure of wheat ribosome reveals unique features of the plant ribosomes
8JIW	;	2.88	;	Atomic structure of wheat ribosome reveals unique features of the plant ribosomes
6NHJ	;	5.0	;	Atomic structures and deletion mutant reveal different capsid-binding patterns and functional significance of tegument protein pp150 in murine and human cytomegaloviruses with implications for therapeutic development
3J9Q	;	3.5	;	Atomic structures of a bactericidal contractile nanotube in its pre- and post-contraction states
3J9R	;	3.9	;	Atomic structures of a bactericidal contractile nanotube in its pre- and post-contraction states
3FAP	;	1.85	;	ATOMIC STRUCTURES OF THE RAPAMYCIN ANALOGS IN COMPLEX WITH BOTH HUMAN FKBP12 AND FRB DOMAIN OF FRAP
4FAP	;	2.8	;	ATOMIC STRUCTURES OF THE RAPAMYCIN ANALOGS IN COMPLEX WITH BOTH HUMAN FKBP12 AND FRB DOMAIN OF FRAP
1SOS	;	2.5	;	ATOMIC STRUCTURES OF WILD-TYPE AND THERMOSTABLE MUTANT RECOMBINANT HUMAN CU, ZN SUPEROXIDE DISMUTASE
1HET	;	1.15	;	atomic X-ray structure of liver alcohol dehydrogenase containing a hydroxide adduct to NADH
1HEU	;	1.15	;	ATOMIC X-RAY STRUCTURE OF LIVER ALCOHOL DEHYDROGENASE CONTAINING Cadmium and a hydroxide adduct to NADH
1HF3	;	1.95	;	ATOMIC X-RAY STRUCTURE OF LIVER ALCOHOL DEHYDROGENASE CONTAINING Cadmium and a hydroxide adduct to NADH
3J3Q	;		;	Atomic-level structure of the entire HIV-1 capsid
3J3Y	;		;	Atomic-level structure of the entire HIV-1 capsid (186 hexamers + 12 pentamers)
2MVX	;		;	Atomic-resolution 3D structure of amyloid-beta fibrils: the Osaka mutation
6U0V	;	3.02	;	Atomic-Resolution Cryo-EM Structure of AAV2 VLP
2G8C	;	1.15	;	Atomic-resolution crystal structure of Borrelia burgdorferi OspA via surface entropy reduction
2J9J	;	1.04	;	Atomic-resolution Crystal Structure of Chemically-Synthesized HIV-1 Protease Complexed with Inhibitor JG-365
2J9K	;	1.2	;	Atomic-resolution Crystal Structure of Chemically-Synthesized HIV-1 Protease Complexed with Inhibitor MVT-101
2JE4	;	1.07	;	Atomic-resolution crystal structure of chemically-synthesized HIV-1 protease in complex with JG-365
2QT4	;	1.3	;	Atomic-resolution crystal structure of the natural form of Scytovirin
2QSK	;	1.0	;	Atomic-resolution crystal structure of the Recombinant form of Scytovirin
2A28	;	1.07	;	Atomic-resolution crystal structure of the second SH3 domain of yeast Bzz1 determined from a pseudomerohedrally twinned crystal
2M5N	;		;	Atomic-resolution structure of a cross-beta protofilament
2M5K	;	12.7	;	Atomic-resolution structure of a doublet cross-beta amyloid fibril
3ZPK	;		;	Atomic-resolution structure of a quadruplet cross-beta amyloid fibril.
2M5M	;	12.2	;	Atomic-resolution structure of a triplet cross-beta amyloid fibril
2N0A	;		;	Atomic-resolution structure of alpha-synuclein fibrils
6WAP	;		;	Atomic-Resolution Structure of HIV-1 Capsid Tubes by Magic Angle Spinning NMR
6X63	;		;	Atomic-Resolution Structure of HIV-1 Capsid Tubes by Magic Angle Spinning NMR
6YTU	;	0.95	;	Atomic-resolution structure of the coiled-coil dimerisation domain of human Arc
2V1Q	;	1.2	;	Atomic-resolution structure of the yeast Sla1 SH3 domain 3
5BPT	;	3.2	;	Atomic-resolution structures of the APC/C subunits Apc4 and the Apc5 N-terminal domain
5BPW	;	3.4	;	Atomic-resolution structures of the APC/C subunits Apc4 and the Apc5 N-terminal domain
5BPZ	;	2.18	;	Atomic-resolution structures of the APC/C subunits Apc4 and the Apc5 N-terminal domain
8GRN	;	2.5	;	AtOSCA1.1 extended state
8GSO	;	3.3	;	AtOSCA3.1 channel extended state
8GRO	;	3.5	;	AtOSCA3.1 contracted state
5H5K	;	2.3	;	ATP and CMP bound Crystal structure of thymidylate kinase (aq_969) from Aquifex Aeolicus VF5
7TVE	;	3.8	;	ATP and DNA bound SMC5/6 core complex
1RAW	;		;	ATP BINDING RNA APTAMER IN COMPLEX WITH AMP, NMR, 10 STRUCTURES
1AM1	;	2.0	;	ATP BINDING SITE IN THE HSP90 MOLECULAR CHAPERONE
4C69	;	2.277	;	ATP binding to murine voltage-dependent anion channel 1 (mVDAC1).
7UUX	;	2.26	;	ATP binds to Cyclic GMP AMP synthase (cGAS) through Mg coordination
2NT8	;	1.68	;	ATP bound at the active site of a PduO type ATP:co(I)rrinoid adenosyltransferase from Lactobacillus reuteri
2FGH	;	2.8	;	ATP bound gelsolin
1W7A	;	2.27	;	ATP bound MutS
7C1Z	;	2.09617	;	ATP bound structure of Pseudouridine kinase (PUKI) from Arabidopsis thaliana
4U07	;	2.64	;	ATP bound to eukaryotic FIC domain containing protein
7D4U	;	2.7	;	ATP complex with double mutant cyclic trinucleotide synthase CdnD
2HIX	;	2.87	;	ATP dependent DNA ligase from S. solfataricus bound to ATP
6KR1	;	2.0	;	ATP dependent protease HslV from Staphylococcus aureus
3SL2	;	1.61	;	ATP Forms a Stable Complex with the Essential Histidine Kinase WalK (YycG) Domain
1USY	;	2.52	;	ATP phosphoribosyl transferase (HisG:HisZ) complex from Thermotoga maritima
1Z7M	;	2.9	;	ATP Phosphoribosyl transferase (HisZG ATP-PRTase) from Lactococcus lactis
1Z7N	;	3.25	;	ATP Phosphoribosyl transferase (HisZG ATP-PRTase) from Lactococcus lactis with bound PRPP substrate
1NH7	;	2.7	;	ATP PHOSPHORIBOSYLTRANSFERASE (ATP-PRTASE) FROM MYCOBACTERIUM TUBERCULOSIS
1NH8	;	1.8	;	ATP PHOSPHORIBOSYLTRANSFERASE (ATP-PRTASE) FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH AMP AND HISTIDINE
8OY0	;	2.4	;	ATP phosphoribosyltransferase (HisZG ATPPRT) from Acinetobacter baumanii
5M8H	;	2.34	;	ATP phosphoribosyltransferase (HisZG ATPPRT) from Psychrobacter arcticus
6FU7	;	2.31	;	ATP phosphoribosyltransferase (HisZG ATPPRT) from Psychrobacter arcticus in complex with PRATP
6FTT	;	2.29	;	ATP phosphoribosyltransferase (HisZG ATPPRT) from Psychrobacter arcticus in complex with PRPP
6FUA	;	2.8	;	ATP phosphoribosyltransferase (HisZG ATPPRT) from Psychrobacter arcticus in complex with PRPP and ADP
6FU2	;	2.71	;	ATP phosphoribosyltransferase (HisZG ATPPRT) from Psychrobacter arcticus in complex with PRPP and ATP
5LHT	;	2.0601	;	ATP Phosphoribosyltransferase from Mycobacterium tuberculosis in complex with the allosteric activator 3-(2-Thienyl)-L-alanine
5LHU	;	2.02	;	ATP Phosphoribosyltransferase from Mycobacterium tuberculosis in complex with the allosteric inhibitor L-Histidine
8A8D	;	2.1	;	ATP sulfurylase from Methanothermococcus thermolithotrophicus - monoclinic form
8A8G	;	1.97	;	ATP sulfurylase from Methanothermococcus thermolithotrophicus - orthorhombic form
1G8F	;	1.95	;	ATP SULFURYLASE FROM S. CEREVISIAE
1G8G	;	2.6	;	ATP SULFURYLASE FROM S. CEREVISIAE: THE BINARY PRODUCT COMPLEX WITH APS
1G8H	;	2.8	;	ATP SULFURYLASE FROM S. CEREVISIAE: THE TERNARY PRODUCT COMPLEX WITH APS AND PPI
1L2P	;	1.55	;	ATP Synthase b Subunit Dimerization Domain
3UD0	;	2.0	;	ATP synthase C10 ring in proton-unlocked conformation at PH 5.5
3U2Y	;	2.5	;	ATP synthase c10 ring in proton-unlocked conformation at pH 6.1
3U2F	;	2.0	;	ATP synthase c10 ring in proton-unlocked conformation at PH 8.3
3U32	;	2.0	;	ATP synthase c10 ring reacted with DCCD at pH 5.5
5DN6	;	3.98	;	ATP synthase from Paracoccus denitrificans
8G7N	;	2.7	;	ATP- and mtHsp10-bound mtHsp60 V72I
8G7O	;	3.4	;	ATP- and mtHsp10-bound mtHsp60 V72I focus
1MT0	;	2.6	;	ATP-binding domain of hemolysin B from Escherichia coli
7RAX	;	1.41	;	ATP-binding state of the nucleotide-binding domain of Hsp70 DnaK mutant T199A
1B0U	;	1.5	;	ATP-BINDING SUBUNIT OF THE HISTIDINE PERMEASE FROM SALMONELLA TYPHIMURIUM
7JIJ	;	5.5	;	ATP-bound AMP-activated protein kinase
7M74	;	3.93	;	ATP-bound AMP-activated protein kinase
6M96	;	2.05	;	ATP-bound conformation of the WzmWzt O antigen ABC transporter
4GT3	;	1.68	;	ATP-bound form of the ERK2 kinase
3WV8	;	1.8	;	ATP-bound HcgE from Methanothermobacter marburgensis
8G7L	;	2.5	;	ATP-bound mtHsp60 V72I
8G7M	;	3.2	;	ATP-bound mtHsp60 V72I focus
5E84	;	2.99	;	ATP-bound state of BiP
4U1R	;	2.8	;	ATP-bound structure of human platelet phosphofructokinase in an R-state, crystal form II
7N6I	;	3.9	;	ATP-bound TnsC-TniQ complex from ShCAST system
7BMK	;	1.85	;	ATP-Competitive Partial Antagonists-'PAIR's-Rheostatically Modulate IRE1alpha's Kinase Helix-alphaC to Segregate its RNase-Mediated Biological Outputs
1R6O	;	2.25	;	ATP-dependent Clp protease ATP-binding subunit clpA/ATP-dependent Clp protease adaptor protein clpS
1A0I	;	2.6	;	ATP-DEPENDENT DNA LIGASE FROM BACTERIOPHAGE T7 COMPLEX WITH ATP
2CFM	;	1.8	;	ATP-DEPENDENT DNA LIGASE FROM PYROCOCCUS FURIOSUS
2HIV	;	2.05	;	ATP-dependent DNA ligase from S. solfataricus
8U6X	;	2.44	;	ATP-dependent DNA ligase Lig E from Neisseria gonorrhoeae
3TY6	;	2.498	;	ATP-dependent Protease HslV from Bacillus anthracis str. Ames
8IJU	;	1.82	;	ATP-dependent RNA helicase DDX39A (URH49delta41)
4XQK	;	2.7	;	ATP-dependent Type ISP restriction-modification enzyme LlaBIII bound to DNA
7ZBH	;	3.3	;	ATP-dependent zinc metalloprotease FtsH (BB0789) from Borrelia burgdorferi
5C76	;	3.94	;	ATP-driven lipid-linked oligosaccharide flippase PglK in apo-inward facing state (2)
5C78	;	2.9	;	ATP-driven lipid-linked oligosaccharide flippase PglK in apo-inward state (1)
5C73	;	5.9	;	ATP-driven lipid-linked oligosaccharide flippase PglK in outward-occluded conformation
5DAC	;	2.503	;	ATP-gamma-S bound Rad50 from Chaetomium thermophilum in complex with DNA
5DA9	;	3.0	;	ATP-gamma-S bound Rad50 from Chaetomium thermophilum in complex with the Rad50-binding domain of Mre11
1VE4	;	1.2	;	ATP-Phosphoribosyltransferase(hisG) from Thermus thermophilus HB8
4AAQ	;	8.0	;	ATP-triggered molecular mechanics of the chaperonin GroEL
4AAR	;	8.0	;	ATP-triggered molecular mechanics of the chaperonin GroEL
4AAS	;	8.5	;	ATP-triggered molecular mechanics of the chaperonin GroEL
4AAU	;	8.5	;	ATP-triggered molecular mechanics of the chaperonin GroEL
4AB2	;	8.5	;	ATP-triggered molecular mechanics of the chaperonin GroEL
4AB3	;	8.5	;	ATP-triggered molecular mechanics of the chaperonin GroEL
6WLJ	;	9.6	;	ATP-TTR-3 with AMP models, 9.6 Angstrom resolution
1MO7	;		;	ATPase
1MO8	;		;	ATPase
6J17	;	1.975	;	ATPase
6J18	;	2.0	;	ATPase
6J19	;	1.978	;	ATPase
6JD4	;	2.1	;	ATPase
6JD5	;	2.2	;	ATPase
4BYG	;	2.85	;	ATPase crystal structure
4BEV	;	3.583	;	ATPase crystal structure with bound phosphate analogue
6TV1	;	1.7	;	ATPase domain D3 of the EssC coupling protein from S. aureus USA300
3BH0	;	2.35	;	ATPase Domain of G40P
1HJO	;	2.3	;	ATPase domain of human heat shock 70kDa protein 1
5UBV	;	2.45	;	ATPase domain of i-AAA protease from Myceliophthora thermophila
8RU5	;	1.36	;	ATPase family AAA domain containing 2 with crystallization epitope mutations V1022R:Q1027E
4PHT	;	2.83	;	ATPase GspE in complex with the cytoplasmic domain of GspL from the Vibrio vulnificus type II Secretion system
1T4G	;	2.0	;	ATPase in complex with AMP-PNP
1XU4	;	2.4	;	ATPASE IN COMPLEX WITH AMP-PNP, MAGNESIUM AND POTASSIUM CO-F
6UKS	;	3.2	;	ATPgammaS bound mBcs1
1XXH	;	3.45	;	ATPgS Bound E. Coli Clamp Loader Complex
7M99	;	3.2	;	ATPgS bound TnsC filament from ShCAST system
7CS9	;	2.80114	;	AtPrR1 in apo form
7CSA	;	1.96213	;	AtPrR1 with NADP+
7CSD	;	1.7971	;	AtPrR1 with NADP+ and (+)lariciresinol
7CSB	;	2.00202	;	AtPrR1 with NADP+ and (+)pinoresinol
7CSE	;	2.44019	;	AtPrR1 with NADP+ and (-)lariciresinol
7CSC	;	2.51512	;	AtPrR1 with NADP+ and (-)pinoresinol
7CSF	;	1.98242	;	AtPrR1 with NADP+ and (-)secoisolariciresinol
7CSG	;	1.99689	;	AtPrR2 in apo form
7CSH	;	1.59078	;	AtPrR2 with NADP+ and (+)pinoresinol
1AXH	;		;	ATRACOTOXIN-HVI FROM HADRONYCHE VERSUTA (AUSTRALIAN FUNNEL-WEB SPIDER, NMR, 20 STRUCTURES
7BRK	;	2.85	;	Atrial Natriuretic Peptide Receptor complexed with deletion mutant of human Atrial Natriuretic Peptide[5-27]
7BRJ	;	2.7	;	Atrial Natriuretic Peptide Receptor complexed with deletion mutant of human Atrial Natriuretic Peptide[7-28]
7BRL	;	3.2	;	Atrial Natriuretic Peptide Receptor complexed with Deletion mutant of rat Atrial Natriuretic Peptide[4-17,23]
7BRI	;	2.45	;	Atrial Natriuretic Peptide Receptor complexed with Dendroaspis Natriuretic Peptide
7BRH	;	2.45	;	Atrial Natriuretic Peptide Receptor complexed with human Atrial Natriuretic Peptide
7BRG	;	2.45	;	Atrial Natriuretic Peptide Receptor complexed with rat Atrial Natriuretic Peptide
8GW6	;	3.3	;	AtSLAC1 6D mutant in closed state
8GW7	;	3.3	;	AtSLAC1 6D mutant in open state
8J0J	;	2.7	;	AtSLAC1 8D mutant in closed state
8J1E	;	3.84	;	AtSLAC1 in open state
2KBT	;		;	Attachment of an NMR-invisible solubility enhancement tag (INSET) using a sortase-mediated protein ligation method
7TBG	;	2.5	;	AtTPC1 D454N with 1 mM Ca2+
7TDF	;	2.7	;	AtTPC1 D454N with 1 mM EDTA state I
7TDD	;	3.5	;	AtTPC1 D454N-EDTA state II
7TDE	;	3.2	;	AtTPC1 DDE mutant with 1 mM Ca2+
8PKF	;	2.3673	;	ATTRG47E amyloid fibril from hereditary ATTR amloidosis
8PKG	;	2.99	;	ATTRV122I amyloid fibril from hereditary ATTR amloidosis
8PKE	;	3.39	;	ATTRV20I amyloid fibril from hereditary ATTR amloidosis
5YZY	;	2.61	;	AtVAL1 B3 domain in complex with 13bp-DNA
5YZZ	;	2.58	;	AtVAL1 B3 domain in complex with 13bp-DNA
5Z00	;	2.587	;	AtVAL1 B3 domain in complex with 15bp-DNA
5YUG	;	1.57	;	AtVAL1 PHD-Like domain in the P31 space group
5YUH	;	1.801	;	AtVAL1 PHD-Like domain in the P6122 space group
5Z28	;	2.245	;	AtVAL2 PHD-Like domain
2JP5	;		;	ATWLPPR an anti-angiogenic peptide
7Z0R	;	1.66	;	AtWRKY18 DNA-binding domain
4R6I	;	2.65	;	AtxA protein, a virulence regulator from Bacillus anthracis.
5TXC	;	2.401	;	AtxE2 Isopeptidase - APO
5TXE	;	2.2	;	AtxE2 Isopeptidase - S527A Variant with Astexin3-dC4 Bound
2J7I	;	2.9	;	ATYPICAL POLYPROLINE RECOGNITION BY THE CMS N-TERMINAL SH3 DOMAIN. CMS:CD2 HETERODIMER
2J6O	;	2.23	;	ATYPICAL POLYPROLINE RECOGNITION BY THE CMS N-TERMINAL SH3 DOMAIN. CMS:CD2 HETEROTRIMER
7KUB	;		;	Au1 Domain of VEGF Readthrough Element
7MZX	;		;	AUGalpha - FAM150B - ALKL2 77-152
7MZZ	;		;	AUGbeta - FAM150A - ALKL1 60-128
7MK7	;	2.42815	;	Augmentor domain of augmentor-beta
8SSP	;	2.6	;	AurA bound to danusertib and activating monobody Mb1
8SSO	;	1.97	;	AurA bound to danusertib and inhibiting monobody Mb2
2AAN	;	1.85	;	Auracyanin A: A ""blue"" copper protein from the green thermophilic photosynthetic bacterium,chloroflexus aurantiacus
1OV8	;	1.9	;	Auracyanin B structure in space group, P65
1QHQ	;	1.55	;	AURACYANIN, A BLUE COPPER PROTEIN FROM THE GREEN THERMOPHILIC PHOTOSYNTHETIC BACTERIUM CHLOROFLEXUS AURANTIACUS
1BQB	;	1.72	;	AUREOLYSIN, STAPHYLOCOCCUS AUREUS METALLOPROTEINASE
7JFR	;	2.35	;	Auristatin bound to tubulin
3H0Y	;	2.5	;	Aurora A in complex with a bisanilinopyrimidine
3H0Z	;	2.92	;	Aurora A in complex with a bisanilinopyrimidine
4DEE	;	2.3	;	Aurora A in complex with ADP
5DN3	;	2.05	;	Aurora A in complex with ATP and AA35.
4J8M	;	1.853	;	Aurora A in complex with CD532
4DEB	;	3.05	;	Aurora A in complex with RK2-17-01
3UNZ	;	2.8	;	Aurora A in Complex with RPM1679
3UO4	;	2.45	;	Aurora A in complex with RPM1680
3UP2	;	2.3001	;	Aurora A in complex with RPM1686
3UOD	;	2.5002	;	Aurora A in complex with RPM1693
3UOJ	;	2.9003	;	Aurora A in complex with RPM1715
3UOH	;	2.8002	;	Aurora A in complex with RPM1722
3UOL	;	2.4	;	Aurora A in complex with SO2-162
3UP7	;	3.05	;	Aurora A in complex with YL1-038-09
4DEA	;	2.45	;	Aurora A in complex with YL1-038-18
4DED	;	3.05	;	Aurora A in complex with YL1-038-21
3UO5	;	2.7012	;	Aurora A in complex with YL1-038-31
3UO6	;	2.8002	;	Aurora A in complex with YL5-083
3UOK	;	2.9506	;	Aurora A in complex with YL5-81-1
3H10	;	2.2	;	Aurora A inhibitor complex
2C6E	;	2.1	;	Aurora A kinase activated mutant (T287D) in complex with a 5- aminopyrimidinyl quinazoline inhibitor
2C6D	;	2.2	;	Aurora A kinase activated mutant (T287D) in complex with ADPNP
4J8N	;	3.135	;	Aurora A Kinase Apo
4BYI	;	2.6	;	Aurora A kinase bound to a highly selective imidazopyridine inhibitor
4BYJ	;	2.75	;	Aurora A kinase bound to a highly selective imidazopyridine inhibitor
5AAF	;	2.78	;	Aurora A kinase bound to an imidazopyridine inhibitor (14a)
5AAG	;	2.85	;	Aurora A kinase bound to an imidazopyridine inhibitor (14b)
5AAE	;	3.11	;	Aurora A kinase bound to an imidazopyridine inhibitor (14d)
5AAD	;	3.1	;	Aurora A kinase bound to an imidazopyridine inhibitor (7a)
3MYG	;	2.4	;	Aurora A Kinase complexed with SCH 1473759
4PRJ	;	2.8	;	Aurora A kinase domain with compound 2 (N-[1-(3-cyanobenzyl)-1H-pyrazol-4-yl]-6-(1H-pyrazol-4-yl)-1H-indazole-3-carboxamide)
3P9J	;	2.8	;	Aurora A kinase domain with phthalazinone pyrazole inhibitor
5OBR	;	2.62	;	Aurora A kinase in complex with 2-(3-chloro-5-fluorophenyl)quinoline-4-carboxylic acid and JNJ-7706621
5OBJ	;	2.901	;	Aurora A kinase in complex with 2-(3-fluorophenyl)quinoline-4-carboxylic acid and ATP
5DR9	;	2.47	;	Aurora A Kinase in Complex with AA29 and JNJ-7706621 in Space Group P6122
5DR2	;	2.46	;	Aurora A Kinase in Complex with AA30 and ATP in Space Group P6122
5DR6	;	2.534	;	Aurora A Kinase in Complex with AA30 and JNJ-7706621 in Space Group P6122
5DOS	;	2.98	;	Aurora A Kinase in Complex with AA35 and ATP in Space Group P6122
5DT4	;	2.86	;	Aurora A Kinase in Complex with AA35 and ATP in Space Group P6122
5DPV	;	2.285	;	Aurora A Kinase in Complex with AA35 and JNJ-7706621 in Space Group P6122
5DNR	;	1.95	;	Aurora A Kinase in complex with ATP in space group P41212
5DRD	;	2.13	;	Aurora A Kinase in Complex with ATP in Space Group P6122
5DT3	;	2.33	;	Aurora A Kinase in Complex with ATP in Space Group P6122
5DT0	;	2.15	;	Aurora A Kinase in Complex with JNJ-7706621 in Space Group P6122
8C1I	;	2.81	;	Aurora A kinase in complex with TPX2-inhibitor 10
8C1M	;	2.84	;	Aurora A kinase in complex with TPX2-inhibitor 2
8C15	;	2.41	;	Aurora A kinase in complex with TPX2-inhibitor 3
8C1F	;	1.924	;	Aurora A kinase in complex with TPX2-inhibitor 6
8C1G	;	1.96	;	Aurora A kinase in complex with TPX2-inhibitor 7
8C1H	;	2.233	;	Aurora A kinase in complex with TPX2-inhibitor 8
8C14	;	1.93	;	Aurora A kinase in complex with TPX2-inhibitor 9
8C1D	;	2.115	;	Aurora A kinase in complex with TPX2-inhibitor 9
8C1E	;	2.798	;	Aurora A kinase in complex with TPX2-inhibitor 9
8C1K	;	2.43	;	Aurora A kinase in complex with TPX2-inhibitor CAM2602
6C2R	;	1.96	;	Aurora A ligand complex
6C2T	;	1.73	;	Aurora A ligand complex
4C2V	;	1.49	;	Aurora B kinase in complex with the specific inhibitor Barasertib
4B8M	;	1.85	;	Aurora B kinase in complex with VX-680
4B8L	;	3.0	;	Aurora B kinase P353G mutant
3W10	;	2.7	;	Aurora kinase A complexed to pyrazole aminoquinoline I
7O2V	;	3.1	;	AURORA KINASE A IN COMPLEX WITH THE AUR-A/PDK1 INHIBITOR VI8
3ZTX	;	1.95	;	Aurora kinase selective inhibitors identified using a Taxol-induced checkpoint sensitivity screen.
2BMC	;	2.6	;	Aurora-2 T287D T288D complexed with PHA-680632
2X6D	;	2.796	;	Aurora-A bound to an inhibitor
2X6E	;	3.35	;	Aurora-A bound to an inhibitor
6R49	;	2.209	;	Aurora-A in complex with shape-diverse fragment 39
6R4A	;	1.937	;	Aurora-A in complex with shape-diverse fragment 55
6R4B	;	2.15	;	Aurora-A in complex with shape-diverse fragment 56
6R4C	;	2.04	;	Aurora-A in complex with shape-diverse fragment 57
6R4D	;	2.009	;	Aurora-A in complex with shape-diverse fragment 58
5ODT	;	2.021	;	Aurora-A in complex with TACC3
2WTV	;	2.4	;	Aurora-A Inhibitor Structure
2WTW	;	3.302	;	Aurora-A Inhibitor Structure (2nd crystal form)
2DWB	;	2.5	;	Aurora-A kinase complexed with AMPPNP
6I2U	;	2.5	;	Aurora-A kinase domain in complex with Coenzyme A
5L8L	;	1.67	;	Aurora-A kinase domain in complex with vNAR-D01 (crystal form 1)
5L8K	;	1.79	;	Aurora-A kinase domain in complex with vNAR-D01 (crystal form 2)
5L8J	;	1.68	;	Aurora-A kinase domain in complex with vNAR-D01 S93R
2XRU	;	2.9	;	AURORA-A T288E COMPLEXED WITH PHA-828300
4IRH	;	2.1	;	Auto-inhibited ERG Ets domain
4IRI	;	2.77	;	Auto-inhibited ERG Ets Domain-DNA Complex
4K44	;	1.7	;	Auto-inhibition and phosphorylation-induced activation of PLC-gamma isozymes
4K45	;	1.5	;	Auto-inhibition and phosphorylation-induced activation of PLC-gamma isozymes
4ROU	;	2.713	;	Auto-inhibition Mechanism of Human Mitochondrial RNase P Protein Complex
1U37	;		;	Auto-inhibition Mechanism of X11s/Mints Family Scaffold Proteins Revealed by the Closed Conformation of the Tandem PDZ Domains
1U38	;		;	Auto-inhibition Mechanism of X11s/Mints Family Scaffold Proteins Revealed by the Closed Conformation of the Tandem PDZ Domains
1U39	;		;	Auto-inhibition Mechanism of X11s/Mints Family Scaffold Proteins Revealed by the Closed Conformation of the Tandem PDZ Domains
1U3B	;		;	Auto-inhibition Mechanism of X11s/Mints Family Scaffold Proteins Revealed by the Closed Conformation of the Tandem PDZ Domains
1QWT	;	2.1	;	Auto-inhibitory interferon regulation factor-3 (IRF3) transactivation domain
1RNR	;	2.5	;	AUTOCATALYTIC GENERATION OF DOPA IN THE ENGINEERED PROTEIN R2 F208Y FROM ESCHERICHIA COLI RIBONUCLEOTIDE REDUCTASE AND CRYSTAL STRUCTURE OF THE DOPA-208 PROTEIN
8TAF	;	3.2	;	Autographa californica multiple nucleopolyhedrovirus VP39
7MFE	;	4.07	;	Autoinhibited BRAF:(14-3-3)2 complex with the BRAF RBD resolved
7MFD	;	3.66	;	Autoinhibited BRAF:(14-3-3)2:MEK complex with the BRAF RBD resolved
5T4O	;	6.9	;	Autoinhibited E. coli ATP synthase state 1
5T4P	;	7.77	;	Autoinhibited E. coli ATP synthase state 2
5T4Q	;	8.53	;	Autoinhibited E. coli ATP synthase state 3
5ILS	;	1.399	;	Autoinhibited ETV1
5ILU	;	1.101	;	Autoinhibited ETV4
3OBV	;	2.75	;	Autoinhibited Formin mDia1 Structure
2OZO	;	2.6	;	Autoinhibited intact human ZAP-70
7MP5	;	5.6	;	Autoinhibited neurofibrobmin
1TKI	;	2.0	;	AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
6F3F	;	2.41796	;	Autoinhibited Src kinase bound to ADP
4L9M	;	3.0	;	Autoinhibited state of the Ras-specific exchange factor RasGRP1
7PGU	;	3.3	;	Autoinhibited structure of human neurofibromin isoform 2 stabilized by Zinc.
3KY9	;	2.731	;	Autoinhibited Vav1
1CXR	;		;	AUTOMATED 2D NOESY ASSIGNMENT AND STRUCTURE CALCULATION OF CRAMBIN(S22/I25) WITH SELF-CORRECTING DISTANCE GEOMETRY BASED NOAH/DIAMOD PROGRAMS
2K22	;		;	Automated NMR Structure of the TA0895 by FAPSY
2K24	;		;	Automated NMR Structure of the TA0956 by FAPSY
2K25	;		;	Automated NMR Structure of the UBB by FAPSY
5OYQ	;	1.49	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 1
5OYZ	;	1.487	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 10
5P1H	;	1.528	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 100
5P1I	;	1.338	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 101
5P1J	;	1.369	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 102
5P1K	;	1.549	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 103
5P1L	;	1.249	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 104
5P1M	;	1.599	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 105
5P1N	;	1.516	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 106
5P1O	;	1.515	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 107
5P1P	;	1.319	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 108
5P1Q	;	1.17	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 109
5OZ0	;	1.449	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 11
5P1R	;	1.329	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 110
5P1S	;	1.319	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 111
5P1T	;	1.403	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 112
5P1U	;	1.499	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 113
5P1V	;	1.301	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 114
5P1W	;	1.23	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 115
5P1X	;	1.196	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 116
5P1Y	;	1.518	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 117
5P1Z	;	1.459	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 118
5P20	;	1.435	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 119
5OZ1	;	1.478	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 12
5P22	;	1.309	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 120
5P23	;	1.713	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 121
5P24	;	1.709	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 122
5P25	;	1.259	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 123
5P26	;	1.411	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 124
5P27	;	1.451	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 125
5P28	;	1.345	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 126
5P29	;	1.477	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 127
5P2A	;	1.373	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 128
5P2B	;	1.7	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 129
5OZ2	;	1.61	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 13
5P2C	;	1.749	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 130
5P2D	;	1.299	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 131
5P2E	;	1.527	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 132
5P2F	;	1.797	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 133
5P2G	;	1.489	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 134
5P2H	;	1.621	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 135
5P2I	;	1.428	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 136
5P2J	;	1.559	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 137
5P2K	;	1.822	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 138
5P2L	;	1.119	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 139
5OZ3	;	1.754	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 14
5P2M	;	1.089	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 140
5P2N	;	1.549	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 141
5P2O	;	1.119	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 142
5P2Q	;	1.35	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 143
5P2R	;	1.169	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 144
5P2S	;	1.078	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 145
5P2T	;	1.098	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 146
5P2U	;	1.379	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 147
5P2V	;	1.317	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 148
5P2W	;	1.518	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 149
5OZ4	;	1.478	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 15
5P2X	;	1.399	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 150
5P2Y	;	1.639	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 151
5P2Z	;	1.519	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 152
5P30	;	1.845	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 153
5P31	;	1.249	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 154
5P32	;	1.119	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 155
5P33	;	1.26	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 156
5P34	;	1.209	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 157
5P35	;	1.24	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 158
5P36	;	1.369	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 159
5OZ5	;	1.485	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 16
5P37	;	1.419	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 160
5P38	;	1.289	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 161
5P39	;	1.188	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 162
5P3A	;	1.177	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 163
5P3B	;	1.239	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 164
5P3C	;	1.266	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 165
5P3D	;	1.18	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 166
5P3E	;	1.17	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 167
5P3F	;	1.257	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 168
5P3G	;	1.389	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 169
5OZ6	;	1.546	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 17
5P3H	;	1.389	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 170
5P3I	;	1.25	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 171
5P3J	;	1.339	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 172
5P3K	;	1.747	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 173
5P3L	;	1.25	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 174
5P3M	;	1.189	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 175
5P3N	;	1.439	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 176
5P3O	;	1.249	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 177
5P3P	;	1.459	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 178
5P3Q	;	1.09	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 179
5OZ7	;	1.608	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 18
5P3R	;	1.369	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 180
5P3S	;	1.17	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 181
5P3T	;	1.188	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 182
5P3U	;	1.2	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 183
5P3V	;	1.468	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 184
5P3W	;	1.238	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 185
5P3X	;	1.42	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 186
5P3Y	;	1.219	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 187
5P3Z	;	1.196	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 188
5P40	;	1.228	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 189
5OZ8	;	1.56	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 19
5P41	;	1.278	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 190
5P42	;	1.179	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 191
5P43	;	1.189	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 192
5P44	;	1.18	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 193
5P45	;	1.189	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 194
5P46	;	1.179	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 195
5P47	;	1.18	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 196
5P48	;	1.17	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 197
5P49	;	1.259	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 198
5P4A	;	1.348	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 199
5OYR	;	1.488	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 2
5OZ9	;	1.609	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 20
5P4B	;	1.199	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 200
5P4C	;	1.257	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 201
5P4D	;	1.247	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 202
5P4E	;	1.399	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 203
5P4F	;	1.409	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 204
5P4G	;	1.159	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 205
5P4H	;	1.448	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 206
5P4I	;	1.416	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 207
5P4J	;	1.517	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 208
5P4K	;	1.47	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 209
5OZA	;	1.49	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 21
5P4L	;	1.079	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 210
5P4M	;	1.07	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 211
5P4N	;	1.247	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 212
5P4O	;	1.06	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 213
5P4P	;	1.569	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 214
5P4Q	;	1.587	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 215
5P4R	;	1.13	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 216
5P4S	;	1.308	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 217
5P4T	;	1.699	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 218
5P4U	;	1.319	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 219
5OZB	;	1.488	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 22
5P4V	;	1.329	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 220
5P4W	;	1.15	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 221
5P4X	;	1.576	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 222
5P4Y	;	1.408	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 223
5P4Z	;	1.248	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 224
5P50	;	1.119	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 225
5P51	;	1.119	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 226
5P52	;	1.27	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 227
5P53	;	1.12	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 228
5P54	;	1.087	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 229
5OZC	;	1.709	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 23
5P55	;	1.299	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 230
5P56	;	1.499	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 231
5P57	;	1.418	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 232
5P58	;	1.12	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 233
5P59	;	1.18	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 234
5P5A	;	1.268	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 235
5P5B	;	1.209	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 236
5P5C	;	1.339	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 237
5P5D	;	1.579	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 238
5P5E	;	1.269	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 239
5OZD	;	1.37	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 24
5P5F	;	1.298	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 240
5P5G	;	1.661	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 241
5P5H	;	1.09	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 242
5P5I	;	1.18	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 243
5P5J	;	1.169	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 244
5P5K	;	1.259	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 245
5P5L	;	1.725	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 246
5P5M	;	1.18	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 247
5P5N	;	1.689	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 248
5P5O	;	1.199	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 249
5OZE	;	1.241	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 25
5P5P	;	1.09	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 250
5P5Q	;	1.284	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 251
5P5R	;	1.308	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 252
5P5S	;	1.139	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 253
5P5T	;	1.179	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 254
5P5U	;	1.419	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 255
5P5V	;	1.059	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 256
5P5W	;	1.299	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 257
5P5X	;	1.069	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 258
5P5Y	;	1.139	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 259
5OZF	;	1.527	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 26
5P5Z	;	1.169	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 260
5P60	;	1.238	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 261
5P61	;	1.089	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 262
5P62	;	1.278	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 263
5P63	;	1.199	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 264
5P64	;	1.069	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 265
5P65	;	1.1	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 266
5P66	;	1.187	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 267
5P67	;	1.116	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 268
5P68	;	1.25	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 269
5OZG	;	1.49	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 27
5P69	;	1.44	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 270
5P6A	;	1.158	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 271
5P6B	;	1.469	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 272
5P6C	;	1.339	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 273
5P6D	;	1.439	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 274
5P6E	;	1.209	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 275
5P6F	;	1.129	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 276
5P6G	;	1.088	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 277
5P6H	;	1.449	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 278
5P6I	;	1.198	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 279
5OZH	;	1.488	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 28
5P6J	;	1.259	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 280
5P6K	;	1.607	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 281
5P6L	;	1.049	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 282
5P6M	;	1.345	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 283
5P6N	;	1.109	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 284
5P6O	;	1.13	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 285
5P6P	;	1.278	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 286
5P6Q	;	1.238	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 287
5P6R	;	1.269	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 288
5P6S	;	1.339	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 289
5OZI	;	1.5	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 29
5P6T	;	1.457	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 290
5P6U	;	1.06	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 291
5P6V	;	1.276	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 292
5P6W	;	1.608	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 293
5P6X	;	1.397	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 294
5P6Y	;	1.18	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 295
5P6Z	;	1.279	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 296
5P70	;	1.019	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 297
5P71	;	1.03	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 298
5P72	;	1.049	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 299
5OYS	;	1.649	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 3
5OZJ	;	1.489	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 30
5P73	;	1.019	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 300
5P74	;	1.04	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 301
5P75	;	1.431	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 302
5P76	;	1.039	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 303
5P77	;	1.029	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 304
5P78	;	1.687	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 305
5P79	;	1.129	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 306
5P7A	;	1.248	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 307
5P7B	;	1.407	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 308
5P7C	;	1.269	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 309
5OZK	;	1.328	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 31
5P7D	;	1.169	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 310
5P7E	;	1.234	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 311
5P7F	;	1.079	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 312
5P7G	;	1.099	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 313
5P7H	;	1.188	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 314
5P7I	;	1.187	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 315
5P7J	;	1.307	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 316
5P7K	;	1.099	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 317
5P7L	;	1.17	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 318
5P7M	;	1.329	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 319
5OZL	;	1.74	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 32
5P7N	;	1.647	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 320
5P7O	;	1.482	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 321
5P7P	;	1.439	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 322
5P7Q	;	1.108	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 323
5P7R	;	1.476	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 324
5P7S	;	1.189	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 325
5P7T	;	1.459	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 326
5P7U	;	1.098	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 327
5P7V	;	1.28	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 328
5P7W	;	1.36	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 329
5OZM	;	1.487	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 33
5P7X	;	1.469	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 330
5P7Y	;	1.654	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 331
5P7Z	;	1.259	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 332
5P80	;	1.239	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 333
5P81	;	1.6	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 334
5P82	;	1.22	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 335
5P83	;	1.518	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 336
5P84	;	1.289	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 337
5P85	;	1.229	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 338
5P86	;	1.33	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 339
5OZN	;	1.489	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 34
5P87	;	1.349	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 340
5P88	;	1.219	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 341
5P89	;	1.269	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 342
5P8A	;	1.268	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 343
5P8B	;	1.548	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 344
5P8C	;	1.299	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 345
5P8D	;	1.179	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 346
5P8E	;	1.219	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 347
5P8F	;	1.269	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 348
5P8G	;	1.279	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 349
5OZO	;	1.579	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 35
5P8H	;	1.24	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 350
5P8I	;	1.219	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 351
5P8J	;	1.329	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 352
5P8K	;	1.259	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 353
5P8L	;	1.239	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 354
5P8M	;	1.199	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 355
5P8N	;	1.488	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 356
5P8O	;	1.477	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 357
5P8P	;	1.219	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 358
5P8Q	;	1.139	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 359
5OZP	;	1.49	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 36
5P8R	;	1.07	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 360
5P8S	;	1.109	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 361
5P8T	;	1.03	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 362
5P8U	;	1.44	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 363
5P8V	;	1.579	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 364
5OZQ	;	1.503	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 37
5OZR	;	1.769	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 38
5OZS	;	1.72	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 39
5OYT	;	1.589	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 4
5OZT	;	1.8	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 40
5OZU	;	1.118	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 41
5OZV	;	1.476	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 42
5OZW	;	1.54	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 43
5OZX	;	1.484	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 44
5OZY	;	1.489	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 45
5OZZ	;	1.527	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 46
5P00	;	1.508	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 47
5P01	;	1.514	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 48
5P02	;	1.487	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 49
5OYU	;	1.25	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 5
5P03	;	1.49	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 50
5P04	;	1.669	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 51
5P05	;	1.603	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 52
5P06	;	1.319	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 53
5P07	;	1.619	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 54
5P08	;	1.605	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 55
5P09	;	1.609	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 56
5P0A	;	1.818	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 57
5P0B	;	1.63	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 58
5P0C	;	1.819	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 59
5OYV	;	1.439	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 6
5P0D	;	1.849	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 60
5P0E	;	1.799	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 61
5P0F	;	1.249	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 62
5P0G	;	1.49	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 63
5P0H	;	1.8	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 64
5P0I	;	1.149	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 65
5P0J	;	1.15	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 66
5P0K	;	1.6	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 67
5P0L	;	1.508	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 68
5P0M	;	1.119	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 69
5OYW	;	1.483	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 7
5P0N	;	1.138	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 70
5P0O	;	1.328	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 71
5P0P	;	1.3	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 72
5P0Q	;	1.48	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 73
5P0R	;	1.249	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 74
5P0S	;	1.2	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 75
5P0T	;	1.129	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 76
5P0U	;	1.46	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 77
5P0V	;	1.4	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 78
5P0W	;	1.269	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 79
5OYX	;	1.654	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 8
5P0X	;	1.27	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 80
5P0Y	;	1.32	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 81
5P0Z	;	1.26	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 82
5P10	;	1.488	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 83
5P11	;	1.38	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 84
5P12	;	1.549	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 85
5P13	;	1.399	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 86
5P14	;	1.24	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 87
5P15	;	1.41	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 88
5P16	;	1.64	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 89
5OYY	;	1.447	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 9
5P17	;	1.399	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 90
5P18	;	1.349	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 91
5P19	;	1.129	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 92
5P1A	;	1.4	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 93
5P1B	;	1.378	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 94
5P1C	;	1.347	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 95
5P1D	;	1.279	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 96
5P1E	;	1.589	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 97
5P1F	;	1.259	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 98
5P1G	;	1.478	;	Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 99
8B7V	;	3.0	;	Automated simulation-based refinement of maltoporin into a cryo-EM density
1NH5	;		;	AUTOMATIC ASSIGNMENT OF NMR DATA AND DETERMINATION OF THE PROTEIN STRUCTURE OF A NEW WORLD SCORPION NEUROTOXIN USING NOAH/DIAMOD
7F07	;	2.25	;	Autonomous VH domain that interacts with eIF4E at the Capped mRNA Binding site.
2K6X	;		;	Autoregulation of a Group 1 Bacterial Sigma Factor Involves the Formation of a Region 1.1- Induced Compacted Structure
7Z3L	;	2.4	;	Autotaxin in complex with hybrid compound ziritaxestat (GLPG1690)
7Z3K	;	2.0	;	Autotaxin in complex with orthosteric site-binder CpdA
5S9M	;	1.8	;	AUTOTAXIN, (3,5-dichlorophenyl)methyl (3aS,8aR)-2-(1H-benzotriazole-5-carbonyl)-1,3,3a,4,5,7,8,8a-octahydropyrrolo[3,4-d]azepine-6-carboxylate, 1.80A, P212121, Rfree=21.1%
5S9L	;	1.9	;	AUTOTAXIN, 4-[3-Oxo-3-(2-oxo-2,3-dihydro-benzooxazol-6-yl)-propyl]-piperazine-1-carboxylic acid 3,5-dichloro-benzyl ester, 1.90A, P212121, Rfree=19.1%
5S9N	;	1.8	;	AUTOTAXIN, [4-(trifluoromethoxy)phenyl]methyl (3aS,6aS)-2-(1H-benzotriazole-5-carbonyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylate, 1.80A, P212121, Rfree=23.3%
5NLN	;	1.9	;	Auxiliary activity 9
5NLO	;	1.33	;	Auxiliary activity 9
5NLP	;	1.59	;	Auxiliary activity 9
5NLQ	;	1.5	;	Auxiliary activity 9
5NLR	;	2.0	;	Auxiliary activity 9
5NLS	;	1.75	;	Auxiliary activity 9
4ND8	;	2.0	;	Av Nitrogenase MoFe Protein High pH Form
6G3B	;	1.8	;	AvaII restriction endonuclease in complex with an RNA/DNA hybrid
6S48	;	1.9	;	AvaII RESTRICTION ENDONUCLEASE IN COMPLEX WITH PARTIALLY CLEAVED dsDNA
6S58	;	2.32	;	AvaII restriction endonuclease in the absence of nucleic acids
6WP9	;	2.0	;	AvaR1 bound to Avenolide
4DWL	;	2.69	;	Avd molecule from Bordetella bacteriophage DGR
6WP7	;	2.4	;	Avenolide Binding Autoregulator AvaR1
1ITT	;	1.0	;	Average Crystal Structure of (Pro-Pro-Gly)9 at 1.0 angstroms Resolution
1KSM	;		;	AVERAGE NMR SOLUTION STRUCTURE OF CA LN CALBINDIN D9K
1C9Q	;		;	AVERAGE NMR SOLUTION STRUCTURE OF THE BIR-2 DOMAIN OF XIAP
1F9X	;		;	AVERAGE NMR SOLUTION STRUCTURE OF THE BIR-3 DOMAIN OF XIAP
1JAV	;		;	AVERAGE NMR SOLUTION STRUCTURE OF THE TRP-RICH PEPTIDE OF HIV GP41 BOUND TO DPC MICELLES
2JOL	;		;	Average NMR structure of the catalytic domain of guanine nucleotide exchange factor BopE from Burkholderia pseudomallei
1S2F	;		;	Average solution structure of a pseudo-5'-splice site from the negative regulator of splicing of Rous Sarcoma virus
1EKI	;		;	AVERAGE SOLUTION STRUCTURE OF D(TTGGCCAA)2 BOUND TO CHROMOMYCIN-A3 AND COBALT
1N6V	;		;	Average structure of the interferon-binding ectodomain of the human type I interferon receptor
1QTG	;		;	AVERAGED NMR MODEL OF SWITCH ARC, A DOUBLE MUTANT OF ARC REPRESSOR
6IZV	;	4.2	;	Averaged strand structure of a 15-stranded ParM filament from Clostridium botulinum
1JOK	;		;	Averaged structure for Staphylococcal nuclease-H124L in ternary complex with Ca2+ and thymidine-3',5'-bisphosphate
1JOO	;		;	Averaged structure for unligated Staphylococcal nuclease-H124L
4X3R	;	1.86	;	Avi-GCPII structure in complex with FITC-conjugated GCPII-specific inhibitor
8TEX	;	2.54	;	Avian Adeno-associated virus - empty capsid
8TEY	;	3.06	;	Avian Adeno-associated virus - empty capsid
6MYU	;	1.97	;	Avian mitochondrial complex II crystallized in the presence of HQNO
6MYT	;	2.27	;	Avian mitochondrial complex II with Atpenin A5 bound, sidechain in pocket
6MYS	;	2.37	;	Avian mitochondrial complex II with Atpenin A5 bound, sidechain outside
6MYQ	;	1.97	;	Avian mitochondrial complex II with ferulenol bound
6MYO	;	2.2	;	Avian mitochondrial complex II with flutolanyl bound
6MYR	;	2.15	;	Avian mitochondrial complex II with thiapronil bound
6MYP	;	2.1	;	Avian mitochondrial complex II with TTFA (thenoyltrifluoroacetone) bound
2H88	;	1.74	;	Avian Mitochondrial Respiratory Complex II at 1.8 Angstrom Resolution
1YQ4	;	2.33	;	Avian respiratory complex ii with 3-nitropropionate and ubiquinone
2FBW	;	2.06	;	Avian respiratory complex II with carboxin bound
2H89	;	2.4	;	Avian Respiratory Complex II with Malonate Bound
1YQ3	;	2.2	;	Avian respiratory complex ii with oxaloacetate and ubiquinone
1ASV	;	2.2	;	Avian sarcoma virus integrase catalytic core domain
1ASU	;	1.7	;	AVIAN SARCOMA VIRUS INTEGRASE CATALYTIC CORE DOMAIN CRYSTALLIZED FROM 2% PEG 400, 2M AMMONIUM SULFATE, HEPES PH 7.5
1ASW	;	1.8	;	AVIAN SARCOMA VIRUS INTEGRASE CATALYTIC CORE DOMAIN CRYSTALLIZED FROM 20% PEG 4000, 10% ISOPROPANOL, HEPES PH 7.5 USING SELENOMETHIONINE SUBSTITUTED PROTEIN; DATA COLLECTED AT-165 DEGREES C
4OOY	;	1.1	;	Avibactam and class C beta-lactamases: mechanism of inhibition, conservation of binding pocket and implications for resistance
7KEP	;	1.92	;	avibactam-CDD-1 2 minute complex
7KER	;	1.93	;	avibactam-CDD-1 45 minute complex
7KEQ	;	2.0	;	avibactam-CDD-1 6 minute complex
7ZN1	;	2.33	;	Avidin + Biotin-Tempo
7ZYL	;	2.08	;	Avidin + Biotin-Tempo
8CK7	;	2.2	;	Avidin complexed to theophylline
2A5B	;	2.49	;	Avidin complexed with 8-oxodeoxyguanosine
2CAM	;	2.2	;	AVIDIN MUTANT (K3E,K9E,R26D,R124L)
2FHL	;	1.05	;	avidin related protein (AVR4)-BNA complex
2FHN	;	1.3	;	Avidin related protein AVR4 (C122S, K109I mutant) in complex with BNA
6XND	;	1.58	;	Avidin-Biotin-Phenol
1LDQ	;	2.7	;	avidin-homobiotin complex
1LDO	;	2.2	;	avidin-norbioitn complex
6BN0	;	1.95	;	Avirulence protein 4 (Avr4) from Cladosporium fulvum bound to the hexasaccharide of chitin
4Z4A	;	1.7	;	Avirulence protein 4 (Avr4) from Pseudocercospora fuligena
7FE0	;	2.2	;	AvmM Catalyzes Macrocyclization in Alchivemycin A Biosynthesis
7FE5	;	2.09	;	AvmM Catalyzes Macrocyclization in Alchivemycin A Biosynthesis
7FE6	;	2.5	;	AvmM Catalyzes Macrocyclization in Alchivemycin A Biosynthesis
3M5M	;	1.7	;	Avoiding drug resistance against HCV NS3/4A protease inhibitors
7BB6	;	4.2	;	AVP-V2R-Galphas-beta1-gamma2-Nb35 (L state)
7BB7	;	4.4	;	AVP-V2R-Galphas-beta1-gamma2-Nb35(T state)
2OPZ	;	3.0	;	AVPF bound to BIR3-XIAP
7C96	;	2.51	;	Avr1d:GmPUB13 U-box
1WBI	;	1.4	;	AVR2
5OD4	;	1.1	;	Avr2 effector protein from the fungal plant pathogen Fusarium oxysporum
6BE0	;	2.438	;	AvrA delL154 with IP6, CoA
8TXF	;	1.29	;	AvrB bound with RIN4 C-NOI motif
8TWO	;	2.09	;	AvrB bound with UDP and RIN4_T166-Rha
8TWS	;	2.85	;	AvrB bound with UDP-rhamnose and RIN4 C-NOI motif
8TWJ	;	1.9	;	AvrB_R266A bound with UDP
8DGC	;	3.4	;	Avs3 bound to phage PhiV-1 terminase
8DGF	;	2.9	;	Avs4 bound to phage PhiV-1 portal
7KUC	;		;	Ax1 Domain of VEGF Readthrough Element
7KUD	;		;	Ax2 Domain of VEGF Readthrough Element
1OA8	;	1.7	;	AXH domain of human spinocerebellar ataxin-1
1V06	;		;	AXH domain of the transcription factor HBP1 from M.musculus
3MFL	;	1.78	;	Axial Ligand Swapping In Double Mutant Maintains Intradiol-cleavage Chemistry in Protocatechuate 3,4-Dioxygenase
3MI1	;	1.74	;	Axial Ligand Swapping In Double Mutant Maintains Intradiol-cleavage Chemistry in Protocatechuate 3,4-Dioxygenase
3MI5	;	1.78	;	Axial Ligand Swapping In Double Mutant Maintains Intradiol-cleavage Chemistry in Protocatechuate 3,4-Dioxygenase
3MV4	;	1.59	;	Axial Ligand Swapping In Double Mutant Maintains Intradiol-cleavage Chemistry in Protocatechuate 3,4-Dioxygenase
3MV6	;	1.86	;	Axial Ligand Swapping In Double Mutant Maintains Intradiol-cleavage Chemistry in Protocatechuate 3,4-Dioxygenase
3T63	;	1.54	;	Axial Ligand Swapping In Double Mutant Maintains Intradiol-cleavage Chemistry in Protocatechuate 3,4-Dioxygenase
3T67	;	1.67	;	Axial Ligand Swapping In Double Mutant Maintains Intradiol-cleavage Chemistry in Protocatechuate 3,4-Dioxygenase
4HLJ	;	1.8	;	Axon Guidance Receptor
8QD4	;	1.8	;	Ayg1p active site converted to tetrahedral sulfonate ester
8QD1	;	1.7	;	Ayg1p from A. fumigatus catalyzes polyketide shortening in the biosynthesis of DHN-melanin
8QD3	;	1.7	;	Ayg1p in complex with 1,3,6,8-Tetrahydroxynaphthalene
8QD2	;	1.75	;	Ayg1p in complex with 1,3-Dihydroxynaphthalene
4RAB	;	2.264	;	Aza-acyclic nucleoside phosphonates containing a second phosphonate group as inhibitors of the human, Plasmodium falciparum and vivax 6-oxopurine phosphoribosyltransferases and their pro-drugs as antimalarial agents
4RAC	;	2.05	;	Aza-acyclic nucleoside phosphonates containing a second phosphonate group as inhibitors of the human, Plasmodium falciparum and vivax 6-oxopurine phosphoribosyltransferases and their pro-drugs as antimalarial agents
4RAD	;	2.0	;	Aza-acyclic nucleoside phosphonates containing a second phosphonate group as inhibitors of the human, Plasmodium falciparum and vivax 6-oxopurine phosphoribosyltransferases and their pro-drugs as antimalarial agents
4RAN	;	2.549	;	Aza-acyclic nucleoside phosphonates containing a second phosphonate group as inhibitors of the human, Plasmodium falciparum and vivax 6-oxopurine phosphoribosyltransferases and their pro-drugs as antimalarial agents
4RAO	;	1.871	;	Aza-acyclic nucleoside phosphonates containing a second phosphonate group as inhibitors of the human, Plasmodium falciparum and vivax 6-oxopurine phosphoribosyltransferases and their pro-drugs as antimalarial agents
4RAQ	;	2.53	;	Aza-acyclic nucleoside phosphonates containing a second phosphonate group as inhibitors of the human, Plasmodium falciparum and vivax 6-oxopurine phosphoribosyltransferases and their pro-drugs as antimalarial agents
5K86	;	1.127	;	Aza-glycine containing collagen peptide
7OME	;	1.501	;	Azacoelenterazine-bound Renilla-type engineered ancestral luciferase variant (AncFT7)
7QXR	;	2.052	;	Azacoelenterazine-bound Renilla-type luciferase (AncFT)
4ZAU	;	2.8	;	AZD9291 complex with wild type EGFR
2VHB	;	1.76	;	AZIDE ADDUCT OF THE BACTERIAL HEMOGLOBIN FROM VITREOSCILLA STERCORARIA
4PJY	;	1.501	;	Azide bound Cysteine Dioxygenase at pH 6.2
2E86	;	1.5	;	Azide bound to copper containing nitrite reductase from A. faecalis S-6
3BGO	;	1.8	;	Azide complex of Engineered Subtilisin SUBT_BACAM
1RSV	;	2.2	;	azide complex of the diferrous E238A mutant R2 subunit of ribonucleotide reductase
1RSR	;	2.0	;	azide complex of the diferrous F208A mutant R2 subunit of ribonucleotide reductase
2CK3	;	1.95	;	Azide inhibited bovine F1-ATPase
5ZCQ	;	1.65	;	Azide-bound cytochrome c oxidase structure determined using the crystals exposed to 10 mM azide solution for 2 days
5ZCO	;	1.9	;	azide-bound cytochrome c oxidase structure determined using the crystals exposed to 2 mM azide solution for 2 days
5ZCP	;	1.65	;	azide-bound cytochrome c oxidase structure determined using the crystals exposed to 20 mM azide solution for 2 days
5Z86	;	1.85	;	azide-bound cytochrome c oxidase structure determined using the crystals exposed to 20 mM azide solution for 3 days
1YAZ	;	1.7	;	AZIDE-BOUND YEAST CU(II)/ZN SUPEROXIDE DISMUTASE ROOM TEMPERATURE (298K) STRUCTURE
6UBE	;	1.6	;	Azide-triggered subtilisin SUBT_BACAM complexed with the peptide LFRAL
1NNI	;	2.5	;	Azobenzene Reductase from Bacillus subtilis
7A20	;	2.5	;	Azobenzene-Based Inhibitors for Tryptophan Synthase
7AWV	;	2.2	;	Azoreductase (AzoRo) from Rhodococcus opacus 1CP
7ZL5	;	1.479	;	Azosemide in complex with Carbonic Anhydrase I
7ZL6	;	1.383	;	Azosemide in complex with human Carbonic anhydrase II (hCA II)
1FRH	;	2.3	;	AZOTOBACTER VINELANDII FERREDOXIN I: ALTERATION OF INDIVIDUAL SURFACE CHARGES AND THE [4FE-4S] CLUSTER REDUCTION POTENTIAL
1FRI	;	2.1	;	AZOTOBACTER VINELANDII FERREDOXIN I: ALTERATION OF INDIVIDUAL SURFACE CHARGES AND THE [4FE-4S] CLUSTER REDUCTION POTENTIAL
1FRJ	;	2.3	;	AZOTOBACTER VINELANDII FERREDOXIN I: ALTERATION OF INDIVIDUAL SURFACE CHARGES AND THE [4FE-4S] CLUSTER REDUCTION POTENTIAL
1FRK	;	2.1	;	AZOTOBACTER VINELANDII FERREDOXIN I: ALTERATION OF INDIVIDUAL SURFACE CHARGES AND THE [4FE-4S] CLUSTER REDUCTION POTENTIAL
1FRL	;	2.3	;	AZOTOBACTER VINELANDII FERREDOXIN I: ALTERATION OF INDIVIDUAL SURFACE CHARGES AND THE [4FE-4S] CLUSTER REDUCTION POTENTIAL
1FRM	;	2.3	;	AZOTOBACTER VINELANDII FERREDOXIN I: ALTERATION OF INDIVIDUAL SURFACE CHARGES AND THE [4FE-4S] CLUSTER REDUCTION POTENTIAL
1FDD	;	1.9	;	AZOTOBACTER VINELANDII FERREDOXIN I: ASPARTATE 15 FACILITATES PROTON TRANSFER TO THE REDUCED [3FE-4S] CLUSTER
5K9B	;	1.174	;	Azotobacter vinelandii Flavodoxin II
2PYG	;	2.1	;	Azotobacter vinelandii Mannuronan C-5 epimerase AlgE4 A-module
2PYH	;	2.7	;	Azotobacter vinelandii Mannuronan C-5 epimerase AlgE4 A-module complexed with mannuronan trisaccharide
5LW3	;	1.19	;	Azotobacter vinelandii Mannuronan C-5 epimerase AlgE6 A-module
1ATG	;	1.2	;	AZOTOBACTER VINELANDII PERIPLASMIC MOLYBDATE-BINDING PROTEIN
5N6Y	;	1.35	;	Azotobacter vinelandii vanadium nitrogenase
1LWX	;	2.3	;	AZT DIPHOSPHATE BINDING TO NUCLEOSIDE DIPHOSPHATE KINASE
1RT3	;	3.0	;	AZT DRUG RESISTANT HIV-1 REVERSE TRANSCRIPTASE COMPLEXED WITH 1051U91
2ZQC	;	1.07	;	Aztreonam acyl-intermediate structure of class a beta-lactam Toho-1 E166A/R274N/R276N triple mutant
7VT2	;	2.4	;	Azumapecten Farreri ferritin
6MJT	;	1.893	;	Azurin 122F/124W/126Re
6MJR	;	2.012	;	Azurin 122W/124F/126Re
6MJS	;	1.85	;	Azurin 122W/124W/126Re
3FQY	;	1.9	;	Azurin C112D
3FQ2	;	1.91	;	Azurin C112D/M121F
3FQ1	;	1.9	;	Azurin C112D/M121I
3FPY	;	2.1	;	Azurin C112D/M121L
1JVL	;	2.0	;	Azurin dimer, covalently crosslinked through bis-maleimidomethylether
1JVO	;	2.75	;	Azurin dimer, crosslinked via disulfide bridge
6GYI	;	1.6	;	Azurin fom Pseudomonas aeruginosa treated with hydrosulfide
1E65	;	1.85	;	Azurin from Pseudomonas aeruginosa, apo form
1E5Y	;	2.0	;	Azurin from Pseudomonas aeruginosa, reduced form, pH 5.5
1E5Z	;	2.0	;	Azurin from Pseudomonas aeruginosa, reduced form, pH 9.0
8F5K	;	1.25	;	Azurin from Pseudomonas aeruginosa, Y72F/Y108F/F110A mutant
8F5L	;	1.15	;	Azurin from Pseudomonas aeruginosa, Y72F/Y108F/F110L mutant
3N2J	;	1.35	;	Azurin H117G, oxidized form
2TSA	;	2.2	;	AZURIN MUTANT M121A
2TSB	;	2.3	;	AZURIN MUTANT M121A-AZIDE
4QLW	;	2.0	;	Azurin mutant M121E with iron
4QKT	;	1.641	;	Azurin mutant M121EM44K with copper
1URI	;	1.94	;	AZURIN MUTANT WITH MET 121 REPLACED BY GLN
1ETJ	;	2.3	;	AZURIN MUTANT WITH MET 121 REPLACED BY GLU
1A4C	;	2.45	;	AZURIN MUTANT WITH MET 121 REPLACED BY HIS, PH 3.5 CRYSTAL FORM, DATA COLLECTED AT-180 DEGREES CELSIUS
1A4A	;	1.89	;	AZURIN MUTANT WITH MET 121 REPLACED BY HIS, PH 6.5 CRYSTAL FORM, DATA COLLECTED AT 16 DEGREES CELSIUS
1A4B	;	1.91	;	AZURIN MUTANT WITH MET 121 REPLACED BY HIS, PH 6.5 CRYSTAL FORM, DATA COLLECTED AT-180 DEGREES CELSIUS
5I26	;	1.888	;	Azurin T30R1, crystal form I
5I28	;	1.95	;	Azurin T30R1, crystal form II
7TIO	;		;	B Domain of Staphylococcal protein A: Native backbone
7NPN	;	10.38	;	B-brick bare in 5 mM Mg2+
7SCB	;	2.5	;	B-cylinder of Synechocystis PCC 6803 Phycobilisome, complex with OCP - local refinement
1ZEW	;	2.25	;	B-DNA
1ZF0	;	1.5	;	B-DNA
5T3L	;	1.58	;	B-DNA (CGCGAATTCGCG)2 soaked with selenourea for 1 min
1DCV	;	2.5	;	B-DNA DECAMER WITH CENTRAL TA DINUCLEOTIDE
1EI4	;	1.43	;	B-DNA DODECAMER CGCGAAT(TLC)CGCG WITH INCORPORATED [3.3.0]BICYCLO-ARABINO-THYMINE-5'-PHOSPHATE
1QV4	;	2.5	;	B-DNA Dodecamer CGTGAATTCACG complexed with minor groove binder methylproamine
1QV8	;	2.5	;	B-DNA Dodecamer d(CGCGAATTCGCG)2 complexed with proamine
2QEG	;	1.6	;	B-DNA with 7-deaza-dG modification
1DPN	;	0.95	;	B-DODECAMER CGCGAA(TAF)TCGCG WITH INCORPORATED 2'-DEOXY-2'-FLUORO-ARABINO-FURANOSYL THYMINE
2LY7	;		;	B-flap domain of RNA polymerase (B. subtilis)
3IE4	;	1.45	;	b-glucan binding domain of Drosophila GNBP3 defines a novel family of pattern recognition receptor
1GNX	;	1.68	;	b-glucosidase from Streptomyces sp
1GON	;	2.2	;	b-glucosidase from Streptomyces sp
6JZ6	;	1.605	;	b-glucuronidase from Ruminococcus gnavus in complex with C6-substituted uronic isofagomine
6JZ8	;	1.583	;	b-glucuronidase from Ruminococcus gnavus in complex with D-glucaro 1,5-lactone
6JZ4	;	1.712	;	b-glucuronidase from Ruminococcus gnavus in complex with D-glucaro-d-lactam
6JZ5	;	1.58	;	b-glucuronidase from Ruminococcus gnavus in complex with D-glucuronic acid
6JZ7	;	1.45	;	b-glucuronidase from Ruminococcus gnavus in complex with N1-substituted uronic isofagomine
6JZ3	;	1.502	;	b-glucuronidase from Ruminococcus gnavus in complex with uronic deoxynojirimycin
6JZ2	;	1.29	;	b-glucuronidase from Ruminococcus gnavus in complex with uronic isofagomine at 1.3 Angstroms resolution
4H29	;	1.991	;	B-raf dimer DNA quadruplex
5CSW	;	2.66	;	B-RAF in complex with Dabrafenib
3Q96	;	3.1	;	B-Raf kinase domain in complex with a tetrahydronaphthalene inhibitor
4EHG	;	3.5	;	B-Raf Kinase Domain in Complex with an Aminopyridimine-based Inhibitor
4EHE	;	3.3	;	B-Raf Kinase Domain in Complex with an Aminothienopyrimidine-based Inhibitor
4XV9	;	2.0	;	B-Raf Kinase domain in complex with PLX5568
4JVG	;	3.09	;	B-Raf Kinase in Complex with Birb796
3C4C	;	2.57	;	B-Raf Kinase in Complex with PLX4720
4CQE	;	2.3	;	B-Raf Kinase V600E mutant in complex with a diarylthiazole B-Raf Inhibitor
4XV2	;	2.5	;	B-Raf Kinase V600E oncogenic mutant in complex with Dabrafenib
4FK3	;	2.65	;	B-Raf Kinase V600E Oncogenic Mutant in Complex with PLX3203
3OG7	;	2.45	;	B-Raf Kinase V600E oncogenic mutant in complex with PLX4032
4XV1	;	2.47	;	B-Raf Kinase V600E oncogenic mutant in complex with PLX7904
4XV3	;	2.8	;	B-Raf Kinase V600E oncogenic mutant in complex with PLX7922
4G9R	;	3.2	;	B-Raf V600E Kinase Domain Bound to a Type II Dihydroquinazoline Inhibitor
3IDP	;	2.7	;	B-Raf V600E kinase domain in complex with an aminoisoquinoline inhibitor
7P3V	;	2.37	;	B-Raf V600E structure bound to a new inhibitor
5FD2	;	2.89	;	B-Raf wild-type kinase domain in complex with a purinylpyridinylamino-based inhibitor
6UAN	;	3.9	;	B-Raf:14-3-3 complex
2Y5P	;	1.3	;	B-repeat of Listeria monocytogenes InlB (internalin B)
2RJ4	;	1.47	;	B-specific alpha-1,3-galactosyltransferase  G176R +UDP+ADA
2RJ9	;	1.69	;	B-specific alpha-1,3-galactosyltransferase (GTB) + UDP+ Amino-deoxy-acceptor
2RJ8	;	1.69	;	B-specific alpha-1,3-galactosyltransferase (GTB) +UDP+ H-antigen disaccharide
2RJ1	;	1.55	;	B-specific alpha-1,3-galactosyltransferase (GTB) G176R mutant + UDP + H-antigen disaccharide
2RJ0	;	1.52	;	B-specific alpha-1,3-galactosyltransferase G176R mutant + UDP+ Mn2+
2RJ6	;	1.41	;	B-specific alpha-1,3-galactosyltransferase G176R S235G mutant (AABB) + H-antigen disaccharide
2RJ7	;	1.7	;	B-specific alpha-1,3-galactosyltransferase G176R S235G mutant (AABB) + UDPGal + Deoxy-acceptor
2RJ5	;	1.45	;	B-specific alpha-1,3-galactosyltransferase G176R S235G mutant (AABB) +UDP
2RIY	;	1.55	;	B-specific-1,3-galactosyltransferase (GTB)+H-antigen acceptor
2RIX	;	1.75	;	B-specific-1,3-galactosyltransferase)(GTB) + UDP
7QE4	;	1.7	;	B-trefoil lectin from Salpingoeca rosetta in complex with GalNAc
7R55	;	1.84	;	B-trefoil lectin from Salpingoeca rosetta in complex with Gb3
5DYN	;	2.48	;	B. fragilis cysteine protease
4L7T	;	1.61	;	B. fragilis NanU
2G8U	;	2.7	;	B. halodurans RNase H catalytic domain D132N mutant in complex with Mg2+ and RNA/DNA hybrid (non-P nick at the active site)
2G8K	;	1.65	;	B. halodurans RNase H catalytic domain D192N mutant in complex with Ca2+ and RNA/DNA hybrid (non-P nick at the active site)
2G8H	;	1.85	;	B. halodurans RNase H catalytic domain D192N mutant in complex with Mg2+ and RNA/DNA hybrid (non-P nick at the active site)
2G8I	;	1.65	;	B. halodurans RNase H catalytic domain D192N mutant in complex with Mn2+ and RNA/DNA hybrid (non-P nick at the active site)
2G8W	;	2.05	;	B. halodurans RNase H catalytic domain E188A mutant in complex with Ca2+ and RNA/DNA hybrid
2G8F	;	1.65	;	B. halodurans RNase H catalytic domain E188A mutant in complex with Mg2+ and RNA/DNA hybrid (non-P nick at the active site)
2G8V	;	1.85	;	B. halodurans RNase H catalytic domain E188A mutant in complex with Mg2+ and RNA/DNA hybrid (reaction product)
7RPS	;	2.09	;	B. miyamotoi FbpB complement inhibitory domain
6MQ1	;	2.5	;	B. pseudomallei KatG crystalized in the presence of ABTS
6MPY	;	2.0	;	B. pseudomallei KatG crystallized in the presence of benzoyl hydrazide
6MQ0	;	1.9	;	B. pseudomallei KatG crystallized in the presence of furoyl hydrazide
5SYL	;	1.95	;	B. pseudomallei KatG with KCN bound
8QCQ	;	2.3	;	B. subtilis ApdA-stalled ribosomal complex
4AOO	;	2.3	;	B. subtilis dUTPase YncF in complex with dU PPi and Mg in H32
4AOZ	;	2.05	;	B. subtilis dUTPase YncF in complex with dU, PPi and Mg (P212121)
4B0H	;	1.18	;	B. subtilis dUTPase YncF in complex with dU, PPi and Mg b (P212121)
4LNO	;	2.9	;	B. subtilis glutamine synthetase structures reveal large active site conformational changes and basis for isoenzyme specific regulation: form two of GS-1
4LNN	;	3.1	;	B. subtilis glutamine synthetase structures reveal large active site conformational changes and basis for isoenzyme specific regulation: structure of apo form of GS
4LNK	;	2.87	;	B. subtilis glutamine synthetase structures reveal large active site conformational changes and basis for isoenzyme specific regulation: structure of GS-glutamate-AMPPCP complex
4LNF	;	2.949	;	B. subtilis glutamine synthetase structures reveal large active site conformational changes and basis for isoenzyme specific regulation: structure of GS-Q
4LNI	;	2.5793	;	B. subtilis glutamine synthetase structures reveal large active site conformational changes and basis for isoenzyme specific regulation: structure of the transition state complex
5AN5	;	1.2	;	B. subtilis GpsB C-terminal Domain
4UG3	;	2.8	;	B. subtilis GpsB N-terminal Domain
7TFC	;	1.96	;	B. subtilis GS(14)-Q-GlnR peptide
3ZQD	;		;	B. subtilis L,D-transpeptidase
4AO5	;	1.6	;	B. subtilis prophage dUTPase YosS in complex with dUMP
6BHW	;	2.208	;	B. subtilis SsbA
6BHX	;	2.936	;	B. subtilis SsbA with DNA
3VDY	;	2.8	;	B. subtilis SsbB/ssDNA
6UFY	;	2.71	;	B. theta Bile Salt Hydrolase
6UH4	;	3.51	;	B. theta Bile Salt Hydrolase with covalent inhibitor
3CKC	;	1.5	;	B. thetaiotaomicron SusD
3CK7	;	2.1	;	B. thetaiotaomicron SusD with alpha-cyclodextrin
3CK8	;	2.1	;	B. thetaiotaomicron SusD with beta-cyclodextrin
3CK9	;	2.2	;	B. thetaiotaomicron SusD with maltoheptaose
3CKB	;	2.3	;	B. thetaiotaomicron SusD with maltotriose
3LCZ	;	2.06	;	B.licheniformis Anti-TRAP can assemble into two types of dodecameric particles with the same symmetry but inverted orientation of trimers
3B3D	;	2.3	;	B.subtilis YtbE
3F7J	;	1.7	;	B.subtilis YvgN
3I97	;	2.9	;	B1 domain of human Neuropilin-1 bound with small molecule EG00229
4RN5	;	1.73	;	B1 domain of human Neuropilin-1 with acetate ion in a ligand-binding site
1A6U	;	2.1	;	B1-8 FV FRAGMENT
1A6V	;	1.8	;	B1-8 FV fragment complexed with a (4-hydroxy-3-nitrophenyl) acetate compound
1A6W	;	2.0	;	B1-8 FV FRAGMENT COMPLEXED WITH A (4-HYDROXY-5-IODO-3-NITROPHENYL) ACETATE COMPOUND
6H0Q	;		;	B1-type ACP domain from module 7 of MLSB
2J85	;	2.39	;	B116 of Sulfolobus turreted icosahedral virus (STIV)
7QBV	;	2.701	;	B12-dependent radical SAM methyltransferase, Mmp10 with [4Fe-4S] cluster, cobalamin, and S-adenosyl-L-homocysteine bound.
7QBT	;	1.9	;	B12-dependent radical SAM methyltransferase, Mmp10 with [4Fe-4S] cluster, cobalamin, and S-methyl-5'-thioadenosine bound.
7QBU	;	2.298	;	B12-dependent radical SAM methyltransferase, Mmp10 with [4Fe-4S] cluster, cobalamin, and S-methyl-5'-thioadenosine bound.
7QBS	;	2.327	;	B12-dependent radical SAM methyltransferase, Mmp10 with [4Fe-4S] cluster, cobalamin, S-adenosyl-L-methionine, and peptide bound.
4AQZ	;		;	B2 domain of Neisseria meningitidis Pilus assembly protein PilQ
2IV9	;	1.9	;	B2-appendage from AP2 in complex with Eps15 peptide
6X4X	;		;	B24Y DKP insulin
8HQ4	;	2.12	;	B27 in complex with CRM1-Ran-RanBP1
8HUF	;	2.29	;	B28 in complex with CRM1-Ran-RanBP1
6NI3	;	3.8	;	B2V2R-Gs protein subcomplex of a GPCR-G protein-beta-arrestin mega-complex
6EDU	;	4.06	;	B41 SOSIP.664 in complex with soluble CD4 (D1-D2), the co-receptor mimicking antibody 21c and the broadly neutralizing antibody 8ANC195
6OKP	;	3.28	;	B41 SOSIP.664 in complex with the silent-face antibody SF12 and V3-targeting antibody 10-1074
1JY4	;		;	B4DIMER: A DE NOVO DESIGNED EIGHT-STRANDED BETA-SHEET ASSEMBLED USING A DISULFIDE BOND
1JY6	;		;	B4DIMERA: A DE NOVO DESIGNED FOUR-STRANDED BETA-SHEET ASSEMBLED USING A DISULFIDE BOND
7M52	;	1.5	;	B6 Fab fragment bound to the HKU4 spike stem helix peptide
7M55	;	1.4	;	B6 Fab fragment bound to the MERS-CoV spike stem helix peptide
7M51	;	1.8	;	B6 Fab fragment bound to the OC43 spike stem helix peptide
7M53	;	1.4	;	B6 Fab fragment bound to the SARS-CoV/SARS-CoV-2 spike stem helix peptide
8AQU	;	3.22	;	BA.1 SARS-CoV-2 Spike bound to mouse ACE2 (local)
8WGV	;	2.92	;	BA.2(S375) Spike (S6P)/hACE2 complex
8CIM	;	3.0	;	BA.2-07 FAB IN COMPLEX WITH SARS-COV-2 BA.2.12.1 SPIKE GLYCOPROTEIN
8AQV	;	2.96	;	BA.2.12.1 SARS-CoV-2 Spike bound to mouse ACE2 (local)
8AQS	;	2.92	;	BA.4/5 SARS-CoV-2 Spike bound to human ACE2 (local)
8AQW	;	3.3	;	BA.4/5 SARS-CoV-2 Spike bound to mouse ACE2 (local)
8CIN	;	2.7	;	BA.4/5-5 FAB IN COMPLEX WITH SARS-COV-2 BA.4 SPIKE GLYCOPROTEIN
6K12	;	2.794	;	Babesia microti lactate dehydrogenase apo form (BmLDH)
6J9D	;	2.904	;	Babesia microti lactate dehydrogenase R99A (BmLDHR99A)
7W8A	;	2.671	;	Babesia orientalis lactate dehydrogenase, BoLDH apo
1W51	;	2.55	;	BACE (Beta Secretase) in complex with a nanomolar non-peptidic inhibitor
4ZSM	;	1.96	;	BACE crystal structure with bicyclic aminothiazine fragment
4ZSP	;	1.91	;	BACE crystal structure with bicyclic aminothiazine inhibitor
6BFW	;	1.84	;	BACE crystal structure with hydroxy morpholine inhibitor
6BFD	;	1.62	;	BACE crystal structure with hydroxy pyrrolidine inhibitor
6BFE	;	1.51	;	BACE crystal structure with hydroxy pyrrolidine inhibitor
6BFX	;	1.99	;	BACE crystal structure with hydroxy pyrrolidine inhibitor
4ZSQ	;	2.3	;	BACE crystal structure with tricyclic aminothiazine inhibitor
4ZSR	;	1.65	;	BACE crystal structure with tricyclic aminothiazine inhibitor
3BRA	;	2.3	;	BACE-1 complexed with compound 1
3BUF	;	2.3	;	BACE-1 complexed with compound 2
3BUG	;	2.5	;	BACE-1 complexed with compound 3
3BUH	;	2.3	;	BACE-1 complexed with compound 4
5HE7	;	1.71	;	BACE-1 in complex with (4aR,7aS)-7a-(2,4-difluorophenyl)-6-(5-fluoro-4-methoxy-6-methylpyrimidin-2-yl)-2-imino-3-methyloctahydro-4H-pyrrolo[3,4-d]pyrimidin-4-one
5HE4	;	1.53	;	BACE-1 in complex with (4aR,7aS)-7a-(2,6-difluorophenyl)-6-(5-fluoro-4-methoxy-6-methylpyrimidin-2-yl)-3-methyl-4-oxooctahydro-2H-pyrrolo[3,4-d]pyrimidin-2-iminium
5HD0	;	1.65	;	BACE-1 in complex with (7aR)-7a-(4-(3-cyanophenyl)thiophen-2-yl)-6-(5-fluoropyrimidin-2-yl)-3-methyl-4-oxooctahydro-2H-pyrrolo[3,4-d]pyrimidin-2-iminium
5HDX	;	1.602	;	BACE-1 in complex with (7aR)-7a-(5-cyanothiophen-2-yl)-6-(4-ethoxy-5-fluoro-6-methylpyrimidin-2-yl)-3-methyl-4-oxooctahydro-2H-pyrrolo[3,4-d]pyrimidin-2-iminium
5HE5	;	1.55	;	BACE-1 in complex with (7aR)-7a-(5-cyanothiophen-2-yl)-6-(5-fluoro-4-methyl-6-(methylamino)pyrimidin-2-yl)-3-methyl-4-oxooctahydro-2H-pyrrolo[3,4-d]pyrimidin-2-iminium
5HDZ	;	1.49	;	BACE-1 in complex with (7aR)-7a-(5-cyanothiophen-2-yl)-6-(5-fluoro-4-methyl-6-(methylthio)pyrimidin-2-yl)-3-methyl-4-oxooctahydro-2H-pyrrolo[3,4-d]pyrimidin-2-iminium
4R93	;	1.71	;	BACE-1 in complex with (R)-4-(2-cyclohexylethyl)-1-methyl-5-oxo-4-(((1S,3R)-3-(3-phenylureido)cyclohexyl)methyl)imidazolidin-2-iminium
4R91	;	1.58	;	BACE-1 in complex with (R)-4-(2-cyclohexylethyl)-4-(((1S,3R)-3-(cyclopentylamino)cyclohexyl)methyl)-1-methyl-5-oxoimidazolidin-2-iminium
4R92	;	1.71	;	BACE-1 in complex with (R)-4-(2-cyclohexylethyl)-4-(((1S,3R)-3-(isonicotinamido)cyclohexyl)methyl)-1-methyl-5-oxoimidazolidin-2-iminium
4R8Y	;	1.9	;	BACE-1 in complex with (R)-4-(2-cyclohexylethyl)-4-(((R)-1-(2-cyclopentylacetyl)pyrrolidin-3-yl)methyl)-1-methyl-5-oxoimidazolidin-2-iminium
4R95	;	1.99	;	BACE-1 in complex with 2-(((1R,3S)-3-(((R)-4-(2-cyclohexylethyl)-2-iminio-1-methyl-5-oxoimidazolidin-4-yl)methyl)cyclohexyl)amino)quinolin-1-ium
4DPF	;	1.8	;	BACE-1 in complex with a HEA-macrocyclic type inhibitor
3KYR	;	2.6	;	Bace-1 in complex with a norstatine type inhibitor
6UVV	;	1.63	;	BACE-1 in complex with compound #17
6UVY	;	1.71	;	BACE-1 in complex with compound #18
7MYR	;	1.72	;	BACE-1 in complex with compound #18
7MYU	;	1.94	;	BACE-1 in complex with compound #22
6UVP	;	1.56	;	BACE-1 in complex with compound #3
6UWP	;	1.29	;	BACE-1 in complex with compound #32
6UWV	;	1.47	;	BACE-1 in complex with compound #34
7MYI	;	1.25	;	BACE-1 in complex with compound #6
3N4L	;	2.7	;	BACE-1 in complex with ELN380842
3NSH	;	2.2	;	BACE-1 in complex with ELN475957
4DPI	;	1.9	;	BACE-1 in complex with HEA-macrocyclic inhibitor, MV078512
4GMI	;	1.8	;	BACE-1 in complex with HEA-type macrocyclic inhibitor, MV078571
7N66	;	2.1	;	BACE-1 in complex with ligand 12
5MXD	;	2.52	;	BACE-1 IN COMPLEX WITH LIGAND 32397778
5HDU	;	1.58	;	BACE-1 incomplex with (7aR)-7a-(4-(3-cyanophenyl)thiophen-2-yl)-6-(5-fluoro-4-methoxypyrimidin-2-yl)-3-methyl-4-oxooctahydro-2H-pyrrolo[3,4-d]pyrimidin-2-iminium
5HDV	;	1.71	;	BACE-1 incomplex with (7aR)-7a-(5-cyanothiophen-2-yl)-6-(5-fluoro-4-methoxy-6-methylpyrimidin-2-yl)-3-methyl-4-oxooctahydro-2H-pyrrolo[3,4-d]pyrimidin-2-iminium
4K9H	;	2.29	;	Bace-1 inhibitor complex
3IGB	;	2.238	;	Bace-1 with Compound 3
3L3A	;	2.362	;	Bace-1 with the aminopyridine Compound 32
7N4N	;	1.41	;	BACE-2 in complex with ligand 36
6EJ3	;	1.94	;	BACE1 compound 23
6EJ2	;	1.46	;	BACE1 compound 28
5HU1	;	1.5	;	BACE1 in complex with (R)-N-(3-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl)-4-fluorophenyl)-5-fluoropicolinamide
5HTZ	;	1.95	;	BACE1 in complex with (S)-5-(3-chloro-5-(5-(prop-1-yn-1-yl)pyridin-3-yl)thiophen-2-yl)-2,5-dimethyl-1,2,4-thiadiazinan-3-iminium 1,1-dioxide
5HU0	;	1.83	;	BACE1 in complex with 4-(3-(furan-2-carboxamido)phenyl)-1-methyl-5-oxo-4-phenylimidazolidin-2-iminium
4ZPE	;	1.7	;	BACE1 in complex with 4-(cyclohexylamino)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-1,3,8-triazaspiro[4.5]dec-3-en-2-one
4ZPF	;	1.8	;	BACE1 in complex with 8-(3-((1-aminopropan-2-yl)oxy)benzyl)-4-(cyclohexylamino)-1-(3-fluorophenyl)-1,3,8-triazaspiro[4.5]dec-3-en-2-one
4ZPG	;	2.0	;	BACE1 in complex with 8-benzyl-4-(cyclohexylamino)-1-(3-fluorophenyl)-7-methyl-1,3,8-triazaspiro[4.5]dec-3-en-2-one
6NV7	;	2.132	;	BACE1 in complex with a macrocyclic inhibitor
6NV9	;	2.13	;	BACE1 in complex with a macrocyclic inhibitor
6NW3	;	2.352	;	BACE1 in complex with a macrocyclic inhibitor
7B1E	;	1.62	;	BACE1 IN COMPLEX WITH compound 3 (NB-641)
5V0N	;	2.155	;	BACE1 in complex with inhibitor 5g
3OOZ	;	1.8	;	Bace1 in complex with the aminohydantoin Compound 102
3LHG	;	2.1	;	Bace1 in complex with the aminohydantoin Compound 4g
3L38	;	2.1	;	Bace1 in complex with the aminopyridine Compound 44
2QU2	;	2.6	;	BACE1 with Compound 1
2QU3	;	2.0	;	BACE1 with Compound 2
3IN3	;	2.0	;	Bace1 with Compound 30
3IN4	;	2.3	;	Bace1 with Compound 38
3IND	;	2.246	;	Bace1 with the aminohydantoin Compound 29
3INF	;	1.852	;	Bace1 with the aminohydantoin Compound 37
3INH	;	1.8	;	Bace1 with the aminohydantoin Compound R-58
3INE	;	1.996	;	Bace1 with the aminohydantoin Compound S-34
3ZKM	;	1.85	;	BACE2 FAB COMPLEX
3ZKN	;	2.0	;	BACE2 FAB INHIBITOR COMPLEX
3ZL7	;	3.2	;	BACE2 FYNOMER COMPLEX
3ZKG	;	1.9	;	BACE2 MUTANT APO STRUCTURE
6UJ1	;	3.03	;	BACE2 mutant in complex with a macrocyclic compound
3ZKI	;	2.4	;	BACE2 MUTANT STRUCTURE WITH LIGAND
3ZKQ	;	1.51	;	BACE2 XAPERONE COMPLEX
3ZLQ	;	2.1	;	BACE2 XAPERONE COMPLEX
4BEL	;	1.85	;	BACE2 XAPERONE COMPLEX
4BFB	;	2.21	;	BACE2 XAPERONE COMPLEX
3ZKS	;	2.11	;	BACE2 XAPERONE COMPLEX WITH INHIBITOR
7F1G	;	1.5	;	BACE2 xaperone complex with N-{3-[(4R,5R,6R)-2-amino-5-fluoro-4,6-dimethyl-5,6-dihydro-4H-1,3-thiazin-4-yl]-4-fluorophenyl}-2H,3H-[1,4]dioxino[2,3-c]pyridine-7-carboxamide
7D5B	;	1.31	;	BACE2 xaperone complex with N-{3-[(5R)-3-amino-2,5-dimethyl-1,1-dioxo-5,6-dihydro-2H-1lambda6,2,4-thiadiazin-5-yl]-4-fluorophenyl}-5-fluoropyridine-2-carboxamide
6JSZ	;	1.53	;	BACE2 xaperone complex with N-{3-[(5R)-3-amino-5-methyl-9,9-dioxo-2,9lambda6-dithia-4-azaspiro[5.5]undec-3-en-5-yl]-4-fluorophenyl}-5-(fluoromethoxy)pyrazine-2-carboxamide
7D5U	;	2.04	;	BACE2 xaperone complex with N-{3-[(9S)-7-amino-2,2-difluoro-9-(prop-1-yn-1-yl)-6-oxa-8-azaspiro[3.5]non-7-en-9-yl]-4-fluorophenyl}-5-cyanopyridine-2-carboxamide
7F65	;	2.202	;	Bacetrial Cocaine Esterase with mutations T172R/G173Q/V116K/S117A/A51L, bound to benzoic acid
7NS0	;	2.4	;	Bacilladnavirus capsid structure
7A76	;	1.65	;	Bacillithiol Disulfide Reductase Bdr (YpdA) from Bacillus cereus
7A7B	;	2.9	;	Bacillithiol Disulfide Reductase Bdr (YpdA) from Staphylococcus aureus
7APR	;	3.1	;	Bacillithiol Disulfide Reductase Bdr (YpdA) from Staphylococcus aureus
2YOW	;	1.8	;	Bacillus amyloliquefaciens CBM33
2YOX	;	1.9	;	Bacillus amyloliquefaciens CBM33 in complex with Cu(I) after photoreduction
2YOY	;	1.7	;	Bacillus amyloliquefaciens CBM33 in complex with Cu(I) reduced using ascorbate
3S9U	;	1.9	;	Bacillus anthracis Dihydrofolate Reductase bound to propargyl-linked TMP analog, UCP120J
3E0B	;	2.25	;	Bacillus anthracis Dihydrofolate Reductase complexed with NADPH and 2,4-diamino-5-(3-(2,5-dimethoxyphenyl)prop-1-ynyl)-6-ethylpyrimidine (UCP120B)
3MMX	;	2.552	;	Bacillus anthracis NadD (baNadD) in complex with compound 1_02_3
3HFJ	;	2.02	;	Bacillus anthracis nicotinate mononucleotide adenylytransferase (nadD) in complex with inhibitor CID 3289443
1HZ9	;	1.8	;	BACILLUS CALDOLYTICUS COLD-SHOCK PROTEIN MUTANTS TO STUDY DETERMINANTS OF PROTEIN STABILITY
1HZA	;	1.8	;	BACILLUS CALDOLYTICUS COLD-SHOCK PROTEIN MUTANTS TO STUDY DETERMINANTS OF PROTEIN STABILITY
1HZB	;	1.28	;	BACILLUS CALDOLYTICUS COLD-SHOCK PROTEIN MUTANTS TO STUDY DETERMINANTS OF PROTEIN STABILITY
1HZC	;	1.32	;	BACILLUS CALDOLYTICUS COLD-SHOCK PROTEIN MUTANTS TO STUDY DETERMINANTS OF PROTEIN STABILITY
1I5F	;	1.4	;	BACILLUS CALDOLYTICUS COLD-SHOCK PROTEIN MUTANTS TO STUDY DETERMINANTS OF PROTEIN STABILITY
3JX7	;	1.6	;	Bacillus cereus alkylpurine DNA glycosylase AlkD bound to DNA containing a 3-METHYLADENINE analog
3JXY	;	1.5	;	Bacillus cereus Alkylpurine DNA Glycosylase AlkD Bound to DNA Containing a GT Mismatch
3JY1	;	1.754	;	Bacillus cereus Alkylpurine DNA Glycosylase AlkD Bound to DNA Containing an Abasic Site (across from C)
3JXZ	;	1.75	;	Bacillus cereus Alkylpurine DNA Glycosylase AlkD Bound to DNA Containing an Abasic Site (across from T)
1B90	;	2.5	;	BACILLUS CEREUS BETA-AMYLASE APO FORM
1B9Z	;	2.1	;	BACILLUS CEREUS BETA-AMYLASE COMPLEXED WITH MALTOSE
5JD9	;	1.63	;	Bacillus cereus CotH kinase
5JDA	;	1.401	;	Bacillus cereus CotH kinase plus Mg2+/AMP
5KUB	;	1.73	;	Bacillus cereus DNA glycosylase AlkD bound to 7-methylguanine nucleobase and DNA containing an oxocarbenium-intermediate analog
7LXH	;	1.667	;	Bacillus cereus DNA glycosylase AlkD bound to a CC1065-adenine nucleobase adduct and DNA containing an abasic site
7LXJ	;	1.93	;	Bacillus cereus DNA glycosylase AlkD bound to a duocarmycin SA-adenine nucleobase adduct and DNA containing an abasic site
5UUH	;	1.569	;	Bacillus cereus DNA glycosylase AlkD bound to a yatakemycin-adenine nucleobase adduct and DNA containing a fluorinated abasic site (9-mer product complex)
5UUF	;	1.612	;	Bacillus cereus DNA glycosylase AlkD bound to a yatakemycin-adenine nucleobase adduct and DNA containing an abasic site (12-mer product complex)
5UUG	;	1.712	;	Bacillus cereus DNA glycosylase AlkD bound to a yatakemycin-adenine nucleobase adduct and DNA containing an abasic site (9-mer product complex)
5G3P	;	1.78	;	Bacillus cereus formamidase (BceAmiF) acetylated at the active site.
5G3O	;	2.15	;	Bacillus cereus formamidase (BceAmiF) inhibited with urea.
7NMQ	;	1.36	;	Bacillus cereus HblL1 toxin component
2BG8	;	2.5	;	Bacillus cereus metallo-beta-lactamase (BcII) Arg (121) Cys mutant. Solved at pH4.5 using 20 Micromolar ZnSO4 in the buffer. 1mM DTT and 1mM TCEP-HCl were used as reducing agents.
2BG7	;	2.1	;	Bacillus cereus metallo-beta-lactamase (BcII) Arg (121) Cys mutant. Solved at pH4.5 using 20 Micromolar ZnSO4 in the buffer. 1mM DTT was used as a reducing agent. Cys221 is oxidized.
2BFZ	;	2.3	;	Bacillus cereus metallo-beta-lactamase (BcII) Arg (121) Cys mutant. Solved at pH4.5 using 20mM ZnSO4 in buffer. 1mM DTT was used as a reducing agent. Cys221 is oxidized.
2BG2	;	2.4	;	Bacillus cereus metallo-beta-lactamase (BcII) Arg (121) Cys mutant. Solved at pH4.5 using 20mM ZnSO4 in the buffer. 1mM DTT and 1mM TCEP- HCl were used as reducing agents. Cys221 is reduced.
2BG6	;	2.3	;	Bacillus cereus metallo-beta-lactamase (BcII) Arg (121) Cys mutant. Solved at pH5 using 20 Micromolar ZnSO4 in the buffer. 1mM DTT was used as a reducing agent. Cys221 is oxidized.
2BFL	;	1.8	;	Bacillus cereus metallo-beta-lactamase (BcII) Arg (121) Cys mutant. Solved at pH5 using 20mM ZnSO4 in buffer. 1mM DTT was used as a reducing agent.
2BGA	;	2.7	;	Bacillus cereus metallo-beta-lactamase (BcII) Arg (121) Cys mutant. Solved at pH7 using 20 Micromolar ZnSO4 in the buffer. 1mM DTT was used as a reducing agent. Cys221 is oxidized.
2BFK	;	2.0	;	Bacillus cereus metallo-beta-lactamase (BcII) Arg (121) Cys mutant. Solved at pH7 using 20mM ZnSO4 in buffer. 1mM DTT was used as a reducing agent
3KNR	;	1.71	;	Bacillus cereus metallo-beta-lactamase Cys221Asp mutant, 1 mM Zn(II)
3KNS	;	1.58	;	Bacillus cereus metallo-beta-lactamase Cys221Asp mutant, 20 mM Zn(II)
3I0V	;	1.6	;	Bacillus cereus metallo-beta-lactamase: apo form
3UN5	;	1.8	;	Bacillus cereus phosphopentomutase T85E variant
3UNY	;	1.95	;	Bacillus cereus phosphopentomutase T85E variant soaked with glucose 1,6-bisphosphate
3I13	;	1.74	;	Bacillus cereus Zn-dependent metallo-beta-lactamase at pH 5.8
4NQ4	;	1.67	;	Bacillus cereus Zn-dependent metallo-beta-lactamase at pH 7
5W8W	;	2.25	;	Bacillus cereus Zn-dependent metallo-beta-lactamase at pH 7 - new refinement
4NQ5	;	2.29	;	Bacillus cereus Zn-dependent metallo-beta-lactamase at pH 7 complexed with compound CS319
4NQ6	;	1.8	;	Bacillus cereus Zn-dependent metallo-beta-lactamase at pH 7 complexed with compound L-CS319
1OT1	;	2.0	;	Bacillus circulans strain 251 Cyclodextrin glycosyl transferase mutant D135A
1OT2	;	2.1	;	Bacillus circulans strain 251 Cyclodextrin glycosyl transferase mutant D135N
1KCK	;	2.43	;	Bacillus circulans strain 251 Cyclodextrin glycosyl transferase mutant N193G
1EO5	;	2.0	;	Bacillus circulans strain 251 cyclodextrin glycosyltransferase in complex with maltoheptaose
1EO7	;	2.48	;	BACILLUS CIRCULANS STRAIN 251 CYCLODEXTRIN GLYCOSYLTRANSFERASE IN COMPLEX WITH MALTOHEXAOSE
1DTU	;	2.4	;	BACILLUS CIRCULANS STRAIN 251 CYCLODEXTRIN GLYCOSYLTRANSFERASE: A MUTANT Y89D/S146P COMPLEXED TO AN HEXASACCHARIDE INHIBITOR
1PJ9	;	2.0	;	Bacillus circulans strain 251 loop mutant 183-195
1PEZ	;	2.32	;	Bacillus circulans strain 251 mutant A230V
1KCL	;	1.94	;	Bacillus ciruclans strain 251 Cyclodextrin glycosyl transferase mutant G179L
3TYJ	;	2.15	;	Bacillus collagen-like protein of anthracis P159S mutant
4EZ6	;	1.64	;	Bacillus DNA Polymerase I Large Fragment Complex 1
4EZ9	;	1.64	;	Bacillus DNA Polymerase I Large Fragment Complex 2
4F8R	;	1.64	;	Bacillus DNA Polymerase I Large Fragment complex 7
7A02	;	3.0	;	Bacillus endospore appendages form a novel family of disulfide-linked pili
6P5C	;	2.2	;	Bacillus Fragment DNA polymerase mutant I716M
1W9X	;	2.1	;	Bacillus halmapalus alpha amylase
5CJ9	;	2.409	;	Bacillus halodurans Arginine repressor, ArgR
1ZBI	;	1.85	;	Bacillus halodurans RNase H catalytic domain mutant D132N in complex with 12-mer RNA/DNA hybrid
1ZBL	;	2.2	;	Bacillus halodurans RNase H catalytic domain mutant D192N in complex with 12-mer RNA/DNA hybrid
5SWM	;	1.5	;	BACILLUS HALODURANS RNASE H MUTANT D132N IN COMPLEX WITH 12-MER FRNA/DNA HYBRID
3ZZL	;	1.67	;	Bacillus halodurans trp RNA-binding attenuation protein (TRAP): a 12- subunit assembly
1C9N	;	1.5	;	BACILLUS LENTUS SUBSTILISIN VARIANT (SER 87) K27R/V104Y/N123S/T274A
1NDQ	;	1.8	;	Bacillus lentus subtilisin
1C9J	;	1.8	;	BACILLUS LENTUS SUBTILISIN K27R/N87S/V104Y/N123S/T274A VARIANT
1NDU	;	1.6	;	Bacillus lentus subtilisin variant S101G/V104N
1C9M	;	1.67	;	BACILLUS LENTUS SUBTILSIN (SER 87) N76D/S103A/V104I
1BLI	;	1.9	;	BACILLUS LICHENIFORMIS ALPHA-AMYLASE
1GBG	;	1.8	;	BACILLUS LICHENIFORMIS BETA-GLUCANASE
4CAG	;	2.498	;	Bacillus licheniformis Rhamnogalacturonan Lyase PL11
5OV4	;	2.692	;	Bacillus megaterium porphobilinogen deaminase D82A mutant
5OV5	;	1.81	;	Bacillus megaterium porphobilinogen deaminase D82E mutant
5OV6	;	1.87	;	Bacillus megaterium porphobilinogen deaminase D82N mutant
5BOI	;	1.8	;	Bacillus megaterium YpeB C-terminal domain
5IZO	;	1.95	;	Bacillus NanoRNase A (H103A) + 2 divalent cations + PO4 at the active site
5IUF	;	1.95	;	Bacillus NanoRNase A active site mutant bound to pAp
8AIL	;	2.45	;	Bacillus phage VMY22 p56 in complex with Bacillus weidmannii Ung
6N2Y	;	3.0	;	Bacillus PS3 ATP synthase class 1
6N2Z	;	3.0	;	Bacillus PS3 ATP synthase class 2
6N30	;	3.2	;	Bacillus PS3 ATP synthase class 3
6N2D	;	3.3	;	Bacillus PS3 ATP synthase membrane region
4QOM	;	1.65	;	Bacillus pumilus catalase with pyrogallol bound
7R25	;	0.87	;	Bacillus pumilus Lipase A
1XWL	;	1.7	;	BACILLUS STEAROTHERMOPHILUS (NEWLY IDENTIFIED STRAIN AS YET UNNAMED) DNA POLYMERASE FRAGMENT
1ZIP	;	1.85	;	BACILLUS STEAROTHERMOPHILUS ADENYLATE KINASE
1HVX	;	2.0	;	BACILLUS STEAROTHERMOPHILUS ALPHA-AMYLASE
1JQA	;	2.05	;	Bacillus stearothermophilus glycerol dehydrogenase complex with glycerol
1JQ5	;	1.7	;	Bacillus Stearothermophilus Glycerol dehydrogenase complex with NAD+
1H2E	;	1.69	;	BACILLUS STEAROTHERMOPHILUS PHOE (previously known as yhfr) in complex with phosphate
1H2F	;	2.0	;	BACILLUS STEAROTHERMOPHILUS PHOE (previously known as yhfr) in complex with trivanadate
1EBB	;	2.3	;	Bacillus stearothermophilus YhfR
4YZR	;	1.35	;	Bacillus subtilis 168 Bacillaene Polyketide Synthase (PKS) Cytochrome P450 PksS
5CFE	;	1.84	;	Bacillus subtilis AP endonuclease ExoA
6WNN	;	2.59	;	Bacillus subtilis BioA in complex with amino donor L-Lys
7QV2	;	3.5	;	Bacillus subtilis collided disome (Collided 70S)
7QV1	;	3.5	;	Bacillus subtilis collided disome (Leading 70S)
7OLH	;	3.65	;	Bacillus subtilis Complex structure 1 of diadenylate cyclase CdaA cytoplasmic domain (CdaACD) and the phosphoglucomutase GlmM short variant (GlmMF369)
1UX1	;	2.36	;	Bacillus subtilis cytidine deaminase with a Cys53His and an Arg56Gln substitution
1UWZ	;	1.99	;	Bacillus subtilis cytidine deaminase with an Arg56 - Ala substitution
1UX0	;	1.99	;	Bacillus subtilis cytidine deaminase with an Arg56 - Gln substitution
8UVZ	;	0.93	;	Bacillus subtilis DHFR bound to NADP+ and folate
3ZH9	;	2.1	;	Bacillus subtilis DNA clamp loader delta protein (YqeN)
8BV3	;	2.38	;	Bacillus subtilis DnaA domain III structure
7O9F	;	2.51	;	Bacillus subtilis Ffh in complex with ppGpp
4OZ5	;	2.71	;	Bacillus subtilis HmoB
7OJ1	;	2.44	;	Bacillus subtilis IMPDH in complex with Ap4A
7OJ2	;	1.76	;	Bacillus subtilis IMPDH in complex with Ap4A
7BRA	;	1.785	;	Bacillus subtilis IRG1
1R4Z	;	1.8	;	Bacillus subtilis lipase A with covalently bound Rc-IPG-phosphonate-inhibitor
1R50	;	1.45	;	Bacillus subtilis lipase A with covalently bound Sc-IPG-phosphonate-inhibitor
2EV0	;	1.65	;	Bacillus subtilis manganese transport regulator (MNTR) bound to cadmium
2EV5	;	2.0	;	Bacillus subtilis manganese transport regulator (MNTR) bound to calcium
2F5E	;	2.2	;	Bacillus subtilis manganese transport regulator (MNTR) bound to manganese, AB conformation, pH 6.5
1ON1	;	1.75	;	Bacillus Subtilis Manganese Transport Regulator (Mntr) Bound To Manganese, AB Conformation.
2F5D	;	1.9	;	Bacillus subtilis manganese transport regulator (MNTR) bound to manganese, AC conformation, pH 6.5
2F5F	;	2.4	;	Bacillus subtilis manganese transport regulator (MNTR) bound to manganese, AC conformation, pH 8.5
2F5C	;	2.4	;	Bacillus subtilis Manganese transport regulator (MNTR) bound to manganese, hexagonal crystal form
2EV6	;	1.7	;	Bacillus subtilis manganese transport regulator (MNTR) bound to zinc
1ON2	;	1.61	;	Bacillus subtilis Manganese Transport Regulator (MntR), D8M Mutant, Bound to Manganese
8R55	;	3.57	;	Bacillus subtilis MutS2-collided disome complex (collided 70S)
7QV3	;	5.14	;	Bacillus subtilis MutS2-collided disome complex (MutS2 conf.2; Leading 70S)
8QPP	;	3.4	;	Bacillus subtilis MutS2-collided disome complex (stalled 70S)
7PI1	;	1.729	;	Bacillus subtilis PabB
1BN8	;	1.8	;	BACILLUS SUBTILIS PECTATE LYASE
2BSP	;	1.8	;	BACILLUS SUBTILIS PECTATE LYASE R279K MUTANT
7OML	;	2.9	;	Bacillus subtilis phosphoglucomutase GlmM (metal bound)
7OJR	;	3.05	;	Bacillus subtilis phosphoglucomutase GlmM (phosphate bound)
2Y1T	;	1.89	;	Bacillus subtilis prophage dUTPase in complex with dUDP
7AS8	;	2.9	;	Bacillus subtilis ribosome quality control complex state B. Ribosomal 50S subunit with P-tRNA, RqcH, and RqcP/YabO
7AS9	;	3.5	;	Bacillus subtilis ribosome-associated quality control complex state A. Ribosomal 50S subunit with peptidyl tRNA in the A/P position and RqcH.
7ASA	;	3.5	;	Bacillus subtilis ribosome-associated quality control complex state B, multibody refinement focussed on RqcH. Ribosomal 50S subunit with P-tRNA, RqcH, and RqcP/YabO
8T9N	;	1.9	;	Bacillus subtilis RsgI GGG mutant
3ZII	;	2.2	;	Bacillus subtilis SepF G109K, C-terminal domain
8HZT	;		;	Bacillus subtilis SepF protein assembly (G137N mutant)
8HZQ	;		;	Bacillus subtilis SepF protein assembly (wild type)
3ZIH	;	2.0	;	Bacillus subtilis SepF, C-terminal domain
8A0A	;	2.9	;	Bacillus subtilis SPbeta prophage master regulator MrpR
2FXV	;	2.05	;	Bacillus subtilis Xanthine Phosphoribosyltransferase in Complex with Guanosine 5'-monophosphate (GMP)
1QD9	;	1.7	;	Bacillus subtilis YABJ
4KQY	;	3.02	;	Bacillus subtilis yitJ S box/SAM-I riboswitch
4XHP	;	3.2	;	Bacillus thuringiensis ParM hybrid protein with ADP, containing two ParM mutants
4XE7	;	2.0	;	Bacillus thuringiensis ParM in apo form
4XE8	;	2.381	;	Bacillus thuringiensis ParM with ADP
4XHN	;	2.6	;	Bacillus thuringiensis ParM with AMPPNP
4XHO	;	2.65	;	Bacillus thuringiensis ParM with ATP
5VOL	;	1.98	;	Bacint_04212 ferulic acid esterase
4O0R	;	2.4	;	Back pocket flexibility provides group-II PAK selectivity for type 1 kinase inhibitors
4O0T	;	2.6	;	Back pocket flexibility provides group-II PAK selectivity for type 1 kinase inhibitors
4O0V	;	2.8	;	Back pocket flexibility provides group-II PAK selectivity for type 1 kinase inhibitors
4O0X	;	2.483	;	Back pocket flexibility provides group-II PAK selectivity for type 1 kinase inhibitors
4O0Y	;	2.2	;	Back pocket flexibility provides group-II PAK selectivity for type 1 kinase inhibitors
7VBC	;	3.01	;	Back track state of human RNA Polymerase I Elongation Complex
1WAC	;	3.0	;	Back-priming mode of Phi6 RNA-dependent RNA polymerase
2MBE	;		;	Backbone 1H and 15N Chemical Shift Assignments for the first domain of FAT10
2MES	;		;	Backbone 1H, 13C, 15N resonance assignments of calcium-bound calmodulin in complex with PSD95 N-terminal peptide
2MRL	;		;	Backbone 1H, 13C, and 15N Chemical Shift Assignments and NMR structure for potential drug target from Burkholderia thailandensis E264
2MJ3	;		;	Backbone 1H, 13C, and 15N Chemical Shift Assignments and structure of Iron-sulfur cluster binding protein from Ehrlichia chaffeensis
2MAZ	;		;	Backbone 1H, 13C, and 15N Chemical Shift Assignments for Bovine Apo Calbindin
2LXK	;		;	Backbone 1H, 13C, and 15N Chemical Shift Assignments for cold shock protein, LmCsp
2LXJ	;		;	Backbone 1H, 13C, and 15N Chemical Shift Assignments for cold shock protein, LmCsp with dT7
2MO0	;		;	Backbone 1H, 13C, and 15N Chemical Shift Assignments for cold shock protein, TaCsp
2MO1	;		;	Backbone 1H, 13C, and 15N Chemical Shift Assignments for cold shock protein, TaCsp with dT7
2NBS	;		;	Backbone 1H, 13C, and 15N Chemical Shift Assignments for designed protein E_1r26
2LJP	;		;	Backbone 1H, 13C, and 15N Chemical Shift Assignments for E.coli Ribonuclease P protein
2KZ3	;		;	Backbone 1H, 13C, and 15N Chemical Shift Assignments for human Rad51D from 1 to 83
2LXD	;		;	Backbone 1H, 13C, and 15N Chemical Shift Assignments for LMO2(LIM2)-Ldb1(LID)
2MCK	;		;	Backbone 1H, 13C, and 15N Chemical Shift Assignments for murine norovirus CR6 NS1/2 protein
2MCH	;		;	Backbone 1H, 13C, and 15N Chemical Shift Assignments for murine norovirus NS1/2 CW3 WT
2MCD	;		;	Backbone 1H, 13C, and 15N Chemical Shift Assignments for murine norovirus NS1/2 D94E mutant
2KSW	;		;	Backbone 1H, 13C, and 15N Chemical Shift Assignments for Oryctin
2RT6	;		;	Backbone 1H, 13C, and 15N Chemical Shift Assignments for PriC N-terminal domain
2LGT	;		;	Backbone 1H, 13C, and 15N Chemical Shift Assignments for QFM(Y)F
2LN7	;		;	Backbone 1H, 13C, and 15N Chemical Shift Assignments for the catalytic domain of B. anthracis SrtD
2L2N	;		;	Backbone 1H, 13C, and 15N Chemical Shift Assignments for the first dsRBD of protein HYL1
2N0V	;		;	Backbone 1H, Chemical Shift Assignments for Cn-APM1
2MNU	;		;	Backbone and side chain 1H, 13C, and 15N Chemical Shift Assignments for EDB and specific binding aptide
2GI9	;	1.14	;	Backbone Conformational Constraints in a Microcrystalline U-15N-Labeled Protein by 3D Dipolar-Shift Solid-State NMR Spectroscopy
6CGX	;		;	Backbone cyclised conotoxin Vc1.1 mutant - D11A, E14A
8T0I	;		;	Backbone Dialkylation in Peptide Hairpins: (R)-Ethylpropylglycine variant
8T0H	;		;	Backbone Dialkylation in Peptide Hairpins: (S)-Ethylpropylglycine variant
8T0G	;		;	Backbone Dialkylation in Peptide Hairpins: Natural Backbone Prototype
2MW5	;		;	Backbone fold of Human Small Ubiquitin like Modifier protein-1 (SUMO-1) based on Prot3D-NMR approach.
1FH1	;		;	BACKBONE FOLD OF NODF
6E5P	;	8.8	;	Backbone model based on cryo-EM map at 8.5 A of domain-swapped, glycan-reactive, neutralizing antibody 2G12 bound to HIV-1 Env BG505 DS-SOSIP, which was also bound to CD4-binding site antibody VRC03
5VLZ	;	4.4	;	Backbone model for phage Qbeta capsid
3K1Q	;	4.5	;	Backbone model of an aquareovirus virion by cryo-electron microscopy and bioinformatics
8GLT	;	6.5	;	Backbone model of de novo-designed chlorophyll-binding nanocage O32-15
8ES2	;		;	Backbone modifications in the inter-helix loop of designed miniprotein oPPalpha: Aib10Asn11 turn
8ERZ	;		;	Backbone modifications in the inter-helix loop of designed miniprotein oPPalpha: Aib10Gly11 turn
8ERY	;		;	Backbone modifications in the inter-helix loop of designed miniprotein oPPalpha: Asp10Asn11 turn
8ES1	;		;	Backbone modifications in the inter-helix loop of designed miniprotein oPPalpha: deltaOrn10-11 turn
8ES0	;		;	Backbone modifications in the inter-helix loop of designed miniprotein oPPalpha: DPro10Gly11 turn
8ES3	;		;	Backbone modifications in the inter-helix loop of designed miniprotein oPPalpha: DPro10Pro11 turn
8G0Y	;		;	Backbone modifications in the inter-helix loop of designed miniprotein oPPalpha: Iva10Asn11 turn
8G0X	;		;	Backbone modifications in the inter-helix loop of designed miniprotein oPPalpha: Pro10DPro11 turn
4OZC	;	2.301	;	Backbone Modifications in the Protein GB1 Helix and Loops: beta-ACPC21, beta-ACPC24, beta-3-Lys28, beta-3-Lys31, beta-ACPC35, beta-ACPC40
5HI1	;	2.15	;	Backbone Modifications in the Protein GB1 Helix: Aib24, beta-3-Lys28, beta-3-Lys31, Aib35
5HFY	;	1.95	;	Backbone Modifications in the Protein GB1 Helix: beta-2-Ala24, beta-3-Lys28, beta-3-Lys31, beta-3-Asn35
4OZA	;	2.201	;	Backbone Modifications in the Protein GB1 Helix: beta-3-Ala24, beta-3-Lys28, beta-3-Gln32, beta-3-Asp36
5HG2	;	1.8	;	Backbone Modifications in the Protein GB1 Helix: beta-3-Ala24, beta-3-Lys28, beta-3-Lys31, beta-2-Asn35
4KGR	;	2.0	;	Backbone Modifications in the Protein GB1 Helix: beta-3-Ala24, beta-3-Lys28, beta-3-Lys31, beta-3-Asn35
4OZB	;	1.8	;	Backbone Modifications in the Protein GB1 Helix: beta-ACPC24, beta-3-Lys28, beta-3-Lys31, beta-ACPC35
4KGS	;	1.95	;	Backbone Modifications in the Protein GB1 Loops: beta-3-Val21, beta-3-Asp40
4KGT	;	2.0	;	Backbone Modifications in the Protein GB1 Turns: Aib10, D-Pro47
1RWD	;		;	Backbone NMR Structure of a Mutant P. Furiosus Rubredoxin Using Residual Dipolar Couplings
1RWS	;		;	Backbone Solution Structure of mixed alpha/beta protein PF1061
1SF0	;		;	BACKBONE SOLUTION STRUCTURE OF MIXED ALPHA/BETA PROTEIN PF1061
2MOT	;		;	Backbone Structure of Actin Depolymerizing Factor (ADF) of Toxoplasma gondii Based on Prot3DNMR Approach
6F3V	;		;	Backbone structure of bradykinin (BK) peptide bound to human Bradykinin 2 Receptor (B2R) determined by MAS SSNMR
1XGF	;	2.61	;	Backbone Structure of COCOSIN, an 11S storage protein from cocos nucifera
6F3Y	;		;	Backbone structure of Des-Arg10-Kallidin (DAKD) peptide bound to human Bradykinin 1 Receptor (B1R) determined by DNP-enhanced MAS SSNMR
6F3X	;		;	Backbone structure of Des-Arg10-Kallidin (DAKD) peptide in frozen DDM/CHS detergent micelle solution determined by DNP-enhanced MAS SSNMR
6F3W	;		;	Backbone structure of free bradykinin (BK) in DDM/CHS detergent micelle determined by MAS SSNMR
2LOQ	;		;	Backbone structure of human membrane protein FAM14B (Interferon alpha-inducible protein 27-like protein 1)
2LOM	;		;	Backbone structure of human membrane protein HIGD1A
2LON	;		;	Backbone structure of human membrane protein HIGD1B
2LOR	;		;	Backbone structure of human membrane protein TMEM141
2LOP	;		;	Backbone structure of human membrane protein TMEM14A
2LOO	;		;	Backbone structure of human membrane protein TMEM14A from NOE data
2LOS	;		;	Backbone structure of human membrane protein TMEM14C
2KSD	;		;	Backbone structure of the membrane domain of E. coli histidine kinase receptor ArcB, Center for Structures of Membrane Proteins (CSMP) target 4310C
2KSF	;		;	Backbone structure of the membrane domain of E. coli histidine kinase receptor KdpD, Center for Structures of Membrane Proteins (CSMP) target 4312C
2KSE	;		;	Backbone structure of the membrane domain of E. coli histidine kinase receptor QseC, Center for Structures of Membrane Proteins (CSMP) target 4311C
5VJ8	;		;	Backbone structure of the Yersinia pestis outer membrane protein Ail in phospholipid bilayer nanodisc
2LD9	;		;	Backbone Structure of Ubiquitin determined using Backbone amide NOEs and Backbone N-H and N-C RDCs
3IYM	;	4.7	;	Backbone Trace of the Capsid Protein Dimer of a Fungal Partitivirus from Electron Cryomicroscopy and Homology Modeling
7TIQ	;		;	Backbone-modified variant of the B domain of Staphylococcal protein A: Aib residues in helix 2
7TIS	;		;	Backbone-modified variant of the B domain of Staphylococcal protein A: Aib residues in helix 3
7URJ	;		;	Backbone-modified variant of the B domain of Staphylococcal protein A: beta3- and ACPC-residues in helix 2
7TIP	;		;	Backbone-modified variant of the B domain of Staphylococcal protein A: beta3-residues in helix 2
7TIR	;		;	Backbone-modified variant of the B domain of Staphylococcal protein A: beta3-residues in helix 3
6PV1	;		;	Backbone-modified variant of zinc finger 2 from the transcription factor Sp1 DNA binding domain: Aib in the metal-binding turn
6PV3	;		;	Backbone-modified variant of zinc finger 2 from the transcription factor Sp1 DNA binding domain: altered helix, loop, turn, and sheet
6UCO	;		;	Backbone-modified variant of zinc finger 2 from the transcription factor Sp1 DNA binding domain: BTD in the metal-binding turn
6PV0	;		;	Backbone-modified variant of zinc finger 2 from the transcription factor Sp1 DNA binding domain: D-Pro in the metal-binding turn
6PV2	;		;	Backbone-modified variant of zinc finger 2 from the transcription factor Sp1 DNA binding domain: Orn in the metal-binding turn
3GTQ	;	3.8	;	Backtracked RNA polymerase II complex induced by damage
3GTG	;	3.78	;	Backtracked RNA polymerase II complex with 12mer RNA
3GTJ	;	3.42	;	Backtracked RNA polymerase II complex with 13mer RNA
3GTL	;	3.38	;	Backtracked RNA polymerase II complex with 13mer with G<>U mismatch
3GTO	;	4.0	;	Backtracked RNA polymerase II complex with 15mer RNA
3GTK	;	3.8	;	Backtracked RNA polymerase II complex with 18mer RNA
3GTP	;	3.9	;	Backtracked RNA polymerase II complex with 24mer RNA
7NYI	;		;	BacSp222 bacteriocin: succinyl-K20 form
7NAT	;	3.59	;	Bacterial 30S ribosomal subunit assembly complex state A (Consensus refinement)
7AFD	;	3.44	;	Bacterial 30S ribosomal subunit assembly complex state A (head domain)
7NAS	;	3.31	;	Bacterial 30S ribosomal subunit assembly complex state A (multibody refinement for body domain of 30S ribosome)
7AFO	;	3.93	;	Bacterial 30S ribosomal subunit assembly complex state B (body domain)
7AFN	;	3.86	;	Bacterial 30S ribosomal subunit assembly complex state B (head domain)
7AFI	;	3.53	;	Bacterial 30S ribosomal subunit assembly complex state C (body domain)
7NAU	;	3.78	;	Bacterial 30S ribosomal subunit assembly complex state C (Consensus Refinement)
7AFH	;	3.59	;	Bacterial 30S ribosomal subunit assembly complex state C (head domain)
7NAV	;	4.8	;	Bacterial 30S ribosomal subunit assembly complex state D (Consensus refinement)
7AFK	;	4.9	;	Bacterial 30S ribosomal subunit assembly complex state D (head domain)
7AFL	;	4.2	;	Bacterial 30S ribosomal subunit assembly complex state D (multibody refinement for body domain of 30S ribosome)
7BOG	;	2.75	;	Bacterial 30S ribosomal subunit assembly complex state E (body domain)
7AF8	;	2.75	;	Bacterial 30S ribosomal subunit assembly complex state E (head domain)
7AFA	;	2.95	;	Bacterial 30S ribosomal subunit assembly complex state F (head domain)
7BOI	;	2.98	;	Bacterial 30S ribosomal subunit assembly complex state F (multibody refinement for body domain of 30S ribosome)
7BOF	;	2.92	;	Bacterial 30S ribosomal subunit assembly complex state I (body domain)
7AF5	;	2.96	;	Bacterial 30S ribosomal subunit assembly complex state I (head domain)
7BOD	;	2.88	;	Bacterial 30S ribosomal subunit assembly complex state M (body domain)
7BOE	;	2.9	;	Bacterial 30S ribosomal subunit assembly complex state M (Consensus refinement)
7AF3	;	2.82	;	Bacterial 30S ribosomal subunit assembly complex state M (head domain)
6PVK	;	3.4	;	Bacterial 45SRbgA ribosomal particle class A
6PPF	;	3.4	;	Bacterial 45SRbgA ribosomal particle class B
8A1H	;	1.65	;	Bacterial 6-4 photolyase from Vibrio cholerase
1L7V	;	3.2	;	Bacterial ABC Transporter Involved in B12 Uptake
2WUS	;	2.9	;	Bacterial actin MreB assembles in complex with cell shape protein RodZ
5U5O	;	1.15	;	Bacterial adhesin from Mobiluncus mulieris containing intramolecular disulfide, isopeptide, and ester bond cross-links (space group P1)
5U6F	;	1.5	;	Bacterial adhesin from Mobiluncus mulieris containing intramolecular disulfide, isopeptide, and ester bond cross-links (space group P21)
3TEG	;	2.2044	;	Bacterial and Eukaryotic Phenylalanyl-tRNA Synthetases Catalyze Misaminoacylation of tRNAPhe with 3,4-Dihydroxy-L-Phenylalanine (L-Dopa)
4P07	;	2.59	;	Bacterial aryl sulfotransferase (ASST) soaked with human urine
4P06	;	2.1	;	Bacterial arylsulfate sulfotransferase (ASST) H436N mutant with 4-methylumbelliferyl sulfate (MUS) in the active site
4P05	;	2.05	;	Bacterial arylsulfate sulfotransferase (ASST) H436N mutant with 4-nitrophenyl sulfate (PNS) in the active site
6F2G	;	2.92	;	Bacterial asc transporter crystal structure in open to in conformation
6F2W	;	3.4	;	Bacterial asc transporter crystal structure in open to in conformation
6M1T	;	1.9	;	Bacterial beta class Sphingomonas chungbukensis Glutathione S-transferase
6HQ6	;	2.05	;	Bacterial beta-1,3-oligosaccharide phosphorylase from GH149
6HQ8	;	2.25	;	Bacterial beta-1,3-oligosaccharide phosphorylase from GH149 with laminarihexaose bound at a surface site
5FJS	;	2.6	;	Bacterial beta-glucosidase reveals the structural and functional basis of genetic defects in human glucocerebrosidase 2 (GBA2)
7L2Z	;	3.4	;	Bacterial cellulose synthase BcsB hexamer
7LBY	;	4.2	;	Bacterial cellulose synthase BcsB with polyalanine BcsA model
5EIY	;	2.95	;	Bacterial cellulose synthase bound to a substrate analogue
4P00	;	3.2	;	Bacterial Cellulose Synthase in complex with cyclic-di-GMP and UDP
6TZK	;	1.852	;	Bacterial cellulose synthase outermembrane channel BcsC with terminal TPR repeat
5EJZ	;	2.94	;	Bacterial Cellulose Synthase Product-Bound State
7SHH	;	1.9	;	Bacterial cereblon homologue in complex with (R)-3-(4-methoxyphenyl)piperidine-2,6-dione
4D06	;	2.0	;	Bacterial chalcone isomerase complexed with naringenin
8B7U	;	2.8	;	Bacterial chalcone isomerase H33A with taxifolin
8B7Z	;	3.0	;	Bacterial chalcone isomerase H33A with taxifolin
3ZPH	;	2.8	;	Bacterial chalcone isomerase in closed conformation from Eubacterium ramulus at 2.8 A resolution
4C9S	;	1.8	;	BACTERIAL CHALCONE ISOMERASE IN open CONFORMATION FROM EUBACTERIUM RAMULUS AT 1.8 A RESOLUTION
4C9T	;	1.98	;	BACTERIAL CHALCONE ISOMERASE IN open CONFORMATION FROM EUBACTERIUM RAMULUS AT 2.0 A RESOLUTION, SelenoMet derivative
8B7R	;	2.15	;	Bacterial chalcone isomerase with taxifolin chalcone
1QBB	;	2.0	;	BACTERIAL CHITOBIASE COMPLEXED WITH CHITOBIOSE (DINAG)
1QBA	;	1.85	;	BACTERIAL CHITOBIASE, GLYCOSYL HYDROLASE FAMILY 20
1JU4	;	1.63	;	BACTERIAL COCAINE ESTERASE COMPLEX WITH PRODUCT
1JU3	;	1.58	;	BACTERIAL COCAINE ESTERASE COMPLEX WITH TRANSITION STATE ANALOG
1E9R	;	2.4	;	Bacterial conjugative coupling protein TrwBdeltaN70. Trigonal form in complex with sulphate.
1E9S	;	2.5	;	Bacterial conjugative coupling protein TrwBdeltaN70. Unbound monoclinic form.
6KGZ	;	2.3	;	bacterial cystathionine gamma-lyase MccB of Staphylococcus aureus
6KHQ	;	2.3	;	bacterial cystathionine gamma-lyase MccB of Staphylococcus aureus with cofactor PLP
1RA5	;	1.4	;	Bacterial cytosine deaminase D314A mutant bound to 5-fluoro-4-(S)-hydroxyl-3,4-dihydropyrimidine.
1R9Y	;	1.57	;	Bacterial cytosine deaminase D314A mutant.
1RA0	;	1.12	;	Bacterial cytosine deaminase D314G mutant bound to 5-fluoro-4-(S)-hydroxy-3,4-dihydropyrimidine.
1R9X	;	1.58	;	Bacterial cytosine deaminase D314G mutant.
1RAK	;	1.32	;	Bacterial cytosine deaminase D314S mutant bound to 5-fluoro-4-(S)-hydroxyl-3,4-dihydropyrimidine.
1R9Z	;	1.32	;	Bacterial cytosine deaminase D314S mutant.
3G77	;	1.8	;	Bacterial cytosine deaminase V152A/F316C/D317G mutant
1VHB	;	1.83	;	BACTERIAL DIMERIC HEMOGLOBIN FROM VITREOSCILLA STERCORARIA
7Y4F	;	1.918	;	bacterial DPP4
2J69	;	3.0	;	Bacterial dynamin-like protein BDLP
2J68	;	3.1	;	Bacterial dynamin-like protein BDLP, GDP bound
2W6D	;	9.0	;	BACTERIAL DYNAMIN-LIKE PROTEIN LIPID TUBE BOUND
4LRJ	;	1.619	;	Bacterial Effector NleH1 Kinase Domain with AMPPNP and Mg2+
4LRK	;	2.274	;	Bacterial Effector NleH2 Kinase Domain
2VQ7	;	2.6	;	Bacterial flavin-containing monooxygenase in complex with NADP: native data
2VQB	;	2.8	;	Bacterial flavin-containing monooxygenase in complex with NADP: soaking in aerated solution
5Z9B	;	2.1	;	Bacterial GyrB ATPase domain in complex with (3,4-dichlorophenyl)hydrazine
5Z4H	;	2.0	;	Bacterial GyrB ATPase domain in complex with a chemical fragment
5Z4O	;	1.73	;	Bacterial GyrB ATPase domain in complex with a chemical fragment
5Z9E	;	1.8	;	Bacterial GyrB ATPase domain in complex with a chemical fragment
5Z9F	;	1.76	;	Bacterial GyrB ATPase domain in complex with a chemical fragment
5Z9L	;	1.6	;	Bacterial GyrB ATPase domain in complex with a chemical fragment
5Z9M	;	2.74	;	Bacterial GyrB ATPase domain in complex with a chemical fragment
5Z9P	;	1.45	;	Bacterial GyrB ATPase domain in complex with a chemical fragment
5Z9Q	;	1.8	;	Bacterial GyrB ATPase domain in complex with a chemical fragment
1LZL	;	1.3	;	Bacterial Heroin Esterase
1LZK	;	1.45	;	BACTERIAL HEROIN ESTERASE COMPLEX WITH TRANSITION STATE ANALOG DIMETHYLARSENIC ACID
7QBJ	;	2.27	;	bacterial IMPDH chimera
7QDX	;	2.9	;	bacterial IMPDH chimera
7QEM	;	3.09	;	bacterial IMPDH chimera
5HE8	;	2.6	;	Bacterial initiation protein
5HE9	;	1.9	;	Bacterial initiation protein in complex with Phage inhibitor protein
1LUC	;	1.5	;	BACTERIAL LUCIFERASE
1XKJ	;	2.5	;	BACTERIAL LUCIFERASE BETA2 HOMODIMER
6RYO	;	1.924	;	Bacterial membrane enzyme structure by the in meso method at 1.9 A resolution
6RYP	;	2.3	;	Bacterial membrane enzyme structure by the in meso method at 2.3 A resolution
7K41	;	2.0	;	Bacterial O-GlcNAcase (OGA) with compound
3RCE	;	3.4	;	Bacterial oligosaccharyltransferase PglB
6GXC	;	3.401	;	Bacterial oligosaccharyltransferase PglB in complex with an inhibitory peptide and a reactive lipid-linked oligosaccharide analog
4FPP	;	2.2	;	Bacterial phosphotransferase
4HBH	;	2.93	;	Bacterial Photosynthetic Reaction Center from Rhodobacter sphaeroides with ILE M265 replaced with ASN
4HBJ	;	2.74	;	Bacterial Photosynthetic Reaction Center from Rhodobacter sphaeroides with ILE M265 replaced with GLN
4H9L	;	2.77	;	Bacterial Photosynthetic Reaction Center from Rhodobacter sphaeroides with ILE M265 replaced with SER
4H99	;	2.97	;	Bacterial Photosynthetic Reaction Center from Rhodobacter sphaeroides with ILE M265 replaced with THR
4Y25	;	2.821	;	Bacterial polysaccharide outer membrane secretin
7E5C	;	2.22	;	Bacterial prolidase mutant D45W/L225Y/H226L/H343I
6NAK	;	3.14	;	BACTERIAL PROTEIN COMPLEX TM BDE complex
6A7H	;	2.301	;	Bacterial protein toxins
1GYZ	;		;	Bacterial ribosomal protein L20 from Aquifex aeolicus
1PED	;	2.15	;	BACTERIAL SECONDARY ALCOHOL DEHYDROGENASE (APO-FORM)
4LTO	;	3.46	;	Bacterial sodium channel in high calcium, I222 space group
4LTP	;	3.8	;	Bacterial sodium channel in high calcium, I222 space group, crystal 2
4LTQ	;	5.5	;	Bacterial sodium channel in low calcium, P42 space group
5HJ8	;	3.7	;	Bacterial sodium channel neck 3G mutant
5HK6	;	5.5	;	Bacterial sodium channel neck 3G mutant, SAD
5HKD	;	3.8	;	Bacterial sodium channel neck 7G mutant
5IWN	;	3.75	;	Bacterial sodium channel pore domain, high bromide
5IWO	;	3.33	;	Bacterial sodium channel pore domain, low bromide
5HK7	;	2.95	;	Bacterial sodium channel pore, 2.95 Angstrom resolution
4LTR	;	5.8	;	Bacterial sodium channel, His245Gly mutant, I222 space group
8HY8	;	2.568	;	Bacterial STING from Epilithonimonas lactis
8HWJ	;	2.553	;	Bacterial STING from Epilithonimonas lactis in complex with 3'3'-c-di-AMP
8HWI	;	2.73	;	Bacterial STING from Larkinella arboricola in complex with 3'3'-c-di-GMP
8HYN	;	2.089	;	Bacterial STING from Riemerella anatipestifer
8HY9	;	1.462	;	Bacterial STING from Riemerella anatipestifer in complex with 3'3'-c-di-GMP
7EBD	;	2.25	;	Bacterial STING in complex with c-di-GMP
7EBL	;	2.17	;	Bacterial STING in complex with c-di-GMP
8Q3N	;	2.63	;	Bacterial transcription termination factor Rho + ADP
8Q3O	;	3.0	;	Bacterial transcription termination factor Rho + pppGpp
8Q3P	;	3.5	;	Bacterial transcription termination factor Rho G150D mutant
8Q3Q	;	3.3	;	Bacterial transcription termination factor Rho G152D mutant
4B3X	;	1.95	;	Bacterial translation initiation factor IF2 (1-363), apo form
4B43	;	1.937	;	Bacterial translation initiation factor IF2 (1-363), apo form, double mutant K86L H130A
4B47	;	2.301	;	Bacterial translation initiation factor IF2 (1-363), complex with GDP at pH6.5
4B44	;	2.7	;	Bacterial translation initiation factor IF2 (1-363), complex with GDP at pH8.0
4B48	;	2.8	;	Bacterial translation initiation factor IF2 (1-363), complex with GTP
4KGM	;	2.361	;	Bacterial tRNA(HIS) Guanylyltransferase (Thg1)-Like Protein in complex with ATP
4KGK	;	2.95	;	Bacterial tRNA(HIS) Guanylyltransferase (Thg1)-Like Protein in complex with GTP
1NBC	;	1.75	;	BACTERIAL TYPE 3A CELLULOSE-BINDING DOMAIN
4RP9	;	1.651	;	Bacterial vitamin C transporter UlaA/SgaT in C2 form
4RP8	;	2.359	;	Bacterial vitamin C transporter UlaA/SgaT in P21 form
4JNW	;	2.06	;	Bacterially expressed Titin Kinase
1MPA	;	2.6	;	BACTERICIDAL ANTIBODY AGAINST NEISSERIA MENINGITIDIS
2MPA	;	2.6	;	BACTERICIDAL ANTIBODY AGAINST NEISSERIA MENINGITIDIS
6D41	;	1.9	;	Bacteriodes uniformis beta-glucuronidase 1 bound to D-glucaro-1,5-lactone
4AM2	;	1.8	;	Bacterioferritin from Blastochloris viridis
4AM4	;	1.68	;	Bacterioferritin from Blastochloris viridis
4AM5	;	1.58	;	Bacterioferritin from Blastochloris viridis
5FS4	;	1.73	;	Bacteriophage AP205 coat protein
6YFI	;	1.248	;	Bacteriophage EMS014 coat protein
6IBG	;	1.95	;	Bacteriophage G20c portal protein crystal structure for construct with intact N-terminus
1GAV	;	3.4	;	BACTERIOPHAGE GA PROTEIN CAPSID
1HJI	;		;	BACTERIOPHAGE HK022 NUN-PROTEIN-NUTBOXB-RNA COMPLEX
2FRP	;	7.5	;	Bacteriophage HK97 Expansion Intermediate IV
2FTE	;		;	Bacteriophage HK97 Expansion Intermediate IV
2FT1	;	3.9	;	Bacteriophage HK97 Head II
2FS3	;	4.2	;	Bacteriophage HK97 K169Y Head I
2FSY	;	3.8	;	Bacteriophage HK97 Pepsin-treated Expansion Intermediate IV
2GP1	;	5.2	;	Bacteriophage HK97 Prohead II crystal structure
8ELD	;	3.3	;	Bacteriophage HRP29 Icosohedral Reconstruction
8EM6	;	3.5	;	Bacteriophage HRP29 Procapsid Icosohedral Reconstruction
1RH6	;	1.7	;	Bacteriophage Lambda Excisionase (Xis)-DNA Complex
1C5E	;	1.1	;	BACTERIOPHAGE LAMBDA HEAD PROTEIN D
3D3D	;	2.6	;	Bacteriophage lambda lysozyme complexed with a chitohexasaccharide
1D9U	;	2.6	;	BACTERIOPHAGE LAMBDA LYSOZYME COMPLEXED WITH A CHITOHEXASACHARIDE
7SJ5	;	2.695	;	Bacteriophage lambda major capsid protein mutant - W308A
1QFQ	;		;	Bacteriophage Lambda N-protein-NutboxB-RNA Complex
7UJL	;	3.3	;	Bacteriophage Lambda Red-Beta N-terminal domain helical assembly in complex with dsDNA
1G5B	;	2.15	;	BACTERIOPHAGE LAMBDA SER/THR PROTEIN PHOSPHATASE
3C82	;	1.68	;	Bacteriophage lysozyme T4 lysozyme mutant K85A/R96H
1AQ3	;	2.8	;	BACTERIOPHAGE MS2 CAPSID PROTEIN/RNA COMPLEX
1BCO	;	2.4	;	BACTERIOPHAGE MU TRANSPOSASE CORE DOMAIN
1BCM	;	2.8	;	BACTERIOPHAGE MU TRANSPOSASE CORE DOMAIN WITH 2 MONOMERS PER ASYMMETRIC UNIT
6DT7	;	2.5	;	Bacteriophage N4 RNA polymerase II and DNA complex
6DT8	;	3.2	;	Bacteriophage N4 RNA polymerase II elongation complex 1
6DTA	;	2.694	;	Bacteriophage N4 RNA polymerase II elongation complex 2
5C6K	;	1.9	;	Bacteriophage P2 integrase catalytic domain
5UU5	;	3.3	;	Bacteriophage P22 mature virion capsid protein
4V4K	;	3.251	;	Bacteriophage P22 Portal Protein bound to middle Tail Factor GP4. This file contain the second biological assembly
2EX3	;	3.0	;	Bacteriophage phi29 DNA polymerase bound to terminal protein
5LII	;	3.8	;	bacteriophage phi812K1-420 major capsid protein
5LI2	;	6.2	;	bacteriophage phi812K1-420 tail sheath and tail tube protein in native tail
5LI4	;	4.2	;	bacteriophage phi812K1-420 tail sheath protein after contraction
7ZZZ	;	4.1	;	Bacteriophage phiCjT23 capsid
8A01	;	3.2	;	Bacteriophage phiCjT23 major capsid protein trimer type 1
8A02	;	3.2	;	Bacteriophage phiCjT23 major capsid protein trimer type 2
8A03	;	3.2	;	Bacteriophage phiCjT23 major capsid protein trimer type 3
8A04	;	3.2	;	Bacteriophage phiCjT23 major capsid protein trimer type 4
8A05	;	3.4	;	Bacteriophage phiCjT23 spike protein penton domain
6P20	;	1.749	;	Bacteriophage phiKZ gp163.1 PAAR repeat protein in complex with a T4 gp5 beta-helix fragment modified to mimic the phiKZ central spike gp164
6P1Z	;	2.099	;	Bacteriophage phiKZ gp163.1 PAAR repeat protein in complex with the C-terminal part of the T4 gp5 beta-helical domain
4JPN	;	2.101	;	Bacteriophage phiX174 H protein residues 143-221
4JPP	;	2.4	;	Bacteriophage phiX174 H protein residues 143-282
7OOK	;	2.23	;	Bacteriophage PRD1 Major Capsid Protein P3 in complex with CPZ
1QBE	;	3.5	;	BACTERIOPHAGE Q BETA CAPSID
7TJE	;	2.799	;	Bacteriophage Q beta capsid protein A38K
7TJD	;	3.5	;	Bacteriophage Q beta capsid protein in T1 symmetry
7TJM	;	3.54	;	Bacteriophage Q beta capsid protein in T3 symmetry
7TJG	;	3.903	;	Bacteriophage Q beta capsid protein, A38K/A40C/D102C in T1 symmetry
4L8H	;	2.4	;	Bacteriophage Qbeta coat protein in complex with RNA operator hairpin
5MNT	;	3.32	;	Bacteriophage Qbeta maturation protein
7BY7	;		;	Bacteriophage SPO1 protein Gp46
6R3A	;	4.0	;	BACTERIOPHAGE SPP1 MATURE CAPSID PROTEIN
6R3B	;	4.5	;	BACTERIOPHAGE SPP1 PROCAPSID-I PROTEIN
6RTL	;	4.2	;	BACTERIOPHAGE SPP1 PROCAPSID-II PROTEIN
7Z4A	;	4.6	;	Bacteriophage SU10 tail and bottom part of the capsid (C1)
7Z4B	;	7.4	;	Bacteriophage SU10 virion (C1)
1N80	;	2.45	;	Bacteriophage T4 baseplate structural protein gp8
1N8B	;	2.9	;	Bacteriophage T4 baseplate structural protein gp8
8GMO	;	3.9	;	Bacteriophage T4 capsid shell containing 9DE insertions into the gp23* major capsid protein subunits
1YUE	;	2.9	;	Bacteriophage T4 capsid vertex protein gp24
1C1K	;	1.45	;	BACTERIOPHAGE T4 GENE 59 HELICASE ASSEMBLY PROTEIN
1QEX	;	2.3	;	BACTERIOPHAGE T4 GENE PRODUCT 9 (GP9), THE TRIGGER OF TAIL CONTRACTION AND THE LONG TAIL FIBERS CONNECTOR
1S2E	;	2.3	;	BACTERIOPHAGE T4 GENE PRODUCT 9 (GP9), THE TRIGGER OF TAIL CONTRACTION AND THE LONG TAIL FIBERS CONNECTOR, ALTERNATIVE FIT OF THE FIRST 19 RESIDUES
3EZK	;	34.0	;	Bacteriophage T4 gp17 motor assembly based on crystal structures and cryo-EM reconstructions
5VF3	;	3.3	;	Bacteriophage T4 isometric capsid
256L	;	1.8	;	BACTERIOPHAGE T4 LYSOZYME
1D9W	;	1.91	;	BACTERIOPHAGE T4 LYSOZYME MUTANT
3C83	;	1.84	;	Bacteriophage T4 lysozyme mutant D89A in wildtype background at room temperature
3CDO	;	1.87	;	Bacteriophage T4 lysozyme mutant R96V in wildtype background at low temperature
8GAO	;	4.1	;	bacteriophage T4 stalled primosome with mutant gp41-E227Q
5MF2	;	2.0	;	Bacteriophage T5 distal tail protein pb9 co-crystallized with Tb-Xo4
8QKY	;	2.0	;	Bacteriophage T5 dUTPase
8QLD	;	2.1	;	Bacteriophage T5 dUTPase mutant with loop deletion (30-35 aa)
4BG7	;	1.9	;	Bacteriophage T5 Homolog of the Eukaryotic Transcription Coactivator PC4 Implicated in Recombination-Dependent DNA Replication
2MXZ	;		;	Bacteriophage T5 l-alanoyl-d-glutamate peptidase comlpex with Zn2+ (Endo T5-ZN2+)
8P3A	;		;	bacteriophage T5 l-alanoyl-d-glutamate peptidase Zn2+/Ca2+ form
3IZG	;	10.9	;	Bacteriophage T7 prohead shell EM-derived atomic model
4RNP	;	3.0	;	BACTERIOPHAGE T7 RNA POLYMERASE, HIGH SALT CRYSTAL FORM, LOW TEMPERATURE DATA, ALPHA-CARBONS ONLY
7EY7	;	4.3	;	bacteriophage T7 tail complex
5LLW	;	3.0	;	Bacteriophytochrome activated diguanylyl cyclase from Idiomarina species A28L
5LLX	;	2.8	;	Bacteriophytochrome activated diguanylyl cyclase from Idiomarina species A28L with GTP bound
6XVU	;	2.1	;	Bacteriophytochrome response regulator from Deinococcus radiodurans
5IC5	;	1.9	;	Bacteriophytochrome response regulator RtBRR
1PY6	;	1.8	;	Bacteriorhodopsin crystallized from bicells
1XJI	;	2.2	;	Bacteriorhodopsin crystallized in bicelles at room temperature
1JV6	;	2.0	;	BACTERIORHODOPSIN D85S/F219L DOUBLE MUTANT AT 2.00 ANGSTROM RESOLUTION
1C8R	;	1.8	;	BACTERIORHODOPSIN D96N BR STATE AT 2.0 A RESOLUTION
1C8S	;	2.0	;	BACTERIORHODOPSIN D96N LATE M STATE INTERMEDIATE
4X32	;	1.9	;	Bacteriorhodopsin ground state structure collected in cryo conditions from crystals obtained in LCP with PEG as a precipitant.
5J7A	;	2.3	;	Bacteriorhodopsin ground state structure obtained with Serial Femtosecond Crystallography
1M0K	;	1.43	;	BACTERIORHODOPSIN K INTERMEDIATE AT 1.43 A RESOLUTION
1O0A	;	1.62	;	BACTERIORHODOPSIN L INTERMEDIATE AT 1.62 A RESOLUTION
1M0M	;	1.43	;	BACTERIORHODOPSIN M1 INTERMEDIATE AT 1.43 A RESOLUTION
1P8H	;	1.52	;	BACTERIORHODOPSIN M1 INTERMEDIATE PRODUCED AT ROOM TEMPERATURE
2WJL	;	2.15	;	Bacteriorhodopsin mutant E194D
2WJK	;	2.3	;	Bacteriorhodopsin mutant E204D
1P8U	;	1.62	;	BACTERIORHODOPSIN N' INTERMEDIATE AT 1.62 A RESOLUTION
1JV7	;	2.25	;	BACTERIORHODOPSIN O-LIKE INTERMEDIATE STATE OF THE D85S MUTANT AT 2.25 ANGSTROM RESOLUTION
6GA4	;	1.8	;	Bacteriorhodopsin, 1 ps state, real-space refined against 15% extrapolated map
6GA6	;	1.8	;	Bacteriorhodopsin, 10 ps state, real-space refined against 10% extrapolated map
6GA7	;	1.8	;	BACTERIORHODOPSIN, 240FS STATE, REAL-SPACE REFINED AGAINST 10% EXTRAPOLATED MAP
6GA5	;	1.9	;	Bacteriorhodopsin, 3 ps state, REAL-SPACE REFINEMED AGAINST 10% EXTRAPOLATED MAP
6GA3	;	2.1	;	Bacteriorhodopsin, 33 ms state, ensemble refinement
6GA8	;	1.8	;	BACTERIORHODOPSIN, 330 FS STATE, REAL-SPACE REFINED AGAINST 15% EXTRAPOLATED STRUCTURE FACTORS
6GA9	;	1.8	;	BACTERIORHODOPSIN, 390 FS STATE, REAL-SPACE REFINED AGAINST 15% EXTRAPOLATED STRUCTURE FACTORS
6GAA	;	1.8	;	BACTERIORHODOPSIN, 430 FS STATE, REAL-SPACE REFINED AGAINST 15% EXTRAPOLATED STRUCTURE FACTORS
6GAB	;	1.8	;	BACTERIORHODOPSIN, 460 FS STATE, REAL-SPACE REFINED AGAINST 15% EXTRAPOLATED STRUCTURE FACTORS
6GAC	;	1.8	;	BACTERIORHODOPSIN, 490 FS STATE, REAL-SPACE REFINED AGAINST 15% EXTRAPOLATED STRUCTURE FACTORS
6GAD	;	1.8	;	BACTERIORHODOPSIN, 530 FS STATE, REAL-SPACE REFINED AGAINST 15% EXTRAPOLATED STRUCTURE FACTORS
6GAE	;	1.8	;	BACTERIORHODOPSIN, 560 FS STATE, REAL-SPACE REFINED AGAINST 15% EXTRAPOLATED STRUCTURE FACTORS
6GAF	;	1.8	;	BACTERIORHODOPSIN, 590 FS STATE, REAL-SPACE REFINED AGAINST 15% EXTRAPOLATED STRUCTURE FACTORS
6GAG	;	1.8	;	BACTERIORHODOPSIN, 630 FS STATE, REAL-SPACE REFINED AGAINST 15% EXTRAPOLATED STRUCTURE FACTORS
6GAH	;	1.8	;	BACTERIORHODOPSIN, 680 FS STATE, REAL-SPACE REFINED AGAINST 15% EXTRAPOLATED STRUCTURE FACTORS
6GAI	;	1.8	;	BACTERIORHODOPSIN, 740 FS STATE, REAL-SPACE REFINED AGAINST 15% EXTRAPOLATED STRUCTURE FACTORS
6GA1	;	1.7	;	Bacteriorhodopsin, dark state, cell 1
6GA2	;	1.8	;	Bacteriorhodopsin, dark state, cell 2
6RMK	;	1.8	;	Bacteriorhodopsin, dark state, cell 2, refined using the same protocol as sub-ps time delays
2NTW	;	1.53	;	Bacteriorhodopsin, wild type, after illumination to produce the L intermediate
2NTU	;	1.53	;	Bacteriorhodopsin, wild type, before illumination
1F50	;	1.7	;	BACTERIORHODOPSIN-BR STATE OF THE E204Q MUTANT AT 1.7 ANGSTROM RESOLUTION
1F4Z	;	1.8	;	BACTERIORHODOPSIN-M PHOTOINTERMEDIATE STATE OF THE E204Q MUTANT AT 1.8 ANGSTROM RESOLUTION
1BRX	;	2.3	;	BACTERIORHODOPSIN/LIPID COMPLEX
1M0L	;	1.47	;	BACTERIORHODOPSIN/LIPID COMPLEX AT 1.47 A RESOLUTION
1C3W	;	1.55	;	BACTERIORHODOPSIN/LIPID COMPLEX AT 1.55 A RESOLUTION
2I1X	;	2.0	;	Bacteriorhodopsin/lipid complex, D96A mutant
2I20	;	2.08	;	Bacteriorhodopsin/lipid complex, M state of D96A mutant
2I21	;	1.84	;	Bacteriorhodopsin/lipid complex, T46V mutant
2Z55	;	2.5	;	Bacterioruberin in the trimeric structure of archaerhodopsin-2
8H3X	;	1.66	;	Bacteroide Fragilis Toxin in complex with nanobody 282
8H3Y	;	2.25	;	Bacteroide Fragilis Toxin in complex with nanobody 327
6ED1	;	2.9	;	Bacteroides dorei Beta-glucuronidase
8DEB	;	1.94	;	Bacteroides fragilis carboxyspermidine dehydrogenase
7YW0	;	1.98	;	Bacteroides fragilis Hcp5
6NE9	;	1.738	;	Bacteroides intestinalis acetyl xylan esterase (BACINT_01039)
6MOT	;	1.71	;	Bacteroides intestinalis feruloyl esterase, Bacint_01033
6MOU	;	2.24	;	Bacteroides intestinalis feruloyl esterase, Bacint_01033
6D8K	;	2.65	;	Bacteroides multiple species beta-glucuronidase
8G0K	;	2.2	;	Bacteroides multispecies type VI secretion system Ntox15 domain effector and immunity Tde1/Tdi1
3ZMR	;	1.43	;	Bacteroides ovatus GH5 xyloglucanase in complex with a XXXG heptasaccharide
6DHT	;	1.42	;	Bacteroides ovatus GH9 Bacova_02649
5NBO	;	1.8	;	Bacteroides ovatus mixed linkage glucan PUL (MLGUL) GH16
5NBP	;	1.8	;	Bacteroides ovatus mixed linkage glucan PUL (MLGUL) GH16 in complex with G4G4G3G Product
6E60	;	1.5	;	Bacteroides ovatus mixed-linkage glucan utilization locus (MLGUL) SGBP-A
6E61	;	2.51	;	Bacteroides ovatus mixed-linkage glucan utilization locus (MLGUL) SGBP-A in complex with mixed-linkage heptasaccharide
6DMF	;	2.4	;	Bacteroides ovatus mixed-linkage glucan utilization locus (MLGUL) SGBP-A with cellohexaose
6E57	;	2.71	;	Bacteroides ovatus mixed-linkage glucan utilization locus (MLGUL) SGBP-B in complex with mixed-linkage heptasaccharide
6E9B	;	3.15	;	Bacteroides ovatus mixed-linkage glucan utilization locus (MLGUL) SGBP-B in complex with mixed-linkage heptasaccharide
5JOU	;	1.5	;	Bacteroides ovatus Xyloglucan PUL GH31
5JOV	;	1.5	;	Bacteroides ovatus Xyloglucan PUL GH31 with bound 5FIdoF
5JP0	;	2.3	;	Bacteroides ovatus Xyloglucan PUL GH3B with bound glucose
5JOW	;	1.6	;	Bacteroides ovatus Xyloglucan PUL GH43A
5JOX	;	1.8	;	Bacteroides ovatus Xyloglucan PUL GH43A in complex with AraDNJ
5JOY	;	1.9	;	Bacteroides ovatus Xyloglucan PUL GH43A in complex with AraLOG
5JOZ	;	2.28	;	Bacteroides ovatus Xyloglucan PUL GH43B
6T5O	;	1.91	;	Bacteroides salyersiae GH164 beta-mannosidase
6T75	;	2.55	;	Bacteroides salyersiae GH164 beta-mannosidase 2-deoxy-2-fluoro-beta-D-mannosyl enzyme intermediate
6T7G	;	1.8	;	Bacteroides salyersiae GH164 beta-mannosidase in complex with mannoimidazole
6T6G	;	2.06	;	Bacteroides salyersiae GH164 beta-mannosidase in complex with noeuromycin
8FZY	;	2.9	;	Bacteroides spp. Ntox15 domain type VI secretion system effector Tde1
8BMX	;	3.72	;	Bacteroides thetaiotaomicron B12 TonB dependent transporter in complex with a surface lipoprotein
7XRT	;	2.007	;	Bacteroides thetaiotaomicron ferulic acid esterase (BT_4077)
7XRV	;	2.713	;	Bacteroides thetaiotaomicron ferulic acid esterase - S150A (BT_4077-S150A) complex with trans-methylferulate
2JIW	;	1.95	;	Bacteroides thetaiotaomicron GH84 O-GlcNAcase in complex with 2- Acetylamino-2-deoxy-1-epivalienamine
2J47	;	1.98	;	Bacteroides thetaiotaomicron GH84 O-GlcNAcase in complex with a imidazole-pugnac hybrid inhibitor
2J4G	;	2.25	;	Bacteroides thetaiotaomicron GH84 O-GlcNAcase in complex with n-butyl- thiazoline inhibitor
2CHO	;	1.85	;	Bacteroides thetaiotaomicron hexosaminidase with O-GlcNAcase activity
2CHN	;	1.95	;	Bacteroides thetaiotaomicron hexosaminidase with O-GlcNAcase activity- NAG-thiazoline complex
7OP6	;	2.05	;	Bacteroides thetaiotaomicron mannosidase GH2 with beta-manno-configured cyclophellitol aziridine
7OP7	;	1.85	;	Bacteroides thetaiotaomicron mannosidase GH2 with beta-manno-configured N-alkyl cyclophellitol aziridine
5CU7	;	1.73	;	Bacteroides Thetaiotaomicron Multiple Inositol Polyphosphate Phosphatase A324D Mutant
8BMY	;	1.72	;	Bacteroides thetaiotaomicron surface lipoprotein bound to cyanocobalamin
8BMZ	;	2.3	;	Bacteroides thetaiotaomicron surface lipoprotein BT1954 bound to adenosylcobalamin
8BN0	;	1.33	;	Bacteroides thetaiotaomicron surface protein BT1954 bound to
4C1R	;	2.1	;	Bacteroides thetaiotaomicron VPI-5482 mannosyl-6-phosphatase Bt3783
7DWC	;	1.804	;	Bacteroides thetaiotaomicron VPI5482 BTAxe1
6D6W	;	1.8	;	Bacteroides uniformis beta-glucuronidase 1 bound to glucuronate
6D7F	;	2.4	;	Bacteroides uniformis beta-glucuronidase 1 bound to thiophenyl-beta-D-glucuronide
6D89	;	2.0	;	Bacteroides uniformis beta-glucuronidase 1 with N-terminal loop deletion
6NZG	;	2.43	;	Bacteroides uniformis beta-glucuronidase 2 covalently bound to cyclophellitol-6-carboxylate aziridine
6PAL	;	1.818	;	Bacteroides uniformis endo-laminarinase BuGH158 from the beta(1,3)-glucan utilization locus
6D50	;	2.5	;	Bacteroides uniforms beta-glucuronidase 2 bound to D-glucaro-1,5-lactone
6DK2	;	2.02	;	Bacteroidetes AC2a SusD-like
6RIA	;	3.5	;	Bactofilin from Thermus thermophilus, F105R mutant crystal structure
3SA2	;	2.25	;	Bacuills anthracis Dihydrofolate Reductase bound propargyl-linked TMP analog, UCP1014
3SA1	;	2.5	;	Bacuills anthracis Dihydrofolate Reductase bound propargyl-linked TMP analog, UCP1021
3SAI	;	2.25	;	Bacuills anthracis Dihydrofolate Reductase bound to propargyl-linked TMP analog, UCP1015
6Y48	;	2.087	;	Baeyer-Villiger monooxygenase BVMOAFL210 from Aspergillus flavus in complex with NADP
5J7X	;	1.9	;	Baeyer-Villiger monooxygenase BVMOAFL838 from Aspergillus flavus
7Z21	;	1.629	;	BAF A12T bound to the lamin A/C Ig-fold domain
5Y9J	;	2.05	;	BAFF in complex with belimumab
1I6Z	;		;	BAG DOMAIN OF BAG1 COCHAPERONE
4U2V	;	2.3	;	Bak BH3-in-Groove dimer (GFP)
5VWV	;	1.897	;	Bak core latch dimer in complex with Bim-BH3 - Cubic
5VWX	;	2.489	;	Bak core latch dimer in complex with Bim-h0-h3Glt
5VWY	;	1.555	;	Bak core latch dimer in complex with Bim-h3Pc-RT
5VWW	;	2.802	;	Bak core latch dimer in complex with Bim-RT - Tetragonal
4U2U	;	2.9	;	Bak domain swapped dimer induced by BidBH3 with CHAPS
5VX0	;	1.599	;	Bak in complex with Bim-h3Glg
5VWZ	;	1.622	;	Bak in complex with Bim-h3Pc
5VX1	;	1.224	;	Bak L100A
3QBR	;	2.601	;	BakBH3 in complex with sjA
1HHU	;	0.89	;	Balhimycin in complex with D-Ala-D-Ala
1GO6	;	0.98	;	Balhimycin in complex with Lys-D-ala-D-ala
7YE4	;	3.4	;	BAM-EspP complex structure with BamA-G431C and G781C/EspP-N1293C and A1043C mutations in nanodisc
8BNZ	;	3.5	;	BAM-EspP complex structure with BamA-G431C/EspP-N1293C mutations in nanodisc
7YE6	;	3.4	;	BAM-EspP complex structure with BamA-N427C/EspP-R1297C mutations in nanodisc
8BO2	;	3.1	;	BAM-EspP complex structure with BamA-S425C/EspP-S1299C mutations in nanodisc
5OR1	;	2.92	;	BamA structure of Salmonella enterica
7TTC	;	3.6	;	BamABCDE bound to substrate EspP
7TSZ	;	4.5	;	BamABCDE bound to substrate EspP class 1
7TT0	;	4.3	;	BamABCDE bound to substrate EspP class 2
7TT2	;	4.2	;	BamABCDE bound to substrate EspP class 3
7TT1	;	4.3	;	BamABCDE bound to substrate EspP class 4
7TT3	;	4.3	;	BamABCDE bound to substrate EspP class 5
7TT4	;	4.2	;	BamABCDE bound to substrate EspP class 6
7TT7	;	4.8	;	BamABCDE bound to substrate EspP in the barrelized EspP/continuous open BamA state
7TT6	;	4.3	;	BamABCDE bound to substrate EspP in the intermediate-open EspP state
7TT5	;	4.3	;	BamABCDE bound to substrate EspP in the open-sheet EspP state
5D0O	;	2.9	;	BamABCDE complex, outer membrane beta barrel assembly machinery entire complex
6SMX	;	6.65	;	BamABCDE in MSP1D1 nanodisc
6SN0	;	10.8	;	BamABCDE in MSP1D1 nanodisc ensemble 0-1
6SN2	;	9.5	;	BamABCDE in MSP1D1 nanodisc ensemble 0-2
6SN3	;	8.4	;	BamABCDE in MSP1D1 nanodisc ensemble 0-3
6SN4	;	9.5	;	BamABCDE in MSP1D1 nanodisc ensemble 0-4
6SN5	;	9.8	;	BamABCDE in MSP1D1 nanodisc ensemble 0-5
6SN7	;	8.9	;	BamABCDE in MSP1D1 nanodisc ensemble 0-6
6SN8	;	8.4	;	BamABCDE in MSP1D1 nanodisc ensemble 0-7
6SN9	;	9.8	;	BamABCDE in MSP1D1 nanodisc ensemble 0-8
6SOA	;	10.8	;	BamABCDE in MSP1D1 nanodisc ensemble 0-9
6SO7	;	10.5	;	BamABCDE in MSP1D1 nanodisc ensemble 1-2
6SO8	;	9.8	;	BamABCDE in MSP1D1 nanodisc ensemble 1-3
6SOB	;	8.5	;	BamABCDE in MSP1D1 nanodisc ensemble 1-4
6SOC	;	9.0	;	BamABCDE in MSP1D1 nanodisc ensemble 1-5
6SOG	;	8.3	;	BamABCDE in MSP1D1 nanodisc ensemble 1-6
6SOH	;	9.5	;	BamABCDE in MSP1D1 nanodisc ensemble 1-7
6SOJ	;	10.4	;	BamABCDE in MSP1D1 nanodisc ensemble 1-8
5D0Q	;	3.5	;	BamACDE complex, outer membrane beta-barrel assembly machinery (BAM) complex
3ZZV	;	1.68	;	BambL complexed with Htype2 tetrasaccharide
5MTI	;		;	Bamb_5917 Acyl-Carrier Protein
6TDM	;		;	Bam_5920cDD 5919nDD docking domains
6TDD	;		;	Bam_5924 docking domain
6TDN	;		;	Bam_5925cDD 5924nDD docking domains
3MLA	;	1.75	;	BaNadD in complex with inhibitor 1_02
3MLB	;	1.8	;	BaNadD in complex with inhibitor 1_02_1
8HXK	;	3.8	;	BANAL-20-236 S1 in complex with R. Affinis ACE2
8I3W	;	2.8	;	BANAL-20-236 Spike trimer
8HXJ	;	3.5	;	BANAL-20-52 Spike trimer
2BMY	;	2.5	;	Banana Lectin
2BN0	;	2.8	;	Banana Lectin bound to Laminaribiose
2BMZ	;	2.4	;	Banana Lectin bound to Xyl-b1,3 Man-a-O-Methyl (XM)
7UZ3	;	2.35	;	Band 3-Glycophorin A complex, outward facing
7V07	;	2.8	;	Band 3-I-TM local refinement from erythrocyte ankyrin-1 complex consensus reconstruction
2K56	;		;	Bank Vole Prion Protein (121-231)
4CUO	;	1.67	;	Banyan peroxidase with glycosylation
8SVF	;	3.2	;	BAP1/ASXL1 bound to the H2AK119Ub Nucleosome
8CEG	;	2.03	;	BAR domain protein FAM92A1 essential for mitochondrial membrane remodeling
1C40	;	2.3	;	BAR-HEADED GOOSE HEMOGLOBIN (AQUOMET FORM)
1A4F	;	2.0	;	BAR-HEADED GOOSE HEMOGLOBIN (OXY FORM)
3KCH	;	1.94	;	Baranase crosslinked by glutaraldehyde
6UC4	;	9.2	;	Barbed end side of a cofilactin cluster
4YD8	;	1.8	;	Bardet-Biedl Syndrome 9 Protein (aa1-407), Homo sapiens
6VAU	;	3.5	;	Bare actin filament from a partially cofilin-decorated sample
3GOM	;	2.3	;	Barium bound to the Holliday junction sequence d(TCGGCGCCGA)4
3GOJ	;	2.6	;	Barium bound to the Holliday sequence d(CCGGCGCCGG)4
3VG5	;	2.0	;	Barium derivative of human LFABP
3VG6	;	2.22	;	Barium derivative of human LFABP
3FQB	;	1.67	;	Barium interactions with Z-DNA
6CMC	;	3.671	;	Barium sites in the structure of a desensitized acid sensing ion channel
5WKX	;	4.034	;	Barium sites in the structure of a resting acid sensing ion channel
1AQ0	;	2.0	;	BARLEY 1,3-1,4-BETA-GLUCANASE IN MONOCLINIC SPACE GROUP
2VDG	;	1.92	;	Barley Aldose Reductase 1 complex with butanol
3BSH	;	3.0	;	Barley alpha-amylase isozyme 1 (AMY1) double mutant Y105A/Y380A in complex with inhibitor acarbose
3BSG	;	1.95	;	Barley alpha-amylase isozyme 1 (AMY1) H395A mutant
1BG9	;	2.8	;	BARLEY ALPHA-AMYLASE WITH SUBSTRATE ANALOGUE ACARBOSE
2Y5E	;	2.49	;	BARLEY LIMIT DEXTRINASE IN COMPLEX WITH ALPHA-CYCLODEXTRIN
2Y4S	;	2.1	;	BARLEY LIMIT DEXTRINASE IN COMPLEX WITH BETA-CYCLODEXTRIN
1LIP	;		;	BARLEY LIPID TRANSFER PROTEIN (NMR, 4 STRUCTURES)
2WHD	;	2.6	;	Barley NADPH-dependent thioredoxin reductase 2
7EW6	;	3.4	;	Barley photosystem I-LHCI-Lhca5 supercomplex
7EWK	;	3.88	;	Barley photosystem I-LHCI-Lhca6 supercomplex
1BNR	;		;	BARNASE
1BNE	;	2.1	;	BARNASE A43C/S80C DISULFIDE MUTANT
2KF6	;		;	Barnase bound to d(CGAC) high pressure
2KF5	;		;	Barnase bound to d(CGAC), low pressure
2F4Y	;	2.15	;	Barnase cross-linked with glutaraldehyde
2F56	;	1.955	;	Barnase cross-linked with glutaraldehyde soaked in 6M urea
2KF4	;		;	Barnase high pressure structure
1BRI	;	1.9	;	BARNASE MUTANT WITH ILE 76 REPLACED BY ALA
1BRJ	;	2.0	;	BARNASE MUTANT WITH ILE 88 REPLACED BY ALA
1BRK	;	2.0	;	BARNASE MUTANT WITH ILE 96 REPLACED BY ALA
1BRH	;	2.0	;	BARNASE MUTANT WITH LEU 14 REPLACED BY ALA
1BNG	;	2.1	;	BARNASE S85C/H102C DISULFIDE MUTANT
1BNF	;	2.0	;	BARNASE T70C/S92C DISULFIDE MUTANT
1A2P	;	1.5	;	BARNASE WILDTYPE STRUCTURE AT 1.5 ANGSTROMS RESOLUTION
1BNI	;	2.1	;	BARNASE WILDTYPE STRUCTURE AT PH 6.0
1B2X	;	1.8	;	BARNASE WILDTYPE STRUCTURE AT PH 7.5 FROM A CRYO_COOLED CRYSTAL AT 100K
1BNJ	;	2.1	;	BARNASE WILDTYPE STRUCTURE AT PH 9.0
2KF3	;		;	Barnase, low pressure reference NMR structure
6URE	;	1.653	;	Barrier-to-autointegration factor Aqueous: 1 of 14 in MSCS set
6USI	;	1.653	;	Barrier-to-autointegration factor soaked in 1,6-hexanediol: 1 of 14 in MSCS set
6URJ	;	1.653	;	Barrier-to-autointegration factor soaked in Acetone: 1 of 14 in MSCS set
6URR	;	1.8	;	Barrier-to-autointegration factor soaked in Dioxane: 1 of 14 in MSCS set
6UNT	;	1.75	;	Barrier-to-autointegration factor soaked in DMSO: 1 of 14 in MSCS set
6USD	;	1.653	;	Barrier-to-autointegration factor soaked in ethanol: 1 of 14 in MSCS set
6URK	;	1.86	;	Barrier-to-autointegration factor soaked in Glycerol: 1 of 14 in MSCS set
6US1	;	1.653	;	Barrier-to-autointegration factor soaked in isobutanol: 1 of 14 in MSCS set
6URL	;	1.72	;	Barrier-to-autointegration factor soaked in isopropanol: 1 of 14 in MSCS set
6URZ	;	1.653	;	Barrier-to-autointegration factor soaked in methanol: 1 of 14 in MSCS set
6US0	;	1.653	;	Barrier-to-autointegration factor soaked in R,S,R-bisfuranol (RSR): 1 of 14 in MSCS set
6US7	;	1.653	;	Barrier-to-autointegration factor soaked in TMAO: 1 of 14 in MSCS set
6USB	;	1.68	;	Barrier-to-autointegration factor soaked in urea: 1 of 14 in MSCS set
6URN	;	1.68	;	Barrier-to-autointegration factor t-butanol: 1 of 14 in MSCS set
1A19	;	2.76	;	BARSTAR (FREE), C82A MUTANT
4ZI3	;	2.0	;	BART-like domain of BARTL1/CCDC104 aa1-133 in complex with Arl3FL bound to GppNHp in P1 21 1
4ZI2	;	2.2	;	BART-like domain of BARTL1/CCDC104 in complex with Arl3FL bound to GppNHp in P21 21 21
5NH2	;	2.321	;	Bartonella henselae BepA Fic domain in complex with its antitoxin homologue BiaA
7MPM	;	1.95	;	Bartonella henselae NrnC bound to pAA
7MPO	;	1.95	;	Bartonella henselae NrnC bound to pAp
7MPN	;	1.94	;	Bartonella henselae NrnC bound to pGC
7MPL	;	1.8	;	Bartonella henselae NrnC bound to pGG
7MQC	;	3.64	;	Bartonella henselae NrnC bound to pGG. C1 reconstruction.
7MQB	;	3.25	;	Bartonella henselae NrnC bound to pGG. D4 Symmetry
7MPP	;	2.0	;	Bartonella henselae NrnC cleaving pGG in the presence of Mg2+
7MPQ	;	2.35	;	Bartonella henselae NrnC cleaving pGG in the presence of Mn2+
7MQI	;	3.21	;	Bartonella henselae NrnC complexed with pAAAGG in the presence of Ca2+. C1 reconstruction.
7MQH	;	3.1	;	Bartonella henselae NrnC complexed with pAAAGG in the presence of Ca2+. D4 Symmetry.
7MQG	;	3.25	;	Bartonella henselae NrnC complexed with pAAAGG. C1 reconstruction.
7MQF	;	2.88	;	Bartonella henselae NrnC complexed with pAAAGG. D4 symmetry.
7MQE	;	3.69	;	Bartonella henselae NrnC complexed with pAGG. C1 reconstruction.
7MQD	;	3.25	;	Bartonella henselae NrnC complexed with pAGG. D4 symmetry.
3NAZ	;	3.0	;	Basal state form of Yeast Glycogen Synthase
8HMC	;	3.6	;	base module state 1 of Tetrahymena IFT-A
8HMD	;	4.7	;	base module state 2 of Tetrahymena IFT-A
1DNS	;	2.0	;	BASE ONLY BINDING OF SPERMINE IN THE DEEP GROOVE OF THE A-DNA OCTAMER D(GTGTACAC)
5HN2	;	1.5	;	Base Pairing and Structure Insights into the 5-Formylcytosine in RNA Duplex
5HNJ	;	1.24	;	Base Pairing and Structure Insights into the 5-Formylcytosine in RNA Duplex
5HNQ	;	2.4	;	Base Pairing and Structure Insights into the 5-Formylcytosine in RNA Duplex
4FS2	;	2.05	;	Base pairing mechanism of N2,3-ethenoguanine with dCTP by human polymerase iota
4FS1	;	2.5	;	Base pairing mechanism of N2,3-ethenoguanine with dTTP by human polymerase iota
1D40	;	1.3	;	BASE SPECIFIC BINDING OF COPPER(II) TO Z-DNA: THE 1.3-ANGSTROMS SINGLE CRYSTAL STRUCTURE OF D(M5CGUAM5CG) IN THE PRESENCE OF CUCL2
2N4M	;		;	Base-displaced intercalated structure of the N-(2'deoxyguanosin-8-yl)-3-aminobenzanthrone DNA adduct
206D	;	2.5	;	BASE-PAIR OPENING AND SPERMINE BINDING-B-DNA FEATURES DISPLAYED IN THE CRYSTAL STRUCTURE OF A GAL OPERON FRAGMENT: IMPLICATIONS FOR PROTEIN-DNA RECOGNITION
1QP5	;	2.6	;	BASE-PAIRING SHIFT IN A DODECAMER CONTAINING A (CA)N TRACT
330D	;	2.7	;	BASE-PAIRING SHIFT IN THE MAJOR GROOVE OF (CA)N TRACTS BY B-DNA CRYSTAL STRUCTURES
2AWE	;	2.1	;	Base-Tetrad Swapping Results in Dimerization of RNA Quadruplexes: Implications for Formation of I-Motif RNA Octaplex
7KH1	;	3.2	;	Baseplate Complex for Myoviridae Phage XM1
8HQZ	;	3.8	;	Baseplate of DT57C bacteriophage in the full state
6TEH	;	3.99	;	Baseplate of native GTA particle computed with C3 symmetry
8TEK	;	3.6	;	Baseplate of Nexin-dynein regulatory complex from Tetrahymena thermophila
1BLA	;		;	BASIC FIBROBLAST GROWTH FACTOR (FGF-2) MUTANT WITH CYS 78 REPLACED BY SER AND CYS 96 REPLACED BY SER, NMR
1BLD	;		;	BASIC FIBROBLAST GROWTH FACTOR (FGF-2) MUTANT WITH CYS 78 REPLACED BY SER AND CYS 96 REPLACED BY SER, NMR
1BFC	;	2.2	;	BASIC FIBROBLAST GROWTH FACTOR COMPLEXED WITH HEPARIN HEXAMER FRAGMENT
1BFB	;	1.9	;	BASIC FIBROBLAST GROWTH FACTOR COMPLEXED WITH HEPARIN TETRAMER FRAGMENT
9PTI	;	1.22	;	BASIC PANCREATIC TRYPSIN INHIBITOR (MET 52 OXIDIZED)
1B4W	;	2.6	;	BASIC PHOSPHOLIPASE A2 FROM AGKISTRODON HALYS PALLAS-IMPLICATIONS FOR ITS ASSOCIATION AND ANTICOAGULANT ACTIVITIES BY X-RAY CRYSTALLOGRAPHY
1PVP	;	2.35	;	BASIS FOR A SWITCH IN SUBSTRATE SPECIFICITY: CRYSTAL STRUCTURE OF SELECTED VARIANT OF CRE SITE-SPECIFIC RECOMBINASE, ALSHG BOUND TO THE ENGINEERED RECOGNITION SITE LOXM7
1PVQ	;	2.75	;	BASIS FOR A SWITCH IN SUBSTRATE SPECIFICITY: CRYSTAL STRUCTURE OF SELECTED VARIANT OF CRE SITE-SPECIFIC RECOMBINASE, LNSGG BOUND TO THE ENGINEERED RECOGNITION SITE LOXM7
1PVR	;	2.65	;	BASIS FOR A SWITCH IN SUBSTRATE SPECIFICITY: CRYSTAL STRUCTURE OF SELECTED VARIANT OF CRE SITE-SPECIFIC RECOMBINASE, LNSGG BOUND TO THE LOXP (WILDTYPE) RECOGNITION SITE
6RPO	;	2.39	;	bat circovirus without DNA VLP
6MWM	;		;	Bat coronavirus HKU4 SUD-C
6T0V	;	3.02	;	Bat Influenza A polymerase elongation complex with incoming UTP analogue (complete polymerase)
6SZV	;	2.5	;	Bat Influenza A polymerase elongation complex with incoming UTP analogue (core + endonuclease only)
6T0N	;	2.54	;	Bat Influenza A polymerase pre-initiation complex
6SZU	;	2.41	;	Bat Influenza A polymerase pre-termination complex with pyrophosphate using 44-mer vRNA template with mutated oligo(U) sequence
6T0U	;	3.12	;	Bat Influenza A polymerase product dissociation complex using 44-mer vRNA template with intact oligo(U) sequence
6T0R	;	2.82	;	Bat Influenza A polymerase product dissociation complex using 44-mer vRNA template with mutated oligo(U) sequence
6T2C	;	3.52	;	Bat Influenza A polymerase recycling complex
6T0S	;	3.04	;	Bat Influenza A polymerase stuttering complex using 44-mer vRNA template with intact oligo(U) sequence
6TW1	;	2.7	;	Bat Influenza A polymerase termination complex with pyrophosphate using 44-mer vRNA template with mutated oligo(U) sequence
4WSB	;	2.65	;	Bat Influenza A polymerase with bound vRNA promoter
5M3H	;	2.5	;	Bat influenza A/H17N10 polymerase bound to four heptad repeats of serine 5 phosphorylated Pol II CTD
4QZV	;	2.592	;	Bat-derived coronavirus HKU4 uses MERS-CoV receptor human CD26 for cell entry
8PPK	;	2.98	;	Bat-Hp-CoV Nsp1 and eIF1 bound to the human 40S small ribosomal subunit
6WFU	;	3.03	;	BatAAV-10HB - empty particles
6WFT	;	3.03	;	BatAAV-10HB - genome-containing particles
2GZB	;	1.7	;	Bauhinia bauhinioides cruzipain inhibitor (BbCI)
2K7W	;		;	BAX Activation is Initiated at a Novel Interaction Site
4BDU	;	2.998	;	Bax BH3-in-Groove dimer (GFP)
4BD6	;	2.494	;	Bax domain swapped dimer in complex with BaxBH3
4BD2	;	2.206	;	Bax domain swapped dimer in complex with BidBH3
4BD8	;	2.22	;	Bax domain swapped dimer induced by BimBH3 with CHAPS
4BD7	;	2.801	;	Bax domain swapped dimer induced by octylmaltoside
6FOE	;	2.6	;	BaxB01 Fab fragment
5NHY	;	1.72	;	BAY-707 in complex with MTH1
7QZC	;	2.1	;	BAZ2A bromodomain in complex with acetylpyrrole derivative compound 104
7QYV	;	2.25	;	BAZ2A bromodomain in complex with acetylpyrrole derivative compound 109
7QYW	;	2.1	;	BAZ2A bromodomain in complex with acetylpyrrole derivative compound 111
7QZI	;	1.98	;	BAZ2A bromodomain in complex with acetylpyrrole derivative compound 113
7QWU	;	1.6	;	BAZ2A bromodomain in complex with acetylpyrrole derivative compound 44
7QWF	;	2.25	;	BAZ2A bromodomain in complex with acetylpyrrole derivative compound 45
7R0B	;	2.345	;	BAZ2A bromodomain in complex with acetylpyrrole derivative compound 47
7QWY	;	2.443	;	BAZ2A bromodomain in complex with acetylpyrrole derivative compound 61
7QX2	;	1.428	;	BAZ2A bromodomain in complex with acetylpyrrole derivative compound 63
7QX9	;	1.5	;	BAZ2A bromodomain in complex with acetylpyrrole derivative compound 65
7QXL	;	1.15	;	BAZ2A bromodomain in complex with acetylpyrrole derivative compound 77
7QYE	;	1.65	;	BAZ2A bromodomain in complex with acetylpyrrole derivative compound 78
7QYO	;	0.983	;	BAZ2A bromodomain in complex with acetylpyrrole derivative compound 79
7QYT	;	2.6	;	BAZ2A bromodomain in complex with acetylpyrrole derivative compound 80
7QZ0	;	2.1	;	BAZ2A bromodomain in complex with acetylpyrrole derivative compound 83
7QZ4	;	2.3	;	BAZ2A bromodomain in complex with acetylpyrrole derivative compound 87
7QYU	;	1.5	;	BAZ2A bromodomain in complex with acetylpyrrole derivative compound 88
7QZB	;	2.151	;	BAZ2A bromodomain in complex with acetylpyrrole derivative compound 98
7QVU	;	2.4	;	BAZ2A bromodomain in complex with acetylpyrrole derivative fragment 25
7BLC	;	2.3	;	BAZ2A bromodomain in complex with compound UP39
7BLD	;	2.35	;	BAZ2A bromodomain in complex with compound UZH23
7B7G	;	1.428	;	BAZ2A bromodomain in complex with compounds MS04 and B11
7BL9	;	1.3	;	BAZ2A bromodomain in complex with GSK2801 chemical probe
7BLB	;	2.3	;	BAZ2A bromodomain in complex with GSK4027 chemical probe
7QZT	;	2.183	;	BAZ2A bromodomain in complex with isoquinoline derivative fragment 9
7R01	;	2.256	;	BAZ2A bromodomain in complex with N-acetylpiperazine derivative fragment 18
7QVT	;	2.6	;	BAZ2A bromodomain in complex with picolinamide derivative fragment 13
7QVV	;	2.601	;	BAZ2A bromodomain in complex with pyridone derivative fragment 36
7BL8	;	2.5	;	BAZ2A bromodomain in complex with the chemical probe BAZ2-ICR
7BLA	;	1.086	;	BAZ2A bromodomain in complex with TP-238 chemical probe
7B7B	;	1.4	;	BAZ2A bromodomain in complex with triazole compound MS04
7B7I	;	1.15	;	BAZ2A bromodomain in complex with triazole compound MS04-TN02
7B82	;	1.25	;	BAZ2A bromodomain in complex with triazole compound MS04-TN03
7BC2	;	2.0	;	BAZ2A bromodomain in complex with triazole compound MS04-TN04
6PSJ	;	1.8	;	Bazedoxifene in Complex with Y537S Estrogen Receptor Alpha Ligand Binding Domain
8P33	;	2.1	;	BB0238 from Borrelia burgdorferi
8P32	;	2.15	;	BB0238 from Borrelia burgdorferi, Se-Met data for Leu240Met mutant
1W33	;	2.7	;	BbCRASP-1 from Borrelia Burgdorferi
6FXE	;	2.4	;	BBE31 from Lyme disease agent Borrelia (Borreliella) burgdorferi playing a vital role in successful colonization of the mammalian host
6FZE	;	2.26	;	BBE31 from Lyme disease agent Borrelia (Borreliella) burgdorferi playing a vital role in successful colonization of the mammalian host (native data)
8D1N	;	1.93	;	bBest2_345 Ca2+-bound open state
6B40	;	4.3	;	BbRAGL-3'TIR synaptic complex with nicked DNA refined with C2 symmetry
5BKK	;	3.5	;	bbTBA-bound closed MthK channel in nanodisc
6EG7	;	3.0	;	BbvCI B2 dimer with I3C clusters
6M9G	;	2.35	;	BbvCI B2 dimer with Ta6Br14 clusters
4HQ6	;	2.7	;	BC domain in the presence of citrate
2XNX	;	3.3	;	BC1 fragment of streptococcal M1 protein in complex with human fibrinogen
5IVO	;	1.8	;	BC2 nanobody
5IVN	;	1.0	;	BC2 nanobody in complex with the BC2 peptide tag
7TCH	;	3.7	;	BceAB E169Q variant ATP-bound conformation
7TCG	;	3.8	;	BceAB nucleotide-free conformation
8G3F	;	3.7	;	BceAB-S nucleotide free BceS state 1
8G3L	;	3.5	;	BceAB-S nucleotide free BceS state 2
8G3A	;	3.4	;	BceAB-S nucleotide free TM state 1
8G3B	;	3.5	;	BceAB-S nucleotide free TM state 2
8G4C	;	3.1	;	BceABS ATPgS high res TM
8G4D	;	3.6	;	BceABS ATPgS tilted BceS
2Y0E	;	1.75	;	BceC and the final step of UGDs reaction
2Y0D	;	2.8	;	BceC mutation Y10K
2Y0C	;	1.75	;	BceC mutation Y10S
6Z0P	;	1.85	;	BceF Tyrosine Kinase Domain
5AGW	;	2.695	;	Bcl-2 alpha beta-1 complex
5AGX	;	2.24	;	Bcl-2 alpha beta-1 LINEAR complex
5VAU	;	1.754	;	Bcl-2 complex with Beclin 1 BH3 domain
5VAX	;	2.0	;	Bcl-2 complex with Beclin 1 BH3 domain
5VAY	;	1.804	;	Bcl-2 complex with Beclin 1 T108D BH3 domain
8U27	;		;	Bcl-2-xL complexed with compound 35
2B48	;	3.45	;	Bcl-XL 3D Domain Swapped Dimer
4BPK	;	1.756	;	Bcl-xL bound to alpha beta Puma BH3 peptide 5
6DCO	;	2.198	;	Bcl-xL complex with Beclin 1 BH3 domain T108D
6DCN	;	2.444	;	Bcl-xL complex with Beclin 1 BH3 domain T108pThr
6RNU	;	2.4	;	BCL-XL in a complex with a covalent small molecule inhibitor
5VX3	;	1.945	;	Bcl-xL in complex with Bim-h3Pc-RT
8WLS	;		;	Bcl-xL in complex with HBx BH3 delta C peptide
4TUH	;	1.8	;	Bcl-xL in complex with inhibitor (Compound 10)
5FMK	;	1.731	;	Bcl-xL with Bak BH3 complex
5FMJ	;	2.43	;	Bcl-xL with mouse Bak BH3 Q75L complex
5JSN	;	2.1	;	Bcl2-inhibitor complex
6CQ1	;	1.69921	;	BCL6 BTB domain in complex with 15a
2WRA	;	1.1	;	BclA lectin from Burkholderia cenocepacia complexed with aMan1(aMan1- 6)-3Man trisaccharide
4LVT	;	2.05	;	Bcl_2-Navitoclax (ABT-263) Complex
4MAN	;	2.07	;	Bcl_2-Navitoclax Analog (with Indole) Complex
4LXD	;	1.9	;	Bcl_2-Navitoclax Analog (without Thiophenyl) Complex
6U1Y	;	2.17	;	bcs1 AAA domain
7ZZQ	;	2.6	;	BcsH-BcsD 'beads-on-a-string' filament, local refine
4D3F	;	1.81	;	BcSIRED from Bacillus cereus in complex with NADPH
6TAD	;	1.822	;	Bd0314 DslA E143Q mutant
6TAF	;	1.336	;	Bd0314 DslA E154Q mutant
6TA9	;	1.361	;	Bd0314 DslA wild-type form 1
6TAB	;	1.26	;	Bd0314 DslA wild-type form 2
5CER	;	2.48	;	Bd0816 Predatory Endopeptidase from Bdellovibrio bacteriovorus in complex with immunity protein Bd3460
3TM8	;	1.28	;	Bd1817, a HDG""Y""P protein from Bdellovibrio bacteriovorus
3TMB	;	1.7	;	Bd1817, a HDG""Y""P protein from Bdellovibrio bacteriovorus
3TMC	;	1.55	;	Bd1817, a HDG""Y""P protein from Bdellovibrio bacteriovorus
3TMD	;	2.641	;	Bd1817, a HDG""Y""P protein from Bdellovibrio bacteriovorus
7S3P	;	2.89	;	BD2 domain of human BRD3 bound to Physachenolide C
7BYR	;	3.84	;	BD23-Fab in complex with the S ectodomain trimer
6SD8	;	1.51	;	Bd2924 apo-form
6SDA	;	1.87	;	Bd2924 C10 acyl-coenzymeA bound form
5CEC	;	1.36	;	Bd3459 Predatory Endopeptidase from Bdellovibrio bacteriovorus in complex with immunity protein Bd3460
5CEB	;	1.93	;	Bd3459 Predatory Endopeptidase from Bdellovibrio bacteriovorus, K38M form
3V39	;	1.45	;	Bd3459, A Predatory Peptidoglycan Endopeptidase from Bdellovibrio bacteriovorus
5CEA	;	1.85	;	Bd3460 Immunity Protein from Bdellovibrio bacteriovorus
7KEJ	;	3.8	;	BDBV-289 bound to EBOV GPdMuc Makona
6N7J	;	3.684	;	BDBV223 Fab bound to synthetic peptide of Bundibugyo virus Glycoprotein Stalk
6HC0	;	1.87	;	Bdellovibrio bacteriovorus DgcB FHA domain, tail complex
6HC1	;	1.49	;	Bdellovibrio bacteriovorus DgcB FHA in complex with phosphorylated N-terminal peptide
6HBZ	;	1.79	;	Bdellovibrio bacteriovorus DgcB Full-length
5JP6	;	1.5	;	Bdellovibrio bacteriovorus peptidoglycan deacetylase Bd3279
7NTG	;	1.67	;	Bdellovibrio bacteriovorus PGI in complex with fructose-6-phosphate
7O0A	;	1.74	;	Bdellovibrio bacteriovorus PGI in P1211 spacegroup
7NSS	;	1.84	;	Bdellovibrio bacteriovorus PGI in P3121 spacegroup
5GNT	;	2.665	;	BDLP-like folding of Mitofusin 1
7OUL	;	2.8	;	BDM88832 inhibitor bound to the transmembrane domain of AcrB-R971A
7OUK	;	2.6	;	BDM88855 inhibitor bound to the transmembrane domain of AcrB
7OUM	;	2.45	;	BDM88855 inhibitor bound to the transmembrane domain of AcrB-R971A
1PGL	;	2.8	;	BEAN POD MOTTLE VIRUS (BPMV), MIDDLE COMPONENT
1PGW	;	2.9	;	BEAN POD MOTTLE VIRUS (BPMV), TOP COMPONENT
5M3V	;	1.97	;	BEAT Fc
6G1E	;	1.88	;	BEAT Fc with improved heterodimerization (Q3A-D84.4Q)
5EFM	;	1.95	;	Beclin 1 Flexible-helical Domian (FHD) (141-171)
5K7B	;	2.3	;	Beclin 2 CCD homodimer
5K9L	;	2.52	;	Beclin 2 CCD N187L mutant homodimer
8EYW	;	2.1	;	Beetroot dimer bound to ThT
3NNS	;	1.9	;	BeF3 Activated DrrB Receiver Domain
3NNN	;	2.2	;	BeF3 Activated DrrD Receiver Domain
8CNN	;	1.48	;	BeF3 Phospho-HRas GSA complex
1ZES	;	1.9	;	BeF3- activated PhoB receiver domain
6M0D	;	2.2	;	Beijerinckia indica beta-fructosyltransferase
6M0E	;	1.35	;	Beijerinckia indica beta-fructosyltransferase complexed with fructose
8I2Q	;	2.15	;	Beijerinckia indica beta-fructosyltransferase variant H395R/F473Y
8I2R	;	1.36	;	Beijerinckia indica beta-fructosyltransferase variant H395R/F473Y in complex with fructose
7ZYB	;	1.5	;	BeKdgF with Ca
7ZYC	;	2.0	;	BeKdgF with Zn
4I4O	;	1.12	;	BEL beta-trefoil apo crystal form 1
4I4P	;	1.279	;	BEL beta-trefoil apo crystal form 2
4I4Q	;	1.51	;	BEL beta-trefoil apo crystal form 3
4I4R	;	1.77	;	BEL beta-trefoil apo crystal form 4
4I4U	;	1.57	;	BEL beta-trefoil complex with galactose
4I4S	;	1.4	;	BEL beta-trefoil complex with lactose
4I4V	;	1.5	;	BEL beta-trefoil complex with N-acetylgalactosamine
4I4Y	;	1.9	;	BEL beta-trefoil complex with T-Antigen
4I4X	;	1.72	;	BEL beta-trefoil complex with T-Antigen disaccharide
5KS9	;	2.55	;	Bel502-DQ8-glia-alpha1 complex
5KSA	;	2.0	;	Bel602-DQ8.5-glia-gamma1 complex
2OMB	;	2.9	;	Bence Jones KWR Protein- Immunoglobulin Light Chain Dimer, P3(1)21 Crystal Form
2OLD	;	2.6	;	Bence Jones KWR Protein- Immunoglobulin Light Chain Dimer, P3(2)21 Crystal Form
2OMN	;	2.2	;	Bence Jones KWR Protein- Immunoglobulin Light Chain Dimer, P4(3)2(1)2 Crystal Form
1LIL	;	2.65	;	BENCE JONES PROTEIN CLE, A LAMBDA III IMMUNOGLOBULIN LIGHT-CHAIN DIMER
1B6D	;	2.74	;	BENCE JONES PROTEIN DEL: AN ENTIRE IMMUNOGLOBULIN KAPPA LIGHT-CHAIN DIMER
4L1H	;	1.68	;	Bence-Jones immunoglobulin REI variable portion with seven point mutations
1BWW	;	1.7	;	BENCE-JONES IMMUNOGLOBULIN REI VARIABLE PORTION, T39K MUTANT
8JLV	;	2.99864	;	Beneficial flip of substrate orientation enable determine substrate specificity for zearalenone lactone hydrolase
5TJ1	;		;	Benenodin-1-dC5, state 1
6B5W	;		;	Benenodin-1-dC5, state 2
2F6G	;	1.908	;	BenM effector binding domain
2F78	;	2.05	;	BenM effector binding domain with its effector benzoate
2F7A	;	1.9	;	BenM effector binding domain with its effector, cis,cis-muconate
2F6P	;	2.001	;	BenM effector binding domain- SeMet derivative
2F8D	;	2.7	;	BenM effector-Binding domain crystallized from high pH conditions
8D15	;	3.61	;	Bent ADP-F-actin
8D16	;	3.71	;	Bent ADP-Pi-F-actin
2E7E	;	1.85	;	Bent-binding of cyanide to the heme iron in rat heme oxygenase-1
3A5S	;	1.8	;	Benzalacetone synthase (I207L/L208F)
3A5Q	;	1.8	;	Benzalacetone synthase from Rheum palmatum
3A5R	;	1.6	;	Benzalacetone synthase from Rheum palmatum complexed with 4-coumaroyl-primed monoketide intermediate
5UCD	;	2.28	;	Benzaldehyde Dehydrogenase, a Class 3 Aldehyde Dehydrogenase, with bound NADP+ and Benzoate Adduct
1V2V	;	1.8	;	Benzamidine in complex with bovine trypsin variant X(SSAI)bT.C1
1V2S	;	1.72	;	Benzamidine in complex with bovine trypsin variant X(SSFI.Glu)bT.D1
1V2J	;	1.9	;	BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSRI)bT.C1
1V2M	;	1.65	;	Benzamidine in complex with bovine trypsin variant X(triple.Glu)bT.A1
1V2L	;	1.6	;	Benzamidine in complex with bovine trypsin variant X(triple.Glu)bT.D1
1V2U	;	1.8	;	Benzamidine in complex with bovine trypsin varinat X(SSAI)bT.D1
1J15	;	2.0	;	BENZAMIDINE IN COMPLEX WITH RAT TRYPSIN MUTANT X99/175/190RT
1J16	;	1.6	;	BENZAMIDINE IN COMPLEX WITH RAT TRYPSIN MUTANT X99/175/190RT
1J14	;	2.4	;	BENZAMIDINE IN COMPLEX WITH RAT TRYPSIN MUTANT X99RT
3DMX	;	1.8	;	Benzene binding in the hydrophobic cavity of T4 lysozyme L99A mutant
4JSZ	;	1.9	;	Benzenesulfonamide bound to hCAII H94C
4JSA	;	1.5	;	Benzenesulfonamide complexed with hCAII H94D
6ODZ	;	1.3	;	Benzensulfonamides bearing spyrohydantoin moieties act as potent inhibitors of human carbonic anhydrases II and VII and show neuropathic pain attenuating effects
6OE0	;	1.3	;	Benzensulfonamides bearing spyrohydantoin moieties act as potent inhibitors of human carbonic anhydrases II and VII and show neuropathic pain attenuating effects
6OE1	;	1.45	;	Benzensulfonamides bearing spyrohydantoin moieties act as potent inhibitors of human carbonic anhydrases II and VII and show neuropathic pain attenuating effects
4ALU	;	2.6	;	Benzofuropyrimidinone Inhibitors of Pim-1
4ALV	;	2.59	;	Benzofuropyrimidinone Inhibitors of Pim-1
4ALW	;	1.92	;	Benzofuropyrimidinone Inhibitors of Pim-1
5UCO	;	2.85	;	Benzophenone synthase from Hypericum androsaemum
5VOM	;	1.67	;	Benzopiperazine BET bromodomain inhibitor in complex with BD1 of Brd4
2I0G	;	2.5	;	Benzopyrans are Selective Estrogen Receptor beta Agonists (SERBAs) with Novel Activity in Models of Benign Prostatic Hyperplasia
2I0J	;	2.9	;	Benzopyrans are Selective Estrogen Receptor beta Agonists (SERBAs) with Novel Activity in Models of Benign Prostatic Hyperplasia
2POG	;	1.84	;	Benzopyrans as Selective Estrogen Receptor b Agonists (SERBAs). Part 2: Structure Activity Relationship Studies on the Benzopyran Scaffold.
3SOS	;	2.58	;	Benzothiazinone inhibitor in complex with FXIa
3LC3	;	1.9	;	Benzothiophene Inhibitors of Factor IXa
5DGD	;	1.13	;	Benzoylformate decarboxylase F464I and A460V mutant from Pseudomonas putida
1BFD	;	1.6	;	BENZOYLFORMATE DECARBOXYLASE FROM PSEUDOMONAS PUTIDA
5DEI	;	1.3	;	BENZOYLFORMATE DECARBOXYLASE FROM PSEUDOMONAS PUTIDA
1MCZ	;	2.8	;	BENZOYLFORMATE DECARBOXYLASE FROM PSEUDOMONAS PUTIDA COMPLEXED WITH AN INHIBITOR, R-MANDELATE
5DGT	;	1.081	;	BENZOYLFORMATE DECARBOXYLASE H70A MUTANT at pH 8.5 FROM PSEUDOMONAS PUTIDA
4MPR	;	1.401	;	Benzoylformate Decarboxylase: Is the tetramer vital for activity?
7PXP	;	2.0	;	Benzoylsuccinyl-CoA thiolase
7PYT	;	1.7	;	Benzoylsuccinyl-CoA thiolase with coenzyme A
7YXM	;	1.7	;	Benzoylsuccinyl-CoA thiolase with coenzyme A
1DXA	;		;	BENZO[A]PYRENE DIOL EPOXIDE ADDUCT OF DA IN DUPLEX DNA
1BMA	;	1.8	;	BENZYL METHYL AMINIMIDE INHIBITOR COMPLEXED TO PORCINE PANCREATIC ELASTASE
3HUK	;	1.29	;	Benzylacetate in complex with T4 lysozyme L99A/M102Q
1EH8	;	2.5	;	BENZYLATED HUMAN O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE
2IWC	;	2.1	;	Benzylpenicilloyl-acylated MecR1 extracellular antibiotic-sensor domain.
5BWD	;	2.0	;	Benzylsuccinate alpha-gamma bound to fumarate
4PKC	;	2.6	;	Benzylsuccinate alpha-gamma complex
4PKF	;	2.002	;	Benzylsuccinate synthase alpha-beta-gamma complex
5BWE	;	3.3	;	Benzylsuccinate synthase alpha-beta-gamma complex with bound toluene and fumarate
4PZF	;	2.2	;	Berberine bridge enzyme G164A variant, a reticuline dehydrogenase
2PL1	;	1.9	;	Berrylium Fluoride activated receiver domain of E.coli PhoP
7QTV	;	4.05	;	Beryllium fluoride form of the Na+,K+-ATPase (E2-BeFx)
1W0J	;	2.2	;	Beryllium fluoride inhibited bovine F1-ATPase
6BR7	;	1.86	;	Beryllium fluorinated receiver domain of BfmR from Acinetobacter baumannii
2FTK	;	3.05	;	berylloflouride Spo0F complex with Spo0B
6NIE	;	1.95	;	BesD with Fe(II), chloride, and alpha-ketoglutarate
1HO9	;		;	BEST 20 NMR CONFORMERS OF D130I MUTANT T3-I2, A 32 RESIDUE PEPTIDE FROM THE ALPHA 2A ADRENERGIC RECEPTOR
6U3E	;	53.0	;	Best fitting antiparallel model for Volume 1 of truncated dimeric Cytohesin-3 (Grp1; amino acids 14-399)
6U3G	;	53.0	;	Best fitting antiparallel model for Volume 2 of truncated dimeric Cytohesin-3 (Grp1; amino acids 14-399)
1GX7	;		;	Best model of the electron transfer complex between cytochrome c3 and [Fe]-hydrogenase
6N27	;	3.0	;	BEST1 calcium-bound closed state
6N28	;	2.9	;	BEST1 calcium-bound open state
6N26	;	3.0	;	BEST1 calcium-free closed state
6N23	;	3.1	;	BEST1 in a calcium-bound inactivated state
6N25	;	2.7	;	BEST1 open state W287F mutant, calcium-bound
6N24	;	3.0	;	BEST1 open state W287F mutant, calcium-free
4ZLA	;	1.9	;	Bestatin complex structure of leucine aminopeptidase from Helicobacter pylori
3H8G	;	1.5	;	Bestatin complex structure of leucine aminopeptidase from Pseudomonas putida
6VX5	;	3.03	;	bestrophin-2 Ca2+- unbound state (250 nM Ca2+)
6VX9	;	2.17	;	bestrophin-2 Ca2+- unbound state 1 (EGTA only)
6VX8	;	2.33	;	bestrophin-2 Ca2+- unbound state 2 (EGTA only)
6VX6	;	3.0	;	bestrophin-2 Ca2+-bound state (250 nM Ca2+)
6VX7	;	2.36	;	bestrophin-2 Ca2+-bound state (5 mM Ca2+)
3DHM	;	1.8	;	Beta 2 microglobulin mutant D59P
3DHJ	;	2.0	;	Beta 2 microglobulin mutant W60C
2IV8	;	2.8	;	beta appendage in complex with b-arrestin peptide
2G30	;	1.6	;	beta appendage of AP2 complexed with ARH peptide
2FGY	;	2.2	;	Beta Carbonic Anhydrase from the Carboxysomal Shell of Halothiobacillus neapolitanus (CsoSCA)
8THM	;	2.3	;	Beta carbonic anhydrase from the carboxysome of Cyanobium PCC 7001
6D2O	;	1.9	;	Beta Carbonic anhydrase in complex with 4-methylimidazole
6D2N	;	1.9	;	Beta Carbonic anhydrase in complex with a sulfonamide anion
6D2J	;	2.1	;	Beta Carbonic anhydrase in complex with thiocyanate
6D2M	;	1.9	;	Beta Carbonic anhydrase in complex with thiocyanate
1BEC	;	1.7	;	BETA CHAIN OF A T CELL ANTIGEN RECEPTOR
5DWU	;	3.97	;	Beta common receptor in complex with a Fab
5NSA	;	1.273	;	Beta domain of human transcobalamin bound to Co-beta-[2-(2,4-difluorophenyl)ethinyl]cobalamin
5NRP	;	1.569	;	Beta domain of human transcobalamin bound to cobinamide
5NP4	;	1.434	;	Beta domain of human transcobalamin bound to cyanocobalamin
5NO0	;	1.57	;	Beta domain of human transcobalamin in apo form
1C4P	;	2.4	;	BETA DOMAIN OF STREPTOKINASE
1CPX	;	2.0	;	BETA FORM OF CARBOXYPEPTIDASE A (RESIDUES 3-307) FROM BOVINE PANCREAS IN AN ORTHORHOMBIC CRYSTAL FORM WITH TWO ZINC IONS IN THE ACTIVE SITE.
2BV2	;	1.55	;	beta gamma crystallin from Ciona Intestinalis
7JXN	;	2.0	;	Beta hairpin derived from Abeta17-36 with an F20Cha mutation
1E5M	;	1.54	;	Beta ketoacyl acyl carrier protein synthase II (KASII) from Synechocystis sp.
6ZBS	;	2.35	;	Beta ODAP Synthetase (BOS)
2AK5	;	1.85	;	beta PIX-SH3 complexed with a Cbl-b peptide
1ZSG	;		;	beta PIX-SH3 complexed with an atypical peptide from alpha-PAK
8AQT	;	4.4	;	Beta SARS-CoV-2 Spike bound to mouse ACE2 (local)
3KNQ	;	2.13	;	Beta Turn Optimization of the Gene-3-Protein of Filamentous Phage Fd
7R16	;	3.5	;	Beta Variant SARS-CoV-2 Spike with 1 Erect RBD
7R17	;	3.7	;	Beta Variant SARS-CoV-2 Spike with 2 Erect RBDs
4UNI	;	2.6	;	beta-(1,6)-galactosidase from Bifidobacterium animalis subsp. lactis Bl-04 in complex with galactose
4UOZ	;	2.3	;	beta-(1,6)-galactosidase from Bifidobacterium animalis subsp. lactis Bl-04 nucleophile mutant E324A in complex with galactose
7Q9P	;	4.5	;	Beta-06 fab in complex with SARS-CoV-2 beta-Spike glycoprotein
5B0R	;	1.8	;	Beta-1,2-Mannobiose phosphorylase from Listeria innocua - beta-1,2-mannobiose complex
5B0S	;	2.1	;	Beta-1,2-Mannobiose phosphorylase from Listeria innocua - beta-1,2-mannotriose complex
5B0P	;	1.9	;	Beta-1,2-Mannobiose phosphorylase from Listeria innocua - glycerol complex
5B0Q	;	2.3	;	beta-1,2-Mannobiose phosphorylase from Listeria innocua - mannose complex
1WC2	;	1.2	;	Beta-1,4-D-endoglucanase Cel45A from blue mussel Mytilus edulis at 1.2A
8BZQ	;	1.3	;	Beta-1,4-D-endoglucanase Cel45A from Gloeophyllum trabeum
6GP5	;	1.93	;	Beta-1,4-galactanase from Bacteroides thetaiotaomicron
6GPA	;	1.79	;	Beta-1,4-galactanase from Bacteroides thetaiotaomicron with galactose
1NWG	;	2.32	;	BETA-1,4-GALACTOSYLTRANSFERASE COMPLEX WITH ALPHA-LACTALBUMIN AND N-BUTANOYL-GLUCOAMINE
1NMM	;	2.0	;	beta-1,4-galactosyltransferase mutant Cys342Thr complex with alpha-lactalbumin and GlcNAc
1TW1	;	2.3	;	beta-1,4-galactosyltransferase mutant Met344His (m344H-Gal-T1) complex with UDP-galactose and magnesium
1TVY	;	2.3	;	beta-1,4-galactosyltransferase mutant Met344His (M344H-Gal-T1) complex with UDP-galactose and manganese
1EXP	;	1.8	;	BETA-1,4-GLYCANASE CEX-CD
3VUP	;	1.05	;	Beta-1,4-mannanase from the common sea hare Aplysia kurodai
5XXA	;	1.76	;	beta-1,4-mannanase-SeMet-RmMan134A
1XNK	;	1.55	;	Beta-1,4-xylanase from Chaetomium thermophilum complexed with methyl thioxylopentoside
8A7T	;	3.0	;	beta-2-microglobulin D76N amyloid fibril form 2PFa
8A7O	;	3.0	;	beta-2-microglobulin DeltaN6 amyloid fibril form 2PFa
8A7P	;	3.4	;	beta-2-microglobulin DeltaN6 amyloid fibril form 2PFb
8A7Q	;	2.8	;	beta-2-microglobulin V27M amyloid fibril form 4PF
7Q9J	;	4.0	;	Beta-26 fab in complex with SARS-CoV-2 beta-Spike glycoprotein
7Q9K	;	4.5	;	Beta-32 fab in complex with SARS-CoV-2 beta-Spike glycoprotein
7Q9I	;	4.9	;	Beta-43 fab in complex with SARS-CoV-2 beta-Spike glycoprotein
7Q9F	;	3.6	;	Beta-50 fab in complex with SARS-CoV-2 beta-Spike glycoprotein
7Q9M	;	3.7	;	Beta-53 fab in complex with SARS-CoV-2 beta-Spike glycoprotein
4MTU	;	0.97	;	beta-Alanyl-CoA:Ammonia Lyase from Clostridium propionicum
4MZQ	;	1.587	;	beta-Alanyl-CoA:Ammonia Lyase from Clostridium propionicum in complex with propionyl-CoA
5BCA	;	2.2	;	BETA-AMYLASE FROM BACILLUS CEREUS VAR. MYCOIDES
1ITC	;	2.1	;	Beta-Amylase from Bacillus cereus var. mycoides Complexed with Maltopentaose
1J12	;	2.1	;	Beta-Amylase from Bacillus cereus var. mycoides in Complex with alpha-EBG
1J11	;	2.0	;	beta-amylase from Bacillus cereus var. mycoides in complex with alpha-EPG
1J10	;	2.1	;	beta-amylase from Bacillus cereus var. mycoides in complex with GGX
1J0Y	;	2.1	;	Beta-amylase from Bacillus cereus var. mycoides in complex with glucose
1J0Z	;	2.2	;	Beta-amylase from Bacillus cereus var. mycoides in complex with maltose
1BFN	;	2.07	;	BETA-AMYLASE/BETA-CYCLODEXTRIN COMPLEX
1E0R	;	2.8	;	Beta-apical domain of thermosome
8D9W	;	9.3	;	beta-Arf1 homodimeric interface within AP-1, Arf1, Nef, MHC-I lattice on narrow tubes
8D4C	;	9.3	;	beta-Arf1 mediated dimeric assembly of AP-1, Arf1, Nef complex within lattice on MHC-I lipopeptide incorporated narrow membrane tubes
8D4F	;	9.8	;	beta-Arf1 mediated dimeric assembly of AP-1, Arf1, Nef complex within lattice on MHC-I lipopeptide incorporated wide(r) membrane tubes
6KL7	;	2.794	;	Beta-arrestin 1 mutant S13D/T275D
8QYP	;	2.759	;	Beta-cardiac myosin motor domain in the pre-powerstroke state
8QYR	;	1.8	;	Beta-cardiac myosin motor domain in the pre-powerstroke state complexed to Mavacamten
6FSA	;	2.33	;	Beta-Cardiac myosin post-rigor
8QYQ	;	2.61	;	Beta-cardiac myosin S1 fragment in the pre-powerstroke state complexed to Mavacamten
8QYU	;	1.96	;	Beta-cardiac myosin S1 fragment in the pre-powerstroke state complexed to Omecamtiv mecarbil
1M1E	;	2.1	;	Beta-catenin armadillo repeat domain bound to ICAT
1QZ7	;	2.2	;	Beta-catenin binding domain of Axin in complex with beta-catenin
8Y14	;	2.8	;	Beta-catenin Crystal Structure
1TH1	;	2.5	;	Beta-catenin in complex with a phosphorylated APC 20aa repeat fragment
7AFW	;	1.814	;	Beta-Catenin in complex with compound 6
1I7X	;	3.0	;	BETA-CATENIN/E-CADHERIN COMPLEX
1I7W	;	2.0	;	BETA-CATENIN/PHOSPHORYLATED E-CADHERIN COMPLEX
2RAY	;	1.798	;	beta-chlorophenetole in complex with T4 lysozyme L99A
2A8F	;	1.35	;	beta-cinnamomin after sterol removal
2AIB	;	1.1	;	beta-cinnamomin in complex with ergosterol
1BEO	;	2.2	;	BETA-CRYPTOGEIN
1LRI	;	1.45	;	BETA-CRYPTOGEIN-CHOLESTEROL COMPLEX
1EX1	;	2.2	;	BETA-D-GLUCAN EXOHYDROLASE FROM BARLEY
1YI7	;	1.9	;	Beta-d-xylosidase (selenomethionine) XYND from Clostridium Acetobutylicum
1Y7B	;	1.6	;	BETA-D-XYLOSIDASE, A FAMILY 43 GLYCOSIDE HYDROLASE
6TUB	;		;	Beta-endorphin amyloid fibril
3PIG	;	1.87	;	beta-fructofuranosidase from Bifidobacterium longum
3PIJ	;	1.8	;	beta-fructofuranosidase from Bifidobacterium longum - complex with fructose
1W2T	;	1.87	;	beta-fructosidase from Thermotoga maritima in complex with raffinose
4V40	;	2.5	;	BETA-GALACTOSIDASE
6DRV	;	2.2	;	Beta-galactosidase
4TTG	;	1.6	;	Beta-galactosidase (E. coli) in the presence of potassium chloride.
5DMY	;	1.95	;	Beta-galactosidase - construct 33-930
1YQ2	;	1.9	;	beta-galactosidase from Arthrobacter sp. C2-2 (isoenzyme C2-2-1)
6TSH	;	2.3	;	Beta-galactosidase in complex with deoxygalacto-nojirimycin
6TSK	;	2.3	;	Beta-galactosidase in complex with L-ribose
6TTE	;	2.2	;	Beta-galactosidase in complex with PETG
1TBG	;	2.1	;	BETA-GAMMA DIMER OF THE HETEROTRIMERIC G-PROTEIN TRANSDUCIN
5XIV	;		;	Beta-Ginkgotides: Hyperdisulfide-constrained peptides from Ginkgo biloba
6QZG	;	2.47	;	Beta-glucose 1,6-bisphosphonate bound to wild type beta-phosphoglucomutse in an open conformation.
7F1N	;	2.14	;	Beta-Glucosidase
1BGA	;	2.4	;	BETA-GLUCOSIDASE A FROM BACILLUS POLYMYXA
3TA9	;	3.0	;	beta-Glucosidase A from the halothermophile H. orenii
2O9R	;	2.3	;	beta-glucosidase B complexed with thiocellobiose
2JIE	;	2.3	;	BETA-GLUCOSIDASE B FROM BACILLUS POLYMYXA COMPLEXED WITH 2-F-GLUCOSE
2O9T	;	2.15	;	beta-glucosidase B from Bacillus polymyxa complexed with glucose
2O9P	;	2.1	;	beta-glucosidase B from Paenibacillus polymyxa
2Z1S	;	2.46	;	Beta-glucosidase B from paenibacillus polymyxa complexed with cellotetraose
8IVY	;	1.95	;	Beta-Glucosidase BglA mutant E166Q in complex with glucose
8IDZ	;	4.0	;	Beta-glucosidase BglPcC1
1QOX	;	2.7	;	Beta-glucosidase from Bacillus circulans sp. alkalophilus
5OST	;	2.1	;	Beta-glucosidase from Thermoanaerobacterium xylolyticum GH116 in complex with Gluco-1H-imidazole
2J7H	;	1.95	;	Beta-glucosidase from Thermotoga maritima in complex with azafagomine
2CBV	;	1.95	;	Beta-glucosidase from Thermotoga maritima in complex with calystegine B2
2J7F	;	2.28	;	Beta-glucosidase from Thermotoga maritima in complex with carboxylate- substituted glucoimidazole
2CBU	;	1.85	;	Beta-glucosidase from Thermotoga maritima in complex with castanospermine
2JAL	;	1.9	;	Beta-glucosidase from Thermotoga maritima in complex with cyclophellitol
2J77	;	2.1	;	Beta-glucosidase from Thermotoga maritima in complex with deoxynojirimycin
2J79	;	1.94	;	Beta-glucosidase from Thermotoga maritima in complex with galacto- hydroximolactam
2J78	;	1.65	;	Beta-glucosidase from Thermotoga maritima in complex with gluco- hydroximolactam
2J7B	;	1.87	;	Beta-glucosidase from Thermotoga maritima in complex with gluco- tetrazole
5OSS	;	1.7	;	Beta-glucosidase from Thermotoga maritima in complex with Gluco-1H-imidazole
2CES	;	2.15	;	Beta-glucosidase from Thermotoga maritima in complex with glucoimidazole
2J7D	;	2.24	;	Beta-glucosidase from Thermotoga maritima in complex with methoxycarbonyl-substituted glucoimidazole
2J7E	;	2.19	;	Beta-glucosidase from Thermotoga maritima in complex with methyl acetate-substituted glucoimidazole
2J7G	;	1.91	;	Beta-glucosidase from Thermotoga maritima in complex with methyl acetic acid-substituted glucoimidazole
2VRJ	;	1.9	;	Beta-glucosidase from Thermotoga maritima in complex with N-octyl-5- deoxy-6-oxa-N-(thio)carbamoylcalystegine
2J75	;	1.85	;	Beta-glucosidase from Thermotoga maritima in complex with noeuromycin
2CET	;	1.97	;	Beta-glucosidase from Thermotoga maritima in complex with phenethyl- substituted glucoimidazole
2J7C	;	2.09	;	Beta-glucosidase from Thermotoga maritima in complex with phenylaminomethyl-derived glucoimidazole
8IN1	;	2.7	;	beta-glucosidase protein from Aplysia kurodai
5VQD	;	2.1	;	Beta-glucoside phosphorylase BglX
5VQE	;	1.889	;	Beta-glucoside phosphorylase BglX bound to 2FGlc
8OGX	;	2.0	;	Beta-glucuronidase from Acidobacterium capsulatum in complex with inhibitor R3794
7KGY	;	2.2	;	Beta-glucuronidase from Faecalibacterium prausnitzii bound to the inhibitor UNC10201652-glucuronide
5G0M	;	1.8	;	beta-glucuronidase with an activity-based probe (N-acyl cyclophellitol aziridine) bound
5G0Q	;	1.65	;	beta-glucuronidase with an activity-based probe (N-alkyl cyclophellitol aziridine) bound
1VFF	;	2.5	;	beta-glycosidase from Pyrococcus horikoshii
1GOW	;	2.6	;	BETA-GLYCOSIDASE FROM SULFOLOBUS SOLFATARICUS
2CEQ	;	2.14	;	Beta-glycosidase from Sulfolobus solfataricus in complex with glucoimidazole
2CER	;	2.29	;	Beta-glycosidase from Sulfolobus solfataricus in complex with phenethyl-substituted glucoimidazole
3AZ8	;	3.1	;	Beta-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Plasmodium falciparum in complex with NAS21
3AZ9	;	2.75	;	Beta-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Plasmodium falciparum in complex with NAS91
3AZA	;	2.7	;	Beta-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Plasmodium falciparum in complex with NAS91-10
3AZB	;	2.6	;	Beta-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Plasmodium falciparum in complex with NAS91-11
1B3N	;	2.65	;	BETA-KETOACYL CARRIER PROTEIN SYNTHASE AS A DRUG TARGET, IMPLICATIONS FROM THE CRYSTAL STRUCTURE OF A COMPLEX WITH THE INHIBITOR CERULENIN.
1EK4	;	1.85	;	BETA-KETOACYL [ACYL CARRIER PROTEIN] SYNTHASE I IN COMPLEX WITH DODECANOIC ACID TO 1.85 RESOLUTION
4X0O	;	2.2	;	Beta-ketoacyl-(acyl carrier protein) synthase III-2 (FabH2) from Vibrio cholerae soaked with Acetyl-CoA
2VBA	;	1.36	;	beta-ketoacyl-ACP synthase I (KAS) from E. coli with bound amino- thiazole inhibitor
2VB8	;	1.52	;	beta-ketoacyl-ACP synthase I (KAS) from E. coli with bound inhibitor thiolactomycin
2VB9	;	1.5	;	beta-ketoacyl-ACP synthase I (KAS) from E. coli, apo structure
2VB7	;	1.6	;	beta-ketoacyl-ACP synthase I (KAS) from E. coli, apo structure after soak in PEG solution
1KAS	;	2.4	;	BETA-KETOACYL-ACP SYNTHASE II FROM ESCHERICHIA COLI
5KP2	;	2.0	;	Beta-ketoacyl-ACP synthase III -2 (FabH2) (C113A) from Vibrio Cholerae cocrystallized with octanoyl-CoA: hydrolzed ligand
4X9O	;	2.3	;	Beta-ketoacyl-ACP synthase III -2 (FabH2) (C113A) from Vibrio Cholerae soaked with octanoyl-CoA: conformational changes without clearly bound substrate
4X9K	;	1.61	;	Beta-ketoacyl-acyl carrier protein synthase III-2 (FabH2)(C113A) from Vibrio cholerae
1F91	;	2.4	;	BETA-KETOACYL-[ACYL-CARRIER-PROTEIN] SYNTHASE I IN COMPLEX WITH C10 FATTY ACID SUBSTRATE
8QF2	;	2.35	;	Beta-L-Arabinofurano-cyclitol Aziridines are Cysteine-directed Broad-spectrum Inhibitors and Activity-based Probes for Retaining Beta-L-arabinofuranosidases
5OPJ	;	2.05	;	Beta-L-arabinofuranosidase
1M1Z	;	1.95	;	BETA-LACTAM SYNTHETASE APO ENZYME
1MB9	;	2.11	;	BETA-LACTAM SYNTHETASE COMPLEXED WITH ATP
1MC1	;	2.16	;	BETA-LACTAM SYNTHETASE WITH PRODUCT (DGPC), AMP AND PPI
1MBZ	;	2.47	;	BETA-LACTAM SYNTHETASE WITH TRAPPED INTERMEDIATE
3Q7V	;	2.1	;	Beta-Lactam-Sensor Domain of BlaR1 (Apo) from Staphylococcus Aureus with Carboxylated Lys392
8SJ3	;	1.5	;	Beta-lactamase CTX-M-14 E166Y/N170G
8DPQ	;	1.67	;	Beta-lactamase CTX-M-14 N170A
8DOD	;	1.61	;	Beta-lactamase CTX-M-14 S130A
8DON	;	1.36	;	Beta-lactamase CTX-M-14 T215A
8DP4	;	1.402	;	Beta-lactamase CTX-M-14 T235A
1I2S	;	1.7	;	BETA-LACTAMASE FROM BACILLUS LICHENIFORMIS BS3
1I2W	;	1.7	;	BETA-LACTAMASE FROM BACILLUS LICHENIFORMIS BS3 COMPLEXED WITH CEFOXITIN
6N36	;	1.45	;	Beta-lactamase from Chitinophaga pinensis
6N9K	;	1.6	;	Beta-lactamase from Escherichia coli str. Sakai
1BSG	;	1.85	;	BETA-LACTAMASE FROM STREPTOMYCES ALBUS G
7K8F	;	2.60003	;	Beta-lactamase mixed with Ceftriaxone, 10ms
7K8H	;	2.60006	;	Beta-lactamase mixed with Ceftriaxone, 50ms
7K8E	;	2.40006	;	Beta-lactamase mixed with Ceftriaxone, 5ms
7K8K	;	2.7	;	Beta-lactamase mixed with Sulbactam, 60ms
2BLM	;	2.0	;	BETA-LACTAMASE OF BACILLUS LICHENIFORMIS 749(SLASH)C AT 2 ANGSTROMS RESOLUTION
4BLM	;	2.0	;	BETA-LACTAMASE OF BACILLUS LICHENIFORMIS 749(SLASH)C. REFINEMENT AT 2 ANGSTROMS RESOLUTION AND ANALYSIS OF HYDRATION
6MU9	;	0.97	;	Beta-lactamase penicillinase from Bacillus megaterium
6NFD	;	1.17	;	beta-lactamase SHV-11 from Klebsiella pneumoniae strain NTUH-K2044
1BZA	;	1.8	;	BETA-LACTAMASE TOHO-1 FROM ESCHERICHIA COLI TUH12191
5O7N	;	1.5	;	Beta-lactamase VIM-2 in complex with (2R)-1-(2-Benzyl-3-mercaptopropanoyl)piperidine-2-carboxylic acid
6B68	;	2.15	;	Beta-Lactamase, 100ms timepoint, mixed, shards crystal form
6B6A	;	2.298	;	Beta-Lactamase, 2secs timepoint, mixed, shards crystal form
6B69	;	2.2	;	Beta-Lactamase, 500ms timepoint, mixed, shards crystal form
6B5Y	;	2.75	;	Beta-lactamase, mixed with Ceftriaxone, 30ms time point, Shards crystal form
6B6D	;	1.8	;	Beta-Lactamase, mixed with Ceftriaxone, needles crystal form, 100ms
6B6F	;	2.05	;	Beta-Lactamase, mixed with Ceftriaxone, needles crystal form, 2sec
6B6C	;	1.9	;	Beta-Lactamase, mixed with Ceftriaxone, needles crystal form, 30ms
6B6E	;	1.901	;	Beta-Lactamase, mixed with Ceftriaxone, needles crystal form, 500ms
7K8L	;	2.80001	;	Beta-lactamase, Unmixed
6B6B	;	1.8	;	Beta-Lactamase, unmixed needles crystal form
6B5X	;	2.45	;	Beta-Lactamase, unmixed shards crystal form
2Q39	;	2.5	;	Beta-lactoglobulin (low humidity)
2Q2M	;	2.1	;	Beta-lactoglobulin (native)
2Q2P	;	2.96	;	Beta-lactoglobulin (reverse native)
4KII	;	1.85	;	Beta-lactoglobulin in complex with Cp*Rh(III)Cl N,N-di(pyridin-2-yl)dodecanamide
7Q2N	;	1.7	;	Beta-lactoglobulin mutant FAF (I56F/L39A/M107F) in complex with desipramine (FAF-DSM)
7Q18	;	1.804	;	Beta-lactoglobulin mutant FAF (I56F/L39A/M107F), unliganded form
7Q2O	;	1.8	;	Beta-lactoglobulin mutant FAW (I56F/L39A/M107W) in complex with desipramine (FAW-DSM#1)
7Q2P	;	1.69	;	Beta-lactoglobulin mutant FAW (I56F/L39A/M107W) in complex with desipramine (FAW-DSM#2)
7Q19	;	1.55	;	Beta-lactoglobulin mutant FAW (I56F/L39A/M107W) in complex with desipramine (FAW-DSM#3)
7Q17	;	1.8	;	Beta-lactoglobulin mutant FAW (I56F/L39A/M107W), unliganded form
8AF1	;	1.57	;	Beta-Lytic Protease from Lysobacter capsici
1BQC	;	1.5	;	BETA-MANNANASE FROM THERMOMONOSPORA FUSCA
1CF5	;	2.55	;	BETA-MOMORCHARIN STRUCTURE AT 2.55 A
8P4L	;	2.79	;	Beta-N-acetylgalactosaminidase from Niabella aurantiaca
1C7S	;	1.8	;	BETA-N-ACETYLHEXOSAMINIDASE MUTANT D539A COMPLEXED WITH DI-N-ACETYL-BETA-D-GLUCOSAMINE (CHITOBIASE)
1C7T	;	1.9	;	BETA-N-ACETYLHEXOSAMINIDASE MUTANT E540D COMPLEXED WITH DI-N ACETYL-D-GLUCOSAMINE (CHITOBIASE)
3BMX	;	1.4	;	Beta-N-hexosaminidase (YbbD) from Bacillus subtilis
3LK6	;	2.88	;	Beta-N-hexosaminidase N318D mutant (YBBD_N318D) from bacillus subtilis
6H8W	;	1.98	;	Beta-phosphoglucomutase from Lactococcus lactis in an open conformer complexed with aluminium tetrafluoride to 1.9 A.
6H8X	;	1.83	;	Beta-phosphoglucomutase from Lactococcus lactis in an open conformer complexed with magnesium trifluoride to 1.8 A.
6H8V	;	1.84	;	Beta-phosphoglucomutase from Lactococcus lactis in an open conformer in the P21 spacegroup to 1.8 A.
6H8U	;	1.9	;	Beta-phosphoglucomutase from Lactococcus lactis in an open conformer to 1.9 A.
6YDM	;	2.1	;	beta-phosphoglucomutase from Lactococcus lactis with citrate, tris and acetate bound
6H93	;	1.77	;	Beta-phosphoglucomutase from Lactococcus lactis with inorganic phosphate bound in an open conformer to 1.8 A.
3WQ6	;	1.8	;	beta-Primeverosidase in complex with disaccharide substrate-analog N-beta-primeverosylamidine, artificial aglycone derivative
3WQ5	;	1.8	;	beta-Primeverosidase in complex with disaccharide substrate-analog N-beta-primeverosylamidine, natural aglycone derivative
1H6L	;	1.8	;	beta-propeller phytase in complex with phosphate and calcium ions
4KYP	;	1.7	;	Beta-Scorpion Toxin folded in the periplasm of E.coli
3DM6	;	2.6	;	Beta-secretase 1 complexed with statine-based inhibitor
7CRG	;	1.8	;	Beta-strand-mediated dimeric formation of the extended Ig-like domains of human lamin A/C
4OW4	;	2.148	;	Beta-trefoil designed by folding nucleus symmetric expansion (""Phifoil"")
1BJU	;	1.8	;	BETA-TRYPSIN COMPLEXED WITH ACPU
1BJV	;	1.8	;	BETA-TRYPSIN COMPLEXED WITH APPU
1MAX	;	1.8	;	BETA-TRYPSIN PHOSPHONATE INHIBITED
1MAY	;	1.8	;	BETA-TRYPSIN PHOSPHONATE INHIBITED
4A6L	;	2.05	;	beta-tryptase inhibitor
8PT4	;	3.33	;	beta-Ureidopropionase tetramer
3K1U	;	1.55	;	Beta-xylosidase, family 43 glycosyl hydrolase from Clostridium acetobutylicum
7Q6E	;	2.7	;	Beta049 fab in complex with SARS-CoV2 beta-Spike glycoprotein, The Beta mAb response underscores the antigenic distance to other SARS-CoV-2 variants
4YEF	;	1.72	;	beta1 carbohydrate binding module (CBM) of AMP-activated protein kinase (AMPK) in complex with glucosyl-beta-cyclododextrin
7C12	;	2.803	;	beta1 domain-swapped structure of monothiol cGrx1(C16S)
7C13	;	2.799	;	beta1 domain-swapped structure of monothiol cGrx1(C16S)
4YC5	;	1.755	;	Beta1 synthetic solenoid protein
4YCQ	;	2.405	;	Beta1 synthetic solenoid protein
4YDT	;	3.31	;	Beta1 synthetic solenoid protein
5DI5	;	2.28	;	beta1 t801 loop variant in P3221
1TW5	;	2.3	;	beta1,4-galactosyltransferase mutant M344H-Gal-T1 in complex with Chitobiose
4YEI	;	3.55	;	Beta1mut synthetic solenoid protein
4YFO	;	3.39	;	beta1_ex1
7OM8	;	10.5	;	Beta2 appendage domain of AP2 bound to terminal domains beneath the hub of the 28 triskelia mini clathrin coat complex, class 15
4Y0G	;	1.6	;	beta2 carbohydrate binding module (CBM) of AMP-activated protein kinase (AMPK)
4YEE	;	2.0	;	beta2 carbohydrate binding module (CBM) of AMP-activated protein kinase (AMPK) in complex with glucosyl-beta-cyclodextrin
1PY4	;	2.9	;	Beta2 microglobulin mutant H31Y displays hints for amyloid formations
1E42	;	1.7	;	Beta2-adaptin appendage domain, from clathrin adaptor AP2
3O81	;	2.0	;	Beta2-microglobulin from Gallus gallus
5D6L	;	3.2	;	beta2AR-T4L - CIM
1VYT	;	2.6	;	beta3 subunit complexed with aid
1VYU	;	2.3	;	Beta3 subunit of Voltage-gated Ca2+-channel
1VYV	;	3.0	;	beta4 subunit of Ca2+ channel
7K7U	;	3.03	;	BetaB2-crystallin
1A4S	;	2.1	;	BETAINE ALDEHYDE DEHYDROGENASE FROM COD LIVER
1BPW	;	2.8	;	BETAINE ALDEHYDE DEHYDROGENASE FROM COD LIVER
2WOX	;	2.3	;	Betaine aldehyde dehydrogenase from Pseudomonas aeruginosa with NAD(P) H-catalytic thiol adduct.
4M3P	;	1.895	;	Betaine-Homocysteine S-Methyltransferase from Homo sapiens complexed with Homocysteine
7WBI	;	1.8	;	BF2*1901-FLU
7WBG	;	2.0	;	BF2*1901/RY8
7YNP	;	2.8	;	BF227-bound alpha-synuclein fibrils
6RJP	;	2.57	;	Bfl-1 in complex with alpha helical peptide
8DI0	;	2.85	;	Bfo2290: Tannerella forsythia chondroitin sulfate A sulfatase
8DI1	;	2.2	;	Bfo2294: Tannerella forsythia 2-Keto-3-deoxy-6-phosphogluconate aldolase (KDPG) and 4-Hydroxy-2-oxoglutarate aldolase (KHG)
8SW7	;	3.37	;	BG505 Boost2 SOSIP.664 in complex with NHP polyclonal antibody FP1
6DFG	;	4.42	;	BG505 MD39 SOSIP trimer in complex with mature BG18 fragment antigen binding
6DFH	;	3.85	;	BG505 MD64 N332-GT2 SOSIP trimer in complex with germline-reverted BG18 fragment antigen binding
6NF5	;	3.71	;	BG505 MD64 N332-GT5 SOSIP trimer in complex with BG18-like precursor HMP1 fragmentantigen binding and base-binding RM20A3 fragment antigen binding
6NFC	;	3.43	;	BG505 MD64 N332-GT5 SOSIP trimer in complex with BG18-like precursor HMP42 fragmentantigen binding and base-binding RM20A3 fragment antigen binding
6CM3	;	3.54	;	BG505 SOSIP in complex with sCD4, 17b, 8ANC195
7MDU	;	3.3	;	BG505 SOSIP MD39 in complex with the monoclonal antibodies Rh.33104 mAb.1 and RM20A3
7L86	;	3.4	;	BG505 SOSIP MD39 in complex with the polyclonal Fab pAbC-1 from animal Rh.32034 (Wk26 time point)
7L8A	;	3.3	;	BG505 SOSIP MD39 in complex with the polyclonal Fab pAbC-1 from animal Rh.33104 (Wk26 time point)
7L87	;	3.6	;	BG505 SOSIP MD39 in complex with the polyclonal Fab pAbC-2 from animal Rh.32034 (Wk26 time point)
7L8B	;	3.7	;	BG505 SOSIP MD39 in complex with the polyclonal Fab pAbC-2 from animal Rh.33104 (Wk26 time point)
7L88	;	3.6	;	BG505 SOSIP MD39 in complex with the polyclonal Fab pAbC-3 from animal Rh.32034 (Wk26 time point)
7L8C	;	3.4	;	BG505 SOSIP MD39 in complex with the polyclonal Fab pAbC-3 from animal Rh.33104 (Wk26 time point)
7L89	;	3.8	;	BG505 SOSIP MD39 in complex with the polyclonal Fab pAbC-4 from animal Rh.32034 (Wk26 time point)
7L8D	;	4.6	;	BG505 SOSIP MD39 in complex with the polyclonal Fab pAbC-4 from animal Rh.33104 (Wk26 time point)
7L7T	;	3.7	;	BG505 SOSIP reconstructed from a designed nanoparticle, BG505 SOSIP-T33-31 (Component A)
7L7U	;	3.8	;	BG505 SOSIP reconstructed from a designed nanoparticle, BG505 SOSIP-T33-31 (Component B)
6VL5	;	4.5	;	BG505 SOSIP reconstructed from a designed tetrahedral nanoparticle, BG505 SOSIP-T33_dn2
6P6F	;	4.5	;	BG505 SOSIP-I53-50NP
5VIY	;	6.2	;	BG505 SOSIP.664 in complex with broadly neutralizing antibodies BG1 and 8ANC195
5VJ6	;	11.5	;	BG505 SOSIP.664 in complex with broadly neutralizing antibodies PG9 and 8ANC195
7KDE	;	3.55	;	BG505 SOSIP.664 in complex with the V3-targeting rhesus macaque antibody 1485 and human gp120-gp41 interface antibody 8ANC195
6V0R	;	3.87	;	BG505 SOSIP.664 Trimer
5V8L	;	4.3	;	BG505 SOSIP.664 trimer in complex with broadly neutralizing HIV antibodies 3BNC117 and PGT145
5V8M	;	4.4	;	BG505 SOSIP.664 trimer in complex with broadly neutralizing HIV antibody 3BNC117
6OZC	;	3.79	;	BG505 SOSIP.664 with 2G12 Fab2
6VN0	;	4.25	;	BG505 SOSIP.v4.1 in complex with rhesus macaque Fab RM20F
6VO0	;	3.52	;	BG505 SOSIP.v5.2 in complex with rabbit Fab 43A2
6VLR	;	4.42	;	BG505 SOSIP.v5.2 in complex with rhesus macaque Fab RM20E1 and PGT122 Fab
6VO1	;	3.88	;	BG505 SOSIP.v5.2 in complex with rhesus macaque Fab RM20J
7MDT	;	3.6	;	BG505 SOSIP.v5.2 in complex with the monoclonal antibody Rh4O9.8 (as Fab fragment)
7LG6	;	3.28	;	BG505 SOSIP.v5.2 in complex with VRC40.01 and RM19R Fabs
7L8T	;	3.7	;	BG505 SOSIP.v5.2 N241/N289 in complex with the polyclonal Fab pAbC-1 from animal Rh.33311 (Wk26 time point)
7L8U	;	4.5	;	BG505 SOSIP.v5.2 N241/N289 in complex with the polyclonal Fab pAbC-2 from animal Rh.33311 (Wk26 time point)
7L8W	;	4.1	;	BG505 SOSIP.v5.2 N241/N289 in complex with the polyclonal Fab pAbC-3 from animal Rh.33311 (Wk26 time point)
7L8X	;	3.0	;	BG505 SOSIP.v5.2 N241/N289 in complex with the polyclonal Fab pAbC-4 from animal Rh.33311 (Wk26 time point)
7L8Y	;	4.2	;	BG505 SOSIP.v5.2 N241/N289 in complex with the polyclonal Fab pAbC-5 from animal Rh.33311 (Wk26 time point)
7L8Z	;	3.8	;	BG505 SOSIP.v5.2 N241/N289 in complex with the polyclonal Fab pAbC-7 from animal Rh.33311 (Wk26 time point)
7L90	;	4.5	;	BG505 SOSIP.v5.2 N241/N289 in complex with the polyclonal Fab pAbC-8 from animal Rh.33311 (Wk26 time point)
7MEP	;	3.5	;	BG505 SOSIP.v5.2(7S) in complex with the monoclonal antibodies Rh.33172 mAb.1 and RM19R
7L8E	;	4.2	;	BG505 SOSIP.v5.2(7S) in complex with the polyclonal Fab pAbC-1 from animal Rh.33172 (Wk38 time point)
7L8F	;	3.66	;	BG505 SOSIP.v5.2(7S) in complex with the polyclonal Fab pAbC-2 from animal Rh.33172 (Wk38 time point)
7L8G	;	4.3	;	BG505 SOSIP.v5.2(7S) in complex with the polyclonal Fab pAbC-3 from animal Rh.33172 (Wk38 time point)
7L8S	;	4.3	;	BG505 SOSIP.v5.2(7S) in complex with the polyclonal Fab pAbC-4 from animal Rh.33172 (Wk38 time point)
6VKN	;	3.7	;	BG505 SOSIP.v5.2.N241.N289 in complex with rhesus macaque Fab RM19R
8EQN	;	3.7	;	BG505 UFO-E2p-L4P nanoparticle reconstructed by focused refinement with a mask around the nanoparticle core
6VFL	;	4.14	;	BG505-SOSIP model reconstructed by subparticle extraction and refinement from a tetrahedral nanoparticle T33_dn10
7SQ1	;	3.8	;	BG505.MD39TS Env trimer in complex with Fab from antibody C05
1SXP	;	2.5	;	BGT in complex with a 13mer DNA containing a central A:G mismatch
1SXQ	;	1.8	;	BGT in complex with a 13mer DNA containing a central C:G base pair and UDP
4OPK	;	1.539	;	Bh-RNaseH:2'-SMe-DNA complex
4OPJ	;	1.541	;	Bh-RNaseH:tcdA-DNA complex
6ODH	;	2.3	;	BH3 domain swapped dimer of a BAK fragment
1MQL	;	2.9	;	BHA of Ukr/63
1MQM	;	2.6	;	BHA/LSTa
1MQN	;	3.2	;	BHA/LSTc
3HC3	;	1.72	;	BHA10 IgG1 Fab double mutant variant - antibody directed at human LTBR
3HC4	;	1.62	;	BHA10 IgG1 Fab quadruple mutant variant - antibody directed at human LTBR
3HC0	;	1.9	;	BHA10 IgG1 wild-type Fab - antibody directed at human LTBR
1UMY	;	2.5	;	BHMT from rat liver
5VAJ	;	1.95	;	BhRNase H - amide-RNA/DNA complex
8HJW	;	4.1	;	Bi-functional malonyl-CoA reductuase from Chloroflexus aurantiacus
2AB5	;	2.2	;	bI3 LAGLIDADG Maturase
4GIU	;	1.667	;	Bianthranilate-like analogue bound in inner site of anthranilate phosphoribosyltransferase (AnPRT; trpD).
4GKM	;	1.6683	;	Bianthranilate-like analogue bound in the outer site of anthranilate phosphoribosyltransferase (AnPRT; trpD)
4IJ1	;	1.79	;	Bianthranilate-like analogue bound to anthranilate phosphoribosyltransferase (AnPRT; trpD) in absence of substrates.
5BO2	;	2.0	;	Bianthranilate-like inhibitor with 4-atom ""line"" and phosphonate ""hook"" fishing for hydrogen bond donors in Mycobacterium tuberculosis anthranilate phosphoribosyltransferase (AnPRT; trpD)
5BO3	;	1.75	;	Bianthranilate-like inhibitor with 5 atom ""line"" and phosphonate ""hook"" fishing for hydrogen bond donors in Mycobacterium tuberculosis anthranilate phosphoribosyltransferase (AnPRT; trpD)
5BNE	;	2.15	;	Bianthranilate-like inhibitor with 6 atom ""line"" and phosphonate ""hook"" fishing for hydrogen bond donors in Mycobacterium tuberculosis anthranilate phosphoribosyltransferase (AnPRT; trpD)
7EGK	;	2.7	;	Bicarbonate transporter complex SbtA-SbtB bound to AMP
7EGL	;	3.2	;	Bicarbonate transporter complex SbtA-SbtB bound to HCO3-
4BL6	;	2.18	;	Bicaudal-D uses a parallel, homodimeric coiled coil with heterotypic registry to co-ordinate recruitment of cargos to dynein
2K1A	;		;	Bicelle-embedded integrin alpha(IIB) transmembrane segment
2RMZ	;		;	Bicelle-embedded integrin beta3 transmembrane segment
6RW2	;	2.26	;	Bicycle Toxin Conjugate bound to EphA2
5I8M	;	2.13	;	Bicyclic antimibrocial peptides
5I8X	;	1.89	;	Bicyclic antimibrocial peptides
5NGQ	;	1.17	;	Bicyclic antimicrobial peptides
8PI1	;	2.5	;	Bicyclic INCYPRO Pseudomonas fluorescens esterase
6Y14	;	0.9	;	Bicyclic peptide bp65 crystallized as racemic mixture at 0.9 Angstrom resolution
6Y1S	;	1.04	;	Bicyclic peptide bp70 in I4132 at 1.0 Angstrom resolution
6Y13	;	1.112	;	Bicyclic stapled peptide bp70 at 1.1 Angstrom resolution
5I6A	;	0.813	;	bicyclo[3.3.2]decapeptide
8P1R	;	1.659	;	Bifidobacterium asteroides alpha-L-fucosidase (TT1819) catalytic mutant.
2HEZ	;	2.5	;	Bifidobacterium longum bile salt hydrolase
2HF0	;	2.3	;	Bifidobacterium longum bile salt hydrolase
4A7K	;	2.0	;	Bifunctional Aldos-2-ulose dehydratase
8CQ3	;	1.55	;	Bifunctional chorismate mutase/cyclohexadienyl dehydratase from Aequoribacter fuscus
8CQ6	;	2.44	;	Bifunctional cyclohexadienyl dehydratase/chorismate mutase from Duganella sacchari
8CQ4	;	1.65	;	Bifunctional cyclohexadienyl dehydratase/chorismate mutase from Janthinobacterium sp. HH01
2HXD	;	2.3	;	Bifunctional dCTP deaminase-dUTPase mutant enzyme variant E145A from Methanocaldococcus jannaschii in complex with alpha,beta-imido dUTP and magnesium
3GF0	;	2.62	;	Bifunctional dCTP deaminase-dUTPase mutant enzyme variant E145Q from Methanocaldococcus jannaschii in complex with pyrophosphate and magnesium
2QXX	;	2.0	;	Bifunctional dCTP deaminase: dUTPase from Mycobacterium tuberculosis in complex with dTTP
2QLP	;	2.47	;	Bifunctional dCTP deaminase:dUTPase from Mycobacterium tuberculosis, apo form
5D2A	;	2.134	;	Bifunctional dendrimers
1RNI	;	1.85	;	Bifunctional DNA primase/polymerase domain of ORF904 from the archaeal plasmid pRN1
1RO2	;	1.6	;	Bifunctional DNA primase/polymerase domain of ORF904 from the archaeal plasmid pRN1- Triple mutant F50M/L107M/L110M manganese soak
1RO0	;	1.8	;	Bifunctional DNA primase/polymerase domain of ORF904 from the archaeal plasmid pRN1- Triple mutant F50M/L107M/L110M SeMet remote
4CXO	;	1.67	;	bifunctional endonuclease in complex with ssDNA
7KR9	;	1.9	;	Bifunctional enzyme GlmU bound to Zn(II)
6MLY	;	2.7	;	Bifunctional GH43-CE Bacteroides eggerthii, BACEGG_01304
1BEA	;	1.95	;	BIFUNCTIONAL HAGEMAN FACTOR/AMYLASE INHIBITOR FROM MAIZE
5IDM	;	1.9	;	Bifunctional histidine kinase CckA (domain, CA) in complex with c-di-GMP and AMPPNP/Mg2+
5IDJ	;	3.02	;	Bifunctional histidine kinase CckA (domains DHp-CA) in complex with ADP/Mg2+
8D7I	;	3.63	;	Bifunctional Inhibition of Neutrophil Elastase and Cathepsin G by Eap1 from S. aureus
8D7K	;	3.1	;	Bifunctional Inhibition of Neutrophil Elastase and Cathepsin G by Eap2 from S. aureus
8F8U	;	2.85	;	Bifunctional ligase/repressor BirA from Klebsiella pneumoniae (Domain Swapped Dimer)
8FI3	;	2.9	;	Bifunctional ligase/repressor BirA from Klebsiella pneumoniae complexed with biotin (Domain Swapped Dimer)
5K2M	;	2.18	;	Bifunctional LysX/ArgX from Thermococcus kodakarensis with LysW-gamma-AAA
5FA9	;	2.302	;	Bifunctional Methionine Sulfoxide Reductase AB (MsrAB) from Treponema denticola
1BIP	;		;	BIFUNCTIONAL PROTEINASE INHIBITOR TRYPSIN/A-AMYLASE FROM SEEDS OF RAGI (ELEUSINE CORACANA GAERTNERI)
8KHQ	;	2.69	;	Bifunctional sulfoxide synthase OvoA_Th2 in complex with histidine and cysteine
3AWI	;	3.0	;	Bifunctional tRNA modification enzyme MnmC from Escherichia coli
6JBS	;	2.4	;	Bifunctional xylosidase/glucosidase LXYL
7EY2	;	2.43	;	Bifunctional xylosidase/glucosidase LXYL D300N mutant with intermediate substrate xylose
6KJ0	;	2.27	;	Bifunctional xylosidase/glucosidase LXYL mutant E529Q C2221
7EY1	;	2.46	;	Bifunctional xylosidase/glucosidase LXYL with intermediate substrate xylose
7YO6	;	2.54	;	Bifunctional xylosidase/glucosidase LXYL with intermediate substrate xylose for 5 sec
8GYY	;	2.07	;	Bifunctional xylosidase/glucosidase LXYL with intermediate substrate xylose, 120 seconds
7YO7	;	1.81	;	Bifunctional xylosidase/glucosidase LXYL with intermediate substrate xylose, 5 seconds
6FC5	;	1.88	;	Bik1 CAP-Gly domain
6FC6	;	1.8	;	Bik1 CAP-Gly domain with ETF peptide from Bim1
6TMM	;	2.398	;	BIL2 domain from T.thermophila BUBL1 locus (C1A-N143A)
6Y75	;	2.3	;	BIL2 domain from T.thermophila BUBL1 locus (C1A-N143A)
7SVE	;	2.15	;	Bile Salt Hydrolase A from Lactobacillus acidophilus
8ETK	;	1.83	;	Bile salt hydrolase A from Lactobacillus gasseri bound to covalent probe
8EWT	;	2.03	;	Bile salt hydrolase A from Lactobacillus gasseri bound to covalent probe
7SVG	;	1.35	;	Bile Salt Hydrolase A from Lactobacillus gasseri with chenodeoxycholate and taurine bound
7SVF	;	2.05	;	Bile salt hydrolase A from Lactobacillus gasseri with taurine bound
7SVH	;	1.56	;	Bile Salt Hydrolase B from Lactobacillus gasseri
8ESG	;	2.18	;	Bile Salt Hydrolase B from Lactobacillus gasseri with covalent inhibitor bound
8ETF	;	1.79	;	Bile Salt Hydrolase B from Lactobacillus gasseri with covalent inhibitor bound
8FAO	;	2.14	;	Bile Salt Hydrolase B from Lactobacillus gasseri with covalent inhibitor bound
7SVI	;	1.45	;	Bile Salt Hydrolase C from Lactobacillus johnsonii
8ESL	;	3.11	;	Bile Salt Hydrolase from a Bacteroidales species with covalent inhibitor bound
8VRX	;	2.04	;	Bile salt hydrolase from Arthrobacter citreus
8VSY	;	1.6	;	Bile salt hydrolase from Arthrobacter citreus with covalent inhibitor AAA-10 bound
8ESI	;	2.35	;	Bile Salt Hydrolase from B. longum with covalent inhibitor bound
8ETE	;	2.3	;	Bile Salt Hydrolase from B. longum with covalent inhibitor bound
7SVJ	;	1.43	;	Bile Salt Hydrolase from Lactobacillus ingluviei
7SVK	;	1.66	;	Bile Salt Hydrolase from Lactobacillus reuteri
5HKE	;	1.9	;	bile salt hydrolase from Lactobacillus salivarius
5Y7P	;	2.1	;	Bile salt hydrolase from lactobacillus salivarius complex with glycocholic acid and cholic acid
6P4L	;	3.1	;	Bile salts alter the mouse norovirus capsid conformation; possible implications for cell attachment and immune evasion.
7Z5P	;	2.991	;	Bilirubin oxidase from Bacillus pumilus
6I3J	;	2.59	;	Bilirubin oxidase from Myrothecium verrucaria in complex with ferricyanide
6I3K	;	1.6	;	Bilirubin oxidase from Myrothecium verrucaria, mutant W396A in complex with ferricyanide
6I3L	;	2.1	;	Bilirubin oxidase from Myrothecium verrucaria, mutant W396F
3FDL	;	1.78	;	Bim BH3 peptide in complex with Bcl-xL
6X8O	;	1.31	;	BimBH3 peptide tetramer
6OT9	;	2.4	;	Bimetallic dodecameric cage design 1 (BMC1) from cytochrome cb562
6OT4	;	1.4	;	Bimetallic dodecameric cage design 2 (BMC2) from cytochrome cb562
6OT7	;	1.85	;	Bimetallic dodecameric cage design 3 (BMC3) from cytochrome cb562
6OT8	;	1.5	;	Bimetallic hexameric cage design 4 (BMC4) from cytochrome cb562
3IO8	;	2.3	;	BimL12F in complex with Bcl-xL
3IO9	;	2.4	;	BimL12Y in complex with Mcl-1
6MB7	;	2.2	;	Binary (paromomycin) structure of AAC-IIIb
6MB4	;	2.302	;	Binary (sisomicin) structure of AAC-IIIb
1SKS	;	2.3	;	Binary 3' complex of T7 DNA polymerase with a DNA primer/template containing a cis-syn thymine dimer on the template
1SKW	;	2.3	;	Binary 3' complex of T7 DNA polymerase with a DNA primer/template containing a disordered cis-syn thymine dimer on the template
1SL1	;	2.2	;	Binary 5' complex of T7 DNA polymerase with a DNA primer/template containing a cis-syn thymine dimer on the template
3HB5	;	2.0	;	Binary and ternary crystal structures of a novel inhibitor of 17 beta-HSD type 1: a lead compound for breast cancer therapy
3S9D	;	1.9999	;	binary complex between IFNa2 and IFNAR2
8BV0	;	4.5	;	Binary complex between the NB-ARC domain from the Tomato immune receptor NRC1 and the SPRY domain-containing effector SS15 from the potato cyst nematode
6N2R	;	2.1	;	Binary complex crystal structure of DNA polymerase Beta with 5-carboxy-dC (5-caC) at the templating position
5J0O	;	2.0	;	Binary complex crystal structure of DNA polymerase Beta with A:A mismatch at the primer terminus
5J0P	;	2.2	;	Binary complex crystal structure of DNA polymerase Beta with A:C mismatch at the primer terminus
5J0Q	;	2.0	;	Binary complex crystal structure of DNA polymerase Beta with A:G mismatch at the primer terminus
5J0R	;	2.001	;	Binary complex crystal structure of DNA polymerase Beta with C:A mismatch at the primer terminus
5J0S	;	2.0	;	Binary complex crystal structure of DNA polymerase Beta with C:T mismatch at the primer terminus
5J0T	;	2.0	;	Binary complex crystal structure of DNA polymerase Beta with G:A mismatch at the primer terminus
5J0U	;	2.1	;	Binary complex crystal structure of DNA polymerase Beta with G:G mismatch at the primer terminus
5TZV	;	2.0	;	Binary complex crystal structure of DNA Polymerase Beta with G:T mismatch at the primer terminus
5J0W	;	2.4	;	Binary complex crystal structure of DNA polymerase Beta with T:C mismatch at the primer terminus
5J0X	;	2.0	;	Binary complex crystal structure of DNA polymerase Beta with T:G mismatch at the primer terminus
5J0Y	;	2.0	;	Binary complex crystal structure of DNA polymerase Beta with T:T mismatch at the primer terminus
4R64	;	2.2	;	Binary complex crystal structure of E295K mutant of DNA polymerase Beta
4R63	;	1.85	;	Binary complex crystal structure of R258A mutant of DNA polymerase Beta
6Y1D	;	1.38	;	Binary complex of 14-3-3 sigma (C38N) with the Estrogen Related Receptor gamma (DBD) phosphopeptide
6Y58	;	1.904	;	Binary complex of 14-3-3 sigma (C38N) with the Estrogen Related Receptor gamma (LBD) phosphopeptide
6TCH	;	1.801	;	Binary complex of 14-3-3 sigma and a high-affinity non-canonical 9-mer peptide binder
3LW1	;	1.28	;	Binary complex of 14-3-3 sigma and p53 pT387-peptide
8A9G	;	1.961	;	Binary complex of 14-3-3 zeta Glucocorticoid Receptor (GR) pT524 peptide stabilised by (R)-para chloropyrrolidone1
6YMO	;	2.02	;	Binary complex of 14-3-3 zeta with Glucocorticoid Receptor (GR) pS617 peptide
6YO8	;	2.09	;	Binary complex of 14-3-3 zeta with Glucocorticoid Receptor (GR) pT524 peptide
6YOS	;	2.75	;	Binary complex of 14-3-3 zeta with Glucocorticoid Receptor (GR) pT524 pS617 peptide
6F09	;	1.594	;	Binary complex of 14-3-3 zeta with ubiquitin specific protease 8 (USP8) pSer718 peptide
4K8X	;	2.28	;	Binary complex of 9N DNA polymerase in the replicative state
6F9Q	;	1.4	;	Binary complex of a 7S-cis-cis-nepetalactol cyclase from Nepeta mussinii with NAD+
3MGH	;	2.4	;	Binary complex of a DNA polymerase lambda loop mutant
3PVX	;	3.03	;	Binary complex of Aflatoxin B1 Adduct modified DNA (AFB1-FAPY) with DNA Polymerase IV
2M2U	;		;	Binary complex of African Swine Fever Virus Pol X with MgdGTP
4DQS	;	1.66	;	Binary complex of Bacillus DNA Polymerase I Large Fragment and duplex DNA with rC in primer terminus paired with dG of template
4E0D	;	1.58	;	Binary complex of Bacillus DNA Polymerase I Large Fragment E658A and duplex DNA
1EH4	;	2.8	;	BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR, IC261
2CSN	;	2.5	;	BINARY COMPLEX OF CASEIN KINASE-1 WITH CKI7
1CSN	;	2.0	;	BINARY COMPLEX OF CASEIN KINASE-1 WITH MGATP
2FLN	;	2.5	;	binary complex of catalytic core of human DNA polymerase iota with DNA (template A)
5O98	;	1.55	;	Binary complex of Catharanthus roseus Vitrosamine Synthase with NADP+
3RJG	;	2.0	;	Binary complex of DNA Polymerase Beta with a gapped DNA containing 8odG:dA base-pair at primer Terminus
7S9N	;	1.71	;	Binary complex of DNA Polymerase Beta with Fapy-dG in the template position
7S9O	;	2.23	;	Binary complex of DNA Polymerase Beta with Ring open Intermediate Fapy-dG in the template position
7CO6	;	1.9	;	Binary complex of DNA polymerase Mu with 1-nt gapped DNA (templating thymine)
2W9B	;	2.28	;	Binary complex of Dpo4 bound to N2,N2-dimethyl-deoxyguanosine modified DNA
2HMY	;	2.61	;	BINARY COMPLEX OF HHAI METHYLTRANSFERASE WITH ADOMET FORMED IN THE PRESENCE OF A SHORT NONPSECIFIC DNA OLIGONUCLEOTIDE
3ISB	;	2.0	;	Binary complex of human DNA polymerase beta with a gapped DNA
3ISC	;	2.0	;	Binary complex of human DNA polymerase beta with an abasic site (THF) in the gapped DNA
3H40	;	2.3	;	Binary complex of human DNA polymerase iota with template U/T
6P1M	;	1.65	;	Binary complex of human DNA Polymerase Mu with 1-nt gapped substrate containing template 8OG
4YCX	;	2.1	;	Binary complex of human DNA Polymerase Mu with 2-nt gapped DNA substrate
4LZG	;	1.599	;	Binary complex of human DNA Polymerase Mu with DNA
6IPL	;	1.64	;	Binary Complex of Human DNA Polymerase Mu with MgdATP
6IPM	;	1.72	;	Binary Complex of Human DNA Polymerase Mu with MgdCTP
6IPN	;	1.6	;	Binary Complex of Human DNA Polymerase Mu with MgdGTP
6IPK	;	2.15	;	Binary Complex of Human DNA Polymerase Mu with Mn8oxodGTP
6AEC	;	1.72	;	Binary complex of human DNA Polymerase Mu with MnATP
6AK6	;	1.75	;	Binary Complex of Human DNA Polymerase Mu with MnCTP
6IPH	;	1.65	;	Binary Complex of Human DNA Polymerase Mu with MndATP
6IPI	;	1.8	;	Binary Complex of Human DNA Polymerase Mu with MndCTP
5ZLC	;	2.0	;	Binary complex of human DNA Polymerase Mu with MndGTP
6IPJ	;	1.98	;	Binary Complex of Human DNA Polymerase Mu with MndTTP
6AK5	;	1.7	;	Binary Complex of Human DNA Polymerase Mu with MnGTP
6AEH	;	1.64	;	Binary complex of human DNA Polymerase Mu with MnUTP
1M6W	;	2.3	;	Binary complex of Human glutathione-dependent formaldehyde dehydrogenase and 12-Hydroxydodecanoic acid
1MP0	;	2.2	;	Binary Complex of Human Glutathione-Dependent Formaldehyde Dehydrogenase with NAD(H)
6E8Z	;	2.1	;	Binary complex of Human glycerol 3-phosphate dehydrogenase with NAD
6PYP	;	1.95	;	Binary Complex of Human Glycerol 3-Phosphate Dehydrogenase, R269A mutant
5DDY	;	3.36	;	Binary complex of human Polymerase lambda with dCTP
4XVI	;	3.1	;	Binary complex of human polymerase nu and DNA with the finger domain ajar
4XVK	;	2.95	;	Binary complex of human polymerase nu and DNA with the finger domain closed
4XVM	;	3.2	;	Binary complex of human polymerase nu and DNA with the finger domain closed and thumb domain rotated out
4XVL	;	3.301	;	Binary complex of human polymerase nu and DNA with the finger domain open
1JCN	;	2.5	;	BINARY COMPLEX OF HUMAN TYPE-I INOSINE MONOPHOSPHATE DEHYDROGENASE WITH 6-CL-IMP
4O22	;	1.7	;	Binary complex of metal-free PKAc with SP20.
4I2D	;	2.3	;	Binary complex of mouse TdT with AMPcPP
4I2I	;	2.5	;	Binary complex of mouse TdT with AP5A
4I2J	;	2.7	;	Binary complex of mouse TdT with dCTP
4I2F	;	2.1	;	Binary complex of mouse TdT with ssDNA
4I2G	;	2.5	;	Binary complex of mouse TdT with ssDNA
4I29	;	2.2	;	Binary complex of mouse TdT with ssDNA and Mn++
4I28	;	2.15	;	Binary complex of mouse TdT with ssDNA and Zn++
4I2A	;	1.9	;	Binary complex of mouse TdT with ssDNA in absence of divalent transition metal ion
1KDH	;	3.0	;	Binary Complex of Murine Terminal Deoxynucleotidyl Transferase with a Primer Single Stranded DNA
6O4X	;	2.3	;	Binary complex of native hAChE with 9-aminoacridine
6O50	;	2.352	;	Binary complex of native hAChE with BW284c51
6O4W	;	2.35	;	Binary complex of native hAChE with Donepezil
6U3P	;	3.0	;	Binary complex of native hAChE with oxime reactivator LG-703
6O5V	;	2.152	;	Binary complex of native hAChE with oxime reactivator RS-170B
6U34	;	2.4	;	Binary complex of native hAChE with oxime reactivator RS194B
4NNB	;	2.0	;	Binary complex of ObcA with oxaloacetate
1BCP	;	2.7	;	BINARY COMPLEX OF PERTUSSIS TOXIN AND ATP
5XFP	;	2.3	;	Binary complex of PHF1 and a double stranded DNA
1Q5M	;	1.32	;	Binary complex of rabbit 20alpha-hydroxysteroid dehydrogenase with NADPH
2FL3	;	2.39	;	Binary Complex of Restriction Endonuclease HinP1I with Cognate DNA
2XC9	;	2.2	;	BINARY COMPLEX OF SULFOLOBUS SOLFATARICUS DPO4 DNA POLYMERASE AND 1, N2-ETHENOGUANINE MODIFIED DNA, MAGNESIUM FORM
7KQM	;	2.73	;	Binary complex of TERT (telomerase reverse transcriptase) with RNA/telomeric DNA hybrid
2FLP	;	2.4	;	Binary complex of the catalytic core of human DNA polymerase iota with DNA (template G)
4KTQ	;	2.5	;	BINARY COMPLEX OF THE LARGE FRAGMENT OF DNA POLYMERASE I FROM T. AQUATICUS BOUND TO A PRIMER/TEMPLATE DNA
4C8M	;	1.568	;	Binary complex of the large fragment of DNA polymerase I from Thermus Aquaticus with the aritificial base pair d5SICS-dNaM at the postinsertion site (sequence context 2)
4C8O	;	1.75	;	Binary complex of the large fragment of DNA polymerase I from Thermus Aquaticus with the aritificial base pair dNaM-d5SICS at the postinsertion site (sequence context 2)
4C8N	;	1.88	;	Binary complex of the large fragment of DNA polymerase I from Thermus Aquaticus with the aritificial base pair dNaM-d5SICS at the postinsertion site (sequence context 3)
4C8L	;	1.7	;	Binary complex of the large fragment of DNA polymerase I from Thermus Aquaticus with the artificial base pair dNaM-d5SICS at the postinsertion site (sequence context 1)
2W5Y	;	2.0	;	Binary Complex of the Mixed Lineage Leukaemia (MLL1) SET Domain with the cofactor product S-Adenosylhomocysteine.
1J8R	;	1.8	;	BINARY COMPLEX OF THE PAPG RECEPTOR-BINDING DOMAIN BOUND TO GBO4 RECEPTOR
5X8G	;	1.9	;	Binary complex structure of a double mutant I454RA456K of o-Succinylbenzoate CoA Synthetase (MenE) from Bacillus Subtilis bound with its product analogue OSB-NCoA at 1.90 angstrom
1J1C	;	2.1	;	Binary complex structure of human tau protein kinase I with ADP
1J1B	;	1.8	;	Binary complex structure of human tau protein kinase I with AMPPNP
4N56	;	2.2	;	Binary complex structure of Klenow fragment of Taq DNA polymerase I707L mutant (Cs3C KlenTaq) with DNA
4XIU	;	2.5	;	Binary complex structure of Klenow fragment of Taq DNA polymerase I707L mutant with DNA containing TTT overhang
6NMK	;	1.94	;	Binary complex structure of the T130K mutant of ANT-4'' with Neomycin
5JKM	;	1.8	;	Binary crystal structure of positively and negatively supercharged variants Ftn(pos) and Ftn(neg) from human heavy chain ferritin (Mg acetate condition)
5JKL	;	1.8	;	Binary crystal structure of positively and negatively supercharged variants Ftn(pos) and Ftn(neg) from human heavy chain ferritin (Mg formate condition)
6H6T	;	1.9	;	Binary crystal structure of positively and negatively supercharged variants Ftn(pos) and Ftn(neg) from human heavy chain ferritin (propandiol condition, coordination number 8)
8PP3	;	1.55	;	Binary crystal structure of positively supercharged ferritin variant Ftn(pos) and crystal contact tuned negatively supercharged ferritin variant Ftn(neg)-m1 (Mg formate condition)
8PP2	;	2.001	;	Binary crystal structure of positively supercharged ferritin variant Ftn(pos) and native(K86Q) human heavy chain ferritin (Mg formate condition)
8PP4	;	1.999	;	Binary crystal structure of positively supercharged ferritin variant Ftn(pos) and reduced charge negatively supercharged ferritin variant Ftn(neg)-m3 (Mg formate condition)
1OS9	;	1.85	;	Binary enzyme-product complexes of human MMP12
2JYB	;		;	binary hvDHFR1:folate complex
6PH5	;	2.602	;	Binary product complex crystal structure of DNA polymerase Beta with an extra-helical template base
7JYB	;	2.76	;	Binary soak structure of alkanesulfonate monooxygenase MsuD from Pseudomonas fluorescens with FMN
8BI7	;	1.4	;	Binary structure of 14-3-3s and PKR phosphopeptide
8BFC	;	1.4	;	Binary structure of 14-3-3s and RND3 phosphopeptide
6MP3	;	1.907	;	Binary structure of DNA polymerase eta in complex with templating hypoxanthine
6MQ8	;	1.969	;	Binary structure of DNA polymerase eta in complex with templating hypoxanthine
2ORE	;	2.99	;	Binary Structure of Escherichia coli DNA Adenine Methyltransferase and S-adenosylhomocysteine
1W73	;	2.1	;	Binary structure of human DECR solved by SeMet SAD.
1W8D	;	2.2	;	Binary structure of human DECR.
1Q0S	;	2.3	;	Binary Structure of T4DAM with AdoHcy
6P04	;	2.3	;	Binary structure of the E52D mutant of ANT-4'' with Neomycin
3RR7	;	1.95	;	Binary Structure of the large fragment of Taq DNA polymerase bound to an abasic site
7K64	;	2.8	;	Binary titrated soak structure of alkanesulfonate monooxygenase MsuD from Pseudomonas fluorescens with FMN
2MUF	;		;	Binding activity, structure, and immunogenicity of synthetic peptides derived from Plasmodium falciparum CelTOS and TRSP proteins
5ZUJ	;	2.6	;	Binding and Enhanced Binding between Key Immunity Proteins TRAF6 and TIFA
6A33	;	2.1	;	Binding and Enhanced Binding between Key Immunity Proteins TRAF6 and TIFA
5FIU	;	1.84	;	Binding and structural studies of a 5,5-difluoromethyl adenosine nucleoside with the fluorinase enzyme
5TPC	;	2.0	;	Binding domain of BoNT/A complexed with ganglioside
5TPB	;	2.6	;	Binding domain of BoNT/A complexed with ganglioside variant
6TWP	;	1.15	;	Binding domain of BoNT/A5
6TWO	;	1.35	;	Binding domain of BoNT/A6
4ISQ	;	2.65	;	Binding domain of Botulinum neurotoxin DC in complex with human synaptotagmin I
4ISR	;	2.59	;	Binding domain of Botulinum neurotoxin DC in complex with rat synaptotagmin II
5LR0	;	2.59	;	Binding domain of Botulinum Neurotoxin DC in complex with SialylT
7OVW	;	2.2	;	Binding domain of botulinum neurotoxin E in complex with GD1a
1C47	;	2.7	;	BINDING DRIVEN STRUCTURAL CHANGES IN CRYSTALINE PHOSPHOGLUCOMUTASE ASSOCIATED WITH CHEMICAL REACTION
7CYH	;	3.9	;	Binding interface of SARS-CoV-2 RBD and its neutralizing antibody HB27
5MBA	;	1.9	;	BINDING MODE OF AZIDE TO FERRIC APLYSIA LIMACINA MYOGLOBIN. CRYSTALLOGRAPHIC ANALYSIS AT 1.9 ANGSTROMS RESOLUTION
1HSR	;	1.6	;	BINDING MODE OF BENZHYDROXAMIC ACID TO ARTHROMYCES RAMOSUS PEROXIDASE
1C8I	;	2.0	;	BINDING MODE OF HYDROXYLAMINE TO ARTHROMYCES RAMOSUS PEROXIDASE
1CK6	;	1.9	;	BINDING MODE OF SALICYLHYDROXAMIC ACID TO ARTHROMYCES RAMOSUS PEROXIDASE
7RKY	;	3.8	;	Binding mode of US27-Gi-scFv16 in OCL-state
4UVR	;	2.48	;	Binding mode, selectivity and potency of N-indolyl-oxopyridinyl-4- amino-propanyl-based inhibitors targeting Trypanosoma cruzi CYP51
1KTI	;	1.97	;	BINDING OF 100 MM N-ACETYL-N'-BETA-D-GLUCOPYRANOSYL UREA TO GLYCOGEN PHOSPHORYLASE B: KINETIC AND CRYSTALLOGRAPHIC STUDIES
2PRI	;	2.3	;	BINDING OF 2-DEOXY-GLUCOSE-6-PHOSPHATE TO GLYCOGEN PHOSPHORYLASE B
3JQM	;	2.5	;	Binding of 5'-GTP to molybdenum cofactor biosynthesis protein MoaC from Thermus theromophilus HB8
1SPR	;	2.5	;	BINDING OF A HIGH AFFINITY PHOSPHOTYROSYL PEPTIDE TO THE SRC SH2 DOMAIN: CRYSTAL STRUCTURES OF THE COMPLEXED AND PEPTIDE-FREE FORMS
1SPS	;	2.7	;	BINDING OF A HIGH AFFINITY PHOSPHOTYROSYL PEPTIDE TO THE SRC SH2 DOMAIN: CRYSTAL STRUCTURES OF THE COMPLEXED AND PEPTIDE-FREE FORMS
1FDG	;	1.6	;	BINDING OF A MACROCYCLIC BISACRIDINE AND AMETANTRONE TO CGTACG INVOLVES SIMILAR UNUSUAL INTERCALATION PLATFORMS (AMETANTRONE COMPLEX)
1FD5	;	1.1	;	BINDING OF A MACROCYCLIC BISACRIDINE AND AMETANTRONE TO CGTACG INVOLVES SIMILAR UNUSUAL INTERCALATION PLATFORMS (BISACRIDINE COMPLEX)
3APR	;	1.8	;	BINDING OF A REDUCED PEPTIDE INHIBITOR TO THE ASPARTIC PROTEINASE FROM RHIZOPUS CHINENSIS. IMPLICATIONS FOR A MECHANISM OF ACTION
11BA	;	2.06	;	BINDING OF A SUBSTRATE ANALOGUE TO A DOMAIN SWAPPING PROTEIN IN THE COMPLEX OF BOVINE SEMINAL RIBONUCLEASE WITH URIDYLYL-2',5'-ADENOSINE
6BNA	;	2.21	;	BINDING OF AN ANTITUMOR DRUG TO DNA. NETROPSIN AND C-G-C-G-A-A-T-T-BRC-G-C-G
2BZS	;	2.0	;	Binding of anti-cancer prodrug CB1954 to the activating enzyme NQO2 revealed by the crystal structure of their complex.
1B0S	;		;	BINDING OF AR-1-144, A TRI-IMIDAZOLE DNA MINOR GROOVE BINDER, TO CCGG SEQUENCE ANALYZED BY NMR SPECTROSCOPY
6V7G	;	1.4	;	Binding of Benzoic Acid and Anions Within the Cupin Domains of the Vicillin Protein Canavalin from Jack Bean (canavalia ensiformis): Crystal Structures
1XC7	;	1.83	;	Binding of beta-D-glucopyranosyl bismethoxyphosphoramidate to glycogen phosphorylase b: Kinetic and crystallographic studies
3MGS	;	3.15	;	Binding of Cesium ions to the Nucleosome Core particle
2DSU	;	2.2	;	Binding of chitin-like polysaccharide to protective signalling factor: Crystal structure of the complex formed between signalling protein from sheep (SPS-40) with a tetrasaccharide at 2.2 A resolution
2DSW	;	2.8	;	Binding of chitin-like polysaccharides to protective signalling factor: crystal structure of the complex of signalling protein from sheep (SPS-40) with a pentasaccharide at 2.8 A resolution
1PAD	;	2.8	;	Binding of chloromethyl ketone substrate analogues to crystalline papain
2PAD	;	2.8	;	BINDING OF CHLOROMETHYL KETONE SUBSTRATE ANALOGUES TO CRYSTALLINE PAPAIN
4PAD	;	2.8	;	Binding of chloromethyl ketone substrate analogues to crystalline papain
5PAD	;	2.8	;	BINDING OF CHLOROMETHYL KETONE SUBSTRATE ANALOGUES TO CRYSTALLINE PAPAIN
6PAD	;	2.8	;	Binding of chloromethyl ketone substrate analogues to crystalline papain
3MGP	;	2.44	;	Binding of Cobalt ions to the Nucleosome Core Particle
1V5Y	;	1.9	;	Binding of coumarins to NAD(P)H:FMN oxidoreductase
1V5Z	;	2.0	;	Binding of coumarins to NAD(P)H:FMN oxidoreductase
308D	;	1.5	;	BINDING OF DAUNOMYCIN TO B-D-GLUCOSYLATED DNA FOUND IN PROTOZOA TRYPANOSOMA BRUCEI STUDIED BY X-RAY CRYSTALLOGRAPH
1C4A	;	2.4	;	BINDING OF EXOGENOUSLY ADDED CARBON MONOXIDE AT THE ACTIVE SITE OF THE FE-ONLY HYDROGENASE (CPI) FROM CLOSTRIDIUM PASTEURIANUM
1C4C	;	2.4	;	BINDING OF EXOGENOUSLY ADDED CARBON MONOXIDE AT THE ACTIVE SITE OF THE FE-ONLY HYDROGENASE (CPI) FROM CLOSTRIDIUM PASTEURIANUM
1HLF	;	2.26	;	BINDING OF GLUCOPYRANOSYLIDENE-SPIRO-THIOHYDANTOIN TO GLYCOGEN PHOSPHORYLASE B: KINETIC AND CRYSTALLOGRAPHIC STUD
3U82	;	3.164	;	Binding of herpes simplex virus glycoprotein D to nectin-1 exploits host cell adhesion
1SFG	;		;	BINDING OF HEXA-N-ACETYLCHITOHEXAOSE: A POWDER DIFFRACTION STUDY
8BNA	;	2.2	;	BINDING OF HOECHST 33258 TO THE MINOR GROOVE OF B-DNA
4TLN	;	2.3	;	BINDING OF HYDROXAMIC ACID INHIBITORS TO CRYSTALLINE THERMOLYSIN SUGGESTS A PENTACOORDINATE ZINC INTERMEDIATE IN CATALYSIS
5TLN	;	2.3	;	BINDING OF HYDROXAMIC ACID INHIBITORS TO CRYSTALLINE THERMOLYSIN SUGGESTS A PENTACOORDINATE ZINC INTERMEDIATE IN CATALYSIS
1HGD	;	2.7	;	BINDING OF INFLUENZA VIRUS HEMAGGLUTININ TO ANALOGS OF ITS CELL-SURFACE RECEPTOR, SIALIC ACID: ANALYSIS BY PROTON NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY AND X-RAY CRYSTALLOGRAPHY
1HGE	;	2.6	;	BINDING OF INFLUENZA VIRUS HEMAGGLUTININ TO ANALOGS OF ITS CELL-SURFACE RECEPTOR, SIALIC ACID: ANALYSIS BY PROTON NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY AND X-RAY CRYSTALLOGRAPHY
1HGF	;	3.0	;	BINDING OF INFLUENZA VIRUS HEMAGGLUTININ TO ANALOGS OF ITS CELL-SURFACE RECEPTOR, SIALIC ACID: ANALYSIS BY PROTON NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY AND X-RAY CRYSTALLOGRAPHY
1HGG	;	2.9	;	BINDING OF INFLUENZA VIRUS HEMAGGLUTININ TO ANALOGS OF ITS CELL-SURFACE RECEPTOR, SIALIC ACID: ANALYSIS BY PROTON NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY AND X-RAY CRYSTALLOGRAPHY
1HGH	;	2.7	;	BINDING OF INFLUENZA VIRUS HEMAGGLUTININ TO ANALOGS OF ITS CELL-SURFACE RECEPTOR, SIALIC ACID: ANALYSIS BY PROTON NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY AND X-RAY CRYSTALLOGRAPHY
1HGI	;	2.7	;	BINDING OF INFLUENZA VIRUS HEMAGGLUTININ TO ANALOGS OF ITS CELL-SURFACE RECEPTOR, SIALIC ACID: ANALYSIS BY PROTON NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY AND X-RAY CRYSTALLOGRAPHY
1HGJ	;	2.7	;	BINDING OF INFLUENZA VIRUS HEMAGGLUTININ TO ANALOGS OF ITS CELL-SURFACE RECEPTOR, SIALIC ACID: ANALYSIS BY PROTON NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY AND X-RAY CRYSTALLOGRAPHY
2HU7	;	2.01	;	Binding of inhibitors by Acylaminoacyl peptidase
2HU8	;	2.4	;	Binding of inhibitors by Acylaminoacyl peptidase
2HU5	;	2.0	;	Binding of inhibitors by Acylaminoacyl-peptidase
3O5W	;	2.7	;	Binding of kinetin in the active site of mistletoe lectin I
1SF6	;		;	BINDING OF N,N',N""-TRIACETYLCHITOTRIOSE TO HEW LYSOZYME: A POWDER DIFFRACTION STUDY
1SF4	;		;	BINDING OF N,N'-DIACETYLCHITOBIOSE TO HEW LYSOZYME: A POWDER DIFFRACTION STUDY
2PRJ	;	2.3	;	Binding of N-acetyl-beta-D-glucopyranosylamine to Glycogen Phosphorylase B
1JA2	;	2.87	;	BINDING OF N-ACETYLGLUCOSAMINE TO CHICKEN EGG LYSOZYME: A POWDER DIFFRACTION STUDY
1JA4	;	2.94	;	BINDING OF N-ACETYLGLUCOSAMINE TO CHICKEN EGG LYSOZYME: A POWDER DIFFRACTION STUDY
1JA6	;	2.96	;	BINDING OF N-ACETYLGLUCOSAMINE TO CHICKEN EGG LYSOZYME: A POWDER DIFFRACTION STUDY
1JA7	;	2.98	;	BINDING OF N-ACETYLGLUCOSAMINE TO CHICKEN EGG LYSOZYME: A POWDER DIFFRACTION STUDY
1TMN	;	1.9	;	Binding of n-carboxymethyl dipeptide inhibitors to thermolysin determined by x-ray crystallography. a novel class of transition-state analogues for zinc peptidases
4EJ1	;	1.75	;	Binding of Nb113 camelid antibody fragment with the binary DHFR:folate complex
3MGQ	;	2.65	;	Binding of Nickel ions to the Nucleosome Core Particle
1W4O	;	1.6	;	Binding of Nonnatural 3'-Nucleotides to Ribonuclease A
1W4P	;	1.69	;	Binding of Nonnatural 3'-Nucleotides to Ribonuclease A
1W4Q	;	1.68	;	Binding of Nonnatural 3'-Nucleotides to Ribonuclease A
1HIY	;	2.6	;	Binding of nucleotides to NDP kinase
1SFB	;		;	BINDING OF PENTA-N-ACETYLCHITOPENTAOSE TO HEW LYSOZYME: A POWDER DIFFRACTION STUDY
1H52	;	2.0	;	Binding of Phosphate and Pyrophosphate ions at the active site of human Angiogenin as revealed by X-ray Crystallography
1H53	;	2.0	;	Binding of Phosphate and Pyrophosphate ions at the active site of human Angiogenin as revealed by X-ray Crystallography
1HBY	;	2.0	;	Binding of Phosphate and Pyrophosphate ions at the active site of human angiogenin as revealed by X-ray Crystallography
3MGR	;	2.3	;	Binding of Rubidium ions to the Nucleosome Core Particle
1SF7	;		;	BINDING OF TETRA-N-ACETYLCHITOTETRAOSE TO HEW LYSOZYME: A POWDER DIFFRACTION STUDY
2KCE	;	2.2	;	BINDING OF THE ANTICANCER DRUG ZD1694 TO E. COLI THYMIDYLATE SYNTHASE: ASSESSING SPECIFICITY AND AFFINITY
1D21	;	1.7	;	BINDING OF THE ANTITUMOR DRUG NOGALAMYCIN AND ITS DERIVATIVES TO DNA: STRUCTURAL COMPARISON
1D22	;	1.8	;	BINDING OF THE ANTITUMOR DRUG NOGALAMYCIN AND ITS DERIVATIVES TO DNA: STRUCTURAL COMPARISON
1PIV	;	2.9	;	BINDING OF THE ANTIVIRAL DRUG WIN51711 TO THE SABIN STRAIN OF TYPE 3 POLIOVIRUS: STRUCTURAL COMPARISON WITH DRUG BINDING IN RHINOVIRUS 14
5LZP	;	3.5	;	Binding of the C-terminal GQYL motif of the bacterial proteasome activator Bpa to the 20S proteasome
380D	;	2.0	;	BINDING OF THE MODIFIED DAUNORUBICIN WP401 ADJACENT TO A T-G BASE PAIR INDUCES THE REVERSE WATSON-CRICK CONFORMATION: CRYSTAL STRUCTURES OF THE WP401-TGGCCG AND WP401-CGG[BR5C]CG COMPLEXES
381D	;	2.1	;	BINDING OF THE MODIFIED DAUNORUBICIN WP401 ADJACENT TO A T-G BASE PAIR INDUCES THE REVERSE WATSON-CRICK CONFORMATION: CRYSTAL STRUCTURES OF THE WP401-TGGCCG AND WP401-CGG[BR5C]CG COMPLEXES
6ZO9	;	2.7	;	Binding of two rifabutins to the access pocket of AcrB-G621P T protomer
3BXX	;	2.9	;	Binding of two substrate analogue molecules to dihydroflavonol 4-reductase alters the functional geometry of the catalytic site
3C1T	;	2.252	;	Binding of two substrate analogue molecules to dihydroflavonol 4-reductase alters the functional geometry of the catalytic site
2IOD	;	2.06	;	Binding of two substrate analogue molecules to dihydroflavonol-4-reductase alters the functional geometry of the catalytic site
2NNL	;	2.1	;	Binding of two substrate analogue molecules to dihydroflavonol-4-reductase alters the functional geometry of the catalytic site
6KD9	;	2.44	;	Binding pose 1 of 2-CF3 bound AsqJ complex
6K30	;	2.684	;	Binding pose 2 of 2-CF3 bound AsqJ complex
1T1M	;	12.0	;	Binding position of ribosome recycling factor (RRF) on the E. coli 70S ribosome
3Q2C	;	2.5	;	Binding properties to HLA class I molecules and the structure of the leukocyte Ig-like receptor A3 (LILRA3/ILT6/LIR4/CD85e)
5HI3	;	2.15	;	Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists
5HI4	;	1.8	;	Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists
5HI5	;	1.8	;	Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists
3GOK	;	3.2	;	Binding site mapping of protein ligands
5JDB	;	1.901	;	Binding specificity of P[8] VP8* proteins of rotavirus vaccine strains with histo-blood group antigens
1OKX	;	2.8	;	Binding Structure of Elastase Inhibitor Scyptolin A
1UY1	;	1.8	;	Binding sub-site dissection of a family 6 carbohydrate-binding module by X-ray crystallography and isothermal titration calorimetry
1UY2	;	1.7	;	Binding sub-site dissection of a family 6 carbohydrate-binding module by X-ray crystallography and isothermal titration calorimetry
1UY3	;	1.89	;	Binding sub-site dissection of a family 6 carbohydrate-binding module by X-ray crystallography and isothermal titration calorimetry
1UY4	;	1.69	;	Binding sub-site dissection of a family 6 carbohydrate-binding module by X-ray crystallography and isothermal titration calorimetry
7L30	;	4.4	;	Binjari virus (BinJV)
7SXF	;	1.94	;	BIO-2895 (BRD0705) bound GSK3alpha-axin complex
7SXJ	;	1.85	;	BIO-2895 (BRD0705) bound GSK3beta-axin complex
7SXG	;	2.4	;	BIO-8546 bound GSK3alpha-axin complex
7SXH	;	2.09	;	BIO-8546 bound GSK3beta-axin complex
3FNN	;	2.3	;	Biochemical and structural analysis of an atypical ThyX: Corynebacterium glutamicum NCHU 87078 depends on ThyA for thymidine biosynthesis
2JAH	;	1.8	;	Biochemical and structural analysis of the Clavulanic acid dehydeogenase (CAD) from Streptomyces clavuligerus
1H4C	;	1.65	;	Biochemical and Structural Analysis of the Molybdenum Cofactor Biosynthesis protein MobA
1H4D	;	1.74	;	Biochemical and Structural Analysis of the Molybdenum Cofactor Biosynthesis protein MobA
1H4E	;	1.65	;	Biochemical and Structural Analysis of the Molybdenum Cofactor Biosynthesis protein MobA
1HJJ	;	1.65	;	Biochemical and Structural Analysis of the Molybdenum Cofactor Biosynthesis protein MobA
1HJL	;	2.0	;	Biochemical and Structural Analysis of the Molybdenum Cofactor Biosynthesis protein MobA
4BIF	;	2.46	;	Biochemical and structural characterisation of a novel manganese- dependent hydroxynitrile lyase from bacteria
8C10	;	1.0	;	Biochemical and structural characterisation of an alkaline family GH5 cellulase from a shipworm symbiont
1DYW	;	1.8	;	Biochemical and structural characterization of a divergent loop cyclophilin from Caenorhabditis elegans
3NNK	;	2.58	;	Biochemical and Structural Characterization of a Ureidoglycine Aminotransferase in the Klebsiella pneumoniae Uric Acid Catabolic Pathway
4RMF	;	2.4	;	Biochemical and structural characterization of mycobacterial aspartyl-tRNA synthetase AspS, a promising TB drug target
4AXV	;	2.17	;	Biochemical and structural characterization of the MpaA amidase as part of a conserved scavenging pathway for peptidoglycan derived peptides in gamma-proteobacteria
3DVT	;	2.3	;	Biochemical and structural characterization of the PAK1- LC8 interaction
5W11	;	2.311	;	Biochemical and structural insights into the catalytic mechanism of thermostable cellobiohydrolase Cel7A from industrially relevant fungus Myceliophthora thermophila
4G68	;	1.8	;	Biochemical and structural insights into xylan utilization by the thermophilic bacteriumcaldanaerobius polysaccharolyticus
2A8N	;	1.6	;	Biochemical and Structural Studies of A-to-I Editing by tRNA:A34 Deaminases at the Wobble Position of Transfer RNA
1N8I	;	2.1	;	Biochemical and Structural Studies of Malate Synthase from Mycobacterium tuberculosis
1N8W	;	2.7	;	Biochemical and Structural Studies of Malate Synthase from Mycobacterium tuberculosis
4V2I	;	1.686	;	Biochemical characterization and structural analysis of a new cold- active and salt tolerant esterase from the marine bacterium Thalassospira sp
2HDH	;	2.2	;	BIOCHEMICAL CHARACTERIZATION AND STRUCTURE DETERMINATION OF HUMAN HEART SHORT CHAIN L-3-HYDROXYACYL COA DEHYDROGENASE PROVIDE INSIGHT INTO CATALYTIC MECHANISM
3HAD	;	2.0	;	BIOCHEMICAL CHARACTERIZATION AND STRUCTURE DETERMINATION OF HUMAN HEART SHORT CHAIN L-3-HYDROXYACYL COA DEHYDROGENASE PROVIDE INSIGHT INTO CATALYTIC MECHANISM
7Z1U	;	2.24	;	Biochemical implications of the substitution of a unique cysteine residue in sugar beet phytoglobin BvPgb 1.2
4AO9	;	1.5	;	Biochemical properties and crystal structure of a novel beta- phenylalanine aminotransferase from Variovorax paradoxus
4AOA	;	2.28	;	Biochemical properties and crystal structure of a novel beta- phenylalanine aminotransferase from Variovorax paradoxus
4X9X	;	1.199	;	Biochemical Roles for Conserved Residues in the Bacterial Fatty Acid Binding Protein Family
3PS7	;	2.85	;	Biochemical studies and crystal structure determination of dihydrodipicolinate synthase from Pseudomonas aeruginosa
6YKY	;	2.52	;	Biochemical, Cellular and Structural Characterization of Novel ERK3 Inhibitors
6YLC	;	2.43	;	Biochemical, Cellular and Structural Characterization of Novel ERK3 Inhibitors
6YLL	;	2.89	;	Biochemical, Cellular and Structural Characterization of Novel ERK3 Inhibitors
7C7R	;	3.07	;	Biofilm associated protein - B domain
7C7U	;	1.93	;	Biofilm associated protein - BSP domain
7DM0	;	1.55	;	Biofilm associated protein - C region
7V9A	;	3.94	;	biogenesis module of human telomerase holoenzyme
4HFO	;	3.0	;	Biogenic amine-binding protein selenomethionine derivative
8BV2	;	2.0	;	Biological and structural analysis of new potent Integrase-LEDGF allosteric HIV-1 inhibitors
2J4T	;	2.02	;	Biological and Structural Features of Murine Angiogenin-4, an Angiogenic Protein
1ANT	;	3.0	;	BIOLOGICAL IMPLICATIONS OF A 3 ANGSTROMS STRUCTURE OF DIMERIC ANTITHROMBIN
4B97	;	1.276	;	Biomass sensing modules from putative Rsgi-like proteins of Clostridium thermocellum resemble family 3 carbohydrate-binding module of cellulosome
4B9P	;	1.182	;	Biomass sensoring module from putative Rsgi2 protein of Clostridium thermocellum resemble family 3 carbohydrate-binding module of cellulosome
4B9C	;	1.171	;	Biomass sensoring modules from putative Rsgi-like proteins of Clostridium thermocellum resemble family 3 carbohydrate-binding module of cellulosome
5F1U	;	2.35	;	biomimetic design results in a potent allosteric inhibitor of dihydrodipicolinate synthase from Campylobacter jejuni
5F1V	;	2.2	;	biomimetic design results in a potent allosteric inhibitor of dihydrodipicolinate synthase from Campylobacter jejuni
4AOD	;	6.0	;	Biomphalaria glabrata Acetylcholine-binding protein type 1 (BgAChBP1)
4AOE	;	6.0	;	Biomphalaria glabrata Acetylcholine-binding protein type 2 (BgAChBP2)
5FUC	;	2.7	;	Biophysical and cellular characterisation of a junctional epitope antibody that locks IL-6 and gp80 together in a stable complex: implications for new therapeutic strategies
8FTG	;	1.13	;	Biophysical and Structural Characterization of an Anti-Caffeine VHH Antibody
5YZV	;	2.6	;	Biophysical and structural characterization of the thermostable WD40 domain of a prokaryotic protein, Thermomonospora curvata PkwA
2L7C	;		;	Biophysical studies of lipid interacting regions of DGD2 in Arabidopsis thaliana
6EBE	;	1.88	;	Bioreductive 4-hydroxy-3-nitro-5-ureido-benzenesulfonamides selectively target the tumor-associated carbonic anhydrase isoforms IX and XII and show hypoxia-enhanced cytotoxicity against human cancer cell lines.
6ECZ	;	2.21	;	Bioreductive 4-hydroxy-3-nitro-5-ureido-benzenesulfonamides selectively target the tumor-associated carbonic anhydrase isoforms IX and XII and show hypoxia-enhanced cytotoxicity against human cancer cell lines.
6EDA	;	1.879	;	Bioreductive 4-hydroxy-3-nitro-5-ureido-benzenesulfonamides selectively target the tumor-associated carbonic anhydrase isoforms IX and XII and show hypoxia-enhanced cytotoxicity against human cancer cell lines.
6EEA	;	1.63	;	Bioreductive 4-hydroxy-3-nitro-5-ureido-benzenesulfonamides selectively target the tumor-associated carbonic anhydrase isoforms IX and XII and show hypoxia-enhanced cytotoxicity against human cancer cell lines.
6EEH	;	1.629	;	Bioreductive 4-hydroxy-3-nitro-5-ureido-benzenesulfonamides selectively target the tumor-associated carbonic anhydrase isoforms IX and XII and show hypoxia-enhanced cytotoxicity against human cancer cell lines.
6EEO	;	1.719	;	Bioreductive 4-hydroxy-3-nitro-5-ureido-benzenesulfonamides selectively target the tumor-associated carbonic anhydrase isoforms IX and XII and show hypoxia-enhanced cytotoxicity against human cancer cell lines.
1N3R	;	2.8	;	Biosynthesis of pteridins. Reaction mechanism of GTP cyclohydrolase I
1N3S	;	2.55	;	Biosynthesis of pteridins. Reaction mechanism of GTP cyclohydrolase I
1N3T	;	3.2	;	Biosynthesis of pteridins. Reaction mechanism of GTP cyclohydrolase I
5MWQ	;		;	Biosynthetic engineered A21K-B31K-B32R human insulin monomer structure in water/acetonitrile solution
5MHD	;		;	Biosynthetic engineered A22S-B3K-B31R human insulin monomer structure in water/acetonitrile solutions.
2M1E	;		;	Biosynthetic engineered B28K-B29P human insulin monomer structure in in water solutions.
2M1D	;		;	Biosynthetic engineered B28K-B29P human insulin monomer structure in in water/acetonitrile solutions.
4DD5	;	1.25	;	Biosynthetic Thiolase (ThlA1) from Clostridium difficile
2VTZ	;	2.3	;	Biosynthetic thiolase from Z. ramigera. Complex of the C89A mutant with coenzyme A.
2WL4	;	1.8	;	BIOSYNTHETIC THIOLASE FROM Z. RAMIGERA. COMPLEX OF THE H348A MUTANT WITH COENZYME A.
2WL5	;	1.8	;	BIOSYNTHETIC THIOLASE FROM Z. RAMIGERA. COMPLEX OF THE H348N MUTANT WITH COENZYME A.
2WKT	;	2.0	;	BIOSYNTHETIC THIOLASE FROM Z. RAMIGERA. COMPLEX OF THE N316A MUTANT WITH COENZYME A.
2WKV	;	2.5	;	BIOSYNTHETIC THIOLASE FROM Z. RAMIGERA. COMPLEX OF THE N316D MUTANT WITH COENZYME A.
2VU0	;	1.87	;	Biosynthetic thiolase from Z. ramigera. Complex of the oxidised enzyme with coenzyme A.
2VU1	;	1.51	;	Biosynthetic thiolase from Z. ramigera. Complex of with O-pantheteine- 11-pivalate.
2VU2	;	2.65	;	Biosynthetic thiolase from Z. ramigera. Complex with S-pantetheine-11- pivalate.
2WKU	;	2.3	;	BIOSYNTHETIC THIOLASE FROM Z. RAMIGERA. THE N316H MUTANT.
2WL6	;	2.98	;	BIOSYNTHETIC THIOLASE FROM Z. RAMIGERA. THE N316H-H348N MUTANT.
1QFL	;	1.92	;	BIOSYNTHETIC THIOLASE FROM ZOOGLOEA RAMIGERA IN COMPLEX WITH A REACTION INTERMEDIATE.
1OU6	;	2.07	;	Biosynthetic thiolase from Zoogloea ramigera in complex with acetyl-O-pantetheine-11-pivalate
1DLV	;	2.29	;	BIOSYNTHETIC THIOLASE FROM ZOOGLOEA RAMIGERA IN COMPLEX WITH COA
1M3Z	;	1.87	;	Biosynthetic thiolase, C89A mutant, complexed with acetyl coenzyme A
1M4S	;	1.87	;	Biosynthetic thiolase, Cys89 acetylated, unliganded form
1M4T	;	1.77	;	Biosynthetic thiolase, Cys89 butyrylated
1M3K	;	1.7	;	biosynthetic thiolase, inactive C89A mutant
1M1T	;	1.94	;	Biosynthetic thiolase, Q64A mutant
1XNY	;	2.2	;	Biotin and propionyl-CoA bound to Acyl-CoA Carboxylase Beta Subunit from S. coelicolor (PccB)
1O78	;		;	Biotin carboxyl carrier domain of transcarboxylase (1.3S) [10-48] deletion mutant
1DCZ	;		;	BIOTIN CARBOXYL CARRIER DOMAIN OF TRANSCARBOXYLASE (TC 1.3S)
1DD2	;		;	BIOTIN CARBOXYL CARRIER DOMAIN OF TRANSCARBOXYLASE (TC 1.3S)
5H80	;	1.7	;	Biotin Carboxylase domain of single-chain bacterial carboxylase
7KC7	;	2.2	;	Biotin Carboxylase domain of Thermophilic 2-Oxoglutarate Carboxylase bound to ADP without Magnesium with disordered phosphate tail
7KBL	;	2.3	;	Biotin Carboxylase domain of Thermophilic 2-Oxoglutarate Carboxylase bound to Bicarbonate
3T6F	;	1.22	;	Biotin complex of Y54F core streptavidin
5MLK	;	1.939	;	Biotin dependent carboxylase AccA3 dimer from Mycobacterium tuberculosis (Rv3285)
3EFS	;	2.3	;	Biotin protein ligase from Aquifex aeolicus in complex with biotin and ATP
3EFR	;	2.55	;	Biotin protein ligase R40G mutant from Aquifex aeolicus in complex with biotin
6J6J	;	3.2	;	Biotin-bound streptavidin
5TV5	;	2.5	;	BioW from Aquifex aeoulicus
6ASY	;	1.85	;	BiP-ATP2
8OK2	;	4.1	;	Bipartite interaction of TOPBP1 with the GINS complex
8G8S	;	2.1	;	bipartite p52 NLS in complex with Importin alpha 2
2IZP	;	2.1	;	BipD - an invasion protein associated with the type-III secretion system of Burkholderia pseudomallei.
2IXR	;	2.6	;	BipD of Burkholderia Pseudomallei
2J9T	;	2.7	;	BipD of Burkholderia Pseudomallei
1ULI	;	2.2	;	Biphenyl dioxygenase (BphA1A2) derived from Rhodococcus sp. strain RHA1
1ULJ	;	2.6	;	Biphenyl dioxygenase (BphA1A2) in complex with the substrate
6LLF	;	1.93	;	Biphenyl-2,2',3-triol-soaked resting complex of Oxy and Fd in carbazole 1,9a-dioxygenase
6LLK	;	2.3	;	Biphenyl-2,2',3-triol-soaked terminal oxygenase of carbazole 1,9a-dioxygenase
6LLH	;	1.99	;	Biphenyl-2,3-diol-soaked resting complex of Oxy and Fd in carbazole 1,9a-dioxygenase
6LLM	;	1.9	;	Biphenyl-2,3-diol-soaked terminal oxygenase of carbazole 1,9a-dioxygenase
4S0I	;	2.36	;	Biphenylalanine modified threonyl-tRNA synthetase from Pyrococcus abyssi: 11BIF, 42F, 79S, and 123A mutant
4S0J	;	2.1	;	Biphenylalanine modified threonyl-tRNA synthetase from Pyrococcus abyssi: 11BIF, 42F, 79S, and 123V mutant
4S0K	;	2.1	;	Biphenylalanine modified threonyl-tRNA synthetase from Pyrococcus abyssi: 11BIF, 42F, 79V, and 123A mutant
4S02	;	1.95	;	Biphenylalanine modified threonyl-tRNA synthetase from Pyrococcus abyssi: I11BIF, F42W, Y79A, and F123Y mutant
4S03	;	2.05	;	Biphenylalanine modified threonyl-tRNA synthetase from Pyrococcus abyssi: I11BIF, Y79I, and F123A mutant
4S0L	;	2.5	;	Biphenylalanine modified threonyl-tRNA synthetase from Pyrococcus abyssi: I11BIF, Y79V, and F123V mutant
2LJE	;		;	Biphosphorylated (747pY, 759pY) beta3 integrin cytoplasmic tail under membrane mimetic conditions
5O6T	;	1.57	;	BIRC4 RING in complex with dimeric ubiquitin variant
1B6F	;		;	BIRCH POLLEN ALLERGEN BET V 1
1BV1	;	2.0	;	BIRCH POLLEN ALLERGEN BET V 1
1LLT	;	3.1	;	BIRCH POLLEN ALLERGEN BET V 1 MUTANT E45S
1QMR	;	2.15	;	BIRCH POLLEN ALLERGEN BET V 1 MUTANT N28T, K32Q, E45S, P108G
1CQA	;	2.4	;	BIRCH POLLEN PROFILIN
1A49	;	2.1	;	BIS MG-ATP-K-OXALATE COMPLEX OF PYRUVATE KINASE
4H0W	;	2.4	;	Bismuth bound human serum transferrin
3RA7	;	2.798	;	Bispecific digoxigenin binding antibodies for targeted payload delivery
2ZO3	;	1.7	;	Bisphenylic Thrombin Inhibitors
3DHK	;	1.73	;	Bisphenylic Thrombin Inhibitors
6XK1	;	1.7	;	Biuret Hydrolase (BiuH) from Rhodococcus sp. Mel C169S Apo form
6XJM	;	2.05	;	Biuret Hydrolase (BiuH) from Rhodococcus sp. Mel C169S bound with biuret
1MNB	;		;	BIV TAT PEPTIDE (RESIDUES 68-81), NMR, MINIMIZED AVERAGE STRUCTURE
5JWM	;	1.71	;	Bivalent BET Bromodomain Inhibition
5AD2	;	2.01	;	Bivalent binding to BET bromodomains
5AD3	;	1.49	;	Bivalent binding to BET bromodomains
6FIC	;	2.18	;	Bivalent Inhibitor UNC4512 Bound to the TAF1 Bromodomain Tandem
4MGS	;	1.8	;	BiXyn10A CBM1 APO
4QPW	;	1.14	;	BiXyn10A CBM1 with Xylohexaose Bound
2VV6	;	1.5	;	BJFIXLH IN FERRIC FORM
1XJ3	;	1.9	;	bjFixLH in unliganded ferrous form
2VV7	;	1.81	;	BJFIXLH IN UNLIGANDED FERROUS FORM
8JTD	;	4.9	;	BJOX2000.664 trimer in complex with Fab fragment of broadly neutralizing HIV antibody PGT145
6ESB	;	3.4	;	BK polyomavirus + 20 mM GT1b oligosaccharide
7ZIQ	;	1.9	;	BK Polyomavirus VP1 in complex with 6'-Sialyllactose glycomacromolecules (aromatic linker)
7PA7	;	2.6	;	BK polyomavirus VP1 in complex with scFv 29B1
8AGH	;	1.887	;	BK Polyomavirus VP1 mutant E73A
8AGO	;	1.853	;	BK Polyomavirus VP1 mutant E73Q
8AH1	;	2.006	;	BK Polyomavirus VP1 mutant N-Q
8AH0	;	1.798	;	BK Polyomavirus VP1 mutant VQQ
7B6A	;	1.44	;	BK Polyomavirus VP1 pentamer core (residues 30-299)
7B69	;	1.474	;	BK Polyomavirus VP1 pentamer core(residues 26-299) mutant C104S
7B6C	;	2.484	;	BK Polyomavirus VP1 pentamer fusion with long C-terminal extended arm
4MJ0	;	1.7	;	BK Polyomavirus VP1 pentamer in complex with GD3 oligosaccharide
1JXP	;	2.2	;	BK STRAIN HEPATITIS C VIRUS (HCV) NS3-NS4A
4X6B	;	2.1	;	BK6 TCR apo structure
4EBN	;	2.85	;	BlaC Amoxicillin Acyl-Intermediate Complex
3VFH	;	2.57	;	BlaC E166A CDC-1 Acyl-Intermediate
3VFF	;	2.777	;	BlaC E166A CDC-OMe Acyl-Intermediate Complex
4EBP	;	2.29	;	BlaC E166A Cefotaxime Acyl-Intermediate Complex
4EBL	;	2.1	;	BlaC E166A Faropenem Acyl-Intermediate Complex
3QM9	;	0.91	;	Blackfin tuna azido-myoglobin, atomic resolution
3QM7	;	0.96	;	Blackfin tuna carbonmonoxy-myoglobin, atomic resolution
3QM8	;	0.91	;	Blackfin tuna cyanomet-myoglobin, atomic resolution
3QM6	;	0.91	;	Blackfin tuna deoxy-myoglobin, atomic resolution
2NRL	;	0.91	;	Blackfin tuna myoglobin
3QMA	;	0.94	;	Blackfin tuna myoglobin imidazole complex, atomic resolution
3QM5	;	0.91	;	Blackfin tuna oxy-myoglobin, atomic resolution
3UY6	;	2.1	;	BlaR1 sensor domain from Staphylococcus aureus with N439V mutation
8H49	;	2.0	;	Blasnase-M57P
8H44	;	1.8	;	Blasnase-P55N
7C8Q	;	1.89	;	Blasnase-T13A with D-asn
7C91	;	1.98	;	Blasnase-T13A with D-asn
7CBR	;	1.8	;	Blasnase-T13A with D-asn
7CBW	;	1.978	;	Blasnase-T13A with D-asn
7C8X	;	1.994	;	Blasnase-T13A with L-asn
7CBU	;	2.25	;	Blasnase-T13A with L-Asp
8H4D	;	1.9	;	Blasnase-T13A/M57N
8H4G	;	1.81	;	Blasnase-T13A/M57N
8H4A	;	1.9	;	Blasnase-T13A/M57P
8H4C	;	1.6	;	Blasnase-T13A/M57P
8H4B	;	2.0	;	Blasnase-T13A/M57P with L-asn
8H47	;	1.9	;	Blasnase-T13A/P55F
8H4F	;	1.9	;	Blasnase-T13A/P55F with D-asn
8H48	;	1.8	;	Blasnase-T13A/P55F with L-asn
8H45	;	1.97	;	Blasnase-T13A/P55N
8H4E	;	2.06	;	Blasnase-T13A/P55N with D-asn
8H46	;	1.8	;	Blasnase-T13A/P55N with L-asn
5M7K	;	3.5	;	Blastochloris viridis photosynthetic reaction center - RC_vir_xfel
5M7J	;	3.5	;	Blastochloris viridis photosynthetic reaction center structure using best crystal approach
5M7L	;	3.6	;	Blastochloris viridis photosynthetic reaction center synchrotron structure
4OAY	;	1.95	;	BldD CTD-c-di-GMP complex
4OAZ	;	2.25	;	BldD CTD-c-di-GMP complex
2VZ3	;	1.9	;	bleached galactose oxidase
1BYL	;	2.3	;	BLEOMYCIN RESISTANCE PROTEIN FROM STREPTOALLOTEICHUS HINDUSTANUS
2J9A	;	1.73	;	blLAP in Complex with Microginin FR1
6I5R	;	1.6	;	BlMnBP1 binding protein of an ABC transporter from Bifidobacterium animalis subsp. lactis ATCC27673 in complex with mannobiose
6I5W	;	1.9	;	BlMnBP1 binding protein of an ABC transporter from Bifidobacterium animalis subsp. lactis ATCC27673 in complex with mannobiose
6I5V	;	2.01	;	BlMnBP1 binding protein of an ABC transporter from Bifidobacterium animalis subsp. lactis ATCC27673 in complex with mannotriose
5BKI	;	3.1	;	Blocker-free closed MthK channel in nanodisc
6NMR	;	2.42	;	Blocking Fab 119 anti-SIRP-alpha antibody in complex with SIRP-alpha Variant 1
6NMS	;	2.11	;	Blocking Fab 136 anti-SIRP-alpha antibody in complex with SIRP-alpha Variant 1
7KPG	;	2.27	;	Blocking Fab 25 anti-SIRP-alpha antibody in complex with SIRP-alpha Variant 1
4ZET	;	2.9	;	Blood dendritic cell antigen 2 (BDCA-2) complexed with GalGlcNAcMan
4ZES	;	1.65	;	Blood dendritic cell antigen 2 (BDCA-2) complexed with methyl-mannoside
5F7N	;	2.28	;	Blood group antigen binding adhesin BabA of Helicobacter pylori strain 17875 in complex with blood group A Lewis b pentasaccharide
5F7Y	;	2.44	;	Blood group antigen binding adhesin BabA of Helicobacter pylori strain 17875 in complex with blood group A type-1 hexasaccharide
5F7W	;	2.81	;	Blood group antigen binding adhesin BabA of Helicobacter pylori strain 17875 in complex with blood group B Lewis b heptasaccharide
5F7M	;	2.72	;	Blood group antigen binding adhesin BabA of Helicobacter pylori strain 17875 in complex with blood group H Lewis b hexasaccharide
5F7L	;	2.74	;	Blood group antigen binding adhesin BabA of Helicobacter pylori strain 17875 in complex with Nanobody Nb-ER14
5F7K	;	2.17	;	Blood group antigen binding adhesin BabA of Helicobacter pylori strain 17875 in complex with Nanobody Nb-ER19
5F97	;	2.62	;	Blood group antigen binding adhesin BabA of Helicobacter pylori strain A730 in complex with blood group A type 1 hexasaccharide
5F93	;	2.99	;	Blood group antigen binding adhesin BabA of Helicobacter pylori strain A730 in complex with blood group H Lewis b hexasaccharide
5F9A	;	2.44	;	Blood group antigen binding adhesin BabA of Helicobacter pylori strain P436 in complex with blood group H Lewis b hexasaccharide
5F9D	;	2.59	;	Blood group antigen binding adhesin BabA of Helicobacter pylori strain P436 in complex with Lewis b blood group B heptasaccharide
5F8R	;	2.44	;	Blood group antigen binding adhesin BabA of Helicobacter pylori strain S831 in complex with blood group H Lewis b hexasaccharide
5F8Q	;	2.59	;	Blood group antigen binding adhesin BabA of Helicobacter pylori strain S831 in complex with Nanobody Nb-ER19
5M7B	;	1.5	;	Blood group synthase AAGlyB in complex with UDP and cryoprotected with glycerol
5M7C	;	1.6	;	Blood group synthase AAGlyB in complex with UDP and cryoprotected with PEG 3350
5M7D	;	1.2	;	Blood group synthase AAGlyB in complex with UDP-Gal and cryoprotected with glycerol
6GX0	;	1.25	;	Blood group synthase AAGlyB in complex with UDP-Gal and cryoprotected with PEG 3350
6GX2	;	1.07	;	Blood group synthase AAGlyB in complex with UDP-GalNAc and cryoprotected with glycerol
6GX1	;	1.6	;	Blood group synthase AAGlyB in complex with UDP-GalNAc and cryoprotected with PEG 3350
5M79	;	1.3	;	Blood group synthase AAGlyB in complex with UMP and cryoprotected with glycerol
5M7A	;	1.304	;	Blood group synthase AAGlyB in complex with UMP and cryoprotected with PEG 3350
6GWY	;	1.4	;	Blood group synthase AAGlyB in its apo form cryoprotected with glycerol
6GWZ	;	1.65	;	Blood group synthase AAGlyB in its apo form cryoprotected with PEG 3350
2BYC	;	1.9	;	BlrB - a BLUF protein, dark state structure
2KB2	;		;	BlrP1 BLUF
6W6Z	;	1.71	;	BlsA ground state
6W72	;	1.76	;	BlsA photo-activated state
2ISK	;	2.1	;	BluB bound to flavin anion (charge transfer complex)
2ISJ	;	2.3	;	BluB bound to oxidized FMN
2ISL	;	2.9	;	BluB bound to reduced flavin (FMNH2) and molecular oxygen. (clear crystal form)
4ORN	;	1.71	;	Blue Fluorescent Protein mKalama1
2M7U	;		;	Blue Light-Absorbing State of TePixJ, an Active Cyanobacteriochrome Domain
1BFP	;	2.1	;	BLUE VARIANT OF GREEN FLUORESCENT PROTEIN
3IYK	;	7.0	;	Bluetongue virus structure reveals a sialic acid binding domain, amphipathic helices and a central coiled coil in the outer capsid proteins
2XZ3	;	1.95	;	BLV TM hairpin
1BMO	;	3.1	;	BM-40, FS/EC DOMAIN PAIR
3RPG	;	2.6485	;	Bmi1/Ring1b-UbcH5c complex structure
1BKT	;		;	BMKTX TOXIN FROM SCORPION BUTHUS MARTENSII KARSCH, NMR, 25 STRUCTURES
4IY9	;	2.1	;	Bmlp3 - C2 crystal form
4IY8	;	2.36	;	Bmlp3 - P21 crystal form
6BTO	;	2.05	;	BMP1 complexed with (2~{S})-2-[[(1~{R},3~{S},4~{S})-2-[(2~{R})-2-[2-(oxidanylamino)-2-oxidanylidene-ethyl]heptanoyl]-2-azabicyclo[2.2.1]heptan-3-yl]carbonylamino]-2-phenyl-ethanoic acid
6BTP	;	1.93	;	BMP1 complexed with a hydroxamate
6BTQ	;	1.75	;	BMP1 complexed with a hydroxamate - compound 2
6BSM	;	2.33	;	BMP1 complexed with a reverse hydroxamate - compound 4
6BTN	;	2.05	;	BMP1 complexed with a reverse hydroxymate - compound 1
6BSL	;	1.45	;	BMP1 complexed with a reverse hydroxymate - compound 22
8E3G	;	2.8	;	BMP2/GDF5 heterodimer
7YI6	;	2.28	;	bnAb 3D1 in complex with 6-mer HR1 peptide from HCoV-229E S protein
6KPP	;	2.74524	;	BNC105 in complex with tubulin
1Y64	;	3.05	;	Bni1p Formin Homology 2 Domain complexed with ATP-actin
1DKJ	;	2.0	;	BOBWHITE QUAIL LYSOZYME
1DKK	;	1.9	;	BOBWHITE QUAIL LYSOZYME WITH NITRATE
6SGA	;	3.1	;	Body domain of the mt-SSU assemblosome from Trypanosoma brucei
5GAP	;	3.6	;	Body region of the U4/U6.U5 tri-snRNP
2BW2	;		;	BofC from Bacillus subtilis
8DGE	;	1.89	;	BoGH13ASus from Bacteroides ovatus
8DL2	;	1.99	;	BoGH13ASus from Bacteroides ovatus bound to acarbose
8DL1	;	2.09	;	BoGH13ASus-E523Q from Bacteroides ovatus bound to maltoheptaose
1SI9	;	2.27	;	Boiling stable protein isolated from Populus tremula
4PUI	;	1.698	;	BolA domain of SufE1 from Arabidopsis thaliana
4PUG	;	1.998	;	BolA1 from Arabidopsis thaliana
6LGA	;	1.85	;	Bombyx mori GH13 sucrose hydrolase
6LGD	;	1.75	;	Bombyx mori GH13 sucrose hydrolase complexed with 1,4-dideoxy-1,4-imino-D-arabinitol
6LGC	;	1.9	;	Bombyx mori GH13 sucrose hydrolase complexed with 1-deoxynojirimycin
6LGE	;	1.75	;	Bombyx mori GH13 sucrose hydrolase complexed with acarbose
6LGB	;	1.7	;	Bombyx mori GH13 sucrose hydrolase complexed with glucose
6LGF	;	1.85	;	Bombyx mori GH13 sucrose hydrolase mutant D247N complexed with sucrose
6LGG	;	1.84	;	Bombyx mori GH13 sucrose hydrolase mutant E322Q complexed with sucrose
6LGH	;	1.7	;	Bombyx mori GH13 sucrose hydrolase mutant E322Q covalent intermediate
6LGI	;	1.6	;	Bombyx mori GH13 sucrose hydrolase mutant E322Q covalent intermediate complexed with fructose
7BWB	;	1.8	;	Bombyx mori GH32 beta-fructofuranosidase BmSUC1
7BWC	;	1.95	;	Bombyx mori GH32 beta-fructofuranosidase BmSUC1 mutant D63A in complex with sucrose
4PC4	;	1.8	;	Bombyx mori lipoprotein 6
4EFR	;	2.5	;	Bombyx mori lipoprotein 7 (crystal form II) at 2.50 A resolution
4EFQ	;	1.94	;	Bombyx mori lipoprotein 7 - platinum derivative at 1.94 A resolution
4EFP	;	1.33	;	Bombyx mori lipoprotein 7 isolated from its natural source at 1.33 A resolution
1DQE	;	1.8	;	BOMBYX MORI PHEROMONE BINDING PROTEIN
2P70	;	2.1	;	Bombyx mori pheromone binding protein bound to bell pepper odorant
2P71	;	2.006	;	Bombyx mori pheromone binding protein bound to iodohexadecane
8GH6	;	3.08	;	Bombyx mori R2 retrotransposon initiating target-primed reverse transcription
6KXK	;	2.5	;	BON1
6KXU	;	2.83	;	BON1
6KXT	;	1.25	;	BON1-C2B
3ONB	;	1.45	;	Bond breakage and relocation of a covalently bound bromine of IDD594 in a complex with hAR T113A mutant after extensive radiation dose
3ONC	;	1.06	;	Bond breakage and relocation of a covalently bound bromine of IDD594 in a complex with hAR T113A mutant after moderate radiation dose
3UNX	;	1.26	;	Bond length analysis of asp, glu and his residues in subtilisin Carlsberg at 1.26A resolution
4YTA	;	1.2	;	BOND LENGTH ANALYSIS OF ASP, GLU AND HIS RESIDUES IN TRYPSIN AT 1.2A RESOLUTION
4NY7	;	1.44	;	Bond length analysis of the PqqC Y175F mutant structure shows evidence for bound PQQ in the reduced form
6I99	;	2.001	;	Bone Marrow Tyrosine Kinase in Chromosome X in complex with a newly designed covalent inhibitor JS24
6SF1	;	2.8	;	Bone morphogenetic protein 10 (BMP10) complexed with extracellular domain of activin receptor-like kinase 1 (ALK1).
6SF3	;	2.30001	;	Bone morphogenetic protein 10 (BMP10) in complex with extracellular domain of activin receptor-like kinase 1 (ALK1) at 2.3 Angstrom
1BMP	;	2.8	;	BONE MORPHOGENETIC PROTEIN-7
1S3T	;	2.1	;	BORATE INHIBITED BACILLUS PASTEURII UREASE CRYSTAL STRUCTURE
5G17	;	1.51	;	Bordetella Alcaligenes HDAH (T101A) bound to 9,9,9-trifluoro-8,8- dihydroxy-N-phenylnonanamide.
5G1A	;	1.42	;	Bordetella Alcaligenes HDAH bound to PFSAHA
5G1B	;	1.7	;	Bordetella Alcaligenes HDAH native
1Y9U	;	1.39	;	Bordetella ferric binding protein
6RFM	;		;	Bordetella pertussis adenylate cyclase toxin transmembrane segment 411-490 in DPC micelles
6M9A	;	2.3	;	Bordetella pertussis globin coupled sensor regulatory domain (BpeGReg)
7RW6	;	2.55	;	BORF2-APOBEC3Bctd Complex
1LWV	;	2.3	;	Borohydride-trapped hOgg1 Intermediate Structure Co-Crystallized with 8-aminoguanine
1LWW	;	2.1	;	Borohydride-trapped hOgg1 Intermediate Structure Co-Crystallized with 8-bromoguanine
8PKH	;	3.35	;	Borrelia bacteriophage BB1 procapsid, fivefold-symmetrized outer shell
7MZT	;	4.07	;	Borrelia burgdorferi BBK32-C in complex with an autolytic fragment of human C1r at 4.1A
6SHU	;	1.43003	;	Borrelia burgdorferi BmpD nucleoside binding protein bound to adenosine
7U4C	;	2.28	;	Borrelia burgdorferi HtpG N-terminal domain (1-228) in complex with BX-2819
6J6B	;	1.901	;	Borrelia burgdorferi OspA via surface entropy reduction (form2)
6J6C	;	1.6	;	Borrelia burgdorferi OspA via surface entropy reduction (form3)
6J6D	;	1.9	;	Borrelia burgdorferi OspA via surface entropy reduction (form4)
6J6E	;	1.5	;	Borrelia burgdorferi OspA via surface entropy reduction (form5)
4ALY	;	2.4	;	Borrelia burgdorferi outer surface lipoprotein BBA64
4AXZ	;	2.09	;	Borrelia burgdorferi outer surface lipoprotein BBA73
7RPR	;	1.9	;	Borrelia miyamotoi FbpA complement inhibitory domain
7TAY	;	2.95	;	Bos Taurus Mitochondrial BC1 in complex with Pyramoxadone
6CFX	;	2.0	;	Bosea sp GapR solved in the presence of DNA
6CFY	;	2.4	;	Bosea sp Root 381 apo GapR structure
3VEK	;	2.63	;	Both Zn Fingers of GATA1 Bound to Palindromic DNA Recognition Site, P1 Crystal Form
3VD6	;	1.98	;	Both Zn Fingers of GATA1 Bound to Palindromic DNA Recognition Site, P21 Crystal Form
5TOS	;	2.35	;	Botrytis-induced kinase 1 (BIK1) from Arabidopsis thaliana
8PHS	;	2.82	;	Bottom cap of the Borrelia bacteriophage BB1 procapsid, fivefold-symmetrized outer shell
7Z48	;	4.0	;	Bottom part (C5) of bacteriophage SU10 capsid
8IXK	;	3.3	;	bottom segment of the bacteriophage M13 mini variant
8JWX	;	3.3	;	bottom segment of the bacteriophage M13 mini variant
5LHJ	;	1.76	;	Bottromycin maturation enzyme BotP
5LHK	;	2.32	;	Bottromycin maturation enzyme BotP in complex with Mn
2ISE	;	2.2	;	Botulinum Neurotoxin A Light Chain WT Crystal Form A
2ISG	;	2.0	;	Botulinum Neurotoxin A Light Chain WT Crystal Form B
2ISH	;	2.0	;	Botulinum Neurotoxin A Light Chain WT Crystal Form C
6F0O	;	1.6	;	Botulinum neurotoxin A3 Hc domain
6THY	;	1.75	;	Botulinum neurotoxin A3 Hc domain in complex with GD1a
7QPT	;	2.3	;	Botulinum neurotoxin A4 cell binding domain in complex with GD1a oligosaccharide
6F0P	;	1.34	;	Botulinum neurotoxin A4 Hc domain
7QPU	;	2.4	;	Botulinum neurotoxin A5 cell binding domain in complex with GM1b oligosaccharide
8ALP	;	1.5	;	Botulinum neurotoxin A6 cell binding domain crystal form II
6ZVM	;	1.8	;	Botulinum neurotoxin B2 binding domain in complex with GD1a
6ZVN	;	2.5	;	Botulinum neurotoxin B2 binding domain in complex with human synaptotagmin I
8BYP	;	3.12	;	Botulinum neurotoxin serotype X in complex with NTNH/X
8AGK	;	1.5	;	Botulinum neurotoxin subtype A6 cell binding domain in complex with GD1a ganglioside
1F82	;	2.2	;	BOTULINUM NEUROTOXIN TYPE B CATALYTIC DOMAIN
7T5F	;	2.6	;	Botulinum neurotoxin Type B Light Chain complexed with nanobodies JLJ-G3 and JNE-B10
3MPP	;	1.98	;	Botulinum Neurotoxin Type G Receptor Binding Domain
7KY2	;	2.78	;	Botulism Neurooxin Light Chain A app form
7KYF	;	2.33	;	Botulism Neurooxin Light Chain A app form
7KYH	;	2.91	;	Botulism Neurooxin Light Chain A app form
1BFZ	;		;	BOUND CONFORMATION OF N-TERMINAL CLEAVAGE PRODUCT PEPTIDE MIMIC (P1-P9 OF RELEASE SITE) WHILE BOUND TO HCMV PROTEASE AS DETERMINED BY TRANSFERRED NOESY EXPERIMENTS (P1-P5 SHOWN ONLY), NMR, 32 STRUCTURES
2O8Z	;		;	Bound Structure of CRF1 Extracellular Domain Antagonist
4OI0	;	2.2	;	bound to ssRNA dinucleotide GC, ADP, AlF4-, and Mg2+(transition state, data set I)
4OHZ	;	2.4	;	bound to ssRNA tetranucleotide GAAA, ADP, and Mg2+
1VFA	;	1.8	;	BOUND WATER MOLECULES AND CONFORMATIONAL STABILIZATION HELP MEDIATE AN ANTIGEN-ANTIBODY ASSOCIATION
1VFB	;	1.8	;	BOUND WATER MOLECULES AND CONFORMATIONAL STABILIZATION HELP MEDIATE AN ANTIGEN-ANTIBODY ASSOCIATION
7WQG	;	2.5	;	Bovin Alpha-lactalbumin binding with zinc ions
7WQL	;	2.001	;	Bovin Beta-lactoglobulin binding with zinc ions
4BS3	;	2.301	;	Bovin insulin structure determined by in situ crystal analysis and sulfur-SAD phasing at room temperature
7DR7	;	3.3	;	bovine 20S immunoproteasome
7DRW	;	4.2	;	Bovine 20S immunoproteasome in complex with two human PA28alpha-beta activators
8AZK	;	3.1	;	Bovine 20S proteasome, untreated
2X24	;	2.4	;	bovine ACC2 CT domain in complex with inhibitor
1AYF	;	1.85	;	BOVINE ADRENODOXIN (OXIDIZED)
4WFV	;	1.4	;	Bovine allergen Bos d 2 in the monoclinic space group C2.
4WFU	;	1.75	;	Bovine allergen Bos d 2 in the trigonal space group P3221.
4Q2K	;	2.2	;	Bovine alpha chymotrypsin bound to a cyclic peptide inhibitor, 5b
1MTN	;	2.8	;	BOVINE ALPHA-CHYMOTRYPSIN:BPTI CRYSTALLIZATION
3L1F	;	1.53	;	Bovine AlphaA crystallin
3L1E	;	1.15	;	Bovine AlphaA crystallin Zinc Bound
1AVC	;	2.9	;	BOVINE ANNEXIN VI (CALCIUM-BOUND)
7AJB	;	9.2	;	bovine ATP synthase dimer state1:state1
7AJC	;	11.9	;	bovine ATP synthase dimer state1:state2
7AJD	;	9.0	;	bovine ATP synthase dimer state1:state3
7AJE	;	9.4	;	bovine ATP synthase dimer state2:state1
7AJF	;	8.45	;	bovine ATP synthase dimer state2:state2
7AJG	;	10.7	;	bovine ATP synthase dimer state2:state3
7AJH	;	9.7	;	bovine ATP synthase dimer state3:state1
7AJI	;	11.4	;	bovine ATP synthase dimer state3:state2
7AJJ	;	13.1	;	bovine ATP synthase dimer state3:state3
6YY0	;	3.23	;	bovine ATP synthase F1-peripheral stalk domain, state 1
6Z1R	;	3.29	;	bovine ATP synthase F1-peripheral stalk domain, state 2
6Z1U	;	3.47	;	bovine ATP synthase F1c8-peripheral stalk domain, state 3
6ZBB	;	3.61	;	bovine ATP synthase Fo domain
6ZPO	;	4.0	;	bovine ATP synthase monomer state 1 (combined)
6ZQM	;	3.29	;	bovine ATP synthase monomer state 2 (combined)
6ZQN	;	4.0	;	bovine ATP synthase monomer state 3 (combined)
6ZG8	;	3.49	;	bovine ATP synthase rotor domain state 2
6ZG7	;	3.49	;	bovine ATP synthase rotor domain, state 1
6ZIK	;	3.66	;	bovine ATP synthase rotor domain, state 3
6ZIQ	;	4.33	;	bovine ATP synthase stator domain, state 1
6ZIT	;	3.49	;	bovine ATP synthase Stator domain, state 2
6ZIU	;	6.02	;	bovine ATP synthase stator domain, state 3
3PH5	;	2.4	;	Bovine beta lactoglobulin crystallized through ligandation of yttrium cations
3PH6	;	2.53	;	Bovine beta lactoglobulin crytsallized through ligandation of yttrium
3NPO	;	2.2	;	Bovine beta lactoglobulin unliganded form
4IB8	;	2.3	;	Bovine beta-lactoglobulin (isoform A) in complex with dodecyl sulphate (SDS)
4IB7	;	2.2	;	Bovine beta-lactoglobulin (isoform A) in complex with dodecyltrimethylammonium (DTAC)
4IB6	;	2.2	;	Bovine beta-lactoglobulin (isoform A) in complex with lauric acid (C12)
4IBA	;	2.3	;	Bovine beta-lactoglobulin (isoform B) in complex with dodecyl sulphate (SDS)
4IB9	;	2.2	;	Bovine beta-lactoglobulin (isoform B) in complex with dodecyltrimethylammonium (DTAC)
1CJ5	;		;	BOVINE BETA-LACTOGLOBULIN A
3NQ3	;	1.9	;	Bovine beta-lactoglobulin complex with capric acid
3NQ9	;	1.9	;	Bovine beta-lactoglobulin complex with caprylic acid
5IO7	;	2.85	;	Bovine beta-lactoglobulin complex with dodecane at high pressure (0.43 GPa)
5IO6	;	2.851	;	Bovine beta-lactoglobulin complex with dodecane, ambient pressure
4GNY	;	1.6367	;	Bovine beta-lactoglobulin complex with dodecyl sulfate
3UEU	;	2.1	;	Bovine beta-lactoglobulin complex with lauric acid
4DQ4	;	2.1	;	Bovine beta-lactoglobulin complex with linoleic acid
3UEV	;	1.9	;	Bovine beta-lactoglobulin complex with myristic acid
5LKF	;	2.5	;	Bovine beta-lactoglobulin complex with myristic acid at high pressure (0.55 GPa)
5LKE	;	2.8	;	Bovine beta-lactoglobulin complex with myristic acid, ambient pressure
4DQ3	;	2.1	;	Bovine beta-lactoglobulin complex with oleic acid
3UEW	;	2.0	;	Bovine beta-lactoglobulin complex with palmitic acid
4Y0R	;	2.3	;	Bovine beta-lactoglobulin complex with pramocaine crystallized from ammonium sulphate (BLG-PRM2)
4Y0Q	;	2.0	;	Bovine beta-lactoglobulin complex with pramocaine crystallized from sodium citrate (BLG-PRM1)
3UEX	;	2.1	;	Bovine beta-lactoglobulin complex with stearic acid
4Y0P	;	2.2	;	Bovine beta-lactoglobulin complex with tetracaine (BLG-TET)
1B0O	;	2.5	;	BOVINE BETA-LACTOGLOBULIN COMPLEXED WITH PALMITATE, LATTICE Z
1GX9	;	2.34	;	BOVINE BETA-LACTOGLOBULIN COMPLEXED WITH RETINOIC ACID, TRIGONAL LATTICE Z
1GXA	;	2.35	;	BOVINE BETA-LACTOGLOBULIN COMPLEXED WITH RETINOL AND PALMITIC ACID, TRIGONAL LATTICE Z
1GX8	;	2.4	;	BOVINE BETA-LACTOGLOBULIN COMPLEXED WITH RETINOL, TRIGONAL LATTICE Z
4LZU	;	2.4	;	Bovine beta-lactoglobulin crystallized in the presence of 2 mM zinc chloride
4LZV	;	2.44	;	Bovine beta-lactoglobulin crystallized in the presence of 20 mM zinc chloride
6FXB	;	2.0	;	Bovine beta-lactoglobulin variant A at pH 4.0
1BEB	;	1.8	;	BOVINE BETA-LACTOGLOBULIN, LATTICE X
1G3D	;	1.8	;	BOVINE BETA-TRYPSIN BOUND TO META-AMIDINO SCHIFF BASE COPPER (II) CHELATE
1G3B	;	1.8	;	BOVINE BETA-TRYPSIN BOUND TO META-AMIDINO SCHIFF BASE MAGNESIUM(II) CHELATE
3AAV	;	1.7	;	Bovine beta-trypsin bound to meta-diamidino schiff base copper (II) chelate
3AAU	;	1.8	;	Bovine beta-trypsin bound to meta-diguanidino schiff base copper (II) chelate
3AAS	;	1.75	;	Bovine beta-trypsin bound to meta-guanidino schiff base copper (II) chelate
1G3C	;	1.8	;	BOVINE BETA-TRYPSIN BOUND TO PARA-AMIDINO SCHIFF BASE IRON(III) CHELATE
1G3E	;	1.8	;	BOVINE BETA-TRYPSIN BOUND TO PARA-AMIDINO SCHIFF-BASE COPPER (II) CHELATE
1IG5	;	1.5	;	BOVINE CALBINDIN D9K BINDING MG2+
1IGV	;	1.85	;	BOVINE CALBINDIN D9K BINDING MN2+
6X5Z	;	4.24	;	Bovine Cardiac Myosin in Complex with Chicken Skeletal Actin and Human Cardiac Tropomyosin in the Rigor State
4AA8	;	1.801	;	Bovine chymosin at 1.8A resolution
4AUC	;	1.6	;	Bovine chymosin in complex with Pepstatin A
1CA0	;	2.1	;	BOVINE CHYMOTRYPSIN COMPLEXED TO APPI
1CBW	;	2.6	;	BOVINE CHYMOTRYPSIN COMPLEXED TO BPTI
2CGA	;	1.8	;	BOVINE CHYMOTRYPSINOGEN A. X-RAY CRYSTAL STRUCTURE ANALYSIS AND REFINEMENT OF A NEW CRYSTAL FORM AT 1.8 ANGSTROMS RESOLUTION
7QSL	;	2.76	;	Bovine complex I in lipid nanodisc, Active-apo
7QSK	;	2.84	;	Bovine complex I in lipid nanodisc, Active-Q10
7QSN	;	2.81	;	Bovine complex I in lipid nanodisc, Deactive-apo
7QSM	;	2.3	;	Bovine complex I in lipid nanodisc, Deactive-ligand (composite)
7QSO	;	3.02	;	Bovine complex I in lipid nanodisc, State 3 (Slack)
7QSD	;	3.1	;	Bovine complex I in the active state at 3.1 A
7R41	;	2.3	;	Bovine complex I in the presence of IM1761092, active class i (Composite map)
7R42	;	2.3	;	Bovine complex I in the presence of IM1761092, active class ii (Composite map)
7R43	;	2.4	;	Bovine complex I in the presence of IM1761092, active class iii (Composite map)
7R44	;	2.4	;	Bovine complex I in the presence of IM1761092, active class iv (Composite map)
7R45	;	2.4	;	Bovine complex I in the presence of IM1761092, deactive class i (Composite map)
7R46	;	2.4	;	Bovine complex I in the presence of IM1761092, deactive class ii (Composite map)
7R47	;	2.3	;	Bovine complex I in the presence of IM1761092, deactive class iii (Composite map)
7R48	;	2.3	;	Bovine complex I in the presence of IM1761092, deactive class iv (Composite map)
7R4C	;	2.3	;	Bovine complex I in the presence of IM1761092, deactive class v (Composite map)
7R4D	;	2.3	;	Bovine complex I in the presence of IM1761092, deactive class vi (Composite map)
7R4F	;	2.4	;	Bovine complex I in the presence of IM1761092, slack class i (Composite map)
7R4G	;	2.5	;	Bovine complex I in the presence of IM1761092, slack class ii (Composite map)
1VIN	;	2.0	;	BOVINE CYCLIN A3
1IHG	;	1.8	;	Bovine Cyclophilin 40, monoclinic form
1IIP	;	2.0	;	Bovine Cyclophilin 40, Tetragonal Form
1CYO	;	1.5	;	BOVINE CYTOCHROME B(5)
1PPJ	;	2.1	;	Bovine cytochrome bc1 complex with stigmatellin and antimycin
1PP9	;	2.1	;	Bovine cytochrome bc1 complex with stigmatellin bound
2A06	;	2.1	;	Bovine cytochrome bc1 complex with stigmatellin bound
7W3E	;	1.45	;	Bovine cytochrome c oxidese in CN-bound fully reduced state at 50 K
7VVR	;	1.65	;	Bovine cytochrome c oxidese in CN-bound mixed valence state at 50 K
1PID	;	1.3	;	BOVINE DESPENTAPEPTIDE INSULIN
1EUF	;	2.4	;	BOVINE DUODENASE(NEW SERINE PROTEASE), CRYSTAL STRUCTURE
1NSE	;	1.9	;	BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE
1DM8	;	2.25	;	BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH 1,2,4-TRIAZOLE-CARBOXAMIDINE (H4B BOUND)
1D1Y	;	2.2	;	BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH 1,3-PBITU (H4B FREE)
1D1X	;	2.0	;	BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH 1,4-PBITU (H4B BOUND)
1FOI	;	1.93	;	BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH 1400W(H4B-FREE)
1D1W	;	2.0	;	BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH 2-AMINOTHIAZOLINE (H4B BOUND)
1D0C	;	1.65	;	BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH 3-BROMO-7-NITROINDAZOLE (H4B FREE)
1D0O	;	1.95	;	BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH 3-BROMO-7-NITROINDAZOLE (H4B PRESENT)
1DMK	;	1.9	;	BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH 4-AMINO-6-PHENYL-TETRAHYDROPTERIDINE
1DMJ	;	2.35	;	BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH 5,6-CYCLIC-TETRAHYDROPTERIDINE
1DMI	;	2.0	;	BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH 6S-H4B
1FOJ	;	2.1	;	BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH 7-NITROINDAZOLE-2-CARBOXAMIDINE (H4B PRESENT)
1DM7	;	2.1	;	BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH HOMOARGININE (H4B FREE)
1ED4	;	1.86	;	BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH IPITU (H4B FREE)
1FOP	;	2.3	;	BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH L-ARG AND NO(H4B-BOUND)
1FOO	;	2.0	;	BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH L-ARG AND NO(H4B-FREE)
1ED6	;	2.05	;	BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH L-NIO (H4B FREE)
1DM6	;	1.95	;	BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH N-(4-CHLOROPHENYL)-N'-HYDROXYGUANIDINE (H4B FREE)
1I83	;	2.0	;	BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH N1,N14-BIS((S-METHYL)ISOTHIOUREIDO)TETRADECANE (H4B FREE)
1ED5	;	1.8	;	BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH NNA(H4B FREE)
1D1V	;	1.93	;	BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH S-ETHYL-N-PHENYL-ISOTHIOUREA (H4B BOUND)
1Q2O	;	1.74	;	Bovine endothelial nitric oxide synthase N368D mutant heme domain dimer with L-N(omega)-nitroarginine-2,4-L-diaminobutyramide bound
2NSE	;	2.34	;	BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE SUBSTRATE COMPLEX
9NSE	;	2.24	;	BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE, ETHYL-ISOSELENOUREA COMPLEX
7NSE	;	2.35	;	BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE, H4B-FREE, ADMA COMPLEX
6NSE	;	2.35	;	BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE, H4B-FREE, CANAVANINE COMPLEX
5NSE	;	1.9	;	BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE, H4B-FREE, HYDROXY-ARG COMPLEX
4NSE	;	1.95	;	BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE, H4B-FREE, L-ARG COMPLEX
8NSE	;	2.25	;	BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE, NNA COMPLEX
1P6M	;	2.27	;	Bovine endothelial NOS heme domain with (4S)-N-(4-amino-5-[aminoethyl]aminopentyl)-N'-nitroguanidine bound
1RS8	;	2.3	;	Bovine endothelial NOS heme domain with D-lysine-D-nitroarginine amide bound
1RS9	;	2.22	;	Bovine endothelial NOS heme domain with D-phenylalanine-D-nitroarginine amide bound
1P6N	;	2.5	;	Bovine endothelial NOS heme domain with L-N(omega)-nitroarginine-(4R)-amino-L-proline amide bound
1P6L	;	2.35	;	Bovine endothelial NOS heme domain with L-N(omega)-nitroarginine-2,4-L-diaminobutyric amide bound
2HX2	;	1.95	;	Bovine eNOS heme domain complexed with (4S)-N-{4-Amino-5-[(2-aminoethyl)-hydroxyamino]-pentyl}-N'-nitroguanidine
1ZZS	;	1.85	;	Bovine eNOS N368D single mutant with L-N(omega)-Nitroarginine-(4R)-Amino-L-Proline Amide Bound
1ZZT	;	2.14	;	Bovine eNOS N368D/V106M double mutant with L-N(omega)-Nitroarginine-(4R)-Amino-L-Proline Amide Bound
3NSE	;	2.1	;	BOVINE ENOS, H4B-FREE, SEITU COMPLEX
6T40	;	1.67	;	Bovine enterovirus F3 in complex with a Cysteinylglycine dipeptide
6T4C	;	1.8	;	Bovine enterovirus F3 in complex with glutathione
6T48	;	2.17	;	Bovine enterovirus F3 in complex with glutathione and a Cysteinylglycine dipeptide
1BEV	;	3.0	;	BOVINE ENTEROVIRUS VG-5-27
1E79	;	2.4	;	Bovine F1-ATPase inhibited by DCCD (dicyclohexylcarbodiimide)
4Z1M	;	3.3	;	Bovine F1-ATPase inhibited by three copies of the inhibitor protein IF1 crystallised in the presence of thiophosphate.
8ECV	;	1.81	;	Bovine Fab 2F12
8ECQ	;	2.0	;	Bovine Fab 2G3
8ECZ	;	2.82	;	Bovine Fab 4C1
8ED1	;	2.31	;	Bovine Fab 5C1
5E99	;	2.06	;	Bovine Fab fragment F08_B11
8EDF	;	3.4	;	Bovine Fab SKD in complex with Sars COV-2 receptor binding domain
1KIG	;	3.0	;	BOVINE FACTOR XA
2BAF	;		;	Bovine Fibrinogen alpha-C Domain
4WBO	;	2.81	;	Bovine G Protein Coupled Receptor Kinase 1 in Complex with Amlexanox
4L9I	;	2.32	;	Bovine G Protein Coupled Receptor Kinase 1 in Complex with Paroxetine
4PNI	;	1.85	;	Bovine G protein-coupled receptor kinase 1 in complex with GSK2163632A
6DHK	;	3.5	;	Bovine glutamate dehydrogenase complexed with ADP
6DHL	;	3.624	;	Bovine glutamate dehydrogenase complexed with epicatechin-3-gallate (ECG)
6DHN	;	3.3	;	Bovine glutamate dehydrogenase complexed with Eu3+
1HWY	;	3.2	;	BOVINE GLUTAMATE DEHYDROGENASE COMPLEXED WITH NAD AND 2-OXOGLUTARATE
6DHD	;	2.5	;	Bovine glutamate dehydrogenase complexed with NADH, GTP, glutamate
6DHQ	;	2.3	;	Bovine glutamate dehydrogenase complexed with NADPH, glutamate, and GTP
6DHM	;	3.0	;	Bovine glutamate dehydrogenase complexed with zinc
8AR8	;	2.4	;	Bovine glutamate dehydrogenase in complex with ADP at 2.4 A resolution
8AR7	;	2.448	;	Bovine glutamate dehydrogenase in ternary complex with the allosteric activators ADP and leucine
7PK1	;	1.65	;	Bovine Glycine N-Acyltransferase
7PK2	;	1.25	;	Bovine Glycine N-Acyltransferase
7PK0	;	1.5	;	Bovine Glycine N-Acyltransferase complexed with Benzoyl-CoA
3PSC	;	2.67	;	Bovine GRK2 in complex with Gbetagamma subunits
3PVU	;	2.48	;	Bovine GRK2 in complex with Gbetagamma subunits and a selective kinase inhibitor (CMPD101)
3PVW	;	2.49	;	Bovine GRK2 in complex with Gbetagamma subunits and a selective kinase inhibitor (CMPD103A)
5HE0	;	2.56	;	Bovine GRK2 in complex with Gbetagamma subunits and CCG215022
5HE2	;	2.79	;	Bovine GRK2 in complex with Gbetagamma subunits and CCG224406
5HE3	;	2.74	;	Bovine GRK2 in complex with Gbetagamma subunits and CCG224411
5UKM	;	3.03	;	bovine GRK2 in complex with human Gbetagamma subunits and CCG258208 (14as)
3KLR	;	0.88	;	Bovine H-protein at 0.88 angstrom resolution
5HR5	;	1.82	;	Bovine Heart 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase (PFKFB2)
5COD	;	6.74	;	Bovine heart complex I membrane domain
1V54	;	1.8	;	Bovine heart cytochrome c oxidase at the fully oxidized state
2DYR	;	1.8	;	Bovine heart cytochrome C oxidase at the fully oxidized state
2OCC	;	2.3	;	BOVINE HEART CYTOCHROME C OXIDASE AT THE FULLY OXIDIZED STATE
2ZXW	;	2.5	;	Bovine heart cytochrome c oxidase at the fully oxidized state (1-s X-ray exposure dataset)
3ABL	;	2.1	;	Bovine heart cytochrome c oxidase at the fully oxidized state (15-s X-ray exposure dataset)
3ABM	;	1.95	;	Bovine heart cytochrome c oxidase at the fully oxidized state (200-s X-ray exposure dataset)
1V55	;	1.9	;	Bovine heart cytochrome c oxidase at the fully reduced state
3ABK	;	2.0	;	Bovine heart cytochrome c oxidase at the NO-bound fully reduced state (50K)
7CP5	;	1.76	;	Bovine heart cytochrome c oxidase in a catalytic intermediate of E at 1.76 angstrom resolution
7D5W	;	1.84	;	Bovine heart cytochrome c oxidase in a catalytic intermediate of O at 1.84 angstrom resolution
7D5X	;	1.74	;	Bovine heart cytochrome c oxidase in a catalytic intermediate, IO10, at 1.74 angstrom resolution
1OCZ	;	2.9	;	BOVINE HEART CYTOCHROME C OXIDASE IN AZIDE-BOUND STATE
1OCO	;	2.8	;	BOVINE HEART CYTOCHROME C OXIDASE IN CARBON MONOXIDE-BOUND STATE
6JUW	;	1.8	;	BOVINE HEART CYTOCHROME C OXIDASE IN CATALITIC INTERMEDIATES AT 1.80 ANGSTROM RESOLUTION
7YPY	;	1.5	;	Bovine heart cytochrome c oxidase in fully oxidized state at 1.5 angstrom resolution
8H8R	;	1.7	;	Bovine Heart Cytochrome c Oxidase in the Calcium-bound Fully Oxidized State
8H8S	;	1.7	;	Bovine Heart Cytochrome c Oxidase in the Calcium-bound Fully Reduced State
3AG2	;	1.802	;	Bovine Heart Cytochrome c Oxidase in the Carbon Monoxide-bound Fully Reduced State at 100 K
3AG1	;	2.2	;	Bovine Heart Cytochrome c Oxidase in the Carbon Monoxide-bound Fully Reduced State at 280 K
7EV7	;	1.7	;	Bovine heart cytochrome c oxidase in the carbon monoxide-bound fully reduced state at a 50 K
5B3S	;	1.68	;	Bovine heart cytochrome c oxidase in the carbon monoxide-bound mixed-valence state at 1.68 angstrom resolution (50 K)
3AG4	;	2.05	;	Bovine Heart Cytochrome c Oxidase in the Cyanide Ion-bound Fully Reduced State at 100 K
7VUW	;	1.6	;	Bovine heart cytochrome c oxidase in the cyanide-bound fully oxidized state at 50 K
5B1A	;	1.5	;	Bovine heart cytochrome c oxidase in the fully oxidized state at 1.5 angstrom resolution
3ASO	;	2.3	;	Bovine heart cytochrome C oxidase in the fully oxidized state measured at 0.9 angstrom wavelength
3ASN	;	3.0	;	Bovine heart cytochrome C oxidase in the fully oxidized state measured at 1.7470 angstrom wavelength
5XDQ	;	1.77	;	Bovine heart cytochrome c oxidase in the fully oxidized state with pH 7.3 at 1.77 angstrom resolution
1OCR	;	2.35	;	BOVINE HEART CYTOCHROME C OXIDASE IN THE FULLY REDUCED STATE
2EIJ	;	1.9	;	Bovine heart cytochrome C oxidase in the fully reduced state
5B1B	;	1.6	;	Bovine heart cytochrome c oxidase in the fully reduced state at 1.6 angstrom resolution
3AG3	;	1.8	;	Bovine Heart Cytochrome c Oxidase in the Nitric Oxide-bound Fully Reduced State at 100 K
8IJN	;	1.8	;	Bovine Heart Cytochrome c Oxidase in the Nitric Oxide-Bound Fully Reduced State at 100 K
5XDX	;	1.99	;	Bovine heart cytochrome c oxidase in the reduced state with pH 7.3 at 1.99 angstrom resolution
2DYS	;	2.2	;	Bovine heart cytochrome C oxidase modified by DCCD
2Y69	;	1.95	;	Bovine heart cytochrome c oxidase re-refined with molecular oxygen
4YXW	;	3.1	;	Bovine heart mitochondrial F1-ATPase inhibited by AMP-PNP and ADP in the presence of thiophosphate.
2QSP	;	1.85	;	Bovine Hemoglobin at pH 5.7
2QSS	;	1.75	;	Bovine hemoglobin at pH 6.3
1BIV	;		;	BOVINE IMMUNODEFICIENCY VIRUS TAT-TAR COMPLEX, NMR, 5 STRUCTURES
6QQ7	;	1.65	;	Bovine insulin at ambient pressure
6Q8Q	;	2.0	;	Bovine Insulin under 2 kbar of argon
1D9C	;	2.0	;	BOVINE INTERFERON-GAMMA AT 2.0 ANGSTROMS
1D9G	;	2.9	;	BOVINE INTERFERON-GAMMA AT 2.9 ANGSTROMS
1LFC	;		;	BOVINE LACTOFERRICIN (LFCINB), NMR, 20 STRUCTURES
6T42	;	1.95	;	Bovine lactoglobulin complex with decanol
1LCP	;	1.65	;	BOVINE LENS LEUCINE AMINOPEPTIDASE COMPLEXED WITH L-LEUCINE PHOSPHONIC ACID
1BJ7	;	1.8	;	BOVINE LIPOCALIN ALLERGEN BOS D 2
1VDV	;	1.98	;	Bovine Milk Xanthine Dehydrogenase Y-700 Bound Form
5ARA	;	7.4	;	Bovine mitochondrial ATP synthase state 1a
5ARE	;	6.7	;	Bovine mitochondrial ATP synthase state 1b
5ARH	;	7.2	;	Bovine mitochondrial ATP synthase state 2a
5ARI	;	7.4	;	Bovine mitochondrial ATP synthase state 2b
5FIJ	;	7.4	;	Bovine mitochondrial ATP synthase state 2c
5FIK	;	6.4	;	Bovine mitochondrial ATP synthase state 3a
5FIL	;	7.1	;	Bovine mitochondrial ATP synthase state 3b
1BMF	;	2.85	;	BOVINE MITOCHONDRIAL F1-ATPASE
1E1Q	;	2.61	;	BOVINE MITOCHONDRIAL F1-ATPASE AT 100K
1COW	;	3.1	;	BOVINE MITOCHONDRIAL F1-ATPASE COMPLEXED WITH AUROVERTIN B
1OHH	;	2.8	;	BOVINE MITOCHONDRIAL F1-ATPASE complexed with the inhibitor protein IF1
1EFR	;	3.1	;	BOVINE MITOCHONDRIAL F1-ATPASE COMPLEXED WITH THE PEPTIDE ANTIBIOTIC EFRAPEPTIN
1H8H	;	2.9	;	Bovine mitochondrial F1-ATPase crystallised in the presence of 5mm AMPPNP
1E1R	;	2.5	;	BOVINE MITOCHONDRIAL F1-ATPASE INHIBITED BY MG2+ADP AND ALUMINIUM FLUORIDE
8F4B	;	3.27	;	Bovine multidrug resistance protein 1 (MRP1) bound to cyclic peptide inhibitor 1 (CPI1)
8SX7	;	2.7	;	Bovine multidrug resistance protein 4 (MRP4) bound to DHEA-S in MSP lipid nanodisc
8SX8	;	3.5	;	Bovine multidrug resistance protein 4 (MRP4) bound to prostaglandin E1 in MSP lipid nanodisc
8SXB	;	2.9	;	Bovine multidrug resistance protein 4 (MRP4) bound to prostaglandin E2 in MSP lipid nanodisc
8SWN	;	3.1	;	Bovine multidrug resistance protein 4 (MRP4) E1202Q mutant bound to ATP in MSP lipid nanodisc
8BS8	;	1.59	;	Bovine naive ultralong antibody AbD08 collected at 100K
8CIF	;	2.2	;	Bovine naive ultralong antibody AbD08 collected at 293K
1NPO	;	3.0	;	BOVINE NEUROPHYSIN II COMPLEX WITH OXYTOCIN
2HLV	;	1.65	;	Bovine Odorant Binding Protein deswapped triple mutant
2BO5	;		;	Bovine oligomycin sensitivity conferral protein N-terminal domain
1CE5	;	1.9	;	BOVINE PANCREAS BETA-TRYPSIN IN COMPLEX WITH BENZAMIDINE
2BZA	;	1.9	;	BOVINE PANCREAS BETA-TRYPSIN IN COMPLEX WITH BENZYLAMINE
1LJV	;		;	Bovine Pancreatic Polypeptide Bound to DPC Micelles
1C0B	;	1.9	;	BOVINE PANCREATIC RIBONUCLEASE A DESICCATED FOR 2.5 DAYS
1C0C	;	2.0	;	BOVINE PANCREATIC RIBONUCLEASE A DESICCATED FOR 4.0 DAYS
1S0R	;	1.02	;	Bovine Pancreatic Trypsin inhibited with Benzamidine at Atomic resolution
2ZJX	;	1.09	;	Bovine pancreatic trypsin inhibitor (BPTI) containing only the [5,55] disulfide bond
1QLQ	;	1.42	;	Bovine Pancreatic Trypsin Inhibitor (BPTI) Mutant with Altered Binding Loop Sequence
1BHC	;	2.7	;	BOVINE PANCREATIC TRYPSIN INHIBITOR CRYSTALLIZED FROM THIOCYANATE
7BS6	;	1.04	;	Bovine Pancreatic Trypsin with 2-Methyltryptamine (Cryo)
7BRZ	;	1.3	;	Bovine Pancreatic Trypsin with 2-Methyltryptamine (Room Temperature)
7BS3	;	1.28	;	Bovine Pancreatic Trypsin with 4-Bromo-benzamidine (Cryo)
7BRV	;	1.55	;	Bovine Pancreatic Trypsin with 4-Bromobenzamidine (Room Temperature)
7BSA	;	1.22	;	Bovine Pancreatic Trypsin with 5-Chlorotryptamine (Cryo)
7BRW	;	1.6	;	Bovine Pancreatic Trypsin with 5-chlorotryptamine (Room Temperature)
7BS4	;	1.04	;	Bovine Pancreatic Trypsin with 5-Methoxytryptamine (Cryo)
7BRX	;	1.35	;	Bovine Pancreatic Trypsin with 5-Methoxytryptamine (Room Temperature)
7BS5	;	1.17	;	Bovine Pancreatic Trypsin with 6-Methoxytryptamine (Cryo)
7BRY	;	1.65	;	Bovine Pancreatic Trypsin with 6-Methoxytryptamine (Room Temperature)
7BS7	;	1.04	;	Bovine Pancreatic Trypsin with aniline (Cryo)
7BS0	;	1.85	;	Bovine Pancreatic Trypsin with aniline (Room Temperature)
7BS8	;	1.37	;	Bovine Pancreatic Trypsin with Benzamidine (Cryo)
7BS1	;	1.5	;	Bovine Pancreatic Trypsin with benzamidine (Room Temperature)
7BS9	;	1.05	;	Bovine Pancreatic Trypsin with serotonin (Cryo)
7BS2	;	1.8	;	Bovine Pancreatic Trypsin with serotonin (Room Temperature)
7APD	;	3.9	;	Bovine Papillomavirus E1 DNA helicase-replication fork complex
3IYJ	;	4.2	;	Bovine papillomavirus type 1 outer capsid
4IJ9	;	2.55	;	Bovine PKA C-alpha in complex with 2-[[5-(4-pyridyl)-1H-1,2,4-triazol-3-yl]sulfanyl]-1-(2-thiophenyl)ethanone
4IE9	;	1.92	;	Bovine PKA C-alpha in complex with 3-pyridylmethyl-5-methyl-1H-pyrazole-3-carboxylate
1DWY	;		;	Bovine prion protein fragment 121-230
1DWZ	;		;	Bovine prion protein fragment 121-230
1DX0	;		;	BOVINE PRION PROTEIN RESIDUES 23-230
1DX1	;		;	BOVINE PRION PROTEIN RESIDUES 23-230
1NL2	;	2.3	;	BOVINE PROTHROMBIN FRAGMENT 1 IN COMPLEX WITH CALCIUM AND LYSOPHOSPHOTIDYLSERINE
1NL1	;	1.9	;	BOVINE PROTHROMBIN FRAGMENT 1 IN COMPLEX WITH CALCIUM ION
1A9P	;	2.4	;	BOVINE PURINE NUCLEOSIDE PHOSPHORYLASE COMPLEXED WITH 9-DEAZAINOSINE AND PHOSPHATE
1A9T	;	2.0	;	BOVINE PURINE NUCLEOSIDE PHOSPHORYLASE COMPLEXED WITH 9-DEAZAINOSINE AND PHOSPHATE
1A9R	;	2.0	;	BOVINE PURINE NUCLEOSIDE PHOSPHORYLASE COMPLEXED WITH HYPOXANTHINE AND SULFATE
1A9Q	;	2.0	;	BOVINE PURINE NUCLEOSIDE PHOSPHORYLASE COMPLEXED WITH INOSINE
1A9S	;	2.0	;	BOVINE PURINE NUCLEOSIDE PHOSPHORYLASE COMPLEXED WITH INOSINE AND SULFATE
1A9O	;	2.0	;	BOVINE PURINE NUCLEOSIDE PHOSPHORYLASE COMPLEXED WITH PHOSPHATE
1XPT	;	1.9	;	BOVINE RIBONUCLEASE A (PHOSPHATE-FREE)
1XPS	;	1.8	;	BOVINE RIBONUCLEASE A (PHOSPHATE-FREE) (93 % HUMIDITY)
5WD6	;	2.0	;	bovine salivary protein form 30b
6O1T	;	2.3	;	BOVINE SALIVARY PROTEIN FORM 30B WITH OLEIC ACID
1BSR	;	1.9	;	BOVINE SEMINAL RIBONUCLEASE STRUCTURE AT 1.9 ANGSTROMS RESOLUTION
3DJO	;	1.6	;	Bovine Seminal Ribonuclease uridine 2' phosphate complex
3DJV	;	1.6	;	Bovine Seminal Ribonuclease- cytidine 3' phosphate complex
3DJX	;	1.69	;	Bovine Seminal Ribonuclease- cytidine 5' phosphate complex
3DJP	;	1.6	;	Bovine Seminal Ribonuclease- Uridine 3' phosphate complex
3DJQ	;	1.53	;	Bovine Seminal Ribonuclease- Uridine 5' diphosphate complex
6QS9	;	2.802	;	Bovine Serum Albumin in complex with Ketoprofen
7MFI	;	2.81	;	Bovine sigma-2 receptor bound to cholesterol
7M93	;	2.94	;	Bovine sigma-2 receptor bound to PB28
7M94	;	2.71	;	Bovine sigma-2 receptor bound to Roluperidone
7M95	;	2.41	;	Bovine sigma-2 receptor bound to Z1241145220
7M96	;	2.41	;	Bovine sigma-2 receptor bound to Z4857158944
8OU0	;	3.5	;	bovine sperm endpiece singlet microtubules (one tubulin dimer and associated microtubule inner proteins)
1UVU	;	2.8	;	BOVINE THROMBIN--BM12.1700 COMPLEX
1UVT	;	2.5	;	BOVINE THROMBIN--BM14.1248 COMPLEX
1UVS	;	2.8	;	BOVINE THROMBIN--BM51.1011 COMPLEX
3D4U	;	1.7	;	Bovine thrombin-activatable fibrinolysis inhibitor (TAFIa) in complex with tick-derived carboxypeptidase inhibitor.
1QA0	;	1.8	;	BOVINE TRYPSIN 2-AMINOBENZIMIDAZOLE COMPLEX
1QBN	;	1.8	;	Bovine Trypsin 2-[amino(imino)methyl]-2-hydroxyphenoxy]-6-[3-(4,5-dihydro-1H-imidazol-2-yl)phenoxy]pyridine-4-carboxylic Acid (ZK-806688) Complex
1QB6	;	1.8	;	BOVINE TRYPSIN 3,3'-[3,5-DIFLUORO-4-METHYL-2, 6-PYRIDINEDIYLBIS(OXY)]BIS(BENZENECARBOXIMIDAMIDE) (ZK-805623) COMPLEX
1QB9	;	1.8	;	BOVINE TRYPSIN 7-[[2-[[1-(1-IMINOETHYL)PIPERIDIN-4-YL]OXY]-9H-CARBOZOL-9-YL] METHYL]NAPHTHALENE-2-CARBOXIMIDAMIDE (ZK-806450) COMPLEX
1QBO	;	1.8	;	BOVINE TRYPSIN 7-[[6-[[1-(1-IMINOETHYL)PIPERIDIN-4-YL]OXY]-2-METHYL-BENZIMIDAZOL-1-YL]METHYL]NAPHTHALENE-2-CARBOXIMIDAMID ZK-806711 INHIBITOR COMPLEX
4I8H	;	0.75	;	Bovine trypsin at 0.75 resolution
3MI4	;	0.8	;	Bovine trypsin at 0.8 A resolution, non-restrained refinement
3MFJ	;	0.8	;	Bovine trypsin at 0.8 A resolution, restrained refinement
4I8G	;	0.8	;	Bovine trypsin at 0.8 resolution
4I8K	;	0.85	;	Bovine trypsin at 0.85 resolution
4I8J	;	0.87	;	Bovine trypsin at 0.87 A resolution
4I8L	;	0.87	;	Bovine trypsin at 0.87 resolution
2FX4	;	1.65	;	Bovine trypsin bound by 4-piperidinebutyrate to make acylenzyme complex
6BFP	;	1.292	;	Bovine trypsin bound to potent inhibitor
7Q0W	;	1.2	;	Bovine Trypsin co-crystallized with V(IV)OSO4 and phen
7Q0X	;	1.09	;	Bovine Trypsin co-crystallized with V(IV)OSO4 and pic
1TAW	;	1.8	;	BOVINE TRYPSIN COMPLEXED TO APPI
1AZ8	;	1.8	;	BOVINE TRYPSIN COMPLEXED TO BIS-PHENYLAMIDINE INHIBITOR
1AUJ	;	2.1	;	BOVINE TRYPSIN COMPLEXED TO META-CYANO-BENZYLIC INHIBITOR
2FX6	;	1.57	;	bovine trypsin complexed with 2-aminobenzamidazole
1TX8	;	1.7	;	Bovine Trypsin complexed with AMSO
1TX7	;	1.75	;	Bovine Trypsin complexed with p-amidinophenylmethylphosphinic acid (AMPA)
1F0U	;	1.9	;	BOVINE TRYPSIN COMPLEXED WITH RPR128515
1F0T	;	1.8	;	BOVINE TRYPSIN COMPLEXED WITH RPR131247
5EG4	;	1.32	;	BOVINE TRYPSIN IN COMPLEX WITH CYCLIC INHIBITOR
8UO7	;	2.2	;	Bovine trypsin in complex with deacetylated wild type microviridin J
2XTT	;	0.93	;	Bovine trypsin in complex with evolutionary enhanced Schistocerca gregaria protease inhibitor 1 (SGPI-1-P02)
4KTU	;	1.35	;	Bovine trypsin in complex with microviridin J at pH 6.5
4KTS	;	1.3	;	Bovine trypsin in complex with microviridin J at pH 8.5
4MTB	;	1.22	;	Bovine trypsin in complex with small molecule inhibitor
2BTC	;	1.5	;	BOVINE TRYPSIN IN COMPLEX WITH SQUASH SEED INHIBITOR (CUCURBITA PEPO TRYPSIN INHIBITOR II)
6T9V	;	1.12643	;	Bovine Trypsin in complex with the synthetic inhibitor (S)-3-(3-(4-(3-(tert-butyl)ureido)piperidin-1-yl)-2-((3'-fluoro-4'-(hydroxymethyl)-[1,1'-biphenyl])-3-sulfonamido)-3-oxopropyl)benzimidamide (MI-1904)
8UTL	;	1.56	;	Bovine trypsin in complex with Thr3Dap mutated microviridin J
3LJJ	;	1.55	;	Bovine trypsin in complex with UB-THR 10
3LJO	;	1.5	;	Bovine trypsin in complex with UB-THR 11
5T3H	;	1.55	;	bovine trypsin soaked with selenourea for 5 min
6FID	;	2.2	;	Bovine trypsin solved by S-SAD on ID30B
3PWB	;	1.63	;	Bovine trypsin variant X(tripleGlu217Ile227) in complex with small molecule inhibitor
3PWC	;	1.6	;	Bovine trypsin variant X(tripleGlu217Ile227) in complex with small molecule inhibitor
3PYH	;	2.0	;	Bovine trypsin variant X(tripleGlu217Ile227) in complex with small molecule inhibitor
3Q00	;	1.7	;	Bovine trypsin variant X(tripleGlu217Ile227) in complex with small molecule inhibitor
3UWI	;	1.43	;	Bovine trypsin variant X(tripleGlu217Phe227) in complex with small molecule inhibitor
3UY9	;	3.22	;	Bovine trypsin variant X(tripleGlu217Phe227) in complex with small molecule inhibitor
3V0X	;	1.9	;	Bovine trypsin variant X(tripleGlu217Phe227) in complex with small molecule inhibitor
3V12	;	1.8	;	Bovine trypsin variant X(tripleGlu217Phe227) in complex with small molecule inhibitor
3V13	;	1.63	;	Bovine trypsin variant X(tripleGlu217Phe227) in complex with small molecule inhibitor
3PLB	;	1.18	;	Bovine trypsin variant X(tripleIle227) in complex with small molecule inhibitor
3PLK	;	1.53	;	Bovine trypsin variant X(tripleIle227) in complex with small molecule inhibitor
3PLP	;	1.63	;	Bovine trypsin variant X(tripleIle227) in complex with small molecule inhibitor
3PM3	;	1.53	;	Bovine trypsin variant X(tripleIle227) in complex with small molecule inhibitor
3PMJ	;	1.45	;	Bovine trypsin variant X(tripleIle227) in complex with small molecule inhibitor
3UNQ	;	1.62	;	Bovine trypsin variant X(triplePhe227) in complex with small molecule inhibitor
3UNS	;	1.8	;	Bovine trypsin variant X(triplePhe227) in complex with small molecule inhibitor
3UOP	;	1.69	;	Bovine trypsin variant X(triplePhe227) in complex with small molecule inhibitor
3UPE	;	1.54	;	Bovine trypsin variant X(triplePhe227) in complex with small molecule inhibitor
3UQO	;	1.8	;	Bovine trypsin variant X(triplePhe227) in complex with small molecule inhibitor
3UQV	;	2.4	;	Bovine trypsin variant X(triplePhe227) in complex with small molecule inhibitor
3UUZ	;	2.1	;	Bovine trypsin variant X(triplePhe227) in complex with small molecule inhibitor
1QB1	;	1.8	;	Bovine Trypsin with 1-[2-[5-[amino(imino)methyl]-2-hydroxyphenoxy]-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]piperidine-3-carboxylic Acid (ZK-806974)
1K1I	;	2.2	;	BOVINE TRYPSIN-INHIBITOR COMPLEX
1K1J	;	2.2	;	BOVINE TRYPSIN-INHIBITOR COMPLEX
1K1L	;	2.5	;	BOVINE TRYPSIN-INHIBITOR COMPLEX
1K1M	;	2.2	;	BOVINE TRYPSIN-INHIBITOR COMPLEX
1K1N	;	2.0	;	BOVINE TRYPSIN-INHIBITOR COMPLEX
1K1O	;	2.0	;	BOVINE TRYPSIN-INHIBITOR COMPLEX
1K1P	;	1.9	;	BOVINE TRYPSIN-INHIBITOR COMPLEX
6T9U	;	1.06751	;	Bovine Trypsine in complex with the synthetic inhibitor (S)-3'-(N-(1-(4-(3-(tert-butyl)ureido)piperidin-1-yl)-3-(3-carbamimidoylphenyl)-1-oxopropan-2-yl)sulfamoyl)-[1,1'-biphenyl]-3-carboximidamide (MI-490)
2CJQ	;	2.6	;	Bovine viral diarrhea virus CP7-R12 RNA-dependent RNA polymerase
3AX7	;	2.34	;	Bovine Xanthine Oxidase, protease cleaved form
3AX9	;	2.3	;	Bovine xanthine oxidase, protease cleaved form
8J79	;	1.99	;	Bovine Xanthine Oxidoreductase Crystallized with oxypurinol
3AMZ	;	2.1	;	Bovine Xanthine Oxidoreductase urate bound form
2W3P	;	1.5	;	BoxC crystal structure
6HZE	;	2.7	;	BP0997, GH138 enzyme targeting pectin rhamnogalacturonan II
6HZF	;	1.95	;	BP0997, GH138 enzyme targeting pectin rhamnogalacturonan II
6HZG	;	1.6	;	BP0997, GH138 enzyme targeting pectin rhamnogalacturonan II
4AK6	;	1.9	;	BpGH117_H302E mutant glycoside hydrolase
4AW7	;	1.33	;	BpGH86A: A beta-porphyranase of glycoside hydrolase family 86 from the human gut bacterium Bacteroides plebeius
2JPF	;		;	Bpp3783_115-220
2H05	;	1.8	;	Br Derivitation of A-DNA Octamer GTG(Ubr)ACAC
4YHT	;	3.05	;	bRaf complexed with an inhibitor
6U2H	;	2.5	;	BRAF dimer bound to 14-3-3
4E26	;	2.55	;	BRAF in complex with an organic inhibitor 7898734
4H58	;	3.1	;	BRAF in complex with compound 3
6N0P	;	2.37	;	BRAF in complex with N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide (LXH254)
5VAL	;	2.26	;	BRAF in Complex with N-(3-(tert-butyl)phenyl)-4-methyl-3-(6-morpholinopyrimidin-4-yl)benzamide
6N0Q	;	2.04	;	BRAF in complex with N-(4-methyl-3-(1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)phenyl)-3-(trifluoromethyl)benzamide.
5CT7	;	3.17	;	BRAF in Complex with RAF265
5VAM	;	2.1	;	BRAF in Complex with RAF709
5HID	;	2.5	;	BRAF Kinase domain b3aC loop deletion mutant in complex with AZ628
5HIE	;	3.0	;	BRAF Kinase domain b3aC loop deletion mutant in complex with dabrafenib
5HI2	;	2.512	;	BRAF Kinase domain b3aC loop deletion mutant in complex with sorafenib
8F7P	;	2.74	;	BRAF kinase in complex with LXH254 (naporafenib)
8F7O	;	3.54	;	BRAF kinase in complex with TAK580 (tovorafenib)
6U2G	;	2.886	;	BRAF-MEK complex with AMP-PCP bound to BRAF
5JSM	;	2.19	;	BRAFV600E Kinase Domain In Complex with Chemically Linked Vemurafenib Inhibitor VEM-3-VEM
5JRQ	;	2.287	;	BRAFV600E Kinase Domain In Complex with Chemically Linked Vemurafenib Inhibitor VEM-6-VEM
5JT2	;	2.702	;	BRAFV600E Kinase Domain In Complex with Chemically Linked Vemurafenib Inhibitor VEM-BISAMIDE
5NLV	;	2.4	;	Brag2 Sec7-PH (390-763)
5NLY	;	2.0	;	Brag2 Sec7-PH (390-763), P212121
6W3H	;	3.38	;	Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys
1B8M	;	2.75	;	BRAIN DERIVED NEUROTROPHIC FACTOR, NEUROTROPHIN-4
5KYA	;	2.598	;	Brain penetrant liver X receptor (LXR) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core
5KYJ	;	2.8	;	Brain penetrant liver X receptor (LXR) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core
1Q7F	;	1.95	;	Brain Tumor NHL domain
8EZD	;	2.83	;	Brain-derived 42-residue amyloid-beta fibril type A
8EZE	;	2.76	;	Brain-derived 42-residue amyloid-beta fibril type B
3LQV	;	2.38	;	Branch Recognition by SF3b14
8EGQ	;	1.955	;	Branched chain ketoacid dehydrogenase kinase complexes
8EGU	;	1.923	;	Branched chain ketoacid dehydrogenase kinase complexes
8EGD	;	2.047	;	Branched chain ketoacid dehydrogenase kinase in complex with inhibitor
8EGF	;	1.85	;	Branched chain ketoacid dehydrogenase kinase in complex with inhibitor
7NPO	;	2.19	;	Branched K48-K63-Ub3
8A67	;	1.86	;	Branched Lys48- and Lys63-linked tri-ubiquitin (K48-K63-Ub3) in complex with matured synthetic nanobody NbSL3.3Q (3rd generation)
7NBB	;	1.55	;	Branched Lys48- and Lys63-linked tri-ubiquitin (K48-K63-Ub3) in complex with synthetic nanobody NbSL3
1UM9	;	2.2	;	branched-chain 2-oxo acid dehydrogenase (E1) from Thermus thermophilus HB8 in apo-form
1UMB	;	2.1	;	branched-chain 2-oxo acid dehydrogenase (E1) from Thermus thermophilus HB8 in holo-form
1UMD	;	1.9	;	branched-chain 2-oxo acid dehydrogenase (E1) from Thermus thermophilus HB8 with 4-methyl-2-oxopentanoate as an intermediate
1UMC	;	2.4	;	branched-chain 2-oxo acid dehydrogenase (E1) from Thermus thermophilus HB8 with 4-methylpentanoate
1GKX	;	2.3	;	Branched-chain alpha-ketoacid dehydrogenase kinase (BCK)
1GKZ	;	2.2	;	Branched-chain alpha-ketoacid dehydrogenase kinase (BCK) complxed with ADP
1GJV	;	2.7	;	Branched-chain alpha-ketoacid dehydrogenase kinase (BCK) complxed with ATP-gamma-S
1A3G	;	2.5	;	BRANCHED-CHAIN AMINO ACID AMINOTRANSFERASE FROM ESCHERICHIA COLI
7SFA	;	1.65	;	Branchiostoma floridae fluorescent protein LanFP10A2
7SF9	;	1.8	;	Branchiostoma Floridae Violet Fluorescent Protein
17RA	;		;	BRANCHPOINT HELIX FROM YEAST AND BINDING SITE FOR PHAGE GA/MS2 COAT PROTEINS, NMR, 12 STRUCTURES
5UZL	;		;	Brassica napus DGAT1 exosite
1CWU	;	2.5	;	BRASSICA NAPUS ENOYL ACP REDUCTASE A138G MUTANT COMPLEXED WITH NAD+ AND THIENODIAZABORINE
1ENO	;	1.9	;	BRASSICA NAPUS ENOYL ACP REDUCTASE/NAD BINARY COMPLEX AT PH 8.0 AND ROOM TEMPERATURE
1ENP	;	2.6	;	BRASSICA NAPUS ENOYL ACP REDUCTASE/NADH BINARY COMPLEX AT PH 8.0 AND ROOM TEMPERATURE
1CDZ	;	3.2	;	BRCT DOMAIN FROM DNA-REPAIR PROTEIN XRCC1
5UEW	;	1.83	;	BRD2 Bromodomain2 with A-1360579
8DNQ	;	1.84	;	BRD2-BD1 in complex with cyclic peptide 2.2B
7USI	;	2.5	;	BRD2-BD1 in complex with MDP5
6U61	;	2.29	;	BRD2-BD1 in complex with the cyclic peptide 3.1_3
6U8H	;	2.07	;	BRD2-BD1 in complex with the cyclic peptide 3.2_2
6ULQ	;	2.7	;	BRD2-BD1 in complex with the cyclic peptide 4.2_3
7JX7	;	1.75	;	BRD2-BD2 in complex with a diacetylated-H2A.Z peptide
7USG	;	1.2	;	BRD2-BD2 in complex with MDP5
7USH	;	1.27	;	BRD2-BD2 in complex with SF2523
6U71	;	1.47	;	BRD2-BD2 in complex with the cyclic peptide 3.1_3
6ULT	;	2.8	;	BRD2-BD2 in complex with the cyclic peptide 4.2_3
6ONY	;	1.98	;	BRD2_Bromodomain1 complex with inhibitor 744
6E6J	;	2.44	;	BRD2_Bromodomain2 complex with inhibitor 744
6VIY	;	1.904	;	BRD2_Bromodomain2 complex with pyrrolopyridone compound 27
5HJC	;	2.6	;	BRD3 second bromodomain in complex with histone H3 acetylation at K18
7TO7	;	1.93	;	BRD3-BD1 in complex with RaPID linear peptide 1xAcK.4XE (monoAcK.4xE)
7TO8	;	1.5	;	BRD3-BD1 in complex with RaPID linear peptide 2xAcK.1 (diAcK.1)
7TO9	;	1.6	;	BRD3-BD1 in complex with RaPID linear peptide 2xAcK.4xE (diAcK.4xE)
7TOA	;	1.41	;	BRD3-BD1 in complex with RaPID linear peptide 3xAcK.1 (triAcK.1)
6U4A	;	1.88	;	BRD3-BD1 in complex with the cyclic peptide 3.1_3
6ULP	;	2.8	;	BRD3-BD2 in complex with the cyclic peptide 3.2_3
6G0E	;	1.613	;	BRD4 (BD1) in complex with APSC-derived ligands
6G0D	;	1.314	;	BRD4 (BD1) in complex with APSC-derived ligands (e.g. LY294002)
6G0H	;	1.907	;	BRD4 (BD1) in complex with APSC-derived ligands (e.g. SSLH01 a sulfasalazine derivate)
6G0G	;	1.478	;	BRD4 (BD1) in complex with APSC-derived ligands (e.g. sulfasalazine)
6G0F	;	1.618	;	BRD4 (BD1) in complex with docking-derived ligand
6LIH	;	1.62031	;	BRD4 BD1 bound with compound 10
6C7R	;	1.5	;	BRD4 BD1 in complex with compound CF53
6C7Q	;	1.51	;	BRD4 BD2 in complex with compound CE277
5XHY	;	1.976	;	BRD4 bound with compound Bdi1
5XI2	;	1.909	;	BRD4 bound with compound Bdi2
5XI3	;	1.674	;	BRD4 bound with compound Bdi3
5XI4	;	1.486	;	BRD4 bound with compound Bdi4
4HXL	;	1.52	;	Brd4 Bromodomain 1 complex with 3-CYCLOHEXYL-N-{3-(2-OXO-2,3-DIHYDRO-1,3-THIAZOL-4-YL)-5-[(THIOPHEN-2-YLSULFONYL)AMINO]PHENYL}PROPANAMIDE inhibitor
4HXO	;	1.76	;	Brd4 Bromodomain 1 complex with 3-{[(3-METHYL-1,2-OXAZOL-5-YL)METHYL]SULFANYL}[1,2,4]TRIAZOLO[4,3-A]PYRIDINE inhibitor
4HXN	;	1.49	;	Brd4 Bromodomain 1 complex with 4-(2-FLUOROPHENYL)-1,3-THIAZOL-2(3H)-ONE inhibitor
4HXP	;	1.73	;	Brd4 Bromodomain 1 complex with 4-(2-OXO-1,3-OXAZOLIDIN-3-YL)BENZAMIDE inhibitor
4HXK	;	1.61	;	Brd4 Bromodomain 1 complex with 6,7-DIHYDROTHIENO[3,2-C]PYRIDIN-5(4H)-YL(1H-IMIDAZOL-1-YL)METHANONE inhibitor
4DON	;	1.52	;	Brd4 Bromodomain 1 complex with a fragment 3,4-Dihydro-3-methyl-2(1H)-quinazolinon
4QR3	;	1.374	;	Brd4 Bromodomain 1 complex with its novel inhibitors
4QR4	;	1.28	;	Brd4 Bromodomain 1 complex with its novel inhibitors
4QR5	;	1.41	;	Brd4 Bromodomain 1 complex with its novel inhibitors
4HXS	;	1.43	;	Brd4 Bromodomain 1 complex with N-[3-(2-OXO-2,3-DIHYDRO-1,3-THIAZOL-4-YL)PHENYL]-1-PHENYLMETHANESULFONAMIDE inhibitor
4HXR	;	1.53	;	Brd4 Bromodomain 1 complex with N-[3-(2-OXO-2,3-DIHYDRO-1,3-THIAZOL-4-YL)PHENYL]THIOPHENE-2-SULFONAMIDE inhibitor
4HXM	;	1.5	;	Brd4 Bromodomain 1 complex with N-{3-(2-OXO-2,3-DIHYDRO-1,3-THIAZOL-4-YL)-5-[(THIOPHEN-2-YLSULFONYL)AMINO]PHENYL}BUTANAMIDE inhibitor
6DL2	;	1.47	;	BRD4 bromodomain 1 in complex with HYB157
6X7D	;	2.5	;	BRD4 Bromodomain 1 in complex with multi-action inhibitor SF2523P
6X7C	;	2.7	;	BRD4 Bromodomain 1 in complex with multi-action inhibitor SRX3212
6X7B	;	1.951	;	BRD4 Bromodomain 1 in complex with multi-action inhibitor SRX3212P
6WW8	;	2.302	;	BRD4 Bromodomain 1 in complex with triple CDK4/6-PI3K-BET inhibitor
5Z8G	;	1.701	;	BRD4 Bromodomain 1 with an inhibitor
5Z8R	;	2.0	;	BRD4 Bromodomain 1 with an inhibitor
5Z8Z	;	1.8	;	BRD4 Bromodomain 1 with an inhibitor
5Z90	;	1.8	;	BRD4 Bromodomain 1 with an inhibitor
5Z9K	;	1.89	;	BRD4 Bromodomain 1 with an inhibitor
4KV4	;	2.0	;	Brd4 Bromodomain 2 in Complex with Acetylated Rel Peptide
5UOO	;	1.69	;	BRD4 bromodomain 2 in complex with CD161
4Z93	;	1.27	;	BRD4 bromodomain 2 in complex with gamma-carboline-containing compound, number 18.
5UVY	;	2.25	;	BRD4 Bromodomain 2 with A-1349391
5UVZ	;	1.63	;	BRD4 Bromodomain 2 with A-1354689
5UVX	;	1.53	;	BRD4 Bromodomain 2 with A-1359643
5UVV	;	1.99	;	BRD4 Bromodomain 2 with A-1457066
5KU3	;	1.14	;	BRD4 bromodomain in complex with Cpd59 ((S)-1-(3-((2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)amino)-1-(tetrahydrofuran-3-yl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)ethanone)
6KED	;	2.54845	;	BRD4 Bromodomain1 with an inhibitor
6KEF	;	2.44468	;	BRD4 Bromodomain1 with an inhibitor
6KEG	;	2.232	;	BRD4 Bromodomain1 with an inhibitor
5U2E	;	1.991	;	BRD4 first bromodomain (BD1) in complex with dual PI3 kinase (PI3K) inhibitor SF2535
5U2F	;	2.525	;	BRD4 first bromodomain (BD1) in complex with dual PI3 kinase (PI3K) inhibitor SF2558HA
5U28	;	1.798	;	BRD4 first bromodomain (BD1) in complex with dual PI3 kinase inhibitor SF2523
6JJ3	;	1.718	;	BRD4 in complex with 138A
8C11	;	1.8	;	BRD4 in complex with 2-(2-(4-(3,5-dimethylisoxazol-4-yl)-1H-pyrazol-1-yl)acetamido)-N-ethylpropanamide
6JJ5	;	1.2	;	BRD4 in complex with 259
6JJ6	;	1.4	;	BRD4 in complex with 500
7ZG2	;	1.18	;	BRD4 in complex with Acetyl-Lys
5I80	;	1.4501	;	BRD4 in complex with Cpd2 (N,N-dimethyl-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)benzamide)
5I88	;	1.4	;	BRD4 in complex with Cpd4 ((E)-3-(6-(but-2-en-1-yl)-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-N,N-dimethylbenzamide)
5LRQ	;	1.7	;	BRD4 in complex with ERK5 inhibitor XMD8-92
7Z9W	;	0.988	;	BRD4 in complex with FragLite1
7ZE6	;	1.04	;	BRD4 in complex with FragLite10
7ZAA	;	1.15	;	BRD4 in complex with FragLite11
7ZAD	;	1.07	;	BRD4 in complex with FragLite12
7ZAE	;	1.1	;	BRD4 in complex with FragLite15
7ZAJ	;	1.0	;	BRD4 in complex with FragLite16
7ZAR	;	1.14	;	BRD4 in complex with FragLite18
7ZAQ	;	1.11	;	BRD4 in complex with FragLite19
7Z9Y	;	1.04	;	BRD4 in complex with FragLite2
7ZAT	;	1.15	;	BRD4 in complex with FragLite20
7ZE7	;	1.23	;	BRD4 in complex with FragLite21
7ZEF	;	1.12	;	BRD4 in complex with FragLite22
7ZEN	;	1.14	;	BRD4 in complex with FragLite23
7ZFN	;	1.12	;	BRD4 in complex with FragLite24
7ZFO	;	1.09	;	BRD4 in complex with FragLite28
7ZFS	;	1.25	;	BRD4 in complex with FragLite32
7ZFT	;	1.28	;	BRD4 in complex with FragLite33
7ZA6	;	1.12	;	BRD4 in complex with FragLite4
7ZA7	;	1.06	;	BRD4 in complex with FragLite5
7ZA8	;	1.04	;	BRD4 in complex with FragLite6
7ZA9	;	1.05	;	BRD4 in complex with FragLite7
7ZFV	;	1.37	;	BRD4 in complex with PepLite-Ala
7ZFY	;	1.15	;	BRD4 in complex with PepLite-Gly
7ZFU	;	1.29	;	BRD4 in complex with PepLite-Pro
7ZG1	;	1.16	;	BRD4 in complex with PepLite-Tyr
7ZFZ	;	1.08	;	BRD4 in complex with PepLite-Val
6JJB	;	1.508	;	BRD4 in complex with ZZM1
5U2C	;	3.3	;	BRD4 second bromodomain (BD2) in complex with dual PI3 kinase (PI3K) inhibitor SF2558HA
6CZV	;	1.88	;	BRD4(BD1) complexed with 2759
6CZU	;	1.47	;	BRD4(BD1) complexed with 3219
6LIM	;	1.7591	;	BRD4-BD1 bound with compound 40
6JI3	;	2.2	;	BRD4-BD1 bound with ligand 103
6JI4	;	1.6	;	brd4-bd1 bound with ligand 138
6JI5	;	2.0	;	brd4-bd1 bound with ligand 167
7WWZ	;	1.16	;	BRD4-BD1 complexed with NEO2734
7KHL	;	1.286	;	BRD4-BD1 Compound6 (methyl 4-(3,5-difluoropyridin-2-yl)-10-methyl-7-((methylsulfonyl)methyl)-11-oxo-3,4,10,11-tetrahydro-1H-1,4,10-triazadibenzo[cd,f]azulene-6-carboxylate)
5VZS	;	1.707	;	BRD4-BD1 in complex with Cpd19 (3-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-N-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide)
7EHY	;	1.51	;	BRD4-BD1 in complex with LT-448-138
7EHW	;	1.65	;	BRD4-BD1 in complex with LT-642-602
7EIG	;	1.3	;	BRD4-BD1 in complex with LT-730-903
7EIL	;	1.7	;	BRD4-BD1 in complex with LT-909-110
6ULS	;	1.5	;	BRD4-BD1 in complex with the a diacetylated-E2F1 peptide
6U74	;	1.85	;	BRD4-BD1 in complex with the cyclic peptide 3.1_2
6U72	;	2.3	;	BRD4-BD1 in complex with the cyclic peptide 3.1_2_AcK5toA
6U6K	;	1.7	;	BRD4-BD1 in complex with the cyclic peptide 3.1_3
6U8M	;	1.95	;	BRD4-BD1 in complex with the cyclic peptide 3.2_1
6ULV	;	2.2	;	BRD4-BD1 in complex with the cyclic peptide 4.2_1
7USJ	;	2.08	;	BRD4-BD2 in complex with SF2523
6U6L	;	2.6	;	BRD4-BD2 in complex with the cyclic peptide 3.1_2
6U8G	;	2.6	;	BRD4-BD2 in complex with the cyclic peptide 3.1_2_AcK7toA
6U8I	;	2.5	;	BRD4-BD2 in complex with the cyclic peptide 3.2_2
7USK	;	1.22	;	BRD4-BD2 Ligand free
8DYR	;	1.47	;	BRD4-D1 in complex with BET inhibitor
8E17	;	1.47	;	BRD4-D1 in complex with BET inhibitor
8E3W	;	1.47	;	BRD4-D1 in complex with BET inhibitor
5UF0	;	1.35	;	BRD4_BD2-A-35165
5UEU	;	2.26	;	BRD4_BD2_A-1107604
5UET	;	2.29	;	BRD4_BD2_A-1308586
5UEZ	;	1.51	;	BRD4_BD2_A-1342843
5UES	;	1.62	;	BRD4_BD2_A-1344772
5UER	;	1.87	;	BRD4_BD2_A-1359930
5UEQ	;	1.7	;	BRD4_BD2_A-1390146
5UEO	;	1.85	;	BRD4_BD2_A-1395017
5UVS	;	2.15	;	BRD4_BD2_A-1406537
5UEY	;	2.41	;	BRD4_BD2_A-1412838
5UVT	;	1.67	;	BRD4_BD2_A-1454056
5UVU	;	1.66	;	BRD4_BD2_A-1461028
5UEX	;	2.29	;	BRD4_BD2_A-1497627
5UEV	;	1.94	;	BRD4_BD2_A-556343
5UEP	;	1.77	;	BRD4_BD2_A-581577
6VIW	;	2.429	;	BRD4_Bromodomain1 complex with pyrrolopyridone compound 18
6VIZ	;	2.391	;	BRD4_Bromodomain1 complex with pyrrolopyridone compound 27
5UVW	;	2.14	;	BRD4_Bromodomain1-A1376855
6VIX	;	2.116	;	BRD4_Bromodomain2 complex with pyrrolopyridone compound 18
6BQA	;	1.031	;	BRD9 bromodomain in complex with 3-(6-(but-3-en-1-yl)-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-N,N-dimethylbenzamide
5I40	;	1.0402	;	BRD9 in complex with Cpd1 (6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one)
5I7X	;	1.1752	;	BRD9 in complex with Cpd2 (N,N-dimethyl-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)benzamide)
5I7Y	;	1.4514	;	BRD9 in complex with Cpd4 ((E)-3-(6-(but-2-en-1-yl)-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-N,N-dimethylbenzamide)
6YQW	;	1.5	;	BRD9 with 4-chloro-2-methyl-methylamino-pyridazinone
6YQR	;	1.684	;	BRD9 with Biphenyl-methylamino-dimethylpyridazinone
6YQS	;	1.683	;	BRD9 with methylpiperazinyl-benzyl-amino-dimethylpyridazinone
4KCX	;	2.0	;	BRDT in complex with Dinaciclib
8IEG	;	3.44	;	Bre1(mRBD-RING)/Rad6-Ub/nucleosome complex
8GUI	;	2.81	;	Bre1-nucleosome complex (Model I)
8GUJ	;	2.8	;	Bre1-nucleosome complex (Model II)
2NOV	;	2.67	;	Breakage-reunion domain of S.pneumoniae topo IV: crystal structure of a gram-positive quinolone target
5FS5	;	1.42	;	Breaking down the wall: mutation of the tyrosine gate of the universal Escherichia coli fimbrial adhesin FimH
5FWR	;	2.13	;	Breaking down the wall: mutation of the tyrosine gate of the universal Escherichia coli fimbrial adhesin FimH
5FX3	;	1.9	;	Breaking down the wall: mutation of the tyrosine gate of the universal Escherichia coli fimbrial adhesin FimH
1JKM	;	1.85	;	BREFELDIN A ESTERASE, A BACTERIAL HOMOLOGUE OF HUMAN HORMONE SENSITIVE LIPASE
7BCV	;	2.28	;	Brevibacterium linens encapsulin structure
8QJR	;	3.17	;	BRG1 bromodomain in complex with VBC via compound 17
2YAD	;	2.2	;	BRICHOS domain of Surfactant protein C precursor protein
6WZ5	;	2.2	;	Bridging of double-strand DNA break activates PARP2/HPF1 to modify chromatin
6WZ9	;	2.8	;	Bridging of double-strand DNA break activates PARP2/HPF1 to modify chromatin
6X0L	;	3.9	;	Bridging of double-strand DNA break activates PARP2/HPF1 to modify chromatin
6X0M	;	6.3	;	Bridging of double-strand DNA break activates PARP2/HPF1 to modify chromatin
6X0N	;	10.0	;	Bridging of double-strand DNA break activates PARP2/HPF1 to modify chromatin
8BVG	;	2.38	;	Bright fluorescent protein BrUSLEE with subnanosecond fluorescence lifetime
2IOV	;	1.8	;	Bright-state structure of the reversibly switchable fluorescent protein Dronpa
2V0E	;		;	BRK domain from human CHD7
2V0F	;		;	BRK domain from human CHD7
8QJT	;	2.568	;	BRM (SMARCA2) Bromodomain in complex with ligand 10
4JIO	;	3.6	;	Bro1 V domain and ubiquitin
8CQM	;	2.0	;	Broad-range phospholipase C from Listeria monocytogenes
8ELI	;	1.49	;	Broadly neutralizing antibody VRC34-combo.1 in complex with HIV fusion peptide (residue 512-519)
7B4T	;	1.95	;	Broadly neutralizing DARPin bnD.1 in complex with the HIV-1 envelope variable loop 3 crown mimetic peptide V3-IF (BG505)
7B4U	;	1.45	;	Broadly neutralizing DARPin bnD.2 in complex with the HIV-1 envelope variable loop 3 crown mimetic peptide V3-IF (BG505)
7B4V	;	1.4	;	Broadly neutralizing DARPin bnD.2 in complex with the HIV-1 envelope variable loop 3 crown mimetic peptide V3-IF (BG505)
7B4W	;	1.9	;	Broadly neutralizing DARPin bnD.3 in complex with the HIV-1 envelope variable loop 3 crown mimetic peptide V3-IF (BG505)
7Z7C	;	1.22	;	Broadly neutralizing DARPin bnD.8 in complex with the HIV-1 envelope variable loop 3 peptide V3 (BF520)
8AED	;	1.17	;	Broadly neutralizing DARPin bnD.9 in complex with the HIV-1 envelope variable loop 3 peptide V3 (BG505)
6N5B	;	3.5	;	Broadly protective antibodies directed to a subdominant influenza hemagglutinin epitope
6N5D	;	3.0	;	Broadly protective antibodies directed to a subdominant influenza hemagglutinin epitope
6N5E	;	3.0	;	Broadly protective antibodies directed to a subdominant influenza hemagglutinin epitope
1JS9	;	3.4	;	Brome Mosaic Virus
5WKY	;	4.0	;	Bromide sites in the structure of an acid sensing ion channel in a resting state
3S8Y	;	2.1	;	Bromide soaked structure of an esterase from the oil-degrading bacterium Oleispira antarctica
5AHZ	;	2.45	;	Bromide-bound form of Halorhodopsin from Halobacterium salinarum in a new rhombohedral crystal form
3QBK	;	2.2	;	Bromide-bound form of pharaonis halorhodopsin
3VQH	;	1.95	;	Bromine SAD partially resolves multiple binding modes for PKA inhibitor H-89
4WHU	;	2.11	;	BROMO domain of CREB binding protein
3SGM	;	1.7006	;	Bromoderivative-2 of amyloid-related segment of alphaB-crystallin residues 90-100
3SGN	;	2.807	;	Bromoderivative-8 of amyloid-related segment of alphaB-crystallin residues 90-100
8IBQ	;	1.45	;	Bromodomain and Extra-terminal Domain (BET) BRD4
8IDH	;	1.57	;	Bromodomain and Extra-terminal Domain (BET) BRD4
8WIU	;	1.4	;	Bromodomain and Extra-terminal Domain (BET) BRD4
1E6I	;	1.87	;	Bromodomain from GCN5 complexed with acetylated H4 peptide
5TPX	;	2.1	;	Bromodomain from Plasmodium Faciparum Gcn5, complexed with compound
5KO4	;	1.44	;	Bromodomain from Trypanosoma brucei Tb427.10.8150
7UGE	;	2.004	;	Bromodomain of CBP liganded with BMS-536924
8FUP	;	1.7	;	Bromodomain of CBP liganded with BMS-536924 and CCS-1477
7UGL	;	1.5	;	Bromodomain of CBP liganded with BMS-536924 and SGC-CBP30
8FV2	;	1.87	;	Bromodomain of CBP liganded with CCS-1477
8FVS	;	1.75	;	Bromodomain of CBP liganded with CCS1477int
8FXA	;	1.65	;	Bromodomain of CBP liganded with iCBP4
8FXE	;	1.55	;	Bromodomain of CBP liganded with iCBP6
8FXN	;	2.0	;	Bromodomain of CBP liganded with iCBP7
8FXO	;	1.74	;	Bromodomain of CBP liganded with iCBP8
8G6T	;	1.75	;	Bromodomain of CBP liganded with inhibitor iCBP2
8GA2	;	1.85	;	Bromodomain of CBP liganded with inhibitor iCBP5
7UGI	;	2.0	;	Bromodomain of EP300 liganded with BMS-536924
8FVF	;	2.1	;	Bromodomain of EP300 liganded with CCS-1477
5MKY	;	1.67	;	BROMODOMAIN OF HUMAN BRD9 WITH 4-chloro-2-methyl-5-((2-methyl-1,2,3,4-tetrahydroisoquinolin-5-yl)amino)pyridazin-3(2H)-one
4UIT	;	1.3	;	BROMODOMAIN OF HUMAN BRD9 WITH 7-(3,4-dimethoxyphenyl)-2-(4- methanesulfonylpiperazine-1-carbonyl)-5-methyl-4H,5H-thieno-3,2-c- pyridin-4-one
4UIU	;	1.64	;	BROMODOMAIN OF HUMAN BRD9 WITH 7-(3,4-dimethoxyphenyl)-N-(1,1-dioxo-1- thian-4-yl)-5-methyl-4-oxo-4H,5H-thieno-3,2-c-pyridine-2-carboxamide
4UIW	;	1.73	;	BROMODOMAIN OF HUMAN BRD9 WITH N-(1,1-dioxo-1-thian-4-yl)-5-ethyl-4- oxo-7-3-(trifluoromethyl)phenyl-4H,5H-thieno-3,2-c-pyridine-2- carboximidamide
4UIV	;	1.72	;	BROMODOMAIN OF HUMAN BRD9 WITH N-(1,1-dioxo-1-thian-4-yl)-5-methyl-4- oxo-7-3-(trifluoromethyl)phenyl-4H,5H-thieno-3,2-c-pyridine-2- carboximidamide
4UYE	;	1.65	;	BROMODOMAIN OF HUMAN BRPF1 WITH N-1,3-dimethyl-2-oxo-6-(piperidin-1- yl)-2,3-dihydro-1H-1,3-benzodiazol-5-yl-2-methoxybenzamide
5G4R	;	1.96	;	BROMODOMAIN OF HUMAN BRPF1 WITH N-1,3-dimethyl-6-2R-2- methylpiperazin-1-yl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-yl-2- methoxybenzamide
5G4S	;	1.6	;	BROMODOMAIN OF HUMAN BRPF1 WITH N-1,3-dimethyl-6-2R-2- methylpiperazin-1-yl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-yl-N- ethyl-2-methoxybenzamide
4A9K	;	1.81	;	BROMODOMAIN OF HUMAN CREBBP WITH N-(4-hydroxyphenyl)acetamide
5MLJ	;	1.8	;	Bromodomain of Human GCN5 with 4-bromo-2-methyl-5-(((3R,5R)-1-methyl-5-phenylpiperidin-3-yl)amino)pyridazin-3(2H)-one
7P4S	;	2.17	;	BROMODOMAIN OF HUMAN TAF1 (2) WITH naphthyridinone compound
5ML0	;	1.64	;	Bromodomain of Mouse PCAF with (R)-4-chloro-2-methyl-5-((1-methylpiperidin-3-yl)amino)pyridazin-3(2H)-one
5VS7	;	2.04	;	Bromodomain of PF3D7_1475600 from Plasmodium falciparum complexed with peptide H4K5ac
4PKL	;	1.251	;	Bromodomain of Trypanosoma brucei BDF2 With IBET-151
7Q5O	;	1.519	;	Bromodomain-containing 2 BD2 in complex with the inhibitor CRCM5484
7C2Z	;	1.3	;	Bromodomain-containing 4 BD1 in complex with 3',4',7,8-Tetrahydroxyflavone
7Q3F	;	1.21	;	Bromodomain-containing 4 BD1 in complex with the inhibitor CRCM5484
7C6P	;	1.73	;	Bromodomain-containing 4 BD2 in complex with 3',4',7,8- Tetrahydroxyflavonoid
6P05	;	1.54	;	Bromodomain-containing protein 4 (BRD4) bromodomain 1 (BD1) complexed with compound 27
7RUI	;	1.35	;	Bromodomain-containing protein 4 (BRD4) bromodomain 1 (BD1) complexed with XR844
7JKY	;	1.16	;	Bromodomain-containing protein 4 (BRD4) bromodomain 1 (BD1) complexed with YF3-126
7JKX	;	1.2	;	Bromodomain-containing protein 4 (BRD4) bromodomain 1 (BD1) complexed with YF3-6
7JKW	;	1.2	;	Bromodomain-containing protein 4 (BRD4) bromodomain 1 (BD1) complexed with ZN1-99
7RUH	;	1.7	;	Bromodomain-containing protein 4 (BRD4) bromodomain 2 (BD2) complexed with XR844
7JKZ	;	2.49	;	Bromodomain-containing protein 4 (BRD4) bromodomain 2 (BD2) complexed with YF3-126
3DN2	;	1.8	;	Bromopentafluorobenzene binding in the hydrophobic cavity of T4 lysozyme L99A mutant
1A8Q	;	1.75	;	BROMOPEROXIDASE A1
1BRO	;	2.05	;	BROMOPEROXIDASE A2
1BRT	;	1.5	;	BROMOPEROXIDASE A2 MUTANT M99T
4RIP	;	2.1	;	BromoUracil substituted structure of intercalation-locked DNA tetraplex
5N49	;	1.94	;	BRPF2 in complex with Compound 7
4F91	;	2.697	;	Brr2 Helicase Region
4F92	;	2.662	;	Brr2 Helicase Region S1087L
4F93	;	2.92	;	Brr2 Helicase Region S1087L, Mg-ATP
8HDN	;	1.7	;	Brucella melitensis 7-alpha-Hydroxysteroid Dehydrogenase mutant: 1-53 truncation-I258M/K262T
8HS5	;	2.3	;	Brucella melitensis 7-alpha-Hydroxysteroid Dehydrogenase mutant: 1-53 truncation-I258M/K262T-NAD+
8HDE	;	2.7	;	Brucella melitensis 7-alpha-Hydroxysteroid Dehydrogenase mutant: 1-53 truncation/I258M
8HDI	;	1.99	;	Brucella melitensis 7-alpha-Hydroxysteroid Dehydrogenase mutant: 1-53 truncation/K262T
8HS4	;	2.0	;	Brucella melitensis 7-alpha-Hydroxysteroid Dehydrogenase mutant: 1-53 truncation/K262T-NAD+
8HSA	;	3.0	;	Brucella melitensis 7-alpha-Hydroxysteroid Dehydrogenase mutant: 1-53 truncation/M196I/I258M/K262T-NAD+
8HS6	;	2.35	;	Brucella melitensis 7-alpha-Hydroxysteroid Dehydrogenase mutant:1-53 truncation
8HS9	;	3.25	;	Brucella melitensis 7-alpha-Hydroxysteroid Dehydrogenase mutant:I258M/K262T
8HAX	;	3.25	;	Brucella melitensis 7alpha-Hydroxysteroid Dehydrogenase mutant-I258M/K262T
7MPR	;	1.42	;	Brucella melitensis NrnC
7MPU	;	1.72	;	Brucella melitensis NrnC bound to pGG
7MPT	;	1.75	;	Brucella melitensis NrnC with bound Mg2+
7MPS	;	1.45	;	Brucella melitensis NrnC with engaged loop
5TEU	;	1.62	;	Brucella periplasmic binding protein YehZ
5E0O	;	3.0	;	Brugia malayi Trehalose-6 Phosphate Phosphatase in complex with PEG at the active site.
2KHC	;		;	Bruno RRM3+
8E2M	;	1.904	;	Bruton's tyrosine kinase (BTK) with compound 13
5VGO	;	1.621	;	Bruton's tyrosine kinase (BTK) with compound G-744
5VFI	;	1.59	;	Bruton's tyrosine kinase (BTK) with GDC-0853
4RX5	;	1.356	;	Bruton's tyrosine kinase (BTK) with pyridazinone compound 23
5KUP	;	1.389	;	Bruton's tyrosine kinase (BTK) with pyridazinone compound 9
8EJB	;	1.58	;	Bruton's tyrosine kinase in complex with 3-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-5-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazine-2-carboxamide
8GC7	;	1.9	;	Bruton's tyrosine kinase in complex with 5-(piperidin-1-yl)-3-{[4-(piperidin-4-yl)phenyl]amino}pyrazine-2-carboxamide
4YHF	;	2.2	;	Bruton's tyrosine kinase in complex with a t-butyl cyanoacrylamide inhibitor
8FLG	;	2.2	;	Bruton's tyrosine kinase in complex with an orthosteric inhibitor
8FLH	;	1.55	;	Bruton's tyrosine kinase in complex with an orthosteric inhibitor
6W07	;	1.51	;	Bruton's tyrosine kinase in complex with compound 1
7N4R	;	1.62	;	Bruton's tyrosine kinase in complex with compound 21
7LTY	;	1.69	;	Bruton's tyrosine kinase in complex with compound 23
8FLV	;	1.3	;	Bruton's tyrosine kinase in complex with compound 34
7N4Q	;	1.5	;	Bruton's tyrosine kinase in complex with compound 45
6VXQ	;	1.4	;	Bruton's tyrosine kinase in complex with compound 5
7LTZ	;	1.53	;	Bruton's tyrosine kinase in complex with compound 51
6W06	;	1.55	;	Bruton's tyrosine kinase in complex with compound 6
7N4S	;	2.05	;	Bruton's tyrosine kinase in complex with compound 65
8U2D	;	1.95	;	Bruton's tyrosine kinase in complex with N-[(2R)-1-[(3R)-3-(methylcarbamoyl)-1H,2H,3H,4H,9H-pyrido[3,4-b]indol-2-yl]-3-(3-methylphenyl)-1-oxopropan-2-yl]-1H-indazole-5-carboxamide
8U2E	;	1.9	;	Bruton's tyrosine kinase in complex with N-[(2R)-1-[(3R)-3-(methylcarbamoyl)-1H,2H,3H,4H,9H-pyrido[3,4-b]indol-2-yl]-3-(3-methylphenyl)-1-oxopropan-2-yl]-1H-indazole-5-carboxamide
8GC8	;	1.75	;	Bruton's tyrosine kinase L528W mutant in complex with 5-(piperidin-1-yl)-3-{[4-(piperidin-4-yl)phenyl]amino}pyrazine-2-carboxamide
6NZM	;	1.72	;	Brutons tyrosine kinase in complex with compound 50.
6FRL	;	2.5	;	BrvH, a flavin-dependent halogenase from Brevundimonas sp. BAL3
7RZB	;	1.6	;	BrxA from Staphylococcus aureus with bacillithiol mixed disulfide
7ZGE	;	2.09	;	BrxA, BREX phage defence protein
7T8L	;	2.0	;	BrxR from Acinetobacter BREX type I phage restriction system
7T8K	;	2.3	;	BrxR from Acinetobacter BREX type I phage restriction system bound to DNA
7QFZ	;	2.15	;	BrxR, a WYL-domain containing transcriptional regulator
7P9K	;	2.12	;	BrxU, GmrSD-family Type IV restriction enzyme
7P9M	;	2.85	;	BrxU, GmrSD-family Type IV restriction enzyme
8HPD	;	2.74	;	Bry-LHCII heterotrimer of Bryopsis corticulans
8HLV	;	2.55	;	Bry-LHCII homotrimer of Bryopsis corticulans
8HQ8	;	2.6	;	Bry-LHCII homotrimer of Bryopsis corticulans
1BRY	;	2.1	;	BRYODIN TYPE I RIP
7PUD	;	1.25	;	Bryoporin - actinoporin from moss Physcomitrium patens
7OMS	;	2.05	;	Bs164 in complex with mannocyclophellitol aziridine
7OMI	;	1.76	;	Bs164 in complex with mannocyclophellitol epoxide
1KNV	;	2.17	;	Bse634I restriction endonuclease
6D9T	;	2.0	;	BshA from Staphylococcus aureus complexed with UDP
6N1X	;	2.35	;	BshA from Staphylococcus aureus complexed with UDP and N-acetylglucosamine
6ULL	;	1.45	;	BshB from Bacillus subtilis complexed with a substrate analogue
6P2T	;	1.853	;	BshB from Bacillus subtilis complexed with citrate
3LVV	;	2.2	;	BSO-inhibited ScGCL
4Z1P	;	1.89	;	BspA_C_mut
4Z23	;	2.45	;	BspA_C_WT
7AGZ	;	1.52	;	BsrV no-histagged
6MU4	;	1.62	;	Bst DNA polymerase I FANA/DNA binary complex
8SCG	;	2.0	;	Bst DNA polymerase I Large Fragment mutant F710Y/D598A with 3'-amino primer, dGTP, and calcium time-resolved 0h (Ground State)
8SCI	;	2.67	;	Bst DNA polymerase I Large Fragment mutant F710Y/D598A with 3'-amino primer, dGTP, and calcium time-resolved 1h
8SCN	;	2.3	;	Bst DNA polymerase I Large Fragment mutant F710Y/D598A with 3'-amino primer, dGTP, and calcium time-resolved 24h (Product State)
8SCJ	;	2.68	;	Bst DNA polymerase I Large Fragment mutant F710Y/D598A with 3'-amino primer, dGTP, and calcium time-resolved 2h
8SCK	;	2.3	;	Bst DNA polymerase I Large Fragment mutant F710Y/D598A with 3'-amino primer, dGTP, and calcium time-resolved 4h
8SCL	;	2.44	;	Bst DNA polymerase I Large Fragment mutant F710Y/D598A with 3'-amino primer, dGTP, and calcium time-resolved 6h
8SCM	;	2.3	;	Bst DNA polymerase I Large Fragment mutant F710Y/D598A with 3'-amino primer, dGTP, and calcium time-resolved 8h
8SCO	;	1.92	;	Bst DNA polymerase I Large Fragment wildtype D598A with 3'-amino primer, dGTP, and calcium time-resolved 0h (Ground State)
8SCP	;	2.08	;	Bst DNA polymerase I Large Fragment wildtype D598A with 3'-amino primer, dGTP, and calcium time-resolved 1h
8SCT	;	2.34	;	Bst DNA polymerase I Large Fragment wildtype D598A with 3'-amino primer, dGTP, and calcium time-resolved 24h
8SCQ	;	2.18	;	Bst DNA polymerase I Large Fragment wildtype D598A with 3'-amino primer, dGTP, and calcium time-resolved 2h
8SCU	;	2.38	;	Bst DNA polymerase I Large Fragment wildtype D598A with 3'-amino primer, dGTP, and calcium time-resolved 48h (Product State)
8SCR	;	2.0	;	Bst DNA polymerase I Large Fragment wildtype D598A with 3'-amino primer, dGTP, and calcium time-resolved 4h
8SCS	;	2.1	;	Bst DNA polymerase I Large Fragment wildtype D598A with 3'-amino primer, dGTP, and calcium time-resolved 8h
6DSX	;	1.99	;	Bst DNA polymerase I post-chemistry (n+1 with dATP soak) structure
6DSY	;	1.98	;	Bst DNA polymerase I post-chemistry (n+1) structure
6DSV	;	1.99	;	Bst DNA polymerase I post-chemistry (n+2) structure
6DSW	;	1.589	;	Bst DNA polymerase I pre-chemistry (n) structure
6DSU	;	1.98	;	Bst DNA polymerase I pre-insertion complex structure
7K5O	;	2.16	;	Bst DNA polymerase I time-resolved structure, 1 min post dATP addition
7K5R	;	2.3	;	Bst DNA polymerase I time-resolved structure, 120 min post dATP addition
7K5T	;	2.3	;	Bst DNA polymerase I time-resolved structure, 25.5 hr post dATP and dCTP addition
7K5S	;	1.67	;	Bst DNA polymerase I time-resolved structure, 4 hr post dATP and dCTP addition
7K5P	;	1.97	;	Bst DNA polymerase I time-resolved structure, 4 min post dATP addition
7K5U	;	2.0	;	Bst DNA polymerase I time-resolved structure, 48 hr post dATP and dCTP addition
7K5Q	;	2.0	;	Bst DNA polymerase I time-resolved structure, 8 min post dATP addition
6MU5	;	1.912	;	Bst DNA polymerase I TNA/DNA binary complex
3HQ2	;	2.9	;	BsuCP Crystal Structure
6Q63	;	2.44	;	BT0459
5MUJ	;	1.37	;	BT0996 RGII Chain B Complex
3EHN	;	2.8	;	BT1043 with N-acetyllactosamine
6Q64	;	2.4	;	BT1044SeMet E190Q
5G2T	;	1.9	;	BT1596 in complex with its substrate 4,5 unsaturated uronic acid alpha 1,4 D-Glucosamine-2-N, 6-O-disulfate
7BR2	;	2.33	;	BT4096 a gut microbial diltiazem-metabolizing enzyme
5CK0	;	1.996	;	BT4246
5CJZ	;	1.803	;	BT4246 with galactose
4U77	;	2.03	;	BTB domain from Drosophila CP190
1BUO	;	1.9	;	BTB DOMAIN FROM PLZF
4CXI	;	2.35	;	BTB domain of KEAP1
4CXJ	;	2.8	;	BTB domain of KEAP1 C151W mutant
4CXT	;	2.66	;	BTB domain of KEAP1 in complex with CDDO
7X4X	;	2.96	;	BTB domain of KEAP1 in complex with MEF
5GIT	;	2.19	;	BTB domain of KEAP1 in complex with XX3
6GUV	;	2.29	;	BTB domain of mouse PATZ1
6GUW	;	1.8	;	BTB domain of zebrafish PATZ1
6ML4	;	1.482	;	BTB24 Zinc Fingers 4-8 with 19+1mer DNA Oligonucleotide (Sequence 3)
8SAK	;	3.0	;	BtCoV-422 in complex with neutralizing antibody JC57-11
8UYE	;	5.9	;	BtCoV-HKU5 5' proximal stem-loop 5, conformation 1
8UYG	;	6.4	;	BtCoV-HKU5 5' proximal stem-loop 5, conformation 2
8UYJ	;	7.3	;	BtCoV-HKU5 5' proximal stem-loop 5, conformation 4
6RGN	;	2.01	;	BteA131
2WZH	;	2.2	;	BtGH84 D242N in complex with MeUMB-derived oxazoline
2WZI	;	1.9	;	BtGH84 D243N in complex with 5F-oxazoline
2XJ7	;	2.0	;	BtGH84 in complex with 6-acetamido-6-deoxy-castanospermine
2W67	;	2.25	;	BtGH84 in complex with FMA34
2W66	;	2.27	;	BtGH84 in complex with HQ602
2XM2	;	1.95	;	BtGH84 in complex with LOGNAc
2XM1	;	2.0	;	BtGH84 in complex with N-acetyl gluconolactam
2WCA	;	2.3	;	BtGH84 in complex with n-butyl pugnac
2VVN	;	1.85	;	BtGH84 in complex with NH-Butylthiazoline
2W4X	;	2.42	;	BtGH84 in complex with STZ
2X0H	;	2.21	;	BtGH84 Michaelis complex
5MI4	;	1.8	;	BtGH84 mutant with covalent modification by MA3
5MI5	;	2.15	;	BtGH84 mutant with covalent modification by MA3 in complex with PUGNAc
5MI6	;	2.0	;	BtGH84 mutant with covalent modification by MA3 in complex with Thiamet G
5MI7	;	2.1	;	BtGH84 mutant with covalent modification by MA4 in complex with PUGNAc
2VVS	;	2.24	;	BtGH84 structure in complex with PUGNAc
7ROX	;	2.1	;	BthTX-I complexed with inhibitor MMV
4WTB	;	2.16	;	BthTX-I, a svPLA2s-like toxin, complexed with zinc ions
7RJZ	;	1.7	;	BthTX-II variant a, from Bothrops jararacussu venom, complexed with benzoic acid
7RJI	;	1.71	;	BthTX-II variant b, from Bothrops jararacussu venom, complexed with stearic acid
6BKE	;	1.95	;	BTK complex with compound 10
6BKH	;	1.792	;	BTK complex with compound 11
6BKW	;	1.499	;	BTK complex with compound 12
6BLN	;	1.3	;	BTK complex with compound 13
6BIK	;	1.901	;	BTK complex with compound 7
6XE4	;	1.6	;	BTK Fluorocyclopropyl amide inhibitor, Compound 25
7R60	;	1.94	;	BTK in complex with 18A
7R61	;	1.52	;	BTK in complex with 25A
6S90	;	1.82	;	BTK in complex with an inhibitor
5P9F	;	1.71	;	BTK IN COMPLEX WITH GDC-0834
6O8I	;	1.42	;	BTK In Complex With Inhibitor
6NFH	;	1.4	;	BTK in complex with inhibitor 8-(2,3-dihydro-1H-inden-5-yl)-2-({4-[(2S)-3-(dimethylamino)-2-hydroxypropoxy]phenyl}amino)-5,8-dihydropteridine-6,7-dione
6NFI	;	2.41	;	BTK in complex with inhibitor N-(3-{[(2,6-dimethylphenyl)methyl]amino}-7-methoxyindeno[1,2-c]pyrazol-6-yl)methanesulfonamide
6TFP	;	2.0	;	BTK in complex with LOU064, a potent and highly selective covalent inhibitor
5FBN	;	1.8	;	BTK kinase domain with inhibitor 1
5FBO	;	1.894	;	BTK-inhibitor co-structure
5P9M	;	1.41	;	BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059
5P9J	;	1.08	;	BTK1 COCRYSTALLIZED WITH IBRUTINIB
5P9H	;	1.95	;	BTK1 COCRYSTALLIZED WITH RN983
5P9L	;	1.25	;	BTK1 IN COMPLEX WITH CC 292
7KXO	;	1.94	;	BTK1 SOAKED WITH COMPOUND 24
7KXP	;	1.83	;	BTK1 SOAKED WITH COMPOUND 25
7KXN	;	1.34	;	BTK1 SOAKED WITH COMPOUND 26
7KXQ	;	1.38	;	BTK1 SOAKED WITH COMPOUND 30
7KXL	;	1.84	;	BTK1 SOAKED WITH COMPOUND 5, Y551 IS SEQUESTERED
7KXM	;	1.33	;	BTK1 SOAKED WITH COMPOUND 5, Y551 IS SEQUESTERED
5P9I	;	1.11	;	BTK1 SOAKED WITH IBRUTINIB-Rev
4V1P	;	2.04	;	BTN3 Structure
7SKR	;	2.89	;	BtSCoV-Rf1.2004 Papain-Like protease bound to the non-covalent inhibitor 37
7SKQ	;	3.16	;	BtSCoV-Rf1.2004 Papain-Like protease bound to the non-covalent inhibitor GRL-0617
8P97	;	2.75	;	BtuB3G3 bound to cyanocobalamin with disordered EL8
8P98	;	2.97	;	BtuB3G3 bound to cyanocobalamin with ordered EL8
7QUQ	;	2.6	;	BtubA(R284G,K286D,F287G):BtubB bacterial tubulin M-loop mutant forming a single protofilament (Prosthecobacter dejongeii)
5O09	;	3.6	;	BtubABC mini microtubule
5KD2	;	2.15	;	BT_4244 metallopeptidase from Bacteroides thetaiotaomicron
5KD5	;	1.65	;	BT_4244 metallopeptidase from Bacteroides thetaiotaomicron
5KD8	;	2.3	;	BT_4244 metallopeptidase in complex with Tn antigen.
2I3S	;	1.9	;	Bub3 complex with Bub1 GLEBS motif
2I3T	;	2.8	;	Bub3 complex with Mad3 (BubR1) GLEBS motif
2H8U	;	2.1	;	Bucain, a cardiotoxin from the Malayan Krait Bungarus candidus
1B77	;	2.1	;	BUILDING A REPLISOME STRUCTURE FROM INTERACTING PIECES: A SLIDING CLAMP COMPLEXED WITH AN INTERACTION PEPTIDE FROM DNA POLYMERASE
5MPQ	;	1.78	;	Bulgecin A: The key to a broad-spectrum inhibitor that targets lytic transglycosylases
1K8S	;		;	BULGED ADENOSINE IN AN RNA DUPLEX
7EEN	;	1.7	;	Bulged-G motif composed of RNA, DNA and 2'-O-methyl RNA
7EEO	;	2.701	;	Bulged-G motif composed of RNA, DNA and 2'-O-methyl RNA
1H8P	;	1.82	;	Bull seminal plasma PDC-109 fibronectin type II module
3RBC	;	2.7	;	Bullfrog M ferritin with iron(III) bound to the ferroxidase site
1RCE	;	2.4	;	BULLFROG RED CELL L FERRITIN SULFATE/MN/PH 6.3
1RCG	;	2.2	;	BULLFROG RED CELL L FERRITIN SULFATE/MN/PH 6.3
1RCC	;	2.4	;	BULLFROG RED CELL L FERRITIN TARTRATE/MG/PH 5.5
1RCD	;	2.0	;	BULLFROG RED CELL L FERRITIN TARTRATE/MG/PH 5.5
1RCI	;	2.0	;	BULLFROG RED CELL L FERRITIN TARTRATE/MG/PH 5.5
7KFE	;	6.6	;	Bundibugyo virus GP (mucin deleted) bound to antibody Fab BDBV-329
7KEW	;	4.16	;	Bundibugyo virus GP (mucin deleted) bound to antibody Fab BDBV-43
6DZM	;	4.29	;	Bundibugyo virus GP (mucin-deleted) in complex with pan-ebolavirus human antibody ADI-15878 Fab
6H3V	;	2.9	;	Bunyamwera Virus Glycoprotein Gc Head Domain
7PCE	;	2.9	;	BurG (apo): Biosynthesis of cyclopropanol rings in bacterial toxins
7PCM	;	2.05	;	BurG (holo) in complex with (Z)-2,3-dihydroxy-6-methyl-hept-2-enoate (13): Biosynthesis of cyclopropanol rings in bacterial toxins
7PCL	;	2.05	;	BurG (holo) in complex with 2-hydroxy-2-(hydroxy(isopropyl)amino)acetate (11): Biosynthesis of cyclopropanolrings in bacterial toxins
7PCG	;	1.9	;	BurG (holo) in complex with cyclopropane-1,1-dicarboxylate (7): Biosynthesis of cyclopropanol rings in bacterial toxins
7PCN	;	1.6	;	BurG (holo) in complex with gonyenediol (14), trigonic acid (6) and DMS: Biosynthesis of cyclopropanol rings in bacterial toxins
7PCI	;	1.9	;	BurG (holo) in complex with hydroxypyruvate-enol (8): Biosynthesis of cyclopropanol rings in bacterial toxins
7PCO	;	1.55	;	BurG E232Q mutant (holo) in complex with 2R,3R-2,3-dihydroxy-6-methyl-heptanoate (12): Biosynthesis of cyclopropanol rings in bacterial toxins
7PCT	;	1.35	;	BurG E232Q mutant (holo) in complex with enol-oxalacetate (15): Biosynthesis of cyclopropanol rings in bacterial toxins
7PCC	;	1.85	;	BurG in complex with Mg2+ and NAD+ (holo): Biosynthesis of cyclopropanol rings in bacterial toxins
1GEV	;	2.1	;	BURIED POLAR MUTANT HUMAN LYSOZYME
1GEZ	;	1.8	;	BURIED POLAR MUTANT HUMAN LYSOZYME
1GF0	;	1.8	;	BURIED POLAR MUTANT HUMAN LYSOZYME
1GF3	;	1.8	;	BURIED POLAR MUTANT HUMAN LYSOZYME
1GF4	;	1.8	;	BURIED POLAR MUTANT HUMAN LYSOZYME
1GF5	;	1.8	;	BURIED POLAR MUTANT HUMAN LYSOZYME
1GF6	;	1.8	;	BURIED POLAR MUTANT HUMAN LYSOZYME
1GF7	;	1.8	;	BURIED POLAR MUTANT HUMAN LYSOZYME
1YS1	;	1.1	;	Burkholderia cepacia lipase complexed with hexylphosphonic acid (R)-2-methyl-3-phenylpropyl ester
1YS2	;	1.5	;	Burkholderia cepacia lipase complexed with hexylphosphonic acid (S) 2-methyl-3-phenylpropyl ester
2NW6	;	1.8	;	Burkholderia cepacia lipase complexed with S-inhibitor
7LUJ	;	2.31	;	Burkholderia pseudomallei Disulfide bond forming protein A (DsbA) liganded with fragment 4-methoxy-N-phenylbenzenesulfonamide
7LUH	;	1.84	;	Burkholderia pseudomallei Disulfide bond forming protein A (DsbA) liganded with fragment bromophenoxy propanamide
4UT4	;	1.94	;	Burkholderia pseudomallei heptokinase WcbL, D-mannose complex.
4UTG	;	1.93	;	Burkholderia pseudomallei heptokinase WcbL,AMPPNP (ATP analogue) complex.
5TZB	;	1.977	;	Burkholderia sp. beta-aminopeptidase
7MLW	;	2.7	;	Burkholderia sp. TJI49 Guanidine-I riboswitch
4CJA	;	2.651	;	BurrH DNA-binding protein from Burkholderia rhizoxinica in complex with its target DNA
4CJ9	;	2.214	;	BurrH DNA-binding protein from Burkholderia rhizoxinica in its apo form
6DHI	;	3.1	;	Butelase 1: Auto-Catalytic Cleavage as an Evolutionary Constraint for Macrocyclizing Endopeptidases
8SL7	;	2.07	;	Butyricicoccus sp. BIOML-A1 tryptophanase complex with (3S) ALG-05
6EYF	;	2.6	;	Butyrylcolinesterase expressed in CHO cells co-crystallised with a rivastigmine analogue
7V51	;	2.42	;	BVMO_negative mutant D432V
4RZR	;	2.2	;	Bypass of a bulky adduct dG1,8 by DPO4
2IA6	;	2.5	;	Bypass of Major Benzopyrene-dG Adduct by Y-Family DNA Polymerase with Unique Structural Gap
2IBK	;	2.25	;	Bypass of Major Benzopyrene-dG Adduct by Y-Family DNA Polymerase with Unique Structural Gap
1ZMF	;	1.88	;	C domain of human cyclophilin-33(hcyp33)
4ZMD	;	1.87	;	C domain of staphylococcal protein A mutant - Q9W
5EWR	;	2.35	;	C merolae U4 snRNP protein Snu13
7PON	;	2.1	;	C TERMINAL DOMAIN OF NIPAH VIRUS PHOSPHOPROTEIN
7PNO	;	2.79	;	C terminal domain of Nipah Virus Phosphoprotein fused to the Ntail alpha more of the Nucleoprotein.
6F1V	;	3.4	;	C terminal region of the dynein heavy chains in the dynein tail/dynactin/BICDR1 complex
1QVP	;		;	C terminal SH3-like domain from Diphtheria toxin Repressor residues 144-226.
4OFT	;	2.6	;	C- Orthorombic NaGST1
6NPU	;	2.33	;	C-abl Kinase domain with the activator(cmpd29), N-(1-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl)acetamide
6NPV	;	1.86	;	C-abl Kinase domain with the activator(cmpd51), N-(1-(3,4-dichlorophenyl)-4-(2-hydroxyethyl)-4,5-dihydro-1H-pyrazol-3-yl)isonicotinamide
6NPE	;	2.15	;	C-abl Kinase domain with the activator(cmpd6), 2-cyano-N-(4-(3,4-dichlorophenyl)thiazol-2-yl)acetamide
4BML	;	4.7	;	C-alpha backbone trace of major capsid protein gp39 found in marine virus Syn5.
3IZ1	;	6.0	;	C-alpha model fitted into the EM structure of Cx26M34A
3IZ2	;	10.0	;	C-alpha model fitted into the EM structure of Cx26M34Adel2-7
2D25	;	1.75	;	C-C-A-G-G-C-M5C-T-G-G; HELICAL FINE STRUCTURE, HYDRATION, AND COMPARISON WITH C-C-A-G-G-C-C-T-G-G
1L3W	;	3.08	;	C-cadherin Ectodomain
1N2T	;	2.0	;	C-DES Mutant K223A with GLY Covalenty Linked to the PLP-cofactor
4QKA	;	3.2	;	c-di-AMP riboswitch from Thermoanaerobacter pseudethanolicus, iridium hexamine soak
1OZS	;		;	C-domain of human cardiac troponin C in complex with the inhibitory region of human cardiac troponin I
3H13	;	2.2	;	c-FLIPL protease-like domain
2I0V	;	2.8	;	c-FMS tyrosine kinase in complex with a quinolone inhibitor
1IAQ	;	2.9	;	C-H-RAS P21 PROTEIN MUTANT WITH THR 35 REPLACED BY SER (T35S) COMPLEXED WITH GUANOSINE-5'-[B,G-IMIDO] TRIPHOSPHATE
4YC8	;	2.9	;	C-Helix-Out Binding of Dasatinib Analog to c-Abl Kinase
4YBK	;	2.5	;	C-Helix-Out Dasatinib Analog Crystallized with c-Src Kinase
2R9S	;	2.4	;	c-Jun N-terminal Kinase 3 with 3,5-Disubstituted Quinoline inhibitor
8PQ9	;	1.7	;	c-KIT kinase domain in complex with avapritinib
8PQD	;	1.5	;	c-KIT kinase domain in complex with avapritinib derivative 10
8PQE	;	2.0	;	c-KIT kinase domain in complex with avapritinib derivative 11
8PQF	;	1.9	;	c-KIT kinase domain in complex with avapritinib derivative 12
8PQA	;	1.65	;	c-KIT kinase domain in complex with avapritinib derivative 4
8PQB	;	1.87	;	c-KIT kinase domain in complex with avapritinib derivative 8
8PQC	;	1.77	;	c-KIT kinase domain in complex with avapritinib derivative 9
8PQG	;	2.4	;	c-KIT T670I mutated kinase domain in complex with avapritinib
8AU5	;	2.72	;	c-MET F1200I mutant in complex with Tepotinib
4KNB	;	2.4	;	C-Met in complex with OSI ligand
3QTI	;	2.0	;	c-Met Kinase in Complex with NVP-BVU972
8AU3	;	2.26	;	c-MET Y1234E,Y1235E mutant in complex with Tepotinib
8AW1	;	2.14	;	c-MET Y1235D mutant in complex with Tepotinib
7ZGT	;	2.05	;	C-Methyltransferase PsmD from Streptomyces griseofuscus (apo form)
7ZKH	;	1.4	;	C-Methyltransferase PsmD from Streptomyces griseofuscus with bound cofactor (crystal form 1)
7ZKG	;	2.3	;	C-Methyltransferase PsmD from Streptomyces griseofuscus with bound cofactor (crystal form 2)
6M75	;	2.57	;	C-Myc DNA binding protein complex
7C36	;		;	c-Myc DNA binding protein structure
2OKV	;	2.0	;	c-Myc DNA Unwinding Element Binding Protein
6HRN	;	1.513	;	C-Phycocyanin from heterocyst forming filamentous cyanobacterium Nostoc sp. WR13
7PKF	;	2.8	;	C-reactive protein decamer at pH 5
7PKH	;	3.0	;	C-reactive protein decamer at pH 5 with phosphocholine ligand
7PK9	;	2.8	;	C-reactive protein decamer at pH 7.5
7PKD	;	3.3	;	C-reactive protein decamer at pH 7.5 with phosphocholine ligand
7PKG	;	3.3	;	C-reactive protein pentamer at pH 5
7PKB	;	3.2	;	C-reactive protein pentamer at pH 7.5
7PKE	;	3.3	;	C-reactive protein pentamer at pH 7.5 with phosphocholine ligand
6R5G	;		;	C-SH2 domain of SHP-2 in complex with phospho-ITSM of PD-1
1A1A	;	2.0	;	C-SRC (SH2 DOMAIN WITH C188A MUTATION) COMPLEXED WITH ACE-FORMYL PHOSPHOTYR-GLU-(N,N-DIPENTYL AMINE)
1A08	;	2.2	;	C-SRC (SH2 DOMAIN) COMPLEXED WITH ACE-DIFLUORO PHOSPHOTYR-GLU-(N,N-DIPENTYL AMINE)
1A09	;	2.0	;	C-src (SH2 domain) complexed with ace-formyl phosphotyr-glu-(n,n-dipentyl amine)
1A07	;	2.2	;	C-SRC (SH2 DOMAIN) COMPLEXED WITH ACE-MALONYL TYR-GLU-(N,N-DIPENTYL AMINE)
1A1E	;	2.2	;	C-SRC (SH2 DOMAIN) COMPLEXED WITH ACE-PHOSPHOTYR-GLU-(3-BUTYLPIPERIDINE)
1A1B	;	2.2	;	C-SRC (SH2 DOMAIN) COMPLEXED WITH ACE-PHOSPHOTYR-GLU-(N,N-DIPENTYL AMINE)
1A1C	;	2.4	;	C-SRC (SH2 DOMAIN) COMPLEXED WITH ACE-PHOSPHOTYR-GLU-(N-ME(-(CH2)3-CYCLOPENTYL))
6WIW	;	2.3	;	c-Src Bound to ATP-Competitive Inhibitor I14
5XP7	;	2.012	;	C-Src in complex with ATP-CHCl
5XP5	;	2.101	;	C-Src in complex with ATP-Chf
8JF3	;	2.84648	;	C-Src in complex with compound 9
7D57	;	2.104	;	C-Src in complex with FIIN-2
6L8L	;	2.888	;	C-Src in complex with ibrutinib
7WF5	;	1.798	;	c-Src in complex with ponatinib
4U5J	;	2.26	;	C-Src in complex with Ruxolitinib
7D5O	;	2.69	;	C-Src in complex with TAS-120
3UQF	;	2.27	;	c-SRC kinase domain in complex with BKI RM-1-89
3UQG	;	2.2	;	c-SRC kinase domain in complex with bumpless BKI analog UW1243
5T0P	;	2.5	;	c-Src kinase domain in complex with Rao-IV-151
4DGG	;	2.65	;	c-SRC kinase domain in complex with RM-1-176
3F6X	;	2.35	;	c-Src kinase domain in complex with small molecule inhibitor
3DQW	;	2.017	;	c-Src kinase domain Thr338Ile mutant in complex with ATPgS
1QWE	;		;	C-SRC SH3 DOMAIN COMPLEXED WITH LIGAND APP12
1QWF	;		;	C-SRC SH3 DOMAIN COMPLEXED WITH LIGAND VSL12
5SYS	;	2.8	;	c-Src V281C bound to N-[3-({6-[(1E)-2-cyano-3-(methylamino)-3-oxoprop-1-en-1-yl]-7-(2-methoxyethyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl}ethynyl)-4-methylphenyl]-3-(trifluoromethyl)benzamide inhibitor
5SWH	;	2.5	;	c-Src V281C kinase domain in complex with Rao-IV-151
5TEH	;	2.99	;	c-Src V281C kinase domain in complex with Rao-IV-156
1YI6	;	2.0	;	C-term tail segment of human tyrosine kinase (258-533)
3K7D	;	2.4	;	C-terminal (adenylylation) domain of E.coli Glutamine Synthetase Adenylyltransferase
8EBF	;	2.5	;	C-terminal (TPR) domain of LIC11990 from Leptospira interrogans
5U0J	;	1.72	;	C-terminal ankyrin repeats from human kidney-type glutaminase (KGA) - monoclinic crystal form
5U0I	;	1.423	;	C-terminal ankyrin repeats from human kidney-type glutaminase (KGA) - tetragonal crystal form
5U0K	;	2.548	;	C-terminal ankyrin repeats from human liver-type glutaminase (GAB/LGA)
3DIW	;	2.1	;	c-terminal beta-catenin bound TIP-1 structure
6MOA	;	1.271	;	C-terminal bromodomain of human BRD2 in complex with 4-(2-cyclopropyl-7-(6-methylquinolin-5-yl)-1H-benzo[d]imidazol-5-yl)-3,5-dimethylisoxazole inhibitor
8B5H	;	1.603	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH (R)-7-((R)-1,2-dihydroxyethyl)-1,3-dimethyl-5-(1-methyl-1H-pyrazol-4-yl)-1,3-dihydro-2H-benzo[d]azepin-2-one
7NPZ	;	1.28	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH (R)-N5-cyclopropyl-N3-methyl-2-oxo-1-(1-phenylethyl)-1,2-dihydropyridine-3,5-dicarboxamide
8PX8	;	1.603	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH (S)-5-(1-((1-acetylpiperidin-3-yl)methyl)-5-bromo-1H-benzo[d]imidazol-2-yl)-1,3-dimethylpyridin-2(1H)-one
7NQ7	;	1.7	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH (S)-N-ethyl-3-(1-methyl-1H-1,2,3-triazol-4-yl)-4-(1-phenylethoxy)benzamide
7NQ2	;	1.735	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH (S)-N4-cyclopropyl-N2-methyl-6-(1-phenylethyl)pyridine-2,4-dicarboxamide
8PX2	;	1.622	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 1,3-dimethyl-5-(1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one
7OET	;	1.41	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 1,5-dimethyl-N-(2-(methylamino)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)ethyl)-6-oxo-N-(2-phenyl-2-(pyridin-2-yl)ethyl)-1,6-dihydropyridine-3-carboxamide
7OES	;	1.602	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 1,5-dimethyl-N-(2-(methylamino)-2-oxoethyl)-6-oxo-N-(2-phenylpropyl)-1,6-dihydropyridine-3-carboxamide
6ZB0	;	1.613	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 1-benzyl-N-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide
7OGY	;	1.602	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 1-benzyl-N5-cyclopropyl-N3-methyl-1H-pyrazole-3,5-dicarboxamide
7NQ9	;	1.602	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 2-benzyl-N-cyclopropyl-6-(1-methyl-1H-1,2,3-triazol-4-yl)isonicotinamide
7NQI	;	1.603	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 2-benzyl-N-cyclopropyl-6-(1-methyl-1H-1,2,3-triazol-4-yl)isonicotinamide
7NQ5	;	1.6	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 3-(2-(benzyloxy)phenyl)-5-methyl-1H-1,2,4-triazole
7OEP	;	1.801	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 5-(1-(1,3-dimethoxypropan-2-yl)-5-morpholino-1H-benzo[d]imidazol-2-yl)-1,3-dimethylpyridin-2(1H)-one
7NQ1	;	1.6	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 6-((S)-hydroxy(phenyl)methyl)-N2-methyl-N4-((1S,2S)-2-methylcyclopropyl)pyridine-2,4-dicarboxamide
7NPY	;	1.601	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 6-benzyl-N2-methyl-N4-((1S,2S)-2-methylcyclopropyl)pyridine-2,4-dicarboxamide
8B5I	;	1.604	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 7,8-dimethoxy-1,3-dimethyl-1,3-dihydro-2H-benzo[d]azepin-2-one
8B5J	;	1.603	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 7,8-dimethoxy-1,3-dimethyl-1,3-dihydro-2H-benzo[d]azepin-2-one
8B5G	;	1.619	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 7,8-dimethoxy-3-methyl-1,3-dihydro-2H-benzo[d]azepin-2-one
6ZB2	;	2.282	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH GSK549
6ZB1	;	1.6	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH GSK620
6Z8P	;	1.55	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH GSK973
4UYG	;	2.5	;	C-Terminal bromodomain of Human BRD2 with I-BET726 (GSK1324726A)
6SWO	;	1.601	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH iBET-BD1 (GSK778)
6SWP	;	1.604	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH iBET-BD2 (GSK046)
7OER	;	1.602	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N-(2,2-diphenylethyl)-1,5-dimethyl-N-(2-(methylamino)-2-oxoethyl)-6-oxo-1,6-dihydropyridine-3-carboxamide
6Z7F	;	1.605	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N-(2-(1H-imidazol-4-yl)ethyl)-4-acetamido-3-(benzyloxy)benzamide
7NQJ	;	1.734	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N-ethyl-2-(1-methyl-1H-1,2,3-triazol-4-yl)-6-(1-phenylethyl)isonicotinamide
7NQ8	;	1.602	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N-ethyl-3-(1-methyl-1H-1,2,3-triazol-4-yl)-4-(pyridin-2-ylmethoxy)benzamide
7OE4	;	1.653	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N-methyl-4-propionyl-1H-pyrrole-2-carboxamide
7NQ3	;	1.603	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N4-((1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-yl)-6-((S)-methoxy(phenyl)methyl)-N2-methylpyridine-2,4-dicarboxamide
7OE6	;	1.762	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N4-hydroxycyclohexyl-N2-methyl-5-phenylethyl-furan-2,4-dicarboxamide
7OE8	;	1.301	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N5-((1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-yl)-3-(1H-indol-4-yl)-N7-methyl-2,3-dihydrobenzofuran-5,7-dicarboxamide
7OE5	;	1.602	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N5-hydroxycyclohexyl-N3-methyl-1-phenylethyl-1H-pyrazole-3,5-dicarboxamide
7NQ0	;	1.3	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH oxabicyclo(hexan-6-yl)-N2-methyl-6-((S)-1-phenylethyl)pyridine-2,4-dicarboxamide
7OE9	;	1.602	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH rac-N5-((1R,5S)-3-oxabicyclo[3.1.0]hexan-6-yl)-N7,3-dimethyl-3-phenyl-2,3-dihydrobenzofuran-5,7-dicarboxamide
7OEO	;	1.51	;	C-TERMINAL BROMODOMAIN OF HUMAN BRD4 N-(2,2-diphenylethyl)-4-methoxy-3,5-dimethyl-N-(2-(methylamino)-2-oxoethyl)benzamide
7L4V	;	1.75	;	C-terminal bZIP domain of human C/EBPbeta Bound to DNA with Consensus Recognition with GT Mismatch
6MG1	;	1.75	;	C-terminal bZIP domain of human C/EBPbeta with 16bp Methylated Oligonucleotide Containing Consensus Recognition Sequence-C2 Crystal Form
6MG2	;	1.928	;	C-terminal bZIP domain of human C/EBPbeta with 16bp Methylated Oligonucleotide Containing Consensus Recognition Sequence-C2221 Crystal Form
2VZQ	;	1.7	;	C-terminal CBM35 from Amycolatopsis orientalis exo-chitosanase CsxA in complex with digalacturonic acid
2VZR	;	1.95	;	C-terminal CBM35 from Amycolatopsis orientalis exo-chitosanase CsxA in complex with glucuronic acid
6IRB	;	2.661	;	C-terminal coiled coil domain of Drosophila phospholipase C beta NORPA, selenomethionine
1HF9	;		;	C-Terminal Coiled-Coil Domain from Bovine IF1
4GIF	;	2.8	;	C-terminal coiled-coil domain of transient receptor potential channel TRPP3 (PKD2L1, Polycystin-L)
6DYM	;	2.02	;	C-terminal condensation domain of Ebony
6DYS	;	2.3	;	C-terminal condensation domain of Ebony in complex with beta-alanyl-dopamine
6DYR	;	2.45	;	C-terminal condensation domain of Ebony in complex with Carcinine
6DYN	;	2.102	;	C-terminal condensation domain of Ebony in complex with Histamine
6DYO	;	2.84	;	C-terminal condensation domain of Ebony in complex with L-Dopamine
2XOZ	;	2.374	;	C-terminal cysteine rich domain of human CHFR bound to AMP
2XP0	;	1.978	;	C-terminal cysteine-rich domain of human CHFR
2XOC	;	1.89	;	C-terminal cysteine-rich domain of human CHFR bound to mADPr
2XOY	;	2.6	;	C-terminal cysteine-rich domain of human CHFR bound to P(1),P(2)- Diadenosine-5'-pyrophosphate
1SOP	;		;	C-terminal cystine-rich domain of Minicollagen-I from Hydra
2B0L	;	2.9	;	C-terminal DNA binding domain of transcriptional pleiotropic repressor CodY.
1QMC	;		;	C-terminal DNA-binding domain of HIV-1 integrase, NMR, 42 structures
1VPC	;		;	C-TERMINAL DOMAIN (52-96) OF THE HIV-1 REGULATORY PROTEIN VPR, NMR, 1 STRUCTURE
1RTG	;	2.6	;	C-TERMINAL DOMAIN (HAEMOPEXIN-LIKE DOMAIN) OF HUMAN MATRIX METALLOPROTEINASE-2
2P5M	;	1.95	;	C-terminal domain hexamer of AhrC bound with L-arginine
4AM6	;	2.7	;	C-TERMINAL DOMAIN OF ACTIN-RELATED PROTEIN ARP8 FROM S. CEREVISIAE
7C7Y	;	2.6	;	C-terminal domain of B. cereus TubY
3GAB	;	2.5	;	C-terminal domain of Bacillus subtilis MutL crystal form I
3KDG	;	2.0	;	C-terminal domain of Bacillus subtilis MutL crystal form II
2XR4	;	1.9	;	C-terminal domain of BC2L-C Lectin from Burkholderia cenocepacia
8EIL	;	2.25	;	C-Terminal Domain of BrxL from Acinetobacter BREX type I phage restriction system
4PH1	;	2.46	;	C-terminal domain of capsid protein from bovine leukemia virus
2N5X	;		;	C-terminal domain of Cdc37 cochaperone
6F1S	;	2.4	;	C-terminal domain of CglI restriction endonuclease H subunit
4CU2	;	2.11	;	C-terminal domain of CTP1L endolysin mutant V195P that reduces autoproteolysis
1K4Z	;	2.3	;	C-terminal Domain of Cyclase Associated Protein
1KQ5	;	3.0	;	C-terminal Domain of Cyclase Associated Protein with PRO 505 Replaced by SER (P505S)
4PQK	;	3.401	;	C-Terminal domain of DNA binding protein
6IRC	;	3.538	;	C-terminal domain of Drosophila phospholipase b NORPA, methylated
5J3N	;	2.45	;	C-terminal domain of EcoR124I HsdR subunit fused with the pH-sensitive GFP variant ratiometric pHluorin
1WSU	;	2.3	;	C-terminal domain of elongation factor selB complexed with SECIS RNA
4CU5	;	2.24	;	C-terminal domain of endolysin from phage CD27L is a trigger and release factor
2E5U	;		;	C-terminal domain of Epsilon subunit of F1F0-ATP synthase from the Thermophilic Bacillus PS3
2E5T	;		;	C-terminal domain of Epsilon subunit of F1F0-ATP synthase from the Thermophilic bacillus PS3 in the presence of ATP condition
1XXC	;	2.8	;	C-TERMINAL DOMAIN OF ESCHERICHIA COLI ARGININE REPRESSOR
1XXB	;	2.6	;	C-TERMINAL DOMAIN OF ESCHERICHIA COLI ARGININE REPRESSOR/ L-ARGININE COMPLEX
1XXA	;	2.2	;	C-TERMINAL DOMAIN OF ESCHERICHIA COLI ARGININE REPRESSOR/ L-ARGININE COMPLEX; PB DERIVATIVE
1YUA	;		;	C-TERMINAL DOMAIN OF ESCHERICHIA COLI TOPOISOMERASE I
6E0T	;	2.02	;	C-terminal domain of Fission Yeast OFD1
1GEN	;	2.15	;	C-TERMINAL DOMAIN OF GELATINASE A
3TBF	;	2.28	;	C-terminal domain of glucosamine-fructose-6-phosphate aminotransferase from Francisella tularensis.
7R1Z	;	1.94	;	C-terminal domain of hArc in complex with nanobodies H11 and C11, collapsed crystal form
2N67	;		;	C-terminal domain of Hemolysin II-P87M-BMRB
5TC2	;	1.84	;	C-terminal domain of HIV-1 integrase, crystal structure
5EPW	;	1.5	;	C-Terminal Domain Of Human Coronavirus Nl63 Nucleocapsid Protein
3LOF	;	2.4	;	C-terminal domain of human heat shock 70kDa protein 1B.
2LSK	;		;	C-terminal domain of human REV1 in complex with DNA-polymerase H (eta)
2JDQ	;	2.2	;	C-terminal domain of influenza A virus polymerase PB2 subunit in complex with human importin alpha5
6SYI	;	1.6	;	C-TERMINAL DOMAIN OF INFLUENZA POLYMERASE PA SUBUNIT AND OPTIMIZED SMALL PEPTIDE INHIBITOR
4EW5	;	1.87	;	C-terminal domain of inner membrane protein CigR from Salmonella enterica.
1RMJ	;		;	C-terminal domain of insulin-like growth factor (IGF) binding protein-6: structure and interaction with IGF-II
1ZT3	;	1.8	;	C-terminal domain of Insulin-like Growth Factor Binding Protein-1 isolated from human amniotic fluid
1ZT5	;	1.818	;	C-terminal domain of Insulin-like Growth Factor Binding Protein-1 isolated from human amniotic fluid complexed with Iron(II)
2ZP2	;	3.01	;	C-terminal domain of KipI from Bacillus subtilis
6ELT	;	1.35	;	C-terminal domain of MdPPO1 upon self-cleavage (Ccleaved-domain)
6G13	;	1.97	;	C-terminal domain of MERS-CoV nucleocapsid
2KVE	;		;	C-terminal domain of mesencephalic astrocyte-derived neurotrophic factor (MANF)
1MKH	;	2.01	;	C-terminal domain of methionyl-tRNA synthetase from Pyrococcus abyssi
1MKC	;		;	C-TERMINAL DOMAIN OF MIDKINE
8QB1	;	1.601	;	C-terminal domain of mirolase from Tannerella forsythia
1C8Z	;	1.9	;	C-TERMINAL DOMAIN OF MOUSE BRAIN TUBBY PROTEIN
1I7E	;	1.95	;	C-Terminal Domain Of Mouse Brain Tubby Protein bound to Phosphatidylinositol 4,5-bis-phosphate
6VZ0	;	1.75	;	C-terminal domain of mouse surfactant protein B crystallized at high pH
6VZE	;	1.9	;	C-terminal domain of mouse surfactant protein B crystallized at low pH
3KZ7	;	1.95	;	C-terminal domain of Murine FKBP25 rapamycin complex
2JRB	;		;	C-terminal domain of ORF1p from mouse LINE-1
3IR9	;	2.207	;	C-terminal domain of Peptide Chain Release Factor from Methanosarcina mazei.
3DED	;	2.14	;	C-terminal domain of Probable hemolysin from Chromobacterium violaceum
3RKV	;	2.41	;	C-terminal domain of protein C56C10.10, a putative peptidylprolyl isomerase, from Caenorhabditis elegans
3FW2	;	1.74	;	C-terminal domain of putative thiol-disulfide oxidoreductase from Bacteroides thetaiotaomicron.
7LRH	;	1.92	;	C-terminal domain of RibD from Brucella abortus (5-amino-6-ribosylamino-2,4(1H,3H)-pyrimidinedione 5'-phosphate reductase)
5F22	;	2.155	;	C-terminal domain of SARS-CoV nsp8 complex with nsp7
4KSN	;	1.86	;	C-terminal domain of SdbC protein from Legionella pneumophila.
3WWV	;	2.4	;	C-terminal domain of stomatin operon partner protein 1510-C from Pyrococcus horikoshii
5EOV	;	1.701	;	C-terminal domain of the 16S/23S rRNA (cytidine-2'-O)-methyltransferase TlyA.
1NRF	;	2.5	;	C-terminal domain of the Bacillus licheniformis BlaR penicillin-receptor
1AA3	;		;	C-TERMINAL DOMAIN OF THE E. COLI RECA, NMR, MINIMIZED AVERAGE STRUCTURE
1H8G	;	2.4	;	C-terminal domain of the major autolysin (C-LytA) from Streptococcus pneumoniae
5CES	;	2.102	;	C-terminal domain of the R-type pyocin baseplate protein PA0618
4IP6	;	2.23	;	C-terminal domain of the thiol:disulfide interchange protein DsbD, Q488A mutant
4IP1	;	2.47	;	C-terminal domain of the thiol:disulfide interchange protein DsbD, Q488K mutant
1IGU	;	2.2	;	C-terminal Domain of the Transcriptional Repressor Protein KorB
6HS6	;	3.08	;	C-terminal domain of the TssA component of the type VI secretion system from Burkholderia cenocepacia
1IGQ	;	1.7	;	C-terminal Domain of Transcriptional Repressor Protein KorB
6RJU	;	3.2	;	C-terminal domain of TssA protein from T6SS of Escherichia coli.
6RIU	;	3.9	;	C-terminal domain of TssA protein from T6SS of Vibrio cholerae.
1JAD	;	2.4	;	C-terminal Domain of Turkey PLC-beta
3N1B	;	2.398	;	C-terminal domain of Vps54 subunit of the GARP complex
7VE4	;	1.87	;	C-terminal domain of VraR
7VE5	;	2.0	;	C-terminal domain of VraR
5DCF	;	2.3	;	C-terminal domain of XerD recombinase in complex with gamma domain of FtsK
5M4T	;		;	C-terminal domain structure of VSG M1.1
6CTD	;	5.8	;	C-terminal domain truncation of the Mycobacterium tuberculosis Mechanosensitive Channel of Large Conductance MscL
2UWM	;	2.31	;	C-TERMINAL DOMAIN(WH2-WH4) OF ELONGATION FACTOR SELB IN COMPLEX WITH SECIS RNA
6IPA	;	2.47	;	C-terminal EMAP II-like domain of p43 refined against twinned data
3WYD	;	1.53	;	C-terminal esterase domain of LC-Est1
4CQ4	;	1.7	;	C-terminal fragment of Af1503-sol: transmembrane receptor Af1503 from Archaeoglobus fulgidus engineered for solubility
4M03	;	2.24	;	C-terminal fragment(residues 576-751) of binding region of SraP
2FH2	;	2.5	;	C-terminal half of gelsolin soaked in EGTA at pH 4.5
2FH4	;	3.0	;	C-terminal half of gelsolin soaked in EGTA at pH 8
2FH1	;	1.55	;	C-terminal half of gelsolin soaked in low calcium at pH 4.5
2FH3	;	2.87	;	C-terminal half of gelsolin soaked in low calcium at pH 8
1VVD	;		;	C-TERMINAL HALF OF VACCINIA VIRUS COMPLEMENT CONTROL PROTEIN, NMR, 21 STRUCTURES
1VVE	;		;	C-TERMINAL HALF OF VACCINIA VIRUS COMPLEMENT CONTROL PROTEIN, NMR, 21 STRUCTURES
1VVC	;		;	C-TERMINAL HALF OF VACCINIA VIRUS COMPLEMENT CONTROL PROTEIN, NMR, MINIMIZED AVERAGE STRUCTURE
7O23	;	1.4	;	C-terminal head domain of the trimeric autotransporter adhesin BpaC from Burkholderia pseudomallei fused to a GCN4 anchor
5DKU	;	2.9	;	C-terminal His tagged apPOL exonuclease mutant
6SK3	;	2.7	;	C-terminal HsNMT1 deltaC3 truncation in complex with both MyrCoA and GNCFSKPR substrates
1KHM	;		;	C-TERMINAL KH DOMAIN OF HNRNP K (KH3)
1H30	;	2.2	;	C-terminal LG domain pair of human Gas6
1B9W	;	1.8	;	C-TERMINAL MEROZOITE SURFACE PROTEIN 1 FROM PLASMODIUM CYNOMOLGI
4ETP	;	2.3	;	C-terminal motor and motor homology domain of Kar3Vik1 fused to a synthetic heterodimeric coiled coil
4RY7	;	3.0	;	C-terminal mutant (D559E) of HCV/J4 RNA polymerase
4RY6	;	2.52	;	C-terminal mutant (W550A) of HCV/J4 RNA polymerase
4RY5	;	2.71	;	C-terminal mutant (W550N) of HCV/J4 RNA polymerase
4RY4	;	2.59	;	C-terminal mutant (Y448F) of HCV/J4 RNA polymerase
6EY5	;	2.85	;	C-terminal part (residues 224-515) of PorM
6EY6	;	2.1	;	C-terminal part (residues 315-516) of PorM with the llama nanobody nb130
5XZT	;	1.8	;	C-terminal peptide depleted mutant of hydroxynitrile lyase from Passiflora edulis (PeHNL)
5Y02	;	1.8	;	C-terminal peptide depleted mutant of hydroxynitrile lyase from Passiflora edulis (PeHNL) bound with (R)-mandelonitrile
1UG3	;	2.24	;	C-terminal portion of human eIF4GI
1RXZ	;	2.0	;	C-terminal region of A. fulgidus FEN-1 complexed with A. fulgidus PCNA
1RXM	;	2.8	;	C-terminal region of FEN-1 bound to A. fulgidus PCNA
6NK8	;	2.24	;	C-terminal region of the Burkholderia pseudomallei OLD protein
6NJV	;	2.3	;	C-terminal region of the Xanthomonas campestris pv. campestris OLD protein phased with iodine
6NJX	;	1.95	;	C-terminal region of the Xanthomonas campestris pv. campestris OLD protein phased with mercury
6NJW	;	1.86	;	C-terminal region of the Xanthomonas campestris pv. campestris OLD protein phased with platinum
6VWA	;	2.196	;	C-terminal regulatory domain of the chloride transporter KCC-1 from C. elegans
6VW9	;	1.8	;	C-terminal regulatory domain of the chloride transporter KCC-1 from C. elegans, proteolyzed during crystallization
8R07	;	1.74	;	C-terminal Rel-homology Domain of NFAT1
8R3F	;	1.55	;	C-terminal Rel-homology Domain of NFAT1
3EGN	;	2.5	;	C-terminal RNA Recognition Motif of the U11/U12 65K Protein
8D4Y	;	2.9	;	C-terminal SANT-SLIDE domain of human Chromodomain-helicase-DNA-binding protein 4 (CHD4)
6WAX	;	1.5	;	C-terminal SH2 domain of p120RasGAP
6WAY	;	1.5	;	C-terminal SH2 domain of p120RasGAP in complex with p190RhoGAP phosphotyrosine peptide
2EYX	;		;	C-Terminal SH3 domain of CT10-Regulated Kinase
2M7N	;		;	C-terminal structure of (Y81F)-EhCaBP1
6IFV	;	3.11	;	C-terminal truncated KsgA from Bacillus subtilis 168
1HP3	;		;	C-TERMINAL TRUNCATION OF OMEGA-ATRACOTOXIN-HV2A (CT-HV2A)
1HEH	;		;	C-terminal xylan binding domain from Cellulomonas fimi xylanase 11A
1HEJ	;		;	C-terminal xylan binding domain from Cellulomonas fimi xylanase 11A
5XEK	;		;	C-terminal zinc finger of RING finger protein 141
2L46	;		;	C-terminal zinc finger of the HIVNCp7 with platinated DNA
2L44	;		;	C-terminal zinc knuckle of the HIVNCp7
2L45	;		;	C-terminal zinc knuckle of the HIVNCp7 with DNA
6S09	;	1.502	;	C-terminally extended and N-terminally truncated variant of FimA E. coli at 1.5 Angstrom resolution
5OXI	;	1.63	;	C-terminally retracted ubiquitin L67S mutant
5OXH	;	1.601	;	C-terminally retracted ubiquitin T66V/L67N mutant
7L68	;	1.4	;	C-type carbohydrate-recognition domain 4 of the mannose receptor
7L67	;	1.2	;	C-type carbohydrate-recognition domain 4 of the mannose receptor complexed with Fuc-(alpha1-3)-GlcNAc
7L61	;	1.35	;	C-type carbohydrate-recognition domain 4 of the mannose receptor complexed with L-fucose-(alpha 1-2)-D-galactose-(beta1-4)-D-glucose
7L62	;	1.55	;	C-type carbohydrate-recognition domain 4 of the mannose receptor complexed with L-fucose-(alpha 1-2)-D-galactose-(beta1-4)-D-glucose
7L63	;	1.65	;	C-type carbohydrate-recognition domain 4 of the mannose receptor complexed with L-fucose-(alpha 1-2)-D-galactose-(beta1-4)-D-glucose
7L64	;	1.35	;	C-type carbohydrate-recognition domain 4 of the mannose receptor complexed with Lewis-a
7JUE	;	1.4	;	C-type carbohydrate-recognition domain 4 of the mannose receptor complexed with Man-alpha1-2Man
7JUF	;	1.4	;	C-type carbohydrate-recognition domain 4 of the mannose receptor complexed with Man-alpha1-2Man
7JUG	;	1.4	;	C-type carbohydrate-recognition domain 4 of the mannose receptor complexed with Man-alpha1-6Man
7JUH	;	1.4	;	C-type carbohydrate-recognition domain 4 of the mannose receptor complexed with Man-alpha1-6Man
7L65	;	1.35	;	C-type carbohydrate-recognition domain 4 of the mannose receptor complexed with Methyl-GlcNAc
7L66	;	1.75	;	C-type carbohydrate-recognition domain 4 of the mannose receptor complexed with Methyl-GlcNAc
7JUB	;	1.2	;	C-type carbohydrate-recognition domain 4 of the mannose receptor complexed with methyl-mannoside
7JUC	;	1.4	;	C-type carbohydrate-recognition domain 4 of the mannose receptor complexed with methyl-mannoside
7JUD	;	1.4	;	C-type carbohydrate-recognition domain 4 of the mannose receptor complexed with methyl-mannoside
6TP9	;	2.19	;	c-type cytochrome NirC
7SIZ	;	3.1	;	C-type inactivation in a voltage gated K+ channel
5F2Q	;	2.95	;	C-type lectin from Bothrops jararacussu
3WHD	;	2.29	;	C-type lectin, human MCL
8A59	;	1.92	;	C-type lectin-like domain (CTLD) and Sushi-like domain of human CD93
6M4C	;	2.65	;	C. albicans actin interacting protein Aip5
8EEL	;	1.97	;	C. ammoniagenes monoamine oxidase (MAO) bound to 5-aminopentanol
8EEG	;	2.15	;	C. ammoniagenes monoamine oxidase (MAO) bound to dopamine
8EEM	;	1.56	;	C. ammoniagenes monoamine oxidase (MAO) bound to norepinephrine
8EEF	;	2.21	;	C. ammoniagenes monoamine oxidase (MAO) bound to octopamine
8EEH	;	1.78	;	C. ammoniagenes monoamine oxidase (MAO) bound to tryptamine
8EEK	;	1.51	;	C. ammoniagenes monoamine oxidase (MAO) bound to tyramine
8EEN	;	1.46	;	C. ammoniagenes monoamine oxidase (MAO) C424S variant
8EEJ	;	1.54	;	C. ammoniagenes monoamine oxidase (MAO) C424S variant bound to dopamine
8EEO	;	1.94	;	C. ammoniagenes monoamine oxidase bound to cadaverine
4Z03	;	1.4	;	C. bescii Family 3 pectate lyase double mutant K108A in complex with trigalacturonic acid
4YZX	;	1.25	;	C. bescii Family 3 pectate lyase double mutant K108A/D107N in complex with trigalacturonic acid
4YZ0	;	1.15	;	C. bescii Family 3 pectate lyase double mutant K108A/E39Q in complex with trigalacturonic acid
4YZA	;	1.25	;	C. bescii Family 3 pectate lyase double mutant K108A/Q111A in complex with trigalacturonic acid
4YZQ	;	1.48	;	C. bescii Family 3 pectate lyase double mutant K108A/Q111N in complex with trigalacturonic acid
4Z06	;	1.55	;	C. bescii Family 3 pectate lyase double mutant K108A/R133A in complex with ALPHA-D-GALACTOPYRANURONIC ACID
4Z05	;	1.5	;	C. bescii Family 3 pectate lyase mutant E84A
4CZJ	;	2.0	;	C. crescentus MreB, double filament, AMPPNP
4CZE	;	2.0	;	C. crescentus MreB, double filament, empty
4CZL	;	1.6	;	C. crescentus MreB, monomeric, ADP
4CZM	;	2.2	;	C. crescentus MreB, monomeric, AMPPNP
4CZF	;	1.64	;	C. crescentus MreB, single filament, ADP
4CZG	;	1.5	;	C. crescentus MreB, single filament, ADP, A22 inhibitor
4CZH	;	1.644	;	C. crescentus MreB, single filament, ADP, MP265 inhibitor
4CZK	;	2.602	;	C. crescentus MreB, single filament, AMPPNP, MP265 inhibitor
4CZI	;	1.8	;	C. crescentus MreB, single filament, empty
4OI2	;	2.6	;	C. Elegans Clp1 and ADP and Mg2+ (turnover state)
4OHX	;	1.98	;	C. Elegans Clp1 bound to ADP and Mg2+ (RNA released state)
4OHV	;	2.3	;	C. Elegans Clp1 bound to AMP-PNP, and Mg2+
4OHW	;	2.3	;	C. Elegans Clp1 bound to ATP, and Mn2+(ATP-bound state)
4OHY	;	2.0	;	C. Elegans Clp1 bound to ssRNA dinucleotide GC, AMP-PNP, and Mg2+(inhibited substrate bound state)
3KBF	;	1.3	;	C. elegans Cu,Zn Superoxide Dismutase
5TD6	;	2.034	;	C. elegans FOG-3 BTG/Tob domain - H47N, C117A
4AG7	;	1.55	;	C. elegans glucosamine-6-phosphate N-acetyltransferase (GNA1): coenzyme A adduct
4AG9	;	1.76	;	C. elegans glucosamine-6-phosphate N-acetyltransferase (GNA1): ternary complex with coenzyme A and GlcNAc
3RHW	;	3.26	;	C. elegans glutamate-gated chloride channel (GluCl) in complex with Fab and ivermectin
4TNW	;	3.2	;	C. elegans glutamate-gated chloride channel (GluCl) in complex with Fab and POPC in a lipid-modulated conformation
4TNV	;	3.6	;	C. elegans glutamate-gated chloride channel (GluCl) in complex with Fab in a non-conducting conformation
3RIF	;	3.345	;	C. elegans glutamate-gated chloride channel (GluCl) in complex with Fab, ivermectin and glutamate.
3RIA	;	3.8	;	C. elegans glutamate-gated chloride channel (GluCl) in complex with Fab, ivermectin and iodide.
3RI5	;	3.4	;	C. elegans glutamate-gated chloride channel (GluCl) in complex with Fab, ivermectin and picrotoxin
4TZM	;	2.3	;	C. elegans HTP-2 bound to HTP-3 closure motif 1
5H1R	;	3.6	;	C. elegans INX-6 gap junction channel
5H1Q	;	3.3	;	C. elegans INX-6 gap junction hemichannel
1GRW	;	2.6	;	C. elegans major sperm protein
5CV1	;	3.599	;	C. elegans PGL-1 Dimerization Domain
8P2M	;	3.82	;	C. elegans TIR-1 protein.
8BY5	;	1.73	;	C. elegans TOFU-6 eTUDOR TOFU-1 peptide complex
4XLG	;	1.78	;	C. glabrata Slx1 in complex with Slx4CCD.
4XM5	;	2.34	;	C. glabrata Slx1.
2DAP	;	2.2	;	C. GLUTAMICUM DAP DEHYDROGENASE IN COMPLEX WITH DAP
1DAP	;	2.2	;	C. GLUTAMICUM DAP DEHYDROGENASE IN COMPLEX WITH NADP+
3DAP	;	2.2	;	C. GLUTAMICUM DAP DEHYDROGENASE IN COMPLEX WITH NADP+ AND THE INHIBITOR 5S-ISOXAZOLINE
8JZH	;	2.2	;	C. glutamicum S-adenosylmethionine synthase
8JZG	;	2.39	;	C. glutamicum S-adenosylmethionine synthase co-crystallized with Adenosine, triphosphate, and SAM
1D2K	;	2.2	;	C. IMMITIS CHITINASE 1 AT 2.2 ANGSTROMS RESOLUTION
5W4A	;	1.5	;	C. japonica N-domain
5W4D	;	1.599	;	C. japonica N-domain, Selenomethionine mutant
6B10	;	2.09	;	C. Jejuni Agmatine Deiminase
6B2W	;	2.5	;	C. Jejuni C315S Agmatine Deiminase with Substrate Bound
3KHJ	;	2.8	;	C. parvum inosine monophosphate dehydrogenase bound by inhibitor C64
8OSE	;	1.35	;	C. perfringens chitinase CP4_3455 in complex with inhibitor bisdionin C
5COW	;	1.6	;	C. remanei PGL-1 Dimerization Domain
5CV3	;	3.17015	;	C. remanei PGL-1 Dimerization Domain - Hg
7KGM	;	2.6	;	C. rodentium YcbB - ertapenem complex
7BGJ	;	6.9	;	C. thermophilum Pyruvate Dehydrogenase Complex Core
2IUA	;	2.7	;	C. trachomatis LpxD
2B5A	;	1.543	;	C.BclI, Control Element of the BclI Restriction-Modification System
6ELK	;	1.65	;	C.elegans MnSOD-3 mutant - Q142H
4I8T	;	3.0	;	C.Esp1396I bound to a 19 base pair DNA duplex
4IWR	;	2.4	;	C.Esp1396I bound to a 25 base pair operator site
3UFD	;	2.8	;	C.Esp1396I bound to its highest affinity operator site OM
2XKG	;	1.6	;	C.lacteus mini-Hb Leu86Ala mutant
4AVD	;	1.5	;	C.lacteus nerve Hb in complex with CO
4AVE	;	1.9	;	C.lacteus nerve Hb in the deoxy form
7YNR	;	2.9	;	C05-03-bound alpha-synuclein fibrils
7ETO	;	4.0	;	C1 CVSC-binding penton vertex in the virion capsid of Human Cytomegalovirus
2FNF	;		;	C1 domain of Nore1
7N6G	;	3.6	;	C1 of central pair
7UT6	;	1.91	;	C1 symmetric cryoEM structure of Azotobacter vinelandii MoFeP under non-turnover conditions
5B3K	;	1.7	;	C101A mutant of Flavodoxin from Pseudomonas aeruginosa
5B3L	;	1.8	;	C101S mutant of Flavodoxin from Pseudomonas aeruginosa
6ZVR	;	8.2	;	C11 symmetry: Bacterial Vipp1 and PspA are members of the ancient ESCRT-III membrane-remodeling superfamily.
3OQR	;	2.4	;	C112D/M121E Azurin, pH 10.0
3NP3	;	2.1	;	C112D/M121E Pseudomonas Aeruginosa Azurin
3NP4	;	2.25	;	C112D/M121E Pseudomonas aeruginosa Azurin
1RYW	;	2.3	;	C115S MurA liganded with reaction products
8HEU	;	4.6	;	C12 portal in HCMV A-capsid
8HEV	;	4.2	;	C12 portal in HCMV B-capsid
6ZVS	;	7.2	;	C12 symmetry: Bacterial Vipp1 and PspA are members of the ancient ESCRT-III membrane-remodeling superfamily.
2NU6	;	2.55	;	C123aA Mutant of E. coli Succinyl-CoA Synthetase
2NU7	;	2.2	;	C123aS Mutant of E. coli Succinyl-CoA Synthetase
2NU8	;	2.15	;	C123aT Mutant of E. coli Succinyl-CoA Synthetase
2NU9	;	2.9	;	C123aT Mutant of E. coli Succinyl-CoA Synthetase Orthorhombic Crystal Form
2NUA	;	2.95	;	C123aV Mutant of E. coli Succinyl-CoA Synthetase
6ZVT	;	7.0	;	C13 symmetry: Bacterial Vipp1 and PspA are members of the ancient ESCRT-III membrane-remodeling superfamily.
5YTM	;	1.5	;	C135A mutant of copper-containing nitrite reductase from Geobacillus thermodenitrificans determined by in-ouse source
5YTN	;	1.75	;	C135A mutant of copper-containing nitrite reductase from Geobacillus thermodenitrificans in complex with peroxide
3WKP	;	1.901	;	C135A mutant of Geobacillus thermodenitrificans copper-containing nitrite reductase in complex with nitrite
6ZW4	;	6.5	;	C14 symmetry: Bacterial Vipp1 and PspA are members of the ancient ESCRT-III membrane-remodeling superfamily.
8GI7	;	3.3	;	C143A variant of Citrate Synthase (CitA) in Mycobacterium tuberculosis
8GIW	;	3.15	;	C143K variant of Citrate Synthase (CitA) in Mycobacterium tuberculosis
8S9D	;	2.57	;	C143S variant of Citrate Synthase (CitA) in Mycobacterium tuberculosis
8S97	;	2.7	;	C143W variant of Citrate Synthase (CitA) in Mycobacterium tuberculosis
6ZW5	;	7.0	;	C15 symmetry: Bacterial Vipp1 and PspA are members of the ancient ESCRT-III membrane-remodeling superfamily.
1DBZ	;	2.65	;	C153S MUTANT OF PEA FRUCTOSE-1,6-BISPHOSPHATASE
6ZW6	;	7.4	;	C16 symmetry: Bacterial Vipp1 and PspA are members of the ancient ESCRT-III membrane-remodeling superfamily.
7ZJE	;	3.12	;	C16-2
6ZW7	;	9.4	;	C17 symmetry: Bacterial Vipp1 and PspA are members of the ancient ESCRT-III membrane-remodeling superfamily.
6T9H	;	2.58	;	C171S mutant of Linalool Dehydratase Isomerase
4JIW	;	3.402	;	c1882 PAAR-repeat protein from Escherichia coli in complex with a VgrG-like beta-helix that is based on a fragment of T4 gp5
3OOJ	;	2.5	;	C1A mutant of E. coli GlmS in complex with glucose-6P and glutamate
7KND	;	1.39	;	C1B domain of Protein kinase C in apo form
7L92	;	1.75	;	C1B domain of Protein kinase C in complex with diacylglycerol and dodecyl 2-(trimethylammonio)ethyl phosphate
7LEO	;	1.65	;	C1B domain of Protein kinase C in complex with diacylglycerol-lactone (AJH-836) and 1,2-diheptanoyl-sn-glycero-3-phosphocholine
7LF3	;	1.13	;	C1B domain of Protein kinase C in complex with diacylglycerol-lactone AJH-836
7KO6	;	1.8	;	C1B domain of Protein kinase C in complex with ingenol-3-angelate and phosphocholine
7KNJ	;	1.57	;	C1B domain of Protein kinase C in complex with Phorbol ester and Phosphatidylcholine
7LCB	;	1.7	;	C1B domain of Protein kinase C in complex with prostratin and phosphatidylcholine
1AB0	;	1.9	;	C1G/V32D/F57H MUTANT OF MURINE ADIPOCYTE LIPID BINDING PROTEIN AT PH 4.5
6F39	;	5.801	;	C1r homodimer CUB1-EGF-CUB2
6F1C	;	4.2	;	C1rC1s complex
6F1H	;	4.5	;	C1rC1s complex
4LMF	;	2.921	;	C1s CUB1-EGF-CUB2
4LOR	;	2.5	;	C1s CUB1-EGF-CUB2 in complex with a collagen-like peptide from C1q
4LOS	;	1.996	;	C1s CUB2-CCP1
4LOT	;	2.92	;	C1s CUB2-CCP1-CCP2
5CFG	;	1.8	;	C2 crystal form of APE1 with Mg2+
3F5V	;	1.36	;	C2 Crystal form of mite allergen DER P 1
3PZV	;	2.867	;	C2 crystal form of the endo-1,4-beta-glucanase from Bacillus subtilis 168
1F4N	;	1.9	;	C2 CRYSTAL STRUCTURE OF ALA2ILE2-6, A VERSION OF ROP WITH A REPACKED HYDROPHOBIC CORE AND A NEW FOLD.
1DSY	;	2.6	;	C2 DOMAIN FROM PROTEIN KINASE C (ALPHA) COMPLEXED WITH CA2+ AND PHOSPHATIDYLSERINE
1A25	;	2.7	;	C2 DOMAIN FROM PROTEIN KINASE C (BETA)
1BDY	;	2.2	;	C2 DOMAIN FROM PROTEIN KINASE C DELTA
1BCI	;		;	C2 DOMAIN OF CYTOSOLIC PHOSPHOLIPASE A2, NMR, MINIMIZED AVERAGE STRUCTURE
1WFJ	;		;	C2 domain-containing protein from putative elicitor-responsive gene
8IGG	;	4.09	;	C2 reconstruction of the concave tetramer in the cube-like assembly of 201Phi2-1 gp105
7UT7	;	1.91	;	C2 symmetric cryoEM structure of Azotobacter vinelandii MoFeP under non-turnover conditions
6UFU	;	1.101	;	C2 symmetric peptide design number 1, Zappy, crystal form 1
6UG2	;	1.1	;	C2 symmetric peptide design number 1, Zappy, crystal form 2
8T8G	;	1.5	;	C208A Streptococcus pyogenes Sortase A (spySrtA) bound to LPALA peptide
5TEQ	;	2.3	;	C20S C293G MUTANT N-TERMINAL HUMAN ATP CITRATE LYASE BOUND TO CITRATE
5TE1	;	2.25	;	C20S, C293G Mutant N-terminal Human ATP Citrate Lyase Bound to 4R-Hydroxycitrate
4NV6	;	4.19	;	C212A mutant of Synechococcus VKOR
7XX0	;	2.199	;	C281S glycylthricin complex
2NRC	;	2.05	;	C28A Mutant of Succinyl-CoA:3-Ketoacid CoA Transferase from Pig Heart
2NRB	;	2.0	;	C28S Mutant of Succinyl-CoA:3-Ketoacid CoA Transferase from Pig Heart
7ZX3	;	1.683	;	C295D Mutant of Recombinant CODH-II
2K45	;		;	C2A domain of synaptototagmin I solution structure in the FGF-1-C2A binary complex: key component in the fibroblast growthfactor non-classical pathway
6KAF	;	3.73	;	C2S2M2N2-type PSII-LHCII
2WIN	;	3.9	;	C3 convertase (C3bBb) stabilized by SCIN
1UZI	;	1.89	;	C3 EXOENZYME FROM CLOSTRIDIUM BOTULINUM, TETRAGONAL FORM
6UG3	;	1.1	;	C3 symmetric peptide design number 1, Sporty, crystal form 1
6UG6	;	1.1	;	C3 symmetric peptide design number 1, Sporty, crystal form 2
6UGB	;	0.95	;	C3 symmetric peptide design number 2, Baby Basil
6UGC	;	0.9	;	C3 symmetric peptide design number 3
5JVN	;	2.9	;	C3-type pyruvate phosphate dikinase: intermediate state of the central domain in the swiveling mechanism
1XMC	;	2.0	;	C323M mutant structure of mouse carnitine octanoyltransferase
3K79	;	1.96	;	C38A, C52V Cysteine-Free Variant of Rop (Rom)
8HK3	;	3.2	;	C3aR-Gi-apo protein complex
8HK2	;	2.9	;	C3aR-Gi-C3a protein complex
3G6J	;	3.1	;	C3b in complex with a C3b specific Fab
7BAG	;	2.0	;	C3b in complex with CP40
8G8I	;	3.92	;	C3HR3_9r_shift4: Extendable repeat protein fiber
4TR5	;	2.3	;	C3larvin toxin, an ADP-ribosyltransferase from Paenibacillus larvae
5DZQ	;	1.892	;	C3larvin toxin, an ADP-ribosyltransferase from Paenibacillus larvae, Orthorhombic Form
6XNS	;	3.19	;	C3_crown-05
6XT4	;	2.4	;	C3_HD-1069 (1BH-69) - fusion protein of helical bundle and repeat protein
7W0V	;		;	C4'-SCF3-DT modifeid DNA-DNA duplex
5JVL	;	2.9	;	C4-type pyruvate phospate dikinase: nucleotide binding domain with bound ATP analogue
5LU4	;	2.9	;	C4-type pyruvate phosphate dikinase: conformational intermediate of central domain in the swiveling mechanism
5JVJ	;	2.898	;	C4-type pyruvate phosphate dikinase: different conformational states of the nucleotide binding domain in the dimer
3VCB	;	2.4	;	C425S mutant of the C-terminal cytoplasmic domain of non-structural protein 4 from mouse hepatitis virus A59
1HZF	;	2.3	;	C4ADG FRAGMENT OF HUMAN COMPLEMENT FACTOR C4A
8GA9	;	3.71	;	C4HR1_4r: Extendable repeat protein tetramer
2ZIA	;	1.8	;	C4S dCK variant of dCK in complex with cladribine+UDP
2ZI6	;	1.77	;	C4S dCK variant of dCK in complex with D-dA+UDP
2NO1	;	1.91	;	C4S dCK variant of dCK in complex with D-dC+ADP
2ZI7	;	1.97	;	C4S dCK variant of dCK in complex with D-dG+UDP
2NO6	;	1.9	;	C4S dCK variant of dCK in complex with FTC+ADP
2NO0	;	1.8	;	C4S dCK variant of dCK in complex with gemcitabine+ADP
2ZI4	;	2.1	;	C4S dCK variant of dCK in complex with L-dA+ADP
2ZI5	;	1.77	;	C4S dCK variant of dCK in complex with L-dA+UDP
2NO7	;	1.7	;	C4S dCK variant of dCK in complex with L-dC+ADP
2ZI9	;	2.51	;	C4S-E247A dCK variant of dCK in complex with cladribine+ADP
2ZI3	;	2.3	;	C4S-E247A dCK variant of dCK in complex with D-dA+ADP
8HEX	;	4.0	;	C5 portal vertex in HCMV B-capsid
7ET3	;	4.2	;	C5 portal vertex in the enveloped virion capsid
7ETJ	;	4.0	;	C5 portal vertex in the partially-enveloped virion capsid
3NT0	;	1.8	;	C500S (T1D) Mutant of CueO soaked in and bound to Cu(I)
3NSC	;	1.5	;	C500S MUTANT OF CueO BOUND TO Cu(II)
4NV5	;	2.79	;	C50A mutant of Synechococcus VKOR, C2 crystal form (dehydrated)
4NV2	;	3.61	;	C50A mutant of Synechococcus VKOR, C2221 crystal form
7PTH	;	1.85	;	C54S mutant of choline-sulfatase from E. meliloti CECT4857 bound to choline
7PTJ	;	2.1	;	C54S mutant of choline-sulfatase from E. meliloti CECT4857 bound to HEPES
7FB6	;	1.8	;	C57D/C146D mutant of Human Cu, Zn Superoxide Dismutase (SOD1)
8HK5	;	3.0	;	C5aR1-Gi-C5a protein complex
7U2L	;	3.2	;	C5guano-uOR-Gi-scFv16
8GAQ	;	3.73	;	C5HR2_4r: Extendable repeat protein pentamer
7ETM	;	5.9	;	C6 portal vertex in the enveloped virion capsid
7U2K	;	3.3	;	C6-guano bound Mu Opioid Receptor-Gi Protein Complex
2JRE	;		;	C60-1, a PDZ domain designed using statistical coupling analysis
4AF2	;	1.97	;	C61S mutant of thiol peroxidase form E. coli.
5HBQ	;	1.66	;	C63D mutant of the rhodanese domain of YgaP
1YOB	;	2.25	;	C69A Flavodoxin II from Azotobacter vinelandii
2GBT	;	1.7	;	C6A/C111A CuZn Superoxide dismutase
2GBU	;	2.0	;	C6A/C111A/C57A/C146A apo CuZn Superoxide dismutase
2GBV	;	2.0	;	C6A/C111A/C57A/C146A holo CuZn Superoxide dismutase
8GAA	;	4.24	;	C6HR1_4r: Extendable repeat protein hexamer
3C9V	;	4.7	;	C7 Symmetrized Structure of Unliganded GroEL at 4.7 Angstrom Resolution from CryoEM
1RWJ	;	1.7	;	c7-type three-heme cytochrome domain
3QD9	;	3.3	;	C72S/C353S mutant of Trypanosoma brucei QSOX containing an interdomain disulfide
3T58	;	2.4	;	C76A/C455S mutant of mouse QSOX1 containing an interdomain disulfide
3T59	;	2.8	;	C76A/C455S mutant of mouse QSOX1 containing an interdomain disulfide
7B6Y	;	5.7	;	C8(355-600) from the MiniTRAPPIII complex
1GPX	;		;	C85S GAPDX, NMR, 20 STRUCTURES
1ES3	;	2.2	;	C98A mutant of streptomyces K15 DD-transpeptidase
7SWO	;	4.1	;	C98C7 Fab in complex with SARS-CoV-2 Spike 6P (RBD local reconstruction)
1ES4	;	1.9	;	C98N mutant of streptomyces K15 DD-transpeptidase
5IMG	;	1.844	;	C9A mutant of C69-family cysteine dipeptidase from Lactobacillus farciminis
7MQ3	;	1.4	;	C9A N55A Streptococcus pneumoniae CstR in the reduced state
7MQ1	;	2.02	;	C9A Streptococcus pneumoniae CstR in the reduced state, space group C2
7MQ2	;	2.29	;	C9A Streptococcus pneumoniae CstR in the reduced state, space group P21
2LJT	;		;	C9L,C14L-LeuA
2HHU	;	1.8	;	C:O6-methyl-guanine in the polymerase postinsertion site (-1 basepair position)
2HHT	;	2.05	;	C:O6-methyl-guanine pair in the polymerase-2 basepair position
8DVQ	;	2.19	;	CA domain of VanSA histidine kinase
8DWZ	;	2.21	;	CA domain of VanSA histidine kinase, 7 keV data
8SAF	;	1.23	;	CA II in complex with the coumarin benzene sulfonamide SG1-51
6E8X	;	1.6	;	CA IX mimic Complexed with Steroidal Sulfamate Compound STX 140
6E91	;	1.8	;	CA IX mimic Complexed with Steroidal Sulfamate Compound STX 2484
6E92	;	1.772	;	CA IX mimic Complexed with Steroidal Sulfamate Compound STX 2845
6E8P	;	1.9	;	CA IX mimic Complexed with Steroidal Sulfamate Compound STX 49
3IYG	;	4.0	;	Ca model of bovine TRiC/CCT derived from a 4.0 Angstrom cryo-EM map
5E1P	;	1.01	;	Ca(2+)-Calmodulin from Paramecium tetraurelia qFit disorder model
4CFR	;	1.4	;	Ca-bound S100A4 C3S, C81S, C86S and F45W mutant complexed with non- muscle myosin IIA
4CFQ	;	1.37	;	Ca-bound truncated (delta13C) and C3S, C81S and C86S mutated S100A4 complexed with non-muscle myosin IIA
3JXH	;	1.701	;	CA-like domain of human PTPRG
3JXF	;	2.004	;	CA-like domain of human PTPRZ
3JXG	;	1.7	;	CA-like domain of mouse PTPRG
2KBM	;		;	Ca-S100A1 interacting with TRTK12
1W2M	;	2.4	;	Ca-substituted form of E. coli aminopeptidase P
7N9U	;	3.19	;	CA-targeting nanobody is a tool for studying HIV-1 capsid lattice interactions
7N9V	;	3.45	;	CA-targeting nanobody is a tool for studying HIV-1 capsid lattice interactions
7N9X	;	3.511	;	CA-targeting nanobody is a tool for studying HIV-1 capsid lattice interactions
4XYL	;	1.95	;	Ca. Korarchaeum cryptofilum ACD1 in complex with coenzyme A
4YAJ	;	2.2	;	Ca. Korarchaeum cryptofilum dinucleotide forming Acetyl-coenzyme A synthetase 1 (apo form)
4XZ3	;	2.398	;	Ca. Korarchaeum cryptofilum dinucleotide forming Acetyl-coenzyme A synthetase 1 (Se-Met derivative) in complex with coenzyme A and Mg-AMPPCP, phosphohistidine segment pointing towards nucleotide binding site
4Y8V	;	2.099	;	Ca. Korarchaeum cryptofilum dinucleotide forming Acetyl-coenzyme A synthetase 1 in complex with ADP and additional ADP bound to phosphate binding site
4YBZ	;	2.1	;	Ca. Korarchaeum cryptofilum dinucleotide forming Acetyl-coenzyme A synthetase 1 in complex with ADP and with phosphorylated phosphohistidine segment (site I orientation)
4YAK	;	2.464	;	Ca. Korarchaeum cryptofilum dinucleotide forming Acetyl-coenzyme A synthetase 1 in complex with coenzyme A, acetyl-coenzyme A and with phosphorylated phosphohistidine segment (site I orientation)
4XYM	;	1.9	;	Ca. Korarchaeum cryptofilum dinucleotide forming Acetyl-coenzyme A synthetase 1 in complex with coenzyme A, Ca-AMPCP and HgCl+
4YB8	;	1.9	;	Ca. Korarchaeum cryptofilum dinucleotide forming Acetyl-coenzyme A synthetase 1 in complex with phosphate and ADP
5HBR	;	1.995	;	Ca. Korarchaeum cryptofilum dinucleotide forming Acetyl-coenzyme A synthetase 1 in complex with phosphate and coenzyme A
7TE8	;	1.998	;	CA14-CBD-DB21 ternary complex
4EIG	;	2.5	;	CA1698 camel antibody fragment in complex with DHFR
5TJ6	;	3.5	;	Ca2+ bound aplysia Slo1
5TJI	;	3.8	;	Ca2+ bound aplysia Slo1
7PXE	;	2.38	;	Ca2+ bound Drosophila Slo channel
5DBR	;	2.25	;	Ca2+ CaM with human cardiac Na+ channel (NaV1.5) inactivation gate
3UOM	;	2.02	;	Ca2+ complex of Human skeletal calsequestrin
7PXF	;	2.68	;	Ca2+ free Drosophila Slo channel
3KLA	;	1.65	;	Ca2+ release from the endoplasmic reticulum of NY-ESO-1 specific T cells is modulated by the affinity of T cell receptor and by the use of the CD8 co-receptor
6ZHG	;	4.0	;	Ca2+-ATPase from Listeria Monocytogenes in complex with AlF
6ZHH	;	3.0	;	Ca2+-ATPase from Listeria Monocytogenes with G4 insertion.
1KJU	;	6.0	;	Ca2+-ATPase in the E2 State
1JHW	;	2.8	;	Ca2+-binding Mimicry in the Crystal Structure of the Eu3+-Bound Mutant Human Macrophage Capping Protein Cap G
6Y94	;		;	Ca2+-bound Calmodulin mutant N53I
4L75	;	2.393	;	Ca2+-bound D184N mutant MthK RCK domain at 2.4 Angstrom
4L76	;	2.992	;	Ca2+-bound E212Q mutant MthK RCK domain
6DR2	;	4.33	;	Ca2+-bound human type 3 1,4,5-inositol trisphosphate receptor
4L74	;	1.841	;	Ca2+-bound MthK RCK domain at 1.9 Angstrom with single ligand
4L73	;	2.5	;	Ca2+-bound MthK RCK domain at 2.5 Angstrom
3ZWH	;	1.94	;	Ca2+-bound S100A4 C3S, C81S, C86S and F45W mutant complexed with myosin IIA
1IJ6	;	3.1	;	CA2+-BOUND STRUCTURE OF MULTIDOMAIN EF-HAND PROTEIN, CBP40, FROM TRUE SLIME MOLD
7BF2	;	1.43	;	Ca2+-Calmodulin in complex with human muscle form creatine kinase peptide in extended 1:2 binding mode
7BF1	;	1.24	;	Ca2+-Calmodulin in complex with peptide from brain-type creatine kinase in extended 1:2 binding mode
6JK4	;	1.06	;	Ca2+-dependent type II antifreeze protein
6JK5	;	1.25	;	Ca2+-dependent type II antifreeze protein (Ca2+-free form)
6Y95	;		;	Ca2+-free Calmodulin mutant N53I
6A7T	;	1.6	;	Ca2+-independent C-type lectin SPL-1 from Saxidomus purpuratus
6A7S	;	2.0	;	Ca2+-independent C-type lectin SPL-2 from Saxidomus purpuratus
5NOG	;	11.0	;	Ca2+-induced Movement of Tropomyosin on Native Cardiac Thin Filaments - ""Blocked"" state
5NOL	;	8.0	;	Ca2+-induced Movement of Tropomyosin on Native Cardiac Thin Filaments - ""Closed"" state
5NOJ	;	11.0	;	Ca2+-induced Movement of Tropomyosin on Native Cardiac Thin Filaments - ""OPEN"" state
1JWD	;		;	Ca2+-induced Structural Changes in Calcyclin: High-resolution Solution Structure of Ca2+-bound Calcyclin.
1S6I	;		;	Ca2+-regulatory region (CLD) from soybean calcium-dependent protein kinase-alpha (CDPK) in the presence of Ca2+ and the junction domain (JD)
2K7O	;		;	Ca2+-S100B, refined with RDCs
1MQ1	;		;	Ca2+-S100B-TRTK-12 complex
4P99	;	1.8	;	Ca2+-stabilized adhesin helps an Antarctic bacterium reach out and bind ice
8T65	;	2.09	;	cA4 bound Cam1
8PHJ	;	3.67	;	cA4-bound Cami1 in complex with 70S ribosome
8T66	;	1.85	;	cA6 bound Cam1
6AIM	;	2.04	;	Cab2 mutant H337A complex with phosphopantothenate-cysteine
6AIK	;	1.83	;	Cab2 mutant H337A complex with phosphopantothenoyl-CMP
6AI8	;	2.3	;	Cab2 mutant-H337A
6AI9	;	2.09	;	Cab2 mutant-H337A complex with phosphopantothenate
6AIP	;	1.99	;	Cab2 mutant-H337A complex with phosphopantothenoylcystine
1YC7	;	1.6	;	cAbAn33 VHH fragment against VSG
1YC8	;	2.7	;	cAbAn33- Y37V/E44G/R45L triple mutant
1ZMY	;	3.0	;	cAbBCII-10 VHH framework with CDR loops of cAbLys3 grafted on it and in complex with hen egg white lysozyme
3EBA	;	1.85	;	CAbHul6 FGLW mutant (humanized) in complex with human lysozyme
3S6U	;	2.7	;	Caclcium-bound Ac-ASP-7
1BHL	;	2.2	;	CACODYLATED CATALYTIC DOMAIN OF HIV-1 INTEGRASE
3PM8	;	2.0	;	CAD domain of PFF0520w, Calcium dependent protein kinase
7A7D	;	26.0	;	Cadherin fit into cryo-ET map
2X28	;	2.15	;	cadmium bound structure of SporoSAG
3VG3	;	2.22	;	Cadmium derivative of human LFABP
3VG4	;	2.5	;	Cadmium derivative of human LFABP
5Y4A	;	2.34	;	Cadmium directed assembly of adenine phosphoribosyltransferase from Yersinia pseudotuberculosis.
1CVM	;	2.4	;	CADMIUM INHIBITED CRYSTAL STRUCTURE OF PHYTASE FROM BACILLUS AMYLOLIQUEFACIENS
2EIL	;	2.1	;	Cadmium ion binding structure of bovine heart cytochrome C oxidase in the fully oxidized state
2EIK	;	2.1	;	Cadmium ion binding structure of bovine heart cytochrome C oxidase in the fully reduced state
6GV7	;		;	Cadmium(II) form of A44H mutant of shortened metallothionein from Pseudomonas fluorescens Q2-87 (residues 1-52)
6GRV	;		;	Cadmium(II) form of full-length metallothionein from Pseudomonas fluorescens Q2-87 (PflQ2 MT)
6GV6	;		;	Cadmium(II) form of shortened metallothionein from Pseudomonas fluorescens Q2-87 (residues: 1-52)
8AP5	;		;	Cadmium-loaded form of Caenorhabditis elegans MTL-2
1ELM	;	2.0	;	CADMIUM-SUBSTITUTED BOVINE PACREATIC CARBOXYPEPTIDASE A (ALFA-FORM) AT PH 5.5 AND 2 MM CHLORIDE IN MONOCLINIC CRYSTAL FORM.
1ELL	;	1.76	;	CADMIUM-SUBSTITUTED BOVINE PANCREATIC CARBOXYPEPTIDASE A (ALFA-FORM) AT PH 7.5 AND 0.25 M CHLORIDE IN MONOCLINIC CRYSTAL FORM.
1EE3	;	1.7	;	Cadmium-substituted bovine pancreatic carboxypeptidase A (alfa-form) at pH 7.5 and 2 mM chloride in monoclinic crystal form
1R0I	;	1.5	;	cadmium-substituted rubredoxin
6DY3	;	2.7	;	Caenorhabditis elegans N-acylethanolamine-hydrolyzing acid amidase (NAAA) ortholog
7LHY	;	1.3	;	Caenorhabditis elegans SWSN-4 (SMARCA4-BRG1) ATPase Bromodomain in complex with a modified histone H3, N6-epsilon-acetyl-L-lysine 14 (H3K14ac) polypeptide
6OM8	;	2.449	;	Caenorhabditis Elegans UDP-Glucose Dehydrogenase in complex with UDP-Xylose
2OS7	;	2.9	;	Caf1M periplasmic chaperone tetramer
4PGG	;	2.015	;	Caffeic acid O-methyltransferase from Sorghum bicolor
4PGH	;	2.8	;	Caffeic acid O-methyltransferase from Sorghum bicolor
6QTL	;	2.25	;	Caffeine recognizing nanobody
8AA6	;	1.15	;	CAII in complex with meta-carboran-propylsulfonamid
8AAE	;	1.15	;	CAII in complex with para-carboran-propylsulfonamid
7TR0	;	2.7	;	CaKip3[2-436] - AMP-PNP in complex with a microtubule
7TR1	;	3.1	;	CaKip3[2-436]-L2-mutant(HsKHC) - AMP-PNP in complex with a microtubule
7TQY	;	2.6	;	CaKip3[2-482] - ADP-AlFx in complex with a microtubule
7TR3	;	3.9	;	CaKip3[2-482] - AMP-PNP in complex with a dolastatin-10-stabilized tubulin ring
7TQX	;	2.8	;	CaKip3[2-482] - AMP-PNP in complex with a microtubule
5IC3	;	1.7	;	CAL PDZ domain with peptide and inhibitor
5K4F	;	1.36	;	CAL PDZ mutant C319A with a peptide
8I4Y	;	3.84	;	CalA3 complex structure with amidation product
8I4Z	;	3.97	;	CalA3 with hydrolysis product
7WVZ	;	3.38	;	CalA3_modular PKS_KS-AT-DH-KR
6D00	;	4.0	;	Calcarisporiella thermophila Hsp104
1BF0	;		;	CALCICLUDINE (CAC) FROM GREEN MAMBA DENDROASPIS ANGUSTICEPS, NMR, 15 STRUCTURES
7TYO	;	2.7	;	Calcitonin receptor in complex with Gs and human calcitonin peptide
8F0J	;	2.0	;	Calcitonin Receptor in complex with Gs and Pramlintide analogue peptide San45
7TYL	;	3.3	;	Calcitonin Receptor in complex with Gs and rat amylin peptide, bypass motif
7TYI	;	3.3	;	Calcitonin Receptor in complex with Gs and rat amylin peptide, CT-like state
7TYN	;	2.6	;	Calcitonin Receptor in complex with Gs and salmon calcitonin peptide
6PYO	;	2.0	;	Calcium Activated Chloride Channel Regulator 1 (CLCA1) VWA Domain
6PYX	;	2.6	;	Calcium Activated Chloride Channel Regulator 1 (CLCA1) VWA Domain
5CBG	;	3.14	;	Calcium activated non-selective cation channel
3J7T	;	3.4	;	Calcium atpase structure with two bound calcium ions determined by electron crystallography of thin 3D crystals
6ZHF	;	4.0	;	Calcium ATPase-1 from Listeria monocytogenes in complex with BeF
1UOV	;	1.65	;	Calcium binding domain C2B
1UOW	;	1.04	;	Calcium binding domain C2B
2AAA	;	2.12	;	CALCIUM BINDING IN ALPHA-AMYLASES: AN X-RAY DIFFRACTION STUDY AT 2.1 ANGSTROMS RESOLUTION OF TWO ENZYMES FROM ASPERGILLUS
2P0Q	;		;	Calcium binding protein in the calcium-binding form
2P0P	;		;	Calcium binding protein in the free form
3TEC	;	2.0	;	CALCIUM BINDING TO THERMITASE. CRYSTALLOGRAPHIC STUDIES OF THERMITASE AT 0, 5 AND 100 MM CALCIUM
1QMD	;	2.2	;	calcium bound closed form alpha-toxin from Clostridium perfringens
1ALV	;	1.9	;	CALCIUM BOUND DOMAIN VI OF PORCINE CALPAIN
6GDK	;		;	Calcium bound form of human calmodulin mutant F141L
1WD9	;	2.6	;	Calcium bound form of human peptidylarginine deiminase type4 (PAD4)
2WFK	;	2.3	;	Calcium bound LipL32
5UG7	;	1.8	;	Calcium bound Perforin C2 Domain - T431D
2IIC	;	2.93	;	Calcium bound structure of alpha-11 giardin
3CHK	;	1.65	;	Calcium bound structure of alpha-14 giardin
3GNK	;	2.1	;	Calcium bound to the Holliday junction sequence d(TCGGCGCCGA)4
6KZP	;	3.1	;	calcium channel-ligand
2C4S	;	3.0	;	CALCIUM CHONDROITIN 4-SULFATE. MOLECULAR CONFORMATION AND ORGANIZATION OF POLYSACCHARIDE CHAINS IN A PROTEOGLYCAN
476D	;	1.3	;	CALCIUM FORM OF B-DNA UNDECAMER GCGAATTCGCG
463D	;	1.45	;	CALCIUM FORM OF D(CGCGAATTCGCG)2
1UWO	;		;	CALCIUM FORM OF HUMAN S100B, NMR, 20 STRUCTURES
477D	;	1.7	;	CALCIUM FORM OF THE B-DNA DODECAMER GGCGAATTCGCG
1WD8	;	2.8	;	Calcium free form of human peptidylarginine deiminase type4 (PAD4)
1GNV	;	1.9	;	CALCIUM INDEPENDENT SUBTILISIN BPN' MUTANT
3AR3	;	2.3	;	Calcium pump crystal structure with bound ADP and TG
2ZBG	;	2.55	;	Calcium pump crystal structure with bound AlF4 and TG in the absence of calcium
3AR8	;	2.6	;	Calcium pump crystal structure with bound AlF4, TNP-AMP and TG
3AR2	;	2.5	;	Calcium pump crystal structure with bound AMPPCP and Ca2+
3AR4	;	2.15	;	Calcium pump crystal structure with bound ATP and TG in the absence of Ca2+
2ZBF	;	2.4	;	Calcium pump crystal structure with bound BeF3 and TG in the absence of calcium
2ZBE	;	3.8	;	Calcium pump crystal structure with bound BeF3 in the absence of calcium and TG
3AR9	;	2.6	;	Calcium pump crystal structure with bound BeF3, TNP-AMP and TG in the absence of calcium
3AR6	;	2.2	;	Calcium pump crystal structure with bound TNP-ADP and TG in the absence of calcium
3AR5	;	2.2	;	Calcium pump crystal structure with bound TNP-AMP and TG
3AR7	;	2.15	;	Calcium pump crystal structure with bound TNP-ATP and TG in the absence of Ca2+
4HKR	;	3.3511	;	Calcium release-activated calcium (CRAC) channel ORAI
4HKS	;	3.3516	;	Calcium release-activated calcium (CRAC) channel ORAI, K163W mutant
6AKI	;	4.496	;	Calcium release-activated calcium channel protein 1, P288L mutant
2LUX	;		;	Calcium saturated form of human C85M S100A1 mutant
6I1T	;	1.8	;	Calcium structure of Trichoderma reesei Carbohydrate-Active Enzymes Family AA12
4XQZ	;	2.151	;	Calcium(II) and copper(II) bound to the Z-DNA form of d(CGCGCG), complexed by chloride and MES
5IHD	;	1.57	;	Calcium(II) and copper(II) bound to the Z-DNA form of d(CGCGCG), complexed by L-lactate and succinate
5T5N	;	3.1	;	Calcium-activated chloride channel bestrophin-1 (BEST1), triple mutant: I76A, F80A, F84A; in complex with an Fab antibody fragment, chloride, and calcium
4RDQ	;	2.85	;	Calcium-activated chloride channel bestrophin-1, from chicken, in complex with Fab antibody fragments, chloride and calcium
1OTM	;	1.93	;	Calcium-binding mutant of the internalin B LRR domain
1OTN	;	1.97	;	Calcium-binding mutant of the Internalin B LRR domain
1OTO	;	1.96	;	Calcium-binding mutant of the internalin B LRR domain
1NKF	;		;	CALCIUM-BINDING PEPTIDE, NMR, 30 STRUCTURES
7JOF	;	2.0	;	Calcium-bound C2A Domain from Human Dysferlin
8BD2	;		;	Calcium-bound Calmodulin variant G113R
1B8L	;	1.7	;	Calcium-bound D51A/E101D/F102W Triple Mutant of Beta Carp Parvalbumin
1SMG	;		;	CALCIUM-BOUND E41A MUTANT OF THE N-DOMAIN OF CHICKEN TROPONIN C, NMR, 40 STRUCTURES
1KP4	;	1.6	;	CALCIUM-BOUND FORM OF PROKARYOTIC PHOSPHOLIPASE A2
6QW3	;	1.3	;	Calcium-bound gelsolin domain 2
3SH5	;	2.8	;	Calcium-bound Laminin G like domain 3 from human perlecan
6U5R	;	3.6	;	Calcium-bound MthK closed state
6U5P	;	3.3	;	Calcium-bound MthK gating ring state 1
6U5N	;	3.2	;	Calcium-bound MthK gating ring state 2
6U68	;	4.5	;	Calcium-bound MthK open-inactivated state 1
6U6E	;	6.3	;	Calcium-bound MthK open-inactivated state 2
6U6H	;	5.0	;	Calcium-bound MthK open-inactivated state 3
3JVT	;	2.1	;	Calcium-bound Scallop Myosin Regulatory Domain (Lever Arm) with Reconstituted Complete Light Chains
4QNH	;	2.02	;	Calcium-calmodulin (T79D) complexed with the calmodulin binding domain from a small conductance potassium channel SK2-a
4J9Y	;	1.51	;	Calcium-calmodulin complexed with the calmodulin binding domain from a small conductance potassium channel splice variant
4G28	;	1.63	;	Calcium-calmodulin complexed with the calmodulin binding domain from a small conductance potassium channel splice variant and EBIO-1
4J9Z	;	1.66	;	Calcium-calmodulin complexed with the calmodulin binding domain from a small conductance potassium channel splice variant and NS309
4G27	;	1.65	;	Calcium-calmodulin complexed with the calmodulin binding domain from a small conductance potassium channel splice variant and phenylurea
3DF0	;	2.95	;	Calcium-dependent complex between m-calpain and calpastatin
5FYO	;	1.5	;	Calcium-dependent phosphoinositol-specific phospholipase C from a Gram-negative bacterium, Pseudomonas sp, apo form, crystal form 1
5FYP	;	1.17	;	Calcium-dependent phosphoinositol-specific phospholipase C from a Gram-negative bacterium, Pseudomonas sp, apo form, crystal form 2
5FYR	;	1.45	;	Calcium-dependent phosphoinositol-specific phospholipase C from a Gram-negative bacterium, Pseudomonas sp, apo form, myoinositol complex
4M97	;	2.05	;	Calcium-Dependent Protein Kinase 1 from Neospora caninum
3I79	;	2.04	;	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1)
3I7C	;	1.98	;	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with bumped kinase inhibitor NA-PP2
3I7B	;	1.988	;	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with bumped kinase inhibitor NM-PP1
3N51	;	2.1	;	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with bumped kinase inhibitor RM-1-95
3T3U	;	2.1	;	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with Bumped Kinase Inhibitor, RM-1-130
3SX9	;	2.65	;	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with Bumped Kinase Inhibitor, RM-1-132
3T3V	;	2.04	;	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with Bumped Kinase Inhibitor, RM-1-87
3SXF	;	2.04	;	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with Bumped Kinase Inhibitor, RM-1-89
3UPZ	;	2.2	;	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with bumpless BKI analog UW1243
3V51	;	1.95	;	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor RM-1-176
4JBV	;	1.95	;	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1268
3V5P	;	2.1	;	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1288
3V5T	;	2.13	;	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1299
3UPX	;	2.27	;	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1300
4M84	;	1.998	;	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1455
4ONA	;	2.4	;	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1517
6BFA	;	2.8	;	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1553
4TZR	;	2.0	;	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1561
4WG3	;	2.2	;	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1610
4WG4	;	2.3	;	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1613
4YJN	;	2.6	;	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1639
4WG5	;	2.3	;	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1647
3NYV	;	1.88	;	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with non-specific inhibitor WHI-P180
4YSM	;	3.19	;	Calcium-Dependent Protein Kinase from Eimeria tenella
4YSJ	;	2.7	;	Calcium-Dependent Protein Kinase from Eimeria tenella in complex with ADP
2WCE	;	1.77	;	calcium-free (apo) S100A12
2WCF	;	2.78	;	calcium-free (apo) S100A12
1CFC	;		;	CALCIUM-FREE CALMODULIN
1CFD	;		;	CALCIUM-FREE CALMODULIN
4OY4	;	2.03	;	calcium-free CaMPARI v0.2
5JOL	;		;	Calcium-free EF-hand domain of L-plastin
3EKJ	;	2.8	;	Calcium-free GCaMP2 (calcium binding deficient mutant)
2JWW	;		;	Calcium-free rat alpha-parvalbumin
3JTD	;	2.57	;	Calcium-free Scallop Myosin Regulatory Domain with ELC-D19A Point Mutation
6AUN	;	3.951	;	calcium-independent phospholipase A2 beta
1SUB	;	1.75	;	CALCIUM-INDEPENDENT SUBTILISIN BY DESIGN
1SUC	;	1.8	;	CALCIUM-INDEPENDENT SUBTILISIN BY DESIGN
1SUD	;	1.9	;	CALCIUM-INDEPENDENT SUBTILISIN BY DESIGN
1SL8	;	1.7	;	Calcium-loaded apo-aequorin from Aequorea victoria
5JOJ	;		;	Calcium-loaded EF-hand domain of L-plastin
1RLW	;	2.4	;	CALCIUM-PHOSPHOLIPID BINDING DOMAIN FROM CYTOSOLIC PHOSPHOLIPASE A2
3EK7	;	1.85	;	Calcium-saturated GCaMP2 dimer
3EK4	;	2.65	;	Calcium-saturated GCaMP2 Monomer
3EK8	;	2.8	;	Calcium-saturated GCaMP2 T116V/G87R mutant monomer
3EKH	;	2.0	;	Calcium-saturated GCaMP2 T116V/K378W mutant monomer
7ST4	;	2.0	;	Calcium-saturated jGCaMP8.410.80
7PGF	;	3.5	;	Calcium-selective Sp1 channel pore domain only
1DQ1	;	2.15	;	Calcium;Calcium concanavalin A
5L34	;		;	Calculated solution structure of [D-Trp3]-Contryphan-Vc2
5IK2	;	2.6	;	Caldalaklibacillus thermarum F1-ATPase (epsilon mutant)
5HKK	;	3.0	;	Caldalaklibacillus thermarum F1-ATPase (wild type)
6FJ7	;	1.05	;	Caldiarchaeum Subterraneum Ubiquitin
6FNN	;	1.85	;	Caldiarchaeum Subterraneum Ubiquitin:Rpn11-homolog complex
6FNO	;	1.95	;	Caldiarchaeum Subterraneum Ubiquitin:Rpn11-homolog complex, zinc soak
1V48	;	2.2	;	Calf spleen purine nucleoside phosphorylase (PNP) binary complex with 9-(5,5-difluoro-5-phosphonopenthyl)guanine
7DSD	;	2.9	;	CALHM1 close state with disordered CTH
7DSE	;	3.2	;	CALHM1 close state with ordered CTH
7DSC	;	3.5	;	CALHM1 open state with disordered CTH
2PIK	;		;	CALICHEAMICIN GAMMA1I-DNA COMPLEX, NMR, 6 STRUCTURES
1HF8	;	2.0	;	CALM-N N-terminal domain of clathrin assembly lymphoid myeloid leukaemia protein
1HG5	;	2.0	;	CALM-N N-terminal domain of clathrin assembly lymphoid myeloid leukaemia protein, inositol(1,2,3,4,5,6)P6 complex
1HG2	;	2.0	;	CALM-N N-terminal domain of clathrin assembly lymphoid myeloid leukaemia protein, Inositol(4,5)P2 complex
1HFA	;	2.0	;	CALM-N N-terminal domain of clathrin assembly lymphoid myeloid leukaemia protein, PI(4,5)P2 complex
4E50	;	2.7	;	Calmodulin and Ng peptide complex
4E53	;	2.69	;	Calmodulin and Nm peptide complex
6Y4O	;	1.83549	;	Calmodulin bound to cardiac ryanodine receptor (RyR2) calmodulin binding domain
3GP2	;	1.46	;	Calmodulin bound to peptide from calmodulin kinase II (CaMKII)
3GOF	;	1.45	;	Calmodulin bound to peptide from macrophage nitric oxide synthase
2O60	;	1.55	;	Calmodulin bound to peptide from neuronal nitric oxide synthase
1WRZ	;	2.0	;	Calmodulin complexed with a peptide from a human death-associated protein kinase
2K0F	;		;	Calmodulin complexed with calmodulin-binding peptide from smooth muscle myosin light chain kinase
2VAY	;	1.94	;	Calmodulin complexed with CaV1.1 IQ peptide
1QIW	;	2.3	;	Calmodulin complexed with N-(3,3,-diphenylpropyl)-N'-[1-R-(3,4-bis-butoxyphenyl)-ethyl]-propylenediamine (DPD)
1QIV	;	2.64	;	CALMODULIN COMPLEXED WITH N-(3,3,-DIPHENYLPROPYL)-N'-[1-R-(3,4-BIS-BUTOXYPHENYL)-ETHYL]-PROPYLENEDIAMINE (DPD), 1:2 COMPLEX
1A29	;	2.74	;	CALMODULIN COMPLEXED WITH TRIFLUOPERAZINE (1:2 COMPLEX)
1LIN	;	2.0	;	CALMODULIN COMPLEXED WITH TRIFLUOPERAZINE (1:4 COMPLEX)
7NQC	;		;	Calmodulin extracts the Ras family protein RalA from lipid bilayers by engagement with two membrane targeting motifs
1ZUZ	;	1.91	;	Calmodulin in complex with a mutant peptide from human DRP-1 kinase
6OS4	;	2.05	;	Calmodulin in complex with farnesyl cysteine methyl ester
6O5G	;	1.89	;	Calmodulin in complex with isomalbrancheamide D
6EEB	;	1.96	;	Calmodulin in complex with malbrancheamide
4BW7	;	1.81	;	Calmodulin in complex with strontium
6GDL	;		;	Calmodulin mutant - F141L apo-form Unstructured C-domain
1AHR	;	1.8	;	CALMODULIN MUTANT WITH A TWO RESIDUE DELETION IN THE CENTRAL HELIX
6Y4P	;	2.13326	;	Calmodulin N53I variant bound to cardiac ryanodine receptor (RyR2) calmodulin binding domain
1CLL	;	1.7	;	CALMODULIN STRUCTURE REFINED AT 1.7 ANGSTROMS RESOLUTION
4BW8	;	1.8	;	Calmodulin with small bend in central helix
2KNE	;		;	Calmodulin wraps around its binding domain in the plasma membrane CA2+ pump anchored by a novel 18-1 motif
2KZ2	;		;	Calmodulin, C-terminal domain, F92E mutant
4BYA	;		;	Calmodulin, C-terminal domain, M144H mutant
2M3S	;		;	Calmodulin, i85l, f92e, h107i, l112r, a128t, m144r mutant
1DMO	;		;	CALMODULIN, NMR, 30 STRUCTURES
6DMW	;	4.4	;	Calmodulin-bound full-length rbTRPV5
1A06	;	2.5	;	CALMODULIN-DEPENDENT PROTEIN KINASE FROM RAT
2LC5	;		;	Calmodulin-like Protein from Entamoeba histolytica: Solution Structure and Calcium-Binding Properties of a Partially Folded Protein
2O5G	;	1.08	;	Calmodulin-smooth muscle light chain kinase peptide complex
2F3Y	;	1.45	;	Calmodulin/IQ domain complex
2F3Z	;	1.6	;	Calmodulin/IQ-AA domain complex
1IQ5	;	1.8	;	Calmodulin/nematode CA2+/Calmodulin dependent kinase kinase fragment
1CKK	;		;	CALMODULIN/RAT CA2+/CALMODULIN DEPENDENT PROTEIN KINASE FRAGMENT
2G8E	;	2.25	;	Calpain 1 proteolytic core in complex with SNJ-1715, a cyclic hemiacetal-type inhibitor
2G8J	;	1.61	;	Calpain 1 proteolytic core in complex with SNJ-1945, a alpha-ketoamide-type inhibitor.
2NQI	;	2.04	;	Calpain 1 proteolytic core inactivated by WR13(R,R), an epoxysuccinyl-type inhibitor.
2NQG	;	2.04	;	Calpain 1 proteolytic core inactivated by WR18(S,S), an epoxysuccinyl-type inhibitor.
2R9C	;	1.8	;	Calpain 1 proteolytic core inactivated by ZLAK-3001, an alpha-ketoamide
2R9F	;	1.6	;	Calpain 1 proteolytic core inactivated by ZLAK-3002, an alpha-ketoamide
1NX2	;	2.2	;	Calpain Domain VI
1AJ5	;	2.3	;	CALPAIN DOMAIN VI APO
1NX1	;	2.0	;	Calpain Domain VI Complexed with Calpastatin Inhibitory Domain C (DIC)
1NX3	;	2.45	;	Calpain Domain VI in Complex with the Inhibitor PD150606
1DVI	;	2.3	;	CALPAIN DOMAIN VI WITH CALCIUM BOUND
6QLB	;	2.32	;	Calpain small subunit 1, RNA-binding protein Hfq
6P3Q	;	2.8	;	Calpain-5 (CAPN5) Protease Core (PC)
8UC6	;	2.701	;	Calpain-7:IST1 Complex
1AA2	;	2.0	;	CALPONIN HOMOLOGY (CH) DOMAIN FROM HUMAN BETA-SPECTRIN
1BKR	;	1.1	;	CALPONIN HOMOLOGY (CH) DOMAIN FROM HUMAN BETA-SPECTRIN AT 1.1 ANGSTROM RESOLUTION
1HHN	;		;	Calreticulin P-domain
6YNU	;	3.12	;	CaM-P458 complex (crystal form 1)
6YNS	;	3.94	;	CaM-P458 complex (crystal form 2)
5JQA	;	1.8	;	CaM:RM20 complex
7LNJ	;	2.68	;	CamA Adenine Methyltransferase Complexed to Cognate Substrate DNA
7LT5	;	2.54	;	CamA Adenine Methyltransferase Complexed to Cognate Substrate DNA and Cofactor SAH
8CY3	;	2.65	;	CamA Adenine Methyltransferase Complexed to Cognate Substrate DNA and Compound 15
8CY4	;	2.34	;	CamA Adenine Methyltransferase Complexed to Cognate Substrate DNA and Compound 16
8CY1	;	2.38	;	CamA Adenine Methyltransferase Complexed to Cognate Substrate DNA and Compound 19
8CXU	;	2.28	;	CamA Adenine Methyltransferase Complexed to Cognate Substrate DNA and Compound 2
8CXV	;	2.26	;	CamA Adenine Methyltransferase Complexed to Cognate Substrate DNA and Compound 3
8CY5	;	2.5	;	CamA Adenine Methyltransferase Complexed to Cognate Substrate DNA and Compound 39
8CXX	;	2.34	;	CamA Adenine Methyltransferase Complexed to Cognate Substrate DNA and Compound 6
8FS1	;	2.74	;	CamA Adenine Methyltransferase Complexed to Cognate Substrate DNA and Inhibitor 11a (YD905)
8FS2	;	2.59	;	CamA Adenine Methyltransferase Complexed to Cognate Substrate DNA and Inhibitor 11b (YD907)
8CY2	;	2.81	;	CamA Adenine Methyltransferase Complexed to Cognate Substrate DNA and Inhibitor APNEA (Compound 9)
7RFM	;	2.68	;	CamA Adenine Methyltransferase Complexed to Cognate Substrate DNA and Inhibitor EPZ004777
8CY0	;	2.65	;	CamA Adenine Methyltransferase Complexed to Cognate Substrate DNA and Inhibitor MC4756 (Compound 178)
8CXS	;	2.49	;	CamA Adenine Methyltransferase Complexed to Cognate Substrate DNA and Inhibitor MTA
8CXY	;	2.19	;	CamA Adenine Methyltransferase Complexed to Cognate Substrate DNA and Inhibitor N6-(2-Phenethyl)adenosine (Compound 8)
8CXZ	;	2.35	;	CamA Adenine Methyltransferase Complexed to Cognate Substrate DNA and Inhibitor N6-(3-Phenylpropyl)adenosine (Compound 14)
8CXT	;	2.61	;	CamA Adenine Methyltransferase Complexed to Cognate Substrate DNA and Inhibitor N6-benzyladenosine (Compound 1)
8CXW	;	2.78	;	CamA Adenine Methyltransferase Complexed to Cognate Substrate DNA and Inhibitor piclidenoson (Compound 4)
7RFL	;	2.38	;	CamA Adenine Methyltransferase Complexed to Cognate Substrate DNA and Inhibitor SGC0946
7RFN	;	2.5	;	CamA Adenine Methyltransferase Complexed to Cognate Substrate DNA and Inhibitor SGC8158
7RFK	;	2.05	;	CamA Adenine Methyltransferase Complexed to Cognate Substrate DNA and Inhibitor Sinefungin
1QNN	;	1.8	;	Cambialistic superoxide dismutase from Porphyromonas gingivalis
8APQ	;	2.49	;	CaMct - Mesaconyl-CoA C1:C4 CoA Transferase of Chloroflexus aurantiacus
8APR	;	2.1	;	CaMct - Mesaconyl-CoA C1:C4 CoA Transferase of Chloroflexus aurantiacus
4AA9	;	1.6	;	Camel chymosin at 1.6A resolution
7OPZ	;	2.55	;	Camel GSTM1-1 in complex with glutathione
7OPY	;	2.05	;	Camel GSTM1-1 in complex with S-(p-nitrobenzyl)glutathione
7TPR	;	2.39	;	Camel nanobodies 7A3 and 8A2 broadly neutralize SARS-CoV-2 variants
5U64	;	1.153	;	Camel nanobody VHH-28
5U65	;	2.3	;	Camel Nanobody VHH-5
4QGY	;	1.38	;	Camelid (llama) nanobody n25 (VHH) against type 6 secretion system TssM protein
1QD0	;	2.5	;	CAMELID HEAVY CHAIN VARIABLE DOMAINS PROVIDE EFFICIENT COMBINING SITES TO HAPTENS
1KXQ	;	1.6	;	Camelid VHH Domain in Complex with Porcine Pancreatic alpha-Amylase
1KXT	;	2.0	;	Camelid VHH Domains in Complex with Porcine Pancreatic alpha-Amylase
1KXV	;	1.6	;	Camelid VHH Domains in Complex with Porcine Pancreatic alpha-Amylase
6W4O	;	4.8	;	CaMKII alpha-30 Cryo-EM reconstruction
6W4P	;	6.6	;	CaMKII alpha-30 Cryo-EM reconstruction - Class B
3KK8	;	1.72	;	CaMKII Substrate Complex A
3KK9	;	3.206	;	CaMKII Substrate Complex B
3KL8	;	3.372	;	CaMKIINtide Inhibitor Complex
5KBF	;	2.0	;	cAMP bound PfPKA-R (141-441)
5K8S	;	1.15	;	cAMP bound PfPKA-R (297-441)
3D0S	;	2.0	;	cAMP receptor protein from m.tuberculosis, cAMP-free form
4OLL	;	1.9	;	cAMP-binding acyltransferase from Mycobacterium smegmatis
4ONU	;	2.25	;	cAMP-binding acyltransferase from Mycobacterium smegmatis, E234A mutant
4ORF	;	2.0	;	cAMP-binding acyltransferase from Mycobacterium smegmatis, mutant R95K
7NP4	;	3.3	;	cAMP-bound rabbit HCN4 stabilized in LMNG-CHS detergent mixture
8PD8	;	3.3	;	cAMP-bound SpSLC9C1 in lipid nanodiscs, dimer
8PD9	;	3.6	;	cAMP-bound SpSLC9C1 in lipid nanodiscs, protomer state 1
5MHI	;	1.489	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule (5-chloro-2-methoxyphenyl)methanamine
5N1M	;	1.436	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule (5-chloro-2-methoxyphenyl)methanamine
5N3G	;	1.16	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule (R)-1,4-oxazepan-6-ol
5N3P	;	1.58	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 1H-Indol-5-ol
5N1L	;	1.489	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 2,5-dimethyl-N-pyridin-4-ylfuran-3-carboxamide
5N39	;	1.45	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)pyrrolidine
5N3R	;	1.36	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 2-(carbamoylamino)-4-methylsulfanylbutanoic acid
5N3B	;	1.64	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 2-(pyridin-3-yl)ethanamine
5N1K	;	1.8	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 2-amino-1-(4-fluorophenyl)ethanol
5N1O	;	1.8	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 2-chloro-4-(chloromethyl)-5-hydroxyphenyl)ethan-1-one
5N1N	;	1.405	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 2-chloro-9-propan-2-ylpurine
5N3O	;	1.32	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 3-(1,3-oxazol-5-yl)aniline
5N7P	;	1.501	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 3-amino-5-(pyrrolidin-1-yl)-1H-pyrazole-4-carbonitrile
5N33	;	1.434	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 3-amino-5-(trifluoromethyl)-1H-pyridin-2-one
5N3Q	;	1.31	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 3-Aminobenzamide
5N36	;	1.58	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 3H-isoindol-2-ium-1-amine
5N1G	;	1.14	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 4-(2-Amino-1,3-thiazol-4-yl)-1-oxaspiro[4.5]decan-2-one
5N3D	;	1.77	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 4-(trifluoromethyl)benzenecarboximidamide
5N7U	;	1.371	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 4-Bromo-3,5-dimethyl-1H-pyrazole
5N32	;	1.833	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 4-chlorobenzyl carbamimidothioate
5N3S	;	1.14	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 4-Hydroxybenzamide
5N3A	;	1.404	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 4-methyl-5-(1-methylimidazol-2-yl)-1,3-thiazol-2-amine
5N3J	;	1.12	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 4-Nitrobenzoic acid
5N3L	;	1.38	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol
5N3T	;	1.209	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 5-Chlorothiophene-2-sulfonamide
5N3E	;	1.529	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 6-dimethylaminopyridine-3-carboxylic acid
5N3M	;	1.229	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule D-arginine
5N3I	;	1.14	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule methyl (2S)-2-amino-3-phenylpropanoate
5N1H	;	1.18	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule Methyl 4-(aminomethyl)benzoate
5N1E	;	1.529	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule N-(1,3-benzodioxol-5-yl)-2-piperidin-1-ylacetamide
5N37	;	1.589	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule N-(1,3-benzodioxol-5-ylmethyl)cyclopentanamine
5N1D	;	1.609	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule N-methyl-1-(5-pyridin-3-yloxyfuran-2-yl)methanamine
5N1F	;	1.12	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule N-quinolin-5-ylpyridine-3-carboxamide
5N3F	;	1.68	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule N-[3-(aminomethyl)phenyl]acetamide
5N3K	;	1.33	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule O-guanidino-L-homoserine
5N3H	;	1.36	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule pyridine-3-carboxamide
5N3C	;	1.772	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule Thiophene-3-Carboximidamide
5N3N	;	1.224	;	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule [(2R)-2,4-dihydroxy-4-oxobutyl]-trimethylazanium
1CDK	;	2.0	;	CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
2GFC	;	1.87	;	cAMP-dependent protein kinase PKA catalytic subunit with PKI-5-24
3DND	;	2.26	;	cAMP-dependent protein kinase PKA catalytic subunit with PKI-5-24
3DNE	;	2.0	;	cAMP-dependent protein kinase PKA catalytic subunit with PKI-5-24
4YXS	;	2.11	;	CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1STC	;	2.3	;	CAMP-DEPENDENT PROTEIN KINASE, ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH STAUROSPORINE
7NP3	;	3.3	;	cAMP-free rabbit HCN4 stabilized in LMNG-CHS detergent mixture
1BFO	;	2.6	;	CAMPATH-1G IGG2B RAT MONOCLONAL FAB
6WE6	;	2.16	;	Camphor bound P450cam D251E structure
6WFL	;	1.6	;	Camphor soaked P450cam D251E
8UUZ	;	3.77	;	Campylobacter jejuni CosR apo form
6D57	;	1.81	;	Campylobacter jejuni ferric uptake regulator S1 metalated
7LAT	;	2.47	;	Campylobacter jejuni keto-acid reductoisomerase in complex with Mg2+
6Z05	;	5.8	;	Campylobacter jejuni serine protease HtrA
5E6F	;	2.6	;	Canarypox virus resolvase
2EF6	;	2.1	;	Canavalia gladiata lectin complexed with Man1-3Man-OMe
5BYN	;	2.651	;	Canavalia maritima lectin complexed with synthetic selenoamino acid
8SZO	;	2.5	;	Canavalia villosa lectin in complex with alpha-methyl-mannoside
2CAU	;	2.1	;	CANAVALIN FROM JACK BEAN
2CAV	;	2.0	;	CANAVALIN FROM JACK BEAN
5BK8	;	2.25	;	Cancer-associated SHP2/T507K mutant
8CDK	;	3.32	;	CAND1 b-hairpin++-SCF-SKP2 CAND1 partly engaged SCF partly rocked
8CDJ	;	3.4	;	CAND1 b-hairpin++-SCF-SKP2 CAND1 rolling SCF engaged
7ZBZ	;	3.1	;	CAND1 delhairpin-SCF-SKP2 CAND1 partly engaged SCF partly rocked
7Z8R	;	2.7	;	CAND1-CUL1-RBX1
8OR2	;	3.2	;	CAND1-CUL1-RBX1-DCNL1
8OR0	;	3.1	;	CAND1-CUL1-RBX1-SKP1-SKP2-CKS1-CDK2
8OR3	;	2.9	;	CAND1-CUL1-RBX1-SKP1-SKP2-DCNL1
7Z8V	;	2.7	;	CAND1-SCF-SKP2 (SKP1deldel) CAND1 engaged SCF rocked
7Z8T	;	3.0	;	CAND1-SCF-SKP2 CAND1 engaged SCF rocked
7ZBW	;	3.5	;	CAND1-SCF-SKP2 CAND1 rolling-2 SCF engaged
1AI9	;	1.85	;	CANDIDA ALBICANS DIHYDROFOLATE REDUCTASE
1IA3	;	1.78	;	Candida albicans dihydrofolate reductase complex in which the dihydronicotinamide moiety of dihydro-nicotinamide-adenine-dinucleotide phosphate (NADPH) is displaced by 5-[(4-TERT-BUTYLPHENYL)SULFANYL]-2,4-QUINAZOLINEDIAMINE (GW995)
1IA4	;	1.85	;	Candida albicans dihydrofolate reductase complex in which the dihydronicotinamide moiety of dihydro-nicotinamide-adenine-dinucleotide phosphate (NADPH) is displaced by 5-{[4-(4-MORPHOLINYL)PHENYL]SULFANYL}-2,4-QUINAZOLINEDIAMIN (GW2021)
1AOE	;	1.6	;	CANDIDA ALBICANS DIHYDROFOLATE REDUCTASE COMPLEXED WITH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE (NADPH) AND 1,3-DIAMINO-7-(1-ETHYEPROPYE)-7H-PYRRALO-[3,2-F]QUINAZOLINE (GW345)
1M79	;	1.7	;	Candida albicans Dihydrofolate Reductase Complexed with Dihydro-Nicotinamide-Adenine-Dinucleotide Phosphate (NADPH) and 5-(4-methoxyphenoxy)-2,4-quinazolinediamine (GW1466)
1IA1	;	1.7	;	Candida albicans dihydrofolate reductase complexed with dihydro-nicotinamide-adenine-dinucleotide phosphate (NADPH) and 5-(PHENYLSULFANYL)-2,4-QUINAZOLINEDIAMINE (GW997)
1M78	;	1.71	;	CANDIDA ALBICANS DIHYDROFOLATE REDUCTASE COMPLEXED WITH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE (NADPH) AND 5-CHLORYL-2,4,6-QUINAZOLINETRIAMINE (GW1225)
1IA2	;	1.82	;	Candida albicans dihydrofolate reductase complexed with dihydro-nicotinamide-adenine-dinucleotide phosphate (NADPH) and 5-[(4-METHYLPHENYL)SULFANYL]-2,4-QUINAZOLINEDIAMINE (GW578)
1M7A	;	1.76	;	CANDIDA ALBICANS DIHYDROFOLATE REDUCTASE COMPLEXED WITH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE (NADPH) AND 7-[2-methoxy-1-(methoxymethyl)ethyl]-7H-pyrrolo[3,2-f] quinazoline-1,3-diamine (GW557)
4HOE	;	1.76	;	Candida albicans dihydrofolate reductase complexed with NADPH and 5-[3-(2,5-dimethoxy-4-phenylphenyl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine (UCP111E)
3QLW	;	2.504	;	Candida albicans dihydrofolate reductase complexed with NADPH and 5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]-6-ethylpyrimidine-2,4-diamine (UCP120B)
4HOF	;	1.76	;	Candida albicans dihydrofolate reductase complexed with NADPH and 5-[3-(2-methoxy-4-phenylphenyl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine (UCP111H)
4H96	;	2.6	;	Candida albicans dihydrofolate reductase complexed with NADPH and 5-{3-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methoxyphenyl]prop-1-yn-1-yl}-6-ethylpyrimidine-2,4-diamine (UCP1018)
4H97	;	2.2	;	Candida albicans dihydrofolate reductase complexed with NADPH and 5-{3-[3-methoxy-5-(4-methylphenyl)phenyl]but-1-yn-1-yl}-6-methylpyrimidine-2,4-diamine (UCP111D4M)
4H95	;	2.6	;	Candida albicans dihydrofolate reductase complexed with NADPH and 6-ethyl-5-{3-[3-methoxy-5-(pyridin-4-yl)phenyl]but-1-yn-1-yl}pyrimidine-2,4-diamine (UCP1006)
3QLR	;	2.149	;	Candida albicans dihydrofolate reductase complexed with NADPH and 6-methyl-5-[(3R)-3-(3,4,5-trimethoxyphenyl)pent-1-yn-1-yl]pyrimidine-2,4-diamine (UCP112A)
3QLS	;	1.733	;	Candida albicans dihydrofolate reductase complexed with NADPH and 6-methyl-5-[3-methyl-3-(3,4,5-trimethoxyphenyl)but-1-yn-1-yl]pyrimidine-2,4-diamine (UCP115A)
5HW6	;	2.401	;	Candida albicans FKBP12 apo protein in C2 space group
5HW7	;	2.291	;	Candida albicans FKBP12 apo protein in P21212 space group
5HW8	;	2.86	;	Candida albicans FKBP12 P104G protein bound with FK506 in C2 space group
6LNK	;	2.639	;	Candida albicans Fructose-1,6-bisphosphate aldolase
8UK6	;	2.73	;	Candida albicans glutaminyl tRNA synthetase (GLN4) in complex with N-pyrimidinyl-beta-thiophenylacrylamide
6CJI	;	1.64	;	Candida albicans Hsp90 nucleotide binding domain
6CJJ	;	1.74	;	Candida albicans Hsp90 nucleotide binding domain in complex with ADP
6CJS	;	1.9	;	Candida albicans Hsp90 nucleotide binding domain in complex with AUY922
6CJL	;	1.6972	;	Candida albicans Hsp90 nucleotide binding domain in complex with radicicol
6CJP	;	2.6	;	Candida albicans Hsp90 nucleotide binding domain in complex with radicicol
6CJR	;	1.8	;	Candida albicans Hsp90 nucleotide binding domain in complex with SNX-2112
1PMI	;	1.7	;	Candida Albicans Phosphomannose Isomerase
4C0T	;	3.16	;	Candida albicans PKh Kinase Domain
3DRA	;	1.8	;	Candida albicans protein geranylgeranyltransferase-I complexed with GGPP
3QNE	;	2.0	;	Candida albicans seryl-tRNA synthetase
5CU9	;	1.48	;	CANDIDA ALBICANS SUPEROXIDE DISMUTASE 5 (SOD5), APO
4N3T	;	1.4	;	Candida albicans Superoxide Dismutase 5 (SOD5), Cu(I)
4N3U	;	1.75	;	Candida albicans Superoxide Dismutase 5 (SOD5), Cu(II)
5KBM	;	1.416	;	Candida Albicans Superoxide Dismutase 5 (SOD5), D113N Mutant
5KBK	;	1.411	;	Candida Albicans Superoxide Dismutase 5 (SOD5), E110A Mutant
5KBL	;	1.414	;	Candida Albicans Superoxide Dismutase 5 (SOD5), E110Q Mutant
2J6I	;	1.55	;	Candida boidinii formate dehydrogenase (FDH) C-terminal mutant
2FSS	;	1.7	;	Candida boidinii formate dehydrogenase (FDH) K47E mutant
8HTY	;	1.4	;	Candida boidinii Formate Dehydrogenase Crystal Structure at 1.4 Angstrom Resolution
8IVJ	;	1.9	;	Candida boidinii Formate Dehydrogenase V120T Mutant
3EEM	;	2.11	;	Candida glabrata Dihydrofolate Reductase complexed with 2,4-diamino-5-[3-methyl-3-(3-methoxy-5-(2,6-dimethylphenyl)phenyl)prop-1-ynyl]-6-methylpyrimidine(UCP111D26M) and NADPH
3EEL	;	1.95	;	Candida glabrata Dihydrofolate Reductase complexed with 2,4-diamino-5-[3-methyl-3-(3-methoxy-5-(3,5-dimethylphenyl)phenyl)prop-1-ynyl]-6-methylpyrimidine(UCP11153TM) and NADPH
3EEK	;	2.03	;	Candida glabrata Dihydrofolate Reductase complexed with 2,4-diamino-5-[3-methyl-3-(3-methoxy-5-(4-methylphenyl)phenyl)prop-1-ynyl]-6-methylpyrimidine(UCP111D4M) and NADPH
3EEJ	;	2.11	;	Candida glabrata Dihydrofolate Reductase complexed with 2,4-diamino-5-[3-methyl-3-(3-methoxy-5-phenylphenyl)prop-1-ynyl]-6-methylpyrimidine(UCP111D) and NADPH
3CSE	;	1.6	;	Candida glabrata Dihydrofolate Reductase complexed with NADPH and 2,4-diamino-5-(3-(2,5-dimethoxyphenyl)prop-1-ynyl)-6-ethylpyrimidine (UCP120B)
3QLZ	;	1.94	;	Candida glabrata dihydrofolate reductase complexed with NADPH and 5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]-6-propylpyrimidine-2,4-diamine (UCP130B)
4HOG	;	2.0	;	Candida glabrata dihydrofolate reductase complexed with NADPH and 5-[3-(2-methoxy-4-phenylphenyl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine (UCP111H)
4H98	;	2.9	;	Candida glabrata dihydrofolate reductase complexed with NADPH and 5-{3-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methoxyphenyl]prop-1-yn-1-yl}-6-ethylpyrimidine-2,4-diamine (UCP1018)
3ROA	;	2.301	;	Candida glabrata dihydrofolate reductase complexed with NADPH and 6-ethyl-5-[(3R)-3-[3-methoxy-5-(morpholin-4-yl)phenyl]but-1-yn-1-yl]pyrimidine-2,4-diamine (UCP1004)
3RO9	;	2.596	;	Candida glabrata dihydrofolate reductase complexed with NADPH and 6-ethyl-5-[(3R)-3-[3-methoxy-5-(pyridin-4-yl)phenyl]but-1-yn-1-yl]pyrimidine-2,4-diamine (UCP1006)
3QLX	;	2.239	;	Candida glabrata dihydrofolate reductase complexed with NADPH and 6-methyl-5-[(3R)-3-(3,4,5-trimethoxyphenyl)pent-1-yn-1-yl]pyrimidine-2,4-diamine (UCP112A)
3QLY	;	2.519	;	Candida glabrata dihydrofolate reductase complexed with NADPH and 6-methyl-5-[3-methyl-3-(3,4,5-trimethoxyphenyl)but-1-yn-1-yl]pyrimidine-2,4-diamine (UCP115A)
8UPT	;	2.8	;	Candidatus Methanomethylophilus alvus tRNAPyl in A-site of ribosome
2WBV	;	1.9	;	Canine adenovirus 2 fibre head in complex with sialic acid
2J2J	;	1.5	;	Canine adenovirus fibre head at 1.5 A resolution
2W9L	;	2.91	;	CANINE ADENOVIRUS TYPE 2 FIBRE HEAD IN COMPLEX WITH CAR DOMAIN D1 AND SIALIC ACID
1BYU	;	2.15	;	CANINE GDP-RAN
1QG4	;	2.5	;	CANINE GDP-RAN F72Y MUTANT
3RAN	;	2.15	;	CANINE GDP-RAN Q69L MUTANT
1QG2	;	2.5	;	CANINE GDP-RAN R76E MUTANT
1C8D	;	3.0	;	CANINE PANLEUKOPENIA VIRUS EMPTY CAPSID STRUCTURE
7M3N	;	2.4	;	Canine parvovirus and Fab14 asymmetric reconstruction
7M3L	;	3.2	;	Canine parvovirus and Fab14 at partial occupancy
7M3M	;	2.26	;	Canine parvovirus and Fab14 at partial occupancy
7M3O	;	2.4	;	Canine parvovirus asymmetric map
3JCX	;	4.1	;	Canine Parvovirus complexed with Fab E
1C8H	;	3.5	;	CANINE PARVOVIRUS STRAIN D EMPTY CAPSID STRUCTURE AT PH 5.5
8K8J	;	2.88	;	Cannabinoid Receptor 1 bound to Fenofibrate coupling MiniGsq and Nb35 Complex
6N4B	;	3.0	;	Cannabinoid Receptor 1-G Protein Complex
8GHV	;	2.8	;	Cannabinoid Receptor 1-G Protein Complex
8GAG	;	3.3	;	Cannabinoid receptor 1-Gi complex with novel ligand
7SGY	;	2.5	;	Cannabis sativa bibenzyl synthase
4EPP	;	1.95	;	Canonical poly(ADP-ribose) glycohydrolase from Tetrahymena thermophila.
4EPQ	;	2.399	;	canonical poly(ADP-ribose) glycohydrolase RBPI inhibitor complex from Tetrahymena thermophila
1N52	;	2.11	;	Cap Binding Complex
1N54	;	2.72	;	Cap Binding Complex m7GpppG free
6Z9K	;	1.5	;	CAP domain of Enterococcal PrgA
6XYA	;	1.35	;	Cap-binding domain of SFTSV L protein
2GPQ	;		;	Cap-free structure of eIF4E suggests basis for its allosteric regulation
4N48	;	2.704	;	Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1 Protein in complex with capped RNA fragment
4N49	;	1.9	;	Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1 Protein in complex with m7GpppG and SAM
6VVJ	;		;	Cap1G-TPUA
6VU1	;		;	Cap3G-TAR-F1 is an RNA hairpin. The 1H-1H NOESY data was collected at 308 K in 10 mM KH2PO4 pH 7.4.
4AFH	;	1.88	;	Capitella teleta AChBP in complex with lobeline
4B5D	;	2.195	;	Capitella teleta AChBP in complex with psychonicline (3-((2(S)- Azetidinyl)methoxy)-5-((1S,2R)-2-(2-hydroxyethyl)cyclopropyl)pyridine)
4AFG	;	2.001	;	Capitella teleta AChBP in complex with varenicline
7E13	;	2.86	;	Caprylic acid targets a serine hydroxymethyltransferase to kill horseweed
3J7V	;	4.6	;	Capsid Expansion Mechanism Of Bacteriophage T7 Revealed By Multi-State Atomic Models Derived From Cryo-EM Reconstructions
3J7W	;	3.5	;	Capsid Expansion Mechanism Of Bacteriophage T7 Revealed By Multi-State Atomic Models Derived From Cryo-EM Reconstructions
3J7X	;	3.6	;	Capsid Expansion Mechanism Of Bacteriophage T7 Revealed By Multi-State Atomic Models Derived From Cryo-EM Reconstructions
2MJZ	;		;	Capsid model of M13 bacteriophage virus from Magic-angle spinning NMR and Rosetta modeling
8HQK	;	3.6	;	Capsid of DT57C bacteriophage in the empty state
8HO3	;	2.9	;	Capsid of DT57C bacteriophage in the full state
6TSU	;	3.42	;	Capsid of empty GTA particle computed with C5 symmetry
8TUX	;	3.9	;	Capsid of mature PP7 virion with 3'end region of PP7 genomic RNA
6TB9	;	3.56	;	Capsid of native GTA particle computed with C5 symmetry
8H89	;	3.7	;	Capsid of Ralstonia phage GP4
6OMC	;	3.8	;	capsid of T5 virion
6B23	;	3.7	;	Capsid protein and C-terminal part of CpmB protein in the Staphylococcus aureus pathogenicity island 1 80alpha-derived procapsid
6B0X	;	3.8	;	Capsid protein and C-terminal part of scaffolding protein in the Staphylococcus aureus phage 80alpha procapsid
4PH0	;	2.7497	;	capsid protein from bovine leukemia virus
6C21	;	5.2	;	Capsid protein in the Staphylococcus aureus phage 80alpha mature capsid
6C22	;	8.4	;	Capsid protein in the Staphylococcus aureus phage 80alpha-derived SaPI1 mature capsid
6E39	;	3.5	;	Capsid protein of PCV2 with 2-O-sulfo-alpha-L-idopyranuronic acid and N,O6-DISULFO-GLUCOSAMINE
6E32	;	3.4	;	Capsid protein of PCV2 with N,O6-DISULFO-GLUCOSAMINE
6E34	;	3.6	;	Capsid protein of PCV2 with N,O6-DISULFO-GLUCOSAMINE and 2-O-sulfo-alpha-L-idopyranuronic acid
1VD0	;		;	Capsid stabilizing protein GPD, NMR, 20 Structures
4AN5	;	8.8	;	Capsid structure and its Stability at the Late Stages of Bacteriophage SPP1 Assembly
6J3Q	;	3.53	;	Capsid structure of a freshwater cyanophage Siphoviridae Mic1
8R0G	;	2.6	;	Capsid structure of Giardiavirus (GLV) CAT strain
8R0F	;	2.14	;	Capsid structure of Giardiavirus (GLV) HP strain
7DOD	;	2.9	;	Capsid structure of human sapovirus
6Y83	;	3.65	;	Capsid structure of Leishmania RNA virus 1
6WH3	;	2.96	;	Capsid structure of Penaeus monodon metallodensovirus at pH 8.2
6WH7	;	2.78	;	Capsid structure of Penaeus monodon metallodensovirus following EDTA treatment
2VQ0	;	3.6	;	Capsid structure of Sesbania mosaic virus coat protein deletion mutant rCP(delta 48 to 59)
7X30	;	3.6	;	Capsid structure of Staphylococcus jumbo bacteriophage S6
8EGT	;	3.5	;	Capsid structure of Staphylococcus phage Andhra
8I4L	;	3.23	;	Capsid structure of the Cyanophage P-SCSP1u
2XD8	;	4.6	;	Capsid structure of the infectious Prochlorococcus Cyanophage P-SSP7
8A5T	;	3.78	;	Capsid structure of the L-A helper virus from native viral communities
3JB5	;	3.7	;	Capsid Structure of the Propionibacterium acnes Bacteriophage ATCC_Clear
8A0M	;	3.6	;	Capsular polysaccharide synthesis multienzyme in complex with capsular polymer fragment
8A0C	;	2.9	;	Capsular polysaccharide synthesis multienzyme in complex with CMP
6YUV	;	2.0	;	Capsule O-acetyltransferase of Neisseria meningitidis serogroup A
6YUS	;	2.0	;	Capsule O-acetyltransferase of Neisseria meningitidis serogroup A H228A mutant in complex with CoA
6YUO	;	2.2	;	Capsule O-acetyltransferase of Neisseria meningitidis serogroup A in complex with caged Gadolinium
6YUQ	;	1.95	;	Capsule O-acetyltransferase of Neisseria meningitidis serogroup A in complex with polysaccharide
4AY2	;	2.8	;	Capturing 5' tri-phosphorylated RNA duplex by RIG-I
5BQ1	;	1.6	;	Capturing Carbon Dioxide in beta Carbonic Anhydrase
4N7N	;	2.754	;	Capturing the haemoglobin allosteric transition in a single crystal form; Crystal structure of full-liganded human haemoglobin with phosphate at 2.75 A resolution.
4N7O	;	2.502	;	Capturing the haemoglobin allosteric transition in a single crystal form; Crystal structure of half-liganded human haemoglobin with phosphate at 2.5 A resolution.
4N7P	;	2.809	;	Capturing the haemoglobin allosteric transition in a single crystal form; Crystal structure of half-liganded human haemoglobin without phosphate at 2.8 A resolution.
301D	;	3.0	;	CAPTURING THE STRUCTURE OF A CATALYTIC RNA INTERMEDIATE: RNA HAMMERHEAD RIBOZYME, MG(II)-SOAKED
300D	;	3.0	;	CAPTURING THE STRUCTURE OF A CATALYTIC RNA INTERMEDIATE: RNA HAMMERHEAD RIBOZYME, MN(II)-SOAKED
299D	;	3.0	;	CAPTURING THE STRUCTURE OF A CATALYTIC RNA INTERMEDIATE: THE HAMMERHEAD RIBOZYME
1B7B	;	2.8	;	Carbamate kinase from Enterococcus faecalis
2WE4	;	2.02	;	Carbamate kinase from Enterococcus faecalis bound to a sulfate ion and two water molecules, which mimic the substrate carbamyl phosphate
2WE5	;	1.39	;	Carbamate kinase from Enterococcus faecalis bound to MgADP
4JZ7	;	2.6	;	Carbamate kinase from Giardia lamblia bound to AMP-PNP
4JZ8	;	2.1	;	Carbamate kinase from Giardia lamblia bound to citric acid
4JZ9	;	2.4	;	Carbamate kinase from Giardia lamblia bound to citric acid
4OLC	;	2.6	;	Carbamate kinase from Giardia lamblia thiocarbamoylated by disulfiram on Cys242
6TFB	;	1.68	;	Carbamazepine binds Frizzled8
1JDB	;	2.1	;	CARBAMOYL PHOSPHATE SYNTHETASE FROM ESCHERICHIA COLI
1CE8	;	2.1	;	CARBAMOYL PHOSPHATE SYNTHETASE FROM ESCHERICHIS COLI WITH COMPLEXED WITH THE ALLOSTERIC LIGAND IMP
1A9X	;	1.8	;	CARBAMOYL PHOSPHATE SYNTHETASE: CAUGHT IN THE ACT OF GLUTAMINE HYDROLYSIS
6FLD	;	2.4	;	Carbamylated T. californica acetylcholineterase bound to uncharged hybrid reactivator 1
6FQN	;	2.30003	;	Carbamylated T. californica acetylcholineterase bound to uncharged hybrid reactivator 2
1Q15	;	2.3	;	Carbapenam Synthetase
1Q19	;	2.4	;	Carbapenam Synthetase
6MKQ	;	1.9	;	Carbapenemase VCC-1 bound to avibactam
6MK6	;	1.7	;	Carbapenemase VCC-1 from Vibrio cholerae N14-02106
7VWT	;	1.73	;	Carbazole Prenyl Transferase CqsB4
7VWS	;	1.71	;	Carbazole Prenyl Transferase LvqB4
3VMI	;	2.0	;	Carbazole- and oxygen-bound complex between oxygenase and ferredoxin in carbazole 1,9a-dioxygenase
4NBB	;	2.05	;	Carbazole- and oxygen-bound oxygenase with Ile262 replaced by Val and ferredoxin complex of carbazole 1,9a-dioxygenase
4NBH	;	2.15	;	Carbazole-bound Oxygenase with Gln282 replaced by Tyr and ferredoxin complex of carbazole 1,9a-dioxygenase
4NBA	;	2.1	;	Carbazole-bound oxygenase with Ile262 replaced by Val and ferredoxin complex of carbazole 1,9a-dioxygenase
4NBD	;	1.95	;	Carbazole-bound oxygenase with Phe275 replaced by Trp and ferredoxin complex of carbazole 1,9a-dioxygenase (form2)
6LL0	;	2.2	;	Carbazole-soaked reduced oxygenase in carbazole 1,9a-dioxygenase
7ZOH	;	1.56	;	Carbohydrate binding domain CBMXX from a multi-catalytic glucanase-chitinase from Chitinophaga pinensis DSM 2588
7ZOI	;	1.4	;	Carbohydrate binding domain CBMXX from a multi-catalytic glucanase-chitinase from Chitinophaga pinensis DSM 2588
7ZOO	;	1.84	;	Carbohydrate binding domain CBMXX from a multi-catalytic glucanase-chitinase from Chitinophaga pinensis DSM 2588 in complex with gentiobiose
7ZON	;	1.77	;	Carbohydrate binding domain CBMXX from a multi-catalytic glucanase-chitinase from Chitinophaga pinensis DSM 2588 in complex with glucose
7ZOP	;	1.68	;	Carbohydrate binding domain CBMXX from a multi-catalytic glucanase-chitinase from Chitinophaga pinensis DSM 2588 in complex with sophorose.
4ZXK	;	1.84	;	Carbohydrate binding domain from Streptococcus pneumoniae NanA sialidase
4C1W	;	1.84	;	Carbohydrate binding domain from Streptococcus pneumoniae NanA sialidase complexed with 3'-sialyllactose
4C1X	;	1.84	;	Carbohydrate binding domain from Streptococcus pneumoniae NanA sialidase complexed with 6'-sialyllactose
1UXZ	;	1.4	;	Carbohydrate binding module (CBM6cm-2) from Cellvibrio mixtus lichenase 5A
1UYX	;	1.47	;	Carbohydrate binding module (CBM6cm-2) from Cellvibrio mixtus lichenase 5A in complex with cellobiose
1UYY	;	1.47	;	Carbohydrate binding module (CBM6cm-2) from Cellvibrio mixtus lichenase 5A in complex with cellotriose
1UY0	;	1.65	;	Carbohydrate binding module (CBM6cm-2) from Cellvibrio mixtus lichenase 5A in complex with glc-1,3-glc-1,4-glc-1,3-glc
1UZ0	;	2.0	;	Carbohydrate binding module (CBM6cm-2) from Cellvibrio mixtus lichenase 5A in complex with Glc-4Glc-3Glc-4Glc
1UYZ	;	1.6	;	Carbohydrate binding module (CBM6cm-2) from Cellvibrio mixtus lichenase 5A in complex with xylotetraose
1GMM	;	2.0	;	Carbohydrate binding module CBM6 from xylanase U Clostridium thermocellum
4AZZ	;	1.7	;	Carbohydrate binding module CBM66 from Bacillus subtilis
4B1L	;	1.65	;	CARBOHYDRATE BINDING MODULE CBM66 FROM BACILLUS SUBTILIS
4B1M	;	1.1	;	CARBOHYDRATE BINDING MODULE CBM66 FROM BACILLUS SUBTILIS
1GWK	;	2.34	;	Carbohydrate binding module family29
1GWM	;	1.15	;	Carbohydrate binding module family29 complexed with glucohexaose
1GWL	;	1.51	;	Carbohydrate binding module family29 complexed with mannohexaose
6TKX	;	2.06	;	Carbohydrate esterase from gut microbiota
2NWH	;	1.86	;	Carbohydrate kinase from Agrobacterium tumefaciens
1R13	;	2.1	;	Carbohydrate recognition and neck domains of surfactant protein A (SP-A)
1R14	;	2.5	;	Carbohydrate recognition and neck domains of surfactant protein A (Sp-A) containing samarium
2DP8	;	2.5	;	Carbohydrate recognition by lactoferrin: Crystal structure of the complex of C-terminal lobe of bovine lactoferrin with trisaccharide at 2.5 A resolution
2E0S	;	2.15	;	Carbohydrate recognition of C-terminal half of lactoferrin: Crystal structure of the complex of C-lobe with rhamnose at 2.15 A resolution
1UX7	;	1.5	;	Carbohydrate-Binding Module CBM36 in complex with calcium and xylotriose
2YLK	;	2.2	;	Carbohydrate-binding module CBM3b from the cellulosomal cellobiohydrolase 9A from Clostridium thermocellum
3ZQX	;	1.04	;	Carbohydrate-binding module CBM3b from the cellulosomal cellobiohydrolase 9A from Clostridium thermocellum
2V8L	;	1.8	;	Carbohydrate-binding of the starch binding domain of Rhizopus oryzae glucoamylase in complex with beta-cyclodextrin and maltoheptaose
2V8M	;	2.3	;	Carbohydrate-binding of the starch binding domain of Rhizopus oryzae glucoamylase in complex with beta-cyclodextrin and maltoheptaose
2VQ4	;	1.25	;	Carbohydrate-binding of the starch binding domain of Rhizopus oryzae glucoamylase in complex with beta-cyclodextrin and maltoheptaose
6H6C	;	1.75	;	Carbomonoxy murine neuroglobin F106A mutant
6H6J	;	2.6	;	Carbomonoxy murine neuroglobin Gly-loop mutant
1SU7	;	1.12	;	Carbon Monoxide Dehydrogenase from Carboxydothermus hydrogenoformans- DTT reduced state
1SUF	;	1.15	;	Carbon Monoxide Dehydrogenase from Carboxydothermus hydrogenoformans-Inactive state
1SU6	;	1.64	;	Carbon monoxide dehydrogenase from Carboxydothermus hydrogenoformans: CO reduced state
1FFV	;	2.25	;	CARBON MONOXIDE DEHYDROGENASE FROM HYDROGENOPHAGA PSEUDOFLAVA
1FFU	;	2.35	;	CARBON MONOXIDE DEHYDROGENASE FROM HYDROGENOPHAGA PSEUDOFLAVA WHICH LACKS THE MO-PYRANOPTERIN MOIETY OF THE MOLYBDENUM COFACTOR
6ELQ	;	2.52	;	Carbon Monoxide Dehydrogenase IV from Carboxydothermus hydrogenoformans
1SU8	;	1.1	;	Carbon Monoxide Induced Decomposition of the Active Site [Ni-4Fe-5S] Cluster of CO Dehydrogenase
6MMC	;	1.42	;	Carbon regulatory PII-like protein SbtB from Cyanobium sp. 7001 bound to ADP
6MMO	;	1.86	;	Carbon regulatory PII-like protein SbtB from Cyanobium sp. 7001 bound to AMP
6MM2	;	1.04	;	Carbon regulatory PII-like protein SbtB from Cyanobium sp. 7001 bound to ATP and calcium
6MMQ	;	2.02	;	Carbon regulatory PII-like protein SbtB from Cyanobium sp. 7001 bound to cAMP
5O3S	;	2.2	;	Carbon regulatory PII-like protein SbtB from Synechocystis sp. 6803 in Apo state, hexagonal crystal form
5O3P	;	1.75	;	Carbon regulatory PII-like protein SbtB from Synechocystis sp. 6803 in Apo state, trigonal crystal form
7R30	;	1.9	;	Carbon regulatory PII-like protein SbtB from Synechocystis sp. 6803 in complex with ADP and AMP resulting from ADP soak
5O3R	;	1.9	;	Carbon regulatory PII-like protein SbtB from Synechocystis sp. 6803 in complex with AMP
7R2Z	;	2.4	;	Carbon regulatory PII-like protein SbtB from Synechocystis sp. 6803 in complex with ATP and ADP resulting from long ATP soak
7R2Y	;	2.15	;	Carbon regulatory PII-like protein SbtB from Synechocystis sp. 6803 in complex with ATP resulting from short ATP soak, conflicting T-loop and C-loop with partial occupancy
5O3Q	;	1.75	;	Carbon regulatory PII-like protein SbtB from Synechocystis sp. 6803 in complex with cyclic AMP (cAMP)
7OBJ	;	2.0	;	Carbon regulatory PII-like protein SbtB from Synechocystis sp. 6803 in complex with cyclic di-AMP (c-di-AMP)
7R31	;	1.52	;	Carbon regulatory PII-like protein SbtB from Synechocystis sp. 6803, C105A+C110A variant, in complex with ATP (co-crystal), tetragonal crystal form
7R32	;	1.75	;	Carbon regulatory PII-like protein SbtB from Synechocystis sp. 6803, delta104 variant, in complex with ADP (co-crystal), tetragonal crystal form
8IRK	;	2.35	;	Carbon Sulfoxide lyase
8IRY	;	2.35	;	Carbon Sulfoxide lyase
8IRZ	;	2.86	;	Carbon Sulfoxide lyase
8IS0	;	3.02	;	Carbon Sulfoxide lyase - Y106F
5UTS	;	2.303	;	Carbon Sulfoxide lyase, Egt2 in the Ergothioneine biosynthesis pathway
5V1X	;	2.558	;	Carbon Sulfoxide lyase, Egt2 Y134F in complex with its substrate
6C7X	;	1.5	;	Carbonic anhydrase 2 in complex with 2-chloro-5'-O-sulfamoyladenosine
6U4Q	;	1.306	;	Carbonic anhydrase 2 in complex with SB4197
8OLM	;	1.5	;	Carbonic Anhydrase 2 in Complex with Steriod_Sulphamoyl AKI1
8OMP	;	1.41	;	Carbonic Anhydrase 2 in Complex with Steriod_Sulphamoyl AKI33
8OLI	;	1.4	;	Carbonic Anhydrase 2 in Complex with Steriod_Sulphamoyl AKI_12
8OLK	;	1.27	;	Carbonic Anhydrase 2 in Complex with Steriod_Sulphamoyl AKI_13
8OKQ	;	1.0	;	Carbonic Anhydrase 2 in Complex with Steriod_Sulphamoyl AKI_2
8OMB	;	1.35	;	Carbonic Anhydrase 2 in Complex with Steriod_Sulphamoyl VK42
6C7W	;	1.28	;	Carbonic anhydrase 2 in complex with [(2R,3S,4R,5R)-5-(6-AMINO-9H-PURIN-9-YL)-3,4-DIHYDROXYTETRAHYDRO-2-FURANYL]METHYL SULFAMATE inhibitor
6UFB	;	1.67	;	Carbonic anhydrase 2 with inhibitor (2Z)-2-benzylidene-3-oxo-N-(4-sulfamoylphenyl)butanamide (11a/D1)
6UFC	;	1.325	;	Carbonic anhydrase 2 with inhibitor (2Z)-2-[(4-methoxyphenyl)methylidene]-3-oxo-N-(4-sulfamoylphenyl)butanamide (11d/D4)
6UFD	;	1.48	;	Carbonic anhydrase 2 with inhibitor (2Z)-3-oxo-N-(4-sulfamoylphenyl)-2-[(thiophen-2-yl)methylidene]butanamide (11g/D7)
6U4T	;	1.356	;	Carbonic anhydrase 9 in complex with SB4197
2FMG	;	1.6	;	Carbonic anhydrase activators. Activation of isoforms I, II, IV, VA, VII and XIV with L- and D- phenylalanine and crystallographic analysis of their adducts with isozyme II: sterospecific recognition within the active site of an enzyme and its consequences for the drug design, structure with L-phenylalanine
2FMZ	;	1.6	;	Carbonic anhydrase activators. Activation of isoforms I, II, IV, VA, VII and XIV with L- and D- phenylalanine, structure with D-Phenylalanine.
2EZ7	;	2.0	;	Carbonic anhydrase activators. Activation of isozymes I, II, IV, VA, VII and XIV with L- and D-histidine and crystallographic analysis of their adducts with isoform II: engineering proton transfer processes within the active site of an enzyme
2FW4	;	2.0	;	Carbonic anhydrase activators. The first X-ray crystallographic study of an activator of isoform I, structure with L-histidine.
3EFI	;	1.75	;	Carbonic anhydrase activators: Kinetic and X-ray crystallographic study for the interaction of d- and l-tryptophan with the mammalian isoforms I-XIV
2HKK	;	1.9	;	Carbonic anhydrase activators: Solution and X-ray crystallography for the interaction of andrenaline with various carbonic anhydrase isoforms
2ABE	;	2.0	;	Carbonic anhydrase activators: X-ray crystal structure of the adduct of human isozyme II with L-histidine as a platform for the design of stronger activators
4XIW	;	2.6	;	Carbonic anhydrase Cah3 from Chlamydomonas reinhardtii in complex with acetazolamide
4XIX	;	2.7	;	Carbonic anhydrase Cah3 from Chlamydomonas reinhardtii in complex with phosphate.
6RZX	;	1.0	;	Carbonic Anhydrase CAIX mimic in complex with inhibitor FBSA
6S03	;	1.38	;	Carbonic Anhydrase CAIX mimic in complex with inhibitor I39LT379
6GXB	;	1.35	;	Carbonic Anhydrase CAIX mimic in complex with inhibitor JS13
6GXE	;	1.3	;	Carbonic Anhydrase CAIX mimic in complex with inhibitor JS14
6GWU	;	2.2	;	Carbonic anhydrase CaNce103p from Candida albicans
3RYJ	;	1.39	;	Carbonic Anhydrase complexed with 4-sulfamoyl-N-(2,2,2-trifluoroethyl)benzamide
3RYV	;	1.2	;	Carbonic Anhydrase complexed with N-ethyl-4-sulfamoylbenzamide
5ZTP	;	2.96	;	Carbonic anhydrase from Glaciozyma antarctica
3BOH	;	1.7	;	Carbonic anhydrase from marine diatom Thalassiosira weissflogii- cadmium bound domain 1 with acetate (CDCA1-R1)
3BOJ	;	1.45	;	Carbonic anhydrase from marine diatom Thalassiosira weissflogii- cadmium bound domain 1 without bound metal (CDCA1-R1)
3BOB	;	1.45	;	Carbonic anhydrase from marine diatom Thalassiosira weissflogii- cadmium bound domain 2
3BOE	;	1.4	;	Carbonic anhydrase from marine diatom Thalassiosira weissflogii- cadmium bound domain 2 with acetate (CDCA1-R2)
3BOC	;	1.8	;	Carbonic anhydrase from marine diatom Thalassiosira weissflogii- zinc bound domain 2 (CDCA1-R2)
1THJ	;	2.8	;	CARBONIC ANHYDRASE FROM METHANOSARCINA
7PRI	;	1.679	;	Carbonic Anhydrase from Schistosoma Mansoni in complex with clorsulon
1HEA	;	2.0	;	CARBONIC ANHYDRASE II (CARBONATE DEHYDRATASE) (HCA II) (E.C.4.2.1.1) MUTANT WITH LEU 198 REPLACED BY ARG (L198R)
1G3Z	;	1.86	;	CARBONIC ANHYDRASE II (F131V)
1G4O	;	1.96	;	CARBONIC ANHYDRASE II (F131V) COMPLEXED WITH 4-(AMINOSULFONYL)-N-PHENYLMETHYLBENZAMIDE
1G4J	;	1.84	;	CARBONIC ANHYDRASE II (F131V) COMPLEXED WITH 4-(AMINOSULFONYL)-N-[(2,3,4,5,6-PENTAFLUOROPHENYL)METHYL]-BENZAMIDE
1I9O	;	1.86	;	CARBONIC ANHYDRASE II (F131V) COMPLEXED WITH 4-(AMINOSULFONYL)-N-[(2,3,4-TRIFLUOROPHENYL)METHYL]-BENZAMIDE
1G46	;	1.84	;	CARBONIC ANHYDRASE II (F131V) COMPLEXED WITH 4-(AMINOSULFONYL)-N-[(2,3-DIFLUOROPHENYL)METHYL]-BENZAMIDE
1I9P	;	1.92	;	CARBONIC ANHYDRASE II (F131V) COMPLEXED WITH 4-(AMINOSULFONYL)-N-[(2,4,6-TRIFLUOROPHENYL)METHYL]-BENZAMIDE
1I9M	;	1.84	;	CARBONIC ANHYDRASE II (F131V) COMPLEXED WITH 4-(AMINOSULFONYL)-N-[(2,4-DIFLUOROPHENYL)METHYL]-BENZAMIDE
1I9N	;	1.86	;	CARBONIC ANHYDRASE II (F131V) COMPLEXED WITH 4-(AMINOSULFONYL)-N-[(2,5-DIFLUOROPHENYL)METHYL]-BENZAMIDE
1G48	;	1.86	;	CARBONIC ANHYDRASE II (F131V) COMPLEXED WITH 4-(AMINOSULFONYL)-N-[(2,6-DIFLUOROPHENYL)METHYL]-BENZAMIDE
1G45	;	1.83	;	CARBONIC ANHYDRASE II (F131V) COMPLEXED WITH 4-(AMINOSULFONYL)-N-[(2-FLUOROPHENYL)METHYL]-BENZAMIDE
1I9Q	;	1.8	;	CARBONIC ANHYDRASE II (F131V) COMPLEXED WITH 4-(AMINOSULFONYL)-N-[(3,4,5-TRIFLUOROPHENYL)METHYL]-BENZAMIDE
1I9L	;	1.93	;	CARBONIC ANHYDRASE II (F131V) COMPLEXED WITH 4-(AMINOSULFONYL)-N-[(4-FLUOROPHENYL)METHYL]-BENZAMIDE
1OKL	;	2.1	;	CARBONIC ANHYDRASE II COMPLEX WITH THE 1OKL INHIBITOR 5-DIMETHYLAMINO-NAPHTHALENE-1-SULFONAMIDE
1OKM	;	2.2	;	CARBONIC ANHYDRASE II COMPLEX WITH THE 1OKM INHIBITOR 4-SULFONAMIDE-[1-(4-AMINOBUTANE)]BENZAMIDE
1OKN	;	2.4	;	CARBONIC ANHYDRASE II COMPLEX WITH THE 1OKN INHIBITOR 4-SULFONAMIDE-[1-(4-N-(5-FLUORESCEIN THIOUREA)BUTANE)]
1IF7	;	1.98	;	Carbonic Anhydrase II Complexed With (R)-N-(3-Indol-1-yl-2-methyl-propyl)-4-sulfamoyl-benzamide
1IF8	;	1.94	;	Carbonic Anhydrase II Complexed With (S)-N-(3-Indol-1-yl-2-methyl-propyl)-4-sulfamoyl-benzamide
1IF5	;	2.0	;	Carbonic Anhydrase II Complexed With 2,6-difluorobenzenesulfonamide
6WQ4	;	1.35	;	Carbonic Anhydrase II Complexed with 2-((2-Cyanoethyl)(phenethyl)amino)-N-phenethyl-N-(4-sulfamoylphenethyl)acetamide
6WQ7	;	1.304	;	Carbonic Anhydrase II Complexed with 2-((3-Aminopropyl)(phenethyl)amino)-N-(4-fluorobenzyl)-N-(4-sulfamoylphenethyl)acetamide
6WQ5	;	1.304	;	Carbonic Anhydrase II Complexed with 2-((3-Aminopropyl)(phenethyl)amino)-N-(furan-2-ylmethyl)-N-(4-sulfamoylphenethyl)acetamide
1IF6	;	2.09	;	Carbonic Anhydrase II Complexed With 3,5-difluorobenzenesulfonamide
6WQ8	;	1.405	;	Carbonic Anhydrase II Complexed with 3-((2-((Furan-2-ylmethyl)(4-sulfamoylphenethyl)amino)-2-oxoethyl)(phenethyl)amino)propanoic acid
6WQ9	;	1.305	;	Carbonic Anhydrase II Complexed with 3-((2-((Naphthalen-2-ylmethyl)(4-sulfamoylphenethyl)amino)-2-oxoethyl)(phenethyl)amino)propanoic acid
7K6K	;	1.306	;	Carbonic Anhydrase II complexed with 4-(2-(3-(3,5-dimethylphenyl)ureido)ethylsulfonamido)benzenesulfonamide
7K6L	;	1.655	;	Carbonic Anhydrase II complexed with 4-(2-(3-(4-fluorophenyl)ureido)ethylsulfonamido)benzenesulfonamide
7K6J	;	1.755	;	Carbonic Anhydrase II complexed with 4-(2-(3-(4-methylphenyl)ureido)ethylsulfonamido)benzenesulfonamide
7K6I	;	1.406	;	Carbonic Anhydrase II complexed with 4-(2-(3-phenylureido)ethylsulfonamido)benzenesulfonamide
1G54	;	1.86	;	CARBONIC ANHYDRASE II COMPLEXED WITH 4-(AMINOSULFONYL)-N-[(2,3,4,5,6-PENTAFLUOROPHENYL)METHYL]-BENZAMIDE
1G52	;	1.8	;	CARBONIC ANHYDRASE II COMPLEXED WITH 4-(AMINOSULFONYL)-N-[(2,3-DIFLUOROPHENYL)METHYL]-BENZAMIDE
1G53	;	1.94	;	CARBONIC ANHYDRASE II COMPLEXED WITH 4-(AMINOSULFONYL)-N-[(2,6-DIFLUOROPHENYL)METHYL]-BENZAMIDE
1G1D	;	2.04	;	CARBONIC ANHYDRASE II COMPLEXED WITH 4-(AMINOSULFONYL)-N-[(2-FLUOROPHENYL)METHYL]-BENZAMIDE
1IF4	;	1.93	;	Carbonic Anhydrase II Complexed With 4-fluorobenzenesulfonamide
1I91	;	2.0	;	CARBONIC ANHYDRASE II COMPLEXED WITH AL-6619 2H-THIENO[3,2-E]-1,2-THIAZINE-6-SULFONAMIDE, 2-(3-HYDROXYPHENYL)-3-(4-MORPHOLINYL)-, 1,1-DIOXIDE
1I8Z	;	1.93	;	CARBONIC ANHYDRASE II COMPLEXED WITH AL-6629 2H-THIENO[3,2-E]-1,2-THIAZINE-6-SULFONAMIDE, 2-(3-METHOXYPHENYL)-3-(4-MORPHOLINYL)-, 1,1-DIOXIDE
1I90	;	2.0	;	CARBONIC ANHYDRASE II COMPLEXED WITH AL-8520 2H-THIENO[3,2-E]-1,2-THIAZINE-6-SULFONAMIDE, 4-AMINO-3,4-DIHYDRO-2-(3-METHOXYPROPYL)-, 1,1-DIOXIDE, (R)
6OUK	;	1.498	;	Carbonic Anhydrase II complexed with benzene sulfonamide MB10-580B
6OUJ	;	1.466	;	Carbonic Anhydrase II complexed with benzene sulfonamide MB11-689A
6OUB	;	1.418	;	Carbonic Anhydrase II complexed with benzene sulfonamide MB11-694B
6OUE	;	1.415	;	Carbonic Anhydrase II complexed with benzene sulfonamide MB11-707A
7JNV	;	1.49	;	Carbonic Anhydrase II Complexed with N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)butyramide
7JNZ	;	1.289	;	Carbonic Anhydrase II Complexed with N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)cyclohexanecarboxamide
7JNW	;	1.292	;	Carbonic Anhydrase II Complexed with N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)isobutyramide
7JNX	;	1.286	;	Carbonic Anhydrase II Complexed with N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)pivalamide
7JNR	;	1.443	;	Carbonic Anhydrase II Complexed with N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)propionamide
1IF9	;	2.0	;	Carbonic Anhydrase II Complexed With N-[2-(1H-Indol-5-yl)-butyl]-4-sulfamoyl-benzamide
6UX1	;	1.36	;	Carbonic Anhydrase II Complexed with Salicylic Acid
6OTP	;	1.466	;	Carbonic Anhydrase II complexed with ureic benzene sulfonamide MB10-586B
6OTQ	;	1.467	;	Carbonic Anhydrase II complexed with ureic benzene sulfonamide MB10-596B
6OTO	;	1.496	;	Carbonic Anhydrase II complexed with ureic benzene sulfonamide MB9-561B
3KNE	;	1.35	;	Carbonic Anhydrase II H64C mutant in complex with an in situ formed triazole
7RNY	;	1.29	;	Carbonic Anhydrase II in complex with 3-ureido benzenesulfonamide derivative
5SZ1	;	1.55	;	Carbonic anhydrase II in complex with 4-(2-methylphenyl)-benzenesulfonamide
5SZ2	;	1.63	;	Carbonic anhydrase II in complex with 4-(3-formylphenyl)-benzenesulfonamide
5SZ3	;	1.689	;	Carbonic anhydrase II in complex with 4-(3-quinolinyl)-benzenesulfonamide
5SZ0	;	1.63	;	Carbonic anhydrase II in complex with 4-(phenyl)-benzenesulfonamide
7RNZ	;	1.3	;	Carbonic Anhydrase II in complex with 4-ureido benzenesulfonamide derivative
1ZE8	;	2.0	;	Carbonic anhydrase II in complex with a membrane-impermeant sulfonamide inhibitor
5W8B	;	1.601	;	Carbonic anhydrase II in complex with activating histamine pyridinium derivative
5WLV	;	1.4	;	Carbonic Anhydrase II in complex with aryloxy-2-hydroxypropylammine sulfonamide
7RRE	;	1.44	;	Carbonic Anhydrase II in complex with Beta-Galactose-2C
4M2U	;	1.999	;	Carbonic Anhydrase II in complex with Dorzolamide
1ZFQ	;	1.55	;	carbonic anhydrase II in complex with ethoxzolamidphenole as sulfonamide inhibitor
4FPT	;	0.98	;	Carbonic Anhydrase II in complex with ethyl (2Z,4R)-2-(sulfamoylimino)-1,3-thiazolidine-4-carboxylate
6MBY	;	1.496	;	Carbonic Anhydrase II in complex with Ferulic Acid
1Z9Y	;	1.66	;	carbonic anhydrase II in complex with furosemide as sulfonamide inhibitor
7OYM	;	0.98	;	Carbonic anhydrase II in complex with Hit2 (MH65)
7OYN	;	0.98	;	Carbonic anhydrase II in complex with Hit3 (MH57)
7OYP	;	1.05	;	Carbonic anhydrase II in complex with Hit3-t1 (MH172)
7OYQ	;	1.15	;	Carbonic anhydrase II in complex with Hit3-t2 (MH174)
7OYR	;	1.15	;	Carbonic anhydrase II in complex with Hit3-t4 (MH181)
7OYO	;	1.03	;	Carbonic anhydrase II in complex with Hit4 (MH70)
8DJ9	;	1.54	;	Carbonic Anhydrase II in complex with Ibuprofen
4FRC	;	0.98	;	Carbonic Anhydrase II in complex with N'-sulfamoylpyrrolidine-1-carboximidamide
4FVN	;	1.05	;	Carbonic Anhydrase II in complex with N-(tetrahydropyrimidin-2(1H)-ylidene)sulfuric diamide
1ZH9	;	1.7	;	carbonic anhydrase II in complex with N-4-Methyl-1-piperazinyl-N'-(p-sulfonamide)phenylthiourea as sulfonamide inhibitor
1ZFK	;	1.56	;	carbonic anhydrase II in complex with N-4-sulfonamidphenyl-N'-4-methylbenzosulfonylurease as sulfonamide inhibitor
4FVO	;	1.05	;	Carbonic Anhydrase II in complex with N-[(2E)-3,4-dihydroquinazolin-2(1H)-ylidene]sulfuric diamide
4FU5	;	0.98	;	Carbonic Anhydrase II in complex with N-[(2Z)-1,3-oxazolidin-2-ylidene]sulfuric diamide
1OQ5	;	1.5	;	CARBONIC ANHYDRASE II IN COMPLEX WITH NANOMOLAR INHIBITOR
6MBV	;	1.695	;	Carbonic Anhydrase II in complex with Nicotinic Acid
6B59	;	1.638	;	Carbonic anhydrase II in complex with nitrogenous base-bearing benezenesulfonamide
3M04	;	1.4	;	Carbonic Anhydrase II in complex with novel sulfonamide inhibitor
3M14	;	1.38	;	Carbonic Anhydrase II in complex with novel sulfonamide inhibitor
3M2X	;	1.87	;	Carbonic Anhydrase II in complex with novel sulfonamide inhibitor
3M2Y	;	1.17	;	Carbonic Anhydrase II in complex with novel sulfonamide inhibitor
1ZGE	;	1.65	;	carbonic anhydrase II in complex with p-Sulfonamido-o,o'-dichloroaniline as sulfonamide inhibitor
6VJ3	;	1.35	;	Carbonic Anhydrase II in complex with pyrimidine-based inhibitor
2Q1B	;	1.7	;	Carbonic Anhydrase II in Complex with Saccharin
2Q38	;	1.95	;	Carbonic Anhydrase II in complex with Saccharin at 1.95 Angstrom
8OMH	;	1.45	;	Carbonic Anhydrase II in Complex with Steriod_Sulphamoyl (BS1982)
8OMN	;	1.4	;	Carbonic Anhydrase II in Complex with Steriod_Sulphamoyl VK4
5EIJ	;	1.99	;	Carbonic Anhydrase II in complex with Sulfonamide Inhibitor
8FQY	;	1.466	;	Carbonic Anhydrase II in complex with the alkyl urea 3h
8FQZ	;	1.467	;	Carbonic Anhydrase II in complex with the alkyl urea 3j
8FQX	;	1.496	;	Carbonic Anhydrase II in complex with the alkyl ureas 3g
8SAG	;	1.52	;	Carbonic anhydrase II in complex with the coumarin benzene sulfonamide SG1-57
8EM3	;	1.62	;	Carbonic Anhydrase II in complex with the diaryl urea molecule J2
1ZGF	;	1.75	;	carbonic anhydrase II in complex with trichloromethiazide as sulfonamide inhibitor
5JN7	;	1.517	;	Carbonic Anhydrase II In Complex WITH U-CH3
1BN1	;	2.1	;	CARBONIC ANHYDRASE II INHIBITOR
1BN3	;	2.2	;	CARBONIC ANHYDRASE II INHIBITOR
1BN4	;	2.1	;	CARBONIC ANHYDRASE II INHIBITOR
1BNM	;	2.6	;	CARBONIC ANHYDRASE II INHIBITOR
1BNN	;	2.3	;	CARBONIC ANHYDRASE II INHIBITOR
1BNQ	;	2.4	;	CARBONIC ANHYDRASE II INHIBITOR
1BNT	;	2.15	;	CARBONIC ANHYDRASE II INHIBITOR
1BNU	;	2.15	;	CARBONIC ANHYDRASE II INHIBITOR
1BNV	;	2.4	;	CARBONIC ANHYDRASE II INHIBITOR
1BNW	;	2.25	;	CARBONIC ANHYDRASE II INHIBITOR
5NXG	;	1.2	;	Carbonic Anhydrase II Inhibitor RA1
5NXM	;	1.25	;	Carbonic Anhydrase II Inhibitor RA1
5NY1	;	1.1	;	Carbonic Anhydrase II Inhibitor RA10
5NY3	;	1.4	;	Carbonic Anhydrase II Inhibitor RA11
5NY6	;	1.1	;	Carbonic Anhydrase II Inhibitor RA12
5NYA	;	1.2	;	Carbonic Anhydrase II Inhibitor RA13
5NXI	;	1.16	;	Carbonic Anhydrase II Inhibitor RA2
5NXO	;	1.2	;	Carbonic Anhydrase II Inhibitor RA6
5NXP	;	1.25	;	Carbonic Anhydrase II Inhibitor RA7
5NXV	;	1.1	;	Carbonic Anhydrase II Inhibitor RA8
5NXW	;	1.1	;	Carbonic Anhydrase II Inhibitor RA9
1AM6	;	2.0	;	CARBONIC ANHYDRASE II INHIBITOR: ACETOHYDROXAMATE
6OUH	;	1.449	;	Carbonic Anhydrase II mimic complexed with benzene sulfonamide MB11-710A
7ONQ	;	1.65	;	Carbonic anhydrase II mutant (E69C) dually binding an IrCp* complex to generate an artificial transfer hydrogenase (ATHase)
7ONV	;	1.04	;	Carbonic anhydrase II mutant (I91C) dually binding an IrCp* complex to generate an artificial transfer hydrogenase (ATHase)
7ONM	;	1.769	;	Carbonic anhydrase II mutant (N67G-E69R-I91C) dually binding an IrCp* complex to generate an artificial transfer hydrogenase (ATHase)
1ZSA	;	2.5	;	CARBONIC ANHYDRASE II MUTANT E117Q, APO FORM
1ZSC	;	1.8	;	CARBONIC ANHYDRASE II MUTANT E117Q, HOLO FORM
1ZSB	;	2.0	;	CARBONIC ANHYDRASE II MUTANT E117Q, TRANSITION STATE ANALOGUE ACETAZOLAMIDE
3M5S	;	1.4	;	Carbonic Anhydrase II mutant H64C in complex with carbonate
3M1Q	;	1.69	;	Carbonic Anhydrase II mutant W5C-H64C with opened disulfide bond
8SD1	;	1.298	;	Carbonic anhydrase II radiation damage RT 1-30
8SD9	;	1.904	;	Carbonic anhydrase II radiation damage RT 121-150
8SD6	;	1.397	;	Carbonic anhydrase II radiation damage RT 31-60
8SD7	;	1.704	;	Carbonic anhydrase II radiation damage RT 61-90
8SD8	;	1.789	;	Carbonic anhydrase II radiation damage RT 91-120
8SF1	;	1.7	;	Carbonic anhydrase II XFEL radiation damage RT
6XWZ	;	1.38	;	Carbonic Anhydrase II-mediated hydrolysis of selenolester
3M1K	;	1.35	;	Carbonic Anhydrase in complex with fragment
3NI5	;	2.1	;	Carbonic anhydrase inhibitor: C1 family
3F4X	;	1.9	;	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules make the difference
3B4F	;	1.89	;	Carbonic anhydrase inhibitors. Interaction of 2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide with twelve mammalian isoforms: kinetic and X-Ray crystallographic studies
3BL0	;	1.9	;	Carbonic anhydrase inhibitors. Interaction of 2-N,N-Dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with twelve mammalian isoforms: kinetic and X-Ray crystallographic studies
2Q1Q	;	1.9	;	Carbonic anhydrase inhibitors. Interaction of the antiepileptic drug sulthiame with twelve mammalian isoforms: kinetic and X-Ray crystallographic studies
3DD8	;	1.9	;	Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD-486019 with twelve mammalian isoforms: kinetic and X-Ray crystallographic studies
3BL1	;	2.1	;	Carbonic anhydrase inhibitors. Sulfonamide diuretics revisited old leads for new applications
2H15	;	1.9	;	Carbonic anhydrase inhibitors: Clashing with Ala65 as a means of designing isozyme-selective inhibitors that show low affinity for the ubiquitous isozyme II
3MNU	;	1.8	;	Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron containing aromatic sulfamide with mammalian isoforms I-XV
4Z0Q	;	1.45	;	Carbonic anhydrase inhibitors: Design and synthesis of new heteroaryl-N-carbonylbenzenesulfonamides targeting druggable human carbonic anhydrase isoforms (hCA VII, hCA IX, and hCA XIV)
4Z1E	;	2.01	;	Carbonic anhydrase inhibitors: Design and synthesis of new heteroaryl-N-carbonylbenzenesulfonamides targeting druggable human carbonic anhydrase isoforms (hCA VII, hCA IX, and hCA XIV)
4Z1J	;	1.27	;	Carbonic anhydrase inhibitors: Design and synthesis of new heteroaryl-N-carbonylbenzenesulfonamides targeting druggable human carbonic anhydrase isoforms (hCA VII, hCA IX, and hCA XIV)
4Z1K	;	1.35	;	Carbonic anhydrase inhibitors: Design and synthesis of new heteroaryl-N-carbonylbenzenesulfonamides targeting druggable human carbonic anhydrase isoforms (hCA VII, hCA IX, and hCA XIV)
4Z1N	;	1.47	;	Carbonic anhydrase inhibitors: Design and synthesis of new heteroaryl-N-carbonylbenzenesulfonamides targeting druggable human carbonic anhydrase isoforms (hCA VII, hCA IX, and hCA XIV)
2AW1	;	1.46	;	Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II ""selective"" inhibitor Celecoxib
8FR1	;	2.0	;	Carbonic Anhydrase IX in complex with the alkyl urea compound 3g
8OKE	;	1.05	;	Carbonic Anhydrase IX like mutant in Complex with Steriod_Sulphamoyl inhibitor AKI_1
8OKJ	;	1.4	;	Carbonic Anhydrase IX like mutant in Complex with Steriod_Sulphamoyl inhibitor AKI_12
8OKO	;	1.25	;	Carbonic Anhydrase IX like mutant in Complex with Steriod_Sulphamoyl inhibitor AKI_2
8OKP	;	1.25	;	Carbonic Anhydrase IX like mutant in Complex with Steriod_Sulphamoyl inhibitor AKI_33
8OLF	;	1.45	;	Carbonic Anhydrase IX like mutant in Complex with Steriod_Sulphamoyl inhibitor BS1982
8OLA	;	1.4	;	Carbonic Anhydrase IX like mutant in Complex with Steriod_Sulphamoyl inhibitor VK4
8OKT	;	1.5	;	Carbonic Anhydrase IX like mutant in Complex with Steriod_Sulphamoyl inhibitor VK42
7K6X	;	1.76	;	Carbonic Anhydrase IX mimic complexed with 4-(2-(3-(3,5-dimethylphenyl)ureido)ethylsulfonamido)benzenesulfonamide
7K6Z	;	1.657	;	Carbonic Anhydrase IX mimic complexed with 4-(2-(3-(4-fluorophenyl)ureido)ethylsulfonamido)benzenesulfonamide
7K6U	;	1.605	;	Carbonic Anhydrase IX mimic complexed with 4-(2-(3-(4-methylphenyl)ureido)ethylsulfonamido)benzenesulfonamide
7K6T	;	1.759	;	Carbonic Anhydrase IX mimic complexed with 4-(2-(3-phenylureido)ethylsulfonamido)benzenesulfonamide
6OUM	;	1.559	;	Carbonic Anhydrase IX mimic complexed with benzene sulfonamide MB10-580B
6OUD	;	1.256	;	Carbonic Anhydrase IX mimic complexed with benzene sulfonamide MB11-694B
6OUF	;	1.358	;	Carbonic Anhydrase IX mimic complexed with benzene sulfonamide MB11-707A
6OUI	;	1.528	;	Carbonic Anhydrase IX mimic complexed with benzene sulfonamide MB11-710A
7JOC	;	1.385	;	Carbonic Anhydrase IX Mimic Complexed with N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)adamantanecarboxamide
7JO1	;	1.499	;	Carbonic Anhydrase IX Mimic Complexed with N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)butyramide
7JOB	;	1.381	;	Carbonic Anhydrase IX Mimic Complexed with N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)cyclohexanecarboxamide
7JO2	;	1.307	;	Carbonic Anhydrase IX Mimic Complexed with N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)isobutyramide
7JO3	;	1.454	;	Carbonic Anhydrase IX Mimic Complexed with N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)pivalamide
7JO0	;	1.607	;	Carbonic Anhydrase IX Mimic Complexed with N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)propionamide
6OTM	;	1.307	;	Carbonic Anhydrase IX mimic complexed with ureic benzene sulfonamide MB10-586B
6OTI	;	2.0	;	Carbonic Anhydrase IX mimic complexed with ureic benzene sulfonamide MB9-561B
6OTK	;	1.123	;	Carbonic Anhydrase IX mimic complexed with ureido benzene sulfonamide MB10-596B
4BCW	;	1.5	;	Carbonic anhydrase IX mimic in complex with (E)-2-(5-bromo-2- hydroxyphenyl)ethenesulfonic acid
7SUY	;	1.405	;	Carbonic Anhydrase IX-mimic Complexed with 2-((3-Aminopropyl)(phenethyl)amino)-N-(4-fluorobenzyl)-N-(4-sulfamoylphenethyl)acetamide
7SV8	;	1.388	;	Carbonic Anhydrase IX-mimic Complexed with 3-((2-((Furan-2-ylmethyl)(4-sulfamoylphenethyl)amino)-2-oxoethyl)(phenethyl)amino)propanoic acid
7SV1	;	1.559	;	Carbonic Anhydrase IX-mimic Complexed with 3-((2-((Naphthalen-2-ylmethyl)(4-sulfamoylphenethyl)amino)-2-oxoethyl)(phenethyl)amino)propanoic acid
5SZ5	;	1.274	;	Carbonic anhydrase IX-mimic in complex with 4-(2-methylphenyl)-benzenesulfonamide
5SZ6	;	1.15	;	Carbonic anhydrase IX-mimic in complex with 4-(3-formylphenyl)-benzenesulfonamide
5SZ7	;	1.776	;	Carbonic anhydrase IX-mimic in complex with 4-(3-quinolinyl)-benzenesulfonamide
5SZ4	;	1.6	;	Carbonic anhydrase IX-mimic in complex with 4-(phenyl)-benzenesulfonamide
5WLR	;	1.49	;	Carbonic Anhydrase IX-mimic in complex with aryloxy-2-hydroxypropylammine sulfonamide
5WLT	;	1.57	;	Carbonic Anhydrase IX-mimic in complex with aryloxy-2-hydroxypropylammine sulfonamide
5WLU	;	1.39	;	Carbonic Anhydrase IX-mimic in complex with aryloxy-2-hydroxypropylammine sulfonamide
7RRF	;	1.45	;	Carbonic Anhydrase IX-mimic in complex with Beta-Galactose_2C
6B5A	;	1.622	;	Carbonic anhydrase IX-mimic in complex with nitrogenous base-bearing benezenesulfonamide
6CJV	;	1.547	;	Carbonic anhydrase IX-mimic in complex with sucralose
8FR2	;	1.307	;	Carbonic Anhydrase IX-mimic in complex with the alkyl urea compound 3h
8FR4	;	1.123	;	Carbonic Anhydrase IX-mimic in complex with the alkyl urea compound 3j
6UZU	;	1.5	;	Carbonic Anhydrase IX-mimic In Complex WITH U-CH3
5JN3	;	1.6	;	Carbonic Anhydrase IX-mimic IN Complex WITH U-F
5JMZ	;	1.9	;	Carbonic Anhydrase IX-mimic IN Complex WITH U-NO2
7SUW	;	1.456	;	Carbonic Anhydrase IX-mimic with 2-((3-Aminopropyl)(phenethyl)amino)-N-(furan-2-ylmethyl)-N-(4-sulfamoylphenethyl)acetamide
7P1A	;	1.58	;	Carbonic Anhydrase VII Sultam Based Inhibitors
6XVH	;	1.8	;	carbonic anhydrase with bound arylsulfonamide- boronic acid
3M1W	;	1.38	;	Carbonic Anhyrdase II mutant W5CH64C with closed disulfide bond in complex with sulfate
4DWU	;	1.44	;	Carbonmonoxy dehaloperoxidase-hemoglobin A structure at 1.44 Angstrom resolution
4DWT	;	2.05	;	Carbonmonoxy dehaloperoxidase-hemoglobin A structure at 2.05 Angstrom resolution
1SPG	;	1.95	;	CARBONMONOXY HEMOGLOBIN FROM THE TELEOST FISH LEIOSTOMUS XANTHURUS
6XD9	;	2.1	;	Carbonmonoxy hemoglobin in complex with the antisickling agent 2-hydroxy-6-((6-(hydroxymethyl)pyridin-2-yl)methoxy)benzaldehyde (VZHE039)
6BNR	;	1.95	;	Carbonmonoxy hemoglobin in complex with the antisickling agent 5-methoxy-2-(pyridin-2-ylmethoxy)benzaldehyde (INN310)
6XE7	;	2.0	;	Carbonmonoxy hemoglobin in complex with the antisickling agent methyl 2-((2-formyl-3-hydroxyphenoxy)methyl)nicotinate
6XDT	;	1.9	;	Carbonmonoxy hemoglobin in complex with the antisickling agent methyl 5-((2-formyl-4-methoxyphenoxy)methyl)picolinate
6KAU	;	1.6	;	Carbonmonoxy human hemoglobin A in the R2 quaternary structure at 140 K: Dark
6KAV	;	1.7	;	Carbonmonoxy human hemoglobin A in the R2 quaternary structure at 140 K: Light
6L5Y	;	1.65	;	Carbonmonoxy human hemoglobin A in the R2 quaternary structure at 140 K: Light (2 min)
6KAS	;	1.65	;	Carbonmonoxy human hemoglobin A in the R2 quaternary structure at 95 K: Dark
6KAT	;	1.7	;	Carbonmonoxy human hemoglobin A in the R2 quaternary structure at 95 K: Light
6L5X	;	1.65	;	Carbonmonoxy human hemoglobin A in the R2 quaternary structure at 95 K: Light (2 min)
6KAQ	;	1.5	;	Carbonmonoxy human hemoglobin C in the R quaternary structure at 140 K: Dark
6KAR	;	1.6	;	Carbonmonoxy human hemoglobin C in the R quaternary structure at 140 K: Light
6L5W	;	1.5	;	Carbonmonoxy human hemoglobin C in the R quaternary structure at 140 K: Light (2 min)
6KAO	;	1.4	;	Carbonmonoxy human hemoglobin C in the R quaternary structure at 95 K: Dark
6KAP	;	1.45	;	Carbonmonoxy human hemoglobin C in the R quaternary structure at 95 K: Light
6L5V	;	1.45	;	Carbonmonoxy human hemoglobin C in the R quaternary structure at 95 K: Light (2 min)
1G08	;	1.9	;	CARBONMONOXY LIGANDED BOVINE HEMOGLOBIN PH 5.0
1G09	;	2.04	;	CARBONMONOXY LIGANDED BOVINE HEMOGLOBIN PH 7.2
1G0A	;	2.04	;	CARBONMONOXY LIGANDED BOVINE HEMOGLOBIN PH 8.5
1G0B	;	1.9	;	CARBONMONOXY LIGANDED EQUINE HEMOGLOBIN PH 8.5
1AJG	;	1.69	;	CARBONMONOXY MYOGLOBIN AT 40 K
3GLN	;	2.26	;	Carbonmonoxy Ngb under Xenon pressure
3E55	;	1.21	;	Carbonmonoxy Sperm Whale Myoglobin at 100 K: Laser off
3EDA	;	1.21	;	Carbonmonoxy Sperm Whale Myoglobin at 100 K: Laser on [150 min]
3ECX	;	1.21	;	Carbonmonoxy Sperm Whale Myoglobin at 100 K: Laser on [30 min]
2ZSN	;	1.21	;	Carbonmonoxy Sperm Whale Myoglobin at 100 K: Laser on [300 min]
2ZSO	;	1.21	;	Carbonmonoxy Sperm Whale Myoglobin at 100 K: Laser on [450 min]
2ZSZ	;	1.21	;	Carbonmonoxy Sperm Whale Myoglobin at 100 K: Laser on [600 min]
2ZT0	;	1.21	;	Carbonmonoxy Sperm Whale Myoglobin at 100 K: Laser on [750 min]
2ZT1	;	1.21	;	Carbonmonoxy Sperm Whale Myoglobin at 100 K: Laser on [810 min]
3E5I	;	1.22	;	Carbonmonoxy Sperm Whale Myoglobin at 120 K: Laser off
3EDB	;	1.21	;	Carbonmonoxy Sperm Whale Myoglobin at 120 K: Laser on [150 min]
3ECZ	;	1.21	;	Carbonmonoxy Sperm Whale Myoglobin at 120 K: Laser on [30 min]
2ZSP	;	1.21	;	Carbonmonoxy Sperm Whale Myoglobin at 120 K: Laser on [300 min]
2ZSR	;	1.21	;	Carbonmonoxy Sperm Whale Myoglobin at 120 K: Laser on [450 min]
2ZT2	;	1.21	;	Carbonmonoxy Sperm Whale Myoglobin at 120 K: Laser on [600 min]
2ZT3	;	1.21	;	Carbonmonoxy Sperm Whale Myoglobin at 120 K: Laser on [750 min]
2ZT4	;	1.21	;	Carbonmonoxy Sperm Whale Myoglobin at 120 K: Laser on [810 min]
3E5O	;	1.21	;	Carbonmonoxy Sperm Whale Myoglobin at 140 K: Laser off
2ZSQ	;	1.21	;	Carbonmonoxy Sperm Whale Myoglobin at 140 K: Laser on [150 min]
3ED9	;	1.21	;	Carbonmonoxy Sperm Whale Myoglobin at 140 K: Laser on [30 min]
2ZSS	;	1.21	;	Carbonmonoxy Sperm Whale Myoglobin at 140 K: Laser on [300 min]
2ZST	;	1.21	;	Carbonmonoxy Sperm Whale Myoglobin at 140 K: Laser on [450 min]
2ZSX	;	1.21	;	Carbonmonoxy Sperm Whale Myoglobin at 140 K: Laser on [600 min]
2ZSY	;	1.21	;	Carbonmonoxy Sperm Whale Myoglobin at 140 K: Laser on [750 min]
3E4N	;	1.21	;	Carbonmonoxy Sperm Whale Myoglobin at 40 K: Laser off
3ECL	;	1.21	;	Carbonmonoxy Sperm Whale Myoglobin at 40 K: Laser on
4MQC	;	2.2	;	Carbonmonoxy Structure of Hemoglobin Evans alphaV62Mbetawt
4F6F	;	1.56	;	Carbonmonoxy structure of His100Phe Cerebratulus lacteus mini-hemoglobin
4F6J	;	1.45	;	Carbonmonoxy structure of His100Trp Cerebratulus lacteus mini-hemoglobin
4MQK	;	2.242	;	Carbonmonoxy Structure of the Human Fetal Hemoglobin Mutant HbF Toms River alphawtgammaV67M
4F69	;	1.6	;	Carbonmonoxy structure of Tyr11Phe/Gln44Leu/Thr48Val/Ala55Trp Cerebratulus lacteus mini-hemoglobin
1OUU	;	2.5	;	CARBONMONOXY TROUT HEMOGLOBIN I
1DO4	;	1.7	;	CARBONMONOXY-MYOGLOBIN (MUTANT L29W) AFTER PHOTOLYSIS AT T<180K
1DO3	;	1.55	;	CARBONMONOXY-MYOGLOBIN (MUTANT L29W) AFTER PHOTOLYSIS AT T>180K
1DO7	;	1.85	;	CARBONMONOXY-MYOGLOBIN (MUTANT L29W) REBINDING STRUCTURE AFTER PHOTOLYSIS AT T< 180K
1DO1	;	1.5	;	CARBONMONOXY-MYOGLOBIN MUTANT L29W AT 105K
1A6G	;	1.15	;	CARBONMONOXY-MYOGLOBIN, ATOMIC RESOLUTION
1CYD	;	1.8	;	CARBONYL REDUCTASE COMPLEXED WITH NADPH AND 2-PROPANOL
1SNY	;	1.75	;	Carbonyl reductase Sniffer of D. melanogaster
7EMG	;	2.449	;	Carbonyl Reductase Variant 4 (R123C/L209P/F183Y/V61K) from Serratia marcescens complexed with NADP+
4NSH	;	2.1	;	Carboplatin binding to HEWL in 0.2M NH4SO4, 0.1M NaAc in 25% PEG 4000 at pH 4.6
4NSI	;	2.3	;	Carboplatin binding to HEWL in 20% propanol, 20% PEG 4000 at pH5.6
4NSJ	;	1.7	;	Carboplatin binding to HEWL in 2M NH4formate, 0.1M HEPES at pH 7.5
4YEM	;	1.47	;	Carboplatin binding to HEWL in NaBr crystallisation conditions studied at an X-ray wavelength of 0.9163A - new refinement
4NSG	;	2.0	;	Carboplatin binding to HEWL in NaBr crystallisation conditions studied at an X-ray wavelength of 1.5418A
4OWA	;	1.796	;	Carboplatin binding to HEWL under sodium iodide crystallisation conditions
6YZQ	;	1.04	;	Carborane closo-butyl-sulfonamide in complex with CA II
6YZW	;	1.03	;	Carborane closo-hexyl-sulfonamide in complex with CA II
6YZO	;	1.5	;	Carborane closo-hexyl-sulfonamide in complex with CA IX mimic
6YZS	;	1.05	;	Carborane closo-pentyl-sulfonamide in complex with CA II
6YZK	;	0.99	;	Carborane closo-pentyl-sulfonamide in complex with CA IX mimic
6T7U	;	1.2	;	Carborane inhibitor of Carbonic Anhydrase IX
6YZR	;	1.2	;	Carborane nido-butyl-sulfonamide in complex with CA II
6YZX	;	1.1	;	Carborane nido-hexyl-sulfonamide in complex with CA II
6YZP	;	1.35	;	Carborane nido-hexyl-sulfonamide in complex with CA IX mimic
6YZU	;	1.0	;	Carborane nido-pentyl-sulfonamide in complex with CA II
6YZM	;	1.5	;	Carborane nido-pentyl-sulfonamide in complex with CA IX mimic
8UM2	;		;	Carboxy terminus of Oleate Hydratase in phosphate buffer
1UPB	;	2.35	;	Carboxyethylarginine synthase from Streptomyces clavuligerus
1UPC	;	2.45	;	Carboxyethylarginine synthase from Streptomyces clavuligerus
1UPA	;	2.35	;	Carboxyethylarginine synthase from Streptomyces clavuligerus (SeMet structure)
2IHV	;	2.3	;	Carboxyethylarginine synthase from Streptomyces clavuligerus: 5-guanidinovaleric acid complex
2IHU	;	2.05	;	Carboxyethylarginine synthase from Streptomyces clavuligerus: putative reaction intermediate complex
2IHT	;	2.0	;	Carboxyethylarginine synthase from Streptomyces clavuligerus: SeMet structure
7YII	;	1.78	;	Carboxylesterase - RoCE
2O7V	;	2.3	;	Carboxylesterase AeCXE1 from Actinidia eriantha covalently inhibited by paraoxon
1AUO	;	1.8	;	CARBOXYLESTERASE FROM PSEUDOMONAS FLUORESCENS
1IRB	;	1.9	;	CARBOXYLIC ESTER HYDROLASE
1FDK	;	1.91	;	CARBOXYLIC ESTER HYDROLASE (PLA2-MJ33 INHIBITOR COMPLEX)
1L8S	;	1.55	;	CARBOXYLIC ESTER HYDROLASE COMPLEX (DIMERIC PLA2 + LPC-ether + ACETATE + PHOSPHATE IONS)
1FXF	;	1.85	;	CARBOXYLIC ESTER HYDROLASE COMPLEX (DIMERIC PLA2 + MJ33 INHIBITOR + PHOSPHATE IONS)
1FX9	;	2.0	;	CARBOXYLIC ESTER HYDROLASE COMPLEX (DIMERIC PLA2 + MJ33 INHIBITOR + SULPHATE IONS)
1MKV	;	1.89	;	CARBOXYLIC ESTER HYDROLASE COMPLEX (PLA2 + TRANSITION STATE ANALOG COMPLEX)
1UNE	;	1.5	;	CARBOXYLIC ESTER HYDROLASE, 1.5 ANGSTROM ORTHORHOMBIC FORM OF THE BOVINE RECOMBINANT PLA2
1MKT	;	1.72	;	CARBOXYLIC ESTER HYDROLASE, 1.72 ANGSTROM TRIGONAL FORM OF THE BOVINE RECOMBINANT PLA2 ENZYME
1LE7	;	2.09	;	CARBOXYLIC ESTER HYDROLASE, C 2 2 21 space group
1MKU	;	1.8	;	CARBOXYLIC ESTER HYDROLASE, ORTHORHOMBIC FORM OF THE TRIPLE MUTANT
1LE6	;	1.97	;	CARBOXYLIC ESTER HYDROLASE, P 1 21 1 SPACE GROUP
1KVY	;	1.9	;	CARBOXYLIC ESTER HYDROLASE, SINGLE MUTANT D49E COORDINATED TO CALCIUM
2ZP5	;	1.9	;	Carboxylic ester hydrolase, single mutant d49k of bovine pancreatic pla2 enzyme
2ZP3	;	1.9	;	Carboxylic ester hydrolase, single mutant d49n of bovine pancreatic pla2 enzyme
1KVX	;	1.9	;	CARBOXYLIC ESTER HYDROLASE, SINGLE MUTANT D99A OF BOVINE PANCREATIC PLA2, 1.9 A ORTHORHOMBIC FORM
2ZP4	;	1.9	;	Carboxylic ester hydrolase, single mutant h48n of bovine pancreatic pla2 enzyme
1KVW	;	1.95	;	CARBOXYLIC ESTER HYDROLASE, SINGLE MUTANT H48Q OF BOVINE PANCREATIC PLA2 ENZYME
1MKS	;	1.9	;	CARBOXYLIC ESTER HYDROLASE, TRIGONAL FORM OF THE TRIPLE MUTANT
5FIF	;	2.494	;	Carboxyltransferase domain of a single-chain bacterial carboxylase
4L6W	;	1.95	;	Carboxyltransferase subunit (AccD6) of Mycobacterium tuberculosis acetyl-CoA carboxylase
2A7K	;	2.24	;	carboxymethylproline synthase (CarB) from pectobacterium carotovora, apo enzyme
2A81	;	3.15	;	carboxymethylproline synthase (CarB) from pectobacterium carotovora, complexed with acetyl CoA and bicine
8BKN	;	1.29	;	Carboxymyoglobin dark state for comparison with 5 mJ/cm2 time series
8BKH	;	1.35	;	Carboxymyoglobin dark state for comparison with power titration and 23 / 101 mJ/cm2 time series
1F57	;	1.75	;	CARBOXYPEPTIDASE A COMPLEX WITH D-CYSTEINE AT 1.75 A
1BAV	;	1.6	;	CARBOXYPEPTIDASE A COMPLEXED WITH 2-BENZYL-3-IODO-PROPANOIC ACID (BIP)
3I1U	;	1.391	;	Carboxypeptidase A Inhibited by a Thiirane Mechanism-Based inactivator
3HLP	;	1.6	;	Carboxypeptidase A liganded to an organic small-molecule: conformational changes
3HUV	;	1.9	;	Carboxypeptidase A liganded to an organic small-molecule: conformational changes
3KGQ	;	1.7	;	Carboxypeptidase A liganded to an organic small-molecule: conformational changes
1ARL	;	1.88	;	CARBOXYPEPTIDASE A WITH ZN REMOVED
1ARM	;	1.76	;	CARBOXYPEPTIDASE A WITH ZN REPLACED BY HG
3WC6	;	1.65	;	Carboxypeptidase B in complex with 2nd zinc
3WAB	;	2.154	;	Carboxypeptidase B in complex with DD2
5ZEQ	;	1.9	;	Carboxypeptidase B in complex with DD28
3WC5	;	1.7	;	Carboxypeptidase B in complex with DD9
3WC7	;	1.9	;	Carboxypeptidase B in complex with EF6265
5JC6	;	1.4	;	Carboxypeptidase B with 2-nd zinc and acetate ion
4Z65	;	1.25	;	Carboxypeptidase B with Sulphamoil Arginine
5J1Q	;	1.74	;	Carboxypeptidase B with Sulphamoil Phenylalanine
1CG2	;	2.5	;	CARBOXYPEPTIDASE G2
6XJ5	;	3.11	;	Carboxypeptidase G2 modified with a versatile bioconjugate for metalloprotein design
1OBR	;	2.3	;	CARBOXYPEPTIDASE T
3QNV	;	1.69	;	Carboxypeptidase T
6F79	;	1.9	;	Carboxypeptidase T mutant L211Q with Sulphamoil Arginine
3V38	;	1.5	;	Carboxypeptidase T mutant L254N
6Z28	;	2.3	;	Carboxypeptidase T mutant L254N with N-sulfamoyl-L-glutamic acid
6F6Q	;	1.79	;	Carboxypeptidase T mutant L254N with Sulphamoil Arginine
6F75	;	1.89	;	Carboxypeptidase T mutant L254N with Sulphamoil Leucine
7Q87	;	1.73	;	Carboxypeptidase T with (S)-3-phenyllactic acid
4F8Z	;	1.38	;	Carboxypeptidase T with Boc-Leu
3V7Z	;	1.61	;	Carboxypeptidase T with GEMSA
4DUK	;	1.57	;	Carboxypeptidase T with L-BENZYLSUCCINIC ACID
6SN6	;	1.93	;	CARBOXYPEPTIDASE T WITH N-SULFAMOYL-L-GLUTAMIC ACID
6GO2	;	1.9	;	Carboxypeptidase T with N-sulfamoyl-L-Leucine
6T9Y	;	1.92	;	CARBOXYPEPTIDASE T WITH N-SULFAMOYL-L-LYSIN
4DJL	;	1.55	;	Carboxypeptidase T with N-sulfamoyl-L-phenylalanine
6TNK	;	1.9	;	CARBOXYPEPTIDASE T WITH N-SULFAMOYL-L-VALINE
4GM5	;	1.39	;	Carboxypeptidase T with Sulphamoil Arginine
2EWH	;	1.4	;	Carboxysome protein CsoS1A from Halothiobacillus neapolitanus
2A1B	;	2.9	;	Carboxysome shell protein ccmK2
2A10	;	1.803	;	carboxysome shell protein ccmK4
2A18	;	2.28	;	carboxysome shell protein ccmK4, crystal form 2
5LSR	;	1.65	;	Carboxysome shell protein CcmP from Synechococcus elongatus PCC 7942
5LT5	;	1.45	;	Carboxysome shell protein CcmP from Synechococcus elongatus PCC 7942
3CIM	;	1.3	;	Carboxysome shell protein, CcmK2 C-terminal deletion mutant
3DNC	;	2.05	;	Carboxysome shell protein, CcmK2 C-terminal deletion mutant, with a closer spacing between hexamers
2RCF	;	2.15	;	Carboxysome Shell protein, OrfA from H. Neapolitanus
3BN4	;	2.0	;	Carboxysome Subunit, CcmK1
3DN9	;	2.28	;	Carboxysome Subunit, CcmK1 C-terminal deletion mutant
2QW7	;	2.4	;	Carboxysome Subunit, CcmL
2YGS	;	1.6	;	CARD DOMAIN FROM APAF-1
7JH7	;	3.8	;	cardiac actomyosin complex
8G9R	;	3.28	;	Cardiac amyloid fibrils extracted from a wild-type ATTR amyloidosis patient
8GBR	;	3.4	;	Cardiac amyloid fibrils extracted from a wild-type ATTR amyloidosis patient
7TIJ	;	8.0	;	Cardiac F-actin decorated with regulatory M-domain of cardiac myosin binding protein C
4DB1	;	2.6	;	Cardiac human myosin S1dC, beta isoform complexed with Mn-AMPPNP
5N6A	;	3.1	;	Cardiac muscle myosin motor domain in the pre-powerstroke state
5N69	;	2.45	;	Cardiac muscle myosin S1 fragment in the pre-powerstroke state co-crystallized with the activator Omecamtiv Mecarbil
6UZ3	;	3.5	;	Cardiac sodium channel
7XSU	;	3.4	;	Cardiac sodium channel in complex with LqhIII
6UZ0	;	3.24	;	Cardiac sodium channel with flecainide
7K18	;	3.3	;	Cardiac Sodium channel with toxin bound
6CXI	;	11.0	;	Cardiac thin filament decorated with C0C1 fragment of cardiac myosin binding protein C mode 1
6CXJ	;	11.0	;	Cardiac thin filament decorated with C0C1 fragment of cardiac myosin binding protein C mode 2
7TJ7	;	8.0	;	Cardiac thin filament decorated with C1 Ig-domain and regulatory M-domain of cardiac myosin binding protein C (cMyBP-C)
7TIT	;	8.0	;	Cardiac thin filament decorated with regulatory M-domain of cardiac myosin binding protein C
1CRE	;		;	CARDIOTOXIN II FROM TAIWAN COBRA VENOM, NAJA NAJA ATRA: STRUCTURE IN SOLUTION AND COMPARISION AMONG HOMOLOGOUS CARDIOTOXINS
1CRF	;		;	CARDIOTOXIN II FROM TAIWAN COBRA VENOM, NAJA NAJA ATRA: STRUCTURE IN SOLUTION AND COMPARISION AMONG HOMOLOGOUS CARDIOTOXINS
2CRS	;		;	CARDIOTOXIN III FROM TAIWAN COBRA (NAJA NAJA ATRA) DETERMINATION OF STRUCTURE IN SOLUTION AND COMPARISON WITH SHORT NEUROTOXINS
2CRT	;		;	CARDIOTOXIN III FROM TAIWAN COBRA (NAJA NAJA ATRA) DETERMINATION OF STRUCTURE IN SOLUTION AND COMPARISON WITH SHORT NEUROTOXINS
1CDT	;	2.5	;	CARDIOTOXIN V4/II FROM NAJA MOSSAMBICA MOSSAMBICA: THE REFINED CRYSTAL STRUCTURE
4TLW	;	2.55	;	CARDS TOXIN, FULL-LENGTH
4TLV	;	1.9	;	CARDS TOXIN, NICKED
1YAL	;	1.7	;	CARICA PAPAYA CHYMOPAPAIN AT 1.7 ANGSTROMS RESOLUTION
8CK1	;	3.9	;	Carin 1 bacteriophage tail, connector and tail fibers assembly
8CJZ	;	3.5	;	Carin1 bacteriophage mature capsid
8CK0	;	3.8	;	Carin1 bacteriophage portal assembly
5XD6	;	1.898	;	CARK1 phosphorylates ABA receptors
7FAJ	;	2.24507	;	CARM1 bound with compound 43
7FAI	;	2.09749	;	CARM1 bound with compound 9
7PPY	;	2.42	;	CARM1 in complex with EML709
7PV6	;	2.4	;	CARM1 in complex with EML734
7PPQ	;	2.1	;	CARM1 in complex with EML736
7PU8	;	2.19	;	CARM1 in complex with EML980
7PUC	;	2.19	;	CARM1 in complex with EML981
7PUQ	;	2.09	;	CARM1 in complex with EML982
4WXH	;	1.9	;	Carminomycin-4-O-methyltransferase (DnrK) variant (298Ser insert) in complex with S-adenosyl-L-homocysteine (SAH) and aclacinomycin T
1NDF	;	1.9	;	Carnitine Acetyltransferase in Complex with Carnitine
1NDI	;	2.3	;	Carnitine Acetyltransferase in complex with CoA
7VUD	;	2.8	;	Carotenoid Cleavage Dioxygenase 1 from Osmanthus fragrans
6FM2	;	2.8	;	CARP domain of mouse cyclase-associated protein 1 (CAP1) bound to ADP-actin
4RUQ	;	1.35	;	Carp Fishelectin, apo form
4RUS	;	1.7	;	Carp Fishelectin, holo form
7LIX	;	2.8	;	CaRSP1 and scaffolded phycoerythrin beta subunits from the phycobilisome of Porphyridium purpureum
7LIY	;	2.8	;	CaRSP2 and scaffolded phycoerythrin beta subunits from the phycobilisome of Porphyridium purpureum
6AY7	;	1.77	;	Cartilage homing cysteine-dense-peptides
6AY8	;	1.78	;	Cartilage homing cysteine-dense-peptides
8IEW	;	3.1	;	Cas005-crRNA-DNA complex
5VVK	;	2.9	;	Cas1-Cas2 bound to full-site mimic
5VVL	;	3.31	;	Cas1-Cas2 bound to full-site mimic with Ni
5VVJ	;	3.89	;	Cas1-Cas2 bound to half-site intermediate
6QXF	;	3.6	;	Cas1-Cas2-Csn2-DNA complex from the Type II-A CRISPR-Cas system
6QXT	;	8.9	;	Cas1-Cas2-Csn2-DNA dimer complex from the Type II-A CRISPR-Cas system
5WFE	;	3.64	;	Cas1-Cas2-IHF-DNA holo-complex
8FLJ	;	3.48	;	Cas1-Cas2/3 integrase and IHF bound to CRISPR leader, repeat and foreign DNA
8D4A	;	2.74	;	Cas12a2 quaternary complex
8BD5	;	3.3	;	Cas12k-sgRNA-dsDNA-S15-TniQ-TnsC transposon recruitment complex
8BD6	;	4.1	;	Cas12k-sgRNA-dsDNA-TnsC non-productive complex.
5B7I	;	2.6	;	Cas3-AcrF3 complex
4C97	;	1.7	;	Cas6 (TTHA0078) H37A mutant
4C8Z	;	2.503	;	Cas6 (TTHA0078) product complex
4C8Y	;	1.8	;	Cas6 (TTHA0078) substrate mimic complex
4C9D	;	3.0	;	Cas6 (TTHB231) product complex
7KFU	;	3.9	;	Cas6-RT-Cas1--Cas2 complex
8EEX	;	2.95	;	Cas7-11 in complex with Csx29
8EEY	;	2.53	;	Cas7-11 in complex with DR-mismatched target RNA, Csx29 and Csx30
7S4V	;	3.28	;	Cas9 bound to 12-14MM DNA, 60 min time-point, kinked conformation
7S4X	;	2.76	;	Cas9:gRNA in complex with 18-20MM DNA, 1 minute time-point, kinked active conformation
7S37	;	3.2	;	Cas9:sgRNA (S. pyogenes) in the open-protein conformation
7S38	;	3.3	;	Cas9:sgRNA:DNA (S. pyogenes) forming a 3-base-pair R-loop
7S36	;	3.2	;	Cas9:sgRNA:DNA (S. pyogenes) with 0 RNA:DNA base pairs, closed-protein/bent-DNA conformation
7S3H	;	2.5	;	Cas9:sgRNA:DNA (S. pyogenes) with 0 RNA:DNA base pairs, open-protein/linear-DNA conformation
7TR6	;	3.4	;	Cascade complex from type I-A CRISPR-Cas system
7TR8	;	3.6	;	Cascade complex from type I-A CRISPR-Cas system
7TR9	;	3.9	;	Cascade complex from type I-A CRISPR-Cas system
7TRA	;	3.3	;	Cascade complex from type I-A CRISPR-Cas system
4GRB	;	2.15	;	Casein kinase 2 (CK2) bound to inhibitor
3U4U	;	2.2	;	Casein kinase 2 in complex with AZ-Inhibitor
1CKJ	;	2.46	;	CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
4GUB	;	2.2	;	Casein Kinase II bound to Inhibitor
6DKF	;	3.7	;	Caseinolytic protease (ClpP) from Staphylococcus aureus mutant - V7A
3NFR	;	1.57	;	Casimiroin analog inhibitor of quinone reductase 2
3C0G	;	2.19	;	CASK CaM-Kinase Domain- 3'-AMP complex, P1 form
3C0I	;	1.85	;	CASK CaM-Kinase Domain- 3'-AMP complex, P212121 form
3C0H	;	2.3	;	CASK CaM-Kinase Domain- AMPPNP complex, P1 form
3MFS	;	2.1	;	CASK-4M CaM Kinase Domain, AMPPNP
3MFU	;	2.3	;	CASK-4M CaM Kinase Domain, AMPPNP-Mn2+
3MFT	;	2.2	;	CASK-4M CaM Kinase Domain, Mn2+
3MFR	;	2.0	;	CASK-4M CaM Kinase Domain, native
5L1M	;	2.751	;	CASKIN2 SAM domain tandem
7LVM	;	1.47	;	CASP8 isoform B DED domain
7LVJ	;	1.5	;	CASP8 isoform G DED domain
3KJF	;	2.0	;	Caspase 3 Bound to a covalent inhibitor
5I9B	;	1.8	;	Caspase 3 V266A
5I9T	;	1.95	;	Caspase 3 V266C
5IAB	;	1.79	;	Caspase 3 V266D
5IAE	;	1.55	;	Caspase 3 V266F
5IBC	;	1.66	;	Caspase 3 V266I
5IBR	;	1.74	;	Caspase 3 V266K
5IAJ	;	1.58	;	Caspase 3 V266L
5IBP	;	1.38	;	Caspase 3 V266M
5IAN	;	2.7	;	Caspase 3 V266N
5IAG	;	1.98	;	Caspase 3 V266Q
5IAK	;	1.82	;	Caspase 3 V266S
5IAR	;	1.76	;	Caspase 3 V266W
5IAS	;	1.54	;	Caspase 3 V266Y
3KJN	;	1.8	;	Caspase 8 bound to a covalent inhibitor
3KJQ	;	1.8	;	Caspase 8 with covalent inhibitor
6KN0	;	2.793	;	caspase-1 P20/P10 C285A in complex with human GSDMD-C domain
6KMV	;	3.35	;	caspase-11 C254A P22/P10 in complex with mouse GSDMD-C domain
3R7B	;	1.8	;	Caspase-2 bound to one copy of Ac-DVAD-CHO
3R7N	;	2.33	;	Caspase-2 bound with two copies of Ac-DVAD-CHO
3R6L	;	1.9	;	Caspase-2 T380A bound with Ac-VDVAD-CHO
3GJQ	;	2.6	;	Caspase-3 Binds Diverse P4 Residues in Peptides
3GJR	;	2.2	;	Caspase-3 Binds Diverse P4 Residues in Peptides
3GJS	;	1.9	;	Caspase-3 Binds Diverse P4 Residues in Peptides
3GJT	;	2.2	;	Caspase-3 Binds Diverse P4 Residues in Peptides
4QTY	;	1.602	;	Caspase-3 E190A
3PD0	;	2.0	;	Caspase-3 E246A
3PCX	;	1.5	;	Caspase-3 E246A, K242A Double Mutant
4QU9	;	1.561	;	Caspase-3 F128A
4QUI	;	1.758	;	Caspase-3 F128AV266H
4QUL	;	1.898	;	Caspase-3 F55W
2XZD	;	2.1	;	Caspase-3 in Complex with an Inhibitory DARPin-3.4
2Y0B	;	2.1	;	Caspase-3 in Complex with an Inhibitory DARPin-3.4_S76R
2XZT	;	2.7	;	Caspase-3 in Complex with DARPin-3.4_I78S
6X8K	;	2.17	;	Caspase-3 in complex with elongated ketomethylene inhibitor
6X8I	;	1.5	;	Caspase-3 in complex with ketomethylene inhibitor reveals tetrahedral adduct
4QUB	;	1.689	;	Caspase-3 K137A
3PD1	;	1.62	;	Caspase-3 K242A
4QUG	;	1.917	;	Caspase-3 M61A
4QU8	;	1.715	;	Caspase-3 M61A V266H
6BG0	;	2.125	;	Caspase-3 Mutant - D9A,D28A,S150D
6BG1	;	1.88	;	Caspase-3 Mutant - D9A,D28A,S150E
6BGQ	;	1.97	;	Caspase-3 Mutant - S150D
6BGR	;	2.16	;	Caspase-3 Mutant - S150E
6BGS	;	1.6	;	Caspase-3 Mutant - S150Y
6BH9	;	1.94	;	Caspase-3 Mutant - T152A
6BHA	;	1.603	;	Caspase-3 Mutant - T152V
6BFJ	;	1.543	;	Caspase-3 Mutant - T245D,S249D
6BGK	;	1.87	;	Caspase-3 Mutant- D9A,D28A,T152D
6BFL	;	1.87	;	Caspase-3 Mutant- D9A,D28A,T245D
6BG4	;	1.87	;	Caspase-3 Mutant- T152D
6BFK	;	1.753	;	Caspase-3 Mutant- T245A
6BFO	;	1.54	;	Caspase-3 Mutant- T245D
4JJ8	;	2.937	;	Caspase-3 specific unnatural amino acid peptides
4JJE	;	1.481	;	Caspase-3 specific unnatural amino acid peptides
4JJ7	;	1.178	;	Caspase-3 specific unnatural amino acid-based peptides
4QUD	;	1.995	;	Caspase-3 T140F
4QUH	;	1.759	;	Caspase-3 T140G
4QUJ	;	1.498	;	Caspase-3 T140GV266H
4QU5	;	1.908	;	Caspase-3 T140V
1NMS	;	1.7	;	Caspase-3 tethered to irreversible inhibitor
4QTX	;	1.974	;	Caspase-3 Y195A
4QU0	;	1.954	;	Caspase-3 Y195AV266H
4QUA	;	1.892	;	Caspase-3 Y195F
4QUE	;	1.843	;	Caspase-3 Y195FV266H
2XYP	;	1.86	;	Caspase-3:CAS26049945
2XYG	;	1.54	;	Caspase-3:CAS329306
2XYH	;	1.89	;	Caspase-3:CAS60254719
6KMZ	;	3.61	;	caspase-4 P22/P10 C258A in complex with human GSDMD-C domain
8SPB	;	3.2	;	Caspase-4/Pro-IL-18 complex
3QNW	;	2.65	;	Caspase-6 in complex with Z-VAD-FMK inhibitor
8DJ3	;	3.2	;	Caspase-7 bound to novel allosteric inhibitor
8DGZ	;	2.8	;	Caspase-7 bound to substrate mimic and allosteric inhibitor
6CL2	;	2.35	;	Caspase-7 in complex with Ac-ATS009-KE
6CL1	;	2.651	;	Caspase-7 in complex with Ac-DW3-KE
4JB8	;	1.7	;	Caspase-7 in Complex with DARPin C7_16
4LSZ	;	2.26	;	Caspase-7 in Complex with DARPin D7.18
1SHJ	;	2.8	;	Caspase-7 in complex with DICA allosteric inhibitor
6X8L	;	2.45	;	Caspase-7 in complex with elongated ketomethylene inhibitor
1SHL	;	3.0	;	CASPASE-7 IN COMPLEX WITH FICA ALLOSTERIC INHIBITOR
6X8J	;	2.604	;	Caspase-7 in complex with ketomethylene inhibitor reveals tetrahedral adduct
5K20	;	2.2	;	Caspase-7 S239E Phosphomimetic
4ZVS	;	2.5	;	Caspase-7 Variant 1 (V1) with reprogrammed substrate specificity due to Y230A/W232M/S234N substitutions, bound to DEVD inhibitor.
4ZVT	;	2.85	;	Caspase-7 Variant 1 (V1) with reprogrammed substrate specificity due to Y230A/W232M/S234N substitutions, bound to VEID inhibitor.
4ZVP	;	2.5	;	Caspase-7 Variant 2 (V2) with reprogrammed substrate specificity due to Y230V/W232M/Q276C substitutions bound to DEVD inhibitor.
4ZVQ	;	2.5	;	Caspase-7 Variant 2 (V2) with reprogrammed substrate specificity due to Y230V/W232M/Q276C substitutions bound to VEID inhibitor.
4ZVR	;	2.3	;	Caspase-7 Variant 4 (V4) with reprogrammed substrate specificity due to Y230V/W232Y/S234V/Q276D substitutions bound to DEVD inhibitor.
4ZVO	;	2.85	;	Caspase-7 Variant 4 (V4) with reprogrammed substrate specificity due to Y230V/W232Y/S234V/Q276D substitutions bound to VEID inhibitor.
4ZVU	;	2.601	;	Caspase-7 wild-type bound to the caspase-6 cognate tetrapeptide inhibitor Ac-VEID-cho
6X8H	;	1.48	;	Caspase-8 in complex with AOMK inhibitor, Ac-DW3-KE, forms tetrahedral adduct
2Y1L	;	1.8	;	Caspase-8 in Complex with DARPin-8.4
4PRY	;	1.7	;	Caspase-8 specific unnatural amino acid peptides
4PRZ	;	2.123	;	Caspase-8 specific unnatural amino acid peptides
4PS0	;	1.63	;	Caspase-8 specific unnatural amino acid peptides
4PS1	;	1.731	;	Caspase-8 specific unnatural amino acid peptides
1F9E	;	2.9	;	CASPASE-8 SPECIFICITY PROBED AT SUBSITE S4: CRYSTAL STRUCTURE OF THE CASPASE-8-Z-DEVD-CHO
3RJM	;	2.55	;	CASPASE2 IN COMPLEX WITH CHDI LIGAND 33c
6WI4	;	1.57	;	Caspases from Scleractinian Coral
6OPM	;	3.1	;	Casposase bound to integration product
6NY3	;	3.7	;	CasX ternary complex with 30bp target DNA
6NY1	;	4.2	;	CasX-gRNA-DNA(30bp) State II
6NY2	;	3.2	;	CasX-gRNA-DNA(45bp) state I
8SZQ	;	2.711	;	Cat DHX9 bound to ADP
8SZS	;	2.38	;	Cat DHX9 bound to GDP
2MC9	;		;	Cat r 1
6AMM	;	2.8	;	CAT192 Fab Insertion Mutant H0/L1
6AO0	;	2.35	;	CAT192 Fab Insertion Mutant H2/L2
6ANP	;	2.45	;	CAT192 Fab Insertion Mutant H5/L0
6AMJ	;	2.49	;	CAT192 Fab Wild Type
1DXH	;	2.5	;	Catabolic ornithine carbamoyltransferase from Pseudomonas aeruginosa
7XJT	;	2.598	;	Catabolic ornithine carbamoyltransferases (OTCs) from Psychrobacter sp. PAMC 21119
6ZY1	;	1.99	;	Catabolic reductive dehalogenase NpRdhA, N-terminally tagged in complex with 3-bromo-4-hydroxybenzoic acid
6ZY0	;	2.13	;	Catabolic reductive dehalogenase NpRdhA, N-terminally tagged, K488Q variant
6ZXU	;	1.73	;	Catabolic reductive dehalogenase NpRdhA, N-terminally tagged.
6ZXX	;	1.99	;	Catabolic reductive dehalogenase NpRdhA, N-terminally tagged.
5ONC	;	2.19	;	Catabolism of the Cholesterol Side Chain in Mycobacterium tuberculosis is Controlled by a Redox-Sensitive Thiol Switch
1RUO	;	2.7	;	CATABOLITE GENE ACTIVATOR PROTEIN (CAP) MUTANT/DNA COMPLEX + ADENOSINE-3',5'-CYCLIC-MONOPHOSPHATE
1CGP	;	3.0	;	CATABOLITE GENE ACTIVATOR PROTEIN (CAP)/DNA COMPLEX + ADENOSINE-3',5'-CYCLIC-MONOPHOSPHATE
1J59	;	2.5	;	CATABOLITE GENE ACTIVATOR PROTEIN (CAP)/DNA COMPLEX + ADENOSINE-3',5'-CYCLIC-MONOPHOSPHATE
1RUN	;	2.7	;	CATABOLITE GENE ACTIVATOR PROTEIN (CAP)/DNA COMPLEX + ADENOSINE-3',5'-CYCLIC-MONOPHOSPHATE
2CGP	;	2.2	;	CATABOLITE GENE ACTIVATOR PROTEIN/DNA COMPLEX, ADENOSINE-3',5'-CYCLIC-MONOPHOSPHATE
6NT1	;	2.2	;	Catalase 3 from N.Crassa in ferrous state (2.89 MGy)
6NT0	;	2.2	;	Catalase 3 from N.Crassa in ferrous state, X-ray reduced (1.315 MGy)
4AJ9	;	1.85	;	Catalase 3 from Neurospora crassa
4BIM	;	2.95	;	CATALASE 3 FROM NEUROSPORA CRASSA IN TETRAGONAL FORM EXPOSES A MODIFIED TETRAMERIC ORGANIZATION
1A4E	;	2.4	;	CATALASE A FROM SACCHAROMYCES CEREVISIAE
2CAG	;	2.7	;	CATALASE COMPOUND II
1HBZ	;	1.5	;	Catalase from Micrococcus lysodeikticu
3J7B	;	3.2	;	Catalase solved at 3.2 Angstrom resolution by MicroED
6JNT	;	3.0	;	Catalase structure determined by eEFD (dataset 1)
6JNU	;	3.0	;	Catalase structure determined by eEFD (dataset 2)
5GKN	;	3.2	;	Catalase structure determined by electron crystallography of thin 3D crystals
5A0T	;	2.283	;	Catalysis and 5' end sensing by ribonuclease RNase J of the metallo- beta-lactamase family
5A0V	;	2.8	;	Catalysis and 5' end sensing by ribonuclease RNase J of the metallo- beta-lactamase family
1QH6	;	2.0	;	CATALYSIS AND SPECIFICITY IN ENZYMATIC GLYCOSIDE HYDROLASES: A 2,5B CONFORMATION FOR THE GLYCOSYL-ENZYME INTERMIDIATE REVEALED BY THE STRUCTURE OF THE BACILLUS AGARADHAERENS FAMILY 11 XYLANASE
1QH7	;	1.78	;	CATALYSIS AND SPECIFICITY IN ENZYMATIC GLYCOSIDE HYDROLASES: A 2,5B CONFORMATION FOR THE GLYCOSYL-ENZYME INTERMIDIATE REVEALED BY THE STRUCTURE OF THE BACILLUS AGARADHAERENS FAMILY 11 XYLANASE
2PGJ	;	1.71	;	Catalysis associated conformational changes revealed by human cd38 complexed with a non-hydrolyzable substrate analog
2PGL	;	1.76	;	Catalysis associated conformational changes revealed by human CD38 complexed with a non-hydrolyzable substrate analog
4TGL	;	2.6	;	CATALYSIS AT THE INTERFACE: THE ANATOMY OF A CONFORMATIONAL CHANGE IN A TRIGLYCERIDE LIPASE
1A3L	;	1.95	;	CATALYSIS OF A DISFAVORED REACTION: AN ANTIBODY EXO DIELS-ALDERASE-TSA-INHIBITOR COMPLEX AT 1.95 A RESOLUTION
4IVV	;	1.05	;	Catalytic amidase domain of the major autolysin LytA from Streptococcus pneumaniae
8B3A	;	3.8	;	catalytic amyloid fibril formed by Ac-LHLHLRL-amide
8T9F	;	2.6	;	Catalytic and non-catalytic mechanisms of histone H4 lysine 20 methyltransferase SUV420H1
8T9H	;	3.37	;	Catalytic and non-catalytic mechanisms of histone H4 lysine 20 methyltransferase SUV420H1
8THU	;	3.1	;	Catalytic and non-catalytic mechanisms of histone H4 lysine 20 methyltransferase SUV420H1
1LUV	;	1.85	;	CATALYTIC AND STRUCTURAL EFFECTS OF AMINO-ACID SUBSTITUTION AT HIS 30 IN HUMAN MANGANESE SUPEROXIDE DISMUTASE: INSERTION OF VAL CGAMMA INTO THE SUBSTRATE ACCESS CHANNEL
1LUW	;	2.3	;	CATALYTIC AND STRUCTURAL EFFECTS OF AMINO-ACID SUBSTITUTION AT HIS 30 IN HUMAN MANGANESE SUPEROXIDE DISMUTASE: INSERTION OF VAL CGAMMA INTO THE SUBSTRATE ACCESS CHANNEL
1N0N	;	1.82	;	Catalytic and Structural Effects of Amino-Acid Substitution at His30 in Human Manganese Superoxide Dismutase
2WZJ	;	2.786	;	Catalytic and UBA domain of kinase MARK2/(Par-1) K82R, T208E double mutant
2HAK	;	2.6	;	Catalytic and ubiqutin-associated domains of MARK1/PAR-1
1Y8G	;	2.501	;	Catalytic and ubiqutin-associated domains of MARK2/PAR-1: Inactive double mutant with selenomethionine
1ZMV	;	3.105	;	Catalytic and ubiqutin-associated domains of MARK2/PAR-1: K82R mutant
1ZMW	;	2.802	;	Catalytic and ubiqutin-associated domains of MARK2/PAR-1: T208A/S212A inactive double mutant
1ZMU	;	2.9	;	Catalytic and ubiqutin-associated domains of MARK2/PAR-1: Wild type
1UM6	;	1.8	;	catalytic antibody 21h3
1UM5	;	1.6	;	Catalytic Antibody 21H3 with alcohol substrate
1UM4	;	1.8	;	Catalytic Antibody 21H3 with hapten
1KEM	;	2.2	;	CATALYTIC ANTIBODY 28B4 FAB FRAGMENT
1KEL	;	1.9	;	CATALYTIC ANTIBODY 28B4 FAB FRAGMENT COMPLEXED WITH HAPTEN (1-[N-4'-NITROBENZYL-N-4'-CARBOXYBUTYLAMINO] METHYLPHOSPHONIC ACID)
1F3D	;	1.87	;	CATALYTIC ANTIBODY 4B2 IN COMPLEX WITH ITS AMIDINIUM HAPTEN.
25C8	;	2.0	;	CATALYTIC ANTIBODY 5C8, FAB-HAPTEN COMPLEX
35C8	;	2.0	;	CATALYTIC ANTIBODY 5C8, FAB-INHIBITOR COMPLEX
15C8	;	2.5	;	CATALYTIC ANTIBODY 5C8, FREE FAB
5XQW	;	2.2	;	Catalytic antibody 7B9
1CT8	;	2.2	;	CATALYTIC ANTIBODY 7C8 COMPLEX
1YEJ	;	1.85	;	CATALYTIC ANTIBODY COMPLEX
1KN2	;	1.9	;	CATALYTIC ANTIBODY D2.3 COMPLEX
1KN4	;	1.9	;	CATALYTIC ANTIBODY D2.3 COMPLEX
1YEI	;	1.9	;	CATALYTIC ANTIBODY D2.3 COMPLEX
1YEK	;	2.1	;	CATALYTIC ANTIBODY D2.3 COMPLEX
2CWT	;	1.82	;	Catalytic base deletion in copper amine oxidase from arthrobacter globiformis
7QPB	;	2.342	;	Catalytic C-lobe of the HECT-type ubiquitin ligase E6AP in complex with a hybrid foldamer-peptide macrocycle
1CGU	;	2.5	;	CATALYTIC CENTER OF CYCLODEXTRIN GLYCOSYLTRANSFERASE DERIVED FROM X-RAY STRUCTURE ANALYSIS COMBINED WITH SITE-DIRECTED MUTAGENESIS
1PYD	;	2.4	;	CATALYTIC CENTERS IN THE THIAMIN DIPHOSPHATE DEPENDENT ENZYME PYRUVATE DECARBOXYLASE AT 2.4 ANGSTROMS RESOLUTION
3FGU	;	2.15	;	Catalytic complex of Human Glucokinase
2GSM	;	2.0	;	Catalytic Core (Subunits I and II) of Cytochrome c oxidase from Rhodobacter sphaeroides
1FL2	;	1.9	;	CATALYTIC CORE COMPONENT OF THE ALKYLHYDROPEROXIDE REDUCTASE AHPF FROM E.COLI
1QOZ	;	1.9	;	Catalytic core domain of acetyl xylan esterase from Trichoderma reesei
5UB9	;	1.9	;	Catalytic core domain of Adenosine triphosphate phosphoribosyltransferase from Campylobacter jejuni
5UBH	;	2.0	;	Catalytic core domain of Adenosine triphosphate phosphoribosyltransferase from Campylobacter jejuni with bound ATP
5UBG	;	1.9	;	Catalytic core domain of Adenosine triphosphate phosphoribosyltransferase from Campylobacter jejuni with bound Phosphoribosyl-ATP
5UBI	;	2.14	;	Catalytic core domain of Adenosine triphosphate phosphoribosyltransferase from Campylobacter jejuni with bound PRPP
8CT5	;	1.97	;	Catalytic Core Domain of HIV-1 Integrase (F185K)
8CT7	;	2.13	;	Catalytic Core Domain of HIV-1 Integrase (F185K) bound with BI-224436
8QYE	;	2.05	;	Catalytic core of endo-alpha-N-acetylgalactosaminidase from Bifidobacterium longum (EngBF) concieved by deep network hallucination: dEngBF4
8QZK	;	3.25	;	Catalytic core of endo-alpha-N-acetylgalactosaminidase from Bifidobacterium longum (EngBF) concieved by deep network hallucination: dEngBF4 Hexagonal form
7V99	;	3.54	;	catalytic core of human telomerase holoenzyme
3BJY	;	2.41	;	Catalytic core of Rev1 in complex with DNA (modified template guanine) and incoming nucleotide
1CLX	;	1.8	;	CATALYTIC CORE OF XYLANASE A
1XYS	;	2.5	;	CATALYTIC CORE OF XYLANASE A E246C MUTANT
3DTU	;	2.15	;	Catalytic core subunits (I and II) of cytochrome c oxidase from Rhodobacter sphaeroides complexed with deoxycholic acid
3FYE	;	2.15	;	Catalytic core subunits (I and II) of cytochrome c oxidase from Rhodobacter sphaeroides in the reduced state
3FYI	;	2.2	;	Catalytic core subunits (I and II) of cytochrome C oxidase from Rhodobacter sphaeroides in the reduced state bound with cyanide
3OMI	;	2.15	;	Catalytic core subunits (I and II) of cytochrome C oxidase from Rhodobacter sphaeroides with D132A mutation
3OMN	;	2.15	;	Catalytic core subunits (I and II) of cytochrome C oxidase from Rhodobacter sphaeroides with D132A mutation in the reduced state
6CI0	;	2.4	;	Catalytic core subunits (I and II) of cytochrome C oxidase from Rhodobacter sphaeroides with E101A (II) mutation
3OMA	;	2.3	;	Catalytic core subunits (I and II) of cytochrome C oxidase from Rhodobacter sphaeroides with K362M mutation
3OM3	;	2.6	;	Catalytic core subunits (I and II) of cytochrome C oxidase from Rhodobacter sphaeroides with K362M mutation in the reduced state
3DJG	;	1.8	;	Catalytic cycle of human glutathione reductase near 1 A resolution
3DJJ	;	1.1	;	Catalytic cycle of human glutathione reductase near 1 A resolution
3DK4	;	1.2	;	Catalytic cycle of human glutathione reductase near 1 A resolution
3DK8	;	1.1	;	Catalytic cycle of human glutathione reductase near 1 A resolution
3DK9	;	0.95	;	Catalytic cycle of human glutathione reductase near 1 A resolution
6IBO	;	2.17	;	Catalytic deficiency of O-GlcNAc transferase leads to X-linked intellectual disability
4N72	;	2.25	;	Catalytic domain from dihydrolipoamide acetyltransferase of pyruvate dehydrogenase from Escherichia coli
1E2O	;	3.0	;	CATALYTIC DOMAIN FROM DIHYDROLIPOAMIDE SUCCINYLTRANSFERASE
7OKR	;	1.35	;	Catalytic domain from the Aliivibrio salmonicida lytic polysaccharide monooxygenase AsLPMO10B
1C4T	;	3.0	;	CATALYTIC DOMAIN FROM TRIMERIC DIHYDROLIPOAMIDE SUCCINYLTRANSFERASE
4YN5	;	1.8	;	Catalytic domain of Bacillus sp. JAMB-750 GH26 Endo-beta-1,4-mannanase
1AIH	;	2.5	;	CATALYTIC DOMAIN OF BACTERIOPHAGE HP1 INTEGRASE
3WZ1	;	1.6	;	Catalytic domain of beta-agarase from Microbulbifer thermotolerans JAMB-A94
2FYD	;	2.0	;	catalytic domain of bovine beta 1, 4-galactosyltransferase in complex with alpha-lactalbumin, glucose, Mn, and UDP-N-acetylgalactosamine
3QAY	;	2.0	;	Catalytic domain of CD27L endolysin targeting Clostridia Difficile
2FW2	;	2.2	;	Catalytic domain of CDY
7CBD	;	1.3	;	Catalytic domain of Cellulomonas fimi Cel6B
1ITX	;	1.1	;	Catalytic Domain of Chitinase A1 from Bacillus circulans WL-12
4XWL	;	2.051	;	Catalytic domain of Clostridium Cellulovorans Exgs
2YIK	;	2.1	;	Catalytic domain of Clostridium thermocellum CelT
5B6S	;	1.7	;	Catalytic domain of Coprinopsis cinerea GH62 alpha-L-arabinofuranosidase
5B6T	;	1.48	;	Catalytic domain of Coprinopsis cinerea GH62 alpha-L-arabinofuranosidase complexed with Pb
6MJF	;	2.198	;	Catalytic Domain of dbOphMA
2BX2	;	2.85	;	Catalytic domain of E. coli RNase E
2C4R	;	3.6	;	Catalytic domain of E. coli RNase E
2C0B	;	3.18	;	Catalytic domain of E. coli RNase E in complex with 13-mer RNA
6PBR	;	3.0	;	Catalytic domain of E.coli dihydrolipoamide succinyltransferase in I4 space group
1RR9	;	2.1	;	Catalytic domain of E.coli Lon protease
2BOD	;	1.5	;	Catalytic domain of endo-1,4-glucanase Cel6A from Thermobifida fusca in complex with methyl cellobiosyl-4-thio-beta-cellobioside
2BOE	;	1.15	;	Catalytic domain of endo-1,4-glucanase Cel6A mutant Y73S from Thermobifida fusca
2BOF	;	1.64	;	Catalytic domain of endo-1,4-glucanase Cel6A mutant Y73S from Thermobifida fusca in complex with cellotetrose
2BOG	;	1.04	;	Catalytic domain of endo-1,4-glucanase Cel6A mutant Y73S from Thermobifida fusca in complex with methyl cellobiosyl-4-thio-beta- cellobioside
4FET	;	1.909	;	Catalytic domain of germination-specific lytic tansglycosylase SleB from Bacillus anthracis
6M5Z	;	1.65	;	Catalytic domain of GH30 xylanase C from Talaromyces cellulolyticus
6K0P	;	1.424	;	Catalytic domain of GH87 alpha-1,3-glucanase D1045A in complex with nigerose
6K0Q	;	1.564	;	Catalytic domain of GH87 alpha-1,3-glucanase D1068A in complex with nigerose
6K0U	;	1.95	;	Catalytic domain of GH87 alpha-1,3-glucanase D1068A in complex with tetrasaccharides
6K0S	;	1.534	;	Catalytic domain of GH87 alpha-1,3-glucanase D1069A in complex with nigerose
6K0V	;	2.504	;	Catalytic domain of GH87 alpha-1,3-glucanase D1069A in complex with tetrasaccharides
6K0M	;	1.6	;	Catalytic domain of GH87 alpha-1,3-glucanase from Paenibacillus glycanilyticus FH11
6K0N	;	1.6	;	Catalytic domain of GH87 alpha-1,3-glucanase in complex with nigerose
3EQA	;	1.9	;	Catalytic domain of glucoamylase from aspergillus niger complexed with tris and glycerol
8FG8	;	2.35	;	Catalytic domain of GtfB in complex with inhibitor 2-[(2,4,5-Trihydroxyphenyl)methylidene]-1-benzofuran-3-one
8UF5	;	2.5	;	Catalytic domain of GtfB in complex with inhibitor G43
3A0X	;	1.89	;	Catalytic domain of histidine kinase ThkA (TM1359) (nucleotide free form 1: ammomium phosphate, monoclinic)
3A0Y	;	1.57	;	Catalytic domain of histidine kinase ThkA (TM1359) (nucleotide free form 3: 1,2-propanediol, orthorombic)
3A0Z	;	1.75	;	Catalytic domain of histidine kinase ThkA (TM1359) (nucleotide free form 4: isopropanol, orthorombic)
3A0W	;	1.69	;	Catalytic domain of histidine kinase ThkA (TM1359) for MAD phasing (nucleotide free form 2, orthorombic)
3A0T	;	1.91	;	Catalytic domain of histidine kinase ThkA (TM1359) in complex with ADP and Mg ion (trigonal)
1BI4	;	2.5	;	CATALYTIC DOMAIN OF HIV-1 INTEGRASE
1BL3	;	2.0	;	CATALYTIC DOMAIN OF HIV-1 INTEGRASE
2ITG	;	2.6	;	CATALYTIC DOMAIN OF HIV-1 INTEGRASE: ORDERED ACTIVE SITE IN THE F185H CONSTRUCT
3ITM	;	2.49	;	Catalytic domain of hPDE2A
2NQA	;	2.2	;	Catalytic Domain of Human Calpain 8
2ARY	;	2.4	;	Catalytic domain of Human Calpain-1
1ZIV	;	2.31	;	Catalytic Domain of Human Calpain-9
3LKA	;	1.8	;	Catalytic domain of human MMP-12 complexed with hydroxamic acid and paramethoxy-sulfonyl amide
4FIG	;	3.01	;	Catalytic domain of human PAK4
4FIJ	;	2.3	;	Catalytic domain of human PAK4
4FIH	;	1.97	;	Catalytic domain of human PAK4 with QKFTGLPRQW peptide
4FIF	;	2.6	;	Catalytic domain of human PAK4 with RPKPLVDP peptide
4FII	;	2.0	;	Catalytic domain of human PAK4 with RPKPLVDP peptide
6XVW	;	2.0	;	Catalytic domain of human PARP-1 in complex with the inhibitor MC2050
1KW0	;	2.5	;	Catalytic Domain of Human Phenylalanine Hydroxylase (Fe(II)) in Complex with Tetrahydrobiopterin and Thienylalanine
1J8T	;	1.7	;	Catalytic Domain of Human Phenylalanine Hydroxylase Fe(II)
1J8U	;	1.5	;	Catalytic Domain of Human Phenylalanine Hydroxylase Fe(II) in Complex with Tetrahydrobiopterin
1TAZ	;	1.77	;	Catalytic Domain Of Human Phosphodiesterase 1B
1SO2	;	2.4	;	CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B In COMPLEX WITH A DIHYDROPYRIDAZINE INHIBITOR
1SOJ	;	2.9	;	CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX
1XM6	;	1.92	;	Catalytic Domain Of Human Phosphodiesterase 4B In Complex With (R)-Mesopram
1XMY	;	2.4	;	Catalytic Domain Of Human Phosphodiesterase 4B In Complex With (R)-Rolipram
1XN0	;	2.31	;	Catalytic Domain Of Human Phosphodiesterase 4B In Complex With (R,S)-Rolipram
1Y2H	;	2.4	;	Catalytic Domain Of Human Phosphodiesterase 4B In Complex With 1-(2-chloro-phenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylic acid ethyl ester
1Y2J	;	2.55	;	Catalytic Domain Of Human Phosphodiesterase 4B In Complex With 3,5-dimethyl-1-(3-nitro-phenyl)-1H-pyrazole-4-carboxylic acid ethyl ester
3LY2	;	2.6	;	Catalytic Domain of Human Phosphodiesterase 4B in Complex with A Coumarin-Based Inhibitor
1TB5	;	2.15	;	Catalytic Domain Of Human Phosphodiesterase 4B In Complex With AMP
1XLX	;	2.19	;	Catalytic Domain Of Human Phosphodiesterase 4B In Complex With Cilomilast
1XLZ	;	2.06	;	Catalytic Domain Of Human Phosphodiesterase 4B In Complex With Filaminast
1XM4	;	2.31	;	Catalytic Domain Of Human Phosphodiesterase 4B In Complex With Piclamilast
1XMU	;	2.3	;	Catalytic Domain Of Human Phosphodiesterase 4B In Complex With Roflumilast
1XOS	;	2.28	;	Catalytic Domain Of Human Phosphodiesterase 4B In Complex With Sildenafil
1XOT	;	2.34	;	Catalytic Domain Of Human Phosphodiesterase 4B In Complex With Vardenafil
1F0J	;	1.77	;	CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B2B
3O56	;	2.42	;	Catalytic domain of human phosphodiesterase 4b2b in complex with a 5-heterocycle pyrazolopyridine inhibitor
3O57	;	2.0	;	Catalytic domain of human phosphodiesterase 4b2b in complex with a 5-heterocycle pyrazolopyridine inhibitor
3FRG	;	1.7	;	Catalytic Domain of Human Phosphodiesterase 4B2B in Complex with a Quinoline Inhibitor
3GWT	;	1.75	;	Catalytic domain of human phosphodiesterase 4B2B in complex with a quinoline inhibitor
3HMV	;	2.23	;	Catalytic domain of human phosphodiesterase 4B2B in complex with a tetrahydrobenzothiophene inhibitor
1Y2E	;	2.1	;	Catalytic Domain Of Human Phosphodiesterase 4D In Complex With 1-(4-amino-phenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylic acid ethyl ester
1Y2D	;	1.7	;	Catalytic Domain Of Human Phosphodiesterase 4D In Complex With 1-(4-methoxy-phenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylic acid ethyl ester
1Y2K	;	1.36	;	Catalytic Domain Of Human Phosphodiesterase 4D In Complex With 3,5-dimethyl-1-(3-nitro-phenyl)-1H-pyrazole-4-carboxylic acid ethyl ester
1Y2C	;	1.67	;	Catalytic Domain Of Human Phosphodiesterase 4D In Complex With 3,5-dimethyl-1-phenyl-1H-pyrazole-4-carboxylic acid ethyl ester
1Y2B	;	1.4	;	Catalytic Domain Of Human Phosphodiesterase 4D In Complex With 3,5-dimethyl-1H-pyrazole-4-carboxylic acid ethyl ester
1TB7	;	1.63	;	Catalytic Domain Of Human Phosphodiesterase 4D In Complex With AMP
1XOM	;	1.55	;	Catalytic Domain Of Human Phosphodiesterase 4D In Complex With Cilomilast
1XON	;	1.72	;	Catalytic Domain Of Human Phosphodiesterase 4D In Complex With Piclamilast
1XOQ	;	1.83	;	Catalytic Domain Of Human Phosphodiesterase 4D In Complex With Roflumilast
1TBB	;	1.6	;	Catalytic Domain Of Human Phosphodiesterase 4D In Complex With Rolipram
1XOR	;	1.54	;	Catalytic Domain Of Human Phosphodiesterase 4D In Complex With Zardaverine
1T9R	;	2.1	;	Catalytic Domain Of Human Phosphodiesterase 5A
1T9S	;	2.0	;	Catalytic Domain Of Human Phosphodiesterase 5A in Complex with GMP
1TBF	;	1.3	;	Catalytic Domain Of Human Phosphodiesterase 5A in Complex with Sildenafil
1XOZ	;	1.37	;	Catalytic Domain Of Human Phosphodiesterase 5A In Complex With Tadalafil
1XP0	;	1.79	;	Catalytic Domain Of Human Phosphodiesterase 5A In Complex With Vardenafil
3H62	;	1.4	;	Catalytic domain of human Serine/Threonine Phosphatase 5 (PP5c) with two Mn2+ atoms complexed with cantharidic acid
3H64	;	1.9	;	Catalytic domain of human Serine/Threonine Phosphatase 5 (PP5c) with two Mn2+ atoms complexed with endothall
3H63	;	1.3	;	Catalytic domain of human Serine/Threonine Phosphatase 5 (PP5c) with two Mn2+ atoms originally soaked with cantharidin (which is present in the structure in the hydrolyzed form)
3H61	;	1.45	;	Catalytic domain of human Serine/Threonine Phosphatase 5 (PP5c) with two Mn2+ atoms originally soaked with norcantharidin (which is present in the structure in the hydrolyzed form)
3H66	;	2.59	;	Catalytic domain of human Serine/Threonine Phosphatase 5 (PP5c) with two Zn2+ atoms
3H69	;	2.1	;	Catalytic domain of human Serine/Threonine Phosphatase 5 (PP5c) with two Zn2+ atoms complexed with endothall
3H60	;	2.0	;	Catalytic domain of human Serine/Threonine Phosphatase 5 (PP5c)with two Mn2+ atoms
3H67	;	1.65	;	Catalytic domain of human Serine/Threonine Phosphatase 5 (PP5c)with two Zn2+ atoms complexed with cantharidic acid
3H68	;	1.5	;	Catalytic domain of human Serine/Threonine Phosphatase 5 (PP5c)with two Zn2+ atoms originally soaked with cantharidin (which is present in the structure in the hydrolyzed form)
3ZM0	;	1.5	;	Catalytic domain of human SHP2
3ZM1	;	1.4	;	Catalytic domain of human SHP2
3ZM2	;	1.5	;	Catalytic domain of human SHP2
3ZM3	;	1.5	;	Catalytic domain of human SHP2
1BDA	;	3.35	;	CATALYTIC DOMAIN OF HUMAN SINGLE CHAIN TISSUE PLASMINOGEN ACTIVATOR IN COMPLEX WITH DANSYL-EGR-CMK (DANSYL-GLU-GLY-ARG CHLOROMETHYL KETONE)
2SRT	;		;	CATALYTIC DOMAIN OF HUMAN STROMELYSIN-1 AT PH 5.5 AND 40OC COMPLEXED WITH INHIBITOR
1A5H	;	2.9	;	CATALYTIC DOMAIN OF HUMAN TWO-CHAIN TISSUE PLASMINOGEN ACTIVATOR COMPLEX OF A BIS-BENZAMIDINE
1YRP	;	3.1	;	Catalytic domain of human ZIP kinase phosphorylated at Thr265
1MK0	;	1.6	;	catalytic domain of intron endonuclease I-TevI, E75A mutant
5L2V	;	1.1	;	Catalytic domain of LPMO Lmo2467 from Listeria monocytogenes
5CTV	;	1.05	;	Catalytic domain of LytA, the major autolysin of Streptococcus pneumoniae, (C60A, H133A, C136A mutant) complexed with peptidoglycan fragment
5K4P	;	1.318	;	Catalytic Domain of MCR-1 phosphoethanolamine transferase
2XMI	;	1.74	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, complexed with citrate
2Y1P	;	1.82	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, complexed with citrate
2Y3X	;	2.1	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, complexed with sulfate
2YOZ	;	2.1	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, crystallized with 2'-AMPS
2YP0	;	2.3	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, crystallized with 2'-AMPS
2YDD	;	2.4	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, soaked with 2',3'-cyclic AMP
2YDB	;	2.15	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, soaked with 2',3'-cyclic NADP
2YDC	;	2.05	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, soaked with GTP
4WBL	;	2.501	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, with mutation F235A
4WC9	;	2.0	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, with mutation F235L
4WCA	;	1.85	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, with mutation H230Q, complexed with citrate
2YPH	;	2.1	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, with mutation H230S, crystallized with 2',3-(RP)- cyclic-AMPS
3ZBR	;	2.304	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, with mutation H230S, crystallized with NADP
4WCB	;	1.57	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, with mutation H309Q
2YPE	;	1.9	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, with mutation H309S, crystallized with 2',3'- cyclic AMP
2YPC	;	1.894	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, with mutation H309S, crystallized with 2',3-(SP)-Cyclic-AMPS
4WCC	;	2.7	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, with mutation P225G
4WDA	;	1.85	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, with mutation P296G, complexed with 2'-AMP
4WDB	;	1.6	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, with mutation R307Q, complexed with 2'-AMP
4WFR	;	2.0	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, with mutation T232A, complexed with 2'-AMP
4WDD	;	2.101	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, with mutation T232A, complexed with citrate
4WDE	;	2.4	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, with mutation T311A
4WDF	;	2.0	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, with mutation V321A, complexed with 2',5'-ADP
4WDG	;	2.05	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, with mutation V321A, complexed with 2',5'-ADP
2YQ9	;	1.9	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, with mutation V321A, crystallized with 2'-AMP
3ZBS	;	2.45	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, with mutation V321A, crystallized with 2'-AMPS
3ZBZ	;	2.1	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, with mutation V321A, crystallized with 2'-AMPS
4WDH	;	1.9	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, with mutation Y168A
4WEX	;	2.1	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, with mutation Y168S
4WBI	;	2.0	;	Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, with mutations H230Q and H309Q
5HQN	;	2.6	;	Catalytic domain of murine Acid Sphingomyelinase (ASMase, ASM, SMPD1)
1MUY	;	1.4	;	CATALYTIC DOMAIN OF MUTY FROM ESCHERICHIA COLI
1MUN	;	1.2	;	CATALYTIC DOMAIN OF MUTY FROM ESCHERICHIA COLI D138N MUTANT
1WEG	;	1.8	;	Catalytic Domain Of Muty From Escherichia Coli K142A Mutant
1WEF	;	1.9	;	Catalytic Domain Of Muty From Escherichia Coli K20A Mutant
1WEI	;	1.45	;	Catalytic Domain Of Muty From Escherichia Coli K20A Mutant Complexed To Adenine
1MUD	;	1.8	;	CATALYTIC DOMAIN OF MUTY FROM ESCHERICHIA COLI, D138N MUTANT COMPLEXED TO ADENINE
6AII	;	1.63	;	Catalytic domain of PdAgaC
1O6Y	;	2.2	;	Catalytic domain of PknB kinase from Mycobacterium tuberculosis
1QRZ	;	2.0	;	CATALYTIC DOMAIN OF PLASMINOGEN
5K1P	;	1.499	;	Catalytic domain of polyspecific pyrrolysyl-tRNA synthetase mutant N346A/C348A in complex with AMPPNP
5K1X	;	1.95	;	Catalytic domain of polyspecific pyrrolysyl-tRNA synthetase mutant Y306A/N346A/C348A/Y384F in complex with AMPPNP
1EAK	;	2.66	;	Catalytic domain of proMMP-2 E404Q mutant
2FUM	;	2.89	;	Catalytic domain of protein kinase PknB from Mycobacterium tuberculosis in complex with mitoxantrone
6NEN	;	2.151	;	Catalytic domain of Proteus mirabilis ScsC
4CS4	;	1.349	;	Catalytic domain of Pyrrolysyl-tRNA synthetase mutant Y306A, Y384F in complex with AMPPNP
4CS3	;	1.499	;	Catalytic domain of Pyrrolysyl-tRNA synthetase mutant Y306A, Y384F in complex with an adenylated furan-bearing noncanonical amino acid and pyrophosphate
4CS2	;	1.9	;	Catalytic domain of Pyrrolysyl-tRNA synthetase mutant Y306A, Y384F in its apo form
4ZD5	;	2.07	;	Catalytic domain of Sst2 F403A mutant
4ZFR	;	1.72	;	Catalytic domain of Sst2 F403A mutant bound to ubiquitin
4ZD4	;	1.634	;	Catalytic domain of Sst2 F403W mutant
4ZFT	;	2.304	;	Catalytic domain of Sst2 F403W mutant bound to ubiquitin
6GNE	;	2.55	;	Catalytic domain of Starch Synthase IV from Arabidopsis thaliana bound to ADP and acarbose
3OHL	;	2.36	;	catalytic domain of stromelysin-1 in complex with N-Hydroxy-2-(4-methoxy-N-(pyridine-3-ylmethyl)phenylsulfonamido)acetamide
3OHO	;	2.5	;	catalytic domain of stromelysin-1 in complex with N-Hydroxy-2-(4-methylphenylsulfonamido)acetamide
5GCN	;		;	CATALYTIC DOMAIN OF TETRAHYMENA GCN5 HISTONE ACETYLTRANSFERASE IN COMPLEX WITH COENZYME A
1M55	;	1.4	;	Catalytic domain of the Adeno Associated Virus type 5 Rep protein
4QPB	;	1.78	;	Catalytic domain of the antimicrobial peptidase lysostaphin from Staphylococcus simulans crystallized in the absence of phosphate
4QP5	;	1.26	;	Catalytic domain of the antimicrobial peptidase lysostaphin from Staphylococcus simulans crystallized in the presence of phosphate
3VOG	;	1.45	;	Catalytic domain of the cellobiohydrolase, CcCel6A, from Coprinopsis cinerea
3G1N	;	2.6	;	Catalytic domain of the human E3 ubiquitin-protein ligase HUWE1
2ONI	;	2.2	;	Catalytic Domain of the Human NEDD4-like E3 Ligase
6QH3	;	2.9	;	Catalytic domain of the human ubiquitin-conjugating enzyme UBE2S C118M
4TUF	;	2.7	;	Catalytic domain of the major endoglucanase from Xanthomonas campestris pv. campestris
2P0C	;	2.4	;	Catalytic Domain of the Proto-oncogene Tyrosine-protein Kinase MER
5FUV	;	2.3	;	catalytic domain of Thymidine kinase from Trypanosoma brucei with dThd
5FUX	;	2.2	;	catalytic domain of Thymidine kinase from Trypanosoma brucei with dTMP
5FUY	;	2.8	;	catalytic domain of Thymidine kinase from Trypanosoma brucei with dTMP
5FUW	;	2.2	;	catalytic domain of Thymidine kinase from Trypanosoma brucei with dTMP or dThd
1BKC	;	2.0	;	CATALYTIC DOMAIN OF TNF-ALPHA CONVERTING ENZYME (TACE)
3A7S	;	2.2	;	Catalytic domain of UCH37
7ZKC	;	1.769	;	Catalytic domain of UDP-Glucose Glycoprotein Glucosyltransferase from Chaetomium thermophilum (apo form)
7ZLL	;	1.649	;	Catalytic domain of UDP-Glucose Glycoprotein Glucosyltransferase from Chaetomium thermophilum in complex with the 5-[(morpholin-4-yl)methyl]quinolin-8-ol inhibitor
7ZXW	;	2.246	;	Catalytic domain of UDP-Glucose Glycoprotein Glucosyltransferase from Chaetomium thermophilum in complex with the 5-[(morpholin-4-yl)methyl]quinolin-8-ol inhibitor
7ZLE	;	1.823	;	Catalytic domain of UDP-Glucose Glycoprotein Glucosyltransferase from Chaetomium thermophilum in complex with UDP
7ZLU	;	2.049	;	Catalytic domain of UDP-Glucose Glycoprotein Glucosyltransferase from Chaetomium thermophilum in complex with UDP-2-deoxy-2-fluoro-D-glucose
6FSN	;	1.19	;	Catalytic domain of UDP-Glucose Glycoprotein Glucosyltransferase from Chaetomium thermophilum in complex with UDP-glucose (conformation 1)
7ZHB	;	1.89	;	Catalytic domain of UDP-Glucose Glycoprotein Glucosyltransferase from Chaetomium thermophilum in complex with UDP-glucose (conformation 2)
4FML	;	1.93	;	Catalytic domain of VahC from Aeromonas hydrophila
1A5I	;	2.9	;	CATALYTIC DOMAIN OF VAMPIRE BAT (DESMODUS ROTUNDUS) SALIVA PLASMINOGEN ACTIVATOR IN COMPLEX WITH EGR-CMK (GLU-GLY-ARG CHLOROMETHYL KETONE)
8HRF	;	2.5	;	Catalytic domain of Vibrio parahaemolyticus chitinase 1
3NTS	;	3.4	;	Catalytic domain of VsdC from Aeromonas hydrophila
1Y0L	;	2.5	;	Catalytic elimination antibody 34E4 in complex with hapten
3KI0	;	1.29	;	Catalytic fragment of Cholix toxin from Vibrio Cholerae in complex with inhibitor GP-D
3KI1	;	1.43	;	Catalytic fragment of Cholix toxin from Vibrio Cholerae in complex with inhibitor GP-F
3KI2	;	1.28	;	Catalytic fragment of Cholix toxin from Vibrio Cholerae in complex with inhibitor GP-G
3KI3	;	1.27	;	Catalytic fragment of Cholix toxin from Vibrio Cholerae in complex with inhibitor GP-H
3KI7	;	1.32	;	Catalytic fragment of Cholix toxin from Vibrio Cholerae in complex with inhibitor GP-I
3KI6	;	1.54	;	Catalytic fragment of Cholix toxin from Vibrio Cholerae in complex with inhibitor GP-L
3KI5	;	1.55	;	Catalytic fragment of Cholix toxin from Vibrio Cholerae in complex with inhibitor GP-M
3KI4	;	1.65	;	Catalytic fragment of Cholix toxin from Vibrio Cholerae in complex with inhibitor GP-P
3NY6	;	1.68	;	Catalytic fragment of cholix toxin from vibrio cholerae in complex with inhibitor V30
3ESS	;	1.191	;	Catalytic fragment of Cholix toxin from Vibrio Cholerae in complex with the 1,8-Naphthalimide inhibitor
2Q6M	;	1.25	;	Catalytic fragment of Cholix toxin from Vibrio Cholerae in complex with the PJ34 inhibitor
4AYK	;		;	CATALYTIC FRAGMENT OF HUMAN FIBROBLAST COLLAGENASE COMPLEXED WITH CGS-27023A, NMR, 30 STRUCTURES
3AYK	;		;	CATALYTIC FRAGMENT OF HUMAN FIBROBLAST COLLAGENASE COMPLEXED WITH CGS-27023A, NMR, MINIMIZED AVERAGE STRUCTURE
4DJZ	;	3.2	;	Catalytic fragment of masp-1 in complex with its specific inhibitor developed by directed evolution on sgci scaffold
7PQO	;	3.39	;	Catalytic fragment of MASP-1 in complex with P1 site mutant ecotin
7PQN	;	2.40002	;	Catalytic fragment of MASP-2 in complex with ecotin
3TVJ	;	1.28	;	Catalytic fragment of MASP-2 in complex with its specific inhibitor developed by directed evolution on SGCI scaffold
3AVR	;	1.803	;	Catalytic fragment of UTX/KDM6A bound with histone H3K27me3 peptide, N-oxyalylglycine, and Ni(II)
3AVS	;	1.85	;	Catalytic fragment of UTX/KDM6A bound with N-oxyalylglycine, and Ni(II)
3ZSC	;	1.94	;	Catalytic function and substrate recognition of the pectate lyase from Thermotoga maritima
5BRU	;	1.6	;	Catalytic Improvement of an Artificial Metalloenzyme by Computational Design
5BRV	;	1.6	;	Catalytic Improvement of an Artificial Metalloenzyme by Computational Design
5BRW	;	1.4	;	Catalytic Improvement of an Artificial Metalloenzyme by Computational Design
3AEX	;	2.1	;	Catalytic intermediate analogue of threonine synthase from Thermus thermophilus HB8
7YNH	;	1.94	;	Catalytic intermediate of copper amine oxidase determined by serial femtosecond X-ray crystallography using a single-flow liquid jet system
2AU8	;	1.65	;	Catalytic intermediate structure of inorganic pyrophosphatase
7WIS	;	1.9	;	Catalytic intermediate structure of N381A mutant of copper amine oxidase from Arthrobacter globiformis
7VQK	;	2.0	;	Catalytic manifolds of a FMN-dependent oxidoreductase RubE7, expanding the functional diversity of the flavoenzyme superfamily
1JYK	;	1.5	;	Catalytic Mechanism of CTP:phosphocholine Cytidylyltransferase from Streptococcus pneumoniae (LicC)
1JYL	;	2.4	;	Catalytic Mechanism of CTP:phosphocholine Cytidylyltransferase from Streptococcus pneumoniae (LicC)
9ICD	;	2.5	;	CATALYTIC MECHANISM OF NADP+-DEPENDENT ISOCITRATE DEHYDROGENASE: IMPLICATIONS FROM THE STRUCTURES OF MAGNESIUM-ISOCITRATE AND NADP+ COMPLEXES
1G72	;	1.9	;	CATALYTIC MECHANISM OF QUINOPROTEIN METHANOL DEHYDROGENASE: A THEORETICAL AND X-RAY CRYSTALLOGRAPHIC INVESTIGATION
1ELS	;	2.4	;	CATALYTIC METAL ION BINDING IN ENOLASE: THE CRYSTAL STRUCTURE OF ENOLASE-MN2+-PHOSPHONOACETOHYDROXAMATE COMPLEX AT 2.4 ANGSTROMS RESOLUTION
8PJN	;	3.4	;	Catalytic module of human CTLH E3 ligase bound to multiphosphorylated UBE2H~ubiquitin
2YA0	;	1.85	;	Catalytic Module of the Multi-modular glycogen-degrading pneumococcal virulence factor SpuA
2YA2	;	2.37	;	Catalytic Module of the Multi-modular glycogen-degrading pneumococcal virulence factor SpuA in complex with an inhibitor.
7NS4	;	3.9	;	Catalytic module of yeast Chelator-GID SR4 E3 ubiquitin ligase
8PMQ	;	3.53	;	Catalytic module of yeast GID E3 ligase bound to multiphosphorylated Ubc8~ubiquitin
1LO0	;	2.0	;	Catalytic Retro-Diels-Alderase Transition State Analogue Complex
488D	;	3.1	;	CATALYTIC RNA ENZYME-PRODUCT COMPLEX
3WFA	;	2.0	;	Catalytic role of the calcium ion in GH97 inverting glycoside hydrolase
6USS	;	2.5	;	Catalytic S88C mutant of gut microbial sulfatase from Bacteroides fragilis CAG:558
6FCC	;	1.89	;	Catalytic subunit HisG from Psychrobacter arcticus ATP phosphoribosyltransferase (HisZG ATPPRT)
6FD9	;	2.2	;	Catalytic subunit HisG from Psychrobacter arcticus ATP phosphoribosyltransferase (HisZG ATPPRT) in complex with AMP
6FCW	;	2.0	;	Catalytic subunit HisG from Psychrobacter arcticus ATP phosphoribosyltransferase (HisZG ATPPRT) in complex with PRATP
6FCA	;	2.09	;	Catalytic subunit HisG from Psychrobacter arcticus ATP phosphoribosyltransferase (HisZG ATPPRT) in complex with PRPP
6FCY	;	1.96	;	Catalytic subunit HisG from Psychrobacter arcticus ATP phosphoribosyltransferase (HisZG ATPPRT) in complex with PRPP and ADP
6FCT	;	1.89	;	Catalytic subunit HisG from Psychrobacter arcticus ATP phosphoribosyltransferase (HisZG ATPPRT) in complex with PRPP and ATP
7Z8U	;	2.0	;	Catalytic subunit HisG R56A mutant from Psychrobacter arcticus ATPPRT (HisGZ) in complex with ATP and PRPP
6MM7	;	1.85	;	Catalytic subunit of cAMP-dependent protein kinase A in complex with RyR2 K2879A, S2813D phosphomimetic (2699-2904) crystal form 1
6MM8	;	1.85	;	Catalytic subunit of cAMP-dependent protein kinase A in complex with RyR2 K2879A, S2813D phosphomimetic (2699-2904) crystal form 2
6MM5	;	1.95	;	Catalytic subunit of cAMP-dependent protein kinase A in complex with RyR2 peptide (2799-2810)
6MM6	;	2.39	;	Catalytic subunit of cAMP-dependent protein kinase A in complex with RyR2 phosphorylation domain (2699-2904)
7C6O	;	1.801	;	Catalytic Subunit of Cobaltochelatase from Mycobacterium tuberculosis
2RGW	;	2.8	;	Catalytic Subunit of M. jannaschii Aspartate Transcarbamoylase
3E2P	;	3.0	;	Catalytic subunit of M. Jannaschii aspartate transcarbamoylase in an orthorhombic crystal form
3CSU	;	1.88	;	CATALYTIC TRIMER OF ESCHERICHIA COLI ASPARTATE TRANSCARBAMOYLASE
4HVB	;	2.35	;	Catalytic unit of PI3Kg in complex with PI3K/mTOR dual inhibitor PF-04979064
1LVM	;	1.8	;	CATALYTICALLY ACTIVE TOBACCO ETCH VIRUS PROTEASE COMPLEXED WITH PRODUCT
2F5S	;	2.35	;	Catalytically inactive (E3Q) MutM crosslinked to oxoG:C containing DNA CC1
2F5Q	;	2.35	;	Catalytically inactive (E3Q) MutM crosslinked to oxoG:C containing DNA CC2
1YQL	;	2.6	;	Catalytically inactive hOGG1 crosslinked with 7-deaza-8-azaguanine containing DNA
1YQM	;	2.5	;	Catalytically inactive human 8-oxoguanine glycosylase crosslinked to 7-deazaguanine containing DNA
1YQR	;	2.43	;	Catalytically inactive human 8-oxoguanine glycosylase crosslinked to oxoG containing DNA
1LVB	;	2.2	;	CATALYTICALLY INACTIVE TOBACCO ETCH VIRUS PROTEASE COMPLEXED WITH SUBSTRATE
7R9G	;	2.4	;	Catalytically inactive yeast Pseudouridine Synthase, PUS1, bound to RNA
7ZJZ	;	1.9	;	catalytically non active S532A mutant of oligopeptidase B from S. proteomaculans
7NE5	;	1.88	;	catalytically non active S532A mutant of oligopeptidase B from S. proteomaculans with modified hinge region
5ZSZ	;	2.4	;	Catechol 2,3-dioxygenase (C23O64) from Diaphorobacter sp DS2
5ZSX	;	2.2	;	Catechol 2,3-dioxygenase with 3-fluorocatechol from Diaphorobacter sp DS2
5ZNH	;	2.4	;	Catechol 2,3-dioxygenase with 4-methyl catechol from Diaphorobacter sp DS2
1XEP	;	1.55	;	Catechol in complex with T4 lysozyme L99A/M102Q
5ZY6	;	2.099	;	catechol methyltransferase spCOMT
1H1D	;	2.0	;	Catechol O-Methyltransferase
1VID	;	2.0	;	CATECHOL O-METHYLTRANSFERASE
1JR4	;	2.63	;	CATECHOL O-METHYLTRANSFERASE BISUBSTRATE-INHIBITOR COMPLEX
8C9T	;	1.5	;	Catechol O-methyltransferase from Streptomyces avermitilis
8C9S	;	1.8	;	Catechol O-methyltransferase from Streptomyces avermitilis in complex with SAH
1BT1	;	2.7	;	CATECHOL OXIDASE FROM IPOMOEA BATATAS (SWEET POTATOES) IN THE NATIVE CU(II)-CU(II) STATE
1BT3	;	2.5	;	CATECHOL OXIDASE FROM IPOMOEA BATATAS (SWEET POTATOES) IN THE NATIVE CU(II)-CU(II) STATE
1BT2	;	2.7	;	CATECHOL OXIDASE FROM IPOMOEA BATATAS (SWEET POTATOES) IN THE REDUCED CU(I)-CU(I) STATE
1BUG	;	2.7	;	CATECHOL OXIDASE FROM IPOMOEA BATATAS (SWEET POTATOES)-INHIBITOR COMPLEX WITH PHENYLTHIOUREA (PTU)
2CL5	;	1.6	;	Catechol-O-methyltransferase in complex with an inhibitor
2LR7	;		;	Cathelicidin-PY
1PFP	;	2.3	;	CATHELIN-LIKE MOTIF OF PROTEGRIN-3
1GMY	;	1.9	;	Cathepsin B complexed with dipeptidyl nitrile inhibitor
5MBL	;	1.81	;	Cathepsin B in complex with DARPin 81
5MBM	;	2.76	;	Cathepsin B in complex with DARPin 8h6
3K9M	;	2.61	;	Cathepsin B in complex with stefin A
3AI8	;	2.11	;	Cathepsin B in complex with the nitroxoline
8CC2	;	1.2	;	Cathepsin B1 from Schistosoma mansoni in complex with gallinamide A
8CCU	;	1.6	;	Cathepsin B1 from Schistosoma mansoni in complex with gallinamide analog 1
8CD9	;	1.55	;	Cathepsin B1 from Schistosoma mansoni in complex with gallinamide analog 6
1LYW	;	2.5	;	CATHEPSIN D AT PH 7.5
4N8W	;	2.02	;	cathepsin K - chondroitin sulfate complex
4YVA	;	1.8	;	Cathepsin K co-crystallized with actinomycetes extract
1YT7	;	2.3	;	Cathepsin K complexed with a constrained ketoamide inhibitor
1YK8	;	2.6	;	Cathepsin K complexed with a cyanamide-based inhibitor
1YK7	;	2.5	;	Cathepsin K complexed with a cyanopyrrolidine inhibitor
1TU6	;	1.75	;	Cathepsin K complexed with a ketoamide inhibitor
2BDL	;	2.0	;	Cathepsin K complexed with a pyrrolidine ketoamide-based inhibitor
2AUX	;	2.4	;	Cathepsin K complexed with a semicarbazone inhibitor
2AUZ	;	2.3	;	Cathepsin K complexed with a semicarbazone inhibitor
1SNK	;	2.4	;	Cathepsin K complexed with carbamate derivatized norleucine aldehyde
1Q6K	;	2.1	;	Cathepsin K complexed with t-butyl(1S)-1-cyclohexyl-2-oxoethylcarbamate
3O1G	;	1.65	;	Cathepsin K covalently bound to a 2-cyano pyrimidine inhibitor with a benzyl P3 group.
3O0U	;	1.8	;	Cathepsin K covalently bound to a cyano-pyrimidine inhibitor with improved selectivity over hERG
3OVZ	;	2.02	;	Cathepsin K in complex with a covalent inhibitor with a ketoamide warhead
3KWZ	;	1.49	;	Cathepsin K in complex with a non-selective 2-cyano-pyrimidine inhibitor
3KX1	;	1.51	;	Cathepsin K in complex with a selective 2-cyano-pyrimidine inhibitor
4DMX	;	1.7	;	Cathepsin K inhibitor
4DMY	;	1.63	;	Cathepsin K inhibitor
5MAE	;	1.0	;	CATHEPSIN L IN COMPLEX WITH (2S,4R)-4-(2-Chloro-4-methoxy-benzenesulfonyl)-1-[3-(5-chloro-pyridin-2-yl)-azetidine-3-carbonyl]-pyrrolidine-2-car boxylic acid (1-cyano-cyclopropyl)-amide
5F02	;	1.43	;	CATHEPSIN L IN COMPLEX WITH (2S,4R)-4-(2-Chloro-4-methoxy-benzenesulfonyl)-1-[3-(5-chloro-pyridin-2-yl)-azetidine-3-carbonyl]-pyrrolidine-2-carboxylic acid (1-cyano-cyclopropyl)-amide
6EZP	;	1.37	;	CATHEPSIN L IN COMPLEX WITH (3S,14E)-19-chloro-N-(1-cyanocyclopropyl)-5-oxo-12,17-dioxa-4-azatricyclo[16.2.2.06,11]docosa-1(21),6(11),7,9,14,18(22),19-heptaene-3-carboxamide
6EZX	;	2.34	;	CATHEPSIN L IN COMPLEX WITH (3S,14E)-19-chloro-N-(1-cyanocyclopropyl)-5-oxo-17-oxa-4-azatricyclo[16.2.2.06,11]docosa-1(21),6,8,10,14,18(22),19-heptaene-3-carboxamide
6F06	;	2.02	;	CATHEPSIN L IN COMPLEX WITH (3S,14E)-8-(azetidin-3-yl)-19-chloro-N-(1-cyanocyclopropyl)-5-oxo-12,17-dioxa-4-azatricyclo[16.2.2.06,11]docosa-1(21),6,8,10,14,18(22),19-heptaene-3-carboxamide
5MQY	;	1.13	;	CATHEPSIN L IN COMPLEX WITH 4-[1,3-benzodioxol-5-ylmethyl(2-phenoxyethyl)amino]-5-fluoropyrimidine-2-carbonitrile
5MAJ	;	1.0	;	CATHEPSIN L IN COMPLEX WITH 4-[cyclopentyl(imidazo[1,2-a]pyridin-2-ylmethyl)amino]-6-morpholino-1,3,5-triazine-2-carbonitrile
8UAC	;	1.4	;	CATHEPSIN L IN COMPLEX WITH AC1115
2XU1	;	1.45	;	CATHEPSIN L WITH A NITRILE INHIBITOR
2XU3	;	0.9	;	CATHEPSIN L WITH A NITRILE INHIBITOR
2XU4	;	1.12	;	CATHEPSIN L WITH A NITRILE INHIBITOR
2XU5	;	1.6	;	CATHEPSIN L WITH A NITRILE INHIBITOR
2YJ2	;	1.15	;	CATHEPSIN L WITH A NITRILE INHIBITOR
2YJ8	;	1.3	;	CATHEPSIN L WITH A NITRILE INHIBITOR
2YJ9	;	1.35	;	CATHEPSIN L WITH A NITRILE INHIBITOR
2YJB	;	1.4	;	CATHEPSIN L WITH A NITRILE INHIBITOR
2YJC	;	1.14	;	CATHEPSIN L WITH A NITRILE INHIBITOR
3HWN	;	2.33	;	CATHEPSIN L with AZ13010160
2R9M	;	1.97	;	Cathepsin S complexed with Compound 15
2R9N	;	2.0	;	Cathepsin S complexed with Compound 26
2R9O	;	2.0	;	Cathepsin S complexed with Compound 8
3OVX	;	1.49	;	Cathepsin S in complex with a covalent inhibitor with an aldehyde warhead
2HHN	;	1.55	;	Cathepsin S in complex with non covalent arylaminoethyl amide.
2F1G	;	1.9	;	Cathepsin S in complex with non-covalent 2-(Benzoxazol-2-ylamino)-acetamide
2FQ9	;	1.65	;	Cathepsin S with nitrile inhibitor
1KYN	;	3.5	;	Cathepsin-G
6QM0	;	1.9	;	Cathepsin-K in complex with amino-oxaazabicyclo[3.3.0]octanyl containing inhibitor
6QLX	;	2.1	;	Cathepsin-K in complex with fluoro-oxa-azabicyclo[3.3.0]octanyl containing inhibitor
6QLM	;	1.5	;	Cathepsin-K in complex with MIV-701
6QLW	;	2.0	;	Cathepsin-K in complex with MIV-710
6QL8	;	1.8	;	Cathepsin-K in complex with MIV-711
2VHS	;	1.5	;	Cathsilicatein, a chimera
1GLH	;	2.0	;	CATION BINDING TO A BACILLUS (1,3-1,4)-BETA-GLUCANASE. GEOMETRY, AFFINITY AND EFFECT ON PROTEIN STABILITY
8GI9	;	2.84	;	Cation channelrhodopsin from Hyphochytrium catenoides (HcCCR) embedded in peptidisc
1GLC	;	2.65	;	CATION PROMOTED ASSOCIATION (CPA) OF A REGULATORY AND TARGET PROTEIN IS CONTROLLED BY PHOSPHORYLATION
1GLD	;	2.93	;	CATION PROMOTED ASSOCIATION (CPA) OF A REGULATORY AND TARGET PROTEIN IS CONTROLLED BY PHOSPHORYLATION
1GLE	;	2.94	;	CATION PROMOTED ASSOCIATION (CPA) OF A REGULATORY AND TARGET PROTEIN IS CONTROLLED BY PHOSPHORYLATION
3HWB	;	3.0	;	Cation selective pathway of OmpF porin revealed by anomalous diffraction
3HW9	;	2.61	;	Cation selective pathway of OmpF porin revealed by anomalous x-ray diffraction
3FAR	;	2.4	;	Cation-dependent self-cleavage activity in the duplex form of the subtype-B HIV-1 RNA Dimerization Initiation Site
1ND0	;	2.45	;	CATIONIC CYCLIZATION ANTIBODY 4C6 COMPLEX WITH TRANSITION STATE ANALOG
1NCW	;	1.3	;	Cationic Cyclization Antibody 4C6 in Complex with Benzoic Acid
5HCJ	;	2.95	;	Cationic Ligand-Gated Ion Channel
5MN1	;	0.79	;	Cationic trypsin in complex with 2-aminopyridine (deuterated sample at 100 K)
5MNB	;	0.939	;	Cationic trypsin in complex with 2-aminopyridine (deuterated sample at 295 K)
6SY3	;	0.95	;	Cationic Trypsin in Complex with a D-DiPhe-Pro-pyridine derivative
6T0P	;	1.19	;	Cationic Trypsin in Complex with a D-Phe-Pro-2-aminopyridine derivative
6YDY	;	1.45	;	Cationic Trypsin in Complex with a D-Phe-Pro-benzylamine derivative
6T0M	;	1.51	;	Cationic Trypsin in Complex with a D-Phe-Pro-diaminopyridine derivative
6QL0	;	1.634	;	Cationic Trypsin in Complex with a D-Phe-Pro-p-aminopyridine derivative
6T5W	;	1.13	;	Cationic Trypsin in Complex with a D-Phe-Pro-p-aminopyridine Derivative (cocrystallizaton at 291 K)
6ZQ2	;	1.29	;	Cationic trypsin in complex with a derivative of benzamidine
5MNQ	;	1.337	;	Cationic trypsin in complex with a derivative of N-amidinopiperidine
5MNC	;	0.916	;	Cationic trypsin in complex with aniline (deuterated sample at 100 K)
5MNA	;	1.441	;	Cationic trypsin in complex with aniline (deuterated sample at 295 K)
5MNG	;	0.86	;	Cationic trypsin in complex with benzamidine (deuterated sample at 100 K)
5MNH	;	0.93	;	Cationic trypsin in complex with benzamidine (deuterated sample at 295 K)
5MNM	;	0.98	;	Cationic trypsin in complex with benzylamine (at 295 K)
5MNK	;	0.799	;	Cationic trypsin in complex with benzylamine (deuterated sample at 100 K)
5MNL	;	1.039	;	Cationic trypsin in complex with benzylamine (deuterated sample at 295 K)
4AOQ	;	2.0	;	Cationic trypsin in complex with mutated Spinacia oleracea trypsin inhibitor III (SOTI-III) (F14A)
5MNP	;	1.01	;	Cationic trypsin in complex with N-amidinopiperidine (at 295 K)
5MNN	;	0.859	;	Cationic trypsin in complex with N-amidinopiperidine (deuterated sample at 100 K)
5MNO	;	0.96	;	Cationic trypsin in complex with N-amidinopiperidine (deuterated sample at 295 K)
4AOR	;	1.702	;	Cationic trypsin in complex with the Spinacia oleracea trypsin inhibitor III (SOTI-III)
5MNE	;	1.008	;	Cationic trypsin in its apo form (deuterated sample at 100 K)
5MNF	;	0.99	;	Cationic trypsin in its apo form (deuterated sample at 295 K)
5GXP	;	2.8	;	Cationic Trypsin With GOL/PGE as Dimer at pH 4.6
2F7B	;	1.9	;	CatM effector binding domain
2F7C	;	2.162	;	CatM effector binding domain with its effector cis,cis-muconate
5Y17	;	2.3	;	CATPO mutant - E316F
7WCA	;	1.78	;	CATPO mutant - E484A
5XVZ	;	1.9	;	CATPO mutant - H246W
7VN0	;	1.4	;	CATPO mutant - T188A
5YEM	;	1.49	;	CATPO mutant - T188F
5XZN	;	1.47	;	CATPO mutant - V228C
5XZM	;	1.41	;	CATPO mutant - V228I
5XY4	;	1.8	;	CATPO mutant - V536W
2XFX	;	1.9	;	cattle MHC class I N01301 presenting an 11mer from Theileria parva
5I4H	;	1.42	;	Caught in the Act: The Crystal Structure of cleaved Cathepsin L bound to the active site of Cathepsin L
4P4H	;	3.4	;	Caught-in-action signaling complex of RIG-I 2CARD domain and MAVS CARD domain
2W4Z	;	3.6	;	Caulobacter bacteriophage 5
2W4Y	;	2.9	;	Caulobacter bacteriophage 5 - virus-like particle
6XL0	;	3.4	;	Caulobacter crescentus FljK filament
6XKY	;	3.2	;	Caulobacter crescentus FljK filament, straightened
5YIU	;	1.42	;	Caulobacter crescentus GcrA DNA-binding domain (DBD)
5YIW	;	1.551	;	Caulobacter crescentus GcrA DNA-binding domain (DBD) in complex with methylated dsDNA (crystal form 2)
5YIV	;	2.914	;	Caulobacter crescentus GcrA DNA-binding domain(DBD) in complex with methylated dsDNA(crystal form 1)
5Z7I	;	1.601	;	Caulobacter crescentus GcrA DNA-binding domain(DBD)in complex with unmethylated dsDNA
5YIX	;	2.302	;	Caulobacter crescentus GcrA sigma-interacting domain (SID) in complex with domain 2 of sigma 70
5WCE	;	1.9	;	Caulobacter crescentus pol III beta
6ESX	;	2.797	;	Caulobacter crescentus Trx1
7PLD	;	1.7	;	Caulobacter crescentus xylonolactonase with (R)-4-hydroxy-2-pyrrolidone
7PLB	;	1.73	;	Caulobacter crescentus xylonolactonase with D-xylose
7PLC	;	2.15	;	Caulobacter crescentus xylonolactonase with D-xylose, P21 space group
7TNB	;	1.79	;	Caulobacter segnis arene reductase (CSAR) - WT
5V2P	;	2.0	;	CaV beta2a subunit: CaV1.2 AID-CAP complex
5V2Q	;	1.7	;	CaV beta2a subunit: CaV1.2 AID-CEN complex
2J1K	;	2.3	;	CAV-2 fibre head in complex with CAR D1
8GAI	;	2.65	;	Cavia porcellus (guinea pig) importin-alpha 1 in complex with Bimax2 peptide
1QSQ	;	1.9	;	CAVITY CREATING MUTATION
3Q7Z	;	1.87	;	CBAP-acylated BlaR1 sensor domain from Staphylococcus aureus
6U8A	;	3.4	;	CBD-bound full-length rat TRPV2 in nanodiscs, state 1
6U88	;	3.2	;	CBD-bound full-length rat TRPV2 in nanodiscs, state 2
6S4S	;	2.15	;	CBDP35 Native structure
6THJ	;	2.2	;	CBDP35 Native structure
6S3Y	;	2.043	;	CBDP35 SeMet structure
7K79	;	4.0	;	CBF3
6F07	;	3.6	;	CBF3 Core Complex
3MQK	;	2.8	;	Cbf5-Nop10-Gar1 complex binding with 17mer RNA containing ACA trinucleotide
6CEL	;	1.7	;	CBH1 (E212Q) CELLOPENTAOSE COMPLEX
5CEL	;	1.9	;	CBH1 (E212Q) CELLOTETRAOSE COMPLEX
7CEL	;	1.9	;	CBH1 (E217Q) IN COMPLEX WITH CELLOHEXAOSE AND CELLOBIOSE
1DY4	;	1.9	;	CBH1 IN COMPLEX WITH S-PROPRANOLOL
1W90	;	2.5	;	CBM29-2 mutant D114A: Probing the Mechanism of Ligand Recognition by Family 29 Carbohydrate Binding Modules
1W8U	;	1.3	;	CBM29-2 mutant D83A complexed with mannohexaose: Probing the Mechanism of Ligand Recognition by Family 29 Carbohydrate Binding Modules
1W8T	;	1.4	;	CBM29-2 mutant K74A complexed with cellulohexaose: Probing the Mechanism of Ligand Recognition by Family 29 Carbohydrate Binding Modules
1W8Z	;	1.85	;	CBM29-2 mutant K85A: Probing the Mechanism of Ligand Recognition by Family 29 Carbohydrate Binding Modules
1W9F	;	2.25	;	CBM29-2 mutant R112A: Probing the Mechanism of Ligand Recognition by Family 29 Carbohydrate Binding Modules
1W8W	;	2.1	;	CBM29-2 mutant Y46A: Probing the Mechanism of Ligand Recognition by Family 29 Carbohydrate Binding Modules
1WCU	;	1.5	;	CBM29_1, A Family 29 Carbohydrate Binding Module from Piromyces equi
7D29	;	1.7	;	CBM32 of AlyQ
7D2A	;	1.57	;	CBM32 of AlyQ in complex with 4,5-unsaturated mannuronic acid
2W46	;	1.9	;	CBM35 from Cellvibrio japonicus Abf62
4JO5	;	1.98	;	CBM3a-L domain with flanking linkers from scaffoldin cipA of cellulosome of Clostridium thermocellum
1GU3	;	2.3	;	CBM4 structure and function
1GUI	;	1.9	;	CBM4 structure and function
5FRA	;	2.0	;	CBM40_CPF0721-6'SL
2YFU	;	1.65	;	CBM62 FROM CLOSTRIDIUM THERMOCELLUM XYL5A
2YFZ	;	1.8	;	CBM62 FROM CLOSTRIDIUM THERMOCELLUM XYL5A
2YG0	;	1.8	;	CBM62 FROM CLOSTRIDIUM THERMOCELLUM XYL5A
2YB7	;	1.7	;	CBM62 in complex with 6-alpha-D-Galactosyl-mannotriose
1UXX	;	1.6	;	CBM6ct from Clostridium thermocellum in complex with xylopentaose
7UWV	;	1.7	;	CBM74 from Ruminococcus bromii Sas6 with maltodecaose
7JUO	;	2.2	;	CBP bromodomain complexed with YF2-23
5I8B	;	1.5218	;	CBP in complex with Cpd23 ((R)-6-(3-(benzyloxy)phenyl)-4-methyl-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-one)
5I8G	;	1.41	;	CBP in complex with Cpd637 ((R)-4-methyl-6-(1-methyl-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-5-yl)-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-one)
7WX2	;	1.24	;	CBP-BrD complexed with NEO2734
1PBJ	;	1.4	;	CBS domain protein
2RIH	;	2.1	;	CBS domain protein PAE2072 from Pyrobaculum aerophilum
2RIF	;	2.35	;	CBS domain protein PAE2072 from Pyrobaculum aerophilum complexed with AMP
5G5R	;	2.4	;	CBS domain tandem of site-2 protease from Archaeoglobus fulgidus in complex with llama Nanobody - apo form
5G5X	;	2.8	;	CBS domain tandem of site-2 protease from Archaeoglobus fulgidus in complex with llama Nanobody - nucleotide-bound form
5T1I	;	1.6	;	CBX3 chromo shadow domain in complex with histone H3 peptide
7QWC	;	1.69	;	CC-Type1-(UbUc)4
7QWB	;	1.64	;	CC-Type2-(Ue)4
7QWD	;	1.35	;	CC-Type2-(Ug)4
7QWE	;	1.34	;	CC-Type2-(Ug)4
7QWA	;	1.54	;	CC-Type2-(UgUe)4
6EI6	;	2.461	;	CC2D1B coordinates ESRCT-III activity during the mitotic reformation of the nuclear envelope
2BKA	;	1.7	;	CC3(TIP30)Crystal Structure
1YMZ	;		;	CC45, An Artificial WW Domain Designed Using Statistical Coupling Analysis
7RU5	;	3.6	;	CC6.30 fragment antigen binding in complex with SARS-CoV-2-6P-Mut7 S protein (non-uniform refinement)
7RU8	;	3.8	;	CC6.30 fragment antigen binding in complex with SARS-CoV-2-6P-Mut7 S protein (RBD/Fv local refinement)
7RU3	;	3.3	;	CC6.33 IgG in complex with SARS-CoV-2-6P-Mut7 S protein (non-uniform refinement)
7RU4	;	3.3	;	CC6.33 IgG in complex with SARS-CoV-2-6P-Mut7 S protein (RBD/Fv local refinement)
7YNF	;	2.5	;	CCA-bound alpha-synuclein fibrils
7AW9	;	3.5	;	CCAAT-binding complex and HapX bound to Aspergillus fumigatus cccA DNA
7AW7	;	3.4	;	CCAAT-binding complex and HapX bound to Aspergillus nidulans cccA DNA
6Y36	;	2.3	;	CCAAT-binding complex from Aspergillus fumigatus with cccA DNA
6Y35	;	2.6	;	CCAAT-binding complex from Aspergillus fumigatus with cycA DNA
4G91	;	1.9	;	CCAAT-binding complex from Aspergillus nidulans
6Y37	;	2.2	;	CCAAT-binding complex from Aspergillus nidulans with cccA DNA
4G92	;	1.8	;	CCAAT-binding complex from Aspergillus nidulans with DNA
7SIY	;	1.48	;	cCBL TKB domain in complex with pZAP70 peptide
1ZF1	;	1.35	;	CCC A-DNA
3VOH	;	2.4	;	CcCel6A catalytic domain complexed with cellobiose
3VOI	;	2.0	;	CcCel6A catalytic domain complexed with p-nitrophenyl beta-D-cellotrioside
3VOJ	;	2.29	;	CcCel6A catalytic domain mutant D164A
3A9B	;	1.2	;	CcCel6C, a glycoside hydrolase family 6 enzyme, complexed with cellobiose
3ABX	;	1.4	;	CcCel6C, a glycoside hydrolase family 6 enzyme, complexed with p-nitrophenyl beta-D-cellotrioside
3TCJ	;	1.93	;	CcdB dimer from V. fisheri in complex with one C-terminal domain of F-plasmid CcdA
3HPW	;	1.452	;	CcdB dimer in complex with one C-terminal CcdA domain
3G7Z	;	2.351	;	CcdB dimer in complex with two C-terminal CcdA domains
1VUB	;	2.6	;	CCDB, A TOPOISOMERASE POISON FROM E. COLI
2VUB	;	2.45	;	CCDB, A TOPOISOMERASE POISON FROM E. COLI
3VUB	;	1.4	;	CCDB, A TOPOISOMERASE POISON FROM E. COLI
4VUB	;	1.45	;	CCDB, A TOPOISOMERASE POISON FROM ESCHERICHIA COLI
1X75	;	2.8	;	CcdB:GyrA14 complex
3JSC	;	1.5	;	CcdBVfi-FormI-pH7.0
3JRZ	;	1.7	;	CcdBVfi-FormII-pH5.6
4ELY	;	1.932	;	CCDBVFI:GYRA14EC
4ELZ	;	2.2	;	CCDBVFI:GYRA14VFI
1ZEX	;	1.65	;	CCG A-DNA
8JLX	;	3.0	;	CCHFV envelope protein Gc in complex with Gc13
8JLW	;	3.0	;	CCHFV envelope protein Gc in complex with Gc8
7L7R	;	2.1	;	CCHFV Gc prefusion monomer bound to ADI-36121 and ADI-37801 Fabs
6VKF	;	2.524	;	CCHFV GP38 (IbAr10200)
8DC5	;	3.21	;	CCHFV GP38 Hoti/Kosovo
8DCY	;	3.62	;	CCHFV GP38 Hoti/Kosovo bound with 13G8 Fab
8DDK	;	3.86	;	CCHFV GP38 Hoti/Kosovo bound with CC5_17
4Y5O	;	2.35	;	CCM2 HHD in complex with MEKK3 NPB1
4WJ7	;	2.753	;	CCM2 PTB domain in complex with KRIT1 NPxY/F3
4TVQ	;	2.8	;	CCM3 in complex with CCM2 LD-like motif
4LIW	;	1.6	;	CcmK1 Carboxysome Shell Protein from Synechocystis PCC6803, L11K Point Mutant
3SSS	;	2.05	;	CcmK1 with residues 103-113 deleted
3SSQ	;	2.2	;	CcmK2 - form 1 dodecamer
3SSR	;	1.6	;	CcmK2 dodecamer - form 2
4N8F	;	2.0	;	CcmL from Thermosynechococcus elongatus BP-1
7US9	;	3.8	;	CCoV-HuPn-2018 S in the proximal conformation (local refinement of domain 0)
7USB	;	3.1	;	CCoV-HuPn-2018 S in the swung out conformation (local refinement of domain 0)
4XV4	;	1.69	;	CcP gateless cavity
4XV5	;	1.65	;	CcP gateless cavity
4XV6	;	1.55	;	CcP gateless cavity
4XV7	;	1.62	;	CcP gateless cavity
4XV8	;	1.57	;	CcP gateless cavity
5U5U	;	1.33	;	CcP gateless cavity
5U5V	;	1.222	;	CcP gateless cavity
5U5W	;	1.29	;	CcP gateless cavity
5U5X	;	1.55	;	CcP gateless cavity
5U5Y	;	1.3	;	CcP gateless cavity
5U5Z	;	1.26	;	CcP gateless cavity
5U60	;	1.5	;	CcP gateless cavity
5U61	;	1.222	;	CcP gateless cavity
5UG2	;	1.34	;	CcP gateless cavity
3HQ8	;	2.4	;	CcpA from G. sulfurreducens S134P/V135K variant
3HQ7	;	2.31	;	CcpA from G. sulfurreducens, G94K/K97Q/R100I variant
3HQ9	;	1.52	;	CcpA from G. sulfurreducens, S134P variant
3OQO	;	2.97	;	Ccpa-hpr-ser46p-syn cre
7Y8Z	;	1.6	;	CcpS
7Y86	;	1.5	;	CcpS mutant
2RLL	;		;	CCR5 Nt(7-15)
2MZX	;		;	CCR5-ECL2 helical structure, residues Q186-T195
8SH9	;	2.7	;	CCT G beta 5 complex best PhLP1 class
8SHO	;	3.0	;	CCT G beta 5 complex close state 11
8SFF	;	3.2	;	CCT G beta 5 complex closed state 0
8SG8	;	3.0	;	CCT G beta 5 complex closed state 1
8SHD	;	2.9	;	CCT G beta 5 complex closed state 10
8SHQ	;	2.9	;	CCT G beta 5 complex closed state 12
8SHP	;	3.0	;	CCT G beta 5 complex closed state 13
8SHT	;	3.0	;	CCT G beta 5 complex closed state 14
8SGL	;	2.9	;	CCT G beta 5 complex closed state 15
8SGC	;	2.9	;	CCT G beta 5 complex closed state 2
8SG9	;	2.9	;	CCT G beta 5 complex closed state 3
8SHL	;	3.0	;	CCT G beta 5 complex closed state 5
8SHG	;	2.8	;	CCT G beta 5 complex closed state 9
8SGQ	;	3.7	;	CCT G beta 5 complex intermediate state
8SHA	;	3.0	;	CCT-G beta 5 complex closed state 4
8SHN	;	2.8	;	CCT-G beta 5 complex closed state 6
8SHF	;	3.0	;	CCT-G beta 5 complex closed state 7
8SHE	;	2.8	;	CCT-G beta 5 complex closed state 8
5MHQ	;	1.3	;	CCT068127 in complex with CDK2
8T8O	;	4.0	;	CCW Flagellar Switch Complex - FliF, FliG, FliM, and FliN forming 34-mer C-ring from Salmonella
4LYC	;	1.35	;	Cd ions within a lysoyzme single crystal
1G3W	;	2.4	;	CD-CYS102SER DTXR
7X4G	;	2.6	;	CD-NTase ClCdnE in complex with substrate UTP
7X4P	;	1.6	;	CD-NTase EfCdnE in complex with intermediate pppUpU
8HYK	;	2.021	;	CD-NTase EfCdnE in complex with intermediate pppU[2'-5']p
7UTW	;	1.33	;	Cd-substituted Horse Liver Alcohol Dehydrogenase in Complex with NADH and N-Cyclohexylformamide
6TSI	;	2.38	;	cd1 nitrite reductase NirS with bound dihydro-heme d1
1CD1	;	2.67	;	CD1(MOUSE) ANTIGEN PRESENTING MOLECULE
2O7N	;	1.75	;	CD11A (LFA1) I-domain complexed with 7A-[(4-cyanophenyl)methyl]-6-(3,5-dichlorophenyl)-5-oxo-2,3,5,7A-tetrahydro-1H-pyrrolo[1,2-A]pyrrole-7-carbonitrile
2ICA	;	1.56	;	CD11a (LFA1) I-domain complexed with BMS-587101 aka 5-[(5S, 9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro [4.4]non-7-yl]methyl]-3-thiophenecarboxylicacid
3M6F	;	1.85	;	CD11A I-domain complexed with 6-((5S,9R)-9-(4-CYANOPHENYL)-3-(3,5-DICHLOROPHENYL)-1-METHYL-2,4-DIOXO-1,3,7- TRIAZASPIRO[4.4]NON-7-YL)NICOTINIC ACID
1ZOO	;	3.0	;	CD11A I-DOMAIN WITH BOUND MAGNESIUM ION
1ZOP	;	2.0	;	CD11A I-DOMAIN WITH BOUND MAGNESIUM ION
1LFA	;	1.8	;	CD11A I-DOMAIN WITH BOUND MN++
1ZON	;	2.0	;	CD11A I-DOMAIN WITHOUT BOUND CATION
6LYN	;	2.776	;	CD146 D4-D5/AA98 Fab
4X6E	;	2.1	;	CD1a binary complex with lysophosphatidylcholine
4X6F	;	1.91	;	CD1a binary complex with sphingomyelin
4X6D	;	2.98	;	CD1a ternary complex with endogenous lipids and BK6 TCR
4X6C	;	2.8	;	CD1a ternary complex with lysophosphatidylcholine and BK6 TCR
7KOZ	;	2.25	;	CD1a-36:2 SM binary complex
7KP0	;	2.4	;	CD1a-42:1 SM binary complex
7KP1	;	2.02	;	CD1a-42:2 SM binary complex
7RYO	;	3.0	;	CD1a-dideoxymycobactin-gdTCR complex
7RYM	;	3.2	;	CD1a-endo-gdTCR complex
6NUX	;	2.2	;	CD1a-lipid binary complex
7SH4	;	2.0	;	CD1a-phosphatidylglycerol binary structure
7RYN	;	2.7	;	CD1a-sulfatide-gdTCR complex
1GZP	;	2.8	;	CD1b in complex with GM2 ganglioside
1GZQ	;	2.26	;	CD1b in complex with Phophatidylinositol
3OV6	;	2.502	;	CD1c in complex with MPM (mannosyl-beta1-phosphomycoketide)
6C15	;	3.21	;	CD1c in complex with phosphatidylcholine
4ONO	;	2.705	;	CD1c in complex with PM (phosphomycoketide)
7MX4	;	1.73	;	CD1c with antigen analogue 1
7MXF	;	2.0	;	CD1c with antigen analogue 2
7MXH	;	2.11	;	CD1c with antigen analogue 3
1CDC	;	2.0	;	CD2, N-TERMINAL DOMAIN (1-99), TRUNCATED FORM
5VL3	;	3.1	;	CD22 d1-d3 in complex with therapeutic Fab Epratuzumab
7O52	;	2.41	;	CD22 d6-d7 in complex with Fab m971
2H2T	;	1.3	;	CD23 Lectin domain, Calcium 2+-bound
7F9W	;	3.2	;	CD25 in complex with Fab
1L2Z	;		;	CD2BP2-GYF domain in complex with proline-rich CD2 tail segment peptide
1XMW	;		;	CD3 EPSILON AND DELTA ECTODOMAIN FRAGMENT COMPLEX IN SINGLE-CHAIN CONSTRUCT
1JBJ	;		;	CD3 Epsilon and gamma Ectodomain Fragment Complex in Single-Chain Construct
3U4H	;	1.878	;	CD38 structure-based inhibitor design using the N1-cyclic inosine 5'-diphosphate ribose template
3U4I	;	2.118	;	CD38 structure-based inhibitor design using the N1-cyclic inosine 5'-diphosphate ribose template
3B71	;	2.82	;	CD4 endocytosis motif bound to the Focal Adhesion Targeting (FAT) domain of the Focal Adhesion Kinase
6OPQ	;	3.8	;	CD4- and 17-bound HIV-1 Env B41 SOSIP frozen with LMNG
6OPN	;	3.5	;	CD4- and 17-bound HIV-1 Env B41 SOSIP in complex with small molecule GO35
5SC6	;	1.327	;	CD44 PanDDA analysis group deposition -- The hyaluronan-binding domain of CD44 in complex with POB0019
5SC7	;	1.197	;	CD44 PanDDA analysis group deposition -- The hyaluronan-binding domain of CD44 in complex with POB0120
5SBP	;	1.275	;	CD44 PanDDA analysis group deposition -- The hyaluronan-binding domain of CD44 in complex with Z1229798311
5SBK	;	1.23	;	CD44 PanDDA analysis group deposition -- The hyaluronan-binding domain of CD44 in complex with Z1258992717
5SBR	;	1.286	;	CD44 PanDDA analysis group deposition -- The hyaluronan-binding domain of CD44 in complex with Z1259341012
5SBM	;	1.14	;	CD44 PanDDA analysis group deposition -- The hyaluronan-binding domain of CD44 in complex with Z1267885772
5SBL	;	1.198	;	CD44 PanDDA analysis group deposition -- The hyaluronan-binding domain of CD44 in complex with Z126932614
5SBY	;	1.217	;	CD44 PanDDA analysis group deposition -- The hyaluronan-binding domain of CD44 in complex with Z1878656559
5SC2	;	1.208	;	CD44 PanDDA analysis group deposition -- The hyaluronan-binding domain of CD44 in complex with Z190780124
5SBW	;	1.148	;	CD44 PanDDA analysis group deposition -- The hyaluronan-binding domain of CD44 in complex with Z2856434874
5SBO	;	1.274	;	CD44 PanDDA analysis group deposition -- The hyaluronan-binding domain of CD44 in complex with Z2856434878
5SC0	;	1.192	;	CD44 PanDDA analysis group deposition -- The hyaluronan-binding domain of CD44 in complex with Z2856434899
5SBV	;	1.109	;	CD44 PanDDA analysis group deposition -- The hyaluronan-binding domain of CD44 in complex with Z31721798
5SBS	;	1.024	;	CD44 PanDDA analysis group deposition -- The hyaluronan-binding domain of CD44 in complex with Z340495298
5SC3	;	1.24	;	CD44 PanDDA analysis group deposition -- The hyaluronan-binding domain of CD44 in complex with Z422471910
5SC1	;	1.165	;	CD44 PanDDA analysis group deposition -- The hyaluronan-binding domain of CD44 in complex with Z431807512
5SBT	;	1.16	;	CD44 PanDDA analysis group deposition -- The hyaluronan-binding domain of CD44 in complex with Z445856640
5SBQ	;	0.988	;	CD44 PanDDA analysis group deposition -- The hyaluronan-binding domain of CD44 in complex with Z44592329
5SBX	;	1.051	;	CD44 PanDDA analysis group deposition -- The hyaluronan-binding domain of CD44 in complex with Z53825479
5SC5	;	1.171	;	CD44 PanDDA analysis group deposition -- The hyaluronan-binding domain of CD44 in complex with Z56827661
5SBN	;	1.181	;	CD44 PanDDA analysis group deposition -- The hyaluronan-binding domain of CD44 in complex with Z57040482
5SBZ	;	1.17	;	CD44 PanDDA analysis group deposition -- The hyaluronan-binding domain of CD44 in complex with Z768399682
5SBU	;	1.044	;	CD44 PanDDA analysis group deposition -- The hyaluronan-binding domain of CD44 in complex with Z839988838
5SC4	;	1.165	;	CD44 PanDDA analysis group deposition -- The hyaluronan-binding domain of CD44 in complex with Z927412236
5IWL	;	2.8	;	CD47-diabody complex
7BBJ	;	2.72	;	CD73 in complex with the humanized antagonistic antibody mAb19
2ARJ	;	2.88	;	CD8alpha-alpha in complex with YTS 105.18 Fab
6JMR	;	4.1	;	CD98hc extracellular domain bound to HBJ127 Fab and MEM-108 Fab
6HVL	;	2.8	;	CdaA complex with c-di-AMP and AMP
8C4R	;	1.55	;	CdaA-adenine complex
8C4M	;	1.51	;	CdaA-Adenosine complex
8C4N	;	1.75	;	CdaA-AMP complex
8C4Q	;	1.45	;	CdaA-Apo
6HVN	;	2.234	;	CdaA-APO Y187A Mutant
8C4O	;	1.97	;	CdaA-ATP complex
8C4J	;	1.83	;	CdaA-compound 4 complex
8C4P	;	1.2	;	CdaA-compound 7 complex
6SBW	;	2.24	;	CdbA Form One
6SBX	;	2.33	;	CdbA Form Two
6XD4	;	2.1	;	CDC-like protein
3KAE	;	2.298	;	Cdc27 N-terminus
4MDK	;	2.6095	;	Cdc34-ubiquitin-CC0651 complex
7M2K	;	2.47	;	CDC34A-Ubiquitin-2ab inhibitor complex
5UPL	;	3.003	;	CDC42 binds PAK4 via an extended GTPase-effector inteface - 2 peptide: PAK4FL, CDC42 - UNREFINED
5UPK	;	2.4	;	CDC42 binds PAK4 via an extended GTPase-effector interface - 3 peptide: PAK4cat, PAK4-N45, CDC42
2QRZ	;	2.4	;	Cdc42 bound to GMP-PCP: Induced Fit by Effector is Required
1E0A	;		;	Cdc42 complexed with the GTPase binding domain of p21 activated kinase
1AJE	;		;	CDC42 FROM HUMAN, NMR, 20 STRUCTURES
2KB0	;		;	Cdc42(T35A)
1CF4	;		;	CDC42/ACK GTPASE-BINDING DOMAIN COMPLEX
1AN0	;	2.8	;	CDC42HS-GDP COMPLEX
6OMB	;	3.7	;	Cdc48 Hexamer (Subunits A to E) with substrate bound to the central pore
6OPC	;	3.7	;	Cdc48 Hexamer in a complex with substrate and Shp1(Ubx Domain)
6CHS	;	4.3	;	Cdc48-Npl4 complex in the presence of ATP-gamma-S
6OAA	;	4.1	;	Cdc48-Npl4 complex processing poly-ubiquitinated substrate in the presence of ADP-BeFx, state 1
6OAB	;	3.6	;	Cdc48-Npl4 complex processing poly-ubiquitinated substrate in the presence of ADP-BeFx, state 2
6OA9	;	3.9	;	Cdc48-Npl4 complex processing poly-ubiquitinated substrate in the presence of ATP
1GGW	;		;	CDC4P FROM SCHIZOSACCHAROMYCES POMBE
6YA8	;	1.79	;	Cdc7-Dbf4 bound to ADP-BeF3
6YA7	;	1.67	;	Cdc7-Dbf4 bound to an Mcm2-S40 derived bivalent substrate
7MEA	;	1.73	;	CDD-1 beta-lactamase in imidazole/MPD 1 minute avibactam complex
7MEF	;	1.9	;	CDD-1 beta-lactamase in imidazole/MPD 10 minute avibactam complex
7MEB	;	1.8	;	CDD-1 beta-lactamase in imidazole/MPD 2 minute avibactam complex
7MEG	;	1.8	;	CDD-1 beta-lactamase in imidazole/MPD 30 minute avibactam complex
7ME9	;	1.7	;	CDD-1 beta-lactamase in imidazole/MPD 30 seconds avibactam complex
7MEC	;	1.73	;	CDD-1 beta-lactamase in imidazole/MPD 4 minute avibactam complex
7MED	;	1.78	;	CDD-1 beta-lactamase in imidazole/MPD 5 minute avibactam complex
7MEE	;	1.88	;	CDD-1 beta-lactamase in imidazole/MPD 6 minute avibactam complex
7MEH	;	1.8	;	CDD-1 beta-lactamase in imidazole/MPD 60 minute avibactam complex
5J5V	;	2.75	;	CdiA-CT from uropathogenic Escherichia coli in complex with cognate immunity protein and CysK
5J43	;	2.7	;	CdiA-CT from uropathogenic Escherichia coli in complex with CysK
5J4A	;	2.004	;	CdiA-CT toxin from Burkholderia pseudomallei E479 in complex with cognate CdiI immunity protein
4G6V	;	2.64	;	CdiA-CT/CdiI toxin and immunity complex from Burkholderia pseudomallei
4NTQ	;	2.4	;	CdiA-CT/CdiI toxin and immunity complex from Enterobacter cloacae
4G6U	;	2.353	;	CdiA-CT/CdiI toxin and immunity complex from Escherichia coli
4ZQU	;	2.09	;	CdiA-CT/CdiI toxin and immunity complex from Yersinia pseudotuberculosis
6WIL	;	2.4	;	CdiB from Acinetobacter baumannii
6WIM	;	2.6	;	CdiB from Escherichia coli
4ZQW	;	2.001	;	CdiI from Escherichia coli EC869 in complex with a macrocyclic peptide
4ZQV	;	1.803	;	CdiI Immunity protein from Yersinia kristensenii
3EZR	;	1.9	;	CDK-2 with indazole inhibitor 17 bound at its active site
3EZV	;	1.99	;	CDK-2 with indazole inhibitor 9 bound at its active site
3F5X	;	2.4	;	CDK-2-Cyclin complex with indazole inhibitor 9 bound at its active site
4YC6	;	2.6	;	CDK1/CKS1
6GU7	;	2.75	;	CDK1/Cks2 in complex with AZD5438
6GU6	;	2.33	;	CDK1/Cks2 in complex with Dinaciclib
6GU3	;	2.65	;	CDK1/CyclinB/Cks2 in complex with AZD5438
6GU4	;	2.73	;	CDK1/CyclinB/Cks2 in complex with CGP74514A
6GU2	;	2.0	;	CDK1/CyclinB/Cks2 in complex with Flavopiridol
4YC3	;	2.7	;	CDK1/CyclinB1/CKS2 Apo
5LQF	;	2.06	;	CDK1/CyclinB1/CKS2 in complex with NU6102
7UKZ	;	2.6	;	CDK11 in complex with small molecule inhibitor OTS964
1R78	;	2.0	;	CDK2 complex with a 4-alkynyl oxindole inhibitor
1KE5	;	2.2	;	CDK2 complexed with N-methyl-4-{[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}benzenesulfonamide
7ZPC	;	1.4	;	CDK2 in complex 9K-DOS
3PXQ	;	1.9	;	CDK2 in complex with 3 molecules of 8-anilino-1-naphthalene sulfonate
4ACM	;	1.63	;	CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL]SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE
1H01	;	1.79	;	CDK2 in complex with a disubstituted 2, 4-bis anilino pyrimidine CDK4 inhibitor
1H08	;	1.8	;	CDK2 in complex with a disubstituted 2, 4-bis anilino pyrimidine CDK4 inhibitor
1H00	;	1.6	;	CDK2 in complex with a disubstituted 4, 6-bis anilino pyrimidine CDK4 inhibitor
1H07	;	1.85	;	CDK2 in complex with a disubstituted 4, 6-bis anilino pyrimidine CDK4 inhibitor
1V1K	;	2.31	;	CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
4D1Z	;	1.851	;	CDK2 in complex with a Luciferin derivate
2VV9	;	1.9	;	CDK2 in complex with an imidazole piperazine
1URW	;	1.6	;	CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-b]PYRIDAZINE
6GUH	;	1.5	;	CDK2 in complex with AZD5438
6GUK	;	1.3	;	CDK2 in complex with CGP74514A
7RA5	;	1.67	;	CDK2 IN COMPLEX WITH COMPOUND 4
6OQI	;	2.0	;	CDK2 in complex with Cpd14 (5-fluoro-4-(4-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]azepin-3-yl)-N-(5-(4-methylpiperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine)
4KD1	;	1.7	;	CDK2 in complex with Dinaciclib
6Q3C	;	1.29	;	CDK2 in complex with FragLite1
6Q4B	;	1.12	;	CDK2 in complex with FragLite13
6Q4A	;	1.13	;	CDK2 in complex with FragLite14
6Q4C	;	1.73	;	CDK2 in complex with FragLite16
6Q3B	;	1.11	;	CDK2 in complex with FragLite2
6Q3F	;	1.18	;	CDK2 in complex with FragLite2
6Q4D	;	1.07	;	CDK2 in complex with FragLite31
6Q4F	;	1.21	;	CDK2 in complex with FragLite32
6Q4E	;	1.06	;	CDK2 in complex with FragLite33
6Q4J	;	1.05	;	CDK2 in complex with FragLite34
6Q4I	;	1.11	;	CDK2 in complex with FragLite35
6Q4H	;	1.0	;	CDK2 in complex with FragLite36
6Q4G	;	0.98	;	CDK2 in complex with FragLite37
6Q4K	;	1.06	;	CDK2 in complex with FragLite38
6Q49	;	1.0	;	CDK2 in complex with FragLite6
6Q48	;	1.03	;	CDK2 in complex with FragLite7
3QL8	;	1.9	;	CDK2 in complex with inhibitor JWS-6-260
3QZF	;	2.0	;	CDK2 in complex with inhibitor JWS-6-52
3QZG	;	1.75	;	CDK2 in complex with inhibitor JWS-6-76
3PXY	;	1.8	;	CDK2 in complex with inhibitor JWS648
3R1Q	;	1.85	;	CDK2 in complex with inhibitor KVR-1-102
3QZH	;	1.95	;	CDK2 in complex with inhibitor KVR-1-124
3QZI	;	1.75	;	CDK2 in complex with inhibitor KVR-1-126
3R1S	;	1.8	;	CDK2 in complex with inhibitor KVR-1-127
3R1Y	;	1.8	;	CDK2 in complex with inhibitor KVR-1-134
3R28	;	1.75	;	CDK2 in complex with inhibitor KVR-1-140
3QWJ	;	1.75	;	CDK2 in complex with inhibitor KVR-1-142
3QWK	;	1.85	;	CDK2 in complex with inhibitor KVR-1-150
3ROY	;	1.75	;	CDK2 in complex with inhibitor KVR-1-154
3RPO	;	1.75	;	CDK2 in complex with inhibitor KVR-1-156
3R6X	;	1.75	;	CDK2 in complex with inhibitor KVR-1-158
3RAI	;	1.7	;	CDK2 in complex with inhibitor KVR-1-160
3R71	;	1.75	;	CDK2 in complex with inhibitor KVR-1-162
3R73	;	1.7	;	CDK2 in complex with inhibitor KVR-1-164
3QX2	;	1.75	;	CDK2 in complex with inhibitor KVR-1-190
3R7E	;	1.9	;	CDK2 in complex with inhibitor KVR-1-67
3R7I	;	1.85	;	CDK2 in complex with inhibitor KVR-1-74
3R7U	;	1.75	;	CDK2 in complex with inhibitor KVR-1-75
3QX4	;	1.92	;	CDK2 in complex with inhibitor KVR-1-78
3QXO	;	1.75	;	CDK2 in complex with inhibitor KVR-1-84
3R7V	;	1.95	;	CDK2 in complex with inhibitor KVR-1-9
3RM7	;	1.85	;	CDK2 in complex with inhibitor KVR-1-91
3RM6	;	1.6	;	CDK2 in complex with inhibitor KVR-2-80
3R7Y	;	1.9	;	CDK2 in complex with inhibitor KVR-2-88
3R83	;	1.75	;	CDK2 in complex with inhibitor KVR-2-92
3QQF	;	1.75	;	CDK2 in complex with inhibitor L1
3QQJ	;	1.7	;	CDK2 in complex with inhibitor L2
3QQH	;	1.87	;	CDK2 in complex with inhibitor L2-2
3QQG	;	1.9	;	CDK2 in complex with inhibitor L2-5
3QQL	;	1.85	;	CDK2 in complex with inhibitor L3
3R8M	;	1.8	;	CDK2 in complex with inhibitor L3-3
3R8L	;	1.9	;	CDK2 in complex with inhibitor L3-4
3QQK	;	1.86	;	CDK2 in complex with inhibitor L4
3RJC	;	1.85	;	CDK2 in complex with inhibitor L4-12
3S00	;	1.8	;	CDK2 in complex with inhibitor L4-14
3QRU	;	1.95	;	CDK2 in complex with inhibitor NSK-MC1-12
3R8P	;	1.8	;	CDK2 in complex with inhibitor NSK-MC1-6
3QRT	;	1.75	;	CDK2 in complex with inhibitor NSK-MC2-55
3R8U	;	2.0	;	CDK2 in complex with inhibitor RC-1-132
3R8V	;	1.9	;	CDK2 in complex with inhibitor RC-1-135
3R8Z	;	1.85	;	CDK2 in complex with inhibitor RC-1-136
3QTQ	;	1.8	;	CDK2 in complex with inhibitor RC-1-137
3S0O	;	2.0	;	CDK2 in complex with inhibitor RC-1-138
3QTR	;	1.85	;	CDK2 in complex with inhibitor RC-1-148
3QTS	;	1.9	;	CDK2 in complex with inhibitor RC-2-12
3QTW	;	1.85	;	CDK2 in complex with inhibitor RC-2-13
3QTU	;	1.82	;	CDK2 in complex with inhibitor RC-2-132
3R9D	;	1.95	;	CDK2 in complex with inhibitor RC-2-135
3R9H	;	2.1	;	CDK2 in complex with inhibitor RC-2-142
3R9O	;	1.9	;	CDK2 in complex with inhibitor RC-2-143
3R9N	;	1.75	;	CDK2 in complex with inhibitor RC-2-21
3RAH	;	1.75	;	CDK2 in complex with inhibitor RC-2-22
3RZB	;	1.9	;	CDK2 in complex with inhibitor RC-2-23
3RAK	;	1.75	;	CDK2 in complex with inhibitor RC-2-32
3RMF	;	1.75	;	CDK2 in complex with inhibitor RC-2-33
3RAL	;	1.75	;	CDK2 in complex with inhibitor RC-2-34
3QTX	;	1.95	;	CDK2 in complex with inhibitor RC-2-35
3QTZ	;	2.0	;	CDK2 in complex with inhibitor RC-2-36
3QU0	;	1.95	;	CDK2 in complex with inhibitor RC-2-38
3S1H	;	1.75	;	CDK2 in complex with inhibitor RC-2-39
3RPY	;	1.9	;	CDK2 in complex with inhibitor RC-2-40
3RPR	;	1.75	;	CDK2 in complex with inhibitor RC-2-49
3RK7	;	1.8	;	CDK2 in complex with inhibitor RC-2-71
3RK5	;	2.0	;	CDK2 in complex with inhibitor RC-2-72
3RKB	;	2.0	;	CDK2 in complex with inhibitor RC-2-73
3RK9	;	1.85	;	CDK2 in complex with inhibitor RC-2-74
3RPV	;	1.8	;	CDK2 in complex with inhibitor RC-2-88
3RNI	;	1.95	;	CDK2 in complex with inhibitor RC-3-86
3QXP	;	1.75	;	CDK2 in complex with inhibitor RC-3-89
4GCJ	;	1.42	;	CDK2 in complex with inhibitor RC-3-89
3SQQ	;	1.85	;	CDK2 in complex with inhibitor RC-3-96
3PY0	;	1.75	;	CDK2 in complex with inhibitor SU9516
3UNJ	;	1.9001	;	CDK2 in complex with inhibitor YL1-038-31
3UNK	;	2.1	;	CDK2 in complex with inhibitor YL5-083
4D1X	;	2.1	;	CDK2 in complex with Luciferin
3TIZ	;	2.02	;	CDK2 in complex with NSC 111848
4EZ3	;	2.0	;	CDK2 in complex with NSC 134199
3TIY	;	1.84	;	CDK2 in complex with NSC 35676
4ERW	;	2.0	;	CDK2 in complex with staurosporine
4EZ7	;	2.49	;	CDK2 in complex with staurosporine and 2 molecules of 8-anilino-1-naphthalene sulfonic acid
3TI1	;	1.99	;	CDK2 in complex with SUNITINIB
2W17	;	2.15	;	CDK2 in complex with the imidazole pyrimidine amide, compound (S)-8b
3PXF	;	1.8	;	CDK2 in complex with two molecules of 8-anilino-1-naphthalene sulfonate
8FP5	;	1.7	;	CDK2 liganded with ATP and Mg2+
7UG1	;	1.84	;	CDK2 liganded with para chloro ANS
3PXZ	;	1.7	;	CDK2 ternary complex with JWS648 and ANS
3PY1	;	2.05	;	CDK2 ternary complex with SU9516 and ANS
7M2F	;	1.632	;	CDK2 with compound 14 inhibitor with carboxylate
4RJ3	;	1.63	;	CDK2 with EGFR inhibitor compound 8
6YL6	;	1.7	;	Cdk2(F80C)
6YLK	;	1.65	;	Cdk2(F80C) with Covalent Adduct TK22 at F80C
6YL1	;	1.66	;	Cdk2(F80C) with Covalent Adduct TK37 at F80C
5OO1	;	2.0	;	Cdk2(F80C, C177A) covalent adduct with C37 at F80C
5OSM	;	1.77	;	Cdk2(F80C, C177A) with covalent adduct at C80
5OO3	;	1.73	;	Cdk2(F80C, C177A) with covalent ligand at F80C
5OO0	;	1.6	;	Cdk2(WT) covalent adduct with D28 at C177
5OSJ	;	1.83	;	Cdk2(WT) with covalent adduct at C177
8VQ4	;	1.9	;	CDK2-CyclinE1 in complex with allosteric inhibitor I-125A.
8VQ3	;	1.84	;	CDK2-CyclinE1 in complex with allosteric inhibitor I-198.
2I40	;	2.8	;	Cdk2/Cyclin A complexed with a thiophene carboxamide inhibitor
5CYI	;	2.0	;	CDK2/Cyclin A covalent complex with 6-(cyclohexylmethoxy)-N-(4-(vinylsulfonyl)phenyl)-9H-purin-2-amine (NU6300)
1H25	;	2.5	;	CDK2/Cyclin A in complex with an 11-residue recruitment peptide from retinoblastoma-associated protein
5NEV	;	2.97	;	CDK2/Cyclin A in complex with compound 73
6ATH	;	1.82	;	Cdk2/cyclin A/p27-KID-deltaC
7B7S	;	2.54	;	CDK2/cyclin A2 in complex with 3H-pyrazolo[4,3-f]quinoline-based derivative HSD1368
7ACK	;	1.8	;	CDK2/cyclin A2 in complex with an imidazo[1,2-c]pyrimidin-5-one inhibitor
6RIJ	;	2.2	;	CDK2/cyclin A2 in complex with open-ring 5-nitrosopyrimidine inhibitor LC436
6GVA	;	2.15	;	CDK2/cyclin A2 in complex with pyrazolo[4,3-d]pyrimidine inhibitor LGR4455
8B54	;	2.6	;	CDK2/cyclin A2 in complex with pyrazolo[4,3-d]pyrimidine inhibitor LGR6768
3EOC	;	3.2	;	Cdk2/CyclinA complexed with a imidazo triazin-2-amine
3EID	;	3.15	;	CDK2/CyclinA complexed with a pyrazolopyridazine inhibitor
3EJ1	;	3.22	;	CDK2/CyclinA complexed with a pyrazolopyridazine inhibitor
1H24	;	2.5	;	CDK2/CyclinA in complex with a 9 residue recruitment peptide from E2F
1H28	;	2.8	;	CDK2/CyclinA in complex with an 11-residue recruitment peptide from p107
1H27	;	2.2	;	CDK2/CyclinA in complex with an 11-residue recruitment peptide from p27
1H26	;	2.24	;	CDK2/CyclinA in complex with an 11-residue recruitment peptide from p53
6GUE	;	1.99	;	CDK2/CyclinA in complex with AZD5438
6GUF	;	2.65	;	CDK2/CyclinA in complex with CGP74514A
3MY5	;	2.1	;	CDk2/cyclinA in complex with DRB
6GUB	;	2.52	;	CDK2/CyclinA in complex with Flavopiridol
6GUC	;	2.0	;	CDK2/CyclinA in complex with SU9516
3NUP	;	2.6	;	CDK6 (monomeric) in complex with inhibitor
3NUX	;	2.7	;	CDK6 (monomeric) in complex with inhibitor
4EZ5	;	2.7	;	CDK6 (monomeric) in complex with inhibitor
6OQL	;	2.707	;	CDK6 in complex with Cpd13 (R)-5-fluoro-4-(4-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]azepin-3-yl)-N-(5-(4-methylpiperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine
6OQO	;	1.977	;	CDK6 in complex with Cpd24 N-(5-(6-ethyl-2,6-diazaspiro[3.3]heptan-2-yl)pyridin-2-yl)-5-fluoro-4-(4-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]azepin-3-yl)pyrimidin-2-amine
5IDP	;	2.65	;	CDK8-CYCC IN COMPLEX WITH (3-Amino-1H-indazol-5-yl)-[(S)-2-(4-fluoro-phenyl)-piperidin-1-yl]-methanone
5HBH	;	2.5	;	CDK8-CYCC IN COMPLEX WITH 5-{5-Chloro-4-[1-(2-methoxy-ethyl)-1,8-diaza-spiro[4.5]dec-8-yl]-pyridin-3-yl}-1-methyl-1,3-dihydro-benzo[c]isothiazole 2,2-dioxide
5I5Z	;	2.6	;	CDK8-CYCC IN COMPLEX WITH 8-(1-Methyl-2,2-dioxo-2,3-dihydro-1H-2l6-benzo[c]isothiazol-5-yl)-[1,6]naphthyridine-2-carboxylic acid methylamide
5HBJ	;	3.0	;	CDK8-CYCC IN COMPLEX WITH 8-[2-Amino-3-chloro-5-(1-methyl-1H-indazol-5-yl)-pyridin-4-yl]-2,8-diaza-spiro[4.5]decan-1-one
5FGK	;	2.36	;	CDK8-CYCC IN COMPLEX WITH 8-[3-(3-Amino-1H-indazol-6-yl)-5-chloro- pyridine-4-yl]-2,8-diaza-spiro[4.5]decan-1-one
5HBE	;	2.38	;	CDK8-CYCC IN COMPLEX WITH 8-[3-Chloro-5-(1-methyl-2,2-dioxo-2, 3-dihydro-1H-2l6-benzo[c]isothiazol-5-yl)-pyridin- 4-yl]-1-oxa-3,8-diaza-spiro[4.5]decan-2-one
5XS2	;	2.04	;	CDK8-CYCC IN COMPLEX WITH COMPOUND 17:3-chloro-4-(4-pyridyl)-1H-pyrrole-2-carboxamide
5IDN	;	2.26	;	CDK8-CYCC IN COMPLEX WITH [(S)-2-(4-Chloro-phenyl)-pyrrolidin-1-yl]-(3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-methanone
5ICP	;	2.18	;	CDK8-CYCC IN COMPLEX WITH [(S)-2-(4-Chloro-phenyl)-pyrrolidin-1-yl]-(5-methyl-imidazo[5,1-b][1,3,4]thiadiazol-2-yl)-methanone
5HNB	;	2.35	;	CDK8-CYCC IN COMPLEX WITH [6-Hydroxy-3-(3-methyl-benzyl)-1H-indazol-5-yl]-((S)-3-hydroxy-pyrrolidin-1-yl)-methanone
5BNJ	;	2.64	;	CDK8/CYCC IN COMPLEX WITH 8-{3-Chloro-5-[4-(1-methyl-1H-pyrazol-4-yl)-phenyl]-pyridin- 4-yl}-2,8-diaza-spiro[4.5]decan-1-one
5HVY	;	2.39	;	CDK8/CYCC IN COMPLEX WITH COMPOUND 20
6T41	;	2.45	;	CDK8/Cyclin C in complex with N-(4-chlorobenzyl)isoquinolin-4-amine
6TPA	;	2.8	;	CDK8/CyclinC in complex with drug ETP-50775
6Z45	;	3.37	;	CDK9-Cyclin-T1 complex bound by compound 24
3TN8	;	2.95	;	CDK9/cyclin T in complex with CAN508
3TNH	;	3.202	;	CDK9/cyclin T in complex with CAN508
8K5R	;	3.751	;	CDK9/cyclin T1 in complex with KB-0742
2GSJ	;	1.73	;	cDNA cloning and 1.75A crystal structure determination of PPL2, a novel chimerolectin from Parkia platycephala seeds exhibiting endochitinolytic activity
2LT4	;		;	CdnLNt from Myxoccoccus xanthus
4YUQ	;	2.8	;	CDPK1 from Eimeria tenella in complex with inhibitor UW1354
4YZB	;	2.9	;	CDPK1 from Eimeria tenella in complex with inhibitor UW1521
4MXA	;	3.0	;	CDPK1 from Neospora caninum in complex with inhibitor RM-1-132
4MX9	;	3.1	;	CDPK1 from Neospora caninum in complex with inhibitor UW1294
4YGA	;	2.94	;	CDPK1, from Toxoplasma gondii, bound to inhibitory VHH-1B7
8T6J	;	3.5	;	CDPPB-bound inactive mGlu5
4LYB	;	1.21	;	CdS within a lysoyzme single crystal
4QQ0	;	2.0	;	CdsD - The structural protein of the Type III secretion system of Chlamydia trachomatis: C-terminal domain
6RP4	;	2.5	;	CDT of SidD, deAMPylase from Legionella pneumophila
6OKS	;	4.2	;	CDTb Double Heptamer Long Form Mask 1 Modeled from Cryo-EM Map Reconstructed using C7 Symmetry
6OKT	;	4.2	;	CDTb Double Heptamer Long Form Mask 1 Modeled from Cryo-EM Map Reconstructed using C7 Symmetry
6OKU	;	3.8	;	CDTb Double Heptamer Long Form Mask 3 Modeled from Cryo-EM Map Reconstructed using C7 Symmetry
6O2M	;	6.3	;	CDTb Double Heptamer Long Form Modeled from Cryo-EM Map Reconstructed using C7 Symmetry
6O2O	;	4.53	;	CDTb Double Heptamer Short Form Modeled from Cryo-EM Map Reconstructed using C1 Symmetry
6O2N	;	3.7	;	CDTb Double Heptamer Short Form Modeled from Cryo-EM Map Reconstructed using C7 Symmetry
6OKR	;	4.2	;	CDTb Pre-Insertion form Modeled from Cryo-EM Map Reconstructed using C7 Symmetry
6V8W	;	2.8	;	CDYL2 chromodomain in complex with a synthetic peptide
5V84	;	2.7	;	CECR2 in complex with Cpd6 (6-allyl-N,2-dimethyl-7-oxo-N-(1-(1-phenylethyl)piperidin-4-yl)-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-4-carboxamide)
1F0H	;		;	Cecropin A(1-8)-magainin 2(1-12) A2 in dodecylphosphocholine micelles
1F0F	;		;	Cecropin A(1-8)-magainin 2(1-12) gig deletion modification in dodecylphosphocholine micelles
1F0D	;		;	Cecropin A(1-8)-magainin 2(1-12) in dodecylphosphocholine micelles
1F0G	;		;	Cecropin A(1-8)-magainin 2(1-12) L2 in dodecylphosphocholine micelles
1F0E	;		;	Cecropin A(1-8)-magainin 2(1-12) modified gig to P in dodecylphosphocholine micelles
3QWY	;	2.52	;	CED-2
3QWX	;	2.01	;	CED-2 1-174
6THG	;	4.074	;	Cedar Virus attachment glycoprotein (G) in complex with human ephrin-B1
2Z2M	;	2.6	;	Cefditoren-Acylated Penicillin-Binding Protein 2X (PBP2X) from Streptococcus pneumoniae
2ZQA	;	0.95	;	Cefotaxime acyl-intermediate structure of class a beta-lacta Toho-1 E166A/R274N/R276N triple mutant
1CEF	;	2.04	;	CEFOTAXIME COMPLEXED WITH THE STREPTOMYCES R61 DD-PEPTIDASE
2ZQD	;	1.19	;	Ceftazidime acyl-intermediate structure of class a beta-lact Toho-1 E166A/R274N/R276N triple mutant
3N9M	;	2.493	;	ceKDM7A from C.elegans, alone
3PUQ	;	2.25	;	CEKDM7A from C.Elegans, complex with alpha-KG
3PUR	;	2.1	;	CEKDM7A from C.Elegans, complex with D-2-HG
3N9L	;	2.796	;	ceKDM7A from C.elegans, complex with H3K4me3 peptide and NOG
3N9Q	;	2.3	;	ceKDM7A from C.elegans, complex with H3K4me3 peptide, H3K27me2 peptide and NOG
3N9O	;	2.309	;	ceKDM7A from C.elegans, complex with H3K4me3 peptide, H3K9me2 peptide and NOG
3N9P	;	2.388	;	ceKDM7A from C.elegans, complex with H3K4me3K27me2 peptide and NOG
3N9N	;	2.299	;	ceKDM7A from C.elegans, complex with H3K4me3K9me2 peptide and NOG
1QJW	;	1.9	;	CEL6A (Y169F) WITH A NON-HYDROLYSABLE CELLOTETRAOSE
1HGW	;	2.1	;	CEL6A D175A mutant
1HGY	;	2.2	;	CEL6A D221A mutant
1QK0	;	2.1	;	CEL6A WITH A NON-HYDROLYSABLE CELLOTETRAOSE
3ALP	;	2.804	;	Cell adhesion protein
4DRR	;	1.5	;	Cell attachment protein VP8* of a human rotavirus specifically interacts with A-type histo-blood group antigen
4DRV	;	1.56	;	Cell attachment protein VP8* of a human rotavirus specifically interacts with A-type histo-blood group antigen
4DS0	;	1.56	;	Cell attachment protein VP8* of a human rotavirus specifically interacts with A-type histo-blood group antigen
2CEA	;	2.75	;	CELL DIVISION PROTEIN FTSH
6RVM	;	2.155	;	Cell division protein FtsZ from Staphylococcus aureus, apo form
7AL1	;	1.4	;	Cell division protein SepF from Methanobrevibacter smithii
7AL2	;	2.701	;	Cell division protein SepF from Methanobrevibacter smithii in complex with FtsZ-CTD
6SAT	;	1.6	;	Cell Division Protein SepF in complex with C-terminal domain of FtsZ
6SCP	;	1.8	;	Cell Division Protein SepF in complex with C-terminal domain of FtsZ
6SCQ	;	1.5	;	Cell Division Protein SepF in complex with C-terminal domain of FtsZ
6SCS	;	2.2	;	Cell Division Protein SepF in complex with C-terminal domain of FtsZ
2FPH	;	1.7	;	Cell division protein ylmH from Streptococcus pneumoniae
6GPZ	;	1.6	;	Cell division regulator GpsB in complex with peptide fragment of L. monocytogenes Penicillin Binding Protein PBPA1
6GQA	;	1.9	;	Cell division regulator S. pneumoniae GpsB
6GP7	;	1.95002	;	Cell division regulator, B. subtilis GpsB, in complex with peptide fragment of Penicillin Binding Protein PBP1A
6GQN	;	1.8	;	Cell division regulator, S. pneumoniae GpsB, in complex with peptide fragment of Penicillin Binding Protein PBP2a
8HD0	;	3.11	;	Cell divisome sPG hydrolysis machinery FtsEX-EnvC
3R4S	;	2.15	;	Cell entry of botulinum neurotoxin type C is dependent upon interaction with two ganglioside molecules
3R4U	;	2.2	;	Cell entry of botulinum neurotoxin type C is dependent upon interaction with two ganglioside molecules
5FP3	;	2.05	;	Cell penetrant inhibitors of the JMJD2 (KDM4) and JARID1 (KDM5) families of histone lysine demethylases
5IX9	;		;	Cell surface anchoring domain
7YL4	;	2.5	;	Cell surface protein YwfG protein (apo form)
7YL6	;	2.95	;	Cell surface protein YwfG protein complexed with alpha-1,2-mannobiose
7YL5	;	3.0	;	Cell surface protein YwfG protein complexed with mannose
6D48	;	1.776	;	Cell Surface Receptor
6D49	;	1.801	;	Cell Surface Receptor in Complex with Ligand at 1.80-A Resolution
6D4A	;	1.751	;	Cell Surface Receptor with Bound Ligand at 1.75-A Resolution
1JZU	;		;	Cell transformation by the myc oncogene activates expression of a lipocalin: analysis of the gene (Q83) and solution structure of its protein product
6HX0	;	1.59	;	Cell wall binding domain of endolysin from Listeria phage A500.
7AQH	;	2.49	;	Cell wall binding domain of the Staphylococcal phage 2638A endolysin
2XPK	;	2.4	;	Cell-penetrant, nanomolar O-GlcNAcase inhibitors selective against lysosomal hexosaminidases
1EGN	;	1.6	;	CELLOBIOHYDROLASE CEL7A (E223S, A224H, L225V, T226A, D262G) MUTANT
5O59	;	1.75	;	Cellobiohydrolase Cel7A from T. atroviride
5O5D	;	1.72	;	Cellobiohydrolase Cel7A from T. atroviride
1Q2B	;	1.6	;	CELLOBIOHYDROLASE CEL7A WITH DISULPHIDE BRIDGE ADDED ACROSS EXO-LOOP BY MUTATIONS D241C AND D249C
1Q2E	;	1.75	;	CELLOBIOHYDROLASE CEL7A WITH LOOP DELETION 245-252 AND BOUND NON-HYDROLYSABLE CELLOTETRAOSE
1GPI	;	1.32	;	Cellobiohydrolase Cel7D (CBH 58) from Phanerochaete chrysosporium. Catalytic module at 1.32 Angstrom resolution
5OA5	;	2.1	;	CELLOBIOHYDROLASE I (CEL7A) FROM HYPOCREA JECORINA WITH IMPROVED THERMAL STABILITY
6GRN	;	1.79	;	CELLOBIOHYDROLASE I (CEL7A) FROM Trichoderma reesei with S-dihydroxypropranolol in the active site
2YOK	;	1.67	;	Cellobiohydrolase I Cel7A from Trichoderma harzianum at 1.7 A resolution
2Y9N	;	2.89	;	Cellobiohydrolase I Cel7A from Trichoderma harzianum at 2.9 A resolution
1BVW	;	1.92	;	CELLOBIOHYDROLASE II (CEL6A) FROM HUMICOLA INSOLENS
2BVW	;	1.7	;	CELLOBIOHYDROLASE II (CEL6A) FROM HUMICOLA INSOLENS IN COMPLEX WITH GLUCOSE AND CELLOTETRAOSE
1CB2	;	2.0	;	CELLOBIOHYDROLASE II, CATALYTIC DOMAIN, MUTANT Y169F
3VOF	;	1.6	;	Cellobiohydrolase mutant, CcCel6C D102A, in the closed form
4ZLI	;	1.8	;	Cellobionic acid phosphorylase - 3-O-beta-D-glucopyranosyl-alpha-D-glucopyranuronic acid complex
4ZLF	;	1.6	;	Cellobionic acid phosphorylase - cellobionic acid complex
4ZLG	;	1.75	;	Cellobionic acid phosphorylase - gluconic acid complex
4ZLE	;	2.1	;	Cellobionic acid phosphorylase - ligand free structure
6MVJ	;	1.809	;	Cellobiose complex Cel45A from Neurospora crassa OR74A
2A3H	;	2.0	;	CELLOBIOSE COMPLEX OF THE ENDOGLUCANASE CEL5A FROM BACILLUS AGARADHERANS AT 2.0 A RESOLUTION
1NAA	;	1.8	;	Cellobiose Dehydrogenase Flavoprotein Fragment in Complex with Cellobionolactam
4QI6	;	3.2	;	Cellobiose dehydrogenase from Myriococcum thermophilum, MtCDH
4QI7	;	2.9	;	Cellobiose dehydrogenase from Neurospora crassa, NcCDH
3S4A	;	1.99	;	Cellobiose phosphorylase from Cellulomonas uda in complex with cellobiose
3S4B	;	2.4	;	Cellobiose phosphorylase from Cellulomonas uda in complex with glucose
3RSY	;	1.81	;	Cellobiose phosphorylase from Cellulomonas uda in complex with sulfate and glycerol
8A3H	;	0.97	;	Cellobiose-derived imidazole complex of the endoglucanase cel5A from Bacillus agaradhaerens at 0.97 A resolution
8H2K	;	1.37	;	Cellodextrin phosphorylase from Clostridium thermocellum mutant - all cysteine residues were substituted with serines
8H2V	;	1.68	;	Cellodextrin phosphorylase from Clostridium thermocellum mutant - all cysteine residues were substituted with serines
8H2W	;	1.21	;	Cellodextrin phosphorylase from Clostridium thermocellum mutant - all cysteine residues were substituted with serines
8HNU	;	2.28	;	Cellodextrin phosphorylase stable variant from Clostridium thermocellum
2Y6G	;	1.3	;	Cellopentaose binding mutated (X-2 L110F) CBM4-2 Carbohydrate Binding Module from a Thermostable Rhodothermus marinus Xylanase
3AMM	;	1.98	;	Cellotetraose complex of cellulase 12A from thermotoga maritima
3A3H	;	1.64	;	CELLOTRIOSE COMPLEX OF THE ENDOGLUCANASE CEL5A FROM BACILLUS AGARADHERANS AT 1.6 A RESOLUTION
2W7X	;	2.07	;	Cellular inhibition of checkpoint kinase 2 and potentiation of cytotoxic drugs by novel Chk2 inhibitor PV1019
2G19	;	1.7	;	Cellular Oxygen Sensing: Crystal Structure of Hypoxia-Inducible Factor Prolyl Hydroxylase (PHD2)
2G1M	;	2.2	;	Cellular Oxygen Sensing: Crystal Structure of Hypoxia-Inducible Factor Prolyl Hydroxylase (PHD2)
4P76	;	2.9	;	Cellular response to a crystal-forming protein
2CBR	;	2.8	;	CELLULAR RETINOIC ACID BINDING PROTEIN I IN COMPLEX WITH A RETINOBENZOIC ACID (AM80)
3CBS	;	2.0	;	CELLULAR RETINOIC ACID BINDING PROTEIN II IN COMPLEX WITH A SYNTHETIC RETINOIC ACID (RO-12 7310)
2CBS	;	2.1	;	CELLULAR RETINOIC ACID BINDING PROTEIN II IN COMPLEX WITH A SYNTHETIC RETINOIC ACID (RO-13 6307)
7RY5	;	2.0	;	Cellular Retinoic Acid Binding Protein II with Bound Inhibitor 4-[6-({4-[(fluorosulfonyl)oxy]phenyl}ethynyl)-4,4-dimethyl-3,4-dihydroquinolin-1(2H)-yl]-4-oxobutanoic acid
7JVG	;	1.4	;	Cellular retinol-binding protein 2 (CRBP2) in complex with 1-arachidonoylglycerol
7JZ5	;	1.567	;	Cellular retinol-binding protein 2 (CRBP2) in complex with 1-arachodonoyl-1-thio-glycerol
7JVY	;	1.3	;	Cellular retinol-binding protein 2 (CRBP2) in complex with 2-arachidonylglyceryl ether
7K3I	;	1.2	;	Cellular retinol-binding protein 2 (CRBP2) in complex with 2-lauroylglycerol
7JWD	;	1.35	;	Cellular retinol-binding protein 2 (CRBP2) in complex with 2-linoleoylglycerol
7JWR	;	1.3	;	Cellular retinol-binding protein 2 (CRBP2) in complex with 2-oleoylglycerol
7JX2	;	1.8	;	Cellular retinol-binding protein 2 (CRBP2) in complex with 2-palmitoylglycerol
1CEO	;	1.9	;	CELLULASE (CELC) MUTANT WITH GLU 140 REPLACED BY GLN
1CEN	;	2.3	;	CELLULASE (CELC) MUTANT WITH GLU 140 REPLACED BY GLN COMPLEXED WITH CELLOHEXAOSE
1EGZ	;	2.3	;	CELLULASE CEL5 FROM ERWINIA CHRYSANTHEMI, A FAMILY GH 5-2 ENZYME
5WH8	;	1.57	;	Cellulase Cel5C_n
1TVN	;	1.41	;	Cellulase cel5G from Pseudoalteromonas haloplanktis, A family GH 5-2 enzyme
2X2Y	;	2.35	;	Cellulomonas fimi endo-beta-1,4-mannanase double mutant
3CUF	;	1.67	;	Cellulomonas fimi Xylanase/Cellulase Cex (Cf Xyn10A) in complex with cellobiose-like isofagomine
3CUG	;	1.68	;	Cellulomonas fimi Xylanase/Cellulase Cex (Cf Xyn10A) in complex with cellotetraose-like isofagomine
3CUH	;	1.89	;	Cellulomonas fimi Xylanase/Cellulase Cex (Cf Xyn10A) in complex with cellotriose-like isofagomine
3CUJ	;	1.7	;	Cellulomonas fimi Xylanase/Cellulase Cex (Cf Xyn10A) in complex with sulfur substituted beta-1,4 xylopentaose.
3CUI	;	1.5	;	Cellulomonas fimi Xylanase/Cellulase Cex (Cf Xyn10A) in complex with sulfur substituted beta-1,4 xylotetraose
2XYL	;	1.9	;	CELLULOMONAS FIMI XYLANASE/CELLULASE COMPLEXED WITH 2-DEOXY-2-FLUORO-XYLOBIOSE
2HIS	;	1.84	;	CELLULOMONAS FIMI XYLANASE/CELLULASE DOUBLE MUTANT E127A/H205N WITH COVALENT CELLOBIOSE
3ZYP	;	1.5	;	Cellulose induced protein, Cip1
2WHM	;	1.5	;	Cellvibrio japonicus Man26A E121A and E320G double mutant in complex with mannobiose
2VX6	;	1.57	;	CELLVIBRIO JAPONICUS MANNANASE CJMAN26C Gal1Man4-BOUND FORM
2VX7	;	1.8	;	CELLVIBRIO JAPONICUS MANNANASE CJMAN26C MANNOBIOSE-BOUND FORM
2VX5	;	1.47	;	CELLVIBRIO JAPONICUS MANNANASE CJMAN26C MANNOSE-BOUND FORM
2VX4	;	1.7	;	CELLVIBRIO JAPONICUS MANNANASE CJMAN26C NATIVE FORM
7S5L	;	1.58	;	Cembrene A synthase from Eleutherobia rubra
1QOU	;	1.9	;	CEN (Centroradialis) protein from Antirrhinum
6MUO	;	3.6	;	CENP-A nucleosome bound by two copies of CENP-C(CD) and one copy CENP-N(NT)
6MUP	;	3.5	;	CENP-A nucleosome bound by two copies of CENP-C(CD) and two copies CENP-N(NT)
6TEM	;	3.9	;	CENP-A nucleosome core particle with 145 base pairs of the Widom 601 sequence by cryo-EM
7ON1	;	3.35	;	Cenp-A nucleosome in complex with Cenp-C
8HFH	;	1.8	;	CENP-E motor domain in complex with AMPPNP and Mg2+
7PB4	;	2.49	;	Cenp-HIK 3-protein complex
2KSM	;		;	Central B domain of Rv0899 from Mycobacterium tuberculosis
5AL6	;	0.8	;	Central Coiled-Coil Domain (CCCD) of Drosophila melanogaster Ana2. A natural, parallel, tetrameric coiled-coil bundle.
5LHW	;	0.91	;	Central Coiled-Coil Domain of Human STIL
1GXE	;		;	Central domain of cardiac myosin binding protein C
6JDL	;	2.249	;	Central domain of FleQ H287A mutant in complex with ATPgS and Mg
6JDI	;	1.95	;	Central domain of FleQ H287N mutant in complex with ATPgS and Mg
4XNG	;	3.0	;	Central Domain of Mycoplasma Genitalium Terminal Organelle protein MG491
4GCO	;	1.6	;	Central domain of stress-induced protein-1 (STI-1) from C.elegans
5DGG	;	1.93	;	Central domain of uncharacterized Lpg1148 protein from Legionella pneumophila
6Q9M	;	2.453	;	Central Fibronectin-III array of RIM-binding protein
7Z45	;	3.5	;	Central part (C10) of bacteriophage SU10 capsid
6ORJ	;	2.37	;	Central spike of phiKZ phage tail
2OBH	;	1.8	;	Centrin-XPC peptide
5I7C	;	2.804	;	Centrosomin-motif 2 (CM2) domain of Drosophila melanogaster Centrosomin (Cnn)
5JO8	;	1.4	;	CEP104 TOG domain
8IBH	;	2.1	;	Cep57 C-terminal domain
1OB4	;	0.95	;	Cephaibol A
1OB6	;	0.89	;	Cephaibol B
1OB7	;	0.89	;	Cephaibol C
1ODS	;	1.9	;	Cephalosporin C deacetylase from Bacillus subtilis
1ODT	;	1.7	;	cephalosporin C deacetylase mutated, in complex with acetate
2ZQ9	;	1.07	;	Cephalothin acyl-intermediate structure of class a beta-lactamase Toho-1 E166A/R274N/R276N triple mutant
1CEG	;	1.8	;	CEPHALOTHIN COMPLEXED WITH DD-PEPTIDASE
2ZXC	;	2.2	;	Ceramidase complexed with C2
5EPM	;	1.75	;	Ceratotoxin variant in complex with specific antibody Fab fragment
5V3O	;	3.2	;	Cereblon in complex with DDB1 and CC-220
5HXB	;	3.6	;	Cereblon in complex with DDB1, CC-885, and GSPT1
6XK9	;	3.64	;	Cereblon in complex with DDB1, CC-90009, and GSPT1
7BQV	;	1.8	;	Cereblon in complex with SALL4 and (S)-5-hydroxythalidomide
7BQU	;	1.9	;	Cereblon in complex with SALL4 and (S)-thalidomide
8C3H	;	1.71	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex a long aspartimide degron peptide
8BC7	;	1.719	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex an aminoglutarimide degron peptide
8BC6	;	1.72	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex an aspartimide degron peptide
5OHA	;	1.55	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with 2-Thiohydantoin
7PJK	;	1.99	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with a benzotriazole analog of thalidomide
5OH1	;	1.7	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Aminoglutethimide
7PSO	;	1.52	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Avadomide (CC-122)
6R18	;	1.35	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 11a
6R1C	;	1.5	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 12a
8AOP	;	1.944	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 14r
6R1W	;	1.35	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 16b
6R19	;	1.45	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 20a
8AOQ	;	2.088	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 20a
6R1A	;	1.54	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 20b
6R0S	;	1.55	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 4a and hydrolysis product
6R0U	;	1.7	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 5a and hydrolysis product
6R11	;	1.75	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 5b
6R1X	;	1.8	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7a
6R12	;	1.74	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7b
6R1K	;	1.94	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7c
6R1D	;	1.1	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7d, co-crystallized
6R13	;	1.65	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7f
4V31	;	1.8	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Deoxyuridine
5OH3	;	2.1	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Ethosuximide
6R0V	;	1.6	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with hydrolysis product of compound 4b
7PS9	;	1.8	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Iberdomide (CC-220)
5OH7	;	1.85	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Imidazolidine-2,4-dione (Hydantoin)
4V30	;	1.85	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Lenalidomide
5OHB	;	1.7	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Piperidin-2-one (Valerolactam)
5OH4	;	2.3	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Piperidine-2,6-dione (Glutarimide)
4V2Z	;	1.45	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Pomalidomide
5OH2	;	1.9	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Pyrrolidin-2-one (Butyrolactam)
5OH8	;	1.95	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Rolipram
8RDP	;	1.76	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8a
8RDQ	;	2.03	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8b
8RDR	;	1.58	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8g
8RDS	;	2.0	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8i
8RDT	;	1.95	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8j
4V2Y	;	1.4	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide
5AMH	;	1.2	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide, trigonal crystal form
5AMI	;	1.75	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide, Wash I structure
5AMJ	;	1.75	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide, Wash II structure
4V32	;	1.9	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide, Y101F mutant
5OH9	;	1.65	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thiazolidine-2,4-dione
5AMK	;	2.9	;	Cereblon isoform 4 from Magnetospirillum gryphiswaldense in multiple conformations, hexagonal crystal form
8OU4	;	2.25	;	Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 11a
8OU5	;	2.3	;	Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 11b
8OU6	;	1.84	;	Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 11c
8OU7	;	1.7	;	Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 11d
8OU9	;	1.75	;	Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 11e
8OUA	;	1.85	;	Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 11f
8OU3	;	1.47	;	Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 8d
8D7Z	;	3.1	;	Cereblon-DDB1 bound to CC-92480 and Ikaros ZF1-2-3
8CVP	;	3.4	;	Cereblon-DDB1 in the Apo form
8D7Y	;	3.4	;	Cereblon-DDB1 in the Apo form with DDB1 in the twisted conformation
8D7W	;	3.1	;	Cereblon~DDB1 bound to CC-92480 with DDB1 in the hinged conformation
8D7U	;	3.1	;	Cereblon~DDB1 bound to CC-92480 with DDB1 in the linear conformation
8D7V	;	3.2	;	Cereblon~DDB1 bound to CC-92480 with DDB1 in the twisted conformation
8D80	;	3.6	;	Cereblon~DDB1 bound to Iberdomide and Ikaros ZF1-2-3
8D81	;	3.9	;	Cereblon~DDB1 bound to Pomalidomide
8D7X	;	3.4	;	Cereblon~DDB1 in the Apo form with DDB1 in the hinged conformation
3RQE	;	2.8	;	Cerebral cavernous malformation 3 (CCM3) in complex with paxillin LD1
3RQF	;	2.7	;	Cerebral cavernous malformation 3 (CCM3) in complex with paxillin LD2
3RQG	;	2.5	;	Cerebral cavernous malformation 3 (CCM3) in complex with paxillin LD4
2J5W	;	2.8	;	Ceruloplasmin revisited: structural and functional roles of various metal cation binding sites
3IJ4	;	3.0	;	Cesium sites in the crystal structure of a functional acid sensing ion channel in the desensitized state
4NTY	;	2.65	;	Cesium sites in the crystal structure of acid-sensing ion channel in complex with snake toxin
5ITF	;	2.51	;	Cetuximab Fab in complex with 2-bromophenylalanine meditope variant
5IR1	;	2.482	;	Cetuximab Fab in complex with 3-bromophenylalanine meditope variant
5IOP	;	2.499	;	Cetuximab Fab in complex with 4-bromophenylalanine meditope variant
5HYQ	;	2.477	;	Cetuximab Fab in complex with amidated meditope
5ID0	;	2.48	;	Cetuximab Fab in complex with aminoheptanoic acid-linked meditope
5IVZ	;	2.48	;	Cetuximab Fab in complex with Arg8Cir meditope variant
5IV2	;	2.481	;	Cetuximab Fab in complex with Arg9Cir meditope variant
5T1L	;	2.48	;	Cetuximab Fab in complex with CQA(Ph)2DLSTRRLKC peptide
5T1K	;	2.48	;	Cetuximab Fab in complex with CQFDA(Ph)2STRRLKC
5ICX	;	2.6	;	Cetuximab Fab in complex with CQFDLSTRRLRCGGSK meditope
5T1M	;	2.53	;	Cetuximab Fab in complex with CQYDLSTRRLKC
5ESQ	;	2.55	;	Cetuximab Fab in complex with cyclic beta-alanine-linked meditope
5HPM	;	2.67	;	Cetuximab Fab in complex with cyclic linked meditope
5EUK	;	2.5	;	Cetuximab Fab in complex with F3H meditope variant
5ICZ	;	2.55	;	Cetuximab Fab in complex with GQFDLSTRRLKG peptide
5FF6	;	2.5	;	Cetuximab Fab in complex with L10Q meditope variant
5ETU	;	2.53	;	Cetuximab Fab in complex with L5E meditope variant
5TH2	;	1.84	;	Cetuximab Fab in complex with L5Q meditope variant
5F88	;	2.481	;	Cetuximab Fab in complex with L5Y meditope variant
5ICY	;	2.5	;	Cetuximab Fab in complex with linear meditope
5ID1	;	2.49	;	Cetuximab Fab in complex with MPT-Cys meditope
3ZID	;	2.0	;	CetZ from Methanosaeta thermophila strain DSM 6194
4B46	;	1.9	;	CetZ1 from Haloferax volcanii - GDP bound monomer
4B45	;	2.1	;	CetZ2 from Haloferax volcanii - GTPgS bound protofilament
5MBQ	;	1.33	;	CeuE (H227A variant) a periplasmic protein from Campylobacter jejuni
5MBU	;	1.81	;	CeuE (H227A, Y288F variant) a periplasmic protein from Campylobacter jejuni
5LWQ	;	1.52	;	CeuE (H227L variant) a periplasmic protein from Campylobacter jejuni
5MBT	;	1.8	;	CeuE (H227L, Y288F variant) a periplasmic protein from Campylobacter jejuni
5LWH	;	1.47	;	CeuE (Y288F variant) a periplasmic protein from Campylobacter jejuni.
2CHU	;	2.4	;	CeuE in complex with mecam
3P6Y	;	2.9	;	CF Im25-CF Im68-UGUAA complex
8I56	;	2.84	;	CfbA S11T variant
8IYU	;	2.1	;	CfbA S11T variant with Ni(II) ions
6TV4	;	1.53	;	CFF-Notum complex
3P5T	;	2.7	;	CFIm25-CFIm68 complex
2I0Y	;	1.9	;	cFMS tyrosine kinase (FGF KID) in complex with an arylamide inhibitor
3BEA	;	2.02	;	cFMS tyrosine kinase (tie2 KID) in complex with a pyrimidinopyridone inhibitor
2I1M	;	1.8	;	cFMS tyrosine kinase (tie2 KID) in complex with an arylamide inhibitor
3KRJ	;	2.1	;	cFMS tyrosine kinase in complex with 4-Cyano-1H-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide
3KRL	;	2.4	;	cFMS Tyrosine kinase in complex with 5-Cyano-furan-2-carboxylic acid [4-(4-methyl-piperazin-1-yl)-2-piperidin-1-yl-phenyl]-amide
3DPK	;	1.95	;	cFMS tyrosine kinase in complex with a pyridopyrimidinone inhibitor
7LVK	;	2.2	;	Cfr-modified 50S subunit from Escherichia coli
7S1K	;	2.42	;	Cfr-modified Escherichia coli stalled ribosome with antibiotic radezolid
4Q6H	;	1.903	;	CFTR Associated Ligand (CAL) bound to last 6 residues of CFTR (decameric peptide: iCAL36VQDTRL)
4JOJ	;	1.2	;	CFTR Associated Ligand (CAL) domain bound to peptide F-iCAL36 (ANSRFPTSII)
4K78	;	1.8	;	CFTR Associated Ligand (CAL) E317A PDZ domain bound to peptide iCAL36-QDTRL (ANSRWQDTRL)
4Q6S	;	1.45	;	CFTR Associated Ligand (CAL) PDZ bound to biotinylated peptide BT-L-iCAL36
4JOP	;	1.8	;	CFTR Associated Ligand (CAL) PDZ bound to HPV16 E6 oncoprotein C-terminal peptide (TRRETQL)
4JOR	;	1.34	;	CFTR Associated Ligand (CAL) PDZ domain bound to HPV18 E6 oncoprotein C-terminal peptide (RLQRRRETQV)
4JOE	;	1.14	;	CFTR Associated Ligand (CAL) PDZ domain bound to peptide A-iCAL36 (ANSRAPTSII)
4JOH	;	1.47	;	CFTR Associated Ligand (CAL) PDZ domain bound to peptide H-iCAL36 (ANSRHPTSII)
4NMO	;	1.4	;	CFTR Associated Ligand (CAL) PDZ domain bound to peptide iCAL36(Ac-K-1)(ANSRWPTS[Ac-K]I)
4NMP	;	1.3	;	CFTR Associated Ligand (CAL) PDZ domain bound to peptide iCAL36(Ac-K-3) (ANSRWP[Ac-K]SII)
4NMQ	;	1.4	;	CFTR Associated Ligand (CAL) PDZ domain bound to peptide iCAL36(Ac-K-4) (ANSRW[Ac-K]TSII)
4NMR	;	1.55	;	CFTR Associated Ligand (CAL) PDZ domain bound to peptide iCAL36(Ac-K-5) (ANSR[Ac-K]PTSII)
4NMV	;	1.4	;	CFTR Associated Ligand (CAL) PDZ domain bound to peptide iCAL36(BRB-K-1) (ANSRWPTS[4-bromobenzoic-acyl-K]I)
4NMT	;	1.4	;	CFTR Associated Ligand (CAL) PDZ domain bound to peptide iCAL36(TFA-K-1) (ANSRWPTS[Tfa-acyl-K]I)
4K6Y	;	1.48	;	CFTR Associated Ligand (CAL) PDZ domain bound to peptide iCAL36-Q (ANSRWQTSII)
4K75	;	1.5	;	CFTR Associated Ligand (CAL) PDZ domain bound to peptide iCAL36-QDTRL (ANSRWQDTRL)
4K76	;	1.75	;	CFTR Associated Ligand (CAL) PDZ domain bound to peptide iCAL36-TRL (ANSRWPTTRL)
4K72	;	1.9	;	CFTR Associated Ligand (CAL) PDZ domain bound to peptide iCAL36-VQD (ANSRVQDSII)
6OV7	;	1.71	;	CFTR Associated Ligand (CAL) PDZ domain bound to peptide kCAL01
4JOF	;	1.2	;	CFTR Associated Ligand (CAL) PDZ domain bound to peptide L-iCAL36 (ANSRLPTSII)
4JOG	;	1.465	;	CFTR Associated Ligand (CAL) PDZ domain bound to peptide V-iCAL36 (ANSRVPTSII)
4JOK	;	1.09	;	CFTR Associated Ligand (CAL) PDZ domain bound to peptide Y-iCAL36 (ANSRYPTSII)
6V84	;	1.64	;	CFTR Associated Ligand (CAL) PDZ domain bound to peptidomimetic LyCALAc
7JZR	;	1.54	;	CFTR Associated Ligand (CAL) PDZ domain bound to peptidomimetic LyCALAEB
7JZP	;	1.95	;	CFTR Associated Ligand (CAL) PDZ domain bound to peptidomimetic LyCALBF
7JZQ	;	1.35	;	CFTR Associated Ligand (CAL) PDZ domain bound to peptidomimetic LyCALPMB
7JZO	;	1.61	;	CFTR Associated Ligand (CAL) PDZ domain bound to peptidomimetic LyCALTPP
4NMS	;	1.7	;	CFTR Associated Ligand (CAL)PDZ domain bound to peptide iCAL36(FLB-K-1) (ANSRWPTS[4-fluorobenzoic-acyl-K]I)
6S7G	;	1.841	;	Cfucosylated linker peptide SBL1 bound to Fucose binding Lectin LecB (PA-IIL) from Pseudomonas aeruginosa at 1.84 Angstrom resolution
6S5P	;	1.46	;	Cfucosylated peptide SBL2 bound to Fucose binding Lectin LecB (PA-IIL) from Pseudomonas aeruginosa at 1.46 Angstrom resolution
6S5R	;	2.076	;	Cfucosylated second generation peptide dendrimer SBD6 bound to Fucose binding Lectin LecB (PA-IIL) from Pseudomonas aeruginosa at 2.08 Angstrom resolution, incomplete structure
6S5S	;	1.433	;	Cfucosylated second generation peptide dendrimer SBD8 bound to Fucose binding Lectin LecB (PA-IIL) from Pseudomonas aeruginosa at 1.43 Angstrom resolution
1QMJ	;	2.15	;	CG-16, a homodimeric agglutinin from chicken liver
2JYZ	;		;	CG7054 solution structure
8OL1	;	3.5	;	cGAS-Nucleosome in complex with SPSB3-ELOBC (composite structure)
1ZEY	;	1.7	;	CGG A-DNA
7KJU	;	3.102	;	Cgi121-tRNA complex
1ULF	;	2.36	;	CGL2 in complex with Blood Group A tetrasaccharide
1ULD	;	2.1	;	CGL2 in complex with blood group H type II
1ULC	;	2.6	;	CGL2 in complex with lactose
1ULE	;	2.15	;	CGL2 in complex with linear B2 trisaccharide
1ULG	;	2.2	;	CGL2 in complex with Thomsen-Friedenreich antigen
1UL9	;	2.22	;	CGL2 ligandfree
8PDU	;	3.22	;	cGMP-bound SpSLC9C1 in lipid nanodiscs, dimer
8PDV	;	3.26	;	cGMP-bound SpSLC9C1 in lipid nanodiscs, protomer
8RF9	;	3.28	;	CgsiGP1 sample in nanodisc
8RFE	;	3.8	;	CgsiGP2 sample in nanodisc
8RFG	;	3.35	;	CgsiGP3 sample in nanodisc
1VF4	;	2.45	;	cGSTA1-1 apo form
1VF1	;	1.77	;	cGSTA1-1 in complex with glutathione
1VF3	;	2.15	;	cGSTA1-1 in complex with glutathione conjugate of CDNB
1VF2	;	2.15	;	cGSTA1-1 in complex with S-hexyl-glutathione
5HEC	;	2.395	;	CgT structure in dimer
5HEA	;	2.003	;	CgT structure in hexamer
1A47	;	2.56	;	CGTASE FROM THERMOANAEROBACTERIUM THERMOSULFURIGENES EM1 IN COMPLEX WITH A MALTOHEXAOSE INHIBITOR
6L2H	;	2.096	;	CGTase mutant-Y167H
3U4B	;	2.893	;	CH04H/CH02L Fab P4
3U46	;	2.906	;	CH04H/CH02L P212121
5OKF	;	3.2	;	CH1 chimera of human 14-3-3 sigma with the HSPB6 phosphopeptide in a conformation with self-bound phosphopeptides
5OK9	;	2.35	;	CH1 chimera of human 14-3-3 sigma with the HSPB6 phosphopeptide in a conformation with swapped phosphopeptides
5VR9	;	2.15	;	CH1/Ckappa Fab based on Matuzumab
5VSI	;	1.51	;	CH1/Ckappa Fab mutant 15.1
5VSH	;	2.55	;	CH1/Clambda Fab based on Pertuzumab
5OM0	;	3.2	;	CH2 chimera of human 14-3-3 sigma with the Gli1 phosphopeptide around Ser640
6UGA	;	2.5	;	ch28/11 Fab (monoclinic form)
5OMA	;	3.9	;	CH3 chimera of human 14-3-3 sigma with the StARD1 peptide including Ser57
8SXI	;	4.5	;	CH505 Disulfide Stapled SOSIP Bound to b12 Fab
8SXJ	;	4.0	;	CH505 Disulfide Stapled SOSIP Bound to CH235.12 Fab
4HKB	;	3.6	;	CH67 Fab (unbound) from the CH65-67 Lineage
7OP2	;	1.59	;	Chadox1/ Chimpanzee adenovirus Y25 fiber knob protein
8B3J	;	3.1	;	Chaetoceros socialis forma radians RNA virus 1 empty capsid atomic model
8B38	;	3.0	;	Chaetoceros socialis forma radians RNA virus 1 full capsid atomic model
4WP2	;	1.7	;	Chaetomium Mex67 UBA domain
5M5Z	;	1.25	;	Chaetomium thermophilum beta-1-3-glucanase
5M60	;	1.5	;	Chaetomium thermophilum beta-1-3-glucanase
6SZ6	;	2.988	;	Chaetomium thermophilum beta-glucosidase
5T8V	;	2.798	;	Chaetomium thermophilum cohesin loader SCC2, C-terminal fragment
6ZS1	;	1.56	;	Chaetomium thermophilum CuZn-superoxide dismutase
6ZE7	;	1.5	;	Chaetomium thermophilum FAD-dependent oxidoreductase in complex with 4-nitrophenol
7AA2	;	1.4	;	Chaetomium thermophilum FAD-dependent oxidoreductase in complex with ABTS
8ODU	;	5.0	;	Chaetomium thermophilum Get1/Get2 heterotetramer in complex with a Get3 dimer (amphipol)
8ODV	;	4.7	;	Chaetomium thermophilum Get1/Get2 heterotetramer in complex with a Get3 dimer (nanodisc)
8PUW	;	3.01	;	Chaetomium thermophilum Las1-Grc3-complex
8ONZ	;	2.94	;	Chaetomium thermophilum Methionine Aminopeptidase 2 at the 80S ribosome
8OO0	;	3.1	;	Chaetomium thermophilum Methionine Aminopeptidase 2 autoproteolysis product at the 80S ribosome
4WP5	;	2.9	;	Chaetomium thermophilum Mex67 NTF2-like domain complexed with Mtr2
7ZR1	;	4.0	;	Chaetomium thermophilum Mre11-Rad50-Nbs1 complex bound to ATPyS (composite structure)
7OJU	;	1.1	;	Chaetomium thermophilum Naa50 GNAT-domain in complex with bisubstrate analogue CoA-Ac-MVNAL
4CYJ	;	2.59	;	Chaetomium thermophilum Pan2:Pan3 complex
4CYI	;	2.42	;	Chaetomium thermophilum Pan3
5WF7	;	2.5	;	Chaetomium thermophilum Polycomb Repressive Complex 2 bound to GSK126
8PV7	;	2.12	;	Chaetomium thermophilum pre-60S State 1 - pre-5S rotation (Arx1/Nog2 state) - Composite structure
8PV2	;	2.63	;	Chaetomium thermophilum pre-60S State 10 - pre-5S rotation with Ytm1-Erb1
8PV4	;	2.9	;	Chaetomium thermophilum pre-60S State 2 - pre-5S rotation with Rix1 complex - composite structure
8PV6	;	2.94	;	Chaetomium thermophilum pre-60S State 3 - post-5S rotation with Rix1 complex with Foot - composite structure
8PV8	;	2.91	;	Chaetomium thermophilum pre-60S State 4 - post-5S rotation with Rix1 complex without Foot - composite structure
8PVK	;	2.55	;	Chaetomium thermophilum pre-60S State 5 - pre-5S rotation - L1 inward - composite structure
8PV1	;	2.56	;	Chaetomium thermophilum pre-60S State 6 - pre-5S rotation - L1 intermediate - composite structure
8PVL	;	2.19	;	Chaetomium thermophilum pre-60S State 7 - pre-5S rotation lacking Utp30/ITS2 - composite structure
8PV5	;	2.86	;	Chaetomium thermophilum pre-60S State 8 - pre-5S rotation without Foot - composite structure
8PV3	;	2.8	;	Chaetomium thermophilum pre-60S State 9 - pre-5S rotation - immature H68/H69 - composite structure
7ZQY	;	2.51	;	Chaetomium thermophilum Rad50 Zn hook
8PTW	;	2.91	;	Chaetomium thermophilum Rix1-complex
8FTK	;	4.56	;	Chaetomium thermophilum SETX (Full-length)
8FTH	;	3.17	;	Chaetomium thermophilum SETX - NPPC internal deletion
6TS8	;	4.6	;	Chaetomium thermophilum UDP-Glucose Glucosyl Transferase (UGGT) double cysteine mutant G177C/A786C.
6TRT	;	4.58	;	Chaetomium thermophilum UDP-Glucose Glucosyl Transferase (UGGT) double cysteine mutant S180C/T742C.
6TRF	;	4.106	;	Chaetomium thermophilum UDP-Glucose Glucosyl Transferase (UGGT) purified from cells treated with kifunensine.
4WPX	;	3.31	;	Chaetomium theromophilum TREX2 CID domain complex
3CBK	;	2.67	;	chagasin-cathepsin B
3CBJ	;	1.8	;	Chagasin-Cathepsin B complex
6MAE	;	1.8	;	CHAIN A. UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase PA-LPXC Complexed with (R)-3-((S)-3-(4-(cyclopropylethynyl)phenyl)-2-oxooxazolidin-5-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)propenamide
1EYP	;	2.5	;	CHALCONE ISOMERASE
1EYQ	;	1.85	;	Chalcone isomerase and naringenin
1JEP	;	2.1	;	Chalcone Isomerase Complexed with 4'-hydroxyflavanone
1FM8	;	2.3	;	CHALCONE ISOMERASE COMPLEXED WITH 5,4'-DIDEOXYFLAVANONE
1FM7	;	2.3	;	CHALCONE ISOMERASE COMPLEXED WITH 5-DEOXYFLAVANONE
5YX3	;	2.7	;	Chalcone isomerase from the Antarctic vascular plant Deschampsia Antarctica (DaCHI1)
1JX1	;	2.3	;	Chalcone Isomerase--T48A mutant
1JX0	;	2.85	;	Chalcone Isomerase--Y106F mutant
1ZGD	;	1.7	;	Chalcone Reductase Complexed With NADP+ at 1.7 Angstrom Resolution
1I8B	;	1.95	;	Chalcone synthase (G256F)
1I89	;	1.86	;	Chalcone synthase (G256L)
1I88	;	1.45	;	CHALCONE SYNTHASE (G256V)
1D6I	;	2.0	;	CHALCONE SYNTHASE (H303Q MUTANT)
1D6F	;	1.69	;	CHALCONE SYNTHASE C164A MUTANT
1BI5	;	1.56	;	CHALCONE SYNTHASE FROM ALFALFA
1CHW	;	1.9	;	CHALCONE SYNTHASE FROM ALFALFA COMPLEXED WITH HEXANOYL-COA
1CML	;	1.69	;	CHALCONE SYNTHASE FROM ALFALFA COMPLEXED WITH MALONYL-COA
1CGK	;	1.84	;	CHALCONE SYNTHASE FROM ALFALFA COMPLEXED WITH NARINGENIN
1CGZ	;	1.7	;	CHALCONE SYNTHASE FROM ALFALFA COMPLEXED WITH RESVERATROL
1BQ6	;	1.56	;	CHALCONE SYNTHASE FROM ALFALFA WITH COENZYME A
7BUS	;	2.52	;	Chalcone synthase from Glycine max (L.) Merr (soybean)
7BUR	;	1.82	;	Chalcone synthase from Glycine max (L.) Merr (soybean) complexed with naringenin
8B32	;	1.7	;	Chalcone synthase from Hordeum vulgare complexed with CoA
8B3C	;	2.0	;	Chalcone synthase from Hordeum vulgare complexed with CoA and eriodictyol
8B35	;	2.0	;	Chalcone synthase from Hordeum vulgare complexed with CoA and naringenin
5UC5	;	2.102	;	Chalcone synthase from Malus domestica
1I86	;	1.5	;	CHALCONE SYNTHASE, G256A MUTANT
1JWX	;	1.63	;	Chalcone Synthase--F215S mutant
1D6H	;	2.15	;	CHALONE SYNTHASE (N336A MUTANT COMPLEXED WITH COA)
1QAC	;	1.8	;	CHANGE IN DIMERIZATION MODE BY REMOVAL OF A SINGLE UNSATISFIED POLAR RESIDUE
5N2V	;	3.1	;	Changes in conformational equilibria regulate the activity of the Dcp2 decapping enzyme
2MEA	;	2.2	;	CHANGES IN CONFORMATIONAL STABILITY OF A SERIES OF MUTANT HUMAN LYSOZYMES AT CONSTANT POSITIONS
2MEB	;	1.8	;	CHANGES IN CONFORMATIONAL STABILITY OF A SERIES OF MUTANT HUMAN LYSOZYMES AT CONSTANT POSITIONS
2MEC	;	2.2	;	CHANGES IN CONFORMATIONAL STABILITY OF A SERIES OF MUTANT HUMAN LYSOZYMES AT CONSTANT POSITIONS
2MEG	;	1.8	;	CHANGES IN CONFORMATIONAL STABILITY OF A SERIES OF MUTANT HUMAN LYSOZYMES AT CONSTANT POSITIONS.
3SOD	;	2.1	;	CHANGES IN CRYSTALLOGRAPHIC STRUCTURE AND THERMOSTABILITY OF A CU,ZN SUPEROXIDE DISMUTASE MUTANT RESULTING FROM THE REMOVAL OF BURIED CYSTEINE
1TMT	;	2.2	;	CHANGES IN INTERACTIONS IN COMPLEXES OF HIRUDIN DERIVATIVES AND HUMAN ALPHA-THROMBIN DUE TO DIFFERENT CRYSTAL FORMS
1TMU	;	2.5	;	Changes in interactions in complexes of hirudin derivatives and human alpha-thrombin due to different crystal forms
2MU9	;		;	Changing ABRA protein peptide to fit the HLA-DR B1*0301 molecule renders it protection-inducing
3DGS	;	1.9	;	Changing the determinants of protein stability from covalent to non-covalent interactions by in-vitro evolution: a structural and energetic analysis
2KIX	;		;	Channel domain of BM2 protein from influenza B virus
3CQX	;	2.3	;	Chaperone Complex
4IT5	;	2.152	;	Chaperone HscB from Vibrio cholerae
5WO2	;	1.769	;	Chaperone Spy bound to Casein Fragment (Casein un-modeled)
5WO3	;	1.87	;	Chaperone Spy bound to Im7 (Im7 un-modeled)
5WNW	;	1.79	;	Chaperone Spy bound to Im7 6-45 ensemble
5WO1	;	1.87	;	Chaperone Spy H96L bound to Im7 L18A L19A L37A (Im7 un-modeled)
6K73	;	2.7742	;	Chaperone-tip adhesin complex is vital for synergistic activation of CFA/I fimbriae biogenesis
2WPU	;	1.92	;	Chaperoned ruthenium metallodrugs that recognize telomeric DNA
8PBB	;	2.49	;	CHAPSO treated partial catalytic component (comprising only AnfD & AnfK, lacking AnfG and FeFeco) of iron nitrogenase from Rhodobacter capsulatus
8CXP	;	2.47	;	Characterisation of a Seneca Valley Virus Thermostable Mutant
4YEG	;	2.23	;	Characterisation of Polyphosphate Kinase 2 from the Intracellular Pathogen Francisella tularensis
1E8P	;		;	Characterisation of the cellulose docking domain from Piromyces equi
1E8Q	;		;	Characterisation of the cellulose docking domain from Piromyces equi
3PB0	;	2.0	;	Characterisation of the first monomeric dihydrodipicolinate synthase variant reveals evolutionary insights
3PB2	;	1.9	;	Characterisation of the first monomeric dihydrodipicolinate synthase variant reveals evolutionary insights
2K8P	;		;	Characterisation of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation
3S1S	;	2.35	;	Characterization and crystal structure of the type IIG restriction endonuclease BpuSI
2VCE	;	1.9	;	Characterization and engineering of the bifunctional N- and O- glucosyltransferase involved in xenobiotic metabolism in plants
2VCH	;	1.45	;	Characterization and engineering of the bifunctional N- and O- glucosyltransferase involved in xenobiotic metabolism in plants
2VG8	;	1.75	;	Characterization and engineering of the bifunctional N- and O- glucosyltransferase involved in xenobiotic metabolism in plants
6L7M	;	2.4	;	Characterization and structural analysis of a thermostable zearalenone-degrading enzyme
2MPK	;		;	Characterization and structure of the MIT1 domain of a chitin synthase from the Oomycete Saprolegnia monoica
6EVS	;	1.9	;	Characterization of 2-deoxyribosyltransferase from psychrotolerant bacterium Bacillus psychrosaccharolyticus: a suitable biocatalyst for the industrial synthesis of antiviral and antitumoral nucleosides
3UFC	;	2.03	;	Characterization of a Cas6-related gene from Pyrococcus furiosus
2J7M	;	2.3	;	Characterization of a Family 32 CBM
2M3I	;		;	Characterization of a Novel Alpha4/6-Conotoxin TxIC from Conus textile that Potently Blocks alpha3beta4 Nicotinic Acetylcholine Receptors
5FRE	;	1.9	;	Characterization of a novel CBM from Clostridium perfringens
4UHM	;	1.33	;	Characterization of a Novel Transaminase from Pseudomonas sp. Strain AAC
4UHN	;	2.21	;	Characterization of a Novel Transaminase from Pseudomonas sp. Strain AAC
4UHO	;	1.24	;	Characterization of a Novel Transaminase from Pseudomonas sp. Strain AAC
2QY2	;	2.0	;	Characterization of a trifunctional mimivirus mRNA capping enzyme and crystal structure of the RNA triphosphatase domainm.
4RV7	;	2.8	;	Characterization of an essential diadenylate cyclase
6RK6	;	3.15	;	Characterization of an intertidal zone metagenome oligoribonuclease and the role of the intermolecular disulfide bond for homodimer formation and nuclease activity.
5TWT	;	1.296	;	Characterization of class III peroxidase from switchgrass (Panicum virgatum)
6GV5	;	1.55	;	Characterization of extracellular matrix binding protein- (Embp)-mediated Staphylococcus epidermidis adherence to fibronectin
6GV8	;	1.394	;	Characterization of extracellular matrix binding protein- (Embp)-mediated Staphylococcus epidermidis adherence to fibronectin
6D43	;	2.04	;	CHARACTERIZATION OF HUMAN TRIOSEPHOSPHATE ISOMERASE S-NITROSYLATION
1N4H	;	2.1	;	Characterization of ligands for the orphan nuclear receptor RORbeta
1NQ7	;	1.5	;	Characterization of ligands for the orphan nuclear receptor RORbeta
4GRQ	;	1.65	;	Characterization of N- and C- terminus mutants of human MIF
4GRR	;	1.47	;	characterization of N- and C- terminus mutants of human MIF
7DNO	;	2.03	;	Characterization of Peptide Ligands Against WDR5 Isolated Using Phage Display Technique
3JBB	;	26.0	;	Characterization of red-shifted phycobiliprotein complexes isolated from the chlorophyll f-containing cyanobacterium Halomicronema hongdechloris
4LZI	;	2.2	;	Characterization of Solanum tuberosum Multicystatin and Significance of Core Domains
2V0H	;	1.79	;	Characterization of Substrate Binding and Catalysis of the Potential Antibacterial Target N-acetylglucosamine-1-phosphate Uridyltransferase (GlmU)
2V0I	;	1.89	;	Characterization of Substrate Binding and Catalysis of the Potential Antibacterial Target N-acetylglucosamine-1-phosphate Uridyltransferase (GlmU)
2V0J	;	2.0	;	Characterization of Substrate Binding and Catalysis of the Potential Antibacterial Target N-acetylglucosamine-1-phosphate Uridyltransferase (GlmU)
2V0K	;	2.3	;	Characterization of Substrate Binding and Catalysis of the Potential Antibacterial Target N-acetylglucosamine-1-phosphate Uridyltransferase (GlmU)
2V0L	;	2.2	;	Characterization of Substrate Binding and Catalysis of the Potential Antibacterial Target N-acetylglucosamine-1-phosphate Uridyltransferase (GlmU)
2LDX	;	2.96	;	CHARACTERIZATION OF THE ANTIGENIC SITES ON THE REFINED 3-ANGSTROMS RESOLUTION STRUCTURE OF MOUSE TESTICULAR LACTATE DEHYDROGENASE C4
3JVR	;	1.76	;	Characterization of the Chk1 allosteric inhibitor binding site
3JVS	;	1.9	;	Characterization of the Chk1 allosteric inhibitor binding site
8TX1	;	3.62	;	Characterization of the Chlamydomonas Flagellar Mastigoneme Filament Structure at 3.6A
8TXB	;	3.9	;	Characterization of the Chlamydomonas Flagellar Mastigoneme Filament Structure at 3.9A
8TXC	;	3.9	;	Characterization of the Chlamydomonas Flagellar Mastigoneme Filament Subunit MST1 Structure at 3.9 angstrom
1R0Q	;	1.61	;	Characterization of the conversion of the malformed, recombinant cytochrome rc552 to a 2-formyl-4-vinyl (Spirographis) heme
3MOU	;	1.711	;	Characterization of the Inhibitor Binding Site of the Dehaloperoxidase-Hemoglobin from Amphitrite ornata using High-Pressure Xenon Derivatization
1QYZ	;	1.4	;	Characterization of the malformed, recombinant cytochrome rC552
6CDK	;	2.1	;	Characterization of the P1+ intermediate state of nitrogenase P-cluster
2MZD	;		;	Characterization of the p300 Taz2-p53 TAD2 Complex and Comparison with the p300 Taz2-p53 TAD1 Complex
6X6P	;	3.22	;	Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic Analysis
1G9X	;	2.6	;	CHARACTERIZATION OF THE TWINNING STRUCTURE OF MJ1267, AN ATP-BINDING CASSETTE OF AN ABC TRANSPORTER
8Q5B	;		;	Characterization of the zinc finger u-protein HVO_0758 from Haloferax volcanii: biological roles, zinc binding, and NMR solution structure
1LCL	;	1.8	;	CHARCOT-LEYDEN CRYSTAL PROTEIN
1QKQ	;	1.8	;	CHARCOT-LEYDEN CRYSTAL PROTEIN - MANNOSE COMPLEX
1HDK	;	1.8	;	Charcot-Leyden Crystal Protein - pCMBS Complex
6A1S	;	1.63	;	Charcot-Leyden crystal protein/Galectin-10 variant E33A
6A1T	;	1.97	;	Charcot-Leyden crystal protein/Galectin-10 variant E33A with lactose
6A1U	;	1.62	;	Charcot-Leyden crystal protein/Galectin-10 variant E33D
6A1V	;	1.984	;	Charcot-Leyden crystal protein/Galectin-10 variant E33Q
6A1X	;	1.99	;	Charcot-Leyden crystal protein/Galectin-10 variant W127A
6A1Y	;	1.63	;	Charcot-Leyden crystal protein/Galectin-10 variant Y35A
1G86	;	1.8	;	CHARCOT-LEYDEN CRYSTAL PROTEIN/N-ETHYLMALEIMIDE COMPLEX
2AZX	;	2.8	;	Charged and uncharged tRNAs adopt distinct conformations when complexed with human tryptophanyl-tRNA synthetase
6QFS	;	2.2	;	Chargeless variant of the Cellulose-binding domain from Cellulomonas fimi
4IHF	;	2.1	;	Chasing Acyl Carrier Protein Through a Catalytic Cycle of Lipid A Production
4IHG	;	2.89	;	Chasing Acyl Carrier Protein Through a Catalytic Cycle of Lipid A Production
4IHH	;	2.132	;	Chasing Acyl Carrier Protein Through a Catalytic Cycle of Lipid A Production
7XDM	;	1.74	;	ChCODH2 A559W mutant in anaerobic condition
8OO2	;	1.85	;	ChdA complex with amido-chelocardin
6Y1Y	;	1.5	;	CheA dimerization domain of Treponema denticola
1TQG	;	0.98	;	CheA phosphotransferase domain from Thermotoga maritima
1CHD	;	1.75	;	CHEB METHYLESTERASE DOMAIN
1EBG	;	2.1	;	CHELATION OF SER 39 TO MG2+ LATCHES A GATE AT THE ACTIVE SITE OF ENOLASE: STRUCTURE OF THE BIS(MG2+) COMPLEX OF YEAST ENOLASE AND THE INTERMEDIATE ANALOG PHOSPHONOACETOHYDROXAMATE AT 2.1 ANGSTROMS RESOLUTION
1M1Y	;	3.2	;	Chemical Crosslink of Nitrogenase MoFe Protein and Fe Protein
2VUR	;	2.2	;	Chemical dissection of the link between Streptozotocin, O-GlcNAc and pancreatic cell death
2L8H	;		;	Chemical probe bound to HIV TAR RNA
2LPM	;		;	Chemical Shift and Structure Assignments for Sma0114
2LEQ	;		;	Chemical Shift Assignment and Solution Structure of ChR145 from Cytophaga Hutchinsonii, Northeast Structural Genomics Consortium Target ChR145
2LRQ	;		;	Chemical Shift Assignment and Solution Structure of Fr822A from Drosophila melanogaster. Northeast Structural Genomics Consortium Target Fr822A
2LCE	;		;	Chemical shift assignment of Hr4436B from Homo Sapiens, Northeast Structural Genomics Consortium
2LHL	;		;	Chemical Shift Assignments and solution structure of human apo-S100A1 E32Q mutant
2N8F	;		;	Chemical shift assignments and structure calculation of spider toxin pi-hexatoxin-Hi1a
2N8K	;		;	Chemical Shift Assignments and Structure Determination for spider toxin, U33-theraphotoxin-Cg1c
2MNI	;		;	Chemical Shift Assignments and structure of Q4D059, a hypothetical protein from Trypanosoma cruzi
2N0K	;		;	Chemical shift assignments and structure of the alpha-crystallin domain from human, HSPB5
2RUH	;		;	Chemical Shift Assignments for MIP and MDM2 in bound state
2KJA	;		;	Chemical shift assignments, constraints, and coordinates for CN5 scorpion toxin
2K5X	;		;	Chemical shift structure of COLICIN E9 DNASE domain with its cognate immunity protein IM9
8GJV	;	0.9	;	Chemical synthesis of maxamycins: Intermediate compound 10
1Q2R	;	2.9	;	Chemical trapping and crystal structure of a catalytic tRNA guanine transglycosylase covalent intermediate
1Q2S	;	3.2	;	Chemical trapping and crystal structure of a catalytic tRNA guanine transglycosylase covalent intermediate
3KWX	;	2.4	;	Chemically modified Taka alpha-amylase
3OCH	;	1.79	;	Chemically Self-assembled Antibody Nanorings (CSANs): Design and Characterization of an Anti-CD3 IgM Biomimetic
5GCH	;	2.7	;	CHEMISTRY OF CAGED ENZYMES /II$. PHOTOACTIVATION OF INHIBITED CHYMOTRYPSIN
3GCH	;	1.9	;	CHEMISTRY OF CAGED ENZYMES. BINDING OF PHOTOREVERSIBLE CINNAMATES TO CHYMOTRYPSIN
1N8U	;	1.8	;	Chemosensory Protein in Complex with bromo-dodecanol
1N8V	;	1.39	;	Chemosensory Protein in complex with bromo-dodecanol
8C5V	;	12.0	;	Chemotaxis core signalling unit from E protein lysed E. coli cells
1U0S	;	1.9	;	Chemotaxis kinase CheA P2 domain in complex with response regulator CheY from the thermophile thermotoga maritima
6ER7	;	2.62	;	CHEMOTAXIS PROTEIN CHEY FROM Pyrococcus horikoshiI
6EXR	;	2.16	;	CHEMOTAXIS PROTEIN CHEY FROM Pyrococcus horikoshiI
1BC5	;	2.2	;	CHEMOTAXIS RECEPTOR RECOGNITION BY PROTEIN METHYLTRANSFERASE CHER
1AF7	;	2.0	;	CHER FROM SALMONELLA TYPHIMURIUM
1TMY	;	1.9	;	CHEY FROM THERMOTOGA MARITIMA (APO-I)
2TMY	;	2.3	;	CHEY FROM THERMOTOGA MARITIMA (APO-II)
4TMY	;	2.8	;	CHEY FROM THERMOTOGA MARITIMA (MG-IV)
3TMY	;	2.2	;	CHEY FROM THERMOTOGA MARITIMA (MN-III)
1UDR	;	1.9	;	CHEY MUTANT WITH LYS 91 REPLACED BY ASP, LYS 92 REPLACED BY ALA, ILE 96 REPLACED BY LYS AND ALA 98 REPLACED BY LEU (STABILIZING MUTATIONS IN HELIX 4)
1EAY	;	2.0	;	CHEY-BINDING (P2) DOMAIN OF CHEA IN COMPLEX WITH CHEY FROM ESCHERICHIA COLI
1FWP	;		;	CHEY-BINDING DOMAIN OF CHEA (RESIDUES 159-227), NMR, MINIMIZED AVERAGE STRUCTURE
1A0O	;	2.95	;	CHEY-BINDING DOMAIN OF CHEA IN COMPLEX WITH CHEY
1FFG	;	2.1	;	CHEY-BINDING DOMAIN OF CHEA IN COMPLEX WITH CHEY AT 2.1 A RESOLUTION
1FFS	;	2.4	;	CHEY-BINDING DOMAIN OF CHEA IN COMPLEX WITH CHEY FROM CRYSTALS SOAKED IN ACETYL PHOSPHATE
1FFW	;	2.7	;	CHEY-BINDING DOMAIN OF CHEA IN COMPLEX WITH CHEY WITH A BOUND IMIDO DIPHOSPHATE
6C40	;	2.7	;	CheY41PyTyrD54K from Thermotoga maritima
8DF1	;	3.3	;	Chi3l1 bound by antibody C59
2XTK	;	2.0	;	ChiA1 from Aspergillus fumigatus in complex with acetazolamide
2XVP	;	2.0	;	ChiA1 from Aspergillus fumigatus, apostructure
3U18	;	1.9	;	Chicago Sky Blue 6B, A Novel Inhibitor for Macrophage Migration Inhibitory Factor
8DZV	;	1.2	;	Chicken anti-cardiac Troponin I antibody in complex with peptide
1A5J	;		;	CHICKEN B-MYB DNA BINDING DOMAIN, REPEAT 2 AND REPEAT3, NMR, 32 STRUCTURES
3DQX	;	2.3	;	chicken c-Src kinase domain in complex with ATPgS
8GMQ	;	3.36	;	Chicken CALHM1 purified from mammalian cells
1UP5	;	1.9	;	Chicken Calmodulin
1AL6	;	1.85	;	CHICKEN CITRATE SYNTHASE COMPLEX WITH N-HYDROXYAMIDO-COA AND OXALOACETATE
1AMZ	;	1.8	;	CHICKEN CITRATE SYNTHASE COMPLEX WITH NITROMETHYLDE-COA AND MALATE
6CSC	;	2.25	;	CHICKEN CITRATE SYNTHASE COMPLEX WITH TRIFLUOROACETONYL-COA AND CITRATE
7MRM	;	2.75	;	Chicken CNTN3 APP complex
7MRK	;	2.05	;	Chicken CNTN4 APP complex
7MRQ	;	3.2	;	Chicken CNTN4 FN1-FN3 domains with T751A, V752A, Y781A, E786A mutations
3CWB	;	3.51	;	Chicken Cytochrome BC1 Complex inhibited by an iodinated analogue of the polyketide Crocacin-D
3H1L	;	3.21	;	Chicken cytochrome BC1 complex with ascochlorin bound at QO and QI sites
3L72	;	3.06	;	Chicken cytochrome BC1 complex with kresoxim-I-dimethyl bound
3H1K	;	3.48	;	Chicken cytochrome BC1 complex with ZN++ and an iodinated derivative of kresoxim-methyl bound
1A67	;		;	CHICKEN EGG WHITE CYSTATIN WILDTYPE, NMR, 16 STRUCTURES
3IJV	;	1.7	;	Chicken egg white lysozyme by classical hanging drop vapour diffusion method
3IJU	;	1.6	;	Chicken egg white lysozyme by highly ordered APA (Anodic Porous Alumina) nanotemplate crystallization method
1AZF	;	1.8	;	CHICKEN EGG WHITE LYSOZYME CRYSTAL GROWN IN BROMIDE SOLUTION
4WVW	;	1.47	;	Chicken Galectin-8 N-terminal domain complexed with 3'-sialyl-lactose
4WVV	;	1.205	;	Chicken Galectin-8 N-terminal domain complexed with lactose
5NM6	;	1.458	;	Chicken GRIFIN (crystallisation pH: 4.6)
5NM1	;	2.099	;	Chicken GRIFIN (crystallisation pH: 6.2)
5NMJ	;	1.399	;	Chicken GRIFIN (crystallisation pH: 6.5)
5NLD	;	0.96	;	Chicken GRIFIN (crystallisation pH: 7.5)
5NLE	;	1.845	;	Chicken GRIFIN (crystallisation pH: 8.0)
5NLH	;	1.1	;	Chicken GRIFIN (crystallisation pH: 8.5)
7P8H	;	1.13	;	chicken GRIFIN bound to blood group tetrasaccharide B (type 1)
2L21	;		;	chicken IGF2R domain 11
7Y7I	;	3.42	;	chicken KNL2 in complex with the CENP-A nucleosome
1IIU	;	2.5	;	Chicken plasma retinol-binding protein (RBP)
5EZB	;	2.3	;	Chicken prestin STAS domain
7LKH	;	3.5	;	Chicken Scap D435V L1-L7 domain / Fab complex focused map
5U76	;	3.76	;	Chicken Slo2.2 in a closed conformation vitrified in the presence of 300 mM NaCl
5U70	;	3.76	;	Chicken Slo2.2 in an open conformation vitrified in the presence of 300 mM NaCl
5M05	;	2.675	;	Chicken smooth muscle myosin motor domain co-crystallized with the specific CK-571 inhibitor, MgADP form
5T45	;	2.8	;	Chicken smooth muscle myosin motor domain co-crystallized with the specific CK-571 inhibitor, MgADP.BeFx form
6WVE	;	2.429	;	Chicken SPCS1
2PTK	;	2.35	;	CHICKEN SRC TYROSINE KINASE
3R18	;	2.4	;	Chicken sulfite oxidase double mutant with altered activity and substrate affinity
3R19	;	2.1	;	Chicken sulfite oxidase triple mutant with altered activity and substrate affinity
4P61	;	1.34	;	CHICKEN TRIOSEPHOSPHATE ISOMERASE WITH LOOP6 MUTATIONS, V167P AND W168E.
2F4K	;	1.05	;	Chicken villin subdomain HP-35, K65(NLE), N68H, K70(NLE), PH9
1WY4	;	1.55	;	Chicken villin subdomain HP-35, K65(NLE), N68H, pH5.1
1WY3	;	0.95	;	Chicken villin subdomain HP-35, K65(NLE), N68H, pH7.0
1YRI	;	1.0	;	Chicken villin subdomain HP-35, N68H, pH6.4
1YRF	;	1.07	;	Chicken villin subdomain HP-35, N68H, pH6.7
7TH8	;		;	Chickpea (Cicer arientinum) nodule-specific cysteine-rich peptide NCR13: Solution NMR structure of the isomer with C4:C10, C15:C30, and C23:C28 disulfide bonds
8ULM	;		;	Chickpea (Cicer arientinum) nodule-specific cysteine-rich peptide NCR13: Solution NMR structure of the isomer with C4:C23, C15:C30, and C10:C28 disulfide bonds
2XFC	;	9.0	;	CHIKUNGUNYA E1 E2 ENVELOPE GLYCOPROTEINS FITTED IN SEMLIKI FOREST VIRUS cryo-EM MAP
2XFB	;	9.0	;	CHIKUNGUNYA E1 E2 ENVELOPE GLYCOPROTEINS FITTED IN SINDBIS VIRUS cryo- EM MAP
4GQ9	;	2.995	;	Chikungunya virus neutralizing antibody 9.8B Fab fragment
8DWW	;	3.13	;	Chikungunya VLP in complex with neutralizing Fab 506.A08 (asymmetric unit)
8DWX	;	3.27	;	Chikungunya VLP in complex with neutralizing Fab 506.C01 (asymmetric unit)
8DWY	;	3.18	;	Chikungunya VLP in complex with neutralizing Fab CHK-265 (asymmetric unit)
6TKB	;	2.0	;	ChiLob 7/4 H2 HC-C224S F(ab')2
6TKE	;	2.35	;	ChiLob 7/4 H2 HC-C224S Kappa LC-C214S F(ab')2
6TKC	;	2.3	;	ChiLob 7/4 H2 HC-C225S F(ab')2
6TKF	;	2.18	;	ChiLob 7/4 H2 HC-C225S KappaLC-C214S F(ab')2
6TKD	;	1.9	;	ChiLob 7/4 H2 HC-C228S F(ab')2
8EB1	;		;	Chim2 - Intragenic antimicrobial peptide
2JMC	;		;	Chimer between Spc-SH3 and P41
3VML	;	1.56	;	Chimera 3-isopropylmalate dehydrogenase between Shewanella oneidensis MR-1 (O) and Shewanella benthica DB21 MT-2 (M) from N-terminal: 20% O middle 70% M residual 10% O
1XAC	;	2.1	;	CHIMERA ISOPROPYLMALATE DEHYDROGENASE BETWEEN BACILLUS SUBTILIS (M) AND THERMUS THERMOPHILUS (T) FROM N-TERMINAL: 20% T MIDDLE 20% M RESIDUAL 60% T, MUTATED AT S82R. LOW TEMPERATURE (100K) STRUCTURE.
1XAD	;	2.1	;	CHIMERA ISOPROPYLMALATE DEHYDROGENASE BETWEEN BACILLUS SUBTILIS (M) AND THERMUS THERMOPHILUS (T) FROM N-TERMINAL: 20% T MIDDLE 20% M RESIDUAL 60% T, MUTATED AT S82R. LOW TEMPERATURE (150K) STRUCTURE.
3FPC	;	1.4	;	Chimera of alcohol dehydrogenase by exchange of the cofactor binding domain res 153-294 of T. brockii ADH by E. histolytica ADH
3FPL	;	1.9	;	Chimera of alcohol dehydrogenase by exchange of the cofactor binding domain res 153-295 of C. beijerinckii ADH by T. brockii ADH
3FSR	;	2.2	;	Chimera of alcohol dehydrogenase by exchange of the cofactor binding domain res 153-295 of T. brockii ADH by C. beijerinckii ADH
7Z5C	;	4.16	;	Chimera of AP2 with FCHO2 linker domain as a fusion on Cmu2 subunit
6P2A	;	1.9	;	Chimera of bacteriophage OBP gp146 central spike protein and a T4 gp5 beta-helix fragment
8BJI	;	1.75	;	chimera of ExoY Nucleotidyl Cyclase domain from Vibrio nigripulchritudo fused to a proline-Rich-Domain (PRD) and profilin, bound to ADP-Mg-actin and a sulfate ion
6CGB	;	2.994	;	chimera of mouse cadherin-11 EC1 and mouse cadherin-6 EC2
8BJH	;	1.69	;	chimera of the inactive ExoY Nucleotidyl Cyclase domain from Vibrio nigripulchritudo MARTX toxin, with the double mutation K3528M and K3535I, fused to a proline-Rich-Domain (PRD) and profilin, bound to Latrunculin B-ADP-Mg-actin
4R98	;	2.22	;	Chimera of the N-terminal domain of E. coli FeoB
4Z8G	;	2.1	;	Chimera of Tropomodulin-1 and Leiomodin-1 Actin-Binding Site 2 (TL1 ABS2)
8QBX	;	2.2	;	Chimeric Adenovirus-derived dodecamer
1NGW	;	2.6	;	Chimeric Affinity Matured Fab 7g12 complexed with mesoporphyrin
1HO6	;		;	CHIMERIC ARABINONUCLEIC ACID (ANA) HAIRPIN WITH ANA/RNA HYBRID STEM
6KHT	;	3.305	;	Chimeric beta-glucosidase Cel1b-H13
7PHD	;	1.53	;	Chimeric carminomycin-4-O-methyltransferase (DnrK) with a region from 10-decarboxylase TamK
7OWB	;	2.45	;	Chimeric carminomycin-4-O-methyltransferase (DnrK) with a region from 10-hydroxylase CalMB
7PGJ	;	2.13	;	Chimeric carminomycin-4-O-methyltransferase (DnrK) with regions from 10-decarboxylate TamK and 10-hydroxylase RdmB, together with a single point mutation F297G
7PGA	;	2.77	;	Chimeric carminomycin-4-O-methyltransferase (DnrK) with regions from 10-hydroxylase RdmB and 10-decarboxylase TamK
7PHE	;	2.32	;	Chimeric carminomycin-4-O-methyltransferase (DnrK) with regions from 10-hydroxylase RdmB and 10-decarboxylase TamK
7PHF	;	2.21	;	Chimeric carminomycin-4-O-methyltransferase (DnrK) with regions from 10-hydroxylase RdmB and 10-decarboxylase TamK
8SMH	;	1.37	;	Chimeric ETS-domain of murine PU.1 harboring the corresponding beta-strand 3 (S3) residues from murine Ets-1 in complex with d(AATAAGCGGAAGTGGG)
8SMJ	;	1.39	;	Chimeric ETS-domain of murine PU.1 harboring the corresponding beta-strand 3 (S3) residues from murine Ets-1 in complex with d(AATAAGCGGAATGGGG)
8SP1	;	1.62	;	Chimeric ETS-domain of murine PU.1 harboring the corresponding beta-strand 3 (S3) residues from murine Ets-1 in complex with d(AATAAGCGIAAGTGGG)
4GXP	;	3.0	;	Chimeric Family 1 beta-glucosidase made with non-contiguous SCHEMA
7KV8	;	2.5	;	Chimeric flavivirus between Binjari virus and Dengue virus serotype-2
7KVB	;	3.7	;	Chimeric flavivirus between Binjari virus and Murray Valley encephalitis virus
7KV9	;	2.9	;	Chimeric flavivirus between Binjari virus and West Nile (Kunjin) virus
1NGX	;	1.8	;	Chimeric Germline Fab 7g12 with jeffamine fragment bound
1NGZ	;	1.6	;	Chimeric Germline Fab 7g12-apo
3H4I	;	1.3	;	Chimeric Glycosyltransferase for the generation of novel natural products
3H4T	;	1.15	;	Chimeric Glycosyltransferase for the generation of novel natural products - GtfAH1 in complex with UDP-2F-Glc
4RIG	;	1.9	;	Chimeric Glycosyltransferase LanGT2S8Ac
4RIH	;	2.22	;	Chimeric Glycosyltransferase LanGT2S8Ac, carbasugar substrate complex
4RII	;	2.0	;	Chimeric Glycosyltransferase LanGT2S8Ac, TDP complex
5LCZ	;	2.325	;	Chimeric GST
5LD0	;	1.6	;	Chimeric GST
4ECB	;	2.2	;	Chimeric GST Containing Inserts of Kininogen Peptides
4ECC	;	2.2	;	Chimeric GST Containing Inserts of Kininogen Peptides
1ME0	;		;	Chimeric hairpin with 2',5'-linked RNA loop and DNA stem
1ME1	;		;	Chimeric hairpin with 2',5'-linked RNA loop and RNA stem
8FW5	;	3.08	;	Chimeric HsGATOR1-SpGtr-SpLam complex
1JEB	;	2.1	;	Chimeric Human/Mouse Carbonmonoxy Hemoglobin (Human Zeta2 / Mouse Beta2)
1BYX	;		;	CHIMERIC HYBRID DUPLEX R(GCAGUGGC).R(GCCA)D(CTGC) COMPRISING THE TRNA-DNA JUNCTION FORMED DURING INITIATION OF HIV-1 REVERSE TRANSCRIPTION
1NGY	;	2.2	;	Chimeric Mature Fab 7g12-Apo
6C59	;	2.03	;	Chimeric Pol kappa RIR Rev1 C-terminal domain
6C8C	;	1.5	;	Chimeric Pol kappa RIR Rev1 C-terminal domain in complex with JHRE06
8B9X	;	3.066	;	Chimeric protein of human UFM1 E3 ligase, UFL1, and DDRGK1
1ROD	;		;	CHIMERIC PROTEIN OF INTERLEUKIN 8 AND HUMAN MELANOMA GROWTH STIMULATING ACTIVITY PROTEIN, NMR
6JV7	;	1.309	;	Chimeric Rat C5a
1HOQ	;		;	CHIMERIC RNA/DNA HAIRPIN
7B74	;	1.85	;	Chimeric Streptavidin With A Dimerization Domain For Artificial Transfer Hydrogenation
6E52	;	1.93	;	Chimeric structure of Saccharomyces cerevisiae GCN4 leucine zipper fused to Staphylococcus aureus AgrC cytoplasmic histidine kinase module (dataset anisotropically truncated by STARANISO)
6E95	;	2.25	;	Chimeric structure of Saccharomyces cerevisiae GCN4 leucine zipper fused to Staphylococcus aureus AgrC cytoplasmic histidine kinase module (dataset isotropically truncated by HKL2000)
6SDB	;	2.8	;	Chimeric titin Z1Z2 functionalized with a KLER exogenous peptide from decorin
6FWX	;	3.0	;	Chimeric titin Z1Z2-Z1Z2 tandem (Z1212) functionalized with a GRGDS exogenous peptide from fibronectin
7QR3	;	2.18	;	Chimpanzee CPEB3 HDV-like ribozyme
6OHY	;	4.1	;	Chimpanzee SIV Env trimeric ectodomain.
8SUV	;	1.63	;	CHIP-TPR in complex with the C-terminus of CHIC2
1D97	;	2.17	;	CHIRAL PHOSPHOROTHIOATE ANALOGUES OF B-DNA: THE CRYSTAL STRUCTURE OF RP-D(GP(S) CPGP(S)CPGP(S)C)
2RTS	;		;	Chitin binding domain1
8J0P	;	2.4	;	Chitin binding SusD-like protein AqSusD from a marine Bacteroidetes
8JXZ	;	2.2	;	Chitin binding SusD-like protein AqSusD in complex with (GlcNAc)3
2VYO	;	1.5	;	Chitin deacetylase family member from Encephalitozoon cuniculi
7EHO	;	1.79	;	Chitin oligosaccharide binding protein
7EHP	;	2.01	;	Chitin oligosaccharide binding protein
7EHQ	;	1.7	;	Chitin oligosaccharide binding protein
7EHU	;	1.2	;	Chitin oligosaccharide binding protein
7STL	;	2.95	;	Chitin Synthase 2 from Candida albicans at the apo state
7STN	;	3.19	;	Chitin Synthase 2 from Candida albicans bound to Nikkomycin Z
7STO	;	3.15	;	Chitin Synthase 2 from Candida albicans bound to polyoxin D
7STM	;	3.02	;	Chitin Synthase 2 from Candida albicans bound to UDP-GlcNAc
8GUL	;	2.44	;	Chitin-active AA10 LPMO (GbpA) complexed with Cu(II) from Vibrio campbellii
8GUM	;	2.35	;	Chitin-active AA10 LPMO (GbpA) from Vibrio campbellii
7P3U	;	1.5	;	Chitin-active fungal AA11 LPMO
7EBI	;	1.5	;	Chitin-specific solute binding protein from Vibrio harveyi co-crystalized with chitotetraose.
6LZQ	;	1.8	;	Chitin-specific solute binding protein from Vibrio harveyi in complex with chitotriose.
1K9T	;	1.8	;	Chitinase a complexed with tetra-N-acetylchitotriose
2WM0	;	1.9	;	Chitinase A from Serratia marcescens ATCC990 in complex with Chitobio- thiazoline thioamide.
2WLZ	;	1.82	;	Chitinase A from Serratia marcescens ATCC990 in complex with Chitobio- thiazoline.
2WK2	;	2.05	;	Chitinase A from Serratia marcescens ATCC990 in complex with Chitotrio-thiazoline dithioamide.
2WLY	;	2.4	;	Chitinase A from Serratia marcescens ATCC990 in complex with Chitotrio-thiazoline.
1E15	;	1.9	;	Chitinase B from Serratia Marcescens
1O6I	;	1.7	;	Chitinase B from Serratia marcescens complexed with the catalytic intermediate mimic cyclic dipeptide CI4.
1GPF	;	1.85	;	CHITINASE B FROM SERRATIA MARCESCENS IN COMPLEX WITH INHIBITOR PSAMMAPLIN
1E6P	;	1.7	;	Chitinase B from Serratia marcescens inactive mutant E144Q
1E6N	;	2.25	;	Chitinase B from Serratia marcescens inactive mutant E144Q in complex with N-acetylglucosamine-pentamer
1OGB	;	1.85	;	Chitinase b from Serratia marcescens mutant D142N
1OGG	;	1.97	;	chitinase b from serratia marcescens mutant d142n in complex with inhibitor allosamidin
1E6Z	;	1.99	;	CHITINASE B FROM SERRATIA MARCESCENS WILDTYPE IN COMPLEX WITH CATALYTIC INTERMEDIATE
1E6R	;	2.5	;	Chitinase B from Serratia marcescens wildtype in complex with inhibitor allosamidin
6BT9	;	2.26	;	Chitinase ChiA74 from Bacillus thuringiensis
6Y0R	;	1.611	;	Chitooligosaccharide oxidase
7VTZ	;	2.1	;	Chitoporin from Escherichia coli
7VU0	;	1.85	;	Chitoporin from Escherichia coli
7VU1	;	1.9	;	Chitoporin from Escherichia coli complex with chitohexaose
7VU2	;	1.85	;	Chitoporin from Serratia marcescens
7VU3	;	2.7	;	Chitoporin from Serratia marcescens in-complex with chitohexaose
2VZS	;	1.85	;	Chitosan Product complex of Amycolatopsis orientalis exo-chitosanase CsxA
4OLT	;	1.59	;	Chitosanase complex structure
1QGI	;	1.6	;	CHITOSANASE FROM BACILLUS CIRCULANS
2D05	;	2.0	;	Chitosanase From Bacillus circulans mutant K218P
4QYF	;	2.15	;	CHK1 kinase domain in complex with aminopyrazine compound 13
4QYE	;	2.05	;	CHK1 kinase domain in complex with diarylpyrazine compound 1
4QYG	;	1.75	;	CHK1 kinase domain in complex with diazacarbazole compound 14
4QYH	;	1.9	;	CHK1 kinase domain in complex with diazacarbazole GNE-783
4RVM	;	1.86	;	CHK1 kinase domain with diazacarbazole compound 19
4RVL	;	1.85	;	CHK1 kinase domain with diazacarbazole compound 7: 3-(2-hydroxyphenyl)-9H-pyrrolo[2,3-b:5,4-c']dipyridine-6-carbonitrile
4RVK	;	1.85	;	CHK1 kinase domain with diazacarbazole compound 8: N-[3-(6-cyano-9H-pyrrolo[2,3-b:5,4-c']dipyridin-3-yl)phenyl]acetamide
6FC8	;	1.61	;	CHK1 KINASE IN COMPLEX WITH COMPOUND 13
6FCK	;	1.9	;	CHK1 KINASE IN COMPLEX WITH COMPOUND 13
6FCF	;	1.85	;	CHK1 KINASE IN COMPLEX WITH COMPOUND 44
4P40	;	1.2	;	Chlamydia pneumoniae CopN
4P3Z	;	1.77	;	Chlamydia pneumoniae CopN (D29 construct)
6GJT	;	1.98	;	Chlamydia protein Pgp3 studied at high resolution in a new crystal form
2IU9	;	3.1	;	Chlamydia trachomatis LpxD with 100mM UDPGlcNAc (Complex II)
2IU8	;	2.2	;	Chlamydia trachomatis LpxD with 25mM UDPGlcNAc (Complex I)
4D8F	;	2.2	;	Chlamydia trachomatis NrdB with a Mn/Fe cofactor (procedure 1 - high Mn)
4D8G	;	1.75	;	Chlamydia trachomatis NrdB with a Mn/Fe cofactor (procedure 2 - low Mn)
3QRX	;	2.2	;	Chlamydomonas reinhardtii centrin bound to melittin
9B4H	;	3.1	;	Chlamydomonas reinhardtii mastigoneme filament
7P9E	;	2.36	;	Chlamydomonas reinhardtii NADPH Dependent Thioredoxin Reductase 1 domain CS mutant
7JRJ	;	3.03	;	Chlamydomonas reinhardtii radial spoke head and neck (recombinant)
7JR9	;	2.95	;	Chlamydomonas reinhardtii radial spoke minimal head complex
7R3K	;	2.52	;	Chlamydomonas reinhardtii TSP9 mutant small Photosystem I complex
1UZD	;	2.4	;	Chlamydomonas,Spinach Chimeric Rubisco
7EQI	;	3.1	;	ChlB3 [Aceyltransferase]
7FCO	;	2.51	;	ChlB4 Halogenase
2I9D	;	2.3	;	chloramphenicol acetyltransferase
6X7Q	;	1.68	;	Chloramphenicol acetyltransferase type III in complex with chloramphenicol and acetyl-oxa(dethia)-CoA
1QHN	;	2.7	;	CHLORAMPHENICOL PHOSPHOTRANSFERASE FROM STREPTOMYCES VENEZUELAE
1QHY	;	2.6	;	CHLORAMPHENICOL PHOSPHOTRANSFERASE FROM STREPTOMYCES VENEZUELAE IN COMPLEX WITH ATPGAMMAS AND CHLORAMPHENICOL
1GRR	;	2.9	;	CHLORAMPHENICOL PHOSPHOTRANSFERASE IN COMPLEX WITH 2-Nac-CHLORAMPHENICOL FROM STREPTOMYCES VENEZUELAE
1QHX	;	2.5	;	CHLORAMPHENICOL PHOSPHOTRANSFERASE IN COMPLEX WITH ATP FROM STREPTOMYCES VENEZUELAE
1QHS	;	2.8	;	CHLORAMPHENICOL PHOSPHOTRANSFERASE IN COMPLEX WITH CHLORAMPHENICOL FROM STREPTOMYCES VENEZUELAE
1GRQ	;	2.9	;	CHLORAMPHENICOL PHOSPHOTRANSFERASE IN COMPLEX WITH P-AMINO-CHLORAMPHENICOL FROM STREPTOMYCES VENEZUELAE
3SO2	;	1.6428	;	Chlorella dUTPase
7SP6	;	3.1	;	Chlorella virus hyaluronan synthase
7SP8	;	2.7	;	Chlorella virus Hyaluronan Synthase bound to UDP-GlcNAc
7SP9	;	2.9	;	Chlorella virus Hyaluronan Synthase in the GlcNAc-primed channel-closed state
7SPA	;	2.8	;	Chlorella virus Hyaluronan Synthase in the GlcNAc-primed, channel-open state
7SP7	;	3.1	;	Chlorella virus hyaluronan synthase inhibited by UDP
1K0N	;	1.8	;	Chloride Intracellular Channel 1 (CLIC1) complexed with glutathione
9AZ7	;	2.0	;	Chloride Sites in Photoactive Yellow Protein
9AZ9	;	2.0	;	Chloride Sites in Photoactive Yellow Protein (Chloride-Free Reference Structure)
5D4J	;	2.0	;	Chloride-bound form of a copper nitrite reductase from Alcaligenes faecals
2W3T	;	1.69	;	Chloro complex of the Ni-Form of E.coli deformylase
2YMP	;	1.96	;	Chloroacetic acid complex bound L-haloacid dehalogenase from a Rhodobacteraceae family bacterium
4CMY	;	2.59	;	Chlorobium tepidum Ferritin
2BD0	;	1.7	;	Chlorobium tepidum Sepiapterin Reductase complexed with NADP and Sepiapterin
1A7D	;	1.8	;	CHLOROMET MYOHEMERYTHRIN FROM THEMISTE ZOSTERICOLA
3DN1	;	1.8	;	Chloropentafluorobenzene binding in the hydrophobic cavity of T4 lysozyme L99A mutant
1CPO	;	1.9	;	CHLOROPEROXIDASE
2CPO	;	2.1	;	CHLOROPEROXIDASE
2CIV	;	1.8	;	Chloroperoxidase bromide complex
2CIZ	;	1.3	;	chloroperoxidase complexed with acetate
2CIY	;	1.7	;	Chloroperoxidase complexed with cyanide and DMSO
2CIX	;	1.8	;	chloroperoxidase complexed with cyclopentanedione
2CJ1	;	1.7	;	chloroperoxidase complexed with formate (ethylene glycol cryoprotectant)
2CJ2	;	1.6	;	chloroperoxidase complexed with formate (sugar cryoprotectant)
2CJ0	;	1.75	;	chloroperoxidase complexed with nitrate
1A8S	;	1.8	;	CHLOROPEROXIDASE F/PROPIONATE COMPLEX
1VNC	;	2.1	;	CHLOROPEROXIDASE FROM THE FUNGUS CURVULARIA INAEQUALIS
1VNE	;	2.15	;	CHLOROPEROXIDASE FROM THE FUNGUS CURVULARIA INAEQUALIS: MUTANT D292A
1VNG	;	2.2	;	CHLOROPEROXIDASE FROM THE FUNGUS CURVULARIA INAEQUALIS: MUTANT H404A
1VNH	;	2.11	;	CHLOROPEROXIDASE FROM THE FUNGUS CURVULARIA INAEQUALIS: MUTANT H496A
1VNF	;	2.35	;	CHLOROPEROXIDASE FROM THE FUNGUS CURVULARIA INAEQUALIS: MUTANT R360A
1VNI	;	2.15	;	CHLOROPEROXIDASE FROM THE FUNGUS CURVULARIA INAEQUALIS: RECOMBINANT HOLO-CHLOROPEROXIDASE
2CIW	;	1.15	;	Chloroperoxidase iodide complex
1A88	;	1.9	;	CHLOROPEROXIDASE L
2J18	;	1.75	;	Chloroperoxidase mixture of ferric and ferrous states (low dose data set)
1A7U	;	1.75	;	CHLOROPEROXIDASE T
1A8U	;	1.6	;	CHLOROPEROXIDASE T/BENZOATE COMPLEX
6VMD	;	4.53	;	Chloroplast ATP synthase (C1, CF1)
6VMB	;	5.23	;	Chloroplast ATP synthase (C1, CF1FO)
6VM4	;	7.08	;	Chloroplast ATP synthase (C2, CF1FO)
6VM1	;	7.9	;	Chloroplast ATP synthase (C3, CF1FO)
6VOI	;	4.03	;	Chloroplast ATP synthase (O1, CF1)
6VOH	;	4.16	;	Chloroplast ATP synthase (O1, CF1FO)
6VOG	;	4.35	;	Chloroplast ATP synthase (O2, CF1)
6VOF	;	4.51	;	Chloroplast ATP synthase (O2, CF1FO)
6VMG	;	6.46	;	Chloroplast ATP synthase (O3, CF1FO)
6VOO	;	3.05	;	Chloroplast ATP synthase (R1, CF1)
6VON	;	3.35	;	Chloroplast ATP synthase (R1, CF1FO)
6VOM	;	3.6	;	Chloroplast ATP synthase (R2, CF1)
6VOL	;	4.06	;	Chloroplast ATP synthase (R2, CF1FO)
6VOK	;	3.85	;	Chloroplast ATP synthase (R3, CF1)
6VOJ	;	4.34	;	Chloroplast ATP synthase (R3, CF1FO)
5CDI	;	3.807	;	Chloroplast chaperonin 60b1 of Chlamydomonas
6FKF	;	3.15	;	Chloroplast F1Fo conformation 1
6FKH	;	4.2	;	Chloroplast F1Fo conformation 2
6FKI	;	4.3	;	Chloroplast F1Fo conformation 3
4BM5	;	4.2	;	Chloroplast inner membrane protein TIC110
1CIV	;	2.8	;	CHLOROPLAST NADP-DEPENDENT MALATE DEHYDROGENASE FROM FLAVERIA BIDENTIS
7EU3	;	3.7	;	Chloroplast NDH complex
7ZGI	;	2.6	;	chloroplast trigger factor (TIG1)
2YMQ	;	1.72	;	Chloropropionic acid complex bound L-haloacid dehalogenase from a Rhodobacteraceae family bacterium
1CEQ	;	2.0	;	CHLOROQUINE BINDS IN THE COFACTOR BINDING SITE OF PLASMODIUM FALCIPARUM LACTATE DEHYDROGENASE.
1CET	;	2.05	;	CHLOROQUINE BINDS IN THE COFACTOR BINDING SITE OF PLASMODIUM FALCIPARUM LACTATE DEHYDROGENASE.
7FH4	;	1.996	;	Chlorovirus PBCV-1 bi-functional dCMP/dCTP deaminase bi-DCD
7FH9	;	1.9	;	chlorovirus PBCV-1 bi-functional dCMP/dCTP deaminase bi-DCD with dTTP/dTMP bound
3RTF	;	1.7	;	Chlorowillardiine bound to the ligand binding domain of GluA2
3RT8	;	2.426	;	Chlorowillardiine bound to the ligand binding domain of GluA3
7ZCH	;	3.6	;	CHMP2A-CHMP3 heterodimer (410 Angstrom diameter)
7ZCG	;	3.3	;	CHMP2A-CHMP3 heterodimer (430 Angstrom diameter)
5WA1	;	1.868	;	CHMP4C A232T in complex with ALIX BRO1
5V3R	;	1.906	;	CHMP4C in complex with ALIX BRO1
1C9W	;	2.4	;	CHO REDUCTASE WITH NADP+
5WDS	;	1.85	;	Choanoflagellate Salpingoeca rosetta Ras with GDP bound
5WDR	;	1.6	;	Choanoflagellate Salpingoeca rosetta Ras with GMP-PNP
1S5B	;	2.13	;	Cholera holotoxin with an A-subunit Y30S mutation Form 3
1S5C	;	2.5	;	Cholera holotoxin with an A-subunit Y30S mutation, Crystal form 1
1S5D	;	1.75	;	Cholera holotoxin with an A-subunit Y30S mutation, Crystal form 2
1S5E	;	1.9	;	Cholera holotoxin, Crystal form 1
1S5F	;	2.6	;	Cholera holotoxin, Crystal form 2
1XTC	;	2.4	;	CHOLERA TOXIN
2A5G	;	2.66	;	Cholera toxin A1 subunit bound to ARF6(Q67L)
2A5F	;	2.02	;	Cholera toxin A1 subunit bound to its substrate, NAD+, and its human protein activator, ARF6
7LVB	;	2.25	;	CHOLERA TOXIN B SUBUNIT WITH ATTACHED SIV EPITOPE
1RCV	;	1.6	;	Cholera Toxin B-Pentamer Complexed With Bivalent Nitrophenol-Galactoside Ligand BV1
1RD9	;	1.44	;	Cholera Toxin B-Pentamer Complexed With Bivalent Nitrophenol-Galactoside Ligand BV2
1RDP	;	1.35	;	Cholera Toxin B-Pentamer Complexed With Bivalent Nitrophenol-Galactoside Ligand BV3
1RF2	;	1.35	;	Cholera Toxin B-Pentamer Complexed With Bivalent Nitrophenol-Galactoside Ligand BV4
2CHB	;	2.0	;	CHOLERA TOXIN B-PENTAMER COMPLEXED WITH GM1 PENTASACCHARIDE
3CHB	;	1.25	;	CHOLERA TOXIN B-PENTAMER COMPLEXED WITH GM1 PENTASACCHARIDE
1EEI	;	2.0	;	CHOLERA TOXIN B-PENTAMER COMPLEXED WITH METANITROPHENYL-ALPHA-D-GALACTOSE
1PZK	;	1.35	;	Cholera Toxin B-Pentamer Complexed With N-Acyl Phenyl Galactoside 9h
1PZJ	;	1.46	;	Cholera Toxin B-Pentamer Complexed With Nitrophenyl Galactoside 5
1CT1	;	2.3	;	CHOLERA TOXIN B-PENTAMER MUTANT G33R BOUND TO RECEPTOR PENTASACCHARIDE
1MD2	;	1.45	;	CHOLERA TOXIN B-PENTAMER WITH DECAVALENT LIGAND BMSC-0013
1JR0	;	1.3	;	CHOLERA TOXIN B-PENTAMER WITH LIGAND BMSC-0011
1LLR	;	1.46	;	CHOLERA TOXIN B-PENTAMER WITH LIGAND BMSC-0012
5ELD	;	1.4	;	Cholera toxin classical B-pentamer in complex with A Lewis-y
6HMW	;	1.95	;	Cholera toxin classical B-pentamer in complex with fucose
6HMY	;	1.6	;	Cholera toxin classical B-pentamer in complex with fucosyl-GM1
5LZH	;	1.13	;	Cholera toxin classical B-pentamer in complex with inhibitor PC262
6HJD	;	1.54	;	Cholera toxin classical B-pentamer in complex with Lewis-x
5ELB	;	1.08	;	Cholera toxin classical B-pentamer in complex with Lewis-y
5ELE	;	1.6	;	Cholera toxin El Tor B-pentamer in complex with A Lewis-y
5ELF	;	1.55	;	Cholera toxin El Tor B-pentamer in complex with A-pentasaccharide
5LZJ	;	1.2	;	Cholera toxin El Tor B-pentamer in complex with inhibitor Laura237
5LZG	;	1.13	;	Cholera toxin El Tor B-pentamer in complex with inhibitor PC262
5ELC	;	1.5	;	Cholera toxin El Tor B-pentamer in complex with Lewis-y
2YOO	;	1.69	;	Cholest-4-en-3-one bound structure of CYP142 from Mycobacterium smegmatis
3D4S	;	2.8	;	Cholesterol bound form of human beta2 adrenergic receptor.
7XEM	;	3.17	;	Cholesterol bound state of mTRPV2
1LLF	;	1.4	;	Cholesterol Esterase (Candida Cylindracea) Crystal Structure at 1.4A resolution
2BCE	;	1.6	;	CHOLESTEROL ESTERASE FROM BOS TAURUS
7COG	;	2.098	;	Cholesterol esterase from Burkholderia stabilis (monoclinic crystal form)
7COF	;	1.084	;	Cholesterol esterase from Burkholderia stabilis (orthorhombic crystal form)
2I0K	;	1.6	;	Cholesterol Oxidase from Brevibacterium sterolicum- His121Ala Mutant
1B4V	;	1.5	;	CHOLESTEROL OXIDASE FROM STREPTOMYCES
1N4U	;	0.95	;	CHOLESTEROL OXIDASE FROM STREPTOMYCES @ pH 4.5 (STREPTOMYCES SP. SA-COO)
1IJH	;	1.53	;	CHOLESTEROL OXIDASE FROM STREPTOMYCES ASN485LEU MUTANT
1B8S	;	1.65	;	CHOLESTEROL OXIDASE FROM STREPTOMYCES GLU361GLN MUTANT
1CBO	;	1.8	;	CHOLESTEROL OXIDASE FROM STREPTOMYCES HIS447ASN MUTANT
1CC2	;	2.2	;	CHOLESTEROL OXIDASE FROM STREPTOMYCES HIS447GLN MUTANT
3CNJ	;	0.95	;	Cholesterol oxidase from Streptomyces sp. F359W mutant (0.95A)
3GYI	;	1.0	;	Cholesterol oxidase from Streptomyces sp. N485D mutant (1.0A)
3GYJ	;	0.92	;	Cholesterol oxidase from Streptomyces sp. N485L mutant (0.92A)
4U2T	;	1.223	;	Cholesterol oxidase in the oxidised state complexed with isopropanol
4U2S	;	1.12	;	Cholesterol oxidase in the reduced state complexed with isopropanol
1GVM	;	2.8	;	CHOLINE BINDING DOMAIN OF THE MAJOR AUTOLYSIN (C-LYTA) FROM STREPTOCOCCUS PNEUMONIAE
1HCX	;	2.6	;	Choline binding domain of the major autolysin (C-LytA) from Streptococcus pneumoniae
4DA5	;	2.4	;	Choline Kinase alpha acts through a double-displacement kinetic mechanism involving enzyme isomerisation, as determined through enzyme and inhibitor kinetics and structural biology
5W6O	;	2.35	;	Choline Kinase Alpha in Complex with TCD-717
6G5Z	;	1.98	;	Choline sulfatase from Ensifer (Sinorhizobium) meliloti
6G60	;	1.84	;	Choline sulfatase from Ensifer (Sinorhizobium) meliloti cocrystalized with choline
7WWB	;	3.86	;	Choline transporter-like protein 1
8UBW	;	2.59	;	Choline-bound FLVCR1
8UBY	;	2.67	;	Choline-bound FLVCR1
8UBZ	;	3.02	;	Choline-bound FLVCR1
6J66	;	1.953	;	Chondroitin sulfate/dermatan sulfate endolytic 4-O-sulfatase
1C4S	;	3.0	;	CHONDROITIN-4-SULFATE. THE STRUCTURE OF A SULFATED GLYCOSAMINOGLYCAN
1CB8	;	1.9	;	CHONDROITINASE AC LYASE FROM FLAVOBACTERIUM HEPARINUM
5A3K	;	2.753	;	Chorismatase mechanisms reveal fundamentally different types of reaction in a single conserved protein fold
5AG3	;	1.898	;	Chorismatase mechanisms reveal fundamentally different types of reaction in a single conserved protein fold
1G1B	;	1.99	;	CHORISMATE LYASE (WILD-TYPE) WITH BOUND PRODUCT
1JD3	;	2.03	;	Chorismate lyase G90A mutant with bound product
1FW9	;	1.4	;	CHORISMATE LYASE WITH BOUND PRODUCT
1G81	;	1.71	;	CHORISMATE LYASE WITH BOUND PRODUCT, ORTHORHOMBIC CRYSTAL FORM
2AHC	;	2.4	;	Chorismate lyase with inhibitor Vanilate
1XLR	;	1.94	;	CHORISMATE LYASE WITH INHIBITOR VANILLATE
1TT8	;	1.0	;	CHORISMATE LYASE WITH PRODUCT, 1.0 A RESOLUTION
1DBF	;	1.3	;	CHORISMATE MUTASE FROM BACILLUS SUBTILIS AT 1.30 ANGSTROM
1XHO	;	2.2	;	Chorismate mutase from Clostridium thermocellum Cth-682
1L0S	;	2.3	;	Choristoneura fumiferana (spruce budworm) antifreeze protein isoform 337
1M8N	;	2.45	;	Choristoneura Fumiferana (Spruce Budworm) Antifreeze Protein Isoform 501
7SFJ	;	2.74	;	ChRmine in MSP1E3D1 lipid nanodisc
7SFK	;	2.74	;	ChRmine in MSP1E3D1 lipid nanodisc
2Y9Y	;	3.25	;	Chromatin Remodeling Factor ISW1a(del_ATPase)
2Y9Z	;	3.601	;	Chromatin Remodeling Factor ISW1a(del_ATPase) in DNA complex
8RU1	;	1.66	;	Chromatin remodeling regulator CECR2 with in crystallo disulfide bond
6GEJ	;	3.6	;	Chromatin remodeller-nucleosome complex at 3.6 A resolution.
6GEN	;	3.6	;	Chromatin remodeller-nucleosome complex at 4.5 A resolution.
1KNA	;	2.1	;	Chromo domain of HP1 complexed with histone H3 tail containing dimethyllysine 9.
1KNE	;	2.4	;	Chromo domain of HP1 complexed with histone H3 tail containing trimethyllysine 9
5JJZ	;	2.0	;	Chromo domain of human Chromodomain Protein, Y-Like 2
3MTS	;	2.2	;	Chromo Domain of Human Histone-Lysine N-Methyltransferase SUV39H1
1E0B	;	1.9	;	Chromo shadow domain from fission yeast swi6 protein.
5T1G	;	1.9	;	chromo shadow domain of CBX1 in complex with a histone peptide
8UX2	;	1.87	;	Chromobacterium violaceum mono-ADP-ribosyltransferase CteC in complex with NAD+
2N88	;		;	Chromodomain 3 (CD3) of cpSRP43
4MN3	;	1.542	;	Chromodomain antagonists that target the polycomb-group methyllysine reader protein Chromobox homolog 7 (CBX7)
6AT0	;	1.285	;	Chromodomain HP1 with a p-nitro-L-phenylalanine mutation at position 24 bound to histone H3 peptide containing trimethyl lysine
6ASZ	;	1.518	;	Chromodomain HP1 with Y24F mutation bound to histone H3 peptide containing trimethyl lysine
3G7L	;	2.2	;	Chromodomain of Chp1 in complex with Histone H3K9me3 peptide
1Q3L	;	1.64	;	Chromodomain Of HP1 Complexed With Histone H3 Tail Containing monomethyllysine 9.
6SAW	;	3.0	;	Chromophore binding domain of bacteriophytochrome linked diguanylyl cyclase from Idiomarina species A28L (dimeric Pfr-like state).
6SAX	;	2.4	;	Chromophore binding domain of bacteriophytochrome linked diguanylyl cyclase from Idiomarina species A28L (Pr-state monomer).
2R0G	;	2.37	;	Chromopyrrolic acid-soaked RebC with bound 7-carboxy-K252c
4EIQ	;	2.76	;	Chromopyrrolic acid-soaked RebC-10x with bound 7-carboxy-K252c
1BF4	;	1.6	;	CHROMOSOMAL DNA-BINDING PROTEIN SSO7D/D(GCGAACGC) COMPLEX
6XRW	;	1.77	;	Chromosomal ParDE TA system from P. aeruginosa
6CJ0	;	1.9	;	Chromosomal trehalose-6-phosphate phosphatase from P. aeruginosa
6D3V	;	1.8	;	Chromosomal trehalose-6-phosphate phosphatase from P. aeruginosa
6D3W	;	1.9	;	Chromosomal trehalose-6-phosphate phosphatase from P. aeruginosa
1VZ0	;	2.3	;	Chromosome segregation protein Spo0J from Thermus thermophilus
8BYN	;	2.6	;	Chronic traumatic encephalopathy tau filaments with PET ligand flortaucipir
6NWP	;	2.3	;	Chronic traumatic encephalopathy Type I Tau filament
6NWQ	;	3.4	;	Chronic traumatic encephalopathy Type II Tau filament
3NE9	;	2.5	;	Chronobacterium ammoiniagenes apo-ACPS structure
3NFD	;	1.89	;	Chronobacterium ammoniagenes ACPS-CoA complex
7MGV	;	2.44	;	Chryseobacterium gregarium RiPP-associated ATP-grasp ligase in complex with ADP, and a leader and core peptide
7LG9	;	2.03	;	ChsB1
7LGB	;	2.21	;	ChsB1 in complex with NAD+
5FFQ	;	2.0	;	ChuY: An Anaerobillin Reductase from Escherichia coli O157:H7
1CZI	;	2.3	;	CHYMOSIN COMPLEX WITH THE INHIBITOR CP-113972
7UBZ	;	1.75	;	Chymotrypsin digested toxin/immunity complex for a T6SS lipase effector from E. cloacae
1QH2	;		;	CHYMOTRYPSIN INHIBITOR (C2) FROM NICOTIANA ALATA
2JZM	;		;	Chymotrypsin inhibitor C1 from Nicotiana alata
1CHG	;	2.5	;	CHYMOTRYPSINOGEN,2.5 ANGSTROMS CRYSTAL STRUCTURE, COMPARISON WITH ALPHA-CHYMOTRYPSIN,AND IMPLICATIONS FOR ZYMOGEN ACTIVATION
6Q9B	;	3.9	;	CI Membrane Arm focused refinement from Ovine respiratory SC I+III2
6Q9D	;	3.8	;	CI Peripheral Arm focused refinement from Ovine respiratory SC I+III2
6QIY	;	1.5	;	CI-2, conformation 1
6QIZ	;	1.65	;	CI-2, conformation 2
6TRI	;	2.277	;	CI-MOR repressor-antirepressor complex of the temperate bacteriophage TP901-1 from Lactococcus lactis
1CQ4	;	1.8	;	CI2 MUTANT WITH TETRAGLUTAMINE (MGQQQQGM) REPLACING MET59
3MUP	;	2.6	;	cIAP1-BIR3 domain in complex with the Smac-mimetic compound Smac037
3OZ1	;	3.0	;	cIAP1-BIR3 domain in complex with the Smac-mimetic compound Smac066
4EB9	;	2.6	;	cIAP1-BIR3 in complex with a divalent Smac mimetic
3D9T	;	1.5	;	CIAP1-BIR3 in complex with N-terminal peptide from Caspase-9 (ATPFQE)
6J10	;	2.3	;	Ciclopirox inhibits Hepatitis B Virus secretion by blocking capsid assembly
4JXT	;	1.9	;	CID of human RPRD1A in complex with a phosphorylated peptide from RPB1-CTD
4FU3	;	1.9	;	CID of human RPRD1B
4HFG	;	2.0	;	CID of human RPRD1B
4Q96	;	1.85	;	CID of human RPRD1B in complex with an unmodified CTD peptide
4FLB	;	1.802	;	CID of human RPRD2
1D4B	;		;	CIDE-N DOMAIN OF HUMAN CIDE-B
6YMX	;	3.17	;	CIII2/CIV respiratory supercomplex from Saccharomyces cerevisiae
7SQC	;	3.8	;	Ciliary C1 central pair apparatus isolated from Chlamydomonas reinhardtii
7SOM	;	3.7	;	Ciliary C2 central pair apparatus isolated from Chlamydomonas reinhardtii
3JAO	;	23.0	;	Ciliary microtubule doublet
1CNT	;	2.4	;	CILIARY NEUROTROPHIC FACTOR
2K6D	;		;	CIN85 Sh3-C domain in complex with ubiquitin
6VBY	;	1.7	;	Cinnamate 4-hydroxylase (C4H1) from Sorghum bicolor
5TQM	;	2.9	;	Cinnamoyl-CoA Reductase 1 from Sorghum bicolor in complex with NADP+
5VKT	;	1.827	;	Cinnamyl alcohol dehydrogenases (SbCAD4) from Sorghum bicolor (L.) Moench
2JGS	;	1.9	;	Circular permutant of avidin
6I69	;	1.2	;	Circular permutant of ribosomal protein S6, adding 5aa to C terminal of P97-3, L10A mutant
6I6W	;	1.49	;	Circular permutant of ribosomal protein S6, adding 6aa to C terminal of P68-69
6I6I	;	1.5	;	Circular permutant of ribosomal protein S6, adding 6aa to C terminal of P68-69, L75A mutant
6I6S	;	1.46	;	Circular permutant of ribosomal protein S6, adding 9aa to C terminal of P68-69, L75A mutant
6I6U	;	1.57	;	Circular permutant of ribosomal protein S6, adding 9aa to N terminal of P81-82, L75A mutant
3ZZP	;	0.96	;	Circular permutant of ribosomal protein S6, lacking edge strand beta- 2 of wild-type S6.
7B8V	;	1.863	;	Circular permutant of ribosomal protein S6, P54-55
7BFC	;	2.13	;	Circular permutant of ribosomal protein S6, P54-55 truncated,
7BFF	;	1.66	;	Circular permutant of ribosomal protein S6, P54-55 truncated, I25A mutant.
7B90	;	2.05	;	Circular permutant of ribosomal protein S6, P54-55 truncated, I8A mutant
7BFE	;	1.95	;	Circular permutant of ribosomal protein S6, P54-55 truncated, L21A mutant.
7BFG	;	2.01	;	Circular permutant of ribosomal protein S6, P54-55 truncated, V37A mutant.
7BFD	;	2.57	;	Circular permutant of ribosomal protein S6, P54-55 truncated, Y4A mutant.
6I6Y	;	2.15	;	Circular permutant of ribosomal protein S6, swap helix 2
6I6O	;	1.9	;	Circular permutant of ribosomal protein S6, swap helix 2, L75A mutant
7OS7	;	1.65	;	Circular permutant of ribosomal protein S6, swap helix 2, L75A, A92K mutant
6I6E	;	1.2	;	Circular permutant of ribosomal protein S6, swap strand 1 , L10A mutant
3KML	;	3.011	;	Circular Permutant of the Tobacco Mosaic Virus
2MDU	;		;	Circular Permutant of the WW Domain with Loop 1 Excised
1P5C	;	2.5	;	Circular permutation of Helix A in T4 lysozyme
2M7C	;		;	Circular Permutation of the Trp-cage: Fold Rescue upon Addition of a Hydrophobic Staple
2XHH	;	1.6	;	Circular permutation provides an evolutionary link between two families of calcium-dependent carbohydrate binding modules
2XHJ	;	1.73	;	Circular permutation provides an evolutionary link between two families of calcium-dependent carbohydrate binding modules. SeMet form of vCBM60.
4GDA	;	1.0	;	Circular Permuted Streptavidin A50/N49
1SWF	;	2.0	;	CIRCULAR PERMUTED STREPTAVIDIN E51/A46
1SWG	;	1.8	;	CIRCULAR PERMUTED STREPTAVIDIN E51/A46 IN COMPLEX WITH BIOTIN
4GD9	;	1.5	;	Circular Permuted Streptavidin N49/G48
7RDR	;	6.5	;	Circular tandem repeat protein with novel repeat topology and enhanced subunit contact surfaces
5SYD	;	2.397	;	Circularly permutated azurin (cpAz) based on P. aeruginosa azurin sequence
1AJO	;	2.07	;	CIRCULARLY PERMUTED (1-3,1-4)-BETA-D-GLUCAN 4-GLUCANOHYDROLASE CPA16M-127
1AJK	;	1.8	;	CIRCULARLY PERMUTED (1-3,1-4)-BETA-D-GLUCAN 4-GLUCANOHYDROLASE CPA16M-84
1BD7	;	2.78	;	CIRCULARLY PERMUTED BB2-CRYSTALLIN
1ALQ	;	1.8	;	CIRCULARLY PERMUTED BETA-LACTAMASE FROM STAPHYLOCOCCUS AUREUS PC1
6NLU	;	1.607	;	Circularly permuted Haliangium ochraceum BMC-H
1FW8	;	2.3	;	CIRCULARLY PERMUTED PHOSPHOGLYCERATE KINASE FROM YEAST: PGK P72
7L0N	;	2.78	;	Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
1BH4	;		;	CIRCULIN A FROM CHASSALIA PARVIFLORA, NMR, 12 STRUCTURES
7B26	;	3.4	;	CirpA1 in complex with pseudo-monomeric Properdin lacking TSR2-3
6BJG	;	2.29	;	CIRV p19 mutant T111H in complex with siRNA
6BJH	;	2.58	;	CIRV p19 mutant T111S in complex with siRNA
6BJV	;	2.198	;	CIRV p19 protein in complex with siRNA
2M0Z	;		;	cis form of a photoswitchable PDZ domain crosslinked with an azobenzene derivative
6D5Z	;		;	Cis form of Hemolysin II C-terminal domain
7QLK	;	1.458	;	Cis structure intermediate of rsKiiro Illuminated at 200 K
7QLI	;	1.155	;	Cis structure of rsKiiro at 290 K
2H4B	;		;	cis-4-aminomethylphenylazobenzoic acid-avian pancreatic polypeptide
1ANR	;		;	CIS-ACTING RNA REGULATORY ELEMENT (HIV-1 TAR), NMR, 20 STRUCTURES
2H3S	;		;	cis-Azobenzene-avian pancreatic polypeptide bound to DPC micelles
1BDB	;	2.0	;	CIS-BIPHENYL-2,3-DIHYDRODIOL-2,3-DEHYDROGENASE FROM PSEUDOMONAS SP. LB400
4BX5	;	1.431	;	cis-divalent streptavidin
6LUA	;	3.1	;	Cis-mutant R349A of the central AAA+ domain of the flagellar regulatory protein FlrC
1KV0	;	1.4	;	Cis/trans Isomerization of Non-prolyl Peptide Bond Observed in Crystal Structure of an Scorpion Toxin
4OWB	;	1.69	;	Cisplatin binding to HEWL under sodium bromide crystallisation conditions
2R7Z	;	3.8	;	Cisplatin lesion containing RNA polymerase II elongation complex
1AZ2	;	2.9	;	CITRATE BOUND, C298A/W219Y MUTANT HUMAN ALDOSE REDUCTASE
5H5B	;	2.05	;	Citrate ion bound crystal structure of thymidylate kinase (aq_969) from Aquifex Aeolicus VF5
1Z6K	;	2.3	;	Citrate lyase beta subunit complexed with oxaloacetate and magnesium from M. tuberculosis
8GMI	;	2.7	;	Citrate Synthase (CitA) in Mycobacterium tuberculosis modified by Ebselen at C143 residue
1AJ8	;	1.9	;	CITRATE SYNTHASE FROM PYROCOCCUS FURIOSUS
1O7X	;	2.7	;	Citrate synthase from Sulfolobus solfataricus
7WBR	;	2.19	;	Citrate synthase/lyase from Desulfurella acetivorans Desace_08345
5LTG	;	2.0	;	Citrate-bound Pichia angusta Atg18
8BIY	;	1.61	;	Citrate-free extracytoplasmic PAS domain mutant R93A of sensor histidine kinase CitA from Geobacillus thermodenitrificans
6G2D	;	5.4	;	Citrate-induced acetyl-CoA carboxylase (ACC-Cit) filament at 5.4 A resolution
6MQQ	;	2.05	;	Citrobacter freundii F448A mutant tyrosine phenol-lyase complexed with 4-hydroxypyridine and aminoacrylate from S-ethyl-L-cysteine
1RGY	;	1.52	;	Citrobacter freundii GN346 Class C beta-Lactamase Complexed with Transition-State Analog of Cefotaxime
6MPD	;	1.79	;	Citrobacter freundii tyrosine phenol-lyase complexed with 4-hydroxypyridine and aminoacrylate from 3-F-L-tyrosine
6MO3	;	1.79	;	Citrobacter freundii tyrosine phenol-lyase complexed with 4-hydroxypyridine and aminoacrylate from L-serine
6MLS	;	1.77	;	Citrobacter freundii tyrosine phenol-lyase complexed with 4-hydroxypyridine and aminoacrylate from L-tyrosine
6MME	;	1.9	;	Citrobacter freundii tyrosine phenol-lyase complexed with 4-hydroxypyridine and aminoacrylate from S-ethyl-L-cysteine
6DUR	;	1.8	;	Citrobacter freundii tyrosine phenol-lyase complexed with L-phenylalanine
6DXV	;	2.2	;	Citrobacter freundii tyrosine phenol-lyase F448A mutant
6DYT	;	2.05	;	Citrobacter freundii tyrosine phenol-lyase F448A mutant complexed with L-alanine
6DZ5	;	2.26	;	Citrobacter freundii tyrosine phenol-lyase F448A mutant complexed with L-alanine
6ECG	;	2.27	;	Citrobacter freundii tyrosine phenol-lyase F448A mutant complexed with L-methionine
6DVX	;	2.27	;	Citrobacter freundii tyrosine phenol-lyase F448A mutant complexed with L-phenylalanine
6LLN	;	1.8	;	citronellol catabolism dehydrogenase (AtuB) [Pseudomonas aeruginosa PAO1]
3B3I	;	1.86	;	Citrullination-dependent differential presentation of a self-peptide by HLA-B27 subtypes
7UW9	;	4.2	;	Citrus V-ATPase State 1, H in contact with subunit a
7UWA	;	4.3	;	Citrus V-ATPase State 1, H in contact with subunits AB
7UWC	;	4.0	;	Citrus V-ATPase State 2, H in contact with subunit a
7UWD	;	4.1	;	Citrus V-ATPase State 2, H in contact with subunits AB
7UWB	;	3.9	;	Citrus V-ATPase State 2, Highest-Resolution Class
6QCL	;	1.6	;	Citryl-CoA lyase core module of Chlorobium limicola ATP citrate lyase in complex with acetyl-CoA and L-malate
6Z2H	;	1.8	;	Citryl-CoA lyase module of human ATP citrate lyase in complex with (3S)-citryl-CoA.
7KWS	;	2.09	;	Cj1441 with NAD+ and UDP-glucose
8BQC	;	1.57	;	CjCel5B endo-glucanase
8BQA	;	1.67	;	CjCel5B endo-glucanase bound to CB665 covalent inhibitor
8BN7	;	2.182	;	CjCel5C endo-glucanase
8BQB	;	2.701	;	CjCel5C endo-glucanase bound to CB396 covalent inhibitor
8OZ1	;	1.3	;	CjCel5D endo-xyloglucanase bounc to CB665 covalent inhibitor
8PEJ	;	1.5	;	CjGH35 with a Galactosidase Activity-Based Probe
6JMS	;	1.5	;	CJP38, a beta-1,3-glucanase and allergen of Cryptomeria japonica pollen
4KBK	;	2.1	;	CK1d in complex with (3S)-3-{4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridin-2-yl}morpholine inhibitor
4KB8	;	1.95	;	CK1d in complex with 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE ligand
4KBA	;	1.98	;	CK1d in complex with 9-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2,3,4,5-tetrahydropyrido[2,3-f][1,4]oxazepine inhibitor
4TN6	;	2.41	;	CK1d in complex with inhibitor
4KBC	;	1.98	;	CK1d in complex with {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2-YL}METHANOL inhibitor
6Z83	;	2.171	;	CK2 alpha bound to chemical probe SGC-CK2-1
6Z84	;	2.5	;	CK2 alpha bound to chemical probe SGC-CK2-1 derivative
6YUL	;	2.4	;	CK2 alpha bound to Macrocycle
6YUM	;	2.75	;	CK2 alpha bound to unclosed Macrocycle
8C5Q	;	2.5	;	CK2 kinase bound to inhibitor AB668
5NQC	;	2.0	;	CK2alpha in complex with NMR154
1DKT	;	2.9	;	CKSHS1: HUMAN CYCLIN DEPENDENT KINASE SUBUNIT, TYPE 1 COMPLEX WITH METAVANADATE
1DKS	;	3.2	;	CKSHS1: HUMAN CYCLIN DEPENDENT KINASE SUBUNIT, TYPE 1 IN COMPLEX WITH PHOSPHATE
3ARK	;	1.81	;	Cl- binding hemoglobin component V form Propsilocerus akamusi under 1 M NaCl at pH 4.6
3ARJ	;	1.81	;	Cl- binding hemoglobin component V form Propsilocerus akamusi under 500 mM NaCl at pH 4.6
3ARL	;	1.81	;	Cl- binding hemoglobin component V form Propsilocerus akamusi under 500 mM NaCl at pH 5.5
4YLI	;	2.45	;	CL-K1 trimer
4YMD	;	2.87	;	CL-K1 trimer bound to man(alpha1-2)man
8AM4	;	2.02	;	Cl-rsEGFP2 Long Wavelength Structure
4B8V	;	1.59	;	Cladosporium fulvum LysM effector Ecp6 in complex with a beta-1,4- linked N-acetyl-D-glucosamine tetramer
4B9H	;	2.1	;	Cladosporium fulvum LysM effector Ecp6 in complex with a beta-1,4- linked N-acetyl-D-glucosamine tetramer: I3C heavy atom derivative
6FQ5	;	3.8	;	Class 1 : canonical nucleosome
6SE0	;	3.8	;	Class 1 : CENP-A nucleosome
6DQN	;	3.33	;	Class 1 IP3-bound human type 3 1,4,5-inositol trisphosphate receptor
7ZOS	;	1.9	;	Class 1 Phytoglobin from Sugar beet (BvPgb1.2)
6FQ6	;	4.0	;	Class 2 : distorted nucleosome
6DQV	;	3.82	;	Class 2 IP3-bound human type 3 1,4,5-inositol trisphosphate receptor
8CTE	;	2.9	;	Class 2 of erythrocyte ankyrin-1 complex (Composite map)
6FQ8	;	4.8	;	Class 3 : translocated nucleosome
1AD3	;	2.6	;	CLASS 3 ALDEHYDE DEHYDROGENASE COMPLEX WITH NICOTINAMIDE-ADENINE-DINUCLEOTIDE
6DQS	;	4.12	;	Class 3 IP3-bound human type 3 1,4,5-inositol trisphosphate receptor
6DQZ	;	6.01	;	Class 4 IP3-bound human type 3 1,4,5-inositol trisphosphate receptor
6DR0	;	4.47	;	Class 5 IP3-bound human type 3 1,4,5-inositol trisphosphate receptor
6WIP	;	1.4	;	Class A beta-lactamase from Micromonospora aurantiaca ATCC 27029
4YFM	;	1.4	;	Class A beta-lactamase from Mycobacterium abscessus
3BFF	;	1.9	;	class A beta-lactamase SED-G238C complexed with faropenem
3BFC	;	2.2	;	class A beta-lactamase SED-G238C complexed with imipenem
3BFG	;	2.0	;	class A beta-lactamase SED-G238C complexed with meropenem
6WIF	;	2.15	;	Class C beta-lactamase from Acinetobacter baumannii in complex with 4-(Ethyl(methyl)carbamoyl)phenyl boronic acid
6XG1	;	1.22	;	Class C beta-lactamase from Escherichia coli
6WHF	;	1.4	;	class C beta-lactamase from Escherichia coli in complex with cephalothin
6XFS	;	2.7	;	Class C beta-lactamase from Escherichia coli in complex with Tazobactam
6W5G	;	1.451	;	Class D beta-lactamase BAT-2
6W5O	;	2.55	;	Class D beta-lactamase BAT-2 delta mutant
6W5E	;	1.3	;	Class D beta-lactamase BSU-2
6W5F	;	1.5	;	Class D beta-lactamase BSU-2 delta mutant
6PXX	;	1.5	;	Class D beta-lactamase in complex with beta-lactam antibiotic
7AD3	;	3.3	;	Class D GPCR Ste2 dimer coupled to two G proteins
7Y50	;	2.0	;	Class I diterpene synthase (CyS) from Streptomyces cattleya
7Y88	;	1.87	;	class I diterpene synthase (CyS-GGPP-Mg2+) from Streptomyces cattleya
7Y87	;	2.3	;	class I diterpene synthase mutant (CyS-C59A) from Streptomyces cattleya
2AU4	;		;	Class I GTP aptamer
1B0G	;	2.5	;	CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A2.1)/BETA 2-MICROGLOBULIN/PEPTIDE P1049 COMPLEX
7RE8	;	2.82	;	Class I MHC (HLA-A*02) presenting alpha fetoprotein peptide (AFP)
7E4O	;	2.5	;	Class I Pimarane-Type Diterpene Synthases from Actinomycetes
7E4M	;	1.57	;	Class I Pimarane-Type Diterpene Synthases Stt4548
8H4P	;	1.47	;	class I sesquiterpene synthase
8H6Q	;	2.0	;	Class I sesquiterpene synthase BCBOT2 (apo)
8H6U	;	2.78	;	Class I sesquiterpene synthase BCBOT2 (complex)
8H72	;	2.09	;	Class I sesquiterpene synthase DbPROS (complex)
8FZA	;	2.3	;	Class I type III preQ1 riboswitch from E. coli
2V5K	;	2.2	;	Class II aldolase HpcH - magnesium - oxamate complex
1ASY	;	2.9	;	CLASS II AMINOACYL TRANSFER RNA SYNTHETASES: CRYSTAL STRUCTURE OF YEAST ASPARTYL-TRNA SYNTHETASE COMPLEXED WITH TRNA ASP
1GYN	;	2.0	;	Class II fructose 1,6-bisphosphate aldolase with Cadmium (not Zinc) in the active site
1ZEN	;	2.5	;	CLASS II FRUCTOSE-1,6-BISPHOSPHATE ALDOLASE
5UCN	;	1.67	;	Class II fructose-1,6-bisphosphate aldolase E142A variant of Helicobacter pylori with DHAP
5UCP	;	1.444	;	Class II fructose-1,6-bisphosphate aldolase E142A variant of Helicobacter pylori with FBP and cleavage products
5UCS	;	1.408	;	Class II fructose-1,6-bisphosphate aldolase E149A variant of Helicobacter pylori
5UD0	;	1.647	;	Class II fructose-1,6-bisphosphate aldolase E149A variant of Helicobacter pylori with cleavage products
5UCZ	;	1.78	;	Class II fructose-1,6-bisphosphate aldolase E149A variant of Helicobacter pylori with DHAP
3C56	;	2.3	;	Class II fructose-1,6-bisphosphate aldolase from helicobacter pylori in complex with N-(3-Hydroxypropyl)-glycolohydroxamic acid bisphosphate, a competitive inhibitor
3N9S	;	1.85	;	Class II fructose-1,6-bisphosphate aldolase from helicobacter pylori in complex with N-(4-hydroxybutyl)- glycolohydroxamic acid bis-phosphate, a competitive inhibitor
3N9R	;	1.8	;	Class II fructose-1,6-bisphosphate aldolase from helicobacter pylori in complex with N-(4-hydroxybutyl)-phosphoglycolohydroxamic acid, a competitive inhibitor
3C52	;	2.3	;	Class II fructose-1,6-bisphosphate aldolase from helicobacter pylori in complex with phosphoglycolohydroxamic acid, a competitive inhibitor
1RV8	;	2.3	;	Class II fructose-1,6-bisphosphate aldolase from Thermus aquaticus in complex with cobalt
5UD1	;	1.795	;	Class II fructose-1,6-bisphosphate aldolase H180Q variant of Helicobacter pylori
5UD2	;	1.775	;	Class II fructose-1,6-bisphosphate aldolase H180Q variant of Helicobacter pylori with DHAP
5UD3	;	1.44	;	Class II fructose-1,6-bisphosphate aldolase H180Q variant of Helicobacter pylori with FBP
5UD4	;	1.5	;	Class II fructose-1,6-bisphosphate aldolase H180Q variant of Helicobacter pylori with TBP
1B57	;	2.0	;	CLASS II FRUCTOSE-1,6-BISPHOSPHATE ALDOLASE IN COMPLEX WITH PHOSPHOGLYCOLOHYDROXAMATE
5VJE	;	1.65	;	Class II fructose-1,6-bisphosphate aldolase of Escherichia coli with D-glucitol 1,6-bisphosphate
5VJD	;	1.701	;	Class II fructose-1,6-bisphosphate aldolase of Escherichia coli with DHAP
5UCK	;	1.782	;	Class II fructose-1,6-bisphosphate aldolase of Helicobacter pylori with cleavage products
5VJF	;	1.85	;	Class II fructose-1,6-bisphosphate aldolase of Helicobacter pylori with DHAP
3FTM	;	2.7	;	Class II ligase ribozyme product-template duplex, structure 1
3FS0	;	2.3	;	Class II ligase ribozyme product-template duplex, structure 2
2IAD	;	2.4	;	CLASS II MHC I-AD IN COMPLEX WITH AN INFLUENZA HEMAGGLUTININ PEPTIDE 126-138
1IAO	;	2.6	;	CLASS II MHC I-AD IN COMPLEX WITH OVALBUMIN PEPTIDE 323-339
7VJ4	;	3.0	;	class II photolyase MmCPDII oxidized to semiquinone TR-SFX studies (1 ms time-point)
7VJ0	;	2.3	;	class II photolyase MmCPDII oxidized to semiquinone TR-SFX studies (1 us time-point)
7VIX	;	2.5	;	class II photolyase MmCPDII oxidized to semiquinone TR-SFX studies (10 ns time-point)
7VJ1	;	2.25	;	class II photolyase MmCPDII oxidized to semiquinone TR-SFX studies (10 us time-point)
7VJ2	;	3.0	;	class II photolyase MmCPDII oxidized to semiquinone TR-SFX studies (125 us time-point)
7VIZ	;	2.4	;	class II photolyase MmCPDII oxidized to semiquinone TR-SFX studies (250 ns time-point)
7VJ3	;	2.4	;	class II photolyase MmCPDII oxidized to semiquinone TR-SFX studies (400 us time-point)
7VJ5	;	1.87	;	class II photolyase MmCPDII oxidized to semiquinone TR-SFX studies (5 ms time-point)
7VIY	;	2.25	;	class II photolyase MmCPDII oxidized to semiquinone TR-SFX studies (50 ns time-point)
7VJG	;	2.1	;	class II photolyase MmCPDII semiquinone to fully reduced TR-SFX studies (1 us time-point)
7VJA	;	2.15	;	class II photolyase MmCPDII semiquinone to fully reduced TR-SFX studies (10 ns time-point)
7VJI	;	2.1	;	class II photolyase MmCPDII semiquinone to fully reduced TR-SFX studies (10 us time-point)
7VJC	;	2.3	;	class II photolyase MmCPDII semiquinone to fully reduced TR-SFX studies (100 ns time-point)
7VJK	;	2.15	;	class II photolyase MmCPDII semiquinone to fully reduced TR-SFX studies (100 us time-point)
7VJB	;	2.1	;	class II photolyase MmCPDII semiquinone to fully reduced TR-SFX studies (30 ns time-point)
7VJJ	;	2.1	;	class II photolyase MmCPDII semiquinone to fully reduced TR-SFX studies (30 us time-point)
7VJE	;	2.5	;	class II photolyase MmCPDII semiquinone to fully reduced TR-SFX studies (300 ns time-point)
7VJH	;	2.1	;	class II photolyase MmCPDII semiquinone to fully reduced TR-SFX studies (5 us time-point)
7VJ9	;	2.1	;	class II photolyase MmCPDII semiquinone to fully reduced TR-SFX studies (semiquinone dark structure)
7SH1	;	2.04	;	Class II UvrA protein - Ecm16
7WSX	;	3.0	;	Class III hybrid cluster protein (HCP) C67Y variant from Methanothermobacter marburgensis
7E0L	;	2.82	;	Class III hybrid cluster protein (HCP) from Methanothermobacter marburgensis
6XKN	;	2.73	;	Class III PreQ1 riboswitch mutant A52G
6XKO	;	2.75	;	Class III PreQ1 riboswitch mutant A84G
3HBE	;	1.55	;	Class IV chitinase structure from Picea abies at 1.55A
3HBD	;	1.8	;	Class IV chitinase structure from Picea abies at 1.8A
3HBH	;	2.25	;	Class IV chitinase structure from Picea abies at 2.25A
8ETS	;	3.04	;	Class1 of the INO80-Hexasome complex
8ETT	;	6.68	;	Class1 of the INO80-Hexasome complex
8EU9	;	3.48	;	Class1 of the INO80-Nucleosome complex
8EUE	;	3.48	;	Class1 of the INO80-Nucleosome complex
6SEG	;	3.1	;	Class1: CENP-A nucleosome in complex with CENP-C central region
6SE6	;	3.5	;	Class2 : CENP-A nucleosome in complex with CENP-C central region
8ETU	;	2.8	;	Class2 of the INO80-Hexasome complex
8ETV	;	3.16	;	Class2 of the INO80-Hexasome complex
8EUF	;	3.41	;	Class2 of the INO80-Nucleosome complex
8EUJ	;	3.36	;	Class2 of the INO80-Nucleosome complex
6SEE	;	4.2	;	Class2A : CENP-A nucleosome in complex with CENP-C central region
6SEF	;	3.7	;	Class2C : CENP-A nucleosome in complex with CENP-C central region
8ETW	;	2.64	;	Class3 of INO80-Hexasome complex
8EU2	;	2.93	;	Class3 of the INO80-Hexasome complex
3JSO	;	2.29	;	Classic Protein With a New Twist: crystal structure of a LexA repressor DNA complex
3JSP	;	2.9	;	Classic Protein With a New Twist: crystal structure of a LexA repressor DNA complex
3PSH	;	1.5	;	Classification of a Haemophilus influenzae ABC transporter HI1470/71 through its cognate molybdate periplasmic binding protein MolA (MolA bound to Molybdate)
3PSA	;	1.7	;	Classification of a Haemophilus influenzae ABC transporter HI1470/71 through its cognate molybdate periplasmic binding protein MolA (MolA bound to tungstate)
1XI4	;	7.9	;	Clathrin D6 Coat
3IYV	;	7.9	;	Clathrin D6 coat as full-length Triskelions
1XI5	;	12.0	;	Clathrin D6 coat with auxilin J-domain
5M5U	;	2.15	;	Clathrin heavy chain N-terminal domain bound to a clathrin-box motif from hepatitis D virus large antigen (clade 1)
5M5V	;	1.96	;	Clathrin heavy chain N-terminal domain bound to a clathrin-box motif from hepatitis D virus large antigen (clade 2)
5M5T	;	1.7	;	Clathrin heavy chain N-terminal domain bound to a non-natural clathrin-box motif peptide (Amph4T1)
5M5S	;	1.88	;	Clathrin heavy chain N-terminal domain bound to amphiphysin clathrin-box motif
5M61	;	1.84	;	Clathrin heavy chain N-terminal domain bound to an extended amphiphysin clathrin-box motif
5M5R	;	1.76	;	Clathrin heavy chain N-terminal domain bound to beta2 adaptin clathrin box motif
6QNN	;	2.03	;	CLATHRIN HEAVY CHAIN N-TERMINAL DOMAIN BOUND TO GTSE1 LIDL MOTIF
6QNP	;	2.7	;	CLATHRIN HEAVY CHAIN N-TERMINAL DOMAIN BOUND TO GTSE1 LIDL MOTIF
7BN2	;	1.965	;	Clathrin heavy chain N-terminal domain bound to Non structured protein 3 from Eastern Equine Encephalitis Virus
7BN1	;	1.97	;	Clathrin heavy chain N-terminal domain complexed with peptide from Protein mu-NS of Reovirus type 1
1B89	;	2.6	;	CLATHRIN HEAVY CHAIN PROXIMAL LEG SEGMENT (BOVINE)
1BPO	;	2.6	;	CLATHRIN HEAVY-CHAIN TERMINAL DOMAIN AND LINKER
7ZX4	;	2.08	;	Clathrin N-terminal domain in complex with a HURP phospho-peptide
2XZG	;	1.7	;	Clathrin Terminal Domain Complexed with Pitstop 1
4G55	;	1.69	;	Clathrin terminal domain complexed with pitstop 2
1UTC	;	2.3	;	Clathrin terminal domain complexed with TLPWDLWTT
6YAI	;	9.2	;	Clathrin with bound beta2 appendage of AP2
2WOL	;	1.45	;	Clavulanic acid biosynthesis oligopeptide binding protein 2
2WOP	;	1.7	;	Clavulanic acid biosynthesis oligopeptide binding protein 2 complexed with arginine
2WOK	;	1.7	;	Clavulanic acid biosynthesis oligopeptide binding protein 2 complexed with bradykinin
2IOT	;	1.6	;	Clavulanic Acid bound to Elastase
2JAP	;	2.1	;	Clavulanic Acid Dehydrogenase: Structural and Biochemical Analysis of the Final Step in the Biosynthesis of the beta-Lactamase Inhibitor Clavulanic acid
7U48	;	1.67	;	Clavulanic acid-CTX-M-15
4E6X	;	2.24	;	ClbP in complex boron-based inhibitor
4E6W	;	2.19	;	ClbP in complex with 3-aminophenyl boronic acid
7BXU	;	3.7	;	CLC-7/Ostm1 membrane protein complex
7RP6	;	3.78	;	CLC-ec1 at pH 4.5 100 mM NaGluconate Swap
7RSB	;	3.68	;	CLC-ec1 at pH 4.5 100 mM NaGluconate Turn
7N8P	;	3.42	;	CLC-ec1 at pH 4.5 100mM Cl Swap
7RP5	;	3.72	;	CLC-ec1 at pH 4.5 100mM Cl Turn
7RQ7	;	3.95	;	CLC-ec1 at pH 4.5 100mM Cl TWIST2
7RO0	;	3.75	;	CLC-ec1 at pH 7.5 100 mM NaGluconate Swap
7RNX	;	3.42	;	CLC-ec1 at pH 7.5 100mM Cl Swap
8GA0	;	3.5	;	CLC-ec1 E202Y at pH 4.5 100mM Cl Turn
4MQX	;	3.516	;	CLC-ec1 Fab Complex Cysless A399C-A432C mutant
8GA5	;	2.6	;	CLC-ec1 L25C/A450C/C85A at pH 4.5 100mM Cl Intermediate
8GAH	;	2.9	;	CLC-ec1 L25C/A450C/C85A at pH 4.5 100mM Cl Twist
7N9W	;	4.16	;	CLC-ec1 pH 4.5 100mM Cl Twist1
8GA1	;	2.6	;	CLC-ec1 R230C/L249C/C85A at pH 4.5 100mM Cl Swap
8GA3	;	3.1	;	CLC-ec1 R230C/L249C/C85A at pH 4.5 100mM Cl Turn
6M8Q	;	2.49	;	Cleavage and Polyadenylation Specificity Factor Subunit 3 (CPSF3) in complex with NVP-LTM531
5CF9	;	1.52	;	Cleavage of nicotinamide adenine dinucleotide by the ribosome inactivating protein of Momordica charantia - enzyme-NADP+ co-crystallisation.
4YP2	;	1.35	;	Cleavage of nicotinamide adenine dinucleotides by the ribosome inactivating protein from Momordica charantia
1QMB	;	2.6	;	Cleaved alpha-1-antitrypsin polymer
3CAA	;	2.4	;	CLEAVED ANTICHYMOTRYPSIN A347R
1AS4	;	2.1	;	CLEAVED ANTICHYMOTRYPSIN A349R
4CAA	;	2.9	;	CLEAVED ANTICHYMOTRYPSIN T345R
3NDD	;	1.5	;	Cleaved antitrypsin with P10 Pro, and P9-P6 Asp
3NDF	;	2.7	;	Cleaved antitrypsin with P8-P6 Asp
6MAM	;	4.1	;	Cleaved Ebola GP in complex with a broadly neutralizing human antibody, ADI-15946
6SAZ	;	3.0	;	Cleaved human fetuin-b in complex with crayfish astacin
3F02	;	1.8	;	Cleaved human neuroserpin
4P0O	;	1.8	;	Cleaved Serpin 42Da
4P0F	;	1.7	;	Cleaved Serpin 42Da (C 2 2 21)
9PAI	;	2.7	;	CLEAVED SUBSTRATE VARIANT OF PLASMINOGEN ACTIVATOR INHIBITOR-1
7DJX	;	1.98	;	Clec4f Nanobody 246
7DJY	;	2.7	;	Clec4f Nanobody 322
8F0A	;	2.6	;	Client-bound structure of a DegP trimer within a 12mer cage
8CGD	;	1.98	;	Clindamycin bound to the 50S subunit
3Q4B	;	2.19	;	Clinically Useful Alkyl Amine Renin Inhibitors
3Q5H	;	2.16	;	Clinically Useful Alkyl Amine Renin Inhibitors
6ZWA	;	1.68	;	CLIP peptide bound to chicken MHC class II molecule (BL-2) from B19 haplotype
7APZ	;	1.97	;	CLIP peptide bound to chicken MHC class II molecule (BL-2) from B2 haplotype with a decamer mode of binding
5XAC	;	1.701	;	CLIR - LC3B
3NBC	;	1.01	;	Clitocybe nebularis ricin B-like lectin (CNL) in complex with lactose, crystallized at pH 4.4
3NBD	;	1.15	;	Clitocybe nebularis ricin B-like lectin (CNL) in complex with lactose, crystallized at pH 7.1
3NBE	;	1.86	;	Clitocybe nebularis ricin B-like lectin (CNL) in complex with N,N'-diacetyllactosediamine
3H6R	;	1.948	;	Clitocypin, a beta-trefoil cysteine protease inhibitor
6YTE	;	2.3	;	CLK1 bound with benzothiazole Tg003 (Cpd 2)
6YTG	;	1.95	;	CLK1 bound with beta-carboline KH-CARB13 (Cpd 3)
7AK3	;	2.5	;	CLK1 bound with CAF052
6YTI	;	2.4	;	CLK1 bound with ETH1610 (Cpd 17)
6ZLN	;	1.7	;	CLK1 bound with GW807982X (Cpd 8)
6YTA	;	2.3	;	CLK1 bound with imidazopyridazine (Cpd 1)
6RAA	;	2.1	;	CLK1 Kinase domain with bound imidazopyridin inhibitor TP003
6YTD	;	2.0	;	CLK1 V324A mutant bound with benzothiazole Tg003 (Cpd 2)
6Q8K	;	2.29	;	CLK1 with bound pyridoquinazoline
6YTY	;	1.76	;	CLK3 A319V mutant bound with benzothiazole Tg003 (Cpd 2)
6Z2V	;	2.6	;	CLK3 A319V mutant bound with beta-carboline KH-CARB13 (Cpd 3)
6YTW	;	2.0	;	CLK3 bound with benzothiazole Tg003 (Cpd 2)
6YU1	;	1.9	;	CLK3 bound with beta-carboline KH-CARB13 (Cpd 3)
1ZOX	;	2.1	;	CLM-1 Mouse Myeloid Receptor Extracellular Domain
8JXX	;	3.06	;	Clobenpropit-bound H4R/Gi complex
7LAD	;	2.65	;	Clobetasol propionate bound to CYP3A5
2B2C	;	2.5	;	Cloning, expression, characterisation and three- dimensional structure determination of the Caenorhabditis elegans spermidine synthase
1DT0	;	2.1	;	CLONING, SEQUENCE, AND CRYSTALLOGRAPHIC STRUCTURE OF RECOMBINANT IRON SUPEROXIDE DISMUTASE FROM PSEUDOMONAS OVALIS
8XJK	;	2.63	;	Cloprosetnol bound Prostaglandin F2-alpha receptor-Gq Protein Complex
8XJN	;	3.06	;	Cloprosetnol bound Thromboxane A2 receptor-Gq Protein Complex
3LNW	;	2.302	;	Close correlation of protein thermostability and self-buried area rate revealed by crystal structure of HPr from Thermoanaerobacter tengcongensis MB4
1BLB	;	3.3	;	CLOSE PACKING OF AN OLIGOMERIC EYE LENS BETA-CRYSTALLIN INDUCES LOSS OF SYMMETRY AND ORDERING OF SEQUENCE EXTENSIONS
8DTP	;	2.7	;	Close state of T4 bacteriophage gp41 hexamer bound with single strand DNA
7YPK	;	3.4	;	Close-ring hexamer of the substrate-bound Lon protease with an S678A mutation
6BY2	;	2.35	;	Closed and deep-inactivated conformation of KcsA-T75A mutant
3KD1	;	2.66	;	Closed binary complex of an RB69 gp43 fingers domain mutant complexed with an acyclic GMP terminated primer template pair.
2ZTL	;	1.8	;	Closed conformation of D-3-hydroxybutyrate dehydrogenase complexed with NAD+ and L-3-hydroxybutyrate
7BNM	;	3.6	;	Closed conformation of D614G SARS-CoV-2 spike protein
3LI2	;	2.2	;	Closed Conformation of HtsA Complexed with Staphyloferrin A
5VKH	;	2.25	;	Closed conformation of KcsA Y82A-F103A mutant
4BE4	;	2.6	;	Closed conformation of O. piceae sterol esterase
7YWP	;	2.2	;	Closed conformation of Oligopeptidase B from Serratia proteomaculans with covalently bound TCK
6H04	;	5.6	;	Closed conformation of the Membrane Attack Complex
7M2Y	;	4.03	;	Closed conformation of the Yeast wild-type gamma-TuRC
3GWD	;	2.3	;	Closed crystal structure of cyclohexanone monooxygenase
3R1A	;	3.5	;	Closed crystal structure of cytochrome P450 2B4 covalently bound to the mechanism-based inactivator tert-butylphenylacetylene
5NP0	;	5.7	;	Closed dimer of human ATM (Ataxia telangiectasia mutated)
6UAG	;	2.709	;	Closed Dimer of Y77A Mutant Putative Ryanodine Receptor from Bacteroides thetaiotaomicron VPI-5482
6UG5	;	2.357	;	Closed Dimer of Y77A Mutant Putative Ryanodine Receptor from Bacteroides thetaiotaomicron VPI-5482
1QM6	;	2.5	;	Closed form of Clostridium perfringens alpha-toxin strain NCTC8237
5FI9	;	2.543	;	Closed form of murine Acid Sphingomyelinase in complex with bisphosphonate inhibitor AbPA
7CTR	;	1.2	;	Closed form of PET-degrading cutinase Cut190 with thermostability-improving mutations of S226P/R228S/Q138A/D250C-E296C/Q123H/N202H
7R8Q	;	2.0	;	Closed form of SAOUHSC_02373 in complex with ADP, citrate, Mg2+ and Na+
3MA0	;	2.2	;	Closed liganded crystal structure of xylose binding protein from Escherichia coli
5MLY	;	1.598	;	Closed loop conformation of PhaZ7 Y105E mutant
7WHM	;	2.7	;	Closed spike of Bombyx mori cytoplasmic polyhedrosis virus
5VJH	;	4.0	;	Closed State CryoEM Reconstruction of Hsp104:ATPyS and FITC casein
4UEJ	;	1.74	;	Closed state of galactitol-1-phosphate 5-dehydrogenase from E. coli in complex with glycerol.
7SBK	;	3.1	;	Closed state of pre-fusion SARS-CoV-2 Delta variant spike protein
7SBP	;	3.1	;	Closed state of pre-fusion SARS-CoV-2 Kappa variant spike protein
7STB	;	2.72	;	Closed state of Rad24-RFC:9-1-1 bound to a 5' ss/dsDNA junction
8DR0	;	2.42	;	Closed state of RFC:PCNA bound to a 3' ss/dsDNA junction
8DR3	;	2.2	;	Closed state of RFC:PCNA bound to a 3' ss/dsDNA junction (DNA2) with NTD
8DR6	;	2.39	;	Closed state of RFC:PCNA bound to a nicked dsDNA
8D55	;	2.8	;	Closed state of SARS-CoV-2 BA.2 variant spike protein
6CMR	;	2.21	;	Closed structure of active SHP2 mutant E76D bound to SHP099 inhibitor
6CMS	;	2.68	;	Closed structure of active SHP2 mutant E76K bound to SHP099 inhibitor
6CMP	;	1.8	;	Closed structure of inactive SHP2 mutant C459E
3KD5	;	2.69	;	Closed ternary complex of an RB69 gp43 fingers domain mutant complexed with an acyclic GMP terminated primer template pair and phosphonoformic acid.
4F5Q	;	2.25	;	Closed ternary complex of R283K DNA polymerase beta
3HPH	;	2.64	;	Closed tetramer of Visna virus integrase (residues 1-219) in complex with LEDGF IBD
4P19	;	3.25	;	Closed, apo inward-facing state of the glutamate transporter homologue GltPh
5OMF	;	2.092	;	Closed, ternary structure of KOD DNA polymerase
6ZLU	;	4.2	;	Closed-closed state of the Bt1762-Bt1763 levan transport system
6UHI	;	2.88	;	Closed-form Crystal Structure of Chimera Bt-hRyR_12 from Bacteroides thetaiotaomicron /human
6UHE	;	2.892	;	Closed-form Crystal Structure of Human RYR Receptor 3 ( 848-1055)
6W0J	;	2.5	;	Closed-gate KcsA incubated in BaCl2/NaCl
6W0F	;	2.4	;	Closed-gate KcsA soaked in 0mM KCl/5mM BaCl2
6W0I	;	2.328	;	Closed-gate KcsA soaked in 10mM KCl/5mM BaCl2
6W0G	;	2.6	;	Closed-gate KcsA soaked in 1mM KCl/5mM BaCl2
6W0H	;	2.6	;	Closed-gate KcsA soaked in 5mM KCl/5mM BaCl2
8T1E	;	2.77	;	Closed-state cryo-EM structure of full-length human TRPV4 in the presence of 4a-PDD
4MDG	;	1.35	;	Closo Carborane Carbonic Anhydrase Inhibitor
6YZN	;	0.95	;	Closo-carborane butyl-sulfonamide in complex with CA IX mimic
6YZV	;	1.65	;	Closo-carborane ethyl-sulfonamide in complex with CA II
6YZJ	;	1.2	;	Closo-carborane ethyl-sulfonamide in complex with CA IX mimic
6YZL	;	1.2	;	Closo-carborane methyl-sulfonamide in complex with CA IX mimic
6YZT	;	1.05	;	Closo-carborane propyl-sulfonamide in complex with CA II
4D59	;	1.84	;	Clostridial Cysteine protease Cwp84 C116A after propeptide cleavage
4D5A	;	1.6	;	Clostridial Cysteine protease Cwp84 C116A after propeptide cleavage
8EKM	;	3.56	;	Clostridioides difficile binary toxin translocase CDTb double mutant - D623A D734A
8EKL	;	3.06	;	Clostridioides difficile binary toxin translocase CDTb wild-type after calcium depletion from receptor binding domain 1 (RBD1) - Class 1
8EKK	;	3.28	;	Clostridioides difficile binary toxin translocase CDTb wild-type after calcium depletion from receptor binding domain 1 (RBD1) - Class 2
8DX4	;	2.487	;	Clostridioides difficile R20291 minor pilin - PilW fused with Maltose Binding Protein
7L7B	;	3.26	;	Clostridioides difficile RNAP with fidaxomicin
6AR6	;	9.0	;	Clostridioides difficile toxinB with DLD-4 darpin
6HG6	;	1.75	;	Clostridium beijerinckii aldo-keto reductase Cbei_3974 with NADPH
2FDX	;	1.65	;	CLOSTRIDIUM BEIJERINCKII FLAVODOXIN MUTANT N137A OXIDIZED
4NUL	;	1.9	;	CLOSTRIDIUM BEIJERINCKII FLAVODOXIN MUTANT: D58P OXIDIZED
1FLN	;	1.9	;	CLOSTRIDIUM BEIJERINCKII FLAVODOXIN MUTANT: D58P REDUCED
3NLL	;	2.4	;	CLOSTRIDIUM BEIJERINCKII FLAVODOXIN MUTANT: G57A OXIDIZED
4NLL	;	1.9	;	CLOSTRIDIUM BEIJERINCKII FLAVODOXIN MUTANT: G57D OXIDIZED
1FLA	;	1.9	;	CLOSTRIDIUM BEIJERINCKII FLAVODOXIN MUTANT: G57D REDUCED
1FVX	;	1.9	;	CLOSTRIDIUM BEIJERINCKII FLAVODOXIN MUTANT: G57N OXIDIZED
1FLD	;	1.8	;	CLOSTRIDIUM BEIJERINCKII FLAVODOXIN MUTANT: G57T OXIDIZED
2FLV	;	1.8	;	CLOSTRIDIUM BEIJERINCKII FLAVODOXIN MUTANT: G57T REDUCED (150K)
2FVX	;	1.8	;	CLOSTRIDIUM BEIJERINCKII FLAVODOXIN MUTANT: G57T REDUCED (277K)
5NUL	;	1.6	;	CLOSTRIDIUM BEIJERINCKII FLAVODOXIN MUTANT: G57T SEMIQUINONE (150K)
2FAX	;	1.8	;	CLOSTRIDIUM BEIJERINCKII FLAVODOXIN MUTANT: N137A OXIDIZED (150K)
6NUL	;	1.8	;	CLOSTRIDIUM BEIJERINCKII FLAVODOXIN MUTANT: N137A REDUCED (150K)
5NLL	;	1.75	;	CLOSTRIDIUM BEIJERINCKII FLAVODOXIN: OXIDIZED
5ULL	;	1.8	;	CLOSTRIDIUM BEIJERINCKII FLAVODOXIN: REDUCED
2FOX	;	1.8	;	CLOSTRIDIUM BEIJERINCKII FLAVODOXIN: SEMIQUINONE
3WIN	;	3.5	;	Clostridium botulinum Hemagglutinin
2IMA	;	1.94	;	Clostridium botulinum Neurotoxin Serotype A Light Chain Inhibited by 2,4-dichlorocinnamic hydroxamate
7N18	;	2.03	;	Clostridium botulinum Neurotoxin Serotype A Light Chain Inhibited by a Chiral Hydroxamic Acid
2IMB	;	2.41	;	Clostridium botulinum Neurotoxin Serotype A Light Chain Inhibited by L-arginine hydroxamate
2IMC	;	2.0	;	Clostridium botulinum Neurotoxin Serotype A Light Chain, Residues 1-424
4XCQ	;	2.39	;	Clostridium botulinum phage c-st TubZ (C-terminal tail truncated protein)
2ILP	;	1.9	;	Clostridium botulinum Serotype A Light Chain inhibited by 4-chlorocinnamic hydroxamate
4HEV	;	2.5	;	Clostridium Botulinum Serotype A Light Chain Inhibited By Adamantane Hydroxamate
4KYS	;	2.18	;	Clostridium botulinum thiaminase I in complex with thiamin
1T3C	;	1.9	;	Clostridium botulinum type E catalytic domain E212Q mutant
6UWR	;	2.8	;	Clostridium difficile binary toxin translocase CDTb in asymmetric tetradecamer conformation
6UWT	;	3.1	;	Clostridium difficile binary toxin translocase CDTb tetradecamer in symmetric conformation
4X2C	;	1.8	;	Clostridium difficile Fic protein_0569 mutant S31A, E35A
4X2D	;	2.5	;	Clostridium difficile Fic protein_0569 mutant S31A, E35A in complex with ATP
5UMI	;	3.23	;	Clostridium difficile TcdA-CROPs bound to PA50 Fab
5VQM	;	2.79	;	Clostridium difficile TcdB-GTD bound to PA41 Fab
4R04	;	3.26	;	Clostridium difficile Toxin A (TcdA)
3SS1	;	2.202	;	Clostridium difficile toxin A (TcdA) glucolsyltransferase domain
3SRZ	;	2.58	;	Clostridium difficile toxin A (TcdA) glucolsyltransferase domain bound to UDP-glucose
5UQK	;	1.851	;	Clostridium difficile toxin A (TcdA) glucosyltransferase domain in complex with U2F
5UQL	;	1.97	;	Clostridium difficile toxin A (TcdA) glucosyltransferase domain in complex with U2F
2F6E	;	1.85	;	Clostridium difficile Toxin A C-terminal fragment 1 (TcdA-f1)
2G7C	;	2.0	;	Clostridium difficile Toxin A Fragment Bound to aGal(1,3)bGal(1,4)bGlcNAc
5UQT	;	2.75	;	Clostridium difficile Toxin B (TcdB) glucosyltransferase domain co-crystallized with apigenin
5UQM	;	2.03	;	Clostridium difficile Toxin B (TcdB) glucosyltransferase domain in complex with U2F
5UQN	;	2.06	;	Clostridium difficile Toxin B (TcdB) glucosyltransferase domain in complex with U2F
4NP4	;	2.89	;	Clostridium difficile toxin B CROP domain in complex with FAB domains of neutralizing antibody bezlotoxumab
4X2E	;	3.104	;	Clostridium difficile wild type Fic protein
1CLF	;		;	CLOSTRIDIUM PASTEURIANUM FERREDOXIN
1BE7	;	1.65	;	CLOSTRIDIUM PASTEURIANUM RUBREDOXIN C42S MUTANT
1B13	;	1.5	;	CLOSTRIDIUM PASTEURIANUM RUBREDOXIN G10A MUTANT
1B2O	;	1.9	;	CLOSTRIDIUM PASTEURIANUM RUBREDOXIN G10VG43A MUTANT
1B2J	;	1.6	;	CLOSTRIDIUM PASTEURIANUM RUBREDOXIN G43A MUTANT
2WXT	;	2.0	;	Clostridium perfringens alpha-toxin strain NCTC8237
2WXU	;	1.8	;	Clostridium perfringens alpha-toxin strain NCTC8237 mutant T74I
2WY6	;	3.2	;	Clostridium perfringens alpha-toxin strain NCTC8237 mutant T74I
8OTB	;	1.5	;	Clostridium perfringens chitinase CP4_3455
8OYE	;	1.35	;	Clostridium perfringens chitinase CP4_3455 E196Q with chitin
8OWF	;	1.3	;	Clostridium perfringens chitinase CP4_3455 with chitosan
8OVR	;	1.6	;	Clostridium perfringens chitinase CP56_3454 apo form
2YGT	;	2.4	;	Clostridium perfringens delta-toxin
2XH6	;	2.69	;	Clostridium perfringens enterotoxin
3AM2	;	2.51	;	Clostridium perfringens enterotoxin
2YHJ	;	4.0	;	Clostridium perfringens Enterotoxin at 4.0 Angstrom Resolution
3ZIX	;	1.9	;	Clostridium perfringens Enterotoxin with the N-terminal 37 residues deleted
3ZIW	;	1.9	;	Clostridium perfringens enterotoxin, D48A mutation and N-terminal 37 residues deleted
3ZJX	;	2.4	;	Clostridium perfringens epsilon toxin mutant H149A bound to octyl glucoside
1UYJ	;	2.6	;	Clostridium perfringens epsilon toxin shows structural similarity with the pore forming toxin aerolysin
6AZH	;	1.75	;	Clostridium perfringens putative fatty acid metabolism regulator
2W47	;	1.4	;	Clostridium thermocellum CBM35 in complex with delta-4,5- anhydrogalacturonic acid
5NZ7	;	2.3	;	Clostridium thermocellum cellodextrin phosphorylase ligand free form
5NZ8	;	3.0	;	Clostridium thermocellum cellodextrin phosphorylase with cellotetraose and phosphate bound
7R1L	;	1.45	;	Clostridium thermocellum CtCBM50 structure in complex with beta-1,4-GlcNAc trisaccharide
2VPT	;	1.4	;	Clostridium thermocellum family 3 carbohydrate esterase
3PH4	;	2.07	;	Clostridium thermocellum Ribose-5-Phosphate Isomerase B with d-allose
3PH3	;	2.07	;	Clostridium thermocellum Ribose-5-Phosphate Isomerase B with d-ribose
8I23	;	3.03	;	Clostridium thermocellum RNA polymerase transcription open complex with SigI1 and its promoter
8I24	;	3.36	;	Clostridium thermocellum RNA polymerase transcription open complex with SigI6 and its promoter
6UW2	;	2.92	;	Clotrimazole bound complex of Acanthamoeba castellanii CYP51
3MDV	;	2.4	;	Clotrimazole complex of Cytochrome P450 46A1
8JXV	;	3.21	;	Clozapine-bound H4R/Gi complex
4OI1	;	2.3	;	Clp1 bound to ssRNA dinucleotide GC, ADP, AlF4-, and Mg2+(transition state, data set II)
2NPI	;	2.95	;	Clp1-ATP-Pcf11 complex
6W23	;	3.1	;	ClpA Disengaged State bound to RepA-GFP (Focused Classification)
6W22	;	3.0	;	ClpA Engaged1 State bound to RepA-GFP (ClpA Focused Refinement)
6W24	;	3.4	;	ClpA Engaged2 State bound to RepA-GFP (Focused Classification)
6UQE	;	3.0	;	ClpA/ClpP Disengaged State bound to RepA-GFP
6UQO	;	3.1	;	ClpA/ClpP Engaged State bound to RepA-GFP
7UIX	;	3.24	;	ClpAP complex bound to ClpS N-terminal extension, class I
7UIV	;	3.38	;	ClpAP complex bound to ClpS N-terminal extension, class IIa
7UIW	;	3.33	;	ClpAP complex bound to ClpS N-terminal extension, class IIb
7UIZ	;	3.24	;	ClpAP complex bound to ClpS N-terminal extension, class IIc
7UIY	;	3.22	;	ClpAP complex bound to ClpS N-terminal extension, class IIIa
7UJ0	;	3.26	;	ClpAP complex bound to ClpS N-terminal extension, class IIIb
6W20	;	3.0	;	ClpAP Disengaged State bound to RepA-GFP
6W1Z	;	2.7	;	ClpAP Engaged1 State bound to RepA-GFP
6W21	;	3.3	;	ClpAP Engaged2 State bound to RepA-GFP
6QS6	;	3.9	;	ClpB (DWB and K476C mutant) bound to casein in presence of ATPgammaS - state KC-1
6QS7	;	3.8	;	ClpB (DWB and K476C mutant) bound to casein in presence of ATPgammaS - state KC-2A
6QS8	;	3.9	;	ClpB (DWB and K476C mutant) bound to casein in presence of ATPgammaS - state KC-2B
6RN2	;	6.2	;	ClpB (DWB mutant) bound to casein in presence of ATPgammaS - state WT-1
6RN3	;	4.0	;	ClpB (DWB mutant) bound to casein in presence of ATPgammaS - state WT-2A
6RN4	;	4.2	;	ClpB (DWB mutant) bound to casein in presence of ATPgammaS - state WT-2B
4LJ5	;	2.4	;	ClpB NBD2 from T. thermophilus in complex with ADP
4LJ6	;	1.9	;	ClpB NBD2 from T. thermophilus in complex with AMPPCP
4LJ4	;	2.8	;	ClpB NBD2 from T. thermophilus, nucleotide-free
4LJ7	;	2.8	;	ClpB NBD2 K601Q from T. thermophilus in complex with MANT-dADP
4LJ8	;	2.1	;	ClpB NBD2 R621Q from T. thermophilus in complex with ADP
4LJ9	;	1.7	;	ClpB NBD2 R621Q from T. thermophilus in complex with AMPPCP
4LJA	;	2.0	;	ClpB NBD2 R621Q from T. thermophilus in complex with AMPPCP and guanidinium chloride
5HBN	;	1.602	;	ClpC N-terminal domain with bound phospho-arginine
1R6Q	;	2.35	;	ClpNS with fragments
1YG6	;	1.9	;	ClpP
6WR2	;	2.88	;	ClpP and ClpX IGF loop in ClpX-ClpP complex bound to ssrA tagged GFP
6PPE	;	3.19	;	ClpP and ClpX IGF loop in ClpX-ClpP complex with D7 symmetry
7KR2	;	3.2	;	ClpP from Neisseria meningitidis - Compressed conformation
5DL1	;	3.0	;	ClpP from Staphylococcus aureus in complex with AV145
4MXI	;	2.3	;	ClpP Ser98dhA
4JCQ	;	2.0	;	ClpP1 from Listeria monocytogenes
6PBU	;	2.0	;	ClpP1 from Mycobacterium smegmatis
4JCR	;	2.1	;	ClpP1 N165D mutant from Listeria monocytogenes
4RYF	;	2.8	;	ClpP1/2 heterocomplex from Listeria monocytogenes
6VGK	;	3.1	;	ClpP1P2 complex from M. tuberculosis
6VGN	;	3.1	;	ClpP1P2 complex from M. tuberculosis bound to ADEP
6VGQ	;	3.5	;	ClpP1P2 complex from M. tuberculosis with GLF-CMK bound to ClpP1
8DLA	;	2.66	;	ClpP2 from Chlamydia trachomatis bound by MAS1-12
6X60	;	2.81	;	ClpP2 from Chlamydia trachomatis with resolved handle loop
4JCT	;	2.6	;	ClpP2 from Listeria monocytogenes
6PP8	;	4.12	;	ClpX in ClpX-ClpP complex bound to substrate and ATP-gamma-S, class 1
6PP7	;	4.05	;	ClpX in ClpX-ClpP complex bound to substrate and ATP-gamma-S, class 2
6PP6	;	4.28	;	ClpX in ClpX-ClpP complex bound to substrate and ATP-gamma-S, class 3
6PP5	;	3.98	;	ClpX in ClpX-ClpP complex bound to substrate and ATP-gamma-S, class 4
6WRF	;	3.14	;	ClpX-ClpP complex bound to GFP-ssrA, recognition complex
6WSG	;	3.16	;	ClpX-ClpP complex bound to ssrA-tagged GFP, intermediate complex
6POS	;	4.12	;	ClpX-ClpP complex bound to substrate and ATP-gamma-S, class 1
6POD	;	4.05	;	ClpX-ClpP complex bound to substrate and ATP-gamma-S, class 2
6PO3	;	4.28	;	ClpX-ClpP complex bound to substrate and ATP-gamma-S, class 3
6PO1	;	4.2	;	ClpX-ClpP complex bound to substrate and ATP-gamma-S, class 4
6VFS	;	3.3	;	ClpXP from Neisseria meningitidis - Conformation A
6VFX	;	2.9	;	ClpXP from Neisseria meningitidis - Conformation B
1N67	;	1.9	;	Clumping Factor A from Staphylococcus aureus
1YCT	;		;	Clustered abasic lesions in dna: nmr solution structure of clustered bistranded +1 abasic lesion
1YCW	;		;	Clustered abasic lesions in dna: nmr solution structures of clustered bistranded-1 abasic lesion
4PHO	;	2.123	;	ClyA CC6/264 ox (2-303)
4PHQ	;	1.94	;	ClyA CC6/264 ox (6-303)
7MGP	;	1.65	;	CmcA from Type II Cut MCP
7MN4	;	1.8	;	CmcB E35G mutant from Type II Cut MCP
7MPW	;	3.001	;	CmcB from Type II Cut MCP
7MPX	;	2.1	;	CmcC E36G mutant from Type II Cut MCP
7MPV	;	2.292	;	CmcC from Type II Cut MCP
2BR3	;	2.79	;	cmcI-D160 Mg
2BR4	;	2.59	;	cmcI-D160 Mg-SAM
2BM8	;	2.5	;	CmcI-N160 apo-structure
2BM9	;	2.94	;	cmcI-N160 in complex with SAM
2BR5	;	2.83	;	cmcI-N160 SAH
6ZU2	;	1.55	;	CML1 crystal structure in complex with H-type 1 trisaccharide
6ZV5	;	1.95	;	CML1 crystal structure in complex with Lewis a tetrasaccharide
5KIL	;	2.72	;	CmlA beta-hydroxylase E377D mutant
5KIK	;	2.2	;	CmlA beta-hydroxylase in chemically reduced diferrous state
5HYH	;	2.03	;	CmlI (chemically reduced state), arylamine oxygenase of chloramphenicol biosynthetic pathway
5HYG	;	2.03	;	CmlI (peroxo bound state), arylamine oxygenase of chloramphenicol biosynthetic pathway
1CKE	;	1.75	;	CMP KINASE FROM ESCHERICHIA COLI FREE ENZYME STRUCTURE
3ASZ	;	2.25	;	CMP-complex structure of uridine kinase from Thermus thermophilus HB8
6QVT	;	1.7	;	CMP-Sialic acid bound structure of the human wild type Beta-galactoside alpha-2,6-sialyltransferase 1 (ST6Gal1)
8DI7	;	1.89	;	CMY-2
8JTM	;	5.14	;	CNE55.664 trimer in complex with broadly neutralizing HIV antibody PGT145
3SWF	;	2.14	;	CNGA1 621-690 containing CLZ domain
3SWY	;	1.9	;	CNGA3 626-672 containing CLZ domain
4CT4	;	2.3	;	CNOT1 MIF4G domain - DDX6 complex
8BFH	;	2.2	;	CNOT11
8BFJ	;	2.23	;	CNOT11-GGNBP2 complex
4CT6	;	2.099	;	CNOT9-CNOT1 complex
4CT7	;	1.897	;	CNOT9-CNOT1 complex with bound tryptophan
3T9V	;	1.975	;	CNQX bound to a reduced double cysteine mutant (A452C/S652C) of the ligand binding domain of GluA2
3T9U	;	1.97	;	CNQX bound to an oxidized double cysteine mutant (A452C/S652C) of the ligand binding domain of GluA2
4F1Y	;	1.79	;	CNQX bound to the ligand binding domain of GluA3
7ADR	;	1.0	;	CO bound as bridging ligand at the active site of vanadium nitrogenase VFe protein
5X19	;	2.2	;	CO bound cytochrome c oxidase at 100 micro sec after pump laser irradiation to release CO from O2 reduction center
5X1B	;	2.4	;	CO bound cytochrome c oxidase at 20 nsec after pump laser irradiation to release CO from O2 reduction center
5X1F	;	2.2	;	CO bound cytochrome c oxidase without pump laser irradiation at 278K
1DXC	;	1.4	;	CO complex of Myoglobin Mb-YQR at 100K
1MYZ	;	1.6	;	CO COMPLEX OF MYOGLOBIN MB-YQR AT RT SOLVED FROM LAUE DATA.
6NA4	;	1.722	;	Co crystal structure of ECR with Butryl-CoA
1CG8	;	1.9	;	CO Form Hemoglobin from Dasyatis Akajei
1GCW	;	2.0	;	CO form hemoglobin from mustelus griseus
6DYC	;	1.33	;	Co(II)-bound structure of the engineered cyt cb562 variant, CH3
6DYI	;	1.964	;	Co(II)-bound structure of the engineered cyt cb562 variant, H3
3SCH	;	2.1	;	Co(II)-HppE with R-HPP
6HY4	;	1.83	;	Co(II)-substituted Wells-Dawson binding to Hen Egg-White Lysozyme (HEWL)
1G5L	;		;	CO(III)-BLEOMYCIN-OOH BOUND TO AN OLIGONUCLEOTIDE CONTAINING A PHOSPHOGLYCOLATE LESION
1GJ2	;		;	CO(III)-BLEOMYCIN-OOH BOUND TO AN OLIGONUCLEOTIDE CONTAINING A PHOSPHOGLYCOLATE LESION
2R2U	;	2.3	;	Co(III)bleomycinB2 bithiazole/C-terminal tail domain bound to d(ATTTAGTTAACTAAAT) complexed with MMLV RT catalytic fragment
2R2S	;	2.8	;	Co(III)bleomycinB2 bound to d(ATTAGTTATAACTAAT) complexed with MMLV RT catalytic fragment
6LV3	;	1.2	;	Co- Carbonic Anhydrase II pH 11.0 0 atm CO2
6LV4	;	1.2	;	Co- Carbonic Anhydrase II pH 11.0 20 atm CO2
6LV1	;	1.2	;	Co- Carbonic Anhydrase II pH 7.8 0 atm CO2
6LV2	;	1.2	;	Co- Carbonic Anhydrase II pH 7.8 20 atm CO2
6PZ6	;	1.7	;	Co-assembly of VIQKI D452(beta-L-homoaspartic acid) with human parainfluenza virus type 3 (HPIV3) fusion glycoprotein N-terminal heptad repeat domain
2C32	;	7.01	;	Co-axial association of recombinant eye lens aquaporin-0 observed in loosely packed 3D-crystals
6IAV	;	2.0	;	CO-AZURIN FROM PSEUDOMONAS AERUGINOSA TREATED WITH HYDROSULFIDE
7N4G	;	1.93	;	Co-bound crystal structure of the engineered cyt cb562 variant, AB2-H100A, crystallized in the presence of Co(II)
7MK4	;	1.27	;	Co-bound crystal structure of the engineered cyt cb562 variant, DiCyt2
7LRR	;	1.89	;	Co-bound crystal structure of the engineered cyt cb562 variant, DiCyt2, crystallized in the presence of Cu(II) (M1) and Co(II) (M2)
5U7F	;	1.789	;	Co-bound dihydroneopterin triphosphate pyrophosphohydrolase from E. coli
2Y3B	;	1.554	;	Co-bound form of Cupriavidus metallidurans CH34 CnrXs
5BVH	;	1.53	;	CO-bound form of Selenium incorporated nitrogenase MoFe-protein (Av1-Se-CO) from A. vinelandii
4TKV	;	1.5	;	CO-bound Nitrogenase MoFe-protein from A. vinelandii
7A45	;	1.75	;	CO-bound sperm whale myoglobin measured by serial femtosecond crystallography
7A44	;	1.75	;	CO-bound sperm whale myoglobin measured by serial synchrotron crystallography
6MV0	;	1.97	;	CO-bound Sperm Whale Myoglobin, room temperature structure solved by serial 5degree oscillation crystallography
6N02	;	2.0	;	CO-bound Sperm Whale Myoglobin, room temperature structure, first 2 degrees of 5 degree total oscillation
6N03	;	2.1	;	CO-bound Sperm Whale Myoglobin, room temperature structure, last 2 degrees of 5 degree total oscillation and 160 kGy dose
6WZ2	;	2.0006	;	Co-bound structure of an engineered protein trimer, TriCyt3
6X7E	;	1.9987	;	Co-bound structure of an engineered protein trimer, TriCyt3, with delta isomerism at the hexahistidine coordination site
1XJ2	;	2.0	;	CO-bound structure of bjFixLH
1XJ4	;	1.8	;	CO-bound structure of BjFixLH
2VV8	;	1.61	;	Co-bound structure of bjFixLH
8AIO	;	1.52	;	CO-bound [FeFe]-hydrogenase I from Clostridium pasteurianum (CpI)
8ALN	;	1.34	;	CO-bound [FeFe]-hydrogenase I from Clostridium pasteurianum (CpI) at 1.34 Angstrom
7JRF	;	1.33	;	CO-CO-BOUND NITROGENASE MOFE-PROTEIN FROM A. VINELANDII
7N3L	;	1.631	;	Co-complex CYP46A1 with 0420 (compound 6)
7N3M	;	1.698	;	Co-complex CYP46A1 with 0431 (compound 17)
7LRL	;	1.995	;	Co-complex CYP46A1 with 7742 (Soticlestat/TAK-935))
7LS3	;	2.15	;	Co-complex CYP46A1 with 8114 (3f)
7LS4	;	2.05	;	Co-complex CYP46A1 with 9129 (1b)
7N6F	;	1.4	;	Co-complex CYP46A1 with compound 3f
3GTM	;	3.8	;	Co-complex of Backtracked RNA polymerase II with TFIIS
6UKD	;	1.589	;	Co-complex of S. pyogenes 10782 streptopain bound with a nitrile-based specific covalent inhibitor
6UQD	;	2.02	;	Co-complex of S. pyogenes 10782 streptopain bound with a SuFEx-based optimized small molecule inhibitor
7N0E	;	2.3	;	Co-complex of the histidine kinase region of RetS and the dimerization and histidine phosphotransfer domain of GacS
4A1T	;	2.05	;	Co-Complex of the of NS3-4A protease with the inhibitory peptide CP5- 46-A (in-House data)
2W03	;	2.95	;	Co-complex Structure of Achromobactin Synthetase Protein D (AcsD) with adenosine, sulfate and citrate from Pectobacterium Chrysanthemi
2X3K	;	2.5	;	CO-COMPLEX STRUCTURE OF ACHROMOBACTIN SYNTHETASE PROTEIN D (ACSD) WITH AMP AND SULFATE FROM PECTOBACTERIUM CHRYSANTHEMI
2X3J	;	2.0	;	CO-COMPLEX STRUCTURE OF ACHROMOBACTIN SYNTHETASE PROTEIN D (ACSD) WITH ATP AND N-CITRYL-ETHYLENEDIAMINE FROM PECTOBACTERIUM CHRYSANTHEMI
2W02	;	2.2	;	Co-complex Structure of Achromobactin Synthetase Protein D (AcsD) with ATP from Pectobacterium Chrysanthemi
2W04	;	2.8	;	Co-complex Structure of Achromobactin Synthetase Protein D (AcsD) with citrate in ATP binding site from Pectobacterium Chrysanthemi
2X0Q	;	1.96	;	CO-COMPLEX STRUCTURE OF ALCALIGIN BIOSYNTHESIS PROTEIN C (ALCC) WITH ATP FROM Bordetella bronchiseptica
2X0P	;	2.1	;	CO-COMPLEX STRUCTURE OF ALCALIGIN BIOSYNTHETASE PROTEIN C (ALCC) WITH ADENOSINE FROM Bordetella bronchiseptica
4ABJ	;	1.45	;	Co-complex structure of bovine trypsin with a modified Bowman-Birk inhibitor (IcA)SFTI-1(1,14), that was 1,5-disubstituted with 1,2,3- trizol to mimic a cis amide bond
4ABI	;	1.55	;	Co-complex structure of bovine trypsin with a modified Bowman-Birk inhibitor (PtA)SFTI-1(1,14), that was 1,4-disubstituted with a 1,2,3- trizol to mimic a trans amide bond
4A1X	;	1.9	;	Co-Complex structure of NS3-4A protease with the inhibitory peptide CP5-46-A (Synchrotron data)
4A1V	;	2.2	;	Co-Complex structure of NS3-4A protease with the optimized inhibitory peptide CP5-46A-4D5E
5OJY	;	1.851	;	Co-complex structure of regulator protein 2 (PamR2) with pamamycin 607 from Streptomyces alboniger
4WEM	;	1.55	;	Co-complex structure of the F4 fimbrial adhesin FaeG variant ac with llama single domain antibody V1
4WEN	;	1.89	;	Co-complex structure of the F4 fimbrial adhesin FaeG variant ac with llama single domain antibody V2
4WEU	;	2.61	;	Co-complex structure of the F4 fimbrial adhesin FaeG variant ad with llama single domain antibody V3
4W6W	;	2.51	;	Co-complex structure of the lectin domain of F18 fimbrial adhesin FedF with inhibitory nanobody NbFedF6
4W6X	;	1.88	;	Co-complex structure of the lectin domain of F18 fimbrial adhesin FedF with inhibitory nanobody NbFedF7
4W6Y	;	1.57	;	Co-complex structure of the lectin domain of F18 fimbrial adhesin FedF with inhibitory nanobody NbFedF9
4EAJ	;	2.609	;	Co-crystal of AMPK core with AMP soaked with ATP
4EAL	;	2.506	;	Co-crystal of AMPK core with ATP soaked with AMP
5DQC	;	2.4651	;	Co-crystal of BACE1 with compound 0211
2IHN	;	3.0	;	Co-crystal of Bacteriophage T4 RNase H with a fork DNA substrate
1G15	;	1.9	;	CO-CRYSTAL OF E. COLI RNASE HI WITH TWO MN2+ IONS BOUND IN THE THE ACTIVE SITE
7EBA	;	2.3	;	Co-crystal of kurarinone with sEH
6EAS	;	2.0	;	Co-crystal of pseudokinase DRIK1 (drought responsive inactive kinase 1) bound to ENMD-2076
8B1S	;	1.6	;	co-crystal of SUDV VP40 with salicylic acid
7EQ7	;	2.111	;	Co-Crystal Structure Analysis of Annexin A2 and 5alpha-EAL
2DWX	;	2.55	;	Co-crystal Structure Analysis of GGA1-GAE with the WNSF motif
1KNJ	;	2.8	;	Co-Crystal Structure of 2-C-methyl-D-erythritol 2,4-cyclodiphosphate Synthase (ispF) from E. coli Involved in Mevalonate-Independent Isoprenoid Biosynthesis, Complexed with CMP/MECDP/Mn2+
4YS7	;	2.502	;	Co-crystal structure of 2-[2-(5,8-dimethyl[1,2,4]triazolo[1,5-a]pyrazin-2-yl)ethyl]-3-methyl-3H-imidazo[4,5-f]quinoline (compound 39) with PDE10A
3K14	;	1.7	;	Co-crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Burkholderia pseudomallei with FOL fragment 535, ethyl 3-methyl-5,6-dihydroimidazo[2,1-b][1,3]thiazole-2-carboxylate
3F0F	;	2.09	;	Co-crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Burkholderia pseudomallei with hydrolyzed CDP
3F0G	;	2.08	;	Co-crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase with CMP
4Y2B	;	2.2	;	Co-crystal structure of 3-ethyl-2-(isopropylamino)-7-(pyridin-3-yl)thieno[3,2-d]pyrimidin-4(3H)-one bound to PDE7A
5F6R	;	1.179	;	Co-crystal Structure of 3-hydroxydecanoyl-(acyl carrier protein) Dehydratase from Yersinia pestis with 5-Benzoylpentanoic Acid
8SWJ	;	1.6	;	Co-crystal structure of 53BP1 tandem Tudor domains in complex with UNC8531
1W8C	;	2.05	;	CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H-PURIN-2- YLAMINE AND MONOMERIC CDK2
3IWN	;	3.2	;	Co-crystal structure of a bacterial c-di-GMP riboswitch
5O14	;	2.195	;	Co-crystal structure of a cross-reactive bactericidal human antibody targeting meningococcal vaccine antigen factor H binding protein
7C52	;	2.89	;	Co-crystal structure of a photosynthetic LH1-RC in complex with electron donor HiPIP
2XM8	;	3.4	;	Co-crystal structure of a small molecule inhibitor bound to the kinase domain of Chk2
4LCK	;	3.2	;	Co-crystal structure of a T-box riboswitch stem I domain in complex with its cognate tRNA
5XGL	;	3.439	;	Co-crystal structure of Ac-AChBPP in complex with alpha-conotoxin LvIA
6M4Z	;	2.803	;	Co-crystal structure of Ac-AChBPP in complex with alpha-conotoxin [D11A]LvIA
7EGR	;	2.503	;	Co-crystal structure of Ac-AChBPP in complex with RgIA
6M4X	;	2.998	;	Co-crystal structure of Ac-AChBPP in complex with [N9A]LvIA
4EWH	;	2.5	;	Co-crystal structure of ACK1 with inhibitor
6C6B	;	2.0	;	Co-crystal structure of adenylyl-sulfate kinase from Cryptococcus neoformans bound to ADP
7NH4	;	2.3	;	Co-Crystal Structure of Akt1 in Complex with Covalent-Allosteric Akt Inhibitor 3
7NH5	;	1.9	;	Co-Crystal Structure of Akt1 in Complex with Covalent-Allosteric Akt Inhibitor 6
7JTY	;	2.21	;	Co-crystal structure of alpha glucosidase with compound 1
7KBR	;	2.09	;	Co-crystal structure of alpha glucosidase with compound 10
7KRY	;	2.55	;	Co-crystal structure of alpha glucosidase with compound 11
7K9N	;	2.07	;	Co-crystal structure of alpha glucosidase with compound 2
7K9O	;	2.302	;	Co-crystal structure of alpha glucosidase with compound 3
7K9Q	;	2.3	;	Co-crystal structure of alpha glucosidase with compound 4
7K9T	;	2.1	;	Co-crystal structure of alpha glucosidase with compound 5
7KAD	;	2.506	;	Co-crystal structure of alpha glucosidase with compound 6
7KB6	;	2.2	;	Co-crystal structure of alpha glucosidase with compound 7
7KB8	;	2.385	;	Co-crystal structure of alpha glucosidase with compound 8
7KBJ	;	2.21	;	Co-crystal structure of alpha glucosidase with compound 9
4EAI	;	2.285	;	Co-crystal structure of an AMPK core with AMP
4EAK	;	2.5	;	Co-crystal structure of an AMPK core with ATP
4EAG	;	2.701	;	Co-crystal structure of an chimeric AMPK core with ATP
5ZXI	;	2.1	;	Co-crystal structure of an Inhibitor in complex with human PPARdelta LBD
5NAF	;	2.493	;	Co-crystal structure of an MeCP2 peptide with TBLR1 WD40 domain
1K73	;	3.01	;	Co-crystal Structure of Anisomycin Bound to the 50S Ribosomal Subunit
3CC4	;	2.7	;	Co-crystal Structure of Anisomycin Bound to the 50S Ribosomal Subunit
4QIC	;	2.05	;	Co-Crystal Structure of Anti-anti-sigma factor PhyR complexed with Anti-sigma factor NepR from Bartonella quintana
1M1K	;	3.2	;	Co-crystal structure of azithromycin bound to the 50S ribosomal subunit of Haloarcula marismortui
6PZ4	;	1.85	;	co-crystal structure of BACE with inhibitor AM-6494
1KC8	;	3.01	;	Co-crystal Structure of Blasticidin S Bound to the 50S Ribosomal Subunit
3G71	;	2.85	;	Co-crystal structure of Bruceantin bound to the large ribosomal subunit
7YC9	;	1.4	;	Co-crystal structure of BTK kinase domain with inhibitor
6J6M	;	1.25	;	Co-crystal structure of BTK kinase domain with Zanubrutinib
8HIG	;	2.329	;	Co-crystal structure of C-terminal DNA binding domain of Saccharopolyspora erythraea GlnR in complex with its cognate promoter DNA
8GL9	;	2.81	;	Co-crystal structure of caPCNA bound to AOH1160 derivative 1LE
8GLA	;	3.77	;	Co-crystal structure of caPCNA bound to the AOH1996 derivative, AOH1996-1LE
1K8A	;	3.0	;	Co-crystal structure of Carbomycin A bound to the 50S ribosomal subunit of Haloarcula marismortui
4OFG	;	2.0	;	Co-crystal structure of carboxy cGMP binding domain of Plasmodium falciparum PKG with cGMP
8GCY	;	1.81	;	Co-crystal structure of CBL-B in complex with N-Aryl isoindolin-1-one inhibitor
1M90	;	2.8	;	Co-crystal structure of CCA-Phe-caproic acid-biotin and sparsomycin bound to the 50S ribosomal subunit
7XBE	;	1.65	;	co-crystal structure of CcpE-RD with citrate
7T8V	;	2.3	;	Co-crystal structure of Chaetomium glucosidase I with EB-0159
7R6J	;	1.905	;	Co-crystal structure of Chaetomium glucosidase with compound 1
8E6G	;	2.3	;	Co-crystal structure of Chaetomium glucosidase with compound 10
8ECW	;	2.25	;	Co-crystal structure of Chaetomium glucosidase with compound 11
8EGV	;	2.09	;	Co-crystal structure of Chaetomium glucosidase with compound 12
8EHP	;	2.68	;	Co-crystal structure of Chaetomium glucosidase with compound 13
8EID	;	2.3	;	Co-crystal structure of Chaetomium glucosidase with compound 14
8EKN	;	2.29	;	Co-crystal structure of Chaetomium glucosidase with compound 15
8ELE	;	2.6	;	Co-crystal structure of Chaetomium glucosidase with compound 16
8EPJ	;	2.15	;	Co-crystal structure of Chaetomium glucosidase with compound 17
8EPO	;	2.2	;	Co-crystal structure of Chaetomium glucosidase with compound 18
8EPR	;	1.99	;	Co-crystal structure of Chaetomium glucosidase with compound 19
7RD2	;	2.61	;	Co-crystal structure of Chaetomium glucosidase with compound 2
8EQ7	;	2.21	;	Co-crystal structure of Chaetomium glucosidase with compound 20
8EQX	;	2.5	;	Co-crystal structure of Chaetomium glucosidase with compound 21
8EUD	;	2.37	;	Co-crystal structure of Chaetomium glucosidase with compound 22
8ER4	;	2.3	;	Co-crystal structure of Chaetomium glucosidase with compound 23
8ETL	;	2.3	;	Co-crystal structure of Chaetomium glucosidase with compound 24
8ETO	;	2.3	;	Co-crystal structure of Chaetomium glucosidase with compound 25
8EUR	;	2.61	;	Co-crystal structure of Chaetomium glucosidase with compound 26
8EUT	;	2.8	;	Co-crystal structure of Chaetomium glucosidase with compound 27
8EUX	;	2.8	;	Co-crystal structure of Chaetomium glucosidase with compound 28
7REV	;	2.3	;	Co-crystal structure of Chaetomium glucosidase with compound 3
8E3J	;	2.71	;	Co-crystal structure of Chaetomium glucosidase with compound 4
8E3P	;	2.3	;	Co-crystal structure of Chaetomium glucosidase with compound 5
8E4I	;	2.2	;	Co-crystal structure of Chaetomium glucosidase with compound 6
8E4K	;	2.2	;	Co-crystal structure of Chaetomium glucosidase with compound 7
8E4Z	;	2.37	;	Co-crystal structure of Chaetomium glucosidase with compound 8
8E5U	;	2.33	;	Co-crystal structure of Chaetomium glucosidase with compound 9
7T66	;	2.19	;	Co-crystal structure of Chaetomium glucosidase with compound UV-4
7T68	;	2.32	;	Co-crystal structure of Chaetomium glucosidase with compound UV-5
1ZYS	;	1.7	;	Co-crystal structure of Checkpoint Kinase Chk1 with a pyrrolo-pyridine inhibitor
4QWP	;	1.7	;	co-crystal structure of chitosanase OU01 with substrate
6UD2	;	1.7	;	co-crystal structure of compound 1 bound to human Mcl-1
8G1Q	;	3.73	;	Co-crystal structure of Compound 1 in complex with the bromodomain of human SMARCA4 and pVHL:ElonginC:ElonginB
8G1P	;	2.7	;	Co-crystal structure of Compound 11 in complex with the bromodomain of human SMARCA2 and pVHL:ElonginC:ElonginB
4QFD	;	2.85	;	Co-crystal structure of compound 2 (3-(7-hydroxy-2-oxo-4-phenyl-2H-chromen-6-yl)propanoic acid) and FAD bound to human DAAO at 2.85A
4QFC	;	2.4	;	Co-crystal structure of compound 3 (4-hydroxy-6-[2-(7-hydroxy-2-oxo-4-phenyl-2h-chromen-6-yl)ethyl]pyridazin-3(2h)-one) and FAD bound to human DAAO at 2.4A
8XAM	;	1.3	;	Co-crystal structure of compound 7 in complex with MAT2A
4EA1	;	2.46	;	Co-crystal structure of dehydrosqualene synthase (Crtm) from S. aureus with SQ-109
3UFM	;	1.95	;	Co-crystal structure of Deinococcus radiodurans uracil-DNA glycosylase and the C-terminus of the single-stranded DNA-binding protein
5K5M	;	2.01	;	Co-Crystal Structure of Dengue Virus Serotype 2 RNA Dependent RNA Polymerase with Compound 27
3NRR	;	1.8	;	Co-crystal structure of dihydrofolate reductase-thymidylate synthase from Babesia bovis with dUMP, Raltitrexed and NADP
3K2H	;	2.2	;	Co-crystal structure of dihydrofolate reductase/thymidylate synthase from Babesia bovis with dUMP, Pemetrexed and NADP
5VTA	;	2.8	;	Co-Crystal Structure of DPPIV with a Chemibody Inhibitor
1WSF	;	2.3	;	Co-crystal structure of E.coli RNase HI active site mutant (D134A*) with Mn2+
1WSE	;	2.3	;	Co-crystal structure of E.coli RNase HI active site mutant (E48A*) with Mn2+
1WSG	;	2.2	;	Co-crystal structure of E.coli RNase HI active site mutant (E48A/D134N*) with Mn2+
4DT6	;	2.6	;	Co-crystal structure of eIF4E with inhibitor
4DUM	;	2.95	;	Co-crystal structure of eIF4E with inhibitor
5EHC	;	2.4	;	Co-crystal structure of eIF4E with nucleotide mimetic inhibitor.
5EI3	;	1.71	;	Co-crystal structure of eIF4E with nucleotide mimetic inhibitor.
5EIR	;	2.69	;	Co-crystal structure of eIF4E with nucleotide mimetic inhibitor.
5EKV	;	3.61	;	Co-crystal structure of eIF4E with nucleotide mimetic inhibitor.
3UF7	;	1.2	;	Co-crystal structure of Escherichia coli uracil-DNA glycosylase and a C-terminal fragement of the single-stranded DNA-binding protein
8PPZ	;	1.85	;	Co-crystal structure of FKBP12, compound 7 and the FRB fragment of mTOR
8IT9	;	2.14	;	Co-crystal structure of FTO bound to 22
7WCV	;	2.3	;	Co-crystal structure of FTO bound to 6e
6VKV	;	2.22	;	Co-crystal structure of GS-6207 bound to HIV-1 capsid hexamer
3I7E	;	1.7	;	Co-crystal structure of HIV-1 protease bound to a mutant resistant inhibitor UIC-98038
6CMN	;	1.796	;	Co-Crystal Structure of HIV-1 TAR Bound to Lab-Evolved RRM TBP6.7
6XH2	;	1.71	;	Co-crystal structure of HIV-1 TAR RNA in complex with lab-evolved RRM 6.6
6XH3	;	2.353	;	Co-crystal structure of HIV-1 TAR RNA in complex with lab-evolved RRM TBP6.3
6XH1	;	2.601	;	Co-crystal structure of HIV-1 TAR RNA in complex with lab-evolved RRM TBP6.7 mutant
6XH0	;	3.1	;	Co-crystal structure of HIV-1 TAR RNA in complex with lab-evolved RRM TBP6.9
3G6E	;	2.7	;	Co-crystal structure of Homoharringtonine bound to the large ribosomal subunit
8Q61	;	2.32	;	Co-crystal structure of human AKT2 with compound 3
7U9I	;	2.0	;	Co-crystal structure of human CARM1 in complex with MT556 inhibitor
1MZC	;	2.0	;	Co-Crystal Structure Of Human Farnesyltransferase With Farnesyldiphosphate and Inhibitor Compound 33a
1LD8	;	1.8	;	Co-crystal structure of Human Farnesyltransferase with farnesyldiphosphate and inhibitor compound 49
1LD7	;	2.0	;	Co-crystal structure of Human Farnesyltransferase with farnesyldiphosphate and inhibitor compound 66
5YJF	;	2.49	;	Co-crystal structure of Human Nicotinamide N-methyltransferase (NNMT) with small molecule analog of Nicotinamide
7NBJ	;	2.275	;	Co-crystal structure of Human Nicotinamide N-methyltransferase (NNMT) with the bisubstrate-like inhibitor (1)
7NBM	;	2.691	;	Co-crystal structure of Human Nicotinamide N-methyltransferase (NNMT) with the bisubstrate-like inhibitor (33)
7BKG	;	2.326	;	Co-crystal structure of Human Nicotinamide N-methyltransferase (NNMT) with the tricyclic inhibitor (2)
7BLE	;	2.809	;	Co-crystal structure of Human Nicotinamide N-methyltransferase (NNMT) with the tricyclic inhibitor (3)
7NBQ	;	2.479	;	Co-crystal structure of Human Nicotinamide N-methyltransferase (NNMT) with the tricyclic inhibitor (4)
7ET7	;	2.61	;	Co-crystal structure of Human Nicotinamide N-methyltransferase (NNMT) with tricyclic small molecule inhibitor JBSNF-000028
7EU5	;	2.731	;	Co-crystal structure of Human Nicotinamide N-methyltransferase (NNMT) with tricyclic small molecule inhibitor JBSNF-000107
6ORR	;	2.25	;	Co-crystal structure of human NicotinamideN-Methyltransferase (NNMT) in complex with High-Affinity Alkynyl Bisubstrate Inhibitor NS1
6VQN	;	2.49	;	Co-crystal structure of human PD-L1 complexed with Compound A
7T39	;	2.81	;	Co-crystal structure of human PRMT9 in complex with MT221 inhibitor
7RBQ	;	2.2	;	Co-crystal structure of human PRMT9 in complex with MT556 inhibitor
8GOD	;	2.88	;	Co-crystal structure of Human Protein-arginine deiminase type-4 (PAD4) with small molecule inhibitor JBI-589
6M5W	;	3.1	;	Co-crystal structure of human serine hydroxymethyltransferase 1 in complex with Pyridoxal 5'-phosphate (PLP) and glycodeoxycholic acid
6M5O	;	2.30001	;	Co-crystal structure of human serine hydroxymethyltransferase 2 in complex with Pyridoxal 5'-phosphate (PLP) and glycodeoxycholic acid
5HQ8	;	1.72	;	Co-crystal Structure of human SMYD3 with a MEKK2 peptide at 2.13A
5HI7	;	2.15	;	Co-crystal structure of human SMYD3 with an aza-SAH compound
6P6G	;	1.59	;	Co-crystal Structure of human SMYD3 with Isoxazole Amides Inhibitors
6P6K	;	1.55	;	Co-crystal Structure of human SMYD3 with Isoxazole Amides Inhibitors
6P7Z	;	1.19	;	Co-crystal Structure of human SMYD3 with Isoxazole Amides Inhibitors
6PAF	;	1.241	;	Co-crystal Structure of human SMYD3 with Isoxazole Amides Inhibitors
6I7A	;	2.2	;	Co-crystal structure of human SPOP MATH domain (D140N) and human BRD3 fragment
6I5P	;	1.81	;	Co-crystal structure of human SPOP MATH domain (E47K) and human BRD3 fragment
6I68	;	1.85	;	Co-crystal structure of human SPOP MATH domain (M117V) and human BRD3 fragment
6I41	;	1.9	;	Co-crystal structure of human SPOP MATH domain (wild-type) and human BRD3 fragment
8VL7	;	1.88	;	Co-crystal structure of human TREX1 in complex with an inhibitor
3RBQ	;	2.0	;	Co-crystal structure of human UNC119 (retina gene 4) and an N-terminal Transducin-alpha mimicking peptide
1UBD	;	2.5	;	CO-CRYSTAL STRUCTURE OF HUMAN YY1 ZINC FINGER DOMAIN BOUND TO THE ADENO-ASSOCIATED VIRUS P5 INITIATOR ELEMENT
4JIF	;	1.701	;	Co-crystal structure of ICAP1 PTB domain in complex with a KRIT1 peptide
5WL0	;	2.4	;	Co-crystal structure of Influenza A H3N2 PB2 (241-741) bound to VX-787
5XMX	;	2.0	;	Co-crystal structure of Inhibitor compound in complex with human PPARdelta LBD
7F80	;	2.8	;	Co-crystal structure of Inhibitor compound MA-211 in complex with human PPARdelta LBD
3TJD	;	2.9	;	co-crystal structure of Jak2 with thienopyridine 19
3TJC	;	2.4	;	Co-crystal structure of jak2 with thienopyridine 8
4L7F	;	1.95	;	Co-crystal Structure of JNK1 and AX13587
3V7K	;	2.271	;	Co-crystal structure of K72E variant of rat polymerase beta: Enzyme-DNA binary complex
5YXZ	;	1.7	;	Co-crystal Structure of KRAS (G12C) covalently bound with Quinazoline based inhibitor JBI484
5YY1	;	1.69	;	Co-crystal Structure of KRAS (G12C) covalently bound with Quinazoline based inhibitor JBI739
8T7V	;	2.25	;	Co-crystal structure of KRIT1 with a 1-hydroxy 2-naphthaldehyde derivative (6-(furan-2-yl)-2-hydroxy-1-naphthaldehyde)
8SU8	;	2.01	;	Co-crystal structure of KRIT1 with a 1-hydroxy 2-naphthaldehyde derivative (6-(furan-2-yl)-2-hydroxy-1-naphthaldehyde).
8T09	;	2.15	;	Co-crystal structure of KRIT1 with a 1-hydroxy 2-naphthaldehyde derivative (6-ethynyl-2-hydroxy-1-naphthaldehyde)
3BYS	;	2.2	;	co-crystal structure of Lck and aminopyrimidine amide 10b
3BYU	;	2.3	;	co-crystal structure of Lck and aminopyrimidine reverse amide 23
5ES3	;	2.29	;	Co-crystal structure of LDH liganded with oxamate
7RJ4	;	3.32	;	Co-crystal structure of lenacapavir bound to N74D mutant of disulfide stabilized HIV-1 CA hexamer
7RJ2	;	2.32	;	Co-crystal structure of lenacapavir bound to Q67H/N74D mutant of disulfide stabilized HIV-1 CA hexamer
1Z56	;	3.92	;	Co-Crystal Structure of Lif1p-Lig4p
4ZOP	;	2.62	;	Co-crystal Structure of Lipid Kinase PI3K alpha with a selective phosphatidylinositol-3 kinase alpha inhibitor
5KQG	;	1.5	;	Co-crystal structure of LMW-PTP in complex with 2-(benzothiazol-2-ylamino)-2-oxo-1-phenylethanesulfonic acid
5KQL	;	1.45	;	Co-crystal structure of LMW-PTP in complex with 2-oxo-1-phenyl-2-(phenylamino)ethanesulfonic acid
5KQM	;	1.91	;	Co-crystal structure of LMW-PTP in complex with MES
6UFH	;	3.104	;	Co-crystal structure of M. tuberculosis ileS T-box in complex with tRNA-3'-2'3'cyclic phosphate
6UFG	;	2.929	;	Co-crystal structure of M. tuberculosis ileS T-box in complex with tRNA-3'-OH
7PQK	;	1.15	;	Co-Crystal Structure of M. tuberculosis LeuRS in Complex with the Adduct Formed by Prodrug Cmpd1 with Adenosine-monophosphate
6O4U	;	1.7	;	Co-crystal structure of Mcl1 with inhibitor
6O6F	;	1.6	;	Co-crystal structure of Mcl1 with inhibitor
6O6G	;	2.4	;	Co-crystal structure of Mcl1 with inhibitor
6OQB	;	1.6	;	Co-crystal structure of Mcl1 with inhibitor 10
4OAS	;	1.7	;	co-crystal structure of MDM2 (17-111) in complex with compound 25
4QO4	;	1.7	;	co-crystal structure of MDM2 (17-111) with compound 16, {(3R,5R,6S)-5-(3-CHLOROPHENYL)-6-(4-CHLOROPHENYL)-1-[(1S)-1-(6-CYCLOPROPYLPYRIDIN-2-YL)PROPYL]-3-METHYL-2-OXOPIPERIDIN-3-YL}ACETIC ACID
4WT2	;	1.42	;	Co-crystal Structure of MDM2 in Complex with AM-7209
4OGN	;	1.377	;	Co-Crystal Structure of MDM2 with Inhbitor Compound 3
4OGT	;	1.5361	;	Co-Crystal Structure of MDM2 with Inhbitor Compound 46
4JVR	;	1.7	;	Co-crystal structure of MDM2 with inhibitor (2'S,3R,4'S,5'R)-N-(2-aminoethyl)-6-chloro-4'-(3-chloro-2-fluorophenyl)-2'-(2,2-dimethylpropyl)-2-oxo-1,2-dihydrospiro[indole-3,3'-pyrrolidine]-5'-carboxamide
4JVE	;	2.3	;	Co-crystal structure of MDM2 with inhibitor (2R,3E)-2-[(2S,3R,6S)-2,3-bis(4-chlorophenyl)-6-(4-fluorobenzyl)-5-oxomorpholin-4-yl]pent-3-enoic acid
4JV7	;	2.2	;	Co-crystal structure of MDM2 with inhibitor (2S,5R,6S)-2-benzyl-5,6-bis(4-bromophenyl)-4-methylmorpholin-3-one
4JV9	;	2.5	;	Co-crystal structure of MDM2 with inhibitor (2S,5R,6S)-2-benzyl-5,6-bis(4-chlorophenyl)-4-methylmorpholin-3-one
4OBA	;	1.602	;	Co-crystal structure of MDM2 with Inhibitor Compound 4
4ODE	;	1.8	;	Co-Crystal Structure of MDM2 with Inhibitor Compound 4
4ODF	;	2.2006	;	Co-Crystal Structure of MDM2 with Inhibitor Compound 47
4OGV	;	2.197	;	Co-Crystal Structure of MDM2 with Inhibitor Compound 49
4JWR	;	2.35	;	Co-crystal structure of MDM2 with inhibitor {(2S,5R,6S)-6-(3-chlorophenyl)-5-(4-chlorophenyl)-4-[(2S)-1-hydroxybutan-2-yl]-3-oxomorpholin-2-yl}acetic acid
4OCC	;	1.8	;	co-crystal structure of MDM2(17-111) in complex with compound 48
6CJH	;	3.6	;	Co-crystal structure of MNK2 in complex with an inhibitor
6CKI	;	2.95	;	Co-crystal structure of MNK2 in Complex With Inhibitor
5YJI	;	1.99	;	Co-crystal structure of Mouse Nicotinamide N-methyltransferase (NNMT) with small molecule analog of Nicotinamide
3I55	;	3.11	;	Co-crystal structure of Mycalamide A Bound to the Large Ribosomal Subunit
5NSD	;	2.046	;	Co-crystal structure of NAMPT dimer with KPT-9274
5FGL	;	2.4	;	Co-crystal Structure of NicR2_Hsp
3VNR	;	1.75	;	Co-crystal structure of NRPS adenylation protein CytC1 with aminobutyric acid and AMP from streptomyces
3VNQ	;	2.1	;	Co-crystal structure of NRPS adenylation protein CytC1 with ATP from streptomyces
3VNS	;	2.001	;	Co-crystal structure of NRPS adenylation protein CytC1 with D-valine and AMP from streptomyces
8U0Q	;	1.69	;	Co-crystal structure of optimized analog TDI-13537 provided new insights into the potency determinants of the sulfonamide inhibitor series
1ZCW	;	2.25	;	Co-crystal structure of Orf2 an aromatic prenyl transferase from Streptomyces sp. strain CL190 complexed with GPP
1ZB6	;	1.95	;	Co-Crystal Structure of ORF2 an Aromatic Prenyl Transferase from Streptomyces sp. strain cl190 complexed with GSPP and 1,6-dihydroxynaphtalene
1ZDW	;	2.02	;	Co-crystal structure of Orf2 an aromatic prenyl transferase from Streptomyces sp. strain CL190 complexed with GSPP and Flaviolin
1ZDY	;	1.44	;	Co-crystal structure of Orf2 an aromatic prenyl transferase from Streptomyces sp. strain CL190 complexed with TAPS
6MO4	;	1.844	;	Co-Crystal structure of P. aeruginosa LpxC-50067 complex
6MO5	;	1.851	;	Co-Crystal structure of P. aeruginosa LpxC-50228 complex
6MOD	;	1.85	;	Co-Crystal structure of P. aeruginosa LpxC-50432 complex
6MOO	;	2.2	;	Co-Crystal structure of P. aeruginosa LpxC-achn975 complex
8P64	;	3.312	;	Co-crystal structure of PD-L1 with low molecular weight inhibitor
8R6Q	;	2.17	;	Co-crystal structure of PD-L1 with low molecular weight inhibitor
6W4N	;	2.623	;	Co-crystal structure of Pd_dinase with probe glycine-propargylglycine-AOMK
4X7O	;	2.65	;	Co-crystal Structure of PERK bound to 1-[5-(4-amino-2,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydro-1H-indol-1-yl]-2-[3-fluoro-5-(trifluoromethyl)phenyl]ethanone inhibitor
4X7N	;	2.35	;	Co-crystal Structure of PERK bound to 4-[2-amino-4-methyl-3-(2-methylquinolin-6-yl)benzoyl]-1-methyl-2,5-diphenyl-1,2-dihydro-3H-pyrazol-3-one inhibitor
4X7K	;	1.8	;	Co-crystal Structure of PERK bound to 4-{2-amino-3-[5-fluoro-2-(methylamino)quinazolin-6-yl]-4-methylbenzoyl}-1-methyl-2,5-diphenyl-1,2-dihydro-3H-pyrazol-3-one inhibitor
4X7L	;	1.9	;	Co-crystal Structure of PERK bound to 4-{2-amino-4-methyl-3-[2-(methylamino)-1,3-benzothiazol-6-yl]benzoyl}-1-methyl-2,5-diphenyl-1,2-dihydro-3H-pyrazol-3-one inhibitor
4X7H	;	2.0	;	Co-crystal Structure of PERK bound to N-{5-[(6,7-dimethoxyquinolin-4-yl)oxy]pyridin-2-yl}-1-methyl-3-oxo-2-phenyl-5-(pyridin-4-yl)-2,3-dihydro-1H-pyrazole-4-carboxamide inhibitor
4X7J	;	2.3	;	Co-crystal Structure of PERK with 2-amino-N-[4-methoxy-3-(trifluoromethyl)phenyl]-4-methyl-3-[2-(methylamino)quinazolin-6-yl]benzamide inhibitor
8EQ9	;	2.86	;	Co-crystal structure of PERK with compound 11
8EQD	;	2.92	;	Co-crystal structure of PERK with compound 24
8EQE	;	2.559	;	Co-crystal structure of PERK with compound 26
7MF0	;	2.809	;	Co-crystal structure of PERK with inhibitor (R)-2-amino-N-cyclopropyl-5-(4-(2-(3,5-difluorophenyl)-2-hydroxyacetamido)-2-methylphenyl)nicotinamide
8U8J	;	2.1	;	Co-crystal structure of phosphorylated ERK2 in complex with ERK1/2 inhibitor #16
8U8K	;	2.1	;	Co-crystal structure of phosphorylated ERK2 in complex with ERK1/2 inhibitor #8
4RPV	;	3.05	;	co-crystal structure of Pim1 with compound 3
5KJX	;	1.9	;	Co-crystal Structure of PKA RI alpha CNB-B domain with cAMP
5KJY	;	2.0	;	Co-crystal structure of PKA RI alpha CNB-B mutant (G316R/A336T) with cAMP
5KJZ	;	1.347	;	Co-crystal structure of PKA RI alpha CNB-B mutant (G316R/A336T) with cGMP
1FT2	;	3.4	;	CO-CRYSTAL STRUCTURE OF PROTEIN FARNESYLTRANSFERASE COMPLEXED WITH A FARNESYL DIPHOSPHATE SUBSTRATE
7N10	;	1.65	;	Co-crystal structure of Prx with ComR DNA binding domain
7RHN	;	2.46	;	Co-crystal structure of Q67H mutant of disulfide stabilized HIV-1 CA hexamer and lenacapavir
4DXA	;	1.95	;	Co-crystal structure of Rap1 in complex with KRIT1
3UXP	;	2.723	;	Co-crystal Structure of Rat DNA polymerase beta Mutator I260Q: Enzyme-DNA-ddTTP
1D8D	;	2.0	;	CO-CRYSTAL STRUCTURE OF RAT PROTEIN FARNESYLTRANSFERASE COMPLEXED WITH A K-RAS4B PEPTIDE SUBSTRATE AND FPP ANALOG AT 2.0A RESOLUTION
3BPC	;	1.85	;	co-crystal structure of S25-2 Fab in complex with 5-deoxy-4-epi-2,3-dehydro Kdo (4.8) Kdo
7UO3	;	1.8	;	Co-crystal structure of Salmonella Typhimurium Tlde1a in complex with D-alanine
7UO8	;	1.6	;	Co-crystal structure of Salmonella Typhimurium Tlde1a in complex with D-methionine
7TA7	;	2.28	;	Co-crystal structure of SARS-CoV-2 Mpro C145A with substrate peptide 10/11
7TB2	;	1.8	;	Co-crystal structure of SARS-CoV-2 Mpro C145A with substrate peptide 12/13
7TBT	;	2.45	;	Co-crystal structure of SARS-CoV-2 Mpro C145A with substrate peptide 13/14
7TC4	;	1.94	;	Co-crystal structure of SARS-CoV-2 Mpro C145A with substrate peptide 15/16
7T70	;	2.35	;	Co-crystal structure of SARS-CoV-2 Mpro C145A with substrate peptide 4/5
7T8M	;	1.6	;	Co-crystal structure of SARS-CoV-2 Mpro C145A with substrate peptide 5/6
7T8R	;	1.74	;	Co-crystal structure of SARS-CoV-2 Mpro C145A with substrate peptide 7/8
7T9Y	;	2.18	;	Co-crystal structure of SARS-CoV-2 Mpro C145A with substrate peptide 8/9
7TA4	;	1.78	;	Co-crystal structure of SARS-CoV-2 Mpro C145A with substrate peptide 9/10
8TBE	;	2.15	;	Co-crystal structure of SARS-CoV-2 Mpro with Pomotrelvir
4RDD	;	1.601	;	Co-crystal structure of SHP2 in complex with a Cefsulodin derivative
7ZLS	;	1.92	;	co-crystal structure of SOCS2:ElonginB:ElonginC in complex with compound 13
1KD1	;	3.0	;	Co-crystal Structure of Spiramycin bound to the 50S Ribosomal Subunit of Haloarcula marismortui
6F8G	;	2.03	;	Co-crystal structure of SPOP MATH domain and hamster Pdx1 fragment
6F8F	;	2.0	;	Co-crystal structure of SPOP MATH domain and human Pdx1 fragment
6USN	;	2.773	;	Co-crystal structure of SPR with compound 5
1SVL	;	1.95	;	Co-crystal structure of SV40 large T antigen helicase domain and ADP
1SVM	;	1.94	;	Co-crystal structure of SV40 large T antigen helicase domain and ATP
4N3R	;	1.9	;	Co-crystal structure of tankyrase 1 with compound 2 (5-(2-aminoquinazolin-6-yl)-N-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)-2-fluorobenzamide)
4N4T	;	2.315	;	Co-crystal structure of tankyrase 1 with compound 3 [(4S)-3-{4-[6-amino-5-(pyrimidin-2-yl)pyridin-3-yl]phenyl}-5,5-dimethyl-4-phenyl-1,3-oxazolidin-2-one]
4MSK	;	2.3	;	Co-crystal structure of tankyrase 1 with compound 34
4N4V	;	2.0	;	Co-crystal structure of tankyrase 1 with compound 4 [(4S)-3-{trans-4-[6-amino-5-(pyrimidin-2-yl)pyridin-3-yl]cyclohexyl}-5,5-dimethyl-4-phenyl-1,3-oxazolidin-2-one]
4MT9	;	2.0	;	Co-crystal structure of tankyrase 1 with compound 49
1VTL	;	2.25	;	CO-CRYSTAL STRUCTURE OF TBP RECOGNIZING THE MINOR GROOVE OF A TATA ELEMENT
8HML	;	2.95	;	Co-crystal structure of the C terminal DNA binding domain of Saccharopolyspora erythraea GlnR in complex with its conserved promoter DNA in 2.95 Angstrom resolution
4RV8	;	2.053	;	Co-Crystal Structure of the Catalytic Domain of the Inosine Monophosphate Dehydrogenase from Cryptosporidium parvum and the inhibitor p131
4QJ1	;	2.415	;	Co-crystal structure of the catalytic domain of the inosine monophosphate dehydrogenase from Cryptosporidium parvum with inhibitor N109
8EM8	;	2.54	;	Co-crystal structure of the cGMP-dependent protein kinase PKG from Plasmodium falciparum in complex with RY-1-165
5GPG	;	1.67	;	Co-crystal structure of the FK506 binding domain of human FKBP25, Rapamycin and the FRB domain of human mTOR
6V9B	;	2.4	;	Co-crystal structure of the fluorogenic Mango-IV homodimer bound to TO1-Biotin
6V9D	;	2.8	;	Co-crystal structure of the fluorogenic Mango-IV homodimer bound to TO1-Biotin
5V3F	;	1.7	;	Co-crystal structure of the fluorogenic RNA Mango
6OD9	;	4.102	;	Co-crystal structure of the Fusobacterium ulcerans ZTP riboswitch using an X-ray free-electron laser
4MGN	;	3.2	;	Co-crystal structure of the G. kaustophilus glyQS T box riboswitch Stem I in complex with tRNA
6PMO	;	2.65703	;	Co-crystal structure of the Geobacillus kaustophilus glyQ T-box riboswitch discriminator domain in complex with tRNA-Gly
1VTN	;	2.5	;	CO-CRYSTAL STRUCTURE OF THE HNF-3/FORK HEAD DNA-RECOGNITION MOTIF RESEMBLES HISTONE H5
3RLR	;	1.7	;	Co-crystal structure of the HSP90 ATP binding domain in complex with 4-(2,4-dichloro-5-methoxyphenyl)-2,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
3RLQ	;	1.9	;	Co-crystal structure of the HSP90 ATP binding domain in complex with 4-(2,4-dichloro-5-methoxyphenyl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5- carbonitrile
3RLP	;	1.7	;	Co-crystal structure of the HSP90 ATP binding domain in complex with 4-(2,4-dichloro-5-methoxyphenyl)-6-methylpyrimidin-2-amine
3K3B	;	2.4	;	Co-crystal structure of the human kinesin Eg5 with a novel tetrahydro-beta-carboline
5E16	;	1.65	;	Co-crystal structure of the N-termial cGMP binding domain of Plasmodium falciparum PKG with cGMP
4DRI	;	1.45	;	Co-crystal structure of the PPIase domain of FKBP51, Rapamycin and the FRB fragment of mTOR
4DRH	;	2.3	;	Co-crystal structure of the PPIase domain of FKBP51, Rapamycin and the FRB fragment of mTOR at low pH
5J3U	;	1.8	;	Co-crystal structure of the regulatory domain of Toxoplasma gondii PKA with cAMP
5KBX	;	2.8	;	Co-crystal structure of the Saccharomyces cerevisiae histidine phosphotransfer signaling protein Ypd1 and the receiver domain of its downstream response regulator Ssk1
3KKA	;	2.4	;	Co-crystal structure of the sam domains of EPHA1 AND EPHA2
8PH4	;	1.69	;	Co-Crystal structure of the SARS-CoV2 main protease Nsp5 with an Uracil-carrying X77-like inhibitor
5UXX	;	2.45	;	Co-crystal structure of the sigma factor RpoE in complex with the anti-sigma factor NepR from Bartonella quintana
4Z07	;	2.5	;	Co-crystal structure of the tandem CNB (CNB-A/B) domains of human PKG I beta with cGMP
8T55	;	2.2	;	Co-crystal structure of the WD-repeat domain of human WDR91 in complex with MR46654
3G4S	;	3.2	;	Co-crystal structure of Tiamulin bound to the large ribosomal subunit
4K4F	;	2.9	;	Co-crystal structure of TNKS1 with compound 18 [4-[(4S)-5,5-dimethyl-2-oxo-4-phenyl-1,3-oxazolidin-3-yl]-N-(quinolin-8-yl)benzamide]
4K4E	;	2.3	;	Co-crystal structure of tnks1 with compound 52 [N~2-(5-chloro-2-methoxyphenyl)-N-[trans-4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)cyclohexyl]glycinamide]
7EVU	;	1.697	;	Co-crystal Structure of Toxoplasma gondii Prolyl tRNA Synthetase (TgPRS) in complex with HFG and JE6
7EVV	;	1.704	;	Co-crystal Structure of Toxoplasma gondii Prolyl tRNA Synthetase (TgPRS) in complex with JE6 and L-pro
7FAK	;	1.899	;	Co-crystal Structure of Toxoplasma gondii Prolyl tRNA Synthetase (TgPRS) in complex with L96 and L-pro
7FAM	;	2.42	;	Co-crystal Structure of Toxoplasma gondii Prolyl tRNA Synthetase (TgPRS) in complex with L97 and L-pro
7FAN	;	1.769	;	Co-crystal Structure of Toxoplasma gondii Prolyl tRNA Synthetase (TgPRS) in complex with T35 and L-pro
7FAL	;	3.219	;	Co-crystal Structure of Toxoplasma gondii Prolyl tRNA Synthetase (TgPRS) in complex with T36 and L-pro
3D8A	;	2.55	;	Co-crystal structure of TraM-TraD complex.
3I56	;	2.9	;	Co-crystal structure of Triacetyloleandomcyin Bound to the Large Ribosomal Subunit
1K9M	;	3.0	;	Co-crystal structure of tylosin bound to the 50S ribosomal subunit of Haloarcula marismortui
7QG6	;	2.95	;	Co-crystal structure of UPF3A-RRM-NOPS-L with UPF2-MIF4GIII
7NWU	;	2.6	;	Co-crystal structure of UPF3B-RRM-NOPS-L with UPF2-MIF4GIII
7AQY	;	1.9	;	Co-Crystal Structure of Variant Surface Glycoprotein VSG2 in complex with Nanobody VSG2(NB11)
7AQZ	;	1.3	;	Co-Crystal Structure of Variant Surface Glycoprotein VSG2 in complex with Nanobody VSG2(NB14)
7AR0	;	2.139	;	Co-Crystal Structure of Variant Surface Glycoprotein VSG2 in complex with Nanobody VSG2(NB19)
7AQX	;	1.499	;	Co-Crystal Structure of Variant Surface Glycoprotein VSG2 in complex with Nanobody VSG2(NB9)
4AZV	;	3.291	;	Co-crystal structure of WbdD and kinase inhibitor GW435821x.
4AZT	;	2.34	;	Co-crystal structure of WbdD and kinase inhibitor LY294002.
3V7J	;	2.25	;	Co-crystal structure of Wild Type Rat polymerase beta: Enzyme-DNA binary complex
4DI5	;	2.3	;	Co-crystal structure of WT 5-epi-Aristolochene synthase from Nicotiana tobaccum with geraniline
1TF6	;	3.1	;	CO-CRYSTAL STRUCTURE OF XENOPUS TFIIIA ZINC FINGER DOMAIN BOUND TO THE 5S RIBOSOMAL RNA GENE INTERNAL CONTROL REGION
2H7V	;	2.6	;	Co-crystal structure of YpkA-Rac1
2G45	;	1.99	;	Co-crystal structure of znf ubp domain from the deubiquitinating enzyme isopeptidase T (isot) in complex with ubiquitin
6W0T	;	1.95	;	Co-crystal structures of CHIKV nsP3 macrodomain with pyrimidone fragments
6W7H	;	1.95	;	Co-crystal structures of CHIKV nsP3 macrodomain with pyrimidone fragments
6W8K	;	1.8	;	Co-crystal structures of CHIKV nsP3 macrodomain with pyrimidone fragments
6W8M	;	1.75	;	Co-crystal structures of CHIKV nsP3 macrodomain with pyrimidone fragments
6W8Q	;	2.34	;	Co-crystal structures of CHIKV nsP3 macrodomain with pyrimidone fragments
6W8Y	;	2.1	;	Co-crystal structures of CHIKV nsP3 macrodomain with pyrimidone fragments
6W8Z	;	1.9	;	Co-crystal structures of CHIKV nsP3 macrodomain with pyrimidone fragments
6W91	;	2.21	;	Co-crystal structures of CHIKV nsP3 macrodomain with pyrimidone fragments
4ZVZ	;	2.0	;	Co-crystal structures of PP5 in complex with 5-methyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylic acid
4ZX2	;	1.23	;	Co-crystal structures of PP5 in complex with 5-methyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylic acid
4JPS	;	2.2	;	Co-crystal Structures of the Lipid Kinase PI3K alpha with Pan and Isoform Selective Inhibitors
8OR1	;	3.5	;	Co-crystal strucutre of PD-L1 with low molecular weight inhibitor
7RH3	;	1.05	;	Co-crystallization of human galectin-3 CRD complex with Methyl 2-O-(2-nitro-4-chloro)-benzoyl-3-O-toluoyl-b-D-talopyranoside
7RH4	;	1.201	;	Co-crystallization of human galectin-3 CRD complex with Methyl 2-O-(2-nitro-4-fluoro)-benzoyl-3-O-toluoyl-b-D-talopyranoside
4IRW	;	1.396	;	Co-crystallization of streptavidin-biotin complex with a lanthanide-ligand complex gives rise to a novel crystal form
3EOG	;	3.391	;	Co-crystallization showing exon recognition by a group II intron
3O9M	;	2.98	;	Co-crystallization studies of full length recombinant BChE with cocaine offers insights into cocaine detoxification
4K5A	;	1.5	;	Co-crystallization with conformation-specific designed ankyrin repeat proteins explains the conformational flexibility of BCL-W
4K5B	;	1.85	;	Co-crystallization with conformation-specific designed ankyrin repeat proteins explains the conformational flexibility of BCL-W
6YHW	;	1.962	;	Co-crystals in the P212121 space group, of a beta-cyclodextrin spacered by triazole heptyl from alpha-D-mannose, with FimH lectin at 2.00 A resolution.
6VJT	;	1.782	;	Co-crystals of broadly neutralizing antibody with the linear epitope from Hepatitis B surface antigen
1ONA	;	2.35	;	CO-CRYSTALS OF CONCANAVALIN A WITH METHYL-3,6-DI-O-(ALPHA-D-MANNOPYRANOSYL)-ALPHA-D-MANNOPYRANOSIDE
2ENR	;	2.35	;	CO-CRYSTALS OF DEMETALLIZED CONCANAVALIN A WITH CADMIUM HAVING A CADMIUM ION BOUND IN BOTH THE S1 SITE AND THE S2 SITE
1ENR	;	1.83	;	CO-CRYSTALS OF DEMETALLIZED CONCANAVALIN A WITH ZINC AND CALCIUM HAVING A ZINC ION BOUND IN THE S1 SITE AND A CALCIUM ION BOUND IN THE S2 SITE
1ENQ	;	2.5	;	CO-CRYSTALS OF DEMETALLIZED CONCANAVALIN A WITH ZINC HAVING A ZINC ION BOUND IN THE S1 SITE
4TZZ	;	3.64	;	Co-crystals of the Ternary Complex Containing a T-box Stem I RNA, its Cognate tRNAGly, and B. subtilis YbxF protein, treated by removing lithium sulfate and increasing PEG3350 concentration from 20% to 45% post crystallization
4TZW	;	4.671	;	Co-crystals of the Ternary Complex Containing a T-box Stem I RNA, its Cognate tRNAGly, and B. subtilis YbxF protein, treated by removing lithium sulfate and replacing Mg2+ with Sr2+ post crystallization
4TZV	;	5.03	;	Co-crystals of the Ternary Complex Containing a T-box Stem I RNA, its Cognate tRNAGly, and B. subtilis YbxF protein, treated by removing lithium sulfate post crystallization
6CK3	;	2.9	;	Co-crytsal Structure of MNK2 in Complex With an Inhibitor
3CD6	;	2.75	;	Co-cystal of large Ribosomal Subunit mutant G2616A with CC-Puromycin
6YUA	;	3.16	;	CO-dehydrogenase coupled to the N-terminal domain of the Acetyl-CoA synthase from Clostridium autoethanogenum isolated after tryptic digestion.
6YU9	;	1.904	;	CO-dehydrogenase homodimer from Clostridium autoethanogenum at 1.90-A resolution
6YTT	;	3.01	;	CO-dehydrogenase/Acetyl-CoA synthase (CODH/ACS) from Clostridium autoethanogenum at 3.0-A resolution
2FMY	;	2.2	;	CO-dependent transcription factor CooA from Carboxydothermus hydrogenoformans (Imidazole-bound form)
4O59	;	1.52	;	Co-enzyme Induced Conformational Changes in Bovine Eye Glyceraldehyde 3-Phosphate Dehydrogenase
4O63	;	1.93	;	Co-enzyme Induced Conformational Changes in Bovine Eye Glyceraldehyde 3-Phosphate Dehydrogenase
1Y39	;	2.8	;	Co-evolution of protein and RNA structures within a highly conserved ribosomal domain
5ZTX	;	2.0	;	co-factor free Transaminase
7JH5	;	2.103	;	Co-LOCKR: de novo designed protein switch
2L5G	;		;	Co-ordinates and 1H, 13C and 15N chemical shift assignments for the complex of GPS2 53-90 and SMRT 167-207
6JSI	;	4.7	;	Co-purified Fatty Acid Synthase
7ADY	;	1.05	;	CO-removed state of the active site of vanadium nitrogenase VFe protein
7RZK	;	1.9	;	Co-soak crystal structure of the N-terminal domain of Staphylococcus aureus Fatty Acid Kinase A (FakA, residues 1-208) in complex with ADP to 1.9 Angstrom resolution - SAD data
8BZB	;	1.7	;	co-soak stabilizers for ERa - 14-3-3 interaction (884_AZ275)
8BZW	;	1.1	;	Co-soaked stabilizers for ERa - 14-3-3 interaction (844_AZ210)
8BZC	;	1.1	;	co-soaked stabilizers for ERa - 14-3-3 interaction (884_AZ244)
8C04	;	1.1	;	Co-soaked stabilizers for ERa - 14-3-3 interaction (884_AZ354)
2Y8T	;	1.95	;	Co-structure of AMA1 with a surface exposed region of RON2 from Toxoplasma gondii
2Y8S	;	2.55	;	Co-structure of an AMA1 mutant (Y230A) with a surface exposed region of RON2 from Toxoplasma gondii
6X3N	;	1.95	;	Co-structure of BTK kinase domain with L-005085737 inhibitor
6X3O	;	1.9	;	Co-structure of BTK kinase domain with L-005191930 inhibitor
6X3P	;	1.34	;	Co-structure of BTK kinase domain with L-005298385 inhibitor
3TT0	;	2.8	;	Co-structure of Fibroblast Growth Factor Receptor 1 kinase domain with 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (BGJ398)
1X0X	;	2.75	;	Co-Structure of Homo Sapiens Glycerol-3-Phosphate Dehydrogenase 1 complex with NAD
6V6L	;	2.19	;	Co-structure of human glycogen synthase kinase beta with 1-(6-((2-((6-amino-5-nitropyridin-2-yl)amino)ethyl)amino)-2-(2,4-dichlorophenyl)pyridin-3-yl)-4-methylpiperazin-2-one
6B8J	;	2.595	;	Co-structure of human glycogen synthase kinase beta with a selective (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine inhibitor
8SBC	;	2.3	;	Co-structure of Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform and brain penetrant inhibitors
7SSB	;	1.4	;	Co-structure of PKG1 regulatory domain with compound 33
2WOR	;	1.7	;	co-structure of S100A7 with 1,8 ANS
8SKH	;	1.882	;	Co-structure of SARS-CoV-2 (COVID-19 with covalent pyrazoline based inhibitors
8SK4	;	2.0	;	Co-structure of SARS-CoV-2 (COVID-19 with covalent pyrazoline based inhibitors)
8FPJ	;	2.74	;	Co-structure of the Human Metapneunomovirus RNA-dependent RNA polymerase with MRK-1
8FPI	;	2.52	;	Co-structure of the Respiratory Syncytial Virus RNA-dependent RNA polymerase with MRK-1
8SBJ	;	3.1	;	Co-structure Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform complexed with brain penetrant inhibitors
6RUN	;	1.1	;	Co-substituted alpha-Keggin bound to Proteinase K solved by EP
6RUG	;	1.1	;	Co-substituted alpha-Keggin bound to Proteinase K solved by MR
6RVE	;	1.15	;	Co-substituted beta-Keggin bound to Proteinase K solved by MR
6RVG	;	1.1	;	Co-substituted beta-Keggin bound to Proteinase K solved by MR
7A9F	;	1.62	;	Co-substituted Keggin silicotungstate with covalent bond to proteinase K
7A9K	;	1.62	;	Co-substituted Keggin silicotungstate with covalent bond to proteinase K
7EGQ	;	3.35	;	Co-transcriptional capping machineries in SARS-CoV-2 RTC: Coupling of N7-methyltransferase and 3'-5' exoribonuclease with polymerase reveals mechanisms for capping and proofreading
6FPK	;	1.95	;	Co-translational folding intermediate dictates membrane targeting of the signal recognition particle (SRP)- receptor
6FPR	;	2.65	;	Co-translational folding intermediate dictates membrane targeting of the signal recognition particle (SRP)- receptor
4UDX	;	1.03	;	CO2 bound to cluster C of Ni,Fe-CO dehydrogenase at true-atomic resolution
4HT5	;	2.51	;	CO2 concentrating mechanism protein P, CcmP form 1
4HT7	;	3.301	;	CO2 concentrating mechanism protein P, CcmP form 2
5YUI	;	1.2	;	CO2 release in human carbonic anhydrase II crystals: reveal histidine 64 and solvent dynamics
5YUJ	;	1.25	;	CO2 release in human carbonic anhydrase II crystals: reveal histidine 64 and solvent dynamics
5YUK	;	1.45	;	CO2 release in human carbonic anhydrase II crystals: reveal histidine 64 and solvent dynamics
3IUH	;	2.0	;	Co2+-bound form of Pseudomonas stutzeri L-rhamnose isomerase
4XX0	;	2.1	;	CoA bound to pig GTP-specific succinyl-CoA synthetase
5U4X	;	1.88	;	Coactivator-associated arginine methyltransferase 1 with TP-064
1JBU	;	2.0	;	Coagulation Factor VII Zymogen (EGF2/Protease) in Complex with Inhibitory Exosite Peptide A-183
8G6I	;	4.23	;	Coagulation factor VIII bound to a patient-derived anti-C1 domain antibody inhibitor
1FAC	;		;	COAGULATION FACTOR VIII, NMR, 1 STRUCTURE
1FAX	;	3.0	;	COAGULATION FACTOR XA INHIBITOR COMPLEX
1FXY	;	2.15	;	COAGULATION FACTOR XA-TRYPSIN CHIMERA INHIBITED WITH D-PHE-PRO-ARG-CHLOROMETHYLKETONE
6USY	;	1.26	;	COAGULATION FACTOR XI CATALYTIC DOMAIN (C123S) IN COMPLEX WITH NVP-XIV936
6R8X	;	2.04	;	COAGULATION FACTOR XI CATALYTIC DOMAIN IN COMPLEX WITH FAB-PORTION OF MAA868
6TS4	;	1.17	;	Coagulation factor XI protease domain in complex with active site inhibitor
6TS5	;	1.29	;	Coagulation factor XI protease domain in complex with active site inhibitor
6TS6	;	1.33	;	Coagulation factor XI protease domain in complex with active site inhibitor
6TS7	;	2.63	;	Coagulation factor XI protease domain in complex with active site inhibitor
8BO4	;	1.75	;	COAGULATION FACTOR XI PROTEASE DOMAIN IN COMPLEX WITH ACTIVE SITE INHIBITOR 1
8BO6	;	1.25	;	COAGULATION FACTOR XI PROTEASE DOMAIN IN COMPLEX WITH ACTIVE SITE INHIBITOR 2
8BO5	;	1.7	;	COAGULATION FACTOR XI PROTEASE DOMAIN IN COMPLEX WITH ACTIVE SITE INHIBITOR 3
8BO7	;	1.25	;	COAGULATION FACTOR XI PROTEASE DOMAIN IN COMPLEX WITH ACTIVE SITE INHIBITOR 34
8BO3	;	1.841	;	COAGULATION FACTOR XI PROTEASE DOMAIN IN COMPLEX WITH ACTIVE SITE INHIBITOR Asundexian
4XDE	;	2.14	;	Coagulation Factor XII protease domain crystal structure
4XE4	;	2.4	;	Coagulation Factor XII protease domain crystal structure
1MGX	;		;	COAGULATION FACTOR, MG(II), NMR, 7 STRUCTURES (BACKBONE ATOMS ONLY)
1WHF	;		;	COAGULATION FACTOR, NMR, 15 STRUCTURES
1WHE	;		;	COAGULATION FACTOR, NMR, 20 STRUCTURES
1MOF	;	1.7	;	COAT PROTEIN
1Q7Q	;	3.1	;	Cobalamin-dependent methionine synthase (1-566) from T. maritima (Oxidized, Orthorhombic)
1Q7Z	;	1.7	;	Cobalamin-dependent methionine synthase (1-566) from Thermotoga maritima (Cd2+ complex)
1Q85	;	2.0	;	Cobalamin-dependent methionine synthase (1-566) from Thermotoga maritima (Cd2+ complex, Se-Met)
1Q8J	;	1.9	;	Cobalamin-dependent methionine synthase (1-566) from Thermotoga maritima (Cd2+, Hcy, methyltetrahydrofolate complex)
1Q8A	;	1.7	;	Cobalamin-dependent methionine synthase (1-566) from Thermotoga maritima (Cd2+:L-Hcy complex, Se-Met)
3BOL	;	1.85	;	Cobalamin-dependent methionine synthase (1-566) from Thermotoga maritima complexed with Zn2+
3BOF	;	1.7	;	Cobalamin-dependent methionine synthase (1-566) from Thermotoga maritima complexed with Zn2+ and Homocysteine
1Q7M	;	2.1	;	Cobalamin-dependent methionine synthase (MetH) from Thermotoga maritima (Oxidized, Monoclinic)
8I7Q	;	2.83	;	Cobalt and Calcium coordinated Concanavalin A at pH 7.4 from Canavalia ensiformis
4JKY	;	2.373	;	Cobalt between two ADP's in the active site of adenylate kinase
3TA5	;	1.52	;	Cobalt bound structure of an archaeal member of the LigD 3'-phosphoesterase DNA repair enzyme family
2XVZ	;	2.4	;	Cobalt chelatase CbiK (periplasmatic) from Desulvobrio vulgaris Hildenborough (co-crystallized with cobalt)
2XVX	;	1.9	;	Cobalt chelatase CbiK (periplasmatic) from Desulvobrio vulgaris Hildenborough (Native)
2XVY	;	1.7	;	Cobalt chelatase CbiK (periplasmic) from Desulvobrio vulgaris Hildenborough (co-crystallised with cobalt and SHC)
1BSJ	;	3.0	;	COBALT DEFORMYLASE INHIBITOR COMPLEX FROM E.COLI
1XAM	;	1.86	;	Cobalt hexammine induced tautameric shift in Z-DNA: structure of d(CGCGCA).d(TGCGCG) in two crystal forms.
1XA2	;	1.71	;	Cobalt hexammine induced tautomeric shift in Z-DNA: the structure of d(CGCGCA).d(TGCGCG) in two crystal forms
2O5S	;	1.6	;	Cobalt horse heart myoglobin, nitrite modified
2O5T	;	1.6	;	Cobalt horse heart myoglobin, oxidized
1YOG	;	1.65	;	COBALT MYOGLOBIN (DEOXY)
1YOH	;	1.65	;	COBALT MYOGLOBIN (MET)
1YOI	;	1.65	;	COBALT MYOGLOBIN (OXY)
1QQ0	;	1.76	;	COBALT SUBSTITUTED CARBONIC ANHYDRASE FROM METHANOSARCINA THERMOPHILA
1H0N	;	2.4	;	Cobalt substitution of mouse R2 ribonucleotide reductase to model the reactive diferrous state
1H0O	;	2.2	;	Cobalt substitution of mouse R2 ribonucleotide reductase to model the reactive diferrous state
4MKI	;	2.3	;	Cobalt transporter ATP-binding subunit
8ASM	;	1.7	;	Cobalt(II) bound to a non-canonical quadruplex
3MF3	;	2.5	;	Cobalt(II)-Substituted Haemophilus influenzae B-Carbonic Anhydrase
8EIW	;	1.65	;	Cobalt(II)-substituted Horse Liver Alcohol Dehydrogenase in Complex with NADH and N-Cyclohexylformamide
8EIX	;	2.46	;	Cobalt(II)-substituted S48A Horse Liver Alcohol Dehydrogenase in Complex with NADH and N-Cyclohexylformamide
8EIY	;	2.55	;	Cobalt(II)-substituted S48T Horse Liver Alcohol Dehydrogenase in Complex with NADH and N-Cyclohexylformamide
1AO2	;		;	cobalt(III)-deglycopepleomycin determined by NMR studies
1AO4	;		;	COBALT(III)-PEPLOMYCIN COMPLEX DETERMINED BY NMR STUDIES
8E3V	;	2.0	;	Cobalt-reconstituted nitrogenase MoFeP mutant S188A from Azotobacter vinelandii after IDS oxidation
6P5Z	;	2.26	;	Cobalt-sirohydrochlorin-bound S. typhimurium siroheme synthase
3I11	;	1.45	;	Cobalt-substituted metallo-beta-lactamase from Bacillus cereus
3I15	;	1.55	;	Cobalt-substituted metallo-beta-lactamase from Bacillus cereus: residue Cys168 fully oxidized
3I14	;	1.55	;	Cobalt-substituted metallo-beta-lactamase from Bacillus cereus: residue Cys168 partially oxidized
1R0H	;	1.7	;	cobalt-substituted rubredoxin
1PJV	;		;	Cobatoxin 1 from Centruroides noxius Scorpion venom: Chemical Synthesis, 3-D Structure in Solution, Pharmacology and Docking on K+ channels
4FDV	;	1.68	;	CobH from Rhodobacter capsulatus (SB1003) in complex with HBA
4X7G	;	1.22	;	CobK precorrin-6A reductase
5C4N	;	1.63	;	CobK precorrin-6A reductase
5C4R	;	3.17	;	CobK precorrin-6A reductase
3CB0	;	1.6	;	CobR
4IRA	;	2.2	;	CobR in complex with FAD
4EC7	;	2.6	;	Cobra NGF in complex with lipid
3HRZ	;	2.2	;	Cobra Venom Factor (CVF) in complex with human factor B
3HS0	;	3.0	;	Cobra Venom Factor (CVF) in complex with human factor B
6PU6	;	2.293	;	CobT from Methanocaldococcus jannaschii in complex with Alpha-Ribozole 5'-Phosphate, Nicotinic Acid, and Nicotinic Acid Mononucleotide
1HY9	;		;	COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT
3I2G	;	2.5	;	Cocaine Esterase with mutation G173Q, bound to DTT adduct
3I2H	;	1.65	;	Cocaine Esterase with mutation L169K, bound to DTT adduct
3I2I	;	2.14	;	Cocaine Esterase with mutation T172R, bound to DTT adduct
3PUI	;	1.53	;	Cocaine Esterase with mutations G4C, S10C
3I2F	;	2.5	;	Cocaine Esterase with mutations T172R / G173Q, bound to DTT adduct
3I2K	;	1.51	;	Cocaine Esterase, wild type, bound to a DTT adduct
3I2J	;	2.01	;	Cocaine Esterase, wild type, without a ligand
3PUH	;	2.3	;	Cocaine Esterase, wild-type biologically active dimer
1NJ9	;	2.35	;	Cocaine hydrolytic antibody 15A10
3UCJ	;	1.85	;	Coccomyxa beta-carbonic anhydrase in complex with acetazolamide
3UCN	;	2.25	;	Coccomyxa beta-carbonic anhydrase in complex with azide
3UCO	;	2.5	;	Coccomyxa beta-carbonic anhydrase in complex with iodide
3UCK	;	2.5	;	Coccomyxa beta-carbonic anhydrase in complex with phosphate
3UCM	;	2.513	;	Coccomyxa beta-carbonic anhydrase in complex with thiocyanate
5MB0	;	1.149	;	Cocktail experiment A: fragments 63, 267, and 291 in complex with Endothiapepsin
5MB7	;	1.299	;	Cocktail experiment B: fragments 224 and 236 at 50mM concentration
5MB5	;	0.98	;	Cocktail experiment C: fragments 103 and 171 in complex with Endothiapepsin
5MB6	;	1.201	;	Cocktail experiment D: fragments 308 and 333 at 50mM concentration
6ZZ2	;	1.14885	;	Cocktail experiment E: fragments 52, 58, and 63 at 90 mM concentration in complex with Endothiapepsin
7ADG	;	1.07946	;	Cocktail experiment G: fragments 216 and 338 at 90 mM concentration in complex with Endothiapepsin
8HBJ	;	2.9	;	cocktail of FMDV (A/TUR/14/98) in complex with M678F and M688F
6PGR	;	1.95	;	Cocomplex structure of Deoxyhypusine synthase with inhibitor 6-BROMO-N-(1H-INDOL-4-YL)-1-BENZOTHIOPHENE-2-CARBOXAMIDE
6WKZ	;	2.23	;	Cocomplex structure of Deoxyhypusine synthase with inhibitor 6-[(1R)-2-AMINO-1-PHENYLETHYL]-3-(PYRIDIN-3-YL)-4H,5H,6H,7H-THIENO[2,3-C]PYRIDIN-7-ONE
6WL6	;	2.12	;	Cocomplex structure of Deoxyhypusine synthase with inhibitor 6-[(2R)-1-AMINO-4-METHYLPENTAN-2-YL]-3-(PYRIDIN-3-YL)-4H,5H,6H,7H-THIENO[2,3-C]PYRIDIN-7-ONE
7PR3	;	2.37	;	Cocrystal Form I of a cytochrome c, sulfonato-thiacalix[4]arene - zinc cluster
8R3B	;	1.66	;	Cocrystal form I of the Pent - sulfonato-calix[8]arene complex
7PR4	;	1.32	;	Cocrystal Form II of a cytochrome c, sulfonato-thiacalix[4]arene - zinc cluster
8R3C	;	1.58	;	Cocrystal form II of the Pent - sulfonato-calix[8]arene complex
7PR5	;	1.94	;	Cocrystal of an RSL-N23H and sulfonato-thiacalix[4]arene - zinc complex
6UWX	;	1.307	;	Cocrystal of BRD4(D1) with a ethyl carbamate thiazepane inhibitor
6UVJ	;	1.38	;	Cocrystal of BRD4(D1) with a methyl carbamate thiazepane inhibitor
6UVM	;	1.51	;	Cocrystal of BRD4(D1) with a methyl carbamate thiazepane inhibitor
6WGX	;	1.53	;	Cocrystal of BRD4(D1) with a selective inhibitor
7R9C	;	1.5	;	Cocrystal of BRD4(D1) with N,N-dimethyl-2-[(3R)-3-(5-{2-[2-methyl-5-(propan-2-yl)phenoxy]pyrimidin-4-yl}-4-[4-(trifluoromethyl)phenyl]-1H-imidazol-1-yl)pyrrolidin-1-yl]ethan-1-amine
7PR2	;	1.73	;	Cocrystal of cytochrome c and sulfonato-thiacalix[4]arene
3FU2	;	2.85	;	Cocrystal structure of a class-I preQ1 riboswitch
3K1V	;	2.2	;	Cocrystal structure of a mutant class-I preQ1 riboswitch
2RKJ	;	4.5	;	Cocrystal structure of a tyrosyl-tRNA synthetase splicing factor with a group I intron RNA
5HIX	;	2.48	;	Cocrystal structure of an anti-parallel DNA G-quadruplex and a tetra-Quinoline Foldamer
2DEU	;	3.4	;	Cocrystal structure of an RNA sulfuration enzyme MnmA and tRNA-Glu in the adenylated intermediate state
2DER	;	3.1	;	Cocrystal structure of an RNA sulfuration enzyme MnmA and tRNA-Glu in the initial tRNA binding state
2DET	;	3.4	;	Cocrystal structure of an RNA sulfuration enzyme MnmA and tRNA-Glu in the pre-reaction state
3EYZ	;	2.1	;	Cocrystal structure of Bacillus fragment DNA polymerase I with duplex DNA (open form)
3EZ5	;	1.9	;	Cocrystal structure of Bacillus fragment DNA polymerase I with duplex DNA , dCTP, and zinc (closed form).
5M75	;	1.538	;	Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with a (S)-methyl substitued Fasudil-derivative
5M6V	;	1.418	;	Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with a double methylated Fasudil-derivative
5M6Y	;	1.367	;	Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with a methylisoquinoline Fasudil-derivative
5LCT	;	1.615	;	Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with a R-methyl-piperazine substituted Fasudil-derivative (Ligand 02)
5LCU	;	1.579	;	Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with a S-methyl-piperazine substituted Fasudil-derivative (Ligand 01)
5M0B	;	1.506	;	Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with a short-chained N-(2-aminoethyl)isoquinoline-5-sulfonamide) Fasudil-derivative (Ligand 03)
5M71	;	1.488	;	Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with an (R)-methyl substitued Fasudil-derivative.
5LCP	;	1.433	;	Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with Fasudil (M77)
5LCQ	;	1.423	;	Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with long-chain Fasudil-derivative (Ligand 05)
5LCR	;	1.565	;	Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with open-chain Fasudil-derivative (Ligand 04)
5M0C	;	1.734	;	Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with the Fasudil-fragment isoquinoline-5-sulfonamide
5M0L	;	1.465	;	Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with the methylated Fasudil-derived fragment N-methylisoquinoline-5-sulfonamide (Ligand 02)
1BKM	;	2.0	;	COCRYSTAL STRUCTURE OF D-AMINO ACID SUBSTITUTED PHOSPHOPEPTIDE COMPLEX
4PV7	;	3.24	;	Cocrystal structure of dipeptidyl-peptidase 4 with an indole scaffold inhibitor
1EJ4	;	2.25	;	COCRYSTAL STRUCTURE OF EIF4E/4E-BP1 PEPTIDE
5ML9	;	2.35	;	Cocrystal structure of Fc gamma receptor IIIa interacting with Affimer F4, a specific binding protein which blocks IgG binding to the receptor.
5MN2	;	2.35	;	Cocrystal structure of Fc gamma receptor IIIa interacting with Affimer G3, a specific binding protein which blocks IgG binding to the receptor.
4H1D	;	2.8975	;	Cocrystal structure of GlpG and DFP
6X5Q	;	2.14	;	Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluA1
7UJP	;	2.56	;	Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluN2B
7UJQ	;	2.25	;	Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluN2B
7UJR	;	1.95	;	Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluN2B
7UJS	;	2.75	;	Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluN2B in complex with ADP
7KL0	;	2.4	;	Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluN2B(S1303D)
7KL1	;	2.4	;	Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluN2B(S1303D)
7KL2	;	2.56	;	Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluN2B(S1303D)
7UIS	;	2.58	;	Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluN2B(S1303D)
7UJT	;	2.1	;	Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluN2B(S1303D) in complex with ATP
6X5G	;	1.85	;	Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and LRRC7 inhibitory domain
7UIQ	;	3.11	;	Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and Tiam1
7UIR	;	3.1	;	Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and Tiam1 in complex with ATP
3RU0	;	1.849	;	Cocrystal structure of human SMYD3 with inhibitor Sinefungin bound
4J36	;	2.13	;	Cocrystal Structure of kynurenine 3-monooxygenase in complex with UPF 648 inhibitor(KMO-394UPF)
3GZ8	;	2.43	;	Cocrystal structure of NUDIX domain of Shewanella oneidensis NrtR complexed with ADP ribose
7Q9R	;	2.5	;	Cocrystal structure of PDE6D bound to NRAS peptide
3R9V	;	1.9	;	Cocrystal Structure of Proteolytically Truncated Form of IpaD from Shigella flexneri Bound to Deoxycholate
1DP7	;	1.5	;	COCRYSTAL STRUCTURE OF RFX-DBD IN COMPLEX WITH ITS COGNATE X-BOX BINDING SITE
1F2I	;	2.35	;	COCRYSTAL STRUCTURE OF SELECTED ZINC FINGER DIMER BOUND TO DNA
1RP3	;	2.3	;	Cocrystal structure of the flagellar sigma/anti-sigma complex, Sigma-28/FlgM
5SYM	;	1.55	;	Cocrystal structure of the human acyl protein thioesterase 1 with an isoform-selective inhibitor, ML348
5SYN	;	1.64	;	Cocrystal structure of the human acyl protein thioesterase 2 with an isoform-selective inhibitor, ML349
5U9O	;	3.37	;	Cocrystal structure of the intermembrane space region of the plastid division proteins PARC6 and PDV1
1EJ1	;	2.2	;	COCRYSTAL STRUCTURE OF THE MESSENGER RNA 5' CAP-BINDING PROTEIN (EIF4E) BOUND TO 7-METHYL-GDP
1L8B	;	1.8	;	Cocrystal Structure of the Messenger RNA 5' Cap-binding Protein (eIF4E) bound to 7-methylGpppG
6UFM	;	2.82	;	Cocrystal Structure of the Nocardia farcinica ileS T-box riboswitch in complex with its cognate tRNA
3QQU	;	2.9	;	Cocrystal structure of unphosphorylated igf with pyrimidine 8
1SKJ	;	2.0	;	COCRYSTAL STRUCTURE OF UREA-SUBSTITUTED PHOSPHOPEPTIDE COMPLEX
7F3B	;	2.81	;	cocrystallization of Escherichia coli dihydrofolate reductase (DHFR) and its pyrrolo[3,2-f]quinazoline inhibitor.
7MBF	;	2.4	;	codeinone reductase isoform 1.3 Apo form
7ZKJ	;	2.04	;	CODH/ACS complex of C. hydrogenoformans
7QXQ	;	2.251	;	Coelenteramide-bound Renilla-type luciferase (AncFT)
8A56	;	2.05	;	Coenzyme A-persulfide reductase (CoAPR) from Enterococcus faecalis
1QV9	;	1.54	;	Coenzyme F420-dependent methylenetetrahydromethanopterin dehydrogenase (Mtd) from Methanopyrus kandleri: A methanogenic enzyme with an unusual quarternary structure
4XOM	;	1.9	;	Coenzyme F420:L-glutamate ligase (FbiB) from Mycobacterium tuberculosis (C-terminal domain).
2GD1	;	2.5	;	COENZYME-INDUCED CONFORMATIONAL CHANGES IN GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE FROM BACILLUS STEAROTHERMOPHILLUS
2QOJ	;	2.4	;	Coevolution of a homing endonuclease and its host target sequence
4UQW	;	1.5	;	Coevolution of the ATPase ClpV, the TssB-TssC Sheath and the Accessory HsiE Protein Distinguishes Two Type VI Secretion Classes
4UQX	;	1.2	;	Coevolution of the ATPase ClpV, the TssB-TssC Sheath and the Accessory HsiE Protein Distinguishes Two Type VI Secretion Classes
4UQY	;	1.6	;	Coevolution of the ATPase ClpV, the TssB-TssC Sheath and the Accessory HsiE Protein Distinguishes Two Type VI Secretion Classes
4UQZ	;	1.599	;	Coevolution of the ATPase ClpV, the TssB-TssC Sheath and the Accessory HsiE Protein Distinguishes Two Type VI Secretion Classes
8DA3	;	1.06	;	Coevolved affibody-Z domain pair LL1.c1
8DA4	;	1.92	;	Coevolved affibody-Z domain pair LL1.c2
8DA5	;	1.0	;	Coevolved affibody-Z domain pair LL1.c4
8DA6	;	1.5	;	Coevolved affibody-Z domain pair LL1.c5
8DA7	;	1.02	;	Coevolved affibody-Z domain pair LL1.c6
8DA8	;	1.29	;	Coevolved affibody-Z domain pair LL2.c1
8DAB	;	1.134	;	Coevolved affibody-Z domain pair LL2.c17
8DAC	;	1.19	;	Coevolved affibody-Z domain pair LL2.c22
8DA9	;	1.35	;	Coevolved affibody-Z domain pair LL2.c3
8DAA	;	1.75	;	Coevolved affibody-Z domain pair LL2.c7
4OUA	;	2.763	;	Coexistent single-crystal structure of latent and active mushroom tyrosinase (abPPO4) mediated by a hexatungstotellurate(VI)
2G5G	;	1.9	;	Cofacial heme binding to ChaN of Campylobacter jejuni
1AL3	;	1.8	;	COFACTOR BINDING FRAGMENT OF CYSB FROM KLEBSIELLA AEROGENES
1KLI	;	1.69	;	Cofactor-and substrate-assisted activation of factor VIIa
2FL5	;	3.0	;	Cofactor-containing antibodies: Crystal structure of the original yellow antibody
8R3T	;	3.1	;	Cofactor-free Tau 4R2N isoform
3IDD	;	2.8	;	Cofactor-Independent Phosphoglycerate Mutase from Thermoplasma acidophilum DSM 1728
3KD8	;	2.6	;	Cofactor-Independent Phosphoglycerate mutase from Thermoplasma Acidophilum DSM 1728
6JI7	;		;	Coffeetides: iron-binding cysteine rich peptides from coffee waste
5YU8	;	3.8	;	Cofilin decorated actin filament
1HQZ	;	2.1	;	Cofilin homology domain of a yeast actin-binding protein ABP1P
2W1N	;	1.8	;	cohesin and fibronectin type-III double module construct from the Clostridium perfringens glycoside hydrolase GH84C
6YUF	;	3.94	;	Cohesin complex with loader gripping DNA
2VO8	;	1.7	;	Cohesin module from Clostridium perfringens ATCC13124 family 33 glycoside hydrolase.
1G1K	;	2.0	;	COHESIN MODULE FROM THE CELLULOSOME OF CLOSTRIDIUM CELLULOLYTICUM
4UX3	;	3.3	;	cohesin Smc3-HD:Scc1-N complex from yeast
5F0N	;	3.2	;	Cohesin subunit Pds5
5F0O	;	3.5	;	Cohesin subunit Pds5 in complex with Scc1
4UVJ	;	2.1	;	Cohesin subunit Scc3 from yeast, 674-1072
4UVK	;	2.6	;	Cohesin subunit Scc3 from Z. rouxii, 88-1035
1ANU	;	2.15	;	COHESIN-2 DOMAIN OF THE CELLULOSOME FROM CLOSTRIDIUM THERMOCELLUM
4IU2	;	2.001	;	Cohesin-dockerin -X domain complex from Ruminococcus flavefacience
4IU3	;	1.97	;	Cohesin-dockerin -X domain complex from Ruminococcus flavefacience
1OHZ	;	2.2	;	Cohesin-Dockerin complex from the cellulosome of Clostridium thermocellum
6LK9	;	2.099	;	Coho salmon ferritin
8I33	;	1.62	;	Coil 1a of lamin A (residue 25-65)
5M48	;	2.593	;	Coiled coil domain of Rtt103p
4C1A	;	1.55	;	Coiled coil domain of the ZfL2-1 ORF1 protein from the zebrafish ZfL2- 1 retrotransposon
5U5A	;	3.23	;	Coiled Coil Peptide Metal Coordination Framework: Dimer Fold
5U59	;	2.2	;	Coiled Coil Peptide Metal Coordination Framework: Dimer Fold Grown with Citrate
5U5C	;	2.1	;	Coiled Coil Peptide Metal Coordination Framework: Tetramer Fold
5U5B	;	2.4	;	Coiled Coil Peptide Metal Coordination Framework: Trimer Fold
1IJ0	;	1.86	;	Coiled Coil Trimer GCN4-pVLS Ser at Buried D Position
1D7M	;	2.7	;	COILED-COIL DIMERIZATION DOMAIN FROM CORTEXILLIN I
1WT6	;	1.6	;	Coiled-Coil domain of DMPK
6J9R	;	2.5	;	Coiled-coil Domain of Drosophila TRIM Protein Brat
8OYK	;	1.9	;	Coiled-Coil Domain of Human STIL, L736E Mutant
8OYL	;	1.92	;	Coiled-Coil Domain of Human STIL, Q729L Mutant
8AMR	;	3.8	;	Coiled-coil domain of human TRIM3
4LTB	;	2.59	;	Coiled-coil domain of TRIM25
3IV1	;	2.5	;	Coiled-coil domain of tumor susceptibility gene 101
6H9M	;	2.1	;	Coiled-coil domain-containing protein 90B residues 43-125 from Homo sapiens fused to a GCN4 adaptor
3QFL	;	1.997	;	Coiled-Coil Domain-Dependent Homodimerization of Intracellular MLA Immune Receptors Defines a Minimal Functional Module for Triggering Cell Death
3TE3	;	2.694	;	Coiled-coil oligomerization domain of the polycystin transient receptor potential channel PKD2L1
5LXN	;	2.08	;	Coiled-coil protein
5LXO	;	2.179	;	Coiled-coil protein
8P4Y	;	2.052	;	Coiled-coil protein origami triangle
2V71	;	2.24	;	Coiled-coil region of NudEL
6TZW	;	2.35	;	Coiled-coil registry shifts in the F684I mutant of Bicaudal D result in cargo-independent activation of dynein motility
7D2G	;	1.7	;	Coiled-coil structure of liprin-alpha2_H2delC
1UIX	;	1.8	;	Coiled-coil structure of the RhoA-binding domain in Rho-kinase
6V5I	;	1.9	;	Coiled-coil Trimer with Ala:Leu:Ala Triad
6V5G	;	1.68	;	Coiled-coil Trimer with Ala:Leu:Lys Triad
6OVU	;	2.101	;	Coiled-coil Trimer with Glu:3,4-difluorophenylalanine:Lys Triad
6OVV	;	2.201	;	Coiled-coil Trimer with Glu:4-pyridinylalanine:Lys Triad
6U47	;	2.301	;	Coiled-coil Trimer with Glu:Ala:Lys Triad
6Q22	;	1.599	;	Coiled-coil Trimer with Glu:Aminobutyric acid:Lys Triad
6V5J	;	1.7	;	Coiled-coil Trimer with Glu:Leu:Ala Triad
6Q25	;	1.893	;	Coiled-coil Trimer with Glu:Leu:Lys Triad
6V58	;	2.201	;	Coiled-coil Trimer with Glu:Norleucine:Lys Triad
6V57	;	1.696	;	Coiled-coil Trimer with Glu:Norvaline:Lys Triad
6OS8	;	2.15	;	Coiled-coil Trimer with Glu:p-fluorophenylalanine:Lys Triad
6OV9	;	2.1	;	Coiled-coil Trimer with Glu:p-nitrophenylalanine:Lys Triad
6OSD	;	2.15	;	Coiled-coil Trimer with Glu:Phe:Lys Triad
6V50	;	2.285	;	Coiled-coil Trimer with Glu:Ser:Lys Triad with K7A mutation
5UXT	;	2.197	;	Coiled-coil Trimer with Glu:Trp:Lys Triad
6OVS	;	1.8	;	Coiled-coil Trimer with Glu:Tyr:Lys Triad
6V4Y	;	1.85	;	Coiled-coil Trimer with Glu:Tyr:Lys Triad with a K7A mutation
6Q1W	;	1.498	;	Coiled-coil Trimer with Glu:Val:Lys Triad
1P9I	;	1.17	;	Coiled-coil X-ray structure at 1.17 A resolution
8CLB	;	3.0	;	Colchicine bound to tubulin (T2R-TTL) complex
6ZXS	;	3.0	;	Cold grown Pea Photosystem I
1A59	;	2.09	;	COLD-ACTIVE CITRATE SYNTHASE
6ETZ	;	1.8	;	Cold-adapted beta-D-galactosidase from Arthrobacter sp. 32cB
6H1P	;	3.009	;	Cold-adapted beta-D-galactosidase from Arthrobacter sp. 32cB - data collected at room temperature
6SED	;	2.233	;	Cold-adapted beta-D-galactosidase from Arthrobacter sp. 32cB in complex with galactose
6SEB	;	2.272	;	Cold-adapted beta-D-galactosidase from Arthrobacter sp. 32cB in complex with IPTG
6ZJV	;	2.25	;	Cold-adapted beta-D-galactosidase from Arthrobacter sp. 32cB mutant D207A
6ZJW	;	2.119	;	Cold-adapted beta-D-galactosidase from Arthrobacter sp. 32cB mutant D207A in complex with galactose
6ZJX	;	2.206	;	Cold-adapted beta-D-galactosidase from Arthrobacter sp. 32cB mutant D207A in complex with saccharose
6SE8	;	1.835	;	Cold-adapted beta-D-galactosidase from Arthrobacter sp. 32cB mutant E441Q
6ZJS	;	1.5	;	Cold-adapted beta-D-galactosidase from Arthrobacter sp. 32cB mutant E441Q in complex with galactose
6SEA	;	1.869	;	Cold-adapted beta-D-galactosidase from Arthrobacter sp. 32cB mutant E441Q in complex with lactose bound in deep mode
6SE9	;	1.965	;	Cold-adapted beta-D-galactosidase from Arthrobacter sp. 32cB mutant E441Q in complex with lactose bound in shallow mode
6ZJT	;	1.97	;	Cold-adapted beta-D-galactosidase from Arthrobacter sp. 32cB mutant E441Q in complex with lactulose
6ZJU	;	1.75	;	Cold-adapted beta-D-galactosidase from Arthrobacter sp. 32cB mutant E441Q in complex with saccharose
6ZJP	;	1.85	;	Cold-adapted beta-D-galactosidase from Arthrobacter sp. 32cB mutant E517Q
6ZJQ	;	1.7	;	Cold-adapted beta-D-galactosidase from Arthrobacter sp. 32cB mutant E517Q in complex with galactose
6ZJR	;	2.0	;	Cold-adapted beta-D-galactosidase from Arthrobacter sp. 32cB mutant E517Q in complex with lactulose
6SEC	;	2.768	;	Cold-adapted beta-D-galactosidase from Arthrobacter sp. 32cBon complex with ONPG
4UUR	;	2.21	;	Cold-adapted truncated hemoglobin from the Antarctic marine bacterium Pseudoalteromonas haloplanktis TAC125
2TBS	;	1.8	;	COLD-ADAPTION OF ENZYMES: STRUCTURAL COMPARISON BETWEEN SALMON AND BOVINE TRYPSINS
4WMJ	;	1.5	;	Colias eurytheme Phosphoglucose isomerase. Homodimer from 4-5(18) genotype.
5ZNM	;	1.85	;	Colicin D Central Domain and C-terminal tRNase domain
6WXH	;	3.09	;	Colicin E1 fragment in nanodisc-embedded TolC
6WXI	;	2.84	;	Colicin E1 fragment in nanodisc-embedded TolC
1AYI	;	2.0	;	COLICIN E7 IMMUNITY PROTEIN IM7
1GXH	;		;	Colicin E8 DNAse immunity protein: Im8
1IMP	;		;	COLICIN E9 IMMUNITY PROTEIN IM9, NMR, 21 STRUCTURES
1IMQ	;		;	COLICIN E9 IMMUNITY PROTEIN IM9, NMR, MINIMIZED AVERAGE STRUCTURE
1CII	;	3.0	;	COLICIN IA
1A87	;	3.1	;	COLICIN N
7NSU	;	4.7	;	ColicinE9 intact translocation complex
7NST	;	3.7	;	ColicinE9 partial translocation complex
2X3H	;	1.6	;	COLIPHAGE K5A LYASE
1BKV	;	2.0	;	COLLAGEN
2F6A	;	3.29	;	Collagen Adhesin and Collagen Complex Structure
7LXQ	;	1.3	;	Collagen Mimetic Peptide with a Yaa-position Aza-proline
7LXP	;	1.4	;	Collagen Mimetic Peptide with an Xaa-position Aza-proline
2CUO	;	1.33	;	Collagen model peptide (PRO-PRO-GLY)9
6M80	;	1.1	;	Collagen peptide containing aza-proline and aza-glycine
1AMX	;	2.0	;	COLLAGEN-BINDING DOMAIN FROM A STAPHYLOCOCCUS AUREUS ADHESIN
7WSS	;	2.19	;	Collagenase from Grimontia (Vibrio) hollisae 1706B
7XEB	;	2.39	;	Collagenase from Grimontia (Vibrio) hollisae 1706B complexed with Gly-Pro-Hyp
8JT1	;	2.0	;	COLLAGENASE FROM GRIMONTIA (VIBRIO) HOLLISAE 1706B COMPLEXED WITH GLY-PRO-HYP-GLY-PRO-HYP
1PEX	;	2.7	;	COLLAGENASE-3 (MMP-13) C-TERMINAL HEMOPEXIN-LIKE DOMAIN
2D1N	;	2.37	;	Collagenase-3 (MMP-13) complexed to a hydroxamic acid inhibitor
830C	;	1.6	;	COLLAGENASE-3 (MMP-13) COMPLEXED TO A SULPHONE-BASED HYDROXAMIC ACID
8FWC	;	2.96	;	Collar sheath structure of Agrobacterium phage Milano
7ZUX	;	2.5	;	Collided ribosome in a disome unit from S. cerevisiae
6ANI	;	2.4	;	Coltuximab Fab in complex with anti-Kappa VHH domain
1HXH	;	1.22	;	COMAMONAS TESTOSTERONI 3BETA/17BETA HYDROXYSTEROID DEHYDROGENASE
5NX1	;	1.853	;	Combinatorial Engineering of Proteolytically Resistant APPI Variants that Selectively Inhibit Human Kallikrein 6 for Cancer Therapy
5NX3	;	2.296	;	Combinatorial Engineering of Proteolytically Resistant APPI Variants that Selectively Inhibit Human Kallikrein 6 for Cancer Therapy
2BH8	;	1.9	;	Combinatorial Protein 1b11
5RXN	;	1.2	;	COMBINED CRYSTALLOGRAPHIC REFINEMENT AND ENERGY MINIMIZATION OF RUBREDOXIN AT 1.2 ANGSTROM RESOLUTION
2KMS	;		;	Combined high- and low-resolution techniques reveal compact structure in central portion of factor H despite long inter-modular linkers
8TID	;	3.6	;	Combined linker domain of N-DRC and associated proteins Tetrahymena
1F6H	;	3.31	;	COMBINED RIETVELD AND STEREOCHEMICAL RESTRAINT REFINEMENT OF A PROTEIN
6F3K	;	4.1	;	Combined solid-state NMR, solution-state NMR and EM data for structure determination of the tetrahedral aminopeptidase TET2 from P. horikoshii
3SCZ	;	1.95	;	Combining crystallographic, thermodynamic, and molecular dynamics studies of Mycobacterium tuberculosis purine nucleoside phosphorylase
2WGR	;	1.7	;	Combining crystallography and molecular dynamics: The case of Schistosoma mansoni phospholipid glutathione peroxidase
1K1T	;	1.2	;	Combining Mutations in HIV-1 Protease to Understand Mechanisms of Resistance
1K1U	;	1.55	;	Combining Mutations in HIV-1 Protease to Understand Mechanisms of Resistance
1K2B	;	1.7	;	Combining Mutations in HIV-1 Protease to Understand Mechanisms of Resistance
1K2C	;	2.2	;	Combining Mutations in HIV-1 Protease to Understand Mechanisms of Resistance
5HQ1	;	1.0	;	Comment on S. W. M. Tanley and J. R. Helliwell Structural dynamics of cisplatin binding to histidine in a protein Struct. Dyn. 1, 034701 (2014) regarding the refinement of 4mwk, 4mwm, 4mwn and 4oxe and the method we have adopted.
5IDD	;	1.13	;	Comment on S. W. M. Tanley and J. R. Helliwell Structural dynamics of cisplatin binding to histidine in a protein Struct. Dyn. 1, 034701 (2014) regarding the refinement of 4mwk, 4mwm, 4mwn and 4oxe and the method we have adopted.
1UZ4	;	1.71	;	Common inhibition of beta-glucosidase and beta-mannosidase by isofagomine lactam reflects different conformational intineraries for glucoside and mannoside hydrolysis
6HD0	;	3.728	;	Common mode of remodeling AAA ATPases p97/CDC48 by their disassembly cofactors ASPL/PUX1
6HD3	;	2.8	;	Common mode of remodeling AAA ATPases p97/CDC48 by their disassembly cofactors ASPL/PUX1
7UNQ	;	3.4	;	Compact IF2-GDP bound to the Pseudomonas aeruginosa 70S ribosome initiation complex, from focused classification and refinement (I-A)
7UNT	;	3.6	;	Compact IF2-GDP bound to the Pseudomonas aeruginosa 70S ribosome initiation complex, from focused classification and refinement (I-B)
1HIH	;	2.2	;	COMPARATIVE ANALYSIS OF THE X-RAY STRUCTURES OF HIV-1 AND HIV-2 PROTEASES IN COMPLEX WITH CGP 53820, A NOVEL PSEUDOSYMMETRIC INHIBITOR
1HII	;	2.3	;	COMPARATIVE ANALYSIS OF THE X-RAY STRUCTURES OF HIV-1 AND HIV-2 PROTEASES IN COMPLEX WITH CGP 53820, A NOVEL PSEUDOSYMMETRIC INHIBITOR
6OJN	;	8.6	;	Comparative Model of SGIV Major Coat Protein (MCP) Trimer Based on Cryo-EM Map
1SJI	;	2.4	;	Comparing skeletal and cardiac calsequestrin structures and their calcium binding: a proposed mechanism for coupled calcium binding and protein polymerization
1SGU	;	1.9	;	Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease
1SH9	;	2.5	;	Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease
1NI6	;	2.1	;	Comparisions of the Heme-Free and-Bound Crystal Structures of Human Heme Oxygenase-1
2PAS	;		;	COMPARISON BETWEEN THE CRYSTAL AND THE SOLUTION STRUCTURES OF THE EF HAND PARVALBUMIN
3PAT	;		;	COMPARISON BETWEEN THE CRYSTAL AND THE SOLUTION STRUCTURES OF THE EF HAND PARVALBUMIN
1PVA	;	1.65	;	COMPARISON BETWEEN THE CRYSTAL AND THE SOLUTION STRUCTURES OF THE EF HAND PARVALBUMIN (ALPHA COMPONENT FROM PIKE MUSCLE)
3LLN	;	3.0	;	Comparison between the orthorhombic an tetragonal form of the heptamer sequence d(GCG(xT)GCG)/d(CGCACGC).
1XIA	;	2.3	;	COMPARISON OF BACKBONE STRUCTURES OF GLUCOSE ISOMERASE FROM STREPTOMYCES AND ARTHROBACTER
1P1X	;	0.99	;	Comparison of class I aldolase binding site architecture based on the crystal structure of 2-deoxyribose-5-phosphate aldolase determined at 0.99 Angstrom resolution
1WTL	;	1.9	;	COMPARISON OF CRYSTAL STRUCTURES OF TWO HOMOLOGOUS PROTEINS: STRUCTURAL ORIGIN OF ALTERED DOMAIN INTERACTIONS IN IMMUNOGLOBULIN LIGHT CHAIN DIMERS
1OA2	;	1.5	;	Comparison of Family 12 Glycoside Hydrolases and Recruited Substitutions Important for Thermal Stability
1OA3	;	1.7	;	Comparison of Family 12 Glycoside Hydrolases and Recruited Substitutions Important for Thermal Stability
1OA4	;	1.5	;	Comparison of Family 12 Glycoside Hydrolases and Recruited Substitutions Important for Thermal Stability
3LYT	;	1.9	;	COMPARISON OF RADIATION-INDUCED DECAY AND STRUCTURE REFINEMENT FROM X-RAY DATA COLLECTED FROM LYSOZYME CRYSTALS AT LOW AND AMBIENT TEMPERATURES
4LYT	;	1.9	;	COMPARISON OF RADIATION-INDUCED DECAY AND STRUCTURE REFINEMENT FROM X-RAY DATA COLLECTED FROM LYSOZYME CRYSTALS AT LOW AND AMBIENT TEMPERATURES
5LYT	;	1.9	;	COMPARISON OF RADIATION-INDUCED DECAY AND STRUCTURE REFINEMENT FROM X-RAY DATA COLLECTED FROM LYSOZYME CRYSTALS AT LOW AND AMBIENT TEMPERATURES
6LYT	;	1.9	;	COMPARISON OF RADIATION-INDUCED DECAY AND STRUCTURE REFINEMENT FROM X-RAY DATA COLLECTED FROM LYSOZYME CRYSTALS AT LOW AND AMBIENT TEMPERATURES
8QVI	;	2.2	;	Comparison of room-temperature and cryogenic structures of soluble Epoxide Hydrolase with ligands bound.
1DAJ	;	2.3	;	COMPARISON OF TERNARY COMPLEXES OF PNEUMOCYSTIS CARINII AND WILD TYPE HUMAN DIHYDROFOLATE REDUCTASE WITH COENZYME NADPH AND A NOVEL CLASSICAL ANTITUMOR FURO[2,3D]PYRIMIDINE ANTIFOLATE
1HFP	;	2.1	;	COMPARISON OF TERNARY CRYSTAL COMPLEXES OF HUMAN DIHYDROFOLATE REDUCTASE WITH NADPH AND A CLASSICAL ANTITUMOR FUROPYRIMDINE
1HFQ	;	2.1	;	COMPARISON OF TERNARY CRYSTAL COMPLEXES OF HUMAN DIHYDROFOLATE REDUCTASE WITH NADPH AND A CLASSICAL ANTITUMOR FUROPYRIMDINE
1HFR	;	2.1	;	COMPARISON OF TERNARY CRYSTAL COMPLEXES OF HUMAN DIHYDROFOLATE REDUCTASE WITH NADPH AND A CLASSICAL ANTITUMOR FUROPYRIMDINE
2GPB	;	2.3	;	COMPARISON OF THE BINDING OF GLUCOSE AND GLUCOSE-1-PHOSPHATE DERIVATIVES TO T-STATE GLYCOGEN PHOSPHORYLASE B
3GPB	;	2.3	;	COMPARISON OF THE BINDING OF GLUCOSE AND GLUCOSE-1-PHOSPHATE DERIVATIVES TO T-STATE GLYCOGEN PHOSPHORYLASE B
4GPB	;	2.3	;	COMPARISON OF THE BINDING OF GLUCOSE AND GLUCOSE-1-PHOSPHATE DERIVATIVES TO T-STATE GLYCOGEN PHOSPHORYLASE B
5GPB	;	2.3	;	COMPARISON OF THE BINDING OF GLUCOSE AND GLUCOSE-1-PHOSPHATE DERIVATIVES TO T-STATE GLYCOGEN PHOSPHORYLASE B
3MU1	;	1.74	;	Comparison of the character and the speed of X-ray-induced structural changes of porcine pancreatic elastase at two temperatures, 100 and 15K. The data set was collected from region A of the crystal. Fifth step of radiation damage
3MTY	;	1.101	;	Comparison of the character and the speed of X-ray-induced structural changes of porcine pancreatic elastase at two temperatures, 100 and 15K. The data set was collected from region A of the crystal. First step of radiation damage
3ODF	;	1.1	;	Comparison of the character and the speed of X-ray-induced structural changes of porcine pancreatic elastase at two temperatures, 100 and 15K. The data set was collected from region A of the crystal. Second step of radiation damage
3MU0	;	1.401	;	Comparison of the character and the speed of X-ray-induced structural changes of porcine pancreatic elastase at two temperatures, 100 and 15K. The data set was collected from region A of the crystal. Third step of radiation damage
3MU8	;	1.553	;	Comparison of the character and the speed of X-ray-induced structural changes of porcine pancreatic elastase at two temperatures, 100 and 15K. The data set was collected from region B of the crystal. Fifth step of radiation damage
3MU4	;	1.101	;	Comparison of the character and the speed of X-ray-induced structural changes of porcine pancreatic elastase at two temperatures, 100 and 15K. The data set was collected from region B of the crystal. First step of radiation damage
3ODD	;	1.1	;	Comparison of the character and the speed of X-ray-induced structural changes of porcine pancreatic elastase at two temperatures, 100 and 15K. The data set was collected from region B of the crystal. Second step of radiation damage
3MU5	;	1.404	;	Comparison of the character and the speed of X-ray-induced structural changes of porcine pancreatic elastase at two temperatures, 100 and 15K. The data set was collected from region B of the crystal. Third step of radiation damage
4LZM	;	1.7	;	COMPARISON OF THE CRYSTAL STRUCTURE OF BACTERIOPHAGE T4 LYSOZYME AT LOW, MEDIUM, AND HIGH IONIC STRENGTHS
5LZM	;	1.8	;	COMPARISON OF THE CRYSTAL STRUCTURE OF BACTERIOPHAGE T4 LYSOZYME AT LOW, MEDIUM, AND HIGH IONIC STRENGTHS
6LZM	;	1.8	;	COMPARISON OF THE CRYSTAL STRUCTURE OF BACTERIOPHAGE T4 LYSOZYME AT LOW, MEDIUM, AND HIGH IONIC STRENGTHS
7LZM	;	1.8	;	COMPARISON OF THE CRYSTAL STRUCTURE OF BACTERIOPHAGE T4 LYSOZYME AT LOW, MEDIUM, AND HIGH IONIC STRENGTHS
2FX2	;	1.9	;	COMPARISON OF THE CRYSTAL STRUCTURES OF A FLAVODOXIN IN ITS THREE OXIDATION STATES AT CRYOGENIC TEMPERATURES
3FX2	;	1.9	;	COMPARISON OF THE CRYSTAL STRUCTURES OF A FLAVODOXIN IN ITS THREE OXIDATION STATES AT CRYOGENIC TEMPERATURES
4FX2	;	1.9	;	COMPARISON OF THE CRYSTAL STRUCTURES OF A FLAVODOXIN IN ITS THREE OXIDATION STATES AT CRYOGENIC TEMPERATURES
5FX2	;	1.9	;	COMPARISON OF THE CRYSTAL STRUCTURES OF A FLAVODOXIN IN ITS THREE OXIDATION STATES AT CRYOGENIC TEMPERATURES
1MSD	;	3.2	;	COMPARISON OF THE CRYSTAL STRUCTURES OF GENETICALLY ENGINEERED HUMAN MANGANESE SUPEROXIDE DISMUTASE AND MANGANESE SUPEROXIDE DISMUTASE FROM THERMUS THERMOPHILUS. DIFFERENCES IN DIMER-DIMER INTERACTIONS.
4MT2	;	2.0	;	COMPARISON OF THE NMR SOLUTION STRUCTURE AND THE X-RAY CRYSTAL STRUCTURE OF RAT METALLOTHIONEIN-2
4MGW	;	1.93	;	Comparison of the structural and dynamic effects of 5-methylcytosine and 5-chlorocytosine in a CpG dinucleotide sequence
4MKW	;	1.219	;	Comparison of the structural and dynamic effects of 5-methylcytosine and 5-chlorocytosine in a CpG dinucleotide sequence
5A7F	;	1.86	;	Comparison of the structure and activity of glycosylated and aglycosylated Human Carboxylesterase 1
5A7G	;	1.48	;	Comparison of the structure and activity of glycosylated and aglycosylated Human Carboxylesterase 1
5A7H	;	2.01	;	Comparison of the structure and activity of glycosylated and aglycosylated Human Carboxylesterase 1
1R8H	;	1.9	;	Comparison of the structure and DNA binding properties of the E2 proteins from an oncogenic and a non-oncogenic human papillomavirus
1TPE	;	2.1	;	COMPARISON OF THE STRUCTURES AND THE CRYSTAL CONTACTS OF TRYPANOSOMAL TRIOSEPHOSPHATE ISOMERASE IN FOUR DIFFERENT CRYSTAL FORMS
1TPF	;	1.8	;	COMPARISON OF THE STRUCTURES AND THE CRYSTAL CONTACTS OF TRYPANOSOMAL TRIOSEPHOSPHATE ISOMERASE IN FOUR DIFFERENT CRYSTAL FORMS
1LRP	;	3.2	;	COMPARISON OF THE STRUCTURES OF CRO AND LAMBDA REPRESSOR PROTEINS FROM BACTERIOPHAGE LAMBDA
2HPE	;	2.0	;	COMPARISON OF THE STRUCTURES OF HIV-2 PROTEASE COMPLEXES IN THREE CRYSTAL SPACE GROUPS WITH AN HIV-1 PROTEASE COMPLEX STRUCTURE
2HPF	;	3.0	;	COMPARISON OF THE STRUCTURES OF HIV-2 PROTEASE COMPLEXES IN THREE CRYSTAL SPACE GROUPS WITH AN HIV-1 PROTEASE COMPLEX STRUCTURE
7CPA	;	2.0	;	COMPARISON OF THE STRUCTURES OF THREE CARBOXYPEPTIDASE A-PHOSPHONATE COMPLEXES DETERMINED BY X-RAY CRYSTALLOGRAPHY
8CPA	;	2.0	;	COMPARISON OF THE STRUCTURES OF THREE CARBOXYPEPTIDASE A-PHOSPHONATE COMPLEXES DETERMINED BY X-RAY CRYSTALLOGRAPHY
1GAD	;	1.8	;	COMPARISON OF THE STRUCTURES OF WILD TYPE AND A N313T MUTANT OF ESCHERICHIA COLI GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASES: IMPLICATION FOR NAD BINDING AND COOPERATIVITY
1GAE	;	2.17	;	COMPARISON OF THE STRUCTURES OF WILD TYPE AND A N313T MUTANT OF ESCHERICHIA COLI GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASES: IMPLICATION FOR NAD BINDING AND COOPERATIVITY
1B2W	;	2.9	;	COMPARISON OF THE THREE-DIMENSIONAL STRUCTURES OF A HUMANIZED AND A CHIMERIC FAB OF AN ANTI-GAMMA-INTERFERON ANTIBODY
1B4J	;	2.9	;	COMPARISON OF THE THREE-DIMENSIONAL STRUCTURES OF A HUMANIZED AND A CHIMERIC FAB OF AN ANTI-GAMMA-INTERFERON ANTIBODY
5RSA	;	2.0	;	COMPARISON OF TWO INDEPENDENTLY REFINED MODELS OF RIBONUCLEASE-A
5RSA	;	2.0	;	COMPARISON OF TWO INDEPENDENTLY REFINED MODELS OF RIBONUCLEASE-A
5IYE	;	1.694	;	Comparison of X-ray crystal structures of a tetradecamer sequence d(CCCGGGTACCCGGG)2 at 1.7 resolution
5IYG	;	1.701	;	Comparison of X-ray crystal structures of a tetradecamer sequence d(CCCGGGTACCCGGG)2 at 1.7 resolution
5IYJ	;	1.701	;	Comparison of X-ray crystal structures of a tetradecamer sequence d(CCCGGGTACCCGGG)2 at 1.7 resolution
1CZH	;	1.86	;	COMPARISONS OF WILD TYPE AND MUTANT FLAVODOXINS FROM ANACYSTIS NIDULANS. STRUCTURAL DETERMINANTS OF THE REDOX POTENTIALS.
1CZK	;	1.9	;	COMPARISONS OF WILD TYPE AND MUTANT FLAVODOXINS FROM ANACYSTIS NIDULANS. STRUCTURAL DETERMINANTS OF THE REDOX POTENTIALS.
1CZL	;	1.8	;	COMPARISONS OF WILD TYPE AND MUTANT FLAVODOXINS FROM ANACYSTIS NIDULANS. STRUCTURAL DETERMINANTS OF THE REDOX POTENTIALS.
1CZO	;	1.85	;	COMPARISONS OF WILD TYPE AND MUTANT FLAVODOXINS FROM ANACYSTIS NIDULANS. STRUCTURAL DETERMINANTS OF THE REDOX POTENTIALS.
1CZR	;	1.9	;	COMPARISONS OF WILD TYPE AND MUTANT FLAVODOXINS FROM ANACYSTIS NIDULANS. STRUCTURAL DETERMINANTS OF THE REDOX POTENTIALS.
1D04	;	1.85	;	COMPARISONS OF WILD TYPE AND MUTANT FLAVODOXINS FROM ANACYSTIS NIDULANS. STRUCTURAL DETERMINANTS OF THE REDOX POTENTIALS.
3V2N	;	1.8	;	COMPcc in complex with fatty acids
3V2P	;	1.873	;	COMPcc in complex with fatty acids
3V2Q	;	2.2	;	COMPcc in complex with fatty acids
3V2R	;	2.75	;	COMPcc in complex with fatty acids
1SS7	;		;	Compensating bends in a 16 base-pair DNA oligomer containing a T3A3 segment
1SSV	;		;	Compensating bends in a 16 base-pair DNA oligomer containing a T3A3 segment
5CPF	;	3.409	;	Compensation of the effect of isoleucine to alanine mutation by designed inhibition in the InhA enzyme
1CNB	;	2.35	;	COMPENSATORY PLASTIC EFFECTS IN THE REDESIGN OF PROTEIN-ZINC BINDING SITES
1CNC	;	2.2	;	COMPENSATORY PLASTIC EFFECTS IN THE REDESIGN OF PROTEIN-ZINC BINDING SITES
4CT8	;	2.16	;	Competence or damage-inducible protein CinA from Thermus thermophilus
4CT9	;	2.14	;	Competence or damage-inducible protein CinA from Thermus thermophilus
4CTA	;	2.21	;	Competence or damage-inducible protein CinA from Thermus thermophilus
4UOC	;	2.46	;	Competence or damage-inducible protein CinA from Thermus thermophilus
4UUW	;	1.98	;	Competence or damage-inducible protein CinA from Thermus thermophilus
4UUX	;	1.99	;	Competence or damage-inducible protein CinA from Thermus thermophilus
4OYR	;	2.2995	;	Competition of the small inhibitor PT91 with large fatty acyl substrate of the Mycobacterium tuberculosis enoyl-ACP reductase InhA by induced substrate-binding loop refolding
2N27	;		;	Competitive inhibition of TRPV1 calmodulin interaction by vanilloids
3TDA	;	2.67	;	Competitive replacement of thioridazine by prinomastat in crystals of cytochrome P450 2D6
2WII	;	2.7	;	Complement C3b in complex with factor H domains 1-4
8COE	;	4.2	;	complement C5 in complex with the LCP0195 nanobody
7Q6C	;	2.29274	;	complement C6 FIM1-2 bound to CP010 antibody
2I6Q	;	2.1	;	Complement component C2a
2I6S	;	2.7	;	Complement component C2a
2ODP	;	1.9	;	Complement component C2a, the catalytic fragment of C3- and C5-convertase of human complement
2ODQ	;	2.3	;	Complement component C2a, the catalytic fragment of C3- and C5-convertase of human complement
6EHG	;	2.65	;	complement component C3b in complex with a nanobody
6DLW	;	3.9	;	Complement component polyC9
6CXO	;	2.2	;	Complement component-9
3RJ3	;	2.35	;	Complement components factor H CCP19-20 (S1191L mutant) and C3D in complex
3OXU	;	2.1	;	Complement components factor H CCP19-20 and C3d in complex
6T8W	;	1.7	;	Complement factor B in complex with (-)-4-(1-((5,7-Dimethyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid
6T8V	;	2.29	;	Complement factor B in complex with (S)-5,7-Dimethyl-4-((2-phenylpiperidin-1-yl)methyl)-1H-indole
6T8U	;	2.84	;	Complement factor B in complex with 5-Bromo-3-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-7-methyl-1H-indol-4-amine
6QSX	;	1.77	;	Complement factor B protease domain in complex with the reversible inhibitor ((2S,4S)-1-((5,7-dimethyl-1H-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)methanol.
6RAV	;	1.7	;	Complement factor B protease domain in complex with the reversible inhibitor 4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid
6QSW	;	1.64	;	Complement factor B protease domain in complex with the reversible inhibitor N-(2-bromo-4-methylnaphthalen-1-yl)-4,5-dihydro-1H-imidazol-2-amine.
5NB7	;	1.33	;	Complement factor D
6FTY	;	1.67	;	COMPLEMENT FACTOR D COMPLEXED WITH COMPOUND 5
6FTZ	;	1.67	;	COMPLEMENT FACTOR D COMPLEXED WITH COMPOUND 6
5MT4	;	1.65	;	COMPLEMENT FACTOR D IN COMPLEX WITH A REVERSIBLE BENZOIC ACID BASED INHIBITOR
5MT0	;	1.29	;	COMPLEMENT FACTOR D IN COMPLEX WITH A REVERSIBLE INDOLE CARBOXYLIC ACID BASED INHIBITOR
5FBI	;	1.47	;	COMPLEMENT FACTOR D IN COMPLEX WITH COMPOUND 3b
5FCK	;	1.86	;	COMPLEMENT FACTOR D IN COMPLEX WITH COMPOUND 5
5FBE	;	1.43	;	COMPLEMENT FACTOR D IN COMPLEX WITH COMPOUND2
5NAW	;	1.25	;	Complement factor D in complex with the inhibitor (1R,3S,5R)-2-Aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid 2-[(1-carbamoyl-1H-indol-3-yl)-amide] 3-[(3-trifluoromethoxy-phenyl)-amide]
5NBA	;	1.87	;	Complement factor D in complex with the inhibitor (2S,4R)-4-Fluoro-pyrrolidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxy-phenyl)-amide]
5NB6	;	1.75	;	Complement factor D in complex with the inhibitor (2S,4S)-4-Amino-pyrrolidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxy-phenyl)-amide]
6FUH	;	1.37	;	Complement factor D in complex with the inhibitor (4-((3-(aminomethyl)phenyl)amino)quinazolin-2-yl)-L-valine
6QMR	;	2.0	;	Complement factor D in complex with the inhibitor (S)-2-(2-((3'-(1-amino-2-hydroxyethyl)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)acetic acid
6FUT	;	1.5	;	Complement factor D in complex with the inhibitor (S)-3'-(aminomethyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-[1,1'-biphenyl]-3-carboxamide
5NAR	;	1.55	;	Complement factor D in complex with the inhibitor (S)-pyrrolidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxy-phenyl)-amide]
5NAT	;	1.17	;	Complement factor D in complex with the inhibitor (S)-Pyrrolidine-1,2-dicarboxylic acid 1-[(1-methyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxy-phenyl)-amide]
6QMT	;	1.8	;	Complement factor D in complex with the inhibitor 2-(2-(3'-(aminomethyl)-[1,1'-biphenyl]-3-carboxamido)phenyl)acetic acid
6FUG	;	2.21	;	Complement factor D in complex with the inhibitor 3-((3-((3-(aminomethyl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenol
6FUI	;	1.38	;	Complement factor D in complex with the inhibitor 3-((3-((3-(aminomethyl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenol
6FUJ	;	2.25	;	Complement factor D in complex with the inhibitor N-(3'-(aminomethyl)-[1,1'-biphenyl]-3-yl)-3-methylbutanamide
5TCA	;	3.15	;	Complement Factor D inhibited with JH3
5TCC	;	3.37	;	Complement Factor D inhibited with JH4
4ZH1	;	2.24	;	Complement factor H in complex with the GM1 glycan
7B2D	;	1.96	;	Complement inhibitor CirpA1 from Rhipicephalus pulchellus
7B28	;	2.1	;	Complement inhibitor CirpA3 from Rhipicephalus pulchellus
7B29	;	1.83	;	Complement inhibitor CirpA4 from Rhipicephalus appendiculatus
7B2A	;	1.91	;	Complement inhibitor CirpA5 from Rhipicephalus appendiculatus
8TYP	;	1.8	;	Complement Protease C1s Inhibited by 6-(4-phenylpiperazin-1-yl)pyridine-3-carboximidamide
2ATY	;		;	Complement receptor chimaeric conjugate CR2-Ig
2GSX	;		;	Complement Receptor Type 2
4BOD	;	3.15	;	Complement regulator acquiring outer surface protein BbCRASP-4 or ErpC from Borrelia burgdorferi
4BXM	;	2.15	;	Complement regulator acquiring outer surface protein BbCRASP-4 or ErpC from Borrelia burgdorferi
1NT9	;	4.2	;	Complete 12-subunit RNA polymerase II
1WCM	;	3.8	;	Complete 12-Subunit RNA Polymerase II at 3.8 Angstrom
8G9F	;	3.2	;	Complete auto-inhibitory complex of Xenopus laevis DNA polymerase alpha-primase
7BOH	;	2.82	;	Complete Bacterial 30S ribosomal subunit assembly complex state E (+RbfA)(Consensus Refinement)
7NAR	;	3.0	;	Complete Bacterial 30S ribosomal subunit assembly complex state F (+RsgA)(Consensus Refinement)
7NAX	;	2.96	;	Complete Bacterial 30S ribosomal subunit assembly complex state I (Consensus Refinement)
4C01	;	2.3	;	Complete crystal structure of carboxylesterase Cest-2923 (lp_2923) from Lactobacillus plantarum WCFS1
4BZZ	;	3.0	;	Complete crystal structure of carboxylesterase Cest-2923 from Lactobacillus plantarum WCFS1
4BZW	;	2.148	;	Complete crystal structure of the carboxylesterase Cest-2923 (lp_2923) from Lactobacillus plantarum WCFS1
6SL0	;	3.7	;	Complete CtTel1 dimer with C2 symmetry
4R24	;	2.25	;	Complete dissection of B. subtilis nitrogen homeostatic circuitry
8G9O	;	4.4	;	Complete DNA elongation subcomplex of Xenopus laevis DNA polymerase alpha-primase
8UCV	;	3.81	;	Complete DNA termination subcomplex 1 of Xenopus laevis DNA polymerase alpha-primase
8UCW	;	3.64	;	Complete DNA termination subcomplex 2 of Xenopus laevis DNA polymerase alpha-primase
2HYN	;		;	Complete ensemble of NMR structures of unphosphorylated human phospholamban pentamer
2WNG	;	2.49	;	complete extracellular structure of human signal regulatory protein (SIRP) alpha
4OAV	;	2.1	;	Complete human RNase L in complex with 2-5A (5'-ppp heptamer), AMPPCP and RNA substrate.
4OAU	;	2.6	;	Complete human RNase L in complex with biological activators.
2WGM	;	2.35	;	Complete ion-coordination structure in the rotor ring of Na-dependent F-ATP synthase
2KTX	;		;	COMPLETE KALIOTOXIN FROM ANDROCTONUS MAURETANICUS MAURETANICUS, NMR, 18 STRUCTURES
6PH2	;	2.34	;	Complete LOV domain from the LOV-HK sensory protein from Brucella abortus (mutant C69S, construct 15-155)
7ANQ	;	2.2	;	Complete PCSK9 C-ter domain in complex with VHH P1.40
2JQ4	;		;	Complete resonance assignments and solution structure calculation of ATC2521 (NESG ID: AtT6) from Agrobacterium tumefaciens
1Y1W	;	4.0	;	Complete RNA Polymerase II elongation complex
3HOU	;	3.2	;	Complete RNA polymerase II elongation complex I with a T-U mismatch
3HOV	;	3.5	;	Complete RNA polymerase II elongation complex II
3HOW	;	3.6	;	Complete RNA polymerase II elongation complex III with a T-U mismatch and a frayed RNA 3'-uridine
3HOZ	;	3.65	;	Complete RNA polymerase II elongation complex IV with a T-U mismatch and a frayed RNA 3'-guanine
3HOX	;	3.65	;	Complete RNA polymerase II elongation complex V
3HOY	;	3.4	;	Complete RNA polymerase II elongation complex VI
1Y77	;	4.5	;	Complete RNA Polymerase II elongation complex with substrate analogue GMPCPP
2B63	;	3.8	;	Complete RNA Polymerase II-RNA inhibitor complex
5XA7	;	3.2	;	Complete structure factors and an atomic model of the calcium pump (SERCA1A) and associated phospholipids in the E1-2CA2+ crystals
5XA8	;	3.2	;	Complete structure factors and an atomic model of the calcium pump (SERCA1A) and associated phospholipids in the E1-ALF4-ADP-2CA2+ crystals
5XAB	;	3.2	;	Complete structure factors and an atomic model of the calcium pump (SERCA1A) and associated phospholipids in the E2(TG) crystals
5XA9	;	3.2	;	Complete structure factors and an atomic model of the calcium pump (SERCA1A) and associated phospholipids in the E2-ALF-(TG) crystals of C2 symmetry
5XAA	;	3.2	;	Complete structure factors and an atomic model of the calcium pump (SERCA1A) and associated phospholipids in the E2-ALF-(TG) crystals of P21212 symmetry
5FX8	;	2.6	;	Complete structure of manganese lipoxygenase of Gaeumannomyces graminis and partial structure of zonadhesin of Komagataella pastoris
3QE5	;	2.5	;	Complete structure of Streptococcus mutans Antigen I/II carboxy-terminus
2YCL	;	1.95	;	complete structure of the corrinoid,iron-sulfur protein including the N-terminal domain with a 4Fe-4S cluster
5KWA	;	2.9	;	complete structure of the Mycobacterium tuberculosis proteasomal ATPase Mpa
7TMM	;	3.5	;	Complete V1 Complex from Saccharomyces cerevisiae
4YSC	;	2.03	;	Completely oxidized structure of copper nitrite reductase from Alcaligenes faecalis
4YSA	;	1.43	;	Completely oxidized structure of copper nitrite reductase from Geobacillus thermodenitrificans
1JRH	;	2.8	;	COMPLEX (ANTIBODY/ANTIGEN)
1XJ7	;	2.7	;	Complex Androgen Receptor LBD and RAC3 peptide
6KYU	;	1.5	;	Complex assembly, crystallization and preliminary X-ray crystallographic studies of duck MHC class I molecule
3QDQ	;	2.6	;	Complex between 4-hydroxybutyrate CoA-transferase from Clostridium aminobutyricum and CoA
1CXL	;	1.81	;	COMPLEX BETWEEN A COVALENT INTERMEDIATE AND BACILLUS CIRCULANS STRAIN 251 CGTASE E257Q
6CCU	;	1.75	;	Complex between a GID4 fragment and a short peptide
6ZT5	;	2.2	;	Complex between a homodimer of Mycobacterium smegmatis MfpA and a single copy of the N-terminal 47 kDa fragment of the Mycobacterium smegmatis DNA Gyrase B subunit
1CXK	;	2.09	;	COMPLEX BETWEEN A MALTONONAOSE SUBSTRATE AND BACILLUS CIRCULANS STRAIN 251 CGTASE E257Q/D229N
6SU7	;	2.75	;	Complex between a UDP-glucosyltransferase from Polygonum tinctorium capable of glucosylating indoxyl and 3,4-Dichloroaniline
5NLM	;	2.14	;	Complex between a UDP-glucosyltransferase from Polygonum tinctorium capable of glucosylating indoxyl and indoxyl sulfate
6SU6	;	2.4	;	Complex between a UDP-glucosyltransferase from Polygonum tinctorium capable of glucosylating indoxyl and UDP-glucose
2CH4	;	3.5	;	Complex between Bacterial Chemotaxis histidine kinase CheA domains P4 and P5 and receptor-adaptor protein CheW
1OSG	;	3.0	;	Complex between BAFF and a BR3 derived peptide presented in a beta-hairpin scaffold
2L5E	;		;	Complex between BD1 of Brd3 and GATA-1 C-tail
1ES7	;	2.9	;	COMPLEX BETWEEN BMP-2 AND TWO BMP RECEPTOR IA ECTODOMAINS
2WNV	;	1.25	;	Complex between C1q globular heads and deoxyribose
2WNU	;	2.3	;	Complex between c1q globular heads and heparan sulfate
6AL5	;	3.0	;	COMPLEX BETWEEN CD19 (N138Q MUTANT) AND B43 FAB
1AM4	;	2.7	;	COMPLEX BETWEEN CDC42HS.GMPPNP AND P50 RHOGAP (H. SAPIENS)
8PE9	;	3.152	;	Complex between DDR1 DS-like domain and PRTH-101 Fab
1VOM	;	1.9	;	COMPLEX BETWEEN DICTYOSTELIUM MYOSIN AND MGADP AND VANADATE AT 1.9A RESOLUTION
1TEZ	;	1.8	;	COMPLEX BETWEEN DNA AND THE DNA PHOTOLYASE FROM ANACYSTIS NIDULANS
5H5J	;	2.5	;	Complex between ferredoxin and ferredoxin-NADP+ reductase from maize root
1F3R	;		;	COMPLEX BETWEEN FV ANTIBODY FRAGMENT AND AN ANALOGUE OF THE MAIN IMMUNOGENIC REGION OF THE ACETYLCHOLINE RECEPTOR
1OQO	;	2.3	;	Complex between G0 version of an Fc bound to a minimized version of Protein A called Mini-Z
2ET3	;	2.8	;	Complex Between Gentamicin C1A and the 16S-RRNA A-Site
5TL5	;	1.8	;	COMPLEX BETWEEN HUMAN CD27 AND ANTIBODY M2177
5TLK	;	2.7	;	COMPLEX BETWEEN HUMAN CD27 AND FAB FRAGMENTS OF ANTIBODIES M2177 AND H2191
5TLJ	;	3.5	;	COMPLEX BETWEEN HUMAN CD27 AND FAB FRAGMENTS OF ANTIBODIES M2177 AND M2191
3UIP	;	2.293	;	Complex between human RanGAP1-SUMO1, UBC9 and the IR1 domain from RanBP2 containing IR2 Motif II
3UIN	;	2.597	;	Complex between human RanGAP1-SUMO2, UBC9 and the IR1 domain from RanBP2
3UIO	;	2.602	;	Complex between human RanGAP1-SUMO2, UBC9 and the IR1 domain from RanBP2 containing IR2 Motif II
5D2M	;	2.4	;	Complex between human SUMO2-RANGAP1, UBC9 and ZNF451
1BD2	;	2.5	;	COMPLEX BETWEEN HUMAN T-CELL RECEPTOR B7, VIRAL PEPTIDE (TAX) AND MHC CLASS I MOLECULE HLA-A 0201
1AO7	;	2.6	;	COMPLEX BETWEEN HUMAN T-CELL RECEPTOR, VIRAL PEPTIDE (TAX), AND HLA-A 0201
5M2J	;	1.9	;	Complex between human TNF alpha and Llama VHH2
5M2M	;	2.3	;	Complex between human TNF alpha and Llama VHH3
5VJQ	;	1.9	;	Complex between HyHEL10 Fab fragment heavy chain mutant (I29F, S52T, Y53F) and Pekin duck egg lysozyme isoform I (DEL-I)
5VJO	;	2.43	;	Complex between HyHEL10 Fab fragment heavy chain mutant I29F and Pekin duck egg lysozyme isoform I (DEL-I)
2ESI	;	3.0	;	Complex between Kanamycin A and the 16S-Rrna A Site.
5E7F	;	2.7	;	Complex between lactococcal phage Tuc2009 RBP head domain and a nanobody (L06)
1ESV	;	2.0	;	COMPLEX BETWEEN LATRUNCULIN A:RABBIT MUSCLE ALPHA ACTIN:HUMAN GELSOLIN DOMAIN 1
2ESJ	;	2.2	;	Complex between Lividomycin A and the 16S-Rrna A Site
7UD5	;	4.25	;	Complex between MLL1-WRAD and an H2B-ubiquitinated nucleosome
7PNL	;	1.83	;	Complex between monomolecular human telomeric G-quadruplex and a sulfonamide derivative of the natural alkaloid Berberine
6F20	;	2.0	;	Complex between MTH1 and compound 1 (a 7-azaindole-4-ester derivative)
6F23	;	1.84	;	Complex between MTH1 and compound 16 (a 4-amino-7-azaindole derivative)
6F22	;	1.55	;	Complex between MTH1 and compound 29 (a 4-amino-2,7-diazaindole derivative)
6F1X	;	1.9	;	Complex between MTH1 and compound 7 (a 7-azaindole-2-amide derivative)
1DMY	;	2.45	;	COMPLEX BETWEEN MURINE MITOCHONDRIAL CARBONIC ANYHDRASE V AND THE TRANSITION STATE ANALOGUE ACETAZOLAMIDE
8QF5	;	1.5	;	Complex between N-lobe of Arc and nanobody E5
8QF4	;	1.02	;	Complex between N-lobe of Arc and nanobody H11
1NMC	;	2.5	;	COMPLEX BETWEEN NC10 ANTI-INFLUENZA VIRUS NEURAMINIDASE SINGLE CHAIN ANTIBODY WITH A 15 RESIDUE LINKER AND INFLUENZA VIRUS NEURAMINIDASE
1A14	;	2.5	;	COMPLEX BETWEEN NC10 ANTI-INFLUENZA VIRUS NEURAMINIDASE SINGLE CHAIN ANTIBODY WITH A 5 RESIDUE LINKER AND INFLUENZA VIRUS NEURAMINIDASE
2ET8	;	2.5	;	Complex Between Neamine and the 16S-RRNA A-Site
2ET4	;	2.4	;	Complex Between Neomycin B and the 16S-RRNA A-Site
1QO3	;	2.3	;	Complex between NK cell receptor Ly49A and its MHC class I ligand H-2Dd
1AOI	;	2.8	;	COMPLEX BETWEEN NUCLEOSOME CORE PARTICLE (H3,H4,H2A,H2B) AND 146 BP LONG DNA FRAGMENT
1J7T	;	2.5	;	Complex between Paromomycin and the 16S-rRNA A-site at 2.5 A resolution
2BEE	;	2.6	;	Complex Between Paromomycin derivative JS4 and the 16S-Rrna A Site
2BE0	;	2.63	;	Complex Between Paromomycin Derivative JS5-39 and the 16S-Rrna A-Site.
5LP5	;	2.74	;	Complex between Penicillin-Binding Protein (PBP2) and MreC from Helicobacter pylori
3C5W	;	2.8	;	Complex between PP2A-specific methylesterase PME-1 and PP2A core enzyme
1S70	;	2.7	;	Complex between protein ser/thr phosphatase-1 (delta) and the myosin phosphatase targeting subunit 1 (MYPT1)
1EQY	;	2.3	;	COMPLEX BETWEEN RABBIT MUSCLE ALPHA-ACTIN: HUMAN GELSOLIN DOMAIN 1
1P8Z	;	2.6	;	Complex Between Rabbit Muscle alpha-Actin: Human Gelsolin Residues Val26-Glu156
8DU4	;	3.55	;	Complex between RbBP5-WDR5 and an H2B-ubiquitinated nucleosome
2ET5	;	2.2	;	Complex Between Ribostamycin and the 16S-RRNA A-Site
7SKL	;	1.6	;	Complex between S. aureus aureolysin and IMPI mutant I57I
7SKM	;	1.85	;	Complex between S. aureus aureolysin and wt IMPI.
6ZVQ	;	2.03	;	Complex between SMAD2 MH2 domain and peptide from Ski corepressor
6O1F	;	2.15	;	Complex between soybean trypsin inhibitor beta1-tryptase and a humanized fab
1RSU	;	1.7	;	COMPLEX BETWEEN STREPTAVIDIN AND THE STREP-TAG II PEPTIDE
1RST	;	1.7	;	COMPLEX BETWEEN STREPTAVIDIN AND THE STREP-TAG PEPTIDE
1OAI	;	1.0	;	Complex between Tap UBA domain and FxFG nucleoporin peptide
3BX1	;	1.85	;	Complex between the Barley alpha-Amylase/Subtilisin Inhibitor and the subtilisin Savinase
7PA5	;	3.184	;	Complex between the beta-lactamase CMY-2 with an inhibitory nanobody
7AG0	;	3.104	;	Complex between the bone morphogenetic protein 2 and its antagonist Noggin
2F9Z	;	2.4	;	Complex between the chemotaxis deamidase CheD and the chemotaxis phosphatase CheC from Thermotoga maritima
1ELU	;	1.55	;	COMPLEX BETWEEN THE CYSTINE C-S LYASE C-DES AND ITS REACTION PRODUCT CYSTEINE PERSULFIDE.
6GZL	;	1.953	;	Complex between the dynein light chain DYNLL1/DLC8 and a peptide from the large myelin-associated glycoprotein L-MAG
6GZJ	;	1.977	;	Complex between the dynein light chain DYNLL1/DLC8 and the specific domain of large myelin-associated glycoprotein L-MAG
1EBP	;	2.8	;	COMPLEX BETWEEN THE EXTRACELLULAR DOMAIN OF ERYTHROPOIETIN (EPO) RECEPTOR [EBP] AND AN AGONIST PEPTIDE [EMP1]
1EBA	;	2.7	;	COMPLEX BETWEEN THE EXTRACELLULAR DOMAIN OF ERYTHROPOIETIN (EPO) RECEPTOR [EBP] AND AN INACTIVE PEPTIDE [EMP33] CONTAINS 3,5-DIBROMOTYROSINE IN POSITION 4 (DENOTED DBY)
7MSQ	;	2.29	;	Complex between the Fab arm of AB-3467 and the SARS-CoV-2 receptor binding domain (RBD)
6F5Z	;	1.35	;	Complex between the Haloferax volcanii Trm112 methyltransferase activator and the Hvo_0019 putative methyltransferase
3TVL	;	2.3	;	Complex between the human thiamine triphosphatase and triphosphate
3DKO	;	2.0	;	Complex between the kinase domain of human ephrin type-a receptor 7 (epha7) and inhibitor alw-ii-49-7
1PJJ	;	1.9	;	Complex between the Lactococcus lactis Fpg and an abasic site containing DNA.
5MVW	;	1.82	;	Complex between the Leucine Zipper (LZ) and Centrosomin-motif 2 (CM2) domains of Drosophila melanogaster Centrosomin (Cnn)
5MW0	;	2.0	;	Complex between the Leucine Zipper (LZ) and Centrosomin-motif 2 (CM2) domains of Drosophila melanogaster Centrosomin (Cnn) - L535E mutant form
5MW9	;	2.2	;	Complex between the Leucine Zipper (LZ) and Centrosomin-motif 2 (CM2) domains of Drosophila melanogaster Centrosomin (Cnn) - L535E mutant form
5MWE	;	2.02	;	Complex between the Leucine Zipper (LZ, residues 490-567) and Centrosomin-motif 2 (CM2) domains of Drosophila melanogaster Centrosomin (Cnn)
2IWG	;	2.35	;	COMPLEX BETWEEN THE PRYSPRY DOMAIN OF TRIM21 AND IGG FC
4EMJ	;	2.4	;	Complex between the reductase and ferredoxin components of toluene dioxygenase
4PUF	;	3.296	;	Complex between the Salmonella T3SS effector SlrP and its human target thioredoxin-1
2V9T	;	1.7	;	Complex between the second LRR domain of Slit2 and The first Ig domain from Robo1
3S9M	;	3.32	;	Complex between transferrin receptor 1 and transferrin with iron in the N-Lobe, cryocooled 1
3S9L	;	3.22	;	Complex between transferrin receptor 1 and transferrin with iron in the N-Lobe, cryocooled 2
3S9N	;	3.25	;	Complex between transferrin receptor 1 and transferrin with iron in the N-Lobe, room temperature
4AFI	;	2.8	;	Complex between Vamp7 longin domain and fragment of delta-adaptin from AP3
1VPP	;	1.9	;	COMPLEX BETWEEN VEGF AND A RECEPTOR BLOCKING PEPTIDE
1OXB	;	2.3	;	Complex between YPD1 and SLN1 response regulator domain in space group P2(1)2(1)2(1)
1OXK	;	2.1	;	Complex between YPD1 and SLN1 response regulator domain in space group P3(2)
4R41	;	1.61	;	Complex Crystal structure of 4-nitro-2-phosphono-benzoic acid with sp-Aspartate-Semialdehyde Dehydrogenase and Nicotinamide-dinucleotide
3M94	;	2.05	;	Complex crystal structure of Ascaris suum eIF4E-3 with m2,2,7G cap
3M93	;	2.9	;	Complex crystal structure of Ascaris suum eIF4E-3 with m7G cap
4FAS	;	2.1	;	Complex crystal structure of hydroxylamine oxidoreductase and NE1300 from Nitrosomonas europaea
8PTC	;	1.51	;	COMPLEX CRYSTAL STRUCTURE OF MUTANT HUMAN MONOGLYCERIDE LIPASE WITH COMPOUND 5d
8PTQ	;	1.55	;	COMPLEX CRYSTAL STRUCTURE OF MUTANT HUMAN MONOGLYCERIDE LIPASE WITH COMPOUND 5l
8PTR	;	1.73	;	COMPLEX CRYSTAL STRUCTURE OF MUTANT HUMAN MONOGLYCERIDE LIPASE WITH COMPOUND 5r
4R54	;	1.81	;	Complex crystal structure of sp-Aspartate-Semialdehyde-Dehydrogenase with 3-carboxy-ethyl-phthalic acid
1TXC	;	2.3	;	Complex crystal structure of SPE16 with ANS
7ZEW	;		;	Complex Cyp33-RRM : AAUAAA RNA
7ZEY	;		;	Complex Cyp33-RRM : MLL1-PHD3
7ZEX	;		;	Complex Cyp33-RRMdelta alpha : UAAUGUCG RNA
8IIE	;	1.67	;	Complex form of MsmUdgX and uracil- obtained from uracil DNA (ttUtt) post its cleavage by MsmUdgX
8IIG	;	2.3	;	Complex form of MsmUdgX H109A mutant and uracil- obtained from uracil DNA (ttUtt) post its cleavage by UdgX H109A
8III	;	1.72	;	Complex form of MsmUdgX H109C mutant and uracil- obtained from uracil DNA (ttUtt) post its cleavage by MsmUdgX H109C
8IIL	;	2.3	;	Complex form of MsmUdgX H109G mutant and uracil- obtained from uracil DNA (ttUtt) post its cleavage by MsmUdgX H109G
8IIN	;	1.61	;	Complex form of MsmUdgX H109K mutant and uracil- obtained from uracil DNA (ttUtt) post its cleavage by MsmUdgX H109K
8IIP	;	1.63	;	Complex form of MsmUdgX H109Q mutant and uracil- obtained from uracil DNA (ttUtt) post its cleavage by MsmUdgX H109Q
8IIT	;	1.61	;	Complex form of MsmUdgX H109S/R184A double mutant and uracil- obtained from uracil DNA (ttUtt) post its cleavage by MsmUdgX H109S/R184A
6AJP	;	1.334	;	Complex form of Uracil DNA glycosylase X and deoxyuridine monophosphate.
6AJR	;	1.341	;	Complex form of Uracil DNA glycosylase X and uracil
6AJO	;	2.269	;	Complex form of Uracil DNA glycosylase X and uracil-DNA.
1FSK	;	2.9	;	COMPLEX FORMATION BETWEEN A FAB FRAGMENT OF A MONOCLONAL IGG ANTIBODY AND THE MAJOR ALLERGEN FROM BIRCH POLLEN BET V 1
1BJR	;	2.44	;	COMPLEX FORMED BETWEEN PROTEOLYTICALLY GENERATED LACTOFERRIN FRAGMENT AND PROTEINASE K
7TNP	;	3.96	;	Complex GGGG of AMPA-subtype iGluR GluA2 in complex with auxiliary subunit gamma2 (Stargazin) at low glutamate concentration (20 uM) in the presence of cyclothiazide (100 uM)
7TNO	;	4.02	;	Complex GGGN of AMPA-subtype iGluR GluA2 in complex with auxiliary subunit gamma2 (Stargazin) at low glutamate concentration (20 uM) in the presence of cyclothiazide (100 uM)
7TNN	;	3.91	;	Complex GGNN of AMPA-subtype iGluR GluA2 in complex with auxiliary subunit gamma2 (Stargazin) at low glutamate concentration (20 uM) in the presence of cyclothiazide (100 uM)
7TNL	;	3.59	;	Complex GNGN1 of AMPA-subtype iGluR GluA2 in complex with auxiliary subunit gamma2 (Stargazin) at low glutamate concentration (20 uM) in the presence of cyclothiazide (100 uM)
7TNM	;	4.74	;	Complex GNGN2 of AMPA-subtype iGluR GluA2 in complex with auxiliary subunit gamma2 (Stargazin) at low glutamate concentration (20 uM) in the presence of cyclothiazide (100 uM)
7TNK	;	4.5	;	Complex GNNN of AMPA-subtype iGluR GluA2 in complex with auxiliary subunit gamma2 (Stargazin) at low glutamate concentration (20 uM) in the presence of cyclothiazide (100 uM)
1XCT	;	3.05	;	Complex HCV core-Fab 19D9D6-Protein L mutant (D55A, L57H, Y64W) in space group P21212
1XCQ	;	3.5	;	Complex HCV core-Fab 19D9D6-Protein L mutant (D55A,L57H,Y64W) in space group P21
1XF5	;	2.6	;	Complex HCV core-Fab 19D9D6-Protein L mutant (H74C, Y64W)in space group P21212
2L0Y	;		;	Complex hMia40-hCox17
6ZKC	;	3.1	;	Complex I during turnover, closed
6ZKD	;	2.7	;	Complex I during turnover, open1
6ZKE	;	2.6	;	Complex I during turnover, open2
6ZKF	;	2.8	;	Complex I during turnover, open3
7P62	;	3.6	;	Complex I from E. coli, DDM-purified, Apo, Resting state
7P61	;	3.2	;	Complex I from E. coli, DDM-purified, with NADH, Resting state
7P7C	;	2.4	;	Complex I from E. coli, DDM/LMNG-purified, Apo, Open state
7P7E	;	2.7	;	Complex I from E. coli, DDM/LMNG-purified, Apo, Resting state
7P7M	;	3.2	;	Complex I from E. coli, DDM/LMNG-purified, inhibited by Piericidin A, Open state
7P63	;	3.4	;	Complex I from E. coli, DDM/LMNG-purified, under Turnover at pH 6, Closed state
7P64	;	2.5	;	Complex I from E. coli, DDM/LMNG-purified, under Turnover at pH 6, Open state
7P69	;	3.0	;	Complex I from E. coli, DDM/LMNG-purified, under Turnover at pH 6, Resting state
7Z80	;	2.93	;	Complex I from E. coli, DDM/LMNG-purified, under Turnover at pH 8, Closed state
7Z83	;	2.88	;	Complex I from E. coli, DDM/LMNG-purified, under Turnover at pH 8, Open state
7Z84	;	2.87	;	Complex I from E. coli, DDM/LMNG-purified, under Turnover at pH 8, Open-ready state
7ZC5	;	3.0	;	Complex I from E. coli, DDM/LMNG-purified, under Turnover at pH 8, Resting state
7P7J	;	2.7	;	Complex I from E. coli, DDM/LMNG-purified, with DQ, Open state
7P7K	;	3.1	;	Complex I from E. coli, DDM/LMNG-purified, with DQ, Resting state
7P7L	;	3.0	;	Complex I from E. coli, DDM/LMNG-purified, with NADH and FMN, Open state
7Z7R	;	3.36	;	Complex I from E. coli, LMNG-purified, Apo, Open-ready state
7Z7S	;	2.4	;	Complex I from E. coli, LMNG-purified, under Turnover at pH 6, Closed state
7Z7T	;	3.1	;	Complex I from E. coli, LMNG-purified, under Turnover at pH 6, Open state
7Z7V	;	2.29	;	Complex I from E. coli, LMNG-purified, under Turnover at pH 6, Open-ready state
7ZCI	;	2.69	;	Complex I from E. coli, LMNG-purified, under Turnover at pH 6, Resting state
7ZDM	;	3.44	;	Complex I from Ovis aries at pH5.5, Closed state
7ZDJ	;	3.25	;	Complex I from Ovis aries at pH5.5, Open state
7ZDH	;	3.46	;	Complex I from Ovis aries at pH7.4, Closed state
7ZEB	;	3.8	;	Complex I from Ovis aries at pH9, Closed state
7ZDP	;	3.88	;	Complex I from Ovis aries at pH9, Open state
7ZD6	;	3.16	;	Complex I from Ovis aries, at pH7.4, Open state
6ZKK	;	3.7	;	Complex I inhibited by rotenone, closed
6ZKL	;	3.1	;	Complex I inhibited by rotenone, open1
6ZKM	;	2.8	;	Complex I inhibited by rotenone, open2
6ZKN	;	2.9	;	Complex I inhibited by rotenone, open3
6ZKG	;	3.4	;	Complex I with NADH, closed
6ZKH	;	3.0	;	Complex I with NADH, open1
6ZKI	;	2.8	;	Complex I with NADH, open2
6ZKJ	;	3.0	;	Complex I with NADH, open3
2ACZ	;	3.1	;	Complex II (Succinate Dehydrogenase) From E. Coli with Atpenin A5 inhibitor co-crystallized at the ubiquinone binding site
1NEN	;	2.9	;	Complex II (Succinate Dehydrogenase) From E. Coli with Dinitrophenol-17 inhibitor co-crystallized at the ubiquinone binding site
1NEK	;	2.6	;	Complex II (Succinate Dehydrogenase) From E. Coli with ubiquinone bound
6Q9E	;	3.9	;	Complex III2 focused refinement from Ovine respiratory supercomplex I+III2
7RJA	;	3.0	;	Complex III2 from Candida albicans, inhibitor free
7RJB	;	3.2	;	Complex III2 from Candida albicans, inhibitor free, Rieske head domain in b position
7RJD	;	3.2	;	Complex III2 from Candida albicans, inhibitor free, Rieske head domain in c position
7RJC	;	3.3	;	Complex III2 from Candida albicans, inhibitor free, Rieske head domain in intermediate position
7RJE	;	3.3	;	Complex III2 from Candida albicans, Inz-5 bound
8ABH	;	3.0	;	Complex III2 from Yarrowia lipolytica, antimycin A bound, b-position
8ABJ	;	3.7	;	Complex III2 from Yarrowia lipolytica, antimycin A bound, c-position
8ABM	;	2.8	;	Complex III2 from Yarrowia lipolytica, apo, b-position
8AC4	;	2.7	;	Complex III2 from Yarrowia lipolytica, apo, c-position
8AC3	;	2.8	;	Complex III2 from Yarrowia lipolytica, apo, int-position
8AB9	;	3.3	;	Complex III2 from Yarrowia lipolytica, ascorbate-reduced, b-position
8ABB	;	3.2	;	Complex III2 from Yarrowia lipolytica, ascorbate-reduced, c-position
8ABA	;	3.2	;	Complex III2 from Yarrowia lipolytica, ascorbate-reduced, int-position
8AB7	;	3.3	;	Complex III2 from Yarrowia lipolytica, atovaquone and antimycin A bound
8AB6	;	2.0	;	Complex III2 from Yarrowia lipolytica, combined datasets, consensus refinement
8ABK	;	2.5	;	Complex III2 from Yarrowia lipolytica, decylubiquinol bound, b-position
8ABE	;	2.3	;	Complex III2 from Yarrowia lipolytica, oxidised with ferricyanide, b-position
8ABG	;	2.3	;	Complex III2 from Yarrowia lipolytica, oxidised with ferricyanide, c-position
8ABF	;	2.3	;	Complex III2 from Yarrowia lipolytica, oxidised with ferricyanide, int-position
8ABL	;	2.1	;	Complex III2 from Yarrowia lipolytica, with decylubiquinol and antimycin A, consensus refinement
8AC5	;	3.1	;	Complex III2 from Yarrowia lipolytica, with decylubiquinol, oxidised, b-position
8ABI	;	3.0	;	Complex III2 from Yarrowia lipolytica,antimycin A bound, int-position
8AB8	;	2.6	;	Complex III2, b-position, with decylubiquinone and ascorbate-reduced
8B7W	;	2.85	;	Complex IL-17A/anti-IL-17A-76
3MA2	;	2.05	;	Complex membrane type-1 matrix metalloproteinase (MT1-MMP) with tissue inhibitor of metalloproteinase-1 (TIMP-1)
7TNJ	;	4.02	;	Complex NNNN of AMPA-subtype iGluR GluA2 in complex with auxiliary subunit gamma2 (Stargazin) at low glutamate concentration (20 uM) in the presence of cyclothiazide (100 uM)
1JAQ	;	2.4	;	COMPLEX OF 1-HYDROXYLAMINE-2-ISOBUTYLMALONYL-ALA-GLY-NH2 WITH THE CATALYTIC DOMAIN OF MATRIX METALLO PROTEINASE-8 (MET80 FORM)
3UBW	;	1.9	;	Complex of 14-3-3 isoform epsilon, a Mlf1 phosphopeptide and a small fragment hit from a FBDD screen
6BD2	;	2.9	;	Complex of 14-3-3 theta with an IRSp53 peptide doubly-phosphorylated at T340 and S366
6BQT	;	2.8	;	Complex of 14-3-3 theta with an IRSp53 peptide doubly-phosphorylated at T340 and T360
6BD1	;	2.35	;	Complex of 14-3-3 theta with an IRSp53 peptide phosphorylated at S366
6BCR	;	1.986	;	Complex of 14-3-3 theta with an IRSp53 peptide phosphorylated at T340
6BCY	;	2.3	;	Complex of 14-3-3 theta with an IRSp53 peptide phosphorylated at T360
5EN4	;	1.52	;	Complex of 17-beta-hydroxysteroid dehydrogenase type 14 with inhibitor.
1I76	;	1.2	;	COMPLEX OF 2-(BIPHENYL-4-SULFONYL)-1,2,3,4-TETRAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID (D-TIC DERIVATIVE) WITH T CATALITIC DOMAIN OF MATRIX METALLO PROTEINASE-8 (MET80 FORM)
2KMB	;	2.0	;	COMPLEX OF 3'-NEUAC-LEWIS-X WITH A SELECTIN-LIKE MUTANT OF MANNOSE-BINDING PROTEIN A
3KMB	;	1.95	;	COMPLEX OF 3'-SULFO-LEWIS-X WITH A SELECTIN-LIKE MUTANT OF MANNOSE-BINDING PROTEIN A
4DZU	;	2.1	;	Complex of 3-alpha bound to gp41-5
1JAO	;	2.4	;	COMPLEX OF 3-MERCAPTO-2-BENZYLPROPANOYL-ALA-GLY-NH2 WITH THE CATALYTIC DOMAIN OF MATRIX METALLO PROTEINASE-8 (MET80 FORM)
4KMB	;	2.0	;	COMPLEX OF 4'-SULFO-LEWIS-X WITH A SELECTIN-LIKE MUTANT OF MANNOSE-BINDING PROTEIN A
4DZV	;	2.1	;	Complex of 4-alpha/beta bound to gp41-5
3NK2	;	2.65	;	Complex of 6-hydroxy-L-nicotine oxidase with dopamine
3NH3	;	2.1	;	Complex of 6-hydroxy-L-nicotine oxidase with final ketone product formed during catalytic turnover
3NK0	;	2.15	;	Complex of 6-hydroxy-L-nicotine oxidase with inhibitor bound at active site and turnover product at exit cavity
3NGC	;	2.25	;	Complex of 6-hydroxy-L-nicotine oxidase with intermediate methylmyosmine product formed during catalytic turnover
3NN0	;	2.75	;	Complex of 6-hydroxy-L-nicotine oxidase with nicotinamide
3NHO	;	2.85	;	Complex of 6-hydroxy-L-nicotine oxidase with product bound at active site
3NK1	;	2.2	;	Complex of 6-hydroxy-L-nicotine oxidase with serotonin
2DHN	;	2.2	;	COMPLEX OF 7,8-DIHYDRONEOPTERIN ALDOLASE FROM STAPHYLOCOCCUS AUREUS WITH 6-HYDROXYMETHYL-7,8-DIHYDROPTERIN AT 2.2 A RESOLUTION
4WZD	;	3.1	;	Complex of 70S ribosome with cognate tRNA-Tyr in the P-site
4WZO	;	3.3	;	Complex of 70S ribosome with tRNA-fMet and mRNA
4WSM	;	3.3	;	Complex of 70S ribosome with tRNA-Leu and mRNA with G-U mismatch in the first position in the A- and P-sites
4WT1	;	3.05	;	Complex of 70S ribosome with tRNA-Phe and mRNA with A-A mismatch in the second position in the A-site
4WQR	;	3.15	;	Complex of 70S ribosome with tRNA-Phe and mRNA with C-A mismatch in the first position in the A-site.
4WRO	;	3.05	;	Complex of 70S ribosome with tRNA-Phe and mRNA with C-A mismatch in the second position in the A-site
4WSD	;	2.95	;	Complex of 70S ribosome with tRNA-Phe and mRNA with C-A mismatch in the second position in the A-site and with antibiotic paromomycin.
4WRA	;	3.05	;	Complex of 70S ribosome with tRNA-Tyr and mRNA with A-A mismatch in the first position in the A-site and with antibiotic paromomycin.
4WR6	;	3.05	;	Complex of 70S ribosome with tRNA-Tyr and mRNA with A-A mismatch in the first position in the A-site.
4WQ1	;	3.1	;	Complex of 70S ribosome with tRNA-Tyr and mRNA with C-A mismatch in the first position in the A-site.
4WU1	;	3.2	;	Complex of 70S ribosome with tRNA-Tyr and mRNA with G-U mismatch in the second position in the P-site
1CXF	;	2.1	;	COMPLEX OF A (D229N/E257Q) DOUBLE MUTANT CGTASE FROM BACILLUS CIRCULANS STRAIN 251 WITH MALTOTETRAOSE AT 120 K AND PH 9.1 OBTAINED AFTER SOAKING THE CRYSTAL WITH ALPHA-CYCLODEXTRIN
4CW1	;	2.58	;	COMPLEX OF A B14 CHICKEN MHC CLASS I MOLECULE AND A 9MER CHICKEN PEPTIDE
4D0D	;	3.13	;	COMPLEX OF A B2 CHICKEN MHC CLASS I MOLECULE AND A 8MER CHICKEN PEPTIDE
4CVX	;	3.3	;	COMPLEX OF A B2 CHICKEN MHC CLASS I MOLECULE AND A 9MER CHICKEN PEPTIDE
2YEZ	;	2.9	;	COMPLEX OF A B21 CHICKEN MHC CLASS I MOLECULE AND A 10MER CHICKEN PEPTIDE
4CVZ	;	2.39	;	COMPLEX OF A B21 CHICKEN MHC CLASS I MOLECULE AND A 10MER CHICKEN PEPTIDE
4D0B	;	2.8	;	COMPLEX OF A B21 CHICKEN MHC CLASS I MOLECULE AND A 10MER CHICKEN PEPTIDE
4D0C	;	2.81	;	COMPLEX OF A B21 CHICKEN MHC CLASS I MOLECULE AND A 10MER CHICKEN PEPTIDE
5ACZ	;	2.69	;	COMPLEX OF A B21 CHICKEN MHC CLASS I MOLECULE AND A 11MER CHICKEN PEPTIDE
5AD0	;	2.84	;	COMPLEX OF A B21 CHICKEN MHC CLASS I MOLECULE AND A 11MER CHICKEN PEPTIDE
4CIM	;	1.5	;	Complex of a Bcl-w BH3 mutant with a BH3 domain
5OGI	;	2.8	;	Complex of a binding protein and human adenovirus C 5 hexon
4GQJ	;	2.951	;	Complex of a binuclear Ruthenium compound D,D-([mu-(11,11')-bi(dppz)-(1,10-phenanthroline)4-Ru2]4+) bound to d(CGTACG)
5OXD	;	2.6	;	Complex of a C. perfringens O-GlcNAcase with a fragment hit
2P45	;	1.1	;	Complex of a camelid single-domain vhh antibody fragment with RNASE A at 1.1A resolution: SE5B-ORTHO-1 crystal form with five se-met sites (L4M, M34, M51, F68M, M83) in vhh scaffold.
2P49	;	1.38	;	Complex of a camelid single-domain vhh antibody fragment with RNASE A at 1.4A resolution: native mono_1 crystal form
2P43	;	1.65	;	Complex of a camelid single-domain vhh antibody fragment with RNASE A at 1.65A resolution: SE3-mono-1 crystal form with three se-met sites (M34, M51, M83) in vhh scaffold
2P42	;	1.8	;	Complex of a camelid single-domain vhh antibody fragment with RNASE A at 1.8A resolution: SE3-mono-2 crystal form with three se-met sites (M34, M51, M83) in vhh scaffold
2P44	;	1.8	;	Complex of a camelid single-domain vhh antibody fragment with RNASE A at 1.8A resolution: SE5A-mono-1 crystal form with five se-met sites (M34, M51, F68M, M83, L86M) in vhh scaffold
2P48	;	2.3	;	Complex of a camelid single-domain vhh antibody fragment with RNASE A at 2.3A resolution: SE5B-tetra crystal form with five se-met sites (L4M, M34, M51, F68M, M83) in vhh scaffold.
2P46	;	2.5	;	Complex of a camelid single-domain vhh antibody fragment with RNASE A at 2.5A resolution: se5b-ortho-2 crystal form with five se-met sites (L4M, M34, M51, F68M, M83) in vhh scaffold.
2P47	;	2.5	;	Complex of a camelid single-domain vhh antibody fragment with RNASE A at 2.5A resolution: SE5B-TRI crystal form with five se-met sites (L4M, M34, M51, F68M, M83) in vhh scaffold.
3O3Z	;	2.6	;	Complex of a chimeric alpha/beta-peptide based on the gp41 CHR domain bound to a gp41 NHR domain peptide
3O40	;	2.1	;	Complex of a chimeric alpha/beta-peptide based on the gp41 CHR domain bound to gp41-5
1H0G	;	2.0	;	Complex of a chitinase with the natural product cyclopentapeptide argadin from Clonostachys
1H0I	;	2.0	;	Complex of a chitinase with the natural product cyclopentapeptide argifin from Gliocladium
1DIT	;	2.3	;	COMPLEX OF A DIVALENT INHIBITOR WITH THROMBIN
1BZQ	;	2.8	;	COMPLEX OF A DROMEDARY SINGLE-DOMAIN VHH ANTIBODY FRAGMENT WITH RNASE A
7QP4	;	2.3	;	Complex of a Gemini-cholesterol analogue with Retinoid-related Orphan Receptor gamma
7WX7	;	1.781	;	complex of a legionella acetyltransferase VipF and COA/ACO
3GXE	;	2.6	;	Complex of a Low Affinity Collagen Site with the Fibronectin 8-9FnI Domain Pair
1GZG	;	1.66	;	Complex of a Mg2-dependent porphobilinogen synthase from Pseudomonas aeruginosa (mutant D139N) with 5-fluorolevulinic acid
3HHW	;	2.7	;	Complex of a vesicular stomatitis virus empty capsid with the nucleocapsid-binding domain of the phosphoprotein
2DIJ	;	2.6	;	COMPLEX OF A Y195F MUTANT CGTASE FROM B. CIRCULANS STRAIN 251 COMPLEXED WITH A MALTONONAOSE INHIBITOR AT PH 9.8 OBTAINED AFTER SOAKING THE CRYSTAL WITH ACARBOSE AND MALTOHEXAOSE
1DJ6	;	1.0	;	COMPLEX OF A Z-DNA HEXAMER, D(CG)3, WITH SYNTHETIC POLYAMINE AT ROOM TEMPERATURE
1H9A	;	2.16	;	COMPLEX OF ACTIVE MUTANT (Q365->C) OF GLUCOSE 6-PHOSPHATE DEHYDROGENASE FROM L. MESENTEROIDES WITH COENZYME NADP
1E77	;	2.69	;	COMPLEX OF ACTIVE MUTANT (Q365->C) OF GLUCOSE 6-PHOSPHATE DEHYDROGENASE FROM LEUCONOSTOC MESENTEROIDES WITH SUBSTRATE
1H94	;	2.5	;	COMPLEX OF ACTIVE MUTANT (S215->C) OF GLUCOSE 6-PHOSPHATE DEHYDROGENASE FROM L.MESENTEROIDES WITH COENZYME NAD
1DAN	;	2.0	;	Complex of active site inhibited human blood coagulation factor VIIA with human recombinant soluble tissue factor
2A2Q	;	1.8	;	Complex of Active-site Inhibited Human Coagulation Factor VIIa with Human Soluble Tissue Factor in the Presence of Ca2+, Mg2+, Na+, and Zn2+
8GH4	;	3.8	;	Complex of Adam 10 disentegrin cysteine rich domains with human monoclonal antibody
4PKH	;	2.15	;	Complex of ADP-actin With the N-terminal Actin-Binding Domain of Tropomodulin
4GCA	;	0.9	;	Complex of Aldose Reductase with inhibitor IDD 1219
2PEV	;	0.9	;	Complex of Aldose Reductase with NADP+ and simaltaneously bound competetive inhibitors Fidarestat and IDD594. Concentration of Fidarestat in soaking solution exceeds concentration of IDD594.
2PF8	;	0.85	;	Complex of Aldose Reductase with NADP+ and simaltaneously bound competetive inhibitors Fidarestat and IDD594. Concentration of Fidarestat in soaking solution is equal to concentration of IDD594.
2PFH	;	0.85	;	Complex of Aldose Reductase with NADP+ and simaltaneously bound competetive inhibitors Fidarestat and IDD594. Concentration of Fidarestat in soaking solution is less than concentration of IDD594.
1AGR	;	2.8	;	COMPLEX OF ALF4-ACTIVATED GI-ALPHA-1 WITH RGS4
1JL8	;	3.2	;	Complex of alpha-amylase II (TVA II) from Thermoactinomyces vulgaris R-47 with beta-cyclodextrin based on a co-crystallization with methyl beta-cyclodextrin
1JIB	;	3.3	;	Complex of Alpha-amylase II (TVA II) from Thermoactinomyces vulgaris R-47 with Maltotetraose Based on a Crystal Soaked with Maltohexaose.
7RX0	;	3.89	;	Complex of AMPPNP-Kif7 and Gli2 Zinc-Finger domain bound to microtubules
2VZU	;	2.1	;	Complex of Amycolatopsis orientalis exo-chitosanase CsxA D469A with PNP-beta-D-glucosamine
2VZT	;	2.2	;	Complex of Amycolatopsis orientalis exo-chitosanase CsxA E541A with PNP-beta-D-glucosamine
3O42	;	3.0	;	Complex of an alpha/beta-peptide based on the gp41 CHR domain bound to gp41-5
3O43	;	2.8	;	Complex of an alpha/beta-peptide based on the gp41 CHR domain bound to gp41-5
7DR4	;	2.49	;	Complex of anti-human IL-2 antibody and human IL-2
6ERF	;	3.01	;	Complex of APLF factor and Ku heterodimer bound to DNA
1XZ3	;	1.75	;	Complex of apoferritin with isoflurane
6Q37	;	2.211	;	Complex of Arginase 2 with Example 23
6Q39	;	2.213	;	Complex of Arginase 2 with Example 49
3DOE	;	2.25	;	Complex of ARL2 and BART, Crystal Form 1
3DOF	;	3.3	;	Complex of ARL2 and BART, Crystal Form 2
1KSG	;	2.3	;	Complex of Arl2 and PDE delta, Crystal Form 1
1KSH	;	1.8	;	Complex of Arl2 and PDE delta, Crystal Form 2 (native)
1KSJ	;	2.6	;	Complex of Arl2 and PDE delta, Crystal Form 2 (SeMet)
1EAI	;	2.4	;	COMPLEX OF ASCARIS CHYMOTRPSIN/ELASTASE INHIBITOR WITH PORCINE ELASTASE
3G0I	;	2.1	;	Complex of Aspergillus niger epoxide hydrolase with valpromide (2-propylpentanamide)
4PKI	;	2.3	;	Complex of ATP-actin With the C-terminal Actin-Binding Domain of Tropomodulin
4PKG	;	1.8	;	Complex of ATP-actin With the N-terminal Actin-Binding Domain of Tropomodulin
4B0G	;	2.5	;	Complex of Aurora-A bound to an Imidazopyridine-based inhibitor
2BFY	;	1.8	;	Complex of Aurora-B with INCENP and Hesperadin.
4WKZ	;	1.79	;	Complex of autonomous ScaG cohesin CohG and X-doc domains
1YAK	;	2.5	;	Complex of Bacillus subtilis TenA with 4-amino-2-methyl-5-hydroxymethylpyrimidine
2ODG	;		;	Complex of barrier-to-autointegration factor and LEM-domain of emerin
1MMB	;	2.1	;	COMPLEX OF BB94 WITH THE CATALYTIC DOMAIN OF MATRIX METALLOPROTEINASE-8
4CIN	;	2.693	;	Complex of Bcl-xL with its BH3 domain
1G5J	;		;	COMPLEX OF BCL-XL WITH PEPTIDE FROM BAD
1C9T	;	3.3	;	COMPLEX OF BDELLASTASIN WITH BOVINE TRYPSIN
1C9P	;	2.8	;	COMPLEX OF BDELLASTASIN WITH PORCINE TRYPSIN
1RTF	;	2.3	;	COMPLEX OF BENZAMIDINE WITH THE CATALYTIC DOMAIN OF HUMAN TWO CHAIN TISSUE PLASMINOGEN ACTIVATOR [(TC)-T-PA]
7MXL	;	3.2	;	Complex of Bet v 1 with the Fab fragments of a three antibody cocktail
1UNN	;	1.9	;	Complex of beta-clamp processivity factor and little finger domain of PolIV
6PSE	;	2.404	;	Complex of BICD2 with a Dynein Light Intermediate Chain Peptide
4A7Z	;	2.6	;	Complex of bifunctional aldos-2-ulose dehydratase with the reaction intermediate ascopyrone M
1PBO	;	2.2	;	COMPLEX OF BOVINE ODORANT BINDING PROTEIN (OBP) WITH A SELENIUM CONTAINING ODORANT
1GT1	;	1.71	;	Complex of Bovine Odorant Binding Protein with Aminoanthracene and pyrazine
1GT3	;	1.8	;	Complex of Bovine Odorant Binding Protein with dihydromyrcenol
1GT4	;	2.1	;	Complex of Bovine Odorant Binding Protein with undecanal
3AM9	;	2.17	;	Complex of bovine xanthine dehydrogenase and trihydroxy FYX-051
6XZU	;	1.5	;	Complex of C-terminal domain of murine complement C3b with the hC3Nb3 nanobody
5ABY	;	1.95	;	Complex of C. elegans eIF4E-3 with the 4E-binding protein Mextli
5ABX	;	1.66	;	Complex of C. elegans eIF4E-3 with the 4E-binding protein Mextli and cap analog
2YGG	;	2.227	;	Complex of CaMBR and CaM
6HN1	;	1.55	;	Complex of Caprine Serum Albumin with diclofenac
4LL8	;	3.578	;	Complex of carboxy terminal domain of Myo4p and She3p middle fragment
1DQ9	;	2.8	;	COMPLEX OF CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH HMG-COA
4JS0	;	1.9	;	Complex of Cdc42 with the CRIB-PR domain of IRSp53
1CXE	;	2.1	;	COMPLEX OF CGTASE WITH MALTOTETRAOSE AT ROOM TEMPERATURE AND PH 9.1 BASED ON DIFFRACTION DATA OF A CRYSTAL SOAKED WITH ALPHA-CYCLODEXTRIN
1CXH	;	2.41	;	COMPLEX OF CGTASE WITH MALTOTETRAOSE AT ROOM TEMPERATURE AND PH 9.6 BASED ON DIFFRACTION DATA OF A CRYSTAL SOAKED WITH MALTOHEPTAOSE
6UG9	;	2.74	;	Complex of ch28/11 Fab and SSEA-4 (hexagonal form)
6UG8	;	1.89	;	Complex of ch28/11 Fab and SSEA-4 (monoclinic form)
6UG7	;	1.52	;	Complex of ch28/11 Fab and SSEA-4 (tetragonal form)
4D0K	;	1.89	;	Complex of Chaetomium thermophilum PAN2 (WD40-CS1) with PAN3 (C-term)
4GNT	;	2.41	;	Complex of ChREBP and 14-3-3beta
4ANM	;	1.7	;	Complex of CK2 with a CDC7 inhibitor
3ZRJ	;	1.94	;	Complex of ClpV N-domain with VipB peptide
6PSD	;	2.66	;	Complex of CRACR2a with a Dynein Light Intermediate Chain Peptide
4K9T	;	2.5	;	Complex of CYP3A4 with a desoxyritonavir analog
4K9V	;	2.6	;	Complex of CYP3A4 with a desoxyritonavir analog
5GUW	;	3.2	;	Complex of Cytochrome cd1 Nitrite Reductase and Nitric Oxide Reductase in Denitrification of Pseudomonas aeruginosa
1EM0	;	0.9	;	COMPLEX OF D(CCTAGG) WITH TETRA-[N-METHYL-PYRIDYL] PORPHYRIN
1IOV	;	2.2	;	COMPLEX OF D-ALA:D-ALA LIGASE WITH ADP AND A PHOSPHORYL PHOSPHONATE
8GQP	;	2.0	;	Complex of D-protein binder D-19437 and L-target L-Pep-1
4UEA	;	2.62	;	Complex of D. melanogaster eIF4E with a designed 4E-binding protein (Form I)
4UEB	;	2.52	;	Complex of D. melanogaster eIF4E with a designed 4E-binding protein (Form II)
4UEC	;	2.4	;	Complex of D. melanogaster eIF4E with eIF4G and cap analog
4UE8	;	1.1	;	Complex of D. melanogaster eIF4E with the 4E binding protein Thor
4UE9	;	2.15	;	Complex of D. melanogaster eIF4E with the 4E-binding protein 4E-T
5ABV	;	2.13	;	Complex of D. melanogaster eIF4E with the 4E-binding protein Mextli
5ABU	;	2.16	;	Complex of D. melanogaster eIF4E with the 4E-binding protein Mextli and cap analog
1K9I	;	2.5	;	Complex of DC-SIGN and GlcNAc2Man3
1K9J	;	1.9	;	Complex of DC-SIGNR and GlcNAc2Man3
3CIP	;	1.6	;	Complex of Dictyostelium Discoideum Actin with Gelsolin
3CHW	;	2.3	;	Complex of Dictyostelium discoideum Actin with Profilin and the Last Poly-Pro of Human VASP
1XDT	;	2.65	;	COMPLEX OF DIPHTHERIA TOXIN AND HEPARIN-BINDING EPIDERMAL GROWTH FACTOR
3NG7	;	1.95	;	Complex of dithionite-reduced 6-hydroxy-L-nicotine oxidase with substrate bound at active site and inhibitor at exit cavity
7QO1	;	4.4	;	complex of DNA ligase I and FEN1 on PCNA and DNA
6L84	;	2.602	;	Complex of DNA polymerase IV and D-DNA duplex
6L97	;	2.362	;	Complex of DNA polymerase IV and L-DNA duplex
5JUW	;	2.28	;	complex of Dot1l with SS148
6V2A	;	2.0	;	Complex of double mutant (T89V,K162T) of E. coli L-asparaginase II with L-Asn
6V2B	;	2.05	;	Complex of double mutant (T89V,K162T) of E. coli L-asparaginase II with L-Asn
6V27	;	2.3	;	Complex of double mutant (T89V,K162T) of E. coli L-asparaginase II with L-Asp
6V28	;	1.95	;	Complex of double mutant (T89V,K162T) of E. coli L-asparaginase II with L-Asp
6V29	;	2.0	;	Complex of double mutant (T89V,K162T) of E. coli L-asparaginase II with L-Asp
1OOH	;	1.25	;	Complex of Drosophila odorant binding protein LUSH with butanol
1OOF	;	1.49	;	Complex of Drosophila odorant binding protein LUSH with ethanol
1OOG	;	1.45	;	Complex of Drosophila odorant binding protein LUSH with propanol
1KKF	;	2.6	;	Complex of E. coli Adenylosuccinate Synthetase with IMP, Hadacidin, Pyrophosphate, and Mg
1USQ	;	1.9	;	Complex of E. Coli DraE adhesin with Chloramphenicol
7Z6W	;	1.84	;	Complex of E. coli LolA and lipoprotein
6F3Z	;	2.0	;	Complex of E. coli LolA and periplasmic domain of LolC
7Z6X	;	2.06	;	Complex of E. coli LolA R43L mutant and lipoprotein
5TMP	;	1.98	;	COMPLEX OF E. COLI THYMIDYLATE KINASE WITH THE BISUBSTRATE INHIBITOR AZTP5A
4TMK	;	1.98	;	COMPLEX OF E. COLI THYMIDYLATE KINASE WITH THE BISUBSTRATE INHIBITOR TP5A
1CY6	;	2.5	;	COMPLEX OF E.COLI DNA TOPOISOMERASE I WITH 3' THYMIDINE MONOPHOSPHATE
1CY0	;	2.45	;	COMPLEX OF E.COLI DNA TOPOISOMERASE I WITH 3'-5'-ADENOSINE DIPHOSPHATE
1CY7	;	2.4	;	COMPLEX OF E.COLI DNA TOPOISOMERASE I WITH 5'-THYMIDINE MONOPHOSPHATE
1CY8	;	2.45	;	COMPLEX OF E.COLI DNA TOPOISOMERASE I WITH 5'-THYMIDINE MONOPHOSPHATE AND 3'-THYMIDINE MONOPHOSPHATE
1CY1	;	2.3	;	COMPLEX OF E.COLI DNA TOPOISOMERASE I WITH 5'PTPTPT
1CY4	;	2.55	;	COMPLEX OF E.COLI DNA TOPOISOMERASE I WITH 5'pTpTpTp3'
1CY2	;	2.3	;	COMPLEX OF E.COLI DNA TOPOISOMERASE I WITH TPTPTP3'
7XXA	;	3.09	;	Complex of Echo 18 and FcRn at pH7.4
8B8R	;	3.1	;	Complex of Echovirus 11 with its attaching receptor decay-accelerating factor (CD55)
2C8I	;	14.0	;	Complex Of Echovirus Type 12 With Domains 1, 2, 3 and 4 Of Its Receptor Decay Accelerating Factor (Cd55) By Cryo Electron Microscopy At 16 A
1UPN	;	16.0	;	COMPLEX OF ECHOVIRUS TYPE 12 WITH DOMAINS 3 AND 4 OF ITS RECEPTOR DECAY ACCELERATING FACTOR (CD55) BY CRYO ELECTRON MICROSCOPY AT 16 A
1RV5	;	2.1	;	COMPLEX OF ECORV ENDONUCLEASE WITH D(AAAGAT)/D(ATCTT)
1H9I	;	1.9	;	COMPLEX OF EETI-II MUTANT WITH PORCINE TRYPSIN
1H9H	;	1.5	;	COMPLEX OF EETI-II WITH PORCINE TRYPSIN
3DEG	;	10.9	;	Complex of elongating Escherichia coli 70S ribosome and EF4(LepA)-GMPPNP
5H7L	;	3.1	;	Complex of Elongation factor 2-50S ribosomal protein L12
1O2F	;		;	COMPLEX OF ENZYME IIAGLC AND IIBGLC PHOSPHOCARRIER PROTEIN HPR FROM ESCHERICHIA COLI NMR, RESTRAINED REGULARIZED MEAN STRUCTURE
1GGR	;		;	COMPLEX OF ENZYME IIAGLC AND THE HISTIDINE-CONTAINING PHOSPHOCARRIER PROTEIN HPR FROM ESCHERICHIA COLI NMR, RESTRAINED REGULARIZED MEAN STRUCTURE
1VRC	;		;	Complex of enzyme IIAmannose and the histidine-containing phosphocarrier protein HPr from escherichia coli nmr, restrained regularized mean structure
2FEW	;		;	Complex of enzyme IIAMTL and phosphorylated enzyme IIBMTL from Escherichia coli NMR, restrained regularized mean structure
1J6T	;		;	COMPLEX OF ENZYME IIAMTL AND THE HISTIDINE-CONTAINING PHOSPHOCARRIER PROTEIN HPR FROM ESCHERICHIA COLI NMR, RESTRAINED REGULARIZED MEAN STRUCTURE
2GYD	;	1.72	;	Complex of equine apoferritin with the H-diaziflurane photolabeling reagent
5WP1	;	1.4	;	Complex of ERK2 with 5,7-dihydroxychromone
4N0S	;	1.7992	;	Complex of ERK2 with caffeic acid
4ZXT	;	2.0	;	Complex of ERK2 with catechol
3SA0	;	1.5947	;	Complex of ERK2 with norathyriol
1KKB	;	2.6	;	Complex of Escherichia coli Adenylosuccinate Synthetase with IMP and Hadacidin
4RTQ	;	1.997	;	Complex of Escherichia coli DNA Adenine Methyltransferase (DAM) with AdoHcy and a 5-bp non-canonical site (GTTTA )
4RTN	;	2.59	;	Complex of Escherichia coli DNA Adenine Methyltransferase (DAM) with AdoHcy and with DNA Containing Proximal Pap Regulon Sequence
4RTS	;	2.49	;	Complex of Escherichia coli DNA Adenine Methyltransferase (DAM) with AdoMet and a 5-bp non-canonical site (GTCTA)
4RTR	;	2.393	;	Complex of Escherichia coli DNA Adenine Methyltransferase (DAM) with AdoMet and a 5-bp non-canonical site (GTTTA )
4RTM	;	2.5	;	Complex of Escherichia coli DNA Adenine Methyltransferase (DAM) with AdoMet and with DNA Containing Distal Pap Regulon Sequence
4RTP	;	2.39	;	Complex of Escherichia coli DNA Adenine Methyltransferase (DAM) with AdoMet and with DNA Containing Proximal Pap Regulon Sequence
4RTK	;	1.96	;	Complex of Escherichia coli DNA Adenine Methyltransferase (DAM) with SAH and with DNA Containing Distal Pap Regulon Sequence
4RTL	;	2.193	;	Complex of Escherichia coli DNA Adenine Methyltransferase (DAM) with Sinefungin and with DNA Containing Distal Pap Regulon Sequence
4RTO	;	2.69	;	Complex of Escherichia coli DNA Adenine Methyltransferase (DAM) with Sinefungin and with DNA Containing Proximal Pap Regulon Sequence
8VGC	;	1.42	;	Complex of ExbD with D-box peptide: Orthorhombic form
8VGD	;	1.42	;	Complex of ExbD with D-box peptide: Tetragonal form
7LR4	;	2.1	;	Complex of Fab 2/1.12 with domain 3 of P. berghei HAP2
7LR3	;	2.8	;	Complex of Fab 2/6.14 with domain 3 of P. berghei HAP2
8EGW	;	2.3	;	Complex of Fat4(EC1-4) bound to Dchs1(EC1-3)
8EGX	;	3.688	;	Complex of Fat4(EC1-4) bound to Dchs1(EC1-4)
3RY6	;	3.8	;	Complex of fcgammariia (CD32) and the FC of human IGG1
2D0Q	;	1.65	;	Complex of Fe-type NHase with Cyclohexyl isocyanide, photo-activated for 1hr at 277K
2ZPG	;	1.39	;	Complex of Fe-type nitrile hydratase with tert-butylisonitrile, photo-activated for 120min at 293K
2ZPF	;	1.482	;	Complex of Fe-type nitrile hydratase with tert-butylisonitrile, photo-activated for 18min at 293K
2ZPH	;	1.59	;	Complex of Fe-type nitrile hydratase with tert-butylisonitrile, photo-activated for 340min at 293K
2ZPI	;	1.491	;	Complex of Fe-type nitrile hydratase with tert-butylisonitrile, photo-activated for 440min at 293K
3JWN	;	2.69	;	Complex of FimC, FimF, FimG and FimH
5MTS	;	2.6	;	Complex of FimH lectin with a TazMan (thiazolylaminomannosides) family member known as potent anti-adhesive agent at 2.6 A resolution
3O5R	;	1.1	;	Complex of Fk506 with the Fk1 domain mutant A19T of FKBP51
4YXC	;	2.3	;	Complex of FliM(SPOA)::FliN fusion protein and FliH(APAR)::T4lysozyme fusion protein
7FEJ	;	3.91	;	Complex of FMDV A/AF/72 and bovine neutralizing scFv antibody R55
7FEI	;	3.91	;	Complex of FMDV A/WH/CHA/09 and bovine neutralizing scFv antibody R55
8GRR	;	3.72	;	Complex of FMDV A/WH/CHA/09 and bovine neutralizing scFv antibody W125
8GSP	;	3.75	;	Complex of FMDV A/WH/CHA/09 and bovine neutralizing scFv antibody W2
7DSS	;	3.9	;	Complex of FMDV and M8 Nab
4H0B	;	1.26	;	Complex of G65T Myoglobin with DMSO in its Distal Cavity
4H07	;	1.14	;	Complex of G65T Myoglobin with Phenol in its Proximal Cavity
3D32	;	1.3	;	Complex of GABA(A) receptor-associated protein (GABARAP) with a synthetic peptide
7T0W	;	3.0	;	Complex of GABA-A synaptic receptor with autoimmune antibody Fab115
7T0Z	;	3.0	;	Complex of GABA-A synaptic receptor with autoimmune antibody Fab175
1FS0	;	2.1	;	COMPLEX OF GAMMA/EPSILON ATP SYNTHASE FROM E.COLI
1PY1	;	2.6	;	Complex of GGA1-VHS domain and beta-secretase C-terminal phosphopeptide
1LF8	;	2.3	;	Complex of GGA3-VHS Domain and CI-MPR C-terminal Phosphopeptide
6J74	;	3.212	;	Complex of GGTaseIII and full-length Ykt6
6J7F	;	2.883	;	Complex of GGTaseIII, farnesyl-Ykt6 (C-terminal methylated), and GGPP
6J7X	;	2.75	;	Complex of GGTaseIII, farnesyl-Ykt6, and GGPP
6CD8	;	1.6	;	Complex of GID4 fragment with short peptide
2I55	;	2.9	;	Complex of glucose-1,6-bisphosphate with phosphomannomutase from Leishmania mexicana
1NOI	;	2.5	;	COMPLEX OF GLYCOGEN PHOSPHORYLASE WITH A TRANSITION STATE ANALOGUE NOJIRIMYCIN TETRAZOLE AND PHOSPHATE IN THE T AND R STATES
1NOJ	;	2.4	;	COMPLEX OF GLYCOGEN PHOSPHORYLASE WITH A TRANSITION STATE ANALOGUE NOJIRIMYCIN TETRAZOLE AND PHOSPHATE IN THE T STATE
1NOK	;	2.4	;	COMPLEX OF GLYCOGEN PHOSPHORYLASE WITH A TRANSITION STATE ANALOGUE NOJIRIMYCIN TETRAZOLE AND PHOSPHATE IN THE T STATE
5D28	;	2.845	;	Complex of GM-CSF/IL-2 inhibition factor with Granulocyte-macrophage colony-stimulating factor
1TL7	;	2.8	;	Complex Of Gs- With The Catalytic Domains Of Mammalian Adenylyl Cyclase: Complex With 2'(3')-O-(N-methylanthraniloyl)-guanosine 5'-triphosphate and Mn
2GVD	;	2.9	;	Complex Of Gs- With The Catalytic Domains Of Mammalian Adenylyl Cyclase: Complex With TNP-ATP and Mn
1AZS	;	2.3	;	COMPLEX OF GS-ALPHA WITH THE CATALYTIC DOMAINS OF MAMMALIAN ADENYLYL CYCLASE
1CUL	;	2.4	;	COMPLEX OF GS-ALPHA WITH THE CATALYTIC DOMAINS OF MAMMALIAN ADENYLYL CYCLASE: COMPLEX WITH 2',5'-DIDEOXY-ADENOSINE 3'-TRIPHOSPHATE AND MG
1CS4	;	2.5	;	COMPLEX OF GS-ALPHA WITH THE CATALYTIC DOMAINS OF MAMMALIAN ADENYLYL CYCLASE: COMPLEX WITH 2'-DEOXY-ADENOSINE 3'-MONOPHOSPHATE, PYROPHOSPHATE AND MG
1CJK	;	3.0	;	COMPLEX OF GS-ALPHA WITH THE CATALYTIC DOMAINS OF MAMMALIAN ADENYLYL CYCLASE: COMPLEX WITH ADENOSINE 5'-(ALPHA THIO)-TRIPHOSPHATE (RP), MG, AND MN
3MAA	;	3.0	;	Complex of GS-Alpha with the Catalytic Domains of Mammalian Adenylyl Cyclase: Complex with Adenosine 5-O-(l-Thiophosphate) and Low Ca Concentration
3C16	;	2.87	;	Complex of GS-Alpha with the Catalytic Domains of Mammalian Adenylyl Cyclase: Complex with Adenosine-5'-Triphosphate and Ca
1CJU	;	2.8	;	COMPLEX OF GS-ALPHA WITH THE CATALYTIC DOMAINS OF MAMMALIAN ADENYLYL CYCLASE: COMPLEX WITH BETA-L-2',3'-DIDEOXYATP AND MG
1CJV	;	3.0	;	COMPLEX OF GS-ALPHA WITH THE CATALYTIC DOMAINS OF MAMMALIAN ADENYLYL CYCLASE: COMPLEX WITH BETA-L-2',3'-DIDEOXYATP, MG, AND ZN
1CJT	;	2.8	;	COMPLEX OF GS-ALPHA WITH THE CATALYTIC DOMAINS OF MAMMALIAN ADENYLYL CYCLASE: COMPLEX WITH BETA-L-2',3'-DIDEOXYATP, MN, AND MG
3G82	;	3.11	;	Complex of GS-alpha with the catalytic domains of mammalian adenylyl cyclase: complex with MANT-ITP and Mn
3C14	;	2.68	;	Complex of GS-Alpha with the Catalytic Domains of Mammalian Adenylyl Cyclase: Complex with Pyrophosphate and Ca
3C15	;	2.78	;	Complex of GS-Alpha with the Catalytic Domains of Mammalian Adenylyl Cyclase: Complex with Pyrophosphate and Mg
6LWU	;	2.419	;	Complex of Gynuella sunshinyii GH46 chitosanase GsCsn46A E19A with chitopentaose
6X2Q	;	2.27	;	Complex of Gynuella sunshinyii GH46 chitosanase GsCsn46A with chitotetraose
5NWE	;	2.0	;	Complex of H275Y mutant variant of neuraminidase from H1N1 influenza virus with oseltamivir
5NZF	;	1.75	;	Complex of H275Y/I223V mutant variant of neuraminidase from H1N1 influenza virus with oseltamivir
5NZN	;	1.73	;	Complex of H275Y/S247N mutant variant of neuraminidase from H1N1 influenza virus with oseltamivir
1XZ1	;	1.75	;	Complex of halothane with apoferritin
1HTW	;	1.7	;	COMPLEX OF HI0065 WITH ADP AND MAGNESIUM
4KJY	;	1.93	;	Complex of high-affinity SIRP alpha variant FD6 with CD47
1UU1	;	2.38	;	Complex of Histidinol-phosphate aminotransferase (HisC) from Thermotoga maritima (Apo-form)
1G70	;		;	COMPLEX OF HIV-1 RRE-IIB RNA WITH RSG-1.2 PEPTIDE
6VR1	;	2.37	;	Complex of HLA-A2, a class I MHC, with a p53 peptide
6VR5	;	2.38	;	Complex of HLA-A2, a class I MHC, with a p53 peptide
8ECG	;	2.13	;	Complex of HMG1 with pitavastatin
6B9H	;	1.5	;	Complex of Hook Domain with a Dynein Light Intermediate Chain Peptide
1US7	;	2.3	;	Complex of Hsp90 and P50
4AWO	;	1.7	;	Complex of HSP90 ATPase domain with tropane derived inhibitors
4AWP	;	1.82	;	Complex of HSP90 ATPase domain with tropane derived inhibitors
4AWQ	;	1.6	;	Complex of HSP90 ATPase domain with tropane derived inhibitors
2JKI	;	3.3	;	Complex of Hsp90 N-terminal and Sgt1 CS domain
2XCM	;	2.2	;	COMPLEX OF HSP90 N-TERMINAL, SGT1 CS AND RAR1 CHORD2 DOMAIN
5LTW	;	4.5	;	Complex of human 14-3-3 sigma CLU1 mutant with phosphorylated heat shock protein B6
1HAO	;	2.8	;	COMPLEX OF HUMAN ALPHA-THROMBIN WITH A 15MER OLIGONUCLEOTIDE GGTTGGTGTGGTTGG (BASED ON NMR MODEL OF DNA)
1HAP	;	2.8	;	COMPLEX OF HUMAN ALPHA-THROMBIN WITH A 15MER OLIGONUCLEOTIDE GGTTGGTGTGGTTGG (BASED ON X-RAY MODEL OF DNA)
1A3B	;	1.8	;	COMPLEX OF HUMAN ALPHA-THROMBIN WITH THE BIFUNCTIONAL BORONATE INHIBITOR BOROLOG1
1A3E	;	1.85	;	COMPLEX OF HUMAN ALPHA-THROMBIN WITH THE BIFUNCTIONAL BORONATE INHIBITOR BOROLOG2
3VBD	;	1.05	;	Complex of human carbonic anhydrase II with 4-(6-methoxy-3,4-dihydroisoquinolin-1-yl)benzenesulfonamide
3V7X	;	1.03	;	Complex of human carbonic anhydrase II with N-[2-(3,4-dimethoxyphenyl)ethyl]-4-sulfamoylbenzamide
6FAX	;	2.99	;	Complex of Human CD40 Ectodomain with Lob 7.4 Fab
4CRU	;	1.65	;	Complex of human CNOT9 and CNOT1 including one tryptophan
4CRV	;	2.05	;	Complex of human CNOT9 and CNOT1 including two tryptophans
6FP6	;	3.0	;	Complex of human Cu,Zn SOD1 with the human copper chaperone for SOD1 in a compact conformation
4K9U	;	2.85	;	Complex of human CYP3A4 with a desoxyritonavir analog
4K9W	;	2.399	;	Complex of human CYP3A4 with a desoxyritonavir analog
4K9X	;	2.76	;	Complex of human CYP3A4 with a desoxyritonavir analog
6O1V	;	3.2	;	Complex of human cystic fibrosis transmembrane conductance regulator (CFTR) and GLPG1837
4CRW	;	1.75	;	Complex of human DDX6 (RECA-C) and CNOT1 (MIF4G)
2WV8	;	1.9	;	Complex of human dihydroorotate dehydrogenase with the inhibitor 221290
4UED	;	1.75	;	Complex of human eIF4E with the 4E binding protein 4E-BP1
4Y22	;	2.5	;	Complex of human Galectin-1 and (3OSO3)Galbeta1-3GlcNAc
4Y1Y	;	1.86	;	Complex of human Galectin-1 and (6OSO3)Galbeta1-3GlcNAc
4Y1V	;	2.32	;	Complex of human Galectin-1 and Galbeta1-3GlcNAc
4Y1Z	;	2.23	;	Complex of human Galectin-1 and Galbeta1-4(6CO2)GlcNAc
4Y1X	;	2.45	;	Complex of human Galectin-1 and Galbeta1-4(6OSO3)GlcNAc
4Y1U	;	1.762	;	Complex of human Galectin-1 and Galbeta1-4GlcNAc
4Y20	;	2.204	;	Complex of human Galectin-1 and NeuAcalpha2-3Galbeta1-4Glc
4Y24	;	2.32	;	Complex of human Galectin-1 and TD-139
4Y26	;	2.611	;	Complex of human Galectin-7 and Galbeta1-3(6OSO3)GlcNAc
7AIA	;	2.2	;	Complex of human GDAP1 with hexadecanedioic acid
1YD8	;	2.8	;	COMPLEX OF HUMAN GGA3 GAT DOMAIN AND UBIQUITIN
1BKD	;	2.8	;	COMPLEX OF HUMAN H-RAS WITH HUMAN SOS-1
5AIS	;	1.85	;	Complex of human hematopoietic prostagandin D2 synthase (hH-PGDS) in complex with an active site inhibitor.
5AIV	;	2.04	;	Complex of human hematopoietic prostagandin D2 synthase (hH-PGDS) in complex with an active site inhibitor.
5AIX	;	2.1	;	Complex of human hematopoietic prostagandin D2 synthase (hH-PGDS) in complex with an active site inhibitor.
2VJ8	;	1.8	;	Complex of human leukotriene A4 hydrolase with a hydroxamic acid inhibitor
1OP9	;	1.86	;	Complex of human lysozyme with camelid VHH HL6 antibody fragment
1B59	;	1.8	;	COMPLEX OF HUMAN METHIONINE AMINOPEPTIDASE-2 COMPLEXED WITH OVALICIN
1KBQ	;	1.8	;	Complex of Human NAD(P)H quinone Oxidoreductase with 5-methoxy-1,2-dimethyl-3-(4-nitrophenoxymethyl)indole-4,7-dione (ES936)
5MGT	;	1.9	;	Complex of human NKR-P1 and LLT1 in deglycosylated forms
5OO6	;	2.8	;	Complex of human nuclear cap-binding complex with ARS2 C-terminal peptide
5OOB	;	2.79	;	COMPLEX OF HUMAN NUCLEAR CAP-BINDING COMPLEX WITH M7GTP AND NELF-E C-TERMINAL PEPTIDE
2V4L	;	2.5	;	complex of human phosphoinositide 3-kinase catalytic subunit gamma (p110 gamma) with PIK-284
1KBO	;	2.3	;	Complex of Human recombinant NAD(P)H:Quinone Oxide reductase type 1 with 5-methoxy-1,2-dimethyl-3-(phenoxymethyl)indole-4,7-dione (ES1340)
4C78	;	2.0	;	Complex of human Sirt3 with Bromo-Resveratrol and ACS2 peptide
4C7B	;	2.1	;	Complex of human Sirt3 with Bromo-Resveratrol and Fluor-De-Lys peptide
8COT	;	2.1	;	Complex of human soluble adenylyl cyclase 10 catalytic core with inhibitor TDI-10962
7MJ5	;	2.15	;	complex of human thrombin with XC-43
8DW5	;	1.52	;	Complex of Human Transthyretin with 3',5'-Dichlorophenylanthranilic Acid
8AMS	;	2.4	;	Complex of human TRIM2 RING domain, UBCH5C, and Ubiquitin
4CC3	;	1.97	;	Complex of human Tuba C-terminal SH3 domain and Mena proline-rich peptide - H3
4CC2	;	1.55	;	Complex of human Tuba C-terminal SH3 domain with human N-WASP proline- rich peptide - P212121
4CYM	;	2.8	;	Complex of human VARP-ANKRD1 with Rab32-GppCp
4CZ2	;	2.97	;	Complex of human VARP-ANKRD1 with Rab32-GppCp. Selenomet derivative.
1K6E	;	1.85	;	COMPLEX OF HYDROLYTIC HALOALKANE DEHALOGENASE LINB FROM SPHINGOMONAS PAUCIMOBILIS UT26 WITH 1,2-PROPANEDIOL (PRODUCT OF DEHALOGENATION OF 1,2-DIBROMOPROPANE) AT 1.85A
1K63	;	1.8	;	Complex of hydrolytic haloalkane dehalogenase linb from sphingomonas paucimobilis with UT26 2-BROMO-2-PROPENE-1-OL at 1.8A resolution
2GGQ	;	2.0	;	complex of hypothetical glucose-1-phosphate thymidylyltransferase from sulfolobus tokodaii
5NZ4	;	1.36	;	Complex of I223V mutant variant of neuraminidase from H1N1 influenza virus with oseltamivir
6UQR	;	3.65029	;	Complex of IgE and Ligelizumab
1H59	;	2.1	;	Complex of IGFBP-5 with IGF-I
2CZ6	;	1.5	;	Complex of Inactive Fe-type NHase with Cyclohexyl isocyanide
2DPG	;	2.5	;	COMPLEX OF INACTIVE MUTANT (H240->N) OF GLUCOSE 6-PHOSPHATE DEHYDROGENASE FROM LEUCONOSTOC MESENTEROIDES WITH NADP+
1A53	;	2.0	;	COMPLEX OF INDOLE-3-GLYCEROLPHOSPHATE SYNTHASE FROM SULFOLOBUS SOLFATARICUS WITH INDOLE-3-GLYCEROLPHOSPHATE AT 2.0 A RESOLUTION
5NT1	;	2.82	;	Complex of influenza A NS1 effector domain with TRIM25 coiled coil
5NT2	;	4.259	;	Complex of influenza A NS1 with TRIM25 coiled coil domain
5DLM	;	2.2	;	Complex of Influenza M2e and Antibody
3RT3	;	2.006	;	Complex of influenza virus protein with host anti-viral factor
4CC4	;	2.6	;	Complex of InlC of Listeria monocytogenes and human Tuba C-terminal SH3 domain
7Y1T	;	3.24	;	Complex of integrin alphaV/beta8 and L-TGF-beta1 at a ratio of 1:2
4M1L	;	2.1	;	Complex of IQCG and Ca2+-bound CaM
4LZX	;	1.5	;	Complex of IQCG and Ca2+-free CaM
5JEM	;	2.5	;	Complex of IRF-3 with CBP
6O2P	;	3.3	;	Complex of ivacaftor with cystic fibrosis transmembrane conductance regulator (CFTR)
6RGO	;	3.701	;	Complex of KlAtg21 with coiled-coil of AgAtg16
4HEP	;	1.75	;	Complex of lactococcal phage TP901-1 with a llama vHH (vHH17) binder (nanobody)
5B6B	;	3.536	;	Complex of LATS1 and phosphomimetic MOB1b
1LDT	;	1.9	;	COMPLEX OF LEECH-DERIVED TRYPTASE INHIBITOR WITH PORCINE TRYPSIN
8BSG	;	1.89	;	COMPLEX OF LEPORINE SERUM ALBUMIN WITH DICLOFENAC
1RUT	;	1.3	;	Complex of LMO4 LIM domains 1 and 2 with the ldb1 LID domain
3ZX7	;	2.84	;	Complex of lysenin with phosphocholine
7JTR	;	2.5	;	Complex of maltose-binding protein (MBP) with single-chain Fv (scFv)
2Q97	;	2.5	;	Complex of mammalian actin with toxofilin from toxoplasma gondii
6JTF	;		;	Complex of MarH and L-Trp
3V96	;	1.9	;	Complex of matrix metalloproteinase-10 catalytic domain (MMP-10cd) with tissue inhibitor of metalloproteinases-1 (TIMP-1)
4ILW	;	2.103	;	Complex of matrix metalloproteinase-10 catalytic domain (MMP-10cd) with tissue inhibitor of metalloproteinases-2 (TIMP-2)
6D1T	;	2.25	;	Complex of MBD1-MBD and methylated DNA
1KZE	;	1.8	;	Complex of MBP-C and bivalent Man-terminated glycopeptide
1KZD	;	1.9	;	Complex of MBP-C and GlcNAc-terminated core
1KZC	;	1.85	;	Complex of MBP-C and high-affinity linear trimannose
1KZA	;	1.74	;	Complex of MBP-C and Man-a13-Man
1KZB	;	1.8	;	Complex of MBP-C and trimannosyl core
4JA8	;	1.55	;	Complex of Mitochondrial Isocitrate Dehydrogenase R140Q Mutant with AGI-6780 Inhibitor
5IBW	;	1.9	;	Complex of MlcC bound to the tandem IQ motif of MyoC
1EL5	;	1.8	;	COMPLEX OF MONOMERIC SARCOSINE OXIDASE WITH THE INHIBITOR DIMETHYLGLYCINE
1ELI	;	2.0	;	COMPLEX OF MONOMERIC SARCOSINE OXIDASE WITH THE INHIBITOR PYRROLE-2-CARBOXYLATE
1EL8	;	1.9	;	COMPLEX OF MONOMERIC SARCOSINE OXIDASE WITH THE INHIBITOR [METHYLSELENO]CETATE
1EL9	;	2.0	;	COMPLEX OF MONOMERIC SARCOSINE OXIDASE WITH THE INHIBITOR [METHYLTHIO]ACETATE
1EL7	;	1.9	;	COMPLEX OF MONOMERIC SARCOSINE OXIDASE WITH THE INHIBITOR [METHYTELLURO]ACETATE
4GZA	;	7.0	;	Complex of mouse Plexin A2 - Semaphorin 3A - Neuropilin-1
3G2D	;	2.3	;	Complex of Mth0212 and a 4 bp dsDNA with 3'-overhang
3G0R	;	2.4	;	Complex of Mth0212 and an 8bp dsDNA with distorted ends
5YVQ	;	2.103	;	Complex of Mu phage tail fiber and its chaperone
5H9O	;	2.37	;	Complex of Murine endoplasmic reticulum alpha-glucosidase II with D-Glucose
6V25	;	1.78	;	Complex of mutant (K162M) of E. coli L-asparaginase II with L-Asp
6V26	;	1.8	;	Complex of mutant (K162M) of E. coli L-asparaginase II with L-Asp
6V2C	;	2.0	;	Complex of mutant (K162M) of E. coli L-asparaginase II with L-Asp. Covalent acyl-enzyme intermediate and tetrahedral intermediate
6V2G	;	1.9	;	Complex of mutant (K162M) of E. coli L-asparaginase II with L-Asp. Covalent acyl-enzyme intermediate and tetrahedral intermediate.
6V24	;	1.9	;	Complex of mutant (K162M) of E. coli L-asparaginase II with L-Asp. Covalent acyl-enzyme intermediate.
6WZ4	;	1.58	;	Complex of mutant (K173M) of Pseudomonas 7A Glutaminase-Asparaginase with L-Asp at pH 6. Covalent acyl-enzyme intermediate
6WZ6	;	1.15	;	Complex of mutant (K173M) of Pseudomonas 7A Glutaminase-Asparaginase with L-Glu at pH 5. Covalent acyl-enzyme intermediate
5JY7	;	3.6	;	Complex of Mycobacterium smegmatis trehalose synthase with maltokinase
8ATC	;	2.5	;	COMPLEX OF N-PHOSPHONACETYL-L-ASPARTATE WITH ASPARTATE CARBAMOYLTRANSFERASE. X-RAY REFINEMENT, ANALYSIS OF CONFORMATIONAL CHANGES AND CATALYTIC AND ALLOSTERIC MECHANISMS
6HP0	;	1.88	;	Complex of Neuraminidase from H1N1 Influenza Virus in Complex with Oseltamivir Triazol Derivative
6G01	;	1.61	;	Complex of neuraminidase from H1N1 influenza virus with tamiphosphor monomethyl ester
6G02	;	1.84	;	Complex of neuraminidase from H1N1 influenza virus with tamiphosphor omega-azidohexyl ester
4CZX	;	1.85	;	Complex of Neurospora crassa PAN2 (WD40) with PAN3 (C-TERM)
4CZY	;	3.4	;	Complex of Neurospora crassa PAN2 (WD40-CS1) with PAN3 (pseudokinase and C-term)
5V5V	;	4.11	;	Complex of NLGN2 with MDGA1 Ig1-Ig2
4XL1	;	2.3	;	Complex of Notch1 (EGF11-13) bound to Delta-like 4 (N-EGF1)
4XLW	;	3.39	;	Complex of Notch1 (EGF11-13) bound to Delta-like 4 (N-EGF2)
5UK5	;	2.506	;	Complex of Notch1(EGF8-12) bound to Jagged1(N-EGF3)
7L05	;	2.21	;	Complex of novel maytansinoid M24 bound to T2R-TTL (two tubulin alpha/beta heterodimers, RB3 stathmin-like domain, and tubulin tyrosine ligase)
7NOW	;	1.85	;	Complex of Nucleoporin-98 and nanobody MS98-27 solved at 1.85A resolution
7KB1	;	1.85	;	Complex of O-acety-L-homoserine aminocarboxypropyltransferase (MetY) from Thermotoga maritima and a key reaction intermediate
4LUH	;	2.2	;	Complex of ovine serum albumin with 3,5-diiodosalicylic acid
6HN0	;	2.12	;	Complex of Ovine Serum Albumin with diclofenac
6M7L	;	2.6483	;	Complex of OxyA with the X-domain from GPA biosynthesis
8AOM	;	2.202	;	Complex of PD-L1 with VHH1
8AOK	;	1.6	;	Complex of PD-L1 with VHH6
3CI5	;	1.7	;	Complex of Phosphorylated Dictyostelium Discoideum Actin with Gelsolin
3ENE	;	2.4	;	Complex of PI3K gamma with an inhibitor
3AG9	;	2.0	;	Complex of PKA with the bisubstrate protein kinase inhibitor ARC-1012
3AGL	;	2.1	;	Complex of PKA with the bisubstrate protein kinase inhibitor ARC-1039
5IZF	;	2.1	;	Complex of PKA with the bisubstrate protein kinase inhibitor ARC-1408
5IZJ	;	1.85	;	Complex of PKA with the bisubstrate protein kinase inhibitor ARC-1411
5J5X	;	2.6	;	Complex of PKA with the bisubstrate protein kinase inhibitor ARC-1416
3AGM	;	2.0	;	Complex of PKA with the bisubstrate protein kinase inhibitor ARC-670
3BWJ	;	2.3	;	Complex of PKA with the bisubstrate protein kinase inhibitor lead compound Arc-1034
7V05	;	3.4	;	Complex of Plasmodium falciparum circumsporozoite protein with 850 Fab
2H4L	;	2.4	;	Complex of PMM/PGM with ribose 1-phosphate
3JBF	;	4.8	;	Complex of poliovirus with VHH PVSP19B
3JBC	;	6.5	;	Complex of Poliovirus with VHH PVSP29F
3JBD	;	4.8	;	Complex of poliovirus with VHH PVSP6A
3JBG	;	3.8	;	Complex of poliovirus with VHH PVSS21E
3JBE	;	4.2	;	Complex of poliovirus with VHH PVSS8A
4IEF	;	2.3	;	Complex of Porphyromonas gingivalis RgpB pro- and mature domains
5L83	;	1.9	;	Complex of potato ATG8 protein with a peptide from Irish potato famine pathogen effector protein PexRD54
8HM3	;	2.26	;	Complex of PPIase-BfUbb
1JAP	;	1.82	;	COMPLEX OF PRO-LEU-GLY-HYDROXYLAMINE WITH THE CATALYTIC DOMAIN OF MATRIX METALLO PROTEINASE-8 (MET80 FORM)
1JAN	;	2.5	;	COMPLEX OF PRO-LEU-GLY-HYDROXYLAMINE WITH THE CATALYTIC DOMAIN OF MATRIX METALLO PROTEINASE-8 (PHE79 FORM)
1I73	;	1.4	;	COMPLEX OF PRO-LEU-L-TRP PHOSPHONATE WITH THE CATALITIC DOMAIN OF MATRIX METALLO PROTEINASE-8 (MET80 FORM)
6WZ8	;	1.7	;	Complex of Pseudomonas 7A Glutaminase-Asparaginase with Citrate Anion at pH 5.5. Covalent Acyl-Enzyme Intermediate
4KT1	;	2.497	;	Complex of R-spondin 1 with LGR4 extracellular domain
2XGY	;	1.8	;	Complex of Rabbit Endogenous Lentivirus (RELIK)Capsid with Cyclophilin A
8F6M	;	2.15	;	Complex of Rabbit muscle pyruvate kinase with ADP and the phosphonate analogue of PEP mimicking the Michaelis complex.
2W2X	;	2.3	;	Complex of Rac2 and PLCg2 spPH Domain
2YBF	;	2.0	;	Complex of Rad18 (Rad6 binding domain) with Rad6b
1IBR	;	2.3	;	COMPLEX OF RAN WITH IMPORTIN BETA
3KUC	;	1.92	;	Complex of Rap1A(E30D/K31E)GDP with RafRBD(A85K/N71R)
3L8Y	;	2.02	;	Complex of Ras with cyclen
3KUD	;	2.15	;	Complex of Ras-GDP with RafRBD(A85K)
8A8J	;	3.1	;	Complex of RecF and DNA from Thermus thermophilus.
8BPR	;	3.65	;	Complex of RecF-RecO-RecR-DNA from Thermus thermophilus (low resolution reconstruction).
8A93	;	3.05	;	Complex of RecF-RecR-DNA from Thermus thermophilus.
8AB0	;	6.09	;	Complex of RecO-RecR-DNA from Thermus thermophilus.
7N0U	;	3.0	;	Complex of recombinant Bet v 1 with Fab fragment of REGN5713
7N0V	;	3.71	;	Complex of recombinant Bet v 1 with Fab fragment of REGN5715
1OYT	;	1.67	;	COMPLEX OF RECOMBINANT HUMAN THROMBIN WITH A DESIGNED FLUORINATED INHIBITOR
2CN0	;	1.3	;	Complex of Recombinant Human Thrombin with a Designed Inhibitor
2CF8	;	1.3	;	Complex of recombinant human thrombin with an inhibitor
2CF9	;	1.79	;	Complex of recombinant human thrombin with an inhibitor
7BUI	;	2.15	;	Complex of reduced oxygenase and oxidized ferredoxin in carbazole 1,9a- dioxygenase
1QUQ	;	2.5	;	COMPLEX OF REPLICATION PROTEIN A SUBUNITS RPA14 AND RPA32
1GMP	;	1.7	;	COMPLEX OF RIBONUCLEASE FROM STREPTOMYCES AUREOFACIENS WITH 2'-GMP AT 1.7 ANGSTROMS RESOLUTION
1GMQ	;	1.8	;	COMPLEX OF RIBONUCLEASE FROM STREPTOMYCES AUREOFACIENS WITH 2'-GMP AT 1.7 ANGSTROMS RESOLUTION
1GMR	;	1.77	;	COMPLEX OF RIBONUCLEASE FROM STREPTOMYCES AUREOFACIENS WITH 2'-GMP AT 1.7 ANGSTROMS RESOLUTION
7NLJ	;	1.8	;	Complex of rice blast (Magnaporthe oryzae) effector protein APikL2A with host target sHMA25 from Setaria italica
7NMM	;	2.3	;	Complex of rice blast (Magnaporthe oryzae) effector protein APikL2F with the host target sHMA94 from Setaria italica
6Q76	;	1.9	;	Complex of rice blast (Magnaporthe oryzae) effector protein AVR-Pia with the HMA domain of Pikp-1 from rice (Oryza sativa)
7PP2	;	2.69	;	Complex of rice blast (Magnaporthe oryzae) effector protein AVR-Pii with the host target Exo70F2 from Rice (Oryza sativa)
6FUD	;	1.3	;	Complex of rice blast (Magnaporthe oryzae) effector protein AVR-PikA with the HMA domain of Pikm-1 from rice (Oryza sativa)
7QPX	;	2.05	;	Complex of rice blast (Magnaporthe oryzae) effector protein AVR-PikC with an engineered HMA domain of Pikp-1 (Pikp-SNK-EKE) from rice (Oryza sativa)
7A8W	;	2.15	;	Complex of rice blast (Magnaporthe oryzae) effector protein AVR-PikC with an engineered HMA domain of Pikp-1 from rice (Oryza sativa)
7A8X	;	2.3	;	Complex of rice blast (Magnaporthe oryzae) effector protein AVR-PikC with the HMA domain of Pikh-1 from rice (Oryza sativa)
7BNT	;	1.32	;	Complex of rice blast (Magnaporthe oryzae) effector protein AVR-PikD with a predicted ancestral HMA domain of Pik-1 from Oryza spp.
6R8K	;	1.6	;	Complex of rice blast (Magnaporthe oryzae) effector protein AVR-PikD with an engineered HMA domain of Pikp-1 from rice (Oryza sativa)
6FU9	;	1.2	;	Complex of rice blast (Magnaporthe oryzae) effector protein AVR-PikD with the HMA domain of Pikm-1 from rice (Oryza sativa)
6G10	;	1.35	;	Complex of rice blast (Magnaporthe oryzae) effector protein AVR-PikD with the HMA domain of Pikp-1 from rice (Oryza sativa)
5A6W	;	1.6	;	Complex of rice blast (Magnaporthe oryzae) effector protein AVR-PikD with the HMA domain of Pikp1 from rice (Oryza sativa)
6R8M	;	1.85	;	Complex of rice blast (Magnaporthe oryzae) effector protein AVR-PikE with an engineered HMA domain of Pikp-1 from rice (Oryza sativa)
6FUB	;	1.3	;	Complex of rice blast (Magnaporthe oryzae) effector protein AVR-PikE with the HMA domain of Pikm-1 from rice (Oryza sativa)
6G11	;	1.9	;	Complex of rice blast (Magnaporthe oryzae) effector protein AVR-PikE with the HMA domain of Pikp-1 from rice (Oryza sativa)
8B2R	;	1.22	;	Complex of rice blast (Magnaporthe oryzae) effector protein AVR-PikF with a rice (Oryza sativa) RGA5 HMA domain mutant.
7QZD	;	2.2	;	Complex of rice blast (Magnaporthe oryzae) effector protein AVR-PikF with an engineered HMA domain of Pikp-1 (Pikp-SNK-EKE) from rice (Oryza sativa)
7B1I	;	1.9	;	Complex of rice blast (Magnaporthe oryzae) effector protein AVR-PikF with the HMA domain of OsHIPP19 from rice (Oryza sativa)
8R7A	;	1.8	;	Complex of rice blast (Magnaporthe oryzae) effector protein PWL2 with the HMA domain of OsHIPP43 from rice (Oryza sativa)
8R7D	;	2.5	;	Complex of rice blast (Magnaporthe oryzae) mutant effector protein PWL2-SNDE with the HMA domain of OsHIPP43 from rice (Oryza sativa)
3EJ5	;	2.5	;	complex of Ricin A chain and pyrimidine-based inhibitor
5EME	;	1.15	;	Complex of RNA r(GCAGCAGC) with antisense PNA p(CTGCTGC)
1TDG	;	1.8	;	Complex of S130G SHV-1 beta-lactamase with tazobactam
5NZE	;	1.69	;	Complex of S247N mutant variant of neuraminidase from H1N1 influenza virus with oseltamivir
3B7A	;	1.9	;	Complex of S52A Substituted Droposphila LUSH protein with Ethanol
3B6X	;	2.0	;	Complex of S52A Substituted Drosophila LUSH protein with Butanol
7M42	;	3.3	;	Complex of SARS-CoV-2 receptor binding domain with the Fab fragments of neutralizing antibodies REGN10985 and REGN10989
6XDG	;	3.9	;	Complex of SARS-CoV-2 receptor binding domain with the Fab fragments of two neutralizing antibodies
7A5S	;	3.9	;	Complex of SARS-CoV-2 spike and CR3022 Fab (Homogeneous Refinement)
7A5R	;	3.7	;	Complex of SARS-CoV-2 spike and CR3022 Fab (Non-Uniform Refinement)
7CWM	;	3.6	;	Complex of SARS-CoV-2 spike protein and Fab P17 with one RBD in open state and two RBD in closed state
7CYP	;	3.5	;	Complex of SARS-CoV-2 spike trimer with its neutralizing antibody HB27
5TH7	;	1.95	;	Complex of SETD8 with MS453
8IYA	;	2.43	;	Complex of SETDB1-derived peptide bound to UBE2E1
4P2C	;	2.818	;	Complex of Shiga toxin 2e with a neutralizing single-domain antibody
3V50	;	1.45	;	Complex of SHV S130G mutant beta-lactamase complexed to SA2-13
4V8Q	;	3.1	;	Complex of SmpB, a tmRNA fragment and EF-Tu-GDP-Kirromycin with the 70S ribosome
5X0X	;	3.97	;	Complex of Snf2-Nucleosome complex with Snf2 bound to position +6 of the nucleosome
5X0Y	;	4.69	;	Complex of Snf2-Nucleosome complex with Snf2 bound to SHL2 of the nucleosome
4YXA	;	2.35	;	Complex of SpaO(SPOA1,2 SeMet) and OrgB(APAR)::T4lysozyme fusion protein
4YX7	;	2.0007	;	Complex of SpaO(SPOA1,2) and OrgB(APAR)::T4lysozyme fusion protein
1KTK	;	3.0	;	Complex of Streptococcal pyrogenic enterotoxin C (SpeC) with a human T cell receptor beta chain (Vbeta2.1)
1IKI	;	1.25	;	COMPLEX OF STREPTOMYCES R61 DD-PEPTIDASE WITH THE PRODUCTS OF A SPECIFIC PEPTIDOGLYCAN SUBSTRATE FRAGMENT
3EWR	;	2.01	;	complex of substrate ADP-ribose with HCoV-229E Nsp3 ADRP domain
3EWP	;	2.0	;	complex of substrate ADP-ribose with IBV Nsp3 ADRP domain
5FFN	;	1.8	;	Complex of subtilase SubTY from Bacillus sp. TY145 with chymotrypsin inhibitor CI2A
6K5T	;		;	Complex of SUMO1 and phosphorylated hcmv protein IE2
6JXW	;		;	Complex of SUMO2 bound SLS4 from ICP0.
6K5R	;		;	Complex of SUMO2 with Phosphorylated viral SIM IE2
6UK4	;	2.7	;	Complex of T cell Receptor with HHAT Neoantigen Peptide KQWLVWLFL Presented by HLA-A206
6UK2	;	3.13881	;	Complex of T cell Receptor with HHAT Wild Type Peptide KQWLVWLLL Presented by HLA-A206
3B87	;	2.0	;	Complex of T57A Substituted Droposphila LUSH protein with Butanol
3B88	;	2.0	;	Complex of T57A Substituted Drosophila LUSH Protein with Ethanol
1W4L	;	2.16	;	Complex of TcAChE with bis-acting galanthamine derivative
1W6R	;	2.05	;	Complex of TcAChE with galanthamine derivative
2A5R	;		;	Complex of tetra-(4-n-methylpyridyl) porphin with monomeric parallel-stranded DNA tetraplex, snap-back 3+1 3' G-tetrad, single-residue chain reversal loops, GAG triad in the context of GAAG diagonal loop, C-MYC promoter, NMR, 6 struct.
3TDT	;	2.0	;	COMPLEX OF TETRAHYDRODIPICOLINATE N-SUCCINYLTRANSFERASE WITH 2-AMINO-6-OXOPIMELATE AND COENZYME A
2TDT	;	2.0	;	COMPLEX OF TETRAHYDRODIPICOLINATE N-SUCCINYLTRANSFERASE WITH 2-AMINOPIMELATE AND COENZYME A
2XQN	;	2.62	;	Complex of the 2nd and 3rd LIM domains of TES with the EVH1 DOMAIN of MENA and the N-Terminal domain of actin-like protein Arp7A
1SLY	;	2.8	;	COMPLEX OF THE 70-KDA SOLUBLE LYTIC TRANSGLYCOSYLASE WITH BULGECIN A
3EZB	;		;	COMPLEX OF THE AMINO TERMINAL DOMAIN OF ENZYME I AND THE HISTIDINE-CONTAINING PHOSPHOCARRIER PROTEIN HPR FROM ESCHERICHIA COLI
3EZA	;		;	COMPLEX OF THE AMINO TERMINAL DOMAIN OF ENZYME I AND THE HISTIDINE-CONTAINING PHOSPHOCARRIER PROTEIN HPR FROM ESCHERICHIA COLI NMR, RESTRAINED REGULARIZED MEAN STRUCTURE
3EZE	;		;	COMPLEX OF THE AMINO TERMINAL DOMAIN OF ENZYME I AND THE HISTIDINE-CONTAINING PHOSPHOCARRIER PROTEIN HPR FROM ESCHERICHIA COLI NMR, RESTRAINED REGULARIZED MEAN STRUCTURE
1UZF	;	2.0	;	Complex of the anti-hypertensive drug captopril an the human testicular angiotensin I-converting enzyme
1UZE	;	1.82	;	Complex of the anti-hypertensive drug enalaprilat and the human testicular angiotensin I-converting enzyme
1JC2	;		;	COMPLEX OF THE C-DOMAIN OF TROPONIN C WITH RESIDUES 1-40 OF TROPONIN I
2LEX	;		;	Complex of the C-terminal WRKY domain of AtWRKY4 and a W-box DNA
4B0M	;	1.8	;	Complex of the Caf1AN usher domain, Caf1M chaperone and Caf1 subunit from Yersinia pestis
1G6V	;	3.5	;	Complex of the camelid heavy-chain antibody fragment CAB-CA05 with bovine carbonic anhydrase
1BML	;	2.9	;	COMPLEX OF THE CATALYTIC DOMAIN OF HUMAN PLASMIN AND STREPTOKINASE
1HWK	;	2.22	;	COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH ATORVASTATIN
1HWJ	;	2.26	;	COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH CERIVASTATIN
1HW8	;	2.1	;	COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH COMPACTIN (ALSO KNOWN AS MEVASTATIN)
1HWI	;	2.3	;	COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH FLUVASTATIN
1DQ8	;	2.1	;	COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH HMG AND COA
1DQA	;	2.0	;	COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH HMG, COA, AND NADP+
1HWL	;	2.1	;	COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH ROSUVASTATIN (FORMALLY KNOWN AS ZD4522)
1HW9	;	2.33	;	COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH SIMVASTATIN
1C7U	;		;	Complex of the DNA binding core domain of the transcription factor MEF2A with a 20mer oligonucleotide
2BRU	;		;	Complex of the domain I and domain III of Escherichia coli transhydrogenase
1OCQ	;	1.08	;	COMPLEX OF THE ENDOGLUCANASE CEL5A FROM BACILLUS AGARADHEARANS AT 1.08 ANGSTROM RESOLUTION with cellobio-derived isofagomine
2H5A	;	1.72	;	Complex of the enzyme PMM/PGM with xylose 1-phosphate
4AW5	;	2.33	;	Complex of the EphB4 kinase domain with an oxindole inhibitor
5ABZ	;	2.4	;	Complex of the FimH lectin with a C-linked naphtyl alpha-D-mannoside in soaked trigonal crystals at 2.40 A resolution
5AAL	;	2.45	;	Complex of the FimH lectin with a C-linked para-biphenyl ethylene alpha-D-mannoside in soaked trigonal crystals at 2.45 A resolution
5AAP	;	1.302	;	Complex of the FimH lectin with a C-linked para-biphenyl methylene alpha-D-mannoside
2HA1	;		;	Complex of the first and second type III domains of human Fibronectin in solution
5BXJ	;	1.24	;	Complex of the Fk1 domain mutant A19T of FKBP51 with 4-Nitrophenol
2OCY	;	3.3	;	Complex of the guanine exchange factor Sec2p and the Rab GTPase Sec4p
1BVY	;	2.03	;	COMPLEX OF THE HEME AND FMN-BINDING DOMAINS OF THE CYTOCHROME P450(BM-3)
2XAT	;	3.2	;	COMPLEX OF THE HEXAPEPTIDE XENOBIOTIC ACETYLTRANSFERASE WITH CHLORAMPHENICOL AND DESULFO-COENZYME A
5ZAU	;		;	Complex of the human FYN SH3 and monobody binder
1AKJ	;	2.65	;	COMPLEX OF THE HUMAN MHC CLASS I GLYCOPROTEIN HLA-A2 AND THE T CELL CORECEPTOR CD8
1SEB	;	2.7	;	COMPLEX OF THE HUMAN MHC CLASS II GLYCOPROTEIN HLA-DR1 AND THE BACTERIAL SUPERANTIGEN SEB
1IRA	;	2.7	;	COMPLEX OF THE INTERLEUKIN-1 RECEPTOR WITH THE INTERLEUKIN-1 RECEPTOR ANTAGONIST (IL1RA)
1J4W	;		;	COMPLEX OF THE KH3 and KH4 DOMAINS OF FBP WITH A SINGLE_STRANDED 29mer DNA OLIGONUCLEOTIDE FROM THE FUSE ELEMENT OF THE C-MYC ONCOGENE
1J5K	;		;	COMPLEX OF THE KH3 DOMAIN OF HNRNP K WITH A SINGLE_STRANDED 10MER DNA OLIGONUCLEOTIDE
1NWX	;	3.5	;	COMPLEX OF THE LARGE RIBOSOMAL SUBUNIT FROM DEINOCOCCUS RADIODURANS WITH ABT-773
1NWY	;	3.3	;	COMPLEX OF THE LARGE RIBOSOMAL SUBUNIT FROM DEINOCOCCUS RADIODURANS WITH AZITHROMYCIN
1SM1	;	3.42	;	COMPLEX OF THE LARGE RIBOSOMAL SUBUNIT FROM DEINOCOCCUS RADIODURANS WITH QUINUPRISTIN AND DALFOPRISTIN
3D2Z	;	2.8	;	Complex of the N-acetylmuramyl-L-alanine amidase AmiD from E.coli with the product L-Ala-D-gamma-Glu-L-Lys
3D2Y	;	1.75	;	Complex of the N-acetylmuramyl-L-alanine amidase AmiD from E.coli with the substrate anhydro-N-acetylmuramic acid-L-Ala-D-gamma-Glu-L-Lys
2BRR	;	1.95	;	Complex of the neisserial PorA P1.4 epitope peptide and two Fab- fragments (antibody MN20B9.34)
6H9N	;	2.6	;	Complex of the periplasmic domains of bacterial cell division proteins FtsQ and FtsB
6H9O	;	2.8	;	Complex of the periplasmic domains of bacterial cell division proteins FtsQ and FtsB
8UBR	;	2.7	;	Complex of the phosphorylated human cystic fibrosis transmembrane conductance regulator (CFTR) with CFTRinh-172 and ATP/Mg
1ZHI	;	2.7	;	Complex of the S. cerevisiae Orc1 and Sir1 interacting domains
1TFX	;	2.6	;	COMPLEX OF THE SECOND KUNITZ DOMAIN OF TISSUE FACTOR PATHWAY INHIBITOR WITH PORCINE TRYPSIN
3HHZ	;	3.5	;	Complex of the vesicular stomatitis virus nucleocapsid and the nucleocapsid-binding domain of the phosphoprotein
1BCR	;	2.5	;	COMPLEX OF THE WHEAT SERINE CARBOXYPEPTIDASE, CPDW-II, WITH THE MICROBIAL PEPTIDE ALDEHYDE INHIBITOR, ANTIPAIN, AND ARGININE AT ROOM TEMPERATURE
1BCS	;	2.08	;	COMPLEX OF THE WHEAT SERINE CARBOXYPEPTIDASE, CPDW-II, WITH THE MICROBIAL PEPTIDE ALDEHYDE INHIBITOR, CHYMOSTATIN, AND ARGININE AT 100 DEGREES KELVIN
4TX3	;	2.5	;	Complex of the X-domain and OxyB from Teicoplanin Biosynthesis
7QIJ	;	4.1	;	Complex of the Yersinia enterocolitica Type III secretion export gate YscV with substrate:chaperone complex YscX:YscY
7QIH	;	1.92	;	Complex of the Yersinia enterocolitica Type III secretion proteins YscX and YscY
7QII	;	3.29	;	Complex of the Yersinia enterocolitica Type III secretion proteins YscX and YscY
5AA0	;	5.0	;	Complex of Thermous thermophilus ribosome (A-and P-site tRNA) bound to BipA-GDPCP
5A9Z	;	4.7	;	Complex of Thermous thermophilus ribosome bound to BipA-GDPCP
1NG3	;	2.6	;	Complex of ThiO (glycine oxidase) with acetyl-glycine
1AD8	;	2.0	;	COMPLEX OF THROMBIN WITH AND INHIBITOR CONTAINING A NOVEL P1 MOIETY
1VZQ	;	1.54	;	Complex of thrombin with designed inhibitor 7165
6MAV	;	2.37	;	Complex of tissue inhibitor of metalloproteinase-1 (TIMP-1) mutant L34G with matrix metalloproteinase-3 catalytic domain (MMP-3cd)
6N9D	;	2.67	;	Complex of tissue inhibitor of metalloproteinases-1 (TIMP-1) mutant (L34G/L133P/L151C/G154A) with matrix metalloproteinase-3 catalytic domain (MMP-3cd)
7S7M	;	3.0	;	Complex of tissue inhibitor of metalloproteinases-1 (TIMP-1) mutant (L34G/M66D/T98G/P131S/Q153N) with matrix metalloproteinase-3 catalytic domain (MMP-3cd)
7S7L	;	2.34	;	Complex of tissue inhibitor of metalloproteinases-1 (TIMP-1) mutant (L34G/M66S/E67Y/L133N/S155L) with matrix metalloproteinase-3 catalytic domain (MMP-3cd)
2G9J	;		;	Complex of TM1a(1-14)Zip with TM9a(251-284): a model for the polymerization domain (""overlap region"") of tropomyosin, Northeast Structural Genomics Target OR9
1GAN	;	2.23	;	COMPLEX OF TOAD OVARY GALECTIN WITH N-ACETYLGALACTOSE
1A78	;	2.0	;	COMPLEX OF TOAD OVARY GALECTIN WITH THIO-DIGALACTOSE
1UCW	;	2.2	;	COMPLEX OF TRANSALDOLASE WITH THE REDUCED SCHIFF-BASE INTERMEDIATE
1NGS	;	2.4	;	COMPLEX OF TRANSKETOLASE WITH THIAMIN DIPHOSPHATE, CA2+ AND ACCEPTOR SUBSTRATE ERYTHROSE-4-PHOSPHATE
2Z5N	;	3.2	;	Complex of Transportin 1 with hnRNP D NLS
2Z5O	;	3.2	;	Complex of Transportin 1 with JKTBP NLS
2Z5K	;	2.6	;	Complex of Transportin 1 with TAP NLS
2Z5M	;	3.0	;	Complex of Transportin 1 with TAP NLS, crystal form 2
7Q9O	;	1.35	;	Complex of Transthyretin with resveratrol exhibits multiple binding modes
5FER	;	2.34	;	Complex of TRIM25 RING with UbcH5-Ub
1A2X	;	2.3	;	COMPLEX OF TROPONIN C WITH A 47 RESIDUE (1-47) FRAGMENT OF TROPONIN I
7CQP	;	1.9	;	Complex of TRPC4 and Calmodulin_Nlobe
7CQV	;	1.78	;	Complex of TRP_CBS1 and Calmodulin_Nlobe
7CQH	;	2.15	;	Complex of TRP_CBS2 and Calmodulin_Clobe
3K8C	;	2.1	;	Complex of Trypanosoma cruzi ribose 5-phosphate isomerase type B with 4-deoxy-4-phospho-D-erythronohydroxamic acid
3K7S	;	1.9	;	Complex of Trypanosoma cruzi ribose 5-phosphate isomerase type B with ribose 5-phosphate
2WQA	;	2.85	;	Complex of TTR and RBP4 and Oleic Acid
1CIR	;		;	COMPLEX OF TWO FRAGMENTS OF CI2 [(1-40)(DOT)(41-64)]
1CIQ	;	2.2	;	COMPLEX OF TWO FRAGMENTS OF CI2, RESIDUES 1-40 AND 41-64
7D2Y	;	2.68	;	complex of two RRM domains
4TKP	;	2.08	;	Complex of Ubc13 with the RING domain of the TRIM5alpha retroviral restriction factor
7UN6	;	3.3	;	Complex of UBE2O with NAP1L1
7UN3	;	3.5	;	Complex of UBE2O with NAP1L1 and ubiquitylated uL2
3FCK	;	1.64	;	Complex of UNG2 and a fragment-based design inhibitor
3FCF	;	1.84	;	Complex of UNG2 and a fragment-based designed inhibitor
3FCI	;	1.27	;	Complex of UNG2 and a fragment-based designed inhibitor
3FCL	;	1.7	;	Complex of UNG2 and a fragment-based designed inhibitor
2HXM	;	1.3	;	Complex of UNG2 and a small Molecule synthetic Inhibitor
4B93	;	2.0	;	Complex of Vamp7 cytoplasmic domain with 2nd ankyrin repeat domain of Varp
1C0Q	;	1.0	;	COMPLEX OF VANCOMYCIN WITH 2-ACETOXY-D-PROPANOIC ACID
1C0R	;	1.0	;	COMPLEX OF VANCOMYCIN WITH D-LACTIC ACID
1FVM	;	1.8	;	Complex of vancomycin with DI-acetyl-LYS-D-ALA-D-ALA
1QD8	;	1.0	;	COMPLEX OF VANCOMYCIN WITH N-ACETYL GLYCINE
4P9O	;	2.89	;	Complex of Voltage-gated ion channel in a the presence of channel blocking compound
6A90	;	2.8	;	Complex of voltage-gated sodium channel NavPaS from American cockroach Periplaneta americana and Dc1a
6A91	;	3.2	;	Complex of voltage-gated sodium channel NavPaS from American cockroach Periplaneta americana bound with saxitoxin and Dc1a
6A95	;	2.6	;	Complex of voltage-gated sodium channel NavPaS from American cockroach Periplaneta americana bound with tetrodotoxin and Dc1a
5LS7	;	1.16	;	Complex of wild type E. coli alpha aspartate decarboxylase with its processing factor PanZ
3U3E	;	1.21	;	Complex of Wild Type Myoglobin with Phenol in its Proximal Cavity
4QTJ	;	2.1	;	Complex of WOPR domain of Wor1 in Candida albicans with the 13bp dsDNA
4QTK	;	2.99	;	Complex of WOPR domain of Wor1 in Candida albicans with the 17bp dsDNA
6ERG	;	2.9	;	Complex of XLF and heterodimer Ku bound to DNA
6ERH	;	2.8	;	Complex of XLF and heterodimer Ku bound to DNA
6P4O	;	3.15	;	Complex of XPB helicase with Bax1 endonuclease from Sulfurisphaera tokodaii at 3.15 Angstroms resolution
1IOW	;	1.9	;	COMPLEX OF Y216F D-ALA:D-ALA LIGASE WITH ADP AND A PHOSPHORYL PHOSPHINATE
5DAT	;	3.15	;	Complex of yeast 80S ribosome with hypusine-containing eIF5A
5DGF	;	3.3	;	Complex of yeast 80S ribosome with hypusine-containing/non-modified eIF5A and/or a peptidyl-tRNA analog
5DGV	;	3.1	;	Complex of yeast 80S ribosome with hypusine-containing/non-modified eIF5A and/or a peptidyl-tRNA analog
5DC3	;	3.25	;	Complex of yeast 80S ribosome with non-modified eIF5A
4P4Q	;	2.01	;	Complex of yeast cytochrome c peroxidase (W191F) with iso-1 cytochrome c
5CIF	;	2.01	;	Complex of yeast cytochrome c peroxidase (W191F) with iso-1 cytochrome c
5CIB	;	3.011	;	Complex of yeast cytochrome c peroxidase (W191G) bound to 2,4-dimethylaniline with iso-1 cytochrome c
5CIC	;	2.103	;	Complex of yeast cytochrome c peroxidase (W191G) bound to 3-aminobenzotrifluoride with iso-1 cytochrome c
5CIE	;	2.6	;	Complex of yeast cytochrome c peroxidase (W191G) bound to aniline with iso-1 cytochrome c
5CID	;	2.763	;	Complex of yeast cytochrome c peroxidase (W191G) bound to o-toluidine with iso-1 cytochrome c
5CIG	;	2.06	;	Complex of yeast cytochrome c peroxidase (W191G) with iso-1 cytochrome c
5CIH	;	2.6	;	Complex of yeast cytochrome c peroxidase (W191Y) with iso-1 cytochrome c
6KIQ	;	3.62	;	Complex of yeast cytoplasmic dynein MTBD-High and MT with DTT
6KIO	;	3.94	;	Complex of yeast cytoplasmic dynein MTBD-High and MT without DTT
3ESW	;	3.4	;	Complex of yeast PNGase with GlcNAc2-IAc.
2R25	;	1.7	;	Complex of YPD1 and SLN1-R1 with bound Mg2+ and BeF3-
1NLI	;	1.93	;	Complex of [E160A-E189A] trichosanthin and adenine
1THD	;	9.5	;	COMPLEX ORGANIZATION OF DENGUE VIRUS E PROTEIN AS REVEALED BY 9.5 ANGSTROM CRYO-EM RECONSTRUCTION
1P58	;	9.5	;	Complex Organization of Dengue Virus Membrane Proteins as Revealed by 9.5 Angstrom Cryo-EM reconstruction
1AVW	;	1.75	;	COMPLEX PORCINE PANCREATIC TRYPSIN/SOYBEAN TRYPSIN INHIBITOR, ORTHORHOMBIC CRYSTAL FORM
1AVX	;	1.9	;	COMPLEX PORCINE PANCREATIC TRYPSIN/SOYBEAN TRYPSIN INHIBITOR, TETRAGONAL CRYSTAL FORM
1CG9	;	2.7	;	COMPLEX RECOGNITION OF THE SUPERTYPIC BW6-DETERMINANT ON HLA-B AND-C MOLECULES BY THE MONOCLONAL ANTIBODY SFR8-B6
2FSI	;	2.11	;	Complex SecA:ADP from Escherichia coli
2FSH	;	2.0	;	Complex SecA:AMP-PNP from Escherichia coli
2FSG	;	2.2	;	Complex SecA:ATP from Escherichia coli
5XUL	;	1.98	;	Complex structure (RmMan134A-M6).
5Z4T	;	1.68	;	Complex structure - AxMan113A-M3
4H9N	;	1.95	;	Complex structure 1 of DAXX/H3.3(sub5)/H4
4H9O	;	2.053	;	Complex structure 2 of DAXX/H3.3(sub5,G90M)/H4
7OJS	;	4.2	;	Complex structure 2 of the Bacillus subtilis CdaA c-di-AMP cyclase domain (CdaACD) and the phosphoglucomutase GlmM short variant (GlmMF369)
4H9P	;	2.198	;	Complex structure 3 of DAXX/H3.3(sub5,G90A)/H4
4H9Q	;	1.95	;	Complex structure 4 of DAXX(E225A)/H3.3(sub5)/H4
4H9R	;	2.197	;	Complex structure 5 of DAXX(E225A)/H3.3(sub5,G90A)/H4
4H9S	;	2.6	;	Complex structure 6 of DAXX/H3.3(sub7)/H4
7BNH	;	0.84	;	Complex structure at atomic resolution of SH3b domain with benzoic acid
5LB7	;	1.5	;	Complex structure between p60N/p80C katanin and a peptide derived from ASPM
3KDJ	;	1.878	;	Complex structure of (+)-ABA-bound PYL1 and ABI1
7BSC	;	2.31	;	Complex structure of 1G5.3 Fab bound to DENV2 NS1c
7BSD	;	2.53	;	Complex structure of 1G5.3 Fab bound to ZIKV NS1c
3RRL	;	2.29	;	Complex structure of 3-oxoadipate coA-transferase subunit A and B from Helicobacter pylori 26695
6A3W	;	2.0	;	Complex structure of 4-1BB and utomilumab
4FS9	;	3.1	;	Complex structure of a broad specificity amino acid racemase (Bar) within the reactive intermediate
7XHL	;	3.25	;	Complex structure of a Glucose 6-Phosphate Dehydrogenase from Zymomonas mobilis
7CR5	;	2.08	;	Complex structure of a human monoclonal antibody with SARS-CoV-2 nucleocapsid protein NTD
7VVE	;	1.98	;	Complex structure of a leaf-branch compost cutinase variant in complex with mono(2-hydroxyethyl) terephthalic acid
7W45	;	1.94	;	Complex structure of a leaf-branch compost cutinase variant LCC ICCG_KIP
7W1N	;	1.88	;	Complex structure of a leaf-branch compost cutinase variant LCC ICCG_KRP
7W44	;	1.85	;	Complex structure of a leaf-branch compost cutinase variant LCC ICCG_RIP
7CDX	;	2.103	;	Complex STRUCTURE OF A NOVEL VIRULENCE REGULATION FACTOR SghR with its effector sucrose
8H3E	;	3.06	;	Complex structure of a small molecule (SPC-14) bound SARS-CoV-2 spike protein, closed state
4DSC	;	1.95	;	Complex structure of abscisic acid receptor PYL3 with (+)-ABA in spacegroup of H32 at 1.95A
4DSB	;	2.7	;	Complex Structure of Abscisic Acid Receptor PYL3 with (+)-ABA in Spacegroup of I 212121 at 2.70A
4JDA	;	2.65	;	Complex structure of abscisic acid receptor PYL3 with (-)-ABA
4DS8	;	2.21	;	Complex structure of abscisic acid receptor PYL3-(+)-ABA-HAB1 in the presence of Mn2+
2ZH1	;	2.8	;	Complex structure of AFCCA with tRNAminiDA
2ZH2	;	2.66	;	Complex structure of AFCCA with tRNAminiDAC
2ZH3	;	2.5	;	Complex structure of AFCCA with tRNAminiDCA
2ZH4	;	2.65	;	Complex structure of AFCCA with tRNAminiDCG
2ZH5	;	2.6	;	Complex structure of AFCCA with tRNAminiDCU
2ZH6	;	2.5	;	Complex structure of AFCCA with tRNAminiDCU and ATP
2ZH7	;	3.0	;	Complex structure of AFCCA with tRNAminiDG
2ZH8	;	2.65	;	Complex structure of AFCCA with tRNAminiDGC
2ZH9	;	2.9	;	Complex structure of AFCCA with tRNAminiDU
2ZHA	;	2.95	;	Complex structure of AFCCA with tRNAminiDU and CTP
2ZHB	;	3.05	;	Complex structure of AFCCA with tRNAminiDUC
7W12	;	2.25	;	Complex structure of alginate lyase AlyB-OU02 with G9
6A40	;	1.8	;	complex structure of Alginate lyase AlyF-OU02 with G4
7BZ0	;	1.8	;	complex structure of alginate lyase AlyF-OU02 with G6
7W16	;	1.9	;	Complex structure of alginate lyase AlyV with M8
7W18	;	1.7	;	Complex structure of alginate lyase PyAly with M5
7W13	;	1.65	;	Complex structure of alginate lyase PyAly with M8
4RFR	;	1.5	;	Complex structure of AlkB/rhein
4JOL	;	2.906	;	Complex structure of AML1-ETO NHR2 domain with HEB fragment
6JIT	;	2.052	;	Complex structure of an imine reductase at 2.05 Angstrom resolution
3WKT	;	4.3	;	Complex structure of an open form of NADPH-cytochrome P450 reductase and heme oxygenase-1
5XJM	;	3.2	;	Complex structure of angiotensin II type 2 receptor with Fab
7EJY	;	3.04	;	Complex Structure of antibody BD-503 and RBD of COVID-19
7F6Z	;	3.0	;	Complex Structure of antibody BD-503 and RBD-501Y.V2 of COVID-19
7F6Y	;	3.0	;	Complex Structure of antibody BD-503 and RBD-E484K of COVID-19
7EK0	;	2.7	;	Complex Structure of antibody BD-503 and RBD-N501Y of COVID-19
7EJZ	;	3.63	;	Complex Structure of antibody BD-503 and RBD-S477N of COVID-19
8GQD	;	3.41	;	Complex Structure of Arginine Kinase McsB and McsA from Staphylococcus aureus
4N0O	;	2.65	;	Complex structure of Arterivirus nonstructural protein 10 (helicase) with DNA
7VC8	;	1.606	;	Complex structure of AtHPPD with inhibitor PYQ3
7EZQ	;	1.886	;	Complex structure of AtHPPD with inhibitor Y15832
7CJK	;	1.698	;	Complex structure of AtHPPD with inhibitor Y18093
8WQM	;	1.796	;	Complex structure of AtHPPD with LB553
7WJ8	;	1.805	;	Complex structure of AtHPPD-PyQ1
7WJJ	;	1.603	;	Complex structure of AtHPPD-PyQ2
7WJK	;	1.704	;	Complex structure of AtHPPD-ZWJ
4W5A	;	2.6	;	Complex structure of ATRX ADD bound to H3K9me3S10ph peptide
3QLC	;	2.5	;	Complex structure of ATRX ADD domain bound to unmodified H3 1-15 peptide
7Y9I	;	2.07	;	Complex structure of AtYchF1 with ppGpp
6JCK	;	3.09	;	Complex structure of Axin-DIX and Dvl2-DIX
3EX8	;	2.56	;	Complex structure of bacillus subtilis RibG reduction mechanism in riboflavin biosynthesis
4G3M	;	2.56	;	Complex Structure of Bacillus subtilis RibG: The Deamination Process in Riboflavin Biosynthesis
3AQN	;	3.3	;	Complex structure of bacterial protein (apo form II)
7YUK	;	2.11	;	Complex structure of BANP BEN domain bound to DNA
6L8Q	;	3.1	;	Complex structure of bat CD26 and MERS-RBD
4YK9	;	1.7	;	Complex structure of BCL-XL and mutated BIM BH3 domain
8GNH	;	3.74	;	Complex structure of BD-218 and Spike protein
3OGR	;	1.5	;	Complex structure of beta-galactosidase from Trichoderma reesei with galactose
3OGS	;	1.75	;	Complex structure of beta-galactosidase from Trichoderma reesei with IPTG
3OGV	;	1.4	;	Complex structure of beta-galactosidase from Trichoderma reesei with PETG
6LSA	;	2.204	;	Complex structure of bovine herpesvirus 1 glycoprotein D and bovine nectin-1 IgV
4U4A	;	3.51	;	Complex Structure of BRCA1 BRCT with singly phospho Abraxas
2M0U	;		;	Complex structure of C-terminal CFTR peptide and extended PDZ1 domain from NHERF1
2M0V	;		;	Complex structure of C-terminal CFTR peptide and extended PDZ2 domain from NHERF1
4XWM	;	1.703	;	Complex structure of catalytic domain of Clostridium Cellulovorans Exgs and Cellobiose
4XWN	;	2.884	;	Complex structure of catalytic domain of Clostridium Cellulovorans Exgs and Cellotetraose
8HDD	;	3.0	;	Complex structure of catalytic, small, and a partial electron transfer subunits from Burkholderia cepacia FAD glucose dehydrogenase
2DR5	;	2.8	;	Complex structure of CCA adding enzyme with mini-helix lacking CCA
2DRB	;	2.8	;	Complex structure of CCA-adding enzyme with tRNAminiCCA
2DR7	;	2.8	;	Complex structure of CCA-adding enzyme with tRNAminiDC
2DR8	;	2.5	;	Complex structure of CCA-adding enzyme with tRNAminiDC and CTP
2DR9	;	2.8	;	Complex structure of CCA-adding enzyme with tRNAminiDCC
2DRA	;	2.5	;	Complex structure of CCA-adding enzyme with tRNAminiDCC and ATP
2DVI	;	2.61	;	Complex structure of CCA-adding enzyme, mini-DCC and CTP
8IVD	;	3.24	;	COMPLEX STRUCTURE OF CD93-IGFBP7
8H6P	;	2.44	;	Complex structure of CDK2/Cyclin E1 and a potent, selective macrocyclic inhibitor
8H6T	;	3.0	;	Complex structure of CDK2/Cyclin E1 and a potent, selective small molecule inhibitor
7SLW	;	2.3	;	Complex structure of CDYL2 with an antagonist
8SP6	;	1.45	;	COMPLEX STRUCTURE OF CDYL2 WITH AN ANTAGONIST
6LQL	;	1.8	;	Complex structure of CHAO with product from Erythrobacteraceae bacterium
7YVQ	;	3.18	;	Complex structure of Clostridioides difficile binary toxin folded CDTa-bound CDTb-pore (short).
7YVS	;	2.8	;	Complex structure of Clostridioides difficile binary toxin unfolded CDTa-bound CDTb-pore (short).
7VNN	;	2.64	;	Complex structure of Clostridioides difficile enzymatic component (CDTa) and binding component (CDTb) pore with long stem
7VNJ	;	2.56	;	Complex structure of Clostridioides difficile enzymatic component (CDTa) and binding component (CDTb) pore with short stem
2ZU2	;	1.8	;	complex structure of CoV 229E 3CL protease with EPDTC
6A73	;	2.447	;	Complex structure of CSN2 with IP6
2ZTX	;	1.72	;	Complex structure of CVB3 3C protease with EPDTC
2ZU3	;	1.75	;	Complex structure of CVB3 3C protease with TG-0204998
5Y7Z	;	2.804	;	Complex structure of cyclin G-associated kinase with gefitinib
5Y80	;	2.5	;	Complex structure of cyclin G-associated kinase with gefitinib
3LQS	;	1.9	;	Complex Structure of D-Amino Acid Aminotransferase and 4-amino-4,5-dihydro-thiophenecarboxylic acid (ADTA)
7XPC	;	3.31	;	Complex structure of D-glycerate-3-kinase(GLYK) and AVRvnt1
3P13	;	2.35	;	Complex Structure of D-ribose Pyranase Sa240 with D-ribose
2QKY	;	3.1	;	complex structure of dipeptidyl peptidase IV and a oxadiazolyl ketone
7CPW	;	2.849	;	Complex structure of DNA with self-catalyzed depurination activity
7ZHH	;	1.6	;	Complex structure of drosophila Unr CSD789 and a poly(A) RNA sequence
7ZHR	;	2.99	;	Complex structure of drosophila Unr CSD789 and pAbp RRM3
5XJ4	;	2.3	;	Complex structure of durvalumab-scFv/PD-L1
2MX6	;		;	Complex structure of Dvl PDZ domain with ligand
2L29	;		;	Complex structure of E4 mutant human IGF2R domain 11 bound to IGF-II
3K26	;	1.58	;	Complex structure of EED and trimethylated H3K4
3K27	;	1.76	;	Complex structure of EED and trimethylated H3K9
7F9H	;	1.78	;	complex structure of EnrR-DNA
4OB6	;	1.7	;	Complex structure of esterase rPPE S159A/W187H and substrate (S)-Ac-CPA
5IYT	;	1.73	;	Complex structure of EV-B93 main protease 3C with N-Ethyl 4-((1-cycloheptyl-1,2-dihydropyrazol-3-one-5-yl)-amino)-4-oxo-2Z-butenamide
5HBT	;	2.61	;	Complex structure of Fab35 and human nAChR alpha1
5HBV	;	2.7	;	Complex structure of Fab35 and mouse nAChR alpha1
6BZ3	;	2.497	;	Complex structure of FAK FAT domain and DCC P3 motif
3L1B	;	1.9	;	Complex Structure of FXR Ligand-binding domain with a tetrahydroazepinoindole compound
3DOW	;	2.3	;	Complex structure of GABA type A receptor associated protein and its binding epitope on calreticulin
5YLK	;	2.09	;	Complex structure of GH 113 family beta-1,4-mannanase with mannobiose
5YLI	;	2.37	;	Complex structure of GH113 beta-1,4-mannanase
6KO5	;	3.3	;	Complex structure of Ghrelin receptor with Fab
7N54	;	2.0	;	Complex structure of GLAU4 with glaucine
7EEJ	;	1.47798	;	Complex structure of glycoside hydrolase family 12 beta-1,3-1,4-glucanase with cellobiose
7EEE	;	1.66079	;	Complex structure of glycoside hydrolase family 12 beta-1,3-1,4-glucanase with gentiobiose
6J14	;	1.4	;	Complex structure of GY-14 and PD-1
6J15	;	2.6	;	Complex structure of GY-5 Fab and PD-1
5XL3	;	2.203	;	Complex structure of H4 hemagglutinin from avian influenza H4N6 virus with LSTa
1NJT	;	2.5	;	COMPLEX STRUCTURE OF HCMV PROTEASE AND A PEPTIDOMIMETIC INHIBITOR
1NJU	;	2.7	;	Complex structure of HCMV Protease and a peptidomimetic inhibitor
1NKK	;	2.6	;	COMPLEX STRUCTURE OF HCMV PROTEASE AND A PEPTIDOMIMETIC INHIBITOR
1NKM	;	2.7	;	Complex structure of HCMV Protease and a peptidomimetic inhibitor
3Q3Y	;	1.32	;	Complex structure of HEVB EV93 main protease 3C with Compound 1 (AG7404)
3RUO	;	1.5	;	Complex structure of HevB EV93 main protease 3C with Rupintrivir (AG7088)
7N65	;	4.15	;	Complex structure of HIV superinfection Fab QA013.2 and BG505.SOSIP.664
7EJL	;	1.89	;	Complex Structure of HLA-A*2402 with the Peptide from HCoV(CoV-2) spike protein
7EJM	;	1.71	;	Complex Structure of HLA-A*2402 with the Peptide from HCoV(CoV-229E) spike protein
7EJN	;	2.11	;	Complex Structure of HLA-A*2402 with the Peptide from HCoV(CoV-HKU1) spike protein
7EU2	;	2.8	;	Complex structure of HLA0201 with recognizing SARS-CoV-2 epitope S1
7F4W	;	2.9	;	Complex structure of HLA2402 with recognizing SARS-CoV-2 epitope pep4
8HN4	;	2.853	;	Complex structure of HLA2402 with recognizing SARS-CoV-2 epitope QYIKWPWYI
8IF1	;	2.5	;	Complex structure of HLA2402 with recognizing SARS-CoV-2 Y453F epitope NYNYLFRLF
6LGT	;	1.794	;	Complex structure of HPPD with an inhibitor Y16542
7CQS	;	1.998	;	Complex structure of HPPD with Topramezone
7CQR	;	1.947	;	Complex structure of HPPD with Y16550
1BDJ	;	2.68	;	COMPLEX STRUCTURE OF HPT DOMAIN AND CHEY
6A3V	;	3.391	;	Complex structure of human 4-1BB and 4-1BBL
5B4P	;	2.4	;	Complex structure of human C5a and its binding repebody
8J3S	;	3.09	;	Complex structure of human cytomegalovirus protease and a macrocyclic peptide ligand
8J3T	;	2.9	;	Complex structure of human cytomegalovirus protease and a non-covalent small-molecule ligand
5DQS	;	2.1	;	Complex structure of human elongation factor 1B alpha and gamma GST-like domains
5JPO	;	1.998	;	Complex structure of human elongation factor 1B gamma GST-liked domain and delta N-terminal domain
1MEN	;	2.23	;	complex structure of human GAR Tfase and substrate beta-GAR
2V5P	;	4.1	;	COMPLEX STRUCTURE OF HUMAN IGF2R DOMAINS 11-13 BOUND TO IGF-II
5LQB	;	1.95	;	Complex structure of human IL2 mutant, Proleukin, with Fab fragment of NARA1 antibody
6URQ	;	2.05	;	Complex structure of human poly-ADP-ribosyltransferase TNKS1 ARC2-ARC3 and P antigen family member 4 (PAGE4)
7UK1	;	2.7	;	Complex Structure of Human Polypyrimidine Splicing Factor (PSF/SFPQ) with Murine Virus-like 30S Transcript-1 (VS30-1) Reveals Cooperative Binding of RNA
4FBX	;	2.33	;	Complex structure of human protein kinase CK2 catalytic subunit crystallized in the presence of a bisubstrate inhibitor
5M44	;	2.71	;	Complex structure of human protein kinase CK2 catalytic subunit with a thieno[2,3-d]pyrimidin inhibitor crystallized under high-salt conditions
5M4C	;	1.935	;	Complex structure of human protein kinase CK2 catalytic subunit with a thieno[2,3-d]pyrimidin inhibitor crystallized under low-salt conditions
5M4I	;	2.218	;	Complex structure of human protein kinase CK2 catalytic subunit with the inhibitor 4'-carboxy-6,8-chloro-flavonol (FLC21) crystallized under high-salt conditions
5M4F	;	1.519	;	Complex structure of human protein kinase CK2 catalytic subunit with the inhibitor 4'-carboxy-6,8-chloro-flavonol (FLC21) crystallized under low-salt conditions
5WRV	;	1.7	;	Complex structure of human SRP72/SRP68
4HL5	;	2.2	;	Complex structure of human tankyrase 2 with 7-hydroxy -4'-methoxyflavone
4HKK	;	1.95	;	Complex structure of human tankyrase 2 with apigenin
4HKN	;	2.05	;	Complex structure of human tankyrase 2 with luteolin
3U9H	;	1.75	;	Complex structure of human tankyrase 2 with nicotinamide
1EB1	;	1.8	;	Complex structure of human thrombin with N-methyl-arginine inhibitor
6IRE	;	3.25	;	Complex structure of INAD PDZ45 and NORPA CC-PBM
6IRD	;	2.813	;	Complex structure of INADL PDZ89 and PLCb4 C-terminal CC-PBM
3F5P	;	2.9	;	Complex Structure of Insulin-like Growth Factor Receptor and 3-Cyanoquinoline Inhibitor
2ZM3	;	2.5	;	Complex Structure of Insulin-like Growth Factor Receptor and Isoquinolinedione Inhibitor
6KLW	;	2.9	;	Complex structure of Iota toxin enzymatic component (Ia) and binding component (Ib) pore with long stem
6KLO	;	2.8	;	Complex structure of Iota toxin enzymatic component (Ia) and binding component (Ib) pore with short stem
5XJ3	;	3.2	;	Complex structure of ipilimumab-scFv and CTLA-4
5FBJ	;	2.42	;	Complex structure of JMJD5 and substrate
6AX3	;	2.25	;	Complex structure of JMJD5 and Symmetric Dimethyl-Arginine (SDMA)
6AVS	;	2.02	;	Complex structure of JMJD5 and Symmetric Monomethyl-Arginine (MMA)
7C88	;	1.997	;	Complex structure of JS003 and PD-L1
8FMN	;	3.101	;	Complex structure of K210 deletion Troponin complex
8FMQ	;	3.248	;	Complex structure of K210 deletion Troponin complex with alendronate
8FMR	;	3.238	;	Complex structure of K210 deletion Troponin complex with ibandronate
8FMS	;	3.435	;	Complex structure of K210 deletion Troponin complex with neridronate
8FMP	;	3.24	;	Complex structure of K210 deletion Troponin complex with pamidronate
8FMO	;	2.612	;	Complex structure of K210 deletion Troponin complex with risedronate
6J9U	;	2.79	;	Complex structure of Lactobacillus casei lactate dehydrogenase penta mutant with pyruvate
6J9T	;	2.7	;	Complex structure of Lactobacillus casei lactate dehydrogenase with fructose-1,6-bisphosphate
7XQL	;	2.272	;	complex structure of LegA15 with GNP
2Z3M	;	2.7	;	complex structure of LF-transferase and dAF
2Z3P	;	2.5	;	complex structure of LF-transferase and leucine
2Z3L	;	2.75	;	complex structure of LF-transferase and peptide A
2Z3N	;	2.5	;	complex structure of LF-transferase and peptide B
2Z3O	;	2.4	;	complex structure of LF-transferase and phenylalanine
2Z3K	;	2.85	;	complex structure of LF-transferase and rAF
6K7O	;	3.004	;	Complex structure of LILRB4 and h128-3 antibody
6BYX	;	2.208	;	Complex structure of LOR107 mutant (R259N) with tetrasaccharide substrate
6BYT	;	2.2	;	Complex structure of LOR107 mutant (R320) with tetrasaccharide substrate
4FWF	;	2.7	;	Complex structure of LSD2/AOF1/KDM1b with H3K4 mimic
3KFC	;	2.4	;	Complex Structure of LXR with an agonist
7YMR	;	2.69	;	Complex structure of lysoplasmalogen specific phopholipase D, F211L mutant with LPC
5LEO	;	1.6	;	Complex structure of lysostaphin SH3b domain with peptidoglycan fragment
6J5D	;	1.8	;	Complex structure of MAb 4.2-scFv with louping ill virus envelope protein Domain III
6J5G	;	3.291	;	Complex structure of MAb 4.2-scFv with tick-borne encephalitis virus envelope protein
6J5F	;	1.801	;	Complex structure of MAb 4.2-scFv with tick-borne encephalitis virus envelope protein Domain III
6ISC	;	2.2	;	complex structure of mCD226-ecto and hCD155-D1
4KR0	;	2.702	;	Complex structure of MERS-CoV spike RBD bound to CD26
5DO2	;	2.409	;	Complex structure of MERS-RBD bound with 4C2 antibody
4GAM	;	2.902	;	Complex structure of Methane monooxygenase hydroxylase and regulatory subunit
7S6S	;	1.98	;	Complex structure of Methane monooxygenase hydroxylase and regulatory subunit DBL1
7S6Q	;	1.96	;	Complex structure of Methane monooxygenase hydroxylase and regulatory subunit DBL2
7S7H	;	2.4	;	Complex structure of Methane monooxygenase hydroxylase and regulatory subunit DBL2
7S6T	;	1.82	;	Complex structure of Methane monooxygenase hydroxylase and regulatory subunit H33A
7M8Q	;	2.08	;	Complex structure of Methane monooxygenase hydroxylase and regulatory subunit with fluorosubstituted tryptophans
7M8R	;	2.22	;	Complex structure of Methane monooxygenase hydroxylase and regulatory subunit with fluorosubstituted tryptophans
7S6R	;	1.89	;	Complex structure of Methane monooxygenase hydroxylase and regulatory subunit with H5A mutation
6D7K	;	2.6	;	Complex structure of Methane monooxygenase hydroxylase in complex with inhibitory subunit
7W9G	;	2.5	;	Complex structure of Mpro with ebselen-derivative inhibitor
4U5K	;	2.65	;	Complex structure of mutant CtCel5E (E314A) with cellobiose
4U5I	;	2.5	;	Complex structure of mutant CtCel5E (E314A) with xylobiose
2N13	;		;	Complex structure of MyUb (1080-1122) of human Myosin VI with K63-diUb
4F8Y	;	1.796	;	Complex structure of NADPH:quinone oxidoreductase with menadione in Streptococcus mutans
4H5S	;	1.7	;	Complex structure of Necl-2 and CRTAM
4GJT	;	3.1001	;	complex structure of nectin-4 bound to MV-H
7YOO	;	3.11	;	Complex structure of Neuropeptide Y Y2 receptor in complex with NPY and Gi
7YON	;	2.95	;	Complex structure of Neuropeptide Y Y2 receptor in complex with PYY(3-36) and Gi
5Y1Y	;	1.912	;	Complex structure of nitroxoline with the first bromodomain of BRD4
5CL1	;	3.8	;	Complex structure of Norrin with human Frizzled 4
7N4Z	;	2.21	;	Complex structure of NOS4 with noscapine
4IP3	;	2.3	;	Complex structure of OspI and Ubc13
5EE3	;	2.9	;	COMPLEX STRUCTURE OF OSYCHF1 WITH AMP-PNP
5EE9	;	2.75	;	Complex structure of OSYCHF1 with GMP-PNP
6F55	;		;	Complex structure of PACSIN SH3 domain and TRPV4 proline rich region
7N53	;	1.6	;	Complex structure of PAP4 with papaverine
7CMW	;	2.7	;	Complex structure of PARP1 catalytic domain with pamiparib
1WUG	;		;	complex structure of PCAF bromodomain with small chemical ligand NP1
1WUM	;		;	Complex structure of PCAF bromodomain with small chemical ligand NP2
5YCO	;	2.199	;	Complex structure of PCNA with UHRF2
4ZM4	;	2.4	;	Complex structure of PctV K276R mutant with PMP and 3-dehydroshkimate
5WT9	;	2.401	;	Complex structure of PD-1 and nivolumab-Fab
7CGW	;	3.2	;	Complex structure of PD-1 and tislelizumab Fab
7VUX	;	1.64	;	Complex structure of PD1 and 609A-Fab
7WEG	;	2.0	;	Complex structure of PDZD7 and FCHSD2
4ZUH	;	2.394	;	Complex structure of PEDV 3CLpro mutant (C144A) with a peptide substrate.
5ZQG	;	1.6	;	Complex structure of PEDV 3CLpro mutant (C144A) with NEMO-231 peptite substrate
6L70	;	1.56	;	Complex structure of PEDV 3CLpro with GC376
1N5Z	;	2.7	;	Complex structure of Pex13p SH3 domain with a peptide of Pex14p
6WAT	;	1.8	;	complex structure of PHF1
6WAU	;	1.75	;	Complex structure of PHF19
4Y6K	;	3.855	;	Complex structure of presenilin homologue PSH bound to an inhibitor
2VCQ	;	1.95	;	Complex structure of prostaglandin D2 synthase at 1.95A.
2VCW	;	1.95	;	Complex structure of prostaglandin D2 synthase at 1.95A.
2VCZ	;	1.95	;	Complex structure of prostaglandin D2 synthase at 1.95A.
2VCX	;	2.1	;	Complex structure of prostaglandin D2 synthase at 2.1A.
2VD1	;	2.25	;	Complex structure of prostaglandin D2 synthase at 2.25A.
2VD0	;	2.2	;	Complex structure of prostaglandin D2 synthase at 2.2A.
4OD7	;	1.597	;	Complex structure of Proteus mirablis DsbA (C30S) with a non-covalently bound peptide PWATCDS
6IF3	;	1.5	;	Complex structure of Rab35 and its effector ACAP2
6IF2	;	2.4	;	Complex structure of Rab35 and its effector RUSC2
5XU5	;	2.02	;	Complex structure of RmMan134A-M4
8GXP	;	2.45	;	Complex structure of RORgama with betulinic acid
7N4W	;	1.64	;	Complex structure of ROTU4 with rotundine
3T7K	;	2.028	;	Complex structure of Rtt107p and phosphorylated histone H2A
7DWH	;	3.1	;	Complex structure of SAM-dependent methyltransferase ribozyme
2Z9J	;	1.95	;	Complex structure of SARS-CoV 3C-like protease with EPDTC
2Z9L	;	2.1	;	complex structure of SARS-CoV 3C-like protease with JMF1586
2Z9K	;	1.85	;	Complex structure of SARS-CoV 3C-like protease with JMF1600
2Z9G	;	1.86	;	Complex structure of SARS-CoV 3C-like protease with PMA
2Z94	;	1.78	;	Complex structure of SARS-CoV 3C-like protease with TDT
2ZU4	;	1.93	;	Complex structure of SARS-CoV 3CL protease with TG-0204998
2ZU5	;	1.65	;	complex structure of SARS-CoV 3CL protease with TG-0205486
7C8R	;	2.3	;	Complex Structure of SARS-CoV-2 3CL Protease with TG-0203770
7C8T	;	2.05	;	Complex Structure of SARS-CoV-2 3CL Protease with TG-0205221
7BQG	;	1.55011	;	Complex structure of SAV1 and Dendrin
7V3D	;	2.28	;	Complex structure of serine hydroxymethyltransferase from Enterococcus faecium and its inhibitor
3MP6	;	1.48	;	Complex Structure of Sgf29 and dimethylated H3K4
3MP1	;	2.6	;	Complex structure of Sgf29 and trimethylated H3K4
7BNI	;	1.31	;	Complex structure of SH3b domain with 2-hydroxybenzoic acid
7BNG	;	1.47	;	Complex structure of SH3b domain with L-canavanine
3L0I	;	2.85	;	Complex structure of SidM/DrrA with the wild type Rab1
7EYS	;	1.95	;	Complex structure of SptF with Fe, alpha-ketoglutarate, and andiconin D
5WTB	;	3.3	;	Complex Structure of Staphylococcus aureus SdrE with human complement factor H
2R66	;	2.8	;	Complex Structure of Sucrose Phosphate Synthase (SPS)-F6P of Halothermothrix orenii
2R68	;	2.4	;	Complex Structure of Sucrose Phosphate Synthase (SPS)-S6P of Halothermothrix orenii
2V9W	;	3.0	;	Complex structure of Sulfolobus solfataricus DPO4 and DNA duplex containing a hydrophobic thymine isostere 2,4-difluorotoluene nucleotide in the template strand
2VA2	;	2.8	;	Complex structure of Sulfolobus solfataricus DPO4 and DNA duplex containing a hydrophobic thymine isostere 2,4-difluorotoluene nucleotide in the template strand
2VA3	;	2.98	;	Complex structure of Sulfolobus solfataricus DPO4 and DNA duplex containing a hydrophobic thymine isostere 2,4-difluorotoluene nucleotide in the template strand
3IMA	;	2.03	;	Complex structure of tarocystatin and papain
7FAX	;	1.8	;	Complex structure of TbLeo1 and LW domain from Trypanosoma brucei
1G9Q	;	2.3	;	COMPLEX STRUCTURE OF THE ADPR-ASE AND ITS SUBSTRATE ADP-RIBOSE
5V1D	;	2.799	;	Complex structure of the bovine PERK luminal domain and its substrate peptide
1WTB	;		;	Complex structure of the C-terminal RNA-binding domain of hnRNP D (AUF1) with telomere DNA
1X0F	;		;	Complex structure of the C-terminal RNA-binding domain of hnRNP D(AUF1) with telomeric DNA
2K2Q	;		;	complex structure of the external thioesterase of the Surfactin-synthetase with a carrier domain
5WUU	;	1.724	;	Complex structure of the first bromodomain of BRD4 with an inhibitor that containing a 2H-chromen-2-one ring
5GRS	;	5.4	;	Complex structure of the fission yeast SREBP-SCAP binding domains
5C2J	;	2.5	;	Complex structure of the GAP domain of MgcRacGAP and Cdc42
2W5O	;	2.05	;	Complex structure of the GH93 alpha-L-arabinofuranosidase of Fusarium graminearum with arabinobiose
6IIR	;	2.2	;	Complex structure of the HRP3 PWWP domain with a 10-bp GC-rich DNA
6IIQ	;	1.85	;	Complex structure of the HRP3 PWWP domain with a 16-bp TA-rich DNA
6IIT	;	2.1	;	Complex structure of the HRP3 PWWP domain with both a 16-bp TA-rich DNA and an H3K36me2-containing histone peptide
6IIS	;	2.358	;	Complex structure of the HRP3 PWWP domain with both a 16-bp TA-rich DNA and an H3K36me3-containing histone peptide
2XFM	;		;	Complex structure of the MIWI Paz domain bound to methylated single stranded RNA
6J7M	;	2.301	;	Complex structure of the Pseudomonas aeruginosa rhamnosyltransferase EarP with the acceptor elongation factor EF-P
2RR4	;		;	Complex structure of the zf-CW domain and the H3K4me3 peptide
4XSE	;	3.1	;	Complex structure of thymidylate synthase from varicella zoster virus
4XSD	;	2.9	;	Complex structure of thymidylate synthase from varicella zoster virus with a dUMP
4XSC	;	2.901	;	Complex structure of thymidylate synthase from varicella zoster virus with a phosphorylated BVDU
8FMT	;	2.8	;	Complex structure of TnnT-R205L Troponin complex
6JBT	;	2.47	;	Complex structure of toripalimab-Fab and PD-1
7MK9	;	3.54	;	Complex structure of trailing EC of EC+EC (trailing EC-focused)
7CE1	;	3.2	;	Complex STRUCTURE OF TRANSCRIPTION FACTOR SghR with its COGNATE DNA
5H1T	;	1.951	;	Complex structure of TRIM24 PHD-bromodomain and inhibitor 1
5H1U	;	1.901	;	Complex structure of TRIM24 PHD-bromodomain and inhibitor 2
5H1V	;	2.002	;	Complex structure of TRIM24 PHD-bromodomain and inhibitor 6
2EJU	;	1.95	;	Complex structure of Trm1 from Pyrococcus horikoshii with S-adenosyl-L-Homocystein
2YTZ	;	2.65	;	Complex structure of Trm1 from Pyrococcus horikoshii with S-adenosyl-L-Homocystein in the orthorhombic crystal-lattice
2EJT	;	2.2	;	Complex structure of Trm1 from Pyrococcus horikoshii with S-adenosyl-L-Methionine
3AXT	;	2.491	;	Complex structure of tRNA methyltransferase Trm1 from Aquifex aeolicus with S-adenosyl-L-Methionine
3AXS	;	2.162	;	Complex structure of tRNA methyltransferase Trm1 from Aquifex aeolicus with sinefungin
4M5F	;	2.5	;	complex structure of Tse3-Tsi3
7D1L	;	1.95	;	complex structure of two RRM domains
7C1M	;		;	Complex structure of tyrosinated alpha-tubulin carboxy-terminal peptide and A1aY1 binder
6D3U	;	2.21	;	Complex structure of Ulvan lyase from Nonlaben Ulvanivorans- NLR48
3WV5	;	2.2	;	Complex structure of VinN with 3-methylaspartate
3WVN	;	2.2	;	Complex structure of VinN with L-aspartate
4Q7J	;	2.9	;	Complex structure of viral RNA polymerase
4FWT	;	3.2	;	Complex structure of viral RNA polymerase form III
3VNU	;	3.2	;	Complex structure of viral RNA polymerase I
3VNV	;	2.604	;	Complex structure of viral RNA polymerase II
6RJM	;	2.112	;	Complex structure of virulence factor SghA and its hydrolysis product glucose
6RK2	;	2.09	;	Complex structure of virulence factor SghA mutant with its substrate SAG
6RJO	;	1.804	;	Complex structure of virulence factor SghA with its substrate analog salicin
6ONO	;	1.85	;	Complex structure of WhiB1 and region 4 of SigA in C2221 space group
6ONU	;	1.85	;	Complex structure of WhiB1 and region 4 of SigA in P21 space group.
8CWT	;	1.35	;	Complex structure of WhiB3 and the SigmaAr4-RNAP Beta flap tip chimera in space group P43212
8CWR	;	1.5	;	Complex structure of WhiB3 and the SigmaAr4-RNAP Beta flap tip chimera in space group R3
6KZ1	;	1.694	;	Complex structure of Whirlin and Myosin XVa
8FMM	;	3.112	;	Complex structure of wild type Troponin complex
2X0E	;	2.81	;	Complex structure of WsaF with dTDP
2RSF	;		;	Complex structure of WWE in RNF146 with ATP
1XL3	;	2.2	;	Complex structure of Y.pestis virulence Factors YopN and TyeA
8FSR	;	1.78	;	Complex Structure of YejA with fMccA
8FSS	;	2.0	;	Complex Structure of YejA-S481A with Microcin C7
5NXU	;	3.0	;	Complex structure with maltose of Providencia stuartii Omp-Pst1 porin
5XUG	;	2.31	;	Complex structure(RmMan134A-M5).
2RNY	;		;	Complex Structures of CBP Bromodomain with H4 ack20 Peptide
2Z59	;		;	Complex Structures of Mouse Rpn13 (22-130aa) and ubiquitin
5OID	;	4.6	;	Complex Trichoplax STIL-NTD:human CEP85 coiled coil domain 4
1FGH	;	2.05	;	COMPLEX WITH 4-HYDROXY-TRANS-ACONITATE
6T6C	;	1.25	;	Complex with chitin oligomer of C-type lysozyme from the upper gastrointestinal tract of Opisthocomus hoatzin
5OEX	;	2.0	;	Complex with iodine ion for thiocyanate dehydrogenase from Thioalkalivibrio paradoxus
2UXR	;	2.3	;	Complex with isocitrate and the protein isocitrate dehydrogenase from the psychrophilic bacterium Desulfotalea psychrophila
7O25	;	1.34	;	Complex-B bound [FeFe]-hydrogenase maturase HydE from T. maritima (reaction triggered in the crystal)
7O26	;	1.5	;	Complex-B bound [FeFe]-hydrogenase maturase HydE fromT. Maritima (5'dA + Methionine)
7O1O	;	1.25	;	Complex-B bound [FeFe]-hydrogenase maturase HydE fromT. Maritima (Auxiliary cluster deleted variant)
7O1S	;	1.39	;	Complex-B bound [FeFe]-hydrogenase maturase HydE fromT. Maritima (Wild-type protein)
4JMO	;	1.8	;	Complexe of ARNO Sec7 domain with the protein-protein interaction inhibitor N-(4-hydroxy-2,6-dimethylphenyl)-4-methoxybenzenesulfonamide
4JXH	;	1.47	;	Complexe of ARNO Sec7 domain with the protein-protein interaction inhibitor N-(4-hydroxy-2,6-dimethylphenyl)benzenesulfonamide at pH 8.5
4L5M	;	1.8	;	Complexe of ARNO Sec7 domain with the protein-protein interaction inhibitor N-(4-hydroxy-2,6-dimethylphenyl)benzenesulfonamide at pH6.5
4JWL	;	1.95	;	Complexe of ARNO Sec7 domain with the protein-protein interaction inhibitor N-(4-hydroxy-2,6-dimethylphenyl)benzenesulfonamide at pH7.5
1GT5	;	2.08	;	Complexe of Bovine Odorant Binding Protein with benzophenone
6JDG	;	2.388	;	Complexed crystal structure of PaSSB with ssDNA dT20 at 2.39 angstrom resolution
6IRQ	;	1.91	;	Complexed crystal structure of PaSSB with ssDNA dT25 at 1.91 angstrom resolution
2CC6	;	1.27	;	Complexes of Dodecin with Flavin and Flavin-like Ligands
2CC7	;	1.8	;	Complexes of Dodecin with Flavin and Flavin-like Ligands
2CC8	;	1.9	;	Complexes of Dodecin with Flavin and Flavin-like Ligands
2CC9	;	1.55	;	Complexes of Dodecin with Flavin and Flavin-like Ligands
2CCB	;	1.65	;	Complexes of Dodecin with Flavin and Flavin-like Ligands
2CCC	;	1.7	;	Complexes of Dodecin with Flavin and Flavin-like Ligands
2CIE	;	1.8	;	Complexes of Dodecin with Flavin and Flavin-like Ligands
2CIF	;	2.8	;	Complexes of Dodecin with Flavin and Flavin-like Ligands
2CJC	;	1.85	;	Complexes of Dodecin with Flavin and Flavin-like Ligands
2VKF	;	1.7	;	COMPLEXES OF DODECIN WITH FLAVIN AND FLAVIN-LIKE LIGANDS
2VKG	;	1.8	;	COMPLEXES OF DODECIN WITH FLAVIN AND FLAVIN-LIKE LIGANDS
4B2H	;	1.6	;	COMPLEXES OF DODECIN WITH FLAVIN AND FLAVIN-LIKE LIGANDS
4B2J	;	1.9	;	COMPLEXES OF DODECIN WITH FLAVIN AND FLAVIN-LIKE LIGANDS
4B2K	;	1.7	;	COMPLEXES OF DODECIN WITH FLAVIN AND FLAVIN-LIKE LIGANDS
4B2M	;	2.0	;	COMPLEXES OF DODECIN WITH FLAVIN AND FLAVIN-LIKE LIGANDS
4ANU	;	2.81	;	Complexes of PI3Kgamma with isoform selective inhibitors.
4ANV	;	2.13	;	Complexes of PI3Kgamma with isoform selective inhibitors.
4ANW	;	2.31	;	Complexes of PI3Kgamma with isoform selective inhibitors.
4ANX	;	2.73	;	Complexes of PI3Kgamma with isoform selective inhibitors.
1WQZ	;	3.0	;	Complicated water orientations in the minor groove of B-DNA decamer D(CCATTAATGG)2 observed by neutron diffraction measurements
1HQI	;		;	COMPONENT P2 FROM THE MULTICOMPONENT PHENOL HYDROXYLASE, NMR, 11 STRUCTURES
1T1O	;	12.0	;	Components of the control 70S ribosome to provide reference for the RRF binding site
8EMM	;	2.1	;	Composite 70S ribosome structure for ""Atomistic simulations of the E. coli ribosome provide selection criteria for translationally active substrates
6V8I	;	3.7	;	Composite atomic model of the Staphylococcus aureus phage 80alpha baseplate
8HY0	;	3.1	;	Composite cryo-EM structure of the histone deacetylase complex Rpd3S in complex with nucleosome
8F5Z	;	3.2	;	Composite map of CryoEM structure of Arabidopsis thaliana phytochrome A
7WF3	;	3.4	;	Composite map of human Kv1.3 channel in apo state with beta subunits
7WF4	;	3.4	;	Composite map of human Kv1.3 channel in dalazatide-bound state with beta subunits
7TN2	;	2.3	;	Composite model of a Chd1-nucleosome complex in the nucleotide-free state derived from 2.3A and 2.7A Cryo-EM maps
6Z7P	;	4.8	;	Composite model of the Caulobacter crescentus S-layer bound to the O-antigen of lipopolysaccharide
8CS9	;	2.74	;	Composite reconstruction of Class 1 of the erythrocyte ankyrin-1 complex
7Z8F	;	20.0	;	Composite structure of dynein-dynactin-BICDR on microtubules
8PTK	;	10.0	;	Composite structure of Dynein-Dynactin-JIP3-LIS1
7MEI	;	3.54	;	Composite structure of EC+EC
7N5D	;	2.8	;	Composite Structure of Mechanosensitive Ion Channel Flycatcher1 in GDN
5O8C	;	1.7	;	Composite structure of rsEGFP2 1ps following 400nm-laser irradiation of the off-state.
7TBM	;	37.0	;	Composite structure of the dilated human nuclear pore complex (NPC) generated with a 37A in situ cryo-ET map of CD4+ T cell NPC
7TBK	;	37.0	;	Composite structure of the dilated human nuclear pore complex (NPC) symmetric core generated with a 37A in situ cryo-ET map of CD4+ T cell NPC
7TBL	;	23.0	;	Composite structure of the human nuclear pore complex (NPC) cytoplasmic face generated with a 12A cryo-ET map of the purified HeLa cell NPC
7TBJ	;	23.0	;	Composite structure of the human nuclear pore complex (NPC) symmetric core generated with a 12A cryo-ET map of the purified HeLa cell NPC
5IJN	;	21.4	;	Composite structure of the inner ring of the human nuclear pore complex (32 copies of Nup205)
7TBI	;	25.0	;	Composite structure of the S. cerevisiae nuclear pore complex (NPC)
8F78	;	2.65	;	Compound 1 bound to procaspase-6
5ENM	;	1.98	;	Compound 10
8F99	;	2.86	;	Compound 10 bound to procaspase-6
8F9A	;	2.55	;	Compound 11 bound to procaspase-6
5ENK	;	2.11	;	Compound 18
8F9B	;	2.65	;	Compound 19 bound to procaspase-6
6OB0	;	2.81	;	Compound 2 bound structure of WT Lipoprotein Lipase in Complex with GPIHBP1 Mutant N78D N82D produced in HEK293-F cells
7ZYR	;	1.85	;	Compound 20 Bound to CK2alpha
8F9C	;	2.8	;	Compound 20 bound to procaspase-6
4HLE	;	2.78	;	Compound 21 (1-alkyl-substituted 1,2,4-triazoles)
8F9D	;	2.65	;	Compound 21 bound to procaspase-6
8F96	;	2.95	;	Compound 3 bound to procaspase-6
8F97	;	2.32	;	Compound 5 bound to procaspase-6
8FBV	;	2.86	;	Compound 7 bound to procaspase-6
8F98	;	2.7	;	Compound 8 bound to procaspase-6
7ZYK	;	1.31	;	Compound 9 Bound to CK2alpha
7ZYO	;	1.58	;	Compound 9 Bound to CK2alpha
5JAD	;	2.05	;	Compound binding to Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2)discovered through fragment screening
1MQF	;	2.5	;	Compound I from Proteus mirabilis catalase
1GWF	;	1.96	;	Compound II structure of Micrococcus Lysodeikticus catalase
7E14	;	2.9	;	Compound2_GLP-1R_OWL833_Gs complex structure
5THQ	;	2.3	;	Comprehensive Analysis of a Novel Ketoreductase for Pentangular Polyphenol Biosynthesis
5TII	;	2.6	;	Comprehensive Analysis of a Novel Ketoreductase for Pentangular Polyphenol Biosynthesis
5G1Q	;	2.84	;	Compressed conformation of Francisella tularensis ClpP at 2.84 A
7S65	;	3.2	;	Compressed conformation of nighttime state KaiC
1A1P	;		;	COMPSTATIN, NMR, 21 STRUCTURES
2HP4	;	2.1	;	Computational design and crystal structure of an enhanced affinity mutant human CD8-alpha-alpha co-receptor
4NDL	;	3.5	;	Computational design and experimental verification of a symmetric homodimer
2MG4	;		;	Computational design and experimental verification of a symmetric protein homodimer
5EIL	;	2.25	;	Computational design of a high-affinity metalloprotein homotrimer containing a metal chelating non-canonical amino acid
3V86	;	2.91	;	Computational Design of a Protein Crystal
2LLE	;		;	Computational design of an eight-stranded (beta/alpha)-barrel from fragments of different folds
4IWW	;	2.3	;	Computational Design of an Unnatural Amino Acid Metalloprotein with Atomic Level Accuracy
4IX0	;	2.5	;	Computational Design of an Unnatural Amino Acid Metalloprotein with Atomic Level Accuracy
4QTR	;	3.2	;	Computational design of co-assembling protein-DNA nanowires
7KXS	;	2.6	;	Computational design of constitutively active cGAS
7LZ3	;	2.18	;	Computational design of constitutively active cGAS
8EJA	;	2.81	;	Computational design of potent and selective inhibitors of Bak and Bax
5K7V	;	3.165	;	Computational Design of Self-Assembling Cyclic Protein Homooligomers
5KBA	;	2.601	;	Computational Design of Self-Assembling Cyclic Protein Homooligomers
8A9Q	;	2.0	;	Computational design of stable mammalian serum albumins for bacterial expression
8V2D	;	6.77	;	Computational Designed Nanocage O43_129
8V3B	;	6.4	;	Computational Designed Nanocage O43_129_+4
6U07	;	1.76	;	Computational Stabilization of T Cell Receptor Constant Domains
3E0L	;	2.37	;	Computationally Designed Ammelide Deaminase
6VEH	;	2.303	;	Computationally designed C3-symmetric homotrimer from HEAT repeat protein
6V8E	;	2.53	;	Computationally designed C3-symmetric homotrimer from TPR repeat protein
5HRY	;	2.0	;	Computationally Designed Cyclic Dimer ank3C2_1
5HS0	;	2.4	;	Computationally Designed Cyclic Tetramer ank1C4_7
3MFC	;	1.7	;	Computationally designed end0-1,4-beta,xylanase
3MF6	;	1.28	;	Computationally designed endo-1,4-beta-xylanase
3MF9	;	1.7	;	Computationally designed endo-1,4-beta-xylanase
3MFA	;	1.63	;	Computationally designed endo-1,4-beta-xylanase
5TVY	;	1.0	;	Computationally Designed Fentanyl Binder - Fen49
5TVV	;	1.79	;	Computationally Designed Fentanyl Binder - Fen49* Apo
5TZO	;	1.67	;	Computationally Designed Fentanyl Binder - Fen49*-Complex
5N7W	;	1.96	;	Computationally designed functional antibody
5VLI	;	1.799	;	Computationally designed inhibitor peptide HB1.6928.2.3 in complex with influenza hemagglutinin (A/PuertoRico/8/1934)
5BYO	;	2.503	;	Computationally designed left-handed alpha/alpha toroid with 12 repeats
4YY2	;	1.854	;	Computationally designed left-handed alpha/alpha toroid with 3 repeats in space group P212121
4YY5	;	2.78	;	Computationally designed left-handed alpha/alpha toroid with 3 repeats in space group P43212
4YXX	;	2.18	;	Computationally designed left-handed alpha/alpha toroid with 6 repeats
4YXZ	;	2.496	;	Computationally designed left-handed alpha/alpha toroid with 9 repeats
4YXY	;	3.203	;	Computationally designed left-handed alpha/alpha toroid with 9 repeats; two linked rings of 12 repeats each structure
7UCP	;	0.85	;	computationally designed macrocycle
6DVK	;	2.55	;	Computationally designed mini tetraloop-tetraloop receptor by the RNAMake program - construct 6 (miniTTR 6)
1PSV	;		;	COMPUTATIONALLY DESIGNED PEPTIDE WITH A BETA-BETA-ALPHA FOLD SELECTION, NMR, 32 STRUCTURES
6XR2	;	3.2	;	Computationally designed right-handed alpha/alpha homotrimeric toroid with 3 repeats per subunit
6XR1	;	2.1	;	Computationally designed right-handed alpha/alpha single-chain toroid with 9 repeats
4DDF	;	3.15	;	Computationally Designed Self-assembling Octahedral Cage protein, O333, Crystallized in space group P4
3VCD	;	2.35	;	Computationally Designed Self-assembling Octahedral Cage protein, O333, Crystallized in space group R32
4DCL	;	3.35	;	Computationally Designed Self-assembling tetrahedron protein, T308, Crystallized in space group F23
4EGG	;	2.21	;	Computationally Designed Self-assembling tetrahedron protein, T310
5KWD	;	2.75	;	Computationally Designed Symmetric Homotetramer
5J7D	;	2.4	;	Computationally Designed Thioredoxin dF106
7Q3J	;	1.9	;	Computationally designed thioredoxin subjected to stability optimizing mutations.
7Q3K	;	2.25	;	Computationally designed thioredoxin subjected to stability optimizing mutations.
4TQL	;	2.8	;	Computationally designed three helix bundle
3TDM	;	2.4	;	Computationally designed TIM-barrel protein, HalfFLR
5HRZ	;	2.15	;	Computationally Designed Trimer 1na0C3_3
7RKC	;	2.35	;	Computationally designed tunable C2 symmetric tandem repeat homodimer, D_3_633
4NWN	;	4.5	;	Computationally Designed Two-Component Self-Assembling Tetrahedral Cage T32-28
4NWO	;	2.8	;	Computationally Designed Two-Component Self-Assembling Tetrahedral Cage T33-15
4NWR	;	3.5	;	Computationally Designed Two-Component Self-Assembling Tetrahedral Cage T33-28
4NWQ	;	2.8	;	Computationally Designed Two-Component Self-Assembling Tetrahedral Cage, T33-21, Crystallized in Space Group F4132
4NWP	;	2.1	;	Computationally Designed Two-Component Self-Assembling Tetrahedral Cage, T33-21, Crystallized in Space Group R32
3TDN	;	1.4	;	Computationally designed two-fold symmetric Tim-barrel protein, FLR
6OB5	;	2.208	;	Computationally-designed, modular sense/response system (S3-2D)
5TJD	;	2.1	;	Computer-based rational design of improved functionality for antibody catalysts toward organophosphorus compounds
3B83	;	2.4	;	Computer-Based Redesign of a beta Sandwich Protein Suggests that Extensive Negative Design Is Not Required for De Novo beta Sheet Design.
7XGI	;	2.0	;	COMT SAH Mg opicapone complex
6VEQ	;	3.25	;	Con-Ins G1 in complex with the human insulin microreceptor in turn in complex with Fv 83-7
5KKM	;		;	Con-Vc11-22
1JBC	;	1.15	;	CONCANAVALIN A
1NLS	;	0.94	;	CONCANAVALIN A AND ITS BOUND SOLVENT AT 0.94A RESOLUTION
7MGB	;	2.45	;	Concanavalin A bound to a DNA glycoconjugate, A(Man-T)AT
7MGC	;	2.92	;	Concanavalin A bound to a DNA glycoconjugate, G(Man-T)AC
7MGA	;	2.0	;	Concanavalin A bound to a DNA glycoconjugate, Man-AAATTT
7MG6	;	1.7	;	Concanavalin A bound to a DNA glycoconjugate, Man-AGCT
7MG5	;	2.1	;	Concanavalin A bound to a DNA glycoconjugate, Man-ATAT
7MG8	;	3.0	;	Concanavalin A bound to a DNA glycoconjugate, Man-CGCG
7MG7	;	1.75	;	Concanavalin A bound to a DNA glycoconjugate, Man-GTAC
7MGD	;	2.05	;	Concanavalin A bound to a DNA glycoconjugate, T(Man-T)TT
7MG9	;	2.55	;	Concanavalin A bound to DNA glycoconjugates, Man-TTTT and Man-AAAA
1CJP	;	2.78	;	CONCANAVALIN A COMPLEX WITH 4'-METHYLUMBELLIFERYL-ALPHA-D-GLUCOPYRANOSIDE
1VAL	;	3.0	;	CONCANAVALIN A COMPLEX WITH 4'-NITROPHENYL-ALPHA-D-GLUCOPYRANOSIDE
1VAM	;	2.75	;	CONCANAVALIN A COMPLEX WITH 4'-NITROPHENYL-ALPHA-D-MANNOPYRANOSIDE
3D4K	;	1.8	;	Concanavalin A Complexed to a Synthetic Analog of the Trimannoside
1BXH	;	2.75	;	CONCANAVALIN A COMPLEXED TO METHYL ALPHA1-2 MANNOBIOSIDE
1CVN	;	2.3	;	CONCANAVALIN A COMPLEXED TO TRIMANNOSIDE
1GIC	;	2.0	;	CONCANAVALIN A COMPLEXED WITH METHYL ALPHA-D-GLUCOPYRANOSIDE
7MG4	;	2.0	;	Concanavalin A crystallized in the presence of Gal-ATAT
7MG3	;	1.6	;	Concanavalin A crystallized in the presence of H2N-ATAT
7MG2	;	1.8	;	Concanavalin A crystallized in the presence of Man-8
7MG1	;	2.0	;	Concanavalin A crystallized without DNA glycoconjugate
6GW9	;	2.1	;	Concanavalin A structure determined with data from the EuXFEL, the first MHz free electron laser
1GKB	;	1.56	;	CONCANAVALIN A, NEW CRYSTAL FORM
1JUI	;	2.75	;	CONCANAVALIN A-CARBOHYDRATE MIMICKING 10-MER PEPTIDE COMPLEX
1I3H	;	1.2	;	CONCANAVALIN A-DIMANNOSE STRUCTURE
1JOJ	;	3.0	;	CONCANAVALIN A-HEXAPEPTIDE COMPLEX
1JYI	;	2.75	;	CONCANAVALIN A/12-MER PEPTIDE COMPLEX
1JYC	;	2.75	;	CONCANAVALIN A/15-mer PEPTIDE COMPLEX
6GWA	;	2.1	;	Concanavalin B structure determined with data from the EuXFEL, the first MHz free electron laser
1AZD	;	3.0	;	CONCANAVALIN FROM CANAVALIA BRASILIENSIS
6RLS	;		;	Concerted dynamics of metallo-base pairs in an A/B-form helical transition (apo species)
6FY6	;		;	Concerted dynamics of metallo-base pairs in an A/B-form helical transition (major species)
6FY7	;		;	Concerted dynamics of metallo-base pairs in an A/B-form helical transition (minor species)
5A6C	;	2.901	;	Concomitant binding of Afadin to LGN and F-actin directs planar spindle orientation
8OEL	;	8.2	;	Condensed RPA-DNA nucleoprotein filament
6YVV	;	7.5	;	Condensin complex from S.cerevisiae ATP-free apo bridged state
6YVU	;	7.5	;	Condensin complex from S.cerevisiae ATP-free apo non-engaged state
5BP1	;	2.203	;	Condensing di-domain (KS-AT) of a mycocerosic acid synthase-like (MAS-like) PKS
2K10	;		;	Confirmational analysis of the broad-spectrum antibacterial peptide, rantuerin-2csa: identification of a full length helix-turn-helix motif
2C7U	;	2.38	;	Conflicting selective forces affect CD8 T-cell receptor contact sites in an HLA-A2 immunodominant HIV epitope.
7DWX	;	8.3	;	Conformation 1 of S-ACE2-B0AT1 ternary complex
8H3M	;	2.48	;	Conformation 1 of SARS-CoV-2 Omicron BA.1 Variant Spike protein complexed with MO1 Fab
7NRS	;	2.68	;	Conformation 1 of straight filament from primary age-related tauopathy brain
8FPC	;	2.78	;	Conformation 1 of the ligand binding domain (LBDconf1) of GluA2 flip Q isoform of AMPA receptor in complex with gain-of-function TARP gamma-2, with 10mM CaCl2, 150mM NaCl, 1mM MgCl2, 330uM CTZ, and 100mM glutamate (Open-CaNaMg)
8JET	;	3.1	;	Conformation 1 of the plant potassium channel SKOR
8H3N	;	2.73	;	Conformation 2 of SARS-CoV-2 Omicron BA.1 Variant Spike protein complexed with MO1 Fab
7NRT	;	2.68	;	Conformation 2 of straight filament from primary age-related tauopathy brain
8FPH	;	3.14	;	Conformation 2 of the ligand binding domain (LBDconf2) of GluA2 flip Q isoform of AMPA receptor in complex with gain-of-function TARP gamma-2, with 10mM CaCl2, 150mM NaCl, 1mM MgCl2, 330uM CTZ, and 100mM glutamate (Open-CaNaMg)
8JEU	;	3.5	;	Conformation 2 of the plant potassium channel SKOR
1ZNA	;	1.5	;	CONFORMATION AND DYNAMICS IN A Z-DNA TETRAMER
1CAP	;	3.0	;	CONFORMATION AND MOLECULAR ORGANIZATION IN FIBERS OF THE CAPSULAR POLYSACCHARIDE FROM ESCHERICHIA COLI M41 MUTANT
1D6V	;	2.0	;	CONFORMATION EFFECTS IN BIOLOGICAL CATALYSIS INTRODUCED BY OXY-COPE ANTIBODY MATURATION
2LBR	;		;	Conformation Effects of Base Modification on the Anticodon Stem-loop of Bacillus subtilis tRNATYR
7XLC	;	5.0	;	conformation II of apo-IGF1R states
1EFS	;		;	CONFORMATION OF A DNA-RNA HYBRID
1KAJ	;		;	CONFORMATION OF AN RNA PSEUDOKNOT FROM MOUSE MAMMARY TUMOR VIRUS, NMR, 1 STRUCTURE
1MRT	;		;	CONFORMATION OF CD-7 METALLOTHIONEIN-2 FROM RAT LIVER IN AQUEOUS SOLUTION DETERMINED BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
2MRT	;		;	CONFORMATION OF CD-7 METALLOTHIONEIN-2 FROM RAT LIVER IN AQUEOUS SOLUTION DETERMINED BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
6TPO	;	1.861	;	Conformation of cd1 nitrite reductase NirS without bound heme d1
2JQS	;		;	Conformation of DIP-AST5 from 2D NMR data
2JQU	;		;	Conformation of DIP-AST8 from 2D NMR data
3IZP	;		;	Conformation of EF-G during translocation
1KES	;	3.0	;	CONFORMATION OF KERATAN SULPHATE
6C4I	;	3.24	;	Conformation of methylated GGQ in the peptidyl transferase center during translation termination
6C4H	;	3.1	;	Conformation of methylated GGQ in the peptidyl transferase center during translation termination (PTC region)
6C5L	;	3.2	;	Conformation of methylated GGQ in the Peptidyl Transferase Center during translation termination (T. thermophilus)
2HQC	;	3.56	;	Conformation of the AcrB Multidrug Efflux Pump in Mutants of the Putative Proton Relay Pathway
2HQD	;	3.65	;	Conformation of the AcrB Multidrug Efflux Pump in Mutants of the Putative Proton Relay Pathway
2HQF	;	3.38	;	Conformation of the AcrB Multidrug Efflux Pump in Mutants of the Putative Proton Relay Pathway
2HQG	;	3.38	;	Conformation of the AcrB Multidrug Efflux Pump in Mutants of the Putative Proton Relay Pathway
1D75	;	2.8	;	CONFORMATION OF THE GUANINE.8-OXOADENINE BASE PAIRS IN THE CRYSTAL STRUCTURE OF D(CGCGAATT(O8A)GCG)
1ALE	;		;	CONFORMATION OF TWO PEPTIDES CORRESPONDING TO HUMAN APOLIPOPROTEIN C-I RESIDUES 7-24 AND 35-53 IN THE PRESENCE OF SODIUM DODECYLSULFATE BY CD AND NMR SPECTROSCOPY
1ALF	;		;	CONFORMATION OF TWO PEPTIDES CORRESPONDING TO HUMAN APOLIPOPROTEIN C-I RESIDUES 7-24 AND 35-53 IN THE PRESENCE OF SODIUM DODECYLSULFATE BY CD AND NMR SPECTROSCOPY
1Y4S	;	2.9	;	Conformation rearrangement of heat shock protein 90 upon ADP binding
1Y4U	;	2.9	;	Conformation rearrangement of heat shock protein 90 upon ADP binding
5C4L	;	2.35	;	Conformational alternate of sisomicin in complex with APH(2"")-IVa
2LTJ	;		;	Conformational analysis of StrH, the surface-attached exo- beta-D-N-acetylglucosaminidase from Streptococcus pneumoniae
2L5R	;		;	Conformational and membrane interactins studies of antimicrobial peptide Alyteserin-1C
1ZE1	;	2.9	;	Conformational Change of Pseudouridine 55 Synthase upon Its Association with RNA Substrate
1ZE2	;	3.0	;	Conformational change of pseudouridine 55 synthase upon its association with RNA substrate
5JBS	;	1.95	;	Conformational changes during monomer-to-dimer transition of Brucella suis VirB8
6C79	;	1.1	;	Conformational Changes in a Class A Beta lactamase that Prime it for Catalysis
6C7A	;	1.05	;	Conformational Changes in a Class A Beta lactamase that Prime it for Catalysis
1APH	;	2.0	;	CONFORMATIONAL CHANGES IN CUBIC INSULIN CRYSTALS IN THE PH RANGE 7-11
1BPH	;	2.0	;	CONFORMATIONAL CHANGES IN CUBIC INSULIN CRYSTALS IN THE PH RANGE 7-11
1CPH	;	1.9	;	CONFORMATIONAL CHANGES IN CUBIC INSULIN CRYSTALS IN THE PH RANGE 7-11
1DPH	;	1.9	;	CONFORMATIONAL CHANGES IN CUBIC INSULIN CRYSTALS IN THE PH RANGE 7-11
2TUN	;	3.1	;	CONFORMATIONAL CHANGES IN THE (ALA-84-VAL) MUTANT OF TUMOR NECROSIS FACTOR
2YJ3	;	2.2	;	Conformational changes in the catalytic domain of the CPx-ATPase CopB- B upon nucleotide binding
2YJ4	;	2.4	;	Conformational changes in the catalytic domain of the CPx-ATPase CopB- B upon nucleotide binding
2YJ5	;	2.4	;	Conformational changes in the catalytic domain of the CPx-ATPase CopB- B upon nucleotide binding
2YJ6	;	2.2	;	Conformational changes in the catalytic domain of the CPx-ATPase CopB- B upon nucleotide binding
1NNO	;	2.65	;	CONFORMATIONAL CHANGES OCCURRING UPON NO BINDING IN NITRITE REDUCTASE FROM PSEUDOMONAS AERUGINOSA
1BL9	;	2.9	;	CONFORMATIONAL CHANGES OCCURRING UPON REDUCTION IN NITRITE REDUCTASE FROM PSEUDOMONAS AERUGINOSA
3BCG	;	2.48	;	Conformational changes of the AcrR regulator reveal a mechanism of induction
4YS0	;	1.897	;	Conformational changes of the clamp of the protein translocation ATPase SecA from Thermotoga maritima
3F6Y	;	1.45	;	Conformational Closure of the Catalytic Site of Human CD38 Induced by Calcium
4AOK	;	1.5	;	Conformational dynamics of aspartate alpha-decarboxylase active site revealed by protein-ligand complexes: 1-methyl-L-aspartate complex
4AON	;	1.5	;	Conformational dynamics of aspartate alpha-decarboxylase active site revealed by protein-ligand complexes: 1-methyl-L-aspartate complex
4F7Z	;	2.6	;	Conformational dynamics of exchange protein directly activated by cAMP
2L0R	;		;	Conformational Dynamics of the Anthrax Lethal Factor Catalytic Center
8IF6	;	7.09	;	Conformational Dynamics of the D53-D3-D14 Complex in Strigolactone Signaling
5O8Y	;	2.3	;	Conformational dynamism for DNA interaction in Salmonella typhimurium RcsB response regulator.
5O8Z	;	2.1	;	Conformational dynamism for DNA interaction in Salmonella typhimurium RcsB response regulator.
6EO2	;	2.6	;	Conformational dynamism for DNA interaction in Salmonella typhimurium RcsB response regulator. S207C crossed
6EO3	;	2.5	;	Conformational dynamism for DNA interaction in Salmonella typhimurium RcsB response regulator. S207C P212121
2LWA	;		;	Conformational ensemble for the G8A mutant of the influenza hemagglutinin fusion peptide
7QLF	;		;	Conformational ensemble of solnatide in solution
2F1M	;	2.71	;	Conformational flexibility in the multidrug efflux system protein AcrA
2CEK	;	2.2	;	Conformational Flexibility in the Peripheral Site of Torpedo californica Acetylcholinesterase Revealed by the Complex Structure with a Bifunctional Inhibitor
1W28	;	2.3	;	Conformational flexibility of the C-terminus with implications for substrate binding and catalysis in a new crystal form of deacetoxycephalosporin C synthase
2BKE	;	3.2	;	Conformational Flexibility Revealed by the Crystal Structure of a Crenarchaeal RadA
1ND7	;	2.1	;	Conformational Flexibility Underlies Ubiquitin Ligation Mediated by the WWP1 HECT domain E3 Ligase
6SLH	;	1.89	;	Conformational flexibility within the small domain of human serine racemase.
1D87	;	2.25	;	CONFORMATIONAL INFLUENCE OF THE RIBOSE 2'-HYDROXYL GROUP: CRYSTAL STRUCTURES OF DNA-RNA CHIMERIC DUPLEXES
1D88	;	2.0	;	CONFORMATIONAL INFLUENCE OF THE RIBOSE 2'-HYDROXYL GROUP: CRYSTAL STRUCTURES OF DNA-RNA CHIMERIC DUPLEXES
1EDP	;		;	CONFORMATIONAL ISOMERISM OF ENDOTHELIN IN ACIDIC AQUEOUS MEDIA: A QUANTITATIVE NOESY ANALYSIS
1TIB	;	1.84	;	CONFORMATIONAL LABILITY OF LIPASES OBSERVED IN THE ABSENCE OF AN OIL-WATER INTERFACE: CRYSTALLOGRAPHIC STUDIES OF ENZYMES FROM THE FUNGI HUMICOLA LANUGINOSA AND RHIZOPUS DELEMAR
1TIC	;	2.6	;	CONFORMATIONAL LABILITY OF LIPASES OBSERVED IN THE ABSENCE OF AN OIL-WATER INTERFACE: CRYSTALLOGRAPHIC STUDIES OF ENZYMES FROM THE FUNGI HUMICOLA LANUGINOSA AND RHIZOPUS DELEMAR
5VGZ	;	4.5	;	Conformational Landscape of the p28-Bound Human Proteasome Regulatory Particle
5VHF	;	5.7	;	Conformational Landscape of the p28-Bound Human Proteasome Regulatory Particle
5VHH	;	6.1	;	Conformational Landscape of the p28-Bound Human Proteasome Regulatory Particle
5VHI	;	6.8	;	Conformational Landscape of the p28-Bound Human Proteasome Regulatory Particle
5VHJ	;	8.5	;	Conformational Landscape of the p28-Bound Human Proteasome Regulatory Particle
5VHM	;	8.3	;	Conformational Landscape of the p28-Bound Human Proteasome Regulatory Particle
5VHN	;	7.3	;	Conformational Landscape of the p28-Bound Human Proteasome Regulatory Particle
5VHO	;	8.3	;	Conformational Landscape of the p28-Bound Human Proteasome Regulatory Particle
5VHP	;	7.9	;	Conformational Landscape of the p28-Bound Human Proteasome Regulatory Particle
5VHQ	;	8.9	;	Conformational Landscape of the p28-Bound Human Proteasome Regulatory Particle
5VHR	;	7.7	;	Conformational Landscape of the p28-Bound Human Proteasome Regulatory Particle
5VHS	;	8.8	;	Conformational Landscape of the p28-Bound Human Proteasome Regulatory Particle
1SSZ	;		;	Conformational Mapping of Mini-B: An N-terminal/C-terminal Construct of Surfactant Protein B Using 13C-Enhanced Fourier Transform Infrared (FTIR) Spectroscopy
1ERF	;		;	CONFORMATIONAL MAPPING OF THE N-TERMINAL FUSION PEPTIDE OF HIV-1 GP41 USING 13C-ENHANCED FOURIER TRANSFORM INFRARED SPECTROSCOPY (FTIR)
1P5A	;		;	Conformational Mapping of the N-terminal Peptide of HIV-1 GP41 in lipid detergent and aqueous environments using 13C-enhanced Fourier Transform Infrared Spectroscopy
1DFW	;		;	CONFORMATIONAL MAPPING OF THE N-TERMINAL SEGMENT OF SURFACTANT PROTEIN B IN LIPID USING 13C-ENHANCED FOURIER TRANSFORM INFRARED SPECTROSCOPY (FTIR)
2GGN	;	1.35	;	Conformational mobility in the active site of a heme peroxidase
2GHC	;	1.25	;	Conformational mobility in the active site of a heme peroxidase
2GHD	;	1.4	;	Conformational mobility in the active site of a heme peroxidase
2GHE	;	1.75	;	Conformational mobility in the active site of a heme peroxidase
2GHH	;	2.013	;	Conformational mobility in the active site of a heme peroxidase
2GHK	;	1.999	;	Conformational mobility in the active site of a heme peroxidase
5CA2	;	2.1	;	CONFORMATIONAL MOBILITY OF HIS-64 IN THE THR-200 (RIGHT ARROW) SER MUTANT OF HUMAN CARBONIC ANHYDRASE II
1CE4	;		;	CONFORMATIONAL MODEL FOR THE CONSENSUS V3 LOOP OF THE ENVELOPE PROTEIN GP120 OF HIV-1
3MPA	;	2.1	;	Conformational plasticity of p38 MAP kinase DFG motif mutants in response to inhibitor binding
3O8P	;	2.1	;	Conformational plasticity of p38 MAP kinase DFG motif mutants in response to inhibitor binding
3O8U	;	2.1	;	Conformational plasticity of p38 MAP kinase DFG motif mutants in response to inhibitor binding
3OC1	;	2.59	;	Conformational plasticity of p38 MAP kinase DFG motif mutants in response to inhibitor binding
3OBG	;	2.8	;	Conformational plasticity of p38 MAP kinase DFG mutants in response to inhibitor binding
3OBJ	;	2.4	;	Conformational plasticity of p38 MAP kinase DFG mutants in response to inhibitor binding
3O8T	;	2.0	;	Conformational plasticity of p38 MAP kinase DFG-motif mutants in response to inhibitor binding
3IAO	;	2.8	;	Conformational plasticity of the coiled coil domain of BmrR is required for bmr promoter binding-the unliganded structure of BmrR
1XH3	;	1.48	;	Conformational Restraints and Flexibility of 14-Meric Peptides in Complex with HLA-B*3501
1QX3	;	1.9	;	Conformational restrictions in the active site of unliganded human caspase-3
5T9I	;	2.091	;	Conformational Sampling Differences across the Arrhenius Plot Biphasic Break Point at Ambient Temperature in the Enzyme Thermolysin
5T9K	;	2.1	;	Conformational Sampling Differences across the Arrhenius Plot Biphasic Break Point at Ambient Temperature in the Enzyme Thermolysin
5T9Q	;	2.1	;	Conformational Sampling Differences across the Arrhenius Plot Biphasic Break Point at Ambient Temperature in the Enzyme Thermolysin
5TAC	;	2.04	;	Conformational Sampling Differences across the Arrhenius Plot Biphasic Break Point at Ambient Temperature in the Enzyme Thermolysin
5TAD	;	2.09	;	Conformational Sampling Differences across the Arrhenius Plot Biphasic Break Point at Ambient Temperature in the Enzyme Thermolysin
5TAE	;	2.302	;	Conformational Sampling Differences across the Arrhenius Plot Biphasic Break Point at Ambient Temperature in the Enzyme Thermolysin
5TAI	;	2.301	;	Conformational Sampling Differences across the Arrhenius Plot Biphasic Break Point at Ambient Temperature in the Enzyme Thermolysin
5TAJ	;	2.031	;	Conformational Sampling Differences across the Arrhenius Plot Biphasic Break Point at Ambient Temperature in the Enzyme Thermolysin
5TAK	;	2.003	;	Conformational Sampling Differences across the Arrhenius Plot Biphasic Break Point at Ambient Temperature in the Enzyme Thermolysin
3J3P	;	9.1	;	Conformational Shift of a Major Poliovirus Antigen Confirmed by Immuno-Cryogenic Electron Microscopy: 135S Poliovirus and C3-Fab Complex
3J3O	;	11.1	;	Conformational Shift of a Major Poliovirus Antigen Confirmed by Immuno-Cryogenic Electron Microscopy: 160S Poliovirus and C3-Fab Complex
6O0X	;	3.28	;	Conformational states of Cas9-sgRNA-DNA ternary complex in the presence of magnesium
6O0Y	;	3.37	;	Conformational states of Cas9-sgRNA-DNA ternary complex in the presence of magnesium
6O0Z	;	3.3	;	Conformational states of Cas9-sgRNA-DNA ternary complex in the presence of magnesium
1SRB	;		;	CONFORMATIONAL STUDIES ON SRTB, A NON-SELECTIVE ENDOTHELIN RECEPTOR AGONIST, AND ON IRL 1620, AN ETB RECEPTOR SPECIFIC AGONIST
1T0M	;	2.0	;	Conformational switch in polymorphic H-2K molecules containing an HSV peptide
1T0N	;	1.8	;	Conformational switch in polymorphic H-2K molecules containing an HSV peptide
6ND4	;	4.3	;	Conformational switches control early maturation of the eukaryotic small ribosomal subunit
2GUS	;	1.75	;	Conformational Transition between Four- and Five-stranded Phenylalanine Zippers Determined by a Local Packing Interaction
2GUV	;	1.4	;	Conformational Transition between Four- and Five-stranded Phenylalanine Zippers Determined by a Local Packing Interaction
4FBP	;	2.5	;	CONFORMATIONAL TRANSITION OF FRUCTOSE-1,6-BISPHOSPHATASE: STRUCTURE COMPARISON BETWEEN THE AMP COMPLEX (T FORM) AND THE FRUCTOSE 6-PHOSPHATE COMPLEX (R FORM)
1OEL	;	2.8	;	CONFORMATIONAL VARIABILITY IN THE REFINED STRUCTURE OF THE CHAPERONIN GROEL AT 2.8 ANGSTROM RESOLUTION
1MEC	;	3.2	;	CONFORMATIONAL VARIABILITY OF A PICORNAVIRUS CAPSID: PH-DEPENDENT STRUCTURAL CHANGES OF MENGO VIRUS RELATED TO ITS HOST RECEPTOR ATTACHMENT SITE AND DISASSEMBLY
4EBC	;	2.901	;	Conformationally Restrained North-methanocarba-2'-deoxyadenosine Corrects the Error-Prone Nature of Human DNA Polymerase Iota
4EBD	;	2.571	;	Conformationally Restrained North-methanocarba-2'-deoxyadenosine Corrects the Error-Prone Nature of Human DNA Polymerase Iota
4EBE	;	2.1	;	Conformationally Restrained North-methanocarba-2'-deoxyadenosine Corrects the Error-Prone Nature of Human DNA Polymerase Iota
8Q7J	;		;	Conformations of macrocyclic peptides sampled by exact NOEs: models for cell-permeability
8QAQ	;		;	Conformations of macrocyclic peptides sampled by exact NOEs: models for cell-permeability. Conformation 1 of omphalotin A in apolar solvents.
8QAS	;		;	Conformations of macrocyclic peptides sampled by exact NOEs: models for cell-permeability. NMR structure of Omphalotin A in methanol / water indoleOut conformation.
8QBP	;		;	Conformations of macrocyclic peptides sampled by exact NOEs: models for cell-permeability. NMR structure of Omphalotin A in methanol / water indoleOut conformation.
1CCJ	;	2.1	;	CONFORMER SELECTION BY LIGAND BINDING OBSERVED WITH PROTEIN CRYSTALLOGRAPHY
1WLD	;	1.6	;	Congerin II T88I single mutant
1WLW	;	1.8	;	Congerin II Y16S single mutant
1WLC	;	2.0	;	Congerin II Y16S/T88I double mutant
5CVV	;	1.73	;	coniferyl alcohol bound monolignol 4-O-methyltransferase 9
6XZ1	;	2.3	;	Conjugate of the HECT domain of HUWE1 with ubiquitin
4PCB	;	2.5	;	Conjugative Relaxase TrwC in complex with mutant OriT Dna
1ZM5	;	2.5	;	Conjugative Relaxase TRWC in complex with ORIT dna, cooper-bound structure
1QX0	;	2.26	;	CONJUGATIVE RELAXASE TRWC IN COMPLEX WITH ORIT DNA. METAL-BOUND STRUCTURE
1S6M	;	2.28	;	Conjugative Relaxase Trwc In Complex With Orit DNA. Metal-Bound Structure
1OMH	;	1.95	;	Conjugative Relaxase TrwC in complex with OriT Dna. Metal-free structure.
1OSB	;	2.65	;	Conjugative Relaxase TrwC in complex with OriT Dna. Metal-free structure.
2CA7	;		;	Conkunitzin-S1 Is The First Member Of A New Kunitz-Type Neurotoxin Family- Structural and Functional Characterization
2J6D	;		;	CONKUNITZIN-S2 - CONE SNAIL NEUROTOXIN - DENOVO STRUCTURE
6ZVZ	;	2.3	;	Connectase MJ0548 from Methanocaldococcus jannaschii
6ZW0	;	3.05	;	Connectase MJ0548 from Methanocaldococcus jannaschii in complex with an MtrA-derived peptide
7L96	;		;	Connecting hydrophobic surfaces in cyclic peptides increases membrane permeability
7L98	;		;	Connecting hydrophobic surfaces in cyclic peptides increases membrane permeability
7L9D	;		;	Connecting hydrophobic surfaces in cyclic peptides increases membrane permeability
1FOU	;	3.2	;	CONNECTOR PROTEIN FROM BACTERIOPHAGE PHI29
1JNB	;	3.2	;	CONNECTOR PROTEIN FROM BACTERIOPHAGE PHI29
5KJG	;		;	Connexin 26 G12R mutant NMR structure
5KJ3	;		;	Connexin 26 WT peptide NMR Structure
5KK9	;		;	Connexin 32 G12R N-Terminal Mutant,
1R5S	;		;	Connexin 43 Carboxyl Terminal Domain
5ER7	;	3.286	;	Connexin-26 Bound to Calcium
7Z1T	;	2.26	;	Connexin43 gap junction channel structure in digitonin
7Z22	;	2.95	;	Connexin43 gap junction channel structure in nanodisc
7Z23	;	3.98	;	Connexin43 hemi channel in nanodisc
2LOC	;		;	Conotoxin analogue [D-Ala2]BuIIIB
7PX1	;	2.33	;	Conotoxin from Conus mucronatus
1AG7	;		;	CONOTOXIN GS, NMR, 20 STRUCTURES
7PX2	;	2.12	;	Conotoxin Mu8.1 from Conus mucronatus
2LER	;		;	Conotoxin pc16a
4C75	;	2.2	;	Consensus (ALL-CON) beta-lactamase class A
7BWE	;		;	Consensus Chitin binding domain
7BWO	;		;	Consensus chitin binding protein
8DR1	;	2.14	;	Consensus closed state of RFC:PCNA bound to a 3' ss/dsDNA junction (DNA2)
6DSL	;		;	Consensus engineered intein (Cat) with atypical split site
7CCS	;	6.2	;	Consensus mutated xCT-CD98hc complex
7V0K	;	2.4	;	Consensus refinement of human erythrocyte ankyrin-1 complex (Composite map)
7SI3	;	3.19	;	Consensus structure of ATP7B
7PGS	;	3.4	;	Consensus structure of human Neurofibromin isoform 2
2XKM	;	3.3	;	Consensus structure of Pf1 filamentous bacteriophage from X-ray fibre diffraction and solid-state NMR
6XM0	;	2.7	;	Consensus structure of SARS-CoV-2 spike at pH 5.5
7OBI	;	3.0	;	Consensus tetratricopeptide repeat protein type RV4
7ST3	;	2.78	;	Consequences of HLA single chain trimer mutations on peptide presentation and binding affinity
7STG	;	2.7	;	Consequences of HLA single chain trimer mutations on peptide presentation and binding affinity
149L	;	2.6	;	CONSERVATION OF SOLVENT-BINDING SITES IN 10 CRYSTAL FORMS OF T4 LYSOZYME
150L	;	2.2	;	CONSERVATION OF SOLVENT-BINDING SITES IN 10 CRYSTAL FORMS OF T4 LYSOZYME
151L	;	2.2	;	CONSERVATION OF SOLVENT-BINDING SITES IN 10 CRYSTAL FORMS OF T4 LYSOZYME
152L	;	2.0	;	CONSERVATION OF SOLVENT-BINDING SITES IN 10 CRYSTAL FORMS OF T4 LYSOZYME
5OK7	;	1.34	;	Conservatively refined structure of Gan1D-E170Q, a catalytic mutant of a putative 6-phospho-beta-galactosidase from Geobacillus stearothermophilus
5OKE	;	1.31	;	Conservatively refined structure of Gan1D-E170Q, a catalytic mutant of a putative 6-phospho-beta-galactosidase from Geobacillus stearothermophilus, in complex with cellobiose-6-phosphate
5OKK	;	2.02	;	Conservatively refined structure of Gan1D-WT, a putative 6-phospho-beta-galactosidase from Geobacillus stearothermophilus, in complex with 6-phospho-beta-galactose
5OKR	;	2.15	;	Conservatively refined structure of Gan1D-WT, a putative 6-phospho-beta-galactosidase from Geobacillus stearothermophilus, in complex with 6-phospho-beta-glucose
5OKH	;	1.98	;	Conservatively refined structure of Gan1D-WT, a putative 6-phospho-beta-galactosidase from Geobacillus stearothermophilus, in the C2 spacegroup
7F5W	;	1.654	;	Conserved and divergent strigolactone signaling in Saccharum spontaneum
16VP	;	2.1	;	CONSERVED CORE OF THE HERPES SIMPLEX VIRUS TRANSCRIPTIONAL REGULATORY PROTEIN VP16
2G7Z	;	2.05	;	Conserved DegV-like Protein of Unknown Function from Streptococcus pyogenes M1 GAS Binds Long-chain Fatty Acids
2FPE	;	1.75	;	Conserved dimerization of the ib1 src-homology 3 domain
1EO0	;		;	CONSERVED DOMAIN COMMON TO TRANSCRIPTION FACTORS TFIIS, ELONGIN A, CRSP70
2I7R	;	2.2	;	conserved domain protein
3HVP	;	2.8	;	CONSERVED FOLDING IN RETROVIRAL PROTEASES. CRYSTAL STRUCTURE OF A SYNTHETIC HIV-1 PROTEASE
2XET	;	1.6	;	Conserved hydrophobic clusters on the surface of the Caf1A usher C-terminal domain are important for F1 antigen assembly
2EHW	;	2.22	;	Conserved hypothetical proteim (TTHB059) from Thermo thermophilus HB8
2EJQ	;	2.08	;	Conserved hypothetical protein (TTHA0227) from Thermo thermophilus HB8
1YBX	;	1.8	;	Conserved hypothetical protein Cth-383 from Clostridium thermocellum
1YBY	;	1.95	;	Conserved hypothetical protein Cth-95 from Clostridium thermocellum
1XRG	;	2.2	;	Conserved hypothetical protein from Clostridium thermocellum Cth-2968
1YBZ	;	1.82	;	Conserved hypothetical protein from Pyrococcus furiosus Pfu-1581948-001
1VK1	;	1.2	;	Conserved hypothetical protein from Pyrococcus furiosus Pfu-392566-001
1XX7	;	2.261	;	Conserved hypothetical protein from Pyrococcus furiosus Pfu-403030-001
4WBX	;	2.301	;	Conserved hypothetical protein PF1771 from Pyrococcus furiosus solved by sulfur SAD using Swiss Light Source data
1YD7	;	2.3	;	Conserved hypothetical protein Pfu-1647980-001 from Pyrococcus furiosus
1YB3	;	1.6	;	Conserved hypothetical protein Pfu-178653-001 from Pyrococcus furiosus
1YCY	;	2.8	;	Conserved hypothetical protein Pfu-1806301-001 from Pyrococcus furiosus
1Y82	;	2.3	;	Conserved hypothetical protein Pfu-367848-001 from Pyrococcus furiosus
1Y81	;	1.701	;	Conserved hypothetical protein Pfu-723267-001 from Pyrococcus furiosus
1YEM	;	2.3	;	Conserved hypothetical protein Pfu-838710-001 from Pyrococcus furiosus
1XG7	;	1.88	;	Conserved hypothetical protein Pfu-877259-001 from Pyrococcus furiosus
7OAA	;	1.4	;	conserved hypothetical protein residues 311-335 from Candidatus Magnetomorum sp. HK-1 fused to GCN4 adaptors
7OAC	;	2.15	;	conserved hypothetical protein residues 311-335 from Candidatus Magnetomorum sp. HK-1 fused to GCN4 adaptors, mutant beta1/A, crystal form I
7OAD	;	2.0	;	conserved hypothetical protein residues 311-335 from Candidatus Magnetomorum sp. HK-1 fused to GCN4 adaptors, mutant beta1/A, crystal form II
7OAF	;	1.45	;	conserved hypothetical protein residues 311-335 from Candidatus Magnetomorum sp. HK-1 fused to GCN4 adaptors, mutant beta1/A, crystal form III
7OAH	;	1.694	;	conserved hypothetical protein residues 311-335 from Candidatus Magnetomorum sp. HK-1 fused to GCN4 adaptors, mutant beta2/A
1WCJ	;		;	Conserved Hypothetical Protein TM0487 from Thermotoga maritima
2ESR	;	1.8	;	conserved hypothetical protein- streptococcus pyogenes
4UXO	;	6.3	;	Conserved mechanisms of microtubule-stimulated ADP release, ATP binding, and force generation in transport kinesins
4UXP	;	6.3	;	Conserved mechanisms of microtubule-stimulated ADP release, ATP binding, and force generation in transport kinesins
4UXR	;	7.0	;	Conserved mechanisms of microtubule-stimulated ADP release, ATP binding, and force generation in transport kinesins
4UXS	;	7.0	;	Conserved mechanisms of microtubule-stimulated ADP release, ATP binding, and force generation in transport kinesins
4UXT	;	7.4	;	Conserved mechanisms of microtubule-stimulated ADP release, ATP binding, and force generation in transport kinesins
4UXY	;	6.5	;	Conserved mechanisms of microtubule-stimulated ADP release, ATP binding, and force generation in transport kinesins
4UY0	;	7.7	;	Conserved mechanisms of microtubule-stimulated ADP release, ATP binding, and force generation in transport kinesins
2YGV	;	2.94	;	Conserved N-terminal domain of the yeast Histone Chaperone Asf1 in complex with the C-terminal fragment of Rad53
4LX3	;	1.5	;	Conserved Residues that Modulate Protein trans-Splicing of Npu DnaE Split Intein
1VOP	;		;	CONSERVED RNA COMPONENT OF THE PEPTIDYL TRANSFERASE CENTER, NMR, 33 STRUCTURES
1KP7	;		;	Conserved RNA Structure within the HCV IRES eIF3 Binding Site
8QO2	;	7.1	;	Conserved Structures and Dynamics in 5-Proximal Regions of Betacoronavirus RNA Genomes
8QO3	;	6.6	;	Conserved Structures and Dynamics in 5-Proximal Regions of Betacoronavirus RNA Genomes
8QO4	;	5.9	;	Conserved Structures and Dynamics in 5-Proximal Regions of Betacoronavirus RNA Genomes
8QO5	;	6.5	;	Conserved Structures and Dynamics in 5-Proximal Regions of Betacoronavirus RNA Genomes
6XWW	;		;	Constitutive decay element CDE1 from human 3'UTR
6XXB	;		;	Constitutive decay element CDE1 from human 3'UTR
6XWJ	;		;	Constitutive decay element CDE2 from human 3'UTR
6XXA	;		;	Constitutive decay element CDE2 from human 3'UTR
5C32	;	3.053	;	Constitutively active Sin recombinase cataltyic domain - I100T
5C34	;	2.655	;	Constitutively active Sin recombinase cataltyic domain - I100T/Q115R
5C35	;	2.4	;	Constitutively active Sin recombinase cataltyic domain - T77II100T/Q115R
5C31	;	3.1	;	Constitutively active Sin recombinase catalytic domain reveals two rotational intermediates
2R27	;	2.0	;	Constitutively zinc-deficient mutant of human superoxide dismutase (SOD), C6A, H80S, H83S, C111S
4TXI	;	2.309	;	Construct of MICAL-1 containing the monooxygenase and calponin homology domains
4TXK	;	2.878	;	Construct of MICAL-1 containing the monooxygenase and calponin homology domains
4OPT	;	2.6	;	Constructing tailored isoprenoid products by structure-guided modification of geranylgeranyl reductase
4OPU	;	2.7	;	Constructing tailored isoprenoid products by structure-guided modification of geranylgeranyl reductase
4OPC	;	1.4	;	Constructing tailored isoprenoid products by structure-guided modification of geranylgeranyl reductase.
4OPD	;	1.81	;	Constructing tailored isoprenoid products by structure-guided modification of geranylgeranyl reductase.
4OPG	;	2.07	;	Constructing tailored isoprenoid products by structure-guided modification of geranylgeranyl reductase.
4OPI	;	2.24	;	Constructing tailored isoprenoid products by structure-guided modification of geranylgeranyl reductase.
4OPL	;	2.51	;	Constructing tailored isoprenoid products by structure-guided modification of geranylgeranyl reductase.
1CCE	;	2.3	;	CONSTRUCTION OF A BIS-AQUO HEME ENZYME AND REPLACEMENT WITH EXOGENOUS LIGAND
1CCG	;	2.1	;	CONSTRUCTION OF A BIS-AQUO HEME ENZYME AND REPLACEMENT WITH EXOGENOUS LIGAND
4JD9	;	2.601	;	Contact pathway inhibitor from a sand fly
1X18	;	13.5	;	Contact sites of ERA GTPase on the THERMUS THERMOPHILUS 30S SUBUNIT
8EY3	;	1.0	;	Contact-dependent growth inhibition (CDI) immunity protein from E. coli O32:H37
6CP9	;	2.55	;	Contact-dependent growth inhibition toxin - immunity protein complex from Klebsiella pneumoniae 342
8EY4	;	1.83	;	Contact-dependent growth inhibition toxin-immunity protein complex from E. coli O32:H37
6CP8	;	2.201	;	Contact-dependent growth inhibition toxin-immunity protein complex from from E. coli 3006
6VEK	;	2.25	;	Contact-dependent growth inhibition toxin-immunity protein complex from from E. coli 3006, full-length
5I4Q	;	2.35	;	Contact-dependent inhibition system from Escherichia coli NC101 - ternary CdiA/CdiI/EF-Tu complex (domains 2 and 3)
5I4R	;	3.3	;	Contact-dependent inhibition system from Escherichia coli NC101 - ternary CdiA/CdiI/EF-Tu complex (trypsin-modified)
7M5F	;	1.59	;	Contact-dependent inhibition system from Serratia marcescens BWH57
1CIS	;		;	CONTEXT DEPENDENCE OF PROTEIN SECONDARY STRUCTURE FORMATION. THE THREE-DIMENSIONAL STRUCTURE AND STABILITY OF A HYBRID BETWEEN CHYMOTRYPSIN INHIBITOR 2 AND HELIX E FROM SUBTILISIN CARLSBERG
5DRN	;	1.994	;	Context-independent anti-hypusine antibody FabHpu24 in complex with hypusine
5DSC	;	2.4	;	Context-independent anti-hypusine antibody FabHpu24.B in complex with hypusine
5DUB	;	2.0	;	Context-independent anti-hypusine antibody FabHpu98 in complex with deoxyhypusine
5DS8	;	1.95	;	Context-independent anti-hypusine antibody FabHpu98 in complex with hypusine
5DTF	;	1.9	;	context-independent anti-hypusine antibody FabHpu98.61 in complex with hypusine
7AZY	;	2.877	;	Context-specific inhibition of eukaryotic translation by macrolide antibiotics
8QQO	;	2.47	;	Continuously illuminated structure of Sensory Rhodopsin II solved by serial millisecond crystallography
8C38	;	1.64	;	Contracted cowpea chlorotic mottle virus
6B8F	;	1.06	;	Contracted Human Heavy-Chain Ferritin Crystal-Hydrogel Hybrid
5N8N	;	3.28	;	Contracted sheath of a Pseudomonas aeruginosa type six secretion system consisting of TssB1 and TssC1
1F23	;	2.3	;	CONTRIBUTION OF A BURIED HYDROGEN BOND TO HIV-1 ENVELOPE GLYCOPROTEIN STRUCTURE AND FUNCTION
3C8Q	;	1.64	;	Contribution of all 20 amino acids at site 96 to the stability and structure of T4 lysozyme
1FFA	;	1.69	;	CONTRIBUTION OF CUTINASE SERINE 42 SIDE CHAIN TO THE STABILIZATION OF THE OXYANION TRANSITION STATE
1FFB	;	1.75	;	CONTRIBUTION OF CUTINASE SERINE 42 SIDE CHAIN TO THE STABILIZATION OF THE OXYANION TRANSITION STATE
1FFC	;	1.75	;	CONTRIBUTION OF CUTINASE SERINE 42 SIDE CHAIN TO THE STABILIZATION OF THE OXYANION TRANSITION STATE
1FFD	;	1.69	;	CONTRIBUTION OF CUTINASE SERINE 42 SIDE CHAIN TO THE STABILIZATION OF THE OXYANION TRANSITION STATE
1FFE	;	1.69	;	CONTRIBUTION OF CUTINASE SERINE 42 SIDE CHAIN TO THE STABILIZATION OF THE OXYANION TRANSITION STATE
3W6L	;	1.751	;	Contribution of disulfide bond toward thermostability in hyperthermostable endocellulase
3W6M	;	1.948	;	Contribution of disulfide bond toward thermostability in hyperthermostable endocellulase
4DM1	;	1.75	;	Contribution of disulfide bond toward thermostability in hyperthermostable endocellulase
4DM2	;	1.95	;	Contribution of disulfide bond toward thermostability in hyperthermostable endocellulase
1WQM	;	1.8	;	CONTRIBUTION OF HYDROGEN BONDS TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME
1WQN	;	1.8	;	CONTRIBUTION OF HYDROGEN BONDS TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME
1WQO	;	1.8	;	CONTRIBUTION OF HYDROGEN BONDS TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME
1WQP	;	1.8	;	CONTRIBUTION OF HYDROGEN BONDS TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME
1WQQ	;	1.8	;	CONTRIBUTION OF HYDROGEN BONDS TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME
1WQR	;	1.8	;	CONTRIBUTION OF HYDROGEN BONDS TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME
1B5U	;	1.8	;	CONTRIBUTION OF HYDROGEN BONDS TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME: CALORIMETRY AND X-RAY ANALYSIS OF SIX SER->ALA MUTANT
1B5V	;	2.17	;	CONTRIBUTION OF HYDROGEN BONDS TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME: CALORIMETRY AND X-RAY ANALYSIS OF SIX SER->ALA MUTANTS
1B5W	;	2.17	;	CONTRIBUTION OF HYDROGEN BONDS TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME: CALORIMETRY AND X-RAY ANALYSIS OF SIX SER->ALA MUTANTS
1B5X	;	2.0	;	Contribution of hydrogen bonds to the conformational stability of human lysozyme: calorimetry and x-ray analysis of six ser->ala mutants
1B5Y	;	2.2	;	CONTRIBUTION OF HYDROGEN BONDS TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME: CALORIMETRY AND X-RAY ANALYSIS OF SIX SER->ALA MUTANTS
1B5Z	;	2.2	;	CONTRIBUTION OF HYDROGEN BONDS TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME: CALORIMETRY AND X-RAY ANALYSIS OF SIX SER->ALA MUTANTS
2BQA	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME
2BQB	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME
2BQC	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME
2BQD	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME
2BQE	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME
2BQF	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME
2BQG	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME
2BQH	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME
2BQI	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME
2BQJ	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME
2BQK	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME
2BQL	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME
2BQM	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME
2BQN	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME
2BQO	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME
2MED	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME
2MEE	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME
2MEF	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME
2MEH	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME
2MEI	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME
1YAM	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: CALORIMETRIC STUDIES AND X-RAY STRUCTURAL ANALYSIS OF THE FIVE ISOLEUCINE TO VALINE MUTANTS
1YAN	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: CALORIMETRIC STUDIES AND X-RAY STRUCTURAL ANALYSIS OF THE FIVE ISOLEUCINE TO VALINE MUTANTS
1YAO	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: CALORIMETRIC STUDIES AND X-RAY STRUCTURAL ANALYSIS OF THE FIVE ISOLEUCINE TO VALINE MUTANTS
1YAP	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: CALORIMETRIC STUDIES AND X-RAY STRUCTURAL ANALYSIS OF THE FIVE ISOLEUCINE TO VALINE MUTANTS
1YAQ	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: CALORIMETRIC STUDIES AND X-RAY STRUCTURAL ANALYSIS OF THE FIVE ISOLEUCINE TO VALINE MUTANTS
1OUA	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: X-RAY STRUCTURE OF THE I56T MUTANT
1OUB	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: X-RAY STRUCTURE OF THE V100A MUTANT
1OUC	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: X-RAY STRUCTURE OF THE V110A MUTANT
1OUD	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: X-RAY STRUCTURE OF THE V121A MUTANT
1OUE	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: X-RAY STRUCTURE OF THE V125A MUTANT
1OUF	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: X-RAY STRUCTURE OF THE V130A MUTANT
1OUG	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: X-RAY STRUCTURE OF THE V2A MUTANT
1OUH	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: X-RAY STRUCTURE OF THE V74A MUTANT
1OUI	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: X-RAY STRUCTURE OF THE V93A MUTANT
1OUJ	;	1.8	;	CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: X-RAY STRUCTURE OF THE V99A MUTANT
2NVB	;	2.8	;	Contribution of Pro275 to the Thermostability of the Alcohol Dehydrogenases (ADHs)
1W8O	;	1.7	;	Contribution of the Active Site Aspartic Acid to Catalysis in the Bacterial Neuraminidase from Micromonospora viridifaciens
1W8N	;	2.1	;	Contribution of the Active Site Aspartic Acid to Catalysis in the Bacterial Neuraminidase from Micromonospora viridifaciens.
3VKE	;	1.77	;	Contribution of the first K-homology domain of poly(C)-binding protein 1 to its affinity and specificity for C-rich oligonucleotides
2HEA	;	1.8	;	CONTRIBUTION OF WATER MOLECULES IN THE INTERIOR OF A PROTEIN TO THE CONFORMATIONAL STABILITY
2HEB	;	2.2	;	CONTRIBUTION OF WATER MOLECULES IN THE INTERIOR OF A PROTEIN TO THE CONFORMATIONAL STABILITY
2HEC	;	1.8	;	CONTRIBUTION OF WATER MOLECULES IN THE INTERIOR OF A PROTEIN TO THE CONFORMATIONAL STABILITY
2HED	;	1.8	;	CONTRIBUTION OF WATER MOLECULES IN THE INTERIOR OF A PROTEIN TO THE CONFORMATIONAL STABILITY
2HEE	;	1.8	;	CONTRIBUTION OF WATER MOLECULES IN THE INTERIOR OF A PROTEIN TO THE CONFORMATIONAL STABILITY
2HEF	;	1.8	;	CONTRIBUTION OF WATER MOLECULES IN THE INTERIOR OF A PROTEIN TO THE CONFORMATIONAL STABILITY
1ZTE	;	1.85	;	Contribution to Structure and Catalysis of Tyrosine 34 in Human Manganese Suerpoxide Dismutase
1ZSP	;	1.9	;	Contribution to Structure and Catalysis of Tyrosine 34 in Human Manganese Superoxide Dismutase
1ZUQ	;	2.0	;	Contribution to Structure and Catalysis of Tyrosine 34 in Human Manganese Superoxide Dismutase
2P4K	;	1.48	;	Contribution to Structure and Catalysis of Tyrosine 34 in Human Manganese Superoxide Dismutase
3C8R	;	1.8	;	Contributions of all 20 amino acids at site 96 to stability and structure of T4 lysozyme
3C7W	;	1.77	;	Contributions of all 20 amino acids at site 96 to the stability and structure of T4 lysozyme
3C8S	;	1.68	;	Contributions of all 20 amino acids at site 96 to the stability and structure of T4 lysozyme
3CDQ	;	1.68	;	Contributions of all 20 amino acids at site 96 to the stability and structure of T4 lysozyme
3CDT	;	1.63	;	Contributions of all 20 amino acids at site 96 to the stability and structure of T4 lysozyme
3CDV	;	1.73	;	Contributions of all 20 amino acids at site 96 to the stability and structure of T4 lysozyme
1L37	;	1.85	;	CONTRIBUTIONS OF ENGINEERED SURFACE SALT BRIDGES TO THE STABILITY OF T4 LYSOZYME DETERMINED BY DIRECTED MUTAGENESIS
1L38	;	1.8	;	CONTRIBUTIONS OF ENGINEERED SURFACE SALT BRIDGES TO THE STABILITY OF T4 LYSOZYME DETERMINED BY DIRECTED MUTAGENESIS
1L39	;	1.85	;	CONTRIBUTIONS OF ENGINEERED SURFACE SALT BRIDGES TO THE STABILITY OF T4 LYSOZYME DETERMINED BY DIRECTED MUTAGENESIS
1L40	;	1.85	;	CONTRIBUTIONS OF ENGINEERED SURFACE SALT BRIDGES TO THE STABILITY OF T4 LYSOZYME DETERMINED BY DIRECTED MUTAGENESIS
1L41	;	1.75	;	CONTRIBUTIONS OF ENGINEERED SURFACE SALT BRIDGES TO THE STABILITY OF T4 LYSOZYME DETERMINED BY DIRECTED MUTAGENESIS
1L02	;	1.7	;	CONTRIBUTIONS OF HYDROGEN BONDS OF THR 157 TO THE THERMODYNAMIC STABILITY OF PHAGE T4 LYSOZYME
1L03	;	1.7	;	CONTRIBUTIONS OF HYDROGEN BONDS OF THR 157 TO THE THERMODYNAMIC STABILITY OF PHAGE T4 LYSOZYME
1L04	;	1.7	;	CONTRIBUTIONS OF HYDROGEN BONDS OF THR 157 TO THE THERMODYNAMIC STABILITY OF PHAGE T4 LYSOZYME
1L05	;	1.7	;	CONTRIBUTIONS OF HYDROGEN BONDS OF THR 157 TO THE THERMODYNAMIC STABILITY OF PHAGE T4 LYSOZYME
1L06	;	1.7	;	CONTRIBUTIONS OF HYDROGEN BONDS OF THR 157 TO THE THERMODYNAMIC STABILITY OF PHAGE T4 LYSOZYME
1L07	;	1.7	;	CONTRIBUTIONS OF HYDROGEN BONDS OF THR 157 TO THE THERMODYNAMIC STABILITY OF PHAGE T4 LYSOZYME
1L08	;	1.7	;	CONTRIBUTIONS OF HYDROGEN BONDS OF THR 157 TO THE THERMODYNAMIC STABILITY OF PHAGE T4 LYSOZYME
1L09	;	1.7	;	CONTRIBUTIONS OF HYDROGEN BONDS OF THR 157 TO THE THERMODYNAMIC STABILITY OF PHAGE T4 LYSOZYME
1L11	;	1.7	;	CONTRIBUTIONS OF HYDROGEN BONDS OF THR 157 TO THE THERMODYNAMIC STABILITY OF PHAGE T4 LYSOZYME
1L12	;	1.7	;	CONTRIBUTIONS OF HYDROGEN BONDS OF THR 157 TO THE THERMODYNAMIC STABILITY OF PHAGE T4 LYSOZYME
1L13	;	1.7	;	CONTRIBUTIONS OF HYDROGEN BONDS OF THR 157 TO THE THERMODYNAMIC STABILITY OF PHAGE T4 LYSOZYME
1L14	;	1.7	;	CONTRIBUTIONS OF HYDROGEN BONDS OF THR 157 TO THE THERMODYNAMIC STABILITY OF PHAGE T4 LYSOZYME
1L15	;	1.7	;	CONTRIBUTIONS OF HYDROGEN BONDS OF THR 157 TO THE THERMODYNAMIC STABILITY OF PHAGE T4 LYSOZYME
1L21	;	1.85	;	CONTRIBUTIONS OF LEFT-HANDED HELICAL RESIDUES TO THE STRUCTURE AND STABILITY OF BACTERIOPHAGE T4 LYSOZYME
1L22	;	1.7	;	CONTRIBUTIONS OF LEFT-HANDED HELICAL RESIDUES TO THE STRUCTURE AND STABILITY OF BACTERIOPHAGE T4 LYSOZYME
1L33	;	1.7	;	CONTRIBUTIONS OF LEFT-HANDED HELICAL RESIDUES TO THE STRUCTURE AND STABILITY OF BACTERIOPHAGE T4 LYSOZYME
1JMF	;	2.5	;	CONTRIBUTIONS OF ORIENTATION AND HYDROGEN BONDING TO CATALYSIS IN ASN-229 MUTANTS OF THYMIDYLATE SYNTHASE
1JMG	;	2.2	;	CONTRIBUTIONS OF ORIENTATION AND HYDROGEN BONDING TO CATALYSIS IN ASN-229 MUTANTS OF THYMIDYLATE SYNTHASE
1JMH	;	2.5	;	CONTRIBUTIONS OF ORIENTATION AND HYDROGEN BONDING TO CATALYSIS IN ASN-229 MUTANTS OF THYMIDYLATE SYNTHASE
1JMI	;	2.5	;	CONTRIBUTIONS OF ORIENTATION AND HYDROGEN BONDING TO CATALYSIS IN ASN-229 MUTANTS OF THYMIDYLATE SYNTHASE
1TVU	;	2.5	;	CONTRIBUTIONS OF ORIENTATION AND HYDROGEN BONDING TO CATALYSIS IN ASN-229 MUTANTS OF THYMIDYLATE SYNTHASE
1TVV	;	2.3	;	CONTRIBUTIONS OF ORIENTATION AND HYDROGEN BONDING TO CATALYSIS IN ASN-229 MUTANTS OF THYMIDYLATE SYNTHASE
1TVW	;	2.5	;	CONTRIBUTIONS OF ORIENTATION AND HYDROGEN BONDING TO CATALYSIS IN ASN-229 MUTANTS OF THYMIDYLATE SYNTHASE
155L	;	1.85	;	CONTROL OF ENZYME ACTIVITY BY AN ENGINEERED DISULFIDE BOND
156L	;	1.8	;	CONTROL OF ENZYME ACTIVITY BY AN ENGINEERED DISULFIDE BOND
157L	;	1.85	;	CONTROL OF ENZYME ACTIVITY BY AN ENGINEERED DISULFIDE BOND
158L	;	1.8	;	CONTROL OF ENZYME ACTIVITY BY AN ENGINEERED DISULFIDE BOND
159L	;	1.8	;	CONTROL OF ENZYME ACTIVITY BY AN ENGINEERED DISULFIDE BOND
160L	;	1.8	;	CONTROL OF ENZYME ACTIVITY BY AN ENGINEERED DISULFIDE BOND
161L	;	1.7	;	CONTROL OF ENZYME ACTIVITY BY AN ENGINEERED DISULFIDE BOND
162L	;	1.8	;	CONTROL OF ENZYME ACTIVITY BY AN ENGINEERED DISULFIDE BOND
163L	;	1.8	;	CONTROL OF ENZYME ACTIVITY BY AN ENGINEERED DISULFIDE BOND
164L	;	1.8	;	CONTROL OF ENZYME ACTIVITY BY AN ENGINEERED DISULFIDE BOND
165L	;	1.75	;	CONTROL OF ENZYME ACTIVITY BY AN ENGINEERED DISULFIDE BOND
166L	;	1.75	;	CONTROL OF ENZYME ACTIVITY BY AN ENGINEERED DISULFIDE BOND
1B4G	;		;	CONTROL OF K+ CHANNEL GATING BY PROTEIN PHOSPHORYLATION: STRUCTURAL SWITCHES OF THE INACTIVATION GATE, NMR, 22 STRUCTURES
1B4I	;		;	Control of K+ Channel Gating by protein phosphorylation: structural switches of the inactivation gate, NMR, 22 structures
1ABB	;	2.8	;	CONTROL OF PHOSPHORYLASE B CONFORMATION BY A MODIFIED COFACTOR: CRYSTALLOGRAPHIC STUDIES ON R-STATE GLYCOGEN PHOSPHORYLASE RECONSTITUTED WITH PYRIDOXAL 5'-DIPHOSPHATE
4V9O	;	2.9	;	Control of ribosomal subunit rotation by elongation factor G
4V9P	;	2.9	;	Control of ribosomal subunit rotation by elongation factor G
5AP9	;	1.8	;	Controlled lid-opening in Thermomyces lanuginosus lipase - a switch for activity and binding
7Y1H	;	1.99	;	Controlling fibrosis using compound with novel binding mode to prolyl-tRNA synthetase 1
7Y1W	;	2.5	;	Controlling fibrosis using compound with novel binding mode to prolyl-tRNA synthetase 1
7Y28	;	2.29	;	Controlling fibrosis using compound with novel binding mode to prolyl-tRNA synthetase 1
7Y3S	;	2.6	;	Controlling fibrosis using compound with novel binding mode to prolyl-tRNA synthetase 1
6OLO	;	2.3	;	Controlling the Self-Assembly of Synthetic Metal-Coordinating Coiled-Coil Peptides: Hexagonal Lattice from a Trimeric Coiled Coil
6OLN	;	2.5	;	Controlling the Self-Assembly of Synthetic Metal-Coordinating Coiled-Coil Peptides: Orthorhombic Lattice from a Trimeric Coiled Coil
2V5H	;	2.75	;	Controlling the storage of nitrogen as arginine: the complex of PII and acetylglutamate kinase from Synechococcus elongatus PCC 7942
1CF8	;	2.7	;	Convergence of catalytic antibody and terpene cyclase mechanisms: polyene cyclization directed by carbocation-pi interactions
5MYD	;	2.3	;	Convergent evolution involving dimeric and trimeric dUTPases in signalling.
5MYF	;	1.85	;	Convergent evolution involving dimeric and trimeric dUTPases in signalling.
5MYI	;	1.9	;	Convergent evolution involving dimeric and trimeric dUTPases in signalling.
1TRB	;	2.0	;	CONVERGENT EVOLUTION OF SIMILAR FUNCTION IN TWO STRUCTURALLY DIVERGENT ENZYMES
1SHM	;	1.9	;	Convergent solutions to VHH domain stabilization from natural and in vitro evolution
4NEC	;	1.5	;	Conversion of a Disulfide Bond into a Thioacetal Group during Echinomycin Biosynthesis
7YLO	;	1.83	;	Conversion of indole-3-acetic acid into indole-3-aldehyde in bacteria Metabolic network of tryptophan around the indole-3-aldehyde formation
1JML	;	1.9	;	Conversion of Monomeric Protein L to an Obligate Dimer by Computational Protein Design
7E4L	;	1.6	;	Conversion of pyrophosphate-dependent myo-inositol-1 kinase into myo-inositol-3 kinase by N78L/S89L mutation
4F4J	;	2.45	;	Conversion of the enzyme guanylate kinase into a mitotic spindle orienting protein by a single mutation that inhibits gmp- induced closing
7O3D	;	3.71	;	Cooperation between the intrinsically disordered and ordered regions of Spt6 regulates nucleosome and Pol II CTD binding, and nucleosome assembly
7O6B	;	3.88	;	Cooperation between the intrinsically disordered and ordered regions of Spt6 regulates nucleosome and Pol II CTD binding, and nucleosome assembly
5AQE	;	1.1	;	Cooperative bio-metallic selectivity in a tailored protease enables creation of a C-C cross-coupling Heckase
5ARB	;	1.15	;	Cooperative bio-metallic selectivity in a tailored protease enables creation of a C-C cross-coupling Heckase
5ARC	;	1.1	;	Cooperative bio-metallic selectivity in a tailored protease enables creation of a C-C cross-coupling Heckase
5ARD	;	1.55	;	Cooperative bio-metallic selectivity in a tailored protease enables creation of a C-C cross-coupling Heckase
5U01	;	2.5	;	Cooperative DNA binding by two RelA dimers
1RWB	;	2.0	;	Cooperative Effect of Two Surface Amino Acid Mutations (Q252L and E170K) of Glucose Dehydrogenase from Bacillus megaterium IWG3 for the stabilization of Oligomeric State
7X8V	;	1.84	;	Cooperative regulation of PBI1 and MAPKs controls WRKY45 transcription factor in rice immunity
1GOA	;	1.9	;	COOPERATIVE STABILIZATION OF ESCHERICHIA COLI RIBONUCLEASE HI BY INSERTION OF GLY-80B AND GLY-77-> ALA SUBSTITUTION
1GOB	;	2.0	;	COOPERATIVE STABILIZATION OF ESCHERICHIA COLI RIBONUCLEASE HI BY INSERTION OF GLY-80B AND GLY-77-> ALA SUBSTITUTION
1GOC	;	2.0	;	COOPERATIVE STABILIZATION OF ESCHERICHIA COLI RIBONUCLEASE HI BY INSERTION OF GLY-80B AND GLY-77-> ALA SUBSTITUTION
2MKC	;		;	Cooperative Structure of the Heterotrimeric pre-mRNA Retention and Splicing Complex
5DHB	;	1.8	;	Cooperativity and Downstream Binding in RNA Replication
5DHC	;	1.55	;	Cooperativity and Downstream Binding in RNA Replication
1AXR	;	2.3	;	COOPERATIVITY BETWEEN HYDROGEN-BONDING AND CHARGE-DIPOLE INTERACTIONS IN THE INHIBITION OF BETA-GLYCOSIDASES BY AZOLOPYRIDINES: EVIDENCE FROM A STUDY WITH GLYCOGEN PHOSPHORYLASE B
1D1O	;		;	COOPERATIVITY IN EF-HAND CA2+-BINDING PROTEINS: EVIDENCE OF SITE-SITE COMMUNICATION FROM BINDING-INDUCED CHANGES IN STRUCTURE AND DYNAMICS OF N56A CALBINDIN D9K
2JYP	;		;	Coordinates for lowest energy structure of Aragonite protein-7, C-terminal domain
3DG2	;	10.0	;	Coordinates of 16S and 23S rRNAs fitted into the cryo-EM map of a pretranslocation complex
3DG0	;	10.8	;	Coordinates of 16S and 23S rRNAs fitted into the cryo-EM map of EF-G-bound translocation complex
3DG4	;	12.8	;	Coordinates of 16S and 23S rRNAs fitted into the cryo-EM map of RF1-bound termination complex
3DG5	;	15.5	;	Coordinates of 16S and 23S rRNAs fitted into the cryo-EM map of RF3-bound termination complex
8J7A	;	3.06	;	Coordinates of Cryo-EM structure of the Arabidopsis thaliana PSI in state 1 (PSI-ST1)
8J7B	;	3.22	;	Coordinates of Cryo-EM structure of the Arabidopsis thaliana PSI in state 2 (PSI-ST2)
1R2X	;	9.0	;	Coordinates of L11 with 58nts of 23S rRNA fitted into the cryo-EM map of EF-Tu ternary complex (GDP.Kirromycin) bound 70S ribosome
1R2W	;	9.0	;	Coordinates of L11 with 58nts of 23S rRNA fitted into the cryo-EM map of the 70S ribosome
6WG7	;	8.3	;	Coordinates of NanR dimer fitted in Hexameric NanR-DNA hetero-complex cryo-EM map
1GOL	;	2.8	;	COORDINATES OF RAT MAP KINASE ERK2 WITH AN ARGININE MUTATION AT POSITION 52
1ZN0	;	15.5	;	Coordinates of RRF and EF-G fitted into Cryo-EM map of the 50S subunit bound with both EF-G (GDPNP) and RRF
1ZN1	;	14.1	;	Coordinates of RRF fitted into Cryo-EM map of the 70S post-termination complex
1PN8	;	10.8	;	Coordinates of S12, L11 proteins and E-site tRNA from 70S crystal structure separately fitted into the Cryo-EM map of E.coli 70S.EF-G.GDPNP complex. The atomic coordinates originally from the E-site tRNA were fitted in the position of the hybrid P/E-site tRNA.
1PN7	;	10.8	;	Coordinates of S12, L11 proteins and P-tRNA, from the 70S X-ray structure aligned to the 70S Cryo-EM map of E.coli ribosome
1QZC	;	9.0	;	Coordinates of S12, SH44, LH69 and SRL separately fitted into the cryo-EM map of EF-Tu ternary complex (GDP.Kirromycin) bound 70S ribosome
1QZB	;	9.0	;	Coordinates of the A-site tRNA model fitted into the cryo-EM map of 70S ribosome in the pre-translocational state
1QZA	;	10.0	;	Coordinates of the A/T site tRNA model fitted into the cryo-EM map of EF-Tu ternary complex (GDP.Kirromycin) bound 70S ribosome
3IYX	;	9.0	;	Coordinates of the b1b bridge-forming protein structures fitted into the Cryo-EM map of E.coli 70S ribosome (EMD-1056)
3IYY	;	10.9	;	Coordinates of the b1b bridge-forming protein structures fitted into the Cryo-EM map of EFG.GDPNP-bound E.coli 70S ribosome(EMD-1363)
4BTG	;	4.4	;	Coordinates of the bacteriophage phi6 capsid subunits (P1A and P1B) fitted into the cryoEM reconstruction of the procapsid at 4.4 A resolution
4BTQ	;	7.5	;	Coordinates of the bacteriophage phi6 capsid subunits fitted into the cryoEM map EMD-1206
2BCW	;	11.2	;	Coordinates of the N-terminal domain of ribosomal protein L11,C-terminal domain of ribosomal protein L7/L12 and a portion of the G' domain of elongation factor G, as fitted into cryo-em map of an Escherichia coli 70S*EF-G*GDP*fusidic acid complex
2R1G	;	12.5	;	Coordinates of the thermus thermophilus 30S components neighboring RbfA as obtained by fitting into the CRYO-EM map of A 30S-RBFA complex
2R1C	;	12.5	;	Coordinates of the thermus thermophilus ribosome binding factor A (RbfA) homology model as fitted into the CRYO-EM map of a 30S-RBFA complex
1ZC8	;	13.0	;	Coordinates of tmRNA, SmpB, EF-Tu and h44 fitted into Cryo-EM map of the 70S ribosome and tmRNA complex
5VKX	;	1.37	;	Coordination Chemistry within a Protein Host: Regulation of the Secondary Coordination Sphere
5VL5	;	1.46	;	Coordination Chemistry within a Protein Host: Regulation of the Secondary Coordination Sphere
5VL8	;	1.7	;	Coordination Chemistry within a Protein Host: Regulation of the Secondary Coordination Sphere
7B7Q	;	1.35	;	CooS-V with oxidized hybrid cluster
7B7T	;	1.38	;	CooS-V with oxidized hybrid cluster
7B97	;	1.45	;	CooS-V with oxidized hybrid cluster by hydroxylamine for 30 min
7B95	;	1.4	;	CooS-V with partially oxidized hybrid cluster by hydroxylamine
7B9A	;	2.5	;	CooS-V with Xe-soaked
8GR5	;	2.1	;	Cop4 from Antrodia cinnamomea in apo form
8GR7	;	1.9	;	Cop4 from Antrodia cinnamomea in complex with pyrophosphate and magnesium
2B8E	;	2.3	;	CopA ATP Binding Domain
6NFQ	;	2.0	;	CopC from Pseudomonas fluorescens
6NFR	;	1.0	;	CopC from Pseudomonas fluorescens
6NFS	;	1.5	;	CopC from Pseudomonas fluorescens
8BSH	;	3.8	;	COPII inner coat
6ZGA	;	4.6	;	COPII on membranes, inner coat
6ZL0	;	40.0	;	COPII on membranes, outer coat left-handed rod
6ZG5	;	40.0	;	COPII on membranes, outer coat right-handed rod, class1
6ZG6	;	12.0	;	COPII on membranes, outer coat vertex
5DGE	;	3.45	;	Coping with proline stalling: structural basis of hypusine-induced protein synthesis by the eukaryotic ribosome
6HUF	;	2.82	;	Coping with strong translational non-crystallographic symmetry and extreme anisotropy in molecular replacement with Phaser: human Rab27a
5FFA	;	1.501	;	CopM (with an N-terminal His-tag) in the apo form
5FFD	;	1.451	;	CopM in the Ag-bound form (by co-crystallization)
5FFE	;	2.096	;	CopM in the Ag-bound form (by soaking)
5FFB	;	1.702	;	CopM in the apo form
5FEJ	;	2.5	;	CopM in the Cu(I)-bound form
5FFC	;	2.007	;	CopM in the Cu(II)-bound form
4NRH	;	2.2	;	CopN-Scc3 complex
3RE7	;	2.82	;	Copper (II) loaded Bullfrog Ferritin M chain
5ZP3	;	1.782	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by ethylamine at pH 10 at 288 K (1)
5ZP4	;	1.799	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by ethylamine at pH 10 at 288 K (2)
5ZP5	;	1.767	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by ethylamine at pH 6 at 277 K (1)
5ZP6	;	1.688	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by ethylamine at pH 6 at 277 K (2)
5ZP7	;	1.631	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by ethylamine at pH 6 at 277 K (3)
5ZP8	;	1.66	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by ethylamine at pH 6 at 277 K (4)
5ZP9	;	1.7	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by ethylamine at pH 6 at 283 K (1)
5ZPA	;	1.689	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by ethylamine at pH 6 at 283 K (2)
5ZPB	;	1.793	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by ethylamine at pH 6 at 283 K (3)
5ZPC	;	1.741	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by ethylamine at pH 6 at 283 K (4)
5ZPD	;	1.665	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by ethylamine at pH 6 at 288 K (1)
5ZOW	;	1.778	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by ethylamine at pH 6 at 288 K (2)
5ZPE	;	1.689	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by ethylamine at pH 6 at 288 K (2)
5ZPF	;	1.759	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by ethylamine at pH 6 at 288 K (3)
5ZPI	;	1.747	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by ethylamine at pH 6 at 293 K (3)
5ZOX	;	1.691	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by ethylamine at pH 7 at 288 K (1)
5ZOY	;	1.695	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by ethylamine at pH 7 at 288 K (2)
5ZOZ	;	1.702	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by ethylamine at pH 8 at 288 K (1)
5ZP0	;	1.738	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by ethylamine at pH 8 at 288 K (2)
5ZP1	;	1.669	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by ethylamine at pH 9 at 288 K (1)
5ZP2	;	1.748	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by ethylamine at pH 9 at 288 K (2)
5ZOU	;	1.68	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by ethylamine at pH6 at 288 K (1)
5ZPG	;	1.649	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by ethylamine at pH6 at 293K (1)
5ZPH	;	1.72	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by ethylamine at pH6 at 293K (2)
3X3Y	;	1.499	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by histamine
3X3X	;	1.57	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by phenylethylamine
5ZPS	;	1.748	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by phenylethylamine at pH 10 at 288 K (1)
5ZPT	;	1.902	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by phenylethylamine at pH 10 at 288 K (2)
5ZPJ	;	1.647	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by phenylethylamine at pH 6 at 288 K (1)
5ZPK	;	1.65	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by phenylethylamine at pH 6 at 288 K (2)
5ZPL	;	1.6	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by phenylethylamine at pH 7 at 288 K (1)
5ZPM	;	1.65	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by phenylethylamine at pH 7 at 288 K (2)
5ZPN	;	1.6	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by phenylethylamine at pH 8 at 288 K (1)
5ZPO	;	1.73	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by phenylethylamine at pH 8 at 288 K (2)
5ZPP	;	1.81	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by phenylethylamine at pH 8 at 288 K (3)
5ZPQ	;	1.849	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by phenylethylamine at pH 9 at 288 K (1)
5ZPR	;	1.922	;	Copper amine oxidase from Arthrobacter globiformis anaerobically reduced by phenylethylamine at pH 9 at 288 K (2)
3X3Z	;	1.51	;	Copper amine oxidase from Arthrobacter globiformis: Aminoresorcinol form produced by anaerobic reduction with ethylamine hydrochloride
3X41	;	1.87	;	Copper amine oxidase from Arthrobacter globiformis: Product Schiff-base form produced by anaerobic reduction in the presence of sodium bromide
3X40	;	1.85	;	Copper amine oxidase from Arthrobacter globiformis: Product Schiff-base form produced by anaerobic reduction in the presence of sodium chloride
1A2V	;	2.4	;	COPPER AMINE OXIDASE FROM HANSENULA POLYMORPHA
6IBH	;	1.82	;	Copper binding protein from Laetisaria arvalis (LaX325)
6IBI	;	2.08	;	Copper binding protein from Laetisaria arvalis (LaX325)
6IBJ	;	2.1	;	Copper binding protein from Laetisaria arvalis (LaX325)
1N68	;	1.7	;	Copper bound to the Multicopper Oxidase CueO
2XMT	;	1.5	;	Copper chaperone Atx1 from Synechocystis PCC6803 (Cu1 form)
2XMV	;	1.8	;	Copper chaperone Atx1 from Synechocystis PCC6803 (Cu1, trimeric form, His61Tyr mutant)
2XMU	;	1.75	;	Copper chaperone Atx1 from Synechocystis PCC6803 (Cu2 form)
1CPZ	;		;	COPPER CHAPERONE OF ENTEROCOCCUS HIRAE (APO-FORM)
8SY3	;	3.2	;	Copper Complex of Peanut USP-type BURP Domain Peptide Cyclase
6Q58	;	1.5	;	Copper loading to a cytosolic copper storage protein from Streptomyces lividans (five coppers)
6GBB	;	1.48	;	Copper nitrite reductase from Achromobacter cycloclastes: large cell polymorph dataset 1
6GCG	;	1.80015	;	Copper nitrite reductase from Achromobacter cycloclastes: large polymorph dataset 15
6GBY	;	1.48	;	Copper nitrite reductase from Achromobacter cycloclastes: non-polymorph separated dataset 1
6GB8	;	1.48	;	Copper nitrite reductase from Achromobacter cycloclastes: small cell polymorph dataset 1
4YSO	;	1.5	;	Copper nitrite reductase from Geobacillus thermodenitrificans - 0.064 MGy
4KNU	;	1.8	;	Copper nitrite reductase from Nitrosomonas europaea at pH 6.5
4KNT	;	1.9	;	Copper nitrite reductase from Nitrosomonas europaea pH 8.5
6RYV	;	2.3	;	Copper oxidase from Colletotrichum graminicola
6RYW	;	2.6	;	Copper oxidase from Colletotrichum graminicola
6RYX	;	2.65	;	Copper oxidase from Colletotrichum graminicola
6STX	;	1.9	;	Copper oxidase from Colletotrichum graminicola
6WIS	;	2.0	;	Copper resistance protein copG- Form 1
6WJE	;	2.5	;	Copper resistance protein copG- Form 2
1K0V	;		;	Copper trafficking: the solution structure of Bacillus subtilis CopZ
6FOK	;	1.97	;	Copper transporter OprC
6FOM	;	2.9	;	Copper transporter OprC
6Z8Q	;	2.71	;	Copper transporter OprC
6Z8R	;	2.38	;	Copper transporter OprC
6Z8S	;	2.37	;	Copper transporter OprC
6Z8T	;	2.86	;	Copper transporter OprC
6Z8U	;	2.61	;	Copper transporter OprC
6Z8Y	;	2.78	;	Copper transporter OprC
6Z8Z	;	2.56	;	Copper transporter OprC
6Z91	;	2.6	;	Copper transporter OprC
6Z99	;	2.68	;	Copper transporter OprC
6Z9N	;	2.73	;	Copper transporter OprC
6Z9Y	;	2.95	;	Copper transporter OprC
7PGE	;	2.0	;	copper transporter PcoB
6A72	;	2.1	;	Copper transporter protein
2RSQ	;		;	Copper(I) loaded form of the first domain of the human copper chaperone for SOD1, CCS
8BAE	;	1.2	;	Copper(II) bound to a non-canonical quadruplex
8BAG	;	1.13	;	Copper(II) bound to a non-canonical quadruplex containing the damaged base 8-oxoguanine
4XSN	;	1.452	;	Copper(II) bound to the Z-DNA form of d(CGCGCG)
3BKT	;	1.5	;	Copper-bound C-terminal Domain of NikR
6WEF	;	2.501	;	Copper-bound D92H variant of Campylobacter jejuni P19
6WED	;	1.9	;	Copper-bound E44Q variant of Campylobacter jejuni P19
5I0Y	;	1.4	;	COPPER-BOUND E46Q VARIANT OF UROPATHOGENIC ESCHERICHIA COLI STRAIN F11 FETP
6WEE	;	2.3	;	Copper-bound M88I variant of Campylobacter jejuni P19
5I0X	;	1.5	;	COPPER-BOUND M90I VARIANT OF UROPATHOGENIC ESCHERICHIA COLI STRAIN F11 FETP
6P1G	;	2.05	;	Copper-bound PCuAC domain from PmoF2
3WKQ	;	1.15	;	Copper-containing nitrite reductase from Geobacillus thermodenitrificans in complex with formate
4ZK8	;	1.15	;	Copper-containing nitrite reductase from thermophilic bacterium Geobacillus thermodenitrificans (Re-refined)
3S0P	;	3.0	;	Copper-reconstituted Tomato Chloroplast Superoxide Dismutase
6AHX	;	2.0	;	Copper-Sensing Operon Regulator Protein (CsoRGz)
4BBJ	;	2.75	;	Copper-transporting PIB-ATPase in complex with beryllium fluoride representing the E2P state
5U9M	;	2.35	;	Copper-Zinc Superoxide Dismutase is Activated through a Sulfenic Acid Intermediate at a Copper-ion Entry Site
2K4B	;		;	CopR Repressor Structure
8BBV	;	2.19	;	Coproporphyrin III - LmCpfC complex soaked 2min with Fe2+
8OMM	;	2.15	;	Coproporphyrin III - LmCpfC complex soaked 3min with Fe2+
8OFL	;	2.1	;	Coproporphyrin III - LmCpfC complex soaked 4min with Fe2+
5EO6	;	1.45	;	Coproporphyrinogen III oxidase (HemF) from Acinetobacter baumannii
1OLT	;	2.07	;	Coproporphyrinogen III oxidase (HemN) from Escherichia coli is a Radical SAM enzyme.
3EJO	;	2.3	;	Coproporphyrinogen III oxidase from Leishmania donovani
1VJU	;	1.401	;	Coproporphyrinogen III oxidase from Leishmania major
2QT8	;	1.75	;	Coproporphyrinogen III oxidase from Leishmania major
3E8J	;	2.27	;	Coproporphyrinogen III oxidase from Leishmania naiffi
5M5Q	;	2.2	;	COPS5(2-257) IN COMPLEX WITH A AZAINDOLE (COMPOUND 4)
6FF2	;	1.3	;	CopZ metallochaperone
3DPT	;	2.9	;	COR domain of Rab family protein (Roco)
4EEB	;	3.8	;	CorA coiled-coil mutant under Mg2+ absence
4EED	;	3.92	;	CorA coiled-coil mutant under Mg2+ presence
4BZ4	;	1.6	;	CorA is a surface-associated copper-binding protein important in Methylomicrobium album BG8 copper acquisition
1SFK	;	3.2	;	Core (C) protein from West Nile Virus, subtype Kunjin
2JHB	;		;	CORE BINDING FACTOR BETA
6VLM	;	2.32	;	Core Catalytic Domain of HIV Integrase in complex with virtual screening hit
6GSA	;	4.2	;	Core Centromere Binding Factor 3 (CBF3) with monomeric Ndc10
8BH1	;	3.8	;	Core divisome complex FtsWIQBL from Pseudomonas aeruginosa
1QS4	;	2.1	;	Core domain of HIV-1 integrase complexed with Mg++ and 1-(5-chloroindol-3-yl)-3-hydroxy-3-(2H-tetrazol-5-yl)-propenone
4Y99	;	2.0	;	Core domain of human cardiac troponin
5DS2	;	1.85	;	Core domain of the class I small heat-shock protein HSP 18.1 from Pisum sativum
5DS1	;	2.63	;	Core domain of the class II small heat-shock protein HSP 17.7 from Pisum sativum
1GPC	;	2.2	;	CORE GP32, DNA-BINDING PROTEIN
7PFO	;	3.2	;	Core human replisome
5N9J	;	3.4	;	Core Mediator of transcriptional regulation
7UI9	;	3.3	;	Core Mediator-PICearly (Copy A)
3JCA	;	4.8	;	Core model of the Mouse Mammary Tumor Virus intasome
7YFN	;	3.8	;	Core module of the NuA4 complex in S. cerevisiae
3J0P	;	10.6	;	Core of mammalian 80S pre-ribosome in complex with tRNAs fitted to a 10.6A cryo-em map: rotated PRE state 1
3J0Q	;	10.6	;	Core of mammalian 80S pre-ribosome in complex with tRNAs fitted to a 10.6A cryo-em map: rotated PRE state 2
3J0L	;	9.8	;	Core of mammalian 80S pre-ribosome in complex with tRNAs fitted to a 9.8A cryo-EM map: classic PRE state 1
3J0O	;	9.0	;	Core of mammalian 80S pre-ribosome in complex with tRNAs fitted to a 9A cryo-EM map: classic PRE state 2
1E8O	;	3.2	;	Core of the Alu domain of the mammalian SRP
6H55	;	6.0	;	core of the human pyruvate dehydrogenase (E2)
7EYB	;	3.7	;	core proteins
1P3N	;	1.55	;	CORE REDESIGN BACK-REVERTANT I103V/CORE10
1KFM	;	2.0	;	Core side-chain packing and backbone conformation in Lpp-56 coiled-coil mutants
1KFN	;	1.65	;	Core side-chain packing and backbone conformation in Lpp-56 coiled-coil mutants
1I9H	;	2.4	;	CORE STREPTAVIDIN-BNA COMPLEX
2EBO	;	1.9	;	CORE STRUCTURE OF GP2 FROM EBOLA VIRUS
2IEQ	;	1.747	;	Core Structure of S2 from the Human Coronavirus NL63 Spike Glycoprotein
1EQ7	;	1.9	;	CORE STRUCTURE OF THE OUTER MEMBRANE LIPOPROTEIN FROM ESCHERICHIA COLI AT 1.9 ANGSTROM RESOLUTION
4N0T	;	1.7	;	Core structure of the U6 small nuclear ribonucleoprotein at 1.7 Angstrom resolution
8AA3	;	2.7	;	Core SusCD transporter units from the inactive levan utilisome in the presence of levan fructo-oligosaccharides DP 15-25
8AA1	;	2.9	;	Core SusCD transporter units from the levan utilisome with levan fructo-oligosaccharides DP 8-12
7AD8	;	3.5	;	Core TFIIH-XPA-DNA complex with modelled p62 subunit
4DFC	;	2.803	;	Core UvrA/TRCF complex
8OHS	;	4.1	;	Core-binding domain of fungal E3-binding domain bound to the native pyruvate dehydrogenase E2 core
7R5M	;	3.3	;	Core-binding domain of fungal E3-binding domain bound to the pyruvate dehydrogenase E2 core
1SWS	;	2.0	;	CORE-STREPTAVIDIN MUTANT D128A AT PH 4.5
1SWT	;	2.0	;	CORE-STREPTAVIDIN MUTANT D128A IN COMPLEX WITH BIOTIN AT PH 4.5
3MG5	;	1.3	;	Core-streptavidin mutant F130L in complex with biotin
1SWL	;	1.8	;	CORE-STREPTAVIDIN MUTANT W108F AT PH 7.0
1SWN	;	2.2	;	CORE-STREPTAVIDIN MUTANT W108F IN COMPLEX WITH BIOTIN AT PH 7.0
1SWQ	;	1.9	;	CORE-STREPTAVIDIN MUTANT W120A AT PH 7.5
1SWR	;	1.9	;	CORE-STREPTAVIDIN MUTANT W120A IN COMPLEX WITH BIOTIN AT PH 7.5
1SWO	;	1.95	;	CORE-STREPTAVIDIN MUTANT W120F AT PH 7.5
1SWP	;	2.0	;	CORE-STREPTAVIDIN MUTANT W120F IN COMPLEX WITH BIOTIN AT PH 7.5
1SWH	;	1.7	;	CORE-STREPTAVIDIN MUTANT W79F AT PH 4.5
1SWJ	;	2.0	;	CORE-STREPTAVIDIN MUTANT W79F AT PH 4.5
1SWK	;	2.0	;	CORE-STREPTAVIDIN MUTANT W79F IN COMPLEX WITH BIOTIN AT PH 4.5
4A2F	;	1.9	;	Coriolopsis gallica laccase collected at 12.65 keV
4A2G	;	1.8	;	Coriolopsis gallica laccase collected at 8.98 keV
4A2D	;	2.3	;	Coriolopsis gallica Laccase T2 Copper Depleted at pH 4.5
5DLI	;	2.1	;	Corkscrew assembly of SOD1 residues 28-38
5WOR	;	2.77	;	Corkscrew assembly of SOD1 residues 28-38 with familial mutation G37R
5IIW	;	2.0	;	Corkscrew assembly of SOD1 residues 28-38 without potassium iodide
1P9S	;	2.54	;	Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of anti-SARS Drugs
1P9U	;	2.37	;	Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of anti-SARS Drugs
4M1M	;	3.8	;	Corrected Structure of Mouse P-glycoprotein
4M2S	;	4.4	;	Corrected Structure of Mouse P-glycoprotein bound to QZ59-RRR
4M2T	;	4.35	;	Corrected Structure of Mouse P-glycoprotein bound to QZ59-SSS
1YYF	;	4.16	;	Correction of X-ray Intensities from an HslV-HslU co-crystal containing lattice translocation defects
1CNR	;	1.05	;	CORRELATED DISORDER OF THE PURE PRO22(SLASH)LEU25 FORM OF CRAMBIN AT 150K REFINED TO 1.05 ANGSTROMS RESOLUTION
4NH7	;	2.0	;	Correlation between chemotype-dependent binding conformations of HSP90 alpha/beta and isoform selectivity
4NH8	;	1.65	;	Correlation between chemotype-dependent binding conformations of HSP90 alpha/beta and isoform selectivity
4NH9	;	2.77	;	Correlation between chemotype-dependent binding conformations of HSP90 alpha/beta and isoform selectivity
2TMD	;	2.4	;	CORRELATION OF X-RAY DEDUCED AND EXPERIMENTAL AMINO ACID SEQUENCES OF TRIMETHYLAMINE DEHYDROGENASE
3F8Y	;	1.45	;	Correlations of Human Dihydrofolate Reductase with Structural Data for Human Active Site Mutant Enzyme Complexes
3FS6	;	1.23	;	Correlations of Inhibitor Kinetics for Pneumocystis jirovecii and Human Dihydrofolate Reductase with Structural Data for Human Active Site Mutant Enzyme Complexes
2H9A	;	1.9	;	Corrinoid Iron-Sulfur Protein
4C1N	;	2.53	;	Corrinoid protein reactivation complex with activator
4C41	;	1.8	;	Corticosteroid-binding globulin with engineered disulphide bridge between residues 100 and 236
8GTM	;	2.6	;	Corticotropin-releasing hormone receptor 1(CRF1R) bound with BMK-C203 by XFEL
8GTI	;	2.2	;	Corticotropin-releasing hormone receptor 1(CRF1R) bound with BMK-C205 by XFEL
8GTG	;	2.75	;	Corticotropin-releasing hormone receptor 1(CRF1R) bound with BMK-I-152 by XFEL
6Y1Q	;		;	Cortistatin analog with improved immunoregulatory activity
1M9H	;	2.0	;	Corynebacterium 2,5-DKGR A and Phe 22 replaced with Tyr (F22Y), Lys 232 replaced with Gly (K232G), Arg 238 replaced with His (R238H)and Ala 272 replaced with Gly (A272G)in presence of NADH cofactor
6TR8	;		;	Corynebacterium diphtheriae methionine sulfoxide reductase B (MsrB) solution structure - reduced form
4AC6	;	2.54	;	Corynebacterium glutamicum AcnR AU derivative structure
5WAT	;	2.141	;	Corynebacterium glutamicum Full length Homoserine kinase
5WAS	;	1.799	;	Corynebacterium glutamicum Hydrolyzed Homoserine kinase
3RH0	;	1.724	;	Corynebacterium glutamicum mycothiol/mycoredoxin1-dependent arsenate reductase Cg_ArsC2
6G1D	;	1.992	;	Corynebacterium glutamicum OxyR C206 mutant
6G4R	;	2.62	;	Corynebacterium glutamicum OxyR C206S mutant, H2O2-bound
6G1B	;	2.28	;	Corynebacterium glutamicum OxyR, oxidized form
3T38	;	2.2	;	Corynebacterium glutamicum thioredoxin-dependent arsenate reductase Cg_ArsC1'
8UVX	;	2.9	;	CosR DNA bound form I
8UVK	;	2.21	;	CosR DNA bound form II
3F8E	;	2.0	;	Coumarins are a novel class of suicide carbonic anhydrase inhibitors
1BV7	;	2.0	;	COUNTERACTING HIV-1 PROTEASE DRUG RESISTANCE: STRUCTURAL ANALYSIS OF MUTANT PROTEASES COMPLEXED WITH XV638 AND SD146, CYCLIC UREA AMIDES WITH BROAD SPECIFICITIES
1ZL3	;	2.8	;	Coupling of active site motions and RNA binding
1FN7	;	2.6	;	COUPLING OF DAMAGE RECOGNITION AND CATALYSIS BY A HUMAN BASE-EXCISION DNA REPAIR PROTEIN
1N3H	;		;	Coupling of Folding and Binding in the PTB Domain of the Signaling Protein Shc
1OY2	;		;	Coupling of Folding and Binding in the PTB Domain of the Signaling Protein Shc
7EIZ	;		;	Coupling of N7-methyltransferase and 3'-5' exoribonuclease with SARS-CoV-2 polymerase reveals mechanisms for capping and proofreading
4U8V	;	2.298	;	Coupling of remote alternating-access transport mechanisms for protons and substrates in the multidrug efflux pump AcrB
4U8Y	;	2.099	;	Coupling of remote alternating-access transport mechanisms for protons and substrates in the multidrug efflux pump AcrB
4U95	;	2.0	;	Coupling of remote alternating-access transport mechanisms for protons and substrates in the multidrug efflux pump AcrB
4U96	;	2.2	;	Coupling of remote alternating-access transport mechanisms for protons and substrates in the multidrug efflux pump AcrB
6G79	;	3.78	;	Coupling specificity of heterotrimeric Go to the serotonin 5-HT1B receptor
1PW8	;	1.3	;	Covalent Acyl Enzyme Complex Of The R61 DD-Peptidase with A Highly Specific Cephalosporin
1PWD	;	1.2	;	Covalent acyl enzyme complex of the Streptomyces R61 DD-peptidase with cephalosporin C
1H84	;	2.0	;	COVALENT ADDUCT BETWEEN POLYAMINE OXIDASE AND N1ethylN11((cycloheptyl)methyl)4,8diazaundecane at pH 4.6
1H86	;	2.0	;	COVALENT ADDUCT BETWEEN POLYAMINE OXIDASE AND N1ethylN11((cycloheptyl)methyl)4,8diazaundecane at pH 7.0
6VB9	;	1.881	;	Covalent adduct of cis-2,3-epoxysuccinic acid with Isocitrate Lyase-1 from Mycobacterium tuberculosis
1DAO	;	3.2	;	COVALENT ADDUCT OF D-AMINO ACID OXIDASE FROM PIG KIDNEY WITH 3-METHYL-2-OXO-VALERIC ACID
8AOA	;	1.62	;	Covalent and non-covalent inhibitor of ERK2 (two sites)
1GJM	;	2.2	;	Covalent attachment of an electroactive sulphydryl reagent in the active site of cytochrome P450cam
3U9X	;	1.8	;	Covalent attachment of pyridoxal-phosphate derivatives to 14-3-3 proteins
8HHQ	;	2.4	;	Covalent bond formation between cysteine of PPARg-LBD and iodoacetic acid
5ZWF	;	2.1	;	Covalent bond formation between histidine of Vitamin D receptor (VDR) and a full agonist having a enone with a beta methyl group via conjugate addition reaction
5ZWE	;	2.72	;	Covalent bond formation between histidine of Vitamin D receptor (VDR) and a full agonist having a vinyl ketone group via conjugate addition reaction
5ZWH	;	2.38	;	Covalent bond formation between histidine of Vitamin D receptor (VDR) and a full agonist having an ene-ynone group via conjugate addition reaction
6JEY	;	2.2	;	Covalent bond formation between ynone moiety of synthetic fatty acid and hPPARg-LBD
5WR1	;	2.34	;	Covalent bond formation of bifunctional ligand with hPPARg-LBD
5WQX	;	2.29	;	Covalent bond formation of synthetic ligand with hPPARg-LBD
7QV0	;	2.49	;	Covalent complex between Scalindua brodae amxFabZ and amxACP
4S2C	;	2.2	;	Covalent complex of E. coli transaldolase TalB with fructose-6-phosphate
4S2B	;	1.46	;	Covalent complex of E. coli transaldolase TalB with tagatose-6-phosphate
2E6Y	;	1.6	;	Covalent complex of orotidine 5'-monophosphate decarboxylase (ODCase) with 6-Iodo-UMP
2ZZ3	;	1.8	;	Covalent complex of orotidine monophosphate decarboxylase D70A mutant from M. thermoautotrophicus with 6-cyano-UMP
2ZZ4	;	1.67	;	Covalent complex of orotidine monophosphate decarboxylase D75N mutant from M. thermoautotrophicum with 6-cyano-UMP
2ZZ6	;	1.66	;	Covalent complex of orotidine monophosphate decarboxylase from M. thermoautotrophicum with 6-azido-UMP
6XHN	;	1.377	;	Covalent complex of SARS-CoV main protease with 4-methoxy-N-[(2S)-4-methyl-1-oxo-1-({(2S)-3-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl}amino)pentan-2-yl]-1H-indole-2-carboxamide
6XHO	;	1.446	;	Covalent complex of SARS-CoV main protease with ethyl (4R)-4-({N-[(4-methoxy-1H-indol-2-yl)carbonyl]-L-leucyl}amino)-5-[(3S)-2-oxopyrrolidin-3-yl]pentanoate
6XHL	;	1.471	;	Covalent complex of SARS-CoV main protease with N-[(2S)-1-({(2S,3S)-3,4-dihydroxy-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl}amino)-4-methyl-1-oxopentan-2-yl]-4-methoxy-1H-indole-2-carboxamide
6XHM	;	1.406	;	Covalent complex of SARS-CoV-2 main protease with N-[(2S)-1-({(2S,3S)-3,4-dihydroxy-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl}amino)-4-methyl-1-oxopentan-2-yl]-4-methoxy-1H-indole-2-carboxamide
2QCN	;	1.85	;	Covalent complex of the orotidine-5'-monophosphate decarboxylase domain of human UMP synthase with 6-iodo-UMP
2RG3	;	1.8	;	Covalent complex structure of elastase
7ACE	;		;	Covalent dimer of Capra hircus Cathelicidin-1 in water
4UNV	;	1.6	;	Covalent dimer of lambda variable domains
5QIO	;	1.46	;	Covalent fragment group deposition -- Crystal Structure of OUTB2 in complex with P11
5QIP	;	1.63	;	Covalent fragment group deposition -- Crystal Structure of OUTB2 in complex with PCM-0102153
5QIR	;	1.43	;	Covalent fragment group deposition -- Crystal Structure of OUTB2 in complex with PCM-0102305
5QIS	;	1.53	;	Covalent fragment group deposition -- Crystal Structure of OUTB2 in complex with PCM-0102500
5QIW	;	1.71	;	Covalent fragment group deposition -- Crystal Structure of OUTB2 in complex with PCM-0102660
5QIT	;	1.46	;	Covalent fragment group deposition -- Crystal Structure of OUTB2 in complex with PCM-0102821
5QIY	;	1.58	;	Covalent fragment group deposition -- Crystal Structure of OUTB2 in complex with PCM-0102954
5QIV	;	1.39	;	Covalent fragment group deposition -- Crystal Structure of OUTB2 in complex with PCM-0102998
5QIX	;	1.39	;	Covalent fragment group deposition -- Crystal Structure of OUTB2 in complex with PCM-0103007
5QIU	;	1.56	;	Covalent fragment group deposition -- Crystal Structure of OUTB2 in complex with PCM-0103011
5QIQ	;	1.44	;	Covalent fragment group deposition -- Crystal Structure of OUTB2 in complex with PCM-0103050
5QIZ	;	1.63	;	Covalent fragment group deposition -- Crystal Structure of OUTB2 in complex with PCM-0103080
1H6M	;	1.64	;	Covalent glycosyl-enzyme intermediate of hen egg white lysozyme
4C4D	;	1.32	;	Covalent glycosyl-enzyme intermediate of Hypocrea jecorina Cel7a E217Q mutant trapped using DNP-2-deoxy-2-fluoro-cellotrioside
5KYK	;	2.702	;	Covalent GTP-competitive inhibitors of KRAS G12C: Guanosine bisphosphonate Analogs
5O8V	;	2.0	;	Covalent Inhibitor 4a bound to the Lipid Pocket of p38alpha Mutant S251C
5O8U	;	2.0	;	Covalent Inhibitor 4b bound to the Lipid Pocket of p38alpha Mutant S252C
5KRE	;	2.0	;	Covalent inhibitor of LYPLAL1
2OWW	;	2.2	;	Covalent intermediate in amylomaltase in complex with the acceptor analog 4-deoxyglucose
1S46	;	2.2	;	Covalent intermediate of the E328Q amylosucrase mutant
6JF0	;	3.4	;	Covalent labeling of hPPARg-LBD by turn-on fluorescent probe mediated by conjugate addition and cyclization
6JEZ	;	2.3	;	Covalent labeling of rVDR-LBD by turn-on fluorescent probe mediated by conjugate addition and cyclization
1D39	;	1.2	;	COVALENT MODIFICATION OF GUANINE BASES IN DOUBLE STRANDED DNA: THE 1.2 ANGSTROMS Z-DNA STRUCTURE OF D(CGCGCG) IN THE PRESENCE OF CUCL2
4L1S	;	1.5	;	Covalent modification of transthyretin K15 by yielding the fluorescent conjugate (E)-3-(dimethylamino)-5-(4-hydroxy-3,5-dimethylstyryl)benzamide
1PWG	;	1.074	;	Covalent Penicilloyl Acyl Enzyme Complex Of The Streptomyces R61 DD-Peptidase With A Highly Specific Penicillin
1TQH	;	1.63	;	Covalent Reaction intermediate Revealed in Crystal Structure of the Geobacillus stearothermophilus Carboxylesterase Est30
8D2M	;	1.821	;	Covalent Schiff base complex of YedK C2A and abasic DNA
1MHT	;	2.6	;	COVALENT TERNARY STRUCTURE OF HHAI METHYLTRANSFERASE, DNA AND S-ADENOSYL-L-HOMOCYSTEINE
2IBI	;	2.2	;	Covalent Ubiquitin-USP2 Complex
3IHP	;	2.8	;	Covalent Ubiquitin-Usp5 Complex
7ACB	;		;	Covalent/noncovalent tetramer of Capra hircus Cathelicidin-1 in DPC (dodecylphosphocholine) micelles
6CG5	;	2.08	;	Covalently crosslinked trimer of a macrocyclic peptide derived from Abeta (17-36) - (ORN)LCVFFCED(ORN)AII(2-nitrobenzylglycine)L(ORN)V
6CG4	;	2.083	;	Covalently crosslinked trimer of a macrocyclic peptide derived from Abeta(17-36) - (ORN)LCVFFCED(ORN)AII(2-nitrobenzylglycine)L(ORN)V
7U4P	;	1.803	;	Covalently stabilized triangular trimer composed of Abeta17-36 beta-hairpins
8ECA	;	2.27	;	Covalently stabilized triangular trimer derived from Abeta16-36
8EC9	;	2.169	;	Covalently stabilized triangular trimer derived from Abeta16-36 with p-iodo-phenylalanine
7BZF	;	3.26	;	COVID-19 RNA-dependent RNA polymerase post-translocated catalytic complex
7C2K	;	2.93	;	COVID-19 RNA-dependent RNA polymerase pre-translocated catalytic complex
7Q9G	;	3.3	;	COVOX-222 fab in complex with SARS-CoV-2 beta-Spike glycoprotein
1NY7	;	3.0	;	COWPEA MOSAIC VIRUS (CPMV)
5MS1	;	4.25	;	Cowpea mosaic virus top component (CPMV-T) - naturally occurring empty particles
5MSH	;	4.25	;	Cowpea mosaic virus top component (CPMV-T) - naturally occurring empty particles
5WBE	;	2.75	;	COX-1:MOFEZOLAC COMPLEX STRUCTURE
5U6X	;	2.93	;	COX-1:P6 COMPLEX STRUCTURE
6S3A	;	1.52	;	Coxsackie B3 2C protein in complex with S-Fluoxetine
6T3W	;	1.82	;	Coxsackie B3 2C protein in complex with S-Fluoxetine
7TQU	;	3.8	;	Coxsackievirus A21 capsid subdomain in complex with mouse polyclonal antibody pAbC-1
7TQS	;	3.9	;	Coxsackievirus A21 capsid subdomain in complex with mouse polyclonal antibody pAbC-3
7TQT	;	4.1	;	Coxsackievirus A21 capsid subdomain in complex with mouse polyclonal antibody pAbC-5
7QB5	;	1.728	;	Coxsackievirus A24v (CVA24v) in complex with a dimeric C2-C9-linked sialic acid inhibitor
6EIT	;	3.9	;	Coxsackievirus A24v in complex with the D1-D2 fragment of ICAM-1
7C9Z	;	3.6	;	Coxsackievirus B1 F-particle
7VY5	;	3.15	;	Coxsackievirus B3 (VP3-234Q) incubation with CD55 at pH7.4
3DDK	;	2.25	;	Coxsackievirus B3 3Dpol RNA Dependent RNA Polymerase
4WFZ	;	1.803	;	Coxsackievirus B3 3Dpol RNA Dependent RNA Polymerase - NaCl Crystal Form
7VXL	;	3.3	;	Coxsackievirus B3 A-particle at pH7.4 (VP3-234Q)
7VYL	;	2.79	;	Coxsackievirus B3 at pH5.5 (VP3-234Q) incubation with coxsackievirus and adenovirus receptor for 20min
7VYM	;	3.68	;	Coxsackievirus B3 at pH7.4 (VP3-234E) incubation with coxsackievirus and adenovirus receptor for 10min
7W14	;	2.2	;	Coxsackievirus B3 at pH7.4 (VP3-234E) incubation with coxsackievirus and adenovirus receptor for 20min
7VYK	;	2.79	;	Coxsackievirus B3 at pH7.4 (VP3-234Q) incubation with coxsackievirus and adenovirus receptor for 10min
7VXZ	;	3.19	;	Coxsackievirus B3 at pH7.4 (VP3-234Q) incubation with coxsackievirus and adenovirus receptor for 20min
1COV	;	3.5	;	COXSACKIEVIRUS B3 COAT PROTEIN
7VXN	;	3.53	;	Coxsackievirus B3 Empty particle at pH7.4 (VP3-234Q)
7W17	;	2.5	;	Coxsackievirus B3 full particle at pH7.4 (VP3-234E)
7VY0	;	2.7	;	Coxsackievirus B3 full particle at pH7.4 (VP3-234N)
7VXH	;	2.95	;	Coxsackievirus B3 full particle at pH7.4 (VP3-234Q)
6ZCL	;	2.8	;	Coxsackievirus B3 in complex with capsid binder compound 17
4ZPC	;	1.59	;	Coxsackievirus B3 Polymerase - A341G mutant
4ZPD	;	1.797	;	Coxsackievirus B3 Polymerase - A345V mutant
4WFY	;	2.06	;	Coxsackievirus B3 Polymerase - F232L Mutant - AmSO4 Crystal Form
4WFX	;	1.808	;	Coxsackievirus B3 Polymerase - F232L Mutant - NaCl Crystal Form
4ZP6	;	1.648	;	Coxsackievirus B3 Polymerase - F364A mutant
4ZP9	;	1.799	;	Coxsackievirus B3 Polymerase - F364I mutant
4ZP8	;	1.894	;	Coxsackievirus B3 Polymerase - F364L mutant
4ZP7	;	1.901	;	Coxsackievirus B3 Polymerase - F364V mutant
4ZPB	;	1.797	;	Coxsackievirus B3 Polymerase - F364W mutant
4ZPA	;	2.665	;	Coxsackievirus B3 Polymerase - F364Y mutant
4K4Y	;	2.72	;	Coxsackievirus B3 polymerase elongation complex (r2+1_form)
4K4X	;	2.37	;	Coxsackievirus B3 polymerase elongation complex (r2_form), rna
4K4Z	;	2.17	;	Coxsackievirus B3 polymerase elongation complex (r2_Mg_form)
7VY6	;	3.02	;	Coxsackievirus B3(VP3-234N) incubate with CD55 at pH7.4
6ZCK	;	2.7	;	Coxsackievirus B4 in complex with capsid binder compound 48
6ZMS	;	3.4	;	Coxsackievirus B4 strain E2
7C9Y	;	3.5	;	Coxsackievirus B5 (CVB5) F-particle
2GG4	;	2.1	;	CP4 EPSP synthase (unliganded)
2GGD	;	1.7	;	CP4 EPSP synthase Ala100Gly liganded with S3P and Glyphosate
2GG6	;	1.64	;	CP4 EPSP synthase liganded with S3P
2GGA	;	1.7	;	CP4 EPSP synthase liganded with S3P and Glyphosate
2PQB	;	1.8	;	CP4 EPSPS liganded with (R)-difluoromethyl tetrahedral intermediate analog
2PQC	;	1.6	;	CP4 EPSPS liganded with (R)-phosphonate tetrahedral reaction intermediate analog
7Z0F	;	2.396	;	CPAP:S-TUBULIN:IIH5 ALPHAREP COMPLEX
7Q1F	;	2.347	;	CPAP:TUBULIN:IE5 ALPHAREP COMPLEX
7Z0G	;	3.487	;	CPAP:TUBULIN:IE5 ALPHAREP COMPLEX P1 SPACE GROUP
7Q1E	;	2.7	;	CPAP:TUBULIN:IIH5 ALPHAREP COMPLEX
2JA5	;	3.8	;	CPD lesion containing RNA Polymerase II elongation complex A
2JA6	;	4.0	;	CPD lesion containing RNA Polymerase II elongation complex B
2JA7	;	3.8	;	CPD lesion containing RNA Polymerase II elongation complex C
2JA8	;	3.8	;	CPD lesion containing RNA Polymerase II elongation complex D
3REN	;	2.0	;	CPF_2247, a novel alpha-amylase from Clostridium perfringens
8C56	;	2.4	;	CpG specific M.MpeI methyltransferase crystallized in the presence of 2'-deoxy-5-methylzebularine (5mZ) and 5-methylcytosine containing dsDNA
8C57	;	1.95	;	CpG specific M.MpeI methyltransferase crystallized in the presence of 5,6-dihydro-5-azacytosine (converted to 5m-dhaC) and 5-methylcytosine containing dsDNA
8C59	;	1.7	;	CpG specific M.MpeI methyltransferase crystallized in the presence of 5-bromocytosine (converted to 5mC) and 5-methylcytosine containing dsDNA
8C58	;	1.85	;	CpG specific M.MpeI methyltransferase crystallized in the presence of 5-hydroxycytosine and 5-methylcytosine containing dsDNA
4DKJ	;	2.15	;	CpG specific methyltransferase in complex with target DNA
4A4A	;	1.9	;	CpGH89 (E483Q, E601Q), from Clostridium perfringens, in complex with its substrate GlcNAc-alpha-1,4-galactose
4A3Z	;	1.55	;	CpGH89CBM32-4 (seleno-methionine labeled) produced by Clostridium perfringens
4A6O	;	2.8	;	CpGH89CBM32-4, produced by Clostridium perfringens, in complex with glcNAc-alpha-1,4-galactose
4A41	;	1.55	;	CpGH89CBM32-5, from Clostridium perfringens, in complex with galactose
4A45	;	1.75	;	CpGH89CBM32-5, from Clostridium perfringens, in complex with GalNAc- beta-1,3-galactose
4AAX	;	1.9	;	CpGH89CBM32-5, from Clostridium perfringens, in complex with N- acetylgalactosamine
4A44	;	1.7	;	CpGH89CBM32-5, from Clostridium perfringens, in complex with the Tn Antigen
4A42	;	1.55	;	CpGH89CBM32-6 produced by Clostridium perfringens
1K5O	;		;	CPI-17(35-120) deletion mutant
4R9F	;	1.4	;	CpMnBP1 with Mannobiose Bound
4R9G	;	2.2	;	CpMnBP1 with Mannotriose Bound
3N26	;	2.1	;	Cpn0482 : the arginine binding protein from the periplasm of chlamydia Pneumoniae
4ZXL	;	2.6	;	CpOGA D298N in complex with Drosophila HCF -derived Thr-O-GlcNAc peptide
2YDQ	;	2.6	;	CpOGA D298N in complex with hOGA-derived O-GlcNAc peptide
6RHE	;	3.1	;	CpOGA D298N in complex with hOGA-derived S-GlcNAc peptide
2YDR	;	2.75	;	CpOGA D298N in complex with p53-derived O-GlcNAc peptide
2YDS	;	2.55	;	CpOGA D298N in complex with TAB1-derived O-GlcNAc peptide
7KHV	;	2.3	;	CpOGA IN COMPLEX WITH LIGAND 54
7OB6	;	2.598	;	CPR-C4 - a conserved novel protease from the Candidate Phyla Radiation
7OB7	;	2.682	;	CPR-C4 - novel protease from the Candidate Phyla Radiation (CPR)
3E6C	;	1.8	;	CprK OCPA DNA Complex
6UEL	;	1.9	;	CPS1 bound to allosteric inhibitor H3B-193
6W2J	;	2.62	;	CPS1 bound to allosteric inhibitor H3B-374
4B4N	;	1.813	;	CPSF6 defines a conserved capsid interface that modulates HIV-1 replication
8B7T	;		;	CPSF73 CTD3
1IJS	;	3.25	;	CPV (STRAIN D) mutant A300D, complex (VIRAL COAT/DNA), VP2, PH=7.5, T=4 DEGREES C
7UTP	;	3.8	;	CPV Affinity Purified Polyclonal Fab A Site Fab
7UTR	;	3.7	;	CPV Affinity Purified Polyclonal Fab B Site Fab
7UTS	;	3.6	;	CPV Total-Fab Polyclonal A Site Fab
7UTU	;	3.0	;	CPV Total-Fab Polyclonal B Site Fab (1 of 2)
7UTV	;	3.0	;	CPV Total-Fab Polyclonal B Site Fab (2 of 2)
4GW1	;	2.24	;	cQFD Meditope
4GW5	;	2.2	;	cQYN meditope - Cetuximab Fab
7YNG	;	3.1	;	CR-bound alpha-synuclein fibrils
2MCZ	;		;	CR1 Sushi domains 1 and 2
2MCY	;		;	CR1 Sushi domains 2 and 3
5W1G	;	2.0	;	CR1-07 unliganded Fab
6H6M	;	2.38	;	CR10 murine norovirus protruding domain in complex with the CD300lf receptor and glycochenodeoxycholate (GCDCA)
1GHQ	;	2.04	;	CR2-C3D COMPLEX STRUCTURE
7OXX	;	1.33	;	CrabP2 mutant R30AK31A
7OXW	;	1.16	;	CrabP2 mutant R30DK31D
1EJG	;	0.54	;	CRAMBIN AT ULTRA-HIGH RESOLUTION: VALENCE ELECTRON DENSITY.
1JXT	;	0.89	;	CRAMBIN MIXED SEQUENCE FORM AT 160 K. PROTEIN/WATER SUBSTATES
1JXW	;	0.89	;	CRAMBIN MIXED SEQUENCE FORM AT 180 K. PROTEIN/WATER SUBSTATES
1JXX	;	0.89	;	CRAMBIN MIXED SEQUENCE FORM AT 200 K. PROTEIN/WATER SUBSTATES
1JXY	;	0.89	;	CRAMBIN MIXED SEQUENCE FORM AT 220 K. PROTEIN/WATER SUBSTATES
1JXU	;	0.99	;	CRAMBIN MIXED SEQUENCE FORM AT 240 K. PROTEIN/WATER SUBSTATES
6LIJ	;	2.1	;	Crassostrea gigas ferritin
6LJG	;	1.799	;	Crassostrea gigas ferritin mutant-D119G
7DLB	;	2.502	;	Crassostrea gigas ferritin mutant-D119K
2D3P	;	2.8	;	Cratylia Floribunda seed lectin crystallized at basic pH
2D3R	;	2.9	;	Cratylia folibunda seed lectin at acidic pH
1MVQ	;	1.77	;	Cratylia mollis lectin (isoform 1) in complex with methyl-alpha-D-mannose
5FCM	;	2.229	;	CrBld10-N 1-70
7EKO	;	3.3	;	CrClpP-S1
7EKQ	;	3.6	;	CrClpP-S2c
1KBU	;	2.2	;	CRE RECOMBINASE BOUND TO A LOXP HOLLIDAY JUNCTION
7RHY	;	3.91	;	Cre recombinase mutant (D33A/A36V/R192A) in complex with loxA DNA hairpin
3MGV	;	2.29	;	Cre recombinase-DNA transition state
3CRX	;	2.5	;	CRE RECOMBINASE/DNA COMPLEX INTERMEDIATE I
1CRX	;	2.4	;	CRE RECOMBINASE/DNA COMPLEX REACTION INTERMEDIATE I
3C29	;	2.2	;	Cre-loxP Synaptic structure
4CR5	;	2.0	;	Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design
4CR9	;	1.7	;	Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design
4CRA	;	1.8	;	Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design
4CRB	;	1.85	;	Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design
4CRC	;	1.6	;	Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design
4CRD	;	2.1	;	Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design
4CRE	;	1.73	;	Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design
4CRF	;	2.3	;	Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design
4CRG	;	1.25	;	Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design
3A6D	;	1.9	;	Creatininase complexed with 1-methylguanidine
1J2T	;	1.8	;	Creatininase Mn
1J2U	;	1.85	;	Creatininase Zn
1V7Z	;	1.6	;	creatininase-product complex
6ALB	;	2.053	;	CREBBP bromodomain in complex with Cpd 30 (1-(3-(3-(1-methyl-1H-pyrazol-4-yl)isoquinolin-8-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-1-one)
6ALC	;	1.391	;	CREBBP bromodomain in complex with Cpd 4 (1-(1-(cyclopropylmethyl)-3-(1H-indol-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-1-one)
5KTW	;	1.087	;	CREBBP bromodomain in complex with Cpd 44 (3-((5-acetyl-1-(cyclopropylmethyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)amino)-N-isopropylbenzamide)
5W0L	;	1.549	;	CREBBP Bromodomain in complex with Cpd10 (1-(3-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-1-one)
6AY3	;	1.391	;	CREBBP bromodomain in complex with Cpd16 (5-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-N-methyl-1H-indole-3-carboxamide)
6AY5	;	1.44	;	CREBBP bromodomain in complex with Cpd17 (5-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-3-methylbenzo[d]thiazol-2(3H)-one)
5W0Q	;	1.7	;	CREBBP Bromodomain in complex with Cpd17 (N,2,7-trimethyl-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxamide)
5W0E	;	1.41	;	CREBBP bromodomain in complex with Cpd19 (3-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-N-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide)
5W0F	;	1.6	;	CREBBP Bromodomain in complex with Cpd3 ((S)-1-(3-(6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-1-(tetrahydrofuran-3-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-1-one)
5KTX	;	1.27	;	CREBBP bromodomain in complex with Cpd59 ((S)-1-(3-((2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)amino)-1-(tetrahydrofuran-3-yl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)ethanone)
6AXQ	;	1.3	;	CREBBP bromodomain in complex with Cpd6 (methyl 1H-indole-3-carboxylate)
5W0I	;	1.43	;	CREBBP Bromodomain in complex with Cpd8 (1-(3-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-1-(tetrahydrofuran-3-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-1-one)
5DN7	;	2.2	;	Crescerin uses a TOG domain array to regulate microtubules in the primary cilium
1BTI	;	2.2	;	CREVICE-FORMING MUTANTS IN THE RIGID CORE OF BOVINE PANCREATIC TRYPSIN INHIBITOR: CRYSTAL STRUCTURES OF F22A, Y23A, N43G, AND F45A
1FAN	;	2.0	;	CREVICE-FORMING MUTANTS IN THE RIGID CORE OF BOVINE PANCREATIC TRYPSIN INHIBITOR: CRYSTAL STRUCTURES OF F22A, Y23A, N43G, AND F45A
1NAG	;	1.9	;	CREVICE-FORMING MUTANTS IN THE RIGID CORE OF BOVINE PANCREATIC TRYPSIN INHIBITOR: CRYSTAL STRUCTURES OF F22A, Y23A, N43G, AND F45A
1BPT	;	2.0	;	CREVICE-FORMING MUTANTS OF BPTI: CRYSTAL STRUCTURES OF F22A, Y23A, N43G, AND F45A
6P9X	;	2.91	;	CRF1 Receptor Gs GPCR protein complex with CRF1 peptide
6IBW	;	2.8	;	Crh5 transglycosylase in complex with NAG
1B35	;	2.4	;	CRICKET PARALYSIS VIRUS (CRPV)
3MJ3	;	3.1	;	Cricket Paralysis Virus IGR IRES Domain 3 RNA bound to selenate
3MJA	;	2.8	;	Cricket Paralysis Virus IGR IRES Domain 3 RNA bound to selenate, structure #2
3MJB	;	2.8	;	Cricket Paralysis Virus IGR IRES Domain 3 RNA bound to sulfate
6C3R	;	2.6	;	Cricket paralysis virus RNAi suppressor protein CrPV-1A
5FMR	;	2.0	;	crIFT52 N-terminal domain
5FMT	;	1.878	;	CrIFT54 CH-domain
2ICF	;	4.1	;	CRIg bound to C3b
2ICE	;	3.1	;	CRIg bound to C3c
2L7X	;		;	Crimean Congo Hemorrhagic Fever Gn zinc finger
3ZNH	;	2.3	;	Crimean Congo Hemorrhagic Fever Virus OTU domain in complex with ubiquitin-propargyl.
7A5A	;	2.989	;	Crimean-Congo Hemorrhagic Fever Virus Envelope Glycoprotein Gc W1191H/W1197A/W1199A Mutant in Postfusion Conformation (Monoclinic Crystal Form)
7A59	;	2.197	;	Crimean-Congo Hemorrhagic Fever Virus Envelope Glycoprotein Gc W1191H/W1197A/W1199A Mutant in Postfusion Conformation (Orthorhombic Crystal Form)
6WEM	;	2.04	;	Crimson 0.9
5YI6	;	1.852	;	CRISPR associated protein Cas6
6NBU	;	2.75	;	CRISPR Complex Subunit Csm2 from Staphylococcus epidermidis RP62a
6NBT	;	2.4	;	CRISPR Complex Subunit Csm3 from Staphylococcus epidermidis RP62a
4ILM	;	3.068	;	CRISPR RNA Processing endoribonuclease
5U07	;	3.8	;	CRISPR RNA-guided surveillance complex
5U0A	;	3.3	;	CRISPR RNA-guided surveillance complex
6C66	;	3.66	;	CRISPR RNA-guided surveillance complex, pre-nicking
5H1O	;	1.65	;	CRISPR-associated protein
5H1P	;	1.75	;	CRISPR-associated protein
2YK3	;	1.55	;	CRITHIDIA FASCICULATA CYTOCHROME C
5UNI	;	2.2	;	Critical role of water molecules for proton translocation of the membrane-bound transhydrogenase
2VRW	;	1.85	;	Critical structural role for the PH and C1 domains of the Vav1 exchange factor
1B07	;	2.5	;	CRK SH3 DOMAIN COMPLEXED WITH PEPTOID INHIBITOR
5JN0	;	1.677	;	CRK-II SH2 domain
6LIX	;	2.385	;	CRL Protein of Arabidopsis
8B3I	;	3.5	;	CRL4CSA-E2-Ub (state 2)
1ORC	;	1.54	;	CRO REPRESSOR INSERTION MUTANT K56-[DGEVK]
2ORC	;		;	CRO REPRESSOR INSERTION MUTANT K56-[DGEVK], NMR, 32 STRUCTURES
6I86	;	2.0	;	Crocagin biosynthetic gene J
7PD7	;	1.96	;	Crocagin methyl transferase CgnL
6DN4	;	1.99	;	Cronobacter sakazakii (Enterobacter sakazakii) Metallo-beta-lactamse HARLDQ motif
6DQH	;	1.104	;	Cronobacter sakazakii (Enterobacter sakazakii) Metallo-beta-lactamse HARLDQ motif
6NC5	;	2.074	;	Cronobacter sakazakii (Enterobacter sakazakii) Metallo-beta-lactamse HARLDQ motif
6DQ2	;	2.158	;	Cronobacter sakazakii (Enterobacter sakazakii) Metallo-beta-lactamse HARLDQ motif mutant S60
6DGN	;	1.999	;	Cronobacter turicensis BDSF synthase RpfF in complex with the RpfR quorum-sensing receptor FI domain
6DGJ	;	2.294	;	Cronobacter turicensis RpfR quorum-sensing receptor PAS domain in complex with BDSF
6DGG	;	1.498	;	Cronobacter turicensis RpfR quorum-sensing receptor PAS domain in complex with C12:0
6DGA	;	1.19	;	Cronobacter turicensis RpfR quorum-sensing receptor RpfF interaction domain
6O3N	;	3.7	;	Cross-alpha Amyloid-like Structure alphaAmA
6C4Y	;	2.5	;	Cross-alpha Amyloid-like Structure alphaAmG
6C4Z	;	3.3	;	Cross-alpha Amyloid-like Structure alphaAmG - low resolution
6C51	;	2.0	;	Cross-alpha Amyloid-like Structure alphaAmL
6D02	;	2.5	;	Cross-alpha Amyloid-like Structure alphaAmL, 2nd form
6C4X	;	3.55	;	Cross-alpha Amyloid-like Structure alphaAmmem
6C50	;	2.503	;	Cross-alpha Amyloid-like Structure alphaAmS
6C52	;	1.6	;	Cross-alpha Amyloid-like Structure alphaTet
1ZEI	;	1.9	;	CROSS-LINKED B28 ASP INSULIN
2F5W	;	2.001	;	Cross-linked barnase soaked in 3 M thiourea
2F5M	;	1.95	;	Cross-linked barnase soaked in bromo-ethanol
2LYO	;	1.93	;	CROSS-LINKED CHICKEN LYSOZYME CRYSTAL IN 90% ACETONITRILE-WATER
3LYO	;	1.93	;	CROSS-LINKED CHICKEN LYSOZYME CRYSTAL IN 95% ACETONITRILE-WATER
4LYO	;	2.05	;	CROSS-LINKED CHICKEN LYSOZYME CRYSTAL IN NEAT ACETONITRILE, THEN BACK-SOAKED IN WATER
3W5U	;	2.7	;	Cross-linked complex between Ferredoxin and Ferredoxin-NADP+ reductase
3W5V	;	3.81	;	Cross-linked complex between Ferredoxin and Ferredoxin-NADP+ reductase
8OQG	;	1.6	;	Cross-linked crystal of dirhodium tetraacetate/ribonuclease A adduct in the P3221 space group (high temperature data collection)
8OQF	;	1.5	;	Cross-linked crystal of Dirhodium tetraacetate/ribonuclease A adduct in the P3221 space group (low temperature data collection)
1CLS	;	1.9	;	CROSS-LINKED HUMAN HEMOGLOBIN DEOXY
1LYO	;	1.93	;	CROSS-LINKED LYSOZYME CRYSTAL IN NEAT WATER
1SDK	;	1.8	;	CROSS-LINKED, CARBONMONOXY HEMOGLOBIN A
1SDL	;	1.8	;	CROSS-LINKED, CARBONMONOXY HEMOGLOBIN A
8EN8	;	2.70001	;	Cross-reactive 3180 TCR recognition of HLA-B*35:01-NP4 epitope from 1972 influenza strain
8ENH	;	2.50003	;	Cross-reactive 3180 TCR recognition of HLA-B*35:01-NP7 epitope from 2002 H3N2 influenza strain
8EO8	;	2.3	;	Cross-reactive 3180 TCR recognition of HLA-B*35:01-NP8 epitope from 2005 H1N1 influenza strain
2J23	;	1.41	;	Cross-reactivity and crystal structure of Malassezia sympodialis Thioredoxin (Mala s 13), a member of a new pan-allergen family
4IML	;	2.931	;	CrossFab binding to human Angiopoietin 2
6N3P	;	2.5	;	Crosslinked AcpP=FabZ complex from E. coli Type II FAS
6KA9	;	1.4	;	Crosslinked alpha(Fe-CO)-beta(Ni) human hemoglobin A in the T quaternary structure at 95 K: Dark
6KAE	;	1.45	;	Crosslinked alpha(Fe-CO)-beta(Ni) human hemoglobin A in the T quaternary structure at 95 K: Light
6KAI	;	1.45	;	Crosslinked alpha(Ni)-beta(Fe) human hemoglobin A in the T quaternary structure at 95 K: Light
6KAH	;	1.45	;	Crosslinked alpha(Ni)-beta(Fe-CO) human hemoglobin A in the T quaternary structure at 95 K: Dark
6LCW	;	1.4	;	Crosslinked alpha(Ni)-beta(Ni) human hemoglobin A in the T quaternary structure at 95 K: Dark
6LCX	;	1.4	;	Crosslinked alpha(Ni)-beta(Ni) human hemoglobin A in the T quaternary structure at 95 K: Light
3M1F	;	2.89	;	Crosslinked complex of actin with first W domain of Vibrio parahaemolyticus VopL
6U0J	;	1.9	;	Crosslinked Crystal Structure of Malonyl-CoA Acyl Carrier Protein Transacylase, FabD, and Acyl Carrier Protein, AcpP
8DLE	;	2.3	;	Crosslinked Crystal Structure of the 8-amino-7-oxonanoate synthase, BioF, and Benzene Sulfonyl Fluoride-crypto Acyl Carrier Protein, BSF-ACP
5KOF	;	2.4	;	Crosslinked Crystal Structure of Type II Fatty Acid Synthase Ketosynthase, FabB, and Acyl Carrier Protein, AcpP
6OKC	;	1.55	;	Crosslinked Crystal Structure of Type II Fatty Acid Synthase Ketosynthase, FabB, and C12-crypto Acyl Carrier Protein, AcpP
7SQI	;	1.7	;	Crosslinked Crystal Structure of Type II Fatty Acid Synthase Ketosynthase, FabB, and C14-crypto Acyl Carrier Protein, AcpP
6OKF	;	2.5	;	Crosslinked Crystal Structure of Type II Fatty Acid Synthase Ketosynthase, FabB, and C16-crypto Acyl Carrier Protein, AcpP
7SZ9	;	2.2	;	Crosslinked Crystal Structure of Type II Fatty Acid Synthase Ketosynthase, FabB, and C16:1-crypto Acyl Carrier Protein, AcpP
6OLT	;	2.35	;	Crosslinked Crystal Structure of Type II Fatty Acid Synthase Ketosynthase, FabF, and C12-crypto Acyl Carrier Protein, AcpP
6OKG	;	2.3	;	Crosslinked Crystal Structure of Type II Fatty Acid Synthase Ketosynthase, FabF, and C16-crypto Acyl Carrier Protein, AcpP
7L4E	;	2.0	;	Crosslinked Crystal Structure of Type II Fatty Acid Synthase Ketosynthase, FabF, and C16:1-crypto Acyl Carrier Protein, AcpP
7L4L	;	2.65	;	Crosslinked Crystal Structure of Type II Fatty Acid Synthase Ketosynthase, FabF, and C8-crypto Acyl Carrier Protein, AcpP
8SMS	;	1.93	;	Crosslinked Crystal Structure of Type II Fatty Acid Synthase, FabB, and cerulenin crosslinker-crypto Acyl Carrier Protein, AcpP
4KEH	;	1.901	;	Crosslinked Crystal Structure of Type II Fatty Synthase Dehydratase, FabA, and Acyl Carrier Protein, AcpP
1HAB	;	2.3	;	CROSSLINKED HAEMOGLOBIN
1HAC	;	2.6	;	CROSSLINKED HAEMOGLOBIN
1NYI	;	2.85	;	Crosslinked Hammerhead Ribozyme Initial State
1BIJ	;	2.3	;	CROSSLINKED, DEOXY HUMAN HEMOGLOBIN A
2GJB	;	2.2	;	Crosslinking of DNA duplexes: X-ray crystal structure of an unsubstituted bisacridine with the oligonucleotide d(CGTACG)
1E4W	;	1.95	;	crossreactive binding of a circularized peptide to an anti-TGFalpha antibody Fab-fragment
1E4X	;	1.9	;	crossreactive binding of a circularized peptide to an anti-TGFalpha antibody Fab-fragment
1V11	;	1.95	;	CROSSTALK BETWEEN COFACTOR BINDING AND THE PHOSPHORYLATION LOOP CONFORMATION IN THE BCKD MACHINE
1V16	;	1.9	;	CROSSTALK BETWEEN COFACTOR BINDING AND THE PHOSPHORYLATION LOOP CONFORMATION IN THE BCKD MACHINE
1V1M	;	2.0	;	CROSSTALK BETWEEN COFACTOR BINDING AND THE PHOSPHORYLATION LOOP CONFORMATION IN THE BCKD MACHINE
1V1R	;	1.8	;	CROSSTALK BETWEEN COFACTOR BINDING AND THE PHOSPHORYLATION LOOP CONFORMATION IN THE BCKD MACHINE
4A46	;	1.85	;	Crosstalk between Cu(I) and Zn(II) homeostasis
4A47	;	1.9	;	Crosstalk between Cu(I) and Zn(II) homeostasis
4A48	;	1.4	;	Crosstalk between Cu(I) and Zn(II) homeostasis
4A4J	;	1.25	;	Crosstalk between Cu(I) and Zn(II) homeostasis
4GI2	;	3.0	;	Crotonyl-CoA Carboxylase/Reductase
2QOG	;	2.28	;	Crotoxin B, the basic PLA2 from Crotalus durissus terrificus.
4A2U	;	2.63	;	CRP(CAP) from Myco. Tuberculosis, with cAMP
7AKT	;	1.11	;	CrPetF variant - A39G_A41V
7D54	;	1.85	;	Crstal structure MsGATase with Gln
6LL6	;	2.5	;	Crsyal structure of EcFtsZ (residues 11-316)
4YOA	;	1.697	;	Crsystal structure HIV-1 Protease MDR769 L33F Complexed with darunavir
6JP9	;	2.1	;	Crsytal structure of a XMP complexed ATPPase subunit of M. jannaschii GMP synthetase
6T65	;	2.35	;	Crsytal structure of Acinetobacter baumannii FabG inhibitor complex at 2.35 A resolution
6M0V	;	3.0	;	Crsytal structure of streptococcus thermophilus Cas9 in complex with the GGAA PAM
7D8P	;	2.0	;	CRTC1 pSer151 peptide in complex with 14-3-3 zeta
7D9V	;	2.21	;	CRTC1 pSer245 peptide in complex with 14-3-3 zeta
7D8H	;	2.42	;	CRTC1 pSer64 peptide in complex with 14-3-3 zeta
8J9G	;	3.5	;	CrtSPARTA hetero-dimer bound with guide-target, state 1
8JAY	;	4.2	;	CrtSPARTA Octamer bound with guide-target
3WFL	;	1.6	;	Crtstal structure of glycoside hydrolase family 5 beta-mannanase from Talaromyces trachyspermus
7JUJ	;	2.2	;	Cruzain bound to Gallinamide inhibitor
1EWP	;	1.75	;	CRUZAIN BOUND TO MOR-LEU-HPQ
6UX6	;	1.94	;	Cruzain covalently bound by a vinylsulfone compound
3KKU	;	1.28	;	Cruzain in complex with a non-covalent ligand
1AIM	;	2.0	;	CRUZAIN INHIBITED BY BENZOYL-TYROSINE-ALANINE-FLUOROMETHYLKETONE
2AIM	;	2.2	;	CRUZAIN INHIBITED WITH BENZOYL-ARGININE-ALANINE-FLUOROMETHYLKETONE
8WRZ	;	3.6	;	Cry-EM structure of cannabinoid receptor-arrestin 2 complex
7V6A	;	3.6	;	Cry-EM structure of M4-c110-G protein complex
7XF2	;	3.73	;	Cry-EM structure of vp51 in white spot syndrome virus capsid
4QX2	;	2.9	;	Cry3A Toxin structure obtained by injecting Bacillus thuringiensis cells in an XFEL beam, collecting data by serial femtosecond crystallographic methods and processing data with the cctbx.xfel software suite
4QX3	;	2.9	;	Cry3A Toxin structure obtained by injecting Bacillus thuringiensis cells in an XFEL beam, collecting data by serial femtosecond crystallographic methods and processing data with the CrystFEL software suite
4QX0	;	2.8	;	Cry3A Toxin structure obtained by Serial Femtosecond Crystallography from in vivo grown crystals isolated from Bacillus thuringiensis and data processed with the cctbx.xfel software suite
4QX1	;	2.8	;	Cry3A Toxin structure obtained by Serial Femtosecond Crystallography from in vivo grown crystals isolated from Bacillus thuringiensis and data processed with the CrystFEL software suite
6LFP	;	3.31	;	Cry3Aa protein for enzyme entrapment
1GEG	;	1.7	;	CRYATAL STRUCTURE ANALYSIS OF MESO-2,3-BUTANEDIOL DEHYDROGENASE
4OCA	;	2.3	;	Cryatal structure of ArnB K188A complexted with PLP and UDP-Ara4N
3N9T	;	2.0	;	Cryatal structure of Hydroxyquinol 1,2-dioxygenase from Pseudomonas putida DLL-E4
7WR2	;	1.54	;	Cryatal structure of OspC3 C-terminal ankyrin-repeat domain
5FVM	;	6.7	;	Cryo electron microscopy of a complex of Tor and Lst8
5AJ0	;	3.5	;	Cryo electron microscopy of actively translating human polysomes (POST state).
5FOJ	;	2.8	;	Cryo electron microscopy structure of Grapevine Fanleaf Virus complex with Nanobody
6U9V	;	2.9	;	Cryo electron microscopy structure of the ATP-gated rat P2X7 ion channel in the apo, closed state
6U9W	;	3.3	;	Cryo electron microscopy structure of the ATP-gated rat P2X7 ion channel in the ATP-bound, open state
5AJ2	;	40.0	;	Cryo electron tomography of the Naip5-Nlrc4 inflammasome
7RYJ	;	3.3	;	Cryo EM analysis reveals inherent flexibility of authentic murine papillomavirus capsids
5IJ0	;	3.8	;	Cryo EM density of microtubule assembled from human TUBB3
5IJ9	;	3.7	;	Cryo EM density of microtubule assembled from human TUBB3-D417H mutant
7ARQ	;	10.0	;	Cryo EM of 3D DNA origami 16 helix bundle
7E20	;	2.7	;	Cryo EM structure of a K+-bound Na+,K+-ATPase in the E2 state
7E1Z	;	3.2	;	Cryo EM structure of a Na+-bound Na+,K+-ATPase in the E1 state
7E21	;	2.9	;	Cryo EM structure of a Na+-bound Na+,K+-ATPase in the E1 state with ATP-gamma-S
5UZ9	;	3.4	;	Cryo EM structure of anti-CRISPRs, AcrF1 and AcrF2, bound to type I-F crRNA-guided CRISPR surveillance complex
8IZ8	;	3.13	;	cryo EM structure of apo hMRP4
7P1I	;	3.15	;	Cryo EM structure of bison NHA2 in detergent and N-terminal extension helix
7P1J	;	3.04	;	Cryo EM structure of bison NHA2 in detergent structure
7P1K	;	3.64	;	Cryo EM structure of bison NHA2 in nano disc structure
7YDJ	;	3.03	;	Cryo EM structure of CD97/miniG12 complex
7YDH	;	3.1	;	Cryo EM structure of CD97/miniG13 complex
2B6B	;	25.0	;	Cryo EM structure of Dengue complexed with CRD of DC-SIGN
6DS5	;	3.8	;	Cryo EM structure of human SEIPIN
7FJM	;	3.3	;	Cryo EM structure of lysosomal ATPase
7FJP	;	3.0	;	Cryo EM structure of lysosomal ATPase
7FJQ	;	3.6	;	Cryo EM structure of lysosomal ATPase
7XC2	;	3.0	;	Cryo EM structure of oligomeric complex formed by wheat CNL Sr35 and the effector AvrSr35 of the wheat stem rust pathogen
7WCD	;	3.3	;	Cryo EM structure of SARS-CoV-2 spike in complex with TAU-2212 mAbs in conformation 4
7P9V	;	3.4	;	Cryo EM structure of System XC-
7P9U	;	3.7	;	Cryo EM structure of System XC- in complex with glutamate
5N8O	;	3.9	;	Cryo EM structure of the conjugative relaxase TraI of the F/R1 plasmid system
5OG1	;	4.5	;	Cryo EM structure of the E. coli disaggregase ClpB (BAP form, DWB mutant), in the ATPgammaS state
5OFO	;	4.6	;	Cryo EM structure of the E. coli disaggregase ClpB (BAP form, DWB mutant), in the ATPgammaS state, bound to the model substrate casein
6QCM	;	4.21	;	Cryo em structure of the Listeria stressosome
7D06	;	3.1	;	Cryo EM structure of the nucleotide free Acinetobacter MlaFEDB complex
8K9R	;	2.68	;	Cryo EM structure of the products-bound PGAP1(Bst1)-H443N from Chaetomium thermophilum
8C8H	;	3.84	;	Cryo EM structure of the vaccinia complete RNA polymerase complex lacking the capping enzyme
8EVU	;	2.5804	;	Cryo EM structure of Vibrio cholerae NQR
8EW3	;	2.65159	;	Cryo EM structure of Vibrio cholerae NQR
7Q22	;	6.3	;	cryo iDPC-STEM structure recorded with CSA 2.0
7Q23	;	4.3	;	cryo iDPC-STEM structure recorded with CSA 3.0
7Q2Q	;	4.3	;	cryo iDPC-STEM structure recorded with CSA 3.5
7Q2R	;	3.5	;	cryo iDPC-STEM structure recorded with CSA 4.0
7Q2S	;	3.7	;	cryo iDPC-STEM structure recorded with CSA 4.5
6Q8T	;	1.74009	;	Cryo structure of HEWL at 81 kGy
8ECF	;	2.736	;	Cryo structure of Mycobacterium tuberculosis beta lactamase microcrystals mixed with sulbactam for 3 hours
6BC4	;	2.049	;	Cryo X-ray structure of acetyl coenzyme A bound AAC-VIa
6BC2	;	2.195	;	Cryo X-ray structure of acetylsisomicin bound AAC-VIa
6BC6	;	2.2	;	Cryo X-ray structure of apo AAC-VIa
6BC5	;	2.2	;	Cryo X-ray structure of coenzyme A bound AAC-VIa
6BC3	;	2.047	;	Cryo X-ray structure of sisomicin bound AAC-VIa
6BC7	;	1.8	;	Cryo X-ray structure of sisomicin bound AAC-VIa
8WIF	;	2.9	;	Cryo- EM structure of Mycobacterium smegmatis 30S ribosomal subunit (body 2) of 70S ribosome and RafH.
8WI9	;	3.5	;	Cryo- EM structure of Mycobacterium smegmatis 30S ribosomal subunit (body 2) of 70S ribosome, bS1 and RafH.
8WID	;	3.5	;	Cryo- EM structure of Mycobacterium smegmatis 30S ribosomal subunit (body 2) of 70S ribosome, E- tRNA and RafH.
8WHY	;	2.7	;	Cryo- EM structure of Mycobacterium smegmatis 50S ribosomal subunit (body 1) of 70S ribosome and RafH.
8WI8	;	2.7	;	Cryo- EM structure of Mycobacterium smegmatis 50S ribosomal subunit (body 1) of 70S ribosome, bS1 and RafH.
8WIC	;	3.5	;	Cryo- EM structure of Mycobacterium smegmatis 50S ribosomal subunit (body 1) of 70S ribosome, E- tRNA and RafH.
8WHX	;	2.8	;	Cryo- EM structure of Mycobacterium smegmatis 70S ribosome and RafH.
8WI7	;	3.5	;	Cryo- EM structure of Mycobacterium smegmatis 70S ribosome, bS1 and RafH.
8WIB	;	3.5	;	Cryo- EM structure of Mycobacterium smegmatis 70S ribosome, E- tRNA and RafH.
6TRA	;	2.85	;	Cryo- EM structure of the Thermosynechococcus elongatus photosystem I in the presence of cytochrome c6
6TRC	;	2.98	;	Cryo- EM structure of the Thermosynechococcus elongatus photosystem I in the presence of cytochrome c6
6TRD	;	3.16	;	Cryo- EM structure of the Thermosynechococcus elongatus photosystem I in the presence of cytochrome c6
1A5B	;	2.0	;	CRYO-CRYSTALLOGRAPHY OF A TRUE SUBSTRATE, INDOLE-3-GLYCEROL PHOSPHATE, BOUND TO A MUTANT (ALPHA D60N) TRYPTOPHAN SYNTHASE ALPHA2BETA2 COMPLEX REVEALS THE CORRECT ORIENTATION OF ACTIVE SITE ALPHA GLU 49
1A5A	;	1.9	;	CRYO-CRYSTALLOGRAPHY OF A TRUE SUBSTRATE, INDOLE-3-GLYCEROL PHOSPHATE, BOUND TO A MUTANT (ALPHAD60N) TRYPTOPHAN SYNTHASE ALPHA2BETA2 COMPLEX REVEALS THE CORRECT ORIENTATION OF ACTIVE SITE ALPHA GLU 49
7WGR	;	2.92	;	Cryo-electron microscopic structure of the 2-oxoglutarate dehydrogenase (E1) component of the human alpha-ketoglutarate (2-oxoglutarate) dehydrogenase complex
6H05	;	2.9	;	Cryo-electron microscopic structure of the dihydrolipoamide succinyltransferase (E2) component of the human alpha-ketoglutarate (2-oxoglutarate) dehydrogenase complex [residues 218-453]
7THR	;	2.21	;	Cryo-electron microscopy of Adeno-associated virus serotype 4 at 2.2 A
3J91	;	8.8	;	Cryo-electron microscopy of Enterovirus 71 (EV71) procapsid in complex with Fab fragments of neutralizing antibody 22A12
4D1K	;	9.4	;	Cryo-electron microscopy of tubular arrays of HIV-1 Gag resolves structures essential for immature virus assembly.
4BBL	;	18.0	;	Cryo-electron microscopy reconstruction of the helical part of influenza A virus ribonucleoprotein isolated from virions.
3JBP	;	6.7	;	Cryo-electron microscopy reconstruction of the Plasmodium falciparum 80S ribosome bound to E-tRNA
3JBN	;	4.7	;	Cryo-electron microscopy reconstruction of the Plasmodium falciparum 80S ribosome bound to P-tRNA
3JBO	;	5.8	;	Cryo-electron microscopy reconstruction of the Plasmodium falciparum 80S ribosome bound to P/E-tRNA
5TR1	;	3.95	;	Cryo-electron microscopy structure of a bovine CLC-K chloride channel, alternate (class 2) conformation
5TQQ	;	3.76	;	Cryo-electron microscopy structure of a bovine CLC-K chloride channel, main (class 1) conformation
3JCL	;	4.0	;	Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer
6SMH	;	4.3	;	Cryo-electron microscopy structure of a RbcL-Raf1 supercomplex from Synechococcus elongatus PCC 7942
5W3S	;	2.94	;	Cryo-electron microscopy structure of a TRPML3 ion channel
8D46	;	2.84	;	Cryo-electron microscopy structure of human kidney Aldehyde Dehydrogenase 1A1
8D44	;	2.8	;	Cryo-electron microscopy structure of human kidney Fructose-bisphosphate aldolase B
7U2A	;	4.1	;	Cryo-electron microscopy structure of human mt-SerRS in complex with mt-tRNA (GCU)
7U2B	;	4.1	;	Cryo-electron microscopy structure of human mt-SerRS in complex with mt-tRNA(GCU-TL)
8FFY	;	3.6	;	Cryo-electron microscopy structure of human mt-SerRS in complex with mt-tRNA(UGA-TL)
6CV0	;	3.93	;	Cryo-electron microscopy structure of infectious bronchitis coronavirus spike protein
6VSJ	;	3.94	;	Cryo-electron microscopy structure of mouse coronavirus spike protein complexed with its murine receptor
8DEU	;	2.95	;	Cryo-electron microscopy structure of Neisseria gonorrhoeae multidrug efflux pump MtrD with CASP peptide complex
8DEV	;	3.08	;	Cryo-electron microscopy structure of Neisseria gonorrhoeae multidrug efflux pump MtrD with colistin complex
8DEW	;	2.89	;	Cryo-electron microscopy structure of Neisseria gonorrhoeae multidrug efflux pump MtrD with LL-37 complex
6MPV	;	7.17	;	Cryo-electron microscopy structure of Plasmodium falciparum Rh5/CyRPA/Ripr invasion complex
6B7N	;	3.3	;	Cryo-electron microscopy structure of porcine delta coronavirus spike protein in the pre-fusion state
5AN8	;	3.8	;	Cryo-electron microscopy structure of rabbit TRPV2 ion channel
3JBY	;	3.7	;	Cryo-electron microscopy structure of RAG Paired Complex (C2 symmetry)
3JBW	;	4.6	;	Cryo-electron microscopy structure of RAG Paired Complex (with NBD, no symmetry)
3JBX	;	3.4	;	Cryo-electron microscopy structure of RAG Signal End Complex (C2 symmetry)
5TX1	;	3.7	;	Cryo-Electron microscopy structure of species-D human adenovirus 26
4A2I	;	16.5	;	Cryo-electron Microscopy Structure of the 30S Subunit in Complex with the YjeQ Biogenesis Factor
7KF7	;	2.8	;	Cryo-electron microscopy structure of the heavy metal efflux pump CusA in a heterogeneous 1 open and 2 closed protomer conformation
7KF8	;	3.0	;	Cryo-electron microscopy structure of the heavy metal efflux pump CusA in a heterogeneous 2 open and 1 closed protomer conformation
7KF6	;	3.4	;	Cryo-electron microscopy structure of the heavy metal efflux pump CusA in a homogeneous binding copper(1) state
7KF5	;	3.2	;	Cryo-electron microscopy structure of the heavy metal efflux pump CusA in the symmetric closed state
5IV5	;	4.11	;	Cryo-electron microscopy structure of the hexagonal pre-attachment T4 baseplate-tail tube complex
5IV7	;	6.77	;	Cryo-electron microscopy structure of the star-shaped, hubless post-attachment T4 baseplate
6WHI	;	4.2	;	Cryo-electron microscopy structure of the type I-F CRISPR RNA-guided surveillance complex bound to the anti-CRISPR AcrIF9
8GHT	;	3.05	;	Cryo-electron microscopy structure of the zinc transporter from Bordetella bronchiseptica
7MCS	;	3.56	;	Cryo-electron microscopy structure of TnsC(1-503)A225V bound to DNA
6VKS	;	3.02	;	Cryo-electron microscopy structures of a gonococcal multidrug efflux pump illuminate a mechanism of drug recognition with ampicillin
6VKT	;	2.72	;	Cryo-electron microscopy structures of a gonococcal multidrug efflux pump illuminate a mechanism of erythromycin drug recognition
3JA6	;	12.7	;	Cryo-electron Tomography and All-atom Molecular Dynamics Simulations Reveal a Novel Kinase Conformational Switch in Bacterial Chemotaxis Signaling
5A9E	;	7.7	;	Cryo-electron tomography and subtomogram averaging of Rous-Sarcoma- Virus deltaMBD virus-like particles
7SOX	;	7.6	;	Cryo-electron tomography structure of membrane-bound EHD4 complex
7EYF	;	5.3	;	Cryo-EM (SPA) structure of human Nup155 C-terminus (864-1337) at 5.3 Angstroms resolution
7EYQ	;	5.4	;	Cryo-EM (SPA) structure of human Nup155 Longer N-terminus (19-1069) at 5.4 Angstrom resolution
7EYE	;	5.1	;	Cryo-EM (SPA) structure of Nup155 N-terminus (19-863) at 5.1 Angstrom resolution
2X8Q	;	18.3	;	Cryo-EM 3D model of the icosahedral particle composed of Rous sarcoma virus capsid protein pentamers
8EMT	;	2.92	;	Cryo-EM analysis of the human aldehyde oxidase from liver
5XTI	;	17.4	;	Cryo-EM architecture of human respiratory chain megacomplex-I2III2IV2
8CYE	;	3.9	;	Cryo-EM asymmetric reconstruction of the EPEC H6 bacterial flagellar filament Normal Waveform
6QCC	;	3.22	;	Cryo-EM Atomic Structure of Broad Bean Stain Virus (BBSV)
2I68	;	7.5	;	Cryo-EM based theoretical model structure of transmembrane domain of the multidrug-resistance antiporter from E. coli EmrE
8C8X	;	3.93	;	Cryo-EM captures early ribosome assembly in action
8C8Y	;	3.03	;	Cryo-EM captures early ribosome assembly in action
8C8Z	;	3.12	;	Cryo-EM captures early ribosome assembly in action
8C90	;	3.15	;	Cryo-EM captures early ribosome assembly in action
8C91	;	4.19	;	Cryo-EM captures early ribosome assembly in action
8C92	;	3.79	;	Cryo-EM captures early ribosome assembly in action
8C93	;	4.17	;	Cryo-EM captures early ribosome assembly in action
8C94	;	3.8	;	Cryo-EM captures early ribosome assembly in action
8C95	;	4.92	;	Cryo-EM captures early ribosome assembly in action
8C96	;	4.43	;	Cryo-EM captures early ribosome assembly in action
8C97	;	4.07	;	Cryo-EM captures early ribosome assembly in action
8C98	;	3.66	;	Cryo-EM captures early ribosome assembly in action
8C99	;	3.29	;	Cryo-EM captures early ribosome assembly in action
8C9A	;	4.86	;	Cryo-EM captures early ribosome assembly in action
8C9B	;	5.9	;	Cryo-EM captures early ribosome assembly in action
8C9C	;	6.62	;	Cryo-EM captures early ribosome assembly in action
8F3C	;	3.4	;	Cryo-EM consensus structure of Escherichia coli que-PEC (paused elongation complex) RNA Polymerase minus preQ1 ligand
8G4W	;	3.8	;	Cryo-EM consensus structure of Escherichia coli que-PEC (paused elongation complex) RNA Polymerase plus preQ1 ligand
4UQJ	;	10.4	;	Cryo-EM density map of GluA2em in complex with ZK200775
6O8W	;	3.53	;	Cryo-EM image reconstruction of the 70S Ribosome Enterococcus faecalis Class01
6O8X	;	3.68	;	Cryo-EM image reconstruction of the 70S Ribosome Enterococcus faecalis Class02
6O8Y	;	4.14	;	Cryo-EM image reconstruction of the 70S Ribosome Enterococcus faecalis Class03
6O8Z	;	3.49	;	Cryo-EM image reconstruction of the 70S Ribosome Enterococcus faecalis Class04
6O90	;	3.49	;	Cryo-EM image reconstruction of the 70S Ribosome Enterococcus faecalis Class05
8G3K	;	2.2	;	Cryo-EM imaging scaffold subunits A and B used to display KRAS G12C complex with GDP
6I00	;	3.4	;	Cryo-EM informed directed evolution of Nitrilase 4 leads to a change in quaternary structure.
6I5T	;	3.9	;	Cryo-EM informed directed evolution of Nitrilase 4 leads to a change in quaternary structure.
6I5U	;	3.9	;	Cryo-EM informed directed evolution of Nitrilase 4 leads to a change in quaternary structure.
8OII	;	2.84	;	Cryo-EM KSB domain of RhiE from Burkholderia rhizoxinica
8DEQ	;	6.0	;	Cryo-EM local refinement of antibody SKV09 in complex with VEEV alphavirus spike glycoprotein
8DER	;	3.3	;	Cryo-EM local refinement of antibody SKV16 in complex with VEEV alphavirus spike glycoprotein
3J1N	;	16.0	;	Cryo-EM map of a yeast minimal preinitiation complex interacting with the Mediator Head module
3J1O	;	16.0	;	Cryo-EM map of a yeast minimal preinitiation complex interacting with the Mediator Head module
6HMS	;	7.1	;	Cryo-EM map of DNA polymerase D from Pyrococcus abyssi in complex with DNA
7QXA	;	3.2	;	Cryo-EM map of human telomerase-DNA-TPP1 complex (sharpened)
7QXB	;	3.9	;	Cryo-EM map of human telomerase-DNA-TPP1-POT1 complex (sharpened map)
6H5S	;	3.3	;	Cryo-EM map of in vitro assembled Measles virus N into nucleocapsid-like particles (NCLPs) bound to viral genomic 5-prime RNA hexamers.
7Y6T	;	4.2	;	Cryo-EM map of IPEC-J2 cell-derived PEDV PT52 S protein one D0-down and two D0-up
7Y6S	;	3.1	;	Cryo-EM map of IPEC-J2 cell-derived PEDV PT52 S protein with three D0-up
7RYQ	;	4.6	;	Cryo-EM map of KIFBP
7W6M	;	4.7	;	Cryo-EM map of PEDV (Pintung 52) S protein with all three protomers in the D0-down conformation determined in situ on intact viral particles.
7W73	;	6.4	;	Cryo-EM map of PEDV S protein with one protomer in the D0-up conformation while the other two in the D0-down conformation
5UCY	;	4.6	;	Cryo-EM map of protofilament of microtubule doublet
8EKD	;	3.6	;	Cryo-EM map of SARS-CoV-2 Omicron BA.2 spike in complex with 2130-1-0114-112
7MO9	;	4.0	;	Cryo-EM map of the c-MET II/HGF I/HGF II (K4 and SPH) sub-complex
4C4Q	;	8.5	;	Cryo-EM map of the CSFV IRES in complex with the small ribosomal 40S subunit and DHX29
8OOH	;	7.0	;	Cryo-EM map of the focused refinement of the subfamily III haloalkane dehalogenase from Haloferax mediterranei dimer forming hexameric assembly.
7A1D	;	4.19	;	Cryo-EM map of the large glutamate dehydrogenase composed of 180 kDa subunits from Mycobacterium smegmatis (open conformation)
8C7H	;	2.7	;	Cryo-EM Map of the latTGF-beta 28G11 Fab complex
7ZRM	;	3.7	;	Cryo-EM map of the unphosphorylated KdpFABC complex in the E1-P_ADP conformation, under turnover conditions
7ZRL	;	4.0	;	Cryo-EM map of the unphosphorylated KdpFABC complex in the E2-P conformation, under turnover conditions
7ZRD	;	3.3	;	Cryo-EM map of the WT KdpFABC complex in the E1-P tight conformation, stabilised with the inhibitor orthovanadate
7ZRE	;	3.4	;	Cryo-EM map of the WT KdpFABC complex in the E1-P tight conformation, under turnover conditions
7ZRK	;	3.1	;	Cryo-EM map of the WT KdpFABC complex in the E1-P_ADP conformation, under turnover conditions
7ZRG	;	3.5	;	Cryo-EM map of the WT KdpFABC complex in the E1_ATPearly conformation, under turnover conditions
4URD	;	7.7	;	Cryo-EM map of Trigger Factor bound to a translating ribosome
8ORD	;	3.9	;	Cryo-EM map of zebrafish cardiac F-actin
5VN8	;	3.6	;	Cryo-EM model of B41 SOSIP.664 in complex with fragment antigen binding variable domain of b12
5VN3	;	3.7	;	Cryo-EM model of B41 SOSIP.664 in complex with soluble CD4 (D1-D2) and fragment antigen binding variable domain of 17b
6X96	;	3.4	;	Cryo-EM model of HIV-1 Env BG505 SOSIP.664 in complex with rabbit monoclonal antibody 10A fragment antigen binding variable domain
6X97	;	3.65	;	Cryo-EM model of HIV-1 Env BG505 SOSIP.664 in complex with rabbit monoclonal antibody 11A fragment antigen binding variable domain
6X98	;	3.38	;	Cryo-EM model of HIV-1 Env BG505 SOSIP.664 in complex with rabbit monoclonal antibody 11B fragment antigen binding variable domain
7TDZ	;	6.9	;	Cryo-EM model of protomer of the cytoplasmic ring of the nuclear pore complex from Xenopus laevis
8GTC	;	4.5	;	Cryo-EM model of the marine siphophage vB_DshS-R4C baseplate-tail complex
8GTD	;	4.7	;	Cryo-EM model of the marine siphophage vB_DshS-R4C portal-adaptor complex
8GTF	;	6.6	;	Cryo-EM model of the marine siphophage vB_DshS-R4C stopper-terminator complex
3IYO	;	10.5	;	Cryo-EM model of virion-sized HEV virion-sized capsid
7LQE	;	3.4	;	Cryo-EM of 1-protofilament of the KFE8 thinner nanotube
4CRM	;	8.75	;	Cryo-EM of a pre-recycling complex with eRF1 and ABCE1
4CRN	;	9.1	;	Cryo-EM of a pretermination complex with eRF1 and eRF3
7TXI	;	3.5	;	Cryo-EM of A. pernix flagellum
8E5G	;	3.9	;	Cryo-EM of A. veneficus cytochrome filament
7B1D	;	3.41	;	Cryo-EM of Aedes Aegypti Toll5A
7B1B	;	4.23	;	Cryo-EM of Aedes Aegypti Toll5A dimer bound to Spz1C
7B1C	;	3.74	;	Cryo-EM of Aedes Aegypti Toll5A trimer bound to Spz1C
7TXJ	;	3.9	;	Cryo-EM of AFV6
5FUA	;	7.6	;	Cryo-EM of BK polyomavirus
5LUF	;	9.1	;	Cryo-EM of bovine respirasome
8FOF	;	2.6	;	Cryo-EM of BP-ffsy filaments
7UEG	;	4.0	;	Cryo-EM of bundling pili from Pyrobaculum calidifontis
8U1K	;	3.5	;	Cryo-EM of Caulobacter crescentus Tad pilus
6TQL	;	3.96	;	Cryo-EM of elastase-treated human uromodulin (UMOD)/Tamm-Horsfall protein (THP) filament
6WD0	;	3.0	;	Cryo-EM of elongating ribosome with EF-Tu*GTP elucidates tRNA proofreading (Cognate Structure I-A)
6WD1	;	3.3	;	Cryo-EM of elongating ribosome with EF-Tu*GTP elucidates tRNA proofreading (Cognate Structure I-B)
6WD2	;	3.6	;	Cryo-EM of elongating ribosome with EF-Tu*GTP elucidates tRNA proofreading (Cognate Structure II-A)
6WD3	;	3.6	;	Cryo-EM of elongating ribosome with EF-Tu*GTP elucidates tRNA proofreading (Cognate Structure II-B1)
6WD4	;	3.7	;	Cryo-EM of elongating ribosome with EF-Tu*GTP elucidates tRNA proofreading (Cognate Structure II-B2)
6WD5	;	3.6	;	Cryo-EM of elongating ribosome with EF-Tu*GTP elucidates tRNA proofreading (Cognate Structure II-C1)
6WD6	;	3.7	;	Cryo-EM of elongating ribosome with EF-Tu*GTP elucidates tRNA proofreading (Cognate Structure II-C2)
6WD7	;	3.9	;	Cryo-EM of elongating ribosome with EF-Tu*GTP elucidates tRNA proofreading (Cognate Structure II-D)
6WD8	;	3.7	;	Cryo-EM of elongating ribosome with EF-Tu*GTP elucidates tRNA proofreading (Cognate Structure III-A)
6WD9	;	3.7	;	Cryo-EM of elongating ribosome with EF-Tu*GTP elucidates tRNA proofreading (Cognate Structure III-B)
6WDA	;	3.8	;	Cryo-EM of elongating ribosome with EF-Tu*GTP elucidates tRNA proofreading (Cognate Structure III-C)
6WDB	;	4.0	;	Cryo-EM of elongating ribosome with EF-Tu*GTP elucidates tRNA proofreading (Cognate Structure IV-A)
6WDC	;	4.2	;	Cryo-EM of elongating ribosome with EF-Tu*GTP elucidates tRNA proofreading (Cognate Structure IV-B)
6WDD	;	3.2	;	Cryo-EM of elongating ribosome with EF-Tu*GTP elucidates tRNA proofreading (Cognate Structure V-A)
6WDE	;	3.0	;	Cryo-EM of elongating ribosome with EF-Tu*GTP elucidates tRNA proofreading (Cognate Structure V-B)
6WDF	;	3.3	;	Cryo-EM of elongating ribosome with EF-Tu*GTP elucidates tRNA proofreading (Cognate Structure VI-A)
6WDG	;	3.3	;	Cryo-EM of elongating ribosome with EF-Tu*GTP elucidates tRNA proofreading (Cognate Structure VI-B)
6WDH	;	4.3	;	Cryo-EM of elongating ribosome with EF-Tu*GTP elucidates tRNA proofreading (Non-cognate Structure IV-B1)
6WDI	;	4.0	;	Cryo-EM of elongating ribosome with EF-Tu*GTP elucidates tRNA proofreading (Non-cognate Structure IV-B2)
6WDJ	;	3.7	;	Cryo-EM of elongating ribosome with EF-Tu*GTP elucidates tRNA proofreading (Non-cognate Structure V-A1)
6WDK	;	3.6	;	Cryo-EM of elongating ribosome with EF-Tu*GTP elucidates tRNA proofreading (Non-cognate Structure V-A2)
6WDL	;	3.7	;	Cryo-EM of elongating ribosome with EF-Tu*GTP elucidates tRNA proofreading (Non-cognate Structure V-B1)
6WDM	;	3.6	;	Cryo-EM of elongating ribosome with EF-Tu*GTP elucidates tRNA proofreading (Non-cognate Structure V-B2)
6WKX	;	4.2	;	Cryo-EM of Form 1 related peptide filament, 15-10-3
6WKY	;	4.2	;	Cryo-EM of Form 1 related peptide filament, 29-24-3
6WL1	;	4.0	;	Cryo-EM of Form 1 related peptide filament, 36-31-3
6WL0	;	4.4	;	Cryo-EM of Form 1 related peptide filament, 36-31-3-RD
6WL7	;	3.8	;	Cryo-EM of Form 2 like peptide filament, 29-20-2
6WL9	;	4.2	;	Cryo-EM of Form 2 like peptide filament, Form2a
6WL8	;	4.1	;	Cryo-EM of Form 2 peptide filament
7RA3	;	3.24	;	cryo-EM of human Gastric inhibitory polypeptide receptor GIPR bound to GIP
6XOX	;	3.1	;	cryo-EM of human GLP-1R bound to non-peptide agonist LY3502970
7RGP	;	2.9	;	cryo-EM of human Glucagon-like peptide 1 receptor GLP-1R bound to tirzepatide
7RG9	;	3.2	;	cryo-EM of human Glucagon-like peptide 1 receptor GLP-1R in apo form
7LQF	;	3.8	;	Cryo-EM of KFE8 ribbon filament
7LQI	;	3.5	;	Cryo-EM of KFE8 thicker nanotube
7LQH	;	3.4	;	Cryo-EM of KFE8 thinner nanotube (class 2, 2-sub-1)
8TIF	;	3.89	;	Cryo-EM of mono-pilus from S. islandicus REY15A
6TQK	;	3.35	;	Cryo-EM of native human uromodulin (UMOD)/Tamm-Horsfall protein (THP) filament.
7T6E	;	3.1	;	Cryo-EM of NBD-ffsy filaments (class 1)
8DST	;	3.2	;	Cryo-EM of NBD-ffsy filaments (class 2)
8E5F	;	3.8	;	Cryo-EM of P. calidifontis cytochrome filament
6X5I	;	4.3	;	Cryo-EM of peptide-like filament of 1-KMe3
7UIT	;	3.9	;	Cryo-EM of pH-controlled and self-assembled fibers, peptide 2
7UII	;	2.6	;	Cryo-EM of self-assembled cannula CanA
7UUQ	;	3.1	;	Cryo-EM of self-assembling pyrene IDP
8GI5	;	3.0	;	Cryo-EM of self-assembling pyrene peptide with Ca2+
6MK1	;	6.0	;	Cryo-EM of self-assembly peptide filament HEAT_R1
6HQE	;	4.4	;	Cryo-EM of self-assembly peptide filament LRV_M3delta1
7EO4	;	2.86	;	Cryo-EM of Sphingosine 1-phosphate receptor 1 / Gi complex bound to BAF312
7EO2	;	2.89	;	Cryo-EM of Sphingosine 1-phosphate receptor 1 / Gi complex bound to FTY720p
7WF7	;	3.4	;	Cryo-EM of Sphingosine 1-phosphate receptor 1 / Gi complex bound to S1P
7Q3N	;	7.4	;	Cryo-EM of the complex between human uromodulin (UMOD)/Tamm-Horsfall protein (THP) and the FimH lectin domain from uropathogenic E. coli
6DLU	;	3.75	;	Cryo-EM of the GMPPCP-bound human dynamin-1 polymer assembled on the membrane in the constricted state
6DLV	;	10.1	;	Cryo-EM of the GTP-bound human dynamin-1 polymer assembled on the membrane in the super constricted state
7LQG	;	3.4	;	Cryo-EM of the KFE8 thinner nanotube (class 1, C2)
7TFS	;	4.3	;	Cryo-EM of the OmcE nanowires from Geobacter sulfurreducens
6EF8	;	3.7	;	Cryo-EM of the OmcS nanowires from Geobacter sulfurreducens
8D9M	;	4.2	;	Cryo-EM of the OmcZ nanowires from Geobacter sulfurreducens
6W8U	;	3.8	;	Cryo-EM of the Pyrobaculum arsenaticum pilus
6WQ2	;	4.0	;	Cryo-EM of the S. islandicus filamentous virus, SIFV
6W8X	;	3.4	;	Cryo-EM of the S. solfataricus pilus
6WQ0	;	2.8	;	Cryo-EM of the S. solfataricus rod-shaped virus, SSRV1
4CG6	;	7.8	;	Cryo-em of the Sec61-complex bound to the 80s ribosome translating a membrane-inserting substrate
4CG5	;	7.4	;	Cryo-EM of the Sec61-complex bound to the 80S ribosome translating a secretory substrate
4CG7	;	6.9	;	Cryo-EM of the Sec61-complex bound to the idle 80S ribosome
7LRD	;	3.22	;	Cryo-EM of the SLFN12-PDE3A complex: Consensus subset model
7LRC	;	2.97	;	Cryo-EM of the SLFN12-PDE3A complex: PDE3A body refinement
7LRE	;	2.76	;	Cryo-EM of the SLFN12-PDE3A complex: SLFN12 body refinement
8TIB	;	3.47	;	Cryo-EM of tri-pilus from S. islandicus REY15A
8UHF	;	3.8	;	Cryo-EM of Vibrio cholerae toxin co-regulated pilus - asymmetric reconstruction
6EQC	;	7.4	;	Cryo-EM reconstruction of a complex of a binding protein and human adenovirus C5 hexon
7RX4	;	3.8	;	Cryo-EM reconstruction of AS2 nanotube (Form II like)
5LQP	;	6.0	;	Cryo-EM reconstruction of bacteriophage AP205 virus-like particles.
5FNA	;	4.8	;	Cryo-EM reconstruction of caspase-1 CARD
6NRV	;	4.0	;	Cryo-EM reconstruction of CFA/I pili
3J35	;	35.0	;	Cryo-EM reconstruction of Dengue virus at 37 C
4C0Y	;	16.0	;	Cryo-EM reconstruction of empty enterovirus 71 in complex with a neutralizing antibody E18
4C10	;	13.0	;	Cryo-EM reconstruction of empty enterovirus 71 in complex with a neutralizing antibody E19
4C0U	;	10.0	;	Cryo-EM reconstruction of enterovirus 71 in complex with a neutralizing antibody E18
3JBJ	;	7.6	;	Cryo-EM reconstruction of F-actin
7RX5	;	3.4	;	Cryo-EM reconstruction of Form1-N2 nanotube (Form I like)
6D5F	;	3.7	;	Cryo-EM reconstruction of membrane-enveloped filamentous virus SFV1 (Sulfolobus filamentous virus 1)
3ZX8	;	11.5	;	Cryo-EM reconstruction of native and expanded Turnip Crinkle virus
3ZX9	;	17.0	;	Cryo-EM reconstruction of native and expanded Turnip Crinkle virus
5VXX	;	5.1	;	Cryo-EM reconstruction of Neisseria gonorrhoeae Type IV pilus
5KUA	;	6.0	;	Cryo-EM reconstruction of Neisseria meningitidis Type IV pilus
5VXY	;	8.0	;	Cryo-EM reconstruction of PAK pilus from Pseudomonas aeruginosa
3J8F	;	4.0	;	Cryo-EM reconstruction of poliovirus-receptor complex
6NXE	;	3.16	;	Cryo-EM Reconstruction of Protease-Activateable Adeno-Associated Virus 9 (AAV9-L001)
6V7B	;	3.4	;	Cryo-EM reconstruction of Pyrobaculum filamentous virus 2 (PFV2)
3J8V	;	13.9	;	Cryo-EM reconstruction of quasi-HPV16 complex with H16.14J Fab
3J8Z	;	14.0	;	Cryo-EM reconstruction of quasi-HPV16 complex with H16.1A Fab
3J8W	;	13.0	;	Cryo-EM reconstruction of quasi-HPV16 complex with H263.A2 Fab
8UR6	;	3.03	;	Cryo-EM reconstruction of Staphylococcus aureus oleate hydratase (OhyA) dimer with a disordered C-terminal membrane-association domain
8UR3	;	2.61	;	Cryo-EM reconstruction of Staphylococcus aureus Oleate hydratase (OhyA) dimer with an ordered C-terminal membrane-association domain
6NAV	;	4.1	;	Cryo-EM reconstruction of Sulfolobus islandicus LAL14/1 Pilus
7RO2	;	5.1	;	Cryo-EM reconstruction of Sulfolobus monocaudavirus SMV1, symmetry 1
7ROG	;	3.8	;	Cryo-EM reconstruction of Sulfolobus monocaudavirus SMV1, symmetry 10
7ROH	;	4.0	;	Cryo-EM reconstruction of Sulfolobus monocaudavirus SMV1, symmetry 11
7ROI	;	4.3	;	Cryo-EM reconstruction of Sulfolobus monocaudavirus SMV1, symmetry 12
7RO3	;	4.8	;	Cryo-EM reconstruction of Sulfolobus monocaudavirus SMV1, symmetry 2
7RO4	;	4.3	;	Cryo-EM reconstruction of Sulfolobus monocaudavirus SMV1, symmetry 3
7RO5	;	4.1	;	Cryo-EM reconstruction of Sulfolobus monocaudavirus SMV1, symmetry 4
7RO6	;	4.1	;	Cryo-EM reconstruction of Sulfolobus monocaudavirus SMV1, symmetry 5
7ROB	;	3.9	;	Cryo-EM reconstruction of Sulfolobus monocaudavirus SMV1, symmetry 6
7ROC	;	3.7	;	Cryo-EM reconstruction of Sulfolobus monocaudavirus SMV1, symmetry 7
7ROD	;	3.8	;	Cryo-EM reconstruction of Sulfolobus monocaudavirus SMV1, symmetry 8
7ROE	;	3.7	;	Cryo-EM reconstruction of Sulfolobus monocaudavirus SMV1, symmetry 9
6OJ0	;	3.7	;	Cryo-EM reconstruction of Sulfolobus polyhedral virus 1 (SPV1)
4V8Y	;	4.3	;	Cryo-EM reconstruction of the 80S-eIF5B-Met-itRNAMet Eukaryotic Translation Initiation Complex
4V8Z	;	6.6	;	Cryo-EM reconstruction of the 80S-eIF5B-Met-itRNAMet Eukaryotic Translation Initiation Complex
8EHR	;	3.2	;	Cryo-EM reconstruction of the CFA/I bacterial adhesion pili
8EHS	;	3.3	;	Cryo-EM reconstruction of the CS17 bacterial adhesion pili
8EHT	;	3.4	;	Cryo-EM reconstruction of the CS20 bacterial adhesion pili
7R4X	;	2.15	;	Cryo-EM reconstruction of the human 40S ribosomal subunit - Full map
5M0R	;	8.2	;	Cryo-EM reconstruction of the maedi-visna virus (MVV) strand transfer complex
3JBK	;	8.2	;	Cryo-EM reconstruction of the metavinculin-actin interface
8OIU	;	3.35	;	Cryo-EM reconstruction of the native 24-mer E2o core of the 2-oxoglutarate dehydrogenase complex of C. thermophilum at 3.35 A resolution
6UOV	;	3.5	;	Cryo-EM reconstruction of the PrgHK periplasmic ring from Salmonella's needle complex assembled in the absence of the export apparatus
6V1I	;	3.8	;	Cryo-EM reconstruction of the thermophilic bacteriophage P74-26 small terminase- symmetric
6RIB	;	4.2	;	Cryo-EM reconstruction of Thermus thermophilus bactofilin double helical filaments
6RLP	;	2.3	;	Cryo-EM reconstruction of TMV coat protein
6WXF	;	4.3	;	Cryo-EM reconstruction of VP5*/VP8* assembly from rhesus rotavirus particles - Intermediate conformation
6WXG	;	3.3	;	Cryo-EM reconstruction of VP5*/VP8* assembly from rhesus rotavirus particles - Reversed conformation
6WXE	;	3.4	;	Cryo-EM reconstruction of VP5*/VP8* assembly from rhesus rotavirus particles - Upright conformation
3J0B	;	10.3	;	cryo-EM reconstruction of West Nile virus
6GQB	;	3.9	;	Cryo-EM reconstruction of yeast 80S ribosome in complex with mRNA, tRNA and eEF2 (GDP+AlF4/sordarin)
6GQ1	;	4.4	;	Cryo-EM reconstruction of yeast 80S ribosome in complex with mRNA, tRNA and eEF2 (GMPPCP/sordarin)
5SYG	;	3.5	;	Cryo-EM reconstruction of zampanolide-bound microtubule
6GQV	;	4.0	;	Cryo-EM recosntruction of yeast 80S ribosome in complex with mRNA, tRNA and eEF2 (GMPPCP)
7MLY	;	2.7	;	Cryo-EM reveals partially and fully assembled native glycine receptors,heteromeric pentamer
7MLU	;	4.1	;	Cryo-EM reveals partially and fully assembled native glycine receptors,homomeric pentamer
7MLV	;	4.1	;	Cryo-EM reveals partially and fully assembled native glycine receptors,homomeric tetramer
5A0Q	;	3.5	;	Cryo-EM reveals the conformation of a substrate analogue in the human 20S proteasome core
8DMK	;	3.7	;	Cryo-EM reveals the molecular basis of laminin polymerization and LN-lamininopathies
5A42	;	16.0	;	Cryo-EM single particle 3D reconstruction of the native conformation of E. coli alpha-2-macroglobulin (ECAM)
7XJZ	;	3.9	;	Cryo-EM strucrture of Oryza sativa plastid glycyl-tRNA synthetase in complex with tRNA (tRNA binding state)
7XK0	;	3.59	;	Cryo-EM strucrture of Oryza sativa plastid glycyl-tRNA synthetase in complex with tRNA (tRNA locked state)
7O0U	;	2.35	;	Cryo-EM structure (model_1a) of the RC-dLH complex from Gemmatimonas phototrophica at 2.4 A
7O0V	;	2.5	;	Cryo-EM structure (model_2a) of the RC-dLH complex from Gemmatimonas phototrophica at 2.5 A
7O0X	;	2.44	;	Cryo-EM structure (model_2b) of the RC-dLH complex from Gemmatimonas phototrophica at 2.44 A
6JBH	;	3.94	;	Cryo-EM structure and transport mechanism of a wall teichoic acid ABC transporter
8B0O	;	3.02	;	Cryo-EM structure apolipoprotein N-acyltransferase Lnt from E.coli in complex with FP3
6MPG	;	3.2	;	Cryo-EM structure at 3.2 A resolution of HIV-1 fusion peptide-directed antibody, A12V163-b.01, elicited by vaccination of Rhesus macaques, in complex with stabilized HIV-1 Env BG505 DS-SOSIP, which was also bound to antibodies VRC03 and PGT122
6CDI	;	3.6	;	Cryo-EM structure at 3.6 A resolution of vaccine-elicited antibody vFP16.02 in complex with HIV-1 Env BG505 DS-SOSIP, and antibodies VRC03 and PGT122
6MPH	;	3.8	;	Cryo-EM structure at 3.8 A resolution of HIV-1 fusion peptide-directed antibody, DF1W-a.01, elicited by vaccination of Rhesus macaques, in complex with stabilized HIV-1 Env BG505 DS-SOSIP, which was also bound to antibodies VRC03 and PGT122
6CDE	;	3.8	;	Cryo-EM structure at 3.8 A resolution of vaccine-elicited antibody vFP20.01 in complex with HIV-1 Env BG505 DS-SOSIP, and antibodies VRC03 and PGT122
6N1V	;	4.0	;	Cryo-EM structure at 4.0 A resolution of vaccine-elicited antibody A12V163-a.01 in complex with HIV-1 Env BG505 DS-SOSIP, and antibodies VRC03 and PGT122
6CUE	;	4.0	;	Cryo-EM structure at 4.0 A resolution of vaccine-elicited antibody vFP7.04 in complex with HIV-1 Env BG505 DS-SOSIP, and antibodies VRC03 and PGT122
6N1W	;	4.2	;	Cryo-EM structure at 4.2 A resolution of vaccine-elicited antibody DFPH-a.15 in complex with HIV-1 Env BG505 DS-SOSIP, and antibodies VRC03 and PGT122
6CUF	;	4.0	;	Cryo-EM structure at 4.2 A resolution of vaccine-elicited antibody vFP1.01 in complex with HIV-1 Env BG505 DS-SOSIP, and antibodies VRC03 and PGT122
8QEO	;	3.26	;	cryo-EM structure complex of Frizzled-7 and Clostridioides difficile toxin B
8AVD	;	4.42	;	Cryo-EM structure for a 3:3 complex between mouse leptin and the mouse LEP-R ectodomain (local refinement)
5WTH	;	4.2	;	Cryo-EM structure for Hepatitis A virus complexed with FAB
5WTF	;	3.9	;	Cryo-EM structure for Hepatitis A virus empty particle
5WTE	;	3.4	;	Cryo-EM structure for Hepatitis A virus full particle
8AVB	;	4.43	;	Cryo-EM structure for mouse leptin in complex with the mouse LEP-R ectodomain (1:2 mLEP:mLEPR model).
7BW7	;	4.1	;	Cryo-EM Structure for the Ectodomain of the Full-length Human Insulin Receptor in Complex with 1 Insulin.
7BWA	;	4.9	;	Cryo-EM Structure for the Ectodomain of the Full-length Human Insulin Receptor in Complex with 2 Insulin
7BW8	;	3.8	;	Cryo-EM Structure for the Insulin Binding Region in the Ectodomain of the Full-length Human Insulin Receptor in Complex with 1 Insulin
8B7Q	;	4.02	;	Cryo-EM structure for the mouse LEPR-CRH2:Leptin:LEPR-Ig complex following symmetry expansion in combination with local refinement
7Y6P	;	3.3	;	Cryo-EM structure if bacterioferritin holoform
8C2S	;	3.9	;	Cryo-EM structure NDUFS4 knockout complex I from Mus musculus heart (Class 1).
8CA4	;	3.25	;	Cryo-EM structure NDUFS4 knockout complex I from Mus musculus heart (Class 2 N-domain).
8CA3	;	3.2	;	Cryo-EM structure NDUFS4 knockout complex I from Mus musculus heart (Class 2).
8CA5	;	3.9	;	Cryo-EM structure NDUFS4 knockout complex I from Mus musculus heart (Class 3).
7ZZ4	;	2.63	;	Cryo-EM structure of ""BC closed"" conformation of Lactococcus lactis pyruvate carboxylase with acetyl-CoA
7ZZ5	;	2.43	;	Cryo-EM structure of ""BC open"" conformation of Lactococcus lactis pyruvate carboxylase with acetyl-CoA
7ZZ3	;	2.41	;	Cryo-EM structure of ""BC react"" conformation of Lactococcus lactis pyruvate carboxylase with acetyl-CoA
7ZZ0	;	2.26	;	Cryo-EM structure of ""CT empty"" conformation of Lactococcus lactis pyruvate carboxylase with acetyl-CoA
7ZYZ	;	2.47	;	Cryo-EM structure of ""CT oxa"" conformation of Lactococcus lactis pyruvate carboxylase with acetyl-CoA
7ZZ2	;	2.48	;	Cryo-EM structure of ""CT pyr"" conformation of Lactococcus lactis pyruvate carboxylase with acetyl-CoA
7ZZ1	;	2.27	;	Cryo-EM structure of ""CT react"" conformation of Lactococcus lactis pyruvate carboxylase with acetyl-CoA
7ZZ6	;	2.15	;	Cryo-EM structure of ""CT-CT dimer"" of Lactococcus lactis pyruvate carboxylase with acetyl-CoA
7LSX	;	3.61	;	Cryo-EM structure of 13S proteasome core particle assembly intermediate purified from Pre3-1 proteasome mutant (G34D)
8SCZ	;	3.4	;	Cryo-EM structure of 14aa-GS RIG-I in complex with p3SLR30
7K61	;	2.85	;	Cryo-EM structure of 197bp nucleosome aided by scFv
7MO8	;	4.5	;	Cryo-EM structure of 1:1 c-MET I/HGF I complex after focused 3D refinement of holo-complex
8DYT	;	3.3	;	Cryo-EM structure of 227 Fab in complex with (NPNA)8 peptide
8DYW	;	3.72	;	Cryo-EM structure of 239 Fab in complex with recombinant shortened Plasmodium falciparum circumsporozoite protein (rsCSP)
7SZK	;	2.94	;	Cryo-EM structure of 27a bound to E. coli RNAP and rrnBP1 promoter complex
7LY9	;	3.91	;	Cryo-EM structure of 2909 Fab in complex with 3BNC117 Fab and CAP256.wk34.c80 SOSIP.RnS2 N160K HIV-1 Env trimer
7MO7	;	4.8	;	Cryo-EM structure of 2:2 c-MET/HGF holo-complex
7MOB	;	5.0	;	Cryo-EM structure of 2:2 c-MET/NK1 complex
8JIF	;	2.28	;	Cryo-EM Structure of 3-axis block of AAV9P31-Car4 complex
8DYX	;	3.0	;	Cryo-EM structure of 311 Fab in complex with recombinant shortened Plasmodium falciparum circumsporozoite protein (rsCSP)
8DYY	;	3.62	;	Cryo-EM structure of 334 Fab in complex with recombinant shortened Plasmodium falciparum circumsporozoite protein (rsCSP)
8DZ3	;	2.7	;	Cryo-EM structure of 337 Fab in complex with recombinant shortened Plasmodium falciparum circumsporozoite protein (rsCSP)
8DZ4	;	3.2	;	Cryo-EM structure of 356 Fab in complex with recombinant shortened Plasmodium falciparum circumsporozoite protein (rsCSP)
8DZ5	;	3.84	;	Cryo-EM structure of 364 Fab in complex with recombinant shortened Plasmodium falciparum circumsporozoite protein (rsCSP)
8G00	;	3.4	;	Cryo-EM structure of 3DVA component 0 of Escherichia coli que-PEC (paused elongation complex) RNA Polymerase minus preQ1 ligand
8G7E	;	3.9	;	Cryo-EM structure of 3DVA component 0 of Escherichia coli que-PEC (paused elongation complex) RNA Polymerase plus preQ1 ligand
8G1S	;	3.7	;	Cryo-EM structure of 3DVA component 1 of Escherichia coli que-PEC (paused elongation complex) RNA Polymerase minus preQ1 ligand
8G8Z	;	4.3	;	Cryo-EM structure of 3DVA component 1 of Escherichia coli que-PEC (paused elongation complex) RNA Polymerase plus preQ1 ligand
8G2W	;	3.7	;	Cryo-EM structure of 3DVA component 2 of Escherichia coli que-PEC (paused elongation complex) RNA Polymerase minus preQ1 ligand
8EYY	;	4.9	;	Cryo-EM structure of 4 insulins bound full-length mouse IR mutant with physically decoupled alpha CTs (C684S/C685S/C687S, denoted as IR-3CS) Asymmetric conformation 2
8EYX	;	4.5	;	Cryo-EM structure of 4 insulins bound full-length mouse IR mutant with physically decoupled alpha CTs (C684S/C685S/C687S; denoted as IR-3CS) Asymmetric conformation 1
8EZ0	;	3.7	;	Cryo-EM structure of 4 insulins bound full-length mouse IR mutant with physically decoupled alpha CTs (C684S/C685S/C687S; denoted as IR-3CS) Symmetric conformation
7YLA	;	2.52	;	Cryo-EM structure of 50S-HflX complex
6SJ6	;	3.23	;	Cryo-EM structure of 50S-RsfS complex from Staphylococcus aureus
6W1J	;	2.92	;	Cryo-EM structure of 5HT3A receptor in presence of Alosetron
6NP0	;	2.92	;	Cryo-EM structure of 5HT3A receptor in presence of granisetron
6W1M	;	3.06	;	Cryo-EM structure of 5HT3A receptor in presence of Ondansetron
6W1Y	;	3.35	;	Cryo-EM structure of 5HT3A receptor in presence of Palonosetron
7OIZ	;	2.9	;	Cryo-EM structure of 70S ribosome stalled with TnaC peptide
7P3K	;	2.9	;	Cryo-EM structure of 70S ribosome stalled with TnaC peptide (control)
7OJ0	;	3.5	;	Cryo-EM structure of 70S ribosome stalled with TnaC peptide and RF2
7TUZ	;	3.12	;	Cryo-EM structure of 7alpha,25-dihydroxycholesterol-bound EBI2/GPR183 in complex with Gi protein
7SLQ	;	3.7	;	Cryo-EM structure of 7SK core RNP with circular RNA
7SLP	;	4.1	;	Cryo-EM structure of 7SK core RNP with linear RNA
3J1B	;	4.9	;	Cryo-EM structure of 8-fold symmetric rATcpn-alpha in apo state
7YQH	;	5.6	;	Cryo-EM structure of 8-subunit Smc5/6
7YLM	;	6.17	;	Cryo-EM structure of 8-subunit Smc5/6 hinge region
7CPU	;	2.82	;	Cryo-EM structure of 80S ribosome from mouse kidney
7CPV	;	3.03	;	Cryo-EM structure of 80S ribosome from mouse testis
3J1C	;	9.1	;	Cryo-EM structure of 9-fold symmetric rATcpn-alpha in apo state
3J1E	;	8.3	;	Cryo-EM structure of 9-fold symmetric rATcpn-beta in apo state
3J1F	;	6.2	;	Cryo-EM structure of 9-fold symmetric rATcpn-beta in ATP-binding state
7D5S	;	4.6	;	Cryo-EM structure of 90S preribosome with inactive Utp24 (state A2)
7D63	;	12.3	;	Cryo-EM structure of 90S preribosome with inactive Utp24 (state C)
7D5T	;	6.0	;	Cryo-EM structure of 90S preribosome with inactive Utp24 (state F1)
7D4I	;	4.0	;	Cryo-EM structure of 90S small ribosomal precursors complex with the DEAH-box RNA helicase Dhr1 (State F)
6LQP	;	3.2	;	Cryo-EM structure of 90S small subunit preribosomes in transition states (State A)
6LQU	;	3.7	;	Cryo-EM structure of 90S small subunit preribosomes in transition states (State A1)
6LQQ	;	4.1	;	Cryo-EM structure of 90S small subunit preribosomes in transition states (State B)
6LQR	;	8.6	;	Cryo-EM structure of 90S small subunit preribosomes in transition states (State C)
6LQV	;	4.8	;	Cryo-EM structure of 90S small subunit preribosomes in transition states (State C1)
6LQS	;	3.8	;	Cryo-EM structure of 90S small subunit preribosomes in transition states (State D)
6LQT	;	4.9	;	Cryo-EM structure of 90S small subunit preribosomes in transition states (State E)
6HA1	;	3.1	;	Cryo-EM structure of a 70S Bacillus subtilis ribosome translating the ErmD leader peptide in complex with telithromycin
7O5B	;	3.33	;	Cryo-EM structure of a Bacillus subtilis MifM-stalled ribosome-nascent chain complex with (p)ppGpp-SRP bound
7X7R	;	3.5	;	Cryo-EM structure of a bacterial protein
7X8A	;	2.8	;	Cryo-EM structure of a bacterial protein complex
7XC7	;	3.1	;	Cryo-EM structure of a bacterial protein complex
6YG8	;	3.0	;	Cryo-EM structure of a BcsB pentamer in the context of an assembled Bcs macrocomplex
5THR	;	8.9	;	Cryo-EM structure of a BG505 Env-sCD4-17b-8ANC195 complex
6XF6	;	4.0	;	Cryo-EM structure of a biotinylated SARS-CoV-2 spike probe in the prefusion state (1 RBD up)
6XF5	;	3.45	;	Cryo-EM structure of a biotinylated SARS-CoV-2 spike probe in the prefusion state (RBDs down)
8BC3	;	2.1	;	Cryo-EM Structure of a BmSF-TAL - Sulfofructose Schiff Base Complex
8BC4	;	2.7	;	Cryo-EM Structure of a BmSF-TAL - Sulfofructose Schiff Base Complex in symmetry group C1
8JNS	;	4.2	;	cryo-EM structure of a CED-4 hexamer
8I9W	;	3.1	;	Cryo-EM structure of a Chaetomium thermophilum pre-60S ribosomal subunit - Dbp10-3
8I9R	;	3.1	;	Cryo-EM structure of a Chaetomium thermophilum pre-60S ribosomal subunit - State 5S RNP
8I9T	;	3.6	;	Cryo-EM structure of a Chaetomium thermophilum pre-60S ribosomal subunit - State Dbp10-1
8I9V	;	3.1	;	Cryo-EM structure of a Chaetomium thermophilum pre-60S ribosomal subunit - State Dbp10-2
8I9P	;	3.0	;	Cryo-EM structure of a Chaetomium thermophilum pre-60S ribosomal subunit - State Mak16
8IA0	;	2.7	;	Cryo-EM structure of a Chaetomium thermophilum pre-60S ribosomal subunit - State Puf6
8I9Z	;	2.7	;	Cryo-EM structure of a Chaetomium thermophilum pre-60S ribosomal subunit - State Spb4
8I9X	;	2.8	;	Cryo-EM structure of a Chaetomium thermophilum pre-60S ribosomal subunit - Ytm1-1
8I9Y	;	3.1	;	Cryo-EM structure of a Chaetomium thermophilum pre-60S ribosomal subunit - Ytm1-2
7K63	;	3.03	;	Cryo-EM structure of a chromatosome containing chimeric linker histone gH1.10-ncH1.4
7K5X	;	2.93	;	Cryo-EM structure of a chromatosome containing human linker histone H1.0
7K60	;	3.12	;	Cryo-EM structure of a chromatosome containing human linker histone H1.10
7K5Y	;	2.76	;	Cryo-EM structure of a chromatosome containing human linker histone H1.4
6LFM	;	3.5	;	Cryo-EM structure of a class A GPCR
6LFO	;	3.4	;	Cryo-EM structure of a class A GPCR monomer
6KPF	;	2.9	;	Cryo-EM structure of a class A GPCR with G protein complex
7V69	;	3.4	;	Cryo-EM structure of a class A GPCR-G protein complex
7VUH	;	3.22	;	Cryo-EM structure of a class A orphan GPCR
7VUI	;	3.3	;	Cryo-EM structure of a class A orphan GPCR
7VUJ	;	3.8	;	Cryo-EM structure of a class A orphan GPCR
7Y3G	;	2.77	;	Cryo-EM structure of a class A orphan GPCR
7VUG	;	3.2	;	Cryo-EM structure of a class A orphan GPCR in complex with Gi
7XP6	;	3.01	;	Cryo-EM structure of a class T GPCR in active state
7XP4	;	3.01	;	Cryo-EM structure of a class T GPCR in apo state
7XP5	;	3.08	;	Cryo-EM structure of a class T GPCR in ligand-free state
8UPL	;	5.4	;	Cryo-EM structure of a Clockwise locked form of the Salmonella enterica Typhimurium flagellar C-ring, with C34 symmetry applied
8BKY	;	3.6	;	Cryo-EM structure of a contractile injection system in Streptomyces coelicolor, the contracted sheath shell.
8BL4	;	3.9	;	Cryo-EM structure of a contractile injection system in Streptomyces coelicolor, the sheath-tube module in extended state.
8UOX	;	4.6	;	Cryo-EM structure of a Counterclockwise locked form of the Salmonella enterica Typhimurium flagellar C-ring, with C34 symmetry applied
7ZOQ	;	3.2	;	Cryo-EM structure of a CRISPR effector in complex with a caspase regulator
7ZOL	;	3.03	;	Cryo-EM structure of a CRISPR effector in complex with regulator
7L48	;	3.9	;	Cryo-EM structure of a CRISPR-Cas12f Binary Complex
6U1S	;	7.6	;	Cryo-EM structure of a de novo designed 16-helix transmembrane nanopore, TMHC8_R.
8ET3	;	3.7	;	Cryo-EM structure of a delivery complex containing the SspB adaptor, an ssrA-tagged substrate, and the AAA+ ClpXP protease
6YTK	;	4.07	;	Cryo-EM structure of a dimer of decameric human CALHM4 in the absence of Ca2+
6YTO	;	4.24	;	Cryo-EM structure of a dimer of decameric human CALHM4 in the presence of Ca2+
6VAI	;	3.68	;	Cryo-EM structure of a dimer of undecameric human CALHM2
6YTL	;	3.82	;	Cryo-EM structure of a dimer of undecameric human CALHM4 in the absence of Ca2+
6YTQ	;	4.02	;	Cryo-EM structure of a dimer of undecameric human CALHM4 in the presence of Ca2+
7W0N	;	4.21	;	Cryo-EM structure of a dimeric GPCR-Gi complex with peptide
7W0L	;	3.57	;	Cryo-EM structure of a dimeric GPCR-Gi complex with small molecule
8SEA	;	3.4	;	Cryo-EM structure of a double loaded human UBA7-UBE2L6-ISG15 thioester mimetic complex (Form 1)
8SE9	;	3.2	;	Cryo-EM structure of a double loaded human UBA7-UBE2L6-ISG15 thioester mimetic complex (Form 2)
8SV8	;	3.38	;	Cryo-EM structure of a double loaded human UBA7-UBE2L6-ISG15 thioester mimetic complex from a composite map
7Y5H	;	3.72	;	Cryo-EM structure of a eukaryotic ZnT8 at a low pH
7Y5G	;	3.85	;	Cryo-EM structure of a eukaryotic ZnT8 in the presence of zinc
5JBH	;	5.34	;	Cryo-EM structure of a full archaeal ribosomal translation initiation complex in the P-IN conformation
5JB3	;	5.34	;	Cryo-EM structure of a full archaeal ribosomal translation initiation complex in the P-REMOTE conformation
8PWL	;	4.73	;	Cryo-EM structure of a full-length HACE1 dimer
8T1H	;	5.97	;	Cryo-EM structure of a full-length, native Drp1 dimer
7W0P	;	3.16	;	Cryo-EM structure of a GPCR-Gi complex with peptide
8H2H	;	3.2	;	Cryo-EM structure of a Group II Intron Complexed with its Reverse Transcriptase
8FLI	;	3.8	;	Cryo-EM structure of a group II intron immediately before branching
7D1A	;	3.8	;	cryo-EM structure of a group II intron RNP complexed with its reverse transcriptase
7DEG	;	3.4	;	Cryo-EM structure of a heme-copper terminal oxidase dimer provides insights into its catalytic mechanism
8DIT	;	5.1	;	Cryo-EM structure of a HOPS core complex containing Vps33, Vps16, and Vps18
5Z58	;	4.9	;	Cryo-EM structure of a human activated spliceosome (early Bact) at 4.9 angstrom.
5Z56	;	5.1	;	cryo-EM structure of a human activated spliceosome (mature Bact) at 5.1 angstrom.
7BSP	;	4.0	;	Cryo-EM structure of a human ATP11C-CDC50A flippase in E1-AMPPCP state
7BSS	;	3.3	;	Cryo-EM structure of a human ATP11C-CDC50A flippase in E1AlF state
7BSQ	;	3.2	;	Cryo-EM structure of a human ATP11C-CDC50A flippase in E1AlF-ADP state
7BSW	;	3.9	;	Cryo-EM structure of a human ATP11C-CDC50A flippase in PtdEtn-occluded E2-AlF state
7BSU	;	3.2	;	Cryo-EM structure of a human ATP11C-CDC50A flippase in PtdSer-bound E2BeF state
7BSV	;	3.0	;	Cryo-EM structure of a human ATP11C-CDC50A flippase in PtdSer-occluded E2-AlF state
7VSH	;	3.4	;	Cryo-EM structure of a human ATP11C-CDC50A flippase reconstituted in the Nanodisc in E1P state.
7VSG	;	3.9	;	Cryo-EM structure of a human ATP11C-CDC50A flippase reconstituted in the Nanodisc in PtdSer-occluded E2-Pi state.
8GBJ	;	3.11	;	Cryo-EM structure of a human BCDX2/ssDNA complex
5JLH	;	3.9	;	Cryo-EM structure of a human cytoplasmic actomyosin complex at near-atomic resolution
6ID1	;	2.86	;	Cryo-EM structure of a human intron lariat spliceosome after Prp43 loaded (ILS2 complex) at 2.9 angstrom resolution
6ID0	;	2.9	;	Cryo-EM structure of a human intron lariat spliceosome prior to Prp43 loaded (ILS1 complex) at 2.9 angstrom resolution
6ICZ	;	3.0	;	Cryo-EM structure of a human post-catalytic spliceosome (P complex) at 3.0 angstrom
7WTT	;	3.1	;	Cryo-EM structure of a human pre-40S ribosomal subunit - State RRP12-A1 (with CK1)
7WTU	;	3.0	;	Cryo-EM structure of a human pre-40S ribosomal subunit - State RRP12-A1 (without CK1)
7WTV	;	3.5	;	Cryo-EM structure of a human pre-40S ribosomal subunit - State RRP12-A2
7WTW	;	3.2	;	Cryo-EM structure of a human pre-40S ribosomal subunit - State RRP12-A3
7WTX	;	3.1	;	Cryo-EM structure of a human pre-40S ribosomal subunit - State RRP12-B1
7WTZ	;	3.0	;	Cryo-EM structure of a human pre-40S ribosomal subunit - State RRP12-B2
7WU0	;	3.3	;	Cryo-EM structure of a human pre-40S ribosomal subunit - State RRP12-B3
7WTS	;	3.2	;	Cryo-EM structure of a human pre-40S ribosomal subunit - State UTP14
6LU8	;	3.13	;	Cryo-EM structure of a human pre-60S ribosomal subunit - state A
8QO9	;	5.29	;	Cryo-EM structure of a human spliceosomal B complex protomer
5MQF	;	5.9	;	Cryo-EM structure of a human spliceosome activated for step 2 of splicing (C* complex)
5WP6	;	3.8	;	Cryo-EM structure of a human TRPM4 channel in complex with calcium and decavanadate
6NT4	;	3.5	;	Cryo-EM structure of a human-cockroach hybrid Nav channel bound to alpha-scorpion toxin AaH2.
6NT3	;	3.4	;	Cryo-EM structure of a human-cockroach hybrid Nav channel.
6G5H	;	3.6	;	Cryo-EM structure of a late human pre-40S ribosomal subunit - Mature
6G4W	;	4.5	;	Cryo-EM structure of a late human pre-40S ribosomal subunit - State A
6G4S	;	4.0	;	Cryo-EM structure of a late human pre-40S ribosomal subunit - State B
6G18	;	3.6	;	Cryo-EM structure of a late human pre-40S ribosomal subunit - State C
6G51	;	4.1	;	Cryo-EM structure of a late human pre-40S ribosomal subunit - State D
6G53	;	4.5	;	Cryo-EM structure of a late human pre-40S ribosomal subunit - State E
6ZXD	;	3.2	;	Cryo-EM structure of a late human pre-40S ribosomal subunit - State F1
6ZXE	;	3.0	;	Cryo-EM structure of a late human pre-40S ribosomal subunit - State F2
6ZXF	;	3.7	;	Cryo-EM structure of a late human pre-40S ribosomal subunit - State G
6ZXG	;	2.6	;	Cryo-EM structure of a late human pre-40S ribosomal subunit - State H1
6ZXH	;	2.7	;	Cryo-EM structure of a late human pre-40S ribosomal subunit - State H2
6G5I	;	3.5	;	Cryo-EM structure of a late human pre-40S ribosomal subunit - State R
6EML	;	3.6	;	Cryo-EM structure of a late pre-40S ribosomal subunit from Saccharomyces cerevisiae
7S8U	;	3.7	;	Cryo-EM structure of a mammalian peptide transporter (PepT1/slc15a1) in nanodisc
7FJF	;	3.1	;	Cryo-EM structure of a membrane protein(CS)
7FJE	;	3.0	;	Cryo-EM structure of a membrane protein(LL)
7FJD	;	3.2	;	Cryo-EM structure of a membrane protein(WT)
6DT0	;	3.7	;	Cryo-EM structure of a mitochondrial calcium uniporter
7W0O	;	3.78	;	Cryo-EM structure of a monomeric GPCR-Gi complex with peptide
7W0M	;	3.71	;	Cryo-EM structure of a monomeric GPCR-Gi complex with small molecule
5MC6	;	3.8	;	Cryo-EM structure of a native ribosome-Ski2-Ski3-Ski8 complex from S. cerevisiae
7M5D	;	2.8	;	Cryo-EM structure of a non-rotated E.coli 70S ribosome in complex with RF3-GTP, RF1 and P-tRNA (state I)
5Z3G	;	3.65	;	Cryo-EM structure of a nucleolar pre-60S ribosome (Rpf1-TAP)
6A69	;	4.11	;	Cryo-EM structure of a P-type ATPase
7C4W	;	3.4	;	Cryo-EM structure of A particle Coxsackievirus A10 at pH 5.5
7C4T	;	3.6	;	Cryo-EM structure of A particle Coxsackievirus A10 at pH 7.4
6Y6K	;	3.78	;	Cryo-EM structure of a Phenuiviridae L protein
6D03	;	3.68	;	Cryo-EM structure of a Plasmodium vivax invasion complex essential for entry into human reticulocytes; one molecule of parasite ligand.
6D04	;	3.74	;	Cryo-EM structure of a Plasmodium vivax invasion complex essential for entry into human reticulocytes; two molecules of parasite ligand, subclass 1.
6D05	;	3.8	;	Cryo-EM structure of a Plasmodium vivax invasion complex essential for entry into human reticulocytes; two molecules of parasite ligand, subclass 2.
6R5K	;	4.8	;	Cryo-EM structure of a poly(A) RNP bound to the Pan2-Pan3 deadenylase
6ENF	;	3.2	;	Cryo-EM structure of a polyproline-stalled ribosome in the absence of EF-P
8EKA	;	3.7	;	Cryo-EM structure of a potent anti-malarial antibody L9 in complex with Plasmodium falciparum circumsporozoite protein (PfCSP)(class 2)
8EK1	;	3.6	;	Cryo-EM structure of a potent anti-malarial antibody L9 in complex with Plasmodium falciparum circumsporozoite protein (PfCSP)(dominant class)
6LSR	;	3.13	;	Cryo-EM structure of a pre-60S ribosomal subunit - state B
6LQM	;	3.09	;	Cryo-EM structure of a pre-60S ribosomal subunit - state C
6LSS	;	3.23	;	Cryo-EM structure of a pre-60S ribosomal subunit - state preA
7D0G	;	5.0	;	Cryo-EM structure of a pre-catalytic group II intron
7D0F	;	5.0	;	cryo-EM structure of a pre-catalytic group II intron RNP
5O9Z	;	4.5	;	Cryo-EM structure of a pre-catalytic human spliceosome primed for activation (B complex)
8OE4	;	3.6	;	Cryo-EM structure of a pre-dimerized human IL-23 complete extracellular signaling complex.
8PB1	;	3.5	;	Cryo-EM structure of a pre-dimerized murine IL-12 complete extracellular signaling complex (Class 1), obtained after local refinement.
8ODZ	;	3.6	;	Cryo-EM structure of a pre-dimerized murine IL-12 complete extracellular signaling complex (Class 1).
8OE0	;	4.6	;	Cryo-EM structure of a pre-dimerized murine IL-12 complete extracellular signaling complex (Class 2).
7AD1	;	2.92	;	Cryo-EM structure of a prefusion stabilized SARS-CoV-2 Spike (D614N, R682S, R685G, A892P, A942P and V987P)(One up trimer)
7A4N	;	2.75	;	Cryo-EM structure of a prefusion stabilized SARS-CoV-2 Spike (D614N, R682S, R685G, A892P, A942P and V987P)(S-closed trimer)
7F4V	;	2.04	;	Cryo-EM structure of a primordial cyanobacterial photosystem I
7JI3	;	3.46	;	Cryo-EM structure of a proton-activated chloride channel
7ZAI	;	2.6	;	Cryo-EM structure of a Pyrococcus abyssi 30S bound to Met-initiator tRNA, mRNA and aIF1A.
7ZAH	;	2.7	;	Cryo-EM structure of a Pyrococcus abyssi 30S bound to Met-initiator tRNA, mRNA, aIF1A and aIF5B
7ZAG	;	2.77	;	Cryo-EM structure of a Pyrococcus abyssi 30S bound to Met-initiator tRNA,mRNA, aIF1A and the C-terminal domain of aIF5B.
6JNX	;	4.08	;	Cryo-EM structure of a Q-engaged arrested complex
7OYD	;	2.3	;	Cryo-EM structure of a rabbit 80S ribosome with zebrafish Dap1b
8DGS	;	4.3	;	Cryo-EM structure of a RAS/RAF complex (state 1)
8DGT	;	3.9	;	Cryo-EM structure of a RAS/RAF complex (state 2)
7O71	;	2.4	;	Cryo-EM structure of a respiratory complex I
6RFQ	;	3.3	;	Cryo-EM structure of a respiratory complex I assembly intermediate with NDUFAF2
6Y79	;	2.96	;	Cryo-EM structure of a respiratory complex I F89A mutant
6RFS	;	4.04	;	Cryo-EM structure of a respiratory complex I mutant lacking NDUFS4
8EWG	;	2.9	;	Cryo-EM structure of a riboendonclease
8H4U	;	3.5	;	Cryo-EM structure of a riboendonuclease
6GXP	;	4.4	;	Cryo-EM structure of a rotated E. coli 70S ribosome in complex with RF3-GDPCP(RF3-only)
6GXO	;	3.9	;	Cryo-EM structure of a rotated E. coli 70S ribosome in complex with RF3-GDPCP, RF1(GAQ) and P/E-tRNA (State IV)
5MZ6	;	3.8	;	Cryo-EM structure of a Separase-Securin complex from Caenorhabditis elegans at 3.8 A resolution
8HPO	;	2.6	;	Cryo-EM structure of a SIN3/HDAC complex from budding yeast
6F3A	;	8.2	;	Cryo-EM structure of a single dynein tail domain bound to dynactin and BICD2N
8SEB	;	3.24	;	Cryo-EM structure of a single loaded human UBA7-UBE2L6-ISG15 adenylate complex
8UMX	;	4.0	;	Cryo-EM structure of a single subunit of a Clockwise-locked form of the Salmonella enterica Typhimurium flagellar C-ring.
8UMD	;	3.6	;	Cryo-EM structure of a single subunit of a Counterclockwise-locked form of the Salmonella enterica Typhimurium flagellar C-ring.
8BYV	;	2.89	;	Cryo-EM structure of a Staphylococus aureus 30S-RbfA complex
8F6X	;	3.25	;	cryo-EM structure of a structurally designed Human metapneumovirus F protein in complex with antibody MPE8
8AFA	;	3.16	;	Cryo-EM structure of a substrate-bound glutamate transporter homologue GltTk encapsulated within a nanodisc
6V05	;	4.1	;	Cryo-EM structure of a substrate-engaged Bam complex
8TI1	;	2.9	;	Cryo-EM structure of a SUR1/Kir6.2-Q52R ATP-sensitive potassium channel in the presence of PIP2 in the open conformation
8TI2	;	3.28	;	Cryo-EM structure of a SUR1/Kir6.2-Q52R ATP-sensitive potassium channel in the presence of PIP2 in the open conformation
7UDB	;	3.5	;	Cryo-EM structure of a synaptobrevin-Munc18-1-syntaxin-1 complex class 2
8AUR	;	3.47	;	Cryo-EM structure of a TasA fibre
7KQ5	;	2.0	;	Cryo-EM structure of a thermostable encapsulin from T. maritima
7T5Q	;	3.4	;	Cryo-EM Structure of a Transition State of Arp2/3 Complex Activation
7RTT	;	3.5	;	Cryo-EM structure of a TTYH2 cis-dimer
7RTU	;	3.89	;	Cryo-EM structure of a TTYH2 trans-dimer
7RTW	;	3.23	;	Cryo-EM structure of a TTYH3 cis-dimer
7OB4	;	3.22	;	Cryo-EM structure of a twisted-dimer transthyretin amyloid fibril from vitreous body of the eye
7WTL	;	3.3	;	Cryo-EM structure of a yeast pre-40S ribosomal subunit - State Dis-D
7WTM	;	3.5	;	Cryo-EM structure of a yeast pre-40S ribosomal subunit - State Dis-E
7WTN	;	3.4	;	Cryo-EM structure of a yeast pre-40S ribosomal subunit - State Tsr1-1 (with Rps2)
7WTO	;	3.5	;	Cryo-EM structure of a yeast pre-40S ribosomal subunit - State Tsr1-1 (without Rps2)
7WTP	;	3.8	;	Cryo-EM structure of a yeast pre-40S ribosomal subunit - State Tsr1-2 (with Rps2)
7WTQ	;	3.7	;	Cryo-EM structure of a yeast pre-40S ribosomal subunit - State Tsr1-2 (without Rps2)
7WTR	;	3.5	;	Cryo-EM structure of a yeast pre-40S ribosomal subunit - State Tsr1-3
8F6H	;	3.9	;	Cryo-EM structure of a Zinc-loaded asymmetrical TMD D70A mutant of the YiiP-Fab complex
8F6J	;	3.7	;	Cryo-EM structure of a Zinc-loaded D287A mutant of the YiiP-Fab complex
8F6F	;	3.6	;	Cryo-EM structure of a Zinc-loaded D51A mutant of the YiiP-Fab complex
8F6K	;	3.46	;	Cryo-EM structure of a Zinc-loaded H263A/D287A mutant of the YiiP-Fab complex
8F6I	;	4.03	;	Cryo-EM structure of a Zinc-loaded symmetrical D70A mutant of the YiiP-Fab complex
8F6E	;	3.8	;	Cryo-EM structure of a Zinc-loaded wild-type YiiP-Fab complex
7F53	;	3.0	;	Cryo-EM structure of a-MSH-MC4R-Gs_Nb35 complex
6LRQ	;	3.49	;	Cryo-EM structure of A53T alpha-synuclein amyloid fibril
8THK	;	2.6	;	Cryo-EM structure of A61603-bound alpha-1A-adrenergic receptor in complex with heterotrimeric Gq-protein
7CKX	;	3.54	;	Cryo-EM structure of A77636 bound dopamine receptor DRD1-Gs signaling complex
7NA6	;	3.35	;	Cryo-EM structure of AAV True Type
6NZ0	;	2.4	;	Cryo-EM structure of AAV-2 in complex with AAVR PKD domains 1 and 2
7UD4	;	2.24	;	Cryo-EM structure of AAV-PHP.eB
8FZN	;	3.62	;	Cryo-EM Structure of AAV2-R404A Variant
8HVH	;	3.07	;	Cryo-EM structure of ABC transporter ABCC3
7QKS	;	3.1	;	Cryo-EM structure of ABC transporter STE6-2p from Pichia pastoris in apo conformation at 3.1 A resolution
7QKR	;	3.2	;	Cryo-EM structure of ABC transporter STE6-2p from Pichia pastoris with Verapamil at 3.2 A resolution
7OZ1	;	4.0	;	Cryo-EM structure of ABCG1 E242Q mutant with ATP and cholesteryl hemisuccinate bound
7JR7	;	3.3	;	Cryo-EM structure of ABCG5/G8 in complex with Fab 2E10 and 11F4
8GZ8	;	2.35	;	Cryo-EM structure of Abeta2 fibril polymorph1
8GZ9	;	2.62	;	Cryo-EM structure of Abeta2 fibril polymorph2
8I3D	;	2.81	;	Cryo-EM structure of abscisic acid transporter AtABCG25
8I38	;	2.9	;	Cryo-EM structure of abscisic acid transporter AtABCG25 in inward conformation
8I3B	;	3.08	;	Cryo-EM structure of abscisic acid transporter AtABCG25 in nanodisc
8I3A	;	3.04	;	Cryo-EM structure of abscisic acid transporter AtABCG25 in outward conformation
8I39	;	2.85	;	Cryo-EM structure of abscisic acid transporter AtABCG25 with ABA
8I3C	;	2.85	;	Cryo-EM structure of abscisic acid transporter AtABCG25 with CHS
8HRN	;	3.9	;	Cryo-EM structure of ACE2
8HRU	;	3.9	;	Cryo-EM structure of ACE2
7T8X	;	3.21	;	Cryo-EM structure of ACh-bound M2R-Go signaling complex in S1 state
7T90	;	3.32	;	Cryo-EM structure of ACh-bound M2R-Go signaling complex in S2 state
8DZJ	;	2.9	;	Cryo-EM structure of Acidibacillus sulfuroxidans Cas12f in complex with sgRNA and target DNA
8K5C	;	3.13	;	Cryo-EM structure of Acipimox bound human hydroxy-carboxylic acid receptor 2 (Local refinement)
8I7V	;	2.77	;	Cryo-EM structure of Acipimox bound human hydroxy-carboxylic acid receptor 2 in complex with Gi heterotrimer
7SK4	;	3.3	;	Cryo-EM structure of ACKR3 in complex with chemokine N-terminal mutant CXCL12_LRHQ, an intracellular Fab, and an extracellular Fab
7SK5	;	4.0	;	Cryo-EM structure of ACKR3 in complex with CXCL12 and an intracellular Fab
7SK3	;	3.8	;	Cryo-EM structure of ACKR3 in complex with CXCL12, an intracellular Fab, and an extracellular Fab
7BC5	;	3.1	;	Cryo-EM structure of ACP domain from Pichia pastoris fatty acid synthase (FAS)
6IV6	;	3.6	;	Cryo-EM structure of AcrVA5-acetylated MbCas12a in complex with crRNA
6VRB	;	3.0	;	Cryo-EM structure of AcrVIA1-Cas13(crRNA) complex
8GY7	;	3.3	;	Cryo-EM structure of ACTH-bound melanocortin-2 receptor in complex with MRAP1 and Gs protein
3G37	;	6.0	;	Cryo-EM structure of actin filament in the presence of phosphate
4C3G	;	8.6	;	cryo-EM structure of activated and oligomeric restriction endonuclease SgrAI
7NAL	;	3.0	;	Cryo-EM structure of activated human SARM1 in complex with NMN and 1AD (ARM and SAM domains)
7NAK	;	2.9	;	Cryo-EM structure of activated human SARM1 in complex with NMN and 1AD (TIR:1AD)
7K0Y	;	3.7	;	Cryo-EM structure of activated-form DNA-PK (complex VI)
8XEG	;	1.76	;	Cryo-EM structure of Adeno-associated Virus 9P31 in 1.76 angstrom.
7RK9	;	2.32	;	Cryo-EM Structure of Adeno-Associated Virus Serotype 1 with Engineered Peptide Domain PHP.B (AAV1-PHP.B)
7RK8	;	2.27	;	Cryo-EM Structure of Adeno-Associated Virus Serotype 9 with Engineered Peptide Domain PHP.B (AAV9-PHP.B)
8Q7C	;	2.9	;	Cryo-EM structure of Adenovirus C5 hexon
8G2Y	;	3.44	;	Cryo-EM structure of ADGRF1 coupled to miniGs/q
6PPJ	;	3.5	;	Cryo-EM structure of AdnA(D934A)-AdnB(D1014A) in complex with AMPPNP
6PPR	;	3.5	;	Cryo-EM structure of AdnA(D934A)-AdnB(D1014A) in complex with AMPPNP and DNA
7SJR	;	3.8	;	Cryo-EM structure of AdnA-AdnB(W325A) in complex with DNA and AMPPNP
6PPU	;	3.5	;	Cryo-EM structure of AdnAB-AMPPNP-DNA complex
6DJO	;	3.6	;	Cryo-EM structure of ADP-actin filaments
8OID	;	2.3	;	Cryo-EM structure of ADP-bound, filamentous beta-actin harboring the N111S mutation
8OI8	;	2.28	;	Cryo-EM structure of ADP-bound, filamentous beta-actin harboring the R183W mutation
6DJN	;	3.1	;	Cryo-EM structure of ADP-Pi-actin filaments
8HN1	;	2.9	;	Cryo-EM structure of AdTx1-alpha1AAR-Nb6
5JZT	;	7.4	;	Cryo-EM structure of aerolysin pore in LMNG micelle
5JZH	;	3.9	;	Cryo-EM structure of aerolysin prepore
7F4F	;	2.9	;	Cryo-EM structure of afamelanotide-bound melanocortin-1 receptor in complex with Gs protein and scFv16
7F4H	;	2.7	;	Cryo-EM structure of afamelanotide-bound melanocortin-1 receptor in complex with Gs protein, Nb35 and scFv16
7F54	;	3.0	;	Cryo-EM structure of afamelanotide-MC4R-Gs_Nb35 complex
8HVR	;	3.35	;	Cryo-EM structure of AfsR-dependent transcription activation complex with afsS promoter
7ZKI	;	3.6	;	Cryo-EM structure of aIF1A:aIF5B:Met-tRNAiMet complex from a Pyrococcus abyssi 30S initiation complex
7K3R	;	3.2	;	Cryo-EM structure of AIM2-PYD filament
7WM2	;	2.69	;	Cryo-EM structure of AKT1
7WM1	;	2.8	;	Cryo-EM structure of AKT1-AtKC1
8B0A	;	3.0	;	Cryo-EM structure of ALC1 bound to an asymmetric, site-specifically PARylated nucleosome
7OTQ	;	4.8	;	Cryo-EM structure of ALC1/CHD1L bound to a PARylated nucleosome
6AHC	;	3.45	;	Cryo-EM structure of aldehyde-alcohol dehydrogenase reveals a high-order helical architecture critical for its activity
7U5J	;	2.96	;	Cryo-EM Structure of ALDOA
8EW2	;	3.1	;	Cryo-EM structure of Aldolase embedded in crystalline ice
8F6T	;	2.76	;	Cryo-EM structure of alkane 1-monooxygenase AlkB-AlkG complex from Fontimonas thermophila
7E55	;	5.9	;	Cryo-EM structure of alpha 7 homo-tetradecamer
7F4D	;	3.0	;	Cryo-EM structure of alpha-MSH-bound melanocortin-1 receptor in complex with Gs protein and Nb35
6A6B	;	3.07	;	cryo-em structure of alpha-synuclein fiber
6L4S	;	3.37	;	cryo-em structure of alpha-synuclein fiber mutation type E46K
6RT0	;	3.1	;	cryo-em structure of alpha-synuclein fibril polymorph 2A
6SSX	;	2.98	;	cryo-em structure of alpha-synuclein fibril polymorph 2A
6RTB	;	3.46	;	cryo-em structure of alpha-synuclein fibril polymorph 2B
6SST	;	3.4	;	cryo-em structure of alpha-synuclein fibril polymorph 2B
8BQW	;	2.3	;	Cryo-EM structure of alpha-synuclein filaments doublet from Juvenile-onset synucleinopathy
8A9L	;	2.2	;	Cryo-EM structure of alpha-synuclein filaments from Parkinson's disease and dementia with Lewy bodies
6PEO	;	3.3	;	Cryo-EM structure of alpha-synuclein H50Q Narrow Fibril
6PES	;	3.6	;	Cryo-EM structure of alpha-synuclein H50Q Wide Fibril
8BQV	;	2.0	;	Cryo-EM structure of alpha-synuclein singlet filament from Juvenile-onset synucleinopathy
7YMJ	;	3.35	;	Cryo-EM structure of alpha1AAR-Nb6 complex bound to tamsulosin
6K42	;	4.1	;	cryo-EM structure of alpha2BAR-Gi1 complex
6K41	;	2.9	;	cryo-EM structure of alpha2BAR-GoA complex
7V4T	;	4.04	;	Cryo-EM structure of Alphavirus M1
7VGA	;	6.0	;	Cryo-EM structure of alphavirus, Getah virus
7WC2	;	3.5	;	Cryo-EM structure of alphavirus, Getah virus
7WCO	;	3.8	;	Cryo-EM structure of alphavirus, Getah virus
7VGF	;	3.3	;	cryo-EM structure of AMP-PNP bound human ABCB7
6DJM	;	3.1	;	Cryo-EM structure of AMPPNP-actin filaments
7VQO	;	2.19	;	Cryo-EM structure of Ams1 bound to the FW domain of Nbr1
7DWV	;	3.07	;	Cryo-EM structure of amyloid fibril formed by familial prion disease-related mutation E196K
6LNI	;	2.702	;	Cryo-EM structure of amyloid fibril formed by full-length human prion protein
7VZF	;	2.95	;	Cryo-EM structure of amyloid fibril formed by full-length human SOD1
7VQQ	;	2.9	;	Cryo-EM structure of amyloid fibril formed by FUS low complexity domain
7BX7	;	2.8	;	Cryo-EM structure of amyloid fibril formed by hnRNPA1 low complexity domain
7DA4	;	4.24	;	Cryo-EM structure of amyloid fibril formed by human RIPK3
7YPG	;	2.5	;	Cryo-EM structure of amyloid fibril formed by tau (297-391)
7YYO	;	2.87	;	Cryo-EM structure of an a-carboxysome RuBisCO enzyme at 2.9 A resolution
6OWS	;	2.98	;	Cryo-EM structure of an Acinetobacter baumannii multidrug efflux pump
7EZH	;	3.2	;	Cryo-EM structure of an activated Cholecystokinin A receptor (CCKAR)-Gi complex
7EZM	;	2.9	;	Cryo-EM structure of an activated Cholecystokinin A receptor (CCKAR)-Gq complex
7EZK	;	3.1	;	Cryo-EM structure of an activated Cholecystokinin A receptor (CCKAR)-Gs complex
6VN7	;	3.2	;	Cryo-EM structure of an activated VIP1 receptor-G protein complex
6V4X	;	3.2	;	Cryo-EM structure of an active human histone pre-mRNA 3'-end processing machinery at 3.2 Angstrom resolution
7FD2	;	2.81	;	Cryo-EM structure of an alphavirus, Getah virus
6IMM	;	3.5	;	Cryo-EM structure of an alphavirus, Sindbis virus
7XW3	;	4.04	;	Cryo-EM structure of an apo-form of human DICER
6K0A	;	4.6	;	cryo-EM structure of an archaeal Ribonuclease P
6GWT	;	3.8	;	Cryo-EM structure of an E. coli 70S ribosome in complex with RF3-GDPCP, RF1(GAQ) and Pint-tRNA (State I)
6GXM	;	3.8	;	Cryo-EM structure of an E. coli 70S ribosome in complex with RF3-GDPCP, RF1(GAQ) and Pint-tRNA (State II)
6GXN	;	3.9	;	Cryo-EM structure of an E. coli 70S ribosome in complex with RF3-GDPCP, RF1(GAQ) and Pint-tRNA (State III)
5JTE	;	3.6	;	Cryo-EM structure of an ErmBL-stalled ribosome in complex with A-, P-, and E-tRNA
5JU8	;	3.6	;	Cryo-EM structure of an ErmBL-stalled ribosome in complex with P-, and E-tRNA
6Y69	;	2.86	;	Cryo-EM structure of an Escherichia coli 70S ribosome in complex with antibiotic TetracenomycinX
7OTC	;	2.9	;	Cryo-EM structure of an Escherichia coli 70S ribosome in complex with elongation factor G and the antibiotic Argyrin B
6X6T	;	3.2	;	Cryo-EM structure of an Escherichia coli coupled transcription-translation complex B1 (TTC-B1) containing an mRNA with a 24 nt long spacer, transcription factors NusA and NusG, and fMet-tRNAs at P-site and E-site
6X7F	;	3.5	;	Cryo-EM structure of an Escherichia coli coupled transcription-translation complex B2 (TTC-B2) containing an mRNA with a 24 nt long spacer, transcription factors NusA and NusG, and fMet-tRNAs at P-site and E-site
6X7K	;	3.1	;	Cryo-EM structure of an Escherichia coli coupled transcription-translation complex B3 (TTC-B3) containing an mRNA with a 24 nt long spacer, transcription factors NusA and NusG, and fMet-tRNAs at P-site and E-site
6X9Q	;	4.8	;	Cryo-EM structure of an Escherichia coli coupled transcription-translation complex B3 (TTC-B3) containing an mRNA with a 27 nt long spacer, transcription factors NusA and NusG, and fMet-tRNAs at P-site and E-site
6XDQ	;	3.7	;	Cryo-EM structure of an Escherichia coli coupled transcription-translation complex B3 (TTC-B3) containing an mRNA with a 30 nt long spacer, transcription factors NusA and NusG, and fMet-tRNAs at P-site and E-site
6TC3	;	2.7	;	Cryo-EM structure of an Escherichia coli ribosome-SpeFL complex stalled in response to L-ornithine (Replicate 1)
6TBV	;	2.7	;	Cryo-EM structure of an Escherichia coli ribosome-SpeFL complex stalled in response to L-ornithine (Replicate 2)
7CHW	;	3.58	;	Cryo-EM structure of an Escherichia coli RNAP-promoter open complex (RPo)
7C97	;	3.68	;	Cryo-EM structure of an Escherichia coli RNAP-promoter open complex (RPo) with SspA
7O1A	;	2.4	;	Cryo-EM structure of an Escherichia coli TnaC(R23F)-ribosome complex stalled in response to L-tryptophan
7O1C	;	2.6	;	Cryo-EM structure of an Escherichia coli TnaC(R23F)-ribosome-RF2 complex stalled in response to L-tryptophan
7O19	;	2.9	;	Cryo-EM structure of an Escherichia coli TnaC-ribosome complex stalled in response to L-tryptophan
7CYQ	;	2.83	;	Cryo-EM structure of an extended SARS-CoV-2 replication and transcription complex reveals an intermediate state in cap synthesis
7AEF	;	2.8	;	Cryo-EM structure of an extracellular contractile injection system in marine bacterium Algoriphagus machipongonensis, the baseplate complex in extended state applied 3-fold symmetry.
7AEB	;	2.7	;	Cryo-EM structure of an extracellular contractile injection system in marine bacterium Algoriphagus machipongonensis, the baseplate complex in extended state applied 6-fold symmetry.
7ADZ	;	2.5	;	Cryo-EM structure of an extracellular contractile injection system in marine bacterium Algoriphagus machipongonensis, the cap portion in extended state.
7AEK	;	2.5	;	Cryo-EM structure of an extracellular contractile injection system in marine bacterium Algoriphagus machipongonensis, the contracted sheath shell.
7AE0	;	2.4	;	Cryo-EM structure of an extracellular contractile injection system in marine bacterium Algoriphagus machipongonensis, the sheath-tube module in extended state.
6J0N	;	3.5	;	Cryo-EM Structure of an Extracellular Contractile Injection System, baseplate in extended state, refined in C6 symmetry
6J0M	;	3.9	;	Cryo-EM Structure of an Extracellular Contractile Injection System, PVC baseplate in extended state (reconstructed with C3 symmetry)
6J0C	;	3.7	;	Cryo-EM Structure of an Extracellular Contractile Injection System, PVC sheath complex in contracted state
6J0B	;	2.9	;	Cryo-EM Structure of an Extracellular Contractile Injection System, PVC sheath-tube complex in extended state
6J0F	;	3.8	;	Cryo-EM Structure of an Extracellular Contractile Injection System, PVC sheath/tube terminator in extended state
6RQC	;	4.4	;	Cryo-EM structure of an MCM loading intermediate
8G05	;	3.0	;	Cryo-EM structure of an orphan GPCR-Gi protein signaling complex
6VAL	;	3.87	;	Cryo-EM structure of an undecameric chicken CALHM1 and human CALHM2 chimera
7EG0	;	3.4	;	Cryo-EM structure of anagrelide-induced PDE3A-SLFN12 complex
4UX1	;	8.0	;	Cryo-EM structure of antagonist-bound E2P gastric H,K-ATPase (SCH.E2. AlF)
4UX2	;	7.0	;	Cryo-EM structure of antagonist-bound E2P gastric H,K-ATPase (SCH.E2. MgF)
6W1X	;	3.9	;	Cryo-EM structure of anti-CRISPR AcrIF9, bound to the type I-F crRNA-guided CRISPR surveillance complex
7UKL	;	3.09	;	Cryo-EM structure of Antibody 12-16 in complex with prefusion SARS-CoV-2 Spike glycoprotein
7UKM	;	3.03	;	Cryo-EM structure of Antibody 12-19 in complex with prefusion SARS-CoV-2 Spike glycoprotein
8DUL	;	4.17	;	Cryo-EM Structure of Antibody SKT05 in complex with Western Equine Encephalitis Virus spike (local refinement from VLP particles)
8DUN	;	5.84	;	Cryo-EM Structure of Antibody SKW11 in complex with Western Equine Encephalitis Virus spike (local refinement from VLP particles)
7TZ5	;	3.41	;	Cryo-EM structure of antibody TJ5-5 bound to H3 COBRA TJ5 hemagglutinin
7FES	;	3.4	;	Cryo-EM structure of apo BsClpP at pH 4.2
7FEQ	;	3.2	;	Cryo-EM structure of apo BsClpP at pH 6.5
8QEN	;	3.4	;	cryo-EM structure of apo Clostridioides difficile toxin B
8E76	;	2.51	;	Cryo-EM structure of Apo form ME3
7Y6F	;	2.7	;	Cryo-EM structure of Apo form of ScBfr
7EWL	;	3.52	;	cryo-EM structure of apo GPR158
7E1V	;	2.68	;	Cryo-EM structure of apo hybrid respiratory supercomplex consisting of Mycobacterium tuberculosis complexIII and Mycobacterium smegmatis complexIV
7Y49	;	3.67	;	Cryo-EM Structure of apo mitochondrial ABC transporter ABCB10 from Biortus
6ZY2	;	3.6	;	Cryo-EM structure of apo MlaFEDB
7Y9S	;	3.0	;	Cryo-EM structure of apo SARS-CoV-2 Omicron spike protein (S-2P-GSAS)
8J1D	;	3.59	;	Cryo-EM structure of apo state mTRPV4
7YK2	;	2.8	;	Cryo-EM structure of Apo-alpha-syn fibril
6K3O	;	3.4	;	Cryo-EM structure of Apo-bacterioferritin from Streptomyces coelicolor
6VNW	;	3.44	;	Cryo-EM structure of apo-BBSome
8I4B	;	3.13	;	Cryo-EM structure of apo-form ABCC4
8XOG	;	2.9	;	Cryo-EM structure of apo-GPR30-Gq complex structure
7XGD	;	4.0	;	Cryo-EM structure of Apo-IGF1R map 1
6WJ6	;	2.58	;	Cryo-EM structure of apo-Photosystem II from Synechocystis sp. PCC 6803
7Y15	;	2.9	;	Cryo-EM structure of apo-state MrgD-Gi complex
7Y13	;	3.1	;	Cryo-EM structure of apo-state MrgD-Gi complex (local)
7RHS	;	2.93	;	Cryo-EM structure of apo-state of human CNGA3/CNGB3 channel
8H0I	;	2.8	;	Cryo-EM structure of APOBEC3G-Vif complex
8J62	;	2.5	;	Cryo-EM structure of APOBEC3G-Vif complex
8B0K	;	3.0	;	Cryo-EM structure of apolipoprotein N-acyltransferase Lnt from E. coli (Apo form)
8B0N	;	2.67	;	Cryo-EM structure of apolipoprotein N-acyltransferase Lnt from E. coli in complex with Lyso-PE
8B0P	;	2.86	;	Cryo-EM structure of apolipoprotein N-acyltransferase Lnt from E. coli in complex with Pam3
8B0L	;	3.13	;	Cryo-EM structure of apolipoprotein N-acyltransferase Lnt from E. coli in complex with PE
8B0M	;	3.01	;	Cryo-EM structure of apolipoprotein N-acyltransferase Lnt from E. coli in complex with PE (C387S mutant)
7JVQ	;	3.0	;	Cryo-EM structure of apomorphine-bound dopamine receptor 1 in complex with Gs protein
7CHK	;	2.87	;	Cryo-EM Structure of Apple Latent Spherical Virus (ALSV)
7NZ3	;	11.0	;	Cryo-EM structure of apposed MukBEF-MatP monomers on DNA
7SVA	;	3.26	;	Cryo-EM structure of Arabidopsis Ago10-guide RNA complex
7SWQ	;	3.79	;	Cryo-EM structure of Arabidopsis Ago10-guide-target RNA complex in a bent duplex conformation
7SWF	;	3.79	;	Cryo-EM structure of Arabidopsis Ago10-guide-target RNA complex in a central duplex conformation
6M79	;	3.1	;	Cryo-EM structure of Arabidopsis CRY under blue light-mediated activation
7X0X	;	2.56	;	Cryo-EM Structure of Arabidopsis CRY2 in active conformation
7X0Y	;	3.89	;	Cryo-EM Structure of Arabidopsis CRY2 tetramer in complex with CIB1 fragment
7ELE	;	4.9	;	Cryo-EM structure of Arabidopsis DCL1 in complex with pre-miRNA 166f
7ELD	;	4.6	;	Cryo-EM structure of Arabidopsis DCL1 in complex with pri-miRNA 166f
7VG3	;	3.73	;	Cryo-EM structure of Arabidopsis DCL3 in complex with a 30-bp RNA
7VG2	;	3.1	;	Cryo-EM structure of Arabidopsis DCL3 in complex with a 40-bp RNA
8IFF	;	3.1	;	Cryo-EM structure of Arabidopsis phytochrome A.
8DTG	;	3.9	;	Cryo-EM structure of Arabidopsis SPY alternative conformation 1
8DTH	;	3.6	;	Cryo-EM structure of Arabidopsis SPY alternative conformation 2
8DTI	;	3.8	;	Cryo-EM structure of Arabidopsis SPY in complex with GDP-fucose
7AR8	;	3.53	;	Cryo-EM structure of Arabidopsis thaliana complex-I (closed conformation)
7ARB	;	3.41	;	Cryo-EM structure of Arabidopsis thaliana Complex-I (complete composition)
7AQQ	;	3.06	;	Cryo-EM structure of Arabidopsis thaliana Complex-I (membrane core)
7AQW	;	3.17	;	Cryo-EM structure of Arabidopsis thaliana Complex-I (membrane tip)
7AR7	;	3.72	;	Cryo-EM structure of Arabidopsis thaliana complex-I (open conformation)
7AQR	;	2.91	;	Cryo-EM structure of Arabidopsis thaliana Complex-I (peripheral arm)
6VXM	;	3.06	;	Cryo-EM structure of Arabidopsis thaliana MSL1
6VXN	;	2.96	;	Cryo-EM structure of Arabidopsis thaliana MSL1 A320V
6VXP	;	3.39	;	Cryo-EM structure of Arabidopsis thaliana MSL1 in lipid nanodisc
7Y3E	;	2.8	;	Cryo-EM structure of Arabidopsis thaliana SOS1 in an occluded state
8HYA	;	3.4	;	Cryo-EM structure of Arabidopsis thaliana SOS1 in an occluded state, with expanded TMD
6H9C	;	3.74	;	Cryo-EM structure of archaeal extremophilic internal membrane-containing Haloarcula californiae icosahedral virus 1 (HCIV-1) at 3.74 Angstroms resolution.
6K0B	;	4.3	;	cryo-EM structure of archaeal Ribonuclease P with mature tRNA
7ZL4	;	3.45	;	Cryo-EM structure of archaic chaperone-usher Csu pilus of Acinetobacter baumannii
7TAP	;	2.8	;	Cryo-EM structure of archazolid A bound to yeast VO V-ATPase
7XRD	;	3.9	;	Cryo-EM structure of Arf6 helical polymer assembled on lipid membrane
7JPN	;	3.24	;	Cryo-EM structure of Arpin-bound Arp2/3 complex
6TGA	;	3.26	;	Cryo-EM Structure of as isolated form of NAD+-dependent Formate Dehydrogenase from Rhodobacter capsulatus
6N1H	;	3.17	;	Cryo-EM structure of ASC-CARD filament
8ALZ	;	3.4	;	Cryo-EM structure of ASCC3 in complex with ASC1
8J89	;	2.31	;	Cryo-EM structure of Asfv topoisomerase 2 - apo conformer IIa
8J8A	;	2.51	;	Cryo-EM structure of Asfv topoisomerase 2 - apo conformer IIb
8J8B	;	2.43	;	Cryo-EM structure of Asfv topoisomerase 2 - apo conformer IIIa
8J8C	;	2.69	;	Cryo-EM structure of Asfv topoisomerase 2 - apo conformer IIIb
8J3W	;	3.07	;	Cryo-EM structure of aspirin-bound ABCC4
6LYP	;	3.3	;	Cryo-EM structure of AtMSL1 wild type
8TDK	;	3.5	;	Cryo-EM structure of AtMSL10-G556V
8TDM	;	3.7	;	Cryo-EM structure of AtMSL10-K539E
6TGN	;	3.9	;	Cryo-EM structure of AtNBR1-PB1 filament (L-type)
6TGP	;	4.4	;	Cryo-EM structure of AtNBR1-PB1 filament (S-type)
8JPO	;	3.4	;	Cryo-EM structure of ATP bound human ClC-6
7W02	;	3.3	;	Cryo-EM structure of ATP-bound ABCA3
7JHG	;	3.47	;	Cryo-EM structure of ATP-bound fully inactive AMPK in complex with Dorsomorphin (Compound C) and Fab-nanobody
7JHH	;	3.92	;	Cryo-EM structure of ATP-bound fully inactive AMPK in complex with Fab and nanobody
8IZA	;	3.48	;	cryo-EM structure of ATP-bound hMRP4
7SHM	;	3.14	;	Cryo-EM structure of ATP-bound human peroxisomal fatty acid transporter ABCD1
7VX8	;	2.8	;	Cryo-EM structure of ATP-bound human very long-chain fatty acid ABC transporter ABCD1
7T54	;	4.5	;	Cryo-EM structure of ATP-bound PCAT1 in the outward-facing conformation
6BHU	;	3.14	;	Cryo-EM structure of ATP-bound, outward-facing bovine multidrug resistance protein 1 (MRP1)
8J3Z	;	3.17	;	Cryo-EM structure of ATP-U46619-bound ABCC4
7N77	;	3.2	;	Cryo-EM structure of ATP13A2 D458N/D962N mutant in the AlF-bound E1P-like state
7N75	;	2.9	;	Cryo-EM structure of ATP13A2 D458N/D962N mutant in the E1-apo state, Conformation 1
7N76	;	2.9	;	Cryo-EM structure of ATP13A2 D458N/D962N mutant in the E1-apo state, Conformation 2
7N74	;	2.8	;	Cryo-EM structure of ATP13A2 D508N mutant in the E1-ATP-like state
7N73	;	2.9	;	Cryo-EM structure of ATP13A2 in the ADP-AlF-bound E1P-ADP-like state
7N72	;	2.5	;	Cryo-EM structure of ATP13A2 in the AlF-bound E2-Pi-like state
7N70	;	2.8	;	Cryo-EM structure of ATP13A2 in the BeF-bound E2P-like state
8IEK	;	3.2	;	Cryo-EM structure of ATP13A2 in the E1-ATP state
8IEL	;	5.65	;	Cryo-EM structure of ATP13A2 in the E1-like state
8IES	;	3.73	;	Cryo-EM structure of ATP13A2 in the E1P-ADP state
7N78	;	3.0	;	Cryo-EM structure of ATP13A2 in the E2-Pi state
8IEN	;	3.25	;	Cryo-EM structure of ATP13A2 in the E2-Pi state
8IEM	;	3.35	;	Cryo-EM structure of ATP13A2 in the E2P state
8IEO	;	3.78	;	Cryo-EM structure of ATP13A2 in the nominal E1P state
8IER	;	4.87	;	Cryo-EM structure of ATP13A2 in the putative of E2 state
8OX4	;	3.4	;	Cryo-EM structure of ATP8B1-CDC50A in E1-ATP conformation
8OX6	;	2.39	;	Cryo-EM structure of ATP8B1-CDC50A in E1P conformation
8OX5	;	2.9	;	Cryo-EM structure of ATP8B1-CDC50A in E1P-ADP conformation
8OXB	;	2.99	;	Cryo-EM structure of ATP8B1-CDC50A in E2-Pi conformation with occluded PC
8OXC	;	2.58	;	Cryo-EM structure of ATP8B1-CDC50A in E2-Pi conformation with occluded PI
8OXA	;	2.76	;	Cryo-EM structure of ATP8B1-CDC50A in E2-Pi conformation with occluded PS
8OX9	;	2.72	;	Cryo-EM structure of ATP8B1-CDC50A in E2P active conformation with bound PC
8OX7	;	2.56	;	Cryo-EM structure of ATP8B1-CDC50A in E2P autoinhibited ""closed"" conformation
8OX8	;	2.98	;	Cryo-EM structure of ATP8B1-CDC50A in E2P autoinhibited ""open"" conformation
7PY4	;	3.1	;	Cryo-EM structure of ATP8B1-CDC50A in E2P autoinhibited state
7WNQ	;	2.7	;	Cryo-EM structure of AtSLAC1 S59A mutant
6R9T	;	6.2	;	Cryo-EM structure of autoinhibited human talin-1
7ABR	;	3.7	;	Cryo-EM structure of B. subtilis ClpC (DWB mutant) hexamer bound to a substrate polypeptide
5WJV	;	5.5	;	Cryo-EM structure of B. subtilis flagellar filaments A233V
5WJU	;	4.3	;	Cryo-EM structure of B. subtilis flagellar filaments A39V, N133H
5WJZ	;	5.7	;	Cryo-EM structure of B. subtilis flagellar filaments E115G
5WJW	;	4.4	;	Cryo-EM structure of B. subtilis flagellar filaments H84R
5WJT	;	3.8	;	Cryo-EM structure of B. subtilis flagellar filaments N226Y
5WJX	;	6.7	;	Cryo-EM structure of B. subtilis flagellar filaments S17P
5WJY	;	4.5	;	Cryo-EM structure of B. subtilis flagellar filaments S285P
7R1C	;	3.2	;	Cryo-EM structure of Bacillus megaterium gas vesicles
6WVJ	;	3.36	;	Cryo-EM structure of Bacillus subtilis RNA Polymerase elongation complex
6WVK	;	3.36	;	Cryo-EM structure of Bacillus subtilis RNA Polymerase in complex with HelD
8TVV	;	3.7	;	Cryo-EM structure of backtracked Pol II
8TVS	;	4.4	;	Cryo-EM structure of backtracked Pol II in complex with Rad26
6GFW	;	3.7	;	Cryo-EM structure of bacterial RNA polymerase-sigma54 holoenzyme initial transcribing complex
6GH6	;	4.1	;	Cryo-EM structure of bacterial RNA polymerase-sigma54 holoenzyme intermediate partially loaded complex
6GH5	;	3.4	;	Cryo-EM structure of bacterial RNA polymerase-sigma54 holoenzyme transcription open complex
8REA	;	3.4	;	Cryo-EM structure of bacterial RNA polymerase-sigma54 initial transcribing complex - 5nt post-translocated complex
8RE4	;	2.8	;	Cryo-EM structure of bacterial RNA polymerase-sigma54 initial transcribing complex - 5nt pre-translocated complex
8REB	;	3.4	;	Cryo-EM structure of bacterial RNA polymerase-sigma54 initial transcribing complex - 6nt complex
8REC	;	3.5	;	Cryo-EM structure of bacterial RNA polymerase-sigma54 initial transcribing complex - 7nt complex
8RED	;	3.9	;	Cryo-EM structure of bacterial RNA polymerase-sigma54 initial transcribing complex - 8nt complex
8REE	;	3.8	;	Cryo-EM structure of bacterial RNA polymerase-sigma54 initial transcribing complex - 9nt complex
6R9B	;	3.8	;	Cryo-EM structure of bacterial RNAP with a DNA mimic protein Ocr from T7 phage
7Y6G	;	3.6	;	Cryo-EM structure of bacterioferritin holoform 1a
7VI9	;	5.03	;	Cryo-EM structure of bacteriophage lambda procapsid at 5.03 Angstrom
5L35	;	2.89	;	Cryo-EM structure of bacteriophage Sf6 at 2.9 Angstrom resolution
7YPO	;	3.5	;	Cryo-EM structure of baculovirus LEF-3 in complex with ssDNA
7TAO	;	3.2	;	Cryo-EM structure of bafilomycin A1 bound to yeast VO V-ATPase
7KHR	;	3.62	;	Cryo-EM structure of bafilomycin A1-bound intact V-ATPase from bovine brain
8H1T	;	3.0	;	Cryo-EM structure of BAP1-ASXL1 bound to chromatosome
6SCL	;	3.0	;	Cryo-EM Structure of Barley Yellow Dwarf Virus VLP
7CN4	;	2.93	;	Cryo-EM structure of bat RaTG13 spike glycoprotein
8CZO	;	4.3	;	Cryo-EM structure of BCL10 CARD - MALT1 DD filament
6BZE	;	4.0	;	Cryo-EM structure of BCL10 CARD filament
8CZD	;	4.6	;	Cryo-EM structure of BCL10 R58Q filament
6XMX	;	3.7	;	Cryo-EM structure of BCL6 bound to BI-3802
7JGB	;	3.5	;	Cryo-EM structure of bedaquiline-free Mycobacterium smegmatis ATP synthase FO region
7JG5	;	3.4	;	Cryo-EM structure of bedaquiline-free Mycobacterium smegmatis ATP synthase rotational state 1
7JG6	;	3.7	;	Cryo-EM structure of bedaquiline-free Mycobacterium smegmatis ATP synthase rotational state 2 (backbone model)
7JG7	;	3.5	;	Cryo-EM structure of bedaquiline-free Mycobacterium smegmatis ATP synthase rotational state 3 (backbone model)
7JGC	;	3.4	;	Cryo-EM structure of bedaquiline-saturated Mycobacterium smegmatis ATP synthase FO region
7JG8	;	3.3	;	Cryo-EM structure of bedaquiline-saturated Mycobacterium smegmatis ATP synthase rotational state 1 (backbone model)
7JG9	;	3.4	;	Cryo-EM structure of bedaquiline-saturated mycobacterium smegmatis ATP synthase rotational state 2 (backbone model)
7JGA	;	3.2	;	Cryo-EM structure of bedaquiline-saturated Mycobacterium smegmatis ATP synthase rotational state 3
7PL9	;	3.21	;	Cryo-EM structure of Bestrhodopsin (rhodopsin-rhodopsin-bestrophin) complex
8HW2	;	3.65	;	Cryo-EM structure of beta-estradiol 17-(beta-D-glucuronide)-bound human ABC transporter ABCC3 in nanodiscs
8BK8	;	2.9	;	Cryo-EM structure of beta-galactosidase at 2.9 A resolution plunged 205 ms after mixing with apoferritin
8BKG	;	3.2	;	Cryo-EM structure of beta-galactosidase at 3.2 A resolution plunged 35 ms after mixing with apoferritin
8BK7	;	3.3	;	Cryo-EM structure of beta-galactosidase at 3.3 A resolution plunged 5 ms after mixing with apoferritin
7UGQ	;	3.4	;	Cryo-EM structure of BG24 Fabs with an inferred germline CDRL1 and 10-1074 Fabs in complex with HIV-1 Env 6405-SOSIP.664
7UGP	;	4.2	;	Cryo-EM structure of BG24 Fabs with an inferred germline light chain and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1 containing the N276 gp120 glycan- Class 1
7UGN	;	3.4	;	Cryo-EM structure of BG24 inferred germline Fabs with germline CDR3s and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1 - Class 1
7UGO	;	4.1	;	Cryo-EM structure of BG24 inferred germline Fabs with mature CDR3s and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1
7LL2	;	3.73	;	Cryo-EM structure of BG505 DS-SOSIP in complex with Glycan276-Dependent Broadly Neutralizing Antibody VRC33.01 Fab
7LL1	;	3.73	;	Cryo-EM structure of BG505 DS-SOSIP in complex with glycan276-dependent broadly neutralizing antibody VRC40.01 Fab
7TXD	;	3.87	;	Cryo-EM structure of BG505 SOSIP HIV-1 Env trimer in complex with CD4 receptor (D1D2) and broadly neutralizing darpin bnD.9
8C8T	;	3.2	;	cryo-EM structure of BG505 SOSIP.664 HIV-1 Env trimer in complex with bNAbs EPTC112 and 3BNC117
8TTW	;	2.96	;	Cryo-EM structure of BG505 SOSIP.664 HIV-1 Env trimer in complex with temsavir, 8ANC195, and 10-1074
6MN7	;	4.8	;	Cryo-EM structure of BG505.SOSIP.664 in complex with BF520.1 antigen binding fragment
7CYF	;	3.15	;	Cryo-EM structure of bicarbonate transporter SbtA in complex with PII-like signaling protein SbtB from Synechocystis sp. PCC 6803
8JXQ	;	3.32	;	Cryo-EM structure of bilirubin ditaurate (BDT) bound human ABC transporter ABCC2
7Y48	;	2.85	;	Cryo-EM Structure of biliverdin-bound mitochondrial ABC transporter ABCB10 from Biortus
6OVH	;	2.6	;	Cryo-EM structure of Bimetallic dodecameric cage design 3 (BMC3) from cytochrome cb562
7XVG	;	3.6	;	Cryo-EM structure of binary complex of plant NLR Sr35 and effector AvrSr35
8HLB	;	3.63	;	Cryo-EM structure of biparatopic antibody Bp109-92 in complex with TNFR2
8E2D	;	2.07	;	Cryo-EM structure of BIRC6 (consensus)
8E2K	;	3.21	;	Cryo-EM structure of BIRC6/HtrA2-S306A
8E2I	;	3.04	;	Cryo-EM structure of BIRC6/Smac
8E2J	;	3.44	;	Cryo-EM structure of BIRC6/Smac (from local refinement 1)
6GG0	;	4.24	;	Cryo-EM structure of BK polyomavirus like particle in complex with single chain antibody ScFv41F17
7RTN	;	3.4	;	Cryo-EM structure of bluetongue virus capsid protein VP5 at low endosomal pH
7RTO	;	3.8	;	Cryo-EM structure of bluetongue virus capsid protein VP5 at low endosomal pH intermediate state 2
7UFR	;	2.7	;	Cryo-EM Structure of Bl_Man38A at 2.7 A
7UFU	;	2.7	;	Cryo-EM Structure of Bl_Man38A nucleophile mutant in complex with mannose at 2.7 A
7UFS	;	3.4	;	Cryo-EM Structure of Bl_Man38B at 3.4 A
7UFT	;	2.9	;	Cryo-EM Structure of Bl_Man38C at 2.9 A
7Y66	;	2.9	;	Cryo-EM structure of BM213-bound C5aR1 in complex with Gi protein
7PE2	;	3.2	;	Cryo-EM structure of BMV-derived VLP expressed in E. coli (eVLP)
7PE1	;	3.0	;	Cryo-EM structure of BMV-derived VLP expressed in E. coli and assembled in the presence of tRNA (tVLP)
8C8G	;	2.98	;	Cryo-EM structure of BoNT/Wo-NTNH complex
7QFQ	;	3.6	;	Cryo-EM structure of Botulinum neurotoxin serotype B
7QFP	;	3.7	;	Cryo-EM structure of Botulinum neurotoxin serotype E
8TZ3	;	2.31	;	Cryo-EM structure of bovine concentrative nucleoside transporter 3 in complex with GS-441524, consensus reconstruction
8TZ4	;	3.23	;	Cryo-EM structure of bovine concentrative nucleoside transporter 3 in complex with GS-441524, subset reconstruction
8TZ7	;	3.0	;	Cryo-EM structure of bovine concentrative nucleoside transporter 3 in complex with Molnupiravir, condition 1, INT1-INT1-INT1 conformation
8TZ8	;	3.19	;	Cryo-EM structure of bovine concentrative nucleoside transporter 3 in complex with Molnupiravir, condition 1, INT1-INT1-INT3 conformation
8TZD	;	3.2	;	Cryo-EM structure of bovine concentrative nucleoside transporter 3 in complex with Molnupiravir, condition 1, INT1-INT1-OFS conformation (3DVA analysis)
8TZA	;	3.43	;	Cryo-EM structure of bovine concentrative nucleoside transporter 3 in complex with Molnupiravir, condition 2, INT2-INT1-INT1 conformation
8TZ9	;	3.67	;	Cryo-EM structure of bovine concentrative nucleoside transporter 3 in complex with Molnupiravir, condition 2, INT2-INT2-INT2 conformation
8TZ5	;	2.74	;	Cryo-EM structure of bovine concentrative nucleoside transporter 3 in complex with N-hydroxycytidine
8TZ6	;	2.69	;	Cryo-EM structure of bovine concentrative nucleoside transporter 3 in complex with PSI-6206
8TZ1	;	2.54	;	Cryo-EM structure of bovine concentrative nucleoside transporter 3 in complex with Ribavirin
8TZ2	;	2.8	;	Cryo-EM structure of bovine concentrative nucleoside transporter 3 in MSP2N2 nanodiscs, apo state
5UJ9	;	3.49	;	Cryo-EM structure of bovine multidrug resistance protein 1 (MRP1)
5UJA	;	3.34	;	Cryo-EM structure of bovine multidrug resistance protein 1 (MRP1) bound to leukotriene C4
7WBU	;	3.42	;	Cryo-EM structure of bovine NLRP9
7VAE	;	3.55	;	Cryo-EM structure of bovine NTCP complexed with YN69202Fab
8UFI	;	3.1	;	Cryo-EM structure of bovine phosphodiesterase 6
8UGS	;	3.2	;	Cryo-EM structure of bovine phosphodiesterase 6 bound to cGMP
8ULG	;	3.2	;	Cryo-EM structure of bovine phosphodiesterase 6 bound to IBMX
8UGB	;	3.0	;	Cryo-EM structure of bovine phosphodiesterase 6 bound to udenafil
7M8K	;		;	Cryo-EM structure of Brazil (P.1) SARS-CoV-2 spike glycoprotein variant in the prefusion state (1 RBD up)
8GRQ	;	3.87	;	Cryo-EM structure of BRCA1/BARD1 bound to H2AK127-UbcH5c-Ub nucleosome
7F55	;	3.1	;	Cryo-EM structure of bremelanotide-MC4R-Gs_Nb35 complex
7N5H	;	3.24	;	Cryo-EM structure of broadly neutralizing antibody 2-36 in complex with prefusion SARS-CoV-2 spike glycoprotein
7N28	;	4.2	;	Cryo-EM structure of broadly neutralizing V2-apex-targeting antibody J033 in complex with HIV-1 Env
7MXD	;	3.4	;	Cryo-EM structure of broadly neutralizing V2-apex-targeting antibody J038 in complex with HIV-1 Env
7JVR	;	2.8	;	Cryo-EM structure of Bromocriptine-bound dopamine receptor 2 in complex with Gi protein
7OS1	;	3.3	;	Cryo-EM structure of Brr2 in complex with Fbp21
7OS2	;	2.76	;	Cryo-EM structure of Brr2 in complex with Jab1/MPN and C9ORF78
7FER	;	3.4	;	Cryo-EM structure of BsClpP-ADEP1 complex at pH 4.2
7FEP	;	3.1	;	Cryo-EM structure of BsClpP-ADEP1 complex at pH 6.5
8DZE	;	2.99	;	Cryo-EM structure of bundle-forming pilus extension ATPase from E. coli in the presence of AMP-PNP (class-1)
8DZG	;	3.1	;	Cryo-EM structure of bundle-forming pilus extension ATPase from E.coli in the presence of ADP
8DZF	;	3.69	;	Cryo-EM structure of bundle-forming pilus extension ATPase from E.coli in the presence of AMP-PNP (class-2)
7ZLH	;	2.75	;	Cryo-EM structure of C-mannosyltransferase CeDPY19, in apo state, bound to CMT2-Fab and anti-Fab nanobody
7ZLG	;	2.72	;	Cryo-EM structure of C-mannosyltransferase CeDPY19, in complex with acceptor peptide and bound to CMT2-Fab and anti-Fab nanobody
7ZLI	;	2.99	;	Cryo-EM structure of C-mannosyltransferase CeDPY19, in complex with Dol25-P-Man and bound to CMT2-Fab and anti-Fab nanobody
7ZLJ	;	3.63	;	Cryo-EM structure of C-mannosyltransferase CeDPY19, in ternary complex with Dol25-P-C-Man and acceptor peptide, bound to CMT2-Fab and anti-Fab nanobody
8E2H	;	2.3	;	Cryo-EM structure of C-terminal arm of BIRC6 (from local refinement 4)
6LTN	;	3.1	;	cryo-EM structure of C-terminal truncated human Pannexin1
8QGY	;	3.71	;	Cryo-EM structure of C-terminally truncated Apoptosis signal-regulating kinase 1 (ASK1)
6E88	;	4.8	;	Cryo-EM structure of C. elegans GDP-microtubule
7Y67	;	2.8	;	Cryo-EM structure of C089-bound C5aR1(I116A) mutant in complex with Gi protein
7VZB	;	3.59	;	Cryo-EM structure of C22:0-CoA bound human very long-chain fatty acid ABC transporter ABCD1
8IA8	;	2.86	;	Cryo-EM structure of C3aR-Gi-scFv16 bound with E7 peptide
7Y65	;	3.2	;	Cryo-EM structure of C5a peptide-bound C5aR1 in complex with Gi protein
7Y64	;	2.9	;	Cryo-EM structure of C5a-bound C5aR1 in complex with Gi protein
6LT0	;	3.2	;	cryo-EM structure of C9ORF72-SMCR8-WDR41
6V38	;	3.8	;	Cryo-EM structure of Ca2+-bound hsSlo1 channel
6V22	;	3.2	;	Cryo-EM structure of Ca2+-bound hsSlo1-beta4 channel complex
8BC0	;	3.09	;	Cryo-EM structure of Ca2+-bound mTMEM16F F518A Q623A mutant in GDN open/closed
8BC1	;	2.93	;	Cryo-EM Structure of Ca2+-bound mTMEM16F F518A_Q623A mutant in GDN
8B8J	;	2.96	;	Cryo-EM structure of Ca2+-bound mTMEM16F F518H mutant in Digitonin
8B8K	;	3.01	;	Cryo-EM structure of Ca2+-bound mTMEM16F N562A mutant in Digitonin closed/closed
8B8M	;	3.49	;	Cryo-EM structure of Ca2+-bound mTMEM16F N562A mutant in Digitonin open/closed
6V3G	;	4.0	;	Cryo-EM structure of Ca2+-free hsSlo1 channel
6V35	;	3.5	;	Cryo-EM structure of Ca2+-free hsSlo1-beta4 channel complex
8B8G	;	3.39	;	Cryo-EM structure of Ca2+-free mTMEM16F F518H mutant in Digitonin
6X6L	;	3.0	;	Cryo-EM Structure of CagX and CagY within the dCag3 Helicobacter pylori PR
6X6J	;	3.5	;	Cryo-EM Structure of CagX and CagY within the Helicobacter pylori PR
8P6W	;	1.9	;	Cryo-EM structure of CAK in complex with inhibitor BS-181
8P6X	;	1.9	;	Cryo-EM structure of CAK in complex with inhibitor BS-194
8PLZ	;	1.9	;	Cryo-EM structure of CAK in complex with inhibitor CT7030
8P78	;	1.9	;	Cryo-EM structure of CAK in complex with inhibitor dinaciclib
8P6Z	;	2.1	;	Cryo-EM structure of CAK in complex with inhibitor ICEC0510-R
8P70	;	2.0	;	Cryo-EM structure of CAK in complex with inhibitor ICEC0510-S
8P71	;	2.0	;	Cryo-EM structure of CAK in complex with inhibitor ICEC0574
8P72	;	1.9	;	Cryo-EM structure of CAK in complex with inhibitor ICEC0768
8P73	;	2.0	;	Cryo-EM structure of CAK in complex with inhibitor ICEC0829
8P75	;	2.0	;	Cryo-EM structure of CAK in complex with inhibitor ICEC0880 (ring-down conformation)
8P74	;	2.2	;	Cryo-EM structure of CAK in complex with inhibitor ICEC0880 (ring-up conformation)
8P76	;	2.0	;	Cryo-EM structure of CAK in complex with inhibitor ICEC0914
8P6V	;	1.9	;	Cryo-EM structure of CAK in complex with inhibitor ICEC0942
8P77	;	1.8	;	Cryo-EM structure of CAK in complex with inhibitor ICEC0943
8P6Y	;	1.9	;	Cryo-EM structure of CAK in complex with nucleotide analogue ATPgS
8P79	;	1.7	;	Cryo-EM structure of CAK with averaged inhibitor density
8ORM	;	1.9	;	Cryo-EM structure of CAK-THZ1
6QP6	;	3.2	;	Cryo-EM structure of calcium-bound mTMEM16F lipid scramblase in digitonin
6QPC	;	3.5	;	Cryo-EM structure of calcium-bound mTMEM16F lipid scramblase in nanodisc
6QM5	;	3.6	;	Cryo-EM structure of calcium-bound nhTMEM16 lipid scramblase in DDM
6QMB	;	3.6	;	Cryo-EM structure of calcium-bound nhTMEM16 lipid scramblase in nanodisc (closed state)
6QMA	;	3.7	;	Cryo-EM structure of calcium-bound nhTMEM16 lipid scramblase in nanodisc (intermediate state)
6QM9	;	3.6	;	Cryo-EM structure of calcium-bound nhTMEM16 lipid scramblase in nanodisc (open state)
6P48	;	3.2	;	Cryo-EM structure of calcium-bound TMEM16F in nanodisc with supplement of PIP2 in Cl1
6P49	;	3.3	;	Cryo-EM structure of calcium-bound TMEM16F in nanodisc with supplement of PIP2 in Cl2
6QPB	;	3.6	;	Cryo-EM structure of calcium-free mTMEM16F lipid scramblase in digitonin
6QPI	;	3.3	;	Cryo-EM structure of calcium-free mTMEM16F lipid scramblase in nanodisc
6QM6	;	3.7	;	Cryo-EM structure of calcium-free nhTMEM16 lipid scramblase in DDM
6QM4	;	3.8	;	Cryo-EM structure of calcium-free nhTMEM16 lipid scramblase in nanodisc
7V4I	;	3.3	;	Cryo-EM Structure of Camellia sinensis glutamine synthetase CsGSIb decamer assembly
7V4J	;	3.5	;	Cryo-EM Structure of Camellia sinensis glutamine synthetase CsGSIb inactive Pentamer State I
7V4K	;		;	Cryo-EM Structure of Camellia sinensis glutamine synthetase CsGSIb inactive Pentamer State II
7V4L	;	3.4	;	Cryo-EM Structure of Camellia sinensis glutamine synthetase CsGSIb inactive Pentamer State III
8GUA	;	2.77	;	Cryo-EM structure of cancer-specific PI3Kalpha mutant E542K in complex with BYL-719
8GUD	;	2.62	;	Cryo-EM structure of cancer-specific PI3Kalpha mutant E545K in complex with BYL-719
8GUB	;	2.73	;	Cryo-EM structure of cancer-specific PI3Kalpha mutant H1047R in complex with BYL-719
6VTT	;	3.7	;	Cryo-EM Structure of CAP256-VRC26.25 Fab bound to HIV-1 Env trimer CAP256.wk34.c80 SOSIP.RnS2
7DQ4	;	3.8	;	Cryo-EM structure of CAR triggered Coxsackievirus B1 A-particle
8IQ4	;	2.7	;	Cryo-EM structure of Carboprost-bound prostaglandin-F2-alpha receptor-miniGq-Nb35 complex
8B11	;	2.52	;	cryo-EM structure of carboxysomal mini-shell: icosahedral assembly from CsoS4A/1A and CsoS2 co-expression (T = 4)
8B12	;	1.86	;	cryo-EM structure of carboxysomal mini-shell: icosahedral assembly from CsoS4A/1A and CsoS2 co-expression (T = 9)
8B0Y	;	2.79	;	cryo-EM structure of carboxysomal mini-shell: icosahedral assembly from CsoS4A/1A co-expression (T = 3)
6XKJ	;	3.54	;	Cryo-EM structure of CARD8-CARD filament
8E7E	;	3.61	;	Cryo-EM structure of cardiac amyloid fibril from a variant ATTR I84S amyloidosis patient
8E7J	;	3.1	;	Cryo-EM structure of cardiac amyloid fibril from a variant ATTR I84S amyloidosis patient
8TDO	;	3.1	;	Cryo-EM structure of cardiac amyloid fibril from a variant ATTR I84S amyloidosis patient-3, variant-type morphology
8TDN	;	3.1	;	Cryo-EM structure of cardiac amyloid fibril from a variant ATTR I84S amyloidosis patient-3, wild-type morphology
8E7I	;	3.65	;	Cryo-EM structure of cardiac amyloid fibril from a variant ATTR P24S amyloidosis patient
8E7H	;	3.7	;	Cryo-EM structure of cardiac amyloid fibril from a wild-type amyloidosis patient
6HUD	;	4.0	;	Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain (AL) amyloidosis patient.
8DMY	;	3.07	;	Cryo-EM structure of cardiac muscle alpha-actin
8HJV	;	3.1	;	Cryo-EM structure of carotenoid-depleted RC-LH complex from Roseiflexus castenholzii at 10,000 lux
6XMF	;	3.1	;	Cryo-EM structure of Cas12g binary complex
6XMG	;	4.8	;	Cryo-EM structure of Cas12g ternary complex
8I3Q	;	3.1	;	Cryo-EM structure of Cas12g-sgRNA binary complex
6W5C	;	2.9	;	Cryo-EM structure of Cas12i(E894A)-crRNA-dsDNA complex
6W62	;	3.9	;	Cryo-EM structure of Cas12i-crRNA complex
6W64	;	3.9	;	Cryo-EM structure of Cas12i-crRNA-dsDNA complex in I1 state
8INB	;	3.1	;	Cryo-EM structure of Cas12j-SF05-crRNA-dsDNA complex
8AXB	;	2.87	;	Cryo-EM structure of Cas12k-sgRNA binary complex (type V-K CRISPR-associated transposon)
6VRC	;	3.2	;	Cryo-EM structure of Cas13(crRNA)
8FYB	;	3.1	;	Cryo-EM structure of Cas1:Cas2-DEDDh:half-site integration complex
8FYD	;	3.9	;	Cryo-EM structure of Cas1:Cas2-DEDDh:half-site integration complex bent CRISPR repeat conformation
8FYC	;	4.1	;	Cryo-EM structure of Cas1:Cas2-DEDDh:half-site integration complex linear CRISPR repeat conformation
8FYA	;	2.91	;	Cryo-EM structure of Cas1:Cas2-DEDDh:PAM-containing prespacer complex
8FY9	;	3.1	;	Cryo-EM structure of Cas1:Cas2-DEDDh:PAM-deficient prespacer complex
7YN9	;	3.53	;	Cryo-EM structure of Cas7-11-crRNA binary complex
7YNA	;	3.64	;	Cryo-EM structure of Cas7-11-crRNA bound to target RNA-1
7YNB	;	3.46	;	Cryo-EM structure of Cas7-11-crRNA bound to target RNA-2
7YNC	;	3.14	;	Cryo-EM structure of Cas7-11-crRNA bound to target RNA-3
7YND	;	3.29	;	Cryo-EM structure of Cas7-11-crRNA-Csx29 ternary complex
7S4U	;	3.56	;	Cryo-EM structure of Cas9 in complex with 12-14MM DNA substrate, 5 minute time-point
8FD2	;	3.65	;	Cryo-EM structure of Cascade complex in type I-B CAST system
8FCJ	;	2.83	;	Cryo-EM structure of Cascade-DNA (P23) complex in type I-B CAST system
8FF5	;	3.13	;	Cryo-EM structure of Cascade-DNA-fullRloop in type I-B CAST system
8FF4	;	3.6	;	Cryo-EM structure of Cascade-DNA-TniQ-TnsC complex (composite) in type I-B CAST system
8FCU	;	3.19	;	Cryo-EM structure of Cascade-DNA-TniQ-TnsC complex in type I-B CAST system
8FD3	;	3.12	;	Cryo-EM structure of Cascade-PAM complex in type I-B CAST system
6V9Q	;	2.9	;	Cryo-EM structure of Cascade-TniQ binary complex
6VBW	;	3.2	;	Cryo-EM structure of Cascade-TniQ-dsDNA ternary complex
8DC2	;	2.99	;	Cryo-EM structure of CasLambda (Cas12l) bound to crRNA and DNA
5L08	;	4.6	;	Cryo-EM structure of Casp-8 tDED filament
7M5O	;	3.54	;	Cryo-EM structure of CasPhi-2 (Cas12j) bound to crRNA
7LYS	;	3.05	;	Cryo-EM structure of CasPhi-2 (Cas12j) bound to crRNA and DNA
7LYT	;	2.9	;	Cryo-EM structure of CasPhi-2 (Cas12j) bound to crRNA and Phosphorothioate-DNA
7C8D	;	3.0	;	Cryo-EM structure of cat ACE2 and SARS-CoV-2 RBD
7ZYV	;	2.13	;	Cryo-EM structure of catalytically active Spinacia oleracea cytochrome b6f in complex with endogenous plastoquinones at 2.13 A resolution
7QRM	;	2.7	;	Cryo-EM structure of catalytically active Spinacia oleracea cytochrome b6f in complex with endogenous plastoquinones at 2.7 A resolution
8WU1	;	3.2	;	Cryo-EM structure of CB1-beta-arrestin1 complex
6KPG	;	3.0	;	Cryo-EM structure of CB1-G protein complex
8GUQ	;	3.08	;	Cryo-EM structure of CB2-G protein complex
8OW0	;	3.4	;	Cryo-EM structure of CBF1-CCAN bound topologically to a centromeric CENP-A nucleosome
8OVW	;	3.4	;	Cryo-EM structure of CBF1-CCAN bound topologically to centromeric DNA
7FGF	;	2.8	;	Cryo-EM structure of CCHFV envelope protein Gc in postfusion conformation
8JKD	;	2.6	;	Cryo-EM structure of CCHFV envelope protein Gc trimer in complex with Gc13 Fab
8IL3	;	3.86	;	Cryo-EM structure of CD38 in complex with FTL004
7TFN	;	4.0	;	Cryo-EM structure of CD4bs antibody Ab1303 in complex with HIV-1 Env trimer BG505 SOSIP.664
7YDM	;	2.89	;	Cryo-EM structure of CD97/Gq complex
7YDP	;	3.1	;	Cryo-EM structure of CD97/miniGs complex
8BZO	;	3.5	;	Cryo-EM structure of CDK2-CyclinA in complex with p27 from the SCFSKP2 E3 ligase Complex
8P7L	;	2.1	;	Cryo-EM structure of CDK7 subunit of CAK in complex with inhibitor LDC4297
8POK	;	3.4	;	Cryo-EM structure of cell-free synthesized human histamine H2 receptor coupled to heterotrimeric Gs protein in lipid environment
8H6H	;	2.3	;	cryo-EM structure of cellodextrin phosphorylase from Clostridium thermocellum
7EVZ	;	3.07	;	Cryo-EM structure of cenerimod -bound Sphingosine-1-phosphate receptor 1 in complex with Gi protein
7U46	;	2.68	;	Cryo-EM structure of CENP-A nucleosome (palindromic alpha satellite DNA) in complex with CENP-N
6BUZ	;	3.92	;	Cryo-EM structure of CENP-A nucleosome in complex with kinetochore protein CENP-N
8ETP	;	3.52	;	Cryo-EM structure of cGMP bound closed state of human CNGA3/CNGB3 channel in GDN
8EU3	;	3.62	;	Cryo-EM structure of cGMP bound human CNGA3/CNGB3 channel in GDN, transition state 1
8EUC	;	3.61	;	Cryo-EM structure of cGMP bound human CNGA3/CNGB3 channel in GDN, transition state 2
8EV8	;	3.11	;	Cryo-EM structure of cGMP bound truncated human CNGA3/CNGB3 channel in lipid nanodisc, closed state
8EVC	;	3.33	;	Cryo-EM structure of cGMP bound truncated human CNGA3/CNGB3 channel in lipid nanodisc, open state
8EVB	;	3.6	;	Cryo-EM structure of cGMP bound truncated human CNGA3/CNGB3 channel in lipid nanodisc, pre-open state
8EV9	;	3.33	;	Cryo-EM structure of cGMP bound truncated human CNGA3/CNGB3 channel in lipid nanodisc, transition state 1
8EVA	;	3.33	;	Cryo-EM structure of cGMP bound truncated human CNGA3/CNGB3 channel in lipid nanodisc, transition state 2
7ZNU	;	4.0	;	cryo-EM structure of CGT ABC transporter in detergent micelle
7ZO8	;	3.6	;	cryo-EM structure of CGT ABC transporter in nanodisc apo state
7ZOA	;	4.0	;	cryo-EM structure of CGT ABC transporter in presence of CBG substrate
7ZO9	;	3.5	;	cryo-EM structure of CGT ABC transporter in vanadate trapped state
7TCO	;	4.19	;	Cryo-EM structure of CH235.12 in complex with HIV-1 Env trimer CH505TF.N279K.G458Y.SOSIP.664 with high-mannose glycans
7T9T	;	3.7	;	Cryo-EM structure of CH235.12 in complex with HIV-1 Env trimer CH505TF.N279K.SOSIP.664 with complex glycans
7TCN	;	4.1	;	Cryo-EM structure of CH235.12 in complex with HIV-1 Env trimer CH505TF.N279K.SOSIP.664 with high-mannose glycans
6UDA	;	4.2	;	Cryo-EM structure of CH235UCA bound to Man5-enriched CH505.N279K.G458Y.SOSIP.664
8EU8	;	3.73	;	Cryo-EM structure of CH848 10.17DT DS-SOSIP-2P Env
8DZZ	;	4.1	;	Cryo-EM structure of chi dynein bound to Lis1
1SJJ	;	20.0	;	Cryo-EM Structure of Chicken Gizzard Smooth Muscle alpha-Actinin
8FCG	;	3.09	;	Cryo-EM structure of Chikungunya virus asymmetric unit
7CVY	;	5.2	;	Cryo-EM structure of Chikungunya virus in complex with Fab fragments of mAb CHK-124
7CVZ	;	4.7	;	Cryo-EM structure of Chikungunya virus in complex with Fab fragments of mAb CHK-263
7CW2	;	4.5	;	Cryo-EM structure of Chikungunya virus in complex with Fab fragments of mAb CHK-263 (subregion around icosahedral 5-fold vertex)
7CW0	;	5.9	;	Cryo-EM structure of Chikungunya virus in complex with mAb CHK-263 IgG
7CW3	;	9.4	;	Cryo-EM structure of Chikungunya virus in complex with mAb CHK-263 IgG (subregion around icosahedral 2-fold vertex)
7X01	;	2.62	;	Cryo-EM Structure of Chikungunya Virus Nonstructural Protein 1 with inhibitor FHA
7FGH	;	2.18	;	Cryo-EM Structure of Chikungunya Virus Nonstructural Protein 1 with m7GMP
7FGI	;	2.51	;	Cryo-EM Structure of Chikungunya Virus Nonstructural Protein 1 with m7Gppp-AU
8JCE	;	2.41	;	Cryo-EM Structure of Chikungunya Virus Nonstructural Protein 1 with m7GpppAmU
7FGG	;	2.19	;	Cryo-EM Structure of Chikungunya Virus Nonstructural Protein 1 with m7GTP
7VCF	;	2.5	;	Cryo-EM structure of Chlamydomonas TOC-TIC supercomplex
8IGR	;	3.1	;	Cryo-EM structure of CII-dependent transcription activation complex
5UBQ	;	5.7	;	Cryo-EM structure of ciliary microtubule doublet
8SZF	;	2.8	;	Cryo-EM structure of cinacalcet-bound active-state human calcium-sensing receptor CaSR in lipid nanodiscs
8SZH	;	3.1	;	Cryo-EM structure of cinacalcet-bound human calcium-sensing receptor CaSR-Gi complex in lipid nanodiscs
8SZG	;	3.6	;	Cryo-EM structure of cinacalcet-bound human calcium-sensing receptor CaSR-Gq complex in lipid nanodiscs
7Q2X	;	3.0	;	Cryo-EM structure of clamped S.cerevisiae condensin-DNA complex (Form I)
7Q2Y	;	3.0	;	Cryo-EM structure of clamped S.cerevisiae condensin-DNA complex (form II)
8JPJ	;	3.5	;	Cryo-EM structure of ClC-6 apo state
8OSK	;	3.6	;	Cryo-EM structure of CLOCK-BMAL1 bound to a nucleosomal E-box at position SHL+5.8 (composite map)
8OSJ	;	6.2	;	Cryo-EM structure of CLOCK-BMAL1 bound to a nucleosomal E-box at position SHL-6.2 (DNA conformation 1)
8OSL	;	4.9	;	Cryo-EM structure of CLOCK-BMAL1 bound to the native Por enhancer nucleosome (map 2, additional 3D classification and flexible refinement)
6SFX	;	4.0	;	Cryo-EM structure of ClpP1/2 in the LmClpXP1/2 complex
8XOP	;	2.8	;	Cryo-EM structure of ClpP1P2 in complex with ADEP1 from Streptomyces hawaiiensis
8OUW	;	3.75	;	Cryo-EM structure of CMG helicase bound to TIM-1/TIPN-1 and homodimeric DNSN-1 on fork DNA (Caenorhabditis elegans)
8SG1	;	2.94	;	Cryo-EM structure of CMKLR1 signaling complex
8R8D	;	2.6	;	Cryo-EM structure of coagulation factor beta-XIIa in complex with the garadacimab Fab fragment (symmetric dimer)
8FDG	;	3.2	;	Cryo-EM structure of coagulation factor V short
8TY1	;	3.46	;	Cryo-EM structure of coagulation factor VIII bound to NB2E9
8HF7	;	3.8	;	Cryo-EM structure of ComA bound to its mature substrate CSP peptide
5G05	;	3.4	;	Cryo-EM structure of combined apo phosphorylated APC
7YRF	;	2.91	;	Cryo-EM structure of compact CA16 empty particle in complex with a neutralizing antibody 8C4
7YRH	;	3.35	;	Cryo-EM structure of compact coxsackievirus A16 empty particle in complex with a neutralizing antibody 9B5
7B2Q	;	3.76	;	Cryo-EM structure of complement C4b in complex with nanobody B12
7B2P	;	3.43	;	Cryo-EM structure of complement C4b in complex with nanobody B5
7B2M	;	3.39	;	Cryo-EM structure of complement C4b in complex with nanobody E3
8CML	;	3.6	;	Cryo-EM structure of complement C5 in complex with nanobodies UNbC5-1 and UNbC5-2
7YL9	;	4.7	;	Cryo-EM structure of complete transmembrane channel E289A mutant Vibrio cholerae Cytolysin
8JII	;	3.17	;	Cryo-EM structure of compound 9n and niacin bound ketone body receptor HCAR2-Gi signaling complex
8JHY	;	2.87	;	Cryo-EM structure of compound 9n bound ketone body receptor HCAR2-Gi signaling complex
8DFU	;	3.44	;	Cryo-EM structure of conjugation pili from Aeropyrum pernix
7JSV	;	3.9	;	Cryo-EM structure of conjugative pili from carbapenem-resistant Klebsiella pneumoniae
8DFT	;	4.1	;	Cryo-EM structure of conjugative pili from Pyrobaculum calidifontis
7LXM	;	3.41	;	Cryo-EM structure of ConM SOSIP.v7 (ConM) in complex with bNAb PGT122
7ZXM	;	2.14	;	cryo-EM structure of Connexin 32 gap junction channel
7ZXN	;	3.06	;	cryo-EM structure of Connexin 32 gap junction channel
7ZXO	;	2.5	;	cryo-EM structure of Connexin 32 gap junction channel
7ZXP	;	2.39	;	cryo-EM structure of Connexin 32 R22G mutation gap junction channel
7ZXQ	;	3.53	;	cryo-EM structure of Connexin 32 R22G mutation hemi channel
7ZXT	;	2.9	;	cryo-EM structure of Connexin 32 W3S mutation hemi channel
8EG8	;	3.3	;	Cryo-EM structure of consensus elemental paused elongation complex with a folded TL
8EGB	;	3.8	;	Cryo-EM structure of consensus elemental paused elongation complex with an unfolded TL
7LX2	;	3.12	;	Cryo-EM structure of ConSOSL.UFO.664 (ConS) in complex with bNAb PGT122
7XN5	;	3.18	;	Cryo-EM structure of CopC-CaM-caspase-3 with ADPR
7XN6	;	3.45	;	Cryo-EM structure of CopC-CaM-caspase-3 with ADPR-deacylization
7XN4	;	3.35	;	Cryo-EM structure of CopC-CaM-caspase-3 with NAD+
8P94	;	3.3	;	Cryo-EM structure of cortactin stabilized Arp2/3-complex nucleated actin branches
8TAH	;	2.89	;	Cryo-EM structure of Cortactin-bound to Arp2/3 complex
7TRY	;	3.7	;	Cryo-EM structure of corticotropin releasing factor receptor 2 bound to Urocortin 1 and coupled with heterotrimeric G11 protein
7TS0	;	2.8	;	Cryo-EM structure of corticotropin releasing factor receptor 2 bound to Urocortin 1 and coupled with heterotrimeric Go protein
7YMS	;	2.9	;	Cryo-EM structure of Coxsackievirus A16 in complex with a neutralizing antibody 9B5
7QVX	;	2.5	;	Cryo-EM structure of coxsackievirus A6 altered particle
7QVY	;	2.82	;	Cryo-EM structure of coxsackievirus A6 empty particle
7QW9	;	2.68	;	Cryo-EM structure of coxsackievirus A6 mature virion
7X37	;	3.31	;	Cryo-EM structure of Coxsackievirus B1 A particle in complex with nAb 2E6 (CVB1-A:2E6)
7X46	;	3.85	;	Cryo-EM structure of Coxsackievirus B1 A-particle in complex with nAb 2E6 (classified from CVB1 mature virion in complex with 8A10 and 2E6)
7X3F	;	3.52	;	Cryo-EM structure of Coxsackievirus B1 A-particle in complex with nAb 9A3 (CVB1-A:9A3)
7DPG	;	3.4	;	Cryo-EM structure of Coxsackievirus B1 empty particle
7X47	;	3.66	;	Cryo-EM structure of Coxsackievirus B1 empty particle in complex with nAb 2E6 (classified from CVB1 mature virion in complex with 8A10 and 2E6)
7X38	;	3.52	;	Cryo-EM structure of Coxsackievirus B1 empty particle in complex with nAb 8A10 (CVB1-E:8A10)
7X4K	;	3.82	;	Cryo-EM structure of Coxsackievirus B1 empty particle in complex with nAb 9A3 (classified from CVB1 mature virion in complex with 8A10 and 9A3)
7X3Y	;	3.32	;	Cryo-EM structure of Coxsackievirus B1 empty particle in complex with nAb 9A3 (CVB1-E:9A3)
7X2G	;	3.58	;	Cryo-EM structure of Coxsackievirus B1 empty particle in complex with nAb nAb 2E6 (CVB1-E:2E6)
7DPF	;	3.2	;	Cryo-EM structure of Coxsackievirus B1 mature virion
7X2O	;	3.15	;	Cryo-EM structure of Coxsackievirus B1 mature virion in complex with nAb 2E6 (CVB1-M:2E6)
7DQ7	;	3.2	;	Cryo-EM structure of Coxsackievirus B1 mature virion in complex with nAb 5F5
7X40	;	3.02	;	Cryo-EM structure of Coxsackievirus B1 mature virion in complex with nAb 8A10 (classified from CVB1 mature virion in complex with 8A10 and 2E6)
7X49	;	3.13	;	Cryo-EM structure of Coxsackievirus B1 mature virion in complex with nAb 8A10 (classified from CVB1 mature virion in complex with 8A10 and 9A3)
7X4M	;	3.34	;	Cryo-EM structure of Coxsackievirus B1 mature virion in complex with nAb 8A10 (classified from CVB1 mature virion in complex with 8A10, 2E6 and 9A3)
7X2T	;	3.69	;	Cryo-EM structure of Coxsackievirus B1 mature virion in complex with nAb 8A10 (CVB1-M:8A10)
7X3D	;	3.48	;	Cryo-EM structure of Coxsackievirus B1 mature virion in complex with nAb 9A3 (CVB1-M:9A3)
7X3C	;	3.03	;	Cryo-EM structure of Coxsackievirus B1 muture virion in complex with nAbs 8A10 and 5F5 (CVB1-M:8A10:5F5)
7X2I	;	3.29	;	Cryo-EM structure of Coxsackievirus B1 pre-A particle in complex with nAb 2E6 (CVB1-pre-A:2E6)
7X2W	;	3.24	;	Cryo-EM structure of Coxsackievirus B1 pre-A particle in complex with nAb 8A10 (CVB1-pre-A:8A10)
7X42	;	3.88	;	Cryo-EM structure of Coxsackievirus B1 pre-A-particle in complex with nAb 8A10 (classified from CVB1 mature virion in complex with 8A10 and 2E6)
7X3E	;	3.44	;	Cryo-EM structure of Coxsackievirus B1 pre-A-particle in complex with nAb 9A3 (CVB1-pre-A:9A3)
7DPZ	;	3.8	;	Cryo-EM structure of Coxsackievirus B1 virion in complex with CAR
7DQ1	;	3.6	;	Cryo-EM structure of Coxsackievirus B1 virion in complex with CAR at physiological temperature
1JEW	;	22.0	;	CRYO-EM STRUCTURE OF COXSACKIEVIRUS B3(M STRAIN) WITH ITS CELLULAR RECEPTOR, COXSACKIEVIRUS AND ADENOVIRUS RECEPTOR (CAR).
8GUR	;	2.84	;	Cryo-EM structure of CP-CB2-G protein complex
8HFQ	;	2.64	;	Cryo-EM structure of CpcL-PBS from cyanobacterium Synechocystis sp. PCC 6803
8TVY	;	3.1	;	Cryo-EM structure of CPD lesion containing RNA Polymerase II elongation complex with Rad26 and Elf1 (closed state)
8TVQ	;	4.6	;	Cryo-EM structure of CPD stalled 10-subunit Pol II in complex with Rad26
8TVW	;	3.6	;	Cryo-EM structure of CPD-stalled Pol II (conformation 1)
8TVX	;	3.7	;	Cryo-EM structure of CPD-stalled Pol II (Conformation 2)
8TUG	;	3.5	;	Cryo-EM structure of CPD-stalled Pol II in complex with Rad26 (engaged state)
8TVP	;	3.7	;	Cryo-EM structure of CPD-stalled Pol II in complex with Rad26 (open state)
8CPD	;	3.46	;	Cryo-EM structure of CRaf dimer with 14:3:3
8CHF	;	4.25	;	cryo-EM Structure of Craf:14-3-3:Mek1
8AHL	;	4.1	;	Cryo-EM structure of crescentin filaments (stutter mutant, C1 symmetry and large box)
8AFE	;	3.3	;	Cryo-EM structure of crescentin filaments (stutter mutant, C1 symmetry and small box)
8AJB	;	4.3	;	Cryo-EM structure of crescentin filaments (stutter mutant, C2 symmetry and large box)
8AFH	;	3.9	;	Cryo-EM structure of crescentin filaments (stutter mutant, C2, symmetry and small box)
8AIA	;	5.1	;	Cryo-EM structure of crescentin filaments (wildtype, C1 symmetry and large box)
8AFL	;	4.4	;	Cryo-EM structure of crescentin filaments (wildtype, C1 symmetry and small box)
8AIX	;	5.8	;	Cryo-EM structure of crescentin filaments (wildtype, C2 symmetry and large box)
8AFM	;	4.8	;	Cryo-EM structure of crescentin filaments (wildtype, C2 symmetry and small box)
7JZZ	;	3.2	;	Cryo-EM structure of CRISPR-Cas surveillance complex with AcrIF14
7JZW	;	3.2	;	Cryo-EM structure of CRISPR-Cas surveillance complex with AcrIF4
7JZX	;	3.4	;	Cryo-EM structure of CRISPR-Cas surveillance complex with AcrIF7
7L49	;	3.1	;	Cryo-EM structure of CRISPR-Cas12f Ternary Complex
8K9G	;	3.49	;	Cryo-EM structure of Crt-SPARTA-gRNA-tDNA dimer (conformation-1)
8IT0	;	3.5	;	Cryo-EM structure of Crt-SPARTA-gRNA-tDNA dimer (conformation-2)
8ISZ	;	3.27	;	Cryo-EM structure of Crt-SPARTA-gRNA-tDNA monomer
8IT1	;	3.41	;	Cryo-EM structure of Crt-SPARTA-gRNA-tDNA tetramer (NADase active form)
8FO1	;	3.3	;	Cryo-EM structure of Cryptococcus neoformans trehalose-6-phosphate synthase homotetramer in apo form
8FHW	;	3.2	;	Cryo-EM structure of Cryptococcus neoformans trehalose-6-phosphate synthase homotetramer in complex with uridine diphosphate and glucose-6-phosphate
7Y7B	;	2.66	;	Cryo-EM structure of cryptophyte photosystem I
7Y8A	;	2.71	;	Cryo-EM structure of cryptophyte photosystem I
6IQW	;	3.35	;	Cryo-EM structure of Csm effector complex
6MUU	;	3.0	;	Cryo-EM structure of Csm-crRNA binary complex in type III-A CRISPR-Cas system
6O7I	;	3.2	;	Cryo-EM structure of Csm-crRNA-target RNA ternary bigger complex in complex with cA4 in type III-A CRISPR-Cas system
6O7E	;	3.2	;	Cryo-EM structure of Csm-crRNA-target RNA ternary complex in complex with AMPPNP in type III-A CRISPR-Cas system
6O7H	;	2.9	;	Cryo-EM structure of Csm-crRNA-target RNA ternary complex in complex with cA4 in type III-A CRISPR-Cas system
6MUR	;	3.1	;	Cryo-EM structure of Csm-crRNA-target RNA ternary complex in type III-A CRISPR-Cas system
6W6W	;	3.0	;	Cryo-EM structure of CST bound to telomeric single-stranded DNA
7T3J	;	3.2	;	Cryo-EM structure of Csy-AcrIF24
7T3K	;	3.5	;	Cryo-EM structure of Csy-AcrIF24 dimer
7T3L	;	3.6	;	Cryo-EM structure of Csy-AcrIF24-DNA dimer
6S2E	;	4.2	;	Cryo-EM structure of Ctf18-1-8 in complex with the catalytic domain of DNA polymerase epsilon
6S2F	;	5.8	;	Cryo-EM structure of Ctf18-1-8 in complex with the catalytic domain of DNA polymerase epsilon (Class 2)
8WQA	;	3.39	;	Cryo-EM structure of CUL2-RBX1-ELOB-ELOC-FEM1B bound with the C-degron of CCDC89 (conformation 1)
8WQB	;	3.37	;	Cryo-EM structure of CUL2-RBX1-ELOB-ELOC-FEM1B bound with the C-degron of CCDC89 (conformation 2)
8WQE	;	3.38	;	Cryo-EM structure of CUL2-RBX1-ELOB-ELOC-FEM1B bound with the C-degron of CUX1 (conformation 1)
8WQF	;	3.27	;	cryo-EM structure of CUL2-RBX1-ELOB-ELOC-FEM1B bound with the C-degron of CUX1 (conformation 2)
6V9I	;	5.2	;	cryo-EM structure of Cullin5 bound to RING-box protein 2 (Cul5-Rbx2)
6IIJ	;	2.84	;	Cryo-EM structure of CV-A10 mature virion
6IIO	;	3.12	;	Cryo-EM structure of CV-A10 native empty particle
6AKT	;	2.8	;	Cryo-EM structure of CVA10 A-particle
6AKU	;	2.7	;	Cryo-EM structure of CVA10 empty particle
6AKS	;	3.0	;	Cryo-EM structure of CVA10 mature virus
5YHQ	;	3.0	;	Cryo-EM Structure of CVA6 VLP
8IC0	;	3.41	;	Cryo-EM structure of CXCL8 bound C-X-C chemokine receptor 1 in complex with Gi heterotrimer
6L7O	;	3.2	;	cryo-EM structure of cyanobacteria Fd-NDH-1L complex
6L7P	;	3.6	;	cryo-EM structure of cyanobacteria NDH-1LdelV complex
8IOA	;	2.63	;	Cryo-EM structure of cyanobacteria phosphoketolase
8IO9	;	2.36	;	Cryo-EM structure of cyanobacteria phosphoketolase complexed with AMPPNP in dodecameric assembly
8IO8	;	2.17	;	Cryo-EM structure of cyanobacteria phosphoketolase complexed with AMPPNPin dimeric assembly
8IOE	;	2.86	;	Cryo-EM structure of cyanobacteria phosphoketolase in dodecameric assembly
8WM8	;	3.54	;	Cryo-EM structure of cyanobacterial nitrate/nitrite transporter NrtBCD in complex with nitrate
8WM7	;	3.53	;	Cryo-EM structure of cyanobacterial nitrate/nitrite transporter NrtBCD in complex with signalling protein PII
7FIX	;	1.97	;	Cryo-EM structure of cyanobacterial photosystem I in the presence of ferredoxin and cytochrome c6
7EYD	;	3.9	;	Cryo-EM structure of cyanobacterial phycobilisome from Anabaena sp. PCC 7120
7EXT	;	3.5	;	Cryo-EM structure of cyanobacterial phycobilisome from Synechococcus sp. PCC 7002
8DCS	;	2.5	;	Cryo-EM structure of cyanopindolol-bound beta1-adrenergic receptor in complex with heterotrimeric Gs-protein
7EW4	;	3.2	;	Cryo-EM structure of CYM-5541-bound Sphingosine 1-phosphate receptor 3 in complex with Gi protein
8DKM	;	3.39	;	Cryo-EM structure of cystine-bound cystinosin in a lumen-open state
8DKE	;	3.18	;	Cryo-EM structure of cystinosin in a cytosol-open state
8DKI	;	3.32	;	Cryo-EM structure of cystinosin in a lumen-open state
8DKW	;	3.09	;	Cryo-EM structure of cystinosin N288K mutant in a cytosol-open state at pH5.0
8DKX	;	3.0	;	Cryo-EM structure of cystinosin N288K mutant in a cytosol-open state at pH7.5
8B6J	;	2.8	;	Cryo-EM structure of cytochrome bc1 complex (complex-III) from respiratory supercomplex of Tetrahymena thermophila
8B4O	;	2.0	;	Cryo-EM structure of cytochrome bd oxidase from C. glutamicum
7XMC	;	3.09	;	Cryo-EM structure of Cytochrome bo3 from Escherichia coli, apo structure with DMSO
7XMD	;	2.99	;	Cryo-EM structure of Cytochrome bo3 from Escherichia coli, the structure complexed with an allosteric inhibitor N4
8B6H	;	2.6	;	Cryo-EM structure of cytochrome c oxidase dimer (complex IV) from respiratory supercomplex of Tetrahymena thermophila
7USD	;	3.0	;	Cryo-EM structure of D-site Rac1-bound WAVE Regulatory Complex
8HWD	;	3.3	;	Cryo-EM Structure of D5 ADP form
8HWF	;	3.3	;	Cryo-EM Structure of D5 ADP-ssDNA form
8HWC	;	3.3	;	Cryo-EM Structure of D5 Apo
8HWH	;	3.6	;	Cryo-EM Structure of D5 Apo-ssDNA form
8HWE	;	3.3	;	Cryo-EM Structure of D5 ATP-ADP form
7ZSS	;	2.63	;	cryo-EM structure of D614 spike in complex with de novo designed binder
8ADG	;	3.0	;	Cryo-EM structure of Darobactin 22 bound BAM complex
8ADI	;	3.4	;	Cryo-EM structure of Darobactin 9 bound BAM complex
8TNP	;	3.3	;	Cryo-EM structure of DDB1dB:CRBN:Pomalidomide:SD40
8TNQ	;	2.41	;	Cryo-EM structure of DDB1dB:CRBN:PT-179:SD40, conformation 1
8TNR	;	2.5	;	Cryo-EM structure of DDB1dB:CRBN:PT-179:SD40, conformation 2
8G46	;	2.2	;	Cryo-EM structure of DDB1deltaB-DDA1-DCAF16-BRD4(BD2)-MMH2
8TL6	;	2.63	;	Cryo-EM structure of DDB1deltaB-DDA1-DCAF5
6YTV	;	4.39	;	Cryo-EM structure of decameric human CALHM6 in the presence of Ca2+
2ZLE	;	28.0	;	Cryo-EM structure of DegP12/OMP
8HW4	;	3.52	;	Cryo-EM structure of dehydroepiandrosterone sulfate-bound human ABC transporter ABCC3 in nanodiscs
4C2I	;	6.0	;	Cryo-EM structure of Dengue virus serotype 1 complexed with Fab fragments of human antibody 1F4
7DWT	;	19.0	;	Cryo-EM structure of Dengue virus serotype 1 strain WestPac 74 in complex with human antibody 1C19 Fab at 37 deg C (Class 1 particle)
7DWU	;	19.0	;	Cryo-EM structure of Dengue virus serotype 1 strain WestPac 74 in complex with human antibody 1C19 Fab at 37 deg C (Class 2 particle)
7BUE	;	7.8	;	Cryo-EM structure of Dengue virus serotype 2 complexed with Fab SIgN-3C at pH 5.0
7BUB	;	4.2	;	Cryo-EM structure of Dengue virus serotype 2 complexed with Fab SIgN-3C at pH 6.5
7BUD	;	4.5	;	Cryo-EM structure of Dengue virus serotype 2 complexed with Fab SIgN-3C at pH 8.0
7BUF	;	6.1	;	Cryo-EM structure of Dengue virus serotype 2 complexed with SIgN-3C IgG
4UIF	;	6.5	;	Cryo-EM structure of Dengue virus serotype 2 in complex with antigen-binding fragments of human antibody 2D22
7CTH	;	3.5	;	Cryo-EM structure of dengue virus serotype 2 in complex with the scFv fragment of the broadly neutralizing antibody EDE1 C10
4UIH	;	20.0	;	Cryo-EM structure of Dengue virus serotype 2 strain New Guinea-C complexed with human antibody 2D22 Fab at 37 degree C. The Fab molecules were added to the virus before 37 degree C incubation.
5A1Z	;	6.9	;	Cryo-EM structure of Dengue virus serotype 2 strain PVP94-07 complexed with human antibody 2D22 Fab at 37 degrees C
3J6S	;	6.0	;	Cryo-EM structure of Dengue virus serotype 3 at 28 degrees C
3J6T	;	7.0	;	Cryo-EM structure of Dengue virus serotype 3 at 37 degrees C
3J6U	;	9.0	;	Cryo-EM structure of Dengue virus serotype 3 in complex with human antibody 5J7 Fab
8T13	;	3.45	;	Cryo-EM structure of DENV2 NS5 in complex with human STAT2 with the N-terminal domain of STAT2 disordered
8T12	;	3.34	;	Cryo-EM structure of DENV2 NS5 in complex with human STAT2 with the N-terminal domain of STAT2 ordered.
7VYV	;	2.32	;	Cryo-EM structure of Depo32, a Klebsiella phage depolymerase targets the K2 serotype K. pneumoniae
7VZ3	;	2.46	;	Cryo-EM structure of Depo32, a Klebsiella phage depolymerase targets the K2 serotype K. pneumoniae
7PEC	;	4.24	;	cryo-EM structure of DEPTOR bound to human mTOR complex 1, DEPt-bound subset local refinement
7PEB	;	3.67	;	cryo-EM structure of DEPTOR bound to human mTOR complex 1, focussed on one protomer
7PEA	;	4.07	;	cryo-EM structure of DEPTOR bound to human mTOR complex 1, overall refinement
7PE9	;	3.7	;	cryo-EM structure of DEPTOR bound to human mTOR complex 2, DEPt-bound subset local refinement
7PE8	;	3.2	;	cryo-EM structure of DEPTOR bound to human mTOR complex 2, focussed on one protomer
7PE7	;	3.41	;	cryo-EM structure of DEPTOR bound to human mTOR complex 2, overall refinement
8SK7	;	2.93	;	Cryo-EM structure of designed Influenza HA binder, HA_20, bound to Influenza HA (Strain: Iowa43)
7EQ9	;	3.3	;	Cryo-EM structure of designed protein nanoparticle TIP60 (Truncated Icosahedral Protein composed of 60-mer fusion proteins)
7DRE	;	2.54	;	Cryo-EM structure of DfgA-B at 2.54 angstrom resolution
7DRD	;	2.85	;	Cryo-EM structure of DgpB-C at 2.85 angstrom resolution
7LU9	;	5.6	;	Cryo-EM structure of DH851.3 bound to HIV-1 CH505 Env
7LUA	;	4.7	;	Cryo-EM structure of DH898.1 Fab-dimer bound near the CD4 binding site of HIV-1 Env CH848 SOSIP trimer
7L6M	;	4.7	;	Cryo-EM structure of DH898.1 Fab-dimer from local refinement of the Fab-dimer bound near the CD4 binding site of HIV-1 Env CH848 SOSIP trimer
7XKD	;	2.4	;	Cryo-EM structure of DHEA-ADGRG2-BT-Gs complex
7XKF	;	2.4	;	Cryo-EM structure of DHEA-ADGRG2-BT-Gs complex at lower state
7XKE	;	2.9	;	Cryo-EM structure of DHEA-ADGRG2-FL-Gs complex
8POC	;	4.0	;	Cryo-EM structure of Dickeya dadantii BcsD
6QQ5	;	3.9	;	Cryo-EM structure of dimeric quinol dependent nitric oxide reductase (qNOR) from Alcaligenes xylosoxidans
6L3H	;	3.06	;	Cryo-EM structure of dimeric quinol dependent Nitric Oxide Reductase (qNOR) from the pathogen Neisseria meninigitidis
6QQ6	;	3.3	;	Cryo-EM structure of dimeric quinol dependent nitric oxide reductase (qNOR) Val495Ala mutant from Alcaligenes xylosoxidans
8P82	;	3.36	;	Cryo-EM structure of dimeric UBR5
8IY7	;	3.71	;	Cryo-EM structure of DIP-2I8I fibril polymorph1
8IZZ	;	3.75	;	Cryo-EM structure of DIP-2I8I polymorph 2
8I4A	;	3.4	;	Cryo-EM structure of dipyridamole-bound ABCC4
7LZE	;	3.23	;	Cryo-EM Structure of disulfide stabilized HMPV F v4-B
7L2S	;	2.71	;	cryo-EM structure of DkTx-bound minimal TRPV1 at the pre-bound state
7L2R	;	3.3	;	Cryo-EM structure of DkTx-bound minimal TRPV1 at the pre-open state
7L2U	;	3.47	;	cryo-EM structure of DkTx-bound minimal TRPV1 in open state
7L2T	;	3.08	;	cryo-EM structure of DkTx-bound minimal TRPV1 in partial open state
7L2M	;	3.84	;	Cryo-EM structure of DkTx/RTX-bound full-length TRPV1
7YK8	;	2.8	;	Cryo-EM structure of dLAG3-alpha-syn fibril
6P1H	;	3.2	;	Cryo-EM Structure of DNA Polymerase Delta Holoenzyme
6ZHE	;	7.24	;	Cryo-EM structure of DNA-PK dimer
6ZHA	;	3.91	;	Cryo-EM structure of DNA-PK monomer
6ZH2	;	3.92	;	Cryo-EM structure of DNA-PKcs (State 1)
6ZFP	;	3.24	;	Cryo-EM structure of DNA-PKcs (State 2)
6ZH4	;	3.62	;	Cryo-EM structure of DNA-PKcs (State 3)
7OTM	;	3.33	;	Cryo-EM structure of DNA-PKcs in complex with NU7441
6ZH8	;	4.14	;	Cryo-EM structure of DNA-PKcs:DNA
6ZH6	;	3.93	;	Cryo-EM structure of DNA-PKcs:Ku80ct194
5W1R	;	4.4	;	Cryo-EM structure of DNAPKcs
6LCR	;	3.4	;	Cryo-EM structure of Dnf1 from Chaetomium thermophilum in the E1-ATP state
6LCP	;	3.48	;	Cryo-EM structure of Dnf1 from Chaetomium thermophilum in the E2P state
7DSH	;	3.67	;	Cryo-EM structure of Dnf1 from Saccharomyces cerevisiae in 90PS with AMPPCP (E1-ATP state)
7DRX	;	2.9	;	Cryo-EM structure of Dnf1 from Saccharomyces cerevisiae in 90PS with beryllium fluoride (E2P state)
7WHW	;	3.1	;	Cryo-EM structure of Dnf1 from Saccharomyces cerevisiae in detergent with AMPPCP (E1-ATP state)
7WHV	;	2.8	;	Cryo-EM structure of Dnf1 from Saccharomyces cerevisiae in detergent with beryllium fluoride (E2P state)
7DSI	;	3.21	;	Cryo-EM structure of Dnf1 from Saccharomyces cerevisiae in yeast lipids with AMPPCP ( resting state )
7F7F	;	3.81	;	Cryo-EM structure of Dnf1 from Saccharomyces cerevisiae in yeast lipids with beryllium fluoride (resting state)
7EG1	;	3.2	;	Cryo-EM structure of DNMDP-induced PDE3A-SLFN12 complex
7R77	;	3.0	;	Cryo-EM structure of DNMT5 binary complex with hemimethylated DNA
7R76	;	3.2	;	Cryo-EM structure of DNMT5 in apo state
7T02	;	3.8	;	Cryo-EM structure of DNMT5 pseudo-ternary complex solved by incubation with hemimethylated DNA and SAM
7R78	;	3.5	;	cryo-EM structure of DNMT5 quaternary complex with hemimethylated DNA, AMP-PNP and SAH
7U5H	;	3.32	;	Cryo-EM Structure of DNPEP
8PD0	;	3.58	;	cryo-EM structure of Doa10 in MSP1E3D1
8PDA	;	3.58	;	cryo-EM structure of Doa10 with RING domain in MSP1E3D1
8DCR	;	2.6	;	Cryo-EM structure of dobutamine-bound beta1-adrenergic receptor in complex with heterotrimeric Gs-protein
7WUB	;	3.0	;	Cryo-EM structure of dodecamer P97
8UC1	;	3.4	;	Cryo-EM structure of dolphin Prestin in low Cl buffer
7S9A	;	3.8	;	Cryo-EM Structure of dolphin Prestin: Inhibited I (Chloride + Salicylate)
7S9E	;	3.7	;	Cryo-EM Structure of dolphin Prestin: Inhibited II (Sulfate +Salicylate) state
7S9D	;	4.6	;	Cryo-EM Structure of dolphin Prestin: Intermediate state
7S9B	;	4.2	;	Cryo-EM Structure of dolphin Prestin: Sensor Down I (Expanded) state
7S9C	;	6.7	;	Cryo-EM Structure of dolphin Prestin: Sensor Down II (Expanded II) state
7S8X	;	3.3	;	Cryo-EM Structure of dolphin Prestin: Sensor Up (compact) state
7CKZ	;	3.1	;	Cryo-EM structure of Dopamine and LY3154207 bound dopamine receptor DRD1-Gs signaling complex
7F0T	;	3.1	;	Cryo-EM structure of dopamine receptor 1 and mini-Gs complex with dopamine bound
7XCR	;	2.57	;	Cryo-EM structure of Dot1L and H2BK34ub-H3K79Nle nucleosome 1:1 complex
7XCT	;	2.72	;	Cryo-EM structure of Dot1L and H2BK34ub-H3K79Nle nucleosome 2:1 complex
6JMA	;	6.8	;	cryo-EM structure of DOT1L bound to H2B ubiquitinated nucleosome
6JM9	;	7.3	;	cryo-EM structure of DOT1L bound to unmodified nucleosome
7KNH	;	3.74	;	Cryo-EM Structure of Double ACE2-Bound SARS-CoV-2 Trimer Spike at pH 5.5
7KMZ	;	3.62	;	Cryo-EM structure of double ACE2-bound SARS-CoV-2 trimer Spike at pH 7.4
7XOK	;	2.7	;	Cryo-EM structure of double occupied ring (DOR) of GroEL-UGT1A complex at 2.7 Ang. resolution
8V6V	;	2.8	;	Cryo-EM structure of doubly-bound SNF2h-nucleosome complex
7U5K	;	2.78	;	Cryo-EM Structure of DPYSL2
8AVX	;	3.5	;	Cryo-EM structure of DrBphP in Pfr state
8AVW	;	3.62	;	Cryo-EM structure of DrBphP in Pr state
8AVV	;	3.4	;	Cryo-EM structure of DrBphP photosensory module in Pr state
7YKT	;	5.9	;	Cryo-EM structure of Drg1 hexamer in helical state treated with ADP/AMPPNP/benzo-diazaborine
7YKZ	;	4.3	;	Cryo-EM structure of Drg1 hexamer in the planar state treated with ADP/AMPPNP/Diazaborine
7YKK	;	5.9	;	Cryo-EM structure of Drg1 hexamer treated with ADP
7YKL	;	5.6	;	Cryo-EM structure of Drg1 hexamer treated with AMPPNP
7WD3	;	3.8	;	Cryo-EM structure of Drg1 hexamer treated with ATP and benzo-diazaborine
7SN8	;	2.74	;	Cryo-EM structure of Drosophila Integrator cleavage module (IntS4-IntS9-IntS11) in complex with IP6
7OH4	;	3.0	;	Cryo-EM structure of Drs2p-Cdc50p in the E1 state with PI4P and Mg2+ bound
7OH5	;	2.9	;	Cryo-EM structure of Drs2p-Cdc50p in the E1-AlFx-ADP state
7OH7	;	3.8	;	Cryo-EM structure of Drs2p-Cdc50p in the E1-AMPPCP state with PI4P bound
7OH6	;	3.0	;	Cryo-EM structure of Drs2p-Cdc50p in the [PS]E2-AlFx state
8WYC	;	3.0	;	Cryo-EM structure of DSR2 (H171A)-tube-NAD+ (partial) complex
8WYB	;	3.37	;	Cryo-EM structure of DSR2 (H171A)-tube-NAD+ complex
8WY9	;	2.57	;	Cryo-EM structure of DSR2 apo (partial) complex
8WY8	;	3.1	;	Cryo-EM structure of DSR2 apo complex
8WYE	;	2.49	;	Cryo-EM structure of DSR2-DSAD1 (partial) complex
8WYD	;	2.56	;	Cryo-EM structure of DSR2-DSAD1 complex
8WYF	;	2.85	;	Cryo-EM structure of DSR2-DSAD1-NAD+ (partial) complex
8WYA	;	3.62	;	Cryo-EM structure of DSR2-tube complex
3JAS	;	3.5	;	Cryo-EM structure of dynamic GDP-microtubule (14 protofilaments) decorated with kinesin
5AFU	;	8.2	;	Cryo-EM structure of dynein tail-dynactin-BICD2N complex
8FIZ	;	3.8	;	Cryo-EM structure of E. coli 70S Ribosome containing mRNA and tRNA (in the transcription-translation complex)
8ENR	;	3.8	;	Cryo-EM structure of E. coli CsgA fibril (260 pixel box size)
6U5Z	;	3.5	;	Cryo-EM structure of E. coli LonA S679A
8U3B	;	3.23	;	Cryo-EM structure of E. coli NarL-transcription activation complex at 3.2A
6WTZ	;	3.15	;	Cryo-EM structure of E. Coli OmpF
7LHI	;	7.6	;	Cryo-EM structure of E. coli P pilus tip assembly intermediate PapC-PapD-PapK-PapF-PapG
7LHG	;	3.8	;	Cryo-EM structure of E. coli P pilus tip assembly intermediate PapC-PapD-PapK-PapG in the first conformation
7LHH	;	7.2	;	Cryo-EM structure of E. coli P pilus tip assembly intermediate PapC-PapD-PapK-PapG in the second conformation
6RIN	;	3.7	;	Cryo-EM structure of E. coli RNA polymerase backtracked elongation complex bound to GreB transcription factor
8FIX	;	3.9	;	Cryo-EM structure of E. coli RNA polymerase backtracked elongation complex harboring a terminal mismatch
6RI9	;	3.7	;	Cryo-EM structure of E. coli RNA polymerase backtracked elongation complex in non-swiveled state
6RIP	;	3.4	;	Cryo-EM structure of E. coli RNA polymerase backtracked elongation complex in swiveled state
6RH3	;	3.6	;	Cryo-EM structure of E. coli RNA polymerase elongation complex bound to CTP substrate
6RI7	;	3.9	;	Cryo-EM structure of E. coli RNA polymerase elongation complex bound to GreB transcription factor
8FIY	;	7.3	;	Cryo-EM structure of E. coli RNA polymerase Elongation complex in the Transcription-Translation Complex (RNAP in an anti-swiveled conformation)
8HKC	;	2.49	;	Cryo-EM structure of E. coli RNAP sigma32 complex
6C9Y	;	4.25	;	Cryo-EM structure of E. coli RNAP sigma70 holoenzyme
6CA0	;	5.75	;	Cryo-EM structure of E. coli RNAP sigma70 open complex
6XLN	;	2.8	;	Cryo-EM structure of E. coli RNAP-DNA elongation complex 2 (RDe2) in EcmrR-dependent transcription
6XLL	;	2.7	;	Cryo-EM structure of E. coli RNAP-promoter initial transcribing complex with 5-nt RNA transcript (RPitc-5nt)
7PIK	;	2.68	;	Cryo-EM structure of E. coli TnsB in complex with right end fragment of Tn7 transposon
7WI4	;	3.4	;	Cryo-EM structure of E.Coli FtsH protease cytosolic domains
7WI3	;	4.0	;	Cryo-EM structure of E.Coli FtsH-HflkC AAA protease complex
7CH7	;	3.9	;	Cryo-EM structure of E.coli MlaFEB
7CH6	;	3.4	;	Cryo-EM structure of E.coli MlaFEB with AMPPNP
7V9U	;	3.12	;	Cryo-EM structure of E.coli retron-Ec86 (RT-msDNA-RNA) at 3.2 angstrom
7XJG	;	2.51	;	Cryo-EM structure of E.coli retron-Ec86 in complex with its effector at 2.5 angstrom
7V9X	;	2.82	;	Cryo-EM structure of E.coli retron-Ec86 in complex with its effector at 2.8 angstrom
6XLM	;	3.2	;	Cryo-EM structure of E.coli RNAP-DNA elongation complex 1 (RDe1) in EcmrR-dependent transcription
8TQM	;	3.2	;	Cryo-EM structure of E3 ubiquitin ligase Doa10 from Saccharomyces cerevisiae
7YI1	;	2.8	;	Cryo-EM structure of Eaf3 CHD bound to H3K36me3 nucleosome
8HXZ	;	3.4	;	Cryo-EM structure of Eaf3 CHD in complex with nucleosome
6N8K	;	3.6	;	Cryo-EM structure of early cytoplasmic-immediate (ECI) pre-60S ribosomal subunit
6N8L	;	3.6	;	Cryo-EM structure of early cytoplasmic-late (ECL) pre-60S ribosomal subunit
8DWO	;	3.5	;	Cryo-EM Structure of Eastern Equine Encephalitis Virus in complex with SKE26 Fab
6XFA	;	3.6	;	Cryo-EM structure of EBV BFLF1
7FBI	;	3.9	;	Cryo-EM structure of EBV gB in complex with nAbs 3A3 and 3A5
7YP1	;	3.54	;	Cryo-EM structure of EBV gHgL-gp42 in complex with mAb 10E4 (localized refinement)
7YP2	;	3.52	;	Cryo-EM structure of EBV gHgL-gp42 in complex with mAb 6H2 (localized refinement)
7YOY	;	3.64	;	Cryo-EM structure of EBV gHgL-gp42 in complex with mAbs 3E8 and 5E3 (localized refinement)
6LB1	;	2.58	;	Cryo-EM structure of echovirus 11 A-particle at pH 5.5
6LAP	;	2.49	;	Cryo-EM structure of echovirus 11 A-particle at pH 7.4
6LAO	;	2.64	;	Cryo-EM structure of echovirus 11 complexed with its attaching receptor CD55 at pH 5.5
6LA5	;	2.86	;	Cryo-EM structure of echovirus 11 complexed with its attaching receptor CD55 at pH 7.4
6LA7	;	2.82	;	Cryo-EM structure of echovirus 11 complexed with its uncoating receptor FcRn at pH 5.5
6LA6	;	2.39	;	Cryo-EM structure of echovirus 11 complexed with its uncoating receptor FcRn at pH 7.4
6LBQ	;	2.6	;	Cryo-EM structure of echovirus 11 empty particle at pH 5.5
6LBO	;	3.18	;	Cryo-EM structure of echovirus 11 empty particle at pH 7.4
6ILJ	;	3.6	;	Cryo-EM structure of Echovirus 6 complexed with its attachment receptor CD55 at PH 5.5
6ILK	;	3.0	;	Cryo-EM structure of Echovirus 6 complexed with its attachment receptor CD55 at PH 7.4
6ILL	;	3.8	;	Cryo-EM structure of Echovirus 6 complexed with its uncoating receptor FcRn at PH 5.5
6ILM	;	3.4	;	Cryo-EM structure of Echovirus 6 complexed with its uncoating receptor FcRn at PH 7.4
6XLA	;	3.1	;	Cryo-EM structure of EcmrR-DNA complex in EcmrR-RPitc-3nt
6XLK	;	3.3	;	Cryo-EM structure of EcmrR-DNA complex in EcmrR-RPitc-4nt
6XL6	;	3.0	;	Cryo-EM structure of EcmrR-DNA complex in EcmrR-RPo
6XL9	;	2.5	;	Cryo-EM structure of EcmrR-RNAP-promoter initial transcribing complex with 3-nt RNA transcript (EcmrR-RPitc-3nt)
6XLJ	;	2.7	;	Cryo-EM structure of EcmrR-RNAP-promoter initial transcribing complex with 4-nt RNA transcript (EcmrR-RPitc-4nt)
6XL5	;	2.5	;	Cryo-EM structure of EcmrR-RNAP-promoter open complex (EcmrR-RPo)
7LXN	;	3.85	;	Cryo-EM structure of EDC-crosslinked ConM SOSIP.v7 (ConM-EDC) in complex with bNAb PGT122
7LX3	;	3.45	;	Cryo-EM structure of EDC-crosslinked ConSOSL.UFO.664 (ConS-EDC) in complex with bNAb PGT122
7XDD	;	2.93	;	Cryo-EM structure of EDS1 and PAD4
7XJP	;	2.71	;	Cryo-EM structure of EDS1 and SAG101 with ATP-APDR
8FZ0	;	2.94	;	Cryo-EM Structure of empty AAV2 capsid
7C4Z	;	3.3	;	Cryo-EM structure of empty Coxsackievirus A10 at pH 5.5
7C4Y	;	3.5	;	Cryo-EM structure of empty Coxsackievirus A10 at pH 7.4
6ILO	;	3.2	;	Cryo-EM structure of empty Echovirus 6 particle at PH 7.4
7XON	;	3.1	;	Cryo-EM structure of empty ring subunit 1 (ER1) from single empty ring of GroEL-UGT1A complex
7XOO	;	3.0	;	Cryo-EM structure of empty ring subunit 2 (ER2) from GroEL-UGT1A single empty ring complex
6BQN	;	3.9	;	Cryo-EM structure of ENaC
7P1T	;	2.29	;	Cryo-EM structure of encapsulin from Mycobacterium tuberculosis
8HCQ	;	3.01	;	Cryo-EM structure of endothelin1-bound ETAR-Gq complex
8HCX	;	3.5	;	Cryo-EM structure of Endothelin1-bound ETBR-Gq complex
8FSJ	;	3.65	;	Cryo-EM structure of engineered hepatitis C virus E1E2 ectodomain in complex with antibodies AR4A, HEPC74, and IGH520
6WKV	;	2.99	;	Cryo-EM structure of engineered variant of the Encapsulin from Thermotoga maritima (TmE)
8SOY	;	2.85	;	Cryo-EM structure of Enoyl-CoA hydratase from Mycobacterium smegmatis
8POG	;	4.15	;	Cryo-EM structure of Enterobacter sp. 638 BcsD
7KHW	;	3.4	;	Cryo-EM structure of enteropathogenic Escherichia coli type III secretion system EspA filament
7KX7	;	3.8	;	Cryo-EM structure of Ephydatia fluviatilis PiwiA-piRNA complex
7KX9	;	3.5	;	Cryo-EM structure of Ephydatia fluviatilis PiwiA-piRNA-target complex
8THL	;	3.1	;	Cryo-EM structure of epinephrine-bound alpha-1A-adrenergic receptor in complex with heterotrimeric Gq-protein
5V7V	;	3.9	;	Cryo-EM structure of ERAD-associated E3 ubiquitin-protein ligase component HRD3
6VEF	;	4.08	;	Cryo-EM Structure of Escherichia coli 2-oxoglutarate dehydrogenase E1 component sucA
6SGU	;	3.27	;	Cryo-EM structure of Escherichia coli AcrB and DARPin in Saposin A-nanodisc
6SGT	;	3.46	;	Cryo-EM structure of Escherichia coli AcrB and DARPin in Saposin A-nanodisc with cardiolipin
6SGS	;	3.2	;	Cryo-EM structure of Escherichia coli AcrBZ and DARPin in Saposin A-nanodisc
6SGR	;	3.17	;	Cryo-EM structure of Escherichia coli AcrBZ and DARPin in Saposin A-nanodisc with cardiolipin
6KJ6	;	3.8	;	cryo-EM structure of Escherichia coli Crl transcription activation complex
8GO3	;	3.09	;	Cryo-EM structure of Escherichia coli cytochrome bo3 in DDM detergent
7YPA	;	3.05	;	Cryo-EM structure of Escherichia coli hairpin-nucleation complex of transcription termination (TTC-hairpin)
7YP9	;	3.58	;	Cryo-EM structure of Escherichia coli paused complex of transcription termination (TTC-pause)
7YPB	;	3.48	;	Cryo-EM structure of Escherichia coli release complex of transcription termination (TTC-release)
7MKI	;	3.5	;	Cryo-EM structure of Escherichia coli RNA polymerase bound to lambda PR (-5G to C) promoter DNA
7MKD	;	3.2	;	Cryo-EM structure of Escherichia coli RNA polymerase bound to lambda PR promoter DNA (class 1)
7MKE	;	3.7	;	Cryo-EM structure of Escherichia coli RNA polymerase bound to lambda PR promoter DNA (class 2)
7MKJ	;	2.9	;	Cryo-EM structure of Escherichia coli RNA polymerase bound to T7A1 promoter DNA
6OUL	;	3.4	;	Cryo-EM structure of Escherichia coli RNAP polymerase bound to rpsTP2 promoter DNA
6N57	;	3.7	;	Cryo-EM structure of Escherichia coli RNAP polymerase bound with TraR in conformation I
6N58	;	3.78	;	Cryo-EM structure of Escherichia coli RNAP polymerase bound with TraR in conformation II
6P1K	;	4.05	;	Cryo-EM structure of Escherichia coli sigma70 bound RNAP polymerase holoenzyme
8W6J	;	3.4	;	Cryo-EM structure of Escherichia coli Str K12 FtsE(E163Q)X/EnvC complex with ATP in peptidisc
8W6I	;	3.7	;	Cryo-EM structure of Escherichia coli Str K12 FtsEX complex with ATP-gamma-S in peptidisc
6VU3	;	3.7	;	Cryo-EM structure of Escherichia coli transcription-translation complex A (TTC-A) containing mRNA with a 12 nt long spacer
6ZH3	;	3.2	;	Cryo-EM structure of ESCRT-III helical Vps24 filaments
8J9J	;	3.03	;	Cryo-EM structure of Euglena gracilis complex I, NADH state
8J9I	;	2.87	;	Cryo-EM structure of Euglena gracilis complex I, turnover state
6TDU	;	4.32	;	Cryo-EM structure of Euglena gracilis mitochondrial ATP synthase, full dimer, rotational states 1
6TDV	;	2.8	;	Cryo-EM structure of Euglena gracilis mitochondrial ATP synthase, membrane region
6TDY	;	3.04	;	Cryo-EM structure of Euglena gracilis mitochondrial ATP synthase, OSCP/F1/c-ring in rotational state 1
6TDZ	;	3.14	;	Cryo-EM structure of Euglena gracilis mitochondrial ATP synthase, OSCP/F1/c-ring, rotational state 2
6TE0	;	3.92	;	Cryo-EM structure of Euglena gracilis mitochondrial ATP synthase, OSCP/F1/c-ring, rotational state 3
6TDW	;	3.8	;	Cryo-EM structure of Euglena gracilis mitochondrial ATP synthase, peripheral stalk, rotational state 1
6TDX	;	3.3	;	Cryo-EM structure of Euglena gracilis mitochondrial ATP synthase, rotor, rotational state 1
8J9H	;	3.11	;	Cryo-EM structure of Euglena gracilis respiratory complex I, deactive state
8IUF	;	2.81	;	Cryo-EM structure of Euglena gracilis super-complex I+III2+IV, composite
8IUJ	;	3.06	;	Cryo-EM structure of Euglena gracilis super-complex III2+IV2, composite
3JCT	;	3.08	;	Cryo-em structure of eukaryotic pre-60S ribosomal subunits
6M62	;	3.2	;	Cryo-Em structure of eukaryotic pre-60S ribosome subunit from Saccharomyces cerevisiae rpf2 delta 255-344 strain, C4 state.
7ZH7	;	3.3	;	Cryo-EM structure of ex vivo AA amyloid from renal tissue of a short hair cat deceased in a shelter
7AJQ	;	4.0	;	cryo-EM structure of ExbBD from Serratia Marcescens
7YV2	;	3.36	;	Cryo-EM structure of expanded coxsackievirus A16 empty particle after incubation with 8C4 antibody
7YV7	;	3.8	;	Cryo-EM structure of expanded coxsackievirus A16 empty particle in complex with antibody 9B5
6Q2J	;	4.1	;	Cryo-EM structure of extracellular dimeric complex of RET/GFRAL/GDF15
6ANU	;	7.0	;	Cryo-EM structure of F-actin complexed with the beta-III-spectrin actin-binding domain
5ONV	;	4.1	;	Cryo-EM structure of F-actin in complex with ADP
5OOF	;	3.4	;	Cryo-EM structure of F-actin in complex with ADP-BeFx
6FHL	;	3.3	;	Cryo-EM structure of F-actin in complex with ADP-Pi
5OOE	;	3.6	;	Cryo-EM structure of F-actin in complex with AppNHp (AMPPNP)
8F8P	;	2.26	;	Cryo-EM structure of F-actin in the ADP state
8A2Z	;	2.15	;	Cryo-EM structure of F-actin in the Ca2+-ADP nucleotide state.
8A2U	;	2.21	;	Cryo-EM structure of F-actin in the Ca2+-ADP-BeF3- nucleotide state.
8A2Y	;	2.15	;	Cryo-EM structure of F-actin in the Ca2+-ADP-Pi nucleotide state.
8A2T	;	2.24	;	Cryo-EM structure of F-actin in the Mg2+-ADP nucleotide state.
8A2R	;	2.17	;	Cryo-EM structure of F-actin in the Mg2+-ADP-BeF3- nucleotide state.
8A2S	;	2.22	;	Cryo-EM structure of F-actin in the Mg2+-ADP-Pi nucleotide state.
7AHN	;	2.9	;	Cryo-EM structure of F-actin stabilized by cis-optoJASP-8
7AHQ	;	3.6	;	Cryo-EM structure of F-actin stabilized by trans-optoJASP-8
6VEC	;	3.9	;	Cryo-EM structure of F-actin/Plastin2-ABD2 complex
7Y5B	;	4.4	;	Cryo-EM structure of F-ATP synthase from Mycolicibacterium smegmatis (rotational state 1)
7Y5C	;	4.7	;	Cryo-EM structure of F-ATP synthase from Mycolicibacterium smegmatis (rotational state 2)
7Y5D	;	7.3	;	Cryo-EM structure of F-ATP synthase from Mycolicibacterium smegmatis (rotational state 3) (backbone)
7BC4	;	3.1	;	Cryo-EM structure of fatty acid synthase (FAS) from Pichia pastoris
7CTT	;	3.2	;	Cryo-EM structure of Favipiravir bound to replicating polymerase complex of SARS-CoV-2 in the pre-catalytic state.
7CKW	;	3.22	;	Cryo-EM structure of Fenoldopam bound dopamine receptor DRD1-Gs signaling complex
7U5L	;	2.67	;	Cryo-EM Structure of Ferritin
8CU8	;	1.91	;	Cryo-EM structure of Ferritin 2 from Caenorhabditis elegans, FTN-2
8J24	;	2.6	;	Cryo-EM structure of FFAR2 complex bound with acetic acid
8J22	;	3.2	;	Cryo-EM structure of FFAR2 complex bound with TUG-1375
8J20	;	3.2	;	Cryo-EM structure of FFAR3 bound with valeric acid and AR420626
8J21	;	3.3	;	Cryo-EM structure of FFAR3 complex bound with butyrate acid
7XYF	;	4.3	;	Cryo-EM structure of Fft3-nucleosome complex with Fft3 bound to SHL+2 position of the nucleosome
7XYG	;	5.4	;	Cryo-EM structure of Fft3-nucleosome complex with Fft3 bound to SHL+3 position of the nucleosome
7YSH	;	2.74	;	Cryo-EM Structure of FGF23-FGFR1c-aKlotho-HS Quaternary Complex
7YSU	;	3.2	;	Cryo-EM Structure of FGF23-FGFR3c-aKlotho-HS Quaternary Complex
7YSW	;	3.03	;	Cryo-EM Structure of FGF23-FGFR4-aKlotho-HS Quaternary Complex
6VY1	;	6.0	;	Cryo-EM structure of filamentous PFD from Methanocaldococcus jannaschii
8GHZ	;	2.78	;	Cryo-EM structure of fish immunogloblin M-Fc
6D8C	;	3.54	;	Cryo-EM structure of FLNaABD E254K bound to phalloidin-stabilized F-actin
6M32	;	2.7	;	Cryo-EM structure of FMO-RC complex from green sulfur bacteria
7VW6	;	2.19	;	Cryo-EM Structure of Formate Dehydrogenase 1 from Methylorubrum extorquens AM1
6OMM	;	3.17	;	Cryo-EM structure of formyl peptide receptor 2/lipoxin A4 receptor in complex with Gi
7YTD	;	3.71	;	Cryo-EM structure of four human FcmR bound to IgM-Fc/J
8ISY	;	3.27	;	Cryo-EM structure of free-state Crt-SPARTA
8SBB	;	3.59	;	Cryo-EM structure of FtAlkB
6LA4	;	2.34	;	Cryo-EM structure of full echovirus 11 particle at pH 5.5
6LA3	;	2.32	;	Cryo-EM structure of full echovirus 11 particle at pH 7.4
6ILN	;	3.4	;	Cryo-EM structure of full Echovirus 6 particle at PH 5.5
6ILP	;	2.9	;	Cryo-EM structure of full Echovirus 6 particle at PH 7.4
6LTO	;	3.1	;	cryo-EM structure of full length human Pannexin1
6O1P	;	3.0	;	Cryo-EM structure of full length TRPV5 in nanodisc
6NT6	;	4.0	;	Cryo-EM structure of full-length chicken STING in the apo state
6NT7	;	4.0	;	Cryo-EM structure of full-length chicken STING in the cGAMP-bound dimeric state
6NT8	;	6.5	;	Cryo-EM structure of full-length chicken STING in the cGAMP-bound tetrameric state
7T6X	;	3.83	;	Cryo-EM structure of full-length hepatitis C virus E1E2 glycoprotein in complex with AR4A, AT12009, and IGH505 Fabs
8ADY	;	5.2	;	Cryo-EM structure of full-length human immunoglobulin M - F(ab')2 conformation 1
8ADZ	;	6.7	;	Cryo-EM structure of full-length human immunoglobulin M - F(ab')2 conformation 2
8AE0	;	7.1	;	Cryo-EM structure of full-length human immunoglobulin M - F(ab')2 conformation 3
8AE3	;	6.8	;	Cryo-EM structure of full-length human immunoglobulin M - F(ab')2 conformation 4
8AE2	;	8.5	;	Cryo-EM structure of full-length human immunoglobulin M - F(ab')2 conformation 5
8FW2	;	3.8	;	Cryo-EM structure of full-length human NLRC4 inflammasome with C11 symmetry
8FW9	;	4.46	;	Cryo-EM structure of full-length human NLRC4 inflammasome with C12 symmetry
6NT5	;	4.1	;	Cryo-EM structure of full-length human STING in the apo state
8T1B	;	3.0	;	Cryo-EM structure of full-length human TRPV4 in apo state
8T1F	;	3.49	;	Cryo-EM structure of full-length human TRPV4 in complex with antagonist HC-067047
8P83	;	3.87	;	Cryo-EM structure of full-length human UBR5 (homotetramer)
6PYH	;	4.3	;	Cryo-EM structure of full-length IGF1R-IGF1 complex. Only the extracellular region of the complex is resolved.
6PXV	;	3.2	;	Cryo-EM structure of full-length insulin receptor bound to 4 insulin. 3D refinement was focused on the extracellular region.
6PXW	;	3.1	;	Cryo-EM structure of full-length insulin receptor bound to 4 insulin. 3D refinement was focused on the top part of the receptor complex.
7SGS	;	3.3	;	Cryo-EM structure of full-length MAP7 bound to the microtubule
7YV9	;	4.78	;	Cryo-EM structure of full-length Myosin Va in the autoinhibited state
7WO9	;	2.81	;	Cryo-EM structure of full-length Nup188
7LP9	;	2.63	;	Cryo-EM structure of full-length TRPV1 at 4 degrees Celsius
7LPC	;	3.06	;	Cryo-EM structure of full-length TRPV1 at 48 degrees Celsius
7L2I	;	3.7	;	Cryo-EM structure of full-length TRPV1 at pH6a state
7L2K	;	3.89	;	Cryo-EM structure of full-length TRPV1 at pH6b state
7L2J	;	3.66	;	Cryo-EM structure of full-length TRPV1 at pH6c state
7LPB	;	3.54	;	Cryo-EM structure of full-length TRPV1 with capsaicin at 25 degrees Celsius
7LPA	;	3.37	;	Cryo-EM structure of full-length TRPV1 with capsaicin at 4 degrees Celsius
7LPD	;	3.55	;	Cryo-EM structure of full-length TRPV1 with capsaicin at 48 degrees Celsius, in an intermediate state, class 2
7LPE	;	3.72	;	Cryo-EM structure of full-length TRPV1 with capsaicin at 48 degrees Celsius, in an open state, class 1
8JD2	;	2.8	;	Cryo-EM structure of G protein-free mGlu2-mGlu3 heterodimer in Acc state
8JD4	;	2.9	;	Cryo-EM structure of G protein-free mGlu2-mGlu4 heterodimer in Acc state
8IEQ	;	2.73	;	Cryo-EM structure of G-protein free GPR156
8X51	;	2.92	;	Cryo-EM structure of Gabija GajA in complex with DNA(focused refinement)
5FN3	;	4.1	;	Cryo-EM structure of gamma secretase in class 1 of the apo- state ensemble
5FN4	;	4.0	;	Cryo-EM structure of gamma secretase in class 2 of the apo- state ensemble
5FN5	;	4.3	;	Cryo-EM structure of gamma secretase in class 3 of the apo- state ensemble
5FN2	;	4.2	;	Cryo-EM structure of gamma secretase in complex with a drug DAPT
6IDF	;	2.7	;	Cryo-EM structure of gamma secretase in complex with a Notch fragment
5FLZ	;	6.9	;	Cryo-EM structure of gamma-TuSC oligomers in a closed conformation
7YQK	;	3.38	;	cryo-EM structure of gammaH2AXK15ub-H4K20me2 nucleosome bound to 53BP1
7U5M	;	2.28	;	Cryo-EM Structure of GAPDH
2YN9	;	8.0	;	Cryo-EM structure of gastric H+,K+-ATPase with bound rubidium
6CET	;	4.4	;	Cryo-EM structure of GATOR1
6CES	;	4.0	;	Cryo-EM structure of GATOR1-RAG
6EVZ	;	3.8	;	Cryo-EM structure of GDP-microtubule co-polymerised with doublecortin
6EW0	;	3.8	;	Cryo-EM structure of GDP-microtubule co-polymerised with doublecortin and supplemented with Taxol
3JAR	;	3.4	;	Cryo-EM structure of GDP-microtubule co-polymerized with EB3
6EVX	;	4.2	;	Cryo-EM structure of GDP.Pi-microtubule rapidly co-polymerised with doublecortin
8FYW	;	2.84	;	Cryo-EM Structure of genome containing AAV2
7WLG	;	2.73	;	Cryo-EM structure of GH31 alpha-1,3-glucosidase from Lactococcus lactis subsp. cremoris
7VIF	;	2.83	;	Cryo-EM structure of Gi coupled Sphingosine 1-phosphate receptor bound with (S)-FTY720-P
7VIG	;	2.89	;	Cryo-EM structure of Gi coupled Sphingosine 1-phosphate receptor bound with CBP-307
7VIH	;	2.98	;	Cryo-EM structure of Gi coupled Sphingosine 1-phosphate receptor bound with CBP-307
7VIE	;	2.86	;	Cryo-EM structure of Gi coupled Sphingosine 1-phosphate receptor bound with S1P
7E9G	;	3.5	;	Cryo-EM structure of Gi-bound metabotropic glutamate receptor mGlu2
7E9H	;	4.0	;	Cryo-EM structure of Gi-bound metabotropic glutamate receptor mGlu4
8JD6	;	3.4	;	Cryo-EM structure of Gi1-bound metabotropic glutamate receptor mGlu4
8JD3	;	3.3	;	Cryo-EM structure of Gi1-bound mGlu2-mGlu3 heterodimer
8JD5	;	3.6	;	Cryo-EM structure of Gi1-bound mGlu2-mGlu4 heterodimer
6JJA	;	2.91	;	Cryo-EM structure of giant freshwater prawn Macrobrachium rosenbergii extra small virus (XSV) VLP
6JJD	;	3.21	;	Cryo-EM structure of giant freshwater prawn Macrobrachium rosenbergii nodavirus (MrNV) full VLP
6JJC	;	2.92	;	Cryo-EM structure of giant freshwater prawn Macrobrachium rosenbergii nodavirus (MrNV) semi-empty VLP
7PWO	;	2.75	;	Cryo-EM structure of Giardia lamblia ribosome at 2.75 A resolution
8ITL	;	3.23	;	Cryo-EM structure of GIPR splice variant 1 (SV1) in complex with Gs protein
8ITM	;	3.13	;	Cryo-EM structure of GIPR splice variant 2 (SV2) in complex with Gs protein
6WYL	;	3.9	;	Cryo-EM structure of GltPh L152C-G351C mutant in the intermediate outward-facing state.
5KBV	;	6.8	;	Cryo-EM structure of GluA2 bound to antagonist ZK200775 at 6.8 Angstrom resolution
5KBS	;	8.7	;	Cryo-EM structure of GluA2-0xSTZ at 8.7 Angstrom resolution
5KBT	;	6.4	;	Cryo-EM structure of GluA2-1xSTZ complex at 6.4 Angstrom resolution
5KBU	;	7.8	;	Cryo-EM structure of GluA2-2xSTZ complex at 7.8 Angstrom resolution
5IDE	;	8.25	;	Cryo-EM structure of GluA2/3 AMPA receptor heterotetramer (model I)
5IDF	;	10.31	;	Cryo-EM structure of GluA2/3 AMPA receptor heterotetramer (model II)
5IPV	;	9.25	;	Cryo-EM structure of GluN1/GluN2B NMDA receptor in the DCKA/D-APV-bound conformation, state 1
5IPQ	;	13.5	;	Cryo-EM structure of GluN1/GluN2B NMDA receptor in the DCKA/D-APV-bound conformation, state 2
5IPR	;	14.1	;	Cryo-EM structure of GluN1/GluN2B NMDA receptor in the DCKA/D-APV-bound conformation, state 3
5IPS	;	13.5	;	Cryo-EM structure of GluN1/GluN2B NMDA receptor in the DCKA/D-APV-bound conformation, state 4
5IPT	;	14.1	;	Cryo-EM structure of GluN1/GluN2B NMDA receptor in the DCKA/D-APV-bound conformation, state 5
5IPU	;	15.4	;	Cryo-EM structure of GluN1/GluN2B NMDA receptor in the DCKA/D-APV-bound conformation, state 6
5IOU	;	7.0	;	Cryo-EM structure of GluN1/GluN2B NMDA receptor in the glutamate/glycine-bound conformation
5IOV	;	7.5	;	Cryo-EM structure of GluN1/GluN2B NMDA receptor in the glutamate/glycine/Ro25-6981-bound conformation
7TE9	;	3.92	;	Cryo-EM structure of GluN1b-2B NMDAR complexed to Fab2 class1
7TEB	;	4.23	;	Cryo-EM structure of GluN1b-2B NMDAR complexed to Fab2 non-active1-like
7TEE	;	6.59	;	Cryo-EM structure of GluN1b-2B NMDAR complexed to Fab2 Non-active2-like
7TEQ	;	7.51	;	Cryo-EM structure of GluN1b-2B NMDAR in complex with Fab5 active conformation
7TES	;	4.7	;	Cryo-EM structure of GluN1b-2B NMDAR in complex with Fab5 in Non-active1 conformation
7TET	;	4.45	;	Cryo-EM structure of GluN1b-2B NMDAR in complex with Fab5 in non-active2-like conformation
7TER	;	5.23	;	Cryo-EM structure of GluN1b-2B NMDAR in complex with Fab5 non-active2 conformation
5K12	;	1.8	;	Cryo-EM structure of glutamate dehydrogenase at 1.8 A resolution
6JN9	;	3.8	;	Cryo-EM structure of glutamate dehydrogenase from Thermococcus profundus
6JNA	;	3.8	;	Cryo-EM structure of glutamate dehydrogenase from Thermococcus profundus
6JNC	;	3.7	;	Cryo-EM structure of glutamate dehydrogenase from Thermococcus profundus
6JND	;	3.9	;	Cryo-EM structure of glutamate dehydrogenase from Thermococcus profundus
8XCR	;	2.6	;	Cryo-EM structure of Glutamate dehydrogenase from Thermococcus profundus in complex with NADP and GLU in the initial stage of reaction
8XD5	;	2.75	;	Cryo-EM structure of Glutamate dehydrogenase from Thermococcus profundus in complex with NADP and GLU in the steady stage of reaction
8XCS	;	2.63	;	Cryo-EM structure of Glutamate dehydrogenase from Thermococcus profundus in complex with NADPH, AKG and NH4 in the initial stage of reaction
8XD6	;	2.79	;	Cryo-EM structure of Glutamate dehydrogenase from Thermococcus profundus in complex with NADPH, AKG and NH4 in the steady stage of reaction
8XCP	;	2.64	;	Cryo-EM structure of Glutamate dehydrogenase from Thermococcus profundus incorporating NADP and GLU in the initial stage of reaction
8XCQ	;	2.6	;	Cryo-EM structure of Glutamate dehydrogenase from Thermococcus profundus incorporating NADP and GLU in the initial stage of reaction
8XCX	;	2.83	;	Cryo-EM structure of Glutamate dehydrogenase from Thermococcus profundus incorporating NADP and GLU in the steady stage of reaction
8XCY	;	2.91	;	Cryo-EM structure of Glutamate dehydrogenase from Thermococcus profundus incorporating NADP and GLU in the steady stage of reaction
8XCZ	;	2.83	;	Cryo-EM structure of glutamate dehydrogenase from thermococcus profundus incorporating NADP and GLU in the steady stage of reaction
8XD2	;	2.64	;	Cryo-EM structure of Glutamate dehydrogenase from Thermococcus profundus incorporating NADP and GLU in the steady stage of reaction
8XD3	;	2.87	;	Cryo-EM structure of Glutamate dehydrogenase from Thermococcus profundus incorporating NADP and GLU in the steady stage of reaction
8XD4	;	2.87	;	Cryo-EM structure of Glutamate dehydrogenase from Thermococcus profundus incorporating NADP and GLU in the steady stage of reaction
8XCV	;	2.83	;	Cryo-EM structure of Glutamate dehydrogenase from Thermococcus profundus incorporating NADP in the steady stage of reaction
8XD1	;	2.96	;	Cryo-EM structure of Glutamate dehydrogenase from Thermococcus profundus incorporating NADP in the steady stage of reaction
8XCW	;	2.87	;	Cryo-EM structure of Glutamate dehydrogenase from Thermococcus profundus incorporating NADPH and AKG in the steady stage of reaction
8XD0	;	2.83	;	Cryo-EM structure of Glutamate dehydrogenase from Thermococcus profundus incorporating NADPH and AKG in the steady stage of reaction
8XCO	;	2.64	;	Cryo-EM structure of Glutamate dehydrogenase from Thermococcus profundus incorporating NADPH in the initial stage of reaction
8XCT	;	2.87	;	Cryo-EM structure of Glutamate dehydrogenase from Thermococcus profundus incorporating NADPH in the steady stage of reaction
8XCU	;	2.83	;	Cryo-EM structure of Glutamate dehydrogenase from Thermococcus profundus incorporating NADPH, AKG and GLU in the steady stage of reaction
8EW0	;	2.7	;	Cryo-EM structure of glutamate dehydrogenase frozen at various temperature
7U5N	;	2.58	;	Cryo-EM Structure of Glutamine Synthetase
7V4H	;	2.9	;	Cryo-EM Structure of Glycine max glutamine synthetase GmGS Beta2
7W6K	;	3.5	;	Cryo-EM structure of GmALMT12/QUAC1 anion channel
7W7P	;	3.67	;	Cryo-EM structure of gMCM8/9 helicase
3JAT	;	3.5	;	Cryo-EM structure of GMPCPP-microtubule (14 protofilaments) decorated with kinesin
6EVW	;	4.4	;	Cryo-EM structure of GMPCPP-microtubule co-polymerised with doublecortin
3JAL	;	3.5	;	Cryo-EM structure of GMPCPP-microtubule co-polymerized with EB3
7ZCW	;	3.6	;	Cryo-EM structure of GMPCPP-microtubules in complex with VASH2-SVBP
7D73	;	3.0	;	Cryo-EM structure of GMPPA/GMPPB complex bound to GTP (State I)
7D74	;	3.1	;	Cryo-EM structure of GMPPA/GMPPB complex bound to GTP (state II)
8IMY	;	3.22	;	Cryo-EM structure of GPI-T (inactive mutant) with GPI and proULBP2, a proprotein substrate
8IMX	;	2.85	;	Cryo-EM structure of GPI-T with a chimeric GPI-anchored protein
7WCN	;	2.87	;	Cryo-EM structure of GPR119-Gs Complex with small molecule agonist AR231453
7WCM	;	2.33	;	Cryo-EM structure of GPR119-Gs Complex with small molecule agonist MBX-2982
8IEB	;	3.03	;	Cryo-EM structure of GPR156 of GPR156-miniGo-scFv16 complex (local refine)
8IED	;	3.33	;	Cryo-EM structure of GPR156-miniGo-scFv16 complex
8IEI	;	2.62	;	Cryo-EM structure of GPR156A/B of G-protein free GPR156 (local refine)
8IEP	;	2.61	;	Cryo-EM structure of GPR156C/D of G-protein free GPR156 (local refine)
7SHF	;	3.4	;	Cryo-EM structure of GPR158 coupled to the RGS7-Gbeta5 complex
8HIX	;	3.12	;	Cryo-EM structure of GPR21_m5_Gs
8XOH	;	3.2	;	Cryo-EM structure of GPR30-Gq complex structure in the presence of E2
8XOI	;	3.2	;	Cryo-EM structure of GPR30-Gq complex structure in the presence of fulvestrant
8XOJ	;	3.1	;	Cryo-EM structure of GPR30-Gq complex structure in the presence of G-1
8SAI	;	3.27	;	Cryo-EM structure of GPR34-Gi complex
6LI3	;	3.32	;	cryo-EM structure of GPR52-miniGs-NB35
8TB7	;	2.94	;	Cryo-EM Structure of GPR61-
8TB0	;	3.47	;	Cryo-EM Structure of GPR61-G protein complex stabilized by scFv16
8HJ5	;	3.0	;	Cryo-EM structure of Gq-coupled MRGPRX1 bound with Compound-16
7XOJ	;	2.8	;	Cryo-EM structure of GroEL bound to unfolded substrate (UGT1A) at 2.8 Ang. resolution (Consensus Refinement)
8K5D	;	3.74	;	Cryo-EM structure of GSK256073 bound human hydroxy-carboxylic acid receptor 2 (Local refinement)
8I7W	;	3.39	;	Cryo-EM structure of GSK256073 bound human hydroxy-carboxylic acid receptor 2 in complex with Gi heterotrimer
7TUY	;	2.98	;	Cryo-EM structure of GSK682753A-bound EBI2/GPR183
6EVY	;	4.4	;	Cryo-EM structure of GTPgammaS-microtubule co-polymerised with doublecortin
3JAK	;	3.3	;	Cryo-EM structure of GTPgammaS-microtubule co-polymerized with EB3 (merged dataset with and without kinesin bound)
8D1V	;	2.82	;	Cryo-EM structure of guide RNA and target RNA bound Cas7-11
8WUC	;	2.5	;	Cryo-EM structure of H. thermoluteolus GroEL-GroES2 football complex
8WUX	;	2.6	;	Cryo-EM structure of H. thermophilus GroEL-GroES bullet complex
8WUW	;	2.6	;	Cryo-EM structure of H. thermophilus GroEL-GroES2 asymmetric football complex
7X6O	;	3.5	;	Cryo-EM structure of H1 hemagglutinin from A/Washington/05/2011 in complex with a neutralizing antibody 28-12
7XD0	;	3.48	;	cryo-EM structure of H2BK34ub nucleosome
7X6L	;	3.7	;	Cryo-EM structure of H3 hemagglutinin from A/HongKong/01/1968 in complex with a neutralizing antibody 28-12
8HAE	;	4.55	;	Cryo-EM structure of HACE1 dimer
8H8X	;	3.92	;	Cryo-EM structure of HACE1 monomer
7YA1	;	3.11	;	Cryo-EM structure of hACE2-bound SARS-CoV-2 Omicron spike protein with L371S, P373S and F375S mutations (local refinement)
7YA0	;	3.1	;	Cryo-EM structure of hACE2-bound SARS-CoV-2 Omicron spike protein with L371S, P373S and F375S mutations (S-6P-RRAR)
8GCL	;	2.89	;	Cryo-EM structure of hAQP2 in DDM
8IHI	;	3.11	;	Cryo-EM structure of HCA2-Gi complex with acifran
8IHB	;	2.85	;	Cryo-EM structure of HCA2-Gi complex with GSK256073
8IHH	;	3.06	;	Cryo-EM structure of HCA2-Gi complex with LUF6283
8IHF	;	2.97	;	Cryo-EM structure of HCA2-Gi complex with MK6892
8IHJ	;	3.07	;	Cryo-EM structure of HCA3-Gi complex with acifran
8IHK	;	3.21	;	Cryo-EM structure of HCA3-Gi complex with acifran (local)
7E2G	;	3.61	;	Cryo-EM structure of hDisp1NNN-3C
7E2H	;	3.68	;	Cryo-EM structure of hDisp1NNN-3C-Cleavage
7E2I	;	4.07	;	Cryo-EM structure of hDisp1NNN-ShhN
7KOD	;	1.655	;	Cryo-EM structure of heavy chain mouse apoferritin
5AHV	;	13.6	;	Cryo-EM structure of helical ANTH and ENTH tubules on PI(4,5)P2-containing membranes
8E2E	;	1.98	;	Cryo-EM structure of helical arch of BIRC6 (from local refinement 1)
6U7M	;	3.8	;	Cryo-EM Structure of Helical Lipoprotein Lipase
6ODY	;	3.8	;	Cryo-EM structure of Helicobacter pylori VacA hexamer
8AW5	;	2.8	;	Cryo-EM structure of heme A synthase trimer from Aquifex aeolicus
8IPS	;	3.6	;	Cryo-EM structure of heme transporter CydDC from Escherichia coli in the inward facing heme loading state
8IPT	;	3.5	;	Cryo-EM structure of heme transporter CydDC from Escherichia coli in the occluded ATP bound state
8IPQ	;	3.5	;	Cryo-EM structure of heme transporter CydDC from Mycobacterium smegmatis in the inward facing apo state
8IPR	;	3.0	;	Cryo-EM structure of heme transporter CydDC from Mycobacterium smegmatis in the outward facing ATP bound state
7XGY	;	3.5	;	cryo-EM structure of hemoglobin
6QJQ	;	3.7	;	Cryo-EM structure of heparin-induced 2N3R tau filaments
6QJP	;	3.5	;	Cryo-EM structure of heparin-induced 2N4R tau jagged filaments
6QJH	;	3.3	;	Cryo-EM structure of heparin-induced 2N4R tau snake filaments
6QJM	;	3.3	;	Cryo-EM structure of heparin-induced 2N4R tau twister filaments
6BVN	;	4.0	;	Cryo-EM Structure of Hepatitis B virus T=3 capsid in complex with the fluorescent allosteric modulator HAP-TAMRA
6WFS	;	4.6	;	Cryo-EM Structure of Hepatitis B virus T=4 capsid in complex with the antiviral molecule DBT1
6BVF	;	4.0	;	Cryo-EM Structure of Hepatitis B virus T=4 capsid in complex with the fluorescent allosteric modulator HAP-TAMRA
6OGE	;	4.36	;	Cryo-EM structure of Her2 extracellular domain-Trastuzumab Fab-Pertuzumab Fab complex
7K5W	;	2.87	;	Cryo-EM structure of heterologous protein complex loaded Thermotoga maritima encapsulin capsid
8A57	;	2.3	;	Cryo-EM structure of HflXr bound to the Listeria monocytogenes 50S ribosomal subunit.
8BVM	;	3.8	;	Cryo-EM structure of Hfq-Crc-rbsB translation repression complex
8TU9	;	3.26	;	Cryo-EM structure of HGSNAT-acetyl-CoA complex at pH 7.5
7YFX	;	3.4	;	Cryo-EM structure of Hili in complex with piRNA
8EH8	;	3.4	;	Cryo-EM structure of his-elemental paused elongation complex with a folded TL and a rotated RH-FL (1)
8EH9	;	3.9	;	Cryo-EM structure of his-elemental paused elongation complex with a folded TL and a rotated RH-FL (2)
8EHA	;	3.7	;	Cryo-EM structure of his-elemental paused elongation complex with a folded TL and a rotated RH-FL (out)
8EHF	;	3.3	;	Cryo-EM structure of his-elemental paused elongation complex with an unfolded TL (1)
8EHI	;	5.5	;	Cryo-EM structure of his-elemental paused elongation complex with an unfolded TL (2)
7DFL	;	3.3	;	Cryo-EM structure of histamine H1 receptor Gq complex
8EUU	;	2.7	;	Cryo-EM structure of HIV-1 BG505 DS-SOSIP ENV trimer bound to VRC34.01 FAB
8EUV	;	2.6	;	Cryo-EM structure of HIV-1 BG505 DS-SOSIP ENV trimer bound to VRC34.01-COMBO1 FAB
8EUW	;	2.7	;	Cryo-EM structure of HIV-1 BG505 DS-SOSIP ENV trimer bound to VRC34.01-MM28 FAB
7L6O	;	3.9	;	Cryo-EM structure of HIV-1 Env CH848.3.D0949.10.17chim.6R.DS.SOSIP.664
7TFO	;	4.1	;	Cryo-EM structure of HIV-1 Env trimer BG505 SOSIP.664 in complex with CD4bs antibody Ab1573
8DP1	;	3.46	;	Cryo-EM structure of HIV-1 Env(BG505.T332N SOSIP) in complex with DH1030.1 Fab
8DOW	;	3.69	;	Cryo-EM structure of HIV-1 Env(CH848 10.17 DS.SOSIP_DT) in complex with DH1030.1 Fab
6UM5	;	4.2	;	Cryo-EM structure of HIV-1 neutralizing antibody DH270 UCA3 in complex with CH848 10.17DT Env
6UM6	;	4.3	;	Cryo-EM structure of HIV-1 neutralizing antibody DH270.6 in complex with CH848 10.17DT Env
7Z2G	;	3.65	;	Cryo-EM structure of HIV-1 reverse transcriptase with a DNA aptamer in complex with doravirine
7OZW	;	3.38	;	Cryo-EM structure of HIV-1 reverse transcriptase with a DNA aptamer in complex with fragment 166 at the transient P-pocket
7P15	;	3.58	;	Cryo-EM structure of HIV-1 reverse transcriptase with a DNA aptamer in complex with fragment F04 at the transient P-pocket
7Z24	;	3.32	;	Cryo-EM structure of HIV-1 reverse transcriptase with a DNA aptamer in complex with nevirapine
7Z2D	;	3.38	;	Cryo-EM structure of HIV-1 reverse transcriptase with a DNA aptamer in complex with rilpivirine
7XUE	;	3.17	;	Cryo-EM structure of HK022 putRNA-associated E.coli RNA polymerase elongation complex
7XUG	;	3.57	;	cryo-EM structure of HK022 putRNA-less E.coli RNA polymerase elongation complex
7TL0	;	3.06	;	Cryo-EM structure of hMPV preF bound by Fabs MPE8 and SAN32-2
8IP4	;	2.7	;	Cryo-EM structure of hMRS-highEDTA
8IP5	;	2.5	;	Cryo-EM structure of hMRS2-lowEDTA
8IP3	;	2.6	;	Cryo-EM structure of hMRS2-Mg
8IP6	;	2.9	;	Cryo-EM structure of hMRS2-rest
8IK7	;	3.69	;	Cryo-EM structure of hnRAC1 fibril.
8IKB	;	3.71	;	Cryo-EM structure of hnRAC1-2I fibril.
8IKS	;	3.75	;	Cryo-EM structure of hnRAC1-2I8I fibril.
8IKP	;	2.98	;	Cryo-EM structure of hnRAC1-8I fibril
7ZIR	;	2.5	;	Cryo-EM structure of hnRNPDL amyloid fibrils
8JB0	;	4.2	;	Cryo-EM structure of Holo form of ScBfr in C1 symmetry
8JAX	;	3.27	;	Cryo-EM structure of Holo form of ScBfr with O symmetry
6K4M	;	4.5	;	Cryo-EM structure of Holo-bacterioferritin form-II from Streptomyces coelicolor
6K43	;	3.7	;	Cryo-EM structure of Holo-bacterioferritin-form-I from Streptomyces coelicolor
7ZPA	;	3.9	;	Cryo-EM structure of holo-PdxR from Bacillus clausii bound to its target DNA in the closed conformation, C1 symmetry
7ZN5	;	3.7	;	Cryo-EM structure of holo-PdxR from Bacillus clausii bound to its target DNA in the closed conformation, C2 symmetry.
7ZLA	;	3.99	;	Cryo-EM structure of holo-PdxR from Bacillus clausii bound to its target DNA in the half-closed conformation
7ZTH	;	4.0	;	Cryo-EM structure of holo-PdxR from Bacillus clausii bound to its target DNA in the open conformation
8F0O	;	2.99	;	cryo-EM structure of homomeric kainate receptor GluK2 in resting (apo) state
8DG8	;	3.62	;	Cryo-EM Structure of HPIV3 prefusion F trimer in complex with 3x1 Fab
6VJY	;	4.3	;	Cryo-EM structure of Hrd1/Hrd3 monomer
8GHG	;	3.3	;	Cryo-EM structure of hSlo1 in digitonin, Ca2+-free and EDTA-free
8GHF	;	2.7	;	cryo-EM structure of hSlo1 in plasma membrane vesicles
8GH9	;	3.8	;	Cryo-EM structure of hSlo1 in total membrane vesicles
7L7I	;	3.3	;	Cryo-EM structure of Hsp90:FKBP51:p23 closed-state complex
7L7J	;	3.1	;	Cryo-EM structure of Hsp90:p23 closed-state complex
8KFA	;	3.04	;	Cryo-EM structure of HSV-1 gB with D48 Fab complex
6VOY	;	3.7	;	Cryo-EM structure of HTLV-1 instasome
8GUS	;	2.97	;	Cryo-EM structure of HU-CB2-G protein complex
8CVN	;	2.4	;	Cryo-EM Structure of Human 15-PGDH in Complex with Small Molecule SW209415
8CWL	;	2.9	;	Cryo-EM structure of Human 15-PGDH in complex with small molecule SW222746
6Z6M	;	3.1	;	Cryo-EM structure of human 80S ribosomes bound to EBP1, eEF2 and SERBP1
6MST	;	2.7	;	Cryo-EM structure of human AA amyloid fibril
8JX7	;	3.6	;	Cryo-EM structure of human ABC transporter ABCC2
8JY5	;	4.17	;	Cryo-EM structure of human ABC transporter ABCC2 in apo"" state
8JY4	;	3.58	;	Cryo-EM structure of human ABC transporter ABCC2 in apo' state
8JXU	;	3.55	;	Cryo-EM structure of human ABC transporter ABCC2 under active turnover condition
5XJY	;	4.1	;	Cryo-EM structure of human ABCA1
7E7Q	;	3.3	;	Cryo-EM structure of human ABCA4 in ATP-bound state
7E7O	;	3.4	;	Cryo-EM structure of human ABCA4 in NRPE-bound state
7E7I	;	3.3	;	Cryo-EM structure of human ABCA4 in the apo state
8EDW	;	3.6	;	Cryo-EM Structure of human ABCA7 in BPL/Ch Nanodiscs
8EEB	;	3.9	;	Cryo-EM structure of human ABCA7 in Digitonin
8EE6	;	4.0	;	Cryo-EM Structure of human ABCA7 in PE/Ch nanodiscs
7D7N	;	5.2	;	Cryo-EM structure of human ABCB6 transporter
7EHL	;		;	Cryo-EM structure of human ABCB8 transporter in nucleotide binding state
7X0Z	;	2.96	;	Cryo-EM structure of human ABCD1 E630Q in the presence of ATP and Magnesium in outward-facing state
7X1W	;	3.3	;	Cryo-EM structure of human ABCD1 E630Q in the presence of ATP in inward-facing state
7XEC	;	3.34	;	Cryo-EM structure of human ABCD1 E630Q in the presence of ATP in inward-facing state 2
7X0T	;	3.3	;	Cryo-EM structure of human ABCD1 E630Q in the presence of C26:0-CoA and ATP
7X07	;	3.78	;	Cryo-EM structure of human ABCD1 in the presence of C26:0
8PHF	;	3.6	;	Cryo-EM structure of human ACAD9-S191A
7DDO	;	3.4	;	Cryo-EM structure of human ACE2 and GD/1/2019 RBD
7DDP	;	3.4	;	Cryo-EM structure of human ACE2 and GX/P2V/2017 RBD
7ZDQ	;	3.2	;	Cryo-EM structure of Human ACE2 bound to a high-affinity SARS CoV-2 mutant
7WBL	;	3.4	;	Cryo-EM structure of human ACE2 complexed with SARS-CoV-2 Omicron RBD
7L7F	;	3.24	;	Cryo-EM structure of human ACE2 receptor bound to protein encoded by vaccine candidate BNT162b1
7SK9	;	3.7	;	Cryo-EM structure of human ACKR3 in complex with a small molecule partial agonist CCX662, and an intracellular Fab
7SK6	;	4.0	;	Cryo-EM structure of human ACKR3 in complex with chemokine N-terminal mutant CXCL12_LRHQ and an intracellular Fab
7SK8	;	3.3	;	Cryo-EM structure of human ACKR3 in complex with CXCL12, a small molecule partial agonist CCX662, an extracellular Fab, and an intracellular Fab
7SK7	;	3.3	;	Cryo-EM structure of human ACKR3 in complex with CXCL12, a small molecule partial agonist CCX662, and an extracellular Fab
5GKA	;	3.7	;	cryo-EM structure of human Aichi virus
7YIM	;	2.6	;	Cryo-EM structure of human Alpha-fetoprotein
7F6G	;	2.9	;	Cryo-EM structure of human angiotensin receptor AT1R in complex Gq proteins and Sar1-AngII
7TY4	;	2.99	;	Cryo-EM structure of human Anion Exchanger 1
7TY6	;	2.98	;	Cryo-EM structure of human Anion Exchanger 1 bound to 4,4'-Diisothiocyanatodihydrostilbene-2,2'-Disulfonic Acid (H2DIDS)
8T6V	;	2.95	;	Cryo-EM structure of human Anion Exchanger 1 bound to 4,4'-Diisothiocyanatostilbene-2,2'-Disulfonic Acid (DIDS)
7TY7	;	3.37	;	Cryo-EM structure of human Anion Exchanger 1 bound to Bicarbonate
8T6U	;	3.13	;	Cryo-EM structure of human Anion Exchanger 1 bound to Dipyridamole
7TY8	;	3.18	;	Cryo-EM structure of human Anion Exchanger 1 bound to Niflumic Acid
7TYA	;	3.07	;	Cryo-EM structure of human Anion Exchanger 1 modified with Diethyl Pyrocarbonate (DEPC)
7TW3	;	4.4	;	Cryo-EM structure of human ankyrin complex (B2P1A1) from red blood cell
7TW5	;	5.7	;	Cryo-EM structure of human ankyrin complex (B2P1A2) from red blood cell
7TW6	;	5.6	;	Cryo-EM structure of human ankyrin complex (B4P1A1) from red blood cell
7LFT	;	2.6	;	Cryo-EM structure of human Apo CNGA1 channel in K+/Ca2+
7Y7V	;	2.2	;	Cryo-EM structure of human apo GABA transporter GAT1 in an inward-open state
7A6H	;	3.3	;	Cryo-EM structure of human apo RNA Polymerase III
8CX1	;	3.3	;	Cryo-EM structure of human APOBEC3G/HIV-1 Vif/CBFbeta/ELOB/ELOC dimeric complex in State 1
8CX2	;	3.2	;	Cryo-EM structure of human APOBEC3G/HIV-1 Vif/CBFbeta/ELOB/ELOC dimeric complex in State 2
8CX0	;	2.7	;	Cryo-EM structure of human APOBEC3G/HIV-1 Vif/CBFbeta/ELOB/ELOC monomeric complex
6WX6	;	2.0	;	Cryo-EM Structure of Human Apoferritin Light Chain Vitrified Using Back-it-up
7JLO	;	3.4	;	Cryo-EM structure of human ATG9A in amphipols
7JLQ	;	4.0	;	cryo-EM structure of human ATG9A in LMNG micelles
7JLP	;	3.4	;	cryo-EM structure of human ATG9A in nanodiscs
6O0H	;	3.67	;	Cryo-EM structure of human ATP-citrate lyase in complex with inhibitor NDI-091143
5YZ0	;	4.7	;	Cryo-EM Structure of human ATR-ATRIP complex
7TW2	;	4.8	;	Cryo-EM structure of human band 3 dimer from red blood cell
7TW1	;	4.6	;	Cryo-EM structure of human band 3-protein 4.2 complex (B2P2vertical)
7TVZ	;	3.6	;	Cryo-EM structure of human band 3-protein 4.2 complex in diagonal conformation
7TW0	;	4.6	;	Cryo-EM structure of human band 3-protein 4.2 complex in vertical conformation
7RB3	;	3.1	;	Cryo-EM structure of human binary NatC complex with a Bisubstrate inhibitor
8ATU	;	3.3	;	Cryo-EM structure of human BIRC6
8ATX	;	7.0	;	Cryo-EM structure of human BIRC6 - no substrate
8AUK	;	6.2	;	Cryo-EM structure of human BIRC6 in complex with HTRA2.
8AUW	;	7.2	;	Cryo-EM structure of human BIRC6 in complex with SMAC.
7F6H	;	2.9	;	Cryo-EM structure of human bradykinin receptor BK2R in complex Gq proteins and bradykinin
7F6I	;	2.8	;	Cryo-EM structure of human bradykinin receptor BK2R in complex Gq proteins and kallidin
7X1G	;	2.94	;	Cryo-EM structure of human BTR1 in the inward-facing state at pH 5.5
7X1H	;	2.96	;	Cryo-EM structure of human BTR1 in the inward-facing state with R125H mutation
7X1J	;	2.84	;	Cryo-EM structure of human BTR1 in the outward-facing state in the presence of NH4Cl.
7X1I	;	2.94	;	Cryo-EM structure of human BTR1 in the outward-facing state.
7Y60	;	3.8	;	Cryo-EM structure of human CAF1LC bound right-handed Di-tetrasome
6VAK	;	3.48	;	Cryo-EM structure of human CALHM2
6UIX	;	3.5	;	Cryo-EM structure of human CALHM2 gap junction
6UIW	;	2.7	;	Cryo-EM structure of human CALHM2 in a ruthenium red-bound inhibited state
6UIV	;	3.3	;	Cryo-EM structure of human CALHM2 in an active/open state
7D65	;	2.94	;	Cryo-EM Structure of human CALHM5 in the presence of Ca2+
7D61	;	2.8	;	Cryo-EM Structure of human CALHM5 in the presence of EDTA
7D60	;	2.61	;	Cryo-EM Structure of human CALHM5 in the presence of rubidium red
6PT0	;	3.2	;	Cryo-EM structure of human cannabinoid receptor 2-Gi protein in complex with agonist WIN 55,212-2
8EL9	;	2.27	;	Cryo-EM structure of human catalase
6Z6L	;	3.0	;	Cryo-EM structure of human CCDC124 bound to 80S ribosomes
8GYX	;	3.7	;	Cryo-EM structure of human CEPT1
8GYW	;	3.9	;	Cryo-EM structure of human CEPT1 complexed with CDP-choline
7LG1	;	2.7	;	Cryo-EM structure of human cGMP-bound CNGA1_E365Q channel in Na+/Ca2+
7LFW	;	2.9	;	Cryo-EM structure of human cGMP-bound open CNGA1 channel in K+/Ca2+
7LFY	;	3.6	;	Cryo-EM structure of human cGMP-bound open CNGA1 channel in Na+
7LFX	;	3.1	;	Cryo-EM structure of human cGMP-bound open CNGA1 channel in Na+/Ca2+
8U5B	;	5.3	;	Cryo-EM structure of human claudin-4 complex with Clostridium perfringens enterotoxin C-terminal domain and sFab COP-1
8U4V	;	2.99	;	Cryo-EM structure of human claudin-4 complex with Clostridium perfringens enterotoxin C-terminal domain, sFab COP-1, and Nanobody
8D7H	;	3.4	;	Cryo-EM structure of human CLCF1 in complex with CRLF1 and CNTFR alpha
8D7R	;	3.9	;	Cryo-EM structure of human CLCF1 signaling complex: model containing the interaction core region
8D74	;	3.03	;	Cryo-EM structure of human CNTF signaling complex: model containing the interaction core region
8D7E	;	2.93	;	Cryo-EM structure of human CNTFR alpha in complex with the Fab fragments of two antibodies
7W1M	;	6.5	;	Cryo-EM structure of human cohesin-CTCF-DNA complex
6WG3	;	5.3	;	Cryo-EM structure of human Cohesin-NIPBL-DNA complex
6WGE	;	3.9	;	Cryo-EM structure of human Cohesin-NIPBL-DNA complex without STAG1
1Z7Z	;	8.0	;	Cryo-em structure of human coxsackievirus A21 complexed with five domain icam-1kilifi
6BLY	;	3.36	;	Cryo-EM structure of human CPSF-160-WDR33 complex at 3.36A resolution
6BM0	;	3.8	;	Cryo-EM structure of human CPSF-160-WDR33 complex at 3.8 A resolution
6DNH	;	3.4	;	Cryo-EM structure of human CPSF-160-WDR33-CPSF-30-PAS RNA complex at 3.4 A resolution
6URG	;	3.0	;	Cryo-EM structure of human CPSF160-WDR33-CPSF30-CPSF100 PIM complex
6URO	;	3.6	;	Cryo-EM structure of human CPSF160-WDR33-CPSF30-PAS RNA-CstF77 complex
7U5C	;	4.6	;	Cryo-EM structure of human CST bound to DNA polymerase alpha-primase in a recruitment state
8SOJ	;	3.8	;	Cryo-EM structure of human CST bound to POT1(ESDL)/TPP1 in the absence of telomeric ssDNA
8SOK	;	4.1	;	Cryo-EM structure of human CST bound to POT1(ESDL)/TPP1 in the presence of telomeric ssDNA
8ARI	;	3.0	;	Cryo-EM structure of human CtBP1/RAI2(303-362) delta(331-341) filament
8D9X	;	3.8	;	Cryo-EM structure of human DELE1 in oligomeric form
6VYI	;	3.0	;	Cryo-EM structure of human diacylglycerol O-acyltransferase 1
6VZ1	;	3.2	;	Cryo-EM structure of human diacylglycerol O-acyltransferase 1 complexed with acyl-CoA substrate
5ZAK	;	4.4	;	Cryo-EM structure of human Dicer and its complexes with a pre-miRNA substrate
5ZAL	;	4.7	;	Cryo-EM structure of human Dicer and its complexes with a pre-miRNA substrate
5ZAM	;	5.7	;	Cryo-EM structure of human Dicer and its complexes with a pre-miRNA substrate
7XW2	;	3.04	;	Cryo-EM structure of human DICER-pre-miRNA in a dicing state
8QJ7	;	3.07	;	Cryo-EM structure of human DNA polymerase alpha-primase in pre-initiation stage 1
5Y3R	;	6.6	;	Cryo-EM structure of Human DNA-PK Holoenzyme
7XIB	;	2.23	;	Cryo-EM structure of human DNMT1 (aa:351-1616) in complex with ubiquitinated H3 and hemimethylated DNA analog (CXXC-disordered form)
7XI9	;	2.52	;	Cryo-EM structure of human DNMT1 (aa:351-1616) in complex with ubiquitinated H3 and hemimethylated DNA analog (CXXC-ordered form)
8EIK	;	3.19	;	Cryo-EM structure of human DNMT3B homo-hexamer
8EIH	;	3.04	;	Cryo-EM structure of human DNMT3B homo-tetramer (form I)
8EII	;	3.12	;	Cryo-EM structure of human DNMT3B homo-tetramer (form II)
8EIJ	;	3.34	;	Cryo-EM structure of human DNMT3B homo-trimer
6J99	;	4.1	;	Cryo-EM structure of human DOT1L in complex with an H2B-monoubiquitinated nucleosome
7D3F	;	2.6	;	Cryo-EM structure of human DUOX1-DUOXA1 in high-calcium state
7D3E	;	2.8	;	Cryo-EM structure of human DUOX1-DUOXA1 in low-calcium state
6Z6N	;	2.9	;	Cryo-EM structure of human EBP1-80S ribosomes (focus on EBP1)
8J0N	;	3.47	;	cryo-EM structure of human EMC
8J0O	;	3.32	;	cryo-EM structure of human EMC and VDAC
7TAH	;	2.3	;	Cryo-EM structure of Human Enterovirus D68 US/MO/14-18947 strain in complex with inhibitor 11526091 (no/low occupancy-no inhibitor modeled)
7TAJ	;	2.0	;	Cryo-EM structure of Human Enterovirus D68 US/MO/14-18947 strain in complex with inhibitor 11526093 (no/low occupancy-no inhibitor modeled)
7T9P	;	2.0	;	Cryo-EM structure of Human Enterovirus D68 US/MO/14-18947 strain native virion
7TAF	;	2.0	;	Cryo-EM structure of Human Enterovirus D68 US/MO/14-18947 strain virion in complex with inhibitor 11526092
7TAG	;	2.7	;	Cryo-EM structure of Human Enterovirus D68 US/MO/14-18947 strain virion in complex with pleconaril
7ADP	;	3.6	;	Cryo-EM structure of human ER membrane protein complex in GDN detergent
7ADO	;	3.39	;	Cryo-EM structure of human ER membrane protein complex in lipid nanodiscs
7NPW	;	3.99	;	Cryo-EM structure of Human excitatory amino acid transporters-1 (EAAT1) in potassium buffer
7AU2	;	2.43	;	Cryo-EM structure of human exostosin-like 3 (EXTL3)
7AUA	;	2.93	;	Cryo-EM structure of human exostosin-like 3 (EXTL3) in complex with UDP
7KVE	;	3.3	;	Cryo-EM structure of human Factor V at 3.3 Angstrom resolution
7KVF	;	3.6	;	Cryo-EM structure of human Factor V at 3.6 Angstrom resolution
7KXY	;	4.4	;	Cryo-EM structure of human Factor Va at 4.4 Angstrom resolution
7YTC	;	3.39	;	Cryo-EM structure of human FcmR bound to IgM-Fc/J
7YSG	;	3.18	;	Cryo-EM structure of human FcmR bound to sIgM
8DL6	;	3.0	;	Cryo-EM structure of human ferroportin/slc40 bound to Ca2+ in nanodisc
8DL8	;	3.0	;	Cryo-EM structure of human ferroportin/slc40 bound to Co2+ in nanodisc
8DL7	;	2.7	;	Cryo-EM structure of human ferroportin/slc40 bound to minihepcidin PR73 in nanodisc
7QNA	;	3.0	;	Cryo-EM structure of human full-length alpha4beta3gamma2 GABA(A)R in complex with GABA and nanobody Nb25
7QN8	;	3.1	;	Cryo-EM structure of human full-length beta3delta GABA(A)R in complex with histamine and nanobody Nb25
7QN6	;	2.9	;	Cryo-EM structure of human full-length beta3delta GABA(A)R in complex with nanobody Nb25
7QNB	;	3.1	;	Cryo-EM structure of human full-length beta3gamma2 GABA(A)R in complex with GABA and nanobody Nb25
7QN7	;	3.0	;	Cryo-EM structure of human full-length extrasynaptic alpha4beta3delta GABA(A)R in complex with GABA, histamine and nanobody Nb25
7QN9	;	2.9	;	Cryo-EM structure of human full-length extrasynaptic alpha4beta3delta GABA(A)R in complex with GABA, histamine and nanobody Nb25 in a pre-open/closed state
7QN5	;	2.5	;	Cryo-EM structure of human full-length extrasynaptic alpha4beta3delta GABA(A)R in complex with nanobody Nb25
7QNC	;	2.9	;	Cryo-EM structure of human full-length extrasynaptic alpha4beta3delta GABA(A)R in complex with THIP (gaboxadol), histamine and nanobody Nb25
7QND	;	3.4	;	Cryo-EM structure of human full-length extrasynaptic beta3delta GABA(A)R in complex with THIP (gaboxadol), histamine and nanobody Nb25
7QNE	;	2.7	;	Cryo-EM structure of human full-length synaptic alpha1beta3gamma2 GABA(A)R in complex with Ro15-4513 and megabody Mb38
7Y7W	;	2.4	;	Cryo-EM structure of human GABA transporter GAT1 bound with GABA in NaCl solution in an inward-occluded state at 2.4 angstrom
7Y7Y	;	2.4	;	Cryo-EM structure of human GABA transporter GAT1 bound with nipecotic acid in NaCl solution in an inward-occluded state at 2.4 angstrom
7Y7Z	;	3.2	;	Cryo-EM structure of human GABA transporter GAT1 bound with tiagabine in NaCl solution in an inward-open state at 3.2 angstrom
7CUM	;	3.52	;	Cryo-EM structure of human GABA(B) receptor bound to the antagonist CGP54626
7CA3	;	4.5	;	Cryo-EM structure of human GABA(B) receptor bound to the positive allosteric modulator rac-BHFF
7CA5	;	7.6	;	Cryo-EM structure of human GABA(B) receptor in apo state
7EB2	;	3.5	;	Cryo-EM structure of human GABA(B) receptor-Gi protein complex
7XBD	;	3.11	;	Cryo-EM structure of human galanin receptor 2
7RBT	;	3.08	;	cryo-EM structure of human Gastric inhibitory polypeptide receptor GIPR bound to tirzepatide
7W40	;	3.0	;	Cryo-EM Structure of Human Gastrin Releasing Peptide Receptor in complex with the agonist Bombesin (6-14) [D-Phe6, beta-Ala11, Phe13, Nle14] and Gq heterotrimers
7W3Z	;	3.0	;	Cryo-EM Structure of Human Gastrin Releasing Peptide Receptor in complex with the agonist Gastrin Releasing Peptide and Gq heterotrimers
7S05	;	3.1	;	Cryo-EM structure of human GlcNAc-1-phosphotransferase A2B2 subcomplex
7S06	;	3.3	;	Cryo-EM structure of human GlcNAc-1-phosphotransferase A2B2 subcomplex
7WSN	;	3.31	;	Cryo-EM structure of human glucose transporter GLUT4 bound to cytochalasin B in detergent micelles
7WSM	;	3.25	;	Cryo-EM structure of human glucose transporter GLUT4 bound to cytochalasin B in lipid nanodiscs
8E4Y	;	3.4	;	Cryo-EM structure of human glycerol-3-phosphate acyltransferase 1 (GPAT1) in complex with 2-oxohexadecyl-CoA
8E50	;	3.67	;	Cryo-EM structure of human glycerol-3-phosphate acyltransferase 1 (GPAT1) in complex with CoA and palmitoyl-LPA
8DN4	;	4.1	;	Cryo-EM structure of human Glycine Receptor alpha-1 beta heteromer, glycine-bound state3(desensitized state)
8DN3	;	3.55	;	Cryo-EM structure of human Glycine Receptor alpha1-beta heteromer, apo state
8DN2	;	3.9	;	Cryo-EM structure of human Glycine Receptor alpha1-beta heteromer, glycine-bound state 2(expanded open)
8DN5	;	3.63	;	Cryo-EM structure of human Glycine Receptor alpha1-beta heteromer, glycine-bound state1(open state)
7SHE	;	3.4	;	Cryo-EM structure of human GPR158
7EWP	;	4.3	;	Cryo-EM structure of human GPR158 in complex with RGS7-Gbeta5 in a 2:1:1 ratio
7EWR	;	4.7	;	Cryo-EM structure of human GPR158 in complex with RGS7-Gbeta5 in a 2:2:2 ratio
8IJB	;	3.23	;	Cryo-EM structure of human HCAR2-Gi complex with acipimox
8IJD	;	3.25	;	Cryo-EM structure of human HCAR2-Gi complex with MK-6892
8IJA	;	2.69	;	Cryo-EM structure of human HCAR2-Gi complex with niacin
8IJ3	;	3.28	;	Cryo-EM structure of human HCAR2-Gi complex without ligand (apo state)
8INZ	;	2.72	;	Cryo-EM structure of human HCN3 channel in apo state
8IO3	;	3.02	;	Cryo-EM structure of human HCN3 channel with cilobradine
8EOB	;	3.1	;	Cryo-EM structure of human HSP90B in the closed state
8EOA	;	3.9	;	Cryo-EM structure of human HSP90B-AIPL1 complex
7JQ9	;	3.1	;	Cryo-EM structure of human HUWE1
7MOP	;	3.3	;	Cryo-EM structure of human HUWE1 in complex with DDIT4
7Y09	;	3.71	;	Cryo-EM structure of human IgM-Fc in complex with the J chain and the DBL domain of DBLMSP
7YG2	;	3.32	;	Cryo-EM structure of human IgM-Fc in complex with the J chain and the DBL domain of DBLMSP2
6KXS	;	3.4	;	Cryo-EM structure of human IgM-Fc in complex with the J chain and the ectodomain of pIgR
7Y0J	;	3.62	;	Cryo-EM structure of human IgM-Fc in complex with the J chain and the P. falciparum TM284VAR1
7Y0H	;	3.56	;	Cryo-EM structure of human IgM-Fc in complex with the J chain and the P. falciparum VAR2CSA FCR3
8D85	;	3.81	;	Cryo-EM structure of human IL-27 signaling complex: model containing the interaction core region
8D82	;	3.22	;	Cryo-EM structure of human IL-6 signaling complex in detergent: model containing full extracellular domains
6AVO	;	3.8	;	Cryo-EM structure of human immunoproteasome with a novel noncompetitive inhibitor that selectively inhibits activated lymphocytes
6B7Y	;	6.5	;	Cryo-EM structure of human insulin degrading enzyme
6BF6	;	6.5	;	Cryo-EM structure of human insulin degrading enzyme
6B7Z	;	6.5	;	Cryo-EM structure of human insulin degrading enzyme in complex with FAB H11 heavy chain and FAB H11 light chain
6BF7	;	6.5	;	Cryo-EM structure of human insulin degrading enzyme in complex with FAB H11-E heavy chain, FAB H11-E light chain
6BF9	;	7.2	;	Cryo-EM structure of human insulin degrading enzyme in complex with FAB H11-E heavy chain, FAB H11-E light chain
6B70	;	3.7	;	Cryo-EM structure of human insulin degrading enzyme in complex with FAB H11-E heavy chain, FAB H11-E light chain and insulin
6B3Q	;	3.7	;	Cryo-EM structure of human insulin degrading enzyme in complex with insulin
6BF8	;	4.2	;	Cryo-EM structure of human insulin degrading enzyme in complex with insulin
6BFC	;	3.7	;	Cryo-EM structure of human insulin degrading enzyme in complex with insulin
7NWL	;	3.1	;	Cryo-EM structure of human integrin alpha5beta1 (open form) in complex with fibronectin and TS2/16 Fv-clasp
7NXD	;	4.6	;	Cryo-EM structure of human integrin alpha5beta1 in the half-bent conformation
8R4I	;	4.01	;	Cryo-EM structure of human islet amyloid polypeptide (hIAPP)
6VW2	;	3.4	;	Cryo-EM structure of human islet amyloid polypeptide (hIAPP, or amylin) fibrils
7M61	;	3.8	;	Cryo-EM structure of human islet amyloid polypeptide (hIAPP, or amylin) fibrils seeded by patient extracted fibrils, polymorph 1
7M62	;	3.9	;	Cryo-EM structure of human islet amyloid polypeptide (hIAPP, or amylin) fibrils seeded by patient extracted fibrils, polymorph 2
7M64	;	4.0	;	Cryo-EM structure of human islet amyloid polypeptide (hIAPP, or amylin) fibrils seeded by patient extracted fibrils, polymorph 3
7M65	;	4.1	;	Cryo-EM structure of human islet amyloid polypeptide (hIAPP, or amylin) fibrils seeded by patient extracted fibrils, polymorph 4
7Y1F	;	3.3	;	Cryo-EM structure of human k-opioid receptor-Gi complex
6C3P	;	5.6	;	Cryo-EM structure of human KATP bound to ATP and ADP in propeller form
6C3O	;	3.9	;	Cryo-EM structure of human KATP bound to ATP and ADP in quatrefoil form
7BYL	;	2.5	;	Cryo-EM structure of human KCNQ4
7BYN	;	3.3	;	Cryo-EM structure of human KCNQ4 with linopirdine
7BYM	;	3.1	;	Cryo-EM structure of human KCNQ4 with retigabine
8D45	;	2.62	;	Cryo-EM structure of human Kidney Betaine-Homocysteine Methyltransferase
8D43	;	2.88	;	Cryo-EM structure of human Kidney Glucosidase II
6C0W	;	4.0	;	Cryo-EM structure of human kinetochore protein CENP-N with the centromeric nucleosome containing CENP-A
8QUC	;	2.9	;	Cryo-EM Structure of Human Kv3.1 in Complex with Modulator AUT1
8QUD	;	2.5	;	Cryo-EM Structure of Human Kv3.1 in Complex with Modulator AUT5
8D6A	;	3.54	;	Cryo-EM structure of human LIF signaling complex: model containing the interaction core region
8EMR	;	2.92	;	Cryo-EM structure of human liver glucosidase II
8EMS	;	2.65	;	Cryo-EM structure of human liver glycogen phosphorylase
7XZH	;	2.78	;	Cryo-EM structure of human LRRC8A
6JBJ	;	3.6	;	Cryo-EM structure of human lysosomal cobalamin exporter ABCD4
6LZ0	;	3.3	;	Cryo-EM structure of human MCT1 in complex with Basigin-2 in the presence of lactate
8E78	;	2.77	;	Cryo-EM structure of human ME3 in the presence of citrate
8E8O	;	2.77	;	Cryo-EM structure of human ME3 in the presence of citrate
8CTH	;	3.3	;	Cryo-EM structure of human METTL1-WDR4-tRNA(Phe) complex
8CTI	;	3.6	;	Cryo-EM structure of human METTL1-WDR4-tRNA(Val) complex
7CP9	;	3.0	;	Cryo-EM structure of human mitochondrial translocase TOM complex at 3.0 angstrom.
6KIX	;	4.1	;	Cryo-EM structure of human MLL1-NCP complex, binding mode1
6KIZ	;	4.5	;	Cryo-EM structure of human MLL1-NCP complex, binding mode2
6KIU	;	3.2	;	Cryo-EM structure of human MLL1-ubNCP complex (3.2 angstrom)
6KIV	;	4.0	;	Cryo-EM structure of human MLL1-ubNCP complex (4.0 angstrom)
6KIW	;	4.0	;	Cryo-EM structure of human MLL3-ubNCP complex (4.0 angstrom)
7QDO	;	3.6	;	Cryo-EM structure of human monomeric IgM-Fc
6ZWO	;	3.0	;	cryo-EM structure of human mTOR complex 2, focused on one half
6ZWM	;	3.2	;	cryo-EM structure of human mTOR complex 2, overall refinement
7CM3	;	3.1	;	Cryo-EM structure of human NALCN in complex with FAM155A
6VP9	;	3.46	;	Cryo-EM structure of human NatB complex
7STX	;	3.14	;	Cryo-EM structure of human NatB in complex with CoA-Alpha-Synuclein
6PPL	;	3.02	;	Cryo-EM structure of human NatE complex (NatA/Naa50)
6PW9	;	4.03	;	Cryo-EM structure of human NatE/HYPK complex
7W77	;	3.3	;	cryo-EM structure of human NaV1.3/beta1/beta2-bulleyaconitineA
7W7F	;	3.35	;	Cryo-EM structure of human NaV1.3/beta1/beta2-ICA121431
8GZ1	;	3.4	;	Cryo-EM structure of human NaV1.6/beta1/beta2,apo state
8GZ2	;	3.3	;	Cryo-EM structure of human NaV1.6/beta1/beta2-4,9-anhydro-tetrodotoxin
7W9T	;	3.0	;	Cryo-EM structure of human Nav1.7(E406K) in complex with auxiliary beta subunits, huwentoxin-IV and saxitoxin (S6IV alpha helix conformer)
7W9P	;	2.9	;	Cryo-EM structure of human Nav1.7(E406K) in complex with auxiliary beta subunits, huwentoxin-IV and saxitoxin (S6IV pi helix conformer)
7W9M	;	3.0	;	Cryo-EM structure of human Nav1.7(E406K) in complex with auxiliary beta subunits, ProTx-II and tetrodotoxin (S6IV pi helix conformer)
7W9L	;	3.5	;	Cryo-EM structure of human Nav1.7(E406K)-beta1-beta2 complex
7W9K	;	2.2	;	Cryo-EM structure of human Nav1.7-beta1-beta2 complex at 2.2 angstrom resolution
7XMF	;	3.07	;	Cryo-EM structure of human NaV1.7/beta1/beta2-Nav1.7-IN2
7XMG	;	3.09	;	Cryo-EM structure of human NaV1.7/beta1/beta2-TCN-1752
7XM9	;	3.22	;	Cryo-EM structure of human NaV1.7/beta1/beta2-XEN907
8FHT	;	3.02	;	Cryo-EM structure of human NCC
8FHO	;	2.95	;	Cryo-EM structure of human NCC (class 1)
8FHN	;	3.0	;	Cryo-EM structure of human NCC (class 2)
8FHP	;	3.04	;	Cryo-EM structure of human NCC (class 3-1)
8FHQ	;	2.81	;	Cryo-EM structure of human NCC (class 3-2)
8FHR	;	2.9	;	Cryo-EM structure of human NCC (class 3-3)
8SGJ	;	3.1	;	Cryo-EM structure of human NCX1 in apo inactivated state
8SGT	;	3.6	;	Cryo-EM structure of human NCX1 in Ca2+ bound, activated state (group II in the presence of 0.5 mM Ca2+)
8FVU	;	3.6	;	Cryo-EM structure of human Needle/NAIP/NLRC4 (R288A)
8GS4	;	3.5	;	Cryo-EM structure of human Neuroligin 2
8GS3	;	3.9	;	Cryo-EM structure of human Neuroligin 3
7XK2	;	3.1	;	Cryo-EM Structure of Human Niacin Receptor HCA2-Gi protein complex
6PZT	;	3.46	;	cryo-EM structure of human NKCC1
7ZGO	;	2.55	;	Cryo-EM structure of human NKCC1 (TM domain)
7S1Y	;	3.6	;	Cryo-EM structure of human NKCC1 K289NA492E bound with bumetanide
7S1Z	;	3.3	;	Cryo-EM structure of Human NKCC1 K289NA492EL671C
7S1X	;	2.9	;	Cryo-EM structure of human NKCC1 K289NA492EL671C bound with bumetanide
7WSI	;	3.32	;	Cryo-EM structure of human NTCP (wild-type) complexed with YN69202Fab
7VAD	;	3.41	;	Cryo-EM structure of human NTCP complexed with YN69202Fab
7VAG	;	3.32	;	Cryo-EM structure of human NTCP complexed with YN69202Fab in the presence of myristoylated preS1 peptide
8RQF	;	3.41	;	Cryo-EM structure of human NTCP-Bulevirtide complex
8HRY	;	3.11	;	Cryo-EM structure of human NTCP-myr-preS1-YN9016Fab complex
8HRX	;	2.89	;	Cryo-EM structure of human NTCP-myr-preS1-YN9048Fab complex
7VZ4	;	1.89	;	Cryo-EM structure of human nucleosome core particle composed of the Widom 601L DNA sequence
8HNB	;	3.53	;	Cryo-EM structure of human OATP1B1 in apo state
8HNC	;	3.73	;	Cryo-EM structure of human OATP1B1 in complex with bilirubin
8K6L	;	2.92	;	Cryo-EM structure of human OATP1B1 in complex with DCF
8HND	;	3.19	;	Cryo-EM structure of human OATP1B1 in complex with estrone-3-sulfate
8HNH	;	3.73	;	Cryo-EM structure of human OATP1B1 in complex with simeprevir
7YEH	;	3.92	;	Cryo-EM structure of human OGT-OGA complex
6S7O	;	3.5	;	Cryo-EM structure of human oligosaccharyltransferase complex OST-A
6S7T	;	3.5	;	Cryo-EM structure of human oligosaccharyltransferase complex OST-B
5FTK	;	2.4	;	Cryo-EM structure of human p97 bound to ADP
5FTL	;	3.3	;	Cryo-EM structure of human p97 bound to ATPgS (Conformation I)
5FTM	;	3.2	;	Cryo-EM structure of human p97 bound to ATPgS (Conformation II)
5FTN	;	3.3	;	Cryo-EM structure of human p97 bound to ATPgS (Conformation III)
7RLI	;	3.1	;	Cryo-EM structure of human p97 bound to CB-5083 and ADP.
7RLJ	;	3.8	;	Cryo-EM structure of human p97 bound to CB-5083 and ATPgS.
5FTJ	;	2.3	;	Cryo-EM structure of human p97 bound to UPCDC30245 inhibitor
7LMY	;	2.4	;	Cryo-EM structure of human p97 in complex with NMS-873 in the presence of ATP, Npl4/Ufd1, and Ub6
7LN5	;	3.09	;	Cryo-EM structure of human p97 in complex with Npl4/Ufd1 and polyubiquitinated Ub-Eos (CHAPSO, Class 1, Close State)
7LN6	;	3.58	;	Cryo-EM structure of human p97 in complex with Npl4/Ufd1 and polyubiquitinated Ub-Eos (CHAPSO, Class 2, Open State)
7LN2	;	3.63	;	Cryo-EM structure of human p97 in complex with Npl4/Ufd1 and polyubiquitinated Ub-Eos (FOM, Class 1)
7LN3	;	3.45	;	Cryo-EM structure of human p97 in complex with Npl4/Ufd1 and polyubiquitinated Ub-Eos (FOM, Class 2)
7LN4	;	3.0	;	Cryo-EM structure of human p97 in complex with Npl4/Ufd1 and polyubiquitinated Ub-Eos (FOM, Class 3)
7LMZ	;	3.06	;	Cryo-EM structure of human p97 in complex with Npl4/Ufd1 and Ub6 (Class 1)
7LN0	;	2.98	;	Cryo-EM structure of human p97 in complex with Npl4/Ufd1 and Ub6 (Class 2)
7LN1	;	3.4	;	Cryo-EM structure of human p97 in complex with Npl4/Ufd1 and Ub6 (Class 3)
7RLB	;	3.3	;	Cryo-EM structure of human p97-A232E mutant bound to ADP
7RLC	;	3.2	;	Cryo-EM structure of human p97-A232E mutant bound to ATPgS.
7RLG	;	3.7	;	Cryo-EM structure of human p97-D592N mutant bound to ADP.
7RLH	;	3.0	;	Cryo-EM structure of human p97-D592N mutant bound to ATPgS.
7RLD	;	3.4	;	Cryo-EM structure of human p97-E470D mutant bound to ADP.
7RLF	;	3.1	;	Cryo-EM structure of human p97-E470D mutant bound to ATPgS.
7RL6	;	3.7	;	Cryo-EM structure of human p97-R155H mutant bound to ADP.
7RL7	;	3.0	;	Cryo-EM structure of human p97-R155H mutant bound to ATPgS.
7RL9	;	3.3	;	Cryo-EM structure of human p97-R191Q mutant bound to ADP.
7RLA	;	3.1	;	Cryo-EM structure of human p97-R191Q mutant bound to ATPgS.
6KWX	;	3.75	;	cryo-EM structure of human PA200
6V6D	;	3.77	;	Cryo-EM structure of human pannexin 1
6M02	;	3.2	;	cryo-EM structure of human Pannexin 1 channel
6WBM	;	2.86	;	Cryo-EM structure of human Pannexin 1 channel N255A mutant
6WBN	;	2.83	;	Cryo-EM structure of human Pannexin 1 channel N255A mutant, gap junction
6WBK	;	6.01	;	Cryo-EM structure of human Pannexin 1 channel with deletion of N-terminal helix and C-terminal tail
6WBL	;	5.13	;	Cryo-EM structure of human Pannexin 1 channel with deletion of N-terminal helix and C-terminal tail, in complex with CBX
6WBG	;	2.97	;	Cryo-EM structure of human Pannexin 1 channel with its C-terminal tail cleaved by caspase-7
6WBI	;	4.39	;	Cryo-EM structure of human Pannexin 1 channel with its C-terminal tail cleaved by caspase-7, in complex with CBX
7XLB	;	3.44	;	Cryo-EM structure of human pannexin 2
8F7C	;	3.92	;	Cryo-EM structure of human pannexin 2
7XL6	;	3.25	;	Cryo-EM structure of human pannexin 3
8HWQ	;	3.58	;	Cryo-EM structure of human pannexin 3 with C-terminal truncated
7F8J	;	3.6	;	Cryo-EM structure of human pannexin-1 in a nanodisc
8GTT	;	3.2	;	Cryo-EM structure of human Pannexin1 resembling Pannexin2 pore with W74R/R75Dmutations
6MJZ	;	4.3	;	Cryo-EM structure of Human Parainfluenza Virus Type 3 (hPIV3) in complex with antibody PIA174
7YRQ	;	3.35	;	Cryo-EM structure of human Peroxisomal ABC Transporter ABCD1
1DGI	;	22.0	;	Cryo-EM structure of human poliovirus(serotype 1)complexed with three domain CD155
8EKW	;	2.83	;	Cryo-EM structure of human PRDX4
7TPP	;	4.1	;	Cryo-em structure of human prothrombin:prothrombinase at 4.1 Angstrom resolution
7TPQ	;	5.3	;	Cryo-em structure of human prothrombinase on a nanodisc at 5.3 Angstrom resolution
7JNC	;	3.73	;	cryo-EM structure of human proton-activated chloride channel PAC at pH 4
7JNA	;	3.6	;	Cryo-EM structure of human proton-activated chloride channel PAC at pH 8
7RL4	;	2.86	;	Cryo-EM structure of human PrP23-144 amyloid fibrils
6DMB	;	3.9	;	Cryo-EM structure of human Ptch1
6DMY	;	3.6	;	Cryo-EM structure of human Ptch1 and ShhN complex
6DMO	;	4.1	;	Cryo-EM structure of human Ptch1 with three mutations L282Q/T500F/P504L
7WTA	;	3.9	;	Cryo-EM structure of human pyruvate carboxylase in apo state
7WTB	;	3.7	;	Cryo-EM structure of human pyruvate carboxylase with acetyl-CoA
7WTC	;	4.0	;	Cryo-EM structure of human pyruvate carboxylase with acetyl-CoA in the ground state
7WTD	;	3.9	;	Cryo-EM structure of human pyruvate carboxylase with acetyl-CoA in the intermediate state 1
7WTE	;	3.3	;	Cryo-EM structure of human pyruvate carboxylase with acetyl-CoA in the intermediate state 2
5XTD	;	3.7	;	Cryo-EM structure of human respiratory complex I
5XTB	;	3.4	;	Cryo-EM structure of human respiratory complex I matrix arm
5XTC	;	3.7	;	Cryo-EM structure of human respiratory complex I transmembrane arm
5XTE	;	3.4	;	Cryo-EM structure of human respiratory complex III (cytochrome bc1 complex)
5XTH	;	3.9	;	Cryo-EM structure of human respiratory supercomplex I1III2IV1
7UJA	;	3.7	;	Cryo-EM structure of Human respiratory syncytial virus F variant (construct pXCS847A)
1D3I	;	26.0	;	CRYO-EM STRUCTURE OF HUMAN RHINOVIRUS 14 (HRV14) COMPLEXED WITH A TWO-DOMAIN FRAGMENT OF ITS CELLULAR RECEPTOR, INTERCELLULAR ADHESION MOLECULE-1 (D1D2-ICAM-1). IMPLICATIONS FOR VIRUS-RECEPTOR INTERACTIONS. ALPHA CARBONS ONLY
1D3E	;	28.0	;	CRYO-EM STRUCTURE OF HUMAN RHINOVIRUS 16 (HRV16) COMPLEXED WITH A TWO-DOMAIN FRAGMENT OF ITS CELLULAR RECEPTOR, INTERCELLULAR ADHESION MOLECULE-1 (D1D2-ICAM-1). IMPLICATIONS FOR VIRUS-RECEPTOR INTERACTIONS. ALPHA CARBONS ONLY
6AHR	;	3.92	;	Cryo-EM structure of human Ribonuclease P
6AHU	;	3.66	;	Cryo-EM structure of human Ribonuclease P with mature tRNA
7OBA	;	3.1	;	Cryo-EM structure of human RNA Polymerase I in complex with RRN3
7OB9	;	2.7	;	Cryo-EM structure of human RNA Polymerase I in elongation state
7OBB	;	3.3	;	Cryo-EM structure of human RNA Polymerase I Open Complex
7AE1	;	2.8	;	Cryo-EM structure of human RNA Polymerase III elongation complex 1
7AEA	;	3.4	;	Cryo-EM structure of human RNA Polymerase III elongation complex 2
7AE3	;	3.1	;	Cryo-EM structure of human RNA Polymerase III elongation complex 3
7D59	;	3.1	;	cryo-EM structure of human RNA polymerase III in apo state
7D58	;	2.9	;	cryo-EM structure of human RNA polymerase III in elongating state
7RHL	;	3.03	;	Cryo-EM structure of human rod Apo CNGA1/B1 channel with CLZ coiled coil
7RH9	;	2.61	;	Cryo-EM structure of human rod CNGA1/B1 channel in apo state
7RHG	;	2.88	;	Cryo-EM structure of human rod CNGA1/B1 channel in cAMP-bound state
7RHH	;	3.31	;	Cryo-EM structure of human rod CNGA1/B1 channel in cGMP-bound openI state
7RHI	;	3.31	;	Cryo-EM structure of human rod CNGA1/B1 channel in cGMP-bound openII state
7RHJ	;	2.88	;	Cryo-EM structure of human rod CNGA1/B1 channel in L-cis-Diltiazem-blocked open state
7RHK	;	3.27	;	Cryo-EM structure of human rod CNGA1/B1 channel in L-cis-Diltiazem-trapped closed state
8JHR	;	3.52	;	Cryo-EM structure of human S1P transporter SPNS2 bound with an inhibitor 16d
8JHQ	;	3.6	;	Cryo-EM structure of human S1P transporter SPNS2 bound with S1P
6LX3	;	3.15	;	Cryo-EM structure of human secretory immunoglobulin A
6LXW	;	3.27	;	Cryo-EM structure of human secretory immunoglobulin A in complex with the N-terminal domain of SpsA
8QI7	;	2.9	;	Cryo-EM Structure of Human Serine Hydroxymethyltransferase, isoform 2 (SHMT2)
8WOS	;	3.37	;	Cryo-EM structure of human SIDT1 protein with C1 symmetry at low pH
8WOQ	;	2.85	;	Cryo-EM structure of human SIDT1 protein with C1 symmetry at neutral pH
8WOT	;	3.18	;	Cryo-EM structure of human SIDT1 protein with C2 symmetry at low pH
8WOR	;	2.66	;	Cryo-EM structure of human SIDT1 protein with C2 symmetry at neutral pH
7T5P	;	3.4	;	Cryo-EM structure of human SIMC1-SLF2 complex
8WX2	;	3.44	;	Cryo-EM structure of human SLC15A3 (outward-facing partially occluded)
8WX3	;	2.83	;	Cryo-EM structure of human SLC15A4 (outward-facing open)
8QSL	;	2.81	;	Cryo-EM structure of human SLC15A4 dimer in outward open state in LMNG
8QSK	;	3.3	;	Cryo-EM structure of human SLC15A4 dimer in outward open state in MSP1D1 nanodisc
8WX4	;	3.12	;	Cryo-EM structure of human SLC15A4 in complex with Lys-Leu (outward-facing open)
8WX5	;	3.91	;	Cryo-EM structure of human SLC15A4 in complex with TASL (inward-facing open)
8P6A	;	3.63	;	cryo-EM structure of human SLC15A4 in outward-open state
8QSM	;	3.69	;	Cryo-EM structure of human SLC15A4 monomer in outward open state in LMNG
8QSN	;	3.54	;	Cryo-EM structure of human SLC15A4 monomer in outward open state in PMAL C8
7YNZ	;	3.5	;	Cryo-EM structure of human Slo1-LRRC26 complex with C1 symmetry
7YO3	;	3.1	;	Cryo-EM structure of human Slo1-LRRC26 complex with C4 symmetry
7YO0	;	3.6	;	Cryo-EM structure of human Slo1-LRRC26 complex with Symmetry Expansion
7Y6I	;	2.85	;	Cryo-EM structure of human sodium-chloride cotransporter
7YG0	;	3.75	;	Cryo-EM structure of human sodium-chloride cotransporter
7WJ5	;	3.72	;	Cryo-EM structure of human somatostatin receptor 2 complex with its agonist somatostatin delineates the ligand binding specificity
6IGM	;	4.0	;	Cryo-EM Structure of Human SRCAP Complex
8UCD	;	3.0	;	Cryo-EM structure of human STEAP1 in complex with AMG 509 Fab
7X57	;	3.63	;	Cryo-EM structure of human subnucleosome (closed form)
7YOZ	;	4.3	;	Cryo-EM structure of human subnucleosome (intermediate form)
7X58	;	3.93	;	Cryo-EM structure of human subnucleosome (open form)
8ALY	;	2.98	;	Cryo-EM structure of human tankyrase 2 SAM-PARP filament (G1032W mutant)
7QXS	;	3.9	;	Cryo-EM structure of human telomerase-DNA-TPP1-POT1 complex (with POT1 side chains)
7MX2	;	3.64	;	Cryo-EM structure of human ternary NatC complex with a Bisubstrate inhibitor
7X1R	;	3.9	;	Cryo-EM structure of human thioredoxin reductase bound by Au
7B75	;	3.2	;	Cryo-EM Structure of Human Thyroglobulin
7C76	;	3.4	;	Cryo-EM structure of human TLR3 in complex with UNC93B1
7CYN	;	4.2	;	Cryo-EM structure of human TLR7 in complex with UNC93B1
7N7P	;	3.24	;	Cryo-EM structure of human TMEM120A
7F3T	;	3.69	;	Cryo-EM structure of human TMEM120A in the CoASH-bound state
7F3U	;	4.0	;	Cryo-EM structure of human TMEM120A in the CoASH-free state
7CXR	;	3.4	;	Cryo-EM structure of human TMEM120A/TACAN
7F73	;	4.0	;	Cryo-EM structure of human TMEM120B
7OQZ	;	3.27	;	Cryo-EM structure of human TMEM45A
8WUA	;	3.6	;	cryo-EM structure of human TMEM63A
8HTT	;	3.6	;	Cryo-EM structure of human TMEM87A, gluconate-bound
8HSI	;	3.1	;	Cryo-EM structure of human TMEM87A, PE-bound
7YQ8	;	3.9	;	Cryo-EM structure of human topoisomerase II beta in complex with DNA and etoposide
6OIF	;	4.4	;	Cryo-EM structure of human TorsinA filament
6NQ1	;	3.5	;	Cryo-EM structure of human TPC2 channel in the apo state
6NQ2	;	3.4	;	Cryo-EM structure of human TPC2 channel in the ligand-bound closed state
6NQ0	;	3.7	;	Cryo-EM structure of human TPC2 channel in the ligand-bound open state
7WIY	;	3.09	;	Cryo-EM structure of human TPH2 tetramer
7ZQS	;	2.54	;	Cryo-EM Structure of Human Transferrin Receptor 1 bound to DNA Aptamer
7X3U	;	3.3	;	cryo-EM structure of human TRiC-ADP
7X0V	;	3.2	;	cryo-EM structure of human TRiC-ADP-AlFx
7X6Q	;	4.5	;	cryo-EM structure of human TRiC-ATP-closed state
7X7Y	;	3.8	;	Cryo-EM structure of Human TRiC-ATP-open state
7X0A	;	3.1	;	Cryo-EM structure of human TRiC-NPP state
7WZ3	;	4.1	;	Cryo-EM structure of human TRiC-tubulin-S1 state
7X3J	;	4.2	;	Cryo-EM structure of human TRiC-tubulin-S2
6PQQ	;	2.81	;	Cryo-EM structure of human TRPA1 C621S mutant in the apo state
5ZBG	;	4.36	;	Cryo-EM structure of human TRPC3 at 4.36A resolution
5YX9	;	3.8	;	Cryo-EM structure of human TRPC6 at 3.8A resolution
6UZ8	;	2.84	;	Cryo-EM structure of human TRPC6 in complex with agonist AM-0883
6UZA	;	3.08	;	Cryo-EM structure of human TRPC6 in complex with antagonist AM-1473
6E7Z	;	3.73	;	cryo-EM structure of human TRPML1 with ML-SA1 and PI35P2
6E7P	;	3.5	;	cryo-EM structure of human TRPML1 with PI35P2
6E7Y	;	3.57	;	cryo-EM structure of human TRPML1 with PI45P2
8GF9	;	2.58	;	Cryo-EM structure of human TRPV1 in cNW11 nanodisc and POPC:POPE:POPG lipids
8GF8	;	2.9	;	Cryo-EM structure of human TRPV1 in cNW11 nanodisc and soybean lipids
8GFA	;	2.29	;	Cryo-EM structure of human TRPV1 in complex with the analgesic drug SB-366791
6UW4	;	3.1	;	Cryo-EM structure of human TRPV3 determined in lipid nanodisc
8T1C	;	3.49	;	Cryo-EM structure of human TRPV4 ankyrin repeat domain in complex with GTPase RhoA
6BO9	;	4.0	;	Cryo-EM structure of human TRPV6 in amphipols
7K4E	;	4.34	;	Cryo-EM structure of human TRPV6 in complex with (4- phenylcyclohexyl)piperazine inhibitor 30
7K4F	;	3.75	;	Cryo-EM structure of human TRPV6 in complex with (4- phenylcyclohexyl)piperazine inhibitor 31
7K4D	;	3.66	;	Cryo-EM structure of human TRPV6 in complex with (4- phenylcyclohexyl)piperazine inhibitor 3OG
7K4C	;	3.78	;	Cryo-EM structure of human TRPV6 in complex with (4- phenylcyclohexyl)piperazine inhibitor Br-cis-22a
7K4B	;	3.1	;	Cryo-EM structure of human TRPV6 in complex with (4- phenylcyclohexyl)piperazine inhibitor cis-22a
6E2F	;	3.9	;	Cryo-EM structure of human TRPV6 in complex with Calmodulin
7S8B	;	2.43	;	Cryo-EM structure of human TRPV6 in complex with channel blocker ruthenium red
7S8C	;	2.85	;	Cryo-EM structure of human TRPV6 in complex with inhibitor econazole
8FOA	;	2.66	;	Cryo-EM structure of human TRPV6 in complex with the natural phytoestrogen genistein
6BO8	;	3.6	;	Cryo-EM structure of human TRPV6 in nanodiscs
7K4A	;	3.26	;	Cryo-EM structure of human TRPV6 in the open state
8FOB	;	2.71	;	Cryo-EM structure of human TRPV6 in the open state
6BOA	;	4.2	;	Cryo-EM structure of human TRPV6-R470E in amphipols
6D7S	;	4.34	;	Cryo-EM structure of human TRPV6-Y467A in amphipols
6D7T	;	4.44	;	Cryo-EM structure of human TRPV6-Y467A in complex with 2-Aminoethoxydiphenyl borate (2-APB)
7DL2	;	4.4	;	Cryo-EM structure of human TSC complex
7P5J	;	4.0	;	Cryo-EM structure of human TTYH1 in GDN
7P54	;	3.3	;	Cryo-EM structure of human TTYH2 in GDN
7P5M	;	3.92	;	Cryo-EM structure of human TTYH2 in lipid nanodiscs
7P5C	;	3.2	;	Cryo-EM structure of human TTYH3 in Ca2+ and GDN
7DW9	;	2.6	;	Cryo-EM structure of human V2 vasopressin receptor in complex with an Gs protein
7VQX	;	2.74	;	Cryo-EM structure of human vasoactive intestinal polypeptide receptor 2 (VIP2R) in complex with PACAP27 and Gs
7VWC	;	3.53	;	Cryo-EM structure of human very long-chain fatty acid ABC transporter ABCD1
8FHD	;	3.1	;	Cryo-EM structure of human voltage-gated sodium channel Nav1.6
7DCE	;	3.8	;	Cryo-EM structure of human XKR8-basigin complex bound to Fab fragment
8XEJ	;	3.66	;	Cryo-EM structure of human XKR8-basigin complex in lipid nanodisc
8HF3	;	3.4	;	Cryo-EM structure of human ZDHHC9/GCP16 complex
6XPD	;	3.8	;	Cryo-EM structure of human ZnT8 double mutant - D110N and D224N, determined in outward-facing conformation
6XPF	;	5.9	;	Cryo-EM structure of human ZnT8 WT, in the absence of zinc, determined in heterogeneous conformations- one subunit in an inward-facing and the other in an outward-facing conformation
6XPE	;	4.1	;	Cryo-EM structure of human ZnT8 WT, in the presence of zinc, determined in outward-facing conformation
7E1X	;	2.93	;	Cryo-EM structure of hybrid respiratory supercomplex consisting of Mycobacterium tuberculosis complexIII and Mycobacterium smegmatis complexIV in presence of TB47
7E1W	;	2.67	;	Cryo-EM structure of hybrid respiratory supercomplex consisting of Mycobacterium tuberculosis complexIII and Mycobacterium smegmatis complexIV in the presence of Q203
7QV7	;	3.4	;	Cryo-EM structure of Hydrogen-dependent CO2 reductase.
8J80	;	2.68	;	Cryo-EM structure of hZnT7-Fab complex in zinc state 1, determined in heterogeneous conformations- one subunit in an inward-facing zinc-bound and the other in an outward-facing zinc-unbound conformation
8J7W	;	2.92	;	Cryo-EM structure of hZnT7-Fab complex in zinc state 2, determined in heterogeneous conformations- one subunit in an inward-facing zinc-bound and the other in an outward-facing zinc-bound conformation
8J7U	;	3.12	;	Cryo-EM structure of hZnT7-Fab complex in zinc-bound state, determined in outward-facing conformation
8J7V	;	2.79	;	Cryo-EM structure of hZnT7-Fab complex in zinc-unbound state, determined in heterogeneous conformations- one subunit in an inward-facing and the other in an outward-facing conformation
8J7T	;	2.2	;	Cryo-EM structure of hZnT7-Fab complex in zinc-unbound state, determined in outward-facing conformation
8J7Y	;	3.4	;	Cryo-EM structure of hZnT7DeltaHis-loop-Fab complex in zinc-bound state, determined in outward-facing conformation
8J7X	;	3.4	;	Cryo-EM structure of hZnT7DeltaHis-loop-Fab complex in zinc-unbound state, determined in outward-facing conformation
6PR5	;	3.3	;	Cryo-EM structure of HzTransib strand transfer complex (STC)
6PQR	;	3.4	;	Cryo-EM structure of HzTransib/intact TIR substrate DNA pre-reaction complex (PRC)
6PQX	;	4.6	;	Cryo-EM structure of HzTransib/nicked TIR substrate DNA hairpin forming complex (HFC)
6PQU	;	3.3	;	Cryo-EM structure of HzTransib/nicked TIR substrate DNA pre-reaction complex (PRC)
6PQY	;	4.2	;	Cryo-EM structure of HzTransib/TIR DNA transposon end complex (TEC)
8H2T	;	2.59	;	Cryo-EM structure of IadD/E dioxygenase bound with IAA
8Q63	;	3.68	;	Cryo-EM structure of IC8', a second state of yeast mitochondrial RNA polymerase transcription initiation complex with 8-mer RNA, pppGpGpUpApApApUpG
2WWA	;	8.9	;	Cryo-EM structure of idle yeast Ssh1 complex bound to the yeast 80S ribosome
7YRR	;	4.3	;	Cryo-EM structure of IGF1R with two IGF1 complex
6IDK	;	25.0	;	Cryo-EM structure of Immature Dengue virus serotype 3 in complex with human antibody 1H10 Fab at pH 5.0 (Class I particle)
6IDL	;	25.0	;	Cryo-EM structure of Immature Dengue virus serotype 3 in complex with human antibody 1H10 Fab at pH 5.0 (Class II particle)
6IDI	;	12.0	;	Cryo-EM structure of Immature Dengue virus serotype 3 in complex with human antibody 1H10 Fab at pH 8.0.
6ZQW	;	7.8	;	Cryo-EM structure of immature Spondweni virus
5U4W	;	9.1	;	Cryo-EM Structure of Immature Zika Virus
6LNU	;	9.0	;	Cryo-EM structure of immature Zika virus
6LNT	;	8.0	;	Cryo-EM structure of immature Zika virus in complex with human antibody DV62.5 Fab
8GCN	;	3.95	;	CRYO-EM STRUCTURE OF IMPORTIN ALPHA1/BETA HETERODIMER
8DYO	;	7.1	;	Cryo-EM structure of Importin-4 bound to RanGTP
8F7A	;	3.78	;	Cryo-EM structure of Importin-9 bound to RanGTP
6H5Q	;	3.3	;	Cryo-EM structure of in vitro assembled Measles virus N into nucleocapsid-like particles (NCLPs) bound to polyA RNA hexamers.
7YMN	;	3.46	;	Cryo-EM structure of in vitro PHF fibril
8C83	;	3.0	;	Cryo-EM structure of in vitro reconstituted Otu2-bound Ub-40S complex
8EAN	;	3.7	;	Cryo-EM structure of in-situ tailspike in bacteriophage P22
8J9O	;	3.4	;	Cryo-EM structure of inactive FZD1
7EPA	;	3.6	;	Cryo-EM structure of inactive mGlu2 homodimer
7EPD	;	3.9	;	Cryo-EM structure of inactive mGlu2-7 heterodimer
7WI8	;	4.17	;	Cryo-EM structure of inactive mGlu3 bound to LY341495
7EPC	;	4.0	;	Cryo-EM structure of inactive mGlu7 homodimer
8DIU	;	2.61	;	Cryo-EM structure of influenza A virus A/Bayern/7/1995 hemagglutinin bound to CR6261 Fab
6WXB	;	2.9	;	Cryo-EM Structure of Influenza Hemagglutinin (HA) Trimer Vitrified Using Back-it-up
8H69	;	3.7	;	Cryo-EM structure of influenza RNA polymerase
8SBD	;	3.2	;	Cryo-EM structure of insulin amyloid-like fibril that is composed of two antiparallel protofilaments
8DTM	;	3.5	;	Cryo-EM structure of insulin receptor (IR) bound with S597 component 2
8DTL	;	5.4	;	Cryo-EM structure of insulin receptor (IR) bound with S597 peptide
7TYM	;	3.4	;	Cryo-EM Structure of insulin receptor-related receptor (IRR) in active-state captured at pH 9. The 3D refinement was applied with C2 symmetry
7TYK	;	3.5	;	Cryo-EM Structure of insulin receptor-related receptor (IRR) in apo-state captured at pH 7. The 3D refinement was applied with C2 symmetry
7TYJ	;	3.3	;	Cryo-EM Structure of insulin receptor-related receptor (IRR) in apo-state captured at pH 7. The 3D refinement was focused on one of two halves with C1 symmetry applied
8IJ5	;	3.0	;	Cryo-EM structure of Integrin AVB3
7X3V	;	3.09	;	Cryo-EM structure of IOC3-N2 nucleosome
8HBD	;	2.99	;	Cryo-EM structure of IRL1620-bound ETBR-Gi complex
6VCD	;	3.0	;	Cryo-EM structure of IRP2-FBXL5-SKP1 complex
5K10	;	3.8	;	Cryo-EM structure of isocitrate dehydrogenase (IDH1)
5K11	;	3.8	;	Cryo-EM structure of isocitrate dehydrogenase (IDH1) in inhibitor-bound state
7EBF	;	2.63	;	Cryo-EM structure of Isocitrate lyase-1 from Candida albicans
7X3W	;	3.1	;	Cryo-EM structure of ISW1-N1 nucleosome
7X3T	;	5.4	;	Cryo-EM structure of ISW1a-dinucleosome
7KNS	;	2.77	;	Cryo-EM structure of jack bean urease
6T23	;	3.1	;	Cryo-EM structure of jasplakinolide-stabilized F-actin (aged)
6T24	;	3.7	;	Cryo-EM structure of jasplakinolide-stabilized F-actin (aged)
5OOC	;	3.6	;	Cryo-EM structure of jasplakinolide-stabilized F-actin in complex with ADP
5OOD	;	3.7	;	Cryo-EM structure of jasplakinolide-stabilized F-actin in complex with ADP-Pi
5OGW	;	3.8	;	Cryo-EM structure of jasplakinolide-stabilized malaria parasite F-actin at near-atomic resolution
7CN0	;	3.9	;	Cryo-EM structure of K+-bound hERG channel
7CN1	;	3.7	;	Cryo-EM structure of K+-bound hERG channel in the presence of astemizole
8JEK	;	2.7	;	Cryo-EM Structure of K-ferricyanide Oxidized Membrane-bound Fructose Dehydrogenase from Gluconobacter japonicus
6XIR	;	3.2	;	Cryo-EM Structure of K63 Ubiquitinated Yeast Translocating Ribosome under Oxidative Stress
6XIQ	;	4.2	;	Cryo-EM Structure of K63R Ubiquitin Mutant Ribosome under Oxidative Stress
8F19	;	3.49	;	Cryo-EM structure of Kap114 bound to Gsp1 (RanGTP)
8F1E	;	3.28	;	Cryo-EM structure of Kap114 bound to Gsp1 (RanGTP) and H2A-H2B
8F0X	;	3.21	;	Cryo-EM structure of Kap114 bound to H2A-H2B
8SGH	;	3.17	;	Cryo-EM structure of Karyopherin-beta2 bound to HNRNPH2 PY-NLS
8JKB	;	3.27	;	Cryo-EM structure of KCTD5 in complex with Gbeta gamma subunits
8I79	;	2.8	;	Cryo-EM structure of KCTD7 in complex with Cullin3
7BH1	;	3.38	;	Cryo-EM Structure of KdpFABC in E1 state with K
7LC6	;	3.7	;	Cryo-EM Structure of KdpFABC in E2-P state with BeF3
7BH2	;	3.0	;	Cryo-EM Structure of KdpFABC in E2Pi state with BeF3 and K+
7BGY	;	2.9	;	Cryo-EM Structure of KdpFABC in E2Pi state with MgF4
8K20	;	3.7	;	Cryo-EM structure of KEOPS complex from Arabidopsis thaliana
7RSQ	;	3.8	;	Cryo-EM structure of KIFBP core
7RYP	;	4.8	;	Cryo-EM structure of KIFBP:KIF15
7RS6	;	4.1	;	Cryo-EM structure of Kip3 (AMPPNP) bound to GMPCPP-Stabilized Microtubules
7RS5	;	3.9	;	Cryo-EM structure of Kip3 (AMPPNP) bound to Taxol-Stabilized Microtubules
7XY1	;	3.3	;	Cryo-EM structure of Klebsiella phage Kp9 type I tail fiber gp42 in vitro
8IBN	;	3.03	;	Cryo-EM structure of KpFtsZ single filament
8H1O	;	2.67	;	Cryo-EM structure of KpFtsZ-monobody double helical tube
7ZT6	;	3.5	;	Cryo-EM structure of Ku 70/80 bound to inositol hexakisphosphate
5YYS	;	4.2	;	Cryo-EM structure of L-fucokinase, GDP-fucose pyrophosphorylase (FKP)in Bacteroides fragilis
8EH5	;	3.36	;	Cryo-EM structure of L9 Fab in complex with rsCSP
6Z6G	;	3.06	;	Cryo-EM structure of La Crosse virus polymerase at pre-initiation stage
5K0Z	;	2.8	;	Cryo-EM structure of lactate dehydrogenase (LDH) in inhibitor-bound state
7ZYY	;	2.12	;	Cryo-EM structure of Lactococcus lactis pyruvate carboxylase with acetyl-CoA
7ZZ8	;	3.29	;	Cryo-EM structure of Lactococcus lactis pyruvate carboxylase with acetyl-CoA and cyclic di-AMP
5MBV	;	3.8	;	Cryo-EM structure of Lambda Phage protein GamS bound to RecBCD.
7PWG	;	2.75	;	Cryo-EM structure of large subunit of Giardia lamblia ribosome at 2.7 A resolution
6MUS	;	3.6	;	Cryo-EM structure of larger Csm-crRNA-target RNA ternary complex in type III-A CRISPR-Cas system
8IQ6	;	3.4	;	Cryo-EM structure of Latanoprost-bound prostaglandin-F2-alpha receptor-miniGq-Nb35 complex
7OI6	;	5.7	;	Cryo-EM structure of late human 39S mitoribosome assembly intermediates, state 1
7OI7	;	3.5	;	Cryo-EM structure of late human 39S mitoribosome assembly intermediates, state 2
7OI8	;	3.5	;	Cryo-EM structure of late human 39S mitoribosome assembly intermediates, state 3A
7OI9	;	3.3	;	Cryo-EM structure of late human 39S mitoribosome assembly intermediates, state 3B
7OIA	;	3.2	;	Cryo-EM structure of late human 39S mitoribosome assembly intermediates, state 3C
7OIB	;	3.3	;	Cryo-EM structure of late human 39S mitoribosome assembly intermediates, state 3D
7OIC	;	3.1	;	Cryo-EM structure of late human 39S mitoribosome assembly intermediates, state 4
7OID	;	3.7	;	Cryo-EM structure of late human 39S mitoribosome assembly intermediates, state 5A
7OIE	;	3.5	;	Cryo-EM structure of late human 39S mitoribosome assembly intermediates, state 5B
6N8J	;	3.5	;	Cryo-EM structure of late nuclear (LN) pre-60S ribosomal subunit
6P7M	;	3.0	;	Cryo-EM structure of LbCas12a-crRNA: AcrVA4 (1:2 complex)
6P7N	;	4.9	;	Cryo-EM structure of LbCas12a-crRNA: AcrVA4 (2:2 complex)
7QH2	;	2.43	;	Cryo-EM structure of Ldh-EtfAB complex from Acetobacterium woodii
8GUT	;	2.98	;	Cryo-EM structure of LEI-CB2-Gi complex
8A98	;	2.46	;	CRYO-EM STRUCTURE OF LEISHMANIA MAJOR 80S RIBOSOME : snoRNA MUTANT
8A3W	;	2.89	;	CRYO-EM STRUCTURE OF LEISHMANIA MAJOR 80S RIBOSOME : WILD TYPE
7WHR	;	3.4	;	Cryo-EM Structure of Leishmanial GDP-mannose pyrophosphorylase
7WHT	;	3.5	;	Cryo-EM Structure of Leishmanial GDP-mannose pyrophosphorylase in complex with GDP-Mannose
7WHS	;	3.1	;	Cryo-EM Structure of Leishmanial GDP-mannose pyrophosphorylase in complex with GTP
8HN8	;	3.0	;	Cryo-EM structure of ligand histamine-bound Histamine H4 receptor Gi complex
8HOC	;	3.0	;	Cryo-EM structure of ligand histamine-bound Histamine H4 receptor Gi complex
7LD0	;	3.1	;	Cryo-EM structure of ligand-free Human SARM1
7PBW	;	2.1	;	Cryo-EM structure of light harvesting complex 2 from Rba. sphaeroides.
8A5I	;	2.3	;	Cryo-EM structure of Lincomycin bound to the Listeria monocytogenes 50S ribosomal subunit.
6BAJ	;	3.2	;	Cryo-EM structure of lipid bilayer in the native cell membrane nanoparticles of AcrB
6MLU	;	4.0	;	Cryo-EM structure of lipid droplet formation protein Seipin/BSCL2
8A63	;	3.1	;	Cryo-EM structure of Listeria monocytogenes 50S ribosomal subunit.
7VLY	;	2.45	;	Cryo-EM structure of Listeria monocytogenes man-PTS complexed with pediocin PA-1
7XTG	;	2.2	;	Cryo-EM structure of Listeria monocytogenes man-PTS complexed with pediocin PA-1
7LPN	;	3.61	;	Cryo-EM structure of llama J3 VHH antibody in complex with HIV-1 Env BG505 DS-SOSIP.664
8U4B	;	3.9	;	Cryo-EM structure of long form insulin receptor (IR-B) in the apo state
8U4C	;	3.6	;	Cryo-EM structure of long form insulin receptor (IR-B) with four IGF2 bound, symmetric conformation.
8U4E	;	4.2	;	Cryo-EM structure of long form insulin receptor (IR-B) with three IGF2 bound, asymmetric conformation.
8IU2	;	3.35	;	Cryo-EM structure of Long-wave-sensitive opsin 1
7XV3	;	2.76	;	Cryo-EM structure of LPS-bound GPR174 in complex with Gs protein
6S8H	;	3.7	;	Cryo-EM structure of LptB2FG in complex with LPS
6S8G	;	3.5	;	Cryo-EM structure of LptB2FGC in complex with AMP-PNP
6S8N	;	3.1	;	Cryo-EM structure of LptB2FGC in complex with lipopolysaccharide
8EM7	;	2.97	;	Cryo-EM structure of LRP2 at pH 5.2
8EM4	;	2.83	;	Cryo-EM structure of LRP2 at pH 7.5
8U7H	;	3.8	;	Cryo-EM structure of LRRK2 bound to type I inhibitor GNE-7915
8FO7	;	3.52	;	Cryo-EM structure of LRRK2 bound to type I inhibitor LRRK2-IN-1
8U7L	;	3.6	;	Cryo-EM structure of LRRK2 bound to type II inhibitor GZD824
8U8A	;	3.4	;	Cryo-EM structure of LRRK2 bound to type II inhibitor ponatinib
8U8B	;	3.7	;	Cryo-EM structure of LRRK2 bound to type II inhibitor rebastinib
8SMC	;	4.02	;	Cryo-EM structure of LRRK2 bound with type-I inhibitor DNL201
6N8N	;	3.8	;	Cryo-EM structure of Lsg1-engaged (LE) pre-60S ribosomal subunit
7DMQ	;	3.06	;	Cryo-EM structure of LshCas13a-crRNA-anti-tag RNA complex
7VKT	;	2.9	;	cryo-EM structure of LTB4-bound BLT1 in complex with Gi protein
8F25	;	2.6	;	Cryo-EM structure of Lumazine synthase nanoparticle linked to VP8* antigen
7WIH	;	3.68	;	Cryo-EM structure of LY2794193-bound mGlu3
7WI6	;	3.71	;	Cryo-EM structure of LY341495/NAM-bound mGlu3
7EPB	;	3.1	;	Cryo-EM structure of LY354740-bound mGlu2 homodimer
8XOF	;	2.6	;	Cryo-EM structure of Lys05 bound GPR30-Gq complex structure
6VY2	;	4.86	;	Cryo-EM structure of M1214_N1 Fab in complex with CH505 TF chimeric SOSIP.664 Env trimer
7RAI	;	3.24	;	Cryo-EM structure of M4008_N1 Fab in complex with BG505 DS-SOSIP.664 Env trimer
7VH1	;	4.2	;	Cryo-EM structure of Machupo virus dimeric L-Z complex
7VH2	;	5.1	;	Cryo-EM structure of Machupo virus dimeric polymerase L
7VH3	;	3.6	;	Cryo-EM structure of Machupo virus polymerase L
7VGQ	;	4.0	;	Cryo-EM structure of Machupo virus polymerase L in complex with matrix protein Z
8UH4	;	3.72	;	Cryo-EM structure of Maize Streak Virus (MSV) - single head Geminivirus
7KVC	;	4.7	;	Cryo-EM structure of Mal de Rio Cuarto virus P9-1 viroplasm protein (decamer)
7KVD	;	6.8	;	Cryo-EM structure of Mal de Rio Cuarto virus P9-1 viroplasm protein (dodecamer)
8YBE	;	2.3	;	Cryo-EM structure of Maltose Binding Protein
5WPV	;	3.59	;	Cryo-EM structure of mammalian endolysosomal TRPML1 channel in nanodiscs at 3.59 Angstrom resolution
5WPQ	;	3.64	;	Cryo-EM structure of mammalian endolysosomal TRPML1 channel in nanodiscs in closed I conformation at 3.64 Angstrom resolution
5WPT	;	3.75	;	Cryo-EM structure of mammalian endolysosomal TRPML1 channel in nanodiscs in closed II conformation at 3.75 Angstrom resolution
5GUP	;	4.0	;	Cryo-EM structure of mammalian respiratory supercomplex I1III2IV1
6UKT	;	3.87	;	Cryo-EM structure of mammalian Ric-8A:Galpha(i):nanobody complex
7B7U	;	2.8	;	Cryo-EM structure of mammalian RNA polymerase II in complex with human RPAP2
7BZO	;	3.2	;	Cryo-EM structure of mature Coxsackievirus A10 at pH 5.5
7BZN	;	3.1	;	Cryo-EM structure of mature Coxsackievirus A10 at pH 7.4
7BZU	;	3.0	;	Cryo-EM structure of mature Coxsackievirus A10 in complex with KRM1 at pH 5.5
7BZT	;	3.0	;	Cryo-EM structure of mature Coxsackievirus A10 in complex with KRM1 at pH 7.4
6ZQU	;	3.1	;	Cryo-EM structure of mature Dengue virus 2 at 3.1 angstrom resolution
6ZQV	;	2.6	;	Cryo-EM structure of mature Spondweni virus
3J6C	;	9.6	;	Cryo-EM structure of MAVS CARD filament
7TB3	;	2.57	;	cryo-EM structure of MBP-KIX-apoferritin
7TBH	;	2.3	;	cryo-EM structure of MBP-KIX-apoferritin complex with peptide 7
7W8G	;	2.52	;	Cryo-EM structure of MCM double hexamer
7V3V	;	2.9	;	Cryo-EM structure of MCM double hexamer bound with DDK in State I
7V3U	;	3.2	;	Cryo-EM structure of MCM double hexamer with structured Mcm4-NSD
5BK4	;	3.9	;	Cryo-EM structure of Mcm2-7 double hexamer on dsDNA
7JL2	;	4.3	;	Cryo-EM structure of MDA5-dsRNA filament in complex with TRIM65 PSpry domain (Trimer)
7JL0	;	4.3	;	Cryo-EM structure of MDA5-dsRNA in complex with TRIM65 PSpry domain (Monomer)
7WZW	;	4.0	;	Cryo-EM structure of MEC1-DDC2-MMS
7WZR	;	4.7	;	Cryo-EM structure of Mec1-HU
6VYL	;	3.4	;	Cryo-EM structure of mechanosensitive channel MscS in PC-10 nanodiscs
6VYK	;	3.2	;	Cryo-EM structure of mechanosensitive channel MscS in PC-18:1 nanodiscs
6VYM	;	3.7	;	Cryo-EM structure of mechanosensitive channel MscS in PC-18:1 nanodiscs treated with beta-cyclodextran
6UZH	;	3.3	;	Cryo-EM structure of mechanosensitive channel MscS reconstituted into peptidiscs
7OJ5	;	2.4	;	Cryo-EM structure of Medicago truncatula HISN5 protein
8GY2	;	2.5	;	Cryo-EM Structure of Membrane-Bound Alcohol Dehydrogenase from Gluconobacter oxydans
8GY3	;	2.7	;	Cryo-EM Structure of Membrane-Bound Aldehyde Dehydrogenase from Gluconobacter oxydans
7W2J	;	3.6	;	Cryo-EM Structure of Membrane-bound Fructose Dehydrogenase from Gluconobacter japonicus
7WSQ	;	3.8	;	Cryo-EM Structure of Membrane-bound Fructose Dehydrogenase from Gluconobacter japonicus
7YN0	;	4.1	;	Cryo-EM structure of MERS-CoV spike protein, all RBD-down conformation
7YMZ	;	4.39	;	Cryo-EM structure of MERS-CoV spike protein, intermediate conformation
7YMY	;	4.96	;	Cryo-EM structure of MERS-CoV spike protein, One RBD-up conformation 1
7YMX	;	4.44	;	Cryo-EM structure of MERS-CoV spike protein, One RBD-up conformation 2
7YMW	;	6.05	;	Cryo-EM structure of MERS-CoV spike protein, One RBD-up conformation 4
7YMV	;	6.74	;	Cryo-EM structure of MERS-CoV spike protein, Two RBD-up conformation 1
7YMT	;	6.55	;	Cryo-EM structure of MERS-CoV spike protein, Two RBD-up conformation 2
7TC8	;	2.4	;	Cryo-EM structure of methane monooxygenase hydroxylase (by graphene)
7TC7	;	2.9	;	Cryo-EM structure of methane monooxygenase hydroxylase (by quantifoil)
5Z1L	;	4.0	;	Cryo-EM structure of Methanoccus maripaludis archaellum
8TFC	;	6.9	;	Cryo-EM structure of Methanosarcina mazie glutamine synthetase captured as partial oligomer
7N98	;	3.5	;	Cryo-EM structure of MFSD2A
8JCU	;	2.8	;	Cryo-EM structure of mGlu2-mGlu3 heterodimer in presence of LY341495 (dimerization mode I)
8JCV	;	3.4	;	Cryo-EM structure of mGlu2-mGlu3 heterodimer in presence of LY341495 (dimerization mode II)
8JCW	;	3.0	;	Cryo-EM structure of mGlu2-mGlu3 heterodimer in presence of LY341495 and NAM563 (dimerization mode I)
8JCX	;	3.0	;	Cryo-EM structure of mGlu2-mGlu3 heterodimer in presence of LY341495 and NAM563 (dimerization mode II)
8JCY	;	2.9	;	Cryo-EM structure of mGlu2-mGlu3 heterodimer in presence of LY341495, NAM563, and LY2389575 (dimerization mode I)
8JCZ	;	3.0	;	Cryo-EM structure of mGlu2-mGlu3 heterodimer in presence of LY341495, NAM563, and LY2389575 (dimerization mode III)
8JD0	;	3.3	;	Cryo-EM structure of mGlu2-mGlu3 heterodimer in presence of NAM563
8JD1	;	3.7	;	Cryo-EM structure of mGlu2-mGlu3 heterodimer in Rco state
6MLQ	;	4.2	;	Cryo-EM structure of microtubule-bound Kif7 in the ADP state
6MLR	;	4.2	;	Cryo-EM structure of microtubule-bound Kif7 in the AMPPNP state
6VPO	;	4.4	;	Cryo-EM structure of microtubule-bound KLP61F motor domain in the AMPPNP state
6VPP	;	4.4	;	Cryo-EM structure of microtubule-bound KLP61F motor with tail domain in the nucleotide-free state
8IEC	;	3.18	;	Cryo-EM structure of miniGo-scFv16 of GPR156-miniGo-scFv16 complex (local refine)
7MZ9	;	3.18	;	Cryo-EM structure of minimal TRPV1 with 1 partially bound RTX
7MZ6	;	2.91	;	Cryo-EM structure of minimal TRPV1 with 1 perturbed PI
7MZA	;	3.46	;	Cryo-EM structure of minimal TRPV1 with 2 bound RTX in adjacent pockets
7MZE	;	3.42	;	Cryo-EM structure of minimal TRPV1 with 2 bound RTX in opposite pockets
7MZB	;	3.72	;	Cryo-EM structure of minimal TRPV1 with 3 bound RTX and 1 perturbed PI
7MZ7	;	3.35	;	Cryo-EM structure of minimal TRPV1 with 4 partially bound RTX
7MZC	;	3.03	;	Cryo-EM structure of minimal TRPV1 with RTX bound in C1 state
7MZD	;	2.9	;	Cryo-EM structure of minimal TRPV1 with RTX bound in C2 state
8T21	;	3.6	;	Cryo-EM structure of mink variant Y453F trimeric spike protein
8TAZ	;	3.75	;	Cryo-EM structure of mink variant Y453F trimeric spike protein bound to one mink ACE2 receptors
8T22	;	3.83	;	Cryo-EM structure of mink variant Y453F trimeric spike protein bound to one mink ACE2 receptors at downRBD conformation
8T20	;	3.36	;	Cryo-EM structure of mink variant Y453F trimeric spike protein bound to two mink ACE2 receptors
6WDO	;	3.6	;	Cryo-EM structure of mitochondrial calcium uniporter holocomplex in high Ca2+
6WDN	;	3.2	;	Cryo-EM structure of mitochondrial calcium uniporter holocomplex in low Ca2+
7B93	;	3.04	;	Cryo-EM structure of mitochondrial complex I from Mus musculus inhibited by IACS-2858 at 3.0 A
7U5I	;	3.26	;	Cryo-EM Structure of Mitochondrial Creatine Kinase
8JZ7	;	2.6	;	Cryo-EM structure of MK-6892-bound HCAR2 in complex with Gi protein
6ZY4	;	4.1	;	Cryo-EM structure of MlaFEDB in complex with ADP
6ZY9	;	3.3	;	Cryo-EM structure of MlaFEDB in complex with AMP-PNP
6ZY3	;	3.3	;	Cryo-EM structure of MlaFEDB in complex with phospholipid
6XBD	;	3.05	;	Cryo-EM structure of MlaFEDB in nanodiscs with phospholipid substrates
8B9L	;	3.45	;	Cryo-EM structure of MLE
8B9J	;	3.45	;	Cryo-EM structure of MLE in complex with ADP:AlF4
8B9K	;	4.04	;	Cryo-EM structure of MLE in complex with ADP:AlF4 and SL7modUUC RNA
8B9G	;	2.86	;	Cryo-EM structure of MLE in complex with ADP:AlF4 and U10 RNA
8B9I	;	2.95	;	Cryo-EM structure of MLE in complex with ADP:AlF4 and UUC RNA
8PJJ	;	4.24	;	Cryo-EM structure of MLE in complex with SL7UUC RNA and ADP
8PJB	;	3.62	;	Cryo-EM structure of MLE in complex with UUC RNA and ADP
6PWV	;	6.2	;	Cryo-EM structure of MLL1 core complex bound to the nucleosome
6PWW	;	4.4	;	Cryo-EM structure of MLL1 in complex with RbBP5 and WDR5 bound to the nucleosome
6W5I	;	6.9	;	Cryo-EM structure of MLL1 in complex with RbBP5, WDR5, SET1, and ASH2L bound to the nucleosome (Class01)
6W5M	;	4.6	;	Cryo-EM structure of MLL1 in complex with RbBP5, WDR5, SET1, and ASH2L bound to the nucleosome (Class02)
6W5N	;	6.0	;	Cryo-EM structure of MLL1 in complex with RbBP5, WDR5, SET1, and ASH2L bound to the nucleosome (Class05)
7MBM	;		;	Cryo-EM structure of MLL1-NCP (H3K4M) complex, mode01
7MBN	;		;	Cryo-EM structure of MLL1-NCP (H3K4M) complex, mode02
8JIM	;	2.98	;	Cryo-EM structure of MMF bound ketone body receptor HCAR2-Gi signaling complex
8QKK	;	3.23	;	Cryo-EM structure of MmpL3 from Mycobacterium smegmatis reconstituted into peptidiscs
8HOY	;	2.76	;	Cryo-EM structure of monkeypox virus DNA replication holoenzyme F8, A22 and E4 complex without DNA at 2.76 angostram
8IFK	;	2.54	;	Cryo-EM structure of monomeric SPARTA gRNA-ssDNA target complex
7RTV	;	3.96	;	Cryo-EM structure of monomeric TTYH2
6RW9	;	3.27	;	Cryo-EM structure of Morganella morganii TcdA4
7SQ6	;	2.32	;	Cryo-EM structure of mouse agonist ML-SA1-bound TRPML1 channel at 2.32 Angstrom resolution
7SQ8	;	2.598	;	Cryo-EM structure of mouse apo TRPML1 channel at 2.598 Angstrom resolution
8IVQ	;	3.6	;	Cryo-EM structure of mouse BIRC6, Global map
6RZB	;	4.1	;	Cryo-EM structure of mouse cytoplasmic dynein-1 microtubule binding domain bound to microtubules
8AVG	;	4.01	;	Cryo-EM structure of mouse Elp123 with bound SAM
8RQB	;	1.09	;	Cryo-EM structure of mouse heavy-chain apoferritin
7A4M	;	1.22	;	Cryo-EM structure of mouse heavy-chain apoferritin at 1.22 A
8BK9	;	2.1	;	Cryo-EM structure of mouse heavy-chain apoferritin at 2.1 A plunged 5ms after mixing with b-galactosidase
8BKB	;	2.2	;	Cryo-EM structure of mouse heavy-chain apoferritin at 2.2 A plunged 205ms after mixing with b-galactosidase
8BKA	;	2.7	;	Cryo-EM structure of mouse heavy-chain apoferritin at 2.7 A plunged 35ms after mixing with b-galactosidase
7VTQ	;	3.55	;	Cryo-EM structure of mouse NLRP3 (full-length) dodecamer
8A3B	;	3.1	;	Cryo-EM structure of mouse Pannexin 1 purified in Salipro nanoparticles
7SQ7	;	2.41	;	Cryo-EM structure of mouse PI(3,5)P2-bound TRPML1 channel at 2.41 Angstrom resolution
8IMZ	;	3.66	;	Cryo-EM structure of mouse Piezo1-MDFIC complex (composite map)
8DJA	;	3.92	;	Cryo-EM structure of mouse PrP23-144 amyloid fibrils (polymorph 1)
6OEP	;	3.7	;	Cryo-EM structure of mouse RAG1/2 12RSS-NFC/23RSS-PRC complex (DNA1)
6OEQ	;	4.3	;	Cryo-EM structure of mouse RAG1/2 12RSS-PRC/23RSS-NFC complex (DNA1)
6CG0	;	3.17	;	Cryo-EM structure of mouse RAG1/2 HFC complex (3.17 A)
6CIJ	;	3.9	;	Cryo-EM structure of mouse RAG1/2 HFC complex containing partial HMGB1 linker(3.9 A)
6OEO	;	3.69	;	Cryo-EM structure of mouse RAG1/2 NFC complex (DNA1)
6OER	;	3.29	;	Cryo-EM structure of mouse RAG1/2 NFC complex (DNA2)
6OEM	;	3.6	;	Cryo-EM structure of mouse RAG1/2 PRC complex (DNA0)
6OEN	;	4.3	;	Cryo-EM structure of mouse RAG1/2 PRC complex (DNA1)
6OET	;	3.4	;	Cryo-EM structure of mouse RAG1/2 STC complex
6OES	;	3.06	;	Cryo-EM structure of mouse RAG1/2 STC complex (without NBD domain)
7SQ9	;	2.11	;	Cryo-EM structure of mouse temsirolimus/PI(3,5)P2-bound TRPML1 channel at 2.11 Angstrom resolution
7C77	;	3.3	;	Cryo-EM structure of mouse TLR3 in complex with UNC93B1
6C96	;	3.4	;	Cryo-EM structure of mouse TPC1 channel in the apo state
6C9A	;	3.2	;	Cryo-EM structure of mouse TPC1 channel in the PtdIns(3,5)P2-bound state
6DVW	;	4.3	;	Cryo-EM structure of mouse TRPV3
6PVL	;	4.4	;	Cryo-EM structure of mouse TRPV3 in closed state at 42 degrees Celsius
6DVY	;	4.0	;	Cryo-EM structure of mouse TRPV3 in complex with 2-Aminoethoxydiphenyl borate (2-APB)
6PVM	;	4.5	;	Cryo-EM structure of mouse TRPV3 in putative sensitized state at 42 degrees Celsius
6DVZ	;	4.24	;	Cryo-EM structure of mouse TRPV3-Y564A in complex with 2-Aminoethoxydiphenyl borate (2-APB)
6PVQ	;	4.75	;	Cryo-EM structure of mouse TRPV3-Y564A in intermediate state at 37 degrees Celsius
6PVP	;	4.48	;	Cryo-EM structure of mouse TRPV3-Y564A in open state at 37 degrees Celsius
6PVO	;	5.18	;	Cryo-EM structure of mouse TRPV3-Y564A in putative sensitized state at 37 degrees Celsius
6PVN	;	4.07	;	Cryo-EM structure of mouse TRPV3-Y564A in putative sensitized state at 4 degrees Celsius
6V0V	;	3.61	;	Cryo-EM structure of mouse WT RAG1/2 NFC complex (DNA0)
8HXC	;	3.12	;	Cryo-EM structure of MPXV M2 heptamer in complex with human B7.2
8HXB	;	2.7	;	Cryo-EM structure of MPXV M2 hexamer in complex with human B7.2
8HXA	;	3.04	;	Cryo-EM structure of MPXV M2 in complex with human B7.1
7Y12	;	3.1	;	Cryo-EM structure of MrgD-Gi complex with beta-alanine
7Y14	;	3.2	;	Cryo-EM structure of MrgD-Gi complex with beta-alanine (local)
5TTP	;	4.8	;	Cryo-EM structure of MsbA-nanodisc with ADP-vanadate
5Y4O	;	3.8	;	Cryo-EM structure of MscS channel, YnaI
8CT4	;	2.17	;	Cryo-EM structure of Mtb Lpd bound to inhibitor complex with 2-((2-cyano-N,5-dimethyl-1H-indole)-7-sulfonamido)-N-(4-(oxetan-3-yl)-3,4-dihydro-2H-benzo[b] [1,4]oxazin-7-yl)acetamide
7XM1	;	3.96	;	Cryo-EM structure of mTIP60-Ba (metal-ion induced TIP60 (K67E) complex with barium ions
5H64	;	4.4	;	Cryo-EM structure of mTORC1
6SB2	;	6.2	;	cryo-EM structure of mTORC1 bound to active RagA/C GTPases
6SB0	;	5.5	;	cryo-EM structure of mTORC1 bound to PRAS40-fused active RagA/C GTPases
6IZL	;	3.3	;	Cryo-EM structure of Mud crab tombus-like virus at 3.3 Angstroms resolution
6IOK	;	3.64	;	Cryo-EM structure of multidrug efflux pump MexAB-OprM (0 degree state)
6IOL	;	3.76	;	Cryo-EM structure of multidrug efflux pump MexAB-OprM (60 degree state)
6DSO	;	3.0	;	Cryo-EM structure of murine AA amyloid fibril
7RPH	;	2.5	;	Cryo-EM structure of murine Dispatched 'R' conformation
7RPI	;	2.5	;	Cryo-EM structure of murine Dispatched 'T' conformation
7RPK	;	2.7	;	Cryo-EM structure of murine Dispatched in complex with Sonic hedgehog
7RPJ	;	3.2	;	Cryo-EM structure of murine Dispatched NNN mutant
6S6L	;	3.1	;	Cryo-EM structure of murine norovirus (MNV-1)
6IUK	;	3.5	;	Cryo-EM structure of Murine Norovirus capsid
8U18	;	3.6	;	Cryo-EM structure of murine Thrombopoietin receptor ectodomain in complex with Tpo
6DZI	;	3.46	;	Cryo-EM Structure of Mycobacterium smegmatis 70S C(minus) ribosome 70S-MPY complex
7BVG	;	3.1	;	Cryo-EM structure of Mycobacterium smegmatis arabinosyltransferase EmbA-EmbB-AcpM2 in complex with di-arabinose.
7BVC	;	2.9	;	Cryo-EM structure of Mycobacterium smegmatis arabinosyltransferase EmbA-EmbB-AcpM2 in complex with ethambutol
7BVE	;	2.81	;	Cryo-EM structure of Mycobacterium smegmatis arabinosyltransferase EmbC2-AcpM2 in complex with ethambutol
6DZK	;	3.6	;	Cryo-EM Structure of Mycobacterium smegmatis C(minus) 30S ribosomal subunit with MPY
6DZP	;	3.42	;	Cryo-EM Structure of Mycobacterium smegmatis C(minus) 50S ribosomal subunit
7LHL	;	3.6	;	cryo-EM structure of Mycobacterium smegmatis Lhr helicase C-terminal domain
7WNX	;	3.36	;	Cryo-EM structure of Mycobacterium smegmatis MmpL3 complexed with ST004 in lipid nanodiscs
7F0D	;	3.3	;	Cryo-EM structure of Mycobacterium tuberculosis 50S ribosome subunit bound with clarithromycin
8IGQ	;	5.7	;	Cryo-EM structure of Mycobacterium tuberculosis ADP bound FtsEX/RipC complex in peptidisc
7BVF	;	2.97	;	Cryo-EM structure of Mycobacterium tuberculosis arabinosyltransferase EmbA-EmbB-AcpM2 in complex with ethambutol
8JIA	;	3.9	;	Cryo-EM structure of Mycobacterium tuberculosis ATP bound FtsE(E165Q)X/RipC complex in peptidisc
8IDD	;	4.0	;	Cryo-EM structure of Mycobacterium tuberculosis ATP bound FtsEX/RipC complex in peptidisc
7PHM	;	2.2	;	Cryo-EM structure of Mycobacterium tuberculosis encapsulin
8IDB	;	3.9	;	Cryo-EM structure of Mycobacterium tuberculosis FtsEX complex in peptidisc
8IDC	;	3.9	;	Cryo-EM structure of Mycobacterium tuberculosis FtsEX/RipC complex in peptidisc
7WIW	;	3.12	;	Cryo-EM structure of Mycobacterium tuberculosis irtAB complexed with ATP in an occluded conformation
7WIX	;	3.53	;	Cryo-EM structure of Mycobacterium tuberculosis irtAB in complex with ADP
7WIV	;	2.88	;	Cryo-EM structure of Mycobacterium tuberculosis irtAB in complex with an AMP-PNP
7WIU	;	3.48	;	Cryo-EM structure of Mycobacterium tuberculosis irtAB in inward-facing state
8JA7	;	3.02	;	Cryo-EM structure of Mycobacterium tuberculosis LpqY-SugABC in complex with trehalose
8J5T	;	2.98	;	Cryo-EM structure of Mycobacterium tuberculosis OppABCD in the catalytic intermediate state
8J5S	;	3.0	;	Cryo-EM structure of Mycobacterium tuberculosis OppABCD in the pre-catalytic intermediate state
8J5Q	;	3.25	;	Cryo-EM structure of Mycobacterium tuberculosis OppABCD in the pre-translocation state
8J5R	;	3.28	;	Cryo-EM structure of Mycobacterium tuberculosis OppABCD in the resting state
7Z8Q	;	4.08	;	Cryo-EM structure of Mycobacterium tuberculosis RNA polymerase core
7PP4	;	3.84	;	Cryo-EM structure of Mycobacterium tuberculosis RNA polymerase holoenzyme comprising sigma factor SigB
7Q59	;	4.36	;	Cryo-EM structure of Mycobacterium tuberculosis RNA polymerase holoenzyme dimer comprising sigma factor SigB
7Q4U	;	4.39	;	Cryo-EM structure of Mycobacterium tuberculosis RNA polymerase holoenzyme octamer comprising sigma factor SigB
8HIH	;	3.66	;	Cryo-EM structure of Mycobacterium tuberculosis transcription initiation complex with transcription factor GlnR
8W41	;	3.54	;	Cryo-EM structure of Myosin VI in the autoinhibited state
8E2G	;	2.99	;	Cryo-EM structure of N-terminal arm (aa68-966) of BIRC6 (from local refinement 3)
8E2F	;	2.47	;	Cryo-EM structure of N-terminal arm of BIRC6 (from local refinement 2)
7WBJ	;	3.42	;	Cryo-EM structure of N-terminal modified human vasoactive intestinal polypeptide receptor 2 (VIP2R) in complex with PACAP27 and Gs
7OMM	;	3.4	;	Cryo-EM structure of N. gonorhoeae LptDE in complex with ProMacrobodies (MBPs have not been built de novo)
7X3X	;	3.2	;	Cryo-EM structure of N1 nucleosome-RA
8K1L	;	3.44	;	Cryo-EM structure of Na+,K+-ATPase alpha2 from Artemia salina in cation-free E2P form
8JFZ	;	3.5	;	Cryo-EM structure of Na+,K+-ATPase in the E1.Mg2+ state.
7WYU	;	3.4	;	Cryo-EM structure of Na+,K+-ATPase in the E2P state formed by ATP
7WYV	;	3.7	;	Cryo-EM structure of Na+,K+-ATPase in the E2P state formed by ATP in the presence of 40 mM Mg2+
7WYX	;	3.4	;	Cryo-EM structure of Na+,K+-ATPase in the E2P state formed by ATP with istaroxime
7WYZ	;	3.4	;	Cryo-EM structure of Na+,K+-ATPase in the E2P state formed by ATP with ouabain
7WYW	;	3.8	;	Cryo-EM structure of Na+,K+-ATPase in the E2P state formed by inorganic phosphate
7WYY	;	3.9	;	Cryo-EM structure of Na+,K+-ATPase in the E2P state formed by inorganic phosphate with istaroxime
7WZ0	;	3.0	;	Cryo-EM structure of Na+,K+-ATPase in the E2P state formed by inorganic phosphate with ouabain
7XK3	;	3.1	;	Cryo-EM structure of Na+-pumping NADH-ubiquinone oxidoreductase from Vibrio cholerae, state 1
7XK4	;	3.1	;	Cryo-EM structure of Na+-pumping NADH-ubiquinone oxidoreductase from Vibrio cholerae, state 2
7XK5	;	3.1	;	Cryo-EM structure of Na+-pumping NADH-ubiquinone oxidoreductase from Vibrio cholerae, state 3
7XK6	;	3.0	;	Cryo-EM structure of Na+-pumping NADH-ubiquinone oxidoreductase from Vibrio cholerae, with aurachin D-42
7XK7	;	2.9	;	Cryo-EM structure of Na+-pumping NADH-ubiquinone oxidoreductase from Vibrio cholerae, with korormicin
8JEJ	;	2.5	;	Cryo-EM Structure of Na-dithionite Reduced Membrane-bound Fructose Dehydrogenase from Gluconobacter japonicus
8C54	;	2.52	;	Cryo-EM structure of NADH bound SLA dehydrogenase RlGabD from Rhizobium leguminosarum bv. trifolii SRD1565
6TG9	;	3.24	;	Cryo-EM Structure of NADH reduced form of NAD+-dependent Formate Dehydrogenase from Rhodobacter capsulatus
8B6F	;	2.8	;	Cryo-EM structure of NADH:ubiquinone oxidoreductase (complex-I) from respiratory supercomplex of Tetrahymena thermophila
8I41	;	3.42	;	Cryo-EM structure of nanodisc (asolectin) reconstituted GLIC at pH 7.5
8I42	;	2.92	;	Cryo-EM structure of nanodisc (PE:PS:PC) reconstituted GLIC at pH 7.5
7RRA	;	4.4	;	Cryo-EM Structure of Nanodisc reconstituted ABCD1 in inward open conformation
7RR9	;	3.5	;	Cryo-EM Structure of Nanodisc reconstituted ABCD1 in nucleotide bound outward open conformation
8EOP	;	3.7	;	Cryo-EM Structure of Nanodisc reconstituted human ABCA7 EQ mutant in ATP bound closed state
6SNI	;	3.0	;	Cryo-EM structure of nanodisc reconstituted yeast ALG6 in complex with 6AG9 Fab
7TDT	;	4.0	;	Cryo-EM structure of nanodisc-embedded human ABCA1
8BWO	;	3.2	;	Cryo-EM structure of nanodisc-reconstituted human MRP4 with E1202Q mutation (outward-facing occluded conformation)
8BWP	;	3.6	;	Cryo-EM structure of nanodisc-reconstituted wildtype human MRP4 (in complex with methotrexate)
8BWR	;	4.0	;	Cryo-EM structure of nanodisc-reconstituted wildtype human MRP4 (in complex with prostaglandin E2)
8BWQ	;	3.9	;	Cryo-EM structure of nanodisc-reconstituted wildtype human MRP4 (in complex with topotecan)
8BJF	;	3.0	;	Cryo-EM structure of nanodisc-reconstituted wildtype human MRP4 (inward-facing conformation)
8WU4	;	3.3	;	Cryo-EM structure of native H. thermoluteolus TH-1 GroEL
7Q5Z	;	3.25	;	Cryo-EM structure of native human A2ML1
8WA2	;	3.0	;	cryo-EM structure of native mastigonemes isolated from Chlamydomonas reinhardtii at 3.0 angstrom resolution
8FJP	;	3.3	;	Cryo-EM structure of native mosquito salivary gland surface protein 1 (SGS1)
8CAH	;	3.0	;	Cryo-EM structure of native Otu2-bound ubiquitinated 43S pre-initiation complex
8CAS	;	3.3	;	Cryo-EM structure of native Otu2-bound ubiquitinated 48S initiation complex (partial)
8R2I	;	2.9	;	Cryo-EM Structure of native Photosystem II assembly intermediate from Chlamydomonas reinhardtii
8HJU	;	2.8	;	Cryo-EM structure of native RC-LH complex from Roseiflexus castenholzii at 10,000 lux
8J5O	;	2.9	;	Cryo-EM structure of native RC-LH complex from Roseiflexus castenholzii at 100lux
8J5P	;	3.1	;	Cryo-EM structure of native RC-LH complex from Roseiflexus castenholzii at 2,000lux
8GI2	;	3.0	;	Cryo-EM structure of Natrinema sp. J7-2 Type IV pilus
7EG4	;	3.2	;	Cryo-EM structure of nauclefine-induced PDE3A-SLFN12 complex
8G1A	;	2.8	;	Cryo-EM structure of Nav1.7 with CBD
8S9C	;	3.2	;	Cryo-EM structure of Nav1.7 with CBZ
8S9B	;	2.9	;	Cryo-EM structure of Nav1.7 with LCM
8THH	;	2.7	;	Cryo-EM structure of Nav1.7 with LTG
8THG	;	2.9	;	Cryo-EM structure of Nav1.7 with RLZ
7YMH	;	3.52	;	Cryo-EM structure of Nb29-alpha1AAR-miniGsq complex bound to noradrenaline
7YM8	;	2.92	;	Cryo-EM structure of Nb29-alpha1AAR-miniGsq complex bound to oxymetazoline
6R93	;	4.0	;	Cryo-EM structure of NCP-6-4PP
6R8Y	;	4.3	;	Cryo-EM structure of NCP-6-4PP(-1)-UV-DDB
6R90	;	4.5	;	Cryo-EM structure of NCP-THF2(+1)-UV-DDB class A
6R92	;	4.8	;	Cryo-EM structure of NCP-THF2(+1)-UV-DDB class B
6R8Z	;	3.9	;	Cryo-EM structure of NCP_THF2(-1)-UV-DDB
6R94	;	3.5	;	Cryo-EM structure of NCP_THF2(-3)
6R91	;	4.1	;	Cryo-EM structure of NCP_THF2(-3)-UV-DDB
7AK6	;	3.82	;	Cryo-EM structure of ND6-P25L mutant respiratory complex I from Mus musculus at 3.8 A
8WQG	;	4.09	;	cryo-EM structure of neddylated CUL2-RBX1-ELOB-ELOC-FEM1B bound with the C-degron of CCDC89 (conformation 1)
8WQH	;	3.44	;	cryo-EM structure of neddylated CUL2-RBX1-ELOB-ELOC-FEM1B bound with the C-degron of CCDC89 (conformation 2)
8WQC	;	3.54	;	cryo-EM structure of neddylated CUL2-RBX1-ELOB-ELOC-FEM1B bound with the C-degron of CDK5R1
8JE2	;	3.63	;	Cryo-EM structure of neddylated Cul2-Rbx1-EloBC-FEM1B complexed with FNIP1-FLCN
7X9A	;	3.2	;	Cryo-EM structure of neuropeptide Y Y1 receptor in complex with NPY and Gi
7X9B	;	3.4	;	Cryo-EM structure of neuropeptide Y Y2 receptor in complex with NPY and Gi
7X9C	;	3.0	;	Cryo-EM structure of neuropeptide Y Y4 receptor in complex with PP and Gi
7LS9	;	3.42	;	Cryo-EM structure of neutralizing antibody 1-57 in complex with prefusion SARS-CoV-2 spike glycoprotein
7NFC	;	4.14	;	Cryo-EM structure of NHEJ super-complex (dimer)
7NFE	;	4.29	;	Cryo-EM structure of NHEJ super-complex (monomer)
8BOT	;	7.76	;	Cryo-EM structure of NHEJ supercomplex(trimer)
8K5B	;	3.43	;	Cryo-EM structure of niacin bound human hydroxy-carboxylic acid receptor 2 (Local refinement)
8H2G	;	3.01	;	Cryo-EM structure of niacin bound human hydroxy-carboxylic acid receptor 2 in complex with Gi heterotrimer
8JIL	;	3.5	;	Cryo-EM structure of niacin bound ketone body receptor HCAR2-Gi signaling complex
8SZA	;	2.75	;	Cryo-EM Structure of NINJ1 Filament at 2.75 Angstrom Resolution
8SZB	;	3.07	;	Cryo-EM Structure of NINJ2 Filament at 3.07 Angstrom Resolution
6NPL	;	2.9	;	Cryo-EM structure of NKCC1
8STE	;	3.34	;	Cryo-EM structure of NKCC1 Fu_CTD
8FML	;	2.93	;	Cryo-EM structure of NLR family apoptosis inhibitory protein 5 (NAIP5) in complex with a full-length flagellin (FliC) ligand
6MKS	;	3.4	;	Cryo-EM structure of NLRC4-CARD filament
6N1I	;	3.58	;	Cryo-EM structure of NLRC4-CARD filament
6X6A	;	3.6	;	Cryo-EM structure of NLRP1-DPP9 complex
6X6C	;	2.9	;	Cryo-EM structure of NLRP1-DPP9-VbP complex
6NPY	;	3.8	;	Cryo-EM structure of NLRP3 bound to NEK7
8SWK	;	4.32	;	Cryo-EM structure of NLRP3 closed hexamer
7LFH	;	4.2	;	Cryo-EM structure of NLRP3 double-ring cage, 6-fold (12-mer)
8SWF	;	3.39	;	Cryo-EM structure of NLRP3 open octamer
6NCV	;	3.7	;	Cryo-EM structure of NLRP6 PYD filament
7Z2H	;	3.58	;	Cryo-EM structure of NNRTI resistant M184I/E138K mutant HIV-1 reverse transcriptase with a DNA aptamer in complex with doravirine
7Z29	;	3.38	;	Cryo-EM structure of NNRTI resistant M184I/E138K mutant HIV-1 reverse transcriptase with a DNA aptamer in complex with nevirapine
7Z2E	;	3.45	;	Cryo-EM structure of NNRTI resistant M184I/E138K mutant HIV-1 reverse transcriptase with a DNA aptamer in complex with rilpivirine
7X21	;	2.8	;	Cryo-EM structure of non gastric H,K-ATPase alpha2 K794A in (K+)E2-AlF state
7X22	;	3.0	;	Cryo-EM structure of non gastric H,K-ATPase alpha2 K794S in (2K+)E2-AlF state
7X24	;	3.4	;	Cryo-EM structure of non gastric H,K-ATPase alpha2 SPWC mutant in (2K+)E2-AlF state
7X23	;	3.2	;	Cryo-EM structure of non gastric H,K-ATPase alpha2 SPWC mutant in 3Na+E1-AMPPCPF state
7OSL	;	3.1	;	Cryo-EM structure of nonameric EPEC SctV-C
8DNH	;	2.99	;	Cryo-EM structure of nonmuscle beta-actin
8DNF	;	3.38	;	Cryo-EM structure of nonmuscle gamma-actin
8PKI	;	2.58	;	Cryo-EM structure of NR5A2-nucleosome complex SHL+5.5
7YMD	;	4.176	;	Cryo-EM structure of Nse1/3/4
7SDE	;	3.2	;	Cryo-EM structure of Nse5/6 heterodimer
7L2D	;	3.55	;	Cryo-EM structure of NTD-directed neutralizing antibody 1-87 in complex with prefusion SARS-CoV-2 spike glycoprotein
7LQW	;	4.47	;	Cryo-EM structure of NTD-directed neutralizing antibody 2-17 Fab in complex with SARS-CoV-2 S2P spike
7L2E	;	2.97	;	Cryo-EM structure of NTD-directed neutralizing antibody 4-18 in complex with prefusion SARS-CoV-2 spike glycoprotein
7LQV	;	3.25	;	Cryo-EM structure of NTD-directed neutralizing antibody 4-8 Fab in complex with SARS-CoV-2 S2P spike
7L2F	;	3.9	;	Cryo-EM structure of NTD-directed neutralizing antibody 5-24 in complex with prefusion SARS-CoV-2 spike glycoprotein
7RW2	;	3.5	;	Cryo-EM structure of NTD-directed neutralizing antibody 5-7 in complex with prefusion SARS-CoV-2 spike glycoprotein
7MXP	;	4.46	;	Cryo-EM structure of NTD-directed neutralizing antibody LP5 Fab in complex with SARS-CoV-2 S2P spike
8CSJ	;	3.53	;	Cryo-EM structure of NTD-directed non-neutralizing antibody 4-33 in complex with prefusion SARS-CoV-2 spike glycoprotein
8JPB	;	3.07	;	cryo-EM structure of NTSR1-GRK2-Galpha(q) complexes 1
8JPC	;	3.07	;	cryo-EM structure of NTSR1-GRK2-Galpha(q) complexes 2
7M1X	;	3.7	;	Cryo-EM Structure of Nucleosome containing mouse histone variant H2A.Z
6PWE	;	3.95	;	Cryo-EM structure of nucleosome core particle
7OHC	;	2.5	;	Cryo-EM structure of nucleosome core particle composed of the Widom 601 DNA sequence
6DZT	;	2.99	;	Cryo-EM structure of nucleosome in complex with a single chain antibody fragment
7W9V	;	3.95	;	Cryo-EM structure of nucleosome in complex with p300 acetyltransferase catalytic core (complex I)
8HF4	;	2.8	;	Cryo-EM structure of nucleotide-bound ComA at outward-facing state with EC gate closed conformation
8HF5	;	2.9	;	Cryo-EM structure of nucleotide-bound ComA at outward-facing state with EC gate open conformation
8HF6	;	3.1	;	Cryo-EM structure of nucleotide-bound ComA E647Q mutant
8K7A	;	4.2	;	Cryo-EM structure of nucleotide-bound ComA E647Q mutant with Mg2+
8K4B	;	3.9	;	Cryo-EM structure of nucleotide-bound ComA with ZinC ion
7W01	;	3.3	;	Cryo-EM structure of nucleotide-free ABCA3
6UZ2	;	4.2	;	Cryo-EM structure of nucleotide-free MsbA reconstituted into peptidiscs, conformation 1
6UZL	;	4.4	;	Cryo-EM structure of nucleotide-free MsbA reconstituted into peptidiscs, conformation 2
6XE0	;	6.8	;	Cryo-EM structure of NusG-CTD bound to 70S ribosome (30S: NusG-CTD fragment)
7XOP	;	3.2	;	Cryo-EM structure of occupied ring subunit 1 (OR1) of GroEL from GroEL-UGT1A double occupied ring complex
7XOQ	;	3.3	;	Cryo-EM structure of occupied ring subunit 2 (OR2) of GroEL from GroEL-UGT1A double occupied ring complex
7XOR	;	3.3	;	Cryo-EM structure of occupied ring subunit 3 (OR3) of GroEL from GroEL-UGT1A double occupied ring complex
7XOM	;	3.2	;	Cryo-EM structure of occupied ring subunit 4 (OR4) of GroEL complexed with polyalanine model of UGT1A from GroEL-UGT1A double occupied ring complex
7XOS	;	3.2	;	Cryo-EM structure of occupied ring subunit 4 (OR4) of GroEL from GroEL-UGT1A double occupied ring complex
8IHQ	;	2.71	;	Cryo-EM structure of ochratoxin A-detoxifying amidohydrolase ADH3
8IHS	;	2.5	;	Cryo-EM structure of ochratoxin A-detoxifying amidohydrolase ADH3 in complex with ochratoxin A
8IHR	;	2.5	;	Cryo-EM structure of ochratoxin A-detoxifying amidohydrolase ADH3 in complex with Phe
8J85	;	2.7	;	Cryo-EM structure of ochratoxin A-detoxifying amidohydrolase ADH3 mutant S88E in complex with ochratoxin A
6XHI	;	4.19	;	Cryo-EM structure of octadecameric TF55 (beta-only) complex from S. solfataricus bound to ADP
6XHJ	;	3.62	;	Cryo-EM structure of octadecameric TF55 (beta-only) complex from S. solfataricus bound to ATP
6VAM	;	3.63	;	Cryo-EM structure of octameric chicken CALHM1
8GMR	;	3.76	;	Cryo-EM structure of octameric human CALHM1
8S8Z	;	3.91	;	Cryo-EM structure of octameric human CALHM1 (I109W) in complex with ruthenium red
8S90	;	4.73	;	Cryo-EM structure of octameric human CALHM1 (I109W) in complex with ruthenium red (C1)
8GMP	;	2.8	;	Cryo-EM structure of octameric human CALHM1 with a I109W point mutation
8EIS	;	2.62	;	Cryo-EM structure of octopus sensory receptor CRT1
6AZ3	;	2.5	;	Cryo-EM structure of of the large subunit of Leishmania ribosome bound to paromomycin
7SHN	;	3.1	;	Cryo-EM structure of oleoyl-CoA-bound human peroxisomal fatty acid transporter ABCD1
7LQ5	;	3.4	;	Cryo-EM structure of OmcZ nanowire from Geobacter sulfurreducens
8GTQ	;	3.1	;	cryo-EM structure of Omicron BA.5 S protein in complex with S2L20
8GTO	;	3.2	;	cryo-EM structure of Omicron BA.5 S protein in complex with XGv282
8GTP	;	3.1	;	cryo-EM structure of Omicron BA.5 S protein in complex with XGv289
7XCP	;	3.05	;	Cryo-EM structure of Omicron RBD complexed with ACE2 and 304 Fab
7WK5	;	3.66	;	Cryo-EM structure of Omicron S-ACE2, C2 state
7ZRV	;	2.8	;	cryo-EM structure of omicron spike in complex with de novo designed binder, full map
7ZSD	;	3.29	;	cryo-EM structure of omicron spike in complex with de novo designed binder, local
8I8R	;	2.93	;	Cryo-EM Structure of OmpC3-MlaA Complex in MSP2N2 Nanodiscs
8I8X	;	3.25	;	Cryo-EM Structure of OmpC3-MlaA-MlaC Complex in MSP2N2 Nanodiscs
7SZI	;	2.7	;	Cryo-EM structure of OmpK36-TraN mating pair stabilization proteins from carbapenem-resistant Klebsiella pneumoniae
7YPQ	;	3.1	;	Cryo-EM structure of one baculovirus LEF-3 molecule in complex with ssDNA
6C70	;	3.5	;	Cryo-EM structure of Orco
8PKD	;	2.33	;	Cryo-EM structure of Orrella dioscoreae BcsD
8K66	;	2.53	;	Cryo-EM structure of Oryza sativa HKT2;1 at 2.5 angstrom
8K69	;	2.33	;	Cryo-EM structure of Oryza sativa HKT2;2/1 at 2.3 angstrom
7XJY	;	3.6	;	Cryo-EM structure of Oryza sativa plastid glycyl-tRNA synthetase (apo form)
7XK1	;	4.3	;	Cryo-EM structure of Oryza sativa plastid glycyl-tRNA synthetase in complex with two tRNAs (both in tRNA binding states)
8H1C	;	4.5	;	Cryo-EM structure of Oryza sativa plastid glycyl-tRNA synthetase in complex with two tRNAs (one in tRNA binding state and the other in tRNA locked state)
8XS4	;	3.23	;	Cryo-EM structure of OSCA1.2-DOPC-1:20-contracted1 state
8XS5	;	3.33	;	Cryo-EM structure of OSCA1.2-DOPC-1:20-contracted2 state
8XVX	;	3.32	;	Cryo-EM structure of OSCA1.2-DOPC-1:20-expanded state
8XW2	;	3.59	;	Cryo-EM structure of OSCA1.2-DOPC-1:50-contracted state
8XW3	;	3.63	;	Cryo-EM structure of OSCA1.2-DOPC-1:50-expanded state
8XAJ	;	3.29	;	Cryo-EM structure of OSCA1.2-liposome-inside-in open state
8XNG	;	3.56	;	Cryo-EM structure of OSCA1.2-liposome-inside-out closed state
8XW1	;	4.49	;	Cryo-EM structure of OSCA1.2-V335W-DDM state
8XS0	;	3.89	;	Cryo-EM structure of OSCA3.1-1.1ver(Y367N-G454S-Y458I)-open/'desensitized' state
8XRY	;	3.84	;	Cryo-EM structure of OSCA3.1-1.1ver(Y367N-G454S-Y458I)-open/open state
8XVZ	;	3.78	;	Cryo-EM structure of OSCA3.1-2E(R611E-R619E)-closed/'desensitized' state
8XVY	;	3.71	;	Cryo-EM structure of OSCA3.1-2E(R611E-R619E)-closed/open state
8XW0	;	3.11	;	Cryo-EM structure of OSCA3.1-GDN state
6O84	;	3.92	;	Cryo-EM structure of OTOP3 from xenopus tropicalis
8CBJ	;	3.8	;	Cryo-EM structure of Otu2-bound cytoplasmic pre-40S ribosome biogenesis complex
7EW0	;	3.42	;	Cryo-EM structure of ozanimod -bound Sphingosine-1-phosphate receptor 1 in complex with Gi protein
5WK5	;	4.2	;	Cryo-EM structure of P. aeruginosa flagellar filaments A443V
5WK6	;	4.3	;	Cryo-EM structure of P. aeruginosa flagellar filaments G420A
7JGD	;	3.38	;	Cryo-EM structure of P. falciparum VAR2CSA FCR3 core at 3.4 A
7JGE	;	4.0	;	Cryo-EM structure of P. falciparum VAR2CSA FCR3 core at 4 A
7JGF	;	4.69	;	Cryo-EM structure of P. falciparum VAR2CSA FCR3 domains DBL5 and DBL6 at 4.69 A
7JGG	;	4.88	;	Cryo-EM structure of P. falciparum VAR2CSA NF45 DBL5 and DBL6 domains at 4.88 A
7JGH	;	3.36	;	Cryo-EM structure of P. falciparum VAR2CSA NF54 core in complex with CSA at 3.36 A
8RDW	;	2.74	;	Cryo-EM structure of P. urativorans 70S ribosome in complex with hibernation factor Balon and EF-Tu(GDP) (structure 3).
8RDV	;	2.6	;	Cryo-EM structure of P. urativorans 70S ribosome in complex with hibernation factor Balon, mRNA and P-site tRNA (structure 2).
8RD8	;	2.62	;	Cryo-EM structure of P. urativorans 70S ribosome in complex with hibernation factors Balon and RaiA (structure 1).
7CH9	;	3.5	;	Cryo-EM structure of P.aeruginosa MlaFEBD
7CH8	;	3.9	;	Cryo-EM structure of P.aeruginosa MlaFEBD with ADP-V
7CHA	;	3.9	;	Cryo-EM structure of P.aeruginosa MlaFEBD with AMPPNP
7MYN	;	2.79	;	Cryo-EM Structure of p110alpha in complex with p85alpha
7MYO	;	2.92	;	Cryo-EM structure of p110alpha in complex with p85alpha inhibited by BYL-719
6K4N	;	9.8	;	Cryo-EM structure of p300
5XZC	;	10.7	;	Cryo-EM structure of p300-p53 protein complex
7OP5	;	3.7	;	Cryo-EM structure of P5B-ATPase E2P
7OP1	;	3.7	;	Cryo-EM structure of P5B-ATPase E2PiAlF/SPM
7OP8	;	3.5	;	Cryo-EM structure of P5B-ATPase E2Pinhibit
7OP3	;	3.5	;	Cryo-EM structure of P5B-ATPase E2PiSPM
6TGY	;	3.5	;	Cryo-EM structure of p62-PB1 filament (L-type)
6TH3	;	4.0	;	Cryo-EM structure of p62-PB1 filament (S-type)
8EDX	;	2.81	;	Cryo-EM Structure of P74-26 tail-like tubes
8FCL	;	3.51	;	Cryo-EM structure of p97:UBXD1 closed state
8FCR	;	4.12	;	Cryo-EM structure of p97:UBXD1 H4-bound state
8FCT	;	3.42	;	Cryo-EM structure of p97:UBXD1 lariat mutant
8FCO	;	3.31	;	Cryo-EM structure of p97:UBXD1 meta state
8FCM	;	3.27	;	Cryo-EM structure of p97:UBXD1 open state
8FCP	;	3.52	;	Cryo-EM structure of p97:UBXD1 para state
8FCQ	;	3.93	;	Cryo-EM structure of p97:UBXD1 PUB-in state
8FCN	;	2.95	;	Cryo-EM structure of p97:UBXD1 VIM-only state
5GQH	;	4.2	;	Cryo-EM structure of PaeCas3-AcrF3 complex
8SZI	;	3.5	;	Cryo-EM structure of PAM-free human calcium-sensing receptor CaSR-Gi complex in lipid nanodiscs
8WCN	;	3.2	;	Cryo-EM structure of PAO1-ImcA with GMPCPP
7UFG	;	3.28	;	Cryo-EM structure of PAPP-A in complex with IGFBP5
8SL1	;	3.13	;	Cryo-EM structure of PAPP-A2
6NBF	;	3.0	;	Cryo-EM structure of parathyroid hormone receptor type 1 in complex with a long-acting parathyroid hormone analog and G protein
6NBH	;	3.5	;	Cryo-EM structure of parathyroid hormone receptor type 1 in complex with a long-acting parathyroid hormone analog and G protein
6NBI	;	4.0	;	Cryo-EM structure of parathyroid hormone receptor type 1 in complex with a long-acting parathyroid hormone analog and G protein
7F16	;	2.8	;	Cryo-EM structure of parathyroid hormone receptor type 2 in complex with a tuberoinfundibular peptide of 39 residues and G protein
7V6Y	;	3.5	;	Cryo-EM structure of Patched in lipid nanodisc - the wildtype, 3.5 angstrom (re-processed with dataset of 7dzq)
7V6Z	;	3.64	;	Cryo-EM structure of Patched1 (V1084A mutant) in lipid nanodisc, 3.64 angstrom (reprocessed with the dataset of 7dzp)
6V9Z	;	3.35	;	Cryo-EM structure of PCAT1 bound to its CtA peptide substrate
7T56	;	3.7	;	Cryo-EM structure of PCAT1 in the inward-facing intermediate conformation under ATP turnover condition
7T57	;	3.7	;	Cryo-EM structure of PCAT1 in the inward-facing narrow conformation under ATP turnover condition
7T55	;	4.1	;	Cryo-EM structure of PCAT1 in the inward-facing wide conformation under ATP turnover condition
7CN8	;	2.5	;	Cryo-EM structure of PCoV_GX spike glycoprotein
8CRB	;	4.6	;	Cryo-EM structure of PcrV/Fab(11-E5)
8CR9	;	4.2	;	Cryo-EM structure of PcrV/Fab(30-B8)
7LAR	;	3.8	;	Cryo-EM structure of PCV2 Replicase bound to ssDNA
7LAS	;	4.4	;	Cryo-EM structure of PCV2 Replicase bound to ssDNA
5ZBO	;	4.12	;	Cryo-EM structure of PCV2 VLPs
7U6R	;	2.5	;	Cryo-EM structure of PDF-2180 Spike glycoprotein
7P04	;	2.85	;	Cryo-EM structure of Pdr5 from Saccharomyces cerevisiae in inward-facing conformation with ADP/ATP
7P05	;	3.13	;	Cryo-EM structure of Pdr5 from Saccharomyces cerevisiae in inward-facing conformation with ADP/ATP and rhodamine 6G
7P03	;	3.45	;	Cryo-EM structure of Pdr5 from Saccharomyces cerevisiae in inward-facing conformation without nucleotides
7P06	;	3.77	;	Cryo-EM structure of Pdr5 from Saccharomyces cerevisiae in outward-facing conformation with ADP-orthovanadate/ATP
7XML	;	3.2	;	Cryo-EM structure of PEIP-Bs_enolase complex
7NCR	;	2.9	;	Cryo-EM structure of Pepper cryptic virus 1 VLP
8WA3	;	2.86	;	Cryo-EM structure of peptide free and Gs-coupled GIPR
6TUP	;	3.2	;	Cryo-EM structure of Pf4 bacteriophage coat protein with single-stranded DNA
6TUQ	;	3.9	;	Cryo-EM structure of Pf4 bacteriophage coat protein without ssDNA
8JPX	;	2.9	;	Cryo-EM structure of PfAgo-guide DNA-target DNA complex
7MXY	;	2.18	;	Cryo-EM structure of PfFNT-inhibitor complex
7EW2	;	3.1	;	Cryo-EM structure of pFTY720-bound Sphingosine 1-phosphate receptor 3 in complex with Gi protein
8FK5	;	3.4	;	Cryo-EM Structure of PG9RSH DU011 Fab in complex with BG505 DS-SOSIP.664
8FL1	;	3.75	;	Cryo-EM Structure of PG9RSH DU025 Fab in complex with BG505 DS-SOSIP.664
8IZ9	;	2.95	;	cryo-EM structure of PGE1-bound hMRP4
5ACO	;	4.36	;	Cryo-EM structure of PGT128 Fab in complex with BG505 SOSIP.664 Env trimer
8FLW	;	3.58	;	Cryo-EM Structure of PGT145 DU303 Fab in complex with BG505 DS-SOSIP.664
8VXQ	;	3.1	;	Cryo-EM structure of phage DEV ejection proteins gp72:gp73
6T25	;	3.6	;	Cryo-EM structure of phalloidin-Alexa Flour-546-stabilized F-actin (copolymerized)
6T20	;	3.7	;	Cryo-EM structure of phalloidin-stabilized F-actin (aged)
6T1Y	;	3.3	;	Cryo-EM structure of phalloidin-stabilized F-actin (copolymerized)
7PEM	;	3.1	;	Cryo-EM structure of phophorylated Drs2p-Cdc50p in a PS and ATP-bound E2P state
6MZB	;	3.4	;	Cryo-EM structure of phosphodiesterase 6
6LXV	;	2.1	;	Cryo-EM structure of phosphoketolase from Bifidobacterium longum
8IO7	;	2.62	;	Cryo-EM structure of phosphoketolase from Bifidobacterium longum in dimeric assembly
8IO6	;	2.68	;	Cryo-EM structure of phosphoketolase from Bifidobacterium longum in octameric assembly
6OXL	;	3.5	;	CRYO-EM STRUCTURE OF PHOSPHORYLATED AP-2 (mu E302K) BOUND TO NECAP IN THE PRESENCE OF SS DNA
6OWO	;	3.2	;	CRYO-EM STRUCTURE OF PHOSPHORYLATED AP-2 CORE BOUND TO NECAP
6L1T	;	3.22	;	Cryo-EM structure of phosphorylated Tyr39 a-synuclein amyloid fibril
6L1U	;	3.37	;	Cryo-EM structure of phosphorylated Tyr39 alpha-synuclein amyloid fibril
6RW6	;	2.75	;	Cryo-EM structure of Photorhabdus luminescens TcdA1
6RWA	;	4.0	;	Cryo-EM structure of Photorhabdus luminescens TcdA4
8C29	;	2.785	;	Cryo-EM structure of photosystem II C2S2 supercomplex from Norway spruce (Picea abies) at 2.8 Angstrom resolution
8ILR	;	3.05	;	Cryo-EM structure of PI3Kalpha in complex with compound 16
8ILS	;	3.1	;	Cryo-EM structure of PI3Kalpha in complex with compound 17
8ILV	;	3.19	;	Cryo-EM structure of PI3Kalpha in complex with compound 18
6X67	;	3.47	;	Cryo-EM structure of piggyBac transposase strand transfer complex (STC)
6X68	;	3.66	;	Cryo-EM structure of piggyBac transposase synaptic complex with hairpin DNA (SNHP)
7TGG	;	4.1	;	Cryo-EM structure of PilA-N and PilA-C from Geobacter sulfurreducens
6VK9	;	3.8	;	Cryo-EM structure of PilA-N/C from Geobacter sulfurreducens
7SSA	;	3.2	;	Cryo-EM structure of pioneer factor Cbf1 bound to the nucleosome
6WB8	;	3.24	;	Cryo-EM structure of PKD2 C331S disease variant
7CRB	;	3.16	;	Cryo-EM structure of plant NLR RPP1 LRR-ID domain in complex with ATR1
7DFV	;	2.99	;	Cryo-EM structure of plant NLR RPP1 tetramer core part
7CRC	;	3.02	;	Cryo-EM structure of plant NLR RPP1 tetramer in complex with ATR1
7XE0	;	3.33	;	Cryo-EM structure of plant NLR Sr35 resistosome
7W3T	;	3.59	;	Cryo-EM structure of plant receptor like kinase NbBAK1 in RXEG1-BAK1-XEG1 complex
7W3X	;	3.21	;	Cryo-EM structure of plant receptor like protein RXEG1
7DRC	;	2.92	;	Cryo-EM structure of plant receptor like protein RXEG1 in complex with xyloglucanase XEG1 and BAK1
8JVH	;	3.19	;	Cryo-EM structure of Plasmodium falciparum multidrug resistance protein 1 in the apo state with H1 helix
8JW4	;	3.13	;	Cryo-EM structure of Plasmodium falciparum multidrug resistance protein 1 in the apo state without H1 helix
8JWF	;	3.64	;	Cryo-EM structure of Plasmodium falciparum multidrug resistance protein 1 with H1 helix in complex with MFQ
8JWG	;	3.54	;	Cryo-EM structure of Plasmodium falciparum multidrug resistance protein 1 without H1 helix in complex with MFQ
6VYG	;	3.5	;	Cryo-EM structure of Plasmodium vivax hexokinase (Closed state)
6VYF	;	3.3	;	Cryo-EM structure of Plasmodium vivax hexokinase (Open state)
3J48	;	5.5	;	Cryo-EM structure of Poliovirus 135S particles
7PZR	;	3.0	;	Cryo-EM structure of POLRMT in free form.
7ZC4	;	3.24	;	Cryo-EM structure of POLRMT mutant.
5T4D	;	3.0	;	Cryo-EM structure of Polycystic Kidney Disease protein 2 (PKD2), residues 198-703
5Z1W	;	3.38	;	Cryo-EM structure of polycystic kidney disease-like channel PKD2L1
7ARD	;	3.11	;	Cryo-EM structure of Polytomella Complex-I (complete composition)
7AR9	;	2.97	;	Cryo-EM structure of Polytomella Complex-I (membrane arm)
7ARC	;	2.88	;	Cryo-EM structure of Polytomella Complex-I (peripheral arm)
6RDD	;	3.2	;	Cryo-EM structure of Polytomella F-ATP synthase, Primary rotary state 2, monomer-masked refinement
6REP	;	3.1	;	Cryo-EM structure of Polytomella F-ATP synthase, Primary rotary state 3, composite map
6RDJ	;	2.9	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 1A, focussed refinement of F1 head and rotor
6RDI	;	3.2	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 1A, monomer-masked refinement
6RDK	;	3.7	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 1B, composite map
6RDM	;	3.44	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 1B, focussed refinement of F1 head and rotor
6RDL	;	3.7	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 1B, monomer-masked refinement
6RDO	;	3.1	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 1C, composite map
6RDP	;	2.8	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 1C, focussed refinement of F1 head and rotor
6RDN	;	3.2	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 1C, monomer-masked refinement
6RDQ	;	4.0	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 1D, composite map
6RDS	;	3.8	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 1D, focussed refinement of F1 head and rotor
6RDR	;	4.1	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 1D, monomer-masked refinement
6RDT	;	3.4	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 1E, composite map
6RDV	;	3.1	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 1E, focussed refinement of F1 head and rotor
6RDU	;	3.5	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 1E, monomer-masked refinement
6RDW	;	3.8	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 1F, composite map
6RDY	;	3.6	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 1F, focussed refinement of F1 head and rotor
6RDX	;	3.9	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 1F, monomer-masked refinement
6RDZ	;	3.5	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 2A, composite map
6RE1	;	3.2	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 2A, focussed refinement of F1 head and rotor
6RE0	;	3.6	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 2A, monomer-masked refinement
6RE2	;	3.2	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 2B, composite map
6RE4	;	3.0	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 2B, focussed refinement of F1 head and rotor
6RE3	;	3.3	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 2B, monomer-masked refinement
6RE5	;	3.2	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 2C, composite map
6RE7	;	3.1	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 2C, focussed refinement of F1 head and rotor
6RE6	;	3.4	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 2C, monomer-masked refinement
6RE8	;	3.8	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 2D, composite map
6REA	;	3.6	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 2D, focussed refinement of F1 head and rotor
6RE9	;	3.9	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 2D, monomer-masked refinement
6REB	;	3.2	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 3A, composite map
6RED	;	3.0	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 3A, focussed refinement of F1 head and rotor
6REC	;	3.3	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 3A, monomer-masked refinement
6REE	;	3.1	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 3B, composite map
6RER	;	2.9	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 3B, focussed refinement of F1 head and rotor
6REF	;	3.3	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 3B, monomer-masked refinement
6RES	;	4.3	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 3C, composite map
6REU	;	4.2	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 3C, focussed refinement of F1 head and rotor
6RET	;	4.3	;	Cryo-EM structure of Polytomella F-ATP synthase, Rotary substate 3C, monomer-masked refinement
8UF7	;	3.2	;	Cryo-EM structure of POmAb, a Type-I anti-prothrombin antiphospholipid antibody, bound to kringle-1 of human prothrombin
6VV5	;	3.5	;	Cryo-EM structure of porcine epidemic diarrhea virus (PEDV) spike protein
6SCO	;	3.3	;	Cryo-EM Structure of Potato Leaf Roll Virus VLP
8HTU	;	2.87	;	Cryo-EM structure of PpPSI-L
8GRM	;	3.05	;	Cryo-EM structure of PRC1 bound to H2AK119-UbcH5b-Ub nucleosome
6C23	;	3.9	;	Cryo-EM structure of PRC2 bound to cofactors AEBP2 and JARID2 in the Compact Active State
6C24	;	3.5	;	Cryo-EM structure of PRC2 bound to cofactors AEBP2 and JARID2 in the Extended Active State
7KSO	;	3.9	;	Cryo-EM structure of PRC2:EZH1-AEBP2-JARID2
7LS6	;	3.17	;	Cryo-EM structure of Pre-15S proteasome core particle assembly intermediate purified from Pre3-1 proteasome mutant (G34D)
7UG6	;	2.9	;	Cryo-EM structure of pre-60S ribosomal subunit, unmethylated G2922
7BT6	;	3.12	;	Cryo-EM structure of pre-60S ribosome from Saccharomyces cerevisiae rpl4delta63-87 strain at 3.12 Angstroms resolution(state R1)
7BTB	;	3.22	;	Cryo-EM structure of pre-60S ribosome from Saccharomyces cerevisiae rpl4delta63-87 strain at 3.22 Angstroms resolution(state R2)
8EG7	;	3.2	;	Cryo-EM structure of pre-consensus elemental paused elongation complex
7NZM	;	3.96	;	Cryo-EM structure of pre-dephosphorylation complex of phosphorylated eIF2alpha with trapped holophosphatase (PP1A_D64A/PPP1R15A/G-actin/DNase I)
6N8M	;	3.5	;	Cryo-EM structure of pre-Lsg1 (PL) pre-60S ribosomal subunit
7RHX	;	3.23	;	Cryo-EM structure of precleavage Cre tetrameric complex
7KS9	;	4.75	;	Cryo-EM structure of prefusion SARS-CoV-2 spike glycoprotein in complex with 910-30 Fab
7THK	;	3.11	;	Cryo-EM structure of prefusion SARS-CoV-2 spike omicron B.1.1.529 variant
7MPG	;	3.4	;	Cryo-EM structure of Prefusion-stabilized RSV F (DS-Cav1) in complex with Fab AM14
7WIJ	;	3.17	;	Cryo-EM structure of prenyltransferase domain of Macrophoma phaseolina macrophomene synthase
7L7K	;	3.29	;	Cryo-EM structure of protein encoded by vaccine candidate BNT162b2
8IWY	;	2.68	;	Cryo-EM structure of protonated LHCII in detergent solution at low pH value
8IX1	;	2.63	;	Cryo-EM structure of protonated LHCII nanodisc at low pH value
7FJ3	;	4.53	;	Cryo-EM structure of PRV A-capid
7VV6	;	3.3	;	Cryo-EM structure of pseudoallergen receptor MRGPRX2 complex with C48/80 (local)
7VV5	;	2.76	;	Cryo-EM structure of pseudoallergen receptor MRGPRX2 complex with C48/80, state1
7VDH	;	2.9	;	Cryo-EM structure of pseudoallergen receptor MRGPRX2 complex with C48/80, state2
7VDL	;	3.22	;	Cryo-EM structure of pseudoallergen receptor MRGPRX2 complex with circular cortistatin-14
7VV3	;	2.97	;	Cryo-EM structure of pseudoallergen receptor MRGPRX2 complex with linear cortistatin-14
7VV4	;	2.97	;	Cryo-EM structure of pseudoallergen receptor MRGPRX2 complex with linear cortistatin-14, local
7VV0	;	3.5	;	Cryo-EM structure of pseudoallergen receptor MRGPRX2 complex with PAMP-12, local
7VUZ	;	2.89	;	Cryo-EM structure of pseudoallergen receptor MRGPRX2 complex with PAMP-12, state2
7VUY	;	2.84	;	Cryo-EM structure of pseudoallergen receptor MRGPRX2 complex with PAMP-12. state1
7VDM	;	2.98	;	Cryo-EM structure of pseudoallergen receptor MRGPRX2 complex with substance P
8I6R	;	4.0	;	Cryo-EM structure of Pseudomonas aeruginosa FtsE(E163Q)X/EnvC complex with ATP in peptidisc
8I6S	;	4.4	;	Cryo-EM structure of Pseudomonas aeruginosa FtsE(E163Q)X/EnvC complex with ATP in peptidisc
8I6Q	;	4.23	;	Cryo-EM structure of Pseudomonas aeruginosa FtsE(WT)X complex in peptidisc
8I6O	;	3.8	;	Cryo-EM structure of Pseudomonas aeruginosa FtsE(WT)X/EnvC complex in peptidisc
7VF9	;	4.04	;	Cryo-EM structure of Pseudomonas aeruginosa RNAP sigmaS holoenzyme complexes
7XL4	;	3.86	;	Cryo-EM structure of Pseudomonas aeruginosa RNAP sigmaS holoenzyme complexes with transcription factor SutA (closed lobe)
7XL3	;	3.13	;	Cryo-EM structure of Pseudomonas aeruginosa RNAP sigmaS holoenzyme complexes with transcription factor SutA (open lobe)
7YR7	;	3.8	;	Cryo-EM structure of Pseudomonas aeruginosa RsmZ RNA in complex with three RsmA protein dimers
7YR6	;	4.8	;	Cryo-EM structure of Pseudomonas aeruginosa RsmZ RNA in complex with two RsmA protein dimers
7F0R	;	5.8	;	Cryo-EM structure of Pseudomonas aeruginosa SutA transcription activation complex
8THE	;	2.5	;	Cryo-EM structure of Pseudomonas aeruginosa TonB-dependent transporter PhuR in complex with synthetic antibody and heme
7FJ1	;	4.43	;	Cryo-EM structure of pseudorabies virus C-capsid
7D1T	;	1.95	;	Cryo-EM Structure of PSII at 1.95 angstrom resolution
7D1U	;	2.08	;	Cryo-EM Structure of PSII at 2.08 angstrom resolution
7DXH	;	3.14	;	Cryo-EM structure of PSII intermediate Psb28-PSII complex
7XAQ	;	3.59	;	Cryo-EM structure of PvrA-DNA complex
7CKY	;	3.2	;	Cryo-EM structure of PW0464 bound dopamine receptor DRD1-Gs signaling complex
7VTP	;	3.23	;	Cryo-EM structure of PYD-deleted human NLRP3 hexamer
7K20	;	3.2	;	Cryo-EM structure of pyrene-labeled ADP-actin filaments
7K21	;	3.0	;	Cryo-EM structure of pyrene-labeled ADP-Pi-actin filaments
7OHF	;	3.0	;	Cryo-EM structure of pyrococcus furiosus apoferritin in nanofluidic channels
7LLK	;	4.8	;	Cryo-EM structure of Q23.17_DS-SOSIP in complex with Glycan276-Dependent Broadly Neutralizing Antibody 179NC75 Fab
7XLT	;	4.4	;	Cryo-EM Structure of R-loop monoclonal antibody S9.6 in recognizing RNA:DNA hybrids
8FO8	;	3.88	;	Cryo-EM structure of Rab29-LRRK2 complex in the LRRK2 dimer state
8FO2	;	4.13	;	Cryo-EM structure of Rab29-LRRK2 complex in the LRRK2 monomer state
8FO9	;	3.48	;	Cryo-EM structure of Rab29-LRRK2 complex in the LRRK2 tetramer state
7K0T	;	4.3	;	Cryo-EM structure of rabbit RyR1 in the presence of AMP-PCP in nanodisc
7UMZ	;	3.09	;	Cryo-EM structure of rabbit RyR1 in the presence of high Mg2+ and AMP-PCP in nanodisc
7K0S	;	4.5	;	Cryo-EM structure of rabbit RyR1 in the presence of Mg2+ and AMP-PCP in nanodisc
7X3K	;	6.0	;	Cryo-EM structure of RAC in the State C2 RNC-RAC complex
6DBI	;	3.4	;	Cryo-EM structure of RAG in complex with 12-RSS and 23-RSS nicked DNA intermediates
6DBJ	;	3.0	;	Cryo-EM structure of RAG in complex with 12-RSS and 23-RSS nicked DNA intermediates
6DBL	;	5.0	;	Cryo-EM structure of RAG in complex with 12-RSS and 23-RSS substrate DNAs
6DBO	;	4.4	;	Cryo-EM structure of RAG in complex with 12-RSS and 23-RSS substrate DNAs
6DBQ	;	4.22	;	Cryo-EM structure of RAG in complex with 12-RSS and 23-RSS substrate DNAs
6DBT	;	4.3	;	Cryo-EM structure of RAG in complex with 12-RSS and 23-RSS substrate DNAs
6DBU	;	3.9	;	Cryo-EM structure of RAG in complex with 12-RSS and 23-RSS substrate DNAs
6DBV	;	4.29	;	Cryo-EM structure of RAG in complex with 12-RSS and 23-RSS substrate DNAs
6DBW	;	4.7	;	Cryo-EM structure of RAG in complex with 12-RSS substrate DNA
6DBX	;	4.2	;	Cryo-EM structure of RAG in complex with 12-RSS substrate DNA
6DBR	;	4.0	;	Cryo-EM structure of RAG in complex with one melted RSS and one unmelted RSS
8UX1	;	2.5	;	Cryo-EM structure of Ran bound to RCC1 and the nucleosome core particle
8T6L	;	3.3	;	Cryo-EM structure of rat cardiac sodium channel NaV1.5 with batrachotoxin analog BTX-B
7VAF	;	3.11	;	Cryo-EM structure of Rat NTCP complexed with YN69202Fab
8BW7	;	3.53	;	Cryo-EM structure of rat SLC22A6 bound to alpha-ketoglutaric acid
8OMU	;	3.43	;	Cryo-EM structure of rat SLC22A6 bound to alpha-ketoglutaric acid in a low occupancy state
8BVT	;	3.94	;	Cryo-EM structure of rat SLC22A6 bound to probenecid
8BVS	;	3.61	;	Cryo-EM structure of rat SLC22A6 bound to tenofovir
8BVR	;	3.52	;	Cryo-EM structure of rat SLC22A6 in the apo state
6E2G	;	3.6	;	Cryo-EM structure of rat TRPV6 in complex with Calmodulin
6BOB	;	3.9	;	Cryo-EM structure of rat TRPV6* in nanodiscs
6PWX	;	4.2	;	Cryo-EM structure of RbBP5 bound to the nucleosome
6LRS	;	3.37	;	Cryo-EM structure of RbcL8-RbcS4 from Anabaena sp. PCC 7120
8DXS	;	3.76	;	Cryo-EM structure of RBD-directed neutralizing antibody P2B4 in complex with prefusion SARS-CoV-2 spike glycoprotein
8IDN	;	3.35	;	Cryo-EM structure of RBD/E77-Fab complex
8B64	;	2.589	;	Cryo-EM structure of RC-LH1-PufX photosynthetic core complex from Rba. capsulatus
7YO5	;	3.9	;	Cryo-EM structure of RCK1 mutated human Slo1 apo
7YO1	;	3.6	;	Cryo-EM structure of RCK1 mutated human Slo1-LRRC26 complex
7YO2	;	3.3	;	Cryo-EM structure of RCK1-RCK2 mutated human Slo1 apo
7YO4	;	3.9	;	Cryo-EM structure of RCK1-RCK2 mutated human Slo1-LRRC26 complex
7ZNN	;	4.8	;	Cryo-EM structure of RCMV-E E27 bound to human DDB1 (deltaBPB) and full-length rat STAT2
7ZN7	;	3.78	;	Cryo-EM structure of RCMV-E E27 bound to human DDB1 (deltaBPB) and rat STAT2 CCD
7MR0	;	3.7	;	Cryo-EM structure of RecBCD with docked RecBNuc and flexible RecD
7MR2	;	4.3	;	Cryo-EM structure of RecBCD with undocked RecBNuc and flexible RecD
7MR1	;	4.2	;	Cryo-EM structure of RecBCD with undocked RecBNuc and flexible RecD C-terminus
5LD2	;	3.83	;	Cryo-EM structure of RecBCD+DNA complex revealing activated nuclease domain
7MR3	;	3.6	;	Cryo-EM structure of RecBCD-DNA complex with docked RecBNuc and stabilized RecD
7MR4	;	4.5	;	Cryo-EM structure of RecBCD-DNA complex with undocked RecBNuc and flexible RecD
8G2V	;	2.715	;	Cryo-EM structure of recombinant human LECT2 amyloid fibril core
6WOU	;	3.27	;	Cryo-EM structure of recombinant mouse Ryanodine Receptor type 2 mutant R176Q in complex with FKBP12.6 in nanodisc
6WOV	;	5.1	;	Cryo-EM structure of recombinant mouse Ryanodine Receptor type 2 wild type in complex with FKBP12.6
6WOT	;	3.54	;	Cryo-EM structure of recombinant rabbit Ryanodine Receptor type 1 mutant R164C in complex with FKBP12.6
6ZTQ	;	3.0	;	Cryo-EM structure of respiratory complex I from Mus musculus inhibited by piericidin A at 3.0 A
6GCS	;	4.32	;	Cryo-EM structure of respiratory complex I from Yarrowia lipolytica
6RFR	;	3.2	;	Cryo-EM structure of respiratory complex I from Yarrowia lipolytica at 3.2 A resolution
6ZR2	;	3.1	;	Cryo-EM structure of respiratory complex I in the active state from Mus musculus at 3.1 A
7AK5	;	3.17	;	Cryo-EM structure of respiratory complex I in the deactive state from Mus musculus at 3.2 A
7O6Y	;	3.4	;	Cryo-EM structure of respiratory complex I under turnover
7TGH	;	2.6	;	Cryo-EM structure of respiratory super-complex CI+III2 from Tetrahymena thermophila
6Q2N	;	4.4	;	Cryo-EM structure of RET/GFRa1/GDNF extracellular complex
6Q2R	;	4.3	;	Cryo-EM structure of RET/GFRa2/NRTN extracellular complex in the tetrameric form
6Q2O	;	3.65	;	Cryo-EM structure of RET/GFRa2/NRTN extracellular complex. The 3D refinement was applied with C2 symmetry.
6Q2S	;	3.8	;	Cryo-EM structure of RET/GFRa3/ARTN extracellular complex. The 3D refinement was applied with C2 symmetry.
6SK7	;	2.9	;	Cryo-EM structure of rhinovirus-A89
6SK6	;	3.2	;	Cryo-EM structure of rhinovirus-B5
6SK5	;	3.6	;	Cryo-EM structure of rhinovirus-B5 complexed to antiviral OBR-5-340
7F47	;	2.99	;	Cryo-EM structure of Rhizobium etli MprF
7URG	;	3.46	;	cryo-EM structure of ribonucleotide reductase from Synechococcus phage S-CBP4 bound with TTP
8B6C	;	2.79	;	Cryo-EM structure of ribosome-Sec61 in complex with cyclotriazadisulfonamide derivative CK147
8B5L	;	2.86	;	Cryo-EM structure of ribosome-Sec61-TRAP (TRanslocon Associated Protein) translocon complex
7SZJ	;	3.11	;	Cryo-EM structure of Rifamycin bound to E. coli RNAP and rrnBP1 promoter complex
8DVS	;	3.0	;	Cryo-EM structure of RIG-I bound to the end of OHSLR30 (+ATP)
8DVR	;	3.3	;	Cryo-EM structure of RIG-I bound to the end of p3SLR30 (+AMPPNP)
7TO1	;	3.66	;	Cryo-EM structure of RIG-I bound to the end of p3SLR30 (+ATP)
8DVU	;	2.9	;	Cryo-EM structure of RIG-I bound to the internal sites of OHSLR30 (+ATP)
7TO2	;	3.2	;	Cryo-EM structure of RIG-I bound to the internal sites of p3SLR30 (+ATP)
7TO0	;	3.5	;	Cryo-EM structure of RIG-I in complex with OHdsRNA
7TNZ	;	3.54	;	Cryo-EM structure of RIG-I in complex with p1dsRNA
7TNY	;	3.2	;	Cryo-EM structure of RIG-I in complex with p2dsRNA
7TNX	;	3.54	;	Cryo-EM structure of RIG-I in complex with p3dsRNA
8SD0	;	3.8	;	Cryo-EM structure of RIG-I in complex with p3SLR14
7JL3	;	4.2	;	Cryo-EM structure of RIG-I:dsRNA filament in complex with RIPLET PrySpry domain (trimer)
7JL1	;	3.9	;	Cryo-EM structure of RIG-I:dsRNA in complex with RIPLET PrySpry domain (monomer)
5N60	;	7.7	;	Cryo-EM structure of RNA polymerase I in complex with Rrn3 and Core Factor (Orientation I)
5N5Z	;	7.7	;	Cryo-EM structure of RNA polymerase I in complex with Rrn3 and Core Factor (Orientation II)
5N5Y	;	7.7	;	Cryo-EM structure of RNA polymerase I in complex with Rrn3 and Core Factor (Orientation III)
7YOT	;	3.0	;	Cryo-EM structure of RNA polymerase in complex with P protein tetramer of Newcastle disease virus
7YOU	;	3.41	;	Cryo-EM structure of RNA polymerase in complex with P protein tetramer of Newcastle disease virus
7YOV	;	3.25	;	Cryo-EM structure of RNA polymerase in complex with P protein tetramer of Newcastle disease virus
5NSR	;	3.8	;	Cryo-EM structure of RNA polymerase-sigma54 holo enzyme with promoter DNA closed complex
7QXI	;	3.4	;	Cryo-EM structure of RNA polymerase-sigma54 holo enzyme with promoter DNA closed complex
5NSS	;	5.8	;	Cryo-EM structure of RNA polymerase-sigma54 holoenzyme with promoter DNA and transcription activator PspF intermedate complex
8IGS	;	3.4	;	Cryo-EM structure of RNAP-promoter open complex at lambda promoter PRE
8CGL	;	4.1	;	Cryo-EM structure of RNase J from Helicobacter pylori
8FN4	;	3.7	;	Cryo-EM structure of RNase-treated RESC-A in trypanosomal RNA editing
8FNI	;	3.4	;	Cryo-EM structure of RNase-treated RESC-B in trypanosomal RNA editing
8FNC	;	3.3	;	Cryo-EM structure of RNase-treated RESC-C in trypanosomal RNA editing
8FN6	;	3.7	;	Cryo-EM structure of RNase-untreated RESC-A in trypanosomal RNA editing
8FNK	;	3.7	;	Cryo-EM structure of RNase-untreated RESC-B in trypanosomal RNA editing
8FNF	;	3.5	;	Cryo-EM structure of RNase-untreated RESC-C in trypanosomal RNA editing
7X34	;	3.1	;	Cryo-EM structure of RNC-RAC complex in presence of Ssb from S. cerevisiae 2
7CRW	;	3.18	;	Cryo-EM structure of rNLRP1-rDPP9 complex
8G7T	;	3.2	;	Cryo-EM structure of RNP end
8G7U	;	4.0	;	Cryo-EM structure of RNP end 2
8G7V	;	3.9	;	Cryo-EM structure of RNP inter
7VWY	;	4.57	;	Cryo-EM structure of Rob-dependent transcription activation complex in a unique conformation
7VWZ	;	4.0	;	Cryo-EM structure of Rob-dependent transcription activation complex in a unique conformation
8P00	;	3.8	;	Cryo-EM structure of Rotavirus B NSP2
7JN3	;	3.21	;	Cryo-EM structure of Rous sarcoma virus cleaved synaptic complex (CSC) with HIV-1 integrase strand transfer inhibitor MK-2048
7KUI	;	3.4	;	Cryo-EM structure of Rous sarcoma virus cleaved synaptic complex (CSC) with HIV-1 integrase strand transfer inhibitor MK-2048. CIC region of a cluster identified by 3-dimensional variability analysis in cryoSPARC.
7KU7	;	3.4	;	Cryo-EM structure of Rous sarcoma virus cleaved synaptic complex (CSC) with HIV-1 integrase strand transfer inhibitor MK-2048. Cluster identified by 3-dimensional variability analysis in cryoSPARC.
8E14	;	3.36	;	Cryo-EM structure of Rous sarcoma virus strand transfer complex
7YI0	;	3.2	;	Cryo-EM structure of Rpd3S complex
7YI4	;	3.96	;	Cryo-EM structure of Rpd3S complex bound to H3K36me3 nucleosome in close state
7YI5	;	3.96	;	Cryo-EM structure of Rpd3S complex bound to H3K36me3 nucleosome in loose state
7YI3	;	3.3	;	Cryo-EM structure of Rpd3S in close-state Rpd3S-NCP complex
7YI2	;	3.4	;	Cryo-EM structure of Rpd3S in loose-state Rpd3S-NCP complex
6N8O	;	3.5	;	Cryo-EM structure of Rpl10-inserted (RI) pre-60S ribosomal subunit
7LUC	;	3.21	;	Cryo-EM structure of RSV preF bound by Fabs 32.4K and 01.4B
8T7A	;	2.8	;	Cryo-EM structure of RSV preF in complex with Fab 2.4K
8DG9	;	2.24	;	Cryo-EM Structure of RSV prefusion F trimer in complex with three MxR Fabs
7L2O	;	3.64	;	Cryo-EM structure of RTX-bound full-length TRPV1 at pH 5.5
7L2N	;	3.09	;	Cryo-EM structure of RTX-bound full-length TRPV1 in C1 state
7MZ5	;	2.76	;	Cryo-EM structure of RTX-bound full-length TRPV1 in C2 state
7L2L	;	3.42	;	Cryo-EM structure of RTX-bound full-length TRPV1 in O1 state
7L2W	;	3.16	;	cryo-EM structure of RTX-bound minimal TRPV1 with NMDG at state a
7L2V	;	3.64	;	cryo-EM structure of RTX-bound minimal TRPV1 with NMDG at state b
7L2X	;	3.26	;	cryo-EM structure of RTX-bound minimal TRPV1 with NMDG at state c
7XSD	;	3.3	;	Cryo-EM structure of RuBisCO assembly intermediate RbcL8Raf18RbcX16
6LRR	;	3.37	;	Cryo-EM structure of RuBisCO-Raf1 from Anabaena sp. PCC 7120
8SEN	;	3.49	;	Cryo-EM Structure of RyR1
8SEU	;	3.0	;	Cryo-EM Structure of RyR1 (Local Refinement of TMD)
8SES	;	3.98	;	Cryo-EM Structure of RyR1 + Adenine
8SEZ	;	3.54	;	Cryo-EM Structure of RyR1 + Adenine (Local Refinement of TMD)
8SER	;	3.42	;	Cryo-EM Structure of RyR1 + Adenosine
8SEY	;	2.99	;	Cryo-EM Structure of RyR1 + Adenosine (Local Refinement of TMD)
8SEP	;	3.57	;	Cryo-EM Structure of RyR1 + ADP
8SEW	;	2.89	;	Cryo-EM Structure of RyR1 + ADP (Local Refinement of TMD)
8SEQ	;	3.4	;	Cryo-EM Structure of RyR1 + AMP
8SEX	;	2.84	;	Cryo-EM Structure of RyR1 + AMP (Local Refinement of TMD)
8SEO	;	3.92	;	Cryo-EM Structure of RyR1 + ATP-gamma-S
8SEV	;	3.17	;	Cryo-EM Structure of RyR1 + ATP-gamma-S (Local Refinement of TMD)
8SET	;	3.42	;	Cryo-EM Structure of RyR1 + cAMP
8SF0	;	2.9	;	Cryo-EM Structure of RyR1 + cAMP (Local Refinement of TMD)
6JG3	;	6.1	;	Cryo-EM structure of RyR2 (Ca2+ alone dataset)
5GO9	;	4.4	;	Cryo-EM structure of RyR2 in closed state
5GOA	;	4.2	;	Cryo-EM structure of RyR2 in open state
7XOG	;	3.5	;	Cryo-EM structure of S glycoprotein encoded by the Covid-19 mRNA vaccine candidate RQ3013 (Postfusion state)
7XOE	;	3.9	;	Cryo-EM structure of S glycoprotein encoded by the Covid-19 mRNA vaccine candidate RQ3013 (Prefusion state)
7FG7	;	6.9	;	Cryo-EM structure of S protein trimer of SARS-CoV2
8EXS	;	4.3	;	Cryo-EM structure of S. aureus BlaR1 F284A mutant
8EXT	;	4.6	;	Cryo-EM structure of S. aureus BlaR1 F284A mutant in complex with ampicillin
8EXR	;	3.8	;	Cryo-EM structure of S. aureus BlaR1 TM and zinc metalloprotease domain
8EXQ	;	4.9	;	Cryo-EM structure of S. aureus BlaR1 with C1 symmetry
8EXP	;	4.2	;	Cryo-EM structure of S. aureus BlaR1 with C2 symmetry
8FOE	;	5.6	;	Cryo-EM structure of S. cerevisiae DNA polymerase alpha-primase complex bound to a template DNA
8FOD	;	3.8	;	Cryo-EM structure of S. cerevisiae DNA polymerase alpha-primase complex in Apo state conformation II
8FOK	;	3.56	;	Cryo-EM structure of S. cerevisiae DNA polymerase alpha-primase complex in the DNA elongation state
8FOJ	;	4.8	;	Cryo-EM structure of S. cerevisiae DNA polymerase alpha-primase complex in the post RNA handoff state
8FOH	;	4.6	;	Cryo-EM structure of S. cerevisiae DNA polymerase alpha-primase complex in the RNA synthesis state
8FOC	;	3.7	;	Cryo-EM structure of S. cerevisiae DNA polymerase alpha-primase in Apo state conformation I
6PSY	;	2.8	;	Cryo-EM structure of S. cerevisiae Drs2p-Cdc50p in the autoinhibited apo form
6PSX	;	3.3	;	Cryo-EM structure of S. cerevisiae Drs2p-Cdc50p in the PI4P-activated form
6HV8	;	4.4	;	Cryo-EM structure of S. cerevisiae Polymerase epsilon deltacat mutant
8E9B	;	3.5	;	Cryo-EM structure of S. pombe Arp2/3 complex in the branch junction
7L1K	;	3.16	;	Cryo-EM structure of S. Pombe NatC complex with a Bisubstrate inhibitor and inositol hexaphosphate
6ZZ6	;	3.4	;	Cryo-EM structure of S.cerevisiae cohesin-Scc2-DNA complex
7Q2Z	;	3.2	;	Cryo-EM structure of S.cerevisiae condensin Ycg1-Brn1-DNA complex
7NTM	;	2.86	;	Cryo-EM structure of S.cerevisiae native alcohol dehydrogenase 1 (ADH1) in its tetrameric apo state
7T94	;	3.16	;	Cryo-EM structure of S1 state ACh-bound M2R-Go signaling complex with a PAM
7EW3	;	3.1	;	Cryo-EM structure of S1P-bound Sphingosine 1-phosphate receptor 3 in complex with Gi protein
7T96	;	3.22	;	Cryo-EM structure of S2 state ACh-bound M2R-Go signaling complex with a PAM
7YAD	;	2.66	;	Cryo-EM structure of S309-RBD-RBD-S309 in the S309-bound Omicron spike protein (local refinement)
8JFT	;	3.31	;	Cryo-EM structure of SaCas9-AcrIIA15 CTD-sgRNA complex
7VW3	;	3.8	;	Cryo-EM structure of SaCas9-sgRNA-DNA ternary complex
8DH6	;	2.94	;	Cryo-EM structure of Saccharomyces cerevisiae cytochrome c oxidase (Complex IV) extracted in lipid nanodiscs
7KTX	;	4.3	;	Cryo-EM structure of Saccharomyces cerevisiae ER membrane protein complex bound to a Fab in DDM detergent
7KRA	;	3.2	;	Cryo-EM structure of Saccharomyces cerevisiae ER membrane protein complex bound to Fab-DH4 in lipid nanodiscs
8DH7	;	2.99	;	Cryo-EM structure of Saccharomyces cerevisiae Succinyl-CoA:acetate CoA-transferase (Ach1p)
6EMK	;	8.0	;	Cryo-EM Structure of Saccharomyces cerevisiae Target of Rapamycin Complex 2
7PQH	;	3.87	;	Cryo-EM structure of Saccharomyces cerevisiae TOROID (TORC1 Organized in Inhibited Domains).
6M39	;	3.55	;	Cryo-EM structure of SADS-CoV spike
7YI8	;	2.7	;	Cryo-EM structure of SAH-bound MTA1-MTA9-p1-p2 complex
7YI9	;	2.6	;	Cryo-EM structure of SAM-bound MTA1-MTA9-p1-p2 complex
7VKU	;	3.2	;	Cryo-EM structure of SAM-Tom40 intermediate complex
8EKE	;	3.36	;	Cryo-EM structure of SARS CoV-2 Mpro WT protease
8WOZ	;	3.25	;	Cryo-EM structure of SARS-CoV RBD in complex with rabbit ACE2
7X7V	;	3.83	;	Cryo-EM structure of SARS-CoV spike protein in complex with three nAbs X01, X10 and X17
7WSF	;	2.87	;	Cryo-EM structure of SARS-CoV spike receptor-binding domain in complex with minke whale ACE2
7WSG	;	3.03	;	Cryo-EM structure of SARS-CoV spike receptor-binding domain in complex with sea lion ACE2
7L09	;	3.1	;	Cryo-EM structure of SARS-CoV-2 2P S ectodomain bound domain-swapped antibody 2G12 from masked 3D refinement
7L02	;	3.2	;	Cryo-EM structure of SARS-CoV-2 2P S ectodomain bound to one copy of domain-swapped antibody 2G12
7L06	;	3.3	;	Cryo-EM structure of SARS-CoV-2 2P S ectodomain bound to two copies of domain-swapped antibody 2G12
8DLI	;	2.56	;	Cryo-EM structure of SARS-CoV-2 Alpha (B.1.1.7) spike protein
8DLJ	;	2.91	;	Cryo-EM structure of SARS-CoV-2 Alpha (B.1.1.7) spike protein in complex with human ACE2
8DLK	;	3.04	;	Cryo-EM structure of SARS-CoV-2 Alpha (B.1.1.7) spike protein in complex with human ACE2 (focused refinement of RBD and ACE2)
8H7Z	;	3.07	;	Cryo-EM structure of SARS-CoV-2 BA.2 RBD in complex with BA7535 fab (local refinement)
8H7L	;	2.44	;	Cryo-EM Structure of SARS-CoV-2 BA.2 Spike protein in complex with BA7535
8KC2	;	2.6	;	Cryo-EM structure of SARS-CoV-2 BA.3 RBD in complex with golden hamster ACE2 (local refinement)
8IX3	;	3.98	;	Cryo-EM structure of SARS-CoV-2 BA.4/5 spike protein in complex with 1G11 (local refinement)
8DLL	;	2.56	;	Cryo-EM structure of SARS-CoV-2 Beta (B.1.351) spike protein
8DLM	;	2.89	;	Cryo-EM structure of SARS-CoV-2 Beta (B.1.351) spike protein in complex with human ACE2
8DLN	;	3.04	;	Cryo-EM structure of SARS-CoV-2 Beta (B.1.351) spike protein in complex with human ACE2 (focused refinement of RBD and ACE2)
8DI5	;	3.04	;	Cryo-EM structure of SARS-CoV-2 Beta (B.1.351) spike protein in complex with VH domain F6 (focused refinement of RBD and VH F6)
7WP2	;	3.52	;	Cryo-EM structure of SARS-CoV-2 C.1.2 S6P trimer in complex with neutralizing antibody VacW-209 (local refinement)
8DLZ	;	2.57	;	Cryo-EM structure of SARS-CoV-2 D614G spike protein in complex with VH ab6
8DM0	;	3.21	;	Cryo-EM structure of SARS-CoV-2 D614G spike protein in complex with VH ab6 (focused refinement of NTD and VH ab6)
7TEY	;	2.25	;	Cryo-EM structure of SARS-CoV-2 Delta (B.1.617.2) spike protein
7TEX	;	3.27	;	Cryo-EM structure of SARS-CoV-2 Delta (B.1.617.2) spike protein in complex with human ACE2
7TEW	;	3.52	;	Cryo-EM structure of SARS-CoV-2 Delta (B.1.617.2) spike protein in complex with human ACE2 (focused refinement of RBD and ACE2)
7XCZ	;	3.2	;	Cryo-EM structure of SARS-CoV-2 Delta RBD in complex with BA7054 and BA7125 fab (local refinement)
7XDA	;	2.98	;	Cryo-EM structure of SARS-CoV-2 Delta RBD in complex with BA7208 and BA7125 fab (local refinement)
8KA8	;	2.96	;	Cryo-EM structure of SARS-CoV-2 Delta RBD in complex with golden hamster ACE2 (local refinement)
7WP0	;	3.71	;	Cryo-EM structure of SARS-CoV-2 Delta S6P trimer in complex with neutralizing antibody VacW-209 (local refinement)
7XDK	;	3.2	;	Cryo-EM structure of SARS-CoV-2 Delta Spike protein in complex with BA7054 and BA7125 fab
7XDL	;	3.08	;	Cryo-EM structure of SARS-CoV-2 Delta Spike protein in complex with BA7208 and BA7125 fab
7X7U	;	3.77	;	Cryo-EM structure of SARS-CoV-2 Delta variant spike protein in complex with three nAbs X01, X10 and X17
7Y6D	;	4.39	;	Cryo-EM structure of SARS-CoV-2 Delta variant spike proteins on intact virions: 3 Closed RBD
8DLT	;	2.4	;	Cryo-EM structure of SARS-CoV-2 Epsilon (B.1.429) spike protein
8DLW	;	2.16	;	Cryo-EM structure of SARS-CoV-2 Epsilon (B.1.429) spike protein in complex with Fab S2M11
8DLU	;	3.14	;	Cryo-EM structure of SARS-CoV-2 Epsilon (B.1.429) spike protein in complex with human ACE2
8DLV	;	3.11	;	Cryo-EM structure of SARS-CoV-2 Epsilon (B.1.429) spike protein in complex with human ACE2 (focused refinement of RBD and ACE2)
8DLX	;	2.45	;	Cryo-EM structure of SARS-CoV-2 Epsilon (B.1.429) spike protein in complex with VH ab6
8DLY	;	3.0	;	Cryo-EM structure of SARS-CoV-2 Epsilon (B.1.429) spike protein in complex with VH ab6 (focused refinement of NTD and VH ab6)
8DLO	;	2.25	;	Cryo-EM structure of SARS-CoV-2 Gamma (P.1) spike protein
8DLR	;	2.51	;	Cryo-EM structure of SARS-CoV-2 Gamma (P.1) spike protein in complex with Fab 4-8 (focused refinement of NTD and 4-8)
8DLS	;	2.66	;	Cryo-EM structure of SARS-CoV-2 Gamma (P.1) spike protein in complex with Fab 4A8 (focused refinement of NTD and 4A8)
8DLP	;	2.64	;	Cryo-EM structure of SARS-CoV-2 Gamma (P.1) spike protein in complex with human ACE2
8DLQ	;	2.77	;	Cryo-EM structure of SARS-CoV-2 Gamma (P.1) spike protein in complex with human ACE2 (focused refinement of RBD and ACE2)
7TF3	;	2.25	;	Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) Q484A spike protein
7TF2	;	3.62	;	Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) Q484I spike protein
7TF1	;	3.57	;	Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) Q484I spike protein (focused refinement of RBD)
7TF5	;	3.16	;	Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) spike protein
7TF4	;	3.01	;	Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) spike protein (focused refinement of RBD)
7TF0	;	3.02	;	Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) spike protein in complex with human ACE2
7TEZ	;	3.27	;	Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) spike protein in complex with human ACE2 (focused refinement of RBD and ACE2)
8CTK	;	3.52	;	Cryo-EM structure of SARS-CoV-2 M protein in a lipid nanodisc
7S82	;	3.5	;	Cryo-EM structure of SARS-CoV-2 Main protease C145S in complex with N-terminal peptide
8EY2	;	3.5	;	Cryo-EM structure of SARS-CoV-2 Main protease C145S in complex with N-terminal peptide
7WP1	;	3.77	;	Cryo-EM structure of SARS-CoV-2 Mu S6P trimer in complex with neutralizing antibody VacW-209 (local refinement)
7N0B	;	3.9	;	Cryo-EM structure of SARS-CoV-2 nsp10-nsp14 (WT)-RNA complex
7ME0	;	2.48	;	Cryo-EM structure of SARS-CoV-2 NSP15 NendoU at pH 6.0
7RB0	;	2.98	;	Cryo-EM structure of SARS-CoV-2 NSP15 NendoU at pH 7.5
7RB2	;	3.27	;	Cryo-EM structure of SARS-CoV-2 NSP15 NendoU in BIS-Tris pH 6.0
7WRH	;	2.66	;	Cryo-EM structure of SARS-CoV-2 Omicron BA.1 spike protein in complex with mouse ACE2
8DM9	;	2.56	;	Cryo-EM structure of SARS-CoV-2 Omicron BA.1 spike protein in complex with mouse ACE2
8DMA	;	2.79	;	Cryo-EM structure of SARS-CoV-2 Omicron BA.1 spike protein in complex with mouse ACE2 (focused refinement of RBD and ACE2)
8HFX	;	2.98	;	Cryo-EM structure of SARS-CoV-2 Omicron BA.1 spike protein in complex with white-tailed deer ACE2
8HPF	;	2.34	;	Cryo-EM structure of SARS-CoV-2 Omicron BA.2 RBD in complex with fab L4.65 and L5.34
7YV8	;	2.94	;	Cryo-EM structure of SARS-CoV-2 Omicron BA.2 RBD in complex with golden hamster ACE2 (local refinement)
7YJ3	;	3.14	;	Cryo-EM structure of SARS-CoV-2 Omicron BA.2 RBD in complex with human ACE2 (local refinement)
7YVU	;	3.2	;	Cryo-EM structure of SARS-CoV-2 Omicron BA.2 RBD in complex with mouse ACE2 (local refinement)
8GRY	;	3.29	;	Cryo-EM structure of SARS-CoV-2 Omicron BA.2 RBD in complex with rat ACE2 (local refinement)
8HP9	;	2.75	;	Cryo-EM structure of SARS-CoV-2 Omicron BA.2 S-trimer in complex with fab L4.65 and L5.34
8DM1	;	3.04	;	Cryo-EM structure of SARS-CoV-2 Omicron BA.2 spike protein
8DM2	;	2.91	;	Cryo-EM structure of SARS-CoV-2 Omicron BA.2 spike protein (focused refinement of NTD)
8DM3	;	2.37	;	Cryo-EM structure of SARS-CoV-2 Omicron BA.2 spike protein in complex with Fab 4A8
8DM4	;	2.45	;	Cryo-EM structure of SARS-CoV-2 Omicron BA.2 spike protein in complex with Fab 4A8 (focused refinement of NTD and 4A8)
8DM5	;	2.51	;	Cryo-EM structure of SARS-CoV-2 Omicron BA.2 spike protein in complex with human ACE2
8DM6	;	2.77	;	Cryo-EM structure of SARS-CoV-2 Omicron BA.2 spike protein in complex with human ACE2 (focused refinement of RBD and ACE2)
8DM7	;	2.49	;	Cryo-EM structure of SARS-CoV-2 Omicron BA.2 spike protein in complex with mouse ACE2
8DM8	;	2.68	;	Cryo-EM structure of SARS-CoV-2 Omicron BA.2 spike protein in complex with mouse ACE2 (focused refinement of RBD and ACE2)
7YHW	;	3.09	;	Cryo-EM structure of SARS-CoV-2 Omicron BA.2.12.1 RBD in complex with human ACE2 (local refinement)
8HPU	;	2.56	;	Cryo-EM structure of SARS-CoV-2 Omicron BA.4 RBD in complex with fab L4.65 and L5.34
8HPQ	;	2.85	;	Cryo-EM structure of SARS-CoV-2 Omicron BA.4 S-trimer in complex with fab L4.65 and L5.34
8H06	;	2.66	;	Cryo-EM structure of SARS-CoV-2 Omicron BA.4/5 RBD in complex with human ACE2 (local refinement)
8WOY	;	3.14	;	Cryo-EM structure of SARS-CoV-2 Omicron BA.4/5 RBD in complex with rabbit ACE2 (local refinement)
8IFY	;	2.55	;	Cryo-EM structure of SARS-CoV-2 Omicron BA.4/5 spike protein in complex with white-tailed deer ACE2
8IFZ	;	2.85	;	Cryo-EM structure of SARS-CoV-2 Omicron BA.4/5 spike protein receptor-binding domain in complex with white-tailed deer ACE2
8HQ7	;	2.7	;	Cryo-EM structure of SARS-CoV-2 Omicron Prototype RBD in complex with fab L4.65 and L5.34
8HPV	;	2.65	;	Cryo-EM structure of SARS-CoV-2 Omicron Prototype S-trimer in complex with fab L4.65 and L5.34
7XCI	;	3.2	;	Cryo-EM structure of SARS-CoV-2 Omicron RBD in complex with human ACE2 ectodomain (local refinement)
7XCK	;	2.5	;	Cryo-EM structure of SARS-CoV-2 Omicron RBD in complex with S309 fab (local refinement)
7WP5	;	3.9	;	Cryo-EM structure of SARS-CoV-2 Omicron S6P trimer in complex with neutralizing antibody VacW-209 (local refinement)
7XST	;	3.04	;	Cryo-EM structure of SARS-CoV-2 Omicron spike glycoprotein in complex with three F61 Fab and three D2 Fab
7TCC	;	3.86	;	Cryo-EM structure of SARS-CoV-2 Omicron spike in complex with antibodies A19-46.1 and B1-182.1
7TCA	;	3.85	;	Cryo-EM structure of SARS-CoV-2 Omicron spike in complex with antibody A19-46.1
7Y9Z	;	2.85	;	Cryo-EM structure of SARS-CoV-2 Omicron spike protein (S-6P-RRAR) in complex with human ACE2 ectodomain (one-RBD-up state)
7XCH	;	3.4	;	Cryo-EM structure of SARS-CoV-2 Omicron spike protein (S-6P-RRAR) in complex with human ACE2 ectodomain (two-RBD-up state)
7XCO	;	2.5	;	Cryo-EM structure of SARS-CoV-2 Omicron spike protein (S-6P-RRAR) in complex with S309 fab
7XDB	;	2.62	;	Cryo-EM structure of SARS-CoV-2 Omicron Spike protein in complex with BA7208 fab
7T9K	;	2.45	;	Cryo-EM structure of SARS-CoV-2 Omicron spike protein in complex with human ACE2
7T9L	;	2.66	;	Cryo-EM structure of SARS-CoV-2 Omicron spike protein in complex with human ACE2 (focused refinement of RBD and ACE2)
7WK4	;	3.69	;	Cryo-EM structure of SARS-CoV-2 Omicron spike protein with ACE2, C1 state
7WK6	;	3.67	;	Cryo-EM structure of SARS-CoV-2 Omicron spike protein with human ACE2 (focus refinement on RBD-1/ACE2)
7WVP	;	3.7	;	Cryo-EM structure of SARS-CoV-2 Omicron Spike protein with human ACE2 receptor, C2 state
7WVQ	;	4.04	;	Cryo-EM structure of SARS-CoV-2 Omicron Spike protein with human ACE2 receptor, C3 state
7WRI	;	3.03	;	Cryo-EM structure of SARS-CoV-2 Omicron spike receptor-binding domain in complex with mouse ACE2
6XDC	;	2.9	;	Cryo-EM structure of SARS-CoV-2 ORF3a
7KJR	;	2.08	;	Cryo-EM structure of SARS-CoV-2 ORF3a
8FDW	;	2.9	;	Cryo-EM structure of SARS-CoV-2 postfusion spike in membrane
8WOX	;	2.75	;	Cryo-EM structure of SARS-CoV-2 prototype RBD in complex with rabbit ACE2 (local refinement)
8WLO	;	2.62	;	Cryo-EM structure of SARS-CoV-2 prototype spike protein in complex with hippopotamus ACE2
8HFZ	;	2.71	;	Cryo-EM structure of SARS-CoV-2 prototype spike protein in complex with white-tailed deer ACE2
8WLR	;	3.12	;	Cryo-EM structure of SARS-CoV-2 prototype spike protein receptor-binding domain in complex with hippopotamus ACE2
8HG0	;	3.51	;	Cryo-EM structure of SARS-CoV-2 prototype spike protein receptor-binding domain in complex with white-tailed deer ACE2
8DW3	;	4.26	;	Cryo-EM structure of SARS-CoV-2 RBD in complex with anti-SARS-CoV-2 DARPin,SR16m, and two antibody Fabs, S309 and CR3022
8DW2	;	4.11	;	Cryo-EM structure of SARS-CoV-2 RBD in complex with anti-SARS-CoV-2 DARPin,SR22, and two antibody Fabs, S309 and CR3022
7Y6K	;	3.34	;	Cryo-EM structure of SARS-CoV-2 receptor binding domain in complex with K202.B bispecific antibody
7WP6	;	3.81	;	Cryo-EM structure of SARS-CoV-2 recombinant spike protein STFK in complex with three neutralizing antibodies
7WP8	;	3.88	;	Cryo-EM structure of SARS-CoV-2 recombinant spike protein STFK1628x in complex with three neutralizing antibodies
7V7Z	;	3.1	;	Cryo-EM structure of SARS-CoV-2 S-Beta variant (B.1.351) in complex with Angiotensin-converting enzyme 2 (ACE2) ectodomain, three ACE2-bound form
7V8C	;	3.4	;	Cryo-EM structure of SARS-CoV-2 S-Beta variant (B.1.351), Cleavable form, one RBD-up conformation
7V76	;	3.2	;	Cryo-EM structure of SARS-CoV-2 S-Beta variant (B.1.351), uncleavable form, one RBD-up conformation
7V77	;	3.3	;	Cryo-EM structure of SARS-CoV-2 S-Beta variant (B.1.351), uncleavable form, two RBD-up conformation
7EH5	;	4.0	;	Cryo-EM structure of SARS-CoV-2 S-D614G variant in complex with neutralizing antibodies, RBD-chAb15 and RBD-chAb45
7V89	;	2.8	;	Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2) in complex with Angiotensin-converting enzyme 2 (ACE2) ectodomain, three ACE2-bound form conformation 1
7V8A	;	2.7	;	Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2) in complex with Angiotensin-converting enzyme 2 (ACE2) ectodomain, three ACE2-bound form conformation 2
7V88	;	3.3	;	Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2) in complex with Angiotensin-converting enzyme 2 (ACE2) ectodomain, two ACE2-bound form
7V7N	;	2.9	;	Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2), all RBD-down conformation
7V7O	;	2.9	;	Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2), one RBD-up conformation 1
7V7P	;	2.9	;	Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2), one RBD-up conformation 2
7V7Q	;	2.8	;	Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2), one RBD-up conformation 3
7V7R	;	2.9	;	Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2), one RBD-up conformation 4
7V7S	;	3.0	;	Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2), one RBD-up conformation 5
7V7T	;	3.0	;	Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2), two RBD-up conformation 1
7V7U	;	3.0	;	Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2), two RBD-up conformation 2
7V7V	;	3.1	;	Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2), two RBD-up conformation 3
7V82	;	2.8	;	Cryo-EM structure of SARS-CoV-2 S-Gamma variant (P.1) in complex with Angiotensin-converting enzyme 2 (ACE2) ectodomain, three ACE2-bound form conformation 1
7V83	;	2.8	;	Cryo-EM structure of SARS-CoV-2 S-Gamma variant (P.1) in complex with Angiotensin-converting enzyme 2 (ACE2) ectodomain, three ACE2-bound form conformation 2
7V81	;	3.2	;	Cryo-EM structure of SARS-CoV-2 S-Gamma variant (P.1) in complex with Angiotensin-converting enzyme 2 (ACE2) ectodomain, two ACE2-bound form
7V78	;	3.4	;	Cryo-EM structure of SARS-CoV-2 S-Gamma variant (P.1), one RBD-up conformation 1
7V79	;	3.3	;	Cryo-EM structure of SARS-CoV-2 S-Gamma variant (P.1), one RBD-up conformation 2
7V7A	;	3.4	;	Cryo-EM structure of SARS-CoV-2 S-Gamma variant (P.1), two RBD-up conformation
7V86	;	2.8	;	Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1) in complex with Angiotensin-converting enzyme 2 (ACE2) ectodomain, three ACE2-bound form
7V85	;	3.3	;	Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1) in complex with Angiotensin-converting enzyme 2 (ACE2) ectodomain, two ACE2-bound form
7V7D	;	3.0	;	Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1), all RBD-down conformation
7V7H	;	3.2	;	Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1), dimer of S trimer conformation 1
7V7I	;	3.3	;	Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1), dimer of S trimer conformation 2
7V7J	;	3.4	;	Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1), dimer of S trimer conformation 3
7V7E	;	2.9	;	Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1), one RBD-up conformation 1
7V7F	;	2.9	;	Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1), one RBD-up conformation 2
7V7G	;	3.1	;	Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1), two RBD-up conformation
7EDJ	;	3.3	;	Cryo-EM structure of SARS-CoV-2 S-UK variant (B.1.1.7) in complex with Angiotensin-converting enzyme 2 (ACE2) ectodomain
7EDF	;	3.2	;	Cryo-EM structure of SARS-CoV-2 S-UK variant (B.1.1.7), one RBD-up conformation 1
7EDG	;	3.2	;	Cryo-EM structure of SARS-CoV-2 S-UK variant (B.1.1.7), one RBD-up conformation 2
7EDH	;	3.6	;	Cryo-EM structure of SARS-CoV-2 S-UK variant (B.1.1.7), one RBD-up conformation 3
7EDI	;	3.3	;	Cryo-EM structure of SARS-CoV-2 S-UK variant (B.1.1.7), two RBD-up conformation
7WON	;	3.9	;	Cryo-EM structure of SARS-CoV-2 S2P trimer in complex with neutralizing antibody VacW-209 (local refinement)
8BEV	;	5.92	;	Cryo-EM structure of SARS-CoV-2 spike (HexaPro variant) in complex with nanobody W25 (map 3, focus refinement on RBD, W25 and adjacent NTD)
8BGG	;	6.04	;	Cryo-EM structure of SARS-CoV-2 spike (Omicron BA.1 variant) in complex with nanobody W25 (map 5, focus refinement on RBD, W25 and adjacent NTD)
7Z6V	;	3.1	;	CRYO-EM STRUCTURE OF SARS-COV-2 SPIKE : H11 nanobody complex
7Z9Q	;	3.6	;	CRYO-EM STRUCTURE OF SARS-COV-2 SPIKE : H11-A10 nanobody complex
7Z85	;	3.1	;	CRYO-EM STRUCTURE OF SARS-COV-2 SPIKE : H11-B5 nanobody complex
6Z43	;	3.3	;	Cryo-EM Structure of SARS-CoV-2 Spike : H11-D4 Nanobody Complex
7Z86	;	3.4	;	CRYO-EM STRUCTURE OF SARS-COV-2 SPIKE : H11-H4 Q98R H100E nanobody complex in 1Up2Down conformation
7Z9R	;	4.2	;	CRYO-EM STRUCTURE OF SARS-COV-2 SPIKE : H11-H4 Q98R H100E nanobody complex in 2Up1Down conformation
7Z7X	;	3.3	;	CRYO-EM STRUCTURE OF SARS-COV-2 SPIKE : H11-H6 nanobody complex
7EAZ	;	3.5	;	Cryo-EM structure of SARS-CoV-2 Spike D614G variant, one RBD-up conformation 1
7EB0	;	3.6	;	Cryo-EM structure of SARS-CoV-2 Spike D614G variant, one RBD-up conformation 2
7EB3	;	3.6	;	Cryo-EM structure of SARS-CoV-2 Spike D614G variant, one RBD-up conformation 3
7EB4	;	3.5	;	Cryo-EM structure of SARS-CoV-2 Spike D614G variant, two RBD-up conformation 1
7EB5	;	3.4	;	Cryo-EM structure of SARS-CoV-2 Spike D614G variant, two RBD-up conformation 2
7CN9	;	4.7	;	Cryo-EM structure of SARS-CoV-2 Spike ectodomain
7XMZ	;	3.25	;	Cryo-EM structure of SARS-CoV-2 spike glycoprotein in complex with three D2 Fab
7XMX	;	3.62	;	Cryo-EM structure of SARS-CoV-2 spike glycoprotein in complex with three F61 Fab
7F62	;	3.6	;	Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody chAb-25 (Focused refinement of S-RBD and chAb-25 region)
7F63	;	3.9	;	Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody chAb-45 (Focused refinement of S-RBD and chAb-45 region)
7EJ4	;	3.6	;	Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody RBD-chAb-25
7EJ5	;	3.5	;	Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody RBD-chAb-45
7TB8	;	2.83	;	Cryo-EM structure of SARS-CoV-2 spike in complex with antibodies B1-182.1 and A19-61.1
7KML	;	3.8	;	cryo-EM structure of SARS-CoV-2 spike in complex with Fab 15033-7, three RBDs bound
7KMK	;	4.2	;	cryo-EM structure of SARS-CoV-2 spike in complex with Fab 15033-7, two RBDs bound
7TYZ	;	3.51	;	Cryo-EM structure of SARS-CoV-2 spike in complex with FSR22, an anti-SARS-CoV-2 DARPin
7TZ0	;	4.17	;	Cryo-EM structure of SARS-CoV-2 spike in complex with FSR22, an anti-SARS-CoV-2 DARPin (Local refinement of FSR22 and RBD)
7YC5	;	3.1	;	Cryo-EM structure of SARS-CoV-2 spike in complex with K202.B bispecific antibody
7LRS	;	3.89	;	Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody A23-58.1 that targets the receptor-binding domain
7LRT	;	3.54	;	Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody A23-58.1 that targets the receptor-binding domain
7MLZ	;	3.71	;	Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody B1-182.1 that targets the receptor-binding domain
7MM0	;	3.15	;	Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody B1-182.1 that targets the receptor-binding domain
7RQ6	;	4.18	;	Cryo-EM structure of SARS-CoV-2 spike in complex with non-neutralizing NTD-directed CV3-13 Fab isolated from convalescent individual
7XY3	;	4.6	;	Cryo-EM structure of SARS-CoV-2 spike in complex with VHH14
7XY4	;	3.3	;	Cryo-EM structure of SARS-CoV-2 spike in complex with VHH21
8H6F	;	3.3	;	Cryo-EM structure of SARS-CoV-2 Spike protein in complex with A6 repebody
8IV8	;	3.92	;	Cryo-EM structure of SARS-CoV-2 spike protein in complex with double nAbs 3E2 and 1C4 (local refinement)
8IV5	;	3.77	;	Cryo-EM structure of SARS-CoV-2 spike protein in complex with double nAbs 8H12 and 1C4 (local refinement)
8IV4	;	3.59	;	Cryo-EM structure of SARS-CoV-2 spike protein in complex with double nAbs 8H12 and 3E2 (local refinement)
8IVA	;	3.95	;	Cryo-EM structure of SARS-CoV-2 spike protein in complex with double nAbs XMA01 and 3E2 (local refinement)
7XRP	;	3.88	;	Cryo-EM structure of SARS-CoV-2 spike protein in complex with nanobody C5G2 (localized refinement)
7X7T	;	3.48	;	Cryo-EM structure of SARS-CoV-2 spike protein in complex with three nAbs X01, X10 and X17
6ZWV	;	3.5	;	Cryo-EM structure of SARS-CoV-2 Spike Proteins on intact virions: 3 Closed RBDs
7WSE	;	2.93	;	Cryo-EM structure of SARS-CoV-2 spike receptor-binding domain complexed with its receptor minke whale ACE2
7WSH	;	2.89	;	Cryo-EM structure of SARS-CoV-2 spike receptor-binding domain in complex with sea lion ACE2
8EPN	;	2.8	;	Cryo-EM structure of SARS-CoV-2 Spike trimer S2D14 in the 3-RBD Down conformation
8EPQ	;	3.3	;	Cryo-EM structure of SARS-CoV-2 Spike trimer S2D14 with two RBDs exposed
8EPP	;	3.1	;	Cryo-EM structure of SARS-CoV-2 Spike trimer S2D14 with two RBDs in the open conformation
8VKK	;	2.81	;	Cryo-EM structure of SARS-CoV-2 XBB.1.5 spike protein
8VKO	;	2.68	;	Cryo-EM structure of SARS-CoV-2 XBB.1.5 spike protein in complex with human ACE2
8VKP	;	2.77	;	Cryo-EM structure of SARS-CoV-2 XBB.1.5 spike protein in complex with human ACE2 (focused refinement of RBD and ACE2)
8VKM	;	2.83	;	Cryo-EM structure of SARS-CoV-2 XBB.1.5 spike protein in complex with mouse ACE2 (conformation 1)
8VKL	;	2.91	;	Cryo-EM structure of SARS-CoV-2 XBB.1.5 spike protein in complex with mouse ACE2 (conformation 2)
8VKN	;	2.93	;	Cryo-EM structure of SARS-CoV-2 XBB.1.5 spike protein in complex with mouse ACE2 (focused refinement of RBD and mouse ACE2)
8J1V	;	3.01	;	Cryo-EM structure of SARS-CoV2 Omicron BA.5 spike in complex with 8-9D Fabs
7DQA	;	2.8	;	Cryo-EM structure of SARS-CoV2 RBD-ACE2 complex
7X7A	;	3.2	;	Cryo-EM structure of SbCas7-11 in complex with crRNA and target RNA
6M49	;	3.7	;	cryo-EM structure of Scap/Insig complex in the present of 25-hydroxyl cholesterol.
7ETW	;	4.1	;	Cryo-EM structure of Scap/Insig complex in the present of digitonin.
7D0I	;	3.0	;	Cryo-EM structure of Schizosaccharomyces pombe Atg9
7XY9	;	2.12	;	Cryo-EM structure of secondary alcohol dehydrogenases TbSADH after carrier-free immobilization based on weak intermolecular interactions
6CX1	;	3.8	;	Cryo-EM structure of Seneca Valley Virus-Anthrax Toxin Receptor 1 complex
8W8B	;	3.0	;	Cryo-EM structure of SEP-363856 bounded serotonin 1A (5-HT1A) receptor-Gi protein complex
8GF7	;	4.8	;	Cryo-EM structure of serine 87 O-GlcNAc-modified alpha-synuclein fibrils
6BE1	;	4.31	;	Cryo-EM structure of serotonin receptor
7D20	;	3.0	;	Cryo-EM structure of SET8-CENP-A-nucleosome complex
7D1Z	;	3.15	;	Cryo-EM structure of SET8-nucleosome complex
7EW7	;	3.27	;	Cryo-EM structure of SEW2871-bound Sphingosine-1-phosphate receptor 1 in complex with Gi protein
8ORE	;	2.5	;	Cryo-EM structure of SH-SY5Y seeded with filaments from Alzheimer's Disease
8ORF	;	2.5	;	Cryo-EM structure of SH-SY5Y seeded with filaments from corticobasal degeneration extracts
8ORG	;	2.3	;	Cryo-EM structure of SH-SY5Y seeded with filaments from corticobasal degeneration extracts (Type II)
6QT9	;	3.8	;	Cryo-EM structure of SH1 full particle.
7PLA	;	3.04	;	Cryo-EM structure of ShCas12k in complex with a sgRNA and a dsDNA target
8AXA	;	2.96	;	Cryo-EM structure of shCas12k-sgRNA-dsDNA ternary complex (type V-K CRISPR-associated transposon)
7U6V	;	4.1	;	Cryo-EM structure of Shiga toxin 2 in complex with the native ribosomal P-stalk
6XRT	;	3.9	;	Cryo-EM structure of SHIV-elicited RHA1.V2.01 in complex with HIV-1 Env BG505 DS-SOSIP.664
7UR6	;	3.46	;	Cryo-EM structure of SHIV-elicited, FP-directed Rhesus Fab RM6561.DH1021.14 in complex with stabilized HIV-1 Env Ce1176 DS-SOSIP.664
7UPI	;	2.89	;	Cryo-EM structure of SHOC2-PP1c-MRAS holophosphatase complex
8VJB	;	3.6	;	Cryo-EM structure of short form insulin receptor (IR-A) with four IGF2 bound, symmetric conformation.
8VJC	;	3.8	;	Cryo-EM structure of short form insulin receptor (IR-A) with three IGF2 bound, asymmetric conformation.
7F4I	;	3.1	;	Cryo-EM structure of SHU9119-bound melanocortin-1 receptor in complex with Gs protein and Nb35
8QFS	;	2.7	;	Cryo-EM structure of SidH from Legionella pneumophila
8QHC	;	3.1	;	Cryo-EM structure of SidH from Legionella pneumophila in complex with LubX
7MIR	;	2.5	;	Cryo-EM structure of SidJ-SdeA-CaM reaction intermediate complex
7MIS	;	2.8	;	Cryo-EM structure of SidJ-SdeC-CaM reaction intermediate complex
8JUN	;	2.38	;	Cryo-EM structure of SIDT1 E555Q mutant
8JUL	;	2.92	;	Cryo-EM structure of SIDT1 in complex with phosphatidic acid
7XUI	;	3.61	;	Cryo-EM structure of sigma70 bound HK022 putRNA-associated E.coli RNA polymerase elongation complex
7KNE	;	3.85	;	Cryo-EM structure of single ACE2-bound SARS-CoV-2 trimer spike at pH 5.5
7KNB	;	3.93	;	Cryo-EM structure of single ACE2-bound SARS-CoV-2 trimer spike at pH 7.4
7XOL	;	3.26	;	Cryo-EM structure of single empty ring 2 (SER2) of GroEL-UGT1A complex at 3.2 Ang. resolution
8V4Y	;	2.8	;	Cryo-EM structure of singly-bound SNF2h-nucleosome complex with SNF2h at inactive SHL2 (conformation 1)
8V7L	;	2.9	;	Cryo-EM structure of singly-bound SNF2h-nucleosome complex with SNF2h at inactive SHL2 (conformation 2)
6NE3	;	3.9	;	Cryo-EM structure of singly-bound SNF2h-nucleosome complex with SNF2h bound at SHL-2
7V0N	;	5.9	;	Cryo-EM structure of SINV/EEEV in complex with Fab fragment of a moderately/weakly neutralizing human antibody IgG-21
7V0O	;	6.6	;	Cryo-EM structure of SINV/EEEV in complex with Fab fragment of a moderately/weakly neutralizing human antibody IgG-94
7V0P	;	5.2	;	Cryo-EM structure of SINV/EEEV in complex with Fab fragment of a potently neutralizing human antibody IgG-106
7EVY	;	2.98	;	Cryo-EM structure of siponimod -bound Sphingosine-1-phosphate receptor 1 in complex with Gi protein
7EW1	;	3.4	;	Cryo-EM structure of siponimod -bound Sphingosine-1-phosphate receptor 5 in complex with Gi protein
8DVD	;	4.12	;	Cryo-EM structure of SIVmac239 SOS-2P Env trimer in complex with human bNAb PGT145
8DMX	;	3.37	;	Cryo-EM structure of skeletal muscle alpha-actin
7JV5	;	3.0	;	Cryo-EM structure of SKF-81297-bound dopamine receptor 1 in complex with Gs protein
7JVP	;	2.9	;	Cryo-EM structure of SKF-83959-bound dopamine receptor 1 in complex with Gs protein
7CRH	;	3.3	;	Cryo-EM structure of SKF83959 bound dopamine receptor DRD1-Gs signaling complex
8BYL	;	3.5	;	Cryo-EM structure of SKP1-SKP2-CKS1 from the SCFSKP2 E3 ligase complex
8BYA	;	3.38	;	Cryo-EM structure of SKP1-SKP2-CKS1-CDK2-CyclinA-p27KIP1 Complex
7XTK	;	2.89	;	Cryo-EM structure of SLC19A1
6VYH	;	3.0	;	Cryo-EM structure of SLC40/ferroportin in complex with Fab
6WIK	;	3.4	;	Cryo-EM structure of SLC40/ferroportin with Fab in the presence of hepcidin
7OJF	;	3.9	;	CRYO-EM STRUCTURE OF SLYB13-BAMA FROM ESCHERICHIA COLI
7PWF	;	2.85	;	Cryo-EM structure of small subunit of Giardia lamblia ribosome at 2.9 A resolution
6V4U	;	3.8	;	Cryo-EM structure of SMCR8-C9orf72-WDR41 complex
8PS0	;	3.37	;	Cryo-EM structure of Sodium proton exchanger NhaA with bound cardiolipin
7CYE	;	3.54	;	Cryo-EM structure of sodium-dependent bicarbonate transporter SbtA from Synechocystis sp. PCC 6803
7FJO	;	3.34	;	Cryo-EM structure of South African (B.1.351) SARS-CoV-2 spike glycoprotein in complex with three T6 Fab
7FJN	;	3.25	;	Cryo-EM structure of South African (B.1.351) SARS-CoV-2 spike glycoprotein in complex with two T6 Fab
7W5Y	;	4.2	;	Cryo-EM structure of SoxS-dependent transcription activation complex with fpr promoter DNA
7W5W	;	4.55	;	Cryo-EM structure of SoxS-dependent transcription activation complex with micF promoter DNA
7W5X	;	3.4	;	Cryo-EM structure of SoxS-dependent transcription activation complex with zwf promoter DNA
8K34	;	2.81	;	Cryo-EM structure of SPARTA gRNA binary complex
5Y36	;	5.2	;	Cryo-EM structure of SpCas9-sgRNA-DNA ternary complex
8DT3	;	3.3	;	Cryo-EM structure of spike binding to Fab of neutralizing antibody (locally refined)
6JX7	;	3.31	;	Cryo-EM structure of spike protein of feline infectious peritonitis virus strain UU4
3JCU	;	3.2	;	Cryo-EM structure of spinach PSII-LHCII supercomplex at 3.2 Angstrom resolution
6ZQI	;	3.8	;	Cryo-EM structure of Spondweni virus prME
7YJ1	;	3.1	;	Cryo-EM structure of SPT-ORMDL3 (ORMDL3-deltaN2) complex
7YJ2	;	2.9	;	Cryo-EM structure of SPT-ORMDL3 (ORMDL3-N13A) complex
7YIY	;	2.7	;	Cryo-EM structure of SPT-ORMDL3 complex
7F75	;	4.2	;	Cryo-EM structure of Spx-dependent transcription activation complex
7V59	;	5.26	;	Cryo-EM structure of spyCas9-sgRNA-DNA dimer
8G07	;	2.8	;	Cryo-EM structure of SQ31f-bound Mycobacterium smegmatis ATP synthase FO region
8G08	;	2.8	;	Cryo-EM structure of SQ31f-bound Mycobacterium smegmatis ATP synthase rotational state 1 (backbone model)
8G09	;	3.1	;	Cryo-EM structure of SQ31f-bound Mycobacterium smegmatis ATP synthase rotational state 2 (backbone model)
8G0A	;	2.9	;	Cryo-EM structure of SQ31f-bound Mycobacterium smegmatis ATP synthase rotational state 3
8EIZ	;	3.13	;	Cryo-EM structure of squid sensory receptor CRB1
7XX2	;	3.6	;	Cryo-EM structure of Sr35 resistosome induced by AvrSr35 R381A
7KC1	;	3.41	;	Cryo-EM structure of SRR2899884.46167H+MEDI8852L fab in complex with Victoria HA
8HQY	;	3.05	;	Cryo-EM structure of SSX1 bound to the H2AK119Ub nucleosome at a resolution of 3.05 angstrom
8HR1	;	3.02	;	Cryo-EM structure of SSX1 bound to the unmodified nucleosome at a resolution of 3.02 angstrom
6RJG	;	3.2	;	Cryo-EM structure of St1Cas9-sgRNA-AcrIIA6-tDNA59-ntPAM complex.
6RJA	;	3.0	;	Cryo-EM structure of St1Cas9-sgRNA-tDNA20-AcrIIA6 dimeric assembly.
6RJ9	;	3.2	;	Cryo-EM structure of St1Cas9-sgRNA-tDNA20-AcrIIA6 monomeric assembly.
6RJD	;	3.3	;	Cryo-EM structure of St1Cas9-sgRNA-tDNA59-ntPAM complex.
6VRW	;	3.71	;	Cryo-EM structure of stabilized HIV-1 Env trimer CAP256.wk34.c80 SOSIP.RnS2
8BHF	;	3.1	;	Cryo-EM structure of stalled rabbit 80S ribosomes in complex with human CCR4-NOT and CNOT4
8FXH	;	2.8	;	Cryo-EM structure of Stanieria sp. CphA2
8FXI	;	2.7	;	Cryo-EM structure of Stanieria sp. CphA2 in complex with ADPCP and 4x(beta-Asp-Arg)
8J5D	;	3.0	;	Cryo-EM structure of starch degradation complex of BAM1-LSF1-MDH
6VZG	;	4.2	;	Cryo-EM structure of Sth1-Arp7-Arp9-Rtt102
6VZ4	;	3.9	;	Cryo-EM structure of Sth1-Arp7-Arp9-Rtt102 bound to the nucleosome in ADP Beryllium Fluoride state
8IK0	;	3.3	;	Cryo-EM structure of Stimulator of interferon genes
8FLK	;	4.0	;	Cryo-EM structure of STING oligomer bound to cGAMP and NVS-STG2
8FLM	;	2.9	;	Cryo-EM structure of STING oligomer bound to cGAMP, NVS-STG2 and C53
8GVK	;	2.2	;	Cryo-EM structure of streptavidin
8HRM	;	2.56	;	Cryo-EM structure of streptavidin
7VPD	;	3.77	;	Cryo-EM structure of Streptomyces coelicolor RNAP-promoter open complex with one Zur dimers
7X75	;	3.45	;	Cryo-EM structure of Streptomyces coelicolor RNAP-promoter open complex with three Zur dimers
7X76	;	3.67	;	Cryo-EM structure of Streptomyces coelicolor RNAP-promoter open complex with two Zur dimers
7VPZ	;	4.14	;	Cryo-EM structure of Streptomyces coelicolor transcription initial complex with one Zur dimer
7X74	;	3.7	;	Cryo-EM structure of Streptomyces coelicolor transcription initial complex with two Zur dimers.
5L3P	;	3.7	;	Cryo-EM structure of stringent response factor RelA bound to ErmCL-stalled ribosome complex
7K36	;	3.3	;	Cryo-EM structure of STRIPAK complex
8OTW	;	3.68	;	Cryo-EM structure of Strongylocentrotus purpuratus SLC9C1 in presence of cAMP
8OTQ	;	3.22	;	Cryo-EM structure of Strongylocentrotus purpuratus sperm-specific Na+/H+ exchanger SLC9C1 in GDN
8OTX	;	3.08	;	Cryo-EM structure of Strongylocentrotus purpuratus sperm-specific Na+/H+ exchanger SLC9C1 in nanodisc
8PNV	;	2.048	;	Cryo-EM structure of styrene oxide isomerase
8PNU	;	2.12	;	Cryo-EM structure of styrene oxide isomerase bound to benzylamine inhibitor
7WBB	;	3.6	;	Cryo-EM structure of substrate engaged Drg1 hexamer
8D8O	;	3.35	;	Cryo-EM structure of substrate unbound PAPP-A
8E91	;	2.57	;	Cryo-EM structure of substrate-free ClpX.ClpP
8E8Q	;	3.12	;	Cryo-EM structure of substrate-free DNClpX.ClpP
8E7V	;	3.1	;	Cryo-EM structure of substrate-free DNClpX.ClpP from singly capped particles
8B6G	;	3.0	;	Cryo-EM structure of succinate dehydrogenase complex (complex-II) in respiratory supercomplex of Tetrahymena thermophila
6JD1	;	3.38	;	Cryo-EM Structure of Sulfolobus solfataricus ketol-acid reductoisomerase (Sso-KARI) in complex with Mg2+, NADH, and CPD at pH7.5
6JCZ	;	3.35	;	Cryo-EM Structure of Sulfolobus solfataricus ketol-acid reductoisomerase (Sso-KARI) in complex with Mg2+, NADPH, and CPD at pH7.5
6JCV	;	2.92	;	Cryo-EM structure of Sulfolobus solfataricus ketol-acid reductoisomerase (Sso-KARI) with Mg2+ at pH7.5
6JCW	;	3.04	;	Cryo-EM Structure of Sulfolobus solfataricus ketol-acid reductoisomerase (Sso-KARI) with Mg2+ at pH8.5
6M3X	;	2.24	;	Cryo-EM structure of sulfur oxygenase reductase from Sulfurisphaera tokodaii
8IZ7	;	3.8	;	cryo-EM structure of sulindac-bound hMRP4
8GZH	;	2.96	;	Cryo-EM structure of Synechocystis sp. PCC 6803 CTP-bound RPitc
8GZG	;	3.13	;	Cryo-EM structure of Synechocystis sp. PCC 6803 RPitc
8H7Q	;	3.8	;	Cryo-EM structure of Synechocystis sp. PCC6714 Cascade at 3.8 angstrom resolution
8GEL	;	3.9	;	Cryo-EM structure of synthetic tetrameric building block sC4
6SKF	;	2.95	;	Cryo-EM Structure of T. kodakarensis 70S ribosome
6TH6	;	2.55	;	Cryo-EM Structure of T. kodakarensis 70S ribosome
6SKG	;	2.65	;	Cryo-EM Structure of T. kodakarensis 70S ribosome in TkNat10 deleted strain
8DOK	;	3.2	;	Cryo-EM structure of T/F100 SOSIP.664 HIV-1 Env trimer in complex with 8ANC195 and 10-1074
6NQD	;	3.9	;	Cryo-EM structure of T/F100 SOSIP.664 HIV-1 Env trimer in complex with 8ANC195 Fab
8G6U	;	3.16	;	Cryo-EM structure of T/F100 SOSIP.664 HIV-1 Env trimer with LMHS mutations in complex with 8ANC195 and 10-1074
8CZZ	;	3.14	;	Cryo-EM structure of T/F100 SOSIP.664 HIV-1 Env trimer with LMHS mutations in complex with Temsavir, 8ANC195, and 10-1074
7A8Z	;	3.35	;	Cryo-EM structure of T275P KatG from M. tuberculosis
8UNH	;	3.21	;	Cryo-EM structure of T4 Bacteriophage Clamp Loader with Sliding Clamp
8UNF	;	3.15	;	Cryo-EM structure of T4 Bacteriophage Clamp Loader with Sliding Clamp and DNA
6YSZ	;	3.6	;	Cryo-EM structure of T7 bacteriophage DNA translocation gp15 core protein intermediate assembly
6YT5	;	3.0	;	Cryo-EM structure of T7 bacteriophage DNA translocation gp15-gp16 core complex intermediate assembly
6R21	;	3.33	;	Cryo-EM structure of T7 bacteriophage fiberless tail complex
6QXM	;	4.1	;	Cryo-EM structure of T7 bacteriophage portal protein, 12mer, open valve
6AB5	;	3.7	;	Cryo-EM structure of T=1 Penaeus vannamei nodavirus
6AB6	;	3.5	;	Cryo-EM structure of T=3 Penaeus vannamei nodavirus
7N0K	;	3.5	;	Cryo-EM structure of TACAN in the apo form (TMEM120A)
7N0L	;	2.8	;	Cryo-EM structure of TACAN in the H196A H197A mutant form (TMEM120A)
8G0B	;	2.8	;	Cryo-EM structure of TBAJ-876-bound Mycobacterium smegmatis ATP synthase FO region
8G0C	;	2.8	;	Cryo-EM structure of TBAJ-876-bound Mycobacterium smegmatis ATP synthase rotational state 1 (backbone model)
8G0D	;	2.9	;	Cryo-EM structure of TBAJ-876-bound Mycobacterium smegmatis ATP synthase rotational state 2 (backbone model)
8G0E	;	2.6	;	Cryo-EM structure of TBAJ-876-bound Mycobacterium smegmatis ATP synthase rotational state 3
7Q3U	;	3.7	;	Cryo-EM structure of TDP43 core peptide amyloid fiber
7F4U	;	4.2	;	Cryo-EM structure of TELO2-TTI1-TTI2 complex
6MUT	;	3.1	;	Cryo-EM structure of ternary Csm-crRNA-target RNA with anti-tag sequence complex in type III-A CRISPR-Cas system
3J9Y	;	3.9	;	Cryo-EM structure of tetracycline resistance protein TetM bound to a translating E.coli ribosome
7YC8	;	4.14	;	Cryo-EM structure of Tetrahymena ribozyme conformation 1 undergoing the first-step self-splicing
7YG9	;	2.68	;	Cryo-EM structure of Tetrahymena ribozyme conformation 1 undergoing the second-step self-splicing
7YCG	;	3.18	;	Cryo-EM structure of Tetrahymena ribozyme conformation 2 undergoing the first-step self-splicing
7YGA	;	2.35	;	Cryo-EM structure of Tetrahymena ribozyme conformation 2 undergoing the second-step self-splicing
7YCH	;	3.09	;	Cryo-EM structure of Tetrahymena ribozyme conformation 3 undergoing the first-step self-splicing
7YGB	;	2.62	;	Cryo-EM structure of Tetrahymena ribozyme conformation 3 undergoing the second-step self-splicing
7YCI	;	2.98	;	Cryo-EM structure of Tetrahymena ribozyme conformation 4 undergoing the first-step self-splicing
7YGC	;	2.65	;	Cryo-EM structure of Tetrahymena ribozyme conformation 4 undergoing the second-step self-splicing
7YG8	;	2.97	;	Cryo-EM structure of Tetrahymena ribozyme conformation 5 undergoing the second-step self-splicing
7YGD	;	3.41	;	Cryo-EM structure of Tetrahymena ribozyme conformation 6 undergoing the second-step self-splicing
6YNW	;	3.1	;	Cryo-EM structure of Tetrahymena thermophila mitochondrial ATP synthase - central stalk/cring
6YO0	;	2.9	;	Cryo-EM structure of Tetrahymena thermophila mitochondrial ATP synthase - F1/peripheral stalk
6YNY	;	2.7	;	Cryo-EM structure of Tetrahymena thermophila mitochondrial ATP synthase - F1Fo composite dimer model
6YNZ	;	3.1	;	Cryo-EM structure of Tetrahymena thermophila mitochondrial ATP synthase - F1Fo composite tetramer model
6YNX	;	2.5	;	Cryo-EM structure of Tetrahymena thermophila mitochondrial ATP synthase - Fo-subcomplex
6YNV	;	2.8	;	Cryo-EM structure of Tetrahymena thermophila mitochondrial ATP synthase - Fo-wing region
7W5Z	;	3.02	;	Cryo-EM structure of Tetrahymena thermophila mitochondrial complex IV, composite dimer model
8GYM	;	2.96	;	Cryo-EM structure of Tetrahymena thermophila respiratory mega-complex MC IV2+(I+III2+II)2
8GZU	;	4.18	;	Cryo-EM structure of Tetrahymena thermophila respiratory Megacomplex MC (IV2+I+III2+II)2
6N7G	;	6.8	;	Cryo-EM structure of tetrameric Ptch1 in complex with ShhNp (form I)
6N7K	;	6.5	;	Cryo-EM structure of tetrameric Ptch1 in complex with ShhNp (form II)
8IFL	;	3.11	;	Cryo-EM structure of tetrameric SPARTA gRNA-ssDNA target complex in state 1
8IFM	;	2.92	;	Cryo-EM structure of tetrameric SPARTA gRNA-ssDNA target complex in state 2
7WM4	;	3.2	;	Cryo-EM structure of tetrameric TLR3 in complex with dsRNA (90 bp)
7TAC	;	3.6	;	Cryo-EM structure of the (TGA3)2-(NPR1)2-(TGA3)2 complex
7OYA	;	3.2	;	Cryo-EM structure of the 1 hpf zebrafish embryo 80S ribosome
8JLD	;	2.48	;	Cryo-EM structure of the 145 bp human nucleosome containing acetylated H3 tail
8JLB	;	2.36	;	Cryo-EM structure of the 145 bp human nucleosome containing H3.2 C110A mutant
7E9C	;	3.5	;	Cryo-EM structure of the 1:1 Orc1 BAH domain in complex with nucleosome
7TEJ	;	2.74	;	Cryo-EM structure of the 20S Alpha 3 Deletion proteasome core particle
7TEO	;	2.97	;	Cryo-EM structure of the 20S Alpha 3 Deletion proteasome core particle in complex with FUB1
6N7H	;	3.6	;	Cryo-EM structure of the 2:1 hPtch1-Shhp complex
7E9F	;	4.0	;	Cryo-EM structure of the 2:1 Orc1 BAH domain in complex with nucleosome
8J6Q	;	2.6	;	Cryo-EM structure of the 3-HB and compound 9n-bound human HCAR2-Gi1 complex
8J18	;	2.89	;	Cryo-EM structure of the 3-OH-C12-bound GPR84 receptor-Gi complex
8IYJ	;	3.5	;	Cryo-EM structure of the 48-nm repeat doublet microtubule from mouse sperm
6YS3	;	2.58	;	Cryo-EM structure of the 50S ribosomal subunit at 2.58 Angstroms with modeled GBC SecM peptide
6QDW	;	2.83	;	Cryo-EM structure of the 50S ribosomal subunit at 2.83 Angstroms with modeled GBC SecM peptide
8DPF	;	2.84	;	Cryo-EM structure of the 5HT2C receptor (INI isoform) bound to lorcaserin
8DPG	;	3.6	;	Cryo-EM structure of the 5HT2C receptor (INI isoform) bound to psilocin
8DPH	;	3.2	;	Cryo-EM structure of the 5HT2C receptor (VGV isoform) bound to lorcaserin
8DPI	;	3.4	;	Cryo-EM structure of the 5HT2C receptor (VSV isoform) bound to lorcaserin
7OYB	;	2.4	;	Cryo-EM structure of the 6 hpf zebrafish embryo 80S ribosome
4V8T	;	8.1	;	Cryo-EM Structure of the 60S Ribosomal Subunit in Complex with Arx1 and Rei1
5V93	;	4.0	;	Cryo-EM structure of the 70S ribosome from Mycobacterium tuberculosis bound with Capreomycin
8ID3	;	3.1	;	Cryo-EM structure of the 9-hydroxystearic acid bound GPR120-Gi complex
5JPQ	;	7.3	;	Cryo-EM structure of the 90S pre-ribosome
6RXT	;	7.0	;	Cryo-EM structure of the 90S pre-ribosome (Kre33-Noc4) from Chaetomium thermophilum, state A
6RXY	;	4.7	;	Cryo-EM structure of the 90S pre-ribosome (Kre33-Noc4) from Chaetomium thermophilum, state a
6RXZ	;	4.4	;	Cryo-EM structure of the 90S pre-ribosome (Kre33-Noc4) from Chaetomium thermophilum, state b
6RXU	;	3.5	;	Cryo-EM structure of the 90S pre-ribosome (Kre33-Noc4) from Chaetomium thermophilum, state B1
6RXV	;	4.0	;	Cryo-EM structure of the 90S pre-ribosome (Kre33-Noc4) from Chaetomium thermophilum, state B2
6RXX	;	7.1	;	Cryo-EM structure of the 90S pre-ribosome (Kre33-Noc4) from Chaetomium thermophilum, state C, Poly-Ala
5OQL	;	3.2	;	Cryo-EM structure of the 90S pre-ribosome from Chaetomium thermophilum
6ZQA	;	4.4	;	Cryo-EM structure of the 90S pre-ribosome from Saccharomyces cerevisiae, state A (Poly-Ala)
6ZQB	;	3.9	;	Cryo-EM structure of the 90S pre-ribosome from Saccharomyces cerevisiae, state B2
6ZQE	;	7.1	;	Cryo-EM structure of the 90S pre-ribosome from Saccharomyces cerevisiae, state Dis-A (Poly-Ala)
6ZQF	;	4.9	;	Cryo-EM structure of the 90S pre-ribosome from Saccharomyces cerevisiae, state Dis-B (Poly-Ala)
6ZQG	;	3.5	;	Cryo-EM structure of the 90S pre-ribosome from Saccharomyces cerevisiae, state Dis-C
6ZQD	;	3.8	;	Cryo-EM structure of the 90S pre-ribosome from Saccharomyces cerevisiae, state Post-A1
6ZQC	;	3.8	;	Cryo-EM structure of the 90S pre-ribosome from Saccharomyces cerevisiae, state Pre-A1
5WYJ	;	8.7	;	Cryo-EM structure of the 90S small subunit pre-ribosome (Dhr1-depleted, Enp1-TAP, state 1)
5WYK	;	4.5	;	Cryo-EM structure of the 90S small subunit pre-ribosome (Mtr4-depleted, Enp1-TAP)
7AJU	;	3.8	;	Cryo-EM structure of the 90S-exosome super-complex (state Post-A1-exosome)
7AJT	;	4.6	;	Cryo-EM structure of the 90S-exosome super-complex (state Pre-A1-exosome)
6IC4	;	8.7	;	Cryo-EM structure of the A. baumannii MLA complex at 8.7 A resolution
6Z5U	;	3.9	;	Cryo-EM structure of the A. baumannii MlaBDEF complex bound to APPNHP
8W8R	;	3.3	;	Cryo-EM structure of the AA-14-bound GPR101-Gs complex
8W8S	;	3.3	;	Cryo-EM structure of the AA14-bound GPR101 complex
7Y35	;	2.9	;	Cryo-EM structure of the Abaloparatide-bound human PTH1R-Gs complex
6HA8	;	3.5	;	Cryo-EM structure of the ABCF protein VmlR bound to the Bacillus subtilis ribosome
6HBU	;	3.09	;	Cryo-EM structure of the ABCG2 E211Q mutant bound to ATP and Magnesium
6HZM	;	3.09	;	Cryo-EM structure of the ABCG2 E211Q mutant bound to ATP and Magnesium (alternative placement of Magnesium into the cryo-EM density)
6HCO	;	3.58	;	Cryo-EM structure of the ABCG2 E211Q mutant bound to estrone 3-sulfate and 5D3-Fab
8WD6	;	2.87	;	Cryo-EM structure of the ABCG25
8WBX	;	3.23	;	Cryo-EM structure of the ABCG25 bound to ABA
8WBA	;	3.1	;	Cryo-EM structure of the ABCG25 bound to CHS
8WAM	;	3.23	;	Cryo-EM structure of the ABCG25 E232Q mutant bound to ATP and Magnesium
8CA1	;	4.3	;	Cryo-EM structure of the ACADVL dimer from Mus musculus.
7SQD	;	3.7	;	Cryo-EM structure of the Achromobacter flagellar filament
6V3E	;	4.4	;	Cryo-EM structure of the Acinetobacter baumannii Ribosome: 30S subunit
6V3D	;	2.95	;	Cryo-EM structure of the Acinetobacter baumannii Ribosome: 50S subunit
6V3B	;	2.91	;	Cryo-EM structure of the Acinetobacter baumannii Ribosome: 70S in Empty state
6V3A	;	2.82	;	Cryo-EM structure of the Acinetobacter baumannii Ribosome: 70S with E-site tRNA
6V39	;	3.04	;	Cryo-EM structure of the Acinetobacter baumannii Ribosome: 70S with P-site tRNA
6ROJ	;	2.9	;	Cryo-EM structure of the activated Drs2p-Cdc50p
5VAI	;	4.1	;	Cryo-EM structure of the activated Glucagon-like peptide-1 receptor in complex with G protein
7DVQ	;	2.89	;	Cryo-EM Structure of the Activated Human Minor Spliceosome (minor Bact Complex)
3JBL	;	4.7	;	Cryo-EM Structure of the Activated NAIP2/NLRC4 Inflammasome Reveals Nucleated Polymerization
6BCU	;	3.8	;	Cryo-EM structure of the activated RHEB-mTORC1 refined to 3.4 angstrom
5GM6	;	3.5	;	Cryo-EM structure of the activated spliceosome (Bact complex) at 3.5 angstrom resolution
7DCO	;	2.5	;	Cryo-EM structure of the activated spliceosome (Bact complex) at an atomic resolution of 2.5 angstrom
8EJ4	;	3.4	;	Cryo-EM structure of the active NLRP3 inflammasome disk
2WW9	;	8.6	;	Cryo-EM structure of the active yeast Ssh1 complex bound to the yeast 80S ribosome
6E3Y	;	3.3	;	Cryo-EM structure of the active, Gs-protein complexed, human CGRP receptor
7PMD	;	2.9	;	Cryo-EM structure of the actomyosin-V complex in the post-rigor transition state (AppNHp, central 1er)
7PMF	;	3.4	;	Cryo-EM structure of the actomyosin-V complex in the post-rigor transition state (AppNHp, central 1er, class 1)
7PMG	;	3.3	;	Cryo-EM structure of the actomyosin-V complex in the post-rigor transition state (AppNHp, central 1er, class 3)
7PMH	;	3.4	;	Cryo-EM structure of the actomyosin-V complex in the post-rigor transition state (AppNHp, central 1er, class 4)
7PMI	;	3.3	;	Cryo-EM structure of the actomyosin-V complex in the post-rigor transition state (AppNHp, central 1er, class 5)
7PMJ	;	3.4	;	Cryo-EM structure of the actomyosin-V complex in the post-rigor transition state (AppNHp, central 1er, class 6)
7PML	;	3.3	;	Cryo-EM structure of the actomyosin-V complex in the post-rigor transition state (AppNHp, central 1er, class 8)
7PME	;	2.9	;	Cryo-EM structure of the actomyosin-V complex in the post-rigor transition state (AppNHp, central 3er/2er)
7PLT	;	3.3	;	Cryo-EM structure of the actomyosin-V complex in the rigor state (central 1er)
7PLV	;	3.5	;	Cryo-EM structure of the actomyosin-V complex in the rigor state (central 1er, class 1)
7PLW	;	3.5	;	Cryo-EM structure of the actomyosin-V complex in the rigor state (central 1er, class 2)
7PLX	;	3.6	;	Cryo-EM structure of the actomyosin-V complex in the rigor state (central 1er, class 4)
7PLY	;	3.2	;	Cryo-EM structure of the actomyosin-V complex in the rigor state (central 1er, young JASP-stabilized F-actin)
7PM0	;	3.6	;	Cryo-EM structure of the actomyosin-V complex in the rigor state (central 1er, young JASP-stabilized F-actin, class 1)
7PM1	;	3.5	;	Cryo-EM structure of the actomyosin-V complex in the rigor state (central 1er, young JASP-stabilized F-actin, class 2)
7PM2	;	3.6	;	Cryo-EM structure of the actomyosin-V complex in the rigor state (central 1er, young JASP-stabilized F-actin, class 4)
7PLU	;	3.2	;	Cryo-EM structure of the actomyosin-V complex in the rigor state (central 3er/2er)
7PLZ	;	3.2	;	Cryo-EM structure of the actomyosin-V complex in the rigor state (central 3er/2er, young JASP-stabilized F-actin)
7PM5	;	3.1	;	Cryo-EM structure of the actomyosin-V complex in the strong-ADP state (central 1er)
7PM7	;	3.5	;	Cryo-EM structure of the actomyosin-V complex in the strong-ADP state (central 1er, class 2)
7PM8	;	3.5	;	Cryo-EM structure of the actomyosin-V complex in the strong-ADP state (central 1er, class 3)
7PM9	;	3.7	;	Cryo-EM structure of the actomyosin-V complex in the strong-ADP state (central 1er, class 4)
7PMA	;	3.6	;	Cryo-EM structure of the actomyosin-V complex in the strong-ADP state (central 1er, class 5)
7PMB	;	3.6	;	Cryo-EM structure of the actomyosin-V complex in the strong-ADP state (central 1er, class 6)
7PMC	;	3.7	;	Cryo-EM structure of the actomyosin-V complex in the strong-ADP state (central 1er, class 7)
7PM6	;	3.0	;	Cryo-EM structure of the actomyosin-V complex in the strong-ADP state (central 3er/2er)
6GDG	;	4.11	;	Cryo-EM structure of the adenosine A2A receptor bound to a miniGs heterotrimer
7WU2	;	2.8	;	Cryo-EM structure of the adhesion GPCR ADGRD1 in complex with miniGs
7WU4	;	3.4	;	Cryo-EM structure of the adhesion GPCR ADGRF1 in complex with miniGi
7WU3	;	3.1	;	Cryo-EM structure of the adhesion GPCR ADGRF1 in complex with miniGs
7WU5	;	3.0	;	Cryo-EM structure of the adhesion GPCR ADGRF1(H565A/T567A) in complex with miniGi
7R8V	;	2.82	;	Cryo-EM structure of the ADP state actin filament
7RB8	;	3.63	;	cryo-EM structure of the ADP state wild type myosin-15-F-actin complex
7UDU	;	4.15	;	cryo-EM structure of the ADP state wild type myosin-15-F-actin complex (symmetry expansion and re-centering)
8J9V	;	2.71	;	Cryo-EM structure of the African swine fever virus topoisomerase 2 complexed with Cut02aDNA and etoposide (EDI-1)
8J9X	;	3.0	;	Cryo-EM structure of the African swine fever virus topoisomerase 2 complexed with Cut02aDNA and m-AMSA (EDI-3)
8J9W	;	2.76	;	Cryo-EM structure of the African swine fever virus topoisomerase 2 complexed with Cut02bDNA and etoposide (EDI-2)
7PIU	;	2.58	;	Cryo-EM structure of the agonist setmelanotide bound to the active melanocortin-4 receptor (MC4R) in complex with the heterotrimeric Gs protein at 2.6 A resolution.
8FAI	;	3.0	;	Cryo-EM structure of the Agrobacterium T-pilus
6LOD	;	3.2	;	Cryo-EM structure of the air-oxidized photosynthetic alternative complex III from Roseiflexus castenholzii
7XUF	;	3.3	;	Cryo-EM structure of the AKT1-AtKC1 complex from Arabidopsis thaliana
8WXB	;	4.2	;	Cryo-EM structure of the alpha-carboxysome shell vertex from Prochlorococcus MED4
8INR	;	2.73	;	Cryo-EM structure of the alpha-MSH-bound human melanocortin receptor 5 (MC5R)-Gs complex
7W7E	;	3.4	;	Cryo-EM structure of the alpha2A adrenergic receptor GoA signaling complex bound to a biased agonist
7W6P	;	3.47	;	Cryo-EM structure of the alpha2A adrenergic receptor GoA signaling complex bound to a G protein biased agonist
7DD9	;	2.4	;	Cryo-EM structure of the Ams1 and Nbr1 complex
6VPS	;	2.6	;	Cryo-EM structure of the amyloid core of Drosophila Orb2 isolated from head
8P23	;	3.17	;	Cryo-EM structure of the anaerobic ribonucleotide reductase from Prevotella copri in its dimeric, ATP/CTP-bound state
8P2S	;	2.4	;	Cryo-EM structure of the anaerobic ribonucleotide reductase from Prevotella copri in its dimeric, ATP/dTTP/GTP-bound state
8P27	;	2.73	;	Cryo-EM structure of the anaerobic ribonucleotide reductase from Prevotella copri in its dimeric, dATP-bound state
8P39	;	2.58	;	Cryo-EM structure of the anaerobic ribonucleotide reductase from Prevotella copri in its dimeric, dGTP/ATP-bound state
8P2C	;	2.59	;	Cryo-EM structure of the anaerobic ribonucleotide reductase from Prevotella copri in its tetrameric state produced in the presence of dATP and CTP
8P28	;	2.77	;	Cryo-EM structure of the anaerobic ribonucleotide reductase from Prevotella copri in its tetrameric, dATP-bound state
8S4G	;	3.2	;	Cryo-EM structure of the Anaphase-promoting complex/cyclosome (APC/C) bound to co-activator Cdh1 at 3.2 Angstrom resolution
6TLJ	;	3.8	;	Cryo-EM structure of the Anaphase-promoting complex/Cyclosome, in complex with the Mitotic checkpoint complex (APC/C-MCC) at 3.8 angstrom resolution
5LCW	;	4.2	;	Cryo-EM structure of the Anaphase-promoting complex/Cyclosome, in complex with the Mitotic checkpoint complex (APC/C-MCC) at 4.2 angstrom resolution
6TM5	;	3.9	;	Cryo-EM structure of the Anaphase-promoting complex/Cyclosome, in complex with the Nek2A substrate at 3.9 angstrom resolution
6RGL	;	5.4	;	Cryo-EM structure of the anti-feeding prophage (AFP) baseplate in contracted state
6RBK	;	3.4	;	Cryo-EM structure of the anti-feeding prophage (AFP) baseplate in extended state, 3-fold symmetrised
6RAO	;	3.1	;	Cryo-EM structure of the anti-feeding prophage (AFP) baseplate, 6-fold symmetrised
6RC8	;	3.8	;	Cryo-EM structure of the anti-feeding prophage (AFP) helical sheath in contracted state
6RBN	;	2.8	;	Cryo-EM structure of the anti-feeding prophage (AFP) helical sheath-tube complex in extended state
6RAP	;	3.3	;	Cryo-EM structure of the anti-feeding prophage cap (AFP tube terminating cap)
6Q6G	;	3.2	;	Cryo-EM structure of the APC/C-Cdc20-Cdk2-cyclinA2-Cks2 complex, the D1 box class
6Q6H	;	3.2	;	Cryo-EM structure of the APC/C-Cdc20-Cdk2-cyclinA2-Cks2 complex, the D2 box class
7DDE	;	2.26	;	Cryo-EM structure of the Ape4 and Nbr1 complex
8PKP	;	3.2	;	Cryo-EM structure of the apo Anaphase-promoting complex/cyclosome (APC/C) at 3.2 Angstrom resolution
7VL8	;	2.9	;	Cryo-EM structure of the Apo CCR1-Gi complex
7X9Y	;	3.1	;	Cryo-EM structure of the apo CCR3-Gi complex
7F1S	;	2.8	;	Cryo-EM structure of the apo chemokine receptor CCR5 in complex with Gi
6UGH	;	3.4	;	Cryo-EM structure of the apo form of human PRMT5:MEP50 complex at a resolution of 3.4 angstrom
7BV1	;	2.8	;	Cryo-EM structure of the apo nsp12-nsp7-nsp8 complex
8HQE	;	2.97	;	Cryo-EM structure of the apo-GPR132-Gi
8BEF	;	2.13	;	Cryo-EM structure of the Arabidopsis thaliana I+III2 supercomplex (CI membrane core)
8BEH	;	2.29	;	Cryo-EM structure of the Arabidopsis thaliana I+III2 supercomplex (CI membrane tip)
8BEE	;	2.04	;	Cryo-EM structure of the Arabidopsis thaliana I+III2 supercomplex (CI peripheral core)
8BED	;	2.03	;	Cryo-EM structure of the Arabidopsis thaliana I+III2 supercomplex (CI peripheral tip)
8BEL	;	2.25	;	Cryo-EM structure of the Arabidopsis thaliana I+III2 supercomplex (CIII membrane domain)
8BEP	;	2.29	;	Cryo-EM structure of the Arabidopsis thaliana I+III2 supercomplex (CIII MPP domain)
8BPX	;	2.09	;	Cryo-EM structure of the Arabidopsis thaliana I+III2 supercomplex (Complete composition)
8BQ5	;	2.73	;	Cryo-EM structure of the Arabidopsis thaliana I+III2 supercomplex (Complete conformation 1 composition)
8BQ6	;	2.8	;	Cryo-EM structure of the Arabidopsis thaliana I+III2 supercomplex (Complete conformation 2 composition)
8J6Z	;	2.79	;	Cryo-EM structure of the Arabidopsis thaliana photosystem I(PSI-LHCII-ST2)
6H82	;	3.78	;	Cryo-EM structure of the archaeal extremophilic internal membrane containing Haloarcula hispanica icosahedral virus 2 (HHIV-2) at 3.78 Angstroms resolution.
6YW7	;	4.5	;	Cryo-EM structure of the ARP2/3 1A5C isoform complex.
6YW6	;	4.2	;	Cryo-EM structure of the ARP2/3 1B5CL isoform complex.
8J3R	;	2.95	;	Cryo-EM structure of the AsCas12f-HKRA-sgRNAS3-5v7-target DNA
8J12	;	3.08	;	Cryo-EM structure of the AsCas12f-sgRNA-target DNA ternary complex
8J1J	;	2.91	;	Cryo-EM structure of the AsCas12f-YHAM-sgRNAS3-5v7-target DNA
7WJU	;	2.69	;	Cryo-EM structure of the AsCas12f1-sgRNAv1-dsDNA ternary complex
6UT4	;	3.1	;	Cryo-EM structure of the asymmetric AAA+ domain hexamer from Thermococcus gammatolerans McrB
6LBA	;	4.1	;	Cryo-EM structure of the AtMLKL2 tetramer
6KA4	;	3.4	;	Cryo-EM structure of the AtMLKL3 tetramer
7VR1	;	3.4	;	Cryo-EM structure of the ATP-binding cassette sub-family D member 1 from Homo sapiens
5XMK	;	4.18	;	Cryo-EM structure of the ATP-bound Vps4 mutant-E233Q complex with Vta1 (masked)
5XMI	;	3.9	;	Cryo-EM Structure of the ATP-bound VPS4 mutant-E233Q hexamer (masked)
6PWF	;	4.07	;	Cryo-EM structure of the ATPase domain of chromatin remodeling factor ISWI bound to the nucleosome
7OQ4	;	3.27	;	Cryo-EM structure of the ATV RNAP Inhibitory Protein (RIP) bound to the DNA-binding channel of the host's RNA polymerase
6ROH	;	2.8	;	Cryo-EM structure of the autoinhibited Drs2p-Cdc50p
7LJY	;	5.6	;	Cryo-EM structure of the B dENE construct complexed with a 28-mer poly(A)
3J9W	;	3.9	;	Cryo-EM structure of the Bacillus subtilis MifM-stalled ribosome complex
8T7E	;	3.08	;	Cryo-EM structure of the Backtracking Initiation Complex (VII) of Human Mitochondrial DNA Polymerase Gamma
7C7Q	;	3.0	;	Cryo-EM structure of the baclofen/BHFF-bound human GABA(B) receptor in active state
6GYB	;	3.28	;	Cryo-EM structure of the bacteria-killing type IV secretion system core complex from Xanthomonas citri
8BTG	;	3.2	;	Cryo-EM structure of the bacterial replication origin opening basal unwinding system
7XNO	;	2.54	;	Cryo-EM structure of the bacteriocin-receptor-immunity ternary complex from Lactobacillus sakei
3JA7	;	3.6	;	Cryo-EM structure of the bacteriophage T4 portal protein assembly at near-atomic resolution
7WSR	;	2.9	;	Cryo-EM structure of the barley Yellow stripe 1 transporter
7WST	;	2.7	;	Cryo-EM structure of the barley Yellow stripe 1 transporter in complex with Fe(III)-DMA
7WSU	;	2.9	;	Cryo-EM structure of the barley Yellow stripe 1 transporter in complex with Fe(III)-PDMA
7TYR	;	3.33	;	Cryo-EM structure of the basal state of the Artemis:DNA-PKcs complex (see COMPND 13/14)
6VOA	;	4.0	;	Cryo-EM structure of the BBSome-ARL6 complex
7D76	;	3.1	;	Cryo-EM structure of the beclomethasone-bound adhesion receptor GPR97-Go complex
6DW1	;	3.1	;	Cryo-EM structure of the benzodiazepine-sensitive alpha1beta1gamma2S tri-heteromeric GABAA receptor in complex with GABA (ECD map)
6DW0	;	3.8	;	Cryo-EM structure of the benzodiazepine-sensitive alpha1beta1gamma2S tri-heteromeric GABAA receptor in complex with GABA (Whole map)
8QMO	;	2.76	;	Cryo-EM structure of the benzo[a]pyrene-bound Hsp90-XAP2-AHR complex
8JJL	;	3.2	;	cryo-EM structure of the beta2-AR-mBRIL/1b3 Fab/Glue complex with a full agonist
8JJ8	;	3.2	;	Cryo-EM structure of the beta2AR-mBRIL/1b3 Fab/Glue complex with a partial agonist
8JJO	;	3.4	;	Cryo-EM structure of the beta2AR-mBRIL/1b3 Fab/Glue complex with an antagonist
3J5M	;	5.8	;	Cryo-EM structure of the BG505 SOSIP.664 HIV-1 Env trimer with 3 PGV04 Fabs
8HI4	;	3.35	;	Cryo-EM structure of the bi-functional malonyl-CoA reductase from Roseiflexus castenholzii
7X8R	;	2.61	;	Cryo-EM structure of the Boc5-bound hGLP-1R-Gs complex
7JZV	;	3.9	;	Cryo-EM structure of the BRCA1-UbcH5c/BARD1 E3-E2 module bound to a nucleosome
6H3C	;	3.9	;	Cryo-EM structure of the BRISC complex bound to SHMT2
8T3S	;	3.07	;	Cryo-EM structure of the Butyrate bound FFA2-Gq complex
8PB9	;	3.3	;	Cryo-EM structure of the c-di-GMP-bound FleQ-FleN master regulator complex from Pseudomonas aeruginosa
8P53	;	2.7	;	Cryo-EM structure of the c-di-GMP-free FleQ-FleN master regulator complex of P. aeruginosa
7MOA	;	4.9	;	Cryo-EM structure of the c-MET II/HGF I complex bound with HGF II in a rigid conformation
6RF2	;	4.2	;	Cryo-EM structure of the C-terminal DC repeat (CDC) of human doublecortin (DCX) bound to 13-protofilament GDP.Pi-microtubule
7F8O	;	3.6	;	Cryo-EM structure of the C-terminal deletion mutant of human PANX1 in a nanodisc
7YG1	;	3.77	;	Cryo-EM structure of the C-terminal domain of the human sodium-chloride cotransporter
6VNO	;	3.5	;	Cryo-EM structure of the C-terminal half of the Parkinson's Disease-linked protein Leucine Rich Repeat Kinase 2 (LRRK2)
6VP6	;	3.47	;	Cryo-EM structure of the C-terminal half of the Parkinson's Disease-linked protein Leucine Rich Repeat Kinase 2 (LRRK2)
6VP7	;	3.5	;	Cryo-EM structure of the C-terminal half of the Parkinson's Disease-linked protein Leucine Rich Repeat Kinase 2 (LRRK2)
6VP8	;	3.5	;	Cryo-EM structure of the C-terminal half of the Parkinson's Disease-linked protein Leucine Rich Repeat Kinase 2 (LRRK2)
6LMV	;	3.6	;	Cryo-EM structure of the C. elegans CLHM-1
6OO4	;	3.3	;	Cryo-EM structure of the C2-symmetric TRPV2/RTx complex in amphipol resolved to 3.3 A
6OO5	;	4.2	;	Cryo-EM structure of the C2-symmetric TRPV2/RTx complex in amphipol resolved to 4.2 A
6OO7	;	3.8	;	Cryo-EM structure of the C2-symmetric TRPV2/RTx complex in nanodiscs
8IZD	;	3.09	;	Cryo-EM structure of the C26-CoA-bound Lac1-Lip1 complex
6KAC	;	2.7	;	Cryo-EM structure of the C2S2-type PSII-LHCII supercomplex from Chlamydomonas reihardtii
6KAD	;	3.4	;	Cryo-EM structure of the C2S2M2L2-type PSII-LHCII supercomplex from Chlamydomonas reihardtii
6OO3	;	2.9	;	Cryo-EM structure of the C4-symmetric TRPV2/RTx complex in amphipol resolved to 2.9 A
7YIU	;	2.9	;	Cryo-EM structure of the C6-ceramide-bound SPT-ORMDL3 complex
8IW9	;	3.08	;	Cryo-EM structure of the CAD-bound mTAAR9-Gs complex
6LYG	;	3.1	;	Cryo-EM structure of the calcium homeostasis modulator 1 channel
6LMW	;	3.4	;	Cryo-EM structure of the CALHM chimeric construct (8-mer)
6LMX	;	3.4	;	Cryo-EM structure of the CALHM chimeric construct (9-mer)
8H3Q	;	3.76	;	Cryo-EM Structure of the CAND1-Cul3-Rbx1 complex
7ZNY	;	3.26	;	Cryo-EM structure of the canine distemper virus tetrameric attachment glycoprotein
8F8Q	;	2.79	;	Cryo-EM structure of the CapZ-capped barbed end of F-actin
7V93	;	3.0	;	Cryo-EM structure of the Cas12c2-sgRNA binary complex
7V94	;	2.7	;	Cryo-EM structure of the Cas12c2-sgRNA-target DNA ternary complex
7C7L	;	3.3	;	Cryo-EM structure of the Cas12f1-sgRNA-target DNA complex
7N3O	;	3.8	;	Cryo-EM structure of the Cas12k-sgRNA complex
7N3P	;	3.65	;	Cryo-EM structure of the Cas12k-sgRNA-dsDNA complex
8PM4	;	2.93	;	Cryo-EM structure of the Cas12m-crRNA-target DNA complex
8HIO	;	3.73	;	Cryo-EM structure of the Cas12m2-crRNA binary complex
8HHL	;	2.87	;	Cryo-EM structure of the Cas12m2-crRNA-target DNA full R-loop complex
8HHM	;	3.08	;	Cryo-EM structure of the Cas12m2-crRNA-target DNA ternary complex intermediate state
7VTN	;	3.38	;	Cryo-EM structure of the Cas13bt3-crRNA-target RNA ternary complex
8FTI	;	3.5	;	Cryo-EM structure of the Cas13bt3-crRNA-target RNA ternary complex in activated state
5VZL	;	3.9	;	cryo-EM structure of the Cas9-sgRNA-AcrIIA4 anti-CRISPR complex
7KEU	;	3.9	;	Cryo-EM structure of the Caspase-1-CARD:ASC-CARD octamer
5GMK	;	3.4	;	Cryo-EM structure of the Catalytic Step I spliceosome (C complex) at 3.4 angstrom resolution
5WSG	;	4.0	;	Cryo-EM structure of the Catalytic Step II spliceosome (C* complex) at 4.0 angstrom resolution
6GYS	;	4.4	;	Cryo-EM structure of the CBF3-CEN3 complex of the budding yeast kinetochore
6GYP	;	3.6	;	Cryo-EM structure of the CBF3-core-Ndc10-DBD complex of the budding yeast kinetochore
6GYU	;	3.0	;	Cryo-EM structure of the CBF3-msk complex of the budding yeast kinetochore
8HAL	;	4.4	;	Cryo-EM structure of the CBP catalytic core bound to the H4K12acK16ac nucleosome, class 1
8HAM	;	4.5	;	Cryo-EM structure of the CBP catalytic core bound to the H4K12acK16ac nucleosome, class 2
8HAN	;	4.2	;	Cryo-EM structure of the CBP catalytic core bound to the H4K12acK16ac nucleosome, class 3
7VL9	;	2.6	;	Cryo-EM structure of the CCL15(26-92) bound CCR1-Gi complex
7VLA	;	2.7	;	Cryo-EM structure of the CCL15(27-92) bound CCR1-Gi complex
7XA3	;	2.9	;	Cryo-EM structure of the CCL2 bound CCR2-Gi complex
8IKL	;	2.33	;	Cryo-EM structure of the CD97-G13 complex
5XF8	;	7.1	;	Cryo-EM structure of the Cdt1-MCM2-7 complex in AMPPNP state
8JOL	;	3.0	;	cryo-EM structure of the CED-4/CED-3 holoenzyme
7OQY	;	2.61	;	Cryo-EM structure of the cellular negative regulator TFS4 bound to the archaeal RNA polymerase
6E0C	;	2.63	;	Cryo-EM structure of the CENP-A nucleosome (W601) in complex with a single chain antibody fragment
6E0P	;	2.6	;	Cryo-EM structure of the centromeric nucleosome (Native alpha satellite DNA) in complex with a single chain antibody fragment
6O1D	;	3.395	;	Cryo-EM structure of the centromeric nucleosome with native alpha satellite DNA
8CAD	;	2.85	;	Cryo-EM structure of the Ceres homohexamer from Galleria mellonella saliva
6MDR	;	3.47	;	Cryo-EM structure of the Ceru+32/GFP-17 protomer
7OI3	;	4.0	;	Cryo-EM structure of the Cetacean morbillivirus nucleoprotein-RNA complex
7C7S	;	2.9	;	Cryo-EM structure of the CGP54626-bound human GABA(B) receptor in inactive state.
8WCC	;	3.04	;	Cryo-EM structure of the CHA-bound mTAAR1 complex
8WCB	;	3.1	;	Cryo-EM structure of the CHA-bound mTAAR1-Gq complex
7F1Q	;	2.9	;	Cryo-EM structure of the chemokine receptor CCR5 in complex with MIP-1a and Gi
7F1R	;	3.0	;	Cryo-EM structure of the chemokine receptor CCR5 in complex with RANTES and Gi
6U0R	;	2.91	;	Cryo-EM structure of the chimeric vector AAV2.7m8
7F8V	;	3.3	;	Cryo-EM structure of the cholecystokinin receptor CCKBR in complex with gastrin-17 and Gi
7F8W	;	3.1	;	Cryo-EM structure of the cholecystokinin receptor CCKBR in complex with gastrin-17 and Gq
8CA9	;	2.29	;	Cryo-EM structure of the Cibeles-Demetra 3:3 heterocomplex from Galleria mellonella saliva
6MB3	;	3.37	;	Cryo-EM structure of the circumsporozoite protein of Plasmodium falciparum with a vaccine-elicited antibody reveals maturation of inter-antibody contacts
6MHG	;	3.57	;	Cryo-EM structure of the circumsporozoite protein of Plasmodium falciparum with a vaccine-elicited antibody reveals maturation of inter-antibody contacts
8XON	;	1.96	;	Cryo-EM structure of the ClpC1:ClpP1P2 degradation complex in Streptomyces hawaiiensis
8XOO	;	1.84	;	Cryo-EM structure of the ClpC1:ClpP1P2 degradation complex in Streptomyces hawaiiensis
8XN4	;	2.34	;	Cryo-EM structure of the ClpP degradation system in Streptomyces hawaiiensis
6SFW	;	6.0	;	Cryo-EM Structure of the ClpX component of the ClpXP1/2 degradation machinery.
8IFG	;	3.2	;	Cryo-EM structure of the Clr6S (Clr6-HDAC) complex from S. pombe
8XZI	;	2.7	;	Cryo-EM structure of the CMF-019-bound human APLNR-Gi complex
6SKL	;	3.7	;	Cryo-EM structure of the CMG Fork Protection Complex at a replication fork - Conformation 1
6IP5	;	3.9	;	Cryo-EM structure of the CMV-stalled human 80S ribosome (Structure ii)
6IP6	;	4.5	;	Cryo-EM structure of the CMV-stalled human 80S ribosome with HCV IRES (Structure iii)
8HR5	;	3.73	;	Cryo-EM structure of the CnCas12f1-sgRNA-DNA complex
8BLQ	;	3.97	;	Cryo-EM structure of the CODV-IL13-RefAb triple complex
6NT9	;	3.3	;	Cryo-EM structure of the complex between human TBK1 and chicken STING
7DUQ	;	2.5	;	Cryo-EM structure of the compound 2 and GLP-1-bound human GLP-1 receptor-Gs complex
7DUR	;	3.3	;	Cryo-EM structure of the compound 2-bound human GLP-1 receptor-Gs complex
7EVM	;	2.5	;	Cryo-EM structure of the compound 2-bound human GLP-1 receptor-Gs complex
7YK6	;	3.03	;	Cryo-EM structure of the compound 4-bound human relaxin family peptide receptor 4 (RXFP4)-Gi complex
6SCT	;	4.69	;	Cryo-EM structure of the consensus triskelion hub of the clathrin coat complex
7B5H	;	3.2	;	Cryo-EM structure of the contractile injection system base plate from Anabaena PCC7120
7B5I	;	2.8	;	Cryo-EM structure of the contractile injection system cap complex from Anabaena PCC7120
8CAN	;	1.93	;	Cryo-EM structure of the Cora homohexamer from Galleria mellonella saliva
6FE8	;	3.7	;	Cryo-EM structure of the core Centromere Binding Factor 3 complex
7D7R	;	4.0	;	Cryo-EM structure of the core domain of human ABCB6 transporter
7U8G	;	3.2	;	Cryo-EM structure of the core human NADPH oxidase NOX2
8SCX	;	2.7	;	Cryo-EM structure of the core TIM23 complex from S. cerevisiae
7D77	;	2.9	;	Cryo-EM structure of the cortisol-bound adhesion receptor GPR97-Go complex
7KR5	;	3.3	;	Cryo-EM structure of the CRAC channel Orai in an open conformation; H206A gain-of-function mutation in complex with an antibody
8U1N	;	3.9	;	Cryo-EM structure of the cross-linked HSP90 dimer (NTD-MD) in the semi-open state
8IUN	;	2.85	;	Cryo-EM structure of the CRT-LESS RC-LH core complex from roseiflexus castenholzii
7TAX	;	2.8	;	Cryo-EM structure of the Csy-AcrIF24-promoter DNA complex
7TAW	;	2.7	;	Cryo-EM structure of the Csy-AcrIF24-promoter DNA dimer
8CIO	;	3.5	;	Cryo-EM structure of the CupE pilus from Pseudomonas aeruginosa
8W9M	;	3.1	;	Cryo-EM structure of the cyanobacterial nitrate transporter NrtBCD in complex with ATP
7NKZ	;	2.5	;	Cryo-EM structure of the cytochrome bd oxidase from M. tuberculosis at 2.5 A resolution
7A6U	;	3.62	;	Cryo-EM structure of the cytoplasmic domain of human TRPC6
7YK7	;	2.75	;	Cryo-EM structure of the DC591053-bound human relaxin family peptide receptor 4 (RXFP4)-Gi complex
7OKQ	;	8.4	;	Cryo-EM Structure of the DDB1-DCAF1-CUL4A-RBX1 Complex
7DCQ	;	2.9	;	cryo-EM structure of the DEAH-box helicase Prp2
7DCP	;	3.15	;	cryo-EM structure of the DEAH-box helicase Prp2 and coactivator Spp2
7DCR	;	3.15	;	cryo-EM structure of the DEAH-box helicase Prp2 in complex with its coactivator Spp2
7KHA	;	3.13	;	Cryo-EM Structure of the Desulfovibrio vulgaris Type I-C Apo Cascade
8T3V	;	3.39	;	Cryo-EM structure of the DHA bound FFA1-Gq complex
8T3Q	;	3.14	;	Cryo-EM structure of the DHA bound FFA4-Gq complex
7B9K	;	3.16	;	Cryo-EM structure of the dihydrolipoyl transacetylase cubic core of the E. coli pyruvate dehydrogenase complex including lipoyl domains
7YJK	;	3.2	;	Cryo-EM structure of the dimeric atSPT-ORM1 complex
6B2Z	;	3.6	;	Cryo-EM structure of the dimeric FO region of yeast mitochondrial ATP synthase
8P2D	;	2.59	;	Cryo-EM structure of the dimeric form of the anaerobic ribonucleotide reductase from Prevotella copri produced in the presence of dATP and CTP
8IQF	;	4.6	;	Cryo-EM structure of the dimeric human CAF1-H3-H4 complex
7Y5V	;	6.1	;	Cryo-EM structure of the dimeric human CAF1LC-H3-H4 complex
7PQD	;	2.9	;	Cryo-EM structure of the dimeric Rhodobacter sphaeroides RC-LH1 core complex at 2.9 A: the structural basis for dimerisation
6M4N	;	3.8	;	Cryo-EM structure of the dimeric SPT-ORMDL3 complex
6LOE	;	3.5	;	Cryo-EM structure of the dithionite-reduced photosynthetic alternative complex III from Roseiflexus castenholzii
7ALN	;	3.77	;	Cryo-EM structure of the divergent actomyosin complex from Plasmodium falciparum Myosin A in the Rigor state
8ITF	;	3.46	;	Cryo-EM structure of the DMCHA-bound mTAAR9-Gs complex
6T8H	;	3.77	;	Cryo-EM structure of the DNA-bound PolD-PCNA processive complex from P. abyssi
8OJJ	;	5.47	;	Cryo-EM structure of the DnaD-NTD tetramer
7X2F	;	3.0	;	Cryo-EM structure of the dopamine and LY3154207-bound D1 dopamine receptor and mini-Gs complex
8J6T	;	6.6	;	Cryo-EM structure of the double CAF-1 bound right-handed Di-tetrasome
6LFG	;	9.58	;	Cryo-EM structure of the Drosophila CTP synthase product-bound filament
6L6Z	;	6.09	;	Cryo-EM structure of the Drosophila CTP synthase substrate-bound filament
6VCC	;	3.6	;	Cryo-EM structure of the Dvl2 DIX filament
6ZNL	;	3.8	;	Cryo-EM structure of the dynactin complex
8PYS	;	2.7	;	Cryo-EM structure of the DyP peroxidase-loaded encapsulin nanocompartment from Mycobacterium tuberculosis with icosahedral symmetry imposed.
5U05	;	7.9	;	Cryo-EM structure of the E. coli CTP synthase tetramer
6RKO	;	2.68	;	Cryo-EM structure of the E. coli cytochrome bd-I oxidase at 2.68 A resolution
5FKW	;	7.3	;	cryo-EM structure of the E. coli replicative DNA polymerase complex bound to DNA (DNA polymerase III alpha, beta, epsilon)
5FKV	;	8.04	;	cryo-EM structure of the E. coli replicative DNA polymerase complex bound to DNA (DNA polymerase III alpha, beta, epsilon, tau complex)
5FKU	;	8.34	;	cryo-EM structure of the E. coli replicative DNA polymerase complex in DNA free state (DNA polymerase III alpha, beta, epsilon, tau complex)
5M1S	;	6.7	;	Cryo-EM structure of the E. coli replicative DNA polymerase-clamp-exonuclase-theta complex bound to DNA in the editing mode
7QQ3	;	2.1	;	Cryo-EM structure of the E.coli 50S ribosomal subunit in complex with the antibiotic Myxovalargin A.
8B7Y	;	3.0	;	Cryo-EM structure of the E.coli 70S ribosome in complex with the antibiotic Myxovalargin B.
7YFQ	;	3.2	;	Cryo-EM structure of the EfPiwi (N959K)-piRNA-target ternary complex
7YG6	;	3.2	;	Cryo-EM structure of the EfPiwi(N959K) in complex with piRNA
8ID9	;	3.0	;	Cryo-EM structure of the eicosapentaenoic acid bound GPR120-Gi complex
8A5E	;	3.4	;	Cryo-EM structure of the electron bifurcating Fe-Fe hydrogenase HydABC complex from Acetobacterium woodii in the reduced state
8BEW	;	3.49	;	Cryo-EM structure of the electron bifurcating Fe-Fe hydrogenase HydABC complex from Thermoanaerobacter kivui in the oxidised state
8A6T	;	3.1	;	Cryo-EM structure of the electron bifurcating Fe-Fe hydrogenase HydABC complex from Thermoanaerobacter kivui in the reduced state
8OH9	;	3.2	;	Cryo-EM structure of the electron bifurcating transhydrogenase StnABC complex from Sporomusa Ovata (state 1)
8OH5	;	3.0	;	Cryo-EM structure of the electron bifurcating transhydrogenase StnABC complex from Sporomusa Ovata (state 2)
7LY4	;	3.8	;	Cryo-EM structure of the elongation module of the bacillamide NRPS, BmdB, in complex with the oxidase, BmdC
7BOK	;	3.7	;	Cryo-EM structure of the encapsulated DyP-type peroxidase from Mycobacterium smegmatis
7BOJ	;	2.5	;	Cryo-EM structure of the encapsulin shell from Mycobacterium smegmatis
8IKA	;	2.75	;	Cryo-EM structure of the encapsulin shell from Mycobacterium tuberculosis
8E1M	;	2.9	;	Cryo-EM structure of the endogenous core TIM23 complex from S. cerevisiae
7SN4	;	3.6	;	Cryo-EM structure of the enterohemorrhagic E. coli O157:H7 flagellar filament
7SN7	;	4.2	;	Cryo-EM structure of the enteropathogenic E. coli O127:H6 flagellar filament
6ZY7	;	4.64	;	Cryo-EM structure of the entire Human topoisomerase II alpha in State 1
6ZY8	;	7.4	;	Cryo-EM structure of the entire Human topoisomerase II alpha in State 2
8IBU	;	3.51	;	Cryo-EM structure of the erythromycin-bound motilin receptor-Gq protein complex
8SYL	;	2.9	;	Cryo-EM structure of the Escherichia coli 70S ribosome in complex with amikacin, mRNA, and A-, P-, and E-site tRNAs
5KCR	;	3.6	;	Cryo-EM structure of the Escherichia coli 70S ribosome in complex with antibiotic Avilamycin C, mRNA and P-site tRNA at 3.6A resolution
5KCS	;	3.9	;	Cryo-EM structure of the Escherichia coli 70S ribosome in complex with antibiotic Evernimycin, mRNA, TetM and P-site tRNA at 3.9A resolution
6UT6	;	3.28	;	Cryo-EM structure of the Escherichia coli McrBC complex
6MAT	;	4.5	;	Cryo-EM structure of the essential ribosome assembly AAA-ATPase Rix7
7CX4	;	2.9	;	Cryo-EM structure of the Evatanepag-bound EP2-Gs complex
8HUD	;	3.43	;	Cryo-EM structure of the EvCas9-sgRNA-target DNA ternary complex
5YFP	;	4.4	;	Cryo-EM Structure of the Exocyst Complex
7SYD	;	3.1	;	Cryo-EM structure of the extracellular module of the full-length EGFR bound to EGF ""tips-juxtaposed"" conformation
7SYE	;	3.3	;	Cryo-EM structure of the extracellular module of the full-length EGFR bound to EGF. ""tips-separated"" conformation
7SZ5	;	3.6	;	Cryo-EM structure of the extracellular module of the full-length EGFR bound to TGF-alpha ""tips-separated"" conformation
7SZ7	;	3.4	;	Cryo-EM structure of the extracellular module of the full-length EGFR bound to TGF-alpha. ""tips-juxtaposed"" conformation
7SZ0	;	3.3	;	Cryo-EM structure of the extracellular module of the full-length EGFR L834R bound to EGF. ""tips-juxtaposed"" conformation
7SZ1	;	3.4	;	Cryo-EM structure of the extracellular module of the full-length EGFR L834R bound to EGF. ""tips-separated"" conformation
3ZFS	;	4.0	;	Cryo-EM structure of the F420-reducing NiFe-hydrogenase from a methanogenic archaeon with bound substrate
8CH5	;	3.2	;	Cryo-EM structure of the fd bacteriophage capsid major coat protein pVIII
7X2C	;	3.2	;	Cryo-EM structure of the fenoldopam-bound D1 dopamine receptor and mini-Gs complex
7F29	;	3.1	;	Cryo-EM structure of the fibril formed by disaccharide-modified amyloid-beta(1-42)
7CBM	;	3.2	;	Cryo-EM structure of the flagellar distal rod with partial hook from Salmonella
7CG4	;	3.6	;	Cryo-EM structure of the flagellar export apparatus with FliE from Salmonella
7CGB	;	3.4	;	Cryo-EM structure of the flagellar hook from Salmonella
5JXL	;	3.5	;	Cryo-EM structure of the flagellar hook of Campylobacter jejuni
7CBL	;	2.8	;	Cryo-EM structure of the flagellar LP ring from Salmonella
8UCS	;	2.4	;	Cryo-EM structure of the flagellar MotAB stator bound to FliG
7CGO	;	3.9	;	Cryo-EM structure of the flagellar motor-hook complex from Salmonella
7CG7	;	3.61	;	Cryo-EM structure of the flagellar MS ring with C34 symmetry from Salmonella
7E81	;	4.5	;	Cryo-EM structure of the flagellar MS ring with FlgB-Dc loop and FliE-helix 1 from Salmonella
7CG0	;	3.2	;	Cryo-EM structure of the flagellar proximal rod with FliF peptides from Salmonella
7E80	;	3.67	;	Cryo-EM structure of the flagellar rod with hook and export apparatus from Salmonella
7E82	;	3.3	;	Cryo-EM structure of the flagellar rod with partial hook from Salmonella
6ULG	;	3.31	;	Cryo-EM structure of the FLCN-FNIP2-Rag-Ragulator complex
7NNT	;	3.4	;	Cryo-EM structure of the folate-specific ECF transporter complex in DDM micelles
7NNU	;	2.7	;	Cryo-EM structure of the folate-specific ECF transporter complex in MSP2N2 lipid nanodiscs
8BMQ	;	3.6	;	Cryo-EM structure of the folate-specific ECF transporter complex in MSP2N2 lipid nanodiscs bound to AMP-PNP
8BMP	;	3.2	;	Cryo-EM structure of the folate-specific ECF transporter complex in MSP2N2 lipid nanodiscs bound to ATP and ADP
6SKO	;	3.4	;	Cryo-EM Structure of the Fork Protection Complex Bound to CMG at a Replication Fork - conformation 2 MCM CTD:ssDNA
7BZ2	;	3.82	;	Cryo-EM structure of the formoterol-bound beta2 adrenergic receptor-Gs protein complex.
8F8R	;	3.3	;	Cryo-EM structure of the free barbed end of F-actin
8F8S	;	2.84	;	Cryo-EM structure of the free pointed end of F-actin
7DHR	;	3.8	;	Cryo-EM structure of the full agonist isoprenaline-bound beta2 adrenergic receptor-Gs protein complex.
8DTF	;	3.7	;	Cryo-EM structure of the full length Arabidopsis SPY with complete TPRs
8H3V	;	4.5	;	Cryo-EM structure of the full transcription activation complex NtcA-NtcB-TAC
6VXK	;	3.1	;	Cryo-EM Structure of the full-length A39R/PlexinC1 complex
6POM	;	4.9	;	Cryo-EM structure of the full-length Bacillus subtilis glyQS T-box riboswitch in complex with tRNA-Gly
6YEJ	;	18.2	;	Cryo-EM structure of the Full-length disease type human Huntingtin
6JK8	;	5.0	;	Cryo-EM structure of the full-length human IGF-1R in complex with insulin
8E20	;	3.6	;	Cryo-EM structure of the full-length human NF1 dimer
8EDL	;	3.7	;	Cryo-EM structure of the full-length human NF1 dimer
8EDM	;	3.6	;	Cryo-EM structure of the full-length human NF1 dimer
8EDN	;	3.8	;	Cryo-EM structure of the full-length human NF1 dimer
8EDO	;	3.4	;	Cryo-EM structure of the full-length human NF1 dimer
3JD8	;	4.43	;	cryo-EM structure of the full-length human NPC1 at 4.4 angstrom
7RQX	;	3.36	;	Cryo-EM structure of the full-length TRPV1 with RTx at 25 degrees Celsius, in an intermediate-open state, class A
7RQY	;	3.04	;	Cryo-EM structure of the full-length TRPV1 with RTx at 25 degrees Celsius, in an open state, class B
7RQU	;	3.05	;	Cryo-EM structure of the full-length TRPV1 with RTx at 4 degrees Celsius, in a closed state, class I
7RQV	;	3.45	;	Cryo-EM structure of the full-length TRPV1 with RTx at 4 degrees Celsius, in an intermediate-closed state, class II
7RQW	;	3.11	;	Cryo-EM structure of the full-length TRPV1 with RTx at 4 degrees Celsius, in an open state, class III
7RQZ	;	3.32	;	Cryo-EM structure of the full-length TRPV1 with RTx at 48 degrees Celsius, in an open state, class alpha
6XIS	;	3.9	;	Cryo-EM structure of the G protein-gated inward rectifier K+ channel GIRK2 (Kir3.2) in apo form
6XIT	;	3.3	;	Cryo-EM structure of the G protein-gated inward rectifier K+ channel GIRK2 (Kir3.2) in complex with PIP2
7XJJ	;	3.3	;	Cryo-EM structure of the galanin-bound GALR1-miniGo complex
7XJK	;	3.3	;	Cryo-EM structure of the galanin-bound GALR2-miniGq complex
8IOC	;	2.86	;	Cryo-EM structure of the gamma-MSH-bound human melanocortin receptor 3 (MC3R)-Gs complex
6CB8	;	3.8	;	Cryo-EM structure of the Gasdermin A3 membrane pore
8GTN	;	3.17	;	Cryo-EM structure of the gasdermin B pore
7W4A	;	2.76	;	Cryo-EM structure of the gastric proton pump complexed with revaprazan
7ET1	;	2.6	;	Cryo-EM structure of the gastric proton pump K791S/E820D/Y340N/E936V/Y799W mutant in K+-occluded (K+)E2-AlF state
8IJV	;	2.1	;	Cryo-EM structure of the gastric proton pump with bound DQ-02
8IJW	;	2.19	;	Cryo-EM structure of the gastric proton pump with bound DQ-06
8IJX	;	2.08	;	Cryo-EM structure of the gastric proton pump with bound DQ-18
8JMN	;	2.26	;	Cryo-EM structure of the gastric proton pump with bound DQ-21
8WA5	;	2.51	;	Cryo-EM structure of the gastric proton pump Y799W/E936Q mutant in K+-occluded (K+)E2-AlF state
7F1O	;	3.13	;	Cryo-EM structure of the GDP-bound dopamine receptor 1 and mini-Gs complex with Nb35
7F1Z	;	3.46	;	Cryo-EM structure of the GDP-bound dopamine receptor 1 and mini-Gs complex without Nb35
7W2Z	;	2.8	;	Cryo-EM structure of the ghrelin-bound human ghrelin receptor-Go complex
7V9M	;	3.29	;	Cryo-EM structure of the GHRH-bound human GHRHR splice variant 1 complex
7V35	;	3.5	;	Cryo-EM structure of the GIPR/GLP-1R/GCGR triagonist peptide 20-bound human GCGR-Gs complex
7FIN	;	3.1	;	Cryo-EM structure of the GIPR/GLP-1R/GCGR triagonist peptide 20-bound human GIPR-Gs complex
7VBH	;	3.0	;	Cryo-EM structure of the GIPR/GLP-1R/GCGR triagonist peptide 20-bound human GLP-1R-Gs complex
8JIT	;	2.91	;	Cryo-EM structure of the GLP-1R/GCGR dual agonist MEDI0382-bound human GCGR-Gs complex
8JIP	;	2.85	;	Cryo-EM structure of the GLP-1R/GCGR dual agonist MEDI0382-bound human GLP-1R-Gs complex
8JIQ	;	3.4	;	Cryo-EM structure of the GLP-1R/GCGR dual agonist Peptide 15-bound human GCGR-Gs complex
8JIS	;	2.46	;	Cryo-EM structure of the GLP-1R/GCGR dual agonist peptide15-bound human GLP-1R-Gs complex
8JIU	;	2.76	;	Cryo-EM structure of the GLP-1R/GCGR dual agonist SAR425899-bound human GCGR-Gs complex
8JIR	;	2.57	;	Cryo-EM structure of the GLP-1R/GCGR dual agonist SAR425899-bound human GLP-1R-Gs complex
6WYK	;	4.0	;	Cryo-EM structure of the GltPh L152C-G321C mutant in the intermediate chloride conducting state.
6WYJ	;	3.7	;	Cryo-EM structure of the GltPh L152C-G321C mutant in the intermediate state
8JRU	;	3.5	;	Cryo-EM structure of the glucagon receptor bound to beta-arrestin 1 in ligand-free state
8JRV	;	3.3	;	Cryo-EM structure of the glucagon receptor bound to glucagon and beta-arrestin 1
6VCB	;	3.3	;	Cryo-EM structure of the Glucagon-like peptide-1 receptor in complex with G protein, GLP-1 peptide and a positive allosteric modulator
8EC6	;	3.1	;	Cryo-EM structure of the Glutaminase C core filament (fGAC)
7EVP	;	3.2	;	Cryo-EM structure of the Gp168-beta-clamp complex
8K9Q	;	2.84	;	Cryo-EM structure of the GPI inositol-deacylase (PGAP1/Bst1) from Chaetomium thermophilum
8W8Q	;	2.89	;	Cryo-EM structure of the GPR101-Gs complex
8KH4	;	3.1	;	Cryo-EM structure of the GPR161-Gs complex
8KH5	;	2.83	;	Cryo-EM structure of the GPR174-Gs complex bound to endogenous lysoPS
8IYX	;	3.34	;	Cryo-EM structure of the GPR34 receptor in complex with the antagonist YL-365
8KGK	;	3.16	;	Cryo-EM structure of the GPR61-Gs complex
8J1A	;	3.24	;	Cryo-EM structure of the GPR84 receptor-Gi complex with no ligand modeled
8FFW	;	3.23	;	Cryo-EM structure of the GR-Hsp90-FKBP51 complex
8FFV	;	3.01	;	Cryo-EM structure of the GR-Hsp90-FKBP52 complex
7B03	;	2.93	;	Cryo-EM structure of the green-light absorbing proteorhodopsin
7PBX	;	3.43	;	Cryo-EM structure of the GroEL-GroES complex with ADP bound to both rings (""tight"" conformation).
7PBJ	;	3.4	;	Cryo-EM structure of the GroEL-GroES complex with ADP bound to both rings (""wide"" conformation).
7F23	;	3.58	;	Cryo-EM structure of the GTP-bound dopamine receptor 1 and mini-Gs complex with Nb35
7F24	;	4.16	;	Cryo-EM structure of the GTP-bound dopamine receptor 1 and mini-Gs complex without Nb35
8G5O	;	2.61	;	Cryo-EM structure of the Guide loop Engagement Complex (IV) of Human Mitochondrial DNA Polymerase Gamma
8G5P	;	2.78	;	Cryo-EM structure of the Guide loop Engagement Complex (V) of Human Mitochondrial DNA Polymerase Gamma
8G5N	;	2.73	;	Cryo-EM structure of the Guide loop Engagement Complex (VI) of Human Mitochondrial DNA Polymerase Gamma
7YHK	;	3.14	;	Cryo-EM structure of the HA trimer of A/Beijing/262/1995(H1N1) in complex with neutralizing antibody 12H5
7RAM	;	3.43	;	Cryo-EM Structure of the HCMV gHgLgO Trimer Derived from AD169 and TR strains in complex with PDGFRalpha
7M30	;	3.81	;	Cryo-EM structure of the HCMV pentamer bound by antibodies 1-103, 1-32 and 2-25
7KBB	;	4.02	;	Cryo-EM structure of the HCMV pentamer bound by Fabs 2-18 and 8I21
7M22	;	3.65	;	Cryo-EM structure of the HCMV pentamer bound by human neuropilin 2
6U7H	;	3.1	;	Cryo-EM structure of the HCoV-229E spike glycoprotein
6IP8	;	3.9	;	Cryo-EM structure of the HCV IRES dependently initiated CMV-stalled 80S ribosome (Structure iv)
7C1D	;	3.8	;	Cryo-EM structure of the hE46K cross-seeded hWT alpha-synuclein fibril
6QYD	;	3.2	;	Cryo-EM structure of the head in mature bacteriophage phi29
1I84	;	20.0	;	CRYO-EM STRUCTURE OF THE HEAVY MEROMYOSIN SUBFRAGMENT OF CHICKEN GIZZARD SMOOTH MUSCLE MYOSIN WITH REGULATORY LIGHT CHAIN IN THE DEPHOSPHORYLATED STATE. ONLY C ALPHAS PROVIDED FOR REGULATORY LIGHT CHAIN. ONLY BACKBONE ATOMS PROVIDED FOR S2 FRAGMENT.
7FIF	;	6.5	;	Cryo-EM structure of the hedgehog release protein Disp from water bear (Hypsibius dujardini)
6X6K	;	3.1	;	Cryo-EM Structure of the Helicobacter pylori dCag3 OMC
6X6S	;	3.4	;	Cryo-EM Structure of the Helicobacter pylori OMC
8EDG	;	4.64	;	Cryo-EM structure of the Hermes transposase bound to two left-ends of its DNA transposon
8SJD	;	5.1	;	Cryo-EM structure of the Hermes transposase bound to two right-ends of its DNA transposon.
7VH6	;	3.8	;	Cryo-EM structure of the hexameric plasma membrane H+-ATPase in the active state (pH 6.0, BeF3-, conformation 1, C1 symmetry)
7VH5	;	3.2	;	Cryo-EM structure of the hexameric plasma membrane H+-ATPase in the autoinhibited state (pH 7.4, C1 symmetry)
7P6X	;	4.1	;	Cryo-Em structure of the hexameric RUVBL1-RUVBL2 in complex with ZNHIT2
7EH8	;	3.06	;	Cryo-EM structure of the hexameric state of C-phycocyanin from Thermoleptolyngbya sp. O-77
8BVH	;	3.6	;	Cryo-EM structure of the Hfq-Crc-amiE translation repression assembly.
6ZJ3	;	3.15	;	Cryo-EM structure of the highly atypical cytoplasmic ribosome of Euglena gracilis
7YFC	;	3.0	;	Cryo-EM structure of the histamine-bound histamine H4 receptor and Gq complex
8HXX	;	3.0	;	Cryo-EM structure of the histone deacetylase complex Rpd3S
8JHO	;	7.6	;	Cryo-EM structure of the histone deacetylase complex Rpd3S in complex with di-nucleosome
8HXY	;	3.1	;	Cryo-EM structure of the histone deacetylase complex Rpd3S in complex with nucleosome
7XPX	;	3.2	;	Cryo-EM structure of the histone methyltransferase SET8 bound to H4K20Ecx-nucleosome
7RU6	;	4.4	;	Cryo-EM structure of the HIV-1 restriction factor human SERINC3
6N06	;	3.4	;	Cryo-EM structure of the HO BMC shell: BMC-T1 in the assembled shell
6MZU	;	3.4	;	Cryo-EM structure of the HO BMC shell: BMC-TD focused structure, closed state
6MZV	;	3.4	;	Cryo-EM structure of the HO BMC shell: BMC-TD focused structure, widened inner ring
6MZX	;	3.0	;	Cryo-EM structure of the HO BMC shell: Icosahedral reconstruction (main population)
6MZY	;	3.3	;	Cryo-EM structure of the HO BMC shell: Icosahedral reconstruction of the compacted subpopulation
6N09	;	3.5	;	Cryo-EM structure of the HO BMC shell: subregion classified for BMC-T: TD-TDTDTD
6N0F	;	3.9	;	Cryo-EM structure of the HO BMC shell: subregion classified for BMC-T: TD-TSTSTS
6N0G	;	3.6	;	Cryo-EM structure of the HO BMC shell: subregion classified for BMC-T: TS-TDTDTD
8U1M	;	3.5	;	Cryo-EM structure of the HSP90 dimer (NTD-MD) in the semi-open state
7L20	;	3.15	;	Cryo-EM structure of the human 39S mitoribosomal subunit in complex with RRFmt and EF-G2mt.
7L08	;	3.49	;	Cryo-EM structure of the human 55S mitoribosome-RRFmt complex.
7DNY	;	3.4	;	Cryo-EM structure of the human ABCB6 (coproporphyrin III-bound)
7DNZ	;	3.6	;	Cryo-EM structure of the human ABCB6 (Hemin and GSH-bound)
6HIJ	;	3.56	;	Cryo-EM structure of the human ABCG2-MZ29-Fab complex with cholesterol and PE lipids docked
5Z57	;	6.5	;	Cryo-EM structure of the human activated spliceosome (late Bact) at 6.5 angstrom
6D9H	;	3.6	;	Cryo-EM structure of the human adenosine A1 receptor-Gi2-protein complex bound to its endogenous agonist
7LD4	;	3.3	;	Cryo-EM structure of the human adenosine A1 receptor-Gi2-protein complex bound to its endogenous agonist
7LD3	;	3.2	;	Cryo-EM structure of the human adenosine A1 receptor-Gi2-protein complex bound to its endogenous agonist and an allosteric ligand
6A96	;	3.51	;	Cryo-EM structure of the human alpha5beta3 GABAA receptor in complex with GABA and Nb25
7KH0	;	2.8	;	Cryo-EM structure of the human arginine vasopressin AVP-vasopressin receptor V2R-Gs signaling complex
7VPI	;	3.6	;	Cryo-EM structure of the human ATP13A2 (E1-ATP state)
7VPJ	;	3.54	;	Cryo-EM structure of the human ATP13A2 (E1P-ADP state)
7VPK	;	3.92	;	Cryo-EM structure of the human ATP13A2 (SPM-bound E2P state)
7VPL	;	3.78	;	Cryo-EM structure of the human ATP13A2 (SPM-bound E2Pi state)
7SQK	;	8.0	;	Cryo-EM structure of the human augmin complex
8FAZ	;	2.3	;	Cryo-EM structure of the human BCDX2 complex
6R8F	;	3.8	;	Cryo-EM structure of the Human BRISC-SHMT2 complex
7B5Q	;	2.5	;	Cryo-EM structure of the human CAK bound to ICEC0942 (PHENIX-OPLS3e)
7B5O	;	2.5	;	Cryo-EM structure of the human CAK bound to ICEC0942 at 2.5 Angstroms resolution
6LMU	;	3.4	;	Cryo-EM structure of the human CALHM2
8G4L	;	6.4	;	Cryo-EM structure of the human cardiac myosin filament
7YKD	;	2.81	;	Cryo-EM structure of the human chemerin receptor 1 complex with the C-terminal nonapeptide of chemerin
6WWZ	;	3.34	;	Cryo-EM structure of the human chemokine receptor CCR6 in complex with CCL20 and a Go protein
7XBX	;	3.4	;	Cryo-EM structure of the human chemokine receptor CX3CR1 in complex with CX3CL1 and Gi1
7XBW	;	2.8	;	Cryo-EM structure of the human chemokine receptor CX3CR1 in complex with Gi1
7FDV	;	3.26	;	Cryo-EM structure of the human cholesterol transporter ABCG1 in complex with cholesterol
8TA6	;	4.03	;	Cryo-EM structure of the human CLC-2 chloride channel C-terminal domain
8TA3	;	2.46	;	Cryo-EM structure of the human CLC-2 chloride channel transmembrane domain Apo state with resolved N-terminal hairpin
8TA2	;	2.74	;	Cryo-EM structure of the human CLC-2 chloride channel transmembrane domain with bound inhibitor AK-42
8TA4	;	2.75	;	Cryo-EM structure of the human CLC-2 chloride channel transmembrane domain with symmetric C-terminal
6KSW	;	3.6	;	Cryo-EM structure of the human concentrative nucleoside transporter CNT3
6FUW	;	3.07	;	Cryo-EM structure of the human CPSF160-WDR33-CPSF30 complex bound to the PAS AAUAAA motif at 3.1 Angstrom resolution
5U03	;	6.1	;	Cryo-EM structure of the human CTP synthase filament
7BHP	;	3.3	;	Cryo-EM structure of the human Ebp1 - 80S ribosome
6SXO	;	3.3	;	Cryo-EM structure of the human Ebp1-ribosome complex
7DPA	;	3.8	;	Cryo-EM structure of the human ELMO1-DOCK5-Rac1 complex
7WU9	;	3.375	;	Cryo-EM structure of the human EP3-Gi signaling complex
5VA1	;	3.7	;	Cryo-EM structure of the human ether-a-go-go related K+ channel
5VA2	;	3.8	;	Cryo-EM structure of the human ether-a-go-go related K+ channel
5VA3	;	4.0	;	Cryo-EM structure of the human ether-a-go-go related K+ channel
7SCH	;	3.1	;	Cryo-EM structure of the human Exostosin-1 and Exostosin-2 heterodimer
7SCJ	;	3.4	;	Cryo-EM structure of the human Exostosin-1 and Exostosin-2 heterodimer in complex with a 4-sugar oligosaccharide acceptor analog
7SCK	;	2.8	;	Cryo-EM structure of the human Exostosin-1 and Exostosin-2 heterodimer in complex with a 7-sugar oligosaccharide acceptor analog
7UQY	;	3.0	;	Cryo-EM structure of the human Exostosin-1 and Exostosin-2 heterodimer in complex with UDP-GlcA
7UQX	;	3.3	;	Cryo-EM structure of the human Exostosin-1 and Exostosin-2 heterodimer in complex with UDP-GlcNAc
7ND2	;	4.0	;	Cryo-EM structure of the human FERRY complex
7WVU	;	3.3	;	Cryo-EM structure of the human formyl peptide receptor 1 in complex with fMLF and Gi1
7WVY	;	3.0	;	Cryo-EM structure of the human formyl peptide receptor 2 in complex with Abeta42 and Gi2
7WVX	;	2.8	;	Cryo-EM structure of the human formyl peptide receptor 2 in complex with fhumanin and Gi2
7WVV	;	2.9	;	Cryo-EM structure of the human formyl peptide receptor 2 in complex with fMLFII and Gi2
7WVW	;	3.1	;	Cryo-EM structure of the human formyl peptide receptor 2 in complex with fMYFINILTL and Gi2
5A63	;	3.4	;	Cryo-EM structure of the human gamma-secretase complex at 3.4 angstrom resolution.
8CQB	;	3.7	;	Cryo-EM structure of the human GBP1 dimer bound to GDP-AlF3
8EM2	;	3.02	;	Cryo-EM structure of the human GDH/6PGL endoplasmic bifunctional protein
6LML	;	3.9	;	Cryo-EM structure of the human glucagon receptor in complex with Gi1
6LMK	;	3.7	;	Cryo-EM structure of the human glucagon receptor in complex with Gs
7D68	;	3.0	;	Cryo-EM structure of the human glucagon-like peptide-2 receptor-Gs protein complex
7WLD	;	2.53	;	Cryo-EM structure of the human glycosylphosphatidylinositol transamidase complex at 2.53 Angstrom resolution
7CZ5	;	2.6	;	Cryo-EM structure of the human growth hormone-releasing hormone receptor-Gs protein complex
7ZBN	;	2.62	;	Cryo-EM structure of the human GS-GN complex in the inhibited state
6RZA	;	4.5	;	Cryo-EM structure of the human inner arm dynein DNAH7 microtubule binding domain bound to microtubules
7ZI4	;	3.2	;	Cryo-EM structure of the human INO80 complex bound to a WT nucleosome
6HTS	;	4.8	;	Cryo-EM structure of the human INO80 complex bound to nucleosome
7ZDZ	;	4.3	;	Cryo-EM structure of the human inward-rectifier potassium 2.1 channel (Kir2.1)
7DA5	;	3.3	;	Cryo-EM structure of the human MCT1 D309N mutant in complex with Basigin-2 in the inward-open conformation.
7CKO	;	2.95	;	Cryo-EM structure of the human MCT1/Basigin-2 complex in the presence of anti-cancer drug candidate 7ACC2 in the inward-open conformation
6LYY	;	3.2	;	Cryo-EM structure of the human MCT1/Basigin-2 complex in the presence of anti-cancer drug candidate AZD3965 in the outward-open conformation.
7CKR	;	3.0	;	Cryo-EM structure of the human MCT1/Basigin-2 complex in the presence of anti-cancer drug candidate BAY-8002 in the outward-open conformation.
7BP3	;	3.8	;	Cryo-EM structure of the human MCT2
8Y6O	;	3.38	;	Cryo-EM Structure of the human minor pre-B complex (pre-precatalytic spliceosome) U11 and tri-snRNP part
8Y7E	;	4.66	;	Cryo-EM Structure of the human minor pre-B complex (pre-precatalytic spliceosome) U12 snRNP part
7CGP	;	3.7	;	Cryo-EM structure of the human mitochondrial translocase TIM22 complex at 3.7 angstrom.
8E3Q	;	2.68	;	CRYO-EM STRUCTURE OF the human MPSF
8E3I	;	2.53	;	CRYO-EM STRUCTURE OF the human MPSF IN COMPLEX WITH THE AUUAAA poly(A) signal
8R8R	;	2.79	;	Cryo-EM structure of the human mPSF with PAPOA C-terminus peptide (PAPOAc)
8TUL	;	2.8	;	Cryo-EM structure of the human MRS2 magnesium channel under Mg2+ condition
8TUP	;	3.3	;	Cryo-EM structure of the human MRS2 magnesium channel under Mg2+-free condition
7QH6	;	3.08	;	Cryo-EM structure of the human mtLSU assembly intermediate upon MRM2 depletion - class 1
7QH7	;	2.89	;	Cryo-EM structure of the human mtLSU assembly intermediate upon MRM2 depletion - class 4
7TJ9	;	2.9	;	Cryo-EM structure of the human Nax channel in complex with beta3 solved in GDN
7TJ8	;	3.2	;	Cryo-EM structure of the human Nax channel in complex with beta3 solved in nanodiscs
6GCT	;	3.85	;	cryo-EM structure of the human neutral amino acid transporter ASCT2
6MP6	;	3.54	;	Cryo-EM structure of the human neutral amino acid transporter ASCT2
6MPB	;	3.84	;	Cryo-EM structure of the human neutral amino acid transporter ASCT2
8KB5	;	2.26133	;	Cryo-EM structure of the human nucleosome containing H3.8
7LYB	;	3.28	;	Cryo-EM structure of the human nucleosome core particle in complex with BRCA1-BARD1-UbcH5c
8SN2	;	3.6	;	Cryo-EM structure of the human nucleosome core particle in complex with RNF168 and UbcH5c (UbcH5c chemically conjugated to histone H2A)
8SN9	;	3.9	;	Cryo-EM structure of the human nucleosome core particle in complex with RNF168 and UbcH5c with backside ubiquitin (UbcH5c chemically conjugated to histone H2A) (class 1)
8SNA	;	4.0	;	Cryo-EM structure of the human nucleosome core particle in complex with RNF168 and UbcH5c with backside ubiquitin (UbcH5c chemically conjugated to histone H2A) (class 2)
8SN3	;	3.8	;	Cryo-EM structure of the human nucleosome core particle in complex with RNF168 and UbcH5c~Ub (UbcH5c chemically conjugated to histone H2A) (class 1)
8SN4	;	3.7	;	Cryo-EM structure of the human nucleosome core particle in complex with RNF168 and UbcH5c~Ub (UbcH5c chemically conjugated to histone H2A) (class 2)
8SN5	;	3.9	;	Cryo-EM structure of the human nucleosome core particle in complex with RNF168 and UbcH5c~Ub (UbcH5c chemically conjugated to histone H2A) (class 3)
8SN6	;	3.7	;	Cryo-EM structure of the human nucleosome core particle in complex with RNF168 and UbcH5c~Ub (UbcH5c chemically conjugated to histone H2A) (class 4)
8SN7	;	3.7	;	Cryo-EM structure of the human nucleosome core particle in complex with RNF168 and UbcH5c~Ub (UbcH5c chemically conjugated to histone H2A) (class 5)
8SN8	;	3.7	;	Cryo-EM structure of the human nucleosome core particle in complex with RNF168 and UbcH5c~Ub (UbcH5c chemically conjugated to histone H2A) (class 6)
8SMW	;	3.3	;	Cryo-EM structure of the human nucleosome core particle in complex with RNF168 and UbcH5c~Ub (UbcH5c chemically conjugated to histone H2A. No density for Ub.) (class 1)
8SMX	;	3.2	;	Cryo-EM structure of the human nucleosome core particle in complex with RNF168 and UbcH5c~Ub (UbcH5c chemically conjugated to histone H2A. No density for Ub.) (class 2)
8SMY	;	3.2	;	Cryo-EM structure of the human nucleosome core particle in complex with RNF168 and UbcH5c~Ub (UbcH5c chemically conjugated to histone H2A. No density for Ub.) (class 3)
8SMZ	;	3.2	;	Cryo-EM structure of the human nucleosome core particle in complex with RNF168 and UbcH5c~Ub (UbcH5c chemically conjugated to histone H2A. No density for Ub.) (Class 4)
8SN0	;	3.2	;	Cryo-EM structure of the human nucleosome core particle in complex with RNF168 and UbcH5c~Ub (UbcH5c chemically conjugated to histone H2A. No density for Ub.) (class 5)
8SN1	;	3.3	;	Cryo-EM structure of the human nucleosome core particle in complex with RNF168 and UbcH5c~Ub (UbcH5c chemically conjugated to histone H2A. No density for Ub.) (class 6)
8UPF	;	3.2	;	Cryo-EM structure of the human nucleosome core particle in complex with RNF168-UbcH5c
8TXV	;	3.8	;	Cryo-EM structure of the human nucleosome core particle ubiquitylated at histone H2A K15 in complex with RNF168 (Class 1)
8TXW	;	3.6	;	Cryo-EM structure of the human nucleosome core particle ubiquitylated at histone H2A K15 in complex with RNF168 (Class 2)
8TXX	;	3.7	;	Cryo-EM structure of the human nucleosome core particle ubiquitylated at histone H2A K15 in complex with RNF168 (Class 3)
7LYC	;	2.94	;	Cryo-EM structure of the human nucleosome core particle ubiquitylated at histone H2A Lys13 and Lys15 in complex with BARD1 (residues 415-777)
8U13	;	3.8	;	Cryo-EM structure of the human nucleosome core particle ubiquitylated at histone H2A lysine 15 in complex with RNF168-UbcH5c (class 1)
8U14	;	3.9	;	Cryo-EM structure of the human nucleosome core particle ubiquitylated at histone H2A lysine 15 in complex with RNF168-UbcH5c (class 2)
7LYA	;	2.91	;	Cryo-EM structure of the human nucleosome core particle with linked histone proteins H2A and H2B
8JLA	;	3.44	;	Cryo-EM structure of the human nucleosome lacking N-terminal region of H2A, H2B, H3, and H4
8JL9	;	2.65	;	Cryo-EM structure of the human nucleosome with scFv
6K7G	;	3.3	;	Cryo-EM structure of the human P4-type flippase ATP8A1-CDC50 (E1 state class1)
6K7H	;	3.22	;	Cryo-EM structure of the human P4-type flippase ATP8A1-CDC50 (E1 state class2)
6K7K	;	3.04	;	Cryo-EM structure of the human P4-type flippase ATP8A1-CDC50 (E1-ADP-Pi state)
6K7J	;	3.08	;	Cryo-EM structure of the human P4-type flippase ATP8A1-CDC50 (E1-ATP state class1)
6K7I	;	3.22	;	Cryo-EM structure of the human P4-type flippase ATP8A1-CDC50 (E1-ATP state class2)
6K7N	;	2.84	;	Cryo-EM structure of the human P4-type flippase ATP8A1-CDC50 (E1P state)
6K7L	;	2.83	;	Cryo-EM structure of the human P4-type flippase ATP8A1-CDC50 (E2P state class2)
6K7M	;	2.95	;	Cryo-EM structure of the human P4-type flippase ATP8A1-CDC50 (E2Pi-PL state)
7VGI	;	3.36	;	Cryo-EM structure of the human P4-type flippase ATP8B1-CDC50A in the auto-inhibited E2P state
7VGJ	;	3.98	;	Cryo-EM structure of the human P4-type flippase ATP8B1-CDC50A in the auto-inhibited E2Pi-PS state
7VGH	;	3.39	;	Cryo-EM structure of the human P4-type flippase ATP8B1-CDC50B in the auto-inhibited E2P state
6LPB	;	3.9	;	Cryo-EM structure of the human PAC1 receptor coupled to an engineered heterotrimeric G protein
7BWM	;	2.9	;	Cryo-EM structure of the human pathogen Mycoplasma pneumoniae P1
8HMZ	;	2.9	;	Cryo-EM structure of the human post-catalytic TSEN/pre-tRNA complex
8EKY	;	3.47	;	Cryo-EM structure of the human PRDX4-ErP46 complex
8HMY	;	2.94	;	Cryo-EM structure of the human pre-catalytic TSEN/pre-tRNA complex
8H1P	;	3.48	;	Cryo-EM structure of the human RAD52 protein
7TX7	;	3.8	;	Cryo-EM structure of the human reduced folate carrier
7TX6	;	3.3	;	Cryo-EM structure of the human reduced folate carrier in complex with methotrexate
8DEP	;	3.6	;	Cryo-EM structure of the human reduced folate carrier, apo condition
8GS8	;	2.86	;	cryo-EM structure of the human respiratory complex II
6W6L	;	3.84	;	Cryo-EM structure of the human ribosome-TMCO1 translocon
7KTR	;	2.93	;	Cryo-EM structure of the human SAGA coactivator complex (TRRAP, core)
8H7G	;	3.7	;	Cryo-EM structure of the human SAGA complex
8DNV	;	3.03	;	Cryo-EM structure of the human Sec61 complex in a partially-open apo state (Class 1)
8DNW	;	3.4	;	Cryo-EM structure of the human Sec61 complex in a partially-open apo state (Class 2)
8DNZ	;	2.57	;	Cryo-EM structure of the human Sec61 complex inhibited by apratoxin F
8DNX	;	2.98	;	Cryo-EM structure of the human Sec61 complex inhibited by cotransin
8DO2	;	2.95	;	Cryo-EM structure of the human Sec61 complex inhibited by cyclotriazadisulfonamide (CADA)
8DNY	;	2.85	;	Cryo-EM structure of the human Sec61 complex inhibited by decatransin
8DO3	;	3.22	;	Cryo-EM structure of the human Sec61 complex inhibited by eeyarestatin I
8DO1	;	3.01	;	Cryo-EM structure of the human Sec61 complex inhibited by ipomoeassin F
8DO0	;	2.86	;	Cryo-EM structure of the human Sec61 complex inhibited by mycolactone
8A11	;	3.52	;	Cryo-EM structure of the Human SHMT1-RNA complex
8C60	;	3.4	;	Cryo-EM structure of the human SIN3B full-length complex at 3.4 Angstrom resolution
8BPA	;	3.7	;	Cryo-EM structure of the human SIN3B histone deacetylase complex at 3.7 Angstrom
8BPB	;	2.8	;	Cryo-EM structure of the human SIN3B histone deacetylase core complex at 2.8 Angstrom
8BPC	;	2.8	;	Cryo-EM structure of the human SIN3B histone deacetylase core complex with SAHA at 2.8 Angstrom
6CNM	;	3.4	;	Cryo-EM structure of the human SK4/calmodulin channel complex
6CNN	;	3.5	;	Cryo-EM structure of the human SK4/calmodulin channel complex in the Ca2+ bound state I
6CNO	;	4.7	;	Cryo-EM structure of the human SK4/calmodulin channel complex in the Ca2+ bound state II
8Q7N	;	3.1	;	cryo-EM structure of the human spliceosomal B complex protomer (tri-snRNP core region)
5XJC	;	3.6	;	Cryo-EM structure of the human spliceosome just prior to exon ligation at 3.6 angstrom
7MQA	;	2.7	;	Cryo-EM structure of the human SSU processome, state post-A1
7MQ8	;	3.6	;	Cryo-EM structure of the human SSU processome, state pre-A1
7MQ9	;	3.87	;	Cryo-EM structure of the human SSU processome, state pre-A1*
6I53	;	3.2	;	Cryo-EM structure of the human synaptic alpha1-beta3-gamma2 GABAA receptor in complex with Megabody38 in a lipid nanodisc
7F6V	;	3.66	;	Cryo-EM structure of the human TACAN channel in a closed state
5U1D	;	3.97	;	Cryo-EM structure of the human TAP ATP-Binding Cassette Transporter
6NMI	;	3.7	;	Cryo-EM structure of the human TFIIH core complex
6ZY5	;	3.6	;	Cryo-EM structure of the Human topoisomerase II alpha DNA-binding/cleavage domain in State 1
6ZY6	;	4.1	;	Cryo-EM structure of the Human topoisomerase II alpha DNA-binding/cleavage domain in State 2
7OR1	;	2.64	;	Cryo-EM structure of the human TRPA1 ion channel in complex with the antagonist 3-60, conformation 1
7OR0	;	2.64	;	Cryo-EM structure of the human TRPA1 ion channel in complex with the antagonist 3-60, conformation 2
6PQP	;	3.06	;	Cryo-EM structure of the human TRPA1 ion channel in complex with the covalent agonist BITC
6PQO	;	2.88	;	Cryo-EM structure of the human TRPA1 ion channel in complex with the covalent agonist JT010
7X6I	;	3.93	;	Cryo-EM structure of the human TRPC5 ion channel in complex with G alpha i3 subunits, class1
8GVX	;	3.91	;	Cryo-EM structure of the human TRPC5 ion channel in complex with G alpha i3 subunits, class2
7X6C	;	3.15	;	Cryo-EM structure of the human TRPC5 ion channel in lipid nanodiscs, class1
8GVW	;	3.59	;	Cryo-EM structure of the human TRPC5 ion channel in lipid nanodiscs, class2
6UW8	;	4.02	;	Cryo-EM structure of the human TRPV3 K169A mutant briefly exposed to 2-APB for 3 minutes, determined in lipid nanodisc
6UW6	;	3.66	;	Cryo-EM structure of the human TRPV3 K169A mutant determined in lipid nanodisc
6UW9	;	4.33	;	Cryo-EM structure of the human TRPV3 K169A mutant in the presence of 2-APB, determined in lipid nanodisc
8FCA	;	3.41	;	Cryo-EM structure of the human TRPV4 - RhoA in complex with 4alpha-Phorbol 12,13-didecanoate
8FCB	;	3.55	;	Cryo-EM structure of the human TRPV4 - RhoA in complex with GSK1016790A
8FC7	;	3.3	;	Cryo-EM structure of the human TRPV4 - RhoA in complex with GSK2798745
8FC9	;	3.75	;	Cryo-EM structure of the human TRPV4 - RhoA, apo condition
8FC8	;	3.47	;	Cryo-EM structure of the human TRPV4 in complex with GSK1016790A
7CAL	;	3.2	;	Cryo-EM Structure of the Hyperpolarization-Activated Inwardly Rectifying Potassium Channel KAT1 from Arabidopsis
6V1Y	;	3.8	;	Cryo-EM Structure of the Hyperpolarization-Activated Potassium Channel KAT1: Octamer
6V1X	;	3.5	;	Cryo-EM Structure of the Hyperpolarization-Activated Potassium Channel KAT1: Tetramer
8BQS	;	2.9	;	Cryo-EM structure of the I-II-III2-IV2 respiratory supercomplex from Tetrahymena thermophila
7V3P	;	3.6	;	Cryo-EM structure of the IGF1R/insulin complex
7YFD	;	3.1	;	Cryo-EM structure of the imetit-bound histamine H4 receptor and Gq complex
6N89	;	7.5	;	Cryo-EM structure of the Importin beta:Histone H1.0 complex
6N88	;	6.2	;	Cryo-EM structure of the Importin7:Importin beta:Histone H1.0 complex
8EAO	;	3.2	;	Cryo-EM structure of the in-situ gp1-gp4 complex from bacteriophage P22
8EAP	;	3.3	;	Cryo-EM structure of the in-situ gp10-gp26 from bacteriophage P22
8EB7	;	3.8	;	Cryo-EM structure of the in-situ gp4-gp10-gp9N from bacteriophage P22
8IKJ	;	3.2	;	Cryo-EM structure of the inactive CD97
7ZUB	;	2.85	;	Cryo-EM structure of the indirubin-bound Hsp90-XAP2-AHR complex
7WOT	;	3.73	;	Cryo-EM structure of the inner ring monomer of the Saccharomyces cerevisiae nuclear pore complex
7WOO	;	3.71	;	Cryo-EM structure of the inner ring protomer of the Saccharomyces cerevisiae nuclear pore complex
7YJ4	;	3.19	;	Cryo-EM structure of the INSL5-bound human relaxin family peptidereceptor 4 (RXFP4)-Gi complex
7CFN	;	3.0	;	Cryo-EM structure of the INT-777-bound GPBAR-Gs complex
5Y88	;	3.46	;	Cryo-EM structure of the intron-lariat spliceosome ready for disassembly from S.cerevisiae at 3.5 angstrom
7WKK	;	4.2	;	Cryo-EM structure of the IR subunit from X. laevis NPC
8HUJ	;	3.76	;	Cryo-EM structure of the J-K-St region of EMCV IRES in complex with eIF4G-HEAT1 and eIF4A
8J7R	;	3.7	;	Cryo-EM structure of the J-K-St region of EMCV IRES in complex with eIF4G-HEAT1 and eIF4A (J-K-St/eIF4G focused)
8H3F	;	6.73	;	Cryo-EM Structure of the KBTBD2-CRL3-CSN complex
8H3R	;	6.36	;	Cryo-EM Structure of the KBTBD2-CRL3~N8 dimeric complex
8H3A	;	7.51	;	Cryo-EM Structure of the KBTBD2-CRL3~N8(removed)-CSN complex
8H38	;	4.25	;	Cryo-EM Structure of the KBTBD2-CRL3~N8-CSN(mutate) complex
8GQ6	;	3.96	;	Cryo-EM Structure of the KBTBD2-CUL3-Rbx1 dimeric complex
8H34	;	7.99	;	Cryo-EM Structure of the KBTBD2-Cul3-Rbx1 hexameric complex
8H35	;	7.41	;	Cryo-EM Structure of the KBTBD2-Cul3-Rbx1 octameric complex
8H33	;	7.86	;	Cryo-EM Structure of the KBTBD2-Cul3-Rbx1 tetrameric complex
8H36	;	4.6	;	Cryo-EM Structure of the KBTBD2-CUL3-Rbx1-p85a dimeric complex
8H37	;	7.52	;	Cryo-EM Structure of the KBTBD2-CUL3-Rbx1-p85a tetrameric complex
7ZRH	;	3.4	;	Cryo-EM structure of the KdpFABC complex in a nucleotide-free E1 conformation loaded with K+
7ZRI	;	3.5	;	Cryo-EM structure of the KdpFABC complex in a nucleotide-free E1 conformation loaded with K+
7ZRJ	;	3.7	;	Cryo-EM structure of the KdpFABC complex in a nucleotide-free E1 conformation loaded with K+
6HRA	;	3.7	;	Cryo-EM structure of the KdpFABC complex in an E1 outward-facing state (state 1)
7NNL	;	3.1	;	Cryo-EM structure of the KdpFABC complex in an E1-ATP conformation loaded with K+
6HRB	;	4.0	;	Cryo-EM structure of the KdpFABC complex in an E2 inward-facing state (state 2)
6LMT	;	2.66	;	Cryo-EM structure of the killifish CALHM1
8W4J	;	3.06	;	Cryo-EM structure of the KLHL22 E3 ligase bound to human glutamate dehydrogenase I
7WIG	;	2.7	;	Cryo-EM structure of the L-054,264-bound human SSTR2-Gi1 complex
8IZF	;	3.85	;	Cryo-EM structure of the Lac1-Lip1 (Lip1-S74F) complex
5V7Q	;	3.7	;	Cryo-EM structure of the large ribosomal subunit from Mycobacterium tuberculosis bound with a potent linezolid analog
8IUL	;	2.78	;	Cryo-EM structure of the latanoprost-bound human PTGFR-Gq complex
6NMD	;	3.49	;	cryo-EM Structure of the LbCas12a-crRNA-AcrVA1 complex
7Y5W	;	3.5	;	Cryo-EM structure of the left-handed Di-tetrasome
8HG3	;	2.94	;	Cryo-EM structure of the Lhcp complex from Ostreococcus tauri
7NL0	;	3.5	;	Cryo-EM structure of the Lin28B nucleosome core particle
8ID4	;	3.1	;	Cryo-EM structure of the linoleic acid bound GPR120-Gi complex
8UUA	;	2.7	;	Cryo-EM structure of the Listeria innocua 50S ribosomal subunit in complex with HflXr (structure III)
8UU8	;	3.1	;	Cryo-EM structure of the Listeria innocua 70S ribosome (head-swiveled) in complex with HflXr and pe/E-tRNA (structure II-C)
8UU5	;	3.0	;	Cryo-EM structure of the Listeria innocua 70S ribosome (head-swiveled) in complex with pe/E-tRNA (structure I-B)
8UU7	;	3.2	;	Cryo-EM structure of the Listeria innocua 70S ribosome in complex with HflXr, HPF, and E-site tRNA (structure II-B)
8UU4	;	3.0	;	Cryo-EM structure of the Listeria innocua 70S ribosome in complex with HPF (structure I-A)
8J19	;	3.23	;	Cryo-EM structure of the LY237-bound GPR84 receptor-Gi complex
5GAQ	;	3.1	;	Cryo-EM structure of the Lysenin Pore
6NZD	;	3.6	;	Cryo-EM Structure of the Lysosomal Folliculin Complex (FLCN-FNIP2-RagA-RagC-Ragulator)
3JCF	;	3.8	;	Cryo-EM structure of the magnesium channel CorA in the closed symmetric magnesium-bound state
3JCG	;	7.06	;	Cryo-EM structure of the magnesium channel CorA in the magnesium-free, asymmetric open state I
3JCH	;	7.06	;	Cryo-EM structure of the magnesium channel CorA in the magnesium-free, asymmetric open state II
8I8A	;	3.21	;	Cryo-EM structure of the major capsid protein VP39 of Autographa californica multiple nucleopolyhedrovirus (AcMNPV)
5UZB	;	7.0	;	Cryo-EM structure of the MAL TIR domain filament
5JYG	;	6.5	;	Cryo-EM structure of the MamK filament at 6.5 A
6J5K	;	6.2	;	Cryo-EM structure of the mammalian ATP synthase tetramer bound with inhibitory protein IF1
6J5I	;	3.34	;	Cryo-EM structure of the mammalian DP-state ATP synthase
6J5A	;	4.35	;	Cryo-EM structure of the mammalian DP-state ATP synthase FO section
6J5J	;	3.45	;	Cryo-EM structure of the mammalian E-state ATP synthase
6J54	;	3.94	;	Cryo-EM structure of the mammalian E-state ATP synthase FO section
6FTJ	;	4.7	;	Cryo-EM Structure of the Mammalian Oligosaccharyltransferase Bound to Sec61 and the Non-programmed 80S Ribosome
6FTI	;	4.2	;	Cryo-EM Structure of the Mammalian Oligosaccharyltransferase Bound to Sec61 and the Programmed 80S Ribosome
7NQK	;	3.5	;	Cryo-EM structure of the mammalian peptide transporter PepT2
2WWB	;	6.48	;	CRYO-EM STRUCTURE OF THE MAMMALIAN SEC61 COMPLEX BOUND TO THE ACTIVELY TRANSLATING WHEAT GERM 80S RIBOSOME
6KG7	;	3.8	;	Cryo-EM Structure of the Mammalian Tactile Channel Piezo2
8GTA	;	3.63	;	Cryo-EM structure of the marine siphophage vB_Dshs-R4C capsid
8GTB	;	3.43	;	Cryo-EM structure of the marine siphophage vB_DshS-R4C tail tube protein
7KO8	;	4.4	;	Cryo-EM structure of the mature and infective Mayaro virus
3JA8	;	3.8	;	Cryo-EM structure of the MCM2-7 double hexamer
5U0S	;	7.8	;	Cryo-EM structure of the Mediator-RNAPII complex
8W87	;	2.8	;	Cryo-EM structure of the METH-TAAR1 complex
8TFB	;	2.99	;	Cryo-EM structure of the Methanosarcina mazei apo glutamin synthetase structure: dodecameric form
8TFK	;	2.66	;	Cryo-EM structure of the Methanosarcina mazei glutamine synthetase (GS) with Met-Sox-P and ADP
6LBH	;	3.7	;	Cryo-EM structure of the MgtE Mg2+ channel under Mg2+-free conditions
7YGN	;	3.0	;	Cryo-EM structure of the Mili in complex with piRNA
7YFY	;	3.4	;	Cryo-EM structure of the Mili-piRNA- target ternary complex
7F3E	;	3.62	;	Cryo-EM structure of the minimal protein-only RNase P from Aquifex aeolicus
8G5M	;	2.58	;	Cryo-EM structure of the Mismatch Locking Complex (III) of Human Mitochondrial DNA Polymerase Gamma
8G5I	;	2.75	;	Cryo-EM structure of the Mismatch Sensing Complex (I) of Human Mitochondrial DNA Polymerase Gamma
8G5J	;	2.63	;	Cryo-EM structure of the Mismatch Uncoupling Complex (II) of Human Mitochondrial DNA Polymerase Gamma
6D7W	;	3.8	;	Cryo-EM structure of the mitochondrial calcium uniporter from N. fischeri at 3.8 Angstrom resolution
6D80	;	5.0	;	Cryo-EM structure of the mitochondrial calcium uniporter from N. fischeri bound to saposin
6DNF	;	3.2	;	Cryo-EM structure of the mitochondrial calcium uniporter MCU from the fungus Cyphellophora europaea
6UCU	;	3.06	;	Cryo-EM structure of the mitochondrial TOM complex from yeast (dimer)
6UCV	;	4.1	;	Cryo-EM structure of the mitochondrial TOM complex from yeast (tetramer)
8J6P	;	2.55	;	Cryo-EM structure of the MK-6892-bound human HCAR2-Gi1 complex
8J6R	;	2.76	;	Cryo-EM structure of the MK-6892-bound human HCAR2-Gi1 complex
8XZH	;	2.6	;	Cryo-EM structure of the MM07-bound human APLNR-Gi complex
7YJO	;	2.8	;	Cryo-EM structure of the monomeric atSPT-ORM1 (LCB2a-deltaN5) complex
7YJN	;	3.4	;	Cryo-EM structure of the monomeric atSPT-ORM1 (ORM1-N17A) complex
7YJM	;	3.2	;	Cryo-EM structure of the monomeric atSPT-ORM1 complex
7N0C	;	3.4	;	Cryo-EM structure of the monomeric form of SARS-CoV-2 nsp10-nsp14 (E191A)-RNA complex
8IQG	;	3.5	;	Cryo-EM structure of the monomeric human CAF1-H3-H4 complex
7Y5U	;	3.8	;	Cryo-EM structure of the monomeric human CAF1LC-H3-H4 complex
6M4O	;	3.4	;	Cryo-EM structure of the monomeric SPT-ORMDL3 complex
8IBV	;	3.19	;	Cryo-EM structure of the motilin-bound motilin receptor-Gq protein complex
7V5C	;	3.2	;	Cryo-EM structure of the mouse ABCB9 (ADP.BeF3-bound)
7V5D	;	3.4	;	Cryo-EM structure of the mouse ABCB9 (PG-bound)
6LQI	;	4.5	;	Cryo-EM structure of the mouse Piezo1 isoform Piezo1.1
7VFI	;	3.98	;	Cryo-EM structure of the mouse TAPL (9mer-peptide bound)
7LJF	;	4.0	;	Cryo-EM structure of the Mpa hexamer in the presence of ATP and the Pup-FabD substrate
6Q8Y	;	3.1	;	Cryo-EM structure of the mRNA translating and degrading yeast 80S ribosome-Xrn1 nuclease complex
5NL2	;	6.6	;	cryo-EM structure of the mTMEM16A ion channel at 6.6 A resolution.
7UXH	;	3.2	;	cryo-EM structure of the mTORC1-TFEB-Rag-Ragulator complex
7UXC	;	3.2	;	cryo-EM structure of the mTORC1-TFEB-Rag-Ragulator complex with symmetry expansion
7NZ4	;	13.0	;	Cryo-EM structure of the MukBEF dimer
7NYY	;	6.8	;	Cryo-EM structure of the MukBEF monomer
7NYW	;	3.1	;	Cryo-EM structure of the MukBEF-MatP-DNA head module
7NYX	;	4.6	;	Cryo-EM structure of the MukBEF-MatP-DNA monomer (closed conformation)
7NZ0	;	6.3	;	Cryo-EM structure of the MukBEF-MatP-DNA monomer (open conformation)
7NYZ	;	6.5	;	Cryo-EM structure of the MukBEF-MatP-DNA monomer (partially open conformation)
7NZ2	;	11.0	;	Cryo-EM structure of the MukBEF-MatP-DNA tetrad
6LVF	;	3.7	;	Cryo-EM structure of the multiple peptide resistance factor (MprF) loaded with one lysyl-phosphatidylglycerol molecule
7DUW	;	2.96	;	Cryo-EM structure of the multiple peptide resistance factor (MprF) loaded with two lysyl-phosphatidylglycerol molecules
8BMS	;	2.6	;	Cryo-EM structure of the mutant solitary ECF module 2EQ in MSP2N2 lipid nanodiscs in the ATPase closed and ATP-bound conformation
7ZPP	;	4.5	;	Cryo-EM structure of the MVV CSC intasome at 4.5A resolution
4V8L	;	7.5	;	Cryo-EM Structure of the Mycobacterial Fatty Acid Synthase
8V9J	;	3.1	;	Cryo-EM structure of the Mycobacterium smegmatis 70S ribosome in complex with hibernation factor Msmeg1130 (Balon) (Structure 4)
8V9L	;	3.0	;	Cryo-EM structure of the Mycobacterium smegmatis 70S ribosome in complex with hibernation factor Msmeg1130 (Balon) and MsmegEF-Tu(GDP) (Composite structure 6)
8V9K	;	3.1	;	Cryo-EM structure of the Mycobacterium smegmatis 70S ribosome in complex with hibernation factor Rv2629 (Balon) (Structure 5)
7Y0D	;	3.1	;	Cryo-EM structure of the Mycobacterium smegmatis DNA integrity scanning protein (MsDisA).
8HCR	;		;	Cryo-EM structure of the Mycobacterium tuberculosis cytochrome bcc:aa3 supercomplex and a novel inhibitor targeting subunit cytochrome cI
7NVH	;	3.0	;	Cryo-EM structure of the mycolic acid transporter MmpL3 from M. tuberculosis
7Y5A	;	3.5	;	Cryo-EM structure of the Mycolicibacterium smegmatis F1-ATPase
7LC9	;	3.2	;	Cryo-EM structure of the N-terminal alpha-synuclein truncation 41-140
6REV	;	3.8	;	Cryo-EM structure of the N-terminal DC repeat (NDC) of human doublecortin (DCX) bound to 13-protofilament GDP-microtubule
6RF8	;	3.8	;	Cryo-EM structure of the N-terminal DC repeat (NDC) of NDC-NDC chimera (human sequence) bound to 13-protofilament GDP-microtubule
6RFD	;	3.9	;	Cryo-EM structure of the N-terminal DC repeat (NDC) of NDC-NDC chimera (human sequence) bound to 14-protofilament GDP-microtubule
7WSV	;	4.5	;	Cryo-EM structure of the N-terminal deletion mutant of human pannexin-1 in a nanodisc
7YOX	;	3.95	;	Cryo-EM structure of the N-terminal domain of hMCM8/9 and HROB
6OSM	;	3.4	;	Cryo-EM structure of the N-terminally acetylated C-terminal Alpha-synuclein truncation Ac1-103
6OSL	;	3.0	;	Cryo-EM structure of the N-terminally acetylated C-terminal Alpha-synuclein truncation Ac1-122
6OSJ	;	2.8	;	Cryo-EM structure of the N-terminally acetylated full length alpha-synuclein fibrils (Ac1-140)
7Y45	;	3.3	;	Cryo-EM structure of the Na+,K+-ATPase in the E2.2K+ state
7Y46	;	7.2	;	Cryo-EM structure of the Na+,K+-ATPase in the E2.2K+ state after addition of ATP
6B5B	;	5.2	;	Cryo-EM structure of the NAIP5-NLRC4-flagellin inflammasome
6OFJ	;	4.5	;	Cryo-EM structure of the native rhodopsin dimer from rod photoreceptor cells
4BGN	;	9.0	;	cryo-EM structure of the NavCt voltage-gated sodium channel
7RYE	;	3.9	;	Cryo-EM structure of the needle filament-tip complex of the Salmonella type III secretion injectisome
7W56	;	2.9	;	Cryo-EM structure of the neuromedin S-bound neuromedin U receptor 1-Gq protein complex
7W57	;	3.2	;	Cryo-EM structure of the neuromedin S-bound neuromedin U receptor 2-Gq protein complex
7XK8	;	3.3	;	Cryo-EM structure of the Neuromedin U receptor 2 (NMUR2) in complex with G Protein and its endogeneous Peptide-Agonist NMU25
7W53	;	3.2	;	Cryo-EM structure of the neuromedin U-bound neuromedin U receptor 1-Gq protein complex
7W55	;	2.8	;	Cryo-EM structure of the neuromedin U-bound neuromedin U receptor 2-Gq protein complex
8B4I	;	3.32	;	Cryo-EM structure of the Neurospora crassa TOM core complex at 3.3 angstrom
7UR4	;	3.34	;	Cryo-EM Structure of the Neutralizing Antibody MPV467 in Complex with Prefusion Human Metapneumovirus F Glycoprotein
8CQR	;	3.8	;	Cryo-EM structure of the NINJ1 filament
6ZBY	;	3.1	;	Cryo-EM structure of the nitrilase from Pseudomonas fluorescens EBC191 at 3.3 Angstroms
8AHX	;	3.11	;	Cryo-EM structure of the nitrogen-fixation associated NADH:ferredoxin oxidoreductase RNF from Azotobacter vinelandii
6XKK	;	3.72	;	Cryo-EM structure of the NLRP1-CARD filament
7PZC	;	3.9	;	Cryo-EM structure of the NLRP3 decamer bound to the inhibitor CRID3
7PZD	;	3.6	;	Cryo-EM structure of the NLRP3 PYD filament
8JA0	;	3.52	;	Cryo-EM structure of the NmeCas9-sgRNA-AcrIIC4 ternary complex
7VAB	;	3.2	;	Cryo-EM structure of the non-acylated tirzepatide (LY3298176)-bound human GIPR-Gs complex
7VBI	;	3.0	;	Cryo-EM structure of the non-acylated tirzepatide (LY3298176)-bound human GLP-1R-Gs complex
7K08	;	4.7	;	Cryo-EM structure of the nonameric EscV cytosolic domain from the type III secretion system
7FEB	;	2.11	;	Cryo-EM structure of the nonameric SsaV cytosolic domain in the context of the InvA-SsaV chimeric protein
7FEC	;	3.64	;	Cryo-EM structure of the nonameric SsaV cytosolic domain with C9 symmetry
7FED	;	3.55	;	Cryo-EM structure of the nonameric SsaV cytosolic domain with D9 symmetry
7WB4	;	5.6	;	Cryo-EM structure of the NR subunit from X. laevis NPC
8GZQ	;	3.9	;	Cryo-EM structure of the NS5-NS3-SLA complex
8GZP	;	3.6	;	Cryo-EM structure of the NS5-SLA complex
7Y00	;	3.96	;	Cryo-EM structure of the nucleosome containing 169 base-pair DNA with a p53 target sequence
7XZY	;	3.97	;	Cryo-EM structure of the nucleosome containing 193 base-pair DNA with a p53 target sequence
7D69	;	3.57	;	Cryo-EM structure of the nucleosome containing Giardia histones
7WLR	;	3.54	;	Cryo-EM structure of the nucleosome containing Komagataella pastoris histones
8PKJ	;	2.5	;	Cryo-EM structure of the nucleosome containing Nr5a2 motif at SHL+5.5
7XZZ	;	4.07	;	Cryo-EM structure of the nucleosome in complex with p53
7XZX	;	4.53	;	Cryo-EM structure of the nucleosome in complex with p53 DNA-binding domain
7Q64	;	2.76	;	Cryo-em structure of the Nup98 fibril polymorph 1
7Q65	;	3.32	;	Cryo-em structure of the Nup98 fibril polymorph 2
7Q66	;	2.79	;	Cryo-em structure of the Nup98 fibril polymorph 3
7Q67	;	3.37	;	Cryo-em structure of the Nup98 fibril polymorph 4
8CI8	;	2.67	;	Cryo-EM structure of the Nup98(298-327) fibril
7Q9Y	;	3.84	;	Cryo-EM structure of the octameric pore of Clostridium perfringens beta-toxin.
7EH7	;	3.71	;	Cryo-EM structure of the octameric state of C-phycocyanin from Thermoleptolyngbya sp. O-77
7Y24	;	3.25	;	Cryo-EM structure of the octreotide-bound SSTR2-miniGo-scFv16 complex
7Y26	;	3.3	;	Cryo-EM structure of the octreotide-bound SSTR2-miniGq-scFv16 complex
8ID6	;	2.8	;	Cryo-EM structure of the oleic acid bound GPR120-Gi complex
7WM0	;	3.35	;	Cryo-EM structure of the Omicron RBD in complex with 35B5 Fab( local refinement of the RBD and 35B5 Fab)
7WLY	;	3.4	;	Cryo-EM structure of the Omicron S in complex with 35B5 Fab(1 down- and 2 up RBDs)
7WLZ	;	2.98	;	Cryo-EM structure of the Omicron S in complex with 35B5 Fab(1 down-, 1 up- and 1 invisible RBDs)
8ET7	;	3.77	;	Cryo-EM structure of the organic cation transporter 1 in complex with diphenhydramine
8ET8	;	3.45	;	Cryo-EM structure of the organic cation transporter 1 in complex with verapamil
8ET6	;	3.57	;	Cryo-EM structure of the organic cation transporter 1 in the apo state
8ET9	;	3.61	;	Cryo-EM structure of the organic cation transporter 2 in complex with 1-methyl-4-phenylpyridinium
7BC6	;	3.2	;	Cryo-EM structure of the outward open proton coupled folate transporter at pH 7.5
8JWI	;	2.94	;	Cryo-EM structure of the outward-facing Plasmodium falciparum multidrug resistance protein 1
8HAG	;	3.2	;	Cryo-EM structure of the p300 catalytic core bound to the H4K12acK16ac nucleosome, class 1 (3.2 angstrom resolution)
8HAI	;	4.7	;	Cryo-EM structure of the p300 catalytic core bound to the H4K12acK16ac nucleosome, class 1 (4.7 angstrom resolution)
8HAH	;	3.9	;	Cryo-EM structure of the p300 catalytic core bound to the H4K12acK16ac nucleosome, class 2 (3.9 angstrom resolution)
8HAJ	;	4.8	;	Cryo-EM structure of the p300 catalytic core bound to the H4K12acK16ac nucleosome, class 2 (4.8 angstrom resolution)
8HAK	;	4.5	;	Cryo-EM structure of the p300 catalytic core bound to the H4K12acK16ac nucleosome, class 4 (4.5 angstrom resolution)
7CFM	;	3.0	;	Cryo-EM structure of the P395-bound GPBAR-Gs complex
8ED0	;	2.72	;	Cryo-EM Structure of the P74-26 Tail Tube
8E3X	;	2.3	;	Cryo-EM structure of the PAC1R-PACAP27-Gs complex
5TWV	;	6.3	;	Cryo-EM structure of the pancreatic ATP-sensitive K+ channel SUR1/Kir6.2 in the presence of ATP and glibenclamide
7U24	;	3.58	;	Cryo-EM structure of the pancreatic ATP-sensitive potassium channel bound to ATP and glibenclamide with Kir6.2-CTD in the up conformation
7TYT	;	3.6	;	Cryo-EM structure of the pancreatic ATP-sensitive potassium channel bound to ATP and repaglinide with Kir6.2-CTD in the down conformation
7TYS	;	3.41	;	Cryo-EM structure of the pancreatic ATP-sensitive potassium channel bound to ATP and repaglinide with Kir6.2-CTD in the up conformation
7U1Q	;	3.9	;	Cryo-EM structure of the pancreatic ATP-sensitive potassium channel bound to ATP and repaglinide with SUR1-in conformation
7U1S	;	3.8	;	Cryo-EM structure of the pancreatic ATP-sensitive potassium channel bound to ATP and repaglinide with SUR1-out conformation
7UQR	;	4.55	;	Cryo-EM structure of the pancreatic ATP-sensitive potassium channel in the apo form with Kir6.2-CTD in the down conformation
7U2X	;	4.1	;	Cryo-EM structure of the pancreatic ATP-sensitive potassium channel in the presence of carbamazepine and ATP with Kir6.2-CTD in the down conformation
7U7M	;	5.2	;	Cryo-EM structure of the pancreatic ATP-sensitive potassium channel in the presence of carbamazepine and ATP with Kir6.2-CTD in the up conformation
7U6Y	;	7.4	;	Cryo-EM structure of the pancreatic ATP-sensitive potassium channel in the presence of glibenclamide and ATP with Kir6.2-CTD in the down conformation
6BAA	;	3.63	;	Cryo-EM structure of the pancreatic beta-cell KATP channel bound to ATP and glibenclamide
6PZB	;	4.55	;	Cryo-EM structure of the pancreatic beta-cell SUR1 Apo state
6PZA	;	3.74	;	Cryo-EM structure of the pancreatic beta-cell SUR1 bound to ATP and glibenclamide
6PZ9	;	3.65	;	Cryo-EM structure of the pancreatic beta-cell SUR1 bound to ATP and repaglinide
6PZI	;	4.5	;	Cryo-EM structure of the pancreatic beta-cell SUR1 bound to ATP only
6PZC	;	4.34	;	Cryo-EM structure of the pancreatic beta-cell SUR1 bound to carbamazepine
7DHI	;	3.26	;	Cryo-EM structure of the partial agonist salbutamol-bound beta2 adrenergic receptor-Gs protein complex.
6ROI	;	3.7	;	Cryo-EM structure of the partially activated Drs2p-Cdc50p
8WCA	;	3.48	;	Cryo-EM structure of the PEA-bound hTAAR1-Gs complex
8WC6	;	3.2	;	Cryo-EM structure of the PEA-bound mTAAR1-Gs complex
8IWM	;	3.17	;	Cryo-EM structure of the PEA-bound mTAAR9 complex
8IW1	;	3.4	;	Cryo-EM structure of the PEA-bound mTAAR9-Golf complex
8IW7	;	2.97	;	Cryo-EM structure of the PEA-bound mTAAR9-Gs complex
8W89	;	3.0	;	Cryo-EM structure of the PEA-bound TAAR1-Gs complex
8QVW	;	3.0	;	Cryo-EM structure of the peptide binding domain of human SRP68/72
8IOD	;	2.59	;	Cryo-EM structure of the PG-901-bound human melanocortin receptor 5 (MC5R)-Gs complex
7CX2	;	2.8	;	Cryo-EM structure of the PGE2-bound EP2-Gs complex
8IUK	;	2.67	;	Cryo-EM structure of the PGF2-alpha-bound human PTGFR-Gq complex
8K9F	;	2.9	;	Cryo-EM structure of the photosynthetic alternative complex III from Chloroflexus aurantiacus at 2.9 angstrom
8K9E	;	3.33	;	Cryo-EM structure of the photosynthetic alternative complex III from Chloroflexus aurantiacus at 3.3 angstrom
8X2J	;	2.7	;	Cryo-EM structure of the photosynthetic alternative complex III with a quinone inhibitor HQNO from Chloroflexus aurantiacus
8CMO	;	2.81	;	Cryo-EM structure of the Photosystem I - LHCI supercomplex from Coelastrella sp.
8BD3	;	2.73	;	Cryo-EM structure of the Photosystem II - LHCII supercomplex from Chlorella ohadi
6R4R	;	3.4	;	Cryo-EM Structure of the PI3-Kinase SH3 Domain Amyloid Fibril
8AUV	;	2.38	;	Cryo-EM structure of the plant 40S subunit
8AZW	;	2.14	;	Cryo-EM structure of the plant 60S subunit
8B2L	;	2.2	;	Cryo-EM structure of the plant 80S ribosome
6IUG	;	3.9	;	Cryo-EM structure of the plant actin filaments from Zea mays pollen
3J79	;	3.2	;	Cryo-EM structure of the Plasmodium falciparum 80S ribosome bound to the anti-protozoan drug emetine, large subunit
3J7A	;	3.2	;	Cryo-EM structure of the Plasmodium falciparum 80S ribosome bound to the anti-protozoan drug emetine, small subunit
6OKK	;	3.3	;	Cryo-EM structure of the Plasmodium falciparum 80S ribosome bound to the anti-protozoan drug emetine, small subunit
7OAE	;	2.0	;	Cryo-EM structure of the plectasin fibril (double strands)
7OAG	;	3.4	;	Cryo-EM structure of the plectasin fibril (single strand)
8I6V	;	3.06	;	Cryo-EM structure of the polyphosphate polymerase VTC complex(Vtc4/Vtc3/Vtc1)
5YLZ	;	3.6	;	Cryo-EM Structure of the Post-catalytic Spliceosome from Saccharomyces cerevisiae at 3.6 angstrom
7WSW	;	3.4	;	Cryo-EM structure of the Potassium channel AKT1 from Arabidopsis thaliana
7FCV	;	2.9	;	Cryo-EM structure of the Potassium channel AKT1 mutant from Arabidopsis thaliana
6UKN	;	3.65	;	Cryo-EM structure of the potassium-chloride cotransporter KCC4 in lipid nanodiscs
8IU0	;	2.66	;	Cryo-EM structure of the potassium-selective channelrhodopsin HcKCR1 H225F mutant in lipid nanodisc
8H86	;	2.56	;	Cryo-EM structure of the potassium-selective channelrhodopsin HcKCR1 in lipid nanodisc
8H87	;	2.53	;	Cryo-EM structure of the potassium-selective channelrhodopsin HcKCR2 in lipid nanodisc
8TTB	;	2.77	;	Cryo-EM structure of the PP2A:B55-ARPP19 complex
8SO0	;	2.79961	;	Cryo-EM structure of the PP2A:B55-FAM122A complex
8TWE	;	2.55	;	Cryo-EM structure of the PP2A:B55-FAM122A complex, B55 body
8TWI	;	2.69	;	Cryo-EM structure of the PP2A:B55-FAM122A complex, PP2Ac body
7SJX	;	8.2	;	Cryo-EM Structure of the PR-RT components of the HIV-1 Pol Polyprotein
8HG5	;	2.9	;	Cryo-EM structure of the prasinophyte-specific light-harvesting complex (Lhcp)from Ostreococcus tauri
8HG6	;	3.44	;	Cryo-EM structure of the prasinophyte-specific light-harvesting complex (Lhcp)from Ostreococcus tauri
7DD3	;	3.2	;	Cryo-EM structure of the pre-mRNA-loaded DEAH-box ATPase/helicase Prp2 in complex with Spp2
7LS5	;	2.74	;	Cryo-EM structure of the Pre3-1 20S proteasome core particle
6XYE	;	4.3	;	Cryo-EM structure of the prefusion state of canine distemper virus fusion protein ectodomain
6UOT	;	3.3	;	Cryo-EM structure of the PrgHK periplasmic ring from the Salmonella SPI-1 type III secretion needle complex solved at 3.3 angstrom resolution
8G5L	;	3.0	;	Cryo-EM structure of the Primer Separation Complex (IX) of Human Mitochondrial DNA Polymerase Gamma
8K9T	;	2.66	;	Cryo-EM structure of the products-bound PGAP1(Bst1)-S327A from Chaetonium thermophilum
8JKZ	;	3.6	;	Cryo-EM structure of the prokaryotic SPARSA system complex
8JL0	;	3.1	;	Cryo-EM structure of the prokaryotic SPARSA system complex
5O2R	;	3.4	;	Cryo-EM structure of the proline-rich antimicrobial peptide Api137 bound to the terminating ribosome
8ANA	;	2.1	;	Cryo-EM structure of the proline-rich antimicrobial peptide drosocin bound to the 50S ribosomal subunit
8AM9	;	2.8	;	Cryo-EM structure of the proline-rich antimicrobial peptide drosocin bound to the elongating ribosome
8AKN	;	2.3	;	Cryo-EM structure of the proline-rich antimicrobial peptide drosocin bound to the terminating ribosome
7D7M	;	3.3	;	Cryo-EM Structure of the Prostaglandin E Receptor EP4 Coupled to G Protein
8GCM	;	3.5	;	Cryo-EM Structure of the Prostaglandin E Receptor EP4 Coupled to G Protein
8GDC	;	3.5	;	Cryo-EM Structure of the Prostaglandin E2 Receptor 3 Coupled to G Protein
8GCP	;	3.1	;	Cryo-EM Structure of the Prostaglandin E2 Receptor 4 Coupled to G Protein
8GD9	;	3.2	;	Cryo-EM Structure of the Prostaglandin E2 Receptor 4 Coupled to G Protein
8GDA	;	3.3	;	Cryo-EM Structure of the Prostaglandin E2 Receptor 4 Coupled to G Protein
8GDB	;	3.1	;	Cryo-EM Structure of the Prostaglandin E2 Receptor 4 Coupled to G Protein
7BC7	;	3.3	;	Cryo-EM structure of the proton coupled folate transporter at pH 6.0 bound to pemetrexed
7P34	;	3.59	;	Cryo-EM structure of the proton-dependent antibacterial peptide transporter SbmA-FabS11-1 in nanodiscs
8BCP	;	3.88	;	Cryo-EM structure of the proximal end of bacteriophage T5 tail : p142 tail terminator protein hexamer and pb6 tail tube protein trimer
8BCU	;	4.05	;	Cryo-EM structure of the proximal end of bacteriophage T5 tail, after interaction with its receptor : p142 tail terminator protein hexamer and pb6 tail tube protein trimer
8DSP	;	3.3	;	Cryo-EM structure of the proximal half fiber in del7.3K2R1 mature phage
7YCA	;	2.94	;	Cryo-EM structure of the PSI-LHCI-Lhcp supercomplex from Ostreococcus tauri
5MDX	;	5.3	;	Cryo-EM structure of the PSII supercomplex from Arabidopsis thaliana
7XXI	;	3.0	;	Cryo-EM structure of the purinergic receptor P2Y12R in complex with 2MeSADP and Gi
7XXH	;	2.9	;	Cryo-EM structure of the purinergic receptor P2Y1R in complex with 2MeSADP and G11
6MB2	;	5.0	;	Cryo-EM structure of the PYD filament of AIM2
7XTQ	;	3.2	;	Cryo-EM structure of the R399-bound GPBAR-Gs complex
3JBR	;	4.2	;	Cryo-EM structure of the rabbit voltage-gated calcium channel Cav1.1 complex at 4.2 angstrom
8BW9	;	3.32	;	Cryo-EM structure of the RAF activating complex KSR-MEK-CNK-HYP
8U1L	;	3.7	;	Cryo-EM structure of the RAF1-HSP90-CDC37 complex in the closed state
7UX2	;	2.9	;	cryo-EM structure of the Raptor-TFEB-Rag-Ragulator complex
8RQ3	;	3.21	;	Cryo-em structure of the rat Multidrug resistance-associated protein 2 (rMrp2) in an autoinhibited state (nucleotide-free)
8RQ4	;	3.45	;	Cryo-em structure of the rat Multidrug resistance-associated protein 2 (rMrp2) in complex with probenecid
8UU9	;	3.1	;	Cryo-EM structure of the ratcheted Listeria innocua 70S ribosome (head-swiveled) in complex with HflXr and pe/E-tRNA (structure II-D)
8UU6	;	3.3	;	Cryo-EM structure of the ratcheted Listeria innocua 70S ribosome in complex with p/E-tRNA (structure II-A)
2WVW	;	9.0	;	Cryo-EM structure of the RbcL-RbcX complex
8T25	;	3.62	;	Cryo-EM structure of the RBD-ACE2 interface of the SARS-CoV-2 trimeric spike protein bound to ACE2 receptor after local refinement at downRBD conformation.
8T23	;	3.87	;	Cryo-EM structure of the RBD-ACE2 interface of the SARS-CoV-2 trimeric spike protein bound to ACE2 receptor after local refinement at upRBD conformation
7O0W	;	2.47	;	Cryo-EM structure of the RC-dLH complex (model_1b) from Gemmatimonas phototrophica at 2.47 A
5YQ7	;	4.1	;	Cryo-EM structure of the RC-LH core complex from Roseiflexus castenholzii
8IUG	;	2.86	;	Cryo-EM structure of the RC-LH core complex from roseiflexus castenholzii
8AMF	;	3.8	;	Cryo-EM structure of the RecA postsynaptic filament from S. pneumoniae
8AMD	;	3.9	;	Cryo-EM structure of the RecA presynaptic filament from S.pneumoniae
6SJE	;	4.1	;	Cryo-EM structure of the RecBCD Chi partially-recognised complex
6SJB	;	3.7	;	Cryo-EM structure of the RecBCD Chi recognised complex
6SJF	;	3.9	;	Cryo-EM structure of the RecBCD Chi unrecognised complex
6T2U	;	3.6	;	Cryo-EM structure of the RecBCD in complex with Chi-minus2 substrate
6T2V	;	3.8	;	Cryo-EM structure of the RecBCD in complex with Chi-plus2 substrate
6SJG	;	3.8	;	Cryo-EM structure of the RecBCD no Chi negative control complex
6AEI	;	2.89	;	Cryo-EM structure of the receptor-activated TRPC5 ion channel
5ZGB	;	3.63	;	Cryo-EM structure of the red algal PSI-LHCR
5ZGH	;	3.82	;	Cryo-EM structure of the red algal PSI-LHCR
6ZHY	;	3.0	;	Cryo-EM structure of the regulatory linker of ALC1 bound to the nucleosome's acidic patch: hexasome class.
6ZHX	;	2.5	;	Cryo-EM structure of the regulatory linker of ALC1 bound to the nucleosome's acidic patch: nucleosome class.
7TMW	;	3.2	;	Cryo-EM structure of the relaxin receptor RXFP1 in complex with heterotrimeric Gs
8CDP	;	3.4	;	Cryo-EM structure of the RESC1-RESC2 complex
6PZK	;	3.2	;	Cryo-EM Structure of the Respiratory Syncytial Virus Polymerase (L) Protein Bound by the Tetrameric Phosphoprotein (P)
8SNX	;	3.4	;	Cryo-EM structure of the respiratory syncytial virus polymerase (L:P) bound to the leader promoter
8SNY	;	3.41	;	Cryo-EM structure of the respiratory syncytial virus polymerase (L:P) bound to the trailer complementary promoter
6UEN	;	3.67	;	Cryo-EM structure of the respiratory syncytial virus RNA polymerase
7PIL	;	2.5	;	Cryo-EM structure of the Rhodobacter sphaeroides RC-LH1-PufXY monomer complex at 2.5 A
7OY8	;	2.5	;	Cryo-EM structure of the Rhodospirillum rubrum RC-LH1 complex
7QEP	;	2.7	;	Cryo-EM structure of the ribosome from Encephalitozoon cuniculi
7Z3N	;	3.2	;	Cryo-EM structure of the ribosome-associated RAC complex on the 80S ribosome - RAC-1 conformation
7Z3O	;	3.3	;	Cryo-EM structure of the ribosome-associated RAC complex on the 80S ribosome - RAC-2 conformation
7UVP	;	3.7	;	Cryo-EM structure of the ribosome-bound Bacteroides thetaiotaomicron EF-G2
8DMF	;	4.0	;	Cryo-EM structure of the ribosome-bound Bacteroides thetaiotaomicron EF-G2
6HD5	;	4.8	;	Cryo-EM structure of the ribosome-NatA complex
6HD7	;	3.4	;	Cryo-EM structure of the ribosome-NatA complex
7RB9	;	3.76	;	Cryo-EM structure of the rigor state Jordan myosin-15-F-actin complex
7R91	;	2.83	;	cryo-EM structure of the rigor state wild type myosin-15-F-actin complex
7UDT	;	3.17	;	cryo-EM structure of the rigor state wild type myosin-15-F-actin complex (symmetry expansion and re-centering)
5JCS	;	9.5	;	CRYO-EM STRUCTURE OF THE RIX1-REA1 PRE-60S PARTICLE
6TUT	;	3.25	;	Cryo-EM structure of the RNA Polymerase III-Maf1 complex
8UHB	;	3.35	;	Cryo-EM Structure of the Ro5256390-bound hTA1-Gs heterotrimer signaling complex
8W8A	;	2.8	;	Cryo-EM structure of the RO5256390-TAAR1 complex
8IHN	;	3.37	;	Cryo-EM structure of the Rpd3S core complex
7SEP	;	3.8	;	Cryo-EM Structure of the RT component of the HIV-1 Pol Polyprotein
8EZJ	;	3.3	;	Cryo-EM structure of the S. cerevisiae Arf-like protein Arl1 bound to the Arf guanine nucleotide exchange factor Gea2
7UQI	;	3.8	;	Cryo-EM structure of the S. cerevisiae chromatin remodeler Yta7 hexamer bound to ADP
7UQK	;	3.1	;	Cryo-EM structure of the S. cerevisiae chromatin remodeler Yta7 hexamer bound to ADP
7UQJ	;	3.0	;	Cryo-EM structure of the S. cerevisiae chromatin remodeler Yta7 hexamer bound to ATPgS and histone H3 tail in state II
8EZQ	;	3.7	;	Cryo-EM structure of the S. cerevisiae guanine nucleotide exchange factor Gea2
6IWW	;	3.9	;	Cryo-EM structure of the S. typhimurium oxaloacetate decarboxylase beta-gamma sub-complex
8JG9	;	3.82	;	Cryo-EM structure of the SaCas9-sgRNA-AcrIIA15-promoter DNA dimer
5OJS	;	3.7	;	Cryo-EM structure of the SAGA and NuA4 coactivator subunit Tra1
8IOW	;	3.2	;	Cryo-EM structure of the sarilumab Fab/IL-6R complex
7SXR	;	3.0	;	Cryo-EM structure of the SARS-CoV-2 D614G mutant spike protein ectodomain
7SXY	;	2.79	;	Cryo-EM structure of the SARS-CoV-2 D614G mutant spike protein ectodomain bound to human ACE2 ectodomain (focused refinement of RBD and ACE2)
7SXX	;	2.66	;	Cryo-EM structure of the SARS-CoV-2 D614G mutant spike protein ectodomain bound to human ACE2 ectodomain (global refinement)
7SXS	;	2.64	;	Cryo-EM structure of the SARS-CoV-2 D614G,L452R mutant spike protein ectodomain
7SY0	;	3.0	;	Cryo-EM structure of the SARS-CoV-2 D614G,L452R mutant spike protein ectodomain bound to human ACE2 ectodomain (focused refinement of RBD and ACE2)
7SXZ	;	2.61	;	Cryo-EM structure of the SARS-CoV-2 D614G,L452R mutant spike protein ectodomain bound to human ACE2 ectodomain (global refinement)
7SXT	;	2.31	;	Cryo-EM structure of the SARS-CoV-2 D614G,N501Y mutant spike protein ectodomain
7SY2	;	3.11	;	Cryo-EM structure of the SARS-CoV-2 D614G,N501Y mutant spike protein ectodomain bound to human ACE2 ectodomain (focused refinement of RBD and ACE2)
7SY1	;	2.83	;	Cryo-EM structure of the SARS-CoV-2 D614G,N501Y mutant spike protein ectodomain bound to human ACE2 ectodomain (global refinement)
7SXU	;	3.0	;	Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K mutant spike protein ectodomain
7SY4	;	3.35	;	Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K mutant spike protein ectodomain bound to human ACE2 ectodomain (focused refinement of RBD and ACE2)
7SY3	;	2.95	;	Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K mutant spike protein ectodomain bound to human ACE2 ectodomain (global refinement)
7SXV	;	2.79	;	Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K,K417N mutant spike protein ectodomain
7SY6	;	2.81	;	Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K,K417N mutant spike protein ectodomain bound to human ACE2 ectodomain (focused refinement of RBD and ACE2)
7SY5	;	2.59	;	Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K,K417N mutant spike protein ectodomain bound to human ACE2 ectodomain (global refinement)
7SXW	;	2.85	;	Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K,K417T mutant spike protein ectodomain
7SY8	;	3.14	;	Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K,K417T mutant spike protein ectodomain bound to human ACE2 ectodomain (focused refinement of RBD and ACE2)
7SY7	;	2.81	;	Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K,K417T mutant spike protein ectodomain bound to human ACE2 ectodomain (global refinement)
7E7B	;	2.6	;	Cryo-EM structure of the SARS-CoV-2 furin site mutant S-Trimer from a subunit vaccine candidate
7RZQ	;	2.09	;	Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex
7RZU	;	2.3	;	Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex with A942S mutation
7RZR	;	2.27	;	Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex with D936Y mutation
8CZI	;	2.22	;	Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex with extended HR2
7RZS	;	2.52	;	Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex with L938F mutation
8FA1	;	2.51	;	Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex with N969K mutation
7RZT	;	2.35	;	Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex with S940F mutation
7RZV	;	2.11	;	Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex with V1176F mutation
7MJG	;	2.81	;	Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain
7MJJ	;	3.32	;	Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 (class 1)
7MJK	;	2.73	;	Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 (class 2)
7MJL	;	2.95	;	Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 (focused refinement of RBD and Fab ab1)
7MJM	;	2.83	;	Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to human ACE2 ectodomain
7MJN	;	3.29	;	Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to human ACE2 ectodomain (focused refinement of RBD and ACE2)
7MJH	;	2.66	;	Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to VH ab8
7MJI	;	2.81	;	Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to VH ab8 (focused refinement of RBD and VH ab8)
8FA2	;	2.82	;	Cryo-EM structure of the SARS-CoV-2 Omicron HR1-42G complex
7T9J	;	2.79	;	Cryo-EM structure of the SARS-CoV-2 Omicron spike protein
7F46	;	4.79	;	Cryo-EM structure of the SARS-CoV-2 S-6P in complex with 35B5 Fab (state1, local refinement of the RBD, NTD and 35B5 Fab)
7E9N	;	3.69	;	Cryo-EM structure of the SARS-CoV-2 S-6P in complex with 35B5 Fab(1 down RBD, state1)
7E9Q	;	3.65	;	Cryo-EM structure of the SARS-CoV-2 S-6P in complex with 35B5 Fab(1 out RBD, state3)
7E9O	;	3.41	;	Cryo-EM structure of the SARS-CoV-2 S-6P in complex with 35B5 Fab(3 up RBDs, state2)
7E9P	;	3.69	;	Cryo-EM structure of the SARS-CoV-2 S-6P in complex with 35B5 Fab(state2, local refinement of the RBD and 35B5 Fab)
7CHH	;	3.49	;	Cryo-EM structure of the SARS-CoV-2 S-6P in complex with BD-368-2 Fabs
7ENF	;	2.76	;	Cryo-EM structure of the SARS-CoV-2 S-6P in complex with Fab30
7ENG	;	3.59	;	Cryo-EM structure of the SARS-CoV-2 S-6P in complex with Fab30 (local refinement of the RBD and Fab30)
7L57	;	5.87	;	Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-15
6XEY	;	3.25	;	Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-4
7L56	;	3.6	;	Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-43
7LSS	;	3.72	;	Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-7
7L58	;	5.07	;	Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab H4
7Y42	;	3.45	;	Cryo-EM structure of the SARS-CoV-2 spike glycoprotein in complex with all-trans retinoic acid
7VQ0	;	3.03	;	Cryo-EM structure of the SARS-CoV-2 spike protein (2-up RBD) bound to neutralizing nanobodies P86
6ZXN	;	2.93	;	Cryo-EM structure of the SARS-CoV-2 spike protein bound to neutralizing nanobodies (Ty1)
7A25	;	3.06	;	Cryo-EM structure of the SARS-CoV-2 spike protein bound to neutralizing sybodies (Sb23)
7A29	;	2.94	;	Cryo-EM structure of the SARS-CoV-2 spike protein bound to neutralizing sybodies (Sb23) 2-up conformation
7E7D	;	3.2	;	Cryo-EM structure of the SARS-CoV-2 wild-type S-Trimer from a subunit vaccine candidate
8ADL	;	2.95	;	Cryo-EM structure of the SEA complex
8AE6	;	2.7	;	Cryo-EM structure of the SEA complex wing (SEACIT)
7SQJ	;	6.3	;	Cryo-EM structure of the seam subunits of the enteropathogenic E. coli O127:H6 flagellar filament
7KAP	;	4.1	;	Cryo-EM structure of the Sec complex from S. cerevisiae, Sec61 pore mutant, class with Sec62, conformation 1 (C1)
7KAQ	;	4.0	;	Cryo-EM structure of the Sec complex from S. cerevisiae, Sec61 pore mutant, class with Sec62, conformation 2 (C2)
7KAO	;	4.0	;	Cryo-EM structure of the Sec complex from S. cerevisiae, Sec61 pore mutant, class without Sec62
7KAU	;	4.0	;	Cryo-EM structure of the Sec complex from S. cerevisiae, Sec61 pore ring and Sec63 FN3 double mutant, class with Sec62
7KAT	;	4.4	;	Cryo-EM structure of the Sec complex from S. cerevisiae, Sec61 pore ring and Sec63 FN3 double mutant, class without Sec62
7KAS	;	3.9	;	Cryo-EM structure of the Sec complex from S. cerevisiae, Sec63 FN3 mutant, class with Sec62
7KAR	;	4.0	;	Cryo-EM structure of the Sec complex from S. cerevisiae, Sec63 FN3 mutant, class without Sec62
7KAI	;	3.2	;	Cryo-EM structure of the Sec complex from S. cerevisiae, wild-type, class with Sec62, conformation 1 (C1)
7KAJ	;	3.1	;	Cryo-EM structure of the Sec complex from S. cerevisiae, wild-type, class with Sec62, conformation 2 (C2)
7KAH	;	3.1	;	Cryo-EM structure of the Sec complex from S. cerevisiae, wild-type, class without Sec62
7KAN	;	3.7	;	Cryo-EM structure of the Sec complex from T. lanuginosus, Sec62-lacking mutant (Delta Sec62)
7KAM	;	3.8	;	Cryo-EM structure of the Sec complex from T. lanuginosus, wild-type, class with Sec62, plug-closed conformation
7KAL	;	4.0	;	Cryo-EM structure of the Sec complex from T. lanuginosus, wild-type, class with Sec62, plug-open conformation
7KAK	;	3.9	;	Cryo-EM structure of the Sec complex from T. lanuginosus, wild-type, class without Sec62
7KB5	;	3.8	;	Cryo-EM structure of the Sec complex from yeast, Sec63 FN3 and residues 210-216 mutated
7M0R	;	3.7	;	Cryo-EM structure of the Sema3A/PlexinA4/Neuropilin 1 complex
8WC3	;	3.0	;	Cryo-EM structure of the SEP363856-bound mTAAR1-Gs complex
8W88	;	2.6	;	Cryo-EM structure of the SEP363856-bound TAAR1-Gs complex
7YS6	;	3.0	;	Cryo-EM structure of the Serotonin 6 (5-HT6) receptor-DNGs-scFv16 complex
7SD0	;	2.95	;	Cryo-EM structure of the SHOC2:PP1C:MRAS complex
7AFT	;	4.4	;	Cryo-EM structure of the signal sequence-engaged post-translational Sec translocon
8I03	;	3.2	;	Cryo-EM structure of the SIN3L complex from S. pombe
8I02	;	2.9	;	Cryo-EM structure of the SIN3S complex from S. pombe
8J6S	;	3.8	;	Cryo-EM structure of the single CAF-1 bound right-handed Di-tetrasome
7SN9	;	3.5	;	Cryo-EM structure of the Sinorhizobium meliloti flagellar filament
5A6E	;	4.5	;	Cryo-EM structure of the Slo2.2 Na-activated K channel
5A6F	;	4.2	;	Cryo-EM structure of the Slo2.2 Na-activated K channel
5A6G	;	5.2	;	Cryo-EM structure of the Slo2.2 Na-activated K channel
6AZ1	;	2.7	;	Cryo-EM structure of the small subunit of Leishmania ribosome bound to paromomycin
3JD5	;	7.0	;	Cryo-EM structure of the small subunit of the mammalian mitochondrial ribosome
6XIW	;	2.8	;	Cryo-EM structure of the sodium leak channel NALCN-FAM155A complex
7RTM	;	3.4	;	Cryo-EM Structure of the Sodium-driven Chloride/Bicarbonate Exchanger NDCBE (SLC4A8)
8IW4	;	3.49	;	Cryo-EM structure of the SPE-bound mTAAR9-Gs complex
8IWE	;	3.4	;	Cryo-EM structure of the SPE-mTAAR9 complex
7XJL	;	3.5	;	Cryo-EM structure of the spexin-bound GALR2-miniGq complex
7TB4	;	3.29	;	Cryo-EM structure of the spike of SARS-CoV-2 Omicron variant of concern
5MLC	;	3.6	;	Cryo-EM structure of the spinach chloroplast ribosome reveals the location of plastid-specific ribosomal proteins and extensions
3JCM	;	3.8	;	Cryo-EM structure of the spliceosomal U4/U6.U5 tri-snRNP
7WIC	;	2.8	;	Cryo-EM structure of the SS-14-bound human SSTR2-Gi1 complex
7Y27	;	3.48	;	Cryo-EM structure of the SST-14-bound SSTR2-miniGq-scFv16 complex
8FGX	;	2.62	;	Cryo-EM structure of the STAR-0215 Fab in complex with active human plasma kallikrein
8AA5	;	2.46	;	Cryo-EM structure of the strand transfer complex of the TnsB transposase (type V-K CRISPR-associated transposon)
7CQI	;	3.2	;	Cryo-EM structure of the substrate-bound SPT-ORMDL3 complex
7CQK	;	3.3	;	Cryo-EM structure of the substrate-bound SPT-ORMDL3 complex
7OK0	;	2.9	;	Cryo-EM structure of the Sulfolobus acidocaldarius RNA polymerase at 2.88 A
8CXM	;	3.21	;	Cryo-EM structure of the supercoiled E. coli K12 flagellar filament core, Normal waveform
8CVI	;	3.4	;	Cryo-EM structure of the supercoiled EPEC H6 flagellar filament core Curly I waveform
8CWM	;	3.4	;	Cryo-EM structure of the supercoiled S. islandicus REY15A archaeal flagellar filament
7V9L	;	2.6	;	Cryo-EM structure of the SV1-Gs complex.
6O1O	;	3.8	;	Cryo-EM structure of the T. thermophilus Csm complex bound to target ssRNA
5WLN	;	3.57	;	Cryo-EM structure of the T2SS secretin XcpQ from Pseudomonas aeruginosa
5W5F	;	3.4	;	Cryo-EM structure of the T4 tail tube
7XPG	;	3.51	;	Cryo-EM structure of the T=3 lake sinai virus 1 (delta-N48) virus-like capsid at pH 6.5
7XPD	;	3.74	;	Cryo-EM structure of the T=3 lake sinai virus 2 virus-like capsid at pH 6.5
7XPA	;	3.33	;	Cryo-EM structure of the T=3 lake sinai virus 2 virus-like capsid at pH 7.5
7XPF	;	3.13	;	Cryo-EM structure of the T=3 lake sinai virus 2 virus-like capsid at pH 8.5
7XPB	;	3.91	;	Cryo-EM structure of the T=4 lake sinai virus 2 virus-like capsid at pH 6.5
7XGZ	;	3.24	;	Cryo-EM structure of the T=4 lake sinai virus 2 virus-like capsid at pH 7.5
7XPE	;	3.32	;	Cryo-EM structure of the T=4 lake sinai virus 2 virus-like capsid at pH 8.5
8IUM	;	3.14	;	Cryo-EM structure of the tafluprost acid-bound human PTGFR-Gq complex
7CX3	;	2.8	;	Cryo-EM structure of the Taprenepag-bound EP2-Gs complex
8IN8	;	3.0	;	Cryo-EM structure of the target ssDNA-bound SIR2-APAZ/Ago-gRNA quaternary complex
7X2D	;	3.3	;	Cryo-EM structure of the tavapadon-bound D1 dopamine receptor and mini-Gs complex
8AW3	;	3.6	;	Cryo-EM structure of the Tb ADAT2/3 deaminase in complex with tRNA
5LKI	;	3.46	;	Cryo-EM structure of the Tc toxin TcdA1 in its pore state
5LKH	;	3.46	;	Cryo-EM structure of the Tc toxin TcdA1 in its pore state (obtained by flexible fitting)
8JI0	;	3.0	;	Cryo-EM structure of the TcsH-CROP in complex with TMPRSS2
8JHZ	;	3.2	;	Cryo-EM structure of the TcsH-TMPRSS2 complex
8X2H	;	2.9	;	Cryo-EM structure of the TcsL at pH 5.0 in its closed conformation
8X2I	;	2.5	;	Cryo-EM structure of the TcsL at pH 5.0 in its open conformation
7OLE	;	3.41	;	Cryo-EM structure of the TELO2-TTI1-TTI2-RUVBL1-RUVBL2 complex
7Y36	;	2.8	;	Cryo-EM structure of the Teriparatide-bound human PTH1R-Gs complex
7NDG	;	5.98	;	Cryo-EM structure of the ternary complex between Netrin-1, Neogenin and Repulsive Guidance Molecule B
7N0D	;	2.5	;	Cryo-EM structure of the tetrameric form of SARS-CoV-2 nsp10-nsp14 (E191A)-RNA complex
6K61	;	2.37	;	Cryo-EM structure of the tetrameric photosystem I from a heterocyst-forming cyanobacterium Anabaena sp. PCC7120
8GZR	;	2.8	;	Cryo-EM structure of the the NS5-NS3 RNA-elongation complex
6UT5	;	2.44	;	Cryo-EM structure of the Thermococcus gammatolerans McrBC complex
6LO8	;	3.83	;	Cryo-EM structure of the TIM22 complex from yeast
7FIM	;	3.4	;	Cryo-EM structure of the tirzepatide (LY3298176)-bound human GLP-1R-Gs complex
7FIY	;	3.4	;	Cryo-EM structure of the tirzepatide-bound human GIPR-Gs complex
8WC5	;	3.3	;	Cryo-EM structure of the TMA-bound mTAAR1-Gs complex
7X83	;	3.4	;	Cryo-EM structure of the TMEM106B fibril from normal elder
7X84	;	3.0	;	Cryo-EM structure of the TMEM106B fibril from Parkinson's disease dementia
6BGJ	;	3.8	;	Cryo-EM structure of the TMEM16A calcium-activated chloride channel in LMNG
6BGI	;	3.8	;	Cryo-EM structure of the TMEM16A calcium-activated chloride channel in nanodisc
8H1J	;	3.1	;	Cryo-EM structure of the TnpB-omegaRNA-target DNA ternary complex
8J6F	;	3.3	;	Cryo-EM structure of the Tocilizumab Fab/IL-6R complex
8H40	;	3.6	;	Cryo-EM structure of the transcription activation complex NtcA-TAC
5U0P	;	4.4	;	Cryo-EM structure of the transcriptional Mediator
6JNF	;	3.81	;	Cryo-EM structure of the translocator of the outer mitochondrial membrane
7XW9	;	2.7	;	Cryo-EM structure of the TRH-bound human TRHR-Gq complex
8THJ	;	2.99	;	Cryo-EM structure of the Tripartite ATP-independent Periplasmic (TRAP) transporter SiaQM from Haemophilus influenzae (antiparallel dimer)
8THI	;	3.36	;	Cryo-EM structure of the Tripartite ATP-independent Periplasmic (TRAP) transporter SiaQM from Haemophilus influenzae (parallel dimer)
8B01	;	3.03	;	Cryo-EM structure of the Tripartite ATP-independent Periplasmic (TRAP) transporter SiaQM from Photobacterium profundum in a nanodisc
7QHA	;	2.97	;	Cryo-EM structure of the Tripartite ATP-independent Periplasmic (TRAP) transporter SiaQM from Photobacterium profundum in amphipol
8F8T	;	3.26	;	Cryo-EM structure of the Tropomodulin-capped pointed end of F-actin
6NR3	;	3.4	;	Cryo-EM structure of the TRPM8 ion channel in complex with high occupancy icilin, PI(4,5)P2, and calcium
6NR2	;	4.0	;	Cryo-EM structure of the TRPM8 ion channel in complex with the menthol analog WS-12 and PI(4,5)P2
6NR4	;	4.3	;	Cryo-EM structure of the TRPM8 ion channel with low occupancy icilin, PI(4,5)P2, and calcium
6HIY	;	3.27	;	Cryo-EM structure of the Trypanosoma brucei mitochondrial ribosome - This entry contains the body of the small mitoribosomal subunit in complex with mt-IF-3
6HIV	;	7.8	;	Cryo-EM structure of the Trypanosoma brucei mitochondrial ribosome - This entry contains the complete mitoribosome
6HIW	;	3.37	;	Cryo-EM structure of the Trypanosoma brucei mitochondrial ribosome - This entry contains the complete small mitoribosomal subunit in complex with mt-IF-3
6HIZ	;	3.08	;	Cryo-EM structure of the Trypanosoma brucei mitochondrial ribosome - This entry contains the head of the small mitoribosomal subunit
6HIX	;	3.39	;	Cryo-EM structure of the Trypanosoma brucei mitochondrial ribosome - This entry contains the large mitoribosomal subunit
6DZY	;	4.1	;	Cryo-EM structure of the ts2-active human serotonin transporter in complex with 15B8 Fab and 8B6 ScFv bound to ibogaine
6DZW	;	4.3	;	Cryo-EM structure of the ts2-inactive human serotonin transporter in complex with paroxetine and 15B8 Fab and 8B6 ScFv
8T3O	;	3.06	;	Cryo-EM structure of the TUG-891 bound FFA4-Gq complex
8ID8	;	3.0	;	Cryo-EM structure of the TUG891 bound GPR120-Gi complex
8G59	;	2.64	;	Cryo-EM structure of the TUG891 bound GPR120-Giq complex
7Y61	;	5.6	;	Cryo-EM structure of the two CAF1LCs bound right-handed Di-tetrasome
7EIB	;	3.0	;	Cryo-EM structure of the type 1 bradykinin receptor in complex with the des-Arg10-kallidin and an Gq protein
6C53	;	4.2	;	Cryo-EM structure of the Type 1 pilus rod
7F2O	;	2.9	;	Cryo-EM structure of the type 2 bradykinin receptor in complex with the bradykinin and an Gq protein
6SIC	;	3.52	;	Cryo-EM structure of the Type III-B Cmr-beta bound to cognate target RNA
6S8B	;	2.41	;	Cryo-EM structure of the Type III-B Cmr-beta bound to cognate target RNA and AMPPnP, state 1
6SHB	;	3.07	;	Cryo-EM structure of the Type III-B Cmr-beta bound to cognate target RNA and AMPPnP, state 1, in the presence of ssDNA
6S91	;	2.68	;	Cryo-EM structure of the Type III-B Cmr-beta bound to cognate target RNA and AMPPnP, state 2
6SH8	;	3.14	;	Cryo-EM structure of the Type III-B Cmr-beta bound to cognate target RNA and AMPPnP, state 2, in the presence of ssDNA
6S8E	;	3.1	;	Cryo-EM structure of the type III-B Cmr-beta complex bound to non-cognate target RNA
8OI6	;	3.59	;	Cryo-EM structure of the undecorated barbed end of filamentous beta/gamma actin
7RAV	;	3.3	;	Cryo-EM structure of the unliganded form of NLR family apoptosis inhibitory protein 5 (NAIP5)
8V0F	;	2.81	;	Cryo-EM structure of the unliganded hexameric prenyltransferase in bifunctional copalyl diphosphate synthase from Penicillium fellutanum with an open conformation
8CXO	;	3.7	;	Cryo-EM structure of the unliganded mSMO-PGS2 in a lipidic environment
8E3Y	;	2.3	;	Cryo-EM structure of the VPAC1R-PACAP27-Gs complex
8E3Z	;	2.7	;	Cryo-EM structure of the VPAC1R-VIP-Gs complex
7MFG	;	3.87	;	Cryo-EM structure of the VRC310 clinical trial, vaccine-elicited, human antibody 310-030-1D06 Fab in complex with an H1 NC99 HA trimer
6WXL	;	2.76	;	Cryo-EM structure of the VRC315 clinical trial, vaccine-elicited, human antibody 1D12 in complex with an H7 SH13 HA trimer
7L0L	;	2.85	;	Cryo-EM structure of the VRC316 clinical trial, vaccine-elicited, human antibody 316-310-1B11 in complex with an H2 CAN05 HA trimer
8D21	;	3.96	;	Cryo-EM structure of the VRC321 clinical trial, vaccine-elicited, human antibody 1B06 in complex with a stabilized NC99 HA trimer
7X8S	;	3.09	;	Cryo-EM structure of the WB4-24-bound hGLP-1R-Gs complex
8G5K	;	2.9	;	Cryo-EM structure of the Wedge Alignment Complex (VIII) of Human Mitochondrial DNA Polymerase Gamma
7Z6Q	;	2.5	;	Cryo-EM structure of the whole photosynthetic complex from the green sulfur bacteria
8SUG	;	4.2	;	Cryo-EM structure of the wild type P. aeruginosa flagellar filament
8OQI	;	3.1	;	Cryo-EM structure of the wild-type alpha-synuclein fibril.
8TDJ	;	3.7	;	Cryo-EM structure of the wild-type AtMSL10 in GDN
8TDL	;	3.6	;	Cryo-EM structure of the wild-type AtMSL10 in saposin
6T17	;	2.8	;	Cryo-EM structure of the wild-type flagellar filament of the Firmicute Kurthia
6VRK	;	4.1	;	Cryo-EM structure of the wild-type human serotonin transporter complexed with Br-paroxetine and 8B6 Fab
6VRL	;	3.8	;	Cryo-EM structure of the wild-type human serotonin transporter complexed with I-paroxetine and 8B6 Fab
6VRH	;	3.3	;	Cryo-EM structure of the wild-type human serotonin transporter complexed with paroxetine and 8B6 Fab
7LWD	;	3.65	;	Cryo-EM structure of the wild-type human serotonin transporter complexed with vilazodone, imipramine and 15B8 Fab
6DZZ	;	3.6	;	Cryo-EM Structure of the wild-type human serotonin transporter in complex with ibogaine and 15B8 Fab in the inward conformation
8BMR	;	3.8	;	Cryo-EM structure of the wild-type solitary ECF module in MSP2N2 lipid nanodiscs in the ATPase open and nucleotide-free conformation
8XZJ	;	3.0	;	Cryo-EM structure of the WN353-bound human APLNR-Gi complex
8XZF	;	3.0	;	Cryo-EM structure of the WN561-bound human APLNR-Gi complex
7OYC	;	2.4	;	Cryo-EM structure of the Xenopus egg 80S ribosome
5ZWO	;	3.9	;	Cryo-EM structure of the yeast B complex at average resolution of 3.9 angstrom
6J6H	;	3.6	;	Cryo-EM structure of the yeast B*-a1 complex at an average resolution of 3.6 angstrom
6J6G	;	3.2	;	Cryo-EM structure of the yeast B*-a2 complex at an average resolution of 3.2 angstrom
6J6N	;	3.86	;	Cryo-EM structure of the yeast B*-b1 complex at an average resolution of 3.86 angstrom
6J6Q	;	3.7	;	Cryo-EM structure of the yeast B*-b2 complex at an average resolution of 3.7 angstrom
7MPE	;	3.2	;	Cryo-EM structure of the yeast cadmium factor 1 protein (Ycf1p)
6OUA	;	4.18	;	Cryo-EM structure of the yeast Ctf3 complex
8PRW	;	1.9	;	Cryo-EM structure of the yeast fatty acid synthase at 1.9 angstrom resolution
8OW1	;	3.7	;	Cryo-EM structure of the yeast Inner kinetochore bound to a CENP-A nucleosome.
7E4H	;	3.01	;	Cryo-EM structure of the yeast mitochondrial SAM-Tom40 complex at 3.0 angstrom
7E4I	;	3.05	;	Cryo-EM structure of the yeast mitochondrial SAM-Tom40/Tom5/Tom6 complex at 3.0 angstrom
6EZN	;	3.3	;	Cryo-EM structure of the yeast oligosaccharyltransferase (OST) complex
5ZWN	;	3.4	;	Cryo-EM structure of the yeast pre-B complex at an average resolution of 3.3 angstrom (Part II: U1 snRNP region)
5ZWM	;	3.4	;	Cryo-EM structure of the yeast pre-B complex at an average resolution of 3.4~4.6 angstrom (tri-snRNP and U2 snRNP Part)
6N3Q	;	3.68	;	Cryo-EM structure of the yeast Sec complex
3JB9	;	3.6	;	Cryo-EM structure of the yeast spliceosome at 3.6 angstrom resolution
8C82	;	3.4	;	Cryo-EM structure of the yeast SPT-Orm1-Dimer complex
8C80	;	3.4	;	Cryo-EM structure of the yeast SPT-Orm1-Monomer complex
8C81	;	3.3	;	Cryo-EM structure of the yeast SPT-Orm1-Sac1 complex
8IAJ	;	3.1	;	Cryo-EM structure of the yeast SPT-ORM2 (ORM2-S3A) complex
8IAK	;	3.1	;	Cryo-EM structure of the yeast SPT-ORM2 (ORM2-S3A-N71A) complex
8IAM	;	3.1	;	Cryo-EM structure of the yeast SPT-ORM2 (ORM2-S3D) complex
7C4J	;	2.89	;	Cryo-EM structure of the yeast Swi/Snf complex in a nucleosome free state
7LUV	;	3.7	;	Cryo-EM structure of the yeast THO-Sub2 complex
8W5J	;	4.4	;	Cryo-EM structure of the yeast TOM core complex (from TOM-TIM23 complex)
8W5K	;	3.6	;	Cryo-EM structure of the yeast TOM core complex crosslinked by BS3 (from TOM-TIM23 complex)
8I2Z	;	2.3	;	Cryo-EM structure of the zeaxanthin-bound kin4B8
8JV5	;	3.23	;	Cryo-EM structure of the zebrafish P2X4 receptor in complex with BX430
6PKW	;	4.5	;	Cryo-EM structure of the zebrafish TRPM2 channel in the apo conformation, processed with C2 symmetry (pseudo C4 symmetry)
6PKV	;	4.3	;	Cryo-EM structure of the zebrafish TRPM2 channel in the apo conformation, processed with C4 symmetry
6PKX	;	4.2	;	Cryo-EM structure of the zebrafish TRPM2 channel in the presence of ADPR and Ca2+
6D73	;	3.8	;	Cryo-EM structure of the zebrafish TRPM2 channel in the presence of Ca2+
8DE7	;	3.27	;	Cryo-EM structure of the zebrafish two pore domain K+ channel TREK1 (K2P2.1) in DDM detergent
8DE8	;	2.82	;	Cryo-EM structure of the zebrafish two pore domain K+ channel TREK1 (K2P2.1) in DDM/POPA mixed micelles
8DE9	;	3.4	;	Cryo-EM structure of the zebrafish two pore domain K+ channel TREK1 (K2P2.1) in DDM/POPE mixed micelles
8WC8	;	2.9	;	Cryo-EM structure of the ZH8651-bound hTAAR1-Gs complex
8WC9	;	3.2	;	Cryo-EM structure of the ZH8651-bound mTAAR1-Gq complex
8WC4	;	3.1	;	Cryo-EM structure of the ZH8651-bound mTAAR1-Gs complex
8WC7	;	3.1	;	Cryo-EM structure of the ZH8667-bound mTAAR1-Gs complex
6MID	;	4.0	;	Cryo-EM structure of the ZIKV virion in complex with Fab fragments of the potently neutralizing human monoclonal antibody ZIKV-195
8XZG	;	3.2	;	Cryo-EM structure of the [Pyr1]-apelin-13-bound human APLNR-Gi complex
8J6I	;	2.92	;	Cryo-EM structure of thehydroxycarboxylic acid receptor 2-Gi protein complex bound MK-6892
8J6L	;	3.05	;	Cryo-EM structure of thehydroxycarboxylic acid receptor 2-Gi protein complex bound niacin
8J6J	;	2.8	;	Cryo-EM structure of thehydroxycarboxylic acid receptor 2-Gi protein complex bound with GSK256073
5IZ7	;	3.7	;	Cryo-EM structure of thermally stable Zika virus strain H/PF/2013
6PW4	;	3.53	;	Cryo-EM Structure of Thermo-Sensitive TRP Channel TRP1 from the Alga Chlamydomonas reinhardtii in Detergent
6PW5	;	3.45	;	Cryo-EM Structure of Thermo-Sensitive TRP Channel TRP1 from the Alga Chlamydomonas reinhardtii in Nanodiscs
6KF3	;	3.9	;	Cryo-EM structure of Thermococcus kodakarensis RNA polymerase
6KF4	;	3.97	;	Cryo-EM structure of Thermococcus kodakarensis RNA polymerase
6KF9	;	3.79	;	Cryo-EM structure of Thermococcus kodakarensis RNA polymerase
6M6A	;	5.0	;	Cryo-EM structure of Thermus thermophilus Mfd in complex with RNA polymerase
6M6B	;	4.1	;	Cryo-EM structure of Thermus thermophilus Mfd in complex with RNA polymerase and ATP-gamma-S
7RDQ	;	3.0	;	Cryo-EM structure of Thermus thermophilus reiterative transcription complex with 11nt oligo-G RNA
8A1R	;	3.6	;	cryo-EM structure of thioredoxin glutathione reductase in complex with a non-competitive inhibitor
7F58	;	3.1	;	Cryo-EM structure of THIQ-MC4R-Gs_Nb35 complex
8I88	;	3.7	;	Cryo-EM structure of TIR-APAZ/Ago-gRNA complex
8I87	;	3.1	;	Cryo-EM structure of TIR-APAZ/Ago-gRNA-DNA complex
6LW1	;	2.8	;	Cryo-EM structure of TLR7/Cpd-7 (DSR-139970) complex in open form
7SAQ	;	2.9	;	Cryo-EM structure of TMEM106B fibrils extracted from a FTLD-TDP patient, polymorph 1
7SAR	;	3.2	;	Cryo-EM structure of TMEM106B fibrils extracted from a FTLD-TDP patient, polymorph 2
7SAS	;	3.7	;	Cryo-EM structure of TMEM106B fibrils extracted from a FTLD-TDP patient, polymorph 3
6P46	;	3.5	;	Cryo-EM structure of TMEM16F in digitonin with calcium bound
6P47	;	3.9	;	Cryo-EM structure of TMEM16F in digitonin without calcium
8EHW	;	3.8	;	cryo-EM structure of TMEM63A in nanodisc
8EHX	;	3.6	;	cryo-EM structure of TMEM63B in LMNG
8XW4	;	3.84	;	Cryo-EM structure of TMEM63B-Digitonin state
8K0B	;	3.56	;	Cryo-EM structure of TMEM63C
8CTJ	;	4.74	;	Cryo-EM structure of TMEM87A
4UDV	;	3.35	;	Cryo-EM structure of TMV at 3.35 A resolution
6SAE	;	1.9	;	Cryo-EM structure of TMV in water
6SAG	;	2.0	;	Cryo-EM structure of TMV with Ca2+ at low pH
7QD8	;	3.6	;	Cryo-EM structure of Tn4430 TnpA transposase from Tn3 family in apo state
7QD4	;	2.9	;	Cryo-EM structure of Tn4430 TnpA transposase from Tn3 family in complex with 100 bp long transposon end DNA
7QD5	;	3.1	;	Cryo-EM structure of Tn4430 TnpA transposase from Tn3 family in complex with 48 bp long transposon end DNA
7QD6	;	3.0	;	Cryo-EM structure of Tn4430 TnpA transposase from Tn3 family in complex with strand-transfer like DNA product
8FCX	;	3.04	;	Cryo-EM structure of TnsC oligomer in type I-B CAST system
8FCW	;	2.87	;	Cryo-EM structure of TnsC-DNA complex in type I-B CAST system
8FCV	;	2.95	;	Cryo-EM structure of TnsC-TniQ-DNA complex in type I-B CAST system
7XZJ	;	2.97	;	Cryo-EM structure of TOC complex from Chlamydomonas reinhardtii.
7XZI	;	2.77	;	Cryo-EM structure of TOC-TIC supercomplex from Chlamydomonas reinhardtii
7SMM	;	2.5	;	Cryo-EM structure of Torpedo acetylcholine receptor in apo form
7SMQ	;	2.74	;	Cryo-EM structure of Torpedo acetylcholine receptor in apo form with added cholesterol
6UWZ	;	2.69	;	Cryo-EM structure of Torpedo acetylcholine receptor in complex with alpha-bungarotoxin
7SMR	;	2.77	;	Cryo-EM structure of Torpedo acetylcholine receptor in complex with carbachol, desensitized state
7SMS	;	3.18	;	Cryo-EM structure of Torpedo acetylcholine receptor in complex with d-tubocurarine
7SMT	;	2.56	;	Cryo-EM structure of Torpedo acetylcholine receptor in complex with d-tubocurarine and carbachol
7Z14	;	3.15	;	Cryo-EM structure of Torpedo nicotinic acetylcholine receptor in complex with a short-chain neurotoxin.
8F6Y	;	2.79	;	Cryo-EM structure of Torpedo nicotinic acetylcholine receptor in complex with etomidate, desensitized-like state
8F2S	;	2.9	;	Cryo-EM structure of Torpedo nicotinic acetylcholine receptor in complex with rocuronium, pore-blocked state
8ESK	;	2.9	;	Cryo-EM structure of Torpedo nicotinic acetylcholine receptor in complex with rocuronium, resting-like state
8F6Z	;	2.7	;	Cryo-EM structure of Torpedo nicotinic acetylcholine receptor in complex with succinylcholine, desensitized-like state
6TMK	;	2.9	;	Cryo-EM structure of Toxoplasma gondii mitochondrial ATP synthase dimer, composite model
6TMG	;	2.8	;	Cryo-EM structure of Toxoplasma gondii mitochondrial ATP synthase dimer, membrane region model
6TMH	;	3.1	;	Cryo-EM structure of Toxoplasma gondii mitochondrial ATP synthase dimer, OSCP/F1/c-ring model
6TMI	;	3.5	;	Cryo-EM structure of Toxoplasma gondii mitochondrial ATP synthase dimer, peripheral stalk model
6TMJ	;	3.5	;	Cryo-EM structure of Toxoplasma gondii mitochondrial ATP synthase dimer, rotor-stator model
6TML	;	4.8	;	Cryo-EM structure of Toxoplasma gondii mitochondrial ATP synthase hexamer, composite model
6T9I	;	3.9	;	cryo-EM structure of transcription coactivator SAGA
7TDO	;	3.15	;	Cryo-EM structure of transmembrane AAA+ protease FtsH in the ADP state
6Y9B	;	2.97	;	Cryo-EM structure of trimeric human STEAP1 bound to three Fab120.545 fragments
6ZQJ	;	4.2	;	Cryo-EM structure of trimeric prME spike of Spondweni virus
6F0X	;	4.6	;	Cryo-EM structure of TRIP13 in complex with ATP gamma S, p31comet, C-Mad2 and Cdc20
7KNI	;	3.91	;	Cryo-EM structure of Triple ACE2-bound SARS-CoV-2 Trimer Spike at pH 5.5
7KMS	;	3.64	;	Cryo-EM structure of triple ACE2-bound SARS-CoV-2 trimer spike at pH 7.4
8ED7	;	3.7	;	cryo-EM structure of TRPM3 ion channel in apo state
8DDX	;	3.8	;	cryo-EM structure of TRPM3 ion channel in complex with Gbg in the presence of PIP2, tethered by ALFA-nanobody
8DDW	;	4.7	;	cryo-EM structure of TRPM3 ion channel in complex with Gbg, tethered by ALFA-nanobody
8DDR	;	3.2	;	cryo-EM structure of TRPM3 ion channel in the absence of PIP2
8ED8	;	3.2	;	cryo-EM structure of TRPM3 ion channel in the presence of PIP2 and PregS, state 1
8DDS	;	3.5	;	cryo-EM structure of TRPM3 ion channel in the presence of PIP2, state1
8DDT	;	3.1	;	cryo-EM structure of TRPM3 ion channel in the presence of PIP2, state2
8DDU	;	3.0	;	cryo-EM structure of TRPM3 ion channel in the presence of PIP2, state3
8DDV	;	3.2	;	Cryo-EM structure of TRPM3 ion channel in the presence of PIP2, state4
8DDQ	;	2.7	;	cryo-EM structure of TRPM3 ion channel in the presence of soluble Gbg, focused on channel
8ED9	;	3.4	;	cryo-EM structure of TRPM3 ion channel in the presence with PIP2 and PregS, state 2
6BCL	;	3.54	;	cryo-EM structure of TRPM4 in apo state with long coiled coil at 3.5 angstrom resolution
6BCJ	;	3.14	;	cryo-EM structure of TRPM4 in apo state with short coiled coil at 3.1 angstrom resolution
6BCQ	;	3.25	;	cryo-EM structure of TRPM4 in ATP bound state with long coiled coil at 3.3 angstrom resolution
6BCO	;	2.88	;	cryo-EM structure of TRPM4 in ATP bound state with short coiled coil at 2.9 angstrom resolution
8SI3	;	2.61	;	Cryo-EM structure of TRPM7 in GDN detergent in apo state
8SI7	;	2.59	;	Cryo-EM structure of TRPM7 in GDN detergent in complex with inhibitor VER155008 in closed state
8SI2	;	2.19	;	Cryo-EM structure of TRPM7 in MSP2N2 nanodisc in apo state
8SI6	;	2.44	;	Cryo-EM structure of TRPM7 in MSP2N2 nanodisc in complex with agonist naltriben in closed state
8SI5	;	2.17	;	Cryo-EM structure of TRPM7 in MSP2N2 nanodisc in complex with agonist naltriben in open state
8SIB	;	2.62	;	Cryo-EM structure of TRPM7 MHR1-3 domain
8SIA	;	2.91	;	Cryo-EM structure of TRPM7 N1098Q mutant in GDN detergent in complex with inhibitor NS8593 in closed state
8SI8	;	2.99	;	Cryo-EM structure of TRPM7 N1098Q mutant in GDN detergent in complex with inhibitor VER155008 in closed state
8SI4	;	2.46	;	Cryo-EM structure of TRPM7 N1098Q mutant in GDN detergent in open state
7UGG	;	3.16	;	Cryo-EM structure of TRPV3 in complex with the anesthetic dyclonine
6LGP	;	3.3	;	cryo-EM structure of TRPV3 in lipid nanodisc
6O1N	;	2.9	;	Cryo-EM structure of TRPV5 (1-660) in nanodisc
7T6L	;	3.7	;	Cryo-EM structure of TRPV5 at pH5 in nanodiscs
7T6K	;	3.0	;	Cryo-EM structure of TRPV5 at pH6 in nanodiscs
7T6J	;	3.2	;	Cryo-EM structure of TRPV5 at pH8 in nanodiscs
7T6N	;	2.9	;	Cryo-EM structure of TRPV5 in nanodiscs at pH6 state 2
7T6O	;	2.6	;	Cryo-EM structure of TRPV5 in nanodiscs at pH6 state 3
7T6M	;	2.8	;	Cryo-EM structure of TRPV5 in nanodiscs with PI(4,5)P2 at pH6 state 1
7T6P	;	2.8	;	Cryo-EM structure of TRPV5 T709D in nanodiscs
7T6R	;	3.0	;	Cryo-EM structure of TRPV5 T709D in nanodiscs in the presence of Calmodulin
7T6Q	;	3.4	;	Cryo-EM structure of TRPV5 T709D with PI(4,5)P2 in nanodiscs
6O1U	;	2.8	;	Cryo-EM structure of TRPV5 W583A in nanodisc
6O20	;	3.3	;	Cryo-EM structure of TRPV5 with calmodulin bound
8OVA	;	2.47	;	CRYO-EM STRUCTURE OF TRYPANOSOMA BRUCEI PROCYCLIC FORM 80S RIBOSOME : PARENTAL STRAIN
8OVE	;	2.6	;	CRYO-EM STRUCTURE OF TRYPANOSOMA BRUCEI PROCYCLIC FORM 80S RIBOSOME : TB11CS6H1 snoRNA mutant
5N5N	;	4.2	;	Cryo-EM structure of tsA201 cell alpha1B and betaI and betaIVb microtubules
8WD8	;	2.9	;	Cryo-EM structure of TtdAgo-guide DNA-target DNA complex
8VGR	;	3.2	;	Cryo-EM structure of Tulane virus 9-6-17 variant capsid protein VP1 5-12-18
8VJS	;	2.73	;	Cryo-EM structure of Tulane virus 9-6-17 variant capsid protein VP1 9-14-18 without DTT treatment
8VJR	;	2.63	;	Cryo-EM structure of Tulane virus 9-6-17 variant capsid protein VP1 9-14-18, DTT-treated
6F1T	;	3.5	;	Cryo-EM structure of two dynein tail domains bound to dynactin and BICDR1
6F38	;	6.7	;	Cryo-EM structure of two dynein tail domains bound to dynactin and HOOK3
8EYR	;	4.0	;	Cryo-EM structure of two IGF1 bound full-length mouse IGF1R mutant (four glycine residues inserted in the alpha-CT; IGF1R-P674G4): symmetric conformation
7Q5B	;	3.98	;	Cryo-EM structure of Ty3 retrotransposon targeting a TFIIIB-bound tRNA gene
6UQK	;	3.77	;	Cryo-EM structure of type 3 IP3 receptor revealing presence of a self-binding peptide
8IP0	;	3.6	;	Cryo-EM structure of type I-B Cascade bound to a PAM-containing dsDNA target at 3.6 angstrom resolution
6B45	;	3.5	;	Cryo-EM structure of Type I-F CRISPR crRNA-guided Csy surveillance complex
6B46	;	3.1	;	Cryo-EM structure of Type I-F CRISPR crRNA-guided Csy surveillance complex with bound anti-CRISPR protein AcrF1
6B48	;	3.6	;	Cryo-EM structure of Type I-F CRISPR crRNA-guided Csy surveillance complex with bound anti-CRISPR protein AcrF10
6B47	;	3.2	;	Cryo-EM structure of Type I-F CRISPR crRNA-guided Csy surveillance complex with bound anti-CRISPR protein AcrF2
6B44	;	2.9	;	Cryo-EM structure of Type I-F CRISPR crRNA-guided Csy surveillance complex with bound target dsDNA
6IFK	;	3.2	;	Cryo-EM structure of type III-A Csm-CTR1 complex, AMPPNP bound
6IFU	;	3.05	;	Cryo-EM structure of type III-A Csm-CTR2-dsDNA complex
6IFL	;	3.16	;	Cryo-EM structure of type III-A Csm-NTR complex
6TJO	;	3.2	;	Cryo-EM structure of TypeI tau filaments extracted from the brains of individuals with Corticobasal degeneration
6TJX	;	3.0	;	Cryo-EM structure of TypeII tau filaments extracted from the brains of individuals with Corticobasal degeneration
8I4C	;	3.08	;	Cryo-EM structure of U46619-bound ABCC4
7VGG	;	3.1	;	Cryo-EM structure of Ultraviolet-B activated UVR8 in complex with COP1
6YTX	;	6.23	;	Cryo-EM structure of undecameric human CALHM6 in the presence of Ca2+
7OJG	;	3.4	;	CRYO-EM STRUCTURE OF UNDECAMERIC SLYB FROM ESCHERICHIA COLI K12
7L2H	;	2.63	;	Cryo-EM structure of unliganded full-length TRPV1 at neutral pH
7L2P	;	2.6	;	cryo-EM structure of unliganded minimal TRPV1
7NTF	;	5.32	;	Cryo-EM structure of unliganded O-GlcNAc transferase
7JTH	;	4.0	;	Cryo-EM structure of unliganded octameric prenyltransferase domain of Phomopsis amygdali fusicoccadiene synthase
7XD1	;	3.2	;	cryo-EM structure of unmodified nucleosome
8IWX	;	2.59	;	Cryo-EM structure of unprotonated LHCII in detergent solution at high pH value
8IWZ	;	2.52	;	Cryo-EM structure of unprotonated LHCII in detergent solution at low pH value
8IX0	;	2.64	;	Cryo-EM structure of unprotonated LHCII nanodisc at high pH value
8IX2	;	2.8	;	Cryo-EM structure of unprotonated LHCII nanodisc at low pH value
6PB0	;	3.0	;	Cryo-EM structure of Urocortin 1-bound Corticotropin-releasing factor 1 receptor in complex with Gs protein and Nb35
6PB1	;	2.8	;	Cryo-EM structure of Urocortin 1-bound Corticotropin-releasing factor 2 receptor in complex with Gs protein and Nb35
8A9K	;	2.85	;	Cryo-EM structure of USP1-UAF1 bound to FANCI and mono-ubiquitinated FANCD2 with ML323 (consensus reconstruction)
8A9J	;	2.8	;	Cryo-EM structure of USP1-UAF1 bound to FANCI and mono-ubiquitinated FANCD2 without ML323 (consensus reconstruction)
7AY1	;	3.7	;	Cryo-EM structure of USP1-UAF1 bound to mono-ubiquitinated FANCD2, and FANCI
8WG5	;	3.05	;	Cryo-EM structure of USP16 bound to H2AK119Ub nucleosome
7YXX	;	3.3	;	Cryo-EM structure of USP9X
7YXY	;	3.1	;	Cryo-EM structure of USP9X, local refinement of monomer
6XBW	;	3.37	;	Cryo-EM structure of V-ATPase from bovine brain, state 1
6XBY	;	3.79	;	Cryo-EM structure of V-ATPase from bovine brain, state 2
6OSY	;	4.3	;	Cryo-EM structure of vaccine-elicited antibody 0PV-a.01 in complex with HIV-1 Env BG505 DS-SOSIP and antibodies VRC03 and PGT122
6OT1	;	3.5	;	Cryo-EM structure of vaccine-elicited antibody 0PV-b.01 in complex with HIV-1 Env BG505 DS-SOSIP and antibodies VRC03 and PGT122
6NF2	;	3.7	;	Cryo-EM structure of vaccine-elicited antibody 0PV-c.01 in complex with HIV-1 Env BG505 DS-SOSIP and antibodies VRC03 and PGT122
8U1D	;	4.25	;	Cryo-EM structure of vaccine-elicited CD4 binding site antibody DH1285 bound to HIV-1 CH505TFchim.6R.SOSIP.664v4.1 Env Local Refinement
6UM7	;	3.5	;	Cryo-EM structure of vaccine-elicited HIV-1 neutralizing antibody DH270.mu1 in complex with CH848 10.17DT Env
6XSK	;	3.85	;	Cryo-EM Structure of Vaccine-Elicited Rhesus Antibody 789-203-3C12 in Complex with Stabilized SI06 (A/Solomon Islands/3/06) Influenza Hemagglutinin Trimer
7VFD	;	2.25	;	Cryo-EM structure of Vaccinia virus scaffolding protein D13
7VFG	;	3.87	;	Cryo-EM structure of Vaccinia virus scaffolding protein D13 trimer doublet
7VFH	;	3.9	;	Cryo-EM structure of Vaccinia virus scaffolding protein D13 trimer sextet
7VFF	;	4.1	;	Cryo-EM structure of Vaccinia virus scaffolding protein D13 with N-terminal 17 residue truncation
7VFE	;	2.63	;	Cryo-EM structure of Vaccinia virus scaffolding protein D13 with N-terminal polyhistidine tag
6MI8	;	4.3	;	Cryo-EM Structure of vanadate-trapped E.coli LptB2FGC
7NNH	;	4.0	;	Cryo-EM structure of VAR2CSA FCR3 domain DBL5/6
6WSL	;	3.1	;	Cryo-EM structure of VASH1-SVBP bound to microtubules
7EK1	;	3.0	;	Cryo-EM structure of VCCN1 in detergent
7EK2	;	2.7	;	Cryo-EM structure of VCCN1 in lipid nanodisc
7EK3	;	2.7	;	Cryo-EM structure of VCCN1 Y332A mutant in lipid nanodisc
7FFE	;	3.5	;	Cryo-EM structure of VEEV VLP
7FFQ	;	3.5	;	Cryo-EM structure of VEEV VLP at the 2-fold axes
7FFO	;	3.5	;	Cryo-EM structure of VEEV VLP at the 5-fold axes
7FFL	;	3.1	;	Cryo-EM structure of VEEV VLP-LDLRAD3-D1 complex at the 2-fold axes
7FFN	;	3.0	;	Cryo-EM structure of VEEV VLP-LDLRAD3-D1 complex at the 5-fold axes
8G9W	;	4.66	;	Cryo-EM structure of vFP49.02 Fab in complex with HIV-1 Env BG505 DS-SOSIP.664 (conformation 1)
8G9X	;	4.46	;	Cryo-EM structure of vFP49.02 Fab in complex with HIV-1 Env BG505 DS-SOSIP.664 (conformation 2)
8G9Y	;	4.28	;	Cryo-EM structure of vFP49.02 Fab in complex with HIV-1 Env BG505 DS-SOSIP.664 (conformation 3)
8JC7	;	2.06	;	Cryo-EM structure of Vibrio campbellii alpha-hemolysin
8TZJ	;	3.51	;	Cryo-EM structure of Vibrio cholerae FtsE/FtsX complex
8TZL	;	3.55	;	Cryo-EM structure of Vibrio cholerae FtsE/FtsX/EnvC complex, full-length
8TZK	;	3.55	;	Cryo-EM structure of Vibrio cholerae FtsE/FtsX/EnvC complex, shortened
8J9Y	;	3.16	;	cryo-EM structure of viral topoisomerase in conformation 1
8J9Z	;	3.13	;	cryo-EM structure of viral topoisomerase in conformation 2
6P6W	;	4.0	;	Cryo-EM structure of voltage-gated sodium channel NavAb N49K/L109A/M116V/G94C/Q150C disulfide crosslinked mutant in the resting state
6VI0	;	3.43	;	Cryo-EM structure of VRC01.23 in complex with HIV-1 Env BG505 DS.SOSIP
7YTJ	;	3.0	;	Cryo-EM structure of VTC complex
7WN3	;	3.29	;	Cryo-EM structure of VWF D'D3 dimer (2M mutant) complexed with D1D2 at 3.29 angstron resolution (2 units)
7WN6	;	3.29	;	Cryo-EM structure of VWF D'D3 dimer (R1136M/E1143M mutant) complexed with D1D2 at 3.29 angstron resolution (2 units)
7WN4	;	3.4	;	Cryo-EM structure of VWF D'D3 dimer (wild type) complexed with D1D2 at 3.4 angstron resolution (1 unit)
7WPP	;	2.85	;	Cryo-EM structure of VWF D'D3 dimer complexed with D1D2 at 2.85 angstron resolution (1 unit)
7WPQ	;	3.267	;	Cryo-EM structure of VWF D'D3 dimer complexed with D1D2 at 3.27 angstron resolution (2 units)
7WPS	;	4.32	;	Cryo-EM structure of VWF D'D3 dimer complexed with D1D2 at 4.3 angstron resolution (7 units)
7WQT	;	4.3	;	Cryo-EM structure of VWF D'D3 dimer complexed with D1D2 at 4.3 angstron resolution (VWF tube)
7A7C	;	3.16	;	Cryo-EM structure of W107R after heme uptake (1heme molecule) KatG from M. tuberculosis
7A7A	;	3.08	;	Cryo-EM structure of W107R after heme uptake (2heme molecules) KatG from M. tuberculosis
7A2I	;	3.3	;	Cryo-EM structure of W107R KatG from M. tuberculosis
7THX	;	2.96	;	Cryo-EM structure of W6 possum enterovirus
7USC	;	3.0	;	Cryo-EM structure of WAVE Regulatory Complex
7USE	;	3.0	;	Cryo-EM structure of WAVE regulatory complex with Rac1 bound on both A and D site
8HF2	;	4.14	;	Cryo-EM structure of WeiTsing
8DEC	;	4.7	;	Cryo-EM Structure of Western Equine Encephalitis Virus
8DED	;	4.1	;	Cryo-EM Structure of Western Equine Encephalitis Virus VLP in complex with SKW19 fab
8DEF	;	4.2	;	Cryo-EM Structure of Western Equine Encephalitis Virus VLP in complex with SKW24 fab
6WBF	;	2.83	;	Cryo-EM structure of wild type human Pannexin 1 channel
6UY0	;	3.23	;	Cryo-EM structure of wild-type bovine multidrug resistance protein 1 (MRP1) under active turnover conditions
8ISS	;	3.19	;	Cryo-EM structure of wild-type human tRNA Splicing Endonuclease Complex bound to pre-tRNA-ARG at 3.19 A resolution
6ZJI	;	3.7	;	Cryo-EM structure of wild-type KatG from M. tuberculosis
7AG8	;	2.68	;	Cryo-EM structure of wild-type KatG from M. tuberculosis
8E7D	;	3.31	;	Cryo-EM structure of wild-type transthyretin amyloid from heart tissue
8FFO	;	3.5	;	Cryo-EM structure of wildtype rabbit TRPV5 with PI(4,5)P2 in nanodiscs
6EDJ	;	4.52	;	Cryo-EM structure of Woodchuck hepatitis virus capsid
8F38	;	2.64	;	Cryo-EM structure of X6 COBRA (H1N1) hemagglutinin bound to CR6261 Fab
6J9E	;	3.41	;	Cryo-EM structure of Xanthomonos oryzae transcription elongation complex with NusA and the bacteriophage protein P7
6J9F	;	3.95	;	Cryo-EM structure of Xanthomonos oryzae transcription elongation complex with the bacteriophage protein P7
7VOP	;	8.7	;	Cryo-EM structure of Xenopus laevis nuclear pore complex cytoplasmic ring subunit
7RHQ	;	3.53	;	Cryo-EM structure of Xenopus Patched-1 in complex with GAS1 and Sonic Hedgehog
7RHR	;	3.0	;	Cryo-EM structure of Xenopus Patched-1 in nanodisc
6UZY	;	3.38	;	Cryo-EM structure of Xenopus tropicalis pannexin 1
6VD7	;	3.02	;	Cryo-EM structure of Xenopus tropicalis pannexin 1 channel
6RW8	;	2.84	;	Cryo-EM structure of Xenorhabdus nematophila XptA1
8JPR	;	3.4	;	Cryo-EM structure of Y553C human ClC-6
6SNH	;	3.9	;	Cryo-EM structure of yeast ALG6 in complex with 6AG9 Fab and Dol25-P-Glc
5FJ9	;	4.6	;	Cryo-EM structure of yeast apo RNA polymerase III at 4.6 A
8OVX	;	3.4	;	Cryo-EM structure of yeast CENP-OPQU+ bound to the CENP-A N-terminus
5VLJ	;	10.5	;	Cryo-EM structure of yeast cytoplasmic dynein with Walker B mutation at AAA3 in presence of ATP-VO4
5VH9	;	7.7	;	Cryo-EM structure of yeast cytoplasmic dynein-1 with Lis1 and ATP
5G06	;	4.2	;	Cryo-EM structure of yeast cytoplasmic exosome
8ASV	;	4.35	;	Cryo-EM structure of yeast Elongator complex
8ASW	;	3.96	;	Cryo-EM structure of yeast Elp123 in complex with alanine tRNA
8AT6	;	3.7	;	Cryo-EM structure of yeast Elp456 subcomplex
8HFC	;	3.5	;	Cryo-EM structure of yeast Erf2/Erf4 complex
6Z6J	;	3.4	;	Cryo-EM structure of yeast Lso2 bound to 80S ribosomes under native condition
6YMV	;	3.1	;	Cryo-EM structure of yeast mitochondrial RNA polymerase partially-melted transcription initiation complex (PmIC)
6YMW	;	3.71	;	Cryo-EM structure of yeast mitochondrial RNA polymerase transcription initiation complex
8ATT	;	3.44	;	Cryo-EM structure of yeast mitochondrial RNA polymerase transcription initiation complex with 4-mer RNA, pppGpGpUpA (IC4)
8ATV	;	3.39	;	Cryo-EM structure of yeast mitochondrial RNA polymerase transcription initiation complex with 5-mer RNA, pppGpGpApApA (IC5)
8ATW	;	3.62	;	Cryo-EM structure of yeast mitochondrial RNA polymerase transcription initiation complex with 6-mer RNA, pppGpGpApApApU (IC6)
8C5S	;	3.75	;	Cryo-EM structure of yeast mitochondrial RNA polymerase transcription initiation complex with 7-mer RNA, pppGpGpUpApApApU (IC7)
8C5U	;	3.62	;	Cryo-EM structure of yeast mitochondrial RNA polymerase transcription initiation complex with 8-mer RNA, pppGpGpUpApApApUpG (IC8)
8AP1	;	3.47	;	Cryo-EM structure of yeast mitochondrial RNA polymerase transcription initiation complex with two GTP molecules poised for de novo initiation (IC2)
7OCI	;	3.46	;	Cryo-EM structure of yeast Ost6p containing oligosaccharyltransferase complex
8JCH	;	2.7	;	Cryo-EM structure of yeast Rat1-bound Pol II pre-termination transcription complex 1 (Pol II Rat1-PTTC1)
8K5P	;	2.8	;	Cryo-EM structure of yeast Rat1-bound Pol II pre-termination transcription complex 2 (Pol II Rat1-PTTC2)
6Z6K	;	3.4	;	Cryo-EM structure of yeast reconstituted Lso2 bound to 80S ribosomes
7C79	;	2.5	;	Cryo-EM structure of yeast Ribonuclease MRP
7C7A	;	2.8	;	Cryo-EM structure of yeast Ribonuclease MRP with substrate ITS1
6AGB	;	3.48	;	Cryo-EM structure of yeast Ribonuclease P
6AH3	;	3.48	;	Cryo-EM structure of yeast Ribonuclease P with pre-tRNA substrate
5FJA	;	4.65	;	Cryo-EM structure of yeast RNA polymerase III at 4.7 A
5FJ8	;	3.9	;	Cryo-EM structure of yeast RNA polymerase III elongation complex at 3. 9 A
7OXP	;	2.7	;	Cryo-EM structure of yeast Sei1
7OXR	;	3.3	;	Cryo-EM structure of yeast Sei1 with locking helix deletion
7V2Y	;	3.4	;	cryo-EM structure of yeast THO complex with Sub2
6OGD	;	4.4	;	Cryo-EM structure of YenTcA in its prepore state
6RWB	;	3.25	;	Cryo-EM structure of Yersinia pseudotuberculosis TcaA-TcaB
7KZX	;	4.0	;	Cryo-EM structure of YiiP-Fab complex in Apo state
7KZZ	;	3.42	;	Cryo-EM structure of YiiP-Fab complex in Holo state
7PM3	;	3.1	;	Cryo-EM structure of young JASP-stabilized F-actin (central 3er)
7MBU	;		;	Cryo-EM structure of zebrafish TRPM5 E337A mutant in the presence of 5 mM calcium (high calcium occupancy in the transmembrane domain)
7MBT	;		;	Cryo-EM structure of zebrafish TRPM5 E337A mutant in the presence of 5 mM calcium (low calcium occupancy in the transmembrane domain)
7MBP	;	2.8	;	Cryo-EM structure of zebrafish TRPM5 in the presence of 1 mM EDTA
7MBQ	;	2.3	;	Cryo-EM structure of zebrafish TRPM5 in the presence of 5 mM calcium
7MBV	;	2.8	;	Cryo-EM structure of zebrafish TRPM5 in the presence of 5 mM calcium and 0.5 mM NDNA
7MBR	;		;	Cryo-EM structure of zebrafish TRPM5 in the presence of 6 uM calcium (apo state)
7MBS	;		;	Cryo-EM structure of zebrafish TRPM5 in the presence of 6 uM calcium (open state)
5H32	;	12.0	;	Cryo-EM structure of zika virus complexed with Fab C10 at pH 5.0
5H30	;	4.4	;	Cryo-EM structure of zika virus complexed with Fab C10 at pH 6.5
5H37	;	4.0	;	Cryo-EM structure of zika virus complexed with Fab C10 at pH 8.0
5Y0A	;	22.0	;	Cryo-EM structure of zika virus complexed with Fab of ZKA190 at pH 8.0 and 37 celsius degree
7BU8	;	3.8	;	Cryo-EM structure of zika virus complexed with Fab SIgN-3C at pH 6.5
7BUA	;	4.8	;	Cryo-EM structure of zika virus complexed with Fab SIgN-3C at pH 8.0
7KCR	;	4.0	;	Cryo-EM structure of Zika virus in complex with E protein cross-linking human monoclonal antibody ADI30056
8CYI	;	3.14	;	Cryo-EM structures and computational analysis for enhanced potency in MTA-synergic inhibition of human protein arginine methyltransferase 5
6MSB	;	3.0	;	Cryo-EM structures and dynamics of substrate-engaged human 26S proteasome
6MSD	;	3.2	;	Cryo-EM structures and dynamics of substrate-engaged human 26S proteasome
6MSE	;	3.3	;	Cryo-EM structures and dynamics of substrate-engaged human 26S proteasome
6MSG	;	3.5	;	Cryo-EM structures and dynamics of substrate-engaged human 26S proteasome
6MSH	;	3.6	;	Cryo-EM structures and dynamics of substrate-engaged human 26S proteasome
6MSJ	;	3.3	;	Cryo-EM structures and dynamics of substrate-engaged human 26S proteasome
6MSK	;	3.2	;	Cryo-EM structures and dynamics of substrate-engaged human 26S proteasome
8HKU	;	2.72	;	Cryo-EM Structures and Translocation Mechanism of Crenarchaeota Ribosome
8HKV	;	4.94	;	Cryo-EM Structures and Translocation Mechanism of Crenarchaeota Ribosome
8HKX	;	3.14	;	Cryo-EM Structures and Translocation Mechanism of Crenarchaeota Ribosome
8HKY	;	4.45	;	Cryo-EM Structures and Translocation Mechanism of Crenarchaeota Ribosome
8HKZ	;	4.78	;	Cryo-EM Structures and Translocation Mechanism of Crenarchaeota Ribosome
8HL1	;	3.93	;	Cryo-EM Structures and Translocation Mechanism of Crenarchaeota Ribosome
8HL2	;	4.1	;	Cryo-EM Structures and Translocation Mechanism of Crenarchaeota Ribosome
8HL3	;	4.8	;	Cryo-EM Structures and Translocation Mechanism of Crenarchaeota Ribosome
8HL4	;	4.62	;	Cryo-EM Structures and Translocation Mechanism of Crenarchaeota Ribosome
8HL5	;	5.72	;	Cryo-EM Structures and Translocation Mechanism of Crenarchaeota Ribosome
7UDC	;	3.7	;	cryo-EM structures of a synaptobrevin-Munc18-1-syntaxin-1 complex class1
7KGG	;	2.97	;	Cryo-EM Structures of AdeB from Acinetobacter baumannii: AdeB-ET-I
7KGH	;	3.79	;	Cryo-EM Structures of AdeB from Acinetobacter baumannii: AdeB-ET-II
7KGI	;	3.34	;	Cryo-EM Structures of AdeB from Acinetobacter baumannii: AdeB-ET-III
7KGD	;	3.64	;	Cryo-EM Structures of AdeB from Acinetobacter baumannii: AdeB-I
7KGE	;	3.21	;	Cryo-EM Structures of AdeB from Acinetobacter baumannii: AdeB-II
7KGF	;	3.42	;	Cryo-EM Structures of AdeB from Acinetobacter baumannii: AdeB-III
5JZW	;	4.46	;	Cryo-EM structures of aerolysin post-prepore and quasipore
7CYC	;	3.21	;	Cryo-EM structures of Alphacoronavirus spike glycoprotein
7CYD	;	3.55	;	Cryo-EM structures of Alphacoronavirus spike glycoprotein
8T2V	;	3.4	;	Cryo-EM Structures of Full-length Integrin alphaIIbbeta3 in Native Lipids
8T2U	;	3.1	;	Cryo-EM Structures of Full-length Integrin alphaIIbbeta3 in Native Lipids complexed with Eptifibatide
6M15	;	2.38	;	Cryo-EM structures of HKU2 spike glycoproteins
7PLS	;	2.49	;	Cryo-EM structures of human fucosidase FucA1 reveal insight into substate recognition and catalysis.
7PM4	;	2.49	;	Cryo-EM structures of human fucosidase FucA1 reveal insight into substate recognition and catalysis.
7D72	;	3.4	;	Cryo-EM structures of human GMPPA/GMPPB complex bound to GDP-Mannose
7XDF	;	2.72	;	Cryo-EM structures of human mitochondrial NAD(P)+-dependent malic enzyme in a ternary complex with NAD+ and allosteric inhibitor EA
7XDG	;	2.84	;	Cryo-EM structures of human mitochondrial NAD(P)+-dependent malic enzyme in a ternary complex with NAD+ and allosteric inhibitor MDSA
7XDE	;	2.72	;	Cryo-EM structures of human mitochondrial NAD(P)+-dependent malic enzyme in apo form
7VLX	;	3.12	;	Cryo-EM structures of Listeria monocytogenes man-PTS
6QIK	;	3.1	;	Cryo-EM structures of Lsg1-TAP pre-60S ribosomal particles
6QT0	;	3.4	;	Cryo-EM structures of Lsg1-TAP pre-60S ribosomal particles
6QTZ	;	3.5	;	Cryo-EM structures of Lsg1-TAP pre-60S ribosomal particles
6RI5	;	3.3	;	Cryo-EM structures of Lsg1-TAP pre-60S ribosomal particles
6RZZ	;	3.2	;	Cryo-EM structures of Lsg1-TAP pre-60S ribosomal particles
6S05	;	3.9	;	Cryo-EM structures of Lsg1-TAP pre-60S ribosomal particles
8WG8	;	2.71	;	Cryo-EM structures of peptide free and Gs-coupled GCGR
8WG7	;	2.54	;	Cryo-EM structures of peptide free and Gs-coupled GLP-1R
4D5L	;	9.0	;	Cryo-EM structures of ribosomal 80S complexes with termination factors and cricket paralysis virus IRES reveal the IRES in the translocated state
4D5N	;	9.0	;	Cryo-EM structures of ribosomal 80S complexes with termination factors and cricket paralysis virus IRES reveal the IRES in the translocated state
4D5Y	;	9.0	;	Cryo-EM structures of ribosomal 80S complexes with termination factors and cricket paralysis virus IRES reveal the IRES in the translocated state
4D61	;	9.0	;	Cryo-EM structures of ribosomal 80S complexes with termination factors and cricket paralysis virus IRES reveal the IRES in the translocated state
4D67	;	9.0	;	Cryo-EM structures of ribosomal 80S complexes with termination factors and cricket paralysis virus IRES reveal the IRES in the translocated state
6M16	;	2.83	;	Cryo-EM structures of SADS-CoV spike glycoproteins
5ADY	;	4.5	;	Cryo-EM structures of the 50S ribosome subunit bound with HflX
4CSU	;	5.5	;	Cryo-EM structures of the 50S ribosome subunit bound with ObgE
3J4K	;	8.0	;	Cryo-EM structures of the actin:tropomyosin filament reveal the mechanism for the transition from C- to M-state
8JV7	;	3.6	;	Cryo-EM structures of the panda P2X7 receptor in complex with PPADS
8JV8	;	3.34	;	Cryo-EM structures of the panda P2X7 receptor in complex with PPNDS
8JV6	;	3.43	;	Cryo-EM structures of the zebrafish P2X4 receptor in complex with BAY-1797
3ZIF	;	4.5	;	Cryo-EM structures of two intermediates provide insight into adenovirus assembly and disassembly
7CFS	;	3.56	;	Cryo-EM strucutre of human acid-sensing ion channel 1a at pH 8.0
7CFT	;	3.9	;	Cryo-EM strucutre of human acid-sensing ion channel 1a in complex with snake toxin Mambalgin1 at pH 8.0
3JAC	;	4.8	;	Cryo-EM study of a channel
5A8H	;	23.0	;	cryo-ET subtomogram averaging of BG505 SOSIP.664 in complex with sCD4, 17b, and 8ANC195
1QLE	;	3.0	;	CRYO-STRUCTURE OF THE PARACOCCUS DENITRIFICANS FOUR-SUBUNIT CYTOCHROME C OXIDASE IN THE COMPLETELY OXIDIZED STATE COMPLEXED WITH AN ANTIBODY FV FRAGMENT
6GNI	;	4.9	;	Cryo-tomography and subtomogram averaging of Sar1-Sec23-Sec24 - fitted model.
3U4L	;	2.4	;	Cryocooled bovine profilin:actin crystal structure to 2.4 A
3J8D	;	26.0	;	Cryoelectron microscopy of dengue-Fab E104 complex at pH 5.5
8EMH	;	3.63	;	CryoEM characterization of a unique AAA+ BrxL phage restriction factor
8EMC	;	3.6	;	CryoEM characterization of BrxL -- a unique AAA+ phage restriction Factor.
6PZW	;	3.0	;	CryoEM derived model of NA-22 Fab in complex with N9 Shanghai2
6PZY	;	3.17	;	CryoEM derived model of NA-73 Fab in complex with N9 Shanghai2
6PZZ	;	3.6	;	CryoEM derived model of NA-80 Fab in complex with N9 Shanghai2
3J06	;	3.3	;	CryoEM Helical Reconstruction of TMV
6KNF	;	2.99	;	CryoEM map and model of Nitrite Reductase at pH 6.2
6KNG	;	2.85	;	CryoEM map and model of Nitrite Reductase at pH 8.1
7T3D	;	3.38	;	CryoEM map of anchor 222-1C06 Fab and lateral patch 2B05 Fab binding H1 HA
2VOY	;	18.0	;	CryoEM model of CopA, the copper transporting ATPase from Archaeoglobus fulgidus
2WYY	;	10.6	;	CRYOEM MODEL OF THE VESICULAR STOMATITIS VIRUS
8EF7	;	9.68	;	CryoEM of the soluble OPA1 dimer from the apo helical assembly on a lipid membrane
8EEW	;	5.48	;	CryoEM of the soluble OPA1 dimer from the GDP-AlFx bound helical assembly on a lipid membrane
8EFT	;	9.68	;	CryoEM of the soluble OPA1 interfaces from the apo helical assembly on a lipid membrane
8EFR	;	5.48	;	CryoEM of the soluble OPA1 interfaces with GDP-AlFx bound from the helical assembly on a lipid membrane
8EFS	;	9.68	;	CryoEM of the soluble OPA1 tetramer from the apo helical assembly on a lipid membrane
8EFF	;	5.48	;	CryoEM of the soluble OPA1 tetramer from the GDP-AlFx bound helical assembly on a lipid membrane
6PEW	;	3.2	;	CryoEM Plasmodium falciparum glutamine synthetase
6PEV	;	3.2	;	CryoEM Plasmodium falciparum M18 aspartyl aminopeptidase
3J24	;	9.0	;	CryoEM reconstruction of complement decay-accelerating factor
6QOZ	;	3.4	;	CryoEM reconstruction of Cowpea Mosaic Virus (CPMV) bound to an Affimer reagent
6TZA	;	7.2	;	CryoEM reconstruction of ESCRT-III filament composed of IST1 NTD R16E K27E double mutant
6I2T	;	5.7	;	CryoEM reconstruction of full-length, fully-glycosylated human butyrylcholinesterase tetramer
8PK3	;	3.4	;	CryoEM reconstruction of hemagglutinin HK68 of Influenza A virus bound to an Affimer reagent
5KNE	;	5.64	;	CryoEM Reconstruction of Hsp104 Hexamer
6AHF	;	6.78	;	CryoEM Reconstruction of Hsp104 N728A Hexamer
5TQY	;	5.2	;	CryoEM reconstruction of human IKK1, closed conformation 3
5TQX	;	5.4	;	CryoEM reconstruction of human IKK1, intermediate conformation 2
5TQW	;	5.6	;	CryoEM reconstruction of human IKK1, open conformation 1
6E8G	;	2.9	;	CryoEM reconstruction of IST1-CHMP1B copolymer filament bound to ssDNA at 2.9 Angstrom resolution
6TZ9	;	6.2	;	CryoEM reconstruction of membrane-bound ESCRT-III filament composed of CHMP1B only
6TZ5	;	3.1	;	CryoEM reconstruction of membrane-bound ESCRT-III filament composed of CHMP1B+IST1 (left-handed)
6TZ4	;	3.2	;	CryoEM reconstruction of membrane-bound ESCRT-III filament composed of CHMP1B+IST1 (right-handed)
7PLM	;	2.9	;	CryoEM reconstruction of pyruvate ferredoxin oxidoreductase (PFOR) in anaerobic conditions
7T0O	;	8.7	;	cryoEM reconstruction of the HIV gp140 in complex with the extracellular domains of CD4 and the adnectin domain of Combinectin. The gp140 and CD4 coordinates from entry 6EDU were rigid body fitted to the EM map along withe the crystal structure of CD4+adnectin
3J9C	;	2.9	;	CryoEM single particle reconstruction of anthrax toxin protective antigen pore at 2.9 Angstrom resolution
6B43	;	4.2	;	CryoEM structure and atomic model of the Kaposi's sarcoma-associated herpesvirus capsid
6R83	;	5.1	;	CryoEM structure and molecular model of squid hemocyanin (Todarodes pacificus , TpH)
7LO5	;	2.86	;	cryoEM structure DrdV-DNA complex
7LVV	;	3.25	;	cryoEM structure DrdV-DNA complex
8OOK	;	5.69	;	CryoEM Structure INO80core Hexasome complex Arp5 grappler refinement state1
8OOF	;	2.9	;	CryoEM Structure INO80core Hexasome complex Arp5 Ies6 refinement state1
8OOT	;	2.85	;	CryoEM Structure INO80core Hexasome complex Arp5 Ies6 refinement state2
8OO9	;	3.2	;	CryoEM Structure INO80core Hexasome complex ATPase-DNA refinement state1
8OOS	;	3.29	;	CryoEM Structure INO80core Hexasome complex ATPase-hexasome refinement state 2
8OO7	;	2.8	;	CryoEM Structure INO80core Hexasome complex composite model state1
8OOP	;	2.7	;	CryoEM Structure INO80core Hexasome complex composite model state2
8OOA	;	3.18	;	CryoEM Structure INO80core Hexasome complex Hexasome refinement state1
8OOC	;	2.93	;	CryoEM Structure INO80core Hexasome complex Rvb core refinement state1
8OOR	;	2.87	;	CryoEM Structure INO80core Hexasome complex Rvb core refinement state2
6FML	;	4.34	;	CryoEM Structure INO80core Nucleosome complex
8OIX	;	2.89	;	CryoEM structure of 20S Trichomonas vaginalis proteasome in complex with proteasome inhibitor Salinosporamid A
7NYD	;	3.27	;	cryoEM structure of 2C9-sMAC
7NYC	;	3.54	;	cryoEM structure of 3C9-sMAC
3J80	;	3.75	;	CryoEM structure of 40S-eIF1-eIF1A preinitiation complex
3JAM	;	3.46	;	CryoEM structure of 40S-eIF1A-eIF1 complex from yeast
6QFA	;	2.49	;	CryoEM structure of a beta3K279T GABA(A)R homomer in complex with histamine and megabody Mb25
8EQF	;	3.16	;	cryoEM structure of a broadly neutralizing anti-SARS-CoV-2 antibody STI-9167
8TL7	;	4.05	;	CryoEM Structure of a Computationally Designed T3 Tetrahedral Nanocage
7JZY	;	3.6	;	CryoEM structure of a CRISPR-Cas complex
7WUS	;	3.4	;	CryoEM structure of a dimer of loose sNS1 tetramer
7A5V	;	1.7	;	CryoEM structure of a human gamma-aminobutyric acid receptor, the GABA(A)R-beta3 homopentamer, in complex with histamine and megabody Mb25 in lipid nanodisc
7UNF	;	4.08	;	CryoEM structure of a mEAK7 bound human V-ATPase complex
3J81	;	4.0	;	CryoEM structure of a partial yeast 48S preinitiation complex
5V4S	;	4.2	;	CryoEM Structure of a Prokaryotic Cyclic Nucleotide-Gated Ion Channel
6CFW	;	3.7	;	cryoEM structure of a respiratory membrane-bound hydrogenase
8Q9T	;	2.84	;	CryoEM structure of a S. Cerevisiae Ski238 complex bound to RNA
8QCA	;	2.84	;	CryoEM structure of a S. Cerevisiae Ski2387 complex in the closed state bound to RNA
8QCB	;	2.8	;	CryoEM structure of a S. Cerevisiae Ski2387 complex in the open state
8SO3	;	3.61	;	CryoEM structure of a therapeutic antibody (favezelimab) bound to human LAG3
8SR0	;	3.53	;	CryoEM structure of a therapeutic antibody (favezelimab) bound to human LAG3 local refined
7K8A	;	3.65	;	CryoEM structure of a trehalose monomycolate transporter in lipid nanodiscs
7K8B	;	2.94	;	CryoEM structure of a trehalose monomycolate transporter in lipid nanodiscs
7K8C	;	4.27	;	CryoEM structure of a trehalose monomycolate transporter in lipid nanodiscs
7K8D	;	4.33	;	CryoEM structure of a trehalose monomycolate transporter in TMM lipid nanodiscs (form II)
8C0Z	;	3.22	;	CryoEM structure of a tungsten-containing aldehyde oxidoreductase from Aromatoleum aromaticum
3J9O	;	3.7	;	CryoEM structure of a type VI secretion system
7KGB	;	2.7	;	CryoEM structure of A2296-methylated Mycobacterium tuberculosis ribosome bound with SEQ-9
6JPQ	;	4.44	;	CryoEM structure of Abo1 hexamer - ADP complex
6JPU	;	4.27	;	CryoEM structure of Abo1 hexamer - apo complex
6JQ0	;	3.54	;	CryoEM structure of Abo1 Walker B (E372Q) mutant hexamer - ATP complex
6MCC	;	3.9	;	CryoEM structure of AcrIIA2 homolog in complex with CRISPR-Cas9
6MCB	;	3.4	;	CryoEM structure of AcrIIA2 in complex with CRISPR-Cas9
7K10	;	3.3	;	CryoEM structure of activated-form FATKIN domain of DNA-PK
6F2S	;	3.3	;	CryoEM structure of Ageratum Yellow Vein virus (AYVV)
8CPE	;	4.0	;	CryoEM structure of AL55 amyloid fibrils extracted from the kidney of an AL amyloidosis patient.
8CYX	;	3.0	;	CryoEM structure of amplified alpha-synuclein fibril class A type I with compact core from DLB case III
8CZ2	;	3.0	;	CryoEM structure of amplified alpha-synuclein fibril class A type I with extended core from DLB case VII
8CZ6	;	3.2	;	CryoEM structure of amplified alpha-synuclein fibril class A type I with extended core from DLB case X
8CYY	;	3.1	;	CryoEM structure of amplified alpha-synuclein fibril class B mixed type I/II with extended core from DLB case V
8CZ0	;	2.9	;	CryoEM structure of amplified alpha-synuclein fibril class B type I with extended core from DLB case VII
8CZ3	;	3.2	;	CryoEM structure of amplified alpha-synuclein fibril class B type I with extended core from DLB case X
8CZ1	;	3.0	;	CryoEM structure of amplified alpha-synuclein fibril class B type II with extended core from DLB case VII
8HJ4	;	3.1	;	CryoEM structure of an anti-CRISPR protein AcrIIC5 bound to Nme1Cas9-sgRNA complex
7UIN	;	2.8	;	CryoEM Structure of an Group II Intron Retroelement
7UIM	;	3.1	;	CryoEM Structure of an Group II Intron Retroelement (apo-complex)
5UJZ	;	4.8	;	CryoEM structure of an influenza virus receptor-binding site antibody-antigen interface - Class 1
5UK0	;	4.8	;	CryoEM structure of an influenza virus receptor-binding site antibody-antigen interface - Class 2
5UK1	;	4.8	;	CryoEM structure of an influenza virus receptor-binding site antibody-antigen interface - Class 3
5UK2	;	4.8	;	CryoEM structure of an influenza virus receptor-binding site antibody-antigen interface - Class 4
8T60	;	3.29	;	CryoEM structure of an inward-facing MelBSt at a Na(+)-bound and sugar low-affinity conformation
8DBY	;	2.26	;	CryoEM structure of anaerobically prepared nitrogenase MoFe-protein on ultrathin carbon
7W84	;	3.4	;	CryoEM structure of apo form ZmRDR2 at 3.4 Angstroms resolution
6OIT	;	3.5	;	CryoEM structure of Arabidopsis DDR' complex (DRD1 peptide-DMS3-RDM1)
6OIS	;	3.6	;	CryoEM structure of Arabidopsis DR complex (DMS3-RDM1)
7YHP	;	3.1	;	CryoEM structure of Arabidopsis ROS1 in complex with 5mC-dsDNA at 3.1 Angstroms resolution
7YHQ	;	3.9	;	CryoEM structure of Arabidopsis ROS1 in complex with a covalent-linked reaction intermediate at 3.9 Angstroms resolution
7YHO	;	3.3	;	CryoEM structure of Arabidopsis ROS1 in complex with TG mismatch dsDNA at 3.3 Angstroms resolution
7RZW	;	3.3	;	CryoEM structure of Arabidopsis thaliana phytochrome B
8C0B	;	3.98	;	CryoEM structure of Aspergillus nidulans UTP-glucose-1-phosphate uridylyltransferase
7UT9	;	2.44	;	CryoEM structure of Azotobacter vinelandii nitrogenase complex (1:1 FeP:MoFeP, ADP/ATP-bound) during catalytic N2 reduction
7UT8	;	2.43	;	CryoEM structure of Azotobacter vinelandii nitrogenase complex (1:1 FeP:MoFeP, ATP-bound) during catalytic N2 reduction
7UTA	;	2.4	;	CryoEM structure of Azotobacter vinelandii nitrogenase complex (2:1 FeP:MoFeP) inhibited by BeFx during catalytic N2 reduction
8DPN	;	2.49	;	CryoEM structure of Azotobacter vinelandii nitrogenase MoFeP during catalytic N2 reduction
8B0I	;	4.28	;	CryoEM structure of bacterial RapZ.GlmZ complex central to the control of cell envelope biogenesis
8B0J	;	3.99	;	CryoEM structure of bacterial RNaseE.RapZ.GlmZ complex central to the control of cell envelope biogenesis
7QWP	;	3.4	;	CryoEM structure of bacterial transcription close complex (RPc)
7QV9	;	3.5	;	CryoEM structure of bacterial transcription intermediate complex mediated by activator PspF
7VII	;	5.6	;	cryoEM structure of bacteriophage lambda capsid at 5.6 Angstrom
8FEH	;	3.28	;	CryoEM structure of bacteriophage Q-beta coat protein dimer with AYGG linker
8UNL	;	3.3	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (Class A)
8UNM	;	3.4	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (Class B)
8UNN	;	3.4	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (Class C)
8UNO	;	3.3	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (Class D)
8UNP	;	3.3	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (Class E)
8UNQ	;	3.3	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (Class F)
8UNR	;	3.4	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (Class G)
8UNS	;	3.4	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (Class H)
8UNT	;	3.4	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (Class I)
8UNU	;	3.5	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (Class J)
8UNV	;	3.3	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (Class K)
8UNW	;	3.4	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (Class L)
8UNX	;	3.6	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (Class M)
8UNY	;	3.6	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (Class N)
8UNZ	;	3.8	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (Class O)
8UO0	;	3.5	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (Class P)
8UO1	;	3.6	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (Class Q)
8UO2	;	3.6	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (Class R)
8UO3	;	3.5	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (Class S)
8UO4	;	4.0	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (Class T)
8GFV	;	3.1	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #1 of 20)
8GG4	;	3.2	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #10 of 20)
8GG5	;	3.2	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #11 of 20)
8GG6	;	3.3	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #12 of 20)
8GG7	;	3.3	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #13 of 20)
8GG8	;	3.3	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #14 of 20)
8GG9	;	3.4	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #15 of 20)
8GGA	;	3.5	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #16 of 20)
8GGB	;	3.5	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #17 of 20)
8GGC	;	3.4	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #18 of 20)
8GGE	;	3.5	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #19 of 20)
8GFW	;	3.0	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #2 of 20)
8GGF	;	3.6	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #20 of 20)
8GFX	;	3.0	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #3 of 20)
8GFY	;	3.0	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #4 of 20)
8GFZ	;	3.0	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #5 of 20)
8GG0	;	2.9	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #6 of 20)
8GG1	;	3.0	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #7 of 20)
8GG2	;	3.0	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #8 of 20)
8GG3	;	3.1	;	CryoEM structure of beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #9 of 20)
8GDZ	;	3.5	;	CryoEM structure of beta-2-adrenergic receptor in complex with nucleotide-free Gs heterotrimer (#1 of 20)
8GE9	;	3.5	;	CryoEM structure of beta-2-adrenergic receptor in complex with nucleotide-free Gs heterotrimer (#10 of 20)
8GEA	;	3.5	;	CryoEM structure of beta-2-adrenergic receptor in complex with nucleotide-free Gs heterotrimer (#11 of 20)
8GEB	;	3.6	;	CryoEM structure of beta-2-adrenergic receptor in complex with nucleotide-free Gs heterotrimer (#12 of 20)
8GEC	;	3.5	;	CryoEM structure of beta-2-adrenergic receptor in complex with nucleotide-free Gs heterotrimer (#13 of 20)
8GED	;	3.5	;	CryoEM structure of beta-2-adrenergic receptor in complex with nucleotide-free Gs heterotrimer (#14 of 20)
8GEE	;	3.7	;	CryoEM structure of beta-2-adrenergic receptor in complex with nucleotide-free Gs heterotrimer (#15 of 20)
8GEF	;	3.8	;	CryoEM structure of beta-2-adrenergic receptor in complex with nucleotide-free Gs heterotrimer (#16 of 20)
8GEG	;	3.8	;	CryoEM structure of beta-2-adrenergic receptor in complex with nucleotide-free Gs heterotrimer (#17 of 20)
8GEH	;	4.0	;	CryoEM structure of beta-2-adrenergic receptor in complex with nucleotide-free Gs heterotrimer (#18 of 20)
8GEI	;	4.1	;	CryoEM structure of beta-2-adrenergic receptor in complex with nucleotide-free Gs heterotrimer (#19 of 20)
8GE1	;	3.4	;	CryoEM structure of beta-2-adrenergic receptor in complex with nucleotide-free Gs heterotrimer (#2 of 20)
8GEJ	;	4.2	;	CryoEM structure of beta-2-adrenergic receptor in complex with nucleotide-free Gs heterotrimer (#20 of 20)
8GE2	;	3.3	;	CryoEM structure of beta-2-adrenergic receptor in complex with nucleotide-free Gs heterotrimer (#3 of 20)
8GE3	;	3.3	;	CryoEM structure of beta-2-adrenergic receptor in complex with nucleotide-free Gs heterotrimer (#4 of 20)
8GE4	;	3.3	;	CryoEM structure of beta-2-adrenergic receptor in complex with nucleotide-free Gs heterotrimer (#5 of 20)
8GE5	;	3.2	;	CryoEM structure of beta-2-adrenergic receptor in complex with nucleotide-free Gs heterotrimer (#6 of 20)
8GE6	;	3.4	;	CryoEM structure of beta-2-adrenergic receptor in complex with nucleotide-free Gs heterotrimer (#7 of 20)
8GE7	;	3.4	;	CryoEM structure of beta-2-adrenergic receptor in complex with nucleotide-free Gs heterotrimer (#8 of 20)
8GE8	;	3.4	;	CryoEM structure of beta-2-adrenergic receptor in complex with nucleotide-free Gs heterotrimer (#9 of 20)
8ECY	;	2.0	;	cryoEM structure of bovine bestrophin-2 and glutamine synthetase complex
6FO0	;	4.1	;	CryoEM structure of bovine cytochrome bc1 in complex with the anti-malarial compound GSK932121
6FO6	;	4.1	;	CryoEM structure of bovine cytochrome bc1 in complex with the anti-malarial inhibitor SCR0911
6FO2	;	4.4	;	CryoEM structure of bovine cytochrome bc1 with no ligand bound
6WU0	;	3.59	;	CryoEM structure of Burkholderia pseudomallei hopanoid biosynthesis-associated RND transporter HpnN
8B0F	;	3.0	;	CryoEM structure of C5b8-CD59
6R7X	;	3.47	;	CryoEM structure of calcium-bound human TMEM16K / Anoctamin 10 in detergent (2mM Ca2+, closed form)
6R7Y	;	4.2	;	CryoEM structure of calcium-bound human TMEM16K / Anoctamin 10 in detergent (low Ca2+, closed form)
6R7Z	;	5.14	;	CryoEM structure of calcium-free human TMEM16K / Anoctamin 10 in detergent (closed form)
6LNC	;	3.21	;	CryoEM structure of Cascade-TniQ complex
6LNB	;	3.18	;	CryoEM structure of Cascade-TniQ-dsDNA complex
7U4D	;	8.1	;	CryoEM structure of CENP-N promoted nucleosome stacks with CENP-A and 601 DNA sequence
7U47	;	7.5	;	CryoEM structure of CENP-N promoted nucleosome stacks with CENP-A and palindromic alpha satellite DNA sequence
7A08	;	3.11	;	CryoEM Structure of cGAS Nucleosome complex
6MX4	;	4.4	;	CryoEM structure of chimeric Eastern Equine Encephalitis Virus
6MW9	;	7.3	;	CryoEM structure of chimeric Eastern Equine Encephalitis Virus with Fab of EEEV-3 antibody
6MUI	;	7.7	;	CryoEM structure of chimeric Eastern Equine Encephalitis Virus with Fab of EEEV-42 antibody
6MWC	;	7.5	;	CryoEM structure of chimeric Eastern Equine Encephalitis Virus with Fab of EEEV-5 antibody
6MWV	;	7.3	;	CryoEM structure of Chimeric Eastern Equine Encephalitis Virus with Fab of EEEV-58 Antibody
6MWX	;	8.2	;	CryoEM structure of Chimeric Eastern Equine Encephalitis Virus with Fab of EEEV-69 Antibody
6MX7	;	4.8	;	CryoEM structure of chimeric Eastern Equine Encephalitis Virus: Genome-Binding Capsid N-terminal Domain
7WJM	;	3.3	;	CryoEM structure of chitin synthase 1 from Phytophthora sojae
7WJO	;	3.2	;	CryoEM structure of chitin synthase 1 from Phytophthora sojae complexed with nikkomycin Z
7X05	;	3.9	;	CryoEM structure of chitin synthase 1 from Phytophthora sojae complexed with the nascent chitooligosaccharide
7X06	;	3.1	;	CryoEM structure of chitin synthase 1 from Phytophthora sojae complexed with UDP
7WJN	;	3.3	;	CryoEM structure of chitin synthase 1 mutant E495A from Phytophthora sojae complexed with UDP-GlcNAc
8SZZ	;	2.9	;	CryoEM Structure of Computationally Designed Nanocage O32-ZL4
8FEI	;	3.0	;	CryoEM structure of Conalbumin from chicken egg white (sigma-Cas 1391-06-6)
7D5K	;	3.5	;	CryoEM structure of cotton cellulose synthase isoform 7
5MW1	;	3.8	;	cryoEM structure of crenactin double helical filament at 3.8A resolution
6ALF	;	4.1	;	CryoEM structure of crosslinked E.coli RNA polymerase elongation complex
8G16	;	2.07	;	CryoEM structure of cytoplasmic GAPDH under 24h Oxidative Stress
3IZ3	;	3.9	;	CryoEM structure of cytoplasmic polyhedrosis virus
8GNK	;	3.1	;	CryoEM structure of cytosol-facing, substrate-bound ratGAT1
8G13	;	2.3	;	CryoEM structure of cytosolic GAPDH under 8h Oxidative Stress
8G14	;	2.3	;	CryoEM structure of cytosolic GAPDH under 8h Oxidative Stress, class2
7V7B	;	4.2	;	CryoEM structure of DDB1-VprBP complex in ARM-up conformation
7V7C	;	3.7	;	CryoEM structure of DDB1-VprBP-Vpr-UNG2(94-313) complex
7V20	;	2.86	;	CryoEM structure of del68-76/del679-688 prefusion-stabilized spike
7V23	;	2.96	;	CryoEM structure of del68-76/del679-688 prefusion-stabilized spike in complex with the Fab of N12-9
3J27	;	3.6	;	CryoEM structure of Dengue virus
3J2P	;	3.6	;	CryoEM structure of Dengue virus envelope protein heterotetramer
6XSS	;	3.7	;	CryoEM structure of designed helical fusion protein C4_nat_HFuse-7900
8F6R	;	4.0	;	CryoEM structure of designed modular protein oligomer C6-79
8F6Q	;	3.6	;	CryoEM structure of designed modular protein oligomer C8-71
8SB4	;	3.6	;	CryoEM structure of DH270.1-CH848.10.17
8SB3	;	4.1	;	CryoEM structure of DH270.2-CH848.10.17
8SAY	;	3.4	;	CryoEM structure of DH270.3-CH848.10.17
8SAU	;	3.3	;	CryoEM structure of DH270.4-CH848.10.17
8SAS	;	4.0	;	CryoEM structure of DH270.5-CH848.10.17
8SAQ	;	3.9	;	CryoEM structure of DH270.6-CH848.0526.25
8SAR	;	3.82	;	CryoEM structure of DH270.6-CH848.10.17
8SB5	;	3.9	;	CryoEM structure of DH270.I1.6-CH848.10.17
8SB2	;	3.5	;	CryoEM structure of DH270.I2-CH848.10.17
8SB1	;	4.3	;	CryoEM structure of DH270.I3-CH848.10.17
8SB0	;	4.2	;	CryoEM structure of DH270.I4.6-CH848.10.17
8SAZ	;	3.9	;	CryoEM structure of DH270.I5.6-CH848.10.17
8SAX	;	4.0	;	CryoEM structure of DH270.UCA-CH848.10.17DT
8SAW	;	3.3	;	CryoEM structure of DH270.UCA.G57R-CH848.10.17DT
8A0E	;	2.8	;	CryoEM structure of DHS-eIF5A1 complex
7NIQ	;	4.3	;	CryoEM structure of disease related M854K MDA5-dsRNA filament in complex with ADP-AlF4(Major class)
7NIC	;	4.3	;	CryoEM structure of disease related M854K MDA5-dsRNA filament in complex with ADP-AlF4(minor class)
7BKP	;	2.8	;	CryoEM structure of disease related M854K MDA5-dsRNA filament in complex with ATP
7OPL	;	4.12	;	CryoEM structure of DNA Polymerase alpha - primase bound to SARS CoV nsp1
7K19	;	4.3	;	CryoEM structure of DNA-PK catalytic subunit complexed with DNA (Complex I)
7K1B	;	4.3	;	CryoEM structure of DNA-PK catalytic subunit complexed with DNA (Complex II)
7SU3	;	3.3	;	CryoEM structure of DNA-PK complex VII
7SUD	;	3.6	;	CryoEM structure of DNA-PK complex VIII
7X7P	;	7.02	;	CryoEM structure of dsDNA-RuvB-RuvA domain3 complex
5ADX	;	4.0	;	CryoEM structure of dynactin complex at 4.0 angstrom resolution
6XAS	;	3.8	;	CryoEM Structure of E. coli Rho-dependent Transcription Pre-termination Complex
6XAV	;	7.7	;	CryoEM Structure of E. coli Rho-dependent Transcription Pre-termination Complex bound with NusG
7UWE	;	2.9	;	CryoEM Structure of E. coli Transcription-Coupled Ribonucleotide Excision Repair (TC-RER) complex
7UWH	;	3.1	;	CryoEM Structure of E. coli Transcription-Coupled Ribonucleotide Excision Repair (TC-RER) complex bound to ribonucleotide substrate
6ASX	;	3.8	;	CryoEM structure of E.coli his pause elongation complex
6BJS	;	5.5	;	CryoEM structure of E.coli his pause elongation complex without pause hairpin
6ALH	;	4.4	;	CryoEM structure of E.coli RNA polymerase elongation complex
7PYJ	;	4.2	;	CryoEM structure of E.coli RNA polymerase elongation complex bound to NusA (NusA elongation complex in less-swiveled conformation)
7PYK	;	4.1	;	CryoEM structure of E.coli RNA polymerase elongation complex bound to NusA (NusA elongation complex in more-swiveled conformation)
7PY3	;	3.8	;	CryoEM structure of E.coli RNA polymerase elongation complex bound to NusA (the consensus NusA-EC)
7PY6	;	4.1	;	CryoEM structure of E.coli RNA polymerase elongation complex bound to NusA and NusG (NusA and NusG elongation complex in less-swiveled conformation)
7PY7	;	4.1	;	CryoEM structure of E.coli RNA polymerase elongation complex bound to NusA and NusG (NusA and NusG elongation complex in more-swiveled conformation)
7PY5	;	3.9	;	CryoEM structure of E.coli RNA polymerase elongation complex bound to NusA and NusG (the consensus NusA-NusG-EC)
7PY8	;	3.8	;	CryoEM structure of E.coli RNA polymerase elongation complex bound to NusG (NusG-EC in less-swiveled conformation)
7PY0	;	4.5	;	CryoEM structure of E.coli RNA polymerase elongation complex bound to NusG (NusG-EC in more-swiveled conformation)
7PY1	;	3.8	;	CryoEM structure of E.coli RNA polymerase elongation complex bound to NusG (the consensus NusG-EC)
6C6U	;	3.7	;	CryoEM structure of E.coli RNA polymerase elongation complex bound with NusG
6C6S	;	3.7	;	CryoEM structure of E.coli RNA polymerase elongation complex bound with RfaH
6C6T	;	3.5	;	CryoEM structure of E.coli RNA polymerase elongation complex bound with RfaH
6FLQ	;	3.6	;	CryoEM structure of E.coli RNA polymerase paused elongation complex bound to NusA
6FLP	;	4.1	;	CryoEM structure of E.coli RNA polymerase paused elongation complex without RNA hairpin bound to NusA
8FVR	;	2.42	;	CryoEM structure of E.coli transcription elongation complex
8FVW	;	2.1	;	CryoEM structure of E.coli transcription elongation complex bound to ppGpp
6XO4	;	4.2	;	CryoEM structure of Eastern Equine Encephalitis (EEEV) VLP
6XOB	;	8.5	;	CryoEM structure of Eastern Equine Encephalitis (EEEV) VLP with Fab EEEV-143.
7Q4W	;	3.78	;	CryoEM structure of electron bifurcating Fe-Fe hydrogenase HydABC complex A. woodii in the oxidised state
7LQ6	;	3.28	;	CryoEM structure of Escherichia coli PBP1b
6JBQ	;	4.02	;	CryoEM structure of Escherichia coli sigmaE transcription initiation complex containing 5nt of RNA
5ZDH	;	3.2	;	CryoEM structure of ETEC Pilotin-Secretin AspS-GspD complex
8B6Z	;	2.9	;	CryoEM Structure of Extended eEF1A bound to the Ribosome in the Classical Pre State
5NED	;	3.1	;	CryoEM Structure of Foot and Mouth Disease Virus O PanAsia
5NEJ	;	3.1	;	CryoEM Structure of Foot and Mouth Disease Virus O1 Manisa
7VWX	;	7.6	;	CryoEM structure of football-shaped GroEL:ES2 with RuBisCO
7DYS	;	3.18	;	CryoEM structure of full length mouse TRPML2
7UL6	;	3.73	;	CryoEM structure of full-length dimeric ClbP
7MTR	;	3.3	;	CryoEM Structure of Full-Length mGlu2 Bound to Ago-PAM ADX55164 and Glutamate
7MTQ	;	3.65	;	CryoEM Structure of Full-Length mGlu2 in Inactive-State Bound to Antagonist LY341495
6WCZ	;	4.0	;	CryoEM structure of full-length ZIKV NS5-hSTAT2 complex
7E0F	;	3.02	;	CryoEM structure of G51D alpha-synuclein amyloid fibril
6W2Y	;	3.2	;	CryoEM Structure of GABAB1b Homodimer
8VY9	;	2.88	;	CryoEM structure of Ggust-coupled TAS2R14 with cholesterol and an intracellular tastant
8JGG	;	3.0	;	CryoEM structure of Gi-coupled MRGPRX1 with peptide agonist BAM8-22
8JGB	;	2.84	;	CryoEM structure of Gi-coupled MRGPRX1 with peptide agonist CNF-Tx2
7S8M	;	2.54	;	CryoEM structure of Gi-coupled MRGPRX2 with peptide agonist Cortistatin-14
7S8O	;	2.58	;	CryoEM structure of Gi-coupled MRGPRX2 with small molecule agonist (R)-Zinc-3573
8VY7	;	2.68	;	CryoEM structure of Gi-coupled TAS2R14 with cholesterol and an intracellular tastant
6XEV	;	3.5	;	CryoEM structure of GIRK2-PIP2/CHS - G protein-gated inwardly rectifying potassium channel GIRK2 with modulators cholesteryl hemisuccinate and PIP2
6XEU	;	3.2	;	CryoEM structure of GIRK2PIP2* - G protein-gated inwardly rectifying potassium channel GIRK2 with PIP2
8HHO	;	3.2	;	cryoEM structure of glutamate dehydrogenase from Thermococcus profundus in complex with NADP
8HIQ	;	3.2	;	cryoEM structure of glutamate dehydrogenase from Thermococcus profundus in complex with NADP
8HIZ	;	3.08	;	cryoEM structure of glutamate dehydrogenase from Thermococcus profundus in complex with NADP
8HJ3	;	3.29	;	cryoEM structure of glutamate dehydrogenase from Thermococcus profundus in complex with NADP
8HJ9	;	3.12	;	cryoEM structure of glutamate dehydrogenase from Thermococcus profundus in complex with NADP
8OWN	;	3.26	;	CryoEM structure of glutamate dehydrogenase isoform 2 from Arabidopsis thaliana in apo-form
7UM5	;	2.73	;	CryoEM structure of Go-coupled 5-HT5AR in complex with 5-CT
7UM6	;	2.79	;	CryoEM structure of Go-coupled 5-HT5AR in complex with Lisuride
7UM7	;	2.75	;	CryoEM structure of Go-coupled 5-HT5AR in complex with Methylergometrine
8FN1	;	2.88	;	CryoEM structure of Go-coupled NTSR1
8FN0	;	2.89	;	CryoEM structure of Go-coupled NTSR1 with a biased allosteric modulator
7D7D	;	4.5	;	CryoEM structure of gp45-dependent transcription activation complex
7D7C	;	3.6	;	CryoEM structure of gp55-dependent RNA polymerase-promoter open complex
8DWH	;	3.25	;	CryoEM structure of Gq-coupled MRGPRX1 with ligand Compound-16
8DWC	;	2.87	;	CryoEM structure of Gq-coupled MRGPRX1 with peptide agonist BAM8-22
8JGF	;	2.7	;	CryoEM structure of Gq-coupled MRGPRX1 with peptide agonist BAM8-22
8DWG	;	2.71	;	CryoEM structure of Gq-coupled MRGPRX1 with peptide ligand BAM8-22 and positive allosteric modulator ML382
7S8L	;	2.45	;	CryoEM structure of Gq-coupled MRGPRX2 with peptide agonist Cortistatin-14
7S8N	;	2.9	;	CryoEM structure of Gq-coupled MRGPRX2 with small molecule agonist (R)-Zinc-3573
7S8P	;	2.6	;	CryoEM structure of Gq-coupled MRGPRX4 with small molecule agonist MS47134
8BA8	;	3.4	;	CryoEM structure of GroEL-ADP.BeF3-Rubisco.
8BA9	;	3.7	;	CryoEM structure of GroEL-GroES-ADP.AlF3-Rubisco.
8EFP	;	3.8	;	CryoEM structure of GSDMB in complex with shigella IpaH7.8
8ET1	;	4.48	;	CryoEM structure of GSDMB pore without transmembrane beta-barrel
5NI1	;	3.2	;	CryoEM structure of haemoglobin at 3.2 A determined with the Volta phase plate
8DBZ	;	4.1	;	CryoEM structure of Hantavirus ANDV Gn(H) protein complex with 2Fabs ANDV-5 and ANDV-34
3J2V	;	3.5	;	CryoEM structure of HBV core
6NSJ	;	2.7	;	CryoEM structure of Helicobacter pylori urea channel in closed state
6NSK	;	2.7	;	CryoEM structure of Helicobacter pylori urea channel in open state.
8HC1	;	2.3	;	CryoEM structure of Helicobacter pylori UreFD/urease complex
6CGR	;	4.2	;	CryoEM structure of herpes simplex virus 1 capsid with associated tegument protein complexes.
6U8Q	;	4.67	;	CryoEM structure of HIV-1 cleaved synaptic complex (CSC) intasome
6VDK	;	4.5	;	CryoEM structure of HIV-1 conserved Intasome Core
6ALG	;	3.7	;	CryoEM structure of HK022 Nun - E.coli RNA polymerase elongation complex
8ESA	;	3.4	;	CryoEM structure of HLA-A2 bound to MAGEA4 (230-239) peptide
8ESB	;	3.12	;	CryoEM structure of HLA-A2 bound to MAGEA8 (232-241) peptide
8FJA	;	3.0	;	CryoEM structure of HLA-A2 MAGEA4 (230-239) in complex with REGN6972 Fab
8FJB	;	3.06	;	CryoEM structure of HLA-A2 MAGEA4 (286-294) in complex with H2aM31345N Fab
6Z3Y	;	3.51	;	CryoEM structure of horse sodium/proton exchanger NHE9 in an inward-facing conformation
6Z3Z	;	3.19	;	CryoEM structure of horse sodium/proton exchanger NHE9 without C-terminal regulatory domain in an inward-facing conformation
8HNV	;	3.1	;	CryoEM structure of HpaCas9-sgRNA-dsDNA in the presence of AcrIIC4
6VJZ	;	4.3	;	CryoEM structure of Hrd1-Usa1/Der1/Hrd3 complex of the expected topology
6VK0	;	4.1	;	CryoEM structure of Hrd1-Usa1/Der1/Hrd3 of the flipped topology
6VK1	;	3.9	;	CryoEM structure of Hrd1/Hrd3 part from Hrd1-Usa1/Der1/Hrd3 complex
6VK3	;	3.7	;	CryoEM structure of Hrd3/Yos9 complex
7ZR0	;	3.4	;	CryoEM structure of HSP90-CDC37-BRAF(V600E) complex.
7ZR5	;	3.9	;	CryoEM structure of HSP90-CDC37-BRAF(V600E)-PP5(closed) complex
7ZR6	;	4.2	;	CryoEM structure of HSP90-CDC37-BRAF(V600E)-PP5(open) complex
8FWK	;	3.5	;	CryoEM structure of Human ABCB6 Transporter
7WNZ	;	3.4	;	CryoEM structure of human alpha-synuclein A53T fibril
7WO0	;	2.7	;	CryoEM structure of human alpha-synuclein A53T fibril induced by calcium ions
6UR8	;	3.71	;	CryoEM structure of human alpha4beta2 nicotinic acetylcholine receptor in complex with varenicline
6USF	;	3.87	;	CryoEM structure of human alpha4beta2 nicotinic acetylcholine receptor with varenicline in complex with anti-BRIL synthetic antibody BAK5
6UHC	;	3.9	;	CryoEM structure of human Arp2/3 complex with bound NPFs
6XTY	;	6.77	;	CryoEM structure of human CMG bound to AND-1 (CMGA)
6XTX	;	3.29	;	CryoEM structure of human CMG bound to ATPgammaS and DNA
8T9A	;	3.17	;	CryoEM structure of human DDB1-DCAF12 in complex with MAGEA3
7OZI	;	3.73	;	CryoEM structure of human enterovirus 70 A-particle
7OZJ	;	4.29	;	CryoEM structure of human enterovirus 70 empty particle
7OZK	;	2.31	;	CryoEM structure of human enterovirus 70 in complex with Pleconaril
7OZL	;	2.74	;	CryoEM structure of human enterovirus 70 in complex with WIN51711
7OPX	;	2.63	;	CryoEM structure of human enterovirus 70 native virion
6CS4	;	2.73	;	CryoEM structure of human enterovirus D68 A-particle (pH 5.5 and 33 degrees Celsius)
6CS6	;	3.25	;	CryoEM structure of human enterovirus D68 A-particle (pH 5.5 and room temperature)
6CRS	;	3.24	;	CryoEM structure of human enterovirus D68 A-particle (pH 7.2 and 4 degrees Celsius)
6CRP	;	3.24	;	CryoEM structure of human enterovirus D68 abortive product 1 (pH 7.2 and 4 degrees Celsius)
6CS5	;	3.24	;	CryoEM structure of human enterovirus D68 abortive product 2 (pH 7.2 and 4 degrees Celsius)
6CV3	;	3.56	;	CryoEM structure of human enterovirus D68 emptied particle
6CV4	;	3.03	;	CryoEM structure of human enterovirus D68 emptied particle (after incubation with low molecular weight heparin)
6CSH	;	2.9	;	CryoEM structure of human enterovirus D68 emptied particle (pH 5.5 and 33 degrees Celsius)
6CSA	;	3.75	;	CryoEM structure of human enterovirus D68 emptied particle (pH 5.5 and room temperature)
6CRU	;	3.32	;	CryoEM structure of human enterovirus D68 emptied particle (pH 7.2 and 4 degrees Celsius)
6MZI	;	3.46	;	CryoEM structure of human enterovirus D68 expanded 1 particle (pH 6.5, 4 degrees Celsius, 3 min)
6CS3	;	3.31	;	CryoEM structure of human enterovirus D68 expanded 1 particle (pH 7.2 and 4 degrees Celsius)
6CSG	;	2.17	;	CryoEM structure of human enterovirus D68 full native virion
6CRR	;	3.24	;	CryoEM structure of human enterovirus D68 full native virion (pH 7.2 and 4 degrees Celsius)
6CV1	;	2.76	;	CryoEM structure of human enterovirus D68 full particle (after incubation with heparin-derived hexasaccharide)
6CV5	;	2.79	;	CryoEM structure of human enterovirus D68 full particle (after incubation with low molecular weight heparin)
6CV2	;	2.86	;	CryoEM structure of human enterovirus D68 full virion
6CVB	;	2.43	;	CryoEM structure of human enterovirus D68 in complex with 6'-sialyl-N-acetyllactosamine
6HUK	;	3.69	;	CryoEM structure of human full-length alpha1beta3gamma2L GABA(A)R in complex with bicuculline and megabody Mb38.
6HUP	;	3.58	;	CryoEM structure of human full-length alpha1beta3gamma2L GABA(A)R in complex with diazepam (Valium), GABA and megabody Mb38.
6HUG	;	3.1	;	CryoEM structure of human full-length alpha1beta3gamma2L GABA(A)R in complex with picrotoxin and megabody Mb38.
6HUO	;	3.26	;	CryoEM structure of human full-length heteromeric alpha1beta3gamma2L GABA(A)R in complex with alprazolam (Xanax), GABA and megabody Mb38.
6HUJ	;	3.04	;	CryoEM structure of human full-length heteromeric alpha1beta3gamma2L GABA(A)R in complex with picrotoxin, GABA and megabody Mb38.
7D8X	;	2.6	;	CryoEM structure of human gamma-secretase in complex with E2012 and L685458
7W6N	;	3.4	;	CryoEM structure of human KChIP1-Kv4.3 complex
7W6T	;	3.85	;	CryoEM structure of human KChIP1-Kv4.3-DPP6 complex
7W6S	;	2.8	;	CryoEM structure of human KChIP2-Kv4.3 complex
7F0J	;	2.9	;	CryoEM structure of human Kv4.2
7E8B	;	4.2	;	CryoEM structure of human Kv4.2-DPP6S complex
7E89	;	4.0	;	CryoEM structure of human Kv4.2-DPP6S complex, extracellular region
7E8H	;	4.5	;	CryoEM structure of human Kv4.2-DPP6S-KChIP1 complex
7E8G	;	4.5	;	CryoEM structure of human Kv4.2-DPP6S-KChIP1 complex, extracellular region
7E8E	;	3.9	;	CryoEM structure of human Kv4.2-DPP6S-KChIP1 complex, transmembrane and intracellular region
7E84	;	3.1	;	CryoEM structure of human Kv4.2-KChIP1 complex
7F3F	;	3.1	;	CryoEM structure of human Kv4.2-KChIP1 complex
7W3Y	;	3.0	;	CryoEM structure of human Kv4.3
7ULW	;	3.1	;	CryoEM structure of human LACTB filament
7WLI	;	3.3	;	CryoEM structure of human low-voltage activated T-type calcium channel CaV3.3 (apo)
7WLJ	;	3.9	;	CryoEM structure of human low-voltage activated T-type calcium channel Cav3.3 in complex with mibefradil (MIB)
7WLK	;	3.6	;	CryoEM structure of human low-voltage activated T-type calcium channel Cav3.3 in complex with Otilonium Bromide(OB)
7WLL	;	3.6	;	CryoEM structure of human low-voltage activated T-type calcium channel Cav3.3 in complex with pimozide(PMZ)
8D9K	;	3.72	;	CryoEM structure of human METTL1-WDR4 in complex with Lys-tRNA
8EG0	;	3.53	;	CryoEM structure of human METTL1-WDR4 in complex with Lys-tRNA and SAH
8D9L	;	4.04	;	CryoEM structure of human METTL1-WDR4 in complex with Lys-tRNA and SAM
7MXO	;	3.47	;	CryoEM structure of human NKCC1
7N3N	;	3.33	;	CryoEM structure of human NKCC1 state Fu-I
7R1Y	;	3.0	;	cryoEM structure of human Nup155 (residues 19-981)
8D1B	;	3.57	;	CryoEM structure of human orphan GPCR GPR179 in complex with extracellular matrix protein pikachurin
6M1H	;	3.6	;	CryoEM structure of human PAC1 receptor in complex with maxadilan
6M1I	;	3.5	;	CryoEM structure of human PAC1 receptor in complex with PACAP38
8GTR	;	3.91	;	CryoEM structure of human Pannexin isoform 3
8GTS	;	3.87	;	CryoEM structure of human Pannexin1 with R217H congenital mutation.
6T9O	;	3.39	;	CryoEM structure of human polycystin-2/PKD2 in UDM supplemented with PI(3,5)P2
6T9N	;	2.96	;	CryoEM structure of human polycystin-2/PKD2 in UDM supplemented with PI(4,5)P2
6XOU	;	4.0	;	CryoEM structure of human presequence protease in open state
6XOW	;	4.6	;	CryoEM structure of human presequence protease in partial close state 2, induced by presequence of citrate synthase
6XOV	;	3.3	;	CryoEM structure of human presequence protease in partial closed state 1
6XOS	;	3.7	;	CryoEM structure of human presequence protease in partial open state 1
6XOT	;	3.9	;	CryoEM structure of human presequence protease in partial open state 2
7Y5Z	;	3.4	;	CryoEM structure of human PS2-containing gamma-secretase
5NP7	;	4.2	;	CryoEM structure of Human Rad51 on single-stranded DNA to 4.2A resolution.
8OQ6	;	3.21	;	CryoEM structure of human rho1 GABAA receptor apo state
8OP9	;	3.36	;	CryoEM structure of human rho1 GABAA receptor in complex with GABA
8OQA	;	2.9	;	CryoEM structure of human rho1 GABAA receptor in complex with GABA and picrotoxin
8OQ7	;	2.2	;	CryoEM structure of human rho1 GABAA receptor in complex with inhibitor TPMPA
8OQ8	;	2.9	;	CryoEM structure of human rho1 GABAA receptor in complex with pore blocker picrotoxin
8CT1	;	4.8	;	CryoEM structure of human S-OPA1 assembled on lipid membrane in membrane-adjacent state
8CT9	;	6.8	;	CryoEM structure of human S-OPA1 assembled on lipid membrane in membrane-distal state
6CAA	;	3.9	;	CryoEM structure of human SLC4A4 sodium-coupled acid-base transporter NBCe1
8DQL	;	3.0	;	CryoEM structure of IglD
7K1J	;	3.9	;	CryoEM structure of inactivated-form DNA-PK (Complex III)
7K1K	;	4.1	;	CryoEM structure of inactivated-form DNA-PK (Complex IV)
7K1N	;	3.9	;	CryoEM structure of inactivated-form DNA-PK (Complex V)
7K11	;	3.21	;	CryoEM structure of inactivated-form FATKIN domain of DNA-PK
6W2X	;	3.6	;	CryoEM Structure of Inactive GABAB Heterodimer
7UL3	;	3.0	;	CryoEM Structure of Inactive H2R Bound to Famotidine, Nb6M, and NabFab
7UL4	;	2.8	;	CryoEM Structure of Inactive MOR Bound to Alvimopan and Mb6
7UL2	;	2.4	;	CryoEM Structure of Inactive NTSR1 Bound to SR48692 and Nb6
7UL5	;	3.1	;	CryoEM Structure of Inactive SSTR2 bound to Nb6
8DIS	;	2.62	;	CryoEM structure of Influenza A virus A/Melbourne/1/1946 (H1N1) hemagglutinin bound to CR6261 Fab
8DIM	;	2.62	;	CryoEM structure of Influenza A virus A/Ohio/09/2015 hemagglutinin bound to CR6261 Fab
6XGC	;	4.1	;	CryoEM structure of influenza hemagglutinin A/Michigan/45/2015 in complex with cyno antibody 1C4
6WZT	;	4.7	;	CryoEM structure of influenza hemagglutinin A/Victoria/361/2011 in complex with cyno antibody 3B10
8AV6	;	4.68	;	CryoEM structure of INO80 core nucleosome complex in closed grappler conformation
6FHS	;	3.754	;	CryoEM Structure of INO80core
8VC1	;	2.85	;	CryoEM structure of insect gustatory receptor BmGr9
8VC2	;	3.98	;	CryoEM structure of insect gustatory receptor BmGr9 in the presence of fructose
8DK1	;	2.95	;	CryoEM structure of JetABC (head construct) from Pseudomonas aeruginosa PA14
7TIL	;	3.7	;	CryoEM structure of JetD from Pseudomonas aeruginosa
8FEG	;	2.54	;	CryoEM structure of Kappa Opioid Receptor bound to a semi-peptide and Gi1
7RXC	;	3.2	;	CryoEM structure of KDELR with Legobody
7LC3	;	3.23	;	CryoEM Structure of KdpFABC in E1-ATP state
7Y3T	;	3.9	;	CryoEM structure of Klebsiella phage Kp7 icosahedral head
7Y22	;	4.0	;	CryoEM structure of Klebsiella phage Kp7 tail complex applied with C6 symmetry
7Y5S	;	3.0	;	CryoEM structure of Klebsiella phage Kp7 type I tail fiber gp51 in vitro
7XYC	;	3.8	;	CryoEM structure of Klebsiella phage Kp7 type II tail fiber gp52 in vitro
7Y23	;	3.2	;	CryoEM structure of Klebsiella phage Kp9 icosahedral head
7Y1C	;	3.13	;	CryoEM structure of Klebsiella phage Kp9 tail complex applied with C6 symmetry
8HCN	;	2.7	;	CryoEM Structure of Klebsiella pneumoniae UreD/urease complex
7ZVT	;	2.74	;	CryoEM structure of Ku heterodimer bound to DNA
7ZWA	;	2.8	;	CryoEM structure of Ku heterodimer bound to DNA and PAXX
7ZYG	;	2.68	;	CryoEM structure of Ku heterodimer bound to DNA, PAXX and XLF
7UI6	;	3.7	;	CryoEM structure of LARGE1 from C1 reconstruction
7UI7	;	3.4	;	CryoEM structure of LARGE1 from C2 reconstruction
6N4V	;	3.0	;	CryoEM structure of Leviviridae PP7 WT coat protein dimer capsid (PP7PP7-WT)
7KHF	;	3.54	;	CryoEM structure of LILRB1 D3D4 domain-inserted antibody MDB1 Fab in complex with Plasmodium RIFIN (PF3D7_1373400) V2 domain
8ERL	;	3.9	;	CryoEM Structure of Lipoprotein Lipase Dimer
7WUU	;	8.3	;	CryoEM structure of loose sNS1 tetramer
8UGQ	;	3.17	;	CryoEM Structure of Maize Streak Virus (MSV) - Geminivirus
7QUN	;	2.1	;	CryoEM structure of mammalian AAP in complex with Meropenem
7PX8	;	3.27	;	CryoEM structure of mammalian acylaminoacyl-peptidase
7DYR	;	2.28	;	CryoEM Structure of Mannose Transporter ManYZ and Microcin E492 (MceA) complex
7LIH	;	4.4	;	CryoEM structure of Mayaro virus icosahedral subunit
7BKQ	;	3.4	;	CryoEM structure of MDA5-dsRNA filament in complex with ADP with 92-degree helical twist
6ZML	;	3.4	;	CryoEM Structure of Merkel Cell Polyomavirus Virus-like Particle
7S4H	;	2.14	;	CryoEM structure of Methylococcus capsulatus (Bath) pMMO in a native lipid nanodisc at 2.14 Angstrom resolution
7S4J	;	2.16	;	CryoEM structure of Methylococcus capsulatus (Bath) pMMO in a native lipid nanodisc at 2.16 Angstrom resolution
7S4I	;	2.26	;	CryoEM structure of Methylococcus capsulatus (Bath) pMMO in a native lipid nanodisc at 2.26 Angstrom resolution
7S4K	;	2.36	;	CryoEM structure of Methylococcus capsulatus (Bath) pMMO in a native lipid nanodisc at 2.34 Angstrom resolution
7T4P	;	3.62	;	CryoEM structure of Methylococcus capsulatus (Bath) pMMO treated with potassium cyanide and copper in a native lipid nanodisc at 3.62 Angstrom resolution
7T4O	;	3.65	;	CryoEM structure of Methylococcus capsulatus (Bath) pMMO treated with potassium cyanide in a native lipid nanodisc at 3.65 Angstrom resolution
7S4M	;	2.42	;	CryoEM structure of Methylocystis sp. str. Rockwell pMMO in a POPC nanodisc at 2.42 Angstrom resolution
7S4L	;	2.46	;	CryoEM structure of Methylotuvimicrobium alcaliphilum 20Z pMMO in a POPC nanodisc at 2.46 Angstrom resolution
8TAN	;	3.05	;	CryoEM structure of MFRV-VILP bound to IGF1Rzip
7MTS	;	3.2	;	CryoEM Structure of mGlu2 - Gi Complex
6AV9	;	3.9	;	CryoEM structure of Mical Oxidized Actin (Class 1)
6AVB	;	3.9	;	CryoEM structure of Mical Oxidized Actin (Class 1)
8E9X	;	2.7	;	CryoEM structure of miniGo-coupled hM4Di in complex with DCZ
8E9Y	;	2.79	;	CryoEM structure of miniGq-coupled hM3Dq in complex with CNO
8E9W	;	2.69	;	CryoEM structure of miniGq-coupled hM3Dq in complex with DCZ
8E9Z	;	2.69	;	CryoEM structure of miniGq-coupled hM3R in complex with Iperoxo
8EA0	;	2.56	;	CryoEM structure of miniGq-coupled hM3R in complex with iperoxo (local refinement)
7ZM7	;	2.77	;	CryoEM structure of mitochondrial complex I from Chaetomium thermophilum (inhibited by DDM)
7ZM8	;	2.76	;	CryoEM structure of mitochondrial complex I from Chaetomium thermophilum (inhibited by DDM) - membrane arm
7ZMG	;	2.44	;	CryoEM structure of mitochondrial complex I from Chaetomium thermophilum (state 1)
7ZMH	;	2.47	;	CryoEM structure of mitochondrial complex I from Chaetomium thermophilum (state 1) - membrane arm
7ZMB	;	2.75	;	CryoEM structure of mitochondrial complex I from Chaetomium thermophilum (state 2)
7ZME	;	2.83	;	CryoEM structure of mitochondrial complex I from Chaetomium thermophilum (state 2) - membrane arm
6RTK	;	3.47	;	CryoEM structure of modified Turnip Yellows Virus devoid of minor capsid protein readthrough domain
7S6D	;	3.1	;	CryoEM structure of modular PKS holo-Lsd14 bound to antibody fragment 1B2, composite structure
7S6C	;	3.1	;	CryoEM structure of modular PKS holo-Lsd14 stalled at the condensation step and bound to antibody fragment 1B2, composite structure
7MEM	;	3.2	;	CryoEM structure of monoclonal Fab 045-09 2B05 binding the lateral patch of influenza virus H1 HA
6WXR	;	3.2	;	CryoEM structure of mouse DUOX1-DUOXA1 complex in the absence of NADPH
6WXU	;	2.7	;	CryoEM structure of mouse DUOX1-DUOXA1 complex in the dimer-of-dimer state
6WXV	;	3.3	;	CryoEM structure of mouse DUOX1-DUOXA1 complex in the presence of NADPH
6C14	;	4.5	;	CryoEM structure of mouse PCDH15-1EC-LHFPL5 complex
6C13	;	11.33	;	CryoEM structure of mouse PCDH15-4EC-LHFPL5 complex
7T2H	;	3.2	;	CryoEM structure of mu-opioid receptor - Gi protein complex bound to lofentanil (LFT)
7T2G	;	2.5	;	CryoEM structure of mu-opioid receptor - Gi protein complex bound to mitragynine pseudoindoxyl (MP)
6IIC	;	3.3	;	CryoEM structure of Mud Crab Dicistrovirus
6SB5	;	5.0	;	CryoEM structure of murine perforin-2 ectodomain in a pore form
6SB3	;	3.5	;	CryoEM structure of murine perforin-2 ectodomain in a pre-pore form
7BES	;	2.85	;	CryoEM structure of Mycobacterium tuberculosis UMP Kinase (UMPK) in complex with UDP and UTP
6XLY	;	3.1	;	CRYOEM STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS ZINC METALLOPROTEASE ZMP1 IN OPEN STATE
6BNQ	;	5.5	;	CryoEM structure of Myosin VI-Actin complex in the ADP state
6BNW	;	5.5	;	CryoEM structure of Myosin VI-Actin complex in the ADP state, backbone-averaged with side chains truncated to alanine
6BNP	;	4.6	;	CryoEM structure of MyosinVI-actin complex in the rigor (nucleotide-free) state
6BNV	;	4.6	;	CryoEM structure of MyosinVI-actin complex in the rigor (nucleotide-free) state, backbone-averaged with side chains truncated to alanine
8TJ2	;	3.0	;	CryoEM structure of Myxococcus xanthus type IV pilus
6N4Q	;	3.6	;	CryoEM structure of Nav1.7 VSD2 (actived state) in complex with the gating modifier toxin ProTx2
6N4R	;	4.2	;	CryoEM structure of Nav1.7 VSD2 (deactived state) in complex with the gating modifier toxin ProTx2
7MY3	;	2.9	;	CryoEM structure of neutralizing nanobody Nb12 in complex with SARS-CoV2 spike
7MY2	;	2.65	;	CryoEM structure of neutralizing nanobody Nb30 in complex with SARS-CoV2 spike
8CRS	;	2.04	;	CryoEM Structure of nitrogenase MoFe-protein in detergent
7SMP	;	3.28	;	CryoEM structure of NKCC1 Bu-I
8ETR	;	3.5	;	CryoEM Structure of NLRP3 NACHT domain in complex with G2394
7MK2	;	3.8	;	CryoEM Structure of NPR1
8G15	;	2.07	;	CryoEM structure of nuclear GAPDH under 24h Oxidative Stress
8G12	;	2.17	;	CryoEM structure of nuclear GAPDH under 8h Oxidative Stress
8BA7	;	4.4	;	CryoEM structure of nucleotide-free GroEL-Rubisco.
7W88	;	3.5	;	CryoEM structure of open form ZmRDR2 at 3.5 Angstroms resolution
8DBX	;	1.92	;	CryoEM structure of partially oxidized MoFe-protein on ultrathin carbon
7EV9	;	2.6	;	cryoEM structure of particulate methane monooxygenase associated with Cu(I)
8GQY	;	3.4	;	CryoEM structure of pentameric MotA from Aquifex aeolicus
8TU6	;	3.12	;	CryoEM structure of PI3Kalpha
6OLJ	;	7.8	;	CryoEM structure of PilB from Geobacter metallireducens: C2ccocco conformation
6OLM	;	4.4	;	CryoEM structure of PilT4 from Geobacter metallireducens with added ATP: C6cccccc conformation
6OLL	;	4.1	;	CryoEM structure of PilT4 from Geobacter metallireducens without adding nucleotide: C2oocooc conformation
6OLK	;	4.0	;	CryoEM structure of PilT4 from Geobacter metallireducens without adding nucleotide: C3ocococ conformation
7T8T	;	3.68	;	CryoEM structure of PLCg1
8ES9	;	3.25	;	CryoEM structure of PN45428 TCR-CD3 in complex with HLA-A2 MAGEA4
8ES7	;	3.04	;	CryoEM structure of PN45545 TCR-CD3 complex
8ES8	;	2.65	;	CryoEM structure of PN45545 TCR-CD3 in complex with HLA-A2 MAGEA4 (230-239)
1NN8	;	15.0	;	CryoEM structure of poliovirus receptor bound to poliovirus
3EPC	;	8.0	;	CryoEM structure of poliovirus receptor bound to poliovirus type 1
3EPF	;	9.0	;	CryoEM structure of poliovirus receptor bound to poliovirus type 2
3EPD	;	9.0	;	CryoEM structure of poliovirus receptor bound to poliovirus type 3
5MKF	;	4.2	;	cryoEM Structure of Polycystin-2 in complex with calcium and lipids
5MKE	;	4.3	;	cryoEM Structure of Polycystin-2 in complex with cations and lipids
6RD7	;	2.73	;	CryoEM structure of Polytomella F-ATP synthase, c-ring position 1, focussed refinement of Fo and peripheral stalk
6RD8	;	3.08	;	CryoEM structure of Polytomella F-ATP synthase, c-ring position 2, focussed refinement of Fo and peripheral stalk
6RD5	;	2.69	;	CryoEM structure of Polytomella F-ATP synthase, focussed refinement of Fo and peripheral stalk, C2 symmetry
6RD6	;	2.75	;	CryoEM structure of Polytomella F-ATP synthase, focussed refinement of upper peripheral stalk
6RD4	;	2.9	;	CryoEM structure of Polytomella F-ATP synthase, Full dimer, composite map
6RD9	;	3.0	;	CryoEM structure of Polytomella F-ATP synthase, Primary rotary state 1, composite map
6RDB	;	2.8	;	CryoEM structure of Polytomella F-ATP synthase, Primary rotary state 1, focussed refinement of F1 head and rotor
6RDA	;	3.04	;	CryoEM structure of Polytomella F-ATP synthase, Primary rotary state 1, monomer-masked refinement
6RDC	;	3.2	;	CryoEM structure of Polytomella F-ATP synthase, Primary rotary state 2, composite map
6RDE	;	2.9	;	CryoEM structure of Polytomella F-ATP synthase, Primary rotary state 2, focussed refinement of F1 head and rotor
6RDG	;	2.9	;	CryoEM structure of Polytomella F-ATP synthase, Primary rotary state 3, focussed refinement of F1 head and rotor
6RDF	;	3.2	;	CryoEM structure of Polytomella F-ATP synthase, Primary rotary state 3, monomer-masked refinement
6RDH	;	3.0	;	CryoEM structure of Polytomella F-ATP synthase, Rotary substate 1A, composite map
7M05	;	2.39	;	CryoEM structure of PRMT5 bound to covalent PBM-site inhibitor BRD-6988
7Y5T	;	2.9	;	CryoEM structure of PS1-containing gamma-secretase in complex with MRK-560
7Y5X	;	3.0	;	CryoEM structure of PS2-containing gamma-secretase treated with MRK-560
8DK2	;	4.1	;	CryoEM structure of Pseudomonas aeruginosa PA14 JetABC in an unclamped state trapped in ATP dependent dimeric form
8DK3	;	3.28	;	CryoEM structure of Pseudomonas aeruginosa PA14 JetC ATPase domain bound to DNA and cWHD domain of JetA
6U5K	;	3.5	;	CryoEM Structure of Pyocin R2 - postcontracted - baseplate
6U5J	;	3.5	;	CryoEM Structure of Pyocin R2 - postcontracted - collar
6U5B	;	3.5	;	CryoEM Structure of Pyocin R2 - precontracted - baseplate
6U5F	;	3.8	;	CryoEM Structure of Pyocin R2 - precontracted - collar
6U5H	;	4.0	;	CryoEM Structure of Pyocin R2 - precontracted - hub
6PYT	;	2.9	;	CryoEM Structure of Pyocin R2 - precontracted - trunk
7Y58	;	3.8	;	CryoEM structure of QacA (D411N), an antibacterial efflux transporter from Staphylococcus aureus
8BGW	;	2.2	;	CryoEM structure of quinol-dependent Nitric Oxide Reductase (qNOR) from Alcaligenes xylosoxidans at 2.2 A resolution
8SDA	;	3.32	;	CryoEM structure of rat Kv2.1(1-598) L403A mutant in nanodiscs
8SD3	;	2.95	;	CryoEM structure of rat Kv2.1(1-598) wild type in nanodiscs
7RXD	;	3.6	;	CryoEM structure of RBD domain of COVID-19 in complex with Legobody
5OW6	;	4.2	;	CryoEM structure of recombinant CMV particles with Tetanus-epitope
7FDA	;	4.2	;	CryoEM Structure of Reconstituted V-ATPase, state1
8EL7	;	2.8	;	CryoEM structure of Resistance to Inhibitors of Cholinesterase-8B (Ric-8B) in complex with G alpha s
8EL8	;	3.2	;	CryoEM structure of Resistance to Inhibitors of Cholinesterase-8B (Ric-8B) in complex with olfactory G protein alpha olf
5W3M	;	2.26	;	CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:1, full particle)
5W3O	;	3.01	;	CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:3, empty particle)
5W3E	;	2.53	;	CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:3, full particle)
5W3L	;	2.71	;	CryoEM structure of rhinovirus B14 in complex with C5 Fab (4 degrees Celsius, molar ratio 1:3, full particle)
7PKO	;	3.9	;	CryoEM structure of Rotavirus NSP2
6Z1F	;	2.86	;	CryoEM structure of Rubisco Activase with its substrate Rubisco from Nostoc sp. (strain PCC7120)
7X5A	;	3.01	;	CryoEM structure of RuvA-Holliday junction complex
7X7Q	;	7.02	;	CryoEM structure of RuvA-RuvB-Holliday junction complex
7CLR	;	3.5	;	CryoEM structure of S.typhimurium flagellar LP ring
6JY0	;	3.56	;	CryoEM structure of S.typhimurium R-type straight flagellar filament made of FljB (A461V)
8J1Q	;	3.3	;	CryoEM structure of SARS CoV-2 RBD and Aptamer complex
8J26	;	3.4	;	CryoEM structure of SARS CoV-2 RBD and Aptamer complex
7ME7	;	3.73	;	CryoEM structure of SARS-CoV-2 RBD in complex with nanobodies Nb17 and Nb105
7MDW	;	3.58	;	CryoEM structure of SARS-CoV-2 RBD in complex with nanobodies Nb21 and Nb105
7MEJ	;	3.55	;	CryoEM structure of SARS-CoV-2 RBD in complex with nanobodies Nb21 and Nb36
7THT	;	3.42	;	CryoEM structure of SARS-CoV-2 S protein in complex with Receptor Binding Domain antibody DH1042
7N9T	;	3.18	;	CryoEM structure of SARS-CoV-2 Spike in complex with Nb17
7ZBU	;	4.31	;	CryoEM structure of SARS-CoV-2 spike monomer in complex with neutralising antibody P008_60
7N0G	;	3.02	;	CryoEm structure of SARS-CoV-2 spike protein (S-6P, 1-up) in complex with sybodies (Sb45)
7N0H	;	3.34	;	CryoEM structure of SARS-CoV-2 spike protein (S-6P, 2-up) in complex with sybodies (Sb45)
8UCQ	;	3.7	;	CryoEM structure of Sec7 autoinhibited conformation
6LN5	;	2.8	;	CryoEM structure of SERCA2b T1032stop in E1-2Ca2+-AMPPCP (class1)
6LN6	;	2.9	;	CryoEM structure of SERCA2b T1032stop in E1-2Ca2+-AMPPCP (class2)
6LN7	;	2.8	;	CryoEM structure of SERCA2b T1032stop in E1-2Ca2+-AMPPCP (class3)
6LN8	;	3.1	;	CryoEM structure of SERCA2b T1032stop in E2-BeF3- state (class1)
6LN9	;	3.4	;	CryoEM structure of SERCA2b T1032stop in E2-BeF3- state (class2)
6LLE	;	2.9	;	CryoEM structure of SERCA2b WT in E1-2Ca2+-AMPPCP state.
6LLY	;	2.8	;	CryoEM structure of SERCA2b WT in E2-BeF3- state
6SP2	;	3.33	;	CryoEM structure of SERINC from Drosophila melanogaster
7TDM	;	6.9	;	CryoEM Structure of sFab COP-2 Complex with human claudin-4 and Clostridium perfringens enterotoxin C-terminal domain
7TDN	;	5.0	;	CryoEM Structure of sFab COP-3 Complex with human claudin-4 and Clostridium perfringens enterotoxin C-terminal domain
7SLA	;	3.15	;	CryoEM structure of SGLT1 at 3.15 Angstrom resolution
7SL8	;	3.4	;	CryoEM structure of SGLT1 at 3.4 A resolution
6K4Y	;	3.79	;	CryoEM structure of sigma appropriation complex
6OMF	;	3.26	;	CryoEM structure of SigmaS-transcription initiation complex with activator Crl
7PEL	;	3.34	;	CryoEM structure of simian T-cell lymphotropic virus intasome in complex with PP2A regulatory subunit B56 gamma
8T8E	;	3.3	;	cryoEM structure of Smc5/6 5mer
7SL9	;	3.5	;	CryoEM structure of SMCT1
7WUR	;	3.5	;	CryoEM structure of sNS1 complexed with Fab5E3
7WUV	;	8.0	;	CryoEM structure of sNS1 hexamer
7T11	;	2.7	;	CryoEM structure of somatostatin receptor 2 in complex with Octreotide and Gi3.
7T10	;	2.5	;	CryoEM structure of somatostatin receptor 2 in complex with somatostatin-14 and Gi3
7XMS	;	2.9	;	CryoEM structure of somatostatin receptor 4 (SSTR4) in complex with Gi1 and its endogeneous ligand SST-14
7XMT	;	2.8	;	CryoEM structure of somatostatin receptor 4 (SSTR4) with Gi1 and J-2156
8OZE	;	2.91	;	cryoEM structure of SPARTA complex dimer high resolution
8OZD	;	3.89	;	cryoEM structure of SPARTA complex dimer-3
8OZC	;	4.0	;	cryoEM structure of SPARTA complex heterodimer apo
8OZ6	;	3.97	;	cryoEM structure of SPARTA complex ligand-free
8OZI	;	3.22	;	cryoEM structure of SPARTA complex pre-NAD cleavage
8OZG	;	3.37	;	cryoEM structure of SPARTA complex Tetramer Post-NAD cleavage-1
8OZF	;	3.73	;	cryoEM structure of SPARTA complex Tetramer Post-NAD cleavage-2
7YAG	;	3.1	;	CryoEM structure of SPCA1a in E1-Ca-AMPPCP state subclass 1
7YAH	;	3.12	;	CryoEM structure of SPCA1a in E1-Ca-AMPPCP state subclass 2
7YAI	;	3.14	;	CryoEM structure of SPCA1a in E1-Ca-AMPPCP state subclass 3
7YAJ	;	3.16	;	CryoEM structure of SPCA1a in E1-Mn-AMPPCP state subclass 1
7YAM	;	3.3	;	CryoEM structure of SPCA1a in E2P state
7WUT	;	3.5	;	CryoEM structure of stable sNS1 tetramer
7JI0	;	2.95	;	CryoEM structure of Streptococcus thermophilus SHP pheromone receptor Rgg3 in complex with SHP3
8ACB	;	2.6	;	CryoEM structure of sweet potato feathery mottle virus VLP
8ACC	;	2.9	;	CryoEM structure of sweet potato mild mottle virus VLP
6D6V	;	4.8	;	CryoEM structure of Tetrahymena telomerase with telomeric DNA at 4.8 Angstrom resolution
7TAD	;	3.6	;	CryoEM structure of the (NPR1)2-(TGA3)2 complex
8DFC	;	2.48	;	CryoEM structure of the 1:1 ADP-tetrafluoroaluminate stabilized nitrogenase complex from Azotobacter vinelandii
8DFD	;	2.12	;	CryoEM structure of the 2:1 ADP-tetrafluoroaluminate stabilized nitrogenase complex from Azotobacter vinelandii
8DN8	;	3.7	;	CryoEM structure of the A. aeolicus WzmWzt transporter bound to 3-O-methyl-D-mannose
8DOU	;	3.54	;	CryoEM structure of the A. aeolicus WzmWzt transporter bound to ADP
8DKU	;	3.2	;	CryoEM structure of the A. aeolicus WzmWzt transporter bound to the native O antigen
8DNC	;	3.3	;	CryoEM structure of the A. aeolicus WzmWzt transporter bound to the native O antigen and ADP
8DNE	;	3.5	;	CryoEM structure of the A.aeolicus WzmWzt transporter bound to ATP
7OW8	;	3.5	;	CryoEM structure of the ABC transporter BmrA E504A mutant in complex with ATP-Mg
7QBA	;	3.78	;	CryoEM structure of the ABC transporter NosDFY complexed with nitrous oxide reductase NosZ
6UUN	;	3.0	;	CryoEM Structure of the active Adrenomedullin 1 receptor G protein complex with adrenomedullin peptide
6UVA	;	2.3	;	CryoEM Structure of the active Adrenomedullin 2 receptor G protein complex with adrenomedullin 2 peptide
6UUS	;	2.4	;	CryoEM Structure of the active Adrenomedullin 2 receptor G protein complex with adrenomedullin peptide
7T32	;	3.4	;	CryoEM structure of the adenosine 2A receptor-BRIL/Anti BRIL Fab complex with ZM241385
8QLO	;	2.57	;	CryoEM structure of the apo SPARTA (BabAgo/TIR-APAZ) complex
7KNT	;	3.15	;	CryoEM structure of the apo-CGRP receptor in a detergent micelle
6X8T	;	2.9	;	CryoEM structure of the apo-SrpI encapasulin complex from Synechococcus elongatus PCC 7942
6TGB	;	5.5	;	CryoEM structure of the binary DOCK2-ELMO1 complex
6WTS	;	3.3	;	CryoEM structure of the C. sordellii lethal toxin TcsL in complex with SEMA6A
7U5S	;	4.16	;	CryoEM structure of the Candida albicans Aro1 dimer
8A64	;	4.6	;	cryoEM structure of the catalytically inactive EndoS from S. pyogenes in complex with the Fc region of immunoglobulin G1.
7SC0	;	3.4	;	CryoEM structure of the Caveolin-1 8S complex
8B3Q	;	2.58	;	CryoEM structure of the central filamentous region of the f1 filamentous bacteriophage, consisting of the major capsid protein pVIII
7KNU	;	3.49	;	CryoEM structure of the CGRP receptor with bound CGRP peptide in a detergent micelle
8AOV	;	2.48	;	CryoEM structure of the Chikungunya virus nsP1 capping pores in complex with GTP
8AOW	;	2.7	;	CryoEM structure of the Chikungunya virus nsP1 capping pores in complex with m7GTP and SAH ligands
8AOX	;	2.8	;	CryoEM structure of the Chikungunya virus nsP1 capping pores in complex with SAM
8APX	;	3.2	;	CryoEM structure of the Chikungunya virus nsP1 capping pores in covalent complex with a 7GMP cap structure
6Z0U	;	2.9	;	CryoEM structure of the Chikungunya virus nsP1 complex
6Z0V	;	2.6	;	CryoEM structure of the Chikungunya virus nsP1 complex
6RKW	;	6.6	;	CryoEM structure of the complete E. coli DNA Gyrase complex bound to a 130 bp DNA duplex
7T0V	;	3.67	;	CryoEM structure of the crosslinked Rix7 AAA-ATPase
5U3C	;	4.6	;	CryoEM structure of the CTP synthase filament at 4.6 Angstrom resolution
8EKI	;	4.5	;	CryoEM structure of the Dsl1 complex bound to SNAREs Sec20 and Use1
7QSR	;	3.4	;	CryoEM structure of the Ectodomain of Human PLA2R
5V6P	;	4.1	;	CryoEM structure of the ERAD-associated E3 ubiquitin-protein ligase HRD1
5K0U	;	2.79	;	CryoEM structure of the full virion of a human rhinovirus C
6WHC	;	3.4	;	CryoEM Structure of the glucagon receptor with a dual-agonist peptide
8ET2	;	4.96	;	CryoEM structure of the GSDMB pore
7T4Q	;	2.9	;	CryoEM structure of the HCMV Pentamer gH/gL/UL128/UL130/UL131A in complex with neutralizing fabs 2C12, 7I13 and 13H11
7T4S	;	3.1	;	CryoEM structure of the HCMV Pentamer gH/gL/UL128/UL130/UL131A in complex with NRP2 and neutralizing fabs 8I21 and 13H11
7T4R	;	3.3	;	CryoEM structure of the HCMV Pentamer gH/gL/UL128/UL130/UL131A in complex with THBD and neutralizing fabs MSL-109 and 13H11
7LBF	;	2.8	;	CryoEM structure of the HCMV Trimer gHgLgO in complex with human Platelet-derived growth factor receptor alpha and neutralizing fabs 13H11 and MSL-109
7LBG	;	2.6	;	CryoEM structure of the HCMV Trimer gHgLgO in complex with human Transforming growth factor beta receptor type 3 and neutralizing fabs 13H11 and MSL-109
7LBE	;	2.9	;	CryoEM structure of the HCMV Trimer gHgLgO in complex with neutralizing fabs 13H11 and MSL-109
5UOT	;	4.6	;	CryoEM structure of the helical assembly of full length MxB
8ENM	;	2.14	;	CryoEM structure of the high pH nitrogenase MoFe-protein under non-turnover conditions
8ENL	;	2.37	;	CryoEM structure of the high pH turnover-inactivated nitrogenase MoFe-protein
8T7T	;	3.2	;	CryoEM structure of the HisRS-like domain of human GCN2
8X5X	;	3.5	;	CryoEM structure of the histamine H1 receptor in apo-form
8X5Y	;	3.0	;	CryoEM structure of the histamine H1 receptor-BRIL/Anti BRIL Fab complex with astemizole
8X64	;	3.4	;	CryoEM structure of the histamine H1 receptor-BRIL/Anti BRIL Fab complex with desloratadine
8X63	;	3.2	;	CryoEM structure of the histamine H1 receptor-BRIL/Anti BRIL Fab complex with mepyramine
6X8M	;	2.2	;	CryoEM structure of the holo-SrpI encapsulin complex from Synechococcus elongatus PCC 7942
7TQL	;	3.2	;	CryoEM structure of the human 40S small ribosomal subunit in complex with translation initiation factors eIF1A and eIF5B.
6QVC	;	4.0	;	CryoEM structure of the human ClC-1 chloride channel, CBS state 1
6QVD	;	4.34	;	CryoEM structure of the human ClC-1 chloride channel, CBS state 2
6QVB	;	4.34	;	CryoEM structure of the human ClC-1 chloride channel, CBS state 3
6QVU	;	4.2	;	CryoEM structure of the human ClC-1 chloride channel, low pH
6QV6	;	3.63	;	CryoEM structure of the human ClC-1 chloride channel, membrane domain
7E87	;	3.4	;	CryoEM structure of the human Kv4.2-DPP6S complex, transmembrane and intracellular region
7E83	;	3.1	;	CryoEM structure of the human Kv4.2-KChIP1 complex, intracellular region
7E7Z	;	3.2	;	CryoEM structure of the human Kv4.2-KChIP1 complex, transmembrane region
8AS5	;	3.53	;	CryoEM structure of the human Nucleophosmin 1 core
5K47	;	4.22	;	CryoEM structure of the human Polycystin-2/PKD2 TRP channel
5T2C	;	3.6	;	CryoEM structure of the human ribosome at 3.6 Angstrom resolution
7NJ0	;	3.6	;	CryoEM structure of the human Separase-Cdk1-cyclin B1-Cks1 complex
7NJ1	;	2.9	;	CryoEM structure of the human Separase-Securin complex
7B4L	;	3.1	;	CryoEM structure of the human sodium proton exchanger NHA2
7B4M	;	7.2	;	CryoEM structure of the human sodium proton exchanger NHA2 in nanodisc
6Z1G	;	8.2	;	CryoEM structure of the interaction between Rubisco Activase small-subunit-like (SSUL) domain with Rubisco from Nostoc sp. (strain PCC7120)
6NMC	;	4.24	;	CryoEM structure of the LbCas12a-crRNA-2xAcrVA1 complex
6NMA	;	3.38	;	CryoEM structure of the LbCas12a-crRNA-AcrVA4 complex
6NM9	;	3.38	;	CryoEM structure of the LbCas12a-crRNA-AcrVA4 dimer
6OMV	;	3.9	;	CryoEM structure of the LbCas12a-crRNA-AcrVA4-DNA complex
5T2A	;	2.9	;	CryoEM structure of the Leishmania donovani 80S ribosome at 2.9 Angstrom resolution
7NGA	;	3.9	;	CryoEM structure of the MDA5-dsRNA filament in complex with ADP with 88-degree helical twist
6GKH	;	4.06	;	CryoEM structure of the MDA5-dsRNA filament in complex with ADP-AlF4
6GJZ	;	4.06	;	CryoEM structure of the MDA5-dsRNA filament in complex with AMPPNP
6GKM	;	3.87	;	CryoEM structure of the MDA5-dsRNA filament in complex with ATP (10 mM)
6G19	;	3.68	;	CryoEM structure of the MDA5-dsRNA filament with 74-degree helical twist
6G1S	;	3.93	;	CryoEM structure of the MDA5-dsRNA filament with 87-degree helical twist
6H61	;	4.02	;	CryoEM structure of the MDA5-dsRNA filament with 89 degree twist and without nucleotide
6G1X	;	3.93	;	CryoEM structure of the MDA5-dsRNA filament with 91-degree helical twist
6H66	;	4.16	;	CryoEM structure of the MDA5-dsRNA filament with 93 degree twist and without nucleotide
5LY6	;	4.5	;	CryoEM structure of the membrane pore complex of Pneumolysin at 4.5A
8CW4	;	3.0	;	CryoEM structure of the N-pilus from Escherichia coli
7SWL	;	2.88	;	CryoEM structure of the N-terminal-deleted Rix7 AAA-ATPase
5JZG	;	3.16	;	CryoEM structure of the native empty particle of a human rhinovirus C
7NT5	;	3.5	;	CryoEM structure of the Nipah virus nucleocapsid single helical turn assembly
7NT6	;	4.3	;	CryoEM structure of the Nipah virus nucleocapsid spiral clam-shaped assembly
8DL0	;	4.1	;	CryoEM structure of the nucleotide-free and open channel A.aeolicus WzmWzt transporter
7OFH	;	2.7	;	CryoEM structure of the outer membrane secretin pore pIV from the f1 filamentous bacteriophage.
7U1E	;	4.52	;	CryoEM structure of the pancreatic ATP-sensitive potassium channel bound to ATP with Kir6.2-CTD in the down conformation
7UAA	;	5.7	;	CryoEM structure of the pancreatic ATP-sensitive potassium channel in the ATP-bound state with Kir6.2-CTD in the up conformation
6VQR	;	2.78	;	CryoEM Structure of the PfFNT-inhibitor complex
8RFH	;	3.9	;	CryoEM structure of the plant helper NLR NRC2 in its resting state
6X87	;	3.2	;	CryoEM structure of the Plasmodium berghei circumsporozoite protein in complex with inhibitory mouse antibody 3D11.
6VQQ	;	2.56	;	CryoEM Structure of the Plasmodium falciparum transporter PfFNT
8B3O	;	2.97	;	CryoEM structure of the pointy tip (proteins pIII/pVI/pVIII) from the f1 filamentous bacteriophage
8BR2	;	2.9	;	CryoEM structure of the post-synaptic RAD51 nucleoprotein filament in the presence of ATP and Ca2+
8BQ2	;	3.8	;	CryoEM structure of the pre-synaptic RAD51 nucleoprotein filament in the presence of ATP and Ca2+
6PK7	;	3.1	;	cryoEM structure of the product-bound human CTP synthase 2 filament
8BSC	;	3.6	;	CryoEM structure of the RAD51 nucleoprotein filament in the presence of ADP and Ca2+
8GYK	;	3.14	;	CryoEM structure of the RAD51_ADP filament
6XZC	;	3.37	;	CryoEM structure of the ring-shaped virulence factor EspB from Mycobacterium tuberculosis
7T3I	;	4.3	;	CryoEM structure of the Rix7 D2 Walker B mutant
8QLP	;	3.14	;	CryoEM structure of the RNA/DNA bound SPARTA (BabAgo/TIR-APAZ) tetrameric complex
8B3P	;	2.81	;	CryoEM structure of the round tip (proteins pVII/pVIII/pIX) from the f1 filamentous bacteriophage
7WCH	;	3.19	;	CryoEM structure of the SARS-CoV-2 S6P(B.1.617.2) in complex with SWA9 Fab
7WCP	;	3.01	;	CryoEM structure of the SARS-CoV-2 S6P(B.1.617.2) in complex with SWC11 Fab
6ND1	;	4.1	;	CryoEM structure of the Sec Complex from yeast
5W7V	;	3.8	;	CryoEM structure of the segment, DLIIKGISVHI, assembled into a triple-helical fibril
6WJ3	;	3.9	;	CryoEM structure of the SLC38A9-RagA-RagC-Ragulator complex in the post-GAP state
6WJ2	;	3.2	;	CryoEM structure of the SLC38A9-RagA-RagC-Ragulator complex in the pre-GAP state
7QCD	;	8.0	;	CryoEM structure of the Smc5/6-holocomplex (composite structure)
7XMR	;	3.1	;	CryoEM structure of the somatostatin receptor 2 (SSTR2) in complex with Gi1 and its endogeneous peptide ligand SST-14
6PK4	;	3.5	;	cryoEM structure of the substrate-bound human CTP synthase 2 filament
7AX3	;	3.74	;	CryoEM structure of the super-constricted two-start dynamin 1 filament
8CUE	;	3.2	;	CryoEM structure of the T-pilus from Agrobacterium tumefaciens
6TGC	;	4.1	;	CryoEM structure of the ternary DOCK2-ELMO1-RAC1 complex.
7UXU	;	2.74	;	CryoEM structure of the TIR domain from AbTir in complex with 3AD
7OQH	;	3.32	;	CryoEM structure of the transcription termination factor Rho from Mycobacterium tuberculosis
6NIL	;	3.9	;	cryoEM structure of the truncated HIV-1 Vif/CBFbeta/A3F complex
6XXD	;	3.22	;	CryoEM structure of the type IV pilin PilA4 from Thermus thermophilus
6XXE	;	3.49	;	CryoEM structure of the type IV pilin PilA5 from Thermus thermophilus
7T6D	;	3.9	;	CryoEM structure of the YejM/LapB complex
5VRF	;	4.1	;	CryoEM Structure of the Zinc Transporter YiiP from helical crystals
6M6C	;	3.1	;	CryoEM structure of Thermus thermophilus RNA polymerase elongation complex
5WQ9	;	4.22	;	CryoEM structure of type II secretion system secretin GspD G453A mutant in Vibrio cholerae
5WQ7	;	3.04	;	CryoEM structure of type II secretion system secretin GspD in E.coli K12
5WQ8	;	3.26	;	CryoEM structure of type II secretion system secretin GspD in Vibrio cholerae
7Y80	;	2.71	;	CryoEM structure of type III-E CRISPR Craspase gRAMP-crRNA binary complex
7Y81	;	2.54	;	CryoEM structure of type III-E CRISPR Craspase gRAMP-crRNA complex bound to non-self RNA target
7Y82	;	2.83	;	CryoEM structure of type III-E CRISPR Craspase gRAMP-crRNA complex bound to self RNA target
7Y84	;	2.61	;	CryoEM structure of type III-E CRISPR Craspase gRAMP-crRNA in complex with TPR-CHAT protease
7Y83	;	2.93	;	CryoEM structure of type III-E CRISPR Craspase gRAMP-crRNA in complex with TPR-CHAT protease bound to non-self RNA target
7Y85	;	2.73	;	CryoEM structure of type III-E CRISPR Craspase gRAMP-crRNA in complex with TPR-CHAT protease bound to self RNA target
7XG3	;	3.0	;	CryoEM structure of type IV-A CasDinG bound NTS-nicked Csf-crRNA-dsDNA quaternary complex
7XG4	;	3.7	;	CryoEM structure of type IV-A CasDinG bound NTS-nicked Csf-crRNA-dsDNA quaternary complex in a second state
7XG1	;	3.3	;	CryoEM structure of type IV-A Csf-crRNA binary complex
7XG0	;	2.6	;	CryoEM structure of type IV-A Csf-crRNA-dsDNA ternary complex
7XFZ	;	3.0	;	CryoEM structure of type IV-A Csf-crRNAsp14-dsDNA ternary complex
7XG2	;	2.8	;	CryoEM structure of type IV-A NTS-nicked dsDNA bound Csf-crRNA ternary complex
6UVN	;	3.1	;	CryoEM structure of VcCascasde-TniQ complex
7SFU	;	4.2	;	CryoEM structure of Venezuelan Equine Encephalitis virus (VEEV) TC-83 strain VLP
7SFV	;	4.0	;	CryoEM structure of Venezuelan Equine Encephalitis virus (VEEV) TC-83 strain VLP in complex with Fab hVEEV-63
7SFW	;	3.2	;	CryoEM structure of Venezuelan Equine Encephalitis virus (VEEV) TC-83 strain VLP in complex with Fab hVEEV-63 (focus refine of the asymmetric unit)
7N1I	;	4.2	;	CryoEM structure of Venezuelan equine encephalitis virus VLP
7N1H	;	4.3	;	CryoEM structure of Venezuelan equine encephalitis virus VLP in complex with the LDLRAD3 receptor
7RZY	;	3.5	;	CryoEM structure of Vibrio cholerae transposon Tn6677 AAA+ ATPase TnsC
8SAL	;	4.9	;	CryoEM structure of VRC01-CH848.0358.80
8SAV	;	4.0	;	CryoEM structure of VRC01-CH848.0526.25
8SAN	;	4.6	;	CryoEM structure of VRC01-CH848.0836.10
8SAT	;	4.5	;	CryoEM structure of VRC01-CH848.10.17
8DAQ	;	4.35	;	CryoEM structure of Western equine encephalitis virus VLP
8DAN	;	4.74	;	CryoEM structure of Western equine encephalitis virus VLP in complex with the avian MXRA8 receptor
8EWF	;	3.92	;	CryoEM structure of Western equine encephalitis virus VLP in complex with the avian MXRA8 receptor
8SQN	;	3.89	;	CryoEM structure of Western equine encephalitis virus VLP in complex with the chimeric Du-D1-Mo-D2 MXRA8 receptor
8R6F	;	2.34	;	CryoEM structure of wheat 40S ribosomal subunit, body domain
8R57	;	2.55	;	CryoEM structure of wheat 40S ribosomal subunit, head domain
8G17	;	1.98	;	CryoEM structure of wild-type GAPDH
5VMS	;	3.7	;	CryoEM structure of Xenopus KCNQ1 channel
6WOO	;	2.9	;	CryoEM structure of yeast 80S ribosome with Met-tRNAiMet, eIF5B, and GDP
8E3S	;	3.1	;	CryoEM structure of yeast Arginyltransferase 1 (ATE1)
8FZR	;	3.6	;	CryoEM structure of yeast Arginyltransferase 1 (ATE1)
6PDT	;	3.8	;	cryoEM structure of yeast glucokinase filament
8G3G	;	3.5	;	CryoEM structure of yeast recombination mediator Rad52
7KUE	;	3.5	;	CryoEM structure of Yeast TFIIK (Kin28/Ccl1/Tfb3) Complex
6PLV	;	3.3	;	CryoEM structure of zebra fish alpha-1 glycine receptor bound with GABA in nanodisc, closed state
6PLU	;	3.3	;	CryoEM structure of zebra fish alpha-1 glycine receptor bound with GABA in nanodisc, desensitized state
6PLZ	;	3.0	;	CryoEM structure of zebra fish alpha-1 glycine receptor bound with GABA in SMA, closed state
6PLX	;	2.9	;	CryoEM structure of zebra fish alpha-1 glycine receptor bound with GABA in SMA, desensitized state
6PLY	;	2.9	;	CryoEM structure of zebra fish alpha-1 glycine receptor bound with GABA in SMA, open state
6PLW	;	3.0	;	CryoEM structure of zebra fish alpha-1 glycine receptor bound with GABA in SMA, super-open state
6PLR	;	3.2	;	CryoEM structure of zebra fish alpha-1 glycine receptor bound with glycine in nanodisc, desensitized state
6PM5	;	3.1	;	CryoEM structure of zebra fish alpha-1 glycine receptor bound with Glycine in SMA, desensitized state
6PM6	;	2.9	;	CryoEM structure of zebra fish alpha-1 glycine receptor bound with Glycine in SMA, open state
6PM4	;	4.0	;	CryoEM structure of zebra fish alpha-1 glycine receptor bound with Glycine in SMA, super-open state
6PLT	;	3.2	;	CryoEM structure of zebra fish alpha-1 glycine receptor bound with taurine in nanodisc, closed state
6PLS	;	3.0	;	CryoEM structure of zebra fish alpha-1 glycine receptor bound with taurine in nanodisc, desensitized state
6PM3	;	3.0	;	CryoEM structure of zebra fish alpha-1 glycine receptor bound with Taurine in SMA, closed state
6PM1	;	3.0	;	CryoEM structure of zebra fish alpha-1 glycine receptor bound with Taurine in SMA, desensitized state
6PM2	;	3.0	;	CryoEM structure of zebra fish alpha-1 glycine receptor bound with Taurine in SMA, open state
6PM0	;	3.1	;	CryoEM structure of zebra fish alpha-1 glycine receptor bound with Taurine in SMA, super-open state
6PLP	;	3.3	;	CryoEM structure of zebra fish alpha-1 glycine receptor YGF mutant bound with GABA in SMA, desensitized state
6PLQ	;	3.4	;	CryoEM structure of zebra fish alpha-1 glycine receptor YGF mutant bound with GABA in SMA, super-open state
6PLO	;	3.3	;	CryoEM structure of zebra fish alpha-1 glycine receptor YGF mutant bound with GABA in SMA,open state
6PXD	;	2.9	;	CryoEM structure of zebra fish alpha-1 glycine receptor, Apo state
7CBP	;	4.1	;	CryoEM structure of Zika virus with Fab at 4.1 Angstrom
5UPW	;	5.0	;	CryoEM Structure Refinement by Integrating NMR Chemical Shifts with Molecular Dynamics Simulations
8CYT	;	3.0	;	CryoEM structures of amplified alpha-synuclein fibril class A type I with extended core from DLB case I
8CYV	;	3.5	;	CryoEM structures of amplified alpha-synuclein fibril class B mixed type I/II with extended core from DLB case II
8CYW	;	3.1	;	CryoEM structures of amplified alpha-synuclein fibril class B type I with compact core from DLB case III
8CYS	;	3.1	;	CryoEM structures of amplified alpha-synuclein fibril class B type II with extended core from DLB case I
8E34	;	6.0	;	CryoEM structures of bAE1 captured in multiple states
8D9N	;	4.4	;	CryoEM structures of bAE1 captured in multiple states.
8EEQ	;	6.3	;	CryoEM structures of bAE1 captured in multiple states.
7FDE	;	3.8	;	CryoEM Structures of Reconstituted V-ATPase, Oxr1 bound V1
7FDC	;	6.6	;	CryoEM Structures of Reconstituted V-ATPase, state3
7FDB	;	4.8	;	CryoEM Structures of Reconstituted V-ATPase,State2
8FTE	;	3.8	;	CryoEM strucutre of 22-mer RBM2 of the Salmonella MS-ring
8FTF	;	2.9	;	CryoEM strucutre of 33-mer RBM3 of the Salmonella MS-ring
7YAT	;	2.2	;	CryoEM tetra protofilament structure of the hamster prion 108-144 fibril
6U02	;	3.05	;	CryoEM-derived model of NA-63 Fab in complex with N9 Shanghai2
7S8Y	;	1.59	;	Cryogenic apo Human Hsp90a-NTD
7MRX	;	2.29	;	Cryogenic crystal structure of barnase A43C/S80C bound to barstar C40A/C82A
6PQK	;	1.2	;	Cryogenic crystal structure of barnase A43C/S80C bound to barstar C40A/S59C/A67C/C82A
1CXP	;	1.8	;	CRYOGENIC CRYSTAL STRUCTURE OF HUMAN MYELOPEROXIDASE ISOFORM C
2OEO	;	2.0	;	Cryogenic crystal structure of Staphylococcal Nuclease variant truncated Delta+PHS I92D
1TQO	;	2.0	;	Cryogenic Crystal Structure of Staphylococcal Nuclease Variant truncated Delta+PHS I92E
1TT2	;	1.85	;	Cryogenic crystal structure of Staphylococcal nuclease variant truncated Delta+PHS I92K
8QFE	;	1.5	;	Cryogenic crystal structure of the Photoactivated Adenylate Cyclase OaPAC
8QFG	;	1.7	;	Cryogenic crystal structure of the Photoactivated Adenylate Cyclase OaPAC after 5 seconds of blue light illumination
8QFF	;	2.1	;	Cryogenic crystal structure of the Photoactivated Adenylate Cyclase OaPAC with ATP bound
2OF1	;	1.92	;	Cryogenic crystal structure of the Staphylococcal Nuclease variant truncated Delta+PHS I92W
7UXF	;	2.7	;	Cryogenic electron microscopy 3D map of F-actin
7UTJ	;	2.77	;	Cryogenic electron microscopy 3D map of F-actin bound by human dimeric alpha-catenin
7UUW	;	3.36	;	Cryogenic electron microscopy 3D map of F-actin bound by the Actin Binding Domain of alpha-catenin ortholog, HMP1
7KTT	;	4.17	;	Cryogenic electron microscopy model of full-length human metavinculin
7KTV	;	4.5	;	Cryogenic electron microscopy model of full-length human metavinculin H1' kinked conformation
7KTU	;	4.15	;	Cryogenic electron microscopy model of full-length human metavinculin H1'-parallel conformation 1
7KTW	;	4.27	;	Cryogenic electron microscopy model of full-length human metavinculin H1'-parallel conformation 2
6YX9	;	2.404	;	Cryogenic human adiponectin receptor 2 (ADIPOR2) at 2.4 A resolution determined by Serial Crystallography (SSX) using CrystalDirect
6YXF	;	3.025	;	Cryogenic human adiponectin receptor 2 (ADIPOR2) with Gd-DO3 ligand determined by Serial Crystallography (SSX) using CrystalDirect
6YXG	;	3.01	;	Cryogenic human adiponectin receptor 2 (ADIPOR2) with Tb-XO4 ligand determined by Serial Crystallography (SSX) using CrystalDirect
6YXH	;	2.6	;	Cryogenic human alkaline ceramidase 3 (ACER3) at 2.6 A resolution determined by Serial Crystallography (SSX) using CrystalDirect
7S90	;	1.79	;	Cryogenic Human Hsp90a-NTD bound to adenine
7S9F	;	2.3	;	Cryogenic Human Hsp90a-NTD bound to BIIB021
7S9H	;	1.45	;	Cryogenic Human Hsp90a-NTD bound to EC144
7S98	;	1.9	;	Cryogenic Human Hsp90a-NTD bound to N6M
3K0M	;	1.25	;	Cryogenic structure of CypA
3K0R	;	2.424	;	Cryogenic structure of CypA mutant Arg55Lys
3K0P	;	1.649	;	Cryogenic structure of CypA mutant Ser99Thr
3K0Q	;	2.317	;	Cryogenic structure of CypA mutant Ser99Thr (2)
1BU7	;	1.65	;	CRYOGENIC STRUCTURE OF CYTOCHROME P450BM-3 HEME DOMAIN
6JCF	;	2.153	;	Cryogenic structure of HIV-1 Integrase catalytic core domain by synchrotron
5CP4	;	1.75	;	CRYOGENIC STRUCTURE OF P450CAM
3QOJ	;	1.6	;	Cryogenic structure of Staphylococcal nuclease variant D+PHS/V23K
8IVK	;	1.5	;	Cryogenic temperature crystal structure of Escherichia coli CyaY
8IWI	;	1.3	;	Cryogenic Temperature Crystal Structure of Escherichia coli CyaY protein at pH 5
6QQI	;	1.7	;	Cryogenic temperature structure of blue light-irradiated AtPhot2LOV2 recorded after an accumulated dose of 24 kGy
6QSA	;	1.7	;	Cryogenic temperature structure of blue light-irradiated AtPhot2LOV2 recorded after an accumulated dose of 48 kGy
6QQD	;	1.92	;	Cryogenic temperature structure of Hen Egg White Lysozyme recorded after an accumulated dose of 10 MGy
6QQC	;	1.42	;	Cryogenic temperature structure of Hen Egg White Lysozyme recorded after an accumulated dose of 110 kGy
6QQ8	;	1.46	;	Cryogenic temperature structure of the fluorescent protein Cerulean recorded after an accumulated dose of 290 kGy
6QQ9	;	1.82	;	Cryogenic temperature structure of the fluorescent protein Cerulean recorded after an accumulated dose of 5.8 MGy
6QQH	;	1.38	;	Cryogenic temperature structure of the ground state of AtPhot2LOV2 recorded after an accumulated dose of 2.68 MGy
4KJJ	;	1.15	;	Cryogenic WT DHFR
4P3R	;	1.15	;	Cryogenic WT DHFR, time-averaged ensemble
1OT6	;	0.95	;	CRYOTRAPPED CRYSTAL STRUCTURE OF THE E46Q MUTANT OF PHOTOACTIVE YELLOW PROTEIN UNDER CONTINUOUS ILLUMINATION AT 110K
1OT9	;	1.0	;	CRYOTRAPPED STATE IN WILD TYPE PHOTOACTIVE YELLOW PROTEIN, INDUCED WITH CONTINUOUS ILLUMINATION AT 110K
7DFW	;	2.69	;	Cryo_EM structure of delta N-NPC1L1-CLR
7DFZ	;	3.58	;	Cryo_EM structure of delta N-NPC1L1-EZE
5FOR	;	2.5	;	Cryptic TIR
2J4D	;	1.9	;	Cryptochrome 3 from Arabidopsis thaliana
3ZXS	;	2.7	;	Cryptochrome B from Rhodobacter sphaeroides
5V4L	;	2.1	;	Cryptococcus neoformans adenylosuccinate lyase
7LVP	;	2.24	;	Cryptococcus neoformans AIR synthetase
7LVO	;	2.0	;	Cryptococcus neoformans GAR synthetase
7K9R	;	1.95	;	Cryptococcus neoformans Hsp90 nucleotide binding domain
7K9U	;	1.92	;	Cryptococcus neoformans Hsp90 nucleotide binding domain in complex with BUCMD00429
7K9V	;	1.91	;	Cryptococcus neoformans Hsp90 nucleotide binding domain in complex with BUCMD00452
7K9W	;	2.13	;	Cryptococcus neoformans Hsp90 nucleotide binding domain in complex with BUCMD00461
7K9S	;	3.21	;	Cryptococcus neoformans Hsp90 nucleotide binding domain in complex with NVP-AUY922
7T0A	;	2.099	;	Cryptococcus neoformans protein farnesyltransferase co-crystallized with FPP and inhibitor 2f
3Q79	;	2.506	;	Cryptococcus neoformans protein farnesyltransferase in complex with farnesyl-DDPTASACNIQ product
3Q7F	;	2.2	;	Cryptococcus neoformans protein farnesyltransferase in complex with FPP and ethylenediamine inhibitor 1
7T0E	;	2.223	;	Cryptococcus neoformans protein farnesyltransferase in complex with FPP and inhibitor 2b
7T09	;	1.984	;	Cryptococcus neoformans protein farnesyltransferase in complex with FPP and inhibitor 2d
7T0C	;	1.903	;	Cryptococcus neoformans protein farnesyltransferase in complex with FPP and inhibitor 2e
7T0B	;	2.026	;	Cryptococcus neoformans protein farnesyltransferase in complex with FPP and inhibitor 2g
7T0D	;	1.906	;	Cryptococcus neoformans protein farnesyltransferase in complex with FPP and inhibitor 2k
7T08	;	1.803	;	Cryptococcus neoformans protein farnesyltransferase in complex with FPP and inhibitor 2q
3Q7A	;	2.0	;	Cryptococcus neoformans protein farnesyltransferase in complex with FPP and L-778,123
3SFY	;	2.1	;	Cryptococcus neoformans protein farnesyltransferase in complex with FPT-II and ethylenediamine inhibitor 2
3SFX	;	2.0	;	Cryptococcus neoformans protein farnesyltransferase in complex with FPT-II and tipifarnib
3Q75	;	2.14	;	Cryptococcus neoformans protein farnesyltransferase in complex with FPT-II and TKCVVM peptide
8T70	;	1.892	;	Cryptococcus neoformans protein farnesyltransferase in complex with FPTII and TKCMIIM peptide
3Q78	;	2.2	;	Cryptococcus neoformans protein farnesyltransferase in complex with FSPP and DDPTASACNIQ peptide
3Q73	;	2.3	;	Cryptococcus neoformans protein farnesyltransferase, apo enzyme
2AAZ	;	2.08	;	Cryptococcus neoformans thymidylate synthase complexed with substrate and an antifolate
2QG5	;	2.3	;	Cryptosporidium parvum calcium dependent protein kinase cgd7_1840
3NIZ	;	2.4	;	Cryptosporidium parvum cyclin-dependent kinase cgd5_2510 with ADP bound.
2QKR	;	2.6	;	Cryptosporidium parvum cyclin-dependent kinase cgd5_2510 with indirubin 3'-monoxime bound
2POY	;	1.8	;	Cryptosporidium parvum cyclophilin type peptidyl-prolyl cis-trans isomerase cgd2_4120 in complex with cyclosporin A
2O1O	;	2.42	;	Cryptosporidium parvum putative polyprenyl pyrophosphate synthase (cgd4_2550) in complex with risedronate.
2Q58	;	2.37	;	Cryptosporidium parvum putative polyprenyl pyrophosphate synthase (cgd4_2550) in complex with zoledronate
6P0Y	;	2.6	;	Cryptosporidium parvum pyruvate kinase in complex with ADP
3TD7	;	2.21	;	Crysal structure of the mimivirus sulfhydryl oxidase R596
3K8V	;	2.1	;	Crysatl structure of a bacterial cell-surface flagellin N20C20
3K8W	;	1.7	;	Crysatl structure of a bacterial cell-surface flagellin N20C45
3B8G	;	2.6	;	Crysta structure of N-acetylglutamate synthase from Neisseria gonorrhoeae complexed with coenzyme A and N-acetyl-glutamate
5Y9W	;	1.847	;	Crystal 1 for AtLURE1.2-AtPRK6LRR
5YAH	;	2.104	;	Crystal 2 for AtLURE1.2-AtPRK6LRR
2BJK	;	1.4	;	Crystal Analysis of 1-Pyrroline-5-Carboxylate Dehydrogenase from Thermus with bound NAD and citrate.
2EHU	;	1.8	;	Crystal analysis of 1-pyrroline-5-carboxylate dehydrogenase from thermus with bound NAD and Inhibitor L-serine
2BHP	;	1.8	;	Crystal Analysis of 1-Pyrroline-5-Carboxylate Dehydrogenase from Thermus with bound NAD.
2BJA	;	1.9	;	Crystal Analysis of 1-Pyrroline-5-Carboxylate Dehydrogenase from Thermus with bound NADH
2EHQ	;	1.55	;	Crystal analysis of 1-pyrroline-5-carboxylate dehydrogenase from thermus with bound NADP
2BHQ	;	1.4	;	Crystal Analysis of 1-Pyrroline-5-Carboxylate Dehydrogenase from Thermus with bound product glutamate.
1UFY	;	0.96	;	Crystal analysis of chorismate mutase from thermus thermophilus
1UI9	;	1.65	;	Crystal analysis of chorismate mutase from thermus thermophilus
1ODE	;	1.65	;	Crystal Analysis Of Chorismate Mutase From Thermus Thermophilus.
2EJ6	;	2.06	;	Crystal analysis of delta1-pyrroline-5-carboxylate dehydrogenase from Thermus thermophilus with bound D-proline
2EJD	;	1.85	;	Crystal analysis of delta1-pyrroline-5-carboxylate dehydrogenase from Thermus thermophilus with bound L-alanine
2EIT	;	1.65	;	Crystal analysis of delta1-pyrroline-5-carboxylate dehydrogenase from Thermus thermophilus with bound L-alanine and NAD
2EIW	;	1.9	;	Crystal analysis of delta1-pyrroline-5-carboxylate dehydrogenase from Thermus thermophilus with bound L-proline
2EJL	;	1.5	;	Crystal analysis of delta1-pyrroline-5-carboxylate dehydrogenase from Thermus thermophilus with bound L-serine
2EII	;	1.88	;	Crystal analysis of delta1-pyrroline-5-carboxylate dehydrogenase from Thermus thermophilus with bound L-valine and NAD.
1V9C	;	2.2	;	Crystal Analysis of Precorrin-8x Methyl Mutase from Thermus Thermophilus
3QHN	;	1.99	;	Crystal analysis of the complex structure, E201A-cellotetraose, of endocellulase from pyrococcus horikoshii
3QHM	;	2.01	;	Crystal analysis of the complex structure, E342A-cellotetraose, of endocellulase from pyrococcus horikoshii
3QHO	;	1.65	;	Crystal analysis of the complex structure, Y299F-cellotetraose, of endocellulase from pyrococcus horikoshii
3CSQ	;	1.8	;	Crystal and cryoEM structural studies of a cell wall degrading enzyme in the bacteriophage phi29 tail
3CSR	;	1.8	;	Crystal and cryoEM structural studies of a cell wall degrading enzyme in the bacteriophage phi29 tail
3CSZ	;	1.8	;	Crystal and cryoEM structural studies of a cell wall degrading enzyme in the bacteriophage phi29 tail
3CT0	;	1.77	;	Crystal and cryoEM structural studies of a cell wall degrading enzyme in the bacteriophage phi29 tail
3CT1	;	1.51	;	Crystal and cryoEM structural studies of a cell wall degrading enzyme in the bacteriophage phi29 tail
3CT5	;	1.37	;	Crystal and cryoEM structural studies of a cell wall degrading enzyme in the bacteriophage phi29 tail
2AYH	;	1.6	;	CRYSTAL AND MOLECULAR STRUCTURE AT 1.6 ANGSTROMS RESOLUTION OF THE HYBRID BACILLUS ENDO-1,3-1,4-BETA-D-GLUCAN 4-GLUCANOHYDROLASE H(A16-M)
1CAG	;	1.85	;	CRYSTAL AND MOLECULAR STRUCTURE OF A COLLAGEN-LIKE PEPTIDE AT 1.9 ANGSTROM RESOLUTION
1D24	;	1.9	;	CRYSTAL AND MOLECULAR STRUCTURE OF A DNA DUPLEX CONTAINING THE CARCINOGENIC LESION O6-METHYLGUANINE
1D76	;	1.3	;	CRYSTAL AND MOLECULAR STRUCTURE OF A DNA FRAGMENT CONTAINING A 2-AMINO ADENINE MODIFICATION: THE RELATIONSHIP BETWEEN CONFORMATION, PACKING, AND HYDRATION IN Z-DNA HEXAMERS
1D28	;	2.7	;	CRYSTAL AND MOLECULAR STRUCTURE OF A DNA FRAGMENT: D(CGTGAATTCACG)
210D	;	1.35	;	CRYSTAL AND MOLECULAR STRUCTURE OF A NEW Z-DNA CRYSTAL FORM: D[CGT(2-NH2-A)CG] AND ITS PLATINATED DERIVATIVE
1AMY	;	2.8	;	CRYSTAL AND MOLECULAR STRUCTURE OF BARLEY ALPHA-AMYLASE
1TYT	;	2.6	;	CRYSTAL AND MOLECULAR STRUCTURE OF CRITHIDIA FASCICULATA TRYPANOTHIONE REDUCTASE AT 2.6 ANGSTROMS RESOLUTION
119D	;	2.25	;	CRYSTAL AND MOLECULAR STRUCTURE OF D(CGTAGATCTACG) AT 2.25 ANGSTROMS RESOLUTION
1D82	;	2.5	;	CRYSTAL AND MOLECULAR STRUCTURE OF D(GTCTAGAC)
118D	;	1.64	;	CRYSTAL AND MOLECULAR STRUCTURE OF D(GTGCGCAC): INVESTIGATION OF THE EFFECTS OF BASE SEQUENCE ON THE CONFORMATION OF OCTAMER DUPLEXES
1AVH	;	2.3	;	CRYSTAL AND MOLECULAR STRUCTURE OF HUMAN ANNEXIN V AFTER REFINEMENT. IMPLICATIONS FOR STRUCTURE, MEMBRANE BINDING AND ION CHANNEL FORMATION OF THE ANNEXIN FAMILY OF PROTEINS
1AVR	;	2.3	;	CRYSTAL AND MOLECULAR STRUCTURE OF HUMAN ANNEXIN V AFTER REFINEMENT. IMPLICATIONS FOR STRUCTURE, MEMBRANE BINDING AND ION CHANNEL FORMATION OF THE ANNEXIN FAMILY OF PROTEINS
1PK4	;	1.9	;	CRYSTAL AND MOLECULAR STRUCTURE OF HUMAN PLASMINOGEN KRINGLE 4 REFINED AT 1.9-ANGSTROMS RESOLUTION
157D	;	1.8	;	CRYSTAL AND MOLECULAR STRUCTURE OF R(CGCGAAUUAGCG): AN RNA DUPLEX CONTAINING TWO G(ANTI).A(ANTI) BASE-PAIRS
116D	;	2.5	;	CRYSTAL AND MOLECULAR STRUCTURE OF THE A-DNA DODECAMER D(CCGTACGTACGG): CHOICE OF FRAGMENT HELICAL AXIS
117D	;	2.55	;	CRYSTAL AND MOLECULAR STRUCTURE OF THE ALTERNATING DODECAMER D(GCGTACGTACGC) IN THE A-DNA FORM: COMPARISON WITH THE ISOMORPHOUS NON-ALTERNATING DODECAMER D(CCGTACGTACGG)
1ACB	;	2.0	;	CRYSTAL AND MOLECULAR STRUCTURE OF THE BOVINE ALPHA-CHYMOTRYPSIN-EGLIN C COMPLEX AT 2.0 ANGSTROMS RESOLUTION
2CI2	;	2.0	;	CRYSTAL AND MOLECULAR STRUCTURE OF THE SERINE PROTEINASE INHIBITOR CI-2 FROM BARLEY SEEDS
1HTR	;	1.62	;	CRYSTAL AND MOLECULAR STRUCTURES OF HUMAN PROGASTRICSIN AT 1.62 ANGSTROMS RESOLUTION
2ATC	;	3.0	;	CRYSTAL AND MOLECULAR STRUCTURES OF NATIVE AND CTP-LIGANDED ASPARTATE CARBAMOYLTRANSFERASE FROM ESCHERICHIA COLI
1CHO	;	1.8	;	CRYSTAL AND MOLECULAR STRUCTURES OF THE COMPLEX OF ALPHA-*CHYMOTRYPSIN WITH ITS INHIBITOR TURKEY OVOMUCOID THIRD DOMAIN AT 1.8 ANGSTROMS RESOLUTION
4LRS	;	1.55	;	Crystal and solution structures of the bifunctional enzyme (Aldolase/Aldehyde dehydrogenase) from Thermomonospora curvata, reveal a cofactor-binding domain motion during NAD+ and CoA accommodation whithin the shared cofactor-binding site
4LRT	;	1.5	;	Crystal and solution structures of the bifunctional enzyme (Aldolase/Aldehyde dehydrogenase) from Thermomonospora curvata, reveal a cofactor-binding domain motion during NAD+ and CoA accommodation whithin the shared cofactor-binding site
295D	;	1.5	;	CRYSTAL AND SOLUTION STRUCTURES OF THE OLIGONUCLEOTIDE D(ATGCGCAT)2: A COMBINED X-RAY AND NMR STUDY
1IHO	;	1.7	;	CRYSTAL APO-STRUCTURE OF PANTOTHENATE SYNTHETASE FROM E. COLI
2CMY	;	2.25	;	Crystal complex between bovine trypsin and Veronica hederifolia trypsin inhibitor
6BL3	;	2.217	;	Crystal Complex of Cyclooxygenase-2 with indomethacin-butyldiamine-dansyl conjugate
6BL4	;	2.22	;	Crystal Complex of Cyclooxygenase-2 with indomethacin-ethylenediamine-dansyl conjugate
5W58	;	2.267	;	Crystal Complex of Cyclooxygenase-2: (S)-ARN-2508 (a dual COX and FAAH inhibitor)
6LQY	;	1.598	;	Crystal complex of endo-deglycosylated hydroxynitrile lyase isozyme 5 of Prunus communis with benzaldehyde
7BWP	;	1.802	;	Crystal complex of endo-deglycosylated PcHNL5 with (R)-mandelonitrile
8ET0	;	2.15	;	Crystal Complex of murine Cyclooxygenase-2 with alpaca nanobody F9
3L4T	;	1.9	;	Crystal complex of N-terminal Human Maltase-Glucoamylase with BJ2661
3CTT	;	2.1	;	Crystal complex of N-terminal Human Maltase-Glucoamylase with Casuarine
3L4U	;	1.9	;	Crystal complex of N-terminal Human Maltase-Glucoamylase with de-O-sulfonated kotalanol
3L4V	;	2.1	;	Crystal complex of N-terminal Human Maltase-Glucoamylase with kotalanol
3L4W	;	2.0	;	Crystal complex of N-terminal Human Maltase-Glucoamylase with miglitol
3L4X	;	1.9	;	Crystal complex of N-terminal Human Maltase-Glucoamylase with NR4-8
3L4Y	;	1.8	;	Crystal complex of N-terminal Human Maltase-Glucoamylase with NR4-8II
3L4Z	;	2.0	;	Crystal complex of N-terminal Human Maltase-Glucoamylase with Salacinol
3LPP	;	2.15	;	Crystal complex of N-terminal sucrase-isomaltase with kotalanol
7EAX	;	2.55	;	Crystal complex of p53-V272M and antimony ion
4MQV	;	1.95	;	Crystal complex of Rpa32c and Smarcal1 N-terminus
3C2G	;	2.5	;	Crystal complex of SYS-1/POP-1 at 2.5A resolution
1QA7	;	1.9	;	CRYSTAL COMPLEX OF THE 3C PROTEINASE FROM HEPATITIS A VIRUS WITH ITS INHIBITOR AND IMPLICATIONS FOR THE POLYPROTEIN PROCESSING IN HAV
4R51	;	1.81	;	Crystal complex structure of sp-Aspartate-Semialdehyde-Dehydrogenase with Nicotinamide Adenine dinucleotide phosphate and phthalic acid
3HMS	;	1.7	;	Crystal Crystal structure of the N-terminal fragment (28-126) of the human hepatocyte growth factor/scatter factor, orthorhombic crystal form
6H9S	;	1.9	;	Crystal dimeric structure of Petrotoga mobilis lactate dehydrogenase with NADH
7CGS	;	1.6	;	Crystal endo-deglycosylated hydroxynitrile lyase isozyme 5 mutant L343F from Prunus communis
8G4G	;	2.17	;	Crystal Engineering with One 8-mer DNA
6FTP	;	1.8	;	Crystal form 1 of Alpha1-antichymotrypsin variant DBS-II-allo: an allosterically modulated drug-binding serpin for doxorubicin
7YCW	;	2.2	;	Crystal Form 1 of Truncated Antitoxin ParD (2-54,containg RHH domain) from Pseudoalteromonas rubra
5OM8	;	2.2	;	Crystal form 2 of Alpha1-antichymotrypsin variant DBS-II-allo: an allosterically modulated drug-binding serpin for doxorubicin
6UER	;	2.5	;	Crystal form 2: Structure of TBP bound to C-C mismatch at pH 7
7PJO	;	2.248	;	Crystal form 3 of CPR-C4: a cysteine protease from the Candidate Phyla Radiation
2R6D	;	3.7	;	Crystal Form B1
2R6E	;	5.019	;	Crystal Form B2
2R6A	;	2.9	;	Crystal Form BH1
2R6C	;	4.0	;	Crystal Form BH2
2FKC	;	2.39	;	Crystal Form I of Pre-Reactive Complex of Restriction Endonuclease HinP1I with Cognate DNA and Calcium Ion
4ANC	;	2.8	;	CRYSTAL FORM I OF THE D93N MUTANT OF NUCLEOSIDE DIPHOSPHATE KINASE FROM MYCOBACTERIUM TUBERCULOSIS
5EAZ	;	2.151	;	crystal form I of YfiB belonging to space groups P21
1M3J	;	3.0	;	CRYSTAL form II of perfringolysin O
2FKH	;	3.09	;	Crystal Form II of Pre-Reactive Complex of Restriction Endonuclease HinP1I with Cognate DNA and Calcium Ions
4AND	;	2.808	;	CRYSTAL FORM II OF THE D93N MUTANT OF NUCLEOSIDE DIPHOSPHATE KINASE FROM MYCOBACTERIUM TUBERCULOSIS
5EB0	;	2.8	;	crystal form II of YfiB belonging to P41
2DQU	;	1.7	;	Crystal form II: high resolution crystal structure of the complex of the hydrolytic antibody Fab 6D9 and a transition-state analog
1BDN	;	2.6	;	CRYSTAL LATTICE PACKING IS IMPORTANT IN DETERMINING THE BEND OF A DNA DODECAMER CONTAINING AN ADENINE TRACT
5H9K	;	1.352	;	Crystal of a leukotriene-binding salivary lipocalin
5DXZ	;	2.25	;	Crystal of AmtR from Corynebacterium glutamicum
5DY0	;	3.0	;	Crystal of AmtR from Corynebacterium glutamicum in complex with DNA
7DF9	;	3.17	;	Crystal of Arrestin2-V2Rpp-1-Fab30 complex
7DFC	;	2.49	;	Crystal of Arrestin2-V2Rpp-3-Fab30 complex
7DFA	;	2.54	;	Crystal of Arrestin2-V2Rpp-4-Fab30 complex
7DFB	;	3.28	;	Crystal of Arrestin2-V2Rpp-6-7-Fab30 complex
3HGL	;	1.9	;	crystal of AvrPtoB 121-205
7RXT	;	1.68	;	Crystal of BRD4(D1) with 2-[(3R)-3-{5-[2-(3,5-dimethylphenoxy)pyrimidin-4-yl]-4-(4-iodophenyl)-1H-imidazol-1-yl}pyrrolidin-1-yl]ethan-1-amine
7RXS	;	1.43	;	Crystal of BRD4(D1) with 2-[(3S)-3-{5-[2-(3,5-dimethylphenoxy)pyrimidin-4-yl]-4-(4-iodophenyl)-1H-imidazol-1-yl}pyrrolidin-1-yl]ethan-1-amine
3GMZ	;	1.43	;	Crystal of human arginase in complex with L-ornithine. Resolution 1.43 A.
4Y33	;	2.7	;	Crystal of NO66 in complex with Ni(II)and N-oxalylglycine (NOG)
4MLN	;	2.1	;	Crystal of PhnZ bound to (R)-2-amino-1-hydroxyethylphosphonic acid
3VGJ	;	2.212	;	Crystal of Plasmodium falciparum tyrosyl-tRNA synthetase (PfTyrRS)in complex with adenylate analog
3RZ2	;	2.8	;	Crystal of Prl-1 complexed with peptide
5WSC	;	2.4	;	Crystal of pyruvate kinase (PYK) from Mycobacterium tuberculosis in complex with Oxalate, soaked with allosteric activators AMP and Glucose 6-Phosphate
8HBS	;	1.78	;	Crystal of rAlfNmt
3ZJ6	;	2.4	;	Crystal of Raucaffricine Glucosidase in complex with inhibitor
5DY1	;	2.651	;	Crystal of Selenomethionine substituted AmtR from Corynebacterium glutamicum
2H14	;	1.48	;	Crystal of WDR5 (apo-form)
2QMT	;	1.05	;	Crystal Polymorphism of Protein GB1 Examined by Solid-state NMR and X-ray Diffraction
2NVW	;	2.1	;	Crystal sctucture of transcriptional regulator Gal80p from kluyveromymes lactis
2PVG	;	2.4	;	Crystal srtucture of the binary complex between ferredoxin and ferredoxin:thioredoxin reductase
2PU9	;	1.65	;	Crystal srtucture of the binary complex between ferredoxin: thioredoxin reductase and thioredoxin f
2PUO	;	1.7	;	Crystal srtucture of the NEM modified ferredoxin:thioredoxin reductase
2PVD	;	1.95	;	Crystal srtucture of the reduced ferredoxin:thioredoxin reductase
2PVO	;	3.4	;	Crystal srtucture of the ternary complex between thioredoxin f, ferredoxin, and ferredoxin: thioredoxin reductase
6LST	;	2.94	;	Crystal straucture of Uso1-1
3K1I	;	2.7	;	Crystal strcture of FliS-HP1076 complex in H. pylori
3GUS	;	1.53	;	Crystal strcture of human Pi class glutathione S-transferase GSTP1-1 in complex with 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX)
2OKN	;	2.45	;	Crystal Strcture of Human Prolidase
6A9U	;	2.4	;	Crystal strcture of Icp55 from Saccharomyces cerevisiae bound to apstatin inhibitor
4MUE	;	2.06	;	Crystal strcture of pantothenate synthetase in complex with 2-(5-methoxy-2-(4-(trifluoromethyl)phenylsulfonylcarbamoyl)-1H-indol-1-yl)acetic acid
7FCN	;	1.6	;	Crystal strcture of PirA insecticidal protein from Photorhabdus akhurstii
3VIR	;	2.7	;	Crystal strcture of Swi5 from fission yeast
4XSL	;	1.6	;	Crystal strcutre of D-tagatose 3-epimerase C66S from Pseudomonas cichorii in complex with glycerol
8I4N	;	2.41	;	Crystal strcuture of 6-phosphogluconate dehydrogenase from Corynebacterium glutamicum
7CZ3	;	2.9	;	Crystal strcuture of Acyl-CoA thioesterase from Bacillus cereus ATCC 14579
2I5G	;	2.6	;	Crystal strcuture of amidohydrolase from Pseudomonas aeruginosa
6L3P	;	2.5	;	Crystal strcuture of Feruloyl-CoA hydratase lyase(FCHL) complexed with CoA
6L3O	;	1.65	;	Crystal strcuture of Feruloyl-CoA hydratase lyase(FCHL) from Pseudomonas putida KT2440
7CYX	;	2.41	;	Crystal strcuture of Glycine oxidase from Bacillus cereus ATCC 14579
6KUQ	;	1.91	;	Crystal strcuture of PETase A248D, R280K mutant from Ideonella sakaiensis
6KUO	;	1.9	;	Crystal strcuture of PETase N246D mutant from Ideonella sakaiensis
6KUS	;	1.8	;	Crystal strcuture of PETase S121E, D186H, S242T, N246D mutant from Ideonella sakaiensis
7VSP	;	2.1	;	Crystal strcuture of the tandem B-Box domains of COL2
7VSQ	;	2.7	;	Crystal strcuture of the tandem B-Box domains of CONSTANS
3N12	;	1.2	;	Crystal stricture of chitinase in complex with zinc atoms from Bacillus cereus NCTU2
3N13	;	1.7	;	Crystal stricture of D143A chitinase in complex with NAG from Bacillus cereus NCTU2
3N1A	;	2.0	;	Crystal stricture of E145G/Y227F chitinase in complex with cyclo-(L-His-L-Pro) from Bacillus cereus NCTU2
3N18	;	1.6	;	Crystal stricture of E145G/Y227F chitinase in complex with NAG from Bacillus cereus NCTU2
3N15	;	1.94	;	Crystal stricture of E145Q chitinase in complex with NAG from Bacillus cereus NCTU2
3N17	;	1.2	;	Crystal stricture of E145Q/Y227F chitinase in complex with NAG from Bacillus cereus NCTU2
3N11	;	1.35	;	Crystal stricture of wild-type chitinase from Bacillus cereus NCTU2
3RIR	;	2.6	;	Crystal Strucrture of Biotin Protein Ligase from S. aureus
4PZK	;	1.5	;	Crystal strucrure of putative RNA methyltransferase from Bacillus anthracis.
5OKZ	;	3.20004	;	Crystal Strucrure of the Mpp6 Exosome complex
7XRF	;	2.137	;	Crystal structaure of DgpB/C complex
5JBM	;	3.0	;	Crystal structgure of Cac1 C-terminus
4OIC	;	1.999	;	Crystal structrual of a soluble protein
3S4E	;	1.26	;	Crystal Structrue of a Novel Mitogen-activated Protein Kinase Phosphatase, SKRP1
2PEZ	;	1.4	;	Crystal structrue of deletion mutant of APS-kinase domain of human PAPS-synthetase 1 in complex with cyclic PAPS and dADP
5HOE	;	1.45	;	Crystal structrue of Est24, a carbohydrate acetylesterase from Sinorhizobium meliloti
1XWO	;	2.8	;	crystal structrue of goose delta crystallin
5D43	;	2.82	;	crystal structrue of Mouse centrin 1 in calcium-saturated form
5B77	;	1.551	;	Crystal structrue of MOZ double PHD finger in complex with histone H3 propionylation at K14
8HL8	;	2.5	;	Crystal structrue of MtdL R257K mutant
7XPS	;	2.1	;	Crystal structrue of MtdL:GDP:Mn
7XPT	;	2.0	;	Crystal structrue of MtdL:GDP:Mn soaked with GDP-Glc
6T9B	;	1.46	;	Crystal structrue of RSL W31A lectin mutant in complex with alpha-methylfucoside
6T9A	;	2.0	;	Crystal structrue of RSL W31FW76F lectin mutant in complex with L-fucose
6T99	;	2.7	;	Crystal structrue of RSL W31YW76Y lectin mutant in complex with alpha-methylfucoside
7XPR	;	2.1	;	Crystal structrue of SeMet-MtdL:GDP
5YT1	;	2.0	;	Crystal structrure of near infrared fluoresecent protein mNeptune684
3A1V	;	2.4	;	Crystal structue of the cytosolic domain of T. maritima FeoB iron iransporter in apo form
3A1S	;	1.5	;	Crystal structue of the cytosolic domain of T. maritima FeoB iron iransporter in GDP form I
3A1T	;	1.8	;	Crystal structue of the cytosolic domain of T. maritima FeoB iron iransporter in GDP form II
3A1U	;	1.8	;	Crystal structue of the cytosolic domain of T. maritima FeoB iron iransporter in GMPPNP form
3A1W	;	1.9001	;	Crystal structue of the G domain of T. maritima FeoB iron iransporter
1SL3	;	1.81	;	crystal structue of Thrombin in complex with a potent P1 heterocycle-Aryl based inhibitor
4L1W	;	2.2	;	Crystal Structuer of Human 3-alpha Hydroxysteroid Dehydrogenase Type 3 in Complex with NADP+ and Progesterone
4L1X	;	2.0	;	Crystal Structuer of Human 3-alpha Hydroxysteroid Dehydrogenase Type 3 V54L Mutant in Complex with NADP+ and Progesterone
1W2I	;	1.5	;	Crystal structuore of acylphosphatase from Pyrococcus horikoshii complexed with formate
3KM8	;	2.0	;	Crystal structuore of adenosine deaminase from mus musculus complexed with 9-deazainosine
4Z85	;	1.7	;	Crystal structur of Pseudomonas fluorescens 2-nitrobenzoate 2-nitroreductase NbaA
4MG3	;	1.798	;	Crystal Structural Analysis of 2A Protease from Coxsackievirus A16
1SS9	;	2.6	;	Crystal Structural Analysis of Active Site Mutant Q189E of LgtC
2ZA4	;	1.58	;	Crystal Structural Analysis of Barnase-barstar Complex
3ECY	;	1.88	;	Crystal structural analysis of Drosophila melanogaster dUTPase
3A4K	;	2.17	;	Crystal structural analysis of HindIII restriction endonuclease in complex with cognate DNA and divalent cations at 2.17 angstrom resolution
2E52	;	2.0	;	Crystal structural analysis of HindIII restriction endonuclease in complex with cognate DNA at 2.0 angstrom resolution
1BSA	;	2.0	;	CRYSTAL STRUCTURAL ANALYSIS OF MUTATIONS IN THE HYDROPHOBIC CORES OF BARNASE
1BSB	;	2.0	;	CRYSTAL STRUCTURAL ANALYSIS OF MUTATIONS IN THE HYDROPHOBIC CORES OF BARNASE
1BSC	;	2.0	;	CRYSTAL STRUCTURAL ANALYSIS OF MUTATIONS IN THE HYDROPHOBIC CORES OF BARNASE
1BSD	;	2.3	;	CRYSTAL STRUCTURAL ANALYSIS OF MUTATIONS IN THE HYDROPHOBIC CORES OF BARNASE
1BSE	;	2.0	;	CRYSTAL STRUCTURAL ANALYSIS OF MUTATIONS IN THE HYDROPHOBIC CORES OF BARNASE
8JJ7	;	1.769	;	Crystal structural analysis of PaL
1EJJ	;	1.9	;	CRYSTAL STRUCTURAL ANALYSIS OF PHOSPHOGLYCERATE MUTASE COCRYSTALLIZED WITH 3-PHOSPHOGLYCERATE
7BPD	;	2.04	;	Crystal structural analysis of Swine dUTPase
3DUW	;	1.2	;	Crystal Structural Analysis of the O-methyltransferase from Bacillus cereus in complex SAH
1TNV	;	5.0	;	CRYSTAL STRUCTURAL ANALYSIS OF TOBACCO NECROSIS VIRUS (TNV) AT 5 ANGSTROMS RESOLUTION
2GX0	;	1.9	;	Crystal structural and functional analysis of GFP-like fluorescent protein
2GX2	;	1.8	;	Crystal structural and functional analysis of GFP-like fluorescent protein Dronpa
4WZF	;	1.699	;	Crystal structural basis for Rv0315, an immunostimulatory antigen and pseudo beta-1, 3-glucanase of Mycobacterium tuberculosis
6KY0	;	2.06	;	Crystal structural of active-site human glutathione-specific gamma-glutamylcyclotransferase 2(ChaC2) mutant with Glutamate 74 replaced by Glutamine
3I3C	;	2.48	;	Crystal Structural of CBX5 Chromo Shadow Domain
3D3I	;	1.78	;	Crystal structural of Escherichia coli K12 YgjK, a glucosidase belonging to glycoside hydrolase family 63
6AKP	;	2.323	;	Crystal Structural of FOXC2 DNA binding domain bound to PC promoter
6K95	;	2.29	;	Crystal structural of human glutathione-specific gamma-glutamylcyclotransferase 2 (ChaC2)
6KY1	;	2.04	;	Crystal structural of human glutathione-specific gamma-glutamylcyclotransferase 2 (ChaC2)mutant with Glutamate 83 replaced by Glutamine
5VIA	;	1.764	;	Crystal structural of Leishmania major pseudoperoxidase
6LH4	;	1.999	;	Crystal structural of MacroD1-ADPr complex
7XG9	;	1.5	;	Crystal structural of methylenetetrahydrofolate reductase from Sphingobium sp. SYK-6
2ZJG	;	3.0	;	Crystal structural of mouse kynurenine aminotransferase III
3PDX	;	2.91	;	Crystal structural of mouse tyrosine aminotransferase
3N9H	;	2.5	;	Crystal Structural of mutant Y305A in the copper amine oxidase from hansenula polymorpha
3BZL	;	1.71	;	Crystal structural of native EscU C-terminal domain
3BZO	;	1.5	;	Crystal structural of native EscU C-terminal domain
3C01	;	2.6	;	Crystal structural of native SpaS C-terminal domain
3ULX	;	2.6	;	Crystal structural of the conserved domain of Rice Stress-responsive NAC1
5IL0	;	1.882	;	Crystal structural of the METTL3-METTL14 complex for N6-adenosine methylation
3C00	;	1.41	;	Crystal structural of the mutated G247T EscU/SpaS C-terminal domain
3BZP	;	1.499	;	Crystal structural of the mutated N262A EscU C-terminal domain
3BZT	;	1.5	;	Crystal structural of the mutated P263A EscU C-terminal domain
3BZZ	;	1.407	;	Crystal structural of the mutated R313T EscU/SpaS C-terminal domain
3BZV	;	1.94	;	Crystal structural of the mutated T264A EscU C-terminal domain
5EJC	;	3.1	;	Crystal structural of the TSC1-TBC1D7 complex
4EUK	;	1.95	;	Crystal structure
4LX8	;	2.2	;	Crystal structure (2.2A) of Mg2+ bound CheY3 of Vibrio cholerae
1RU9	;	2.5	;	Crystal Structure (A) of u.v.-irradiated cationic cyclization antibody 4C6 Fab at pH 4.6 with a data set collected in-house.
1RUA	;	1.75	;	Crystal structure (B) of u.v.-irradiated cationic cyclization antibody 4C6 fab at pH 4.6 with a data set collected at SSRL beamline 11-1.
1RUK	;	1.4	;	Crystal structure (C) of native cationic cyclization antibody 4C6 fab at pH 4.6 with a data set collected at SSRL beamline 9-1
6UB4	;	1.6	;	Crystal structure (C2 form) of a GH128 (subgroup IV) endo-beta-1,3-glucanase from Lentinula edodes (LeGH128_IV) in complex with laminaritriose
1RUL	;	1.88	;	Crystal Structure (D) of u.v.-irradiated cationic cyclization antibody 4C6 Fab at pH 5.6 with a data set collected at SSRL beamline 11-1.
1RUM	;	1.48	;	Crystal structure (F) of H2O2-soaked cationic cyclization antibody 4C6 fab at pH 8.5 with a data set collected at SSRL beamline 9-1.
5XAK	;	1.5	;	Crystal structure (form II) of thymidylate kinase from Thermus thermophilus HB8
1RUP	;	1.4	;	Crystal structure (G) of native cationic cyclization antibody 4C6 fab at pH 8.5 with a data set collected at APS beamline 19-ID
1RUQ	;	1.86	;	Crystal Structure (H) of u.v.-irradiated Diels-Alder antibody 13G5 Fab at pH 8.0 with a data set collected in house.
1RUR	;	1.5	;	Crystal Structure (I) of native Diels-Alder antibody 13G5 Fab at pH 8.0 with a data set collected at SSRL beamline 9-1.
2ANN	;	2.3	;	Crystal structure (I) of Nova-1 KH1/KH2 domain tandem with 25 nt RNA hairpin
2ANR	;	1.94	;	Crystal structure (II) of Nova-1 KH1/KH2 domain tandem with 25nt RNA hairpin
6Y2F	;	1.95	;	Crystal structure (monoclinic form) of the complex resulting from the reaction between SARS-CoV-2 (2019-nCoV) main protease and tert-butyl (1-((S)-1-(((S)-4-(benzylamino)-3,4-dioxo-1-((S)-2-oxopyrrolidin-3-yl)butan-2-yl)amino)-3-cyclopropyl-1-oxopropan-2-yl)-2-oxo-1,2-dihydropyridin-3-yl)carbamate (alpha-ketoamide 13b)
1FCQ	;	1.6	;	CRYSTAL STRUCTURE (MONOCLINIC) OF BEE VENOM HYALURONIDASE
7ZJC	;	1.6	;	Crystal structure (native) of outer surface protein BBA14 (OrfD) from Borrelia burgdorferi
6Y2G	;	2.2	;	Crystal structure (orthorhombic form) of the complex resulting from the reaction between SARS-CoV-2 (2019-nCoV) main protease and tert-butyl (1-((S)-1-(((S)-4-(benzylamino)-3,4-dioxo-1-((S)-2-oxopyrrolidin-3-yl)butan-2-yl)amino)-3-cyclopropyl-1-oxopropan-2-yl)-2-oxo-1,2-dihydropyridin-3-yl)carbamate (alpha-ketoamide 13b)
6Q6T	;	0.94	;	Crystal structure (orthorombic form) of C36S mutant of thioredoxin h1 from Chlamydomonas reinhardtii
6UB5	;	1.3	;	Crystal structure (P21 form) of a GH128 (subgroup IV) endo-beta-1,3-glucanase from Lentinula edodes (LeGH128_IV) in complex with laminaritriose
6Q6V	;	1.22	;	Crystal structure (trigonal form) of C36S mutant of thioredoxin h1 from Chlamydomonas reinhardtii
1FCU	;	2.1	;	CRYSTAL STRUCTURE (TRIGONAL) OF BEE VENOM HYALURONIDASE
3U54	;	2.35	;	Crystal structure (Type-1) of SAICAR synthetase from Pyrococcus horikoshii OT3
4NZY	;	2.15	;	Crystal structure (type-2) of dTMP kinase (st1543) from Sulfolobus Tokodaii Strain7
3U55	;	1.9	;	Crystal structure (Type-2) of SAICAR synthetase from Pyrococcus horikoshii OT3
4RZX	;	2.3	;	Crystal structure (type-3) of dTMP kinase (st1543) from Sulfolobus Tokodaii Strain7
5M2D	;	2.097	;	CRYSTAL STRUCTURE 4Ac Endoglucanase-like protein from Acremonium chrysogenum
479D	;	1.9	;	CRYSTAL STRUCTURE A DNA:RNA HYBRID DUPLEX, A DYNAMIC MODEL FOR RNASE H RECOGNITION
3UV1	;	2.0	;	Crystal structure a major allergen from dust mite
6K00	;	2.198	;	Crystal structure A of ceNAP1-H2A-H2B complex
6EN5	;	1.75	;	Crystal structure A of the Angiotensin-1 converting enzyme N-domain in complex with a diprolyl inhibitor.
6XTF	;	2.23	;	Crystal structure a Thioredoxin Reductase from Gloeobacter violaceus bound to its electron donor
3DCY	;	1.748	;	Crystal Structure a TP53-induced glycolysis and apoptosis regulator protein from Homo sapiens.
2J0M	;	2.8	;	Crystal structure a two-chain complex between the FERM and kinase domains of focal adhesion kinase.
5EZ3	;	2.15	;	Crystal structure Acyl-CoA dehydrogenase from Brucella melitensis in complex with FAD
2ZGU	;	2.4	;	Crystal structure Agrocybe aegerita lectin AAL mutant I144G
2X2Z	;	2.0	;	Crystal structure AMA1 from Toxoplasma gondii
3S3Y	;	2.0	;	Crystal Structure an Tandem Cyanovirin-N Dimer, CVN2L0
3S3Z	;	1.75	;	Crystal Structure an Tandem Cyanovirin-N Dimer, CVN2L10
2EBS	;	2.4	;	Crystal Structure Anaalysis of Oligoxyloglucan reducing-end-specific cellobiohydrolase (OXG-RCBH) D465N Mutant Complexed with a Xyloglucan Heptasaccharide
1V8S	;	2.2	;	Crystal structure analusis of the ADP-ribose pyrophosphatase complexed with AMP and Mg
1R4X	;	1.9	;	Crystal Structure Analys of the Gamma-COPI Appendage domain
4PCY	;	2.15	;	CRYSTAL STRUCTURE ANALYSES OF REDUCED (CUI) POPLAR PLASTOCYANIN AT SIX PH VALUES
5PCY	;	1.8	;	CRYSTAL STRUCTURE ANALYSES OF REDUCED (CUI) POPLAR PLASTOCYANIN AT SIX PH VALUES
6PCY	;	1.9	;	CRYSTAL STRUCTURE ANALYSES OF REDUCED (CUI) POPLAR PLASTOCYANIN AT SIX PH VALUES
2OI0	;	2.0	;	Crystal structure analysis 0f the TNF-a Coverting Enzyme (TACE) in complexed with Aryl-sulfonamide
4CTS	;	2.9	;	CRYSTAL STRUCTURE ANALYSIS AND MOLECULAR MODEL OF A COMPLEX OF CITRATE SYNTHASE WITH OXALOACETATE AND S-ACETONYL-COENZYME A
2Z6B	;	3.11	;	Crystal Structure Analysis of (gp27-gp5)3 conjugated with Fe(III) protoporphyrin
3BFJ	;	2.7	;	Crystal structure analysis of 1,3-propanediol oxidoreductase
3D61	;	1.95	;	Crystal Structure Analysis of 1,5-alpha-arabinanase catalytic mutant (AbnBD147A) complexed to arabinobiose
3D5Z	;	1.9	;	Crystal Structure Analysis of 1,5-alpha-arabinanase catalytic mutant (AbnBE201A) complexed to arabinotriose
3D60	;	1.9	;	Crystal Structure Analysis of 1,5-alpha-arabinanase catalytic mutant (D27A)
4KOA	;	1.93	;	Crystal Structure Analysis of 1,5-anhydro-D-fructose reductase from Sinorhizobium meliloti
5XD7	;	2.198	;	Crystal structure analysis of 3,6-anhydro-L-galactonate cycloisomerase
5XD8	;	2.505	;	Crystal structure analysis of 3,6-anhydro-L-galactonate cycloisomerase
5XD9	;	2.6	;	Crystal structure analysis of 3,6-anhydro-L-galactonate cycloisomerase
4GWG	;	1.3907	;	Crystal Structure Analysis of 6-phosphogluconate dehydrogenase apo-form
2QJ6	;	2.5	;	Crystal structure analysis of a 14 repeat C-terminal fragment of toxin TcdA in Clostridium difficile
3BSE	;	1.6	;	Crystal structure analysis of a 16-base-pair B-DNA
1MLX	;	1.25	;	Crystal Structure Analysis of a 2'-O-[2-(Methylthio)-ethyl]-Modified Oligodeoxynucleotide Duplex
2AXB	;	1.61	;	Crystal Structure Analysis Of A 2-O-[2-(methoxy)ethyl]-2-thiothymidine Modified Oligodeoxynucleotide Duplex
1MHK	;	2.5	;	Crystal Structure Analysis of a 26mer RNA molecule, representing a new RNA motif, the hook-turn
3UA8	;	1.9	;	Crystal Structure Analysis of a 6-Amino Quinazolinedione Sulfonamide bound to human GluR2
1WIY	;	2.0	;	Crystal Structure Analysis of a 6-coordinated Cytochorome P450 from Thermus thermophilus HB8
4H0S	;	1.55	;	Crystal structure analysis of a basic phospholipase A2 from Trimeresurus stejnegeri venom
3K83	;	2.251	;	Crystal Structure Analysis of a Biphenyl/Oxazole/Carboxypyridine alpha-ketoheterocycle Inhibitor Bound to a Humanized Variant of Fatty Acid Amide Hydrolase
2NO4	;	1.93	;	Crystal Structure analysis of a Dehalogenase
2NO5	;	2.6	;	Crystal Structure analysis of a Dehalogenase with intermediate complex
1JBZ	;	1.5	;	CRYSTAL STRUCTURE ANALYSIS OF A DUAL-WAVELENGTH EMISSION GREEN FLUORESCENT PROTEIN VARIANT AT HIGH PH
1JBY	;	1.8	;	CRYSTAL STRUCTURE ANALYSIS OF A DUAL-WAVELENGTH EMISSION GREEN FLUORESCENT PROTEIN VARIANT AT LOW PH
6IYX	;	1.8	;	Crystal Structure Analysis of a Eukaryotic Membrane Protein
6IZ0	;	2.3	;	Crystal Structure Analysis of a Eukaryotic Membrane Protein
6IZ1	;	2.399	;	Crystal Structure Analysis of a Eukaryotic Membrane Protein
6IZ5	;	3.701	;	Crystal Structure Analysis of a Eukaryotic Membrane Protein
2CE2	;	1.0	;	CRYSTAL STRUCTURE ANALYSIS OF A FLUORESCENT FORM OF H-RAS P21 IN COMPLEX WITH GDP
2CLD	;	1.22	;	CRYSTAL STRUCTURE ANALYSIS OF A FLUORESCENT FORM OF H-RAS P21 IN COMPLEX WITH GDP (2)
2CL0	;	1.8	;	CRYSTAL STRUCTURE ANALYSIS OF A FLUORESCENT FORM OF H-RAS P21 IN COMPLEX WITH GppNHp
2CL7	;	1.25	;	CRYSTAL STRUCTURE ANALYSIS OF A FLUORESCENT FORM OF H-RAS P21 IN COMPLEX WITH GTP
2CLC	;	1.3	;	CRYSTAL STRUCTURE ANALYSIS OF A FLUORESCENT FORM OF H-RAS P21 IN COMPLEX WITH GTP (2)
2EVW	;	1.05	;	Crystal structure analysis of a fluorescent form of H-Ras p21 in complex with R-caged GTP
2CL6	;	1.24	;	CRYSTAL STRUCTURE ANALYSIS OF A FLUORESCENT FORM OF H-RAS P21 IN COMPLEX WITH S-caged GTP
3F8T	;	1.9	;	Crystal structure analysis of a full-length MCM homolog from Methanopyrus kandleri
4FMV	;	2.01	;	Crystal Structure Analysis of a GH30 Endoxylanase from Clostridium papyrosolvens C71
3I4U	;	2.1	;	Crystal Structure Analysis of a helicase associated domain
1JUC	;	2.35	;	Crystal Structure Analysis of a Holliday Junction Formed by CCGGTACCGG
1QSW	;	1.85	;	CRYSTAL STRUCTURE ANALYSIS OF A HUMAN LYSOZYME MUTANT W64C C65A
1MCV	;	1.8	;	Crystal Structure Analysis of a Hybrid Squash Inhibitor in Complex with Porcine Pancreatic Elastase
2ALM	;	2.6	;	Crystal structure analysis of a mutant beta-ketoacyl-[acyl carrier protein] synthase II from Streptococcus pneumoniae
2TIR	;	2.0	;	CRYSTAL STRUCTURE ANALYSIS OF A MUTANT ESCHERICHIA COLI THIOREDOXIN IN WHICH LYSINE 36 IS REPLACED BY GLUTAMIC ACID
5CDW	;	2.602	;	Crystal Structure Analysis of a mutant Grb2 SH2 domain (W121G) with a pYVNV peptide
1S5T	;	2.3	;	Crystal Structure Analysis of a mutant of DIHYDRODIPICOLINATE SYNTHASE--residue thr44 to val44
1S5V	;	2.35	;	Crystal Structure Analysis of a mutant of DIHYDRODIPICOLINATE SYNTHASE--residue Tyr107 to Phe107
1S5W	;	2.32	;	Crystal Structure Analysis of a mutant of DIHYDRODIPICOLINATE SYNTHASE--residue Tyr133 to Phe133
1HR2	;	2.25	;	CRYSTAL STRUCTURE ANALYSIS OF A MUTANT P4-P6 DOMAIN (DELC209) OF TETRAHYMENA THEMOPHILA GROUP I INTRON.
2D42	;	2.07	;	Crystal structure analysis of a non-toxic crystal protein from Bacillus thuringiensis
1T4U	;	2.0	;	Crystal Structure Analysis of a novel Oxyguanidine bound to Thrombin
1T4V	;	2.0	;	Crystal Structure Analysis of a novel Oxyguanidine bound to Thrombin
3K84	;	2.25	;	Crystal Structure Analysis of a Oleyl/Oxadiazole/pyridine Inhibitor Bound to a Humanized Variant of Fatty Acid Amide Hydrolase
3K7F	;	1.95	;	Crystal Structure Analysis of a Phenhexyl/Oxazole/Carboxypyridine alpha-Ketoheterocycle Inhibitor Bound to a Humanized Variant of Fatty Acid Amide Hydrolase'
6WK7	;	2.423	;	Crystal Structure Analysis of a poly(thymine) DNA duplex
3R7X	;	2.1	;	Crystal Structure Analysis of a Quinazolinedione sulfonamide bound to human GluR2: A Novel Class of Competitive AMPA Receptor Antagonists with Oral Activity
2AHA	;	1.98	;	Crystal structure analysis of a rate-enhanced variant of redox-sensitive green fluorescent protein in the reduced form, roGFP1-R8.
3TKK	;	1.99	;	Crystal Structure Analysis of a recombinant predicted acetamidase/ formamidase from the thermophile thermoanaerobacter tengcongensis
1JC1	;	1.9	;	CRYSTAL STRUCTURE ANALYSIS OF A REDOX-SENSITIVE GREEN FLUORESCENT PROTEIN VARIANT IN A OXIDIZED FORM
1JC0	;	2.0	;	CRYSTAL STRUCTURE ANALYSIS OF A REDOX-SENSITIVE GREEN FLUORESCENT PROTEIN VARIANT IN A REDUCED FORM
1LNI	;	1.0	;	CRYSTAL STRUCTURE ANALYSIS OF A RIBONUCLEASE FROM STREPTOMYCES AUREOFACIENS AT ATOMIC RESOLUTION (1.0 A)
3LLM	;	2.8	;	Crystal Structure Analysis of a RNA Helicase
4KAG	;	1.12	;	Crystal structure analysis of a single amino acid deletion mutation in EGFP
4KEX	;	1.6	;	Crystal structure analysis of a single amino acid deletion mutation in EGFP
2RJT	;	1.75	;	Crystal Structure Analysis of a Surface Entropy Reduction Mutant of S. pneumoniae FabF
1MFQ	;	3.1	;	Crystal Structure Analysis of a Ternary S-Domain Complex of Human Signal Recognition Particle
1I9V	;	2.6	;	CRYSTAL STRUCTURE ANALYSIS OF A TRNA-NEOMYCIN COMPLEX
1QZN	;	1.9	;	Crystal Structure Analysis of a type II cohesin domain from the cellulosome of Acetivibrio cellulolyticus
1ZV9	;	1.28	;	Crystal structure analysis of a type II cohesin domain from the cellulosome of Acetivibrio cellulolyticus- SeMet derivative
8ECM	;	1.89	;	Crystal Structure Analysis of Acetyl-CoA acetyltransferase from Firmicutes bacterium
1V8M	;	1.8	;	Crystal structure analysis of ADP-ribose pyrophosphatase complexed with ADP-ribose and Gd
1EV5	;	1.7	;	CRYSTAL STRUCTURE ANALYSIS OF ALA167 MUTANT OF ESCHERICHIA COLI
7MJC	;	2.68	;	Crystal Structure Analysis of ALDH1B1
7MJD	;	2.12	;	Crystal Structure Analysis of ALDH1B1
7RAD	;	2.3	;	Crystal Structure Analysis of ALDH1B1
4KWG	;	2.1	;	Crystal Structure Analysis of ALDH2+ALDiB13
4KWF	;	2.31	;	Crystal Structure Analysis of ALDH2+ALDiB33
1EPX	;	1.8	;	CRYSTAL STRUCTURE ANALYSIS OF ALDOLASE FROM L. MEXICANA
1F2J	;	1.9	;	CRYSTAL STRUCTURE ANALYSIS OF ALDOLASE FROM T. BRUCEI
1UA7	;	2.21	;	Crystal Structure Analysis of Alpha-Amylase from Bacillus Subtilis complexed with Acarbose
3BT4	;	2.1	;	Crystal Structure Analysis of AmFPI-1, fungal protease inhibitor from Antheraea mylitta
1AAJ	;	1.8	;	CRYSTAL STRUCTURE ANALYSIS OF AMICYANIN AND APOAMICYANIN FROM PARACOCCUS DENITRIFICANS AT 2.0 ANGSTROMS AND 1.8 ANGSTROMS RESOLUTION
1AAN	;	2.0	;	CRYSTAL STRUCTURE ANALYSIS OF AMICYANIN AND APOAMICYANIN FROM PARACOCCUS DENITRIFICANS AT 2.0 ANGSTROMS AND 1.8 ANGSTROMS RESOLUTION
28DN	;	2.4	;	CRYSTAL STRUCTURE ANALYSIS OF AN A(DNA) OCTAMER D(GTACGTAC)
9DNA	;	1.8	;	CRYSTAL STRUCTURE ANALYSIS OF AN A-DNA FRAGMENT AT 1.8 ANGSTROMS RESOLUTION. D(GCCCGGGC)
3HKX	;	1.66	;	Crystal structure analysis of an amidase from Nesterenkonia sp.
1P2C	;	2.0	;	crystal structure analysis of an anti-lysozyme antibody
6IYU	;	2.199	;	Crystal Structure Analysis of an Eukaryotic Membrane Protein
1XQI	;	2.5	;	Crystal Structure Analysis of an NDP kinase from Pyrobaculum aerophilum
1L3Z	;	2.01	;	Crystal Structure Analysis of an RNA Heptamer
1Q1J	;	2.5	;	Crystal Structure Analysis of anti-HIV-1 Fab 447-52D in complex with V3 peptide
2B0S	;	2.3	;	Crystal structure analysis of anti-HIV-1 V3 Fab 2219 in complex with MN peptide
2B1A	;	2.348	;	Crystal structure analysis of anti-HIV-1 V3 Fab 2219 in complex with UG1033 peptide
2B1H	;	2.0	;	Crystal structure analysis of anti-HIV-1 V3 Fab 2219 in complex with UG29 peptide
2QSC	;	2.8	;	Crystal structure analysis of anti-HIV-1 V3-Fab F425-B4e8 in complex with a V3-peptide
1K3O	;	1.8	;	Crystal Structure Analysis of apo Glutathione S-Transferase
2FGZ	;	1.75	;	Crystal Structure Analysis of apo pullulanase from Klebsiella pneumoniae
4HEL	;	3.2	;	Crystal structure analysis of apo-GroEL structure
3NYJ	;	3.2	;	Crystal Structure Analysis of APP E2 domain
4PV6	;	3.32	;	Crystal Structure Analysis of Ard1 from Thermoplasma volcanium
1I49	;	2.8	;	CRYSTAL STRUCTURE ANALYSIS OF ARFAPTIN
1G8J	;	2.03	;	CRYSTAL STRUCTURE ANALYSIS OF ARSENITE OXIDASE FROM ALCALIGENES FAECALIS
1G8K	;	1.64	;	CRYSTAL STRUCTURE ANALYSIS OF ARSENITE OXIDASE FROM ALCALIGENES FAECALIS
3LNB	;	2.01	;	Crystal Structure Analysis of Arylamine N-acetyltransferase C from Bacillus anthracis
8GKO	;	1.06	;	Crystal Structure Analysis of Aspergillus fumigatus alkaline protease
8GKP	;	1.55	;	Crystal Structure Analysis of Aspergillus fumigatus alkaline protease
8GKQ	;	1.65	;	Crystal Structure Analysis of Aspergillus fumigatus alkaline protease
8U45	;	2.1	;	Crystal Structure Analysis of Aspergillus fumigatus alkaline protease
3FI0	;	2.7	;	Crystal Structure Analysis of B. stearothermophilus Tryptophanyl-tRNA Synthetase Complexed with Tryptophan, AMP, and Inorganic Phosphate
1VEM	;	1.85	;	Crystal Structure Analysis of Bacillus Cereus Beta-Amylase at the optimum pH (6.5)
6IA5	;	1.88	;	Crystal Structure Analysis of Bacillus subtilis 168 XepA
2GLX	;	2.2	;	Crystal Structure Analysis of bacterial 1,5-AF Reductase
1HV4	;	2.8	;	CRYSTAL STRUCTURE ANALYSIS OF BAR-HEAD GOOSE HEMOGLOBIN (DEOXY FORM)
6VO4	;	1.74	;	Crystal Structure Analysis of BFL1
2QJ9	;	2.44	;	Crystal structure analysis of BMP-2 in complex with BMPR-IA variant B1
2QJA	;	2.6	;	Crystal structure analysis of BMP-2 in complex with BMPR-IA variant B12
2QJB	;	2.5	;	Crystal structure analysis of BMP-2 in complex with BMPR-IA variant IA/IB
2R52	;	2.5	;	Crystal structure analysis of Bone Morphogenetic Protein-6 (BMP-6)
2R53	;	2.1	;	Crystal structure analysis of Bone Morphogenetic Protein-6 variant B2 (B2-BMP-6)
1SQB	;	2.69	;	Crystal Structure Analysis of Bovine Bc1 with Azoxystrobin
1SQQ	;	3.0	;	Crystal Structure Analysis of Bovine Bc1 with Methoxy Acrylate Stilbene (MOAS)
1SQP	;	2.7	;	Crystal Structure Analysis of Bovine Bc1 with Myxothiazol
1SQX	;	2.6	;	Crystal Structure Analysis of Bovine Bc1 with Stigmatellin A
1SQV	;	2.85	;	Crystal Structure Analysis of Bovine Bc1 with UHDBT
1V9E	;	1.95	;	Crystal Structure Analysis of Bovine Carbonic Anhydrase II
6IHX	;	1.46	;	Crystal Structure Analysis of bovine Hemoglobin modified by SNP
1ZYE	;	3.3	;	Crystal structure analysis of Bovine Mitochondrial Peroxiredoxin III
1ITO	;	2.286	;	Crystal Structure Analysis of Bovine Spleen Cathepsin B-E64c complex
5C4Q	;	1.932	;	Crystal Structure Analysis of bromodomain from Leishmania donovani complexed with bromosporine
1ISF	;	2.5	;	Crystal Structure Analysis of BST-1/CD157
1ISI	;	2.1	;	Crystal Structure Analysis of BST-1/CD157 complexed with ethenoNAD
1ISH	;	2.4	;	Crystal Structure Analysis of BST-1/CD157 complexed with ethenoNADP
1ISM	;	3.0	;	Crystal Structure Analysis of BST-1/CD157 complexed with nicotinamide
1ISJ	;	2.3	;	Crystal Structure Analysis of BST-1/CD157 complexed with NMN
1ISG	;	2.6	;	Crystal Structure Analysis of BST-1/CD157 with ATPgammaS
5C5Z	;	1.45	;	Crystal structure analysis of c4763, a uropathogenic E. coli-specific protein
5HIT	;	2.85	;	Crystal Structure Analysis of Ca2+-calmodulin and a C-terminal EAG1 channel fragment
1KYZ	;	2.2	;	Crystal Structure Analysis of Caffeic acid/5-hydroxyferulic acid 3/5-O-methyltransferase Ferulic Acid Complex
1KYW	;	2.4	;	Crystal Structure Analysis of Caffeic Acid/5-hydroxyferulic acid 3/5-O-methyltransferase in complex with 5-hydroxyconiferaldehyde
2ZIB	;	1.34	;	Crystal structure analysis of calcium-independent type II antifreeze protein
1KRQ	;	2.7	;	CRYSTAL STRUCTURE ANALYSIS OF CAMPYLOBACTER JEJUNI FERRITIN
5GHK	;	3.2	;	Crystal Structure Analysis of Canine serum albumin
2NZ7	;	1.9	;	Crystal Structure Analysis of Caspase-recruitment Domain (CARD) of Nod1
1M7S	;	1.8	;	Crystal Structure Analysis of Catalase CatF of Pseudomonas syringae
2J2M	;	2.4	;	Crystal Structure Analysis of Catalase from Exiguobacterium oxidotolerans
5C1V	;	3.35	;	CRYSTAL STRUCTURE ANALYSIS OF CATALYTIC SUBUNIT OF HUMAN CALCINEURIN
3WT0	;	2.0	;	Crystal Structure Analysis of Cell Division Protein
3RRS	;	1.7	;	Crystal structure analysis of cellobiose phosphorylase from Cellulomonas uda
1FP1	;	1.82	;	CRYSTAL STRUCTURE ANALYSIS OF CHALCONE O-METHYLTRANSFERASE
4EQ2	;	2.502	;	Crystal Structure Analysis of Chicken Interferon Gamma Receptor Alpha Chain
3ARO	;	2.22	;	Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - apo structure
3ARS	;	2.45	;	Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - apo structure of mutant W275G
3ARY	;	1.35	;	Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - complex structure with 2-(imidazolin-2-yl)-5-isothiocyanatobenzofuran
3ARZ	;	1.82	;	Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - complex structure with 2-(imidazolin-2-yl)-5-isothiocyanatobenzofuran
3ARW	;	1.5	;	Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - complex structure with chelerythrine
3ARP	;	1.55	;	Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - complex structure with DEQUALINIUM
3ARQ	;	1.5	;	Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - complex structure with IDARUBICIN
3ARR	;	1.65	;	Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - complex structure with PENTOXIFYLLINE
3ARX	;	1.16	;	Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - complex structure with Propentofylline
3ARV	;	1.5	;	Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - complex structure with Sanguinarine
3AS3	;	2.4	;	Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - W275G mutant complex structure with 2-(imidazolin-2-yl)-5-isothiocyanatobenzofuran
3AS1	;	2.0	;	Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - W275G mutant complex structure with chelerythrine
3ART	;	2.23	;	Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - W275G mutant complex structure with DEQUALINIUM
3ARU	;	1.9	;	Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - W275G mutant complex structure with PENTOXIFYLLINE
3AS2	;	1.8	;	Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - W275G mutant complex structure with Propentofylline
3AS0	;	2.0	;	Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - W275G mutant complex structure with Sanguinarine
1FNK	;	2.0	;	CRYSTAL STRUCTURE ANALYSIS OF CHORISMATE MUTASE MUTANT C88K/R90S
1FNJ	;	1.9	;	CRYSTAL STRUCTURE ANALYSIS OF CHORISMATE MUTASE MUTANT C88S/R90K
1U9T	;	2.16	;	Crystal Structure Analysis of ChuS, an E. coli Heme Oxygenase
5XHZ	;	1.319	;	Crystal Structure Analysis of CIN85-SH3B in complex with ARAP1-P2
3RBG	;	2.3	;	Crystal structure analysis of Class-I MHC restricted T-cell associated molecule
1KHO	;	2.4	;	Crystal Structure Analysis of Clostridium perfringens alpha-Toxin Isolated from Avian Strain SWCP
1QVR	;	3.0	;	Crystal Structure Analysis of ClpB
1MBU	;	2.3	;	Crystal Structure Analysis of ClpSN heterodimer
1MBV	;	3.3	;	CRYSTAL STRUCTURE ANALYSIS OF ClpSN HETERODIMER TETRAGONAL FORM
1MBX	;	2.25	;	CRYSTAL STRUCTURE ANALYSIS OF ClpSN WITH TRANSITION METAL ION BOUND
6II1	;	1.34	;	Crystal Structure Analysis of CO form hemoglobin from Bos taurus
2R7E	;	3.7	;	Crystal Structure Analysis of Coagulation Factor VIII
2IJH	;	1.8	;	Crystal structure analysis of ColE1 ROM mutant F14W
2IJJ	;	1.9	;	Crystal structure analysis of ColE1 ROM mutant F14Y
7RKA	;	1.8	;	Crystal structure analysis of Colorado potato beetle glutathione-S transferase LdGSTu1
4EMS	;	1.7534	;	Crystal Structure Analysis of Coniferyl Alcohol 9-O-Methyltransferase from Linum Nodiflorum
4E70	;	1.6093	;	Crystal Structure Analysis of Coniferyl Alcohol 9-O-Methyltransferase from Linum Nodiflorum in Complex with Coniferyl Alcohol
4EVI	;	2.015	;	Crystal Structure Analysis of Coniferyl Alcohol 9-O-Methyltransferase from Linum Nodiflorum in Complex with Coniferyl Alcohol 9-Methyl Ether and S -Adenosyl-L-Homocysteine
7Y90	;	2.09	;	Crystal Structure Analysis of cp1 bound BCL2
7YA5	;	1.85	;	Crystal structure analysis of cp1 bound BCL2/G101V
7Y99	;	1.9	;	Crystal Structure Analysis of cp2 bound BCLxl
7YAA	;	1.4	;	Crystal structure analysis of cp3 bound BCLxl
2RFH	;	1.7	;	Crystal Structure Analysis of CPA-2-benzyl-3-nitropropanoic acid complex
1K7U	;	2.2	;	Crystal Structure Analysis of crosslinked-WGA3/GlcNAcbeta1,4GlcNAc complex
1K7T	;	2.4	;	Crystal Structure Analysis of crosslinked-WGA3/GlcNAcbeta1,6Gal complex
1K7V	;	2.2	;	Crystal Structure Analysis of crosslinked-WGA3/GlcNAcbeta1,6Galbeta1,4Glc
1F29	;	2.15	;	CRYSTAL STRUCTURE ANALYSIS OF CRUZAIN BOUND TO A VINYL SULFONE DERIVED INHIBITOR (I)
1F2A	;	1.6	;	CRYSTAL STRUCTURE ANALYSIS OF CRUZAIN BOUND TO A VINYL SULFONE DERIVED INHIBITOR (II)
4XUI	;	2.508	;	Crystal structure analysis of cruzain bound to the no-covalent analog of WRR-483 (WRR-669)
4PI3	;	1.27	;	Crystal structure analysis of cruzain bound to vinyl sulfone analog of WRR-483 (WRR-666)
1F2B	;	1.8	;	CRYSTAL STRUCTURE ANALYSIS OF CRUZAIN BOUND TO VINYL SULFONE DERIVED INHIBITOR (III)
2OZ2	;	1.95	;	Crystal structure analysis of cruzain bound to vinyl sulfone derived inhibitor (K11777)
3LXS	;	1.5	;	Crystal structure analysis of cruzain bound to vinyl sulfone derived inhibitor (WRR483)
4W5B	;	2.701	;	Crystal structure analysis of cruzain with Fragment 1 (N-(1H-benzimidazol-2-yl)-1,3-dimethyl-pyrazole-4-carboxamide)
4W5C	;	3.27	;	Crystal structure analysis of cruzain with three Fragments: 1 (N-(1H-benzimidazol-2-yl)-1,3-dimethyl-pyrazole-4-carboxamide), 6 (2-amino-4,6-difluorobenzothiazole) and 9 (N-(1H-benzimidazol-2-yl)-3-(4-fluorophenyl)-1H-pyrazole-4-carboxamide).
1F2C	;	2.0	;	CRYSTAL STRUCTURE ANALYSIS OF CRYZAIN BOUND TO VINYL SULFONE DERIVED INHIBITOR (IV)
3TT8	;	1.12	;	Crystal Structure Analysis of Cu Human Insulin Derivative
2COL	;	2.2	;	Crystal structure analysis of CyaA/C-Cam with Pyrophosphate
3WCQ	;	0.97	;	Crystal structure analysis of Cyanidioschyzon melorae ferredoxin D58N mutant
1EV8	;	2.6	;	CRYSTAL STRUCTURE ANALYSIS OF CYS167 MUTANT OF ESCHERICHIA COLI
1EVF	;	1.7	;	CRYSTAL STRUCTURE ANALYSIS OF CYS167 MUTANT OF ESCHERICHIA COLI
1EVG	;	2.0	;	CRYSTAL STRUCTURE ANALYSIS OF CYS167 MUTANT OF ESCHERICHIA COLI WITH UNMODIFIED CATALYTIC CYSTEINE
1EG6	;	2.0	;	CRYSTAL STRUCTURE ANALYSIS OF D(CG(5-BRU)ACG) COMPLEXES TO A PHENAZINE
1C0K	;	1.46	;	CRYSTAL STRUCTURE ANALYSIS OF D-AMINO ACID OXIDASE IN COMPLEX WITH L-LACTATE
1GG1	;	2.0	;	CRYSTAL STRUCTURE ANALYSIS OF DAHP SYNTHASE IN COMPLEX WITH MN2+ AND 2-PHOSPHOGLYCOLATE
1XY1	;	1.04	;	CRYSTAL STRUCTURE ANALYSIS OF DEAMINO-OXYTOCIN. CONFORMATIONAL FLEXIBILITY AND RECEPTOR BINDING
1XY2	;	1.2	;	CRYSTAL STRUCTURE ANALYSIS OF DEAMINO-OXYTOCIN. CONFORMATIONAL FLEXIBILITY AND RECEPTOR BINDING
1DLK	;	2.14	;	CRYSTAL STRUCTURE ANALYSIS OF DELTA-CHYMOTRYPSIN BOUND TO A PEPTIDYL CHLOROMETHYL KETONE INHIBITOR
3IRC	;	2.25	;	Crystal structure analysis of dengue-1 envelope protein domain III
1MH9	;	1.8	;	Crystal Structure Analysis of deoxyribonucleotidase
2PO3	;	2.1	;	Crystal Structure Analysis of DesI in the presence of its TDP-sugar product
2YXX	;	1.7	;	Crystal structure analysis of Diaminopimelate decarboxylate (lysA)
1JUV	;	1.7	;	Crystal structure analysis of Dihydrofolate reductase from Bacteriophage T4
2E3U	;	2.3	;	Crystal structure analysis of Dim2p from Pyrococcus horikoshii OT3
1YHT	;	2.0	;	Crystal structure analysis of Dispersin B
5AXE	;	0.95	;	Crystal Structure Analysis of DNA Duplexes containing sulfoamide-bridged nucleic acid (SuNA-NH)
5AXF	;	1.13	;	Crystal Structure Analysis of DNA Duplexes containing sulfoamide-bridged nucleic acid (SuNA-NMe)
6U9Q	;	1.83	;	Crystal Structure Analysis of DNA-BCL11A Znf domain complex
2RAL	;	2.8	;	Crystal Structure Analysis of double cysteine mutant of S.epidermidis adhesin SdrG: Evidence for the Dock,Lock and Latch ligand binding mechanism
3EIO	;	2.0	;	Crystal Structure Analysis of DPPIV Inhibitor
4IQH	;	1.764	;	Crystal Structure Analysis of Dysferlin C2A variant 1 (C2Av1)
4TWZ	;	2.8	;	Crystal Structure Analysis of E Coli. RecA Protein
1HO3	;	2.5	;	CRYSTAL STRUCTURE ANALYSIS OF E. COLI L-ASPARAGINASE II (Y25F MUTANT)
1T43	;	3.2	;	Crystal Structure Analysis of E.coli Protein (N5)-Glutamine Methyltransferase (HemK)
3A9Q	;	1.896	;	Crystal Structure Analysis of E173A variant of the soybean ferritin SFER4
3UVH	;	1.84	;	Crystal Structure Analysis of E81M mutant of human CLIC1
5UOE	;	3.8	;	Crystal Structure Analysis of Elbow-Engineered-Fab-Bound Human Insulin Degrading Enzyme (IDE)
5CJO	;	3.287	;	Crystal Structure Analysis of Elbow-Engineered-Fab-Bound Human Insulin Degrading Enzyme (IDE) in Complex with Insulin
6KWC	;	1.3	;	Crystal Structure Analysis of Endo-beta-1,4-xylanase II
6K9R	;	1.3	;	Crystal Structure Analysis of Endo-beta-1,4-xylanase II Complexed with Xylotriose
6KVV	;	1.19	;	Crystal Structure Analysis of Endo-beta-1,4-xylanase II Complexed with Xylotriose
6KW9	;	1.22	;	Crystal Structure Analysis of Endo-beta-1,4-xylanase II Complexed with Xylotriose
6KWD	;	1.298	;	Crystal Structure Analysis of Endo-beta-1,4-Xylanase II Complexed with Xylotriose
6KWE	;	1.503	;	Crystal Structure Analysis of Endo-beta-1,4-xylanase II Complexed with Xylotriose
6KWF	;	1.22	;	Crystal Structure Analysis of Endo-beta-1,4-xylanase II Complexed with Xylotriose
6KWG	;	1.694	;	Crystal Structure Analysis of Endo-beta-1,4-xylanase II Complexed with Xylotriose
6KWH	;	1.808	;	Crystal Structure Analysis of Endo-beta-1,4-xylanase II Complexed with Xylotriose
3JU4	;	0.98	;	Crystal Structure Analysis of EndosialidaseNF at 0.98 A Resolution
2AL1	;	1.5	;	Crystal Structure Analysis of Enolase Mg Subunit Complex at pH 8.0
2AL2	;	1.85	;	Crystal Structure Analysis of Enolase Mg Subunit Complex at pH 8.0
3QTP	;	1.9	;	Crystal Structure Analysis of Entamoeba histolytica Enolase
3E5V	;	2.1	;	Crystal Structure Analysis of eqFP611 Double Mutant T122R, N143S
3WBK	;	3.3	;	crystal structure analysis of eukaryotic translation initiation factor 5B and 1A complex
3WBI	;	2.35	;	Crystal structure analysis of eukaryotic translation initiation factor 5B structure I
3WBJ	;	2.495	;	Crystal structure analysis of eukaryotic translation initiation factor 5B structure II
2OQJ	;	2.8	;	Crystal structure analysis of Fab 2G12 in complex with peptide 2G12.1
4IOF	;	3.353	;	Crystal structure analysis of Fab-bound human Insulin Degrading Enzyme (IDE)
4M1C	;	3.5007	;	Crystal Structure Analysis of Fab-Bound Human Insulin Degrading Enzyme (IDE) in Complex with Amyloid-Beta (1-40)
5WOB	;	3.95	;	Crystal Structure Analysis of Fab1-Bound Human Insulin Degrading Enzyme (IDE) in Complex with Insulin
5YXE	;	3.40242	;	Crystal Structure Analysis of feline serum albumin
1IUE	;	1.7	;	Crystal Structure Analysis of ferredoxin from Plasmodium falciparum
3UD7	;	2.8	;	Crystal Structure Analysis of FGF1-Disaccharide(NI21) complexes
3UD8	;	2.37	;	Crystal Structure Analysis of FGF1-Disaccharide(NI22) complex
3UD9	;	2.34	;	Crystal Structure Analysis of FGF1-Disaccharide(NI23) complex
3UDA	;	2.51	;	Crystal Structure Analysis of FGF1-Disaccharide(NI24) complex
4OEE	;	1.5	;	Crystal Structure Analysis of FGF2-Disaccharide (S3I2) complex
4OEF	;	1.8	;	Crystal Structure Analysis of FGF2-Disaccharide (S6I2) complex
4OEG	;	1.6	;	Crystal Structure Analysis of FGF2-Disaccharide (S9I2) complex
4LAX	;	2.007	;	Crystal Structure Analysis of FKBP52, Complex with FK506
4LAY	;	1.7	;	Crystal Structure Analysis of FKBP52, Complex with I63
4LAV	;	1.8	;	Crystal Structure Analysis of FKBP52, Crystal Form II
4LAW	;	2.4	;	Crystal Structure Analysis of FKBP52, Crystal Form III
3BZ3	;	2.2	;	Crystal Structure Analysis of Focal Adhesion Kinase with a Methanesulfonamide Diaminopyrimidine Inhibitor
3Q9T	;	2.24	;	Crystal structure analysis of formate oxidase
3E5T	;	1.1	;	Crystal Structure Analysis of FP611
3E5W	;	1.71	;	Crystal Structure Analysis of FP611
4QNQ	;	2.3	;	Crystal Structure Analysis of full-length Bcl-XL in complex with the inhibitor ABT-263
1K9A	;	2.5	;	Crystal structure analysis of full-length carboxyl-terminal Src kinase at 2.5 A resolution
3FJW	;	2.8	;	Crystal Structure Analysis of Fungal Versatile Peroxidase from Pleurotus eryngii
3FKG	;	1.81	;	Crystal Structure Analysis of Fungal Versatile Peroxidase from Pleurotus eryngii
3FM1	;	1.78	;	Crystal Structure Analysis of Fungal Versatile Peroxidase from Pleurotus eryngii
3FM4	;	2.11	;	Crystal Structure Analysis of Fungal Versatile Peroxidase from Pleurotus eryngii
3FM6	;	1.13	;	Crystal Structure Analysis of Fungal Versatile Peroxidase from Pleurotus eryngii
3FMU	;	1.04	;	Crystal Structure Analysis of Fungal Versatile Peroxidase from Pleurotus eryngii
5ABO	;	1.095	;	CRYSTAL STRUCTURE ANALYSIS OF FUNGAL VERSATILE PEROXIDASE FROM PLEUROTUS ERYNGII. MUTANT VPi-br. MUTATED RESIDUES T2K, D69S, T70D, S86E, A131K, D146T, Q202L, Q219K, H232E, Q239R, L288R, S301K, A308R, A309K AND A314R.
5ABQ	;	2.293	;	CRYSTAL STRUCTURE ANALYSIS OF FUNGAL VERSATILE PEROXIDASE FROM PLEUROTUS ERYNGII. MUTANT VPi-SS. MUTATED RESIDUES T2K, A49C, A61C, D69S, T70D, S86E, A131K, D146T, Q202L, Q219K, H232E, Q239R, L288R, S301K, A308R,A309K AND A314R.
5ABN	;	2.194	;	CRYSTAL STRUCTURE ANALYSIS OF FUNGAL VERSATILE PEROXIDASE FROM PLEUROTUS ERYNGII. MUTANT VPi. MUTATED RESIDUES D69S, T70D, S86E, D146T, Q202L, H232E, Q239R AND S301K.
2DWY	;	2.3	;	Crystal Structure Analysis of GGA1-GAE
2D7J	;	1.89	;	Crystal Structure Analysis of Glutamine Amidotransferase from Pyrococcus horikoshii OT3
1XA8	;	2.4	;	Crystal Structure Analysis of Glutathione-dependent formaldehyde-activating enzyme (Gfa)
2AF9	;	2.0	;	Crystal Structure analysis of GM2-Activator protein complexed with phosphatidylcholine
2AG2	;	2.0	;	Crystal Structure Analysis of GM2-activator protein complexed with Phosphatidylcholine
2AG4	;	1.8	;	Crystal Structure Analysis of GM2-activator protein complexed with phosphatidylcholine
2P4Q	;	2.37	;	Crystal Structure Analysis of Gnd1 in Saccharomyces cerevisiae
1K34	;	1.88	;	Crystal structure analysis of gp41 core mutant
4HJ2	;	2.1	;	Crystal Structure Analysis of GSTA1-1 in complex with chlorambucil
3A0G	;	2.5	;	Crystal structure analysis of guinea pig oxyhemoglobin at 2.5 angstroms resolution
3QR6	;	1.78	;	Crystal Structure Analysis of H185F Mutant of Human CLIC1
3P90	;	2.3	;	Crystal Structure Analysis of H207F Mutant of Human CLIC1
3SWL	;	2.35	;	Crystal Structure Analysis of H74A Mutant of Human CLIC1
1NNF	;	1.1	;	Crystal Structure Analysis of Haemophlius Influenzae Ferric-ion Binding Protein H9Q Mutant Form
1LGD	;	1.9	;	Crystal Structure Analysis of HCA II Mutant T199P in Complex with Bicarbonate
1LG6	;	2.2	;	Crystal Structure Analysis of HCA II Mutant T199P in Complex with Thiocyanate
3SZS	;	1.95	;	Crystal structure analysis of hellethionin D
2HTX	;	1.56	;	Crystal Structure Analysis of Hen Egg White Lysozyme Crosslinked by Polymerized Glutaraldehyde in Acidic Environment
2EPE	;	2.5	;	Crystal structure analysis of Hen egg white lysozyme grown by capillary method
2HU1	;	1.63	;	Crystal structure Analysis of Hen Egg White Lyszoyme
1Q9B	;	1.5	;	CRYSTAL STRUCTURE ANALYSIS OF Hev b 6.02 (HEVEIN) AT 1.5 ANGSTROMS RESOLUTION
2FBB	;	1.46	;	Crystal Structure Analysis of Hexagonal Lysozyme
1JOV	;	1.57	;	Crystal Structure Analysis of HI1317
2NNK	;	1.25	;	Crystal structure analysis of HIV-1 protease mutant I84V with a inhibitor saquinavir
2NNP	;	1.2	;	Crystal structure analysis of HIV-1 protease mutant I84V with a inhibitor saquinavir
2IEO	;	1.53	;	Crystal structure analysis of HIV-1 protease mutant I84V with a potent non-peptide inhibitor (UIC-94017)
2AOC	;	1.3	;	Crystal structure analysis of HIV-1 protease mutant I84V with a substrate analog P2-NC
2NMY	;	1.1	;	Crystal structure analysis of HIV-1 protease mutant V82A with a inhibitor saquinavir
2NMZ	;	0.97	;	Crystal structure analysis of HIV-1 protease mutant V82A with a inhibitor saquinavir
2IDW	;	1.1	;	Crystal structure analysis of HIV-1 protease mutant V82A with a potent non-peptide inhibitor (UIC-94017)
2AOE	;	1.54	;	crystal structure analysis of HIV-1 protease mutant V82A with a substrate analog CA-P2
2AOF	;	1.32	;	Crystal structure analysis of HIV-1 Protease mutant V82A with a substrate analog P1-P6
2AOG	;	1.1	;	Crystal structure analysis of HIV-1 protease mutant V82A with a substrate analog P2-NC
2AOH	;	1.42	;	Crystal structure analysis of HIV-1 Protease mutant V82A with a substrate analog P6-PR
2IEN	;	1.3	;	Crystal structure analysis of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017)
2AOI	;	1.4	;	Crystal structure analysis of HIV-1 protease with a substrate analog P1-P6
2AOD	;	1.4	;	Crystal structure analysis of HIV-1 protease with a substrate analog P2-NC
2AOJ	;	1.6	;	Crystal structure analysis of HIV-1 protease with a substrate analog P6-PR
2R5P	;	2.3	;	Crystal Structure Analysis of HIV-1 Subtype C Protease Complexed with Indinavir
2R5Q	;	2.3	;	Crystal Structure Analysis of HIV-1 Subtype C Protease Complexed with Nelfinavir
1IXV	;	2.3	;	Crystal Structure Analysis of homolog of oncoprotein gankyrin, an interactor of Rb and CDK4/6
2PLN	;	1.8	;	Crystal structure analysis of HP1043, an orphan resonse regulator of h. pylori
6VQM	;	2.87	;	Crystal Structure Analysis of human ACK1
7U5W	;	1.13	;	Crystal Structure Analysis of human Carbonic anhydrase 2
7U5X	;	1.04	;	Crystal Structure Analysis of human Carbonic anhydrase 2
2HL4	;	1.55	;	Crystal structure analysis of human carbonic anhydrase II in complex with a benzenesulfonamide derivative
7MKX	;	3.08	;	Crystal Structure Analysis of human CDK2 and CCNA2 complex
2B2V	;	2.65	;	Crystal structure analysis of human CHD1 chromodomains 1 and 2 bound to histone H3 resi 1-15 MeK4
7TUN	;	2.93	;	Crystal structure analysis of human CKB complex with a covalent compound
5VXS	;	2.954	;	Crystal Structure Analysis of human CLYBL in apo form
5VXC	;	1.872	;	Crystal Structure Analysis of human CLYBL in complex with free CoASH
5VXO	;	2.266	;	Crystal Structure Analysis of human CLYBL in complex with propionyl-CoA
2O72	;	2.0	;	Crystal Structure Analysis of human E-cadherin (1-213)
2EC9	;	2.0	;	Crystal structure analysis of human Factor VIIa , Souluble tissue factor complexed with BCX-3607
3MX7	;	1.76	;	Crystal Structure Analysis of Human FAIM-NTD
1K3Y	;	1.3	;	Crystal Structure Analysis of human Glutathione S-transferase with S-hexyl glutatione and glycerol at 1.3 Angstrom
3F07	;	3.3	;	Crystal Structure Analysis of Human HDAC8 complexed with APHA in a new monoclinic crystal form
3F0R	;	2.54	;	Crystal Structure Analysis of Human HDAC8 complexed with trichostatin A in a new monoclinic crystal form
3F06	;	2.55	;	Crystal Structure Analysis of Human HDAC8 D101A Variant.
3EZT	;	2.85	;	Crystal Structure Analysis of Human HDAC8 D101E Variant
3EW8	;	1.8	;	Crystal Structure Analysis of human HDAC8 D101L variant
3EZP	;	2.65	;	Crystal Structure Analysis of human HDAC8 D101N variant
3EWF	;	2.5	;	Crystal Structure Analysis of human HDAC8 H143A variant complexed with substrate.
2CVD	;	1.45	;	Crystal structure analysis of human hematopoietic prostaglandin D synthase complexed with HQL-79
1JQE	;	1.91	;	Crystal Structure Analysis of Human Histamine Methyltransferase (Ile105 Polymorphic Variant) Complexed with AdoHcy and Antimalarial Drug Quinacrine
1JQD	;	2.28	;	Crystal Structure Analysis of Human Histamine Methyltransferase (Thr105 Polymorphic Variant) Complexed with AdoHcy and Histamine
4KZO	;	2.204	;	Crystal Structure Analysis of human IDH1 mutants in complex with NADP+ and Ca2+/alpha-Ketoglutarate
4L03	;	2.1	;	Crystal Structure Analysis of human IDH1 mutants in complex with NADP+ and Ca2+/alpha-Ketoglutarate
4L04	;	2.87	;	Crystal Structure Analysis of human IDH1 mutants in complex with NADP+ and Ca2+/alpha-Ketoglutarate
4L06	;	2.282	;	Crystal Structure Analysis of human IDH1 mutants in complex with NADP+ and Ca2+/alpha-Ketoglutarate
3LRE	;	2.2	;	Crystal Structure Analysis of Human Kinesin-8 Motor Domain
7KMR	;	1.51	;	Crystal structure analysis of human KRAS mutant
3PCV	;	1.9	;	Crystal structure analysis of human leukotriene C4 synthase at 1.9 angstrom resolution
3U0V	;	1.72	;	Crystal Structure Analysis of human LYPLAL1
1IWT	;	1.4	;	Crystal Structure Analysis of Human lysozyme at 113K.
1IWU	;	1.4	;	Crystal Structure Analysis of Human lysozyme at 127K.
1IWV	;	1.4	;	Crystal Structure Analysis of Human lysozyme at 147K.
1IWW	;	1.4	;	Crystal Structure Analysis of Human lysozyme at 152K.
1IWX	;	1.4	;	Crystal Structure Analysis of Human lysozyme at 161K.
1IWY	;	1.4	;	Crystal Structure Analysis of Human lysozyme at 170K.
1IWZ	;	1.48	;	Crystal Structure Analysis of Human lysozyme at 178K.
1JIZ	;	2.6	;	Crystal Structure Analysis of human Macrophage Elastase MMP-12
6VAJ	;	1.42	;	Crystal Structure Analysis of human PIN1
7EFJ	;	1.992	;	Crystal Structure Analysis of human PIN1
7SZA	;	1.9	;	Crystal Structure Analysis of human PRPK complex with a compound
7SZB	;	2.02	;	Crystal Structure Analysis of human PRPK complex with a compound
7SZC	;	1.71	;	Crystal Structure Analysis of human PRPK complex with a compound
7SZD	;	2.05	;	Crystal Structure Analysis of human PRPK complex with a compound
2FV2	;	2.2	;	Crystal Structure Analysis of human Rcd-1 conserved region
3T0O	;	1.59	;	Crystal Structure Analysis of Human RNase T2
2H2K	;	2.0	;	Crystal Structure Analysis of Human S100A13
1P5J	;	2.5	;	Crystal Structure Analysis of Human Serine Dehydratase
3A73	;	2.19	;	Crystal Structure Analysis of Human serum albumin complexed with delta 12-prostaglandin J2
4EMX	;	2.3	;	Crystal structure analysis of Human Serum Albumin in complex with chloride anions at cryogenic temperature
2R83	;	2.7	;	Crystal structure analysis of human synaptotagmin 1 C2A-C2B
7LI5	;	1.68	;	Crystal Structure Analysis of human TEAD1
7TUO	;	1.96	;	Crystal structure analysis of human USP28 complex with a compound
7S7G	;	1.34	;	Crystal Structure Analysis of Human VLCAD
5CZG	;	1.451	;	Crystal Structure Analysis of hypothetical bromodomain Tb427.10.7420 from Trypanosoma brucei in complex with bromosporine
1YWR	;	1.95	;	Crystal Structure Analysis of inactive P38 kinase domain in complex with a Monocyclic Pyrazolone Inhibitor
3SNP	;	2.8	;	Crystal structure analysis of iron regulatory protein 1 in complex with ferritin H IRE RNA
3SN2	;	2.99	;	Crystal structure analysis of iron regulatory protein 1 in complex with transferrin receptor IRE B RNA
1FP2	;	1.4	;	CRYSTAL STRUCTURE ANALYSIS OF ISOFLAVONE O-METHYLTRANSFERASE
1CUO	;	1.6	;	CRYSTAL STRUCTURE ANALYSIS OF ISOMER-2 AZURIN FROM METHYLOMONAS J
1R5Q	;	2.0	;	Crystal Structure Analysis of Kai A from PCC7120
1R5P	;	2.2	;	Crystal Structure Analysis of KaiB from PCC7120
1GG0	;	3.0	;	CRYSTAL STRUCTURE ANALYSIS OF KDOP SYNTHASE AT 3.0 A
4ZGC	;	2.5	;	Crystal Structure Analysis of Kelch protein (with disulfide bond) from Plasmodium falciparum
4YY8	;	1.81	;	Crystal Structure Analysis of Kelch protein from Plasmodium falciparum
1FPZ	;	2.0	;	CRYSTAL STRUCTURE ANALYSIS OF KINASE ASSOCIATED PHOSPHATASE (KAP) WITH A SUBSTITUTION OF THE CATALYTIC SITE CYSTEINE (CYS140) TO A SERINE
3H8N	;	2.5	;	Crystal Structure Analysis of KIR2DS4
2FH6	;	1.8	;	Crystal Structure Analysis of Klebsiella pneumoniae pullulanase complexed with glucose
2FH8	;	1.9	;	Crystal Structure Analysis of Klebsiella pneumoniae pullulanase complexed with isomaltose
2FHB	;	1.8	;	Crystal Structure Analysis of Klebsiella pneumoniae pullulanase complexed with maltose
2FHF	;	1.65	;	Crystal Structure Analysis of Klebsiella pneumoniae pullulanase complexed with maltotetraose
2FHC	;	1.85	;	Crystal Structure Analysis of Klebsiella pneumoniae pullulanase complexed with maltotriose
2WNH	;	1.68	;	Crystal Structure Analysis of Klebsiella sp ASR1 Phytase
2WNI	;	2.57	;	Crystal Structure Analysis of Klebsiella sp ASR1 Phytase
2WU0	;	2.57	;	Crystal Structure Analysis of Klebsiella sp ASR1 Phytase
3U6V	;	2.2	;	Crystal Structure Analysis of L23A mutant of human GST A1-1
6C5B	;	1.42	;	Crystal Structure Analysis of LaPhzM
4GNJ	;	1.93	;	Crystal Structure Analysis of Leishmania siamensis Triosephosphate Isomerase
2QEI	;	1.85	;	Crystal structure analysis of LeuT complexed with L-alanine, sodium, and clomipramine
2QB4	;	1.9	;	Crystal Structure Analysis of LeuT complexed with L-leucine, sodium and desipramine
2Q6H	;	1.85	;	Crystal Structure Analysis of LeuT complexed with L-leucine, sodium, and clomipramine
2Q72	;	1.7	;	Crystal Structure Analysis of LeuT complexed with L-leucine, sodium, and imipramine
4EGS	;	2.3	;	Crystal Structure Analysis of Low Molecular Weight Protein Tyrosine Phosphatase from T. tengcongensis
4R36	;	1.9	;	Crystal structure analysis of LpxA, a UDP-N-acetylglucosamine acyltransferase from Bacteroides fragilis 9343
4R37	;	1.9	;	Crystal structure analysis of LpxA, a UDP-N-acetylglucosamine acyltransferase from Bacteroides fragilis 9343 with UDP-GlcNAc
1HQK	;	1.6	;	CRYSTAL STRUCTURE ANALYSIS OF LUMAZINE SYNTHASE FROM AQUIFEX AEOLICUS
3QE8	;	1.49	;	Crystal Structure Analysis of Lysozyme-bound fac-[Re(CO)3(H2O)(Im)]+
3QNG	;	1.55	;	Crystal Structure Analysis of Lysozyme-bound fac-[Re(CO)3(L-serine)]
3O3T	;	1.7	;	Crystal Structure Analysis of M32A mutant of human CLIC1
3LLY	;	2.25	;	Crystal Structure Analysis of Maclura pomifera agglutinin
3LLZ	;	1.55	;	Crystal Structure Analysis of Maclura pomifera agglutinin complex with Gal-beta-1,3-GalNAc
3LM1	;	2.1	;	Crystal Structure Analysis of Maclura pomifera agglutinin complex with p-nitrophenyl-GalNAc
4P0H	;	1.93	;	Crystal Structure Analysis of Macrophage Migration Inhibitory Factor in complex with Dimethylformamide
4P01	;	2.07	;	Crystal Structure Analysis of Macrophage Migration Inhibitory Factor in complex with N-[(4-cyanophenyl)methyl]methanethioamide
1IZC	;	1.7	;	Crystal Structure Analysis of Macrophomate synthase
3LZQ	;	1.41	;	Crystal Structure Analysis of Manganese treated P19 protein from Campylobacter jejuni at 1.41 A at pH 9
3LZR	;	2.73	;	Crystal Structure Analysis of Manganese treated P19 protein from Campylobacter jejuni at 2.73 A at pH 9 and Manganese peak wavelength (1.893 A)
6XDJ	;	2.2	;	Crystal Structure Analysis of MBP-SIN3
1P9E	;	2.4	;	Crystal Structure Analysis of Methyl Parathion Hydrolase from Pseudomonas sp WBC-3
1IXK	;	1.9	;	Crystal Structure Analysis of Methyltransferase Homolog Protein from Pyrococcus Horikoshii
3IF5	;	2.44	;	Crystal Structure Analysis of Mglu
3IHA	;	2.6	;	Crystal Structure Analysis of Mglu in its glutamate form
3IH8	;	2.3	;	Crystal Structure Analysis of Mglu in its native form
3IHB	;	2.4	;	Crystal Structure Analysis of Mglu in its tris and glutamate form
3IH9	;	2.5	;	Crystal Structure Analysis of Mglu in its tris form
3N52	;	1.9	;	crystal Structure analysis of MIP2
2P2V	;	1.85	;	Crystal structure analysis of monofunctional alpha-2,3-sialyltransferase Cst-I from Campylobacter jejuni
3IKK	;	2.5	;	Crystal structure analysis of msp domain
4R43	;	1.8	;	Crystal Structure Analysis of MTB PEPCK
5I67	;	2.602	;	Crystal Structure Analysis of MTB PEPCK mutant C273S
4RCG	;	2.6	;	Crystal Structure Analysis of MTB PEPCK without Mn+2
2QJK	;	3.1	;	Crystal Structure Analysis of mutant rhodobacter sphaeroides bc1 with stigmatellin and antimycin
4DKY	;	2.478	;	Crystal structure Analysis of N terminal region containing the dimerization domain and DNA binding domain of HU protein(Histone like protein-DNA binding) from Mycobacterium tuberculosis [H37Ra]
4PT4	;	2.04	;	Crystal structure Analysis of N terminal region containing the dimerization domain and DNA binding domain of HU protein(Histone like protein-DNA binding) from Mycobacterium tuberculosis [H37Ra]
1F5Z	;	1.88	;	CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM I
1F6K	;	1.6	;	CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM II
1F74	;	1.6	;	CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM II COMPLEXED WITH 4-DEOXY-SIALIC ACID
1F7B	;	1.8	;	CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM II IN COMPLEX WITH 4-OXO-SIALIC ACID
1F6P	;	2.25	;	CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM III
1F73	;	1.95	;	CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM III IN COMPLEX WITH SIALIC ACID ALDITOL
1NEG	;	2.3	;	Crystal Structure Analysis of N-and C-terminal labeled SH3-domain of alpha-Chicken Spectrin
1FO6	;	1.95	;	CRYSTAL STRUCTURE ANALYSIS OF N-CARBAMoYL-D-AMINO-ACID AMIDOHYDROLASE
1JSZ	;	1.93	;	Crystal Structure Analysis of N7,9-dimethylguanine-VP39 complex
1FVF	;	3.2	;	CRYSTAL STRUCTURE ANALYSIS OF NEURONAL SEC1 FROM THE SQUID L. PEALEI
1FVH	;	2.8	;	CRYSTAL STRUCTURE ANALYSIS OF NEURONAL SEC1 FROM THE SQUID L. PEALEI
2ZWS	;	1.4	;	Crystal Structure Analysis of neutral ceramidase from Pseudomonas aeruginosa
4OI6	;	2.04	;	Crystal structure analysis of nickel-bound form SCO4226 from Streptomyces coelicolor A3(2)
1F9A	;	2.0	;	CRYSTAL STRUCTURE ANALYSIS OF NMN ADENYLYLTRANSFERASE FROM METHANOCOCCUS JANNASCHII
3D9W	;	2.7	;	Crystal Structure Analysis of Nocardia farcinica Arylamine N-acetyltransferase
1IHM	;	3.4	;	CRYSTAL STRUCTURE ANALYSIS OF NORWALK VIRUS CAPSID
4XGS	;	2.25	;	Crystal structure analysis of novel iron uptake mechanism of Gram-negative bacterial ferritin
2I0W	;	2.5	;	Crystal structure analysis of NP24-I, a thaumatin-like protein
1F8Y	;	2.4	;	CRYSTAL STRUCTURE ANALYSIS OF NUCLEOSIDE 2-DEOXYRIBOSYLTRANSFERASE COMPLEXED WITH 5-METHYL-2'-DEOXYPSEUDOURIDINE
1S9X	;	2.5	;	Crystal Structure Analysis of NY-ESO-1 epitope analogue, SLLMWITQA, in complex with HLA-A2
1S9Y	;	2.3	;	Crystal Structure Analysis of NY-ESO-1 epitope analogue, SLLMWITQS, in complex with HLA-A2
1S9W	;	2.2	;	Crystal Structure Analysis of NY-ESO-1 epitope, SLLMWITQC, in complex with HLA-A2
4LMA	;	2.3	;	Crystal structure analysis of O-acetylserine sulfhydrylase CysK1 from Microcystis aeruginosa 7806
4LMB	;	1.91	;	Crystal structure analysis of O-acetylserine sulfhydrylase CysK2 complexed with cystine from Microcystis aeruginosa 7806
1FHU	;	1.65	;	CRYSTAL STRUCTURE ANALYSIS OF O-SUCCINYLBENZOATE SYNTHASE FROM E. COLI
1FHV	;	1.77	;	CRYSTAL STRUCTURE ANALYSIS OF O-SUCCINYLBENZOATE SYNTHASE FROM E. COLI COMPLEXED WITH MG AND OSB
1SQJ	;	2.2	;	Crystal Structure Analysis of Oligoxyloglucan reducing-end-specific cellobiohydrolase (OXG-RCBH)
1X7D	;	1.6	;	Crystal Structure Analysis of Ornithine Cyclodeaminase Complexed with NAD and ornithine to 1.6 Angstroms
4G2U	;	1.85	;	Crystal Structure Analysis of Ostertagia ostertagi ASP-1
4AZU	;	1.9	;	CRYSTAL STRUCTURE ANALYSIS OF OXIDIZED PSEUDOMONAS AERUGINOSA AZURIN AT PH 5.5 AND PH 9.0. A PH-INDUCED CONFORMATIONAL TRANSITION INVOLVES A PEPTIDE BOND FLIP
5AZU	;	1.9	;	CRYSTAL STRUCTURE ANALYSIS OF OXIDIZED PSEUDOMONAS AERUGINOSA AZURIN AT PH 5.5 AND PH 9.0. A PH-INDUCED CONFORMATIONAL TRANSITION INVOLVES A PEPTIDE BOND FLIP
2EHD	;	2.4	;	Crystal Structure Analysis of Oxidoreductase
4DQW	;	2.51	;	Crystal Structure Analysis of PA3770
1CVZ	;	1.7	;	CRYSTAL STRUCTURE ANALYSIS OF PAPAIN WITH CLIK148(CATHEPSIN L SPECIFIC INHIBITOR)
3LX2	;	2.4	;	Crystal Structure analysis of PCNA from Thermococcus kodakaraensis tk0582
3LX1	;	2.0	;	Crystal Structure analysis of PCNA1 from Thermococcus kodakaraensis tk0535
2ZPL	;	1.7	;	Crystal structure analysis of PDZ domain A
2ZPM	;	0.98	;	Crystal structure analysis of PDZ domain B
3B4N	;	1.45	;	Crystal Structure Analysis of Pectate Lyase PelI from Erwinia chrysanthemi
1Z15	;	1.7	;	Crystal structure analysis of periplasmic Leu/Ile/Val-binding protein in superopen form
1Z16	;	1.72	;	Crystal structure analysis of periplasmic Leu/Ile/Val-binding protein with bound leucine
1Z17	;	1.96	;	Crystal structure analysis of periplasmic Leu/Ile/Val-binding protein with bound ligand isoleucine
1Z18	;	2.1	;	Crystal structure analysis of periplasmic Leu/Ile/Val-binding protein with bound valine
4REG	;	2.494	;	Crystal Structure Analysis of PF0642
1UB0	;	2.05	;	Crystal Structure Analysis of Phosphomethylpyrimidine Kinase (ThiD) from Thermus Thermophilus Hb8
3KPX	;	1.899	;	Crystal Structure Analysis of photoprotein clytin
3WU2	;	1.9	;	Crystal structure analysis of Photosystem II complex
5B5E	;	1.87	;	Crystal structure analysis of Photosystem II complex
5B66	;	1.85	;	Crystal structure analysis of Photosystem II complex
6DUN	;	1.59	;	Crystal Structure Analysis of PIN1
6O33	;	1.74	;	Crystal Structure Analysis of PIN1
6O34	;	1.57	;	Crystal Structure Analysis of PIN1
6OSP	;	2.21	;	Crystal Structure Analysis of PIP4K2A
6UX9	;	1.71	;	Crystal Structure Analysis of PIP4K2A
3GPE	;	2.0	;	Crystal Structure Analysis of PKC (alpha)-C2 domain complexed with Ca2+ and PtdIns(4,5)P2
3WLH	;	1.65	;	Crystal Structure Analysis of Plant Exohydrolase
3WLI	;	1.45	;	Crystal Structure Analysis of Plant Exohydrolase
3WLO	;	1.55	;	Crystal Structure Analysis of Plant Exohydrolase
3WLP	;	1.57	;	Crystal Structure Analysis of Plant Exohydrolase
3WLQ	;	1.65	;	Crystal Structure Analysis of Plant Exohydrolase
3WLR	;	2.21	;	Crystal Structure Analysis of Plant Exohydrolase
6MD6	;	1.68	;	CRYSTAL STRUCTURE ANALYSIS OF PLANT EXOHYDROLASE IN COMPLEX WITH METHYL 2-THIO-BETA-SOPHOROSIDE
1NHW	;	2.35	;	Crystal Structure Analysis of Plasmodium falciparum enoyl-acyl-carrier-protein reductase
1VRW	;	2.4	;	Crystal structure analysis of plasmodium falciparum enoyl-acyl-carrier-protein reductase with nadh
1NHG	;	2.43	;	CRYSTAL STRUCTURE ANALYSIS OF PLASMODIUM FALCIPARUM ENOYL-ACYL-CARRIER-PROTEIN REDUCTASE WITH TRICLOSAN
1NNU	;	2.5	;	Crystal Structure Analysis of Plasmodium falciparum enoyl-acyl-carrier-protein reductase with Triclosan Analog
3VI2	;	2.1	;	Crystal Structure Analysis of Plasmodium falciparum OMP Decarboxylase in complex with inhibitor HMOA
3PHZ	;	1.7	;	Crystal Structure Analysis of Polyporus squamosus lectin bound to human-type influenza-binding epitope Neu5Aca2-6Galb1-4GlcNAc
5C8G	;	1.95	;	Crystal Structure Analysis of PP-BRD20 from Tb427tmp complexed with BI-2536
1I1H	;	2.6	;	CRYSTAL STRUCTURE ANALYSIS OF PRECORRIN-8X METHYLMUTASE COMPLEX WITH HYDROGENOBYRINIC ACID
1F2V	;	2.1	;	CRYSTAL STRUCTURE ANALYSIS OF PRECORRIN-8X METHYLMUTASE OF AEROBIC VITAMIN B12 SYNTHESIS
5WTN	;	2.8	;	Crystal Structure Analysis of primosome protein DnaB (resiues 1-300) from Geobacillus stearothermophilus
1YJ3	;	1.6	;	Crystal structure analysis of product bound methionine aminopeptidase Type 1c from Mycobacterium Tuberculosis
6K9O	;	1.06	;	Crystal Structure Analysis of Protein
6K9X	;	1.2	;	Crystal Structure Analysis of Protein
2CZW	;	1.9	;	Crystal structure analysis of protein component Ph1496p of P.horikoshii ribonuclease P
1GA1	;	1.4	;	CRYSTAL STRUCTURE ANALYSIS OF PSCP (PSEUDOMONAS SERINE-CARBOXYL PROTEINASE) COMPLEXED WITH A FRAGMENT OF IODOTYROSTATIN (THIS ENZYME RENAMED ""SEDOLISIN"" IN 2003)
1GA6	;	1.0	;	CRYSTAL STRUCTURE ANALYSIS OF PSCP (PSEUDOMONAS SERINE-CARBOXYL PROTEINASE) COMPLEXED WITH A FRAGMENT OF TYROSTATIN (THIS ENZYME RENAMED ""SEDOLISIN"" IN 2003)
1GA4	;	1.4	;	CRYSTAL STRUCTURE ANALYSIS OF PSCP (PSEUDOMONAS SERINE-CARBOXYL PROTEINASE) COMPLEXED WITH INHIBITOR PSEUDOIODOTYROSTATIN (THIS ENZYME RENAMED ""SEDOLISIN"" IN 2003)
1I2H	;	1.8	;	CRYSTAL STRUCTURE ANALYSIS OF PSD-ZIP45(HOMER1C/VESL-1L)CONSERVED HOMER 1 DOMAIN
4R32	;	3.505	;	Crystal Structure Analysis of Pyk2 and Paxillin LD motifs
1G3Q	;	2.0	;	CRYSTAL STRUCTURE ANALYSIS OF PYROCOCCUS FURIOSUS CELL DIVISION ATPASE MIND
1G3R	;	2.7	;	CRYSTAL STRUCTURE ANALYSIS OF PYROCOCCUS FURIOSUS CELL DIVISION ATPASE MIND
2E28	;	2.4	;	Crystal structure analysis of pyruvate kinase from Bacillus stearothermophilus
1SG0	;	1.5	;	Crystal structure analysis of QR2 in complex with resveratrol
3P8W	;	2.0	;	Crystal Structure Analysis of R29M/E81M double mutant of human CLIC1
1G98	;	1.9	;	CRYSTAL STRUCTURE ANALYSIS OF RABBIT PHOSPHOGLUCOSE ISOMERASE COMPLEXED WITH 5-PHOSPHOARABINONATE, A TRANSITION STATE ANALOGUE
1I4D	;	2.5	;	CRYSTAL STRUCTURE ANALYSIS OF RAC1-GDP COMPLEXED WITH ARFAPTIN (P21)
1I4L	;	2.7	;	CRYSTAL STRUCTURE ANALYSIS OF RAC1-GDP IN COMPLEX WITH ARFAPTIN (P41)
1I4T	;	2.6	;	CRYSTAL STRUCTURE ANALYSIS OF RAC1-GMPPNP IN COMPLEX WITH ARFAPTIN
1MJ3	;	2.1	;	Crystal Structure Analysis of rat enoyl-CoA hydratase in complex with hexadienoyl-CoA
2Z9S	;	2.9	;	Crystal Structure Analysis of rat HBP23/Peroxiredoxin I, Cys52Ser mutant
1U5I	;	2.86	;	Crystal Structure analysis of rat m-calpain mutant Lys10 Thr
1TB3	;	2.3	;	Crystal Structure Analysis of Recombinant Rat Kidney Long-chain Hydroxy Acid Oxidase
3OOT	;	2.55	;	Crystal Structure Analysis of Renin-indole-piperazin inhibitor complexes
3OQK	;	2.9	;	Crystal Structure Analysis of Renin-indole-piperazin inhibitor complexes
3OQF	;	2.78	;	Crystal Structure Analysis of Renin-indole-piperazine inhibitor complexes
1P2F	;	1.8	;	Crystal Structure Analysis of Response Regulator DrrB, a Thermotoga maritima OmpR/PhoB Homolog
4V8C	;	3.3	;	Crystal structure analysis of ribosomal decoding (near-cognate tRNA-leu complex with paromomycin).
4V8B	;	3.0	;	Crystal structure analysis of ribosomal decoding (near-cognate tRNA-leu complex).
4V8F	;	3.3	;	Crystal structure analysis of ribosomal decoding (near-cognate tRNA-ttyr complex with paromomycin).
4V8E	;	3.3	;	Crystal structure analysis of ribosomal decoding (near-cognate tRNA-tyr complex).
4V87	;	3.1	;	Crystal structure analysis of ribosomal decoding.
5YSM	;	1.9	;	Crystal Structure Analysis of Rif16
5YSW	;	2.6	;	Crystal Structure Analysis of Rif16 in complex with R-L
3BK1	;	2.33	;	Crystal Structure Analysis of RNase J
1K3L	;	1.5	;	Crystal Structure Analysis of S-hexyl-glutathione Complex of Glutathione Transferase at 1.5 Angstroms Resolution
2IP1	;	1.8	;	Crystal Structure Analysis of S. cerevisiae Tryptophanyl tRNA Synthetase
3GVA	;	2.0	;	Crystal Structure Analysis of S. Pombe ATL
3GYH	;	2.8	;	Crystal Structure Analysis of S. Pombe ATL in complex with damaged DNA containing POB
3GX4	;	2.7	;	Crystal Structure Analysis of S. Pombe ATL in complex with DNA
1R17	;	1.86	;	Crystal Structure Analysis of S.epidermidis adhesin SdrG binding to Fibrinogen (adhesin-ligand complex)
1R19	;	3.51	;	Crystal Structure Analysis of S.epidermidis adhesin SdrG binding to Fibrinogen (Apo structure)
8CUC	;	2.09	;	Crystal structure analysis of SALL4 zinc finger domain in complex with DNA
4OI3	;	1.3	;	Crystal structure analysis of SCO4226 from Streptomyces coelicolor A3(2)
4EQ3	;	2.001	;	Crystal Structure Analysis of Selenomethionine (Se-Met) Substituted Chicken Interferon Gamma Receptor Alpha Chain
1FPQ	;	2.0	;	CRYSTAL STRUCTURE ANALYSIS OF SELENOMETHIONINE SUBSTITUTED CHALCONE O-METHYLTRANSFERASE
6CIG	;	1.65	;	CRYSTAL STRUCTURE ANALYSIS OF SELENOMETHIONINE SUBSTITUTED ISOFLAVONE O-METHYLTRANSFERASE
1QQQ	;	1.5	;	CRYSTAL STRUCTURE ANALYSIS OF SER254 MUTANT OF ESCHERICHIA COLI THYMIDYLATE SYNTHASE
3CH2	;	1.8	;	Crystal Structure Analysis of SERA5E from plasmodium falciparum
3CH3	;	1.79	;	Crystal Structure Analysis of SERA5E from plasmodium falciparum
2WBF	;	1.6	;	Crystal Structure Analysis of SERA5E from plasmodium falciparum with loop 690-700 ordered
1XUZ	;	2.2	;	Crystal structure analysis of sialic acid synthase (NeuB)from Neisseria meningitidis, bound to Mn2+, Phosphoenolpyruvate, and N-acetyl mannosaminitol
6XAW	;	1.84	;	Crystal Structure Analysis of SIN3-UME6
4KA9	;	1.58	;	Crystal structure analysis of single amino acid deletion mutations in EGFP
1QVC	;	2.2	;	CRYSTAL STRUCTURE ANALYSIS OF SINGLE STRANDED DNA BINDING PROTEIN (SSB) FROM E.COLI
3U71	;	2.72	;	Crystal Structure Analysis of South African wild type HIV-1 Subtype C Protease
6W8E	;	2.68	;	Crystal Structure Analysis of Space-grown Lysozyme
6W7P	;	1.6	;	Crystal Structure Analysis of Space-grown Lysozyme - Ground experiment
1K30	;	1.9	;	Crystal Structure Analysis of Squash (Cucurbita moschata) glycerol-3-phosphate (1)-acyltransferase
2QXL	;	2.41	;	Crystal Structure Analysis of Sse1, a yeast Hsp110
4GHO	;	1.1	;	Crystal Structure Analysis of Streptomyces aureofaciens Ribonuclease S24A mutant
4J5G	;	1.31	;	Crystal structure analysis of Streptomyces aureofaciens ribonuclease Sa T95A mutant
4J5K	;	1.23	;	Crystal structure analysis of Streptomyces aureofaciens ribonuclease Sa Y51F mutant
3CZE	;	1.9	;	Crystal Structure Analysis of Sucrose hydrolase (SUH)- Tris complex
3CZG	;	1.8	;	Crystal Structure Analysis of Sucrose hydrolase (SUH)-glucose complex
3CZL	;	2.0	;	Crystal Structure Analysis of Sucrose hydrolase(SUH) E322Q-glucose complex
3CZK	;	2.2	;	Crystal Structure Analysis of Sucrose hydrolase(SUH) E322Q-sucrose complex
3B4X	;	1.94	;	Crystal Structure Analysis of Sulfolobus tokodaii strain7 cytochrom P450
1R5B	;	2.35	;	Crystal structure analysis of sup35
1R5N	;	2.9	;	Crystal Structure Analysis of sup35 complexed with GDP
1R5O	;	3.2	;	crystal structure analysis of sup35 complexed with GMPPNP
6DQY	;	2.3	;	Crystal Structure analysis of Superoxide Dismutase from Trichoderma reesei
1J9J	;	1.9	;	CRYSTAL STRUCTURE ANALYSIS OF SURE PROTEIN FROM T.MARITIMA
2D73	;	1.6	;	Crystal Structure Analysis of SusB
3FFV	;	2.0	;	Crystal Structure Analysis of Syd
1NP7	;	1.9	;	Crystal Structure Analysis of Synechocystis sp. PCC6803 cryptochrome
6P38	;	2.8	;	Crystal Structure Analysis of TAF1 Bromodomain
6P39	;	2.941	;	Crystal Structure Analysis of TAF1 Bromodomain
6P3A	;	2.99	;	Crystal Structure Analysis of TAF1 Bromodomain
2FJ1	;	2.2	;	Crystal Structure Analysis of Tet Repressor (class D) in Complex with 7-Chlortetracycline-Nickel(II)
2O7O	;	1.89	;	Crystal structure analysis of TetR(D) complex with doxycycline
3LZP	;	1.65	;	Crystal Structure Analysis of the 'as-isolated' P19 protein from Campylobacter jejuni at 1.65 A at pH 9.0
4R3W	;	1.91	;	Crystal Structure Analysis of the 1,2,3-tricarboxylate benzoic acid bound to sp-ASADH-2'5'-ADP complex
2EI2	;	1.69	;	Crystal Structure Analysis of the 1,2-dihydroxynaphthalene dioxygenase from Pseudomonas sp. stain C18
4NFO	;	1.96	;	Crystal Structure Analysis of the 16mer GCAGACUUAAGUCUGC
4NFQ	;	1.7	;	Crystal Structure Analysis of the 16mer GCAGNCUUAAGUCUGC containing 7-triazolyl-8-aza-7-deazaadenosine
4NFP	;	1.85	;	Crystal Structure Analysis of the 16mer GCAGNCUUAAGUCUGC containing 8-aza-7-deaza-7-ethynyl Adenosine
3HQ0	;	2.0	;	Crystal Structure Analysis of the 2,3-dioxygenase LapB from Pseudomonas in complex with a product
3HPY	;	1.94	;	Crystal Structure Analysis of the 2,3-dioxygenase LapB from Pseudomonas in the complex with 4-methylcatechol
3HPV	;	2.3	;	Crystal Structure Analysis of the 2,3-dioxygenase LapB from Pseudomonas sp. KL28
1S9C	;	3.0	;	Crystal structure analysis of the 2-enoyl-CoA hydratase 2 domain of human peroxisomal multifunctional enzyme type 2
2YW3	;	1.67	;	Crystal Structure Analysis of the 4-hydroxy-2-oxoglutarate aldolase/2-deydro-3-deoxyphosphogluconate aldolase from TTHB1
2YW4	;	2.53	;	Crystal Structure Analysis of the 4-hydroxy-2-oxoglutarate aldolase/2-deydro-3-deoxyphosphogluconate aldolase from TTHB1
1SZO	;	1.9	;	Crystal Structure Analysis of the 6-Oxo Camphor Hydrolase His122Ala Mutant Bound to Its Natural Product (2S,4S)-alpha-Campholinic Acid
2FIJ	;	1.19	;	Crystal Structure Analysis of the A-DNA Decamer GCGT-2'OMeA-aU-ACGC, with Incorporated 2'-O-Methylated-Adenosine (2'OMeA) and Arabino-Uridine (aU)
2FIL	;	1.69	;	Crystal Structure Analysis of the A-DNA Decamer GCGT-2'OMeA-faT-ACGC, with Incorporated 2'-O-Methylated-Adenosine (2'OMeA) and 2'-Fluoroarabino-Thymidine (faT)
1JI0	;	2.0	;	Crystal Structure Analysis of the ABC transporter from Thermotoga maritima
1J0A	;	2.5	;	Crystal Structure Analysis of the ACC deaminase homologue
1J0B	;	2.7	;	Crystal Structure Analysis of the ACC deaminase homologue complexed with inhibitor
4KSI	;	2.2	;	Crystal Structure Analysis of the Acidic Leucine Aminopeptidase of Tomato
1YRT	;	2.1	;	Crystal Structure analysis of the adenylyl cyclaes catalytic domain of adenylyl cyclase toxin of Bordetella pertussis in presence of c-terminal calmodulin
1YRU	;	2.5	;	Crystal Structure analysis of the adenylyl cyclaes catalytic domain of adenylyl cyclase toxin of Bordetella pertussis in presence of c-terminal calmodulin and 1mM calcium chloride
1V8I	;	1.76	;	Crystal Structure Analysis of the ADP-ribose pyrophosphatase
1V8R	;	1.8	;	Crystal structure analysis of the ADP-ribose pyrophosphatase complexed with ADP-ribose and Zn
1V8T	;	2.6	;	Crystal Structure analysis of the ADP-ribose pyrophosphatase complexed with ribose-5'-phosphate and Zn
1V8N	;	1.74	;	Crystal structure analysis of the ADP-ribose pyrophosphatase complexed with Zn
1V8U	;	1.9	;	Crystal structure analysis of the ADP-ribose pyrophosphatase of E82Q mutant with SO4 and Mg
1V8W	;	1.66	;	Crystal structure analysis of the ADP-ribose pyrophosphatase of E82Q mutant, complexed with SO4 and Zn
1V8V	;	1.97	;	Crystal structure analysis of the ADP-ribose pyrophosphatase of E86Q mutant, complexed with ADP-ribose and Mg
1V8Y	;	1.65	;	Crystal structure analysis of the ADP-ribose pyrophosphatase of E86Q mutant, complexed with ADP-ribose and Zn
1L6B	;	1.5	;	CRYSTAL STRUCTURE ANALYSIS OF THE ALL DNA HOLLIDAY JUNCTION STRUCTURE OF CCGGTACM5CGG
2G91	;	1.5	;	Crystal Structure Analysis of the an RNA nonamer r(GGUGCGC)d(BrC)r(C)
1KGZ	;	2.4	;	Crystal Structure Analysis of the Anthranilate Phosphoribosyltransferase from Erwinia carotovora (current name, Pectobacterium carotovorum)
1KHD	;	1.86	;	Crystal Structure Analysis of the anthranilate phosphoribosyltransferase from Erwinia carotovora at 1.9 resolution (current name, Pectobacterium carotovorum)
2Y06	;	2.5	;	CRYSTAL STRUCTURE ANALYSIS OF THE ANTI-(4-HYDROXY-3-NITROPHENYL) - ACETYL MURINE GERMLINE ANTIBODY BBE6.12H3 FAB FRAGMENT IN COMPLEX WITH A PHAGE DISPLAY DERIVED DODECAPEPTIDE GDPRPSYISHLL
2Y07	;	2.4	;	CRYSTAL STRUCTURE ANALYSIS OF THE ANTI-(4-HYDROXY-3-NITROPHENYL) - ACETYL MURINE GERMLINE MONOCLONAL ANTIBODY BBE6.12H3 FAB FRAGMENT IN COMPLEX WITH A PHAGE DISPLAY DERIVED DODECAPEPTIDE PPYPAWHAPGNI
2Y36	;	2.7	;	Crystal structure analysis of the anti-(4-hydroxy-3-nitrophenyl)- acetyl murine germline antibody BBE6.12H3 Fab fragment in complex with a phage display derived dodecapeptide DLWTTAIPTIPS
2XZQ	;	2.4	;	CRYSTAL STRUCTURE ANALYSIS OF THE ANTI-(4-HYDROXY-3-NITROPHENYL)- ACETYL MURINE GERMLINE MONOCLONAL ANTIBODY BBE6.12H3 FAB FRAGMENT IN COMPLEX WITH A PHAGE DISPLAY DERIVED DODECAPEPTIDE YQLRPNAETLRF
2A6J	;	2.7	;	Crystal structure analysis of the anti-arsonate germline antibody 36-65
2A6I	;	2.5	;	Crystal structure analysis of the anti-arsonate germline antibody 36-65 in complex with a phage display derived dodecapeptide KLASIPTHTSPL
2A6D	;	2.9	;	Crystal structure analysis of the anti-arsonate germline antibody 36-65 in complex with a phage display derived dodecapeptide RLLIADPPSPRE
1L7T	;	2.1	;	Crystal Structure Analysis of the anti-testosterone Fab fragment
1VPO	;	2.15	;	Crystal Structure Analysis of the Anti-testosterone Fab in Complex with Testosterone
3LZN	;	1.59	;	Crystal Structure Analysis of the apo P19 protein from Campylobacter jejuni at 1.59 A at pH 9
1IQV	;	2.1	;	Crystal Structure Analysis of the archaebacterial ribosomal protein S7
4DCN	;	3.01	;	Crystal Structure Analysis of the Arfaptin2 BAR domain in Complex with ARL1
3VLH	;	1.73	;	Crystal Structure Analysis of the Arg409Leu Variants of KatG from HALOARCULA MARISMORTUI
1ULY	;	2.5	;	Crystal structure analysis of the ArsR homologue DNA-binding protein from P. horikoshii OT3
3LZL	;	1.45	;	Crystal Structure Analysis of the as-solated P19 protein from Campylobacter jejuni at 1.45 A at pH 9.0
1S23	;	1.6	;	Crystal Structure Analysis of the B-DNA Decamer CGCAATTGCG
2FIH	;	1.13	;	Crystal Structure Analysis of the B-DNA Dodecamer CGCGAA-aU-TCGCG, with Incorporated Arabino-Uridine (aU)
2FII	;	1.24	;	Crystal Structure Analysis of the B-DNA Dodecamer CGCGAAT-aU-CGCG, with Incorporated Arabino-Uridin (aU)
1N5C	;	1.79	;	Crystal Structure Analysis of the B-DNA Dodecamer CGCGAATT(ethenoC)GCG
1JGR	;	1.2	;	Crystal Structure Analysis of the B-DNA Dodecamer CGCGAATTCGCG with Thallium Ions.
1D29	;	2.5	;	CRYSTAL STRUCTURE ANALYSIS OF THE B-DNA DODECAMER CGTGAATTCACG
1S9B	;	2.81	;	Crystal Structure Analysis of the B-DNA GAATTCG
1C9O	;	1.17	;	CRYSTAL STRUCTURE ANALYSIS OF THE BACILLUS CALDOLYTICUS COLD SHOCK PROTEIN BC-CSP
2ES2	;	1.78	;	Crystal Structure Analysis of the Bacillus Subtilis Cold Shock Protein Bs-CspB in Complex with Hexathymidine
2QXT	;	2.0	;	Crystal Structure Analysis of the Bacillus subtilis lipase crystallized at pH 4.5
2QXU	;	1.9	;	Crystal Structure Analysis of the Bacillus subtilis lipase crystallized at pH 5.0
4HYX	;	1.99	;	Crystal Structure Analysis of the Bacteriorhodopsin in Facial Amphiphile-4 DMPC Bicelle
4HWL	;	2.0	;	Crystal Structure Analysis of the Bacteriorhodopsin in Facial Amphiphile-7 DMPC Bicelle
1RRK	;	2.0	;	Crystal Structure Analysis of the Bb segment of Factor B
1RTK	;	2.3	;	Crystal Structure Analysis of the Bb segment of Factor B complexed with 4-guanidinobenzoic acid
1RS0	;	2.6	;	Crystal Structure Analysis of the Bb segment of Factor B complexed with Di-isopropyl-phosphate (DIP)
1S4U	;	2.1	;	Crystal Structure analysis of the beta-propeller protein Ski8p
1NEP	;	1.7	;	Crystal Structure Analysis of the Bovine NPC2 (Niemann-Pick C2) Protein
5Y8C	;	1.42	;	Crystal Structure Analysis of the BRD4
5Y8W	;	1.76	;	Crystal Structure Analysis of the BRD4
5Y8Y	;	1.87	;	Crystal Structure Analysis of the BRD4
5Y8Z	;	1.84	;	Crystal Structure Analysis of the BRD4
5Y93	;	1.62	;	Crystal Structure Analysis of the BRD4
5Y94	;	2.0	;	Crystal Structure Analysis of the BRD4
5YQX	;	1.82	;	Crystal Structure Analysis of the BRD4
5Z1R	;	1.62	;	Crystal Structure Analysis of the BRD4
7DHS	;	1.76	;	Crystal Structure Analysis of the BRD4
5Z1S	;	1.42	;	Crystal Structure Analysis of the BRD4(1)
5Z1T	;	1.42	;	Crystal Structure Analysis of the BRD4(1)
1I7N	;	1.9	;	CRYSTAL STRUCTURE ANALYSIS OF THE C DOMAIN OF SYNAPSIN II FROM RAT BRAIN
1U13	;	2.01	;	Crystal structure analysis of the C37L/C151T/C442A-triple mutant of CYP51 from Mycobacterium tuberculosis
1Q42	;	1.75	;	Crystal structure analysis of the Candida albicans Mtr2
3CN7	;	2.99	;	Crystal Structure Analysis of the Carboxylesterase PA3859 from Pseudomonas aeruginosa PAO1- MONOCLINIC CRYSTAL FORM
3CN9	;	2.09	;	Crystal Structure Analysis of the Carboxylesterase PA3859 from Pseudomonas aeruginosa PAO1- orthorhombic crystal form
3N5N	;	2.3	;	Crystal structure analysis of the catalytic domain and interdomain connector of human MutY homologue
1KWI	;	2.19	;	Crystal Structure Analysis of the Cathelicidin Motif of Protegrins
5XXH	;	1.62	;	Crystal Structure Analysis of the CBP
3QIL	;	3.92	;	Crystal structure analysis of the clathrin trimerization domain
2E46	;	2.3	;	Crystal Structure Analysis of the clock protein EA4
2E47	;	2.11	;	Crystal Structure Analysis of the clock protein EA4 (glycosylation form)
3VOR	;	0.9	;	Crystal Structure Analysis of the CofA
5E9A	;	2.561	;	Crystal structure analysis of the cold-adamped beta-galactosidase from Rahnella sp. R3
3A1H	;	1.08	;	Crystal Structure Analysis of the Collagen-like Peptide, (PPG)4-OTG-(PPG)4
2EFF	;	1.8	;	Crystal structure analysis of the complex between CyaY and Co(II)
2P1X	;	1.42	;	Crystal structure analysis of the complex between CyaY and Eu(III)
1L0P	;	2.1	;	CRYSTAL STRUCTURE ANALYSIS OF THE COMPLEX BETWEEN PSYCHROPHILIC ALPHA AMYLASE FROM PSEUDOALTEROMONAS HALOPLANCTIS AND NITRATE
1CQP	;	2.6	;	CRYSTAL STRUCTURE ANALYSIS OF THE COMPLEX LFA-1 (CD11A) I-DOMAIN / LOVASTATIN AT 2.6 A RESOLUTION
1I7L	;	2.35	;	CRYSTAL STRUCTURE ANALYSIS OF THE COMPLEX OF THE C DOMAIN OF SYNAPSIN II FROM RAT WITH ATP
3LZO	;	1.65	;	Crystal Structure Analysis of the copper-reconstituted P19 protein from Campylobacter jejuni at 1.65 A at pH 10.0
3QAX	;	2.0	;	Crystal structure analysis of the cpb0502
6KZ5	;	4.45	;	Crystal Structure Analysis of the Csn-B-bounded NUR77 Ligand binding Domain
1ZOT	;	2.2	;	crystal structure analysis of the CyaA/C-Cam with PMEAPP
3VLJ	;	1.7	;	Crystal Structure Analysis of the Cyanide Arg409Leu Variant Complexes with o-Dianisidine in KatG from HALOARCULA MARISMORTUI
3VLI	;	1.7	;	Crystal Structure Analysis of the Cyanide Arg409Leu Variant KatG from HALOARCULA MARISMORTUI
1MJ4	;	1.2	;	Crystal Structure Analysis of the cytochrome b5 domain of human sulfite oxidase
6M4S	;	1.85	;	Crystal Structure Analysis of the cytochrome P450 CYP-Sb21
6CYS	;	1.85	;	Crystal structure analysis of the D150G mutant of Superoxide Dismutase from Trichoderma reesei
1PTJ	;	2.61	;	Crystal structure analysis of the DI and DIII complex of transhydrogenase with a thio-nicotinamide nucleotide analogue
1ZI6	;	1.7	;	Crystal Structure Analysis of the dienelactone hydrolase (C123S) mutant- 1.7 A
1ZIC	;	1.7	;	Crystal Structure Analysis of the dienelactone hydrolase (C123S, R206A) mutant- 1.7 A
1ZI9	;	1.5	;	Crystal Structure Analysis of the dienelactone hydrolase (E36D, C123S) mutant- 1.5 A
1ZIY	;	1.9	;	Crystal Structure Analysis of the dienelactone hydrolase mutant (C123S) bound with the PMS moiety of the protease inhibitor, Phenylmethylsulfonyl fluoride (PMSF)- 1.9 A
1ZJ4	;	1.7	;	Crystal Structure Analysis of the dienelactone hydrolase mutant (E36D, C123S) bound with the PMS moiety of the protease inhibitor, Phenylmethylsulfonyl fluoride (PMSF)- 1.7 A
1ZJ5	;	1.7	;	Crystal Structure Analysis of the dienelactone hydrolase mutant (E36D, C123S, A134S, S208G, A229V, K234R) bound with the PMS moiety of the protease inhibitor, Phenylmethylsulfonyl fluoride (PMSF)- 1.7 A
1ZIX	;	1.8	;	Crystal Structure Analysis of the dienelactone hydrolase mutant (E36D, R105H, C123S, G211D, K234N)- 1.8 A
1ZI8	;	1.4	;	Crystal Structure Analysis of the dienelactone hydrolase mutant(E36D, C123S, A134S, S208G, A229V, K234R)- 1.4 A
2CZS	;	1.5	;	Crystal Structure Analysis of the Diheme c-type Cytochrome DHC2
1PT9	;	2.42	;	Crystal Structure Analysis of the DIII Component of Transhydrogenase with a Thio-Nicotinamide Nucleotide Analogue
2OYA	;	1.77	;	Crystal structure analysis of the dimeric form of the SRCR domain of mouse MARCO
1S45	;	2.2	;	Crystal structure analysis of the DNA quadruplex d(TGGGGT) S1
1S47	;	2.5	;	Crystal structure analysis of the DNA quadruplex d(TGGGGT)S2
4RZG	;	2.7	;	Crystal Structure Analysis of the DNPA-bounded NUR77 Ligand binding Domain
1J0W	;	2.5	;	Crystal Structure Analysis of the Dok-5 PTB Domain
2FYN	;	3.2	;	Crystal Structure Analysis of the double mutant Rhodobacter Sphaeroides bc1 complex
3GLX	;	1.85	;	Crystal Structure Analysis of the DtxR(E175K) complexed with Ni(II)
6ADV	;	1.96	;	Crystal Structure Analysis of the duplex containing the S2T(2',4'-BNA/LNA)G mismatch pairs
1EN4	;	2.0	;	CRYSTAL STRUCTURE ANALYSIS OF THE E. COLI MANGANESE SUPEROXIDE DISMUTASE Q146H MUTANT
1EN6	;	2.0	;	CRYSTAL STRUCTURE ANALYSIS OF THE E. COLI MANGANESE SUPEROXIDE DISMUTASE Q146L MUTANT
1EN5	;	2.3	;	CRYSTAL STRUCTURE ANALYSIS OF THE E. COLI MANGANESE SUPEROXIDE DISMUTASE Y34F MUTANT
4LJZ	;	3.5871	;	Crystal Structure Analysis of the E.coli holoenzyme
4LK1	;	3.8369	;	Crystal Structure Analysis of the E.coli holoenzyme
4LLG	;	3.7936	;	Crystal Structure Analysis of the E.coli holoenzyme/Gp2 complex
4LK0	;	3.9103	;	Crystal Structure Analysis of the E.coli holoenzyme/T7 Gp2 complex
1JLL	;	2.69	;	Crystal Structure Analysis of the E197betaA Mutant of E. coli SCS
4IQA	;	2.49	;	Crystal Structure Analysis of the E228L Mutant of Human CLIC1
3EMR	;	1.85	;	Crystal Structure Analysis of the ectoine hydroxylase ECTD from Salibacillus salexigens
4QP0	;	2.3	;	Crystal Structure Analysis of the Endo-1,4-beta-mannanase from Rhizomucor miehei
6DDM	;	1.3	;	Crystal Structure Analysis of the Epitope of an Anti-MICA Antibody
6DDR	;	1.9	;	Crystal Structure Analysis of the Epitope of an Anti-MICA Antibody
6DDV	;	2.05	;	Crystal Structure Analysis of the Epitope of an Anti-MICA Antibody
3M8L	;	3.4	;	Crystal Structure Analysis of the Feline Calicivirus Capsid Protein
1GAW	;	2.2	;	CRYSTAL STRUCTURE ANALYSIS OF THE FERREDOXIN-NADP+ REDUCTASE FROM MAIZE LEAF
1SM4	;	2.5	;	Crystal Structure Analysis of the Ferredoxin-NADP+ Reductase from Paprika
1NUN	;	2.9	;	Crystal Structure Analysis of the FGF10-FGFR2b Complex
1J4H	;	1.8	;	crystal structure analysis of the FKBP12 complexed with 000107 small molecule
1J4I	;	1.8	;	crystal structure analysis of the FKBP12 complexed with 000308 small molecule
3A8S	;	2.9	;	Crystal structure analysis of the fluorescent protein KillerRed
7SVS	;	2.8	;	Crystal structure analysis of the G73A mutant of Superoxide Dismutase from Trichoderma reesei
2HM7	;	2.0	;	Crystal Structure Analysis of the G84S EST2 mutant
1C16	;	3.1	;	CRYSTAL STRUCTURE ANALYSIS OF THE GAMMA/DELTA T CELL LIGAND T22
2A6K	;	3.0	;	Crystal Structure Analysis of the germline antibody 36-65 Fab in complex with the dodecapeptide SLGDNLTNHNLR
6J31	;	2.244	;	Crystal Structure Analysis of the Glycotransferase of kitacinnamycin
6J32	;	2.5	;	Crystal Structure Analysis of the Glycotransferase of kitacinnamycin
1K33	;	1.75	;	Crystal structure analysis of the gp41 core mutant
1I08	;	2.2	;	CRYSTAL STRUCTURE ANALYSIS OF THE H30A MUTANT OF MANGANESE SUPEROXIDE DISMUTASE FROM E. COLI
6CYP	;	2.0	;	Crystal structure analysis of the H75I mutant of Superoxide Dismutase from Trichoderma reesei
1LG5	;	1.75	;	Crystal Structure Analysis of the HCA II Mutant T199P in complex with beta-mercaptoethanol
2ZZQ	;	3.81	;	Crystal structure analysis of the HEV capsid protein, PORF2
5Z79	;	2.9	;	Crystal Structure Analysis of the HPPK-DHPS in complex with substrates
2GD8	;	1.46	;	Crystal structure analysis of the human carbonic anhydrase II in complex with a 2-substituted estradiol bis-sulfamate
2AAQ	;	2.6	;	Crystal Structure Analysis of the human Glutahione Reductase, complexed with GoPI
1FP5	;	2.3	;	CRYSTAL STRUCTURE ANALYSIS OF THE HUMAN IGE-FC CEPSILON3-CEPSILON4 FRAGMENT.
4FG3	;	2.001	;	Crystal Structure Analysis of the Human Insulin
4RVB	;	1.93	;	Crystal Structure Analysis of the Human Leukotriene A4 Hydrolase
1S31	;	2.704	;	Crystal Structure Analysis of the human Tub protein (isoform a) spanning residues 289 through 561
1MWO	;	2.2	;	Crystal Structure Analysis of the Hyperthermostable Pyrocoocus woesei alpha-amylase
1N64	;	2.34	;	Crystal structure analysis of the immunodominant antigenic site on Hepatitis C virus protein bound to mAb 19D9D6
4ITC	;	1.55	;	Crystal Structure Analysis of the K1 Cleaved Adhesin domain of Lys-gingipain (Kgp) from Porphyromonas gingivalis W83
3F2L	;	1.85	;	Crystal structure analysis of the K171A mutation of N-terminal type II cohesin 1 from the cellulosomal ScaB subunit of Acetivibrio cellulolyticus
3KM5	;	1.4	;	Crystal Structure Analysis of the K2 Cleaved Adhesin Domain of Lys-gingipain (Kgp)
3M1H	;	1.56	;	Crystal Structure Analysis of the K3 Cleaved Adhesin Domain of Lys-gingipain (Kgp) from Porphyromonas gingivalis w83
2DU2	;	2.1	;	Crystal Structure Analysis of the L-Lactate Oxidase
3Q74	;	1.79	;	Crystal Structure Analysis of the L7A Mutant of the Apo Form of Human Alpha Class Glutathione Transferase
6CYX	;	2.3	;	Crystal structure analysis of the L80F mutant of Superoxide Dismutase from Trichoderma reesei
1U4N	;	2.1	;	Crystal Structure Analysis of the M211S/R215L EST2 mutant
1QWR	;	1.8	;	Crystal Structure Analysis of the Mannose 6-Phosphate Isomerase from Bacillus subtilis
4QKY	;	2.9	;	Crystal Structure Analysis of the Membrane Transporter FhaC
4QL0	;	2.5	;	Crystal Structure Analysis of the Membrane Transporter FhaC (double mutant V169T, I176N)
3VLM	;	2.33	;	Crystal Structure Analysis of the Met244Ala Variant of KatG from Haloarcula marismortui
3JWH	;	2.2	;	Crystal structure analysis of the methyltransferase domain of bacterial-AvHen1-C
3JWJ	;	2.5	;	Crystal structure analysis of the methyltransferase domain of bacterial-AvHen1-CN
3JWG	;	1.9	;	Crystal structure analysis of the methyltransferase domain of bacterial-CtHen1-C
3JWI	;	2.2	;	Crystal structure analysis of the methyltransferase domain of bacterial-CtHen1-CN
1IU4	;	2.4	;	Crystal Structure Analysis of the Microbial Transglutaminase
3FCG	;	2.85	;	Crystal Structure Analysis of the Middle Domain of the Caf1A Usher
3VZ8	;	1.9	;	Crystal Structure Analysis of the Mini-chaperonin variant with Leu 185, Val 186, Pro 187, Arg 188 and Ser 190 replaced with all Gly
3VZ7	;	1.8	;	Crystal Structure Analysis of the mini-chaperonin variant with Pro 187 Gly
3VZ6	;	1.5	;	Crystal Structure Analysis of the Mini-chaperonines, variant with Gly 184 replaced with Ile and Leu 185 replaced Val and Val 186 replaced with Leu.
1ZPI	;	1.6	;	Crystal structure analysis of the minor groove binding quinolinium quaternary salt SN 8224 complexed with CGCGAATTCGCG
1ZPH	;	1.8	;	Crystal structure analysis of the minor groove binding quinolinium quaternary salt SN 8315 complexed with CGCGAATTCGCG
2OW9	;	1.74	;	Crystal structure analysis of the MMP13 catalytic domain in complex with specific inhibitor
2OY3	;	1.78	;	Crystal structure analysis of the monomeric SRCR domain of mouse MARCO
1N1X	;	1.45	;	Crystal Structure Analysis of the monomeric [S-carboxyamidomethyl-Cys31, S-carboxyamidomethyl-Cys32] Bovine seminal ribonuclease
3AA9	;	2.3	;	Crystal Structure Analysis of the Mutant CutA1 (E61V) from E. coli
3AA8	;	2.3	;	Crystal Structure Analysis of the Mutant CutA1 (S11V/E61V) from E. coli
1JD9	;	2.5	;	CRYSTAL STRUCTURE ANALYSIS OF THE MUTANT K300Q OF PSEUDOALTEROMONAS HALOPLANCTIS ALPHA-AMYLASE
1JD7	;	2.25	;	CRYSTAL STRUCTURE ANALYSIS OF THE MUTANT K300R OF PSEUDOALTEROMONAS HALOPLANCTIS ALPHA-AMYLASE
1FNQ	;	2.6	;	CRYSTAL STRUCTURE ANALYSIS OF THE MUTANT REACTION CENTER PRO L209-> GLU FROM THE PHOTOSYNTHETIC PURPLE BACTERIUM RHODOBACTER SPHAEROIDES
1FNP	;	2.6	;	CRYSTAL STRUCTURE ANALYSIS OF THE MUTANT REACTION CENTER PRO L209-> PHE FROM THE PHOTOSYNTHETIC PURPLE BACTERIUM RHODOBACTER SPHAEROIDES
1F6N	;	2.8	;	CRYSTAL STRUCTURE ANALYSIS OF THE MUTANT REACTION CENTER PRO L209-> TYR FROM THE PHOTOSYNTHETIC PURPLE BACTERIUM RHODOBACTER SPHAEROIDES
1KDQ	;	2.55	;	Crystal Structure Analysis of the Mutant S189D Rat Chymotrypsin
1X0J	;	1.8	;	Crystal structure analysis of the N-terminal bromodomain of human Brd2
2DVQ	;	2.04	;	Crystal structure analysis of the N-terminal bromodomain of human BRD2 complexed with acetylated histone H4 peptide
2DVR	;	2.3	;	Crystal structure analysis of the N-terminal bromodomain of human BRD2 complexed with acetylated histone H4 peptide
2DVS	;	2.04	;	Crystal structure analysis of the N-terminal bromodomain of human BRD2 complexed with acetylated histone H4 peptide
3W9S	;	1.7	;	Crystal Structure Analysis of the N-terminal Receiver domain of Response Regulator PmrA
1LV1	;	2.1	;	Crystal Structure Analysis of the non-active site mutant of tethered HIV-1 protease to 2.1A resolution
4RZE	;	2.49	;	Crystal Structure Analysis of the NUR77 Ligand Binding Domain, L437W,D594E mutant
4RZF	;	1.99	;	Crystal Structure Analysis of the NUR77 Ligand Binding Domain, S441W mutant
1SQ2	;	1.45	;	Crystal Structure Analysis of the Nurse Shark New Antigen Receptor (NAR) Variable Domain in Complex With Lysozyme
1T6V	;	1.7	;	Crystal structure analysis of the nurse shark new antigen receptor (NAR) variable domain in complex with lysozyme
2I27	;	1.92	;	Crystal Structure Analysis of the Nurse Shark New Antigen Receptor Ancestral variable domain
2I26	;	2.5	;	Crystal structure analysis of the nurse shark new antigen receptor ancestral variable domain in complex with lysozyme
2I24	;	1.35	;	Crystal structure analysis of the nurse shark New Antigen Receptor PBLA8 variable domain
2I25	;	1.8	;	Crystal structure analysis of the nurse shark New antigen Receptor PBLA8 variable domain in complex with lysozyme
3DUL	;	1.8	;	Crystal Structure Analysis of the O-methyltransferase from Bacillus cereus
1YI9	;	1.7	;	Crystal Structure Analysis of the oxidized form of the M314I mutant of Peptidylglycine alpha-Hydroxylating Monooxygenase
3VJJ	;	3.0	;	Crystal Structure Analysis of the P9-1
3VQF	;	1.199	;	Crystal Structure Analysis of the PDZ Domain Derived from the Tight Junction Regulating Protein
3VQG	;	1.35	;	Crystal Structure Analysis of the PDZ Domain Derived from the Tight Junction Regulating Protein
1M21	;	1.8	;	Crystal structure analysis of the peptide amidase PAM in complex with the competitive inhibitor chymostatin
2DX8	;	2.7	;	Crystal Structure Analysis of the PHD domain of the Transcription Coactivator Pygophus
1FU0	;	1.9	;	CRYSTAL STRUCTURE ANALYSIS OF THE PHOSPHO-SERINE 46 HPR FROM ENTEROCOCCUS FAECALIS
3QO6	;	2.5	;	Crystal structure analysis of the plant protease Deg1
1FQ2	;	1.2	;	CRYSTAL STRUCTURE ANALYSIS OF THE POTASSIUM FORM OF B-DNA DODECAMER CGCGAATTCGCG
1QTR	;	2.32	;	CRYSTAL STRUCTURE ANALYSIS OF THE PROLYL AMINOPEPTIDASE FROM SERRATIA MARCESCENS
4MM0	;	2.6	;	Crystal Structure Analysis of the Putative Thioether Synthase SgvP Involved in the Tailoring Step of Griseoviridin
1VB5	;	2.2	;	Crystal Structure Analysis of the Pyrococcus horikoshii OT3 translation initiation factor eIF-2B
1HM5	;	1.8	;	CRYSTAL STRUCTURE ANALYSIS OF THE RABBIT D-GLUCOSE 6-PHOSPHATE ISOMERASE (NO LIGAND BOUND)
2EMS	;	2.9	;	Crystal Structure Analysis of the radixin FERM domain complexed with adhesion molecule CD43
2EMT	;	2.8	;	Crystal Structure Analysis of the radixin FERM domain complexed with adhesion molecule PSGL-1
3LOA	;	2.299	;	Crystal Structure Analysis of the RNA construct with two adjacent ligand binding sites of helix h44 in 16S ribosomal RNA
2G92	;	1.61	;	Crystal Structure Analysis of the RNA Dodecamer CGC-(NF2)-AAUUAGCG, with an Incorporated 2,4-Difluorotoluyl Residue (NF2)
2Q1O	;	1.1	;	Crystal Structure Analysis of the RNA Dodecamer CGC-NF2-AAUUGGCG, with an Incorporated 2,4-Difluorotoluyl Residue (NF2)
2Q1R	;	1.12	;	Crystal Structure Analysis of the RNA Dodecamer CGCGAAUUAGCG, with a G-A mismatch.
3BK2	;	2.1	;	Crystal Structure Analysis of the RNase J/UMP complex
6J1L	;	2.3	;	Crystal Structure Analysis of the ROR gamma(C455E)
1KS2	;	1.5	;	Crystal Structure Analysis of the rpiA, Structural Genomics, protein EC1268.
1S4D	;	2.7	;	Crystal Structure Analysis of the S-adenosyl-L-methionine dependent uroporphyrinogen-III C-methyltransferase SUMT
5XHE	;	1.4	;	Crystal structure analysis of the second bromodomain of BRD2 covalently linked to b-mercaptoethanol
1NTE	;	1.24	;	CRYSTAL STRUCTURE ANALYSIS OF THE SECOND PDZ DOMAIN OF SYNTENIN
1PN2	;	1.95	;	Crystal structure analysis of the selenomethionine labelled 2-enoyl-CoA hydratase 2 domain of Candida tropicalis multifunctional enzyme type 2
1EW0	;	1.4	;	CRYSTAL STRUCTURE ANALYSIS OF THE SENSOR DOMAIN OF RMFIXL(FERROUS FORM)
3VLK	;	2.0	;	Crystal Structure Analysis of the Ser305Ala variant of KatG from Haloarcula marismortui
3VLL	;	2.0	;	Crystal Structure Analysis of the Ser305Ala variant of KatG from HALOARCULA MARISMORTUI Complexes with Inhibitor SHA
3UW8	;	2.35	;	Crystal Structure Analysis of the Ser305Thr Variants of KatG from Haloarcula marismortui
1JWO	;	2.5	;	Crystal Structure Analysis of the SH2 Domain of the Csk Homologous Kinase CHK
1PL5	;	2.5	;	Crystal Structure Analysis of the Sir4p C-terminal Coiled Coil
1V9I	;	2.95	;	Crystal Structure Analysis of the site specific mutant (Q253C) of bovine carbonic anhydrase II
2Z41	;	3.51	;	Crystal Structure Analysis of the Ski2-type RNA helicase
1DD1	;	2.62	;	CRYSTAL STRUCTURE ANALYSIS OF THE SMAD4 ACTIVE FRAGMENT
2ZHJ	;	1.35	;	Crystal Structure Analysis of the Sodium-Bound Annexin A4 at 1.34 A resolution
2ZHI	;	1.58	;	Crystal Structure Analysis of the Sodium-Bound Annexin A4 at 1.58 A resolution
4OYB	;	1.7	;	Crystal Structure Analysis of the solAC
5GHL	;	2.0	;	Crystal structure Analysis of the starch-binding domain of glucoamylase from Aspergillus niger
7E7M	;	2.85	;	Crystal Structure Analysis of the Streptococcus agalactiae Ribose Binding Protein RbsB
3CX3	;	2.4	;	Crystal structure Analysis of the Streptococcus pneumoniae AdcAII protein
3TJT	;	1.801	;	Crystal Structure Analysis of the superoxide dismutase from Clostridium difficile
3W8V	;	2.1	;	Crystal Structure Analysis of the synthetic GCN4 coiled coil peptide
3W93	;	1.5	;	Crystal Structure Analysis of the synthetic GCN4 Ester coiled coil peptide
3W92	;	1.35	;	Crystal Structure Analysis of the synthetic GCN4 Thioester coiled coil peptide
1G94	;	1.74	;	CRYSTAL STRUCTURE ANALYSIS OF THE TERNARY COMPLEX BETWEEN PSYCHROPHILIC ALPHA AMYLASE FROM PSEUDOALTEROMONAS HALOPLANCTIS IN COMPLEX WITH A HEPTA-SACCHARIDE AND A TRIS MOLECULE
1ZZI	;	1.8	;	Crystal Structure Analysis of the third KH domain of hnRNP K in complex with ssDNA
1ILV	;	2.0	;	Crystal Structure Analysis of the TM107
3VQT	;	1.8	;	Crystal structure analysis of the translation factor RF3
3VR1	;	3.0	;	Crystal structure analysis of the translation factor RF3
1J4G	;	2.0	;	crystal structure analysis of the trichosanthin delta C7
2HDZ	;	2.0	;	Crystal Structure Analysis of the UBF HMG box5
6MI1	;	2.3	;	CRYSTAL STRUCTURE ANALYSIS OF THE VARIANT PLANT EXOHYDROLASE ARG158ALA-GLU161ALA IN COMPLEX WITH METHYL 6-THIO-BETA-GENTIOBIOSIDE
2P5P	;	2.8	;	Crystal Structure Analysis of the West Nile virus envelope (E) protein domain III
1LNS	;	2.2	;	Crystal Structure Analysis of the X-Prolyl Dipeptidyl Aminopeptidase From Lactococcus lactis
5O8W	;	1.67	;	CRYSTAL STRUCTURE ANALYSIS OF THE YEAST ELONGATION FACTOR COMPLEX EEF1A:EEF1BA
1Q32	;	2.03	;	Crystal Structure Analysis of the Yeast Tyrosyl-DNA Phosphodiesterase
3SQ8	;	2.1	;	Crystal Structure Analysis of the Yeast Tyrosyl-DNA Phosphodiesterase 1 H432R Mutant (SCAN1 Mutant)
3SQ3	;	2.5	;	Crystal Structure Analysis of the Yeast Tyrosyl-DNA Phosphodiesterase H182A Mutant
3SQ5	;	2.3	;	Crystal Structure Analysis of the Yeast Tyrosyl-DNA Phosphodiesterase H432N Mutant
3SQ7	;	2.0	;	Crystal Structure Analysis of the Yeast Tyrosyl-DNA Phosphodiesterase H432N_Glu Mutant
3WBO	;	0.98	;	Crystal Structure Analysis of the Z-DNA hexamer CGCGCG with 40 mM NaCl
1JI1	;	1.6	;	Crystal Structure Analysis of Thermoactinomyces vulgaris R-47 alpha-Amylase 1
1Z9G	;	1.7	;	Crystal Structure Analysis of Thermolysin Complexed with the Inhibitor (R)-retro-thiorphan
1ZDP	;	1.7	;	Crystal Structure Analysis of Thermolysin Complexed with the Inhibitor (S)-thiorphan
4YZO	;	1.7	;	Crystal Structure Analysis of Thiolase-like protein, ST0096 from Sulfolobus Tokodaii
1V98	;	1.82	;	Crystal Structure Analysis of Thioredoxin from Thermus thermophilus
4LOY	;	1.77	;	Crystal Structure Analysis of thrombin in complex with compound D57, 5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2- oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1- yl)-3-oxopropyl]amide (SAR107375)
4LXB	;	1.61	;	Crystal Structure Analysis of thrombin in complex with compound D58
1M6Y	;	1.9	;	Crystal Structure Analysis of TM0872, a Putative SAM-dependent Methyltransferase, Complexed with SAH
1N2X	;	1.9	;	Crystal Structure Analysis of TM0872, a Putative SAM-dependent Methyltransferase, Complexed with SAM
3SJM	;	1.35	;	Crystal Structure Analysis of TRF2-Dbd-DNA complex
6IZ4	;	3.098	;	Crystal Structure Analysis of TRIC counter-ion channels in calcium release
6IZ6	;	3.293	;	Crystal Structure Analysis of TRIC counter-ion channels in calcium release
3C2J	;	1.78	;	Crystal structure analysis of trioxacarcin A covalently bound to d(AACCGGTT)
3EE6	;	2.35	;	Crystal Structure Analysis of Tripeptidyl peptidase -I
1VEP	;	2.06	;	Crystal Structure Analysis of Triple (T47M/Y164E/T328N)/maltose of Bacillus cereus Beta-Amylase at pH 6.5
2QAE	;	1.9	;	Crystal Structure Analysis of Trypanosoma cruzi Lipoamide dehydrogenase
5DK4	;	1.9	;	Crystal structure analysis of Tryptophanyl-trna synthetase from Bacillus stearothermophilus in complex with indolmycin and Mg*ATP
2DST	;	2.0	;	Crystal Structure Analysis of TT1977
5ZDL	;	2.6	;	Crystal Structure Analysis of TtQRS in co-crystallised with ATP
5ZDO	;	2.8	;	Crystal Structure Analysis of TtQRS in co-crystallised with ATP
5ZDK	;	2.45	;	Crystal Structure Analysis of TtQRS in complex with ATP
1TYJ	;	1.6	;	Crystal Structure Analysis of type II Cohesin A11 from Bacteroides cellulosolvens
1FX5	;	2.2	;	CRYSTAL STRUCTURE ANALYSIS OF ULEX EUROPAEUS LECTIN I
1YBD	;	2.6	;	Crystal structure analysis of uridylate kinase from Neisseria meningitidis
3VE6	;	2.829	;	Crystal Structure Analysis of Venezuelan Equine Encephalitis Virus Capsid Protein NLS and Importin Alpha
1CW0	;	2.3	;	CRYSTAL STRUCTURE ANALYSIS OF VERY SHORT PATCH REPAIR (VSR) ENDONUCLEASE IN COMPLEX WITH A DUPLEX DNA
3AZ1	;	1.5	;	Crystal Structure Analysis of Vitamin D receptor
3AZ2	;	1.69	;	Crystal Structure Analysis of Vitamin D receptor
3AZ3	;	1.36	;	Crystal Structure Analysis of Vitamin D receptor
3W0A	;	1.8	;	Crystal Structure Analysis of Vitamin D receptor
3W0C	;	1.9	;	Crystal Structure Analysis of Vitamin D receptor
3W0Y	;	1.98	;	Crystal Structure Analysis of Vitamin D receptor
3WGP	;	2.0	;	Crystal Structure Analysis of Vitamin D receptor
1JTE	;	2.0	;	Crystal Structure Analysis of VP39 F180W mutant
1JTF	;	2.6	;	Crystal Structure Analysis of VP39-F180W mutant and m7GpppG complex
3L0H	;	2.13	;	Crystal Structure Analysis of W21A mutant of human GSTA1-1 in complex with S-hexylglutathione
3TGZ	;	2.3	;	Crystal Structure Analysis of W35F/H207W Mutant of Human CLIC1
3LU1	;	2.5	;	Crystal Structure Analysis of WbgU: a UDP-GalNAc 4-epimerase
7MW8	;	1.9	;	Crystal Structure Analysis of Xac Nucleotide Pyrophosphatase/Phosphodiesterase
7N1S	;	2.0	;	Crystal Structure Analysis of Xac Nucleotide Pyrophosphatase/Phosphodiesterase
8EBK	;	1.29	;	Crystal Structure Analysis of xHDMX in complex with the stapled peptide PROTAC analog
1VEN	;	2.02	;	Crystal Structure Analysis of Y164E/maltose of Bacilus cereus Beta-amylase at pH 4.6
1VEO	;	2.12	;	Crystal Structure Analysis of Y164F/maltose of Bacillus cereus Beta-Amylase at pH 4.6
1PV1	;	2.3	;	Crystal Structure Analysis of Yeast Hypothetical Protein: YJG8_YEAST
2DZN	;	2.2	;	Crystal structure analysis of yeast Nas6p complexed with the proteasome subunit, rpt3
2DZO	;	3.0	;	Crystal structure analysis of yeast Nas6p complexed with the proteasome subunit, rpt3
3PR6	;	1.8	;	Crystal structure analysis of yeast TRAPP associate protein Tca17
3C8E	;	1.5	;	Crystal Structure Analysis of yghU from E. Coli
3R2Q	;	1.05	;	Crystal Structure Analysis of yibF from E. Coli
6V4E	;	1.62	;	Crystal Structure Analysis of Zebra Fish MDM
6V4F	;	1.35	;	Crystal Structure Analysis of Zebra Fish MDMX
6V4G	;	1.25	;	Crystal Structure Analysis of Zebra fish MDMX
6V4H	;	1.53	;	Crystal Structure Analysis of Zebra Fish MDMX
1NBA	;	2.0	;	CRYSTAL STRUCTURE ANALYSIS, REFINEMENT AND ENZYMATIC REACTION MECHANISM OF N-CARBAMOYLSARCOSINE AMIDOHYDROLASE FROM ARTHROBACTER SP. AT 2.0 ANGSTROMS RESOLUTION
1NZJ	;	1.5	;	Crystal Structure and Activity Studies of Escherichia Coli Yadb ORF
3PFQ	;	4.0	;	Crystal Structure and Allosteric Activation of Protein Kinase C beta II
2HIM	;	1.82	;	Crystal Structure and Allosteric Regulation of the Cytoplasmic Escherichia coli L-Asparaginase I
2P2D	;	1.89	;	Crystal Structure and Allosteric Regulation of the Cytoplasmic Escherichia coli L-Asparaginase I
2P2N	;	1.9	;	Crystal Structure and Allosteric Regulation of the Cytoplasmic Escherichia coli L-Asparaginase I
3F3H	;	2.1	;	Crystal structure and anti-tumor activity of LZ-8 from the fungus Ganoderma lucidium
1GME	;	2.7	;	Crystal structure and assembly of an eukaryotic small heat shock protein
2BOL	;	2.5	;	CRYSTAL STRUCTURE AND ASSEMBLY OF TSP36, A METAZOAN SMALL HEAT SHOCK PROTEIN
2O8T	;	1.45	;	Crystal Structure and Binding Epitopes of Urokinase-type Plasminogen Activator (C122A/N145Q) in complex with Inhibitors
2O8U	;	1.7	;	Crystal Structure and Binding Epitopes of Urokinase-type Plasminogen Activator (C122A/N145Q/S195A) in complex with Inhibitors
2O8W	;	1.86	;	Crystal Structure and Binding Epitopes of Urokinase-type Plasminogen Activator (C122A/N145Q/S195A) in complex with Inhibitors
2DRU	;	2.6	;	Crystal structure and binding properties of the CD2 and CD244 (2B4) binding protein, CD48
3BU7	;	2.8	;	Crystal Structure and Biochemical Characterization of GDOsp, a Gentisate 1,2-Dioxygenase from Silicibacter Pomeroyi
3E3R	;	2.65	;	Crystal structure and biochemical characterization of recombinant human calcyphosine delineates a novel EF-hand-containing protein family
5GT2	;	2.093	;	Crystal Structure and Biochemical Features of dye-decolorizing peroxidase YfeX from Escherichia coli O157
7VEP	;	2.15	;	Crystal structure and biophysical characterization of TPR domain of EccA5 from ESX-5 pathway of Mycobacterium tuberculosis H37RVR
1JTH	;	2.0	;	Crystal structure and biophysical properties of a complex between the N-terminal region of SNAP25 and the SNARE region of syntaxin 1a
7WNJ	;	1.7	;	Crystal structure and Cap Binding analysis of the methyltransferase of Langat virus
4I5Q	;	1.962	;	Crystal structure and catalytic mechanism for peroplasmic disulfide-bond isomerase DsbC from Salmonella enterica serovar Typhimurium
5WYQ	;	2.16	;	Crystal Structure and catalytic mechanism of the essential m1G37 tRNA methyltransferase TrmD from Pseudomonas aeruginosa
5WYR	;	2.45	;	Crystal structure and catalytic mechanism of the essential m1G37 tRNA methyltransferase TrmD from Pseudomonas aeruginosa
6JKI	;	2.59	;	Crystal structure and catalytic mechanism of the essential m1G37 tRNA methyltransferase TrmD from Pseudomonas aeruginosa
2BTN	;	2.0	;	Crystal Structure and Catalytic Mechanism of the Quorum-Quenching N- Acyl Homoserine Lactone Hydrolase
5JVV	;	1.589	;	Crystal structure and characterization an elongating GH family 16 beta-1,3-glucosyltransferase
4GKF	;	2.1	;	Crystal structure and characterization of Cmr5 protein from Pyrococcus furiosus
7KQY	;	2.913	;	Crystal Structure and Characterization of Human Heavy-Chain only Antibodies reveals a novel, stable dimeric structure similar to Monoclonal Antibodies
4REK	;	0.74	;	Crystal structure and charge density studies of cholesterol oxidase from Brevibacterium sterolicum at 0.74 ultra-high resolution
3HWP	;	2.0	;	Crystal structure and computational analyses provide insights into the catalytic mechanism of 2, 4-diacetylphloroglucinol hydrolase PhlG from Pseudomonas fluorescens
4H20	;	1.9	;	Crystal Structure and Computational Modeling of the Fab Fragment from the Protective anti-Ricin Monoclonal Antibody RAC18
3ZX3	;	1.7	;	Crystal Structure and Domain Rotation of NTPDase1 CD39
2CJL	;	1.5	;	CRYSTAL STRUCTURE AND ENZYMATIC PROPERTIES OF A BACTERIAL FAMILY 19 CHITINASE REVEAL DIFFERENCES WITH PLANT ENZYMES
6IUQ	;	2.348	;	Crystal structure and expression patterns of prolyl 4-hydroxylases from Phytophthora capsici
2F0X	;	2.3	;	Crystal structure and function of human thioesterase superfamily member 2(THEM2)
1ENY	;	2.2	;	CRYSTAL STRUCTURE AND FUNCTION OF THE ISONIAZID TARGET OF MYCOBACTERIUM TUBERCULOSIS
1ENZ	;	2.7	;	CRYSTAL STRUCTURE AND FUNCTION OF THE ISONIAZID TARGET OF MYCOBACTERIUM TUBERCULOSIS
1OVN	;	1.9	;	Crystal Structure and Functional Analysis of Drosophila Wind-- a PDI-Related Protein
3E5R	;	2.3	;	Crystal structure and Functional Analysis of Glyceraldehyde-3-phosphate Dehydrogenase from Oryza Sativa
3E6A	;	3.77	;	Crystal structure and Functional Analysis of Glyceraldehyde-3-phosphate Dehydrogenase from Oryza Sativa
4WOY	;	2.4	;	Crystal structure and functional analysis of MiD49, a receptor for the mitochondrial fission protein Drp1
3LUO	;	2.55	;	Crystal Structure and functional characterization of the thermophilic prolyl isomerase and chaperone SlyD
4PQ1	;	2.097	;	Crystal structure and functional implications of a DsbF homologue from Corynebacterium diphtheriae
5CB0	;	3.207	;	Crystal structure and functional implications of the tandem-type universal stress protein UspE from Escherichia coli
4HVK	;	1.43	;	Crystal structure and functional studies of an unusual L-cysteine desulfurase from Archaeoglobus fulgidus.
4MH1	;	2.7	;	Crystal structure and functional studies of quinoprotein L-sorbose dehydrogenase from Ketogulonicigenium vulgare Y25
2B8I	;	1.8	;	Crystal Structure and Functional Studies Reveal that PAS Factor from Vibrio vulnificus is a Novel Member of the Saposin-Fold Family
2QN5	;	3.0	;	Crystal Structure and Functional Study of the Bowman-Birk Inhibitor from Rice Bran in Complex with Bovine Trypsin
3RON	;	2.19	;	Crystal Structure and Hemolytic Activity of the Cyt1Aa Toxin from Bacillus thuringiensis subsp. israelensis
468D	;	1.8	;	CRYSTAL STRUCTURE AND IMPROVED ANTISENSE PROPERTIES OF 2'-O-(2-METHOXYETHYL)-RNA
469D	;	1.7	;	CRYSTAL STRUCTURE AND IMPROVED ANTISENSE PROPERTIES OF 2'-O-(2-METHOXYETHYL)-RNA
470D	;	1.95	;	CRYSTAL STRUCTURE AND IMPROVED ANTISENSE PROPERTIES OF 2'-O-(2-METHOXYETHYL)-RNA
471D	;	2.7	;	CRYSTAL STRUCTURE AND IMPROVED ANTISENSE PROPERTIES OF 2'-O-(2-METHOXYETHYL)-RNA
1PTS	;	2.0	;	CRYSTAL STRUCTURE AND LIGAND BINDING STUDIES OF A SCREENED PEPTIDE COMPLEXED WITH STREPTAVIDIN
5TV0	;	1.648	;	crystal structure and light induced structural changes in orange carotenoid protein bound with 3 'OH echinenone
5TUX	;	1.5	;	crystal structure and light induced structural changes in orange carotenoid protein bound with echinenone
1RQP	;	1.8	;	Crystal structure and mechanism of a bacterial fluorinating enzyme
1RQR	;	2.67	;	Crystal structure and mechanism of a bacterial fluorinating enzyme, product complex
4LGJ	;	1.55	;	Crystal structure and mechanism of a type III secretion protease
4IW0	;	4.0	;	Crystal structure and mechanism of activation of TBK1
4IWO	;	2.61	;	Crystal structure and mechanism of activation of TBK1
4IWP	;	3.065	;	Crystal structure and mechanism of activation of TBK1
4IWQ	;	3.0	;	Crystal structure and mechanism of activation of TBK1
2H94	;	2.9	;	Crystal Structure and Mechanism of human Lysine-Specific Demethylase-1
1JDW	;	1.9	;	CRYSTAL STRUCTURE AND MECHANISM OF L-ARGININE: GLYCINE AMIDINOTRANSFERASE: A MITOCHONDRIAL ENZYME INVOLVED IN CREATINE BIOSYNTHESIS
2JDW	;	2.1	;	CRYSTAL STRUCTURE AND MECHANISM OF L-ARGININE: GLYCINE AMIDINOTRANSFERASE: A MITOCHONDRIAL ENZYME INVOLVED IN CREATINE BIOSYNTHESIS
3JDW	;	2.4	;	CRYSTAL STRUCTURE AND MECHANISM OF L-ARGININE: GLYCINE AMIDINOTRANSFERASE: A MITOCHONDRIAL ENZYME INVOLVED IN CREATINE BIOSYNTHESIS
4JDW	;	2.5	;	CRYSTAL STRUCTURE AND MECHANISM OF L-ARGININE: GLYCINE AMIDINOTRANSFERASE: A MITOCHONDRIAL ENZYME INVOLVED IN CREATINE BIOSYNTHESIS
6VPT	;	2.718	;	Crystal structure and mechanistic molecular modeling studies of Rv3377c: the Mycobacterium tuberculosis diterpene cyclase
3HH8	;	1.87	;	Crystal Structure and metal binding properties of the lipoprotein MtsA
7Q1G	;	1.6	;	Crystal structure and metal binding properties of the periplasmic iron component EfeM from Pseudomonas syringae EfeUOB/M iron-transport system
4RS4	;	2.955	;	Crystal structure and mutational analysis of the endoribonuclease from human coronavirus 229E
3NV0	;	1.84	;	Crystal structure and mutational analysis of the NXF2/NXT1 heterodimeric complex from caenorhabditis elegans at 1.84 A resolution
2V1C	;	3.8	;	Crystal structure and mutational study of RecOR provide insight into its role in DNA repair
4R5Q	;	2.65	;	Crystal structure and nuclease activity of the CRISPR-associated Cas4 protein Pcal_0546 from Pyrobaculum calidifontis containing a [2Fe-2S] cluster
2GER	;	3.1	;	Crystal Structure and Oxidative Mechanism of Human Pyrroline-5-carboxylate Reductase
2ADF	;	1.9	;	Crystal Structure and Paratope Determination of 82D6A3, an Antithrombotic Antibody Directed Against the von Willebrand factor A3-Domain
5FMO	;	2.3	;	Crystal structure and proteomics analysis of empty virus like particles of Cowpea mosaic virus
3CGL	;	2.09	;	Crystal Structure and Raman Studies of dsFP483, a Cyan Fluorescent Protein from Discosoma striata
1U08	;	2.35	;	Crystal Structure and Reactivity of YbdL from Escherichia coli Identify a Methionine Aminotransferase Function.
1CPT	;	2.3	;	CRYSTAL STRUCTURE AND REFINEMENT OF CYTOCHROME P450-TERP AT 2.3 ANGSTROMS RESOLUTION
3THP	;	3.2	;	Crystal structure and RNA binding properties of the RRM/AlkB domains in human ABH8, an enzyme catalyzing tRNA hypermodification, Northeast Structural Genomics Consortium Target HR5601B
3THT	;	3.01	;	Crystal structure and RNA binding properties of the RRM/AlkB domains in human ABH8, an enzyme catalyzing tRNA hypermodification, Northeast Structural Genomics Consortium Target HR5601B
1DNM	;	2.5	;	CRYSTAL STRUCTURE AND SEQUENCE-DEPENDENT CONFORMATION OF THE A.G MIS-PAIRED OLIGONUCLEOTIDE D(CGCAAGCTGGCG)
1MAC	;	2.3	;	CRYSTAL STRUCTURE AND SITE-DIRECTED MUTAGENESIS OF BACILLUS MACERANS ENDO-1,3-1,4-BETA-GLUCANASE
2O6V	;	2.2	;	Crystal structure and solution NMR studies of Lys48-linked tetraubiquitin at neutral pH
3TKA	;	2.25	;	crystal structure and solution saxs of methyltransferase rsmh from E.coli
111D	;	2.25	;	CRYSTAL STRUCTURE AND STABILITY OF A DNA DUPLEX CONTAINING A(ANTI).G(SYN) BASE-PAIRS
1J93	;	2.3	;	Crystal Structure and Substrate Binding Modeling of the Uroporphyrinogen-III Decarboxylase from Nicotiana tabacum: Implications for the Catalytic Mechanism
3ZRP	;	1.75	;	Crystal structure and substrate specificity of a thermophilic archaeal serine : pyruvate aminotransferase from Sulfolobus solfataricus
3ZRQ	;	1.8	;	Crystal structure and substrate specificity of a thermophilic archaeal serine : pyruvate aminotransferase from Sulfolobus solfataricus
3ZRR	;	1.99	;	Crystal structure and substrate specificity of a thermophilic archaeal serine : pyruvate aminotransferase from Sulfolobus solfataricus
1LYN	;	2.75	;	CRYSTAL STRUCTURE AND SUBUNIT DYNAMICS OF THE LYSIN DIMER: EGG ENVELOPES DISSOCIATE DIMERS, THE MONOMER IS THE ACTIVE SPECIES
5D1V	;	1.74	;	Crystal Structure and Thermal Stability of Hemoglobin from Thermophilic Phototrophic Bacterium Chloroflexus aurantiacus
3E8U	;	2.1	;	Crystal structure and thermodynamic analysis of diagnostic Fab 106.3 complexed with BNP 5-13 (C10A) reveal basis of selective molecular recognition
2BBA	;	1.65	;	Crystal Structure and Thermodynamic Characterization of the EphB4 Receptor in Complex with an ephrin-B2 Antagonist Peptide Reveals the Determinants for Receptor Specificity.
3LI6	;	2.502	;	Crystal structure and trimer-monomer transition of N-terminal domain of EhCaBP1 from Entamoeba histolytica
4LCT	;	2.7	;	Crystal Structure and Versatile Functional Roles of the COP9 Signalosome Subunit 1
5U5P	;	2.171	;	Crystal Structure and X-ray Diffraction Data Collection of Importin-alpha from Mus Musculus Complexed with a MLH1 NLS Peptide
5U5R	;	2.1	;	Crystal Structure and X-ray Diffraction Data Collection of Importin-alpha from Mus musculus Complexed with a PMS2 NLS Peptide
7U63	;	2.3	;	Crystal Structure Anti-Oxycodone Antibody HY2-A12 Fab Complexed with Oxycodone
5IF1	;	2.61	;	Crystal structure apo CDK2/cyclin A
6F0F	;	2.0	;	Crystal structure ASF1-ip2_s
6F0G	;	2.3	;	Crystal structure ASF1-ip3
6F0H	;	1.98	;	Crystal structure ASF1-ip4
2CWS	;	1.0	;	Crystal structure at 1.0 A of alginate lyase A1-II', a member of polysaccharide lyase family-7
1M2D	;	1.05	;	Crystal structure at 1.05 Angstroms resolution of the Cys59Ser variant of the thioredoxin-like [2Fe-2S] ferredoxin from Aquifex aeolicus
1M2B	;	1.25	;	Crystal structure at 1.25 Angstroms resolution of the Cys55Ser variant of the thioredoxin-like [2Fe-2S] ferredoxin from Aquifex aeolicus
6AIL	;	1.335	;	CRYSTAL STRUCTURE AT 1.3 ANGSTROMS RESOLUTION OF A NOVEL UDG, UdgX, FROM Mycobacterium smegmatis
2CYG	;	1.45	;	Crystal structure at 1.45- resolution of the major allergen endo-beta-1,3-glucanase of banana as a molecular basis for the latex-fruit syndrome
3RGW	;	1.5	;	Crystal structure at 1.5 A resolution of an H2-reduced, O2-tolerant hydrogenase from Ralstonia eutropha unmasks a novel iron-sulfur cluster
4LJI	;	1.508	;	Crystal structure at 1.5 angstrom resolution of the PsbV2 cytochrome from the cyanobacterium thermosynechococcus elongatus
1D53	;	1.5	;	CRYSTAL STRUCTURE AT 1.5 ANGSTROMS RESOLUTION OF D(CGCICICG), AN OCTANUCLEOTIDE CONTAINING INOSINE, AND ITS COMPARISON WITH D(CGCG) AND D(CGCGCG) STRUCTURES
1M2A	;	1.5	;	Crystal structure at 1.5 Angstroms resolution of the wild type thioredoxin-like [2Fe-2S] ferredoxin from Aquifex aeolicus
1KGS	;	1.5	;	Crystal Structure at 1.50 A of an OmpR/PhoB Homolog from Thermotoga maritima
1HT6	;	1.5	;	CRYSTAL STRUCTURE AT 1.5A RESOLUTION OF THE BARLEY ALPHA-AMYLASE ISOZYME 1
2BOP	;	1.7	;	CRYSTAL STRUCTURE AT 1.7 ANGSTROMS OF THE BOVINE PAPILLOMAVIRUS-1 E2 DNA-BINDING DOMAIN BOUND TO ITS DNA TARGET
1IQ9	;	1.8	;	crystal structure at 1.8 A of toxin a from Naja nigricollis venom
1RKX	;	1.8	;	Crystal Structure at 1.8 Angstrom of CDP-D-glucose 4,6-dehydratase from Yersinia pseudotuberculosis
1MO1	;	1.8	;	CRYSTAL STRUCTURE AT 1.8 ANGSTROMS OF SELENO METHIONYLED CRH, THE BACILLUS SUBTILIS CATABOLITE REPRESSION CONTAINING PROTEIN CRH REVEALS AN UNEXPECTED SWAPPING DOMAIN AS AN UNTERTWINNED DIMER
1MU4	;	1.8	;	CRYSTAL STRUCTURE AT 1.8 ANGSTROMS OF THE BACILLUS SUBTILIS CATABOLITE REPRESSION HISTIDINE CONTAINING PROTEIN (CRH)
1MZN	;	1.9	;	CRYSTAL STRUCTURE at 1.9 ANGSTROEMS RESOLUTION OF THE HOMODIMER OF HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST COMPOUND BMS 649 AND A COACTIVATOR PEPTIDE
1HSG	;	2.0	;	CRYSTAL STRUCTURE AT 1.9 ANGSTROMS RESOLUTION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) II PROTEASE COMPLEXED WITH L-735,524, AN ORALLY BIOAVAILABLE INHIBITOR OF THE HIV PROTEASES
1HSH	;	1.9	;	CRYSTAL STRUCTURE AT 1.9 ANGSTROMS RESOLUTION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) II PROTEASE COMPLEXED WITH L-735,524, AN ORALLY BIOAVAILABLE INHIBITOR OF THE HIV PROTEASES
1HSI	;	2.5	;	CRYSTAL STRUCTURE AT 1.9 ANGSTROMS RESOLUTION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) II PROTEASE COMPLEXED WITH L-735,524, AN ORALLY BIOAVAILABLE INHIBITOR OF THE HIV PROTEASES
3C2E	;	1.9	;	Crystal structure at 1.9A of the apo quinolinate phosphoribosyl transferase (BNA6) from Saccharomyces cerevisiae
3RLB	;	2.0	;	Crystal structure at 2.0 A of the S-component for thiamin from an ECF-type ABC transporter
4DVE	;	2.09	;	Crystal structure at 2.1 A of the S-component for biotin from an ECF-type ABC transporter
3K6K	;	2.2	;	Crystal structure at 2.2 angstrom of HSL-homolog EstE7 from a metagenome library
1DYN	;	2.2	;	CRYSTAL STRUCTURE AT 2.2 ANGSTROMS RESOLUTION OF THE PLECKSTRIN HOMOLOGY DOMAIN FROM HUMAN DYNAMIN
1DFO	;	2.4	;	CRYSTAL STRUCTURE AT 2.4 ANGSTROM RESOLUTION OF E. COLI SERINE HYDROXYMETHYLTRANSFERASE IN COMPLEX WITH GLYCINE AND 5-FORMYL TETRAHYDROFOLATE
1EKM	;	2.5	;	CRYSTAL STRUCTURE AT 2.5 A RESOLUTION OF ZINC-SUBSTITUTED COPPER AMINE OXIDASE OF HANSENULA POLYMORPHA EXPRESSED IN ESCHERICHIA COLI
4AMT	;	2.6	;	Crystal structure at 2.6A of human prorenin
1JVQ	;	2.6	;	Crystal structure at 2.6A of the ternary complex between antithrombin, a P14-P8 reactive loop peptide, and an exogenous tetrapeptide
1JJC	;	2.6	;	Crystal structure at 2.6A resolution of phenylalanyl-tRNA synthetase complexed with phenylalanyl-adenylate in the presence of manganese
1HNG	;	2.8	;	CRYSTAL STRUCTURE AT 2.8 ANGSTROMS RESOLUTION OF A SOLUBLE FORM OF THE CELL ADHESION MOLECULE CD2
5FYJ	;	3.11	;	Crystal Structure at 3.4 A Resolution of Fully Glycosylated HIV-1 Clade G X1193.c1 SOSIP.664 Prefusion Env Trimer in Complex with Broadly Neutralizing Antibodies PGT122, 35O22 and VRC01
7VT9	;	3.3	;	CRYSTAL STRUCTURE AT 3.4 ANGSTROMS RESOLUTION OF Maltodextrin glucosidase, MalZ, FROM Escherichia coli
5FYL	;	3.1	;	Crystal Structure at 3.7 A Resolution of Fully Glycosylated HIV-1 Clade A BG505 SOSIP.664 Prefusion Env Trimer in Complex with Broadly Neutralizing Antibodies PGT122 and 35O22
5FYK	;	3.107	;	Crystal Structure at 3.7 A Resolution of Fully Glycosylated HIV-1 Clade B JR-FL SOSIP.664 Prefusion Env Trimer in Complex with Broadly Neutralizing Antibodies PGT122, 35O22 and VRC01
5V7J	;	2.907	;	Crystal Structure at 3.7 A Resolution of Glycosylated HIV-1 Clade A BG505 SOSIP.664 Prefusion Env Trimer with Four Glycans (N197, N276, N362, and N462) removed in Complex with Neutralizing Antibodies 3H+109L and 35O22.
6DE7	;	4.123	;	Crystal Structure at 4.3 A Resolution of Glycosylated HIV-1 Clade A BG505 SOSIP.664 Prefusion Env Trimer with Interdomain Stabilization 113C-429GCG in Complex with Broadly Neutralizing Antibodies PGT122 and 35O22
3GQG	;	1.73	;	Crystal structure at acidic pH of the ferric form of the Root effect hemoglobin from Trematomus bernacchii.
6JGU	;	1.02	;	Crystal structure at atomic resolution reveals the catalytic mechanism in peptidyl-tRNA hydrolase from Acinetobacter baumannii.
5FNW	;	2.45	;	Crystal structure at pH 7.0 of a potato STI-Kunitz bi-functional inhibitor of serine and aspartic proteases in space group p4322 and ph 9.0
5FNX	;	2.65	;	Crystal structure at pH 9.0 of a potato STI-Kunitz bi-functional inhibitor of serine and aspartic proteases in space group p4322 and ph 9.0
4XNC	;	2.23	;	Crystal structure at room temperature of cyclophilin D in complex with an inhibitor
4XRL	;	2.554	;	Crystal structure at room temperature of Erk2 in complex with an inhibitor
4XN6	;	1.35	;	Crystal structure at room temperature of hen-egg lysozyme in complex with benzamidine
8DO8	;	2.41	;	Crystal structure ATG9 HDIR in complex with the ATG13:ATG101 HORMA dimer
6K09	;	2.248	;	Crystal structure B of ceNAP1-H2A-H2B complex
6EN6	;	1.8	;	Crystal structure B of the Angiotensin-1 converting enzyme N-domain in complex with a diprolyl inhibitor.
5HP4	;	1.86	;	Crystal structure bacteriohage T5 D15 flap endonuclease (D155K) pseudo-enzyme-product complex with DNA and metal ions
6K13	;	1.89	;	Crystal Structure Basis for BmLDH Complex
4XFQ	;	1.65	;	Crystal Structure Basis for PEDV 3C Like Protease
5XBC	;	1.249	;	Crystal Structure Basis for PEDV nsp1
5A8Q	;	1.9	;	Crystal structure beta-glucanase SdGluc5_26A from Saccharophagus degradans in complex with tetrasaccharide A obtained by soaking
5A8P	;	2.2	;	Crystal structure beta-glucanase SdGluc5_26A from Saccharophagus degradans in complex with tetrasaccharide B
3U9Z	;	2.09	;	Crystal structure between actin and a protein construct containing the first beta-thymosin domain of drosophila ciboulot (residues 2-58) with the three mutations N26D/Q27K/D28S
5C7K	;	4.6019	;	Crystal structure BG505 SOSIP gp140 HIV-1 Env trimer bound to broadly neutralizing antibodies PGT128 and 8ANC195
7PLK	;	2.48781	;	Crystal structure bovine Hsc70(aa1-554)E213A/D214A in complex with nicotinic-acid-derivative
5XGG	;	1.72	;	Crystal Structure C-terminal SH3 domain of Myosin IB from Entamoeba histolytica
6A9C	;	1.98	;	Crystal Structure c-terminal SH3 domain of Myosin IB from Entamoeba histolytica bound to EhFP10(GEF) peptide.
4KU2	;	1.974	;	Crystal Structure C143A from Xanthomonas campestris Bound with Myristoyl-CoA
7QBZ	;	3.25	;	Crystal structure Cadmium translocating P-type ATPase
2RL7	;	2.0	;	Crystal Structure cation-dependent mannose 6-phosphate receptor at pH 4.8
2RL8	;	1.45	;	Crystal Structure cation-dependent mannose 6-phosphate receptor at pH 6.5 bound to M6P
2RLB	;	1.75	;	Crystal Structure cation-dependent mannose 6-phosphate receptor at pH 6.5 bound to M6P in absence of Mn
2RL9	;	2.4	;	Crystal Structure cation-dependent mannose 6-phosphate receptor at pH 6.5 bound to trimannoside
3CY4	;	1.51	;	Crystal Structure cation-dependent mannose 6-phosphate receptor at pH 7.4
5NCM	;	2.8	;	Crystal structure Cbk1(NTR)-Mob2 complex
1TDZ	;	1.8	;	Crystal Structure Complex Between the Lactococcus Lactis FPG (Mutm) and a FAPY-dG Containing DNA
1NNJ	;	1.9	;	Crystal structure Complex between the Lactococcus lactis Fpg and an abasic site containing DNA
1XC8	;	1.95	;	CRYSTAL STRUCTURE COMPLEX BETWEEN THE WILD-TYPE LACTOCOCCUS LACTIS FPG (MUTM) AND A FAPY-DG CONTAINING DNA
2O3B	;	2.3	;	Crystal structure complex of Nuclease A (NucA) with intra-cellular inhibitor NuiA
4KE6	;	2.8	;	Crystal structure D196N mutant of Monoglyceride lipase from Bacillus sp. H257 in complex with 1-rac-lauroyl glycerol
5NCN	;	3.501	;	Crystal structure Dbf2(NTR)-Mob1 complex
5HKN	;	1.761	;	Crystal structure de novo designed fullerene organizing protein complex with fullerene
7JZJ	;	2.46	;	Crystal structure demonstrating CTD-CTD interactions of Zaire Ebola virus VP40 dimer
6NW0	;	1.85	;	Crystal Structure Desulfovibrio desulfuricans Nickel-Substituted Rubredoxin
6NW1	;	1.86	;	Crystal Structure Desulfovibrio desulfuricans Nickel-Substituted Rubredoxin V37N
2LAL	;	1.8	;	CRYSTAL STRUCTURE DETERMINATION AND REFINEMENT AT 2.3 ANGSTROMS RESOLUTION OF THE LENTIL LECTIN
1THC	;	2.3	;	CRYSTAL STRUCTURE DETERMINATION AT 2.3A OF HUMAN TRANSTHYRETIN-3',5'-DIBROMO-2',4,4',6-TETRA-HYDROXYAURONE COMPLEX
1GYC	;	1.9	;	CRYSTAL STRUCTURE DETERMINATION AT ROOM TEMPERATURE OF A LACCASE FROM TRAMETES VERSICOLOR IN ITS OXIDISED FORM CONTAINING A FULL COMPLEMENT OF COPPER IONS
5NYV	;	1.6	;	Crystal structure determination from picosecond infrared laser ablated protein crystals by serial synchrotron crystallography
5O2G	;	2.1	;	Crystal structure determination from picosecond infrared laser ablated protein crystals by serial synchrotron crystallography
2QT6	;	1.5	;	Crystal Structure Determination of a Blue Laccase from Lentinus Tigrinus
1RTT	;	1.28	;	Crystal structure determination of a putative NADH-dependent reductase using sulfur anomalous signal
2PHD	;	2.9	;	Crystal Structure Determination of a Salicylate 1,2-Dioxygenase from Pseudaminobacter salicylatoxidans
3FG5	;	2.5	;	Crystal structure determination of a ternary complex of phospholipase A2 with a pentapeptide FLSYK and Ajmaline at 2.5 A resolution
1JFL	;	1.9	;	CRYSTAL STRUCTURE DETERMINATION OF ASPARTATE RACEMASE FROM AN ARCHAEA
4WL3	;	2.01	;	Crystal structure determination of Bile Salt Hydrolase from Enterococcus feacalis
3CY5	;	2.0	;	Crystal structure determination of buffalo (Bubalus bubalis) hemoglobin at 2 angstrom resolution
3GDJ	;	2.0	;	Crystal structure determination of camel(Camelus dromedarius)hemoglobin at 2 angstrom resolution
3GQP	;	2.0	;	Crystal structure determination of cat (Felis silvestris catus) hemoglobin at 2.0 angstrom resolution
3D4X	;	2.2	;	Crystal structure determination of cat (Felis silvestris catus) hemoglobin at 2.2 angstrom resolution
3GQR	;	2.4	;	Crystal structure determination of cat (Felis silvestris catus) hemoglobin at 2.4 angstrom resolution
3GYS	;	2.9	;	Crystal structure determination of cat (Felis silvestris catus) hemoglobin at 2.9 angstrom resolution
3I4Y	;	1.85	;	Crystal structure determination of Catechol 1,2-Dioxygenase from Rhodococcus opacus 1CP in complex with 3,5-dichlorocatechol
3I4V	;	2.0	;	Crystal structure determination of catechol 1,2-dioxygenase from rhodococcus opacus 1CP in complex with 3-chlorocatechol
3I51	;	1.8	;	Crystal structure determination of Catechol 1,2-Dioxygenase from Rhodococcus opacus 1CP in complex with 4,5-dichlorocatechol
3HJ8	;	2.4	;	Crystal structure determination of catechol 1,2-dioxygenase from rhodococcus opacus 1CP in complex with 4-chlorocatechol
3HHY	;	1.55	;	Crystal structure determination of Catechol 1,2-Dioxygenase from Rhodococcus opacus 1CP in complex with catechol
3HKP	;	1.85	;	Crystal structure determination of Catechol 1,2-Dioxygenase from Rhodococcus opacus 1CP in complex with protocatechuate
3HHX	;	2.0	;	Crystal structure determination of Catechol 1,2-Dioxygenase from Rhodococcus opacus 1CP in complex with pyrogallol
5GS7	;	1.5	;	Crystal structure determination of Cys2Ala mutant of Bile Salt Hydrolase from Enterococcus feacalis
3EOK	;	2.1	;	Crystal structure determination of duck (Anas platyrhynchos) hemoglobin at 2.1 Angstrom resolution
8RE2	;	2.2	;	Crystal Structure determination of Dye-decolorizing Peroxidase (DyP) from Deinoccoccus radiodurans
8RE3	;	1.51	;	Crystal Structure determination of Dye-decolorizing Peroxidase (DyP) mutant M190G from Deinoccoccus radiodurans
2FX3	;	3.4	;	Crystal Structure Determination of E. coli Elongation Factor, Tu using a Twinned Data Set
3EU1	;	3.0	;	Crystal Structure determination of goat hemoglobin (Capra hircus) at 3 angstrom resolution
3D1A	;	2.61	;	Crystal Structure Determination of Goat Hemoglobin at 2.61 Angstrom Resolution
2RI4	;	2.7	;	Crystal Structure determination of Goat Methemoglobin at 2.7 Angstrom
1EEY	;	2.25	;	Crystal Structure Determination Of HLA A2 Complexed to Peptide GP2 with the substitution (I2L/V5L/L9V)
1EEZ	;	2.3	;	Crystal Structure Determination of HLA-A2.1 Complexed to GP2 Peptide Variant(I2L/V5L)
6MF0	;	3.2	;	Crystal Structure Determination of Human/Porcine Chimera Coagulation Factor VIII
3FH9	;	1.62	;	Crystal structure determination of indian flying fox (Pteropus giganteus) at 1.62 A resolution
3MJP	;	2.76	;	Crystal structure determination of Japanese quail (Coturnix coturnix japonica) hemoglobin at 2.76 Angstrom resolution
3LQD	;	2.8	;	Crystal structure determination of Lepus europaeus 2.8 A resolution
3DHR	;	2.0	;	Crystal Structure Determination of Methemoglobin from Pigeon at 2 Angstrom Resolution (Columba livia)
3FS4	;	2.22	;	Crystal structure determination of Ostrich hemoglobin at 2.2 Angstrom resolution
3MJU	;	3.5	;	Crystal structure determination of pigeon (columba livia) haemoglobin at 3.5 angstrom resolution
1QPW	;	1.8	;	CRYSTAL STRUCTURE DETERMINATION OF PORCINE HEMOGLOBIN AT 1.8A RESOLUTION
4LX4	;	1.556	;	Crystal Structure Determination of Pseudomonas stutzeri endoglucanase Cel5A using a Twinned Data Set
2QU0	;	2.7	;	Crystal structure determination of sheep methemoglobin at 2.7 Angstrom resolution
3MKB	;	1.9	;	Crystal structure determination of Shortfin Mako (Isurus oxyrinchus) hemoglobin at 1.9 Angstrom resolution
1NJJ	;	2.45	;	Crystal structure determination of T. brucei ornithine decarboxylase bound to D-ornithine and to G418
4EMR	;	1.75	;	Crystal Structure determination of type1 ribosome inactivating protein complexed with 7-methylguanosine-triphosphate at 1.75A
4UQM	;	1.35	;	Crystal structure determination of uracil-DNA N-glycosylase (UNG) from Deinococcus radiodurans in complex with DNA - new insights into the role of the Leucine-loop for damage recognition and repair
1HOE	;	2.0	;	CRYSTAL STRUCTURE DETERMINATION, REFINEMENT AND THE MOLECULAR MODEL OF THE ALPHA-AMYLASE INHIBITOR HOE-467A
3RS6	;	1.8	;	Crystal structure Dioclea virgata lectin in complexed with X-mannose
1RTA	;	2.5	;	CRYSTAL STRUCTURE DISPOSITION OF THYMIDYLIC ACID TETRAMER IN COMPLEX WITH RIBONUCLEASE A
1RTB	;	2.5	;	CRYSTAL STRUCTURE DISPOSITION OF THYMIDYLIC ACID TETRAMER IN COMPLEX WITH RIBONUCLEASE A
3ETJ	;	1.6	;	Crystal structure E. coli Purk in complex with Mg, ADP, and Pi
2X5I	;	3.1	;	Crystal structure echovirus 7
3P85	;	1.9	;	Crystal structure enoyl-coa hydratase from mycobacterium avium
5JDU	;	1.7	;	Crystal structure for human thrombin mutant D189A
5VRC	;	2.0	;	Crystal structure for Methylobacterium extorquens PqqC (truncation of natural CD fusion)
5VRD	;	2.85	;	Crystal structure for Methylobacterium extorquens PqqCD (natural fusion)
6O3V	;	3.5	;	Crystal structure for RVA-VP3
7ASJ	;	1.43	;	Crystal structure for the complex of human carbonic anhydrase II and 3-(3-methyl-3-phenethylureido)benzenesulfonamide
6YPW	;	1.1	;	Crystal structure for the complex of human carbonic anhydrase II and 4-((1-(2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzenesulfonamide
5JNC	;	2.0	;	Crystal structure for the complex of human carbonic anhydrase IV and 4-aminomethylbenzene sulfonamide
5JN8	;	1.85	;	Crystal Structure for the complex of human carbonic anhydrase IV and acetazolamide
5JN9	;	2.1	;	Crystal structure for the complex of human carbonic anhydrase IV and ethoxyzolamide
5KU6	;	1.8	;	Crystal structure for the complex of human carbonic anhydrase IV and methazolamide
5JNA	;	2.0	;	Crystal structure for the complex of human carbonic anhydrase IV and topiramate
3QSE	;	1.75	;	Crystal structure for the complex of substrate-reduced msox with sarcosine
4MLF	;	2.2	;	Crystal structure for the complex of thrombin mutant D102N and hirudin
8AV2	;	1.75	;	Crystal structure for the FnIII module of mouse LEP-R in complex with the anti-LEP-R nanobody VHH-4.80
3QSM	;	1.9	;	Crystal structure for the MSOX.chloride binary complex
3QSS	;	1.85	;	Crystal structure for the MSOX.chloride.MTA ternary complex
2AZJ	;	2.4	;	Crystal structure for the mutant D81C of Sulfolobus solfataricus hexaprenyl pyrophosphate synthase
2AZL	;	2.8	;	Crystal structure for the mutant F117E of Thermotoga maritima octaprenyl pyrophosphate synthase
2AZK	;	2.7	;	Crystal structure for the mutant W136E of Sulfolobus solfataricus hexaprenyl pyrophosphate synthase
2VJZ	;	1.8	;	Crystal structure form ultalente insulin microcrystals
2VK0	;	2.2	;	Crystal structure form ultalente insulin microcrystals
3IT1	;	1.691	;	Crystal Structure Francisella tularensis histidine acid phosphatase complexed with L(+)-tartrate
3IT0	;	1.692	;	Crystal Structure Francisella tularensis histidine acid phosphatase complexed with phosphate
4E3W	;	1.75	;	Crystal Structure Francisella tularensis histidine acid phosphatase cryoprotected with proline
3IT3	;	1.5	;	Crystal Structure Francisella tularensis histidine acid phosphatase D261A mutant complexed with substrate 3'-AMP
5DLE	;	1.55	;	Crystal structure from a domain (Thr161-F265) from fructose-specific iiabc component (Pts system) from Borrelia burgdorferi
2WKC	;	2.6	;	Crystal structure from a single-stranded DNA binding protein from the lactococcal phage p2
7KEH	;	2.59	;	Crystal structure from SARS-CoV-2 NendoU NSP15
7KF4	;	2.61	;	Crystal structure from SARS-CoV-2 NendoU NSP15
7KEG	;	2.9	;	Crystal structure from SARS-COV2 NendoU NSP15
3FYN	;	1.449	;	Crystal structure from the mobile metagenome of Cole Harbour Salt Marsh: Integron Cassette Protein HFX_CASS3
3FXH	;	1.837	;	Crystal structure from the mobile metagenome of Halifax Harbour Sewage Outfall: Integron Cassette Protein HFX_CASS2
3GHJ	;	1.471	;	Crystal structure from the mobile metagenome of Halifax Harbour Sewage Outfall: Integron Cassette Protein HFX_CASS4
3GK6	;	1.8	;	Crystal structure from the mobile metagenome of Vibrio cholerae. Integron cassette protein VCH_CASS2.
2XZ9	;	1.677	;	CRYSTAL STRUCTURE FROM THE PHOSPHOENOLPYRUVATE-BINDING DOMAIN OF ENZYME I IN COMPLEX WITH PYRUVATE FROM THE THERMOANAEROBACTER TENGCONGENSIS PEP-SUGAR PHOSPHOTRANSFERASE SYSTEM (PTS)
4ANO	;	1.7	;	Crystal Structure Geobacillus thermodenitrificans EssB cytoplasmic fragment
5M6G	;	1.829	;	Crystal structure Glucan 1,4-beta-glucosidase from Saccharopolyspora erythraea
6F68	;	1.696	;	Crystal structure glutathione transferase Omega 3S from Trametes versicolor in complex with 2,4,4'-trihydroxybenzophenone
7C5P	;	2.35	;	Crystal Structure Glyceraldehyde-3-phosphate-dehydrogenase1 from Escherichia coli complexed with G3P at 2.35 Angstrom resolution.
3G9D	;	2.5	;	Crystal structure glycohydrolase
5WES	;	2.706	;	Crystal Structure H2-Dd with disulfide-linked 5mer peptide
5EBH	;	1.2	;	Crystal Structure HEW Lysozyme processed with the CrystalDirect automated mounting and cryo-cooling technology
3DNM	;	2.8	;	Crystal Structure Hormone-Sensitive Lipase from a Metagenome Library
4EVD	;	2.2	;	Crystal Structure HP-NAP from strain YS29 cadmium loaded (Cocrystallization 50mM)
4EVE	;	2.1	;	Crystal Structure HP-NAP from strain YS29 in apo form
4EVC	;	2.4	;	Crystal Structure HP-NAP from strain YS39 cadmium loaded (Cocrystallization 50mM)
3T9J	;	2.2	;	Crystal structure HP-NAP from strain YS39 in apo form
3TA8	;	2.5	;	Crystal structure HP-NAP from strain YS39 iron loaded (cocrystallization 5mM)
4EVB	;	2.5	;	Crystal Structure HP-NAP from strain YS39 zinc soaked (20mM)
6AL7	;	1.687	;	Crystal structure HpiC1 F138S
5WPR	;	1.49	;	Crystal structure HpiC1 in C2 space group
6AL6	;	2.088	;	Crystal structure HpiC1 in P42 space group
5WPP	;	1.7	;	Crystal structure HpiC1 W73M/K132M
5WPS	;	1.389	;	Crystal structure HpiC1 Y101F
6AL8	;	1.641	;	Crystal structure HpiC1 Y101F/F138S
5WPU	;	1.39	;	Crystal structure HpiC1 Y101S
8P0S	;	2.2	;	Crystal structure HR1 domain of Rho-associated coiled-coil protein kinases (ROCK-HR1)
5SSX	;	1.02	;	Crystal Structure human formylglycine generating enzyme E130D mutant
7JXR	;	2.04	;	Crystal Structure Human Immunodeficiency Virus-1 Matrix protein Mutant Q63R Crystal Form 1
7JXS	;	2.35	;	Crystal Structure Human Immunodeficiency Virus-1 Matrix protein Mutant Q63R Crystal Form 2
4QF5	;	2.8	;	Crystal structure I of MurF from Acinetobacter baumannii
4QDI	;	1.8	;	Crystal structure II of MurF from Acinetobacter baumannii
8QHE	;	1.6	;	Crystal structure IR-09
2ITF	;	1.9	;	Crystal structure IsdA NEAT domain from Staphylococcus aureus with heme bound
6B1H	;	1.8	;	Crystal structure KPC-2 beta-lactamase complexed with WCK 4234 by co-crystallization
6B1F	;	1.44	;	Crystal structure KPC-2 beta-lactamase complexed with WCK 4234 by soaking
6B1W	;	1.73	;	Crystal structure KPC-2 beta-lactamase complexed with WCK 5107 by co-crystallization
6B1J	;	1.6	;	Crystal structure KPC-2 beta-lactamase complexed with WCK 5107 by soaking
6B1Y	;	1.8	;	Crystal structure KPC-2 beta-lactamase complexed with WCK 5153 by co-crystallization
6B1X	;	1.45	;	Crystal structure KPC-2 beta-lactamase complexed with WCK 5153 by soaking
4COB	;	2.37	;	Crystal structure kynurenine formamidase from Pseudomonas aeruginosa
3E9G	;	2.5	;	Crystal structure long-form (residue1-124) of Eaf3 chromo domain
7WCJ	;	2.24	;	Crystal structure LpqY from Mycobacterium tuberculosis
7WDA	;	1.91	;	Crystal structure LpqY in complex with Trehalose from Mycobacterium tuberculosis
5OVK	;	1.45	;	Crystal structure MabA bound to NADPH from M. smegmatis
8G1W	;	1.2	;	Crystal Structure Matriptase (C731S) in Complex with Inhibitor VD4162B
6CC8	;	1.95	;	Crystal structure MBD3 MBD domain in complex with methylated CpG DNA
6CCG	;	1.9	;	Crystal structure MBD3 MBD domain in complex with methylated CpG DNA
4LG7	;	2.5	;	Crystal structure MBD4 MBD domain in complex with methylated CpG DNA
4JKX	;	2.35	;	Crystal structure Mistletoe Lectin I from Viscum album in complex with kinetin at 2.35 A resolution.
4EB2	;	1.94	;	Crystal structure Mistletoe Lectin I from Viscum album in complex with n-acetyl-d-glucosamine at 1.94 A resolution.
5CUH	;	1.83	;	Crystal structure MMP-9 complexes with a constrained hydroxamate based inhibitor LT4
4NDO	;	1.35	;	Crystal structure Molybdenum Storage Protein with fully Mo-loaded cavity
4NDP	;	1.6	;	Crystal structure Molybdenum Storage Protein with fully Mo-loaded cavity
4NDQ	;	1.751	;	Crystal structure Molybdenum Storage Protein with fully Mo-loaded cavity
4NDR	;	2.0	;	Crystal structure Molybdenum Storage Protein with fully Mo-loaded cavity
4L7W	;	2.305	;	Crystal structure mutant H77A of human HD domain-containing protein 2, Genomics Consortium (NESG) Target HR6723
5IBF	;	1.7	;	Crystal structure Mycobacterium tuberculosis CYP121 in complex with inhibitor fragment 19a
5IBD	;	1.77	;	Crystal structure Mycobacterium tuberculosis CYP121 in complex with inhibitor fragment 24a
5IBE	;	1.624	;	Crystal structure Mycobacterium tuberculosis CYP121 in complex with inhibitor fragment 25a
5IBG	;	2.1	;	Crystal structure Mycobacterium tuberculosis CYP121 in complex with inhibitor fragment 25b
5IBI	;	2.2	;	Crystal structure Mycobacterium tuberculosis CYP121 in complex with inhibitor fragment 26a
5IBH	;	2.0201	;	Crystal structure Mycobacterium tuberculosis CYP121 in complex with inhibitor fragment 26h
5IBJ	;	2.5	;	Crystal structure Mycobacterium tuberculosis CYP121 in complex with inhibitor fragment 6
8UR1	;	2.1	;	Crystal structure N-acetylneuraminate lyase (NanA) from Klebsiella aerogenes (pyruvate bound halide free active site)
6T3F	;	3.2	;	Crystal structure Nipah virus fusion glycoprotein in complex with a neutralising Fab fragment
5D5K	;	1.9	;	Crystal Structure NLS from human PARP-2 complexed with Importin alpha delta IBB
6X5X	;	1.92	;	Crystal structure o BmooMP-I, a P-I metalloproteinase from Bothrops moojeni
4ITM	;	2.1994	;	Crystal structure of ""apo"" form LpxK from Aquifex aeolicus in complex with ATP at 2.2 angstrom resolution
4ITN	;	2.1912	;	Crystal structure of ""compact P-loop"" LpxK from Aquifex aeolicus in complex with chloride at 2.2 angstrom resolution
3O3Q	;	1.6	;	Crystal structure of ""L44F/M67I/L73V/A103G/deletion 104-106/F108Y/V109L/L111I/C117V/R119G/deletion 120-122"" mutant form of Human acidic fibroblast growth factor
1S61	;	2.1	;	Crystal Structure of ""Truncated"" Hemoglobin N (HbN) from Mycobacterium tuberculosis, Soaked with Butyl-isocyanide
1S56	;	2.43	;	Crystal Structure of ""Truncated"" Hemoglobin N (HbN) from Mycobacterium tuberculosis, Soaked with Xe Atoms
3NRP	;	1.6	;	Crystal structure of 'as isolated' uropathogenic E. coli strain F11 FetP recombinantly expressed in the periplasm of E. coli BL21(DE3)
6TT1	;	1.8	;	Crystal structure of 'Res_S2 mutant human Angiotensin-1 converting enzyme N-domain in complex with 33RE.
6TT4	;	1.8	;	Crystal structure of 'Res_S2 mutant human Angiotensin-1 converting enzyme N-domain in complex with omapatrilat.
6TT3	;	1.7	;	Crystal structure of 'Res_S2 mutant human Angiotensin-1 converting enzyme N-domain in complex with SG6.
2JEW	;	1.4	;	Crystal structure of ((2S)-5-amino-2-((1-n-propyl-1H-imidazol-4-yl) methyl)pentanoic acid) UK396,082 a TAFIa inhibitor, Bound to Activated Porcine Pancreatic carboxypeptidaseB
3G4F	;	2.651	;	Crystal Structure of (+)- -Cadinene Synthase from Gossypium arboreum in complex with 2-fluorofarnesyl diphosphate
3JRS	;	2.05	;	Crystal structure of (+)-ABA-bound PYL1
3JRQ	;	2.1	;	Crystal structure of (+)-ABA-bound PYL1 in complex with ABI1
1N1B	;	2.0	;	Crystal Structure of (+)-Bornyl Diphosphate Synthase from Sage
3G4D	;	2.403	;	Crystal Structure of (+)-delta-Cadinene Synthase from Gossypium arboreum and Evolutionary Divergence of Metal Binding Motifs for Catalysis
5UV1	;	2.4	;	Crystal Structure of (+)-Limonene Synthase Complexed with 2-Fluorogeranyl Diphosphate
5UV2	;	2.2	;	Crystal Structure of (+)-Limonene Synthase Complexed with 2-Fluoroneryl Diphosphate
6ONM	;	2.7	;	Crystal Structure of (+)-Limonene Synthase Complexed with 8,9-Difluorolinalyl Diphosphate
5UV0	;	2.3	;	Crystal Structure of (+)-Limonene Synthase from Citrus sinensis
7EQL	;	2.72	;	Crystal structure of (+)-pulegone reductase from Mentha piperita
7VR2	;	2.4	;	Crystal structure of (-)-pulegone reductase PR1292 from Nepeta tenuifolia
7VR4	;	1.69	;	Crystal structure of (-)-pulegone reductase PR1294 from Nepeta tenuifolia in complex with NADPH
3IDC	;	2.7	;	Crystal structure of (102-265)RIIb:C holoenzyme of cAMP-dependent protein kinase
3IDB	;	1.62	;	Crystal structure of (108-268)RIIb:C holoenzyme of cAMP-dependent protein kinase
4L53	;	2.55	;	Crystal Structure of (1R,4R)-4-{4-[7-amino-2-(1,2,3-benzothiadiazol-7-yl)-3-chlorofuro[2,3-c]pyridin-4-yl]-1H-pyrazol-1-yl}cyclohexan-1-ol bound to TAK1-TAB1
6SYS	;	1.3	;	Crystal structure of (3aR,4S,9bS)-4-(4-hydroxyphenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide with carbonic anhydrase 2
4RV2	;	2.7	;	Crystal Structure of (3R)-hydroxyacyl-ACP dehydratase HadAB hetero-dimer from Mycobacterium smegmatis
4RLJ	;	1.75	;	Crystal Structure of (3R)-hydroxyacyl-ACP dehydratase HadAB hetero-dimer from Mycobacterium tuberculosis
4RLU	;	2.198	;	Crystal Structure of (3R)-hydroxyacyl-ACP dehydratase HadAB hetero-dimer from Mycobacterium tuberculosis complexed with 2',4,4'-trihydroxychalcone
4RLW	;	2.196	;	Crystal Structure of (3R)-hydroxyacyl-ACP dehydratase HadAB hetero-dimer from Mycobacterium tuberculosis complexed with Butein
4RLT	;	2.049	;	Crystal Structure of (3R)-hydroxyacyl-ACP dehydratase HadAB hetero-dimer from Mycobacterium tuberculosis complexed with Fisetin
8PWZ	;	2.00197	;	Crystal Structure of (3R)-hydroxyacyl-ACP dehydratase HadBD from Mycobacterium tuberculosis
3CF9	;	2.6	;	Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Helicobacter pylori in complex with apigenin
3DOY	;	2.4	;	Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Helicobacter pylori in complex with compound 3i
3DP2	;	2.4	;	Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Helicobacter pylori in complex with compound 3j
3DOZ	;	2.5	;	Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Helicobacter pylori in complex with compound 3k
3DP0	;	2.5	;	Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Helicobacter pylori in complex with compound 3m
3DP1	;	2.3	;	Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Helicobacter pylori in complex with compound 3n
3DP3	;	2.3	;	Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Helicobacter pylori in complex with compound 3q
3ED0	;	2.3	;	Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Helicobacter pylori in complex with emodin
3CF8	;	2.4	;	Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Helicobacter pylori in complex with quercetin
3D04	;	2.4	;	Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Helicobacter pylori in complex with sakuranetin
2GLL	;	2.2	;	Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase(FabZ) from Helicobacter pylori
2GLP	;	2.42	;	Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase(FabZ) from Helicobacter pylori complexed with compound 1
2GLM	;	2.6	;	Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase(FabZ) from Helicobacter pylori complexed with Compound 2
3B7J	;	2.4	;	Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase(FabZ) from Helicobacter pylori complexed with juglone
4ZJB	;	2.55	;	Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase(FabZ) in complex with holo-ACP from Helicobacter pylori
2GLV	;	2.5	;	Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase(FabZ) mutant(Y100A) from Helicobacter pylori
6IHC	;	2.4	;	Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase(FabZ) Y100A mutant in complex with holo-ACP from Helicobacter pylori
4I83	;	2.6	;	Crystal Structure of (3R)-Hydroxymyristoyl-ACP Dehydratase from Neisseria meningitidis FAM18
4H4G	;	2.65	;	Crystal Structure of (3R)-hydroxymyristoyl-[acyl-carrier-protein] dehydratase from Burkholderia thailandensis E264
5AZ9	;	1.82	;	Crystal structure of (5-residue deleted)MBP-Tom20 fusion protein tethered with ALDH presequence via a disulfide bond
7YKN	;	2.5	;	Crystal structure of (6-4) photolyase from Vibrio cholerae
3PVB	;	3.3	;	Crystal structure of (73-244)RIa:C holoenzyme of cAMP-dependent Protein kinase
2PKR	;	2.4	;	Crystal structure of (A+CTE)4 chimeric form of photosyntetic glyceraldehyde-3-phosphate dehydrogenase, complexed with NADP
3NQJ	;	2.1	;	Crystal structure of (CENP-A/H4)2 heterotetramer
5UHR	;	1.798	;	Crystal structure of (Cit)LANFLV heptapeptide segment from islet amyloid polypeptide (IAPP) incorporated into a macrocyclic beta-sheet template
6OH7	;	2.19	;	Crystal structure of (E)-biformene synthase LrdC from Streptomyces sp. strain K155 in complex with Mg
6OH6	;	2.07	;	Crystal structure of (E)-biformene synthase LrdC from Streptomyces sp. strain K155 in complex with Mg and PPi
6OH8	;	2.17	;	Crystal structure of (E)-biformene synthase LrdC from Streptomyces sp. strain K155 in the dimeric form
4DQF	;	1.9	;	Crystal Structure of (G16A/L38A) HIV-1 Protease in Complex with DRV
4DQC	;	1.94	;	Crystal Structure of (G16C/L38C) HIV-1 Protease in Complex with DRV
4DQE	;	1.3	;	Crystal Structure of (G16C/L38C) HIV-1 Protease in Complex with DRV
4XW1	;	2.302	;	Crystal structure of (GCCU(G-LNA)CCUG)2 duplex
4XW0	;	1.81	;	Crystal structure of (GCCU(G-LNA)CCUGC)2 duplex
3B0S	;	1.45	;	Crystal Structure of (Gly-Pro-Hyp)9
1P92	;	2.1	;	Crystal Structure of (H79A)DtxR
1XCV	;	2.1	;	Crystal Structure Of (H79AC102D)Dtxr complexed with Nickel(II)
2WJZ	;	2.601	;	Crystal structure of (HisH) K181A Y138A mutant of imidazoleglycerolphosphate synthase (HisH HisF) which displays constitutive glutaminase activity
3ABN	;	1.02	;	Crystal structure of (Pro-Pro-Gly)4-Hyp-Asp-Gly-(Pro-Pro-Gly)4 at 1.02 A
3ADM	;	1.18	;	Crystal structure of (Pro-Pro-Gly)4-Hyp-Ser-Gly-(Pro-Pro-Gly)4
3AH9	;	1.08	;	Crystal structure of (Pro-Pro-Gly)9 at 1.1 A resolution
1ZG8	;	2.0	;	Crystal Structure of (R)-2-(3-{[amino(imino)methyl]amino}phenyl)-3-sulfanylpropanoic acid Bound to Activated Porcine Pancreatic Carboxypeptidase B
6ZZS	;	1.85	;	Crystal structure of (R)-3-hydroxybutyrate dehydrogenase from Acinetobacter baumannii complexed with NAD+ and 3-oxovalerate
6ZZQ	;	1.93	;	Crystal structure of (R)-3-hydroxybutyrate dehydrogenase from Acinetobacter baumannii complexed with NAD+ and acetoacetate
6ZZP	;	1.84	;	Crystal structure of (R)-3-hydroxybutyrate dehydrogenase from Psychrobacter arcticus complexed with NAD+ and 3-oxovalerate
6ZZO	;	1.28	;	Crystal structure of (R)-3-hydroxybutyrate dehydrogenase from Psychrobacter arcticus complexed with NAD+ and acetoacetate
4N5L	;	1.65	;	Crystal structure of (R)-3-hydroxybutyryl-CoA dehydrogenase from Ralstonia eutropha
4N5M	;	1.34	;	Crystal structure of (R)-3-hydroxybutyryl-CoA dehydrogenase from Ralstonia eutropha in complexed with acetoacetyl-CoA
4N5N	;	1.9	;	Crystal structure of (R)-3-hydroxybutyryl-CoA dehydrogenase from Ralstonia eutropha in complexed with NADP
3WLF	;	2.3	;	Crystal structure of (R)-carbonyl reductase from Candida Parapsilosis in complex with (R)-1-phenyl-1,2-ethanediol
3WLE	;	2.164	;	Crystal structure of (R)-carbonyl reductase from Candida Parapsilosis in complex with NAD
3WNQ	;	2.95	;	Crystal structure of (R)-carbonyl reductase H49A mutant from Candida Parapsilosis in complex with 2-hydroxyacetophenone
3MF7	;	1.65	;	Crystal Structure of (R)-oxirane-2-carboxylate inhibited cis-CaaD
5IEX	;	2.03	;	Crystal structure of (R,S)-S-{4-[(5-Bromo-4-{[(2R,3R)-2-hydroxy-1-methylpropyl]oxy}- pyrimidin-2-yl)amino]phenyl}-S-cyclopropylsulfoximide bound to CDK2
4DQH	;	1.79	;	Crystal Structure of (R14C/E65C) HIV-1 Protease in complex with DRV
8HP5	;	2.5	;	Crystal structure of (S)-2-haloacid dehalogenase
8HP6	;	2.2	;	Crystal structure of (S)-2-haloacid dehalogenase D12A mutant
8HP7	;	1.43	;	Crystal structure of (S)-2-haloacid dehalogenase K152A mutant trapped with (2R)-4-amino-2-hydroxybutanoic acid
4R1N	;	1.8	;	Crystal structure of (S)-3-hydroxybutylryl-CoA dehydrogenase form the n-butanol sysnthesizing bacterium, Clostridium butyricum.
6ACQ	;	2.5	;	Crystal structure of (S)-3-hydroxybutyryl-CoA dehydrogenase from Clostridium acetobutylicum, apo form
4PZC	;	2.6	;	Crystal structure of (S)-3-hydroxybutyryl-CoA dehydrogenase PaaH1 from Ralstonia eutropha
4PZE	;	2.7	;	Crystal structure of (S)-3-hydroxybutyryl-CoA dehydrogenase PaaH1 in complex with acetoacetyl-CoA
4PZD	;	2.61	;	Crystal structure of (S)-3-hydroxybutyryl-CoA dehydrogenase PaaH1 in complex with NAD+
6AA8	;	2.1	;	Crystal structure of (S)-3-hydroxybutyryl-coenzymeA dehydrogenase from Clostridium acetobutylicum complexed with NAD+
2F6U	;	1.55	;	Crystal Structure of (S)-3-O-Geranylgeranylglyceryl Phosphate Synthase complexed with citrate
2F6X	;	2.0	;	Crystal Structure of (S)-3-O-Geranylgeranylglyceryl Phosphate Synthase complexed with sn-G1P and MPD
6JO3	;	2.35	;	Crystal structure of (S)-3-O-geranylgeranylglyceryl phosphate synthase from Thermoplasma acidophilum in complex with substrate sn-glycerol-1-phosphate
5Z5M	;	1.85	;	Crystal structure of (S)-allantoin synthase
5ICC	;	1.9	;	Crystal structure of (S)-norcoclaurine 6-O-methyltransferase with S-adenosyl-L-homocysteine
5ICE	;	1.6	;	Crystal structure of (S)-norcoclaurine 6-O-methyltransferase with S-adenosyl-L-homocysteine and norlaudanosoline
5ICF	;	1.8	;	Crystal structure of (S)-norcoclaurine 6-O-methyltransferase with S-adenosyl-L-homocysteine and sanguinarine
4E2Q	;	2.5	;	Crystal Structure of (S)-Ureidoglycine Aminohydrolase from Arabidopsis thaliana
4E2S	;	2.59	;	Crystal structure of (S)-Ureidoglycine Aminohydrolase from Arabidopsis thaliana in complex with its substrate, (S)-Ureidoglycine
2C8L	;	3.1	;	Crystal Structure of (SR) Calcium-ATPase E2(Tg) form
4UU0	;	2.5	;	CRYSTAL STRUCTURE OF (SR) CALCIUM-ATPASE E2(TG) IN THE PRESENCE OF 14:1 PC
4UU1	;	2.8	;	CRYSTAL STRUCTURE OF (SR) CALCIUM-ATPASE E2(TG) IN THE PRESENCE OF DOPC
2C8K	;	2.8	;	Crystal Structure of (SR) Calcium-ATPase E2(Tg) with partially occupied AMPPCP site
2C88	;	3.1	;	Crystal Structure Of (SR) Calcium-ATPase E2(Tg):AMPPCP form
2PD2	;	2.06	;	Crystal structure of (ST0148) conserved hypothetical from Sulfolobus Tokodaii Strain7
7O6W	;	2.64	;	Crystal structure of (the) VEL1 VEL polymerising domain (I664D mutant)
5FHQ	;	1.63	;	Crystal structure of (WT) Rat Catechol-O-Methyltransferase in complex with AdoMet and 3,5-dinitrocatechol (DNC)
3VFZ	;	1.901	;	Crystal structure of -35 promoter binding domain of SigD of Mycobacterium tuberculosis
4U4M	;	3.09	;	Crystal structure of 0.5M urea unfolded YagE, a KDG aldolase protein in complex with Pyruvate
5LYD	;	2.02	;	Crystal structure of 1 in complex with tafCPB
5LYF	;	2.01	;	Crystal structure of 1 in complex with tafCPB
5LYI	;	1.64	;	Crystal structure of 1 in complex with tafCPB
5LYL	;	1.83	;	Crystal structure of 1 in complex with tafCPB
2EAB	;	1.12	;	Crystal structure of 1,2-a-L-fucosidase from Bifidobacterium bifidum (apo form)
2EAC	;	2.1	;	Crystal structure of 1,2-a-L-fucosidase from Bifidobacterium bifidum in complex with deoxyfuconojirimycin
2EAD	;	1.89	;	Crystal structure of 1,2-a-L-fucosidase from Bifidobacterium bifidum in complex with substrate
2EAE	;	1.8	;	Crystal structure of 1,2-a-L-fucosidase from Bifidobacterium bifidum in complexes with products
5H3Z	;	2.0	;	Crystal Structure of 1,2-beta-oligoglucan phosphorylase from Lachnoclostridium phytofermentans
5H42	;	2.1	;	Crystal Structure of 1,2-beta-oligoglucan phosphorylase from Lachnoclostridium phytofermentans in complex with alpha-d-glucose-1-phosphate
5H40	;	2.2	;	Crystal Structure of 1,2-beta-oligoglucan phosphorylase from Lachnoclostridium phytofermentans in complex with sophorose
5H41	;	2.0	;	Crystal Structure of 1,2-beta-oligoglucan phosphorylase from Lachnoclostridium phytofermentans in complex with sophorose, isofagomine, sulfate ion
1JA9	;	1.5	;	Crystal structure of 1,3,6,8-tetrahydroxynaphthalene reductase in complex with NADPH and pyroquilon
1U0M	;	2.22	;	Crystal Structure of 1,3,6,8-Tetrahydroxynaphthalene Synthase (THNS) from Streptomyces coelicolor A3(2): a Bacterial Type III Polyketide Synthase (PKS) Provides Insights into Enzymatic Control of Reactive Polyketide Intermediates
1FGG	;	2.3	;	CRYSTAL STRUCTURE OF 1,3-GLUCURONYLTRANSFERASE I (GLCAT-I) COMPLEXED WITH GAL-GAL-XYL, UDP, AND MN2+
3VSF	;	2.757	;	Crystal structure of 1,3Gal43A, an exo-beta-1,3-Galactanase from Clostridium thermocellum
1W91	;	2.2	;	crystal structure of 1,4-BETA-D-XYLAN XYLOHYDROLASE solve using anomalous signal from Seleniomethionine
6OJM	;	1.6	;	Crystal structure of 1,4-dihydroxy-2-naphthoyl-CoA synthase Elizabethkingia anophelis NUHP1
6YYK	;	2.04	;	Crystal Structure of 1,5-dimethylindoline-2,3-dione covalently bound to the PH domain of Bruton's tyrosine kinase mutant R28C
3VSJ	;	2.3	;	Crystal structure of 1,6-APD (2-ANIMOPHENOL-1,6-DIOXYGENASE) complexed with intermediate products
5NX6	;	1.63	;	Crystal structure of 1,8-cineole synthase from Streptomyces clavuligerus in complex with 2-fluoroneryl diphosphate
5NX7	;	1.51	;	Crystal structure of 1,8-cineole synthase from Streptomyces clavuligerus in complex with 2-fluoroneryl diphosphate and 2-fluorogeranyl diphosphate
1M2P	;	2.0	;	Crystal structure of 1,8-di-hydroxy-4-nitro-anthraquinone/CK2 kinase complex
1M2Q	;	1.79	;	Crystal structure of 1,8-di-hydroxy-4-nitro-xanten-9-one/CK2 kinase complex
2XX9	;	1.97	;	Crystal structure of 1-((2-fluoro-4-(3-(trifluoromethyl)-4,5,6,7- tetrahydro-1H-indazol-1-yl)phenyl)methyl)-2-pyrrolidinone in complex with the ligand binding domain of the Rat GluA2 receptor and glutamate at 2.2A resolution.
2XXI	;	1.6	;	Crystal structure of 1-((4-(3-(trifluoromethyl)-6,7-dihydropyrano(4,3- c(pyrazol-1(4H)-yl)phenyl)methyl)-2-pyrrolidinone in complex with the ligand binding domain of the Rat GluA2 receptor and glutamate at 1.6A resolution.
2XX7	;	2.2	;	Crystal structure of 1-(4-(1-pyrrolidinylcarbonyl)phenyl)-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazole in complex with the ligand binding domain of the Rat GluA2 receptor and glutamate at 2.2A resolution.
2XXH	;	1.5	;	Crystal structure of 1-(4-(2-oxo-2-(1-pyrrolidinyl)ethyl)phenyl)-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazole in complex with the ligand binding domain of the Rat GluA2 receptor and glutamate at 1.5A resolution.
4L52	;	2.54	;	Crystal Structure of 1-(4-{4-[7-amino-2-(1,2,3-benzothiadiazol-7-yl)furo[2,3-c]pyridin-4-yl]-1H-pyrazol-1-yl}piperidin-1-yl)ethan-1-one bound to TAK1-TAB1
4GJ1	;	2.152	;	Crystal structure of 1-(5-phosphoribosyl)-5-[(5-phosphoribosylamino)methylideneamino] imidazole-4-carboxamide isomerase (hisA).
3G2I	;	2.0	;	Crystal structure of 1-(beta-D-glucopyranosyl)-4-substituted-1,2,3-triazole
3G2K	;	2.0	;	Crystal structure of 1-(beta-D-glucopyranosyl)-4-substituted-1,2,3-triazole
3G2H	;	2.03	;	Crystal structure of 1-(beta-D-glucopyranosyl)-4-substituted-1,2,3-triazoles in complex with glycogen phosphorylase
3G2J	;	2.14	;	Crystal structure of 1-(beta-D-glucopyranosyl)-4-substituted-1,2,3-triazoles in complex with glycogen phosphorylase
3G2L	;	2.3	;	Crystal structure of 1-(beta-D-glucopyranosyl)-4-substituted-1,2,3-triazoles in complex with glycogen phosphorylase
1TZJ	;	1.99	;	Crystal Structure of 1-aminocyclopropane-1-carboxylate deaminase complexed with d-vinyl glycine
1TZK	;	2.0	;	Crystal structure of 1-aminocyclopropane-1-carboxylate-deaminase complexed with alpha-keto-butyrate
1TZ2	;	2.1	;	Crystal structure of 1-aminocyclopropane-1-carboyxlate deaminase complexed with ACC
1TYZ	;	2.0	;	Crystal structure of 1-Aminocyclopropane-1-carboyxlate Deaminase from Pseudomonas
3ANM	;	2.0	;	Crystal structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR) complexed with 5-phenylpyridin-2-ylmethylphosphonic acid
3RAS	;	2.55	;	Crystal structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR) complexed with a lipophilic phosphonate inhibitor
3ANL	;	2.1	;	Crystal structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR) complexed with pyridin-2-ylmethylphosphonic acid
3ANN	;	2.0	;	Crystal structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR) complexed with quinolin-2-ylmethylphosphonic acid
2EGH	;	2.2	;	Crystal structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase complexed with a magnesium ion, NADPH and fosmidomycin
1R0K	;	1.91	;	Crystal structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase from Zymomonas mobilis
1JVS	;	2.2	;	Crystal structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase; a target enzyme for antimalarial drugs
6MH5	;	2.887	;	Crystal Structure of 1-deoxy-D-xylulose-5-phosphate reductoisomerase from Staphylococcus schleiferi in complex with Fosmidomycin (FOM)
6MH4	;	2.15	;	Crystal Structure of 1-deoxy-D-xylulose-5-phosphate reductoisomerase from Staphylococcus schleiferi, Apoenzyme
4Q83	;	1.55	;	Crystal structure of 1-hydroxy-3-(trifluoromethyl)pyridine-2(1H)-thione bound to human carbonic anhydrase II
4Q7P	;	1.65	;	Crystal Structure of 1-hydroxy-3-methylpyridine-2(1H)-thione bound to hCAII
4Q81	;	1.55	;	Crystal structure of 1-hydroxy-4,6-dimethylpyridine-2(1H)-thione bound to human carbonic anhydrase II
4Q87	;	1.55	;	Crystal structure of 1-hydroxy-4-(trifluoromethyl)pyridine-2(1H)-thione bound to human carbonic anhydrase II
4Q8Z	;	1.5	;	Crystal structure of 1-hydroxy-4-methylpyridin-2(1H)-one bound to human carbonic anhydrase II
4Q7S	;	1.8	;	Crystal Structure of 1-hydroxy-4-methylpyridine-2(1H)-thione bound to human carbonic anhydrase II
4Q8X	;	1.55	;	Crystal structure of 1-hydroxy-5-(trifluoromethyl)pyridine-2(1H)-thione bound to human carbonic anhydrase II
4Q7V	;	1.6	;	Crystal structure of 1-hydroxy-5-methylpyridine-2(1H)-thione bound to human carbonic anhydrase II
4Q7W	;	1.45	;	Crystal structure of 1-hydroxy-6-methylpyridine-2(1H)-thione bound to human carbonic anhydrase II
5TH4	;	1.47	;	Crystal Structure of 1-hydroxypyridine-2(1H)-thione bound to human carbonic anhydrase 2 L198G
6TSE	;	1.41	;	Crystal Structure of 1-methylindoline-2,3-dione covalently bound to the PH domain of Bruton's tyrosine kinase mutant R28C
4O0K	;	1.5	;	Crystal structure of 1-pyrroline-4-hydroxy-2-carboxylate deaminase from Brucella melitensis with covalently bound substrate
3QAN	;	1.95	;	Crystal structure of 1-pyrroline-5-carboxylate dehydrogenase from bacillus halodurans
3RJL	;	2.2	;	Crystal structure of 1-pyrroline-5-carboxylate dehydrogenase from Bacillus licheniformis (Target NYSGRC-000337)
2AMF	;	2.2	;	Crystal structure of 1-Pyrroline-5-Carboxylate Reductase from Human Pathogen Streptococcus Pyogenes
3CQZ	;	2.8	;	Crystal structure of 10 subunit RNA polymerase II in complex with the inhibitor alpha-amanitin
4FQ2	;	1.9	;	Crystal Structure of 10-1074 Fab
7XBO	;	2.2	;	Crystal Structure of 10-dml-bound cytochrome P450 PikC with the unnatural amino acid p-Acetyl-L-Phenylalanine incorporated at position 238
7ZRN	;	1.82	;	Crystal structure of 10-epi-cubebol synthase from Sorangium cellulosum (ScCubS) in complex with Pyrophosphate
6KJ5	;	3.75	;	Crystal structure of 10-Hydroxygeraniol Dehydrogenase apo form from Cantharanthus roseus
6K3G	;	2.41	;	Crystal structure of 10-Hydroxygeraniol Dehydrogenase from Cantharanthus roseus in complex with NADP+
5GRD	;	1.8	;	Crystal structure of 10-mer peptide from EBV in complex with HLA-A1101.
3O41	;	1.95	;	Crystal Structure of 101F Fab Bound to 15-mer Peptide Epitope
3O45	;	2.872	;	Crystal Structure of 101F Fab Bound to 17-mer Peptide Epitope
5JNY	;	3.041	;	Crystal Structure of 10E8 Fab
4U6G	;	4.2012	;	Crystal structure of 10E8 Fab in complex with a hydrocarbon-stapled HIV-1 gp41 MPER peptide
4G6F	;	2.1	;	Crystal Structure of 10E8 Fab in Complex with an HIV-1 gp41 Peptide
5T6L	;	2.1	;	Crystal structure of 10E8 Fab in complex with the MPER epitope scaffold T117v2
5T80	;	2.62	;	Crystal structure of 10E8 Fab in complex with the MPER epitope scaffold T117v2 and phosphatidic acid (06:0 PA)
5T85	;	2.373	;	Crystal structure of 10E8 Fab in complex with the MPER epitope scaffold T117v2 and phosphatidylglycerol (06:0 PG)
5TFW	;	2.168	;	Crystal structure of 10E8 Fab light chain mutant2 against the MPER region of the HIV-1 Env, in complex with T117v2 epitope scaffold
5T29	;	2.03	;	Crystal structure of 10E8 Fab light chain mutant3, against the MPER region of the HIV-1 Env, in complex with the MPER epitope scaffold T117v2
5JO5	;	1.7	;	Crystal structure of 10E8 gHV-gLV antigen-binding fragment.
5JR1	;	1.601	;	Crystal structure of 10E8 gHV-matureL antigen-binding fragment.
5IQ7	;	3.2869	;	Crystal structure of 10E8-S74W Fab in complex with an HIV-1 gp41 peptide.
5IQ9	;	2.4	;	Crystal structure of 10E8v4 Fab in complex with an HIV-1 gp41 peptide.
5WDF	;	3.1	;	Crystal structure of 10E8v4-5R+100cF Fab in complex with HIV-1 gp41 peptide
7CNZ	;	2.7	;	Crystal structure of 10PE bound PSD from E. coli (2.70 A)
4HX5	;	2.19	;	Crystal structure of 11 beta-HSD1 in complex with SAR184841
3A1L	;	2.5	;	Crystal Structure of 11,11'-Dichlorochromopyrrolic Acid Bound Cytochrome P450 StaP (CYP245A1)
7F06	;	1.95	;	Crystal Structure of 1144
3TFQ	;	1.8	;	Crystal structure of 11b-hsd1 double mutant (l262r, f278e) complexed with 8-{[(2-CYANOPYRIDIN-3-YL)METHYL]SULFANYL}-6-HYDROXY-3,4-DIHYDRO-1H-PYRANO[3,4-C]PYRIDINE-5-CARBONITRILE
4IJU	;	2.35	;	Crystal structure of 11b-HSD1 double mutant (L262R, F278E) in complex with (1S,4S)-4-[8-(2-fluorophenoxy)[1,2,4]triazolo[4,3-a]pyridin-3-yl]bicyclo[2.2.1]heptan-1-ol
4IJV	;	2.35	;	Crystal structure of 11b-HSD1 double mutant (L262R, F278E) in complex with 3-[1-(4-chlorophenyl)cyclopropyl]-8-(2-fluorophenoxy)[1,2,4]triazolo[4,3-a]pyridine
4IJW	;	2.35	;	Crystal structure of 11b-HSD1 double mutant (L262R, F278E) in complex with 3-[1-(4-chlorophenyl)cyclopropyl]-8-cyclopropyl[1,2,4]triazolo[4,3-a]pyridine
3D5Q	;	2.55	;	Crystal Structure of 11b-HSD1 in Complex with Triazole Inhibitor
3FRJ	;	2.3	;	Crystal Structure of 11b-Hydroxysteroid Dehydrogenase-1 (11b-HSD1) in Complex with Piperidyl Benzamide Inhibitor
3CH6	;	2.35	;	Crystal Structure of 11beta-HSD1 Double Mutant (L262R, F278E) Complexed with (3,3-dimethylpiperidin-1-yl)(6-(3-fluoro-4-methylphenyl)pyridin-2-yl)methanone
5PGV	;	2.35	;	CRYSTAL STRUCTURE OF 11BETA-HSD1 DOUBLE MUTANT (L262R, F278E) COMPLEXED WITH 1-(3-HYDROXYAZETIDIN-1-YL)-2-[(2S,5R)-2-(4-FLUOROPHENYL)-5-METHOXYADAMANTAN-2-YL]ETHAN-1-ONE
5PGX	;	2.5	;	CRYSTAL STRUCTURE OF 11BETA-HSD1 DOUBLE MUTANT (L262R, F278E) COMPLEXED WITH 2-(2-BENZYL-6-HYDROXYADAMANTAN-2-YL)-1-(3-HYDROXYAZETIDIN-1-YL)ETHAN-1-ONE
5QII	;	2.45	;	CRYSTAL STRUCTURE OF 11BETA-HSD1 DOUBLE MUTANT (L262R, F278E) COMPLEXED WITH 2-(3-(1-(4-CHLOROPHENYL)CYCLOPROPYL) -[1,2,4]TRIAZOLO[4,3-A]PYRIDIN-8-YL)PROPAN-2-OL
5PGW	;	2.37	;	CRYSTAL STRUCTURE OF 11BETA-HSD1 DOUBLE MUTANT (L262R, F278E) COMPLEXED WITH 2-[(1R,3S,5R,7S)-2-[4-(4-FLUOROPHENYL)PHENYL]-6-HYDROXYADAMANTAN-2-YL]-1-(3- HYDROXYAZETIDIN-1-YL)ETHAN-1-ONE
5PGY	;	2.07	;	CRYSTAL STRUCTURE OF 11BETA-HSD1 DOUBLE MUTANT (L262R, F278E) COMPLEXED WITH 2-[(5R,7S)-6-HYDROXY-2-PHENYLADAMANTAN-2-YL]-1-(3-HYDROXYAZETIDIN-1-YL)ETHAN-1-ONE (BMS-816336)
5PGU	;	2.35	;	CRYSTAL STRUCTURE OF 11BETA-HSD1 DOUBLE MUTANT (L262R, F278E) COMPLEXED WITH 2-[2-(4-fluorophenyl)-2-adamantyl]-1-(3-methoxyazetidin-1-yl)ethanone
3FCO	;	2.65	;	Crystal Structure of 11beta-Hydroxysteroid Dehydrogenase 1 (11b-HSD1) in Complex with Benzamide Inhibitor
3QQP	;	2.72	;	Crystal Structure of 11beta-Hydroxysteroid Dehydrogenase 1 (11b-HSD1) in Complex with Urea Inhibitor
3OQ1	;	2.6	;	Crystal Structure of 11beta-Hydroxysteroid Dehydrogenase-1 (11b-HSD1) in Complex with Diarylsulfone Inhibitor
5XTY	;	2.2	;	Crystal Structure of 11S allergen from Cocos nucifera L.
1ICS	;	2.3	;	CRYSTAL STRUCTURE OF 12-OXOPHYTODIENOATE REDUCTASE 1 FROM TOMATO
1ICQ	;	2.0	;	CRYSTAL STRUCTURE OF 12-OXOPHYTODIENOATE REDUCTASE 1 FROM TOMATO COMPLEXED WITH 9R,13R-OPDA
1ICP	;	1.9	;	CRYSTAL STRUCTURE OF 12-OXOPHYTODIENOATE REDUCTASE 1 FROM TOMATO COMPLEXED WITH PEG400
2HSA	;	1.5	;	Crystal structure of 12-oxophytodienoate reductase 3 (OPR3) from tomato
6D01	;	3.2	;	Crystal structure of 1210 Fab in complex with circumsporozoite protein NANP5
5XCS	;	2.2	;	Crystal structure of 12CA5 Fv-clasp fragment with its antigen peptide
5XCU	;	2.454	;	Crystal structure of 12CA5 Fv-clasp fragment with its antigen peptide
2OV3	;	2.4	;	Crystal structure of 138-173 ZnuA deletion mutant plus zinc bound
4HXA	;	2.06	;	Crystal structure of 13D9 FAB
7C8E	;	3.16	;	Crystal Structure of 14-3-3 epsilon with 9J10 peptide
7V9B	;	1.85	;	Crystal Structure of 14-3-3 epsilon with FOXO3a peptide
3UAL	;	1.8	;	Crystal Structure of 14-3-3 epsilon with Mlf1 peptide
3UZD	;	1.86	;	Crystal structure of 14-3-3 GAMMA
2B05	;	2.55	;	Crystal Structure of 14-3-3 gamma in complex with a phosphoserine peptide
8C30	;	1.4	;	Crystal structure of 14-3-3 in complex with PyrinpS242 and a protein/peptide interface fragment
4F7R	;	3.2	;	Crystal structure of 14-3-3 protein from Giardia intestinalis
7NMA	;	1.75	;	Crystal structure of 14-3-3 sigma in complex with 13mer Amot-p130 peptide
7NND	;	1.4	;	Crystal structure of 14-3-3 sigma in complex with 13mer Amot-p130 peptide and fragment 09
7NMX	;	2.3	;	Crystal structure of 14-3-3 sigma in complex with 13mer Amot-p130 peptide and fragment 12
7NNE	;	1.96	;	Crystal structure of 14-3-3 sigma in complex with 13mer Amot-p130 peptide and fragment 22
7NMW	;	1.5	;	Crystal structure of 14-3-3 sigma in complex with 13mer Amot-p130 peptide and fragment 40
7NN2	;	1.8	;	Crystal structure of 14-3-3 sigma in complex with 13mer Amot-p130 peptide and fragment 41
7NP2	;	1.27	;	Crystal structure of 14-3-3 sigma in complex with 20mer Amot-p130 peptide
7NPB	;	1.37	;	Crystal structure of 14-3-3 sigma in complex with 20mer Amot-p130 peptide and fragment 09
7NPG	;	1.37	;	Crystal structure of 14-3-3 sigma in complex with 20mer Amot-p130 peptide and fragment 22
7PWT	;	2.312	;	Crystal structure of 14-3-3 sigma in complex with a C-terminal Estrogen Receptor alpha phosphopeptide, stabilised by pyrrolidone derivative 228
7PWZ	;	2.5	;	Crystal structure of 14-3-3 sigma in complex with a C-terminal Estrogen Receptoralpha phosphopeptide, stabilised by Pyrrolidone1 derivative 228
6QIU	;	1.802	;	Crystal structure of 14-3-3 sigma in complex with Ataxin-1 Ser776 phosphopeptide
7BM9	;	1.8	;	Crystal structure of 14-3-3 sigma in complex with CIP2ApS904 peptide
7BMC	;	2.0	;	Crystal structure of 14-3-3 sigma in complex with CIP2ApS904 peptide and stabilizing Fusicoccin A
7OB5	;	1.8	;	Crystal structure of 14-3-3 sigma in complex with LDB1 phosphopeptide
7OB8	;	1.8	;	Crystal structure of 14-3-3 sigma in complex with LDB1 phosphopeptide and stabilizer Fusicoccin-A
7OBG	;	1.8	;	Crystal structure of 14-3-3 sigma in complex with NPM1 phosphopeptide
7OBH	;	2.0	;	Crystal structure of 14-3-3 sigma in complex with NPM1 phosphopeptide and stabilizer Fusicoccin-A
7OBC	;	1.9	;	Crystal structure of 14-3-3 sigma in complex with Phosphorylated and Farnesylated Rnd3 peptide
7OBD	;	2.0	;	Crystal structure of 14-3-3 sigma in complex with Phosphorylated and Farnesylated Rnd3 peptide and stabilizer Fusicoccin-A
7OBK	;	1.8	;	Crystal structure of 14-3-3 sigma in complex with PKR phosphopeptide
7OBL	;	1.8	;	Crystal structure of 14-3-3 sigma in complex with PKR phosphopeptide and stabilizer Fusicoccin-A
7OBS	;	1.8	;	Crystal structure of 14-3-3 sigma in complex with RIPK2 phosphopeptide
7OBT	;	2.3	;	Crystal structure of 14-3-3 sigma in complex with RIPK2 phosphopeptide and stabilizer Fusicoccin-A
6FCP	;	1.45	;	Crystal structure of 14-3-3 sigma in complex with Shroom3 P1244L
7OBX	;	1.8	;	Crystal structure of 14-3-3 sigma in complex with SSBP4 phosphopeptide
7OBY	;	2.1	;	Crystal structure of 14-3-3 sigma in complex with SSBP4 phosphopeptide and stabilizer Fusicoccin-A
6FBB	;	1.3	;	Crystal structure of 14-3-3 sigma in complex with wild-type Shroom3
5ULO	;	2.14	;	Crystal Structure of 14-3-3 zeta in Complex with a Serine 124-phosphorylated TBC1D7 peptide
4WRQ	;	2.409	;	Crystal Structure of 14-3-3 zeta with Chibby peptide
5MHC	;	1.2	;	Crystal structure of 14-3-3sigma and a p53 C-terminal 12-mer synthetic phosphopeptide
5MOC	;	1.8	;	Crystal structure of 14-3-3sigma and a p53 C-terminal 12-mer synthetic phosphopeptide
5MXO	;	1.2	;	Crystal structure of 14-3-3sigma and a p53 C-terminal 12-mer synthetic phosphopeptide stabilized by Fusicoccin-A
6QDR	;	1.615	;	Crystal structure of 14-3-3sigma in complex with a PAK6 pT99 phosphopeptide
6QDS	;	1.72	;	Crystal structure of 14-3-3sigma in complex with a PAK6 pT99 phosphopeptide stabilized by semi-synthetic fusicoccane FC-NCPC
6QDT	;	1.702	;	Crystal structure of 14-3-3sigma in complex with a RapGef2 pT740 phosphopeptide
6QDU	;	1.632	;	Crystal structure of 14-3-3sigma in complex with a RapGef2 pT740 phosphopeptide inhibited by semi-synthetic fusicoccane FC-NCPC
4N84	;	2.5	;	Crystal structure of 14-3-3zeta in complex with a 12-carbon-linker cyclic peptide derived from ExoS
4N7Y	;	2.16	;	Crystal structure of 14-3-3zeta in complex with a 8-carbon-linker cyclic peptide derived from ExoS
5JM4	;	2.34	;	Crystal structure of 14-3-3zeta in complex with a cyclic peptide involving an adamantyl and a dicarboxy side chain
6RLZ	;	3.7	;	Crystal Structure of 14-3-3zeta in complex with a macrocyclic 8-mer peptide derived from ExoS
4N7G	;	2.25	;	Crystal structure of 14-3-3zeta in complex with a peptide derived from ExoS
5J31	;	2.4	;	Crystal structure of 14-3-3zeta in complex with an alkyne cross-linked cyclic peptide derived from ExoS
4ZDR	;	2.899	;	Crystal structure of 14-3-3[zeta]-LKB1 fusion protein
5JZI	;	2.5	;	Crystal structure of 1406 TCR bound to HLA-A2 with HCV 1406-1415 antigen peptide
6D11	;	3.4	;	Crystal structure of 1450 Fab in complex with circumsporozoite protein NANP5
2GDZ	;	1.65	;	Crystal structure of 15-hydroxyprostaglandin dehydrogenase type1, complexed with NAD+
1Z7F	;	2.1	;	Crystal structure of 16 base pair RNA duplex containing a C-A mismatch
5WCU	;	5.53	;	Crystal structure of 167 bp nucleosome bound to the globular domain of linker histone H5
4J3C	;	2.0	;	Crystal structure of 16S ribosomal RNA methyltransferase RsmE
2DYI	;	2.0	;	Crystal structure of 16S ribosomal RNA processing protein RimM from Thermus thermophilus HB8
3MTE	;	1.805	;	Crystal Structure of 16S rRNA Methyltranferase
3MQ2	;	1.69	;	Crystal Structure of 16S rRNA Methyltranferase KamB
6PI9	;	1.85	;	Crystal structure of 16S rRNA methyltransferase RmtF in complex with S-Adenosyl-L-homocysteine
2PJD	;	2.1	;	Crystal structure of 16S rRNA methyltransferase RsmC
4E8B	;	2.249	;	Crystal structure of 16S rRNA Methyltransferase RsmE from E.coli
2HE5	;	2.9	;	Crystal structure of 17alpha-hydroxysteroid dehydrogenase in binary complex with NADP(H) in an open conformation
2HEJ	;	1.35	;	Crystal structure of 17alpha-hydroxysteroid dehydrogenase in complex with NADP(H) in a closed conformation
2IPF	;	1.85	;	Crystal structure of 17alpha-hydroxysteroid dehydrogenase in complex with NADP+ and epi-testosterone
2HE8	;	1.9	;	Crystal structure of 17alpha-hydroxysteroid dehydrogenase in its apo-form
2IPG	;	1.9	;	Crystal structure of 17alpha-hydroxysteroid dehydrogenase mutant K31A in complex with NADP+ and epi-testosterone
3DEY	;	1.7	;	Crystal structure of 17beta-HSD1 with DHT in normal and reverse orientation.
3IS3	;	1.48	;	Crystal structure of 17beta-Hydroxysteroid dehydrogenase (Apo form) from fungus Cochliobolus lunatus
5JSF	;	1.842	;	Crystal structure of 17beta-hydroxysteroid dehydrogenase 14 S205 variant in complex with NAD.
5JS6	;	2.002	;	Crystal structure of 17beta-hydroxysteroid dehydrogenase 14 T205 variant in complex with NAD.
1JTV	;	1.54	;	Crystal structure of 17beta-Hydroxysteroid Dehydrogenase Type 1 complexed with Testosterone
5ICS	;	1.52	;	Crystal structure of 17beta-hydroxysteroid dehydrogenase type 14 apoenzyme.
6U28	;	2.95	;	Crystal structure of 1918 NS1-ED W187A in complex with the p85-beta-iSH2 domain of human PI3K
4JUG	;	2.7	;	Crystal structure of 1918 pandemic influenza virus hemagglutinin mutant D225G
4JUH	;	2.805	;	Crystal structure of 1918 pandemic influenza virus hemagglutinin mutant D225G complexed with avian receptor analogue LSTa
4JUJ	;	3.013	;	Crystal structure of 1918 pandemic influenza virus hemagglutinin mutant D225G complexed with human receptor analogue LSTc
3TIA	;	1.8	;	Crystal structure of 1957 pandemic H2N2 neuraminidase complexed with laninamivir
3TIB	;	2.201	;	Crystal structure of 1957 pandemic H2N2 neuraminidase complexed with laninamivir octanoate
3TIC	;	1.89	;	Crystal structure of 1957 pandemic H2N2 neuraminidase complexed with zanamivir
3W6I	;	2.693	;	Crystal structure of 19F probe-labeled hCAI
3W6H	;	2.964	;	Crystal structure of 19F probe-labeled hCAI in complex with acetazolamide
4E5C	;	1.7	;	Crystal Structure of 19mer double-helical RNA containing CUG/CGG-repeats
1C0G	;	2.0	;	CRYSTAL STRUCTURE OF 1:1 COMPLEX BETWEEN GELSOLIN SEGMENT 1 AND A DICTYOSTELIUM/TETRAHYMENA CHIMERA ACTIN (MUTANT 228: Q228K/T229A/A230Y/E360H)
2O5X	;	2.05	;	Crystal structure of 1E9 LeuH47Trp/ArgH100Trp, an engineered Diels-Alderase Fab with nM steroid-binding affinity
3O2V	;	2.3	;	Crystal structure of 1E9 PheL89Ser/LeuH47Trp/MetH100bPhe, an engineered Diels-Alderase Fab with modified specificity and catalytic activity
7W7Q	;	1.96	;	Crystal structure of 1F11S antibody(ScFv)
3MKP	;	2.81	;	Crystal structure of 1K1 mutant of Hepatocyte Growth Factor/Scatter Factor fragment NK1 in complex with heparin
4LGH	;	2.84	;	Crystal structure of 1NM-PP1 bound to analog-sensitive Src kinase
4KNQ	;	1.82	;	Crystal structure of 1nt-5'-overhanging double-helical CCG-repetitive RNA 20mer complexed with RSS p19
1VGJ	;	1.94	;	Crystal structure of 2'-5' RNA ligase from Pyrococcus horikoshii
3H5X	;	1.77	;	Crystal Structure of 2'-amino-2'-deoxy-cytidine-5'-triphosphate bound to Norovirus GII RNA polymerase
2R9Q	;	2.2	;	Crystal structure of 2'-deoxycytidine 5'-triphosphate deaminase from Agrobacterium tumefaciens
5DO5	;	1.2	;	Crystal Structure of 2'-Fluoro-RNA bearing a phosphorodithioate
1I7J	;	1.19	;	CRYSTAL STRUCTURE OF 2'-O-ME(CGCGCG)2: AN RNA DUPLEX AT 1.19 A RESOLUTION. 2-METHYL-2,4-PENTANEDIOL AND MAGNESIUM BINDING.
310D	;	1.3	;	Crystal structure of 2'-O-Me(CGCGCG)2: an RNA duplex at 1.3 A resolution. Hydration pattern of 2'-O-methylated RNA
5E36	;	1.6	;	Crystal structure of 2'-propargyl-modified DNA 8mer-duplex
5DW8	;	2.4	;	Crystal structure of 2'AMP bound SaIMPase-II
6M53	;	1.55	;	Crystal structure of 2, 3-dihydroxybenzoic acid decarboxylase from Fusarium oxysporum
7BPC	;	2.45	;	Crystal structure of 2, 3-dihydroxybenzoic acid decarboxylase from Fusarium oxysporum in complex with 2,5-DHBA
7BP1	;	1.97	;	Crystal structure of 2, 3-dihydroxybenzoic acid decarboxylase from Fusarium oxysporum in complex with Catechol
3VB0	;	2.1	;	Crystal structure of 2,2',3-trihydroxybiphenyl 1,2-dioxygenase from dibenzofuran-degrading Sphingomonas wittichii strain RW1
4XMB	;	2.428	;	Crystal structure of 2,2'-(naphthalene-1,4-diylbis(((4-methoxyphenyl)sulfonyl)azanediyl))diacetamide bound to human Keap1 Kelch domain
6CKT	;	1.8	;	Crystal structure of 2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-succinyltransferase from Legionella pneumophila Philadelphia 1
6WQM	;	2.15	;	Crystal structure of 2,3,4,5-tetrahydropyridine-2-carboxylate N-succinyltransferase from Bartonella henselae
3EG4	;	1.87	;	Crystal structure of 2,3,4,5-Tetrahydropyridine-2-carboxylate N-Succinyltransferase from Brucella melitensis biovar abortus 2308
3CJ8	;	1.95	;	Crystal structure of 2,3,4,5-tetrahydropyridine-2-carboxylate N-succinyltransferase from Enterococcus faecalis V583
5UM0	;	1.85	;	Crystal structure of 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase from Neisseria gonorrhoeae
5VPU	;	1.5	;	Crystal Structure of 2,3-bisphosphoglycerate-independent phosphoglycerate mutase bound to 3-phosphoglycerate, from Acinetobacter baumannii
8SBV	;	1.55	;	Crystal Structure of 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase from Klebsiella aerogenes (ADP bound)
8SBX	;	2.1	;	Crystal Structure of 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase from Klebsiella aerogenes (Apo, hexagonal form)
8SBW	;	1.75	;	Crystal Structure of 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase from Klebsiella aerogenes (Apo, orthorhombic form)
8U9A	;	1.5	;	Crystal Structure of 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase from Klebsiella aerogenes (DBH bound)
8SBY	;	2.3	;	Crystal Structure of 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase from Klebsiella aerogenes (NAD and sulfate bound, hexagonal form)
8SBZ	;	1.9	;	Crystal Structure of 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase from Klebsiella aerogenes (NAD bound, No sulfate hexagonal form)
8SC0	;	1.81	;	Crystal Structure of 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase from Klebsiella aerogenes (NAD bound, orthorhombic form)
3LM4	;	1.8	;	Crystal Structure of 2,3-Dihydroxy Biphenyl dioxygenase from Rhodococcus sp. (strain RHA1)
7WKM	;	1.8	;	Crystal Structure of 2,3-Dihydroxybenzoate Decarboxylase Complexed with Catechol
7WMB	;	2.2	;	Crystal structure of 2,3-dihydroxybenzoate decarboxylase mutant W23Y from Aspergillus oryzae in complex with catechol
1KW3	;	1.45	;	Crystal structure of 2,3-dihydroxybiphenyal dioxygenase (BphC) at 1.45 A resolution
1LKD	;	1.7	;	CRYSTAL STRUCTURE OF 2,3-DIHYDROXYBIPHENYL 1,2-DIOXYGENASE (DHBD) COMPLEXED WITH 2',6'-DICL DIHYDROXYBIPHENYL (DHB)
1LGT	;	1.7	;	CRYSTAL STRUCTURE OF 2,3-DIHYDROXYBIPHENYL 1,2-DIOXYGENASE (DHBD) COMPLEXED WITH 2'-Cl DIHYDROXYBIPHENYL (DHB)
1KMY	;	2.0	;	Crystal Structure of 2,3-dihydroxybiphenyl 1,2-dioxygenase Complexed with 2,3-dihydroxybiphenyl under Anaerobic Condition
1KNF	;	1.9	;	Crystal Structure of 2,3-dihydroxybiphenyl 1,2-dioxygenase Complexed with 3-methyl Catechol under Anaerobic Condition
1KND	;	1.9	;	Crystal Structure of 2,3-dihydroxybiphenyl 1,2-dioxygenase Complexed with Catechol under Anaerobic Condition
1KW6	;	1.45	;	Crystal structure of 2,3-dihydroxybiphenyl dioxygenase (BphC) in complex with 2,3-dihydroxybiphenyl at 1.45 A resolution
1KW9	;	1.95	;	Crystal structure of 2,3-dihydroxybiphenyl dioxygenase (BphC) in complex with 2,3-dihydroxybiphenyl at 2.0A resolution
2ZVI	;	2.3	;	Crystal structure of 2,3-diketo-5-methylthiopentyl-1-phosphate enolase from Bacillus subtilis
8DOP	;	2.0	;	Crystal structure of 2,3-diketo-5-methylthiopentyl-1-phosphate enolase-phosphatase from Klebsiella aerogenes (P1 Form)
8DOQ	;	1.65	;	Crystal structure of 2,3-diketo-5-methylthiopentyl-1-phosphate enolase-phosphatase from Klebsiella aerogenes (P21 Form)
3FA4	;	2.18	;	Crystal structure of 2,3-dimethylmalate lyase, a PEP mutase/isocitrate lyase superfamily member, triclinic crystal form
3FA3	;	2.6	;	Crystal structure of 2,3-dimethylmalate lyase, a PEP mutase/isocitrate lyase superfamily member, trigonal crystal form
1VP5	;	2.4	;	Crystal structure of 2,5-diketo-D-gluconic acid reductase (TM1009) from Thermotoga maritima at 2.40 A resolution
2DVU	;	1.9	;	Crystal Structure of 2,6-Dihydroxybenzoate Decarboxylase Complexed with 2,6-Dihydroxybenzoate
2DVX	;	1.7	;	Crystal Structure of 2,6-Dihydroxybenzoate Decarboxylase Complexed with inhibitor 2,3-dihydroxybenzaldehyde
2DVT	;	1.7	;	Crystal Structure of 2,6-Dihydroxybenzoate Decarboxylase from Rhizobium
4L3P	;	2.68	;	Crystal Structure of 2-(1-benzothiophen-7-yl)-4-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]furo[2,3-c]pyridin-7-amine bound to TAK1-TAB1
4TPM	;	2.77	;	Crystal structure of 2-(3-alkoxy-1-azetidinyl) quinolines as PDE10A Inhibitors
1ZG7	;	1.75	;	Crystal Structure of 2-(5-{[amino(imino)methyl]amino}-2-chlorophenyl)-3-sulfanylpropanoic acid Bound to Activated Porcine Pancreatic Carboxypeptidase B
3R74	;	2.9	;	Crystal structure of 2-amino-2-desoxyisochorismate synthase (ADIC) synthase PhzE from Burkholderia lata 383
3R76	;	2.6	;	Crystal structure of 2-amino-2-desoxyisochorismate synthase (ADIC) synthase PhzE from Burkholderia lata 383 in complex with benzoate, pyruvate and glutamine
3R75	;	2.1	;	Crystal structure of 2-amino-2-desoxyisochorismate synthase (ADIC) synthase PhzE from Burkholderia lata 383 in complex with benzoate, pyruvate, glutamine and contaminating Zn2+
1M32	;	2.2	;	Crystal Structure of 2-aminoethylphosphonate Transaminase
5KLN	;	1.992	;	Crystal structure of 2-aminomuconate 6-semialdehyde dehydrogenase N169A in complex with NAD+
5KJ5	;	2.113	;	Crystal structure of 2-aminomuconate 6-semialdehyde dehydrogenase N169D in complex with NAD+
5KLK	;	2.006	;	Crystal structure of 2-aminomuconate 6-semialdehyde dehydrogenase N169D in complex with NAD+ and 2-hydroxymuconate-6-semialdehyde
7BZV	;	1.988	;	Crystal structure of 2-aminomuconic 6-semialdehyde dehydrogenase from Pseudomonas species AP-3
1T0D	;	2.2	;	Crystal Structure of 2-aminopurine labelled bacterial decoding site RNA
1T0E	;	1.7	;	Crystal Structure of 2-aminopurine labelled bacterial decoding site RNA
1KNK	;	2.8	;	Crystal Structure of 2-C-methyl-D-erythritol 2,4-cyclodiphosphate Synthase (ispF) from E. coli involved in Mevalonate-Independent Isoprenoid Biosynthesis
5IWX	;	1.99	;	Crystal structure of 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Bacillus subtitis
5IWY	;	1.99	;	Crystal structure of 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Bacillus subtitis complexed with CMP and Mg2+
3QHD	;	1.7	;	Crystal structure of 2-C-METHYL-D-ERYTHRITOL 2,4-CYCLODIPHOSPHATE Synthase from BURKHOLDERIA PSEUDOMALLEI bound to CYTIDINE, FOL795 and FOL955
5L03	;	1.469	;	Crystal structure of 2-C-METHYL-D-ERYTHRITOL 2,4-CYCLODIPHOSPHATE Synthase from BURKHOLDERIA PSEUDOMALLEI bound to L-tryptophan hydroxamate
3P10	;	1.7	;	Crystal structure of 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Burkholderia pseudomallei with cytidine and FOL694, 2-(thiophen-2-yl)phenyl methanol
3P0Z	;	1.95	;	Crystal structure of 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Burkholderia pseudomallei with cytidine and FOL955, 4-(1H-imidazol)-1-yl)phenol
3RE3	;	2.645	;	Crystal Structure of 2-C-Methyl-D-Erythritol 2,4-Cyclodiphosphate Synthase from Francisella tularensis
3T80	;	2.5	;	Crystal structure of 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Salmonella typhimurium bound to cytidine
3FPI	;	2.8	;	Crystal Structure of 2-C-Methyl-D-Erythritol 2,4-Cyclodiphosphate Synthase IspF complexed with Cytidine Triphosphate
3F6M	;	2.96	;	Crystal Structure of 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase IspF from Yersinia pestis
4YS8	;	2.45	;	Crystal Structure of 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase (IspD) from Burkholderia thailandensis
4ZDQ	;	2.3	;	Crystal Structure of 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase (IspD) from Burkholderia thailandensis complexed with CTP
3N9W	;	1.9	;	Crystal structure of 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase (IspD) in complex with 1,2-Propanediol
1VPA	;	2.67	;	Crystal structure of 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase (TM1393) from Thermotoga maritima at 2.67 A resolution
3F1C	;	2.3	;	CRYSTAL STRUCTURE OF 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase from Listeria monocytogenes
2PX7	;	2.2	;	Crystal structure of 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase from Thermus thermophilus HB8
4M0X	;	2.7	;	Crystal structure of 2-chloromuconate cycloisomerase from Rhodococcus opacus 1CP
1M5A	;	1.2	;	Crystal Structure of 2-Co(2+)-Insulin at 1.2A Resolution
2AFB	;	2.05	;	Crystal structure of 2-dehydro-3- deoxygluconokinase (EC 2.7.1.45) (tm0067) from THERMOTOGA MARITIMA at 2.05 A resolution
3NZR	;	1.9	;	Crystal structure of 2-dehydro-3-deoxyphosphogluconate aldolase from Vibrio fischeri ES114
1VLW	;	2.3	;	Crystal structure of 2-dehydro-3-deoxyphosphogluconate aldolase/4-hydroxy-2-oxoglutarate aldolase (TM0066) from Thermotoga maritima at 2.30 A resolution
3FS2	;	1.85	;	Crystal structure of 2-Dehydro-3-Deoxyphosphooctonate aldolase from Bruciella melitensis at 1.85A resolution
3T4C	;	1.95	;	Crystal structure of 2-dehydro-3-deoxyphosphooctonate aldolase from Burkholderia ambifaria
3TML	;	1.9	;	Crystal structure of 2-dehydro-3-deoxyphosphooctonate aldolase from Burkholderia cenocepacia
3SZ8	;	2.05	;	Crystal structure of 2-dehydro-3-deoxyphosphooctonate aldolase from Burkholderia pseudomallei
3E9A	;	1.8	;	Crystal structure of 2-dehydro-3-deoxyphosphooctonate aldolase from Vibrio cholerae O1 biovar eltor str. N16961
3HN2	;	2.5	;	Crystal structure of 2-dehydropantoate 2-reductase FROM Geobacter metallireducens GS-15
3I83	;	1.9	;	Crystal structure of 2-dehydropantoate 2-reductase from Methylococcus capsulatus
2QYT	;	2.15	;	Crystal structure of 2-dehydropantoate 2-reductase from Porphyromonas gingivalis W83
2D2X	;	2.3	;	Crystal structure of 2-deoxy-scyllo-inosose synthase
2GRU	;	2.15	;	Crystal structure of 2-deoxy-scyllo-inosose synthase complexed with carbaglucose-6-phosphate, NAD+ and Co2+
5DBU	;	2.797	;	Crystal structure of 2-deoxyribose-5-phosphate aldolase (1-220) from Streptococcus suis
2VCY	;	2.41	;	Crystal Structure of 2-Enoyl Thioester Reductase of Human FAS II
1PN4	;	2.35	;	Crystal structure of 2-enoyl-CoA hydratase 2 domain of Candida tropicalis multifunctional enzyme type 2 complexed with (3R)-hydroxydecanoyl-CoA.
3Q8F	;	2.1	;	Crystal structure of 2-Fluorohistine labeled Protective Antigen (pH 5.8)
3VAY	;	1.979	;	Crystal structure of 2-Haloacid Dehalogenase from Pseudomonas syringae pv. Tomato DC3000
1WLY	;	1.3	;	Crystal Structure of 2-Haloacrylate Reductase
6XN8	;	1.95	;	Crystal Structure of 2-hydroxyacyl CoA lyase (HACL) from Rhodospirillales bacterium URHD0017
4Z2R	;	2.3	;	Crystal structure of 2-hydroxybiphenyl 3-monooxygenase from Pseudomonas azelaica
5BRT	;	2.3	;	Crystal Structure of 2-hydroxybiphenyl 3-monooxygenase from Pseudomonas azelaica with 2-hydroxybiphenyl in the active site
6EM0	;	2.78	;	Crystal Structure of 2-hydroxybiphenyl 3-monooxygenase M321A from Pseudomonas azelaica
4Z2U	;	2.5	;	Crystal Structure of 2-hydroxybiphenyl 3-monooxygenase R242Q from Pseudomonas azelaica
4Z2T	;	2.45	;	Crystal Structure of 2-hydroxybiphenyl 3-monooxygenase W225Y from Pseudomonas azelaica
5THJ	;	1.5	;	Crystal Structure of 2-hydroxycyclohepta-2,4,6-trien-1-one bound to human carbonic anhydrase 2
5THI	;	1.5	;	Crystal Structure of 2-hydroxycyclohepta-2,4,6-trien-1-one bound to human carbonic anhydrase 2 L198G
5THN	;	1.33	;	Crystal Structure of 2-Hydroxycyclohepta-2,4,6-triene-1-thione bound to human carbonic anhydrase 2
5TI0	;	1.42	;	Crystal Structure of 2-Hydroxycyclohepta-2,4,6-triene-1-thione bound to human carbonic anhydrase 2 L198G
3QDF	;	2.05	;	Crystal structure of 2-hydroxyhepta-2,4-diene-1,7-dioate isomerase from Mycobacterium marinum
6HE0	;	2.31	;	Crystal structure of 2-Hydroxyisobutyryl-CoA Ligase (HCL) in complex with 2-HIB-AMP and CoA in the thioesterfication state
6HDW	;	2.3	;	Crystal structure of 2-Hydroxyisobutyryl-CoA Ligase (HCL) in the postadenylation state in complex with 2-HIB-AMP
6HDX	;	2.2	;	Crystal structure of 2-Hydroxyisobutyryl-CoA Ligase (HCL) in the postadenylation state in complex with R3-HIB-AMP
6HDY	;	2.2	;	Crystal structure of 2-Hydroxyisobutyryl-CoA Ligase (HCL) in the postadenylation state in complex with S3-HB-AMP
4R3U	;	2.5	;	Crystal structure of 2-Hydroxyisobutyryl-CoA Mutase
4Q8Y	;	1.45	;	Crystal structure of 2-hydroxyisoquinoline-1(2H)-thione bound to human carbonic anhydrase II
5KLM	;	2.102	;	Crystal structure of 2-hydroxymuconate-6-semialdehyde derived intermediate in NAD(+)-bound 2-aminomuconate 6-semialdehyde dehydrogenase N169D
5KLL	;	2.17	;	Crystal structure of 2-hydroxymuconate-6-semialdehyde derived tautomeric intermediate in 2-aminomuconate 6-semialdehyde dehydrogenase N169D
1SV6	;	2.9	;	Crystal structure of 2-hydroxypentadienoic acid hydratase from Escherichia Coli
4BK9	;	2.77	;	Crystal structure of 2-keto-3-deoxy-6-phospho-gluconate aldolase from Zymomonas mobilis ATCC 29191
1MXS	;	2.2	;	Crystal structure of 2-keto-3-deoxy-6-phosphogluconate (KDPG) aldolase from Pseudomonas putida.
4Z9Y	;	1.63	;	Crystal structure of 2-keto-3-deoxy-D-gluconate dehydrogenase from Pectobacterium carotovorum
4U8G	;	2.9	;	Crystal structure of 2-keto-3-deoxy-D-gluconate dehydrogenase from Streptococcus agalactiae
4Z9X	;	1.7	;	Crystal structure of 2-keto-3-deoxy-D-gluconate dehydrogenase from Streptococcus pyogenes
4LU0	;	2.8	;	Crystal structure of 2-Keto-3-deoxy-D-manno-octulosonate-8-phosphate synthase from Pseudomonas aeruginosa.
1WYE	;	2.8	;	Crystal structure of 2-keto-3-deoxygluconate kinase (form 1) from Sulfolobus Tokodaii
2DCN	;	2.25	;	Crystal structure of 2-keto-3-deoxygluconate kinase from Sulfolobus tokodaii complexed with 2-keto-6-phosphogluconate (alpha-furanose form)
4HGN	;	1.8	;	Crystal Structure of 2-keto-3-deoxyoctulosonate 8-phosphate PHOSPHOHYDROLASE from Bacteroides thetaiotaomicron
4HGP	;	1.8	;	Crystal Structure of 2-keto-3-deoxyoctulosonate 8-phosphate phosphohydrolase from Haemophilus influenzae in complex with transition state mimic
4Q99	;	1.5	;	Crystal structure of 2-mercapto-4-methylphenol bound to human carbonic anhydrase II
3GMB	;	2.1	;	Crystal Structure of 2-Methyl-3-hydroxypyridine-5-carboxylic acid Oxygenase
4GF7	;	1.581	;	Crystal structure of 2-Methyl-3-hydroxypyridine-5-carboxylic acid oxygenase (MHPCO), unliganded form
3GMC	;	2.1	;	Crystal Structure of 2-Methyl-3-hydroxypyridine-5-carboxylic acid Oxygenase with substrate bound
4JY3	;	1.77	;	Crystal structure of 2-methyl-3-hydroxypyridine-5-carboxylic acid oxygenase, 5-pyridoxic acid bound form
3ALM	;	1.77	;	Crystal structure of 2-methyl-3-hydroxypyridine-5-carboxylic acid oxygenase, mutant C294A
3ALL	;	1.78	;	Crystal structure of 2-methyl-3-hydroxypyridine-5-carboxylic acid oxygenase, mutant Y270A
4JY2	;	1.935	;	Crystal structure of 2-methyl-3-hydroxypyridine-5-carboxylic acid oxygenase, native and unliganded form
3ALJ	;	1.48	;	Crystal structure of 2-methyl-3-hydroxypyridine-5-carboxylic acid oxygenase, reduced form
1SZQ	;	2.7	;	Crystal Structure of 2-methylcitrate dehydratase
5MUX	;	2.0	;	Crystal structure of 2-methylcitrate dehydratase (MmgE) from Bacillus subtilis.
6S62	;	2.36	;	Crystal structure of 2-methylcitrate dehydratase (PrpD) from Pseudomonas aeruginosa in apo form.
5MVI	;	3.05	;	Crystal structure of 2-methylcitrate dehydratase (PrpD) from Salmonella enterica
6S6F	;	1.53	;	Crystal structure of 2-methylcitrate synthase (PrpC) from Pseudomonas aeruginosa in apo form.
6S87	;	1.65	;	Crystal structure of 2-methylcitrate synthase (PrpC) from Pseudomonas aeruginosa in complex with oxaloacetate.
3O8J	;	2.41	;	Crystal structure of 2-methylcitrate synthase (PrpC) from Salmonella typhimurium
5UQO	;	2.5	;	Crystal structure of 2-methylcitrate synthase from Aspergillus fumigatus
5UQQ	;	2.3	;	Crystal structure of 2-methylcitrate synthase from Aspergillus fumigatus
5UQR	;	1.75	;	Crystal structure of 2-methylcitrate synthase from Aspergillus fumigatus
6BOP	;	2.71	;	Crystal structure of 2-methylcitrate synthase from Aspergillus fumigatus
6BON	;	2.35	;	Crystal structure of 2-methylcitrate synthase from Aspergillus fumigatus with oxaloacetate and coenzyme-A.
6BOO	;	2.6	;	Crystal structure of 2-methylcitrate synthase from Aspergillus fumigatus with oxaloacetate and coenzyme-A.
4LA5	;	1.849	;	Crystal structure of 2-methylisoborneol synthase from Streptomyces coelicolor A3(2)
3V1X	;	1.955	;	Crystal structure of 2-methylisoborneol synthase from Streptomyces coelicolor A3(2) in complex with Mg2+ and 2-fluorogeranyl diphosphate
4LA6	;	2.001	;	Crystal structure of 2-methylisoborneol synthase from Streptomyces coelicolor A3(2) in complex with Mg2+ and 2-fluoroneryl diphosphate
3V1V	;	1.8	;	Crystal structure of 2-methylisoborneol synthase from Streptomyces coelicolor A3(2) in complex with Mg2+ and geranyl-S-thiolodiphosphate
6T4V	;	1.807	;	Crystal structure of 2-methylisocitrate lyase (PrpB) from Pseudomonas aeruginosa in apo form.
6T5M	;	1.76	;	Crystal structure of 2-methylisocitrate lyase (PrpB) from Pseudomonas aeruginosa in complex with Mg(II)-pyruvate.
1UJQ	;	2.1	;	Crystal structure of 2-methylisocitrate lyase (PrpB) from Salmonella enterica serovar typhimurium
2GJL	;	2.0	;	Crystal Structure of 2-nitropropane dioxygenase
2GJN	;	2.3	;	crystal structure of 2-nitropropane dioxygenase complexed with FMN and substrate
4KTP	;	1.9	;	Crystal structure of 2-O-alpha-glucosylglycerol phosphorylase in complex with glucose
4KTR	;	2.3	;	Crystal structure of 2-O-alpha-glucosylglycerol phosphorylase in complex with isofagomine and glycerol
7MWA	;	2.6	;	Crystal structure of 2-octaprenyl-6-methoxyphenol hydroxylase UbiH from Acinetobacter baumannii, apoenzyme
3R1X	;	2.093	;	Crystal structure of 2-oxo-3-deoxygalactonate kinase from Klebsiella pneumoniae
3O7H	;	1.79	;	Crystal structure of 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase from Klebsiella pneumoniae
3O7I	;	1.5	;	Crystal structure of 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase from Klebsiella pneumoniae
3O7J	;	2.0	;	Crystal structure of 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase from Klebsiella pneumoniae
3O7K	;	1.98	;	Crystal structure of 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase from Klebsiella pneumoniae
6N2N	;	1.937	;	Crystal structure of 2-oxoglutarate:ferredoxin oxidoreductase from Magnetococcus marinus
3C3E	;	3.0	;	Crystal structure of 2-phospho-(S)-lactate transferase from Methanosarcina mazei in complex with Fo and GDP. Northeast Structural Genomics Consortium target MaR46
3C3D	;	2.5	;	Crystal structure of 2-phospho-(S)-lactate transferase from Methanosarcina mazei in complex with Fo and phosphate. Northeast Structural Genomics Consortium target MaR46
3CGW	;	3.1	;	Crystal structure of 2-phospho-(S)-lactate transferase from Methanosarcina mazei. Northeast Structural Genomics Consortium target MaR46
3HGD	;	1.57	;	Crystal Structure of 2-Se-Thymidine Derivatized DNA
4F4N	;	1.3	;	Crystal structure of 2-se-thymidine derivatized dna 8mer
4JAH	;	1.5	;	Crystal structure of 2-Selenouridine containing RNA
3LQ1	;	2.6	;	Crystal structure of 2-succinyl-6-hydroxy-2,4-cyclohexadiene 1-carboxylic acid synthase/2-oxoglutarate decarboxylase FROM Listeria monocytogenes str. 4b F2365
5DQL	;	1.782	;	Crystal Structure of 2-vinyl glyoxylate modified isocitrate lyase from Mycobacterium tuberculosis
3TI3	;	1.8	;	Crystal structure of 2009 pandemic H1N1 neuraminidase complexed with laninamivir
3TI4	;	1.602	;	Crystal structure of 2009 pandemic H1N1 neuraminidase complexed with laninamivir octanoate
3TI6	;	1.69	;	Crystal structure of 2009 pandemic H1N1 neuraminidase complexed with oseltamivir
3TI5	;	1.9	;	Crystal structure of 2009 pandemic H1N1 neuraminidase complexed with Zanamivir
4JTV	;	2.997	;	Crystal structure of 2009 pandemic influenza virus hemagglutinin complexed with human receptor analogue LSTc
4JTX	;	2.997	;	Crystal structure of 2009 pandemic influenza virus hemagglutinin mutant D225E
4JU0	;	2.908	;	Crystal structure of 2009 pandemic influenza virus hemagglutinin mutant D225E complexed with human receptor analogue LSTc
4X7D	;	2.15	;	Crystal structure of 2012 NSW GII.4 P domain in complex with Nano-85
7BQ7	;	2.37	;	Crystal structure of 2019-nCoV nsp16-nsp10 complex
6M5I	;	2.496	;	Crystal structure of 2019-nCoV nsp7-nsp8c complex
7CE0	;	1.5	;	Crystal structure of 2019-nCoV nucleocapsid C-terminal domain (CTD) protein
7CDZ	;	1.8	;	Crystal structure of 2019-nCoV nucleocapsid N-terminal domain (NTD) protein
2R40	;	2.402	;	Crystal structure of 20E bound EcR/USP
3HYE	;	2.5	;	Crystal structure of 20S proteasome in complex with hydroxylated salinosporamide
4EU2	;	2.509	;	Crystal structure of 20s proteasome with novel inhibitor K-7174
6O23	;	2.0	;	Crystal structure of 2243 Fab in complex with circumsporozoite protein NANP5
2Z6X	;	2.3	;	Crystal structure of 22G, the wild-type protein of the photoswitchable GFP-like protein Dronpa
3IF1	;	2.39	;	Crystal structure of 237mAb in complex with a GalNAc
3IET	;	2.2	;	Crystal Structure of 237mAb with antigen
6NVM	;	1.75	;	Crystal structure of 23S rRNA methyltransferase ErmE
4DUH	;	1.5	;	Crystal structure of 24 kDa domain of E. coli DNA gyrase B in complex with small molecule inhibitor
6CCB	;	6.5	;	Crystal structure of 253-11 SOSIP trimer in complex with 10-1074 Fab
6ULE	;	2.55	;	Crystal structure of 2541 Fab in complex with circumsporozoite protein NANP5
3AF7	;	1.58	;	Crystal Structure of 25Pd(allyl)/apo-Fr
4L5O	;	2.09	;	Crystal structure of 26 kDa GST D26H mutant of Clonorchis sinensis
4L5L	;	2.2	;	Crystal structure of 26 kDa GST of Clonorchis sinensis in P212121 symmetry
3ISO	;	1.9	;	Crystal structure of 26 kDa GST of Clonorchis sinensis in P3221 symmetry
4ADY	;	2.7	;	Crystal structure of 26S proteasome subunit Rpn2
4X2S	;	4.21	;	Crystal structure of 276S/M395R-GltPh in inward-facing conformation
3CU1	;	2.6	;	Crystal Structure of 2:2:2 FGFR2D2:FGF1:SOS complex
5X45	;	2.602	;	Crystal structure of 2A protease from Human rhinovirus C15
3W95	;	1.85	;	Crystal structure of 2A proteinase (C110A) from enterovirus 71
8V52	;	2.5	;	Crystal structure of 2A10 Fab bound to Human TGF-beta3
5GQ1	;	2.493	;	Crystal structure of 2C helicase from enterovirus 71 (EV71)
5GRB	;	2.803	;	Crystal structure of 2C helicase from enterovirus 71 (EV71) bound with ATPgammaS
3ERN	;	2.1	;	Crystal structure of 2C-methyl-D-erythritol 2,4-clycodiphosphate synthase complexed with AraCMP
3ELC	;	2.5	;	Crystal structure of 2C-methyl-D-erythritol 2,4-clycodiphosphate synthase complexed with ligand
3EOR	;	2.9	;	Crystal structure of 2C-methyl-D-erythritol 2,4-clycodiphosphate synthase complexed with ligand
3ESJ	;	2.7	;	Crystal structure of 2C-methyl-D-erythritol 2,4-clycodiphosphate synthase complexed with ligand
3FBA	;	3.1	;	Crystal structure of 2C-methyl-D-erythritol 2,4-clycodiphosphate synthase complexed with ligand
5L12	;	1.716	;	Crystal structure of 2C-methyl-D-erythritol 2,4-clycodiphosphate synthase from BURKHOLDERIA PSEUDOMALLEI double mutant
1VHA	;	2.35	;	Crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase
6MWI	;	1.75	;	Crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase (IspF) Burkholderia pseudomallei in complex with ligand HGN-0456
6MWF	;	1.75	;	Crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase (IspF) Burkholderia pseudomallei in complex with ligand HGN-0459
6MWJ	;	2.05	;	Crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase (IspF) Burkholderia pseudomallei in complex with ligand HGN-0863
6MWK	;	1.8	;	Crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase (IspF) Burkholderia pseudomallei in complex with ligand HGN-0883
6NMO	;	1.45	;	Crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase (IspF) Burkholderia pseudomallei in complex with ligand SR-4
6V3M	;	1.55	;	Crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase (IspF) Burkholderia pseudomallei in compomplex with ligand HGN-0961 (BSI110840)
3F0E	;	2.05	;	Crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Burkholderia pseudomallei
3K2X	;	1.85	;	Crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Burkholderia pseudomallei in complex with 5'-iodo-cytosine
3KE1	;	2.05	;	Crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Burkholderia pseudomallei in complex with a fragment-nucleoside fusion D000161829
3Q8H	;	1.75	;	Crystal structure of 2c-methyl-d-erythritol 2,4-cyclodiphosphate synthase from burkholderia pseudomallei in complex with cytidine derivative EBSI01028
3IEW	;	2.1	;	Crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Burkholderia pseudomallei with bound CTP and CDP
3IEQ	;	2.1	;	Crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Burkholderia pseudomallei with cytidine
3IKE	;	2.3	;	Crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Burkholderia pseudomallei with cytosine
3MBM	;	1.8	;	Crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Burkholderia pseudomallei with cytosine and FoL fragment 717, imidazo[2,1-b][1,3]thiazol-6-ylmethanol
3IKF	;	2.07	;	Crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Burkholderia pseudomallei with FOL fragment 717, imidazo[2,,1-b][1,3]thiazol-6-ylmethanol
3B6N	;	2.26	;	Crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase PV003920 from Plasmodium vivax
3JVH	;	1.69	;	Crystal structure of 2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase from Burkholderia pseudomallei with FOL fragment 8395
1T0A	;	1.6	;	Crystal Structure of 2C-Methyl-D-Erythritol-2,4-cyclodiphosphate Synthase from Shewanella Oneidensis
5NMV	;	1.65	;	Crystal structure of 2F22 Fab fragment against TFPI1
1RFK	;	1.25	;	Crystal Structure of 2Fe2S Ferredoxin from Thermophilic Cyanobacterium Mastigocladus Laminosus
4NHG	;	8.001	;	Crystal Structure of 2G12 IgG Dimer
5YWF	;	2.206	;	Crystal structure of 2H4 Fab
2JIL	;	1.5	;	Crystal structure of 2nd PDZ domain of glutamate receptor interacting protein-1 (GRIP1)
6GDY	;	2.04	;	Crystal structure of 2OG oxygenase JMJD6 (aa 1-343) in complex with Fe(II) and 2OG
5JYB	;	1.647	;	Crystal structure of 3 mutant of Ba3275 (S116A, E243A, H313A), the member of S66 family of serine peptidases
2IS5	;	1.85	;	Crystal structure of 3 residues truncated version of protein NMB1012 from Neisseria meningitides
4HXV	;	2.6	;	Crystal structure of 3'(2'),5'-bisphosphate nucleotidase1 from Entamoeba histolytica in complex with AMP and metal ions
1J7L	;	2.2	;	Crystal Structure of 3',5""-Aminoglycoside Phosphotransferase Type IIIa ADP Complex
1L8T	;	2.4	;	Crystal Structure Of 3',5""-Aminoglycoside Phosphotransferase Type IIIa ADP Kanamycin A Complex
2B0Q	;	2.7	;	Crystal Structure Of 3',5""-Aminoglycoside Phosphotransferase Type IIIa ADP Neomycin B Complex
3TM0	;	2.1	;	Crystal Structure of 3',5""-Aminoglycoside Phosphotransferase Type IIIa AMPPNP Butirosin A Complex
1J7U	;	2.4	;	Crystal Structure of 3',5""-Aminoglycoside Phosphotransferase Type IIIa AMPPNP Complex
1J7I	;	3.2	;	Crystal Structure of 3',5""-Aminoglycoside Phosphotransferase Type IIIa Apoenzyme
3Q2J	;	2.1501	;	Crystal Structure of 3',5""-Aminoglycoside Phosphotransferase Type IIIa Protein Kinase Inhibitor CKI-7 Complex
6TVV	;	2.8	;	Crystal structure of 3'-5' RecJ exonuclease from M. Jannaschii
8SH5	;	2.75	;	Crystal structure of 3'cap-independent translation enhancers (CITE) from Pea enation mosaic virus RNA 2 (PEMV2) with Fab BL3-6K170A
5WHU	;	2.2	;	Crystal structure of 3'SL bound ArtB
5WHT	;	1.932	;	Crystal structure of 3'SL bound PltB
1G57	;	1.4	;	CRYSTAL STRUCTURE OF 3,4-DIHYDROXY-2-BUTANONE 4-PHOSPHATE SYNTHASE
1K49	;	1.5	;	Crystal Structure of 3,4-dihydroxy-2-butanone 4-phosphate synthase (cation free form)
3LQU	;	2.522	;	Crystal structure of 3,4-Dihydroxy-2-butanone 4-phosphate synthase complexed with Ribulose-5 phosphate
3MIO	;	1.8	;	Crystal structure of 3,4-dihydroxy-2-butanone 4-phosphate synthase domain from Mycobacterium tuberculosis at pH 6.00
3MK5	;	2.06	;	Crystal structure of 3,4-dihydroxy-2-butanone 4-phosphate synthase domain from Mycobacterium tuberculosis with sulfate and zinc at pH 4.00
3H07	;	1.95	;	Crystal structure of 3,4-dihydroxy-2-butanone 4-phosphate synthase from Yersinia pestis CO92
1G58	;	1.55	;	CRYSTAL STRUCTURE OF 3,4-DIHYDROXY-2-BUTANONE 4-PHOSPHATE SYNTHASE GOLD DERIVATIVE
1K4O	;	1.1	;	Crystal Structure of 3,4-dihydroxy-2-butanone 4-phosphate synthase in complex with one Manganese, and a glycerol
3LS6	;	1.86	;	Crystal structure of 3,4-Dihydroxy-2-butanone 4-phosphate synthase in complex with sulfate and zinc
3LRJ	;	2.803	;	Crystal structure of 3,4-Dihydroxy-2-butanone 4-phosphate synthase in complex with sulfate ion.
1K4I	;	0.98	;	Crystal Structure of 3,4-dihydroxy-2-butanone 4-phosphate synthase in complex with two Magnesium ions
1K4L	;	1.6	;	Crystal Structure of 3,4-dihydroxy-2-butanone 4-phosphate synthase in complex with two Manganese ions
1K4P	;	1.0	;	Crystal Structure of 3,4-dihydroxy-2-butanone 4-phosphate synthase in complex with zinc ions
1TKS	;	1.6	;	Crystal structure of 3,4-Dihydroxy-2-butanone 4-phosphate Synthase of Candida albicans
1TKU	;	1.66	;	Crystal Structure of 3,4-Dihydroxy-2-butanone 4-phosphate Synthase of Candida albicans in complex with Ribulose-5-phosphate
2RIS	;	1.6	;	Crystal structure of 3,4-dihydroxy-2-butanone 4-phosphate synthase of candida albicans- alternate interpretation
8IQ8	;	1.8	;	Crystal structure of 3,4-dihydroxyphenylacetate 2,3-dioxygenase (DHPAO) from Acinetobacter baumannii
1B9H	;	2.0	;	CRYSTAL STRUCTURE OF 3-AMINO-5-HYDROXYBENZOIC ACID (AHBA) SYNTHASE
1B9I	;	2.0	;	CRYSTAL STRUCTURE OF 3-AMINO-5-HYDROXYBENZOIC ACID (AHBA) SYNTHASE
1F8M	;	1.8	;	CRYSTAL STRUCTURE OF 3-BROMOPYRUVATE MODIFIED ISOCITRATE LYASE (ICL) FROM MYCOBACTERIUM TUBERCULOSIS
1RE5	;	2.6	;	Crystal structure of 3-carboxy-cis,cis-muconate lactonizing enzyme from Pseudomonas putida
1MQ5	;	2.1	;	Crystal Structure of 3-chloro-N-[4-chloro-2-[[(4-chlorophenyl)amino]carbonyl]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]-2-thiophenecarboxamide Complexed with Human Factor Xa
1MQ6	;	2.1	;	Crystal Structure of 3-chloro-N-[4-chloro-2-[[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[[(4,5-dihydro-2-oxazolyl)methylamino]methyl]-2-thiophenecarboxamide Complexed with Human Factor Xa
2BOY	;	1.9	;	Crystal structure of 3-ChloroCatechol 1,2-Dioxygenase from Rhodococcus Opacus 1CP
1L9W	;	2.1	;	CRYSTAL STRUCTURE OF 3-DEHYDROQUINASE FROM SALMONELLA TYPHI COMPLEXED WITH REACTION PRODUCT
4RHC	;	2.68	;	Crystal structure of 3-Dehydroquinate dehydratase from Acinetobacter baumannii at 2.68 A resolution
2YR1	;	2.0	;	Crystal Structure of 3-dehydroquinate dehydratase from Geobacillus kaustophilus HTA426
3N76	;	1.9	;	Crystal structure of 3-dehydroquinate dehydratase from Mycobacterium tuberculosis in complex with compound 5
3N7A	;	2.0	;	Crystal structure of 3-dehydroquinate dehydratase from Mycobacterium tuberculosis in complex with inhibitor 2
3N87	;	2.4	;	Crystal structure of 3-dehydroquinate dehydratase from Mycobacterium tuberculosis in complex with inhibitor 3
3N86	;	1.9	;	Crystal structure of 3-dehydroquinate dehydratase from Mycobacterium tuberculosis in complex with inhibitor 4
3N8N	;	2.5	;	Crystal structure of 3-dehydroquinate dehydratase from Mycobacterium tuberculosis in complex with inhibitor 6
8DQC	;	2.7	;	Crystal structure of 3-dehydroquinate dehydratase I from Klebsiella oxytoca (I222 Form)
8DQB	;	2.5	;	Crystal structure of 3-dehydroquinate dehydratase I from Klebsiella oxytoca (I23 Form)
6CV6	;	2.6	;	Crystal structure of 3-dehydroquinate dehydratase, type II, from Burkholderia phymatum STM815
1NUA	;	2.85	;	Crystal structure of 3-dehydroquinate synthase (DHQS) in complex with ZN2+
1NVA	;	2.62	;	Crystal structure of 3-dehydroquinate synthase (DHQS) in complex with ZN2+ and ADP
1NVB	;	2.7	;	Crystal structure of 3-dehydroquinate synthase (DHQS) in complex with ZN2+ and carbaphosphonate
1NVD	;	2.51	;	Crystal structure of 3-dehydroquinate synthase (DHQS) in complex with ZN2+ and carbaphosphonate
1NRX	;	2.9	;	Crystal structure of 3-dehydroquinate synthase (DHQS) in complex with ZN2+ and NAD
1NVE	;	2.58	;	Crystal structure of 3-dehydroquinate synthase (DHQS) in complex with ZN2+ and NAD
1NVF	;	2.8	;	Crystal structure of 3-dehydroquinate synthase (DHQS) in complex with ZN2+, ADP and carbaphosphonate
1NR5	;	2.1	;	Crystal structure of 3-dehydroquinate synthase (DHQS) in complex with ZN2+, NAD and carbaphosphonate
3CLH	;	2.4	;	Crystal structure of 3-dehydroquinate synthase (DHQS)from Helicobacter pylori
1VS1	;	2.3	;	Crystal structure of 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase (DAHP synthase) from Aeropyrum pernix in complex with Mn2+ and PEP
1RZM	;	2.2	;	Crystal structure of 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase (DAHPS) from Thermotoga maritima complexed with Cd2+, PEP and E4P
6U8J	;	2.492	;	Crystal structure of 3-deoxy-D-arabinoheptulosonate-7-phosphate synthase/phospho-2-dehydro-3-deoxyheptonate aldolase (Aro3) from Candida auris
4UM7	;	1.64	;	Crystal structure of 3-deoxy-D-manno-octulosonate 8-phosphate phosphatase (kdsC) from Moraxella catarrhalis in complex with Magnesium ion
4UMD	;	2.29	;	Crystal structure of 3-deoxy-D-manno-octulosonate 8-phosphate phosphatase from Moraxella catarrhalis in complex with citrate
4UME	;	2.09	;	Crystal structure of 3-deoxy-D-manno-octulosonate 8-phosphate phosphatase from Moraxella catarrhalis in complex with Magnesium ion and KDO molecule
4UM5	;	2.34	;	Crystal structure of 3-deoxy-D-manno-octulosonate 8-phosphate phosphatase from Moraxella catarrhalis in complex with Magnesium ion and Phosphate ion
4UMF	;	2.28	;	Crystal structure of 3-deoxy-D-manno-octulosonate 8-phosphate phosphatase from Moraxella catarrhalis in complex with Magnesium ion, Phosphate ion and KDO molecule
7T35	;	2.65	;	Crystal Structure of 3-deoxy-D-manno-octulosonate 8-phosphate phosphatase KdsC from Klebsiella pneumoniae subsp. pneumoniae
2QKF	;	1.75	;	Crystal structure of 3-deoxy-d-manno-octulosonate 8-phosphate synthase (KDO8PS) from Neisseria meningitidis
3DUV	;	2.3	;	Crystal structure of 3-deoxy-manno-octulosonate cytidylyltransferase from Haemophilus influenzae complexed with the substrate 3-deoxy-manno-octulosonate in the-configuration
8EES	;	2.5	;	Crystal structure of 3-deoxy-manno-octulosonate cytidylyltransferase from Klebsiella pneumoniae
3AJX	;	1.6	;	Crystal Structure of 3-Hexulose-6-Phosphate Synthase
2RFQ	;	1.65	;	Crystal structure of 3-HSA hydroxylase from Rhodococcus sp. RHA1
1TVZ	;	2.0	;	Crystal structure of 3-hydroxy-3-methylglutaryl-coenzyme A synthase from Staphylococcus aureus
5BUX	;	1.9	;	Crystal Structure of 3-hydroxyacyl-ACP dehydratase (FabZ) from Yersinia pestis with glycerol bound
1ZCJ	;	1.9	;	Crystal structure of 3-hydroxyacyl-CoA dehydrogenase
4J0E	;	1.6	;	Crystal structure of 3-hydroxyacyl-CoA dehydrogenase from Caenorhadbitis elegans in P1 space group
4J0F	;	2.2	;	Crystal structure of 3-hydroxyacyl-CoA dehydrogenase from Caenorhadbitis elegans in P212121 space group
4XGN	;	1.65	;	Crystal structure of 3-hydroxyacyl-CoA dehydrogenase in complex with NAD from Burkholderia thailandensis
3PPI	;	2.0	;	Crystal structure of 3-hydroxyacyl-CoA dehydrogenase type-2 from Mycobacterium avium
4PN3	;	2.15	;	Crystal structure of 3-hydroxyacyl-CoA-dehydrogenase from Brucella melitensis
3FE5	;	2.51	;	Crystal structure of 3-hydroxyanthranilate 3,4-dioxygenase from bovine kidney
1YFU	;	1.9	;	Crystal structure of 3-hydroxyanthranilate-3,4-dioxygenase from Ralstonia metallidurans
1YFY	;	3.2	;	Crystal structure of 3-hydroxyanthranilate-3,4-dioxygenase from Ralstonia metallidurans complexed with 3-hydroxyanthranilic acid
1YFX	;	2.0	;	Crystal structure of 3-hydroxyanthranilate-3,4-dioxygenase from Ralstonia metallidurans complexed with 4-chloro-3-hydroxyanthranilic acid and NO
1YFW	;	2.0	;	Crystal structure of 3-hydroxyanthranilate-3,4-dioxygenase from Ralstonia metallidurans complexed with 4-chloro-3-hydroxyanthranilic acid and O2
6BVR	;	1.9	;	Crystal structure of 3-hydroxyanthranilate-3,4-dioxygenase I142A from Cupriavidus metallidurans
6CD3	;	2.612	;	Crystal structure of 3-hydroxyanthranilate-3,4-dioxygenase I142A from Cupriavidus metallidurans in complex with 3-HAA
6BVS	;	2.318	;	Crystal structure of 3-hydroxyanthranilate-3,4-dioxygenase I142A from Cupriavidus metallidurans in complex with 4-Cl-3-HAA
6D60	;	2.22	;	Crystal structure of 3-hydroxyanthranilate-3,4-dioxygenase I142P from Cupriavidus metallidurans
6D62	;	1.77	;	Crystal structure of 3-hydroxyanthranilate-3,4-dioxygenase I142P from Cupriavidus metallidurans in complex with 3-HAA
6D61	;	1.74	;	Crystal structure of 3-hydroxyanthranilate-3,4-dioxygenase I142P from Cupriavidus metallidurans in complex with 4-Cl-3-HAA
6BVP	;	1.903	;	Crystal structure of 3-hydroxyanthranilate-3,4-dioxygenase N27A from Cupriavidus metallidurans
6BVQ	;	2.084	;	Crystal structure of 3-hydroxyanthranilate-3,4-dioxygenase N27A from Cupriavidus metallidurans in complex with 4-Cl-3-HAA
4BK1	;	1.73	;	Crystal structure of 3-hydroxybenzoate 6-hydroxylase uncovers lipid- assisted flavoprotein strategy for regioselective aromatic hydroxylation: H213S mutant in complex with 3-hydroxybenzoate
4BJZ	;	1.51	;	Crystal structure of 3-hydroxybenzoate 6-hydroxylase uncovers lipid- assisted flavoprotein strategy for regioselective aromatic hydroxylation: Native data
4BJY	;	1.52	;	Crystal structure of 3-hydroxybenzoate 6-hydroxylase uncovers lipid- assisted flavoprotein strategy for regioselective aromatic hydroxylation: Platinum derivative
4BK2	;	2.47	;	Crystal structure of 3-hydroxybenzoate 6-hydroxylase uncovers lipid- assisted flavoprotein strategy for regioselective aromatic hydroxylation: Q301E mutant
4BK3	;	1.78	;	Crystal structure of 3-hydroxybenzoate 6-hydroxylase uncovers lipid- assisted flavoprotein strategy for regioselective aromatic hydroxylation: Y105F mutant
2DKH	;	1.8	;	Crystal structure of 3-hydroxybenzoate hydroxylase from Comamonas testosteroni, in complex with the substrate
2DKI	;	2.5	;	Crystal structure of 3-hydroxybenzoate hydroxylase from Comamonas testosteroni, under pressure of xenon gas (12 atm)
4KUE	;	2.0	;	Crystal structure of 3-hydroxybutylryl-CoA dehydrogenase from Clostridium butyricum
4KUH	;	2.51	;	Crystal structure of 3-hydroxybutylryl-CoA dehydrogenase with acetoacetyl-CoA from Clostridium butyricum
4KUG	;	2.3	;	Crystal structure of 3-hydroxybutylryl-CoA dehydrogenase with NAD from Clostridium butyricum
3MOG	;	2.2	;	Crystal structure of 3-hydroxybutyryl-CoA dehydrogenase from Escherichia coli K12 substr. MG1655
3Q62	;	1.4	;	Crystal Structure of 3-hydroxydecanoyl-(acyl carrier protein) dehydratase from Yersinia pestis
4FQ9	;	2.02	;	Crystal Structure of 3-hydroxydecanoyl-Acyl Carrier Protein Dehydratase (FabA) from Pseudomonas aeruginosa
4B0C	;	2.7	;	Crystal Structure of 3-hydroxydecanoyl-Acyl Carrier Protein Dehydratase (FabA) from Pseudomonas aeruginosa in complex with 3-(pentylthio)-4H-1,2,4-triazole
4B0B	;	1.9	;	Crystal Structure of 3-hydroxydecanoyl-Acyl Carrier Protein Dehydratase (FabA) from Pseudomonas aeruginosa in complex with 3-(pyridin-2-yloxy)aniline
4B0J	;	2.5	;	Crystal Structure of 3-hydroxydecanoyl-Acyl Carrier Protein Dehydratase (FabA) from Pseudomonas aeruginosa in complex with 5-(2- thienyl)-3-isoxazolyl methanol
7BK9	;	1.94	;	Crystal structure of 3-hydroxydecanoyl-acyl carrier protein dehydratase (FabA) from Pseudomonas aeruginosa in complex with DDD00078426
7BHJ	;	2.11	;	Crystal structure of 3-hydroxydecanoyl-acyl carrier protein dehydratase (FabA) from Pseudomonas aeruginosa in complex with DDD00084774
7BKA	;	1.88	;	Crystal structure of 3-hydroxydecanoyl-acyl carrier protein dehydratase (FabA) from Pseudomonas aeruginosa in complex with DDD01870824
4B8U	;	2.76	;	Crystal Structure of 3-hydroxydecanoyl-Acyl Carrier Protein Dehydratase (FabA) from Pseudomonas aeruginosa in complex with N- isobutyl-2-(5-(2-thienyl)-1,2-oxazol-3-yl-)methoxy)acetamide
4CL6	;	2.41	;	Crystal Structure of 3-hydroxydecanoyl-Acyl Carrier Protein Dehydratase (FabA) from Pseudomonas aeruginosa in complex with N-(4- Chlorobenzyl)-3-(2-furyl)-1H-1,2,4-triazol-5-amine
8B72	;	1.87	;	Crystal structure of 3-hydroxydecanoyl-acyl carrier protein dehydratase (FabA) from Pseudomonas aeruginosa in complex with Z30857828
4B0I	;	2.03	;	Crystal Structure of 3-hydroxydecanoyl-Acyl Carrier Protein Dehydratase (FabA) mutant (H70N) from Pseudomonas aeruginosa in complex with 3-hydroxydecanoyl-N-acetyl cysteamine
7BIS	;	1.96	;	Crystal structure of 3-hydroxydecanoyl-acyl carrier protein dehydratase (FabA)from Pseudomonas aeruginosa in complex with DDD00082063
3G0O	;	1.8	;	Crystal structure of 3-hydroxyisobutyrate dehydrogenase (ygbJ) from Salmonella typhimurium
6MFB	;	2.5	;	Crystal structure of 3-hydroxykynurenine transaminase from Aedes aegypti
5ZAI	;	1.8	;	Crystal structure of 3-Hydroxypropionyl-CoA dehydratase from Metallosphaera sedula
2PKP	;	2.1	;	Crystal structure of 3-isopropylmalate dehydratase (leuD)from Methhanocaldococcus Jannaschii DSM2661 (MJ1271)
4Y1P	;	2.2	;	Crystal structure of 3-isopropylmalate dehydrogenase (Saci_0600) from Sulfolobus acidocaldarius complex with 3-isopropylmalate and Mg2+
1VLC	;	1.9	;	Crystal structure of 3-isopropylmalate dehydrogenase (TM0556) from Thermotoga maritima at 1.90 A resolution
4XXV	;	1.7	;	Crystal structure of 3-isopropylmalate dehydrogenase from Burkholderia thailandensis in complex with NAD
6WN6	;	1.86	;	Crystal structure of 3-keto-D-glucoside 4-epimerase, YcjR, from E. coli, apo form
1KV8	;	1.62	;	Crystal Structure of 3-Keto-L-Gulonate 6-Phosphate Decarboxylase
1XBZ	;	1.8	;	Crystal structure of 3-keto-L-gulonate 6-phosphate decarboxylase E112D/R139V/T169A mutant with bound L-xylulose 5-phosphate
1XBV	;	1.66	;	Crystal structure of 3-keto-L-gulonate 6-phosphate decarboxylase with bound D-ribulose 5-phosphate
1KW1	;	2.2	;	Crystal Structure of 3-Keto-L-Gulonate 6-Phosphate Decarboxylase with bound L-gulonate 6-phosphate
3IEB	;	2.1	;	Crystal structure of 3-keto-L-gulonate-6-phosphate decarboxylase from Vibrio cholerae O1 biovar El Tor str. N16961
4M8S	;	2.0	;	Crystal structure of 3-ketoacyl -(acyl carrier protein) reductase (FabG) from Neisseria meningitidis
4WK6	;	2.21	;	Crystal structure of 3-ketoacyl-(acyl-carrier-protein) reductase (FabG) (G141A) from Vibrio cholerae in complex with NADPH
4AFN	;	2.3	;	Crystal structure of 3-ketoacyl-(acyl-carrier-protein) reductase (FabG) from Pseudomonas aeruginosa at 2.3A resolution
4AG3	;	1.8	;	Crystal structure of 3-ketoacyl-(acyl-carrier-protein) reductase (FabG) from Pseudomonas aeruginosa in complex with NADPH at 1.8A resolution
3RRO	;	2.0	;	Crystal structure of 3-ketoacyl-(acyl-carrier-protein) reductase (FabG) from Vibrio cholerae
3TZH	;	2.1	;	Crystal structure of 3-ketoacyl-(acyl-carrier-protein) reductase (FabG)(F187A) from Vibrio cholerae
3TZK	;	1.8	;	Crystal structure of 3-ketoacyl-(acyl-carrier-protein) reductase (FabG)(G92A) from Vibrio cholerae
3U09	;	1.75	;	Crystal structure of 3-ketoacyl-(acyl-carrier-protein) reductase (FabG)(G92D) from Vibrio cholerae
3TZC	;	2.45	;	Crystal structure of 3-ketoacyl-(acyl-carrier-protein) reductase (FabG)(Y155F) from Vibrio cholerae
3N74	;	2.2	;	Crystal structure of 3-ketoacyl-(acyl-carrier-protein) reductase from Brucella melitensis
6B9U	;	1.8	;	Crystal structure of 3-ketoacyl-(acyl-carrier-protein) reductase from Brucella melitensis complexed with NADH
3FTP	;	2.05	;	Crystal structure of 3-Ketoacyl-(acyl-carrier-protein) reductase from Burkholderia pseudomallei at 2.05 A resolution
3LLS	;	2.4	;	Crystal structure of 3-ketoacyl-(acyl-carrier-protein) reductase from Mycobacterium tuberculosis
3F9I	;	2.25	;	Crystal structure of 3-ketoacyl-(acyl-carrier-protein) reductase Rickettsia prowazekii
5LP7	;	2.2	;	Crystal structure of 3-Ketoacyl-CoA Thiolase (MmgA) from Bacillus subtilis.
4C3X	;	2.0	;	Crystal structure of 3-ketosteroid delta1-dehydrogenase from Rhodococcus erythropolis SQ1
4C3Y	;	2.3	;	Crystal structure of 3-ketosteroid delta1-dehydrogenase from Rhodococcus erythropolis SQ1 in complex with 1,4-androstadiene-3,17- dione
8KCZ	;	2.3	;	Crystal structure of 3-ketosteroid delta1-dehydrogenase from Rhodococcus erythropolis SQ1 in complex with 1,4-androstadiene-3,17- dione
8JBZ	;	2.079	;	Crystal structure of 3-ketosteroid delta1-dehydrogenase from Rhodococcus erythropolis SQ1 in complex with 4-androstadiene-3,17- dione
8JOJ	;	2.819	;	Crystal structure of 3-ketosteroid delta1-dehydrogenase from Rhodococcus erythropolis SQ1 in complex with 9,11-epoxy-17-hydroxypregn-4-ene-3,20-dione actate
7P18	;	1.84	;	Crystal structure of 3-ketosteroid delta1-dehydrogenase from Sterolibacterium denitrificans in complex with 1,4-androstadiene-3,17-dione
2ZYL	;	2.3	;	Crystal structure of 3-ketosteroid-9-alpha-hydroxylase (KshA) from M. tuberculosis
4QCK	;	2.46	;	Crystal structure of 3-ketosteroid-9-alpha-hydroxylase (KshA) from M. tuberculosis in complex with 4-androstene-3,17-dione
4QDD	;	2.6	;	Crystal structure of 3-ketosteroid-9-alpha-hydroxylase 5 (KshA5) from R. rhodochrous in complex with 1,4-30Q-CoA
4QDC	;	1.9	;	Crystal structure of 3-ketosteroid-9-alpha-hydroxylase 5 (KshA5) from R. rhodochrous in complex with FE2/S2 (INORGANIC) CLUSTER
1OZ3	;	1.85	;	Crystal Structure of 3-MBT repeats of lethal (3) malignant Brain Tumor (Native-I) at 1.85 angstrom
1OZ2	;	1.55	;	CRYSTAL STRUCTURE OF 3-MBT REPEATS OF LETHAL (3) MALIGNANT BRAIN TUMOR (NATIVE-II) AT 1.55 ANGSTROM
1OYX	;	1.85	;	CRYSTAL STRUCTURE OF 3-MBT REPEATS OF LETHAL (3) MALIGNANT BRAIN TUMOR (SELENO-MET) AT 1.85 ANGSTROM
5WQJ	;	1.2	;	Crystal structure of 3-Mercaptopyruvate Sulfurtransferase(3MST) in complex with compound1
5WQK	;	1.7	;	Crystal structure of 3-Mercaptopyruvate Sulfurtransferase(3MST) in complex with compound1
1O66	;	1.75	;	Crystal structure of 3-methyl-2-oxobutanoate hydroxymethyltransferase
1O68	;	2.1	;	Crystal structure of 3-methyl-2-oxobutanoate hydroxymethyltransferase
3EZ4	;	2.1	;	Crystal structure of 3-methyl-2-oxobutanoate hydroxymethyltransferase from Burkholderia pseudomallei
3VAV	;	1.8	;	Crystal structure of 3-methyl-2-oxobutanoate hydroxymethyltransferase from Burkholderia thailandensis
2OFK	;	1.5	;	Crystal Structure of 3-methyladenine DNA glycosylase I (TAG)
2OFI	;	1.85	;	Crystal Structure of 3-methyladenine DNA Glycosylase I (TAG) bound to DNA/3mA
4Q9Y	;	1.55	;	Crystal structure of 3-methylthiophenol bound to human carbonic anhydrase II
4NDA	;	1.7	;	Crystal structure of 3-nitro-tyrosine tRNA synthetase (5B) bound to 3-nitro-tyrosine
6C4C	;	2.2	;	Crystal structure of 3-nitropropionate modified isocitrate lyase from Mycobacterium tuberculosis with glyoxylate and pyruvate
6C4A	;	1.8	;	Crystal structure of 3-nitropropionate modified isocitrate lyase from Mycobacterium tuberculosis with pyruvate
3UAN	;	1.844	;	Crystal structure of 3-O-sulfotransferase (3-OST-1) with bound PAP and heptasaccharide substrate
6XKG	;	1.55	;	Crystal structure of 3-O-Sulfotransferase isoform 3 in complex with 8mer oligosaccharide with 6S sulfation
6XL8	;	2.34	;	Crystal structure of 3-O-Sulfotransferase isoform 3 in complex with 8mer oligosaccharide with no 6S sulfation
2IDB	;	2.9	;	Crystal Structure of 3-octaprenyl-4-hydroxybenzoate decarboxylase (UbiD) from Escherichia coli, Northeast Structural Genomics Target ER459.
4IMR	;	1.96	;	Crystal structure of 3-oxoacyl (acyl-carrier-protein) reductase (target EFI-506442) from agrobacterium tumefaciens C58 with NADP bound
1O5I	;	2.5	;	Crystal structure of 3-oxoacyl-(acyl carrier protein) reductase (TM1169) from Thermotoga maritima at 2.50 A resolution
3E60	;	1.95	;	Crystal structure of 3-oxoacyl-(acyl carrier protein) synthase II from Bartonella henselae
3KZU	;	1.75	;	Crystal structure of 3-oxoacyl-(acyl carrier protein) synthase II from Brucella melitensis
3LED	;	1.45	;	Crystal structure of 3-oxoacyl-(acyl carrier protein) synthase III from Rhodopseudomonas palustris CGA009
3FK5	;	2.05	;	Crystal structure of 3-oxoacyl-(acyl carrier protein) synthase III, FabH (Xoo4209) from Xanthomonas oryzae pv. oryzae KACC10331
2X3E	;	1.81	;	Crystal structure of 3-oxoacyl-(acyl carrier protein) synthase III, FabH from Pseudomonas aeruginosa PAO1
4EFI	;	1.35	;	Crystal Structure of 3-oxoacyl-(Acyl-carrier protein) Synthase from Burkholderia Xenovorans LB400
1J3N	;	2.0	;	Crystal Structure of 3-oxoacyl-(acyl-carrier protein) Synthase II from Thermus thermophilus HB8
4BO2	;	1.9	;	Crystal structure of 3-oxoacyl-(acyl-carrier-protein) reductase (FabG) from Pseudomonas aeruginosa in complex with 1-(1-ethylbenzimidazol-2- yl)-3-(2-methoxyphenyl)urea at 1.9A resolution
4BO8	;	2.7	;	Crystal structure of 3-oxoacyl-(acyl-carrier-protein) reductase (FabG) from Pseudomonas aeruginosa in complex with 1-(2-amino-4- phenylimidazol-1-yl)-3-(2-fluorophenyl)urea at 2.7A resolution
4BNV	;	2.5	;	Crystal structure of 3-oxoacyl-(acyl-carrier-protein) reductase (FabG) from Pseudomonas aeruginosa in complex with 1-(2-chlorophenyl)-3-(1- methylbenzimidazol-2-yl)urea at 2.5A resolution
4BO0	;	2.4	;	Crystal structure of 3-oxoacyl-(acyl-carrier-protein) reductase (FabG) from Pseudomonas aeruginosa in complex with 1-(4-methoxy-1- methylindazol-3-yl)-3-(2-methoxyphenyl)urea at 2.4A resolution
4BNZ	;	2.5	;	Crystal structure of 3-oxoacyl-(acyl-carrier-protein) reductase (FabG) from Pseudomonas aeruginosa in complex with 1-methyl-N-phenylindole- 3-carboxamide at 2.5A resolution
4BO6	;	2.8	;	Crystal structure of 3-oxoacyl-(acyl-carrier-protein) reductase (FabG) from Pseudomonas aeruginosa in complex with 2,3-dihydroindol-1-yl-(2- thiophen-3-yl-1,3-thiazol-4-yl)methanone at 2.8A resolution
4BO3	;	2.5	;	Crystal structure of 3-oxoacyl-(acyl-carrier-protein) reductase (FabG) from Pseudomonas aeruginosa in complex with 2-(3-(trifluoromethyl) anilino)pyridine-3-sulfonamide at 2.5A resolution
4BNT	;	2.3	;	Crystal structure of 3-oxoacyl-(acyl-carrier-protein) reductase (FabG) from Pseudomonas aeruginosa in complex with 2-(trifluoromethyl)-1H- benzimidazole at 2.3A resolution
4BNU	;	2.0	;	Crystal structure of 3-oxoacyl-(acyl-carrier-protein) reductase (FabG) from Pseudomonas aeruginosa in complex with 2-phenyl-4-(1,2,4- triazol-4-yl)quinazoline at 2.0A resolution
4BNY	;	1.8	;	Crystal structure of 3-oxoacyl-(acyl-carrier-protein) reductase (FabG) from Pseudomonas aeruginosa in complex with 4-(2-phenylthieno(3,2-d) pyrimidin-4-yl)morpholine at 1.8A resolution
4BO9	;	2.9	;	Crystal structure of 3-oxoacyl-(acyl-carrier-protein) reductase (FabG) from Pseudomonas aeruginosa in complex with 5-(2-(furan-2-ylmethoxy) phenyl)-2-phenyltetrazole at 2.9A resolution
4BNX	;	2.3	;	Crystal structure of 3-oxoacyl-(acyl-carrier-protein) reductase (FabG) from Pseudomonas aeruginosa in complex with 6-(4-(2-chloroanilino)- 1H-quinazolin-2-ylidene)cyclohexa-2, 4-dien-1-one at 2.3A resolution
4BNW	;	1.6	;	Crystal structure of 3-oxoacyl-(acyl-carrier-protein) reductase (FabG) from Pseudomonas aeruginosa in complex with an unknown ligand at 1. 6A resolution
4BO7	;	2.6	;	Crystal structure of 3-oxoacyl-(acyl-carrier-protein) reductase (FabG) from Pseudomonas aeruginosa in complex with N-(2,3-dihydro-1H-inden- 5-yl)tetrazolo(1,5-b)pyridazin-6-amine at 2.6A resolution
4BO5	;	2.6	;	Crystal structure of 3-oxoacyl-(acyl-carrier-protein) reductase (FabG) from Pseudomonas aeruginosa in complex with N-(2-chlorophenyl)-4- pyrrol-1-yl-1,3,5-triazin-2-amine at 2.6A resolution
4BO4	;	2.7	;	Crystal structure of 3-oxoacyl-(acyl-carrier-protein) reductase (FabG) from Pseudomonas aeruginosa in complex with N-(2-methoxyphenyl)-3,4- dihydro-2H-quinoline-1-carboxamide at 2.7A resolution
4BO1	;	2.2	;	Crystal structure of 3-oxoacyl-(acyl-carrier-protein) reductase (FabG) from Pseudomonas aeruginosa in complex with N-(4-chloro-2,5- dimethoxyphenyl)quinoline-8-carboxamide at 2.2A resolution
8JF9	;	1.9	;	Crystal structure of 3-oxoacyl-ACP reductase FabG from Helicobacter pylori
8JFI	;	2.38	;	Crystal structure of 3-oxoacyl-ACP reductase FabG in complex with NADP+ and 3-keto-hexanoyl-ACP from Helicobacter pylori
8JFG	;	2.83	;	Crystal structure of 3-oxoacyl-ACP reductase FabG in complex with NADP+ and 3-keto-octanoyl-ACP from Helicobacter pylori
8JFH	;	1.8	;	Crystal structure of 3-oxoacyl-ACP reductase FabG in complex with NADP+ and 3-keto-octanoyl-ACP from Helicobacter pylori in an inactive form that priors the acyl substrate delivery
8JFA	;	2.55	;	Crystal structure of 3-oxoacyl-ACP reductase FabG in complex with NADPH from Helicobacter pylori
2PH3	;	1.91	;	Crystal structure of 3-oxoacyl-[acyl carrier protein] reductase TTHA0415 from Thermus thermophilus
4NBR	;	1.35	;	Crystal Structure of 3-oxoacyl-[acyl-carrier protein] reductase from Brucella melitensis ATCC 23457
5VN2	;	1.9	;	Crystal structure of 3-oxoacyl-[acyl-carrier protein] reductase from Brucella melitensis in complex with NAD
4JRO	;	1.92	;	Crystal structure of 3-oxoacyl-[acyl-carrier protein]reductase (FabG)from Listeria monocytogenes in complex with NADP+
8CXA	;	1.65	;	Crystal Structure of 3-oxoacyl-[acyl-carrier-protein] reductase from Mycobacterium smegmatis with bound NAD
4DDO	;	1.9	;	Crystal structure of 3-oxoacyl-[acyl-carrier-protein] synthase ii from burkholderia vietnamiensis
4F32	;	1.9	;	Crystal structure of 3-oxoacyl-[acyl-carrier-protein] synthase II from Burkholderia vietnamiensis in complex with platencin
2EBD	;	2.1	;	Crystal structure of 3-oxoacyl-[acyl-carrier-protein] synthase III from Aquifex aeolicus VF5
4DFE	;	2.35	;	Crystal structure of 3-oxoacyl-[acyl-carrier-protein] synthase III from Burkholderia xenovorans
4NFY	;	2.45	;	Crystal Structure of 3-phosphoglycerate Dehydrogenase from Entamoeba histolytica
3OZ7	;	2.7	;	Crystal Structure of 3-Phosphopglycerate Kinase of Plasmodium falciparum
3WDS	;	1.72	;	Crystal structure of 3-quinuclidinone reductase from Agrobacterium tumefaciens
7N37	;	1.3	;	Crystal structure of 3-site deamidated variant of human gamma(S)-crystallin
4YHZ	;	2.304	;	Crystal structure of 304M3-B Fab in complex with H3K4me3 peptide
4YHP	;	2.53	;	Crystal structure of 309M3-B Fab in complex with H3K9me3 peptide
4YHY	;	1.9	;	Crystal structure of 309M3-B in complex with trimethylated Lys
7JLZ	;	1.64	;	Crystal structure of 30S ribosomal A1408 methyltransferase from an uncultured bacterium (UncKam)
3R3T	;	2.302	;	Crystal Structure of 30S Ribosomal Protein S from Bacillus anthracis
1VMB	;	1.7	;	Crystal structure of 30S ribosomal protein S6 (TM0603) from Thermotoga maritima at 1.70 A resolution
3RF2	;	2.16	;	Crystal Structure of 30S Ribosomal Protein S8 from Aquifex Aeolicus
4JI0	;	3.492	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
4JI1	;	3.144	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
4JI2	;	3.64	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
4JI3	;	3.35	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
4JI4	;	3.692	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
4JI5	;	3.85	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
4JI6	;	3.55	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
4JI7	;	3.5	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
4JI8	;	3.742	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
4LF4	;	3.3421	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
4LF5	;	3.753	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
4LF6	;	3.3052	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
4LF7	;	3.1484	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
4LF8	;	3.1484	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
4LF9	;	3.2811	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
4LFA	;	3.6461	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
4LFB	;	3.009	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
4LFC	;	3.602	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
4X62	;	3.4492	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
4X64	;	3.35	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
4X65	;	3.345	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
4X66	;	3.446	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
5WNP	;	3.3	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
5WNQ	;	3.5	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
5WNR	;	3.5	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
5WNS	;	3.5	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
5WNT	;	3.3	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
5WNU	;	3.4	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
5WNV	;	3.3	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
6CAQ	;	3.4	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus
6CAP	;	3.4	;	Crystal Structure of 30S ribosomal subunit from Thermus thermophilus in complex with Sisomicin
4I2N	;	1.9	;	Crystal structure of 31kD Heat Shock Protein, VcHsp31 from Vibrio cholerae
4I46	;	2.5	;	Crystal structure of 31kD Heat Shock Protein, VcHsp31 from Vibrio cholerae
6O26	;	1.8	;	Crystal structure of 3246 Fab in complex with circumsporozoite protein NANA
1VQ0	;	2.2	;	Crystal structure of 33 kDa chaperonin (Heat shock protein 33 homolog) (HSP33) (TM1394) from Thermotoga maritima at 2.20 A resolution
4X3N	;	1.89	;	Crystal structure of 34 kDa F-actin bundling protein from Dictyostelium discoideum
5VVF	;	2.0	;	Crystal Structure of 354BG1 Fab
5UD9	;	1.3	;	Crystal structure of 354BG18 Fab
5UEL	;	1.6	;	Crystal structure of 354NC102 Fab
5UEM	;	2.7	;	Crystal structure of 354NC37 Fab in complex with HIV-1 clade AE strain 93TH057 gp120
6O25	;	2.9	;	Crystal structure of 3945 Fab in complex with circumsporozoite protein NANP3 and anti-Kappa VHH domain
4UIA	;	2.18	;	Crystal structure of 3a in complex with tafCPB
1ZGL	;	2.8	;	Crystal structure of 3A6 TCR bound to MBP/HLA-DR2a
3S96	;	1.9	;	Crystal structure of 3B5H10
4QT5	;	2.5	;	Crystal Structure of 3BD10: A Monoclonal Antibody against the TSH Receptor
5I9Q	;	3.0	;	Crystal structure of 3BNC55 Fab in complex with 426c.TM4deltaV1-3 gp120
5FEC	;	3.17	;	Crystal structure of 3BNC60 Fab germline precursor in complex with 426c.TM4deltaV1-3 gp120
4GW4	;	2.65	;	Crystal structure of 3BNC60 Fab with P61A mutation
5HXF	;	1.39	;	Crystal structure of 3C protease from a mild Human enterovirus 71 in complex with rupintrivir
5WQ2	;	1.39	;	Crystal structure of 3C protease from a mild Human enterovirus 71 in complex with rupintrivir
2ZTY	;	1.72	;	crystal structure of 3C protease from CVB3 in space group C2
2ZTZ	;	2.0	;	crystal structure of 3C protease from CVB3 in space group P21
3ZZ3	;	1.89	;	Crystal structure of 3C protease mutant (N126Y) of coxsackievirus B3
3ZZ4	;	2.1	;	Crystal structure of 3C protease mutant (T68A and N126Y) of coxsackievirus B3
3ZZC	;	2.1	;	Crystal structure of 3C protease mutant (T68A and N126Y) of coxsackievirus B3 complexed with alpha, beta-unsaturated ethyl ester inhibitor 83
3ZZD	;	2.1	;	Crystal structure of 3C protease mutant (T68A and N126Y) of coxsackievirus B3 complexed with alpha, beta-unsaturated ethyl ester inhibitor 85
3ZYE	;	1.85	;	Crystal structure of 3C protease mutant (T68A) of coxsackievirus B3
3ZYD	;	1.7	;	Crystal structure of 3C protease of coxsackievirus B3
3ZZ5	;	2.2	;	Crystal structure of 3C protease of coxsackievirus B3 complexed with alpha, beta-unsaturated ethyl ester inhibitor 74
3ZZ7	;	1.8	;	Crystal structure of 3C protease of coxsackievirus B3 complexed with alpha, beta-unsaturated ethyl ester inhibitor 81
3ZZ8	;	1.85	;	Crystal structure of 3C protease of coxsackievirus B3 complexed with alpha, beta-unsaturated ethyl ester inhibitor 82
3ZZ9	;	1.9	;	Crystal structure of 3C protease of coxsackievirus B3 complexed with alpha, beta-unsaturated ethyl ester inhibitor 83
3ZZA	;	1.8	;	Crystal structure of 3C protease of coxsackievirus B3 complexed with alpha, beta-unsaturated ethyl ester inhibitor 84
3ZZB	;	2.1	;	Crystal structure of 3C protease of coxsackievirus B3 complexed with alpha, beta-unsaturated ethyl ester inhibitor 85
3ZZ6	;	2.05	;	Crystal structure of 3C protease of coxsackievirus B3 complexed with Michael receptor inhibitor 75
3ZV8	;	2.4	;	Crystal structure of 3C protease of Enterovirus 68
7XAR	;	1.6	;	Crystal structure of 3C-like protease from SARS-CoV-2 in complex with covalent inhibitor
1JS0	;	2.2	;	Crystal Structure of 3D Domain-swapped RNase A Minor Trimer
6X8U	;	1.55	;	Crystal structure of 3D11 Fab in complex with Plasmodium berghei circumsporozoite protein Mixed peptide
6X8S	;	1.55	;	Crystal structure of 3D11 Fab in complex with Plasmodium berghei circumsporozoite protein NAND peptide
6X8P	;	2.27	;	Crystal structure of 3D11 Fab in complex with Plasmodium berghei circumsporozoite protein NPND peptide
6X8Q	;	1.6	;	Crystal structure of 3D11 Fab in complex with Plasmodium berghei circumsporozoite protein PAPP peptide
4R19	;	1.8	;	Crystal Structure of 3D7 strain Plasmodium falciparum AMA1
4R1B	;	1.6	;	Crystal Structure of 3D7 strain Plasmodium falciparum AMA1
4R1C	;	2.0	;	Crystal Structure of 3D7 strain Plasmodium falciparum AMA1
4HDI	;	2.449	;	Crystal Structure of 3E5 IgG3 FAB from mus musculus
6REO	;	1.5	;	Crystal structure of 3fPizza6-SH with Sulphate ion
6REN	;	1.3	;	Crystal structure of 3fPizza6-SH with Zn2+
4UIB	;	1.94	;	Crystal structure of 3p in complex with tafCPB
3FJG	;	2.2	;	Crystal structure of 3PG bound PEB3
4N7F	;	1.102	;	Crystal structure of 3rd WW domain of human Nedd4-1
6WRK	;	1.95	;	Crystal structure of 3rd-generation Mj 3-nitro-tyrosine tRNA synthetase (""A7"") bound to 3-nitro-tyrosine
1QE1	;	2.85	;	CRYSTAL STRUCTURE OF 3TC-RESISTANT M184I MUTANT OF HIV-1 REVERSE TRANSCRIPTASE
3QMN	;	1.85	;	Crystal Structure of 4'-Phosphopantetheinyl Transferase AcpS from Vibrio cholerae O1 biovar eltor
7Y8P	;	1.5	;	Crystal structure of 4'-selenoRNA duplex
7N14	;	1.537	;	Crystal structure of 4-(1H-1,2,4-triazol-1-yl)benzoic acid-bound CYP199A4
1UEK	;	1.7	;	Crystal structure of 4-(cytidine 5'-diphospho)-2C-methyl-D-erythritol kinase
3D6U	;	2.2	;	Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase
3D6V	;	2.2	;	Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase
7D4B	;	3.14	;	Crystal structure of 4-1BB in complex with a VHH
6CU0	;	3.2	;	Crystal structure of 4-1BBL/4-1BB (C121S) complex in P21 space group
6CPR	;	2.7	;	Crystal structure of 4-1BBL/4-1BB complex in C2 space group
1K1W	;	2.8	;	Crystal structure of 4-alpha-glucanotransferase from thermococcus litoralis
1K1X	;	2.4	;	Crystal structure of 4-alpha-glucanotransferase from thermococcus litoralis
2Y4R	;	1.75	;	CRYSTAL STRUCTURE OF 4-AMINO-4-DEOXYCHORISMATE LYASE FROM PSEUDOMONAS AERUGINOSA
8HX6	;	2.14	;	Crystal structure of 4-amino-4-deoxychorismate synthase from Streptomyces venezuelae
8HX8	;	2.55	;	Crystal structure of 4-amino-4-deoxychorismate synthase from Streptomyces venezuelae co-crystallized with chorismate
8HX7	;	1.95	;	Crystal structure of 4-amino-4-deoxychorismate synthase from Streptomyces venezuelae co-crystallized with L-glutamine
8HX9	;	2.03	;	Crystal structure of 4-amino-4-deoxychorismate synthase from Streptomyces venezuelae with chorismate
2EO5	;	1.9	;	Crystal structure of 4-aminobutyrate aminotransferase from Sulfolobus tokodaii strain7
3R4T	;	2.5	;	Crystal structure of 4-aminobutyrate aminotransferase GabT from Mycobacterium marinum covalently bound to pyridoxal phosphate
7JH3	;	2.68	;	Crystal structure of 4-aminobutyrate aminotransferase PuuE from Escherichia coli in complex with PLP
3OKS	;	1.8	;	Crystal structure of 4-aminobutyrate transaminase from mycobacterium smegmatis
3Q8N	;	2.05	;	Crystal structure of 4-aminobutyrate transaminase from Mycobacterium smegmatis
1S9A	;	2.47	;	Crystal Structure of 4-Chlorocatechol 1,2-dioxygenase from Rhodococcus opacus 1CP
3O32	;	2.85	;	Crystal Structure of 4-Chlorocatechol Dioxygenase from Rhodococcus opacus 1CP in complex with 3,5-dichlorocatechol
3O6J	;	2.9	;	Crystal Structure of 4-Chlorocatechol Dioxygenase from Rhodococcus opacus 1CP in complex with hydroxyquinol
3O5U	;	2.35	;	Crystal Structure of 4-Chlorocatechol Dioxygenase from Rhodococcus opacus 1CP in complex with protocatechuate
3O6R	;	2.6	;	Crystal Structure of 4-Chlorocatechol Dioxygenase from Rhodococcus opacus 1CP in complex with pyrogallol
5BSR	;	1.5	;	Crystal structure of 4-coumarate:CoA ligase complexed with adenosine monophosphate and Coenzyme A
5BSU	;	1.75	;	Crystal structure of 4-coumarate:CoA ligase complexed with caffeoyl adenylate
5BST	;	1.61	;	Crystal structure of 4-coumarate:CoA ligase complexed with coumaroyl adenylate
5BSV	;	1.7	;	Crystal structure of 4-coumarate:CoA ligase complexed with feruloyl adenylate
5BSM	;	2.32	;	Crystal structure of 4-coumarate:CoA ligase complexed with magnesium and Adenosine triphosphate
5BSW	;	2.1	;	Crystal structure of 4-coumarate:CoA ligase delta-V341 mutant complexed with feruloyl adenylate
1YWK	;	2.95	;	Crystal structure of 4-deoxy-1-threo-5-hexosulose-uronate ketol-isomerase from Enterococcus faecalis
4U8F	;	1.55	;	Crystal structure of 4-deoxy-L-threo-5-hexosulose-uronate ketol-isomerase complexed with a tartrate
4U8E	;	2.0	;	Crystal structure of 4-deoxy-L-threo-5-hexosulose-uronate ketol-isomerase from Streptococcus agalactiae
3PYD	;	2.101	;	crystal structure of 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase (IspE) from Mycobacterium tuberculosis
1I52	;	1.5	;	CRYSTAL STRUCTURE OF 4-DIPHOSPHOCYTIDYL-2-C-METHYLERYTHRITOL (CDP-ME) SYNTHASE (YGBP) INVOLVED IN MEVALONATE INDEPENDENT ISOPRENOID BIOSYNTHESIS
1INI	;	1.82	;	CRYSTAL STRUCTURE OF 4-DIPHOSPHOCYTIDYL-2-C-METHYLERYTHRITOL (CDP-ME) SYNTHETASE (YGBP) INVOLVED IN MEVALONATE INDEPENDENT ISOPRENOID BIOSYNTHESIS, COMPLEXED WITH CDP-ME AND MG2+
1VGT	;	1.8	;	Crystal structure of 4-diphosphocytidyl-2C-methyl-D-erythritol synthase
1VGU	;	2.8	;	Crystal structure of 4-diphosphocytidyl-2C-methyl-D-erythritol synthase
1VGW	;	2.35	;	Crystal structure of 4-diphosphocytidyl-2C-methyl-D-erythritol synthase
1VGZ	;	3.0	;	Crystal structure of 4-diphosphocytidyl-2C-methyl-D-erythritol synthase
4NCP	;	2.5	;	Crystal Structure of 4-HBT like thioesterase SAV1878 from Staphylococcus aureus subsp. aureus Mu50
4YWJ	;	1.8	;	Crystal structure of 4-hydroxy-tetrahydrodipicolinate reductase (HTPA reductase) from Pseudomonas aeruginosa
6MQH	;	1.7	;	Crystal structure of 4-hydroxy-tetrahydrodipicolinate synthase (HTPA synthase) from Burkholderia mallei
1Q4U	;	1.6	;	Crystal structure of 4-hydroxybenzoyl CoA thioesterase from arthrobacter sp. strain SU complexed with 4-hydroxybenzyl CoA
1Q4T	;	1.6	;	crystal structure of 4-hydroxybenzoyl CoA thioesterase from Arthrobacter sp. strain SU complexed with 4-hydroxyphenyl CoA
3D3U	;	2.8	;	Crystal structure of 4-hydroxybutyrate CoA-transferase (abfT-2) from Porphyromonas gingivalis. Northeast Structural Genomics Consortium target PgR26
3GK7	;	1.85	;	Crystal structure of 4-hydroxybutyrate CoA-Transferase from Clostridium aminobutyricum
2OAS	;	2.4	;	Crystal Structure of 4-hydroxybutyrate coenzyme A transferase (AtoA) in complex with CoA from Shewanella oneidensis, Northeast Structural Genomics Target SoR119.
1U8V	;	1.6	;	Crystal Structure of 4-Hydroxybutyryl-CoA Dehydratase from Clostridium aminobutyricum: Radical catalysis involving a [4Fe-4S] cluster and flavin
5ZBF	;	1.6	;	Crystal structure of 4-hydroxyphenylpyruvic acid bound AerE from Microcystis aeruginosa
6XMY	;	1.4	;	Crystal Structure of 4-hydroxythreonine-4-phosphate dehydrogenase from Legionella pneumophila in complex with NAD
3LXY	;	1.7	;	Crystal structure of 4-hydroxythreonine-4-phosphate dehydrogenase from Yersinia pestis CO92
6E6I	;	2.4	;	Crystal structure of 4-methyl HOPDA bound to LigY from Sphingobium sp. strain SYK-6
3DZV	;	2.57	;	Crystal structure of 4-methyl-5-(beta-hydroxyethyl)thiazole kinase (NP_816404.1) from ENTEROCOCCUS FAECALIS V583 at 2.57 A resolution
3HFK	;	1.9	;	Crystal structure of 4-methylmuconolactone methylisomerase (H52A) in complex with 4-methylmuconolactone
3HF5	;	1.4	;	Crystal structure of 4-methylmuconolactone methylisomerase in complex with 3-methylmuconolactone
3HDS	;	1.45	;	Crystal structure of 4-methylmuconolactone methylisomerase in complex with MES
4Q90	;	1.54	;	Crystal structure of 4-methylpyridine-2(1H)-thione bound to human carbonic anhydrase II
1VJR	;	2.4	;	Crystal structure of 4-nitrophenylphosphatase (TM1742) from Thermotoga maritima at 2.40 A resolution
3WAU	;	1.7	;	Crystal structure of 4-O-beta-D-mannosyl-D-glucose phosphorylase MGP complexed with M1P
3WAT	;	1.6	;	Crystal structure of 4-O-beta-D-mannosyl-D-glucose phosphorylase MGP complexed with Man+Glc
3WAS	;	1.5	;	Crystal structure of 4-O-beta-D-mannosyl-D-glucose phosphorylase MGP complexed with Man-Glc+PO4
4KMI	;	1.8	;	Crystal structure of 4-O-beta-D-mannosyl-D-glucose phosphorylase MGP complexed with PO4
4X1C	;	1.7	;	Crystal structure of 4-OT from Pseudomonas putida mt-2 with an enamine adduct on the N-terminal proline at 1.7 Angstrom resolution
6BGN	;	1.51	;	Crystal Structure of 4-Oxalocrotonate Tautomerase After Incubation with 5-Fluoro-2-hydroxy-2,4-pentadienoate
1BJP	;	2.4	;	CRYSTAL STRUCTURE OF 4-OXALOCROTONATE TAUTOMERASE INACTIVATED BY 2-OXO-3-PENTYNOATE AT 2.4 ANGSTROMS RESOLUTION
5TIG	;	2.7	;	CRYSTAL STRUCTURE OF 4-OXALOCROTONATE TAUTOMERASE INACTIVATED BY BrHPD
6FPS	;	1.9	;	Crystal structure of 4-oxalocrotonate tautomerase triple mutant L8Y/M45Y/F50A
2GWG	;	1.8	;	Crystal Structure of 4-Oxalomesaconate Hydratase, LigJ, from Rhodopseudomonas palustris, Northeast Structural Genomics Target RpR66.
2D0T	;	2.3	;	Crystal structure of 4-phenylimidazole bound form of human indoleamine 2,3-dioxygenase
4U72	;	2.0	;	Crystal structure of 4-phenylimidazole bound form of human indoleamine 2,3-dioxygenase (A260G mutant)
4U74	;	2.31	;	Crystal structure of 4-phenylimidazole bound form of human indoleamine 2,3-dioxygenase (G262A mutant)
3WDL	;	2.4	;	Crystal structure of 4-phosphopantoate-beta-alanine ligase complexed with ATP
3WDK	;	2.3	;	Crystal structure of 4-phosphopantoate-beta-alanine ligase complexed with reaction intermediate
3WDM	;	2.0	;	Crystal structure of 4-phosphopantoate-beta-alanine ligase from Thermococcus kodakarensis
4KEQ	;	2.279	;	Crystal structure of 4-pyridoxolactonase, 5-pyridoxolactone bound
4KEP	;	1.83	;	Crystal structure of 4-pyridoxolactonase, wild-type
3HGA	;	1.3	;	Crystal Structure of 4-Se-Uridine Derivatized RNA
1D59	;	2.3	;	CRYSTAL STRUCTURE OF 4-STRANDED OXYTRICHA TELOMERIC DNA
1FSU	;	2.5	;	Crystal Structure of 4-Sulfatase (human)
5FA2	;	2.0	;	Crystal structure of 426c.TM4deltaV1-3 p120
6VLW	;	3.42	;	Crystal Structure of 426cOD in Complex with VRC01 Fab
6UTK	;	3.8	;	Crystal structure of 438-B11 Fab in complex with an uncleaved prefusion optimized (UFO) soluble BG505 trimer and Fab 35O22 at 3.80 Angstrom
6O2B	;	2.1	;	Crystal structure of 4493 Fab in complex with circumsporozoite protein DND and anti-kappa VHH domain
6O28	;	1.93	;	Crystal structure of 4493 Fab in complex with circumsporozoite protein KQPA and anti-kappa VHH domain
6O2C	;	2.017	;	Crystal structure of 4493 Fab in complex with circumsporozoite protein NANP3 and anti-kappa VHH domain
6O2A	;	2.15	;	Crystal structure of 4493 Fab in complex with circumsporozoite protein NDN and anti-kappa VHH domain
6O29	;	2.4	;	Crystal structure of 4493 Fab in complex with circumsporozoite protein NPDP and anti-kappa VHH domain
6VLN	;	1.63	;	Crystal structure of 4498 Fab in complex with circumsporozoite protein DND3 and anti-Kappa VHH domain
6O24	;	1.4	;	Crystal structure of 4498 Fab in complex with circumsporozoite protein NANP3 and anti-Kappa VHH domain
6ULF	;	1.7	;	Crystal structure of 4498 Fab in complex with circumsporozoite protein NDN3 and anti-Kappa VHH domain
5YII	;	1.8	;	Crystal Structure of 45 amino acid deleted from N-terminal of Phosphoserine Aminotransferase (PSAT) of Entamoeba histolytica
6JT8	;	1.9	;	Crystal structure of 450-451_deletion mutant of FGAM Synthetase
6JT7	;	1.86	;	Crystal structure of 452-453_deletion mutant of FGAM Synthetase
7EKB	;	1.45	;	Crystal structure of 4E10 modified with pyrene acetamide
4XPC	;	1.68	;	Crystal structure of 5'- CTTATAAATTTATAAG in a host-guest complex
4XPE	;	1.78	;	Crystal structure of 5'-CTTATGGGCCCATAAG in a host-guest complex
4XNO	;	1.985	;	Crystal structure of 5'-CTTATPPPZZZATAAG
4XO0	;	1.7	;	Crystal structure of 5'-CTTATPPTAZZATAAG in a host-guest complex
1WTA	;	1.78	;	Crystal Structure of 5'-Deoxy-5'-methylthioadenosine from Aeropyrum pernix (R32 form)
1JDU	;	2.5	;	CRYSTAL STRUCTURE OF 5'-DEOXY-5'-METHYLTHIOADENOSINE PHOSPHORYLASE
1JP7	;	1.8	;	Crystal Structure of 5'-deoxy-5'-methylthioadenosine phosphorylase
3T94	;	1.452	;	Crystal structure of 5'-deoxy-5'-methylthioadenosine phosphorylase (MTAP) II complexed with 5'-deoxy-5'-methylthioadenosine and sulfate
1JDV	;	2.0	;	CRYSTAL STRUCTURE OF 5'-DEOXY-5'-METHYLTHIOADENOSINE PHOSPHORYLASE COMPLEXED WITH ADENOSINE AND SULFATE ION
1JDT	;	2.0	;	CRYSTAL STRUCTURE OF 5'-DEOXY-5'-METHYLTHIOADENOSINE PHOSPHORYLASE COMPLEXED WITH MTA AND SULFATE ION
1JE0	;	1.6	;	CRYSTAL STRUCTURE OF 5'-DEOXY-5'-METHYLTHIOADENOSINE PHOSPHORYLASE COMPLEXED WITH PHOSPHATE AND TRIS MOLECULE
1JPV	;	1.8	;	Crystal Structure of 5'-deoxy-5'-methylthioadenosine phosphorylase complexed with SO4
1K27	;	1.95	;	Crystal Structure of 5'-Deoxy-5'-Methylthioadenosine Phosphorylase in Complex with a Transition State Analogue
1JDZ	;	2.0	;	CRYSTAL STRUCTURE OF 5'-DEOXY-5'-METHYLTHIOADENOSINE PHOSPHORYLASE WITH FORMYCIN B AND SULFATE ION
2A8Y	;	1.45	;	Crystal structure of 5'-deoxy-5'methylthioadenosine phosphorylase complexed with 5'-deoxy-5'methylthioadenosine and sulfate
4QEZ	;	2.7	;	Crystal structure of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Bacillus anthracis
4FFS	;	1.9	;	Crystal structure of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Helicobacter pylori with butyl-thio-DADMe-Immucillin-A
3EEI	;	1.78	;	Crystal structure of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase from neisseria meningitidis in complex with methylthio-immucillin-A
4F1W	;	1.36	;	Crystal structure of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Salmonella enterica with Adenine
4F3C	;	1.93	;	Crystal structure of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Salmonella enterica with butyl-thio-DADMe-Immucillin-A
4F2P	;	1.64	;	Crystal structure of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Salmonella enterica with diEtglycol-thio-DADMe-Immucillin-A
4F3K	;	1.85	;	Crystal structure of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Salmonella enterica with homocysteine-DADMe-Immucillin-A
4F2W	;	2.0	;	Crystal structure of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Salmonella enterica with methyl-thio-DADMe-Immucillin-A
5UE1	;	1.14	;	Crystal structure of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase in complex with adenine from Vibrio fischeri ES114
3OZB	;	2.8	;	Crystal Structure of 5'-methylthioinosine phosphorylase from Psedomonas aeruginosa in complex with hypoxanthine
3C9F	;	1.9	;	Crystal structure of 5'-nucleotidase from Candida albicans SC5314
5H7W	;	1.9	;	Crystal structure of 5'-nucleotidase from venom of Naja atra
2Z1A	;	1.75	;	Crystal structure of 5'-nucleotidase precursor from Thermus thermophilus HB8
3ONN	;	1.87	;	Crystal structure of 5'-nucleotidase SDT1 from saccharomyces cerevisiae
5UME	;	2.7	;	Crystal Structure of 5,10-Methylenetetrahydrofolate Reductase MetF from Haemophilus influenzae
1M2R	;	1.7	;	Crystal structure of 5,8-di-amino-1,4-di-hydroxy-anthraquinone/CK2 kinase complex
6YYG	;	1.95	;	Crystal Structure of 5-(trifluoromethoxy)indoline-2,3-dione covalently bound to the PH domain of Bruton's tyrosine kinase mutant R28C
1OHP	;	1.53	;	CRYSTAL STRUCTURE OF 5-3-KETOSTEROID ISOMERASE MUTANT D38N FROM PSEUDOMONAS TESTOSTERONI COMPLEXED WITH 5ALPHA-ESTRAN-3,17-DIONE
1OHS	;	1.7	;	CRYSTAL STRUCTURE OF 5-3-KETOSTEROID ISOMERASE MUTANT Y14F/D38N FROM PSEUDOMONAS TESTOSTERONI COMPLEXED WITH ANDROSTANEDIONE
1OGZ	;	2.3	;	Crystal Structure Of 5-3-Ketosteroid Isomerase Mutants P39A Complexed With Equilenin From Pseudomonas Testosteroni
2Z1B	;	3.3	;	Crystal Structure of 5-aminolevulinic acid dehydratase (ALAD) from Mus musculs
2Z0I	;	3.2	;	Crystal Structure of 5-aminolevulinic acid dehydratase (ALAD) from Mus musculus
6TVN	;	2.31	;	Crystal Structure of 5-bromoindoline-2,3-dione covalently bound to the PH domain of Bruton's tyrosine kinase
4Y52	;	3.5	;	Crystal structure of 5-Carboxycytosine Recognition by RNA Polymerase II during Transcription Elongation.
5ZAT	;	1.06	;	Crystal structure of 5-carboxylcytosine containing decamer dsDNA
4JJ9	;	1.76	;	Crystal Structure of 5-carboxymethyl-2-hydroxymuconate delta-isomerase
4NG3	;	1.751	;	Crystal structure of 5-carboxyvanillate decarboxylase from Sphingomonas paucimobilis complexed with 4-Hydroxy-3-methoxy-5-nitrobenzoic acid
4L6D	;	1.449	;	Crystal structure of 5-carboxyvanillate decarboxylase from Sphingomonas paucimobilis complexed with vanillic acid
4ICM	;	1.825	;	Crystal structure of 5-carboxyvanillate decarboxylase LigW from Sphingomonas paucimobilis
4NI8	;	1.64	;	Crystal structure of 5-carboxyvanillate decarboxylase LigW from Sphingomonas paucimobilis complexed with Mn and 5-methoxyisophtalic acid
4QTG	;	1.47	;	CRYSTAL STRUCTURE of 5-CARBOXYVANILLATE DECARBOXYLASE LIGW2 (TARGET EFI-505250) FROM NOVOSPHINGOBIUM AROMATICIVORANS DSM 12444 COMPLEXED WITH MANGANESE
4QS6	;	1.76	;	CRYSTAL STRUCTURE of 5-CARBOXYVANILLATE DECARBOXYLASE LIGW2 FROM NOVOSPHINGOBIUM AROMATICIVORANS DSM 12444 (TARGET EFI-505250) WITH BOUND 4-HYDROXY-3-METHOXY-5-NITROBENZOIC ACID, NO METAL, THE D314N MUTANT
4QS5	;	1.8	;	CRYSTAL STRUCTURE of 5-CARBOXYVANILLATE DECARBOXYLASE LIGW2 FROM NOVOSPHINGOBIUM AROMATICIVORANS DSM 12444 (TARGET EFI-505250) WITH BOUND MANGANESE AND 3-methoxy-4-hydroxy-5-nitrobenzoic acid, THE D314N MUTANT
7XUY	;	2.001	;	Crystal structure of 5-chloro-2-hydroxymuconate tautomerase CnbG
6YYF	;	1.93	;	Crystal Structure of 5-chloroindoline-2,3-dione covalently bound to the PH domain of Bruton's tyrosine kinase mutant R28C
4FPI	;	2.2	;	Crystal Structure of 5-chloromuconolactone isomerase from Rhodococcus opacus 1CP
6ZRZ	;	1.696	;	Crystal structure of 5-dimethylallyl tryptophan synthase from Streptomyces coelicolor in complex with DMASPP and Trp
6ZS0	;	1.5	;	Crystal structure of 5-dimethylallyltryptophan synthase from Streptomyces coelicolor
5XWB	;	2.2	;	Crystal Structure of 5-Enolpyruvulshikimate-3-phosphate Synthase from a Psychrophilic Bacterium, Colwellia psychrerythraea
3M00	;	2.1	;	Crystal Structure of 5-epi-aristolochene synthase M4 mutant complexed with (2-cis,6-trans)-2-fluorofarnesyl diphosphate
1DL8	;	1.55	;	CRYSTAL STRUCTURE OF 5-F-9-AMINO-(N-(2-DIMETHYLAMINO)ETHYL)ACRIDINE-4-CARBOXAMIDE BOUND TO D(CGTACG)2
4OM8	;	1.55	;	Crystal structure of 5-formly-3-hydroxy-2-methylpyridine 4-carboxylic acid (FHMPC) 5-dehydrogenase, an NAD+ dependent dismutase.
5ZAS	;	1.56	;	Crystal structure of 5-formylcytosine containing decamer dsDNA
5V54	;	3.9	;	Crystal structure of 5-HT1B receptor in complex with methiothepin
7C61	;	3.0	;	Crystal structure of 5-HT1B-BRIL and SRP2070_Fab complex
8JT8	;	2.7	;	Crystal structure of 5-HT2AR in complex with (R)-IHCH-7179
7VOE	;	2.9	;	Crystal structure of 5-HT2AR in complex with aripiprazole
7VOD	;	3.3	;	Crystal structure of 5-HT2AR in complex with cariprazine
6A93	;	3.0	;	Crystal structure of 5-HT2AR in complex with risperidone
6A94	;	2.9	;	Crystal structure of 5-HT2AR in complex with zotepine
6BQG	;	3.0	;	Crystal structure of 5-HT2C in complex with ergotamine
6BQH	;	2.7	;	Crystal structure of 5-HT2C in complex with ritanserin
6JV3	;	2.851	;	Crystal structure of 5-hydoxylmethylcytosine containing decamer dsDNA
4F3U	;	1.401	;	Crystal structure of 5-hydroxy-2'-deoxycytidine base paired with 2'-deoxyguanosine in Dickerson Drew Dodecamer
2H1X	;	1.98	;	Crystal structure of 5-hydroxyisourate Hydrolase (formerly known as TRP, Transthyretin Related Protein)
2H6U	;	1.7	;	Crystal structure of 5-hydroxyisourate hydrolase (formerly known as TRP, transthyretin related protein)
4Q14	;	1.7	;	Crystal structure of 5-hydroxyisourate hydrolase from Brucella melitensis
4UDP	;	1.9	;	Crystal structure of 5-hydroxymethylfurfural oxidase (HMFO) in the oxidized state
4UDQ	;	1.6	;	Crystal structure of 5-hydroxymethylfurfural oxidase (HMFO) in the reduced state
1XRU	;	1.94	;	Crystal Structure of 5-keto-4-deoxyuronate Isomerase from Eschericia coli
7COL	;	1.95	;	Crystal structure of 5-ketofructose reductase complexed with NADPH
6JV5	;	1.401	;	Crystal structure of 5-methylcytosine containing decamer dsDNA
4R88	;	1.952	;	Crystal structure of 5-methylcytosine deaminase from Klebsiella pneumoniae liganded with 5-fluorocytosine
4R85	;	1.802	;	Crystal structure of 5-methylcytosine deaminase from Klebsiella pneumoniae liganded with 5-methylcytosine
4R7W	;	1.902	;	Crystal structure of 5-methylcytosine deaminase from Klebsiella pneumoniae liganded with phosphonocytosine
2YRF	;	2.7	;	Crystal structure of 5-methylthioribose 1-phosphate isomerase from Bacillus subtilis complexed with sulfate ion
6A34	;	2.3	;	Crystal structure of 5-methylthioribose 1-phosphate isomerase from Pyrococcus horikoshii OT3 - Form I
6A35	;	2.65	;	Crystal structure of 5-methylthioribose 1-phosphate isomerase from Pyrococcus horikoshii OT3 - Form II
2YVK	;	2.4	;	Crystal structure of 5-methylthioribose 1-phosphate isomerase product complex from Bacillus subtilis
2OLC	;	2.0	;	Crystal structure of 5-methylthioribose kinase in complex with ADP-2Ho
4RY8	;	1.75	;	Crystal structure of 5-methylthioribose transporter solute binding protein TLET_1677 from Thermotoga lettingae TMO TARGET EFI-511109 in complex with 5-methylthioribose
3RSR	;	2.3	;	Crystal Structure of 5-NITP Inhibition of Yeast Ribonucleotide Reductase
7N38	;	1.22	;	Crystal structure of 5-site deamidated variant of human gamma(S)-crystallin
3HG8	;	1.38	;	Crystal Structure of 5-SMe Derivatized DNA
1ZG9	;	2.0	;	Crystal Structure of 5-{[amino(imino)methyl]amino}-2-(sulfanylmethyl)pentanoic acid Bound to Activated Porcine Pancreatic Carboxypeptidase B
2QIH	;	1.897	;	Crystal structure of 527-665 fragment of UspA1 protein from Moraxella catarrhalis
8U4U	;	3.79	;	Crystal structure of 53BP1 tandem Tudor domain homodimer engineered with two disulfide bridges
2G3R	;	1.25	;	Crystal Structure of 53BP1 tandem tudor domains at 1.2 A resolution
4CRI	;	2.35	;	Crystal Structure of 53BP1 tandem tudor domains in complex with methylated K810 Rb peptide
6IVZ	;	2.4	;	Crystal structure of 5A ScFv complexed with YFV-China sE in postfusion state
6IW0	;	3.6	;	Crystal structure of 5A ScFv in complex with YFV-17D sE in postfusion state
6IW2	;	2.9	;	Crystal structure of 5A ScFv in complex with YFV-17D sE in prefusion state
3UZW	;	1.892	;	Crystal structure of 5beta-reductase (AKR1D1) E120H mutant in complex with NADP+
3UZY	;	1.832	;	Crystal structure of 5beta-reductase (AKR1D1) E120H mutant in complex with NADP+ and 5beta-dihydrotestosterone
3UZZ	;	1.82	;	Crystal structure of 5beta-reductase (AKR1D1) E120H mutant in complex with NADP+ and delta4-androstenedione
3UZX	;	1.637	;	Crystal structure of 5beta-reductase (AKR1D1) E120H mutant in complex with NADP+ and epiandrosterone
3CAS	;	2.0	;	Crystal structure of 5beta-reductase (AKR1D1) in complex with NADP+ and 4-androstenedione
3DOP	;	2.0	;	Crystal structure of 5beta-reductase (AKR1D1) in complex with NADP+ and 5beta-dihydrotestosterone, Resolution 2.00A
3CAV	;	1.9	;	Crystal structure of 5beta-reductase (AKR1D1) in complex with NADP+ and 5beta-pregnan-3,20-dione
3CAQ	;	2.2	;	Crystal structure of 5beta-reductase (AKR1D1) in complex with NADPH
5W24	;	1.5	;	Crystal Structure of 5C4 Fab
5NIV	;	1.498	;	Crystal structure of 5D3 Fab
3A5E	;	1.6	;	Crystal structure of 5K RNase Sa
3VWM	;	1.6	;	Crystal structure of 6-aminohexanoate-dimer hydrolase G181D/R187A/H266N/D370Y mutant
3VWN	;	1.2	;	Crystal structure of 6-aminohexanoate-dimer hydrolase G181D/R187G/H266N/D370Y mutant
3VWL	;	1.6	;	Crystal structure of 6-aminohexanoate-dimer hydrolase G181D/R187S/H266N/D370Y mutant
2DCF	;	1.4	;	Crystal structure of 6-aminohexanoate-dimer hydrolase S112A/G181D/H266N mutant with substrate
3A65	;	1.7	;	Crystal structure of 6-aminohexanoate-dimer hydrolase S112A/G181D/H266N mutant with substrate
2ZMA	;	1.51	;	Crystal Structure of 6-Aminohexanoate-dimer Hydrolase S112A/G181D/H266N/D370Y Mutant with Substrate
3A66	;	1.6	;	Crystal structure of 6-aminohexanoate-dimer hydrolase S112A/G181D/H266N/D370Y mutant with substrate
3VWR	;	1.65	;	Crystal structure of 6-aminohexanoate-dimer hydrolase S112A/G181D/R187G/H266N/D370Y mutant complexd with 6-aminohexanoate
3VWP	;	1.55	;	Crystal structure of 6-aminohexanoate-dimer hydrolase S112A/G181D/R187S/H266N/D370Y mutant complexd with 6-aminohexanoate
6ZRX	;	1.7	;	Crystal structure of 6-dimethylallyltryptophan synthase from Micromonospora olivasterospora in complex with DMASPP and Trp
3VPK	;	1.94	;	Crystal Structure of 6-Guanidinohexanoyl Trypsin
2BVG	;	3.18	;	Crystal structure of 6-hydoxy-D-nicotine oxidase from Arthrobacter nicotinovorans. Crystal Form 1 (P21)
2BVH	;	2.9	;	Crystal structure of 6-hydoxy-D-nicotine oxidase from Arthrobacter nicotinovorans. Crystal Form 2 (P21)
2BVF	;	1.92	;	Crystal structure of 6-hydoxy-D-nicotine oxidase from Arthrobacter nicotinovorans. Crystal Form 3 (P1)
3K7M	;	1.95	;	Crystal structure of 6-hydroxy-L-nicotine oxidase from Arthrobacter nicotinovorans
1EX8	;	1.85	;	CRYSTAL STRUCTURE OF 6-HYDROXYMETHYL-7,8-DIHYDROPTERIN PYROPHOSPHOKINASE COMPLEXED WITH HP4A, THE TWO-SUBSTRATE-MIMICKING INHIBITOR
5EOW	;	2.1	;	Crystal Structure of 6-Hydroxynicotinic Acid 3-Monooxygenase from Pseudomonas putida KT2440
3QOM	;	1.498	;	Crystal structure of 6-phospho-beta-glucosidase from Lactobacillus plantarum
4GZE	;	2.31	;	Crystal structure of 6-phospho-beta-glucosidase from Lactobacillus plantarum (apo form)
4GWK	;	1.534	;	Crystal structure of 6-phosphogluconate dehydrogenase complexed with 3-phosphoglyceric acid
8I4Q	;	1.9	;	Crystal structure of 6-phosphogluconate dehydrogenase from Corynebacterium glutamicum
5UQ9	;	3.0	;	Crystal structure of 6-phosphogluconate dehydrogenase with ((4R,5R)-5-(hydroxycarbamoyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl dihydrogen phosphate
1VL1	;	1.55	;	Crystal structure of 6-phosphogluconolactonase (TM1154) from Thermotoga maritima at 1.70A resolution
3CH7	;	2.29	;	Crystal structure of 6-phosphogluconolactonase from Leishmania braziliensis
3CSS	;	1.7	;	Crystal structure of 6-phosphogluconolactonase from Leishmania guyanensis
4TM8	;	1.81	;	Crystal structure of 6-phosphogluconolactonase from Mycobacterium smegmatis N131D mutant
4TM7	;	1.39	;	Crystal structure of 6-phosphogluconolactonase from Mycobacterium smegmatis N131D mutant soaked with CuSO4
3OC6	;	2.1	;	Crystal structure of 6-phosphogluconolactonase from mycobacterium smegmatis, apo form
3ICO	;	2.15	;	Crystal structure of 6-phosphogluconolactonase from Mycobacterium tuberculosis
3E7F	;	2.2	;	Crystal structure of 6-phosphogluconolactonase from Trypanosoma brucei complexed with 6-phosphogluconic acid
3EB9	;	2.0	;	Crystal structure of 6-phosphogluconolactonase from trypanosoma brucei complexed with citrate
2DJ6	;	2.1	;	Crystal structure of 6-pyruvoyl tetrahydrobiopterin synthase from Pyrococcus horikoshii OT3
2DTT	;	2.2	;	Crystal structure of 6-pyruvoyl tetrahydrobiopterin synthase from Pyrococcus horikoshii OT3 complexed with (1'R,2'S)-biopterin
2A0S	;	2.2	;	Crystal structure of 6-pyruvoyl tetrahydropterin synthase (PTPS) from Plasmodium vivax at 2.2 A resolution
5J36	;	2.55	;	Crystal structure of 60-mer BFDV Capsid Protein
5J37	;	2.3	;	Crystal structure of 60-mer BFDV Capsid Protein in complex with single stranded DNA
3PQY	;	3.192	;	Crystal Structure of 6218 TCR in complex with the H2Db-PA224
5BK0	;	3.15	;	Crystal structure of 663 Fab bound to circumsporozoite protein NANP 5-mer
5JPJ	;	2.0	;	Crystal structure of 6aJL2-R24G
4Y0U	;	2.6	;	Crystal Structure of 6Alpha-Hydroxymethylpenicillanate Complexed with OXA-58, a Carbapenem hydrolyzing Class D betalactamase from Acinetobacter baumanii.
4HXB	;	2.45	;	Crystal structure of 6B9 FAB
7XJF	;	2.6	;	Crystal structure of 6MW3211 Fab in complex with CD47
3OGP	;	1.7	;	Crystal Structure of 6s-98S FIV Protease with Darunavir bound
3OGQ	;	1.8	;	Crystal Structure of 6s-98S FIV Protease with Lopinavir bound
6WAE	;	2.13	;	Crystal Structure of 6X-His tagged SmcR
8ANT	;	1.9	;	Crystal structure of 6xhis-tagged phi3T_93 protein
4QKS	;	1.7	;	Crystal Structure of 6xTrp/PV2: de novo designed beta-trefoil architecture with symmetric primary structure (L22W/L44W/L64W/L85W/L108W/L132W his Primitive Version 2)
4QKR	;	1.746	;	Crystal Structure of 6xTyr/PV2: de novo designed beta-trefoil architecture with symmetric primary structure (L22Y/L44Y/L64Y/L85Y/L108Y/L132Y, Primitive Version 2)
3DRD	;	2.17	;	Crystal Structure of 7,8 Diaminopelargonic Acid Synthase Apoenzyme in Bacillus subtilis
1QJ5	;	1.8	;	Crystal structure of 7,8-diaminopelargonic acid synthase
4WYE	;	1.75	;	Crystal structure of 7,8-diaminopelargonic acid synthase (BioA) from Mycobacterium tuberculosis complexed with a DSF fragment hit
4WYG	;	1.62	;	Crystal structure of 7,8-diaminopelargonic acid synthase (BioA) from Mycobacterium tuberculosis complexed with a fragment hit
4W1X	;	1.8	;	Crystal structure of 7,8-diaminopelargonic acid synthase (BioA) from Mycobacterium tuberculosis, complexed with 1-(4-(4-(3-chlorobenzoyl)piperazin-1-yl)phenyl)ethanone
4W1W	;	1.9	;	Crystal structure of 7,8-diaminopelargonic acid synthase (BioA) from Mycobacterium tuberculosis, complexed with 7-(diethylamino)-3-(thiophene-2-carbonyl)-2H-chromen-2-one
4WYF	;	2.25	;	Crystal structure of 7,8-diaminopelargonic acid synthase (BioA) from Mycobacterium tuberculosis, complexed with a DSF fragment hit
4WYA	;	2.5	;	Crystal structure of 7,8-diaminopelargonic acid synthase (BioA) from Mycobacterium tuberculosis, complexed with a fragment hit
4XEW	;	2.47	;	Crystal structure of 7,8-diaminopelargonic acid synthase (BioA) from Mycobacterium tuberculosis, complexed with a HTS lead compound
4XJL	;	1.85	;	Crystal structure of 7,8-diaminopelargonic acid synthase (BioA) from Mycobacterium tuberculosis, complexed with a HTS lead compound
4XJM	;	1.6	;	Crystal structure of 7,8-diaminopelargonic acid synthase (BioA) from Mycobacterium tuberculosis, complexed with a HTS lead compound
5TE2	;	1.8	;	Crystal structure of 7,8-diaminopelargonic acid synthase (BioA) from Mycobacterium tuberculosis, complexed with a mechanism-based inhibitor
4WYC	;	1.7	;	Crystal structure of 7,8-diaminopelargonic acid synthase (BioA) from Mycobacterium tuberculosis, complexed with a thiazole benzamide inhibitor
4W1V	;	2.24	;	Crystal structure of 7,8-diaminopelargonic acid synthase (BioA) from Mycobacterium tuberculosis, complexed with a thiazole inhibitor
4XJO	;	1.5	;	Crystal structure of 7,8-diaminopelargonic acid synthase (BioA) from Mycobacterium tuberculosis, complexed with an inhibitor optimized from HTS lead
4XJP	;	1.6	;	Crystal structure of 7,8-diaminopelargonic acid synthase (BioA) from Mycobacterium tuberculosis, complexed with an inhibitor optimized from HTS lead
5KGT	;	2.25	;	Crystal structure of 7,8-diaminopelargonic acid synthase (BioA) from Mycobacterium tuberculosis, complexed with an inhibitor optimized from HTS lead: 1-[4-[4-(3-chlorophenyl)carbonylpiperidin-1-yl]phenyl]ethanone
5KGS	;	2.1	;	Crystal structure of 7,8-diaminopelargonic acid synthase (BioA) from Mycobacterium tuberculosis, complexed with an inhibitor optimized from HTS lead: 5-[4-(1,3-benzodioxol-5-ylcarbonyl)piperazin-1-yl]-2,3-dihydroinden-1-one
3TFU	;	1.94	;	Crystal structure of 7,8-diaminopelargonic acid synthase (BioA) from Mycobacterium tuberculosis, post-reaction complex with a 3,6-dihydropyrid-2-one heterocycle inhibitor
3TFT	;	1.95	;	Crystal structure of 7,8-diaminopelargonic acid synthase (BioA) from Mycobacterium tuberculosis, pre-reaction complex with a 3,6-dihydropyrid-2-one heterocycle inhibitor
6ED7	;	2.43	;	Crystal structure of 7,8-diaminopelargonic acid synthase bound to inhibitor MAC13772
1QJ3	;	2.7	;	Crystal structure of 7,8-diaminopelargonic acid synthase in complex with 7-keto-8-aminopelargonic acid
1MLY	;	1.81	;	Crystal Structure of 7,8-Diaminopelargonic Acid Synthase in complex with the cis isomer of amiclenomycin
1MLZ	;	2.15	;	Crystal Structure of 7,8-Diaminopelargonic Acid Synthase in complex with the trans-isomer of amiclenomycin.
1SQL	;	2.2	;	Crystal structure of 7,8-dihydroneopterin aldolase in complex with guanine
7D1X	;	2.5	;	Crystal structure of 7-alpha-hydroxyl bile acid sulfotransferase (Sult2a8)
1UNM	;	2.0	;	Crystal structure of 7-Aminoactinomycin D with non-complementary DNA
3RJ4	;	1.75	;	Crystal Structure of 7-cyano-7-deazaguanine Reductase, QueF from Vibrio cholerae
3UXV	;	1.56	;	Crystal Structure of 7-cyano-7-deazaguanine reductase, QueF from Vibrio cholerae complexed with NADP and PreQ
3UXJ	;	1.401	;	Crystal Structure of 7-cyano-7-deazaguanine reductase, QueF from Vibrio cholerae complexed with NADP and PreQ0
4IQI	;	1.5	;	Crystal Structure of 7-cyano-7-deazaguanine Reductase, QueF from Vibrio cholerae O1 biovar El Tor complexed with cytosine
3DU4	;	2.2	;	Crystal structure of 7-keto-8-aminopelargonic acid bound 7,8-diaminopelargonic acid synthase in bacillus subtilis
7N39	;	1.56	;	Crystal structure of 7-site deamidated variant of human gamma(S)-crystallin
4V8U	;	3.7	;	Crystal Structure of 70S Ribosome with Both Cognate tRNAs in the E and P Sites Representing an Authentic Elongation Complex.
4V4P	;	5.5	;	Crystal structure of 70S ribosome with thrS operator and tRNAs.
6LCS	;	2.6	;	Crystal structure of 73MuL9 Fv-clasp fragment in complex with GA-pyridine analogue
7ST8	;	2.75	;	Crystal structure of 7H2.2 Fab in complex with SAS1B C-terminal region
1SGF	;	3.15	;	CRYSTAL STRUCTURE OF 7S NGF: A COMPLEX OF NERVE GROWTH FACTOR WITH FOUR BINDING PROTEINS (SERINE PROTEINASES)
1Z43	;	2.6	;	Crystal structure of 7S.S SRP RNA of M. jannaschii
1DJ9	;	2.0	;	CRYSTAL STRUCTURE OF 8-AMINO-7-OXONANOATE SYNTHASE (OR 7-KETO-8AMINIPELARGONATE OR KAPA SYNTHASE) COMPLEXED WITH PLP AND THE PRODUCT 8(S)-AMINO-7-OXONANONOATE (OR KAPA). THE ENZYME OF BIOTIN BIOSYNTHETIC PATHWAY.
4IW7	;	2.25	;	Crystal structure of 8-amino-7-oxononanoate synthase (bioF) from Francisella tularensis.
6ONN	;	1.8	;	Crystal structure of 8-amino-7-oxononanoate synthase from Burkholderia phymatum
6PET	;	2.203	;	Crystal structure of 8-hydroxychromene compound 30 bound to estrogen receptor alpha
6IRL	;	2.1	;	Crystal structure of 8-mer peptide from avian influenza H5N1 virus in complex with BF2*1501
6KX9	;	2.902	;	Crystal structure of 8-mer peptide from avian influenza H5N1 virus in complex with BF2*1501
5YMW	;	1.997	;	Crystal structure of 8-mer peptide from Rous sarcoma virus in complex with BF2*1201
1XQP	;	1.69	;	Crystal structure of 8-oxoguanosine complexed Pa-AGOG, 8-oxoguanine DNA glycosylase from Pyrobaculum aerophilum
3RDT	;	2.7	;	Crystal Structure of 809.B5 TCR complexed with MHC Class II I-Ab/3k peptide
4YWG	;	2.998	;	Crystal structure of 830A in complex with V1V2
4P9M	;	2.13	;	Crystal structure of 8ANC195 Fab
5CJX	;	3.584	;	Crystal structure of 8ANC195 Fab in complex with BG505 SOSIP.664 HIV-1 Env trimer
4P9H	;	3.0	;	Crystal structure of 8ANC195 Fab in complex with gp120 of 93TH057 HIV-1 and soluble CD4 D1D2
3MBS	;	1.27	;	Crystal structure of 8mer PNA
7CNY	;	2.12	;	Crystal structure of 8PE bound PSD from E. coli (2.12 A)
2CV6	;	2.65	;	Crystal Structure of 8Salpha Globulin, the Major Seed Storage Protein of Mungbean
4LXO	;	1.42	;	Crystal structure of 9,10Fn3-elegantin chimera
1FN1	;	1.6	;	CRYSTAL STRUCTURE OF 9-AMINO-(N-(2-DIMETHYLAMINO)BUTYL)ACRIDINE-4-CARBOXAMIDE BOUND TO D(CG(5BR)UACG)2
1KCI	;	1.8	;	Crystal Structure of 9-amino-N-[2-(4-morpholinyl)ethyl]-4-acridinecarboxamide Bound to d(CGTACG)2
5YMV	;	2.197	;	Crystal structure of 9-mer peptide from influenza virus in complex with BF2*1201
7N3A	;	1.5	;	Crystal structure of 9-site deamidated variant of human gamma(S)-crystallin
4LFH	;	2.3	;	Crystal Structure of 9C2 TCR
4LHU	;	2.87	;	Crystal Structure of 9C2 TCR bound to CD1d
5CKK	;	2.801	;	Crystal structure of 9DB1* deoxyribozyme
5CKI	;	2.985	;	Crystal structure of 9DB1* deoxyribozyme (Cobalt hexammine soaked crystals)
4GH8	;	1.85	;	Crystal structure of a 'humanized' E. coli dihydrofolate reductase
1MXG	;	1.6	;	Crystal Structure of a (Ca,Zn)-dependent alpha-amylase from the hyperthermophilic archaeon Pyrococcus woesei in complex with acarbose
7SMG	;	2.3	;	Crystal structure of a (p)ppApp hydrolase from Bacteroides caccae
6ECL	;	2.385	;	Crystal Structure of a 1,2,4-Triazole Allosteric RNase H Inhibitor in Complex with HIV Reverse Transcriptase
3EDC	;	2.1	;	Crystal Structure of a 1.6-hexanediol Bound Tetrameric Form of Escherichia coli Lac-repressor Refined to 2.1 Resolution
433D	;	2.1	;	CRYSTAL STRUCTURE OF A 14 BASE PAIR RNA DUPLEX WITH NONSYMMETRICAL TANDEM G.U WOBBLE BASE PAIRS
3EFZ	;	2.08	;	Crystal Structure of a 14-3-3 protein from cryptosporidium parvum (cgd1_2980)
1FUF	;	1.7	;	CRYSTAL STRUCTURE OF A 14BP RNA OLIGONUCLEOTIDE CONTAINING DOUBLE UU BULGES: A NOVEL INTRAMOLECULAR U*(AU) BASE TRIPLE
1IK5	;	1.8	;	Crystal Structure of a 14mer RNA Containing Double UU Bulges in Two Crystal Forms: A Novel U*(AU) Intramolecular Base Triple
2QLA	;	2.9	;	Crystal Structure of a 16-Helix Bundle Architecture Produced by the Zinc-Mediated Self Assembly of Four Cytochrome cb562 Molecules
420D	;	1.9	;	CRYSTAL STRUCTURE OF A 16-MER RNA DUPLEX WITH NON-ADJACENT A(ANTI).G(SYN) MISMATCHES
3QWI	;	2.5	;	Crystal structure of a 17beta-hydroxysteroid dehydrogenase (holo form) from fungus Cochliobolus lunatus in complex with NADPH and coumestrol
1QC0	;	1.55	;	CRYSTAL STRUCTURE OF A 19 BASE PAIR COPY CONTROL RELATED RNA DUPLEX
5NL0	;	5.4	;	Crystal structure of a 197-bp palindromic 601L nucleosome in complex with linker histone H1
5W21	;	3.0	;	Crystal Structure of a 1:1:1 FGF23-FGFR1c-aKlotho Ternary Complex
3S7C	;	1.1	;	Crystal structure of a 2'-azido-uridine-modified RNA
6AMY	;	2.85	;	Crystal structure of a 2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-succinyltransferase from Acinetobacter baumannii
3S8U	;	1.2	;	Crystal structure of a 2-azido-adenine-modified RNA
3TMQ	;	2.1	;	Crystal structure of a 2-dehydro-3-deoxyphosphooctonate aldolase from Burkholderia pseudomallei in complex with D-arabinose-5-phosphate
6MDY	;	2.55	;	Crystal structure of a 2-dehydro-3-deoxyphosphooctonate aldolase from Legionella pneumophila Philadelphia 1
3VPL	;	1.2	;	Crystal structure of a 2-fluoroxylotriosyl complex of the Vibrio sp. AX-4 Beta-1,3-xylanase
4DLL	;	2.11	;	Crystal structure of a 2-hydroxy-3-oxopropionate reductase from Polaromonas sp. JS666
5UV5	;	3.0	;	Crystal Structure of a 2-Hydroxyisoquinoline-1,3-dione RNase H Active Site Inhibitor with Multiple Binding Modes to HIV Reverse Transcriptase
3EEG	;	2.78	;	Crystal structure of a 2-isopropylmalate synthase from Cytophaga hutchinsonii
3LZG	;	2.6	;	Crystal structure of a 2009 H1N1 influenza virus hemagglutinin
4M4Y	;	2.2	;	Crystal structure of a 2009 H1N1 influenza virus hemagglutinin with a stabilization mutation HA2 E47G
6JF2	;	2.0	;	Crystal structure of a 20kDa fragment of FlgG
2D4X	;	1.9	;	Crystal structure of a 26K fragment of HAP3 (FlgL)
4DI3	;	3.05	;	Crystal structure of a 2:1 complex of Treponema pallidum TatP(T) (Tp0957) bound to TatT (Tp0956)
1VH8	;	2.35	;	Crystal structure of a 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase
7O62	;	2.4	;	Crystal structure of a 2`-deoxyribosyltransferase from the psychrophilic bacterium Desulfotalea psychrophila.
2R64	;	2.3	;	Crystal structure of a 3-aminoindazole compound with CDK2
4K7G	;	2.0	;	Crystal structure of a 3-hydroxyproline dehydratse from agrobacterium vitis, target efi-506470, with bound pyrrole 2-carboxylate, ordered active site
4IWH	;	1.75	;	Crystal structure of a 3-isopropylmalate dehydrogenase from Burkholderia pseudomallei
3V8B	;	2.7	;	Crystal Structure of a 3-ketoacyl-ACP reductase from Sinorhizobium meliloti 1021
2JG6	;	1.7	;	CRYSTAL STRUCTURE OF A 3-METHYLADENINE DNA GLYCOSYLASE I FROM STAPHYLOCOCCUS AUREUS
5VP5	;	1.8	;	Crystal structure of a 3-oxoacyl-acyl-carrier protein reductase FabG4 from Mycobacterium smegmatis bound to NAD
4O6V	;	1.85	;	Crystal Structure of a 3-oxoacyl-[acyl-carrier protein] reductase (EC 1.1.1.100) from Brucella suis
4ONE	;	1.65	;	Crystal Structure of a 3-oxoacyl-[acyl-carrier protein] reductase from Brucella melitensis
5TS3	;	1.55	;	Crystal Structure of a 3-oxoacyl-[acyl-carrier protein] Reductase with bound NAD from Brucella melitensis
3E4Y	;	2.6	;	Crystal structure of a 33kDa catalase-related protein from Mycobacterium avium subsp. paratuberculosis. I2(1)2(1)2(1) crystal form
3E4W	;	1.8	;	Crystal structure of a 33kDa catalase-related protein from Mycobacterium avium subsp. paratuberculosis. P2(1)2(1)2(1) crystal form.
4DI4	;	2.714	;	Crystal structure of a 3:1 complex of Treponema pallidum TatP(T) (Tp0957) bound to TatT (Tp0956)
4IS3	;	2.0	;	Crystal structure of a 3alpha-hydroxysteroid dehydrogenase (BaiA2) associated with secondary bile acid synthesis from Clostridium scindens VPI12708 in complex with a putative NAD(+)-OH- adduct at 2.0 A resolution
3JUY	;	2.5	;	Crystal Structure of a 3B3 Variant, a Broadly Neutralizing HIV-1 scFv Antibody
1A2W	;	2.1	;	CRYSTAL STRUCTURE OF A 3D DOMAIN-SWAPPED DIMER OF BOVINE PANCREATIC RIBONUCLEASE A
2HJ1	;	2.1	;	Crystal structure of a 3D domain-swapped dimer of protein HI0395 from Haemophilus influenzae
4FFC	;	1.8	;	Crystal structure of a 4-aminobutyrate aminotransferase (GabT) from Mycobacterium abscessus
4G9Q	;	1.77	;	Crystal structure of a 4-carboxymuconolactone decarboxylase
6MFX	;	2.2	;	Crystal structure of a 4-domain construct of a mutant of LgrA in the substrate donation state
6MFW	;	2.5	;	Crystal structure of a 4-domain construct of LgrA in the substrate donation state
4Q60	;	2.1	;	Crystal structure of a 4-hydroxyproline epimerase from Burkholderia Multivorans atcc 17616, target EFI-506586, open form, with bound pyrrole-2-carboxylate
4K7X	;	1.75	;	Crystal structure of a 4-hydroxyproline epimerase from burkholderia multivorans, target efi-506479, with bound phosphate, closed domains
4NV1	;	2.1	;	Crystal structure of a 4-N formyltransferase from Francisella tularensis
3ABF	;	1.94	;	Crystal Structure of a 4-Oxalocrotonate Tautomerase Homologue (TTHB242)
5CLN	;	2.71	;	Crystal structure of a 4-oxalocrotonate tautomerase mutant at 2.7 Angstrom
5CLO	;	2.3	;	Crystal structure of a 4-oxalocrotonate tautomerase mutant in complex with nitrostyrene at 2.3 Angstrom
4KR6	;	2.85	;	Crystal structure of a 4-thiouridine synthetase - RNA complex
4KR9	;	3.5	;	Crystal structure of a 4-thiouridine synthetase - RNA complex at 3.5 Angstrom resolution
4KR7	;	3.421	;	Crystal structure of a 4-thiouridine synthetase - RNA complex with bound ATP
2ESC	;	2.1	;	Crystal structure of a 40 KDa protective signalling protein from Bovine (SPC-40) at 2.1 A resolution
1OWQ	;	2.0	;	Crystal structure of a 40 kDa signalling protein (SPC-40) secreted during involution
1XHG	;	2.9	;	Crystal structure of a 40 kDa signalling protein from Porcine (SPP-40) at 2.89A resolution
2D4Y	;	2.1	;	Crystal structure of a 49K fragment of HAP1 (FlgK)
5DK6	;	2.27	;	CRYSTAL STRUCTURE OF A 5'-METHYLTHIOADENOSINE/S-ADENOSYLHOMOCYSTEINE (MTA/SAH) NUCLEOSIDASE (MTAN) FROM COLWELLIA PSYCHRERYTHRAEA 34H (CPS_4743, TARGET PSI-029300) IN COMPLEX WITH ADENINE AT 2.27 A RESOLUTION
4JCU	;	2.4	;	Crystal structure of a 5-carboxymethyl-2-hydroxymuconate isomerase from Deinococcus radiodurans R1
6MFY	;	2.5	;	Crystal structure of a 5-domain construct of LgrA in the substrate donation state
6MG0	;	6.0	;	Crystal structure of a 5-domain construct of LgrA in the thiolation state
1WKC	;	1.7	;	Crystal structure of a 5-formyltetrahydrofolate cycloligase-related protein from Thermus thermophilus HB8
3PL2	;	1.89	;	Crystal structure of a 5-keto-2-deoxygluconokinase (NCgl0155, Cgl0158) from Corynebacterium glutamicum ATCC 13032 KITASATO at 1.89 A resolution
5J26	;	2.5047	;	Crystal structure of a 53BP1 Tudor domain in complex with a ubiquitin variant
2INR	;	2.8	;	Crystal structure of a 59 kDa fragment of topoisomerase IV subunit A (GrlA) from Staphylococcus aureus
5TUQ	;	2.705	;	Crystal Structure of a 6-Cyclohexylmethyl-3-hydroxypyrimidine-2,4-dione Inhibitor in Complex with HIV Reverse Transcriptase
3R47	;	2.5002	;	Crystal structure of a 6-helix coiled coil CC-hex-H24
4KVU	;	1.8	;	Crystal structure of a 6-helix coiled coil CC-Hex-L17C-W224BF
4KVT	;	1.6	;	Crystal structure of a 6-helix coiled coil CC-Hex-L24C
7M1R	;	1.98	;	Crystal structure of a 6-phospho-beta-galactosidase from Bacillus licheniformis
6WGD	;	2.2	;	Crystal structure of a 6-phospho-beta-glucosidase from Bacillus licheniformis
3NWP	;	1.4	;	Crystal structure of a 6-phosphogluconolactonase (Sbal_2240) from Shewanella baltica OS155 at 1.40 A resolution
3QN9	;	2.93	;	Crystal structure of a 6-pyruvoyltetrahydropterin synthase homologue from Esherichia coli
3QNA	;	2.5	;	Crystal structure of a 6-pyruvoyltetrahydropterin synthase homologue from Esherichia coli complexed sepiapterin
3UGF	;	1.7	;	Crystal structure of a 6-SST/6-SFT from Pachysandra terminalis
3UGG	;	2.9	;	Crystal structure of a 6-SST/6-SFT from Pachysandra terminalis in complex with 1-kestose
3UGH	;	2.9	;	Crystal structure of a 6-SST/6-SFT from Pachysandra terminalis in complex with 6-kestose
1UNJ	;	2.5	;	Crystal structure of a 7-Aminoactinomycin D complex with non-complementary DNA
3S25	;	1.88	;	Crystal structure of a 7-bladed beta-propeller-like protein (EUBREC_1955) from Eubacterium rectale ATCC 33656 at 1.88 A resolution
4V4I	;	3.71	;	Crystal Structure of a 70S Ribosome-tRNA Complex Reveals Functional Interactions and Rearrangements.
5AZ4	;	2.45	;	Crystal structure of a 79KDa fragment of FlgE, the hook protein from Campylobacter jejuni
7S5M	;	2.25	;	Crystal Structure of a 8-amino-7-oxononanoate synthase/2-amino-3-ketobutyrate coenzyme A ligase from Mycobacterium smegmatis
5EK8	;	2.7	;	Crystal structure of a 9R-lipoxygenase from Cyanothece PCC8801 at 2.7 Angstroms
2PGC	;	2.53	;	Crystal structure of a a marine metagenome protein (jcvi_pep_1096685590403) from uncultured marine organism at 2.53 A resolution
3SBT	;	1.799	;	Crystal structure of a Aar2-Prp8 complex
4ONY	;	2.1	;	Crystal structure of a ABC transporter, periplasmic substrate-binding protein from Brucella melitensis
4RFP	;	1.6	;	Crystal structure of a acidic PLA2 from Trimeresurus stejnegeri venom
4TLP	;	1.9	;	Crystal structure of a alanine91 mutant of WCI
1VHE	;	1.9	;	Crystal structure of a aminopeptidase/glucanase homolog
6A8X	;	2.35	;	Crystal structure of a apo form cyclase from Fischerella sp.
7U0U	;	1.9	;	Crystal Structure of a Aspergillus fumigatus Calcineurin A - Calcineurin B fusion bound to FKBP12 and FK-506
4GRL	;	2.86	;	Crystal structure of a autoimmune TCR-MHC complex
1VGX	;	1.9	;	Crystal structure of a autoinducer-2 synthesis protein
1VH2	;	2.0	;	Crystal structure of a autoinducer-2 synthesis protein
1VJE	;	1.64	;	Crystal structure of a autoinducer-2 synthesis protein with bound selenomethionine
1D77	;	2.4	;	CRYSTAL STRUCTURE OF A B-DNA DODECAMER CONTAINING INOSINE, D(CGCIAATTCGCG), AT 2.4 ANGSTROMS RESOLUTION AND ITS COMPARISON WITH OTHER B-DNA DODECAMERS
1N1O	;	1.2	;	Crystal Structure of a B-form DNA Duplex Containing (L)-alpha-threofuranosyl (3'-2') Nucleosides: A Four-Carbon Sugar is Easily Accommodated into the Backbone of DNA
5CJY	;	1.55	;	Crystal structure of a B-form DNA duplex containing 5-hydroxylmethylcytidine
2FNJ	;	1.8	;	Crystal structure of a B30.2/SPRY domain-containing protein GUSTAVUS in complex with Elongin B and Elongin C
8D78	;	2.12	;	Crystal structure of a Ba stabilized four-tetrad, parallel Tetrahymena thermophila telomeric G-quadruplex in complex with N-methyl mesoporphyrin IX
6HPA	;	1.554	;	Crystal structure of a BA3943 mutant,a CE4 family pseudoenzyme
6HM9	;	1.71311	;	Crystal structure of a BA3943 mutant,a CE4 family pseudoenzyme with restored enzymatic activity.
6GO1	;	2.59	;	Crystal Structure of a Bacillus anthracis peptidoglycan deacetylase
6OWK	;	2.698	;	Crystal structure of a Bacillus thuringiensis Cry1B.867 tryptic core variant
6OVB	;	2.611	;	Crystal structure of a Bacillus thuringiensis Cry1Da tryptic core variant
3H16	;	2.5	;	Crystal structure of a bacteria TIR domain, PdTIR from Paracoccus denitrificans
4TQU	;	3.204	;	Crystal structure of a bacterial ABC transporter involved in the import of the acidic polysaccharide alginate
4TQV	;	4.504	;	Crystal structure of a bacterial ABC transporter involved in the import of the acidic polysaccharide alginate
3ELQ	;	2.0	;	Crystal structure of a bacterial arylsulfate sulfotransferase
3ETS	;	2.4	;	Crystal structure of a bacterial arylsulfate sulfotransferase catalytic intermediate with 4-methylumbelliferone bound in the active site
3ETT	;	2.1	;	Crystal structure of a bacterial arylsulfate sulfotransferase catalytic intermediate with 4-nitrophenol bound in the active site
4WD8	;	2.3	;	Crystal structure of a bacterial Bestrophin homolog from Klebsiella pneumoniae
4WD7	;	2.9	;	Crystal structure of a bacterial Bestrophin homolog from Klebsiella pneumoniae by Zn-SAD phasing
6JLF	;	2.548	;	Crystal structure of a bacterial Bestrophin homolog from Klebsiella pneumoniae D179A mutation - HR
6IVW	;	3.72	;	Crystal structure of a bacterial Bestrophin homolog from Klebsiella pneumoniae with a mutation D269A
6IV0	;	2.9	;	Crystal structure of a bacterial Bestrophin homolog from Klebsiella pneumoniae with a mutation I180A
6IV1	;	3.18	;	Crystal structure of a bacterial Bestrophin homolog from Klebsiella pneumoniae with a mutation I180T
5X87	;	3.14	;	Crystal structure of a bacterial Bestrophin homolog from Klebsiella pneumoniae with a mutation L177T
6IV3	;	2.515	;	Crystal structure of a bacterial Bestrophin homolog from Klebsiella pneumoniae with a mutation W252A
6IV4	;	3.14	;	Crystal structure of a bacterial Bestrophin homolog from Klebsiella pneumoniae with a mutation W252F
6IV2	;	2.62	;	Crystal structure of a bacterial Bestrophin homolog from Klebsiella pneumoniae with a mutation Y211A
5OQT	;	2.86	;	Crystal structure of a bacterial cationic amino acid transporter (CAT) homologue
6F34	;	3.13	;	Crystal structure of a bacterial cationic amino acid transporter (CAT) homologue bound to Arginine.
2ZBI	;	2.0	;	Crystal structure of a bacterial cell-surface flagellin
1CTN	;	2.3	;	CRYSTAL STRUCTURE OF A BACTERIAL CHITINASE AT 2.3 ANGSTROMS RESOLUTION
4U63	;	1.67	;	Crystal structure of a bacterial class III photolyase from Agrobacterium tumefaciens at 1.67A resolution
7R65	;	1.45	;	Crystal structure of a bacterial cyclic UMP synthase from Burkholderia cepacia LK29
5LD5	;	2.1906	;	Crystal structure of a bacterial dehydrogenase at 2.19 Angstroms resolution
4F35	;	3.196	;	Crystal Structure of a bacterial dicarboxylate/sodium symporter
2ETS	;	2.25	;	CRYSTAL STRUCTURE OF A BACTERIAL DOMAIN OF UNKNOWN FUNCTION FROM DUF1798 FAMILY (MW1337) FROM STAPHYLOCOCCUS AUREUS SUBSP. AUREUS AT 2.25 A RESOLUTION
4WSJ	;	1.64	;	Crystal structure of a bacterial fucodiase in complex with 1-((1R,2R,3R,4R,5R,6R)-2,3,4-trihydroxy-5-methyl-7-azabicyclo[4.1.0]heptan-7-yl)ethan-1-one
4JL2	;	1.7	;	Crystal structure of a bacterial fucosidase with a monovalent iminocyclitol inhibitor
4JL1	;	1.68	;	Crystal structure of a bacterial fucosidase with a multivalent iminocyclitol inhibitor
4PCT	;	2.1	;	Crystal structure of a bacterial fucosidase with iminocyclitol (2S,3S,4R,5S)-3,4-dihydroxy-2-ethynyl-5-methylpyrrolidine
5HDR	;	2.3	;	Crystal structure of a bacterial fucosidase with iminocyclitol (2S,3S,4R,5S)-3,4-dihydroxy-2-ethynyl-5-methylpyrrolidine
5I5R	;	2.1	;	Crystal structure of a bacterial fucosidase with iminocyclitol (2S,3S,4R,5S)-3,4-dihydroxy-2-ethynyl-5-methylpyrrolidine
4PCS	;	1.77	;	Crystal structure of a bacterial fucosidase with iminosugar (2S,3S,4R,5S)-3,4-dihydroxy-2-[2'-phenyl]ethynyl-5-methylpyrrolidine
4JFU	;	1.66	;	Crystal structure of a bacterial fucosidase with iminosugar inhibitor
4JFV	;	1.88	;	Crystal structure of a bacterial fucosidase with iminosugar inhibitor (2S,3S,4R,5S)-2-[N-(methylferrocene)]aminoethyl-5-methylpyrrolidine-3,4-diol
4JFW	;	2.1	;	Crystal structure of a bacterial fucosidase with iminosugar inhibitor (2S,3S,4R,5S)-2-[N-(propylferrocene)]aminoethyl-5-methylpyrrolidine-3,4-diol
4JFS	;	2.0	;	Crystal structure of a bacterial fucosidase with iminosugar inhibitor 4-epi-(+)-Codonopsinine
4JFT	;	2.1	;	Crystal structure of a bacterial fucosidase with iminosugar inhibitor N-desmethyl-4-epi-(+)-Codonopsinine
4PEE	;	1.95	;	Crystal structure of a bacterial fucosidase with inhibitor 1-phenyl-4-[(2S,3S,4R,5S)-3,4-dihydroxy-5-methylpyrrolidin-2-yl]triazole
6HZY	;	1.7	;	Crystal structure of a bacterial fucosidase with inhibitor FucPUG
4WSK	;	1.92	;	Crystal structure of a bacterial fucosidase with phenyl((1R,2R,3R,4R,5R,6R)-2,3,4-trihydroxy-5-methyl-7-azabicyclo[4.1.0]heptan-7-yl)methanone
2GDR	;	2.1	;	Crystal structure of a bacterial glutathione transferase
1N2A	;	1.9	;	Crystal Structure of a Bacterial Glutathione Transferase from Escherichia coli with Glutathione Sulfonate in the Active Site
6E8J	;	3.091	;	Crystal Structure of A Bacterial Homolog to Human Lysosomal Transporter, Spinster, in Inward-facing And Occupied Conformation
6EBA	;	3.812	;	Crystal Structure of A Bacterial Homolog to Human Lysosomal Transporter, Spinster, in Inward-facing And Unoccupied Conformation
5AYO	;	3.3	;	Crystal structure of a bacterial homologue of iron transporter ferroportin in inward-facing state
5AYN	;	2.202	;	Crystal structure of a bacterial homologue of iron transporter ferroportin in outward-facing state
5AYM	;	3.0	;	Crystal structure of a bacterial homologue of iron transporter ferroportin in outward-facing state with soaked iron
4RNG	;	2.4	;	Crystal structure of a bacterial homologue of SWEET transporters
3ZUX	;	2.2	;	Crystal structure of a bacterial homologue of the bile acid sodium symporter ASBT.
3ZUY	;	2.2	;	Crystal structure of a bacterial homologue of the bile acid sodium symporter ASBT.
4HU8	;	2.0	;	Crystal Structure of a Bacterial Ig-like Domain Containing GH10 Xylanase from Termite Gut
4KDV	;	2.42	;	Crystal structure of a bacterial immunoglobulin-like domain from the M. primoryensis ice-binding adhesin
4KDW	;	1.35	;	Crystal structure of a bacterial immunoglobulin-like domain from the M. primoryensis ice-binding adhesin
7F28	;	1.877	;	Crystal structure of a bacterial ketosynthase
1QWD	;	1.75	;	CRYSTAL STRUCTURE OF A BACTERIAL LIPOCALIN, THE BLC GENE PRODUCT FROM E. COLI
3GF6	;	1.69	;	Crystal structure of a bacterial lipoprotein (bt_1233) from bacteroides thetaiotaomicron vpi-5482 at 1.69 A resolution
1XBN	;	2.5	;	Crystal structure of a bacterial nitric oxide sensor: an ortholog of mammalian soluble guanylate cyclase heme domain
1MMO	;	2.2	;	CRYSTAL STRUCTURE OF A BACTERIAL NON-HAEM IRON HYDROXYLASE THAT CATALYSES THE BIOLOGICAL OXIDATION OF METHANE
7W54	;	2.64	;	Crystal structure of a bacterial OTU DUB with Ub-PA
3OLP	;	1.95	;	Crystal structure of a bacterial phosphoglucomutase, an enzyme important in the virulence of multiple human pathogens
3NA5	;	1.7	;	Crystal structure of a bacterial phosphoglucomutase, an enzyme important in the virulence of several human pathogens.
5ZNJ	;	1.84	;	Crystal structure of a bacterial ProRS with ligands
5ZNK	;	2.07	;	Crystal structure of a bacterial ProRS with ligands
7QFD	;	2.35	;	Crystal structure of a bacterial pyranose 2-oxidase complex with D-glucose
7QF8	;	2.009	;	Crystal structure of a bacterial pyranose 2-oxidase from Pseudoarthrobacter siccitolerans
7QVA	;	2.6	;	Crystal structure of a bacterial pyranose 2-oxidase in complex with mangiferin
1L3L	;	1.66	;	Crystal structure of a bacterial quorum-sensing transcription factor complexed with pheromone and DNA
4ZHU	;	2.3968	;	Crystal structure of a bacterial repressor protein
3Q1R	;	4.21	;	Crystal structure of a bacterial RNase P holoenzyme in complex with TRNA and in the presence of 5' leader
7VKC	;	1.46	;	Crystal structure of a bacterial Ser/Thr kinase
1KN9	;	2.4	;	CRYSTAL STRUCTURE OF A BACTERIAL SIGNAL PEPTIDASE APO-ENZYME, IMPLICATIONS FOR SIGNAL PEPTIDE BINDING AND THE SER-LYS DYAD MECHANISM.
4ZHY	;	1.969	;	Crystal structure of a bacterial signalling complex
4ZHV	;	1.585	;	Crystal structure of a bacterial signalling protein
4ZHW	;	1.391	;	Crystal structure of a bacterial signalling protein (N-terminal truncation)
7T1M	;	1.6	;	Crystal structure of a bacterial sterol transporter
7T1S	;	1.91	;	Crystal structure of a bacterial sterol transporter
3M4A	;	1.65	;	Crystal structure of a bacterial topoisomerase IB in complex with DNA reveals a secondary DNA binding site
6LG3	;	1.90057	;	Crystal structure of a bacterial toxin from Mycobacterium tuberculosis
8G52	;	1.88	;	Crystal structure of a bacterial TPAT family transporter
8G53	;	1.03	;	Crystal structure of a bacterial TPAT family transporter
2CX3	;	2.64	;	Crystal structure of a bacterioferritin comigratory protein peroxiredoxin from the Aeropyrum pernix K1 (form-1 crystal)
2CX4	;	2.3	;	Crystal structure of a bacterioferritin comigratory protein peroxiredoxin from the Aeropyrum pernix K1 (form-2 crystal)
1HX1	;	1.9	;	CRYSTAL STRUCTURE OF A BAG DOMAIN IN COMPLEX WITH THE HSC70 ATPASE DOMAIN
5EFR	;	2.0	;	Crystal Structure of a BamA-BamD fusion
3CAZ	;	3.344	;	Crystal structure of a BAR protein from Galdieria sulphuraria
1RNB	;	1.9	;	CRYSTAL STRUCTURE OF A BARNASE-D(*GP*C) COMPLEX AT 1.9 ANGSTROMS RESOLUTION
3HNW	;	2.196	;	Crystal Structure of a Basic Coiled-Coil Protein of Unknown Function from Eubacterium eligens ATCC 27750
3S99	;	2.05	;	Crystal structure of a basic membrane lipoprotein from brucella melitensis, iodide soak
3JTY	;	2.58	;	Crystal structure of a BenF-like porin from Pseudomonas fluorescens Pf-5
4EAT	;	1.798	;	Crystal structure of a benzoate coenzyme A ligase
4RM2	;	1.77	;	Crystal structure of a benzoate coenzyme A ligase with 2-Fluoro benzoic acid
4RM3	;	1.76	;	Crystal structure of a benzoate coenzyme A ligase with 2-Furoic acid
4RMN	;	1.72	;	Crystal structure of a benzoate coenzyme A ligase with 2-Thiophene Carboxylic acid
4ZJZ	;	1.7	;	Crystal structure of a benzoate coenzyme A ligase with Benzoyl-AMP
4RLQ	;	1.63	;	Crystal structure of a benzoate coenzyme A ligase with o-Toluic acid
4RLF	;	1.73	;	Crystal structure of a benzoate coenzyme A ligase with p-Toluic acid and o-Toluic acid
2P8O	;	1.5	;	Crystal Structure of a Benzohydroxamic Acid/Vanadate complex bound to chymotrypsin A
1S0M	;	2.7	;	Crystal structure of a Benzo[a]pyrene Diol Epoxide adduct in a ternary complex with a DNA polymerase
3FZ1	;	1.9	;	Crystal structure of a benzthiophene inhibitor bound to human Cyclin-dependent Kinase-2 (CDK-2)
3FYK	;	3.5	;	Crystal structure of a benzthiophene lead bound to MAPKAP Kinase-2 (MK-2)
1D63	;	2.0	;	CRYSTAL STRUCTURE OF A BERENIL-D(CGCAAATTTGCG) COMPLEX; AN EXAMPLE OF DRUG-DNA RECOGNITION BASED ON SEQUENCE-DEPENDENT STRUCTURAL FEATURES
2DBE	;	2.5	;	CRYSTAL STRUCTURE OF A BERENIL-DODECANUCLEOTIDE COMPLEX: THE ROLE OF WATER IN SEQUENCE-SPECIFIC LIGAND BINDING
5Z6E	;	1.864	;	Crystal structure of a beta gamma-crystallin domain of Abundant Perithecial Protein (APP) from Neurospora crassa in the Ca2+-bound form
5HW3	;	1.45	;	Crystal structure of a beta lactamase from Burkholderia vietnamiensis
5H4E	;	1.863	;	Crystal structure of a beta-1,3-glucanase domain (GH64) from Clostridium beijerinckii
4PQ9	;	1.2	;	Crystal Structure of a Beta-1,3-glucanase from Mycobacterium marinum
5I77	;	1.8	;	Crystal structure of a beta-1,4-endoglucanase from Aspergillus niger
5I78	;	1.58	;	Crystal structure of a beta-1,4-endoglucanase from Aspergillus niger
5I79	;	2.35	;	Crystal structure of a beta-1,4-endoglucanase mutant from Aspergillus niger in complex with sugar
1J18	;	2.0	;	Crystal Structure of a Beta-Amylase from Bacillus cereus var. mycoides Cocrystallized with Maltose
4PUX	;	1.43	;	Crystal structure of a beta-barrel like protein (ABAYE2633) from Acinetobacter baumannii AYE at 1.43 A resolution
2GL7	;	2.6	;	Crystal Structure of a beta-catenin/BCL9/Tcf4 complex
3D3A	;	2.15	;	Crystal structure of a beta-galactosidase from Bacteroides thetaiotaomicron
6ZIV	;	1.95	;	Crystal structure of a Beta-glucosidase from Alicyclobacillus acidiphilus
6WIU	;	3.511	;	Crystal structure of a beta-glucosidase from Exiguobacterium marinum
3GM8	;	2.4	;	Crystal structure of a beta-glycosidase from Bacteroides vulgatus
7JVI	;	1.85	;	Crystal structure of a beta-helix domain retrieved from capybara gut metagenome
3V1U	;	2.5	;	Crystal structure of a beta-ketoacyl reductase FabG4 from Mycobacterium tuberculosis H37Rv complexed with NAD+ and Hexanoyl-CoA at 2.5 Angstrom resolution
4EWG	;	2.25	;	Crystal structure of a Beta-ketoacyl synthase from Burkholderia phymatum STM815
3I7J	;	2.2	;	Crystal Structure of a beta-lactamase (Mb2281c) from Mycobacterium bovis, Northeast Structural Genomics Consortium Target MbR246
5I0P	;	2.5	;	Crystal Structure of a Beta-lactamase domain protein from Burkholderia ambifaria
5IHV	;	1.1	;	Crystal structure of a beta-lactamase from Burkholderia ambifaria
6AO1	;	1.8	;	Crystal structure of a beta-lactamase from Burkholderia phymatum
3QH8	;	1.6	;	Crystal structure of a beta-lactamase-like protein bound to AMP from brucella melitensis, long wavelength synchrotron data
3MD7	;	1.27	;	Crystal structure of a beta-lactamase-like protein bound to GMP from brucella melitensis
3PY5	;	1.7	;	Crystal structure of a beta-lactamase-like protein from brucella melitensis bound to AMP
3PY6	;	1.7	;	Crystal Structure of a Beta-Lactamase-Like Protein from Brucella Melitensis bound to GMP
6JE8	;	1.798	;	crystal structure of a beta-N-acetylhexosaminidase
6JEA	;	2.275	;	crystal structure of a beta-N-acetylhexosaminidase
6JEB	;	1.498	;	crystal structure of a beta-N-acetylhexosaminidase
3I9H	;	2.0	;	Crystal structure of a betagamma-crystallin domain from Clostridium beijerinckii
3IAJ	;	2.1	;	Crystal structure of a betagamma-crystallin domain from Clostridium beijerinckii-in alternate space group I422
3HZB	;	1.74	;	Crystal structure of a betagamma-crystallin domain from Flavobacterium johnsoniae
3HZ2	;	1.86	;	Crystal structure of a betagamma-crystallin from an Archaea
6WSB	;	1.55	;	Crystal structure of a betaine aldehyde dehydrogenase from Burkholderia pseudomallei bound to cofactor NAD
6WSA	;	2.05	;	Crystal structure of a betaine aldehyde dehydrogenase from Burkholderia pseudomallei without cofactor
3NYW	;	2.16	;	Crystal Structure of a betaketoacyl-[ACP] reductase (FabG) from Bacteroides thetaiotaomicron
2V6Q	;	2.7	;	Crystal Structure of a BHRF-1 : Bim BH3 complex
1NVM	;	1.7	;	Crystal structure of a bifunctional aldolase-dehydrogenase : sequestering a reactive and volatile intermediate
2B3Z	;	2.41	;	Crystal structure of a bifunctional deaminase and reductase involved in riboflavin biosynthesis
2D5N	;	2.97	;	Crystal structure of a bifunctional deaminase and reductase involved in riboflavin biosynthesis
5VMK	;	2.55	;	Crystal structure of a bifunctional GlmU UDP-N-acetylglucosamine diphosphorylase/glucosamine-1- phosphate N-acetyltransferase from Acinetobacter baumannii
3LN7	;	3.2	;	Crystal structure of a bifunctional glutathione synthetase from Pasteurella multocida
3LN6	;	2.95	;	Crystal structure of a bifunctional glutathione synthetase from Streptococcus agalactiae
2W3X	;	1.75	;	Crystal structure of a bifunctional hotdog fold thioesterase in enediyne biosynthesis, CalE7
2QJO	;	2.6	;	crystal structure of a bifunctional NMN adenylyltransferase/ADP ribose pyrophosphatase (NadM) complexed with ADPRP and NAD from Synechocystis sp.
2QJT	;	2.3	;	Crystal structure of a bifunctional NMN adenylyltransferase/ADP ribose pyrophosphatase complexed with AMP and MN ion from Francisella tularensis
2R5W	;	2.3	;	Crystal structure of a bifunctional NMN adenylyltransferase/ADP ribose pyrophosphatase from Francisella tularensis
1GD7	;	2.0	;	CRYSTAL STRUCTURE OF A BIFUNCTIONAL PROTEIN (CSAA) WITH EXPORT-RELATED CHAPERONE AND TRNA-BINDING ACTIVITIES.
4LGC	;	2.19	;	Crystal structure of a bile acid-coenzyme A ligase (baiB) from Clostridium scindens (VPI 12708) at 2.19 A resolution
4L8P	;	1.6	;	Crystal structure of a bile-acid 7-alpha dehydratase (CLOHIR_00079) from Clostridium hiranonis DSM 13275 at 1.60 A resolution
4N3V	;	1.89	;	Crystal structure of a bile-acid 7-alpha dehydratase (CLOHIR_00079) from Clostridium hiranonis DSM 13275 at 1.89 A resolution with product added
4L8O	;	2.2	;	Crystal structure of a bile-acid 7-alpha dehydratase (CLOHYLEM_06634) from Clostridium hylemonae DSM 15053 at 2.20 A resolution
4LEH	;	2.9	;	Crystal structure of a bile-acid 7-alpha dehydratase (CLOSCI_03134) from Clostridium scindens ATCC 35704 at 2.90 A resolution
1LC3	;	1.5	;	Crystal Structure of a Biliverdin Reductase Enzyme-Cofactor Complex
2QYI	;	2.6	;	Crystal structure of a binary complex between an engineered trypsin inhibitor and Bovine trypsin
3I29	;	2.4	;	Crystal structure of a binary complex between an mutant trypsin inhibitor with bovine trypsin
1AJ2	;	2.0	;	CRYSTAL STRUCTURE OF A BINARY COMPLEX OF E. COLI DIHYDROPTEROATE SYNTHASE
1RB0	;	1.35	;	CRYSTAL STRUCTURE OF A BINARY COMPLEX OF E. COLI HPPK WITH 6-HYDROXYMETHYLPTERIN-DIPHOSPHATE AT 1.35 ANGSTROM RESOLUTION
4QRM	;	4.315	;	crystal structure of a binary complex of FliM-FliG middle domains from T.maritima
1DAW	;	2.2	;	CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-AMPPNP
1DAY	;	2.2	;	CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-GMPPNP
1LP4	;	1.86	;	Crystal structure of a binary complex of the catalytic subunit of protein kinase CK2 with Mg-AMPPNP
3N5L	;	1.97	;	Crystal structure of a binding protein component of ABC phosphonate transporter (PA3383) from Pseudomonas aeruginosa at 1.97 A resolution
7CY9	;	1.36	;	Crystal structure of a biodegradable plastic-degrading cutinase from Paraphoma sp. B47-9 solved by getting the phase from anomalous scattering of uncovalently coordinated arsenic (cacodylate).
7CY3	;	1.27	;	Crystal structure of a biodegradable plastic-degrading cutinase from Paraphoma sp. B47-9.
7CW1	;	1.7	;	Crystal structure of a biodegradable plastic-degrading cutinase-like enzyme from the phyllosphere yeast, Pseudozyma antarctica, solved by getting the phase from anomalous scattering of uncovalently coordinated arsenic (cacodylate).
1EKU	;	2.9	;	CRYSTAL STRUCTURE OF A BIOLOGICALLY ACTIVE SINGLE CHAIN MUTANT OF HUMAN IFN-GAMMA
3BFM	;	1.7	;	Crystal structure of a biotin protein ligase-like protein of unknown function (tm1040_0394) from silicibacter sp. tm1040 at 1.70 A resolution
1F27	;	1.3	;	CRYSTAL STRUCTURE OF A BIOTIN-BINDING RNA PSEUDOKNOT
2PXH	;	1.97	;	Crystal structure of a bipyridylalanyl-tRNA synthetase
2PGG	;	2.5	;	Crystal Structure of a Birnavirus (IBDV) RNA-dependent RNA Polymerase VP1
6T9E	;	2.989	;	Crystal structure of a bispecific DutaFab in complex with human PDGF
6T9D	;	2.905	;	Crystal structure of a bispecific DutaFab in complex with human VEGF121
4FR9	;	1.2	;	Crystal structure of a BLIP-like protein (BF1215) from Bacteroides fragilis NCTC 9343 at 1.20 A resolution
4KNF	;	2.6	;	Crystal structure of a blue-light absorbing proteorhodopsin double-mutant D97N/Q105L from HOT75
4KLY	;	2.7	;	Crystal structure of a blue-light absorbing proteorhodopsin mutant D97N from HOT75
1TR0	;	1.8	;	Crystal Structure of a boiling stable protein SP1
3O2E	;	1.95	;	Crystal structure of a bol-like protein from babesia bovis
2VE7	;	2.88	;	Crystal structure of a bonsai version of the human Ndc80 complex
2FID	;	2.8	;	Crystal Structure of a Bovine Rabex-5 fragment complexed with ubiquitin
2FIF	;	2.49	;	Crystal Structure of a Bovine Rabex-5 fragment complexed with ubiquitin
1PBI	;	2.7	;	CRYSTAL STRUCTURE OF A BOWMAN-BIRK INHIBITOR FROM PEA SEEDS
2R33	;	2.5	;	Crystal structure of a Bowman-Birk inhibitor from Vigna unguiculata seeds
2FI4	;	1.58	;	Crystal structure of a BPTI variant (Cys14->Ser) in complex with trypsin
2FI3	;	1.58	;	Crystal structure of a BPTI variant (Cys14->Ser, Cys38->Ser) in complex with trypsin
2FI5	;	1.58	;	Crystal structure of a BPTI variant (Cys38->Ser) in complex with trypsin
4WO5	;	2.83	;	Crystal structure of a BRAF kinase domain monomer
3LKB	;	2.4	;	Crystal structure of a branched chain amino acid ABC transporter from Thermus thermophilus with bound valine
3N0W	;	1.88	;	Crystal structure of a branched chain amino acid ABC transporter periplasmic ligand-binding protein (Bxe_C0949) from BURKHOLDERIA XENOVORANS LB400 at 1.88 A resolution
1YCO	;	2.4	;	Crystal structure of a branched-chain phosphotransacylase from Enterococcus faecalis V583
8R2G	;	3.45	;	Crystal structure of a BRCA2-DMC1 complex
7YAO	;	1.5	;	Crystal structure of a bright green fluorescent protein (oxStayGold) in jellyfish Cytaeis uchidae from Biortus
7Y40	;	1.7	;	Crystal structure of a bright green fluorescent protein (StayGold) in jellyfish Cytaeis uchidae from Biortus
8J2K	;	1.7	;	Crystal structure of a bright green fluorescent protein (StayGold) with double mutation (N137A, Q140S) in jellyfish Cytaeis uchidae from Biortus
8J2L	;	1.7	;	Crystal structure of a bright green fluorescent protein (StayGold) with double mutations (N137A, Y187F) in jellyfish Cytaeis uchidae from Biortus
8J3J	;	1.7	;	Crystal structure of a bright green fluorescent protein (StayGold) with double mutations (Q140S, Y187F) in jellyfish Cytaeis uchidae from Biortus
8GYF	;	2.0	;	Crystal structure of a bright green fluorescent protein (StayGold) with single mutation (K192Y) in jellyfish Cytaeis uchidae from Biortus
8J2H	;	1.7	;	Crystal structure of a bright green fluorescent protein (StayGold) with single mutation (N137A) in jellyfish Cytaeis uchidae from Biortus
8J2I	;	1.75	;	Crystal structure of a bright green fluorescent protein (StayGold) with single mutation (Q140S) in jellyfish Cytaeis uchidae from Biortus
8J2J	;	1.9	;	Crystal structure of a bright green fluorescent protein (StayGold) with single mutation (Y187F) in jellyfish Cytaeis uchidae from Biortus
7YRE	;	2.3	;	Crystal structure of a bright green fluorescent protein (StayGold) with triple mutations (N137A, Q140S, Y187F) in jellyfish Cytaeis uchidae from Biortus
4DYJ	;	2.45	;	Crystal structure of a broad specificity amino acid racemase (Bar) within internal aldimine linkage
1N0X	;	1.8	;	Crystal Structure of a Broadly Neutralizing Anti-HIV-1 Antibody in Complex with a Peptide Mimotope
1QBP	;	2.1	;	CRYSTAL STRUCTURE OF A BROMINATED RNA HELIX WITH FOUR MISMATCHED BASE PAIRS
6V6R	;	2.7	;	Crystal Structure of a Bromine Derivatized Self-Assembling DNA Crystal Scaffold with Rhombohedral Symmetry.
3PL0	;	1.91	;	Crystal structure of a bsmA homolog (Mpe_A2762) from Methylobium petroleophilum PM1 at 1.91 A resolution
1TFV	;	2.9	;	CRYSTAL STRUCTURE OF A BUFFALO SIGNALING GLYCOPROTEIN (SPB-40) SECRETED DURING INVOLUTION
1JZV	;	1.7	;	Crystal structure of a bulged RNA from the SL2 stem-loop of the HIV-1 psi-RNA
1P79	;	1.1	;	Crystal structure of a bulged RNA tetraplex: implications for a novel binding site in RNA tetraplex
2PU5	;	2.3	;	Crystal Structure of a C-C bond hydrolase, BphD, from Burkholderia xenovorans LB400
4O88	;	2.9	;	Crystal structure of a C-tagged Nuclease
3HRN	;	1.9	;	crystal structure of a C-terminal coiled coil domain of Transient receptor potential (TRP) channel subfamily P member 2 (TRPP2, polycystic kidney disease 2)
3HRO	;	1.9	;	Crystal structure of a C-terminal coiled coil domain of Transient receptor potential (TRP) channel subfamily P member 2 (TRPP2, polycystic kidney disease 2)
1PJK	;	2.5	;	Crystal Structure of a C-terminal deletion mutant of human protein kinase CK2 catalytic subunit
3AQJ	;	1.27	;	Crystal Structure of a C-terminal domain of the bacteriophage P2 tail spike protein, gpV
1LVA	;	2.12	;	Crystal structure of a C-terminal fragment of Moorella thermoacetica elongation factor SelB
1O6A	;	1.85	;	CRYSTAL STRUCTURE OF A C-TERMINAL FRAGMENT OF THE PUTATIVE FLAGELLAR MOTOR SWITCH PROTEIN FLIN (TM0680) FROM THERMOTOGA MARITIMA AT 1.85 A RESOLUTION
6H3Z	;	3.0	;	Crystal structure of a C-terminal MIF4G domain in NOT1
4Q20	;	2.5	;	Crystal structure of a C-terminal part of tyrosine kinase (DivL) from Caulobacter crescentus CB15 at 2.50 A resolution (PSI Community Target, Shapiro)
2NV5	;	2.0	;	Crystal structure of a C-terminal phosphatase domain of Rattus norvegicus ortholog of human protein tyrosine phosphatase, receptor type, D (PTPRD)
6CUM	;	1.6	;	Crystal structure of a C-terminal proteolytic fragment of a protein annotated as an LAO/AO transport system ATPase but likely MeaB and MMAA-like GTPase from Mycobacterium smegmatis
5IZT	;	1.9	;	Crystal structure of a C-terminal proteolytic fragment of an outer surface protein from Borrelia burgdorferi
1YZ7	;	2.26	;	Crystal structure of a C-terminal segment of the alpha subunit of aIF2 from Pyrococcus abyssi
3M1L	;	2.52	;	Crystal structure of a C-terminal trunacted mutant of a putative ketoacyl reductase (FabG4) from Mycobacterium tuberculosis H37Rv at 2.5 Angstrom resolution
4ICA	;	2.7	;	Crystal structure of a C-terminal truncated form of the matrix subunit (p15) of Feline Immunodeficiency Virus (FIV)
4JHS	;	3.0	;	Crystal structure of a C-terminal two domain fragment of human beta-2-glycoprotein 1
5IHX	;	2.298	;	Crystal Structure of a C-terminally truncated Aspergillus nidulans mitochondrial tyrosyl-tRNA synthetase
5IJX	;	2.63	;	Crystal Structure of a C-terminally truncated Coccidioides posadasii mitochondrial tyrosyl-tRNA synthetase
1Y42	;	1.95	;	Crystal structure of a C-terminally truncated CYT-18 protein
4OJM	;	1.95	;	Crystal structure of a C-terminally truncated CYT-18 protein including N-terminal residues
6EJQ	;	2.3	;	Crystal structure of a C-terminally truncated small terminase protein from the thermophilic bacteriophage G20c
5OW3	;	2.75	;	Crystal structure of a C-terminally truncated trimeric ectodomain of the Arabidopsis thaliana gamete fusion protein HAP2
4OJE	;	2.57	;	Crystal structure of a C-terminally truncated trimeric ectodomain of the C. elegans fusion protein EFF-1
4OJD	;	2.26	;	Crystal structure of a C-terminally truncated trimeric ectodomain of the C. elegans fusion protein EFF-1 G260A/D321E/D322E mutant
5MF1	;	3.3	;	Crystal structure of a C-terminally truncated trimeric ectodomain of the Chlamydomonas reinhardtii gamete fusion protein HAP2
8QTT	;	2.35	;	Crystal structure of a C-terminally truncated version of Arabidopsis thaliana 14-3-3 omega in complex with a phosphopeptide from the inhibitor protein BKI1.
8QTF	;	1.9	;	Crystal structure of a C-terminally truncated version of Arabidopsis thaliana 14-3-3 omega in complex with a phosphopeptide from the transcription factor BZR1.
1KTG	;	1.8	;	Crystal Structure of a C. elegans Ap4A Hydrolase Binary Complex
5UJC	;	1.35	;	Crystal structure of a C.elegans B12-trafficking protein CblC, a human MMACHC homologue
7XPL	;	2.213	;	Crystal structure of a C/D-free RNA-guided RNA 2'-O-methyltransferase
2R4H	;	2.05	;	Crystal structure of a C1190S mutant of the 6th PDZ domain of human membrane associated guanylate kinase
3FDW	;	2.2	;	Crystal structure of a C2 domain from human synaptotagmin-like protein 4
4DNL	;	1.9	;	Crystal structure of a C2 domain of a protein kinase C alpha (PRKCA) from Homo sapiens at 1.90 A resolution
7DF2	;	1.7	;	Crystal structure of a C2 domain protein from Ramazzottius varieornatus
4PO3	;	1.96	;	Crystal structure of a C4-C4 SN3 tributyrin phosphonate inhibited by ESTERASE B from LACTOBACILLUS RHAMNOSIS
8AJK	;	1.6	;	Crystal structure of a C43S variant from the disulfide reductase MerA from Staphylococcus aureus
1OWS	;	2.3	;	Crystal structure of a C49 Phospholipase A2 from Indian cobra reveals carbohydrate binding in the hydrophobic channel
4OUK	;	2.0	;	Crystal structure of a C6-C4 SN3 inhibited ESTERASE B from LACTOBACILLUS RHAMNOSIS
1SJ4	;	2.7	;	Crystal structure of a C75U mutant Hepatitis Delta Virus ribozyme precursor, in Cu2+ solution
4N5I	;	2.0	;	Crystal Structure of a C8-C4 Sn3 Inhibited Esterase B from Lactobacillus Rhamnosis
1S36	;	1.96	;	Crystal structure of a Ca2+-discharged photoprotein: Implications for the mechanisms of the calcium trigger and the bioluminescence
3B5O	;	1.35	;	CRYSTAL STRUCTURE OF A CADD-LIKE PROTEIN OF UNKNOWN FUNCTION (NPUN_F6505) FROM NOSTOC PUNCTIFORME PCC 73102 AT 1.35 A RESOLUTION
3B5P	;	2.0	;	Crystal structure of a cadd-like protein of unknown function (npun_f6505) from nostoc punctiforme pcc 73102 at 2.00 A resolution
8AK1	;	1.84	;	Crystal structure of a CagI:K2 complex
4ED9	;	1.95	;	Crystal structure of a CAIB/BAIF family protein from Brucella suis
3U1W	;	2.0	;	Crystal structure of a Calcium binding protein (BDI_1975) from Parabacteroides distasonis ATCC 8503 at 2.00 A resolution
6QM3	;	2.0	;	Crystal structure of a calcium- and sodium-bound mouse Olfactomedin-1 disulfide-linked dimer of the Olfactomedin domain and part of coiled coil
2GHS	;	1.55	;	CRYSTAL STRUCTURE OF A CALCIUM-BINDING PROTEIN, REGUCALCIN (AGR_C_1268) FROM AGROBACTERIUM TUMEFACIENS STR. C58 AT 1.55 A RESOLUTION
1MH7	;	2.0	;	Crystal Structure of a Calcium-Free Isoform of Phospholipase A2 from Naja naja sagittifera at 2.0 A Resolution
1CLP	;	2.8	;	CRYSTAL STRUCTURE OF A CALCIUM-INDEPENDENT PHOSPHOLIPASELIKE MYOTOXIC PROTEIN FROM BOTHROPS ASPER VENOM
4PWY	;	1.9	;	Crystal structure of a Calmodulin-lysine N-methyltransferase fragment
1MEL	;	2.5	;	CRYSTAL STRUCTURE OF A CAMEL SINGLE-DOMAIN VH ANTIBODY FRAGMENT IN COMPLEX WITH LYSOZYME
2XXC	;	1.67	;	Crystal structure of a camelid VHH raised against the HIV-1 capsid protein C-terminal domain.
1OL0	;	1.8	;	Crystal structure of a camelised human VH
6M63	;	2.25	;	Crystal structure of a cAMP sensor G-Flamp1.
7OOL	;	2.85	;	Crystal structure of a Candidatus photodesmus katoptron thioredoxin chimera containing an ancestral loop
4QYK	;	3.5	;	Crystal structure of a canine parvovirus variant
6TKU	;	1.8	;	Crystal structure of a capsule-specific depolymerase produced by Klebsiella phage
5B5S	;	1.5	;	Crystal structure of a carbohydrate esterase family 3 from Talaromyces cellulolyticus
1U4J	;	2.18	;	Crystal structure of a carbohydrate induced dimer of group I phospholipase A2 from Bungarus caeruleus at 2.1 A resolution
3K5W	;	2.6	;	Crystal structure of a Carbohydrate kinase (YjeF family)from Helicobacter pylori
4GKX	;	2.7	;	Crystal structure of a carbohydrate-binding domain
4GKY	;	2.4201	;	Crystal structure of a carbohydrate-binding domain
3R1W	;	1.73	;	Crystal structure of a carbonic anhydrase from a crude oil degrading psychrophilic library
3CTM	;	2.69	;	Crystal Structure of a Carbonyl Reductase from Candida Parapsilosis with anti-Prelog Stereo-specificity
5WQM	;	2.6	;	Crystal structure of a carbonyl reductase from Pseudomonas aeruginosa PAO1 (condition I)
5WQN	;	2.0	;	Crystal structure of a carbonyl reductase from Pseudomonas aeruginosa PAO1 (condition II)
5WQO	;	1.78	;	Crystal structure of a carbonyl reductase from Pseudomonas aeruginosa PAO1 in complex with NADP (condition I)
5WQP	;	1.7	;	Crystal structure of a carbonyl reductase from Pseudomonas aeruginosa PAO1 in complex with NADP (condition II)
8JQK	;	1.63	;	Crystal structure of a carbonyl reductase SSCR mutant from Sporobolomyces Salmonicolor
4FHZ	;	2.01	;	Crystal structure of a carboxyl esterase at 2.0 angstrom resolution
4FTW	;	2.3	;	Crystal structure of a carboxyl esterase N110C/L145H at 2.3 angstrom resolution
1MEG	;	2.0	;	CRYSTAL STRUCTURE OF A CARICAIN D158E MUTANT IN COMPLEX WITH E-64
4HDT	;	1.6	;	Crystal structure of a Carnitinyl-CoA dehydratase from Mycobacterium thermoresistibile
5X62	;	2.204	;	Crystal structure of a carnosine N-methyltransferase bound by AdoHcy
1EAP	;	2.4	;	CRYSTAL STRUCTURE OF A CATALYTIC ANTIBODY WITH A SERINE PROTEASE ACTIVE SITE
2GFB	;	3.0	;	CRYSTAL STRUCTURE OF A CATALYTIC FAB HAVING ESTERASE-LIKE ACTIVITY
4JJ4	;	2.13	;	Crystal structure of a catalytic mutant of Axe2 (Axe2-D191A), an acetylxylan esterase from Geobacillus stearothermophilus
4JJ6	;	1.8	;	Crystal structure of a catalytic mutant of Axe2 (Axe2-H194A), an acetylxylan esterase from Geobacillus stearothermophilus
4JKO	;	1.9	;	Crystal structure of a catalytic mutant of Axe2 (Axe2_S15A), an acetylxylan esterase from Geobacillus stearothermophilus
1ZCP	;	2.3	;	Crystal Structure of a catalytic site mutant E. coli TrxA (CACA)
1P14	;	1.9	;	Crystal structure of a catalytic-loop mutant of the insulin receptor tyrosine kinase
3PLA	;	3.15	;	Crystal structure of a catalytically active substrate-bound box C/D RNP from Sulfolobus solfataricus
2W2D	;	2.59	;	Crystal Structure of a Catalytically Active, Non-toxic Endopeptidase Derivative of Clostridium botulinum Toxin A
6VJB	;	2.24	;	Crystal structure of a catalytically inactive CXC Chemokine-degrading protease SpyCEP from Streptococcus pyogenes
2W8S	;	2.4	;	CRYSTAL STRUCTURE OF A catalytically promiscuous PHOSPHONATE MONOESTER HYDROLASE FROM Burkholderia caryophylli
8H0R	;	1.201	;	Crystal structure of a cataract-causing crystallin mutant (mouse CRYBB1 Y202X)
2EY4	;	2.11	;	Crystal Structure of a Cbf5-Nop10-Gar1 Complex
3U28	;	1.9	;	Crystal structure of a Cbf5-Nop10-Gar1 complex from Saccharomyces cerevisiae
2UV4	;	1.33	;	Crystal Structure of a CBS domain pair from the regulatory gamma1 subunit of human AMPK in complex with AMP
2UV5	;	1.69	;	Crystal Structure of a CBS domain pair from the regulatory gamma1 subunit of human AMPK in complex with AMP
2UV6	;	2.0	;	Crystal Structure of a CBS domain pair from the regulatory gamma1 subunit of human AMPK in complex with AMP
2UV7	;	2.0	;	Crystal Structure of a CBS domain pair from the regulatory gamma1 subunit of human AMPK in complex with AMP
1VR9	;	1.7	;	CRYSTAL STRUCTURE OF A CBS DOMAIN PAIR/ACT DOMAIN PROTEIN (TM0892) FROM THERMOTOGA MARITIMA AT 1.70 A RESOLUTION
1O50	;	1.87	;	Crystal structure of a cbs domain-containing protein (tm0935) from thermotoga maritima at 1.87 A resolution
3DDJ	;	1.8	;	Crystal structure of a cbs domain-containing protein in complex with amp (sso3205) from sulfolobus solfataricus at 1.80 A resolution
6Q5P	;	1.44	;	Crystal structure of a CC-Hex mutant that forms a parallel six-helix coiled coil CC-Hex*-II
6Q5J	;	1.69	;	Crystal structure of a CC-Hex mutant that forms a parallel six-helix coiled coil CC-Hex*-L24E
6Q5N	;	2.0	;	Crystal structure of a CC-Hex mutant that forms a parallel six-helix coiled coil CC-Hex*-L24Nle
6Q5H	;	1.2	;	Crystal structure of a CC-Hex mutant that forms an antiparallel four-helix coiled coil CC-Hex*-L24D
6Q5M	;	1.5	;	Crystal structure of a CC-Hex mutant that forms an antiparallel four-helix coiled coil CC-Hex*-L24Dab
6Q5I	;	1.76	;	Crystal structure of a CC-Hex mutant that forms an antiparallel four-helix coiled coil CC-Hex*-L24E
6Q5L	;	1.41	;	Crystal structure of a CC-Hex mutant that forms an antiparallel four-helix coiled coil CC-Hex*-L24H
6Q5K	;	1.65	;	Crystal structure of a CC-Hex mutant that forms an antiparallel four-helix coiled coil CC-Hex*-L24K
6Q5O	;	1.0	;	Crystal structure of a CC-Hex mutant that forms an antiparallel four-helix coiled coil CC-Hex*-LL
6Q5R	;	1.61	;	Crystal structure of a CC-Hex mutant that forms an antiparallel four-helix coiled coil CC-Hex*-LL-KgEb
6Q5Q	;	1.08	;	Crystal structure of a CC-Hex mutant that forms an antiparallel four-helix coiled coil CC-Hex-KgEb
1ZVV	;	2.98	;	Crystal structure of a ccpa-crh-dna complex
3TYF	;	2.806	;	Crystal structure of a CD1d-lysophosphatidylcholine reactive iNKT TCR
2ATP	;	2.4	;	Crystal structure of a CD8ab heterodimer
4LPA	;	2.9	;	Crystal structure of a Cdc6 phosphopeptide in complex with Cks1
5IEY	;	1.66	;	Crystal structure of a CDK inhibitor bound to CDK2
4TTH	;	2.9	;	Crystal structure of a CDK6/Vcyclin complex with inhibitor bound
3HKO	;	1.8	;	Crystal structure of a cdpk kinase domain from cryptosporidium Parvum, cgd7_40
1TY4	;	2.2	;	Crystal structure of a CED-9/EGL-1 complex
1N0E	;	2.7	;	CRYSTAL STRUCTURE OF A CELL DIVISION AND CELL WALL BIOSYNTHESIS PROTEIN UPF0040 FROM MYCOPLASMA PNEUMONIAE: INDICATION OF A NOVEL FOLD WITH A POSSIBLE NEW CONSERVED SEQUENCE MOTIF
1N0F	;	2.8	;	CRYSTAL STRUCTURE OF A CELL DIVISION AND CELL WALL BIOSYNTHESIS PROTEIN UPF0040 FROM MYCOPLASMA PNEUMONIAE: INDICATION OF A NOVEL FOLD WITH A POSSIBLE NEW CONSERVED SEQUENCE MOTIF
1N0G	;	2.8	;	Crystal Structure of A Cell Division and Cell Wall Biosynthesis Protein UPF0040 from Mycoplasma pneumoniae: Indication of A Novel Fold with A Possible New Conserved Sequence Motif
1RJ1	;	1.87	;	Crystal Structure of a Cell Wall Invertase Inhibitor from Tobacco
2CJ5	;	1.84	;	Crystal Structure of a Cell Wall Invertase Inhibitor from Tobacco (pH 5.0)
2CJ6	;	2.0	;	Crystal Structure of a Cell Wall Invertase Inhibitor from Tobacco (pH 7.5)
2CJ7	;	1.8	;	Crystal Structure of a Cell Wall Invertase Inhibitor from Tobacco (pH 9.0)
2CJ8	;	2.38	;	Crystal Structure of a Cell Wall Invertase Inhibitor from Tobacco (pH 9.5)
2CJ4	;	1.63	;	Crystal Structure of a Cell Wall Invertase Inhibitor from Tobacco at pH 4.6
2QQU	;	2.84	;	Crystal structure of a cell-wall invertase (D239A) from Arabidopsis thaliana in complex with sucrose
2QQW	;	2.8	;	Crystal structure of a cell-wall invertase (D23A) from Arabidopsis thaliana in complex with sucrose
2QQV	;	3.01	;	Crystal structure of a cell-wall invertase (E203A) from Arabidopsis thaliana in complex with sucrose
2OXB	;	2.6	;	Crystal structure of a cell-wall invertase (E203Q) from Arabidopsis thaliana in complex with sucrose
2AC1	;	2.15	;	Crystal structure of a cell-wall invertase from Arabidopsis thaliana
5UFV	;	2.45	;	Crystal Structure of a Cellulose-active Polysaccharide Monooxygenase from M. thermophila (MtPMO3*)
7V0J	;	2.4	;	Crystal structure of a CelR catalytic domain active site mutant with bound cellobiose product
7V0I	;	1.9	;	Crystal structure of a CelR catalytic domain active site mutant with bound cellohexaose substrate
4JON	;	2.15	;	Crystal structure of a centrosomal protein 170kDa, transcript variant beta (CEP170) from Homo sapiens at 2.15 A resolution (PSI Community Target, Sundstrom)
7P0I	;	2.3	;	Crystal structure of a CGRP receptor ectodomain heterodimer bound to macrocyclic inhibitor Compound 13
7P0F	;	1.85	;	Crystal structure of a CGRP receptor ectodomain heterodimer bound to macrocyclic inhibitor HTL0028125
8AX5	;	2.75	;	Crystal structure of a CGRP receptor ectodomain heterodimer bound to macrocyclic inhibitor HTL0029881
8AX6	;	1.9	;	Crystal structure of a CGRP receptor ectodomain heterodimer bound to macrocyclic inhibitor HTL0029882
8AX7	;	1.65	;	Crystal structure of a CGRP receptor ectodomain heterodimer bound to macrocyclic inhibitor HTL0031448
6ZHO	;	1.6	;	Crystal structure of a CGRP receptor ectodomain heterodimer with bound high affinity inhibitor
6ZIS	;	1.73	;	Crystal structure of a CGRP receptor ectodomain heterodimer with bound high affinity inhibitor
6QV7	;	1.72	;	Crystal structure of a CHAD domain from Chlorobium tepidum
6QVA	;	2.05	;	Crystal structure of a CHAD domain from Chlorobium tepidum in complex with inorganic polyphosphate
3RG6	;	3.2	;	Crystal structure of a chaperone-bound assembly intermediate of form I Rubisco
3LN2	;	2.037	;	Crystal Structure of a Charge Engineered Human Lysozyme Variant
3QTA	;	2.0	;	Crystal structure of a CheC-like protein (rrnAC0528) from Haloarcula marismortui ATCC 43049 at 2.00 A resolution
2O40	;	1.65	;	Crystal Structure of a Chemically Synthesized 203 Amino Acid 'Covalent Dimer' HIV-1 Protease Molecule
3HZC	;	1.45	;	Crystal structure of a chemically synthesized 203 amino acid 'covalent dimer' [Gly51;Aib51']HIV-1 protease molecule complexed with MVT-101 reduced isostere inhibitor
3IAW	;	1.61	;	Crystal structure of a chemically synthesized 203 amino acid 'covalent dimer' [Gly51;Aib51']HIV-1 protease molecule complexed with MVT-101 reduced isostere inhibitor at 1.6 A resolution
3FSM	;	1.6	;	CRYSTAL STRUCTURE OF A CHEMICALLY SYNTHESIZED 203 AMINO ACID 'COVALENT DIMER' [L-Ala51,D-Ala51'] HIV-1 PROTEASE MOLECULE
3GI0	;	1.8	;	Crystal structure of a chemically synthesized 203 amino acid 'covalent dimer' [l-ala51,d-ala51'] hiv-1 protease molecule complexed with jg-365 inhibitor
3I2L	;	1.5	;	Crystal structure of a chemically synthesized [allo-Ile50/50']HIV-1 protease molecule complexed with MVT-101 reduced isostere inhibitor
3IA9	;	1.3	;	Crystal structure of a chemically synthesized [D25N]HIV-1 protease molecule complexed with MVT-101 reduced isostere inhibitor
4Q6Y	;	3.0	;	Crystal structure of a chemoenzymatic glycoengineered disialylated Fc (di-sFc)
3H2D	;	1.86	;	Crystal structure of a chemotactic chec-like protein (so_3915) from shewanella oneidensis mr-1 at 1.86 A resolution
3HM4	;	1.3	;	CRYSTAL STRUCTURE OF A CHEMOTAXIS PROTEIN CHEX (DDE_0281) FROM DESULFOVIBRIO DESULFURICANS SUBSP. AT 1.30 A RESOLUTION
4LDA	;	2.4	;	Crystal structure of a CheY-like protein (tadZ) from Pseudomonas aeruginosa PAO1 at 2.70 A resolution
3U9D	;	2.5	;	Crystal Structure of a chimera containing the N-terminal domain (residues 8-24) of drosophila Ciboulot and the C-terminal domain (residues 13-44) of bovine Thymosin-beta4, bound to G-actin-ATP
3U8X	;	2.0	;	Crystal Structure of a chimera containing the N-terminal domain (residues 8-29) of drosophila Ciboulot and the C-terminal domain (residues 18-44) of bovine Thymosin-beta4, bound to G-actin-ATP
3SJH	;	1.75	;	Crystal Structure of a chimera containing the N-terminal domain (residues 8-29) of drosophila Ciboulot and the C-terminal domain (residues 18-44) of bovine Thymosin-beta4, bound to G-actin-ATP-Latrunculin A
1DOW	;	1.8	;	CRYSTAL STRUCTURE OF A CHIMERA OF BETA-CATENIN AND ALPHA-CATENIN
5J5J	;	3.29	;	Crystal structure of a chimera of human Desmocollin-2 EC1 and human Desmoglein-2 EC2-EC5
2VFA	;	2.8	;	Crystal structure of a chimera of Plasmodium falciparum and human hypoxanthine-guanine phosphoribosyl transferases
5TVC	;	1.926	;	Crystal structure of a chimeric acetylcholine binding protein from Aplysia californica (Ac-AChBP) containing loop C from the human alpha 3 nicotinic acetylcholine receptor in complex with (E,2S)-N-methyl-5-(5-phenoxy-3-pyridyl)pent-4-en-2-amine (TI-5312)
4ZK4	;	1.901	;	Crystal structure of a chimeric acetylcholine binding protein from Aplysia californica (Ac-AChBP) containing loop C from the human alpha 3 nicotinic acetylcholine receptor in complex with 7-(5-isopropoxy-pyridin-3-yl)-1-methyl-1,7-diaza-spiro[4.4]nonane
5SYO	;	2.0	;	Crystal structure of a chimeric acetylcholine binding protein from Aplysia californica (Ac-AChBP) containing loop C from the human alpha 3 nicotinic acetylcholine receptor in complex with Cytisine
5KE4	;	2.554	;	Crystal structure of a chimeric acetylcholine binding protein from Aplysia californica (Ac-AChBP) containing loop C from the human alpha 6 nicotinic acetylcholine receptor in complex with 2-((5-(3,7-Diazabicyclo[3.3.1]nonan-3-yl)pyridin-3-yl)oxy)- N,N-dimethylethanamine (BPC)
4ZJS	;	2.2301	;	Crystal structure of a chimeric acetylcholine binding protein from Aplysia Californica (Ac-AChBP) containing the main immunogenic region (MIR) from the human alpha 1 subunit of the muscle nicotinic acetylcholine receptor in complex with anatoxin-A.
8CQG	;	1.74	;	Crystal Structure of a Chimeric Alpha-Amylase from Pseudoalteromonas Haloplanktis
8CQF	;	2.05	;	Crystal Structure of a Chimeric Alpha-Amylase from Pseudoalteromonas Haloplanktis Complexed with Rearranged Acarbose
1MHP	;	2.8	;	Crystal structure of a chimeric alpha1 integrin I-domain in complex with the Fab fragment of a humanized neutralizing antibody
7JO8	;	1.399	;	Crystal structure of a Chimeric Antigen Receptor (CAR) scFv domain rearrangement forming a VL-VL dimer
4LE9	;	1.344	;	Crystal structure of a chimeric c-Src-SH3 domain
5EC7	;	1.65	;	Crystal structure of a chimeric c-Src-SH3 domain with the sequence of the RT-loop from the Abl-SH3 domain at pH 5.0
5ECA	;	1.16	;	Crystal structure of a chimeric c-Src-SH3 domain with the sequence of the RT-loop from the Abl-SH3 domain at pH 6.5
5U7N	;	2.3	;	CRYSTAL STRUCTURE OF A CHIMERIC CUA DOMAIN (SUBUNIT II) OF CYTOCHROME BA3 FROM THERMUS THERMOPHILUS WITH THE AMICYANIN LOOP
4GRS	;	3.0	;	Crystal structure of a chimeric DAH7PS
1BBJ	;	3.1	;	CRYSTAL STRUCTURE OF A CHIMERIC FAB' FRAGMENT OF AN ANTIBODY BINDING TUMOUR CELLS
4KK2	;	2.2	;	Crystal structure of a chimeric FPP/GFPP synthase (TARGET EFI-502313c) from Artemisia spiciformiS (1-72:GI751454468,73-346:GI75233326), apo structure
4WB7	;	1.9	;	Crystal structure of a chimeric fusion of human DnaJ (Hsp40) and cAMP-dependent protein kinase A (catalytic alpha subunit)
6CDU	;	3.45	;	Crystal structure of a chimeric human alpha1GABAA receptor in complex with alphaxalone
5J03	;	2.0	;	Crystal Structure of a chimeric Kv7.2 - Kv7.3 proximal C-terminal Domain in Complex with Calmodulin
8A6X	;	2.45	;	Crystal structure of a chimeric LOV-Histidine kinase SB2F1 (asymmetrical variant, trigonal form with long c axis)
8A52	;	2.461	;	Crystal structure of a chimeric LOV-Histidine kinase SB2F1 (asymmetrical variant, trigonal form with long c-axis)
8A3U	;	2.33	;	Crystal structure of a chimeric LOV-Histidine kinase SB2F1 (symmetrical variant, trigonal form with short c-axis)
8A7F	;	2.71	;	Crystal structure of a chimeric LOV-Histidine kinase SB2F1-I66R mutant (asymmetrical variant, trigonal form with long c axis)
8A7H	;	3.145	;	Crystal structure of a chimeric LOV-Histidine kinase SB2F1-I66R mutant (light state; asymmetrical variant, trigonal form with long c axis)
6V4R	;	3.48	;	Crystal structure of a chimeric MR78-like antibody chimera-1 Fab
4X2Y	;	2.417	;	Crystal structure of a chimeric Murine Norovirus NS6 protease (inactive C139A mutant) in which the P4-P4 prime residues of the cleavage junction in the extended C-terminus have been replaced by the corresponding residues from the NS2-3 junction.
6C6I	;	1.65	;	Crystal structure of a chimeric NDM-1 metallo-beta-lactamase harboring the IMP-1 L3 loop
7ZR2	;	1.45	;	Crystal structure of a chimeric protein mimic of SARS-CoV-2 Spike HR1 in complex with HR2
4D7Q	;	2.0	;	Crystal structure of a chimeric protein with the Sec7 domain of Legionella pneumophila RalF and the capping domain of Rickettsia prowazekii RalF
4D7R	;	1.8	;	Crystal structure of a chimeric protein with the Sec7 domain of Rickettsia prowazekii RalF and the capping domain of Legionella pneumophila RalF
3D8M	;	3.35	;	Crystal structure of a chimeric receptor binding protein from lactococcal phages subspecies TP901-1 and p2
3I2X	;	2.85	;	Crystal structure of a chimeric trypsin inhibitor having reactive site loop of ETI on the scaffold of WCI
3I2A	;	2.3	;	Crystal structure of a chimeric trypsin inhibitor protein STI(L)-WCI(S)
6H1Y	;	2.99	;	CRYSTAL STRUCTURE OF A CHIMERIC VARIANT OF THIOREDOXIN FROM ESCHERICHIA COLI
3UAM	;	2.0	;	Crystal structure of a chitin binding domain from Burkholderia pseudomallei
6VJ0	;	1.9	;	Crystal structure of a chitin-binding protein from Moringa oleifera seeds (Mo-CBP4)
3G6M	;	1.65	;	crystal structure of a chitinase CrChi1 from the nematophagous fungus Clonostachys rosea in complex with a potent inhibitor caffeine
3CO4	;	1.92	;	Crystal structure of a chitinase from Bacteroides thetaiotaomicron
3FND	;	1.9	;	Crystal structure of a chitinase from Bacteroides thetaiotaomicron
3IAN	;	1.75	;	Crystal structure of a chitinase from Lactococcus lactis subsp. lactis
4DWS	;	1.8	;	Crystal Structure of a chitinase from the Yersinia entomophaga toxin complex
7TPU	;	2.194	;	Crystal structure of a chitinase-modifying protein from Fusarium vanettenii (Fvan-cmp)
4HSC	;	2.1	;	Crystal structure of a cholesterol dependent cytolysin
6FNY	;	2.79	;	CRYSTAL STRUCTURE OF A CHOLINE SULFATASE FROM SINORHIZOBIUM MELLILOTI
8WAB	;	2.2	;	Crystal structure of a chondroitin sulfate-binding carbohydrate binding module of a chondroitinase
3FBT	;	2.1	;	Crystal structure of a chorismate mutase/shikimate 5-dehydrogenase fusion protein from Clostridium acetobutylicum
4FMT	;	2.3	;	Crystal structure of a ChpT protein (CC_3470) from Caulobacter crescentus CB15 at 2.30 A resolution
3S2Y	;	2.244	;	Crystal structure of a chromate/uranium reductase from Gluconacetobacter hansenii
5UFL	;	3.0	;	Crystal structure of a CIP2A core domain
7M6U	;	2.59	;	Crystal structure of a circular permutation and computationally designed pro-enzyme of carboxypeptidase G2
5ZMU	;	1.5	;	Crystal structure of a cis-epoxysuccinate hydrolase producing D(-)-tartaric acids
5ZMY	;	1.87	;	Crystal structure of a cis-epoxysuccinate hydrolase producing D(-)-tartaric acids
3R4I	;	2.24	;	Crystal structure of a Citrate lyase (Bxe_B2899) from BURKHOLDERIA XENOVORANS LB400 at 2.24 A resolution
3FT2	;	1.8	;	Crystal Structure of a citrulline peptide variant of the minor histocompatibility peptide HA-1 in complex with HLA-A2
8QNN	;	1.25	;	Crystal structure of a Class A beta-lactamase from Nocardia cyriacigeorgica
6LFL	;	3.2	;	Crystal structure of a class A GPCR
6K8X	;	1.59	;	Crystal structure of a class C beta lactamase
6KBY	;	1.097	;	Crystal structure of a class C beta lactamase in complex with AMP
5GSC	;	1.953	;	Crystal structure of a class C beta lactamase of Apo form
5K1D	;	1.94	;	Crystal structure of a class C beta lactamase/compound1 complex
5K1F	;	1.94	;	Crystal structure of a class C beta lactamase/compound2 complex
6K9T	;	1.459	;	Crystal structure of a class C beta-lactamase in complex with cefotaxime
6KA5	;	1.59	;	Crystal structure of a class C beta-lactamase in complex with cefoxitin
7PEH	;	1.92	;	Crystal Structure of a Class D Carbapenemase
7O5N	;	1.6	;	Crystal Structure of a Class D carbapenemase complexed with Avibactam
7O9N	;	1.97	;	Crystal Structure of a Class D Carbapenemase Complexed with Bicarbonate
7O5T	;	1.81	;	Crystal Structure of a Class D Carbapenemase Complexed with Bromide
7PEP	;	1.7	;	Crystal Structure of a Class D Carbapenemase Complexed with Hydrolyzed Imipenem
8QNZ	;	1.53	;	Crystal Structure of a Class D Carbapenemase Complexed with Hydrolyzed Imipenem
7O5Q	;	1.85	;	Crystal Structure of a Class D Carbapenemase Complexed with Hydrolyzed Oxacillin
7PSF	;	2.1	;	Crystal Structure of a Class D Carbapenemase Complexed with Imipenem
7NRJ	;	1.67	;	Crystal Structure of a Class D carbapenemase complexed with iodide
7PEI	;	1.9	;	Crystal Structure of a Class D carbapenemase_E185A/R186A/R206A
7PFN	;	1.8	;	Crystal Structure of a Class D Carbapenemase_K73ALY Complexed with Imipenem
7Q14	;	2.15	;	Crystal Structure of a Class D Carbapenemase_K73ALY Complexed with Imipenem
7PSE	;	2.32	;	Crystal Structure of a Class D Carbapenemase_K73ALY Complexed with Oxacillin
7PGO	;	1.85	;	Crystal Structure of a Class D Carbapenemase_R250A
7E9E	;	1.57	;	Crystal structure of a class I PreQ1 riboswitch aptamer (ab13-14) complexed with a cognate ligand-derived photoaffinity probe
7E9I	;	2.8	;	Crystal structure of a class I PreQ1 riboswitch aptamer (wild-type) complexed with a cognate ligand-derived photoaffinity probe
6E1S	;	1.8	;	Crystal structure of a class I PreQ1 riboswitch complexed with a synthetic compound 1: 2-[(dibenzo[b,d]furan-2-yl)oxy]ethan-1-amine
6E1T	;	1.8	;	Crystal structure of a class I PreQ1 riboswitch complexed with a synthetic compound 1: 2-[(dibenzo[b,d]furan-2-yl)oxy]ethan-1-amine
6E1U	;	1.94	;	Crystal structure of a class I PreQ1 riboswitch complexed with a synthetic compound 2: 2-[(dibenzo[b,d]furan-2-yl)oxy]-N,N-dimethylethan-1-amine
6E1V	;	2.56	;	Crystal structure of a class I PreQ1 riboswitch complexed with a synthetic compound 3: 2-[(9H-carbazol-3-yl)oxy]-N,N-dimethylethan-1-amine
6E1W	;	1.69	;	Crystal structure of a class I PreQ1 riboswitch complexed with PreQ1
3RLH	;	1.72	;	Crystal structure of a class II phospholipase D from Loxosceles intermedia venom
6R62	;	1.55	;	Crystal structure of a class II pyruvate aldolase from Sphingomonas wittichii RW1 in complex with hydroxypyruvate
6YII	;	1.44	;	Crystal structure of a Class III adenylyl cyclase-like ATP-binding protein from Pseudomonas aeruginosa
3HMU	;	2.1	;	Crystal structure of a class III aminotransferase from Silicibacter pomeroyi
4HSR	;	2.13	;	Crystal Structure of a class III engineered cephalosporin acylase
3AQU	;	2.01	;	Crystal structure of a class V chitinase from Arabidopsis thaliana
3LVG	;	7.94	;	Crystal structure of a clathrin heavy chain and clathrin light chain complex
3LVH	;	9.0	;	Crystal structure of a clathrin heavy chain and clathrin light chain complex
6D0J	;	3.0	;	Crystal structure of a CLC-type fluoride/proton antiporter
6D0K	;	3.35	;	Crystal structure of a CLC-type fluoride/proton antiporter, E118Q mutant
6D0N	;	3.12	;	Crystal structure of a CLC-type fluoride/proton antiporter, V319G mutant
3DA0	;	1.65	;	Crystal structure of a cleaved form of a chimeric receptor binding protein from Lactococcal phages subspecies TP901-1 and p2
4ZRS	;	2.0	;	Crystal structure of a cloned feruloyl esterase from a soil metagenomic library
1DO8	;	2.2	;	CRYSTAL STRUCTURE OF A CLOSED FORM OF HUMAN MITOCHONDRIAL NAD(P)+-DEPENDENT MALIC ENZYME
6FZI	;	2.55	;	Crystal Structure of a Clostridial Dehydrogenase at 2.55 Angstroems Resolution
5L20	;	1.45	;	Crystal Structure of a Clostripain (BT_0727) from Bacteroides thetaiotaomicron ATCC 29148 in Complex with Peptide Inhibitor BTN-VLTK-AOMK
3UWS	;	1.7	;	Crystal structure of a clostripain (PARMER_00083) from Parabacteroides merdae ATCC 43184 at 1.70 A resolution
4YEC	;	1.12	;	Crystal structure of a clostripain (PARMER_00083) from Parabacteroides merdae ATCC 43184 in complex with peptide inhibitor Ac-VLTK-AOMK
7DQV	;	2.15	;	Crystal structure of a CmABCB1 mutant
7SU2	;	2.0	;	Crystal structure of a Co-bound RIDC1 variant
4G67	;	1.8	;	Crystal structure of a COG1565 superfamily member and likely methyl transferase from Burkholderia thailandensis bound to S-adenosyl-homocysteine
4GXW	;	1.3	;	Crystal structure of a cog1816 amidohydrolase (target EFI-505188) from Burkhoderia ambifaria, with bound Zn
3O0Z	;	2.33	;	Crystal structure of a coiled-coil domain from human ROCK I
5AJS	;	2.3	;	Crystal structure of a coiled-coil domain from human THAP11
5XG2	;	2.0	;	Crystal structure of a coiled-coil segment (residues 345-468 and 694-814) of Pyrococcus yayanosii Smc
2OVC	;	2.07	;	Crystal structure of a coiled-coil tetramerization domain from Kv7.4 channels
1O0Q	;	2.2	;	Crystal structure of a cold adapted alkaline protease from Pseudomonas TAC II 18, co-crystallized with 1 mM EDTA
1O0T	;	2.5	;	CRYSTAL STRUCTURE OF A COLD ADAPTED ALKALINE PROTEASE FROM PSEUDOMONAS TAC II 18, CO-CRYSTALLIZED WITH 5 mM EDTA (5 DAYS)
1OM6	;	2.0	;	CRYSTAL STRUCTURE OF A COLD ADAPTED ALKALINE PROTEASE FROM PSEUDOMONAS TAC II 18, CO-CRYSTALLIZED WITH 5mM EDTA (2 MONTHS)
1OM8	;	2.0	;	CRYSTAL STRUCTURE OF A COLD ADAPTED ALKALINE PROTEASE FROM PSEUDOMONAS TAC II 18, CO-CRYSTALLYZED WITH 10 mM EDTA
1OM7	;	2.8	;	CRYSTAL STRUCTURE OF A COLD ADAPTED ALKALINE PROTEASE FROM PSEUDOMONAS TAC II 18, SOAKED IN 85 mM EDTA
1S2N	;	2.44	;	Crystal structure of a cold adapted subtilisin-like serine proteinase
1SH7	;	1.84	;	Crystal structure of a cold adapted subtilisin-like serine proteinase
5YNL	;	2.349	;	Crystal structure of a cold-adapted arginase from psychrophilic yeast, Glaciozyma antarctica
5EUV	;	2.4	;	Crystal structure of a cold-adapted dimeric beta-D-galactosidase from Paracoccus sp. 32d strain
5LDR	;	3.15	;	Crystal structure of a cold-adapted dimeric beta-D-galactosidase from Paracoccus sp. 32d strain in complex with galactose
6HG7	;	1.0	;	Crystal structure of a collagen II fragment containing the binding site of PEDF and COMP, (POG)4-LKG HRG FTG LQG-POG(4)
1O91	;	1.9	;	Crystal Structure of a Collagen VIII NC1 Domain Trimer
2G66	;	1.8	;	Crystal structure of a collagen-like peptide with 3(S)Hyp in the Xaa position
5Y45	;	1.03	;	Crystal structure of a collagen-like peptide with interruption sequence
5Y46	;	1.03	;	Crystal structure of a collagen-like peptide with interruption sequence
7S0R	;	2.5	;	Crystal Structure of a Complement Factor H-binding Fragment within the B75KN Region of the Group B Streptococcus Beta Antigen C Protein
2QF7	;	2.0	;	Crystal structure of a complete multifunctional pyruvate carboxylase from Rhizobium etli
2ICW	;	2.41	;	Crystal structure of a complete ternary complex between TCR, superantigen, and peptide-MHC class II molecule
3T0E	;	4.0	;	Crystal structure of a complete ternary complex of T cell receptor, peptide-MHC and CD4
1LBZ	;	2.2	;	Crystal Structure of a complex (P32 crystal form) of dual activity FBPase/IMPase (AF2372) from Archaeoglobus fulgidus with 3 Calcium ions and Fructose-1,6 bisphosphate
1LBY	;	2.25	;	Crystal Structure of a complex (P32 crystal form) of dual activity FBPase/IMPase (AF2372) from Archaeoglobus fulgidus with 3 Manganese ions, Fructose-6-Phosphate, and Phosphate ion
4PD2	;	1.65	;	Crystal structure of a complex between a C248GH LlFpg mutant and a THF containing DNA
2XDM	;	2.4	;	Crystal structure of a complex between Actinomadura R39 DD peptidase and a peptidoglycan mimetic boronate inhibitor
2XK1	;	2.8	;	Crystal structure of a complex between Actinomadura R39 DD-peptidase and a boronate inhibitor
2XLN	;	2.4	;	Crystal structure of a complex between Actinomadura R39 DD-peptidase and a boronate inhibitor
4B4X	;	2.65	;	Crystal structure of a complex between Actinomadura R39 DD-peptidase and a sulfonamide boronate inhibitor
4B4Z	;	2.2	;	Crystal structure of a complex between Actinomadura R39 DD-peptidase and a sulfonamide boronate inhibitor
3ZCZ	;	2.6	;	Crystal structure of a complex between Actinomadura R39 DD-peptidase and a trifluoroketone inhibitor
4PDI	;	2.1	;	Crystal structure of a complex between an inhibited LlFpg and a N7-Benzyl-Fapy-dG containing DNA
4PDG	;	2.4	;	Crystal structure of a complex between an inhibited LlFpg and a THF containing DNA
4ZSO	;	2.5	;	Crystal structure of a complex between B7-H6, a tumor cell ligand for natural cytotoxicity receptor NKp30, and an inhibitory antibody
5GY2	;	2.1	;	Crystal structure of a complex between Bacillus subtilis flagellin and zebrafish Toll-like receptor 5
1N8O	;	2.0	;	Crystal structure of a complex between bovine chymotrypsin and ecotin
7ZJM	;	2.59	;	Crystal structure of a complex between CspZ from Borrelia burgdorferi strain B408 and human FH SCR domains 6-7
3ML4	;	2.6	;	Crystal structure of a complex between Dok7 PH-PTB and the MuSK juxtamembrane region
1G9S	;	2.8	;	CRYSTAL STRUCTURE OF A COMPLEX BETWEEN E.COLI HPRT AND IMP
2PCB	;	2.8	;	CRYSTAL STRUCTURE OF A COMPLEX BETWEEN ELECTRON TRANSFER PARTNERS, CYTOCHROME C PEROXIDASE AND CYTOCHROME C
2PCC	;	2.3	;	CRYSTAL STRUCTURE OF A COMPLEX BETWEEN ELECTRON TRANSFER PARTNERS, CYTOCHROME C PEROXIDASE AND CYTOCHROME C
6B20	;	2.34	;	Crystal structure of a complex between G protein beta gamma dimer and an inhibitory Nanobody regulator
6YJP	;	3.1	;	Crystal structure of a complex between glycosylated NKp30 and its deglycosylated tumour ligand B7-H6
1MW8	;	1.9	;	Crystal Structure of a Complex between H365R mutant of 67 kDA N-terminal fragment of E. coli DNA Topoisomerase I and 5'-ACTTCGGGATG-3'
6M58	;	2.95	;	Crystal structure of a complex between human serum albumin and the antibody Fab SL335
1FQ4	;	2.7	;	CRYSTAL STRUCTURE OF A COMPLEX BETWEEN HYDROXYETHYLENE INHIBITOR CP-108,420 AND YEAST ASPARTIC PROTEINASE A
3F7P	;	2.75	;	Crystal structure of a complex between integrin beta4 and plectin
3HVQ	;	2.2	;	Crystal structure of a complex between Protein Phosphatase 1 alpha (PP1) and the PP1 binding and PDZ domains of Neurabin
3EGG	;	1.85	;	Crystal structure of a complex between Protein Phosphatase 1 alpha (PP1) and the PP1 binding and PDZ domains of Spinophilin
3EGH	;	2.0	;	Crystal structure of a complex between Protein Phosphatase 1 alpha (PP1), the PP1 binding and PDZ domains of Spinophilin and the small natural molecular toxin Nodularin-R
6IXX	;	1.999	;	Crystal structure of a complex between psychrophilic marine protease MP and its inhibitor LupI
2B4S	;	2.3	;	Crystal structure of a complex between PTP1B and the insulin receptor tyrosine kinase
4PCZ	;	1.7	;	Crystal structure of a complex between R247G LlFPG mutant and a THF containing DNA
1SMP	;	2.3	;	CRYSTAL STRUCTURE OF A COMPLEX BETWEEN SERRATIA MARCESCENS METALLO-PROTEASE AND AN INHIBITOR FROM ERWINIA CHRYSANTHEMI
7X9S	;	3.11	;	Crystal structure of a complex between the antirepressor GmaR and the transcriptional repressor MogR
3FHI	;	2.0	;	Crystal structure of a complex between the catalytic and regulatory (RI{alpha}) subunits of PKA
4G7X	;	1.44	;	Crystal structure of a complex between the CTXphi pIII N-terminal domain and the Vibrio cholerae TolA C-terminal domain
1F93	;	2.6	;	CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THE DIMERIZATION DOMAIN OF HNF-1 ALPHA AND THE COACTIVATOR DCOH
6RZ3	;	4.23	;	Crystal structure of a complex between the DNA-binding domain of p53 and the carboxyl-terminal conserved region of iASPP
8BTL	;	3.2	;	Crystal structure of a complex between the E2 conjugating enzyme UBE2A and the E3 ligase module from UBR4
4E5X	;	1.95	;	Crystal structure of a complex between the human adenovirus type 2 E3-19K protein and MHC class I molecule HLA-A2/Tax
5IRO	;	2.64	;	Crystal structure of a complex between the Human adenovirus type 4 E3-19K protein and MHC class molecule HLA-A2/TAX
6RNM	;	1.76	;	Crystal structure of a complex between the LlFpg protein, a THF-DNA and an inhibitor
6RNO	;	2.25	;	Crystal structure of a complex between the LlFpg protein, a THF-DNA and an inhibitor
4MNB	;	1.4	;	Crystal Structure of a complex between the marine anticancer drug Variolin B and DNA
5BV0	;	3.1	;	Crystal Structure of a Complex Between the SNARE Nyv1 and the HOPS Vps33-Vps16 subcomplex from Chaetomium thermophilum
5BUZ	;	3.1	;	Crystal Structure of a Complex Between the SNARE Vam3 and the HOPS Vps33-Vps16 subcomplex from Chaetomium thermophilum
3C58	;	1.9	;	Crystal structure of a complex between the wild-type lactococcus lactis Fpg (MutM) and a N7-Benzyl-Fapy-dG containing DNA
2XZF	;	1.799	;	CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THE WILD-TYPE LACTOCOCCUS LACTIS FPG (MUTM) AND AN OXIDIZED PYRIMIDINE CONTAINING DNA AT 293K
2XZU	;	1.82	;	CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THE WILD-TYPE LACTOCOCCUS LACTIS FPG (MUTM) AND AN OXIDIZED PYRIMIDINE CONTAINING DNA AT 310K
1F6M	;	2.95	;	CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THIOREDOXIN REDUCTASE, THIOREDOXIN, AND THE NADP+ ANALOG, AADP+
1Z5S	;	3.01	;	Crystal structure of a complex between UBC9, SUMO-1, RANGAP1 and NUP358/RANBP2
1T0J	;	2.0	;	Crystal structure of a complex between voltage-gated calcium channel beta2a subunit and a peptide of the alpha1c subunit
1U1Y	;	2.85	;	Crystal structure of a complex between WT bacteriophage MS2 coat protein and an F5 aptamer RNA stemloop with 2aminopurine substituted at the-10 position
4V83	;	3.5	;	Crystal structure of a complex containing domain 3 from the PSIV IGR IRES RNA bound to the 70S ribosome.
4V84	;	3.4	;	Crystal structure of a complex containing domain 3 of CrPV IGR IRES RNA bound to the 70S ribosome.
5A3I	;	2.89	;	Crystal Structure of a Complex formed between FLD194 Fab and Transmissible Mutant H5 Haemagglutinin
1TGM	;	1.86	;	Crystal structure of a complex formed between group II phospholipase A2 and aspirin at 1.86 A resolution
1PO8	;	2.71	;	Crystal structure of a complex formed between krait venom phospholipase A2 and heptanoic acid at 2.7 A resolution.
5U79	;	1.604	;	Crystal structure of a complex formed between MerB and Dimethyltin
5U7A	;	1.532	;	Crystal structure of a complex formed between MerB and Dimethyltin
1OXG	;	2.2	;	Crystal structure of a complex formed between organic solvent treated bovine alpha-chymotrypsin and its autocatalytically produced highly potent 14-residue peptide at 2.2 resolution
1SXK	;	1.21	;	Crystal Structure of a complex formed between phospholipase A2 and a non-specific anti-inflammatory amino salicylic acid at 1.2 A resolution
1JQ9	;	1.8	;	Crystal structure of a complex formed between phospholipase A2 from Daboia russelli pulchella and a designed pentapeptide Phe-Leu-Ser-Tyr-Lys at 1.8 resolution
2GWA	;	1.75	;	Crystal Structure of a Complex Formed Between the DNA Holliday Junction and a Bis-Acridine Molecule.
1FYT	;	2.6	;	CRYSTAL STRUCTURE OF A COMPLEX OF A HUMAN ALPHA/BETA-T CELL RECEPTOR, INFLUENZA HA ANTIGEN PEPTIDE, AND MHC CLASS II MOLECULE, HLA-DR1
1J8H	;	2.4	;	Crystal Structure of a Complex of a Human alpha/beta-T cell Receptor, Influenza HA Antigen Peptide, and MHC Class II Molecule, HLA-DR4
3C84	;	1.94	;	Crystal structure of a complex of AChBP from aplysia californica and the neonicotinoid thiacloprid
2NU5	;	1.564	;	Crystal structure of a complex of griffithsin cocrystallized with N-acetylglucosamine
2HYQ	;	2.0	;	Crystal structure of a complex of griffithsin with 6alpha-mannobiose
2NUO	;	1.5	;	Crystal structure of a complex of griffithsin with glucose
2HYR	;	1.51	;	Crystal structure of a complex of griffithsin with maltose
2GUD	;	0.94	;	Crystal structure of a complex of griffithsin with mannose at 0.94 A resolution
2GUC	;	1.79	;	Crystal structure of a complex of griffithsin with mannose at 1.78 A resolution.
2GUE	;	2.02	;	Crystal structure of a complex of griffithsin with N-acetylglucosamine
1HIV	;	2.0	;	CRYSTAL STRUCTURE OF A COMPLEX OF HIV-1 PROTEASE WITH A DIHYDROETHYLENE-CONTAINING INHIBITOR: COMPARISONS WITH MOLECULAR MODELING
1G4C	;	1.65	;	CRYSTAL STRUCTURE OF A COMPLEX OF HPPK(R92A) FROM E.COLI WITH MG2+ AT 1.65 ANGSTROM RESOLUTION
1JOW	;	3.1	;	Crystal structure of a complex of human CDK6 and a viral cyclin
6P67	;	2.9	;	Crystal Structure of a Complex of human IL-7Ralpha with an anti-IL-7Ralpha 2B8 Fab
6P50	;	2.9	;	Crystal Structure of a Complex of human IL-7Ralpha with an anti-IL-7Ralpha Fab 4A10
1GG5	;	2.5	;	CRYSTAL STRUCTURE OF A COMPLEX OF HUMAN NAD[P]H-QUINONE OXIDOREDUCTASE AND A CHEMOTHERAPEUTIC DRUG (E09) AT 2.5 A RESOLUTION
1QJM	;	3.4	;	Crystal Structure of a Complex of Lactoferrin with a Lanthanide Ion (SM3+) at 3.4 Angstrom Resolution
1ZLF	;	2.3	;	Crystal structure of a complex of mutant HIV-1 protease (A71V, V82T, I84V) with a hydroxyethylamine peptidomimetic inhibitor
1ZBG	;	1.995	;	Crystal structure of a complex of mutant hiv-1 protease (A71V, V82T, I84V) with a hydroxyethylamine peptidomimetic inhibitor BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2
1ZJ7	;	1.93	;	Crystal structure of a complex of mutant HIV-1 protease (A71V, V82T, I84V) with a hydroxyethylamine peptidomimetic inhibitor BOC-PHE-PSI[S-CH(OH)CH2NH]-PHE-GLU-PHE-NH2
4JQW	;	2.9	;	Crystal Structure of a Complex of NOD1 CARD and Ubiquitin
2G58	;	0.98	;	Crystal structure of a complex of phospholipase A2 with a designed peptide inhibitor Dehydro-Ile-Ala-Arg-Ser at 0.98 A resolution
2QHW	;	2.21	;	Crystal structure of a complex of phospholipase A2 with a gramine derivative at 2.2 resolution
2O1N	;	2.8	;	Crystal structure of a complex of phospholipase A2 with a peptide Ala-Ile-Ala-Ser at 2.8 A resolution
2V6T	;	3.1	;	Crystal structure of a complex of pterin-4a-carbinolamine dehydratase from Toxoplasma gondii with 7,8-dihydrobiopterin
3D2F	;	2.3	;	Crystal structure of a complex of Sse1p and Hsp70
3D2E	;	2.35	;	Crystal structure of a complex of Sse1p and Hsp70, Selenomethionine-labeled crystals
3WY9	;	2.3	;	Crystal structure of a complex of the archaeal ribosomal stalk protein aP1 and the GDP-bound archaeal elongation factor aEF1alpha
1JPZ	;	1.65	;	Crystal structure of a complex of the heme domain of P450BM-3 with N-Palmitoylglycine
4U2M	;	2.23	;	Crystal structure of a complex of the Miz1- and BCL6 POZ domains.
4U2N	;	2.3	;	Crystal structure of a complex of the Miz1- and Nac1 POZ domains.
3D3H	;	2.31	;	Crystal structure of a complex of the peptidoglycan glycosyltransferase domain from Aquifex aeolicus and neryl moenomycin A
1Z58	;	3.8	;	Crystal structure of a complex of the ribosome large subunit with rapamycin
1IS0	;	1.9	;	Crystal Structure of a Complex of the Src SH2 Domain with Conformationally Constrained Peptide Inhibitor
1C9S	;	1.9	;	CRYSTAL STRUCTURE OF A COMPLEX OF TRP RNA-BINDING ATTENUATION PROTEIN WITH A 53-BASE SINGLE STRANDED RNA CONTAINING ELEVEN GAG TRIPLETS SEPARATED BY AU DINUCLEOTIDES
1V5V	;	1.5	;	Crystal Structure of a Component of Glycine Cleavage System: T-protein from Pyrococcus horikoshii OT3 at 1.5 A Resolution
4NDJ	;	1.85	;	Crystal Structure of a computational designed engrailed homeodomain variant fused with YFP
4NDK	;	2.3	;	Crystal structure of a computational designed engrailed homeodomain variant fused with YFP
6ERE	;	2.25	;	Crystal structure of a computationally designed colicin endonuclease and immunity pair colEdes3/Imdes3
6ER6	;	1.6	;	Crystal structure of a computationally designed colicin endonuclease and immunity pair colEdes7/Imdes7
8C3W	;	1.6	;	Crystal structure of a computationally designed heme binding protein, dnHEM1
6XXV	;	2.20116	;	Crystal Structure of a computationally designed Immunogen S2_1.2 in complex with its elicited antibody C57
4OYD	;	1.8	;	Crystal structure of a computationally designed inhibitor of an Epstein-Barr viral Bcl-2 protein
6IWB	;	2.5	;	Crystal structure of a computationally designed protein (LD3) in complex with BCL-2
4OU1	;	1.25	;	Crystal structure of a computationally designed retro-aldolase covalently bound to folding probe 1 [(6-methoxynaphthalen-2-yl)(oxiran-2-yl)methanol]
4PEJ	;	1.85	;	Crystal structure of a computationally designed retro-aldolase, RA110.4 (Cys free)
4PEK	;	1.6	;	Crystal structure of a computationally designed retro-aldolase, RA114.3
4N9G	;	2.5	;	Crystal Structure of a Computationally Designed RSV-Presenting Epitope Scaffold And Its Elicited Antibody 17HD9
1ZSZ	;	2.0	;	Crystal structure of a computationally designed SspB heterodimer
6NTF	;	2.8	;	Crystal structure of a computationally optimized H5 influenza hemagglutinin
4YAQ	;	2.3	;	Crystal structure of a computationally optimized PG9 mutant
3TIJ	;	2.436	;	Crystal structure of a concentrative nucleoside transporter from Vibrio cholerae
4HBC	;	1.54	;	Crystal structure of a conformation-dependent rabbit IgG Fab specific for amyloid prefibrillar oligomers
4LBA	;	1.7	;	Crystal structure of a conjugative transposon lipoprotein (BACEGG_03088) from Bacteroides eggerthii DSM 20697 at 1.70 A resolution
6NEK	;	1.63	;	Crystal structure of a consensus PDZ domain
1PVM	;	1.5	;	Crystal Structure of a Conserved CBS Domain Protein TA0289 of Unknown Function from Thermoplasma acidophilum
5D9R	;	2.052	;	Crystal structure of a conserved domain in the intermembrane space region of the plastid division protein ARC6
4IAJ	;	1.91	;	Crystal structure of a conserved domain protein (SP_1775) from Streptococcus pneumoniae TIGR4 at 1.91 A resolution
1LFP	;	1.72	;	Crystal Structure of a Conserved Hypothetical Protein Aq1575 from Aquifex Aeolicus
1T6S	;	1.95	;	Crystal structure of a conserved hypothetical protein from Chlorobium tepidum
4WKW	;	2.3	;	Crystal Structure of a Conserved Hypothetical Protein from Mycobacterium leprae Determined by Iodide SAD Phasing
2CW5	;	1.94	;	Crystal structure of a conserved hypothetical protein from Thermus thermophilus HB8
2CVE	;	1.6	;	Crystal structure of a conserved hypothetical protein TT1547 from thermus thermophilus HB8
2IB0	;	2.0	;	Crystal structure of a conserved hypothetical protein, rv2844, from Mycobacterium tuberculosis
3D19	;	2.3	;	Crystal structure of a conserved metalloprotein from Bacillus cereus
3RCO	;	1.8	;	Crystal structure of a conserved motif in human TDRD7
3CBN	;	1.63	;	Crystal structure of a conserved protein (MTH639) from Methanobacterium thermoautotrophicum
3B4Q	;	1.55	;	Crystal structure of a conserved protein domain (unknown function) from Corynebacterium diphtheriae
3D3Y	;	1.95	;	Crystal structure of a conserved protein from Enterococcus faecalis V583
2P0O	;	2.15	;	Crystal structure of a conserved protein from locus EF_2437 in Enterococcus faecalis with an unknown function
4DPO	;	2.73	;	Crystal structure of a conserved protein MM_1583 from Methanosarcina mazei Go1
3CLQ	;	2.5	;	Crystal structure of a conserved protein of unknown function from Enterococcus faecalis V583
3BRC	;	1.6	;	Crystal structure of a conserved protein of unknown function from Methanobacterium thermoautotrophicum
3BZ6	;	2.21	;	Crystal structure of a conserved protein of unknown function from Pseudomonas syringae pv. tomato str. DC3000
2FYW	;	2.4	;	Crystal Structure of a Conserved Protein of Unknown Function from Streptococcus pneumoniae
2I71	;	1.7	;	Crystal structure of a Conserved Protein of Unknown Function from Sulfolobus solfataricus P2
2IAZ	;	2.4	;	Crystal structure of a Conserved Protein of Unknown Function SP1372 from Streptococcus pneumoniae
1HC8	;	2.8	;	CRYSTAL STRUCTURE OF A CONSERVED RIBOSOMAL PROTEIN-RNA COMPLEX
1QA6	;	2.8	;	CRYSTAL STRUCTURE OF A CONSERVED RIBOSOMAL PROTEIN-RNA COMPLEX
1KMQ	;	1.55	;	Crystal Structure of a Constitutively Activated RhoA Mutant (Q63L)
8GS5	;	4.486	;	Crystal structure of a constitutively active mutant of human IDH3 holoenzyme in apo form
8GRB	;	2.848	;	Crystal structure of a constitutively active mutant of the alpha beta heterodimer of human IDH3
8GRD	;	2.699	;	Crystal structure of a constitutively active mutant of the alpha beta heterodimer of human IDH3 in complex with ADP and Mg
8GRU	;	2.847	;	Crystal structure of a constitutively active mutant of the alpha beta heterodimer of human IDH3 in complex with ICT, NAD and Ca
8GRG	;	2.699	;	Crystal structure of a constitutively active mutant of the alpha gamma heterodimer of human IDH3
8GRH	;	2.506	;	Crystal structure of a constitutively active mutant of the alpha gamma heterodimer of human IDH3 in complex with CIT
1P1Y	;	2.1	;	Crystal structure of a continuous three-dimensional DNA lattice from d(GGACAGATGGGAG)
1JT0	;	2.9	;	Crystal structure of a cooperative QacR-DNA complex
3DXS	;	1.7	;	Crystal structure of a copper binding domain from HMA7, a P-type ATPase
1NPN	;	1.8	;	Crystal structure of a copper reconstituted H145A mutant of nitrite reductase from Alcaligenes faecalis
3LOY	;	2.0	;	Crystal structure of a Copper-containing benzylamine oxidase from Hansenula Polymorpha
1JES	;	1.5	;	Crystal Structure of a Copper-Mediated Base Pair in DNA
3RFU	;	3.2	;	Crystal structure of a copper-transporting PIB-type ATPase
2HN1	;	2.9	;	Crystal structure of a CorA soluble domain from A. fulgidus in complex with Co2+
2P4P	;	1.8	;	Crystal structure of a CorC_HlyC domain from Haemophilus ducreyi
3BK6	;	3.2	;	Crystal structure of a core domain of stomatin from Pyrococcus horikoshii
3OKQ	;	2.044	;	Crystal structure of a core domain of yeast actin nucleation cofactor Bud6
4A2E	;	1.8	;	Crystal Structure of a Coriolopsis gallica Laccase at 1.7 A Resolution pH 5.5
4XVH	;	1.9449	;	Crystal structure of a Corynascus thermopiles (Myceliophthora fergusii) carbohydrate esterase family 2 (CE2) enzyme plus carbohydrate binding domain (CBD)
2C0U	;	2.2	;	Crystal Structure of a Covalent Complex of Nitroalkane Oxidase Trapped During Substrate Turnover
274D	;	2.3	;	CRYSTAL STRUCTURE OF A COVALENT DNA-DRUG ADDUCT: ANTHRAMYCIN BOUND TO C-C-A-A-C-G-T-T-G-G, AND A MOLECULAR EXPLANATION OF SPECIFICITY
1N2K	;	2.75	;	Crystal structure of a covalent intermediate of endogenous human arylsulfatase A
1N2L	;	3.2	;	Crystal structure of a covalent intermediate of endogenous human arylsulfatase A
3PR0	;	2.2	;	Crystal Structure of a Covalently Bound alpha-Ketoheterocycle Inhibitor (Phenhexyl/Oxadiazole/Pyridine) to a Humanized Variant of Fatty Acid Amide Hydrolase
4J5P	;	2.3	;	Crystal Structure of a Covalently Bound alpha-Ketoheterocycle Inhibitor (Phenhexyl/Oxadiazole/Pyridine) to a Humanized Variant of Fatty Acid Amide Hydrolase
4FBK	;	2.379	;	Crystal structure of a covalently fused Nbs1-Mre11 complex with one manganese ion per active site
4FBQ	;	2.5	;	Crystal structure of a covalently fused Nbs1-Mre11 complex with two manganese ions per active site
7ZTL	;	1.9	;	Crystal structure of a covalently linked Aurora-A N-Myc complex
3NO4	;	2.0	;	Crystal structure of a creatinine amidohydrolase (Npun_F1913) from Nostoc punctiforme PCC 73102 at 2.00 A resolution
1DH3	;	3.0	;	CRYSTAL STRUCTURE OF A CREB BZIP-CRE COMPLEX REVEALS THE BASIS FOR CREB FAIMLY SELECTIVE DIMERIZATION AND DNA BINDING
5F8S	;	1.08	;	Crystal structure of a Crenomytilus grayanus lectin
5F8Y	;	1.7	;	Crystal structure of a Crenomytilus grayanus lectin in complex with galactosamine
5F8W	;	1.56	;	Crystal structure of a Crenomytilus grayanus lectin in complex with galactose
5F90	;	1.64	;	Crystal structure of a Crenomytilus grayanus lectin in complex with Gb3 allyl
1WVR	;	2.4	;	Crystal Structure of a CRISP family Ca-channel blocker derived from snake venom
4EJ3	;	2.52	;	Crystal structure of a CRISPR associated protein from Thermus thermophilus HB8
6OAW	;	2.2	;	Crystal structure of a CRISPR Cas-related protein
4MJK	;	1.953	;	Crystal structure of a CRISPR protein from Archaeoglobus fulgidus
4QYZ	;	3.0303	;	Crystal structure of a CRISPR RNA-guided surveillance complex, Cascade, bound to a ssDNA target
1WJ9	;	1.9	;	Crystal structure of a CRISPR-associated protein from thermus thermophilus
5DIS	;	2.85	;	Crystal structure of a CRM1-RanGTP-SPN1 export complex bound to a 113 amino acid FG-repeat containing fragment of Nup214
2A5X	;	2.49	;	Crystal Structure of a Cross-linked Actin Dimer
5U89	;	3.075	;	Crystal structure of a cross-module fragment from the dimodular NRPS DhbF
1FBI	;	3.0	;	CRYSTAL STRUCTURE OF A CROSS-REACTION COMPLEX BETWEEN FAB F9.13.7 AND GUINEA-FOWL LYSOZYME
2AJ3	;	2.03	;	Crystal Structure of a Cross-Reactive HIV-1 Neutralizing CD4-Binding Site Antibody Fab m18
6FOF	;	2.2	;	Crystal structure of a crystallized variant of h-Gal3: Gal-3[NTS/VII-IX]
7TEP	;	2.7	;	Crystal structure of a Cu-bound cytochrome cb562 variant in the presence of reductant
1KYR	;	1.5	;	Crystal Structure of a Cu-bound Green Fluorescent Protein Zn Biosensor
1PZS	;	1.63	;	Crystal Structure of a Cu-Zn Superoxide Dismutase from Mycobacterium tuberculosis at 1.63 resolution
2IHW	;	2.7	;	Crystal structure of a cubic core of the dihydrolipoamide acyltransferase (E2b) component in the branched-chain alpha-ketoacid dehydrogenase complex (BCKDC), apo form
2II4	;	2.59	;	Crystal structure of a cubic core of the dihydrolipoamide acyltransferase (E2b) component in the branched-chain alpha-ketoacid dehydrogenase complex (BCKDC), Coenzyme A-bound form
2II5	;	2.5	;	Crystal structure of a cubic core of the dihydrolipoamide acyltransferase (E2b) component in the branched-chain alpha-ketoacid dehydrogenase complex (BCKDC), Isobutyryl-Coenzyme A-bound form
2II3	;	2.17	;	Crystal structure of a cubic core of the dihydrolipoamide acyltransferase (E2b) component in the branched-chain alpha-ketoacid dehydrogenase complex (BCKDC), Oxidized Coenzyme A-bound form
3KGZ	;	1.85	;	Crystal structure of a cupin 2 conserved barrel domain protein from Rhodopseudomonas palustris
2FQP	;	1.8	;	Crystal structure of a cupin domain (bp2299) from bordetella pertussis tohama i at 1.80 A resolution
3CEW	;	2.31	;	Crystal structure of a cupin protein (BF4112) from Bacteroides fragilis. Northeast Structural Genomics Consortium target BfR205
5WSD	;	1.2	;	Crystal structure of a cupin protein (tm1459) in apo form
6L2D	;	1.198	;	Crystal structure of a cupin protein (tm1459) in copper (Cu) substituted form
5WSE	;	1.12	;	Crystal structure of a cupin protein (tm1459) in osmium (Os) substituted form I
5WSF	;	1.11	;	Crystal structure of a cupin protein (tm1459) in osmium (Os)-substituted form II
6L2E	;	1.201	;	Crystal structure of a cupin protein (tm1459, H52A mutant) in copper (Cu) substituted form
8HJX	;	1.15	;	Crystal structure of a cupin protein (tm1459, H52A/H58E mutant) in copper (Cu) substituted form
8HJY	;	1.18	;	Crystal structure of a cupin protein (tm1459, H52A/H58E/F104W mutant) in copper (Cu) substituted form
8HJZ	;	1.22	;	Crystal structure of a cupin protein (tm1459, H52A/H58Q mutant) in copper (Cu) substituted form
6L2F	;	1.23	;	Crystal structure of a cupin protein (tm1459, H54AH58A mutant) in copper (Cu) substituted form
2OZJ	;	1.6	;	CRYSTAL STRUCTURE OF A CUPIN SUPERFAMILY PROTEIN (DSY2733) FROM DESULFITOBACTERIUM HAFNIENSE DCB-2 AT 1.60 A RESOLUTION
3D82	;	2.05	;	Crystal structure of a cupin-2 domain containing protein (sfri_3543) from shewanella frigidimarina ncimb 400 at 2.05 A resolution
2F4P	;	1.9	;	Crystal structure of a cupin-like protein (tm1010) from thermotoga maritima msb8 at 1.90 A resolution
6BBN	;	3.514	;	Crystal structure of a curved tubulin complex induced by the kinesin-13 Kif2A
7QJO	;	1.933	;	Crystal structure of a cutinase enzyme from Marinactinospora thermotolerans DSM45154 (606)
7QJP	;	1.561	;	Crystal structure of a cutinase enzyme from Saccharopolyspora flava (611)
7QJT	;	1.78	;	Crystal structure of a cutinase enzyme from Thermobifida cellulosilytica TB100 (711)
7QJQ	;	1.64	;	Crystal structure of a cutinase enzyme from Thermobifida fusca NTU22 (702)
7QJS	;	1.429	;	Crystal structure of a cutinase enzyme from Thermobifida fusca YX (705)
5YVK	;	1.292	;	Crystal structure of a cyclase Famc1 from Fischerella ambigua UTEX 1903
5ZFJ	;	1.86	;	Crystal structure of a cyclase Filc from Fischerella sp. in complex with 4-(1H-Indol-3-yl)butan-2-one
5Z53	;	1.86	;	Crystal structure of a cyclase Filc from Fischerella sp. in complex with cyclo-L-Arg-D-Pro
6A92	;	1.58	;	Crystal structure of a cyclase Filc1 from Fischerella sp.
6A98	;	1.82	;	Crystal structure of a cyclase from Fischerella sp. TAU
6A9F	;	1.7	;	Crystal structure of a cyclase from Fischerella sp. TAU in complex with 4-(1H-Indol-3-yl)butan-2-one
5YVL	;	2.059	;	Crystal structure of a cyclase Hpiu5 from Fischerella sp. ATCC 43239
5Z54	;	2.16	;	Crystal structure of a cyclase Hpiu5 from Fischerella sp. ATCC 43239 in complex with cyclo-L-Arg-D-Pro
6J03	;	1.48	;	Crystal structure of a cyclase mutant in apo form
1VH7	;	1.9	;	Crystal structure of a cyclase subunit of imidazolglycerolphosphate synthase
3GYD	;	1.79	;	Crystal structure of a cyclic nucleotide-binding domain (mfla_1926) from methylobacillus flagellatus kt at 1.79 A resolution
2QU1	;	1.7	;	Crystal Structure of a Cyclized GFP Variant
2DFY	;	1.65	;	Crystal structure of a cyclized protein fusion of LMO4 LIM domains 1 and 2 with the LIM interacting domain of LDB1
1XS7	;	2.8	;	Crystal Structure of a cycloamide-urethane-derived novel inhibitor bound to human brain memapsin 2 (beta-secretase).
6ZTU	;	1.69	;	Crystal structure of a cyclodipeptide synthase from Bacillus thermoamylovorans
6ZU3	;	1.78	;	Crystal structure of a cyclodipeptide synthase from Bacillus thermoamylovorans
7AZU	;	1.801	;	Crystal structure of a cyclodipeptide synthase from Bacillus thermoamylovorans
7QAU	;	2.3	;	Crystal structure of a cyclodipeptide synthase from Parcubacteria bacterium RAAC4_OD1_1, D58N mutant
7QAX	;	2.089	;	Crystal structure of a cyclodipeptide synthase from Parcubacteria bacterium RAAC4_OD1_1, E171Q mutant
7QAQ	;	2.4	;	Crystal structure of a cyclodipeptide synthase from Parcubacteria bacterium RAAC4_OD1_1, E174A mutant
7QAT	;	2.402	;	Crystal structure of a cyclodipeptide synthase from Parcubacteria bacterium RAAC4_OD1_1, E174L
7QB8	;	1.9	;	Crystal structure of a cyclodipeptide synthase from Parcubacteria bacterium RAAC4_OD1_1, WT form
7QAW	;	2.285	;	Crystal structure of a cyclodipeptide synthase from Parcubacteria bacterium RAAC4_OD1_1, Y189F mutant
7QAY	;	2.093	;	Crystal structure of a cyclodipeptide synthase from Parcubacteria bacterium RAAC4_OD1_1, Y55F mutant
7Y9O	;	1.84	;	Crystal structure of a CYP109B4 variant from Bacillus sonorensis
3GHD	;	1.81	;	Crystal structure of a cystathionine beta-synthase domain protein fused to a Zn-ribbon-like domain
2OWP	;	2.0	;	Crystal structure of a cystatin-like fold protein (bxe_b1374) from burkholderia xenovorans lb400 at 2.00 A resolution
4R4K	;	1.69	;	Crystal structure of a cystatin-like protein (BACCAC_01506) from Bacteroides caccae ATCC 43185 at 1.69 A resolution
4QAN	;	2.1	;	Crystal structure of a cystatin-like protein (RUMGNA_02398) from Ruminococcus gnavus ATCC 29149 at 2.10 A resolution
3EJV	;	1.4	;	Crystal structure of a cystatin-like protein (saro_2766) from novosphingobium aromaticivorans dsm at 1.40 A resolution
5B89	;	1.5	;	Crystal structure of a Cysteine Desulfurase from Thermococcus onnurineus NA1 in complex with alanine at 1.5 Angstrom resolution
5B87	;	2.28	;	Crystal structure of a Cysteine Desulfurase from Thermococcus onnurineus NA1 in complex with alanine at 2.3 Angstrom resolution
4W91	;	2.45	;	Crystal structure of a cysteine desulfurase SufS from Brucella suis bound to PLP
6WCI	;	2.05	;	Crystal structure of a cysteine desulfurase SufS from Stenotrophomonas maltophilia K279a
3PW3	;	2.23	;	Crystal structure of a cysteine protease (BDI_2249) from Parabacteroides distasonis ATCC 8503 at 2.23 A resolution
1CJL	;	2.2	;	CRYSTAL STRUCTURE OF A CYSTEINE PROTEASE PROFORM
5I7W	;	1.95	;	Crystal Structure of a Cysteine Synthase from Brucella suis
3VUD	;	3.5	;	Crystal structure of a cysteine-deficient mutant M1 in MAP kinase JNK1
3VUL	;	2.81	;	Crystal structure of a cysteine-deficient mutant M1 in MAP kinase JNK1
3VUG	;	3.24	;	Crystal structure of a cysteine-deficient mutant M2 in MAP kinase JNK1
3VUI	;	2.8	;	Crystal structure of a cysteine-deficient mutant M2 in MAP kinase JNK1
3VUH	;	2.7	;	Crystal structure of a cysteine-deficient mutant M3 in MAP kinase JNK1
3VUK	;	2.95	;	Crystal structure of a cysteine-deficient mutant M5 in MAP kinase JNK1
3VUM	;	2.69	;	Crystal structure of a cysteine-deficient mutant M7 in MAP kinase JNK1
6LH0	;	2.812	;	Crystal structure of a cysteine-pair mutant (P10C-S291C) of a bacterial bile acid transporter in an inward-facing apo-state
6LGV	;	1.847	;	Crystal structure of a cysteine-pair mutant (P10C-S291C) of a bacterial bile acid transporter in an inward-facing state complexed with citrate
6LGY	;	2.247	;	Crystal structure of a cysteine-pair mutant (P10C-S291C) of a bacterial bile acid transporter in an inward-facing state complexed with glycine and sodium
6LGZ	;	2.428	;	Crystal structure of a cysteine-pair mutant (P10C-S291C) of a bacterial bile acid transporter in an inward-facing state complexed with sulfate
7CYG	;	3.198	;	Crystal structure of a cysteine-pair mutant (Y113C-P190C) of a bacterial bile acid transporter before disulfide bond formation
6LH1	;	2.861	;	Crystal structure of a cysteine-pair mutant (Y113C-P190C) of a bacterial bile acid transporter trapped in an outward-facing conformation
4H0A	;	1.9	;	Crystal structure of a cysteine-rich secretory protein (SAV1118) from Staphylococcus aureus subsp. aureus Mu50 at 1.90 A resolution
4DIE	;	2.65	;	Crystal structure of a cytidylate kinase CmK from Mycobacterium abscessus bound to cytidine-5'-monophosphate
6N6Q	;	2.5	;	Crystal structure of a Cytochrome P450 (CYP102L1)
4RUI	;	2.61	;	Crystal structure of a cytochrome P450 2A6 in complex with a monoterpene - sabinene.
3IBD	;	2.0	;	Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl)imidazole
2RFB	;	2.5	;	Crystal Structure of a Cytochrome P450 from the Thermoacidophilic Archaeon Picrophilus Torridus
1I1R	;	2.4	;	CRYSTAL STRUCTURE OF A CYTOKINE/RECEPTOR COMPLEX
4E6R	;	2.2	;	Crystal structure of a Cytoplasmic protein NCK2 (NCK2) from Homo sapiens at 2.20 A resolution
1ST6	;	3.1	;	Crystal structure of a cytoskeletal protein
1UNO	;	1.4	;	Crystal structure of a d,l-alternating peptide
1KO0	;	2.2	;	Crystal Structure of a D,L-lysine complex of diaminopimelate decarboxylase
4M0J	;	2.05	;	Crystal structure of a D-amino acid aminotransferase from Burkholderia thailandensis E264
1EI5	;	1.9	;	CRYSTAL STRUCTURE OF A D-AMINOPEPTIDASE FROM OCHROBACTRUM ANTHROPI
5UNL	;	1.65	;	Crystal structure of a D-beta-hydroxybutyrate dehydrogenase from Burkholderia multivorans
3K85	;	2.28	;	Crystal structure of a D-glycero-D-manno-heptose 1-phosphate kinase from Bacteriodes thetaiotaomicron
3QC3	;	2.2	;	Crystal structure of a D-ribulose-5-phosphate-3-epimerase (NP_954699) from HOMO SAPIENS at 2.20 A resolution
2ZVR	;	2.2	;	Crystal structure of a D-tagatose 3-epimerase-related protein from Thermotoga maritima
2XO7	;	2.85	;	Crystal structure of a dA:O-allylhydroxylamine-dC basepair in complex with fragment DNA polymerase I from Bacillus stearothermophilus
3BDE	;	1.79	;	Crystal structure of a dabb family protein with a ferredoxin-like fold (mll5499) from mesorhizobium loti maff303099 at 1.79 A resolution
2XUU	;	1.8	;	Crystal structure of a DAP-kinase 1 mutant
3HG0	;	2.1	;	Crystal structure of a DARPin in complex with ORF49 from Lactococcal phage TP901-1
5B18	;	1.8	;	Crystal Structure of a Darunavir Resistant HIV-1 Protease
2I5A	;	1.65	;	Crystal structure of a DB1055-D(CGCGAATTCGCG)2 complex
5I6I	;	8.4	;	Crystal structure of a dBCCP-variant of Chaetomium thermophilum acetyl-CoA carboxylase
4AG4	;	2.8	;	Crystal structure of a DDR1-Fab complex
5EON	;	1.696	;	Crystal structure of a de novo antiparallel coiled-coil hexamer - ACC-Hex
6Q5S	;	1.89	;	Crystal structure of a de novo designed antiparallel four-helix coiled coil apCC-Tet
4R80	;	2.445	;	Crystal Structure of a De Novo Designed Beta Sheet Protein, Cystatin Fold, Northeast Structural Genomics Consortium (NESG) Target OR486
4RJV	;	1.523	;	Crystal Structure of a De Novo Designed Ferredoxin Fold, Northeast Structural Genomics Consortium (NESG) Target OR461
6TJ1	;	2.4	;	Crystal structure of a de novo designed hexameric helical-bundle protein
6TMS	;	2.7	;	Crystal structure of a de novo designed hexameric helical-bundle protein
6O35	;	2.4	;	Crystal structure of a de novo designed octameric helical-bundle protein
7UEK	;	2.1	;	Crystal structure of a de novo designed ovoid TIM barrel OT3
6XXZ	;	1.7	;	Crystal structure of a de novo designed parallel four-helix coiled coil, 2-EK-4
6XY0	;	1.11	;	Crystal structure of a de novo designed parallel four-helix coiled coil, 3-EK-4
6XY1	;	1.5	;	Crystal structure of a de novo designed parallel four-helix coiled coil, 4-KE-4.
5TPH	;	2.47	;	Crystal structure of a de novo designed protein homodimer with curved beta-sheet
5L33	;	2.0	;	Crystal structure of a de novo designed protein with curved beta-sheet
5TPJ	;	3.101	;	Crystal structure of a de novo designed protein with curved beta-sheet
5TRV	;	2.91	;	Crystal structure of a de novo designed protein with curved beta-sheet
5TS4	;	3.005	;	Crystal structure of a de novo designed protein with curved beta-sheet
5U35	;	1.8	;	Crystal structure of a de novo designed protein with curved beta-sheet
7CBC	;	1.99	;	Crystal structure of a de novo designed switch protein caging a hemagglutinin binder
5BVL	;	1.992	;	Crystal structure of a de novo designed TIM-barrel
1HQJ	;	1.2	;	CRYSTAL STRUCTURE OF A DE NOVO DESIGNED TRIMERIC COILED-COIL PEPTIDE
1KYC	;	1.45	;	CRYSTAL STRUCTURE OF A DE NOVO DESIGNED TRIMERIC COILED-COIL PEPTIDE STABLIZED BY IONIC INTERACTIONS
8H7D	;	2.2	;	Crystal structure of a de novo enzyme, ferric enterobactin esterase Syn-F4 (K4T)
8H7C	;	2.15	;	Crystal structure of a de novo enzyme, ferric enterobactin esterase Syn-F4 (K4T) - Pt derivative
8H7E	;	2.0	;	Crystal structure of a de novo enzyme, ferric enterobactin esterase Syn-F4 (K4T) at 2.0 angstrom resolution
4PA8	;	1.2	;	Crystal structure of a de novo retro-aldolase catalyzing asymmetric Michael additions, with a covalently bound product analog
6EGL	;	1.4	;	Crystal Structure of a de Novo Three-stranded Coiled Coil Peptide Containing a D-Leu in the Second Coordination Sphere of a Non-metalated Tris-thiolate Binding Site
7N2Y	;	2.08	;	Crystal Structure of a de Novo Three-stranded Coiled Coil Peptide Containing a dual Tris-thiolate Binding Site for Heavy Metal Complexes
6EGO	;	1.93	;	Crystal Structure of a de Novo Three-stranded Coiled Coil Peptide Containing an Ala Residue in the Second Coordination Sphere of the Hg(II)S3 Binding Site
6EGM	;	1.84	;	Crystal Structure of a de novo Three-stranded Coiled Coil Peptide Containing D-Leu in a d-site Position of a Tris-thiolate Binding Site
7N2Z	;	1.29	;	Crystal Structure of a de Novo Three-stranded Coiled Coil Peptide Containing Trigonal Pyrmidal Pb(II) complexes in the dual Tris-thiolate Site
7N1K	;	3.01	;	Crystal structure of a de novo-designed mini-protein targeting FGFR
1NJ4	;	1.9	;	Crystal structure of a deacylation-defective mutant of penicillin-binding protein 5 at 1.9 A resolution
1HD8	;	2.3	;	Crystal structure of a deacylation-defective mutant of penicillin-binding protein 5 at 2.3 A resolution
1SDN	;	2.5	;	CRYSTAL STRUCTURE OF A DEACYLATION-DEFECTIVE MUTANT OF PENICILLIN-BINDING PROTEIN 5 MODIFIED BY MERCURY
1HV8	;	3.0	;	CRYSTAL STRUCTURE OF A DEAD BOX PROTEIN FROM THE HYPERTHERMOPHILE METHANOCOCCUS JANNASCHII
2YVI	;	1.92	;	Crystal structure of a death domain of human ankryn protein
2BJ6	;	2.6	;	Crystal Structure of a decameric HNA-RNA hybrid
3MZV	;	1.9	;	Crystal structure of a decaprenyl diphosphate synthase from Rhodobacter capsulatus
8H41	;	1.78	;	Crystal structure of a decarboxylase from Trichosporon moniliiforme in complex with o-nitrophenol
4W7J	;	1.79	;	CRYSTAL STRUCTURE OF A DECOLORIZING PEROXIDASE (DYP) FROM AURICULARIA AURICULA-JUDAE
4W7L	;	1.05	;	CRYSTAL STRUCTURE OF A DECOLORIZING PEROXIDASE (DYP) FROM AURICULARIA AURICULA-JUDAE. D168N MUTANT
4W7O	;	1.2	;	CRYSTAL STRUCTURE OF A DECOLORIZING PEROXIDASE (DYP) FROM AURICULARIA AURICULA-JUDAE. G169L, Y147S AND W377S TRIPLE MUTANT
4W7M	;	1.15	;	CRYSTAL STRUCTURE OF A DECOLORIZING PEROXIDASE (DYP) FROM AURICULARIA AURICULA-JUDAE. W377S MUTANT
4W7N	;	1.401	;	CRYSTAL STRUCTURE OF A DECOLORIZING PEROXIDASE (DYP) FROM AURICULARIA AURICULA-JUDAE. Y147S AND W377S DOUBLE MUTANT
4W7K	;	1.05	;	CRYSTAL STRUCTURE OF A DECOLORIZING PEROXIDASE (DYP) FROM AURICULARIA AURICULA-JUDAE. Y147S MUTANT
2D3Q	;	2.8	;	Crystal Structure of a Decolorizing Peroxidase (DyP) That Catalyses the Biological Oxidation of Anthraquinone Derivatives
4QGR	;	1.75	;	Crystal structure of a DegT DnrJ EryC1 StrS aminotransferase from Brucella abortus
1VPV	;	2.45	;	Crystal structure of a degv lipid binding protein (tm1468) from thermotoga maritima at 2.45 A resolution
7R9X	;	2.14	;	Crystal structure of a dehydrating condensation domain, AmbE-CmodAA, involved in nonribosomal peptide synthesis
3V2G	;	2.3	;	Crystal structure of a dehydrogenase/reductase from Sinorhizobium meliloti 1021
5IYS	;	1.93	;	Crystal structure of a dehydrosqualene synthase in complex with ligand
4J5N	;	2.05	;	Crystal Structure of a Deinococcus radiodurans PTE-like lactonase (drPLL) mutant Y28L/D71N/E101G/E179D/V235L/L270M
3QQ0	;	1.9	;	Crystal structure of a deletion mutant (N59) of 3-deoxy-D-manno-octulosonate 8-phosphate synthase (KDO8PS) from Neisseria meningitidis
4TS1	;	2.5	;	CRYSTAL STRUCTURE OF A DELETION MUTANT OF A TYROSYL-T/RNA SYNTHETASE COMPLEXED WITH TYROSINE
4AD8	;	3.998	;	Crystal structure of a deletion mutant of Deinococcus radiodurans RecN
3N00	;	2.6	;	Crystal Structure of a deletion mutant of human Reverba ligand binding domain bound with an NCoR ID1 peptide determined to 2.60A
1CX4	;	2.45	;	CRYSTAL STRUCTURE OF A DELETION MUTANT OF THE TYPE II BETA REGULATORY SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
3Q4O	;	1.34	;	Crystal Structure of a deletion mutant(11-185) of hypothetical protein MJ0754 determined to 1.34A
3Q4Q	;	1.75	;	Crystal Structure of a deletion mutant(11-185) of hypothetical protein MJ0754 with Mn2+
3Q4R	;	1.6	;	Crystal Structure of a deletion mutant(11-185) of hypothetical protein MJ0754 with Zn2+
7T63	;	2.0	;	Crystal structure of a delta 6 18:0-ACP desaturase from Thunbergia laurifolia
3F63	;	1.8	;	Crystal structure of a Delta class GST (adGSTD4-4) from Anopheles dirus, in complex with S-hexyl glutathione
3G7I	;	2.05	;	Crystal structure of a Delta class GST (adGSTD4-4) from Anopheles dirus, with glutathione complexed in one subunit
4DHK	;	2.05	;	Crystal structure of a deoxycytidine triphosphate deaminase (dCTP deaminase) from Burkholderia thailandensis
3R12	;	1.75	;	Crystal structure of a Deoxyribose-phosphate aldolase (TM_1559) from THERMOTOGA MARITIMA at 1.75 A resolution
3R13	;	1.83	;	Crystal structure of a Deoxyribose-phosphate aldolase (TM_1559) from THERMOTOGA MARITIMA at 1.83 A resolution
4LHR	;	1.5	;	Crystal structure of a deoxyuridine 5'-triphosphate nucleotidohydrolase from Burkholderia thailandensis
4I1V	;	2.6	;	Crystal structure of a dephospho-CoA kinase from Burkholderia vietnamiensis bound to ADP
6ARI	;	2.0	;	Crystal structure of a dephospho-CoA kinase from Escherichia coli in complex with inhibitor CM078
8DV0	;	1.4	;	Crystal Structure of a Dephospho-CoA kinase from Rickettsia felis
3HNU	;	1.56	;	Crystal structure of a designed Cyanovirin-N homolog lectin; LKAMG in P21 space group
3HNX	;	1.37	;	Crystal structure of a designed Cyanovirin-N homolog lectin; LKAMG in P212121 space group
3HP8	;	2.0	;	Crystal structure of a designed Cyanovirin-N homolog lectin; LKAMG, bound to sucrose
2QYJ	;	2.05	;	Crystal structure of a designed full consensus ankyrin
2XGE	;	2.14	;	Crystal structure of a designed heterodimeric variant T-A(A)B of the tetracycline repressor
2XGC	;	2.15	;	Crystal structure of a designed heterodimeric variant T-A(I)B of the tetracycline repressor
2XGD	;	2.25	;	Crystal structure of a designed homodimeric variant T-A(L)A(L) of the tetracycline repressor
5C39	;	1.751	;	Crystal structure of a designed Mn binding peptide
6IEV	;	2.25	;	Crystal structure of a designed protein
7BWN	;	2.396	;	Crystal Structure of a Designed Protein Heterocatenane
4JLR	;	2.71	;	Crystal structure of a designed Respiratory Syncytial Virus Immunogen in complex with Motavizumab
1SVX	;	2.24	;	Crystal structure of a designed selected Ankyrin Repeat protein in complex with the Maltose Binding Protein
3ZU7	;	1.97	;	Crystal structure of a designed selected Ankyrin Repeat protein in complex with the MAP kinase ERK2
3ZUV	;	2.72	;	Crystal structure of a designed selected Ankyrin Repeat protein in complex with the phosphorylated MAP kinase ERK2
8GIE	;	1.85	;	Crystal structure of a designed single-component Plasmodium falciparum AMA1-RON2L insertion fusion immunogen 2
8GIF	;	2.1	;	Crystal structure of a designed single-component Plasmodium falciparum AMA1-RON2L insertion fusion immunogen 3
1MEY	;	2.2	;	CRYSTAL STRUCTURE OF A DESIGNED ZINC FINGER PROTEIN BOUND TO DNA
1BB1	;	1.8	;	CRYSTAL STRUCTURE OF A DESIGNED, THERMOSTABLE HETEROTRIMERIC COILED COIL
6EEN	;	2.01	;	Crystal structure of a designer Pentatrico Peptide RNA binding protein, bound to a complex RNA target and featuring an infinite superhelix and microheterogeneity.
3OF5	;	1.52	;	Crystal Structure of a Dethiobiotin Synthetase from Francisella tularensis subsp. tularensis SCHU S4
4Z8B	;	1.951	;	crystal structure of a DGL mutant - H51G H131N
4NZK	;	1.49	;	Crystal structure of a DHHW family protein (EUBSIR_00411) from Eubacterium siraeum DSM 15702 at 1.49 A resolution
5GO3	;	2.2	;	Crystal structure of a di-nucleotide cyclase Vibrio mutant
2HXV	;	1.8	;	Crystal structure of a diaminohydroxyphosphoribosylaminopyrimidine deaminase/ 5-amino-6-(5-phosphoribosylamino)uracil reductase (tm1828) from thermotoga maritima at 1.80 A resolution
1Q4Q	;	2.1	;	Crystal structure of a DIAP1-Dronc complex
5ZFG	;	1.7	;	Crystal structure of a diazinon-metabolizing glutathione S-transferase in the silkworm, Bombyx mori
6UKL	;	2.02	;	Crystal Structure of a DiB2-split Protein
7W6V	;	2.47	;	Crystal structure of a dicobalt-substituted small laccase at 2.47 angstrom
3A5N	;	2.36	;	Crystal Structure of a Dictyostelium P109A Ca2+-Actin in Complex with Human Gelsolin Segment 1
3A5L	;	2.4	;	Crystal Structure of a Dictyostelium P109A Mg2+-Actin in Complex with Human Gelsolin Segment 1
3A5O	;	2.4	;	Crystal Structure of a Dictyostelium P109I Ca2+-Actin in Complex with Human Gelsolin Segment 1
3A5M	;	2.4	;	Crystal Structure of a Dictyostelium P109I Mg2+-Actin in Complex with Human Gelsolin Segment 1
1DEJ	;	2.4	;	CRYSTAL STRUCTURE OF A DICTYOSTELIUM/TETRAHYMENA CHIMERA ACTIN (MUTANT 646: Q228K/T229A/A230Y/A231K/S232E/E360H) IN COMPLEX WITH HUMAN GELSOLIN SEGMENT 1
1C1E	;	1.9	;	CRYSTAL STRUCTURE OF A DIELS-ALDERASE CATALYTIC ANTIBODY 1E9 IN COMPLEX WITH ITS HAPTEN
3FNI	;	2.3	;	Crystal structure of a diflavin flavoprotein A3 (all3895) from Nostoc sp., Northeast Structural Genomics Consortium Target NsR431A
7RZO	;	1.8	;	Crystal structure of a dihydrofolate reductase (folA) from Stenotrophomonas maltophilia
7TJ3	;	1.55	;	Crystal structure of a dihydrofolate reductase folA from Stenotrophomonas maltophilia bound to NADP and p218
6CXM	;	2.65	;	Crystal structure of a dihydrofolate reductase from Mycobacterium smegmatis in complex with NADP and P218
3URH	;	1.9	;	Crystal structure of a dihydrolipoamide dehydrogenase from Sinorhizobium meliloti 1021
5U25	;	2.3	;	Crystal structure of a dihydrolipoyl dehydrogenase from Neisseria gonorrhoeae bound to FAD
3L8K	;	2.5	;	Crystal structure of a dihydrolipoyl dehydrogenase from Sulfolobus solfataricus
2OGJ	;	2.62	;	Crystal structure of a dihydroorotase
4LFY	;	1.8	;	Crystal structure of a dihydroorotase from Burkholderia cenocepacia J2315
5HBM	;	3.043	;	Crystal Structure of a Dihydroxycoumarin RNase H Active-Site Inhibitor in Complex with HIV-1 Reverse Transcriptase
1M2Z	;	2.5	;	Crystal structure of a dimer complex of the human glucocorticoid receptor ligand-binding domain bound to dexamethasone and a TIF2 coactivator motif
2P5L	;	2.85	;	Crystal structure of a dimer of N-terminal domains of AhrC in complex with an 18bp DNA operator site
3NBN	;	3.45	;	Crystal structure of a dimer of Notch Transcription Complex trimers on HES1 DNA
1U73	;	1.9	;	Crystal structure of a Dimeric Acidic Platelet Aggregation Inhibitor and Hypotensive Phospholipase A2 from Bothrops jararacussu
1RLV	;	3.0	;	Crystal structure of a dimeric Archaeal Splicing Endonuclease
7OVY	;	1.24	;	Crystal structure of a dimeric based inhibitor JG34 in complex with the MMP-12 catalytic domain
2AR9	;	2.8	;	Crystal structure of a dimeric caspase-9
5YB9	;	2.276	;	Crystal structure of a dimeric cyclophilin A from T.vaginalis
3DE8	;	1.72	;	Crystal Structure of a Dimeric Cytochrome cb562 Assembly Induced by Copper Coordination
2QYC	;	1.9	;	Crystal structure of a dimeric ferredoxin-like protein (bb1511) from bordetella bronchiseptica rb50 at 1.90 A resolution
3BN7	;	1.64	;	CRYSTAL STRUCTURE OF A DIMERIC FERREDOXIN-LIKE PROTEIN (CC_2267) FROM CAULOBACTER CRESCENTUS CB15 AT 1.64 A RESOLUTION
2OD4	;	1.7	;	Crystal structure of a dimeric ferredoxin-like protein (jcvi_pep_1096665735785) from uncultured marine organism at 1.70 A resolution
2OP5	;	2.2	;	CRYSTAL STRUCTURE OF A DIMERIC FERREDOXIN-LIKE PROTEIN (JCVI_PEP_1096672785533) FROM UNCULTURED MARINE ORGANISM AT 2.20 A RESOLUTION
2OD6	;	1.85	;	Crystal structure of a dimeric ferredoxin-like protein (jcvi_pep_1096682647733) from uncultured marine organism at 1.85 A resolution
3BB5	;	2.3	;	CRYSTAL STRUCTURE OF A DIMERIC FERREDOXIN-LIKE PROTEIN OF UNKNOWN FUNCTION (JANN_3925) FROM JANNASCHIA SP. CCS1 AT 2.30 A RESOLUTION
3BGU	;	1.5	;	Crystal structure of a dimeric ferredoxin-like protein of unknown function (tfu_0763) from thermobifida fusca yx at 1.50 A resolution
1CVS	;	2.8	;	CRYSTAL STRUCTURE OF A DIMERIC FGF2-FGFR1 COMPLEX
1UUP	;	2.6	;	Crystal Structure of A Dimeric Form of Streptococcal Pyrogenic Exotoxin A (SpeA1).
3IO5	;	2.4	;	Crystal Structure of a dimeric form of the uvsX Recombinase core domain from Enterobacteria Phage T4
6LSO	;	1.76	;	Crystal structure of a dimeric inhibited of peptidyl tRNA hydrolase at 1.76A resolution
7X7G	;	2.19	;	Crystal structure of a dimeric interlocked parallel G-quadruplex
7XDH	;	1.83	;	Crystal structure of a dimeric interlocked parallel G-quadruplex
7XH9	;	1.63	;	Crystal structure of a dimeric interlocked parallel G-quadruplex
7XHD	;	1.66	;	Crystal structure of a dimeric interlocked parallel G-quadruplex
7XIE	;	1.97	;	Crystal structure of a dimeric interlocked parallel G-quadruplex
3UX7	;	2.97	;	Crystal structure of a dimeric myotoxic component of the Vipera ammodytes meridionalis venom reveals determinants of myotoxicity and membrane damaging activity
5YLA	;	1.68	;	Crystal structure of a dimeric peptidyl-tRNA hydrolase from Acinetobacter baumannii at 1.67 A resolution
6LSP	;	1.5	;	Crystal structure of a dimeric Piptidyl t-RNA hydrolase from Acinetobacter baumannii at 1.50 A resolution reveals an inhibited form.
4G2E	;	1.4	;	Crystal structure of a dimeric PrxQ from Sulfolobus tokodaii
4BK6	;	1.63	;	Crystal Structure of a dimeric variant of Bet v 1
6LQW	;	2.6	;	Crystal structure of a dimeric yak lactoperoxidase at 2.59 A resolution.
2NXF	;	1.7	;	Crystal Structure of a dimetal phosphatase from Danio rerio LOC 393393
2H1R	;	1.89	;	Crystal structure of a dimethyladenosine transferase from Plasmodium falciparum
1K1Q	;	2.8	;	Crystal Structure of a DinB Family Error Prone DNA Polymerase from Sulfolobus solfataricus
2OQM	;	1.83	;	Crystal structure of a dinb family member protein (sden_0562) from shewanella denitrificans at 1.83 A resolution
1IM4	;	2.3	;	Crystal Structure of a DinB Homolog (DBH) Lesion Bypass DNA Polymerase Catalytic Fragment from Sulfolobus solfataricus
3DI5	;	2.009	;	Crystal structure of a dinb-like protein (bce_4655) from bacillus cereus atcc 10987 at 2.01 A resolution
3QTH	;	2.2	;	Crystal structure of a DinB-like protein (CPS_3021) from Colwellia psychrerythraea 34H at 2.20 A resolution
3DKA	;	2.3	;	Crystal structure of a dinb-like protein (yjoa, bsu12410) from bacillus subtilis at 2.30 A resolution
7C0R	;	1.77	;	Crystal structure of a dinucleotide-binding protein (F79A) of ABC transporter endogenously bound to uridylyl-3'-5'-phospho-guanosine (Form I)
7C0S	;	1.85	;	Crystal structure of a dinucleotide-binding protein (F79A) of ABC transporter endogenously bound to uridylyl-3'-5'-phospho-guanosine (Form II)
7C1B	;	2.3	;	Crystal structure of a dinucleotide-binding protein (F79A/Y224A/Y246A and deletion of residues 50-75) of ABC transporter (unbound form)
7C0T	;	1.77	;	Crystal structure of a dinucleotide-binding protein (N81A) of ABC transporter endogenously bound to uridylyl-3'-5'-phospho-guanosine
7C14	;	2.4	;	Crystal structure of a dinucleotide-binding protein (Q274A) of ABC transporter endogenously bound to uridylyl-3'-5'-phospho-guanosine (Form I)
7C15	;	1.8	;	Crystal structure of a dinucleotide-binding protein (Q274A) of ABC transporter endogenously bound to uridylyl-3'-5'-phospho-guanosine (Form II)
7C0U	;	1.8	;	Crystal structure of a dinucleotide-binding protein (S127A) of ABC transporter endogenously bound to uridylyl-3'-5'-phospho-guanosine
7C0X	;	1.77	;	Crystal structure of a dinucleotide-binding protein (T240A) of ABC transporter endogenously bound to uridylyl-3'-5'-phospho-guanosine
7C0V	;	1.9	;	Crystal structure of a dinucleotide-binding protein (Y224A) of ABC transporter endogenously bound to uridylyl-3'-5'-phospho-guanosine (Form I)
7C0W	;	2.1	;	Crystal structure of a dinucleotide-binding protein (Y224A) of ABC transporter endogenously bound to uridylyl-3'-5'-phospho-guanosine (Form II)
7C16	;	1.9	;	Crystal structure of a dinucleotide-binding protein (Y224A/Y246A) of ABC transporter endogenously bound to uridylyl-3'-5'-phospho-guanosine (Form I)
7C19	;	1.77	;	Crystal structure of a dinucleotide-binding protein (Y224A/Y246A) of ABC transporter endogenously bound to uridylyl-3'-5'-phospho-guanosine (Form II)
7C0Y	;	1.7	;	Crystal structure of a dinucleotide-binding protein (Y246A) of ABC transporter endogenously bound to uridylyl-3'-5'-phospho-guanosine (Form I)
7C0Z	;	2.2	;	Crystal structure of a dinucleotide-binding protein (Y246A) of ABC transporter endogenously bound to uridylyl-3'-5'-phospho-guanosine (Form II)
7C0O	;	2.0	;	Crystal structure of a dinucleotide-binding protein (Y56F) of ABC transporter endogenously bound to uridylyl-3'-5'-phospho-guanosine
7C0F	;	2.15	;	Crystal structure of a dinucleotide-binding protein of ABC transporter endogenously bound to uridylyl-3'-5'-phospho-guanosine (Form I)
7C0K	;	1.8	;	Crystal structure of a dinucleotide-binding protein of ABC transporter endogenously bound to uridylyl-3'-5'-phospho-guanosine (Form II)
7C0L	;	1.85	;	Crystal structure of a dinucleotide-binding protein of ABC transporter endogenously bound to uridylyl-3'-5'-phospho-guanosine (Form III)
2NP9	;	2.45	;	Crystal structure of a dioxygenase in the Crotonase superfamily
5KAG	;	2.456	;	Crystal structure of a dioxygenase in the Crotonase superfamily in P21
5KAJ	;	2.681	;	Crystal structure of a dioxygenase in the Crotonase superfamily in P21, A319C mutant
5KAH	;	2.779	;	Crystal structure of a dioxygenase in the Crotonase superfamily in P21, V425T mutant
2HNU	;	2.0	;	Crystal Structure of a Dipeptide Complex of Bovine Neurophysin-I
2HNV	;	2.5	;	Crystal Structure of a Dipeptide Complex of the Q58V Mutant of Bovine Neurophysin-I
6VRR	;	1.45	;	Crystal structure of a disease mutant of the Voltage-gated Sodium Channel Beta 2 subunit extracellular domain
6VSV	;	1.62	;	Crystal structure of a disease mutant of the Voltage-gated Sodium Channel Beta 4 subunit extracellular domain
4EOW	;	1.97	;	Crystal structure of a disease-associated anti-human GM-CSF autoantibody MB007
5YDF	;	1.399	;	Crystal structure of a disease-related gene, hCDC73(1-100)
5YDE	;	1.023	;	Crystal structure of a disease-related gene, hCDC73(1-111)
1TEJ	;	1.9	;	Crystal structure of a disintegrin heterodimer at 1.9 A resolution.
1FCS	;	1.6	;	CRYSTAL STRUCTURE OF A DISTAL SITE DOUBLE MUTANT OF SPERM WHALE MYOGLOBIN AT 1.6 ANGSTROMS RESOLUTION
4RDU	;	1.85	;	Crystal structure of a distal-less homeobox protein 5 (Dlx5) from Homo sapiens at 1.85 A resolution
2IPL	;	1.2	;	Crystal structure of a disulfide mutant glucose binding protein
2IPM	;	1.12	;	Crystal structure of a disulfide mutant glucose binding protein
2IPN	;	1.15	;	Crystal structure of a disulfide mutant glucose binding protein
5OQI	;	2.4	;	Crystal Structure of a disulfide trapped single chain trimer composed of the MHC I heavy chain H-2Kb Y84C E63A mutant, beta-2microglobulin, and ovalbumin-derived peptide
5OQH	;	2.05	;	Crystal Structure of a disulfide trapped single chain trimer composed of the MHC I heavy chain H-2Kb Y84C K66A mutant, beta-2microglobulin, and ovalbumin-derived peptide
2QRT	;	1.8	;	Crystal Structure of a disulfide trapped single chain trimer composed of the MHC I heavy chain H-2Kb Y84C, beta-2microglobulin, and ovalbumin-derived peptide.
2IUB	;	2.9	;	Crystal structure of a divalent metal ion transporter CorA at 2.9 A resolution.
4ZGG	;	1.23	;	Crystal structure of a DJ-1 (PARK7) from Homo sapiens at 1.23 A resolution
3BHN	;	1.76	;	Crystal structure of a dj-1/pfpi-like protein (shew_2856) from shewanella loihica pv-4 at 1.76 A resolution
5MH0	;	1.24	;	Crystal structure of a DM9 domain containing protein from Crassostrea gigas
5MH1	;	1.1	;	Crystal structure of a DM9 domain containing protein from Crassostrea gigas
5MH2	;	1.3	;	Crystal structure of a DM9 domain containing protein from Crassostrea gigas with D22A mutation
5MH3	;	1.6	;	Crystal structure of a DM9 domain containing protein from Crassostrea gigas with K43A mutation
4LHF	;	2.401	;	Crystal structure of a DNA binding protein from phage P2
1NH9	;	2.0	;	Crystal Structure of a DNA Binding Protein Mja10b from the hyperthermophile Methanococcus jannaschii
3OT0	;	1.7004	;	Crystal structure of a DNA containing the rigid nitroxide spin-labeled nucleotide C-spin
1N4E	;	2.5	;	Crystal Structure of a DNA Decamer Containing a Thymine-dimer
1SM5	;	2.0	;	Crystal Structure of a DNA Decamer Containing a Thymine-dimer
1T4I	;	2.5	;	Crystal Structure of a DNA Decamer Containing a Thymine-dimer
237D	;	2.5	;	CRYSTAL STRUCTURE OF A DNA DECAMER SHOWING A NOVEL PSEUDO FOUR-WAY HELIX-HELIX JUNCTION
6QJS	;	1.8	;	Crystal structure of a DNA dodecamer containing a tetramethylpiperidinoxyl (nitroxide) spin label
6QJR	;	2.9	;	Crystal structure of a DNA dodecamer containing a tetramethylpyrrolinoxyl (nitroxide) spin label
3GJH	;	2.9	;	Crystal structure of a DNA duplex containing 7,8-dihydropyridol[2,3-d]pyrimidin-2-one
3GJJ	;	2.9	;	crystal structure of a DNA duplex containing 7,8-dihydropyridol[2,3-d]pyrimidin-2-one
3GJK	;	2.2	;	crystal structure of a DNA duplex containing 7,8-dihydropyridol[2,3-d]pyrimidin-2-one
3GJL	;	1.92	;	crystal structure of a DNA duplex containing 7,8-dihydropyridol[2,3-d]pyrimidin-2-one
178D	;	2.5	;	CRYSTAL STRUCTURE OF A DNA DUPLEX CONTAINING 8-HYDROXYDEOXYGUANINE.ADENINE BASE-PAIRS
6IYQ	;	2.01	;	Crystal structure of a DNA duplex cross-linked by 6-thioguanine-6-thioguanine disulfides
5UA3	;	1.8802	;	Crystal Structure of a DNA G-Quadruplex with a Cytosine Bulge
4IEJ	;	1.45	;	Crystal structure of a DNA methyltransferase 1 associated protein 1 (DMAP1) from Homo sapiens at 1.45 A resolution
4GX8	;	1.7	;	Crystal structure of a DNA polymerase III alpha-epsilon chimera
4GX9	;	2.15	;	Crystal structure of a DNA polymerase III alpha-epsilon chimera
6DEG	;	2.45	;	Crystal structure of a DNA polymerase III subunit beta DnaN sliding clamp from Bartonella birtlesii LL-WM9
6D47	;	2.45	;	Crystal structure of a DNA polymerase III subunit beta DnaN sliding clamp from Mycobacterium marinum
6D46	;	2.0	;	Crystal structure of a DNA polymerase III subunit beta DnaN sliding clamp from Rickettsia typhi str. Wilmington
2GNO	;	2.0	;	Crystal structure of a dna polymerase iii, gamma subunit-related protein (tm0771) from thermotoga maritima msb8 at 2.00 A resolution
5VAZ	;	2.4	;	Crystal structure of a DNA primase domain from Pseudomonas aeruginosa
6YXQ	;	2.7	;	Crystal structure of a DNA repair complex ASCC3-ASCC2
6JDE	;	2.8	;	crystal structure of a DNA repair protein
5T4W	;	2.3	;	Crystal structure of a DNA sequence d (CGTGAATTCACG) with DAPI
5JU4	;	2.0	;	Crystal structure of a DNA sequence d(CGTGAATTCACG) at 130K
1XRX	;	2.15	;	Crystal structure of a DNA-binding protein
5EBI	;	1.09	;	Crystal structure of a DNA-RNA chimera in complex with Ba2+ ions: a case of unusual multi-domain twinning
4U92	;	1.5	;	Crystal structure of a DNA/Ba2+ G-quadruplex containing a water-mediated C-tetrad
5EAY	;	1.55	;	Crystal structure of a Dna2 peptide in complex with Rpa 70N
6PTR	;	1.75	;	Crystal structure of a DnaN sliding clamp (DNA polymerase III subunit beta) from Bartonella birtlesii bound to griselimycin
6PTH	;	3.05	;	Crystal structure of a DnaN sliding clamp (DNA polymerase III subunit beta) from Pseudomonas aeruginosa bound to griselimycin
6PTV	;	1.85	;	Crystal structure of a DnaN sliding clamp (DNA polymerase III subunit beta) from Rickettsia rickettsii bound to griselimycin
6MAN	;	2.35	;	Crystal structure of a DnaN sliding clamp DNA polymerase III subunit beta from Rickettsia bellii RML369-C
7RAB	;	1.92	;	Crystal structure of a dodecameric multicopper oxidase from M. hydrothermalis in a cubic lattice
7RAC	;	2.36	;	Crystal structure of a dodecameric multicopper oxidase from M. hydrothermalis in an orthorhombic lattice
4ODD	;	2.6	;	Crystal structure of a dog lipocalin allergen
3TEJ	;	1.9	;	Crystal structure of a domain fragment involved in peptide natural product biosynthesis
4DCZ	;	2.9	;	Crystal structure of a domain from a mycoplasma genitalium terminal organelle protein
3MVN	;	1.9	;	Crystal structure of a domain from a putative UDP-N-acetylmuramate:L-alanyl-gamma-D-glutamyl-medo-diaminopimelate ligase from Haemophilus ducreyi 35000HP
3KW6	;	2.1	;	Crystal Structure of a domain of 26S proteasome regulatory subunit 8 from homo sapiens. Northeast Structural Genomics Consortium target id HR3102A
3ONX	;	2.904	;	Crystal structure of a domain of a protein involved in formation of actin cytoskeleton
3CNI	;	2.3	;	Crystal structure of a domain of a putative ABC type-2 transporter from Thermotoga maritima MSB8
3DM3	;	2.4	;	Crystal structure of a domain of a Replication factor A protein, from Methanocaldococcus jannaschii. NorthEast Structural Genomics target MjR118E
3SWV	;	3.0	;	Crystal Structure of a domain of Brefeldin A-inhibited guanine nucleotide-exchange protein 2 (Brefeldin A-inhibited GEP 2) from Homo sapiens (Human), Northeast Structural Genomics Consortium target id HR5562A
3L8N	;	2.86	;	Crystal Structure of a domain of Brefeldin A-inhibited guanine nucleotide-exchange protein 2 (BrefeldinA-inhibited GEP 2) from Homo sapiens (Human). Northeast Structural Genomics Consortium target id HR5562A
3IX7	;	2.15	;	Crystal structure of a domain of functionally unknown protein from Thermus thermophilus HB8
3GX1	;	2.3	;	Crystal structure of a domain of lin1832 from Listeria innocua
3CAN	;	1.8	;	Crystal structure of a domain of pyruvate-formate lyase-activating enzyme from Bacteroides vulgatus ATCC 8482
3E0E	;	1.6	;	Crystal structure of a domain of replication protein A from Methanococcus maripaludis. NorthEast Structural Genomics targe MrR110B
3LYV	;	2.7	;	Crystal structure of a domain of ribosome-associated factor Y from streptococcus pyogenes serotype M6. Northeast Structural Genomics Consortium target id DR64A
2R2C	;	1.8	;	Crystal structure of a domain of the outer membrane lipoprotein Omp28 from Porphyromonas gingivalis
2RK5	;	1.5	;	Crystal structure of a domain of the putative hemolysin from Streptococcus mutans UA159
2R78	;	1.6	;	Crystal structure of a domain of the sensory box sensor histidine kinase/response regulator from Geobacter sulfurreducens
3PAM	;	2.31	;	Crystal structure of a domain of transmembrane protein of ABC-type oligopeptide transport system from Bartonella henselae str. Houston-1
4XG0	;	1.7	;	Crystal structure of a domain of unknown function (DUF1537) from Bordetella bronchiseptica (BB3215), Target EFI-511620, with bound citrate, domain swapped dimer, space group C2221
4XFR	;	2.0	;	Crystal structure of a domain of unknown function (DUF1537) from Bordetella bronchiseptica (BB3215), Target EFI-511620, with bound citrate, domain swapped dimer, space group P6522
4XGJ	;	1.9	;	Crystal structure of a domain of unknown function (DUF1537) from Pectobacterium atrosepticum (ECA3761), Target EFI-511609, APO structure, domain swapped dimer
4XFM	;	1.55	;	Crystal structure of a domain of unknown function (DUF1537) from Pectobacterium atrosepticum (ECA3761), Target EFI-511609, with bound D-threonate, domain swapped dimer
5DMH	;	1.8	;	Crystal structure of a domain of unknown function (DUF1537) from Ralstonia eutropha H16 (H16_A1561), Target EFI-511666, complex with ADP.
4M1A	;	1.9	;	Crystal structure of a Domain of unknown function (DUF1904) from Sebaldella termitidis ATCC 33386
3CU3	;	2.0	;	Crystal structure of a domain of unknown function with a cystatin-like fold (npun_r1993) from nostoc punctiforme pcc 73102 at 2.00 A resolution
3DDE	;	2.3	;	Crystal structure of a domain of unknown function with a heme oxygenase-like fold (sden_3740) from shewanella denitrificans os217 at 2.30 A resolution
3U6G	;	1.35	;	Crystal structure of a domain of unknown function, DUF4425 (BVU_3708) from Bacteroides vulgatus ATCC 8482 at 1.35 A resolution
6AMZ	;	2.05	;	Crystal structure of a domain swapped 2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-succinyltransferase from Acinetobacter baumannii
1G6U	;	1.48	;	CRYSTAL STRUCTURE OF A DOMAIN SWAPPED DIMER
1L5T	;	3.0	;	Crystal Structure of a Domain-Opened Mutant (R121D) of the Human Lactoferrin N-lobe Refined From a Merohedrally-Twinned Crystal Form.
6H01	;	2.776	;	Crystal structure of a domain-swapped dark-state sfGFP containing the unnatural amino acid ortho-nitrobenzyl-tyrosine (ONBY) at residue 66
5YQQ	;	1.9	;	Crystal structure of a domain-swapped dimer of the second StARkin domain of Lam2
5KKE	;	1.701	;	Crystal Structure of a Domain-swapped Dimer of Yeast Iso-1-cytochrome c with CYMAL5
5KLU	;	1.99	;	Crystal Structure of a Domain-swapped Dimer of Yeast Iso-1-cytochrome c with omega-undecylenyl-beta-D-maltopyranoside
6UKK	;	1.6	;	Crystal Structure of a Domain-swapped Fluorogen Activating Protein DiB3 Dimer
2ZNH	;	2.8	;	Crystal Structure of a Domain-Swapped Serpin Dimer
6MPZ	;	2.0	;	Crystal structure of a double glycine motif protease from AMS/PCAT transporter in complex with the leader peptide
6LH6	;	1.4	;	Crystal structure of a double headed Bowman-birk protease inhibitor protein from chickpea.
2WKD	;	2.1	;	Crystal structure of a double Ile-to-Met mutant of protein ORF34 from lactococcus phage p2
7TE3	;	2.2	;	Crystal Structure of a Double Loop Deletion Mutant in gC1qR/C1qBP/HABP-1
4BI5	;	2.7	;	CRYSTAL STRUCTURE OF A DOUBLE MUTANT (C202A AND C222D) OF TRIOSEPHOSPHATE ISOMERASE FROM GIARDIA LAMBLIA.
2DP3	;	2.1	;	Crystal structure of a double mutant (C202A/A198V) of Triosephosphate isomerase from giardia lamblia
8Q6U	;	1.516	;	Crystal structure of a double mutant acetyltransferase from Bacillus cereus species.
5D3C	;	1.314	;	Crystal structure of a double mutant catalytic domain of Human MMP12 in complex with an hydroxamate analogue of RXP470
4HST	;	1.571	;	Crystal structure of a double mutant of a class III engineered cephalosporin acylase
7OSB	;	1.45	;	Crystal Structure of a Double Mutant PETase (S238F/W159H) from Ideonella sakaiensis
4I5H	;	1.9	;	Crystal Structure of a Double Mutant Rat Erk2 Complexed With a Type II Quinazoline Inhibitor
3SO1	;	1.85	;	Crystal structure of a double mutant T41S T82S of a betagamma-crystallin domain from Clostridium beijerinckii
3QQ1	;	2.7	;	Crystal structure of a double mutant [A58P, DEL(N59)] of 3-deoxy-D-manno-octulosonate 8-phosphate synthase (KDO8PS) from Neisseria meningitidis
6N3I	;	3.69	;	Crystal structure of a double Trp XylE mutants (G58W/L315W)
1JYJ	;	2.0	;	Crystal Structure of a Double Variant (W67L/W91H) of Recombinant Human Serum Retinol-binding Protein at 2.0 A Resolution
7JNH	;	2.89	;	Crystal structure of a double-ENE RNA stability element in complex with a 28-mer poly(A) RNA
1AIO	;	2.6	;	CRYSTAL STRUCTURE OF A DOUBLE-STRANDED DNA CONTAINING THE MAJOR ADDUCT OF THE ANTICANCER DRUG CISPLATIN
1A2E	;	1.63	;	CRYSTAL STRUCTURE OF A DOUBLE-STRANDED DNA DECAMER CONTAINING A CISPLATIN INTERSTRAND CROSS-LINK ADDUCT
1N1Q	;	2.2	;	Crystal structure of a Dps protein from Bacillus brevis
3V8I	;	1.802	;	Crystal Structure of a Drosophila melanogaster Dopamine N-Acetyltransferase
2FNT	;	1.44	;	Crystal structure of a drug-resistant (V82A) inactive (D25N) HIV-1 protease complexed with AP2V variant of HIV-1 NC-p1 substrate.
1DI2	;	1.9	;	CRYSTAL STRUCTURE OF A DSRNA-BINDING DOMAIN COMPLEXED WITH DSRNA: MOLECULAR BASIS OF DOUBLE-STRANDED RNA-PROTEIN INTERACTIONS
1VL0	;	2.05	;	CRYSTAL STRUCTURE OF A DTDP-4-DEHYDRORHAMNOSE REDUCTASE, RFBD ORTHOLOG (CA_C2315) FROM CLOSTRIDIUM ACETOBUTYLICUM ATCC 824 AT 2.05 A RESOLUTION
6F32	;	2.8	;	Crystal structure of a dual function amine oxidase/cyclase in complex with substrate analogues
6OAQ	;	2.54	;	Crystal structure of a dual sensor histidine kinase in BeF3- bound state
6OB8	;	2.3	;	Crystal structure of a dual sensor histidine kinase in green light illuminated state
6OAP	;	1.97	;	Crystal structure of a dual sensor histidine kinase in the green-light absorbing Pg state
5A40	;	3.6	;	Crystal structure of a dual topology fluoride ion channel.
5A43	;	2.58	;	Crystal structure of a dual topology fluoride ion channel.
5NKQ	;	2.17	;	Crystal structure of a dual topology fluoride ion channel.
1U15	;	2.5	;	Crystal structure of a duck-delta-crystallin-1 double loop mutant (DLM)
1U16	;	2.2	;	Crystal structure of a duck-delta-crystallin-1 double loop mutant (DLM) in complex with sulfate
2O3L	;	2.05	;	Crystal structure of a duf1048 protein with a left-handed superhelix fold (bce_3448) from bacillus cereus atcc 10987 at 2.05 A resolution
2H1T	;	1.8	;	Crystal structure of a duf1089 family protein (pa1994) from pseudomonas aeruginosa at 1.80 A resolution
3BYQ	;	1.7	;	Crystal structure of a duf1185 family protein (bb2672) from bordetella bronchiseptica rb50 at 1.70 A resolution
2QTP	;	2.1	;	Crystal structure of a duf1185 family protein (spo0826) from silicibacter pomeroyi dss-3 at 2.10 A resolution
2RA9	;	1.4	;	Crystal structure of a duf1285 family protein (sbal_2486) from shewanella baltica os155 at 1.40 A resolution
2RE3	;	2.5	;	CRYSTAL STRUCTURE OF a DUF1285 family protein (SPO_0140) FROM SILICIBACTER POMEROYI DSS-3 AT 2.50 A RESOLUTION
3GI7	;	1.85	;	Crystal structure of a duf1311 family protein (pp0307) from pseudomonas putida kt2440 at 1.85 A resolution
4OBI	;	1.734	;	Crystal structure of a DUF1312 family protein (EF3258) from Enterococcus faecalis V583 at 1.73 A resolution
4ESN	;	2.2	;	Crystal structure of a DUF1312 family protein (RUMGNA_02503) from Ruminococcus gnavus ATCC 29149 at 2.20 A resolution
4Z48	;	1.75	;	Crystal structure of a DUF1329 family protein (DESPIG_00262) from Desulfovibrio piger ATCC 29098 at 1.75 A resolution
4K05	;	1.65	;	Crystal structure of a DUF1343 family protein (BF0371) from Bacteroides fragilis NCTC 9343 at 1.65 A resolution
4JJA	;	1.3	;	Crystal structure of a DUF1343 family protein (BF0379) from Bacteroides fragilis NCTC 9343 at 1.30 A resolution
3H0N	;	1.45	;	Crystal structure of a duf1470 family protein (jann_2411) from jannaschia sp. ccs1 at 1.45 A resolution
4GOQ	;	1.87	;	Crystal structure of a DUF1491 family protein (CC_1065) from Caulobacter crescentus CB15 at 1.87 A resolution
1VJL	;	1.9	;	Crystal structure of a duf151 family protein (tm0160) from thermotoga maritima at 1.90 A resolution
1SJ5	;	2.8	;	Crystal structure of a duf151 family protein (tm0160) from thermotoga maritima at 2.8 A resolution
4MDW	;	2.0	;	Crystal structure of a DUF1541 family protein (ydhK) from Bacillus subtilis subsp. subtilis str. 168 at 2.00 A resolution
2OBN	;	2.3	;	Crystal structure of a duf1611 family protein (ava_3511) from anabaena variabilis atcc 29413 at 2.30 A resolution
2G40	;	1.7	;	Crystal structure of a duf162 family protein (dr_1909) from deinococcus radiodurans at 1.70 A resolution
4QPV	;	1.8	;	Crystal structure of a DUF1672 family protein (SAV1486) from Staphylococcus aureus subsp. aureus Mu50 at 1.80 A resolution
3DCX	;	2.0	;	Crystal structure of a duf1696 family protein with a pleckstrin-homology domain (shew_0819) from shewanella loihica pv-4 at 2.00 A resolution
2IAY	;	1.2	;	Crystal structure of a duf1831 family protein (lp2179) from lactobacillus plantarum at 1.20 A resolution
1VK9	;	2.7	;	CRYSTAL STRUCTURE OF A DUF1893 family protein (TM1506) FROM THERMOTOGA MARITIMA AT 2.70 A RESOLUTION
3DI4	;	1.6	;	Crystal structure of a duf1989 family protein (spo0365) from silicibacter pomeroyi dss-3 at 1.60 A resolution
3ORU	;	1.11	;	Crystal structure of a DUF1989 family protein (TM1040_0329) from SILICIBACTER SP. TM1040 at 1.11 A resolution
3SIY	;	1.35	;	Crystal structure of a DUF1989 family protein (TM1040_0329) from SILICIBACTER SP. TM1040 at 1.35 A resolution
2HUH	;	1.54	;	Crystal structure of a duf2027 family protein (bt_2179) from bacteroides thetaiotaomicron at 1.54 A resolution
3D4R	;	2.2	;	CRYSTAL STRUCTURE OF a DUF2118 family protein (MMP0046) FROM METHANOCOCCUS MARIPALUDIS AT 2.20 A RESOLUTION
3KE2	;	2.5	;	CRYSTAL STRUCTURE OF a DUF2131 family protein (SAMA_2911) FROM SHEWANELLA AMAZONENSIS SB2B AT 2.50 A RESOLUTION
4F98	;	1.26	;	Crystal structure of a DUF2790 family protein (PA3229) from Pseudomonas aeruginosa PAO1 at 1.26 A resolution
2PYQ	;	1.5	;	Crystal structure of a duf2853 member protein (jann_4075) from jannaschia sp. ccs1 at 1.500 A resolution
4IPB	;	1.62	;	Crystal structure of a DUF2874 family protein (BACOVA_02504) from Bacteroides ovatus ATCC 8483 at 1.62 A resolution
4K61	;	1.7	;	Crystal structure of a DUF2874 family protein (BACUNI_01296) from Bacteroides uniformis ATCC 8492 at 1.70 A resolution
4KQ7	;	1.62	;	Crystal structure of a DUF2961 family protein (BACUNI_00161) from Bacteroides uniformis ATCC 8492 at 1.62 A resolution
3CE8	;	2.4	;	Crystal structure of a duf3240 family protein (sbal_0098) from shewanella baltica os155 at 2.40 A resolution
3D33	;	1.7	;	Crystal structure of a duf3244 family protein with an immunoglobulin-like beta-sandwich fold (bvu_0276) from bacteroides vulgatus atcc 8482 at 1.70 A resolution
4E72	;	2.15	;	Crystal structure of a DUF3298 family protein (PA4972) from Pseudomonas aeruginosa PAO1 at 2.15 A resolution
4HSP	;	2.45	;	Crystal structure of a DUF3299 family protein (PA4066) from Pseudomonas aeruginosa PAO1 at 2.45 A resolution
4L3U	;	1.95	;	Crystal structure of a DUF3571 family protein (ABAYE3784) from Acinetobacter baumannii AYE at 1.95 A resolution
4FXT	;	2.77	;	Crystal structure of a DUF3823 family protein (BACOVA_02663) from Bacteroides ovatus ATCC 8483 at 2.77 A resolution
4EIU	;	1.9	;	Crystal structure of a DUF3823 family protein (BACUNI_03093) from Bacteroides uniformis ATCC 8492 at 1.90 A resolution
4YOK	;	1.8	;	Crystal structure of a DUF3823 family protein (PARMER_04126) from Parabacteroides merdae ATCC 43184 at 1.80 A resolution
4YJW	;	1.8	;	Crystal structure of a DUF3829 family protein (BVU_3067) from Bacteroides vulgatus ATCC 8482 at 1.80 A resolution
4R03	;	1.5	;	Crystal structure of a DUF3836 family protein (BDI_3222) from Parabacteroides distasonis ATCC 8503 at 1.50 A resolution
4R8O	;	2.5	;	Crystal structure of a DUF3836 family protein (BVU_1206) from Bacteroides vulgatus ATCC 8482 at 2.50 A resolution
4HYZ	;	2.25	;	Crystal structure of a DUF3887 family protein (RUMGNA_01855) from Ruminococcus gnavus ATCC 29149 at 2.25 A resolution
4F54	;	1.6	;	Crystal structure of a DUF4136 family protein (BT2437) from Bacteroides thetaiotaomicron VPI-5482 at 1.60 A resolution
3F7C	;	2.0	;	Crystal structure of a duf416 family protein (maqu_0942) from marinobacter aquaeolei vt8 at 2.00 A resolution
2Q9R	;	1.91	;	CRYSTAL STRUCTURE OF a DUF416 family protein (SBAL_3149) FROM SHEWANELLA BALTICA OS155 AT 1.91 A RESOLUTION
4GDZ	;	1.95	;	Crystal structure of a DUF4251 family protein (BACEGG_02002) from Bacteroides eggerthii DSM 20697 at 1.95 A resolution
4YGT	;	2.13	;	Crystal structure of a DUF4309 family protein (YjgB) from Bacillus subtilis subsp. subtilis str. 168 at 2.13 A resolution
2GA1	;	2.0	;	Crystal structure of a duf433 member protein (ava_0674) from anabaena variabilis atcc 29413 at 2.00 A resolution
4MJF	;	1.99	;	Crystal structure of a DUF4348 family protein (BVU_2238) from Bacteroides vulgatus ATCC 8482 at 1.99 A resolution
4FM3	;	2.47	;	Crystal structure of a DUF4398 family protein (PA2901) from Pseudomonas aeruginosa PAO1 at 2.47 A resolution
4QEY	;	2.52	;	Crystal structure of a DUF4425 family protein (BACOVA_05332) from Bacteroides ovatus ATCC 8483 at 2.52 A resolution
3UC2	;	2.09	;	Crystal structure of a DUF4426 family protein (PA0388) from Pseudomonas aeruginosa PAO1 at 2.09 A resolution
4E0E	;	2.9	;	Crystal structure of a DUF4450 family protein (BT_4147) from Bacteroides thetaiotaomicron VPI-5482 at 2.90 A resolution
4JQR	;	2.05	;	Crystal structure of a DUF4465 family protein (BACCAC_02373) from Bacteroides caccae ATCC 43185 at 2.05 A resolution
4E9K	;	2.31	;	Crystal structure of a DUF4465 family protein (BACOVA_04221) from Bacteroides ovatus ATCC 8483 at 2.31 A resolution
4EI0	;	2.0	;	Crystal structure of a DUF4466 family protein (PARMER_03218) from Parabacteroides merdae ATCC 43184 at 2.00 A resolution
4EBG	;	1.2	;	Crystal structure of a DUF4467 family protein (SAV0303) from Staphylococcus aureus subsp. aureus Mu50 at 1.35 A resolution
4E6F	;	1.49	;	Crystal structure of a DUF4468 family protein (BACOVA_04320) from Bacteroides ovatus ATCC 8483 at 1.49 A resolution
4FTD	;	1.91	;	Crystal structure of a DUF4623 family protein (BACEGG_03550) from Bacteroides eggerthii DSM 20697 at 1.91 A resolution
4ID2	;	2.15	;	Crystal structure of a DUF4738 family protein (BACOVA_05496) from Bacteroides ovatus ATCC 8483 at 2.15 A resolution
4ORL	;	1.4	;	Crystal structure of a DUF4783 family protein (BACOVA_04304) from Bacteroides ovatus ATCC 8483 at 1.40 A resolution
4Q53	;	1.27	;	Crystal structure of a DUF4783 family protein (BACUNI_04292) from Bacteroides uniformis ATCC 8492 at 1.27 A resolution
4OUQ	;	1.55	;	Crystal structure of a DUF4783 family protein (BF1468) from Bacteroides fragilis YCH46 at 1.55 A resolution
4M8R	;	2.5	;	Crystal structure of a DUF4784 family protein (BACCAC_01631) from Bacteroides caccae ATCC 43185 at 2.50 A resolution
4KH9	;	2.0	;	Crystal structure of a DUF4785 family protein (lpg0956) from Legionella pneumophila subsp. pneumophila str. Philadelphia 1 at 2.00 A resolution
4NW4	;	1.85	;	Crystal structure of a DUF4822 family protein (EF0375) from Enterococcus faecalis V583 at 1.85 A resolution
4O2T	;	2.4	;	Crystal structure of a DUF4827 family protein (BDI_1692) from Parabacteroides distasonis ATCC 8503 at 2.40 A resolution
4L3R	;	2.23	;	Crystal structure of a DUF4847 family protein (BACEGG_01241) from Bacteroides eggerthii DSM 20697 at 2.23 A resolution
4ZGF	;	1.0	;	Crystal structure of a duf4847 family protein (BVU_2626) from Bacteroides vulgatus ATCC 8482 at 1.00 A resolution
4LB8	;	2.49	;	Crystal structure of a DUF4848 family protein (BT3222) from Bacteroides thetaiotaomicron VPI-5482 at 2.49 A resolution
4MJG	;	2.65	;	Crystal structure of a DUF4853 family protein (ACTODO_00621) from Actinomyces odontolyticus ATCC 17982 at 2.65 A resolution
4LG3	;	2.4	;	Crystal structure of a DUF487 family protein (DESPIG_00776) from Desulfovibrio piger ATCC 29098 at 2.49 A resolution
4Q1Z	;	2.5	;	Crystal structure of a DUF4876 family protein (BT_1938) from Bacteroides thetaiotaomicron VPI-5482 at 2.50 A resolution
4I8I	;	1.5	;	Crystal structure of a DUF4886 family protein (BACUNI_01406) from Bacteroides uniformis ATCC 8492 at 1.50 A resolution
4LQZ	;	1.92	;	Crystal structure of a DUF4909 family protein (SAV1798) from Staphylococcus aureus subsp. aureus Mu50 at 1.92 A resolution
4QVU	;	2.65	;	Crystal structure of a DUF4931 family protein (BCE0241) from Bacillus cereus ATCC 10987 at 2.65 A resolution
4GL6	;	2.55	;	Crystal structure of a DUF5037 family protein (RUMGNA_01148) from Ruminococcus gnavus ATCC 29149 at 2.55 A resolution
4QE0	;	1.85	;	Crystal structure of a DUF5043 family protein (BACUNI_01052) from Bacteroides uniformis ATCC 8492 at 1.85 A resolution
3GIW	;	1.45	;	CRYSTAL STRUCTURE OF a DUF574 family protein (SAV_2177) FROM STREPTOMYCES AVERMITILIS MA-4680 AT 1.45 A RESOLUTION
3GO4	;	1.8	;	Crystal structure of a duf574 family protein (sav_2177) from streptomyces avermitilis ma-4680 at 1.80 A resolution
3BWW	;	2.2	;	Crystal structure of a duf692 family protein (hs_1138) from haemophilus somnus 129pt at 2.20 A resolution
1VPY	;	2.52	;	CRYSTAL STRUCTURE OF a DUF72 family protein (EF0366) FROM ENTEROCOCCUS FAECALIS V583 AT 2.52 A RESOLUTION
1ZTV	;	3.1	;	Crystal structure of a duf72 family protein (ef0366) from enterococcus faecalis v583 at 3.10 A resolution
1VPQ	;	2.2	;	CRYSTAL STRUCTURE OF a DUF72 family protein (TM1631) FROM THERMOTOGA MARITIMA MSB8 AT 2.20 A RESOLUTION
3E02	;	1.9	;	Crystal structure of a duf849 family protein (bxe_c0271) from burkholderia xenovorans lb400 at 1.90 A resolution
3FA5	;	1.9	;	CRYSTAL STRUCTURE OF a DUF849 family protein (PDEN_3495) FROM PARACOCCUS DENITRIFICANS PD1222 AT 1.90 A RESOLUTION
1O5U	;	1.83	;	Crystal structure of a duf861 family protein (tm1112) from thermotoga maritima at 1.83 A resolution
3BCW	;	1.6	;	Crystal structure of a duf861 family protein with a rmlc-like cupin fold (bb1179) from bordetella bronchiseptica rb50 at 1.60 A resolution
2FFJ	;	2.45	;	CRYSTAL STRUCTURE OF a DUF89 family protein (AF1104) FROM ARCHAEOGLOBUS FULGIDUS DSM 4304 AT 2.45 A RESOLUTION
2G8L	;	2.04	;	Crystal structure of a duf89 family protein (ph1575) from pyrococcus horikoshii at 2.04 A resolution
5TCS	;	2.8313	;	Crystal structure of a Dwarf Ndc80 Tetramer
7YZT	;	1.85	;	Crystal structure of a dye-decolorizing (Dyp) peroxidase from Acinetobacter radioresistens
2GVK	;	1.6	;	Crystal structure of a dye-decolorizing peroxidase (DyP) from Bacteroides thetaiotaomicron VPI-5482 at 1.6 A resolution
6FL2	;	1.27	;	Crystal structure of a dye-decolorizing peroxidase D143A variant from Klebsiella pneumoniae (KpDyP)
6FIY	;	1.09	;	Crystal structure of a dye-decolorizing peroxidase D143AR232A variant from Klebsiella pneumoniae (KpDyP)
6FKS	;	1.6	;	Crystal structure of a dye-decolorizing peroxidase from Klebsiella pneumoniae (KpDyP)
6FKT	;	1.86003	;	Crystal structure of a dye-decolorizing peroxidase R232A variant from Klebsiella pneumoniae (KpDyP)
7QZA	;	2.698	;	Crystal structure of a DyP-type peroxidase 29E4 variant from Pseudomonas putida
7PL0	;	2.1	;	Crystal structure of a DyP-type peroxidase 5G5 variant from Bacillus subtilis
7QYZ	;	2.452	;	Crystal structure of a DyP-type peroxidase 6E10 variant from Pseudomonas putida
7PKX	;	2.491	;	Crystal structure of a DyP-type peroxidase from Bacillus subtilis in P3121 space group
7QYQ	;	2.599	;	Crystal structure of a DyP-type peroxidase from Pseudomonas putida
2J4Q	;	2.6	;	Crystal structure of a E138A Escherichia coli dCTP deaminase mutant enzyme in complex with dTTP
3K92	;	2.3	;	Crystal structure of a E93K mutant of the majour Bacillus subtilis glutamate dehydrogenase RocG
3PFM	;	2.908	;	Crystal structure of a EAL domain of GGDEF domain protein from Pseudomonas fluorescens Pf
2EXW	;	3.2	;	Crystal structure of a EcClC-Fab complex in the absence of bound ions
4LK5	;	2.5	;	Crystal structure of a enoyl-CoA hydratase from Mycobacterium avium subsp. paratuberculosis K-10
4JFC	;	2.25	;	Crystal structure of a enoyl-CoA hydratase from Polaromonas sp. JS666
4KPK	;	2.09	;	Crystal structure of a enoyl-CoA hydratase from Shewanella pealeana ATCC 700345
4KD6	;	2.25	;	Crystal structure of a Enoyl-CoA hydratase/isomerase from Burkholderia graminis C4D1M
7U0M	;	1.45	;	Crystal structure of a enoyl-[acyl-carrier-protein] reductase (InhA) from Mycobacterium abscessus bound to NAD and NITD-916
5ZZJ	;	2.6	;	Crystal structure of a enzyme from Santalum album
1KSI	;	2.2	;	CRYSTAL STRUCTURE OF A EUKARYOTIC (PEA SEEDLING) COPPER-CONTAINING AMINE OXIDASE AT 2.2A RESOLUTION
3ORG	;	3.5	;	Crystal Structure of a eukaryotic CLC transporter
4R0D	;	3.676	;	Crystal structure of a eukaryotic group II intron lariat
7SP5	;	2.9	;	Crystal Structure of a Eukaryotic Phosphate Transporter
3G3Q	;	2.64	;	Crystal structure of a eukaryotic polyphosphate polymerase in complex with a phosphate polymer
3G3R	;	2.0	;	Crystal structure of a eukaryotic polyphosphate polymerase in complex with AppNHp-Mn2+
3G3T	;	1.85	;	Crystal structure of a eukaryotic polyphosphate polymerase in complex with orthophosphate
3G3U	;	2.07	;	Crystal structure of a eukaryotic polyphosphate polymerase in complex with pyrophosphate
3CQO	;	2.32	;	Crystal structure of a f-lectin (fucolectin) from morone saxatilis (striped bass) serum
2YIF	;	3.298	;	Crystal structure of a F. nucleatum FMN riboswitch - Free state
2YIE	;	2.941	;	Crystal structure of a F. nucleatum FMN riboswitch bound to FMN
6BFB	;	2.82	;	Crystal structure of a F. nucleatum FMN riboswitch bound to WG-3
4NKI	;	2.41	;	Crystal structure of a Fab
5VEB	;	2.34	;	Crystal structure of a Fab binding to extracellular domain 5 of Cadherin-6
1OB1	;	2.9	;	Crystal structure of a Fab complex whith Plasmodium falciparum MSP1-19
7MFR	;	2.848	;	Crystal Structure of a Fab fragment bound to peptide GGM
8B50	;	1.67	;	Crystal structure of a Fab fragment in complex with L-hydroxycoumarylalanine
5GIR	;	1.93	;	Crystal structure of a Fab fragment with its ligand peptide
5GIS	;	1.93	;	Crystal structure of a Fab fragment with its ligand peptide
5AUM	;	2.05	;	Crystal structure of a Fab fragment with the ligand peptide
7UM3	;	2.3983	;	Crystal structure of a Fab in complex with a peptide derived from the LAG-3 D1 domain loop insertion
6QCU	;	1.56	;	Crystal structure of a Fab portion of the anti EBOV 3T0331 antibody
7SGM	;	2.0	;	Crystal structure of a Fab variant containing a fluorescent noncanonical amino acid with blocked excited state proton transfer and in complex with its antigen, CD40L
7VSW	;	3.0	;	Crystal structure of a Fab-like fragment of anti-mesothelin antibody
2I0Z	;	1.84	;	Crystal structure of a FAD binding protein from Bacillus cereus, a putative NAD(FAD)-utilizing dehydrogenases
8FHJ	;	2.61	;	Crystal structure of a FAD monooxygenease from Methylocystis sp. Strain SB2
2HQ9	;	1.95	;	Crystal structure of a fad-binding protein (mll6688) from mesorhizobium loti at 1.95 A resolution
3IWA	;	2.3	;	Crystal structure of a FAD-dependent pyridine nucleotide-disulphide oxidoreductase from Desulfovibrio vulgaris
6W3I	;	3.802	;	Crystal structure of a FAM46C mutant in complex with Plk4
1PZ3	;	1.75	;	Crystal structure of a family 51 (GH51) alpha-L-arabinofuranosidase from Geobacillus stearothermophilus T6
1QW9	;	1.2	;	Crystal structure of a family 51 alpha-L-arabinofuranosidase in complex with 4-nitrophenyl-Ara
1QW8	;	1.8	;	Crystal structure of a family 51 alpha-L-arabinofuranosidase in complex with Ara-alpha(1,3)-Xyl
2V4V	;	1.5	;	Crystal Structure of a Family 6 Carbohydrate-Binding Module from Clostridium cellulolyticum in complex with xylose
6U4Z	;	1.4	;	Crystal Structure of a family 76 glycoside hydrolase from a bovine Bacteroides thetaiotaomicron strain
4D6G	;	1.24	;	Crystal structure of a family 98 glycoside hydrolase catalytic module (Sp3GH98) in complex with the blood group A-trisaccharide (L19 mutant)
4D6E	;	1.45	;	Crystal structure of a family 98 glycoside hydrolase catalytic module (Sp3GH98) in complex with the blood group A-trisaccharide (X01 mutant)
4D6D	;	1.52	;	Crystal structure of a family 98 glycoside hydrolase catalytic module (Sp3GH98) in complex with the blood group A-trisaccharide (X02 mutant)
4D6I	;	1.99	;	Crystal structure of a family 98 glycoside hydrolase catalytic module (Sp3GH98) in complex with the type 1 blood group A-tetrasaccharide (E558A L19 mutant)
4D6H	;	1.65	;	Crystal structure of a family 98 glycoside hydrolase catalytic module (Sp3GH98) in complex with the type 1 blood group A-tetrasaccharide (E558A X02 mutant)
4D6F	;	2.03	;	Crystal structure of a family 98 glycoside hydrolase catalytic module (Sp3GH98) in complex with the type 1 blood group A-tetrasaccharide (E558A, X01 mutant)
4D72	;	2.11	;	Crystal structure of a family 98 glycoside hydrolase catalytic module (Sp3GH98) in complex with the type 2 blood group A-tetrasaccharide (E558A L19 mutant)
4D6J	;	1.98	;	Crystal structure of a family 98 glycoside hydrolase catalytic module (Sp3GH98) in complex with the type 2 blood group A-tetrasaccharide (E558A X01 mutant)
4D71	;	1.77	;	Crystal structure of a family 98 glycoside hydrolase catalytic module (Sp3GH98) in complex with the type 2 blood group A-tetrasaccharide (E558A X02 mutant)
4D6C	;	1.59	;	Crystal structure of a family 98 glycoside hydrolase catalytic module (Sp3GH98)(L19 mutant)
4DWX	;	1.8	;	Crystal Structure of a Family GH-19 Chitinase from rye seeds
4DYG	;	1.7	;	Crystal Structure of a Family GH-19 Chitinase from rye seeds in complex with (GlcNAc)4
4TX8	;	2.17	;	Crystal Structure of a Family GH18 Chitinase from Chromobacterium violaceum
4TXG	;	1.75	;	Crystal Structure of a Family GH18 Chitinase from Chromobacterium violaceum
4J0L	;	1.9	;	Crystal Structure of a Family GH19 Chitinase (W72A/E67Q mutant) from rye seeds in complex with two (GlcNAc)4 molecules
4IJ4	;	1.58	;	Crystal Structure of a Family GH19 chitinase from Bryum coronatum in complex with (GlcNAc)4
3WH1	;	1.0	;	Crystal Structure of a Family GH19 Chitinase from Bryum coronatum in complex with (GlcNAc)4 at 1.0 A resolution
2JJM	;	3.1	;	Crystal Structure of a family GT4 glycosyltransferase from Bacillus anthracis ORF BA1558.
1G43	;	2.2	;	CRYSTAL STRUCTURE OF A FAMILY IIIA CBD FROM CLOSTRIDIUM CELLULOLYTICUM
5GMX	;	2.0	;	Crystal structure of a family VIII carboxylesterase
4IVI	;	2.0	;	Crystal structure of a family VIII carboxylesterase.
4IVK	;	1.8	;	Crystal structure of a fammily VIII carboxylesterase in a complex with cephalothin.
4LIJ	;	1.8	;	Crystal structure of a far upstream element (FUSE) binding protein 1 (FUBP1) from Homo sapiens at 1.95 A resolution
6UV8	;	2.701	;	Crystal structure of a far-red cyanobacteriochrome photoreceptor at room temperature
5ZOH	;	1.6	;	Crystal structure of a far-red light-absorbing form of AnPixJg2_BV4 in complex with biliverdin
4LLS	;	1.5	;	Crystal structure of a farnesyl diphosphate synthase from Roseobacter denitrificans OCh 114, target EFI-509393, with IPP, GSPP, and calcium bound in active site
4LLT	;	1.55	;	Crystal structure of a farnesyl diphosphate synthase from Roseobacter denitrificans OCh 114, target EFI-509393, with two IPP and calcium bound in active site
3FFA	;	2.3	;	Crystal Structure of a fast activating G protein mutant
1VI1	;	2.95	;	Crystal structure of a fatty acid/phospholipid synthesis protein
6CHF	;	2.4	;	Crystal structure of a Fc fragment LALA mutant (L234A, L235A) of human IgG1 (crystal form 1)
6CJX	;	2.44	;	Crystal structure of a Fc fragment LALA mutant (L234A, L235A) of human IgG1 (crystal form 2)
6CJC	;	2.575	;	CRYSTAL STRUCTURE OF A FC FRAGMENT LALA MUTANT (L234A, L235A) OF HUMAN IGG1 (CRYSTAL FORM 3)
6D58	;	2.39	;	Crystal structure of a Fc fragment of Human IgG3
6D4E	;	2.8	;	Crystal Structure of a Fc Fragment of Rhesus macaque (Macaca mulatta) IgG1.
6D4I	;	2.95	;	Crystal Structure of a Fc Fragment of Rhesus macaque (Macaca mulatta) IgG2
6D4M	;	3.47	;	Crystal Structure of a Fc Fragment of Rhesus macaque (Macaca mulatta) IgG3
6D4N	;	3.25	;	Crystal structure of a Fc fragment of Rhesus macaque (Macaca mulatta) IgG4
2OKF	;	1.6	;	CRYSTAL STRUCTURE OF A FDXN ELEMENT EXCISION CONTROLLING FACTOR PROTEIN (AVA_3312) FROM ANABAENA VARIABILIS AT 1.60 A RESOLUTION
7RWY	;	2.2	;	Crystal structure of a Fe-bound RIDC1 variant in the presence of reductant
8Q3U	;	1.1	;	Crystal structure of a fentanyl derivative in complex with human CA VII
1MIX	;	1.75	;	Crystal structure of a FERM domain of Talin
5TR9	;	1.65	;	Crystal Structure of a ferredoxin NADP+ reductase from Neisseria gonorrhoeae with bound FAD
5UFA	;	2.5	;	Crystal Structure of a ferredoxin NADP+ reductase from Neisseria gonorrhoeae with bound FAD and NADP
5THX	;	1.55	;	Crystal Structure of a ferredoxin NADP+ reductase from Neisseria gonorrhoeae with bound NADP and FAD
6GNA	;	1.295	;	Crystal structure of a Ferredoxin-Flavin Thioredoxin Reductase from Clostridium acetobutylicum at 1.3 A resolution
6GNC	;	1.639	;	Crystal structure of a Ferredoxin-Flavin Thioredoxin Reductase from Clostridium acetobutylicum at 1.64 A resolution
6GNB	;	1.895	;	Crystal structure of a Ferredoxin-Flavin Thioredoxin Reductase from Clostridium acetobutylicum at 1.9 A resolution
3HL1	;	1.95	;	CRYSTAL STRUCTURE OF A FERRITIN LIKE PROTEIN (CC_0557) FROM CAULOBACTER VIBRIOIDES AT 1.95 A RESOLUTION
2OC5	;	1.68	;	Crystal structure of a ferritin-like protein (pmt1231) from prochlorococcus marinus str. mit 9313 at 1.68 A resolution
7EBO	;	2.5	;	Crystal structure of a feruloyl esterase LP_0796 from Lactobacillus plantarum
4H87	;	1.55	;	Crystal structure of a FHA domain of kanadaptin (SLC4A1AP) from Homo sapiens at 1.55 A resolution
1FBN	;	1.6	;	CRYSTAL STRUCTURE OF A FIBRILLARIN HOMOLOGUE FROM METHANOCOCCUS JANNASCHII, A HYPERTHERMOPHILE, AT 1.6 A
3CUC	;	2.71	;	CRYSTAL STRUCTURE OF A FIC DOMAIN CONTAINING SIGNALING PROTEIN (BT_2513) FROM BACTEROIDES THETAIOTAOMICRON VPI-5482 AT 2.71 A RESOLUTION
7XUX	;	2.78	;	Crystal structure of a FIC domain containnig protein
4RGL	;	2.7	;	Crystal structure of a Fic family protein (Dde_2494) from Desulfovibrio desulfuricans G20 at 2.70 A resolution
3EQX	;	1.6	;	CRYSTAL STRUCTURE OF A FIC FAMILY PROTEIN (SO_4266) FROM SHEWANELLA ONEIDENSIS AT 1.6 A RESOLUTION
4M63	;	2.748	;	Crystal Structure of a Filament-Like Actin Trimer Bound to the Bacterial Effector VopL
3R4R	;	2.38	;	Crystal structure of a fimbrial assembly protein (BDI_3522) from Parabacteroides distasonis ATCC 8503 at 2.38 A resolution
3TDQ	;	2.1	;	Crystal structure of a fimbrial biogenesis protein PilY2 (PilY2_PA4555) from Pseudomonas aeruginosa PAO1 at 2.10 A resolution
4EPS	;	1.85	;	Crystal structure of a fimbrial protein (BACOVA_04982) from Bacteroides ovatus ATCC 8483 at 1.85 A resolution
4QB7	;	2.55	;	Crystal structure of a fimbrial protein (BVU_2522) from Bacteroides vulgatus ATCC 8482 at 2.55 A resolution
3SY6	;	1.9	;	Crystal structure of a fimbrial protein BF1861 [Bacteroides fragilis NCTC 9343] (BF1861) from Bacteroides fragilis NCTC 9343 at 1.90 A resolution
4Q98	;	1.3	;	Crystal structure of a fimbrilin (fimA) from Porphyromonas gingivalis W83 at 1.30 A resolution (PSI Community Target, Nakayama)
4XOB	;	3.003	;	Crystal structure of a FimH*DsF complex from E.coli K12 with bound heptyl alpha-D-mannopyrannoside
4XOD	;	1.14	;	Crystal structure of a FimH*DsG complex from E.coli F18
6GTZ	;	1.719	;	Crystal structure of a FimH*DsG complex from E.coli F18 with bound dimannoside Man(alpha1-3)Man in space group P21
6GU0	;	2.501	;	Crystal structure of a FimH*DsG complex from E.coli F18 with bound dimannoside Man(alpha1-3)Man in space group P213
4XOE	;	2.4	;	Crystal structure of a FimH*DsG complex from E.coli F18 with bound heptyl alpha-D-mannopyrannoside
6GTV	;	2.1	;	Crystal structure of a FimH*DsG complex from E.coli F18 with bound trimannose
4XO9	;	1.14	;	Crystal structure of a FimH*DsG complex from E.coli K12 in space group C2
4XOA	;	2.541	;	Crystal structure of a FimH*DsG complex from E.coli K12 in space group P1
2Z21	;	1.8	;	Crystal Structure of a five site mutated Cyanovirin-N
2PYS	;	1.8	;	Crystal Structure of a Five Site Mutated Cyanovirin-N with a Mannose Dimer Bound at 1.8 A Resolution
4ZMH	;	1.93	;	Crystal structure of a five-domain GH115 alpha-Glucuronidase from the Marine Bacterium Saccharophagus degradans 2-40T
1QX8	;	2.02	;	Crystal structure of a five-residue deletion mutant of the Rop protein
1VH6	;	2.5	;	Crystal structure of a flagellar protein
1MRZ	;	1.9	;	Crystal structure of a flavin binding protein from Thermotoga Maritima, TM379
7E8Q	;	2.3	;	Crystal structure of a Flavin-dependent Monooxygenase HadA F441V mutant complexed with reduced FAD and 4-nitrophenol
7E8P	;	2.3	;	Crystal structure of a Flavin-dependent Monooxygenase HadA wild type complexed with reduced FAD and 4-nitrophenol
2HTI	;	2.5	;	CRYSTAL STRUCTURE OF A FLAVIN-NUCLEOTIDE-BINDING PROTEIN (BH_0577) FROM BACILLUS HALODURANS AT 2.50 A RESOLUTION
7R2S	;	2.194	;	Crystal structure of a flavodiiron protein D52K mutant from Escherichia coli pressurized with krypton gas
7R0F	;	1.978	;	Crystal structure of a flavodiiron protein D52K mutant in the oxidized state from Escherichia coli
7R1H	;	1.96	;	Crystal structure of a flavodiiron protein D52K mutant in the reduced state from Escherichia coli
7R2P	;	2.538	;	Crystal structure of a flavodiiron protein D52K/S262Y mutant in the oxidized state from Escherichia coli
7R2R	;	2.198	;	Crystal structure of a flavodiiron protein D52K/S262Y mutant in the reduced state from Escherichia coli
7R2O	;	1.85	;	Crystal structure of a flavodiiron protein S262Y mutant in the oxidized state from Escherichia coli
7R1J	;	1.901	;	Crystal structure of a flavodiiron protein S262Y mutant in the reduced state from Escherichia coli
5WAN	;	1.798	;	Crystal Structure of a flavoenzyme RutA in the pyrimidine catabolic pathway
7CYW	;	1.8	;	Crystal structure of a flavonoid C-glucosyltrasferase from Fagopyrum esculentum (FeCGTa) complexed with BrUTP
6C80	;	1.78	;	Crystal structure of a flax cytokinin oxidase
6G20	;	2.16	;	Crystal structure of a fluorescence optimized bathy phytochrome PAiRFP2 derived from wild-type Agp2 in its functional Meta-F intermediate state.
6G1Z	;	2.03	;	Crystal structure of a fluorescence optimized bathy phytochrome PAiRFP2 derived from wild-type Agp2 in its Pfr state.
1RAR	;	1.9	;	CRYSTAL STRUCTURE OF A FLUORESCENT DERIVATIVE OF RNASE A
1RAS	;	1.7	;	CRYSTAL STRUCTURE OF A FLUORESCENT DERIVATIVE OF RNASE A
6WZN	;	2.5	;	Crystal Structure of a Fluorescent Single Chain Fv Chimera
3HMZ	;	1.5	;	CRYSTAL STRUCTURE OF A FMN-BINDING DOMAIN OF FLAVIN REDUCTASES-LIKE ENZYME (SBAL_0626) FROM SHEWANELLA BALTICA OS155 AT 1.50 A RESOLUTION
3IN6	;	2.12	;	Crystal structure of a fmn-binding protein (swol_0183) from syntrophomonas wolfei subsp. wolfei at 2.12 A resolution
3OF4	;	1.9	;	Crystal structure of a FMN/FAD- and NAD(P)H-dependent nitroreductase (nfnB, IL2077) from Idiomarina loihiensis L2TR at 1.90 A resolution
6M2Z	;	2.35	;	Crystal structure of a formolase, BFD variant M3 from Pseudomonas putida
6M2Y	;	2.1	;	Crystal structure of a formolase, BFD variant M6 from Pseudomonas putida
2GLZ	;	1.45	;	Crystal structure of a formylmethanofuran dehydrogenase subunit e-like protein (dhaf_2992) from desulfitobacterium hafniense dcb-2 at 1.45 A resolution
3OBI	;	1.95	;	Crystal structure of a formyltetrahydrofolate deformylase (NP_949368) from RHODOPSEUDOMONAS PALUSTRIS CGA009 at 1.95 A resolution
3N0V	;	2.25	;	Crystal structure of a formyltetrahydrofolate deformylase (PP_0327) from PSEUDOMONAS PUTIDA KT2440 at 2.25 A resolution
3O1L	;	2.2	;	Crystal structure of a formyltetrahydrofolate deformylase (PSPTO_4314) from Pseudomonas syringae pv. tomato str. DC3000 at 2.20 A resolution
3NRB	;	2.05	;	Crystal structure of a formyltetrahydrofolate deformylase (purU, PP_1943) from PSEUDOMONAS PUTIDA KT2440 at 2.05 A resolution
8HE6	;	1.7	;	Crystal structure of a fosfomycin and bleomycin resistant protein (ALL3014) from Anabaena/Nostoc cyanobacterium at 1.70 A resolution
190D	;	1.8	;	Crystal structure of a four-stranded intercalated DNA: d(C4)
7JKU	;	1.97	;	Crystal structure of a four-tetrad, parallel, and K+ stabilized Tetrahymena thermophila telomeric G-quadruplex
7LL0	;	2.0	;	Crystal structure of a four-tetrad, parallel, and K+ stabilized Tetrahymena thermophila telomeric G-quadruplex
8D79	;	1.99	;	Crystal structure of a four-tetrad, parallel, and Na+ stabilized Tetrahymena thermophila telomeric G-quadruplex in complex with N-methyl mesoporphyrin IX
4KKM	;	1.9	;	Crystal structure of a FPP/GFPP synthase (Target EFI-501952) from Zymomonas mobilis, apo structure
5TV2	;	1.6	;	Crystal structure of a fragment (1-405) of an elongation factor G from Vibrio vulnificus CMCP6
2IAF	;	2.05	;	Crystal structure of a fragment (residues 11 to 161) of L-serine dehydratase from Legionella pneumophila
3TZX	;	2.3	;	Crystal structure of a fragment containing the acyltransferase domain of Pks13 from Mycobacterium tuberculosis in tetragonal apo form at 2.3 A
3TZZ	;	2.49	;	Crystal structure of a fragment containing the acyltransferase domain of Pks13 from Mycobacterium tuberculosis in the carboxypalmitoylated form at 2.5 A
3TZW	;	2.6	;	Crystal structure of a fragment containing the acyltransferase domain of Pks13 from Mycobacterium tuberculosis in the orthorhombic apoform at 2.6 A
3TZY	;	2.2	;	Crystal structure of a fragment containing the acyltransferase domain of Pks13 from Mycobacterium tuberculosis in the palmitoylated form at 2.2 A
3EVY	;	1.95	;	Crystal structure of a fragment of a putative type I restriction enzyme R protein from Bacteroides fragilis
1SL6	;	2.25	;	Crystal Structure of a fragment of DC-SIGNR (containg the carbohydrate recognition domain and two repeats of the neck) complexed with Lewis-x.
1XAR	;	2.25	;	Crystal Structure of a fragment of DC-SIGNR (containing the carbohydrate recognition domain and two repeats of the neck).
6UGI	;	1.75	;	Crystal structure of a fragment of E. coli tRNA(Asp) consisting of its acceptor stem/T stem-loop. Long unit cell.
6UGJ	;	1.6	;	Crystal structure of a fragment of E. coli tRNA(Asp) consisting of its acceptor stem/T stem-loop. Short unit cell.
3O5D	;	4.0	;	Crystal structure of a fragment of FKBP51 comprising the Fk1 and Fk2 domains
2J0J	;	2.8	;	Crystal structure of a fragment of focal adhesion kinase containing the FERM and kinase domains.
2J0K	;	3.0	;	Crystal structure of a fragment of focal adhesion kinase containing the FERM and kinase domains.
4JUS	;	2.5	;	Crystal structure of a fragment of Human HSPB6
3U21	;	2.18	;	Crystal structure of a Fragment of Nuclear factor related to kappa-B-binding protein (residues 370-495) (NFRKB) from Homo sapiens at 2.18 A resolution
6PMP	;	2.73	;	Crystal structure of a fragment of rat phospholipase Cepsilon EF3-RA1
2ODU	;	2.3	;	Crystal structure of a fragment of the plakin domain of plectin
2ODV	;	2.05	;	Crystal structure of a fragment of the plakin domain of plectin, Cys to Ala mutant.
5EVF	;	1.762	;	Crystal structure of a Francisella virulence factor FvfA in the hexagonal form
5EVG	;	1.82	;	Crystal structure of a Francisella virulence factor FvfA in the orthorhombic form
1SGS	;	1.6	;	Crystal structure of a free kB DNA
6J9O	;	1.397	;	Crystal structure of a free scFv molecule from a group 2 influenza A viruses HA binding antibody AF4H1K1
6JL9	;	2.0	;	Crystal structure of a frog ependymin related protein
5U4N	;	1.6	;	Crystal structure of a fructose-bisphosphate aldolase from Neisseria gonorrhoeae
5U7S	;	2.5	;	Crystal structure of a fructose-bisphosphate aldolase, class II, Calvin cycle subtype from Acinetobacter baumannii
3C8L	;	1.22	;	Crystal structure of a ftsz-like protein of unknown function (npun_r1471) from nostoc punctiforme pcc 73102 at 1.22 A resolution
5ZU5	;	1.6	;	Crystal structure of a full length alginate lyase with CBM domain
6NOT	;	2.4	;	Crystal structure of a full length elongation factor G (EF-G) from Rickettsia prowazekii
2Z6G	;	3.4	;	Crystal Structure of a Full-Length Zebrafish Beta-Catenin
2XYB	;	1.75	;	CRYSTAL STRUCTURE OF A FULLY FUNCTIONAL LACCASE FROM THE LIGNINOLYTIC FUNGUS PYCNOPORUS CINNABARINUS
4HGV	;	2.09	;	Crystal structure of a fumarate hydratase
1J7X	;	1.8	;	CRYSTAL STRUCTURE OF A FUNCTIONAL UNIT OF INTERPHOTORECEPTOR RETINOID-BINDING PROTEIN (IRBP)
4QN1	;	2.48	;	Crystal Structure of a Functionally Uncharacterized Domain of E3 Ubiquitin Ligase SHPRH
3KDQ	;	3.0	;	Crystal structure of a functionally unknown conserved protein from Corynebacterium diphtheriae.
3CQY	;	2.3	;	Crystal structure of a functionally unknown protein (SO_1313) from Shewanella oneidensis MR-1
3G74	;	2.43	;	Crystal structure of a functionally unknown protein from Eubacterium ventriosum ATCC 27560
6RJR	;	1.895	;	Crystal structure of a Fungal Catalase at 1.9 Angstrom
6RJN	;	2.295	;	Crystal structure of a Fungal Catalase at 2.3 Angstroms
4I5R	;	1.5	;	Crystal structure of a fungal chimeric cellobiohydrolase Cel6A
4I5U	;	1.22	;	Crystal structure of a fungal chimeric cellobiohydrolase Cel6A
4AU9	;	2.1	;	Crystal Structure of a Fungal DyP-Type Peroxidase from Auricularia auricula-judae
8GU0	;	2.42	;	Crystal structure of a fungal halogenase RadH
5C3U	;	1.76	;	Crystal structure of a fungal L-serine ammonia-lyase from Rhizomucor miehei
6L7N	;	1.8	;	crystal structure of a FUNGAL LIPASES
3EUO	;	1.75	;	crystal structure of a fungal type III polyketide synthase, ORAS
3I5C	;	1.94	;	Crystal structure of a fusion protein containing the leucine zipper of GCN4 and the GGDEF domain of WspR from Pseudomonas aeruginosa
4J8F	;	2.7	;	Crystal structure of a fusion protein containing the NBD of Hsp70 and the middle domain of Hip
4YLQ	;	1.4	;	Crystal Structure of a FVIIa-Trypsin Chimera (FT) in Complex with Soluble Tissue Factor
4ZMA	;	2.3	;	Crystal Structure of a FVIIa-Trypsin Chimera (ST) in Complex with Soluble Tissue Factor
4Z6A	;	2.25	;	Crystal Structure of a FVIIa-Trypsin Chimera (YT) in Complex with Soluble Tissue Factor
1Y02	;	1.8	;	Crystal Structure of a FYVE-type domain from caspase regulator CARP2
4QU6	;	1.75	;	Crystal structure of a G-rich RNA sequence binding factor 1 (GRSF1) from Homo sapiens at 1.75 A resolution
4QU7	;	2.5	;	Crystal structure of a G-rich RNA sequence binding factor 1 (GRSF1) from Homo sapiens at 2.50 A resolution
4NMM	;	1.89	;	Crystal Structure of a G12C Oncogenic Variant of Human KRas Bound to a Novel GDP Competitive Covalent Inhibitor
3E98	;	2.43	;	CRYSTAL STRUCTURE OF a GAF domain containing protein that belongs to Pfam DUF484 family (PA5279) FROM PSEUDOMONAS AERUGINOSA AT 2.43 A RESOLUTION
2VK2	;	1.2	;	Crystal structure of a galactofuranose binding protein
6TEQ	;	1.44	;	Crystal structure of a galactokinase from Bifidobacterium infantis in complex with 2-deoxy-2-fluoro-galactose
6TEP	;	1.45	;	Crystal structure of a galactokinase from Bifidobacterium infantis in complex with ADP
6TER	;	1.68	;	Crystal structure of a galactokinase from Bifidobacterium infantis in complex with Galactose
3OS7	;	1.8	;	Crystal structure of a galactose mutarotase-like protein (CA_C0697) from CLOSTRIDIUM ACETOBUTYLICUM at 1.80 A resolution
3Q1N	;	1.61	;	Crystal structure of a galactose mutarotase-like protein (LSEI_2598) from Lactobacillus casei ATCC 334 at 1.61 A resolution
1TOQ	;	2.5	;	CRYSTAL STRUCTURE OF A GALACTOSE SPECIFIC LECTIN FROM ARTOCARPUS HIRSUTA IN COMPLEX WITH METHYL-a-D-GALACTOSE
1TP8	;	3.0	;	CRYSTAL STRUCTURE OF A GALACTOSE SPECIFIC LECTIN FROM ARTOCARPUS HIRSUTA IN COMPLEX WITH METHYL-a-D-GALACTOSE
5VBK	;	1.788	;	Crystal structure of a galactose-binding Lectin from Mytilus californianus
1JZN	;	2.2	;	crystal structure of a galactose-specific C-type lectin
7ZW9	;	2.1	;	Crystal structure of a gamma-carbonic anhydrase from the pathogenic bacterium Burkholderia pseudomallei
2IFU	;	2.6	;	Crystal Structure of a Gamma-SNAP from Danio rerio
3I1G	;	1.6	;	Crystal structure of a GCN4 leucine zipper mutant at 1.6 A resolution
3TCV	;	1.75	;	Crystal structure of a GCN5-related N-acetyltransferase from Brucella melitensis
1BO4	;	2.3	;	CRYSTAL STRUCTURE OF A GCN5-RELATED N-ACETYLTRANSFERASE: SERRATIA MARESCENS AMINOGLYCOSIDE 3-N-ACETYLTRANSFERASE
7AB8	;	2.2	;	Crystal structure of a GDNF-GFRalpha1 complex
2PK3	;	1.82	;	Crystal Structure of a GDP-4-keto-6-deoxy-D-mannose reductase
7CXT	;	2.05	;	Crystal structure of a GDP-6-OMe-4-keto-L-xylo-heptose reductase from C.jejuni
4LDJ	;	1.15	;	Crystal Structure of a GDP-bound G12C Oncogenic Mutant of Human GTPase KRas
4QL3	;	1.041	;	Crystal Structure of a GDP-bound G12R Oncogenic Mutant of Human GTPase KRas
4TQ9	;	1.491	;	Crystal Structure of a GDP-bound G12V Oncogenic Mutant of Human GTPase KRas
4TQA	;	1.13	;	Crystal Structure of a GDP-bound G13D Oncogenic Mutant of Human GTPase KRas
4WA7	;	1.986	;	Crystal Structure of a GDP-bound Q61L Oncogenic Mutant of Human GT- Pase KRas
6AQY	;	2.55	;	Crystal structure of a gdp-l-fucose synthetase from Naegleria fowleri
6AQZ	;	2.4	;	Crystal structure of a gdp-l-fucose synthetase from Naegleria fowleri bound to NADP
5UZH	;	2.25	;	Crystal structure of a GDP-mannose dehydratase from Naegleria fowleri
1VJG	;	2.01	;	Crystal structure of a gdsl-like lipase (alr1529) from nostoc sp. pcc 7120 at 2.01 A resolution
1Z8H	;	2.02	;	CRYSTAL STRUCTURE OF a GDSL-like lipase (ALR1529) FROM NOSTOC SP. PCC 7120 AT 2.02 A RESOLUTION
3P94	;	1.93	;	Crystal structure of a GDSL-like Lipase (BDI_0976) from Parabacteroides distasonis ATCC 8503 at 1.93 A resolution
4HF7	;	1.77	;	Crystal structure of a GDSL-like lipase (BT0569) from Bacteroides thetaiotaomicron VPI-5482 at 1.77 A resolution
2GJ7	;	5.0	;	Crystal Structure of a gE-gI/Fc complex
6X1G	;	1.6	;	Crystal structure of a GEF domain from the Orientia tsutsugamushi protein OtDUB in complex with Rac1
4ERP	;	4.45	;	Crystal structure of a gemcitabine-diphosphate inhibited E. coli class Ia ribonucleotide reductase complex
5C0R	;	3.188	;	Crystal Structure of a Generation 3 Influenza Hemagglutinin Stabilized Stem Complexed with the Broadly Neutralizing Antibody C179
5C0S	;	4.3	;	Crystal structure of a generation 4 influenza hemagglutinin stabilized stem in complex with the broadly neutralizing antibody CR6261
7LQO	;	2.1	;	Crystal structure of a genetically encoded red fluorescent peroxynitrite biosensor, pnRFP
3F6D	;	1.7	;	Crystal Structure of a Genetically Modified Delta Class GST (adGSTD4-4) from Anopheles dirus, F123A, in Complex with S-Hexyl Glutathione
3G7J	;	2.2	;	Crystal Structure of a Genetically Modified Delta Class GST (adGSTD4-4) from Anopheles dirus, Y119E, in Complex with S-Hexyl Glutathione
5EQS	;	1.839	;	Crystal structure of a genotype 1a/3a chimeric HCV NS3/4A protease in complex with Asunaprevir
5EQR	;	1.96	;	Crystal structure of a genotype 1a/3a chimeric HCV NS3/4A protease in complex with danoprevir
5ESB	;	2.4	;	Crystal structure of a genotype 1a/3a chimeric HCV NS3/4A protease in complex with Vaniprevir
5J7I	;	4.0	;	Crystal structure of a Geobacillus thermoglucosidasius Acetylating Aldehyde Dehydrogenase in complex with ADP
3OZ2	;	1.6	;	Crystal structure of a geranylgeranyl bacteriochlorophyll reductase-like (Ta0516) from Thermoplasma acidophilum at 1.60 A resolution
3IPI	;	1.9	;	Crystal Structure of a Geranyltranstransferase from the Methanosarcina mazei
1XEA	;	2.65	;	Crystal structure of a Gfo/Idh/MocA family oxidoreductase from Vibrio cholerae
6M4E	;	2.1	;	Crystal structure of a GH1 beta-glucosidase from Hamamotoa singularis
4MDO	;	2.6	;	Crystal structure of a GH1 beta-glucosidase from the fungus Humicola insolens
4MDP	;	2.05	;	Crystal structure of a GH1 beta-glucosidase from the fungus Humicola insolens in complex with glucose
5WKA	;	2.75	;	Crystal structure of a GH1 beta-glucosidase retrieved from microbial metagenome of Poraque Amazon lake
7S8K	;	2.55	;	Crystal structure of a GH12-2 family cellulase from Thermococcus sp. 2319x1
6UAT	;	1.9	;	Crystal structure of a GH128 (subgroup I) endo-beta-1,3-glucanase (E102A mutant) from Amycolatopsis mediterranei (AmGH128_I) in complex with laminaripentaose
6UAU	;	1.9	;	Crystal structure of a GH128 (subgroup I) endo-beta-1,3-glucanase (E102A mutant) from Amycolatopsis mediterranei (AmGH128_I) in complex with laminaritriose and laminaribiose
6UAS	;	1.91	;	Crystal structure of a GH128 (subgroup I) endo-beta-1,3-glucanase (E199A mutant) from Amycolatopsis mediterranei (AmGH128_I) in complex with laminaripentaose
6UFZ	;	1.9	;	Crystal structure of a GH128 (subgroup I) endo-beta-1,3-glucanase (E199Q mutant) from Amycolatopsis mediterranei (AmGH128_I)
6UFL	;	1.61	;	Crystal structure of a GH128 (subgroup I) endo-beta-1,3-glucanase (E199Q mutant) from Amycolatopsis mediterranei (AmGH128_I) in the complex with laminarihexaose
6UAQ	;	1.15	;	Crystal structure of a GH128 (subgroup I) endo-beta-1,3-glucanase from Amycolatopsis mediterranei (AmGH128_I)
6UAR	;	1.4	;	Crystal structure of a GH128 (subgroup I) endo-beta-1,3-glucanase from Amycolatopsis mediterranei (AmGH128_I) in complex with laminaritriose
6UAV	;	1.5	;	Crystal structure of a GH128 (subgroup II) endo-beta-1,3-glucanase from Pseudomonas viridiflava (PvGH128_II)
6UAW	;	1.5	;	Crystal structure of a GH128 (subgroup II) endo-beta-1,3-glucanase from Pseudomonas viridiflava (PvGH128_II) in complex with laminaritriose
6UAX	;	1.3	;	Crystal structure of a GH128 (subgroup II) endo-beta-1,3-glucanase from Sorangium cellulosum (ScGH128_II)
6UAY	;	1.8	;	Crystal structure of a GH128 (subgroup III) curdlan-specific exo-beta-1,3-glucanase from Blastomyces gilchristii (BgGH128_III)
6UAZ	;	1.85	;	Crystal structure of a GH128 (subgroup III) curdlan-specific exo-beta-1,3-glucanase from Blastomyces gilchristii (BgGH128_III) in complex with glucose
6UB0	;	1.75	;	Crystal structure of a GH128 (subgroup III) curdlan-specific exo-beta-1,3-glucanase from Blastomyces gilchristii (BgGH128_III) in complex with laminaribiose at -2 and -1 subsites
6UB1	;	1.6	;	Crystal structure of a GH128 (subgroup III) curdlan-specific exo-beta-1,3-glucanase from Blastomyces gilchristii (BgGH128_III) in complex with laminaribiose at -3 and -2 subsites
6UB2	;	1.8	;	Crystal structure of a GH128 (subgroup IV) endo-beta-1,3-glucanase from Lentinula edodes (LeGH128_IV)
6UB6	;	1.25	;	Crystal structure of a GH128 (subgroup IV) endo-beta-1,3-glucanase from Lentinula edodes (LeGH128_IV) in complex with laminaritetraose
6UB3	;	1.85	;	Crystal structure of a GH128 (subgroup IV) endo-beta-1,3-glucanase from Lentinula edodes (LeGH128_IV) with laminaribiose at the surface-binding site
6UB7	;	1.8	;	Crystal structure of a GH128 (subgroup V) exo-beta-1,3-glucanase from Cryptococcus neoformans (CnGH128_V)
6UB8	;	1.9	;	Crystal structure of a GH128 (subgroup VI) exo-beta-1,3-glucanase from Aureobasidium namibiae (AnGH128_VI)
6UBA	;	2.4	;	Crystal structure of a GH128 (subgroup VI) exo-beta-1,3-glucanase from Aureobasidium namibiae (AnGH128_VI) in complex with laminaritriose
6UBB	;	2.35	;	Crystal structure of a GH128 (subgroup VI) exo-beta-1,3-glucanase from Aureobasidium namibiae (AnGH128_VI) with laminaribiose at the surface-binding site
6UBC	;	1.65	;	Crystal structure of a GH128 (subgroup VII) oligosaccharide-binding protein from Cryptococcus neoformans (CnGH128_VII)
6UBD	;	1.25	;	Crystal structure of a GH128 (subgroup VII) oligosaccharide-binding protein from Trichoderma gamsii (TgGH128_VII)
4LE3	;	1.8	;	Crystal structure of a GH131 beta-glucanase catalytic domain from Podospora anserina
8T9W	;	2.2	;	Crystal structure of a GH140 apiosidase derived from a lignocellulolytic enriched mangrove metagenome.
6K7Z	;	1.799	;	Crystal structure of a GH18 chitinase from Pseudoalteromonas aurantia
6NCW	;	2.1	;	Crystal structure of a GH2 beta-galacturonidase from Eisenbergiella tayi bound to glycerol
6KVE	;	1.32	;	Crystal structure of a GH28 endo-polygalacturonase from Talaromyces leycettanus JCM 12802
4J27	;	1.59	;	Crystal structure of a gh29 alpha-l-fucosidase gh29 from bacteroides thetaiotaomicron in a novel crystal form
4J28	;	1.73	;	Crystal structure of a gh29 alpha-l-fucosidase gh29 from bacteroides thetaiotaomicron in complex with a 5-membered iminocyclitol inhibitor
7OFX	;	2.15	;	Crystal structure of a GH31 family sulfoquinovosidase mutant D455N from Agrobacterium tumefaciens in complex with sulfoquinovosyl glycerol (SQGro)
5M8E	;	2.0	;	Crystal structure of a GH43 arabonofuranosidase from Weissella sp. strain 142
7JVH	;	2.48	;	Crystal structure of a GH43_12 retrieved from capybara gut metagenome
4L0G	;	2.0	;	Crystal Structure of a GH48 cellobiohydrolase from Caldicellulosiruptor bescii
4L6X	;	1.7	;	Crystal Structure of a GH48 cellobiohydrolase from Caldicellulosiruptor bescii
4TXT	;	2.0	;	Crystal Structure of a GH48 cellobiohydrolase from Caldicellulosiruptor bescii
7LQX	;	1.3	;	Crystal structure of a GH5_18 from Bifidobacterium longum subsp. infantis
4XNN	;	1.9	;	Crystal Structure of a GH7 Family Cellobiohydrolase from Daphnia pulex
4GWA	;	1.6	;	Crystal Structure of a GH7 Family Cellobiohydrolase from Limnoria quadripunctata
4HAP	;	1.6	;	Crystal Structure of a GH7 family cellobiohydrolase from Limnoria quadripunctata in complex with cellobiose
4HAQ	;	1.9	;	Crystal Structure of a GH7 family cellobiohydrolase from Limnoria quadripunctata in complex with cellobiose and cellotriose
4IPM	;	1.14	;	Crystal structure of a GH7 family cellobiohydrolase from Limnoria quadripunctata in complex with thiocellobiose
6G0N	;	1.8	;	Crystal Structure of a GH8 catalytic mutant xylohexaose complex xylanase from Teredinibacter turnerae
6G00	;	1.4	;	Crystal Structure of a GH8 xylanase from Teredinibacter turnerae
6G09	;	1.4	;	Crystal Structure of a GH8 xylobiose complex from Teredinibacter turnerae
6G0B	;	1.8	;	Crystal Structure of a GH8 xylotriose complex from Teredinibacter Turnerae
6NIR	;	2.704	;	Crystal structure of a GII.4 norovirus HOV protease
4G8T	;	1.7	;	Crystal structure of a glucarate dehydratase related protein, from actinobacillus succinogenes, target EFI-502312, with sodium and sulfate bound, ordered loop
5U9P	;	1.65	;	Crystal structure of a gluconate 5-dehydrogenase from Burkholderia cenocepacia J2315 in complex with NADP and tartrate
3T61	;	2.2	;	Crystal Structure of a gluconokinase from Sinorhizobium meliloti 1021
6N0U	;	2.1	;	Crystal structure of a glucose-1-phosphate thymidylyltransferase from Burkholderia phymatum bound to 2'-deoxy-thymidine-B-L-rhamnose
5IDS	;	2.3	;	Crystal Structure of a Glucose-1-phosphate Thymidylyltransferase from Burkholderia vietnamiensis
5IDT	;	2.35	;	Crystal Structure of a Glucose-1-phosphate Thymidylyltransferase from Burkholderia vietnamiensis with bound Thymidine
6OTU	;	2.25	;	Crystal structure of a glucose-6-phosphate isomerase from Chlamydia trachomatis D/UW-3/Cx
1WIW	;	2.0	;	Crystal structure of a glucose-6-phosphate isomerase like protein from thermus thermophilus HB8
7XDR	;	2.4	;	Crystal structure of a glucosylglycerol phosphorylase from Marinobacter adhaerens
7XDQ	;	2.83	;	Crystal structure of a glucosylglycerol phosphorylase mutant from Marinobacter adhaerens
3QLT	;	2.988	;	Crystal structure of a GluK2 (GluR6) glycan wedge homodimer assembly
4Q1T	;	2.15	;	Crystal structure of a glutamate 5-kinase from Burkholderia thailandensis
6BRL	;	2.0	;	Crystal structure of a glutamate tRNA ligase from Elizabethkingia meningosepticum CCUG26117 in complex with its amino acid
3K28	;	1.95	;	Crystal Structure of a glutamate-1-semialdehyde aminotransferase from Bacillus anthracis with bound Pyridoxal 5'Phosphate
5YKT	;	1.57	;	Crystal structure of a glutamate-1-semialdehyde-aminomutase (K286A) from Pseudomonas aeruginosa PAO1 in complex with PMP
5YKR	;	1.44	;	Crystal structure of a glutamate-1-semialdehyde-aminomutase from Pseudomonas aeruginosa PAO1
1O1Y	;	1.7	;	Crystal structure of a glutamine amidotransferase (tm1158) from thermotoga maritima at 1.70 A resolution
4F4H	;	1.75	;	Crystal structure of a Glutamine dependent NAD+ synthetase from Burkholderia thailandensis
4F3P	;	2.4	;	Crystal structure of a Glutamine-binding periplasmic protein from Burkholderia pseudomallei in complex with glutamine
3ILV	;	1.79	;	Crystal structure of a glutamine-dependent NAD(+) synthetase from Cytophaga hutchinsonii
4MHN	;	1.15	;	Crystal structure of a glutaminyl cyclase from Ixodes scapularis
4MHY	;	1.38	;	Crystal structure of a glutaminyl cyclase from Ixodes scapularis in complex with PBD150
7CM0	;	2.2	;	Crystal structure of a glutaminyl cyclase in complex with NHV-1009
4GRI	;	2.6	;	Crystal structure of a glutamyl-tRNA synthetase GluRS from Borrelia burgdorferi bound to glutamic acid and zinc
4G6Z	;	2.05	;	Crystal structure of a glutamyl-tRNA synthetase GluRS from Burkholderia thailandensis bound to L-glutamate
3SWO	;	1.45	;	Crystal structure of a glutaryl-coa dehydrogenase from mycobacterium smegmatis in complex with FADH2
2FNO	;	2.0	;	Crystal structure of a glutathione s-transferase (atu5508) from agrobacterium tumefaciens str. c58 at 2.00 A resolution
7MIQ	;	1.92	;	Crystal structure of a Glutathione S-transferase class Gtt2 of Vibrio parahaemolyticus (VpGSTT2)
4N0V	;	1.7	;	Crystal structure of a glutathione S-transferase domain-containing protein (Marinobacter aquaeolei VT8), Target EFI-507332
4IEL	;	1.6	;	Crystal structure of a glutathione s-transferase family protein from burkholderia ambifaria, target efi-507141, with bound glutathione
3QAV	;	2.1	;	Crystal structure of a glutathione S-transferase from Antarctic clam Laternula elliptica
4O92	;	2.51	;	Crystal structure of a Glutathione S-transferase from Pichia kudriavzevii (Issatchenkia orientalis), target EFI-501747
4O7H	;	1.6	;	Crystal structure of a glutathione S-transferase from Rhodospirillum rubrum F11, Target EFI-507460
7DW3	;	1.93	;	Crystal structure of a glutathione S-transferase mutant SbGSTU6(I55T) from Salix babylonica
7DW4	;	1.57	;	Crystal structure of a glutathione S-transferase mutant SbGSTU6(I55T) from Salix babylonica in complex with glutathione
7DWF	;	2.21	;	Crystal structure of a glutathione S-transferase mutant SbGSTU7(T53I) from Salix babylonica
7DWG	;	1.67	;	Crystal structure of a glutathione S-transferase mutant SbGSTU7(T53I) from Salix babylonica in complex with glutathione
5HFK	;	1.551	;	CRYSTAL STRUCTURE OF A GLUTATHIONE S-TRANSFERASE PROTEIN FROM ESCHERICHIA COLI OCh 157:H7 STR. SAKAI (ECs3186, TARGET EFI-507414) WITH BOUND GLUTATHIONE
5J4U	;	1.249	;	Crystal structure of a glutathione S-transferase PtGSTU30 from Populus trichocarpa in complex with GSH
7DW2	;	1.74	;	Crystal structure of a glutathione S-transferase SbGSTU6 from Salix babylonica
7DW1	;	2.27	;	Crystal structure of a glutathione S-transferase SbGSTU6 from Salix babylonica in complex with glutathione
7DWD	;	1.58	;	Crystal structure of a glutathione S-transferase SbGSTU7 from Salix babylonica
7DWE	;	1.77	;	Crystal structure of a glutathione S-transferase SbGSTU7 from Salix babylonica in complex with glutathione
7Y55	;	2.19113	;	Crystal structure of a glutathione S-transferase Tau1 from Pinus densata in complex with GSH
4MP4	;	2.498	;	Crystal structure of a glutathione transferase family member from Acinetobacter baumannii, Target EFI-501785, apo structure
4KDX	;	1.35	;	Crystal structure of a glutathione transferase family member from burkholderia graminis, target efi-507264, bound gsh, ordered domains, space group p21, form(1)
4KE3	;	1.9	;	Crystal structure of a glutathione transferase family member from Burkholderia graminis, target efi-507264, no gsh, disordered domains, space group P21, form(2)
4KDU	;	1.6	;	Crystal structure of a glutathione transferase family member from Burkholderia graminis, target efi-507264, no gsh, ordered domains, space group P21, form(1)
4MK3	;	1.501	;	Crystal structure of a glutathione transferase family member from Cupriavidus metallidurans CH34, target EFI-507362, with bound glutathione sulfinic acid (gso2h)
4IKH	;	2.1	;	Crystal structure of a glutathione transferase family member from Pseudomonas fluorescens pf-5, target efi-900003, with two glutathione bound
4IBP	;	1.8	;	Crystal structure of a glutathione transferase family member from Pseudomonas fluorescens Pf-5, target EFI-900011, with bound glutathione
4ID0	;	1.1	;	Crystal structure of a glutathione transferase family member from Pseudomonas fluorescens Pf-5, target EFI-900011, with bound glutathione sulfinic acid (gso2h) and acetate
4IJI	;	1.5	;	Crystal structure of a glutathione transferase family member from Psuedomonas fluorescens Pf-5, target EFI-900011, with bound S-(propanoic acid)-glutathione
4KF9	;	2.3	;	Crystal structure of a glutathione transferase family member from ralstonia solanacearum, target efi-501780, with bound gsh coordinated to a zinc ion, ordered active site
4J2F	;	1.9	;	Crystal structure of a glutathione transferase family member from Ricinus communis, target EFI-501866
4KH7	;	1.5	;	Crystal structure of a glutathione transferase family member from salmonella enterica ty2, target efi-507262, with bound glutathione
4KGI	;	1.6	;	Crystal structure of a glutathione transferase family member from Shigella flexneri, target EFI-507258, bound GSH, TEV-his-tag linker in active site
4L8E	;	1.7	;	Crystal structure of a glutathione transferase family member from xenorhabdus nematophila, target efi-507418, with two gsh per subunit
4PTS	;	2.83	;	Crystal structure of a glutathione transferase from Gordonia bronchialis DSM 43247, target EFI-507405
3QAW	;	2.2	;	Crystal structure of a glutathione-S-transferase from Antarctic clam Laternula elliptica in a complex with glutathione
1HNL	;	1.8	;	CRYSTAL STRUCTURE OF A GLUTATHIONYLATED HUMAN LYSOZYME: A FOLDING INTERMEDIATE MIMIC IN THE FORMATION OF A DISULFIDE BOND
4IEB	;	2.05	;	Crystal Structure of a Gly128Met mutant of the toxoplasma CDPK, TGME49_101440
5VMT	;	2.5	;	Crystal structure of a glyceraldehyde-3-phosphate dehydrogenase from Neisseria gonorrhoeae bound to NAD
1KQ3	;	1.5	;	CRYSTAL STRUCTURE OF A GLYCEROL DEHYDROGENASE (TM0423) FROM THERMOTOGA MARITIMA AT 1.5 A RESOLUTION
1VKF	;	1.65	;	CRYSTAL STRUCTURE OF A GLYCEROL UPTAKE OPERON ANTITERMINATOR-RELATED PROTEIN (TM1436) FROM THERMOTOGA MARITIMA MSB8 AT 1.65 A RESOLUTION
3NO3	;	1.89	;	Crystal structure of a glycerophosphodiester phosphodiesterase (BDI_0402) from Parabacteroides distasonis ATCC 8503 at 1.89 A resolution
2P76	;	2.6	;	Crystal structure of a Glycerophosphodiester Phosphodiesterase from Staphylococcus aureus
3MZ2	;	1.55	;	Crystal structure of a Glycerophosphoryl diester phosphodiesterase (BDI_3922) from Parabacteroides distasonis ATCC 8503 at 1.55 A resolution
3TZU	;	2.3	;	Crystal structure of a glycine cleavage system H protein (GCVH) from Mycobacterium marinum
5VMB	;	2.5	;	Crystal structure of a glycine hydroxymethyltransferase from Acinetobacter baumannii
3P49	;	3.55	;	Crystal Structure of a Glycine Riboswitch from Fusobacterium nucleatum
3DGK	;	1.7	;	Crystal structure of a glycine-rich loop mutant of the death associated protein kinase catalytic domain
3DFC	;	1.9	;	Crystal structure of a glycine-rich loop mutant of the death associated protein kinase catalytic domain with AMPPNP
2I3F	;	1.38	;	Crystal Structure of a Glycolipid transfer-like protein from Galdieria sulphuraria
3W0K	;	1.6	;	Crystal Structure of a glycoside hydrolase
5K9H	;	2.029	;	Crystal structure of a glycoside hydrolase 29 family member from an unknown rumen bacterium
4XUV	;	2.0496	;	Crystal structure of a glycoside hydrolase family 105 (GH105) enzyme from Thielavia terrestris
2QZ2	;	2.8	;	Crystal structure of a glycoside hydrolase family 11 xylanase from Aspergillus niger in complex with xylopentaose
2QZ3	;	1.8	;	Crystal structure of a glycoside hydrolase family 11 xylanase from Bacillus subtilis in complex with xylotetraose
3ZYZ	;	2.1	;	Crystal structure of a glycoside hydrolase family 3 beta-glucosidase, Bgl1 from Hypocrea jecorina at 2.1A resolution.
3ZZ1	;	2.1	;	Crystal structure of a glycoside hydrolase family 3 beta-glucosidase, Bgl1 from Hypocrea jecorina at 2.1A resolution.
4FJ6	;	1.9	;	Crystal structure of a glycoside hydrolase family 33, candidate sialidase (BDI_2946) from Parabacteroides distasonis ATCC 8503 at 1.90 A resolution
3C7O	;	1.8	;	Crystal structure of a glycoside hydrolase family 43 arabinoxylan arabinofuranohydrolase from Bacillus subtilis in complex with cellotetraose.
3C7G	;	2.02	;	Crystal structure of a glycoside hydrolase family 43 arabinoxylan arabinofuranohydrolase from Bacillus subtilis in complex with xylotetraose.
3C7F	;	1.55	;	Crystal structure of a glycoside hydrolase family 43 arabinoxylan arabinofuranohydrolase from bacillus subtilis in complex with xylotriose.
3C7E	;	2.0	;	Crystal structure of a glycoside hydrolase family 43 arabinoxylan arabinofuranohydrolase from Bacillus subtilis.
3IK2	;	2.2	;	Crystal Structure of a Glycoside Hydrolase Family 44 Endoglucanase produced by Clostridium acetobutylium ATCC 824
4QFU	;	1.9	;	Crystal structure of a glycoside hydrolase family 5 (BVU_2644) from Bacteroides vulgatus ATCC 8482 at 1.90 A resolution
4XDQ	;	1.35	;	Crystal structure of a Glycoside hydrolase family protein (Rv0315 ortholog) from Mycobacterium thermorestibile
5GLX	;	1.42	;	Crystal structure of a glycoside hydrolase from Thielavia terrestris NRRL 8126
5GM9	;	1.36	;	Crystal structure of a glycoside hydrolase in complex with cellobiose
5GLY	;	1.58	;	Crystal structure of a glycoside hydrolase in complex with cellotetrose from Thielavia terrestris NRRL 8126
4LSM	;	1.65	;	Crystal structure of a glycosomal glyceraldehyde-3-phosphate dehydrogenase from Trypanosoma cruzi
3QC2	;	2.3	;	Crystal structure of a glycosyl hydrolase (BACOVA_03624) from Bacteroides ovatus at 2.30 A resolution
3NQH	;	2.11	;	Crystal structure of a glycosyl hydrolase (BT_2959) from BACTEROIDES THETAIOTAOMICRON VPI-5482 at 2.11 A resolution
3DEC	;	2.8	;	Crystal structure of a glycosyl hydrolases family 2 protein from Bacteroides thetaiotaomicron
8FTT	;	2.08	;	Crystal structure of a glycosylase specific nanobody
4HPG	;	2.5364	;	Crystal structure of a glycosylated beta-1,3-glucanase (HEV B 2), an allergen from Hevea brasiliensis
4IIS	;	2.6676	;	Crystal structure of a glycosylated beta-1,3-glucanase (HEV B 2), An allergen from Hevea Brasiliensis (Space group P41)
4XX6	;	1.95	;	Crystal structure of a glycosylated endo-beta-1,4-xylanase (glycoside hydrolase family 10/GH10) enzyme from Gloeophyllum trabeum
2AGJ	;	2.6	;	Crystal Structure of a glycosylated Fab from an IgM cryoglobulin with properties of a natural proteolytic antibody
3UYV	;	2.43	;	Crystal structure of a glycosylated ice-binding protein (LeIBP) from Arctic yeast
2P6W	;	1.6	;	Crystal structure of a glycosyltransferase involved in the glycosylation of the major capsid of PBCV-1
2P72	;	2.0	;	crystal structure of a glycosyltransferase involved in the glycosylation of the major capsid of PBCV-1
2P73	;	2.3	;	crystal structure of a glycosyltransferase involved in the glycosylation of the major capsid of PBCV-1
4NUZ	;	1.905	;	Crystal structure of a glycosynthase mutant (D233Q) of EndoS, an endo-beta-N-acetyl-glucosaminidase from Streptococcus pyogenes
2F3O	;	2.9	;	Crystal Structure of a glycyl radical enzyme from Archaeoglobus fulgidus
6OMK	;	2.1	;	Crystal structure of a glycylpeptide N-tetradecanoyltransferase (N-myristoyl transferase, NMT) from Leishmania major Friedlin bound to tetradecanoyl-CoA
2QH0	;	2.45	;	Crystal structure of a glyoxalase from clostridium acetobutylicum
3BT3	;	2.5	;	Crystal structure of a glyoxalase-related enzyme from Clostridium phytofermentans
4MYM	;	1.9	;	Crystal structure of a glyoxalase/ bleomycin resistance protein/ dioxygenase from Nocardioides
4QB5	;	2.05	;	Crystal structure of a glyoxalase/bleomycin resistance protein from Albidiferax ferrireducens T118
2RBB	;	1.82	;	Crystal structure of a glyoxalase/bleomycin resistance protein/dioxygenase family enzyme from Burkholderia phytofirmans PsJN
3KOL	;	1.9	;	Crystal structure of a glyoxalase/dioxygenase from Nostoc punctiforme
3WNV	;	1.75	;	Crystal structure of a glyoxylate reductase from Paecilomyes thermophila
2H1S	;	2.45	;	Crystal Structure of a Glyoxylate/Hydroxypyruvate reductase from Homo sapiens
2BSW	;	1.63	;	Crystal structure of a glyphosate-N-acetyltransferase obtained by DNA shuffling.
5TW7	;	2.35	;	Crystal structure of a GMP synthase (glutamine-hydrolyzing) from Neisseria gonorrhoeae
7SBC	;	1.95	;	Crystal structure of a GMP synthase from Acinetobacter baumannii AB5075-UW
4ZBG	;	1.25	;	Crystal Structure of a GNAT family Acetyltransferase from Brucella melitensis in complex with Acetyl-CoA
6AO7	;	1.85	;	Crystal Structure of a GNAT family acetyltransferase from Elizabethkingia anophelis with acetyl-CoA bound
4KUA	;	1.5	;	Crystal structure of a GNAT superfamily acetyltransferase PA4794
4OAE	;	1.25	;	Crystal structure of a GNAT superfamily acetyltransferase PA4794 C29A/C117A/Y128A mutant in complex with chloramphenicol
4KLW	;	1.3	;	Crystal structure of a GNAT superfamily acetyltransferase PA4794 in complex with 2-(aminocarbonyl)benzoate
4KLV	;	1.3	;	Crystal structure of a GNAT superfamily acetyltransferase PA4794 in complex with 4-methylumbelliferyl phosphate
4KOR	;	1.25	;	Crystal structure of a GNAT superfamily acetyltransferase PA4794 in complex with 7-aminocephalosporanic acid
5VDB	;	1.4	;	Crystal structure of a GNAT superfamily acetyltransferase PA4794 in complex with bisubstrate analog 3
5VD6	;	1.2	;	Crystal structure of a GNAT superfamily acetyltransferase PA4794 in complex with bisubstrate analog 6
4KOX	;	1.8	;	Crystal structure of a GNAT superfamily acetyltransferase PA4794 in complex with Cefalotin
4KOU	;	1.6	;	Crystal structure of a GNAT superfamily acetyltransferase PA4794 in complex with Cefixime
4KOS	;	1.55	;	Crystal structure of a GNAT superfamily acetyltransferase PA4794 in complex with Cefmetazole
4KOT	;	1.55	;	Crystal structure of a GNAT superfamily acetyltransferase PA4794 in complex with Cefotaxime
4KOW	;	1.45	;	Crystal structure of a GNAT superfamily acetyltransferase PA4794 in complex with Cefoxitin
4KOV	;	1.6	;	Crystal structure of a GNAT superfamily acetyltransferase PA4794 in complex with Cefuroxime
4KOY	;	1.4	;	Crystal structure of a GNAT superfamily acetyltransferase PA4794 in complex with Cephalosporin C
4OAD	;	1.45	;	Crystal structure of a GNAT superfamily acetyltransferase PA4794 in complex with chloramphenicol
4KUB	;	1.57	;	Crystal structure of a GNAT superfamily acetyltransferase PA4794 in complex with CoA
4L89	;	1.6	;	Crystal structure of a GNAT superfamily acetyltransferase PA4794 in complex with covalently bound CoA
4M3S	;	1.3	;	Crystal structure of a GNAT superfamily acetyltransferase PA4794 in complex with HEPES
4L8A	;	1.2	;	Crystal structure of a GNAT superfamily acetyltransferase PA4794 in ternary complex with N-Phenylacetyl-Gly-AcLys and CoA
6EDD	;	1.55	;	Crystal structure of a GNAT Superfamily PA3944 acetyltransferase in complex with CoA (P1 space group)
4JXQ	;	1.15	;	Crystal structure of a GNAT superfamily phosphinothricin acetyltransferase (Pat) from Sinorhizobium meliloti 1021
4JXR	;	1.15	;	Crystal structure of a GNAT superfamily phosphinothricin acetyltransferase (Pat) from Sinorhizobium meliloti in complex with AcCoA
2DUG	;	1.4	;	crystal structure of a green fluorescent protein S65T/H148N at pH 5
2DUI	;	1.36	;	crystal structure of a green fluorescent protein variant H148D at pH 9
2DUE	;	1.24	;	crystal structure of a green fluorescent protein variant S65T/H148D at pH 10
2DUF	;	1.5	;	crystal structure of a green fluorescent protein variant S65T/H148D at pH 5.6
2DUH	;	1.2	;	crystal structure of a green fluorescent protein variant S65T/H148N at pH 9.5
4M46	;	2.7	;	Crystal structure of a green-emitter native of Lampyris turkestanicus luciferase
4HQ9	;	2.07	;	Crystal structure of a green-to-red photoconvertible DRONPA, pcDRONPA in the green-off-state
4HQ8	;	1.95	;	Crystal structure of a green-to-red photoconvertible DRONPA, pcDRONPA in the green-on-state
4HQC	;	2.05	;	Crystal structure of a green-to-red photoconvertible DRONPA, pcDRONPA in the red-on-state
1DKD	;	2.1	;	CRYSTAL STRUCTURE OF A GROEL (APICAL DOMAIN) AND A DODECAMERIC PEPTIDE COMPLEX
4WGL	;	3.13	;	Crystal structure of a GroEL D83A/R197A double mutant
4KI8	;	2.722	;	Crystal structure of a GroEL-ADP complex in the relaxed allosteric state
4WSC	;	3.04	;	Crystal structure of a GroELK105A mutant
5Y2L	;	2.902	;	Crystal structure of a group 2 HA binding antibody AF4H1K1 Fab in complex with the 1968 H3N2 pandemic (H3-AC/68) hemagglutinin
5Y2M	;	3.8	;	Crystal structure of a group 2 HA binding antibody AF4H1K1 Fab in complex with the H4N6 duck isolate (H4-CZ/56) hemagglutinin
1ZZN	;	3.37	;	Crystal structure of a group I intron/two exon complex that includes all catalytic metal ion ligands.
1GID	;	2.5	;	CRYSTAL STRUCTURE OF A GROUP I RIBOZYME DOMAIN: PRINCIPLES OF RNA PACKING
3KFB	;	3.2	;	Crystal structure of a group II chaperonin from Methanococcus maripaludis
4DS6	;	3.644	;	Crystal structure of a group II intron in the pre-catalytic state
6CIH	;	3.676	;	Crystal structure of a group II intron lariat in the post-catalytic state
6CHR	;	3.7	;	Crystal structure of a group II intron lariat with an intact 3' splice site (pre-2s state)
6JY1	;	1.72	;	Crystal Structure of a Group II pyridoxal dependent decarboxylase, LLP-bound form from Methanocaldococcus jannaschii at 1.72 A
6GHF	;	3.52	;	Crystal structure of a GST variant
6XRS	;	2.8	;	Crystal structure of a GTP-binding protein EngA (Der homolog) from Neisseria gonorrhoeae bound to GDP
2QTF	;	2.0	;	Crystal structure of a GTP-binding protein from the hyperthermophilic archaeon Sulfolobus solfataricus
2QTH	;	2.0	;	Crystal structure of a GTP-binding protein from the hyperthermophilic archaeon Sulfolobus solfataricus in complex with GDP
1ZUN	;	2.7	;	Crystal Structure of a GTP-Regulated ATP Sulfurylase Heterodimer from Pseudomonas syringae
2XKA	;	3.0	;	Crystal structure of a GTPyS-form protofilament of Bacillus thuringiensis serovar israelensis TubZ
6X1H	;	2.91	;	Crystal structure of a guanine nucleotide exchange factor (GEF) domain from the Orientia tsutsugamushi protein OtDUB
6MFU	;	1.6	;	Crystal structure of a Guanylate kinase from Cryptococcus neoformans var. grubii serotype A in complex with GDP and ADP
6WCT	;	2.1	;	Crystal structure of a guanylate kinase from Stenotrophomonas maltophilia K279a bound to guanosine-5'-monophosphate
7S5E	;	2.4	;	Crystal structure of a guanylate kinase from Stenotrophomonas maltophilia K279a with heterogeneous ligand states of GMP/ADP, GMP/-, GDP/-, and GMP/ATPgS
2J4H	;	2.7	;	Crystal structure of a H121A Escherichia coli dCTP deaminase mutant enzyme
3KU6	;	1.75	;	Crystal structure of a H2N2 influenza virus hemagglutinin, 226L/228G
3KU3	;	1.6	;	Crystal structure of a H2N2 influenza virus hemagglutinin, avian like
3KU5	;	1.73	;	Crystal structure of a H2N2 influenza virus hemagglutinin, human like
3MGO	;	2.297	;	Crystal structure of a H5-specific CTL epitope derived from H5N1 influenza virus in complex with HLA-A*0201
3MGT	;	2.197	;	Crystal structure of a H5-specific CTL epitope variant derived from H5N1 influenza virus in complex with HLA-A*0201
6PD3	;	2.3	;	Crystal Structure of a H5N1 influenza virus hemagglutinin at pH 5.5
6PCX	;	2.11	;	Crystal Structure of a H5N1 influenza virus hemagglutinin at pH 6.0
6PD5	;	2.39	;	Crystal Structure of a H5N1 influenza virus hemagglutinin at pH 6.5
6PD6	;	2.87	;	Crystal Structure of a H5N1 influenza virus hemagglutinin at pH 7.0
4MHI	;	2.595	;	Crystal structure of a H5N1 influenza virus hemagglutinin from A/goose/Guangdong/1/96
6VMZ	;	2.2	;	Crystal Structure of a H5N1 influenza virus hemagglutinin with CBS1117
2FK0	;	2.95	;	Crystal Structure of a H5N1 influenza virus hemagglutinin.
3M5G	;	2.6	;	Crystal structure of a H7 influenza virus hemagglutinin
3M5H	;	2.7	;	Crystal structure of a H7 influenza virus hemagglutinin complexed with 3SLN
3M5I	;	3.0	;	Crystal structure of a H7 influenza virus hemagglutinin complexed with 6SLN
3M5J	;	2.6	;	Crystal structure of a H7 influenza virus hemagglutinin complexed with LSTb
1YV9	;	2.8	;	Crystal structure of a HAD-like phosphatase from Enterococcus faecalis V583
1YDF	;	2.6	;	Crystal structure of a HAD-like phosphatase from Streptococcus pneumoniae
3KZX	;	1.9	;	Crystal structure of a Had-superfamily hydrolase from Ehrlichia chaffeensis at 1.9A resolution
4RN3	;	2.15	;	Crystal structure of a HAD-superfamily hydrolase, subfamily IA, variant 1 (GSU2069) from Geobacter sulfurreducens PCA at 2.15 A resolution
2V0S	;	1.8	;	crystal structure of a hairpin exchange variant (LR1) of the targeting LINE-1 retrotransposon endonuclease
2V0R	;	2.3	;	crystal structure of a hairpin exchange variant (LTx) of the targeting LINE-1 retrotransposon endonuclease
1M5K	;	2.4	;	Crystal structure of a hairpin ribozyme in the catalytically-active conformation
1X42	;	2.0	;	Crystal structure of a haloacid dehalogenase family protein (PH0459) from Pyrococcus horikoshii OT3
3PGV	;	2.39	;	Crystal structure of a haloacid dehalogenase-like hydrolase (KPN_04322) from Klebsiella pneumoniae subsp. pneumoniae MGH 78578 at 2.39 A resolution
4DWO	;	1.5	;	Crystal structure of a haloacid dehalogenase-like hydrolase (Target EFI-900331) from Bacteroides thetaiotaomicron with bound Mg crystal form II
4DW8	;	1.502	;	Crystal structure of a haloacid dehalogenase-like hydrolase (Target EFI-900331) from Bacteroides thetaiotaomicron with bound Na crystal form I
3NIW	;	1.9	;	Crystal structure of a haloacid dehalogenase-like hydrolase from Bacteroides thetaiotaomicron
6U2M	;	2.0	;	Crystal structure of a HaloTag-based calcium indicator, HaloCaMP V2, bound to JF635
3LEZ	;	1.25	;	Crystal structure of a halotolerant bacterial beta-lactamase
1Y7W	;	1.86	;	Crystal structure of a halotolerant carbonic anhydrase from Dunaliella salina
3MZO	;	1.98	;	Crystal structure of a HD-domain phosphohydrolase (lin2634) from LISTERIA INNOCUA at 1.98 A resolution
4MCW	;	2.03	;	Crystal structure of a HD-GYP domain (a cyclic-di-GMP phosphodiesterase) containing a tri-nuclear metal centre
4MDZ	;	2.68	;	Crystal structure of a HD-GYP domain (a cyclic-di-GMP phosphodiesterase) containing a tri-nuclear metal centre
4ME4	;	2.55	;	Crystal structure of a HD-GYP domain (a cyclic-di-GMP phosphodiesterase) containing a tri-nuclear metal centre
3DJB	;	2.9	;	Crystal structure of a HD-superfamily hydrolase (BT9727_1981) from Bacillus thuringiensis, Northeast Structural Genomics Consortium Target BuR114
2VCG	;	1.9	;	Crystal structure of a HDAC-like protein HDAH from Bordetella sp. with the bound inhibitor ST-17
2GH6	;	2.203	;	Crystal structure of a HDAC-like protein with 9,9,9-trifluoro-8-oxo-N-phenylnonan amide bound
1ZZ0	;	1.6	;	Crystal structure of a HDAC-like protein with acetate bound
1ZZ3	;	1.76	;	Crystal structure of a HDAC-like protein with CypX bound
1ZZ1	;	1.57	;	Crystal structure of a HDAC-like protein with SAHA bound
7XUZ	;	3.591	;	Crystal structure of a HDAC4-MEF2A-DNA ternary complex
4FSV	;	1.8	;	Crystal structure of a heat shock 70kDa protein 2 (HSPA2) from Homo sapiens at 1.80 A resolution
3AKJ	;	2.0	;	Crystal structure of A Helicobacter pylori proinflammatory kinase CtkA
3AKK	;	2.5	;	Crystal structure of A Helicobacter pylori proinflammatory kinase CtkA
3AKL	;	2.9	;	Crystal structure of A Helicobacter pylori proinflammatory kinase CtkA
4GQM	;	1.25	;	Crystal structure of a helix-turn-helix containing hypothetical protein (CT009) from Chlamydia trachomatis in a sub-domain swap conformation
2IBL	;	1.32	;	Crystal structure of a helper molecule (HT-mf-thromb) based on mini-fibritin (mf) crystal structure (pdb:1OX3).
1QXM	;	1.7	;	Crystal structure of a hemagglutinin component (HA1) from type C Clostridium botulinum
8SPP	;	1.89	;	Crystal structure of a heme enzyme RufO in rufomycin biosynthesis
1IW0	;	1.4	;	Crystal structure of a heme oxygenase (HmuO) from Corynebacterium diphtheriae complexed with heme in the ferric state
1IW1	;	1.5	;	Crystal structure of a heme oxygenase (HmuO) from Corynebacterium diphtheriae complexed with heme in the ferrous state
1X3K	;	1.64	;	Crystal structure of a hemoglobin component (TA-V) from Tokunagayusurika akamusi
1X46	;	1.5	;	Crystal structure of a hemoglobin component (TA-VII) from Tokunagayusurika akamusi
2ZWJ	;	1.81	;	Crystal structure of a hemoglobin component V from Propsilocerus akamusi (pH4.6 coordinates)
3A5A	;	1.83	;	Crystal structure of a hemoglobin component V from Propsilocerus akamusi (pH5.6 coordinates)
3A5B	;	1.81	;	Crystal structure of a hemoglobin component V from Propsilocerus akamusi (pH6.5 coordinates)
3A5G	;	1.81	;	Crystal structure of a hemoglobin component V from Propsilocerus akamusi (pH7.0 coordinates)
3A9M	;	1.8	;	Crystal structure of a hemoglobin component V from Propsilocerus akamusi (pH9.0 coordinates)
3P4L	;	1.8	;	Crystal structure of a hemojuvelin-binding fragment of neogenin
5EZD	;	2.1	;	Crystal structure of a Hepatocyte growth factor activator inhibitor-1 (HAI-1) fragment covering the PKD-like 'internal' domain and Kunitz domain 1
2HSB	;	1.95	;	Crystal structure of a hepn domain containing protein (af_0298) from archaeoglobus fulgidus at 1.95 A resolution
1I81	;	2.0	;	CRYSTAL STRUCTURE OF A HEPTAMERIC LSM PROTEIN FROM METHANOBACTERIUM THERMOAUTOTROPHICUM
1N9R	;	2.8	;	Crystal structure of a heptameric ring complex of yeast SmF in spacegroup P4122
1MGQ	;	1.7	;	CRYSTAL STRUCTURE OF A HEPTAMERIC SM-LIKE PROTEIN FROM METHANOBACTERIUM THERMOAUTOTROPHICUM
5MY6	;	2.246	;	Crystal structure of a HER2-Nb complex
3R48	;	2.0011	;	Crystal structure of a hetero-hexamer coiled coil
7YH8	;	2.2	;	Crystal structure of a heterochiral protein complex
2QBY	;	3.35	;	Crystal structure of a heterodimer of Cdc6/Orc1 initiators bound to origin DNA (from S. solfataricus)
3QF4	;	2.9	;	Crystal structure of a heterodimeric ABC transporter in its inward-facing conformation
1DKF	;	2.5	;	CRYSTAL STRUCTURE OF A HETERODIMERIC COMPLEX OF RAR AND RXR LIGAND-BINDING DOMAINS
3S7R	;	2.15	;	Crystal structure of a Heterogeneous nuclear ribonucleoprotein A/B (HNRPAB) from HOMO SAPIENS at 2.15 A resolution
3TYT	;	1.6	;	Crystal structure of a Heterogeneous nuclear ribonucleoprotein L (Hnrpl) from Mus musculus at 1.60 A resolution
3S01	;	2.15	;	Crystal structure of a Heterogeneous nuclear ribonucleoprotein L (Hnrpl) from Mus musculus at 2.15 A resolution
4NH1	;	3.3	;	Crystal structure of a heterotetrameric CK2 holoenzyme complex carrying the Andante-mutation in CK2beta and consistent with proposed models of autoinhibition and trans-autophosphorylation
4FID	;	2.62	;	Crystal structure of a heterotrimeric G-Protein subunit from entamoeba histolytica, EHG-ALPHA-1
1WKX	;	1.7	;	Crystal Structure of a Hev b 6.02 Isoallergen
3S5C	;	3.5	;	Crystal Structure of a Hexachlorocyclohexane dehydrochlorinase (LinA) Type2
4XCG	;	3.737	;	Crystal structure of a hexadecameric TF55 complex from S. solfataricus, crystal form I
4XCI	;	3.0023	;	Crystal structure of a hexadecameric TF55 complex from S. solfataricus, crystal form II
4YPL	;	3.45	;	Crystal structure of a hexameric LonA protease bound to three ADPs
481D	;	1.6	;	CRYSTAL STRUCTURE OF A HEXITOL NUCLEIC ACID (HNA) DUPLEX AT 1.6A RESOLUTION
1D7Z	;	2.21	;	CRYSTAL STRUCTURE OF A HEXITOL NUCLEIC ACID (HNA) DUPLEX AT 2.2 A RESOLUTION
4G81	;	1.9	;	Crystal structure of a hexonate dehydrogenase ortholog (target efi-506402 from salmonella enterica, unliganded structure
3F1P	;	1.17	;	Crystal structure of a high affinity heterodimer of HIF2 alpha and ARNT C-terminal PAS domains
3F1N	;	1.479	;	Crystal structure of a high affinity heterodimer of HIF2 alpha and ARNT C-terminal PAS domains, with internally bound ethylene glycol.
4K71	;	2.4	;	Crystal structure of a high affinity Human Serum Albumin variant bound to the Neonatal Fc Receptor
1TJB	;	2.0	;	Crystal Structure of a High Affinity Lanthanide-Binding Peptide (LBT)
6UUV	;	1.8	;	Crystal structure of a high molecular weight 3-oxoacyl-ACP reductase (FabG) from Acinetobacter baumannii crystal form 1
6UUT	;	1.65	;	Crystal structure of a high molecular weight 3-oxoacyl-ACP reductase (FabG) from Acinetobacter baumannii crystal form 2
3GUT	;	3.59	;	Crystal structure of a higher-order complex of p50:RelA bound to the HIV-1 LTR
5C9K	;	1.92	;	Crystal structure of a highly fibrillogenic Arg24Gly mutant of the Recombinant variable domain 6AJL2
8ILL	;	2.2	;	Crystal structure of a highly photostable and bright green fluorescent protein at pH5.6
8ILK	;	1.56	;	Crystal structure of a highly photostable and bright green fluorescent protein at pH8.5
8DCI	;	1.62	;	Crystal Structure of a highly resistant HIV-1 protease Clinical isolate PR10x (inhibitor-free)
8DCH	;	1.25	;	Crystal Structure of a highly resistant HIV-1 protease Clinical isolate PR10x with GRL-0519 (tris-tetrahydrofuran as P2 ligand)
5VBT	;	1.51	;	Crystal structure of a highly specific and potent USP7 ubiquitin variant inhibitor
1AQZ	;	1.7	;	CRYSTAL STRUCTURE OF A HIGHLY SPECIFIC ASPERGILLUS RIBOTOXIN, RESTRICTOCIN
4PXX	;	1.851	;	Crystal structure of a highly thermal stabilized variant of Human Carbonic Anhydrase II
4ZXZ	;	2.2	;	Crystal structure of a highly thermal stable but inactive levoglucosan kinase.
6IM0	;	2.6	;	Crystal structure of a highly thermostable carbonic anhydrase from Persephonella marina EX-H1
6IM1	;	2.0	;	Crystal structure of a highly thermostable carbonic anhydrase from Persephonella marina EX-H1
6IM3	;	2.0	;	Crystal structure of a highly thermostable carbonic anhydrase from Persephonella marina EX-H1
1J1I	;	1.86	;	Crystal structure of a His-tagged Serine Hydrolase Involved in the Carbazole Degradation (CarC enzyme)
8Y4U	;	2.4	;	Crystal structure of a His1 from oryza sativa
7LTQ	;	2.15	;	Crystal Structure of a histidine kinase from Burkholderia ambifaria MC40-6
3H7M	;	2.4	;	Crystal Structure of a Histidine Kinase Sensor Domain with Similarity to Periplasmic Binding Proteins
2OIK	;	1.65	;	Crystal structure of a histidine triad (hit) protein (mfla_2506) from methylobacillus flagellatus kt at 1.65 A resolution
3NRD	;	2.06	;	Crystal structure of a histidine triad (HIT) protein (SMc02904) from SINORHIZOBIUM MELILOTI 1021 at 2.06 A resolution
3OMF	;	1.8	;	Crystal structure of a histidine triad family protein from Entamoeba histolytica, bound to AMP
3OXK	;	1.55	;	Crystal structure of a histidine triad family protein from Entamoeba histolytica, bound to GMP
3OJ7	;	1.4	;	Crystal structure of a histidine triad family protein from entamoeba histolytica, bound to sulfate
3OHE	;	1.2	;	Crystal structure of a Histidine triad protein (Maqu_1709) from Marinobacter aquaeolei VT8 at 1.20 A resolution
3HDO	;	1.61	;	Crystal Structure of a Histidinol-phosphate aminotransferase from Geobacter metallireducens
5E3I	;	2.2	;	Crystal Structure of a Histidyl-tRNA synthetase from Acinetobacter baumannii with bound L-Histidine and ATP
4E51	;	2.65	;	Crystal structure of a histidyl-tRNA synthetase HisRS from Burkholderia thailandensis bound to histidine
5JI5	;	2.1	;	Crystal Structure of a Histone Deacetylase superfamily protein from Burkholderia phymatumphymatum
6N2L	;	1.85	;	Crystal structure of a histone family protein DNA-binding protein from Burkholderia ambifaria
3I24	;	1.5	;	Crystal Structure of a HIT family hydrolase protein from Vibrio fischeri. Northeast Structural Genomics Consortium target id VfR176
4KSE	;	2.677	;	Crystal structure of a HIV p51 (219-230) deletion mutant
6CE0	;	4.602	;	Crystal structure of a HIV-1 clade B tier-3 isolate H078.14 UFO-BG Env trimer in complex with broadly neutralizing Fabs PGT124 and 35O22 at 4.6 Angstrom
7KMD	;	3.39229	;	Crystal structure of a HIV-1 clade C isolate Du172.17 HR1.R4.664 Env trimer in complex with human Fabs PGT124 and 35O22
1U8G	;	2.201	;	Crystal structure of a HIV-1 Protease in complex with peptidomimetic inhibitor KI2-PHE-GLU-GLU-NH2
4DWF	;	1.8	;	Crystal structure of a HLA-B associated transcript 3 (BAT3) from Homo sapiens at 1.80 A resolution
4PRN	;	1.65	;	Crystal structure of a HLA-B*35:01-HPVG-A4
4PR5	;	1.8	;	Crystal structure of a HLA-B*35:01-HPVG-D5
4PRA	;	1.85	;	Crystal structure of a HLA-B*35:01-HPVG-Q5
8EMF	;	1.80482	;	Crystal structure of a HLA-B*35:01-NP6 epitope from 1977 H1N1 influenza strain
8EMG	;	1.83001	;	Crystal structure of a HLA-B*35:01-NP7 epitope from 2002 H2N1 influenza strain
8EMI	;	1.57302	;	Crystal structure of a HLA-B*35:01-NP8 epitope from 2005 H1N1 influenza strain
4PRB	;	1.75	;	Crystal structure of a HLA-B*35:08-HPVG-A4
4PRD	;	1.75	;	Crystal structure of a HLA-B*35:08-HPVG-D5
4PRE	;	1.65	;	Crystal structure of a HLA-B*35:08-HPVG-Q5
4EUW	;	2.77	;	Crystal structure of a HMG domain of transcription factor SOX-9 bound to DNA (SOX-9/DNA) from Homo sapiens at 2.77 A resolution
2WP0	;	2.67	;	Crystal structure of a HobA-DnaA (domain I-II) complex from Helicobacter pylori.
8HCI	;	3.399	;	Crystal structure of a holoenzyme Fe-free TglHI for Pseudomonas syringae Peptidyl (S) 2-mercaptoglycine biosynthesis
5TYQ	;	2.163	;	Crystal structure of a holoenzyme methyltransferase involved in the biosynthesis of gentamicin
8HI8	;	3.49	;	Crystal structure of a holoenzyme TglHI with three Fe ions for Pseudomonas syringae Peptidyl (S) 2-mercaptoglycine biosynthesis
8HI7	;	3.25	;	Crystal structure of a holoenzyme TglHI with two Fe irons for Pseudomonas syringae Peptidyl (S) 2-mercaptoglycine biosynthesis
5GKK	;	2.001	;	Crystal structure of a homing endonuclease, I-TnaI
8DW1	;	1.849	;	Crystal structure of a host-guest complex with 5'-CTTAGTTATAACTAAG-3'
4MF4	;	2.0	;	Crystal structure of a HpcH/Hpal aldolase/citrate lyase family protein from Burkholderia cenocepacia J2315
5KV8	;	1.949	;	Crystal structure of a hPIV haemagglutinin-neuraminidase-inhibitor complex
5KV9	;	2.0	;	Crystal structure of a hPIV haemagglutinin-neuraminidase-inhibitor complex
3AIK	;	1.95	;	Crystal structure of a HSL-like carboxylesterase from Sulfolobus tokodaii
3AIL	;	1.91	;	Crystal structure of a HSL-like carboxylesterase from Sulfolobus tokodaii complexed with paraoxon
4AU2	;	2.3	;	Crystal Structure of a Hsp47-collagen complex
4AU3	;	2.78	;	Crystal Structure of a Hsp47-collagen complex
7BDU	;	2.49	;	Crystal structure of a Hsp47-collagen peptide complex
7BEE	;	1.939	;	Crystal structure of a Hsp47-collagen peptide complex
2PPX	;	2.0	;	Crystal structure of a HTH XRE-family like protein from Agrobacterium tumefaciens
6VSZ	;	2.6	;	Crystal structure of a human afucosylated IgG1 Fc expressed in tobacco plants (Nicotiana benthamiana)
1N3L	;	1.18	;	Crystal structure of a human aminoacyl-tRNA synthetase cytokine
4CAY	;	1.48	;	Crystal structure of a human Anp32e-H2A.Z-H2B complex
6NIP	;	4.16	;	Crystal structure of a human anti-ZIKV-DENV neutralizing antibody MZ1 in complex with ZIKV E glycoprotein
6MTX	;	2.051	;	Crystal structure of a human anti-ZIKV-DENV neutralizing antibody MZ1 isolated following ZPIV vaccination
6NIS	;	2.113	;	Crystal structure of a human anti-ZIKV-DENV neutralizing antibody MZ24 isolated following ZPIV vaccination
6NIU	;	4.303	;	Crystal structure of a human anti-ZIKV-DENV neutralizing antibody MZ4 in complex with ZIKV E glycoprotein
6MTY	;	2.951	;	Crystal structure of a human anti-ZIKV-DENV neutralizing antibody MZ4 isolated following ZPIV vaccination
3O6F	;	2.8	;	Crystal structure of a human autoimmune TCR MS2-3C8 bound to MHC class II self-ligand MBP/HLA-DR4
7U0T	;	2.45	;	Crystal Structure of a human Calcineurin A - Calcineurin B fusion bound to FKBP12 and FK-520
4ORA	;	2.747	;	Crystal structure of a human calcineurin mutant
6NH9	;	1.85	;	Crystal structure of a human calcium/calmodulin dependent serine protein kinase (CASK) PDZ domain
6NID	;	1.86	;	Crystal structure of a human calcium/calmodulin dependent serine protein kinase (CASK) PDZ domain in complex with Neurexin-1 peptide
6OWV	;	1.88	;	Crystal structure of a Human Cardiac Calsequestrin Filament
6OWW	;	3.84	;	Crystal structure of a Human Cardiac Calsequestrin Filament Complexed with Ytterbium
6NYO	;	1.502	;	Crystal structure of a human Cdc34-ubiquitin thioester mimetic
7VMZ	;	2.85	;	Crystal structure of a human Coronavirus 229E antibody C04 Fab
1XO2	;	2.9	;	Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin
4RRT	;	2.2	;	Crystal structure of a human cytochrome P450 2B6 (Y226H/K262R) in complex with (+)-3-carene
4RQL	;	2.105	;	Crystal structure of a human cytochrome P450 2B6 (Y226H/K262R) in complex with a monoterpene - sabinene
3QU8	;	2.8	;	Crystal structure of a human cytochrome P450 2B6 (Y226H/K262R) in complex with the inhibitor 4-(4-Nitrobenzyl)pyridine.
3QOA	;	2.1	;	Crystal structure of a human cytochrome P450 2B6 (Y226H/K262R) in complex with the inhibitor 4-Benzylpyridine.
4PHC	;	2.844	;	Crystal Structure of a human cytosolic histidyl-tRNA synthetase, histidine-bound
6JLD	;	2.0	;	Crystal structure of a human ependymin related protein
2CJI	;	2.1	;	Crystal structure of a Human Factor Xa inhibitor complex
2J2U	;	1.9	;	CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2J34	;	2.01	;	CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2J38	;	2.1	;	CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2J4I	;	1.8	;	CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2J94	;	2.1	;	CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2J95	;	2.01	;	CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
5L19	;	2.0	;	Crystal Structure of a human FasL mutant
5L36	;	3.1	;	Crystal Structure of a human FasL mutant in complex with human DcR3
3FJT	;	2.5	;	Crystal structure of a human Fc fragment engineered for extended serum half-life
3QS7	;	4.3	;	Crystal structure of a human Flt3 ligand-receptor ternary complex
3QS9	;	7.8	;	Crystal structure of a human Flt3 ligand-receptor ternary complex
6VSL	;	2.1	;	Crystal structure of a human fucosylated IgG1 Fc expressed in tobacco plants (Nicotiana benthamiana)
6OCP	;	2.35	;	Crystal structure of a human GABAB receptor peptide bound to KCTD16 T1
4COF	;	2.97	;	Crystal structure of a human gamma-aminobutyric acid receptor, the GABA(A)R-beta3 homopentamer
1SWX	;	1.65	;	Crystal structure of a human glycolipid transfer protein in apo-form
6HSK	;	2.096	;	Crystal structure of a human HDAC8 L6 loop mutant complexed with Quisinostat
3AGV	;	2.15	;	Crystal structure of a human IgG-aptamer complex
1H3Y	;	4.1	;	Crystal structure of a human IgG1 Fc-fragment,high salt condition
1ADQ	;	3.15	;	CRYSTAL STRUCTURE OF A HUMAN IGM RHEUMATOID FACTOR FAB IN COMPLEX WITH ITS AUTOANTIGEN IGG FC
1JK8	;	2.4	;	Crystal structure of a human insulin peptide-HLA-DQ8 complex
4BPM	;	2.08	;	Crystal structure of a human integral membrane enzyme
5BO1	;	2.56	;	Crystal structure of a human Jag1 fragment in complex with an anti-Jag1 Fab
4KGQ	;	2.27	;	Crystal structure of a human light loop mutant in complex with dcr3
5PNT	;	2.2	;	CRYSTAL STRUCTURE OF A HUMAN LOW MOLECULAR WEIGHT PHOSPHOTYROSYL PHOSPHATASE. IMPLICATIONS FOR SUBSTRATE SPECIFICITY
6V7N	;	2.62	;	Crystal Structure of a human Lysosome Resident Glycoprotein, Lysosomal Acid Lipase, and its Implications in Cholesteryl Ester Storage Disease (CESD)
4LCC	;	3.263	;	Crystal structure of a human MAIT TCR in complex with a bacterial antigen bound to humanized bovine MR1
4IIQ	;	2.86	;	Crystal structure of a human MAIT TCR in complex with bovine MR1
3AM8	;	2.8	;	Crystal Structure of a Human Major Histocompatibilty complex
2AW5	;	2.5	;	Crystal structure of a human malic enzyme
6W16	;	3.1	;	Crystal structure of a human metapneumovirus monomeric fusion protein complexed with 458 Fab
7M0I	;	2.81	;	Crystal structure of a human metapneumovirus subtype B2 trimeric fusion protein
1R03	;	1.7	;	crystal structure of a human mitochondrial ferritin
4NRI	;	2.3	;	Crystal Structure of a human Mms2/Ubc13 A122G mutant
4NRG	;	1.95	;	Crystal Structure of a human Mms2/Ubc13 D118G mutant
4NR3	;	1.802	;	Crystal Structure of a human Mms2/Ubc13 L121G mutant
1PI1	;	2.0	;	Crystal structure of a human Mob1 protein; toward understanding Mob-regulated cell cycle pathways.
4MZI	;	1.25	;	Crystal structure of a human mutant p53
5YAX	;	2.5	;	Crystal structure of a human neutralizing antibody bound to a HBV preS1 peptide
2HE0	;	1.9	;	Crystal structure of a human Notch1 ankyrin domain mutant
1ONI	;	1.9	;	Crystal structure of a human p14.5, a translational inhibitor reveals different mode of ligand binding near the invariant residues of the Yjgf/UK114 protein family
1EW2	;	1.82	;	CRYSTAL STRUCTURE OF A HUMAN PHOSPHATASE
3MZG	;	2.1	;	Crystal structure of a human prolactin receptor antagonist in complex with the extracellular domain of the human prolactin receptor
2AJP	;	2.5	;	Crystal structure of a human pyridoxal kinase
5NWL	;	3.93	;	Crystal structure of a human RAD51-ATP filament.
1K5M	;	2.7	;	Crystal Structure of a Human Rhinovirus Type 14:Human Immunodeficiency Virus Type 1 V3 Loop Chimeric Virus MN-III-2
4BLB	;	2.8	;	Crystal structure of a human Suppressor of fused (SUFU)-GLI1p complex
4BLD	;	2.802	;	Crystal structure of a human Suppressor of fused (SUFU)-GLI3p complex
1C9B	;	2.65	;	CRYSTAL STRUCTURE OF A HUMAN TBP CORE DOMAIN-HUMAN TFIIB CORE DOMAIN COMPLEX BOUND TO AN EXTENDED, MODIFIED ADENOVIRAL MAJOR LATE PROMOTER (ADMLP)
1JPW	;	2.5	;	Crystal Structure of a Human Tcf-4 / beta-Catenin Complex
2VUQ	;	1.18	;	Crystal structure of a human tRNAGly acceptor stem microhelix (derived from the gene sequence DG9990) at 1.18 Angstroem resolution
2V7R	;	1.2	;	Crystal structure of a human tRNAGly microhelix at 1.2 Angstrom resolution
1T89	;	3.5	;	CRYSTAL STRUCTURE OF A HUMAN TYPE III FC GAMMA RECEPTOR IN COMPLEX WITH AN FC FRAGMENT OF IGG1 (HEXAGONAL)
1T83	;	3.0	;	CRYSTAL STRUCTURE OF A HUMAN TYPE III FC GAMMA RECEPTOR IN COMPLEX WITH AN FC FRAGMENT OF IGG1 (ORTHORHOMBIC)
1MU7	;	2.0	;	Crystal Structure of a Human Tyrosyl-DNA Phosphodiesterase (Tdp1)-Tungstate Complex
1MU9	;	2.05	;	Crystal Structure of a Human Tyrosyl-DNA Phosphodiesterase (Tdp1)-Vanadate Complex
5THH	;	1.959	;	Crystal structure of a human tyrosyl-tRNA synthetase mutant
4EN3	;	2.568	;	Crystal structure of a human Valpha24(-) NKT TCR in complex with CD1d/alpha-galactosylceramide
4L9L	;	3.4	;	Crystal structure of a human Valpha7.2/Vbeta13.2 MAIT TCR in complex with bovine MR1
4L8S	;	2.9	;	Crystal structure of a human Valpha7.2/Vbeta13.3 MAIT TCR in complex with bovine MR1
1HXM	;	3.12	;	Crystal Structure of a Human Vgamma9/Vdelta2 T Cell Receptor
1T2J	;	1.5	;	Crystal structure of a Human VH domain
5FUG	;	2.7	;	Crystal structure of a human YL1-H2A.Z-H2B complex
4JE6	;	2.0	;	Crystal structure of a human-like mitochondrial peptide deformylase
4JE7	;	2.1	;	Crystal structure of a human-like mitochondrial peptide deformylase in complex with actinonin
4JE8	;	2.4	;	Crystal structure of a human-like mitochondrial peptide deformylase in complex with Met-Ala-Ser
4HIX	;	2.204	;	Crystal structure of a humanised 3D6 Fab bound to amyloid beta peptide
6Z10	;	2.269	;	Crystal structure of a humanized (K18E, K269N) rat succinate receptor SUCNR1 (GPR91) in complex with a nanobody and antagonist
6RNK	;	1.94	;	Crystal structure of a humanized (K18E, K269N) rat succinate receptor SUCNR1 (GPR91) in complex with a nanobody and antagonist NF-56-EJ40.
1S3K	;	1.9	;	Crystal Structure of a Humanized Fab (hu3S193) in Complex with the Lewis Y Tetrasaccharide
1UJ3	;	2.1	;	Crystal structure of a humanized Fab fragment of anti-tissue-factor antibody in complex with tissue factor
1B6V	;	2.0	;	CRYSTAL STRUCTURE OF A HYBRID BETWEEN RIBONUCLEASE A AND BOVINE SEMINAL RIBONUCLEASE
2BO1	;	1.7	;	Crystal structure of a hybrid ribosomal protein L30e with surface residues from T. celer, and core residues from yeast
5TP4	;	1.7	;	Crystal structure of a hydantoinase/carbamoylase family amidase from Burkholderia ambifaria
5XEO	;	2.03	;	Crystal structure of a hydrogen sulfide-producing enzyme (Fn1220) from Fusobacterium nucleatum
5XEM	;	1.84	;	Crystal structure of a hydrogen sulfide-producing enzyme (Fn1220) from Fusobacterium nucleatum in complex with L-lanthionine-PLP Schiff base
5XEN	;	1.94	;	Crystal structure of a hydrogen sulfide-producing enzyme (Fn1220) from Fusobacterium nucleatum in complex with L-serine-PLP Schiff base
6JQW	;	1.437	;	Crystal structure of a hydrogenase from Trichosporon moniliiforme
6JQX	;	1.672	;	Crystal structure of a hydrogenase from Trichosporon moniliiforme
1V8B	;	2.4	;	Crystal structure of a hydrolase
5X5M	;	1.211	;	Crystal structure of a hydrolase encoded by lin2189 from Listeria innocua
2GO7	;	2.1	;	CRYSTAL STRUCTURE OF A HYDROLASE FROM HALOACID DEHALOGENASE-LIKE FAMILY (SP_2064) FROM STREPTOCOCCUS PNEUMONIAE TIGR4 AT 2.10 A RESOLUTION
5X5R	;	1.644	;	Crystal structure of a hydrolase from Listeria innocua
7VME	;	1.78	;	Crystal structure of a hydrolase in apo form 2
6KY5	;	1.631	;	Crystal structure of a hydrolase mutant
6IUX	;	1.195	;	Crystal structure of a hydrolase protein
6NQ4	;	1.45	;	Crystal structure of a Hydrolase, haloacid dehalogenase-like family from Brucella suis 1330
3F6A	;	2.02	;	Crystal structure of a hydrolase, NUDIX family from Clostridium perfringens
7VMD	;	1.69	;	Crystal structure of a hydrolases Ple628 from marine microbial consortium
8B4M	;	3.04	;	Crystal structure of a hydropyrene synthase (M75L variant) in its closed conformation
4XCT	;	1.3	;	Crystal structure of a hydroxamate based inhibitor ARP101 (EN73) in complex with the MMP-9 catalytic domain.
4WZV	;	1.65	;	Crystal structure of a hydroxamate based inhibitor EN140 in complex with the MMP-9 catalytic domain
1LQB	;	2.0	;	Crystal structure of a hydroxylated HIF-1 alpha peptide bound to the pVHL/elongin-C/elongin-B complex
4LB0	;	1.7	;	Crystal structure of a hydroxyproline epimerase from agrobacterium vitis, target efi-506420, with bound trans-4-oh-l-proline
5J1E	;	2.9	;	Crystal Structure of a Hydroxypyridone Carboxylic Acid Active-Site RNase H Inhibitor in Complex with HIV Reverse Transcriptase
3EZW	;	2.0	;	Crystal Structure of a Hyperactive Escherichia coli Glycerol Kinase Mutant Gly230 --> Asp Obtained Using Microfluidic Crystallization Devices
4KFC	;	2.53	;	Crystal structure of a hyperactive mutant of response regulator KdpE complexed to its promoter DNA
2YJ7	;	1.65	;	Crystal structure of a hyperstable protein from the Precambrian period
1U2X	;	2.0	;	Crystal Structure of a Hypothetical ADP-dependent Phosphofructokinase from Pyrococcus horikoshii OT3
5G3Q	;	1.613	;	Crystal structure of a hypothetical domain in WNK1
6JOV	;	1.941	;	Crystal structure of a hypothetical Fe Superoxide dismutase
4EFZ	;	1.6	;	Crystal Structure of a hypothetical metallo-beta-lactamase from Burkholderia pseudomallei
3UMA	;	2.2	;	Crystal structure of a hypothetical peroxiredoxin protein frm Sinorhizobium meliloti
1O6D	;	1.66	;	Crystal structure of a hypothetical protein
1VH0	;	2.31	;	Crystal structure of a hypothetical protein
1VIV	;	2.6	;	Crystal structure of a hypothetical protein
1X94	;	2.5	;	Crystal Structure of a Hypothetical protein
2E8C	;	2.1	;	Crystal structure of a hypothetical protein (Aq_1549) from Aquifex aeolicus VF5
2E8F	;	1.8	;	Crystal Structure of a hypothetical protein (Aq_1549) from Aquifex aeolicus VF5 (Oxidised form)
2E8E	;	1.7	;	Crystal Structure of a hypothetical protein (Aq_1549) from Aquifex aeolicus VF5 (Reduced form)
4RHO	;	2.25	;	Crystal structure of a hypothetical protein (BPSL2088) from Burkholderia pseudomallei K96243 at 2.25 A resolution
4R7F	;	2.3	;	Crystal structure of a hypothetical protein (PARMER_01801) from Parabacteroides merdae ATCC 43184 at 2.30 A resolution
1SUM	;	2.0	;	Crystal structure of a hypothetical protein at 2.0 A resolution
1STZ	;	2.2	;	Crystal structure of a hypothetical protein at 2.2 A resolution
1SU0	;	2.3	;	Crystal structure of a hypothetical protein at 2.3 A resolution
4S1A	;	1.75	;	Crystal structure of a hypothetical protein Cthe_0052 from Ruminiclostridium thermocellum ATCC 27405
2IML	;	1.65	;	Crystal structure of a hypothetical protein from Archaeoglobus fulgidus binding riboflavin 5'-phosphate
2EBY	;	2.25	;	Crystal structure of a hypothetical protein from E. Coli
3KWL	;	1.94	;	Crystal structure of a hypothetical protein from Helicobacter pylori
6ANZ	;	1.6	;	Crystal structure of a hypothetical protein from Neisseria gonorrhoeae
5VOG	;	1.5	;	Crystal Structure of a Hypothetical Protein from Neisseria gonorrhoeae with bound ppGpp
2O4D	;	1.85	;	Crystal Structure of a hypothetical protein from Pseudomonas aeruginosa
3L20	;	2.451	;	Crystal structure of a hypothetical protein from Staphylococcus aureus
3P8A	;	1.95	;	Crystal Structure of a hypothetical protein from Staphylococcus aureus
4QXZ	;	2.49	;	Crystal structure of a hypothetical protein from Staphylococcus aureus
4PEO	;	1.73	;	Crystal structure of a hypothetical protein from Staphylococcus aureus.
5H3K	;	1.702	;	Crystal structure of a hypothetical protein from Synechocystis
2EBG	;	1.8	;	Crystal structure of a hypothetical protein from thermus thermophilus
1WHZ	;	1.52	;	Crystal structure of a hypothetical protein from thermus thermophilus HB8
1WK2	;	2.5	;	Crystal structure of a hypothetical protein from thermus thermophilus HB8
2CV9	;	2.5	;	Crystal structure of a hypothetical protein from Thermus thermophilus HB8
2DBN	;	1.7	;	Crystal Structure of a Hypothetical Protein JW0805 at High pH from Escherichia coli
2DBI	;	2.05	;	Crystal Structure of a Hypothetical Protein JW0805 from Escherichia coli
2EA9	;	2.1	;	Crystal structure of a hypothetical protein JW2626 from E.coli
6L7Q	;	1.16	;	Crystal structure of a hypothetical protein PYCH_01220 derived from Pyrococcus yayanosii
5YRX	;	1.9	;	Crystal structure of a hypothetical protein Rv3716c from Mycobacterium tuberculosis
4HUJ	;	1.77	;	Crystal structure of a hypothetical protein SMa0349 from Sinorhizobium meliloti
3U5R	;	2.05	;	Crystal structure of a hypothetical protein SMc02350 from Sinorhizobium meliloti 1021
3L7V	;	2.256	;	Crystal structure of a hypothetical protein smu.1377c from Streptococcus mutans UA159
1Z54	;	2.1	;	Crystal structure of a hypothetical protein TT1821 from Thermus thermophilus
1ZPW	;	1.64	;	Crystal structure of a hypothetical protein TT1823 from Thermus thermophilus
2YSK	;	1.9	;	Crystal structure of a hypothetical protein TTHA1432 from Thermus thermophilus
2DBS	;	2.1	;	Crystal structure of a hypothetical protein TTHC002 from Thermus thermophilus HB8
1T35	;	2.72	;	CRYSTAL STRUCTURE OF A HYPOTHETICAL PROTEIN YVDD- A PUTATIVE LYSINE DECARBOXYLASE
2EGI	;	2.3	;	Crystal Structure of a Hypothetical Protein(AQ1494) from Aquifex aeolicus
2EFV	;	1.9	;	Crystal Structure of a Hypothetical Protein(MJ0366) from Methanocaldococcus jannaschii
1J27	;	1.7	;	Crystal structure of a hypothetical protein, TT1725, from Thermus thermophilus HB8 at 1.7A resolution
5AWE	;	2.45	;	Crystal structure of a hypothetical protein, TTHA0829 from Thermus thermophilus HB8, composed of cystathionine-beta-synthase (CBS) and aspartate-kinase chorismate-mutase tyrA (ACT) domains
3TPC	;	2.34	;	Crystal structure of a hypothtical protein SMa1452 from Sinorhizobium meliloti 1021
4RQA	;	1.48	;	Crystal Structure of a Hypoxanthine Phosphoribosyltransferase (target ID NYSGRC-029686) from Staphylococcus aureus (orthorhombic space group)
4RQB	;	2.45	;	Crystal Structure of a Hypoxanthine Phosphoribosyltransferase (target ID NYSGRC-029686) from Staphylococcus aureus (tetragonal space group)
3VUN	;	3.0	;	Crystal structure of a influenza A virus (A/Aichi/2/1968 H3N2) hemagglutinin in C2 space group.
5WUP	;	2.3	;	Crystal structure of a insect group III chitinase (CAD1) from Ostrinia furnacalis
5WUS	;	2.201	;	Crystal structure of a insect group III chitinase (CAD2) from Ostrinia furnacalis
5WV9	;	2.105	;	Crystal structure of a insect group III chitinase complex with (GlcNAc)6 (CAD1-(GlcNAc)6 ) from Ostrinia furnacalis
5M5E	;	2.3	;	Crystal structure of a interleukin-2 variant in complex with interleukin-2 receptor
4WK5	;	1.7	;	Crystal structure of a Isoprenoid Synthase family member from Thermotoga neapolitana DSM 4359, target EFI-509458
3O65	;	2.7	;	Crystal structure of a Josephin-ubiquitin complex: Evolutionary restraints on ataxin-3 deubiquitinating activity
4GAZ	;	2.81	;	Crystal Structure of a Jumonji Domain-containing Protein JMJD5
2NPY	;	2.65	;	Crystal Structure of a junctioned hairpin ribozyme incorporating 9atom linker and 2'-deoxy 2'-amino U at A-1
2OUE	;	2.05	;	Crystal structure of a junctionless all-RNA hairpin ribozyme at 2.05 angstroms resolution
8CTX	;	1.99	;	Crystal structure of a K+ selective NaK mutant (NaK2K) -K+,Tl+ complex
8CTW	;	2.0	;	Crystal structure of a K+ selective NaK mutant (NaK2K) -Na+,Tl+ complex
8CTV	;	2.1	;	Crystal structure of a K+ selective NaK mutant (NaK2K) -Tl+ complex
8CTT	;	2.05	;	Crystal structure of a K+ selective NaK mutant (NaK2K) at 100K
8CTU	;	1.65	;	Crystal structure of a K+ selective NaK mutant (NaK2K) at Room temperature
4PDR	;	1.85	;	Crystal Structure of a K+ selective NaK mutant in Barium and Sodium
3ZGD	;	1.98	;	crystal structure of a KEAP1 mutant
3LHX	;	1.87	;	Crystal structure of a Ketodeoxygluconokinase (kdgk) from Shigella flexneri
4J1Q	;	2.35	;	Crystal structure of a ketoreductase domain from the bacillaene assembly line
4J1S	;	3.01	;	Crystal structure of a ketoreductase domain from the bacillaene assembly line
3R1F	;	2.5	;	Crystal structure of a key regulator of virulence in Mycobacterium tuberculosis
3U29	;	2.0	;	Crystal Structure of a KGD Collagen Mimetic Peptide at 2.0 A
3T4F	;	1.68	;	Crystal Structure of a KGE Collagen Mimetic Peptide at 1.68 A
2R0I	;	2.202	;	Crystal structure of a kinase MARK2/Par-1 mutant
7D8V	;	2.3	;	Crystal Structure of A Kinesin-3 KIF13B mutant-T192Y
2QKS	;	2.2	;	Crystal structure of a Kir3.1-prokaryotic Kir channel chimera
7X8C	;	2.73	;	Crystal structure of a KTSC family protein from Euryarchaeon Methanolobus vulcani
5XOZ	;	2.8	;	Crystal structure of a Kunitz type trypsin inhibitor from Cicer arietinumL
1TIE	;	2.5	;	CRYSTAL STRUCTURE OF A KUNITZ-TYPE TRYPSIN INHIBITOR FROM ERYTHRINA CAFFRA SEEDS
2ZO7	;	1.58	;	Crystal Structure of a Kusabira-Cyan Mutant (KCY-R1), a Cyan/Green-Emitting GFP-Like Protein
5WIE	;	3.3	;	Crystal structure of a Kv1.2-2.1 chimera K+ channel V406W mutant in an inactivated state
7ESN	;	2.42	;	Crystal structure of a L-rhamnose-alpha-1,4-D-glucuronate lyase from Fusarium oxysporum 12S, H105F Rha-GlcA complex
7ESM	;	1.4	;	Crystal structure of a L-rhamnose-alpha-1,4-D-glucuronate lyase from Fusarium oxysporum 12S, L-Rha complex
7ESK	;	1.05	;	Crystal structure of a L-rhamnose-alpha-1,4-D-glucuronate lyase from Fusarium oxysporum 12S, Ligand free form
7ESL	;	1.4	;	Crystal structure of a L-rhamnose-alpha-1,4-D-glucuronate lyase from Fusarium oxysporum 12S, N247A N-glycan free form
4EGF	;	2.3	;	Crystal structure of a L-xylulose reductase from Mycobacterium smegmatis
4WB6	;	2.1	;	Crystal structure of a L205R mutant of human cAMP-dependent protein kinase A (catalytic alpha subunit)
5LWW	;	2.65	;	Crystal structure of a laccase-like multicopper oxidase McoG from Aspergillus niger bound to zinc
5LM8	;	1.7	;	Crystal structure of a laccase-like multicopper oxidase McoG from from Aspergillus niger
3KKE	;	2.2	;	Crystal structure of a LacI family transcriptional regulator from Mycobacterium smegmatis
3E3M	;	1.6	;	Crystal structure of a LacI family transcriptional regulator from Silicibacter pomeroyi
4WXE	;	1.5	;	CRYSTAL STRUCTURE OF A LACI REGULATOR FROM LACTOBACILLUS CASEI (LSEI_2103, TARGET EFI-512911) WITH BOUND TRIS
3GYB	;	1.6	;	Crystal structure of a LacI-family transcriptional regulatory protein from Corynebacterium glutamicum
5Z5J	;	2.15	;	Crystal structure of a lactonase double mutant
5Z7J	;	1.98	;	Crystal structure of a lactonase double mutant in complex with ligand l
5Z97	;	2.32	;	Crystal structure of a lactonase double mutant in complex with ligand N
5IE5	;	2.39	;	Crystal structure of a lactonase double mutant in complex with substrate a
5IE7	;	2.5	;	Crystal structure of a lactonase double mutant in complex with substrate b
5XWZ	;	1.75	;	Crystal structure of a lactonase from Cladophialophora bantiana
5IE4	;	2.8	;	Crystal structure of a lactonase mutant in complex with substrate a
5IE6	;	2.67	;	Crystal structure of a lactonase mutant in complex with substrate b
5GXB	;	3.3	;	crystal structure of a LacY/Nanobody complex
1Z1B	;	3.8	;	Crystal structure of a lambda integrase dimer bound to a COC' core site
1Z1G	;	4.4	;	Crystal structure of a lambda integrase tetramer bound to a Holliday junction
1Z19	;	2.8	;	Crystal structure of a lambda integrase(75-356) dimer bound to a COC' core site
7JVT	;	3.16	;	Crystal structure of a lambda-186 hybrid repressor
4ZOQ	;	2.35	;	Crystal Structure of a Lanthipeptide Protease
2X7R	;	2.0	;	Crystal structure of a late fusion intermediate of HIV-1 gp41
3G23	;	1.89	;	Crystal structure of a ld-carboxypeptidase a (saro_1426) from novosphingobium aromaticivorans dsm at 1.89 A resolution
429D	;	2.7	;	CRYSTAL STRUCTURE OF A LEADZYME; METAL BINDING AND IMPLICATIONS FOR CATALYSIS
3U4X	;	2.16	;	Crystal structure of a lectin from Camptosema pedicellatum seeds in complex with 5-bromo-4-chloro-3-indolyl-alpha-D-mannose
3JU9	;	2.1	;	Crystal structure of a lectin from Canavalia brasiliensis seed (ConBr) complexed with alpha-aminobutyric acid
6VB8	;	2.2	;	Crystal structure of a lectin from Canavalia brasiliensis seed (ConBr) complexed with indole-3-acetic acid
2OVU	;	1.5	;	Crystal structure of a lectin from Canavalia gladiata (CGL) in complex with man1-2man-OMe
2P2K	;	1.98	;	Crystal structure of a lectin from Canavalia gladiata seeds (CGL) in complex with man1-4man-OMe
2D7F	;	2.31	;	Crystal structure of A lectin from canavalia gladiata seeds complexed with alpha-methyl-mannoside and alpha-aminobutyric acid
7UOD	;	1.6	;	Crystal structure of a lectin from Canavalia maritima seed (ConM) complexed with 2,4-dichloro-phenoxyacetic acid
7UN2	;	1.8	;	Crystal structure of a lectin from Canavalia maritima seed (ConM) complexed with Indole-3-butyric acid
2P37	;	2.1	;	Crystal structure of a lectin from Canavalia maritima seeds (CML) in complex with man1-3man-OMe
2P34	;	2.1	;	Crystal structure of a lectin from Canavalia maritima seeds (CML) in complex with man1-4man-OMe
2OW4	;	1.6	;	Crystal structure of a lectin from Canavalia maritima seeds (ConM) in complex with man1-2man-OMe
3SNM	;	2.15	;	Crystal structure of a lectin from Canavalia maritima seeds complexed with Indole-3-Acetic Acid
4FYE	;	2.413	;	Crystal structure of a Legionella phosphoinositide phosphatase, SidF
4JZA	;	2.584	;	Crystal structure of a Legionella phosphoinositide phosphatase: insights into lipid metabolism in pathogen host interaction
2ETD	;	2.28	;	Crystal structure of a lema protein (tm0961) from thermotoga maritima msb8 at 2.28 A resolution
2ERE	;	3.0	;	Crystal Structure of a Leu3 DNA-binding domain complexed with a 15mer DNA duplex
4FUU	;	1.3	;	Crystal structure of a leucine aminopeptidase precursor (BT_2548) from Bacteroides thetaiotaomicron VPI-5482 at 1.30 A resolution
3TD9	;	1.9	;	Crystal structure of a Leucine binding protein LivK (TM1135) from Thermotoga maritima MSB8 at 1.90 A resolution
4GT6	;	1.8	;	Crystal structure of a leucine rich cell surface protein (FAEPRAA2165_01021) from Faecalibacterium prausnitzii A2-165 at 1.80 A resolution
3EMU	;	2.3	;	Crystal structure of a leucine rich repeat and phosphatase domain containing protein from Entamoeba histolytica
4OJU	;	2.0	;	Crystal structure of a leucine-rich repeat protein (BACCAP_00569) from Bacteroides capillosus ATCC 29799 at 2.00 A resolution
4ECO	;	2.7	;	Crystal structure of a leucine-rich repeat protein (BACEGG_03329) from Bacteroides eggerthii DSM 20697 at 2.70 A resolution
4FS7	;	1.19	;	Crystal structure of a leucine-rich repeat protein (BACOVA_04585) from Bacteroides ovatus ATCC 8483 at 1.19 A resolution
4ECN	;	2.8	;	Crystal structure of a leucine-rich repeat protein (BT_0210) from Bacteroides thetaiotaomicron VPI-5482 at 2.80 A resolution
3SB4	;	1.99	;	Crystal structure of a leucine-rich repeat protein (BT_1240) from Bacteroides thetaiotaomicron VPI-5482 at 1.99 A resolution
4H09	;	2.5	;	Crystal structure of a leucine-rich repeat protein (EUBVEN_01088) from Eubacterium ventriosum ATCC 27560 at 2.50 A resolution
6X5E	;	2.29	;	Crystal structure of a Lewis-binding Fab (ch88.2)
3K2Z	;	1.37	;	Crystal structure of a LexA protein from Thermotoga maritima
4LH6	;	1.65	;	Crystal structure of a LigA inhibitor
4LH7	;	1.9	;	Crystal structure of a LigA inhibitor
6C9W	;	3.0	;	Crystal Structure of a ligand bound LacY/Nanobody Complex
1XED	;	1.9	;	Crystal Structure of a Ligand-Binding Domain of the Human Polymeric Ig Receptor, pIgR
3H2K	;	2.1	;	Crystal structure of a ligand-bound form of the rice cell wall degrading esterase LipA from Xanthomonas oryzae
3TS5	;	2.393	;	Crystal Structure of a Light Chain Domain of Scallop Smooth Muscle Myosin
7BMH	;	2.2	;	Crystal structure of a light-driven proton pump LR (Mac) from Leptosphaeria maculans
6A6Q	;	1.67	;	Crystal structure of a lignin peroxidase isozyme H8 variant that is stable at very acidic pH
3K17	;	2.1	;	Crystal structure of a Lin0012 protein from Listeria innocua
3SOO	;	2.73	;	Crystal structure of a LINE-1 type transposase domain-containing protein 1 (L1TD1) from HOMO SAPIENS at 2.73 A resolution
3U30	;	2.428	;	Crystal structure of a linear-specific Ubiquitin fab bound to linear ubiquitin
5LK6	;	2.6	;	Crystal structure of a lipase carboxylesterase from Sulfolobus islandicus
3AUK	;	1.66	;	Crystal structure of a lipase from Geobacillus sp. SBS-4S
3V2Y	;	2.8	;	Crystal Structure of a Lipid G protein-Coupled Receptor at 2.80A
3V2W	;	3.35	;	Crystal Structure of a Lipid G protein-Coupled Receptor at 3.35A
6TZY	;	3.0	;	Crystal Structure of a lipin/Pah Phosphatidic Acid Phosphatase
2P0L	;	2.04	;	Crystal structure of a Lipoate-protein ligase A
4GZV	;	1.95	;	Crystal structure of a lipocalin family protein (BACOVA_00364) from Bacteroides ovatus ATCC 8483 at 1.95 A resolution
4I95	;	1.81	;	Crystal structure of a Lipocalin-like protein (BACEGG_00036) from Bacteroides eggerthii DSM 20697 at 1.81 A resolution
4QRL	;	1.79	;	Crystal structure of a lipocalin-like protein (BACUNI_01346) from Bacteroides uniformis ATCC 8492 at 1.79 A resolution
3HTY	;	1.95	;	Crystal structure of a lipocalin-like protein (BT_0869) from Bacteroides thetaiotaomicron VPI-5482 at 1.95 A resolution
4KH8	;	1.6	;	Crystal structure of a Lipocalin-like protein (EF0376) from Enterococcus faecalis V583 at 1.60 A resolution
5TKR	;	1.8	;	Crystal structure of a Lipomyces starkeyi levoglucosan kinase G359R mutant
4HWM	;	1.38	;	Crystal structure of a lipoprotein YedD (KPN_02420) from Klebsiella pneumoniae subsp. pneumoniae MGH 78578 at 1.38 A resolution
4NTL	;	1.799	;	Crystal structure of a lipoprotein, YaeC family (EF3198) from Enterococcus faecalis V583 at 1.80 A resolution
3K3Q	;	2.6	;	Crystal Structure of a Llama Antibody complexed with the C. Botulinum Neurotoxin Serotype A Catalytic Domain
6EZW	;	1.59843	;	Crystal structure of a llama VHH antibody BCD090-M2 against human ErbB3 in space group C2
6F0D	;	1.90001	;	Crystal structure of a llama VHH antibody BCD090-M2 against human ErbB3 in space group P1 with cadmium ions
4YPN	;	2.07	;	Crystal structure of a LonA fragment containing the 3-helix bundle and the AAA-alpha/beta domain
4YPM	;	1.85	;	Crystal structure of a LonA protease domain in complex with bortezomib
5MTZ	;	2.99	;	Crystal structure of a long form RNase Z from yeast
3G7S	;	2.15	;	Crystal structure of a long-chain-fatty-acid-CoA ligase (FadD1) from Archaeoglobus fulgidus
4HBQ	;	1.4	;	Crystal structure of a loop deleted mutant of Human MAdCAM-1 D1D2
4HC1	;	2.871	;	Crystal structure of a loop deleted mutant of human MAdCAM-1 D1D2 complexed with Fab 10G3
5HFN	;	2.75	;	Crystal structure of a loop truncation variant of Thermotoga maritima Acetyl Esterase TM0077 (apo structure) at 2.75 Angstrom resolution
1PV8	;	2.2	;	Crystal structure of a low activity F12L mutant of human porphobilinogen synthase
4LRQ	;	1.45	;	Crystal structure of a Low Molecular Weight Phosphotyrosine phosphatase from Vibrio choleraeO395
5KH9	;	1.07	;	Crystal structure of a low occupancy fragment candidate (5-[(4-Isopropylphenyl)amino]-6-methyl-1,2,4-triazin-3(2H)-one) bound in the ubiquitin binding pocket of the HDAC6 zinc-finger domain
5B8D	;	1.05	;	Crystal structure of a low occupancy fragment candidate (N-(4-Methyl-1,3-thiazol-2-yl)propanamide) bound adjacent to the ubiquitin binding pocket of the HDAC6 zinc-finger domain
6NDQ	;	1.601	;	Crystal structure of a LPMO from Kitasatospora papulosa
4KIS	;	3.2	;	Crystal Structure of a LSR-DNA Complex
1VPR	;	1.8	;	Crystal structure of a luciferase domain from the dinoflagellate Lingulodinium polyedrum
2G0Y	;	2.3	;	Crystal Structure of a Lumenal Pentapeptide Repeat Protein from Cyanothece sp 51142 at 2.3 Angstrom Resolution. Tetragonal Crystal Form
2F3L	;	2.11	;	Crystal Structure of a Lumenal Rfr-domain protein (Contig83.1_1_243_746) from Cyanothece sp. 51142 at 2.1 Angstrom resolution.
2A43	;	1.34	;	Crystal Structure of a Luteoviral RNA Pseudoknot and Model for a Minimal Ribosomal Frameshifting Motif
2QSJ	;	2.1	;	Crystal structure of a LuxR family DNA-binding response regulator from Silicibacter pomeroyi
5V2W	;	2.3	;	Crystal structure of a LuxS from salmonella typhi
3B4S	;	3.1	;	Crystal structure of a LuxT domain from Vibrio parahaemolyticus RIMD 2210633
6JQ9	;	1.81	;	Crystal structure of a lyase from Alteromonas sp.
2NW0	;	1.6	;	Crystal structure of a lysin
6O43	;	2.08223	;	Crystal structure of a lysin protein from Staphylococcus phage P68
1UC8	;	2.0	;	Crystal structure of a lysine biosynthesis enzyme, Lysx, from thermus thermophilus HB8
1UC9	;	2.38	;	Crystal structure of a lysine biosynthesis enzyme, Lysx, from thermus thermophilus HB8
4DZA	;	1.74	;	Crystal structure of a lysine racemase within internal aldimine linkage
5VRE	;	3.299	;	Crystal structure of a lysosomal potassium-selective channel TMEM175 homolog from Chamaesiphon Minutus
8YA4	;	2.1	;	Crystal structure of a lysozyme form hen egg white
8Y9W	;	1.9	;	CRYSTAL STRUCTURE OF A LYSOZYME FROM HEN EGG WHITE
6UKC	;	2.25	;	Crystal structure of a lysozyme from Litopenaeus vannamei
6UL3	;	3.0	;	Crystal structure of a lysozyme from Litopenaeus vannamei
5WSZ	;	2.565	;	Crystal structure of a lytic polysaccharide monooxygenase,BtLPMO10A, from Bacillus thuringiensis
2H4Q	;	2.1	;	Crystal structure of a M-loop deletion variant of MENT in the cleaved conformation
2DUT	;	3.0	;	Crystal structure of a M-loop deletion variant of MENT in the native conformation
2PWY	;	1.7	;	Crystal Structure of a m1A58 tRNA methyltransferase
2POK	;	1.9	;	Crystal structure of a M20 family metallo peptidase from Streptococcus pneumoniae
3PFE	;	1.5	;	Crystal structure of a M20A metallo peptidase (dapE, lpg0809) from Legionella pneumophila subsp. pneumophila str. philadelphia 1 at 1.50 A resolution
7XYO	;	2.7	;	Crystal Structure of a M61 aminopeptidase family member from Myxococcus fulvus
4Q8D	;	1.746	;	Crystal structure of a macrocyclic beta-sheet peptide containing two beta-strands from amyloid beta residues 15-23
5HPP	;	2.082	;	Crystal structure of a macrocyclic beta-sheet peptide derived from transthyretin (106-121) - (ORN)TIA(MAA)LLS(ORN)S(PHI)STTAV
5F1T	;	1.971	;	Crystal structure of a macrocyclic peptide containing fragments from alpha-synuclein 36-55.
3N7T	;	2.1	;	Crystal structure of a macrophage binding protein from Coccidioides immitis
3O7Q	;	3.143	;	Crystal structure of a Major Facilitator Superfamily (MFS) transporter, FucP, in the outward conformation
8IGL	;	2.4	;	Crystal structure of a major fragment of the ASFV inner capsid protein p150
2F08	;	2.2	;	Crystal structure of a major house dust mite allergen, Derf 2
1ZL9	;	2.01	;	Crystal Structure of a major nematode C.elegans specific GST (CE01613)
3DZM	;	2.801	;	Crystal structure of a major outer membrane protein from Thermus thermophilus HB27
6AXE	;	1.6	;	Crystal structure of a malate synthase G from Mycobacterium marinum bound to acetyl CoA
6MPR	;	1.7	;	Crystal structure of a malonate decarboxylase, alpha subunit from Acinetobacter baumannii
1SMA	;	2.8	;	CRYSTAL STRUCTURE OF A MALTOGENIC AMYLASE
1QQ2	;	2.6	;	CRYSTAL STRUCTURE OF A MAMMALIAN 2-CYS PEROXIREDOXIN, HBP23.
3HL4	;	2.2	;	Crystal structure of a mammalian CTP:phosphocholine cytidylyltransferase with CDP-choline
4MVC	;	3.0	;	Crystal Structure of a Mammalian Cytidylyltransferase
4MVD	;	8.0	;	Crystal Structure of a Mammalian Cytidylyltransferase
2ZAT	;	1.5	;	Crystal structure of a mammalian reductase
2WML	;	1.9	;	Crystal Structure of a Mammalian Sialyltransferase
2WNB	;	1.55	;	Crystal Structure of a Mammalian Sialyltransferase in complex with disaccharide and CMP
2WNF	;	1.25	;	Crystal Structure of a Mammalian Sialyltransferase in complex with Gal-beta-1-3GalNAc-ortho-nitrophenol
3U4F	;	1.9	;	Crystal structure of a mandelate racemase (muconate lactonizing enzyme family protein) from Roseovarius nubinhibens
2PMQ	;	1.72	;	Crystal structure of a mandelate racemase/muconate lactonizing enzyme from Roseovarius sp. HTCC2601
3MQT	;	2.1	;	Crystal structure of a mandelate racemase/muconate lactonizing enzyme from Shewanella pealeana
3CYJ	;	2.3	;	Crystal structure of a mandelate racemase/muconate lactonizing enzyme-like protein from Rubrobacter xylanophilus
4J0N	;	2.25	;	Crystal structure of a manganese dependent isatin hydrolase
3DC5	;	1.7	;	Crystal Structure of a manganese superoxide dismutases from Caenorhabditis elegans
3DC6	;	1.8	;	Crystal Structure of a manganese superoxide dismutases from Caenorhabditis elegans
8AWP	;	1.595	;	Crystal structure of a manganese-containing cupin (tm1459) from Thermotoga maritima, variant 208 (V19I/R23H/M38I/I60F/C106Q)
8AWO	;	1.7	;	Crystal structure of a manganese-containing cupin (tm1459) from Thermotoga maritima, variant AIFQ (Y7A/M38I/Y83F/C106Q)
8AWN	;	1.45	;	Crystal structure of a manganese-containing cupin (tm1459) from Thermotoga maritima, variant C106Q
5I7I	;	1.3	;	Crystal structure of a marine metagenome TRAP solute binding protein specific for aromatic acid ligands (Sorcerer II Global Ocean Sampling Expedition, unidentified microbe, locus tag GOS_1523157) in complex with co-crystallized 3-hydroxybenzoate
5I5P	;	1.6	;	Crystal structure of a marine metagenome TRAP solute binding protein specific for aromatic acid ligands (Sorcerer II Global Ocean Sampling Expedition, unidentified microbe, locus tag GOS_1523157) in complex with co-purified 4-hydroxybenzoate
5IGA	;	1.45	;	Crystal structure of a marine metagenome TRAP solute binding protein specific for aromatic acid ligands (Sorcerer II Global Ocean Sampling Expedition, unidentified microbe, locus tag GOS_1523157, Triple Surface Mutant K158A_K223A_K313A) in complex with co-purified parahydroxybenzoate
5IZZ	;	1.6	;	Crystal structure of a marine metagenome TRAP solute binding protein specific for aromatic acid ligands (Sorcerer II Global Ocean Sampling Expedition, unidentified microbe, locus tag GOS_1523157, Triple Surface Mutant K158A_K223A_K313A) in complex with metahydroxyphenylacetate, thermal exchange of ligand
6WGM	;	1.4	;	Crystal structure of a marine metagenome TRAP solute binding protein specific for pyroglutamate (Sorcerer II Global Ocean Sampling Expedition, unidentified microbe, scf7180008839099) in complex with co-purified pyroglutamate
7DVN	;	1.6	;	Crystal structure of a MarR family protein in complex with a lipid-like effector molecule from the psychrophilic bacterium Paenisporosarcina sp. TG-14
3NQO	;	2.2	;	Crystal structure of a MarR family transcriptional regulator (CD1569) from Clostridium difficile 630 at 2.20 A resolution
2ETH	;	2.3	;	Crystal structure of a marr-like transcriptional regulator (tm0816) from thermotoga maritima at 2.50 A resolution
1APL	;	2.7	;	CRYSTAL STRUCTURE OF A MAT-ALPHA2 HOMEODOMAIN-OPERATOR COMPLEX SUGGESTS A GENERAL MODEL FOR HOMEODOMAIN-DNA INTERACTIONS
5XJJ	;	2.9	;	Crystal structure of a MATE family protein
5YCK	;	2.3	;	Crystal structure of a MATE family protein derived from Camelina sativa at 2.3 angstrom
6E1C	;	2.617	;	Crystal structure of a MauG-like protein associated with microbial copper homeostasis
3TK1	;	2.4	;	Crystal structure of a MeaB and Rv1496 ortholog from Mycobacterium thermoresistible bound to GDP
4GT1	;	2.0	;	Crystal structure of a MeaB- and MMAA-like GTPase from Mycobacterium tuberculosis bound to 2'-deoxyguanosine diphosphate
8IVI	;	2.29	;	crystal structure of a medium-long chain fatty acyl-CoA ligase
3S5T	;	2.3	;	Crystal structure of a member of duf3298 family (BF2082) from bacteroides fragilis nctc 9343 at 2.30 A resolution
3S9J	;	1.75	;	Crystal structure of a member of duf4221 family (BVU_1028) from Bacteroides vulgatus atcc 8482 at 1.75 A resolution
2POD	;	2.34	;	Crystal structure of a member of enolase superfamily from Burkholderia pseudomallei K96243
3BJS	;	2.7	;	Crystal structure of a member of enolase superfamily from Polaromonas sp. JS666
2QDD	;	2.3	;	Crystal structure of a member of enolase superfamily from Roseovarius nubinhibens ISM
3FVD	;	2.3	;	Crystal structure of a member of enolase superfamily from ROSEOVARIUS NUBINHIBENS ISM complexed with magnesium
1Y23	;	2.3	;	Crystal structure of a member of HIT family of proteins from bacillus subtilis
2NQL	;	1.8	;	Crystal structure of a member of the enolase superfamily from Agrobacterium tumefaciens
2O56	;	2.0	;	Crystal Structure of a Member of the Enolase Superfamily from Salmonella Typhimurium
4RW0	;	2.0	;	Crystal structure of a member of the lipolytic protein G-D-S-L family from Veillonella parvula DSM 2008
3DBO	;	1.76	;	Crystal structure of a member of the VapBC family of toxin-antitoxin systems, VapBC-5, from Mycobacterium tuberculosis
1X25	;	2.0	;	Crystal Structure of a Member of YjgF Family from Sulfolobus Tokodaii (ST0811)
6I8W	;	2.0	;	Crystal structure of a membrane phospholipase A, a novel bacterial virulence factor
3T9N	;	3.456	;	Crystal structure of a membrane protein
3UDC	;	3.355	;	Crystal structure of a membrane protein
5T0O	;	3.15	;	Crystal Structure of a membrane protein
7K7M	;	3.33	;	Crystal Structure of a membrane protein
5AZO	;	2.7	;	Crystal structure of a membrane protein from Pseudomonas aeruginosa
5AZP	;	1.69	;	Crystal structure of a membrane protein from Pseudomonas aeruginosa
5AZS	;	3.1	;	Crystal structure of a membrane protein from Pseudomonas aeruginosa
6IVK	;	2.65	;	Crystal structure of a membrane protein G175A
6IVJ	;	2.77	;	Crystal structure of a membrane protein G18A
6IVN	;	3.1	;	Crystal structure of a membrane protein G264A
6IVL	;	3.4	;	Crystal structure of a membrane protein L259A
6IVM	;	2.95	;	Crystal structure of a membrane protein P143A
6IVO	;	2.45	;	Crystal structure of a membrane protein P208A
6IVP	;	3.8	;	Crystal structure of a membrane protein P262A
6IVQ	;	2.65	;	Crystal structure of a membrane protein S19A
6IVR	;	2.8	;	Crystal structure of a membrane protein W16A
6BUG	;	3.27	;	Crystal structure of a membrane protein, crystal form I
6BUH	;	3.15	;	Crystal structure of a membrane protein, crystal form II
6BUI	;	3.27	;	Crystal structure of a membrane protein, crystal form III
4IU9	;	3.005	;	Crystal structure of a membrane transporter
4IU8	;	3.11	;	Crystal structure of a membrane transporter (selenomethionine derivative)
5U82	;	1.851	;	Crystal structure of a MerB-triethyltin complex
5U88	;	1.801	;	Crystal structure of a MerB-triimethyllead complex.
5U83	;	1.609	;	Crystal structure of a MerB-trimethytin complex.
3B7M	;	2.1	;	Crystal structure of a meso-active thermo-stable cellulase (MT Cel12A) derived by making non-contiguous mutations in the active surface of the Cel12A cellulase of Rhodothermus marinus
1XXN	;	1.7	;	Crystal structure of a mesophilic xylanase A from Bacillus subtilis 1A1
2D0D	;	1.65	;	Crystal Structure of a Meta-cleavage Product Hydrolase (CumD) A129V Mutant
1UKA	;	1.7	;	Crystal structure of a meta-cleavage product hydrolase (CumD) complexed with (S)-2-methylbutyrate
1UKB	;	1.8	;	Crystal structure of a meta-cleavage product hydrolase (CumD) complexed with benzoate
1UK9	;	1.8	;	Crystal structure of a meta-cleavage product hydrolase (CumD) complexed with isovalerate
1UK7	;	1.7	;	Crystal structure of a meta-cleavage product hydrolase (CumD) complexed with n-butyrate
1UK8	;	1.6	;	Crystal structure of a meta-cleavage product hydrolase (CumD) complexed with n-valerate
1UK6	;	1.95	;	Crystal structure of a meta-cleavage product hydrolase (CumD) complexed with propionate
4XS3	;	3.291	;	Crystal structure of a metabolic reductase with (E)-1-benzyl-5-((1-methyl-5-oxo-2-thioxoimidazolidin-4-ylidene)methyl)pyridin-2(1H)-one
4XRX	;	3.2	;	Crystal structure of a metabolic reductase with (E)-5-((1-methyl-5-oxo-2-thioxoimidazolidin-4-ylidene)methyl)pyridin-2(1H)-one
4I3K	;	3.3056	;	Crystal structure of a metabolic reductase with 1-hydroxy-6-(4-hydroxybenzyl)-4-methylpyridin-2(1H)-one
4I3L	;	3.292	;	Crystal structure of a metabolic reductase with 6-benzyl-1-hydroxy-4-methylpyridin-2(1H)-one
4HTY	;	2.0	;	Crystal Structure of a metagenome-derived cellulase Cel5A
4HU0	;	2.38	;	Crystal Structure of a metagenome-derived cellulase Cel5A in complex with cellotetraose
8FC0	;	2.1	;	Crystal structure of a metagenome-derived GH5 endo-beta-1,4-glucanase
3RKR	;	2.42	;	Crystal structure of a metagenomic short-chain oxidoreductase (SDR) in complex with NADP
3VFI	;	1.75	;	Crystal Structure of a Metagenomic Thioredoxin
3GW7	;	3.3	;	Crystal structure of a metal-dependent phosphohydrolase with conserved HD domain (yedJ) from Escherichia coli in complex with nickel ions. Northeast Structural Genomics Consortium Target ER63
7RWV	;	2.2	;	Crystal structure of a metal-free RIDC1 variant
3I8W	;	1.7	;	Crystal structure of a metallacarborane inhibitor bound to HIV protease
8D2Z	;	1.85	;	Crystal Structure of a Metallo-beta-lactamase superfamily protein from Burkholderia cenocepacia
3P1V	;	1.93	;	Crystal structure of a metallo-endopeptidases (BACOVA_00663) from Bacteroides ovatus at 1.93 A resolution
2QIF	;	1.5	;	Crystal structure of a metallochaperone with a tetranuclear Cu(I) cluster
3I9Z	;	1.9	;	Crystal structure of a metallochaperone with a trinuclear Cu(I) cluster
1LOJ	;	1.9	;	Crystal structure of a Methanobacterial Sm-like archaeal protein (SmAP1) bound to uridine-5'-monophosphate (UMP)
6UNV	;	3.0	;	Crystal structure of a methanol tolerant lipase/esterase from the fungus Rasamsonia emersonii
3TAV	;	2.15	;	Crystal structure of a Methionine Aminopeptidase from Mycobacterium abscessus
6MRF	;	1.65	;	Crystal structure of a Methionine aminopeptidase MetAP from Acinetobacter baumannii
4H9W	;	2.5	;	crystal structure of a METHIONINE mutant of WCI
3EIG	;	1.7	;	Crystal structure of a methotrexate-resistant mutant of human dihydrofolate reductase
7V9E	;	2.3	;	Crystal structure of a methyl transferase ribozyme
3OOV	;	2.2	;	Crystal structure of a methyl-accepting chemotaxis protein, residues 122 to 287
3SQG	;	2.1	;	Crystal structure of a methyl-coenzyme M reductase purified from Black Sea mats
3KJ6	;	3.4	;	Crystal structure of a Methylated beta2 Adrenergic Receptor-Fab complex
5HK8	;	2.8	;	Crystal structure of a methylesterase protein MES16 from Arabidopsis
6DUB	;	1.2	;	Crystal structure of a methyltransferase
3C3P	;	1.9	;	Crystal structure of a methyltransferase (NP_951602.1) from Geobacter sulfurreducens at 1.90 A resolution
5U0N	;	2.115	;	Crystal structure of a methyltransferase in complex with the substrate involved in the biosynthesis of gentamicin
5U4T	;	2.086	;	Crystal structure of a methyltransferase involved in the biosynthesis of gentamicin
5U19	;	1.902	;	Crystal structure of a methyltransferase involved in the biosynthesis of gentamicin in complex with (1R,2S,3S,4R,6R)-4,6-diamino-3-{[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl]oxy}-2-hydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside
5U0T	;	2.109	;	Crystal structure of a methyltransferase involved in the biosynthesis of gentamicin in complex with (1R,2S,3S,4R,6S)-4,6-diamino-3-{[3-deoxy-3-(methylamino)-alpha-D-glucopyranosyl]oxy}-2-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside
5U18	;	2.195	;	Crystal structure of a methyltransferase involved in the biosynthesis of gentamicin in complex with the Geneticin
5U1E	;	2.213	;	Crystal structure of a methyltransferase involved in the biosynthesis of gentamicin in complex with the kanamycin B
5U1I	;	1.932	;	Crystal structure of a methyltransferase involved in the biosynthesis of gentamicin in complex with the methylated Kanamycin B
3CVO	;	1.8	;	Crystal structure of a methyltransferase-like protein (spo2022) from silicibacter pomeroyi dss-3 at 1.80 A resolution
3LTO	;	2.27	;	Crystal structure of a mevalonate diphosphate decarboxylase from Legionella pneumophila
6G9X	;	2.3	;	Crystal structure of a MFS transporter at 2.54 Angstroem resolution
6ZGR	;	2.46	;	Crystal structure of a MFS transporter with bound 1-hydroxynaphthalene-2-carboxylic acid at 2.67 Angstroem resolution
6ZGT	;	2.23	;	Crystal structure of a MFS transporter with bound 2-naphthoic acid at 2.39 Angstroem resolution
6ZGU	;	2.18	;	Crystal structure of a MFS transporter with bound 3-(2-methylphenyl)propanoic acid at 2.41 Angstroem resolution
6ZGS	;	2.151	;	Crystal structure of a MFS transporter with bound 3-phenylpropanoic acid at 2.39 Angstroem resolution
6HCL	;	2.5	;	Crystal structure of a MFS transporter with Ligand at 2.69 Angstroem resolution
1DPF	;	2.0	;	CRYSTAL STRUCTURE OF A MG-FREE FORM OF RHOA COMPLEXED WITH GDP
2XPG	;	2.6	;	Crystal structure of a MHC class I-peptide complex
7PV0	;	2.15	;	Crystal structure of a Mic60-Mic19 fusion protein
3PB1	;	2.3	;	Crystal Structure of a Michaelis Complex between Plasminogen Activator Inhibitor-1 and Urokinase-type Plasminogen Activator
2WVU	;	1.95	;	Crystal structure of a Michaelis complex of alpha-L-fucosidase GH29 from Bacteroides thetaiotaomicron with the synthetic substrate 4- nitrophenyl-alpha-L-fucose
3TBN	;	1.15	;	Crystal structure of a miner2 homolog: a type 6 CDGSH iron-sulfur protein.
6JK2	;	1.06	;	Crystal structure of a mini fungal lectin, PhoSL
6JK3	;	1.12	;	Crystal structure of a mini fungal lectin, PhoSL in complex with core-fucosylated chitobiose
3BM1	;	2.0	;	Crystal structure of a minimal nitroreductase ydjA from Escherichia coli K12 with and without FMN cofactor
3BM2	;	2.1	;	Crystal structure of a minimal nitroreductase ydjA from Escherichia coli K12 with and without FMN cofactor
2FGP	;	2.4	;	Crystal structure of a minimal, all RNA hairpin ribozyme with modifications (g8dap, u39c) at ph 8.6
2D2L	;	2.5	;	Crystal Structure of a minimal, all-RNA hairpin ribozyme with a propyl linker (C3) at position U39
2BCZ	;	2.4	;	Crystal Structure of a minimal, mutant all-RNA hairpin ribozyme (U39C, G8I, 2'deoxy A-1)
2BCY	;	2.7	;	Crystal Structure of a minimal, mutant all-RNA hairpin ribozyme (U39C, G8MTU)
3CR1	;	2.25	;	crystal structure of a minimal, mutant, all-RNA hairpin ribozyme (A38C, A-1OMA) grown from MgCl2
2D2K	;	2.65	;	Crystal Structure of a minimal, native (U39) all-RNA hairpin ribozyme
3B5A	;	2.35	;	Crystal Structure of a Minimally Hinged Hairpin Ribozyme Incorporating A38G mutation with a 2'OMe modification at the active site
3B5F	;	2.7	;	Crystal Structure of a Minimally Hinged Hairpin Ribozyme Incorporating the Ade38Dap Mutation and a 2',5' Phosphodiester Linkage at the Active Site
153D	;	2.9	;	CRYSTAL STRUCTURE OF A MISPAIRED DODECAMER, D(CGAGAATTC(O6ME)GCG)2, CONTAINING A CARCINOGENIC O6-METHYLGUANINE
3SDS	;	2.8	;	Crystal structure of a mitochondrial ornithine carbamoyltransferase from Coccidioides immitis
3A9E	;	2.75	;	Crystal structure of a mixed agonist-bound RAR-alpha and antagonist-bound RXR-alpha heterodimer ligand binding domains
1DDX	;	3.0	;	CRYSTAL STRUCTURE OF A MIXTURE OF ARACHIDONIC ACID AND PROSTAGLANDIN BOUND TO THE CYCLOOXYGENASE ACTIVE SITE OF COX-2: PROSTAGLANDIN STRUCTURE
3UFB	;	1.8	;	Crystal structure of a modification subunit of a putative type I restriction enzyme from Vibrio vulnificus YJ016
4PWU	;	2.45	;	Crystal structure of a modulator protein MzrA (KPN_03524) from Klebsiella pneumoniae subsp. pneumoniae MGH 78578 at 2.45 A resolution
1M3W	;	2.8	;	Crystal Structure of a Molecular Maquette Scaffold
3TCR	;	2.3	;	Crystal structure of a molybdopterin biosynthesis protein from Mycobacterium abscessus
1DIR	;	2.6	;	CRYSTAL STRUCTURE OF A MONOCLINIC FORM OF DIHYDROPTERIDINE REDUCTASE FROM RAT LIVER
2UYL	;	2.5	;	Crystal structure of a monoclonal antibody directed against an antigenic determinant common to Ogawa and Inaba serotypes of Vibrio cholerae O1
1M71	;	2.8	;	Crystal structure of a Monoclonal Fab Specific for Shigella Flexneri Y lipopolysaccharide
1M7I	;	2.5	;	CRYSTAL STRUCTURE OF A MONOCLONAL FAB SPECIFIC FOR SHIGELLA FLEXNERI Y LIPOPOLYSACCHARIDE COMPLEXED WITH A PENTASACCHARIDE
1M7D	;	2.3	;	Crystal structure of a Monoclonal Fab Specific for Shigella flexneri Y Lipopolysaccharide complexed with a trisaccharide
1E1E	;	2.5	;	Crystal structure of a Monocot (Maize ZMGlu1) beta-glucosidase
1E1F	;	2.6	;	Crystal structure of a Monocot (Maize ZMGlu1) beta-glucosidase in complex with p-Nitrophenyl-beta-D-thioglucoside
4EKJ	;	2.5	;	Crystal structure of a monomeric beta-xylosidase from Caulobacter crescentus CB15
2HQK	;	1.19	;	Crystal structure of a monomeric cyan fluorescent protein derived from Clavularia
2OTB	;	1.79	;	Crystal structure of a monomeric cyan fluorescent protein in the fluorescent state
2OTE	;	1.47	;	Crystal structure of a monomeric cyan fluorescent protein in the photobleached state
5E1V	;	1.874	;	Crystal structure of a monomeric dehydratase domain from a trans AT polyketide synthase split module
7NBI	;	1.65	;	Crystal structure of a monomeric FLT3 Ligand variant
1IFG	;	2.0	;	CRYSTAL STRUCTURE OF A MONOMERIC FORM OF GENERAL PROTEASE INHIBITOR, ECOTIN IN ABSENCE OF A PROTEASE
2QCY	;	1.75	;	Crystal Structure of a monomeric form of Severe Acute Respiratory Syndrome (SARS) 3C-like protease mutant
3ADF	;	2.2	;	Crystal structure of a monomeric green fluorescent protein, Azami-Green (mAG)
5W59	;	2.498	;	Crystal structure of a monomeric human FGF9 in complex with the ectodomain of human FGFR1c
5CJS	;	4.3	;	Crystal structure of a monomeric influenza hemagglutinin stem in complex with an broadly neutralizing antibody CR9114
3S7Q	;	1.748	;	Crystal Structure of a Monomeric Infrared Fluorescent Deinococcus radiodurans Bacteriophytochrome chromophore binding domain
2PYC	;	1.5	;	Crystal structure of a monomeric phospholipase A2 from Russell's viper at 1.5A resolution
4EGV	;	2.71	;	Crystal structure of a monomeric SCP2-thiolase like protein type 1 (STLP1) from Mycobacterium smegmatis
4BX0	;	1.75	;	Crystal Structure of a Monomeric Variant of murine Chronophin (Pyridoxal Phosphate phosphatase)
6AJD	;	2.223	;	Crystal structure of a monometallic dihydropyrimidinase from Pseudomonas aeruginosa PAO1 reveals no lysine carbamylation within the active site
1N5Q	;	1.74	;	Crystal structure of a Monooxygenase from the gene ActVA-Orf6 of Streptomyces coelicolor in complex with dehydrated Sancycline
1N5S	;	1.7	;	Crystal structure of a Monooxygenase from the gene ActVA-Orf6 of Streptomyces coelicolor in complex with the ligand Acetyl Dithranol
1N5V	;	2.24	;	Crystal structure of a Monooxygenase from the gene ActVA-Orf6 of Streptomyces coelicolor in complex with the ligand Nanaomycin D
1N5T	;	1.9	;	Crystal structure of a Monooxygenase from the gene ActVA-Orf6 of Streptomyces coelicolor in complex with the ligand Oxidized Acetyl Dithranol
1LQ9	;	1.3	;	Crystal Structure of a Monooxygenase from the Gene ActVA-Orf6 of Streptomyces coelicolor Strain A3(2)
3FJ2	;	1.85	;	CRYSTAL STRUCTURE OF A MONOOXYGENASE-LIKE PROTEIN (LIN2316) FROM LISTERIA INNOCUA AT 1.85 A RESOLUTION
7KGA	;	2.1	;	Crystal structure of a mosquito-borne flavivirus dumbbell RNA
3QWO	;	1.9	;	Crystal structure of a motavizumab epitope-scaffold bound to motavizumab Fab
6JLA	;	2.4	;	Crystal structure of a mouse ependymin related protein
1YN7	;	2.2	;	Crystal structure of a mouse MHC class I protein, H2-Db, in complex with a mutated peptide (R7A) of the influenza A acid polymerase
1YN6	;	2.2	;	Crystal structure of a mouse MHC class I protein, H2-Db, in complex with a peptide from the influenza A acid polymerase
3UTM	;	2.0	;	Crystal structure of a mouse Tankyrase-Axin complex
6V4Q	;	1.39	;	Crystal structure of a MR78-like antibody naive-1 Fab
1QXP	;	2.8	;	Crystal Structure of a mu-like calpain
8AXH	;	1.85	;	Crystal structure of a MUC1-like glycopeptide containing the unnatural L-4-hydroxynorvaline in complex with scFv-SM3
3MY9	;	2.2	;	Crystal structure of a muconate cycloisomerase from Azorhizobium caulinodans
1MWI	;	2.35	;	Crystal structure of a MUG-DNA product complex
1MWJ	;	2.85	;	Crystal Structure of a MUG-DNA pseudo substrate complex
2IF4	;	2.85	;	Crystal structure of a multi-domain immunophilin from Arabidopsis thaliana
4NKK	;	1.8	;	Crystal structure of a multi-drug resistant clinical isolate-769 HIV-1 protease variant that is resistant to the dimerization inhibitory activity of TLF-PafF
8P4G	;	2.59	;	Crystal structure of a multicopper oxidase 3F3 variant from Pyrobaculum aerophilum
3TS8	;	2.8	;	Crystal structure of a multidomain human p53 tetramer bound to the natural CDKN1A(p21) p53-response element
3SOT	;	2.8	;	Crystal structure of a Multidomain protein including DUF1735 (BACOVA_03322) from Bacteroides ovatus at 2.80 A resolution
3GO5	;	1.4	;	Crystal structure of a multidomain protein with nucleic acid binding domains (sp_0946) from streptococcus pneumoniae tigr4 at 1.40 A resolution
2DHH	;	2.8	;	Crystal structure of a multidrug transporter reveal a functionally rotating mechanism
2DR6	;	3.3	;	Crystal structure of a multidrug transporter reveal a functionally rotating mechanism
2DRD	;	3.1	;	Crystal structure of a multidrug transporter reveal a functionally rotating mechanism
4LCZ	;	2.6	;	Crystal structure of a multilayer-packed major light-harvesting complex
1SIF	;	2.18	;	Crystal structure of a multiple hydrophobic core mutant of ubiquitin
4FDT	;	1.93	;	Crystal Structure of a Multiple Inositol Polyphosphate Phosphatase
4FDU	;	2.293	;	Crystal Structure of a Multiple Inositol Polyphosphate Phosphatase
5CX4	;	2.06	;	Crystal Structure of a Multiple Inositol Polyphosphate Phosphatase
8TE5	;	1.502	;	Crystal structure of a multiple lysine-to-arginine substitution mutant of the human CRIg C3b-binding domain
8TE6	;	1.251	;	Crystal structure of a multiple lysine-to-arginine substitution mutant of the human CRIg C3b-binding domain
1NZK	;	1.95	;	Crystal Structure of a Multiple Mutant (L44F, L73V, V109L, L111I, C117V) of Human Acidic Fibroblast Growth Factor
4PYT	;	1.853	;	Crystal structure of a MurB family EP-UDP-N-acetylglucosamine reductase
3HN7	;	1.65	;	Crystal structure of a murein peptide ligase mpl (psyc_0032) from psychrobacter arcticus 273-4 at 1.65 A resolution
2Z4Q	;	2.3	;	Crystal structure of a murine antibody FAB 528
2GSI	;	2.81	;	Crystal Structure of a Murine Fab in Complex with an 11 Residue Peptide Derived from Staphylococcal Nuclease
2VE6	;	2.65	;	Crystal structure of a Murine MHC class I H2-Db molecule in complex with a photocleavable peptide
3SMD	;	1.76	;	Crystal structure of a mut/nudix family protein from bacillus thuringiensis
5AG8	;	1.9	;	CRYSTAL STRUCTURE OF A MUTANT (665I6H) OF THE C-TERMINAL DOMAIN OF RGPB
5AG9	;	2.11	;	CRYSTAL STRUCTURE OF A MUTANT (665sXa) C-TERMINAL DOMAIN OF RGPB
1L8V	;	2.8	;	Crystal Structure of a Mutant (C109G,G212C) P4-P6 Domain of the Group I Intron from Tetrahymena Thermophilia
3PF3	;	2.098	;	Crystal structure of a mutant (C202A) of Triosephosphate isomerase from Giardia lamblia derivatized with MMTS
4BI7	;	1.6	;	CRYSTAL STRUCTURE OF A MUTANT (C202A) OF TRIOSEPHOSPHATE ISOMERASE FROM GIARDIA LAMBLIA. COMPLEXED WITH 2-PHOSPHOGLYCOLIC ACID
4XTQ	;	1.64	;	Crystal structure of a mutant (C20S) of a near-infrared fluorescent protein BphP1-FP
3GLG	;	3.25	;	Crystal Structure of a Mutant (gammaT157A) E. coli Clamp Loader Bound to Primer-Template DNA
3QPY	;	1.95	;	Crystal structure of a mutant (K57A) of 3-deoxy-D-manno-octulosonate 8-phosphate synthase (KDO8PS) from Neisseria meningitidis
7QDT	;	3.0	;	Crystal structure of a mutant (P393GX) Thyroid Receptor Alpha ligand binding domain designed to model dominant negative human mutations.
3STE	;	2.05	;	Crystal structure of a mutant (Q202A) of 3-deoxy-D-manno-octulosonate 8-phosphate synthase (KDO8PS) from Neisseria meningitidis
2E24	;	2.15	;	crystal structure of a mutant (R612A) of xanthan lyase
3STF	;	1.9	;	Crystal structure of a mutant (S211A) of 3-deoxy-D-manno-octulosonate 8-phosphate synthase (KDO8PS) from Neisseria meningitidis
6QTS	;	1.11	;	Crystal structure of a mutant Arabidopsis WD40 domain in complex with a photoreceptor
6QTR	;	1.37	;	Crystal structure of a mutant Arabidopsis WD40 domain in complex with a transcription factor
3AIS	;	2.2	;	Crystal structure of a mutant beta-glucosidase in wheat complexed with DIMBOA-Glc
2YME	;	2.4	;	Crystal structure of a mutant binding protein (5HTBP-AChBP) in complex with granisetron
5LXB	;	2.34	;	Crystal structure of a mutant binding protein (5HTBP-AChBP) in complex with palonosetron
2YMD	;	1.96	;	Crystal structure of a mutant binding protein (5HTBP-AChBP) in complex with serotonin (5-hydroxytryptamine)
1XRK	;	1.5	;	Crystal structure of a mutant bleomycin binding protein from Streptoalloteichus hindustanus displaying increased thermostability
1MK8	;	1.65	;	Crystal Structure of a Mutant Cytochrome c Peroxidase showing a Novel Trp-Tyr Covalent Cross-link
1TI1	;	2.6	;	crystal structure of a mutant DsbA
2BV3	;	2.5	;	Crystal structure of a mutant elongation factor G trapped with a GTP analogue
2HEL	;	2.35	;	Crystal structure of a mutant EphA4 kinase domain (Y742A)
1THO	;	2.3	;	CRYSTAL STRUCTURE OF A MUTANT ESCHERICHIA COLI THIOREDOXIN WITH AN ARGININE INSERTION IN THE ACTIVE SITE
1YK9	;	2.7	;	Crystal structure of a mutant form of the mycobacterial adenylyl cyclase Rv1625c
4JUT	;	2.196	;	Crystal structure of a mutant fragment of Human HSPB6
5V2I	;	1.83	;	Crystal structure of a mutant glycosylasparaginase (G172D) that causes the genetic disease Aspartylglucosaminuria
1LWF	;	2.8	;	CRYSTAL STRUCTURE OF A MUTANT HIV-1 REVERSE TRANSCRIPTASE (RTMQ+M184V: M41L/D67N/K70R/M184V/T215Y) IN COMPLEX WITH NEVIRAPINE
1I3R	;	2.4	;	CRYSTAL STRUCTURE OF A MUTANT IEK CLASS II MHC MOLECULE
1OUZ	;	2.41	;	Crystal structure of a mutant IHF (BetaE44A) complexed with a variant H' Site (T44A)
1OWF	;	1.95	;	Crystal structure of a mutant IHF (BetaE44A) complexed with the native H' Site
5WV8	;	2.042	;	Crystal structure of a mutant insect group III chitinase (CAD1-E217L) from Ostrinia furnacalis
5WVF	;	2.399	;	Crystal structure of a mutant insect group III chitinase (CAD2-E647L) from Ostrinia furnacalis
5WVG	;	2.693	;	Crystal structure of a mutant insect group III chitinase complex with (GlcNAc)5 (CAD1-E647L-(GlcNAc)5 ) from Ostrinia furnacalis
5WVB	;	3.099	;	Crystal structure of a mutant insect group III chitinase complex with (GlcNAc)6 (CAD1-E217L-(GlcNAc)6 ) from Ostrinia furnacalis
5U36	;	3.03	;	Crystal Structure Of A Mutant M. Jannashii Tyrosyl-tRNA Synthetase
1U7X	;	3.0	;	crystal structure of a mutant M. jannashii tyrosyl-tRNA synthetase specific for O-methyl-tyrosine
8GDU	;	2.01	;	Crystal structure of a mutant methyl transferase from Methanosarcina acetivorans, Northeast Structural Genomics Consortium (NESG) Target MvR53-11M
5UBX	;	2.7	;	Crystal structure of a mutant mIgG2b Fc heterodimer in complex with Protein A peptide analog Z34C
8HSO	;	2.1	;	CRYSTAL STRUCTURE OF A MUTANT MYLU-B-67 FOR 2.2 ANGSTROM, 52M 53Q 54Q 55P 56W DELETED
8HT1	;	2.4	;	CRYSTAL STRUCTURE OF A MUTANT MYLU-B-67 FOR 2.4 ANGSTROM, 52M 53Q 54Q 55P 56W DELETED
1IW8	;	2.5	;	Crystal Structure of a mutant of acid phosphatase from Escherichia blattae (G74D/I153T)
7F18	;	3.3	;	Crystal Structure of a mutant of acid phosphatase from Pseudomonas aeruginosa (Q57H/W58P/D135R)
5AWL	;	1.11	;	CRYSTAL STRUCTURE OF A MUTANT OF CHIGNOLIN, CLN025
3HRC	;	1.91	;	Crystal structure of a mutant of human PDK1 Kinase domain in complex with ATP
3JUH	;	1.66	;	Crystal structure of a mutant of human protein kinase CK2alpha with altered cosubstrate specificity
1KQJ	;	1.7	;	Crystal Structure of a Mutant of MutY Catalytic Domain
5B2A	;	1.6	;	Crystal structure of a mutant of OspA
2H0K	;	2.76	;	Crystal Structure of a Mutant of Rat Annexin A5
2H0L	;	2.59	;	Crystal Structure of a Mutant of Rat Annexin A5
3JUZ	;	2.51	;	Crystal structure of a mutant of RelB dimerization domain(M5)
3JV0	;	2.65	;	Crystal structure of a mutant of RelB dimerization domain(M6)
1ISE	;	2.2	;	Crystal structure of a mutant of ribosome recycling factor from Escherichia coli, Arg132Gly
3PY8	;	1.74	;	Crystal structure of a mutant of the large fragment of DNA polymerase I from thermus aquaticus in a closed ternary complex with DNA and ddCTP
1Q93	;	2.25	;	Crystal structure of a mutant of the sarcin/ricin domain from rat 28S rRNA
1Q96	;	1.75	;	Crystal structure of a mutant of the sarcin/ricin domain from rat 28S rRNA
2ZQS	;	1.902	;	Crystal structure of a mutant PIN1 PEPTIDYL-PROLYL CIS-TRANS ISOMERASE
2ZQT	;	1.462	;	Crystal structure of a mutant PIN1 PEPTIDYL-PROLYL CIS-TRANS ISOMERASE
2ZQU	;	2.5	;	Crystal structure of a mutant PIN1 PEPTIDYL-PROLYL CIS-TRANS ISOMERASE
2ZQV	;	2.498	;	Crystal structure of a mutant PIN1 PEPTIDYL-PROLYL CIS-TRANS ISOMERASE
2ZR4	;	2.0	;	Crystal structure of a mutant PIN1 peptidyl-prolyl cis-trans isomerase
2ZR5	;	2.6	;	Crystal structure of a mutant PIN1 peptidyl-prolyl cis-trans isomerase
2ZR6	;	3.2	;	Crystal structure of a mutant PIN1 peptidyl-prolyl cis-trans isomerase
3F1W	;	2.901	;	Crystal structure of a mutant proliferating cell nuclear antigen that blocks translesion synthesis
6ILE	;	2.9	;	CRYSTAL STRUCTURE OF A MUTANT PTAL-N*01:01 FOR 2.9 ANGSTROM, 52M 53D 54L DELETED
2EO8	;	2.3	;	Crystal structure of a mutant pyrrolidone carboxyl peptidase (A199P) from P. furiosus
1C7H	;	2.5	;	CRYSTAL STRUCTURE OF A MUTANT R75A IN KETOSTEROID ISOMERASE FROM PSEDOMONAS PUTIDA BIOTYPE B
3JSS	;	2.6	;	Crystal structure of a mutant RelB dimerization domain
7WNK	;	1.4	;	Crystal structure of a mutant Staphylococcus equorum manganese superoxide dismutase K38R and A121E
7WNL	;	1.51	;	Crystal structure of a mutant Staphylococcus equorum manganese superoxide dismutase K38R and A121Y
7W6W	;	1.94	;	Crystal structure of a mutant Staphylococcus equorum manganese superoxide dismutase L169W
6M30	;	1.74	;	Crystal structure of a mutant Staphylococcus equorum manganese superoxide dismutase N73F
7DDW	;	1.88	;	Crystal structure of a mutant Staphylococcus equorum manganese superoxide dismutase S126C
3SO0	;	1.93	;	Crystal structure of a mutant T41S of a betagamma-crystallin domain from Clostridium beijerinckii
3SNY	;	1.85	;	Crystal structure of a mutant T82R of a betagamma-crystallin domain from Clostridium beijerinckii
1MKR	;	1.58	;	Crystal Structure of a Mutant Variant of Cytochrome c Peroxidase (Plate like crystals)
1ML2	;	1.65	;	Crystal Structure of a Mutant Variant of Cytochrome c Peroxidase with Zn(II)-(20-oxo-Protoporphyrin IX)
3SNZ	;	2.0	;	Crystal structure of a mutant W39D of a betagamma-crystallin domain from Clostridium beijerinckii
1W6Y	;	2.1	;	crystal structure of a mutant W92A in ketosteroid isomerase (KSI) from Pseudomonas putida biotype B
1FMZ	;	2.05	;	CRYSTAL STRUCTURE OF A MUTANT WINGED BEAN CHYMOTRYPSIN INHIBITOR PROTEIN, N14K.
4HHM	;	2.15	;	Crystal structure of a mutant, G219A, of Glucose Isomerase from Streptomyces sp. SK
5D2B	;	1.2	;	Crystal structure of a mutated catalytic domain of Human MMP12 in complex with an hydroxamate analogue of RXP470
5CZM	;	1.303	;	Crystal structure of a mutated catalytic domain of Human MMP12 in complex with RXP470
1K9E	;	1.85	;	Crystal structure of a mutated family-67 alpha-D-glucuronidase (E285N) from Bacillus stearothermophilus T-6, complexed with 4-O-methyl-glucuronic acid
1K9F	;	1.75	;	Crystal structure of a mutated family-67 alpha-D-glucuronidase (E285N) from Bacillus stearothermophilus T-6, complexed with aldotetraouronic acid
7PDT	;	3.3	;	Crystal structure of a mutated form of RXRalpha ligand binding domain in complex with BMS649 and a coactivator fragment
7PDQ	;	1.58	;	Crystal structure of a mutated form of RXRalpha ligand binding domain in complex with LG100268 and a coactivator fragment
6EYQ	;	1.5	;	Crystal structure of a mutated OpuBC in complex with choline
1EP8	;	2.2	;	CRYSTAL STRUCTURE OF A MUTATED THIOREDOXIN, D30A, FROM CHLAMYDOMONAS REINHARDTII
3ID9	;	2.55	;	Crystal structure of a MutT/NUDIX family protein from Bacillus thuringiensis
3I9X	;	2.2	;	Crystal structure of a mutT/nudix family protein from Listeria innocua
4V1G	;	1.55	;	Crystal structure of a mycobacterial ATP synthase rotor ring
4V1F	;	1.697	;	Crystal structure of a mycobacterial ATP synthase rotor ring in complex with Bedaquiline
4V1H	;	1.8	;	Crystal structure of a mycobacterial ATP synthase rotor ring in complex with Iodo-Bedaquiline
1N3N	;	3.0	;	Crystal structure of a mycobacterial hsp60 epitope with the murine class I MHC molecule H-2Db
4XU4	;	1.901	;	Crystal structure of a mycobacterial Insig homolog MvINS from Mycobacterium vanbaalenii at 1.9A resolution
3CKJ	;	1.8	;	Crystal Structure of a Mycobacterial Protein
3CKN	;	2.2	;	Crystal Structure of a Mycobacterial Protein
3CKO	;	2.5	;	Crystal Structure of a Mycobacterial Protein
3CKQ	;	3.0	;	Crystal Structure of a Mycobacterial Protein
3CKV	;	2.0	;	Crystal Structure of a Mycobacterial Protein
4ZY7	;	1.7	;	Crystal structure of a Mycobacterial protein
5D6J	;	2.25	;	Crystal structure of a mycobacterial protein
5D6N	;	2.401	;	Crystal structure of a mycobacterial protein
7R6R	;	3.13	;	Crystal Structure of a Mycobacteriophage Cluster A2 Immunity Repressor:DNA Complex
7TZ1	;	2.79	;	Crystal Structure of a Mycobacteriophage Cluster A2 Immunity Repressor:DNA Complex
2WZM	;	1.64	;	Crystal structure of a mycobacterium aldo-keto reductase in its apo and liganded form
2WZT	;	1.9	;	Crystal structure of a mycobacterium aldo-keto reductase in its apo and liganded form
6VVS	;	3.112	;	Crystal structure of a Mycobacterium smegmatis RNA polymerase transcription initiation complex with antibiotic Sorangicin
6CCE	;	3.05	;	Crystal structure of a Mycobacterium smegmatis RNA polymerase transcription initiation complex with inhibitor Kanglemycin A
6CCV	;	3.05	;	Crystal structure of a Mycobacterium smegmatis RNA polymerase transcription initiation complex with inhibitor Rifampicin
5TW1	;	2.76	;	Crystal structure of a Mycobacterium smegmatis transcription initiation complex with RbpA
6VVV	;	3.2	;	Crystal structure of a Mycobacterium smegmatis transcription initiation complex with Rifampicin-resistant RNA polymerase
6VVT	;	2.901	;	Crystal structure of a Mycobacterium smegmatis transcription initiation complex with Rifampicin-resistant RNA polymerase and antibiotic Sorangicin
6DCF	;	3.45	;	Crystal structure of a Mycobacterium smegmatis transcription initiation complex with Rifampicin-resistant RNA polymerase and bound to kanglemycin A
5MPV	;	1.49	;	Crystal structure of a Mycobacterium tuberculosis chorismate mutase optimized for high autonomous activity by directed evolution
3EUW	;	2.3	;	Crystal Structure of a Myo-inositol dehydrogenase from Corynebacterium glutamicum ATCC 13032
3CIN	;	1.7	;	CRYSTAL STRUCTURE OF A MYO-INOSITOL-1-PHOSPHATE SYNTHASE-RELATED PROTEIN (TM_1419) FROM THERMOTOGA MARITIMA MSB8 AT 1.70 A RESOLUTION
4Q68	;	1.07	;	Crystal structure of a N-acetylmuramoyl-L-alanine amidase (BACUNI_02947) from Bacteroides uniformis ATCC 8492 at 1.07 A resolution
4H4J	;	1.15	;	Crystal structure of a N-acetylmuramoyl-L-alanine amidase (BACUNI_02947) from Bacteroides uniformis ATCC 8492 at 1.15 A resolution
4Q5K	;	1.3	;	Crystal structure of a N-acetylmuramoyl-L-alanine amidase (BACUNI_02947) from Bacteroides uniformis ATCC 8492 at 1.30 A resolution
2GFH	;	1.9	;	Crystal structure of a n-acetylneuraminic acid phosphatase (nanp) from mus musculus at 1.90 A resolution
6LYI	;	2.49	;	Crystal structure of a N-methyltransferase CkTbS from Camellia assamica var. kucha
2QMQ	;	1.7	;	Crystal structure of a n-myc downstream regulated 2 protein (ndrg2, syld, ndr2, ai182517, au040374) from mus musculus at 1.70 A resolution
3GI3	;	2.4	;	Crystal structure of a N-Phenyl-N'-Naphthylurea analog in complex with p38 MAP kinase
4O87	;	1.8	;	Crystal structure of a N-tagged Nuclease
1U5E	;	2.6	;	Crystal Structure of a N-terminal Fragment of SKAP-Hom Containing Both the Helical Dimerization Domain and the PH Domain
2OTX	;	2.6	;	Crystal Structure of A N-terminal Fragment of SKAP-HOM Containing both the Helical Dimerization Domain and the PH Domain
3WGV	;	2.8	;	Crystal structure of a Na+-bound Na+,K+-ATPase preceding the E1P state with oligomycin
3WGU	;	2.8	;	Crystal structure of a Na+-bound Na+,K+-ATPase preceding the E1P state without oligomycin
1Z0U	;	2.0	;	Crystal structure of a NAD kinase from Archaeoglobus fulgidus bound by NADP
1SUW	;	2.45	;	Crystal structure of a NAD kinase from Archaeoglobus fulgidus in complex with its substrate and product: Insights into the catalysis of NAD kinase
1Z0Z	;	2.85	;	Crystal structure of a NAD kinase from Archaeoglobus fulgidus in complex with NAD
1X77	;	2.7	;	Crystal structure of a NAD(P)H-dependent FMN reductase complexed with FMN
5JRY	;	1.2	;	Crystal structure of a NAD-dependent Aldehyde dehydrogenase from Burkholderia multivorans in covalent complex with NAD
3R64	;	2.57	;	Crystal structure of a NAD-dependent benzaldehyde dehydrogenase from Corynebacterium glutamicum
1GDH	;	2.4	;	CRYSTAL STRUCTURE OF A NAD-DEPENDENT D-GLYCERATE DEHYDROGENASE AT 2.4 ANGSTROMS RESOLUTION
7F3P	;	2.6	;	Crystal structure of a nadp-dependent alcohol dehydrogenase mutant in apo form
8SKJ	;	2.01	;	Crystal structure of a Nanobody bound to the V5 peptide.
4ZG1	;	1.85	;	Crystal structure of a nanobody raised against KDM5B
5HDO	;	2.16	;	Crystal structure of a nanobody raised against urokinase-type plasminogen activator
6B73	;	3.1	;	Crystal Structure of a nanobody-stabilized active state of the kappa-opioid receptor
4RBO	;	3.3	;	Crystal structure of a Nanog homeobox (NANOG) from Homo sapiens at 3.30 A resolution
1VJY	;	2.0	;	Crystal Structure of a Naphthyridine Inhibitor of Human TGF-beta Type I Receptor
6YBB	;	2.9	;	Crystal structure of a native BcsE (217-523) - BcsR-BcsQ (R156E mutant) complex with c-di-GMP and ATP bound
6YBU	;	2.49	;	Crystal structure of a native BcsE (349-523) RQ complex with c-di-GMP and ATP bound
6YB3	;	1.59	;	Crystal structure of a native BcsRQ complex purified and crystallized in the absence of nucleotide
1WNO	;	2.1	;	Crystal structure of a native chitinase from Aspergillus fumigatus YJ-407
6CH9	;	4.85	;	Crystal structure of a natively-glycosylated B41 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and 35O22
6CH8	;	4.1	;	Crystal structure of a natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and 35O22
6CHB	;	6.801	;	Crystal structure of a natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and IOMA
1MVE	;	1.7	;	Crystal structure of a natural circularly-permutated jellyroll protein: 1,3-1,4-beta-D-glucanase from Fibrobacter succinogenes
3GD3	;	2.95	;	Crystal structure of a naturally folded murine apoptosis inducing factor
1FE6	;	1.8	;	CRYSTAL STRUCTURE OF A NATURALLY OCCURING PARALLEL RIGHT-HANDED COILED-COIL TETRAMER
3F9V	;	4.35	;	Crystal Structure Of A Near Full-Length Archaeal MCM: Functional Insights For An AAA+ Hexameric Helicase
2E7D	;	2.2	;	Crystal structure of a NEAT domain from Staphylococcus aureus
4OLE	;	2.52	;	Crystal structure of a neighbor of BRCA1 gene 1 (NBR1) from Homo sapiens at 2.52 A resolution
6Y54	;	2.67	;	Crystal structure of a Neisseria meningitidis serogroup A capsular oligosaccharide bound to a functional Fab
3LZU	;	1.76	;	Crystal Structure of a Nelfinavir Resistant HIV-1 CRF01_AE Protease variant (N88S) in Complex with the Protease Inhibitor Darunavir.
2X0L	;	3.0	;	Crystal structure of a neuro-specific splicing variant of human histone lysine demethylase LSD1.
4UBD	;	3.5	;	Crystal structure of a neutralizing human monoclonal antibody with 1968 H3 HA
7WQV	;	2.8	;	Crystal structure of a neutralizing monoclonal antibody (Ab08) in complex with SARS-CoV-2 receptor-binding domain (RBD)
1MPT	;	2.4	;	CRYSTAL STRUCTURE OF A NEW ALKALINE SERINE PROTEASE (M-PROTEASE) FROM BACILLUS SP. KSM-K16
6B9V	;	1.88	;	Crystal Structure of a New Diphosphatase from the PhnP Family
5YFB	;	2.2	;	Crystal structure of a new DPP III family member
5YFC	;	1.76	;	Crystal structure of a new DPP III family member
5YFD	;	1.76	;	Crystal structure of a new DPP III family member
4H3O	;	2.17	;	Crystal structure of a new form of lectin from Allium sativum at 2.17 A resolution
4HSD	;	2.45	;	Crystal structure of a new form of plant lectin from Cicer arietinum at 2.45 Angstrom resolution
6AIE	;	1.74	;	Crystal structure of a new form of RsmD-like RNA methyl transferase from Mycobacterium tuberculosis determined at 1.74 A resolution
3O9N	;	2.4	;	Crystal Structure of a new form of xylanase-A-amylase inhibitor protein(XAIP-III) at 2.4 A resolution
1LN8	;	1.65	;	Crystal Structure of a New Isoform of Phospholipase A2 from Naja naja sagittifera at 1.6 A Resolution
2PVT	;	2.1	;	Crystal structure of a new isoform of phospholipase A2 from russells viper at 2.1 A resolution
1RDT	;	2.4	;	Crystal Structure of a new rexinoid bound to the RXRalpha ligand binding doamin in the RXRalpha/PPARgamma heterodimer
1RL0	;	1.4	;	Crystal structure of a new ribosome-inactivating protein (RIP): dianthin 30
3BMB	;	1.91	;	Crystal structure of a new RNA polymerase interacting protein
4JQH	;	2.3	;	Crystal structure of a new sGC activator (analogue of BAY 58-2667) bound to nostoc H-NOX domain
1JS1	;	2.0	;	Crystal Structure of a new transcarbamylase from the anaerobic bacterium Bacteroides fragilis at 2.0 A resolution
2ZCU	;	1.8	;	Crystal structure of a new type of NADPH-dependent quinone oxidoreductase (QOR2) from escherichia coli
1LE5	;	2.75	;	Crystal structure of a NF-kB heterodimer bound to an IFNb-kB
1LE9	;	3.0	;	Crystal structure of a NF-kB heterodimer bound to the Ig/HIV-kB siti
4XFD	;	1.55	;	Crystal Structure of a NH(3)-dependent NAD(+) synthetase from Pseudomonas aeruginosa
8EEZ	;	2.25	;	Crystal structure of a NHP anti-ZIKV neutralizing antibody rhMZ100-C
8EE8	;	2.803	;	Crystal structure of a NHP anti-ZIKV neutralizing antibody rhMZ100-C in complex with ZIKV E glycoprotein
8EF1	;	1.87	;	Crystal structure of a NHP anti-ZIKV neutralizing antibody rhMZ103-A
8EF0	;	2.55	;	Crystal structure of a NHP anti-ZIKV neutralizing antibody rhMZ104-D
8EEE	;	2.819	;	Crystal structure of a NHP anti-ZIKV neutralizing antibody rhMZ104-d in complex with ZIKV E glycoprotein
8EF2	;	2.102	;	Crystal structure of a NHP anti-ZIKV neutralizing antibody rhMZ107-B
8EED	;	3.487	;	Crystal structure of a NHP anti-ZIKV neutralizing antibody rhMZ107-B in complex with ZIKV E glycoprotein
8EF3	;	1.672	;	Crystal structure of a NHP anti-ZIKV neutralizing antibody rhMZ119-D
8EE5	;	3.583	;	Crystal structure of a NHP anti-ZIKV neutralizing antibody rhMZ119-D in complex with ZIKV E glycoprotein
3L1M	;	2.3	;	Crystal Structure of a Ni-directed Dimer of Cytochrome cb562 with a Quinolate-Histidine Hybrid Coordination Motif
3NMJ	;	3.1	;	Crystal structure of a nickel mediated dimer for the phenanthroline-modified cytochrome cb562 variant, MBP-Phen2
1O4U	;	2.5	;	Crystal structure of a nicotinate nucleotide pyrophosphorylase (tm1645) from thermotoga maritima at 2.50 A resolution
1YBE	;	2.5	;	Crystal Structure of a Nicotinate phosphoribosyltransferase
1YIR	;	2.1	;	Crystal Structure of a Nicotinate Phosphoribosyltransferase
2I1O	;	2.4	;	Crystal Structure of a Nicotinate Phosphoribosyltransferase from Thermoplasma acidophilum
1YTK	;	2.65	;	Crystal structure of a nicotinate phosphoribosyltransferase from Thermoplasma acidophilum with nicotinate mononucleotide
1YTD	;	2.8	;	Crystal structure of a nicotinate phosphoribosyltransferase from Thermoplasma acidophilum, Native Structure
1YTE	;	2.75	;	Crystal structure of a nicotinate phosphoribosyltransferase from Thermoplasma acidophilum, phosphoribosylpyrophosphate bound structure
3WEA	;	1.8	;	Crystal structure of a Niemann-Pick type C2 protein from Japanese carpenter ant
3WEB	;	1.7	;	Crystal structure of a Niemann-Pick type C2 protein from Japanese carpenter ant in complex with oleic acid
3G7P	;	2.0	;	Crystal structure of a nifx-associated protein of unknown function (afe_1514) from acidithiobacillus ferrooxidans atcc at 2.00 A resolution
3QWN	;	2.42	;	Crystal structure of a NigD-like immunity protein (BACCAC_03262) from Bacteroides caccae ATCC 43185 at 2.42 A resolution
4PQX	;	2.39	;	Crystal structure of a NigD-like protein (BACCAC_02139) from Bacteroides caccae ATCC 43185 at 2.39 A resolution
4J8Q	;	2.5	;	Crystal structure of a NigD-like protein (BF0700) from Bacteroides fragilis NCTC 9343 at 2.50 A resolution
4ZA8	;	1.06	;	Crystal structure of A niger Fdc1 in complex with penta-fluorocinnamic acid
2IG6	;	1.8	;	Crystal structure of a nimc/nima family protein (ca_c2569) from clostridium acetobutylicum at 1.80 A resolution
5K9F	;	1.65	;	Crystal structure of a NIPSNAP domain protein from Burkholderia xenovorans
1VQY	;	2.4	;	CRYSTAL STRUCTURE OF a NIPSNAP FAMILY PROTEIN (ATU5224) FROM AGROBACTERIUM TUMEFACIENS STR. C58 AT 2.40 A RESOLUTION
1VQS	;	1.5	;	Crystal structure of a nipsnap family protein with unknown function (atu4242) from agrobacterium tumefaciens str. c58 at 1.50 A resolution
6JR4	;	1.798	;	Crystal structure of a NIR-emitting DNA-stabilized Ag16 nanocluster
6M2P	;	1.13	;	Crystal structure of a NIR-emitting DNA-stabilized Ag16 nanocluster (A10-deletion mutant)
7BSH	;	1.2	;	Crystal structure of a NIR-emitting DNA-stabilized Ag16 nanocluster (Abasic mutant)
7XLV	;	1.1	;	Crystal structure of a NIR-emitting DNA-stabilized Ag16 nanocluster (G7I mutant)
7XLW	;	1.89	;	Crystal structure of a NIR-emitting DNA-stabilized Ag16 nanocluster (G7I/G9I mutant)
7BSE	;	1.5	;	Crystal structure of a NIR-emitting DNA-stabilized Ag16 nanocluster (T5A mutant)
7BSF	;	1.1	;	Crystal structure of a NIR-emitting DNA-stabilized Ag16 nanocluster (T5C mutant)
7BSG	;	2.19	;	Crystal structure of a NIR-emitting DNA-stabilized Ag16 nanocluster (T5G mutant)
4OH3	;	3.25	;	Crystal structure of a nitrate transporter
3NEK	;	2.5	;	Crystal structure of a nitrogen repressor-like protein MJ0159 from Methanococcus jannaschii
5UFT	;	2.35	;	Crystal Structure of a Nitrogen-fixing NifU-like protein (N-terminal) from Brucella abortus
3H4O	;	1.5	;	Crystal structure of a nitroreductase family protein (cd3355) from clostridium difficile 630 at 1.50 A resolution
3KOQ	;	1.58	;	Crystal structure of a nitroreductase family protein (cd3355) from clostridium difficile 630 at 1.58 A resolution
3K6H	;	3.05	;	Crystal structure of a nitroreductase family protein from Agrobacterium tumefaciens str. C58
1YWQ	;	2.3	;	Crystal structure of a nitroreductase family protein from Bacillus cereus ATCC 14579
3PXV	;	2.3	;	Crystal structure of a Nitroreductase with bound FMN (Dhaf_2018) from Desulfitobacterium hafniense DCB-2 at 2.30 A resolution
3GR3	;	1.45	;	Crystal structure of a nitroreductase-like family protein (pnba, bh06130) from bartonella henselae str. houston-1 at 1.45 A resolution
3GAG	;	1.7	;	Crystal structure of a nitroreductase-like protein (smu.346) from streptococcus mutans at 1.70 A resolution
3H41	;	1.79	;	CRYSTAL STRUCTURE OF A NLPC/P60 FAMILY PROTEIN (BCE_2878) FROM BACILLUS CEREUS ATCC 10987 AT 1.79 A RESOLUTION
1KCB	;	1.65	;	Crystal Structure of a NO-forming Nitrite Reductase Mutant: an Analog of a Transition State in Enzymatic Reaction
3LTA	;	2.7	;	Crystal structure of a non-biological ATP binding protein with a TYR-PHE mutation within the ligand binding domain
7D9N	;	3.7	;	Crystal structure of a non-canonic progeria mutation S143F at lamin A/C and its structural implication to the premature aging
6JMP	;	2.2	;	Crystal Structure of a Non-hemolytic Pneumolysin from Streptococcus pneumoniae strain ST306
1YP1	;	1.9	;	Crystal structure of a non-hemorrhagic fibrin(ogen)olytic metalloproteinase from venom of Agkistrodon acutus
4M2O	;	1.5	;	Crystal structure of a non-myristoylated C39A recoverin mutant with one calcium ion bound to EF-hand 3
4M2P	;	1.45	;	Crystal structure of a non-myristoylated C39D recoverin mutant with one calcium ion bound to EF-hand 3
1A0J	;	1.7	;	CRYSTAL STRUCTURE OF A NON-PSYCHROPHILIC TRYPSIN FROM A COLD-ADAPTED FISH SPECIES.
1LP7	;	2.4	;	Crystal Structure of a Non-Self Complementary DNA Dodecamer Containing an A/T Tract: Analysis of the Effect of Crystal Environment on Local Helical Parameters
4GKL	;	2.4	;	Crystal structure of a noncanonic maltogenic alpha-amylase AmyB from Thermotoga neapolitana
5F3P	;	1.904	;	Crystal structure of a noncanonical Dicer protein from Entamoeba histolytica
5F3Q	;	2.1	;	Crystal structure of a noncanonical Dicer protein from Entamoeba histolytica
3PPM	;	1.78	;	Crystal Structure of a Noncovalently Bound alpha-Ketoheterocycle Inhibitor (Phenhexyl/Oxadiazole/Pyridine) to a Humanized Variant of Fatty Acid Amide Hydrolase
5T3E	;	2.297	;	Crystal structure of a nonribosomal peptide synthetase heterocyclization domain.
7DFS	;	1.49	;	Crystal structure of a novel 4-O-alpha-L-rhamnosyl-beta-D-glucuronidase from Fusarium oxysporum 12S - Rha-GlcA complex
7DFQ	;	1.51	;	Crystal Structure of a novel 4-O-alpha-L-rhamnosyl-beta-D-glucuronidase from Fusarium oxysporum 12S, ligand-free form
1GC5	;	2.3	;	CRYSTAL STRUCTURE OF A NOVEL ADP-DEPENDENT GLUCOKINASE FROM THERMOCOCCUS LITORALIS
1JCD	;	1.3	;	Crystal Structure of a Novel Alanine-Zipper Trimer at 1.3 A Resolution, I6A,L9A,V13A,L16A,V20A,L23A,V27A,M30A,V34A,L48A,M51A mutations
1JCC	;	1.7	;	Crystal Structure of a Novel Alanine-Zipper Trimer at 1.7 A Resolution, V13A,L16A,V20A,L23A,V27A,M30A,V34A mutations
5DAN	;	2.0	;	Crystal structure of a novel aldo keto reductase Tm1743 from Thermotoga maritima in complex with NADP+
4XPO	;	2.1	;	Crystal structure of a novel alpha-galactosidase from Pedobacter saltans
8GZD	;	1.1	;	CRYSTAL STRUCTURE OF A NOVEL ALPHA/BETA HYDROLASE FROM THERMOMONOSPORA CURVATA IN APO FORM
7YKP	;	1.18	;	Crystal structure of a novel alpha/beta hydrolase from thermomonospora curvata with glycerol
7CUV	;	1.45	;	Crystal structure of a novel alpha/beta hydrolase in apo form
7E30	;	1.56	;	Crystal structure of a novel alpha/beta hydrolase in apo form in complex with citrate
7YKQ	;	2.36	;	Crystal structure of a novel alpha/beta hydrolase mutant from thermomonospora curvata in apo form
7YKO	;	1.15	;	Crystal structure of a novel alpha/beta hydrolase mutant from thermomonospora curvata in complex with pentane-1,5-diol
7E31	;	1.38	;	Crystal structure of a novel alpha/beta hydrolase mutant in apo form
1P9G	;	0.84	;	Crystal structure of a novel antifungal protein distinct with five disulfide bridges from Ecommia ulmoides Oliver at atomic resolution
2PH4	;	2.05	;	Crystal structure of a novel Arg49 phospholipase A2 homologue from Zhaoermia mangshanensis venom
2Z5B	;	1.96	;	Crystal Structure of a Novel Chaperone Complex for Yeast 20S Proteasome Assembly
2Z5C	;	2.9	;	Crystal Structure of a Novel Chaperone Complex for Yeast 20S Proteasome Assembly
7CWQ	;	1.65	;	Crystal structure of a novel cutinase from Burkhoderiales bacterium RIFCSPLOWO2_02_FULL_57_36
5IBZ	;	1.611	;	Crystal structure of a novel cyclase (pfam04199).
3ANO	;	1.894	;	Crystal Structure of a Novel Diadenosine 5',5'''-P1,P4-Tetraphosphate Phosphorylase from Mycobacterium tuberculosis H37Rv
3FQM	;	1.9	;	Crystal structure of a novel dimeric form of HCV NS5A domain I protein
3FQQ	;	2.2	;	Crystal structure of a novel dimeric form of HCV NS5A domain I protein
1Z1X	;	3.2	;	Crystal Structure of a novel disintegrin from Saw-scaled viper at 3.2 A resolution
5CNW	;	1.65	;	Crystal structure of a novel disulfide oxidoreductase from Deinococcus radiodurans
5COH	;	1.801	;	Crystal structure of a novel disulfide oxidoreductase from Deinococcus radiodurans crystallized in presence of beta-mercaptoethanol
5CO3	;	1.65	;	Crystal structure of a novel disulfide oxidoreductase from Deinococcus radiodurans crystallized in presence of DTT
1POS	;	2.6	;	CRYSTAL STRUCTURE OF A NOVEL DISULFIDE-LINKED ""TREFOIL"" MOTIF FOUND IN A LARGE FAMILY OF PUTATIVE GROWTH FACTORS
6A85	;	1.45	;	Crystal structure of a novel DNA quadruplex
1M6U	;	2.3	;	Crystal Structure of a Novel DNA-binding domain from Ndt80, a Transcriptional Activator Required for Meiosis in Yeast
1M7U	;	2.8	;	Crystal structure of a novel DNA-binding domain from Ndt80, a transcriptional activator required for meiosis in yeast
3I1C	;	2.2	;	Crystal Structure of a Novel Engineered Diels-Alderase: DA_20_00_A74I
3HOJ	;	2.2	;	Crystal Structure of a Novel Engineered Retroaldolase: RA-22
3B5L	;	1.8	;	Crystal Structure of a Novel Engineered Retroaldolase: RA-61
6KMO	;	1.45	;	Crystal structure of a novel esterase CinB from Enterobacter asburiae
3P2M	;	2.8	;	Crystal Structure of a Novel Esterase Rv0045c from Mycobacterium tuberculosis
1VJ2	;	1.65	;	Crystal structure of a novel family of manganese-containing cupin (tm1459) from thermotoga maritima at 1.65 A resolution
8D8P	;	2.75	;	Crystal structure of a novel fatty acid decarboxylase from Rothia nasimurium
6L2W	;	2.29	;	Crystal structure of a novel fold protein Gp72 from the freshwater cyanophage Mic1
1PC8	;	3.8	;	Crystal Structure of a novel form of mistletoe lectin from Himalayan Viscum album L. at 3.8A resolution
2F48	;	2.11	;	Crystal Structure of A Novel Fructose 1,6-Bisphosphate and AlF3 containing Pyrophosphate-dependent Phosphofructo-1-kinase Complex from Borrelia burgdorferi
1C8B	;	3.0	;	CRYSTAL STRUCTURE OF A NOVEL GERMINATION PROTEASE FROM SPORES OF BACILLUS MEGATERIUM: STRUCTURAL REARRANGEMENTS AND ZYMOGEN ACTIVATION
8D89	;	1.6	;	Crystal structure of a novel GH5 enzyme retrieved from capybara gut metagenome
5CZL	;	2.391	;	Crystal structure of a novel GH8 endo-beta-1,4-glucanase from an Achatina fulica gut metagenomic library
2G6X	;	2.0	;	Crystal structure of a novel green fluorescent protein from marine copepod Pontellina plumata
5I2U	;	2.2	;	Crystal structure of a novel Halo-Tolerant Cellulase from Soil Metagenome
7VPB	;	1.68	;	Crystal structure of a novel hydrolase in apo form
1G2I	;	2.0	;	CRYSTAL STRUCTURE OF A NOVEL INTRACELLULAR PROTEASE FROM PYROCOCCUS HORIKOSHII AT 2 A RESOLUTION
3GUD	;	2.2	;	Crystal structure of a novel intramolecular chaperon
3QQY	;	2.401	;	Crystal structure of a novel LAGLIDADG homing endonuclease, I-OnuI (from Ophiostoma novo-ulmi subsp. americana)
5C54	;	1.601	;	Crystal structure of a novel N-acetylneuraminic acid lyase from Corynebacterium glutamicum
3W20	;	1.77	;	Crystal Structure of a Novel N-Substituted L-Amino Acid Dioxygenase from Burkholderia ambifaria AMMD
3W21	;	1.98	;	Crystal Structure of a Novel N-Substituted L-Amino Acid Dioxygenase in complex with alpha-KG from Burkholderia ambifaria AMMD
2A7T	;	2.2	;	Crystal Structure of a novel neurotoxin from Buthus tamalus at 2.2A resolution.
3C0F	;	1.8	;	Crystal Structure of a novel non-Pfam protein AF1514 from Archeoglobus fulgidus DSM 4304 solved by S-SAD using a Cr X-ray source
8AG1	;	3.303	;	Crystal structure of a novel OX40 antibody
3TJL	;	1.5	;	Crystal Structure of a Novel OYE from the Xylose-fermenting Fungus P. stipitis
5GKV	;	1.901	;	Crystal Structure of a Novel Penicillin-Binding Protein (PBP) Homolog from Caulobacter crescentus
5XG0	;	1.58	;	Crystal structure of a novel PET hydrolase from Ideonella sakaiensis 201-F6
5XFZ	;	1.55	;	Crystal structure of a novel PET hydrolase R103G/S131A mutant from Ideonella sakaiensis 201-F6
5XH3	;	1.3	;	Crystal structure of a novel PET hydrolase R103G/S131A mutant in complex with HEMT from Ideonella sakaiensis 201-F6
5XH2	;	1.2	;	Crystal structure of a novel PET hydrolase R103G/S131A mutant in complex with pNP from Ideonella sakaiensis 201-F6
5XFY	;	1.4	;	Crystal structure of a novel PET hydrolase S131A mutant from Ideonella sakaiensis 201-F6
1T70	;	2.3	;	Crystal structure of a novel phosphatase from Deinococcus radiodurans
1T71	;	2.1	;	Crystal structure of a novel phosphatase Mycoplasma pneumoniaefrom
1YXL	;	1.477	;	Crystal structure of a novel phospholipase A2 from Naja naja sagittifera at 1.5 A resolution
1YXH	;	1.86	;	Crystal structure of a novel phospholipase A2 from Naja naja sagittifera with a strong anticoagulant activity
8XMZ	;	2.5	;	Crystal structure of a novel porphyran-binding carbohydrate binding module
7VPF	;	2.983	;	Crystal structure of a novel putative sugar isomerase from the psychrophilic bacterium Paenibacillus sp. R4
5Y57	;	1.961	;	Crystal structure of a Novel Pyrethroid Hydrolase from Sphingobium faniae JZ-2
5Y5V	;	2.98	;	Crystal structure of a novel Pyrethroid Hydrolase PytH (S78A)
5Y5R	;	1.899	;	Crystal structure of a novel Pyrethroid Hydrolase PytH with BIF
3MVE	;	2.2	;	Crystal structure of a novel pyruvate decarboxylase
4PMU	;	2.857	;	Crystal structure of a novel reducing-end xylose-releasing exo-oligoxylanase (XynA) belonging to GH10 family (space group P1211)
4PMV	;	3.001	;	Crystal structure of a novel reducing-end xylose-releasing exo-oligoxylanase (XynA) belonging to GH10 family (space group P43212)
1LJY	;	2.9	;	Crystal Structure of a Novel Regulatory 40 kDa Mammary Gland Protein (MGP-40) secreted during Involution
5XWG	;	3.002	;	Crystal structure of a novel RNA motif that allows for precise positioning of a metal ion
1YKW	;	2.0	;	Crystal Structure of a Novel RuBisCO-Like Protein from the Green Sulfur Bacterium Chlorobium tepidum
1M5Q	;	2.0	;	Crystal structure of a novel Sm-like archaeal protein from Pyrobaculum aerophilum
4G8O	;	2.71	;	Crystal Structure of a novel small molecule inactivator bound to plasminogen activator inhibitor-1
4G8R	;	2.19	;	Crystal Structure of a novel small molecule inactivator bound to plasminogen activator inhibitor-1
3KMH	;	1.58	;	Crystal Structure of a Novel Sugar Isomerase from E. coli O157:H7
4WAF	;	2.39	;	Crystal Structure of a novel tetrahydropyrazolo[1,5-a]pyrazine in an engineered PI3K alpha
6IO1	;	1.803	;	Crystal structure of a novel thermostable (S)-enantioselective omega-transaminase from Thermomicrobium roseum
4OB8	;	1.801	;	Crystal structure of a novel thermostable esterase from Pseudomonas putida ECU1011
7D88	;	2.34482	;	Crystal structure of a novel thermostable GH10 xylanase XynA
8UZ7	;	1.7	;	Crystal structure of a novel triose phosphate isomerase identified on the shrimp transcriptome
3LX7	;	1.78	;	Crystal structure of a Novel Tudor domain-containing protein SGF29
3PM2	;	1.8	;	Crystal structure of a novel type of odorant binding protein from Anopheles gambiae belonging to the c+ class
7MRJ	;	2.12	;	Crystal structure of a novel ubiquitin-like TINCR
4CE7	;	1.9	;	Crystal structure of a novel unsaturated beta-glucuronyl hydrolase enzyme, belonging to family GH105, involved in ulvan degradation
2GEF	;	2.2	;	Crystal structure of a Novel viral protease with a serine/lysine catalytic dyad mechanism
3KPZ	;	1.9	;	Crystal structure of a novel vitamin D3 analogue, ZK203278 showing dissociated profile
5XEV	;	1.4	;	Crystal Structure of a novel Xaa-Pro dipeptidase from Deinococcus radiodurans
5XO6	;	2.38	;	Crystal structure of a novel ZEN lactonase mutant
5XO7	;	1.88	;	Crystal structure of a novel ZEN lactonase mutant with ligand a
5XO8	;	1.88	;	Crystal structure of a novel ZEN lactonase mutant with ligand Z
4IJ5	;	1.5	;	Crystal Structure of a Novel-type Phosphoserine Phosphatase from <i>Hydrogenobacter thermophilus</i> TK-6
4IJ6	;	1.8	;	Crystal Structure of a Novel-type Phosphoserine Phosphatase Mutant (H9A) from <i>Hydrogenobacter thermophilus</i> TK-6 in Complex with L-phosphoserine
3B7C	;	1.7	;	CRYSTAL STRUCTURE OF A NTF-2 LIKE PROTEIN OF UNKNOWN FUNCTION (SO_0125) FROM SHEWANELLA ONEIDENSIS MR-1 AT 1.70 A RESOLUTION
3FKA	;	1.69	;	CRYSTAL STRUCTURE OF A NTF-2 LIKE PROTEIN OF UNKNOWN FUNCTION (SPO1084) FROM SILICIBACTER POMEROYI DSS-3 AT 1.69 A RESOLUTION
3DMC	;	1.65	;	CRYSTAL STRUCTURE OF A NTF2-LIKE PROTEIN (AVA_2261) FROM ANABAENA VARIABILIS ATCC 29413 AT 1.65 A RESOLUTION
3SBU	;	2.15	;	Crystal structure of a ntf2-like protein (BF2862) from Bacteroides fragilis NCTC 9343 at 2.15 A resolution
3EC9	;	1.6	;	CRYSTAL STRUCTURE OF A NTF2-like protein (BTH_I0051) FROM BURKHOLDERIA THAILANDENSIS E264 AT 1.60 A RESOLUTION
3FGY	;	1.59	;	CRYSTAL STRUCTURE OF A NTF2-LIKE PROTEIN (BXE_B1094) FROM BURKHOLDERIA XENOVORANS LB400 AT 1.59 A RESOLUTION
2R4I	;	1.6	;	CRYSTAL STRUCTURE OF A NTF2-LIKE PROTEIN (CHU_1428) FROM CYTOPHAGA HUTCHINSONII ATCC 33406 AT 1.60 A RESOLUTION
4R1K	;	2.56	;	Crystal structure of a NTF2-like protein (EUBSIR_01394) from Eubacterium siraeum DSM 15702 at 2.56 A resolution
3EBT	;	1.3	;	Crystal structure of a ntf2-like protein of unknown function (bpss0132) from burkholderia pseudomallei k96243 at 1.30 A resolution
3DUK	;	2.2	;	CRYSTAL STRUCTURE OF A NTF2-LIKE PROTEIN OF UNKNOWN FUNCTION (MFLA_0564) FROM METHYLOBACILLUS FLAGELLATUS KT AT 2.200 A RESOLUTION
3FH1	;	1.6	;	Crystal structure of a ntf2-like protein of unknown function (mll8193) from mesorhizobium loti at 1.60 A resolution
3F7S	;	2.11	;	CRYSTAL STRUCTURE OF A NTF2-LIKE PROTEIN OF UNKNOWN FUNCTION (PP_4556) FROM PSEUDOMONAS PUTIDA KT2440 AT 2.11 A RESOLUTION
3BLZ	;	1.75	;	Crystal structure of a ntf2-like protein of unknown function (sbal_0622) from shewanella baltica os155 at 1.75 A resolution
6TAH	;	1.3	;	Crystal structure of a Nu-class Glutathione-S-Transferase from Pseudomonas aeruginosa PACS2 bound to glutathione
5I9E	;	2.8	;	Crystal structure of a nuclear actin ternary complex
4DJT	;	1.8	;	Crystal structure of a nuclear GTP-binding protein from Encephalitozoon cuniculi bound to GDP-Mg2+
4ZEY	;	1.5	;	Crystal structure of a nuclear receptor binding factor 2 MIT domain (NRBF2) from Homo sapiens at 1.50 A resolution
7DOG	;	2.91	;	Crystal structure of a nuclease and capping domain of SbcD from Staphylococcus aureus
1EGK	;	3.1	;	CRYSTAL STRUCTURE OF A NUCLEIC ACID FOUR-WAY JUNCTION
4MHC	;	2.4	;	Crystal Structure of a Nucleoporin
4LIR	;	2.46	;	Crystal structure of a nucleoporin 35kDa (NUP35) from Homo sapiens at 2.46 A resolution
3PJ9	;	2.1	;	Crystal structure of a Nucleoside Diphosphate Kinase from Campylobacter jejuni
5U2I	;	1.4	;	Crystal structure of a nucleoside diphosphate kinase from Naegleria fowleri
6AY1	;	2.05	;	Crystal structure of a nucleoside diphosphate kinase NDK from Helicobacter pylori
5U7P	;	1.89	;	Crystal structure of a nucleoside triphosphate diphosphohydrolase (NTPDase) from the legume Trifolium repens
5U7W	;	1.76	;	Crystal structure of a nucleoside triphosphate diphosphohydrolase (NTPDase) from the legume Trifolium repens in complex with adenine and phosphate
5U7V	;	2.15	;	Crystal structure of a nucleoside triphosphate diphosphohydrolase (NTPDase) from the legume Trifolium repens in complex with AMP
5U7X	;	2.6	;	Crystal structure of a nucleoside triphosphate diphosphohydrolase (NTPDase) from the legume Vigna unguiculata subsp. cylindrica (Dolichos biflorus) in complex with phosphate and manganese
3E48	;	1.6	;	Crystal structure of a nucleoside-diphosphate-sugar epimerase (SAV0421) from Staphylococcus aureus, Northeast Structural Genomics Consortium Target ZR319
6KXV	;	3.63	;	Crystal structure of a nucleosome containing Leishmania histone H3
5OGE	;	3.22	;	Crystal structure of a nucleotide sugar transporter
6QSK	;	3.394	;	Crystal structure of a nucleotide sugar transporter with bound nucleotide monophosphate.
5OGK	;	3.6	;	Crystal structure of a nucleotide sugar transporter with bound nucleotide sugar.
1GAJ	;	2.5	;	CRYSTAL STRUCTURE OF A NUCLEOTIDE-FREE ATP-BINDING CASSETTE FROM AN ABC TRANSPORTER
3EXQ	;	2.0	;	Crystal structure of a NUDIX family hydrolase from Lactobacillus brevis
8SXS	;	1.57	;	Crystal structure of a Nudix hydrolase effector from Magnaporthe oryzae
3FCM	;	2.2	;	Crystal structure of a NUDIX hydrolase from Clostridium perfringens
6UUF	;	2.1	;	Crystal structure of a Nudix Hydrolase from M. Smegmatis, RenU
1K2E	;	1.8	;	crystal structure of a nudix protein from Pyrobaculum aerophilum
1JRK	;	2.4	;	Crystal Structure of a Nudix Protein from Pyrobaculum aerophilum Reveals a Dimer with Intertwined Beta Sheets
1ZBX	;	2.5	;	Crystal structure of a Orc1p-Sir1p complex
7BU0	;	2.43	;	Crystal structure of a OTU deubiquitinase in complex with Ub-PA
4E3Z	;	2.0	;	Crystal Structure of a oxidoreductase from Rhizobium etli CFN 42
2HGZ	;	2.5	;	Crystal structure of a p-benzoyl-L-phenylalanyl-tRNA synthetase
5O90	;	2.49	;	Crystal structure of a P38alpha T185G mutant in complex with TAB1 peptide.
2GEQ	;	2.3	;	Crystal Structure of a p53 Core Dimer Bound to DNA
3EXJ	;	2.0	;	Crystal Structure of a p53 Core Tetramer Bound to DNA
3EXL	;	2.2	;	Crystal Structure of a p53 Core Tetramer Bound to DNA
5DYM	;	1.894	;	Crystal structure of a PadR family transcription regulator from hypervirulent Clostridium difficile R20291 - CdPadR_0991 to 1.89 Angstrom resolution
1PDN	;	2.5	;	CRYSTAL STRUCTURE OF A PAIRED DOMAIN-DNA COMPLEX AT 2.5 ANGSTROMS RESOLUTION REVEALS STRUCTURAL BASIS FOR PAX DEVELOPMENTAL MUTATIONS
3EU7	;	2.2	;	Crystal Structure of a PALB2 / BRCA2 complex
5KWV	;	2.25	;	Crystal Structure of a Pantoate-beta-alanine Ligase from Neisseria gonorrhoeae with bound AMPPNP
5UCR	;	2.25	;	Crystal Structure of a Pantoate-beta-alanine Ligase from Neisseria gonorrhoeae with bound AMPPNP and Alanine
2A7X	;	1.7	;	Crystal Structure of A Pantothenate synthetase complexed with AMP
2A86	;	1.85	;	Crystal structure of A Pantothenate synthetase complexed with AMP and beta-alanine
2A84	;	1.55	;	Crystal structure of A Pantothenate synthetase complexed with ATP
1MOP	;	1.6	;	Crystal Structure of a Pantothenate Synthetase from M. tuberculosis
1N2H	;	2.0	;	Crystal Structure of a Pantothenate Synthetase from M. tuberculosis in complex with a reaction intermediate, pantoyl adenylate
1N2G	;	1.8	;	Crystal Structure of a Pantothenate Synthetase from M. tuberculosis in complex with AMPCPP
1N2E	;	1.6	;	Crystal Structure of a Pantothenate Synthetase from M. tuberculosis in complex with AMPCPP and pantoate
1N2B	;	1.7	;	Crystal Structure of a Pantothenate Synthetase from M. tuberculosis in complex with AMPCPP and pantoate, higher occupancy of pantoate and lower occupancy of AMPCPP in subunit A
1N2J	;	1.8	;	Crystal Structure of a Pantothenate Synthetase from M. tuberculosis in complex with pantoate
2A88	;	1.7	;	Crystal structure of A Pantothenate synthetase, apo enzyme in C2 space group
2B1M	;	2.0	;	Crystal structure of a papain-fold protein without the catalytic cysteine from seeds of Pachyrhizus erosus
2B1N	;	2.4	;	Crystal structure of a papain-fold protein without the catalytic cysteine from seeds of Pachyrhizus erosus
3BCN	;	2.85	;	Crystal structure of a papain-like cysteine protease Ervatamin-A complexed with irreversible inhibitor E-64
3S8K	;	1.7	;	Crystal structure of a papaya latex serine protease inhibitor (PPI) at 1.7A resolution
3S8J	;	2.6	;	Crystal structure of a papaya latex serine protease inhibitor (PPI) at 2.6A resolution
5I7Z	;	1.801	;	Crystal structure of a Par-6 PDZ-Crumbs 3 C-terminal peptide complex
1RZX	;	2.1	;	Crystal Structure of a Par-6 PDZ-peptide Complex
4H7R	;	1.33	;	Crystal structure of a parallel 4-helix coiled coil CC-Hex-II
4H8F	;	1.88	;	Crystal structure of a parallel 4-helix coiled coil CC-Hex-II- 22
3R3K	;	2.2009	;	Crystal structure of a parallel 6-helix coiled coil
3R46	;	1.751	;	Crystal structure of a parallel 6-helix coiled coil CC-hex-D24
4H8L	;	1.7501	;	Crystal structure of a parallel 6-helix coiled coil CC-Hex-D24-A5/7C
4H8M	;	1.4292	;	Crystal structure of a parallel 6-helix coiled coil CC-Hex-H24-A5/7C
4H8G	;	1.699	;	crystal structure of a parallel 6-helix coiled coil CC-Hex-IL- 22
4H8O	;	1.598	;	Crystal structure of a parallel 6-helix coiled coil CC-Hex-N24
3VMX	;	1.45	;	Crystal Structure of a parallel coiled-coil dimerization domain from the voltage-gated proton channel
3VN0	;	1.37	;	Crystal Structure of a parallel coiled-coil dimerization domain from the voltage-gated proton channel (mutation/C245S)
3VMZ	;	1.55	;	Crystal Structure of a parallel coiled-coil dimerization domain from the voltage-gated proton channel (oxidation/H2O2)
3VMY	;	1.47	;	Crystal Structure of a parallel coiled-coil dimerization domain from the voltage-gated proton channel (REDUCTION/DTT)
6G67	;	1.77	;	Crystal structure of a parallel eight-helix coiled coil CC-Type2-II
6G6F	;	1.7	;	Crystal structure of a parallel eight-helix coiled coil CC-Type2-LF
6YB2	;	1.18	;	Crystal structure of a parallel hexameric coiled coil CC-Type2-(TaId)2
6YAZ	;	1.94	;	Crystal structure of a parallel hexameric coiled coil CC-Type2-(TaId)5
6YB0	;	1.86	;	Crystal structure of a parallel hexameric coiled coil CC-Type2-(TaSd)2
6G6E	;	1.26	;	Crystal structure of a parallel seven-helix coiled coil CC-Type2-deLI
6G69	;	2.2	;	Crystal structure of a parallel seven-helix coiled coil CC-Type2-IL-Sg-L17E
6G66	;	1.6	;	Crystal structure of a parallel seven-helix coiled coil CC-Type2-IV
6G6G	;	1.7	;	Crystal structure of a parallel six-helix coiled coil CC-Type2-FI
6G68	;	1.95	;	Crystal structure of a parallel six-helix coiled coil CC-Type2-IL-Sg
6G6A	;	2.701	;	Crystal structure of a parallel six-helix coiled coil CC-Type2-LL
6G6C	;	1.55	;	Crystal structure of a parallel six-helix coiled coil CC-Type2-LL-L17E
6G6B	;	2.3	;	Crystal structure of a parallel six-helix coiled coil CC-Type2-LL-L17Q
6G6D	;	2.05	;	Crystal structure of a parallel six-helix coiled coil CC-Type2-LL-Sg
6G65	;	1.15	;	Crystal structure of a parallel six-helix coiled coil CC-Type2-VV
1KZQ	;	1.7	;	crystal structure of a parasite protein
4J76	;	2.34	;	Crystal Structure of a parasite tRNA synthetase, ligand-free
4J75	;	2.4	;	Crystal Structure of a parasite tRNA synthetase, product-bound
3SDE	;	1.9	;	Crystal structure of a paraspeckle-protein heterodimer, PSPC1/NONO
7O0N	;	1.89	;	Crystal structure of a ParB E93A mutant from Myxococcus xanthus bound to CDP and monothiophosphate
7BNR	;	1.7	;	Crystal structure of a ParB Q52A mutant from Myxococcus xanthus bound to CTPyS
4IKE	;	1.48	;	Crystal Structure of a partly open ATP-lid of liganded Adenylate kinase
1XJ9	;	2.6	;	Crystal structure of a partly self-complementary peptide nucleic acid (PNA) oligomer showing a duplex-triplex network
3PXP	;	2.3	;	Crystal structure of a PAS and DNA binding domain containing protein (Caur_2278) from CHLOROFLEXUS AURANTIACUS J-10-FL at 2.30 A resolution
3OLO	;	2.094	;	Crystal structure of a PAS domain from two-component sensor histidine kinase
8P8X	;	1.46	;	Crystal structure of a pathogenic mutant variant of human mitochodnrial PheRS
1ZEV	;	1.58	;	Crystal Structure of a Pathogenic RNA: CUG Repeats
4MJS	;	2.5	;	crystal structure of a PB1 complex
1WMH	;	1.5	;	Crystal structure of a PB1 domain complex of Protein kinase c iota and Par6 alpha
3KE4	;	1.9	;	Crystal structure of a PduO-Type ATP:Cob(I)alamin adenosyltransferase from Bacillus cereus
3KE5	;	2.0	;	Crystal structure of a PduO-Type ATP:Cob(I)alamin adenosyltransferase from Bacillus cereus in a complex with ATP
2ZHY	;	1.8	;	Crystal structure of a pduO-type ATP:cobalamin adenosyltransferase from Burkholderia thailandensis
2ZHZ	;	1.8	;	Crystal structure of a pduO-type ATP:cobalamin adenosyltransferase from Burkholderia thailandensis
4L8N	;	2.5	;	Crystal structure of a PDZ domain protein (BDI_1242) from Parabacteroides distasonis ATCC 8503 at 2.50 A resolution
4W4K	;	1.95	;	Crystal structure of a PE25-PPE41 heterodimer from a type VII secretion system of M. tuberculosis
1X8Z	;	2.86	;	Crystal structure of a pectin methylesterase inhibitor from Arabidopsis thaliana
5ZE8	;	1.6	;	Crystal structure of a penta-heme cytochrome c552 from Thermochromatium tepidum
4RV3	;	2.0	;	Crystal structure of a pentafluoro-Phe incorporated Phosphatidylinositol-specific phospholipase C (H258X)from Staphylococcus aureus
4DMI	;	1.5	;	Crystal Structure of a Pentameric Capsid Protein Isolated from Metagenomic Phage Sequences (CASP)
4E27	;	2.4	;	Crystal Structure of a Pentameric Capsid Protein Isolated from Metagenomic Phage Sequences Solved by Iodide SAD Phasing
1D64	;	2.1	;	CRYSTAL STRUCTURE OF A PENTAMIDINE-OLIGONUCLEOTIDE COMPLEX: IMPLICATIONS FOR DNA-BINDING PROPERTIES
2O6W	;	2.4	;	Crystal Structure of a Pentapeptide Repeat Protein (Rfr23) from the cyanobacterium Cyanothece 51142
6NQC	;	1.94	;	Crystal structure of a peptidase from an acI-B1 Actinobacterium
7SIQ	;	2.95	;	Crystal structure of a peptide chain release factor 3 (prfC) from Stenotrophomonas maltophilia bound to GDP
5HGW	;	1.6	;	Crystal structure of a peptide deformylase from Burkholderia ambifaria
5I2B	;	1.7	;	Crystal structure of a peptide deformylase from Burkholderia ambifaria with actinonin
5J46	;	1.95	;	Crystal structure of a Peptide Deformylase from Burkholderia multivorans
5T8Z	;	1.85	;	Crystal structure of a peptide deformylase from Burkholderia multivorans in complex with actinonin
5KOB	;	1.6	;	Crystal structure of a peptide deformylase from Burkholderia xenovorans
5VCP	;	1.95	;	Crystal structure of a peptide deformylase from Burkholderia xenovorans in complex with actinonin
4WXK	;	2.05	;	Crystal structure of a peptide deformylase from Haemophilus influenzae
4WXL	;	2.33	;	Crystal structure of a peptide deformylase from Haemophilus influenzae complex with Actinonin
6CAZ	;	1.5	;	Crystal structure of a peptide deformylase from Legionella pneumophila
6CK7	;	1.65	;	Crystal structure of a peptide deformylase from Legionella pneumophila bound to actinonin
4DR8	;	1.55	;	Crystal structure of a peptide deformylase from Synechococcus elongatus
4DR9	;	1.9	;	Crystal structure of a peptide deformylase from synechococcus elongatus in complex with actinonin
1PUP	;	1.7	;	CRYSTAL STRUCTURE OF A PEPTIDE NUCLEIC ACID (PNA) DUPLEX AT 1.7 ANGSTROMS RESOLUTION
1HZS	;	1.82	;	Crystal structure of a peptide nucleic acid duplex (BT-PNA) containing a bicyclic analogue of thymine
4W6V	;	3.01819	;	Crystal structure of a peptide transporter from Yersinia enterocolitica at 3 A resolution
3SPV	;	1.3	;	Crystal structure of a peptide-HLA complex
2OQO	;	2.1	;	Crystal structure of a peptidoglycan glycosyltransferase from a class A PBP: insight into bacterial cell wall synthesis
5UY7	;	1.65	;	Crystal structure of a peptidoglycan glycosyltransferase from Burkholderia ambifaria
6U0O	;	2.6	;	Crystal structure of a peptidoglycan release complex, SagB-SpdC, in lipidic cubic phase
1XP4	;	2.8	;	Crystal structure of a peptidoglycan synthesis regulatory factor (PBP3) from Streptococcus pneumoniae
3UCH	;	2.5	;	Crystal structure of a peptidyl-prolyl cis-trans isomerase E (PPIE) from Homo sapiens at 2.50 A resolution
4DZ3	;	2.0	;	Crystal structure of a Peptidyl-prolyl cis-trans isomerase with surface mutation M61H from Burkholderia pseudomallei complexed with FK506
4DZ2	;	2.0	;	Crystal structure of a Peptidyl-prolyl cis-trans isomerase with surface mutation R92G from Burkholderia pseudomallei complexed with FK506
7KGC	;	1.95	;	Crystal structure of a perchloric acid-soluble protein (PSP) from Trichomonas vaginalis at 1.95 A
3I09	;	1.8	;	CRYSTAL STRUCTURE OF A PERIPLASMIC BINDING PROTEIN (BMA2936) FROM BURKHOLDERIA MALLEI AT 1.80 A RESOLUTION
4G54	;	1.55	;	Crystal structure of a periplasmic domain of the EpsAB fusion protein of the Vibrio vulnificus type II secretion system
2R79	;	2.4	;	Crystal Structure of a Periplasmic Heme Binding Protein from Pseudomonas aeruginosa
2R7A	;	2.05	;	Crystal Structure of a Periplasmic Heme Binding Protein from Shigella dysenteriae
3I6V	;	2.0	;	Crystal structure of a periplasmic His/Glu/Gln/Arg/opine family-binding protein from Silicibacter pomeroyi in complex with lysine
3CVG	;	1.97	;	Crystal structure of a periplasmic putative metal binding protein
7CJR	;	2.28	;	Crystal structure of a periplasmic sensor domain of histidine kinase VbrK
4Z0N	;	1.26	;	Crystal Structure of a Periplasmic Solute binding protein (IPR025997) from Streptobacillus moniliformis DSM-12112 (Smon_0317, TARGET EFI-511281) with bound D-Galactose
2ZZV	;	1.4	;	Crystal Structure of a Periplasmic Substrate Binding Protein in Complex with Calcium and Lactate
2ZZX	;	1.75	;	Crystal Structure of a Periplasmic Substrate Binding Protein in Complex with Lactate
2ZZW	;	1.95	;	Crystal Structure of a Periplasmic Substrate Binding Protein in Complex with Zinc and Lactate
2QVC	;	2.4	;	Crystal structure of a periplasmic sugar ABC transporter from Thermotoga maritima
3H75	;	1.6	;	Crystal Structure of a Periplasmic Sugar-binding protein from the Pseudomonas fluorescens
4GXZ	;	2.04	;	Crystal structure of a periplasmic thioredoxin-like protein from Salmonella enterica serovar Typhimurium
5NL9	;	1.9	;	Crystal structure of a peroxide stress regulator from Leptospira interrogans
4ARJ	;	2.593	;	Crystal structure of a pesticin (translocation and receptor binding domain) from Y. pestis and T4-lysozyme chimera
7YM9	;	1.34	;	Crystal structure of a PET hydrolase from Cryptosporangium aurantiacum
7YME	;	1.5	;	Crystal structure of a PET hydrolase M9 variant from Cryptosporangium aurantiacum
7SH6	;	1.44	;	Crystal structure of a PET hydrolase mutant from Ideonella Sakaiensis
3NPP	;	2.15	;	Crystal structure of a Pfam DUF1093 family protein (BSU39620) from Bacillus subtilis at 2.15 A resolution
3O0L	;	1.81	;	Crystal structure of a Pfam DUF1425 family member (Shew_1734) from Shewanella sp. pv-4 at 1.81 a resolution
3NO5	;	1.9	;	Crystal structure of a Pfam DUF849 domain containing protein (Reut_A1631) from Ralstonia eutropha JMP134 at 1.90 A resolution
3L3F	;	1.9	;	Crystal structure of a PFU-PUL domain pair of Saccharomyces cerevisiae Doa1/Ufd3
3B77	;	2.42	;	Crystal structure of a ph domain containing bacterial protein (exig_2160) from exiguobacterium sibiricum 255-15 at 2.42 A resolution
3BJQ	;	2.05	;	CRYSTAL STRUCTURE OF A PHAGE-RELATED PROTEIN (BB3626) FROM BORDETELLA BRONCHISEPTICA RB50 AT 2.05 A RESOLUTION
5FB1	;	2.1	;	Crystal Structure of a PHD finger bound to histone H3 K9me3 peptide
5FB0	;	2.702	;	Crystal Structure of a PHD finger bound to histone H3 T3ph peptide
3FF0	;	1.9	;	Crystal structure of a phenazine biosynthesis-related protein (phzb2) from pseudomonas aeruginosa at 1.90 A resolution
3EGR	;	2.65	;	CRYSTAL STRUCTURE OF A PHENYLACETATE-COA OXYGENASE SUBUNIT PAAB (REUT_A2307) FROM RALSTONIA EUTROPHA JMP134 AT 2.65 A RESOLUTION
3BFH	;	2.0	;	Crystal structure of a pheromone binding protein from Apis mellifera in complex with hexadecanoic acid
3BFB	;	2.15	;	Crystal structure of a pheromone binding protein from Apis mellifera in complex with the 9-keto-2(E)-decenoic acid
3BFA	;	2.25	;	Crystal structure of a pheromone binding protein from Apis mellifera in complex with the Queen mandibular pheromone
3CDN	;	2.0	;	Crystal structure of a pheromone binding protein from Apis mellifera soaked at pH 4.0
3CAB	;	1.95	;	Crystal structure of a pheromone binding protein from Apis mellifera soaked at pH 7.0
3FE6	;	1.8	;	Crystal structure of a pheromone binding protein from Apis mellifera with a serendipitous ligand at pH 5.5
3FE8	;	1.9	;	Crystal structure of a pheromone binding protein from Apis mellifera with a serendipitous ligand soaked at pH 4.0
3FE9	;	1.75	;	Crystal structure of a pheromone binding protein from Apis mellifera with a serendipitous ligand soaked at pH 7.0
1OW4	;	1.6	;	Crystal structure of a pheromone binding protein from the cockroach Leucophaea maderae in complex with the fluorescent reporter ANS (1-anilinonaphtalene-8-sulfonic acid),
3D73	;	2.03	;	Crystal structure of a pheromone binding protein mutant D35A, from Apis mellifera, at pH 7.0
3D74	;	2.1	;	Crystal structure of a pheromone binding protein mutant D35A, from Apis mellifera, soaked at pH 5.5
3D75	;	2.3	;	Crystal structure of a pheromone binding protein mutant D35N, from Apis mellifera, at pH 5.5
3D77	;	1.7	;	Crystal structure of a pheromone binding protein mutant D35N, from Apis mellifera, soaked at pH 4.0
3D76	;	1.9	;	Crystal structure of a pheromone binding protein mutant D35N, from Apis mellifera, soaked at pH 7.0
4EF1	;	1.9	;	Crystal structure of a pheromone cOB1 precursor/lipoprotein, YaeC family (EF2496) from Enterococcus faecalis V583 at 1.90 A resolution
4EF2	;	2.1	;	Crystal structure of a pheromone cOB1 precursor/lipoprotein, YaeC family (EF2496) from Enterococcus faecalis V583 at 2.10 A resolution
6EKE	;	1.7	;	crystal structure of a Pholiota squarrosa lectin unliganded
1MH8	;	1.86	;	Crystal Structure of a Phopholipase A2 Monomer with Isoleucine at Second Position
2ISN	;	1.9	;	Crystal structure of a phosphatase from a pathogenic strain Toxoplasma gondii
3D8K	;	2.71	;	Crystal structure of a phosphatase from a toxoplasma gondii
5YHT	;	2.87	;	Crystal structure of a phosphatase from Mycobacterium tuberculosis in complex with its substrate
1SRR	;	1.9	;	CRYSTAL STRUCTURE OF A PHOSPHATASE RESISTANT MUTANT OF SPORULATION RESPONSE REGULATOR SPO0F FROM BACILLUS SUBTILIS
4H1X	;	1.77	;	Crystal structure of a phosphate ABC transporter, phosphate-binding protein (SP_2084) from Streptococcus pneumoniae TIGR4 at 1.77 A resolution
4PQJ	;	1.86	;	Crystal structure of a phosphate binding protein
4Q8R	;	1.65	;	Crystal structure of a Phosphate Binding Protein (PBP-1) from Clostridium perfringens
3IHS	;	1.15	;	Crystal Structure of a Phosphocarrier Protein HPr from Bacillus anthracis str. Ames
3DRW	;	1.9	;	Crystal Structure of a Phosphofructokinase from Pyrococcus horikoshii OT3 with AMP
1MTO	;	3.2	;	Crystal structure of a Phosphofructokinase mutant from Bacillus stearothermophilus bound with fructose-6-phosphate
4EO9	;	2.45	;	Crystal structure of a phosphoglycerate mutase gpm1 from Mycobacterium leprae
4EMB	;	2.3	;	Crystal structure of a phosphoglycerate mutase gpmA from Borrelia burgdorferi B31
4HY3	;	2.8	;	Crystal structure of a phosphoglycerate oxidoreductase from rhizobium etli
1BYR	;	2.0	;	CRYSTAL STRUCTURE OF A PHOSPHOLIPASE D FAMILY MEMBER, NUC FROM SALMONELLA TYPHIMURIUM
4G32	;	1.75	;	Crystal Structure of a Phospholipid-Lipoxygenase Complex from Pseudomonas aeruginosa at 1.75A (P21212)
4G33	;	2.03	;	Crystal Structure of a Phospholipid-Lipoxygenase Complex from Pseudomonas aeruginosa at 2.0 A (C2221)
2VQR	;	1.42	;	Crystal structure of a phosphonate monoester hydrolase from rhizobium leguminosarum: a new member of the alkaline phosphatase superfamily
5TS2	;	2.3	;	Crystal structure of a phosphopantetheine adenylyltransferase (CoaD, PPAT) from Pseudomonas aeruginosa bound to dephospho coenzyme A
5VK4	;	2.65	;	Crystal structure of a phosphoribosylformylglycinamidine cyclo-ligase from Neisseria gonorrhoeae bound to AMPPNP and magnesium
1VCH	;	1.94	;	Crystal Structure of a Phosphoribosyltransferase-related protein from Thermus thermophilus
1QWO	;	1.5	;	Crystal structure of a phosphorylated phytase from Aspergillus fumigatus, revealing the structural basis for its heat resilience and catalytic pathway
3D5W	;	2.6	;	Crystal structure of a phosphorylated Polo-like kinase 1 (Plk1) catalytic domain in complex with ADP.
1KHX	;	1.8	;	Crystal structure of a phosphorylated Smad2
3FFR	;	1.75	;	CRYSTAL STRUCTURE OF A PHOSPHOSERINE AMINOTRANSFERASE SERC (CHU_0995) FROM CYTOPHAGA HUTCHINSONII ATCC 33406 AT 1.75 A RESOLUTION
3M1Y	;	2.4	;	Crystal Structure of a Phosphoserine phosphatase (SerB) from Helicobacter pylori
3KD3	;	1.7	;	Crystal structure of a phosphoserine phosphohydrolase-like protein from Francisella tularensis subsp. tularensis SCHU S4
4XK1	;	2.15	;	Crystal Structure of a Phosphoserine/phosphohydroxythreonine Aminotransferase (PSAT) from Pseudomonas aeruginosa with cofactor Pyridoxal Phosphate and bound Glutamate
1TD9	;	2.75	;	Crystal Structure of a Phosphotransacetylase from Bacillus subtilis
1XCO	;	2.85	;	Crystal Structure of a Phosphotransacetylase from Bacillus subtilis in complex with acetylphosphate
1R5J	;	2.7	;	Crystal Structure of a Phosphotransacetylase from Streptococcus pyogenes
4WVX	;	1.9	;	Crystal structure of a phosphotriesterase-like lactonase Gkap in native form
3VK6	;	1.9	;	Crystal structure of a phosphotyrosine binding domain
2I37	;	4.15	;	Crystal structure of a photoactivated rhodopsin
6UBP	;	2.95	;	Crystal structure of a photochemical intermediate of human indoleamine 2,3-dioxygenase 1 in complex with carbon monoxide and tryptophan
2Z1O	;	1.75	;	Crystal structure of a photoswitchable GFP-like protein Dronpa in the bright-state
2Z6Y	;	2.0	;	Crystal structure of a photoswitchable GFP-like protein Dronpa in the bright-state
2Z6Z	;	1.8	;	Crystal structure of a photoswitchable GFP-like protein Dronpa in the bright-state
2OLT	;	2.0	;	Crystal structure of a phou-like protein (so_3770) from shewanella oneidensis mr-1 at 2.00 A resolution
1B8D	;	1.9	;	CRYSTAL STRUCTURE OF A PHYCOUROBILIN-CONTAINING PHYCOERYTHRIN
6UHM	;	2.1	;	Crystal Structure of a Physical Mixture of C148 mGFP and scDNA-1
8J45	;	1.49	;	Crystal structure of a Pichia pastoris-expressed IsPETase variant
4N0P	;	1.75	;	Crystal structure of a pilus assembly protein CpaE (CC_2943) from Caulobacter crescentus CB15 at 1.75 A resolution (PSI Community Target, Shapiro)
2GJG	;	2.25	;	CRYSTAL STRUCTURE OF A PILZ-CONTAINING PROTEIN (PP4397) FROM PSEUDOMONAS PUTIDA KT2440 AT 2.25 A RESOLUTION
1O4W	;	1.9	;	CRYSTAL STRUCTURE OF a PIN (PILT N-TERMINUS) DOMAIN CONTAINING PROTEIN (AF0591) FROM ARCHAEOGLOBUS FULGIDUS AT 1.90 A RESOLUTION
4XYP	;	2.1	;	Crystal structure of a piscine viral fusion protein
5XQ3	;	2.85	;	Crystal structure of a PL 26 exo-rhamnogalacturonan lyase from Penicillium chrysogenum
5XQO	;	3.2	;	Crystal structure of a PL 26 exo-rhamnogalacturonan lyase from Penicillium chrysogenum complexed with tetrameric substrate
5XQG	;	2.74	;	Crystal structure of a PL 26 exo-rhamnogalacturonan lyase from Penicillium chrysogenum complexed with unsaturated galacturonosyl rhamnose
5XQJ	;	2.75	;	Crystal structure of a PL 26 exo-rhamnogalacturonan lyase from Penicillium chrysogenum complexed with unsaturated galacturonosyl rhamnose substituted with galactose
3S18	;	2.2	;	Crystal structure of a plant albumin from cicer arietinum showing hemagglutination
3V6N	;	2.2	;	Crystal structure of a plant albumin from Cicer Arietinum showing hemagglutination
3WIJ	;	1.3	;	Crystal structure of a plant class V chitinase mutant from Cycas revoluta in complex with (GlcNAc)3
5JFY	;	2.101	;	Crystal structure of a plant cytidine deaminase
5IE0	;	2.0	;	Crystal structure of a plant enzyme
5IE2	;	1.85	;	Crystal structure of a plant enzyme
5IE3	;	1.9	;	Crystal structure of a plant enzyme
6W78	;	2.311	;	crystal structure of a plant ice-binding protein
4J2K	;	1.75	;	Crystal structure of a plant trypsin inhibitor EcTI
4J2Y	;	2.0	;	Crystal structure of a plant trypsin inhibitor EcTI in complex with bovine trypsin.
5KSD	;	3.5	;	Crystal Structure of a Plasma Membrane Proton Pump
3K9H	;	2.25	;	Crystal structure of a plasmid partition protein from borrelia burgdorferi at 2.25A resolution
3K9G	;	2.25	;	CRYSTAL STRUCTURE OF A PLASMID PARTITION PROTEIN FROM BORRELIA BURGDORFERI AT 2.25A RESOLUTION, iodide soak
1V4L	;	2.8	;	Crystal structure of a platelet agglutination factor isolated from the venom of Taiwan habu (Trimeresurus mucrosquamatus)
2Z8Z	;	1.8	;	Crystal structure of a platinum-bound S445C mutant of Pseudomonas sp. MIS38 lipase
4EYA	;	3.2	;	Crystal Structure of a Plectonemic RNA Supercoil
4DXZ	;	1.25	;	crystal structure of a PliG-Ec mutant, a periplasmic lysozyme inhibitor of g-type lysozyme from Escherichia coli
3OP7	;	1.7	;	Crystal structure of a PLP-dependent aminotransferase (ZP_03625122.1) from Streptococcus suis 89-1591 at 1.70 A resolution
3P6K	;	2.07	;	Crystal structure of a PLP-dependent aminotransferase (ZP_03625122.1) from Streptococcus suis 89-1591 at 2.07 A resolution
1O69	;	1.84	;	Crystal structure of a PLP-dependent enzyme
1O61	;	1.9	;	Crystal structure of a PLP-dependent enzyme with PLP
6MFQ	;	2.6	;	Crystal structure of a PMS2 variant
7RCB	;	2.0	;	Crystal Structure of a PMS2 VUS
7RCI	;	2.12	;	Crystal Structure of a PMS2 VUS with Substrate
3HV1	;	1.9	;	Crystal structure of a polar amino acid ABC uptake transporter substrate binding protein from Streptococcus thermophilus
2P1J	;	2.5	;	Crystal structure of a polC-type DNA polymerase III exonuclease domain from Thermotoga maritima
5WLS	;	2.496	;	Crystal Structure of a Pollen Receptor Kinase 3
5ZQY	;	1.577	;	Crystal structure of a poly(ADP-ribose) glycohydrolase
4IVE	;	2.3	;	Crystal structure of a polyadenylate-binding protein 3 (PABPC3) from Homo sapiens at 2.30 A resolution
6EQD	;	1.7	;	Crystal structure of a polyethylene terephthalate degrading hydrolase from Ideonella sakaiensis collected at long wavelength
6EQH	;	1.58	;	Crystal structure of a polyethylene terephthalate degrading hydrolase from Ideonella sakaiensis in spacegroup C2221
6EQG	;	1.799	;	Crystal structure of a polyethylene terephthalate degrading hydrolase from Ideonella sakaiensis in spacegroup P21
6EQF	;	1.7	;	Crystal structure of a polyethylene terephthalate degrading hydrolase from Ideonella sakaiensis in spacegroup P212121
1FMO	;	2.2	;	CRYSTAL STRUCTURE OF A POLYHISTIDINE-TAGGED RECOMBINANT CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH THE PEPTIDE INHIBITOR PKI(5-24) AND ADENOSINE
8IS2	;	1.32	;	Crystal structure of a polyketide aromatase/cyclase Abx(+)D from Actinomycetes sp. MA7150.
3PML	;	2.6	;	crystal structure of a polymerase lambda variant with a dGTP analog opposite a templating T
4UBY	;	1.0	;	Crystal structure of a polymorphic beta1 peptide
4MZR	;	2.9	;	Crystal structure of a polypeptide p53 mutant bound to DNA
3S6O	;	1.85	;	Crystal structure of a Polysaccharide deacetylase family protein from Burkholderia pseudomallei
6BE2	;	1.7	;	Crystal structure of a polysaccharide-binding human Fab (F598)
6BE3	;	1.6	;	Crystal structure of a polysaccharide-binding human Fab (F598) in complex with N-acetyl-D-glucosamine (GlcNAc)
6BE4	;	1.9	;	Crystal structure of a polysaccharide-binding human Fab (F598) in complex with nona-N-acetyl-D-glucosamine (9NAc)
3D22	;	1.6	;	Crystal structure of a poplar thioredoxin h mutant, PtTrxh4C61S
3D21	;	2.15	;	Crystal structure of a poplar wild-type thioredoxin h, PtTrxh4
4GHB	;	2.32	;	Crystal structure of a porin-like protein (BACUNI_01323) from Bacteroides uniformis ATCC 8492 at 2.32 A resolution
3TZG	;	2.8	;	Crystal structure of a porin-like protein (BVU_2266) from Bacteroides vulgatus ATCC 8482 at 2.80 A resolution
3OBB	;	2.2	;	Crystal structure of a possible 3-hydroxyisobutyrate Dehydrogenase from pseudomonas aeruginosa pao1
3KHP	;	2.3	;	Crystal structure of a possible dehydrogenase from Mycobacterium tuberculosis at 2.3A resolution
5KOI	;	1.7	;	Crystal Structure of a Possible Enoyl-(acyl-carrier-protein) Reductase from Brucella melitensis
3M8N	;	2.04	;	Crystal structure of a possible gutathione S-tranferase from Rhodopseudomonas palustris
3BQY	;	1.95	;	Crystal structure of a possible TetR family transcriptional regulator from Streptomyces coelicolor A3(2).
3C8G	;	2.5	;	Crystal structure of a possible transciptional regulator YggD from Shigella flexneri 2a str. 2457T
3E8V	;	2.4	;	Crystal structure of a possible transglutaminase-family protein proteolytic fragment from Bacteroides fragilis
4E2P	;	2.36	;	Crystal Structure of a Post-tailoring Hydroxylase (HmtN) Involved in the Himastatin Biosynthesis
4APS	;	3.3	;	Crystal structure of a POT family peptide transporter in an inward open conformation.
6H7U	;	2.8	;	Crystal structure of a POT family transporter in complex with 5-aminolevulinic acid
6HZP	;	2.5	;	Crystal structure of a POT family transporter in complex with 5-aminolevulinic acid
6GZ9	;	3.1	;	Crystal structure of a POT family transporter in complex with prodrug valacyclovir
6EXS	;	2.5	;	Crystal structure of a POT family transporter in complex with thioalcohol conjugated peptide.
5G00	;	2.5	;	CRYSTAL STRUCTURE OF A POTATO STI-KUNITZ BIFUNCTIONAL INHIBITOR OF SERINE AND ASPARTIC PROTEASES IN SPACE GROUP P4322 AND PH 7.4
6TT0	;	2.80003	;	Crystal structure of a potent and reversible dual binding site Acetylcholinesterase chiral inhibitor
4P6A	;	1.398	;	Crystal structure of a potent anti-HIV lectin actinohivin in complex with alpha-1,2-mannotriose
1VSN	;	2.0	;	Crystal structure of a potent small molecule inhibitor bound to cathepsin K
1GT0	;	2.6	;	Crystal structure of a POU/HMG/DNA ternary complex
5JJA	;	2.35	;	Crystal structure of a PP2A B56gamma/BubR1 complex
6TOQ	;	3.164	;	Crystal structure of a PP2A B56y/HTLV-1 integrase complex
1PYI	;	3.2	;	CRYSTAL STRUCTURE OF A PPR1-DNA COMPLEX: DNA RECOGNITION BY PROTEINS CONTAINING A ZN2CYS6 BINUCLEAR CLUSTER
3NUF	;	1.38	;	Crystal structure of a PRD-containing transcription regulator (LSEI_2718) from Lactobacillus casei ATCC 334 at 1.38 A resolution
4U7B	;	3.09	;	Crystal structure of a pre-cleavage Mos1 transpososome
3PUZ	;	2.9	;	Crystal Structure of a pre-translocation state MBP-Maltose transporter complex bound to AMP-PNP
3PV0	;	3.1	;	Crystal Structure of a pre-translocation state MBP-Maltose transporter complex without nucleotide
3DMY	;	2.07	;	Crystal Structure of a predicated acyl-CoA synthetase from E.coli
2P06	;	2.1	;	Crystal structure of a predicted coding region AF_0060 from Archaeoglobus fulgidus DSM 4304
2QTQ	;	1.85	;	Crystal structure of a predicted dna-binding transcriptional regulator (saro_1072) from novosphingobium aromaticivorans dsm at 1.85 A resolution
2RHA	;	2.1	;	Crystal structure of a predicted dna-binding transcriptional regulator (saro_1072) from novosphingobium aromaticivorans dsm at 2.10 A resolution
6ALL	;	2.47	;	Crystal structure of a predicted ferric/iron (III) hydroxymate siderophore substrate binding protein from Bacillus anthracis
1VKD	;	2.1	;	Crystal structure of a predicted glycosidase (tm1225) from thermotoga maritima msb8 at 2.10 A resolution
2IL1	;	2.1	;	Crystal structure of a predicted human GTPase in complex with GDP
2QM3	;	2.05	;	Crystal structure of a predicted methyltransferase from Pyrococcus furiosus
3K0B	;	1.5	;	Crystal structure of a predicted N6-adenine-specific DNA methylase from Listeria monocytogenes str. 4b F2365
2OZV	;	1.7	;	Crystal structure of a predicted O-methyltransferase, protein Atu636 from Agrobacterium tumefaciens.
1O4T	;	1.95	;	Crystal structure of a predicted oxalate decarboxylase (tm1287) from thermotoga maritima at 1.95 A resolution
3MC1	;	1.93	;	Crystal structure of a predicted phosphatase from Clostridium acetobutylicum
2HSZ	;	1.9	;	Crystal structure of a predicted phosphoglycolate phosphatase (hs_0176) from haemophilus somnus 129pt at 1.90 A resolution
1Z85	;	2.12	;	Crystal structure of a predicted rna methyltransferase (tm1380) from thermotoga maritima msb8 at 2.12 A resolution
1WG8	;	2.0	;	Crystal structure of a predicted S-adenosylmethionine-dependent methyltransferase TT1512 from Thermus thermophilus HB8.
3E11	;	1.8	;	Crystal structure of a predicted zincin-like metalloprotease (acel_2062) from acidothermus cellulolyticus 11b at 1.80 A resolution
4RZD	;	2.75	;	Crystal Structure of a PreQ1 Riboswitch
5K83	;	2.39	;	Crystal Structure of a Primate APOBEC3G N-Domain, in Complex with ssDNA
5K81	;	2.006	;	Crystal Structure of a Primate APOBEC3G N-Terminal Domain
5K82	;	2.913	;	Crystal Structure of a Primate APOBEC3G N-Terminal Domain
4UBZ	;	1.001	;	Crystal structure of a prion peptide
4W71	;	1.0	;	Crystal structure of a prion peptide
4WBV	;	1.4	;	Crystal structure of a prion peptide
6EVM	;	2.0	;	Crystal structure of a Pro-9 complexed peptide-substrate-binding domain of human type II collagen prolyl 4-hydroxylase
3SH3	;	2.3	;	Crystal structure of a pro-inflammatory lectin from the seeds of Dioclea wilsonii STANDL
4B4S	;	1.9	;	Crystal Structure of a pro-survival Bcl-2:Bim BH3 complex
3R6O	;	1.95	;	Crystal structure of a probable 2-hydroxyhepta-2,4-diene-1, 7-dioateisomerase from Mycobacterium abscessus
2EUI	;	2.8	;	Crystal structure of a probable acetyltransferase
3G8W	;	2.7	;	Crystal structure of a probable acetyltransferase from Staphylococcus epidermidis ATCC 12228
3PZJ	;	1.85	;	Crystal structure of a probable acetyltransferases (GNAT family) from Chromobacterium violaceum ATCC 12472
3R7K	;	2.5	;	Crystal structure of a probable acyl CoA dehydrogenase from Mycobacterium abscessus ATCC 19977 / DSM 44196
2X5D	;	2.25	;	Crystal Structure of a probable aminotransferase from Pseudomonas aeruginosa
1WJG	;	2.1	;	Crystal structure of a probable ATP binding protein from thermus themophilus HB8
6V45	;	2.6	;	Crystal structure of a Probable carnitine operon oxidoreductase caia from Brucella melitensis
6OME	;	1.95	;	Crystal structure of a probable cytosol aminopeptidase (Leucine aminopeptidase, LAP) from Chlamydia trachomatis D/UW-3/Cx
4FGS	;	1.76	;	Crystal structure of a probable dehydrogenase protein
3OME	;	2.05	;	Crystal structure of a probable ENOYL-COA Hydratase from Mycobacterium Smegmatis
3QXZ	;	1.35	;	Crystal structure of a probable enoyl-CoA hydratase/isomerase from Mycobacterium abscessus
3SLL	;	2.35	;	Crystal structure of a probable enoyl-CoA hydratase/isomerase from Mycobacterium abscessus
3SWX	;	2.1	;	Crystal structure of a probable enoyl-CoA hydratase/isomerase from Mycobacterium abscessus
3TRR	;	2.09	;	Crystal structure of a probable enoyl-CoA hydratase/isomerase from Mycobacterium abscessus
3U0I	;	2.2	;	Crystal Structure of a probable FAD-binding, putative uncharacterized protein from Brucella melitensis
3U5W	;	2.05	;	Crystal Structure of a probable FAD-binding, putative uncharacterized protein from Brucella melitensis, apo form
1WGB	;	2.0	;	Crystal structure of a probable flavoprotein from Thermus thermophilus HB8
1YOA	;	1.9	;	Crystal structure of a probable flavoprotein from Thermus thermophilus HB8
1NNR	;	2.25	;	Crystal structure of a probable fosfomycin resistance protein (PA1129) from Pseudomonas aeruginosa with sulfate present in the active site
3UHJ	;	2.34	;	Crystal structure of a probable glycerol dehydrogenase from Sinorhizobium meliloti 1021
2CXX	;	1.7	;	Crystal structure of a probable GTP-binding protein engB
4DHE	;	2.2	;	Crystal structure of a probable GTP-binding protein engB from Burkholderia thailandensis
4F0J	;	1.5	;	Crystal structure of a probable hydrolytic enzyme (PA3053) from Pseudomonas aeruginosa PAO1 at 1.50 A resolution
3BIL	;	2.5	;	Crystal structure of a probable LacI family transcriptional regulator from Corynebacterium glutamicum
4Z04	;	1.45	;	Crystal structure of a probable lactoylglutathione lyase from Brucella melitensis in complex with glutathione
3ESH	;	2.5	;	Crystal structure of a probable metal-dependent hydrolase from Staphylococcus aureus. Northeast Structural Genomics target ZR314
3HNR	;	2.8	;	Crystal Structure of a probable methyltransferase BT9727_4108 from Bacillus thuringiensis subsp. Northeast Structural Genomics Consortium target id BuR219
3F4K	;	2.3	;	Crystal structure of a probable methyltransferase from Bacteroides thetaiotaomicron. Northeast Structural Genomics target BtR309.
3FJY	;	2.15	;	Crystal structure of a probable MutT1 protein from Bifidobacterium adolescentis
3L5A	;	1.65	;	Crystal structure of a probable NADH-dependent flavin oxidoreductase from Staphylococcus aureus
1WTY	;	2.2	;	Crystal structure of a probable nucleotidyl transferase protein from thermus thermophilus HB8
4EYE	;	2.1	;	Crystal structure of a probable oxidoreductase from Mycobacterium abscessus solved by iodide ion SAD
3F4L	;	2.0	;	Crystal structure of a probable oxidoreductase yhhX in Triclinic form. Northeast Structural Genomics target ER647
4FB5	;	2.61	;	Crystal structure of a probable oxidoreduxtase protein
3UWB	;	1.7	;	Crystal structure of a probable peptide deformylase from strucynechococcus phage S-SSM7 in complex with actinonin
3UWA	;	1.95	;	Crystal structure of a probable peptide deformylase from synechococcus phage S-SSM7
4J07	;	1.95	;	Crystal structure of a PROBABLE RIBOFLAVIN SYNTHASE, BETA CHAIN RIBH (6,7-dimethyl-8-ribityllumazine synthase, DMRL synthase, Lumazine synthase) from Mycobacterium leprae
3GKU	;	2.95	;	Crystal structure of a probable RNA-binding protein from Clostridium symbiosum ATCC 14940
6UJK	;	1.2	;	Crystal Structure of a Probable short-chain type dehydrogenase/reductase (Rv1144) from Mycobacterium tuberculosis with bound NAD
4E6P	;	2.096	;	Crystal structure of a probable sorbitol dehydrogenase (Target PSI-012078) from Sinorhizobium meliloti 1021
3GJY	;	1.47	;	Crystal structure of a probable spermidine synthase from Corynebacterium glutamicum ATCC 13032
3TXV	;	2.8	;	Crystal structure of a probable tagatose 6 phosphate kinase from Sinorhizobium meliloti 1021
3L8M	;	2.4	;	Crystal Structure of a probable thiamine pyrophosphokinase from Staphylococcus saprophyticus subsp. saprophyticus. Northeast Structural Genomics Consortium target id SyR86
6UDG	;	2.65	;	Crystal structure of a Probable thiol peroxidase from Elizabethkingia anophelis NUHP1
3UGS	;	2.457	;	Crystal structure of a probable undecaprenyl diphosphate synthase (uppS) from Campylobacter jejuni
4E7A	;	3.0	;	Crystal structure of a product state assembly of HCV NS5B genotype 2a JFH-1 isolate with beta hairpin deletion bound to primer-template RNA with a 2',3'-ddC
4E78	;	2.9	;	Crystal structure of a product state assembly of HCV NS5B genotype 2a JFH-1 isolate with beta hairpin loop deletion bound to primer-template RNA with 3'-dG
4DJA	;	1.45	;	Crystal structure of a prokaryotic (6-4) photolyase PhrB from Agrobacterium Tumefaciens with an Fe-S cluster and a 6,7-dimethyl-8-ribityllumazine antenna chromophore at 1.45A resolution
3I4I	;	1.89	;	Crystal structure of a prokaryotic beta-1,3-1,4-glucanase (lichenase) derived from a mouse hindgut metagenome
3CHV	;	1.45	;	CRYSTAL STRUCTURE OF a prokaryotic domain of unknown function (DUF849) member (SPOA0042) FROM SILICIBACTER POMEROYI DSS-3 AT 1.45 A RESOLUTION
3E49	;	1.75	;	Crystal structure of a prokaryotic domain of unknown function (duf849) with a tim barrel fold (bxe_c0966) from burkholderia xenovorans lb400 at 1.75 A resolution
3RQU	;	3.089	;	Crystal structure of a prokaryotic pentameric ligand-gated ion channel, ELIC
5Y8E	;	1.804	;	Crystal Structure of a prokaryotic SEFIR domain
5Y8F	;	2.0	;	Crystal Structure of a prokaryotic SEFIR domain
5WTR	;	2.2	;	Crystal structure of a prokaryotic TRIC channel in 0.5 M KCl
3D48	;	2.5	;	Crystal structure of a prolactin receptor antagonist bound to the extracellular domain of the prolactin receptor
3PN9	;	2.0	;	Crystal structure of a proline dipeptidase from streptococcus pneumoniae tigr4
5HV4	;	2.35	;	Crystal Structure of a Prolyl 4-Hydroxylase Complexed with Alpha-ketoglutarate from the Pathogenic Bacterium Bacillus anthracis in C2221
3ITQ	;	1.4	;	Crystal Structure of a Prolyl 4-Hydroxylase from Bacillus anthracis
6SYJ	;	0.81	;	Crystal structure of a ProM2 containing triple-helical collagen peptide.
3KHY	;	1.978	;	Crystal Structure of a propionate kinase from Francisella tularensis subsp. tularensis SCHU S4
4GGB	;	2.0	;	Crystal structure of a proposed galactarolactone cycloisomerase from agrobacterium tumefaciens, TARGET EFI-500704, WITH BOUND CA, DISORDERED LOOPS
4HPN	;	1.6	;	Crystal structure of a proposed galactarolactone cycloisomerase from Agrobacterium Tumefaciens, target EFI-500704, with bound Ca, ordered loops
3WOB	;	2.6	;	Crystal structure of a prostate-specific WGA16 glycoprotein lectin, form I
3WOC	;	2.4	;	Crystal structure of a prostate-specific WGA16 glycoprotein lectin, form II
2IAK	;	3.0	;	Crystal Structure of a protease resistant fragment of the plakin domain of Bullous Pemphigoid Antigen1 (BPAG1)
2OL5	;	2.5	;	Crystal Structure of a protease synthase and sporulation negative regulatory protein PAI 2 from Bacillus stearothermophilus
5OW4	;	3.1	;	Crystal structure of a protease-resistant fragment of the Trypanosoma cruzi gamete fusion protein HAP2 ectodomain
4FQZ	;	2.8	;	Crystal structure of a protease-resistant mutant form of human galectin-8
3WV6	;	1.95	;	Crystal Structure of a protease-resistant mutant form of human galectin-9
8IYM	;	1.94	;	Crystal structure of a protein acetyltransferase, HP0935
8IYO	;	2.4	;	Crystal structure of a protein acetyltransferase, HP0935, acetyl-CoA bound form
2O3A	;	2.2	;	Crystal structure of a protein AF_0751 from Archaeoglobus fulgidus
2IJR	;	2.7	;	Crystal structure of a protein api92 from Yersinia pseudotuberculosis, Pfam DUF1281
6CU3	;	2.5	;	Crystal structure of a protein arginine N-methyltransferase from Naegleria fowleri
6CU5	;	2.7	;	Crystal structure of a protein arginine N-methyltransferase from Naegleria fowleri bound to SAH
3BE3	;	2.04	;	Crystal structure of a protein belonging to pfam DUF1653 from Bordetella bronchiseptica
2PPV	;	2.0	;	CRYSTAL STRUCTURE OF a protein belonging to the UPF0052 (SE_0549) FROM STAPHYLOCOCCUS EPIDERMIDIS ATCC 12228 AT 2.00 A RESOLUTION
6IJ1	;	1.521	;	Crystal structure of a protein from Actinoplanes
5ZZD	;	1.85	;	Crystal structure of a protein from Aspergillus flavus
2OC6	;	1.75	;	Crystal structure of a protein from the duf1801 family (ydhg, bsu05750) from bacillus subtilis at 1.75 A resolution
4WNY	;	2.25	;	Crystal structure of a protein from the universal stress protein family from Burkholderia pseudomallei
2QSB	;	1.3	;	Crystal structure of a protein from uncharacterized family UPF0147 from Thermoplasma acidophilum
2QSD	;	2.5	;	Crystal structure of a protein Il1583 from Idiomarina loihiensis
1RI7	;	2.7	;	crystal structure of a protein in the LRP/ASNC family from the hyperthermophilic archaeon Pyrococcus sp. OT3
2O2Z	;	2.6	;	Crystal structure of a protein member of the upf0052 family (bh3568) from bacillus halodurans at 2.60 A resolution
2O4T	;	1.95	;	CRYSTAL STRUCTURE OF a protein of the DUF1048 family with a left-handed superhelix fold (BH3976) FROM BACILLUS HALODURANS AT 1.95 A RESOLUTION
2HUJ	;	1.74	;	Crystal structure of a protein of uknown function (NP_471338.1) from Listeria innocua at 1.74 A resolution
3NO2	;	1.35	;	Crystal structure of a protein of unknown function (BACCAC_01654) from Bacteroides caccae at 1.35 A resolution
3P02	;	1.55	;	Crystal structure of a protein of unknown function (BACOVA_00267) from Bacteroides ovatus at 1.55 A resolution
3FYB	;	1.8	;	Crystal structure of a protein of unknown function (DUF1244) from Alcanivorax borkumensis
3CJL	;	2.2	;	Crystal structure of a protein of unknown function (eca1910) from pectobacterium atrosepticum scri1043 at 2.20 A resolution
2ICG	;	1.65	;	Crystal structure of a protein of unknown function (NP_472245.1) from Listeria innocua at 1.65 A resolution
2ARH	;	2.46	;	Crystal Structure of a Protein of Unknown Function AQ1966 from Aquifex aeolicus VF5
2GMY	;	1.6	;	Crystal Structure of a Protein of Unknown Function ATU0492 from Agrobacterium tumefaciens, Putative Antioxidant Defence Protein AhpD
5U8J	;	2.52	;	Crystal structure of a protein of unknown function ECL_02571 involved in membrane biogenesis from Enterobacter cloacae
1YLX	;	1.6	;	Crystal Structure of a Protein of Unknown Function from Bacillus stearothermophilus
3F5D	;	2.06	;	Crystal Structure of a protein of unknown function from Bacillus subtilis
2GPI	;	1.6	;	Crystal structure of a protein of unknown function from duf1488 family (shew_3726) from shewanella loihica pv-4 at 1.60 A resolution
3DJM	;	2.51	;	CRYSTAL STRUCTURE OF A PROTEIN OF UNKNOWN FUNCTION FROM DUF427 FAMILY (RSPH17029_0682) FROM RHODOBACTER SPHAEROIDES 2.4.1 AT 2.51 A RESOLUTION
2AZ4	;	2.0	;	Crystal Structure of a Protein of Unknown Function from Enterococcus faecalis V583
3BQT	;	2.9	;	Crystal structure of a protein of unknown function from Listeria monocytogenes, tetragonal form
2PMR	;	1.32	;	Crystal structure of a protein of unknown function from Methanobacterium thermoautotrophicum
3GMI	;	1.91	;	Crystal structure of a protein of unknown function from Methanocaldococcus jannaschii
2GJV	;	2.39	;	Crystal Structure of a Protein of Unknown Function from Salmonella typhimurium
2I5E	;	2.1	;	Crystal Structure of a Protein of Unknown Function MM2497 from Methanosarcina mazei Go1, Probable Nucleotidyltransferase
2IKB	;	1.7	;	Crystal Structure of a Protein of Unknown Function NMB1012 from Neisseria meningitidis
2IG8	;	1.9	;	Crystal structure of a Protein of Unknown Function PA3499 from Pseudomonas aeruginosa
1XV2	;	2.0	;	Crystal Structure of a Protein of Unknown Function Similar to Alpha-acetolactate Decarboxylase from Staphylococcus aureus
1QW2	;	1.5	;	Crystal Structure of a Protein of Unknown Function TA1206 from Thermoplasma acidophilum
1ZVP	;	2.2	;	Crystal Structure of a Protein of Unknown Function VC0802 from Vibrio cholerae, Possible Transport Protein
2QIP	;	1.48	;	Crystal structure of a protein of unknown function VPA0982 from Vibrio parahaemolyticus RIMD 2210633
3CJX	;	2.6	;	Crystal structure of a protein of unknown function with a cupin-like fold (reut_b4571) from ralstonia eutropha jmp134 at 2.60 A resolution
2RGQ	;	1.8	;	Crystal structure of a protein of unknown function with a cystatin-like fold (npun_r3134) from nostoc punctiforme pcc 73102 at 1.80 A resolution
3G0K	;	1.3	;	Crystal structure of a protein of unknown function with a cystatin-like fold (saro_2880) from novosphingobium aromaticivorans dsm at 1.30 A resolution
5VYV	;	2.48	;	Crystal structure of a protein of unknown function YceH/ECK1052 involved in membrane biogenesis from Escherichia coli
1TU9	;	1.2	;	Crystal Structure of a Protein PA3967, a Structurally Highly Homologous to a Human Hemoglobin, from Pseudomonas aeruginosa PAO1
2IAE	;	3.5	;	Crystal structure of a protein phosphatase 2A (PP2A) holoenzyme.
1U32	;	2.0	;	Crystal structure of a Protein Phosphatase-1: Calcineurin Hybrid Bound to Okadaic Acid
3BY7	;	2.6	;	CRYSTAL STRUCTURE OF A PROTEIN STRUCTURALLY SIMILAR TO SM/LSM-LIKE RNA-BINDING PROTEINS (JCVI_PEP_1096686650277) FROM UNCULTURED MARINE ORGANISM AT 2.60 A RESOLUTION
2O8Q	;	1.55	;	CRYSTAL STRUCTURE OF A PROTEIN WITH A CUPIN-LIKE FOLD AND UNKNOWN FUNCTION (BXE_C0505) FROM BURKHOLDERIA XENOVORANS LB400 AT 1.55 A RESOLUTION
2NVN	;	2.5	;	Crystal structure of a protein with a cupin-like fold and unknown function (YP_400729.1) from Synechococcus SP. PCC 7942 (Elongatus) at 2.50 A resolution
4JM1	;	1.4	;	Crystal structure of a protein with alpha-lytic protease prodomain-like fold (BDI_0842) from Parabacteroides distasonis ATCC 8503 at 1.40 A resolution
2IAB	;	2.0	;	Crystal structure of a protein with FMN-binding split barrel fold (NP_828636.1) from Streptomyces avermitilis at 2.00 A resolution
1VQW	;	2.4	;	Crystal structure of a protein with similarity to flavin-containing monooxygenases and to mammalian dimethylalanine monooxygenases
3BL4	;	2.2	;	Crystal structure of a protein with unknown function (arth_0117) from arthrobacter sp. fb24 at 2.20 A resolution
3MSW	;	1.9	;	Crystal structure of a Protein with unknown function (BF3112) from Bacteroides fragilis NCTC 9343 at 1.90 A resolution
4PW1	;	2.1	;	Crystal structure of a protein with unknown function (CLOLEP_02462) from Clostridium leptum DSM 753 at 2.10 A resolution
2OOK	;	1.8	;	Crystal structure of a protein with unknown function (YP_749275.1) from Shewanella Frigidimarina NCIMB 400 at 1.80 A resolution
3GBY	;	1.66	;	Crystal structure of a protein with unknown function CT1051 from Chlorobium tepidum
2IT9	;	1.8	;	Crystal structure of a protein with unknown function from DUF155 family (YP_292156.1) from Prochlorococcus sp. NATL2A at 1.80 A resolution
3OAO	;	2.72	;	Crystal structure of a protein with unknown function from DUF2059 family (PA0856) from PSEUDOMONAS AERUGINOSA at 2.72 A resolution
3OHG	;	1.8	;	Crystal structure of a protein with unknown function from DUF2233 family (BACOVA_00430) from Bacteroides ovatus at 1.80 A resolution
2OOJ	;	1.84	;	CRYSTAL STRUCTURE OF A PROTEIN WITH UNKNOWN FUNCTION FROM DUF3224 FAMILY (SO_1590) FROM SHEWANELLA ONEIDENSIS MR-1 AT 1.84 A RESOLUTION
2RCD	;	2.32	;	CRYSTAL STRUCTURE OF A PROTEIN WITH UNKNOWN FUNCTION FROM DUF3225 FAMILY (ECA3500) FROM PECTOBACTERIUM ATROSEPTICUM SCRI1043 AT 2.32 A RESOLUTION
2O62	;	1.75	;	CRYSTAL STRUCTURE OF A PROTEIN WITH UNKNOWN FUNCTION FROM DUF3598 FAMILY (NPUN_R4044) FROM NOSTOC PUNCTIFORME PCC 73102 AT 1.75 A RESOLUTION
3NPG	;	2.7	;	Crystal structure of a protein with unknown function from DUF364 family (PH1506) from PYROCOCCUS HORIKOSHII at 2.70 A resolution
2RLD	;	1.7	;	CRYSTAL STRUCTURE OF A PROTEIN WITH UNKNOWN FUNCTION FROM S23 RIBOSOMAL PROTEIN FAMILY (BT_0352) FROM BACTEROIDES THETAIOTAOMICRON VPI-5482 AT 1.70 A RESOLUTION
3QKB	;	2.73	;	Crystal structure of a Protein with unknown function which belongs to Pfam DUF74 family (PEPE_0654) from Pediococcus pentosaceus ATCC 25745 at 2.73 A resolution
3NQN	;	1.88	;	Crystal structure of a Protein with unknown function. (DR_2006) from DEINOCOCCUS RADIODURANS at 1.88 A resolution
6XYN	;	2.3	;	Crystal structure of a proteolytic fragment of NarQ comprising sensor and TM domains
6V7M	;	2.0	;	Crystal structure of a proteolytically cleaved, amino terminal domain of apolipoprotein E3
4KA4	;	2.6	;	Crystal structure of a proteolytically defined Zbeta domain of human DAI (ZBP1, DLM-1)
1NKX	;	1.9	;	CRYSTAL STRUCTURE OF A PROTEOLYTICALLY GENERATED FUNCTIONAL MONOFERRIC C-LOBE OF BOVINE LACTOFERRIN AT 1.9A RESOLUTION
1W52	;	2.99	;	Crystal structure of a proteolyzed form of pancreatic lipase related protein 2 from horse
2XUT	;	3.62	;	Crystal structure of a proton dependent oligopeptide (POT) family transporter.
1JDR	;	1.5	;	Crystal Structure of a Proximal Domain Potassium Binding Variant of Cytochrome c Peroxidase
4W5L	;	1.0	;	Crystal structure of a prp peptide
3SBG	;	3.28	;	Crystal structure of a Prp8 C-terminal fragment
2H9F	;	1.95	;	CRYSTAL STRUCTURE OF a PrpF family methylaconitate isomerase (PA0793) FROM PSEUDOMONAS AERUGINOSA AT 1.95 A RESOLUTION
1I6J	;	2.0	;	CRYSTAL STRUCTURE OF A PSEUDO-16-MER DNA WITH STACKED GUANINES AND TWO G-A MISPAIRS COMPLEXED WITH THE N-TERMINAL FRAGMENT OF MOLONEY MURINE LEUKEMIA VIRUS REVERSE TRANSCRIPTASE
3DWO	;	2.2	;	Crystal structure of a Pseudomonas aeruginosa FadL homologue
5XQL	;	2.494	;	Crystal structure of a Pseudomonas aeruginosa transcriptional regulator
5YC9	;	2.9	;	Crystal structure of a Pseudomonas aeruginosa transcriptional regulator
5VJ1	;	2.995	;	Crystal structure of a Pseudomonas malonate decarboxylase hetero-tetramer in complex with coenzyme A
5VIT	;	2.203	;	Crystal structure of a Pseudomonas malonate decarboxylase hetero-tetramer in complex with malonate
4J25	;	1.97	;	Crystal structure of a Pseudomonas putida prolyl-4-hydroxylase (P4H)
4IW3	;	2.697	;	Crystal structure of a Pseudomonas putida prolyl-4-hydroxylase (P4H) in complex with elongation factor Tu (EF-Tu)
7E7H	;	2.2	;	Crystal Structure of a pseudooxynicotine amine oxidase Pnao from Pseudomonas putida S16
7W6O	;	2.2	;	Crystal structure of a PSH1 in complex with J1K
7W6C	;	2.3	;	Crystal structure of a PSH1 in complex with ligand J1K
7W6Q	;	2.2	;	Crystal structure of a PSH1 in complex with ligand J1K
7W69	;	1.56	;	Crystal structure of a PSH1 mutant in complex with EDO
7W66	;	1.96	;	Crystal structure of a PSH1 mutant in complex with ligand
3MYX	;	1.3	;	Crystal structure of a PSPTO_0244 (Protein with unknown function which belongs to Pfam DUF861 family) from Pseudomonas syringae pv. tomato str. DC3000 at 1.30 A resolution
1G9K	;	1.96	;	CRYSTAL STRUCTURE OF A PSYCHROPHILIC ALKALINE PROTEASE FROM PSEUDOMONAS TAC II 18
1OMJ	;	2.38	;	CRYSTAL STRUCTURE OF A PSYCHROPHILIC ALKALINE PROTEASE FROM PSEUDOMONAS TAC II 18
7OTR	;	2.25	;	Crystal structure of a psychrophilic CCA-adding enzyme determined by SAD phasing
7OQX	;	2.2	;	Crystal structure of a psychrophilic CCA-adding enzyme in complex with CMPcPP
6IY4	;	1.59	;	Crystal structure of a psychrophilic marine protease MP inhibitor
2ZQB	;	2.49	;	Crystal structure of a psychrotrophic RNaseHI variant with sextuple thermostabilizing mutations
3P3V	;	1.65	;	Crystal structure of a PTS dependent N-acetyl-galactosamine-IIB component (agaV, SPy_0631) from Streptococcus pyogenes at 1.65 A resolution
2CX0	;	1.8	;	Crystal structure of a PUA domain (APE0525) from the Aeropyrum pernix K1 (sulfate complex)
2CX1	;	1.8	;	Crystal structure of a PUA domain (APE0525) from the Aeropyrum pernix K1 (tartrate complex)
1IB2	;	1.9	;	CRYSTAL STRUCTURE OF A PUMILIO-HOMOLOGY DOMAIN
1M8Z	;	1.9	;	Crystal Structure Of A Pumilio-Homology Domain
4UC0	;	2.4	;	Crystal Structure Of a purine nucleoside phosphorylase (PSI-NYSGRC-029736) from Agrobacterium vitis
3U40	;	2.05	;	Crystal structure of a purine nucleoside phosphorylase from Entamoeba histolytica bound to adenosine
2O8P	;	1.82	;	Crystal structure of a putative 14-3-3 protein from Cryptosporidium parvum, cgd7_2470
2F1L	;	2.46	;	CRYSTAL STRUCTURE OF A PUTATIVE 16S RIBOSOMAL RNA PROCESSING PROTEIN RIMM (PA3744) FROM PSEUDOMONAS AERUGINOSA AT 2.46 A RESOLUTION
2RIJ	;	1.9	;	Crystal structure of a putative 2,3,4,5-tetrahydropyridine-2-carboxylate n-succinyltransferase (cj1605c, dapd) from campylobacter jejuni at 1.90 A resolution
2NWB	;	2.4	;	Crystal Structure of a Putative 2,3-dioxygenase (SO4414) from Shewanella oneidensis in complex with ferric heme. Northeast Structural Genomics Target SoR52.
3UP8	;	1.96	;	Crystal structure of a putative 2,5-diketo-D-gluconic acid reductase B
3T69	;	2.55	;	Crystal structure of a putative 2-dehydro-3-deoxygalactonokinase protein from Sinorhizobium meliloti
4HP8	;	1.35	;	Crystal structure of a putative 2-deoxy-d-gluconate 3-dehydrogenase from Agrobacterium Tumefaciens (target EFI-506435) with bound NADP
3KTN	;	2.26	;	Crystal Structure of a putative 2-Keto-3-deoxygluconate Kinase from Enterococcus faecalis
3OOX	;	1.44	;	Crystal structure of a putative 2OG-Fe(II) oxygenase family protein (CC_0200) from CAULOBACTER CRESCENTUS at 1.44 A resolution
3C6C	;	1.72	;	Crystal structure of a putative 3-keto-5-aminohexanoate cleavage enzyme (reut_c6226) from ralstonia eutropha jmp134 at 1.72 A resolution
3SX2	;	1.5	;	Crystal structure of a putative 3-ketoacyl-(acyl-carrier-protein) reductase from Mycobacterium paratuberculosis in complex with NAD
3ICC	;	1.87	;	Crystal structure of a putative 3-oxoacyl-(acyl carrier protein) reductase from Bacillus anthracis at 1.87 A resolution
3TFO	;	2.08	;	Crystal structure of a putative 3-oxoacyl-(acyl-carrier-protein) reductase from Sinorhizobium meliloti
6UDS	;	1.9	;	Crystal structure of a putative 3-oxoacyl-ACP reductase (FabG) from Acinetobacter baumannii
6WPR	;	1.85	;	Crystal structure of a putative 3-oxoacyl-ACP reductase (FabG) with NADP(H) from Acinetobacter baumannii
4IIU	;	2.1	;	Crystal structure of a putative 3-oxoacyl-[acyl-carrier protein]reductase from Escherichia coli strain CFT073 complexed with NADP+ at 2.1 A resolution
4IIV	;	2.5	;	Crystal structure of a putative 3-oxoacyl-[acyl-carrier protein]reductase from Escherichia coli strain CFT073 complexed with NADP+ at 2.5 A resolution
4IJK	;	2.54	;	Crystal structure of a putative 3-oxoacyl-[acyl-carrier protein]reductase from Helicobacter pylori 26695
4IIN	;	2.4	;	Crystal structure of a putative 3-oxoacyl-[acyl-carrier protein]reductase from Helicobacter pylori 26695 complexed with NAD+
3CEB	;	2.4	;	Crystal structure of a putative 4-amino-4-deoxychorismate lyase (hs_0128) from haemophilus somnus 129pt at 2.40 A resolution
3N73	;	2.07	;	Crystal structure of a putative 4-hydroxy-2-oxoglutarate aldolase from Bacillus cereus
4K8L	;	1.9	;	Crystal structure of a putative 4-hydroxyproline epimerase/3-hydroxyproline dehydratse from the soil bacterium ochrobacterium anthropi, target efi-506495, disordered loops
2IFX	;	2.0	;	Crystal structure of a putative 4-methylmuconolactone methylisomerase (YP_295714.1) from Ralstonia eutropha JMP134 at 2.00 A resolution
4LKB	;	2.16	;	Crystal structure of a putative 4-Oxalocrotonate Tautomerase from Nostoc sp. PCC 7120
4L0M	;	1.7	;	Crystal structure of a putative 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Borrelia burgdorferi B31 bound to Adenine (Target NYSGRC-029268 )
4JOS	;	1.45	;	Crystal structure of a putative 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Francisella philomiragia ATCC 25017 (Target NYSGRC-029335)
4JWT	;	2.05	;	Crystal structure of a putative 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Sulfurimonas denitrificans DSM 1251 (Target NYSGRC-029304 )
2QCV	;	1.9	;	CRYSTAL STRUCTURE OF a putative 5-dehydro-2-deoxygluconokinase (IOLC) FROM BACILLUS HALODURANS C-125 AT 1.90 A RESOLUTION
2FG9	;	2.2	;	CRYSTAL STRUCTURE OF A PUTATIVE 5-NITROIMIDAZOLE ANTIBIOTIC RESISTANCE PROTEIN (BT_3078) FROM BACTEROIDES THETAIOTAOMICRON VPI-5482 AT 2.20 A RESOLUTION
4QRJ	;	2.2	;	Crystal structure of a putative 6-phosphogluconolactonase (BACUNI_04672) from Bacteroides uniformis ATCC 8492 at 2.20 A resolution
3SCY	;	1.5	;	Crystal structure of a putative 6-phosphogluconolactonase (BF1038) from Bacteroides fragilis NCTC 9343 at 1.50 A resolution
3CTD	;	2.5	;	Crystal structure of a putative AAA family ATPase from Prochlorococcus marinus subsp. pastoris
2F4L	;	2.5	;	Crystal structure of a putative acetamidase (tm0119) from thermotoga maritima msb8 at 2.50 A resolution
2O16	;	1.9	;	Crystal structure of a putative acetoin utilization protein (AcuB) from Vibrio cholerae
4WEO	;	1.85	;	Crystal Structure of a Putative acetoin(Diacetyl) Reductase Burkholderia cenocepacia
3NUZ	;	2.3	;	Crystal structure of a putative acetyl xylan esterase (BF1801) from Bacteroides fragilis NCTC 9343 at 2.30 A resolution
2O1Q	;	1.5	;	CRYSTAL STRUCTURE OF A PUTATIVE ACETYLACETONE DIOXYGENASE (MPE_A3659) FROM METHYLIBIUM PETROLEIPHILUM PM1 AT 1.50 A RESOLUTION
3PFO	;	1.9	;	Crystal structure of a putative acetylornithine deacetylase (RPA2325) from RHODOPSEUDOMONAS PALUSTRIS CGA009 at 1.90 A resolution
3S6F	;	1.19	;	Crystal structure of a putative acetyltransferase (DR_1678) from Deinococcus radiodurans R1 at 1.19 A resolution
3DDD	;	2.25	;	Crystal structure of A Putative Acetyltransferase (NP_142035.1) from PYROCOCCUS HORIKOSHII at 2.25 A resolution
3C26	;	2.0	;	Crystal structure of a putative acetyltransferase (NP_394282.1) from Thermoplasma acidophilum at 2.00 A resolution
2OZH	;	1.4	;	Crystal structure of a putative acetyltransferase belonging to the gnat family (xcc2953) from xanthomonas campestris pv. campestris at 1.40 A resolution
6ERD	;	2.0	;	Crystal structure of a putative acetyltransferase from Bacillus cereus species.
3FNC	;	1.75	;	Crystal structure of a putative acetyltransferase from Listeria innocua
2GAN	;	2.1	;	Crystal Structure of a Putative Acetyltransferase from Pyrococcus horikoshii, Northeast Structural Genomics Target JR32.
2R7H	;	1.85	;	CRYSTAL STRUCTURE OF A putative acetyltransferase of the GNAT family (DDE_3044) FROM DESULFOVIBRIO DESULFURICANS SUBSP. AT 1.85 A RESOLUTION
5JSC	;	1.5	;	Crystal structure of a Putative acyl-CoA dehydrogenase from Burkholderia xenovorans
3P4T	;	1.7	;	Crystal structure of a putative acyl-CoA dehydrogenase from Mycobacterium smegmatis
3OIB	;	2.1	;	Crystal structure of a putative ACYL-COA Dehydrogenase from mycobacterium smegmatis, Iodide soak
4N5F	;	2.2	;	Crystal Structure of a Putative acyl-CoA dehydrogenase with bound FADH2 from Burkholderia cenocepacia J2315
4RVN	;	2.2	;	Crystal structure of a Putative Acyl-CoA ligase (BT_0428) from Bacteroides thetaiotaomicron VPI-5482 at 2.20 A resolution
4RVO	;	2.41	;	Crystal structure of a Putative Acyl-CoA ligase (BT_0428) from Bacteroides thetaiotaomicron VPI-5482 at 2.41 A resolution
4R1L	;	2.42	;	Crystal structure of a Putative Acyl-CoA ligase (BT_0428) from Bacteroides thetaiotaomicron VPI-5482 at 2.42 A resolution
4R1M	;	2.48	;	Crystal structure of a Putative Acyl-CoA ligase (BT_0428) from Bacteroides thetaiotaomicron VPI-5482 at 2.48 A resolution
5KL9	;	2.22	;	Crystal structure of a putative acyl-CoA thioesterase EC709/ECK0725 from Escherichia coli in complex with CoA
5T07	;	1.717	;	Crystal structure of a putative acyl-CoA thioesterase EC709/ECK0725 from Escherichia coli in complex with Decanoyl-CoA
5T06	;	1.898	;	Crystal structure of a putative acyl-CoA thioesterase EC709/ECK0725 from Escherichia coli in complex with Hexanoyl-CoA
4IYJ	;	1.37	;	Crystal structure of a putative acylhydrolase (BACUNI_03406) from Bacteroides uniformis ATCC 8492 at 1.37 A resolution
4PPY	;	2.0	;	Crystal structure of a putative acylhydrolase (BF3764) from Bacteroides fragilis NCTC 9343 at 2.00 A resolution
2GFG	;	2.12	;	Crystal structure of a putative adenylate cyclase (bh2851) from bacillus halodurans at 2.12 A resolution
4YGU	;	2.2	;	Crystal structure of a putative adhesin (BACEGG_01763) from Bacteroides eggerthii DSM 20697 at 2.20 A resolution
5CAG	;	3.0	;	Crystal structure of a putative adhesin (BACOVA_02677) from Bacteroides ovatus ATCC 8483 at 3.00 A resolution (PSI Community Target, Nakayama)
3PAY	;	2.5	;	Crystal structure of a putative adhesin (BACOVA_04077) from Bacteroides ovatus at 2.50 A resolution
3PET	;	2.07	;	Crystal structure of a putative adhesin (BF0245) from Bacteroides fragilis NCTC 9343 at 2.07 A resolution
4QDG	;	2.2	;	Crystal structure of a putative adhesin (BT2657) from Bacteroides thetaiotaomicron VPI-5482 at 2.20 A resolution (PSI Community Target, Nakayama)
4OPW	;	1.75	;	Crystal structure of a putative adhesin (PARMER_02777) from Parabacteroides merdae ATCC 43184 at 1.75 A resolution
3LHL	;	2.3	;	Crystal structure of a putative agmatinase from Clostridium difficile
6DBB	;	2.1	;	Crystal structure of a Putative aldehyde dehydrogenase family protein Burkholderia cenocepacia J2315 in complex with partially reduced NADH
4O6R	;	1.9	;	Crystal Structure of a Putative Aldehyde Dehydrogenase from Burkholderia cenocepacia
4YWE	;	2.15	;	Crystal Structure of a Putative Aldehyde Dehydrogenase from Burkholderia cenocepacia
3NRE	;	1.59	;	Crystal structure of a Putative aldose 1-epimerase (b2544) from ESCHERICHIA COLI K12 at 1.59 A resolution
3TY1	;	1.9	;	Crystal structure of a putative aldose 1-epimerase (KPN_04629) from Klebsiella pneumoniae subsp. pneumoniae MGH 78578 at 1.90 A resolution
4NZJ	;	1.57	;	Crystal structure of a putative alpha-galactosidase (BF1418) from Bacteroides fragilis NCTC 9343 at 1.57 A resolution
4OGZ	;	2.0	;	Crystal structure of a putative alpha-galactosidase/melibiase (BF4189) from Bacteroides fragilis NCTC 9343 at 2.00 A resolution
3U95	;	1.998	;	Crystal structure of a putative alpha-glucosidase from Thermotoga neapolitana
5J92	;	1.95	;	Crystal structure of a putative alpha-ketoglutarate dependent 2,4-D dioxygenase from Burkholderia xenovorans
5HSX	;	1.8	;	Crystal Structure of a Putative Alpha-ketoglutarate-dependent Taurine Dioxygenase from Burkholderia xenovorans
4ZRX	;	1.59	;	Crystal structure of a putative alpha-L-fucosidase (BACOVA_04357) from Bacteroides ovatus ATCC 8483 at 1.59 A resolution
4H41	;	1.8	;	Crystal structure of a putative alpha-L-fucosidase (BT_0435) from Bacteroides thetaiotaomicron VPI-5482 at 1.80 A resolution
3CC1	;	2.0	;	CRYSTAL STRUCTURE OF A PUTATIVE ALPHA-N-ACETYLGALACTOSAMINIDASE (BH1870) FROM BACILLUS HALODURANS C-125 AT 2.00 A RESOLUTION
3CIH	;	2.33	;	Crystal structure of a putative alpha-rhamnosidase from Bacteroides thetaiotaomicron
3NUR	;	1.75	;	Crystal structure of a putative amidohydrolase from Staphylococcus aureus
3QQM	;	2.3	;	Crystal structure of a Putative amino-acid aminotransferase (NP_104211.1) from Mesorhizobium loti at 2.30 A resolution
3DXP	;	2.32	;	Crystal structure of a putative aminoglycoside phosphotransferase (reut_a1007) from ralstonia eutropha jmp134 at 2.32 A resolution
3CSV	;	2.15	;	Crystal structure of a putative aminoglycoside phosphotransferase (YP_614837.1) from Silicibacter sp. TM1040 at 2.15 A resolution
1VLY	;	1.3	;	Crystal structure of a putative aminomethyltransferase (ygfz) from escherichia coli at 1.30 A resolution
3P1T	;	2.6	;	Crystal structure of a putative aminotransferase (BPSL1724) from Burkholderia pseudomallei K96243 at 2.60 A resolution
3GJU	;	1.55	;	Crystal structure of a putative aminotransferase (mll7127) from mesorhizobium loti maff303099 at 1.55 A resolution
3SNO	;	1.6	;	Crystal structure of a putative aminotransferase (NCgl2491) from Corynebacterium glutamicum ATCC 13032 at 1.60 A resolution
1VP4	;	1.82	;	Crystal structure of a putative aminotransferase (tm1131) from thermotoga maritima msb8 at 1.82 A resolution
3H14	;	1.9	;	Crystal structure of a putative aminotransferase from Silicibacter pomeroyi
4M0N	;	1.65	;	Crystal structure of a putative anti-sigma factor (BDI_1681) from Parabacteroides distasonis ATCC 8503 at 1.65 A resolution
4M0H	;	2.5	;	Crystal structure of a putative anti-sigma factor (BDI_1681) from Parabacteroides distasonis ATCC 8503 at 2.50 A resolution
3F43	;	1.59	;	Crystal structure of a putative anti-sigma factor antagonist (tm1081) from thermotoga maritima at 1.59 A resolution
3BM7	;	1.35	;	CRYSTAL STRUCTURE OF A PUTATIVE ANTIBIOTIC BIOSYNTHESIS MONOOXYGENASE (CC_2132) FROM CAULOBACTER CRESCENTUS CB15 AT 1.35 A RESOLUTION
3E8O	;	1.4	;	CRYSTAL STRUCTURE OF A PUTATIVE ANTIBIOTIC BIOSYNTHESIS MONOOXYGENASE (DR_2100) FROM DEINOCOCCUS RADIODURANS AT 1.40 A RESOLUTION
3FGV	;	1.3	;	CRYSTAL STRUCTURE OF A PUTATIVE ANTIBIOTIC BIOSYNTHESIS MONOOXYGENASE (SPO2313) FROM SILICIBACTER POMEROYI DSS-3 AT 1.30 A RESOLUTION
3CEC	;	1.6	;	Crystal structure of a putative antidote protein of plasmid maintenance system (npun_f2943) from nostoc punctiforme pcc 73102 at 1.60 A resolution
2RKH	;	2.0	;	Crystal structure of a putative AphA-like transcription factor (ZP_00208345.1) from Magnetospirillum magnetotacticum MS-1 at 2.00 A resolution
3FBG	;	1.6	;	Crystal structure of a putative arginate lyase from Staphylococcus haemolyticus
3B8L	;	1.75	;	CRYSTAL STRUCTURE OF A PUTATIVE AROMATIC RING HYDROXYLASE (SARO_3538) FROM NOVOSPHINGOBIUM AROMATICIVORANS DSM AT 1.75 A RESOLUTION
3N0Q	;	1.8	;	Crystal structure of a Putative aromatic-ring hydroxylating dioxygenase (TM1040_3219) from SILICIBACTER SP. TM1040 at 1.80 A resolution
3OJC	;	1.75	;	Crystal structure of a putative Asp/Glu Racemase from Yersinia pestis
4H51	;	1.85	;	Crystal structure of a putative Aspartate Aminotransferase from Leishmania major Friedlin
7K46	;	1.9	;	Crystal Structure of a putative aspartate carbamoyltransferase Leishmania major Friedlin
6OD8	;	1.85	;	Crystal structure of a putative aspartyl-tRNA synthetase from Leishmania major Friedlin
3DF7	;	1.87	;	Crystal structure of a putative ATP-grasp superfamily protein from Archaeoglobus fulgidus
2R44	;	2.0	;	CRYSTAL STRUCTURE OF A PUTATIVE ATPASE (CHU_0153) FROM CYTOPHAGA HUTCHINSONII ATCC 33406 AT 2.00 A RESOLUTION
2ICH	;	2.0	;	CRYSTAL STRUCTURE OF A PUTATIVE ATTH (NE1406) FROM NITROSOMONAS EUROPAEA AT 2.00 A RESOLUTION
4FMR	;	2.25	;	Crystal structure of a Putative bacterial DNA binding protein (BVU_2165) from Bacteroides vulgatus ATCC 8482 at 2.25 A resolution
5HAL	;	2.1507	;	Crystal Structure of a putative beta-lactamase from Burkholderia vietnamiensis
3FJS	;	1.9	;	CRYSTAL STRUCTURE OF A PUTATIVE BIOSYNTHETIC PROTEIN WITH RMLC-LIKE CUPIN FOLD (REUT_B4087) FROM RALSTONIA EUTROPHA JMP134 AT 1.90 A RESOLUTION
3HUT	;	1.93	;	Crystal structure of a putative branched-chain amino acid ABC transporter from Rhodospirillum rubrum
3H5L	;	1.7	;	Crystal structure of a putative branched-chain amino acid ABC transporter from Silicibacter pomeroyi
3CSW	;	2.15	;	Crystal structure of a putative branched-chain amino acid aminotransferase (TM0831) from Thermotoga maritima at 2.15 A resolution
3T32	;	2.0	;	Crystal structure of a putative C-S lyase from Bacillus anthracis
3KSP	;	2.59	;	Crystal structure of a putative ca/calmodulin-dependent kinase ii association domain (exig_1688) from exiguobacterium sibiricum 255-15 at 2.59 A resolution
3NTV	;	1.55	;	Crystal structure of a putative caffeoyl-CoA O-methyltransferase from Staphylococcus aureus
3DB7	;	1.4	;	Crystal structure of a putative calcium-regulated periplasmic protein (bt0923) from bacteroides thetaiotaomicron at 1.40 A resolution
4DQA	;	1.5	;	Crystal structure of a putative carbohydrate binding protein (BACOVA_03559) from Bacteroides ovatus ATCC 8483 at 1.50 A resolution
4IYK	;	2.0	;	Crystal structure of a putative carbohydrate binding protein (BACUNI_04699) from Bacteroides uniformis ATCC 8492 at 2.00 A resolution
3QEC	;	2.61	;	Crystal structure of a putative carbohydrate binding protein (PA1324) from Pseudomonas aeruginosa at 2.61 A resolution
2AX3	;	2.27	;	CRYSTAL STRUCTURE OF A PUTATIVE CARBOHYDRATE KINASE (TM0922) FROM THERMOTOGA MARITIMA MSB8 AT 2.25 A RESOLUTION
4JPQ	;	2.7	;	Crystal structure of a putative carbohydrate-binding protein (BACUNI_03838) from Bacteroides uniformis ATCC 8492 at 2.70 A resolution
1VPZ	;	2.05	;	Crystal structure of a putative carbon storage regulator protein (csra, pa0905) from pseudomonas aeruginosa at 2.05 A resolution
3P8K	;	1.7	;	Crystal Structure of a putative carbon-nitrogen family hydrolase from Staphylococcus aureus
3BJR	;	2.09	;	Crystal structure of a putative carboxylesterase (lp_1002) from lactobacillus plantarum wcfs1 at 2.09 A resolution
3BXP	;	1.7	;	CRYSTAL STRUCTURE OF A PUTATIVE CARBOXYLESTERASE (LP_2923) FROM LACTOBACILLUS PLANTARUM WCFS1 AT 1.70 A RESOLUTION
4RGB	;	1.95	;	Crystal structure of a putative carveol dehydrogenase from Mycobacterium avium bound to NAD
3PGX	;	1.85	;	Crystal structure of a putative carveol dehydrogenase from Mycobacterium paratuberculosis bound to nicotinamide adenine dinucleotide
4W8K	;	2.13	;	Crystal structure of a putative Cas1 enzyme from Vibrio phage ICP1
4MST	;	1.927	;	Crystal Structure of a putative catalytic domain of a chitinase-like protein (HbCLP1) from Hevea brasiliensis
4GPV	;	1.67	;	Crystal structure of a putative cell adhesion protein (BACEGG_00536) from Bacteroides eggerthii DSM 20697 at 1.67 A resolution
4JRF	;	1.98	;	Crystal structure of a putative cell adhesion protein (BACOVA_01548) from Bacteroides ovatus ATCC 8483 at 1.98 A resolution (PSI Community Target, Nakayama)
3UP6	;	2.8	;	Crystal structure of a putative cell adhesion protein (BACOVA_04078) from Bacteroides ovatus ATCC 8483 at 2.80 A resolution
3UFI	;	2.18	;	Crystal structure of a putative cell adhesion protein (BACOVA_04980) from Bacteroides ovatus ATCC 8483 at 2.18 A resolution
4K4K	;	1.67	;	Crystal structure of a putative cell adhesion protein (BACUNI_00621) from Bacteroides uniformis ATCC 8492 at 1.67 A resolution
4JG5	;	2.34	;	Crystal structure of a putative cell adhesion protein (BDI_3519) from Parabacteroides distasonis ATCC 8503 at 2.34 A resolution (PSI Community Target, Nakayama)
3T2L	;	2.33	;	Crystal structure of a Putative cell adhesion protein (BF1858) from Bacteroides fragilis NCTC 9343 at 2.33 A resolution
4H40	;	2.57	;	Crystal structure of a putative cell adhesion protein (BF2867) from Bacteroides fragilis NCTC 9343 at 2.57 A resolution
4DGU	;	2.37	;	Crystal structure of a putative cell adhesion protein (BT0320) from Bacteroides thetaiotaomicron VPI-5482 at 2.37 A resolution
4QRK	;	1.95	;	Crystal structure of a putative cell adhesion protein (CLOSPO_03726) from Clostridium sporogenes ATCC 15579 at 1.95 A resolution
4EZG	;	1.5	;	Crystal structure of a putative cell adhesion protein (LMOf2365_1307) from Listeria monocytogenes str. 4b F2365 at 1.50 A resolution
4E6E	;	2.12	;	Crystal structure of a putative cell division protein FtsZ (Tfu_1113) from Thermobifida fusca YX-ER1 at 2.22 A resolution (PSI Community Target, van Wezel G.P.)
4FD0	;	2.07	;	Crystal structure of a putative cell surface protein (BACCAC_03700) from Bacteroides caccae ATCC 43185 at 2.07 A resolution
4FDW	;	2.05	;	Crystal structure of a putative cell surface protein (BACOVA_01565) from Bacteroides ovatus ATCC 8483 at 2.05 A resolution
4HPE	;	2.38	;	Crystal structure of a putative cell wall hydrolase (CD630_03720) from Clostridium difficile 630 at 2.38 A resolution
2I5I	;	1.7	;	CRYSTAL STRUCTURE OF A PUTATIVE CELLOBIOSE-PHOSPHATE CLEAVAGE PROTEIN (EF3048) FROM ENTEROCOCCUS FAECALIS V583 AT 1.70 A RESOLUTION
4H6P	;	2.556	;	Crystal structure of a putative chromate reductase from Gluconacetobacter hansenii, Gh-ChrR, containing a R101A substitution.
4HS4	;	2.1	;	Crystal structure of a putative chromate reductase from Gluconacetobacter hansenii, Gh-ChrR, containing a Y129N substitution.
6WGY	;	2.3	;	Crystal structure of a Putative citrate synthase 2 from Mycobacterium bovis in complex with citrate
2F8L	;	2.2	;	Crystal structure of a putative class i s-adenosylmethionine-dependent methyltransferase (lmo1582) from listeria monocytogenes at 2.20 A resolution
2AH6	;	1.6	;	Crystal structure of a putative cobalamin adenosyltransferase (bh1595) from bacillus halodurans c-125 at 1.60 A resolution
3EEQ	;	2.3	;	Crystal structure of a putative cobalamin biosynthesis protein G homolog from Sulfolobus solfataricus
4L1N	;	2.7	;	Crystal structure of a putative conserved lipoprotein (NT01CX_1156) from Clostridium novyi NT at 2.70 A resolution
2AJ7	;	1.67	;	Crystal structure of a putative contractile protein (bh3618) from bacillus halodurans at 1.67 A resolution
4MYR	;	2.72	;	Crystal structure of a putative CpaE2 pilus assembly protein (CpaE2) from Sinorhizobium meliloti 1021 at 2.72 A resolution (PSI Community Target, Shapiro)
3H3Z	;	2.35	;	Crystal structure of a putative cyclic nucleotide binding protein (spoa0323) from ruegeria pomeroyi dss-3 at 2.35 A resolution
3MDP	;	1.9	;	Crystal structure of a Putative Cyclic nucleotide-binding protein (Gmet_1532) from Geobacter metallireducens GS-15 at 1.90 A resolution
3JZL	;	1.91	;	CRYSTAL STRUCTURE OF A PUTATIVE CYSTATHIONINE BETA-LYASE INVOLVED IN ALUMINUM RESISTANCE (LMOF2365_1314) FROM LISTERIA MONOCYTOGENES STR. 4B F2365 AT 1.91 A RESOLUTION
4OFX	;	1.74	;	Crystal Structure of a Putative Cystathionine beta-Synthase from Coxiella burnetii
4QM9	;	2.3	;	Crystal Structure of a Putative Cysteine Dioxygenase From Bacillus subtilis with Cys-bound
4QM8	;	2.82	;	Crystal Structure of a Putative Cysteine Dioxygnase From Bacillus subtilis: A Alternative Modeling of 3EQE
4QMA	;	1.65	;	Crystal Structure of a Putative Cysteine Dioxygnase From Ralstonia eutropha: An Alternative Modeling of 2GM6 from JCSG Target 361076
4H7P	;	1.3	;	Crystal structure of a putative Cytosolic malate dehydrogenase from Leishmania major Friedlin
4I1I	;	1.5	;	Crystal structure of a putative Cytosolic malate dehydrogenase from Leishmania major Friedlin in complex with NAD
5TR7	;	2.05	;	Crystal structure of a putative D-alanyl-D-alanine carboxypeptidase from Vibrio cholerae O1 biovar eltor str. N16961
8DT1	;	1.8	;	Crystal Structure of a Putative D-beta-hydroxybutyrate dehydrogenase from Burkholderia cenocepacia J2315 in complex with NAD
5DT9	;	2.663	;	Crystal structure of a putative D-Erythronate-4-Phosphate Dehydrogenase from Vibrio cholerae
4HN8	;	2.2	;	Crystal structure of a putative D-glucarate dehydratase from Pseudomonas mendocina ymp
4WUV	;	1.551	;	Crystal Structure of a putative D-Mannonate oxidoreductase from Haemophilus influenza (Avi_5165, TARGET EFI-513796) with bound NAD
3GWQ	;	2.0	;	Crystal structure of a putative d-serine deaminase (bxe_a4060) from burkholderia xenovorans lb400 at 2.00 A resolution
5GW8	;	2.0	;	Crystal structure of a putative DAG-like lipase (MgMDL2) from Malassezia globosa
2POZ	;	2.04	;	Crystal structure of a putative dehydratase from Mesorhizobium loti
3CNX	;	2.1	;	CRYSTAL STRUCTURE OF A PUTATIVE DEHYDRATASE FROM THE NTF2-LIKE FAMILY (SAV_4671) FROM STREPTOMYCES AVERMITILIS AT 2.10 A RESOLUTION
3PM9	;	2.57	;	Crystal structure of a Putative dehydrogenase (RPA1076) from Rhodopseudomonas palustris CGA009 at 2.57 A resolution
4JIG	;	1.85	;	Crystal structure of a putative dehydrogenase from Burkholderia cenocepacia
5THK	;	1.4	;	Crystal Structure of a Putative Dehydrogenase from Burkholderia cenocepacia with bound NADP
4YQY	;	1.381	;	Crystal Structure of a putative Dehydrogenase from Sulfitobacter sp. (COG1028) (TARGET EFI-513936) in its APO form
3E03	;	1.69	;	Crystal structure of a putative dehydrogenase from Xanthomonas campestris
3F8X	;	1.55	;	Crystal structure of a putative delta-5-3-ketosteroid isomerase (eca2236) from pectobacterium atrosepticum scri1043 at 1.55 A resolution
2PGS	;	2.35	;	Crystal structure of a putative deoxyguanosinetriphosphate triphosphohydrolase from Pseudomonas syringae pv. phaseolicola 1448A
7L9R	;	2.4	;	Crystal Structure of a putative deoxyhypusine synthase from Entamoeba histolytica
3OA3	;	1.6	;	Crystal structure of a putative deoxyribose-phosphate aldolase from Coccidioides immitis
3NGJ	;	1.7	;	Crystal structure of a putative deoxyribose-phosphate aldolase from Entamoeba histolytica
3T5P	;	2.5	;	Crystal structure of a putative diacylglycerol kinase from Bacillus anthracis str. Sterne
2QJC	;	2.05	;	Crystal structure of a putative diadenosine tetraphosphatase
3NA8	;	1.85	;	Crystal Structure of a putative dihydrodipicolinate synthetase from Pseudomonas aeruginosa
2GD9	;	2.3	;	Crystal structure of a putative dihydrofolate reductase (bsu40760, yyap) from bacillus subtilis at 2.30 A resolution
2QTD	;	1.7	;	Crystal structure of a putative dinitrogenase (mj0327) from methanocaldococcus jannaschii dsm at 1.70 A resolution
1O13	;	1.83	;	Crystal structure of a putative dinitrogenase iron-molybdenum cofactor (tm1816) from thermotoga maritima at 1.83 A resolution
2PEB	;	1.46	;	Crystal structure of a putative dioxygenase (npun_f1925) from nostoc punctiforme pcc 73102 at 1.46 A resolution
2QDR	;	2.6	;	Crystal structure of a putative dioxygenase (npun_f5605) from nostoc punctiforme pcc 73102 at 2.60 A resolution
4Q1V	;	2.48	;	Crystal structure of a putative dipeptidyl aminopeptidase IV (BACOVA_01349) from Bacteroides ovatus ATCC 8483 at 2.48 A resolution
3NPF	;	1.72	;	Crystal structure of a putative dipeptidyl-peptidase VI (BACOVA_00612) from Bacteroides ovatus at 1.72 A resolution
4R0K	;	1.75	;	Crystal structure of a putative dipeptidyl-peptidase VI (BT_1314) from Bacteroides thetaiotaomicron VPI-5482 at 1.75 A resolution
3PVQ	;	2.1	;	Crystal structure of a putative dipeptidyl-peptidase VI (BT_1314) from BACTEROIDES THETAIOTAOMICRON VPI-5482 at 2.10 A resolution
1XD7	;	2.3	;	Crystal structure of a putative DNA binding protein
2PG4	;	2.21	;	Crystal structure of a putative dna binding protein (ape_0880a) from aeropyrum pernix k1 at 2.21 A resolution
3HTN	;	1.5	;	Crystal structure of a putative dna binding protein (bt_1116) from bacteroides thetaiotaomicron vpi-5482 at 1.50 A resolution
2F22	;	1.42	;	CRYSTAL STRUCTURE OF A PUTATIVE DNA DAMAGE-INDUCABLE (DINB) PROTEIN (BH3987) FROM BACILLUS HALODURANS AT 1.42 A RESOLUTION
2QNL	;	1.5	;	CRYSTAL STRUCTURE OF A PUTATIVE DNA DAMAGE-INDUCIBLE PROTEIN (CHU_0679) FROM CYTOPHAGA HUTCHINSONII ATCC 33406 AT 1.50 A RESOLUTION
3T0P	;	2.26	;	Crystal structure of a Putative DNA polymerase III beta subunit (EUBREC_0002; ERE_29750) from Eubacterium rectale ATCC 33656 at 2.26 A resolution
3BOS	;	1.75	;	Crystal structure of a putative dna replication regulator HDA (SAMA_1916) from Shewanella amazonensis sb2b at 1.75 A resolution
3SC3	;	3.001	;	Crystal structure of a Putative DNA replication regulator Hda (Sama_1916) from SHEWANELLA AMAZONENSIS SB2B at 3.00 A resolution
1VJF	;	1.62	;	CRYSTAL STRUCTURE OF A PUTATIVE DNA-BINDING PROTEIN (CC_0111) FROM CAULOBACTER CRESCENTUS CB15 AT 1.62 A RESOLUTION
2OBP	;	1.7	;	Crystal structure of a putative dna-binding protein (reut_b4095) from ralstonia eutropha jmp134 at 1.70 A resolution
3BS3	;	1.65	;	Crystal structure of a putative DNA-binding protein from Bacteroides fragilis
2HAG	;	2.75	;	Crystal structure of a putative dyp-type peroxidase protein (so_0740) from shewanella oneidensis at 2.75 A resolution
3FH3	;	2.102	;	Crystal structure of a putative ECF-type sigma factor negative effector from Bacillus anthracis str. Sterne
4L8J	;	2.06	;	Crystal structure of a Putative efflux transporter (BACEGG_01895) from Bacteroides eggerthii DSM 20697 at 2.06 A resolution
3HRL	;	1.95	;	Crystal structure of a putative endonuclease-like protein (ngo0050) from neisseria gonorrhoeae
2HBW	;	1.05	;	Crystal structure of a putative endopeptidase (ava_3396) from anabaena variabilis atcc 29413 at 1.05 A resolution
2OTM	;	1.85	;	Crystal structure of a putative endoribonuclease (so_1960) from shewanella oneidensis mr-1 at 1.85 A resolution
2B33	;	2.3	;	CRYSTAL STRUCTURE OF A PUTATIVE ENDORIBONUCLEASE (TM0215) FROM THERMOTOGA MARITIMA MSB8 AT 2.30 A RESOLUTION
3MQW	;	1.8	;	Crystal structure of a putative endoribonuclease L-PSP from Entamoeba histolytica with higher solvent content and an ordered N-terminal tag
3M4S	;	2.3	;	Crystal structure of a putative endoribonuclease L-PSP from Entamoeba histolytica, orthorhombic form
3M1X	;	1.2	;	Crystal structure of a putative endoribonuclease L-PSP from Entamoeba histolytica, rhomobohedral form
4KNP	;	1.898	;	Crystal Structure Of a Putative enoyl-coA hydratase (PSI-NYSGRC-019597) from Mycobacterium avium paratuberculosis K-10
4OG1	;	2.05	;	Crystal Structure of a Putative Enoyl-CoA Hydratase from Novosphingobium aromaticivorans DSM 12444
3GKB	;	1.8	;	Crystal structure of a putative enoyl-CoA hydratase from Streptomyces avermitilis
3H0U	;	1.5	;	Crystal structure of a putative enoyl-CoA hydratase from Streptomyces avermitilis
4OLQ	;	2.7	;	Crystal Structure of a Putative enoyl-CoA hydratase/isomerase family protein from Hyphomonas neptunium
5C9G	;	2.1	;	Crystal Structure of a Putative enoyl-CoA hydratase/isomerase family protein from Hyphomonas neptunium
3FDU	;	2.0	;	Crystal structure of a putative enoyl-CoA hydratase/isomerase from Acinetobacter baumannii
4WCZ	;	1.82	;	Crystal structure of a putative enoyl-CoA hydratase/isomerase from Novosphingobium aromaticivorans
2FKB	;	2.0	;	Crystal structure of a putative enzyme (possible Nudix hydrolase) from Escherichia Coli K12
4LW8	;	2.1	;	Crystal structure of a putative epimerase from Burkholderia cenocepacia J2315
5BOV	;	1.6	;	Crystal structure of a putative epoxide hydrolase (KPN_01808) from Klebsiella pneumoniae subsp. pneumoniae MGH 78578 at 1.60 A resolution
4Q34	;	1.6	;	Crystal structure of a putative esterase (BDI_1566) from Parabacteroides distasonis ATCC 8503 at 1.60 A resolution
3D7R	;	2.01	;	Crystal structure of a putative esterase from Staphylococcus aureus
2PYT	;	1.9	;	Crystal structure of a putative ethanolamine utilization protein q (eutq, stm2468) from salmonella typhimurium lt2 at 1.90 A resolution
4RAA	;	2.6	;	Crystal structure of a Putative exported protein (BF0058) from Bacteroides fragilis NCTC 9343 at 2.60 A resolution
3FZX	;	2.22	;	CRYSTAL STRUCTURE OF A PUTATIVE EXPORTED PROTEIN WITH YMCC-LIKE FOLD (BF2203) FROM BACTEROIDES FRAGILIS NCTC 9343 AT 2.22 A RESOLUTION
4NKP	;	1.24	;	Crystal structure of a putative extracellular heme-binding protein (DESPIG_02683) from Desulfovibrio piger ATCC 29098 at 1.24 A resolution
3DTT	;	1.7	;	Crystal structure of a putative f420 dependent nadp-reductase (arth_0613) from arthrobacter sp. fb24 at 1.70 A resolution
4HB9	;	1.93	;	Crystal structure of a putative FAD containing monooxygenase from Photorhabdus luminescens subsp. laumondii TTO1 (Target PSI-012791)
4F62	;	2.101	;	Crystal structure of a putative farnesyl-diphosphate synthase from Marinomonas sp. MED121 (Target EFI-501980)
2ETV	;	1.7	;	Crystal structure of a putative fe(iii) abc transporter (tm0189) from thermotoga maritima msb8 at 1.70 A resolution
2QGO	;	2.04	;	Crystal structure of a putative Fe-S biosynthesis protein from Lactobacillus acidophilus
2P2E	;	2.48	;	Crystal structure of a putative Fe-S biosynthesis protein from Lactobacillus salivarius with novel protein fold
1VJX	;	2.3	;	Crystal structure of a putative ferritin-like diiron-carboxylate protein (tm1526) from thermotoga maritima at 2.30 A resolution
2FUP	;	1.48	;	Crystal structure of a putative flagella synthesis protein flgn (pa3352) from pseudomonas aeruginosa at 1.48 A resolution
1VHN	;	1.59	;	Crystal structure of a putative flavin oxidoreductase with flavin
2R0X	;	1.06	;	Crystal structure of a putative flavin reductase (ycdh, hs_1225) from haemophilus somnus 129pt at 1.06 A resolution
4ICI	;	1.4	;	Crystal structure of a putative flavoprotein (BACEGG_01620) from Bacteroides eggerthii DSM 20697 at 1.40 A resolution
4J8P	;	1.5	;	Crystal structure of a Putative flavoprotein (BACUNI_04544) from Bacteroides uniformis ATCC 8492 at 1.50 A resolution
2FUR	;	1.8	;	CRYSTAL STRUCTURE OF A PUTATIVE FMN-BINDING PROTEIN (TA1372) FROM THERMOPLASMA ACIDOPHILUM AT 1.80 A RESOLUTION
2R01	;	1.15	;	Crystal structure of a putative fmn-dependent nitroreductase (ct0345) from chlorobium tepidum tls at 1.15 A resolution
2PW9	;	2.1	;	Crystal structure of a putative formate dehydrogenase accessory protein from Desulfotalea psychrophila
1QP8	;	2.8	;	CRYSTAL STRUCTURE OF A PUTATIVE FORMATE DEHYDROGENASE FROM PYROBACULUM AEROPHILUM
2GVI	;	1.87	;	Crystal structure of a putative formylmethanofuran dehydrogenase subunit e (ta1109) from thermoplasma acidophilum at 1.87 A resolution
3PM6	;	2.2	;	Crystal structure of a putative fructose-1,6-biphosphate aldolase from Coccidioides immitis solved by combined SAD MR
3S52	;	2.012	;	Crystal structure of a putative fumarylacetoacetate hydrolase family protein from Yersinia pestis CO92
3V77	;	2.1	;	Crystal structure of a putative fumarylacetoacetate isomerase/hydrolase from Oleispira antarctica
4MAQ	;	1.4	;	Crystal Structure of a putative fumarylpyruvate hydrolase from Burkholderia cenocepacia
5HL6	;	1.8499	;	Crystal Structure of a Putative GAF sensor protein from Burkholderia vietnamiensis
3STP	;	1.88	;	Crystal structure of a putative galactonate dehydratase
3MWX	;	1.45	;	Crystal structure of a putative galactose mutarotase (BSU18360) from BACILLUS SUBTILIS at 1.45 A resolution
2Q0T	;	1.7	;	Crystal structure of a putative gamma-carboxymuconolactone decarboxylase subunit (bxe_b0980) from burkholderia xenovorans lb400 at 1.70 A resolution
3M1U	;	1.75	;	Crystal structure of a Putative gamma-D-glutamyl-L-diamino acid endopeptidase (DVU_0896) from DESULFOVIBRIO VULGARIS HILDENBOROUGH at 1.75 A resolution
2EVR	;	1.6	;	CRYSTAL STRUCTURE OF A PUTATIVE GAMMA-D-GLUTAMYL-L-DIAMINO ACID ENDOPEPTIDASE (NPUN_R0659) FROM NOSTOC PUNCTIFORME PCC 73102 AT 1.60 A RESOLUTION
2FG0	;	1.79	;	Crystal structure of a putative gamma-d-glutamyl-l-diamino acid endopeptidase (npun_r0659) from nostoc punctiforme pcc 73102 at 1.79 A resolution
4LHS	;	1.4	;	Crystal structure of a putative GDSL-like lipase (BACOVA_00914) from Bacteroides ovatus ATCC 8483 at 1.40 A resolution
4NRD	;	2.1	;	Crystal structure of a putative GDSL-like lipase (BACOVA_04955) from Bacteroides ovatus ATCC 8483 at 2.10 A resolution
4M8K	;	1.9	;	Crystal structure of a putative GDSL-like lipase (BACUNI_00748) from Bacteroides uniformis ATCC 8492 at 1.90 A resolution
4Q9A	;	2.86	;	Crystal structure of a putative GDSL-like lipase (PARMER_00689) from Parabacteroides merdae ATCC 43184 at 2.86 A resolution
3DMB	;	2.3	;	Crystal structure of a putative general stress family protein (xcc2264) from xanthomonas campestris pv. campestris at 2.30 A resolution
2QEA	;	2.46	;	CRYSTAL STRUCTURE OF A PUTATIVE GENERAL STRESS PROTEIN 26 (JANN_0955) FROM JANNASCHIA SP. CCS1 AT 2.46 A RESOLUTION
3D5P	;	1.45	;	CRYSTAL STRUCTURE OF A PUTATIVE GLUCAN SYNTHESIS REGULATOR OF SMI1/KNR4 FAMILY (BF1740) FROM BACTEROIDES FRAGILIS NCTC 9343 AT 1.45 A RESOLUTION
4QT9	;	2.05	;	Crystal structure of a putative glucoamylase (BACCAC_03554) from Bacteroides caccae ATCC 43185 at 2.05 A resolution
4GL3	;	2.01	;	Crystal structure of a putative glucoamylase (BACUNI_03963) from Bacteroides uniformis ATCC 8492 at 2.01 A resolution
4IBO	;	2.1	;	Crystal structure of a putative gluconate dehydrogenase from agrobacterium tumefaciens (target EFI-506446)
2A3N	;	1.23	;	Crystal structure of a putative glucosamine-fructose-6-phosphate aminotransferase (stm4540.s) from salmonella typhimurium lt2 at 1.35 A resolution
4MOW	;	1.95	;	Crystal structure of a putative glucose 1-dehydrogenase from Burkholderia cenocepacia J2315
3CBU	;	2.05	;	Crystal structure of a putative glutathione s-transferase (reut_a1011) from ralstonia eutropha jmp134 at 2.05 A resolution
3N6X	;	2.35	;	Crystal structure of a Putative glutathionylspermidine synthase (Mfla_0391) from METHYLOBACILLUS FLAGELLATUS KT at 2.35 A resolution
2O55	;	2.806	;	Crystal Structure of a putative glycerophosphodiester phosphodiesterase from Galdieria sulphuraria
3R67	;	2.3	;	Crystal structure of a putative glycosidase (BT_4094) from BACTEROIDES THETAIOTAOMICRON VPI-5482 at 2.30 A resolution
2AAM	;	2.2	;	Crystal structure of a putative glycosidase (tm1410) from thermotoga maritima at 2.20 A resolution
4JRL	;	2.1	;	Crystal structure of a putative glycoside hydrolase (BACOVA_00087) from Bacteroides ovatus ATCC 8483 at 2.10 A resolution
4ONZ	;	1.85	;	Crystal structure of a putative glycoside hydrolase (BACOVA_02161) from Bacteroides ovatus ATCC 8483 at 1.85 A resolution
3TAW	;	1.7	;	Crystal structure of a putative glycoside hydrolase (BDI_3141) from Parabacteroides distasonis ATCC 8503 at 1.70 A resolution
4HET	;	2.1	;	Crystal structure of a putative glycoside hydrolase (BT3745) from Bacteroides thetaiotaomicron VPI-5482 at 2.10 A resolution
3HBZ	;	2.05	;	Crystal structure of a putative glycoside hydrolase (bt_2081) from bacteroides thetaiotaomicron vpi-5482 at 2.05 A resolution
3S30	;	2.46	;	Crystal structure of a putative glycoside hydrolase (BVU_0247) from Bacteroides vulgatus ATCC 8482 at 2.46 A resolution
4N0R	;	1.8	;	Crystal structure of a putative glycoside hydrolase (BVU_0362) from Bacteroides vulgatus ATCC 8482 at 1.80 A resolution
2RDY	;	2.03	;	Crystal structure of a putative glycoside hydrolase family protein from Bacillus halodurans
3LM3	;	1.44	;	Crystal structure of a putative glycoside hydrolase/deacetylase (bdi_3119) from parabacteroides distasonis at 1.44 A resolution
4HXC	;	2.15	;	Crystal structure of a putative glycosyl hydrolase (BACUNI_00951) from Bacteroides uniformis ATCC 8492 at 2.15 A resolution
3U1X	;	1.7	;	Crystal structure of a putative glycosyl hydrolase (BDI_1869) from Parabacteroides distasonis ATCC 8503 at 1.70 A resolution
3S5Q	;	1.85	;	Crystal structure of a putative glycosyl hydrolase (BDI_2473) from Parabacteroides distasonis ATCC 8503 at 1.85 A resolution
4QHZ	;	2.13	;	Crystal structure of a putative glycosyl hydrolase (BDI_3914) from Parabacteroides distasonis ATCC 8503 at 2.13 A resolution
3OSD	;	1.8	;	Crystal structure of a putative glycosyl hydrolase (BT2157) from BACTEROIDES THETAIOTAOMICRON VPI-5482 at 1.80 A resolution
4JQT	;	2.49	;	Crystal structure of a putative glycosyl hydrolase (BT3469) from Bacteroides thetaiotaomicron VPI-5482 at 2.49 A resolution
4MXN	;	1.95	;	Crystal structure of a putative glycosyl hydrolase (PARMER_00599) from Parabacteroides merdae ATCC 43184 at 1.95 A resolution
3B7F	;	2.2	;	Crystal structure of a putative glycosyl hydrolase with bnr repeats (reut_b4987) from ralstonia eutropha jmp134 at 2.20 A resolution
4MU9	;	1.89	;	Crystal structure of a putative glycosylhydrolase (BT_3782) from Bacteroides thetaiotaomicron VPI-5482 at 1.89 A resolution
3BCV	;	2.35	;	Crystal structure of a putative glycosyltransferase from Bacteroides fragilis
3OY2	;	2.31	;	Crystal structure of a putative glycosyltransferase from Paramecium bursaria Chlorella virus NY2A
3NYY	;	1.6	;	Crystal structure of a putative glycyl-glycine endopeptidase lytM (RUMGNA_02482) from Ruminococcus gnavus ATCC 29149 at 1.60 A resolution
3CT8	;	2.1	;	Crystal structure of a putative glyoxalase (NP_243026.1) from Bacillus halodurans at 2.10 A resolution
3FCD	;	1.92	;	Crystal Structure of a putative glyoxalase from an environmental bacteria
3E5D	;	2.7	;	Crystal structure of a putative glyoxalase i (lmof2365_0426) from listeria monocytogenes str. 4b f2365 at 2.70 A resolution
3VCX	;	1.39	;	Crystal structure of a putative glyoxalase/bleomycin resistance protein from Rhodopseudomonas palustris CGA009
2A9V	;	2.24	;	Crystal structure of a putative gmp synthase subunit a protein (ta0944m) from thermoplasma acidophilum at 2.45 A resolution
2AJ6	;	1.63	;	Crystal structure of a putative gnat family acetyltransferase (mw0638) from staphylococcus aureus subsp. aureus at 1.63 A resolution
3TAU	;	2.05	;	Crystal Structure of a Putative Guanylate Monophosphaste Kinase from Listeria monocytogenes EGD-e
2O2X	;	1.5	;	Crystal structure of a putative had-like phosphatase (mll2559) from mesorhizobium loti at 1.50 A resolution
2P11	;	2.2	;	CRYSTAL STRUCTURE OF A PUTATIVE HALOACID DEHALOGENASE-LIKE HYDROLASE (BXE_B1342) FROM BURKHOLDERIA XENOVORANS LB400 AT 2.20 A RESOLUTION
2O08	;	1.9	;	CRYSTAL STRUCTURE OF A PUTATIVE HD SUPERFAMILY HYDROLASE (BH1327) FROM BACILLUS HALODURANS AT 1.90 A RESOLUTION
1VL7	;	1.5	;	Crystal structure of a putative heme oxygenase (alr5027) from nostoc sp. pcc 7120 at 1.50 A resolution
3FM2	;	1.8	;	CRYSTAL STRUCTURE OF A PUTATIVE HEME-BINDING PROTEIN (AVA_4353) FROM ANABAENA VARIABILIS ATCC 29413 AT 1.80 A RESOLUTION
4GIC	;	2.052	;	Crystal Structure Of a Putative Histidinol dehydrogenase (Target PSI-014034) from Methylococcus capsulatus
3U22	;	2.12	;	Crystal structure of a putative HmuY_like heme binding protein (BVU_2192) from Bacteroides vulgatus ATCC 8482 at 2.12 A resolution
6V77	;	1.75	;	Crystal structure of a putative HpcE protein from Mycobacterium smegmatis
2HZT	;	2.0	;	Crystal Structure of a putative HTH-type transcriptional regulator ytcD
2QE8	;	1.35	;	Crystal structure of a putative hydrolase (ava_4197) from anabaena variabilis atcc 29413 at 1.35 A resolution
4HBS	;	2.8	;	Crystal structure of a putative hydrolase (BACOVA_04882) from Bacteroides ovatus ATCC 8483 at 2.80 A resolution
4H08	;	1.8	;	Crystal structure of a putative hydrolase (BT3161) from Bacteroides thetaiotaomicron VPI-5482 at 1.80 A resolution
3SGG	;	1.25	;	Crystal structure of a putative hydrolase (BT_2193) from Bacteroides thetaiotaomicron VPI-5482 at 1.25 A resolution
4QHB	;	2.44	;	Crystal structure of a putative hydrolase (BVU_2763) from Bacteroides vulgatus ATCC 8482 at 2.44 A resolution
3G8Y	;	1.9	;	CRYSTAL STRUCTURE OF A PUTATIVE HYDROLASE (BVU_4111) FROM BACTEROIDES VULGATUS ATCC 8482 AT 1.90 A RESOLUTION
4EZI	;	1.15	;	Crystal structure of a putative hydrolase (lpg1103) from Legionella pneumophila subsp. pneumophila str. Philadelphia 1 at 1.15 A resolution
4QKU	;	2.45	;	Crystal structure of a putative hydrolase from Burkholderia cenocepacia
2QJW	;	1.35	;	CRYSTAL STRUCTURE OF A PUTATIVE HYDROLASE OF THE ALPHA/BETA SUPERFAMILY (XCC1541) FROM XANTHOMONAS CAMPESTRIS PV. CAMPESTRIS AT 1.35 A RESOLUTION
3CMN	;	2.25	;	Crystal structure of a putative hydrolase with a novel fold from Chloroflexus aurantiacus
4JUU	;	1.75	;	Crystal structure of a putative hydroxyproline epimerase from xanthomonas campestris (TARGET EFI-506516) with bound phosphate and unknown ligand
3R4K	;	2.46	;	Crystal structure of a putative ICLR transcriptional regulator (TM1040_3717) from SILICIBACTER SP. TM1040 at 2.46 A resolution
3E0Z	;	1.75	;	Crystal structure of a putative imidazole glycerol phosphate synthase homolog (eubrec_1070) from eubacterium rectale at 1.75 A resolution
3N6Z	;	1.3	;	Crystal structure of a putative immunoglobulin A1 protease (BACOVA_03286) from Bacteroides ovatus at 1.30 A resolution
3CNY	;	1.85	;	Crystal structure of a putative inositol catabolism protein iole (iole, lp_3607) from lactobacillus plantarum wcfs1 at 1.85 A resolution
4H3E	;	2.25	;	Crystal structure of a putative iron superoxide dismutase from Trypanosoma cruzi bound to iron
2RE2	;	1.3	;	CRYSTAL STRUCTURE OF A PUTATIVE IRON-MOLYBDENUM COFACTOR (FEMO-CO) DINITROGENASE (TA1041M) FROM THERMOPLASMA ACIDOPHILUM DSM 1728 AT 1.30 A RESOLUTION
4ECG	;	2.3	;	Crystal structure of a putative iron-regulated protein A precursor (BDI_2603) from Parabacteroides distasonis ATCC 8503 at 2.30 A resolution
3OQP	;	1.22	;	Crystal structure of a putative isochorismatase (Bxe_A0706) from BURKHOLDERIA XENOVORANS LB400 at 1.22 A resolution
3KL2	;	2.3	;	Crystal structure of a putative isochorismatase from Streptomyces avermitilis
3DXO	;	2.7	;	CRYSTAL STRUCTURE OF A PUTATIVE ISOMERASE OF THE SNOAL-LIKE FAMILY (ATU_0744) FROM AGROBACTERIUM TUMEFACIENS STR. C58 AT 2.70 A RESOLUTION
4KTO	;	2.137	;	Crystal Structure Of a Putative Isovaleryl-CoA dehydrogenase (PSI-NYSGRC-012251) from Sinorhizobium meliloti 1021
3VCR	;	1.84	;	Crystal structure of a putative Kdpg (2-keto-3-deoxy-6-phosphogluconate) aldolase from Oleispira antarctica
3V1T	;	1.88	;	Crystal structure of a putative ketoacyl reductase (FabG4) from Mycobacterium tuberculosis H37Rv at 1.9 Angstrom resolution
3GHY	;	2.0	;	Crystal structure of a putative ketopantoate reductase from Ralstonia solanacearum MolK2
3BB9	;	1.8	;	Crystal structure of a putative ketosteroid isomerase (sfri_1973) from shewanella frigidimarina ncimb 400 at 1.80 A resolution
1VHC	;	1.89	;	Crystal structure of a putative KHG/KDPG aldolase
2RHM	;	1.7	;	Crystal structure of a putative kinase (caur_3907) from chloroflexus aurantiacus j-10-fl at 1.70 A resolution
3PJ0	;	1.8	;	Crystal structure of a putative L-allo-threonine aldolase (lmo0305) from Listeria monocytogenes EGD-E at 1.80 A resolution
1Z9T	;	1.54	;	CRYSTAL STRUCTURE OF A PUTATIVE LACCASE (YFIH) FROM ESCHERICHIA COLI AT 1.54 A RESOLUTION
3GBV	;	2.2	;	Crystal structure of a putative LacI transcriptional regulator from Bacteroides fragilis
2P4O	;	1.9	;	CRYSTAL STRUCTURE OF A PUTATIVE LACTONASE OF THE SMP-30/GLUCONOLACTONASE/LRE-LIKE REGION FAMILY (NPUN_F0524) FROM NOSTOC PUNCTIFORME PCC 73102 AT 1.90 A RESOLUTION
3G12	;	2.58	;	Crystal structure of a putative lactoylglutathione lyase from Bdellovibrio bacteriovorus
4OPM	;	1.7	;	Crystal structure of a putative lipase (lip1) from Acinetobacter baumannii AYE at 1.70 A resolution
2RAU	;	1.85	;	Crystal structure of a putative lipase (NP_343859.1) from Sulfolobus solfataricus at 1.85 A resolution
3BZW	;	1.87	;	Crystal structure of a putative lipase from Bacteroides thetaiotaomicron
3H3I	;	2.2	;	CRYSTAL STRUCTURE OF A PUTATIVE LIPID BINDING PROTEIN (BT_2261) FROM BACTEROIDES THETAIOTAOMICRON VPI-5482 AT 2.20 A RESOLUTION
2RDC	;	1.8	;	CRYSTAL STRUCTURE OF A PUTATIVE LIPID BINDING PROTEIN (GSU0061) FROM GEOBACTER SULFURREDUCENS PCA AT 1.80 A RESOLUTION
1VQZ	;	1.99	;	Crystal structure of a putative lipoate-protein ligase a (sp_1160) from streptococcus pneumoniae tigr4 at 1.99 A resolution
3UP9	;	2.35	;	Crystal structure of a putative lipoprotein (ACTODO_00931) from Actinomyces odontolyticus ATCC 17982 at 2.35 A resolution
3OQQ	;	2.08	;	Crystal structure of a Putative lipoprotein (BACOVA_00967) from Bacteroides ovatus at 2.08 A resolution
4FVS	;	2.7	;	Crystal structure of a putative lipoprotein (BDI_3050) from Parabacteroides distasonis ATCC 8503 at 2.70 A resolution
4GBS	;	2.48	;	Crystal structure of a putative lipoprotein (BF2707) from Bacteroides fragilis NCTC 9343 at 2.75 A resolution
3NQI	;	1.87	;	Crystal structure of a Putative lipoprotein (BF3042) from Bacteroides fragilis NCTC 9343 at 1.87 A resolution
4KWY	;	2.4	;	Crystal structure of a putative lipoprotein (CC_3750) from Caulobacter crescentus CB15 at 2.40 A resolution
4EXR	;	1.85	;	Crystal structure of a putative lipoprotein (CD1622) from Clostridium difficile 630 at 1.85 A resolution
4OTE	;	2.2	;	Crystal structure of a putative lipoprotein (CD630_1653) from Clostridium difficile 630 at 2.20 A resolution
4IB2	;	1.76	;	Crystal structure of a putative lipoprotein (RUMGNA_00858) from Ruminococcus gnavus ATCC 29149 at 1.76 A resolution
4R4G	;	2.62	;	Crystal structure of a putative lipoprotein (ycdA) from Bacillus subtilis subsp. subtilis str. 168 at 2.62 A resolution
5CAI	;	2.3	;	Crystal structure of a putative lipoprotein from the DUF903 family (KPN_03160) from Klebsiella pneumoniae subsp. pneumoniae MGH 78578 at 2.30 A resolution
3QQW	;	2.44	;	Crystal structure of a putative lyase (Reut_B4148) from Ralstonia eutropha JMP134 at 2.44 A resolution
4LSB	;	1.8	;	Crystal structure of a putative lyase/mutase from Burkholderia cenocepacia J2315
4OMV	;	2.75	;	Crystal Structure of a Putative Macrophage Growth Locus, subunit A From Francisella tularensis SCHU S4
2A9F	;	2.5	;	Crystal structure of a putative malic enzyme ((S)-malate:NAD+ oxidoreductase (decarboxylating))
2HAE	;	3.13	;	Crystal structure of a putative malic enzyme (malate oxidoreductase)
4E5T	;	2.9	;	Crystal structure of a putative Mandelate racemase/Muconate lactonizing enzyme (Target PSI-200750) from Labrenzia alexandrii DFL-11
4E4U	;	1.35	;	Crystal structure of a putative Mandelate racemase/Muconate lactonizing enzyme (Target PSI-200780) from Burkholderia SAR-1
3T9P	;	1.97	;	Crystal structure of a putative mandelate racemase/muconate lactonizing enzyme family protein from Roseovarius
4JHM	;	2.8	;	Crystal structure of a putative mandelate racemase/muconate lactonizing enzyme from Pseudovibrio sp.
3EEZ	;	2.8	;	Crystal structure of a putative mandelate racemase/muconate lactonizing enzyme from Silicibacter pomeroyi
3SQS	;	1.9	;	Crystal Structure of a putative mandelate racemase/muconate lactonizing protein from Dinoroseobacter shibae DFL 12
2OPK	;	2.1	;	CRYSTAL STRUCTURE OF A PUTATIVE MANNOSE-6-PHOSPHATE ISOMERASE (REUT_A1446) FROM RALSTONIA EUTROPHA JMP134 AT 2.10 A RESOLUTION
4G5A	;	1.69	;	Crystal structure of a putative member of duf 3244 protein family (BT_1867) from Bacteroides thetaiotaomicron VPI-5482 at 1.69 A resolution
3SD2	;	1.4	;	Crystal structure of a putative member of duf3244 protein family (BT_3571) from Bacteroides thetaiotaomicron vpi-5482 at 1.40 A resolution
2HKV	;	1.7	;	CRYSTAL STRUCTURE OF A PUTATIVE MEMBER OF THE DINB FAMILY (EXIG_1237) FROM EXIGUOBACTERIUM SIBIRICUM 255-15 AT 1.70 A RESOLUTION
3C8I	;	1.95	;	Crystal structure of a putative membrane protein from Corynebacterium diphtheriae
3DZA	;	1.65	;	Crystal structure of a putative membrane protein of unknown function (yfdx) from klebsiella pneumoniae subsp. at 1.65 A resolution
3U7Z	;	1.3	;	Crystal structure of a putative metal binding protein RUMGNA_00854 (ZP_02040092.1) from Ruminococcus gnavus ATCC 29149 at 1.30 A resolution
2OGI	;	1.85	;	Crystal structure of a putative metal dependent phosphohydrolase (sag1661) from streptococcus agalactiae serogroup v at 1.85 A resolution
2P1A	;	2.1	;	Crystal structure of a putative metal-binding protein (bce_2162) from bacillus cereus atcc 10987 at 2.10 A resolution
2P97	;	1.65	;	CRYSTAL STRUCTURE OF A PUTATIVE METAL-DEPENDENT HYDROLASE (AVA_3068) FROM ANABAENA VARIABILIS ATCC 29413 AT 1.65 A RESOLUTION
2QE9	;	1.9	;	Crystal structure of a putative metal-dependent hydrolase (yiza, bsu10800) from bacillus subtilis at 1.90 A resolution
3KHI	;	1.95	;	Crystal structure of a Putative Metal-dependent Hydrolase (YP_001336084.1) from Klebsiella pneumoniae subsp. pneumoniae MGH 78578 at 1.95 A resolution
3DL1	;	2.2	;	Crystal structure of a Putative Metal-dependent Hydrolase (YP_001336084.1) from Klebsiella pneumoniae subsp. pneumoniae MGH 78578 at 2.20 A resolution
3O0F	;	1.94	;	Crystal structure of a putative metal-dependent phosphoesterase (BAD_1165) from bifidobacterium adolescentis atcc 15703 at 1.94 A resolution
3E0F	;	2.4	;	Crystal structure of a putative metal-dependent phosphoesterase (bad_1165) from bifidobacterium adolescentis atcc 15703 at 2.40 A resolution
1ZTC	;	2.1	;	Crystal structure of a putative metallo-beta-lactamase (tm0894) from Thermotoga maritima at 2.10 A resolution
2OU6	;	1.8	;	Crystal structure of a putative metalloenzyme of the duf664 family (dr_1065) from deinococcus radiodurans at 1.80 A resolution
2QVP	;	2.0	;	CRYSTAL STRUCTURE OF A PUTATIVE METALLOPEPTIDASE (SAMA_0725) FROM SHEWANELLA AMAZONENSIS SB2B AT 2.00 A RESOLUTION
3B2Y	;	1.74	;	CRYSTAL STRUCTURE OF a putative metallopeptidase (SDEN_2526) FROM SHEWANELLA DENITRIFICANS OS217 AT 1.74 A RESOLUTION
4GOT	;	1.95	;	Crystal structure of a putative methionine-binding lipoprotein (BSU32730) from Bacillus subtilis subsp. subtilis str. 168 at 1.95 A resolution
3GM5	;	2.0	;	Crystal structure of a putative methylmalonyl-coenzyme A epimerase from Thermoanaerobacter tengcongensis at 2.0 A resolution
4KN5	;	1.7	;	Crystal structure of a putative methylthioadenosine nucleosidase from Weissella paramesenteroides ATCC 33313 (Target NYSGRC-029342 )
3CC8	;	1.64	;	Crystal structure of a putative methyltransferase (bce_1332) from bacillus cereus atcc 10987 at 1.64 A resolution
1VL5	;	1.95	;	CRYSTAL STRUCTURE OF A PUTATIVE METHYLTRANSFERASE (BH2331) FROM BACILLUS HALODURANS C-125 AT 1.95 A RESOLUTION
2I6G	;	1.9	;	Crystal structure of a putative methyltransferase (tehb, stm1608) from salmonella typhimurium lt2 at 1.90 A resolution
2QE6	;	1.95	;	CRYSTAL STRUCTURE OF A PUTATIVE METHYLTRANSFERASE (TFU_2867) FROM THERMOBIFIDA FUSCA YX AT 1.95 A RESOLUTION
4IWN	;	1.73	;	Crystal structure of a putative methyltransferase CmoA in complex with a novel SAM derivative
4ISC	;	2.78	;	Crystal structure of a putative Methyltransferase from Pseudomonas syringae
1VL4	;	1.95	;	CRYSTAL STRUCTURE OF A PUTATIVE MODULATOR OF A DNA GYRASE (TM0727) FROM THERMOTOGA MARITIMA MSB8 AT 1.95 A RESOLUTION
1VPB	;	1.75	;	CRYSTAL STRUCTURE OF A PUTATIVE MODULATOR OF DNA GYRASE (BT3649) FROM BACTEROIDES THETAIOTAOMICRON VPI-5482 AT 1.75 A RESOLUTION
4Q51	;	1.9	;	Crystal structure of a putative molybdenum cofactor biosynthesis protein F from Burkholderia cenocepacia J2315
2RIL	;	1.26	;	Crystal structure of a putative monooxygenase (YP_001095275.1) from Shewanella loihica PV-4 at 1.26 A resolution
4IAB	;	1.66	;	Crystal structure of a putative monosaccharide binding protein (BACUNI_03039) from Bacteroides uniformis ATCC 8492 at 1.70 A resolution
2PGW	;	1.95	;	Crystal structure of a putative muconate cycloisomerase from Sinorhizobium meliloti 1021
3BDD	;	2.2	;	CRYSTAL STRUCTURE OF A PUTATIVE MULTIPLE ANTIBIOTIC-RESISTANCE REPRESSOR (SSU05_1136) FROM STREPTOCOCCUS SUIS 89/1591 AT 2.20 A RESOLUTION
2HTB	;	2.5	;	Crystal Structure of a putative mutarotase (YeaD) from Salmonella typhimurium in monoclinic form
2HTA	;	1.9	;	Crystal Structure of a putative mutarotase (YeaD) from Salmonella typhimurium in orthorhombic form
4HKT	;	2.0	;	Crystal structure of a putative myo-inositol dehydrogenase from Sinorhizobium meliloti 1021 (Target PSI-012312)
3FIX	;	2.3	;	Crystal structure of a putative n-acetyltransferase (ta0374) from thermoplasma acidophilum
3UF0	;	2.0	;	Crystal structure of a putative NAD(P) dependent gluconate 5-dehydrogenase from Beutenbergia cavernae(EFI target EFI-502044) with bound NADP (low occupancy)
3GE5	;	1.7	;	Crystal structure of a putative nad(p)h:fmn oxidoreductase (pg0310) from porphyromonas gingivalis w83 at 1.70 A resolution
3GBH	;	2.0	;	CRYSTAL STRUCTURE OF A PUTATIVE NAD(P)H:FMN OXIDOREDUCTASE (SE1966) FROM STAPHYLOCOCCUS EPIDERMIDIS ATCC 12228 AT 2.00 A RESOLUTION
3DB2	;	1.7	;	Crystal structure of a putative nadph-dependent oxidoreductase (dhaf_2064) from desulfitobacterium hafniense dcb-2 at 1.70 A resolution
3PI7	;	1.71	;	Crystal structure of a putative NADPH:quinone reductase (mll3093) from Mesorhizobium loti at 1.71 A resolution
4Q6K	;	1.902	;	Crystal structure of a putative neuraminidase (BACCAC_01090) from Bacteroides caccae ATCC 43185 at 1.90 A resolution (PSI Community Target)
4IRT	;	1.74	;	Crystal structure of a putative neuraminidase (BACOVA_03493) from Bacteroides ovatus ATCC 8483 at 1.74 A resolution
3H6J	;	1.6	;	Crystal structure of a putative neuraminidase from Pseudomonas aeruginosa
1VLP	;	1.75	;	Crystal structure of a putative nicotinate phosphoribosyltransferase (yor209c, npt1) from saccharomyces cerevisiae at 1.75 A resolution
3L0Z	;	2.65	;	Crystal structure of a putative Nicotinate-nucleotide-dimethylbenzimidazole phosphoribosyltransferase from Methanocaldococcus jannaschii DSM 2661
3MST	;	1.35	;	Crystal structure of a Putative nitrate transport protein (TVN0104) from THERMOPLASMA VOLCANIUM at 1.35 A resolution
3EO7	;	1.8	;	Crystal structure of a putative nitroreductase (ava_2154) from anabaena variabilis atcc 29413 at 1.80 A resolution
3HJ9	;	2.0	;	Crystal structure of a putative nitroreductase (reut_a1228) from ralstonia eutropha jmp134 at 2.00 A resolution
1VKW	;	2.0	;	Crystal structure of a putative nitroreductase (tm1586) from thermotoga maritima msb8 at 2.00 A resolution
4G8S	;	2.2	;	Crystal Structure Of a Putative Nitroreductase from Geobacter sulfurreducens PCA (Target PSI-013445)
3GFA	;	1.35	;	Crystal structure of a putative nitroreductase in complex with fmn (cd3205) from clostridium difficile 630 at 1.35 A resolution
3E39	;	1.7	;	Crystal structure of a putative nitroreductase in complex with fmn (dde_0787) from desulfovibrio desulfuricans subsp. at 1.70 A resolution
3GE6	;	1.85	;	CRYSTAL STRUCTURE OF A PUTATIVE NITROREDUCTASE IN COMPLEX WITH FMN (EXIG_2970) FROM EXIGUOBACTERIUM SIBIRICUM 255-15 AT 1.85 A RESOLUTION
3NL9	;	1.78	;	Crystal structure of a putative NTP pyrophosphohydrolase (Exig_1061) from EXIGUOBACTERIUM SP. 255-15 at 1.78 A resolution
3OT2	;	1.96	;	Crystal structure of a putative nuclease belonging to DUF820 (Ava_3926) from Anabaena variabilis ATCC 29413 at 1.96 A resolution
1ZUP	;	2.2	;	CRYSTAL STRUCTURE OF A PUTATIVE NUCLEASE WITH A RIBONUCLEASE H-LIKE MOTIF FOLD (TM1739) FROM THERMOTOGA MARITIMA AT 2.20 A RESOLUTION
7JTA	;	2.801	;	Crystal structure of a putative nuclease with anti-Cas9 activity from an uncultured Clostridia bacterium
2OD5	;	1.79	;	CRYSTAL STRUCTURE OF A PUTATIVE NUCLEIC ACID BINDING PROTEIN (JCVI_PEP_1096688149193) FROM UNCULTURED MARINE ORGANISM AT 1.79 A RESOLUTION
2G42	;	2.28	;	Crystal structure of a putative nucleic acid binding protein (tm0693) from thermotoga maritima at 2.28 A resolution
2FZT	;	2.05	;	CRYSTAL STRUCTURE OF a putative nucleic acid binding protein (TM0693) FROM THERMOTOGA MARITIMA MSB8 AT 2.05 A RESOLUTION
4MCJ	;	2.4	;	Crystal structure of a putative nucleoside deoxyribosyltransferase (BDI_0649) from Parabacteroides distasonis ATCC 8503 at 2.40 A resolution
2G0T	;	2.67	;	Crystal structure of a putative nucleotide binding protein (tm0796) from Thermotoga maritima at 2.67 A resolution
2RFF	;	1.4	;	Crystal structure of a putative nucleotidyltransferase (NP_343093.1) from Sulfolobus solfataricus at 1.40 A resolution
2FCL	;	1.2	;	Crystal structure of a putative nucleotidyltransferase (tm1012) from Thermotoga maritima at 1.35 A resolution
2EWR	;	1.6	;	Crystal structure of a putative nucleotidyltransferase (tm1012) from Thermotoga maritima at 1.60 A resolution
4HX0	;	1.87	;	Crystal structure of a putative nucleotidyltransferase (TM1012) from Thermotoga maritima at 1.87 A resolution
4G2A	;	2.33	;	Crystal structure of a putative nutrient binding protein (lpg2210) from Legionella pneumophila subsp. pneumophila str. Philadelphia 1 at 2.33 A resolution
2R3S	;	2.15	;	CRYSTAL STRUCTURE OF A PUTATIVE O-METHYLTRANSFERASE (NPUN_R0239) FROM NOSTOC PUNCTIFORME PCC 73102 AT 2.15 A RESOLUTION
3TFW	;	1.88	;	Crystal structure of a putative O-methyltransferase from Klebsiella pneumoniae
1VKI	;	1.6	;	Crystal structure of a putative oligo-nucleotide binding protein (atu3699, agr_l_2275) from agrobacterium tumefaciens str. c58 at 1.60 A resolution
3SKS	;	2.05	;	Crystal structure of a putative oligoendopeptidase F from Bacillus anthracis str. Ames
6WPN	;	2.29	;	Crystal structure of a putative oligosaccharide periplasmic-binding protein from Synechococcus sp. MITs9220
6WPM	;	2.88	;	Crystal structure of a putative oligosaccharide periplasmic-binding protein from Synechococcus sp. MITs9220 in complex with zinc
3I07	;	1.5	;	Crystal structure of a putative organic hydroperoxide resistance protein from Vibrio cholerae O1 biovar eltor str. N16961
3LUS	;	1.96	;	Crystal structure of a putative organic hydroperoxide resistance protein with molecule of captopril bound in one of the active sites from Vibrio cholerae O1 biovar eltor str. N16961
4NOG	;	1.2	;	Crystal structure of a putative ornithine aminotransferase from Toxoplasma gondii ME49 in complex with pyrodoxal-5'-phosphate
2PN2	;	1.95	;	CRYSTAL STRUCTURE OF A PUTATIVE OSMOTIC STRESS INDUCED AND DETOXIFICATION RESPONSE PROTEIN (PSYC_0566) FROM PSYCHROBACTER ARCTICUS 273-4 AT 2.15 A RESOLUTION
2ONF	;	1.7	;	Crystal structure of a putative osmotically inducible protein c (ta0195) from thermoplasma acidophilum at 1.70 A resolution
4KQT	;	2.83	;	Crystal structure of a putative outer membrane chaperone (OmpH-like) (CC_1914) from Caulobacter crescentus CB15 at 2.83 A resolution (PSI Community Target, Shapiro)
3RWX	;	2.4	;	Crystal structure of a putative outer membrane protein (BF2706) from Bacteroides fragilis NCTC 9343 at 2.40 A resolution
4LER	;	1.42	;	Crystal structure of a putative outer membrane protein, probably involved in nutrient binding (BVU_1254) from Bacteroides vulgatus ATCC 8482 at 1.42 A resolution
2Q9K	;	1.59	;	Crystal structure of a putative oxidoreductase (exig_1997) from exiguobacterium sibiricum 255-15 at 1.59 A resolution
4OO3	;	2.23	;	Crystal structure of a putative oxidoreductase (PARMER_00841) from Parabacteroides merdae ATCC 43184 at 2.23 A resolution
3RH7	;	3.0	;	Crystal structure of a putative oxidoreductase (SMa0793) from Sinorhizobium meliloti 1021 at 3.00 A resolution
1TLT	;	2.7	;	Crystal Structure of a Putative Oxidoreductase (VIRULENCE FACTOR mviM HOMOLOG)
3C24	;	1.62	;	Crystal structure of a putative oxidoreductase (YP_511008.1) from Jannaschia sp. CCS1 at 1.62 A resolution
3C1A	;	1.85	;	Crystal structure of a putative oxidoreductase (ZP_00056571.1) from Magnetospirillum magnetotacticum MS-1 at 1.85 A resolution
3FHL	;	1.93	;	Crystal structure of a putative oxidoreductase from bacteroides fragilis nctc 9343
3E82	;	2.04	;	Crystal structure of a putative oxidoreductase from Klebsiella pneumoniae
3QHA	;	2.25	;	Crystal structure of a Putative oxidoreductase from Mycobacterium avium 104
3U3X	;	2.79	;	Crystal structure of a putative oxidoreductase from Sinorhizobium meliloti 1021
3VC7	;	2.231	;	Crystal Structure of a putative oxidoreductase from Sinorhizobium meliloti 1021
4PMJ	;	2.2	;	Crystal structure of a putative oxidoreductase from Sinorhizobium meliloti 1021 in complex with NADP
4YQZ	;	1.807	;	Crystal Structure of a putative oxidoreductase from Thermus Thermophilus HB27 (TT_P0034, TARGET EFI-513932) in its APO form
2QS7	;	2.09	;	CRYSTAL STRUCTURE OF a putative oxidoreductase of the DsrE/DsrF-like family (SSO1126) FROM SULFOLOBUS SOLFATARICUS P2 AT 2.09 A RESOLUTION
4ESO	;	1.906	;	Crystal structure of a putative oxidoreductase protein from Sinorhizobium meliloti 1021 in complex with NADP
6O15	;	1.35	;	Crystal structure of a putative oxidoreductase YjhC from Escherichia coli in complex with NAD(H)
4Z0T	;	1.5	;	Crystal Structure of a putative oxoacyl-(acyl carrier protein) reductase from Brucella ovis
3ON7	;	2.2	;	Crystal structure of a Putative oxygenase (SO_2589) from Shewanella oneidensis at 2.20 A resolution
2G2D	;	2.0	;	Crystal structure of a putative pduO-type ATP:cobalamin adenosyltransferase from Mycobacterium tuberculosis
4DF9	;	2.17	;	Crystal structure of a putative peptidase (BF3526) from Bacteroides fragilis NCTC 9343 at 2.17 A resolution
4L8K	;	2.26	;	Crystal structure of a putative peptidase (PARMER_02772) from Parabacteroides merdae ATCC 43184 at 2.26 A resolution
1VIX	;	2.5	;	Crystal structure of a putative peptidase T
1VHO	;	1.86	;	Crystal structure of a putative peptidase/endoglucanase
3NOH	;	1.6	;	Crystal structure of a putative peptide binding protein (RUMGNA_00914) from Ruminococcus gnavus ATCC 29149 at 1.60 A resolution
6I3G	;	2.0	;	Crystal structure of a putative peptide binding protein AppA from Clostridium difficile
5K8G	;	2.0	;	Crystal structure of a putative peptide-binding domain of MpAFP
4OVD	;	2.0	;	Crystal structure of a putative peptidoglycan glycosyltransferase from Atopobium parvulum DSM 20469
2CMU	;	2.5	;	Crystal structure of a putative peptidyl-arginine deiminase
4POI	;	2.3	;	Crystal structure of a putative periplasmic protein (BACCAC_02096) from Bacteroides caccae ATCC 43185 at 2.30 A resolution
4DSD	;	1.75	;	Crystal structure of a putative periplasmic protein (BACOVA_05534) from Bacteroides ovatus ATCC 8483 at 1.75 A resolution
4QOA	;	2.75	;	Crystal structure of a putative periplasmic protein (BACUNI_04550) from Bacteroides uniformis ATCC 8492 at 2.75 A resolution
3DUE	;	1.85	;	CRYSTAL STRUCTURE OF A PUTATIVE PERIPLASMIC PROTEIN FROM DUF2874 FAMILY (BVU_2987) FROM BACTEROIDES VULGATUS ATCC 8482 AT 1.85 A RESOLUTION
3ELG	;	1.64	;	Crystal structure of a putative periplasmic protein of unknown function (bvu_2443) from bacteroides vulgatus atcc 8482 at 1.64 A resolution
4HBR	;	2.4	;	Crystal structure of a putative periplasmic proteins (BACEGG_01429) from Bacteroides eggerthii DSM 20697 at 2.40 A resolution
5BRA	;	2.971	;	Crystal Structure of a putative Periplasmic Solute binding protein (IPR025997) from Ochrobactrum Anthropi ATCC49188 (Oant_2843, TARGET EFI-511085)
2F46	;	1.41	;	Crystal structure of a putative phosphatase (nma1982) from neisseria meningitidis z2491 at 1.41 A resolution
3DAO	;	1.8	;	CRYSTAL STRUCTURE OF A PUTATIVE PHOSPHATE (EUBREC_1417) FROM EUBACTERIUM RECTALE AT 1.80 A RESOLUTION
3N08	;	1.25	;	Crystal Structure of a Putative PhosphatidylEthanolamine-Binding Protein (PEBP) Homolog CT736 from Chlamydia trachomatis D/UW-3/CX
2BL1	;	2.0	;	Crystal structure of a putative phosphinothricin Acetyltransferase (PA4866) from Pseudomonas aeruginosa PAC1
1VHS	;	1.8	;	Crystal structure of a putative phosphinothricin N-acetyltransferase
2Q7X	;	2.0	;	Crystal structure of a putative phospho transferase (sp_1565) from streptococcus pneumoniae tigr4 at 2.00 A resolution
2QIW	;	1.8	;	Crystal structure of a putative phosphoenolpyruvate phosphonomutase (ncgl1015, cgl1060) from corynebacterium glutamicum atcc 13032 at 1.80 A resolution
3MTQ	;	1.7	;	Crystal structure of a putative phosphoenolpyruvate-dependent sugar phosphotransferase system (PTS) permease (KPN_04802) from Klebsiella pneumoniae subsp. pneumoniae MGH 78578 at 1.70 A resolution
1VHU	;	1.34	;	Crystal structure of a putative phosphoesterase
2JG5	;	2.3	;	CRYSTAL STRUCTURE OF A PUTATIVE PHOSPHOFRUCTOKINASE FROM STAPHYLOCOCCUS AUREUS
3CVJ	;	2.0	;	Crystal structure of a putative phosphoheptose isomerase (bh3325) from bacillus halodurans c-125 at 2.00 A resolution
3MBH	;	2.0	;	Crystal structure of a putative phosphomethylpyrimidine kinase (BT_4458) from BACTEROIDES THETAIOTAOMICRON VPI-5482 at 2.00 A resolution (orthorhombic form with pyridoxal)
3MBJ	;	2.1	;	Crystal structure of a putative phosphomethylpyrimidine kinase (BT_4458) from BACTEROIDES THETAIOTAOMICRON VPI-5482 at 2.10 A resolution (rhombohedral form)
4MG4	;	1.7	;	Crystal structure of a putative phosphonomutase from Burkholderia cenocepacia J2315
2P10	;	2.15	;	CRYSTAL STRUCTURE OF A PUTATIVE PHOSPHONOPYRUVATE HYDROLASE (MLL9387) FROM MESORHIZOBIUM LOTI MAFF303099 AT 2.15 A RESOLUTION
3MDO	;	1.91	;	Crystal structure of a Putative phosphoribosylformylglycinamidine cyclo-ligase (BDI_2101) from Parabacteroides distasonis ATCC 8503 at 1.91 A resolution
3EUA	;	1.9	;	CRYSTAL STRUCTURE OF A PUTATIVE PHOSPHOSUGAR ISOMERASE (BSU32610) FROM BACILLUS SUBTILIS AT 1.90 A RESOLUTION
3G68	;	1.8	;	CRYSTAL STRUCTURE OF A PUTATIVE PHOSPHOSUGAR ISOMERASE (CD3275) FROM CLOSTRIDIUM DIFFICILE 630 AT 1.80 A RESOLUTION
3HBA	;	2.0	;	Crystal structure of a putative phosphosugar isomerase (sden_2705) from shewanella denitrificans os217 at 2.00 A resolution
3FKJ	;	2.12	;	Crystal structure of a putative phosphosugar isomerase (stm_0572) from salmonella typhimurium lt2 at 2.12 A resolution
2IIU	;	2.28	;	Crystal structure of a putative PhoU-like phosphate regulatory protein (NP_719307.1) from Shewanella oneidensis MR-1 at 2.28 A resolution.
1O51	;	2.5	;	Crystal structure of a putative PII-like signaling protein (TM0021) from Thermotoga maritima at 2.50 A resolution
2CZ4	;	1.93	;	Crystal structure of a putative PII-like signaling protein (TTHA0516) from Thermus thermophilus HB8
3DFE	;	2.35	;	Crystal structure of a Putative Pii-Like Signaling Protein (YP_323533.1) from ANABAENA VARIABILIS ATCC 29413 at 2.35 A resolution
4DN6	;	2.8	;	Crystal structure of a putative pilus assembly protein (cpaE) from Burkholderia thailandensis E264 at 2.80 A resolution
4DAD	;	2.5	;	Crystal structure of a Putative pilus assembly-related protein (BPSS2195) from Burkholderia pseudomallei K96243 at 2.50 A resolution (PSI Community Target, Shapiro L.)
3DZZ	;	1.61	;	CRYSTAL STRUCTURE OF A PUTATIVE PLP-DEPENDENT AMINOTRANSFERASE (LBUL_1103) FROM LACTOBACILLUS DELBRUECKII SUBSP. AT 1.61 A RESOLUTION
3FDB	;	1.99	;	Crystal structure of a putative plp-dependent beta-cystathionase (aecd, dip1736) from corynebacterium diphtheriae at 1.99 A resolution
3HP0	;	2.32	;	Crystal structure of a Putative polyketide biosynthesis enoyl-CoA hydratase (pksH) from Bacillus subtilis
4LGQ	;	2.72	;	Crystal structure of a putative polyketide cyclase (CV_0247) from Chromobacterium violaceum ATCC 12472 at 2.72 A resolution
3F9S	;	1.76	;	Crystal structure of a putative polyketide cyclase (lferr_0659) from acidithiobacillus ferrooxidans atcc at 1.76 A resolution
3F7X	;	1.24	;	Crystal structure of a putative polyketide cyclase (pp0894) from pseudomonas putida kt2440 at 1.24 A resolution
3F8H	;	2.0	;	Crystal structure of a putative polyketide cyclase (tm1040_3560) from silicibacter sp. tm1040 at 2.00 A resolution
3I0Y	;	1.5	;	Crystal structure of a putative polyketide cyclase (xcc0381) from xanthomonas campestris pv. campestris at 1.50 A resolution
4DWE	;	2.01	;	Crystal structure of a putative polysaccharide deacetylase (BACOVA_03992) from Bacteroides ovatus ATCC 8483 at 2.01 A resolution
3HFT	;	1.9	;	Crystal structure of a putative polysaccharide deacetylase involved in o-antigen biosynthesis (wbms, bb0128) from bordetella bronchiseptica at 1.90 A resolution
3KTD	;	2.6	;	CRYSTAL STRUCTURE OF A PUTATIVE PREPHENATE DEHYDROGENASE (CGL0226) FROM CORYNEBACTERIUM GLUTAMICUM ATCC 13032 AT 2.60 A RESOLUTION
2QGZ	;	2.4	;	Crystal structure of a putative primosome component from Streptococcus pyogenes serotype M3. Northeast Structural Genomics target DR58
4GHN	;	1.5	;	Crystal structure of a putative protease (BACUNI_00178) from Bacteroides uniformis ATCC 8492 at 1.50 A resolution
3KD4	;	2.0	;	CRYSTAL STRUCTURE OF A PUTATIVE PROTEASE (BDI_1141) FROM PARABACTEROIDES DISTASONIS ATCC 8503 AT 2.00 A RESOLUTION
4D1Y	;	2.6	;	Crystal structure of a putative protease from Bacteroides thetaiotaomicron.
2EHP	;	1.3	;	Crystal Structure of a Putative protein (AQ1627) from Aquifex aeolicus
2EIU	;	2.0	;	Crystal Structure of a Putative protein (AQ1627) from Aquifex aeolicus
3URZ	;	2.19	;	Crystal structure of a putative protein binding protein (BACOVA_03105) from Bacteroides ovatus ATCC 8483 at 2.19 A resolution
2IN3	;	1.85	;	Crystal structure of a putative protein disulfide isomerase from Nitrosomonas europaea
3GN3	;	2.5	;	Crystal structure of a putative protein-disulfide isomerase from Pseudomonas syringae to 2.5A resolution.
2PBF	;	2.0	;	Crystal structure of a putative protein-L-isoaspartate O-methyltransferase beta-aspartate methyltransferase (PCMT) from Plasmodium falciparum in complex with S-adenosyl-L-homocysteine
4LDN	;	1.48	;	Crystal structure of a putative purine nucleoside phosphorylase from Vibrio fischeri ES114 (Target NYSGRC-029521)
4TRR	;	1.9	;	Crystal structure of a putative Putative D-beta-hydroxybutyrate dehydrogenase from Burkholderia cenocepacia J2315
2HTD	;	1.6	;	CRYSTAL STRUCTURE OF A PUTATIVE PYRIDOXAMINE 5'-PHOSPHATE OXIDASE (LDB0262) FROM LACTOBACILLUS DELBRUECKII SUBSP. AT 1.60 A RESOLUTION
2A2J	;	2.5	;	Crystal structure of a putative pyridoxine 5'-phosphate oxidase (Rv2607) from Mycobacterium tuberculosis
3H5Q	;	1.94	;	Crystal structure of a putative pyrimidine-nucleoside phosphorylase from Staphylococcus aureus
4WR2	;	1.7	;	Crystal structure of a putative pyrimidine-specific ribonucleoside hydrolase (RihA) Protein from Shewanella loihica PV-4 (SHEW_0697, Target PSI-029635) with divalent cation and PEG 400 bound at the active site
2H0V	;	2.6	;	Crystal structure of a putative quercetin 2,3-dioxygenase (yxag, bsu39980) from bacillus subtilis at 2.60 A resolution
4GI5	;	1.75	;	Crystal Structure Of a Putative quinone reductase from Klebsiella pneumoniae (Target PSI-013613)
3MKC	;	1.77	;	Crystal structure of a putative racemase
3TCS	;	1.88	;	Crystal structure of a putative racemase from Roseobacter denitrificans
3NZG	;	2.0	;	Crystal structure of a putative racemase with Mg ion
2O9X	;	3.4	;	Crystal Structure Of A Putative Redox Enzyme Maturation Protein From Archaeoglobus Fulgidus
2QL8	;	1.5	;	Crystal structure of a putative redox protein (lsei_0423) from lactobacillus casei atcc 334 at 1.50 A resolution
3DEE	;	2.1	;	CRYSTAL STRUCTURE OF A PUTATIVE REGULATORY PROTEIN INVOLVED IN TRANSCRIPTION (NGO1945) FROM NEISSERIA GONORRHOEAE FA 1090 AT 2.25 A RESOLUTION
3T6K	;	1.86	;	Crystal structure of a putative response regulator (Caur_3799) from Chloroflexus aurantiacus J-10-fl at 1.86 A resolution
3H49	;	1.8	;	Crystal structure of a putative Ribokinase (Apo Form) from E.coli at 1.8A resolution
2RBC	;	1.9	;	Crystal structure of a putative ribokinase from Agrobacterium tumefaciens
3K9E	;	2.05	;	Crystal structure of a putative Ribokinase II (Apo Form) from E.coli
3IQ0	;	1.79	;	Crystal structure of a putative Ribokinase II in complex with ATP and Mg+2 from E.coli
3IN1	;	2.15	;	Crystal structure of a putative Ribokinase in complex with ADP from E.coli
3C5Y	;	1.81	;	Crystal structure of a putative ribose 5-phosphate isomerase (saro_3514) from novosphingobium aromaticivorans dsm at 1.81 A resolution
3EGC	;	2.35	;	Crystal structure of a putative ribose operon repressor from Burkholderia thailandensis
3QD5	;	1.9	;	Crystal structure of a putative ribose-5-phosphate isomerase from Coccidioides immitis solved by combined iodide ion SAD and MR
1WY7	;	2.2	;	crystal structure of a putative RNA methyltransferase PH1948 from Pyrococcus horikoshii
3DCZ	;	1.65	;	CRYSTAL STRUCTURE OF A PUTATIVE RNFG SUBUNIT OF ELECTRON TRANSPORT COMPLEX (TM0246) FROM THERMOTOGA MARITIMA AT 1.65 A RESOLUTION
3DFU	;	2.07	;	CRYSTAL STRUCTURE OF A PUTATIVE ROSSMANN-LIKE DEHYDROGENASE (CGL2689) FROM CORYNEBACTERIUM GLUTAMICUM AT 2.07 A RESOLUTION
3DLC	;	1.15	;	Crystal structure of a putative s-adenosyl-l-methionine-dependent methyltransferase (mmp1179) from methanococcus maripaludis at 1.15 A resolution
4ODJ	;	1.6	;	Crystal structure of a putative S-adenosylmethionine synthetase from Cryptosporidium hominis in complex with S-adenosyl-methionine
2O57	;	1.946	;	Crystal Structure of a putative sarcosine dimethylglycine methyltransferase from Galdieria sulphuraria
4H3W	;	1.87	;	Crystal structure of a putative secreted protein (BDI_1231) from Parabacteroides distasonis ATCC 8503 at 2.00 A resolution
3OWR	;	1.81	;	Crystal structure of a putative secreted protein (BF4250) from Bacteroides fragilis NCTC 9343 at 1.81 A resolution
3P69	;	2.05	;	Crystal structure of a putative secreted protein (BF4250) from Bacteroides fragilis NCTC 9343 at 2.05 A resolution
4LR4	;	2.43	;	Crystal structure of a putative secreted protein (EUBREC_3654) from Eubacterium rectale at 2.43 A resolution
4JX2	;	2.65	;	Crystal structure of a putative secreted protein (lpg1979) from Legionella pneumophila subsp. pneumophila str. Philadelphia 1 at 2.65 A resolution
3NPD	;	1.6	;	Crystal structure of a putative secreted protein (PA3611) from PSEUDOMONAS AERUGINOSA at 1.60 A resolution
3RJV	;	1.65	;	Crystal structure of a putative sel1 repeat protein (kpn_04481) from Klebsiella pneumoniae subsp. pneumoniae at 1.65 a resolution
3FN2	;	1.9	;	Crystal structure of a putative sensor histidine kinase domain from Clostridium symbiosum ATCC 14940
3KSR	;	2.69	;	CRYSTAL STRUCTURE OF A PUTATIVE SERINE HYDROLASE (XCC3885) FROM XANTHOMONAS CAMPESTRIS PV. CAMPESTRIS AT 2.69 A RESOLUTION
1VKH	;	1.85	;	CRYSTAL STRUCTURE OF A PUTATIVE SERINE HYDROLASE (YDR428C) FROM SACCHAROMYCES CEREVISIAE AT 1.85 A RESOLUTION
5JYD	;	1.65	;	Crystal Structure of a Putative Short Chain Dehydrogenase from Burkholderia cenocepacia
4LVU	;	1.25	;	Crystal Structure of a Putative Short Chain Dehydrogenase from Burkholderia thailandensis
4KZP	;	1.68	;	Crystal Structure of a Putative Short Chain Dehydrogenase from Mycobacterium smegmatis
3RIH	;	2.15	;	Crystal structure of a putative short chain dehydrogenase or reductase from Mycobacterium abscessus
5TT1	;	1.8	;	Crystal Structure of a Putative short-chain alcohol dehydrogenase from Burkholderia multivorans
4J2H	;	2.1	;	Crystal structure of a putative short-chain alcohol dehydrogenase from Sinorhizobium meliloti 1021 (Target NYSGRC-011708)
3QIV	;	2.25	;	Crystal structure of a putative short-chain dehydrogenase or 3-oxoacyl-[acyl-carrier-protein] reductase from Mycobacterium paratuberculosis ATCC BAA-968 / K-10
5IZ4	;	1.75	;	Crystal structure of a putative short-chain dehydrogenase/reductase from Burkholderia xenovorans
5JC8	;	1.45	;	Crystal structure of a putative short-chain dehydrogenase/reductase from Burkholderia xenovorans
3E9N	;	2.4	;	Crystal structure of a putative short-chain dehydrogenase/reductase from Corynebacterium glutamicum
3S55	;	2.1	;	Crystal structure of a putative short-chain dehydrogenase/reductase from Mycobacterium abscessus bound to NAD
3HYN	;	1.2	;	Crystal structure of a putative signal transduction protein (eubrec_0645) from eubacterium rectale atcc 33656 at 1.20 A resolution
3MEM	;	2.25	;	Crystal structure of a Putative signal transduction protein (Maqu_0641) from MARINOBACTER AQUAEOLEI VT8 at 2.25 A resolution
3HK4	;	1.96	;	CRYSTAL STRUCTURE OF A PUTATIVE SNOAL-LIKE POLYKETIDE CYCLASE [CARBOHYDRATE PHOSPHATASE] (MLR7391) FROM MESORHIZOBIUM LOTI AT 1.96 A RESOLUTION
2RBD	;	1.54	;	CRYSTAL STRUCTURE OF A PUTATIVE SPORE COAT PROTEIN (BH2358) FROM BACILLUS HALODURANS C-125 AT 1.54 A RESOLUTION
4MAK	;	1.1	;	Crystal structure of a putative ssRNA endonuclease Cas2, CRISPR adaptation protein from E.coli
3BN8	;	2.11	;	Crystal structure of a putative sterol carrier protein type 2 (af1534) from archaeoglobus fulgidus dsm 4304 at 2.11 A resolution
7TMV	;	2.3	;	Crystal structure of a Putative structural protein from Klebsiella pneumoniae
3ETF	;	1.85	;	Crystal structure of a putative succinate-semialdehyde dehydrogenase from salmonella typhimurium lt2
3EFV	;	1.9	;	Crystal Structure of a Putative Succinate-Semialdehyde Dehydrogenase from Salmonella typhimurium LT2 with bound NAD
3FMC	;	1.8	;	CRYSTAL STRUCTURE OF a putative succinylglutamate desuccinylase / aspartoacylase family protein (SAMA_0604) FROM SHEWANELLA AMAZONENSIS SB2B AT 1.80 A RESOLUTION
3SEE	;	1.25	;	Crystal structure of a putative sugar binding protein (BT_4411) from Bacteroides thetaiotaomicron VPI-5482 at 1.25 A resolution
3NMB	;	2.4	;	Crystal structure of a putative sugar hydrolase (BACOVA_03189) from Bacteroides ovatus at 2.40 A resolution
2G0W	;	1.7	;	CRYSTAL STRUCTURE OF A PUTATIVE SUGAR ISOMERASE (LMO2234) FROM LISTERIA MONOCYTOGENES AT 1.70 A RESOLUTION
3R8E	;	1.65	;	Crystal structure of a putative sugar kinase (CHU_1875) from Cytophaga hutchinsonii ATCC 33406 at 1.65 A resolution
3KZH	;	2.45	;	Crystal structure of a putative sugar kinase from Clostridium perfringens
2QW5	;	1.78	;	CRYSTAL STRUCTURE OF A PUTATIVE SUGAR PHOSPHATE ISOMERASE/EPIMERASE (AVA4194) FROM ANABAENA VARIABILIS ATCC 29413 AT 1.78 A RESOLUTION
3FXA	;	1.6	;	Crystal structure of a putative sugar-phosphate isomerase (lmof2365_0531) from listeria monocytogenes str. 4b f2365 at 1.60 A resolution
3B5Q	;	2.4	;	Crystal structure of a putative sulfatase (NP_810509.1) from Bacteroides thetaiotaomicron VPI-5482 at 2.40 A resolution
3PNX	;	1.92	;	Crystal structure of a putative sulfurtransferase dsrE (Swol_2425) from Syntrophomonas wolfei str. Goettingen at 1.92 A resolution
3QZB	;	1.1	;	Crystal structure of a putative superoxide reductase (TM0658) from THERMOTOGA MARITIMA at 1.10 A resolution
2AMU	;	2.0	;	CRYSTAL STRUCTURE OF A PUTATIVE SUPEROXIDE REDUCTASE (TM0658) FROM THERMOTOGA MARITIMA AT 2.00 A RESOLUTION
5VJ4	;	2.8	;	Crystal structure of a putative surface protein encoded by BTA121
3SNX	;	1.88	;	Crystal structure of a PUTATIVE SUSD-LIKE CARBOHYDRATE BINDING PROTEIN (BT_1439) from BACTEROIDES THETAIOTAOMICRON VPI-5482 at 1.88 A resolution
3ODP	;	2.35	;	Crystal structure of a putative tagatose-6-phosphate ketose/aldose isomerase (NT01CX_0292) from CLOSTRIDIUM NOVYI NT at 2.35 A resolution
4OJ5	;	1.8	;	Crystal Structure of a Putative Tailspike Protein (TSP1, orf210) from Escherichia coli O157:H7 Bacteriohage CBA120
4OJ6	;	1.8	;	Crystal Structure of a Putative Tailspike Protein (TSP1, orf210) from Escherichia coli O157:H7 Bacteriohage CBA120; Se-Met Protein
2QZC	;	1.5	;	Crystal structure of a putative tena-like thiaminase (tena-1, sso2206) from sulfolobus solfataricus p2 at 1.50 A resolution
3PPB	;	2.1	;	Crystal structure of a putative tetR family transcription regulator (Shew_3104) from SHEWANELLA SP. PV-4 at 2.10 A resolution
4ICH	;	1.95	;	Crystal structure of a putative TetR family transcriptional regulator from Saccharomonospora viridis DSM 43017
3BHQ	;	1.54	;	CRYSTAL STRUCTURE OF A PUTATIVE TETR-FAMILY TRANSCRIPTIONAL REGULATOR (MLR_4833) FROM MESORHIZOBIUM LOTI MAFF303099 AT 1.54 A RESOLUTION
3JSJ	;	2.1	;	Crystal structure of a putative tetr-transcriptional regulator (sav143) from streptomyces avermitilis ma-4680 at 2.10 A resolution
2RAS	;	1.8	;	Crystal structure of a putative tetr/acrr family transcriptional regulator (saro_0558) from novosphingobium aromaticivorans dsm at 1.80 A resolution
1VMJ	;	1.52	;	CRYSTAL STRUCTURE OF A PUTATIVE THIAMIN PHOSPHATE SYNTHASE (TM0723) FROM THERMOTOGA MARITIMA MSB8 AT 1.52 A RESOLUTION
3NO6	;	1.65	;	Crystal structure of a putative thiaminase II (SE1693) from Staphylococcus epidermidis ATCC 12228 at 1.65 A resolution
1VK8	;	1.8	;	CRYSTAL STRUCTURE OF A PUTATIVE THIAMINE BIOSYNTHESIS/SALVAGE PROTEIN (TM0486) FROM THERMOTOGA MARITIMA AT 1.80 A RESOLUTION
1VH5	;	1.34	;	Crystal structure of a putative thioesterase
1VH9	;	2.15	;	Crystal structure of a putative thioesterase
1VI8	;	2.2	;	Crystal structure of a putative thioesterase
2HLJ	;	2.0	;	CRYSTAL STRUCTURE OF A PUTATIVE THIOESTERASE (KT2440) FROM PSEUDOMONAS PUTIDA KT2440 AT 2.00 A RESOLUTION
2HX5	;	1.5	;	Crystal structure of a putative thioesterase (pmt_2055) from prochlorococcus marinus str. mit 9313 at 1.50 A resolution
3CK1	;	1.74	;	CRYSTAL STRUCTURE OF a putative thioesterase (REUT_A2179) FROM RALSTONIA EUTROPHA JMP134 AT 1.74 A RESOLUTION
2GF6	;	1.91	;	CRYSTAL STRUCTURE OF A PUTATIVE THIOESTERASE (SSO2295) FROM SULFOLOBUS SOLFATARICUS AT 1.91 A RESOLUTION
3HDU	;	2.5	;	CRYSTAL STRUCTURE OF A PUTATIVE THIOESTERASE (SYN_01977) FROM SYNTROPHUS ACIDITROPHICUS SB AT 2.50 A RESOLUTION
2QWZ	;	2.15	;	CRYSTAL STRUCTURE OF A PUTATIVE THIOESTERASE (TM1040_1390) FROM SILICIBACTER SP. TM1040 AT 2.15 A RESOLUTION
2PBL	;	1.79	;	Crystal structure of a putative thioesterase (tm1040_2492) from silicibacter sp. tm1040 at 1.79 A resolution
3BBJ	;	2.16	;	CRYSTAL STRUCTURE OF A PUTATIVE THIOESTERASE II (TFU_2367) FROM THERMOBIFIDA FUSCA YX AT 2.45 A RESOLUTION
2PIM	;	2.2	;	CRYSTAL STRUCTURE OF A PUTATIVE THIOESTERASE, PHENYLACETIC ACID DEGRADATION-RELATED PROTEIN (REUT_B4779) FROM RALSTONIA EUTROPHA JMP134 AT 2.20 A RESOLUTION
4KA0	;	2.1	;	Crystal structure of a putative thiol-disulfide oxidoreductase from Bacteroides vulgatus (target NYSGRC-011676), space group P21221
4K9Z	;	1.8	;	Crystal structure of a putative thiol-disulfide oxidoreductase from Bacteroides vulgatus (target NYSGRC-011676), space group P6222
3GL3	;	2.09	;	Crystal structure of a putative Thiol:disulfide interchange protein DsbE from Chlorobium tepidum
3P3A	;	2.1	;	Crystal structure of a putative thiosulfate sulfurtransferase from Mycobacterium thermoresistible
4PXY	;	1.5	;	Crystal structure of a Putative thua-like protein (BACUNI_01602) from Bacteroides uniformis ATCC 8492 at 1.50 A resolution
4JQS	;	2.3	;	Crystal structure of a Putative thua-like protein (BACUNI_01602) from Bacteroides uniformis ATCC 8492 at 2.30 A resolution
4E5V	;	1.75	;	Crystal structure of a Putative thua-like protein (PARMER_02418) from Parabacteroides merdae ATCC 43184 at 1.75 A resolution
4K3F	;	1.6	;	Crystal structure of a putative TonB-dependent receptor (PA5505) from Pseudomonas aeruginosa PAO1 at 1.60 A resolution
2CX5	;	1.9	;	Crystal structure of a putative trans-editing enzyme for prolyl tRNA synthetase
2YFK	;	2.55	;	Crystal structure of a putative transcarbamoylase from Enterococcus faecalis
4OBM	;	2.15	;	Crystal structure of a putative transcription regulator (EUBSIR_01389) from Eubacterium siraeum DSM 15702 at 2.15 A resolution
3PJY	;	1.55	;	Crystal structure of a putative transcription regulator (R01717) from Sinorhizobium meliloti 1021 at 1.55 A resolution
2QU7	;	2.3	;	Crystal structure of a putative transcription regulator from Staphylococcus saprophyticus subsp. saprophyticus
3K69	;	1.95	;	CRYSTAL STRUCTURE OF A PUTATIVE TRANSCRIPTIONAL REGULATOR (LP_0360) FROM LACTOBACILLUS PLANTARUM AT 1.95 A RESOLUTION
2A6C	;	1.9	;	CRYSTAL STRUCTURE OF A PUTATIVE TRANSCRIPTIONAL REGULATOR (NE_1354) FROM NITROSOMONAS EUROPAEA AT 1.90 A RESOLUTION
3KNW	;	2.45	;	Crystal structure of a putative transcriptional regulator (TetR/AcrR family member) from putative transcriptional regulator (TetR/AcrR family)
3QI7	;	1.86	;	Crystal structure of a Putative transcriptional regulator (YP_001089212.1) from Clostridium difficile 630 at 1.86 A resolution
4RYK	;	2.09	;	Crystal structure of a putative transcriptional regulator from Listeria monocytogenes EGD-e
4JNN	;	2.35	;	Crystal structure of a putative transcriptional regulator from Saccharomonospora viridis in complex with benzamidine
4KWA	;	1.8	;	Crystal structure of a putative transcriptional regulator from Saccharomonospora viridis in complex with choline
4NEL	;	2.05	;	Crystal structure of a putative transcriptional regulator from Saccharomonospora viridis in complex with N,N-dimethylmethanamine
3DV8	;	2.55	;	Crystal structure of a putative transcriptional regulator of the crp/fnr family (eubrec_1222) from eubacterium rectale atcc 33656 at 2.55 A resolution
2A6B	;	1.7	;	Crystal structure of a putative transcriptional regulator of the tena family (spr0628) from streptococcus pneumoniae r6 at 1.70 A resolution
3S5R	;	2.6	;	Crystal structure of a putative transcriptional regulator of the TETR family (SYN_02108) from Syntrophus aciditrophicus at 2.60 A resolution
3ER6	;	1.9	;	Crystal structure of a putative transcriptional regulator protein from Vibrio parahaemolyticus
3MIZ	;	1.91	;	Crystal structure of a putative transcriptional regulator protein, Lacl family from Rhizobium etli
3E61	;	2.0	;	Crystal structure of a putative transcriptional repressor of ribose operon from Staphylococcus saprophyticus subsp. saprophyticus
3GTZ	;	2.5	;	Crystal structure of a putative translation initiation inhibitor from Salmonella typhimurium
2HAF	;	2.88	;	Crystal structure of a putative translation repressor from Vibrio cholerae
2G1U	;	1.5	;	CRYSTAL STRUCTURE OF A PUTATIVE TRANSPORT PROTEIN (TM1088A) FROM THERMOTOGA MARITIMA AT 1.50 A RESOLUTION
2FYX	;	1.9	;	Crystal structure of a putative transposase (dr_0177) from deinococcus radiodurans r1 at 1.90 A resolution
3S6D	;	2.2	;	Crystal structure of a putative triosephosphate isomerase from Coccidioides immitis
2ITB	;	2.05	;	CRYSTAL STRUCTURE OF A PUTATIVE TRNA-(MS(2)IO(6)A)-HYDROXYLASE (PP_2188) FROM PSEUDOMONAS PUTIDA KT2440 AT 2.05 A RESOLUTION
3KOR	;	1.6	;	Crystal structure of a putative Trp repressor from Staphylococcus aureus
4QHW	;	1.35	;	Crystal structure of a putative two-domain sugar hydrolase (BACCAC_02064) from Bacteroides caccae ATCC 43185 at 1.35 A resolution
4QHX	;	1.8	;	Crystal structure of a putative two-domain sugar hydrolase (BACCAC_02064) from Bacteroides caccae ATCC 43185 at 1.80 A resolution
3I9F	;	2.5	;	Crystal structure of a putative type 11 methyltransferase from Sulfolobus solfataricus
3MSQ	;	2.85	;	Crystal structure of a Putative ubiquinone biosynthesis protein (Npun02000094) from Nostoc punctiforme PCC 73102 at 2.85 A resolution
2PWQ	;	1.9	;	Crystal structure of a putative ubiquitin conjugating enzyme from Plasmodium yoelii
2AYV	;	2.001	;	Crystal structure of a putative ubiquitin-conjugating enzyme E2 from Toxoplasma gondii
5VBD	;	1.5	;	Crystal structure of a putative UBL domain of USP9X
2ICY	;	1.64	;	Crystal Structure of a Putative UDP-glucose Pyrophosphorylase from Arabidopsis Thaliana with Bound UDP-glucose
2ICX	;	1.85	;	Crystal Structure of a Putative UDP-glucose Pyrophosphorylase from Arabidopsis Thaliana with Bound UTP
4PZU	;	2.1	;	Crystal structure of a putative uncharacterize protein Rv3404c and likely sugar N-formyltransferase from Mycobacterium tuberculosis
4KW2	;	2.32	;	Crystal structure of a Putative uncharacterized protein (BDI_1873) from Parabacteroides distasonis ATCC 8503 at 2.32 A resolution
3QUA	;	2.1	;	Crystal structure of a putative uncharacterized protein and possible Molybdenum cofactor protein from Mycobacterium smegmatis
6ANS	;	2.2	;	Crystal structure of a putative uncharacterized protein from Burkholderia cenocepacia
4TV4	;	2.1	;	Crystal structure of a Putative uncharacterized protein from Burkholderia pseudomallei
6AR7	;	2.1	;	Crystal structure of a putative uncharacterized protein from Burkholderia thailandensis
7S5N	;	1.85	;	Crystal Structure of a Putative uncharacterized protein from Mycobacterium marinum
3SBX	;	2.5	;	Crystal structure of a putative uncharacterized protein from Mycobacterium marinum bound to adenosine 5'-monophosphate AMP
3RD5	;	1.5	;	Crystal structure of a putative uncharacterized protein from Mycobacterium Paratuberculosis
3OL3	;	1.95	;	Crystal structure of a putative uncharacterized protein from Mycobacterium smegamtis, an ortholog of Rv0543c, iodide phased
3OL4	;	2.0	;	Crystal structure of a putative uncharacterized protein from Mycobacterium smegmatis, an ortholog of Rv0543c
4HEC	;	1.8	;	Crystal structure of a putative uncharacterized protein from Mycobacterium tuberculosis
4Q6U	;	1.95	;	Crystal structure of a putative uncharacterized protein from Mycobacterium tuberculosis
4HVJ	;	2.1	;	Crystal structure of a putative uncharacterized protein from Mycobacterium tuberculosis in complex with AMP
4Q12	;	2.85	;	Crystal structure of a putative uncharacterized protein Rv3404c and likely sugar N-formyltransferase from Mycobacterium tuberculosis bound to uridine diphosphate
4R31	;	2.0	;	Crystal structure of a putative uridine phosphorylase from Actinobacillus succinogenes 130Z (Target NYSGRC-029667 )
1Z9D	;	2.8	;	Crystal structure of a putative uridylate kinase (UMP-kinase) from Streptococcus pyogenes
4JPI	;	2.1	;	Crystal structure of a putative VRC01 germline precursor Fab
1VP2	;	1.78	;	CRYSTAL STRUCTURE OF A PUTATIVE XANTHOSINE TRIPHOSPHATE PYROPHOSPHATASE/HAM1 PROTEIN HOMOLOG (TM0159) FROM THERMOTOGA MARITIMA AT 1.78 A RESOLUTION
2P1G	;	1.8	;	Crystal structure of a putative xylanase from Bacteroides fragilis
3QXB	;	1.9	;	Crystal structure of a Putative Xylose isomerase (YP_426450.1) from RHODOSPIRILLUM RUBRUM ATCC 11170 at 1.90 A resolution
3BDV	;	1.66	;	Crystal structure of a putative yden-like hydrolase (eca3091) from pectobacterium atrosepticum scri1043 at 1.66 A resolution
2RD9	;	2.3	;	Crystal structure of a putative yfit-like metal-dependent hydrolase (bh0186) from bacillus halodurans c-125 at 2.30 A resolution
3CT9	;	2.31	;	Crystal structure of a putative zinc peptidase (NP_812461.1) from Bacteroides thetaiotaomicron VPI-5482 at 2.31 A resolution
4OH1	;	2.0	;	Crystal structure of a putative zinc-binding dehydrogenase (gutB) from Clostridium scindens ATCC 35704 at 2.00 A resolution
4EJ6	;	1.89	;	Crystal structure of a putative zinc-binding dehydrogenase (Target PSI-012003) from Sinorhizobium meliloti 1021
4EJM	;	2.09	;	Crystal structure of a putative zinc-binding dehydrogenase (Target PSI-012003) from Sinorhizobium meliloti 1021 bound to NADP
4L7A	;	2.09	;	Crystal structure of a putative zinc-binding metallo-peptidase (BACCAC_01431) from Bacteroides caccae ATCC 43185 at 2.10 A resolution
4DVJ	;	1.99	;	Crystal structure of a putative zinc-dependent alcohol dehydrogenase protein from Rhizobium etli CFN 42
3GUX	;	1.8	;	Crystal structure of a putative zn-dependent exopeptidase (bvu_1317) from bacteroides vulgatus atcc 8482 at 1.80 A resolution
1VJN	;	2.0	;	Crystal structure of a putative zn-dependent hydrolase of the metallo-beta-lactamase superfamily (tm0207) from thermotoga maritima at 2.00 A resolution
4J9T	;	1.4	;	Crystal structure of a putative, de novo designed unnatural amino acid dependent metalloprotein, northeast structural genomics consortium target OR61
3SON	;	1.71	;	Crystal structure of a putativel NUDIX hydrolase (LMOf2365_2679) from Listeria monocytogenes str. 4b F2365 at 1.70 A resolution
2A2M	;	1.88	;	CRYSTAL STRUCTURE OF a putativeTenA family transcriptional regulator (BT_3146) FROM BACTEROIDES THETAIOTAOMICRON VPI-5482 AT 1.88 A RESOLUTION
2A2O	;	2.16	;	CRYSTAL STRUCTURE OF a putativeTenA family transcriptional regulator (BT_3146) FROM BACTEROIDES THETAIOTAOMICRON VPI-5482 AT 2.16 A RESOLUTION
3IBE	;	2.798	;	Crystal Structure of a Pyrazolopyrimidine Inhibitor Bound to PI3 Kinase Gamma
3A2C	;	2.9	;	Crystal structure of a pyrazolopyrimidine inhibitor complex bound to MAPKAP Kinase-2 (MK2)
3OC4	;	2.6	;	Crystal Structure of a pyridine nucleotide-disulfide family oxidoreductase from the Enterococcus faecalis V583
5TQI	;	1.5	;	Crystal structure of a pyridoxal kinase from Burkholderia multivorans
2RE7	;	2.5	;	Crystal structure of a pyridoxamine 5'-phosphate oxidase related protein (psyc_0186) from psychrobacter arcticus 273-4 at 2.50 A resolution
2I02	;	1.8	;	CRYSTAL STRUCTURE OF a pyridoxamine 5'-phosphate oxidase-like family protein (NPUN_R6570) FROM NOSTOC PUNCTIFORME PCC 73102 AT 1.80 A RESOLUTION
2OU5	;	1.6	;	Crystal structure of a pyridoxamine 5'-phosphate oxidase-related fmn-binding protein (jann_0254) from jannaschia sp. ccs1 at 1.60 A resolution
2HHZ	;	2.0	;	Crystal structure of a pyridoxamine 5'-phosphate oxidase-related protein (ssuidraft_2804) from streptococcus suis 89/1591 at 2.00 A resolution
2I51	;	1.4	;	CRYSTAL STRUCTURE OF a pyridoxamine 5'-phosphate oxidase-related, FMN binding protein (NPUN_F5749) FROM NOSTOC PUNCTIFORME PCC 73102 AT 1.40 A RESOLUTION
3PZS	;	1.89	;	Crystal Structure of a pyridoxamine kinase from Yersinia pestis CO92
6W6A	;	2.45	;	Crystal structure of a pyridoxine 5'-phosphate synthease from Stenotrophomonas maltophilia K279a
2VHH	;	2.8	;	Crystal structure of a pyrimidine degrading enzyme from Drosophila melanogaster
2VHI	;	3.3	;	Crystal structure of a pyrimidine degrading enzyme from Drosophila melanogaster
1ENI	;	2.2	;	CRYSTAL STRUCTURE OF A PYRIMIDINE DIMER SPECIFIC EXCISION REPAIR ENZYME FROM BACTERIOPHAGE T4: REFINEMENT AT 1.45 ANGSTROMS AND X-RAY ANALYSIS OF THE THREE ACTIVE SITE MUTANTS
1ENJ	;	1.8	;	CRYSTAL STRUCTURE OF A PYRIMIDINE DIMER SPECIFIC EXCISION REPAIR ENZYME FROM BACTERIOPHAGE T4: REFINEMENT AT 1.45 ANGSTROMS AND X-RAY ANALYSIS OF THE THREE ACTIVE SITE MUTANTS
1ENK	;	2.0	;	CRYSTAL STRUCTURE OF A PYRIMIDINE DIMER SPECIFIC EXCISION REPAIR ENZYME FROM BACTERIOPHAGE T4: REFINEMENT AT 1.45 ANGSTROMS AND X-RAY ANALYSIS OF THE THREE ACTIVE SITE MUTANTS
2END	;	1.45	;	CRYSTAL STRUCTURE OF A PYRIMIDINE DIMER SPECIFIC EXCISION REPAIR ENZYME FROM BACTERIOPHAGE T4: REFINEMENT AT 1.45 ANGSTROMS AND X-RAY ANALYSIS OF THE THREE ACTIVE SITE MUTANTS
2P4G	;	2.3	;	CRYSTAL STRUCTURE OF A PYRIMIDINE REDUCTASE-LIKE PROTEIN (DIP1392) FROM CORYNEBACTERIUM DIPHTHERIAE NCTC AT 2.30 A RESOLUTION
1VDX	;	2.4	;	Crystal Structure of a Pyrococcus horikoshii protein with similarities to 2'5' RNA-ligase
4QGP	;	1.78	;	Crystal structure of a pyrophosphatase (AF1178) from Archaeoglobus fulgidus DSM 4304 at 1.80 A resolution
4GXH	;	2.7	;	Crystal Structure of a Pyrrolidone-carboxylate peptidase 1 (target ID NYSGRC-012831) from Xenorhabdus bovienii SS-2004
4HPS	;	1.55	;	Crystal Structure of a Pyrrolidone-carboxylate peptidase 1 (target ID NYSGRC-012831) from Xenorhabdus bovienii SS-2004 in space group P21
1YQG	;	1.9	;	Crystal structure of a pyrroline-5-carboxylate reductase from neisseria meningitides mc58
2P3G	;	3.8	;	Crystal structure of a pyrrolopyridine inhibitor bound to MAPKAP Kinase-2
2R6N	;	1.95	;	Crystal structure of a pyrrolopyrimidine inhibitor in complex with human Cathepsin K
2PG3	;	2.4	;	Crystal structure of a Queuosine biosynthesis protein queC (ECA1155) from Erwinia carotovora subsp. atroseptica SCRI1043 at 2.40 A resolution
1OAC	;	2.0	;	CRYSTAL STRUCTURE OF A QUINOENZYME: COPPER AMINE OXIDASE OF ESCHERICHIA COLI AT 2 ANGSTROEMS RESOLUTION
1JMX	;	1.9	;	crystal structure of a quinohemoprotein amine dehydrogenase from pseudomonas putida
1JMZ	;	2.0	;	crystal structure of a quinohemoprotein amine dehydrogenase from pseudomonas putida with inhibitor
4DUP	;	2.45	;	Crystal Structure of a quinone oxidoreductase from Rhizobium etli CFN 42
4R5O	;	2.64	;	Crystal structure of a Quinonprotein alcohol dehydrogenase-like protein (BT1487) from Bacteroides thetaiotaomicron VPI-5482 at 2.64 A resolution
2NTF	;	3.18	;	Crystal Structure of a Quorum-Quenching Antibody in Complex with an N-Acyl-L-Homoserine Lactone Analog
2Y1J	;	2.15	;	CRYSTAL STRUCTURE OF A R-DIASTEREOMER ANALOGUE OF THE SPORE PHOTOPRODUCT IN COMPLEX WITH FRAGMENT DNA POLYMERASE I FROM BACILLUS STEAROTHERMOPHILUS
7BME	;	2.6	;	Crystal structure of a R18W mutant of the DNA-binding protein RemA from Geobacillus thermodenitrificans
7P1W	;	1.8	;	Crystal structure of a R51 R53 double mutant of the DNA-binding protein RemA from Geobacillus thermodenitrificans
3BV4	;	1.7	;	Crystal structure of a rabbit muscle fructose-1,6-bisphosphate aldolase A dimer variant
1DS6	;	2.35	;	CRYSTAL STRUCTURE OF A RAC-RHOGDI COMPLEX
2OVL	;	2.13	;	Crystal structure of a racemase from Streptomyces coelicolor A3(2)
3CK5	;	2.3	;	Crystal structure of a racemase from Streptomyces coelicolor A3(2) with bound magnesium
1N0W	;	1.7	;	Crystal structure of a RAD51-BRCA2 BRC repeat complex
6FZ6	;	1.42	;	Crystal Structure of a radical SAM methyltransferase from Sphaerobacter thermophilus
4FSS	;	2.25	;	Crystal structure of a RAS p21 protein activator (RASA1) from Homo sapiens at 2.25 A resolution
4KU4	;	1.6	;	Crystal Structure of a Ras-like Protein from Cryphonectria parasitica in Complex with GDP
1WYG	;	2.6	;	Crystal Structure of a Rat Xanthine Dehydrogenase Triple Mutant (C535A, C992R and C1324S)
3QNC	;	1.6	;	Crystal Structure of a Rationally Designed OXA-10 Variant Showing Carbapenemase Activity, OXA-10loop48
4R61	;	3.1	;	Crystal structure of a rationally designed single-chain protein mimicking a trimeric gp41 N-terminal heptad-repeat region
6DKL	;	3.034	;	Crystal Structure of a Rationally Designed Six-Fold Symmetric DNA Scaffold
3ZZY	;	1.4	;	Crystal structure of a Raver1 PRI3 peptide in complex with polypyrimidine tract binding protein RRM2
3ZZZ	;	1.55	;	Crystal structure of a Raver1 PRI4 peptide in complex with polypyrimidine tract binding protein RRM2
7F83	;	2.94	;	Crystal Structure of a receptor in Complex with inverse agonist
7XDV	;	1.97	;	Crystal structure of a receptor like kinase from Arabidopsis
7XDW	;	1.926	;	Crystal structure of a receptor like kinase from Arabidopsis
7XDX	;	2.23	;	Crystal structure of a receptor like kinase from Arabidopsis
7XDY	;	2.28	;	Crystal structure of a receptor like kinase from Arabidopsis
8JUP	;	1.98	;	Crystal structure of a receptor like kinase from rice
8JUV	;	2.09	;	Crystal structure of a receptor like kinase with ADP
1OMY	;	2.0	;	Crystal Structure of a Recombinant alpha-insect Toxin BmKaIT1 from the scorpion Buthus martensii Karsch
1I8M	;	2.1	;	CRYSTAL STRUCTURE OF A RECOMBINANT ANTI-SINGLE-STRANDED DNA ANTIBODY FRAGMENT COMPLEXED WITH DT5
3QYD	;	2.97	;	Crystal structure of a recombinant chimeric trypsin inhibitor
4RR3	;	3.103	;	Crystal structure of a recombinant EV71 virus particle
6BMT	;	2.403	;	Crystal Structure of a Recombinant form of Human Myeloperoxidase Bound to an Inhibitor from Staphylococcus delphini
1LBK	;	1.86	;	Crystal structure of a recombinant glutathione transferase, created by replacing the last seven residues of each subunit of the human class pi isoenzyme with the additional C-terminal helix of human class alpha isoenzyme
5X2J	;	1.4	;	Crystal structure of a recombinant hybrid manganese superoxide dismutase from Staphylococcus equorum and Staphylococcus saprophyticus
2R56	;	2.8	;	Crystal Structure of a Recombinant IgE Fab Fragment in Complex with Bovine Beta-Lactoglobulin Allergen
4XXA	;	1.9	;	Crystal structure of a recombinant Vatairea macrocarpa seed lectin
4XTM	;	2.7	;	Crystal structure of a recombinant Vatairea macrocarpa seed lectin complexed with GalNAc
4WV8	;	1.83	;	Crystal structure of a recombinant Vatairea macrocarpa seed lectin complexed with lactose
4XTP	;	1.97	;	Crystal structure of a recombinant Vatairea macrocarpa seed lectin complexed with Tn antigen
6NEE	;	1.9	;	Crystal structure of a reconstructed ancestor of Triosephosphate isomerase from eukaryotes
8THS	;	1.5	;	Crystal Structure of a reconstructed Kaede-type Red Fluorescent Protein, LEA A69T
8UB6	;	1.7	;	Crystal Structure of a reconstructed Kaede-type Red Fluorescent Protein, LEA H62X, containing 3-methylhistidine at position 62
4DXQ	;	1.95	;	Crystal Structure of a reconstructed Kaede-type Red Fluorescent Protein, LEA Q38A
4DXO	;	2.5	;	Crystal Structure of a reconstructed Kaede-type Red Fluorescent Protein, LEA X(6)
4DXP	;	1.75	;	Crystal Structure of a reconstructed Kaede-type Red Fluorescent Protein, LEA X121
4DXN	;	1.85	;	Crystal Structure of a reconstructed Kaede-type Red Fluorescent Protein, Least Evolved Ancestor (LEA)
5HIF	;	1.6	;	Crystal structure of a reconstructed lactonase ancestor, Anc1-MPH, of the bacterial methyl parathion hydrolase, MPH.
3QYA	;	2.13	;	Crystal structure of a red-emitter mutant of Lampyris turkestanicus luciferase
3FWV	;	2.2	;	Crystal Structure of a Redesigned TPR Protein, T-MOD(VMY), in Complex with MEEVF Peptide
2H8Q	;	2.0	;	Crystal Structure of a Redshifted Mutant (K83M) of the Red Fluorescent Protein dRFP583/dsRed
1CC1	;	2.15	;	CRYSTAL STRUCTURE OF A REDUCED, ACTIVE FORM OF THE NI-FE-SE HYDROGENASE FROM DESULFOMICROBIUM BACULATUM
7JP4	;	2.0	;	Crystal structure of a refolded head domain hemagglutinin HA from Influenza A virus A/Fort Monmouth/1/1947
3BBL	;	2.35	;	Crystal structure of a regulatory protein of LacI family from Chloroflexus aggregans
2IFD	;	2.0	;	Crystal structure of a remote binding site mutant, R492L, of CDC25B Phosphatase catalytic domain
2VLD	;	2.6	;	crystal structure of a repair endonuclease from Pyrococcus abyssi
5H7B	;	3.1	;	Crystal structure of a repeat protein with five Protein A repeat modules
5H7A	;	2.7	;	Crystal structure of a repeat protein with four Protein A repeat module
5H79	;	2.7	;	Crystal structure of a repeat protein with three Protein A repeat module
5H7C	;	2.7	;	Crystal structure of a repeat protein with two Protein A-DHR14 repeat modules
1CLQ	;	2.7	;	CRYSTAL STRUCTURE OF A REPLICATION FORK DNA POLYMERASE EDITING COMPLEX AT 2.7 A RESOLUTION
3RMA	;	2.84	;	Crystal Structure of a replicative DNA polymerase bound to DNA containing Thymine Glycol
3RMB	;	2.65	;	Crystal Structure of a replicative DNA polymerase bound to DNA containing Thymine Glycol
3RMC	;	3.0	;	Crystal Structure of a replicative DNA polymerase bound to DNA containing Thymine Glycol
3RMD	;	2.98	;	Crystal Structure of a replicative DNA polymerase bound to DNA containing Thymine Glycol
3L8B	;	2.15	;	Crystal structure of a replicative DNA polymerase bound to the oxidized guanine lesion guanidinohydantoin
5TFQ	;	1.07	;	Crystal structure of a representative of class A beta-lactamase from Bacteroides cellulosilyticus DSM 14838
3K2G	;	1.8	;	Crystal structure of a Resiniferatoxin-binding protein from Rhodobacter sphaeroides
3GUV	;	2.2	;	Crystal structure of a resolvase family site-specific recombinase from Streptococcus pneumoniae
3SNK	;	2.02	;	Crystal structure of a Response regulator CheY-like protein (mll6475) from MESORHIZOBIUM LOTI at 2.02 A resolution
3EQZ	;	2.15	;	Crystal structure of a response regulator from Colwellia psychrerythraea
3NHM	;	2.19	;	Crystal structure of a response regulator from Myxococcus xanthus
2QXY	;	1.95	;	Crystal structure of a response regulator from Thermotoga maritima
3RQI	;	1.7	;	Crystal structure of a response regulator protein from Burkholderia pseudomallei with a phosphorylated aspartic acid, calcium ion and citrate
2B4A	;	2.42	;	Crystal structure of a response regulator receiver domain protein (bh3024) from bacillus halodurans c-125 at 2.42 A resolution
3N53	;	2.2	;	Crystal structure of a response regulator receiver modulated diguanylate cyclase from Pelobacter carbinolicus
5TE9	;	2.401	;	Crystal structure of a response regulator receiver protein from Burkholderia phymatum
4HYE	;	1.7	;	Crystal structure of a response regulator spr1814 from Streptococcus pneumoniae reveals unique interdomain contacts among NarL family proteins
3WAZ	;	3.0	;	Crystal structure of a restriction enzyme PabI in complex with DNA
8G9A	;	2.03	;	Crystal structure of a resurrected ancestor (AncRNase) of the pancreatic-type RNases 2 and 3 sub-families
5C9B	;	2.4	;	Crystal structure of a retropepsin-like aspartic protease from Rickettsia conorii
5C9D	;	2.59	;	Crystal structure of a retropepsin-like aspartic protease from Rickettsia conorii
5C9F	;	2.0	;	Crystal structure of a retropepsin-like aspartic protease from Rickettsia conorii
5EQZ	;	1.8	;	Crystal structure of a Rev protein from Borrelia burgdorferi at 1.80 A resolution
3IKV	;	2.4	;	Crystal structure of a Rex-family repressor R90D mutant from Thermus aquaticus
3IL2	;	2.49	;	Crystal structure of a Rex-family repressor R90D mutant/DNA complex from Thermus aquaticus
3IKT	;	2.26	;	Crystal structure of a Rex-family repressor/DNA/NAD+ complex from Thermus aquaticus
3KET	;	2.4	;	Crystal structure of a Rex-family transcriptional regulatory protein from Streptococcus agalactiae bound to a palindromic operator
3KEO	;	1.5	;	Crystal Structure of a Rex-family transcriptional regulatory protein from Streptococcus agalactiae complexed with NAD+
3KEQ	;	2.4	;	Crystal structure of a Rex-family transcriptional regulatory protein from Streptococcus agalactiae complexed with NAD+
1ZLD	;	1.65	;	Crystal structure of a RGD-containing host-selective toxin: Pyrenophora tritici-repentis Ptr ToxA
1ZLE	;	1.9	;	Crystal structure of a RGD-containing host-selective toxin: Pyrenophora tritici-repentis Ptr ToxA
5H4S	;	1.8	;	Crystal structure of a rhamnose-binding lectin SUL-I from the toxopneustid sea urchin Toxopneustes pileolus
2J4Y	;	3.4	;	Crystal structure of a rhodopsin stabilizing mutant expressed in mammalian cells
3DZO	;	1.8	;	Crystal structure of a rhoptry kinase from toxoplasma gondii
2R3B	;	1.8	;	CRYSTAL STRUCTURE OF a ribokinase-like superfamily protein (EF1790) FROM ENTEROCOCCUS FAECALIS V583 AT 1.80 A RESOLUTION
2R3E	;	1.95	;	CRYSTAL STRUCTURE OF a ribokinase-like superfamily protein (EF1790) FROM ENTEROCOCCUS FAECALIS V583 AT 1.95 A RESOLUTION
6QMN	;	2.31	;	Crystal structure of a Ribonuclease A-Onconase chimera
4DJN	;	2.2	;	Crystal structure of a ribonucleotide reductase M2 B (RNRR2) from Homo sapiens at 2.20 A resolution
1O1X	;	1.9	;	Crystal structure of a ribose 5-phosphate isomerase rpib (tm1080) from thermotoga maritima at 1.90 A resolution
3SDW	;	1.8	;	Crystal structure of a ribose-5-phosphate isomerase B RpiB from Coccidioides immitis bound to phosphate
7LDA	;	1.45	;	Crystal structure of a ribose-5-phosphate isomerase from Stenotrophomonas maltophilia K279a
3C0K	;	2.0	;	Crystal Structure of a ribosomal RNA methyltranferase
2PLW	;	1.7	;	Crystal structure of a ribosomal RNA methyltransferase, putative, from Plasmodium falciparum (PF13_0052).
5VM8	;	2.4	;	Crystal structure of a Ribosomal RNA small subunit methyltransferase E from Neisseria gonorrhoeae bound to S-adenosyl methionine
5UCV	;	1.8	;	Crystal Structure of a Ribosome Biogenesis GTP-binding protein (YsxC) from Neisseria gonorrhoeae with bound GDP
1TFM	;	2.8	;	CRYSTAL STRUCTURE OF A RIBOSOME INACTIVATING PROTEIN IN ITS NATURALLY INHIBITED FORM
6VUD	;	2.35	;	Crystal structure of a ribosome recycling factor from Ehrlichia chaffeensis
5UMF	;	1.4	;	Crystal Structure of a Ribulose-phosphate 3-epimerase from Neisseria gonorrhoeae with bound phosphate
5JNP	;	2.404	;	Crystal structure of a rice (Oryza Sativa) cellulose synthase plant conserved region (P-CR)
3H2G	;	1.86	;	Crystal structure of a rice cell wall degrading esterase LipA from Xanthomonas oryzae
7XMH	;	1.18	;	Crystal structure of a rice class IIIb chitinase, Oschib2
3GNO	;	1.83	;	Crystal Structure of a Rice Os3BGlu6 Beta-Glucosidase
3GNR	;	1.81	;	Crystal Structure of a Rice Os3BGlu6 Beta-Glucosidase with covalently bound 2-deoxy-2-fluoroglucoside to the catalytic nucleophile E396
3GNP	;	1.8	;	Crystal Structure of a Rice Os3BGlu6 Beta-Glucosidase with Octyl-Beta-D-Thio-Glucoside
7FHR	;	1.84	;	Crystal Structure of a Rieske Oxygenase from Cupriavidus metallidurans
3R6N	;	2.95	;	Crystal structure of a rigid four spectrin repeat fragment of the human desmoplakin plakin domain
4MUD	;	2.43	;	Crystal structure of a ring oxydation complex/ phenylacetic acid degradation-like protein (SSO1313) from Sulfolobus solfataricus P2 at 2.43 A resolution
2PFW	;	1.9	;	CRYSTAL STRUCTURE OF A RMLC-LIKE CUPIN (SFRI_3105) FROM SHEWANELLA FRIGIDIMARINA NCIMB 400 AT 1.90 A RESOLUTION
2B8M	;	1.7	;	Crystal structure of a rmlc-like cupin family protein with a double-stranded beta-helix fold (mj0764) from methanocaldococcus jannaschii at 1.70 A resolution
2Q30	;	1.94	;	Crystal structure of a rmlc-like cupin protein (dde_2303) from desulfovibrio desulfuricans subsp. at 1.94 A resolution
4Z2X	;	2.15	;	Crystal structure of a RNA binding domain of a U2 small nuclear ribonucleoprotein auxiliary factor 2 (U2AF) from mouse at 2.15 A resolution
3V4M	;	1.8	;	Crystal structure of a RNA binding domain of a U2 small nuclear ribonucleoprotein auxiliary factor 2 (U2AF) from Mus musculus at 1.80 A resolution
3UE2	;	1.23	;	Crystal structure of a RNA binding domain of poly-U binding splicing factor 60KDa (PUF60) from Homo sapiens at 1.23 A resolution
3UWT	;	2.5	;	Crystal structure of a RNA binding domain of poly-U binding splicing factor 60KDa (PUF60) from Homo sapiens at 2.50 A resolution
3UCG	;	1.95	;	Crystal structure of a RNA binding domain of polyadenylate-binding protein (PABPN1) from Homo sapiens at 1.95 A resolution
3ULH	;	2.54	;	Crystal structure of a RNA binding domain of THO complex subunit 4 protein (THOC4) from Homo sapiens at 2.54 A resolution
4YUD	;	1.28	;	Crystal structure of a RNA binding motif protein 39 (RBM39) from Homo sapiens at 1.28 A resolution
3S6E	;	0.95	;	Crystal structure of a RNA binding motif protein 39 (RBM39) from Mus musculuS at 0.95 A resolution
1KXK	;	3.0	;	Crystal Structure of a RNA Molecule Containing Domain 5 and 6 of the Yeast ai5g Group II Self-splicing Intron
3US5	;	1.38	;	Crystal structure of a RNA-binding domain of a poly-U binding splicing factor 60KDa (PUF60) from Homo sapiens at 1.38 A resolution
4RU2	;	2.2	;	Crystal structure of a RNA-binding protein 39 (RBM39) in complex with fragment of splicing factor (U2AF) from Mus musculus at 2.20 A resolution
5CXT	;	2.2	;	Crystal structure of a RNA-binding protein 39 (RBM39) in complex with fragment of splicing factor (U2AF) from Unknown at 2.20 A resolution
3O2C	;	1.5	;	Crystal structure of a rod form of c-phycocyanin from Themosynechococcus vulcanus at 1.5 angstroms
3VGK	;	3.25	;	Crystal structure of a ROK family glucokinase from Streptomyces griseus
3VGM	;	1.84	;	Crystal structure of a ROK family glucokinase from Streptomyces griseus in complex with glucose
3VGL	;	1.55	;	Crystal structure of a ROK family glucokinase from Streptomyces griseus in complex with glucose and AMPPNP
3NWR	;	1.498	;	Crystal structure of a rubisco-like protein from Burkholderia fungorum
1TEL	;	2.7	;	Crystal structure of a RubisCO-like protein from Chlorobium tepidum
2OEJ	;	2.55	;	Crystal structure of a rubisco-like protein from Geobacillus kaustophilus (tetramutant form), liganded with phosphate ions
2OEM	;	1.7	;	Crystal structure of a rubisco-like protein from Geobacillus kaustophilus liganded with Mg2+ and 2,3-diketohexane 1-phosphate
2OEL	;	1.8	;	Crystal structure of a rubisco-like protein from Geobacillus kaustophilus liganded with Mg2+ and HCO3- ions
2OEK	;	1.8	;	Crystal structure of a rubisco-like protein from Geobacillus kaustophilus liganded with Mg2+ ions
2QYG	;	3.3	;	Crystal Structure of a RuBisCO-like Protein rlp2 from Rhodopseudomonas palustris
6UEH	;	1.849	;	Crystal structure of a ruminal GH26 endo-beta-1,4-mannanase
3TJR	;	1.6	;	Crystal structure of a Rv0851c ortholog short chain dehydrogenase from Mycobacterium paratuberculosis
5T8T	;	2.1	;	Crystal Structure of a S-adenosylmethionine Synthase from Neisseria gonorrhoeae with bound AMP and Magnesium
5T8S	;	1.7	;	Crystal Structure of a S-adenosylmethionine Synthase from Neisseria gonorrhoeae with bound S-adenosylmethionine, AMP, Pyrophosphate, Phosphate, and Magnesium
1Y8C	;	2.5	;	Crystal structure of a S-adenosylmethionine-dependent methyltransferase from Clostridium acetobutylicum ATCC 824
2Y1I	;	2.78	;	Crystal structure of a S-diastereomer analogue of the spore photoproduct in complex with fragment DNA polymerase I from Bacillus stearothermophilus
6VBM	;	1.71	;	Crystal structure of a S310A mutant of PBP2 from Neisseria gonorrhoeae
3U81	;	1.13	;	Crystal structure of a SAH-bound semi-holo form of rat Catechol-O-methyltransferase
4JZ6	;	2.417	;	Crystal structure of a salicylaldehyde dehydrogenase from Pseudomonas putida G7 complexed with salicylaldehyde
2XY7	;	3.05	;	Crystal structure of a salicylic aldehyde base in the pre-insertion site of fragment DNA polymerase I from Bacillus stearothermophilus
2XY6	;	2.3	;	Crystal structure of a salicylic aldehyde basepair in complex with fragment DNA polymerase I from Bacillus stearothermophilus
4G2S	;	1.858	;	Crystal structure of a Salmonella type III secretion system protein
2P7I	;	1.74	;	CRYSTAL STRUCTURE OF a SAM dependent methyl-transferase type 12 family protein (ECA1738) FROM PECTOBACTERIUM ATROSEPTICUM SCRI1043 AT 1.74 A RESOLUTION
2P7H	;	1.85	;	Crystal structure of a sam dependent methyl-transferase type 12 family protein (eca1738) from pectobacterium atrosepticum scri1043 at 1.85 A resolution
3DH0	;	2.72	;	Crystal structure of a SAM dependent methyltransferase from Aquifex aeolicus
3DLI	;	2.46	;	Crystal structure of a SAM dependent methyltransferase from Archaeoglobus fulgidus
6J1O	;	1.7	;	Crystal structure of a SAM-dependent methyltransferase LepI from Aspergillus flavus
6J24	;	2.244	;	Crystal structure of a SAM-dependent methyltransferase LepI in complex with its substrate
3C9N	;	1.87	;	Crystal Structure of a SARS Corona Virus Derived Peptide Bound to the Human Major Histocompatibility Complex Class I molecule HLA-B*1501
7JMX	;	2.53	;	Crystal structure of a SARS-CoV-2 cross-neutralizing antibody COVA1-16 Fab
5LW6	;	1.8	;	Crystal structure of a Se-Met substituted Dictyostelium discoideum ADP-ribose binding macrodomain (residues 342-563) of DDB_G0293866
2I9W	;	1.75	;	Crystal structure of a sec-c motif containing protein (psyc_2064) from psychrobacter arcticus at 1.75 A resolution
5L0Y	;	2.87	;	Crystal Structure of a Sec72-ssa1 c-terminal peptide fusion protein
7CYK	;	2.785	;	Crystal structure of a second cysteine-pair mutant (V110C-I197C) of a bacterial bile acid transporter before disulfide bond formation
7QBK	;	2.26	;	Crystal structure of a second homolog of R2-like ligand-binding oxidase in Sulfolobus acidocaldarius (SaR2loxII)
2HJD	;	2.1	;	Crystal structure of a second quorum sensing antiactivator TraM2 from A. tumefaciens strain A6
2GJ5	;	2.4	;	Crystal structure of a secondary vitamin D3 binding site of milk beta-lactoglobulin
5XNA	;	1.802	;	Crystal structure of a secretary abundant heat soluble (SAHS) protein from Ramazzottius varieornatus (from dimer sample)
5XN9	;	1.449	;	Crystal structure of a secretary abundant heat soluble (SAHS) protein from Ramazzottius varieornatus (from monomer sample)
3MAY	;	2.5	;	Crystal structure of a secreted Mycobacterium tuberculosis heme-binding protein
2NZO	;	2.0	;	Crystal structure of a secretion chaperone CsaA from Bacillus subtilis in the space group P 32 2 1
2NZH	;	1.9	;	Crystal structure of a secretion chaperone CsaA from Bacillus subtilis in the space group P 4 21 2
2DPE	;	2.07	;	Crystal structure of a secretory 40KDA glycoprotein from sheep at 2.0A resolution
7YGK	;	1.24	;	Crystal structure of a secretory phospholipase A2 from Sciscionella marina
3RA3	;	2.31	;	Crystal structure of a section of a de novo design gigaDalton protein fibre
4U36	;	1.4	;	Crystal structure of a seed lectin from Vatairea macrocarpa complexed with Tn-antigen
5CJ6	;	2.07	;	Crystal Structure of a Selective Androgen Receptor Modulator Bound to the Ligand Binding Domain of the Human Androgen Receptor
6YAY	;	2.09	;	Crystal structure of a Selenium-derivatized complex of the bacterial cellulose secretion regulators BcsR and BcsQ, crystallized in the presence of ADP
6YAR	;	1.9	;	Crystal structure of a Selenium-derivatized complex of the bacterial cellulose secretion regulators BcsR and BcsQ, crystallized in the presence of AppCp
4P31	;	2.05	;	Crystal structure of a selenomethionine derivative of E. coli LptB in complex with ADP-Magensium
7VXT	;	1.88	;	Crystal structure of a selenomethionine-labeled BPSL1038 from Burkholderia pseudomallei
8B4L	;	3.394	;	Crystal structure of a selenomethionine-labeled hydropyrene synthase (M75L variant) in its closed conformation
6RMQ	;	3.0	;	Crystal structure of a selenomethionine-substituted A70M I84M mutant of the essential repressor DdrO from radiation resistant-Deinococcus bacteria (Deinococcus deserti)
6ANR	;	2.098	;	Crystal structure of a self resistance protein ClbS from colibactin biosynthetic gene cluster
6XJQ	;	1.708	;	Crystal structure of a self-alkylating ribozyme - alkylated form with biotinylated epoxide substrate
6XJW	;	1.918	;	Crystal structure of a self-alkylating ribozyme - alkylated form without biotin moiety
6XJZ	;	2.488	;	Crystal structure of a self-alkylating ribozyme - apo form
6XJY	;	2.156	;	Crystal structure of a self-alkylating ribozyme - short time incubation with the epoxide substrate
6U40	;	2.702	;	Crystal Structure of a Self-Assembling DNA Crystal Scaffold with Rhombohedral Symmetry
6WJK	;	4.514	;	Crystal Structure of a Self-Assembling DNA Crystal Scaffold with Rhombohedral Symmetry
6UEF	;	2.95	;	Crystal Structure of a Self-Assembling DNA Scaffold Containing Sequence Modifications to Attempt to Disrupt Crystal Contacts in a Rhombohedral Lattice.
6UDN	;	2.602	;	Crystal Structure of a Self-Assembling DNA Scaffold Containing TA Sticky Ends and Rhombohedral Symmetry
7C0N	;	1.552	;	Crystal structure of a self-assembling galactosylated peptide homodimer
6IA2	;	2.27	;	Crystal structure of a self-complementary RNA duplex recognized by Com
3BWP	;	3.1	;	Crystal structure of a self-spliced group II intron
1U6B	;	3.1	;	CRYSTAL STRUCTURE OF A SELF-SPLICING GROUP I INTRON WITH BOTH EXONS
2BH7	;	2.2	;	Crystal structure of a SeMet derivative of AmiD at 2.2 angstroms
1SD4	;	2.0	;	Crystal Structure of a SeMet derivative of BlaI at 2.0 A
2BH0	;	2.5	;	Crystal structure of a SeMet derivative of EXPA from Bacillus subtilis at 2.5 angstrom
1SD7	;	2.65	;	Crystal Structure of a SeMet derivative of MecI at 2.65 A
8HTC	;	2.2	;	Crystal structure of a SeMet-labeled effector from Chromobacterium violaceum in complex with Ubiquitin
3V4C	;	1.91	;	Crystal structure of a semialdehyde dehydrogenase from Sinorhizobium meliloti 1021
5T57	;	1.65	;	Crystal Structure of a Semialdehyde dehydrogenase NAD-binding Protein from Cupriavidus necator in Complex with Calcium and NAD
4QND	;	1.698	;	Crystal structure of a SemiSWEET
4QNC	;	2.388	;	Crystal structure of a SemiSWEET in an occluded state
3GRC	;	2.21	;	Crystal structure of a sensor protein from Polaromonas sp. JS666
4YME	;	1.4	;	Crystal structure of a sensory box/GGDEF family protein (CC_0091) from Caulobacter crescentus CB15 at 1.40 A resolution (PSI Community Target, Shapiro)
3Q3C	;	2.299	;	Crystal structure of a serine dehydrogenase from Pseudomonas aeruginosa pao1 in complex with NAD
5VC2	;	1.9	;	Crystal structure of a serine hydroxymethyltransferase from Helicobacter pylori
7EDD	;	2.897	;	Crystal structure of a serine protease from Streptococcus pyogenes
5XXZ	;	3.085	;	Crystal structure of a serine protease from Streptococcus species
5XYA	;	3.0	;	Crystal structure of a serine protease from Streptococcus species
5XYR	;	2.8	;	Crystal structure of a serine protease from Streptococcus species
2R0Q	;	3.2	;	Crystal structure of a serine recombinase- DNA regulatory complex
1EZX	;	2.6	;	CRYSTAL STRUCTURE OF A SERPIN:PROTEASE COMPLEX
3US4	;	1.5	;	Crystal structure of a SH2 domain of a megakaryocyte-associated tyrosine kinase (MATK) from Homo sapiens at 1.50 A resolution
3UF4	;	1.98	;	Crystal structure of a SH3 and SH2 domains of FYN protein (Proto-concogene Tyrosine-protein kinase Fyn) from Mus musculus at 1.98 A resolution
4D8K	;	2.36	;	Crystal structure of a SH3-SH2 domains of a lymphocyte-specific protein tyrosine kinase (LCK) from Homo sapiens at 2.36 A resolution
4XIJ	;	1.45	;	Crystal Structure of a Shikimate 5-dehydrogenase from Mycobacterium fortuitum Determined by Iodide SAD Phasing
4PZ1	;	1.73	;	Crystal structure of a sHIP (UniProt Id: Q99XU0) mutant from Streptococcus pyogenes
6DLG	;	1.499	;	Crystal structure of a SHIP1 surface entropy reduction mutant
4H15	;	1.45	;	Crystal Structure of a short chain alcohol dehydrogenase-related dehydrogenase (target ID NYSGRC-011812) from Sinorhizobium meliloti 1021 in space group P21
4H16	;	2.0	;	Crystal Structure of a short chain alcohol dehydrogenase-related dehydrogenase (target ID NYSGRC-011812) from Sinorhizobium meliloti 1021 in space group P6422
3SC4	;	2.5	;	Crystal structure of a Short chain dehydrogenase (A0QTM2 homolog) Mycobacterium thermoresistibile
3EDM	;	2.3	;	Crystal structure of a short chain dehydrogenase from Agrobacterium tumefaciens
4NIM	;	1.8	;	Crystal Structure of a Short Chain Dehydrogenase from Brucella melitensis
4NI5	;	1.7	;	Crystal Structure of a Short Chain Dehydrogenase from Brucella suis
5U8P	;	1.4	;	Crystal structure of a short chain dehydrogenase from Burkholderia cenocepacia J2315 in complex with NAD
5U2W	;	1.55	;	Crystal structure of a Short chain dehydrogenase from Burkholderia cenocepacia J2315 in complex with NADP
5U4S	;	1.4	;	Crystal structure of a Short chain dehydrogenase from Burkholderia cenocepacia J2315 in complex with NADP.
3QLJ	;	1.8	;	Crystal structure of a short chain dehydrogenase from Mycobacterium avium
7ULH	;	2.6	;	Crystal Structure of a Short chain dehydrogenase from Mycobacterium avium 104
3O38	;	1.95	;	Crystal structure of a short chain dehydrogenase from Mycobacterium smegmatis
4WEC	;	1.55	;	Crystal structure of a Short chain dehydrogenase from Mycobacterium smegmatis
4DQX	;	2.0	;	Crystal structure of a short chain dehydrogenase from Rhizobium etli CFN 42
4GKB	;	1.5	;	Crystal structure of a short chain dehydrogenase homolog (target efi-505321) from burkholderia multivorans, unliganded structure
4GLO	;	1.8	;	Crystal structure of a short chain dehydrogenase homolog (target EFI-505321) from burkholderia multivorans, with bound NAD
4GVX	;	1.499	;	Crystal structure of a short chain dehydrogenase homolog (target EFI-505321) from burkholderia multivorans, with bound NADP and L-fucose
3TOX	;	1.93	;	Crystal structure of a short chain dehydrogenase in complex with NAD(P) from Sinorhizobium meliloti 1021
5IG2	;	1.8	;	Crystal structure of a short chain dehydrogenase/reductase SDR from Burkholderia phymatum in complex with NAD
6D9Y	;	1.3	;	Crystal structure of a short chain dehydrogenase/reductase SDR from Burkholderia phymatum with partially occupied NAD
6Y4D	;	2.1	;	Crystal structure of a short-chain dehydrogenase/reductase (SDR) from Zephyranthes treatiae in complex with NADP+
5IDQ	;	1.55	;	Crystal structure of a Short-chain dehydrogenase/reductase (SDR)from Burkholderia vietnamiensis at 1.55 A resolution
3GUY	;	1.9	;	Crystal structure of a short-chain dehydrogenase/reductase from Vibrio parahaemolyticus
5IF3	;	1.65	;	Crystal structure of a Short-chain dehydrogenase/reductase SDR from Burkholderia vietnamiensis
4DYV	;	1.8	;	Crystal structure of a short-chain dehydrogenase/reductase SDR from Xanthobacter autotrophicus Py2
4ID9	;	1.6	;	Crystal structure of a short-chain dehydrogenase/reductase superfamily protein from agrobacterium tumefaciens (TARGET EFI-506441) with bound nad, monoclinic form 1
4IDG	;	1.9	;	Crystal structure of a short-chain dehydrogenase/reductase superfamily protein from agrobacterium tumefaciens (TARGET EFI-506441) with bound NAD, monoclinic form 2
3R1I	;	1.95	;	Crystal structure of a short-chain type dehydrogenase/reductase from Mycobacterium marinum
3TZQ	;	2.5	;	Crystal structure of a short-chain type dehydrogenase/reductase from Mycobacterium marinum
7NRG	;	1.57	;	Crystal structure of a shortened IpgC variant in complex with (1R)-2-amino-1-(4-fluorophenyl)ethanol
7AYW	;	1.78	;	Crystal structure of a shortened IpgC variant in complex with 2H-isoindol-1-amine
7B1U	;	1.59	;	Crystal structure of a shortened IpgC variant in complex with 3-(3,4-difluorophenyl)-1H,4H,6H,7H-imidazo[2,1-c][1,2,4]triazine
7AXY	;	1.63	;	Crystal structure of a shortened IpgC variant in complex with 3-amino-5-(pyrrolidin-1-yl)-1H-pyrazole-4-carbonitrile
7NL8	;	1.59	;	Crystal structure of a shortened IpgC variant in complex with 3-methylbenzohydrazide
7AZV	;	1.68	;	Crystal structure of a shortened IpgC variant in complex with 4-(trifluoromethyl)benzene-1-carboximidamide
7NHW	;	1.92	;	Crystal structure of a shortened IpgC variant in complex with chlorzoxazone
7O6S	;	1.58	;	Crystal structure of a shortened IpgC variant in complex with N-(2H-1,3-benzodioxol-5-ylmethyl)cyclopentanamine
7O04	;	1.74	;	Crystal structure of a shortened IpgC variant in complex with [(2-chloro-5-nitrophenyl)methyl](methyl)amine
6SCB	;	1.58	;	Crystal structure of a shortened IpgC variant with two bound Magnesium and two bound Chlorine atoms each
4YHB	;	1.8892	;	Crystal structure of a siderophore utilization protein from T. fusca
2GPJ	;	2.2	;	CRYSTAL STRUCTURE OF A SIDEROPHORE-INTERACTING PROTEIN (SPUTCN32_0076) FROM SHEWANELLA PUTREFACIENS CN-32 AT 2.20 A RESOLUTION
1OJL	;	3.0	;	Crystal structure of a sigma54-activator suggests the mechanism for the conformational switch necessary for sigma54 binding
1SIG	;	2.6	;	CRYSTAL STRUCTURE OF A SIGMA70 SUBUNIT FRAGMENT FROM ESCHERICHIA COLI RNA POLYMERASE
4ME8	;	2.27	;	Crystal structure of a signal peptidase I (EF3073) from Enterococcus faecalis V583 at 2.27 A resolution
3LUA	;	2.4	;	Crystal structure of a Signal receiver domain of Two component Signal Transduction (Histidine Kinase) from Clostridium thermocellum
4UYJ	;	3.35	;	Crystal structure of a Signal Recognition Particle Alu domain in the elongation arrest conformation
4UYK	;	3.22	;	Crystal structure of a Signal Recognition Particle Alu domain in the elongation arrest conformation
3NDB	;	3.0	;	Crystal structure of a signal sequence bound to the signal recognition particle
2QMS	;	2.1	;	Crystal structure of a signaling molecule
2OLH	;	2.78	;	Crystal structure of a signalling protein (SPG-40) complex with cellobiose at 2.78 A resolution
2O92	;	3.0	;	Crystal structure of a signalling protein (SPG-40) complex with tetrasaccharide at 3.0A resolution
1Y3G	;	2.1	;	Crystal Structure of a Silanediol Protease Inhibitor Bound to Thermolysin
4FDY	;	2.23	;	Crystal structure of a similar to lipoprotein, NLP/P60 family (SAV0400) from Staphylococcus aureus subsp. aureus Mu50 at 2.23 A resolution
7C51	;	2.46	;	Crystal structure of a Simpl-like protein from Campylobacter jejuni (native protein)
7C50	;	1.93	;	Crystal structure of a Simpl-like protein from Campylobacter jejuni (selenomethionine-incorporated protein)
4CS1	;	2.0	;	Crystal structure of a simple duplex kink turn, HmKt-7 with 2 Mg bound.
3CI7	;	1.4	;	Crystal structure of a simplified BPTI containing 20 alanines
1D2O	;	2.0	;	CRYSTAL STRUCTURE OF A SINGLE B REPEAT UNIT (B1) OF COLLAGEN BINDING SURFACE PROTEIN (CNA) OF STAPHYLOCOCCUS AUREUS.
4JZG	;	2.321	;	Crystal structure of a single cambialistic SOD2 occupied by Manganese ion from Clostridium difficile
2GJJ	;	2.1	;	Crystal structure of a single chain antibody scA21 against Her2/ErbB2
3NWM	;	2.7	;	Crystal structure of a single chain construct composed of MHC class I H-2Kd, beta-2microglobulin and a peptide which is an autoantigen for type 1 diabetes
5O7K	;	2.05	;	Crystal structure of a single chain monellin mutant (Y65R) pH 2.0
5O7L	;	2.6	;	Crystal structure of a single chain monellin mutant (Y65R) pH 4.6
5O7Q	;	1.72	;	Crystal structure of a single chain monellin mutant (Y65R) pH 5.5
5O7R	;	2.06	;	Crystal structure of a single chain monellin mutant (Y65R) pH 6.5
5O7S	;	2.02	;	Crystal structure of a single chain monellin mutant (Y65R) pH 8.3
5LC7	;	1.55	;	Crystal structure of a single chain monellin mutant: E23Q/Q28K/C41S/Y65R-MNEI
5LC6	;	1.7	;	Crystal structure of a single chain monellin mutant: Q28K/C41S/Y65R-MNEI
5OQF	;	2.27	;	Crystal structure of a single chain trimer composed of the MHC 1 heavy chain H2-Kb WT, beta-2microglobulin, and ovalbumin derived peptide
5OQG	;	1.9	;	Crystal structure of a single chain trimer composed of the MHC I heavy chain H-2Kb W167A, beta-2microglobulin, and and ovalbumin-derived peptide.
2QRI	;	2.0	;	Crystal structure of a single chain trimer composed of the MHC I heavy chain H-2Kb WT, beta-2microglobulin, and ovalbumin-derived peptide.
2QRS	;	2.0	;	Crystal Structure of a single chain trimer composed of the MHC I heavy chain H-2Kb Y84A, beta-2microglobulin, and ovalbumin-derived peptide.
4UNL	;	1.5	;	Crystal structure of a single mutant (N71D) of triosephosphate isomerase from human
4EMQ	;	1.95	;	Crystal structure of a single mutant of Dronpa, the green-on-state PDM1-4
3PGZ	;	2.1	;	Crystal structure of a single strand binding protein (SSB) from bartonella henselae
6IWV	;	1.52	;	Crystal structure of a single strand DNA binding protein
1O7I	;	1.2	;	Crystal structure of a single stranded DNA binding protein
7MC4	;	2.5	;	Crystal structure of a single-chain E/F type bilin lyase-isomerase MpeQ
7MCH	;	2.95	;	Crystal structure of a single-chain E/F type bilin lyase-isomerase MpeQ in space group C2221
8JZ0	;	1.229	;	Crystal structure of a single-chain monellin mutant C41A
8JZ1	;	1.239	;	Crystal structure of a single-chain monellin mutant C41V
6R2G	;	1.9	;	Crystal structure of a single-chain protein mimetic of the gp41 NHR trimer in complex with the synthetic CHR peptide C34
4DOU	;	2.0	;	Crystal Structure of a Single-chain Trimer of Human Adiponectin Globular Domain
6HMZ	;	1.98	;	Crystal Structure of a Single-Domain Cyclophilin from Brassica napus Phloem Sap
4TX4	;	1.95	;	Crystal Structure of a Single-Domain Cysteine Protease Inhibitor from Cowpea (Vigna unguiculata)
2HJM	;	2.9	;	Crystal structure of a singleton protein PF1176 from P. furiosus
1ICI	;	2.1	;	CRYSTAL STRUCTURE OF A SIR2 HOMOLOG-NAD COMPLEX
1GDT	;	3.0	;	CRYSTAL STRUCTURE OF A SITE-SPECIFIC RECOMBINASE, GAMMA-DELTA RESOLVASE COMPLEXED WITH A 34 BP CLEAVAGE SITE
1MHD	;	2.8	;	CRYSTAL STRUCTURE OF A SMAD MH1 DOMAIN BOUND TO DNA
1MR1	;	2.85	;	Crystal Structure of a Smad4-Ski Complex
3SJQ	;	1.9	;	Crystal structure of a small conductance potassium channel splice variant complexed with calcium-calmodulin
5J7N	;	2.9	;	Crystal structure of a small heat-shock protein from Xylella fastidiosa reveals a distinct high order structure
2HQL	;	2.0	;	Crystal structure of a small single-stranded DNA binding protein from Mycoplasma pneumoniae
3UCF	;	2.347	;	Crystal structure of a small-chain dehydrogenase
3UCE	;	1.798	;	Crystal structure of a small-chain dehydrogenase in complex with NADPH
4GGQ	;	1.95	;	Crystal structure of a SMT fusion Peptidyl-prolyl cis-trans isomerase from Burkholderia pseudomallei complexed with CJ40
3UF8	;	1.5	;	Crystal structure of a SMT fusion Peptidyl-prolyl cis-trans isomerase with a G95A surface mutation from Burkholderia pseudomallei complexed with FK506
3UQA	;	1.55	;	Crystal structure of a SMT fusion Peptidyl-prolyl cis-trans isomerase with surface mutation A54E from Burkholderia pseudomallei complexed with FK506
4G50	;	1.75	;	Crystal structure of a SMT fusion Peptidyl-prolyl cis-trans isomerase with surface mutation D44G from Burkholderia pseudomallei complexed with CJ168
4GIV	;	2.45	;	Crystal structure of a SMT fusion Peptidyl-prolyl cis-trans isomerase with surface mutation D44G from Burkholderia pseudomallei complexed with CJ183
4FN2	;	1.95	;	Crystal structure of a SMT fusion Peptidyl-prolyl cis-trans isomerase with surface mutation D44G from Burkholderia pseudomallei complexed with CJ37
3UQB	;	1.9	;	Crystal structure of a SMT Fusion PEPTIDYL-PROLYL CIS-TRANS ISOMERASE with surface mutation D44G from Burkholderia pseudomallei complexed with FK506
3VAW	;	1.55	;	Crystal structure of a smt fusion peptidyl-prolyl cis-trans isomerase with surface mutation v3i from burkholderia pseudomallei complexed with fk506
3EHC	;	2.12	;	Crystal structure of a snoal-like polyketide cyclase (atu3018) from agrobacterium tumefaciens str. c58 at 2.12 A resolution
3H3H	;	1.6	;	Crystal structure of a snoal-like protein of unknown function (bth_ii0226) from burkholderia thailandensis e264 at 1.60 A resolution
1S4I	;	1.8	;	Crystal structure of a SOD-like protein from Bacillus subtilis
3G67	;	2.17	;	Crystal Structure of a Soluble Chemoreceptor from Thermotoga maritima
3G6B	;	3.0	;	Crystal structure of a Soluble Chemoreceptor from Thermotoga maritima Asn217Ile mutant
3G9V	;	2.756	;	Crystal structure of a soluble decoy receptor IL-22BP bound to interleukin-22
1RK4	;	1.792	;	Crystal Structure of a Soluble Dimeric Form of Oxidised CLIC1
1ST9	;	1.5	;	Crystal Structure of a Soluble Domain of ResA in the Oxidised Form
1DR9	;	3.0	;	CRYSTAL STRUCTURE OF A SOLUBLE FORM OF B7-1 (CD80)
1K0O	;	1.75	;	Crystal structure of a soluble form of CLIC1. An intracellular chloride ion channel
2AHE	;	1.8	;	Crystal structure of a soluble form of CLIC4. intercellular chloride ion channel
3PE6	;	1.35	;	Crystal Structure of a soluble form of human MGLL in complex with an inhibitor
1CD8	;	2.6	;	CRYSTAL STRUCTURE OF A SOLUBLE FORM OF THE HUMAN T CELL CO-RECEPTOR CD8 AT 2.6 ANGSTROMS RESOLUTION
5Z3Q	;	2.545	;	Crystal Structure of a Soluble Fragment of Poliovirus 2C ATPase (2.55 Angstrom)
1K0M	;	1.4	;	Crystal structure of a soluble monomeric form of CLIC1 at 1.4 angstroms
1HUV	;	2.15	;	CRYSTAL STRUCTURE OF A SOLUBLE MUTANT OF THE MEMBRANE-ASSOCIATED (S)-MANDELATE DEHYDROGENASE FROM PSEUDOMONAS PUTIDA AT 2.15A RESOLUTION
2X9C	;	2.45	;	Crystal structure of a soluble PrgI mutant from Salmonella Typhimurium
3D89	;	2.071	;	Crystal Structure of a Soluble Rieske Ferredoxin from Mus musculus
6WMA	;	2.5	;	Crystal structure of a soluble variant of full-length human APOBEC3G (pH 7.6)
6WMB	;	3.02	;	Crystal structure of a soluble variant of full-length human APOBEC3G (pH 8.0)
6WMC	;	3.49	;	Crystal structure of a soluble variant of full-length human APOBEC3G (pH 9.0)
4ZXF	;	2.5	;	Crystal Structure of a Soluble Variant of Monoglyceride Lipase from Saccharomyces Cerevisiae in Complex with a Substrate Analog
4ZWN	;	2.491	;	Crystal Structure of a Soluble Variant of the Monoglyceride Lipase from Saccharomyces Cerevisiae
7UG8	;	1.796	;	Crystal structure of a solute receptor from Synechococcus CC9311 in complex with alpha-ketovaleric and calcium
3POV	;	2.5	;	Crystal structure of a SOX-DNA complex
2V53	;	3.2	;	Crystal structure of a SPARC-collagen complex
5GQT	;	3.022	;	Crystal structure of a specifier Protein from Arabidopsis thaliana
3OAK	;	2.15	;	Crystal structure of a Spn1 (Iws1)-Spt6 complex
2VWA	;	2.5	;	Crystal structure of a sporozoite protein essential for liver stage development of malaria parasite
2XPN	;	1.95	;	Crystal structure of a Spt6-Iws1(Spn1) complex from Encephalitozoon cuniculi, Form I
2XPO	;	2.1	;	Crystal structure of a Spt6-Iws1(Spn1) complex from Encephalitozoon cuniculi, Form II
2XPP	;	1.74	;	Crystal structure of a Spt6-Iws1(Spn1) complex from Encephalitozoon cuniculi, Form III
1GSZ	;	2.8	;	Crystal Structure of a Squalene Cyclase in Complex with the Potential Anticholesteremic Drug Ro48-8071
3FPM	;	3.3	;	Crystal Structure of a Squarate Inhibitor bound to MAPKAP Kinase-2
1SHG	;	1.8	;	CRYSTAL STRUCTURE OF A SRC-HOMOLOGY 3 (SH3) DOMAIN
5UTF	;	3.503	;	Crystal Structure of a Stabilized DS-SOSIP.6mut BG505 gp140 HIV-1 Env Trimer, Containing Mutations I201C-P433C (DS), L154M, Y177W, N300M, N302M, T320L, I420M in Complex with Human Antibodies PGT122 and 35O22 at 4.3 A
5UTY	;	3.412	;	Crystal Structure of a Stabilized DS-SOSIP.mut4 BG505 gp140 HIV-1 Env Trimer, Containing Mutations I201C-P433C (DS), L154M, N300M, N302M, T320L in Complex with Human Antibodies PGT122 and 35O22 at 4.1 Angstrom
6X5N	;	3.3	;	Crystal structure of a stabilized PAN ENE bimolecular triplex with a GC-clamped polyA tail, in complex with Fab-BL-3,6
6X5M	;	2.5	;	Crystal structure of a stabilized PAN ENE bimolecular triplex with a GC-clamped polyA tail, in complex with Fab-BL-3,6.
1VH4	;	1.75	;	Crystal structure of a stabilizer of iron transporter
4QBF	;	1.8	;	Crystal structure of a stable adenylate kinase variant AKlse2
4QBG	;	1.37	;	Crystal structure of a stable adenylate kinase variant AKlse4
4QBH	;	1.67	;	Crystal structure of a stable adenylate kinase variant AKlse5
4QBI	;	1.67	;	Crystal structure of a stable adenylate kinase variant AKlse6
4MKH	;	1.5	;	Crystal structure of a stable adenylate kinase variant AKv18
4MKF	;	1.7	;	Crystal structure of a stable adenylate kinase variant AKv3
4MKG	;	1.45	;	Crystal structure of a stable adenylate kinase variant AKv8
7RG8	;	1.3	;	Crystal Structure of a Stable Heparanase Mutant
6IH7	;	2.25	;	Crystal structure of a standalone versatile EAL protein from Vibrio cholerae O395 - 3',3'-cGAMP bound form
6IJ2	;	1.7	;	Crystal structure of a standalone versatile EAL protein from Vibrio cholerae O395 - 5'-pGpG bound form
6IFQ	;	1.95	;	Crystal structure of a standalone versatile EAL protein from Vibrio cholerae O395 - Apo form
6IH1	;	1.95	;	Crystal structure of a standalone versatile EAL protein from Vibrio cholerae O395 - c-di-GMP bound form
6K6T	;	2.2	;	Crystal structure of a standalone versatile EAL protein from Vibrio cholerae O395 - c-di-IMP bound form
1QWX	;	1.5	;	Crystal Structure of a Staphylococcal Inhibitor/Chaperone
8ABO	;	1.97	;	Crystal structure of a staphylococcal orthologue of CYP134A1 (CYPX) in complex with a fragment
8ADR	;	1.92	;	Crystal structure of a staphylococcal orthologue of CYP134A1 (CYPX) in complex with a fragment
8AA7	;	2.05	;	Crystal structure of a staphylococcal orthologue of CYP134A1 (CYPX) in complex with a heme coordinated fragment
8A8L	;	1.88	;	Crystal structure of a staphylococcal orthologue of CYP134A1 (CYPX) in complex with a heme-coordinated fragment
8A91	;	1.85	;	Crystal structure of a staphylococcal orthologue of CYP134A1 (CYPX) in complex with a heme-coordinated fragment
8AE8	;	1.92	;	Crystal structure of a staphylococcal orthologue of CYP134A1 (CYPX) in complex with a heme-coordinated fragment
7OW9	;	1.8	;	Crystal structure of a staphylococcal orthologue of CYP134A1 (CYPX) in complex with Cyclo-L-leucyl-L-leucine
2QEJ	;	3.2	;	Crystal structure of a Staphylococcus aureus protein (SSL7) in complex with Fc of human IgA1
1T02	;	2.6	;	Crystal structure of a Statin bound to class II HMG-CoA reductase
1ZOI	;	1.6	;	Crystal Structure of a Stereoselective Esterase from Pseudomonas putida IFO12996
3MSO	;	2.57	;	Crystal structure of a STEROID DELTA-ISOMERASE (NP_250810.1) from PSEUDOMONAS AERUGINOSA at 2.57 A resolution
6A99	;	2.29	;	Crystal structure of a Stig cyclases Fisc from Fischerella sp. TAU in complex with (3Z)-3-(1-methyl-2-pyrrolidinylidene)-3H-indole
8GID	;	1.8	;	Crystal structure of a strain-transcending single-component Plasmodium falciparum AMA1-RON2L structure-based design immunogen 1 (SBD1)
4N8P	;	2.299	;	Crystal structure of a strand swapped CTLA-4 from Duckbill Platypus [PSI-NYSGRC-012711]
4ETY	;	1.9	;	Crystal structure of a strand-swapped dimer of Mouse Leukocyte-associated immunoglobulin-like receptor 1 (NYSGRC-006047) Extra Cellular Domain
4ESK	;	1.762	;	Crystal structure of a strand-swapped dimer of Mouse Leukocyte-associated immunoglobulin-like receptor 1 (NYSGRC-006047)IG-like domain
4JGL	;	1.25	;	Crystal structure of a streptavidin-like protein (BACEGG_01519) from Bacteroides eggerthii DSM 20697 at 1.25 A resolution
6FZH	;	1.5	;	Crystal structure of a streptococcal dehydrogenase at 1.5 Angstroem resolution
2ZW0	;	1.4	;	Crystal structure of a Streptococcal protein G B1 mutant
2ZW1	;	1.6	;	Crystal structure of a Streptococcal protein G B1 mutant
6KMC	;	1.84	;	Crystal structure of a Streptococcal protein G B1 mutant
4V49	;	8.7	;	Crystal Structure of a Streptomycin Dependent Ribosome from E. Coli 70S Ribosome.
3NQK	;	2.61	;	Crystal structure of a STRUCTURAL GENOMICS, UNKNOWN FUNCTION (BACOVA_03322) from Bacteroides ovatus at 2.61 A resolution
3N91	;	2.4	;	Crystal structure of a STRUCTURAL GENOMICS, UNKNOWN FUNCTION (BACOVA_03430) from Bacteroides ovatus at 2.40 A resolution
4IX3	;	1.35	;	Crystal structure of a Stt7 homolog from Micromonas algae
4IX4	;	1.499	;	Crystal structure of a Stt7 homolog from Micromonas algae in complex with ADP
4IX5	;	1.7	;	Crystal structure of a Stt7 homolog from Micromonas algae in complex with AMP-PNP
4IX6	;	1.6	;	Crystal structure of a Stt7 homolog from Micromonas algae soaked with ATP
3RA0	;	2.451	;	Crystal Structure of a StWhy2 K67A-dT32 complex
3N1K	;	2.702	;	Crystal Structure of a StWhy2-cERE32 complex
3N1J	;	2.65	;	Crystal structure of a StWhy2-dT32 complex
3N1I	;	2.2	;	Crystal Structure of a StWhy2-ERE32 complex
3N1L	;	2.35	;	Crystal Structure of a StWhy2-rcERE32 complex
3VNN	;	2.903	;	Crystal Structure of a sub-domain of the nucleotidyltransferase (adenylation) domain of human DNA ligase IV
6LU2	;	1.75	;	Crystal structure of a substrate binding protein from Microbacterium hydrocarbonoxydans
6LU3	;	2.2	;	Crystal structure of a substrate binding protein from Microbacterium hydrocarbonoxydans complexed with 4-hydroxybenzoate hydrazide
5Z6V	;	1.87	;	Crystal structure of a substrate-binding protein from Rhodothermus marinus
3HAY	;	4.99	;	Crystal structure of a substrate-bound full H/ACA RNP from Pyrococcus furiosus
3HAX	;	2.11	;	Crystal structure of a substrate-bound Gar1-minus H/ACA RNP from Pyrococcus furiosus
4KY0	;	3.0	;	Crystal structure of a substrate-free glutamate transporter homologue from Thermococcus kodakarensis
5DWY	;	2.7	;	Crystal structure of a substrate-free glutamate transporter homologue GltTk
7L4I	;	2.58	;	Crystal structure of a substrate-trapping variant of PPM1H phosphatase
3LPA	;	2.0	;	Crystal structure of a subtilisin-like protease
3LPC	;	1.7	;	Crystal structure of a subtilisin-like protease
3LPD	;	2.1	;	Crystal structure of a subtilisin-like protease
4I78	;	3.18	;	Crystal structure of a subtype H17 hemagglutinin homologue from A/little yellow-shouldered bat/Guatemala/060/2010 (H17N10)
4K3X	;	2.149	;	Crystal structure of a subtype H18 hemagglutinin homologue from A/flat-faced bat/Peru/033/2010 (H18N11)
4MC5	;	2.238	;	Crystal structure of a subtype H18 hemagglutinin homologue from A/flat-faced bat/Peru/033/2010 (H18N11)
4K3Y	;	2.682	;	Crystal structure of a subtype N11 neuraminidase-like protein of A/flat-faced bat/Peru/033/2010 (H18N11)
4MC7	;	2.99	;	Crystal structure of a subtype N11 neuraminidase-like protein of A/flat-faced bat/Peru/033/2010 (H18N11)
3TX8	;	2.972	;	Crystal structure of a succinyl-diaminopimelate desuccinylase (ArgE) from Corynebacterium glutamicum ATCC 13032 at 2.97 A resolution
3NA6	;	2.0	;	Crystal structure of a succinylglutamate desuccinylase (TM1040_2694) from SILICIBACTER SP. TM1040 at 2.00 A resolution
5BQ3	;	2.6	;	Crystal structure of a sugar ABC transporter (ACTODO_00688) from Actinomyces odontolyticus ATCC 17982 at 2.60 A resolution
3HXK	;	3.2	;	Crystal Structure of a sugar hydrolase (YeeB) from Lactococcus lactis, Northeast Structural Genomics Consortium Target KR108
3QC0	;	1.45	;	Crystal structure of a sugar isomerase (SMc04130) from SINORHIZOBIUM MELILOTI 1021 at 1.45 A resolution
4EUM	;	1.8	;	Crystal structure of a sugar kinase (Target EFI-502132) from Oceanicola granulosus with bound AMP, crystal form II
4E69	;	1.6	;	Crystal structure of a sugar kinase (target EFI-502132) from Oceanicola granulosus, unliganded structure
4EUN	;	1.6	;	Crystal structure of a sugar kinase (Target EFI-502144 from Janibacter sp. HTCC2649), unliganded structure
4EBU	;	2.0	;	Crystal structure of a sugar kinase (Target EFI-502312) from Oceanicola granulosus, with bound AMP/ADP crystal form I
6NBP	;	1.7	;	Crystal Structure of a Sugar N-Formyltransferase from the Plant Pathogen Pantoea ananatis
3P6L	;	1.85	;	Crystal structure of a Sugar phosphate isomerase/epimerase (BDI_1903) from Parabacteroides distasonis ATCC 8503 at 1.85 A resolution
3OBE	;	1.7	;	Crystal structure of a sugar phosphate isomerase/epimerase (BDI_3400) from Parabacteroides distasonis ATCC 8503 at 1.70 A resolution
3ORJ	;	2.16	;	Crystal structure of a sugar-binding protein (BACOVA_04391) from Bacteroides ovatus at 2.16 A resolution
3DWG	;	1.53	;	Crystal structure of a sulfur carrier protein complex found in the cysteine biosynthetic pathway of Mycobacterium tuberculosis
1HQR	;	3.2	;	CRYSTAL STRUCTURE OF A SUPERANTIGEN BOUND TO THE HIGH-AFFINITY, ZINC-DEPENDENT SITE ON MHC CLASS II
3O13	;	2.05	;	Crystal structure of a superantigen-like protein (SAV0433) from Staphylococcus aureus MU50 at 2.05 A resolution
7T1K	;	1.25	;	Crystal structure of a superbinder Fes SH2 domain (sFes1) in complex with a high affinity phosphopeptide
7T1L	;	1.35	;	Crystal structure of a superbinder Fes SH2 domain (sFesS) in complex with a high affinity phosphopeptide
7T1U	;	2.65	;	Crystal structure of a superbinder Src SH2 domain (sSrcF) in complex with a high affinity phosphopeptide
4W6B	;	1.9	;	Crystal Structure of a Superfolder GFP Mutant K26C Disulfide Dimer, P 21 21 21 Space Group
2B3P	;	1.4	;	Crystal structure of a superfolder green fluorescent protein
8BRQ	;	1.63	;	Crystal structure of a surface entropy reduction variant of penicillin G acylase from Bacillaceae i. s. sp. FJAT-27231
7MK8	;	2.15	;	Crystal structure of a surface mutant of human fetal-specific CYP3A7 bound to dithiothreitol
5EFD	;	1.674	;	Crystal structure of a surface pocket creating mutant (W6A) of an alkali thermostable GH10 xylanase from Bacillus sp. NG-27
2H3N	;	2.3	;	Crystal structure of a surrogate light chain (LAMBDA5 and VpreB) homodimer
2QFA	;	1.4	;	Crystal structure of a Survivin-Borealin-INCENP core complex
4F53	;	2.25	;	Crystal structure of a susd homolog (BACOVA_04803) from Bacteroides ovatus ATCC 8483 at 2.25 A resolution
4PUC	;	2.0	;	Crystal structure of a SusD homolog (BACUNI_02643) from Bacteroides uniformis ATCC 8492 at 2.00 A resolution
3P1U	;	2.05	;	Crystal structure of a SusD homolog (BDI_0600) from Parabacteroides distasonis ATCC 8503 AT 2.05 A resolution
3MX3	;	2.0	;	Crystal structure of a SusD homolog (BF0972) from Bacteroides fragilis NCTC 9343 at 2.00 A resolution
3EJN	;	1.5	;	CRYSTAL STRUCTURE OF A SUSD HOMOLOG (BF3025) FROM BACTEROIDES FRAGILIS NCTC 9343 AT 1.50 A RESOLUTION
4MRU	;	1.9	;	Crystal structure of a susD homolog (BT1281) from Bacteroides thetaiotaomicron VPI-5482 at 1.90 A resolution
4Q69	;	2.5	;	Crystal structure of a SusD homolog (BT2259) from Bacteroides thetaiotaomicron VPI-5482 at 2.50 A resolution
3CGH	;	1.7	;	Crystal structure of a susd homolog (bt_3984) from bacteroides thetaiotaomicron vpi-5482 at 1.70 A resolution
4F7A	;	1.85	;	Crystal structure of a susd homolog (BVU_2203) from Bacteroides vulgatus ATCC 8482 at 1.85 A resolution
3OTN	;	1.95	;	Crystal structure of a SusD superfamily protein (BDI_3964) from Parabacteroides distasonis ATCC 8503 at 1.95 A resolution
3NQP	;	1.9	;	Crystal structure of a SusD superfamily protein (BF1802) from Bacteroides fragilis NCTC 9343 at 1.90 A resolution
3GZS	;	2.09	;	Crystal structure of a susd superfamily protein (bf3413) from bacteroides fragilis nctc 9343 at 2.10 A resolution
3L22	;	2.05	;	CRYSTAL STRUCTURE OF A SUSD SUPERFAMILY PROTEIN (BF_0597) FROM BACTEROIDES FRAGILIS AT 2.05 A RESOLUTION
3MYV	;	1.8	;	Crystal structure of a SusD superfamily protein (BVU_0732) from Bacteroides vulgatus ATCC 8482 at 1.80 A resolution
3I4G	;	1.35	;	CRYSTAL STRUCTURE OF A SUSD-LIKE CARBOHYDRATE BINDING PROTEIN (BF0978) FROM BACTEROIDES FRAGILIS NCTC 9343 AT 1.35 A RESOLUTION
3QNK	;	2.7	;	Crystal structure of a SusD-like protein (BF3747) from Bacteroides fragilis NCTC 9343 at 2.70 A resolution
3SGH	;	1.7	;	Crystal structure of a SusD-like protein (BT_3752) from Bacteroides thetaiotaomicron VPI-5482 at 1.70 A resolution
3FDH	;	1.75	;	Crystal structure of a susd/ragb family protein (bt_2033) from bacteroides thetaiotaomicron vpi-5482 at 1.75 A resolution
5WAK	;	3.2	;	Crystal Structure of a Suz12-Rbbp4 Binary Complex
5WAI	;	2.9	;	Crystal Structure of a Suz12-Rbbp4-Jarid2-Aebp2 Heterotetrameric Complex
6NQ3	;	2.89	;	Crystal Structure of a SUZ12-RBBP4-PHF19-JARID2 Heterotetrameric Complex
4F3Z	;	3.2	;	Crystal structure of a swine H1N2 influenza virus hemagglutinin
4H3Z	;	2.15	;	Crystal structure of a symmetric dimer of a tRNA (guanine-(N(1)-)-methyltransferase from Burkholderia phymatum bound to S-adenosyl homocystein in both half-sites
3B3Q	;	2.4	;	Crystal structure of a synaptic adhesion complex
6A1I	;	1.6	;	Crystal structure of a synthase 1 from Santalum album
6A1D	;	1.78	;	Crystal structure of a synthase 1 from Santalum album in complex with ligand
6A1E	;	1.89	;	Crystal structure of a synthase 1 from Santalum album in complex with ligand fps
6A3X	;	1.75	;	Crystal structure of a synthase 1 from Santalum album in complex with ligand s
6A2A	;	1.77	;	Crystal structure of a synthase 2 from santalum album
6A2C	;	1.94	;	Crystal structure of a synthase 2 from santalum album in complex with lig2
6A2D	;	1.96	;	Crystal structure of a synthase 2 from santalum album in complex with ligand1
5YGJ	;	2.648	;	Crystal structure of a synthase from Streptomyces sp. CL190
5YGK	;	2.047	;	Crystal structure of a synthase from Streptomyces sp. CL190 with dmaspp
1COS	;	2.1	;	CRYSTAL STRUCTURE OF A SYNTHETIC TRIPLE-STRANDED ALPHA-HELICAL BUNDLE
1VC9	;	2.3	;	Crystal Structure of a T.thermophilus HB8 Ap6A hydrolase E50Q mutant-Mg2+-ATP complex
1VCD	;	1.7	;	Crystal Structure of a T.thermophilus HB8 Ap6A hydrolase Ndx1
1VC8	;	2.0	;	Crystal Structure of a T.thermophilus HB8 Ap6A Hydrolase Ndx1-Ap6A Complex
5BZ4	;	2.43	;	Crystal structure of a T1-like thiolase (CoA-complex) from Mycobacterium smegmatis
5CBQ	;	2.45	;	Crystal structure of a T1-like thiolase from Mycobacterium smegmatis
4Q5I	;	2.8	;	Crystal structure of a T151A mutant of the E. coli FeoB G-domain
3D68	;	2.8	;	Crystal structure of a T325I/T329I/H333Y/H335Q mutant of Thrombin-Activatable Fibrinolysis Inhibitor (TAFI-IIYQ)
4I6T	;	2.0	;	Crystal Structure of a T36A mutant of the Restriction-Modification Controller Protein C.Esp1396I
3WXX	;	2.7	;	Crystal Structure of a T3SS complex from Aeromonas hydrophila
4Y5R	;	2.8	;	Crystal Structure of a T67A MauG/pre-Methylamine Dehydrogenase Complex
1CEZ	;	2.4	;	CRYSTAL STRUCTURE OF A T7 RNA POLYMERASE-T7 PROMOTER COMPLEX
4RGW	;	2.301	;	Crystal Structure of a TAF1-TAF7 Complex in Human Transcription Factor IID
6FB5	;	2.2	;	Crystal Structure of a Tailored I-CreI Homing Endonuclease Protein (3115 variant) in complex with an altered version of its target DNA (Haemoglobin beta subunit gene) at 5NNN region in the presence of Magnesium
6FB6	;	2.6	;	Crystal Structure of a Tailored I-CreI Homing Endonuclease Protein (3115 variant) in complex with an altered version of its target DNA (Haemoglobin beta subunit gene) at 5NNN region in the presence of Manganese
6FB0	;	2.15	;	Crystal Structure of a Tailored I-CreI Homing Endonuclease Protein (3115 variant) in complex with its target DNA (Haemoglobin beta subunit gene) in the presence of Calcium
6FB1	;	3.024	;	Crystal Structure of a Tailored I-CreI Homing Endonuclease Protein (3115 variant) in complex with its target DNA (Haemoglobin beta subunit gene) in the presence of Magnesium
6FB2	;	2.95	;	Crystal Structure of a Tailored I-CreI Homing Endonuclease Protein (3115 variant) in complex with its target DNA (Haemoglobin beta subunit gene) in the presence of Manganese
8OPZ	;	1.5	;	Crystal structure of a tailspike depolymerase (APK16_gp47) from Acinetobacter phage APK16
6NW9	;	1.85	;	CRYSTAL STRUCTURE OF A TAILSPIKE PROTEIN 3 (TSP3, ORF212) FROM ESCHERICHIA COLI O157:H7 BACTERIOPHAGE CBA120
6C72	;	2.396	;	Crystal structure of a tailspike protein gp49 from Acinetobacter baumannii bacteriophage Fri1, a capsular polysaccharide depolymerase
1KUG	;	1.37	;	Crystal Structure of a Taiwan Habu Venom Metalloproteinase complexed with its endogenous inhibitor pENW
1KUK	;	1.45	;	Crystal Structure of a Taiwan Habu Venom Metalloproteinase complexed with pEKW.
1KUI	;	1.5	;	Crystal Structure of a Taiwan Habu Venom Metalloproteinase complexed with pEQW.
4HPZ	;	2.202	;	Crystal structure of a TALE protein reveals an extended N-terminal DNA binding region
7L18	;	2.542	;	Crystal structure of a tandem deletion mutant of rat NADPH-cytochrome P450 reductase
1QG3	;	2.15	;	CRYSTAL STRUCTURE OF A TANDEM PAIR OF FIBRONECTIN TYPE III DOMAINS FROM THE CYTOPLASMIC TAIL OF INTEGRIN ALPHA6 BETA4
3GEC	;	4.0	;	Crystal structure of a tandem PAS domain fragment of Drosophila PERIOD
1FW6	;	2.7	;	CRYSTAL STRUCTURE OF A TAQ MUTS-DNA-ADP TERNARY COMPLEX
4KEM	;	1.3	;	Crystal structure of a tartrate dehydratase from azospirillum, target efi-502395, with bound mg and a putative acrylate ion, ordered active site
2FMU	;	2.3	;	Crystal structure of a tat-interacting protein homologue (htatip2, aw111545, cc3, tip30) from mus musculus at 2.30 A resolution
4CHS	;	1.6	;	Crystal structure of a tau class glutathione transferase 10 from Glycine max
5AGY	;	1.75	;	CRYSTAL STRUCTURE OF A TAU CLASS GST MUTANT FROM GLYCINE
5KEU	;	1.85	;	Crystal Structure of a Taurine Dioxygenase from Burkholderia xenovorans
7YXV	;	1.7	;	Crystal structure of a tautomerase superfamily member form Acinetobacter baumanii
3NZ4	;	2.38	;	Crystal Structure of a Taxus Phenylalanine Aminomutase
4JHY	;	1.9	;	Crystal structure of a TBP-like protein (BDI_3606) from Parabacteroides distasonis ATCC 8503 at 1.90 A resolution
5KKX	;	2.1	;	Crystal structure of a TbpB C-lobe mutant from Neisseria meningitidis M982
7OW6	;	2.64	;	Crystal structure of a TCR in complex with HLA-A*11:01 bound to KRAS G12D peptide (VVVGADGVGK)
8I5C	;	3.34	;	Crystal structure of a TCR in complex with HLA-A*11:01 bound to KRAS peptide (VVGAVGVGK)
8I5D	;	3.3	;	Crystal structure of a TCR in complex with HLA-A*11:01 bound to KRAS peptide (VVGAVGVGK)
7OW5	;	2.58	;	Crystal structure of a TCR in complex with HLA-A*11:01 bound to KRAS peptide (VVVGAGGVGK)
4X9T	;	1.24	;	Crystal structure of a TctC solute binding protein from Polaromonas (Bpro_3516, Target EFI-510338), no ligand
5JFI	;	2.749	;	Crystal structure of a TDIF-TDR complex
5JFK	;	2.647	;	Crystal structure of a TDR receptor
2OU3	;	1.85	;	Crystal structure of a tellurite resistance protein of cog3793 (npun_f6341) from nostoc punctiforme pcc 73102 at 1.85 A resolution
2I0Q	;	1.91	;	Crystal structure of a telomere single-strand DNA-protein complex from O. nova with full-length alpha and beta telomere proteins
3MIJ	;	2.6	;	Crystal structure of a telomeric RNA G-quadruplex complexed with an acridine-based ligand.
3IBK	;	2.2	;	Crystal structure of a telomeric RNA quadruplex
3MVU	;	1.8	;	Crystal structure of a TenA family transcription regulator (TM1040_3656) from SILICIBACTER SP. TM1040 at 1.80 A resolution
3OQL	;	2.54	;	Crystal structure of a TenA homolog (PSPTO1738) from Pseudomonas syringae pv. tomato str. DC3000 at 2.54 A resolution
4LQX	;	2.34	;	Crystal structure of a TENA/THI-4 domain-containing protein (SSO2700) from Sulfolobus solfataricus P2 at 2.34 A resolution
4ATY	;	1.85	;	Crystal structure of a Terephthalate 1,2-cis-dihydrodioldehydrogenase from Burkholderia xenovorans LB400
2ZCK	;	3.1	;	Crystal structure of a ternary complex between PSA, a substrat-acyl intermediate and an activating antibody
1CQT	;	3.2	;	CRYSTAL STRUCTURE OF A TERNARY COMPLEX CONTAINING AN OCA-B PEPTIDE, THE OCT-1 POU DOMAIN, AND AN OCTAMER ELEMENT
1Q0N	;	1.25	;	CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF 6-HYDROXYMETHYL-7,8-DIHYDROPTERIN PYROPHOSPHOKINASE FROM E. COLI WITH MGAMPCPP AND 6-HYDROXYMETHYL-7,8-DIHYDROPTERIN AT 1.25 ANGSTROM RESOLUTION
3IHG	;	2.49	;	Crystal structure of a ternary complex of aklavinone-11 hydroxylase with FAD and aklavinone
2IPS	;	3.1	;	Crystal structure of a ternary complex of bovine lactoperoxidase with thiocyanate and iodide at 3.1 A resolution
2O86	;	2.8	;	Crystal structure of a ternary complex of buffalo lactoperoxidase with nitrate and iodide at 2.8 A resolution
1LBX	;	2.4	;	Crystal Structure of a ternary complex of dual activity FBPase/IMPase (AF2372) from Archaeoglobus fulgidus with Calcium ions and D-myo-Inositol-1-Phosphate
1AJ0	;	2.0	;	CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF E. COLI DIHYDROPTEROATE SYNTHASE
1RAO	;	1.56	;	CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF E. COLI HPPK WITH AMP AND 6-HYDROXYMETHYLPTERIN-DIPHOSPHATE AT 1.56 ANGSTROM RESOLUTION
1RU1	;	1.4	;	CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF E. COLI HPPK(V83G/DEL84-89) WITH MGAMPCPP AND 6-HYDROXYMETHYL-7,8-DIHYDROPTERIN AT 1.40 ANGSTROM RESOLUTION (MONOCLINIC FORM)
1NCE	;	2.4	;	Crystal structure of a ternary complex of E. coli thymidylate synthase D169C with dUMP and the antifolate CB3717
1HQ2	;	1.25	;	CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF E.COLI HPPK(R82A) WITH MGAMPCPP AND 6-HYDROXYMETHYL-7,8-DIHYDROPTERIN AT 1.25 ANGSTROM RESOLUTION
1RU2	;	1.48	;	CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF E.COLI HPPK(V83G/DEL84-89) WITH MGAMPCPP AND 6-HYDROXYMETHYLPTERIN AT 1.48 ANGSTROM RESOLUTION (ORTHORHOMBIC FORM)
1EMD	;	1.9	;	CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF ESCHERICHIA COLI MALATE DEHYDROGENASE, CITRATE AND NAD AT 1.9 ANGSTROMS RESOLUTION
2AEI	;	2.52	;	Crystal structure of a ternary complex of factor VIIa/tissue factor and 2-[[6-[3-(aminoiminomethyl)phenoxy]-3,5-difluro-4-[(1-methyl-3-phenylpropyl)amino]-2-pyridinyl]oxy]-benzoic acid
1Z6J	;	2.0	;	Crystal Structure of a ternary complex of Factor VIIa/Tissue Factor/Pyrazinone Inhibitor
6PUN	;	2.099	;	Crystal structure of a ternary complex of FBF-2 with LST-1 (site B) and compact FBE RNA
2OJV	;	2.4	;	Crystal structure of a ternary complex of goat lactoperoxidase with cyanide and iodide ions at 2.4 A resolution
4H3K	;	2.0	;	Crystal structure of a ternary complex of human symplekin NTD, human Ssu72 and a RNA polymerase II CTD peptide phosphorylated at Ser-2, Ser-5 and Ser-7
4H3H	;	2.2	;	Crystal structure of a ternary complex of human symplekin NTD, human Ssu72 and a RNA poymerase II CTD peptide phosphorylated at SER-7
2OTH	;	2.9	;	Crystal structure of a ternary complex of phospholipase A2 with indomethacin and nimesulide at 2.9 A resolution
7OUD	;	2.3	;	Crystal structure of a ternary complex of the flavoprotein monooxygenase GrhO5 with FAD and collinone
2BQZ	;	1.5	;	Crystal structure of a ternary complex of the human histone methyltransferase Pr-SET7 (also known as SET8)
1O9S	;	1.75	;	Crystal structure of a ternary complex of the human histone methyltransferase SET7/9
1XQH	;	1.75	;	Crystal structure of a ternary complex of the methyltransferase SET9 (also known as SET7/9) with a P53 peptide and SAH
3BTS	;	2.7	;	Crystal structure of a ternary complex of the transcriptional repressor Gal80p (Gal80S0 [G301R]) and the acidic activation domain of Gal4p (aa 854-874) from Saccharomyces cerevisiae with NAD
2MTA	;	2.4	;	CRYSTAL STRUCTURE OF A TERNARY ELECTRON TRANSFER COMPLEX BETWEEN METHYLAMINE DEHYDROGENASE, AMICYANIN AND A C-TYPE CYTOCHROME
1E0O	;	2.8	;	CRYSTAL STRUCTURE OF A TERNARY FGF1-FGFR2-HEPARIN COMPLEX
1FQ9	;	3.0	;	CRYSTAL STRUCTURE OF A TERNARY FGF2-FGFR1-HEPARIN COMPLEX
2H62	;	1.85	;	Crystal structure of a ternary ligand-receptor complex of BMP-2
2H64	;	1.92	;	Crystal structure of a ternary ligand-receptor complex of BMP-2
6WC2	;	2.1	;	Crystal Structure of a Ternary MEF2 Chimera/NKX2-5/myocardin enhancer DNA Complex
6WC5	;	2.9	;	Crystal Structure of a Ternary MEF2B/NKX2-5/myocardin enhancer DNA Complex
1XD2	;	2.7	;	Crystal Structure of a ternary Ras:SOS:Ras*GDP complex
1K6O	;	3.19	;	Crystal Structure of a Ternary SAP-1/SRF/c-fos SRE DNA Complex
4ZQ8	;	2.0	;	Crystal structure of a terpene synthase from Streptomyces lydicus, target EFI-540129
1HVC	;	1.8	;	CRYSTAL STRUCTURE OF A TETHERED DIMER OF HIV-1 PROTEASE COMPLEXED WITH AN INHIBITOR
3NPI	;	2.96	;	Crystal structure of a TetR family regulatory protein (DIP1788) from CORYNEBACTERIUM DIPHTHERIAE at 2.96 A resolution
3PAS	;	1.9	;	Crystal structure of a TetR family transcription regulator (Maqu_1417) from MARINOBACTER AQUAEOLEI VT8 at 1.90 A resolution
3NRG	;	2.56	;	Crystal structure of a TetR family transcriptional regulator (Caur_2714) from CHLOROFLEXUS AURANTIACUS J-10-FL at 2.56 A resolution
2O7T	;	2.1	;	Crystal structure of a tetr family transcriptional regulator (ncgl1578, cgl1640) from corynebacterium glutamicum at 2.10 A resolution
3CDL	;	2.36	;	Crystal structure of a TetR family transcriptional regulator from Pseudomonas syringae pv. tomato str. DC3000
3C07	;	2.7	;	Crystal structure of a TetR family transcriptional regulator from Streptomyces coelicolor A3(2)
3VPR	;	2.27	;	Crystal Structure of a TetR Family Transcriptional Regulator PfmR from Thermus thermophilus HB8
3CRJ	;	2.6	;	Crystal structure of a TetR transcription regulator from Haloarcula marismortui ATCC 43049
3QBM	;	1.8	;	Crystal structure of a TetR transcriptional regulator (Caur_2221) from CHLOROFLEXUS AURANTIACUS J-10-FL at 1.80 A resolution
3BJB	;	2.5	;	Crystal structure of a TetR transcriptional regulator from Rhodococcus sp. RHA1
3EGQ	;	2.55	;	Crystal structure of a tetr-family transcriptional regulator (af_1817) from archaeoglobus fulgidus at 2.55 A resolution
2HYT	;	1.64	;	CRYSTAL STRUCTURE OF A TETR-FAMILY TRANSCRIPTIONAL REGULATOR (ECA1819) FROM PECTOBACTERIUM ATROSEPTICUM AT 1.64 A RESOLUTION
3QKX	;	2.35	;	Crystal structure of a TetR-family transcriptional regulator (HI0893) from Haemophilus influenzae RD at 2.35 A resolution
3NNR	;	2.49	;	Crystal structure of a TetR-family transcriptional regulator (Maqu_3571) from MARINOBACTER AQUAEOLEI VT8 at 2.49 A resolution
3CCY	;	2.01	;	Crystal structure of a TetR-family transcriptional regulator from Bordetella parapertussis 12822
3RH2	;	2.42	;	Crystal structure of a TetR-like transcriptional regulator (Sama_0099) from Shewanella amazonensis SB2B at 2.42 A resolution
2RAE	;	2.2	;	Crystal structure of a TetR/AcrR family transcriptional regulator from Rhodococcus sp. RHA1
3H50	;	1.6	;	CRYSTAL STRUCTURE OF A TETRACENOMYCIN POLYKETIDE SYNTHESIS PROTEIN (TCMJ) FROM XANTHOMONAS CAMPESTRIS PV. CAMPESTRIS AT 1.60 A RESOLUTION
4Z0I	;	1.45	;	Crystal structure of a tetramer of GluA2 ligand binding domains bound with glutamate at 1.45 Angstrom resolution
4YU0	;	1.26	;	Crystal structure of a tetramer of GluA2 TR mutant ligand binding domains bound with glutamate at 1.26 Angstrom resolution
3ZZI	;	3.8	;	Crystal structure of a tetrameric acetylglutamate kinase from Saccharomyces cerevisiae
4AB7	;	3.25	;	Crystal structure of a tetrameric acetylglutamate kinase from Saccharomyces cerevisiae complexed with its substrate N- acetylglutamate
6MC2	;	1.05	;	Crystal structure of a tetrameric DNA fold-back quadruplex
6MC3	;	1.57	;	Crystal structure of a tetrameric DNA fold-back quadruplex
6MC4	;	2.25	;	Crystal structure of a tetrameric DNA fold-back quadruplex
6N4G	;	1.4	;	Crystal structure of a tetrameric DNA fold-back quadruplex
7O2S	;	2.28	;	Crystal structure of a tetrameric form of Carbonic anhydrase from Schistosoma mansoni
3IQ6	;	2.35	;	Crystal structure of a tetrameric Zn-bound cytochrome cb562 complex with covalently and non-covalently stabilized interfaces
4XK0	;	1.08	;	Crystal structure of a tetramolecular RNA G-quadruplex in potassium
4R7S	;	2.39	;	Crystal structure of a tetratricopeptide repeat protein (PARMER_03812) from Parabacteroides merdae ATCC 43184 at 2.39 A resolution
4XZ7	;	2.101	;	Crystal structure of a TGase
4F2M	;	3.0	;	Crystal structure of a TGEV coronavirus Spike fragment in complex with the TGEV neutralizing monoclonal antibody 1AF10
3QB4	;	2.28	;	Crystal structure of a TGF-beta ligand-receptor complex
2J0L	;	2.3	;	Crystal structure of a the active conformation of the kinase domain of focal adhesion kinase with a phosphorylated activation loop.
1YOE	;	1.78	;	Crystal structure of a the E. coli pyrimidine nucleoside hydrolase YbeK with bound ribose
5U7B	;	2.0	;	Crystal structure of a the tin-bound form of MerB formed from Diethyltin.
6KA3	;	1.951	;	Crystal structure of a Thebaine synthase from Papaver somniferum
6KA2	;	2.35	;	Crystal structure of a Thebaine synthase from Papaver somniferum in complex with TBN
5BMF	;	2.8	;	Crystal Structure of a Theophylline binding antibody Fab fragment
4LAS	;	2.33	;	Crystal structure of a therapeutic single chain antibody in complex with 4-hydroxymethamphetamine
4LAR	;	2.38	;	Crystal structure of a therapeutic single chain antibody in complex with amphetamine
4LAQ	;	2.8	;	Crystal structure of a therapeutic single chain antibody in the free form
1BXZ	;	2.99	;	CRYSTAL STRUCTURE OF A THERMOPHILIC ALCOHOL DEHYDROGENASE SUBSTRATE COMPLEX FROM THERMOANAEROBACTER BROCKII
8AES	;	2.8	;	Crystal structure of a thermophilic O6-alkylguanine-DNA alkyltransferase-derived self-labeling protein-tag
6GA0	;	2.0	;	Crystal structure of a thermophilic O6-alkylguanine-DNA alkyltransferase-derived self-labeling protein-tag in covalent complex with SNAP-Vista Green
2PEF	;	1.6	;	Crystal Structure of a Thermophilic Serpin, Tengpin, in the Latent State
2PEE	;	2.7	;	Crystal Structure of a Thermophilic Serpin, Tengpin, in the Native State
5K9Y	;	2.2	;	Crystal structure of a thermophilic xylanase A from Bacillus subtilis 1A1 quadruple mutant Q7H/G13R/S22P/S179C
5NDZ	;	3.6	;	Crystal structure of a thermostabilised human protease-activated receptor-2 (PAR2) in complex with AZ3451 at 3.6 angstrom resolution
5NDD	;	2.801	;	Crystal structure of a thermostabilised human protease-activated receptor-2 (PAR2) in complex with AZ8838 at 2.8 angstrom resolution
5NJ6	;	4.0	;	Crystal structure of a thermostabilised human protease-activated receptor-2 (PAR2) in ternary complex with Fab3949 and AZ7188 at 4.0 angstrom resolution
4Y2W	;	2.7	;	Crystal structure of a thermostable alanine racemase from Thermoanaerobacter tengcongensis MB4
6KIY	;	1.9	;	Crystal structure of a thermostable aldo-keto reductase Tm1743 in complex with inhibitor Epalrestat
6KIK	;	1.601	;	Crystal structure of a thermostable aldo-keto reductase Tm1743 in complex with inhibitor tolrestat
6KY6	;	2.07	;	Crystal structure of a thermostable aldo-keto reductase Tm1743 in complexs with inhibitor epalrestat in space group P3221cc
3QGV	;	2.1	;	Crystal structure of a thermostable amylase variant
3DOH	;	2.6	;	Crystal Structure of a Thermostable Esterase
3DOI	;	3.0	;	Crystal Structure of a Thermostable Esterase complex with paraoxon
4QQS	;	1.1	;	Crystal structure of a thermostable family-43 glycoside hydrolase
5Z5D	;	1.7	;	Crystal structure of a thermostable glycoside hydrolase family 43 {beta}-1,4-xylosidase from Geobacillus thermoleovorans IT-08
5Z5H	;	1.9	;	Crystal structure of a thermostable glycoside hydrolase family 43 {beta}-1,4-xylosidase from Geobacillus thermoleovorans IT-08 in complex with D-xylose
5Z5F	;	2.1	;	Crystal structure of a thermostable glycoside hydrolase family 43 {beta}-1,4-xylosidase from Geobacillus thermoleovorans IT-08 in complex with L-arabinose
5Z5I	;	1.7	;	Crystal structure of a thermostable glycoside hydrolase family 43 {beta}-1,4-xylosidase from Geobacillus thermoleovorans IT-08 in complex with L-arabinose and D-xylose
6LZ2	;	2.03	;	Crystal structure of a thermostable green fluorescent protein (TGP) with a synthetic nanobody (Sb44)
7CZ0	;	2.77	;	Crystal structure of a thermostable green fluorescent protein (TGP) with a synthetic nanobody (Sb92)
5H6B	;	2.3	;	Crystal structure of a thermostable lipase from Marine Streptomyces
5H6G	;	2.34	;	Crystal structure of a thermostable lipase from Marine Streptomyces
5H9U	;	2.667	;	Crystal structure of a thermostable methionine adenosyltransferase
3W0P	;	2.0	;	Crystal structure of a thermostable mutant of aminoglycoside phosphotransferase APH(4)-Ia (D198A), ternary complex with ADP and hygromycin B
3W0R	;	2.3	;	Crystal structure of a thermostable mutant of aminoglycoside phosphotransferase APH(4)-Ia (N202A), ternary complex with AMP-PNP and hygromycin B
3W0Q	;	1.8	;	Crystal structure of a thermostable mutant of aminoglycoside phosphotransferase APH(4)-Ia (N203A), ternary complex with AMP-PNP and hygromycin B
3W0M	;	1.9	;	Crystal structure of a thermostable mutant of aminoglycoside phosphotransferase APH(4)-Ia, apo form
3W0O	;	1.5	;	Crystal structure of a thermostable mutant of aminoglycoside phosphotransferase APH(4)-Ia, ternary complex with ADP and hygromycin B
3W0N	;	1.9	;	Crystal structure of a thermostable mutant of aminoglycoside phosphotransferase APH(4)-Ia, ternary complex with AMP-PNP and hygromycin B
2ORI	;	1.8	;	Crystal structure of a thermostable mutant of Bacillus subtilis Adenylate Kinase (A193V/Q199R/)
2P3S	;	1.8	;	Crystal structure of a thermostable mutant of Bacillus subtilis Adenylate Kinase (G214R/Q199R)
2OSB	;	1.8	;	Crystal structure of a thermostable mutant of Bacillus subtilis Adenylate Kinase (Q16L/Q199R/)
2EU8	;	1.8	;	Crystal structure of a thermostable mutant of Bacillus subtilis Adenylate Kinase (Q199R)
2QAJ	;	1.8	;	Crystal structure of a thermostable mutant of Bacillus subtilis Adenylate Kinase (Q199R/G213E)
2OO7	;	1.8	;	Crystal structure of a thermostable mutant of Bacillus subtilis Adenylate Kinase (T179I/Q199R)
7V92	;	1.607	;	Crystal Structure of a thermostable mutant of the Catalytic Domain of GH19 Chitinase from Gazyumaru, Ficus microcarpa
1DBI	;	1.8	;	CRYSTAL STRUCTURE OF A THERMOSTABLE SERINE PROTEASE
3CP7	;	1.39	;	Crystal structure of a thermostable serine protease AL20 from extremophilic microoganism
4Y91	;	2.656	;	Crystal Structure of a Thermotoga maritima Hfq homolog
2O18	;	2.2	;	Crystal structure of a Thiamine biosynthesis lipoprotein apbE, NorthEast Strcutural Genomics target ER559
3EWN	;	1.65	;	Crystal structure of a THiJ/PfpI family protein from Pseudomonas syringae
3E1E	;	2.0	;	Crystal structure of a Thioesterase family protein from Silicibacter pomeroyi. NorthEast Structural Genomics target SiR180A
2HBO	;	1.85	;	Crystal structure of a thioesterase superfamily protein (cc_3309) from caulobacter vibrioides at 1.85 A resolution
4Q0Y	;	1.7	;	Crystal structure of a thioesterase-like protein (CLOSPO_01618) from Clostridium sporogenes ATCC 15579 at 1.70 A resolution
2Q78	;	2.2	;	Crystal structure of a thioesterase-like protein (tm0581) from thermotoga maritima msb8 at 2.20 A resolution
3HD5	;	2.35	;	Crystal structure of a thiol:disulfide interchange protein dsbA from Bordetella parapertussis
4FQF	;	2.281	;	Crystal structure of a thionitrate intermediate of human aldehyde dehydrogenase-2
6CKP	;	1.15	;	Crystal structure of a thioredoxin domain 2 from Brucella melitensis at 1.15 Angstrom resolution
6GN9	;	1.75	;	Crystal structure of a thioredoxin from Clostridium acetobutylicum at 1.75 A resolution
4JNQ	;	1.8	;	Crystal structure of a thioredoxin reductase from Brucella melitensis
4POB	;	1.7	;	Crystal structure of a thioredoxin Rv1471 ortholog from Mycobacterium abscessus
4YOD	;	1.9	;	Crystal structure of a thioredoxin-like protein (BACCAC_02376) from Bacteroides caccae ATCC 43185 at 1.90 A resolution
4FO5	;	2.02	;	Crystal structure of a thioredoxin-like protein (BDI_1100) from Parabacteroides distasonis ATCC 8503 at 2.02 A resolution
2CVB	;	1.8	;	Crystal structure of a thioredoxin-like protein from Thermus thermophilus HB8
4GCM	;	1.8	;	Crystal structure of a thioredoxine reductase (trxB) from Staphylococcus aureus subsp. aureus Mu50 at 1.80 A resolution
4RUD	;	1.95	;	Crystal structure of a three finger toxin
3VTS	;	2.426	;	Crystal structure of a three finger toxin from snake venom
5ZOL	;	2.172	;	Crystal structure of a three sites mutantion of FSAA complexed with HA and product
6EGN	;	1.84	;	Crystal Structure of a Three-stranded Coiled Coil Peptide Containing a Trigonal Planar Hg(II)S3 Site Modified by D-Leu in the Second Coordination Sphere
8EDP	;	2.01	;	Crystal structure of a three-tetrad, parallel, and K+ stabilized homopurine G-quadruplex from human chromosome 7
7KLP	;	1.35	;	Crystal structure of a three-tetrad, parallel, K+ stabilized human telomeric G-quadruplex
5O6C	;	1.75	;	Crystal Structure of a threonine-selective RCR E3 ligase
1KQ4	;	2.25	;	CRYSTAL STRUCTURE OF A THY1-COMPLEMENTING PROTEIN (TM0449) FROM THERMOTOGA MARITIMA AT 2.25 A RESOLUTION
1EXD	;	2.7	;	CRYSTAL STRUCTURE OF A TIGHT-BINDING GLUTAMINE TRNA BOUND TO GLUTAMINE AMINOACYL TRNA SYNTHETASE
3ETV	;	1.94	;	Crystal structure of a Tip20p-Dsl1p fusion protein
2D5R	;	2.5	;	Crystal Structure of a Tob-hCaf1 Complex
2BF5	;	1.71	;	Crystal structure of a toluene 4-monooxygenase catalytic effector protein variant missing four N-terminal residues (delta-N4 T4moD)
2BF3	;	1.96	;	Crystal structure of a toluene 4-monooxygenase catalytic effector protein variant missing ten N-terminal residues (delta-N10 T4moD)
8DTE	;	2.2	;	Crystal Structure of a toluene tolerance periplasmic transport protein from Neisseria gonorrhoeae
4EM7	;	1.9	;	Crystal structure of a topoisomerase ATP inhibitor
4EMV	;	1.7	;	Crystal structure of a topoisomerase ATP inhibitor
4LP0	;	1.95	;	Crystal structure of a topoisomerase ATP inhibitor
3TTZ	;	1.63	;	Crystal structure of a topoisomerase ATPase inhibitor
4LPB	;	1.75	;	Crystal structure of a topoisomerase ATPase inhibitor
5BS8	;	2.399	;	Crystal structure of a topoisomerase II complex
5BTA	;	2.55	;	Crystal structure of a topoisomerase II complex
5BTC	;	2.55	;	Crystal structure of a topoisomerase II complex
5BTD	;	2.497	;	Crystal structure of a topoisomerase II complex
5BTF	;	2.61	;	Crystal structure of a topoisomerase II complex
5BTG	;	2.5	;	Crystal structure of a topoisomerase II complex
5BTI	;	2.501	;	Crystal structure of a topoisomerase II complex
5BTL	;	2.5	;	Crystal structure of a topoisomerase II complex
5BTN	;	2.5	;	Crystal structure of a topoisomerase II complex
1SEG	;	1.3	;	Crystal structure of a toxin chimera between Lqh-alpha-IT from the scorpion Leiurus quinquestriatus hebraeus and AAH2 from Androctonus australis hector
4I17	;	1.83	;	Crystal structure of a TPR repeats protein (BF2334) from Bacteroides fragilis NCTC 9343 at 1.50 A resolution
5CD6	;	2.26	;	Crystal structure of a TPR-domain containing protein (BDI_1685) from Parabacteroides distasonis ATCC 8503 at 2.26 A resolution
2HR2	;	2.54	;	Crystal structure of a tpr-like protein (ct2138) from chlorobium tepidum tls at 2.54 A resolution
6AQ3	;	2.4	;	Crystal structure of a trafficking protein particle complex subunit 3 from Naegleria fowleri covalently bound to palmitic acid
5HQW	;	2.39	;	Crystal structure of a trans-AT PKS dehydratase domain of C0ZGQ6 from Brevibacillus brevis
5J6O	;	3.195	;	Crystal structure of a trans-AT PKS dehydratase domain of C0ZGQ7 from Brevibacillus brevis
5C3E	;	3.7	;	Crystal structure of a transcribing RNA Polymerase II complex reveals a complete transcription bubble
5C44	;	3.95	;	Crystal structure of a transcribing RNA Polymerase II complex reveals a complete transcription bubble
5C4A	;	4.2	;	Crystal structure of a transcribing RNA Polymerase II complex reveals a complete transcription bubble
5C4J	;	4.0	;	Crystal structure of a transcribing RNA Polymerase II complex reveals a complete transcription bubble
5C4X	;	4.0	;	Crystal structure of a transcribing RNA Polymerase II complex reveals a complete transcription bubble
4EPZ	;	1.68	;	Crystal structure of a transcription anti-terminator antagonist UpxZ (BACUNI_04315) from Bacteroides uniformis ATCC 8492 at 1.68 A resolution
4HFX	;	2.54	;	Crystal structure of a transcription elongation factor B polypeptide 3 from Homo sapiens, Northeast Structural Genomics consortium target id HR4748B.
7EQE	;	2.399	;	Crystal Structure of a transcription factor
7EQF	;	2.91	;	Crystal Structure of a Transcription Factor in complex with Ligand
3CLK	;	2.08	;	Crystal structure of a transcription regulator from Lactobacillus plantarum
2HQB	;	2.7	;	Crystal Structure of a Transcriptional Activator of comK gene from Bacillus halodurans
1VI0	;	1.65	;	Crystal structure of a transcriptional regulator
2IVM	;	2.5	;	Crystal structure of a transcriptional regulator
4NB5	;	1.641	;	Crystal Structure of a transcriptional regulator
2NP5	;	1.8	;	Crystal structure of a transcriptional regulator (RHA1_ro04179) from Rhodococcus sp. Rha1.
3WHC	;	2.2	;	Crystal structure of a transcriptional regulator FadR from Bacillus subtilis in complex with stearoyl-CoA
3BY6	;	2.2	;	Crystal structure of a transcriptional regulator from Oenococcus oeni
3JTH	;	2.0	;	Crystal structure of a transcriptional regulator HlyU from Vibrio vulnificus CMCP6
3GZI	;	2.05	;	CRYSTAL STRUCTURE OF a transcriptional regulator of the tetR family (SHEW_3567) FROM SHEWANELLA LOIHICA PV-4 AT 2.05 A RESOLUTION
3H5T	;	2.53	;	Crystal structure of a transcriptional regulator, Lacl family protein from Corynebacterium glutamicum
3KJX	;	2.33	;	Crystal structure of a transcriptional regulator, Lacl family protein from Silicibacter pomeroyi
3HH0	;	2.67	;	Crystal structure of a transcriptional regulator, MerR family from Bacillus cereus
3GPV	;	1.9	;	Crystal structure of a transcriptional regulator, MerR family from Bacillus thuringiensis
4ME9	;	2.5	;	Crystal structure of a transcriptional regulator, TetR family (BCE_2991) from Bacillus cereus ATCC 10987 at 2.50 A resolution
1PZ2	;	2.0	;	Crystal structure of a transient covalent reaction intermediate of a family 51 alpha-L-arabinofuranosidase
1L3R	;	2.0	;	Crystal Structure of a Transition State Mimic of the Catalytic Subunit of cAMP-dependent Protein Kinase
4NU1	;	2.5	;	Crystal structure of a transition state mimic of the GSK-3/Axin complex bound to phosphorylated N-terminal auto-inhibitory pS9 peptide
5HT7	;	1.862	;	Crystal structure of a transition-metal-ion-binding betagamma-crystallin from Methanosaeta thermophila
3UPT	;	2.4	;	Crystal structure of a transketolase from Burkholderia pseudomallei bound to TPP, calcium and ribose-5-phosphate
3UK1	;	2.15	;	Crystal structure of a transketolase from Burkholderia thailandensis with an oxidized cysteinesulfonic acid in the active site
5VRB	;	1.85	;	Crystal structure of a transketolase from Neisseria gonorrhoeae
4XEU	;	1.95	;	Crystal structure of a transketolase from Pseudomonas aeruginosa
2VSO	;	2.6	;	Crystal Structure of a Translation Initiation Complex
2VSX	;	2.8	;	Crystal Structure of a Translation Initiation Complex
4V67	;	3.0	;	Crystal structure of a translation termination complex formed with release factor RF2.
5DMB	;	2.301	;	Crystal structure of a translational regulator bound to a flagellar assembly factor
4HUQ	;	2.998	;	Crystal Structure of a transporter
4O8M	;	1.7	;	Crystal structure of a trap periplasmic solute binding protein actinobacillus succinogenes 130z, target EFI-510004, with bound L-galactonate
4N91	;	1.7	;	Crystal structure of a trap periplasmic solute binding protein from anaerococcus prevotii dsm 20548 (Apre_1383), target EFI-510023, with bound alpha/beta d-glucuronate
4P56	;	1.9	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM BORDETELLA BRONCHISEPTICA, TARGET EFI-510038 (BB2442), WITH BOUND (R)-MANDELATE and (S)-MANDELATE
4NQ8	;	1.5	;	Crystal structure of a trap periplasmic solute binding protein from Bordetella bronchispeptica (bb3421), target EFI-510039, with density modeled as pantoate
4N8Y	;	1.5	;	Crystal structure of a trap periplasmic solute binding protein from bradyrhizobium sp. btai1 b (bbta_0128), target EFI-510056 (bbta_0128), complex with alpha/beta-d-galacturonate
4LN5	;	2.1	;	Crystal structure of a trap periplasmic solute binding protein from burkholderia ambifaria (Bamb_6123), TARGET EFI-510059, with bound glycerol and chloride ion
4N17	;	1.501	;	Crystal structure of a TRAP periplasmic solute binding protein from Burkholderia ambifaria (BAM_6123), Target EFI-510059, With bound beta-D-galacturonate
4N15	;	1.651	;	Crystal structure of a TRAP periplasmic solute binding protein from Burkholderia ambifaria (BAM_6123), Target EFI-510059, with bound beta-D-glucuronate
4N8G	;	1.502	;	Crystal structure of a TRAP periplasmic solute binding protein from Chromohalobacter salexigens DSM 3043 (Csal_0660), Target EFI-501075, with bound D-alanine-D-alanine
4XF5	;	1.45	;	Crystal structure of a TRAP periplasmic solute binding protein from Chromohalobacter salexigens DSM 3043 (Csal_0678), Target EFI-501078, with bound (S)-(+)-2-Amino-1-propanol.
4UAB	;	1.4	;	Crystal structure of a TRAP periplasmic solute binding protein from Chromohalobacter salexigens DSM 3043 (Csal_0678), Target EFI-501078, with bound ethanolamine
4P1L	;	1.7	;	Crystal structure of a trap periplasmic solute binding protein from chromohalobacter salexigens dsm 3043 (csal_2479), target EFI-510085, with bound d-glucuronate, spg i213
4P3L	;	1.8	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM CHROMOHALOBACTER SALEXIGENS DSM 3043 (Csal_2479), TARGET EFI-510085, WITH BOUND GLUCURONATE, SPG P6122
4NG7	;	2.3	;	Crystal structure of a TRAP periplasmic solute binding protein from Citrobacter koseri (CKO_04899), Target EFI-510094, apo, open structure
4X04	;	2.5	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM CITROBACTER KOSERI (CKO_04899, TARGET EFI-510094) WITH BOUND D-glucuronate
4PET	;	1.9	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM COLWELLIA PSYCHRERYTHRAEA (CPS_0129, TARGET EFI-510097) WITH BOUND CALCIUM AND PYRUVATE
4NAP	;	2.3	;	Crystal structure of a trap periplasmic solute binding protein from Desulfovibrio alaskensis G20 (DDE_0634), target EFI-510102, with bound d-tryptophan
4PGP	;	2.25	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM DESULFOVIBRIO ALASKENSIS G20 (Dde_0634, TARGET EFI-510120) WITH BOUND 3-INDOLE ACETIC ACID
4PGN	;	1.8	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM DESULFOVIBRIO ALASKENSIS G20 (Dde_0634, TARGET EFI-510120) WITH BOUND INDOLE PYRUVATE
4NGU	;	2.5	;	Crystal structure of a TRAP periplasmic solute binding protein from Desulfovibrio alaskensis G20 (Dde_1548), Target EFI-510103, with bound D-Ala-D-Ala
4NHB	;	1.902	;	Crystal structure of a TRAP periplasmic solute binding protein from Desulfovibrio desulfuricans (Ddes_1525), Target EFI-510107, with bound sn-glycerol-3-phosphate
4NN3	;	1.4	;	Crystal structure of a TRAP periplasmic solute binding protein from Desulfovibrio salexigens (Desal_2161), Target EFI-510109, with bound orotic acid
4N6D	;	1.701	;	Crystal structure of a TRAP periplasmic solute binding protein from Desulfovibrio salexigens DSM2638 (Desal_3247), Target EFI-510112, phased with I3C, open complex, C-terminus of symmetry mate bound in ligand binding site
4N6K	;	1.2	;	Crystal structure of a TRAP periplasmic solute binding protein from Desulfovibrio salexigens DSM2638, Target EFI-510113 (Desal_0342), complex with diglycerolphosphate
4XEQ	;	1.7	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM DESULFOVIBRIO VULGARIS (Deval_0042, TARGET EFI-510114) BOUND TO COPURIFIED (R)-PANTOIC ACID
4P1E	;	1.9	;	Crystal structure of a trap periplasmic solute binding protein from escherichia fergusonii (efer_1530), target EFI-510119, apo open structure, phased with iodide
4PFB	;	2.7	;	Crystal structure of a TRAP periplasmic solute binding protein from Fusobacterium nucleatun (FN1258, TARGET EFI-510120) with bound SN-glycerol-3-phosphate
4PBQ	;	1.65	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE RdAW (HICG_00826, TARGET EFI-510123) WITH BOUND L-GULONATE
4PFI	;	2.3024	;	Crystal structure of a tRAP periplasmic solute binding protein from marinobacter aquaeolei VT8 (Maqu_2829, TARGET EFI-510133), apo open structure
4OVT	;	1.8	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM OCHROBACTERIUM ANTHROPI (Oant_3902), TARGET EFI-510153, WITH BOUND L-FUCONATE
4P47	;	1.3	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM OCHROBACTRUM ANTHROPI (Oant_4429), TARGET EFI-510151, C-TERMIUS BOUND IN LIGAND BINDING POCKET
4PDD	;	1.7	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM POLAROMONAS SP JS666 (Bpro_0088, TARGET EFI-510167) BOUND TO D-ERYTHRONATE
4PDH	;	1.8	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM POLAROMONAS SP JS666 (Bpro_1871, TARGET EFI-510164) BOUND TO D-ERYTHRONATE
4MIJ	;	1.1	;	Crystal structure of a Trap periplasmic solute binding protein from Polaromonas sp. JS666 (Bpro_3107), target EFI-510173, with bound alpha/beta D-Galacturonate, space group P21
4MHF	;	1.46	;	Crystal structure of a TRAP periplasmic solute binding protein from Polaromonas sp. JS666 (Bpro_3107), target EFI-510173, with bound alpha/beta D-Glucuronate, space group P21
4MNC	;	1.05	;	Crystal structure of a TRAP periplasmic solute binding protein from Polaromonas sp. JS666 (Bpro_4736), Target EFI-510156, with bound benzoyl formate, space group P21
4MNI	;	1.9	;	Crystal structure of a TRAP periplasmic solute binding protein from Polaromonas sp. JS666 (Bpro_4736), Target EFI-510156, with bound benzoyl formate, space group P6522
5CM6	;	1.83	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM PSEUDOALTEROMONAS ATLANTICA T6c(Patl_2292, TARGET EFI-510180) WITH BOUND SODIUM AND PYRUVATE
4NF0	;	1.85	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM PSEUDOMONAS AERUGINOSA PAO1 (PA4616), TARGET EFI-510182, WITH BOUND L-Malate
4XFE	;	1.4	;	Crystal structure of a TRAP periplasmic solute binding protein from Pseudomonas putida F1 (Pput_1203), Target EFI-500184, with bound D-glucuronate
4P8B	;	1.3	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM RALSTONIA EUTROPHA H16 (H16_A1328), TARGET EFI-510189, WITH BOUND (S)-2-hydroxy-2-methyl-3-oxobutanoate ((S)-2-Acetolactate)
4X8R	;	1.9	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM Rhodobacter sphaeroides (Rsph17029_2138, TARGET EFI-510205) WITH BOUND Glucuronate
4PFR	;	2.6	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM RHODOBACTER SPHAEROIDES (Rsph17029_3541, TARGET EFI-510203), APO OPEN PARTIALLY DISORDERED
4PE3	;	1.35	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM RHODOBACTER SPHAEROIDES (Rsph17029_3620, TARGET EFI-510199), APO OPEN STRUCTURE
4MCO	;	1.6	;	Crystal structure of a TRAP periplasmic solute binding protein from Rhodoferax ferrireducens (Rfer_1840), target EFI-510211, with bound malonate
4MEV	;	1.8	;	Crystal structure of a TRAP periplasmic solute binding protein from Rhodoferax ferrireducens (Rfer_1840), Target EFI-510211, with bound malonate, space group I422
4OAN	;	1.35	;	Crystal structure of a TRAP periplasmic solute binding protein from rhodopseudomonas palustris HaA2 (RPB_2686), TARGET EFI-510221, with density modeled as (S)-2-hydroxy-2-methyl-3-oxobutanoate ((S)-2-Acetolactate)
4O94	;	2.0	;	Crystal structure of a trap periplasmic solute binding protein from Rhodopseudomonas palustris HaA2 (RPB_3329), Target EFI-510223, with bound succinate
4PC9	;	1.3	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM ROSENBACTER DENITRIFICANS OCh 114 (RD1_1052, TARGET EFI-510238) WITH BOUND D-MANNONATE
4PF6	;	1.75	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM ROSEOBACTER DENITRIFICANS (RD1_0742, TARGET EFI-510239) WITH BOUND 3-DEOXY-D-MANNO-OCT-2-ULOSONIC ACID (KDO)
4PCD	;	1.7	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM ROSEOBACTER DENITRIFICANS OCh 114 (RD1_1052, TARGET EFI-510238) WITH BOUND L-GALACTONATE
4OVQ	;	1.501	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM ROSEOBACTER DENITRIFICANS, TARGET EFI-510230, WITH BOUND BETA-D-GLUCURONATE
4PAF	;	1.6	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM RUEGERIA POMEROYI DSS-3 (SPO1773, TARGET EFI-510260) WITH BOUND 3,4-DIHYDROXYBENZOATE
4PAI	;	1.4	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM RUEGERIA POMEROYI DSS-3 (SPO1773, TARGET EFI-510260) WITH BOUND 3-HYDROXYBENZOATE
4PBH	;	1.2	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM RUEGERIA POMEROYI DSS-3 (SPO1773, TARGET EFI-510260) WITH BOUND BENZOIC ACID
4OA4	;	1.6	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM SHEWANELLA LOIHICA PV-4 (Shew_1446), TARGET EFI-510273, WITH BOUND SUCCINATE
4O7M	;	1.5	;	Crystal structure of a trap periplasmic solute binding protein from shewanella loihica PV-4, target EFI-510273, with bound L-malate
4MX6	;	1.1	;	Crystal structure of a trap periplasmic solute binding protein from shewanella oneidensis (SO_3134), target EFI-510275, with bound succinate
4PF8	;	1.5	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM SULFITOBACTER sp. NAS-14.1 (TARGET EFI-510299) WITH BOUND BETA-D-GALACTURONATE
4OVP	;	1.7	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM SULFITOBACTER sp. NAS-14.1, TARGET EFI-510292, WITH BOUND ALPHA-D-MANURONATE
4NX1	;	1.6	;	Crystal structure of a trap periplasmic solute binding protein from Sulfitobacter sp. nas-14.1, target EFI-510292, with bound alpha-D-taluronate
4OVS	;	1.8	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM SULFUROSPIRILLUM DELEYIANUM DSM 6946 (Sdel_0447), TARGET EFI-510309, WITH BOUND SUCCINATE
4PAK	;	1.2	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM VERMINEPHROBACTER EISENIAE EF01-2 (Veis_3954, TARGET EFI-510324) A NEPHRIDIAL SYMBIONT OF THE EARTHWORM EISENIA FOETIDA, BOUND TO (R)-PANTOIC ACID
4P9K	;	1.4	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM VERMINEPHROBACTER EISENIAE EF01-2 (Veis_3954, TARGET EFI-510324) A NEPHRIDIAL SYMBIONT OF THE EARTHWORM EISENIA FOETIDA, BOUND TO D-ERYTHRONATE WITH RESIDUAL DENSITY SUGGESTIVE OF SUPERPOSITION WITH COPURIFIED ALTERNATIVE LIGAND.
4OVR	;	1.65	;	CRYSTAL STRUCTURE OF A TRAP PERIPLASMIC SOLUTE BINDING PROTEIN FROM XANTHOBACTER AUTOTROPHICUS PY2, TARGET EFI-510329, WITH BOUND BETA-D-GALACTURONATE
5IM2	;	1.7	;	Crystal structure of a TRAP solute binding protein from Rhodoferax ferrireducens T118 (Rfer_2570, TARGET EFI-510210) in complex with copurified benzoate
4YZZ	;	1.3	;	Crystal structure of a TRAP transporter solute binding protein (IPR025997) from Bordetella bronchiseptica RB50 (BB0280, TARGET EFI-500035) mixed occupancy dimer, copurified calcium and picolinate bound active site versus apo site
4YIC	;	1.6	;	CRYSTAL STRUCTURE OF A TRAP TRANSPORTER SOLUTE BINDING PROTEIN (IPR025997) FROM BORDETELLA BRONCHISEPTICA RB50 (BB0280, TARGET EFI-500035) WITH BOUND PICOLINIC ACID
3CUE	;	3.7	;	Crystal structure of a TRAPP subassembly activating the Rab Ypt1p
7P9Z	;	1.33	;	Crystal structure of a trapped Pab-AGOG/double-standed DNA covalent intermediate (DNA containing adenine opposite to lesion)
7OY7	;	1.7	;	Crystal structure of a trapped Pab-AGOG/double-standed DNA covalent intermediate (DNA containing cytosine opposite to lesion)
7P0W	;	1.12	;	Crystal structure of a trapped Pab-AGOG/double-standed DNA covalent intermediate (DNA containing thymine opposite to lesion)
7OUE	;	2.04	;	Crystal structure of a trapped Pab-AGOG/single-standed DNA covalent intermediate
3BB0	;	1.5	;	Crystal Structure of a Trapped Phosphate-Intermediate in Vanadium Apochloroperoxidase Catalyzing a Dephosphorylation Reaction
1K3X	;	1.25	;	Crystal structure of a trapped reaction intermediate of the DNA repair enzyme Endonuclease VIII with Brominated-DNA
1K3W	;	1.42	;	Crystal structure of a trapped reaction intermediate of the DNA Repair Enzyme Endonuclease VIII with DNA
4YZP	;	1.7	;	Crystal structure of a tri-modular GH5 (subfamily 4) endo-beta-1, 4-glucanase from Bacillus licheniformis
4YZT	;	1.665	;	Crystal structure of a tri-modular GH5 (subfamily 4) endo-beta-1, 4-glucanase from Bacillus licheniformis complexed with cellotetraose
3G7N	;	1.3	;	Crystal Structure of a Triacylglycerol Lipase from Penicillium Expansum at 1.3
4WG0	;	1.82	;	Crystal structure of a tridecameric superhelix
6EGP	;	1.77	;	Crystal Structure of a Trigonal Pyramidal Pb(II)S3 Complex in a Three-stranded Coiled coil Peptide
4I61	;	1.64	;	Crystal structure of a trimeric bacterial microcompartment shell protein PduB
4FAY	;	1.56	;	Crystal structure of a trimeric bacterial microcompartment shell protein PduB with glycerol metabolites
3VYI	;	2.305	;	Crystal Structure of a trimeric coiled-coil (I/I-type) assembly domain from the voltage-gated proton channel mutant
3DE9	;	2.04	;	Crystal Structure of a Trimeric Cytochrome cb562 Assembly Induced by Nickel Coordination
4YOR	;	1.52	;	Crystal structure of a trimeric exonuclease PhoExo I from Pyrococcus horikoshii OT3 at 1.52A resolution.
4YOT	;	2.15	;	Crystal structure of a trimeric exonuclease PhoExo I from Pyrococcus horikoshii OT3 at 2.15A resolution
4YOU	;	2.2	;	Crystal structure of a trimeric exonuclease PhoExo I from Pyrococcus horikoshii OT3 at 2.20A resolution.
4YOV	;	2.05	;	Crystal structure of a trimeric exonuclease PhoExo I from Pyrococcus horikoshii OT3 in complex with poly-dA
4YOW	;	2.5	;	Crystal structure of a trimeric exonuclease PhoExo I from Pyrococcus horikoshii OT3 in complex with poly-dC
4YOX	;	2.05	;	Crystal structure of a trimeric exonuclease PhoExo I from Pyrococcus horikoshii OT3 in complex with poly-dT
4YOY	;	1.95	;	Crystal structure of a trimeric exonuclease PhoExo I from Pyrococcus horikoshii OT3 in complex with poly-dT and Mg2+ ion
5CJQ	;	3.6	;	Crystal structure of a trimeric influenza hemagglutinin stem in complex with an broadly neutralizing antibody CR9114
3FVC	;	3.2	;	Crystal structure of a trimeric variant of the Epstein-Barr virus glycoprotein B
8F09	;	2.45	;	Crystal structure of a trimethoprim-resistant dihydrofolate reductase (DHFR) enzyme from an uncultured soil bacterium
6DFP	;	1.5	;	Crystal Structure of a Tripartite Toxin Component VCA0883 from Vibrio cholerae
3RZA	;	2.1	;	Crystal structure of a tripeptidase (SAV1512) from staphylococcus aureus subsp. aureus mu50 at 2.10 A resolution
4BI6	;	1.45	;	CRYSTAL STRUCTURE OF A TRIPLE MUTANT (A198V, C202A AND C222N) OF TRIOSEPHOSPHATE ISOMERASE FROM GIARDIA LAMBLIA. COMPLEXED WITH 2- PHOSPHOGLYCOLIC ACID
3MVB	;	2.786	;	Crystal structure of a triple RFY mutant of human MTERF1 bound to the termination sequence
8HHI	;	1.4	;	Crystal structure of a triple-helix region of human collagen type III
8HHK	;	2.5	;	Crystal structure of a triple-helix region of human collagen type III
8XXB	;	2.4	;	Crystal Structure of a triple-mutant (A69F/M124P/R127G) of halohydrin dehalogenase HheD8 complexed with chloride
4DNE	;	1.88	;	Crystal structure of a triple-mutant of streptavidin in complex with desthiobiotin
5KB1	;	2.09	;	Crystal Structure of a Tris-thiolate Hg(II) Complex in a de Novo Three Stranded Coiled Coil Peptide
5KB0	;	2.13	;	Crystal Structure of a Tris-thiolate Pb(II) Complex in a de Novo Three-stranded Coiled Coil Peptide
5KB2	;	1.89	;	Crystal Structure of a Tris-thiolate Zn(II)S3O Complex in a de Novo Three-stranded Coiled Coil Peptide
4KGN	;	2.15	;	Crystal structure of a tRNA (cytidine(34)-2'-O)-methyltransferase bound to S-adenosyl homocysteine
7MYQ	;	2.55	;	Crystal structure of a tRNA (guanine-N1)-methyltransferase from Acinetobacter baumannii
7MYS	;	2.4	;	Crystal structure of a tRNA (guanine-N1)-methyltransferase from Acinetobacter baumannii AB5075-UW bound to S-adenosyl homocysteine
4IG6	;	2.4	;	Crystal structure of a tRNA (guanine-N1)-methyltransferase from Anaplasma phagocytophilum bound to S-adenosylhomocysteine
3BU2	;	2.7	;	Crystal structure of a tRNA-binding protein from Staphylococcus saprophyticus subsp. saprophyticus. Northeast Structural Genomics Consortium target SyR77
3QUV	;	1.7	;	Crystal structure of a tRNA-guanine-N1-methyltransferase from Mycobacterium abscessus
3UG0	;	2.093	;	Crystal structure of a Trp-less green fluorescent protein translated by the simplified genetic code
3UFZ	;	1.85	;	Crystal structure of a Trp-less green fluorescent protein translated by the universal genetic code
7AOV	;	2.00002	;	Crystal Structure of a TRPM2 Domain
7D51	;	2.68	;	Crystal structure of a truly knotted protein: cyclized YibK from Haemophilus influenzae
3GIT	;	3.0	;	Crystal structure of a truncated acetyl-CoA synthase
4BDV	;	3.98	;	CRYSTAL STRUCTURE OF A TRUNCATED B-DOMAIN HUMAN FACTOR VIII
4OFS	;	4.1	;	Crystal structure of a truncated catalytic core of the 2-oxoacid dehydrogenase multienzyme complex from Thermoplasma acidophilum
1Q6H	;	1.97	;	Crystal structure of a truncated form of FkpA from Escherichia coli
1Q6I	;	2.25	;	Crystal structure of a truncated form of FkpA from Escherichia coli, in complex with immunosuppressant FK506
1HQP	;	2.3	;	CRYSTAL STRUCTURE OF A TRUNCATED FORM OF PORCINE ODORANT-BINDING PROTEIN
7AIE	;	3.287	;	Crystal structure of a truncated form of the KLC1-TPR domain ([A1-B5] fragment) - Monoclinic crystal form
5C8A	;	2.15	;	Crystal structure of a truncated form of Thermus thermophilus CarH bound to adenosylcobalamin (dark state)
1FYF	;	1.65	;	CRYSTAL STRUCTURE OF A TRUNCATED FORM OF THREONYL-TRNA SYNTHETASE COMPLEXED WITH A SERYL ADENYLATE ANALOG
1EVL	;	1.55	;	CRYSTAL STRUCTURE OF A TRUNCATED FORM OF THREONYL-TRNA SYNTHETASE WITH A THREONYL ADENYLATE ANALOG
1EVK	;	2.0	;	CRYSTAL STRUCTURE OF A TRUNCATED FORM OF THREONYL-TRNA SYNTHETASE WITH THE LIGAND THREONINE
1RJU	;	1.44	;	Crystal structure of a truncated form of yeast copper thionein
5GL7	;	2.013	;	Crystal structure of a truncated human cytosolic methionyl-tRNA synthetase
3BDL	;	1.9	;	Crystal structure of a truncated human Tudor-SN
3SU8	;	3.2	;	Crystal structure of a truncated intracellular domain of Plexin-B1 in complex with Rac1
6WC6	;	3.1	;	Crystal structure of a truncated LSD1:CoREST in the presence of an LSD1-NT peptide
2A4V	;	1.8	;	Crystal Structure of a truncated mutant of yeast nuclear thiol peroxidase
4H1S	;	2.2	;	Crystal Structure of a Truncated Soluble form of Human CD73 with Ecto-5'-Nucleotidase activity
2ZY6	;	1.75	;	Crystal structure of a truncated tRNA, TPHE39A
2C3Z	;	2.8	;	Crystal structure of a truncated variant of indole-3-glycerol phosphate synthase from Sulfolobus solfataricus
3ZY0	;	1.9	;	Crystal structure of a truncated variant of the human p63 tetramerization domain lacking the C-terminal helix
2WQJ	;	2.0	;	Crystal structure of a truncated variant of the human p73 tetramerization domain
1TCZ	;	1.85	;	Crystal structure of a truncated version of the phage lamda protein gpD
4JF8	;	1.35	;	Crystal structure of a TrwG component of type IV secretion system protein from Bartonella birtlesii
3FSI	;	1.75	;	Crystal structure of a trypanocidal 4,4'-Bis(imidazolinylamino)diphenylamine bound to DNA
2JET	;	2.2	;	Crystal structure of a trypsin-like mutant (S189D , A226G) chymotrypsin.
5HY5	;	2.68	;	Crystal Structure of a Tryptophan 6-halogenase (SttH) from Streptomyces toxytricini
3TZE	;	2.6	;	Crystal structure of a tryptophanyl-tRNA synthetase from Encephalitozoon cuniculi bound to tryptophan
5TEW	;	2.5	;	Crystal structure of a tryptophanyl-tRNA synthetase from Neisseria gonorrhoeae bound to tryptophan
5TEV	;	2.25	;	Crystal structure of a tryptophanyl-tRNA synthetase from Neisseria gonorrhoeae, apo
6Z9U	;	2.10002	;	Crystal structure of a TSEN15-34 heterodimer.
3UAF	;	2.01	;	Crystal Structure of a TTR-52 mutant of C. elegans
3D00	;	1.9	;	Crystal structure of a tungsten formylmethanofuran dehydrogenase subunit e (fmde)-like protein (syn_00638) from syntrophus aciditrophicus at 1.90 A resolution
3CU5	;	2.6	;	Crystal structure of a two component transcriptional regulator AraC from Clostridium phytofermentans ISDg
4JX0	;	2.9	;	Crystal structure of a two domain protein with unknown function (BF3416) from Bacteroides fragilis NCTC 9343 at 2.90 A resolution
3KNY	;	2.6	;	Crystal structure of a two domain protein with unknown function (bt_3535) from bacteroides thetaiotaomicron vpi-5482 at 2.60 A resolution
2QZJ	;	2.89	;	Crystal structure of a two-component response regulator from Clostridium difficile
6HFZ	;	1.75	;	Crystal structure of a two-domain esterase (CEX) active on acetylated mannans
6HH9	;	2.4	;	Crystal structure of a two-domain esterase (CEX) active on acetylated mannans co-crystallized with mannopentaose
1K6Y	;	2.4	;	Crystal Structure of a Two-Domain Fragment of HIV-1 Integrase
5CZ2	;	2.72	;	Crystal structure of a two-domain fragment of MMTV integrase
2ISZ	;	2.403	;	Crystal structure of a two-domain IdeR-DNA complex crystal form I
2IT0	;	2.6	;	Crystal structure of a two-domain IdeR-DNA complex crystal form II
3FSE	;	1.9	;	Crystal structure of a two-domain protein containing dj-1/thij/pfpi-like and ferritin-like domains (ava_4496) from anabaena variabilis atcc 29413 at 1.90 A resolution
3E38	;	2.2	;	CRYSTAL STRUCTURE OF A TWO-DOMAIN PROTEIN CONTAINING PREDICTED PHP-LIKE METAL-DEPENDENT PHOSPHOESTERASE (BVU_3505) FROM BACTEROIDES VULGATUS ATCC 8482 AT 2.20 A RESOLUTION
6KFL	;	1.92	;	Crystal structure of a two-quartet DNA G-quadruplex complexed with the porphyrin TMPyP4
6JJF	;	1.47	;	Crystal structure of a two-quartet DNA mixed-parallel/antiparallel G-quadruplex
6JJG	;	1.969	;	Crystal structure of a two-quartet DNA mixed-parallel/antiparallel G-quadruplex
6JJE	;	1.378	;	Crystal structure of a two-quartet DNA mixed-parallel/antiparallel G-quadruplex (BrU)
6JJH	;	1.74	;	Crystal structure of a two-quartet RNA parallel G-quadruplex complexed with the porphyrin TMPyP4
6JJI	;	3.1	;	Crystal structure of a two-quartet RNA parallel G-quadruplex complexed with the porphyrin TMPyP4 (1:1)
6MEN	;	1.5	;	Crystal structure of a Tylonycteris bat coronavirus HKU4 macrodomain in complex with adenosine diphosphate glucose (ADP-glucose)
6MEA	;	1.35	;	Crystal structure of a Tylonycteris bat coronavirus HKU4 macrodomain in complex with adenosine diphosphate ribose (ADP-ribose)
3TBO	;	1.5	;	Crystal structure of a type 3 CDGSH iron-sulfur protein.
3TBM	;	1.797	;	Crystal structure of a type 4 CDGSH iron-sulfur protein.
5JJT	;	2.103	;	Crystal structure of a type 5 serine/threonine protein phosphatase from Arabidopsis thaliana
4L0K	;	2.328	;	Crystal structure of a type II restriction endonuclease
2VUP	;	2.1	;	Crystal structure of a type II tryparedoxin-dependant peroxidase from Trypanosoma brucei
2ZF9	;	1.95	;	Crystal structure of a type III cohesin module from the cellulosomal ScaE cell-surface anchoring scaffoldin of Ruminococcus flavefaciens
2GTD	;	2.0	;	Crystal Structure of a Type III Pantothenate Kinase: Insight into the Catalysis of an Essential Coenzyme A Biosynthetic Enzyme Universally Distributed in Bacteria
1TED	;	2.25	;	Crystal structure of a type III polyketide synthase PKS18 from Mycobacterium tuberculosis
3E1H	;	2.58	;	Crystal structure of a type III polyketide synthase PKSIIINc from Neurospora crassa
1Y9T	;	1.87	;	Crystal structure of a type III secretion system protein complexed with the lipid, 1-monohexanoyl-2-hydroxy-sn-glycero-3-phosphate
5H3V	;	1.4	;	Crystal structure of a Type IV Secretion System Component CagX in Helicobacter pylori
2OVS	;	1.9	;	Crystal structure of a Type Three secretion System protein
3V4H	;	2.1	;	Crystal structure of a type VI secretion system effector from Yersinia pestis
7DQ9	;	1.702	;	Crystal structure of a type-A feruloyl esterase from gut Alistipes shahii
8DHT	;	1.699	;	Crystal structure of a typeIII Rubisco
4DNK	;	2.2	;	Crystal structure of a tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta polypeptide (YWHAB) from homo sapiens at 2.20 A resolution.
4E2E	;	2.25	;	Crystal structure of a tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma polypeptide (YWHAG) from Homo sapiens at 2.25 A resolution
7CWX	;	2.15	;	Crystal structure of a tyrosine decarboxylase from Enterococcus faecalis
7CWY	;	2.59	;	Crystal structure of a tyrosine decarboxylase from Enterococcus faecalis in complex with the cofactor PLP
7CX0	;	2.66	;	Crystal structure of a tyrosine decarboxylase from Enterococcus faecalis in complex with the cofactor PLP and inhibitor carbidopa
7CX1	;	2.54	;	Crystal structure of a tyrosine decarboxylase from Enterococcus faecalis in complex with the cofactor PLP and inhibitor methyl-tyrosine
7CWZ	;	2.97	;	Crystal structure of a tyrosine decarboxylase from Enterococcus faecalis K392A mutant in complex with the cofactor PLP and L-dopa
6N0W	;	2.7	;	Crystal structure of a Tyrosine--tRNA ligase from Elizabethkingia anophelis
2QG3	;	1.95	;	CRYSTAL STRUCTURE OF A TYW3 METHYLTRANSFERASE-LIKE PROTEIN (AF_2059) FROM ARCHAEOGLOBUS FULGIDUS DSM 4304 AT 1.95 A RESOLUTION
1MZW	;	2.0	;	Crystal structure of a U4/U6 snRNP complex between human spliceosomal cyclophilin H and a U4/U6-60K peptide
5ULF	;	1.8	;	Crystal Structure of a UbcH5b~Ub conjugate
5BNB	;	2.49	;	Crystal structure of a Ube2S-ubiquitin conjugate
2AVN	;	2.35	;	CRYSTAL STRUCTURE OF A UBIQUINONE/MENAQUINONE BIOSYNTHESIS METHYLTRANSFERASE-RELATED PROTEIN (TM1389) FROM THERMOTOGA MARITIMA MSB8 AT 2.35 A RESOLUTION
1RCM	;	1.9	;	CRYSTAL STRUCTURE OF A UBIQUITIN-DEPENDENT DEGRADATION SUBSTRATE: A THREE-DISULFIDE FORM OF LYSOZYME
1NBF	;	2.3	;	Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde
4CYC	;	2.36	;	CRYSTAL STRUCTURE OF A UBX-EXD-DNA COMPLEX INCLUDING THE HEXAPEPTIDE AND UBDA MOTIFS
4UUS	;	2.55	;	CRYSTAL STRUCTURE OF A UBX-EXD-DNA COMPLEX INCLUDING THE UBDA MOTIF
5DLD	;	1.45	;	Crystal Structure of a UDP-N-acetylglucosamine 2-epimerase from Burkholderia vietnamiensis complexed with UDP-GlcNAc and UDP
7BV3	;	1.85	;	Crystal structure of a ugt transferase from Siraitia grosvenorii in complex with UDP
4P5B	;	2.274	;	Crystal structure of a UMP/dUMP methylase PolB from Streptomyces cacaoi bound with 5-Br dUMP
4P5A	;	1.76	;	Crystal structure of a UMP/dUMP methylase PolB from Streptomyces cacaoi bound with 5-Br UMP
3FIJ	;	2.3	;	Crystal structure of a uncharacterized protein lin1909
2OXM	;	2.5	;	Crystal structure of a UNG2/modified DNA complex that represent a stabilized short-lived extrahelical state in ezymatic DNA base flipping
4QFV	;	1.999	;	Crystal structure of a unique ankyrin
4BKC	;	1.73	;	Crystal Structure of a unusually linked dimeric variant of Bet v 1
4R8X	;	1.401	;	Crystal structure of a uricase from Bacillus fastidious
4R99	;	1.8	;	Crystal structure of a uricase from Bacillus fastidious
3V4R	;	3.25	;	Crystal structure of a UvrB dimer-DNA complex
6FY0	;	2.57	;	Crystal structure of a V2-directed, RV144 vaccine-like antibody from HIV-1 infection, CAP228-16H, bound to a heterologous V2 peptide
6FY3	;	2.6	;	Crystal structure of a V2-directed, RV144 vaccine-like antibody from HIV-1 infection, CAP228-3D, bound to a heterologous V2 peptide
6FY2	;	2.301	;	Crystal structure of a V2p-reactive RV144 vaccine-like antibody, CAP228-16H, in complex with a heterologous CAP225 V1V2
6FY1	;	3.132	;	Crystal structure of a V2p-reactive RV144 vaccine-like antibody, CAP228-16H, in complex with a scaffolded autologous V1V2
6U6M	;	2.683	;	Crystal structure of a vaccine-elicited anti-HIV-1 rhesus macaque antibody DH840.1
6U6O	;	2.806	;	Crystal structure of a vaccine-elicited anti-HIV-1 rhesus macaque antibody DH846
1AC6	;	2.3	;	CRYSTAL STRUCTURE OF A VARIABLE DOMAIN MUTANT OF A T-CELL RECEPTOR ALPHA CHAIN
8GYR	;	1.87	;	Crystal structure of a variable region segment of Leptospira host-interacting outer surface protein, LigA
6H8K	;	3.79	;	Crystal structure of a variant (Q133C in PSST) of Yarrowia lipolytica complex I
5JJ4	;	2.807	;	Crystal Structure of a Variant Human Activation-induced Deoxycytidine Deaminase as an MBP fusion protein
6EMI	;	2.476	;	Crystal structure of a variant of human butyrylcholinesterase expressed in bacteria.
8BRR	;	1.95	;	Crystal structure of a variant of penicillin G acylase from Bacillaceae i. s. sp. FJAT-27231 with reduced surface entropy and additionally engineered crystal contact
8BRT	;	1.31	;	Crystal structure of a variant of penicillin G acylase from Bacillaceae i. s. sp. FJAT-27231 with reduced surface entropy and additionally engineered crystal contact
8BRS	;	1.2	;	Crystal structure of a variant of penicillin G acylase from Bacillaceae i. s. sp. FJAT-27231 with reduced surface entropy and additionally engineered crystal contact.
4BK7	;	1.14	;	Crystal Structure of a variant of the Major Birch Pollen Allergen Bet v 1
2QVJ	;	2.8	;	Crystal structure of a vesicular stomatitis virus nucleocapsid protein Ser290Trp mutant
3PTX	;	3.0	;	Crystal Structure of a vesicular stomatitis virus nucleocapsid-polyA complex
3PU0	;	3.09	;	Crystal Structure of a vesicular stomatitis virus nucleocapsid-polyC complex
3PU1	;	3.14	;	Crystal Structure of a vesicular stomatitis virus nucleocapsid-polyG complex
3PU4	;	3.0	;	Crystal Structure of a vesicular stomatitis virus nucleocapsid-polyU complex
2GIC	;	2.92	;	Crystal Structure of a vesicular stomatitis virus nucleocapsid-RNA complex
3CL3	;	3.2	;	Crystal Structure of a vFLIP-IKKgamma complex: Insights into viral activation of the IKK signalosome
5LDE	;	3.38	;	Crystal structure of a vFLIP-IKKgamma stapled peptide dimer
6OC8	;	2.109	;	Crystal structure of a VHH against the capsid protein from BLV
3KLT	;	2.7	;	Crystal structure of a vimentin fragment
2OSO	;	1.9	;	Crystal structure of a vinyl-4-reductase family protein (mj_1460) from methanocaldococcus jannaschii dsm at 1.90 A resolution
2OSD	;	2.3	;	Crystal structure of a vinyl-4-reductase family protein (mj_1460) from methanocaldococcus jannaschii dsm at 2.40 A resolution
1ZXT	;	1.7	;	Crystal Structure of A Viral Chemokine
4MB7	;	2.04	;	Crystal Structure of a viral DNA glycosylase
2F1S	;	1.4	;	Crystal Structure of a Viral FLIP MC159
2O5N	;	2.4	;	Crystal structure of a Viral Glycoprotein
4MEI	;	2.85	;	Crystal structure of a VirB8 Type IV secretion system machinery soluble domain from Bartonella tribocorum
4O3V	;	1.95	;	Crystal structure of a VirB8-like protein of type IV secretion system from Rickettsia typhi
7SH3	;	3.0	;	Crystal Structure of a VirB8-like Protein of Type IV Secretion System from Rickettsia typhi in Complex with a Synthetic VirB8 Miniprotein Binder
1VQR	;	2.25	;	Crystal structure of a virulence factor (cj0248) from campylobacter jejuni subsp. jejuni at 2.25 A resolution
3OY7	;	2.73	;	Crystal structure of a virus encoded glycosyltransferase in complex with GDP-mannose
4KT0	;	2.8	;	Crystal structure of a virus like photosystem I from the cyanobacterium Synechocystis PCC 6803
4L6V	;	3.8	;	Crystal structure of a virus like photosystem I from the cyanobacterium Synechocystis PCC 6803
1ET4	;	2.3	;	CRYSTAL STRUCTURE OF A VITAMIN B12 BINDING RNA APTAMER WITH LIGAND AT 2.3 A
5A4R	;	2.25	;	Crystal structure of a vitamin B12 trafficking protein
4H37	;	3.35	;	Crystal structure of a voltage-gated K+ channel pore domain in a closed state in lipid membranes
4H33	;	3.1	;	Crystal structure of a voltage-gated K+ channel pore module in a closed state in lipid membranes, tetragonal crystal form
5BV1	;	2.902	;	Crystal Structure of a Vps33-Vps16 Complex from Chaetomium thermophilum
4S1Q	;	2.4	;	Crystal structure of a VRC01-lineage antibody, 45-VRC01.H03+06.D-001739, in complex with clade A/E HIV-1 gp120 core
4S1R	;	3.214	;	Crystal structure of a VRC01-lineage antibody, 45-VRC01.H08.F-117225, in complex with clade A/E HIV-1 gp120 core
4S1S	;	3.39	;	Crystal structure of a VRC01-lineage antibody, 45-VRC01.H5.F-185917, in complex with clade A/E HIV-1 gp120 core
4DMT	;	1.39	;	Crystal structure of a VWF binding collagen III derived triple helical peptide
1YOD	;	1.8	;	Crystal structure of a water soluble analog of phospholamban
2B3Q	;	2.3	;	Crystal structure of a well-folded variant of green fluorescent protein
1EGA	;	2.4	;	CRYSTAL STRUCTURE OF A WIDELY CONSERVED GTPASE ERA
6IST	;	1.75	;	Crystal structure of a wild type endolysin LysIME-EF1
1G50	;	2.9	;	CRYSTAL STRUCTURE OF A WILD TYPE HER ALPHA LBD AT 2.9 ANGSTROM RESOLUTION
1Q3V	;	2.91	;	Crystal structure of a wild-type Cre recombinase-loxP synapse: phosphotyrosine covalent intermediate
1Q3U	;	2.9	;	Crystal structure of a wild-type Cre recombinase-loxP synapse: pre-cleavage complex
3D5U	;	2.8	;	Crystal structure of a wildtype Polo-like kinase 1 (Plk1) catalytic domain.
2QS8	;	2.33	;	Crystal structure of a Xaa-Pro dipeptidase with bound methionine in the active site
3ON5	;	2.8	;	Crystal structure of a xanthine dehydrogenase (BH1974) from Bacillus halodurans at 2.80 A resolution
2NLV	;	1.3	;	CRYSTAL STRUCTURE OF A XISI-LIKE PROTEIN (AVA_3825) FROM ANABAENA VARIABILIS ATCC 29413 AT 1.30 A RESOLUTION
3D7Q	;	2.3	;	Crystal structure of a xisi-like protein (npun_ar114) from nostoc punctiforme pcc 73102 at 2.30 A resolution
1IK9	;	2.3	;	CRYSTAL STRUCTURE OF A XRCC4-DNA LIGASE IV COMPLEX
5NO7	;	3.01	;	Crystal Structure of a Xylan-active Lytic Polysaccharide Monooxygenase from Pycnoporus coccineus.
5JRM	;	1.56	;	Crystal Structure of a Xylanase at 1.56 Angstroem resolution
5JRN	;	2.841	;	Crystal Structure of a Xylanase in Complex with a Monosaccharide at 2.84 Angstroem resolution
2Q02	;	2.4	;	Crystal structure of a xylose isomerase domain containing protein (stm4435) from salmonella typhimurium lt2 at 2.40 A resolution
5TNV	;	1.04	;	Crystal Structure of a Xylose isomerase-like TIM barrel Protein from Mycobacterium smegmatis in Complex with Magnesium
5VM1	;	2.75	;	Crystal structure of a xyloylose kinase from Brucella ovis
1JX4	;	1.7	;	Crystal Structure of a Y-family DNA Polymerase in a Ternary Complex with DNA Substrates and an Incoming Nucleotide
1JXL	;	2.1	;	Crystal Structure of a Y-Family DNA Polymerase in a Ternary Complex with DNA Substrates and an Incoming Nucleotide
8PTI	;	1.8	;	CRYSTAL STRUCTURE OF A Y35G MUTANT OF BOVINE PANCREATIC TRYPSIN INHIBITOR
4IA8	;	1.85	;	Crystal Structure of a Y37A mutant of the Restriction-Modification Controller Protein C.Esp1396I
4I6U	;	1.97	;	Crystal Structure of a Y37F mutant of the Restriction-Modification Controller Protein C.Esp1396I
3S6L	;	2.3	;	Crystal structure of a YadA-like head domain of the trimeric autotransporter adhesin BoaA from Burkholderia pseudomallei solved by iodide ion SAD phasing
4QDY	;	2.74	;	Crystal structure of a YbbR-like protein (SP_1560) from Streptococcus pneumoniae TIGR4 at 2.74 A resolution
1VMF	;	1.46	;	CRYSTAL STRUCTURE OF a YBJQ-LIKE FOLD PROTEIN OF UNKNOWN FUNCTION (BH3498) FROM BACILLUS HALODURANS AT 1.46 A RESOLUTION
1VPH	;	1.764	;	CRYSTAL STRUCTURE OF a YbjQ-like protein of unknown function (SSO2532) FROM SULFOLOBUS SOLFATARICUS P2 AT 1.76 A RESOLUTION
1NGM	;	2.95	;	Crystal structure of a yeast Brf1-TBP-DNA ternary complex
1B54	;	2.1	;	CRYSTAL STRUCTURE OF A YEAST HYPOTHETICAL PROTEIN-A STRUCTURE FROM BNL'S HUMAN PROTEOME PROJECT
1D1P	;	2.2	;	CRYSTAL STRUCTURE OF A YEAST LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LTP1)
1D2A	;	1.9	;	CRYSTAL STRUCTURE OF A YEAST LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LTP1) COMPLEXED WITH THE ACTIVATOR ADENINE
1D1Q	;	1.7	;	CRYSTAL STRUCTURE OF A YEAST LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LTP1) COMPLEXED WITH THE SUBSTRATE PNPP
6CW2	;	2.67	;	Crystal structure of a yeast SAGA transcriptional coactivator Ada2/Gcn5 HAT subcomplex, crystal form 1
6CW3	;	1.98	;	Crystal structure of a yeast SAGA transcriptional coactivator Ada2/Gcn5 HAT subcomplex, crystal form 2
6TEO	;	3.1	;	Crystal structure of a yeast Snu114-Prp8 complex
1YTB	;	1.8	;	CRYSTAL STRUCTURE OF A YEAST TBP/TATA-BOX COMPLEX
1NH2	;	1.9	;	Crystal structure of a yeast TFIIA/TBP/DNA complex
1MYW	;	2.2	;	CRYSTAL STRUCTURE OF A YELLOW FLUORESCENT PROTEIN WITH IMPROVED MATURATION AND REDUCED ENVIRONMENTAL SENSITIVITY
6EFW	;	1.9	;	Crystal structure of a YjeF family protein from Cryptococcus neoformans var. grubii serotype A
6EFX	;	2.0	;	Crystal structure of a YjeF family protein from Cryptococcus neoformans var. grubii serotype A in complex with AMPPNP
4QY7	;	1.55	;	Crystal structure of a yobA protein (BSU18810) from Bacillus subtilis subsp. subtilis str. 168 at 1.55 A resolution
1VTY	;	1.3	;	Crystal structure of a Z-DNA fragment containing thymine/2-aminoadenine base pairs
5IMJ	;	3.1	;	Crystal structure of a Z-ring associated protein from Escherichia coli
5GNP	;	2.8	;	Crystal structure of a Z-ring associated protein from Salmonella typhimurium
3IRQ	;	2.8	;	Crystal structure of a Z-Z junction
3IRR	;	2.65	;	Crystal Structure of a Z-Z junction (with HEPES intercalating)
6H1N	;	2.0	;	Crystal Structure of a Zebra-fish pro-survival protein NRZ-apo
6FBX	;	1.639	;	Crystal Structure of a Zebra-fish pro-survival protein NRZ:Bad BH3 complex
1E6B	;	1.65	;	Crystal structure of a Zeta class glutathione S-transferase from Arabidopsis thaliana
1LLM	;	1.5	;	Crystal Structure of a Zif23-GCN4 Chimera Bound to DNA
1MH2	;	2.7	;	Crystal Structure of a Zinc Containing Dimer of Phospholipase A2 from the Venom of Indian Cobra (Naja Naja Sagittifera)
2GU1	;	1.9	;	Crystal structure of a zinc containing peptidase from vibrio cholerae
3NMK	;	2.8	;	Crystal structure of a zinc mediated dimer for the phenanthroline-modified cytochrome cb562 variant, MBP-Phen2
6NU9	;	1.761	;	Crystal Structure of a Zinc-Binding Non-Structural Protein from the Hepatitis E Virus
3R6F	;	1.85	;	Crystal structure of a zinc-containing HIT family protein from Encephalitozoon cuniculi
6FI9	;	2.8	;	Crystal Structure of a zinc-responsive MarR family member, Lactococcus lactis ZitR
4UMW	;	2.705	;	CRYSTAL STRUCTURE OF A ZINC-TRANSPORTING PIB-TYPE ATPASE IN E2.PI STATE
4UMV	;	3.2	;	CRYSTAL STRUCTURE OF A ZINC-TRANSPORTING PIB-TYPE ATPASE IN THE E2P STATE
1UUF	;	1.76	;	crystal structure of a zinc-type alcohol dehydrogenase-like protein yahK
1KYS	;	1.44	;	Crystal Structure of a Zn-bound Green Fluorescent Protein Biosensor
3O0M	;	1.9	;	Crystal structure of a ZN-bound histidine triad family protein from Mycobacterium smegmatis
7RWW	;	1.7	;	Crystal structure of a Zn-bound RIDC1 variant
7RWX	;	1.6	;	Crystal structure of a Zn-bound RIDC1 variant in the presence of reductant
3TC8	;	1.06	;	Crystal structure of a Zn-dependent exopeptidase (BDI_3547) from Parabacteroides distasonis ATCC 8503 at 1.06 A resolution
5ZBY	;	1.591	;	Crystal structure of a [NiFe] hydrogenase maturation protease HycI from Thermococcus kodakarensis KOD1
2WZY	;	2.51	;	Crystal structure of A-AChBP in complex with 13-desmethyl spirolide C
2X00	;	2.4	;	CRYSTAL STRUCTURE OF A-ACHBP IN COMPLEX WITH GYMNODIMINE A
4XHE	;	1.9	;	Crystal Structure of A-AChBP in complex with pinnatoxin A
4XK9	;	2.2	;	Crystal structure of A-AChBP in complex with pinnatoxin G
3MV2	;	2.9	;	Crystal Structure of a-COP in Complex with e-COP
3MV3	;	3.25	;	Crystal Structure of a-COP in Complex with e-COP
1NZG	;	1.6	;	Crystal structure of A-DNA decamer GCGTA(3ME)ACGC, with a modified 5-methyluridine
3Q3G	;	2.7	;	Crystal Structure of A-domain in complex with antibody
3QA3	;	3.0	;	Crystal Structure of A-domain in complex with antibody
1U2C	;	2.3	;	Crystal Structure of a-dystroglycan
6Q4S	;	1.83	;	Crystal structure of a-eudesmol synthase
1VDZ	;	2.55	;	Crystal structure of A-type ATPase catalytic subunit A from Pyrococcus horikoshii OT3
1YVU	;	2.9	;	Crystal structure of A. aeolicus Argonaute
3FTD	;	1.44	;	Crystal structure of A. aeolicus KsgA at 1.44-Angstrom resolution
3FTC	;	1.68	;	Crystal structure of A. aeolicus KsgA at 1.72-Angstrom resolution
3FTE	;	3.0	;	Crystal structure of A. aeolicus KsgA in complex with RNA
3FTF	;	2.8	;	Crystal structure of A. aeolicus KsgA in complex with RNA and SAH
4G3K	;	3.05	;	Crystal structure of a. aeolicus nlh1 gaf domain in an inactive state
4G3W	;	2.7	;	Crystal structure of a. aeolicus nlh1 gaf domain in an inactive state
4G3V	;	1.7	;	Crystal structure of A. Aeolicus nlh2 gaf domain in an inactive state
4L5E	;	1.34	;	Crystal structure of A. aeolicus NtrC1 DNA binding domain
1ZJR	;	1.85	;	Crystal Structure of A. aeolicus TrmH/SpoU tRNA modifying enzyme
3W3S	;	3.095	;	Crystal structure of A. aeolicus tRNASec in complex with M. kandleri SerRS
7ZG8	;	2.65	;	Crystal structure of A. baumannii penicillin-binding protein 2
1RXV	;	2.5	;	Crystal Structure of A. Fulgidus FEN-1 bound to DNA
1RXW	;	2.0	;	Crystal structure of A. fulgidus FEN-1 bound to DNA
1Z0E	;	2.05	;	Crystal Structure of A. fulgidus Lon proteolytic domain
1Z0G	;	2.27	;	Crystal Structure of A. fulgidus Lon proteolytic domain
1Z0T	;	3.0	;	Crystal Structure of A. fulgidus Lon proteolytic domain
1Z0V	;	3.0	;	Crystal Structure of A. fulgidus Lon proteolytic domain
1Z0W	;	1.2	;	Crystal Structure of A. fulgidus Lon proteolytic domain at 1.2A resolution
1Z0C	;	1.55	;	Crystal Structure of A. fulgidus Lon proteolytic domain D508A mutant
1Z0B	;	1.55	;	Crystal Structure of A. fulgidus Lon proteolytic domain E506A mutant
2ONR	;	1.6	;	Crystal structure of A. fulgidus periplasmic binding protein ModA with bound molybdate
2ONS	;	1.55	;	Crystal structure of A. fulgidus periplasmic binding protein ModA with bound tungstate
3CIJ	;	1.07	;	Crystal structure of A. fulgidus periplasmic binding protein ModA/WtpA with bound tungstate
1TQI	;	2.0	;	Crystal Structure of A. Fulgidus Rio2 Serine Protein Kinase
1TQM	;	1.99	;	Crystal Structure of A. fulgidus Rio2 Serine Protein Kinase Bound to AMPPNP
1TQP	;	2.1	;	Crystal Structure of A. fulgidus Rio2 Serine Protein Kinase Bound to ATP
3LDK	;	2.2	;	Crystal Structure of A. japonicus CB05
4C5Y	;	3.0	;	Crystal structure of A. niger ochratoxinase
4C5Z	;	2.5	;	Crystal structure of A. niger ochratoxinase
4C60	;	2.5	;	Crystal structure of A. niger ochratoxinase
4C65	;	2.2	;	Crystal structure of A. niger ochratoxinase
6H7D	;	2.4	;	Crystal Structure of A. thaliana Sugar Transport Protein 10 in complex with glucose in the outward occluded state
1ZTF	;	1.99	;	Crystal Structure of A.fulgidus Rio1 serine protein kinase
1ZTH	;	1.89	;	Crystal Structure of A.fulgidus Rio1 serine protein kinase bound to ADP and Manganese ion
1ZAR	;	1.75	;	Crystal Structure of A.fulgidus Rio2 Kinase Complexed With ADP and Manganese Ions
1ZAO	;	1.84	;	Crystal Structure of A.fulgidus Rio2 Kinase Complexed With ATP and Manganese Ions
3AEV	;	2.8	;	Crystal structure of a/eIF2alpha-aDim2p-rRNA complex from Pyrococcus horikoshii OT3
5XRT	;	3.15	;	Crystal structure of A/Minnesota/11/2010 (H3N2) influenza virus hemagglutinin
5XRS	;	2.907	;	Crystal structure of A/Minnesota/11/2010 (H3N2) influenza virus hemagglutinin in complex with LSTc
4O5N	;	1.75	;	Crystal structure of A/Victoria/361/2011 (H3N2) influenza virus hemagglutinin
3VWW	;	1.93	;	Crystal structure of a0-domain of P5 from H. sapiens
4YLB	;	2.501	;	Crystal Structure of A102D mutant of hsp14.1 from Sulfolobus solfatataricus P2
4L8V	;	2.09	;	Crystal Structure of A12K/D35S mutant myo-inositol dehydrogenase from Bacillus subtilis with bound cofactor NADP
5UA4	;	2.6	;	Crystal structure of A179L:Bid BH3 complex
5UA5	;	2.5	;	Crystal structure of A179L:Bid BH3 complex
4QA1	;	1.92	;	Crystal structure of A188T HDAC8 in complex with M344
4QA5	;	1.76	;	Crystal structure of A188T/Y306F HDAC8 in complex with a tetrapeptide substrate
5G58	;	2.54	;	Crystal structure of A190T mutant of human hippocalcin AT 2.5 A resolution
2C0N	;	1.86	;	Crystal Structure of A197 from STIV
1OO8	;	2.65	;	CRYSTAL STRUCTURE OF A1PI-PITTSBURGH IN THE NATIVE CONFORMATION
3VUY	;	1.981	;	Crystal structure of A20 ZF7 in complex with linear tetraubiquitin
3VUW	;	1.95	;	Crystal structure of A20 ZF7 in complex with linear ubiquitin, form I
3VUX	;	1.699	;	Crystal structure of A20 ZF7 in complex with linear ubiquitin, form II
3DKB	;	2.5	;	Crystal Structure of A20, 2.5 angstrom
7LZ4	;	4.155	;	Crystal structure of A211D mutant of Protein Kinase A RIa subunit, a Carney Complex mutation
4IL7	;	1.4	;	Crystal structure of A223 C-terminal domain, a structural protein from sulfolobus turreted icosahedral virus (STIV)
5N0A	;	3.9	;	Crystal structure of A259C covalently linked dengue 2 virus envelope glycoprotein dimer in complex with the Fab fragment of the broadly neutralizing human antibody EDE2 A11
6AQF	;	2.51	;	Crystal structure of A2AAR-BRIL in complex with the antagonist ZM241385 produced from Pichia pastoris
8CU7	;	2.05	;	Crystal structure of A2AAR-StaR2-bRIL in complex with a novel A2a antagonist, LJ-4517
8DU3	;	2.5	;	Crystal structure of A2AAR-StaR2-bRIL in complex with compound 21a
8CU6	;	2.8	;	Crystal structure of A2AAR-StaR2-S277-bRIL in complex with a novel A2a antagonist, LJ-4517
8JWY	;	2.33	;	Crystal structure of A2AR-T4L in complex with 2-118
8JWZ	;	2.37	;	Crystal structure of A2AR-T4L in complex with AB928
3TNM	;	1.85	;	Crystal structure of A32 Fab, an ADCC mediating anti-HIV-1 antibody
1ZO4	;	1.46	;	Crystal Structure Of A328S Mutant Of The Heme Domain Of P450BM-3
1ZOA	;	1.74	;	Crystal Structure Of A328V Mutant Of The Heme Domain Of P450Bm-3 With N-Palmitoylglycine
3IOX	;	1.8	;	Crystal Structure of A3VP1 of AgI/II of Streptococcus mutans
3IPK	;	2.04	;	Crystal Structure of A3VP1 of AgI/II of Streptococcus mutans
3V4P	;	3.15	;	crystal structure of a4b7 headpiece complexed with Fab ACT-1
3V4V	;	3.1	;	crystal structure of a4b7 headpiece complexed with Fab ACT-1 and RO0505376
4IRZ	;	2.84	;	Crystal structure of A4b7 headpiece complexed with Fab Natalizumab
6DUJ	;	1.82203	;	Crystal structure of A51V variant of Human Cytochrome c
7A5T	;	1.4	;	Crystal structure of A55E mutant of BlaC from Mycobacterium tuberculosis
3STG	;	2.2	;	Crystal structure of A58P, DEL(N59), and loop 7 truncated mutant of 3-deoxy-D-manno-octulosonate 8-phosphate synthase (KDO8PS) from Neisseria meningitidis
3FJK	;	2.15	;	Crystal structure of A66C mutant of Human acidic fibroblast growth factor
7YOE	;	1.88	;	Crystal Structure of A68P single mutant of O-acetyl-L-serine sulfhydrylase from Haemophilus influenzae at 1.88 A
7YOD	;	2.101	;	Crystal structure of A68P single mutant of O-acetylserine sulfhydrylase from Haemophilus influenzae in complex with high-affinity inhibitory peptide from serine acetyltransferase of Salmonella typhimurium at 2.1 A
8I00	;	1.8	;	Crystal structure of A97S transthyretin
2F8S	;	3.0	;	Crystal structure of Aa-Ago with externally-bound siRNA
2F8T	;	3.1	;	Crystal structure of Aa-Ago with externally-bound siRNA
1WT9	;	2.01	;	crystal structure of Aa-X-bp-I, a snake venom protein with the activity of binding to coagulation factor X from Agkistrodon acutus
1Y17	;	2.4	;	crystal structure of Aa-X-bp-II, a snake venom protein with the activity of binding to coagulation factor X from Agkistrodon acutus
6IF7	;	2.2	;	Crystal Structure of AA10 Lytic Polysaccharide Monooxygenase from Tectaria macrodonta
1S3S	;	2.9	;	Crystal structure of AAA ATPase p97/VCP ND1 in complex with p47 C
5Z6Q	;	3.0	;	Crystal structure of AAA of Spastin
4QHT	;	2.559	;	Crystal structure of AAA+/ sigma 54 activator domain of the flagellar regulatory protein FlrC from Vibrio cholerae in ATP analog bound state
4QHS	;	2.3	;	Crystal structure of AAA+sigma 54 activator domain of the flagellar regulatory protein FlrC of Vibrio cholerae in nucleotide free state
4FQW	;	2.02	;	Crystal Structure of AAAA+UDP+Gal at pH 5.0 with MPD as the cryoprotectant
3SXE	;	1.49	;	Crystal structure of AAAA+UDP+Gal with Glycerol as the cryoprotectant
3SXG	;	1.86	;	Crystal structure of AAAA+UDP+Gal with MPD as the cryoprotectant
5C38	;	1.45	;	Crystal structure of AABB + UDP-C-Gal + DI
5C4F	;	1.41	;	Crystal structure of AABB + UDP-Glc + DI
3SX3	;	1.45	;	Crystal structure of AABB+UDP+Gal with glycerol as the cryoprotectant
3SX5	;	1.43	;	Crystal structure of AABB+UDP+Gal with MPD as the cryoprotectant
6BVC	;	1.808	;	Crystal structure of AAC(3)-Ia in complex with coenzyme A
5U34	;	3.255	;	Crystal structure of AacC2c1-sgRNA binary complex
5U31	;	2.89	;	Crystal structure of AacC2c1-sgRNA-8mer substrate DNA ternary complex
5U33	;	3.75	;	Crystal structure of AacC2c1-sgRNA-extended non-target DNA ternary complex
5U30	;	2.92	;	Crystal structure of AacC2c1-sgRNA-extended target DNA ternary complex
5BKD	;	1.9	;	Crystal structure of AAD-1 in complex with (R)-cyhalofop, Mn(II), and 2-oxoglutarate
5BKB	;	1.582	;	Crystal structure of AAD-1 in complex with (R)-dichlorprop, Mn(II), and 2-oxoglutarate
5BKC	;	1.8	;	Crystal structure of AAD-1 in complex with (R)-diclofop, Mn(II), and 2-oxoglutarate
5BKE	;	2.15	;	Crystal structure of AAD-2 in complex with Mn(II) and N-oxalylglycine
4CS6	;	2.502	;	Crystal structure of AadA - an aminoglycoside adenyltransferase
3HDB	;	2.31	;	Crystal structure of AaHIV, A metalloproteinase from venom of Agkistrodon Acutus
2ZGO	;	2.0	;	Crystal structure of AAL mutant H59Q complex with lactose
2ZGR	;	1.9	;	Crystal structure of AAL mutant L33A in C2 spacegroup
2ZGQ	;	1.9	;	Crystal structure of AAL mutant L33A in P1 spacegroup
8P0Q	;	2.8	;	Crystal structure of AaNGT complexed to UDP and a peptide
8P0P	;	2.73	;	Crystal structure of AaNGT complexed to UDP-2F-Glucose
8P0O	;	1.76	;	Crystal structure of AaNGT complexed to UDP-Gal
6JZY	;	2.1	;	Crystal structure of AAR with NADPH and stearyl in complex with ADO binding a long chain carbohydrate
3SBS	;	2.1	;	Crystal structure of Aar2 protein
4ILG	;	2.1	;	Crystal structure of Aar2p in complex with the Prp8p RNaseH and Jab1/MPN domains
5TOR	;	1.35	;	Crystal structure of AAT D222T mutant
5TON	;	1.4	;	Crystal structure of AAT H143L mutant
5TOT	;	1.4	;	Crystal structure of AAT H143L:H189L double mutant
6LCC	;	2.6	;	Crystal structure of AaTPS apo
6LCD	;	2.7	;	Crystal structure of AaTPS with PPi
4UZI	;	2.1	;	Crystal Structure of AauDyP Complexed with Imidazole
1RZ9	;	3.1	;	Crystal Structure of AAV Rep complexed with the Rep-binding sequence
1OP0	;	2.0	;	Crystal Structure of AaV-SP-I, a Glycosylated Snake Venom Serine Proteinase from Agkistrodon acutus
1OP2	;	2.1	;	Crystal Structure of AaV-SP-II, a Glycosylated Snake Venom Serine Proteinase from Agkistrodon acutus
1U0J	;	2.1	;	Crystal Structure of AAV2 Rep40-ADP complex
3UQH	;	3.0	;	Crystal structure of aba receptor pyl10 (apo)
1U7T	;	2.0	;	Crystal Structure of ABAD/HSD10 with a Bound Inhibitor
5C1G	;	1.46	;	Crystal structure of ABBA + UDP + DI
5C3B	;	1.4	;	Crystal structure of ABBA + UDP-C-Gal (long soak) + DI
5C3A	;	1.33	;	Crystal structure of ABBA + UDP-C-Gal (short soak) + DI
5C8R	;	1.45	;	Crystal structure of ABBA + UDP-Glc + DI
4FRA	;	1.43	;	Crystal Structure of ABBA+UDP+Gal at pH 5.0 with MPD as the cryoprotectant
4FRB	;	1.54	;	Crystal Structure of ABBA+UDP+Gal at pH 8.0 with MPD as the cryoprotectant
4FRD	;	1.55	;	Crystal Structure of ABBA+UDP+Gal at pH 9.0 with MPD as the cryoprotectant
3SX7	;	1.42	;	Crystal structure of ABBA+UDP+Gal with Glycerol as the cryoprotectant
3SX8	;	1.47	;	Crystal structure of ABBA+UDP+Gal with MPD as the cryoprotectant
5C1H	;	1.55	;	Crystal structure of ABBB + UDP + DI
5C47	;	1.39	;	Crystal structure of ABBB + UDP-C-Gal (long soak) + DI
5C3D	;	1.39	;	Crystal structure of ABBB + UDP-C-Gal (short soak) + DI
5C4C	;	1.43	;	Crystal structure of ABBB + UDP-Glc + DI
3SXA	;	1.5	;	Crystal structure of ABBB+UDP+Gal with Glycerol as the cryoprotectant
3SXB	;	1.49	;	Crystal structure of ABBB+UDP+Gal with MPD as the cryoprotectant
6PE7	;	1.74	;	Crystal Structure of ABBV-323 FAB
3ROT	;	1.91	;	Crystal structure of ABC sugar transporter (periplasmic sugar binding protein) from Legionella pneumophila
3L49	;	2.3	;	CRYSTAL STRUCTURE OF ABC SUGAR TRANSPORTER SUBUNIT FROM Rhodobacter sphaeroides 2.4.1
2PCJ	;	1.7	;	Crystal structure of ABC transporter (aq_297) From Aquifex Aeolicus VF5
6JAI	;	2.1	;	Crystal structure of ABC transporter alpha-glycoside-binding mutant protein D118A in complex with maltose
6JAQ	;	1.95	;	Crystal structure of ABC transporter alpha-glycoside-binding mutant protein R356A in complex with glucose
6JAN	;	1.77	;	Crystal structure of ABC transporter alpha-glycoside-binding mutant protein R356A in complex with maltose
6JAO	;	1.77	;	Crystal structure of ABC transporter alpha-glycoside-binding mutant protein R356A in complex with palatinose
6JAP	;	1.77	;	Crystal structure of ABC transporter alpha-glycoside-binding mutant protein R356A in complex with sucrose
6JAM	;	1.63	;	Crystal structure of ABC transporter alpha-glycoside-binding mutant protein R356A in complex with trehalose
6JAL	;	1.56	;	Crystal structure of ABC transporter alpha-glycoside-binding mutant protein R356A in ligand free form
6JAR	;	1.63	;	Crystal structure of ABC transporter alpha-glycoside-binding mutant protein R49A in complex with maltose
6JBE	;	1.75	;	Crystal structure of ABC transporter alpha-glycoside-binding mutant protein W287A in complex with glucose
6JB4	;	1.63	;	Crystal structure of ABC transporter alpha-glycoside-binding mutant protein W287A in complex with maltose
6JBA	;	2.0	;	Crystal structure of ABC transporter alpha-glycoside-binding mutant protein W287A in complex with palatinose
6JBB	;	1.95	;	Crystal structure of ABC transporter alpha-glycoside-binding mutant protein W287A in complex with sucrose
6JB0	;	1.63	;	Crystal structure of ABC transporter alpha-glycoside-binding mutant protein W287A in complex with trehalose
6JAZ	;	1.85	;	Crystal structure of ABC transporter alpha-glycoside-binding mutant protein W287F in complex with trehalose
6JAH	;	1.63	;	Crystal structure of ABC transporter alpha-glycoside-binding protein in complex with glucose
6J9Y	;	1.63	;	Crystal structure of ABC transporter alpha-glycoside-binding protein in complex with maltose
6JAD	;	1.9	;	Crystal structure of ABC transporter alpha-glycoside-binding protein in complex with palatinose
6JAG	;	1.85	;	Crystal structure of ABC transporter alpha-glycoside-binding protein in complex with sucrose
6J9W	;	1.8	;	Crystal structure of ABC transporter alpha-glycoside-binding protein in complex with trehalose
1VPL	;	2.1	;	Crystal structure of ABC transporter ATP-binding protein (TM0544) from Thermotoga maritima at 2.10 A resolution
4EVQ	;	1.4	;	Crystal structure of ABC transporter from R. palustris - solute binding protein (RPA0668) in complex with 4-hydroxybenzoate
4EVR	;	1.84	;	Crystal structure of ABC transporter from R. palustris - solute binding protein (RPA0668) in complex with benzoate
4EVS	;	1.45	;	Crystal structure of ABC transporter from R. palustris - solute binding protein (RPA0985) in complex with 4-hydroxybenzoate
5IAI	;	1.6	;	Crystal structure of ABC transporter Solute Binding Protein Arad_9887 from Agrobacterium radiobacter K84, target EFI-510945 in complex with Ribitol
4RYA	;	1.5	;	Crystal structure of abc transporter solute binding protein AVI_3567 from AGROBACTERIUM VITIS S4, TARGET EFI-510645, with bound D-mannitol
5HQJ	;	1.55	;	Crystal structure of ABC transporter Solute Binding Protein B1G1H7 from Burkholderia graminis C4D1M, target EFI-511179, in complex with D-arabinose
4N4U	;	1.57	;	Crystal structure of ABC transporter solute binding protein BB0719 from Bordetella bronchiseptica RB50, TARGET EFI-510049
4PE6	;	1.86	;	Crystal structure of ABC transporter solute binding protein from Thermobispora bispora DSM 43833
5HKO	;	1.2	;	Crystal structure of ABC transporter Solute Binding Protein MSMEG_3598 from Mycobacterium smegmatis str. MC2 155, target EFI-510969, in complex with L-sorbitol
4NE4	;	1.73	;	Crystal structure of ABC transporter substrate binding protein ProX from Agrobacterium tumefaciens cocrystalized with BTB
4WED	;	2.35	;	Crystal structure of ABC transporter substrate-binding protein from Sinorhizobium meliloti
4Q6B	;	1.667	;	Crystal Structure of ABC Transporter Substrate-Binding Protein fromDesulfitobacterium hafniense complex with Leu
4R6K	;	1.94	;	Crystal structure of ABC transporter substrate-binding protein YesO from Bacillus subtilis, TARGET EFI-510761, an open conformation
5ER3	;	2.105	;	Crystal structure of ABC transporter system solute-binding protein from Rhodopirellula baltica SH 1
4PEV	;	2.58	;	Crystal structure of ABC transporter system solute-binding proteins from Aeropyrum pernix K1
2PCL	;	1.7	;	Crystal structure of ABC transporter with complex (aq_297) from aquifex aeolicus VF5
3LVU	;	1.79	;	Crystal structure of ABC transporter, periplasmic substrate-binding protein SPO2066 from Silicibacter pomeroyi
3EAF	;	2.0	;	Crystal structure of ABC transporter, substrate binding protein Aeropyrum pernix
2FFA	;	1.7	;	Crystal structure of ABC-ATPase H662A of the ABC-transporter HlyB in complex with ADP
5CR9	;	1.7	;	Crystal structure of ABC-type Fe3+-hydroxamate transport system from Saccharomonospora viridis DSM 43017
3L6U	;	1.9	;	Crystal structure of abc-type sugar transport system, Periplasmic component from exiguobacterium sibiricum
3KSM	;	1.9	;	Crystal structure of ABC-type sugar transport system, periplasmic component from Hahella chejuensis
2PWW	;	1.82	;	Crystal structure of ABC2387 from Bacillus clausii
3OZX	;	2.05	;	Crystal structure of ABCE1 of Sulfolubus solfataricus (-FeS domain)
8CUB	;	4.05	;	Crystal Structure of ABCG5/G8 in Complex with Cholesterol
4HBL	;	2.5	;	Crystal structure of AbfR of Staphylococcus epidermidis
7CGU	;	2.4	;	Crystal Structure of AbHAR
8H8Y	;	1.55	;	Crystal structure of AbHheG from Acidimicrobiia bacterium
8HQP	;	1.62	;	Crystal structure of AbHheG mutant from Acidimicrobiia bacterium
7ETA	;	1.9	;	Crystal structure of AbHpaI-Co-pyruvate complex, Class II aldolase, HpaI from Acinetobacter baumannii
7ETG	;	1.9	;	Crystal structure of AbHpaI-Co-pyruvate-succinic semialdehyde complex, Class II aldolase, HpaI from Acinetobacter baumannii
7ETE	;	1.9	;	Crystal structure of AbHpaI-Mg-(4R)-KDGal complex, Class II aldolase, HpaI from Acinetobacter baumannii
7ETB	;	1.85	;	Crystal structure of AbHpaI-Mn-pyruvate complex, Class II aldolase, HpaI from Acinetobacter baumannii
7ETF	;	2.0	;	Crystal structure of AbHpaI-Mn-pyruvate-succinic semialdehyde complex, Class II aldolase, HpaI from Acinetobacter baumannii
7ETC	;	1.95	;	Crystal structure of AbHpaI-Zn-(4R)-KDGal complex, Class II aldolase, HpaI from Acinetobacter baumannii
7ETD	;	1.9	;	Crystal structure of AbHpaI-Zn-(4S)-KDGlu complex, Class II aldolase, HpaI from Acinetobacter baumannii
7ET9	;	1.9	;	Crystal structure of AbHpaI-Zn-pyruvate complex, Class II aldolase, HpaI from Acinetobacter baumannii
7ETI	;	1.95	;	Crystal structure of AbHpaI-Zn-pyruvate-4-hydroxybenzaldehyde complex, Class II aldolase, HpaI from Acinetobacter baumannii
7ETH	;	2.2	;	Crystal structure of AbHpaI-Zn-pyruvate-propionaldehyde complex, Class II aldolase, HpaI from Acinetobacter baumannii
6N6S	;	3.0	;	Crystal structure of ABIN-1 UBAN
6N5M	;	3.01	;	Crystal structure of ABIN-1 UBAN in complex with one M1-linked di-ubiquitin
6N6R	;	1.95	;	Crystal structure of ABIN-1 UBAN in complex with two M1-linked di-ubiquitins
2QOH	;	1.95	;	Crystal Structure of Abl kinase bound with PPY-A
3OXZ	;	2.2	;	Crystal structure of ABL kinase domain bound with a DFG-out inhibitor AP24534
1FPU	;	2.4	;	CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
3OY3	;	1.95	;	Crystal structure of ABL T315I mutant kinase domain bound with a DFG-out inhibitor AP24589
5HU9	;	1.529	;	Crystal structure of ABL1 in complex with CHMFL-074
4XLI	;	2.5	;	Crystal structure of Abl2/Arg kinase in complex with dasatinib
6W6X	;	1.297	;	Crystal Structure of ABLE Apo-protein
5HO0	;	2.35	;	Crystal structure of AbnA (closed conformation), a GH43 extracellular arabinanase from Geobacillus stearothermophilus
5HO2	;	2.37	;	Crystal structure of AbnA (open conformation), a GH43 extracellular arabinanase from Geobacillus stearothermophilus
5HOF	;	2.96	;	Crystal structure of AbnA, a GH43 extracellular arabinanase from Geobacillus stearothermophilus, in complex with arabinopentaose
7DVI	;	2.0	;	Crystal Structure of AbnU: An exo-specific intermolecular Diels-Alderase
4NZF	;	2.19	;	Crystal structure of Abp-D197A (a GH27-b-L-arabinopyranosidase from Geobacillus stearothermophilus), in complex with arabinose
4NXK	;	2.3	;	Crystal structure of Abp-D197A, a catalytic mutant of a GH27-b-L-arabinopyranosidase from Geobacillus stearothermophilus
4NX0	;	2.28	;	Crystal structure of Abp-WT, a GH27-b-L-arabinopyranosidase from Geobacillus stearothermophilus
5Z37	;	1.3	;	Crystal Structure of Abrin A chain (Recombinant) at 1.3 Angstroms
5Z3I	;	1.65	;	Crystal Structure of Abrin A chain (Recombinant) in complex with Adenine at 1.65 Angstroms
5Z3J	;	1.7	;	Crystal Structure of Abrin A chain (Recombinant) in complex with Nicotinamide at 1.7 Angstroms
1ABR	;	2.14	;	CRYSTAL STRUCTURE OF ABRIN-A
3ZMD	;	1.95	;	Crystal structure of AbsC, a MarR family transcriptional regulator from Streptomyces coelicolor
3UJL	;	2.5	;	Crystal structure of abscisic acid bound PYL2 in complex with type 2C protein phosphatase ABI2
3KAY	;	2.4	;	Crystal structure of abscisic acid receptor PYL1
3KAZ	;	1.85	;	Crystal structure of abscisic acid receptor PYL2
3KL1	;	1.55	;	Crystal structure of abscisic acid receptor PYL2 at 1.55 A
5JNN	;	2.3	;	Crystal structure of abscisic acid receptor PYL2 in complex with Phaseic acid.
5JO2	;	2.42	;	Crystal structure of abscisic acid-bound abscisic acid receptor PYL3 in complex with type 2C protein phosphatase HAB1
3R6P	;	2.7	;	Crystal structure of abscisic acid-bound PYL10
3KB0	;	1.95	;	Crystal structure of abscisic acid-bound PYL2
3KB3	;	1.95	;	Crystal structure of abscisic acid-bound PYL2 in complex with HAB1
2JIX	;	3.2	;	Crystal structure of ABT-007 FAB fragment with the soluble domain of EPO receptor
5Z6D	;	1.6	;	Crystal structure of Abundant Perithecial Protein (APP) from Neurospora crassa
5CO5	;	2.1	;	Crystal structure of Ac-AChBP in complex with conotoxin GIC
6SH0	;	2.5	;	Crystal structure of AcAChBP in complex with anatoxin
6SGV	;	2.6	;	Crystal structure of AcAChBP in complex with hosieine
1F2K	;	2.3	;	CRYSTAL STRUCTURE OF ACANTHAMOEBA CASTELLANII PROFILIN II, CUBIC CRYSTAL FORM
2B8P	;	2.55	;	Crystal structure of Acanthamoeba polyphaga mimivirus NDK, the first viral nucleoside diphosphate kinase
3EE3	;	2.4	;	Crystal structure of Acanthamoeba polyphaga mimivirus nucleoside diphosphate kinase complexed with CDP
3B6B	;	2.0	;	Crystal structure of Acanthamoeba polyphaga mimivirus nucleoside diphosphate kinase complexed with dGDP
5XC3	;	1.497	;	Crystal structure of Acanthamoeba polyphaga mimivirus Rab GTPase in complex with GDP
5XC5	;	1.398	;	Crystal structure of Acanthamoeba polyphaga mimivirus Rab GTPase in complex with GTP
3T9K	;	2.3	;	Crystal Structure of ACAP1 C-portion mutant S554D fused with integrin beta1 peptide
6BJ9	;	1.53014	;	Crystal structure of Acat2 thiolase from Ascaris suum
6BJB	;	1.50001	;	Crystal structure of Acat2-C91S thiolase from Ascaris suum in complex with propionyl-CoA and nitrate
6BJA	;	1.60001	;	Crystal structure of Acat5 thiolase from Ascaris suum in complex with coenzyme A
2FDQ	;	3.5	;	crystal structure of ACBP from Armadillo Harderian Gland
3FP5	;	1.61	;	Crystal structure of ACBP from Moniliophthora perniciosa
1RQX	;	2.5	;	Crystal structure of ACC Deaminase complexed with Inhibitor
1TZM	;	2.08	;	Crystal structure of ACC deaminase complexed with substrate analog b-chloro-D-alanine
1IAY	;	2.7	;	CRYSTAL STRUCTURE OF ACC SYNTHASE COMPLEXED WITH COFACTOR PLP AND INHIBITOR AVG
1IAX	;	2.8	;	CRYSTAL STRUCTURE OF ACC SYNTHASE COMPLEXED WITH PLP
2BZR	;	2.2	;	Crystal structure of accD5 (Rv3280), an acyl-CoA carboxylase beta- subunit from Mycobacterium tuberculosis
5VAF	;	2.771	;	Crystal structure of accessory secretion protein 1
5VAE	;	3.106	;	Crystal structure of accessory secretion protein 1 and 3
6LNW	;	2.9	;	Crystal structure of accessory secretory protein 1,2 and 3 in Streptococcus pneumoniae
2OKM	;	1.65	;	Crystal structure of ACE19, the collagen binding subdomain of Enterococcus faecalis surface protein ACE
6WBR	;	2.91	;	Crystal structure of AceCas9 bound with guide RNA and DNA with 5'-NNNCC-3' PAM
6WC0	;	3.61	;	Crystal structure of AceCas9 bound with guide RNA and DNA with 5'-NNNTC-3' PAM
2II1	;	1.95	;	Crystal structure of Acetamidase (10172637) from Bacillus Halodurans at 1.95 A resolution
3S1Z	;	2.0547	;	Crystal structure of acetamide bound Xanthomonas campestri OleA
1K6D	;	1.9	;	CRYSTAL STRUCTURE OF ACETATE COA-TRANSFERASE ALPHA SUBUNIT
4DQ8	;	2.25	;	Crystal structure of acetate kinase AckA from Mycobacterium marinum
4H0P	;	1.894	;	Crystal Structure of Acetate Kinase from Cryptococcus neoformans
4H0O	;	2.4	;	Crystal Structure of Acetate Kinase from Entamoeba histolytica
3P4I	;	2.35	;	Crystal structure of acetate kinase from Mycobacterium avium
3S1J	;	1.8	;	Crystal structure of acetate-bound hell's gate globin I
6LP1	;	2.01	;	Crystal structure of acetate:succinate CoA transferase (ASCT) from Trypanosoma brucei.
3C8W	;	1.6	;	Crystal structure of acetoacetate decarboxylase (ADC) (YP_094708.1) from Legionella pneumophila subsp. pneumophila str. Philadelphia 1 at 1.60 A resolution
3CMB	;	1.6	;	Crystal structure of acetoacetate decarboxylase (YP_001047042.1) from Methanoculleus marisnigri JR1 at 1.60 A resolution
3BH3	;	2.1	;	Crystal structure of acetoacetate decarboxylase from Chromobacterium violaceum in complex with acetyl acetone Schiff base intermediate
3EZL	;	2.25	;	Crystal Structure of Acetoacetyl-CoA Reductase from Burkholderia Pseudomallei 1710b
3GK3	;	2.1	;	Crystal structure of acetoacetyl-CoA reductase from Burkholderia pseudomallei 1710b
5VT6	;	1.7	;	Crystal structure of Acetoacetyl-CoA Reductase from Burkholderia pseudomallei 1710b complexed with NADP
5VML	;	1.7	;	Crystal Structure of Acetoacetyl-CoA Reductase from Burkholderia Pseudomallei 1710b with bound NADP
4KMS	;	2.0	;	Crystal structure of Acetoacetyl-CoA reductase from Rickettsia felis
4E1L	;	2.0	;	Crystal structure of Acetoacetyl-CoA thiolase (thlA2) from Clostridium difficile
5AHK	;	1.55	;	Crystal structure of acetohydroxy acid synthase Pf5 from Pseudomonas protegens
6UX3	;	2.198	;	Crystal structure of acetoin dehydrogenase from Enterobacter cloacae
6WON	;	2.13	;	Crystal structure of acetoin dehydrogenase YohF from Salmonella typhimurium
2Q04	;	2.33	;	Crystal structure of acetoin utilization protein (ZP_00540088.1) from Exiguobacterium sibiricum 255-15 at 2.33 A resolution
6J3D	;	1.7	;	Crystal structure of acetolactate decarboxylase from Bacillus subtilis subspecies spizizenii in space group P21212
6J92	;	2.421	;	Crystal structure of acetolactate decarboxylase from Enterbacter aerogenes
5YHO	;	2.401	;	Crystal structure of acetolactate decarboxylase from Enterobacter cloacae
2FGC	;	2.3	;	Crystal structure of Acetolactate synthase- small subunit from Thermotoga maritima
6A6O	;	1.8	;	Crystal structure of acetyl ester-xyloside bifunctional hydrolase from Caldicellulosiruptor lactoaceticus
5B5L	;	1.4	;	Crystal structure of acetyl esterase mutant S10A with acetate ion
1VLQ	;	2.1	;	Crystal structure of Acetyl xylan esterase (TM0077) from Thermotoga maritima at 2.10 A resolution
3M83	;	2.12	;	Crystal structure of Acetyl xylan esterase (TM0077) from THERMOTOGA MARITIMA at 2.12 A resolution (paraoxon inhibitor complex structure)
3M82	;	2.4	;	Crystal structure of Acetyl xylan esterase (TM0077) from THERMOTOGA MARITIMA at 2.40 A resolution (PMSF inhibitor complex structure)
3M81	;	2.5	;	Crystal structure of Acetyl xylan esterase (TM0077) from THERMOTOGA MARITIMA at 2.50 A resolution (native apo structure)
3FCY	;	2.1	;	Crystal Structure of Acetyl Xylan Esterase 1 from Thermoanaerobacterium sp. JW/SL YS485
3FYU	;	2.62	;	Crystal structure of acetyl xylan esterase from Bacillus pumilus obtained in presence of D-xylose and sodium acetate
3FVR	;	2.5	;	Crystal Structure of Acetyl Xylan Esterase from Bacillus pumilus, monoclinic crystal form I
3FVT	;	1.9	;	Crystal Structure of Acetyl Xylan Esterase from Bacillus pumilus, monoclinic crystal form II
6BN2	;	1.65	;	Crystal structure of Acetyl-CoA acetyltransferase from Elizabethkingia anophelis NUHP1
3SVK	;	2.2	;	Crystal structure of Acetyl-CoA acetyltransferase from Mycobacterium avium
1YTL	;	1.8	;	Crystal Structure of Acetyl-CoA decarboxylase/synthase complex epsilon subunit 2
8W0M	;	3.1	;	Crystal structure of Acetyl-CoA synthetase 2 from Candida albicans in complex with a Acetyl Sulfamate AMP ester inhibitor
8W0C	;	2.35	;	Crystal structure of Acetyl-CoA synthetase 2 from Candida albicans in complex with a cyclopentyl ester AMP inhibitor
8W0B	;	2.3	;	Crystal structure of Acetyl-CoA synthetase 2 from Candida albicans in complex with a cyclopropyl AMP ester inhibitor
8W0J	;	2.85	;	Crystal structure of Acetyl-CoA synthetase 2 from Candida albicans in complex with a propyne AMP ester inhibitor
8W0L	;	2.75	;	Crystal structure of Acetyl-CoA synthetase 2 from Candida albicans in complex with a propyne AMP ester inhibitor and CoA
8W0D	;	2.7	;	Crystal structure of Acetyl-CoA synthetase 2 from Candida albicans in complex with an isopropyl AMP ester inhibitor
8W0H	;	2.95	;	Crystal structure of Acetyl-CoA synthetase 2 from Candida albicans in complex with an isopropyl AMP ester inhibitor (trigonal form)
8V4P	;	2.3	;	Crystal structure of Acetyl-CoA synthetase 2 in complex with Adenosine-5'-allylphosphate from Candida albicans
7KDS	;	2.9	;	Crystal structure of Acetyl-CoA synthetase 2 in complex with Adenosine-5'-propylphosphate from Candida albicans
8V4R	;	2.7	;	Crystal structure of Acetyl-CoA synthetase 2 in complex with AMP and CoA from Candida albicans
8V4O	;	2.7	;	Crystal structure of Acetyl-CoA synthetase 2 in complex with AMP from Candida albicans
8V5G	;	2.5	;	Crystal Structure of Acetyl-CoA synthetase from Cryptococcus neoformans H99 in complex with an ethylsulfamide AMP inhibitor
8G0R	;	2.6	;	Crystal Structure of Acetyl-CoA synthetase in complex with a cyclopentyl ester AMP inhibitor from Cryptococcus neoformans H99
8G0S	;	2.9	;	Crystal Structure of Acetyl-CoA synthetase in complex with a cyclopentyl ester AMP inhibitor from Cryptococcus neoformans H99 (tetragonal form)
8G0T	;	2.45	;	Crystal Structure of Acetyl-CoA synthetase in complex with a cyclopropyl ester AMP inhibitor from Cryptococcus neoformans H99
8G0V	;	1.9	;	Crystal Structure of Acetyl-CoA synthetase in complex with a propyne ester AMP inhibitor from Cryptococcus neoformans H99
7L4G	;	2.2	;	Crystal Structure of Acetyl-CoA synthetase in complex with acetyl adenylate from Cryptococcus neoformans H99
7KNP	;	2.25	;	Crystal structure of Acetyl-CoA synthetase in complex with adenosine-5'-butylphosphate from Cryptococcus neoformans var. grubii serotype A (H99)
7KVY	;	1.9	;	Crystal Structure of Acetyl-CoA synthetase in complex with adenosine-5'-ethylphosphate and Co-enzyme A from Coccidioides immitis RS
7L3P	;	2.1	;	Crystal Structure of Acetyl-CoA synthetase in complex with adenosine-5'-ethylphosphate and Co-enzyme A from Coccidioides immitis RS
7KQZ	;	2.15	;	Crystal Structure of Acetyl-CoA synthetase in complex with adenosine-5'-ethylphosphate from Coccidioides immitis RS
7KNO	;	1.8	;	Crystal structure of Acetyl-CoA synthetase in complex with adenosine-5'-ethylphosphate from Cryptococcus neoformans var. grubii serotype A (H99)
7L3Q	;	2.15	;	Crystal Structure of Acetyl-CoA synthetase in complex with adenosine-5'-methylphosphate and Co-enzyme A from Coccidioides immitis RS
5K85	;	2.3	;	Crystal Structure of Acetyl-CoA Synthetase in Complex with Adenosine-5'-propylphosphate and Coenzyme A from Cryptococcus neoformans H99
7KDN	;	2.8	;	Crystal structure of Acetyl-CoA Synthetase in Complex with Adenosine-5'-propylphosphate from Aspergillus fumigatus
7KCP	;	2.15	;	Crystal structure of Acetyl-CoA Synthetase in Complex with Adenosine-5'-propylphosphate from Coccidioides posadasii C735
5IFI	;	1.95	;	CRYSTAL STRUCTURE OF ACETYL-COA SYNTHETASE IN COMPLEX WITH ADENOSINE-5'-PROPYLPHOSPHATE FROM CRYPTOCOCCUS NEOFORMANS H99
8EPS	;	2.65	;	Crystal Structure of Acetyl-CoA synthetase in complex with an allyl ester AMP inhibitor from Cryptococcus neoformans H99
8G0U	;	1.9	;	Crystal Structure of Acetyl-CoA synthetase in complex with an isopropyl ester AMP inhibitor from Cryptococcus neoformans H99
5K8F	;	2.45	;	Crystal structure of Acetyl-CoA Synthetase in complex with ATP and Acetyl-AMP from Cryptococcus neoformans H99
7KQ6	;	1.8	;	Crystal Structure of Acetyl-coenzyme A synthetase from Coccidioides immitis in complex with PRX
7MMZ	;	2.4	;	Crystal Structure of Acetyl-coenzyme A synthetase from Legionella pneumophila Philadelphia 1 in complex with ethyl-AMP
8SF3	;	1.7	;	Crystal Structure of Acetyl-coenzyme A synthetase from Leishmania infantum (AMP, Acetate and CoA bound)
8U2T	;	1.65	;	Crystal Structure of Acetyl-coenzyme A synthetase from Leishmania infantum (CoA and AMP bound)
8U2U	;	1.97	;	Crystal Structure of Acetyl-coenzyme A synthetase from Leishmania infantum (CoA, AMP and potassium bound)
8U2R	;	1.55	;	Crystal Structure of Acetyl-coenzyme A synthetase from Leishmania infantum (Ethyl AMP bound)
8U2S	;	2.52	;	Crystal Structure of Acetyl-coenzyme A synthetase from Leishmania infantum (Ethyl AMP bound, P21 form)
4EZ1	;	2.49	;	Crystal structure of acetylcholine binding protein (AChBP) from Aplysia Californica in complex with alpha-conotoxin BuIA
2C9T	;	2.25	;	Crystal Structure Of Acetylcholine Binding Protein (AChBP) From Aplysia Californica In Complex With alpha-Conotoxin ImI
5JME	;	2.336	;	Crystal structure of acetylcholine binding protein (AChBP) from Aplysia Californica in complex with alpha-conotoxin PeIA
4WV9	;	2.0	;	Crystal structure of acetylcholine binding protein (AChBP) from Aplysia Californica in complex with click chemistry compound (3-exo)-8,8-dimethyl-3-[4-(pyridin-4-yl)-1H-1,2,3-triazol-1-yl]-8-azoniabicyclo[3.2.1]octane
3PEO	;	2.1	;	Crystal structure of acetylcholine binding protein complexed with metocurine
3RQW	;	2.913	;	Crystal structure of acetylcholine bound to a prokaryotic pentameric ligand-gated ion channel, ELIC
3WIP	;	2.6	;	Crystal structure of acetylcholine bound to Ls-AChBP
2BR8	;	2.4	;	Crystal Structure of Acetylcholine-binding Protein (AChBP) from Aplysia californica in complex with an alpha-conotoxin PnIA variant
2BR7	;	3.0	;	Crystal Structure of Acetylcholine-binding Protein (AChBP) from Aplysia californica in complex with HEPES
5X61	;	3.4	;	Crystal structure of Acetylcholinesterase Catalytic Subunit of the Malaria Vector Anopheles Gambiae, 3.4 A
5YDH	;	3.21	;	Crystal structure of acetylcholinesterase catalytic subunits of the malaria vector anopheles gambiae, 3.2 A
5YDI	;	3.45	;	Crystal structure of acetylcholinesterase catalytic subunits of the malaria vector anopheles gambiae, new crystal packing
5OV9	;	2.4	;	Crystal structure of Acetylcholinesterase in complex with Crystal Violet
2WHR	;	2.545	;	Crystal structure of acetylcholinesterase in complex with K027
3ZLT	;	2.6	;	Crystal structure of acetylcholinesterase in complex with RVX
3M3D	;	2.34	;	Crystal structure of Acetylcholinesterase in complex with Xenon
2WHQ	;	2.15	;	Crystal structure of acetylcholinesterase, phosphonylated by sarin (aged) in complex with HI-6
2WHP	;	2.2	;	Crystal structure of acetylcholinesterase, phosphonylated by sarin and in complex with HI-6
2AP9	;	2.8	;	Crystal structure of acetylglutamate kinase from Mycobacterium tuberculosis CDC1551
3NX3	;	1.8	;	Crystal structure of acetylornithine aminotransferase (argD) from Campylobacter jejuni
2ORD	;	1.4	;	Crystal structure of Acetylornithine aminotransferase (EC 2.6.1.11) (ACOAT) (TM1785) from Thermotoga maritima at 1.40 A resolution
8HT4	;	2.51	;	Crystal structure of Acetylornithine aminotransferase complex with PLP from Corynebacterium glutamicum
2EH6	;	1.9	;	Crystal structure of acetylornithine aminotransferase from Aquifex aeolicus VF5
8HT2	;	2.65	;	Crystal structure of Acetylornithine aminotransferase from Corynebacterium glutamicum
5VIU	;	1.65	;	Crystal Structure of Acetylornithine Aminotransferase from Elizabethkingia anophelis
2E54	;	1.5	;	Crystal structure of acetylornithine aminotransferase from Thermotoga maritima
3KZK	;	1.9	;	Crystal structure of acetylornithine transcarbamylase complexed with acetylcitrulline
4ZUO	;	1.33	;	Crystal structure of acetylpolyamine amidohydrolase from Mycoplana ramosa in complex with a hydroxamate inhibitor
4ZUP	;	1.421	;	Crystal structure of acetylpolyamine amidohydrolase from Mycoplana ramosa in complex with a hydroxamate inhibitor
4ZUQ	;	1.22	;	Crystal structure of acetylpolyamine amidohydrolase from Mycoplana ramosa in complex with a hydroxamate inhibitor
4ZUR	;	1.13	;	Crystal structure of acetylpolyamine amidohydrolase from Mycoplana ramosa in complex with a hydroxamate inhibitor
4ZUN	;	1.4	;	Crystal structure of acetylpolyamine amidohydrolase from Mycoplana ramosa in complex with a thiol inhibitor
4ZUM	;	1.42	;	Crystal structure of acetylpolyamine amidohydrolase from Mycoplana ramosa in complex with a trifluoromethylketone inhibitor
3MEN	;	2.2	;	Crystal structure of acetylpolyamine aminohydrolase from Burkholderia pseudomallei, iodide soak
2I00	;	2.3	;	Crystal structure of acetyltransferase (GNAT family) from Enterococcus faecalis
2Q7B	;	2.0	;	Crystal structure of acetyltransferase (NP_689019.1) from Streptococcus agalactiae 2603 at 2.00 A resolution
8F4U	;	1.91	;	Crystal structure of acetyltransferase Eis from M. tuberculosis in complex with azelastine
8F4A	;	2.41	;	Crystal structure of acetyltransferase Eis from M. tuberculosis in complex with chlorhexidine
8F4Z	;	2.1	;	Crystal structure of acetyltransferase Eis from M. tuberculosis in complex with chloroquine
8F57	;	2.42	;	Crystal structure of acetyltransferase Eis from M. tuberculosis in complex with inhibitor SGT1615
8F58	;	2.3	;	Crystal structure of acetyltransferase Eis from M. tuberculosis in complex with inhibitor SGT1616
8F51	;	2.35	;	Crystal structure of acetyltransferase Eis from M. tuberculosis in complex with mefloquine
8F4T	;	1.93	;	Crystal structure of acetyltransferase Eis from M. tuberculosis in complex with proguanil
8F4W	;	2.1	;	Crystal structure of acetyltransferase Eis from M. tuberculosis in complex with venlafaxine
3R1K	;	1.95	;	Crystal structure of acetyltransferase Eis from Mycobacterium tuberculosis H37Rv in complex with CoA and an acetamide moiety
8F55	;	2.2	;	Crystal structure of acetyltransferase Eis from Mycobacterium tuberculosis H37Rv in complex with inhibitor SGT1614
6B3T	;	2.4	;	Crystal structure of acetyltransferase Eis from Mycobacterium tuberculosis in complex with a 1,2,4-triazino[5,6b]indole-3-thioether inhibitor analogue 39b
6B0U	;	2.8	;	Crystal structure of acetyltransferase Eis from Mycobacterium tuberculosis in complex with a Lys-containing peptide
5TVJ	;	2.3	;	Crystal structure of acetyltransferase Eis from Mycobacterium tuberculosis in complex with CoA and inhibitor 2k*: 1-(4-fluorophenyl)-2-[2-(4-methylphenyl)-2-oxoethyl]pyrrolo[1,2-a]pyrazin-2-ium
6X6G	;	2.15	;	Crystal structure of acetyltransferase Eis from Mycobacterium tuberculosis in complex with droperidol
6X10	;	2.03	;	Crystal structure of acetyltransferase Eis from Mycobacterium tuberculosis in complex with haloperidol
5EBV	;	2.2	;	Crystal structure of acetyltransferase Eis from Mycobacterium tuberculosis in complex with inhibitor 11c and CoA
5EC4	;	2.21	;	Crystal structure of acetyltransferase Eis from Mycobacterium tuberculosis in complex with inhibitor 13g and CoA
6X6Y	;	2.5	;	Crystal structure of acetyltransferase Eis from Mycobacterium tuberculosis in complex with inhibitor SGT1264
8D1R	;	2.19	;	Crystal structure of acetyltransferase Eis from Mycobacterium tuberculosis in complex with inhibitor SGT520
8D23	;	2.14	;	Crystal structure of acetyltransferase Eis from Mycobacterium tuberculosis in complex with inhibitor SGT529
8D25	;	2.05	;	Crystal structure of acetyltransferase Eis from Mycobacterium tuberculosis in complex with inhibitor SGT530
6X6I	;	1.904	;	Crystal structure of acetyltransferase Eis from Mycobacterium tuberculosis in complex with inhibitor SGT543
6X7A	;	2.08	;	Crystal structure of acetyltransferase Eis from Mycobacterium tuberculosis in complex with inhibitor SGT572
3N7Z	;	2.75	;	Crystal structure of acetyltransferase from Bacillus anthracis
3EXN	;	1.8	;	Crystal structure of acetyltransferase from Thermus thermophilus HB8
2PC1	;	1.28	;	Crystal structure of acetyltransferase GNAT family (NP_688560.1) from Streptococcus agalactiae 2603 at 1.28 A resolution
3BLN	;	1.31	;	Crystal structure of acetyltransferase GNAT family (NP_981174.1) from Bacillus cereus ATCC 10987 at 1.31 A resolution
2OH1	;	1.46	;	Crystal structure of acetyltransferase GNAT family (YP_013287.1) from Listeria monocytogenes 4b F2365 at 1.46 A resolution
3D8P	;	2.2	;	Crystal structure of acetyltransferase of GNAT family (NP_373092.1) from STAPHYLOCOCCUS AUREUS MU50 at 2.20 A resolution
2AE6	;	2.19	;	Crystal Structure of Acetyltransferase of GNAT family from Enterococcus faecalis V583
5TSF	;	2.286	;	Crystal structure of AChBP from Aplysia californica complex with 2-aminopyrimidine at pH 7.0 spacegroup P212121
5TVH	;	2.4	;	Crystal structure of AChBP from Aplysia californica complex with 2-aminopyrimidine at pH 8.0 spacegroup P21
2BYS	;	2.05	;	CRYSTAL STRUCTURE OF ACHBP FROM APLYSIA CALIFORNICA IN complex with lobeline
2BYR	;	2.45	;	CRYSTAL STRUCTURE OF ACHBP FROM APLYSIA CALIFORNICA in complex with methyllycaconitine
2BJ0	;	2.0	;	Crystal Structure of AChBP from Bulinus truncatus revals the conserved structural scaffold and sites of variation in nicotinic acetylcholine receptors
4MGU	;	3.5	;	Crystal structure of Acheta domesticus Densovirus
2Y1A	;	1.95	;	Crystal structure of Achromobacter cycloclastes Cu nitrite reductase with bound NO
2VYC	;	2.4	;	Crystal Structure of Acid Induced Arginine Decarboxylase from E. coli
7F17	;	2.8	;	Crystal Structure of acid phosphatase
2P4U	;	1.9	;	Crystal structure of acid phosphatase 1 (Acp1) from Mus musculus
1D2T	;	1.9	;	CRYSTAL STRUCTURE OF ACID PHOSPHATASE FROM ESCHERICHIA BLATTAE
1EOI	;	2.4	;	CRYSTAL STRUCTURE OF ACID PHOSPHATASE FROM ESCHERICHIA BLATTAE COMPLEXED WITH THE TRANSITION STATE ANALOG MOLYBDATE
3GXP	;	2.2	;	Crystal structure of acid-alpha-galactosidase A complexed with galactose at pH 4.5
3GXM	;	2.2	;	Crystal structure of acid-beta-glucosidase at pH 4.5, phosphate crystallization condition
3GXI	;	1.84	;	Crystal structure of acid-beta-glucosidase at pH 5.5
3GXF	;	2.4	;	Crystal structure of acid-beta-glucosidase with isofagomine at neutral pH
4FZ1	;	3.359	;	Crystal structure of acid-sensing ion channel in complex with psalmotoxin 1 at high pH
4FZ0	;	2.8	;	Crystal structure of acid-sensing ion channel in complex with psalmotoxin 1 at low pH
5B43	;	2.8	;	Crystal structure of Acidaminococcus sp. Cpf1 in complex with crRNA and target DNA
1IJL	;	2.6	;	Crystal structure of acidic phospholipase A2 from deinagkistrodon acutus
1SFP	;	1.9	;	CRYSTAL STRUCTURE OF ACIDIC SEMINAL FLUID PROTEIN (ASFP) AT 1.9 A RESOLUTION: A BOVINE POLYPEPTIDE FROM THE SPERMADHESIN FAMILY
7D18	;	1.332	;	Crystal structure of Acidobacteriales bacterium glutaminyl cyclase
7BYU	;	2.206	;	Crystal structure of Acidovorax avenae L-fucose mutarotase (apo form)
7BYW	;	1.75	;	Crystal structure of Acidovorax avenae L-fucose mutarotase (L-fucose-bound form)
4MEB	;	2.0	;	Crystal structure of aCif-D158S
3UE3	;	2.3	;	Crystal structure of Acinetobacter baumanni PBP3
4FUV	;	2.151	;	Crystal Structure of Acinetobacter baumannii CarO
4RL9	;	2.7	;	Crystal structure of Acinetobacter baumannii CarO1
4RLB	;	2.7	;	Crystal structure of Acinetobacter baumannii CarO2
4P3Y	;	2.154	;	Crystal structure of Acinetobacter baumannii DsbA in complex with EF-Tu
6T60	;	1.66	;	Crystal structure of Acinetobacter baumannii FabG at 1.66 A resolution
6T62	;	1.8	;	Crystal structure of Acinetobacter baumannii FabG in complex with NADPH at 1.8 A resolution
7UMX	;	2.39	;	Crystal structure of Acinetobacter baumannii FabI in complex with NAD and (R,E)-3-(7-amino-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)acrylamide
7UMY	;	2.74	;	Crystal structure of Acinetobacter baumannii FabI in complex with NAD and Fabimycin ((S,E)-3-(7-amino-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)acrylamide)
8XKG	;	1.6	;	Crystal structure of Acinetobacter baumannii IspD
7W19	;	1.9	;	Crystal Structure of Acinetobacter baumannii MPH-E
7D1I	;	3.487	;	Crystal structure of acinetobacter baumannii MurG
4B4U	;	1.45	;	Crystal structure of Acinetobacter baumannii N5, N10- methylenetetrahydrofolate dehydrogenase-cyclohydrolase (FolD) complexed with NADP cofactor
4B4W	;	2.0	;	Crystal structure of Acinetobacter baumannii N5, N10- methylenetetrahydrofolate dehydrogenase-cyclohydrolase (FolD) complexed with NADP cofactor and an inhibitor
4B4V	;	2.0	;	Crystal structure of Acinetobacter baumannii N5, N10- methylenetetrahydrofolate dehydrogenase-cyclohydrolase (FolD) complexed with NADP cofactor and inhibitor LY354899
5DL5	;	2.05	;	Crystal structure of Acinetobacter baumannii OccAB1
5DL6	;	2.9	;	Crystal structure of Acinetobacter baumannii OccAB2
5DL7	;	1.75	;	Crystal structure of Acinetobacter baumannii OccAB3
5DL8	;	2.2	;	Crystal structure of Acinetobacter baumannii OccAB4
3UE0	;	2.6	;	Crystal structure of Acinetobacter baumannii PBP1a in complex with Aztreonam
3UDX	;	2.5	;	Crystal structure of Acinetobacter baumannii PBP1a in complex with Imipenem
3UDI	;	2.6	;	Crystal structure of Acinetobacter baumannii PBP1a in complex with penicillin G
4JY7	;	1.9	;	Crystal structure of Acinetobacter baumannii Peptidyl-tRNA Hydrolase
5W5P	;	2.429	;	Crystal structure of Acinetobacter baumannii phage AM24 tailspike protein
7SHJ	;	2.13	;	Crystal structure of Acinetobacter baumannii ZnuA in the metal-free state
1EO2	;	2.25	;	CRYSTAL STRUCTURE OF ACINETOBACTER SP. ADP1 PROTOCATECHUATE 3,4-DIOXYGENASE
1EO9	;	2.0	;	CRYSTAL STRUCTURE OF ACINETOBACTER SP. ADP1 PROTOCATECHUATE 3,4-DIOXYGENASE AT PH < 7.0
1EOB	;	2.2	;	CRYSTAL STRUCTURE OF ACINETOBACTER SP. ADP1 PROTOCATECHUATE 3,4-DIOXYGENASE IN COMPLEX WITH 3,4-DIHYDROXYBENZOATE
1EOC	;	2.25	;	CRYSTAL STRUCTURE OF ACINETOBACTER SP. ADP1 PROTOCATECHUATE 3,4-DIOXYGENASE IN COMPLEX WITH 4-NITROCATECHOL
1EOA	;	2.15	;	CRYSTAL STRUCTURE OF ACINETOBACTER SP. ADP1 PROTOCATECHUATE 3,4-DIOXYGENASE IN COMPLEX WITH CYANIDE
4Q0P	;	1.93	;	Crystal structure of Acinetobacter sp. DL28 L-ribose isomerase in complex with L-ribose
4Q0Q	;	1.93	;	Crystal structure of Acinetobacter sp. DL28 L-ribose isomerase in complex with L-ribulose
4Q0S	;	1.93	;	Crystal structure of Acinetobacter sp. DL28 L-ribose isomerase in complex with ribitol
4Q0U	;	1.98	;	Crystal structure of Acinetobacter sp. DL28 L-ribose isomerase mutant E204Q in complex with L-ribose
4Q0V	;	1.98	;	Crystal structure of Acinetobacter sp. DL28 L-ribose isomerase mutant E204Q in complex with L-ribulose
1VR3	;	2.06	;	Crystal structure of Acireductone dioxygenase (13543033) from Mus musculus at 2.06 A resolution
7D95	;	1.67	;	Crystal structure of acivicin-bound GATase subunit of Methanocaldococcus jannaschii GMP synthetase
3FNM	;	1.7	;	Crystal structure of acivicin-inhibited gamma-glutamyltranspeptidase reveals critical roles for its C-terminus in autoprocessing and catalysis
4HZR	;	1.31	;	Crystal structure of Ack1 kinase domain
4HZS	;	3.23	;	Crystal structure of Ack1 kinase domain with C-terminal SH3 domain
8FE9	;	3.2	;	Crystal structure of Ack1 kinase K161Q mutant in complex with the selective inhibitor (R)-9b
5ZXB	;	2.198	;	Crystal structure of ACK1 with compound 10d
3EQR	;	2.0	;	Crystal Structure of Ack1 with compound T74
3EQP	;	2.3	;	Crystal Structure of Ack1 with compound T95
3R9P	;	1.9	;	Crystal structure of AckA from Mycobacterium paratuberculosis ATCC BAA-968 / K-10
1Q0Z	;	1.95	;	Crystal structure of aclacinomycin methylesterase (RdmC) with bound product analogue, 10-decarboxymethylaclacinomycin A (DcmA)
1Q0R	;	1.45	;	Crystal structure of aclacinomycin methylesterase (RdmC) with bound product analogue, 10-decarboxymethylaclacinomycin T (DcmaT)
2IPI	;	1.65	;	Crystal Structure of Aclacinomycin Oxidoreductase
1R00	;	2.5	;	Crystal structure of aclacinomycin-10-hydroxylase (RdmB) in complex with S-adenosyl-L-homocysteine (SAH)
1QZZ	;	2.1	;	Crystal structure of aclacinomycin-10-hydroxylase (RdmB) in complex with S-adenosyl-L-methionine (SAM)
1XDS	;	2.3	;	Crystal structure of Aclacinomycin-10-hydroxylase (RdmB) in complex with S-adenosyl-L-methionine (SAM) and 11-deoxy-beta-rhodomycin (DbrA)
1XDU	;	2.7	;	Crystal structure of Aclacinomycin-10-hydroxylase (RdmB) in complex with Sinefungin (SFG)
2GEY	;	1.8	;	Crystal Structure of AclR a putative hydroxylase from Streptomyces galilaeus
7BR0	;	2.003	;	Crystal structure of AclR, a thioredoxin oxidoreductase fold protein carrying the CXXH catalytic motif
3JW6	;	2.3	;	Crystal structure of AcMNPV baculovirus polyhedra
5DEZ	;	2.3	;	Crystal structure of AcMNPV Chitinase A
5DF0	;	3.251	;	Crystal structure of AcMNPV Chitinase A in complex WITH CHITOTRIO-THIAZOLINE DITHIOAMIDE
1B0J	;	2.5	;	CRYSTAL STRUCTURE OF ACONITASE WITH ISOCITRATE
1NIS	;	2.05	;	CRYSTAL STRUCTURE OF ACONITASE WITH TRANS-ACONITATE AND NITROCITRATE BOUND
1NIT	;	2.05	;	CRYSTAL STRUCTURE OF ACONITASE WITH TRANS-ACONITATE AND NITROCITRATE BOUND
1ACO	;	2.05	;	CRYSTAL STRUCTURE OF ACONITASE WITH TRANSACONITATE BOUND
3C05	;	1.7	;	Crystal structure of Acostatin from Agkistrodon Contortrix Contortrix
6YXM	;	2.85	;	Crystal structure of ACPA 1F2 in complex with CII-C-39-CIT
6YXK	;	2.0	;	Crystal structure of ACPA 3F3 in complex with cit-vimentin 59-74
5OD0	;	1.8	;	Crystal structure of ACPA E4
5OCK	;	1.6	;	Crystal structure of ACPA E4 in complex with CEP1
5OCX	;	1.75	;	Crystal structure of ACPA E4 in complex with CII-C-13-CIT
5OCY	;	2.6	;	Crystal structure of ACPA E4 in complex with CII-C-48-CIT
6ZJG	;	2.45	;	Crystal structure of ACPA E4 in complex with CII-C-48-CIT
6YXL	;	2.1	;	Crystal structure of ACPA F3
4K7Q	;	3.5	;	Crystal Structure of AcrB Complexed with Linezolid at 3.5 Resolution
4ZJQ	;	3.592	;	Crystal structure of AcrB deletion mutant in complex with antibiotic in P21 space group
4ZIW	;	3.399	;	Crystal structure of AcrB deletion mutant in P21 space group
7O3L	;	3.526	;	Crystal Structure of AcrB Double Mutant
4ZJL	;	3.47	;	Crystal structure of AcrB in complex with antibiotic in P21 space group
4ZIT	;	3.296	;	Crystal structure of AcrB in P21 space group
7O3M	;	3.551	;	Crystal Structure of AcrB Single Mutant - 1
7O3N	;	3.561	;	Crystal Structure of AcrB Single Mutant - 2
4ZJO	;	3.6	;	Crystal structure of AcrB triple mutant in complex with antibiotic in P21 space group
4ZIV	;	3.16	;	Crystal structure of AcrB triple mutant in P21 space group
4C48	;	3.3	;	Crystal structure of AcrB-AcrZ complex
4CDI	;	3.7	;	Crystal structure of AcrB-AcrZ complex
5NC5	;	3.2	;	Crystal structure of AcrBZ in complex with antibiotic puromycin
6IFO	;	3.313	;	Crystal structure of AcrIIA2-SpyCas9-sgRNA ternary complex
6JDJ	;	2.6	;	Crystal structure of AcrIIC2 dimer in complex with partial Nme1Cas9
6JDX	;	2.28	;	Crystal structure of AcrIIC2 dimer in complex with partial Nme1Cas9 preprocessed with protease alpha-Chymotrypsin
7XVQ	;	1.8	;	Crystal structure of AcrIIC4
7CI1	;	2.3	;	Crystal structure of AcrVA2
7CI2	;	2.8	;	Crystal structure of AcrVA2 in complex with partial MbCpf1
5GXE	;	1.696	;	Crystal structure of Acryloyl-CoA reductase AcuI in complex with NADPH
3D3Z	;	1.7	;	Crystal structure of Actibind a T2 RNase
3AA7	;	1.9	;	Crystal structure of Actin capping protein
3AAE	;	3.3	;	Crystal structure of Actin capping protein in complex with CARMIL fragment
3AA0	;	1.7	;	Crystal structure of Actin Capping Protein in complex with the Cp-binding motif derived from CARMIL
3AA6	;	1.9	;	Crystal structure of Actin capping protein in complex with the Cp-binding motif derived from CD2AP
3AA1	;	1.9	;	Crystal structure of Actin capping protein in complex with the Cp-binding motif derived from CKIP-1
7DS2	;	1.95	;	Crystal structure of actin capping protein in complex with twinflin-1 C-terminus tail
7DS4	;	1.85	;	Crystal structure of actin capping protein in complex with twinflin-1 C-terminus tail F323K mutant
7DS8	;	1.95	;	Crystal structure of actin capping protein in complex with twinflin-1/CD2AP CPI chimera peptide (CDN-TWC)
7DS6	;	1.69	;	Crystal structure of actin capping protein in complex with twinflin-1/CD2AP CPI chimera peptide (TWN-CDC)
7DS3	;	2.09	;	Crystal structure of actin capping protein in complex with twinflin-2 C-terminus tail
3AAA	;	2.2	;	Crystal Structure of Actin capping protein in complex with V-1
7DSA	;	2.8	;	Crystal structure of actin capping protein in complex with V-1 (space group P62)
7DSB	;	2.44	;	Crystal structure of actin capping protein in complex with V-1 and twinfilin C-terminal tail
1IZN	;	2.1	;	Crystal Structure of Actin Filament Capping Protein CapZ
3M6G	;	2.0	;	Crystal structure of actin in complex with lobophorolide
4K41	;	1.4	;	Crystal structure of actin in complex with marine macrolide kabiramide C
1YXQ	;	2.01	;	Crystal structure of actin in complex with swinholide A
4K43	;	2.9	;	Crystal structure of actin in complex with synthetic AplC tail analogue GC04 [N-{(1E,4R,5R,7E,9S,10S,11S)-4,10-dimethoxy-11-[(2S,4S,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl]-5,9-dimethyl-6-oxododeca-1,7-dien-1-yl}-N-methylformamide]
4K42	;	2.9	;	Crystal structure of actin in complex with synthetic AplC tail analogue SF01 [(3R,4S,5R,6S,10R,11R,12R)-11-(acetyloxy)-1-(benzyloxy)-14-[formyl(methyl)amino]-5-hydroxy-4,6,10,12-tetramethyl-9-oxotetradecan-3-yl propanoate]
1SH5	;	2.0	;	Crystal structure of actin-binding domain of mouse plectin
1SH6	;	2.0	;	Crystal structure of actin-binding domain of mouse plectin
5EC0	;	2.2	;	Crystal Structure of Actin-like protein Alp7A
3QB0	;	3.404	;	Crystal structure of Actin-related protein Arp4 from S. cerevisiae complexed with ATP
1AEC	;	1.86	;	CRYSTAL STRUCTURE OF ACTINIDIN-E-64 COMPLEX+
3A07	;	1.19	;	Crystal Structure of Actinohivin; Potent anti-HIV Protein
2VGJ	;	2.4	;	Crystal structure of Actinomadura R39 DD-peptidase complexed with a peptidoglycan-mimetic cephalosporin
2VGK	;	2.25	;	Crystal structure of Actinomadura R39 DD-peptidase complexed with a peptidoglycan-mimetic cephalosporin
3QDH	;	1.9	;	Crystal structure of Actinomyces fimbrial adhesin FimA
1A7Y	;	0.94	;	CRYSTAL STRUCTURE OF ACTINOMYCIN D
6J0H	;	1.52	;	Crystal structure of Actinomycin D- d(TTGGCGAA) complex
7DQ8	;	2.4	;	Crystal structure of actinomycin D-echinomycin-d(ACGCGCT/AGCTCGT) complex
7DQ0	;	2.0	;	Crystal structure of actinomycin D-echinomycin-d(ACGTGCT/AGCTCGT) complex
7X6R	;	1.89	;	Crystal structure of actinomycin D-echinomycin-d(AGCACGT/ACGGGCT) complex
7X97	;	1.95	;	Crystal structure of actinomycin D-echinomycin-d(AGCCCGT/ACGGGCT) complex
7XDJ	;	2.435	;	Crystal structure of actinomycin D-echinomycin-d(AGCGCGT/ACGAGCT) complex
7X9F	;	2.96	;	Crystal structure of actinomycin D-echinomycin-d(AGCGCGT/ACGCGCT) complex
1A7Z	;	0.95	;	CRYSTAL STRUCTURE OF ACTINOMYCIN Z3
1WPV	;	1.7	;	Crystal Structure of Activated Binary complex of HutP, an RNA binding anti-termination protein
6ITV	;	1.881	;	Crystal structure of activated c-KIT in complex with compound
1FQW	;	2.37	;	CRYSTAL STRUCTURE OF ACTIVATED CHEY
1F4V	;	2.22	;	CRYSTAL STRUCTURE OF ACTIVATED CHEY BOUND TO THE N-TERMINUS OF FLIM
1ZDM	;	2.4	;	Crystal Structure of Activated CheY Bound to Xe
6EKH	;	2.654	;	Crystal structure of activated CheY from Methanoccocus maripaludis
7OD9	;	2.3	;	Crystal structure of activated CheY fused to the C-terminal domain of CheF
4HNS	;	2.1	;	Crystal structure of activated CheY3 of Vibrio cholerae
3BII	;	2.5	;	Crystal Structure of Activated MPT Synthase
2F8X	;	3.25	;	Crystal structure of activated Notch, CSL and MAML on HES-1 promoter DNA sequence
1Z5R	;	1.4	;	Crystal Structure of Activated Porcine Pancreatic Carboxypeptidase B
2PJ1	;	1.64	;	CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B (3-Aminomethyl-phenyl)-[((R)-1-benzyloxycarbonylamino-2-methyl-propyl)-hydroxy-phosphinoyloxy]-acetic acid COMPLEX
2PJ3	;	1.64	;	CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B (3-Guanidino-phenyl)-{hydroxy-[(R)-2-methyl-1-(3-phenyl-propionylamino)-propyl]-phosphinoyloxy}-acetic acid COMPLEX
2PIY	;	1.43	;	CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B (S)-2-(3-Aminomethyl-phenyl)-3-{hydroxy-[(R)-2-methyl-1-(3-phenyl-propane-1-sulfonylamino)-propyl]-phosphinoyl}-propionic acid {ZK 528} COMPLEX
2PJC	;	1.74	;	CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B ({(R)-1-[(S)-2-Benzyloxycarbonylamino-3-(4-hydroxy-phenyl)-propionylamino]-2-methyl-propyl}-hydroxy-phosphinoyloxy)-(3-guanidino-phenyl)-acetic acid COMPLEX
2PJ7	;	1.77	;	CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B 2-(3-Aminomethyl-phenyl)-3-[((R)-1-benzenesulfonylamino-2-methyl-propyl)-hydroxy-phosphinoyl]-propionic acid COMPLEX
2PJ2	;	1.95	;	CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B 2-(3-Aminomethyl-phenyl)-3-[((R)-1-benzyloxycarbonylamino-2-methyl-propyl)-hydroxy-phosphinoyl]-propionic acid COMPLEX
2PJ6	;	1.6	;	CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B 2-(3-Aminomethyl-phenyl)-3-{hydroxy-[(R)-2-methyl-1-(2-phenyl-ethanesulfonylamino)-propyl]-phosphinoyl}-propionic acid COMPLEX
2PJ9	;	1.56	;	CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B 2-(3-Aminomethyl-phenyl)-3-{[(R)-1-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-2-methyl-propyl]-hydroxy-phosphinoyl}-propionic acid COMPLEX
2PJ8	;	1.7	;	CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B 2-(3-Aminomethyl-phenyl)-3-{[(R)-1-(biphenyl-4-sulfonylamino)-2-methyl-propyl]-hydroxy-phosphinoyl}-propionic acid COMPLEX
2PJB	;	1.7	;	CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B 2-(3-Aminomethyl-phenyl)-3-{[1-((S)-2-benzyloxycarbonylamino-3-phenyl-propane-1-sulfonylamino)-2-methyl-propyl]-hydroxy-phosphinoyl}-propionic acid COMPLEX
2PIZ	;	1.6	;	CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B 2-(3-Guanidino-phenyl)-3-[hydroxy-(3-phenyl-propyl)-phosphinoyl]-propionic acid COMPLEX
2PJA	;	1.7	;	CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B 3-{[(R)-1-((S)-2-Benzyloxycarbonylamino-3-phenyl-propionylamino)-2-methyl-propyl]-hydroxy-phosphinoyl}-2-(3-guanidino-phenyl)-propionic acid COMPLEX
2PJ0	;	1.65	;	CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B [((R)-1-Benzyloxycarbonylamino-2-methyl-propyl)-hydroxy-phosphinoyloxy]-(3-guanidino-phenyl)-acetic acid COMPLEX
2PJ5	;	1.65	;	CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B [((R)-1-Benzyloxycarbonylamino-hexyl)-hydroxy-phosphinoyloxy]-(3-guanidino-phenyl)-acetic acid COMPLEX
2PJ4	;	2.0	;	CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B [((R)-Benzyloxycarbonylamino-cyclohexyl-methyl)-hydroxy-phosphinoyloxy]-(3-guanidino-phenyl)-acetic acid COMPLEX
3GQI	;	2.5	;	Crystal Structure of activated receptor tyrosine kinase in complex with substrates
3GQL	;	2.8	;	Crystal Structure of activated receptor tyrosine kinase in complex with substrates
9RUB	;	2.6	;	CRYSTAL STRUCTURE OF ACTIVATED RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE COMPLEXED WITH ITS SUBSTRATE, RIBULOSE-1,5-BISPHOSPHATE
1IR2	;	1.84	;	Crystal Structure of Activated Ribulose-1,5-bisphosphate Carboxylase/oxygenase (Rubisco) from Green alga, Chlamydomonas reinhardtii Complexed with 2-Carboxyarabinitol-1,5-bisphosphate (2-CABP)
1WDD	;	1.35	;	Crystal Structure of Activated Rice Rubisco Complexed with 2-Carboxyarabinitol-1,5-bisphosphate
3IUW	;	1.58	;	Crystal structure of Activating signal cointegrator (NP_814290.1) from ENTEROCOCCUS FAECALIS V583 at 1.58 A resolution
1J6R	;	2.3	;	Crystal structure of Activation (AdoMet binding) domain of Methionine synthase (TM0269) from Thermotoga maritima at 2.2 A resolution
3R5J	;	1.77	;	Crystal structure of active caspase-2 bound with Ac-ADVAD-CHO
3R6G	;	2.07	;	Crystal structure of active caspase-2 bound with Ac-VDVAD-CHO
3OD5	;	1.6	;	Crystal structure of active caspase-6 bound with Ac-VEID-CHO
3S70	;	1.625	;	Crystal structure of active caspase-6 bound with Ac-VEID-CHO solved by As-SAD
3P4U	;	1.9	;	Crystal structure of active caspase-6 in complex with Ac-VEID-CHO inhibitor
4J4Q	;	2.65	;	Crystal structure of active conformation of GPCR opsin stabilized by octylglucoside
1XJT	;	1.75	;	Crystal structure of active form of P1 phage endolysin Lyz
2ZGH	;	2.17	;	Crystal Structure of active granzyme M bound to its product
4F73	;	1.9	;	Crystal Structure of active HIV-1 Protease in Complex with the N terminal product of CA-p2 cleavage site
4F74	;	2.2	;	Crystal Structure of active HIV-1 Protease in Complex with the N terminal product of the substrate MA-CA.
4F75	;	1.7	;	Crystal Structure of active HIV-1 Protease in Complex with the N terminal product of the substrate RH-IN
4GAW	;	3.0	;	Crystal structure of active human granzyme H
2ZGC	;	1.96	;	Crystal Structure of Active Human Granzyme M
7ACH	;	1.9	;	CRYSTAL STRUCTURE OF ACTIVE KRAS G12D (GPPCP) IN COMPLEX WITH THE SOAKED DIMERIC INHIBITOR BI-5747
4AWB	;	2.7	;	Crystal structure of active legumain in complex with AAN-CMK
4AW9	;	2.2	;	Crystal structure of active legumain in complex with YVAD-CMK
4AWA	;	2.5	;	Crystal structure of active legumain in complex with YVAD-CMK at pH 5.0
5C1M	;	2.07	;	Crystal structure of active mu-opioid receptor bound to the agonist BU72
5EZ5	;	2.4	;	Crystal structure of active Rab11A (S20V) in complex with GTP
2PQI	;	2.5	;	Crystal structure of active ribosome inactivating protein from maize (b-32)
2PQJ	;	2.8	;	Crystal structure of active ribosome inactivating protein from maize (b-32), complex with adenine
1XRM	;	2.7	;	Crystal structure of active site F1-mutant E213Q soaked with peptide Ala-Phe
1XRN	;	2.8	;	Crystal structure of active site F1-mutant E213Q soaked with peptide Phe-Ala
1XRO	;	1.8	;	Crystal structure of active site F1-mutant E213Q soaked with peptide Phe-Leu
1XRP	;	2.3	;	Crystal structure of active site F1-mutant E213Q soaked with peptide Pro-Leu-Gly-Gly
1XRQ	;	2.8	;	Crystal structure of active site F1-mutant E245Q soaked with peptide Phe-Leu
1XRR	;	2.4	;	Crystal structure of active site F1-mutant E245Q soaked with peptide Pro-Pro
1XRL	;	1.82	;	Crystal structure of active site F1-mutant Y205F complex with inhibitor PCK
2PUQ	;	2.05	;	Crystal structure of active site inhibited coagulation factor VIIA in complex with soluble tissue factor
3ELA	;	2.2	;	Crystal structure of active site inhibited coagulation factor VIIA mutant in complex with soluble tissue factor
4FGC	;	2.498	;	Crystal Structure of Active Site Mutant C55A of Nitrile Reductase QueF, Bound to Substrate PreQ0
7AG4	;	2.13	;	Crystal structure of active site mutant of SQ Isomerase (YihS-H248A) from Salmonella enterica in complex with sulfofructose (SF)
1CVW	;	2.28	;	Crystal structure of active site-inhibited human coagulation factor VIIA (DES-GLA)
6O3C	;	2.8	;	Crystal structure of active Smoothened bound to SAG21k, cholesterol, and NbSmo8
4PWN	;	1.84	;	Crystal structure of Active WNK1 kinase
1NYU	;	3.1	;	Crystal Structure of Activin A Bound to the ECD of ActRIIB
1NYS	;	3.05	;	Crystal Structure of Activin A Bound to the ECD of ActRIIB P41
4MID	;	2.139	;	Crystal Structure of Activin A/BMP2 chimera
2QLU	;	2.0	;	Crystal structure of Activin receptor type II kinase domain from human
3SOC	;	1.95	;	Crystal structure of Activin receptor type-IIA (ACVR2A) kinase domain in complex with a quinazolin
4ASX	;	2.05	;	Crystal structure of Activin receptor type-IIA (ACVR2A) kinase domain in complex with dihydro-Bauerine C
3Q4T	;	1.96	;	Crystal structure of Activin receptor type-IIA (ACVR2A) kinase domain in complex with dorsomorphin
1QUA	;	2.2	;	CRYSTAL STRUCTURE OF ACUTOLYSIN-C, A HEMORRHAGIC TOXIN FROM THE SNAKE VENOM OF AGKISTRODON ACUTUS, AT 2.2 A RESOLUTION
1VKU	;	2.0	;	Crystal structure of Acyl carrier protein (TM0175) from Thermotoga maritima at 2.00 A resolution
2EHS	;	1.3	;	Crystal structure of acyl carrier protein from Aquifex aeolicus (form 1)
2EHT	;	1.4	;	Crystal structure of acyl carrier protein from Aquifex aeolicus (form 2)
1TIK	;	2.3	;	CRYSTAL STRUCTURE OF ACYL CARRIER PROTEIN PHOSPHODIESTERASE
2Z1Q	;	2.3	;	Crystal structure of acyl CoA dehydrogenase
4GAK	;	1.9	;	Crystal structure of acyl-ACP thioesterase from Spirosoma linguale
6U1V	;	1.75	;	Crystal structure of acyl-ACP/acyl-CoA dehydrogenase from allylmalonyl-CoA and FK506 biosynthesis, TcsD
7W58	;	2.27	;	Crystal structure of acyl-carrier protein synthase from Mycobacterium smegmatis
3EZO	;	2.05	;	Crystal structure of acyl-carrier-protein s-malonyltransferase from burkholderia pseudomallei 1710b
3QAT	;	1.6	;	Crystal structure of acyl-carrier-protein-S-malonyltransferase from Bartonella henselae
2CX9	;	2.0	;	Crystal structure of acyl-CoA dehydrogenase
8I4R	;	2.51	;	Crystal structure of Acyl-CoA dehydrogenase complexed with Acetyl-CoA from Thermobifida fusca
3OWA	;	1.97	;	Crystal Structure of Acyl-CoA Dehydrogenase complexed with FAD from Bacillus anthracis
6KPT	;	1.963	;	Crystal Structure of Acyl-CoA Dehydrogenase FadE5 from Mycobacteria smegmatis
6KRI	;	1.604	;	Crystal Structure of Acyl-CoA Dehydrogenase FadE5 from Mycobacteria smegmatis with product released
4M9A	;	2.2	;	Crystal structure of Acyl-coA dehydrogenase from Burkholderia thailandensis E264
2PG0	;	1.8	;	Crystal structure of acyl-CoA dehydrogenase from Geobacillus kaustophilus
7SZV	;	2.4	;	Crystal Structure of Acyl-CoA dehydrogenase from Mycobacterium marinum in complex with FDA
3NF4	;	2.35	;	Crystal structure of acyl-CoA dehydrogenase from Mycobacterium thermoresistibile bound to flavin adenine dinucleotide
8I4P	;	1.9	;	crystal structure of Acyl-CoA dehydrogenase from Thermobifida fusca
2GVH	;	2.5	;	Crystal structure of Acyl-CoA hydrolase (15159470) from AGROBACTERIUM TUMEFACIENS at 2.65 A resolution
1VPM	;	1.66	;	Crystal structure of Acyl-CoA hydrolase (NP_241664.1) from Bacillus halodurans at 1.66 A resolution
1Y7U	;	2.8	;	Crystal Structure of Acyl-Coa hydrolase from Bacillus cereus
4IEN	;	2.0	;	Crystal Structure of Acyl-CoA Hydrolase from Neisseria meningitidis FAM18
2DDH	;	2.07	;	Crystal Structure of Acyl-CoA oxidase complexed with 3-OH-dodecanoate
5K3I	;	2.683	;	Crystal structure of Acyl-CoA oxidase-1 in Caenorhabditis elegans complexed with FAD and ATP
5Y9D	;	2.5	;	Crystal structure of acyl-coA oxidase1 from Yarrowia lipolytica
5YS9	;	2.5	;	Crystal structure of acyl-coA oxidase3 from Yarrowia lipolytica
8BIQ	;	2.8	;	Crystal structure of acyl-COA synthetase from Metallosphaera sedula in complex with acetyl-AMP
8BIT	;	3.1	;	Crystal structure of acyl-CoA synthetase from Metallosphaera sedula in complex with Coenzyme A and acetyl-AMP
3RD7	;	1.95	;	Crystal structure of acyl-coa thioesterase from mycobacterium avium
4QFW	;	2.0	;	Crystal structure of acyl-CoA thioesterase tesB from Yersinia pestis
4R4U	;	2.2	;	Crystal structure of acyl-CoA thioesterase tesB from Yersinia pestis in complex with coenzyme A
2AHU	;	1.9	;	Crystal structure of Acyl-CoA transferase (YdiF) apoenzyme from Escherichia coli O157:H7.
2AHV	;	2.0	;	Crystal Structure of Acyl-CoA transferase from E. coli O157:H7 (YdiF)-thioester complex with CoA- 1
2AHW	;	2.15	;	Crystal Structure of Acyl-CoA transferase from E. coli O157:H7 (YdiF)-thioester complex with CoA- 2
4EQY	;	1.8	;	Crystal structure of Acyl-[acyl-carrier-protein]--UDP-N-acetylglucosamine O-acyltransferase from Burkholderia thailandensis
3FNB	;	2.1178	;	Crystal structure of acylaminoacyl peptidase SMU_737 from Streptococcus mutans UA159
3U19	;	2.0	;	CRYSTAL STRUCTURE OF ACYLENZYME INTERMEDIATE OF DE NOVO DESIGNED CYSTEINE ESTERASE ECH13, Northeast Structural Genomics Consortium Target OR51
4HI1	;	1.964	;	Crystal structure of acylphosphatase C20R mutant from Vibrio cholerae0395
3BR8	;	1.33	;	Crystal structure of acylphosphatase from Bacillus subtilis
1V3Z	;	1.72	;	Crystal Structure of Acylphosphatase from Pyrococcus horikoshii
2I0D	;	1.95	;	Crystal structure of AD-81 complexed with wild type HIV-1 protease
3CNC	;	2.4	;	Crystal Structure of Ad16 fiber knob
3BQ4	;	2.7	;	Crystal Structure of Ad35 fiber knob
3N0I	;	1.65	;	Crystal Structure of Ad37 fiber knob in complex with GD1a oligosaccharide
3QND	;	2.4	;	crystal structure of Ad37 fiber knob in complex with trivalent sialic acid inhibitor
4K6T	;	2.0	;	Crystal structure of Ad37 fiber knob in complex with trivalent sialic acid inhibitor ME0385
4K6U	;	1.9	;	Crystal structure of Ad37 fiber knob in complex with trivalent sialic acid inhibitor ME0386
4K6V	;	1.5	;	Crystal structure of Ad37 fiber knob in complex with trivalent sialic acid inhibitor ME0407
4K6W	;	1.5	;	Crystal structure of Ad37 fiber knob in complex with trivalent sialic acid inhibitor ME0408
4XQB	;	1.597	;	CRYSTAL STRUCTURE OF AD37 FIBER KNOB IN COMPLEX WITH TRIVALENT SIALIC ACID INHIBITOR ME0461
4XQA	;	1.4072	;	CRYSTAL STRUCTURE OF AD37 FIBER KNOB IN COMPLEX WITH TRIVALENT SIALIC ACID INHIBITOR ME0462
4NYL	;	2.8	;	Crystal structure of adalimumab FAB fragment
3B2Z	;	2.8	;	Crystal Structure of ADAMTS4 (apo form)
2RJP	;	2.8	;	Crystal structure of ADAMTS4 with inhibitor bound
2RJQ	;	2.6	;	Crystal structure of ADAMTS5 with inhibitor bound
7TQ1	;	2.73	;	Crystal structure of adaptive laboratory evolved sulfonamide-resistant Dihydropteroate Synthase (DHPS) from Escherichia coli in complex with 6-hydroxymethylpterin
5TE0	;	1.9	;	Crystal Structure of Adaptor Protein 2 Associated Kinase (AAK1) in complex with BIBF 1120
4WSQ	;	1.95	;	Crystal Structure of Adaptor Protein 2 Associated Kinase (AAK1) in complex with small molecule inhibitor
5L4Q	;	1.97	;	Crystal Structure of Adaptor Protein 2 Associated Kinase 1 (AAK1) in Complex with LKB1 (AAK1 Dual Inhibitor)
4IKN	;	1.851	;	Crystal structure of adaptor protein complex 3 (AP-3) mu3A subunit C-terminal domain, in complex with a sorting peptide from TGN38
4MDR	;	1.85	;	Crystal structure of adaptor protein complex 4 (AP-4) mu4 subunit C-terminal domain D190A mutant, in complex with a sorting peptide from the amyloid precursor protein (APP)
3L81	;	1.6	;	Crystal structure of adaptor protein complex 4 (AP-4) mu4 subunit C-terminal domain, in complex with a sorting peptide from the amyloid precursor protein (APP)
7ZJ1	;	1.65	;	Crystal structure of ADAR1-dsRBD3 dimer
7ZLQ	;	2.8	;	Crystal structure of ADAR1-dsRBD3 dimer in complex with dsRNA
4NET	;	1.2	;	Crystal structure of ADC-1 beta-lactamase
4U0T	;	1.73	;	Crystal structure of ADC-7 beta-lactamase
4RFE	;	1.91	;	Crystal structure of ADCC-potent ANTI-HIV-1 Rhesus macaque antibody JR4 Fab
4RFN	;	3.21	;	Crystal structure of ADCC-potent Rhesus macaque ANTIBODY JR4 in complex with HIV-1 CLADE A/E GP120 and M48
6IE4	;	2.696	;	Crystal structure of ADCP1 tandem Agenet domain 1-2 in complex with H3K9me1
6IE7	;	2.7	;	Crystal structure of ADCP1 tandem Agenet domain 1-2 in complex with H3K9me2
6IE5	;	2.298	;	Crystal structure of ADCP1 tandem Agenet domain 3-4
6IE6	;	1.7	;	Crystal structure of ADCP1 tandem Agenet domain 3-4 in complex with H3K9me2
7O45	;	2.1	;	Crystal structure of ADD domain of the human DNMT3B methyltransferase
4CEH	;	3.24	;	Crystal structure of AddAB with a forked DNA substrate
3U44	;	3.201	;	Crystal structure of AddAB-DNA complex
4CEJ	;	3.0	;	Crystal structure of AddAB-DNA-ADPNP complex at 3 Angstrom resolution
4XGQ	;	2.7	;	Crystal structure of addiction module from Mycobacterial species
4XGR	;	2.7	;	Crystal structure of addiction module from Mycobacterial species
3NQB	;	2.21	;	Crystal Structure of Adenine Deaminase from Agrobacterium tumefaciens (str. C 58)
3T8L	;	2.8	;	Crystal Structure of adenine deaminase with Mn/Fe
5VN4	;	1.35	;	Crystal structure of adenine phosphoribosyl transferase from Trypanosoma brucei in complex with AMP, pyrophosphate, and ribose-5-phosphate
1G2P	;	1.75	;	CRYSTAL STRUCTURE OF ADENINE PHOSPHORIBOSYLTRANSFERASE
1G2Q	;	1.5	;	CRYSTAL STRUCTURE OF ADENINE PHOSPHORIBOSYLTRANSFERASE
1MZV	;	2.2	;	Crystal Structure of Adenine Phosphoribosyltransferase (APRT) From Leishmania tarentolae
5YW5	;	1.9	;	Crystal structure of Adenine phosphoribosyltransferase from Francisella tularensis in complex with adenine
5YW2	;	2.28	;	Crystal structure of Adenine phosphoribosyltransferase from Francisella tularensis.
4M0K	;	1.4	;	Crystal structure of adenine phosphoribosyltransferase from Rhodothermus marinus DSM 4252, NYSGRC Target 029775.
5VJN	;	1.78	;	Crystal Structure of Adenine Phosphoribosyltransferase from Saccharomyces cerevisiae Complexed with D-2,5-Dideoxy-2,5-Imino-Altritol 1,6-Bisphosphate (D-DIAB) and Adenine
5VJP	;	1.98	;	Crystal Structure of Adenine Phosphoribosyltransferase from Saccharomyces cerevisiae Complexed with L-2,5-Dideoxy-2,5-Imino-Altritol 1,6-Bisphosphate (L-DIAB) and Adenine
4LZA	;	1.84	;	Crystal structure of adenine phosphoribosyltransferase from Thermoanaerobacter pseudethanolicus ATCC 33223, NYSGRC Target 029700.
5Y07	;	2.07	;	Crystal structure of adenine phosphoribosyltransferase from Yersinia pseudotuberculosis with PRPP.
4MB6	;	1.81	;	Crystal structure of adenine phosphoribosyltransferase from Yersinia pseudotuberculosis.
7L04	;	2.26	;	Crystal Structure of Adeno-Associated Virus Porcine Origin capsid protein in complex with Importin-alpha 2
3KIC	;	2.603	;	Crystal structure of adeno-associated virus serotype 3B
3KIE	;	3.0	;	Crystal structure of adeno-associated virus serotype 3B
1S9H	;	2.4	;	Crystal Structure of Adeno-associated virus Type 2 Rep40
1D6J	;	2.0	;	CRYSTAL STRUCTURE OF ADENOSINE 5'-PHOSPHOSULFATE (APS) KINASE FROM PENICILLIUM CHRYSOGENUM
3UIE	;	1.794	;	Crystal structure of adenosine 5'-phosphosulfate kinase from Arabidopsis Thaliana in Complex with AMPPNP and APS
4FXP	;	1.954	;	Crystal structure of adenosine 5'-phosphosulfate kinase from Arabidopsis thaliana in Complex with Sulfate and APS
7YQ0	;	1.58	;	Crystal structure of adenosine 5'-phosphosulfate kinase from Archaeoglobus fulgidus in complex with ADP
7YQ1	;	1.91	;	Crystal structure of adenosine 5'-phosphosulfate kinase from Archaeoglobus fulgidus in complex with AMP-PNP and APS
5UIG	;	3.5	;	Crystal structure of adenosine A2A receptor bound to a novel triazole-carboximidamide antagonist
1O5R	;	2.35	;	Crystal structure of adenosine deaminase complexed with a potent inhibitor
1UML	;	2.5	;	Crystal structure of adenosine deaminase complexed with a potent inhibitor FR233624
1NDV	;	2.3	;	Crystal Structure of Adenosine Deaminase complexed with FR117016
1NDW	;	2.0	;	Crystal Structure of Adenosine Deaminase Complexed with FR221647
1NDY	;	2.0	;	Crystal Structure of Adenosine Deaminase Complexed with FR230513
1QXL	;	2.25	;	Crystal structure of Adenosine deaminase complexed with FR235380
1NDZ	;	2.0	;	Crystal Structure of Adenosine Deaminase Complexed with FR235999
2E1W	;	2.5	;	Crystal structure of adenosine deaminase complexed with potent inhibitors
3EWC	;	2.11	;	Crystal Structure of adenosine deaminase from Plasmodial vivax in complex with MT-coformycin
2PGF	;	1.89	;	Crystal structure of adenosine deaminase from Plasmodium vivax in complex with adenosine
2QVN	;	2.19	;	Crystal structure of adenosine deaminase from Plasmodium vivax in complex with guanosine
2PGR	;	2.3	;	Crystal structure of adenosine deaminase from Plasmodium vivax in complex with pentostatin
4GBD	;	1.975	;	Crystal Structure Of Adenosine Deaminase From Pseudomonas Aeruginosa Pao1 with bound Zn and methylthio-coformycin
6N9M	;	1.449	;	Crystal Structure of Adenosine Deaminase from Salmonella typhimurium with Pentostatin (Deoxycoformycin)
6N91	;	2.05	;	Crystal Structure of Adenosine Deaminase from Vibrio cholerae Complexed with Pentostatin (Deoxycoformycin)
1WXY	;	2.5	;	Crystal structure of adenosine deaminase ligated with a potent inhibitor
1WXZ	;	2.8	;	Crystal structure of adenosine deaminase ligated with a potent inhibitor
2Z7G	;	2.52	;	Crystal structure of adenosine deaminase ligated with EHNA
3EWD	;	1.9	;	Crystal structure of adenosine deaminase mutant (delta Asp172) from Plasmodium vivax in complex with MT-coformycin
1DGM	;	1.8	;	CRYSTAL STRUCTURE OF ADENOSINE KINASE FROM TOXOPLASMA GONDII
2ZE5	;	2.31	;	Crystal Structure of adenosine phosphate-isopentenyltransferase
2ZE8	;	2.8	;	Crystal Structure of adenosine phosphate-isopentenyltransferase complexed with diphosphate
2ZE6	;	2.1	;	Crystal Structure of adenosine phosphate-isopentenyltransferase complexed with substrate analog, DMASPP
2ZE7	;	2.1	;	Crystal Structure of adenosine phosphate-isopentenyltransferase complexed with zinc ion and substrate analog, DMASPP
3UAV	;	1.4	;	Crystal structure of adenosine phosphorylase from Bacillus cereus
3UAW	;	1.2	;	Crystal structure of adenosine phosphorylase from Bacillus cereus complexed with adenosine
3UAX	;	1.2	;	Crystal structure of adenosine phosphorylase from Bacillus cereus complexed with inosine
2AC7	;	1.7	;	Crystal structure of Adenosine Phosphorylase from Bacillus cereus with adenosine bound in the active site
7WZY	;	2.975	;	Crystal structure of Adenosine triphosphate phosphoribosyltransferase (HisG) from Acinetobacter baumannii at 2.975 A resolution
7WGK	;	3.13	;	Crystal structure of Adenosine triphosphate phosphoribosyltransferase (HisG) from Acinetobacter baumannii at 3.13 A resolution
7WGM	;	3.15	;	Crystal structure of Adenosine triphosphate phosphoribosyltransferase (HisG) from Acinetobacter baumannii at 3.15 A resolution
8JUK	;	2.181	;	Crystal structure of Adenosine triphosphate phosphoribosyltransferase from Acinetobacter baumannii at 2.18 A resolution
5CB8	;	1.88	;	Crystal structure of Adenosine-5'-phosphosulfate kinase in complex with APS and sulfate
7LHR	;	3.11	;	Crystal structure of adenosine-5'-phosphosulfate reductase from Mycobacterium tuberculosis
7LHU	;	3.09	;	Crystal structure of adenosine-5'-phosphosulfate reductase from Mycobacterium tuberculosis in a complex with product AMP
7LHS	;	3.11	;	Crystal structure of adenosine-5'-phosphosulfate reductase from Mycobacterium tuberculosis in a complex with substrate APS
6APH	;	1.65	;	Crystal structure of Adenosylhomocysteinase from Elizabethkingia anophelis NUHP1 in complex with NAD and Adenosine
7UG3	;	1.9	;	Crystal structure of adenosylmethionie-8-amino-7-oxononanoate aminotransferase from Klebsiella pneumoniae
1DTY	;	2.14	;	CRYSTAL STRUCTURE OF ADENOSYLMETHIONINE-8-AMINO-7-OXONANOATE AMINOTRANSFERASE WITH PYRIDOXAL PHOSPHATE COFACTOR.
6ZHK	;	1.8	;	Crystal structure of adenosylmethionine-8-amino-7-oxononanoate aminotransferase from Methanocaldococcus jannaschii DSM 2661
4WX4	;	1.03	;	Crystal structure of adenovirus 8 protease in complex with a nitrile inhibitor
4WX7	;	2.4	;	Crystal structure of adenovirus 8 protease with a nitrile inhibitor
3TG7	;	1.57	;	Crystal structure of Adenovirus serotype 5 hexon at 1.6A resolution
5X6K	;	1.99	;	Crystal structure of adenylate kinase
5XZ2	;	1.75	;	Crystal structure of adenylate kinase
5G3Y	;	1.18	;	Crystal structure of adenylate kinase ancestor 1 with Zn and ADP bound
5G3Z	;	1.89	;	Crystal structure of adenylate kinase ancestor 3 with Zn, Mg and Ap5A bound
5G40	;	1.69	;	Crystal structure of adenylate kinase ancestor 4 with Zn and AMP-ADP bound
5G41	;	1.54	;	Crystal structure of adenylate kinase ancestor 4 with Zn, Mg and Ap5A bound
6LN3	;	2.0	;	Crystal structure of adenylate kinase from an extremophilic archaeon Aeropyrum pernix with ATP and AMP
2RGX	;	1.9	;	Crystal Structure of Adenylate Kinase from Aquifex Aeolicus in complex with Ap5A
4CF7	;	1.594	;	Crystal structure of adenylate kinase from Aquifex aeolicus with MgADP bound
1S3G	;	2.25	;	Crystal structure of adenylate kinase from Bacillus globisporus
3GMT	;	2.1	;	Crystal structure of adenylate kinase from burkholderia pseudomallei
3FB4	;	2.0	;	Crystal structure of adenylate kinase from Marinibacillus marinus
3H86	;	2.5	;	Crystal structure of adenylate kinase from Methanococcus maripaludis
4K46	;	2.01	;	Crystal Structure of Adenylate Kinase from Photobacterium profundum
4NTZ	;	1.69	;	Crystal structure of Adenylate kinase from Streptococcus pneumoniae
4NU0	;	1.485	;	Crystal structure of Adenylate kinase from Streptococcus pneumoniae with Ap5A
3CM0	;	1.8	;	Crystal structure of adenylate kinase from Thermus thermophilus HB8
4NP6	;	2.004	;	Crystal Structure of Adenylate Kinase from Vibrio cholerae O1 biovar eltor
4JZK	;	1.63	;	Crystal Structure of Adenylate kinase of E. Coli with ADP/AMP bound
3DKV	;	1.82	;	Crystal structure of adenylate kinase variant AKlse1
3DL0	;	1.58	;	Crystal structure of adenylate kinase variant AKlse3
4JL6	;	1.65	;	Crystal Structure of Adenylate kinase with 2 ADP's
4JLA	;	2.12	;	Crystal Structure of Adenylate kinase with 2 ADP's in the active site
3MR7	;	2.6	;	Crystal Structure of Adenylate/Guanylate Cyclase/Hydrolase from Silicibacter pomeroyi
7T24	;	1.45	;	Crystal Structure of Adenylosuccinate lyase (ASL) from Pseudomonas aeruginosa
7T29	;	1.5	;	Crystal Structure of Adenylosuccinate lyase (ASL) from Pseudomonas aeruginosa complexed with AMP
2PFM	;	2.0	;	Crystal Structure of Adenylosuccinate Lyase (PurB) from Bacillus anthracis
5VKW	;	1.998	;	Crystal structure of adenylosuccinate lyase ADE13 from Candida albicans
4EEI	;	1.921	;	Crystal Structure of Adenylosuccinate Lyase from Francisella tularensis Complexed with AMP and Succinate
5HW2	;	2.054	;	Crystal Structure of Adenylosuccinate Lyase from Francisella tularensis Complexed with fumaric acid
3BHG	;	1.9	;	Crystal structure of adenylosuccinate lyase from Legionella pneumophila
4MX2	;	1.9	;	Crystal Structure of adenylosuccinate lyase from Leishmania donovani
2HVG	;	2.3	;	Crystal Structure of Adenylosuccinate Lyase from Plasmodium Vivax
5EYV	;	2.14	;	Crystal Structure of Adenylosuccinate lyase from Schistosoma mansoni in APO form.
5EYT	;	2.3649	;	Crystal Structure of Adenylosuccinate Lyase from Schistosoma mansoni in complex with AMP
8JBD	;	2.38	;	Crystal structure of Adenylosuccinate lyase from Thermus thermophilus HB8, TtPurB
4EFC	;	2.0	;	Crystal Structure of Adenylosuccinate Lyase from Trypanosoma Brucei, Tb427tmp.160.5560
3UE9	;	1.95	;	Crystal structure of Adenylosuccinate synthetase (AMPSase) (purA) from Burkholderia thailandensis
3R7T	;	2.3	;	Crystal Structure of Adenylosuccinate Synthetase from Campylobacter jejuni
1GIM	;	2.5	;	CRYSTAL STRUCTURE OF ADENYLOSUCCINATE SYNTHETASE FROM ESCHERICHIA COLI COMPLEXED WITH GDP, IMP, HADACIDIN, NO3-, AND MG2+. DATA COLLECTED AT 100K (PH 6.5)
1GIN	;	2.8	;	CRYSTAL STRUCTURE OF ADENYLOSUCCINATE SYNTHETASE FROM ESCHERICHIA COLI COMPLEXED WITH GDP, IMP, HADACIDIN, NO3-, AND MG2+. DATA COLLECTED AT 298K (PH 6.5).
6BS7	;	1.95	;	Crystal structure of Adenylosuccinate synthetase from Legionella pneumophila Philadelphia 1
6C25	;	1.9	;	Crystal structure of Adenylosuccinate synthetase from Legionella pneumophila Philadelphia 1 in complex with GDP
3HID	;	1.6	;	Crystal structure of adenylosuccinate synthetase from Yersinia pestis CO92
6JRQ	;	2.1	;	Crystal structure of adenylosuccinate synthetase, PurA, from Thermus thermophilus
4WP3	;	1.95	;	Crystal Structure of Adenylyl cyclase from Mycobacterium avium Ma1120 wild type
4WP9	;	1.382	;	Crystal structure of Adenylyl cyclase MA1120 from Mycobacterium Avium bound to 2'5'-DD-3'-ATP, Calcium and Magnesium ion
4WPA	;	1.7	;	Crystal structure of Adenylyl cyclase Ma1120 from Mycobacterium Avium bound to Pyrophosphate and Calcium
4WP8	;	1.65	;	Crystal structure of Adenylyl cyclase Ma1120 from Mycobacterium Avium in complex with 2'5'-DD-3'-ATP and Manganese ion
6B8V	;	2.55	;	Crystal structure of adenylyl-sulfate kinase from Cryptococcus neoformans
3GYX	;	3.2	;	Crystal structure of adenylylsulfate reductase from Desulfovibrio gigas
1F7S	;	2.0	;	CRYSTAL STRUCTURE OF ADF1 FROM ARABIDOPSIS THALIANA
5JLU	;	2.2	;	Crystal Structure of Adhesin competence repressor (AdcR) from Streptococcus pyogenes
5JLS	;	2.7	;	Crystal Structure of Adhesin competence repressor (AdcR) from Streptococcus pyogenes (C-terminally His tagged)
6Z2S	;	3.2	;	Crystal structure of adhibin analogue-bound myosin-2
3JS1	;	1.81	;	Crystal structure of adipocyte fatty acid binding protein covalently modified with 4-hydroxy-2-nonenal
3JSQ	;	2.3	;	Crystal structure of adipocyte fatty acid binding protein non-covalently modified with 4-hydroxy-2-nonenal
7LVZ	;	1.89	;	Crystal structure of ADO
5L0Z	;	2.9	;	Crystal Structure of AdoMet bound rRNA methyltransferase from Sinorhizobium meliloti
5C1P	;	2.4	;	Crystal structure of ADP and D-alanyl-D-alanine complexed D-alanine-D-alanine ligase(DDL) from Yersinia pestis
5BPL	;	1.93	;	Crystal structure of ADP and Pi bound human Hsp70 NBD mutant R272K.
5H70	;	2.4	;	Crystal structure of ADP bound dTMP kinase (st1543) from Sulfolobus Tokodaii Strain7
5BN9	;	1.689	;	Crystal structure of ADP bound human Hsp70 NBD mutant R272K.
1X3M	;	2.2	;	Crystal structure of ADP bound Propionate kinase (TdcD) from Salmonella typhimurium
1T6X	;	2.29	;	Crystal structure of ADP bound TM379
1NY3	;	3.0	;	Crystal structure of ADP bound to MAP KAP kinase 2
3QFF	;	1.96	;	Crystal Structure of ADP complex of purK: N5-carboxyaminoimidazole ribonucleotide synthetase
5BPF	;	2.28	;	Crystal structure of ADP complexed D-alanine-D-alanine ligase(DDL) from Yersinia pestis
1VHG	;	2.7	;	Crystal structure of ADP compounds hydrolase
1VHZ	;	2.32	;	Crystal structure of ADP compounds hydrolase
6VXS	;	2.03	;	Crystal Structure of ADP ribose phosphatase of NSP3 from SARS CoV-2
6W6Y	;	1.451	;	Crystal Structure of ADP ribose phosphatase of NSP3 from SARS CoV-2 in complex with AMP
6W02	;	1.5	;	Crystal Structure of ADP ribose phosphatase of NSP3 from SARS CoV-2 in the complex with ADP ribose
6WCF	;	1.065	;	Crystal Structure of ADP ribose phosphatase of NSP3 from SARS-CoV-2 in complex with MES
6WEN	;	1.35	;	Crystal Structure of ADP ribose phosphatase of NSP3 from SARS-CoV-2 in the apo form
3I9J	;	2.18	;	Crystal structure of ADP ribosyl cyclase complexed with a substrate analog and a product nicotinamide
3ZWP	;	2.11	;	Crystal structure of ADP ribosyl cyclase complexed with ara-2'F-ADP- ribose at 2.1 angstrom
3I9L	;	1.75	;	Crystal structure of ADP ribosyl cyclase complexed with N1-cIDPR
3ZWO	;	2.0	;	Crystal structure of ADP ribosyl cyclase complexed with reaction intermediate
3I9O	;	3.0	;	Crystal structure of ADP ribosyl cyclase complexed with ribo-2'F-ADP ribose
3I9K	;	1.83	;	Crystal structure of ADP ribosyl cyclase complexed with substrate NAD
3ZWM	;	2.5	;	Crystal structure of ADP ribosyl cyclase complexed with substrate NAD and product cADPR
6VS4	;	2.4	;	Crystal structure of ADP RIBOSYLATION FACTOR-LIKE GTP BINDING PROTEIN /Small COPII coat GTPase SAR1 from Encephalitozoon cuniculi in complex with GDP
1T6Y	;	2.8	;	Crystal structure of ADP, AMP, and FMN bound TM379
3R5H	;	2.2	;	Crystal Structure of ADP-AIR complex of purK: N5-carboxyaminoimidazole ribonucleotide synthetase
3V4S	;	2.02	;	Crystal Structure of ADP-ATP complex of purK: N5-carboxyaminoimidazole ribonucleotide synthetase
6BS3	;	2.3	;	Crystal structure of ADP-bound bacterial Get3-like A and B in Mycobacterium tuberculosis
7RCL	;	2.4	;	Crystal Structure of ADP-bound Galactokinase
7RCM	;	2.1	;	Crystal Structure of ADP-bound Galactokinase
4IFC	;	2.13	;	Crystal Structure of ADP-bound Human PRPF4B kinase domain
5WC2	;	2.5	;	Crystal Structure of ADP-bound human TRIP13
1L2L	;	2.0	;	Crystal structure of ADP-dependent glucokinase from a Pyrococcus Horikoshii
5OD2	;	1.98	;	Crystal structure of ADP-dependent glucokinase from Methanocaldococcus jannaschii
3BRK	;	2.1	;	Crystal Structure of ADP-Glucose Pyrophosphorylase from Agrobacterium tumefaciens
4EJ0	;	2.609	;	Crystal structure of ADP-L-glycero-D-manno-heptose-6-epimerase from Burkholderia thailandensis
9B22	;	1.3	;	Crystal structure of ADP-ribose diphosphatase from Klebsiella pneumoniae (ADP Ribose and AMP bound)
9B21	;	1.6	;	Crystal structure of ADP-ribose diphosphatase from Klebsiella pneumoniae (ADP Ribose bound, Orthorhombic P form)
9B20	;	1.55	;	Crystal structure of ADP-ribose diphosphatase from Klebsiella pneumoniae (AMP bound)
9B1Z	;	1.25	;	Crystal structure of ADP-ribose diphosphatase from Klebsiella pneumoniae (Apo)
4KYX	;	1.8	;	Crystal structure of ADP-ribose pyrophosphatase MutT from Rickettsia felis
3ZWX	;	2.6	;	Crystal structure of ADP-ribosyl cyclase complexed with 8-bromo-ADP- ribose
3ZWY	;	2.4	;	Crystal structure of ADP-ribosyl cyclase complexed with 8-bromo-ADP- ribose and cyclic 8-bromo-cyclic-ADP-ribose
3ZWV	;	2.3	;	Crystal structure of ADP-ribosyl cyclase complexed with ara-2'F-ADP- ribose at 2.3 angstrom
3ZWW	;	2.3	;	Crystal structure of ADP-ribosyl cyclase complexed with ara-2'F-ADP- ribose at 2.3 angstrom
1R0S	;	2.0	;	Crystal structure of ADP-ribosyl cyclase Glu179Ala mutant
1U2R	;	2.6	;	Crystal Structure of ADP-ribosylated Ribosomal Translocase from Saccharomyces cerevisiae
1NA8	;	2.3	;	Crystal structure of ADP-ribosylation factor binding protein GGA1
2CWC	;	1.65	;	Crystal structure of ADP-ribosylglycohydrolase-related protein from Thermus thermophilus HB8
3U0J	;	2.7	;	Crystal structure of ADP-ribosyltransferase HopU1 of Pseudomonas syringae pv. Tomato DC3000
4XZK	;	1.8	;	Crystal structure of ADP-ribosyltransferase Vis in complex with agmatine
4YC0	;	1.5	;	Crystal structure of ADP-ribosyltransferase Vis in complex with M6 Inhibitor
4XZJ	;	1.8	;	Crystal structure of ADP-ribosyltransferase Vis in complex with NAD
7WR6	;	1.96	;	Crystal structure of ADP-riboxanated caspase-4 in complex with Af1521
3RQ5	;	1.7	;	Crystal Structure of ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Bacillus subtilis co-crystallized with ATP/Mg2+ and soaked with CoA
3RQ2	;	1.8	;	Crystal Structure of ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Bacillus subtilis co-crystallized with ATP/Mg2+ and soaked with NADH
3RPZ	;	1.51	;	Crystal Structure of ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Bacillus subtilis co-crystallized with ATP/Mg2+ and soaked with NADPH
3RPH	;	1.75	;	Crystal Structure of ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Bacillus subtilis co-crystallized with ATP/Mg2+.
3RQQ	;	1.6	;	Crystal Structure of ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Bacillus subtilis in complex with P1,P3-Di(adenosine-5') triphosphate
3RQX	;	1.6	;	Crystal Structure of ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Bacillus subtilis in complex with P1,P4-Di(adenosine-5') tetraphosphate
3RQH	;	1.75	;	Crystal Structure of ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Bacillus subtilis in complex with P1,P6-Di(adenosine-5') hexaphosphate
3RQ6	;	1.65	;	Crystal Structure of ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Bacillus subtilis soaked with ADP-ribose
3RQ8	;	1.9	;	Crystal Structure of ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Bacillus subtilis soaked with P1,P5-Di(adenosine-5') pentaphosphate
4CEI	;	2.8	;	Crystal structure of ADPNP-bound AddAB with a forked DNA substrate
4IYE	;	1.951	;	Crystal structure of AdTx1 (rho-Da1a) from eastern green mamba (Dendroaspis angusticeps)
2EA7	;	1.8	;	Crystal Structure of Adzuki Bean 7S Globulin-1
2EAA	;	2.25	;	Crystal Structure of Adzuki Bean 7S Globulin-3
3DXL	;	1.3	;	Crystal structure of AeD7 from Aedes Aegypti
3DY9	;	1.7	;	Crystal structure of AeD7 potassium bromide soak
3DYE	;	1.75	;	Crystal structure of AED7-norepineprhine complex
2HUF	;	1.75	;	Crystal structure of Aedes aegypti alanine glyoxylate aminotransferase
2HUU	;	2.1	;	Crystal structure of Aedes aegypti alanine glyoxylate aminotransferase in complex with alanine
2HUI	;	1.75	;	Crystal structure of Aedes aegypti alanine glyoxylate aminotransferase in complex with glyoxylic acid
7JW2	;	1.5	;	Crystal structure of Aedes aegypti Nibbler EXO domain
7JW3	;	3.05	;	Crystal structure of Aedes aegypti Nibbler NTD domain
7EBU	;	1.95	;	Crystal structure of Aedes aegypti Noppera-bo, glutathione S-transferase epsilon 8, in Daidzein- and glutathione-bound form
7EBW	;	1.94	;	Crystal structure of Aedes aegypti Noppera-bo, glutathione S-transferase epsilon 8, in desmethylglycitein and glutathione-bound form
7EBT	;	1.51	;	Crystal structure of Aedes aegypti Noppera-bo, glutathione S-transferase epsilon 8, in glutathione-bound form
7EBV	;	1.5	;	Crystal structure of Aedes aegypti Noppera-bo, glutathione S-transferase epsilon 8, in luteolin- and glutathione-bound form
1EJ3	;	2.3	;	CRYSTAL STRUCTURE OF AEQUORIN
5ZBE	;	1.6	;	Crystal structure of AerE from Microcystis aeruginosa
6JH7	;	1.38	;	Crystal structure of AerF from Microcystis aeruginosa
5XLF	;	1.71	;	Crystal structure of aerobically purified and aerobically crystallized D. vulgaris Miyazaki F [NiFe]-hydrogenase
5XLH	;	1.93	;	Crystal structure of aerobically purified and aerobically crystallized for 12weeks D. vulgaris Miyazaki F [NiFe]-hydrogenase
5Y4N	;	1.69	;	Crystal structure of aerobically purified and anaerobically crystallized D. vulgaris Miyazaki F [NiFe]-hydrogenase
6Z5H	;	2.3	;	Crystal structure of Aeromonas exotoxin A
4DZG	;	2.02	;	Crystal structure of Aeromonas hydrophila PliG, a periplasmic lysozyme inhibitor of g-type lysozyme
4PJ2	;	1.24	;	Crystal structure of Aeromonas hydrophila PliI in complex with Meretrix lusoria lysozyme
3WGB	;	2.6	;	Crystal structure of aeromonas jandaei L-allo-threonine aldolase
3VH9	;	1.29	;	Crystal structure of Aeromonas proteolytica aminopeptidase complexed with 8-quinolinol
1XRY	;	2.1	;	Crystal structure of Aeromonas proteolytica aminopeptidase in complex with bestatin
1AMP	;	1.8	;	CRYSTAL STRUCTURE OF AEROMONAS PROTEOLYTICA AMINOPEPTIDASE: A PROTOTYPICAL MEMBER OF THE CO-CATALYTIC ZINC ENZYME FAMILY
3WQB	;	1.41	;	Crystal structure of aeromonas sobria serine protease (ASP) and the chaperone (ORF2) complex
4DF3	;	1.73	;	Crystal Structure of Aeropyrum pernix fibrillarin in complex with natively bound S-adenosyl-L-methionine at 1.7A
4GQC	;	2.0	;	Crystal Structure of Aeropyrum pernix Peroxiredoxin Q Enzyme in Fully-Folded and Locally-Unfolded Conformations
4N5Z	;	2.9537	;	Crystal structure of aerosol transmissible influenza H5 hemagglutinin mutant (N158D, N224K, Q226L and T318I) from the influenza virus A/Viet Nam/1203/2004 (H5N1)
7TE2	;	2.25	;	Crystal Structure of AerR from Rhodobacter capsulatus at 2.25 A.
8JI2	;	1.75	;	Crystal structure of AetD in complex with 5,7-dibromo-L-tryptophan
8JI3	;	1.78	;	Crystal structure of AetD in complex with 5,7-dibromo-L-tryptophan and two Fe2+
8JI4	;	1.67	;	Crystal structure of AetD in complex with 5-bromo-L-tryptophan
8JI5	;	2.01	;	Crystal structure of AetD in complex with 5-bromo-L-tryptophan and two Fe2+
8JI6	;	1.9	;	Crystal structure of AetD in complex with L-tryptophan
8JI7	;	1.61	;	Crystal structure of AetD in complex with L-tryptophan and two Fe2+
8JZ2	;	1.85	;	Crystal structure of AetF in complex with FAD
8JZ4	;	2.08	;	Crystal structure of AetF in complex with FAD and 5-bromo-L-tryptophan
8JZ3	;	2.2	;	Crystal structure of AetF in complex with FAD and L-tryptophan
8JZ5	;	1.86	;	Crystal structure of AetF in complex with FAD and NADP+ at 1.86 angstrom
2Q07	;	2.04	;	Crystal structure of AF0587, a protein of unknown function
7EDP	;	2.2	;	Crystal structure of AF10-DOT1L complex
7EKN	;	2.14	;	Crystal structure of AF10-ipep complex
2QVO	;	1.85	;	Crystal structure of AF1382 from Archaeoglobus fulgidus
3O3K	;	2.3	;	Crystal structure of AF1382 from Archaeoglobus fulgidus
3OV8	;	1.8501	;	Crystal structure of AF1382 from Archaeoglobus fulgidus, High resolution
1HJZ	;	1.7	;	Crystal structure of AF1521 protein containing a macroH2A domain
2I5H	;	1.74	;	Crystal structure of Af1531 from Archaeoglobus fulgidus, Pfam DUF655
4L6U	;	2.5	;	Crystal structure of AF1868: Cmr1 subunit of the Cmr RNA silencing complex
2PH7	;	2.4	;	Crystal structure of AF2093 from Archaeoglobus fulgidus
1OI0	;	1.5	;	CRYSTAL STRUCTURE OF AF2198, A JAB1/MPN DOMAIN PROTEIN FROM ARCHAEOGLOBUS FULGIDUS
4TMP	;	2.3	;	Crystal structure of AF9 YEATS bound to H3K9ac peptide
5YYF	;	1.903	;	Crystal structure of AF9 YEATS domain in complex with a peptide inhibitor ""PHQ-H3(Q5-K9)"" modified at K9 with 2-furancarboyl group
7VKG	;	1.83	;	Crystal structure of AF9 YEATS domain in complex with Compound 10
7EIC	;	1.95	;	Crystal structure of AF9 YEATS domain in complex with H4K5acK8ac peptide
7EID	;	2.0	;	Crystal structure of AF9 YEATS domain in complex with H4K8acK12ac peptide
6MIL	;	1.93	;	Crystal structure of AF9 YEATS domain in complex with histone H3K9bu
7VKH	;	2.25	;	Crystal structure of AF9 YEATS domain in complex with hit 2
6MIM	;	2.525	;	Crystal structure of AF9 YEATS domain Y78W mutant in complex with histone H3K9cr
3AXA	;	2.78	;	Crystal structure of afadin PDZ domain in complex with the C-terminal peptide from nectin-3
3ZC1	;	3.269	;	Crystal structure of AfC3PO
6L1Q	;	2.2	;	Crystal structure of AfCbbQ2, a MoxR AAA+-ATPase and CbbQO-type Rubisco activase from Acidithiobacillus ferrooxidans
3WZG	;	2.95	;	Crystal structure of AfCsx3
3WZH	;	3.31	;	Crystal structure of AfCsx3
3WZI	;	2.9	;	Crystal structure of AfCsx3 in complex with ssRNA
6KN5	;	2.2	;	Crystal structure of AFF4 C-terminal domain
7RPV	;	3.54	;	Crystal structure of affinity-enhancing and catalytically inactive ACE2 in complex with SARS-CoV-2 RBD
7WGI	;	2.5	;	Crystal structure of AflSQS from Aspergillus flavus
7WGH	;	2.36	;	Crystal structure of AflSQS from Aspergillus flavus in complex with FSPP
5J5L	;	1.7	;	CRYSTAL STRUCTURE OF AFMP4P IN COMPLEX WITH ARACHIDONIC ACID
5J5K	;	1.95	;	CRYSTAL STRUCTURE OF AFMP4P IN COMPLEX WITH PALMITIC ACID
6TZC	;	2.41	;	Crystal Structure of African Swine Fever Virus A179L with the Autophagy Regulator Beclin
8HW5	;	2.3	;	Crystal structure of African swine fever virus CP312R
4LMG	;	2.2	;	Crystal structure of AFT2 in complex with DNA
6P2K	;	2.15	;	Crystal structure of AFV00434, an ancestral GH74 enzyme
2WB6	;	1.95	;	Crystal structure of AFV1-102, a protein from the Acidianus Filamentous Virus 1
2J6B	;	1.3	;	crystal structure of AFV3-109, a highly conserved protein from crenarchaeal viruses
2J6C	;	1.3	;	crystal structure of AFV3-109, a highly conserved protein from crenarchaeal viruses
2VB3	;	2.33	;	Crystal structure of Ag(I)CusF
8GY1	;	1.9	;	Crystal structure of Ag+ binding to Dendrorhynchus zhejiangensis ferritin
6LBW	;	1.501	;	Crystal structure of Ag-mediated base pairs in uncanonical DNA duplex
5OCJ	;	1.8	;	Crystal structure of Ag85C bound to cyclophostin 8beta inhibitor
4QDO	;	1.899	;	Crystal structure of Ag85C co-crystallized with p-chloromercuribenzoic acid
3PJI	;	1.704	;	Crystal structure of AgamOBP22a at 1.7 angstrom in the open status for ligand binding.
7YT9	;	2.6	;	crystal structure of AGD1-4 of Arabidopsis AGDP3
6NWZ	;	2.6	;	Crystal structure of Agd3 a novel carbohydrate deacetylase
7P4D	;	1.85	;	Crystal Structure of Agd31B, alpha-transglucosylase in Glycoside Hydrolase Family 31, in complex with covalent Cyclophellitol Sulfamidate probe KK130
5I24	;	1.85	;	Crystal Structure of Agd31B, alpha-transglucosylase in Glycoside Hydrolase Family 31, in complex with Cyclophellitol Aziridine probe CF021
5I23	;	1.95	;	Crystal Structure of Agd31B, alpha-transglucosylase in Glycoside Hydrolase Family 31, in complex with Cyclophellitol Aziridine probe CF022
7P4C	;	1.86	;	Crystal Structure of Agd31B, alpha-transglucosylase in Glycoside Hydrolase Family 31, in complex with noncovalent Cyclophellitol Sulfamidate probe KK131
4BA0	;	1.85	;	Crystal Structure of Agd31B, alpha-transglucosylase, complexed with 5F-alpha-GlcF
4B9Z	;	2.0	;	Crystal Structure of Agd31B, alpha-transglucosylase, complexed with Acarbose
7N3B	;	2.09	;	Crystal structure of aged 9-site deamidated variant of human gamma(S)-crystallin
5MEI	;	3.5	;	Crystal structure of Agelastatin A bound to the 80S ribosome
4PH8	;	1.55	;	Crystal structure of AggA, the major subunit of aggregative adherence fimbriae type I (AAF/I) from the Escherichia coli O4H104
4PHX	;	2.4	;	Crystal structure of AggB, the minor subunit of aggregative adherence fimbriae type I from the Escherichia coli O4H104
3BWE	;	2.4	;	Crystal structure of aggregated form of DJ1
3UBU	;	1.91	;	Crystal structure of agkisacucetin, a GpIb-binding snaclec (snake C-type lectin) that inhibits platelet
5ZRU	;	1.833	;	Crystal structure of Agl-KA catalytic domain
1WOG	;	1.8	;	Crystal Structure of Agmatinase Reveals Structural Conservation and Inhibition Mechanism of the Ureohydrolase Superfamily
1WOH	;	1.75	;	Crystal Structure of Agmatinase Reveals Structural Conservation and Inhibition Mechanism of the Ureohydrolase Superfamily
1WOI	;	1.85	;	Crystal Structure of Agmatinase Reveals Structural Conservation and Inhibition Mechanism of the Ureohydrolase Superfamily
7DTP	;	2.3	;	Crystal structure of agmatine coumaroyltransferase from Triticum aestivum
7CIU	;	1.825	;	Crystal Structure of Agmatine N-Acetyltransferase mutant S171A apo form
7CIW	;	1.6	;	Crystal Structure of Agmatine N-Acetyltransferase mutant S171A in complex with Ac-Agm and CoA
7CIV	;	1.848	;	Crystal Structure of Agmatine N-Acetyltransferase mutant S171A in complex with Ac-CoA
7CIX	;	1.748	;	Crystal Structure of Agmatine N-Acetyltransferase mutant S171A in complex with CoA
6AGG	;	2.706	;	Crystal structure of agmatine-AMPPCP-Mg complexed TiaS (tRNAIle2 agmatidine synthetase)
7C6B	;	1.7	;	Crystal structure of Ago2 MID domain in complex with 6-(3-(2-carboxyethyl)phenyl)purine riboside monophosphate
7D7U	;	2.0	;	Crystal structure of Ago2 MID domain in complex with 8-Br-adenosin-5'-monophosphate
3MQ0	;	1.793	;	Crystal Structure of Agobacterium tumefaciens repressor BlcR
7YXU	;	2.31	;	Crystal structure of agonistic antibody 1618 fab domain bound to human 4-1BB.
4YZW	;	2.6	;	Crystal structure of AgPPO8
4XQJ	;	1.9	;	Crystal structure of AgrA LytTR domain in complex with promoters
4XQN	;	2.3	;	Crystal structure of AgrA LytTR domain in complex with promoters
4XQQ	;	3.05	;	Crystal structure of AgrA LytTR domain in complex with promoters
3V64	;	2.85	;	Crystal Structure of agrin and LRP4
3V65	;	3.3	;	Crystal structure of agrin and LRP4 complex
7CNP	;	1.6	;	Crystal structure of Agrobacterium tumefaciens aconitase X (apo-form)
7CNQ	;	2.0	;	Crystal structure of Agrobacterium tumefaciens aconitase X (holo-form)
7D2R	;	2.005	;	Crystal structure of Agrobacterium tumefaciens aconitase X mutant - S449C/C510V
4MUP	;	1.6	;	Crystal structure of Agrobacterium tumefaciens ATU3138 (EFI target 505157), apo structure
5L9O	;	1.84	;	Crystal structure of Agrobacterium tumefaciens C58 strain PBP SocA in complex with glucopine
1Z2I	;	2.2	;	CRYSTAL STRUCTURE OF Agrobacterium tumefaciens MALATE DEHYDROGENASE, NEW YORK STRUCTURAL GENOMICS CONSORTIUM
7Q92	;	2.18	;	Crystal Structure of Agrobacterium tumefaciens NADQ, ATP complex.
7Q94	;	4.3	;	Crystal Structure of Agrobacterium tumefaciens NADQ, DNA complex.
7Q93	;	2.19	;	Crystal Structure of Agrobacterium tumefaciens NADQ, NAD complex.
7Q91	;	2.31	;	Crystal Structure of Agrobacterium tumefaciens NADQ, native form.
3BTP	;	2.3	;	Crystal structure of Agrobacterium tumefaciens VirE2 in complex with its chaperone VirE1: a novel fold and implications for DNA binding
3M3Q	;	2.2	;	Crystal Structure of Agrocybe aegerita lectin AAL complexed with Ganglosides GM1 pentasaccharide
3M3C	;	2.0	;	Crystal Structure of Agrocybe aegerita lectin AAL complexed with p-Nitrophenyl TF disaccharide
3AFK	;	1.95	;	Crystal Structure of Agrocybe aegerita lectin AAL complexed with Thomsen-Friedenreich antigen
3M3E	;	2.1	;	Crystal Structure of Agrocybe aegerita lectin AAL mutant E66A complexed with p-Nitrophenyl Thomsen-Friedenreich disaccharide
2ZGT	;	2.8	;	Crystal structure of Agrocybe aegerita lectin AAL mutant F93G
2ZGP	;	2.7	;	Crystal structure of Agrocybe aegerita lectin AAL mutant I25G
2ZGS	;	1.9	;	Crystal structure of Agrocybe aegerita lectin AAL mutant L47A
3M3O	;	2.1	;	Crystal Structure of Agrocybe aegerita lectin AAL mutant R85A complexed with p-Nitrophenyl TF disaccharide
3WG2	;	2.2	;	Crystal structure of Agrocybe cylindracea galectin mutant (N46A)
3WG4	;	1.6	;	Crystal structure of Agrocybe cylindracea galectin mutant (N46A) with blood type A antigen tetraose
3WG3	;	1.35	;	Crystal structure of Agrocybe cylindracea galectin with blood type A antigen tetraose
3WG1	;	1.9	;	Crystal structure of Agrocybe cylindracea galectin with lactose
3N72	;	1.77	;	Crystal Structure of Aha-1 from plasmodium falciparum, PFC0270w
6LPI	;	2.849	;	Crystal Structure of AHAS holo-enzyme
6YN7	;	1.98	;	Crystal Structure of AHE enzyme from Alicyclobacillus herbarius
4H86	;	2.004	;	Crystal structure of Ahp1 from Saccharomyces cerevisiae in reduced form
4OWY	;	2.2	;	Crystal Structure of Ahp1 from Saccharomyces cerevisiae. Investigating the electron transfers.
1N8J	;	2.17	;	Crystal Structure of AhpC with Active Site Cysteine mutated to Serine (C46S)
1XVW	;	1.9	;	Crystal Structure of AhpE from Mycobacterium tuberculosis, a 1-Cys peroxiredoxin
1XXU	;	1.9	;	Crystal Structure of AhpE from Mycrobacterium tuberculosis, a 1-Cys peroxiredoxin
3PSS	;	2.0	;	Crystal Structure of AhQnr, the Qnr protein from Aeromonas hydrophila (P21 crystal form)
3PSZ	;	2.2	;	Crystal Structure of AhQnr, the Qnr protein from Aeromonas hydrophila (P21212 crystal form)
1F9N	;	2.7	;	CRYSTAL STRUCTURE OF AHRC, THE ARGININE REPRESSOR/ACTIVATOR PROTEIN FROM BACILLUS SUBTILIS
5Y7Y	;	2.4	;	Crystal structure of AhRR/ARNT complex
1Y01	;	2.8	;	Crystal structure of AHSP bound to Fe(II) alpha-hemoglobin
4HG9	;	1.6	;	Crystal structure of AhV_bPA, a basic PLA2 from Agkistrodon halys pallas venom
4E7N	;	1.75	;	Crystal Structure of AhV_TL-I, a Glycosylated Snake-venom Thrombin-like Enzyme from Agkistrodon halys
5K1S	;	2.55	;	crystal structure of AibC
5K7Z	;	2.92	;	Crystal structure of AibR in complex with isovaleryl coenzyme A and operator DNA
5K7H	;	2.35	;	Crystal structure of AibR in complex with the effector molecule isovaleryl coenzyme A
5UY8	;	2.39	;	Crystal structure of AICARFT bound to an antifolate
5UZ0	;	1.79	;	Crystal structure of AICARFT bound to an antifolate
7ZV6	;	2.83	;	Crystal Structure of Aichivirus A 2A protein
7ZV1	;	1.74	;	Crystal Structure of Aichivirus A 2A protein L64M, L109M mutant
4MO0	;	2.1	;	Crystal structure of aIF1 from Methanocaldococcus jannaschii
4MNO	;	1.35	;	Crystal structure of aIF1A from Pyrococcus abyssi
6R8S	;	2.18	;	Crystal structure of aIF2gamma subunit I181K from archaeon Sulfolobus solfataricus complexed with GDPCP
6R8T	;	2.1	;	Crystal structure of aIF2gamma subunit I181T from archaeon Sulfolobus solfataricus complexed with GDPCP
8C3A	;	3.0	;	Crystal structure of ailanthone bound to the Candida albicans 80S ribosome
3CW3	;	1.88	;	Crystal structure of AIM1g1
6JG5	;	2.221	;	Crystal structure of AimR
5XYB	;	2.198	;	Crystal structure of AimR from Bacillus phage SPbeta
5Y24	;	1.922	;	Crystal structure of AimR from Bacillus phage SPbeta in complex with its signalling peptide
6JG9	;	1.998	;	Crystal structure of AimR in complex with arbitrium peptide
6JG8	;	2.097	;	Crystal structure of AimR in complex with DNA
6VX1	;	2.78	;	Crystal structure of air-exposed C45G/T50C D. vulgaris carbon monoxide dehydrogenase (2 day air exposure)
6VX0	;	2.21	;	Crystal structure of air-exposed C45G/T50C D. vulgaris carbon monoxide dehydrogenase (2 hour air exposure)
6VWZ	;	2.488	;	Crystal structure of air-exposed C45G/T50C D. vulgaris carbon monoxide dehydrogenase (20 minute air exposure)
6WUQ	;	2.003	;	Crystal structure of AjiA1 in apo form
5NIN	;	1.7	;	Crystal Structure of AKAP79 calmodulin binding domain peptide in complex with Ca2+/Calmodulin
4GQG	;	1.92	;	Crystal structure of AKR1B10 complexed with NADP+
4GQ0	;	2.1	;	Crystal structure of AKR1B10 complexed with NADP+ and Caffeic acid phenethyl ester
4JIH	;	2.3	;	Crystal Structure Of AKR1B10 Complexed With NADP+ And Epalrestat
4I5X	;	2.1	;	Crystal Structure Of AKR1B10 Complexed With NADP+ And Flufenamic acid
1ZUA	;	1.25	;	Crystal Structure Of AKR1B10 Complexed With NADP+ And Tolrestat
4JII	;	2.2	;	Crystal Structure Of AKR1B10 Complexed With NADP+ And Zopolrestat
5Y7N	;	2.5	;	Crystal structure of AKR1B10 in complex with NADP+ and Androst-4-ene-3-beta-6-alpha-diol
3O3R	;	1.86	;	Crystal Structure of AKR1B14 in complex with NADP
4YVP	;	2.6	;	Crystal Structure of AKR1C1 complexed with glibenclamide
6IJX	;	2.2	;	Crystal Structure of AKR1C1 complexed with meclofenamic acid
3C3U	;	1.8	;	Crystal structure of AKR1C1 in complex with NADP and 3,5-dichlorosalicylic acid
3NTY	;	1.87	;	Crystal structure of AKR1C1 in complex with NADP and 5-Phenyl,3-chlorosalicylic acid
3GUG	;	1.9	;	Crystal structure of AKR1C1 L308V mutant in complex with NADP and 3,5-dichlorosalicylic acid
5HNT	;	2.0	;	Crystal Structure of AKR1C3 complexed with CAPE
4YVV	;	2.3	;	Crystal structure of AKR1C3 complexed with glibenclamide
4ZFC	;	2.0	;	Crystal structure of AKR1C3 complexed with glicazide
4YVX	;	2.3	;	Crystal structure of AKR1C3 complexed with glimepiride
5HNU	;	2.0	;	Crystal Structure of AKR1C3 complexed with octyl gallate
7W1X	;	1.9	;	Crystal structure of AKR4C16 bound with NADPH
7F7K	;	2.36	;	Crystal structure of AKR4C17 bound with NADP+
7F7L	;	2.25	;	Crystal structure of AKR4C17 bound with NADPH
8XR2	;	2.39	;	Crystal structure of AKRtyl-apo1
8XR3	;	2.31	;	Crystal structure of AKRtyl-apo2
8XR4	;	1.94	;	Crystal structure of AKRtyl-NADP(H) complex
8JWM	;	1.93	;	Crystal structure of AKRtyl-NADP-tylosin complex
8JWN	;	2.25	;	Crystal structure of AKRtyl-NADPH complex
8JWO	;	2.25	;	Crystal structure of AKRtyl-tylosin complex
3CQU	;	2.2	;	Crystal Structure of Akt-1 complexed with substrate peptide and inhibitor
3CQW	;	2.0	;	Crystal Structure of Akt-1 complexed with substrate peptide and inhibitor
3MV5	;	2.47	;	Crystal structure of Akt-1-inhibitor complexes
3MVH	;	2.01	;	Crystal structure of Akt-1-inhibitor complexes
6NPZ	;	2.12	;	Crystal structure of Akt1 (aa 123-480) kinase with a bisubstrate
6BUU	;	2.4	;	Crystal structure of AKT1 (aa 144-480) with a bisubstrate
6CCY	;	2.18	;	Crystal structure of Akt1 in complex with a selective inhibitor
6S9X	;	2.6	;	Crystal Structure of AKT1 in Complex with Covalent-Allosteric AKT Inhibitor 15c
6S9W	;	2.3	;	Crystal Structure of AKT1 in Complex with Covalent-Allosteric AKT Inhibitor 16a
6HHJ	;	2.3	;	Crystal Structure of AKT1 in Complex with Covalent-Allosteric AKT Inhibitor 24b
6HHG	;	2.3	;	Crystal Structure of AKT1 in Complex with Covalent-Allosteric AKT Inhibitor 27
6HHI	;	2.7	;	Crystal Structure of AKT1 in Complex with Covalent-Allosteric AKT Inhibitor 30b
6HHH	;	2.7	;	Crystal Structure of AKT1 in Complex with Covalent-Allosteric AKT Inhibitor 31
6HHF	;	2.9	;	Crystal Structure of AKT1 in Complex with Covalent-Allosteric AKT Inhibitor Borussertib
4IT7	;	2.1	;	Crystal structure of Al-CPI
5Y20	;	2.409	;	Crystal structure of AL1 PHD finger bound to H3K4me3
5XVL	;	1.629	;	Crystal structure of AL2 PAL domain
5Y53	;	1.598	;	Crystal structure of AL2 PAL domain in complex with AtBMI1b binding site
5XVW	;	1.849	;	Crystal structure of AL2 PAL domain in complex with AtRing1a distal site
5Y21	;	1.769	;	Crystal structure of AL2 PAL domain in complex with AtRing1a proximal site
5YC3	;	2.601	;	Crystal structure of AL3 PHD finger bound to H3K4me2
5YC4	;	2.697	;	Crystal structure of AL3 PHD finger bound to H3K4me3
5XVJ	;	1.4	;	Crystal structure of AL7 PAL domain
1AMT	;	1.5	;	Crystal structure of alamethicin at 1.5 angstrom resolution
3TCM	;	2.71	;	Crystal Structure of Alanine Aminotransferase from Hordeum vulgare
1VLL	;	2.8	;	Crystal structure of alanine dehydrogenase (AF1665) from Archaeoglobus fulgidus at 2.80 A resolution
2EEZ	;	2.71	;	Crystal structure of alanine dehydrogenase from themus thermophilus
3P2Y	;	1.82	;	Crystal structure of alanine dehydrogenase/pyridine nucleotide transhydrogenase from Mycobacterium smegmatis
5YYC	;	1.801	;	Crystal structure of alanine racemase from Bacillus pseudofirmus (OF4)
3KW3	;	2.04	;	Crystal structure of alanine racemase from Bartonella henselae with covalently bound pyridoxal phosphate
2DY3	;	2.1	;	Crystal Structure of alanine racemase from Corynebacterium glutamicum
1VFH	;	2.0	;	Crystal structure of alanine racemase from D-cycloserine producing Streptomyces lavendulae
3E5P	;	2.5	;	Crystal structure of alanine racemase from E.faecalis
3E6E	;	2.5	;	Crystal structure of Alanine racemase from E.faecalis complex with cycloserine
3CO8	;	1.7	;	Crystal structure of alanine racemase from Oenococcus oeni
3HUR	;	2.5	;	Crystal structure of alanine racemase from Oenococcus oeni
1FTX	;	2.2	;	Crystal structure of alanine racemase in complex with D-alanine phosphonate
1VJO	;	1.7	;	Crystal structure of Alanine--glyoxylate aminotransferase (ALR1004) from Nostoc sp. at 1.70 A resolution
2YRI	;	2.05	;	Crystal structure of alanine-pyruvate aminotransferase with 2-methylserine
1V4P	;	1.45	;	Crystal structure of Alanyl-tRNA Synthetase from Pyrococcus horikoshii OT3
2ZZG	;	3.1	;	Crystal structure of alanyl-tRNA synthetase in complex with 5''-O-(N-(L-alanyl)-sulfamyoxyl) adenine without oligomerization domain
1YFR	;	2.15	;	crystal structure of alanyl-tRNA synthetase in complex with ATP and magnesium
2ZZF	;	2.7	;	Crystal structure of alanyl-tRNA synthetase without oligomerization domain
2ZZE	;	2.16	;	Crystal structure of alanyl-tRNA synthetase without oligomerization domain in lysine-methylated form
8OI2	;	3.3	;	Crystal structure of Alb1 megabody in complex with human serum albumin
6ET8	;	1.7	;	Crystal structure of AlbA in complex with albicidin
7DL8	;	2.459	;	Crystal structure of ALBA1 from Trypanosoma brucei
3U6Y	;	2.0	;	Crystal structure of ALBA2-DNA complex
7Y8U	;	2.1	;	Crystal structure of AlbEF homolog from Quasibacillus thermotolerans
7Y8X	;	2.25	;	Crystal structure of AlbEF homolog from Quasibacillus thermotolerans in complex with Ni(II)
7Y8V	;	2.3	;	Crystal structure of AlbEF homolog mutant (AlbF-H54A/H58A) from Quasibacillus thermotolerans
7RI3	;	2.69	;	Crystal structure of Albireti Toxin, a diphtheria toxin homolog, from Streptomyces albireticuli
2HJ4	;	1.8	;	Crystal structure of Alcaligenes faecalis AADH complex with p-nitrobenzylamine
2Q7Q	;	1.6	;	Crystal structure of Alcaligenes faecalis AADH in complex with p-chlorobenzylamine.
2HJB	;	1.85	;	Crystal structure of Alcaligenes faecalis AADH in complex with p-methoxybenzylamine
3VDQ	;	2.2	;	Crystal structure of alcaligenes faecalis D-3-hydroxybutyrate dehydrogenase in complex with NAD(+) and acetate
1VJ0	;	2.0	;	Crystal structure of Alcohol dehydrogenase (TM0436) from Thermotoga maritima at 2.00 A resolution
7CYI	;	2.95	;	Crystal structure of Alcohol dehydrogenase 1 from Artemisia annua
6LJH	;	1.8	;	Crystal structure of Alcohol dehydrogenase 1 from Artemisia annua in complex with NAD+
6C49	;	1.85	;	Crystal Structure of Alcohol Dehydrogenase from Acinetobacter baumannii
8CON	;	1.7	;	Crystal structure of alcohol dehydrogenase from Arabidopsis thaliana in complex with NADH
3MEQ	;	2.0	;	Crystal structure of alcohol dehydrogenase from Brucella melitensis
8IJ7	;	2.54	;	Crystal structure of alcohol dehydrogenase from Burkholderia gladioli
8IJ6	;	2.28	;	Crystal structure of alcohol dehydrogenase from Burkholderia gladioli with NADP
8H2A	;	2.5	;	Crystal structure of alcohol dehydrogenase from Formosa agariphila
6IQD	;	2.84	;	Crystal structure of Alcohol dehydrogenase from Geobacillus stearothermophilus
8H2B	;	2.1	;	Crystal structure of alcohol dehydrogenase from Zobellia galactanivorans
8IJ8	;	2.38	;	Crystal structure of alcohol dehydrogenase M4 mutant from Burkholderia gladioli
8IJG	;	2.27	;	Crystal structure of alcohol dehydrogenase M5 from Burkholderia gladioli with NADP
3GOH	;	1.55	;	Crystal structure of alcohol dehydrogenase superfamily protein (NP_718042.1) from Shewanella oneidensis at 1.55 A resolution
5TNX	;	1.7	;	Crystal structure of Alcohol dehydrogenase zinc-binding domain protein from Burkholderia ambifaria
1O2D	;	1.3	;	Crystal structure of Alcohol dehydrogenase, iron-containing (TM0920) from Thermotoga maritima at 1.30 A resolution
8IL4	;	3.355	;	Crystal structure of alcohol oxidase ParAOX(M59V/Q60P/R61N/F101S/N602H)(Polyporus arcularius)
8IL5	;	2.50006	;	Crystal structure of alcohol oxidase PcAOX(M59V/Q60P/R61N)(Phanerochaete chrysosporium)
4FL0	;	2.3	;	Crystal structure of ALD1 from Arabidopsis thaliana
7KQV	;	3.18	;	Crystal Structure of aldehyde dehydrogenase (ChALDH) from Cladosporium herbarum
8IXI	;	2.28	;	Crystal structure of aldehyde dehydrogenase (EC 1.2.1.3) Klebsiella pneumoniae
7YOB	;	2.89	;	Crystal structure of Aldehyde dehydrogenase 1A1 from mouse
5N5S	;	2.3	;	Crystal structure of aldehyde dehydrogenase 21 (ALDH21) from Physcomitrella patens in complex with NADP+
5MZ8	;	2.2	;	Crystal structure of aldehyde dehydrogenase 21 (ALDH21) from Physcomitrella patens in complex with the reaction product succinate
5MZ5	;	2.15	;	Crystal structure of aldehyde dehydrogenase 21 (ALDH21) from Physcomitrella patens in its apoform
6X9L	;	2.52	;	Crystal Structure of Aldehyde Dehydrogenase C (AldC) mutant (C291A) from Pseudomonas syringae in complexed with NAD+ and Octanal
3TY7	;	2.4	;	Crystal Structure of Aldehyde Dehydrogenase family Protein from Staphylococcus aureus
3I44	;	2.0	;	Crystal structure of aldehyde dehydrogenase from bartonella henselae at 2.0A resolution
3EK1	;	2.1	;	Crystal structure of aldehyde dehydrogenase from brucella melitensis biovar abortus 2308
5J6B	;	1.95	;	Crystal structure of Aldehyde dehydrogenase from Burkholderia thailandensis in covelent complex with NADPH
2VRO	;	1.6	;	Crystal structure of aldehyde dehydrogenase from Burkholderia xenovorans LB400
1UJM	;	2.0	;	Crystal structure of aldehyde reductase 2 from Sporobolomyces salmonicolor AKU4429
5L2O	;	2.05	;	Crystal Structure of ALDH1A1 in complex with BUC22
5AZ1	;	2.3	;	Crystal structure of aldo-keto reductase (AKR2E5) complexed with NADPH
5AZ0	;	2.2	;	Crystal structure of aldo-keto reductase (AKR2E5) of the silkworm, Bombyx mori
6GXK	;	1.7	;	Crystal structure of Aldo-Keto Reductase 1C3 (AKR1C3) complexed with inhibitor.
7WQM	;	2.13	;	Crystal structure of Aldo-keto reductase 1C3 complexed with compound 24
7WQS	;	2.07	;	Crystal structure of Aldo-keto reductase 1C3 complexed with compound 25
7WQR	;	2.124	;	Crystal structure of Aldo-keto reductase 1C3 complexed with compound 28
8I0C	;	2.33	;	Crystal structure of Aldo-keto reductase 1C3 complexed with compound S0703
7X3L	;	1.86	;	Crystal structure of Aldo-keto reductase 1C3 complexed with compound S07044
7X3M	;	2.694	;	Crystal structure of Aldo-keto reductase 1C3 complexed with compound S07045
7X3O	;	2.001	;	Crystal structure of Aldo-keto reductase 1C3 complexed with compound S07054
7BC0	;	1.83	;	Crystal structure of aldo-keto reductase from Agrobacterium tumefaciens in a binary complex with NADPH
7BC1	;	1.5	;	Crystal structure of aldo-keto reductase from Agrobacterium tumefaciens in a ternary complex with NADPH and glucose
6CIA	;	2.3	;	Crystal structure of aldo-keto reductase from Klebsiella pneumoniae in complex with NADPH.
4XK2	;	1.9	;	Crystal structure of aldo-keto reductase from Polaromonas sp. JS666
4XAP	;	2.21	;	Crystal structure of aldo-keto reductase from Sinorhizobium meliloti 1021
5C7H	;	1.3	;	Crystal structure of aldo-keto reductase from Sinorhizobium meliloti 1021 in complex with NADPH
7BBY	;	1.83	;	Crystal structure of aldo-keto reductase with C-terminal His tag from Agrobacterium tumefaciens
3O0K	;	1.8	;	Crystal structure of ALDO/KETO reductase from brucella melitensis
4WGH	;	1.8	;	Crystal structure of aldo/keto reductase from Klebsiella pneumoniae in complex with NADP and acetate at 1.8 A resolution
3FO9	;	1.9	;	Crystal structure of aldolase antibody 33F12 Fab' in complex with hapten 1,3-diketone
3OCR	;	1.95	;	Crystal structure of aldolase II superfamily protein from Pseudomonas syringae
8FH5	;	1.62	;	Crystal Structure Of Aldose Reductase (AKR1B1) Complexed With NADP+ And AT-001
8FH7	;	1.45	;	Crystal Structure Of Aldose Reductase (AKR1B1) Complexed With NADP+ And AT-003
8FH8	;	1.6	;	Crystal Structure Of Aldose Reductase (AKR1B1) Complexed With NADP+ And AT-003 Soaked In Hydrogen Peroxide
8FH9	;	1.7	;	Crystal Structure Of Aldose Reductase (AKR1B1) Complexed With NADP+ And AT-007
4JIR	;	2.0	;	Crystal Structure Of Aldose Reductase (AKR1B1) Complexed With NADP+ And Epalrestat
8FH6	;	1.952	;	Crystal Structure Of Aldose Reductase (AKR1B1) Complexed With NADP+ And Two AT-001
3AFN	;	1.63	;	Crystal structure of aldose reductase A1-R complexed with NADP
3AFM	;	1.65	;	Crystal structure of aldose reductase A1-R responsible for alginate metabolism
2INZ	;	1.95	;	Crystal Structure of Aldose Reductase complexed with 2-Hydroxyphenylacetic Acid
1X97	;	1.4	;	Crystal structure of Aldose Reductase complexed with 2R4S (Stereoisomer of Fidarestat, 2S4S)
1X98	;	1.3	;	Crystal structure of Aldose Reductase complexed with 2S4R (Stereoisomer of Fidarestat, 2S4S)
3BCJ	;	0.78	;	Crystal structure of Aldose Reductase complexed with 2S4R (Stereoisomer of Fidarestat, 2S4S) at 0.78 A
2IS7	;	1.7	;	Crystal Structure of Aldose Reductase complexed with Dichlorophenylacetic acid
2IQ0	;	1.95	;	Crystal Structure of Aldose Reductase complexed with Hexanoic Acid
2IQD	;	2.0	;	Crystal Structure of Aldose Reductase complexed with Lipoic Acid
2INE	;	1.9	;	Crystal Structure of Aldose Reductase complexed with Phenylacetic Acid
1X96	;	1.4	;	Crystal structure of Aldose Reductase with citrates bound in the active site
7S5I	;	1.61	;	Crystal structure of Aldose-6-phosphate reductase (Ald6PRase) from peach (Prunus persica) leaves
5A04	;	1.698	;	Crystal structure of aldose-aldose oxidoreductase from Caulobacter crescentus complexed with glucose
5A02	;	2.0	;	Crystal structure of aldose-aldose oxidoreductase from Caulobacter crescentus complexed with glycerol
5A05	;	1.897	;	Crystal structure of aldose-aldose oxidoreductase from Caulobacter crescentus complexed with maltotriose
5A06	;	1.841	;	Crystal structure of aldose-aldose oxidoreductase from Caulobacter crescentus complexed with sorbitol
5A03	;	1.848	;	Crystal structure of aldose-aldose oxidoreductase from Caulobacter crescentus complexed with xylose
3W08	;	1.8	;	Crystal structure of aldoxime dehydratase
3A17	;	2.5	;	Crystal Structure of Aldoxime Dehydratase (OxdRE) in Complex with Butyraldoxime (Co-crystal)
3A18	;	1.8	;	Crystal Structure of Aldoxime Dehydratase (OxdRE) in Complex with Butyraldoxime (soaked crystal)
3A16	;	1.6	;	Crystal Structure of Aldoxime Dehydratase (OxdRE) in Complex with Propionaldoxime
3L7Q	;	2.5	;	Crystal structure of AldR from streptococcus mutans
7OA1	;	2.0	;	Crystal structure of alfa carbonic anhydrase from Schistosoma mansoni with 4-(2-(3-(4-iodophenyl)ureido)ethyl)benzenesulfonamide
1SUS	;	2.7	;	Crystal structure of alfalfa feruoyl coenzyme A 3-O-methyltransferase
1XOK	;	3.0	;	crystal structure of alfalfa mosaic virus RNA 3'UTR in complex with coat protein N terminal peptide
4OK4	;	1.7	;	Crystal Structure of Alg17c Mutant H202L
4OK2	;	2.45	;	Crystal Structure of Alg17c Mutant Y258A
4OJZ	;	1.9	;	Crystal Structure of Alg17c Mutant Y258A Complexed with Alginate Trisaccharide
2ZA9	;	2.1	;	Crystal Structure of Alginate lyase A1-II' N141C/N199C
1HV6	;	2.0	;	CRYSTAL STRUCTURE OF ALGINATE LYASE A1-III COMPLEXED WITH TRISACCHARIDE PRODUCT.
1QAZ	;	1.78	;	CRYSTAL STRUCTURE OF ALGINATE LYASE A1-III FROM SPHINGOMONAS SPECIES A1 AT 1.78A RESOLUTION
3A0O	;	2.11	;	Crystal structure of alginate lyase from Agrobacterium tumefaciens C58
5Y33	;	1.54	;	Crystal structure of alginate lyase from Flavobacterium sp. UMI-01 reveals polymannuronate specificity
6KFN	;	0.89	;	Crystal structure of alginate lyase from Paenibacillus sp. str. FPU-7
1VAV	;	2.0	;	Crystal structure of alginate lyase PA1167 from Pseudomonas aeruginosa at 2.0 A resolution
3GNE	;	1.2	;	Crystal structure of alginate lyase vAL-1 from Chlorella virus
3WSC	;	1.992	;	Crystal structure of alginate-binding protein Algp7
6JHX	;	2.2	;	Crystal structure of alginate-binding protein AlgQ2 without calcium ion
3E4B	;	2.5	;	Crystal structure of AlgK from Pseudomonas fluorescens WCS374r
6IN7	;	1.96	;	Crystal structure of AlgU in complex with MucA(cyto)
3TP9	;	2.7	;	Crystal structure of Alicyclobacillus acidocaldarius protein with beta-lactamase and rhodanese domains
5WQE	;	3.126	;	Crystal structure of Alicyclobacillus acidoterrestris C2c1 in complex with single-guide RNA at 3.1 Angstrom resolution
8CS0	;	1.65	;	Crystal structure of alien DNA CTSZZPBSBSZPPBAG in a host-guest complex with the N-terminal fragment of Moloney murine leukemia virus reverse transcriptase
8CRZ	;	1.2	;	Crystal structure of alien DNA CTSZZPBSBSZPPBAG in a tetragonal lattice
8CRY	;	1.2	;	Crystal structure of alien DNA CTSZZPBSBSZPPBAG in an orthorhombic lattice
7C2A	;	1.18	;	Crystal structure of AlinE4, a SGNH-hydrolase family esterase
7C82	;	1.18	;	Crystal structure of AlinE4, a SGNH-hydrolase family esterase
4Y59	;	1.22	;	Crystal structure of ALiS1-Streptavidin complex
4Y5D	;	1.2	;	CRYSTAL STRUCTURE OF ALiS2-STREPTAVIDIN COMPLEX
5B5F	;	1.2	;	Crystal structure of ALiS3-Streptavidin complex
5B5G	;	1.5	;	Crystal structure of ALiS4-Streptavidin complex
2XS8	;	2.498	;	Crystal Structure of ALIX in complex with the SIVagmTan-1 AYDPARKLL Late Domain
2XS1	;	2.296	;	Crystal Structure of ALIX in complex with the SIVmac239 PYKEVTEDL Late Domain
2OJQ	;	2.87	;	Crystal structure of Alix V domain
2OEV	;	3.3	;	Crystal structure of ALIX/AIP1
2R05	;	2.55	;	Crystal Structure of ALIX/AIP1 in complex with the HIV-1 YPLASL Late Domain
2R02	;	2.6	;	Crystal Structure of ALIX/AIP1 in complex with the HIV-1 YPLTSL Late Domain
2R03	;	2.59	;	Crystal Structure of ALIX/AIP1 in complex with the YPDL Late Domain
7NX3	;	2.81	;	Crystal structure of ALK in complex with Fab324
7EXQ	;	2.2	;	Crystal structure of alkaline alpha-galactosidase D383A mutant from Arabidopsis thaliana complexed with product-galactose and sucrose.
7EXR	;	2.0	;	Crystal structure of alkaline alpha-galactosidase D383A mutant from Arabidopsis thaliana complexed with Stachyose.
7EXJ	;	2.47	;	Crystal structure of alkaline alpha-galctosidase D383A mutant from Arabidopsis thaliana complexed with Raffinose
5GOR	;	2.673	;	Crystal structure of alkaline invertase InvA from Anabaena sp. PCC 7120
5GOO	;	2.11	;	Crystal structure of alkaline invertase InvA from Anabaena sp. PCC 7120 complexed with fructose
5GOQ	;	2.75	;	Crystal structure of alkaline invertase InvA from Anabaena sp. PCC 7120 complexed with glucose
5GOP	;	2.35	;	Crystal structure of alkaline invertase InvA from Anabaena sp. PCC 7120 complexed with sucrose
1WKY	;	1.65	;	Crystal structure of alkaline mannanase from Bacillus sp. strain JAMB-602: catalytic domain and its Carbohydrate Binding Module
5TOO	;	2.031	;	Crystal structure of alkaline phosphatase PafA T79S, N100A, K162A, R164A mutant
1WMD	;	1.3	;	Crystal Structure of alkaline serine protease KP-43 from Bacillus sp. KSM-KP43 (1.30 angstrom, 100 K)
1WME	;	1.5	;	Crystal Structure of alkaline serine protease KP-43 from Bacillus sp. KSM-KP43 (1.50 angstrom, 293 K)
1WMF	;	1.73	;	Crystal Structure of alkaline serine protease KP-43 from Bacillus sp. KSM-KP43 (oxidized form, 1.73 angstrom)
2NQY	;	2.4	;	Crystal structure of alkaline thermophlic xylanase from Bacillus sp. (NCL 86-6-10) with complex xylotriose: Xylotriose cleaved to xylobiose and xylose
5Z73	;	1.93	;	Crystal structure of alkaline/neutral invertase InvB from Anabaena sp. PCC 7120
5Z74	;	1.95	;	Crystal structure of alkaline/neutral invertase InvB from Anabaena sp. PCC 7120 complexed with sucrose
1DED	;	2.0	;	CRYSTAL STRUCTURE OF ALKALOPHILIC ASPARAGINE 233-REPLACED CYCLODEXTRIN GLUCANOTRANSFERASE COMPLEXED WITH AN INHIBITOR, ACARBOSE, AT 2.0 A RESOLUTION
7JV3	;	2.8	;	Crystal structure of alkanesulfonate monooxygenase MsuD from Pseudomonas fluorescens
4NII	;	1.622	;	Crystal structure of AlkB D135I mutant protein with cofactors bound to dsDNA containing m6A/A
4NIG	;	1.52	;	Crystal structure of AlkB D135I/E136H mutant protein with cofactors bound to dsDNA containing m6A/A
4NIH	;	1.374	;	Crystal structure of AlkB E136L mutant protein with cofactors bound to dsDNA containing m6A/A
4JHT	;	1.18	;	Crystal Structure of AlkB in complex with 5-carboxy-8-hydroxyquinoline (IOX1)
2FDF	;	2.1	;	Crystal Structure of AlkB in complex with Co(II), 2-oxoglutarate, and methylated trinucleotide T-meA-T
2FDJ	;	2.1	;	Crystal Structure of AlkB in complex with Fe(II) and succinate
3I2O	;	1.7	;	Crystal Structure of AlkB in complex with Fe(II), 2-oxoglutarate and methylated trinucleotide T-meA-T
3I49	;	1.6	;	Crystal Structure of AlkB in complex with Fe(II), 2-oxoglutarate and methylated trinucleotide T-meC-T
2FD8	;	2.3	;	Crystal Structure of AlkB in complex with Fe(II), 2-oxoglutarate, and methylated trinucleotide T-meA-T
2FDI	;	1.8	;	Crystal Structure of AlkB in complex with Fe(II), 2-oxoglutarate, and methylated trinucleotide T-meA-T (air 3 hours)
2FDK	;	2.3	;	Crystal Structure of AlkB in complex with Fe(II), 2-oxoglutarate, and methylated trinucleotide T-meA-T (air 9 days)
2FDG	;	2.2	;	Crystal Structure of AlkB in complex with Fe(II), succinate, and methylated trinucleotide T-meA-T
3T3Y	;	2.001	;	Crystal structure of AlkB in complex with Fe(III) and 2-(3-hydroxypicolinomido)acetic acid
3T4V	;	1.732	;	Crystal Structure of AlkB in complex with Fe(III) and N-Oxalyl-S-(2-napthalenemethyl)-L-cysteine
3T4H	;	1.65	;	Crystal Structure of AlkB in complex with Fe(III) and N-Oxalyl-S-(3-nitrobenzyl)-L-cysteine
7NRO	;	1.25	;	Crystal structure of AlkB in complex with manganese and N-(4-((6-((carboxymethyl)carbamoyl)-5-hydroxypyridin-2-yl)amino)phenyl)-N-oxohydroxylammonium
3I3Q	;	1.4	;	Crystal Structure of AlkB in complex with Mn(II) and 2-oxoglutarate
3I3M	;	1.5	;	Crystal Structure of AlkB in complex with Mn(II), 2-oxoglutarate and methylated trinucleotide T-meC-T
2FDH	;	2.1	;	Crystal Structure of AlkB in complex with Mn(II), 2-oxoglutarate, and methylated trinucleotide T-meA-T
4NID	;	1.58	;	Crystal structure of AlkB protein with cofactors bound to dsDNA containing m6A
4ZHN	;	1.333	;	Crystal Structure of AlkB T208A mutant protein in complex with Co(II), 2-oxoglutarate, and methylated trinucleotide T-meA-T
6KSF	;	2.4	;	Crystal Structure of ALKBH1 bound to 21-mer DNA bulge
6IMC	;	2.51	;	Crystal Structure of ALKBH1 in complex with Mn(II) and N-Oxalylglycine
6IMA	;	2.593	;	Crystal Structure of ALKBH1 without alpha-1 (N37-C369)
6E8L	;	2.3	;	Crystal Structure of Alkyl hydroperoxidase D (AhpD) from Streptococcus pneumoniae (Strain D39/ NCTC 7466)
6K40	;	2.27	;	Crystal structure of alkyl hydroperoxide reductase from D. radiodurans R1
1ZOF	;	2.95	;	Crystal structure of alkyl hydroperoxide-reductase (AhpC) from Helicobacter Pylori
3DJL	;	1.7	;	Crystal structure of alkylation response protein E. coli AidB
2OUW	;	1.95	;	Crystal structure of Alkylhydroperoxidase AhpD core (YP_425393.1) from Rhodospirillum rubrum ATCC 11170 at 1.95 A resolution
2PRR	;	2.15	;	Crystal structure of alkylhydroperoxidase AhpD core: uncharacterized peroxidase-related protein (YP_296737.1) from Ralstonia eutropha JMP134 at 2.15 A resolution
4XVG	;	2.2	;	Crystal structure of Alkylhydroperoxide Reductase Subunit AhpF from Escherichia coli
4O5R	;	3.33	;	Crystal structure of Alkylhydroperoxide Reductase subunit C from E. coli
4O5U	;	2.65	;	Crystal structure of Alkylhydroperoxide Reductase subunit F from E. coli at 2.65 Ang resolution
2Q33	;	1.8	;	Crystal structure of all-D monellin at 1.8 A resolution
4LW5	;	2.55	;	Crystal structure of all-trans green fluorescent protein
6MQW	;	2.09	;	Crystal Structure of All-trans Retinal-Bound R111K:Y134F:T54V:R132Q:P39Y:R59Y:L121E Human Cellular Retinoic Acid Binding Protein II Irradiated with 400 nm laser (30 seconds) and subsequently dark adapted (10 minutes) at 2.1 Angstrom Resolution
6MQX	;	2.01	;	Crystal Structure of All-trans Retinal-Bound R111K:Y134F:T54V:R132Q:P39Y:R59Y:L121E Human Cellular Retinoic Acid Binding Protein II Irradiated with 400 nm Laser (30 seconds) and Subsequently Dark Adapted (25 minutes) at 2.0 Angstrom Resolution
2IMO	;	2.8	;	Crystal structure of allantoate amidohydrolase from Escherichia coli at pH 4.6
1Z2L	;	2.25	;	Crystal structure of Allantoate-amidohydrolase from E.coli K12 in complex with substrate Allantoate
1O59	;	2.4	;	Crystal structure of Allantoicase (yir029w) from Saccharomyces cerevisiae at 2.40 A resolution
5LFD	;	2.15	;	Crystal structure of allantoin racemase from Pseudomonas fluorescens AllR
5LG5	;	2.1	;	Crystal structure of allantoin racemase from Pseudomonas fluorescens AllR
3HM7	;	2.6	;	Crystal structure of allantoinase from Bacillus halodurans C-125
8HFD	;	2.07	;	Crystal structure of allantoinase from E. coli BL21
3DAM	;	2.4	;	Crystal Structure of Allene oxide synthase
3DAN	;	1.8	;	Crystal Structure of Allene oxide synthase
3DBM	;	2.6	;	Crystal Structure of Allene oxide synthase
4N42	;	2.2	;	Crystal structure of allergen protein scam1 from Scadoxus multiflorus
7VUT	;	1.7	;	Crystal structure of AlleyCat10
7VUU	;	1.95	;	Crystal structure of AlleyCat10 with inhibitor
7VUS	;	1.7	;	Crystal structure of AlleyCat9 with 5-nitro-benzotriazole
7VUR	;	1.7	;	Crystal structure of AlleyCat9 with calcium but no inhibitor
2HOR	;	1.6	;	Crystal structure of alliinase from garlic- apo form
1Q4V	;	2.0	;	CRYSTAL STRUCTURE OF ALLO-ILEA2-INSULIN, AN INACTIVE CHIRAL ANALOGUE: IMPLICATIONS FOR THE MECHANISM OF RECEPTOR
1KN1	;	2.2	;	Crystal structure of allophycocyanin
4PO5	;	1.751	;	Crystal structure of allophycocyanin B from Synechocystis PCC 6803
4RMP	;	2.506	;	Crystal structure of allophycocyanin from marine cyanobacterium Phormidium sp. A09DM
3C1N	;	2.72	;	Crystal Structure of Allosteric Inhibition Threonine-sensitive Aspartokinase from Methanococcus jannaschii with L-threonine
5KCV	;	2.7	;	Crystal structure of allosteric inhibitor, ARQ 092, in complex with autoinhibited form of AKT1
3FZ3	;	2.4	;	Crystal Structure of almond Pru1 protein
5YCZ	;	2.502	;	Crystal structure of Alocasin, protease inhibitor from Giant Taro (Arum macrorrhizon)
8GY4	;	2.5	;	Crystal structure of Alongshan virus methyltransferase
8GYB	;	2.101	;	Crystal structure of Alongshan virus methyltransferase bound to S-adenosyl-L-homocysteine
8GY9	;	2.3	;	Crystal structure of Alongshan virus methyltransferase bound to S-adenosyl-L-methionine
8GYA	;	2.005	;	Crystal structure of Alongshan virus methyltransferase bound to Sinefungin
6RIV	;	1.33	;	Crystal structure of Alopecurus myosuroides GSTF
7CLZ	;	2.10001	;	Crystal structure of Alp1U W187F/Y247F in complex with fluostatin C
3IKQ	;	2.25	;	Crystal structure of alpha 1-2 mannobiose bound trimeric human lung surfactant protein D
3IKR	;	1.65	;	Crystal structure of alpha 1-4 mannobiose bound trimeric human lung surfactant protein D
7NG1	;	1.67	;	Crystal structure of alpha Carbonic anhydrase from Schistoso ma mansoni bound to 1-(4-iodophenyl)-3-[2-(4-sulfamoylphenyl)ethyl]selenourea
7NEX	;	1.81	;	Crystal structure of alpha Carbonic anhydrase from Schistosoma mansoni bound to 1-(4-fluorophenyl)-3-(4-sulfamoylph enyl)thiourea
7BM4	;	1.6	;	Crystal structure of alpha Carbonic anhydrase from Schistosoma mansoni bound to 1-(4-fluorophenyl)-3-(4-sulphamoylphenyl)selenourea
7NWY	;	1.807	;	Crystal structure of alpha carbonic anhydrase from schistosoma mansoni with 4-(3-(4-fluorophenyl)ureido)benzenesulfonamide
3JU3	;	1.9	;	Crystal structure of alpha chain of probable 2-oxoacid ferredoxin oxidoreductase from Thermoplasma acidophilum
2NUZ	;	1.85	;	crystal structure of alpha spectrin SH3 domain measured at room temperature
4GIT	;	2.882	;	Crystal structure of alpha sub-domain of Lon protease from Brevibacillus thermoruber
4UM8	;	2.852	;	Crystal structure of alpha V beta 6
4UM9	;	2.5	;	Crystal structure of alpha V beta 6 with peptide
5UOF	;	1.7	;	Crystal structure of alpha,alpha-trehalose 6-phosphate sythase from Burkholderia multivorans
5MEH	;	0.95	;	Crystal structure of alpha-1,2-mannosidase from Caulobacter K31 strain in complex with 1-deoxymannojirimycin
2WGZ	;	2.12	;	Crystal structure of alpha-1,3 galactosyltransferase (alpha3GT) in a complex with p-nitrophenyl-beta-galactoside (pNP-beta-Gal)
2JCJ	;	2.02	;	Crystal structure of alpha-1,3 Galactosyltransferase (C-terminus truncated mutant-C3) in complex with UDP and Tris
2JCK	;	1.8	;	Crystal structure of alpha-1,3 Galactosyltransferase (R365K) in complex with UDP and 2 manganese ion
2VFZ	;	2.4	;	CRYSTAL STRUCTURE OF ALPHA-1,3 GALACTOSYLTRANSFERASE (R365K) IN COMPLEX WITH UDP-2F-GALACTOSE
2JCL	;	3.29	;	Crystal structure of alpha-1,3 Galactosyltransferase (R365K) in the absence of ligands
7XJV	;	2.8	;	Crystal Structure of Alpha-1,3-mannosyltransferase MNT2 from Saccharomyces cerevisiae, Mn/GDP-mannose form
3UES	;	1.6	;	Crystal structure of alpha-1,3/4-fucosidase from Bifidobacterium longum subsp. infantis complexed with deoxyfuconojirimycin
3UET	;	2.1	;	Crystal structure of alpha-1,3/4-fucosidase from Bifidobacterium longum subsp. infantis D172A/E217A mutant complexed with lacto-N-fucopentaose II
7TM7	;	1.91	;	Crystal structure of Alpha-1,4 glucan phosphorylase from Klebsiella pneumoniae
6DWO	;	2.15	;	Crystal structure of alpha-1-2-mannosidase from Enterococcus faecalis V583
3CWM	;	2.51	;	Crystal structure of alpha-1-antitrypsin complexed with citrate
2QUG	;	2.0	;	Crystal structure of alpha-1-antitrypsin, crystal form A
3CWL	;	2.44	;	Crystal structure of alpha-1-antitrypsin, crystal form B
3QKG	;	2.3	;	Crystal structure of alpha-1-microglobulin at 2.3 A resolution
2II2	;	1.1	;	Crystal Structure of Alpha-11 Giardin
3CHJ	;	1.6	;	Crystal Structure of Alpha-14 Giardin
3CHL	;	1.9	;	Crystal Structure of Alpha-14 Giardin with magnesium bound
2P56	;	2.2	;	Crystal structure of alpha-2,3-sialyltransferase from Campylobacter jejuni in apo form
6MGT	;	2.77	;	Crystal structure of alpha-Amino-beta-Carboxymuconate-epsilon-Semialdehyde Decarboxylase Mutant H110A
2HBV	;	1.65	;	Crystal Structure of alpha-Amino-beta-Carboxymuconate-epsilon-Semialdehyde-Decarboxylase (ACMSD)
2HBX	;	2.5	;	Crystal Structure of alpha-Amino-beta-Carboxymuconate-epsilon-Semialdehyde-Decarboxylase (ACMSD)
6MGS	;	3.131	;	Crystal structure of alpha-Amino-beta-Carboxymuconate-epsilon-Semialdehyde-Decarboxylase with Space Group of C2221
3WN6	;	2.16	;	Crystal structure of alpha-amylase AmyI-1 from Oryza sativa
3VX0	;	1.5	;	Crystal Structure of alpha-amylase from Aspergillus oryzae
3VX1	;	2.2	;	Crystal Structure of alpha-Amylase from Aspergillus oryzae
7P4W	;	2.28	;	Crystal structure of alpha-amylase from Aspergillus oryzae in space group I222
4E2O	;	2.103	;	Crystal structure of alpha-amylase from Geobacillus thermoleovorans, GTA, complexed with acarbose
1WZA	;	1.6	;	Crystal structure of alpha-amylase from H.orenii
1G1Y	;	3.0	;	CRYSTAL STRUCTURE OF ALPHA-AMYLASE II (TVAII) FROM THERMOACTINOMYCES VULGARIS R-47 AND BETA-CYCLODEXTRIN COMPLEX
3OLD	;	2.0	;	Crystal structure of alpha-amylase in complex with acarviostatin I03
4BFH	;	1.25	;	Crystal structure of alpha-amylase inhibitor wrightide R1 (wR1) peptide from Wrightia religiosa
4A1W	;	2.497	;	Crystal structure of alpha-beta foldamer 4c in complex with Bcl-xL
6II2	;	3.5	;	Crystal structure of alpha-beta hydrolase (ABH) and Makes Caterpillars Floppy (MCF)-Like effectors of Vibrio vulnificus MO6-24/O
6IMP	;	2.62	;	Crystal structure of alpha-beta hydrolase (ABH) from Vibrio vulnificus
4A1U	;	1.54	;	Crystal structure of alpha-beta-foldamer 2c in complex with Bcl-xL
4JCL	;	1.7	;	Crystal structure of Alpha-CGT from Paenibacillus macerans at 1.7 Angstrom resolution
1HJE	;	0.75	;	Crystal structure of alpha-conotoxin SI
4J87	;	1.67	;	Crystal structure of alpha-COP
7S22	;	1.75	;	Crystal structure of alpha-COP-WD40 domain
7S16	;	1.24	;	Crystal structure of alpha-COP-WD40 domain R57A mutant
7S23	;	1.49	;	Crystal structure of alpha-COP-WD40 domain, Y139A mutant
4J8G	;	1.895	;	Crystal structure of alpha-COP/E19 complex
4J8B	;	1.878	;	Crystal structure of alpha-COP/Emp47p complex
8EVL	;	1.9	;	Crystal structure of alpha-COPI N-terminal WD40 domain
8EO0	;	1.8	;	Crystal structure of alpha-COPI WD40 domain R300A mutant.
8ENZ	;	1.65	;	Crystal structure of alpha-COPI-WD40 domain K15A mutant.
8ENY	;	1.9	;	Crystal structure of alpha-COPI-WD40 domain R13A mutant.
1DTX	;	2.2	;	CRYSTAL STRUCTURE OF ALPHA-DENDROTOXIN FROM THE GREEN MAMBA VENOM AND ITS COMPARISON WITH THE STRUCTURE OF BOVINE PANCREATIC TRYPSIN INHIBITOR
1ZY9	;	2.34	;	Crystal structure of Alpha-galactosidase (EC 3.2.1.22) (Melibiase) (tm1192) from Thermotoga maritima at 2.34 A resolution
3GXT	;	2.7	;	Crystal structure of alpha-galactosidase A at pH 4.5 complexed with 1-deoxygalactonijirimycin
3A5V	;	2.0	;	Crystal structure of alpha-galactosidase I from Mortierella vinacea
3WY1	;	2.15	;	Crystal structure of alpha-glucosidase
5ZCB	;	2.5	;	Crystal structure of Alpha-glucosidase
7D9B	;	1.58	;	Crystal structure of alpha-glucosidase
1VJT	;	2.5	;	Crystal structure of Alpha-glucosidase (TM0752) from Thermotoga maritima at 2.50 A resolution
8T7Z	;	2.7	;	Crystal structure of alpha-glucosidase (yicI) from Klebsiella aerogenes
7EHH	;	2.0	;	Crystal structure of alpha-glucosidase from Weissella cibaria BKK1 in complex with maltose
3WY2	;	1.471	;	Crystal structure of alpha-glucosidase in complex with glucose
5ZCC	;	1.704	;	Crystal structure of Alpha-glucosidase in complex with maltose
5ZCE	;	1.555	;	Crystal structure of Alpha-glucosidase in complex with maltotetraose
5ZCD	;	1.707	;	Crystal structure of Alpha-glucosidase in complex with maltotriose
3WY3	;	3.0	;	Crystal structure of alpha-glucosidase mutant D202N in complex with glucose and glycerol
3WY4	;	2.5	;	Crystal structure of alpha-glucosidase mutant E271Q in complex with maltose
6AAV	;	1.72	;	Crystal structure of alpha-glucosyl transfer enzyme, XgtA at 1.72 angstrom resolution
3ANZ	;	2.303	;	Crystal Structure of alpha-hemolysin
5X5T	;	2.25	;	Crystal structure of alpha-ketoglutarate semialdehyde dehydrogenase (KGSADH) from Azospirillum brasilense
3R1J	;	2.05	;	Crystal structure of Alpha-ketoglutarate-dependent taurine dioxygenase from Mycobacterium avium, native form
5X5U	;	2.3	;	Crystal structure of alpha-ketoglutarate-semialdehyde dehydrogenase (KGSADH) complexed with NAD
5M8B	;	1.9	;	Crystal structure of alpha-L-arabinofuranosidase from Lactobacillus brevis
3UG4	;	2.15	;	Crystal structure of alpha-L-arabinofuranosidase from Thermotoga maritima arabinose complex
3UG3	;	1.8	;	Crystal structure of alpha-L-arabinofuranosidase from Thermotoga maritima ligand free form
3UG5	;	2.3	;	Crystal structure of alpha-L-arabinofuranosidase from Thermotoga maritima xylose complex
4PSR	;	1.38	;	Crystal Structure of alpha-L-fucosidase from Fusarium graminearum in the open form in complex with L-fucose
7DB5	;	1.9	;	Crystal structure of alpha-L-fucosidase from Vibrio sp. strain EJY3
3B0K	;	1.6	;	Crystal structure of alpha-lactalbumin
3B0O	;	1.61	;	Crystal structure of alpha-lactalbumin
3M7U	;	1.05	;	Crystal Structure of Alpha-Lytic Protease SB1+2 R64A/E182Q Mutant
3M7T	;	1.55	;	Crystal Structure of Alpha-Lytic Protease SB2+3 E8A/R105S Mutant
1F8Q	;	2.2	;	CRYSTAL STRUCTURE OF ALPHA-MOMORCHARIN IN ACETONITRILE-WATER MIXTURE
6LOZ	;	1.08	;	crystal structure of alpha-momorcharin in complex with adenine
6LOR	;	1.35	;	crystal structure of alpha-momorcharin in complex with ADP
6LP0	;	1.519	;	crystal structure of alpha-momorcharin in complex with AMP
6LOQ	;	1.331	;	crystal structure of alpha-momorcharin in complex with cAMP
6LOY	;	1.35	;	crystal structure of alpha-momorcharin in complex with dAMP
6LOW	;	1.39	;	crystal structure of alpha-momorcharin in complex with GMP
6LOV	;	1.35	;	crystal structure of alpha-momorcharin in complex with xanthosine
3R4Y	;	2.0	;	Crystal structure of alpha-neoagarobiose hydrolase (ALPHA-NABH) from Saccharophagus degradans 2-40
3R4Z	;	1.55	;	Crystal structure of alpha-neoagarobiose hydrolase (ALPHA-NABH) in complex with alpha-d-galactopyranose from Saccharophagus degradans 2-40
3VWD	;	1.25	;	Crystal structure of alpha-tubulin acetyltransferase domain of human Mec-17 in complex with acetoacetyl-CoA (P21212 form)
3VWE	;	1.956	;	Crystal structure of alpha-tubulin acetyltransferase domain of human Mec-17 in complex with CoA (P21 form)
2XVG	;	2.6	;	crystal structure of alpha-xylosidase (GH31) from Cellvibrio japonicus
2XVK	;	2.503	;	crystal structure of alpha-xylosidase (GH31) from Cellvibrio japonicus in complex with 5-fluoro-alpha-D-xylopyranosyl fluoride
2XVL	;	2.3	;	crystal structure of alpha-xylosidase (GH31) from Cellvibrio japonicus in complex with Pentaerythritol propoxylate (5 4 PO OH)
1WE5	;	2.4	;	Crystal Structure of Alpha-Xylosidase from Escherichia coli
4PSU	;	2.2	;	Crystal structure of alpha/beta hydrolase from Rhodopseudomonas palustris CGA009
6LZH	;	1.9	;	Crystal structure of Alpha/beta hydrolase GrgF from Penicillium sp. sh18
3FSG	;	2.0	;	Crystal structure of alpha/beta superfamily hydrolase from Oenococcus oeni PSU-1
2ZWI	;	2.01	;	Crystal structure of alpha/beta-Galactoside alpha-2,3-Sialyltransferase from a Luminous Marine Bacterium, <I>Photobacterium phosphoreum</I>
2NZW	;	1.9	;	Crystal Structure of alpha1,3-Fucosyltransferase
5ZOI	;	3.19	;	Crystal Structure of alpha1,3-Fucosyltransferase
2NZX	;	1.9	;	Crystal Structure of alpha1,3-Fucosyltransferase with GDP
2NZY	;	2.05	;	Crystal Structure of alpha1,3-Fucosyltransferase with GDP-fucose
5OM5	;	1.595	;	Crystal structure of Alpha1-antichymotrypsin variant DBS-I-allo1: an allosterically triggered drug-binding serpin for doxycycline
5OM6	;	1.849	;	Crystal structure of Alpha1-antichymotrypsin variant DBS-I-allo2: a MMP9-cleavable drug-binding serpin for doxycycline
5OM2	;	1.47	;	Crystal structure of Alpha1-antichymotrypsin variant DBS-I1: a drug-binding serpin for doxycycline
5OM3	;	2.0	;	Crystal structure of Alpha1-antichymotrypsin variant DBS-I5: a MMP14-cleavable drug-binding serpin for doxycycline
6HGN	;	1.478	;	Crystal structure of Alpha1-antichymotrypsin variant DBS-II-allo-L55V: an allosterically controlled doxorubicin-binding serpin with an unprecedentedly high ligand release efficacy
5OM7	;	1.727	;	Crystal structure of Alpha1-antichymotrypsin variant DBS-II: a drug-binding serpin for doxorubicin
6HGD	;	1.9	;	Crystal structure of Alpha1-antichymotrypsin variant NewBG-0: a new binding globulin variant that is devoid of any cortisol-binding capabilities
6HGE	;	2.8	;	Crystal structure of Alpha1-antichymotrypsin variant NewBG-I in the uncleaved S-conformation
6HGF	;	1.651	;	Crystal structure of Alpha1-antichymotrypsin variant NewBG-II: a new binding globulin in complex with cortisol
6HGM	;	1.369	;	Crystal structure of Alpha1-antichymotrypsin variant NewBG-III-allo: an allosterically controlled new binding globulin with an unprecedentedly high ligand release efficacy
6HGJ	;	1.825	;	Crystal structure of Alpha1-antichymotrypsin variant NewBG-III: a new binding globulin in complex with aldosterone
6HGI	;	1.517	;	Crystal structure of Alpha1-antichymotrypsin variant NewBG-III: a new binding globulin in complex with corticosterone
6HGG	;	1.787	;	Crystal structure of Alpha1-antichymotrypsin variant NewBG-III: a new binding globulin in complex with cortisol
6HGK	;	1.855	;	Crystal structure of Alpha1-antichymotrypsin variant NewBG-III: a new binding globulin in complex with progesterone
6HGL	;	1.92	;	Crystal structure of Alpha1-antichymotrypsin variant NewBG-III: a new binding globulin in complex with testosterone
6HGH	;	1.9	;	Crystal structure of Alpha1-antichymotrypsin variant NewBG-III: a new binding globulin without any bound ligand
1AL1	;	2.7	;	CRYSTAL STRUCTURE OF ALPHA1: IMPLICATIONS FOR PROTEIN DESIGN
3VI3	;	2.9	;	Crystal structure of alpha5beta1 integrin headpiece (ligand-free form)
3VI4	;	2.9	;	Crystal structure of alpha5beta1 integrin headpiece in complex with RGD peptide
7CEB	;	2.89	;	Crystal structure of alpha6beta1 integrin headpiece
6HY7	;	2.26	;	Crystal structure of alpha9 nAChR extracellular domain in complex with alpha-conotoxin RgIA
1MQ8	;	3.3	;	Crystal structure of alphaL I domain in complex with ICAM-1
1K8X	;	1.9	;	Crystal Structure Of AlphaT183V Mutant Of Tryptophan Synthase From Salmonella Typhimurium
1KFB	;	1.9	;	CRYSTAL STRUCTURE OF ALPHAT183V MUTANT OF TRYPTOPHAN SYNTHASE FROM SALMONELLA TYPHIMURIUM WITH Indole Glycerol Phosphate
1KFC	;	1.5	;	CRYSTAL STRUCTURE OF ALPHAT183V MUTANT OF TRYPTOPHAN SYNTHASE FROM SALMONELLA TYPHIMURIUM With Indole Propanol Phosphate
1KFE	;	1.75	;	CRYSTAL STRUCTURE OF ALPHAT183V MUTANT OF TRYPTOPHAN SYNTHASE FROM SALMONELLA TYPHIMURIUM WITH L-Ser Bound To The Beta Site
6J0Z	;	2.889	;	Crystal structure of AlpK
5Z2C	;	2.594	;	Crystal structure of ALPK-1 N-terminal domain in complex with ADP-heptose
7TPS	;	3.15	;	Crystal structure of ALPN-202 (engineered CD80 vIgD) in complex with PD-L1
3QYJ	;	1.778	;	Crystal structure of ALR0039, a putative alpha/beta hydrolase from Nostoc sp PCC 7120.
2BTW	;	2.0	;	Crystal structure of Alr0975
6UV7	;	2.27	;	Crystal structure of alr1298, a pentapeptide repeat protein from Nostoc Pcc 7120, determined at 2.3 Angstrom resolution
6UVI	;	2.1	;	Crystal structure of alr1298, a pentapeptide repeat protein from Nostoc Pcc 7120, determined at 2.3 Angstrom resolution
6OMX	;	1.71	;	Crystal structure of alr5209, a pentapeptide repeat protein from Nostoc Pcc 7120, determined at 1.7 Angstrom resolution
3V0R	;	1.9	;	Crystal structure of Alternaria alternata allergen Alt a 1
4AUD	;	2.67	;	Crystal structure of alternaria alternata major allergen alt a 1
5W1Q	;	1.95	;	Crystal structure of alternate isoform of glutamate racemase from Helicobacter pylori bound to D-glutamate
5GN7	;	3.2	;	Crystal structure of alternative oxidase from Trypanosoma brucei brucei complexed with cumarin derivative-17
5GN9	;	3.2	;	Crystal structure of alternative oxidase from Trypanosoma brucei brucei complexed with cumarin derivative-17b
3K3S	;	2.15	;	Crystal structure of altronate hydrolase (fragment 1-84) from Shigella Flexneri.
2D3I	;	2.15	;	Crystal Structure of Aluminum-Bound Ovotransferrin at 2.15 Angstrom Resolution
3BRN	;	2.0	;	Crystal Structure of AM182 Serotonin Complex
4APM	;	2.3	;	Crystal Structure of AMA1 from Babesia divergens
4APL	;	2.9	;	Crystal Structure of AMA1 from Neospora caninum
4Z81	;	2.05	;	Crystal structure of AMA4 DI-DII-EGF1 from Toxoplasma gondii
1JLY	;	2.2	;	CRYSTAL STRUCTURE OF AMARANTHUS CAUDATUS AGGLUTININ
5EVE	;	2.55	;	Crystal structure of Amb a 8 in complex with poly-Pro10
8XJ0	;	3.3	;	Crystal structure of AmFab mutant - P40C/E165C (Light chain), G10C/P210C(Heavy chain)
2A48	;	2.0	;	Crystal structure of amFP486 E150Q
2A47	;	1.72	;	Crystal structure of amFP486 H199T
5I4L	;	3.1	;	Crystal structure of Amicoumacin A bound to the yeast 80S ribosome
1ID2	;	2.15	;	CRYSTAL STRUCTURE OF AMICYANIN FROM PARACOCCUS VERSUTUS (THIOBACILLUS VERSUTUS)
1T5K	;	1.4	;	Crystal structure of amicyanin substituted with cobalt
2DC0	;	2.0	;	Crystal structure of amidase
5THW	;	2.5	;	Crystal structure of Amidase, hydantoinase/carbamoylase family from Burkholderia multivorans
5I4M	;	1.8	;	Crystal structure of Amidase, hydantoinase/carbamoylase family from Burkholderia vietnamiensis
2IMR	;	1.78	;	Crystal structure of amidohydrolase DR_0824 from Deinococcus radiodurans
3MKV	;	2.4	;	Crystal structure of amidohydrolase eaj56179
3LNP	;	2.1	;	Crystal Structure of Amidohydrolase family Protein OLEI01672_1_465 from Oleispira antarctica
4F0L	;	2.05	;	Crystal structure of Amidohydrolase from Brucella melitensis
3OOQ	;	2.06	;	CRYSTAL STRUCTURE OF amidohydrolase from Thermotoga maritima MSB8
4DZI	;	1.6	;	Crystal structure of amidohydrolase map2389c (target EFI-500390) from Mycobacterium avium subsp. paratuberculosis K-10
4M51	;	1.08	;	Crystal structure of amidohydrolase nis_0429 (ser145ala mutant) from nitratiruptor sp. sb155-2
3V7P	;	1.35	;	Crystal structure of amidohydrolase nis_0429 (target efi-500396) from Nitratiruptor sp. sb155-2
3RHG	;	1.53	;	Crystal structure of amidohydrolase pmi1525 (target efi-500319) from proteus mirabilis hi4320
4QSF	;	1.65	;	CRYSTAL STRUCTURE of AMIDOHYDROLASE PMI1525 (TARGET EFI-500319) FROM PROTEUS MIRABILIS HI4320, A COMPLEX WITH BUTYRIC ACID AND MANGANESE
4INF	;	1.48	;	Crystal structure of amidohydrolase saro_0799 (target efi-505250) from novosphingobium aromaticivorans dsm 12444 with bound calcium
2F6K	;	2.5	;	Crystal Structure of Amidohydrorolase II; Northeast Structural Genomics Target LpR24
4GUD	;	1.911	;	Crystal Structure of Amidotransferase HisH from Vibrio cholerae
1WMP	;	2.0	;	Crystal structure of amine oxidase complexed with cobalt ion
2GLF	;	2.8	;	Crystal structure of Aminipeptidase (M18 family) from Thermotoga Maritima
4IT6	;	1.9	;	Crystal structure of amino acid residues 1-120 of CG17282
3K5P	;	2.15	;	Crystal structure of amino acid-binding ACT: D-isomer specific 2-hydroxyacid dehydrogenase catalytic domain from Brucella melitensis
6PF2	;	2.17	;	Crystal Structure of Amino Acids 1220-1276 of Human Beta Cardiac Myosin Fused to Gp7 and Eb1
6PFP	;	2.2	;	Crystal Structure of Amino Acids 1473-1536 of Human Beta Cardiac Myosin Fused to Gp7 and Eb1
5CJ4	;	3.102	;	Crystal Structure of Amino Acids 1562-1622 of MYH7
5CHX	;	2.3	;	Crystal Structure of amino acids 1590-1657 of MYH7
5CJ0	;	2.3	;	Crystal Structure of Amino Acids 1631-1692 of MYH7
5WLQ	;	3.104	;	Crystal Structure of Amino Acids 1677-1755 of Human Beta Cardiac Myosin Fused to Gp7 and Eb1
5WLZ	;	3.5	;	Crystal Structure of Amino Acids 1677-1758 of Human Beta Cardiac Myosin Fused to Xrcc4
5WME	;	2.3	;	Crystal Structure of Amino Acids 1729-1786 of Human Beta Cardiac Myosin Fused to Gp7 as Anti-Parallel Four-Helix Bundle
5WJB	;	2.905	;	Crystal Structure of Amino Acids 1733-1797 of Human Beta Cardiac Myosin Fused to Gp7
5WJ7	;	2.5	;	Crystal Structure of Amino Acids 1733-1797 of Human Beta Cardiac Myosin Fused to Xrcc4
3QEK	;	2.001	;	Crystal structure of amino terminal domain of the NMDA receptor subunit GluN1
3JPW	;	2.803	;	Crystal structure of amino terminal domain of the NMDA receptor subunit NR2B
5TQ2	;	3.289	;	Crystal structure of amino terminal domains of the NMDA receptor subunit GluN1 and GluN2A in complex with zinc at GluN1 and GluN2A
5TPW	;	2.909	;	Crystal structure of amino terminal domains of the NMDA receptor subunit GluN1 and GluN2A in complex with zinc at the GluN2A
5TQ0	;	2.7	;	Crystal structure of amino terminal domains of the NMDA receptor subunit GluN1 and GluN2A in the presence of EDTA
5TPZ	;	3.095	;	Crystal structure of amino terminal domains of the NMDA receptor subunit GluN1 and GluN2B in apo closed state
5EWM	;	2.76	;	CRYSTAL STRUCTURE OF AMINO TERMINAL DOMAINS OF THE NMDA RECEPTOR SUBUNIT GLUN1 AND GLUN2B IN COMPLEX WITH EVT-101
3QEL	;	2.6	;	Crystal structure of amino terminal domains of the NMDA receptor subunit GluN1 and GluN2B in complex with ifenprodil
5EWJ	;	2.77	;	CRYSTAL STRUCTURE OF AMINO TERMINAL DOMAINS OF THE NMDA RECEPTOR SUBUNIT GLUN1 AND GLUN2B IN COMPLEX WITH IFENPRODIL
5EWL	;	2.98	;	CRYSTAL STRUCTURE OF AMINO TERMINAL DOMAINS OF THE NMDA RECEPTOR SUBUNIT GLUN1 AND GLUN2B IN COMPLEX WITH MK-22
3QEM	;	3.003	;	Crystal structure of amino terminal domains of the NMDA receptor subunit GluN1 and GluN2B in complex with Ro 25-6981
3ELE	;	2.1	;	Crystal structure of Amino Transferase (RER070207001803) from Eubacterium rectale at 2.10 A resolution
1PA7	;	1.45	;	Crystal structure of amino-terminal microtubule binding domain of EB1
1UEG	;	2.4	;	Crystal structure of amino-terminal microtubule binding domain of EB1
3MRU	;	3.0	;	Crystal Structure of Aminoacylhistidine Dipeptidase from Vibrio alginolyticus
3IWK	;	2.4	;	Crystal structure of aminoaldehyde dehydrogenase 1 from Pisum sativum (PsAMADH1)
4I8P	;	1.95	;	Crystal structure of aminoaldehyde dehydrogenase 1a from Zea mays (ZmAMADH1a)
3IWJ	;	2.15	;	Crystal structure of aminoaldehyde dehydrogenase 2 from Pisum sativum (PsAMADH2)
3IO1	;	2.5	;	Crystal Structure of Aminobenzoyl-glutamate utilization protein from Klebsiella pneumoniae
5YSS	;	2.276	;	Crystal structure of aminocaproic acid cyclase in complex with NAD (+)
1ET0	;	2.2	;	CRYSTAL STRUCTURE OF AMINODEOXYCHORISMATE LYASE FROM ESCHERICHIA COLI
4EBJ	;	1.6	;	Crystal structure of aminoglycoside 4'-O-adenylyltransferase ANT(4')-IIb, apo
4EBK	;	2.15	;	Crystal structure of aminoglycoside 4'-O-adenylyltransferase ANT(4')-IIb, tobramycin-bound
5E96	;	2.1	;	Crystal structure of aminoglycoside 6'-acetyltransferase type Ii
1N71	;	1.8	;	Crystal structure of aminoglycoside 6'-acetyltransferase type Ii in complex with coenzyme A
4QC6	;	1.3	;	Crystal structure of aminoglycoside 6'-acetyltransferase-Ie
2A4N	;	2.2	;	Crystal structure of aminoglycoside 6'-N-acetyltransferase complexed with coenzyme A
6IY9	;	2.4	;	Crystal structure of aminoglycoside 7""-phoshotransferase-Ia (APH(7"")-Ia/HYG) from Streptomyces hygroscopicus complexed with hygromycin B
5US1	;	2.48	;	Crystal structure of aminoglycoside acetyltransferase AAC(2')-Ia in complex with N2'-acetylgentamicin C1A and coenzyme A
4YFJ	;	2.2	;	Crystal structure of aminoglycoside acetyltransferase AAC(3)-Ib
7LAO	;	1.92	;	Crystal structure of aminoglycoside acetyltransferase AAC(3)-IIb
6MN3	;	2.4	;	Crystal structure of aminoglycoside acetyltransferase AAC(3)-IVa, apoenzyme
6MN4	;	2.8	;	Crystal structure of aminoglycoside acetyltransferase AAC(3)-IVa, H154A mutant, in complex with apramycin
6MN5	;	2.58	;	Crystal structure of aminoglycoside acetyltransferase AAC(3)-IVa, H154A mutant, in complex with gentamicin C1A
7LAP	;	2.04	;	Crystal structure of aminoglycoside acetyltransferase AAC(3)-Xa
2PRB	;	1.8	;	crystal structure of aminoglycoside acetyltransferase AAC(6')-Ib in complex whith coenzyme A
2QIR	;	2.4	;	Crystal structure of aminoglycoside acetyltransferase AAC(6')-Ib in complex whith coenzyme A and kanamycin
4EVY	;	1.768	;	Crystal structure of aminoglycoside antibiotic 6'-N-acetyltransferase AAC(6')-Ig from Acinetobacter haemolyticus in complex with tobramycin
4F0Y	;	2.56	;	Crystal structure of aminoglycoside antibiotic 6'-N-acetyltransferase AAC(6')-IG from Acinetobacter haemolyticus, apo
4E8O	;	2.138	;	Crystal structure of aminoglycoside antibiotic 6'-N-acetyltransferase AAC(6')-Ih from Acinetobacter baumannii
2PR8	;	2.1	;	crystal structure of aminoglycoside N-acetyltransferase AAC(6')-Ib11
4WQK	;	1.482	;	Crystal structure of aminoglycoside nucleotidylyltransferase ANT(2"")-Ia, apo form
4WQL	;	1.73	;	Crystal structure of aminoglycoside nucleotidylyltransferase ANT(2"")-Ia, kanamycin-bound
4DBX	;	2.004	;	Crystal structure of aminoglycoside phosphotransferase APH(2"")-ID/APH(2"")-IVA
4DE4	;	2.0	;	Crystal structure of aminoglycoside phosphotransferase APH(2"")-Id/APH(2"")-IVa in complex with HEPES
4DFB	;	1.95	;	Crystal structure of aminoglycoside phosphotransferase aph(2"")-id/aph(2"")-iva in complex with kanamycin
4DCA	;	1.8	;	Crystal structure of aminoglycoside phosphotransferase APH(2'')-Ib, ADP-bound
3UZR	;	1.95	;	Crystal structure of aminoglycoside phosphotransferase APH(2'')-Ib, apo form
4N57	;	2.35	;	Crystal structure of aminoglycoside phosphotransferase APH(2'')-IVa ADP complex
2BKK	;	2.15	;	Crystal structure of Aminoglycoside Phosphotransferase APH(3')-IIIa in complex with the inhibitor AR_3a
3TYK	;	1.95	;	Crystal structure of aminoglycoside phosphotransferase APH(4)-Ia
3W0S	;	1.77	;	Crystal structure of aminoglycoside phosphotransferase APH(4)-Ia, ternary complex with AMP-PNP and hygromycin B
4PDY	;	1.35	;	Crystal structure of aminoglycoside phosphotransferase from Alicyclobacillus acidocaldarius subsp. acidocaldarius DSM 446
7UUO	;	2.65	;	Crystal structure of aminoglycoside resistance enzyme ApmA H135A mutant, complex with tobramycin and coenzyme A
7JM0	;	2.08	;	Crystal structure of aminoglycoside resistance enzyme ApmA, apoenzyme
7JM1	;	2.31	;	Crystal structure of aminoglycoside resistance enzyme ApmA, complex with acetyl-CoA
7JM2	;	1.85	;	Crystal structure of aminoglycoside resistance enzyme ApmA, complex with apramycin
7UUJ	;	1.78	;	Crystal structure of aminoglycoside resistance enzyme ApmA, complex with gentamicin
7UUL	;	2.26	;	Crystal structure of aminoglycoside resistance enzyme ApmA, complex with kanamycin B and coenzyme A
7UUN	;	2.83	;	Crystal structure of aminoglycoside resistance enzyme ApmA, complex with neomycin
7UUM	;	2.74	;	Crystal structure of aminoglycoside resistance enzyme ApmA, complex with paromomycin and coenzyme A
7UUK	;	2.82	;	Crystal structure of aminoglycoside resistance enzyme ApmA, complex with tobramycin
5NDW	;	3.7	;	Crystal structure of aminoglycoside TC007 bound to the yeast 80S ribosome
5NDK	;	2.95	;	Crystal structure of aminoglycoside TC007 co-crystallized with 70S ribosome from Thermus thermophilus, three tRNAs and mRNA
5NDJ	;	3.15	;	Crystal structure of aminoglycoside TC007 in complex with 70S ribosome from Thermus thermophilus, three tRNAs and mRNA (soaking)
4DT8	;	2.15	;	Crystal Structure of Aminoglycoside-2''-Phosphotransferase Type IVa in Complex with Adenosine
4DT9	;	2.1	;	Crystal Structure of Aminoglycoside-2''-Phosphotransferase Type IVa in Complex with Guanosine
3SG9	;	2.15	;	Crystal Structure of Aminoglycoside-2''-Phosphotransferase Type IVa Kanamycin A Complex
3SG8	;	1.8	;	Crystal Structure of Aminoglycoside-2''-Phosphotransferase Type IVa Tobramycin Complex
4H05	;	2.15	;	Crystal structure of aminoglycoside-3'-phosphotransferase of type VIII
1ND4	;	2.1	;	Crystal structure of aminoglycoside-3'-phosphotransferase-IIa
6PQB	;	3.14	;	Crystal structure of aminoglycoside-resistance methyltransferase RmtC bound to S-adenosylhomocysteine (SAH)
4R86	;	3.001	;	Crystal Structure of Aminoglycoside/Multidrug Efflux System AcrD from Salmonella typhimurium
2RAG	;	2.0	;	Crystal structure of aminohydrolase from Caulobacter crescentus
1TZ3	;	2.9	;	crystal structure of aminoimidazole riboside kinase complexed with aminoimidazole riboside
1TYY	;	2.6	;	Crystal structure of aminoimidazole riboside kinase from Salmonella enterica
1TZ6	;	2.7	;	Crystal structure of aminoimidazole riboside kinase from Salmonella enterica complexed with aminoimidazole riboside and ATP analog
1VLO	;	1.7	;	Crystal structure of aminomethyltransferase (T protein; tetrahydrofolate-dependent) of glycine cleavage system (np417381) from Escherichia coli k12 at 1.70 A resolution
2IJZ	;	3.0	;	Crystal structure of aminopeptidase
8D1X	;	2.8	;	Crystal Structure of aminopeptidase A from Neisseria gonorrhoeae
5IB9	;	1.4	;	Crystal structure of aminopeptidase equipped with PAD from Aneurinibacillus sp. AM-1
5AB0	;	2.5	;	Crystal structure of aminopeptidase ERAP2 with ligand
5AB2	;	2.729	;	Crystal structure of aminopeptidase ERAP2 with ligand
4PF1	;	2.1	;	Crystal structure of aminopeptidase from marine sediment archaeon Thaumarchaeota archaeon
2GLJ	;	3.2	;	crystal structure of aminopeptidase I from Clostridium acetobutylicum
2DQM	;	1.6	;	Crystal Structure of Aminopeptidase N complexed with bestatin
2DQ6	;	1.5	;	Crystal Structure of Aminopeptidase N from Escherichia coli
2GTQ	;	2.05	;	Crystal structure of aminopeptidase N from human pathogen Neisseria meningitidis
3KED	;	2.3	;	Crystal structure of Aminopeptidase N in complex with 2,4-diaminobutyric acid
4QPE	;	2.004	;	Crystal structure of Aminopeptidase N in complex with N-cyclohexyl-1,2-diaminoethylphosphonic acid
4PW4	;	1.85	;	Crystal structure of Aminopeptidase N in complex with phosphonic acid analogue of homophenylalanine L-(R)-hPheP
4QIR	;	1.701	;	Crystal structure of Aminopeptidase N in complex with the phosphinic dipeptide analogue LL-(R,S)-2-(pyridin-3-yl)ethylGlyP[CH2]Phe
4QME	;	1.601	;	Crystal structure of Aminopeptidase N in complex with the phosphinic dipeptide analogue LL-(R,S)-hPheP[CH2]Phe
4QUO	;	1.65	;	Crystal structure of Aminopeptidase N in complex with the phosphinic dipeptide analogue LL-(R,S)-hPheP[CH2]Phe(3-CH2NH2)
4QHP	;	1.6	;	Crystal structure of Aminopeptidase N in complex with the phosphinic dipeptide analogue LL-(R,S)-hPheP[CH2]Phe(4-CH2NH2)
4PVB	;	2.1	;	Crystal structure of Aminopeptidase N in complex with the phosphonic acid analogue of leucine (D-(S)-LeuP)
4PU2	;	2.095	;	Crystal structure of Aminopeptidase N in complex with the phosphonic acid analogue of leucine L-(R)-LeuP
3GB0	;	2.04	;	Crystal structure of aminopeptidase PepT (NP_980509.1) from Bacillus cereus ATCC 10987 at 2.04 A resolution
8IHG	;	2.858	;	Crystal structure of aminophenol dioxygenase from Pseudomonas species AP-3
2OFV	;	2.0	;	crystal structure of aminoquinazoline 1 bound to Lck
2OG8	;	2.3	;	crystal structure of aminoquinazoline 36 bound to Lck
3JTX	;	1.91	;	Crystal structure of Aminotransferase (NP_283882.1) from NEISSERIA MENINGITIDIS Z2491 at 1.91 A resolution
3F0H	;	1.7	;	Crystal structure of Aminotransferase (RER070207000802) from Eubacterium rectale at 1.70 A resolution
6HNB	;	1.96	;	Crystal structure of aminotransferase Aro8 from Candida albicans
6HNV	;	2.6	;	Crystal structure of aminotransferase Aro9 from C. Albicans with ligands
3EZS	;	2.19	;	Crystal structure of aminotransferase AspB (NP_207418.1) from HELICOBACTER PYLORI 26695 at 2.19 A resolution
4ZWV	;	1.503	;	Crystal Structure of Aminotransferase AtmS13 from Actinomadura melliaura
3RQ1	;	2.2	;	Crystal Structure of Aminotransferase Class I and II from Veillonella parvula
6JCB	;	2.85	;	Crystal structure of aminotransferase CrmG from Actinoalloteichus sp. WH1-2216-6 in C2 space group
6JC7	;	2.2	;	Crystal structure of aminotransferase CrmG from Actinoalloteichus sp. WH1-2216-6 in complex with amino donor L-Ala
8JT3	;	2.35	;	Crystal structure of aminotransferase CrmG from Actinoalloteichus sp. WH1-2216-6 in complex with amino donor L-Arg
6JC9	;	2.35	;	Crystal structure of aminotransferase CrmG from Actinoalloteichus sp. WH1-2216-6 in complex with amino donor L-Gln
6JC8	;	2.25	;	Crystal structure of aminotransferase CrmG from Actinoalloteichus sp. WH1-2216-6 in complex with amino donor L-Glu
5DDS	;	2.6	;	Crystal structure of aminotransferase CrmG from Actinoalloteichus sp. WH1-2216-6 in complex with PLP
5DDU	;	2.46	;	Crystal structure of aminotransferase CrmG from Actinoalloteichus sp. WH1-2216-6 in complex with PMP
5DDW	;	2.3	;	Crystal structure of aminotransferase CrmG from Actinoalloteichus sp. WH1-2216-6 in complex with the PMP external aldimine adduct with Caerulomycin M
6JCA	;	2.1	;	Crystal structure of aminotransferase CrmG from Actinoalloteichus sp. WH1-2216-6 in I222 space group
4EMY	;	2.86	;	Crystal structure of aminotransferase from anaerococcus prevotii dsm 20548.
3I5T	;	2.0	;	CRYSTAL STRUCTURE OF AMINOTRANSFERASE PRK07036 FROM Rhodobacter sphaeroides KD131
3I4J	;	1.7	;	Crystal structure of Aminotransferase, class III from Deinococcus radiodurans
7Z79	;	2.3	;	Crystal structure of aminotransferase-like protein from Variovorax paradoxus
3DIH	;	2.6	;	Crystal structure of ammodytin L
1U77	;	2.0	;	Crystal Structure of Ammonia Channel AmtB from E. Coli
1U7G	;	1.4	;	Crystal Structure of Ammonia Channel AmtB from E. Coli
4AE3	;	2.5	;	Crystal structure of ammosamide 272:myosin-2 motor domain complex
5BPH	;	1.7	;	Crystal structure of AMP complexed D-alanine-D-alanine ligase(DDL) from Yersinia pestis
4H46	;	2.5	;	Crystal Structure of AMP complexes of NEM modified Porcine Liver Fructose-1,6-bisphosphatase
4GBV	;	2.9	;	Crystal Structure of AMP complexes of Porcine Liver Fructose-1,6-bisphosphatase Mutant A54L with 1,2-ethanediol as Cryo-protectant
4GBW	;	2.0	;	Crystal Structure of AMP complexes of Porcine Liver Fructose-1,6-bisphosphatase Mutant A54L with 1,2-propanediol as Cryo-protectant
4KXP	;	2.7	;	Crystal Structure of AMP complexes of Porcine Liver Fructose-1,6-bisphosphatase Mutant I10D in T-state
4GWY	;	3.0	;	Crystal Structure of AMP Complexes of Porcine Liver Fructose-1,6-bisphosphatase with Blocked Subunit Pair Rotation
4GWS	;	2.75	;	Crystal Structure of AMP complexes of Porcine Liver Fructose-1,6-bisphosphatase with Filled Central Cavity
4GWZ	;	2.6	;	Crystal Structure of AMP Complexes of Porcine Liver Fructose-1,6-bisphosphatase with Restrained Subunit Pair Rotation
1YBF	;	2.9	;	Crystal structure of AMP nucleosidase from Bacteroides thetaiotaomicron VPI-5482
2GUW	;	2.64	;	Crystal structure of AMP Nucleosidase from Salmonella typhimurium LT2
4GA6	;	2.21	;	Crystal structure of AMP phosphorylase C-terminal deletion mutant in complex with substrates
4GA5	;	3.25	;	Crystal structure of AMP phosphorylase C-terminal deletion mutant in the apo-form
4GA4	;	3.51	;	Crystal structure of AMP phosphorylase N-terminal deletion mutant
7TGL	;	2.89	;	Crystal structure of AMP+PPi bound DesD, the desferrioxamine synthetase from the Streptomyces griseoflavus ferrimycin biosynthetic pathway
7N8T	;	1.69	;	Crystal Structure of AMP-bound Human JNK2
2QRK	;	1.75	;	Crystal Structure of AMP-bound Saccharopine Dehydrogenase (L-Lys Forming) from Saccharomyces cerevisiae
3VR3	;	3.4	;	Crystal structure of AMP-PNP bound A3B3 complex from Enterococcus hirae V-ATPase [bA3B3]
3VR6	;	2.68	;	Crystal structure of AMP-PNP bound Enterococcus hirae V1-ATPase [bV1]
5ZE9	;	2.102	;	Crystal structure of AMP-PNP bound mutant A3B3 complex from Enterococcus hirae V-ATPase
5C1O	;	2.5	;	Crystal structure of AMP-PNP complexed D-alanine-D-alanine ligase(DDL) from Yersinia pestis
6BS5	;	3.1	;	Crystal structure of AMP-PNP-bound bacterial Get3-like A and B in Mycobacterium tuberculosis
5GZW	;	1.489	;	Crystal structure of AmpC BER adenylylated by acetyl-AMP
5F1G	;	1.76	;	Crystal structure of AmpC BER adenylylated in the cytoplasm
1GA9	;	2.1	;	CRYSTAL STRUCTURE OF AMPC BETA-LACTAMASE FROM E. COLI COMPLEXED WITH NON-BETA-LACTAMASE INHIBITOR (2, 3-(4-BENZENESULFONYL-THIOPHENE-2-SULFONYLAMINO)-PHENYLBORONIC ACID)
1IEM	;	2.3	;	Crystal Structure of AmpC beta-lactamase from E. coli in Complex with a Boronic Acid Inhibitor (1, CefB4)
1LL9	;	1.87	;	Crystal Structure Of AmpC beta-Lactamase From E. Coli In Complex With Amoxicillin
1LLB	;	1.72	;	Crystal Structure Of AmpC beta-Lactamase From E. Coli In Complex With ATMO-penicillin
4KG2	;	1.89	;	Crystal Structure of AmpC beta-lactamase from E. coli in Complex with Cefotaxime
1IEL	;	2.0	;	Crystal Structure of AmpC beta-lactamase from E. coli in Complex with Ceftazidime
4JXG	;	1.65	;	Crystal Structure of AmpC beta-lactamase from E. coli in Complex with Oxacillin
4E3M	;	1.44	;	Crystal structure of AmpC beta-lactamase in complex with a 2-chloro-4-tetrazolyl benzene sulfonamide boronic acid inhibitor
4E3N	;	1.49	;	Crystal structure of AmpC beta-lactamase in complex with a 2-trifluoromethyl-4-tetrazolyl benzene sulfonamide boronic acid inhibitor
4E3L	;	1.43	;	Crystal structure of AmpC beta-lactamase in complex with a 3-chloro-4-tetrazolyl benzene sulfonamide boronic acid inhibitor
4E3I	;	1.6	;	Crystal structure of AmpC beta-lactamase in complex with a designed 3-carboxyl benzyl sulfonamide boronic acid inhibitor
4E3J	;	1.7999	;	Crystal structure of AmpC beta-lactamase in complex with a designed 4-tetrazolyl benzene sulfonamide boronic acid inhibitor
4E3K	;	1.4299	;	Crystal structure of AmpC beta-lactamase in complex with a designed 4-tetrazolyl pyridine sulfonamide boronic acid inhibitor
4E3O	;	1.6	;	Crystal structure of AmpC beta-lactamase in complex with a small chloromethyl sulfonamide boronic acid inhibitor
3O86	;	1.6	;	Crystal structure of AmpC beta-lactamase in complex with a sulfonamide boronic acid inhibitor
3O87	;	1.78	;	Crystal structure of AmpC beta-lactamase in complex with a sulfonamide boronic acid inhibitor
3O88	;	1.64	;	Crystal structure of AmpC beta-lactamase in complex with a sulfonamide boronic acid inhibitor
4OLG	;	1.71	;	Crystal structure of AmpC beta-lactamase in complex with covalently bound N-formyl 7-aminocephalosporanic acid
4KZ6	;	1.68	;	Crystal structure of AmpC beta-lactamase in complex with fragment 13 ((2R,6R)-6-methyl-1-(3-sulfanylpropanoyl)piperidine-2-carboxylic acid)
4KZ7	;	1.43	;	Crystal structure of AmpC beta-lactamase in complex with fragment 16 ((1R,4S)-4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylic acid)
4KZ8	;	2.282	;	Crystal structure of AmpC beta-lactamase in complex with fragment 20 (1,3-diethyl-2-thioxodihydropyrimidine-4,6(1H,5H)-dione)
4KZ9	;	1.72	;	Crystal structure of AmpC beta-lactamase in complex with fragment 41 ((4R,4aS,8aS)-4-phenyldecahydroquinolin-4-ol)
4KZ3	;	1.67	;	Crystal structure of AmpC beta-lactamase in complex with fragment 44 (5-chloro-3-sulfamoylthiophene-2-carboxylic acid)
4KZA	;	1.6	;	Crystal structure of AmpC beta-lactamase in complex with fragment 48 (3-(cyclopropylsulfamoyl)thiophene-2-carboxylic acid)
4KZ5	;	1.35	;	Crystal structure of AmpC beta-lactamase in complex with fragment 5 (N-{[3-(2-chlorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}glycine)
4KZB	;	1.37	;	Crystal structure of AmpC beta-lactamase in complex with fragment 50 (N-(methylsulfonyl)-N-phenyl-alanine)
4KZ4	;	1.42	;	Crystal structure of AmpC beta-lactamase in complex with fragment 60 (2-[(propylsulfonyl)amino]benzoic acid)
4OLD	;	1.48	;	Crystal structure of AmpC beta-lactamase in complex with the product form of (6R,7R)-7-amino-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
4OKP	;	1.37	;	Crystal structure of AmpC beta-lactamase in complex with the product form of 7-amino-desacetoxycephalosporanic acid
4KG6	;	1.75	;	Crystal Structure of AmpC beta-lactamase N152G Mutant from E. coli
4KG5	;	2.11	;	Crystal Structure of AmpC beta-lactamase N152G Mutant in Complex with Cefotaxime
4KEN	;	1.89	;	Crystal Structure of AmpC beta-lactamase N152G Mutant in Complex with Cefoxitin
6LC8	;	1.6	;	Crystal structure of AmpC Ent385 complex form with avibactam
6LC9	;	1.65	;	Crystal structure of AmpC Ent385 complex form with ceftazidime
6LC7	;	1.4	;	Crystal structure of AmpC Ent385 free form
6YEO	;	2.037	;	Crystal structure of AmpC from E. coli with cyclic boronate 2
6YPD	;	1.6	;	Crystal structure of AmpC from E. coli with Cyclic Boronate 3 (CB3 / APC308)
6YEN	;	1.418	;	Crystal structure of AmpC from E. coli with Taniborbactam (VNRX-5133)
6T3D	;	1.5	;	Crystal structure of AmpC from E.coli
6TBW	;	1.51	;	Crystal structure of AmpC from E.coli with Avibactam
6T35	;	1.75	;	Crystal structure of AmpC from E.coli with Enmetazobactam (AAI-101)
6T7L	;	1.47	;	Crystal structure of AmpC from E.coli with Nacubactam (OP0595)
6TPM	;	1.72	;	Crystal structure of AmpC from E.coli with Relebactam (MK-7655)
6T5Y	;	1.3	;	Crystal structure of AmpC from E.coli with Zidebactam (WCK 5107)
6S1S	;	1.78	;	Crystal structure of AmpC from Pseudomonas aeruginosa in complex with [3-(2-carboxyvinyl)phenyl]boronic acid] inhibitor
2Y2C	;	1.802	;	crystal structure of AmpD Apoenzyme
2Y2E	;	2.0	;	crystal structure of AmpD grown at pH 5.5
2Y2D	;	2.0	;	crystal structure of AmpD holoenzyme
2Y2B	;	1.9	;	crystal structure of AmpD in complex with reaction products
4NO3	;	1.703	;	Crystal structure of AMPD2 phosphopeptide bound to HLA-A2
4BPA	;	2.7	;	Crystal structure of AmpDh2 from Pseudomonas aeruginosa in complex with NAG-NAM-NAG-NAM tetrasaccharide
4BOL	;	1.7	;	Crystal structure of AmpDh2 from Pseudomonas aeruginosa in complex with pentapeptide
4BXJ	;	2.35	;	CRYSTAL STRUCTURE OF AMPDH3 FROM PSEUDOMONAS AERUGINOSA
4BXE	;	2.95	;	CRYSTAL STRUCTURE OF AMPDH3 FROM PSEUDOMONAS AERUGINOSA IN COMPLEX WITH ANHYDROMURAMIC PENTAPEPTIDE
4BXD	;	3.1	;	CRYSTAL STRUCTURE OF AMPDH3 FROM PSEUDOMONAS AERUGINOSA IN COMPLEX WITH TETRASACCHARIDE PENTAPEPTIDE
4DKM	;	1.95	;	Crystal Structure of Amphioxus GFPc1a
4DKN	;	1.35	;	Crystal structure of amphioxus green fluorescent protein, GFPA1
6K74	;	2.28	;	Crystal structure of AMPPNP bound Ck1a alpha from C. neoformans
6K77	;	2.4	;	Crystal structure of AMPPNP bound Ck1a alpha from C. neoformans
6ISE	;	2.8	;	Crystal structure of AMPPNP bound CK2 alpha from C. neoformans
6KO6	;	2.4	;	Crystal structure of AMPPNP bound Cka1 from C. neoformans
1X3N	;	2.3	;	Crystal structure of AMPPNP bound Propionate kinase (TdcD) from Salmonella typhimurium
4IIR	;	2.0	;	Crystal Structure of AMPPNP-bound Human PRPF4B kinase domain
3EM3	;	2.2	;	Crystal structure of amprenavir (APV) in complex with a drug resistant HIV-1 protease variant (I50L/A71V).
5O4P	;	1.86	;	Crystal structure of AMPylated GRP78
6EOF	;	1.59	;	Crystal structure of AMPylated GRP78 in ADP state
6EOB	;	2.0	;	Crystal structure of AMPylated GRP78 in apo form (Crystal form 1)
6EOC	;	1.67	;	Crystal structure of AMPylated GRP78 in apo form (Crystal form 2)
6EOE	;	1.71	;	Crystal structure of AMPylated GRP78 with nucleotide
4NH2	;	2.3	;	Crystal structure of AmtB from E. coli bound to phosphatidylglycerol
6B21	;	2.45	;	Crystal structure of AmtB from E. coli bound to TopFluor cardiolipin
1U7C	;	1.85	;	Crystal Structure of AmtB from E.Coli with Methyl Ammonium.
6LAD	;	2.7	;	Crystal structure of Amuc_1100 from Akkermansia muciniphila
7DSZ	;	1.75	;	Crystal structure of Amuc_1102 from Akkermansia muciniphila
5OMS	;	1.95	;	Crystal structure of Amycolatopsis cytochrome P450 GcoA in complex with guaethol.
5NCB	;	1.44	;	Crystal structure of Amycolatopsis cytochrome P450 GcoA in complex with guaiacol.
5OMU	;	1.95	;	Crystal structure of Amycolatopsis cytochrome P450 GcoA in complex with syringol
5OMR	;	1.68	;	Crystal structure of Amycolatopsis cytochrome P450 GcoA in complex with vanillin.
5OGX	;	1.72	;	Crystal structure of Amycolatopsis cytochrome P450 reductase GcoB.
7ZGF	;	2.05	;	Crystal Structure of Amycolatopsis jejuensis Multiple Inositol Polyphosphate Phosphatase, apo-protein
7ZGH	;	1.41	;	Crystal Structure of Amycolatopsis jejuensis Multiple Inositol Polyphosphate Phosphatase, complex with myo-inositol hexakissulfate
7ZGG	;	1.66	;	Crystal Structure of Amycolatopsis jejuensis Multiple Inositol Polyphosphate Phosphatase, phosphate-bound
4N6F	;	2.25	;	Crystal structure of Amycolatopsis orientalis BexX complexed with G6P
4N6E	;	2.6	;	Crystal structure of Amycolatopsis orientalis BexX/CysO complex
2VZO	;	2.24	;	Crystal structure of Amycolatopsis orientalis exo-chitosanase CsxA
1UD3	;	2.15	;	Crystal structure of AmyK38 N289H mutant
1UD8	;	2.88	;	Crystal structure of AmyK38 with lithium ion
1UD6	;	2.5	;	Crystal structure of AmyK38 with potassium ion
1UD5	;	2.7	;	Crystal structure of AmyK38 with rubidium ion
5JJH	;	1.8	;	Crystal structure of amylomaltase from Corynebacterium glutamicum
1CWY	;	2.0	;	CRYSTAL STRUCTURE OF AMYLOMALTASE FROM THERMUS AQUATICUS, A GLYCOSYLTRANSFERASE CATALYSING THE PRODUCTION OF LARGE CYCLIC GLUCANS
4FLO	;	2.2	;	Crystal structure of Amylosucrase double mutant A289P-F290C from Neisseria polysaccharea
4FLQ	;	2.5	;	Crystal structure of Amylosucrase double mutant A289P-F290I from Neisseria polysaccharea.
4FLR	;	2.4	;	Crystal structure of Amylosucrase double mutant A289P-F290L from Neisseria polysaccharea
7ESH	;	2.29	;	Crystal structure of amylosucrase from Calidithermus timidus
3UCQ	;	1.97	;	Crystal structure of amylosucrase from Deinococcus geothermalis
3UER	;	2.1	;	Crystal structure of amylosucrase from Deinococcus geothermalis in complex with turanose
1JG9	;	1.66	;	Crystal Structure of Amylosucrase from Neisseria polysaccharea in Complex with D-glucose
3UEQ	;	1.85	;	Crystal structure of amylosucrase from Neisseria polysaccharea in complex with turanose
4FLS	;	2.3	;	Crystal structure of Amylosucrase inactive double mutant F290K-E328Q from Neisseria polysaccharea in complex with sucrose.
5H05	;	2.55	;	Crystal structure of AmyP E221Q in complex with MALTOTRIOSE
5H06	;	1.95	;	Crystal structure of AmyP in complex with maltose
2X2Q	;	1.9	;	Crystal structure of an 'all locked' LNA duplex at 1.9 angstrom resolution
6FTE	;	1.52	;	Crystal structure of an (R)-selective amine transaminase from Exophiala xenobiotica
7XG6	;	1.32	;	Crystal structure of an (R)-selective omega-transaminase mutant from Aspergillus terreus with covalently bound PLP
7XG5	;	1.76	;	Crystal structure of an (R)-selective omega-transaminase mutant from Aspergillus terreus with PLP
4IFD	;	2.805	;	Crystal structure of an 11-subunit eukaryotic exosome complex bound to RNA
1QCU	;	1.2	;	CRYSTAL STRUCTURE OF AN 18 BASE PAIR COPY CONTROL RELATED RNA DUPLEX
2AVP	;	2.04	;	Crystal structure of an 8 repeat consensus TPR superhelix
2HYZ	;	2.3	;	Crystal structure of an 8 repeat consensus TPR superhelix (orthorombic crystal form)
2FO7	;	2.3	;	Crystal structure of an 8 repeat consensus TPR superhelix (trigonal crystal form)
8BU0	;	1.4	;	Crystal structure of an 8 repeat consensus TPR superhelix with calcium
5VNX	;	1.65	;	Crystal structure of an 8-amino-7-oxononanoate synthase from Burkholderia multivorans with a potential glycine-PLP-Lys242 cyclized intermediate or byproduct
5JAY	;	1.75	;	Crystal Structure of an 8-amino-7-oxononanoate Synthase from Burkholderia xenovorans
8CIG	;	1.4	;	Crystal structure of an 8-repeat consensus TPR superhelix in tris Buffer with Calcium.
8CQP	;	1.7	;	Crystal structure of an 8-repeat consensus TPR superhelix with Calcium (low concentration)
8CQQ	;	2.6	;	Crystal structure of an 8-repeat consensus TPR superhelix with Copper
8CH0	;	1.75	;	Crystal structure of an 8-repeat consensus TPR superhelix with Gadolinium.
8CKR	;	1.3	;	Crystal structure of an 8-repeat consensus TPR superhelix with in Hepes with Ca
8CP8	;	1.68	;	Crystal structure of an 8-repeat consensus TPR superhelix with Lead
8CMQ	;	1.782	;	Crystal structure of an 8-repeat consensus TPR superhelix with Tb
8CHY	;	2.0	;	Crystal structure of an 8-repeat consensus TPR superhelix with Zinc.
1BR3	;	3.0	;	CRYSTAL STRUCTURE OF AN 82-NUCLEOTIDE RNA-DNA COMPLEX FORMED BY THE 10-23 DNA ENZYME
3MCW	;	1.06	;	Crystal structure of an a putative hydrolase of the isochorismatase family (CV_1320) from Chromobacterium violaceum ATCC 12472 at 1.06 A resolution
5MVL	;	1.405	;	Crystal structure of an A-DNA dodecamer containing 5-bromouracil
5MVU	;	2.3	;	Crystal structure of an A-DNA dodecamer containing 5-formylcytosine in 3 consecutive CpG steps
5MVP	;	1.606	;	Crystal structure of an A-DNA dodecamer containing the GGGCCC motif
5MVT	;	1.896	;	Crystal structure of an A-DNA dodecamer featuring an alternating pyrimidine-purine sequence
5CH0	;	1.4	;	Crystal structure of an A-form DNA duplex containing 5-hydroxylmethylcytidine
4JRT	;	2.6	;	Crystal structure of an A-form RNA duplex containing three GU base pairs
4OUE	;	2.35	;	Crystal structure of an a-L-Fucosidase GH29 from Bacteroides thetaiotaomicron (BT2192) in complex with IPTG
4OZO	;	2.6	;	Crystal structure of an a-L-fucosidase GH29 from Bacteroides thetaiotaomicron (BT2192) in complex with oNPTG
1DC0	;	1.3	;	CRYSTAL STRUCTURE OF AN A/B-DNA INTERMEDIATE CATGGGCCCATG
6T5Z	;	1.6	;	Crystal structure of an AA10 LPMO from Photorhabdus luminescens
7OVA	;	1.75	;	Crystal structure of an AA9 LPMO
8B7P	;	2.11	;	Crystal structure of an AA9 LPMO from Aspergillus nidulans, AnLPMOC
4ILH	;	1.85	;	Crystal structure of an Aar2p C-terminal deletion mutant in conplex with Prp8p RNaseH
4ILI	;	3.2046	;	Crystal structure of an Aar2p S253E phosphomimetic mutant protein
5IBQ	;	1.2	;	Crystal structure of an ABC solute binding protein from Rhizobium etli CFN 42 (RHE_PF00037,TARGET EFI-511357) in complex with alpha-D-apiose
3HN0	;	1.75	;	CRYSTAL STRUCTURE OF AN ABC TRANSPORTER (BDI_1369) FROM PARABACTEROIDES DISTASONIS AT 1.75 A RESOLUTION
4YER	;	2.35	;	Crystal structure of an ABC transporter ATP-binding protein (TM_1403) from Thermotoga maritima MSB8 at 2.35 A resolution
5DTE	;	2.7	;	Crystal Structure of an ABC transporter periplasmic solute binding protein (IPR025997) from Actinobacillus succinogenes 130z(Asuc_0081, TARGET EFI-511065) with bound D-allose
4WBS	;	2.0	;	Crystal structure of an ABC transporter related protein from Burkholderia phymatum
6HS3	;	2.4	;	Crystal structure of an ABC transporter related protein from Burkholderia pseudomallei
4YWH	;	2.35	;	CRYSTAL STRUCTURE OF AN ABC TRANSPORTER SOLUTE BINDING PROTEIN (IPR025997) FROM ACTINOBACILLUS SUCCINOGENES 130Z (Asuc_0499, TARGET EFI-511068) WITH BOUND D-XYLOSE
4WUT	;	1.5	;	CRYSTAL STRUCTURE OF AN ABC TRANSPORTER SOLUTE BINDING PROTEIN (IPR025997) FROM AGROBACTERIUM VITIS (Avi_5133, TARGET EFI-511220) WITH BOUND D-FUCOSE
4WT7	;	2.0	;	Crystal structure of an ABC transporter solute binding protein (IPR025997) from Agrobacterium vitis (Avi_5165, Target EFI-511223) with bound allitol
5BR1	;	1.85	;	CRYSTAL STRUCTURE OF AN ABC TRANSPORTER SOLUTE BINDING PROTEIN (IPR025997) FROM AGROBACTERIUM VITIS S4 (Avi_5305, TARGET EFI-511224) WITH BOUND ALPHA-D-GALACTOSAMINE
4Y9T	;	1.801	;	CRYSTAL STRUCTURE OF AN ABC TRANSPORTER SOLUTE BINDING PROTEIN (IPR025997) FROM AGROBACTERIUM VITIS S4 (Avi_5305, TARGET EFI-511224) WITH BOUND ALPHA-D-GLUCOSAMINE
4YO7	;	1.7	;	Crystal Structure of an ABC transporter solute binding protein (IPR025997) from Bacillus halodurans C-125 (BH2323, TARGET EFI-511484) with bound myo-inositol
4YHS	;	1.8	;	CRYSTAL STRUCTURE OF AN ABC TRANSPORTER SOLUTE BINDING PROTEIN (IPR025997) FROM BRADYRHIZOBIUM sp. BTAi1 (BBta_2440, TARGET EFI-511490) WITH BOUND BIS-TRIS
4YS6	;	1.698	;	CRYSTAL STRUCTURE OF AN ABC TRANSPORTER SOLUTE BINDING PROTEIN (IPR025997) FROM CLOSTRIDIUM PHYTOFERMENTANS (Cphy_1585, TARGET EFI-511156) WITH BOUND BETA-D-GLUCOSE
4WZZ	;	1.7	;	CRYSTAL STRUCTURE OF AN ABC TRANSPORTER SOLUTE BINDING PROTEIN (IPR025997) FROM CLOSTRIDIUM PHYTOFERMENTAS (Cphy_0583, TARGET EFI-511148) WITH BOUND L-RHAMNOSE
4WWH	;	1.2	;	CRYSTAL STRUCTURE OF AN ABC TRANSPORTER SOLUTE BINDING PROTEIN (IPR025997) FROM MYCOBACTERIUM SMEGMATIS (MSMEG_1704, TARGET EFI-510967) WITH BOUND D-GALACTOSE
4YV7	;	2.3	;	CRYSTAL STRUCTURE OF AN ABC TRANSPORTER SOLUTE BINDING PROTEIN (IPR025997) FROM MYCOBACTERIUM SMEGMATIS (MSMEI_3018, TARGET EFI-511327) WITH BOUND GLYCEROL
5DKV	;	1.68	;	Crystal Structure of an ABC transporter Solute Binding Protein from Agrobacterium vitis(Avis_5339, TARGET EFI-511225) bound with alpha-D-Tagatopyranose
5HSG	;	1.3	;	Crystal structure of an ABC transporter Solute Binding Protein from Klebsiella pneumoniae (KPN_01730, target EFI-511059), APO open structure
5CI5	;	1.61	;	Crystal Structure of an ABC transporter Solute Binding Protein from Thermotoga Lettingae TMO (Tlet_1705, TARGET EFI-510544) bound with alpha-D-Tagatose
5JOQ	;	1.99	;	Crystal Structure of an ABC Transporter Substrate-Binding Protein from Listeria monocytogenes EGD-e
4N0Q	;	2.3	;	Crystal Structure of an ABC transporter, substrate-binding protein from Brucella melitensis 16M in complex with L-Leucine using a crystal grown in a Crystal Former (Microlytic)
4YLE	;	1.7	;	Crystal structure of an ABC transpoter solute binding protein (IPR025997) from Burkholderia multivorans (Bmul_1631, Target EFI-511115) with an unknown ligand modelled as alpha-D-erythrofuranose
4OHN	;	1.37	;	Crystal structure of an ABC uptake transporter substrate binding protein from Streptococcus pneumoniae with Bound Histidine
3N0X	;	1.5	;	Crystal structure of an ABC-type branched-chain amino acid transporter (RPA4397) from Rhodopseudomonas palustris CGA009 at 1.50 A resolution
1TWY	;	1.65	;	Crystal structure of an ABC-type phosphate transport receptor from Vibrio cholerae
4ECF	;	1.55	;	Crystal structure of an ABC-type phosphate transport system, periplasmic component (LVIS_0633) from Lactobacillus brevis ATCC 367 at 1.55 A resolution
3NP5	;	1.8	;	Crystal structure of an abridged form of the mature ectodomain of the human receptor-type protein tyrosine phosphatase ICA512/IA-2 AT pH 4.5
3N01	;	1.3	;	Crystal structure of an abridged form of the mature ectodomain of the Human Receptor-Type Protein Tyrosine Phosphatase ICA512/IA-2 at pH 8.5
3N4W	;	1.45	;	Crystal structure of an abridged SER to ALA mutant of the mature ectodomain of the human receptor-type protein-tyrosine phosphatase ICA512/IA-2 at pH 7.5
3NG8	;	1.35	;	Crystal structure of an abridged SER TO ALA MUTANT OF THE MATURE ECTODOMAIN of the human receptor-type protein-tyrosine phosphatase ICA512/IA-2 at PH 8.5
6BWW	;	2.1	;	Crystal structure of an acetate and Cymal-5 bound cytochrome P450 2B4 F429H mutant
4IZ9	;	1.98	;	Crystal structure of an acetate kinase from Mycobacterium avium bound to an unknown acid-ApCpp conjugate and manganese
4IJN	;	1.7	;	Crystal structure of an acetate kinase from Mycobacterium smegmatis bound to AMP and sulfate
6INB	;	1.8	;	Crystal structure of an acetolactate decarboxylase from Klebsiella pneumoniae
6INC	;	1.604	;	Crystal structure of an acetolactate decarboxylase from Klebsiella pneumoniae
7DDY	;	2.505	;	Crystal structure of an acetyl xylan esterase AlAXEase
6FKX	;	2.03	;	Crystal structure of an acetyl xylan esterase from a desert metagenome
3BAL	;	1.95	;	Crystal Structure of an Acetylacetone Dioxygenase from Acinetobacter johnsonii
5J78	;	2.1	;	Crystal structure of an Acetylating Aldehyde Dehydrogenase from Geobacillus thermoglucosidasius
5KZU	;	2.3	;	Crystal structure of an acetylcholine binding protein from Aplysia californica (Ac-AChBP) in complex with click chemistry compound 9-[[1-[8-methyl-8-(2-phenylethyl)-8-azoniabicyclo[3.2.1]octan-3-yl]triazol-4-yl]methyl]carbazole
1TIQ	;	1.9	;	Crystal Structure of an Acetyltransferase (PaiA) in complex with CoA and DTT from Bacillus subtilis, Northeast Structural Genomics Target SR64.
4XVV	;	1.7	;	Crystal structure of an Acid stress chaperone HdeB (KPN_03484) from Klebsiella pneumoniae subsp. pneumoniae MGH 78578 at 1.70 A resolution
7SU0	;	2.41	;	Crystal structure of an acidic pH-selective Ipilimumab variant Ipi.105 in complex with CTLA-4
7SU1	;	2.53	;	Crystal structure of an acidic pH-selective Ipilimumab variant Ipi.106 in complex with CTLA-4
1Z76	;	1.85	;	Crystal structure of an acidic phospholipase A2 (BthA-I) from Bothrops jararacussu venom complexed with p-bromophenacyl bromide
1SZ8	;	1.5	;	Crystal Structure of an Acidic Phospholipase A2 from Naja Naja Sagittifera at 1.5 A resolution
1UMV	;	1.79	;	Crystal structure of an acidic, non-myotoxic phospholipase A2 from the venom of Bothrops jararacussu
6C7K	;	2.5	;	Crystal structure of an ACO/RPE65 chimera
5JR7	;	3.56	;	Crystal structure of an ACRDYS heterodimer [RIa(92-365):C] of PKA
3Q2B	;	1.6	;	Crystal Structure of an Actin Depolymerizing Factor
4JHD	;	2.91	;	Crystal Structure of an Actin Dimer in Complex with the Actin Nucleator Cordon-Bleu
6JH8	;	2.149	;	Crystal structure of an actin monomer in complex with a chimeric peptide of Cordon-Bleu WH2 mutant and MIM.
6JH9	;	1.739	;	Crystal structure of an actin monomer in complex with a chimeric peptide of Cordon-Bleu WH2 mutant and MIM. Lys18Arg
6JCU	;	2.297	;	Crystal structure of an actin monomer in complex with a nucleator Cordon-Bleu WH2-motif peptide mutant. T22V, H11R
5YPU	;	2.0	;	Crystal structure of an actin monomer in complex with the nucleator Cordon-Bleu MET72NLE WH2-motif peptide
6JBK	;	2.45	;	Crystal structure of an actin monomer in complex with the nucleator Cordon-Bleu WH2-motif peptide mutant. T22V
3DB8	;	3.15	;	Crystal structure of an activated (Thr->Asp) Polo-like kinase 1 (Plk1) catalytic domain in complex with Compound 041
3DBD	;	3.05	;	Crystal structure of an activated (Thr->Asp) Polo-like kinase 1 (Plk1) catalytic domain in complex with Compound 094
3DBC	;	3.35	;	Crystal structure of an activated (Thr->Asp) Polo-like kinase 1 (Plk1) catalytic domain in complex with Compound 257
3DBE	;	3.32	;	Crystal structure of an activated (Thr->Asp) Polo-like kinase 1 (Plk1) catalytic domain in complex with Compound 557
3DBF	;	3.2	;	Crystal structure of an activated (Thr->Asp) Polo-like kinase 1 (Plk1) catalytic domain in complex with Compound 562
3DB6	;	2.85	;	Crystal structure of an activated (Thr->Asp) Polo-like kinase 1 (Plk1) catalytic domain in complex with Compound 902
3D5X	;	2.8	;	Crystal structure of an activated (Thr->Asp) Polo-like kinase 1 (Plk1) catalytic domain in complex with wortmannin.
3D5V	;	2.4	;	Crystal structure of an activated (Thr->Asp) Polo-like kinase 1 (Plk1) catalytic domain.
1O6L	;	1.6	;	Crystal structure of an activated Akt/protein kinase B (PKB-PIF chimera) ternary complex with AMP-PNP and GSK3 peptide
4ELD	;	2.701	;	Crystal Structure of an Activated Variant of Small Heat Shock Protein Hsp16.5
1TZS	;	2.35	;	Crystal Structure of an activation intermediate of Cathepsin E
1R6U	;	2.0	;	Crystal structure of an active fragment of human tryptophanyl-tRNA synthetase with cytokine activity
1Q11	;	1.6	;	Crystal structure of an active fragment of human tyrosyl-tRNA synthetase with tyrosinol
1Y0Q	;	3.6	;	Crystal structure of an active group I ribozyme-product complex
7ACA	;	1.57	;	CRYSTAL STRUCTURE OF AN ACTIVE KRAS G12D (GPPCP) DIMER IN COMPLEX WITH BI-5747
4R7Y	;	2.7	;	Crystal structure of an active MCM hexamer
5KJI	;	2.71	;	Crystal structure of an active polycomb repressive complex 2 in the basal state
5KJH	;	2.27	;	Crystal structure of an active polycomb repressive complex 2 in the stimulated state
2APQ	;	1.8	;	Crystal Structure of an Active Site Mutant of Bovine Pancreatic Ribonuclease A (H119A-RNase A) with a 10-Glutamine expansion in the C-terminal hinge-loop.
1HYB	;	2.0	;	CRYSTAL STRUCTURE OF AN ACTIVE SITE MUTANT OF METHANOBACTERIUM THERMOAUTOTROPHICUM NICOTINAMIDE MONONUCLEOTIDE ADENYLYLTRANSFERASE
2IFV	;	1.6	;	Crystal structure of an active site mutant, C473D, of CDC25B phosphatase catalytic domain
2A2K	;	1.52	;	Crystal Structure of an active site mutant, C473S, of Cdc25B Phosphatase Catalytic Domain
3KTQ	;	2.3	;	CRYSTAL STRUCTURE OF AN ACTIVE TERNARY COMPLEX OF THE LARGE FRAGMENT OF DNA POLYMERASE I FROM THERMUS AQUATICUS
1SC1	;	2.6	;	Crystal structure of an active-site ligand-free form of the human caspase-1 C285A mutant
4DW7	;	3.08	;	Crystal structure of an active-site mutant of the glycoprotein Erns from the pestivirus BVDV-1 in complex with a CpU dinucleotide
4DWA	;	3.01	;	Crystal structure of an active-site mutant of the glycoprotein Erns from the pestivirus BVDV-1 in complex with a CpUpC trinucleotide
4WVP	;	1.63	;	Crystal structure of an activity-based probe HNE complex
4XVX	;	2.3	;	Crystal structure of an acyl-ACP dehydrogenase
2ESS	;	1.9	;	Crystal structure of an acyl-ACP thioesterase (NP_810988.1) from Bacteroides thetaiotaomicron VPI-5482 at 1.90 A resolution
5IJM	;	1.46	;	Crystal Structure of an Acyl-CoA Binding Protein (LmjF.17.0620) of Leishmania major
5IDU	;	1.95	;	Crystal structure of an acyl-CoA dehydrogenase domain protein from Burkholderia phymatum bound to FAD
4W9U	;	2.4	;	Crystal Structure of an Acyl-CoA dehydrogenase from Brucella melitensis
3PFD	;	2.1	;	Crystal structure of an Acyl-CoA dehydrogenase from Mycobacterium thermoresistibile bound to reduced flavin adenine dinucleotide solved by combined iodide ion SAD MR
1XEB	;	2.35	;	Crystal Structure of an Acyl-CoA N-acyltransferase from Pseudomonas aeruginosa
3U0A	;	2.5	;	Crystal structure of an Acyl-CoA thioesterase II TesB2 from Mycobacterium marinum
1VE6	;	2.1	;	Crystal structure of an acylpeptide hydrolase/esterase from Aeropyrum pernix K1
1VE7	;	2.7	;	Crystal structure of an acylpeptide hydrolase/esterase from Aeropyrum pernix K1 in complex with p-nitrophenyl phosphate
4HI2	;	3.1	;	Crystal structure of an Acylphosphatase protein cage
1EFO	;	2.3	;	CRYSTAL STRUCTURE OF AN ADENINE BULGE IN THE RNA CHAIN OF A DNA/RNA HYBRID, D(CTCCTCTTC)/R(GAAGAGAGAG)
2ICS	;	2.3	;	Crystal structure of an adenine deaminase
4DYK	;	2.0	;	Crystal structure of an adenosine deaminase from pseudomonas aeruginosa pao1 (target nysgrc-200449) with bound zn
4DZH	;	1.552	;	Crystal structure of an adenosine deaminase from xanthomonas campestris (target nysgrc-200456) with bound zn
4F0R	;	1.8	;	Crystal structure of an adenosine deaminase homolog from Chromobacterium violaceum (target NYSGRC-019589) bound Zn and 5'-Methylthioadenosine (unproductive complex)
4F0S	;	1.851	;	Crystal structure of an adenosine deaminase homolog from Chromobacterium violaceum (target NYSGRC-019589) with bound inosine.
6OL3	;	2.74	;	Crystal structure of an adenovirus virus-associated RNA
4TYP	;	2.9	;	Crystal structure of an adenylate kinase mutant--AKm1
4TYQ	;	1.65	;	Crystal structure of an adenylate kinase mutant--AKm2
3H0K	;	3.25	;	Crystal structure of an adenylated kinase related protein from sulfolobus solfataricus to 3.25a
5WMM	;	2.9	;	Crystal structure of an adenylation domain interrupted by a methylation domain (AMA4) from nonribosomal peptide synthetase TioS
5D15	;	1.5	;	Crystal structure of an adenylyl cyclase Ma1120 from Mycobacterium avium in complex with ATP and calcium ion
5D0E	;	1.48	;	Crystal Structure of an adenylyl cyclase Ma1120-Cat in complex with GTP and calcium from Mycobacterium avium
1I9G	;	1.98	;	CRYSTAL STRUCTURE OF AN ADOMET DEPENDENT METHYLTRANSFERASE
1UA4	;	1.9	;	Crystal Structure of an ADP-dependent Glucokinase from Pyrococcus furiosus
2H39	;	2.23	;	Crystal Structure of an ADP-Glucose Phosphorylase from Arabidopsis thaliana with bound ADP-Glucose
3O8S	;	2.27	;	Crystal structure of an ADP-ribose pyrophosphatase (SSU98_1448) from STREPTOCOCCUS SUIS 89-1591 at 2.27 A resolution
5H03	;	1.89	;	Crystal structure of an ADP-ribosylating toxin BECa from C. perfringens
5H04	;	1.825	;	Crystal structure of an ADP-ribosylating toxin BECa of a novel binary enterotoxin of C. perfringens with NADH
7EQX	;	2.08	;	Crystal structure of an Aedes aegypti procarboxypeptidase B1
3PWZ	;	1.705	;	Crystal structure of an Ael1 enzyme from Pseudomonas putida
6CKN	;	2.49	;	Crystal structure of an AF10 fragment
6CKO	;	2.0	;	Crystal structure of an AF10 fragment
6KPC	;	3.2	;	Crystal structure of an agonist bound GPCR
7MCD	;	1.9	;	Crystal structure of an AI-designed TIM-barrel F15C
7MCC	;	1.46	;	Crystal structure of an AI-designed TIM-barrel F2C
1VKB	;	1.9	;	Crystal structure of an aig2-like protein (a2ld1, ggact, mgc7867) from mus musculus at 1.90 A resolution
3LLX	;	1.5	;	Crystal structure of an ala racemase-like protein (il1761) from idiomarina loihiensis at 1.50 A resolution
6N7L	;	2.1	;	Crystal structure of an alcohol dehydrogenase from Elizabethkingia anophelis NUHP1
3GAZ	;	1.96	;	Crystal structure of an alcohol dehydrogenase superfamily protein from Novosphingobium aromaticivorans
5KF0	;	1.7	;	Crystal structure of an Aldedhyde dehydrogenase from Burkholderia vietnamiensis
5Y6Q	;	2.5	;	Crystal structure of an aldehyde oxidase from Methylobacillus sp. KY4400
3NNB	;	1.6	;	Crystal structure of an alginate lyase (BACOVA_01668) from Bacteroides ovatus at 1.60 A resolution
3NFV	;	1.95	;	Crystal structure of an alginate lyase (BACOVA_01668) from Bacteroides ovatus at 1.95 A resolution
3CWU	;	2.8	;	Crystal Structure of an AlkA Host/Guest Complex 2'-fluoro-2'-deoxy-1,N6-ethenoadenine:Thymine Base Pair
3CWT	;	2.3	;	Crystal Structure of an AlkA Host/Guest Complex 2'-fluoro-2'-deoxyinosine:Adenine Base Pair
3CWS	;	2.3	;	Crystal Structure of an AlkA Host/Guest Complex 2'-fluoro-2'-deoxyinosine:Thymine Base Pair
3CVS	;	2.4	;	Crystal Structure of an AlkA Host/Guest Complex 8oxoGuanine:Adenine Base Pair
3CVT	;	2.5	;	Crystal Structure of an AlkA Host/Guest Complex 8oxoGuanine:Cytosine Base Pair
3CW7	;	2.3	;	Crystal Structure of an AlkA Host/Guest Complex 8oxoGuanine:Cytosine Base Pair
3CWA	;	2.4	;	Crystal Structure of an AlkA Host/Guest Complex 8oxoGuanine:Cytosine Base Pair
3D4V	;	2.9	;	Crystal Structure of an AlkA Host/Guest Complex N7MethylGuanine:Cytosine Base Pair
3SYY	;	1.9	;	Crystal Structure of an alkaline exonuclease (LHK-Exo) from Laribacter hongkongensis
1WCZ	;	2.0	;	Crystal structure of an alkaline form of v8 protease from Staphylococcus aureus
7XKS	;	1.78	;	Crystal structure of an alkaline pectate lyase from Bacillus clausii
5ENU	;	1.35	;	Crystal structure of an alkyl hyroperoxide reductase from Burkholderia ambifaria
4KVV	;	1.9	;	Crystal structure of an alkylated Cys mutant of CC-Hex
3IEE	;	1.7	;	Crystal structure of an alpha helical protein (BF3319) from Bacteroides fragilis NCTC 9343 at 1.70 A resolution
3NAV	;	2.1	;	Crystal structure of an alpha subunit of tryptophan synthase from Vibrio cholerae O1 biovar El Tor str. N16961
5TVG	;	2.3	;	Crystal structure of an alpha,alpha-trehalose-phosphate synthase (UDP-forming) from Burkholderia vietnamiensis
5V0T	;	1.95	;	Crystal structure of an alpha,alpha-trehalose-phosphate synthase (UDP-forming) from Burkholderia xenovorans in complex with glucose-6-phosphate
3T1P	;	3.9	;	Crystal structure of an alpha-1-antitrypsin trimer
3DHU	;	2.0	;	Crystal structure of an alpha-amylase from Lactobacillus plantarum
4FJQ	;	2.0001	;	Crystal Structure of an alpha-Bisabolol synthase
4GAX	;	1.9948	;	Crystal Structure of an alpha-Bisabolol synthase mutant
3FCN	;	1.45	;	Crystal structure of an alpha-helical protein of unknown function (rru_a3208) from rhodospirillum rubrum atcc 11170 at 1.45 A resolution
4J5I	;	2.6	;	Crystal structure of an alpha-ketoglutarate-dependent taurine dioxygenase from Mycobacterium smegmatis
2WVV	;	1.73	;	Crystal structure of an alpha-L-fucosidase GH29 from Bacteroides thetaiotaomicron
2WVT	;	1.8	;	Crystal structure of an alpha-L-fucosidase GH29 from Bacteroides thetaiotaomicron in complex with a novel iminosugar fucosidase inhibitor
2XII	;	1.8	;	CRYSTAL STRUCTURE OF AN ALPHA-L-FUCOSIDASE GH29 FROM BACTEROIDES THETAIOTAOMICRON IN COMPLEX WITH AN EXTENDED 9-FLUORENONE IMINOSUGAR INHIBITOR
2XIB	;	2.2	;	CRYSTAL STRUCTURE OF AN ALPHA-L-FUCOSIDASE GH29 FROM BACTEROIDES THETAIOTAOMICRON IN COMPLEX WITH DEOXYFUCONOJIRIMYCIN
2WVS	;	2.19	;	Crystal structure of an alpha-L-fucosidase GH29 trapped covalent intermediate from Bacteroides thetaiotaomicron in complex with 2- fluoro-fucosyl fluoride using an E288Q mutant
1QQ4	;	1.2	;	CRYSTAL STRUCTURE OF AN ALPHA-LYTIC PROTEASE MUTANT WITH ACCELERATED FOLDING KINETICS, R102H/G134S
1QRW	;	1.2	;	CRYSTAL STRUCTURE OF AN ALPHA-LYTIC PROTEASE MUTANT WITH ACCELERATED FOLDING KINETICS, R102H/G134S, PH 8
4HLB	;	1.8	;	Crystal structure of an alpha-lytic protease prodomain-like protein (DESPIG_01740) from Desulfovibrio piger ATCC 29098 at 1.80 A resolution
1VP8	;	1.3	;	CRYSTAL STRUCTURE OF an alpha/beta domain of a putative pyruvate kinase (AF0103) FROM ARCHAEOGLOBUS FULGIDUS DSM 4304 AT 1.30 A RESOLUTION
3BWX	;	1.5	;	Crystal structure of an alpha/beta hydrolase (YP_496220.1) from Novosphingobium aromaticivorans DSM 12444 at 1.50 A resolution
5W15	;	1.75	;	Crystal structure of an alpha/beta hydrolase fold protein from Burkholderia ambifaria.
2QRU	;	1.65	;	Crystal structure of an alpha/beta hydrolase superfamily protein from Enterococcus faecalis
7QJN	;	1.885	;	Crystal structure of an alpha/beta-hydrolase enzyme from Candidatus Kryptobacter tengchongensis (306)
7QJM	;	2.19	;	Crystal structure of an alpha/beta-hydrolase enzyme from Chloroflexus sp. MS-G (202)
1GQU	;	2.5	;	Crystal structure of an alternating A-T oligonucleotide fragment with Hoogsteen base pairing
3C1P	;	1.0	;	Crystal Structure of an alternating D-Alanyl, L-Homoalanyl PNA
315D	;	1.38	;	CRYSTAL STRUCTURE OF AN ALTERNATING OCTAMER R(GUAUGUA)D(C) WITH ADJACENT G-U WOBBLE PAIRS
6C0D	;	1.8	;	Crystal structure of an Amidase (hydantoinase/carbamoylase family) from Burkholderia phymatum
2PHN	;	1.35	;	Crystal structure of an amide bond forming F420-gamma glutamyl ligase from Archaeoglobus fulgidus
4DNM	;	2.15	;	Crystal structure of an amidohydrolase (cog3618) from burkholderia multivorans (target efi-500235) with bound hepes, space group p3221
4DO7	;	1.7	;	Crystal structure of an amidohydrolase (cog3618) from burkholderia multivorans (target efi-500235) with bound zn, space group c2
4DLM	;	1.925	;	Crystal structure of an amidohydrolase (COG3618) from burkholderia multivorans (TARGET EFI-500235) with bound ZN, space group P212121
4DLF	;	1.925	;	Crystal structure of an amidohydrolase (COG3618) from burkholderia multivorans (TARGET EFI-500235) with bound ZN, space group P3221
2PAJ	;	2.7	;	Crystal structure of an amidohydrolase from an environmental sample of Sargasso sea
3HPA	;	2.2	;	Crystal structure of an amidohydrolase gi:44264246 from an evironmental sample of sargasso sea
4YMS	;	2.8	;	Crystal structure of an amino acid ABC transporter
4YMT	;	2.599	;	Crystal structure of an amino acid ABC transporter complex with arginines
4YMU	;	2.503	;	Crystal structure of an amino acid ABC transporter complex with arginines and ATPs
4H5F	;	1.9	;	Crystal structure of an amino acid ABC transporter substrate-binding protein from Streptococcus pneumoniae Canada MDR_19A bound to L-arginine, form 1
4H5G	;	1.78	;	Crystal structure of an amino acid ABC transporter substrate-binding protein from Streptococcus pneumoniae Canada MDR_19A bound to L-arginine, form 2
4YMV	;	3.003	;	Crystal structure of an amino acid ABC transporter with ATPs
4YMW	;	2.804	;	Crystal structure of an amino acid ABC transporter with histidines
1B87	;	2.7	;	CRYSTAL STRUCTURE OF AN AMINOGLYCOSIDE 6'-N-ACETYLTRANSFERASE
2PBE	;	2.65	;	Crystal structure of an aminoglycoside 6-adenyltransferase from Bacillus subtilis
5HMN	;	2.018	;	Crystal structure of an aminoglycoside acetyltransferase HMB0005 from an uncultured soil metagenomic sample, unknown active site density modeled as polyethylene glycol
5F48	;	1.95	;	Crystal structure of an aminoglycoside acetyltransferase meta-AAC0020 from an uncultured soil metagenomic sample in complex with coenzyme A
5F49	;	2.15	;	Crystal structure of an aminoglycoside acetyltransferase meta-AAC0020 from an uncultured soil metagenomic sample in complex with malonyl-coenzyme A
5U08	;	1.52	;	Crystal structure of an aminoglycoside acetyltransferase meta-AAC0020 from an uncultured soil metagenomic sample in complex with sisomicin
5F47	;	1.497	;	Crystal structure of an aminoglycoside acetyltransferase meta-AAC0020 from an uncultured soil metagenomic sample in complex with trehalose
5F46	;	1.85	;	Crystal structure of an aminoglycoside acetyltransferase meta-AAC0020 from an uncultured soil metagenomic sample, apoenzyme form
4CVQ	;	2.11	;	CRYSTAL STRUCTURE OF AN AMINOTRANSFERASE FROM ESCHERICHIA COLI AT 2. 11 ANGSTROEM RESOLUTION
5YHV	;	2.7	;	Crystal structure of an aminotransferase from Mycobacterium tuberculosis
5Z8K	;	1.759	;	Crystal structure of an aminotransferase in complex with product-1
1I3G	;	2.44	;	CRYSTAL STRUCTURE OF AN AMPICILLIN SINGLE CHAIN FV, FORM 1, FREE
4B41	;	1.191	;	Crystal structure of an amyloid-beta binding single chain antibody G7
4B5E	;	1.936	;	Crystal Structure of an amyloid-beta binding single chain antibody PS2-8
5MTL	;	2.45	;	Crystal structure of an amyloidogenic light chain
5MUD	;	2.34	;	Crystal structure of an amyloidogenic light chain dimer H6
5MUH	;	2.65	;	Crystal structure of an amyloidogenic light chain dimer H7
6AT9	;	2.9503	;	Crystal structure of an anaplastic lymphoma kinase-derived neuroblastoma tumor antigen bound to the Human Major Histocompatibility Complex Class I molecule HLA-A*0101
5TXS	;	1.697	;	Crystal structure of an anaplastic lymphoma kinase-derived neuroblastoma tumor antigen bound to the Human Major Histocompatibility Complex Class I molecule HLA-B*1501
5VZ5	;	2.5901	;	Crystal structure of an anaplastic lymphoma kinase-derived neuroblastoma tumor antigen bound to the Human Major Histocompatibility Complex Class I molecule HLA-B*1501
4DXI	;	1.6	;	Crystal Structure of an Ancestor of All Faviina Proteins
5JOS	;	2.1	;	Crystal structure of an ancestral cyclohexadienyl dehydratase, AncCDT-3(P188L).
6WUP	;	1.49	;	Crystal structure of an ancestral cyclohexadienyl dehydratase, AncCDT-5
4DXM	;	1.4	;	Crystal Structure of an ancestral GFP-like protein
6I8R	;	2.0	;	Crystal structure of an ancient sequence-reconstructed Elongation factor Tu (node 170)
6HTW	;	1.8	;	Crystal structure of an ancient sequence-reconstructed Elongation factor Tu (node 184)
6GFU	;	2.0	;	Crystal structure of an ancient sequence-reconstructed Elongation Factor Tu (node 262)
7BBN	;	1.68	;	Crystal structure of an ancient sequence-reconstructed Elongation Factor Tu (node 317)
3QBI	;	2.1	;	Crystal structure of an anion-free yellow form of pharaonis halorhodopsin
5D66	;	1.0	;	Crystal structure of an ankyrin repeat domain (ABAYE2397) from Acinetobacter baumannii AYE at 1.00 A resolution
3L4A	;	1.5	;	Crystal Structure of an Anopheles gambiae Odorant-binding Protein 22a
3L4L	;	1.9	;	Crystal Structure of an Anopheles gambiae Odorant-binding Protein AgamOBP22a with Bound Odorant Benzaldehyde
3QME	;	2.002	;	Crystal Structure of an Anopheles gambiae Odorant-binding Protein AgamOBP22a with Bound Odorant Cyclohexanone
4HKM	;	1.953	;	Crystal Structure of an Anthranilate Phosphoribosyltransferase (target ID NYSGRC-016600) from Xanthomonas campestris
2Q0O	;	2.0	;	Crystal structure of an anti-activation complex in bacterial quorum sensing
6HGU	;	1.5	;	Crystal Structure of an anti-APP-tag Fab
1F4W	;	2.3	;	CRYSTAL STRUCTURE OF AN ANTI-CARBOHYDRATE ANTIBODY DIRECTED AGAINST VIBRIO CHOLERAE O1 IN COMPLEX WITH ANTIGEN
1F4X	;	2.3	;	CRYSTAL STRUCTURE OF AN ANTI-CARBOHYDRATE ANTIBODY DIRECTED AGAINST VIBRIO CHOLERAE O1 IN COMPLEX WITH ANTIGEN
1F4Y	;	2.8	;	CRYSTAL STRUCTURE OF AN ANTI-CARBOHYDRATE ANTIBODY DIRECTED AGAINST VIBRIO CHOLERAE O1 IN COMPLEX WITH ANTIGEN
5WYM	;	2.65	;	Crystal structure of an anti-connexin26 scFv
6KYF	;	3.07	;	Crystal structure of an anti-CRISPR protein
7X4B	;	1.61	;	Crystal Structure of An Anti-CRISPR Protein
8HNS	;	2.54	;	Crystal structure of an anti-CRISPR protein AcrIIC4 in apo form
3O14	;	1.7	;	Crystal structure of an anti-ECFsigma factor, ChrR (Maqu_0586) from MARINOBACTER AQUAEOLEI VT8 at 1.70 A resolution
3V6F	;	2.52	;	Crystal Structure of an anti-HBV e-antigen monoclonal Fab fragment (e6), unbound
1SBS	;	2.0	;	CRYSTAL STRUCTURE OF AN ANTI-HCG FAB
3A0C	;	2.0	;	Crystal Structure of an anti-HIV mannose-binding lectin from Polygonatum cyrtonema Hua
5WK4	;	1.498	;	Crystal structure of an anti-idiotype VLR
7RTH	;	3.19	;	Crystal structure of an anti-lysozyme nanobody in complex with an anti-nanobody Fab ""NabFab""
7AQL	;	1.8	;	Crystal Structure of an Anti-Plasminogen Activator Inhibitor-1 (PAI-1) scFv antibody fragment (scFv-33H1F7)
7N3E	;	2.06	;	Crystal structure of an anti-SARS-CoV-2 human neutralizing antibody Fab fragment C032
7N3F	;	1.9	;	Crystal structure of an anti-SARS-CoV-2 human neutralizing antibody Fab fragment C080
7N3G	;	1.42	;	Crystal structure of an anti-SARS-CoV-2 human neutralizing antibody Fab fragment C098
7N3H	;	1.26	;	Crystal structure of an anti-SARS-CoV-2 human neutralizing antibody Fab fragment C099
7K8O	;	1.95	;	Crystal structure of an anti-SARS-CoV-2 human neutralizing antibody Fab fragment, C002
7K8N	;	1.65	;	Crystal structure of an anti-SARS-CoV-2 human neutralizing antibody Fab fragment, C102
6XCA	;	1.8	;	Crystal structure of an anti-SARS-CoV-2 human neutralizing antibody Fab fragment, C105
7K8P	;	1.8	;	Crystal structure of an anti-SARS-CoV-2 human neutralizing antibody Fab fragment, C110
7K8Q	;	2.0	;	Crystal structure of an anti-SARS-CoV-2 human neutralizing antibody Fab fragment, C121
7K8R	;	2.0	;	Crystal structure of an anti-SARS-CoV-2 human neutralizing antibody Fab fragment, C135
4QTP	;	1.9	;	Crystal Structure of an Anti-sigma Factor Antagonist from Mycobacterium paratuberculosis
1P7K	;	1.75	;	Crystal structure of an anti-ssDNA antigen-binding fragment (Fab) bound to 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES)
5HT0	;	2.752	;	Crystal structure of an Antibiotic_NAT family aminoglycoside acetyltransferase HMB0038 from an uncultured soil metagenomic sample in complex with coenzyme A
8KAD	;	2.0	;	Crystal structure of an antibody light chain tetramer with 3D domain swapping
7OO2	;	2.16	;	Crystal structure of an antibody targeting the capsular polysaccharide of serogroup X Neisseria meningitidis (MenX)
6Z6Z	;	1.78	;	Crystal structure of an Anticalin directed towards colchicine without ligand
5NKN	;	2.2	;	Crystal structure of an Anticalin-colchicine complex
1TET	;	2.3	;	CRYSTAL STRUCTURE OF AN ANTICHOLERA TOXIN PEPTIDE COMPLEX AT 2.3 ANGSTROMS
3A0K	;	1.8	;	Crystal structure of an antiflamatory legume lectin from Cymbosema roseum seeds
1IT9	;	2.8	;	CRYSTAL STRUCTURE OF AN ANTIGEN-BINDING FRAGMENT FROM A HUMANIZED VERSION OF THE ANTI-HUMAN FAS ANTIBODY HFE7A
5CP7	;	3.01	;	Crystal Structure of an Antigen-Binding Fragment of Monoclonal Antibody against Sulfonamides
5CP3	;	1.99	;	Crystal Structure of an Antigen-Binding Fragment of Monoclonal Antibody against Sulfonamides in Complex with Sulfathiazole
5UVD	;	1.86	;	Crystal structure of an antigenic nucleotidyltransferase-like protein from Paracoccidioides brasiliensis
5BUN	;	2.98	;	Crystal structure of an antigenic outer membrane protein ST50 from Salmonella Typhi
3C1L	;	2.0	;	Crystal structure of an antioxidant defense protein (mlr4105) from mesorhizobium loti maff303099 at 2.00 A resolution
3E7K	;	2.01	;	Crystal Structure of an antiparallel coiled-coil tetramerization domain from TRPM7 channels
6G6H	;	1.7	;	Crystal structure of an antiparallel five-helix coiled coil 5H2L_2.1-I9L
5EOJ	;	2.115	;	Crystal structure of an antiparallel hexamer coiled-coil - ACC-Hex-PheI
6YB1	;	2.15	;	Crystal structure of an antiparallel octameric transmembrane coiled coil K2-CCTM-VbIc
3K6Q	;	1.8	;	CRYSTAL STRUCTURE OF An antitoxin part of a putative toxin/antitoxin system (SWOL_0700) FROM SYNTROPHOMONAS WOLFEI SUBSP. WOLFEI AT 1.80 A RESOLUTION
3NRF	;	1.5	;	Crystal structure of an apag protein (PA1934) from pseudomonas aeruginosa pao1 at 1.50 A resolution
3SB3	;	1.83	;	Crystal structure of an apag protein (PA1934) from pseudomonas aeruginosa pao1 at 1.83 A resolution
6D1S	;	3.2	;	Crystal structure of an apo chimeric human alpha1GABAA receptor
5YVP	;	2.051	;	Crystal structure of an apo form cyclase Filc1 from Fischerella sp. TAU
2FZV	;	1.7	;	Crystal Structure of an apo form of a Flavin-binding Protein from Shigella flexneri
6J3E	;	2.455	;	Crystal structure of an apo form of the glutathione S-transferase, CsGST63524, of Ceriporiopsis subvermispora
6J3G	;	1.95	;	Crystal structure of an apo form of the glutathione S-transferase, CsGST83044, of Ceriporiopsis subvermispora
1KYP	;	1.35	;	Crystal Structure of an Apo Green Fluorescent Protein Zn Biosensor
6OKE	;	2.55	;	Crystal structure of an apo Transferrin-Receptor-Binding cystine-dense peptide
5K92	;	1.42	;	Crystal Structure of an apo Tris-thiolate Binding Site in a de novo Three Stranded Coiled Coil Peptide
4LII	;	1.88	;	Crystal structure of an apoptosis-inducing factor, mitochondrion-associated, 1 (AIFM1) from Homo sapiens at 1.88 A resolution
5B6H	;	1.9	;	Crystal structure of an APRT from Yersinia pseudotuberculosis in complex with AMP.
1Q44	;	1.9	;	Crystal Structure of an Arabidopsis Thaliana Putative Steroid Sulfotransferase
6QTW	;	1.39	;	Crystal structure of an Arabidopsis WD40 domain in complex with a blue light photoreceptor
6QTX	;	1.95	;	Crystal structure of an Arabidopsis WD40 domain in complex with a flowering transcription factor homolog
6QTO	;	1.27	;	Crystal structure of an Arabidopsis WD40 domain in complex with a transcription factor
6QTT	;	1.51	;	Crystal structure of an Arabidopsis WD40 domain in complex with a transcription factor homolog
6QTV	;	1.31	;	Crystal structure of an Arabidopsis WD40 domain in complex with an atypical bHLH transcription factor
6QTQ	;	1.3	;	Crystal structure of an Arabidopsis WD40 domain in complex with photoreceptor
2WRZ	;	2.2	;	Crystal structure of an arabinose binding protein with designed serotonin binding site in open, ligand-free state
2FNA	;	2.0	;	Crystal structure of an archaeal aaa+ atpase (sso1545) from sulfolobus solfataricus p2 at 2.00 A resolution
2ZC0	;	2.3	;	Crystal structure of an archaeal alanine:glyoxylate aminotransferase
1XFO	;	1.96	;	Crystal Structure of an archaeal aminopeptidase
6EKG	;	1.15	;	Crystal structure of an archaeal CheY from Methanoccocus maripaludis
5XSV	;	3.723	;	Crystal structure of an archaeal chitinase in the ligand-free form
5XSX	;	2.642	;	Crystal structure of an archaeal chitinase in the substrate-complex form (P212121)
5XSW	;	1.95	;	Crystal structure of an archaeal chitinase in the substrate-complex form (P63)
7MSU	;	2.07	;	Crystal structure of an archaeal CNNM, MtCorB, CBS-pair domain in complex with Mg2+-ATP
7M1U	;	3.8	;	Crystal structure of an archaeal CNNM, MtCorB, R235L mutant with C-terminal deletion
7M1T	;	3.26	;	Crystal structure of an archaeal CNNM, MtCorB, with C-terminal deletion in complex with Mg2+-ATP
3ZFV	;	2.8	;	Crystal structure of an archaeal CRISPR-associated Cas6 nuclease
1MOJ	;	1.9	;	Crystal structure of an archaeal dps-homologue from Halobacterium salinarum
1OJX	;	1.9	;	Crystal structure of an Archaeal fructose 1,6-bisphosphate aldolase
1DQ3	;	2.1	;	CRYSTAL STRUCTURE OF AN ARCHAEAL INTEIN-ENCODED HOMING ENDONUCLEASE PI-PFUI
4FDG	;	4.1	;	Crystal Structure of an Archaeal MCM Filament
2B98	;	2.3	;	Crystal Structure of an archaeal pentameric riboflavin synthase
2B99	;	2.22	;	Crystal Structure of an archaeal pentameric riboflavin synthase Complex with a Substrate analog inhibitor
2CV4	;	2.3	;	Crystal Structure of an Archaeal Peroxiredoxin from the Aerobic Hyperthermophilic Crenarchaeon Aeropyrum pernix K1
1TH7	;	1.68	;	Crystal Structure of an Archaeal Sm Protein from Sulfolobus solfataricus
1QQC	;	2.6	;	CRYSTAL STRUCTURE OF AN ARCHAEBACTERIAL DNA POLYMERASE D.TOK
1D5A	;	2.4	;	CRYSTAL STRUCTURE OF AN ARCHAEBACTERIAL DNA POLYMERASE D.TOK. DEPOSITION OF SECOND NATIVE STRUCTURE AT 2.4 ANGSTROM
1J5U	;	2.0	;	CRYSTAL STRUCTURE OF AN ARCHEASE, POSSIBLE CHAPERONE (TM1083) FROM THERMOTOGA MARITIMA AT 2.0 A RESOLUTION
4B4L	;	1.75	;	CRYSTAL STRUCTURE OF AN ARD DAP-KINASE 1 MUTANT
3KZG	;	2.06	;	Crystal structure of an arginine 3rd transport system periplasmic binding protein from Legionella pneumophila
4WD2	;	1.95	;	Crystal structure of an aromatic amino acid aminotransferase from Burkholderia cenocepacia J2315
5EFF	;	2.23	;	Crystal structure of an aromatic mutant (F4A) of an alkali thermostable GH10 xylanase from Bacillus sp. NG-27
5XC0	;	2.32	;	Crystal structure of an aromatic mutant (W6A) of an alkali thermostable GH10 Xylanase from Bacillus sp. NG-27
5YNT	;	1.79	;	Crystal structure of an aromatic prenyltransferase FAMD1 from Fischerella ambigua UTEX 1903
5YNV	;	1.7	;	Crystal structure of an aromatic prenyltransferase FAMD1 from Fischerella ambigua UTEX 1903 in complex with DMASPP
5YNW	;	1.95	;	Crystal structure of an aromatic prenyltransferase FAMD1 from Fischerella ambigua UTEX 1903 in complex with DMASPP and INN
5YNU	;	1.7	;	Crystal structure of an aromatic prenyltransferase FAMD1 from Fischerella ambigua UTEX 1903 in complex with INN
2W6R	;	2.1	;	Crystal structure of an artificial (ba)8-barrel protein designed from identical half barrels
4F01	;	1.4	;	Crystal structure of an artificial dimeric DnaK complex
2Z68	;	1.58	;	Crystal Structure Of An Artificial Metalloprotein: Cr[N-salicylidene-4-amino-3-hydroxyhydrocinnamic acid]/Wild Type Heme oxygenase
1WZD	;	1.35	;	Crystal Structure Of An Artificial Metalloprotein: Fe(10-CH2CH2COOH-Salophen)/Wild Type Heme oxygenase
1WZF	;	1.85	;	Crystal Structure Of An Artificial Metalloprotein: Fe(10-COOH-Salophen)/Wild Type Heme oxygenase
1WZG	;	1.75	;	Crystal Structure Of An Artificial Metalloprotein: Fe(Salophen)/Wild Type Heme oxygenase
1J3F	;	1.45	;	Crystal Structure of an Artificial Metalloprotein:Cr(III)(3,3'-Me2-salophen)/apo-A71G Myoglobin
1UFJ	;	1.6	;	Crystal Structure of an Artificial Metalloprotein:Fe(III)(3,3'-Me2-salophen)/apo-A71G Myoglobin
1UFP	;	2.1	;	Crystal Structure of an Artificial Metalloprotein:Fe(III)(3,3'-Me2-salophen)/apo-wild type Myoglobin
1V9Q	;	1.45	;	Crystal Structure of an Artificial Metalloprotein:Mn(III)(3,3'-Me2-salophen)/apo-A71G Myoglobin
2EF2	;	1.8	;	Crystal Structure of an Artificial Metalloprotein:Rh(Phebox-Ph)/apo-A71G Myoglobin
6FHT	;	2.35	;	Crystal structure of an artificial phytochrome regulated adenylate/guanylate cyclase in its dark adapted Pr form
2XY5	;	2.22	;	Crystal structure of an artificial salen-copper basepair in complex with fragment DNA polymerase I from Bacillus stearothermophilus
3OG3	;	2.08	;	Crystal structure of an artificial thermostable (BA)8-barrel protein from identical half barrels
1W39	;	3.75	;	Crystal structure of an artificial top component of turnip yellow mosaic virus
1E2S	;	2.35	;	Crystal structure of an Arylsulfatase A mutant C69A
1E1Z	;	2.4	;	Crystal structure of an Arylsulfatase A mutant C69S
1E3C	;	2.65	;	Crystal structure of an Arylsulfatase A mutant C69S soaked in synthetic substrate
1E33	;	2.5	;	Crystal structure of an Arylsulfatase A mutant P426L
5H8D	;	1.89	;	Crystal structure of an ASC binding nanobody
5H8O	;	4.206	;	Crystal structure of an ASC-binding nanobody in complex with the CARD domain of ASC
3PPS	;	2.5	;	Crystal structure of an ascomycete fungal laccase from Thielavia arenaria
2ET2	;	2.1	;	Crystal structure of an Asn to Ala mutant of Winged Bean Chymotrypsin Inhibitor protein
3NRA	;	2.15	;	Crystal structure of an aspartate aminotransferase (YP_354942.1) from Rhodobacter sphaeroides 2.4.1 at 2.15 A resolution
5TI8	;	2.07	;	Crystal Structure of an aspartate aminotransferase from Pseudomonas
6WNG	;	1.55	;	Crystal structure of an aspartate ammonia-lyase from Elizabethkingia anophelis NUHP1
3PPL	;	1.25	;	Crystal structure of an aspartate transaminase (NCgl0237, Cgl0240) from CORYNEBACTERIUM GLUTAMICUM ATCC 13032 KITASATO at 1.25 A resolution
3UW3	;	1.55	;	Crystal Structure of an Aspartate-Semialdehyde Dehydrogenase from Burkholderia Thailandensis
5HQT	;	1.598	;	Crystal structure of an aspartate/glutamate racemase from Escherichia coli O157
5HRA	;	1.597	;	Crystal structure of an aspartate/glutamate racemase in complex with D-aspartate
5HRC	;	1.765	;	Crystal structure of an aspartate/glutamate racemase in complex with L-aspartate
2QJ8	;	2.0	;	Crystal structure of an aspartoacylase family protein (mlr6093) from mesorhizobium loti maff303099 at 2.00 A resolution
2I3C	;	2.8	;	Crystal Structure of an Aspartoacylase from Homo Sapiens
2GU2	;	1.805	;	Crystal Structure of an Aspartoacylase from Rattus norvegicus
4H3Y	;	2.5	;	Crystal structure of an asymmetric dimer of a tRNA (guanine-(N(1)-)-methyltransferase from Burkholderia phymatum bound to S-adenosyl homocystein in one half-site
6PNX	;	2.199	;	Crystal Structure of an Asymmetric Dimer of FGF Receptor 3 Kinases Trapped in A-loop Tyrosine Transphosphorylation Reaction
5H69	;	2.2004	;	Crystal structure of an asymmetric dimer of the Geobacillus stearothermophilus SMC hinge domain
6R9D	;	2.1	;	Crystal structure of an asymmetric dimer of the N-terminal domain of Euprosthenops australis Major Ampullate Spidroin 1 (dragline silk)
5LP8	;	2.7	;	Crystal structure of an asymmetric dimer of the ubiquitin ligase HUWE1
3V8G	;	4.66	;	Crystal structure of an asymmetric trimer of a glutamate transporter homologue (GltPh)
4LJX	;	2.21	;	Crystal structure of an AT-rich interactive domain-containing protein 3A (ARID3A) from Homo sapiens at 2.21 A resolution
4GSK	;	2.9	;	Crystal structure of an Atg7-Atg10 crosslinked complex
4GSL	;	2.703	;	Crystal structure of an Atg7-Atg3 crosslinked complex
4Q5T	;	1.907	;	Crystal structure of an atmB (putative membrane lipoprotein) from Streptococcus mutans UA159 at 1.91 A resolution
1DTS	;	1.65	;	CRYSTAL STRUCTURE OF AN ATP DEPENDENT CARBOXYLASE, DETHIOBIOTIN SYNTHASE, AT 1.65 ANGSTROMS RESOLUTION
1O63	;	2.0	;	Crystal structure of an ATP phosphoribosyltransferase
1O64	;	2.1	;	Crystal structure of an ATP phosphoribosyltransferase
4Q4L	;	2.2	;	Crystal structure of an ATP synthase subunit beta 1 (F1-B1) from Burkholderia thailandensis
4PWX	;	5.4	;	Crystal structure of an ATP-bound Get3-Get4-Get5 complex from S.cerevisiae
1ZX8	;	1.9	;	CRYSTAL STRUCTURE OF an atypical cyclophilin (peptidylprolyl cis-trans isomerase) (TM1367) FROM THERMOTOGA MARITIMA AT 1.90 A RESOLUTION
6OM1	;	2.66	;	Crystal structure of an atypical integrin
7QCE	;	2.1	;	Crystal structure of an atypical PHD finger of VIN3
5NYL	;	1.5	;	Crystal structure of an atypical poplar thioredoxin-like2.1 active site mutant
5NYO	;	2.25	;	Crystal structure of an atypical poplar thioredoxin-like2.1 variant in dimeric form
3P7X	;	1.96	;	Crystal structure of an atypical two-cysteine peroxiredoxin (SAOUHSC_01822) from Staphylococcus aureus NCTC8325
4XI2	;	2.6	;	Crystal Structure of an auto-inhibited form of Bruton's Tryrosine Kinase
2J6E	;	3.0	;	Crystal Structure of an Autoimmune Complex between a Human IgM Rheumatoid Factor and IgG1 Fc reveals a Novel Fc Epitope and Evidence for Affinity Maturation
3B9V	;	1.8	;	Crystal Structure of an Autonomous VH Domain
4HW6	;	1.7	;	Crystal structure of an auxiliary nutrient binding protein (BACOVA_00264) from Bacteroides ovatus ATCC 8483 at 1.70 A resolution
4QNI	;	2.3	;	Crystal structure of an auxiliary nutrient binding protein (BT3507) from Bacteroides thetaiotaomicron VPI-5482 at 2.30 A resolution
3TC9	;	2.23	;	Crystal structure of an auxiliary nutrient binding protein (BT_3476) from Bacteroides thetaiotaomicron VPI-5482 at 2.23 A resolution
3EBJ	;	2.2	;	Crystal structure of an avian influenza virus protein
4BCS	;	1.8	;	Crystal structure of an avidin mutant
4U46	;	1.95	;	Crystal structure of an avidin mutant
4P65	;	1.5	;	Crystal structure of an cyclohexylalanine substituted insulin analog.
6N39	;	2.15	;	Crystal structure of an dephospho-CoA kinase CoaE from Mycobacterium paratuberculosis
2HOO	;	3.0	;	Crystal structure of an E. coli thi-box riboswitch bound to benfotiamine
2HOP	;	3.3	;	Crystal structure of an E. coli thi-box riboswitch bound to pyrithiamine
2HOM	;	2.89	;	Crystal structure of an E. coli thi-box riboswitch bound to thiamine monophosphate
2HOL	;	2.9	;	Crystal structure of an E. coli thi-box riboswitch bound to thiamine pyrophosphate, barium ions
2HOK	;	3.2	;	Crystal structure of an E. coli thi-box riboswitch bound to thiamine pyrophosphate, calcium ions
2HOJ	;	2.5	;	Crystal structure of an E. coli thi-box riboswitch bound to thiamine pyrophosphate, manganese ions
7TD7	;	2.95	;	Crystal structure of an E. coli thiM riboswitch bound to thiamine, manganese ions
1KMI	;	2.9	;	CRYSTAL STRUCTURE OF AN E.COLI CHEMOTAXIS PROTEIN, CHEZ
3BQA	;	2.0	;	Crystal Structure of an E.coli PhoQ Sensor Domain Mutant
5D67	;	2.0	;	Crystal structure of an EF-Hand calcium binding domain of CAP-Binding Protein Complex-Interacting Protein 1 (EFCAB6) from Homo sapiens at 2.00 A resolution
8HTD	;	1.848	;	Crystal structure of an effector from Chromobacterium violaceum in complex with ubiquitin
8HTF	;	2.151	;	Crystal structure of an effector in complex with ubiquitin
8HTE	;	2.307	;	Crystal structure of an effector mutant in complex with ubiquitin
3G6N	;	2.5	;	Crystal structure of an EfPDF complex with Met-Ala-Ser
4RIW	;	3.1	;	Crystal structure of an EGFR/HER3 kinase domain heterodimer
4RIY	;	2.981	;	Crystal structure of an EGFR/HER3 kinase domain heterodimer containing the cancer-associated HER3-E909G mutation
4RIX	;	3.1	;	Crystal structure of an EGFR/HER3 kinase domain heterodimer containing the cancer-associated HER3-Q790R mutation
2QPT	;	3.1	;	Crystal structure of an EHD ATPase involved in membrane remodelling
2I2O	;	1.92	;	Crystal Structure of an eIF4G-like Protein from Danio rerio
4FXV	;	1.9	;	Crystal structure of an ELAV-like protein 1 (ELAVL1) from Homo sapiens at 1.90 A resolution
2H3X	;	2.5	;	Crystal Structure of an Electron Transfer Complex Between Aromatic Amine Dehydrogenase and Azurin from Alcaligenes Faecalis (Form 3)
2H47	;	2.6	;	Crystal Structure of an Electron Transfer Complex Between Aromatic Amine Dephydrogenase and Azurin from Alcaligenes Faecalis (Form 1)
2IAA	;	1.95	;	Crystal Structure of an Electron Transfer Complex Between Aromatic Amine Dephydrogenase and Azurin from Alcaligenes Faecalis (Form 2)
5OW0	;	1.7	;	Crystal structure of an electron transfer flavoprotein from Geobacter metallireducens
1MDA	;	2.5	;	CRYSTAL STRUCTURE OF AN ELECTRON-TRANSFER COMPLEX BETWEEN METHYLAMINE DEHYDROGENASE AND AMICYANIN
4LA9	;	1.3	;	Crystal structure of an empty substrate binding domain 1 (SBD1) OF ABC TRANSPORTER GLNPQ from lactococcus lactis
3PTO	;	3.008	;	Crystal Structure of an empty Vesicular Stomatitis Virus Nucleocapsid Protein Complex
3FM3	;	2.18	;	Crystal structure of an Encephalitozoon cuniculi methionine aminopeptidase type 2
3FMQ	;	2.5	;	Crystal structure of an Encephalitozoon cuniculi methionine aminopeptidase type 2 with angiogenesis inhibitor fumagillin bound
3FMR	;	2.89	;	Crystal structure of an Encephalitozoon cuniculi methionine aminopeptidase type 2 with angiogenesis inhibitor TNP470 bound
3QZ4	;	1.74	;	Crystal structure of an Endo-1,4-beta-xylanase D (BT_3675) from Bacteroides thetaiotaomicron VPI-5482 at 1.74 A resolution
4XUY	;	2.0027	;	Crystal structure of an endo-beta-1,4-xylanase (glycoside hydrolase family 10/GH10) enzyme from Aspergillus niger
4XV0	;	1.9697	;	Crystal structure of an endo-beta-1,4-xylanase (glycoside hydrolase family 10/GH10) enzyme from Trichoderma reesei
3POH	;	1.55	;	Crystal structure of an endo-beta-N-acetylglucosaminidase (BT_3987) from BACTEROIDES THETAIOTAOMICRON VPI-5482 at 1.55 A resolution
6FCG	;	2.6	;	Crystal structure of an endo-laminarinase from Formosa Hel1_33_131
3GVJ	;	1.48	;	Crystal structure of an endo-neuraminidaseNF mutant
6T9G	;	2.29621	;	CRYSTAL STRUCTURE OF AN ENDOGLUCANASE D213A FROM PENICILLIUM VERRUCULOSUM
5I6S	;	2.1	;	Crystal structure of an endoglucanase from Penicillium verruculosum
5L9C	;	1.85	;	Crystal structure of an endoglucanase from Penicillium verruculosum in complex with cellobiose
5X6A	;	1.7	;	Crystal structure of an endoglucanase PMO-5
5WTJ	;	3.503	;	Crystal structure of an endonuclease
1GL2	;	1.9	;	Crystal structure of an endosomal SNARE core complex
5H68	;	1.975	;	Crystal structure of an engaged dimer of the Geobacillus stearothermophilus SMC head domain
3ZUS	;	2.95	;	Crystal structure of an engineered botulinum neurotoxin type A- SNARE23 derivative, LC-A-SNAP23-Hn-A
3ZUR	;	2.71	;	Crystal structure of an engineered botulinum neurotoxin type A- SNARE23 derivative, LC0-A-SNAP25-Hn-A
3ZUQ	;	2.7	;	Crystal structure of an engineered botulinum neurotoxin type B - derivative, LC-B-GS-Hn-B
6G5F	;	2.5	;	Crystal structure of an engineered Botulinum Neurotoxin type B mutant E1191M/S1199Y in complex with human synaptotagmin 1
6G5G	;	2.0	;	Crystal structure of an engineered Botulinum Neurotoxin type B mutant E1191M/S1199Y in complex with human synaptotagmin 2
6D08	;	2.1	;	Crystal structure of an engineered bump-hole complex of mutant human chromobox homolog 1 (CBX1) with H3K9bn peptide
5C46	;	2.65	;	Crystal structure of an engineered construct of phosphatidylinositol 4 kinase III beta in complex with GTP gamma S loaded Rab11
5EUQ	;	3.2	;	Crystal structure of an engineered construct of phosphatidylinositol 4 kinase III beta with a potent and selective inhibitor in complex with GDP loaded Rab11
5C4G	;	3.2	;	Crystal structure of an engineered construct of phosphatidylinositol 4 kinase III beta with the inhibitor BQR695 in complex with GDP loaded Rab11
3ORC	;	3.0	;	CRYSTAL STRUCTURE OF AN ENGINEERED CRO MONOMER BOUND NONSPECIFICALLY TO DNA
3TOL	;	2.0	;	Crystal structure of an engineered cytochrome cb562 that forms 1D, Zn-mediated coordination polymers
3TOM	;	2.3	;	Crystal structure of an engineered cytochrome cb562 that forms 2D, Zn-mediated sheets
2XNC	;	2.9	;	Crystal structure of an engineered Ferredoxin NADP reductase (FNR) from Pisum sativum
2XNJ	;	1.9	;	Crystal structure of an engineered Ferredoxin(flavodoxin) NADP(H) Reductase (FPR) from Escherichia coli
3DLK	;	1.85	;	Crystal Structure of an engineered form of the HIV-1 Reverse Transcriptase, RT69A
7AUC	;	1.53	;	Crystal structure of an engineered helicase domain construct for human Bloom syndrome protein (BLM)
3P9W	;	2.41	;	Crystal structure of an engineered human autonomous VH Domain in complex with VEGF
1SM9	;	2.2	;	Crystal Structure Of An Engineered K274RN276D Double Mutant of Xylose Reductase From Candida Tenuis Optimized To Utilize NAD
4MVL	;	2.3	;	Crystal structure of an engineered lipocalin (Anticalin H1GA) in complex with the Alzheimer amyloid peptide Abeta1-40
4MVI	;	1.7	;	Crystal structure of an engineered lipocalin (Anticalin US7) in complex with the Alzheimer amyloid peptide Abeta(1-40)
4MVK	;	1.5	;	Crystal structure of an engineered lipocalin (Anticalin US7) in complex with the Alzheimer amyloid peptide fragment VFFAED
4QAE	;	2.1	;	Crystal structure of an engineered lipocalin (Anticalin) in complex with human hepcidin
4QAF	;	1.8	;	Crystal structure of an engineered lipocalin (Anticalin) in complex with VEGF(8-109)
4JE9	;	2.12	;	Crystal structure of an engineered metal-free RIDC1 construct with four interfacial disulfide bonds
5L31	;	2.4	;	Crystal structure of an engineered metal-free RIDC1 variant containing five disulfide bonds.
3IQ5	;	2.05	;	Crystal structure of an engineered metal-free tetrameric cytochrome cb562 complex templated by Zn-coordination
3NMO	;	3.1	;	Crystal structure of an engineered monomeric CLC-ec1 Cl-/H+ transporter
3QNB	;	1.95	;	Crystal Structure of an Engineered OXA-10 Variant with Carbapenemase Activity, OXA-10loop24
5BU7	;	2.46	;	Crystal structure of an engineered protein that forms nanotubes with tunable diameters
4NEZ	;	2.395	;	Crystal Structure of an engineered protein with ferredoxin fold, Northeast Structural Genomics Consortium (NESG) Target OR276
4NEY	;	2.323	;	Crystal Structure of an engineered protein with ferredoxin fold, Northeast Structural Genomics Consortium (NESG) Target OR277
4JEB	;	2.3	;	Crystal structure of an engineered RIDC1 tetramer with four interfacial disulfide bonds and four three-coordinate Zn(II) sites
3WWJ	;	2.2	;	Crystal structure of an engineered sitagliptin-producing transaminase, ATA-117-Rd11
2TLD	;	2.6	;	CRYSTAL STRUCTURE OF AN ENGINEERED SUBTILISIN INHIBITOR COMPLEXED WITH BOVINE TRYPSIN
6WY1	;	3.42	;	Crystal structure of an engineered thermostable dengue virus 2 envelope protein dimer
5N82	;	1.708	;	Crystal structure of an engineered TycA variant in complex with an beta-Phe-AMP analog
5N81	;	1.6	;	Crystal structure of an engineered TycA variant in complex with an O-propargyl-beta-Tyr-AMP analog
7YWJ	;	1.749	;	Crystal structure of an engineered TycA variant, TycA pPLA (L313P)
7YWK	;	1.39	;	Crystal structure of an engineered TycA variant, TycApPLA, in complex with AMP
6U8C	;	2.61	;	Crystal structure of an engineered ultra-high affinity Fab-Protein G complex
2B45	;	2.0	;	Crystal structure of an engineered uninhibited Bacillus subtilis xylanase in free state
2B46	;	2.215	;	Crystal structure of an engineered uninhibited Bacillus subtilis xylanase in substrate bound state
2V7G	;	2.0	;	Crystal Structure of an Engineered Urocanase Tetramer
7REP	;	2.192	;	Crystal structure of an engineered variant of single-chain Penicillin G Acylase from Kluyvera cryocrescens (A1-Ac Rd3CHis)
7REO	;	1.812	;	Crystal structure of an engineered variant of single-chain Penicillin G Acylase from Kluyvera cryocrescens (global hydrolysis Rd3CHis)
3PPV	;	1.9	;	Crystal structure of an engineered VWF A2 domain (N1493C and C1670S)
4JEA	;	1.22	;	Crystal structure of an engineered Zn-RIDC1 construct with four interfacial disulfide bonds
1HDD	;	2.8	;	CRYSTAL STRUCTURE OF AN ENGRAILED HOMEODOMAIN-DNA COMPLEX AT 2.8 ANGSTROMS RESOLUTION: A FRAMEWORK FOR UNDERSTANDING HOMEODOMAIN-DNA INTERACTIONS
4H2H	;	1.7	;	Crystal structure of an enolase (mandalate racemase subgroup, target EFI-502101) from Pelagibaca bermudensis htcc2601, with bound mg and l-4-hydroxyproline betaine (betonicine)
4DN1	;	2.05	;	Crystal structure of an ENOLASE (mandelate racemase subgroup member) from Agrobacterium tumefaciens (target EFI-502088) with bound mg and formate
4MGG	;	2.2	;	Crystal structure of an enolase (mandelate racemase subgroup) from labrenzia aggregata iam 12614 (target nysgrc-012903) with bound mg, space group p212121
4IZG	;	1.7	;	Crystal structure of an enolase (mandelate racemase subgroup) from paracococus denitrificans pd1222 (target nysgrc-012907) with bound cis-4oh-d-proline betaine (product)
4J1O	;	1.6	;	Crystal structure of an enolase (mandelate racemase subgroup) from paracococus denitrificans pd1222 (target nysgrc-012907) with bound l-proline betaine (substrate)
4E8G	;	2.0	;	Crystal structure of an enolase (mandelate racemase subgroup) from paracococus denitrificans pd1222 (target nysgrc-012907) with bound mg
4DX3	;	1.65	;	Crystal structure of an enolase (mandelate racemase subgroup, target EFI-502086) from Agrobacterium tumefaciens, with a succinimide residue
4DXK	;	1.25	;	Crystal structure of an enolase (mandelate racemase subgroup, target EFI-502086) from Agrobacterium tumefaciens, with a succinimide residue, na and phosphate
4H19	;	1.8	;	Crystal structure of an enolase (mandelate racemase subgroup, target EFI-502087) from agrobacterium tumefaciens, with bound Mg and d-ribonohydroxamate, ordered loop
4JN7	;	1.15	;	CRYSTAL STRUCTURE OF AN ENOLASE (PUTATIVE GALACTARATE DEHYDRATASE, TARGET EFI-500740) FROM AGROBACTERIUM RADIOBACTER, BOUND NA and L-MALATE, ORDERED ACTIVE SITE
4JN8	;	1.4	;	Crystal structure of an enolase (putative galactarate dehydratase, target efi-500740) from agrobacterium radiobacter, bound sulfate, no metal ion, ordered active site
4DYE	;	1.6	;	Crystal structure of an enolase (putative sugar isomerase, target efi-502095) from streptomyces coelicolor, no mg, ordered loop
4GIR	;	2.0	;	Crystal structure of an enolase family member from vibrio harveyi (efi-target 501692) with homology to mannonate dehydratase, with mg, ethylene glycol and sulfate bound (ordered loops, space group P41212)
4GIS	;	1.8	;	crystal structure of an enolase family member from vibrio harveyi (efi-target 501692) with homology to mannonate dehydratase, with mg, glycerol and dicarboxylates bound (mixed loops, space group I4122)
4GGH	;	1.9	;	Crystal structure of an enolase family member from vibrio harveyi (efi-target 501692) with homology to mannonate dehydratase, with mg, hepes, and ethylene glycol bound (ordered loops, space group c2221)
3TJ4	;	1.5	;	Crystal structure of an enolase from agrobacterium tumefaciens (efi target efi-502087) no mg
3UGV	;	2.3	;	Crystal structure of an enolase from alpha pretobacterium bal199 (EFI TARGET EFI-501650) with bound MG
3UJ2	;	2.0	;	CRYSTAL STRUCTURE OF AN ENOLASE FROM ANAEROSTIPES CACCAE (EFI TARGET EFI-502054) WITH BOUND MG AND SULFATE
3TJI	;	1.8	;	CRYSTAL STRUCTURE OF AN ENOLASE FROM ENTEROBACTER sp. 638 (EFI TARGET EFI-501662) with BOUND MG
3T6C	;	1.598	;	Crystal structure of an enolase from pantoea ananatis (efi target efi-501676) with bound d-gluconate and mg
3THU	;	1.8	;	Crystal structure of an enolase from sphingomonas sp. ska58 (efi target efi-501683) with bound mg
2QGY	;	1.8	;	Crystal structure of an enolase from the environmental genome shotgun sequencing of the Sargasso Sea
3V3W	;	1.4	;	Crystal structure of an enolase from the soil bacterium Cellvibrio japonicus (TARGET EFI-502161) with bound MG and glycerol
3V4B	;	1.4	;	Crystal structure of an enolase from the soil bacterium Cellvibrio japonicus (TARGET EFI-502161) with bound MG and L-tartrate
3DIP	;	2.5	;	Crystal structure of an enolase protein from the environmental genome shotgun sequencing of the Sargasso Sea
4EIT	;	2.4	;	Crystal structure of an enoyl-(acyl carrier protein) reductase from Bartonella henselae
3R6H	;	1.75	;	Crystal structure of an enoyl-CoA hydratase (ECHA3) from Mycobacterium marinum
3QRE	;	2.4	;	Crystal structure of an enoyl-coA hydratase EchA12_1 from Mycobacterium marinum
3OC7	;	1.5	;	Crystal structure of an enoyl-CoA hydratase from Mycobacterium avium
4QFE	;	1.95	;	Crystal Structure of an Enoyl-CoA hydratase from Mycobacterium smegmatis
4J2U	;	2.0	;	Crystal structure of an enoyl-CoA hydratase from Rhodobacter sphaeroides 2.4.1
4K2N	;	2.0	;	Crystal structure of an enoyl-CoA hydratase/ carnithine racemase from Magnetospirillum magneticum
4MOU	;	2.25	;	Crystal Structure of an Enoyl-CoA Hydratase/Isomerase Family Member, NYSGRC target 028282
3OT6	;	2.5	;	Crystal Structure of an enoyl-CoA hydratase/isomerase family protein from Psudomonas syringae
4K3W	;	2.31	;	Crystal structure of an enoyl-CoA hydratase/isomerase from Marinobacter aquaeolei
3P5M	;	2.05	;	Crystal structure of an enoyl-CoA hydratase/isomerase from Mycobacterium avium
3RRV	;	2.45	;	Crystal structure of an enoyl-CoA hydratase/isomerase from Mycobacterium paratuberculosis
3TLF	;	2.15	;	Crystal structure of an enoyl-CoA hydratase/isomerase from Mycobacterium paratuberculosis
4K29	;	1.66	;	Crystal structure of an enoyl-CoA hydratase/isomerase from Xanthobacter autotrophicus Py2
3L3S	;	2.32	;	Crystal structure of an enoyl-CoA hydrotase/isomerase family protein from Silicibacter pomeroyi
7U0O	;	2.05	;	Crystal structure of an enoyl-[acyl-carrier-protein] reductase InhA from Mycobacterium fortuitum bound to NAD and NITD-916
1ZAT	;	2.4	;	Crystal Structure of an Enterococcus faecium peptidoglycan binding protein at 2.4 A resolution
4YVW	;	3.8	;	crystal structure of an enterovirus 71/coxsackievirus A16 chimeric virus-like particle
4HNK	;	2.9	;	Crystal structure of an Enzyme
1CU1	;	2.5	;	CRYSTAL STRUCTURE OF AN ENZYME COMPLEX FROM HEPATITIS C VIRUS
1JP4	;	1.69	;	Crystal Structure of an Enzyme Displaying both Inositol-Polyphosphate 1-Phosphatase and 3'-Phosphoadenosine-5'-Phosphate Phosphatase Activities
6JJT	;	1.33	;	Crystal structure of an enzyme from Penicillium herquei in condition1
6JJS	;	1.62	;	Crystal structure of an enzyme from Penicillium herquei in condition2
6ADU	;	1.96	;	Crystal structure of an enzyme in complex with ligand C
3U0S	;	2.6	;	Crystal Structure of an Enzyme Redesigned Through Multiplayer Online Gaming: CE6
6N3K	;	2.2	;	Crystal structure of an epoxide hydrolase from Trichoderma reesei in complex with inhibitor 1
6N5G	;	2.6	;	Crystal structure of an epoxide hydrolase from Trichoderma reesei in complex with inhibitor 2
6N5F	;	1.93	;	Crystal structure of an epoxide hydrolase from Trichoderma reesei in complex with inhibitor 3
6N3Z	;	2.238	;	Crystal structure of an epoxide hydrolase from Trichoderma reesei in complex with inhibitor 4
6N5H	;	1.717	;	Crystal structure of an epoxide hydrolase from Trichoderma reesei in complex with inhibitor 5
8XIZ	;	2.175	;	Crystal structure of an epoxide hydrolase mutant A250IC/L344V from Aspergillus usamii E001 at 2.17 Angstroms resolution
6N5A	;	3.3	;	Crystal structure of an equine H7 hemagglutinin from A/equine/NY/49/73 (H7N7)
7T1V	;	2.05	;	Crystal structure of an equine H7 hemagglutinin from A/equine/NY/49/73 (H7N7) in complex with 3'-GcLN
2VAL	;	2.0	;	Crystal structure of an Escherichia coli tRNAGly microhelix at 2.0 Angstrom resolution
2HWV	;	1.9	;	Crystal structure of an essential response regulator DNA binding domain, VicRc in Enterococcus faecalis, a member of the YycF subfamily.
7KLD	;	2.25	;	Crystal Structure of an Essential Ribosomal Processing Protease Prp from S. aureus in complex with a covalently linked product Peptide
7JVS	;	2.3	;	Crystal Structure of an Essential Ribosomal Processing Protease Prp from S. aureus in complex with a Substrate Peptide
4MSX	;	1.87	;	Crystal structure of an essential yeast splicing factor
4Q05	;	2.05	;	Crystal structure of an esterase E25
6G21	;	2.1	;	Crystal structure of an esterase from Aspergillus oryzae
4XVC	;	2.0	;	Crystal structure of an esterase from the bacterial hormone-sensitive lipase (HSL) family
4RNC	;	1.95	;	Crystal structure of an esterase RhEst1 from Rhodococcus sp. ECU1013
6TL3	;	2.455	;	Crystal structure of an Estrogen Receptor alpha 8-mer phosphopeptide in complex with 14-3-3sigma stabilized by a Pyrrolidone1 derivative
6TJM	;	1.85	;	Crystal structure of an Estrogen Receptor alpha 8-mer phosphopeptide in complex with 14-3-3sigma stabilized by Pyrrolidone1
3BF4	;	2.1	;	Crystal structure of an ethd-like protein (reut_b5694) from ralstonia eutropha jmp134 at 2.10 A resolution
2FTR	;	1.4	;	Crystal structure of an ethyl tert-butyl ether d (ethd) family protein (bh0200) from bacillus halodurans c-125 at 1.40 A resolution
4P0M	;	2.0	;	Crystal structure of an evolved putative penicillin-binding protein homolog, Rv2911, from Mycobacterium tuberculosis
4AHC	;	2.4	;	Crystal Structure of an Evolved Replicating DNA Polymerase
4AIL	;	2.9	;	Crystal Structure of an Evolved Replicating DNA Polymerase
3P2C	;	1.6	;	Crystal structure of an exo-alpha-1,6-mannosidase (bacova_03347) from bacteroides ovatus at 1.60 a resolution
3ON6	;	1.7	;	Crystal structure of an exo-alpha-1,6-mannosidase (bacova_03626) from bacteroides ovatus at 1.70 a resolution
5TPY	;	2.805	;	Crystal structure of an exonuclease resistant RNA from Zika virus
3MDQ	;	1.5	;	Crystal structure of an Exopolyphosphatase (CHU_0316) from Cytophaga hutchinsonii ATCC 33406 at 1.50 A resolution
4PY9	;	2.25	;	Crystal structure of an exopolyphosphatase-related protein from Bacteroides Fragilis. Northeast Structural Genomics target BFR192
6D3P	;	2.9	;	Crystal structure of an exoribonuclease-resistant RNA from Sweet clover necrotic mosaic virus (SCNMV)
4ZYS	;	2.25	;	Crystal structure of an exotoxin 6 (SAV0422) from Staphylococcus aureus subsp. aureus Mu50 at 2.25 A resolution
4J50	;	1.65	;	Crystal Structure of an Expanded RNA CAG Repeat
6BXF	;	3.2	;	Crystal structure of an extended b3 integrin L33
6BXB	;	2.39	;	Crystal structure of an extended b3 integrin P33
6CKB	;	2.8	;	Crystal structure of an extended beta3 integrin P33
5TD8	;	7.531	;	Crystal structure of an Extended Dwarf Ndc80 Complex
2UXD	;	3.2	;	Crystal structure of an extended tRNA anticodon stem loop in complex with its cognate mRNA CGGG in the context of the Thermus thermophilus 30S subunit.
2UXB	;	3.1	;	Crystal structure of an extended tRNA anticodon stem loop in complex with its cognate mRNA GGGU in the context of the Thermus thermophilus 30S subunit.
2UXC	;	2.9	;	Crystal structure of an extended tRNA anticodon stem loop in complex with its cognate mRNA UCGU in the context of the Thermus thermophilus 30S subunit.
3PWY	;	3.5	;	Crystal structure of an extender (SPD28345)-modified human PDK1 complex 2
1KD7	;	2.8	;	Crystal structure of an extracellular domain fragment of human BAFF
3BYW	;	2.35	;	Crystal structure of an extracellular domain of arabinofuranosyltransferase from Corynebacterium diphtheriae
3FT7	;	2.0	;	Crystal structure of an extremely stable dimeric protein from sulfolobus islandicus
3V3D	;	1.95	;	Crystal Structure of an eYFP single mutant
6U4Y	;	2.91	;	Crystal Structure of an EZH2-EED Complex in an Oligomeric State
5B4M	;	2.4	;	Crystal structure of an Fab against human influenza A
6F7T	;	2.6	;	Crystal Structure of an Fab fragment in complex with a peptide from Bacillus subtilis RNase Y
1EJE	;	2.2	;	CRYSTAL STRUCTURE OF AN FMN-BINDING PROTEIN
3TF8	;	2.1302	;	Crystal structure of an H-NOX protein from Nostoc sp. PCC 7120
3TF9	;	2.5901	;	Crystal structure of an H-NOX protein from Nostoc sp. PCC 7120 under 1 atm of xenon
3TFA	;	2.2711	;	Crystal structure of an H-NOX protein from Nostoc sp. PCC 7120 under 6 atm of xenon
3TFD	;	1.96	;	Crystal structure of an H-NOX protein from Nostoc sp. PCC 7120, L66W mutant
3TFE	;	1.991	;	Crystal structure of an H-NOX protein from Nostoc sp. PCC 7120, L66W mutant under 6 atm of xenon
3TFG	;	1.9003	;	Crystal structure of an H-NOX protein from Nostoc sp. PCC 7120, L66W/L67W double mutant
3TFF	;	1.9401	;	Crystal structure of an H-NOX protein from Nostoc sp. PCC 7120, L67W mutant
4U99	;	2.0	;	Crystal structure of an H-NOX protein from S. oneidensis in the Fe(II) ligation state, Q154A/Q155A/K156A mutant
4U9G	;	2.25	;	Crystal structure of an H-NOX protein from S. oneidensis in the Fe(II)CO ligation state, Q154A/Q155A/K156A mutant
4U9B	;	1.65	;	Crystal structure of an H-NOX protein from S. oneidensis in the Fe(II)NO ligation state
4U9J	;	2.1	;	Crystal structure of an H-NOX protein from S. oneidensis in the Mn(II) ligation state, Q154A/Q155A/K156A mutant
4U9K	;	2.45	;	Crystal structure of an H-NOX protein from S. oneidensis in the Mn(II)NO ligation state, Q154A/Q155A/K156A mutant
3TF0	;	1.743	;	Crystal structure of an H-NOX protein from T. tengcongensis
3TF1	;	2.0369	;	Crystal structure of an H-NOX protein from T. tengcongensis under 6 atm of xenon
2HVY	;	2.3	;	Crystal structure of an H/ACA box RNP from Pyrococcus furiosus
4IL8	;	1.8	;	Crystal structure of an H329A mutant of p. aeruginosa PMM/PGM
4BSG	;	2.1	;	Crystal Structure of an H7N3 Avian Influenza Virus Haemagglutinin
1C3S	;	2.5	;	CRYSTAL STRUCTURE OF AN HDAC HOMOLOG COMPLEXED WITH SAHA
1C3R	;	2.0	;	CRYSTAL STRUCTURE OF AN HDAC HOMOLOG COMPLEXED WITH TRICHOSTATIN A
1C3P	;	1.8	;	CRYSTAL STRUCTURE OF AN HDAC HOMOLOG FROM AQUIFEX AEOLICUS
1O3U	;	1.75	;	Crystal structure of an hepn domain protein (tm0613) from thermotoga maritima at 1.75 A resolution
8PFE	;	1.35	;	Crystal Structure of an Hexavariant of the b1 Domain of Human Neuropilin-1 in Complex with the KDKPPR Peptide
3HFN	;	2.31	;	Crystal Structure of an Hfq protein from Anabaena sp.
3HFO	;	1.3	;	Crystal Structure of an Hfq protein from Synechocystis sp.
2QTX	;	2.5	;	Crystal structure of an Hfq-like protein from Methanococcus jannaschii
1KQ2	;	2.71	;	Crystal Structure of an Hfq-RNA Complex
3P0T	;	1.9	;	Crystal structure of an HIT-like protein from mycobacterium paratuberculosis
5KZC	;	3.25	;	Crystal structure of an HIV-1 gp120 engineered outer domain with a Man9 glycan at position N276, in complex with broadly neutralizing antibody VRC01
1GGI	;	2.8	;	CRYSTAL STRUCTURE OF AN HIV-1 NEUTRALIZING ANTIBODY 50.1 IN COMPLEX WITH ITS V3 LOOP PEPTIDE ANTIGEN
1HU0	;	2.35	;	CRYSTAL STRUCTURE OF AN HOGG1-DNA BOROHYDRIDE TRAPPED INTERMEDIATE COMPLEX
2CG9	;	3.1	;	Crystal structure of an Hsp90-Sba1 closed chaperone complex
2CGE	;	3.0	;	Crystal structure of an Hsp90-Sba1 closed chaperone complex
8OZ8	;	1.85	;	Crystal Structure of an Hydroxynitrile lyase variant (H96A) from Granulicella tundricola
1O65	;	2.33	;	Crystal structure of an hypothetical protein
1O67	;	2.54	;	Crystal structure of an hypothetical protein
1VHK	;	2.6	;	Crystal structure of an hypothetical protein
1VHM	;	2.1	;	Crystal structure of an hypothetical protein
1VI3	;	1.76	;	Crystal structure of an hypothetical protein
1VI7	;	2.8	;	Crystal structure of an hypothetical protein
1VIM	;	1.36	;	Crystal structure of an hypothetical protein
1VIZ	;	1.85	;	Crystal structure of an hypothetical protein
8CXF	;	1.77	;	Crystal structure of an i-motif from the HRAS promoter region
8DHC	;	2.02	;	Crystal structure of an i-motif from the HRAS promoter region
3KTL	;	1.75	;	Crystal Structure of an I71A human GSTA1-1 mutant in complex with S-hexylglutathione
2R6K	;	2.51	;	Crystal structure of an I71V hGSTA1-1 mutant in complex with S-hexylglutathione
6EIO	;	0.84	;	Crystal structure of an ice binding protein from an Antarctic Biological Consortium
4NU2	;	2.1	;	Crystal structure of an ice-binding protein (FfIBP) from the Antarctic bacterium, Flavobacterium frigoris PS1
3ULT	;	1.4	;	Crystal structure of an ice-binding protein from the perennial ryegrass, Lolium perenne
7DQB	;	2.101	;	Crystal structure of an IclR homolog complexed with 4-hydroxybenzoate from Microbacterium hydrocarbonoxydans in P212121 form
5H1A	;	2.1	;	Crystal structure of an IclR homolog from Microbacterium sp. strain HM58-2
5CNL	;	2.65	;	Crystal structure of an IcmL-like type IV secretion system protein (lpg0120) from Legionella pneumophila subsp. pneumophila str. Philadelphia 1 at 2.65 A resolution
1U8R	;	2.75	;	Crystal Structure of an IdeR-DNA Complex Reveals a Conformational Change in Activated IdeR for Base-specific Interactions
2WAH	;	2.51	;	Crystal Structure of an IgG1 Fc Glycoform (Man9GlcNAc2)
5XMH	;	2.8	;	Crystal structure of an IgM rheumatoid factor YES8c in complex with IgG1 Fc
1OY3	;	2.05	;	CRYSTAL STRUCTURE OF AN IKBBETA/NF-KB P65 HOMODIMER COMPLEX
3N8U	;	1.44	;	Crystal structure of an imelysin peptidase (BACOVA_03801) from Bacteroides ovatus at 1.44 A resolution
3OYV	;	1.25	;	Crystal structure of an imelysin peptidase (BACOVA_03801) from Bacteroides ovatus ATCC 8483 at 1.25 A resolution
3PF0	;	2.15	;	Crystal structure of an Imelysin-like protein (Psyc_1802) from PSYCHROBACTER ARCTICUM 273-4 at 2.15 A resolution
5CD5	;	3.396	;	Crystal structure of an immature VRC01-class antibody DRVIA7 from a Chinese donor bound to clade A/E HIV-1 gp120 core
4MAY	;	2.2	;	Crystal structure of an immune complex
4GBX	;	3.0	;	Crystal structure of an immune complex at pH 6.5
3UN9	;	2.65	;	Crystal structure of an immune receptor
2ZRR	;	1.8	;	Crystal structure of an immunity protein that contributes to the self-protection of bacteriocin-producing Enterococcus mundtii 15-1A
2V7H	;	2.8	;	Crystal structure of an immunogen specific anti-mannopyranoside monoclonal antibody Fab fragment
4DDD	;	1.9	;	Crystal structure of an immunogenic protein from ehrlichia chaffeensis
3SO5	;	1.7	;	Crystal structure of an Immunoglobulin I-set domain of Lrig3 protein (Lrig3) from MUS MUSCULUS at 1.70 A resolution
2XQH	;	1.99	;	Crystal structure of an immunoglobulin-binding fragment of the trimeric autotransporter adhesin EibD
3N6Y	;	1.5	;	Crystal structure of an immunoglobulin-like protein (PA1606) from PSEUDOMONAS AERUGINOSA at 1.50 A resolution
4RDB	;	1.45	;	Crystal structure of an immunoreactive 32 kDa antigen PG49 (PG_0181) from Porphyromonas gingivalis W83 at 1.45 A resolution (PSI Community Target, Nakayama)
2PBZ	;	2.5	;	Crystal structure of an IMP biosynthesis protein PurP from Thermococcus kodakaraensis
3EGZ	;	2.2	;	Crystal structure of an in vitro evolved tetracycline aptamer and artificial riboswitch
1FB7	;	2.6	;	CRYSTAL STRUCTURE OF AN IN VIVO HIV-1 PROTEASE MUTANT IN COMPLEX WITH SAQUINAVIR: INSIGHTS INTO THE MECHANISMS OF DRUG RESISTANCE
6D7R	;	2.1	;	Crystal structure of an inactivate variant of the quorum-sensing master regulator HapR from protease-deficient non-O1, non-O139 Vibrio cholerae strain V2
7D89	;	2.89384	;	Crystal structure of an inactivated double mutant (E182AE280A) of a novel thermostable GH10 xylanase XynA
5OL6	;	2.0	;	Crystal structure of an inactivated Npu SICLOPPS intein with CAFHPQ extein
5OL7	;	1.6	;	Crystal structure of an inactivated Npu SICLOPPS intein with CFAHPQ extein
5OL1	;	1.751	;	Crystal structure of an inactivated Ssp SICLOPPS intein with a CAFHPQ extein
5OL5	;	2.329	;	Crystal structure of an inactivated Ssp SICLOPPS intein with CFAHPQ extein
3ITD	;	1.89	;	Crystal structure of an inactive 17beta-Hydroxysteroid dehydrogenase (Y167F mutated form) from fungus Cochliobolus lunatus
1MRV	;	2.8	;	crystal structure of an inactive Akt2 kinase domain
1MRY	;	2.8	;	crystal structure of an inactive akt2 kinase domain
3O2L	;	2.0	;	Crystal Structure of an Inactive Kemp Elimination Design HG-1
4JIJ	;	1.698	;	Crystal structure of an inactive mutant of MMP-9 catalytic domain in complex with a fluorogenic synthetic peptidic substrate
4JQG	;	1.849	;	Crystal structure of an inactive mutant of MMP-9 catalytic domain in complex with a fluorogenic synthetic peptidic substrate with a fluorine atom.
6V6M	;	1.39	;	Crystal structure of an inactive state of GMPPNP-bound RhoA
1VKM	;	1.9	;	Crystal structure of an indigoidine synthase a (idga)-like protein (tm1464) from thermotoga maritima msb8 at 1.90 A resolution
4B2G	;	2.4	;	Crystal Structure of an Indole-3-Acetic Acid Amido Synthase from Vitis vinifera Involved in Auxin Homeostasis
6DLB	;	2.2	;	Crystal Structure of an influenza A hemagglutinin antibody Fab CH65:1203d4 chimera
6DL8	;	3.805	;	Crystal Structure of an influenza A hemagglutinin antibody Fab variant CH67:1203d4 chimera
1MD0	;	2.0	;	CRYSTAL STRUCTURE OF AN INHIBITED FRAGMENT OF Ets-1
4PS6	;	1.25	;	Crystal structure of an inhibitor of vertebrate lysozyme (PA3902) from Pseudomonas aeruginosa PAO1 at 1.25 A resolution
4XG3	;	2.3	;	Crystal structure of an inhibitor-bound Syk
4XG4	;	2.3	;	Crystal structure of an inhibitor-bound Syk
4XG6	;	2.4	;	Crystal structure of an inhibitor-bound Syk
4XG7	;	1.76	;	Crystal structure of an inhibitor-bound Syk
4XG8	;	2.4	;	Crystal structure of an inhibitor-bound Syk
4XG9	;	2.91	;	Crystal structure of an inhibitor-bound Syk
5GHV	;	2.8	;	Crystal structure of an inhibitor-bound Syk
3TZV	;	3.056	;	Crystal structure of an iNKT TCR in complex with CD1d-lysophosphatidylcholine
6WE5	;	2.25	;	Crystal structure of an inorganic pyrophosphatase from Chlamydia trachomatis D/UW-3/Cx
5TEA	;	1.85	;	Crystal structure of an inorganic pyrophosphatase from Neisseria gonorrhoeae
1HOZ	;	1.6	;	CRYSTAL STRUCTURE OF AN INOSINE-ADENOSINE-GUANOSINE-PREFERRING NUCLEOSIDE HYDROLASE FROM TRYPANOSOMA VIVAX
1HP0	;	2.1	;	CRYSTAL STRUCTURE OF AN INOSINE-ADENOSINE-GUANOSINE-PREFERRING NUCLEOSIDE HYDROLASE FROM TRYPANOSOMA VIVAX IN COMPLEX WITH THE SUBSTRATE ANALOGUE 3-DEAZA-ADENOSINE
1XNR	;	3.1	;	Crystal Structure of an Inosine-Cytosine Wobble Base Pair in the Context of the Decoding Center
4O4C	;	2.2	;	Crystal Structure of an Inositol hexakisphosphate kinase apo-EhIP6KA
4O4B	;	1.8	;	Crystal Structure of an Inositol hexakisphosphate kinase EhIP6KA as a fusion protein with maltose binding protein
4O4E	;	1.9	;	Crystal Structure of an Inositol hexakisphosphate kinase EhIP6KA in complexed with ATP and Ins(1,3,4,5,6)P5
4O4D	;	2.1	;	Crystal Structure of an Inositol hexakisphosphate kinase EhIP6KA in complexed with ATP and Ins(1,4,5)P3
4O4F	;	1.7	;	Crystal Structure of an Inositol hexakisphosphate kinase EhIP6KA in complexed with ATP and InsP6
3W4R	;	1.7	;	Crystal structure of an insect chitinase from the Asian corn borer, Ostrinia furnacalis
1PN9	;	2.0	;	Crystal structure of an insect delta-class glutathione S-transferase from a DDT-resistant strain of the malaria vector Anopheles gambiae
5WVH	;	2.801	;	Crystal structure of an insect group III chitinase complex with (GlcNAc)6 (CAD2-(GlcNAc)6 ) from Ostrinia furnacalis
2VU8	;	1.8	;	Crystal structure of an insect inhibitor with a fungal trypsin
6ARY	;	2.257	;	Crystal structure of an insecticide-resistant acetylcholinesterase mutant from the malaria vector Anopheles gambiae in complex with a difluoromethyl ketone inhibitor
6ARX	;	2.302	;	Crystal structure of an insecticide-resistant acetylcholinesterase mutant from the malaria vector Anopheles gambiae in the ligand-free state
2ZBK	;	3.56	;	Crystal structure of an intact type II DNA topoisomerase: insights into DNA transfer mechanisms
6KBH	;	2.6	;	Crystal structure of an intact type IV self-sufficient cytochrome P450 monooxygenase
4D2E	;	2.28	;	Crystal structure of an integral membrane kinase - v2.3
7C83	;	2.0	;	Crystal structure of an integral membrane steroid 5-alpha-reductase PbSRD5A
1MIZ	;	1.9	;	Crystal structure of an integrin beta3-talin chimera
1MK7	;	2.2	;	CRYSTAL STRUCTURE OF AN INTEGRIN BETA3-TALIN CHIMERA
1MK9	;	2.8	;	CRYSTAL STRUCTURE OF AN INTEGRIN BETA3-TALIN CHIMERA
1VCA	;	1.8	;	CRYSTAL STRUCTURE OF AN INTEGRIN-BINDING FRAGMENT OF VASCULAR CELL ADHESION MOLECULE-1 AT 1.8 ANGSTROMS RESOLUTION
7OEC	;	1.48	;	Crystal structure of an intein from a hyperthermophile
3O4O	;	3.3	;	Crystal structure of an Interleukin-1 receptor complex
3JVF	;	3.3	;	Crystal structure of an Interleukin-17 receptor complex
3E2E	;	3.0	;	Crystal Structure of an Intermediate Complex of T7 RNAP and 7nt of RNA
3E3J	;	6.7	;	Crystal Structure of an Intermediate Complex of T7 RNAP and 8nt of RNA
4N68	;	1.8	;	Crystal structure of an internal FN3 domain from human Contactin-5 [PSI-NYSGRC-005804]
4FMZ	;	1.91	;	Crystal structure of an internalin (inlF) from Listeria monocytogenes str. 4b F2365 at 1.91 A resolution
4FHO	;	1.9	;	Crystal structure of an internalin C2 (inlC2) from Listeria monocytogenes str. 4b F2365 at 1.90 A resolution
3ISY	;	2.61	;	Crystal structure of an intracellular proteinase inhibitor (ipi, bsu11130) from bacillus subtilis at 2.61 A resolution
4Q2G	;	3.4	;	CRYSTAL STRUCTURE OF AN INTRAMEMBRANE CDP-DAG SYNTHETASE CENTRAL FOR PHOSPHOLIPID BIOSYNTHESIS (S200C/S223C, inactive mutant)
4Q2E	;	3.4	;	CRYSTAL STRUCTURE OF AN INTRAMEMBRANE CDP-DAG SYNTHETASE CENTRAL FOR PHOSPHOLIPID BIOSYNTHESIS (S200C/S258C, active mutant)
4DAQ	;	2.754	;	Crystal structure of an intramolecular human telomeric DNA G-quadruplex 21-mer bound by the naphthalene diimide compound BMSG-SH-3
4DA3	;	2.4	;	Crystal structure of an intramolecular human telomeric DNA G-quadruplex 21-mer bound by the naphthalene diimide compound MM41.
3SC8	;	2.302	;	Crystal structure of an intramolecular human telomeric DNA G-quadruplex bound by the naphthalene diimide BMSG-SH-3
3T5E	;	2.1	;	Crystal structure of an intramolecular human telomeric DNA G-quadruplex bound by the naphthalene diimide BMSG-SH-4
3UYH	;	1.95	;	Crystal structure of an intramolecular human telomeric DNA G-quadruplex bound by the naphthalene diimide compound, MM41
8AYG	;	2.25	;	Crystal structure of an intramolecular i-motif at the insulin-linked polymorphic region (ILPR)
7XKG	;	2.5	;	Crystal structure of an intramolecular mesacyl-CoA transferase from the 3-hydroxypropionic acid cycle of Roseiflexus castenholzii
5F1C	;	2.9	;	Crystal structure of an invertebrate P2X receptor from the Gulf Coast tick in the presence of ATP and Zn2+ ion at 2.9 Angstroms
6RZD	;	2.0	;	Crystal structure of an inverting family GH156 exosialidase from uncultured bacterium pG7
6S0F	;	2.0	;	Crystal structure of an inverting family GH156 exosialidase from uncultured bacterium pG7 in complex with 3-Deoxy-D-glycero-D-galacto-2-nonulosonic acid
6S0E	;	1.9	;	Crystal structure of an inverting family GH156 exosialidase from uncultured bacterium pG7 in complex with N-Acetyl-2,3-dehydro-2-deoxyneuraminic acid
6S00	;	2.0	;	Crystal structure of an inverting family GH156 exosialidase from uncultured bacterium pG7 in complex with N-acetylneuraminic acid
6S04	;	2.0	;	Crystal structure of an inverting family GH156 exosialidase from uncultured bacterium pG7 in complex with N-glycolylneuraminic acid
1P7B	;	3.65	;	Crystal structure of an inward rectifier potassium channel
3WME	;	2.751	;	Crystal structure of an inward-facing eukaryotic ABC multidrug transporter
3WMG	;	2.4	;	Crystal structure of an inward-facing eukaryotic ABC multidrug transporter G277V/A278V/A279V mutant in complex with an cyclic peptide inhibitor, aCAP
3WMF	;	2.6	;	Crystal structure of an inward-facing eukaryotic ABC multitrug transporter G277V/A278V/A279V mutant
6A6N	;	3.02	;	Crystal structure of an inward-open apo state of the eukaryotic ABC multidrug transporter CmABCB1
5EMS	;	2.3	;	Crystal Structure of an iodinated insulin analog
2QJV	;	1.9	;	Crystal structure of an iolb-like protein (stm4420) from salmonella typhimurium lt2 at 1.90 A resolution
2IRF	;	2.2	;	CRYSTAL STRUCTURE OF AN IRF-2/DNA COMPLEX.
6N63	;	1.72	;	Crystal structure of an Iron binding protein
1VHD	;	1.6	;	Crystal structure of an iron containing alcohol dehydrogenase
6J55	;	2.33	;	Crystal structure of an iron superoxide dismutate (FeSOD) from a pathogenic Acanthamoeba castellanii
3RF7	;	2.12	;	Crystal structure of an Iron-containing alcohol dehydrogenase (Sden_2133) from Shewanella denitrificans OS-217 at 2.12 A resolution
4M8D	;	1.9	;	Crystal structure of an isatin hydrolase bound to product analogue thioisatinate
4H17	;	1.6	;	Crystal structure of an isochorismatase (PP1826) from Pseudomonas putida KT2440 at 1.60 A resolution
3US8	;	2.25	;	Crystal Structure of an isocitrate dehydrogenase from Sinorhizobium meliloti 1021
2QLT	;	1.6	;	Crystal structure of an isoform of DL-glycerol-3-phosphatase, Rhr2p, from Saccharomyces cerevisiae
1DK7	;	2.02	;	CRYSTAL STRUCTURE OF AN ISOLATED APICAL DOMAIN OF GROEL
3DJ9	;	1.75	;	Crystal Structure of an isolated, unglycosylated antibody CH2 domain
2OQH	;	1.98	;	Crystal structure of an isomerase from Streptomyces coelicolor A3(2)
1VGM	;	2.0	;	Crystal Structure of an Isozyme of Citrate Synthase from Sulfolbus tokodaii strain7
1VGP	;	2.7	;	Crystal Structure of an Isozyme of Citrate Synthase from Sulfolbus tokodaii strain7
4NT9	;	1.705	;	Crystal structure of an L,D-carboxypeptidase DacB from Streptococcus pneumonia
4WD3	;	2.8	;	Crystal structure of an L-amino acid ligase RizA
3REW	;	1.9	;	Crystal structure of an lmp2a-derived peptide bound to human class i mhc hla-a2
4HQ1	;	1.55	;	Crystal structure of an LRR protein with two solenoids
4EFD	;	2.45	;	Crystal Structure of an M17 aminopeptidase from Trypanosoma Brucei, Tb427tmp.02.4440
3H4Z	;	2.35	;	Crystal Structure of an MBP-Der p 7 fusion protein
4HG7	;	1.6	;	Crystal Structure of an MDM2/Nutlin-3a complex
4HFZ	;	2.694	;	Crystal Structure of an MDM2/P53 Peptide Complex
4H3X	;	1.764	;	Crystal structure of an MMP broad spectrum hydroxamate based inhibitor CC27 in complex with the MMP-9 catalytic domain
4HMA	;	1.94	;	Crystal structure of an MMP twin carboxylate based inhibitor LC20 in complex with the MMP-9 catalytic domain
4H2E	;	2.902	;	Crystal structure of an MMP twin inhibitor complexing two MMP-9 catalytic domains
7YD4	;	1.896	;	Crystal structure of an N terminal truncated secreted protein, Rv0398c from Mycobacterium tuberculosis
6N1A	;	1.6	;	Crystal structure of an N-acetylgalactosamine deacetylase from F. plautii
6N1B	;	1.3	;	Crystal structure of an N-acetylgalactosamine deacetylase from F. plautii in complex with blood group B trisaccharide
3GT5	;	1.7	;	Crystal structure of an N-acetylglucosamine 2-epimerase family protein from Xylella fastidiosa
7S42	;	1.35	;	Crystal structure of an N-acetyltransferase from Helicobacter pullorum in the presence of Coenzyme A and dTDP-3-acetamido-3,6-dideoxy-D-galactose
7S41	;	1.4	;	Crystal structure of an N-acetyltransferase from Helicobacter pullorum in the presence of Coenzyme A and dTDP-3-acetamido-3,6-dideoxy-D-glucose
7S3W	;	1.25	;	Crystal structure of an N-acetyltransferase from Helicobacter pullorum in the presence of Coenzyme A and dTDP-3-amino-3,6-dideoxy-D-galactose
7S3U	;	1.45	;	Crystal structure of an N-acetyltransferase from Helicobacter pullorum in the presence of Coenzyme A and dTDP-3-amino-3,6-dideoxy-D-glucose
7S45	;	1.2	;	Crystal structure of an N-acetyltransferase, C80T mutant, from Helicobacter pullorum in the presence of Acetyl Coenzyme A and dTDP
7S44	;	1.4	;	Crystal structure of an N-acetyltransferase, C80T mutant, from Helicobacter pullorum in the presence of Coenzyme A and dTDP-3-amino-3,6-dideoxy-D-galactose
7S43	;	1.7	;	Crystal structure of an N-acetyltransferase, C80T mutant, from Helicobacter pullorum in the presence of Coenzyme A and dTDP-3-amino-3,6-dideoxy-D-glucose
6AOC	;	1.8	;	Crystal Structure of an N-Hydroxythienopyrimidine-2,4-dione RNase H Active Site Inhibitor with Multiple Binding Modes to HIV Reverse Transcriptase
4KNA	;	1.95	;	Crystal structure of an N-succinylglutamate 5-semialdehyde dehydrogenase from Burkholderia thailandensis
1BKN	;	2.9	;	CRYSTAL STRUCTURE OF AN N-TERMINAL 40KD FRAGMENT OF E. COLI DNA MISMATCH REPAIR PROTEIN MUTL
3M7D	;	1.815	;	Crystal structure of an N-terminal 44 kDA fragment of topoisomerase V in the presence of dioxane
3M6Z	;	1.4	;	Crystal structure of an N-terminal 44 kDa fragment of topoisomerase V in the presence of guanidium hydrochloride
5KKU	;	2.22	;	Crystal structure of an N-terminal dehydratase from difficidin assembly line
2DGK	;	1.9	;	Crystal structure of an N-terminal deletion mutant of Escherichia coli GadB in an autoinhibited state (aldamine)
8Q0P	;	2.01	;	Crystal Structure of an N-terminal Domain of Variant Surface Glycoprotein 21 (VSG21) of Trypanosome brucei brucei Lister 427
6OTN	;	2.4	;	Crystal Structure of an N-terminal Fragment of Cancer Associated Tropomyosin 3.1 (Tpm3.1)
8BVP	;	2.1	;	Crystal structure of an N-terminal fragment of the effector protein Lpg2504 (SidI) from Legionella pneumophila
4PAY	;	2.77	;	Crystal structure of an N-terminal fragment of the Legionella pneumophila effector protein SidC.
2CXI	;	1.94	;	Crystal Structure Of An N-terminal Fragment Of The Phenylalanyl-tRNA Synthetase Beta-Subunit From Pyrococcus Horikoshii
6CBC	;	3.0	;	Crystal structure of an N-terminal fragment of Vps13.
4QQG	;	2.8	;	Crystal structure of an N-terminal HTATIP fragment
5D2E	;	1.72	;	crystal structure of an N-terminal ketoreductase from macrolactin assembly line
3L6T	;	1.93	;	Crystal Structure of an N-terminal Mutant of the Plasmid pCU1 TraI Relaxase Domain
4NWW	;	3.75	;	Crystal structure of an N-terminally truncated capsid protein mutant of Orsay virus
3ODX	;	3.2	;	Crystal Structure of an N-terminally Truncated Linker-DH/PH Domains of p115-RhoGEF
2ZAU	;	2.0	;	Crystal structure of an N-terminally truncated selenophosphate synthetase from Aquifex aeolicus
1Z0S	;	1.7	;	Crystal structure of an NAD kinase from Archaeoglobus fulgidus in complex with ATP
5HA5	;	1.95	;	Crystal structure of an NAD-bound oxidoreductase from Brucella ovis
6XWF	;	1.6	;	Crystal structure of an NCoR1BBD2-BCL6BTB chimera
6Y17	;	1.56	;	Crystal structure of an NCoR1BBD2-BCL6BTB chimera in complex with nebulinSH3-NCoR1BBD1
6ZBU	;	2.46	;	Crystal structure of an NCoR1BBD2-BCL6BTB chimera in complex with the NcoR1 BBD1 corepressor peptide
6XXS	;	3.25	;	Crystal structure of an NCoR1BBD2-BCL6BTB chimera in complex with the NcoR1 BBD1 corepressor peptide.
2QJU	;	2.9	;	Crystal Structure of an NSS Homolog with Bound Antidepressant
3ECF	;	1.9	;	Crystal structure of an ntf2-like protein (ava_4193) from anabaena variabilis atcc 29413 at 1.90 A resolution
2RFR	;	1.16	;	Crystal structure of an ntf2-like protein with a cystatin-like fold (saro_3722) from novosphingobium aromaticivorans dsm at 1.16 A resolution
3I53	;	2.08	;	Crystal structure of an O-methyltransferase (NcsB1) from neocarzinostatin biosynthesis in complex with S-adenosyl-L-homocysteine (SAH)
3I64	;	3.0	;	Crystal structure of an O-methyltransferase (NcsB1) from neocarzinostatin biosynthesis in complex with S-adenosyl-L-homocysteine (SAH) and 1,4-dihydroxy-2-naphthoic acid (DHN)
3I58	;	2.69	;	Crystal structure of an O-methyltransferase (NcsB1) from neocarzinostatin biosynthesis in complex with S-adenosyl-L-homocysteine (SAH) and 2-hydroxy-7-methoxy-5-methyl naphthoic acid (NA)
3I5U	;	2.6	;	Crystal structure of an O-methyltransferase (NcsB1) from neocarzinostatin biosynthesis in complex with S-adenosylmethionine (SAM) and 2-hydroxy-5-methyl naphthoic acid (MNA)
5MDJ	;	1.48	;	Crystal structure of an O2-tolerant [NiFe]-hydrogenase from Ralstonia eutropha in a its as-isolated high-pressurized form
5MDK	;	1.5	;	Crystal structure of an O2-tolerant [NiFe]-hydrogenase from Ralstonia eutropha in its as-isolated form (oxidized state - state 3)
4IUB	;	1.61	;	Crystal structure of an O2-tolerant [NiFe]-hydrogenase from Ralstonia eutropha in its as-isolated form - oxidized state 1
4IUC	;	1.45	;	Crystal structure of an O2-tolerant [NiFe]-hydrogenase from Ralstonia eutropha in its as-isolated form - oxidized state 2
4TTT	;	1.72	;	Crystal structure of an O2-tolerant [NiFe]-hydrogenase from Ralstonia eutropha in its as-isolated form - oxidized state 3
4IUD	;	1.45	;	Crystal structure of an O2-tolerant [NiFe]-hydrogenase from Ralstonia eutropha in its as-isolated form with ascorbate - partly reduced state
5MDL	;	1.41	;	Crystal structure of an O2-tolerant [NiFe]-hydrogenase from Ralstonia eutropha in its O2-derivatized form by a ""soak-and-freeze"" derivatization method
2F4I	;	2.25	;	Crystal structure of an ob-fold protein (tm0957) from thermotoga maritima msb8 at 1.90 A resolution
4XCD	;	3.79	;	Crystal structure of an octadecameric TF55 complex from S. solfataricus
3JXO	;	1.55	;	Crystal Structure of an Octomeric Two-Subunit TrkA K+ Channel Ring Gating Assembly, TM1088A:TM1088B, from Thermotoga maritima
3L4B	;	3.45	;	Crystal Structure of an Octomeric Two-Subunit TrkA K+ Channel Ring Gating Assembly, TM1088A:TM1088B, from Thermotoga maritima
3OGN	;	1.3	;	Crystal Structure of an Odorant-binding Protein from the Southern House Mosquito Complexed with an Oviposition Pheromone
1OFX	;	2.0	;	CRYSTAL STRUCTURE OF AN OKAZAKI FRAGMENT AT 2 ANGSTROMS RESOLUTION
3OP6	;	2.0	;	Crystal structure of an oligo-nucleotide binding protein (lpg1207) from Legionella pneumophila subsp. pneumophila str. philadelphia 1 at 2.00 A resolution
4QKK	;	1.4	;	Crystal structure of an oligonucleotide containing 5-formylcytosine
1D80	;	2.2	;	CRYSTAL STRUCTURE OF AN OLIGONUCLEOTIDE DUPLEX CONTAINING G.G BASE-PAIRS: THE INFLUENCE OF MISPAIRING ON DNA BACKBONE CONFORMATION
5CY4	;	2.25	;	Crystal structure of an oligoribonuclease from Acinetobacter baumannii
6K8H	;	1.9	;	Crystal structure of an omega-transaminase from Sphaerobacter thermophilus
8X1F	;	2.3	;	Crystal structure of an omega-transaminase mutant from Aspergillus terreus with in complex with PLP
8XIY	;	2.09	;	Crystal structure of an omega-transaminase mutant I77L/Q97E/H210N/N245D from Aspergillus terreus in complex with PLP
6HE2	;	2.3	;	Crystal structure of an open conformation of 2-Hydroxyisobutyryl-CoA Ligase (HCL) in complex with 2-HIB-AMP and CoA
3NS8	;	1.707	;	Crystal structure of an open conformation of Lys48-linked diubiquitin at pH 7.5
4O3B	;	1.906	;	Crystal structure of an open/closed glua2 ligand-binding domain dimer at 1.91 A resolution
3FYJ	;	3.8	;	Crystal structure of an optimzied benzothiophene inhibitor bound to MAPKAP Kinase-2 (MK-2)
4NOZ	;	2.22	;	Crystal Structure of an Organic Hydroperoxide Resistance Protein from Burkholderia cenocepacia
6D9N	;	1.2	;	Crystal structure of an organic hydroperoxide resistance protein from Elizabethkingia anophelis with crystallant-derived thiocyanate bound
6MJN	;	1.75	;	Crystal structure of an organic hydroperoxide resistance protein OsmC, predicted redox protein, regulator of sulfide bond formation from Legionella pneumophila
2F84	;	2.1	;	Crystal Structure of an orotidine-5'-monophosphate decarboxylase homolog from P.falciparum
7FHM	;	1.8	;	Crystal structure of an orphan heme uptake protein (MhuP) of ABC transporter from Mycobacterium tuberculosis (Form I)
7FHP	;	2.01	;	Crystal structure of an orphan heme uptake protein (MhuP) of ABC transporter from Mycobacterium tuberculosis (Form II)
1O22	;	2.0	;	Crystal structure of an orphan protein (TM0875) from Thermotoga maritima at 2.00 A resolution
3CJE	;	1.7	;	Crystal structure of an osmc-like hydroperoxide resistance protein (jann_2040) from jannaschia sp. ccs1 at 1.70 A resolution
2OPL	;	1.5	;	Crystal structure of an osmc-like protein (gsu2788) from geobacter sulfurreducens at 1.50 A resolution
5YS7	;	2.1	;	Crystal structure of an OspA mutant
5Z1O	;	2.0	;	Crystal structure of an OspA mutant
6KT1	;	1.43	;	Crystal structure of an OspA mutant
6W9S	;	2.1	;	Crystal structure of an OTU deubiquitinase from Escherichia albertii bound to ubiquitin
6W9O	;	1.47	;	Crystal structure of an OTU deubiquitinase from Wolbachia pipientis wMel
6W9R	;	1.82	;	Crystal structure of an OTU deubiquitinase from Wolbachia pipientis wMel bound to ubiquitin
3LDT	;	2.3	;	Crystal structure of an Outer membrane protein(OmpA)from Legionella pneumophila
3G6I	;	1.93	;	Crystal structure of an outer membrane protein, part of a putative carbohydrate binding complex (bt_1022) from bacteroides thetaiotaomicron vpi-5482 at 1.93 A resolution
2Y8P	;	1.995	;	Crystal Structure of an Outer Membrane-Anchored Endolytic Peptidoglycan Lytic Transglycosylase (MltE) from Escherichia coli
2YN7	;	2.25	;	Crystal structure of an outer surface protein BBA66 from Borrelia burgdorferi
4MXT	;	1.4	;	Crystal structure of an Outer-membrane lipoprotein carrier protein (BACUNI_04723) from Bacteroides uniformis ATCC 8492 at 1.40 A resolution
3PUW	;	2.3	;	Crystal Structure of an outward-facing MBP-Maltose transporter complex bound to ADP-AlF4
3PUX	;	2.3	;	Crystal Structure of an outward-facing MBP-Maltose transporter complex bound to ADP-BeF3
3PUV	;	2.4	;	Crystal Structure of an outward-facing MBP-Maltose transporter complex bound to ADP-VO4
3PUY	;	3.1	;	Crystal Structure of an outward-facing MBP-Maltose transporter complex bound to AMP-PNP after crystal soaking of the pretranslocation state
6A6M	;	1.9	;	Crystal structure of an outward-open nucleotide-bound state of the eukaryotic ABC multidrug transporter CmABCB1
6I5D	;	1.75	;	Crystal structure of an OXA-48 beta-lactamase synthetic mutant
4MU8	;	1.45	;	Crystal structure of an oxidized form of yeast iso-1-cytochrome c at pH 8.8
6LGJ	;	2.4	;	Crystal structure of an oxido-reductase
6LGK	;	2.0	;	Crystal structure of an oxido-reductase with mutation
6LGM	;	2.4	;	Crystal structure of an oxido-reductase with mutation and inhibitor
3I23	;	2.3	;	Crystal Structure of an Oxidoreductase (Gfo/Idh/MocA family) from Enterococcus faecalis. Northeast Structural Genomics Consortium target id EfR167
5EL0	;	1.85	;	Crystal structure of an Oxidoreductase (short chain dehydrogenase/reductase family) from Brucella ovis in complex with a partially ordered NAD
5TT0	;	1.7	;	Crystal Structure of an Oxidoreductase (short chain dehydrogenase/reductase family) from Burkholderia thailandensis
4X54	;	1.45	;	Crystal structure of an oxidoreductase (short chain dehydrogenase/reductase) from Brucella ovis
5UHW	;	2.24	;	Crystal Structure of an Oxidoreductase from Agrobacterium radiobacter in Complex with NAD+ and Magnesium
5UI9	;	1.92	;	Crystal Structure of an Oxidoreductase from Agrobacterium radiobacter in Complex with NAD+, 2 -hydroxy-2-hydroxymethyl propanoic acid and Magnesium
5UHZ	;	2.2	;	Crystal Structure of an Oxidoreductase from Agrobacterium radiobacter in Complex with NAD+, D-Apionate and Magnesium
5UIB	;	2.65	;	Crystal Structure of an Oxidoreductase from Agrobacterium radiobacter in Complex with NAD+, L-tartaric acid and Magnesium
5UIA	;	2.18	;	Crystal Structure of an Oxidoreductase from Agrobacterium radiobacter in Complex with NAD+, R-2,3-dihydroxyisovalerate and Magnesium
3HNP	;	2.6	;	Crystal Structure of an Oxidoreductase from Bacillus cereus. Northeast Structural Genomics Consortium target id BcR251
5ER6	;	1.55	;	Crystal structure of an oxidoreductase from Brucella ovis
5IDX	;	1.95	;	Crystal structure of an oxidoreductase from Burkholderia vietnamiensis
5IDW	;	2.0	;	Crystal structure of an oxidoreductase from Burkholderia vietnamiensis in complex with NADP
5IDY	;	1.85	;	Crystal structure of an oxidoreductase from Burkholderia vietnamiensis in complex with NADP
3E9M	;	2.7	;	Crystal Structure of an oxidoreductase from Enterococcus faecalis
3FD8	;	2.45	;	Crystal Structure of an oxidoreductase from Enterococcus faecalis
3KA7	;	1.8	;	Crystal Structure of an oxidoreductase from Methanosarcina mazei. Northeast Structural Genomics Consortium target id MaR208
3U0B	;	1.7	;	Crystal structure of an oxidoreductase from Mycobacterium smegmatis
3DTY	;	2.04	;	Crystal structure of an Oxidoreductase from Pseudomonas syringae
3UN1	;	2.45	;	Crystal structure of an oxidoreductase from Sinorhizobium meliloti 1021
4NPC	;	1.75	;	Crystal Structure of an Oxidoreductase, Short-Chain Dehydrogenase/Reductase Family Protein from Brucella suis
5SW6	;	1.9	;	Crystal structure of an oxoferryl species of catalase-peroxidase KatG at pH5.6
5SX0	;	2.0	;	Crystal structure of an oxoferryl species of catalase-peroxidase KatG at pH7.5
1U4H	;	2.07	;	Crystal structure of an oxygen binding H-NOX domain related to soluble guanylate cyclases (oxygen complex)
1U55	;	1.77	;	Crystal structure of an oxygen binding H-NOX domain related to soluble guanylate cyclases (oxygen complex)
1U56	;	1.9	;	Crystal structure of an oxygen binding H-NOX domain related to soluble guanylate cyclases (Water-ligated, ferric form)
4ILJ	;	2.0001	;	Crystal structure of an Prp8p RNaseH W1911A mutant protein
3ERV	;	2.1	;	Crystal structure of an putative C39-like peptidase from Bacillus anthracis
7Y3W	;	1.9	;	Crystal structure of an questin oxidase (BTG13) from Cercospora sp. JNU001
6XWB	;	2.2	;	Crystal structure of an R-selective transaminase from Thermomyces stellatus.
2R3X	;	1.8	;	Crystal structure of an R15L hGSTA1-1 mutant complexed with S-hexyl-glutathione
3FYA	;	3.0	;	Crystal Structure of an R35A mutant of the Restriction-Modification Controller Protein C.Esp1396I
4F8D	;	1.5	;	Crystal Structure of an R46A mutant of the Restriction-Modification Controller Protein C.Esp1396I (Monoclinic Form)
4FBI	;	1.5	;	Crystal Structure of an R46A mutant of the Restriction-Modification Controller Protein C.Esp1396I (Trigonal Form)
3N5U	;	3.2	;	Crystal structure of an Rb C-terminal peptide bound to the catalytic subunit of PP1
5TTE	;	3.501	;	Crystal Structure of an RBR E3 ubiquitin ligase in complex with an E2-Ub thioester intermediate mimic
4GOU	;	2.3	;	Crystal structure of an RGS-RhoGEF from Entamoeba histolytica
3EBR	;	2.6	;	Crystal structure of an rmlc-like cupin protein (reut_a0381) from ralstonia eutropha jmp134 at 2.60 A resolution
4Q9Q	;	2.45	;	Crystal structure of an RNA aptamer bound to bromo-ligand analog in complex with Fab
3DD2	;	1.9	;	Crystal structure of an RNA aptamer bound to human thrombin
4Q9R	;	3.12	;	Crystal structure of an RNA aptamer bound to trifluoroethyl-ligand analog in complex with Fab
4KZE	;	2.404	;	Crystal structure of an RNA aptamer in complex with Fab
4KZD	;	2.186	;	Crystal structure of an RNA aptamer in complex with fluorophore and Fab
1SDR	;	2.6	;	CRYSTAL STRUCTURE OF AN RNA DODECAMER CONTAINING THE ESCHERICHIA COLI SHINE-DALGARNO SEQUENCE
2NOK	;	3.0	;	Crystal Structure of an RNA domain from Hepatitis C virus.
255D	;	2.0	;	CRYSTAL STRUCTURE OF AN RNA DOUBLE HELIX INCORPORATING A TRACK OF NON-WATSON-CRICK BASE PAIRS
1YY0	;	3.2	;	Crystal structure of an RNA duplex containing a 2'-amine substitution and a 2'-amide product produced by in-crystal acylation at a C-A mismatch
1YZD	;	2.35	;	Crystal structure of an RNA duplex containing a site specific 2'-amine substitution at a C-G Watson-Crick base pair
1Z79	;	2.55	;	Crystal structure of an RNA duplex containing site specific 2'-amine substitution at a C-A mismatch (at pH 5)
1YRM	;	2.5	;	Crystal Structure of an RNA duplex containing site specific 2'-amine substitutions at a C-A mismatch
2AO5	;	2.1	;	Crystal structure of an RNA duplex r(GGCGBrUGCGCU)2 with terminal and internal tandem G-U base pairs
1J9H	;	1.4	;	Crystal Structure of an RNA Duplex with Uridine Bulges
1KFO	;	1.6	;	CRYSTAL STRUCTURE OF AN RNA HELIX RECOGNIZED BY A ZINC-FINGER PROTEIN: AN 18 BASE PAIR DUPLEX AT 1.6 RESOLUTION
2JLT	;	2.9	;	Crystal structure of an RNA kissing complex
3K7A	;	3.8	;	Crystal Structure of an RNA polymerase II-TFIIB complex
437D	;	1.6	;	CRYSTAL STRUCTURE OF AN RNA PSEUDOKNOT FROM BEET WESTERN YELLOW VIRUS INVOLVED IN RIBOSOMAL FRAMESHIFTING
2GRB	;	1.4	;	Crystal Structure of an RNA Quadruplex Containing Inosine-tetrad
409D	;	2.5	;	CRYSTAL STRUCTURE OF AN RNA R(CCCIUGGG) WITH THREE INDEPENDENT DUPLEXES INCORPORATING TANDEM I.U WOBBLES
2G32	;	1.3	;	Crystal structure of an RNA racemate
2GPM	;	1.4	;	Crystal structure of an RNA racemate
2GQ4	;	1.35	;	Crystal structure of an RNA racemate
2GQ5	;	1.4	;	Crystal structure of an RNA racemate
2GQ6	;	1.3	;	Crystal structure of an RNA racemate
2GQ7	;	1.6	;	Crystal structure of an RNA racemate
1KH6	;	2.9	;	Crystal Structure of an RNA Tertiary Domain Essential to HCV IRES-mediated Translation Initiation.
1J6S	;	1.4	;	Crystal Structure of an RNA Tetraplex (UGAGGU)4 with A-tetrads, G-tetrads, U-tetrads and G-U octads
7THB	;	1.64	;	Crystal structure of an RNA-5'/DNA-3' strand exchange junction
8WO8	;	2.78	;	Crystal Structure of an RNA-binding protein, FAU-1, from Pyrococcus furiosus
4LDM	;	1.85	;	Crystal Structure of an RNA-free VP40 Octameric Ring
1PJO	;	1.1	;	Crystal Structure of an RNA/DNA hybrid of HIV-1 PPT
1F0V	;	1.7	;	Crystal structure of an Rnase A dimer displaying a new type of 3D domain swapping
5EDL	;	1.95	;	Crystal structure of an S-component of ECF transporter
3LS2	;	2.2	;	Crystal structure of an S-formylglutathione hydrolase from Pseudoalteromonas haloplanktis TAC125
3B1X	;	2.61	;	Crystal structure of an S. thermophilus NFeoB E66A mutant bound to GMPPNP
3B1W	;	2.5	;	Crystal structure of an S. thermophilus NFeoB E67A mutant bound to GDP
3B1V	;	1.85	;	Crystal structure of an S. thermophilus NFeoB E67A mutant bound to mGMPPNP
3TAH	;	1.85	;	Crystal structure of an S. thermophilus NFeoB N11A mutant bound to mGDP
3B1Y	;	2.5	;	Crystal structure of an S. thermophilus NFeoB T35A mutant bound to GDP
3B1Z	;	2.65	;	Crystal structure of an S. thermophilus NFeoB T35S mutant without nucleotide
4Q00	;	2.1	;	Crystal structure of an S150A mutant of the E. coli FeoB G-domain
4FN3	;	1.79	;	Crystal Structure of an S52A mutant of the Restriction-Modification Controller Protein C.Esp1396I
5VPS	;	1.45	;	Crystal structure of an SDR from Burkholderia ambifaria in complex with NADPH with a TCEP adduct
4XEY	;	2.891	;	Crystal structure of an SH2-kinase domain construct of c-Abl tyrosine kinase
1I4K	;	2.5	;	CRYSTAL STRUCTURE OF AN SM-LIKE PROTEIN (AF-SM1) FROM ARCHAEOGLOBUS FULGIDUS AT 2.5A RESOLUTION
1I5L	;	2.75	;	CRYSTAL STRUCTURE OF AN SM-LIKE PROTEIN (AF-SM1) FROM ARCHAEOGLOBUS FULGIDUS COMPLEXED WITH SHORT POLY-U RNA
1LJO	;	1.95	;	CRYSTAL STRUCTURE OF AN SM-LIKE PROTEIN (AF-SM2) FROM ARCHAEOGLOBUS FULGIDUS AT 1.95A RESOLUTION
4M58	;	3.21	;	Crystal Structure of an transition metal transporter
4M5B	;	1.833	;	Crystal Structure of an Truncated Transition Metal Transporter
4M5C	;	2.5	;	Crystal Structure of an Truncated Transition metal Transporter
5HXA	;	2.0	;	Crystal structure of an UDP-forming alpha, alpha-terhalose-phosphate synthase from Burkholderia xenovorans
3INU	;	2.5	;	Crystal structure of an unbound KZ52 neutralizing anti-Ebolavirus antibody.
3CJP	;	1.85	;	Crystal structure of an uncharacterized amidohydrolase CAC3332 from Clostridium acetobutylicum
3E2V	;	1.5	;	Crystal structure of an uncharacterized amidohydrolase from Saccharomyces cerevisiae
1X7F	;	2.3	;	Crystal structure of an uncharacterized B. cereus protein
5BXG	;	1.9	;	Crystal structure of an uncharacterized beta-sandwich protein (CD630_09570) from Clostridium difficile 630 at 1.90 A resolution
3B49	;	1.6	;	Crystal structure of an uncharacterized conserved protein from Listeria innocua
2QYA	;	2.17	;	Crystal structure of an uncharacterized conserved protein from Methanopyrus kandleri
3GMG	;	1.5	;	Crystal structure of an uncharacterized conserved protein from Mycobacterium tuberculosis
2I8D	;	1.69	;	Crystal structure of an uncharacterized conserved protein of COG5646 (ZP_00384875.1) from Lactobacillus casei ATCC 334 at 1.69 A resolution
1VMH	;	1.31	;	Crystal structure of an uncharacterized conserved protein yjbq/upf0047 family, ortholog yugu b.subtilis (ca_c0907) from clostridium acetobutylicum at 1.31 A resolution
3FF2	;	1.9	;	Crystal structure of an uncharacterized cystatin fold protein (saro_2299) from novosphingobium aromaticivorans dsm at 1.90 A resolution
3RH3	;	2.1	;	Crystal structure of an Uncharacterized DUF3829-like protein (BT_1908) from BACTEROIDES THETAIOTAOMICRON VPI-5482 at 2.10 A resolution
3IJ6	;	2.0	;	CRYSTAL STRUCTURE OF AN UNCHARACTERIZED METAL-DEPENDENT HYDROLASE FROM Lactobacillus acidophilus
3ICJ	;	1.95	;	Crystal structure of an uncharacterized metal-dependent hydrolase from pyrococcus furiosus
3IGH	;	1.95	;	Crystal structure of an uncharacterized metal-dependent hydrolase from pyrococcus horikoshii ot3
3GG7	;	1.5	;	Crystal structure of an uncharacterized metalloprotein from Deinococcus radiodurans
5IXU	;	2.5	;	Crystal structure of an uncharacterized NIPSNAP domain protein from Burkholderia xenovorans
5KAK	;	1.65	;	Crystal structure of an uncharacterized NIPSNAP-like domain protein from Burkholderia xenovorans
6III	;	2.113	;	Crystal structure of an uncharacterized protein
6INY	;	1.997	;	Crystal structure of an uncharacterized protein
5BYP	;	2.6	;	Crystal structure of an uncharacterized protein (BACEGG_01585) from Bacteroides eggerthii DSM 20697 at 2.60 A resolution
2QML	;	1.55	;	Crystal structure of an uncharacterized protein (bh2621) from bacillus halodurans at 1.55 A resolution
5COZ	;	1.45	;	Crystal structure of an uncharacterized protein (EUBREC_2869) from Eubacterium rectale ATCC 33656 at 1.45 A resolution
3R6A	;	1.76	;	Crystal structure of an uncharacterized protein (hypothetical protein MM_3218) from Methanosarcina mazei.
3BPD	;	2.8	;	Crystal structure of an uncharacterized protein (O28723_ARCFU) from Archaeoglobus fulgidus
5BMT	;	1.5	;	Crystal structure of an uncharacterized protein (PARMER_03598) from Parabacteroides merdae ATCC 43184 at 1.50 A resolution
4XXP	;	1.6	;	Crystal Structure of an Uncharacterized Protein (Rv0315 ortholog) from Mycobacterium paratuberculosis
4HFS	;	1.55	;	Crystal structure of an uncharacterized protein (yncM) from Bacillus subtilis subsp. subtilis str. 168 at 1.55 A resolution
2PRV	;	1.3	;	Crystal structure of an uncharacterized protein (yobk, bsu18990) from bacillus subtilis at 1.30 A resolution
3K12	;	1.49	;	Crystal structure of an uncharacterized protein A6V7T0 from Pseudomonas aeruginosa
3C4R	;	2.3	;	Crystal structure of an uncharacterized protein encoded by cryptic prophage
3C3K	;	1.99	;	Crystal structure of an uncharacterized protein from Actinobacillus succinogenes
3E0S	;	2.09	;	Crystal structure of an uncharacterized protein from Chlorobium tepidum
3E0H	;	1.81	;	Crystal structure of an uncharacterized protein from Chlorobium tepidum. NorthEast Structural Genomics target CtR107.
2G6T	;	3.0	;	Crystal structure of an uncharacterized protein from Clostridium acetobutylicum
3KQ5	;	2.0	;	Crystal structure of an uncharacterized protein from Coxiella burnetii
2PV4	;	1.95	;	CRYSTAL STRUCTURE OF AN UNCHARACTERIZED PROTEIN FROM DUF3069 FAMILY (SAMA_2622) FROM SHEWANELLA AMAZONENSIS SB2B AT 1.95 A RESOLUTION
2Q3L	;	2.25	;	CRYSTAL STRUCTURE OF AN UNCHARACTERIZED PROTEIN FROM DUF3478 FAMILY WITH A SPOIIAA-LIKE FOLD (SHEW_3102) FROM SHEWANELLA LOIHICA PV-4 AT 2.25 A RESOLUTION
3ESI	;	2.5	;	Crystal structure of an uncharacterized protein from Erwinia carotovora subsp. atroseptica. Northeast Structural Genomics target EwR179
3CYG	;	2.61	;	Crystal structure of an uncharacterized protein from Fervidobacterium nodosum Rt17-B1
6MTZ	;	2.15	;	Crystal structure of an uncharacterized protein from Helicobacter pylori G27
3IB6	;	2.2	;	Crystal structure of an uncharacterized protein from Listeria monocytogenes serotype 4b
3MAB	;	1.42	;	CRYSTAL STRUCTURE OF AN UNCHARACTERIZED PROTEIN FROM LISTERIA MONOCYTOGENES, Triclinic FORM
3BHW	;	1.5	;	Crystal structure of an uncharacterized protein from Magnetospirillum magneticum
3KG4	;	1.95	;	Crystal structure of an uncharacterized protein from Mannheimia succiniciproducens
3CXJ	;	2.8	;	Crystal structure of an uncharacterized protein from Methanothermobacter thermautotrophicus
5V77	;	1.85	;	Crystal structure of an uncharacterized protein from Neisseria gonorrhoeae
3ESM	;	1.65	;	Crystal structure of an uncharacterized protein from Nocardia farcinica reveals an immunoglobulin-like fold
4O5P	;	2.001	;	Crystal structure of an uncharacterized protein from Pseudomonas aeruginosa
2PK8	;	1.85	;	Crystal structure of an uncharacterized protein PF0899 from Pyrococcus furiosus
2RJN	;	2.1	;	Crystal structure of an uncharacterized protein Q2BKU2 from Neptuniibacter caesariensis
3GZR	;	1.4	;	CRYSTAL STRUCTURE OF AN UNCHARACTERIZED PROTEIN WITH A CYSTATIN-LIKE FOLD (CC_2572) FROM CAULOBACTER VIBRIOIDES AT 1.40 A RESOLUTION
5BR9	;	2.35	;	Crystal structure of an uncharacterized protein with similarity to peptidase YEAZ from Pseudomonas aeruginosa
3EWM	;	1.9	;	Crystal structure of an uncharacterized sugar kinase PH1459 from pyrococcus horikoshii
3IH0	;	1.9	;	Crystal structure of an uncharacterized sugar kinase PH1459 from Pyrococcus horikoshii in complex with AMP-PNP
3GBU	;	2.2	;	Crystal structure of an uncharacterized sugar kinase PH1459 from Pyrococcus horikoshii in complex with ATP
3R79	;	1.9	;	Crystal structure of an uncharactertized protein from Agrobacterium tumefaciens
4RS5	;	3.805	;	Crystal structure of an uncoating intermediate of a EV71 recombinant virus
4EYZ	;	1.383	;	Crystal structure of an uncommon cellulosome-related protein module from Ruminococcus flavefaciens that resembles papain-like cysteine peptidases
4FBW	;	2.2	;	Crystal structure of an unfused Mre11-Nbs1 complex with two manganese ions per active site
2GM3	;	2.461	;	Crystal Structure of an Universal Stress Protein Family Protein from Arabidopsis Thaliana At3g01520 with AMP Bound
2OY9	;	1.6	;	Crystal structure of an unknown conserved protein- Pfam: UPF0223
3CPG	;	1.71	;	Crystal structure of an unknown protein from Bifidobacterium adolescentis
2NYI	;	1.8	;	Crystal Structure of an Unknown Protein from Galdieria sulphuraria
1DQL	;	2.6	;	CRYSTAL STRUCTURE OF AN UNLIGANDED (NATIVE) FV FROM A HUMAN IGM ANTI-PEPTIDE ANTIBODY
6EVL	;	1.87	;	Crystal structure of an unlignaded peptide-substrate-binding domain of human type II collagen prolyl 4-hydroxylase
5MVK	;	1.531	;	Crystal structure of an unmodified A-DNA dodecamer containing 3 consecutive CpG steps
5MVQ	;	1.604	;	Crystal structure of an unmodified, self-complementary dodecamer.
1J73	;	2.0	;	Crystal structure of an unstable insulin analog with native activity.
8ES6	;	1.9	;	Crystal structure of an unusual amidase ClbL from colibactin gene cluster
1R8O	;	1.83	;	Crystal structure of an unusual Kunitz-type trypsin inhibitor from Copaifera langsdorffii seeds
4BKD	;	1.17	;	Crystal Structure of an unusually linked dimeric variant of Bet v 1 (b)
2PNK	;	2.0	;	CRYSTAL STRUCTURE OF AN URONATE ISOMERASE (BH0493) FROM BACILLUS HALODURANS C-125 AT 2.00 A RESOLUTION
3MW8	;	1.65	;	Crystal structure of an UROPORPHYRINOGEN-III SYNTHASE (Sama_3255) from SHEWANELLA AMAZONENSIS SB2B at 1.65 A resolution
2INB	;	1.6	;	Crystal structure of an XisH family protein (ZP_00107633.1) from Nostoc punctiforme PCC 73102 at 1.60 A resolution
4A15	;	2.2	;	Crystal structure of an XPD DNA complex
5WOQ	;	1.95	;	Crystal structure of an XRE family protein transcriptional regulator from Mycobacterium smegmatis
4PQV	;	2.463	;	Crystal structure of an Xrn1-resistant RNA from the 3' untranslated region of a flavivirus (Murray Valley Encephalitis virus)
3OVK	;	2.0	;	Crystal structure of an XXA-pro aminopeptidase from Streptococcus pyogenes
4XSP	;	2.15	;	Crystal structure of Anabaena Alr3699/HepE in complex with UDP
4XSU	;	2.48	;	Crystal structure of Anabaena Alr3699/HepE in complex with UDP and glucose
4XSR	;	2.39	;	Crystal structure of Anabaena Alr3699/HepE in complex with UDP-glucose
2GZ6	;	2.0	;	Crystal Structure Of Anabaena sp. CH1 N-acetyl-D-glucosamine 2-epimerase At 2.0 A
5C2I	;	1.89	;	Crystal structure of Anabaena sp. DyP-type peroxidese (AnaPX)
4YRV	;	2.8	;	Crystal structure of Anabaena transcription factor HetR complexed with 21-bp DNA from hetP promoter
4EP1	;	3.25	;	Crystal structure of anabolic ornithine carbamoyltransferase from Bacillus anthracis
4NF2	;	1.74	;	Crystal structure of anabolic ornithine carbamoyltransferase from Bacillus anthracis in complex with carbamoyl phosphate and L-norvaline
3TPF	;	2.7	;	Crystal structure of anabolic ornithine carbamoyltransferase from Campylobacter jejuni subsp. jejuni NCTC 11168
4JFR	;	2.17	;	Crystal structure of anabolic ornithine carbamoyltransferase from Vibrio vulnificus in complex with carbamoyl phosphate
4H31	;	1.7	;	Crystal structure of anabolic ornithine carbamoyltransferase from Vibrio vulnificus in complex with carbamoyl phosphate and L-norvaline
4JHX	;	1.85	;	Crystal structure of anabolic ornithine carbamoyltransferase from Vibrio vulnificus in complex with carbamoylphosphate and arginine
4JQO	;	2.082	;	Crystal structure of anabolic ornithine carbamoyltransferase from Vibrio vulnificus in complex with citrulline and inorganic phosphate
6H9A	;	2.831	;	Crystal structure of anaerobic ergothioneine biosynthesis enzyme from Chlorobium limicola in complex with natural substrate trimethyl histidine.
6H99	;	1.6	;	Crystal structure of anaerobic ergothioneine biosynthesis enzyme from Chlorobium limicola in persulfide form.
2PP7	;	1.65	;	Crystal structure of anaerobically manipulated wild type oxidized AfNiR (acetate bound)
5XLG	;	1.64	;	Crystal structure of anaerobically purified and aerobically crystallized D. vulgaris Miyazaki F [NiFe]-hydrogenase
5XLE	;	1.69	;	Crystal structure of anaerobically purified and anaerobically crystallized D. vulgaris Miyazaki F [NiFe]-hydrogenase
2FJS	;	1.85	;	Crystal Structure of Anaerobically Reduced Wild Type Nitrite Reductase from A. faecalis
1YVY	;	2.35	;	Crystal structure of Anaerobiospirillum succiniciproducens phosphoenolpyruvate carboxykinase
6N0X	;	1.44	;	Crystal structure of Anaerolinea thermophila mevalonate 5-phosphate decarboxylase complexed with (R)-MVAP
6N0Y	;	2.2	;	Crystal structure of Anaerolinea thermophila mevalonate 5-phosphate decarboxylase complexed with (R)-MVAPP
6N0Z	;	1.95	;	Crystal structure of Anaerolinea thermophila mevalonate 5-phosphate decarboxylase N20K H194M mutant complexed with (R)-MVAPP
6MX8	;	1.96	;	Crystal structure of anaplastic lymphoma kinase (ALK) bound by Brigatinib
5IUG	;	1.93	;	Crystal Structure of Anaplastic Lymphoma Kinase (ALK) in complex with 5a
4MKC	;	2.01	;	Crystal Structure of Anaplastic Lymphoma Kinase Complexed with LDK378
5IUI	;	1.88	;	Crystal Structure of Anaplastic Lyphoma Kinase (ALK) in complex with 4
4LD7	;	2.83	;	Crystal structure of AnaPT from Neosartorya fischeri
2X8Y	;	1.9	;	Crystal structure of AnCE
3ZQZ	;	2.35	;	CRYSTAL STRUCTURE OF ANCE IN COMPLEX WITH A SELENIUM ANALOGUE OF CAPTOPRIL
4AA1	;	1.99	;	Crystal structure of ANCE in complex with Angiotensin-II
4ASQ	;	1.99	;	Crystal structure of ANCE in complex with Bradykinin
4AA2	;	1.99	;	Crystal structure of ANCE in complex with bradykinin potentiating peptide b
4ASR	;	1.9	;	Crystal structure of ANCE in complex with Thr6-Bradykinin
2X8Z	;	1.98	;	Crystal structure of AnCE-captopril complex
2X90	;	1.98	;	Crystal structure of AnCE-enalaprilat complex
2XHM	;	1.96	;	Crystal structure of AnCE-K26 complex
2X91	;	1.98	;	Crystal structure of AnCE-lisinopril complex
2X95	;	1.96	;	Crystal structure of AnCE-lisinopril-tryptophan analogue, lisW-S complex
2X94	;	1.88	;	Crystal structure of AnCE-perindoprilat complex
2X92	;	2.11	;	Crystal structure of AnCE-ramiprilat complex
2X97	;	1.85	;	Crystal structure of AnCE-RXP407 complex
2X96	;	1.85	;	Crystal structure of AnCE-RXPA380 complex
2X93	;	1.98	;	Crystal structure of AnCE-trandolaprilat complex
7SCM	;	2.272	;	Crystal Structure of Ancestral Amniote Cadherin-23 EC1-2
6VDH	;	1.85	;	Crystal structure of ancestral apicomplexan lactate dehydrogenase in alternate dimer configuration with sulfate.
4PLF	;	1.35	;	Crystal structure of ancestral apicomplexan lactate dehydrogenase with lactate.
4PLC	;	1.5	;	Crystal structure of ancestral apicomplexan lactate dehydrogenase with malate.
4PLG	;	1.192	;	Crystal structure of ancestral apicomplexan lactate dehydrogenase with oxamate.
6VDJ	;	2.0	;	Crystal structure of ancestral apicomplexan lactate dehydrogenase with sulfate and NADH4.
6VDI	;	2.1	;	Crystal structure of ancestral apicomplexan lactate dehydrogenase with sulfate.
4PLV	;	1.85	;	Crystal structure of ancestral apicomplexan malate dehydrogenase with lactate.
4PLW	;	1.85	;	Crystal structure of ancestral apicomplexan malate dehydrogenase with lactate.
4PLY	;	1.9	;	Crystal structure of ancestral apicomplexan malate dehydrogenase with malate.
4PLH	;	1.9	;	Crystal structure of ancestral apicomplexan malate dehydrogenase with oxamate.
4PLT	;	1.6	;	Crystal structure of ancestral apicomplexan malate dehydrogenase with oxamate.
3AJY	;	2.01	;	Crystal Structure of Ancestral Congerin Con-anc
3AJZ	;	1.5	;	Crystal Structure of Ancestral Congerin Con-anc
3AK0	;	1.59	;	Crystal Structure of Ancestral Congerin Con-anc'-N28K
6SEM	;	2.8	;	Crystal Structure of Ancestral Flavin-containing monooxygenase (FMO) 2
6SF0	;	3.01	;	Crystal Structure of Ancestral Flavin-containing monooxygenase (FMO) 2 in the presence of NADP+
6SE3	;	2.8	;	Crystal Structure of Ancestral Flavin-containing monooxygenase (FMO) 3-6
6SEK	;	2.7	;	Crystal Structure of Ancestral Flavin-containing monooxygenase (FMO) 5
7PW1	;	1.5	;	Crystal structure of ancestral haloalkane dehalogenase AncLinB-DmbA
7SB6	;	2.588	;	Crystal Structure of Ancestral Mammalian Cadherin-23 EC1-2
5K27	;	2.58	;	Crystal structure of ancestral protein ancMT of ADP-dependent sugar kinases family.
2YPM	;	2.199	;	Crystal Structure of Ancestral Thioredoxin Relative to Last Animal and Fungi Common Ancestor (LAFCA) from the Precambrian Period
2YNX	;	1.749	;	Crystal Structure of Ancestral Thioredoxin Relative to Last Archaea Common Ancestor (LACA) from the Precambrian Period
3ZIV	;	2.65	;	Crystal Structure of Ancestral Thioredoxin Relative to last Archaea- Eukaryotes Common Ancestor (AECA) from the Precambrian Period
4BA7	;	2.45	;	Crystal Structure of Ancestral Thioredoxin Relative to Last Bacteria Common Ancestor (LBCA) from the Precambrian Period
2YOI	;	1.3	;	Crystal Structure of Ancestral Thioredoxin Relative to Last Eukaryotes Common Ancestor (LECA) from the Precambrian Period
2YN1	;	1.3	;	Crystal Structure of Ancestral Thioredoxin Relative to Last Gamma- Proteobacteria Common Ancestor (LGPCA) from the Precambrian Period
4ULX	;	2.35	;	Crystal structure of ancestral thioredoxin, relative to the last common ancestor of the Cyanobacterial, Deinococcus and Thermus groups, LPBCA-L89K mutant.
3QVV	;	2.35	;	Crystal structure of Ancestral variant b9 of SULT 1A1 in complex with PAP and 3-CyC
3QVU	;	2.5	;	Crystal structure of Ancestral variant b9 of SULT 1A1 in complex with PAP and p-nitrophenol
3NSW	;	1.75	;	Crystal Structure of Ancylostoma ceylanicum Excretory-Secretory Protein 2
5E04	;	2.25	;	Crystal structure of Andes virus nucleoprotein
1R4I	;	3.1	;	Crystal Structure of Androgen Receptor DNA-Binding Domain Bound to a Direct Repeat Response Element
4QL8	;	2.1	;	Crystal structure of Androgen Receptor in complex with the ligand
5CFP	;	2.066	;	Crystal structure of anemone STING (Nematostella vectensis) 'humanized' F276K in complex with 3', 3' c-di-GMP, c[G(3', 5')pG(3', 5')p]'
5CFO	;	2.102	;	Crystal structure of anemone STING (Nematostella vectensis) in apo 'rotated' open conformation
5CFR	;	2.85	;	Crystal structure of anemone STING (Nematostella vectensis) in apo 'unrotated' closed conformation
5CFQ	;	2.099	;	Crystal structure of anemone STING (Nematostella vectensis) in complex with 2',3' cGAMP, c[G(2',5')pA(3',5')p]
5CFL	;	1.836	;	Crystal structure of anemone STING (Nematostella vectensis) in complex with 3', 3' c-di-GMP, c[G(3', 5')pG(3', 5')p]
5CFM	;	1.994	;	Crystal structure of anemone STING (Nematostella vectensis) in complex with 3', 3' cGAMP, c[G(3', 5')pA(3', 5')p]
5CFN	;	2.95	;	Crystal structure of anemone STING (Nematostella vectensis) in complex with 3',3' c-di-AMP, c[A(3',5')pA(3',5')p]
6RW0	;	1.45	;	Crystal structure of ANGEL2, a 2',3'-cyclic phosphatase
6RVZ	;	2.1	;	Crystal structure of ANGEL2, a 2',3'-cyclic phosphatase, in complex with adenosine-2',3'-vanadate
7Q27	;	1.5	;	Crystal structure of Angiotensin-1 converting enzyme C-domain in complex with dual ACE/NEP inhibitor AD011
7Q28	;	1.65	;	Crystal structure of Angiotensin-1 converting enzyme C-domain in complex with dual ACE/NEP inhibitor AD012
7Q29	;	1.6	;	Crystal structure of Angiotensin-1 converting enzyme C-domain in complex with dual ACE/NEP inhibitor AD013
7Z70	;	1.85	;	Crystal structure of Angiotensin-1 converting enzyme C-domain in complex with fosinoprilat
6ZPU	;	2.0	;	Crystal structure of Angiotensin-1 converting enzyme C-domain with inserted symmetry molecule C-terminus.
7Q24	;	2.0	;	Crystal structure of Angiotensin-1 converting enzyme N-domain in complex with dual ACE/NEP inhibitor AD011
7Q25	;	1.6	;	Crystal structure of Angiotensin-1 converting enzyme N-domain in complex with dual ACE/NEP inhibitor AD012
7Q26	;	1.7	;	Crystal structure of Angiotensin-1 converting enzyme N-domain in complex with dual ACE/NEP inhibitor AD013
7Z6Z	;	1.75	;	Crystal structure of Angiotensin-1 converting enzyme N-domain in complex with fosinoprilat
5XAQ	;	1.86	;	Crystal structure of Animalia-specific tRNA deacylase from Mus musculus
2ZPQ	;	1.9	;	Crystal structure of anionic trypsin isoform 1 from chum salmon
2ZPR	;	1.75	;	Crystal structure of anionic trypsin isoform 2 from chum salmon
2ZPS	;	1.55	;	Crystal structure of anionic trypsin isoform 3 from chum salmon
4U3M	;	3.0	;	Crystal structure of Anisomycin bound to the yeast 80S ribosome
4RLV	;	3.4945	;	Crystal Structure of AnkB 24 Ankyrin Repeats in Complex with AnkR Autoinhibition Segment
4RLY	;	2.5032	;	Crystal Structure of AnkB Ankyrin Repeats (R1-R9) in Complex with Nav1.2 Ankyrin Binding Domain
5Y4D	;	3.3	;	Crystal Structure of AnkB Ankyrin Repeats in Complex with AnkR/AnkB Chimeric Autoinhibition Segment
5Y4F	;	1.953	;	Crystal Structure of AnkB Ankyrin Repeats R13-24 in complex with autoinhibition segment AI-c
5Y4E	;	2.341	;	Crystal Structure of AnkB Ankyrin Repeats R8-14 in complex with autoinhibition segment AI-b
5YIR	;	2.75	;	Crystal Structure of AnkB LIR/GABARAP complex
5YIS	;	2.201	;	Crystal Structure of AnkB LIR/LC3B complex
6M3Q	;	3.436	;	Crystal structure of AnkB/beta4-spectrin complex
5YIP	;	1.85	;	Crystal Structure of AnkG LIR/GABARAPL1 complex
5YIQ	;	2.6	;	Crystal structure of AnkG LIR/LC3B complex
6M3P	;	3.312	;	Crystal structure of AnkG/beta2-spectrin complex
6M3R	;	4.313	;	Crystal structure of AnkG/beta4-spectrin complex
6A9X	;	2.202	;	Crystal Structure of AnkG/GABARAP Complex
3SO8	;	1.9	;	Crystal Structure of ANKRA
4LG6	;	1.8	;	Crystal structure of ANKRA2-CCDC8 complex
4QQI	;	2.03	;	Crystal structure of ANKRA2-RFX7 complex
6KZJ	;	1.5	;	Crystal structure of Ankyrin B/NdeL1 complex
7XCE	;	2.5	;	Crystal structure of Ankyrin G in complex with neurofascin
3ZKJ	;	2.58	;	Crystal Structure of Ankyrin Repeat and Socs Box-Containing Protein 9 (Asb9) in Complex with Elonginb and Elonginc
4TUM	;	2.3	;	Crystal structure of Ankyrin Repeat Domain of AKR2
4MO4	;	1.67	;	Crystal structure of AnmK bound to AMPPCP
4MO5	;	1.75	;	Crystal structure of AnmK bound to AMPPCP and anhMurNAc
1DK5	;	2.8	;	CRYSTAL STRUCTURE OF ANNEXIN 24(CA32) FROM CAPSICUM ANNUUM
5LPU	;	2.1	;	Crystal structure of Annexin A2 complexed with S100A4
1N41	;	2.1	;	Crystal Structure of Annexin V K27E Mutant
1N42	;	2.1	;	Crystal Structure of Annexin V R149E Mutant
1N44	;	3.0	;	Crystal Structure of Annexin V R23E Mutant
7CPO	;	2.5	;	Crystal Structure of Anolis carolinensis MHC I complex
5YDJ	;	3.04	;	Crystal structure of anopheles gambiae acetylcholinesterase in complex with PMSF
3LOO	;	2.0	;	Crystal structure of Anopheles gambiae adenosine kinase in complex with P1,P4-di(adenosine-5) tetraphosphate
6S1Z	;	2.5	;	Crystal structure of Anopheles gambiae AnoACE2 in complex with fosinoprilat
6S1Y	;	2.2	;	Crystal structure of Anopheles gambiae AnoACE2 in complex with gamma-Polyglutamic Acid.
2QEV	;	1.998	;	Crystal Structure of Anopheles gambiae D7r4
2QEB	;	2.003	;	Crystal Structure of Anopheles Gambiae D7R4-Histamine Complex
2QEO	;	2.315	;	Crystal Structure of Anopheles gambiae D7R4-norepinephrine complex
2QEH	;	2.102	;	Crystal Structure of Anopheles gambiae D7r4-serotonin complex
2PQL	;	2.2	;	Crystal Structure of Anopheles gambiae D7R4-tryptamine complex
3Q8I	;	2.0	;	Crystal structure of Anopheles Gambiae odorant binding protein 4 in complex with indole
2I0O	;	1.7	;	Crystal structure of Anopheles gambiae Ser/Thr phosphatase complexed with Zn2+
4OKV	;	1.802	;	Crystal structure of anopheline anti-platelet protein with Fab antibody
3VB1	;	2.0	;	Crystal Structure of Anopholes gambiae odorant binding protein 20 in open state
5A2A	;	1.9	;	Crystal Structure of Anoxybacillus Alpha-amylase Provides Insights into a New Glycosyl Hydrolase Subclass
5A2B	;	1.85	;	Crystal Structure of Anoxybacillus Alpha-amylase Provides Insights into a New Glycosyl Hydrolase Subclass
5A2C	;	1.9	;	Crystal Structure of Anoxybacillus Alpha-amylase Provides Insights into a New Glycosyl Hydrolase Subclass
3NGV	;	1.76	;	Crystal structure of AnSt-D7L1
4XJE	;	1.88	;	CRYSTAL STRUCTURE OF ANT(2"") IN COMPLEX WITH AMP AND TOBRAMYCIN
5CFU	;	1.82	;	Crystal Structure of ANT(2"")-Ia in complex with adenylyl-2""-tobramycin
5CFT	;	1.5	;	Crystal Structure of ANT(2"")-Ia in complex with AMPCPP and gentamicin C1
5CFS	;	1.7	;	Crystal Structure of ANT(2"")-Ia in complex with AMPCPP and tobramycin
2QXS	;	1.7	;	Crystal Structure of Antagonizing Mutant 536S of the Estrogen Receptor Alpha Ligand Binding Domain Complexed to Raloxifene
8SPK	;	1.6	;	Crystal structure of Antarctic PET-degrading enzyme
3VBJ	;	1.8	;	Crystal Structure of AntD, an N-acyltransferase from Bacillus cereus in complex with dTDP and 3-hydroxybutyryl-CoA
3VBI	;	1.8	;	Crystal Structure of AntD, an N-acyltransferase from Bacillus cereus in complex with dTDP-4-amino-4,6-dideoxyglucose and Coenzyme A
5A9C	;	1.71	;	Crystal structure of Antheraea mylitta CPV4 polyhedra base domain deleted mutant
5A8S	;	1.724	;	Crystal structure of Antheraea mylitta CPV4 polyhedra type 1
5A8T	;	2.003	;	Crystal structure of Antheraea mylitta CPV4 polyhedra type 2
3GWJ	;	2.43	;	Crystal structure of Antheraea pernyi arylphorin
8AGQ	;	1.093	;	Crystal structure of anthocyanin-related GSTF8 from Populus trichocarpa in complex with (-)-catechin and glutathione
3O51	;	3.2	;	Crystal structure of anthranilamide 10 bound to AuroraA
1V8G	;	2.1	;	Crystal structure of anthranilate phosphoribosyltransferase (TrpD) from Thermus thermophilus HB8
1VQU	;	1.85	;	Crystal structure of Anthranilate phosphoribosyltransferase 2 (17130499) from Nostoc sp. at 1.85 A resolution
5KCK	;	2.2	;	Crystal structure of anthranilate synthase component I from Streptococcus pneumoniae TIGR4
1XFY	;	3.3	;	Crystal structure of anthrax edema factor (EF) in complex with calmodulin
1XFV	;	3.35	;	Crystal structure of anthrax edema factor (EF) in complex with calmodulin and 3' deoxy-ATP
1XFW	;	3.4	;	Crystal structure of anthrax edema factor (EF) in complex with calmodulin and 3'5' cyclic AMP (cAMP)
1Y0V	;	3.6	;	Crystal structure of anthrax edema factor (EF) in complex with calmodulin and pyrophosphate
1XFZ	;	3.25	;	Crystal structure of anthrax edema factor (EF) in complex with calmodulin in the presence of 1 millimolar exogenously added calcium chloride
1XFX	;	3.2	;	Crystal structure of anthrax edema factor (EF) in complex with calmodulin in the presence of 10 millimolar exogenously added calcium chloride
1XFU	;	3.35	;	Crystal structure of anthrax edema factor (EF) truncation mutant, EF-delta 64 in complex with calmodulin
1PWW	;	2.8	;	Crystal structure of Anthrax Lethal Factor active site mutant protein complexed with an optimised peptide substrate in the presence of zinc.
1PWU	;	2.7	;	Crystal Structure of Anthrax Lethal Factor complexed with (3-(N-hydroxycarboxamido)-2-isobutylpropanoyl-Trp-methylamide), a known small molecule inhibitor of matrix metalloproteases.
1PWQ	;	3.52	;	Crystal structure of Anthrax Lethal Factor complexed with Thioacetyl-Tyr-Pro-Met-Amide, a metal-chelating peptidyl small molecule inhibitor
1PWV	;	2.85	;	Crystal structure of Anthrax Lethal Factor wild-type protein complexed with an optimised peptide substrate.
3TEY	;	2.12	;	Crystal Structure of Anthrax Protective Antigen (Membrane Insertion Loop Deleted) Mutant S337C N664C to 2.06-A resolution
3TEW	;	1.45	;	Crystal Structure of Anthrax Protective Antigen (Membrane Insertion Loop Deleted) to 1.45-A resolution
3TEX	;	1.7	;	Crystal Structure of Anthrax Protective Antigen (Membrane Insertion Loop Deleted) to 1.7-A resolution
4EE2	;	1.91	;	Crystal Structure of Anthrax Protective Antigen K446M Mutant to 1.91-A Resolution
3TEZ	;	1.83	;	Crystal Structure of Anthrax Protective Antigen Mutant S337C N664C and dithiolacetone modified to 1.8-A resolution
3ESU	;	1.3	;	Crystal structure of anthrax-neutralizing single-chain antibody 14b7
7YB1	;	3.3	;	Crystal Structure of anthrol reductase (CbAR) in complex with NADP+
7YB2	;	1.85	;	Crystal Structure of anthrol reductase (CbAR) in complex with NADP+ and emodin
3CQF	;	3.1	;	Crystal structure of anthrolysin O (ALO)
7F2S	;	2.62	;	Crystal structure of anti S-gatifloxacin antibody Fab fragment apo form
7F35	;	2.6	;	Crystal structure of anti S-gatifloxacin antibody Fab fragment in complex with S-gatifloxacin
6NB5	;	3.0	;	Crystal structure of anti- MERS-CoV human neutralizing LCA60 antibody Fab fragment
6NB8	;	1.5	;	Crystal structure of anti- SARS-CoV human neutralizing S230 antibody Fab fragment
4PTT	;	1.8	;	Crystal Structure of anti-23F strep Fab C05
4PTU	;	1.511	;	Crystal Structure of anti-23F strep Fab C05 with rhamnose
8GKV	;	2.351	;	Crystal structure of anti-adaptor IraP that regulates RpoS proteolysis
5OPY	;	2.26	;	Crystal structure of anti-alphaVbeta3 integrin Fab LM609
3BKC	;	1.9	;	Crystal structure of anti-amyloid beta FAB WO2 (P21, FormB)
5UXW	;	2.3	;	Crystal Structure of Anti-anti-sigma factor PhyR from Bartonella quintana
5UXV	;	2.6	;	Crystal Structure of Anti-anti-sigma factor PhyR I40V/S51C mutant from Bartonella quintana
2WH6	;	1.5	;	Crystal structure of anti-apoptotic BHRF1 in complex with the Bim BH3 domain
7D9Z	;	1.123	;	Crystal structure of anti-basigin Fab fragment
3MCK	;	2.3	;	Crystal structure of anti-beta-amyloid antibody C705
5WK2	;	1.5	;	CRYSTAL STRUCTURE OF ANTI-CCL17 ANTIBODY M116
6AL4	;	2.45	;	CRYSTAL STRUCTURE OF ANTI-CD19 ANTIBODY B43 FAB
2DM6	;	2.0	;	Crystal structure of anti-configuration of indomethacin and leukotriene B4 12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase complex
8CBX	;	2.0	;	Crystal Structure of Anti-Cortisol Fab fragment
8CBZ	;	1.86	;	Crystal Structure of Anti-cortisol Fab in Complex with Corticosterone
8CBY	;	2.27	;	Crystal Structure of Anti-cortisol Fab in Complex with Cortisol
8CC0	;	1.85	;	Crystal Structure of Anti-cortisol Fab in Complex with Cortisone
8CC1	;	2.0	;	Crystal Structure of Anti-cortisol Fab in Complex with Prednisolone
8HEK	;	1.23	;	Crystal Structure of Anti-CRISPR AcrIE2
6ANV	;	2.265	;	Crystal structure of anti-CRISPR protein AcrF1
6ANW	;	2.486	;	Crystal structure of anti-CRISPR protein AcrF10
5GNF	;	1.5	;	Crystal structure of anti-CRISPR protein AcrF3
7BB5	;	2.3	;	Crystal structure of anti-CRISPR protein AcrIF9
8JFO	;	2.3	;	Crystal structure of anti-CRISPR protein AcrIIA15
7VLM	;	1.38	;	crystal structure of anti-CRISPR protein AcrIIA18
6JD7	;	2.45	;	Crystal structure of anti-CRISPR protein AcrIIC2 dimer
8HNT	;	3.06	;	Crystal structure of anti-CRISPR protein AcrIIC4 bound to HpaCas9-sgRNA surveillance complex
6IUF	;	2.052	;	Crystal structure of Anti-CRISPR protein AcrVA5
7XMW	;	2.59	;	Crystal structure of anti-CRISPR protein AcrVIA2
7VJN	;	1.799	;	Crystal structure of anti-CRISPR-associated protein Aca1 in Pseudomonas phage JBD30
8HIT	;	3.2	;	Crystal structure of anti-CTLA-4 humanized IgG1 MAb--JS007 in complex with human CTLA-4
7DV4	;	2.38	;	Crystal structure of anti-CTLA-4 VH domain in complex with human CTLA-4
4KUZ	;	2.7	;	Crystal structure of anti-emmprin antibody 4A5 Fab in trigonal form
3NZH	;	2.0	;	Crystal structure of anti-emmprin antibody 5F6 FAB
7D85	;	2.5	;	Crystal structure of anti-ErbB3 Fab ISU104 in complex with human ErbB3 extracellular domain 3
7U64	;	1.75	;	Crystal Structure of Anti-Fentanyl Antibody HY6-F9.6 Fab Complexed with Fentanyl
8GUZ	;	1.79	;	Crystal structure of anti-FIXa IgG fab with FAST-Ig mutations
8GV0	;	3.192	;	Crystal structure of anti-FIXa IgG fab without FAST-Ig mutations
8RMO	;	1.163	;	Crystal structure of anti-FLAG M2 Fab fragment bound to FLAG-tag peptide epitope
4UV4	;	3.08	;	Crystal structure of anti-FPR Fpro0165 Fab fragment
8GV1	;	1.186	;	Crystal structure of anti-FX IgG fab with FAST-Ig mutations
8GV2	;	1.274	;	Crystal structure of anti-FX IgG fab without FAST-Ig mutations
6OBD	;	2.2	;	Crystal structure of anti-GLD52 Fab complex with human GLD52 peptide mimetic
5IHZ	;	1.64	;	Crystal structure of anti-gliadin 1002-1E01 Fab fragment
5IFJ	;	2.35	;	Crystal structure of anti-gliadin 1002-1E01 Fab fragment in complex of peptide PLQPEQPFP
5IG7	;	1.97	;	Crystal structure of anti-gliadin 1002-1E01 Fab fragment in complex of peptide PLQPQQPFP
5IK3	;	1.65	;	Crystal structure of anti-gliadin 1002-1E03 Fab fragment
5IJK	;	2.5	;	Crystal structure of anti-gliadin 1002-1E03 Fab fragment in complex of peptide PLQPEQPFP
5JOP	;	1.75	;	Crystal structure of anti-glycan antibody Fab14.22 in complex with Streptococcus pneumoniae serotype 14 tetrasaccharide at 1.75 A
3OZ9	;	1.6	;	Crystal Structure of anti-gp41 Fab NC-1
5ESA	;	2.6	;	Crystal structure of anti-HCV E2 antibody HC84-26
1NLB	;	1.6	;	crystal structure of anti-HCV monoclonal antibody 19D9D6
8JYR	;	1.69	;	Crystal structure of anti-HER2 antibody H2Mab-119 in complex with HER2 domain I
4LEO	;	2.64	;	Crystal structure of anti-HER3 Fab RG7116 in complex with the extracellular domains of human Her3 (ERBB3)
7U62	;	1.82	;	Crystal structure of Anti-Heroin Antibody HY4-1F9 Fab Complexed with Morphine
4MA3	;	2.0	;	Crystal structure of anti-hinge rabbit antibody C2095
4END	;	1.9	;	Crystal structure of anti-HIV actinohivin in complex with alpha-1,2-mannobiose (P 2 21 21 form)
4G1R	;	1.57	;	Crystal structure of anti-HIV actinohivin in complex with alphs-1,2-mannobiose (Form II)
6B3D	;	2.271	;	Crystal structure of anti-HIV antibody PGT128 in complex with a bacterially derived synthetic mimetic of Man9.
3R0M	;	1.5	;	Crystal structure of anti-HIV llama VHH antibody A12
3RJQ	;	2.601	;	Crystal structure of anti-HIV llama VHH antibody A12 in complex with C186 gp120
7RI2	;	2.8	;	Crystal structure of anti-HIV llama VHH antibody A12 in complex with HIV-1 C1086 gp120
7RI1	;	2.55	;	Crystal structure of anti-HIV llama VHH antibody J3 in complex with HIV-1 C1086 gp120
6VBO	;	1.683	;	Crystal structure of anti-HIV-1 antibody DH813 bound to gp120 V2 peptide
6VBP	;	2.298	;	Crystal structure of anti-HIV-1 antibody DH815 bound to gp120 V2 peptide
6VBQ	;	2.116	;	Crystal structure of anti-HIV-1 antibody DH822 bound to gp120 V2 peptide
5DRZ	;	2.54	;	Crystal structure of anti-HIV-1 antibody F240 Fab in complex with gp41 peptide
3GO1	;	1.89	;	Crystal structure of anti-HIV-1 Fab 268-D in complex with V3 peptide MN
4M1D	;	1.8	;	Crystal structure of anti-HIV-1 Fab 447-52D in complex with V3 cyclic peptide MN
3GHB	;	2.25	;	Crystal structure of anti-HIV-1 Fab 447-52D in complex with V3 peptide W2RW020
3GHE	;	2.4	;	Crystal structure of anti-HIV-1 Fab 537-10D in complex with V3 peptide MN
3MLW	;	2.7	;	Crystal structure of anti-HIV-1 V3 Fab 1006-15D in complex with an MN V3 peptide
6DB7	;	2.213	;	Crystal structure of anti-HIV-1 V3 Fab 1334 in complex with a HIV-1 gp120 V3 peptide from MN strain
3MLR	;	1.8	;	Crystal structure of anti-HIV-1 V3 Fab 2557 in complex with a NY5 V3 peptide
3MLT	;	2.49	;	Crystal structure of anti-HIV-1 V3 Fab 2557 in complex with a UG1033 V3 peptide
3MLU	;	2.77	;	Crystal structure of anti-HIV-1 V3 Fab 2557 in complex with a ZAM18 V3 peptide
3MLV	;	2.48	;	Crystal structure of anti-HIV-1 V3 Fab 2557 in complex with an NOF V3 peptide
3UJI	;	1.6	;	Crystal structure of anti-HIV-1 V3 Fab 2558 in complex with MN peptide
3MLY	;	1.7	;	Crystal structure of anti-HIV-1 V3 Fab 3074 in complex with a UR29 V3 peptide
3MLZ	;	2.99	;	Crystal structure of anti-HIV-1 V3 Fab 3074 in complex with a VI191 V3 peptide
3MLX	;	1.9	;	Crystal structure of anti-HIV-1 V3 Fab 3074 in complex with an MN V3 peptide
6DB6	;	1.978	;	Crystal structure of anti-HIV-1 V3 Fab 311-11D in complex with a HIV-1 gp120 V3 peptide from MN strain
3UJJ	;	2.0	;	Crystal structure of anti-HIV-1 V3 Fab 4025 in complex with Con A peptide
6DB5	;	2.599	;	Crystal structure of anti-HIV-1 V3 Fab TA6 in complex with a HIV-1 gp120 V3 peptide from NY5 strain
3MLS	;	2.5	;	Crystal structure of anti-HIV-1 V3 mAb 2557 Fab in complex with a HIV-1 gp120 V3 mimotope
8W9H	;	2.0	;	Crystal structure of anti-human CLEC12A antibody 50C1
3EYO	;	2.5	;	Crystal structure of anti-human cytomegalovirus antibody 8F9
3EYF	;	2.3	;	Crystal structure of anti-human cytomegalovirus antibody 8f9 plus gB peptide
3L7E	;	2.5	;	Crystal structure of ANTI-IL-13 antibody C836
3G6A	;	2.1	;	Crystal structure of anti-IL-13 antibody CNTO607
5KNG	;	1.35	;	CRYSTAL STRUCTURE OF ANTI-IL-13 DARPIN 6G9
2XQB	;	2.6	;	Crystal Structure of anti-IL-15 Antibody in Complex with human IL-15
4KQ3	;	1.92	;	Crystal structure of Anti-IL-17A antibody CNTO3186
4KQ4	;	2.45	;	Crystal structure of Anti-IL-17A antibody CNTO7357
4M6N	;	2.0	;	Crystal structure of anti-IL-23 antibody CNTO1959 at pH 6.5
4M6M	;	2.0	;	Crystal structure of anti-IL-23 antibody CNTO1959 at pH 9.5
3I2C	;	2.8	;	Crystal structure of anti-IL-23 antibody CNTO4088
6P4Y	;	1.799	;	Crystal Structure of anti-IL-7Ralpha 4A10 Fab
4YDW	;	1.9	;	CRYSTAL STRUCTURE OF ANTI-IL4 DARPIN 44C12V5
6CK8	;	2.05	;	Crystal structure of anti-influenza single-domain llama antibody SD38
4GXV	;	1.449	;	Crystal structure of anti-influenza virus antibody 1F1
1DQM	;	2.1	;	CRYSTAL STRUCTURE OF ANTI-LYSOZYME ANTIBODY
1DQQ	;	1.8	;	CRYSTAL STRUCTURE OF ANTI-LYSOZYME ANTIBODY HYHEL-63
4DN3	;	2.6	;	Crystal structure of anti-mcp-1 antibody cnto888
6WVZ	;	3.1	;	Crystal structure of anti-MET Fab arm of amivantamab in complex with human MET
1XGY	;	2.71	;	Crystal Structure of Anti-Meta I Rhodopsin Fab Fragment K42-41L
3R06	;	2.5	;	Crystal structure of anti-mouse CD3epsilon antibody 2C11 Fab fragment
7X3N	;	2.24	;	Crystal structure of anti-mPEG h15-2b Fab
7Y0G	;	2.08	;	Crystal structure of anti-mPEG h15-2b Fab
7YIZ	;	2.42	;	Crystal structure of anti-mPEG h15-2b Fab W104Y mutant
5TBD	;	2.2	;	Crystal Structure of anti-MSP2 Fv fragment (mAb4D11) in complex with 3D7-MSP2 215-222
4QY8	;	1.353	;	Crystal Structure of anti-MSP2 Fv fragment (mAb6D8) in complex with 3D7-MSP2 14-30
4QXT	;	1.58	;	Crystal Structure of anti-MSP2 Fv fragment (mAb6D8)in complex with FC27-MSP2 14-30
4R3S	;	1.7	;	Crystal Structure of anti-MSP2 Fv fragment (mAb6D8)in complex with MSP2 11-23
4QYO	;	1.208	;	Crystal Structure of anti-MSP2 Fv fragment (mAb6D8)in complex with MSP2 14-22
6FP9	;	2.1	;	Crystal structure of anti-mTFP1 DARPin 1238_E11
6FPB	;	1.617	;	Crystal structure of anti-mTFP1 DARPin 1238_G01 in space group I4
6FPA	;	1.58	;	Crystal structure of anti-mTFP1 DARPin 1238_G01 in space group P212121
7V3Q	;	2.98	;	Crystal structure of anti-MUC1 antibody 16A
6WYR	;	1.8	;	Crystal structure of anti-Muscle Specific Kinase (MuSK) Fab, MuSK1A
6WYT	;	1.75	;	Crystal structure of anti-Muscle Specific Kinase (MuSK) Fab, MuSK1B
1ZAN	;	1.7	;	Crystal structure of anti-NGF AD11 Fab
4M6O	;	2.8	;	Crystal structure of anti-NGF antibody CNTO7309
7U61	;	2.1	;	Crystal Structure of Anti-Nicotine Antibody NIC311 Fab Complexed with Nicotine
6U1T	;	1.483	;	Crystal structure of anti-Nipah virus (NiV) F 5B3 antibody Fab fragment
3CXD	;	2.8	;	Crystal structure of anti-osteopontin antibody 23C3 in complex with its epitope peptide
3DSF	;	2.8	;	Crystal structure of anti-osteopontin antibody 23C3 in complex with W43A mutated epitope peptide
8IQS	;	2.16	;	Crystal structure of Anti-PEG antibody M11 Fv-clasp fragment with PEG (co-crystallization with PEG3350)
8IQQ	;	2.02	;	Crystal structure of Anti-PEG antibody M9 Fv-clasp fragment with PEG (co-crystallization with PEG2000MME)
8IQP	;	1.76	;	Crystal structure of Anti-PEG antibody M9 Fv-clasp fragment with PEG (co-crystallization with PEG3350)
8IQR	;	2.35	;	Crystal structure of Anti-PEG antibody M9 Fv-clasp fragment with PEG (co-crystallization with PEG550DME)
3WBD	;	1.8	;	Crystal structure of anti-polysialic acid antibody single chain Fv fragment (mAb735) complexed with octasialic acid
3WE6	;	2.02	;	Crystal structure of anti-Prostaglandin E2 Fab fragment
3WIF	;	1.7	;	Crystal structure of anti-prostaglandin E2 Fab fragment 9Cl-PGF2beta complex
3WHX	;	1.7	;	Crystal structure of anti-prostaglandin E2 Fab fragment PGE1 complex
3WFH	;	1.9	;	Crystal structure of anti-Prostaglandin E2 Fab fragment PGE2 complex
8JBJ	;	1.61	;	Crystal structure of anti-PVRIG Fab
4M43	;	1.85	;	Crystal structure of anti-rabies glycoprotein Fab 523-11
2G75	;	2.28	;	Crystal Structure of anti-SARS m396 Antibody
7ZOR	;	3.933	;	Crystal structure of anti-Siglec-15 Fab
4MAU	;	1.9	;	Crystal structure of anti-ST2L antibody C2244
5MHE	;	1.9	;	Crystal structure of anti-T4 Fab fragment with T4
5MHG	;	2.801	;	Crystal structure of anti-T4 Fab fragment with tetraiodoBPA
7TUH	;	2.3	;	Crystal structure of anti-tapasin PaSta2-Fab
3O6K	;	2.0	;	Crystal structure of anti-Tat HIV Fab'11H6H1
5E2T	;	2.1	;	Crystal structure of anti-TAU antibody AT8 FAB
6GK7	;	2.95	;	Crystal structure of anti-tau antibody dmCBTAU-27.1, double mutant (S31Y, T100I) of CBTAU-27.1, in complex with Tau peptide A8119B (residues 299-318)
6GK8	;	2.85	;	Crystal structure of anti-tau antibody dmCBTAU-28.1, double mutant (S32R, E35K) of CBTAU-28.1, in complex with Tau peptide A7731 (residues 52-71)
6XLI	;	2.0	;	CRYSTAL STRUCTURE OF ANTI-TAU ANTIBODY PT3 Fab+pT212/pT217-TAU PEPTIDE
3LS4	;	2.0	;	Crystal Structure of Anti-tetrahydrocannabinol Fab Fragment in Complex with THC
4M7K	;	1.9	;	Crystal structure of anti-tissue factor antibody 10H10
3QPQ	;	1.9	;	Crystal structure of ANTI-TLR3 antibody C1068 FAB
4QTH	;	2.17	;	Crystal structure of anti-uPAR Fab 8B12
5VIC	;	3.0	;	Crystal structure of anti-Zika antibody Z004 bound to DENV-1 Envelope protein DIII
5VIG	;	3.0	;	Crystal structure of anti-Zika antibody Z006 bound to Zika virus envelope protein DIII
6DFJ	;	2.07	;	Crystal structure of anti-Zika antibody Z021 bound to DENV-1 envelope protein DIII
6DFI	;	2.48	;	Crystal structure of anti-Zika antibody Z021 bound to Zika virus envelope protein DIII
4HL9	;	1.93	;	Crystal structure of antibiotic biosynthesis monooxygenase
4V9R	;	3.0	;	Crystal structure of antibiotic DITYROMYCIN bound to 70S ribosome
4V9S	;	3.1	;	Crystal structure of antibiotic GE82832 bound to 70S ribosome
3LCU	;	2.1	;	Crystal Structure of Antibiotic related Methyltransferase
3LCV	;	2.0	;	Crystal Structure of Antibiotic related Methyltransferase
4RX1	;	2.472	;	Crystal Structure of antibiotic-resistance methyltransferase Kmr
7WN8	;	2.8	;	Crystal structure of antibody (BC31M5) binds to CD47
7MFB	;	1.74	;	Crystal structure of antibody 10E8v4 Fab - light chain H31F variant
7MF9	;	3.7	;	Crystal structure of antibody 10E8v4-P100fA Fab in space group C2
7MF8	;	2.2	;	Crystal structure of antibody 10E8v4-P100fA Fab in space group P6422
7MFA	;	2.4	;	Crystal structure of antibody 10E8v4-P100fA+P100gA Fab
7MF7	;	2.0	;	Crystal structure of antibody 10E8v4-P100gA Fab
7VAZ	;	2.73	;	Crystal structure of antibody 14A in complex with MUC1 glycopeptide(GlycoS)
7VAC	;	3.5	;	Crystal structure of antibody 14A in complex with MUC1 glycopeptide(GlycoST)
7V8Q	;	3.2	;	Crystal structure of antibody 14A in complex with MUC1 Glycopeptide(GlycoT)
7V7K	;	2.2	;	Crystal structure of Antibody 16A in complex with MUC1 Glycopeptide(GlycoST)
7V64	;	1.56	;	Crystal structure of Antibody 16A in complex with MUC1 Glycopeptide(GlycoT)
7V4W	;	2.1	;	Crystal structure of Antibody 16A in complex with MUC1 peptide
1UB5	;	2.0	;	Crystal structure of Antibody 19G2 with hapten at 100K
1UB6	;	2.12	;	Crystal structure of Antibody 19G2 with sera ligand
4GXU	;	3.294	;	Crystal structure of antibody 1F1 bound to the 1918 influenza hemagglutinin
5YSL	;	2.5	;	Crystal structure of antibody 1H1 Fab
5WKO	;	3.492	;	Crystal structure of antibody 27F3 recognizing the HA from A/California/04/2009 (H1N1) influenza virus
6V6W	;	6.5	;	Crystal structure of antibody 438-B11 DSS mutant (Cys98A-100aA) in complex with an uncleaved prefusion optimized (UFO) soluble BG505 trimer and Fab 35O22
6UUM	;	2.1	;	Crystal structure of antibody 438-B11 DSS mutant (Cys98A-Cys100aA)
6UUD	;	1.85	;	Crystal structure of antibody 5D5 in complex with PfCSP N-terminal peptide
4J1U	;	2.58	;	Crystal structure of antibody 93F3 unstable variant
7U8E	;	2.29	;	Crystal structure of antibody Ab246 in complex with SARS-CoV-2 receptor binding domain
6EV1	;	3.043	;	Crystal structure of antibody against schizophyllan
6EV2	;	2.403	;	Crystal structure of antibody against schizophyllan in complex with laminarihexaose
7PS3	;	1.7	;	Crystal structure of antibody Beta-32 Fab
5N88	;	1.7	;	Crystal structure of antibody bound to viral protein
1K6Q	;	2.4	;	Crystal structure of antibody Fab fragment D3
7XY8	;	2.3	;	Crystal structure of antibody Fab fragment in complex with CD147(EMMPIRIN)
8BJZ	;	1.89	;	crystal structure of antibody Fab with SiaLac-amidine-Lys
8BSO	;	1.92	;	crystal structure of antibody Fab with SiaLac-amidine-Lys
6P8N	;	3.202	;	Crystal Structure of Antibody P-p1f1 in Complex with eOD-GT8
6P8M	;	3.594	;	Crystal Structure of Antibody P-p3b3 A60C Heavy Chain in Complex with 426c HIV-1 gp120 core G459C
1KCV	;	1.8	;	Crystal structure of antibody pc282
1KCS	;	2.5	;	CRYSTAL STRUCTURE OF ANTIBODY PC282 IN COMPLEX WITH PS1 PEPTIDE
1KCR	;	2.9	;	CRYSTAL STRUCTURE OF ANTIBODY PC283 IN COMPLEX WITH PS1 PEPTIDE
1KCU	;	2.2	;	CRYSTAL STRUCTURE OF ANTIBODY PC287
1KC5	;	2.5	;	CRYSTAL STRUCTURE OF ANTIBODY PC287 IN COMPLEX WITH PS1 PEPTIDE
8H3B	;	2.75	;	Crystal structure of antibody scFv against M2e Influenza peptide
8H73	;	1.91	;	Crystal structure of antibody scFv against M2e Influenza peptide
4JB9	;	2.6	;	Crystal structure of antibody VRC06 in complex with HIV-1 gp120 core
4OLU	;	2.202	;	Crystal structure of antibody VRC07 in complex with clade A/E 93TH057 HIV-1 gp120 core
4OLV	;	2.5	;	Crystal structure of antibody VRC07-G54F in complex with clade A/E 93TH057 HIV-1 gp120 core
4OLW	;	2.709	;	Crystal structure of antibody VRC07-G54H in complex with clade A/E 93TH057 HIV-1 gp120 core
4OLX	;	2.2	;	Crystal structure of antibody VRC07-G54L in complex with clade A/E 93TH057 HIV-1 gp120 core
4OLY	;	2.351	;	Crystal structure of antibody VRC07-G54R in complex with clade A/E 93TH057 HIV-1 gp120 core
4OLZ	;	2.1	;	Crystal structure of antibody VRC07-G54W in complex with clade A/E 93TH057 HIV-1 gp120 core
4OM0	;	2.289	;	Crystal structure of antibody VRC07-G54Y in complex with clade A/E 93TH057 HIV-1 gp120 core
4OM1	;	2.131	;	Crystal structure of antibody VRC07-I30Q, G54W, S58N in complex with clade A/E 93TH057 HIV-1 gp120 core
8SMI	;	3.5	;	Crystal structure of antibody WRAIR-2123 in complex with SARS-CoV-2 receptor binding domain
8F2J	;	3.16	;	Crystal structure of antibody WRAIR-2134 in complex with SARS-CoV-2 receptor binding domain
8SMT	;	3.16	;	Crystal structure of antibody WRAIR-2134 in complex with SARS-CoV-2 receptor binding domain
4GH7	;	2.6	;	Crystal structure of Anticalin N7A in complex with oncofetal fibronectin fragment Fn7B8
3WP9	;	1.6	;	Crystal structure of antifreeze protein from an Antarctic sea ice bacterium Colwellia sp.
1EZG	;	1.4	;	CRYSTAL STRUCTURE OF ANTIFREEZE PROTEIN FROM THE BEETLE, TENEBRIO MOLITOR
7KOH	;	2.98	;	Crystal structure of antigen 43 from Escherichia coli EDL933
7KO9	;	2.43	;	Crystal structure of antigen 43 from uropathogenic Escherichia coli UTI89
7KOB	;	2.08	;	Crystal structure of antigen 43b from Escherichia coli CFT073
3HRH	;	2.3	;	Crystal Structure of Antigen 85C and Glycerol
4QDU	;	1.4	;	Crystal structure of Antigen 85C co-crystallized with ebselen
4QDT	;	1.498	;	Crystal structure of Antigen 85C co-crystallized with iodoacetamide
1DQZ	;	1.5	;	CRYSTAL STRUCTURE OF ANTIGEN 85C FROM MYCOBACTERIUM TUBERCULOSIS
1DQY	;	1.83	;	CRYSTAL STRUCTURE OF ANTIGEN 85C FROM MYCOBACTERIUM TUBERCULOSIS WITH DIETHYL PHOSPHATE INHIBITOR
4MQM	;	1.346	;	Crystal structure of Antigen 85C in presence of Ebselen
4QDX	;	1.503	;	Crystal structure of Antigen 85C-C209G mutant
4MQL	;	1.3	;	Crystal structure of Antigen 85C-C209S mutant
4QDZ	;	1.885	;	Crystal structure of Antigen 85C-E228Q mutant
4QE3	;	1.351	;	Crystal structure of Antigen 85C-H260Q mutant
4QEK	;	1.299	;	Crystal structure of Antigen 85C-S124A mutant
2FJC	;	2.5	;	Crystal structure of antigen TpF1 from Treponema pallidum
5J5E	;	2.8	;	crystal structure of antigen-ERAP1 domain complex
5HAU	;	3.0	;	Crystal structure of antimicrobial peptide Bac7(1-19) bound to the Thermus thermophilus 70S ribosome
5HCP	;	2.894	;	Crystal structure of antimicrobial peptide Metalnikowin bound to the Thermus thermophilus 70S ribosome
5HCR	;	2.8	;	Crystal structure of antimicrobial peptide Oncocin 10wt bound to the Thermus thermophilus 70S ribosome
5HCQ	;	2.801	;	Crystal structure of antimicrobial peptide Oncocin d15-19 bound to the Thermus thermophilus 70S ribosome
5HD1	;	2.7	;	Crystal structure of antimicrobial peptide Pyrrhocoricin bound to the Thermus thermophilus 70S ribosome
6I89	;	2.0	;	Crystal structure of Antirestriction ArdC protein from R388 plasmid. Metal-free structure.
6SNA	;	2.7	;	Crystal structure of Antirestriction ArdC protein from R388 plasmid. Mn(II)-bound structure.
3QRG	;	1.699	;	Crystal structure of antiRSVF Fab B21m
3OIZ	;	1.65	;	Crystal structure of antisigma-factor antagonist, STAS domain from Rhodobacter sphaeroides
3R2C	;	1.902	;	Crystal Structure of Antitermination Factors NusB and NusE in complex with BoxA RNA
3R2D	;	2.199	;	Crystal Structure of Antitermination Factors NusB and NusE in complex with dsRNA
4MO1	;	2.099	;	Crystal structure of antitermination protein Q from bacteriophage lambda. Northeast Structural Genomics Consortium target OR18A.
1NQ9	;	2.6	;	Crystal Structure of Antithrombin in the Pentasaccharide-Bound Intermediate State
2BEH	;	2.7	;	Crystal structure of antithrombin variant S137A/V317C/T401C with plasma latent antithrombin
2B4X	;	2.8	;	Crystal Structure of Antithrombin-III
8U12	;	1.6	;	Crystal Structure of Antitoxin Protein Rv0298 of Type II Toxin-antitoxin Systems from Mycobacterium tuberculosis
3BTN	;	2.05	;	Crystal structure of antizyme inhibitor, an ornithine decarboxylase homologous protein
6QLG	;	2.15	;	Crystal structure of AnUbiX (PadA1) in complex with FMN and dimethylallyl pyrophosphate
5Y96	;	1.8	;	Crystal structure of ANXUR1 extracellular domain from Arabidopsis thaliana
5Y92	;	2.004	;	Crystal structure of ANXUR2 extracellular domain from Arabidopsis thaliana
8ASA	;	2.2	;	Crystal structure of AO75L
7C37	;	1.451	;	Crystal structure of AofleA from Arthrobotrys oligospora
7C3D	;	1.596	;	Crystal structure of AofleA from Arthrobotrys oligospora in complex with D-arabinose
7C3C	;	1.301	;	Crystal structure of AofleA from Arthrobotrys oligospora in complex with D-manose
7C38	;	1.2	;	Crystal structure of AofleA from Arthrobotrys oligospora in complex with L-fucose
7C39	;	1.85	;	Crystal structure of AofleA from Arthrobotrys oligospora in complex with methylated L-fucose
5EO7	;	2.3	;	Crystal structure of AOL
5H47	;	2.3	;	Crystal structure of AOL complexed with 2-MeSe-Fuc
5EO8	;	1.6	;	Crystal structure of AOL(868)
8HMM	;	2.7	;	Crystal structure of AoRhaA
6LA0	;	1.75	;	Crystal structure of AoRut
6LPM	;	1.5	;	Crystal structure of AP endonuclease from Deinococcus radioduran
2J63	;	2.48	;	Crystal structure of AP endonuclease LMAP from Leishmania major
3NGF	;	1.8	;	Crystal structure of AP endonuclease, family 2 from Brucella melitensis
4NEE	;	2.8841	;	crystal structure of AP-2 alpha/simga2 complex bound to HIV-1 Nef
2HNX	;	1.5	;	Crystal Structure of aP2
8GMD	;	2.2	;	CRYSTAL STRUCTURE OF AP2 ASSOCIATED KINASE 1 COMPLEXED WITH (5P)-3-({(8R)-5-[(4-aminopiperidin-1-yl)methyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-5-[2-(propan-2-yl)-2H-tetrazol-5-yl]phenol
8GMC	;	2.5	;	CRYSTAL STRUCTURE OF AP2 ASSOCIATED KINASE 1 COMPLEXED WITH 5-[(4-aminopiperidin-1-yl)methyl]-N-{3-[5-(propan-2-yl)-1,3,4-thiadiazol-2-yl]phenyl}pyrrolo[2,1-f][1,2,4]triazin-4-amine
7RJ6	;	2.132	;	CRYSTAL STRUCTURE OF AP2 ASSOCIATED KINASE 1 ISOFORM 1 COMPLEXED WITH LIGAND (2R)-2-AMINO-N-[3-(DIFLUOROM ETHOXY)-4-(1,3-OXAZOL-5-YL)PHENYL]-4-METHYLPENTANAMIDE
7RJ8	;	2.59	;	CRYSTAL STRUCTURE OF AP2 ASSOCIATED KINASE 1 ISOFORM 1 COMPLEXED WITH LIGAND (2R)-2-AMINO-N-[3-(DIFLUOROM ETHOXY)-4-(1,3-OXAZOL-5-YL)PHENYL]-4-METHYLPENTANAMIDE
7LVI	;	2.2	;	CRYSTAL STRUCTURE OF AP2 ASSOCIATED KINASE 1 ISOFORM 1 COMPLEXED WITH LIGAND (2R)-2-AMINO-N-[3-METHOXY-4- (1,3-OXAZOL-5-YL)PHENYL]-4-METHYLPENTANAMIDE
7RJ7	;	2.124	;	CRYSTAL STRUCTURE OF AP2 ASSOCIATED KINASE 1 ISOFORM 1 COMPLEXED WITH LIGAND 2-(1-AMINO-3-METHYLBUTYL)-6- (PYRIDIN-4-YL)QUINOLINE-4-CARBONITRILE
7LVH	;	2.65	;	CRYSTAL STRUCTURE OF AP2 ASSOCIATED KINASE 1 ISOFORM 1 COMPLEXED WITH LIGAND N-[3-METHOXY-4-(1,3-OXAZOL-5-YL)PHENYL]-3-(PROPAN-2-YL)PIPERIDINE-2-CARBOXAMIDE
7OHO	;	2.88	;	Crystal structure of AP2 FCHO2 chimera
6BNT	;	3.2	;	Crystal structure of AP2 mu1 adaptin C-terminal domain with IRS-1 peptide
7OI5	;	2.61	;	Crystal structure of AP2 Mu2 - FCHO2 chimera (GST cleaved)
7OHZ	;	2.27	;	Crystal structure of AP2 Mu2 - FCHO2 chimera (His6-tagged)
7OIQ	;	1.85	;	Crystal structure of AP2 Mu2 in complex with FCHO2 WxxPhi motif (C2 crystal form)
7OIT	;	1.65	;	Crystal structure of AP2 Mu2 in complex with FCHO2 WxxPhi motif (P3221 crystal form)
1TSQ	;	2.0	;	CRYSTAL STRUCTURE OF AP2V SUBSTRATE VARIANT OF NC-P1 DECAMER PEPTIDE IN COMPLEX WITH V82A/D25N HIV-1 PROTEASE MUTANT
3I7U	;	1.8	;	Crystal structure of AP4A hydrolase (aq_158) from Aquifex aeolicus VF5
3I7V	;	1.95	;	Crystal structure of AP4A hydrolase complexed with AP4A (ATP) (aq_158) from Aquifex aeolicus Vf5
4RHW	;	2.1	;	Crystal structure of Apaf-1 CARD and caspase-9 CARD complex
1XVS	;	2.01	;	Crystal structure of apaG Protein from Vibrio cholerae
3Q9F	;	2.35	;	Crystal Structure of APAH complexed with CAPS
3Q9B	;	2.25	;	Crystal Structure of APAH complexed with M344
7F6M	;	2.4	;	Crystal structure of APC complexed with a peptide inhibitor MAI-516
3NMX	;	2.3	;	Crystal structure of APC complexed with Asef
3NMZ	;	3.01	;	Crystal structure of APC complexed with Asef
4YJE	;	1.9	;	Crystal structure of APC-ARM in complexed with Amer1-A1
4YJL	;	2.1	;	Crystal structure of APC-ARM in complexed with Amer1-A2
4YK6	;	1.7	;	Crystal structure of APC-ARM in complexed with Amer1-A4
2XPI	;	2.6	;	Crystal structure of APC/C hetero-tetramer Cut9-Hcn1
4R2Y	;	1.755	;	Crystal structure of APC11 RING domain
3FHK	;	2.3	;	Crystal structure of APC1446, B.subtilis YphP disulfide isomerase
1ORU	;	1.8	;	Crystal Structure of APC1665, YUAD protein from Bacillus subtilis
4RG7	;	4.25	;	Crystal structure of APC3
4RG6	;	3.3	;	Crystal structure of APC3-APC16 complex
4RG9	;	3.25	;	Crystal structure of APC3-APC16 complex (Selenomethionine Derivative)
1U84	;	1.6	;	Crystal Structure of APC36109 from Bacillus stearothermophilus
2QMM	;	1.85	;	Crystal structure of APC86534.1 (C-terminal domain of NCBI AAB90184.1; Pfam BIG 123.1)
3GI8	;	2.59	;	Crystal Structure of ApcT K158A Transporter Bound to 7F11 Monoclonal Fab Fragment
3GIA	;	2.32	;	Crystal Structure of ApcT Transporter
3GI9	;	2.48	;	Crystal Structure of ApcT Transporter Bound to 7F11 Monoclonal Fab Fragment
1WFX	;	2.8	;	Crystal Structure of APE0204 from Aeropyrum pernix
2Z1N	;	1.8	;	Crystal structure of APE0912 from Aeropyrum pernix K1
2ISI	;	2.76	;	Crystal structure of Ape1 from Homo sapiens in a new crystal form complexed with a ligand
2YVU	;	2.1	;	Crystal structure of APE1195
2CWJ	;	3.6	;	crystal structure of APE1501, a putative endonuclease from Aeropyrum pernix
4NWU	;	1.602	;	Crystal structure of APE1551, an anti-human NGF Fab with a nine amino acid insertion in CDR H1
2CY1	;	2.3	;	Crystal structure of APE1850
7SUS	;	2.7	;	Crystal structure of Apelin receptor in complex with small molecule
4PSN	;	2.05	;	Crystal structure of apeThermo-DBP-RP2
4PSO	;	2.9	;	Crystal structure of apeThermo-DBP-RP2 bound to ssDNA dT10
6CD7	;	1.53	;	Crystal structure of APH(2"")-IVa in complex with plazomicin
1RMT	;	1.4	;	Crystal structure of AphA class B acid phosphatase/phosphotransferase complexed with adenosine.
2B8J	;	2.033	;	Crystal structure of AphA class B acid phosphatase/phosphotransferase ternary complex with adenosine and phosphate at 2 A resolution
2B82	;	1.25	;	Crystal structure of AphA class B acid phosphatase/phosphotransferase ternary complex with adenosine and phosphate bound to the catalytic metal at 1.2 A resolution
1RMY	;	1.75	;	Crystal structure of AphA class B acid phosphatase/phosphotransferase ternary complex with deoxycytosine and phosphate bound to the catalytic metal
1RMQ	;	2.0	;	Crystal structure of AphA class B acid phosphatase/phosphotransferase with osmiate mimicking the catalytic intermediate
7Q2A	;	1.6	;	Crystal structure of AphC in complex with 4-ethylcatechol
1E5P	;	1.63	;	Crystal structure of aphrodisin, a sex pheromone from female hamster
6L4O	;	2.6	;	Crystal structure of API5-FGF2 complex
3OSX	;	1.55	;	Crystal Structure of Apical Domain of Insecticidal GroEL from Xenorhapdus nematophila
4UV6	;	2.45	;	Crystal structure of apical membrane antigen 1 from Plasmodium knowlesi
4UAO	;	3.1	;	Crystal structure of Apical Membrane Antigen 1 from Plasmodium Knowlesi in complex with an invasion inhibitory antibody
1W81	;	2.01	;	Crystal structure of apical membrane antigen 1 from Plasmodium vivax
1W8K	;	1.8	;	Crystal structure of apical membrane antigen 1 from Plasmodium vivax
8GZI	;	2.1221	;	Crystal Structure of ApiI in complex with SAH
8Q89	;	2.05	;	Crystal structure of Apis mellifera glutathione transferase delta 1 in a covalent dimeric state
8Q8B	;	1.5	;	Crystal structure of Apis mellifera glutathione transferase delta 1, mutant C127S
8Q8A	;	1.75	;	Crystal structure of Apis mellifera glutathione transferase delta 1, mutant M126L
7ZS6	;	1.31	;	Crystal structure of Apis mellifera RidA
6W70	;	1.296	;	Crystal Structure of apixaban-bound ABLE
3O6N	;	1.85	;	Crystal Structure of APL1 leucine-rich repeat domain
2WN9	;	1.75	;	Crystal structure of Aplysia ACHBP in complex with 4-0H-DMXBA
2WNL	;	2.7	;	CRYSTAL STRUCTURE OF APLYSIA ACHBP IN COMPLEX WITH ANABASEINE
2WNJ	;	1.8	;	CRYSTAL STRUCTURE OF APLYSIA ACHBP IN COMPLEX WITH DMXBA
2WNC	;	2.2	;	Crystal structure of Aplysia ACHBP in complex with tropisetron
2BYP	;	2.07	;	Crystal structure of Aplysia californica AChBP in complex with alpha- conotoxin ImI
2XYT	;	2.05	;	Crystal structure of Aplysia californica AChBP in complex with d- tubocurarine
2BYQ	;	3.4	;	Crystal structure of Aplysia californica AChBP in complex with epibatidine
2XYS	;	1.909	;	Crystal structure of Aplysia californica AChBP in complex with strychnine
3C79	;	2.48	;	Crystal structure of Aplysia californica AChBP in complex with the neonicotinoid imidacloprid
3ZWN	;	1.8	;	Crystal structure of Aplysia cyclase complexed with substrate NGD and product cGDPR
8J30	;	2.89	;	Crystal structure of ApNGT with Q469A and M218A mutations in complex with UDP-GLC
3IIA	;	2.7	;	Crystal structure of apo (91-244) RIa subunit of cAMP-dependent protein kinase
7DVS	;	2.6	;	Crystal structure of Apo (heme-free) PefR
1OTJ	;	1.9	;	Crystal structure of APO (iron-free) TauD
6QO5	;	1.511	;	Crystal structure of apo (metal-free) ribonucleotide reductase NrdF from Bacillus anthracis
6TQX	;	2.05002	;	Crystal structure of apo (metal-free) ribonucleotide reductase NrdF L61G variant from Bacillus anthracis
5ICG	;	2.6	;	Crystal structure of apo (S)-norcoclaurine 6-O-methyltransferase
1P1F	;	2.6	;	Crystal structure of apo 1L-myo-inositol 1-phosphate synthase
4ND7	;	2.0	;	Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the closed form
4ND6	;	2.0	;	Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the open form
7TM4	;	1.7	;	Crystal structure of apo 3-phosphoshikimate 1-carboxyvinyltransferase from Klebsiella pneumoniae
4L9R	;	1.95	;	Crystal Structure of apo A12K/D35S mutant myo-inositol dehydrogenase from Bacillus subtilis
2BYN	;	2.02	;	Crystal structure of apo AChBP from Aplysia californica
3GXD	;	2.5	;	Crystal structure of Apo acid-beta-glucosidase pH 4.5
2OPT	;	2.05	;	Crystal Structure of Apo ActR from Streptomyces coelicolor.
1T8K	;	1.1	;	Crystal Structure of apo acyl carrier protein from E. coli
6LVU	;	2.294	;	Crystal structure of apo acyl carrier protein from Thermotoga maritima
4FB8	;	3.0	;	Crystal Structure of apo Acyl-CoA Carboxylase
4NLE	;	2.16	;	Crystal structure of apo Adenylosuccinate Lyase from Mycobacterium smegmatis
4B9Y	;	1.9	;	Crystal Structure of Apo Agd31B, alpha-transglucosylase in Glycoside Hydrolase Family 31
5K7F	;	1.7	;	Crystal structure of apo AibR
7BBZ	;	1.77	;	Crystal structure of apo aldo-keto reductase from Agrobacterium tumefaciens
4EVF	;	1.9	;	Crystal structure of apo alpha-1 giardin
3GXN	;	3.01	;	Crystal structure of apo alpha-galactosidase A at pH 4.5
2Y8R	;	2.45	;	Crystal structure of apo AMA1 mutant (Tyr230Ala) from Toxoplasma gondii
3SGC	;	2.05	;	Crystal Structure of Apo Aminoglycoside-2''-Phosphotransferase Type IVa
5B68	;	1.7	;	Crystal structure of apo amylomaltase from Corynebacterium glutamicum
4KKG	;	2.4	;	Crystal structure of apo and AMP-bound JNK3
6O8K	;	2.12	;	Crystal Structure of apo and reduced Sulfide-responsive transcriptional repressor (SqrR) from Rhodobacter capsulatus.
4M9B	;	1.6	;	Crystal structure of Apo Ara h 8
4TU6	;	2.27	;	Crystal structure of apo ATAD2A bromodomain with N1064 alternate conformation
6AJM	;	2.604	;	Crystal structure of apo AtaTR
6UVQ	;	1.84	;	Crystal structure of Apo AtmM
6UWD	;	2.04	;	Crystal structure of Apo AtmM
2OF9	;	1.35	;	Crystal structure of apo AVR4 (D39A/C122S)
2OFA	;	1.5	;	Crystal structure of apo AVR4 (R112L,C122S)
3ULZ	;	2.6	;	Crystal structure of apo BAK1
7TWA	;	1.7	;	Crystal structure of apo BesC from Streptomyces cattleya
5WQS	;	1.9	;	Crystal structure of Apo Beta-Amylase from Sweet potato
1NR7	;	3.3	;	Crystal structure of apo bovine glutamate dehydrogenase
5Y0O	;	2.3	;	Crystal structure of apo BsTmcAL
3SVZ	;	2.9	;	Crystal structure of apo BT_2972, a methyltransferase from Bacteroides thetaiotaomicron
3T7R	;	2.9	;	Crystal structure of apo BVU_3255, a methyltransferase from Bacteroides vulgatus ATCC 8482
5DRH	;	2.27	;	Crystal structure of apo C-As lyase
5HKW	;	2.25	;	Crystal Structure of Apo c-Cbl TKBD Refined to 2.25 A Resolution
2V0Y	;	2.0	;	Crystal structure of apo C298S tryptophanase from E.coli
6C1Z	;	1.3	;	Crystal structure of Apo Caenorhabditis elegans lipid binding protein 8 (LBP-8)
8PHB	;	1.7	;	Crystal structure of apo Cami1
8Q3Y	;	2.52	;	Crystal structure of apo Can2 from Thermoanaerobacter brockii
4OFF	;	1.888	;	Crystal structure of apo carboxy cGMP binding domain of Plasmodium falciparum PKG
6WXW	;	2.32	;	crystal structure of apo Card1
3R7S	;	2.252	;	Crystal Structure of Apo Caspase2
4EK3	;	1.34	;	Crystal structure of apo CDK2
4WCK	;	1.4	;	Crystal Structure of apo Cell Shape Determinant protein Csd4 from Helicobacter pylori
4WUK	;	1.7	;	Crystal structure of apo CH65 Fab
1TVQ	;	2.0	;	Crystal Structure of Apo Chicken Liver Basic Fatty Acid Binding Protein (or Bile Acid Binding Protein)
4HOK	;	2.77	;	crystal structure of apo ck1e
7CT8	;	2.1	;	Crystal structure of apo CmoB from Vibrio Vulnificus
2Y3U	;	2.55	;	Crystal structure of apo collagenase G from Clostridium histolyticum at 2.55 Angstrom resolution
3DSP	;	2.2	;	Crystal structure of apo copper resistance protein CopK
6UV0	;	2.601	;	Crystal structure of apo core domain of RNA helicase DDX17
5VPV	;	2.6	;	Crystal structure of Apo Cryptococcus neoformans H99 Acetyl-CoA Synthetase with an Acetylated Active Site Lysine
6O73	;	3.0	;	Crystal structure of apo Csm1-Csm4 cassette
6O6S	;	2.65	;	Crystal structure of Apo Csm6
3F7M	;	1.6	;	Crystal structure of apo Cuticle-Degrading Protease (ver112) from Verticillium psalliotae
4ZQI	;	2.3	;	Crystal structure of Apo D-alanine-D-alanine ligase(DDL) from Yersinia pestis
3LWB	;	2.1	;	Crystal Structure of apo D-alanine:D-alanine Ligase (Ddl) from Mycobacterium tuberculosis
3R0Z	;	2.4	;	Crystal structure of apo D-serine deaminase from Salmonella typhimurium
6IN4	;	1.8	;	Crystal structure of apo DAPK1 in the presence of 18-crown-6
3E4Q	;	2.75	;	Crystal structure of apo DctB
6VSH	;	3.0	;	Crystal structure of apo Dicamba Monooxygenase
4RYJ	;	4.1	;	Crystal structure of apo dimer of BcTSPO
3DFY	;	2.1	;	Crystal structure of apo dipeptide epimerase from Thermotoga maritima
6ON7	;	1.981	;	Crystal Structure of Apo Domain-Swapped Dimer Q108K:T51D:A28C:L36C Mutant of Human Cellular Retinol Binding Protein II
7A3F	;	2.9	;	Crystal structure of apo DPP9
8FFA	;	2.15	;	Crystal structure of Apo Dps protein (PA0962) from Pseudomonas aeruginosa (cubic form)
8FF9	;	1.7	;	Crystal structure of Apo Dps protein (PA0962) from Pseudomonas aeruginosa (orthorhombic form)
3HHQ	;	2.0	;	Crystal structure of apo dUT1p from Saccharomyces cerevisiae
2BZ1	;	1.54	;	CRYSTAL STRUCTURE OF APO E. COLI GTP CYCLOHYDROLASE II
4FE4	;	3.45	;	Crystal structure of apo E. coli XylR
7SI1	;	1.6	;	Crystal structure of apo EGFR kinase domain
7E7A	;	2.64	;	Crystal structure of apo ENL YEATS domain T3 mutant
8JTP	;	2.9	;	Crystal structure of apo Enoyl-Acyl Carrier Protein Reductase (FabI) from Klebsiella pneumoniae
7TY1	;	1.8	;	Crystal structure of apo eosinophil cationic protein (ribonuclease 3) from Macaca fascicularis (MfECP)
6PTM	;	2.0	;	Crystal structure of apo exo-carrageenase GH42 from Bacteroides ovatus
2RKT	;	1.99	;	Crystal Structure of apo F. graminearum TRI101
6EUO	;	2.3	;	Crystal structure of APO Fe(II)/alpha-ketoglutarate dependent dioxygenase KDO5
4AUU	;	1.6	;	Crystal structure of apo FimH lectin domain at 1.5 A resolution
6ASK	;	1.69	;	Crystal Structure of apo Flavin monooxygenase CmoJ (earlier YtnJ)
5XGQ	;	1.899	;	Crystal structure of apo form (free-state) Mycobacterium tuberculosis methionyl-tRNA synthetase
3DEB	;	1.95	;	Crystal Structure of apo form (Zinc removed) of the Botulinum Neurotoxin Type C Light Chain
8FWF	;	1.94	;	Crystal structure of Apo form Fab235
5ZX9	;	1.55	;	Crystal structure of apo form fibronectin-binding protein Apa from Mycobacterium tuberculosis
5XK3	;	1.996	;	Crystal structure of apo form Isosesquilavandulyl Diphosphate Synthase from Streptomyces sp. strain CNH-189
7P82	;	2.042	;	Crystal structure of apo form L147A/I351A variant of S-adenosylmethionine synthetase from Methanocaldococcus jannaschii
3SLC	;	2.7	;	Crystal structure of apo form of acetate kinase (AckA) from Salmonella typhimurium
7CTD	;	2.15	;	Crystal structure of apo form of alpha-glucuronidase (TM0752) from Thermotoga maritima
2I49	;	1.35	;	Crystal structure of apo form of Bicarbonate Transport Protein CmpA from Synechocystis sp. PCC 6803
5GUK	;	2.0	;	Crystal structure of apo form of cyclolavandulyl diphosphate synthase (CLDS) from Streptomyces sp. CL190
3L8E	;	1.64	;	Crystal Structure of apo form of D,D-heptose 1.7-bisphosphate phosphatase from E. Coli
3C4Y	;	7.509	;	Crystal Structure of Apo form of G protein coupled receptor kinase 1 at 7.51A
6F43	;	1.35	;	Crystal structure of apo form of Glutathione transferase Omega 3S from Trametes versicolor
6LTW	;	1.65	;	Crystal structure of Apo form of I122A/I330A variant of S-adenosylmethionine synthetase from Cryptosporidium hominis
4Y0T	;	2.3	;	Crystal structure of apo form of OXA-58, a Carbapenem hydrolyzing Class D beta-lactamase from Acinetobacter baumanii (P21, 4mol/ASU)
5BMN	;	1.27	;	Crystal Structure of APO form of Phosphoglucomutase from Xanthomonas citri
5O06	;	1.547	;	Crystal structure of APO form of Phosphopantetheine adenylyltransferase from Mycobacterium abcessus
2ZLB	;	2.2	;	Crystal structure of APO form of rat catechol-O-methyltransferase
7P83	;	2.218	;	Crystal structure of Apo form of S-adenosylmethionine synthetase from Methanocaldococcus jannaschii
5ZCI	;	2.0	;	Crystal structure of apo form of Xylose reductase from Debaryomyces nepalensis
2OV1	;	2.5	;	Crystal structure of apo form of ZnuA with flexible loop deletion
7E1L	;	2.4	;	Crystal structure of apo form PhlH
6AYY	;	2.601	;	Crystal structure of Apo fructose-1,6-bisphosphatase from Mycobacterium tuberculosis
1YFE	;	2.19	;	Crystal structure of apo fumarase C from Escherichia coli
3NO9	;	2.48	;	Crystal Structure of apo fumarate hydratase from Mycobacterium tuberculosis
6J6X	;	2.962	;	Crystal structure of apo GGTaseIII
3FZ7	;	2.5	;	Crystal structure of apo glutamate decarboxylase beta from Escherichia coli
2UU7	;	3.0	;	Crystal structure of apo glutamine synthetase from dog (Canis familiaris)
3LC7	;	2.5	;	Crystal Structure of apo Glyceraldehyde-3-phosphate dehydrogenase 1 (GAPDH1) from methicllin resistant Staphylococcus aureus (MRSA252)
1F4Q	;	1.9	;	CRYSTAL STRUCTURE OF APO GRANCALCIN
1XCK	;	2.92	;	Crystal structure of apo GroEL
1IRM	;	2.55	;	Crystal structure of apo heme oxygenase-1
4YOB	;	1.504	;	Crystal Structure of Apo HIV-1 Protease MDR769 L33F
7UAJ	;	3.25	;	Crystal structure of apo HPV16 E6
5J80	;	1.17	;	Crystal Structure of Apo Hsp90-alpha N-domain L107A mutant
4QHD	;	1.65	;	Crystal structure of apo human APE1
7Z3T	;	1.6	;	Crystal structure of apo human Cathepsin L
3UYS	;	2.3	;	Crystal structure of apo human ck1d
7FTF	;	1.508	;	Crystal Structure of apo human cyclic GMP-AMP synthase
7FTJ	;	1.461	;	Crystal Structure of apo human cyclic GMP-AMP synthase
7FTK	;	2.125	;	Crystal Structure of apo human cyclic GMP-AMP synthase
7FTX	;	2.831	;	Crystal Structure of apo human cyclic GMP-AMP synthase - hexagonal form
4LKP	;	1.67	;	Crystal Structure of Apo Human Epidermal Fatty Acid Binding Protein (FABP5)
7G1X	;	1.65	;	Crystal Structure of apo human FABP1 - monoclinic form I
7FYA	;	1.88	;	Crystal Structure of apo human FABP1 - orthorhombic form
7FXO	;	1.3	;	Crystal Structure of apo human FABP1 monoclinic form III
7G0W	;	1.64	;	Crystal Structure of apo human FABP1i monoclinic form II, twinned with beta=90deg
7FZA	;	2.601	;	Crystal Structure of apo human FABP4, cubic form
7FX3	;	1.12	;	Crystal Structure of apo human FABP4, tetragonal form
7FY1	;	2.01	;	Crystal Structure of apo human FABP9
1SNZ	;	2.2	;	Crystal structure of apo human galactose mutarotase
3ZSL	;	1.08	;	Crystal structure of Apo Human Galectin-3 CRD at 1.08 angstrom resolution, at cryogenic temperature
3ZSM	;	1.25	;	Crystal structure of Apo Human Galectin-3 CRD at 1.25 angstrom resolution, at room temperature
1EYB	;	1.9	;	CRYSTAL STRUCTURE OF APO HUMAN HOMOGENTISATE DIOXYGENASE
5HGI	;	2.584	;	Crystal structure of apo human IRE1 alpha
1ILG	;	2.52	;	Crystal Structure of Apo Human Pregnane X Receptor Ligand Binding Domain
5LA4	;	1.9	;	Crystal structure of apo human proheparanase
4IAN	;	2.44	;	Crystal Structure of apo Human PRPF4B kinase domain
1I57	;	2.1	;	CRYSTAL STRUCTURE OF APO HUMAN PTP1B (C215S) MUTANT
5V2N	;	2.0	;	Crystal Structure of APO Human SETD8
5WU1	;	2.8	;	Crystal structure of apo human Tut1, form I
5WU5	;	3.404	;	Crystal structure of apo human Tut1, form III
5WU6	;	3.209	;	Crystal structure of apo human Tut1, form IV
5LAD	;	3.0	;	Crystal Structure of apo HydF from thermotoga maritima
4XC9	;	2.4	;	Crystal Structure of apo HygX from Streptomyces hygroscopicus
5ESW	;	2.4	;	Crystal structure of Apo hypoxanthine-guanine phosphoribosyltransferase from Legionella pneumophila
4Z6J	;	2.4	;	Crystal structure of apo intact hoefavidin
1SNX	;	3.2	;	CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4HF0	;	1.9	;	Crystal Structure of Apo IscR
5O3M	;	2.23	;	Crystal structure of apo Klebsiella pneumoniae 3,4-dihydroxybenzoic acid decarboxylase (AroY)
4QDF	;	2.43	;	Crystal structure of apo KshA5 and KshA1 in complex with 1,4-30Q-CoA from R. rhodochrous
2VHY	;	2.3	;	Crystal structure of apo L-alanine dehydrogenase from Mycobacterium tuberculosis
2I5Q	;	2.1	;	Crystal structure of Apo L-rhamnonate dehydratase from Escherichia Coli
7Y1S	;	2.748	;	Crystal structure of apo leucyl aminopeptidase from Bacillus amyloliquefaciens
3ULJ	;	1.06	;	Crystal structure of apo Lin28B cold shock domain
2D4M	;	1.85	;	Crystal Structure of apo M-PMV dUTPase
1U7D	;	2.65	;	crystal structure of apo M. jannashii tyrosyl-tRNA synthetase
3MVT	;	2.2	;	Crystal structure of apo mADA at 2.2A resolution
4NNP	;	2.69	;	Crystal Structure of Apo Manganese ABC transporter MntC from Staphylococcus aureus bound to an antagonistic fab fragment
4FUQ	;	1.702	;	Crystal structure of apo MatB from Rhodopseudomonas palustris
4WLN	;	2.28	;	Crystal structure of apo MDH2
5ERX	;	1.729	;	Crystal Structure of APO MenD from M. tuberculosis - I222
5ERY	;	2.25	;	Crystal Structure of APO MenD from M. tuberculosis - P212121
1XMG	;	2.1	;	Crystal structure of apo methane monooxygenase hydroxylase from M. capsulatus (Bath)
3PVC	;	2.31	;	Crystal structure of apo MnmC from Yersinia Pestis
7LI0	;	1.85	;	Crystal structure of apo Moraxella catarrhalis ferric binding protein A in an open conformation
7FWT	;	1.54	;	Crystal Structure of apo mouse FABP4
7FZG	;	1.49	;	Crystal Structure of apo mouse FABP4, C-centered orthorhombic form
7FYW	;	1.81	;	Crystal Structure of apo mouse FABP5, twinned in P21 with beta=90deg
6AGV	;	1.62	;	Crystal structure of apo mouse MsrA
4ISB	;	2.2	;	Crystal Structure of Apo Mtb FadD10
4RRW	;	2.569	;	Crystal Structure of Apo Murine Cyclooxygenase-2
4RRY	;	2.429	;	Crystal Structure of Apo Murine H90W Cyclooxygenase-2
4RRZ	;	2.569	;	Crystal Structure of Apo Murine H90W Cyclooxygenase-2 Complexed with Lumiracoxib
4G3C	;	2.15	;	Crystal structure of apo murine Nf-kappaB inducing kinase (NIK)
4RRX	;	2.78	;	Crystal Structure of Apo Murine V89W Cyclooxygenase-2 Complexed with Lumiracoxib
1ZHQ	;	1.9	;	Crystal structure of apo MVL
3MZ0	;	1.539	;	Crystal structure of apo myo-inositol dehydrogenase from Bacillus subtilis
4MIE	;	2.0	;	Crystal Structure of apo myo-inositol dehydrogenase from Lactobacillus casei
4XJ8	;	2.749	;	Crystal structure of apo NanB sialidase from streptococcus pneumoniae at pH 5.0 in 50mM sodium Acetate with DMSO
4XJZ	;	1.56	;	Crystal structure of apo NanB sialidase from streptococcus pneumoniae at pH 7.4 in PBS with DMSO
4XIO	;	1.8	;	Crystal structure of apo NanB sialidase from streptococcus pneumoniae at pH 8.0 with MPD as the cryoprotectant
7EUM	;	2.15	;	Crystal structure of apo Nmar_1308 protein at cryogenic temperature
3BVQ	;	2.8	;	Crystal Structure of Apo NotI Restriction Endonuclease
7OJ4	;	1.828	;	Crystal structure of apo NS3 helicase from tick-borne encephalitis virus
4QJN	;	2.613	;	Crystal structure of apo nucleoid associated protein, SAV1473
3UDF	;	1.7	;	Crystal structure of Apo PBP1a from Acinetobacter baumannii
3PBN	;	2.0	;	Crystal Structure of Apo PBP3 from Pseudomonas aeruginosa
1S2T	;	2.0	;	Crystal Structure Of Apo Phosphoenolpyruvate Mutase
5JBN	;	1.45	;	Crystal Structure of Apo Phosphopantetheine Adenylyltransferase (PPAT/CoaD) from E. coli
4U28	;	1.33	;	Crystal structure of apo Phosphoribosyl isomerase A from Streptomyces sviceus ATCC 29083
6R2H	;	2.46	;	Crystal structure of Apo PinO from Porphyromonas gingivitis
6R51	;	1.94	;	Crystal structure of apo PPEP-1(E143A/Y178F) in complex with fibrinogen-derived substrate peptide Ac-SLRPAPP-CONH2
6R4W	;	1.391	;	Crystal structure of apo PPEP-1(E143A/Y178F) in complex with substrate peptide Ac-EVNAPVP-CONH2
7VGB	;	2.227	;	Crystal structure of apo prolyl oligopeptidase from Microbulbifer arenaceous
8DUR	;	1.97	;	Crystal structure of apo protein arginine N-methyltransferase 1 (PRMT1) from Naegleria fowleri
7CNW	;	1.9	;	Crystal structure of Apo PSD from E. coli (1.90 A)
7CNX	;	2.63	;	Crystal structure of Apo PSD from E. coli (2.63 A)
3JS6	;	1.95	;	Crystal structure of apo psk41 parM protein
6PRM	;	2.5	;	Crystal structure of apo PsS1_19B
6PT4	;	1.45	;	Crystal structure of apo PsS1_NC
6OMP	;	1.7	;	Crystal structure of apo PtmU3
8EXI	;	1.599	;	Crystal structure of apo PTP1B D181A/Q262A phosphatase domain
5YN2	;	2.301	;	Crystal structure of apo Pullulanase from Klebsiella pneumoniae in space group P43212
6JHF	;	1.71	;	Crystal structure of apo Pullulanase from Paenibacillus barengoltzii
6JHG	;	1.891	;	Crystal structure of apo Pullulanase from Paenibacillus barengoltzii in space group P212121
5GS5	;	1.84	;	Crystal structure of apo rat STING
8CO4	;	1.9	;	Crystal structure of apo S-nitrosoglutathione reductase from Arabidopsis thalina
1QE0	;	2.7	;	CRYSTAL STRUCTURE OF APO S. AUREUS HISTIDYL-TRNA SYNTHETASE
4X7P	;	3.4	;	Crystal structure of apo S. aureus TarM
1KSO	;	1.7	;	CRYSTAL STRUCTURE OF APO S100A3
2Q5I	;	2.8	;	Crystal structure of apo S581L Glycyl-tRNA synthetase mutant
8IGO	;	2.0	;	Crystal structure of apo SARS-CoV-2 main protease
4MKX	;	1.6	;	Crystal Structure of apo scyllo-inositol dehydrogenase from Lactobacillus casei
4MKZ	;	1.6	;	Crystal Structure of apo scyllo-inositol dehydrogenase from Lactobacillus casei at 77K
6HDS	;	1.74	;	Crystal Structure of apo short afifavidin
4Z27	;	1.34	;	Crystal structure of apo short hoefavidin
3SZH	;	1.07	;	Crystal structure of apo shwanavidin (P1 form)
7QE1	;	1.95	;	Crystal structure of apo SN243
3I1A	;	1.7	;	Crystal Structure of apo Spectinomycin Phosphotransferase, APH(9)-Ia
6EEK	;	2.2	;	Crystal structure of apo Staphylcoccal nuclease variant Delta+PHS T62E/V66K, pH 7 at cryogenic temperature
7EK8	;	1.7	;	Crystal structure of apo streptavidin at ambient temperature
7EK9	;	1.1	;	Crystal structure of apo streptavidin at cryogenic temperature
6CWZ	;	3.1	;	Crystal structure of apo SUMO E1
4DYS	;	2.8	;	Crystal Structure of Apo Swine Flu Influenza Nucleoprotein
1XBA	;	2.0	;	Crystal structure of apo syk tyrosine kinase domain
6XCV	;	1.77	;	Crystal structure of apo SznF from Streptomyces achromogenes var. streptozoticus NRRL 2697
5XP3	;	2.3	;	Crystal structure of apo T2R-TTL
3PR1	;	2.3	;	Crystal structure of apo Thermotoga maritima ribosome biogenesis GTP-binding protein EngB
5Y0S	;	2.103	;	Crystal structure of apo Thermotoga maritima TmcAL(Form II)
5XOB	;	2.48	;	Crystal structure of apo TiaS (tRNAIle2 agmatidine synthetase)
8G5S	;	1.5	;	Crystal structure of apo TnmJ
8E18	;	1.14	;	Crystal structure of apo TnmK1
8G5T	;	1.846	;	Crystal structure of apo TnmK2
6P7T	;	2.5	;	Crystal structure of apo ToxT K231A from Vibrio cholerae strain SCE256
5ND6	;	1.58	;	Crystal structure of apo transketolase from Chlamydomonas reinhardtii
3KOM	;	1.6	;	Crystal structure of apo transketolase from Francisella tularensis
4F0I	;	2.302	;	Crystal structure of apo TrkA
4ASZ	;	1.7	;	Crystal structure of apo TrkB kinase domain
7WM5	;	2.15	;	Crystal structure of apo TrmM from Mycoplasma capricolum
6LIU	;	2.8	;	Crystal structure of apo Tyrosine decarboxylase
4HK4	;	2.298	;	Crystal structure of apo Tyrosine-tRNA ligase mutant protein
8VW1	;	1.7	;	Crystal Structure of Apo UDP-N-acetylmuramoylalanine--D-glutamate ligase (MurD) from E. coli (ADP bound)
8VW0	;	1.7	;	Crystal Structure of Apo UDP-N-acetylmuramoylalanine--D-glutamate ligase (MurD) from E. coli (AMP bound)
8VW2	;	1.95	;	Crystal Structure of Apo UDP-N-acetylmuramoylalanine--D-glutamate ligase (MurD) from E. coli (ATP bound)
8V8Y	;	1.65	;	Crystal Structure of Apo UDP-N-acetylmuramoylalanine--D-glutamate ligase (MurD) from E. coli (Orthorhombic P form)
8V8X	;	2.3	;	Crystal Structure of Apo UDP-N-acetylmuramoylalanine--D-glutamate ligase (MurD) from E. coli (Orthorhombic P form2)
8V8W	;	1.65	;	Crystal Structure of Apo UDP-N-acetylmuramoylalanine--D-glutamate ligase (MurD) from E. coli (Tetragonal P form)
6OGM	;	1.865	;	Crystal structure of apo unFused 4-OT
2Z2O	;	1.9	;	Crystal Structure of apo virginiamycin B lyase from Staphylococcus aureus
5WKW	;	1.79	;	Crystal structure of apo wild type peptidylglycine alpha-hydroxylating monooxygenase (PHM)
5WM0	;	2.4	;	Crystal structure of apo wild type peptidylglycine alpha-hydroxylating monooxygenase (PHM) soaked with peptide (peptide not observed)
7DH7	;	2.2	;	Crystal structure of apo XcZur
5NHM	;	1.67	;	Crystal structure of apo xylose isomerase from Piromyces E2
3ELX	;	1.6	;	Crystal structure of apo Zebrafish Ileal Bile Acid-Binding Protein
4DQG	;	2.79	;	Crystal Structure of apo(G16C/L38C) HIV-1 Protease
1HW6	;	1.9	;	CRYSTAL STRUCTURE OF APO-2,5-DIKETO-D-GLUCONATE REDUCTASE
5ZWS	;	2.0	;	Crystal structure of apo-acyl carrier protein from Leishmania major
7L9E	;	2.29	;	Crystal structure of apo-alpha glucosidase
4MDU	;	2.2	;	Crystal structure of apo-Annexin (Sm)1
2O53	;	2.7	;	Crystal structure of apo-Aspartoacylase from human brain
1F6R	;	2.2	;	CRYSTAL STRUCTURE OF APO-BOVINE ALPHA-LACTALBUMIN
4LYI	;	1.3	;	Crystal Structure of apo-BRD4(1)
1J48	;	1.8	;	Crystal Structure of Apo-C1027
3P45	;	2.53	;	Crystal structure of apo-caspase-6 at physiological pH
5GT8	;	2.8	;	Crystal Structure of apo-CASTOR1
4UAR	;	1.9	;	Crystal structure of apo-CbbY from Rhodobacter sphaeroides
2FS6	;	1.35	;	Crystal Structure of Apo-Cellular Retinoic Acid Binding Protein Type II At 1.35 Angstroms Resolution
2FS7	;	1.55	;	Crystal Structure of Apo-Cellular Retinoic Acid Binding Protein Type II At 1.55 Angstroms Resolution
4JJO	;	1.75	;	crystal structure of apo-clavibacter Michiganensis expansin
4QNX	;	2.619	;	Crystal structure of apo-CmoB
1KQX	;	1.7	;	Crystal structure of apo-CRBP from zebrafish
6N3S	;	1.193	;	Crystal structure of apo-cruzain
3X0X	;	2.11	;	Crystal structure of apo-DszC from Rhodococcus erythropolis D-1
1KBZ	;	2.2	;	Crystal Structure of apo-dTDP-6-deoxy-L-lyxo-4-hexulose reductase (RmlD) from Salmonella enterica serovar Typhimurium
8H8M	;	1.5	;	Crystal structure of apo-E53F/E57F/E60F/E64F-rHLFr
7CZC	;	2.0	;	Crystal structure of apo-FabG from Vibrio harveyi
3E6R	;	2.4	;	Crystal structure of apo-ferritin from Pseudo-nitzschia multiseries
3C8N	;	1.9	;	Crystal structure of apo-FGD1 from Mycobacterium tuberculosis
5JVF	;	1.66	;	Crystal Structure of Apo-FleN
1LBV	;	1.8	;	Crystal Structure of apo-form (P21) of dual activity FBPase/IMPase (AF2372) from Archaeoglobus fulgidus
1LBW	;	2.0	;	Crystal Structure of apo-form (P32) of dual activity FBPase/IMPase (AF2372) from Archaeoglobus fulgidus
3K7T	;	2.85	;	Crystal structure of apo-form 6-hydroxy-L-nicotine oxidase, crystal form P3121
4XSO	;	2.01	;	Crystal structure of apo-form Alr3699/HepE from Anabaena sp. strain PCC 7120
5B3T	;	2.099	;	Crystal structure of apo-form biliverdin reductase from Synechocystis sp. PCC 6803
3E9T	;	1.6	;	Crystal structure of Apo-form Calx CBD1 domain
2WTO	;	1.85	;	Crystal Structure of Apo-form Czce from C. metallidurans CH34
3S1L	;	1.9	;	Crystal Structure of Apo-form FurX
4MHZ	;	1.95	;	Crystal structure of apo-form glutaminyl cyclase from Ixodes scapularis in complex with PBD150
3QAH	;	2.1	;	Crystal structure of apo-form human MOF catalytic domain
5KQP	;	2.052	;	Crystal structure of Apo-form LMW-PTP
4Z5S	;	1.582	;	Crystal structure of apo-form of aldehyde deformylating oxygenase from Synechocystis sp.PCC 6803
4NT1	;	1.8	;	Crystal structure of apo-form of Arabidopsis ACD11 (accelerated-cell-death 11) at 1.8 Angstrom resolution
8IDR	;	1.8	;	Crystal structure of apo-form of dehydroquinate dehydratase from Corynebacterium glutamicum
6NA3	;	1.8	;	Crystal Structure of Apo-form of ECR
4MHP	;	1.1	;	Crystal structure of apo-form of glutaminyl cyclase from Ixodes scapularis
3RWV	;	1.5	;	Crystal Structure of apo-form of Human Glycolipid Transfer Protein at 1.5 A resolution
8I6Z	;	1.95	;	Crystal structure of apo-form of malonyl-CoA reductase C-domain from Chloroflexus aurantiacus
2DUU	;	2.9	;	Crystal Structure of apo-form of NADP-Dependent Glyceraldehyde-3-Phosphate Dehydrogenase from Synechococcus Sp.
1JAM	;	2.18	;	Crystal structure of apo-form of Z. Mays CK2 protein kinase alpha subunit
4YSK	;	2.466	;	Crystal structure of apo-form SdoA from Pseudomonas putida
4FD3	;	2.6	;	Crystal structure of apo-formed ymtOAR1
3DK5	;	2.23	;	Crystal Structure of Apo-GlmU from Mycobacterium tuberculosis
1VSU	;	2.2	;	Crystal Structure of Apo-glyceraldehyde 3-phosphate dehydrogenase from Cryptosporidium parvum
1CRW	;	2.0	;	CRYSTAL STRUCTURE OF APO-GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE FROM PALINURUS VERSICOLOR AT 2.0A RESOLUTION
1BHJ	;	2.5	;	CRYSTAL STRUCTURE OF APO-GLYCINE N-METHYLTRANSFERASE (GNMT)
1OZT	;	2.5	;	Crystal Structure of apo-H46R Familial ALS Mutant human Cu,Zn Superoxide Dismutase (CuZnSOD) to 2.5A resolution
1X2W	;	2.29	;	Crystal Structure of Apo-Habu IX-bp at pH 4.6
5Y2X	;	2.02	;	Crystal structure of apo-HaloTag (M175C)
3SPS	;	2.9	;	Crystal Structure of Apo-Hexameric Acyl-CoA Thioesterase
6ATP	;	1.7	;	Crystal structure of apo-hGSTA1-1 exhibiting a new conformation of C-terminal helix
6ATQ	;	2.0	;	Crystal structure of apo-hGSTA1-1 exhibiting a new conformation of C-terminal helix
7EL2	;	2.2	;	Crystal structure of apo-HpaR from Acinetobacter baumannii
2EB4	;	1.6	;	Crystal structure of apo-HpcG
1ZZ6	;	2.0	;	Crystal Structure of Apo-HppE
4GY2	;	2.71	;	Crystal structure of apo-Ia-actin complex
4MJ2	;	2.1	;	Crystal structure of apo-iduronidase in the R3 form
1X8F	;	2.4	;	Crystal Structure Of apo-Kdo8P Synthase
6JEE	;	1.3	;	Crystal structure of apo-L161C/L165C-Fr
3BRI	;	1.7	;	Crystal Structure of apo-LC8
3EI7	;	1.99	;	Crystal structure of apo-LL-diaminopimelate aminotransferase from Arabidopsis thaliana (no PLP)
3ASA	;	2.05	;	Crystal structure of apo-LL-diaminopimelate aminotransferase from Chlamydia trachomatis
5DIK	;	1.9	;	Crystal structure of apo-lpg0406, a carboxymuconolactone decarboxylase family protein from Legionella pneumophila
8H1S	;	3.28	;	Crystal structure of apo-LptDE complex
1R7O	;	1.85	;	Crystal Structure of apo-mannanase 26A from Psudomonas cellulosa
6LI5	;	1.82	;	Crystal structure of apo-MCR-1-S
3SBZ	;	2.0	;	Crystal Structure of Apo-MMACHC (1-244), a human B12 processing enzyme
4US5	;	1.8	;	Crystal Structure of apo-MsnO8
2OZQ	;	1.8	;	Crystal Structure of apo-MUP
5JR9	;	2.4	;	Crystal structure of apo-NeC3PO
1NOA	;	1.5	;	CRYSTAL STRUCTURE OF APO-NEOCARZINOSTATIN AT 0.15 NM RESOLUTION
7V37	;	2.403	;	Crystal structure of apo-NP exonuclease
7V3A	;	2.1	;	Crystal structure of apo-NP exonuclease C409A
5HWT	;	1.7	;	Crystal structure of apo-PAS1
4WIE	;	2.18	;	Crystal structure of apo-PEPCK from Mycobacterium tuberculosis with glycerol
3BFP	;	1.75	;	Crystal Structure of apo-PglD from Campylobacter jejuni
4MGF	;	2.0	;	Crystal structure of apo-PhuS, a heme-binding protein from Pseudomonas aeruginosa
3UIU	;	2.903	;	Crystal structure of Apo-PKR kinase domain
3RT2	;	1.5	;	Crystal structure of apo-PYL10
6JEF	;	1.58	;	Crystal structure of apo-R168C/L169C-Fr
8H8L	;	1.5	;	Crystal structure of apo-R52F/E56F/R59F/E63F-rHLFr
8H8O	;	1.5	;	Crystal structure of apo-R52W/E56W/R59W/E63W-rHLFr
8H8N	;	1.5	;	Crystal structure of apo-R52Y/E56Y/R59Y/E63Y-rHLFr
8GB2	;	3.07	;	Crystal structure of Apo-SAMHD1
3TTK	;	2.97	;	Crystal structure of apo-SpuD
3TTL	;	2.3	;	Crystal structure of apo-SpuE
6Z66	;	3.192	;	Crystal structure of apo-state neurotensin receptor 1
7O5I	;	1.35	;	Crystal structure of apo-SwHKA (Hydroxy ketone aldolase) from Sphingomonas wittichii RW1
4U02	;	2.399	;	Crystal structure of apo-TTHA1159
3W35	;	2.4	;	Crystal structure of apo-type bacterial Vanadium-dependent chloroperoxidase
3R5S	;	1.791	;	Crystal structure of apo-ViuP
2Q5H	;	3.0	;	Crystal structure of apo-wildtype Glycyl-tRNA synthetase
7MHK	;	1.9601	;	Crystal Structure of Apo/Unliganded SARS-CoV-2 Main Protease (Mpro) at 310 K
1DG6	;	1.3	;	CRYSTAL STRUCTURE OF APO2L/TRAIL
5KEG	;	2.2	;	Crystal structure of APOBEC3A in complex with a single-stranded DNA
7UXD	;	1.5	;	Crystal structure of APOBEC3G Catalytic domain complex with ssDNA containing 2'-deoxy Zebularine.
6BUX	;	1.856	;	CRYSTAL STRUCTURE OF APOBEC3G CATALYTIC DOMAIN COMPLEX WITH SUBSTRATE SSDNA
7UU3	;	3.099	;	Crystal structure of APOBEC3G complex with 3'overhangs RNA-Complex
7UU5	;	2.9	;	Crystal structure of APOBEC3G complex with 5'-Overhang dsRNA
7UU4	;	2.1	;	Crystal structure of APOBEC3G complex with ssRNA
5W45	;	2.486	;	Crystal structure of APOBEC3H
1QX5	;	2.54	;	Crystal structure of apoCalmodulin
1QX7	;	3.09	;	Crystal structure of apoCaM bound to the gating domain of small conductance Ca2+-activated potassium channel
2BIX	;	2.68	;	Crystal structure of apocarotenoid cleavage oxygenase from Synechocystis, Fe-free apoenzyme
2BIW	;	2.39	;	Crystal structure of apocarotenoid cleavage oxygenase from Synechocystis, native enzyme
4OU8	;	2.8	;	Crystal structure of apocarotenoid oxygenase in the presence of C8E6
4OU9	;	2.0	;	Crystal structure of apocarotenoid oxygenase in the presence of Triton X-100
5E4H	;	2.9	;	Crystal Structure of Apoenzyme Alpha-kinase Domain of Myosin-II Heavy Chain Kinase A
1J3H	;	2.9	;	Crystal structure of apoenzyme cAMP-dependent protein kinase catalytic subunit
1UGQ	;	2.0	;	Crystal structure of apoenzyme of Co-type nitrile hydratase
3LE1	;	1.513	;	Crystal structure of apoHPr monomer from Thermoanaerobacter tengcongensis
3LE3	;	1.861	;	Crystal structure of apoHPr monomer from Thermoanaerobacter tengcongensis
2XUW	;	1.703	;	Crystal Structure of Apolaccase from Thermus thermophilus HB27
1M6I	;	1.8	;	Crystal Structure of Apoptosis Inducing Factor (AIF)
4UZ0	;	2.399	;	Crystal Structure of apoptosis repressor with CARD (ARC)
4YN0	;	2.2	;	Crystal structure of APP E2 domain in complex with DR6 CRD domain
3SV1	;	3.3	;	Crystal structure of APP peptide bound rat Mint2 PARM
4HEH	;	2.05	;	Crystal structure of AppA SCHIC domain from Rb. sphaeroides
2EJ8	;	1.84	;	Crystal structure of APPL1 PTB domain at 1.8A
2Z0N	;	1.95	;	Crystal structure of APPL1-BAR domain
2Z0O	;	2.58	;	Crystal structure of APPL1-BAR-PH domain
1M7Y	;	1.6	;	Crystal structure of apple ACC synthase in complex with L-aminoethoxyvinylglycine
1YNU	;	2.25	;	Crystal structure of apple ACC synthase in complex with L-vinylglycine
1M4N	;	2.01	;	CRYSTAL STRUCTURE OF APPLE ACC SYNTHASE IN COMPLEX WITH [2-(AMINO-OXY)ETHYL](5'-DEOXYADENOSIN-5'-YL)(METHYL)SULFONIUM
1YRJ	;	2.7	;	Crystal Structure of Apramycin bound to a Ribosomal RNA A site oligonucleotide
4K31	;	1.415	;	Crystal structure of apramycin bound to the leishmanial rRNA A-site
3SP4	;	1.8	;	Crystal structure of aprataxin ortholog Hnt3 from Schizosaccharomyces pombe
3SPD	;	1.912	;	Crystal structure of aprataxin ortholog Hnt3 in complex with DNA
3SPL	;	2.101	;	Crystal structure of aprataxin ortholog Hnt3 in complex with DNA and AMP
3K48	;	2.8	;	Crystal structure of APRIL bound to a peptide
3LDI	;	2.2	;	Crystal structure of aprotinin in complex with sucrose octasulfate: unusual interactions and implication for heparin binding
3LDJ	;	1.7	;	Crystal structure of aprotinin in complex with sucrose octasulfate: unusual interactions and implication for heparin binding
3LDM	;	2.6	;	Crystal structure of aprotinin in complex with sucrose octasulfate: unusual interactions and implication for heparin binding
6FSP	;	2.7	;	Crystal structure of APRT from Thermus thermophilus
5ZMI	;	2.05	;	Crystal structure of APRT from Y. pseudotuberculosis in complex with adenine.
5ZOC	;	1.98	;	Crystal structure of APRT from Y. pseudotuberculosis with bound adenine (C2 space group).
5ZNQ	;	1.75	;	Crystal structure of APRT from Y. pseudotuberculosis with bound adenine (P21 space group).
5ZC7	;	2.0	;	Crystal structure of APRT from Y. pseudotuberculosis with bound adenine (P63 space group).
5ZGO	;	2.6	;	Crystal structure of APRT2 from Thermus thermophilus HB8
1L1Q	;	1.85	;	Crystal Structure of APRTase from Giardia lamblia Complexed with 9-deazaadenine
1L1R	;	1.95	;	Crystal Structure of APRTase from Giardia lamblia Complexed with 9-deazaadenine, Mg2+ and PRPP
1M7H	;	2.0	;	Crystal Structure of APS kinase from Penicillium Chrysogenum: Structure with APS soaked out of one dimer
1M7G	;	1.43	;	Crystal structure of APS kinase from Penicillium Chrysogenum: Ternary structure with ADP and APS
8I1N	;	2.8	;	Crystal structure of APSK2 domain from human PAPSS2 in complex with endogenous APS and ADP
8I1O	;	2.4	;	Crystal structure of APSK2 domain from human PAPSS2 in complex with exogenous APS and ADP
6QGN	;	2.099	;	Crystal structure of APT1 bound to 2-Bromopalmitate
6QGS	;	2.755	;	Crystal structure of APT1 bound to palmitic acid.
6QGQ	;	2.601	;	Crystal structure of APT1 C2S mutant bound to palmitic acid.
6QGO	;	2.599	;	Crystal structure of APT1 S119A mutant bound to palmitic acid.
2P3E	;	1.99	;	Crystal structure of AQ1208 from Aquifex aeolicus
2P9J	;	2.4	;	Crystal structure of AQ2171 from Aquifex aeolicus
3NKC	;	3.1	;	Crystal structure of AqpZ F43W,H174G,T183F
3NKA	;	2.5	;	Crystal structure of AqpZ H174G,T183F
3NK5	;	2.4	;	Crystal structure of AqpZ mutant F43W
2O9F	;	2.55	;	Crystal Structure of AqpZ mutant L170C
2O9G	;	1.9	;	Crystal Structure of AqpZ mutant L170C complexed with mercury.
2O9E	;	2.2	;	Crystal Structure of AqpZ mutant T183C complexed with mercury
2O9D	;	2.3	;	Crystal Structure of AqpZ mutant T183C.
5AZR	;	1.2	;	Crystal structure of aqua-cobalt(III) tetradehydrocorrin in the heme pocket of horse heart myoglobin
6N1G	;	3.995	;	Crystal structure of Aquaglyceroporin AQP7
8H7O	;	1.55	;	Crystal structure of aqualigase
8H7P	;	1.82	;	Crystal structure of aqualigase bound with Suc-AAPF
2EVU	;	2.3	;	Crystal structure of aquaporin AqpM at 2.3A resolution
2ABM	;	3.2	;	Crystal Structure of Aquaporin Z Tetramer Reveals both Open and Closed Water-conducting Channels
1IH5	;	3.7	;	CRYSTAL STRUCTURE OF AQUAPORIN-1
4JLO	;	1.73	;	Crystal structure of Aquifex adenylate kinase R150K mutant
7C1O	;	2.18	;	Crystal structure of Aquifex aeolicus Era Y63A bound to GDP.AlF4-
5SZD	;	1.494	;	Crystal structure of Aquifex aeolicus Hfq at 1.5A
5SZE	;	1.5	;	Crystal structure of Aquifex aeolicus Hfq-RNA complex at 1.5A
2Z7E	;	2.3	;	Crystal structure of Aquifex aeolicus IscU with bound [2Fe-2S] cluster
2GO3	;	2.0	;	Crystal structure of Aquifex aeolicus LpxC complexed with imidazole.
2IES	;	3.1	;	Crystal Structure of Aquifex aeolicus LpxC Complexed with Pyrophosphate
2GO4	;	2.7	;	Crystal structure of Aquifex aeolicus LpxC complexed with TU-514
2IER	;	2.7	;	Crystal Structure of Aquifex aeolicus LpxC Complexed with Uridine 5'-Diphosphate
1P42	;	2.0	;	Crystal structure of Aquifex aeolicus LpxC Deacetylase (Zinc-Inhibited Form)
1YHC	;	2.1	;	Crystal structure of Aquifex aeolicus LpxC deacetylase complexed with cacodylate
1YH8	;	2.7	;	Crystal structure of Aquifex aeolicus LpxC deacetylase complexed with palmitate
6EBU	;	2.372	;	Crystal structure of Aquifex aeolicus LpxE
2CSX	;	2.7	;	Crystal structure of Aquifex aeolicus methionyl-tRNA synthetase complexed with tRNA(Met)
2CT8	;	2.7	;	Crystal structure of Aquifex aeolicus methionyl-tRNA synthetase complexed with tRNA(Met) and methionyl-adenylate anologue
1M1H	;	1.95	;	Crystal structure of Aquifex aeolicus N-utilization substance G (NusG), Space group I222
1M1G	;	2.0	;	Crystal Structure of Aquifex aeolicus N-utilization substance G (NusG), Space Group P2(1)
6Q9C	;	1.78	;	Crystal structure of Aquifex aeolicus NADH-quinone oxidoreductase subunits NuoE and NuoF bound to NADH under anaerobic conditions
1NPR	;	2.21	;	CRYSTAL STRUCTURE OF AQUIFEX AEOLICUS NUSG IN C222(1)
1NPP	;	2.0	;	CRYSTAL STRUCTURE OF AQUIFEX AEOLICUS NUSG IN P2(1)
3NB7	;	2.65	;	Crystal structure of Aquifex Aeolicus Peptidoglycan Glycosyltransferase in complex with Decarboxylated Neryl Moenomycin
3NB6	;	2.7	;	Crystal structure of Aquifex aeolicus peptidoglycan glycosyltransferase in complex with Methylphosphoryl Neryl Moenomycin
3VN5	;	1.98	;	Crystal structure of Aquifex aeolicus RNase H3
2EZ6	;	2.05	;	Crystal structure of Aquifex aeolicus RNase III (D44N) complexed with product of double-stranded RNA processing
5UI5	;	3.4	;	Crystal structure of Aquifex aeolicus sigmaN bound to promoter DNA
2E89	;	2.5	;	Crystal structure of Aquifex aeolicus TilS in a complex with ATP, Magnesium ion, and L-lysine
1PYB	;	2.5	;	Crystal Structure of Aquifex aeolicus Trbp111: a Structure-Specific tRNA Binding Protein
3D6N	;	2.3	;	Crystal Structure of Aquifex Dihydroorotase Activated by Aspartate Transcarbamoylase
1FHJ	;	1.8	;	CRYSTAL STRUCTURE OF AQUOMET HEMOGLOBIN-I OF THE MANED WOLF (CHRYSOCYON BRACHYURUS) AT 2.0 RESOLUTION.
2EH3	;	1.55	;	Crystal structure of aq_1058, a transcriptional regulator (TerR/AcrR family) from Aquifex aeolicus VF5
1OZ9	;	1.894	;	Crystal structure of AQ_1354, a hypothetical protein from Aquifex aeolicus
2P68	;	1.84	;	Crystal Structure of aq_1716 from Aquifex Aeolicus VF5
2YVT	;	1.6	;	Crystal structure of aq_1956
2DQ3	;	3.0	;	Crystal structure of aq_298
2Z4J	;	2.6	;	Crystal structure of AR LBD with SHP peptide NR Box 2
4OEA	;	2.12	;	Crystal structure of AR-LBD
4OED	;	2.79	;	Crystal structure of AR-LBD bound with co-regulator peptide
4OEY	;	1.83	;	Crystal structure of AR-LBD bound with co-regulator peptide
4OEZ	;	1.8	;	Crystal structure of AR-LBD bound with co-regulator peptide
4OFR	;	2.26	;	Crystal structure of AR-LBD bound with co-regulator peptide
4OFU	;	2.12	;	Crystal structure of AR-LBD bound with co-regulator peptide
3S7E	;	2.71	;	Crystal structure of Ara h 1
3S7I	;	2.35	;	Crystal structure of Ara h 1
4MAP	;	1.9	;	Crystal structure of Ara h 8 purified with heating
4MA6	;	2.0	;	Crystal structure of Ara h 8 with Epicatechin bound
4M9W	;	1.95	;	Crystal Structure of Ara h 8 with MES bound
6V8H	;	2.31	;	Crystal structure of Ara h 8.0201
6V8J	;	1.95	;	Crystal structure of Ara h 8.0201
6V8L	;	1.95	;	Crystal structure of Ara h 8.0201
6V8M	;	1.75	;	Crystal structure of Ara h 8.0201
6V8S	;	2.1	;	Crystal structure of Ara h 8.0201
3SD8	;	1.67	;	Crystal structure of Ara-FHNA decamer DNA
4QK0	;	2.258	;	Crystal structure of Ara127N-Se, a GH127 beta-L-arabinofuranosidase from Geobacillus Stearothermophilus T6
4NT2	;	2.403	;	Crystal structure of Arabidopsis ACD11 (accelerated-cell-death 11) complexed with lyso-sphingomyelin (d18:1) at 2.4 Angstrom resolution
7DLW	;	2.19	;	Crystal structure of Arabidopsis ACS7 in complex with PPG
7DLY	;	2.94	;	Crystal structure of Arabidopsis ACS7 mutant in complex with PPG
6J23	;	1.9	;	Crystal structure of arabidopsis ADAL complexed with GMP
6J4T	;	1.82	;	Crystal structure of arabidopsis ADAL complexed with IMP
4G0Y	;	1.65	;	Crystal structure of Arabidopsis AGO1 in complex with AMP
7CCE	;	2.404	;	crystal structure of Arabidopsis AIPP3 BAH domain in complex with an H3K27me3 peptide
6LQF	;	1.5	;	Crystal structure of Arabidopsis ARID5 ARID-PHD cassette in complex with H3K4me3 peptide and DNA
6LQE	;	1.9	;	Crystal structure of Arabidopsis ARID5 PHD finger in complex with H3K4me3 peptide
7CK1	;	2.35	;	Crystal structure of arabidopsis CESA3 catalytic domain
7CK3	;	2.9	;	Crystal structure of Arabidopsis CESA3 catalytic domain
7CK2	;	2.05	;	Crystal structure of Arabidopsis CESA3 catalytic domain with UDP-Glucose
2Z51	;	1.35	;	Crystal structure of Arabidopsis CnfU involved in iron-sulfur cluster biosynthesis
7CVQ	;	3.3	;	crystal structure of Arabidopsis CO CCT domain in complex with NF-YB2/YC3 and FT CORE1 DNA
7CVO	;	2.6	;	crystal structure of Arabidopsis CO CCT domain in complex with NF-YB3/YC4 and FT CORE2 DNA
6L08	;	2.999	;	Crystal structure of Arabidopsis cytidine deaminase
3VPY	;	1.7	;	Crystal structure of Arabidopsis DDL FHA domain
6BMB	;	2.077	;	Crystal structure of Arabidopsis Dehydroquinate dehydratase-shikimate dehydrogenase (T381G mutant) in complex with tartrate and shikimate
6BMQ	;	2.077	;	Crystal structure of Arabidopsis Dehydroquinate dehydratase-shikimate dehydrogenase (T381G mutant) in complex with tartrate and shikimate
2GPT	;	1.95	;	Crystal structure of Arabidopsis Dehydroquinate dehydratase-shikimate dehydrogenase in complex with tartrate and shikimate
4IH4	;	3.5	;	Crystal structure of Arabidopsis DWARF14 orthologue, AtD14
3T33	;	2.25	;	Crystal Structure of Arabidopsis GCR2
4EPM	;	2.099	;	Crystal Structure of Arabidopsis GH3.12 (PBS3) in Complex with AMP
4N7R	;	2.802	;	Crystal structure of Arabidopsis glutamyl-tRNA reductase in complex with its binding protein
5CHE	;	3.203	;	Crystal structure of Arabidopsis glutamyl-tRNA reductase in complex with its regulatory proteins
5YJL	;	2.7	;	Crystal structure of Arabidopsis glutamyl-tRNA reductase in complex with NADPH and GBP
7EQH	;	2.2	;	Crystal structure of Arabidopsis GUN2/HO1 in complex with heme
4E8U	;	2.701	;	Crystal structure of Arabidopsis IDN2 XS domain along with a small segment of adjacent coiled-coil region
4TNM	;	2.9	;	Crystal structure of Arabidopsis importin-alpha3 armadillo repeat domain
3IPZ	;	2.4	;	Crystal structure of Arabidopsis monothiol glutaredoxin AtGRXcp
6IV5	;	1.749	;	Crystal structure of arabidopsis N6-mAMP deaminase MAPDA
7L7W	;	2.55	;	Crystal structure of Arabidopsis NRG1.1 CC-R domain K94E/K96E mutant
7L7V	;	2.95	;	Crystal structure of Arabidopsis NRG1.1 CC-R domain K94E/K96E/R99E/K100E/R103E/K106E/K110E mutant
5HH7	;	1.901	;	crystal structure of Arabidopsis ORC1b BAH-PHD cassette in complex with unmodified H3 peptide
7DE9	;	1.711	;	crystal structure of Arabidopsis RDM15 tudor domain in complex with an H3K4me1 peptide
5H3C	;	2.596	;	Crystal structure of Arabidopsis SNC1 TIR domain
7ET4	;	2.7	;	Crystal structure of Arabidopsis TEM1 AP2 domain
7ET5	;	1.052	;	Crystal structure of Arabidopsis TEM1 AP2 domain
7ET6	;	2.7	;	Crystal structure of Arabidopsis TEM1 B3-DNA complex
8QT5	;	2.69	;	Crystal structure of Arabidopsis thaliana 14-3-3 isoform lambda in complex with a phosphopeptide from the transcription factor BZR1.
8QTC	;	3.5	;	Crystal structure of Arabidopsis thaliana 14-3-3 omega in complex with a phosphopeptide from the transcription factor BZR1.
5XGK	;	2.8	;	Crystal structure of Arabidopsis thaliana 4-hydroxyphenylpyruvate dioxygenase (AtHPPD) complexed with its substrate 4-hydroxyphenylpyruvate acid (HPPA)
2QTG	;	1.84	;	Crystal Structure of Arabidopsis thaliana 5'-Methylthioadenosine nucleosidase in complex with 5'-methylthiotubercidin
2QTT	;	1.93	;	Crystal Structure of Arabidopsis thaliana 5'-Methylthioadenosine nucleosidase in complex with Formycin A
7PXY	;	1.4	;	Crystal structure of Arabidopsis thaliana 5-enol-pyruvyl-shikimate-3-phosphate synthase (EPSPS) in open conformation
5K6Q	;	2.952	;	Crystal structure of Arabidopsis thaliana acetohydroxyacid synthase catalytic subunit
5K3S	;	2.873	;	Crystal structure of Arabidopsis thaliana acetohydroxyacid synthase in complex with a pyrimidinyl-benzoate herbicide, bispyribac-sodium
5K2O	;	2.873	;	Crystal structure of Arabidopsis thaliana acetohydroxyacid synthase in complex with a pyrimidinyl-benzoate herbicide, pyrithiobac
5K6T	;	2.763	;	Crystal structure of Arabidopsis thaliana acetohydroxyacid synthase in complex with a sulfonylamino-carbonyl-triazolinone herbicide, propoxycarbazone-sodium
5K6R	;	2.734	;	Crystal structure of Arabidopsis thaliana acetohydroxyacid synthase in complex with a sulfonylamino-carbonyl-triazolinone herbicide, thiencarbazone-methyl
1YBH	;	2.5	;	Crystal structure of Arabidopsis thaliana Acetohydroxyacid synthase In Complex With A Sulfonylurea Herbicide Chlorimuron Ethyl
1YHZ	;	2.7	;	Crystal structure of Arabidopsis thaliana Acetohydroxyacid synthase In Complex With A Sulfonylurea Herbicide, Chlorsulfuron
1YHY	;	2.7	;	Crystal structure of Arabidopsis thaliana Acetohydroxyacid synthase In Complex With A Sulfonylurea Herbicide, Metsulfuron methyl
1YI0	;	2.7	;	Crystal structure of Arabidopsis thaliana Acetohydroxyacid synthase In Complex With A Sulfonylurea Herbicide, Sulfometuron methyl
1YI1	;	2.9	;	Crystal structure of Arabidopsis thaliana Acetohydroxyacid synthase In Complex With A Sulfonylurea Herbicide, Tribenuron methyl
5WJ1	;	2.522	;	Crystal structure of Arabidopsis thaliana acetohydroxyacid synthase in complex with a triazolopyrimidine herbicide, penoxsulam
1Z8N	;	2.8	;	Crystal structure of Arabidopsis thaliana Acetohydroxyacid synthase In Complex With An Imidazolinone Herbicide, Imazaquin
7TZZ	;	2.59	;	Crystal structure of arabidopsis thaliana acetohydroxyacid synthase P197T mutant in complex with bispyribac-sodium
7U1D	;	3.11	;	Crystal structure of arabidopsis thaliana acetohydroxyacid synthase P197T mutant in complex with chlorimuron-ethyl
8ET5	;	2.94	;	Crystal structure of arabidopsis thaliana acetohydroxyacid synthase S653T mutant in complex with amidosulfuron
7U1U	;	3.22	;	Crystal structure of arabidopsis thaliana acetohydroxyacid synthase W574L mutant
7U25	;	3.19	;	Crystal structure of arabidopsis thaliana acetohydroxyacid synthase W574L mutant in complex with bispyribac-sodium
7STQ	;	3.3	;	Crystal structure of arabidopsis thaliana acetohydroxyacid synthase W574L mutant in complex with chlorimuron-ethyl
5GJA	;	2.1	;	Crystal structure of Arabidopsis thaliana ACO2 in complex with 2-PA
5GJ9	;	2.1	;	Crystal structure of Arabidopsis thaliana ACO2 in complex with POA
5ZWZ	;	2.0	;	Crystal structure of Arabidopsis thaliana AGDP1 AGD34
3H7K	;	1.84	;	Crystal Structure of Arabidopsis thaliana Agmatine Deiminase Complexed with a Covalently Bound Reaction Intermediate
3H7C	;	1.5	;	Crystal Structure of Arabidopsis thaliana Agmatine Deiminase from Cell Free Expression
4G0X	;	1.35	;	Crystal Structure of Arabidopsis thaliana AGO1 MID domain
4G0Q	;	1.8	;	Crystal structure of Arabidopsis thaliana AGO1 MID domain in complex with CMP
4G0Z	;	1.75	;	Crystal structure of Arabidopsis thaliana AGO1 MID domain in complex with GMP
4G0P	;	1.8	;	Crystal Structure of Arabidopsis thaliana AGO1 MID domain in complex with UMP
4G0M	;	2.306	;	Crystal structure of Arabidopsis thaliana AGO2 MID domain
4G0O	;	2.186	;	Crystal structure of Arabidopsis thaliana AGO5 MID domain
3CLI	;	1.8	;	Crystal Structure of Arabidopsis thaliana Allene Oxide Synthase (AOS, cytochrome P450 74A, CYP74A) at 1.80 A Resolution
2RCL	;	2.41	;	Crystal Structure of Arabidopsis thaliana Allene Oxide Synthase (AOS, cytochrome P450 74A, CYP74A) Complexed with 12R,13S-Vernolic Acid at 2.4 A resolution
2RCH	;	1.85	;	Crystal Structure of Arabidopsis thaliana Allene Oxide Synthase (AOS, cytochrome P450 74A, CYP74A) Complexed with 13(S)-HOD at 1.85 A Resolution
3DSI	;	1.6	;	Crystal Structure of Arabidopsis thaliana Allene Oxide Synthase (AOS, cytochrome P450 74A, CYP74A) Complexed with 13(S)-HOT at 1.60 A resolution
2RCM	;	1.73	;	Crystal Structure of Arabidopsis thaliana Allene Oxide Synthase variant (F137L) (At-AOS(F137L), cytochrome P450 74A) at 1.73 A Resolution
3DSK	;	1.55	;	Crystal Structure of Arabidopsis thaliana Allene Oxide Synthase variant (F137L) (At-AOS(F137L), Cytochrome P450 74A, CYP74A) Complexed with 12R,13S-Vernolic Acid at 1.55 A Resolution
3DSJ	;	1.6	;	Crystal Structure of Arabidopsis thaliana Allene Oxide Synthase Variant (F137L) (At-AOS(F137L), cytochrome P450 74A, CYP74A) Complexed with 13(S)-HOD at 1.60 A Resolution
2CDQ	;	2.85	;	Crystal structure of Arabidopsis thaliana aspartate kinase complexed with lysine and S- adenosylmethionine
3VX8	;	3.11	;	Crystal structure of Arabidopsis thaliana Atg7NTD-Atg3 complex
6K8K	;	2.5	;	Crystal structure of Arabidopsis thaliana BIC2-CRY2 complex
5L25	;	4.11	;	Crystal Structure of Arabidopsis thaliana Bor1
5A2H	;	2.27	;	Crystal Structure of Arabidopsis thaliana Calmodulin-7
4DOI	;	1.55	;	Crystal structure of Arabidopsis thaliana chalcone isomerase At3g55120 (AtCHI)
4DOK	;	1.7	;	Crystal structure of Arabidopsis thaliana chalcone-isomerase like protein At5g05270 (AtCHIL)
6Z1C	;	1.75	;	Crystal structure of Arabidopsis thaliana CK2-alpha-1 in complex with TTP-22
8DQO	;	1.9	;	Crystal structure of Arabidopsis thaliana COSY
8DQP	;	2.48	;	Crystal structure of Arabidopsis thaliana COSY in complex with scopoletin
8DQQ	;	2.33	;	Crystal structure of Arabidopsis thaliana COSY in complex with scopoletin
8DQR	;	2.26	;	Crystal structure of Arabidopsis thaliana COSY in complex with scopoletin
6K8I	;	2.697	;	Crystal structure of Arabidopsis thaliana CRY2
3RFY	;	2.39	;	Crystal structure of arabidopsis thaliana cyclophilin 38 (ATCYP38)
4OBT	;	1.6	;	Crystal structure of Arabidopsis thaliana cytosolic triose phosphate isomerase
6NXQ	;	1.96	;	Crystal structure of Arabidopsis thaliana cytosolic triosephosphate isomerase C13A mutant
6NXR	;	1.3	;	Crystal structure of Arabidopsis thaliana cytosolic triosephosphate isomerase C13D mutant
6NXY	;	1.05	;	Crystal structure of Arabidopsis thaliana cytosolic triosephosphate isomerase C218D mutant
6NXX	;	1.64	;	Crystal structure of Arabidopsis thaliana cytosolic triosephosphate isomerase C218K mutant
6NXW	;	1.95	;	Crystal structure of Arabidopsis thaliana cytosolic triosephosphate isomerase C218S mutant
6NXS	;	1.52	;	Crystal structure of Arabidopsis thaliana cytosolic triosephosphate isomerase C218Y mutant
6DKN	;	1.8	;	CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA DECAPPING NUCLEASE DXO1
3UK7	;	2.05	;	Crystal Structure of Arabidopsis thaliana DJ-1D
4OFW	;	2.3	;	Crystal Structure of Arabidopsis thaliana DJ-1d
4OGG	;	1.6	;	Crystal Structure of Arabidopsis thaliana DJ-1d with glyoxylate as substrate analog
7TVW	;	1.48	;	Crystal structure of Arabidopsis thaliana DLK2
2J3H	;	2.5	;	Crystal structure of Arabidopsis thaliana Double Bond Reductase (AT5G16970)-Apo form
2J3I	;	2.8	;	Crystal structure of Arabidopsis thaliana Double Bond Reductase (AT5G16970)-Binary Complex
2J3J	;	2.8	;	Crystal structure of Arabidopsis thaliana Double Bond Reductase (AT5G16970)-Ternary Complex I
2J3K	;	2.8	;	Crystal structure of Arabidopsis thaliana Double Bond Reductase (AT5G16970)-Ternary Complex II
3W06	;	1.15	;	Crystal structure of Arabidopsis thaliana DWARF14 Like (AtD14L)
5Z8N	;	3.1	;	Crystal structure of Arabidopsis thaliana EBS C-terminal deletion construct in complex with an H3K4me2 peptide
5Z8L	;	2.005	;	crystal structure of Arabidopsis thaliana EBS in complex with an H3K27me3 peptide
4DOL	;	1.7	;	Crystal structure of Arabidopsis thaliana fatty-acid binding protein At1g53520 (AtFAP3)
4DOO	;	1.9	;	Crystal structure of Arabidopsis thaliana fatty-acid binding protein At3g63170 (AtFAP1)
7WIM	;	2.29	;	Crystal structure of Arabidopsis thaliana FKBP43 N-terminal domain
3TWK	;	2.3	;	Crystal structure of arabidopsis thaliana FPG
3TWL	;	1.7	;	Crystal structure of Arabidopsis thaliana FPG
3TWM	;	2.8	;	Crystal structure of Arabidopsis thaliana FPG
4EPL	;	2.007	;	Crystal Structure of Arabidopsis thaliana GH3.11 (JAR1) in Complex with JA-Ile
5HDM	;	1.25	;	Crystal structure of Arabidopsis thaliana glutamate-1-semialdehyde-2,1-aminomutase
5KJS	;	2.203	;	Crystal Structure of Arabidopsis thaliana HCT
5KJT	;	2.5	;	Crystal structure of Arabidopsis thaliana HCT in complex with p-coumaroyl-CoA
5KJU	;	2.44	;	Crystal structure of Arabidopsis thaliana HCT in complex with p-coumaroylshikimate
7VRR	;	2.95	;	Crystal structure of Arabidopsis thaliana HDT1
7VMF	;	1.32	;	Crystal structure of Arabidopsis thaliana HDT2
7VMI	;	1.8	;	Crystal structure of Arabidopsis thaliana HDT3
7VMH	;	1.85	;	Crystal structure of Arabidopsis thaliana HDT4
7E0X	;	1.887	;	Crystal structure of Arabidopsis thaliana HPPD complexed with 4-hydroxyphenylacetic acid
5YY7	;	3.298	;	Crystal structure of Arabidopsis thaliana HPPD complexed with Benquitrione
5YWK	;	2.804	;	Crystal structure of Arabidopsis thaliana HPPD complexed with Benquitrione-Methyl
5YWG	;	2.603	;	Crystal structure of Arabidopsis thaliana HPPD complexed with Mesotrione
6J63	;	2.624	;	Crystal structure of Arabidopsis thaliana HPPD complexed with NTBC
6ISD	;	2.4	;	Crystal structure of Arabidopsis thaliana HPPD complexed with sulcotrione
5YWH	;	2.72	;	Crystal structure of Arabidopsis thaliana HPPD complexed with Y13508
5YY6	;	2.401	;	Crystal structure of Arabidopsis thaliana HPPD truncated mutant complexed with Benquitrione
5YWI	;	2.58	;	Crystal structure of Arabidopsis thaliana HPPD Truncated mutant complexed with NTBC
6WAO	;	1.76	;	Crystal structure of Arabidopsis thaliana isochorismoyl-glutamate A pyruvoyl-glutamate lyase in complex with (2-(3-carboxyphenoxy)acetyl)-L-glutamic acid
6WCS	;	1.87	;	Crystal structure of Arabidopsis thaliana isochorismoyl-glutamate A pyruvoyl-glutamate lyase in complex with tartrate
6IP0	;	2.4	;	Crystal structure of Arabidopsis thaliana JMJ13 catalytic domain in complex with AKG
6IP4	;	2.6	;	Crystal structure of Arabidopsis thaliana JMJ13 catalytic domain in complex with NOG and an H3K27me3 peptide
5YKN	;	2.3	;	crystal structure of Arabidopsis thaliana JMJ14 catalytic domain
5YKO	;	2.9	;	Crystal structure of Arabidopsis thaliana JMJ14 catalytic domain in complex with NOG and H3K4me3 peptide
6YSA	;	2.01	;	Crystal structure of Arabidopsis thaliana legumain isoform beta in zymogen state
5NIJ	;	2.75	;	Crystal structure of arabidopsis thaliana legumain isoform gamma in two-chain activation state
8I6Y	;	3.26	;	Crystal structure of Arabidopsis thaliana LOX1
6N10	;	2.3	;	Crystal structure of Arabidopsis thaliana mevalonate 5-diphosphate decarboxylase 1 complexed with (R)-MVAPP
5CI6	;	3.0	;	Crystal structure of Arabidopsis thaliana MPK6
6TGX	;	1.77	;	Crystal structure of Arabidopsis thaliana NAA60 in complex with a bisubstrate analogue
6TH0	;	1.75	;	Crystal structure of Arabidopsis thaliana NAA60 in complex with acetyl-CoA
7OVU	;	1.45	;	Crystal structure of Arabidopsis thaliana NAT9 in complex with AcCoA
6JQV	;	3.42	;	Crystal structure of Arabidopsis thaliana NRP2
1U8W	;	2.4	;	Crystal structure of Arabidopsis thaliana nucleoside diphosphate kinase 1
8P26	;	3.6	;	Crystal structure of Arabidopsis thaliana PAXX
5LNU	;	1.73	;	Crystal structure of Arabidopsis thaliana Pdx1-I320 complex
5LNV	;	2.24	;	Crystal structure of Arabidopsis thaliana Pdx1-I320 complex from multiple crystals
5LNW	;	1.9	;	Crystal structure of Arabidopsis thaliana Pdx1-I320-G3P complex
5LNR	;	1.61	;	Crystal structure of Arabidopsis thaliana Pdx1-PLP complex
5LNS	;	1.91	;	Crystal structure of Arabidopsis thaliana Pdx1-R5P complex
7NHF	;	2.35	;	Crystal structure of Arabidopsis thaliana Pdx1K166R
7NHE	;	2.23	;	Crystal structure of Arabidopsis thaliana Pdx1K166R-I333 complex
5LNT	;	2.32	;	Crystal structure of Arabidopsis thaliana Pdx1K166R-preI320 complex
3M6O	;	2.0	;	Crystal structure of Arabidopsis thaliana peptide deformylase 1B (AtPDF1B)
3M6R	;	2.4	;	Crystal structure of Arabidopsis thaliana peptide deformylase 1B (AtPDF1B) G41M mutant in complex with actinonin
3M6Q	;	2.4	;	Crystal structure of Arabidopsis thaliana peptide deformylase 1B (AtPDF1B) G41Q mutant in complex with actinonin
3M6P	;	2.0	;	Crystal structure of Arabidopsis thaliana peptide deformylase 1B (AtPDF1B) in complex with actinonin
3O3J	;	3.0	;	Crystal structure of Arabidopsis thaliana peptide deformylase 1B (AtPDF1B) in complex with inhibitor 6b
3PN2	;	2.0	;	Crystal structure of Arabidopsis thaliana petide deformylase 1B (AtPDF1B) (crystallized in PEG-550-MME)
3PN6	;	2.1	;	Crystal structure of Arabidopsis thaliana petide deformylase 1B (AtPDF1B) G41M mutant
3PN5	;	2.3	;	Crystal structure of Arabidopsis thaliana petide deformylase 1B (AtPDF1B) G41Q mutant
3PN4	;	1.9	;	Crystal structure of Arabidopsis thaliana petide deformylase 1B (AtPDF1B) in complex with actinonin (crystallized in PEG-550-MME)
3PN3	;	1.3	;	Crystal structure of Arabidopsis thaliana petide deformylase 1B (AtPDF1B) in complex with inhibitor 21
6EEI	;	1.99001	;	Crystal structure of Arabidopsis thaliana phenylacetaldehyde synthase in complex with L-phenylalanine
6CZX	;	1.57	;	Crystal structure of Arabidopsis thaliana phosphoserine aminotransferase isoform 1 (AtPSAT1) in complex with PLP internal aldimine
6CZZ	;	1.7	;	Crystal structure of Arabidopsis thaliana phosphoserine aminotransferase isoform 1 (AtPSAT1) in complex with PLP-phosphoserine geminal diamine intermediate
6CZY	;	1.75	;	Crystal structure of Arabidopsis thaliana phosphoserine aminotransferase isoform 1 (AtPSAT1) in complex with Pyridoxamine-5'-phosphate (PMP)
4OUR	;	3.4	;	Crystal structure of Arabidopsis thaliana phytochrome B photosensory module
2O66	;	1.9	;	Crystal Structure of Arabidopsis thaliana PII bound to citrate
2O67	;	2.5	;	Crystal structure of Arabidopsis thaliana PII bound to malonate
7MOH	;	1.9	;	Crystal Structure of Arabidopsis thaliana Plant and Fungi Atypical Dual Specificity Phosphatase 1(AtPFA-DSP1 ) Cys150Ser in complex with 5-diphosphoinositol 1,3,4,6-tetrakisphosphate (5PP-InsP4) and phosphate in conformation B (Pi(B))
7MOG	;	1.8	;	Crystal Structure of Arabidopsis thaliana Plant and Fungi Atypical Dual Specificity Phosphatase 1(AtPFA-DSP1 ) Cys150Ser in complex with 5-PCF2 Am-InsP5, an analogue of 5-InsP7
7MOF	;	1.95	;	Crystal Structure of Arabidopsis thaliana Plant and Fungi Atypical Dual Specificity Phosphatase 1(AtPFA-DSP1 ) Cys150Ser in complex with 6-diphosphoinositol 1,2,3,4,5-pentakisphosphate 6-InsP7
7MOJ	;	1.9	;	Crystal Structure of Arabidopsis thaliana Plant and Fungi Atypical Dual Specificity Phosphatase 1(AtPFA-DSP1 ) Cys150Ser in complex with a metaphosphate intermediate
7MOI	;	1.8	;	Crystal Structure of Arabidopsis thaliana Plant and Fungi Atypical Dual Specificity Phosphatase 1(AtPFA-DSP1 ) Cys150Ser in complex with Phenyl Phosphate
7MOD	;	1.65	;	Crystal Structure of Arabidopsis thaliana Plant and Fungi Atypical Dual Specificity Phosphatase 1(AtPFA-DSP1 ) Cys150Ser in Complex with Phosphate in Conformation A (Pi(A))
7MOM	;	1.7	;	Crystal Structure of Arabidopsis thaliana Plant and Fungi Atypical Dual Specificity Phosphatase 1(AtPFA-DSP1 ) in complex with a metaphosphate intermediate
7MOK	;	1.85	;	Crystal Structure of Arabidopsis thaliana Plant and Fungi Atypical Dual Specificity Phosphatase 1(AtPFA-DSP1 ) in Complex with Phosphate in Conformation A (Pi(A))
7MOL	;	1.9	;	Crystal Structure of Arabidopsis thaliana Plant and Fungi Atypical Dual Specificity Phosphatase 1(AtPFA-DSP1 ) in complex with phosphate in conformation B (Pi(B))
7MOE	;	1.7	;	Crystal Structure of Arabidopsis thaliana Plant and Fungi Atypical Dual Specificity Phosphatase 1(AtPFA-DSP1)Cys150Ser in complex with 5-diphosphoinositol 1,2,3,4,6-pentakisphosphate (5-InsP7)
6IQI	;	2.4	;	crystal structure of Arabidopsis thaliana Profilin 2
6IQJ	;	1.922	;	crystal structure of Arabidopsis thaliana Profilin 2 complex with formin1
6IQF	;	1.457	;	crystal structure of Arabidopsis thaliana Profilin 3
6IQK	;	3.6	;	crystal structure of Arabidopsis thaliana Profilin 3
5MPW	;	1.499	;	Crystal structure of Arabidopsis thaliana RNA editing factor MORF1
5MPX	;	1.938	;	Crystal structure of Arabidopsis thaliana RNA editing factor MORF1, space group P2(1)
5MPY	;	2.247	;	Crystal structure of Arabidopsis thaliana RNA editing factor MORF9
6VCX	;	1.1	;	Crystal structure of Arabidopsis thaliana S-adenosylmethionine Synthase 1 (AtMAT1)
6VCY	;	1.82	;	Crystal structure of Arabidopsis thaliana S-adenosylmethionine Synthase 1 (AtMAT1) in complex with 5'-methylthioadenosine
6VCZ	;	1.52	;	Crystal structure of Arabidopsis thaliana S-adenosylmethionine Synthase 2 (AtMAT2)
6VD0	;	2.0	;	Crystal structure of Arabidopsis thaliana S-adenosylmethionine Synthase 2 (AtMAT2) in complex with free Methionine and AMPCPP
6VD2	;	1.97	;	Crystal structure of Arabidopsis thaliana S-adenosylmethionine Synthase 2 (AtMAT2) in complex with S-adenosylmethionine
6VD1	;	1.32	;	Crystal structure of Arabidopsis thaliana S-adenosylmethionine Synthase 2 (AtMAT2) in complex with S-adenosylmethionine and PPNP
6N5U	;	2.66	;	Crystal structure of Arabidopsis thaliana ScoI with copper bound
6AVV	;	1.51003	;	Crystal structure of Arabidopsis thaliana SOBER1
6AVX	;	1.271	;	Crystal structure of Arabidopsis thaliana SOBER1 F65L
6AVW	;	2.14449	;	Crystal structure of Arabidopsis thaliana SOBER1 L63A
7CTV	;	2.88561	;	Crystal structure of Arabidopsis thaliana SOBIR1 kinase domain D489A mutant in complex with AMP-PNP and magnesium
7CTX	;	2.907	;	Crystal structure of Arabidopsis thaliana SOBIR1 kinase domain(residues 388-401 deleted) in complex with AMP-PNP and magnesium
6O63	;	1.8	;	Crystal Structure of Arabidopsis thaliana Spermidine Synthase isoform 1 (AtSPDS1)
6O65	;	1.8	;	Crystal Structure of Arabidopsis thaliana Spermidine Synthase isoform 1 (AtSPDS1) in complex with decarboxylated S-adenosylmethionine and cyclohexylamine
6O64	;	2.0	;	Crystal Structure of Arabidopsis thaliana Spermidine Synthase isoform 2 (AtSPDS2)
8BB6	;	2.68	;	Crystal structure of Arabidopsis thaliana sucrose transporter SUC1
8K9Y	;	1.82	;	Crystal structure of Arabidopsis thaliana sulfotransferase SOT16 involved in glucosinolate biosynthesis
6A5N	;	2.4	;	Crystal structure of Arabidopsis thaliana SUVH6 in complex with methylated DNA
6A5K	;	1.9	;	Crystal structure of Arabidopsis thaliana SUVH6 in complex with SAM, form 1
6A5M	;	2.301	;	Crystal structure of Arabidopsis thaliana SUVH6 in complex with SAM, form 2
4S27	;	1.27	;	Crystal structure of Arabidopsis thaliana ThiC with bound aminoimidazole ribonucleotide, 5'-deoxyadenosine, L-methionine, Fe4S4 cluster and Fe
4S28	;	1.25	;	Crystal structure of Arabidopsis thaliana ThiC with bound aminoimidazole ribonucleotide, S-adenosylhomocysteine, Fe4S4 cluster and Fe
4S29	;	1.382	;	Crystal structure of Arabidopsis thaliana ThiC with bound imidazole ribonucleotide and Fe
4S26	;	1.85	;	Crystal structure of Arabidopsis thaliana ThiC with bound imidazole ribonucleotide, S-adenosylhomocysteine, Fe4S4 cluster and Zn (monoclinic crystal form)
4S25	;	1.45	;	Crystal structure of Arabidopsis thaliana ThiC with bound imidazole ribonucleotide, S-adenosylhomocysteine, Fe4S4 cluster and Zn (trigonal crystal form)
6J9C	;	3.102	;	Crystal structure of Arabidopsis thaliana transcription factor LEC2-DNA complex
6IJ7	;	2.701	;	Crystal Structure of Arabidopsis thaliana UGT89C1
6IJD	;	3.206	;	Crystal Structure of Arabidopsis thaliana UGT89C1 complexed with quercetin
6IJ9	;	3.0	;	Crystal Structure of Arabidopsis thaliana UGT89C1 complexed with UDP
6IJA	;	3.214	;	Crystal Structure of Arabidopsis thaliana UGT89C1 complexed with UDP-L-rhamnose
4D9S	;	1.701	;	Crystal structure of Arabidopsis thaliana UVR8 (UV Resistance locus 8)
6J9A	;	2.915	;	Crystal structure of Arabidopsis thaliana VAL1 in complex with FLC DNA fragment
7WQ5	;	2.35	;	Crystal structure of Arabidopsis transcriptional factor WRINKLED1 with dsDNA
6QTU	;	1.3	;	Crystal structure of Arabidopsis WD40 domain in complex with a BBX transcription factor
1WD3	;	1.75	;	Crystal structure of arabinofuranosidase
2D44	;	2.3	;	Crystal structure of arabinofuranosidase complexed with arabinofuranosyl-alpha-1,2-xylobiose
1WD4	;	2.07	;	Crystal structure of arabinofuranosidase complexed with arabinose
2D43	;	2.8	;	Crystal structure of arabinofuranosidase complexed with arabinotriose
4IJC	;	2.1	;	Crystal structure of arabinose dehydrogenase Ara1 from Saccharomyces cerevisiae
8K1I	;	1.95	;	Crystal structure of arabinose dehydrogenase from Candida auris
7CXO	;	3.2	;	Crystal structure of Arabinose isomerase from hybrid AI10
7CX7	;	2.49	;	Crystal structure of Arabinose isomerase from hybrid AI8
7CYY	;	2.6	;	Crystal structure of Arabinose isomerase from hybrid AI8 with Adonitol
7CH3	;	3.61	;	Crystal structure of Arabinose isomerase from hyper thermophilic bacterium Thermotoga maritima (TMAI) triple mutant (K264A, E265A, K266A)
7CWV	;	3.53	;	Crystal structure of Arabinose isomerase from hyper thermophilic bacterium Thermotoga maritima (TMAI) wt
7BVH	;	3.3	;	Crystal structure of arabinosyltransferase EmbC2-AcpM2 complex from Mycobacterium smegmatis complexed with di-arabinose
3GRA	;	2.3	;	Crystal structure of AraC family transcriptional regulator from Pseudomonas putida
1DIY	;	3.0	;	CRYSTAL STRUCTURE OF ARACHIDONIC ACID BOUND IN THE CYCLOOXYGENASE ACTIVE SITE OF PGHS-1
1U67	;	3.1	;	Crystal Structure of Arachidonic Acid Bound to a Mutant of Prostagladin H Synthase-1 that Forms Predominantly 11-HPETE.
1CVU	;	2.4	;	CRYSTAL STRUCTURE OF ARACHIDONIC ACID BOUND TO THE CYCLOOXYGENASE ACTIVE SITE OF COX-2
6OFY	;	2.2	;	Crystal Structure of Arachidonic Acid bound to V349I murine COX-2
5JD0	;	2.3	;	crystal structure of ARAP3 RhoGAP domain
4EGY	;	2.301	;	Crystal Structure of AraR(DBD) in complex with operator ORA1
5D4R	;	2.07	;	Crystal Structure of AraR(DBD) in complex with operator ORE1
4EGZ	;	2.3	;	Crystal Structure of AraR(DBD) in complex with operator ORR3
5D4S	;	1.972	;	Crystal Structure of AraR(DBD) in complex with operator ORX1
4X3H	;	2.401	;	CRYSTAL STRUCTURE OF ARC N-LOBE COMPLEXED WITH STARGAZIN PEPTIDE
4R1J	;	1.4	;	Crystal structure of Arc1p-C
3TWQ	;	2.151	;	Crystal structure of ARC4 from human Tankyrase 2 (apo form)
3TWR	;	1.55	;	Crystal structure of ARC4 from human Tankyrase 2 in complex with peptide from human 3BP2
3TWX	;	1.8	;	Crystal structure of ARC4 from human Tankyrase 2 in complex with peptide from human FNBP1 (chimeric peptide)
3TWW	;	2.0	;	Crystal structure of ARC4 from human Tankyrase 2 in complex with peptide from human LNPEP (chimeric peptide)
3TWU	;	1.8	;	Crystal structure of ARC4 from human Tankyrase 2 in complex with peptide from human MCL1
3TWT	;	1.85	;	Crystal structure of ARC4 from human Tankyrase 2 in complex with peptide from human MCL1 (chimeric peptide)
3TWV	;	2.301	;	Crystal structure of ARC4 from human Tankyrase 2 in complex with peptide from human NUMA1 (chimeric peptide)
3TWS	;	1.7	;	Crystal structure of ARC4 from human Tankyrase 2 in complex with peptide from human TERF1 (chimeric peptide)
3JRM	;	2.9	;	Crystal structure of archaeal 20S proteasome in complex with mutated P26 activator
3JSE	;	2.9	;	Crystal structure of archaeal 20S proteasome in complex with mutated P26 activator
3JTL	;	3.2	;	Crystal structure of archaeal 20S proteasome in complex with mutated P26 activator
3IPM	;	4.0	;	Crystal Structure of Archaeal 20S Proteasome in Complex with the C-terminus of PAN
4BQL	;	3.34	;	Crystal structure of archaeal actin
6CMV	;	2.45	;	Crystal structure of Archaeal Biofilm Regulator (AbfR2) from Sulfolobus acidocaldarius
1WN7	;	2.75	;	Crystal structure of archaeal family B DNA polymerase mutant
5YA6	;	1.5	;	Crystal structure of archaeal flagellin FlaB1 from Methanocaldococcus jannaschii
2DCH	;	2.06	;	Crystal structure of archaeal intron-encoded homing endonuclease I-Tsp061I
5AYV	;	1.647	;	Crystal structure of archaeal ketopantoate reductase complexed with coenzyme A and 2-oxopantoate
7OZQ	;	1.91	;	Crystal structure of archaeal L7Ae bound to eukaryotic kink-loop
1TR8	;	2.27	;	Crystal Structure of archaeal Nascent Polypeptide-associated Complex (aeNAC)
3A4L	;	1.8	;	Crystal structure of archaeal O-phosphoseryl-tRNA(Sec) kinase
3A4M	;	1.792	;	Crystal structure of archaeal O-phosphoseryl-tRNA(Sec) kinase
3A4N	;	2.5	;	Crystal structure of archaeal O-phosphoseryl-tRNA(Sec) kinase
2Z67	;	2.5	;	Crystal structure of archaeal O-phosphoseryl-tRNA(Sec) selenium transferase (SepSecS)
3WXM	;	2.3	;	Crystal structure of archaeal Pelota and GTP-bound EF1 alpha complex
2E2G	;	2.4	;	Crystal structure of archaeal peroxiredoxin, thioredoxin peroxidase from Aeropyrum pernix K1 (pre-oxidation form)
2E2M	;	2.6	;	Crystal structure of archaeal peroxiredoxin, thioredoxin peroxidase from Aeropyrum pernix K1 (sulfinic acid form)
2NVL	;	2.36	;	Crystal structure of archaeal peroxiredoxin, thioredoxin peroxidase from Aeropyrum pernix K1 (sulfonic acid form)
2E0I	;	2.8	;	Crystal structure of archaeal photolyase from Sulfolobus tokodaii with two FAD molecules: Implication of a novel light-harvesting cofactor
1FXK	;	2.3	;	CRYSTAL STRUCTURE OF ARCHAEAL PREFOLDIN (GIMC).
1WMI	;	2.3	;	Crystal structure of archaeal RelE-RelB complex from Pyrococcus horikoshii OT3
1V76	;	2.0	;	Crystal Structure of Archaeal Ribonuclease P Protein Ph1771p from Pyrococcus horikoshii OT3
6JI2	;	3.0	;	Crystal structure of archaeal ribosomal protein aP1, aPelota, and GTP-bound aEF1A complex
1GEH	;	2.8	;	CRYSTAL STRUCTURE OF ARCHAEAL RUBISCO (RIBULOSE 1,5-BISPHOSPHATE CARBOXYLASE/OXYGENASE)
3QQC	;	3.3	;	Crystal structure of archaeal Spt4/5 bound to the RNAP clamp domain
2CXC	;	2.0	;	Crystal structure of archaeal transcription termination factor NusA
5ZCY	;	1.5	;	Crystal structure of archaeal translation initiation factor 1 at 1.5 Angstroms resolution
3AGK	;	2.1	;	Crystal structure of archaeal translation termination factor, aRF1
2YY8	;	2.48	;	Crystal structure of archaeal tRNA-methylase for position 56 (aTrm56) from Pyrococcus horikoshii, complexed with S-adenosyl-L-methionine
1J1U	;	1.95	;	Crystal structure of archaeal tyrosyl-tRNA synthetase complexed with tRNA(Tyr) and L-tyrosine
2Z2U	;	2.4	;	Crystal structure of archaeal TYW1
1X2I	;	1.45	;	Crystal Structure Of Archaeal Xpf/Mus81 Homolog, Hef From Pyrococcus Furiosus, Helix-hairpin-helix Domain
1J23	;	1.78	;	Crystal structure of archaeal XPF/Mus81 homolog, Hef from Pyrococcus furiosus, nuclease domain
1J24	;	1.78	;	Crystal structure of archaeal XPF/Mus81 homolog, Hef from Pyrococcus furiosus, nuclease domain, Ca cocrystal
1J25	;	1.78	;	Crystal structure of archaeal XPF/Mus81 homolog, Hef from Pyrococcus furiosus, nuclease domain, Mn cocrystal
1J22	;	1.8	;	Crystal structure of archaeal XPF/Mus81 homolog, Hef from Pyrococcus furiosus, nuclease domain, selenomet derivative
4AXQ	;	1.4	;	CRYSTAL STRUCTURE OF ARCHAEMETZINCIN (AMZA) FROM ARCHAEOGLOBUS FULGIDUS AT 1.4 A RESOLUTION
3ZVS	;	1.396	;	Crystal structure of Archaemetzincin (AmzA) from Archaeoglobus fulgidus at 1.4 A resolution complexed with malonate
4A3W	;	2.16	;	Crystal structure of Archaemetzincin (AmzA) from Archaeoglobus fulgidus at 2.16 A resolution complexed with citrate
2X7M	;	1.5	;	Crystal structure of Archaemetzincin (amzA) from Methanopyrus kandleri at 1.5 A resolution
5A1Q	;	1.6	;	Crystal structure of Archaeoglobus fulgidus Af1502
8OLD	;	1.85	;	Crystal structure of Archaeoglobus fulgidus AfAgo-N protein representing N-L1-L2 domains
8OLJ	;	1.4	;	Crystal structure of Archaeoglobus fulgidus AfAgo-N protein representing N-L1-L2 domains
2ZVF	;	3.2	;	Crystal structure of Archaeoglobus fulgidus alanyl-tRNA synthetase C-terminal dimerization domain
3WQZ	;	3.489	;	Crystal structure of Archaeoglobus fulgidus alanyl-tRNA synthetase in complex with a tRNA(Ala) variant having A3.U70
3WQY	;	3.3	;	Crystal structure of Archaeoglobus fulgidus alanyl-tRNA synthetase in complex with wild-type tRNA(Ala) having G3.U70
2ZTG	;	2.2	;	Crystal structure of Archaeoglobus fulgidus alanyl-tRNA synthetase lacking the C-terminal dimerization domain in complex with Ala-SA
6TUO	;	1.8	;	Crystal structure of Archaeoglobus fulgidus Argonaute protein with cognate DNA oligoduplex 5'-pATTGTACGTACAAT
6T5T	;	1.7003	;	Crystal structure of Archaeoglobus fulgidus Argonaute protein with cognate DNA oligoduplex 5'-pATTGTGGCCACAAT
4MND	;	2.66	;	Crystal structure of Archaeoglobus fulgidus IPCT-DIPPS bifunctional membrane protein
3O7B	;	1.45	;	Crystal structure of Archaeoglobus Fulgidus Nep1 bound to S-adenosylhomocysteine
2DU4	;	2.8	;	Crystal structure of Archaeoglobus fulgidus O-phosphoseryl-tRNA synthetase complexed with tRNACys
2DU3	;	2.6	;	Crystal structure of Archaeoglobus fulgidus O-phosphoseryl-tRNA synthetase complexed with tRNACys and O-phosphoserine
2DU6	;	3.3	;	Crystal structure of Archaeoglobus fulgidus O-phosphoseryl-tRNA synthetase E418N/E420N mutant complexed with tRNAAmber and O-phosphoserine (""amber complex"")
2DU5	;	3.2	;	Crystal structure of Archaeoglobus fulgidus O-phosphoseryl-tRNA synthetase E418N/E420N mutant complexed with tRNAOpal and O-phosphoserine (""opal complex"")
3OBY	;	2.9	;	Crystal structure of Archaeoglobus fulgidus Pelota reveals inter-domain structural plasticity
3RE4	;	1.997	;	Crystal Structure of Archaeoglobus Fulgidus Rio1 Kinase bound to Toyocamycin.
1IT7	;	2.3	;	Crystal structure of archaeosine tRNA-guanine transglycosylase complexed with guanine
1J2B	;	3.3	;	Crystal Structure Of Archaeosine tRNA-Guanine Transglycosylase Complexed With lambda-form tRNA(Val)
1IQ8	;	2.2	;	Crystal Structure of archaeosine tRNA-guanine transglycosylase from Pyrococcus horikoshii
1IT8	;	2.5	;	Crystal structure of archaeosine tRNA-guanine transglycosylase from Pyrococcus horikoshii complexed with archaeosine precursor, preQ0
1UAZ	;	3.4	;	Crystal structure of archaerhodopsin-1
1VGO	;	2.5	;	Crystal Structure of Archaerhodopsin-2
3WQJ	;	1.8	;	Crystal structure of archaerhodopsin-2 at 1.8 angstrom resolution
2CZV	;	2.0	;	Crystal structure of archeal RNase P protein ph1481p in complex with ph1877p
6HCT	;	3.091	;	Crystal structure of Archeoglobus fulgidus L7Ae bound to its cognate UTR k-turn
6AG5	;	2.32	;	Crystal structure of Ard1 N-terminal acetyltransferase E88H/H127E mutant from Sulfolobus solfataricus
4R3K	;	2.133	;	Crystal structure of Ard1 N-terminal acetyltransferase from Sulfolobus solfataricus bound to CoA
4R3L	;	1.839	;	Crystal structure of Ard1 N-terminal acetyltransferase from Sulfolobus solfataricus bound to substrate peptide fragment and CoA
5C88	;	2.49	;	Crystal structure of Ard1 N-terminal acetyltransferase from Sulfolobus solfataricus in monoclinic form
6AG4	;	2.256	;	Crystal structure of Ard1 N-terminal acetyltransferase H88A/E127A mutant from Sulfolobus solfataricus
3TJZ	;	2.9	;	Crystal Structure of Arf1 Bound to the gamma/zeta-COP Core Complex
7RLL	;	1.9	;	Crystal structure of ARF3 from Candida albicans in complex with guanosine-3'-monophosphate-5'-diphosphate
3N5C	;	1.82	;	Crystal Structure of Arf6DELTA13 complexed with GDP
3JUE	;	2.3	;	Crystal Structure of ArfGAP and ANK repeat domain of ACAP1
3O47	;	2.8	;	Crystal structure of ARFGAP1-ARF1 fusion protein
2X45	;	1.4	;	Crystal Structure of Arg r 1 in complex with histamine
4EIH	;	1.2	;	Crystal structure of Arg SH2 domain
5GT7	;	2.048	;	Crystal Structure of Arg-bound CASTOR1
4OLJ	;	1.49	;	Crystal structure of Arg119Gln mutant of Peptidyl-tRNA Hydrolase from Acinetobacter Baumannii at 1.49 A resolution
2E17	;	1.9	;	Crystal structure of Arg173 to Ala mutant of Diphthine synthase
2E15	;	1.8	;	Crystal structure of Arg173 to Asn mutant of Diphthine synthase
6H2P	;	1.479	;	Crystal Structure of Arg184Gln mutant of Human Prolidase with Mn ions and Cacodylate ligand
5MBY	;	1.55	;	Crystal Structure of Arg184Gln mutant of Human Prolidase with Mn ions and GlyPro ligand
6H2Q	;	1.78	;	Crystal Structure of Arg184Gln mutant of Human Prolidase with Mn ions and LeuPro ligand
3QAL	;	1.7	;	Crystal Structure of Arg280Ala mutant of Catalytic subunit of cAMP-dependent Protein Kinase
1ZKW	;	2.17	;	Crystal structure of Arg347Ala mutant of botulinum neurotoxin E catalytic domain
1JRX	;	2.0	;	Crystal structure of Arg402Ala mutant flavocytochrome c3 from Shewanella frigidimarina
1JRY	;	2.0	;	Crystal structure of Arg402Lys mutant flavocytochrome c3 from Shewanella frigidimarina
1JRZ	;	2.0	;	Crystal structure of Arg402Tyr mutant flavocytochrome c3 from Shewanella frigidimarina
6QSB	;	1.99	;	Crystal Structure of Arg470His mutant of Human Prolidase with Mn ions
6QSC	;	1.569	;	Crystal Structure of Arg470His mutant of Human Prolidase with Mn ions and GlyPro ligand
6NBK	;	1.91	;	Crystal structure of Arginase from Bacillus cereus
6DKT	;	2.08	;	Crystal structure of Arginase from Bacillus subtilis
6KSY	;	1.649	;	Crystal structure of arginase from Zymomonas mobilis ZM4
1VRA	;	2.0	;	Crystal structure of Arginine biosynthesis bifunctional protein argJ (10175521) from Bacillus halodurans at 2.00 A resolution
5XX1	;	3.1	;	Crystal structure of Arginine decarboxylase (AdiA) from Salmonella typhimurium
1S9R	;	1.6	;	CRYSTAL STRUCTURE OF ARGININE DEIMINASE COVALENTLY LINKED WITH A REACTION INTERMEDIATE
1LXY	;	2.0	;	Crystal Structure of Arginine Deiminase covalently linked with L-citrulline
4BOF	;	2.48	;	Crystal structure of arginine deiminase from group A streptococcus
4E4J	;	2.3	;	Crystal structure of arginine deiminase from Mycoplasma penetrans
4LT4	;	1.69	;	Crystal structure of arginine inhibited Ribosome inactivating protein from Momordica balsamina at 1.69 A resolution
7EWS	;	2.0	;	Crystal structure of arginine kinase (AK3) from the ciliate Paramecium tetraurelia
5U92	;	2.0	;	Crystal Structure of arginine kinase from the spider Polybetes pythagoricus in complex with arginine
4GVZ	;	2.96	;	Crystal structure of arginine kinase in complex with D-arginine, MgADP, and nitrate.
4GW0	;	2.448	;	Crystal structure of arginine kinase in complex with imino-L-ornithine, MgADP, and nitrate.
4GVY	;	2.091	;	Crystal structure of arginine kinase in complex with L-citrulline and MgADP
4GW2	;	2.157	;	Crystal structure of arginine kinase in complex with L-ornithine, MgADP, and nitrate.
6KY2	;	1.87	;	Crystal Structure of Arginine Kinase wild type from Daphnia magna
6WJP	;	1.701	;	Crystal structure of Arginine Repressor P115Q mutant from the pathogenic bacterium Corynebacterium pseudotuberculosis bound to arginine
5GV2	;	2.06	;	Crystal structure of Arginine-bound CASTOR1 from Homo sapiens
3MD0	;	2.45	;	Crystal structure of arginine/ornithine transport system ATPase from Mycobacterium tuberculosis bound to GDP (a RAS-like GTPase superfamily protein)
6IG5	;	2.078	;	Crystal structure of argininosuccinate lyase from Mycobacterium tuberculosis
6IGA	;	2.776	;	Crystal structure of argininosuccinate lyase from Mycobacterium tuberculosis
1VL2	;	1.65	;	Crystal structure of Argininosuccinate synthase (TM1780) from Thermotoga maritima at 1.65 A resolution
6XNQ	;	1.95	;	Crystal Structure of Argininosuccinate synthase from Legionella pneumophila Philadelphia 1
7K5Z	;	1.85	;	Crystal Structure of Argininosuccinate synthase from Legionella pneumophila Philadelphia 1 in complex with ANPPNP and a substrate analogue Arginine
4U7J	;	1.75	;	Crystal structure of Argininosuccinate synthase from Mycobacterium thermoresistibile
4XFJ	;	1.55	;	Crystal structure of Argininosuccinate synthase from Mycobacterium thermoresistibile in complex with AMPPNP and Arginine
4Q2Y	;	2.799	;	Crystal structure of Arginyl-tRNA synthetase
4Q2T	;	2.4	;	Crystal structure of Arginyl-tRNA synthetase complexed with L-arginine
4Q2X	;	2.798	;	Crystal structure of Arginyl-tRNA synthetase complexed with L-canavanine
3GDZ	;	2.2	;	Crystal structure of arginyl-tRNA synthetase from Klebsiella pneumoniae subsp. pneumoniae
5JLD	;	2.2	;	Crystal Structure of Arginyl-tRNA Synthetase from Plasmodium falciparum (PfRRS)
6AO8	;	1.7	;	Crystal structure of arginyl-tRNA_synthetase from Neisseria gonorrhoeae in complex with arginine
3ISP	;	2.7	;	Crystal structure of ArgP from Mycobacterium tuberculosis
6JUY	;	2.97	;	Crystal Structure of ArgZ, apo structure, an Arginine Dihydrolase from the Ornithine-Ammonia Cycle in Cyanobacteria
6K96	;	2.5	;	Crystal structure of Ari2
3A01	;	2.7	;	Crystal structure of Aristaless and Clawless homeodomains bound to DNA
3A02	;	1.0	;	Crystal structure of Aristaless homeodomain
3BNY	;	1.89	;	Crystal structure of aristolochene synthase complexed with 2-fluorofarnesyl diphosphate (2F-FPP)
3BNX	;	2.1	;	Crystal structure of Aristolochene synthase complexed with farnesyl diphosphate
1DI1	;	2.5	;	CRYSTAL STRUCTURE OF ARISTOLOCHENE SYNTHASE FROM PENICILLIUM ROQUEFORTI
3CKE	;	2.4	;	Crystal structure of aristolochene synthase in complex with 12,13-difluorofarnesyl diphosphate
5J5C	;	3.4	;	Crystal structure of ARL1-GTP and DCB domain of BIG1 complex
5DI3	;	2.5	;	Crystal structure of Arl13B in complex with Arl3 of Chlamydomonas reinhardtii
5CYA	;	2.0	;	Crystal structure of Arl2 GTPase-activating protein tubulin cofactor C (TBCC)
3AU3	;	2.1	;	Crystal structure of armadillo repeat domain of APC
3NMW	;	1.6	;	Crystal structure of armadillo repeats domain of APC
1Z75	;	2.4	;	Crystal Structure of ArnA dehydrogenase (decarboxylase) domain, R619M mutant
1MDZ	;	2.07	;	Crystal structure of ArnB aminotransferase with cycloserine and pyridoxal 5' phosphate
1MDO	;	1.7	;	Crystal structure of ArnB aminotransferase with pyridomine 5' phosphate
8SNJ	;	1.75	;	Crystal Structure of ArnB Transferase from Klebsiella aerogenes (Lattice Translocation Disorder, P1 form)
8SU6	;	1.5	;	Crystal Structure of ArnB Transferase from Klebsiella aerogenes (Lattice Translocation Disorder, P1 form2)
8SNG	;	1.55	;	Crystal Structure of ArnB Transferase from Klebsiella aerogenes (Lattice Translocation Disorder, P21 form)
1MDX	;	1.96	;	Crystal structure of ArnB transferase with pyridoxal 5' phosphate
4Z21	;	2.05	;	Crystal structure of ARNO Sec7
5F15	;	3.2	;	Crystal Structure of ArnT from Cupriavidus metallidurans bound to Undecaprenyl phosphate
5EZM	;	2.7	;	Crystal Structure of ArnT from Cupriavidus metallidurans in the apo state
2B02	;	1.5	;	Crystal Structure of ARNT PAS-B Domain
7RCA	;	2.26	;	Crystal structure of Aro2p chorismate synthase from Candida lusitaniae
7REU	;	2.79	;	Crystal structure of Aro4p, 3-deoxy-D-arabino-heptulosonate-7-phosphate (DAHP) synthase from Candida auris, L-Tyr complex
7RJ1	;	2.16	;	Crystal structure of Aro7p chorismate mutase from Candida albicans, complex with L-Trp
2AH1	;	1.2	;	Crystal structure of aromatic amine dehydrogenase (AADH) from Alcaligenes faecalis
2I0R	;	1.4	;	Crystal structure of aromatic amine dehydrogenase TTQ-formamide adduct
2OK6	;	1.45	;	Crystal structure of aromatic amine dehydrogenase TTQ-formamide adduct oxidized with ferricyanide.
2I0S	;	1.4	;	Crystal structure of aromatic amine dehydrogenase TTQ-phenylacetaldehyde adduct
2OK4	;	1.45	;	Crystal structure of aromatic amine dehydrogenase TTQ-phenylacetaldehyde adduct oxidized with ferricyanide
1DJU	;	2.1	;	CRYSTAL STRUCTURE OF AROMATIC AMINOTRANSFERASE FROM PYROCOCCUS HORIKOSHII OT3
5EB8	;	2.22	;	Crystal structure of aromatic mutant (F4W) of an alkali thermostable GH10 xylanase from Bacillus sp. NG-27
5EBA	;	2.3	;	Crystal structure of aromatic mutant (Y343A) of an alkali thermostable GH10 xylanase from Bacillus sp. NG-27
4EFF	;	1.85	;	Crystal structure of aromatic-amino-acid aminotransferase from Burkholderia pseudomallei
4F4E	;	1.8	;	Crystal structure of Aromatic-amino-acid aminotransferase from Burkholderia pseudomallei covalently bound to pyridoxal phosphate
1K8K	;	2.0	;	Crystal Structure of Arp2/3 Complex
1U2V	;	2.55	;	Crystal structure of Arp2/3 complex with bound ADP and calcium
1TYQ	;	2.55	;	Crystal structure of Arp2/3 complex with bound ATP and calcium
6E4F	;	1.15	;	Crystal structure of ARQ 531 in complex with the kinase domain of BTK
3P2D	;	3.0	;	Crystal structure of arrestin-3 reveals the basis of the difference in receptor binding between two non-visual subtypes
3GC3	;	2.2	;	Crystal Structure of Arrestin2S and Clathrin
4HDR	;	1.45	;	Crystal Structure of ArsAB in Complex with 5,6-dimethylbenzimidazole
4HDM	;	1.95	;	Crystal Structure of ArsAB in Complex with p-cresol
4HDS	;	2.4	;	Crystal Structure of ArsAB in Complex with Phenol.
4HDK	;	1.5	;	Crystal Structure of ArsAB in Complex with Phloroglucinol
4HDN	;	2.24	;	Crystal Structure of ArsAB in the Substrate-Free State.
3KGK	;	1.4	;	Crystal structure of ArsD
1Y1L	;	2.8	;	Crystal structure of arsenate reductase from Archaeoglobus fulgidus DSM 4304, structural genomics
3KTB	;	2.1	;	Crystal Structure of Arsenical Resistance Operon Trans-acting Repressor from Bacteroides vulgatus ATCC 8482
8CGS	;	1.84	;	Crystal structure of arsenite oxidase from Alcaligenes faecalis (Af Aio) bound to antimony oxyanion
8CH9	;	1.43	;	Crystal structure of arsenite oxidase from Alcaligenes faecalis (Af Aio) bound to arsenic oxyanion
8CFF	;	1.57	;	Crystal structure of arsenite oxidase from Alcaligenes faecalis (Af Aio) bound to arsenite
8CCQ	;	1.89	;	Crystal structure of arsenite oxidase from Pseudorhizobium banfieldiae str. NT-26 (NT-26 Aio) bound to antimony trioxide
8C63	;	1.52	;	Crystal structure of arsenoplatin-1/B-DNA adduct obtained upon 4 h of soaking
8C64	;	2.51	;	Crystal structure of arsenoplatin-1/B-DNA adduct obtained upon 48 h of soaking
2Q62	;	1.8	;	Crystal Structure of ArsH from Sinorhizobium meliloti
5C4P	;	1.97	;	Crystal structure of ArsI C-As lyase solved by Ni-SAD phasing
5JTF	;	2.156	;	Crystal structure of ArsN N-acetyltransferase from Pseudomonas putida KT2440
5WPH	;	2.19	;	Crystal structure of ArsN, N-acetyltransferase with substrate AST from Pseudomonas putida KT2440
6M7G	;	2.657	;	Crystal structure of ArsN, N-acetyltransferase with substrate phosphinothricin from Pseudomonas putida KT2440
3F6O	;	1.9	;	Crystal structure of ArsR family transcriptional regulator, RHA00566
5WHV	;	2.303	;	Crystal structure of ArtB
4N0N	;	2.0	;	Crystal structure of Arterivirus nonstructural protein 10 (helicase)
1RWA	;	1.3	;	Crystal structure of Arthrobacter aurescens chondroitin AC lyase
1RWC	;	1.9	;	Crystal structure of Arthrobacter aurescens chondroitin AC lyase
1RWF	;	1.45	;	Crystal structure of Arthrobacter aurescens chondroitin AC lyase in complex with chondroitin tetrasaccharide
1RWG	;	1.5	;	Crystal structure of Arthrobacter aurescens chondroitin AC lyase in complex with chondroitin tetrasaccharide
1RWH	;	1.25	;	Crystal structure of Arthrobacter aurescens chondroitin AC lyase in complex with chondroitin tetrasaccharide
5ZFS	;	1.96	;	Crystal structure of Arthrobacter globiformis M30 sugar epimerase which can produce D-allulose from D-fructose
1Q4S	;	1.95	;	Crystal structure of Arthrobacter sp. strain SU 4-hydroxybenzoyl CoA thioesterase complexed with CoA and 4-hydroxybenzoic acid
3TEA	;	1.8	;	Crystal structure of Arthrobacter sp. strain su 4-hydroxybenzoyl CoA thioesterase double mutant Q58E/E73A complexed with 4-hydroxyphenacyl CoA
3R32	;	1.8	;	Crystal structure of Arthrobacter sp. strain SU 4-hydroxybenzoyl CoA thioesterase mutant E73A complexed with 4-hydroxyphenacyl CoA
3R35	;	1.8	;	Crystal structure of Arthrobacter sp. strain SU 4-hydroxybenzoyl CoA thioesterase mutant E73D complexed with 4-hydroxyphenacyl CoA
3R34	;	1.8	;	Crystal structure of Arthrobacter sp. strain SU 4-hydroxybenzoyl CoA thioesterase mutant E73D complexed with CoA
3R36	;	1.95	;	Crystal structure of Arthrobacter sp. strain SU 4-hydroxybenzoyl CoA thioesterase mutant E73Q complexed with 4-hydroxybenzoic acid
3R37	;	1.8	;	Crystal structure of Arthrobacter sp. strain SU 4-hydroxybenzoyl CoA thioesterase mutant E73Q complexed with 4-hydroxyphenacyl CoA
3R3C	;	1.8	;	Crystal structure of Arthrobacter sp. strain SU 4-hydroxybenzoyl CoA thioesterase mutant H64A complexed with 4-hydroxyphenacyl CoA
3R3A	;	1.8	;	Crystal structure of Arthrobacter sp. strain SU 4-hydroxybenzoyl CoA thioesterase mutant Q58A complexed with 4-hydroxybenzoic acid and CoA
3R3B	;	1.8	;	Crystal structure of Arthrobacter sp. strain SU 4-hydroxybenzoyl CoA thioesterase mutant Q58A complexed with 4-hydroxyphenacyl CoA
3R3F	;	1.75	;	Crystal structure of Arthrobacter sp. strain SU 4-hydroxybenzoyl CoA thioesterase mutant T77A complexed with 4-hydroxyphenacyl CoA
3R3D	;	1.75	;	Crystal structure of Arthrobacter sp. strain SU 4-hydroxybenzoyl CoA thioesterase mutant T77S complexed with 4-hydroxyphenacyl CoA
4HLL	;	2.2	;	Crystal structure of Artificial ankyrin repeat protein_Ank(GAG)1D4
4ZFH	;	1.89	;	Crystal structure of Artificial ankyrin repeat protein_Ank(GAG)1D4 mutant -Y56A
4WVZ	;	2.09	;	Crystal structure of artificial crosslinked thiol dioxygenase G95C variant from Pseudomonas aeruginosa
1VBP	;	3.5	;	Crystal structure of artocarpin-mannopentose complex
1VBO	;	2.35	;	Crystal structure of artocarpin-mannotriose complex
6E8O	;	1.7	;	Crystal structure of aryl acid adenylating enzyme FscC from Fuscachelin NRPS in complex with AMP
5OC1	;	2.3	;	Crystal structure of aryl-alcohol oxidase from Pleurotus eryngii in complex with p-anisic acid
3FIM	;	2.55	;	Crystal structure of aryl-alcohol-oxidase from Pleurotus eryingii
4FD5	;	1.64	;	Crystal structure of arylalkylamine N-Acetyltransferase 2 from Aedes aegypti
3DTV	;	2.1	;	Crystal structure of arylmalonate decarboxylase
3EIS	;	2.1	;	Crystal Structure of Arylmalonate Decarboxylase
3IP8	;	1.498	;	Crystal structure of arylmalonate decarboxylase (AMDase) from Bordatella bronchiseptic in complex with benzylphosphonate
6QPU	;	2.25	;	Crystal structure of as isolated synthetic core domain of nitrite reductase from Ralstonia pickettii (residues 1-331)
6TFO	;	2.05	;	Crystal structure of as isolated three-domain copper-containing nitrite reductase from Hyphomicrobium denitrificans strain 1NES1
6QPV	;	1.6	;	Crystal structure of as isolated Y323A mutant of haem-Cu containing nitrite reductase from Ralstonia pickettii
6QPZ	;	1.65	;	Crystal structure of as isolated Y323E mutant of haem-Cu containing nitrite reductase from Ralstonia pickettii
6QQ1	;	1.75	;	Crystal structure of as isolated Y323F mutant of haem-Cu containing nitrite reductase from Ralstonia pickettii
7R2U	;	1.5	;	CRYSTAL STRUCTURE OF AS-ISOLATED Q262N MUTANT OF THREE-DOMAIN HEME-CU NITRITE REDUCTASE FROM RALSTONIA PICKETTII
7QQ2	;	2.1	;	CRYSTAL STRUCTURE OF AS-ISOLATED S321M MUTANT OF THREE-DOMAIN HEME-CU NITRITE REDUCTASE FROM RALSTONIA PICKETTII
7SJZ	;	1.85	;	Crystal structure of aS162A mutant of Co-type nitrile hydratase from Pseudonocardia thermophila
8HLO	;	1.168	;	Crystal structure of ASAP1-SH3 and MICAL1-PRM complex
8OYG	;	2.3	;	Crystal structure of ASBTNM in complex with pantoate
8OYF	;	2.1	;	Crystal structure of ASBTNM in lipidic cubic phase without substrate bound
7E5B	;	2.29	;	Crystal structure of ASC PYD Domain and Rb-B7
1F32	;	1.75	;	CRYSTAL STRUCTURE OF ASCARIS PEPSIN INHIBITOR-3
1F34	;	2.45	;	CRYSTAL STRUCTURE OF ASCARIS PEPSIN INHIBITOR-3 BOUND TO PORCINE PEPSIN
1O0S	;	2.0	;	Crystal Structure of Ascaris suum Malic Enzyme Complexed with NADH
5GUS	;	1.951	;	Crystal structure of ASCH domain from Zymomonas mobilis
5GUQ	;	1.697	;	Crystal structure of ASCH from Zymomonas mobilis
7S10	;	1.40001	;	Crystal Structure of ascorbate peroxidase triple mutant: S160M, L203M, Q204M
4O79	;	2.003	;	Crystal Structure of Ascorbate-bound Cytochrome b561, crystal soaked in 1 M L-ascorbate for 10 minutes
4O7G	;	2.211	;	Crystal Structure of Ascorbate-bound Cytochrome b561, crystal soaked in 1 M L-ascorbate for 40 minutes
8I40	;	2.79	;	Crystal structure of ASCT from Trypanosoma brucei in complex with CoA.
8I3Y	;	2.4	;	Crystal structure of ASCT from Trypanosoma brucei in complex with Succinyl-CoA.
6A6Y	;	2.491	;	Crystal Structure of Asf1 from Plasmodium falciparum
6AYZ	;	2.096	;	Crystal structure of Asf1-Fab 12E complex
6AZ2	;	2.477	;	Crystal structure of Asf1-Fab 12E complex
6KY8	;	2.301	;	Crystal structure of ASFV dUTPase
6KZ6	;	2.187	;	Crystal structure of ASFV dUTPase
6KY9	;	1.7	;	Crystal structure of ASFV dUTPase and UMP complex
7BQ9	;	2.612	;	Crystal structure of ASFV p15
7BQA	;	2.102	;	Crystal structure of ASFV p35
3GWL	;	2.1	;	Crystal structure of ASFV pB119L, a viral sulfhydryl oxidase
6LJB	;	2.487	;	Crystal Structure of ASFV pS273R protease
8HDL	;	3.198	;	Crystal structure of ASFV trans geranylgeranyl diphosphate synthase B318L
7YPF	;	2.5	;	Crystal structure of AsfvPCNA in space group of P1
7YPE	;	2.2	;	Crystal structure of AsfvPCNA in space group of P63
8E9A	;	2.69	;	Crystal structure of AsfvPolX in complex with 10-23 DNAzyme and Mg
5XM8	;	2.55	;	Crystal structure of AsfvPolX in complex with DNA enzyme and Pb.
5XMA	;	3.8	;	Crystal structure of AsfvPolX in complex with DNA enzyme at P43212 space group
5XM9	;	3.053	;	Crystal structure of AsfvPolX in complex with DNA enzyme.
8IQB	;	2.58	;	Crystal structure of AsfvPrimPol N-terminal Prim/Pol domain
8IQC	;	2.0	;	Crystal structure of AsfvPrimPol N-terminal Prim/Pol domain in complex with Mn2+
8IQD	;	2.39	;	Crystal structure of AsfvPrimPol N-terminal Prim/Pol domain in complex with Mn2+ and dCTP
6YAU	;	1.397	;	CRYSTAL STRUCTURE OF ASGPR 1 IN COMPLEX WITH GN-A.
3S32	;	2.45	;	Crystal structure of Ash2L N-terminal domain
4X8N	;	2.1	;	Crystal structure of Ash2L SPRY domain in complex with phosphorylated RbBP5
4X8P	;	2.2	;	Crystal structure of Ash2L SPRY domain in complex with RbBP5
5BTB	;	1.8	;	Crystal Structure of Ashbya gossypii Rai1
5BTE	;	2.4	;	Crystal structure of Ashbya gossypii Rai1 in complex with pU(S)6-Mn2+
1EMY	;	1.78	;	CRYSTAL STRUCTURE OF ASIAN ELEPHANT (ELEPHAS MAXIMUS) CYANO-MET MYOGLOBIN AT 1.78 ANGSTROMS RESOLUTION. PHE 29 (B10) ACCOUNTS FOR ITS UNUSUAL LIGAND BINDING PROPERTIES
5VIO	;	2.84	;	Crystal structure of ASK1 kinase domain with a potent inhibitor (analog 13)
5VIL	;	2.64	;	Crystal structure of ASK1 kinase domain with a potent inhibitor (analog 6)
6BRO	;	2.5	;	Crystal structure of ASK1-D3 ubiquitin ligase form1
4TUC	;	3.6	;	Crystal structure of ASL-SufJ bound to Codon ACC-A on the Ribosome
4TUD	;	3.6	;	Crystal structure of ASL-SufJ bound to Codon ACC-C on the Ribosome
4TUE	;	3.5	;	Crystal structure of ASL-SufJ bound to Codon ACC-U on the Ribosome
4TUA	;	3.6	;	Crystal structure of ASL-Thr bound to Codon ACC-A on the Ribosome
2ESU	;	1.94	;	Crystal structure of Asn to Gln mutant of Winged Bean Chymotrypsin Inhibitor protein
2BEA	;	2.35	;	Crystal structure of Asn14 to Gly mutant of WCI
2DXX	;	1.75	;	Crystal structure of Asn142 to Glu mutant of Diphthine synthase
7A6S	;	1.75	;	Crystal Structure of Asn173Ser variant of Human Deoxyhypusine Synthase
7A6T	;	1.66	;	Crystal Structure of Asn173Ser variant of Human Deoxyhypusine Synthase in complex with NAD and spermidine
2EHC	;	1.8	;	Crystal structure of Asn69 to Lys mutant of Diphthine synthase
3I4P	;	2.3	;	Crystal structure of AsnC family transcriptional regulator from Agrobacterium tumefaciens
5DYP	;	2.4	;	Crystal structure of Asp251Gly/Gln307His mutant of cytochrome P450 BM3
5DYZ	;	1.967	;	Crystal structure of Asp251Gly/Gln307His mutant of cytochrome P450 BM3 in complex with N-palmitoylglycine
5MC1	;	1.43	;	Crystal Structure of Asp276Asn mutant of Human Prolidase with Mn ions and GlyPro ligand
5OC2	;	2.85	;	Crystal structure of Asp295Cys/Lys303Cys Amadoriase I mutant from Aspergillus Fumigatus
2E07	;	1.9	;	Crystal structure of Asp79 to Glu mutant of Diphthine synthase
1D7F	;	1.9	;	CRYSTAL STRUCTURE OF ASPARAGINE 233-REPLACED CYCLODEXTRIN GLUCANOTRANSFERASE FROM ALKALOPHILIC BACILLUS SP. 1011 DETERMINED AT 1.9 A RESOLUTION
2OG5	;	1.45	;	Crystal structure of asparagine oxygenase (AsnO)
2OG6	;	1.916	;	Crystal structure of asparagine oxygenase in complex with Fe(II)
4LNS	;	2.2	;	Crystal structure of Asparagine synthetase A (AsnA) from Trypanosoma brucei
1CT9	;	2.0	;	CRYSTAL STRUCTURE OF ASPARAGINE SYNTHETASE B FROM ESCHERICHIA COLI
6PQH	;	2.0	;	Crystal structure of Asparagine-tRNA ligase from Elizabethkingia sp. CCUG 26117
4NOM	;	2.006	;	Crystal structure of asparaginyl endopeptidase (AEP)/Legumain activated at pH 4.5
5ZBI	;	2.09	;	Crystal structure of asparaginyl endopeptidases from Viola Canadensis
1X56	;	1.98	;	Crystal structure of asparaginyl-tRNA synthetase from Pyrococcus horikoshii
1X54	;	1.45	;	Crystal structure of asparaginyl-tRNA synthetase from Pyrococcus horikoshii complexed with asparaginyl-adenylate
1X55	;	1.8	;	Crystal structure of asparaginyl-tRNA synthetase from Pyrococcus horikoshii complexed with asparaginyl-adenylate analogue
4GBC	;	1.778	;	Crystal structure of aspart insulin at pH 6.5
4GBI	;	2.502	;	Crystal structure of aspart insulin at pH 6.5
4GBN	;	1.872	;	Crystal structure of aspart insulin at pH 6.5
4GBK	;	2.4	;	Crystal structure of aspart insulin at pH 8.5
4GBL	;	2.5	;	Crystal structure of aspart insulin at pH 8.5
1J3U	;	2.5	;	Crystal structure of aspartase from Bacillus sp. YM55-1
3R6V	;	2.6	;	Crystal structure of aspartase from Bacillus sp. YM55-1 with bound L-aspartate
5IWQ	;	2.0	;	Crystal structure of aspartate aminotransferase (AspAT) from Corynebacterium glutamicum ATCC 13032
3F6T	;	2.15	;	Crystal structure of aspartate aminotransferase (E.C. 2.6.1.1) (YP_194538.1) from Lactobacillus acidophilus NCFM at 2.15 A resolution
1O4S	;	1.9	;	Crystal structure of Aspartate aminotransferase (TM1255) from Thermotoga maritima at 1.90 A resolution
2GB3	;	2.5	;	Crystal structure of Aspartate aminotransferase (tm1698) from Thermotoga maritima at 2.50 A resolution
6EZL	;	2.07	;	Crystal structure of aspartate aminotransferase from Trypanosoma cruzi at 2.07 Angstrom resolution
3PWK	;	1.5	;	Crystal Structure of Aspartate beta-Semialdehide Dehydrogenase from Streptococcus pneumoniae with 2',5'-Adenosine diphosphate and D-2-aminoadipate
3PWS	;	2.0	;	Crystal Structure of Aspartate beta-Semialdehide Dehydrogenase from Streptococcus pneumoniae with 2',5'-Adenosine diphosphate and D-2-aminoadipate
3PYL	;	2.2	;	Crystal structure of aspartate beta-semialdehide dehydrogenase from Streptococcus pneumoniae with D-2,3-diaminopropionate
6A4R	;	1.828	;	Crystal structure of aspartate bound peptidase E from Salmonella enterica
2YWW	;	2.0	;	Crystal structure of aspartate carbamoyltransferase regulatory chain from Methanocaldococcus jannaschii
1UHE	;	1.55	;	Crystal structure of aspartate decarboxylase, isoaspargine complex
1UHD	;	2.0	;	Crystal structure of aspartate decarboxylase, pyruvoly group bound form
1J5P	;	1.9	;	Crystal structure of aspartate dehydrogenase (TM1643) from Thermotoga maritima at 1.9 A resolution
3AAW	;	2.5	;	Crystal structure of aspartate kinase from Corynebacterium glutamicum in complex with lysine and threonine
3AB2	;	2.59	;	Crystal structure of aspartate kinase from Corynebacterium glutamicum in complex with threonine
3L76	;	2.54	;	Crystal Structure of Aspartate Kinase from Synechocystis
3VOS	;	2.18	;	Crystal structure of Aspartate semialdehyde dehydrogenase Complexed With glycerol and sulfate From Mycobacterium tuberculosis H37Rv
3TZ6	;	1.95	;	Crystal structure of Aspartate semialdehyde dehydrogenase Complexed With inhibitor SMCS (CYS) And Phosphate From Mycobacterium tuberculosis H37Rv
6C85	;	2.4	;	Crystal structure of aspartate semialdehyde dehydrogenase from Blastomyces dermatitidis with p-benzoquinone
1NWH	;	2.0	;	Crystal Structure of Aspartate Semialdehyde Dehydrogenase from Haemophilus influenzae as a Tetrahedral Hemithioacetal Reaction Intermediate at 2.0 A
1NX6	;	2.15	;	Crystal Structure of Aspartate Semialdehyde Dehydrogenase from Haemophilus influenzae as a Tetrahedral Hemithiocetal Reaction intermediate with Phosphate at 2.15 A
2YV3	;	2.7	;	Crystal Structure of Aspartate Semialdehyde Dehydrogenase from Thermus thermophilus HB8
4ZHS	;	2.603	;	Crystal Structure of Aspartate Semialdehyde Dehydrogenase from Trichophyton rubrum
1MB4	;	1.84	;	Crystal structure of aspartate semialdehyde dehydrogenase from vibrio cholerae with NADP and S-methyl-l-cysteine sulfoxide
2R00	;	2.03	;	crystal structure of aspartate semialdehyde dehydrogenase II complexed with ASA from vibrio cholerae
2QZ9	;	2.2	;	crystal structure of aspartate semialdehyde dehydrogenase II from vibrio cholerae
6C8W	;	2.6	;	Crystal structure of Aspartate Semialdehyde Dehydrogenase with NADP from Blastomyces dermatitidis
3HSK	;	2.2	;	Crystal Structure of Aspartate Semialdehyde Dehydrogenase with NADP from Candida albicans
4ZIC	;	2.553	;	Crystal Structure of Aspartate Semialdehyde Dehydrogenase with NADP from Trichophyton rubrum
5ILN	;	2.21	;	Crystal structure of Aspartate Transcarbamoylase from Plasmodium falciparum (PfATC) with bound citrate
6JKQ	;	2.81	;	Crystal structure of aspartate transcarbamoylase from Trypanosoma cruzi (Ligand-free form)
6JL5	;	2.05	;	Crystal structure of aspartate transcarbamoylase from Trypanosoma cruzi in complex with aspartate (Asp) and phosphate (Pi).
6JL4	;	2.4	;	Crystal structure of aspartate transcarbamoylase from Trypanosoma cruzi in complex with carbamoyl aspartate (CA) and phosphate (Pi)
6JKR	;	1.6	;	Crystal structure of aspartate transcarbamoylase from Trypanosoma cruzi in complex with carbamoyl phosphate (CP)
6JKS	;	2.1	;	Crystal structure of aspartate transcarbamoylase from Trypanosoma cruzi in complex with carbamoyl phosphate (CP) and aspartate (Asp)
6JKT	;	2.3	;	Crystal structure of aspartate transcarbamoylase from Trypanosoma cruzi in complex with N-(PHOSPHONACETYL)-L-ASPARTIC ACID (PALA).
6JL6	;	2.0	;	Crystal structure of aspartate transcarbamoylase from Trypanosoma cruzi in complex with phosphate (Pi).
7SKB	;	1.8	;	Crystal Structure of aspartate-semialdehyde dehydrogenase from Acinetobacter baumannii
7TCM	;	1.95	;	Crystal Structure of aspartate-semialdehyde dehydrogenase from Acinetobacter baumannii in complex with NADP
1NWC	;	2.04	;	Crystal Structure of Aspartate-Semialdehyde Dehydrogenase from Haemophilus influenzae
1TA4	;	2.28	;	Crystal Structure Of Aspartate-Semialdehyde Dehydrogenase From Haemophilus Influenzae with a Bound Arsenate
1TB4	;	2.15	;	Crystal Structure of Aspartate-Semialdehyde Dehydrogenase From Haemophilus influenzae with a Bound Periodate
6BAC	;	2.1	;	Crystal Structure of Aspartate-Semialdehyde Dehydrogenase from Neisseria gonorrhoeae
1MC4	;	2.77	;	Crystal Structure of Aspartate-Semialdehyde dehydrogenase from Vibrio Cholerae El Tor
1WKR	;	1.3	;	Crystal structure of aspartic proteinase from Irpex lacteus
2RE1	;	2.75	;	Crystal structure of aspartokinase alpha and beta subunits
4I9C	;	3.1	;	Crystal structure of aspartyl phosphate phosphatase F from B.subtilis in complex with its inhibitory peptide
4I9E	;	2.4	;	Crystal structure of Aspartyl phosphate phosphatase F from Bacillus subtilis
6WOM	;	2.15	;	Crystal structure of Aspartyl-tRNA ligase from Elizabethkingia sp.
4O2D	;	2.6	;	Crystal structure of aspartyl-tRNA synthetase from Mycobacterium smegmatis with bound aspartic acid
5W25	;	2.65	;	Crystal structure of Aspartyl-tRNA synthetase from Mycobacterium tuberculosis complexed with L-Aspartic Acid
1WYD	;	2.3	;	Crystal Structure of Aspartyl-tRNA synthetase from Sulfolobus tokodaii
1EFW	;	3.0	;	Crystal structure of aspartyl-tRNA synthetase from Thermus thermophilus complexed to tRNAasp from Escherichia coli
5HXX	;	2.0	;	Crystal structure of AspAT from Corynebacterium glutamicum
7S3J	;	1.94	;	Crystal Structure of AspB P450 in complex with brevianamide F substrates
1Y43	;	1.4	;	crystal structure of aspergilloglutamic peptidase from Aspergillus niger
5C5G	;	1.248	;	Crystal Structure of Aspergillus clavatus Sph3
5D6T	;	1.93	;	Crystal Structure of Aspergillus clavatus Sph3 in complex with GalNAc
4YNT	;	1.78	;	Crystal structure of Aspergillus flavus FAD glucose dehydrogenase
4YNU	;	1.57	;	Crystal structure of Aspergillus flavus FADGDH in complex with D-glucono-1,5-lactone
6TZ7	;	2.5	;	Crystal Structure of Aspergillus fumigatus Calcineurin A, Calcineurin B, FKBP12 and FK506 (Tacrolimus)
2A3E	;	1.95	;	Crystal structure of Aspergillus fumigatus chitinase B1 in complex with allosamidin
2IUZ	;	1.95	;	Crystal structure of Aspergillus fumigatus chitinase B1 in complex with C2-dicaffeine
2A3B	;	1.9	;	Crystal structure of Aspergillus fumigatus chitinase B1 in complex with caffeine
3CH9	;	2.2	;	Crystal structure of Aspergillus fumigatus chitinase B1 in complex with dimethylguanylurea
3CHD	;	2.0	;	Crystal structure of Aspergillus fumigatus chitinase B1 in complex with dipeptide
3CHC	;	1.9	;	Crystal structure of Aspergillus fumigatus chitinase B1 in complex with monopeptide
2A3C	;	2.07	;	Crystal structure of Aspergillus fumigatus chitinase B1 in complex with pentoxifylline
3CHF	;	1.95	;	Crystal structure of Aspergillus fumigatus chitinase B1 in complex with tetrapeptide
2A3A	;	2.1	;	Crystal structure of Aspergillus fumigatus chitinase B1 in complex with theophylline
3CHE	;	2.05	;	Crystal structure of Aspergillus fumigatus chitinase B1 in complex with tripeptide
6OJ1	;	1.76	;	Crystal Structure of Aspergillus fumigatus Ega3
6OJB	;	2.093	;	Crystal Structure of Aspergillus fumigatus Ega3 complex with galactosamine
3IBG	;	3.2	;	Crystal structure of Aspergillus fumigatus Get3 with bound ADP
6TDH	;	1.58	;	Crystal structure of Aspergillus fumigatus Glucosamine-6-phosphate N-acetyltransferase 1 in complex with compound 1
6TDG	;	1.74	;	Crystal structure of Aspergillus fumigatus Glucosamine-6-phosphate N-acetyltransferase 1 in complex with compound 2
6TDF	;	2.01	;	Crystal structure of Aspergillus fumigatus Glucosamine-6-phosphate N-acetyltransferase 1 in complex with compound 3
6IDY	;	2.15	;	Crystal structure of Aspergillus fumigatus lipase B
6L2G	;	2.41	;	Crystal structure of Aspergillus fumigatus mitochondrial acetyl-CoA acetyltransferase
6L2C	;	2.44	;	Crystal structure of Aspergillus fumigatus mitochondrial acetyl-CoA acetyltransferase in complex with CoA
1KKC	;	2.0	;	Crystal structure of Aspergillus fumigatus MnSOD
5OAW	;	2.34	;	Crystal structure of Aspergillus fumigatus N-acetylphosphoglucosamine mutase in complex with GlcNAc-6P and magnesium
5O9X	;	1.9	;	Crystal structure of Aspergillus fumigatus N-acetylphosphoglucosamine mutate S69A in complex with glucose1,6bisphosphate
4CAV	;	1.89	;	Crystal structure of Aspergillus fumigatus N-myristoyl transferase in complex with myristoyl CoA and a benzofuran ligand R0-09-4879
4UWJ	;	1.7	;	Crystal structure of Aspergillus fumigatus N-myristoyl transferase in complex with myristoyl CoA and a capped pyrazole sulphonamide ligand
5T6E	;	2.3	;	Crystal structure of Aspergillus fumigatus N-myristoyl transferase in complex with myristoyl CoA and a dichloro-dimethylpyridyl-methoxy-phenyl-pyridyl-piperazine ligand
5T6C	;	1.9	;	Crystal structure of Aspergillus fumigatus N-myristoyl transferase in complex with myristoyl CoA and a dichloro-methylpyridinyl-methoxy-phenyl-pyridine piperazine ligand
5T6H	;	1.8	;	Crystal structure of Aspergillus fumigatus N-myristoyl transferase in complex with myristoyl CoA and a dimethylpyridyl-dipihenyl-pyridine ligand
5T5U	;	1.8	;	Crystal structure of Aspergillus fumigatus N-myristoyl transferase in complex with myristoyl CoA and a methylpyridyl-dipihenyl-pyridine ligand
4CAW	;	2.5	;	Crystal structure of Aspergillus fumigatus N-myristoyl transferase in complex with myristoyl CoA and a pyrazole sulphonamide ligand
4UWI	;	1.8	;	Crystal structure of Aspergillus fumigatus N-myristoyl transferase in complex with myristoyl CoA and a pyrazole sulphonamide ligand
4CAX	;	1.85	;	Crystal structure of Aspergillus fumigatus N-myristoyl transferase in complex with myristoyl CoA and a pyrazole sulphonamide ligand (DDD85646)
7P5O	;	2.48	;	Crystal structure of Aspergillus fumigatus phosphoglucomutase in complex with the reaction intermediate
6I5X	;	2.2	;	Crystal structure of Aspergillus fumigatus phosphomannomutase
4MBG	;	1.74	;	Crystal structure of Aspergillus fumigatus protein farnesyltransferase binary complex with farnesyldiphosphate
4L9P	;	1.45	;	Crystal structure of Aspergillus fumigatus protein farnesyltransferase complexed with the FII analog, FPT-II, and the KCVVM peptide
2XCY	;	1.84	;	Crystal structure of Aspergillus fumigatus sialidase
8EXD	;	3.8	;	Crystal structure of Aspergillus fumigatus sterylglucosidase A
7YTV	;	3.866	;	Crystal structure of Aspergillus fumigatus Thioredoxin reductase in complex with auranofin
3UTH	;	2.25	;	Crystal structure of Aspergillus fumigatus UDP galactopyranose mutase complexed with substrate UDP-Galp in reduced state
3UTG	;	2.25	;	Crystal structure of Aspergillus fumigatus UDP galactopyranose mutase complexed with UDP in reduced state
3UTF	;	2.25	;	Crystal structure of Aspergillus fumigatus UDP galactopyranose mutase in reduced state
3UTE	;	2.35	;	Crystal structure of Aspergillus fumigatus UDP galactopyranose mutase sulfate complex
5HHF	;	2.3	;	Crystal structure of Aspergillus fumigatus UDP-Galactopyranose mutase mutant H63A with covalent FAD-Galactopyranose and bound UDP
6TN3	;	2.282	;	Crystal Structure of Aspergillus fumigatus UDP-N-acetylglucosamine pyrophosphorylase in complex with GlcNAc-1P
6G9W	;	2.4	;	Crystal Structure of Aspergillus fumigatus UDP-N-acetylglucosamine pyrophosphorylase in complex with UTP
6G9V	;	1.75	;	Crystal structure of Aspergillus fumigatus UDP-N-acetylglucosamine pyrophosphorylase(AfUAP1) in complex with UDPGlcNAc, pyrophosphate and Mg2+
1SG6	;	1.7	;	Crystal structure of Aspergillus nidulans 3-dehydroquinate synthase (AnDHQS) in complex with Zn2+ and NAD+, at 1.7D
3PGB	;	2.45	;	Crystal structure of Aspergillus nidulans amine oxidase
5XVI	;	2.8	;	Crystal Structure of Aspergillus niger Apo- Glutamate Dehydrogenase
6IGY	;	1.948	;	Crystal structure of Aspergillus niger chitinase B
1UKC	;	2.1	;	Crystal Structure of Aspergillus niger EstA
6QE8	;	1.79	;	Crystal structure of Aspergillus niger GH11 endoxylanase XynA in complex with xylobiose epoxide activity based probe
5XWC	;	1.75	;	Crystal Structure of Aspergillus niger Glutamate Dehydrogenase Complexed With Alpha-iminoglutarate, 2-amino-2-hydroxyglutarate and NADP
5XVX	;	1.8	;	Crystal Structure of Aspergillus niger Glutamate Dehydrogenase Complexed With Alpha-ketoglutarate and NADPH
5XW0	;	1.9	;	Crystal Structure of Aspergillus niger Glutamate Dehydrogenase Complexed With Isophthalate and NADPH
1IZD	;	1.9	;	Crystal structure of Aspergillus oryzae Aspartic Proteinase
1IZE	;	1.9	;	Crystal structure of Aspergillus oryzae Aspartic proteinase complexed with pepstatin
6GSG	;	2.192	;	Crystal structure of Aspergillus oryzae catechol oxidase complexed with resorcinol
5OR4	;	2.445	;	Crystal structure of Aspergillus oryzae catechol oxidase in deoxy-form
5OR3	;	1.795	;	Crystal structure of Aspergillus oryzae catechol oxidase in met/deoxy-form
3GBS	;	1.75	;	Crystal structure of Aspergillus oryzae cutinase
7DRY	;	1.44	;	Crystal structure of Aspergillus oryzae Rib2 deaminase
7DRZ	;	1.7	;	Crystal structure of Aspergillus oryzae Rib2 deaminase (C-terminal deletion mutant) at pH 4.6
7DS0	;	1.69	;	Crystal structure of Aspergillus oryzae Rib2 deaminase (C-terminal deletion mutant) at pH 6.5
7DS1	;	1.58	;	Crystal structure of Aspergillus oryzae Rib2 deaminase in complex with DARIPP (C-terminal deletion mutant at pH 6.5)
4KWD	;	1.857	;	Crystal structure of Aspergillus terreus aristolochene synthase complexed with (1R,8R,9aS)-1,9a-dimethyl-8-(prop-1-en-2-yl)decahydroquinolizin-5-ium
4KVY	;	1.95	;	Crystal structure of Aspergillus terreus aristolochene synthase complexed with (1S,8S,9aR)-1,9a-dimethyl-8-(prop-1-en-2-yl)decahydroquinolizin-5-ium
4KVW	;	2.102	;	Crystal structure of Aspergillus terreus aristolochene synthase complexed with (3R,6R,9aR)-6,9a-dimethyl-3-(prop-1-en-2-yl)decahydroquinolizin-5-ium
4KVD	;	2.4	;	Crystal structure of Aspergillus terreus aristolochene synthase complexed with (4aS,7S)-1,4a-dimethyl-7-(prop-1-en-2-yl)decahydroquinolin-1-ium
4KVI	;	2.15	;	Crystal structure of Aspergillus terreus aristolochene synthase complexed with (4aS,7S)-4a-methyl-7-(prop-1-en-2-yl)-2,3,4,4a,5,6,7,8-octahydroquinolin-1-ium
4KUX	;	1.9	;	Crystal structure of Aspergillus terreus aristolochene synthase complexed with farnesyl thiolodiphosphate (FSPP)
5IVG	;	1.95	;	Crystal structure of Aspergillus terreus aristolochene synthase N299A complexed with farnesyl thiolodiphosphate
7ECS	;	1.74	;	Crystal Structure of Aspergillus terreus Glutamate Dehydrogenase (AtGDH) Complexed With Malonate and NADPH
7ECR	;	1.73	;	Crystal Structure of Aspergillus terreus Glutamate Dehydrogenase (AtGDH) Complexed With Succinate and ADP-ribose
7ECT	;	2.9	;	Crystal Structure of Aspergillus terreus Glutamate Dehydrogenase (AtGDH) Complexed With Tartrate and NADPH
3B70	;	1.89	;	Crystal structure of Aspergillus terreus trans-acting lovastatin polyketide enoyl reductase (LovC) with bound NADP
5YY3	;	2.305	;	Crystal structure of AsqI
5YY2	;	2.91	;	Crystal structure of AsqI with Zn
5TQB	;	2.4	;	Crystal structure of assembly chaperone of ribosomal protein L4 (Acl4) in complex with ribosomal protein L4 (RpL4)
2GOY	;	2.7	;	Crystal structure of assimilatory adenosine 5'-phosphosulfate reductase with bound APS
3Q8J	;	0.87	;	Crystal Structure of Asteropsin A from Marine Sponge Asteropus sp.
8C16	;	4.2	;	Crystal structure of asymmetric ferredoxin/flavodoxin NADP+ oxidoreductase 2 (FNR2) H326V mutant from Bacillus cereus
7AEJ	;	3.8	;	Crystal structure of asymmetric HIV-1 gp41 containing all membrane anchors
4U97	;	2.65	;	Crystal Structure of Asymmetric IRAK4 Dimer
3WN5	;	2.78	;	Crystal structure of asymmetrically engineered Fc variant in complex with FcgRIIIa
1UGR	;	1.8	;	Crystal structure of aT109S mutant of Co-type nitrile hydratase
6RLM	;	2.5	;	Crystal structure of AT1412dm Fab fragment
6RLO	;	2.2	;	Crystal structure of AT1412dm Fab fragment in complex with CD9 large extracellular loop
2IL4	;	2.054	;	Crystal structure of At1g77540-Coenzyme A Complex
7C6A	;	3.4	;	Crystal structure of AT2R-BRIL and SRP2070_Fab complex
7ZNT	;	3.0	;	CRYSTAL STRUCTURE OF AT7 IN COMPLEX WITH THE SECOND BROMODOMAIN OF HUMAN BRD4 AND PVHL:ELONGINC:ELONGINB
4TU4	;	1.73	;	Crystal structure of ATAD2A bromodomain complexed with 3-(3,5-dimethyl-1,2-oxazol-4-yl)-5-[(phenylsulfonyl)amino]benzoicacid
4TT4	;	2.7	;	Crystal structure of ATAD2A bromodomain complexed with H3(1-21)K14Ac peptide
4TT2	;	2.5	;	Crystal structure of ATAD2A bromodomain complexed with H4(1-20)K5Ac peptide
4TTE	;	1.8	;	Crystal structure of ATAD2A bromodomain complexed with methyl 3-amino-5-(3,5-dimethyl-1,2-oxazol-4-yl)benzoate
4TT6	;	2.0	;	Crystal structure of ATAD2A bromodomain double mutant N1063A-Y1064A in apo form
8XAT	;	2.205	;	Crystal structure of AtARR1(RD-DBD)
8XAS	;	2.346	;	Crystal structure of AtARR1-DBD in complex with a DNA fragment
7F37	;	2.896	;	Crystal structure of AtaT2-AtaR2 complex
6AJN	;	3.302	;	Crystal structure of AtaTR bound with AcCoA
3EL9	;	1.6	;	Crystal structure of atazanavir (ATV) in complex with a multidrug HIV-1 protease (V82T/I84V)
3EM4	;	2.1	;	Crystal structure of atazanavir (ATV) in complex with I50L/A71V drug-resistant HIV-1 protease
4HWI	;	2.273	;	Crystal structure of ATBAG1 in complex with HSP70
4HWD	;	2.312	;	Crystal structure of ATBAG2
4HWF	;	2.0	;	Crystal structure of ATBAG3
4HWH	;	1.895	;	Crystal structure of ATBAG4
4PPV	;	2.45	;	Crystal Structure of AtCM1 with Phenylalanine Bound in Allosteric Site
4PPU	;	2.3	;	Crystal Structure of AtCM1 with Tyrosine Bound in Allosteric Site
5ZUU	;	1.95	;	Crystal structure of AtCPSF30 YTH domain in complex with 10mer m6A-modified RNA
7T34	;	2.89	;	Crystal structure of AtDHDPR1 from Arabidopsis thaliana
7MDS	;	2.295	;	Crystal structure of AtDHDPS1 in complex with MBDTA-2
4K02	;	1.9	;	Crystal structure of AtDHNAT1, a 1,4-dihydroxy-2-naphthoyl-CoA thioesterase from Arabidopsis thaliana
5WX9	;	1.76	;	Crystal Structure of AtERF96 with GCC-box
2I9B	;	2.8	;	Crystal structure of ATF-urokinase receptor complex
1U79	;	1.85	;	Crystal structure of AtFKBP13
6J2M	;	1.13	;	Crystal structure of AtFKBP53 C-terminal domain
7F2J	;	1.6	;	Crystal structure of AtFKBP53 FKBD in complex with rapamycin
4P1N	;	2.2	;	Crystal structure of Atg1-Atg13 complex
5XUY	;	2.2	;	Crystal structure of ATG101-ATG13HORMA
5XV1	;	2.508	;	Crystal structure of ATG101-ATG13HORMA
5XV3	;	2.57	;	Crystal structure of ATG101-ATG13HORMA
5XV4	;	2.95	;	Crystal structure of ATG101-ATG13HORMA
5XV6	;	2.455	;	Crystal structure of ATG101-ATG13HORMA
6VZF	;	2.03	;	Crystal Structure of Atg11 Coiled-Coil 3
3WAN	;	1.77	;	Crystal structure of Atg13 LIR-fused human LC3A_2-121
3WAO	;	2.6	;	Crystal structure of Atg13 LIR-fused human LC3B_2-119
3WAP	;	3.1	;	Crystal structure of Atg13 LIR-fused human LC3C_8-125
5JHF	;	3.21	;	Crystal structure of Atg13(17BR)-Atg13(17LR)-Atg17-Atg29-Atg31 complex
4P1W	;	3.2	;	Crystal structure of Atg13(17BR)-Atg17-Atg29-Atg31 complex
6ZAY	;	2.4	;	Crystal structure of Atg16L in complex with GDP-bound Rab33B
6Y09	;	2.4	;	Crystal structure of Atg16L in complex with GTP-bound Rab33B (Q92L)
6KYB	;	2.8	;	Crystal structure of Atg18 from Saccharomyces cerevisiae
5JGE	;	1.91	;	Crystal structure of Atg19 coiled-coil complexed with Ape1 propeptide
7BRN	;	2.231	;	Crystal structure of Atg40 AIM fused to Atg8
7YDO	;	1.58	;	Crystal structure of Atg44
4GSJ	;	1.695	;	Crystal structure of Atg7 NTD K14A F16A D18A mutant
3RUI	;	1.906	;	Crystal structure of Atg7C-Atg8 complex
3VH3	;	2.0	;	Crystal structure of Atg7CTD-Atg8 complex
3VH4	;	2.65	;	Crystal structure of Atg7CTD-Atg8-MgATP complex
5YEC	;	2.147	;	Crystal structure of Atg7CTD-Atg8-MgATP complex in form II
6QUN	;	3.0	;	Crystal structure of AtGapC1 with the catalytic Cys149 irreversibly oxidized by H2O2 treatment
8H6B	;	1.897	;	Crystal structure of AtHPPD complexed with YH20702
8H6A	;	1.601	;	Crystal structure of AtHPPD complexed with YH21477
7X8H	;	1.986	;	Crystal structure of AtHPPD-(+)-Usnic acid complex
8IOK	;	1.991	;	Crystal structure of AtHPPD-CLJ507 complex
7X5U	;	1.6	;	Crystal structure of AtHPPD-diketonitrile complex
7X5R	;	1.644	;	Crystal structure of AtHPPD-Lancotrione complex
7X8D	;	1.695	;	Crystal structure of AtHPPD-phenylpyruvate complex
8HZ6	;	1.605	;	Crystal structure of AtHPPD-QRY2089 complex
7X8I	;	2.096	;	Crystal structure of AtHPPD-Shikonin complex
8HZU	;	1.796	;	Crystal structure of AtHPPD-XHD complex
7X5Z	;	1.688	;	Crystal structure of AtHPPD-Y13162 complex
7XVH	;	1.83	;	Crystal structure of AtHPPD-Y13287 complex
8HXG	;	1.702	;	Crystal structure of AtHPPD-Y14116 complex
7X5S	;	1.706	;	Crystal structure of AtHPPD-Y14157 complex
7X5Y	;	1.498	;	Crystal structure of AtHPPD-Y14240 complex
7X5W	;	1.598	;	Crystal structure of AtHPPD-Y18022 complex
8HXH	;	1.992	;	Crystal structure of AtHPPD-Y18024 complex
7X64	;	2.288	;	Crystal structure of AtHPPD-Y18027 complex
8HYM	;	1.794	;	Crystal structure of AtHPPD-Y18030 complex
8HYO	;	2.0	;	Crystal structure of AtHPPD-Y18031 complex
8HZ7	;	1.802	;	Crystal structure of AtHPPD-Y181135 complex
8HZ9	;	2.011	;	Crystal structure of AtHPPD-Y181136 complex
8HXF	;	1.697	;	Crystal structure of AtHPPD-Y181188 complex
8HYP	;	1.749	;	Crystal structure of AtHPPD-Y18400 complex
8HX2	;	1.996	;	Crystal structure of AtHPPD-Y18405 complex
7X67	;	1.996	;	Crystal structure of AtHPPD-Y18406 complex
8HX4	;	1.896	;	Crystal structure of AtHPPD-Y18549 complex
8GWD	;	1.889	;	Crystal structure of AtHPPD-Y18734 complex
8I2S	;	1.592	;	Crystal structure of AtHPPD-Y18979 complex
8I36	;	1.887	;	Crystal structure of AtHPPD-Y18980 complex
8I2P	;	1.797	;	Crystal structure of AtHPPD-Y19060 complex
7X62	;	2.004	;	Crystal structure of AtHPPD-Y191051 complex
8HOW	;	1.79	;	Crystal structure of AtHPPD-Y191052 complex
7X69	;	1.797	;	Crystal structure of AtHPPD-Y191053 complex
7X6M	;	1.815	;	Crystal structure of AtHPPD-Y191058 complex
8HWR	;	2.18	;	Crystal structure of AtHPPD-Y191193 complex
7X6N	;	1.691	;	Crystal structure of AtHPPD-Y191710 complex
8I0Y	;	1.792	;	Crystal structure of AtHPPD-Y191713 complex
8I0G	;	1.992	;	Crystal structure of AtHPPD-Y19543 complex
8HYS	;	1.7	;	Crystal structure of AtHPPD-Y19802 complex
8I2U	;	1.989	;	Crystal structure of AtHPPD-YH20282 complex
8HZA	;	1.69	;	Crystal structure of AtHPPD-YH20326 complex
8I15	;	2.19	;	Crystal structure of AtHPPD-YH20335 complex
7X5X	;	2.196	;	Crystal structure of AtHPPD-YH20533 complex
7QFU	;	1.45	;	Crystal Structure of AtlA catalytic domain from Enterococcus feacalis
2EEK	;	1.85	;	Crystal structure of Atlantic cod trypsin complexed with benzamidine
3X1D	;	2.87	;	Crystal Structure of Atlastin from Drosophila melanogaster
7FEO	;	2.2	;	Crystal structure of AtMBD5 MBD domain
7FEF	;	2.39	;	Crystal structure of AtMBD6 with DNA
8A53	;	1.95	;	Crystal structure of AtMCA-IIf C147A (metacaspase 9) from Arabidopsis thaliana
7W5M	;	2.15	;	Crystal structure of AtNASP in complex of H3 alpha3 helix peptide
5WWD	;	1.386	;	Crystal structure of AtNUDX1
5WY6	;	1.779	;	Crystal structure of AtNUDX1 (E56A)
5DBN	;	2.549	;	Crystal structure of AtoDA complex
4BXI	;	2.2	;	Crystal structure of ATP binding domain of AgrC from Staphylococcus aureus
1YSR	;	1.78	;	Crystal Structure of ATP binding domain of PrrB from Mycobacterium Tuberculosis
7TGK	;	2.3	;	Crystal structure of ATP bound DesD, the desferrioxamine synthetase from the Streptomyces griseoflavus ferrimycin biosynthetic pathway
4FUT	;	2.0	;	Crystal structure of ATP bound MatB from Rhodopseudomonas palustris
4GXQ	;	2.0	;	Crystal Structure of ATP bound RpMatB-BxBclM chimera B1
5X8A	;	2.51	;	Crystal structure of ATP bound thymidylate kinase from thermus thermophilus HB8
1I2D	;	2.81	;	CRYSTAL STRUCTURE OF ATP SULFURYLASE FROM PENICILLIUM CHRYSOGENUM
1V47	;	2.49	;	Crystal structure of ATP sulfurylase from Thermus thermophillus HB8 in complex with APS
1JED	;	2.95	;	Crystal Structure of ATP Sulfurylase in complex with ADP
1JEE	;	2.8	;	Crystal Structure of ATP Sulfurylase in complex with chlorate
1JEC	;	2.5	;	Crystal Structure of ATP Sulfurylase in complex with thiosulfate
6PI4	;	2.1	;	Crystal structure of ATP synthase epsion chain ATP synthase epsilon chain (ATP synthase F1 sector epsilon subunit) (F-ATPase epsilon subunit) from Mycobacterium smegmatis
2R9V	;	2.1	;	Crystal structure of ATP synthase subunit alpha (TM1612) from Thermotoga maritima at 2.10 A resolution
5ZXD	;	2.288	;	Crystal structure of ATP-bound human ABCF1
3F5M	;	2.7	;	Crystal Structure of ATP-Bound Phosphofructokinase from Trypanosoma brucei
4DLK	;	2.02	;	Crystal Structure of ATP-Ca++ complex of purK: N5-carboxyaminoimidazole ribonucleotide synthetase
6YRA	;	4.0	;	Crystal structure of ATP-dependent caprolactamase from Pseudomonas jessenii
3P2L	;	2.295	;	Crystal Structure of ATP-dependent Clp protease subunit P from Francisella tularensis
8DVH	;	1.9	;	Crystal structure of ATP-dependent Lon protease from Bacillus subtillis (BsLonBA)
1J3B	;	2.0	;	Crystal structure of ATP-dependent phosphoenolpyruvate carboxykinase from Thermus thermophilus HB8
1XKV	;	2.2	;	Crystal Structure Of ATP-Dependent Phosphoenolpyruvate Carboxykinase From Thermus thermophilus HB8
2PC9	;	2.4	;	Crystal Structure Of ATP-Dependent Phosphoenolpyruvate Carboxykinase From Thermus thermophilus HB8
7MHB	;	2.6	;	Crystal structure of ATP-dependent protease ATPase subunit HslU in complex with Adenosine 5'-diphosphate
8DPE	;	1.531	;	Crystal structure of ATP-dependent RNA helicase DDX42
1F2T	;	1.6	;	Crystal Structure of ATP-Free RAD50 ABC-ATPase
2QJF	;	2.2	;	Crystal structure of ATP-sulfurylase domain of human PAPS synthetase 1
5X8B	;	1.39	;	Crystal structure of ATP-TMP and ADP bound thymidylate kinase from Thermus thermophilus HB8
2P4F	;	1.4	;	Crystal Structure of Atp11 functional domain from Candida Glabrata
6LKN	;	3.9	;	Crystal structure of ATP11C-CDC50A in PtdSer-bound E2P state
2P4X	;	1.9	;	Crystal Structure of Atp12 from Paracoccus Denitrificans
2R31	;	1.0	;	Crystal structure of atp12p from paracoccus denitrificans
7X0Q	;	2.9	;	Crystal structure of ATPase Clo1313_2554 from Clostridium thermocellum
6N6L	;	2.15	;	Crystal Structure of ATPase delta 1-79 Spa47 R189A R191A mutant
6N6Z	;	2.642	;	Crystal Structure of ATPase delta 1-79 Spa47 R189E
5SWJ	;	2.401	;	Crystal Structure of ATPase delta1-79 Spa47
5SWL	;	2.7	;	Crystal Structure of ATPase delta1-79 Spa47 E188A
6N72	;	2.735	;	Crystal Structure of ATPase delta1-79 Spa47 E267R
6N75	;	2.991	;	Crystal Structure of ATPase delta1-79 Spa47 E287A
6N76	;	2.892	;	Crystal Structure of ATPase delta1-79 Spa47 E287R
5SYP	;	2.15	;	Crystal Structure of ATPase delta1-79 Spa47 K165A
6N6M	;	2.788	;	Crystal Structure of ATPase delta1-79 Spa47 R189A
6N70	;	2.738	;	Crystal Structure of ATPase delta1-79 Spa47 R191A
6N71	;	2.45	;	Crystal Structure of ATPase delta1-79 Spa47 R191E
6N73	;	2.398	;	Crystal Structure of ATPase delta1-79 Spa47 R271A
6N74	;	1.852	;	Crystal Structure of ATPase delta1-79 Spa47 R271E
5SYR	;	1.8	;	Crystal Structure of ATPase delta1-79 Spa47 R350A
6CZ1	;	1.68	;	Crystal structure of ATPase domain of Human GRP78 bound to Ver155008
5UMB	;	2.3	;	Crystal structure of ATPase domain of Malaria GRP78 with ADP bound
3GL1	;	1.92	;	Crystal structure of ATPase domain of Ssb1 chaperone, a member of the HSP70 family, from Saccharomyces cerevisiae
6MW7	;	2.194	;	Crystal structure of ATPase module of SMCHD1 bound to ATP
1V43	;	2.2	;	Crystal Structure of ATPase subunit of ABC Sugar Transporter
5AUQ	;	2.525	;	Crystal structure of ATPase-type HypB in the nucleotide free state
6BS4	;	2.5	;	Crystal structure of ATPgammaS-bound bacterial Get3-like A and B in Mycobacterium tuberculosis
4I81	;	3.8182	;	Crystal Structure of ATPgS bound ClpX Hexamer
6KRW	;	1.4	;	Crystal Structure of AtPTP1 at 1.4 angstrom
6KRX	;	1.7	;	Crystal Structure of AtPTP1 at 1.7 angstrom
1ONJ	;	1.555	;	Crystal structure of Atratoxin-b from Chinese cobra venom of Naja atra
3LS9	;	1.4	;	Crystal structure of atrazine chlorohydrolase TrzN from Arthrobacter aurescens TC1 complexed with zinc
4GR6	;	2.0	;	Crystal structure of AtRbcX2 from Arabidopsis thaliana
3AJD	;	1.27	;	Crystal structure of ATRM4
3A4T	;	2.3	;	Crystal structure of aTrm4 from M.jannaschii with sinefungin
3QLN	;	1.901	;	Crystal structure of ATRX ADD domain in free state
4XAU	;	3.0012	;	Crystal structure of AtS13 from Actinomadura melliaura
7Y10	;	2.1	;	Crystal structure of AtSFH5-Sec14 in complex with DPPA
7Y11	;	1.95	;	Crystal structure of AtSFH5-Sec14 in complex with egg PA
5A5Y	;	1.92	;	Crystal structure of AtTTM3 in complex with tripolyphosphate and magnesium ion (form A)
5A66	;	2.05	;	Crystal structure of AtTTM3 in complex with tripolyphosphate and manganese ion (form A)
5A67	;	1.3	;	Crystal structure of AtTTM3 in complex with tripolyphosphate and manganese ion (form B)
2R6I	;	2.59	;	Crystal structure of Atu1473 protein, a putative chaperone from Agrobacterium tumefaciens
2PJS	;	1.85	;	Crystal structure of Atu1953, protein of unknown function
1ZP6	;	3.2	;	Crystal Structure of Atu3015, a Putative Cytidylate Kinase from Agrobacterium tumefaciens, Northeast Structural Genomics Target AtR62
6ITW	;	2.4	;	Crystal structure of Atu4351 from Agrobacterium tumefaciens
4RJZ	;	1.17	;	Crystal structure of ATU4361 sugar transporter from Agrobacterium fabrum C58, target EFI-510558, an open conformation
4QSE	;	1.37	;	Crystal structure of ATU4361 sugar transporter from Agrobacterium Fabrum c58, target efi-510558, with bound glycerol
4QSC	;	1.3	;	Crystal structure of ATU4361 sugar transporter from Agrobacterium Fabrum C58, target efi-510558, with bound maltose
4QSD	;	1.34	;	Crystal structure of atu4361 sugar transporter from Agrobacterium Fabrum C58, target efi-510558, with bound sucrose
7Z0U	;	2.85	;	Crystal structure of AtWRKY18 DNA-binding domain in complex with W-box DNA
5VBC	;	2.1	;	Crystal structure of ATXR5 in complex with histone H3.1
4O30	;	2.1	;	Crystal structure of ATXR5 in complex with histone H3.1 and AdoHcy
5VA6	;	2.4	;	CRYSTAL STRUCTURE OF ATXR5 IN COMPLEX WITH HISTONE H3.1 MONO-METHYLATED ON R26
5VAB	;	1.702	;	Crystal structure of ATXR5 PHD domain in complex with histone H3
5VAH	;	2.4	;	Crystal structure of ATXR5 SET domain in complex with histone H3 di-methylated on R26
5VAC	;	1.949	;	Crystal Structure of ATXR5 SET domain in complex with K36me3 histone H3 peptide
2D2E	;	1.7	;	Crystal structure of atypical cytoplasmic ABC-ATPase SufC from Thermus thermophilus HB8
2D2F	;	1.9	;	Crystal structure of atypical cytoplasmic ABC-ATPase SufC from Thermus thermophilus HB8
6OM2	;	2.77	;	Crystal structure of atypical integrin alphaV beta8 with proTGF-beta1 ligand peptide
7BJG	;	2.45	;	Crystal structure of atypical Tm1 (Tm1-I/C), residues 262-363
7BJN	;	2.3	;	Crystal structure of atypical Tm1 (Tm1-I/C), residues 270-334
7VIR	;	1.9	;	Crystal structure of Au(100EQ)-apo-R168H/L169C-rHLFr
7VIP	;	1.9	;	Crystal structure of Au(10EQ)-apo-R168H/L169C-rHLFr
7VIU	;	1.5	;	Crystal structure of Au(200EQ)-apo-R168C/L169C-rHLFr
7VIS	;	1.85	;	Crystal structure of Au(200EQ)-apo-R168H/L169C-rHLFr
7VIT	;	1.9	;	Crystal structure of Au(400EQ)-apo-R168H/L169C-rHLFr
7VIQ	;	1.9	;	Crystal structure of Au(50EQ)-apo-R168H/L169C-rHLFr
5GU3	;	2.03	;	Crystal structure of Au(E).CL-apo-E45C/R52C-rHLFr
5GU1	;	2.05	;	Crystal structure of Au(L).CL-apo-E45C/R52C-rHLFr
5GU2	;	2.12	;	Crystal structure of Au(M).CL-apo-E45C/R52C-rHLFr
5GU0	;	1.95	;	Crystal structure of Au.CL-apo-E45C/R52C-rHLFr
3C6V	;	1.9	;	Crystal structure of AU4130/APC7354, a probable enzyme from the thermophilic fungus Aspergillus fumigatus
8AMK	;	2.85	;	Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
8AMG	;	2.26	;	Crystal structure of AUGUGGCAU duplex with barium ions (model 1)
8AMI	;	1.79	;	Crystal structure of AUGUGGCAU duplex with barium ions (model 2)
8AML	;	2.75	;	Crystal structure of AUGUGGCAU duplex with cadmium ions
8AMM	;	2.86	;	Crystal structure of AUGUGGCAU duplex with cesium ions
8AMN	;	2.46	;	Crystal structure of AUGUGGCAU duplex with strontium ions
2ZQR	;	2.5	;	Crystal structure of AUH without RNA
5G4B	;	2.24	;	Crystal structure of Aura virus capsid protein in complex with piperazine.
6KOL	;	2.211	;	Crystal structure of auracyanin from photosynthetic bacterium Roseiflexus castenholzii
7FGP	;	1.47	;	Crystal structure of Aureimonas altamirenisis flavin-containing opine dehydrogenase (FAD-bound form)
4F6C	;	2.812	;	Crystal structure of Aureusimine biosynthetic cluster reductase domain
4F6L	;	3.856	;	Crystal structure of Aureusimine biosynthetic cluster reductase domain
6Z4Y	;	2.25	;	Crystal structure of Aurora A (STK6) in complex with macrocycle ODS2003208
4CEG	;	2.1	;	Crystal structure of Aurora A 122-403 C290A, C393A bound to ADP
8OF5	;	1.97	;	Crystal structure of Aurora A 122-403 C290A, N332A, Q335A, C393A bound to ADP
3DAJ	;	2.0	;	Crystal structure of Aurora A complexed with an inhibitor discovered through site-directed dynamic tethering
7AYI	;	2.86	;	Crystal structure of Aurora A in complex with 7-(2-Anilinopyrimidin-4-yl)-1-benzazepin-2-one derivative (compound 2a)
7AYH	;	2.8	;	Crystal structure of Aurora A in complex with 7-(2-Anilinopyrimidin-4-yl)-1-benzazepin-2-one derivative (compound 2c)
3HA6	;	2.36	;	Crystal structure of aurora A in complex with TPX2 and compound 10
3E5A	;	2.3	;	Crystal structure of Aurora A in complex with VX-680 and TPX2
3M11	;	2.75	;	Crystal Structure of Aurora A Kinase complexed with inhibitor
5EW9	;	2.181	;	Crystal Structure of Aurora A Kinase Domain Bound to MK-5108
4C2W	;	1.7	;	Crystal structure of Aurora B in complex with AMP-PNP
5EYK	;	1.93	;	CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
2VGP	;	1.7	;	Crystal structure of Aurora B kinase in complex with a aminothiazole inhibitor
2VGO	;	1.7	;	Crystal structure of Aurora B kinase in complex with Reversine inhibitor
4JAJ	;	2.7	;	Crystal Structure of Aurora Kinase A in complex with BENZO[C][1,8]NAPHTHYRIDIN-6(5H)-ONE
4JAI	;	3.2	;	Crystal Structure of Aurora Kinase A in complex with N-{4-[(6-oxo-5,6-dihydrobenzo[c][1,8]naphthyridin-1-yl)amino]phenyl}benzamide
1MUO	;	2.9	;	CRYSTAL STRUCTURE OF AURORA-2, AN ONCOGENIC SERINE-THREONINE KINASE
5LXM	;	2.08	;	Crystal structure of Aurora-A bound to a hydrocarbon-stapled proteomimetic of TPX2
5ZAN	;	2.85	;	Crystal Structure of Aurora-A in complex with a new Quinazoline inhibitor
3COH	;	2.7	;	Crystal structure of Aurora-A in complex with a pentacyclic inhibitor
5ONE	;	2.6	;	Crystal structure of Aurora-A in complex with FMF-03-145-1 (compound 2)
5ORL	;	1.69	;	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5ORN	;	2.19	;	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5ORO	;	2.12	;	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5ORP	;	2.19	;	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5ORR	;	2.09	;	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5ORS	;	1.98	;	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5ORT	;	2.56	;	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5ORV	;	1.88	;	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5ORW	;	2.0	;	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5ORX	;	1.88	;	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5ORY	;	1.99	;	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5ORZ	;	1.92	;	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5OS0	;	1.74	;	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5OS1	;	1.9	;	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5OS2	;	1.92	;	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5OS3	;	1.81	;	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5OS4	;	1.88	;	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5OS5	;	1.74	;	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5OS6	;	2.2	;	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5OSD	;	1.99	;	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5OSE	;	1.9	;	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5OSF	;	1.89	;	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5G1X	;	1.72	;	Crystal structure of Aurora-A kinase in complex with N-Myc
6HJK	;	2.4	;	Crystal Structure of Aurora-A L210C catalytic domain in complex with ASDO2
6HJJ	;	2.13	;	Crystal structure of Aurora-A L210C catalytic domain in complex with ASDO6 ligand
1MQ4	;	1.9	;	Crystal Structure of Aurora-A Protein Kinase
3LAU	;	2.1	;	Crystal Structure of Aurora2 kinase in complex with a GSK3beta inhibitor
5K3Y	;	1.6	;	Crystal structure of AuroraB/INCENP in complex with BI 811283
8FWL	;	2.19	;	Crystal structure of Australian bat lyssavirus nucleoprotein in complex with phosphoprotein chaperone
2QQP	;	3.8	;	Crystal Structure of Authentic Providence Virus
6EI3	;	2.1	;	Crystal structure of auto inhibited POT family peptide transporter
2PZ1	;	2.25	;	Crystal Structure of Auto-inhibited Asef
6A20	;	2.4	;	Crystal Structure of auto-inhibited Kinesin-3 KIF13B
1JOE	;	2.4	;	Crystal Structure of Autoinducer-2 Production Protein (LuxS) from Heamophilus influenzae
3SIQ	;	2.4	;	Crystal Structure of autoinhibited dIAP1-BIR1 domain
4EJN	;	2.19	;	Crystal structure of autoinhibited form of AKT1 in complex with N-(4-(5-(3-acetamidophenyl)-2-(2-aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-3-yl)benzyl)-3-fluorobenzamide
2R09	;	1.9	;	Crystal Structure of Autoinhibited Form of Grp1 Arf GTPase Exchange Factor
2R0D	;	2.04	;	Crystal Structure of Autoinhibited Form of Grp1 Arf GTPase Exchange Factor
1UEC	;	1.82	;	Crystal structure of autoinhibited form of tandem SH3 domain of p47phox
4EPC	;	2.9	;	Crystal structure of Autolysin repeat domains from Staphylococcus epidermidis
4EBR	;	2.701	;	Crystal structure of Autophagic E2, Atg10
4WY4	;	1.4	;	Crystal structure of autophagic SNARE complex
3M95	;	2.4	;	Crystal structure of autophagy-related protein Atg8 from the silkworm Bombyx mori
2Z2Y	;	1.89	;	Crystal structure of autoprocessed form of Tk-subtilisin
3SDA	;	2.8	;	Crystal structure of autoreactive-Valpha14-Vbeta6 NKT TCR in complex with CD1d-beta-galactosylceramide
3SDD	;	3.0	;	Crystal structure of autoreactive-Valpha14-Vbeta6 NKT TCR in complex with CD1d-beta-lactosylceramide
3SDC	;	3.1	;	Crystal structure of autoreactive-Valpha14-Vbeta6 NKT TCR in complex with CD1d-globotrihexosylceramide
3SCM	;	2.5	;	Crystal structure of autoreactive-Valpha14-Vbeta6 NKT TCR in complex with CD1d-isoglobotrihexosylceramide
4APQ	;	3.0	;	Crystal structure of autoreactive-Valpha14-Vbeta6 NKT TCR in complex with CD1d-sulfatide
2XR9	;	2.05	;	Crystal structure of Autotaxin (ENPP2)
2XRG	;	3.2	;	Crystal structure of Autotaxin (ENPP2) in complex with the HA155 boronic acid inhibitor
5IJQ	;	2.05	;	Crystal structure of autotaxin (ENPP2) re-refined
7P0K	;	2.2	;	Crystal structure of Autotaxin (ENPP2) with 18F-labeled positron emission tomography ligand
5DLT	;	1.6	;	Crystal structure of Autotaxin (ENPP2) with 7-alpha-hydroxycholesterol
5DLV	;	2.0	;	Crystal structure of Autotaxin (ENPP2) with tauroursodeoxycholic acid (TUDCA)
5DLW	;	1.8	;	Crystal structure of Autotaxin (ENPP2) with tauroursodeoxycholic acid (TUDCA) and lysophosphatidic acid (LPA)
7P4O	;	1.69	;	Crystal structure of Autotaxin and 9(R)-delta6a,10a-THC
5L0B	;	2.41	;	Crystal Structure of Autotaxin and Compound 1
5L0E	;	3.06	;	Crystal Structure of Autotaxin and Compound 1
5L0K	;	2.73	;	Crystal Structure of Autotaxin and Compound PF-8380
7P4J	;	1.79	;	Crystal structure of Autotaxin and tetrahydrocannabinol
8C3O	;	2.47	;	Crystal structure of autotaxin gamma and compound MEY-003
8C3P	;	2.38	;	Crystal structure of autotaxin gamma in complex with LPA 18:1
3WAW	;	1.954	;	Crystal Structure of Autotaxin in Complex with 2BoA
3WAX	;	1.899	;	Crystal Structure of Autotaxin in Complex with 3BoA
3WAY	;	1.746	;	Crystal Structure of Autotaxin in Complex with 4BoA
6LEH	;	2.0	;	Crystal structure of Autotaxin in complex with an inhibitor
5OHI	;	1.66	;	Crystal structure of autotaxin in complex with BI-2545
3WAV	;	1.797	;	Crystal Structure of Autotaxin in Complex with Compound 10
5OLB	;	1.82	;	crystal structure of autotaxin in complex with PF-8380
5IJS	;	2.2	;	Crystal structure of autotaxin with orthovanadate bound as a trigonal bipyramidal intermediate analog
5INH	;	1.84	;	Crystal structure of Autotaxin/ENPP2 with a covalent fragment
5BTM	;	2.778	;	Crystal structure of AUUCU repeating RNA that causes spinocerebellar ataxia type 10 (SCA10)
7F60	;	2.85	;	Crystal structure of auxiliary protein in complex with human nuclear protein
7YC2	;	2.9	;	Crystal structure of auxiliary protein in complex with human protein
3N0A	;	2.2	;	Crystal structure of auxilin (40-400)
1NZ6	;	2.5	;	Crystal Structure of Auxilin J-Domain
1LR5	;	1.9	;	Crystal structure of auxin binding protein
1LRH	;	1.9	;	Crystal structure of auxin-binding protein 1 in complex with 1-naphthalene acetic acid
1THZ	;	1.8	;	Crystal Structure of Avian AICAR Transformylase in Complex with a Novel Inhibitor Identified by Virtual Ligand Screening
1G8M	;	1.75	;	CRYSTAL STRUCTURE OF AVIAN ATIC, A BIFUNCTIONAL TRANSFORMYLASE AND CYCLOHYDROLASE ENZYME IN PURINE BIOSYNTHESIS AT 1.75 ANG. RESOLUTION
4CYE	;	3.2	;	Crystal structure of avian FAK FERM domain FAK31-405 at 3.2A
3HW4	;	1.9	;	Crystal structure of avian influenza A virus in complex with TMP
4E5E	;	2.048	;	Crystal structure of avian influenza virus PAn Apo
4E5F	;	2.392	;	Crystal structure of avian influenza virus PAn bound to compound 1
4E5G	;	2.647	;	Crystal structure of avian influenza virus PAn bound to compound 2
4E5H	;	2.158	;	Crystal structure of avian influenza virus PAn bound to compound 3
4E5I	;	2.944	;	Crystal structure of avian influenza virus PAn bound to compound 4
4E5J	;	2.35	;	Crystal structure of avian influenza virus PAn bound to compound 5
4E5L	;	2.469	;	Crystal structure of avian influenza virus PAn bound to compound 6
3HW5	;	1.81	;	crystal structure of avian influenza virus PA_N in complex with AMP
3HW6	;	2.5	;	Crystal structure of avian influenza virus PA_N in complex with Mn
1VYO	;	1.48	;	Crystal structure of avidin
3FDC	;	3.1	;	Crystal Structure of Avidin
4JHQ	;	1.99	;	Crystal structure of avidin - 6-(6-biotinamidohexanamido)hexanoylferrocene complex
4I60	;	2.5	;	Crystal structure of avidin - biotinylruthenocene complex
5CHK	;	2.2	;	Crystal structure of avidin - HABA complex (hexagonal crystal form)
5HLM	;	2.5	;	Crystal structure of avidin complex with a ferrocene biotin derivative
7P4Z	;	2.2	;	Crystal structure of avidin from hen egg white in space group C2
5IRU	;	2.0	;	Crystal structure of avidin in complex with 1-biotinylpyrene
5IRW	;	2.1	;	Crystal structure of avidin in complex with 1-desthiobiotinylpyrene
5MYQ	;	1.89	;	Crystal structure of avidin in complex with ferrocene homobiotin derivative
2IUY	;	2.1	;	Crystal structure of AviGT4, a glycosyltransferase involved in Avilamycin A biosynthesis
2IV3	;	2.3	;	Crystal structure of AviGT4, a glycosyltransferase involved in Avilamycin A biosynthesis
4XAA	;	2.3	;	Crystal Structure of AviO1 from Streptomyces viridochromogenes Tue57
7T6A	;	1.65	;	Crystal structure of Avr1 (SIX4) from Fusarium oxysporum f. sp. lycopersici
7T69	;	1.68	;	Crystal structure of Avr3 (SIX1) from Fusarium oxysporum f. sp. lycopersici
2OF8	;	1.05	;	Crystal structure of AVR4 (D39A/C122S)-BNA complex
2OFB	;	1.16	;	Crystal structure of AVR4 (R112L/C122S)-BNA complex
5Z1V	;	1.661	;	Crystal structure of AvrPib
1S28	;	3.0	;	Crystal Structure of AvrPphF ORF1, the Chaperone for the Type III Effector AvrPphF ORF2 from P. syringae
1S21	;	2.0	;	Crystal Structure of AvrPphF ORF2, A Type III Effector from P. syringae
2FD4	;	1.8	;	Crystal Structure of AvrPtoB (436-553)
4Z8V	;	2.3	;	CRYSTAL STRUCTURE OF AVRRXO1-ORF1:-ORF2 COMPLEX, NATIVE.
4Z8U	;	1.65	;	CRYSTAL STRUCTURE OF AvrRxo1-ORF1:-ORF2 WITH ATP
4Z8Q	;	1.89	;	CRYSTAL STRUCTURE OF AvrRxo1-ORF1:AvrRxo1-ORF2 COMPLEX, SELENOMETHIONINE SUBSTITUTED.
4Z8T	;	1.64	;	CRYSTAL STRUCTURE OF AvrRxo1-ORF1:AvrRxo1-ORF2 WITH SULPHATE IONS
3VYH	;	1.63	;	Crystal structure of aW116R mutant of nitrile hydratase from Pseudonocardia thermophilla
3W7V	;	1.85	;	Crystal Structure of Axe2, an Acetylxylan Esterase from Geobacillus stearothermophilus
4J2J	;	2.5	;	Crystal structure of AXH domain complex with Capicua
4J2L	;	3.15	;	Crystal Structure of AXH domain complexed with Capicua
1WSP	;	2.9	;	Crystal structure of axin dix domain
2FT9	;	2.5	;	Crystal structure of axolotl (Ambystoma mexicanum) liver bile acid-binding protein bound to cholic acid
2FTB	;	2.0	;	Crystal structure of axolotl (Ambystoma mexicanum) liver bile acid-binding protein bound to oleic acid
1UGS	;	2.0	;	Crystal structure of aY114T mutant of Co-type nitrile hydratase
7OMD	;	1.601	;	Crystal structure of azacoelenterazine-bound Renilla reniformis luciferase variant RLuc8-D162A
1YHQ	;	2.4	;	Crystal Structure Of Azithromycin Bound To The G2099A Mutant 50S Ribosomal Subunit Of Haloarcula Marismortui
8GS1	;	2.7	;	Crystal structure of AziU2-U3 complex from Streptomyces sahachiroi NRRL2485
7WUX	;	1.8	;	Crystal structure of AziU3/U2 complexed with (5S,6S)-O7-sulfo DADH from Streptomyces sahachiroi
7WUW	;	1.75	;	Crystal structure of AziU3/U2 from Streptomyces sahachiroi
8H4J	;	2.0	;	Crystal Structure of AzoR-FMN-Lyb24 complex
3W77	;	1.66	;	Crystal Structure of azoreductase AzrA
3W7A	;	2.1	;	Crystal Structure of azoreductase AzrC fin complex with sulfone-modified azo dye Acid Red 88
3W78	;	2.62	;	Crystal Structure of azoreductase AzrC in complex with NAD(P)-inhibitor Cibacron Blue
3W79	;	2.4	;	Crystal Structure of azoreductase AzrC in complex with sulfone-modified azo dye Orange I
3P0R	;	1.799	;	Crystal structure of azoreductase from Bacillus anthracis str. Sterne
7C0E	;	2.204	;	Crystal structure of Azospirillum brasilense L-2-keto-3-deoxyarabonate dehydratase (2-oxobutyrate-bound form)
7C0C	;	1.9	;	Crystal structure of Azospirillum brasilense L-2-keto-3-deoxyarabonate dehydratase (apo form)
7C0D	;	1.6	;	Crystal structure of Azospirillum brasilense L-2-keto-3-deoxyarabonate dehydratase (Hydroxypyruvate-bound form)
6JNJ	;	1.5	;	Crystal structure of Azospirillum brasilense L-arabinose 1-dehydrogenase (apo-form)
6JNK	;	2.2	;	Crystal structure of Azospirillum brasilense L-arabinose 1-dehydrogenase (NADP-bound form)
7CGR	;	2.093	;	Crystal structure of Azospirillum brasilense L-arabinose 1-dehydrogenase E147A mutant (NADP and glycerol bound form)
7CGQ	;	2.208	;	Crystal structure of Azospirillum brasilense L-arabinose 1-dehydrogenase E147A mutant (NADP and L-arabinose bound form)
1CC5	;	2.5	;	CRYSTAL STRUCTURE OF AZOTOBACTER CYTOCHROME C5 AT 2.5 ANGSTROMS RESOLUTION
6XB9	;	2.25	;	Crystal structure of Azotobacter vinelandii 3-mercaptopropionic acid dioxygenase in complex with 3-hydroxypropionic acid
7KOV	;	2.95	;	Crystal structure of Azotobacter vinelandii 3-mercaptopropionic acid dioxygenase in complex with thiocyanate
7B81	;	2.092	;	Crystal structure of Azotobacter vinelandii L-rhamnose 1-dehydrogenase (NAD bound-form)
7DO5	;	1.836	;	Crystal structure of Azotobacter vinelandii L-rhamnose 1-dehydrogenase(apo-form)
7DO7	;	1.57	;	Crystal structure of Azotobacter vinelandii L-rhamnose 1-dehydrogenase(NAD and L-rhamnose bound-form)
7DO6	;	2.37	;	Crystal structure of Azotobacter vinelandii L-rhamnose 1-dehydrogenase(NADP bound-form)
3KLE	;	3.2	;	Crystal structure of AZT-resistant HIV-1 Reverse Transcriptase crosslinked to a DSDNA with a bound excision product, AZTPPPPA
3KLH	;	2.9	;	Crystal structure of AZT-Resistant HIV-1 Reverse Transcriptase crosslinked to post-translocation AZTMP-Terminated DNA (COMPLEX P)
3KLG	;	3.65	;	Crystal structure of AZT-resistant HIV-1 Reverse Transcriptase crosslinked to pre-translocation AZTMP-Terminated DNA (COMPLEX N)
2CCW	;	1.13	;	Crystal structure of Azurin II at atomic resolution (1.13 angstrom)
2GHZ	;	1.6	;	Crystal structure of Azurin Phe114Pro mutant
1RKR	;	2.45	;	CRYSTAL STRUCTURE OF AZURIN-I FROM ALCALIGENES XYLOSOXIDANS NCIMB 11015
8SZX	;	2.0	;	Crystal structure of b'-WD40 Lys17Ala mutant
5DEF	;	1.6	;	Crystal structure of B*27:04 complex bound to the pVIPR peptide
5DEG	;	1.83	;	Crystal structure of B*27:06 bound to the pVIPR peptide
3DX6	;	1.701	;	Crystal Structure of B*4402 presenting a 10mer EBV epitope
3DX8	;	2.1	;	Crystal Structure of B*4405 presenting a 10mer EBV epitope
4UDJ	;	1.94	;	Crystal structure of b-1,4-mannopyranosyl-chitobiose phosphorylase at 1.60 Angstrom in complex with beta-D-mannopyranose and inorganic phosphate
4UDG	;	1.6	;	Crystal structure of b-1,4-mannopyranosyl-chitobiose phosphorylase at 1.60 Angstrom in complex with N-acetylglucosamine and inorganic phosphate
4UDK	;	1.76	;	Crystal structure of b-1,4-mannopyranosyl-chitobiose phosphorylase at 1.76 Angstrom from unknown human gut bacteria (Uhgb_MP) in complex with N-acetyl-D-glucosamine, beta-D-mannopyranose and inorganic phosphate
4UDI	;	1.8	;	Crystal structure of b-1,4-mannopyranosyl-chitobiose phosphorylase at 1.85 Angstrom from unknown human gut bacteria (Uhgb_MP)
1L1L	;	1.75	;	CRYSTAL STRUCTURE OF B-12 DEPENDENT (CLASS II) RIBONUCLEOTIDE REDUCTASE
388D	;	1.55	;	CRYSTAL STRUCTURE OF B-DNA WITH INCORPORATED 2'-DEOXY-2'-FLUORO-ARABINO-FURANOSYL THYMINES: IMPLICATIONS OF CONFORMATIONAL PREORGANIZATION FOR DUPLEX STABILITY
389D	;	1.55	;	CRYSTAL STRUCTURE OF B-DNA WITH INCORPORATED 2'-DEOXY-2'-FLUORO-ARABINO-FURANOSYL THYMINES: IMPLICATIONS OF CONFORMATIONAL PREORGANIZATION FOR DUPLEX STABILITY
7UYN	;	1.65	;	Crystal structure of B-form alien DNA 5'-CTTBPPBBSSZZSAAG in a host-guest complex with the N-terminal fragment of Moloney murine leukemia virus reverse transcriptase
7UYO	;	1.65	;	Crystal structure of B-form alien DNA 5'-CTTSSPBZPSZBBAAG in a host-guest complex with the N-terminal fragment of Moloney murine leukemia virus reverse transcriptase
7UYP	;	1.5	;	Crystal structure of B-form alien DNA 5'-CTTZZPBSBSZPPAAG in a host-guest complex with the N-terminal fragment of Moloney murine leukemia virus reverse transcriptase
2FJY	;	2.3	;	Crystal Structure of B-form Bombyx mori Pheromone Binding Protein
6C48	;	2.32	;	Crystal structure of B-Myb-LIN9-LIN52 complex
5CSX	;	2.51	;	CRYSTAL STRUCTURE OF B-RAF IN COMPLEX WITH BI 882370
4E4X	;	3.6	;	Crystal Structure of B-Raf Kinase Domain in Complex with a Dihydropyrido[2,3-d]pyrimidinone-based Inhibitor
3CWV	;	1.95	;	Crystal structure of B-subunit of the DNA gyrase from Myxococcus xanthus
4NL1	;	2.3	;	Crystal structure of B. anthracis DHPS with compound 11: (E)-N-[4-(trifluoromethyl)benzyl]-1-[4-(trifluoromethyl)phenyl]methanimine
4D9P	;	2.26	;	Crystal structure of B. anthracis DHPS with compound 17
4DAF	;	2.501	;	Crystal structure of B. anthracis DHPS with compound 19
4D8A	;	2.183	;	Crystal structure of B. anthracis DHPS with compound 21
4DAI	;	2.5	;	Crystal structure of B. anthracis DHPS with compound 23
4D8Z	;	2.198	;	Crystal structure of B. anthracis DHPS with compound 24
4DB7	;	2.5	;	Crystal structure of B. anthracis DHPS with compound 25
4NIL	;	2.18	;	Crystal structure of B. anthracis DHPS with compound 5: 4-[(trifluoromethyl)sulfanyl]benzamide
4NIR	;	1.772	;	Crystal structure of B. anthracis DHPS with compound 6: 3-[6-(trifluoromethyl)-1H-benzimidazol-2-yl]propan-1-ol
4NHV	;	1.992	;	Crystal structure of B. anthracis DHPS with interfacial compound 4: 5-(trifluoromethyl)-1,2-benzoxazol-3-amine
3FL8	;	2.2881	;	Crystal structure of B. anthracis dihydrofolate reductase (DHFR) with RAB1, a TMP-dihydrophthalazine derivative
3FL9	;	2.4	;	Crystal structure of B. anthracis dihydrofolate reductase (DHFR) with trimethoprim
1T6B	;	2.5	;	Crystal structure of B. anthracis Protective Antigen complexed with human Anthrax toxin receptor
5FUS	;	1.87	;	Crystal structure of B. cenocepacia DfsA
1UOK	;	2.0	;	CRYSTAL STRUCTURE OF B. CEREUS OLIGO-1,6-GLUCOSIDASE
2G7M	;	2.9	;	Crystal structure of B. fragilis N-succinylornithine transcarbamylase P90E mutant complexed with carbamoyl phosphate and N-acetylnorvaline
5X6J	;	2.1	;	Crystal structure of B. globisporus adenylate kinase variant
6KTA	;	2.3	;	Crystal structure of B. halodurans MntR in apo form
6KTB	;	2.5	;	Crystal structure of B. halodurans MntR in apo form
7CV0	;	1.998	;	Crystal structure of B. halodurans NiaR in apo form
7CV2	;	1.802	;	Crystal structure of B. halodurans NiaR in niacin-bound form
1ZBF	;	1.5	;	Crystal structure of B. halodurans RNase H catalytic domain mutant D132N
3OQH	;	1.901	;	Crystal structure of B. licheniformis CDPS yvmC-BLIC
3OQJ	;	2.399	;	Crystal structure of B. licheniformis CDPS yvmC-BLIC in complex with CAPSO
3OQI	;	1.701	;	Crystal structure of B. licheniformis CDPS yvmC-BLIC in complex with CHES
3OM2	;	1.9	;	Crystal structure of B. megaterium levansucrase mutant D257A
3OM4	;	1.75	;	Crystal structure of B. megaterium levansucrase mutant K373A
3OM5	;	1.95	;	Crystal structure of B. megaterium levansucrase mutant N252A
3OM6	;	1.96	;	Crystal structure of B. megaterium levansucrase mutant Y247A
3OM7	;	1.86	;	Crystal structure of B. megaterium levansucrase mutant Y247W
5I7E	;	1.65	;	Crystal structure of B. pseudomallei FabI in apo form
5I7S	;	1.595	;	Crystal structure of B. pseudomallei FabI in complex with NAD and PT01
5I7V	;	2.6	;	Crystal structure of B. pseudomallei FabI in complex with NAD and PT02
5I8Z	;	1.623	;	Crystal structure of B. pseudomallei FabI in complex with NAD and PT12
5I8W	;	1.629	;	Crystal structure of B. pseudomallei FabI in complex with NAD and PT401
5I9L	;	1.8	;	Crystal structure of B. pseudomallei FabI in complex with NAD and PT404
5I7F	;	2.7	;	Crystal structure of B. pseudomallei FabI in complex with NAD and PT405
5I9M	;	2.25	;	Crystal structure of B. pseudomallei FabI in complex with NAD and PT408
5I9N	;	2.512	;	Crystal structure of B. pseudomallei FabI in complex with NAD and PT412
5IFL	;	2.6	;	Crystal structure of B. pseudomallei FabI in complex with NAD and triclosan
5SYK	;	1.8	;	Crystal structure of B. pseudomallei KatG treated with hydrogen peroxide
5SXQ	;	2.1	;	Crystal structure of B. pseudomallei KatG with isonicotinic acid hydrazide bound
5SXR	;	1.69	;	Crystal structure of B. pseudomallei KatG with NAD bound
2OV4	;	2.5	;	Crystal structure of B. stearothermophilus tryptophanyl tRNA synthetase in complex with adenosine tetraphosphate
1LD3	;	2.6	;	Crystal Structure of B. subilis ferrochelatase with Zn(2+) bound at the active site.
5T91	;	1.53	;	Crystal structure of B. subtilis 168 GlpQ in complex with bicine
5T9C	;	1.48	;	Crystal structure of B. subtilis 168 GlpQ in complex with glycerol-3-phosphate (1 hour soak)
5T9B	;	1.62	;	Crystal structure of B. subtilis 168 GlpQ in complex with glycerol-3-phosphate (5 minute soak)
5X6I	;	2.0	;	Crystal structure of B. subtilis adenylate kinase variant
1JL3	;	1.6	;	Crystal Structure of B. subtilis ArsC
4DCU	;	2.0	;	Crystal Structure of B. subtilis EngA in complex with GDP
4DCV	;	2.6	;	Crystal Structure of B. subtilis EngA in complex with GMPPCP
4DCT	;	2.3	;	Crystal Structure of B. subtilis EngA in complex with half-occupacy GDP
4DCS	;	2.25	;	Crystal Structure of B. subtilis EngA in complex with sulfate ion and GDP
3M4Z	;	1.94	;	Crystal Structure of B. subtilis ferrochelatase with Cobalt bound at the active site
2HK6	;	1.71	;	Crystal Structure of B. subtilis ferrochelatase with Iron bound at the active site
7B1R	;	2.8	;	Crystal structure of B. subtilis glucose-1-phosphate uridylyltransferase YngB
3BYK	;	2.1	;	Crystal structure of B. subtilis levansucrase mutant D247A
3BYJ	;	2.1	;	Crystal structure of B. subtilis levansucrase mutant D86A
3BYL	;	2.1	;	Crystal structure of B. subtilis levansucrase mutant E342A
3BYN	;	2.1	;	Crystal structure of B. subtilis levansucrase mutant E342A bound to raffinose
2FQO	;	1.87	;	Crystal structure of B. subtilis LuxS in complex with (2S)-2-Amino-4-[(2R,3R)-2,3-dihydroxy-3-N- hydroxycarbamoyl-propylmercapto]butyric acid
1YCL	;	1.8	;	Crystal Structure of B. subtilis LuxS in Complex with a Catalytic 2-Ketone Intermediate
1EXC	;	2.7	;	CRYSTAL STRUCTURE OF B. SUBTILIS MAF PROTEIN COMPLEXED WITH D-(UTP)
1NY1	;	1.8	;	CRYSTAL STRUCTURE OF B. SUBTILIS POLYSACCHARIDE DEACETYLASE NORTHEAST STRUCTURAL GENOMICS CONSORTIUM TARGET SR127.
7RMW	;	2.45	;	Crystal structure of B. subtilis PurR bound to ppGpp
1TWJ	;	2.5	;	Crystal Structure of B. subtilis PurS P21 Crystal Form
3JV2	;	2.5	;	Crystal Structure of B. subtilis SecA with bound peptide
2W1T	;	2.6	;	Crystal Structure of B. subtilis SpoVT
6UF5	;	2.8	;	Crystal structure of B. subtilis TagT
6UF6	;	2.2	;	Crystal structure of B. subtilis TagU
6UF3	;	1.6	;	Crystal structure of B. subtilis TagV
7O2N	;	2.8	;	Crystal structure of B. subtilis UGPase YngB
3V7Q	;	1.55	;	Crystal structure of B. subtilis YlxQ at 1.55 A resolution
8SBG	;	1.94	;	Crystal structure of B. theta tryptophanase in holo form
4J5F	;	1.72	;	Crystal Structure of B. thuringiensis AiiA mutant F107W
4J5H	;	1.45	;	Crystal Structure of B. thuringiensis AiiA mutant F107W with N-decanoyl-L-homoserine bound at the active site
3LD0	;	2.2	;	Crystal structure of B.licheniformis Anti-TRAP protein, an antagonist of TRAP-RNA interactions
2BX9	;	2.8	;	Crystal structure of B.subtilis Anti-TRAP protein, an antagonist of TRAP-RNA interactions
1ZUW	;	1.75	;	Crystal structure of B.subtilis glutamate racemase (RacE) with D-Glu
2FQT	;	1.79	;	Crystal structure of B.subtilis LuxS in complex with (2S)-2-Amino-4-[(2R,3S)-2,3-dihydroxy-3-N-hydroxycarbamoyl-propylmercapto]butyric acid
3K36	;	2.2	;	Crystal Structure of B/Perth Neuraminidase
3K38	;	2.19	;	Crystal Structure of B/Perth Neuraminidase D197E mutant
3K3A	;	2.59	;	Crystal Structure of B/Perth Neuraminidase D197E mutant in complex with Oseltamivir
3K39	;	2.54	;	Crystal Structure of B/Perth Neuraminidase D197E mutant in complex with Peramivir
3K37	;	2.0	;	Crystal Structure of B/Perth Neuraminidase in complex with Peramivir
6NL7	;	1.4	;	Crystal structure of B1 immunoglobulin-binding domain of Streptococcal Protein G (T16F, T18A, V21H, T25H, K28Y, V29I, K31R, Q32A, Y33L, N35K, D36A, N37Q)
8HYB	;	2.193	;	Crystal structure of B1 IMP-1 MBL in complex with 2-amino-5-phenethylthiazole-4-carboxylic acid
8JAO	;	2.194	;	Crystal structure of B1 IMP-1 MBL in complex with 2-amino-5-phenethylthiazole-4-carboxylic acid
8HY6	;	1.4	;	Crystal structure of B1 NDM-1 MBL in complex with 2-amino-5-phenethylthiazole-4-carboxylic acid
8HYD	;	1.71	;	Crystal structure of B1 VIM-2 MBL in complex with 2-amino-5-(2-(thiophen-2-yl)ethyl)thiazole-4-carboxylic acid
8HX5	;	2.6	;	Crystal structure of B1 VIM-2 MBL in complex with 2-amino-5-(4-methoxybenzyl)thiazole-4-carboxylic acid
8HXP	;	1.94	;	Crystal structure of B1 VIM-2 MBL in complex with 2-amino-5-(but-3-en-1-yl)thiazole-4-carboxylic acid
8HY1	;	1.937	;	Crystal structure of B1 VIM-2 MBL in complex with 2-amino-5-(thiophen-2-ylmethyl)thiazole-4-carboxylic acid
8HXW	;	2.39	;	Crystal structure of B1 VIM-2 MBL in complex with 2-amino-5-heptylthiazole-4-carboxylic acid
8HXV	;	2.603	;	Crystal structure of B1 VIM-2 MBL in complex with 2-amino-5-hexylthiazole-4-carboxylic acid
8HXO	;	1.902	;	Crystal structure of B1 VIM-2 MBL in complex with 2-amino-5-isobutylthiazole-4-carboxylic acid
8HXU	;	1.945	;	Crystal structure of B1 VIM-2 MBL in complex with 2-amino-5-pentylthiazole-4-carboxylic acid
8HY2	;	2.0	;	Crystal structure of B1 VIM-2 MBL in complex with 2-amino-5-phenethylthiazole-4-carboxylic acid
7JWJ	;	3.251	;	Crystal Structure of B17-C1 TCR-H2Db
7JWI	;	3.02	;	Crystal structure of B17.R2 TCR in complex with H2D-b-NP366
8HXN	;	1.35	;	Crystal structure of B2 Sfh-I MBL in complex with 2-amino-5-(4-(but-3-en-1-yloxy)benzyl)thiazole-4-carboxylic acid
8HXI	;	1.81	;	Crystal structure of B3 L1 MBL in complex with 2-amino-5-(4-isopropylbenzyl)thiazole-4-carboxylic acid
8HXE	;	2.382	;	Crystal structure of B3 L1 MBL in complex with 2-amino-5-(4-propylbenzyl)thiazole-4-carboxylic acid
5HH5	;	1.8	;	Crystal structure of B3 metallo-beta-lactamase L1 complexed with a phosphonate-based inhibitor
5HH6	;	1.8	;	Crystal structure of B3 metallo-beta-lactamase L1 in complex with a phosphonate-based inhibitor
7QRY	;	2.07	;	Crystal structure of B30.2 PRYSPRY domain of MID1
7QRZ	;	1.57	;	Crystal structure of B30.2 PRYSPRY domain of MID2
7QS0	;	2.3	;	Crystal structure of B30.2 PRYSPRY domain of TRIM10
7QS1	;	1.93	;	Crystal structure of B30.2 PRYSPRY domain of TRIM11
7QS2	;	1.7	;	Crystal structure of B30.2 PRYSPRY domain of TRIM15
7QS3	;	1.75	;	Crystal structure of B30.2 PRYSPRY domain of TRIM16
7QS4	;	2.25	;	Crystal structure of B30.2 PRYSPRY domain of TRIM36
7QS5	;	1.65	;	Crystal structure of B30.2 PRYSPRY domain of TRIM67
5IW1	;	3.001	;	Crystal Structure of B4.2.3 T-Cell Receptor
5IVX	;	2.1	;	Crystal Structure of B4.2.3 T-Cell Receptor and H2-Dd P18-I10 Complex
5YO5	;	2.2	;	Crystal Structure of B562RIL with engineered disulfide bond A20C-Q25C
5YO4	;	1.37	;	Crystal Structure of B562RIL with engineered disulfide bond K27C-A79C
5YO6	;	1.204	;	Crystal Structure of B562RIL with engineered disulfide bond T9C-A36C
5YO3	;	1.7	;	Crystal Structure of B562RIL with engineered disulfide bond V16C-A29C
5YM7	;	1.56225	;	Crystal Structure of B562RIL without disulfide bond
1M6T	;	1.81	;	CRYSTAL STRUCTURE OF B562RIL, A REDESIGNED FOUR HELIX BUNDLE
3SLB	;	2.0	;	Crystal structure of BA2930 in complex with AcCoA and cytosine
3SLF	;	2.05	;	Crystal structure of BA2930 in complex with AcCoA and uracil
3IJW	;	1.9	;	Crystal structure of BA2930 in complex with CoA
3N0S	;	2.15	;	Crystal structure of BA2930 mutant (H183A) in complex with AcCoA
3KZL	;	2.1	;	Crystal structure of BA2930 mutant (H183G) in complex with AcCoA
3N0M	;	2.4	;	Crystal structure of BA2930 mutant (H183G) in complex with AcCoA
3E4F	;	2.0	;	Crystal structure of BA2930- a putative aminoglycoside N3-acetyltransferase from Bacillus anthracis
5F1Y	;	2.04	;	Crystal structure of Ba3275, the member of S66 family of serine peptidases
3H7J	;	1.87	;	Crystal structure of BacB, an enzyme involved in Bacilysin synthesis, in monoclinic form
3H7Y	;	2.22	;	Crystal structure of BacB, an enzyme involved in Bacilysin synthesis, in tetragonal form
3H9A	;	2.04	;	Crystal structure of BacB, an enzyme involved in Bacilysin synthesis, in triclinic form
3VMM	;	2.5	;	Crystal structure of BacD, an L-amino acid dipeptide ligase from Bacillus subtilis
5QCT	;	2.05	;	Crystal structure of BACE complex with BMC001
5QDB	;	2.1	;	Crystal structure of BACE complex with BMC002
5QD8	;	2.45	;	Crystal structure of BACE complex with BMC003
5QD6	;	2.51	;	Crystal structure of BACE complex with BMC004
5QD9	;	2.602	;	Crystal structure of BACE complex with BMC005
5QCX	;	2.2	;	Crystal structure of BACE complex with BMC007
5QCY	;	2.15	;	Crystal structure of BACE complex with BMC008
5QD5	;	2.3	;	Crystal structure of BACE complex with BMC009
5QD3	;	2.46	;	Crystal structure of BACE complex with BMC010
5QD1	;	2.4	;	Crystal structure of BACE complex with BMC011
5QDA	;	2.1	;	Crystal structure of BACE complex with BMC013
5QD7	;	2.12	;	Crystal structure of BACE complex with BMC014
5QCZ	;	2.3	;	Crystal structure of BACE complex with BMC015
5QCO	;	2.7	;	Crystal structure of BACE complex with BMC016
5QD2	;	2.5	;	Crystal structure of BACE complex with BMC017
5QCP	;	2.45	;	Crystal structure of BACE complex with BMC018
5QDC	;	2.1	;	Crystal structure of BACE complex with BMC019 hydrolyzed
5QDD	;	2.0	;	Crystal structure of BACE complex with BMC020 hydrolyzed
5QCW	;	2.1	;	Crystal structure of BACE complex with BMC021
5QCU	;	1.951	;	Crystal structure of BACE complex with BMC022
5QCV	;	2.25	;	Crystal structure of BACE complex with BMC023
5QD4	;	2.112	;	Crystal structure of BACE complex with BMC023
5QCS	;	2.31	;	Crystal structure of BACE complex with BMC024
5QCQ	;	1.97	;	Crystal structure of BACE complex with BMC025
5QCR	;	2.2	;	Crystal structure of BACE complex with BMC026
5QD0	;	2.6	;	Crystal structure of BACE complex withBMC006
4YBI	;	1.84	;	Crystal structure of BACE with amino thiazine inhibitor LY2811376
4X7I	;	1.77	;	Crystal Structure of BACE with amino thiazine inhibitor LY2886721
3UDH	;	1.7	;	Crystal Structure of BACE with Compound 1
3UDY	;	2.0	;	Crystal Structure of BACE with Compound 11
3UDP	;	1.95	;	Crystal Structure of BACE with Compound 12
4FM8	;	1.9	;	Crystal Structure of BACE with Compound 12a
3UDQ	;	2.73	;	Crystal Structure of BACE with Compound 13
3UDR	;	1.95	;	Crystal Structure of BACE with Compound 14
4FM7	;	1.56	;	Crystal Structure of BACE with Compound 14g
3UDJ	;	1.8	;	Crystal Structure of BACE with Compound 5
3UDK	;	2.51	;	Crystal Structure of BACE with Compound 6
3UDM	;	1.94	;	Crystal Structure of BACE with Compound 8
3UDN	;	2.193	;	Crystal Structure of BACE with Compound 9
5F01	;	1.52	;	CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH (1SR,2SR)-2-((R)-2-amino-5,5-difluoro-4-methyl-5,6-dihydro-4H-1,3-oxazin-4-yl)-N-(3-chloroquinolin-8-yl)cyclopropanecarboxamide
5EZZ	;	2.1	;	CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH (4S)-4-[3-(5-chloro-3-pyridyl)phenyl]-4-[4-(difluoromethoxy)-3-methyl-phenyl]-5H-oxazol-2-amine
4J0V	;	1.94	;	CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-Cyano-pyridine-2-carboxylic acid [3-((4R,5R)-2-amino-5-fluoro-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
4J1I	;	2.05	;	CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-Cyano-pyridine-2-carboxylic acid [3-((4R,5R,6R)-2-amino-5-fluoro-4-methyl-6-trifluoromethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
4J1K	;	2.18	;	CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-Cyano-pyridine-2-carboxylic acid [3-((4R,5R,6S)-2-amino-5-fluoro-4-methyl-6-trifluoromethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
4J0Y	;	1.77	;	CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-Cyano-pyridine-2-carboxylic acid [3-((4R,5S)-2-amino-5-fluoro-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
4J0Z	;	2.13	;	CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-Cyano-pyridine-2-carboxylic acid [3-((4S,5R)-2-amino-5-fluoro-4-fluoromethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
4J1H	;	2.2	;	CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-Cyano-pyridine-2-carboxylic acid [3-((4S,6R)-2-amino-4-methyl-6-trifluoromethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
4J1E	;	1.78	;	CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-Cyano-pyridine-2-carboxylic acid [3-((4S,6S)-2-amino-4-fluoromethyl-6-trifluoromethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
4J1F	;	2.25	;	CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-Cyano-pyridine-2-carboxylic acid [3-((4S,6S)-2-amino-4-methyl-6-trifluoromethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
4J17	;	1.81	;	CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-Cyano-pyridine-2-carboxylic acid [3-((S)-2-amino-4-difluoromethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
4J0P	;	1.97	;	CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-Cyano-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
4J1C	;	2.01	;	CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-Cyano-pyridine-2-carboxylic acid [3-((S)-2-amino-5,5-difluoro-4-fluoromethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
4J0T	;	2.05	;	CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-Ethoxy-pyridine-2-carboxylic acid [3-((R)-2-amino-5,5-difluoro-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
5F00	;	1.95	;	CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-[3-[(3-chloro-8-quinolyl)amino]phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine
5MCQ	;	1.82	;	CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH ACTIVE SITE AND EXOSITE BINDING PEPTIDE INHIBITOR
5MCO	;	2.49	;	CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH ACTIVE SITE INHIBITOR GRL-8234 AND EXOSITE PEPTIDE
3K5D	;	2.9	;	Crystal Structure of BACE-1 in complex with AHM178
3ZMG	;	1.74	;	CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH CHEMICAL LIGAND
3ZOV	;	2.1	;	CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH CHEMICAL LIGAND
4BEK	;	2.39	;	CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH CHEMICAL LIGAND
4BFD	;	2.3	;	CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH CHEMICAL LIGAND
3CKP	;	2.3	;	Crystal structure of BACE-1 in complex with inhibitor
3CKR	;	2.7	;	Crystal structure of BACE-1 in complex with inhibitor
5MBW	;	2.95	;	CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH Pep#3
5EZX	;	1.9	;	CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH {(1R,2R)-2-[(R)-2-Amino-4-(4-difluoromethoxy-phenyl)-4,5-dihydro-oxazol-4-yl]-cyclopropyl}-(5-chloro-pyridin-3-yl)-methanone
2ZHS	;	2.7	;	Crystal structure of BACE1 at pH 4.0
2ZHT	;	2.35	;	Crystal structure of BACE1 at pH 4.5
2ZHU	;	2.4	;	Crystal structure of BACE1 at pH 5.0
2ZHV	;	1.85	;	Crystal structure of BACE1 at pH 7.0
3EXO	;	2.1	;	Crystal structure of BACE1 bound to inhibitor
3TPP	;	1.6	;	Crystal structure of BACE1 complexed with an inhibitor
3TPR	;	2.55	;	Crystal structure of BACE1 complexed with an inhibitor
5YGY	;	2.3	;	Crystal Structure of BACE1 in complex with (S)-N-(3-(2-amino-6-(fluoromethyl)-4 -methyl-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-5-cyanopicolinamide
6WNY	;	1.86	;	Crystal structure of BACE1 in complex with (Z)-fluoro-olefin containing compound 15
4WTU	;	1.85	;	Crystal structure of BACE1 in complex with 2-aminooxazoline 3-aza-4-fluoro-xanthene inhibitor 22
4XKX	;	1.8	;	Crystal structure of BACE1 in complex with 2-aminooxazoline 3-azaxanthene inhibitor 28
4RCF	;	1.78	;	Crystal structure of BACE1 in complex with 2-aminooxazoline 4-fluoroxanthene inhibitor 49
5UYU	;	1.9	;	Crystal structure of BACE1 in complex with 2-aminooxazoline-3-azaxanthene compound 12
5I3W	;	2.15	;	Crystal structure of BACE1 in complex with 2-aminooxazoline-3-azaxanthene inhibitor 2
5IE1	;	2.298	;	Crystal structure of BACE1 in complex with 3-(2-amino-6-(o-tolyl)quinolin-3-yl)-N-(3,3-dimethylbutyl)propanamide
4RCD	;	1.9	;	Crystal structure of BACE1 in complex with a 2-aminooxazoline 4-azaxanthene inhibitor
4FRK	;	2.1	;	Crystal structure of BACE1 in complex with aminooxazoline xanthene 11a
4FRJ	;	1.95	;	Crystal structure of BACE1 in complex with aminooxazoline xanthene 9l
4RCE	;	2.4	;	Crystal structure of BACE1 in complex with aminooxazoline xanthene inhibitor 2
5I3V	;	1.62	;	Crystal structure of BACE1 in complex with aminoquinoline compound 1
5I3X	;	1.85	;	Crystal structure of BACE1 in complex with aminoquinoline inhibitor 6
5I3Y	;	2.15	;	Crystal structure of BACE1 in complex with aminoquinoline inhibitor 9
4FRI	;	2.3	;	Crystal structure of BACE1 in complex with biarylspiro aminooxazoline 6
4DI2	;	2.0	;	Crystal structure of BACE1 in complex with hydroxyethylamine inhibitor 37
4KE0	;	2.3	;	Crystal structure of BACE1 in complex with hydroxyethylamine-macrocyclic inhibitor 13
4KE1	;	1.91	;	Crystal structure of BACE1 in complex with hydroxyethylamine-macrocyclic inhibitor 19
6JSE	;	2.0	;	Crystal Structure of BACE1 in complex with N-(3-((4S,5R)-2-amino-4-methyl-5-phenyl-5,6-dihydro-4H-1,3-thiazin-4-yl)-4-fluorophenyl)-5-(fluoromethoxy)pyrazine-2-carboxamide
6JSF	;	2.3	;	Crystal Structure of BACE1 in complex with N-(3-((4S,5S)-2-amino-4-methyl-5-phenyl-5,6-dihydro-4H-1,3-thiazin-4-yl)-4-fluorophenyl)-5-(fluoromethoxy)pyrazine-2-carboxamide
7D36	;	2.3	;	Crystal Structure of BACE1 in complex with N-{3-[(3S)-1-amino-5-fluoro-3-methyl-3,4-dihydro-2,6-naphthyridin-3-yl]-4-fluorophenyl}-5-cyano-3-methylpyridine-2-carboxamide
7D2X	;	2.45	;	Crystal Structure of BACE1 in complex with N-{3-[(4R)-2-amino-4-(prop-1-yn-1-yl)-5,6-dihydro-4H-1,3-oxazin-4-yl]-4-fluorophenyl}-5-cyanopyridine-2-carboxamide
7F1D	;	2.05	;	Crystal Structure of BACE1 in complex with N-{3-[(4R,5R,6R)-2-amino-5-fluoro-4,6-dimethyl-5,6-dihydro-4H-1,3-thiazin-4-yl]-4-fluorophenyl}-2H,3H-[1,4]dioxino[2,3-c]pyridine-7-carboxamide
6JT3	;	2.4	;	Crystal Structure of BACE1 in complex with N-{3-[(4R,5R,6R)-2-amino-5-fluoro-4,6-dimethyl-5,6-dihydro-4H-1,3-thiazin-4-yl]-4-fluorophenyl}-5-(fluoromethoxy)pyrazine-2-carboxamide
7DCZ	;	2.3	;	Crystal Structure of BACE1 in complex with N-{3-[(4S)-2-amino-4-methyl-4H-1,3-thiazin-4-yl]-4- fluorophenyl}-5-cyanopyridine-2-carboxamide
6JSG	;	2.3	;	Crystal Structure of BACE1 in complex with N-{3-[(4S)-2-amino-4-methyl-5,6-dihydro-4H-1,3-thiazin-4-yl]-4-fluorophenyl}-5-chloropyridine-2-carboxamide
6JT4	;	2.2	;	Crystal Structure of BACE1 in complex with N-{3-[(4S,6S)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-thiazin-4-yl]-4-fluorophenyl}-5-(fluoromethoxy)pyrazine-2-carboxamide
7D2V	;	2.1	;	Crystal Structure of BACE1 in complex with N-{3-[(5R)-3-amino-2,5-dimethyl-1,1-dioxo-5,6-dihydro-2H-1lambda6,2,4-thiadiazin-5-yl]-4-fluorophenyl}-5-fluoropyridine-2-carboxamide
6JSN	;	2.6	;	Crystal Structure of BACE1 in complex with N-{3-[(5R)-3-amino-5-methyl-9,9-dioxo-2,9lambda6-dithia-4-azaspiro[5.5]undec-3-en-5-yl]-4-fluorophenyl}-5-(fluoromethoxy)pyrazine-2-carboxamide
7D5A	;	2.2	;	Crystal Structure of BACE1 in complex with N-{3-[(9S)-7-amino-2,2-difluoro-9-(prop-1-yn-1-yl)-6-oxa-8-azaspiro[3.5]non-7-en-9-yl]-4-fluorophenyl}-5-cyanopyridine-2-carboxamide
2ZHR	;	2.5	;	Crystal structure of BACE1 in complex with OM99-2 at pH 5.0
4XXS	;	1.86	;	Crystal structure of BACE1 with a pyrazole-substituted tetrahydropyran thioamidine
3UQP	;	1.77	;	Crystal structure of Bace1 with its inhibitor
3UQR	;	3.056	;	Crystal structure of BACE1 with its inhibitor
3UQU	;	1.7	;	Crystal structure of BACE1 with its inhibitor
3UQW	;	2.2	;	Crystal structure of BACE1 with its inhibitor
3UQX	;	1.7	;	Crystal structure of BACE1 with its inhibitor
4DV9	;	2.076	;	Crystal structure of BACE1 with its inhibitor
4DVF	;	1.803	;	Crystal structure of BACE1 with its inhibitor
4FCO	;	1.76	;	Crystal structure of bace1 with its inhibitor
4IVS	;	2.636	;	Crystal structure of BACE1 with its inhibitor
4IVT	;	1.6	;	Crystal structure of BACE1 with its inhibitor
4FGX	;	1.59	;	Crystal structure of bace1 with novel inhibitor
3RNZ	;	2.01	;	Crystal structure of Bacillus Amyloliquefaciens Pyroglutamyl Peptidase I
3RO0	;	1.5	;	Crystal structure of Bacillus amyloliquefaciens pyroglutamyl peptidase I and terpyridine platinum(II)
3JW3	;	2.57	;	Crystal structure of Bacillus anthracis (F96I) dihydrofolate reductase complexed with NADPH and Trimethoprim
3JWF	;	2.57	;	Crystal structure of Bacillus anthracis (Y102F) dihydrofolate reductase complexed with NADPH and (R)-2,4-diamino-5-(3-hydroxy-3-(3,4,5-trimethoxyphenyl)prop-1-ynyl)-6-methylpyrimidine (UCP113A)
3JWK	;	2.08	;	Crystal structure of Bacillus anthracis (Y102F) dihydrofolate reductase complexed with NADPH and (S)-2,4-diamino-5-(3-methoxy-3-(3,4,5-trimethoxyphenyl)prop-1-ynyl)-6-methylpyrimidine (UCP114A)
3JWC	;	2.57	;	Crystal structure of Bacillus anthracis (Y102F) dihydrofolate reductase complexed with NADPH and 2,4-diamino-5-(3-(3,4,5-trimethoxyphenyl)prop-1-ynyl)-6-ethylpyrimidine (UCP120A)
3JW5	;	2.89	;	Crystal structure of Bacillus anthracis (Y102F) dihydrofolate reductase complexed with NADPH and Trimethoprim
8D02	;	1.4	;	Crystal Structure of Bacillus anthracis BxpB
8SSX	;	1.65	;	Crystal structure of Bacillus anthracis dihydrofolate reductase at 1.65-A resolution
3JWM	;	2.57	;	Crystal structure of Bacillus anthracis dihydrofolate reductase complexed with NADPH and (S)-2,4-diamino-5-(3-methoxy-3-(3,4,5-trimethoxyphenyl)prop-1-ynyl)-6-methylpyrimidine (UCP114A)
3JVX	;	2.25	;	Crystal structure of Bacillus anthracis dihydrofolate reductase complexed with NADPH and 2,4-diamino-5-(3-(3,4,5-trimethoxyphenyl)prop-1-ynyl)-6-ethylpyrimidine (UCP120A)
8SU7	;	2.4	;	Crystal structure of Bacillus anthracis dihydroneopterin aldolase
8SV5	;	2.16	;	Crystal structure of Bacillus anthracis dihydroneopterin aldolase in complex with 6-hydroxymethyl-7,8-dihydropterin
3L44	;	2.05	;	Crystal structure of Bacillus anthracis HemL-1, glutamate semialdehyde aminotransferase
4YU6	;	2.6	;	Crystal structure of Bacillus anthracis immune inhibitor A2 peptidase zymogen
3USB	;	2.38	;	Crystal Structure of Bacillus anthracis Inosine Monophosphate Dehydrogenase in the complex with IMP
4AY3	;	1.76	;	Crystal structure of Bacillus anthracis PurE
4AY4	;	2.0	;	crystal structure of Bacillus anthracis PurE
4B4K	;	2.5	;	Crystal structure of Bacillus anthracis PurE
3LAC	;	2.0	;	Crystal structure of Bacillus anthracis pyrrolidone-carboxylate peptidase, pcP
4PDB	;	2.6	;	CRYSTAL STRUCTURE OF BACILLUS ANTHRACIS RIBOSOMAL PROTEIN S8 IN COMPLEX WITH AN RNA APTAMER
3TL2	;	1.7	;	Crystal structure of Bacillus anthracis str. Ames malate dehydrogenase in closed conformation.
2C5S	;	2.5	;	Crystal structure of Bacillus anthracis ThiI, a tRNA-modifying enzyme containing the predicted RNA-binding THUMP domain
3G9K	;	1.79	;	Crystal structure of Bacillus anthracis transpeptidase enzyme CapD
3GA9	;	2.3	;	Crystal structure of Bacillus anthracis transpeptidase enzyme CapD, crystal form II
2HAX	;	1.29	;	Crystal structure of Bacillus caldolyticus cold shock protein in complex with hexathymidine
1I5E	;	3.0	;	CRYSTAL STRUCTURE OF BACILLUS CALDOLYTICUS URACIL PHOSPHORIBOSYLTRANSFERASE WITH BOUND UMP
3UAY	;	1.4	;	Crystal structure of Bacillus cereus adenosine phosphorylase D204N mutant complexed with adenosine
3UAZ	;	1.4	;	Crystal structure of Bacillus cereus adenosine phosphorylase D204N mutant complexed with inosine
3BVS	;	2.1	;	Crystal Structure of Bacillus cereus Alkylpurine DNA Glycosylase AlkD
3FCE	;	1.9	;	Crystal Structure of Bacillus cereus D-alanyl Carrier Protein Ligase DltA in Complex with ATP: Implications for Adenylation Mechanism
5Z7Q	;	1.85	;	Crystal structure of Bacillus cereus flagellin
5ZIY	;	2.2	;	Crystal structure of Bacillus cereus FlgL
1ZSW	;	1.65	;	Crystal Structure of Bacillus cereus Metallo Protein from Glyoxalase family
5FQA	;	1.1	;	Crystal Structure of Bacillus cereus Metallo-Beta-Lactamase II
5FQB	;	1.899	;	Crystal Structure of Bacillus cereus Metallo-Beta-Lactamase with 2C
4BMO	;	1.81	;	Crystal Structure of Bacillus cereus Ribonucleotide Reductase di- iron NrdF in Complex with NrdI (1.8 A resolution)
4BMP	;	2.1	;	Crystal Structure of Bacillus cereus Ribonucleotide Reductase di- iron NrdF in Complex with NrdI (2.1 A resolution)
2UYR	;	2.4	;	Crystal structure of Bacillus cereus sphingomyelinase mutant :N57A
4EI8	;	2.1	;	Crystal structure of Bacillus cereus TubZ, apo-form
4EI7	;	1.9	;	Crystal structure of Bacillus cereus TubZ, GDP-form
4EI9	;	3.3	;	Crystal structure of Bacillus cereus TubZ, GTP-form
3WNK	;	2.3	;	Crystal Structure of Bacillus circulans T-3040 cycloisomaltooligosaccharide glucanotransferase
4BOK	;	2.047	;	Crystal structure of Bacillus circulans TN-31 Aman6
4BOJ	;	1.379	;	Crystal structure of Bacillus circulans TN-31 Aman6 in complex with mannobiose
7PQ9	;	2.8	;	Crystal structure of Bacillus clausii pdxR at 2.8 Angstroms resolution
4BDP	;	1.8	;	CRYSTAL STRUCTURE OF BACILLUS DNA POLYMERASE I FRAGMENT COMPLEXED TO 11 BASE PAIRS OF DUPLEX DNA AFTER ADDITION OF TWO DATP RESIDUES
2BDP	;	1.8	;	CRYSTAL STRUCTURE OF BACILLUS DNA POLYMERASE I FRAGMENT COMPLEXED TO 9 BASE PAIRS OF DUPLEX DNA
1L3S	;	1.7	;	Crystal Structure of Bacillus DNA Polymerase I Fragment complexed to 9 base pairs of duplex DNA.
1L3T	;	1.7	;	Crystal Structure of Bacillus DNA Polymerase I Fragment product complex with 10 base pairs of duplex DNA following addition of a single dTTP residue
1L3U	;	1.8	;	Crystal Structure of Bacillus DNA Polymerase I Fragment product complex with 11 base pairs of duplex DNA following addition of a dTTP and a dATP residue.
1L5U	;	1.95	;	Crystal Structure of Bacillus DNA Polymerase I Fragment product complex with 12 base pairs of duplex DNA following addition of a dTTP, a dATP, and a dCTP residue.
1L3V	;	1.71	;	Crystal Structure of Bacillus DNA Polymerase I Fragment product complex with 15 base pairs of duplex DNA following addition of dTTP, dATP, dCTP, and dGTP residues.
3PX0	;	1.73	;	Crystal Structure of Bacillus DNA Polymerase I Large Fragment Bound to DNA and dCTP-dA Mismatch (tautomer) in Closed Conformation
3THV	;	1.611	;	Crystal Structure of Bacillus DNA Polymerase I Large Fragment Bound to DNA and ddATP-dT in Closed Conformation
3PX6	;	1.59	;	Crystal Structure of Bacillus DNA Polymerase I Large Fragment Bound to DNA and ddCTP-dA Mismatch (tautomer) in Closed Conformation
3PX4	;	1.582	;	Crystal Structure of Bacillus DNA Polymerase I Large Fragment Bound to DNA and ddCTP-dA Mismatch (wobble) in Ajar Conformation
3TI0	;	1.62	;	Crystal Structure of Bacillus DNA Polymerase I Large Fragment Bound to DNA and ddGTP-dC in Closed Conformation
3PV8	;	1.52	;	Crystal Structure of Bacillus DNA Polymerase I Large Fragment Bound to DNA and ddTTP-dA in Closed Conformation
3TAN	;	1.53	;	Crystal Structure of Bacillus DNA Polymerase I Large Fragment Bound to Duplex DNA with Cytosine-Adenine Mismatch at (n-1) Position
3TAP	;	1.655	;	Crystal Structure of Bacillus DNA Polymerase I Large Fragment Bound to Duplex DNA with Cytosine-Adenine Mismatch at (n-3) Position
3TAQ	;	1.65	;	Crystal Structure of Bacillus DNA Polymerase I Large Fragment Bound to Duplex DNA with Cytosine-Adenine Mismatch at (n-4) Position
3TAR	;	1.6	;	Crystal Structure of Bacillus DNA Polymerase I Large Fragment Bound to Duplex DNA with Cytosine-Adenine Mismatch at (n-6) Position
3AGF	;	2.6	;	Crystal structure of Bacillus glutaminase in the presence of 4.3M NaCl
3HDI	;	2.7	;	Crystal structure of Bacillus halodurans metallo peptidase
7K9C	;	1.0	;	Crystal structure of Bacillus halodurans OapB (iodine-derivative) at 1.0 A
7K9B	;	1.202	;	Crystal structure of Bacillus halodurans OapB (native) at 1.2 A
7K9D	;	2.098	;	Crystal structure of Bacillus halodurans OapB in complex with its OLE RNA target (crystal form I)
7K9E	;	2.1	;	Crystal structure of Bacillus halodurans OapB in complex with its OLE RNA target (crystal form II)
7KKV	;	2.0	;	Crystal structure of Bacillus halodurans OapB in complex with its OLE RNA target (native, crystal form I)
6DPN	;	1.493	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 E188A in Complex with an RNA/DNA Hybrid: Reaction in 2 mM Mg2+ and 200 mM K+ for 200 s at 21 C
6DPO	;	1.45	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 E188A in Complex with an RNA/DNA Hybrid: Reaction in 2 mM Mg2+ and 200 mM K+ for 360 s at 21 C
6DPH	;	1.339	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 E188A in Complex with an RNA/DNA Hybrid: Reaction in 2 mM Mn2+ and 200 mM K+ for 120 s at 21 C
6DPG	;	1.38	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 E188A in Complex with an RNA/DNA Hybrid: Reaction in 4 mM Mn2+ and 200 mM K+ for 240 s at 21 C
6DOI	;	1.948	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid (1.54 Angstrom wavelength): Soak in 0.5 mM EGTA and 200 mM K+ at 21 C
6DOZ	;	1.573	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 1 mM Mg2+ and 75 mM K+ for 40 s at 21 C
6DP3	;	1.461	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 10 mM Mg2+ and 75 mM K+ for 40 s at 21 C
6DPC	;	1.34	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 12 mM Mn2+ and 200 mM K+ for 40 s at 21 C
6DPD	;	1.46	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 16 mM Mn2+ and 200 mM K+ for 40 s at 21 C
6DON	;	1.422	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 2 mM Mg2+ and 100 mM K+ for 120 s at 21 C (dataset 1)
6DOO	;	1.44	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 2 mM Mg2+ and 100 mM K+ for 120 s at 21 C (dataset 2)
6DO9	;	1.36	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 2 mM Mg2+ and 200 mM K+ for 120 s at 21 C
6DOP	;	1.25	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 2 mM Mg2+ and 200 mM K+ for 120 s at 21 C (dataset 1)
6DOQ	;	1.422	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 2 mM Mg2+ and 200 mM K+ for 120 s at 21 C (dataset 2)
6DOB	;	1.343	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 2 mM Mg2+ and 200 mM K+ for 200 s at 21 C
6DOC	;	1.496	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 2 mM Mg2+ and 200 mM K+ for 240 s at 21 C
6DOD	;	1.535	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 2 mM Mg2+ and 200 mM K+ for 360 s at 21 C
6DOE	;	1.451	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 2 mM Mg2+ and 200 mM K+ for 420 s at 21 C
6DOA	;	1.474	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 2 mM Mg2+ and 200 mM K+ for 480 s at 21 C
6DOF	;	1.433	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 2 mM Mg2+ and 200 mM K+ for 540 s at 21 C
6DOG	;	1.285	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 2 mM Mg2+ and 200 mM K+ for 600 s at 21 C
6DO8	;	1.414	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 2 mM Mg2+ and 200 mM K+ for 80 s at 21 C
6DOY	;	1.45	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 2 mM Mg2+ and 200 mM Li+ for 120 s at 21 C
6DOK	;	1.38	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 2 mM Mg2+ and 25 mM K+ for 120 s at 21 C (dataset 1)
6DOL	;	1.433	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 2 mM Mg2+ and 25 mM K+ for 120 s at 21 C (dataset 2)
6DOR	;	1.5	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 2 mM Mg2+ and 300 mM K+ for 120 s at 21 C (dataset 1)
6DOS	;	1.318	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 2 mM Mg2+ and 300 mM K+ for 120 s at 21 C (dataset 2)
6DOJ	;	1.403	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 2 mM Mg2+ and 5 mM K+ for 120 s at 21 C
6DOM	;	1.425	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 2 mM Mg2+ and 50 mM K+ for 120 s at 21 C
6DP9	;	1.4	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 2 mM Mn2+ and 200 mM K+ for 40 s at 21 C
6DP0	;	1.451	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 2.5 mM Mg2+ and 75 mM K+ for 40 s at 21 C
6DP4	;	1.374	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 20 mM Mg2+ and 75 mM K+ for 40 s at 21 C
6DPE	;	1.56	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 20 mM Mn2+ and 200 mM K+ for 40 s at 21 C
6DPA	;	1.489	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 4 mM Mn2+ and 200 mM K+ for 40 s at 21 C
6DP5	;	1.432	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 40 mM Mg2+ and 75 mM K+ for 40 s at 21 C
6DPF	;	1.56	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 40 mM Mn2+ and 200 mM K+ for 40 s at 21 C
6DP8	;	1.323	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 5 mM Mg2+ and 200 mM Li+ for 240 s at 21 C
6DOU	;	1.487	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 5 mM Mg2+ and 200 mM Rb+ for 120 s at 21 C
6DOW	;	1.495	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 5 mM Mg2+ and 200 mM Rb+ for 160 s at 21 C
6DPP	;	1.45	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 5 mM Mg2+ and 200 mM Rb+ for 240 s at 21 C
6DOX	;	1.45	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 5 mM Mg2+ and 200 mM Rb+ for 360 s at 21 C
6DOT	;	1.423	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 5 mM Mg2+ and 200 mM Rb+ for 40 s at 21 C
6DOV	;	1.521	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 5 mM Mg2+ and 200 mM Rb+ for 80 s at 21 C
6DP1	;	1.42	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 5 mM Mg2+ and 75 mM K+ for 40 s at 21 C
6DP7	;	1.381	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 500 mM Mn2+ and 200 mM K+ for 40 s at 21 C
6DP2	;	1.662	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 7.5 mM Mg2+ and 75 mM K+ for 40 s at 21 C
6DPB	;	1.324	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 8 mM Mn2+ and 200 mM K+ for 40 s at 21 C
6DP6	;	1.403	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Reaction in 80 mM Mg2+ and 75 mM K+ for 40 s at 21 C
6DOH	;	1.363	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Soak in 0.5 mM EGTA and 200 mM K+ at 21 C
6DMV	;	1.52	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Soaked for 40 s in 2 mM Mg2+ and 200 mM K+ at 21 C
6DMN	;	1.27	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 in Complex with an RNA/DNA Hybrid: Soaked in 2 mM Ca2+ and 200 mM K+ at 21 C
6DPM	;	1.677	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 K196A in Complex with an RNA/DNA Hybrid: Reaction in 10 mM Mg2+ and 200 mM Rb+ for 1800 s at 21 C
6DPI	;	1.347	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 K196A in Complex with an RNA/DNA Hybrid: Reaction in 10 mM Mg2+ and 200 mM Rb+ for 40 s at 21 C
6DPL	;	1.45	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 K196A in Complex with an RNA/DNA Hybrid: Reaction in 10 mM Mg2+ and 200 mM Rb+ for 720 s at 21 C
6DPK	;	1.391	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 K196A in Complex with an RNA/DNA Hybrid: Reaction in 4 mM Mn2+ and 200 mM K+ for 240 s at 21 C
6DPJ	;	1.55	;	Crystal Structure of Bacillus Halodurans Ribonuclease H1 K196A in Complex with an RNA/DNA Hybrid: Reaction in 4 mM Mn2+ and 200 mM K+ for 80 s at 21 C
5Y8X	;	1.97	;	Crystal structure of Bacillus licheniformis Gamma glutamyl transpeptidase with Azaserine
5Y9B	;	2.15	;	Crystal structure of Bacillus licheniformis Gamma glutamyl transpeptidase with DON
6DZD	;	2.66	;	Crystal structure of Bacillus licheniformis hypothetical protein YfiH
6WPY	;	3.6	;	Crystal structure of Bacillus licheniformis lipase BlEst2 in mature form
6WPX	;	2.0	;	Crystal structure of Bacillus licheniformis lipase BlEst2 in propetide form
5BRQ	;	2.003	;	Crystal structure of Bacillus licheniformis trehalose-6-phosphate hydrolase (TreA)
5BRP	;	2.05	;	Crystal structure of Bacillus licheniformis trehalose-6-phosphate hydrolase (TreA), mutant R201Q, in complex with PNG
3KX5	;	1.686	;	Crystal structure of Bacillus megaterium BM3 heme domain mutant F261E
3KX4	;	1.95	;	Crystal structure of Bacillus megaterium BM3 heme domain mutant I401E
3KX3	;	1.803	;	Crystal structure of Bacillus megaterium BM3 heme domain mutant L86E
4O08	;	1.95	;	Crystal structure of bacillus megaterium epoxide hydrolase in complex with an inhibitor
3AY6	;	2.1	;	Crystal structure of Bacillus megaterium glucose dehydrogenase 4 A258F mutant in complex with NADH and D-glucose
3AY7	;	1.9	;	Crystal structure of Bacillus megaterium glucose dehydrogenase 4 G259A mutant
3AUU	;	2.0	;	Crystal structure of Bacillus megaterium glucose dehydrogenase 4 in complex with D-glucose
3AUT	;	2.0	;	Crystal structure of Bacillus megaterium glucose dehydrogenase 4 in complex with NADH
3AUS	;	2.0	;	Crystal structure of Bacillus megaterium glucose dehydrogenase 4 in ligand-free form
4MLQ	;	1.6	;	Crystal structure of Bacillus megaterium porphobilinogen deaminase
4MLV	;	1.455	;	Crystal Structure of Bacillus megaterium porphobilinogen deaminase
6TOZ	;	1.94	;	Crystal structure of Bacillus paralicheniformis alpha-amylase in complex with acarbose
6TP2	;	1.94	;	Crystal structure of Bacillus paralicheniformis alpha-amylase in complex with beta-cyclodextrin
6TP0	;	2.04	;	Crystal structure of Bacillus paralicheniformis alpha-amylase in complex with maltose
6TP1	;	1.94	;	Crystal structure of Bacillus paralicheniformis alpha-amylase in complex with maltotetraose
6TOY	;	1.95	;	Crystal structure of Bacillus paralicheniformis wild-type alpha-amylase
1EAR	;	1.7	;	Crystal structure of Bacillus pasteurii UreE at 1.7 A. Type II crystal form.
1EB0	;	1.85	;	Crystal structure of Bacillus pasteurii UreE at 1.85 A, phased by SIRAS. Type I crystal form.
3ZO6	;	4.104	;	Crystal structure of Bacillus pseudofirmus OF4 mutant ATP synthase c12 ring.
3FYT	;	2.58	;	Crystal structure of Bacillus pumilus acetyl xylan esterase S181A mutant in complex with beta-D-xylopyranose
8IBK	;	1.69	;	Crystal structure of Bacillus sp. AHU2216 GH13_31 Alpha-glucosidase E256Q/N258G in complex with maltotriose
8IDS	;	1.5	;	Crystal structure of Bacillus sp. AHU2216 GH13_31 Alpha-glucosidase E256Q/N258P in complex with maltotriose
1J0M	;	2.3	;	Crystal Structure of Bacillus sp. GL1 Xanthan Lyase that Acts on Side Chains of Xanthan
1J0N	;	2.4	;	Crystal Structure of Bacillus sp. GL1 Xanthan Lyase that Acts on Side Chains of Xanthan
7CMN	;	1.42	;	Crystal Structure of Bacillus sp. TB-90 Urate Oxidase Improved by Humidity Control at 88% RH.
7CMQ	;	1.65	;	Crystal Structure of Bacillus sp. TB-90 Urate Oxidase Improved by Humidity Control at 88% RH.
5Y2P	;	1.5	;	Crystal Structure of Bacillus sp. TB-90 Urate Oxidase Improved by Humidity Control at 89% RH
5YJ2	;	1.71	;	Crystal structure of Bacillus sp. TB-90 urate oxidase without dehydration
1MIV	;	3.5	;	Crystal structure of Bacillus stearothermophilus CCA-adding enzyme
1MIW	;	3.0	;	Crystal structure of Bacillus stearothermophilus CCA-adding enzyme in complex with ATP
1MIY	;	3.52	;	Crystal structure of Bacillus stearothermophilus CCA-adding enzyme in complex with CTP
5AYP	;	2.31	;	Crystal structure of Bacillus stearothermophilus Farnesyl pyrophosphate synthase
1JPU	;	1.8	;	Crystal Structure of Bacillus Stearothermophilus Glycerol Dehydrogenase
1J0H	;	1.9	;	Crystal structure of Bacillus stearothermophilus neopullulanase
1LQY	;	1.9	;	Crystal Structure of Bacillus stearothermophilus Peptide Deformylase Complexed with Antibiotic Actinonin
4I4I	;	2.4948	;	Crystal Structure of Bacillus stearothermophilus Phosphofructokinase mutant T156A bound to PEP
2FCO	;	1.4	;	Crystal Structure of Bacillus stearothermophilus PrfA-Holliday Junction Resolvase
2R6F	;	3.2	;	Crystal Structure of Bacillus stearothermophilus UvrA
3C65	;	1.9	;	Crystal Structure of Bacillus stearothermophilus UvrC 5' endonuclease domain
5ITW	;	1.19	;	Crystal structure of Bacillus subtilis BacC Dihydroanticapsin 7-dehydrogenase
5ITV	;	2.26	;	Crystal structure of Bacillus subtilis BacC Dihydroanticapsin 7-dehydrogenase in complex with NADH
4LS8	;	2.1	;	Crystal structure of Bacillus subtilis beta-ketoacyl-ACP synthase II (FabF) in a covalent complex with cerulenin
4LS7	;	1.674	;	Crystal structure of Bacillus subtilis beta-ketoacyl-ACP synthase II (FabF) in a non-covalent complex with cerulenin
2Z3A	;	3.0	;	Crystal Structure of Bacillus Subtilis CodW, a non-canonical HslV-like peptidase with an impaired catalytic apparatus
2Z3B	;	2.5	;	Crystal Structure of Bacillus Subtilis CodW, a non-canonical HslV-like peptidase with an impaired catalytic apparatus
2I5M	;	2.3	;	Crystal structure of Bacillus subtilis cold shock protein CspB variant A46K S48R
2I5L	;	2.55	;	Crystal structure of Bacillus subtilis Cold Shock Protein variant Bs-CspB M1R/E3K/K65I
1OF0	;	2.45	;	CRYSTAL STRUCTURE OF BACILLUS SUBTILIS COTA AFTER 1H SOAKING WITH ABTS
4W90	;	3.118	;	Crystal structure of Bacillus subtilis cyclic-di-AMP riboswitch ydaO
4W92	;	3.209	;	Crystal structure of Bacillus subtilis cyclic-di-AMP riboswitch ydaO
4DR0	;	1.9	;	Crystal structure of Bacillus subtilis dimanganese(II) NrdF
4BPG	;	2.2	;	Crystal structure of Bacillus subtilis DltC
5M7H	;	3.15	;	Crystal structure of Bacillus subtilis EngA in complex with phosphate ion and GMPPNP
5MBS	;	3.2	;	Crystal structure of Bacillus subtilis EngA in space group P21
4FER	;	2.099	;	Crystal structure of Bacillus Subtilis expansin (EXLX1) in complex with cellohexaose
4FG2	;	2.099	;	Crystal structure of Bacillus Subtilis expansin (EXLX1) in complex with cellotetraose
4FG4	;	2.701	;	Crystal structure of Bacillus Subtilis expansin (EXLX1) in complex with hemithiocellodextrin
4FFT	;	2.1	;	Crystal structure of Bacillus Subtilis expansin (EXLX1) in complex with mixed-linkage glucan
8VD9	;	1.85	;	Crystal structure of Bacillus subtilis FabHA, beta-ketoacyl carrier protein synthase III
8VDA	;	2.02	;	Crystal structure of Bacillus subtilis FabHA-coenzyme A complex
8VDB	;	2.4	;	Crystal structure of Bacillus subtilis FabHB, beta-ketoacyl carrier protein synthase III
2DCY	;	1.4	;	Crystal structure of Bacillus subtilis family-11 xylanase
2Q2N	;	1.8	;	Crystal structure of Bacillus subtilis ferrochelatase in complex with deuteroporphyrin IX 2,4-disulfonic acid dihydrochloride
1C1H	;	1.9	;	CRYSTAL STRUCTURE OF BACILLUS SUBTILIS FERROCHELATASE IN COMPLEX WITH N-METHYL MESOPORPHYRIN
4TV7	;	2.05	;	Crystal structure of Bacillus subtilis GabR at 2.05 Angstroms resolution
4N0B	;	2.705	;	Crystal structure of Bacillus subtilis GabR, an autorepressor and transcriptional activator of GabT
3WHS	;	1.8	;	Crystal structure of Bacillus subtilis gamma-glutamyltranspeptidase in complex with acivicin
1WKQ	;	1.17	;	Crystal Structure of Bacillus subtilis Guanine Deaminase. The first domain-swapped structure in the cytidine deaminase superfamily
1OYG	;	1.5	;	Crystal structure of Bacillus subtilis levansucrase
6VHQ	;	2.047	;	Crystal structure of Bacillus subtilis levansucrase (D86A/E342A) in complex with oligosaccharides
3QZU	;	1.85	;	Crystal structure of Bacillus subtilis Lipase A 7-fold mutant; the outcome of directed evolution towards thermostability
1ISP	;	1.3	;	Crystal structure of Bacillus subtilis lipase at 1.3A resolution
3M6A	;	3.4	;	Crystal structure of Bacillus subtilis Lon C-terminal domain
3M65	;	2.6	;	Crystal structure of Bacillus subtilis Lon N-terminal domain
8I2D	;	1.31	;	Crystal structure of Bacillus subtilis LytE
8I2F	;	2.03	;	Crystal structure of Bacillus subtilis LytE catalytic domain in complex with IseA
8I2E	;	3.2	;	Crystal structure of Bacillus subtilis LytE in complex with IseA
1EX2	;	1.85	;	CRYSTAL STRUCTURE OF BACILLUS SUBTILIS MAF PROTEIN
4MDX	;	1.5	;	Crystal structure of Bacillus subtilis MazF in complex with RNA
6YIR	;	1.68	;	Crystal structure of Bacillus subtilis MsmX ATPase
5X12	;	1.7	;	Crystal structure of Bacillus subtilis PadR
5X14	;	1.68	;	Crystal structure of Bacillus subtilis PadR in complex with ferulic acid
5X11	;	2.65	;	Crystal structure of Bacillus subtilis PadR in complex with operator DNA
5X13	;	1.7	;	Crystal structure of Bacillus subtilis PadR in complex with p-coumaric acid
5Y8T	;	2.0	;	Crystal structure of Bacillus subtilis PadR in complex with p-coumaric acid
7BN9	;	2.65	;	Crystal Structure of Bacillus subtilis Penicillin Binding Protein 3
1MKI	;	2.0	;	Crystal Structure of Bacillus Subtilis Probable Glutaminase, APC1040
1TT7	;	2.7	;	Crystal structure of Bacillus subtilis protein yhfP
1Y9E	;	2.8	;	Crystal structure of Bacillus subtilis protein yhfP with NAD bound
6JHK	;	3.101	;	Crystal Structure of Bacillus subtilis RsbS
3RST	;	2.37	;	Crystal structure of Bacillus subtilis signal peptide peptidase A
6JHE	;	3.101	;	Crystal Structure of Bacillus subtilis SigW domain 4 in complexed with -35 element DNA
2XF5	;	2.0	;	Crystal structure of Bacillus subtilis SPP1 phage gp23.1, a putative chaperone.
2XF6	;	2.12	;	Crystal structure of Bacillus subtilis SPP1 phage gp23.1, a putative chaperone.
2XF7	;	1.61	;	Crystal structure of Bacillus subtilis SPP1 phage gp23.1, a putative chaperone. High-resolution structure.
3GFK	;	2.3	;	Crystal structure of Bacillus subtilis Spx/RNA polymerase alpha subunit C-terminal domain complex
5Z6C	;	1.97	;	Crystal structure of Bacillus subtilis sugar-binding protein YesO involved in import of rhamnogalacturonan
2QCX	;	2.2	;	Crystal structure of Bacillus subtilis TenA Y112F mutant complexed with formyl aminomethyl pyrimidine
3O15	;	1.95	;	Crystal Structure of Bacillus subtilis Thiamin Phosphate Synthase Complexed with a Carboxylated Thiazole Phosphate
3O16	;	2.1	;	Crystal Structure of Bacillus subtilis Thiamin Phosphate Synthase K159A
5Y0P	;	2.3	;	Crystal structure of Bacillus subtilis TmcAL bound with alpha-thio ATP
5Y0N	;	2.302	;	Crystal structure of Bacillus subtilis TmcAL bound with ATP (SeMet derivative)
4ME7	;	2.918	;	Crystal structure of Bacillus subtilis toxin MazF in complex with cognate antitoxin MazE
4FKZ	;	1.69	;	Crystal structure of Bacillus subtilis UDP-GlcNAc 2-epimerase in complex with UDP-GlcNAc and UDP
7JLI	;	1.8	;	Crystal structure of Bacillus subtilis UppS
7JLJ	;	3.1	;	Crystal structure of Bacillus subtilis UppS in complex with clomiphene
7JLR	;	2.2	;	Crystal structure of Bacillus subtilis UppS in complex with JPD447
7JLM	;	2.3	;	Crystal structure of Bacillus subtilis UppS in complex with MAC-0547630
5NP9	;	2.0	;	Crystal structure of Bacillus subtilis YdiB in complex with ADP
1SF9	;	1.71	;	Crystal Structure of Bacillus subtilis YfhH Protein : Putative Transcriptional Regulator
7W42	;	2.619	;	Crystal structure of Bacillus subtilis YjoB
7W43	;	3.0	;	Crystal structure of Bacillus subtilis YjoB N-terminal domain
7W46	;	2.7	;	Crystal structure of Bacillus subtilis YjoB with ADP
4B2O	;	1.64	;	Crystal structure of Bacillus subtilis YmdB, a global regulator of late adaptive responses.
1NJH	;	1.7	;	Crystal Structure of Bacillus subtilis YojF protein
2NN4	;	2.1	;	Crystal structure of Bacillus subtilis yqgQ, Pfam DUF910
7W9Y	;	1.93	;	Crystal structure of Bacillus subtilis YugJ in complex with NADP and nickel
7W9Z	;	1.65	;	Crystal structure of Bacillus subtilis YugJ in complex with NADP and nitrate
7W9X	;	2.151	;	Crystal structure of Bacillus subtilis YugJ in complex with nickel
1RTY	;	2.4	;	Crystal Structure of Bacillus subtilis YvqK, a putative ATP-binding Cobalamin Adenosyltransferase, The North East Structural Genomics Target SR128
5MKD	;	2.51	;	Crystal structure of Bacillus subtilis Ywea
3WO0	;	2.0	;	Crystal structure of Bacillus subtilis YwfE, an L-amino acid ligase, with bound ADP-Mg-Ala
3WNZ	;	1.9	;	Crystal structure of Bacillus subtilis YwfE, an L-amino acid ligase, with bound ADP-Mg-Pi
1YSJ	;	2.4	;	Crystal Structure of Bacillus Subtilis YXEP Protein (APC1829), a Dinuclear Metal Binding Peptidase from M20 Family
5MVR	;	1.762	;	Crystal structure of Bacillus subtilus YdiB
1WTF	;	1.6	;	Crystal structure of Bacillus thermoproteolyticus Ferredoxin Variants Containing Unexpected [3Fe-4S] Cluster that is linked to Coenzyme A at 1.6 A Resolution
6DJ4	;	3.01	;	Crystal Structure of Bacillus thuringiensis Cry1A.105 Tryptic Core
6WPC	;	2.99	;	Crystal structure of Bacillus thuringiensis Cry1A.2 tryptic core variant
4PKM	;	1.65	;	Crystal Structure of Bacillus thuringiensis Cry51Aa1 Protoxin at 1.65 Angstroms Resolution
4D8M	;	2.3	;	Crystal structure of Bacillus thuringiensis Cry5B nematocidal toxin
5GHE	;	1.901	;	Crystal Structure of Bacillus thuringiensis Cry6Aa2 Protoxin
5ZI1	;	2.3	;	Crystal structure of Bacillus thuringiensis insecticidal crystal protein Cry7Ca1 (wild type)
2QFC	;	2.6	;	Crystal Structure of Bacillus thuringiensis PlcR complexed with PapR
3U3W	;	2.4	;	Crystal Structure of Bacillus thuringiensis PlcR in complex with the peptide PapR7 and DNA
4FSC	;	3.65	;	Crystal Structure of Bacillus thuringiensis PlcR in its apo form
1QPY	;	2.2	;	CRYSTAL STRUCTURE OF BACKBONE MODIFIED PNA HEXAMER
5E7G	;	2.37	;	Crystal structure of Bacova_02650 with xylogluco-oligosaccharide
5E75	;	1.36	;	Crystal structure of Bacova_02651
5E76	;	2.3	;	Crystal structure of Bacova_02651 with xylogluco-oligosaccharide
6DD6	;	2.3	;	Crystal structure of bacterial (6-4) photolyase PhrB from in situ serial Laue diffraction
3ETW	;	2.0	;	Crystal Structure of bacterial adhesin FadA
3ETX	;	3.0	;	Crystal structure of bacterial adhesin FadA L14A mutant
3ETY	;	2.9	;	Crystal structure of bacterial adhesin FadA L14A mutant
3ETZ	;	2.0	;	Crystal structure of bacterial adhesin FadA L76A mutant
5DCQ	;	1.83	;	Crystal structure of bacterial adhesin, FNE from Streptococcus equi spp. equi.
4XIG	;	3.402	;	Crystal structure of bacterial alginate ABC transporter determined through humid air and glue-coating method
4XTC	;	3.6	;	Crystal structure of bacterial alginate ABC transporter in complex with alginate pentasaccharide-bound periplasmic protein
7TM9	;	1.95	;	Crystal structure of Bacterial alkaline phosphatase from Klebsiella pneumoniae
1JHD	;	1.7	;	Crystal Structure of Bacterial ATP Sulfurylase from the Riftia pachyptila Symbiont
2VH1	;	2.7	;	Crystal structure of bacterial cell division protein FtsQ from E.coli
3AT7	;	2.1	;	Crystal structure of bacterial cell-surface alginate-binding protein Algp7
7VET	;	2.25	;	Crystal structure of bacterial chemotaxis-dependent pectin-binding protein SPH1118 in a closed conformation
7VER	;	1.699	;	Crystal structure of bacterial chemotaxis-dependent pectin-binding protein SPH1118 in a full open conformation
7VEQ	;	1.696	;	Crystal structure of bacterial chemotaxis-dependent pectin-binding protein SPH1118 in an open conformation
7VEU	;	1.736	;	Crystal structure of bacterial chemotaxis-dependent pectin-binding protein SPH1118 in complex with galacturonic acid
7VEV	;	1.498	;	Crystal structure of bacterial chemotaxis-dependent pectin-binding protein SPH1118 in complex with MES
7VEW	;	1.92	;	Crystal structure of bacterial chemotaxis-dependent pectin-binding protein SPH1118 in complex with unsaturated trigalacturonic acid
4R29	;	2.31	;	Crystal structure of bacterial cysteine methyltransferase effector NleE
8IUD	;	2.0	;	Crystal Structure of bacterial defense protein GajB
1Y53	;	1.2	;	Crystal structure of bacterial expressed avidin related protein 4 (AVR4) C122S
2XVH	;	2.54	;	Crystal structure of bacterial flavin containing monooxygenase in complex with NADP
8B2D	;	1.62	;	CRYSTAL STRUCTURE OF BACTERIAL FLAVIN CONTAINING MONOOXYGENASE THERMORESISTANT MUTANT, IN COMPLEX WITH NADP+
2XVE	;	1.99	;	Crystal structure of bacterial flavin-containing monooxygenase
2XVF	;	2.4	;	Crystal structure of bacterial flavin-containing monooxygenase
2WCV	;	1.9	;	Crystal structure of bacterial FucU
1LF6	;	2.1	;	CRYSTAL STRUCTURE OF BACTERIAL GLUCOAMYLASE
1LF9	;	2.2	;	CRYSTAL STRUCTURE OF BACTERIAL GLUCOAMYLASE COMPLEXED WITH ACARBOSE
7LU4	;	2.5	;	Crystal structure of bacterial glycyl tRNA synthetase in complex with glycine
6UH3	;	2.7	;	Crystal structure of bacterial heliorhodopsin 48C12
4RAP	;	2.881	;	Crystal structure of bacterial iron-containing dodecameric glycosyltransferase TibC from enterotoxigenic E.coli H10407
1CVL	;	1.6	;	CRYSTAL STRUCTURE OF BACTERIAL LIPASE FROM CHROMOBACTERIUM VISCOSUM ATCC 6918
1IWG	;	3.5	;	Crystal structure of Bacterial Multidrug Efflux transporter AcrB
6E66	;	2.1	;	Crystal structure of bacterial N-acetylglucosamine transferase NleB
6SDK	;	1.81	;	Crystal structure of bacterial ParB dimer bound to CDP
8TNE	;	2.3	;	Crystal structure of bacterial pectin methylesterase Pme8A from rumen Butyrivibrio
8TMS	;	2.3	;	Crystal structure of bacterial pectin methylesterase PmeC2 from rumen Butyrivibrio
7V6S	;	1.883	;	Crystal structure of bacterial peptidase
7V6T	;	1.495	;	Crystal structure of bacterial peptidase
7V6U	;	2.144	;	Crystal structure of bacterial peptidase
6UTS	;	3.09	;	Crystal Structure of bacterial pirin YhhW in complex with nickel(II) from Escherichia coli
4DRF	;	2.6	;	Crystal Structure of Bacterial Pnkp-C/Hen1-N Heterodimer
4E6N	;	2.39	;	Crystal structure of bacterial Pnkp-C/Hen1-N heterodimer
7Q6P	;	1.82	;	Crystal Structure of bacterial Prolyl Peptidyl Isomerase with 5,5'-difluoroleucines
6A8J	;	2.711	;	Crystal structure of bacterial protein toxins
7CAW	;	1.876	;	Crystal structure of bacterial reductase
7CAX	;	1.846	;	Crystal structure of bacterial reductase
7CAZ	;	1.79	;	Crystal structure of bacterial reductase
2P19	;	2.1	;	Crystal structure of bacterial regulatory protein of gntR family from Corynebacterium glutamicum
2A64	;	3.3	;	Crystal Structure of Bacterial Ribonuclease P RNA
4ZU9	;	3.191	;	Crystal structure of bacterial selenocysteine-specific elongation factor EF-Sec
6IHL	;	1.573	;	Crystal structure of bacterial serine phosphatase
6IHU	;	1.84	;	Crystal structure of bacterial serine phosphatase bearing R161A mutation
6IHV	;	1.9	;	Crystal structure of bacterial serine phosphatase bearing R161E mutation
6IHW	;	1.55	;	Crystal structure of bacterial serine phosphatase bearing R161K mutation
6IHT	;	1.569	;	Crystal structure of bacterial serine phosphatase bound with phosphorylated peptide
6IHR	;	1.348	;	Crystal structure of bacterial serine phosphatase with His tag
6IHS	;	1.4	;	Crystal structure of bacterial serine phosphatase with His-tag mutation
7BYY	;	2.799	;	Crystal structure of bacterial toxin
1O83	;	1.64	;	Crystal Structure of Bacteriocin AS-48 at pH 7.5, phosphate bound. Crystal form I
1O84	;	2.8	;	Crystal Structure of Bacteriocin AS-48. N-decyl-beta-D-maltoside Bound.
5XX9	;	2.6	;	Crystal structure of Bacterioferritin
8SQQ	;	2.25	;	Crystal Structure of Bacterioferritin (Bfr) from Brucella abortus (Apo Cubic Form 2, F16L mutant)
8SQP	;	2.05	;	Crystal Structure of Bacterioferritin (Bfr) from Brucella abortus (Apo, F16L mutant)
8SQT	;	2.2	;	Crystal Structure of Bacterioferritin (Bfr) from Brucella abortus (iron bound, cubic form 2, F16L mutant)
8SQR	;	1.65	;	Crystal Structure of Bacterioferritin (Bfr) from Brucella abortus (iron bound, F16L mutant)
8SQO	;	1.55	;	Crystal Structure of Bacterioferritin (Bfr) from Brucella abortus (magnesium bound, F16L mutant)
3GVY	;	2.8	;	Crystal structure of bacterioferritin from R.sphaeroides
2FJR	;	1.95	;	Crystal Structure of Bacteriophage 186
6JNY	;	1.451	;	Crystal structure of bacteriophage 21 Q protein
5W6P	;	2.335	;	Crystal structure of Bacteriophage CBA120 tailspike protein 2 enzymatically active domain (TSP2dN, orf211)
5W6S	;	2.263	;	Crystal structure of Bacteriophage CBA120 tailspike protein 2 enzymatically active domain (TSP2dN, orf211) complex with Escherichia Coli O157-antigen
5W6F	;	2.18	;	Crystal structure of Bacteriophage CBA120 tailspike protein 3 (TSP3, orf212)
5W6H	;	2.289	;	Crystal structure of Bacteriophage CBA120 tailspike protein 4 enzymatically active domain (TSP4dN, orf213)
1FRS	;	3.5	;	CRYSTAL STRUCTURE OF BACTERIOPHAGE FR CAPSIDS AT 3.5 ANGSTROMS RESOLUTION
3JVO	;	2.1	;	Crystal structure of bacteriophage HK97 gp6
2VTU	;	3.5	;	crystal structure of bacteriophage MS2 covalent coat protein dimer
2ANX	;	1.04	;	crystal structure of bacteriophage P22 lysozyme mutant L87M
2VF9	;	3.5	;	Crystal structure of bacteriophage PRR1
6XC0	;	1.78	;	Crystal structure of bacteriophage T4 spackle and lysozyme in monoclinic form
6XC1	;	1.92	;	Crystal structure of bacteriophage T4 spackle and lysozyme in orthorhombic form
1FZR	;	2.1	;	CRYSTAL STRUCTURE OF BACTERIOPHAGE T7 ENDONUCLEASE I
1M0I	;	2.55	;	Crystal Structure of Bacteriophage T7 Endonuclease I with a Wild-Type Active Site
1M0D	;	1.9	;	Crystal Structure of Bacteriophage T7 Endonuclease I with a Wild-Type Active Site and Bound Manganese Ions
2O9B	;	2.15	;	Crystal Structure of Bacteriophytochrome chromophore binding domain
2O9C	;	1.45	;	Crystal Structure of Bacteriophytochrome chromophore binding domain at 1.45 angstrom resolution
4R6L	;	3.395	;	Crystal structure of bacteriophytochrome RpBphP2 from photosynthetic bacterium R. palustris
4R70	;	2.85	;	Crystal structure of bacteriophytochrome RpBphP3 from photosynthetic bacterium R. palustris
5ZIM	;	1.25	;	Crystal structure of bacteriorhodopsin at 1.25 A resolution
5ZIN	;	1.27	;	Crystal structure of bacteriorhodopsin at 1.27 A resolution
5ZIL	;	1.29	;	Crystal structure of bacteriorhodopsin at 1.29 A resolution
1X0K	;	2.6	;	Crystal Structure of Bacteriorhodopsin at pH 10
1KME	;	2.0	;	CRYSTAL STRUCTURE OF BACTERIORHODOPSIN CRYSTALLIZED FROM BICELLES
2BRD	;	3.5	;	CRYSTAL STRUCTURE OF BACTERIORHODOPSIN IN PURPLE MEMBRANE
7XJC	;	1.33	;	Crystal structure of bacteriorhodopsin in the ground and K states after green laser irradiation
7XJD	;	1.33	;	Crystal structure of bacteriorhodopsin in the ground state by red laser irradiation
7XJE	;	1.33	;	Crystal structure of bacteriorhodopsin in the K state refined against the extrapolated dataset
1BM1	;	3.5	;	CRYSTAL STRUCTURE OF BACTERIORHODOPSIN IN THE LIGHT-ADAPTED STATE
3T45	;	3.01	;	Crystal structure of bacteriorhodopsin mutant A215T, a phototaxis signaling mutant at 3.0 A resolution
3HAQ	;	2.3	;	Crystal structure of bacteriorhodopsin mutant I148A crystallized from bicelles
3HAR	;	1.7	;	Crystal structure of bacteriorhodopsin mutant I148V crystallized from bicelles
3HAP	;	1.6	;	Crystal structure of bacteriorhodopsin mutant L111A crystallized from bicelles
3HAS	;	1.9	;	Crystal structure of bacteriorhodopsin mutant L152A crystallized from bicelles
3HAO	;	2.49	;	Crystal structure of bacteriorhodopsin mutant L94A crystallized from bicelles
1Q5I	;	2.3	;	Crystal structure of bacteriorhodopsin mutant P186A crystallized from bicelles
3UTY	;	2.37	;	Crystal structure of bacteriorhodopsin mutant P50A/T46A
3UTW	;	2.4	;	Crystal structure of bacteriorhodopsin mutant P50A/Y57F
1Q5J	;	2.1	;	Crystal structure of bacteriorhodopsin mutant P91A crystallized from bicelles
3UTX	;	2.47	;	Crystal structure of bacteriorhodopsin mutant T46A
3HAN	;	2.75	;	Crystal structure of bacteriorhodopsin mutant V49A crystallized from bicelles
3UTV	;	2.06	;	Crystal structure of bacteriorhodopsin mutant Y57F
2ZFE	;	2.5	;	Crystal structure of bacteriorhodopsin-xenon complex
3HXS	;	1.996	;	Crystal Structure of Bacteroides fragilis TrxP
3HYP	;	2.899	;	Crystal structure of Bacteroides fragilis TrxP_S105G mutant
8BDD	;	1.61	;	Crystal structure of Bacteroides ovatus CP926 PL17 alginate lyase
8BDQ	;	2.11	;	Crystal structure of Bacteroides ovatus CP926 PL38 alginate lyase
5FHE	;	2.9	;	Crystal structure of Bacteroides Pif1 bound to ssDNA
8J53	;	3.5	;	Crystal structure of Bacteroides salyersiae GH31 alpha-galactosidase
5FHF	;	2.15	;	Crystal structure of Bacteroides sp Pif1 in complex with ADP-AlF4
7NWF	;	2.0	;	Crystal structure of Bacteroides thetaiotamicron EndoBT-3987 in complex with hybrid-type glycan (GalGlcNAcMan5GlcNAc) product
6T8K	;	2.0	;	Crystal structure of Bacteroides thetaiotamicron EndoBT-3987 in complex with Man9GlcNAc product in P1
6TCV	;	1.311	;	Crystal structure of Bacteroides thetaiotamicron EndoBT-3987 in complex with Man9GlcNAc2Asn substrate
6TCW	;	1.599	;	Crystal structure of Bacteroides thetaiotamicron EndoBT-3987 with Man5GlcNAc product
6T8L	;	1.7	;	Crystal structure of Bacteroides thetaiotamicron EndoBT-3987 with Man9GlcNAc product in P212121
3HRG	;	1.85	;	Crystal structure of Bacteroides thetaiotaomicron BT_3980, protein with actin-like ATPase fold and unknown function (NP_812891.1) from BACTEROIDES THETAIOTAOMICRON VPI-5482 at 1.85 A resolution
7X4R	;	2.6	;	Crystal structure of Bacteroides thetaiotaomicron glutamate decarboxylase
7X52	;	1.9	;	Crystal structure of Bacteroides thetaiotaomicron glutamate decarboxylase BTGAD-PLP complex
7X4Y	;	1.9	;	Crystal structure of Bacteroides thetaiotaomicron glutamate decarboxylase BTGAD-PLP-GABA complex
7X51	;	2.0	;	Crystal structure of Bacteroides thetaiotaomicron glutamate decarboxylase BTGAD-PLP-GUA complex
7X4L	;	2.59	;	Crystal structure of Bacteroides thetaiotaomicron glutamate decarboxylase mutant Y303F-PLP complex
7D1D	;	1.75	;	Crystal structure of Bacteroides thetaiotaomicron glutaminyl cyclase bound to 1-benzylimidazole
7D1E	;	1.85	;	Crystal structure of Bacteroides thetaiotaomicron glutaminyl cyclase bound to N-acetylhistamine
5UJ6	;	1.9	;	Crystal Structure of Bacteroides Uniformis beta-glucuronidase
4WT8	;	3.4	;	Crystal Structure of bactobolin A bound to 70S ribosome-tRNA complex
5XKI	;	2.46	;	Crystal structure of baculoviral sulfhydryl oxidase AcP33 (wide type)
5XTN	;	2.54	;	Crystal structure of baculoviral sulfhydryl oxidase P33 (C155A, C158A mutant)
5XTO	;	2.56	;	Crystal structure of baculoviral sulfhydryl oxidase P33 (H114A mutant)
5XTP	;	2.4	;	Crystal structure of baculoviral sulfhydryl oxidase P33 (H227A mutant)
5XTQ	;	2.04	;	Crystal structure of baculoviral sulfhydryl oxidase P33 (H227D mutant)
5XTR	;	2.25	;	Crystal structure of baculoviral sulfhydryl oxidase P33 (R127A, E183A mutant)
7YNY	;	3.51	;	Crystal structure of baculovirus LEF-3 from Helicoverpa armigera nucleopolyhedrovirus
1P35	;	2.2	;	CRYSTAL STRUCTURE OF BACULOVIRUS P35
1YN9	;	1.5	;	Crystal structure of baculovirus RNA 5'-phosphatase complexed with phosphate
6MHP	;	1.73	;	Crystal structure of BaeC acyltransferase from bacillaene polyketide synthase in Bacillus amyloliquefaciens
5WVM	;	2.9	;	Crystal structure of baeS cocrystallized with 2 mM indole
6JDK	;	2.495	;	Crystal structure of Baeyer-Villiger monooxygenase from Parvibaculum lavamentivorans
5GJK	;	2.052	;	Crystal Structure of BAF47 and BAF155 Complex
4X86	;	1.85	;	Crystal structure of BAG6-Ubl4a complex
4WWR	;	2.0	;	Crystal Structure of Bag6-Ubl4A Dimerization Domain
6IDX	;	1.699	;	Crystal Structure of BAI1/ELMO2 complex
8IGC	;	1.697	;	Crystal structure of Bak bound to Bnip5 BH3
6UXO	;	1.799	;	Crystal structure of BAK core domain BH3-groove-dimer in complex with DDM
6UXM	;	2.49	;	Crystal structure of BAK core domain BH3-groove-dimer in complex with E. coli lipid
6UXR	;	1.8	;	Crystal structure of BAK core domain BH3-groove-dimer in complex with LysoPC
6UXP	;	2.492	;	Crystal structure of BAK core domain BH3-groove-dimer in complex with phosphatidylglycerol
6UXN	;	2.49	;	Crystal structure of BAK core domain BH3-groove-dimer in complex with phosphatidylserine
6UXQ	;	1.696	;	Crystal structure of BAK core domain BH3-groove-dimer in complex with POPC and C8E4
8UKY	;	2.398	;	Crystal structure of BAK in complex with inhibiting antibody 14G6
7LK4	;	3.1	;	Crystal structure of BAK L100A in complex with activating antibody fragments
8SRY	;	2.4	;	Crystal structure of BAK-BAX heterodimer with C12E8
8SRX	;	2.09	;	Crystal structure of BAK-BAX heterodimer with lysoPC
4MPH	;	2.0301	;	Crystal structure of BaLdcB / VanY-like L,D-carboxypeptidase Zinc(II)-bound
4JID	;	2.3	;	Crystal structure of BaLdcB / VanY-like L,D-carboxypeptidase Zinc(II)-free
3OG5	;	2.69	;	Crystal Structure of BamA POTRA45 tandem
4XGA	;	2.15	;	Crystal structure of BamB and BamA P3-5 complex from E.coli
4HDJ	;	1.85	;	Crystal Structure of BamB from Pseudomonas aeruginosa
4PIK	;	1.7	;	Crystal Structure of Banana Lectin bound to dimannose
4PIT	;	1.55	;	Crystal Structure of Banana Lectin H84T bound to dimannose
4PIU	;	1.6	;	CRYSTAL STRUCTURE OF BANANA LECTIN H84T MUTANT
8HYF	;	2.95	;	Crystal Structure of Banana Lectin In-complex with Fucose at 2.95 A Resolution
8HTX	;	2.8	;	Crystal structure of BANP in complex with methylated DNA
4JZP	;	2.1	;	Crystal structure of BAP31 vDED at acidic pH
4JZL	;	2.2	;	Crystal structure of BAP31 vDED at alkaline pH
2Q12	;	1.79	;	Crystal Structure of BAR domain of APPL1
2Z0V	;	2.49	;	Crystal structure of BAR domain of Endophilin-III
2Q13	;	2.05	;	Crystal structure of BAR-PH domain of APPL1
7CYS	;	1.81	;	Crystal structure of barley agmatine coumaroyltransferase (HvACT), an N-acyltransferase in BAHD superfamily
1RPK	;	2.0	;	Crystal structure of barley alpha-amylase isozyme 1 (amy1) in complex with acarbose
1P6W	;	2.0	;	Crystal structure of barley alpha-amylase isozyme 1 (AMY1) in complex with the substrate analogue, methyl 4I,4II,4III-tri-thiomaltotetraoside (thio-DP4)
1RP9	;	2.0	;	Crystal structure of barley alpha-amylase isozyme 1 (amy1) inactive mutant d180a in complex with acarbose
1RP8	;	2.0	;	Crystal structure of barley alpha-amylase isozyme 1 (amy1) inactive mutant d180a in complex with maltoheptaose
1C2A	;	1.9	;	CRYSTAL STRUCTURE OF BARLEY BBI
2XFR	;	0.97	;	Crystal structure of barley beta-amylase at atomic resolution
2XGB	;	1.2	;	Crystal structure of Barley Beta-Amylase complexed with 2,3- epoxypropyl-alpha-D-glucopyranoside
2XGI	;	1.3	;	Crystal structure of Barley Beta-Amylase complexed with 3,4- epoxybutyl alpha-D-glucopyranoside
6F9L	;	1.77	;	Crystal structure of Barley Beta-Amylase complexed with 3-Deoxy-3-fluoro-maltose
2XG9	;	1.8	;	Crystal structure of Barley Beta-Amylase complexed with 4-O-alpha-D- glucopyranosylmoranoline
6F9J	;	1.67	;	Crystal structure of Barley Beta-Amylase complexed with 4-O-alpha-D-mannopyranosyl-(1-deoxynojirimycin)
6F9H	;	1.9	;	Crystal structure of Barley Beta-Amylase complexed with 4-S-alpha-D-glucopyranosyl-(1,4-dideoxy-4-thio-nojirimycin)
2XFF	;	1.309	;	Crystal structure of Barley Beta-Amylase complexed with acarbose
2XFY	;	1.207	;	Crystal structure of Barley Beta-Amylase complexed with alpha- cyclodextrin
1IEQ	;	2.7	;	CRYSTAL STRUCTURE OF BARLEY BETA-D-GLUCAN GLUCOHYDROLASE ISOENZYME EXO1
1IEW	;	2.55	;	Crystal structure of barley beta-D-glucan glucohydrolase isoenzyme Exo1 in complex with 2-deoxy-2-fluoro-alpha-D-glucoside
3WLJ	;	1.67	;	Crystal structure of barley beta-D-glucan glucohydrolase isoenzyme EXO1 in complex with 3-deoxy-glucose
1J8V	;	2.4	;	Crystal structure of barley beta-D-glucan glucohydrolase isoenzyme Exo1 in complex with 4'-nitrophenyl 3I-thiolaminaritrioside
3WLK	;	1.8	;	Crystal structure of barley beta-D-glucan glucohydrolase isoenzyme EXO1 in complex with 4-deoxy-glucose
1IEX	;	2.2	;	Crystal structure of barley beta-D-glucan glucohydrolase isoenzyme Exo1 in complex with 4I,4III,4V-S-trithiocellohexaose
1IEV	;	2.8	;	CRYSTAL STRUCTURE OF BARLEY BETA-D-GLUCAN GLUCOHYDROLASE ISOENZYME EXO1 IN COMPLEX WITH CYCLOHEXITOL
1LQ2	;	2.7	;	Crystal structure of barley beta-D-glucan glucohydrolase isoenzyme Exo1 in complex with gluco-phenylimidazole
1X38	;	1.698	;	crystal structure of barley beta-D-glucan glucohydrolase isoenzyme exo1 in complex with gluco-phenylimidazole
1X39	;	1.8	;	Crystal structure of barley beta-D-glucan glucohydrolase isoenzyme exo1 in complex with gluco-phenylimidazole
3WLM	;	1.9	;	Crystal structure of barley beta-D-glucan glucohydrolase isoenzyme exo1 in complex with octyl-O-glucoside
3WLN	;	2.0	;	Crystal structure of barley beta-D-glucan glucohydrolase isoenzyme EXO1 in complex with octyl-S-glucoside
3WLL	;	1.8	;	Crystal structure of barley beta-D-glucan glucohydrolase isoenzyme EXO1 in complex with PEG400
6JG6	;	1.55	;	Crystal structure of barley exohydrolaseI W286A mutant in complex with methyl 6-thio-beta-gentiobioside
6JGA	;	1.47	;	Crystal structure of barley exohydrolaseI W286F in complex with 4'-nitrophenyl thiolaminaribioside
6JG7	;	2.16	;	Crystal structure of barley exohydrolaseI W286F in complex with methyl 2-thio-beta-sophoroside
6JGB	;	1.47	;	Crystal structure of barley exohydrolaseI W286F mutant in complex with methyl 6-thio-beta-gentiobioside
6JGC	;	2.36	;	Crystal structure of barley exohydrolaseI W286Y mutant in complex with glucose.
6JGD	;	2.13	;	Crystal structure of barley exohydrolaseI W286Y mutant in complex with methyl 6-thio-beta-gentiobioside
6L1J	;	1.8	;	Crystal structure of barley exohydrolaseI W434A mutant in complex with 4'-nitrophenyl thiolaminaritrioside
6LBB	;	1.8	;	Crystal structure of barley exohydrolaseI W434A mutant in complex with 4I,4III,4V-S-trithiocellohexaose
6KUF	;	1.9	;	Crystal structure of barley exohydrolaseI W434A mutant in complex with glucose.
6JGE	;	1.92	;	Crystal structure of barley exohydrolaseI W434A mutant in complex with methyl 2-thio-beta-sophoroside.
6K6V	;	1.98	;	Crystal structure of barley exohydrolaseI W434A mutant in complex with methyl 6-thio-beta-gentiobioside
6LC5	;	1.76	;	Crystal structure of barley exohydrolaseI W434F in complex with 4'-nitrophenyl thiolaminaribioside
6JGK	;	1.66	;	Crystal structure of barley exohydrolaseI W434F mutant in complex with 4I,4III,4V-S-trithiocellohexaose
6JGG	;	1.9	;	Crystal structure of barley exohydrolaseI W434F mutant in complex with methyl 2-thio-beta-sophoroside.
6LBV	;	1.89	;	Crystal structure of barley exohydrolaseI W434F mutant in complex with methyl 6-thio-beta-gentiobioside
6JGN	;	1.98	;	Crystal structure of barley exohydrolaseI W434H in complex with 4'-nitrophenyl thiolaminaribioside
6JGO	;	1.95	;	Crystal structure of barley exohydrolaseI W434H mutant in complex with 4I,4III,4V-S-trithiocellohexaose
6JGL	;	1.92	;	Crystal structure of barley exohydrolaseI W434H mutant in complex with methyl 2-thio-beta-sophoroside
6JGP	;	1.99	;	Crystal structure of barley exohydrolaseI W434H mutant in complex with methyl 6-thio-beta-gentiobioside.
6JGR	;	2.25	;	Crystal structure of barley exohydrolaseI W434Y in complex with 4'-nitrophenyl thiolaminaribioside
6JGS	;	2.03	;	Crystal structure of barley exohydrolaseI W434Y mutant in complex with 4I,4III,4V-S-trithiocellohexaose.
6JGQ	;	2.01	;	Crystal structure of barley exohydrolaseI W434Y mutant in complex with methyl 2-thio-beta-sophoroside.
6JGT	;	1.82	;	Crystal structure of barley exohydrolaseI W434Y mutant in complex with methyl 6-thio-beta-gentiobioside.
6JG2	;	2.0	;	Crystal structure of barley exohydrolaseI wildtype in complex with 4'-nitrophenyl thiolaminaribioside
6JG1	;	1.78	;	Crystal structure of barley exohydrolaseI wildtype in complex with 4I,4III,4V-S-trithiocellohexaose
1BGP	;	1.9	;	CRYSTAL STRUCTURE OF BARLEY GRAIN PEROXIDASE 1
4J3X	;	1.75	;	Crystal structure of barley limit dextrinase (E510A mutant) in complex with a branched maltoheptasaccharide
4J3W	;	1.67	;	Crystal structure of barley limit dextrinase (E510A mutant) in complex with a branched maltohexasaccharide
4J3T	;	1.6	;	Crystal structure of barley Limit dextrinase co-crystallized with 25mM maltotetraose
4J3V	;	1.45	;	Crystal structure of barley limit dextrinase in complex with a branched thio-linked hexasaccharide
4J3U	;	1.7	;	Crystal structure of barley limit dextrinase in complex with maltosyl-S-betacyclodextrin
4J3S	;	1.75	;	Crystal structure of barley limit dextrinase soaked with 300mM maltotetraose
2VM1	;	1.7	;	Crystal structure of barley thioredoxin h isoform 1 crystallized using ammonium sulfate as precipitant
2VM2	;	1.8	;	Crystal structure of barley thioredoxin h isoform 1 crystallized using PEG as precipitant
2VLU	;	1.7	;	Crystal structure of barley thioredoxin h isoform 2 in partially radiation-reduced state
2VLV	;	1.7	;	Crystal structure of barley thioredoxin h isoform 2 in partially radiation-reduced state
2VLT	;	2.0	;	Crystal structure of barley thioredoxin h isoform 2 in the oxidized state
3C5P	;	2.9	;	Crystal structure of BAS0735, a protein of unknown function from Bacillus anthracis str. Sterne
3AUP	;	1.91	;	Crystal structure of Basic 7S globulin from soybean
1BFG	;	1.6	;	CRYSTAL STRUCTURE OF BASIC FIBROBLAST GROWTH FACTOR AT 1.6 ANGSTROMS RESOLUTION
2BFH	;	2.5	;	CRYSTAL STRUCTURE OF BASIC FIBROBLAST GROWTH FACTOR AT 1.6 ANGSTROMS RESOLUTION
3ZDT	;	3.15	;	Crystal structure of basic patch mutant FAK FERM domain FAK31- 405 K216A, K218A, R221A, K222A
2DTY	;	2.65	;	Crystal structure of basic winged bean lectin complexed with N-acetyl-D-galactosamine
2DTW	;	2.4	;	Crystal Structure of basic winged bean lectin in complex with 2Me-O-D-Galactose
2E51	;	2.5	;	Crystal structure of basic winged bean lectin in complex with A blood group disaccharide
2E7T	;	2.65	;	Crystal structure of basic winged bean lectin in complex with a blood group trisaccharide
2DU0	;	2.7	;	Crystal structure of basic winged bean lectin in complex with Alpha-D-galactose
2E53	;	2.4	;	Crystal structure of basic winged bean lectin in complex with B blood group disaccharide
2E7Q	;	2.75	;	Crystal structure of basic winged bean lectin in complex with b blood group trisaccharide
2ZML	;	2.65	;	Crystal structure of basic winged bean lectin in complex with Gal-ALPHA 1,4 Gal
2ZMN	;	2.9	;	Crystal Structure of basic winged bean lectin in complex with Gal-alpha- 1,6 Glc
2DU1	;	2.6	;	Crystal Structure of basic winged bean lectin in complex with Methyl-alpha-N-acetyl-D galactosamine
2D3S	;	2.35	;	Crystal Structure of basic winged bean lectin with Tn-antigen
7DAA	;	2.51	;	Crystal structure of basigin complexed with anti-basigin Fab fragment
2IW4	;	2.15	;	CRYSTAL STRUCTURE OF BASILLUS SUBTILIS FAMILY II INORGANIC PYROPHOSPHATASE MUTANT, H98Q, IN COMPLEX WITH PNP
6J2E	;	2.1	;	Crystal structure of bat (Pteropus Alecto) MHC class I Ptal-N*01:01 in complex with Ebola virus-derived peptide EBOV-NP1
6J2G	;	2.41	;	Crystal structure of bat (Pteropus Alecto) MHC class I Ptal-N*01:01 in complex with Ebola virus-derived peptide EBOV-NP2
6J2I	;	2.3	;	Crystal structure of bat (Pteropus Alecto) MHC class I Ptal-N*01:01 in complex with H17N10 influenza-like virus-derivrd peptide H17N10-NP
6J2D	;	2.313	;	Crystal structure of bat (Pteropus Alecto) MHC class I Ptal-N*01:01 in complex with Hendra virus-derived peptide HeV1
6K7T	;	1.6	;	Crystal structure of bat (Pteropus Alecto) MHC class I Ptal-N*01:01 in complex with Hendra virus-derived peptide HeV1--human beta-2 microglobulin
6J2F	;	1.9	;	Crystal structure of bat (Pteropus Alecto) MHC class I Ptal-N*01:01 in complex with Hendra virus-derived peptide HeV2
6J2J	;	2.5	;	Crystal structure of bat (Pteropus Alecto) MHC class I Ptal-N*01:01 in complex with MERS-CoV-derived peptide MERS-CoV-S3
6J2H	;	2.3	;	Crystal structure of bat (Pteropus Alecto) MHC class I Ptal-N*01:01 mutant (Met52 Asp53 Leu54 deleted) in complex with Hendra virus-derived peptide HeV1
7F8L	;	1.762	;	Crystal structure of Bat coronavirus RaTG13 ORF8 accessory protein
6EVK	;	2.9	;	Crystal structure of bat influenza A/H17N10 polymerase with viral RNA promoter and cap analogue m7GTP
6EVJ	;	3.9	;	Crystal structure of bat influenza A/H17N10 polymerase with viral RNA promoter and capped RNA primer
6FHI	;	2.8	;	Crystal structure of bat influenza A/H17N10 polymerase with viral RNA promoter bound to a 19-mer serine 5 phosphorylated Pol II CTD peptide with a truncated linker.
6FHH	;	2.7	;	Crystal structure of bat influenza A/H17N10 polymerase with viral RNA promoter bound to a 22-mer modified Pol II CTD peptide with serine 5 thiophosphorylated.
8HSM	;	2.2	;	CRYSTAL STRUCTURE OF BAT MHC CLASS I MYLU-B-67
8HSW	;	2.03	;	CRYSTAL STRUCTURE OF BAT MHC CLASS I MYLU-B-67 FOR 2.1 ANGSTROM
8HT9	;	2.2	;	CRYSTAL STRUCTURE OF BAT MHC CLASS I MYLU-B-67 FOR 2.2 ANGSTROM
6ILC	;	2.2	;	CRYSTAL STRUCTURE OF BAT MHC CLASS I PTAL-N*01:01 FOR 2.2 ANGSTROM
6ILG	;	2.6	;	CRYSTAL STRUCTURE OF BAT MHC CLASS I PTAL-N*01:01 FOR 2.6 ANGSTROM
6ILF	;	2.7	;	CRYSTAL STRUCTURE OF BAT MHC CLASS I PTAL-N*01:01 FOR 2.7 ANGSTROM
3EUF	;	1.9	;	Crystal structure of BAU-bound human uridine phosphorylase 1
6H7V	;	2.54	;	Crystal structure of BauA, the Ferric preacinetobactin receptor from Acinetobacter baumannii
6HCP	;	1.83	;	Crystal structure of BauA, the Ferric preacinetobactin receptor from Acinetobacter baumannii
6H7F	;	2.26	;	Crystal structure of BauA, the Ferric preacinetobactin receptor from Acinetobacter baumannii in complex with Fe3+-Preacinetobactin-acinetobactin
8SPF	;	2.2	;	Crystal structure of Bax core domain BH3-groove dimer - hexameric fraction with 2-stearoyl lysoPC
8SPZ	;	2.4	;	Crystal structure of Bax core domain BH3-groove dimer - hexameric fraction with dioctanoyl phosphatidylserine
8G1T	;	2.092	;	Crystal structure of Bax core domain BH3-groove dimer - tetrameric fraction P21
8SPE	;	2.3	;	Crystal structure of Bax core domain BH3-groove dimer - tetrameric fraction P31
8SVK	;	2.25	;	Crystal structure of Bax D71N core domain BH3-groove dimer
6EB6	;	2.023	;	Crystal structure of BAX W139A monomer
5W5X	;	2.502	;	Crystal structure of BAXP168G in complex with an activating antibody
5W5Z	;	1.997	;	Crystal structure of BAXP168G in complex with an activating antibody at high resolution
5W61	;	2.3	;	Crystal structure of BAXP168G monomer co-crystallized with glycerol
5W60	;	1.803	;	Crystal structure of BAXP168G monomer cryo-protected with ethylene glycol
5IEV	;	2.03	;	Crystal structure of BAY 1000394 (Roniciclib) bound to CDK2
4IAH	;	2.8	;	Crystal Structure of BAY 60-2770 bound C139A H-NOX domain with S-nitrosylated conserved C122
4IAE	;	2.05	;	Crystal structure of BAY 60-2770 bound to nostoc H-NOX domain
6YM5	;	2.5	;	Crystal structure of BAY-091 with PIP4K2A
6YM4	;	1.95	;	Crystal structure of BAY-297 with PIP4K2A
5OR8	;	2.4	;	Crystal Structure of BAZ2A bromodomain in complex with 1,3-dimethyl-benzimidazolone compound 1
5MGJ	;	2.1	;	Crystal Structure of BAZ2A bromodomain in complex with 1-methylpyridine derivative 1
6FG6	;	2.401	;	Crystal Structure of BAZ2A bromodomain in complex with 1-methylpyridinone compound 1
6FGF	;	2.801	;	Crystal Structure of BAZ2A bromodomain in complex with 1-methylpyridinone compound 2
6FGV	;	2.5	;	Crystal Structure of BAZ2A bromodomain in complex with 1-methylpyridinone compound 3
6FGW	;	2.725	;	Crystal Structure of BAZ2A bromodomain in complex with 1-methylpyridinone compound 4
6FGG	;	1.1	;	Crystal Structure of BAZ2A bromodomain in complex with 1-methylpyridinone compound 5
6FGH	;	2.1	;	Crystal Structure of BAZ2A bromodomain in complex with 3-amino-2-methylpyridine derivative 1
6FGI	;	2.551	;	Crystal Structure of BAZ2A bromodomain in complex with 3-amino-2-methylpyridine derivative 2
5MGL	;	2.651	;	Crystal Structure of BAZ2A bromodomain in complex with 4-chloropyridine derivative 3
5MGK	;	2.301	;	Crystal Structure of BAZ2A bromodomain in complex with 4-propionyl-pyrrole derivative 2
5MGM	;	2.8	;	Crystal Structure of BAZ2A bromodomain in complex with acetophenone derivative 4
6FGL	;	2.1	;	Crystal Structure of BAZ2A bromodomain in complex with acetylindole compound UZH47
6FI0	;	1.9	;	Crystal structure of BAZ2A PHD zinc finger in complex with Fr 19
6FKP	;	2.0	;	Crystal structure of BAZ2A PHD zinc finger in complex with H3 10-mer AA mutant peptide
6FHU	;	2.0	;	Crystal structure of BAZ2A PHD zinc finger in complex with H3 3-mer peptide
7FHJ	;	2.28	;	Crystal structure of BAZ2A with DNA
7MWH	;	2.28	;	Crystal structure of BAZ2A with DNA
5OR9	;	2.0	;	Crystal Structure of BAZ2B bromodomain in complex with 1-methyl-cyclopentapyrazole compound 13
5ORB	;	2.103	;	Crystal Structure of BAZ2B bromodomain in complex with 1-methyl-cyclopentapyrazole compound 30
5MGE	;	1.95	;	Crystal structure of BAZ2B bromodomain in complex with 1-methylpyridine derivative 1
6FH6	;	2.082	;	Crystal Structure of BAZ2B bromodomain in complex with 1-methylpyridinone compound 1
6FH7	;	2.1	;	Crystal Structure of BAZ2B bromodomain in complex with 1-methylpyridinone compound 2
6FGT	;	2.0	;	Crystal Structure of BAZ2B bromodomain in complex with 1-methylpyridinone compound 3
6FGU	;	2.05	;	Crystal Structure of BAZ2B bromodomain in complex with 1-methylpyridinone compound 4
5L96	;	2.15	;	Crystal Structure of BAZ2B bromodomain in complex with 3-amino-2-methylpyridine derivative 1
5L8T	;	1.85	;	Crystal Structure of BAZ2B bromodomain in complex with 3-amino-2-methylpyridine derivative 2
5L97	;	2.05	;	Crystal Structure of BAZ2B bromodomain in complex with 3-amino-2-methylpyridine derivative 3
5L98	;	2.263	;	Crystal Structure of BAZ2B bromodomain in complex with 3-amino-2-methylpyridine derivative 4
5L8U	;	1.85	;	Crystal Structure of BAZ2B bromodomain in complex with 3-amino-2-methylpyridine derivative 5
5L99	;	2.0	;	Crystal Structure of BAZ2B bromodomain in complex with 3-amino-2-methylpyridine derivative 6
5MGG	;	2.1	;	Crystal Structure of BAZ2B bromodomain in complex with 4-chloropyridine derivative 3
5MGF	;	1.9	;	Crystal Structure of BAZ2B bromodomain in complex with 4-propionyl-pyrrole derivative 2
5E73	;	1.71	;	Crystal Structure of BAZ2B bromodomain in complex with acetylindole compound UZH47
5E74	;	1.783	;	Crystal Structure of BAZ2B bromodomain in complex with acetylindole compound UZH50
5E9L	;	1.9	;	Crystal Structure of BAZ2B bromodomain in complex with fragment F103
5E9K	;	2.067	;	Crystal Structure of BAZ2B bromodomain in complex with fragment F275
5DYU	;	1.65	;	Crystal Structure of BAZ2B bromodomain in complex with fragment F39
5DYX	;	1.85	;	Crystal Structure of BAZ2B bromodomain in complex with fragment F59
5E9I	;	1.96	;	Crystal Structure of BAZ2B bromodomain in complex with fragment F60
5E9Y	;	1.65	;	Crystal Structure of BAZ2B bromodomain in complex with MPD
5E9M	;	1.778	;	Crystal Structure of BAZ2B bromodomain in complex with N-methyltrimethylacetamide
7WIN	;	1.95	;	Crystal structure of BAZ2B TAM domain
5A2U	;	3.3	;	Crystal structure of BBA68 or BbCRASP-1 from Borrelia burgdorferi strain B31
4KXO	;	2.0	;	Crystal Structure of BBBB at pH 10.0 with MPD as the cryoprotectant
4GBP	;	2.15	;	Crystal Structure of BBBB+UDP+Gal at pH 10 with MPD as the cryoprotectant
4FRE	;	1.85	;	Crystal Structure of BBBB+UDP+Gal at pH 6.5 with MPD as the cryoprotectant
4FRM	;	1.9	;	Crystal Structure of BBBB+UDP+Gal at pH 7.0 with MPD as the cryoprotectant
4FRH	;	1.8	;	Crystal Structure of BBBB+UDP+Gal at pH 7.5 with MPD as the cryoprotectant
4FRL	;	1.9	;	Crystal Structure of BBBB+UDP+Gal at pH 8.0 with MPD as the cryoprotectant
4FRP	;	2.0	;	Crystal Structure of BBBB+UDP+Gal at pH 8.5 with MPD as the cryoprotectant
4FRO	;	1.75	;	Crystal Structure of BBBB+UDP+Gal at pH 9.0 with MPD as the cryoprotectant
4FRQ	;	2.35	;	Crystal Structure of BBBB+UDP+Gal at pH 9.5 with MPD as the cryoprotectant
3SXC	;	1.9	;	Crystal structure of BBBB+UDP+Gal with Glycerol as the cryoprotectant
3SXD	;	1.55	;	Crystal structure of BBBB+UDP+Gal with MPD as the cryoprotectant
3E1I	;	2.3	;	Crystal Structure of BbetaD432A Variant Fibrinogen Fragment D with the Peptide Ligand Gly-His-Arg-Pro-amide
7JOE	;	2.6	;	Crystal structure of BbKI complexed with Human Kallikrein 4
7JOS	;	2.1	;	Crystal structure of BbKI complexed with Human Kallikrein 4
7JOW	;	1.91	;	Crystal structure of BbKI complexed with Human Kallikrein 4
4ZOT	;	1.4	;	Crystal structure of BbKI, a disulfide-free plasma kallikrein inhibitor at 1.4 A resolution
2GO2	;	1.87	;	Crystal structure of BbKI, a Kunitz-type kallikrein inhibitor
4V0M	;	3.45	;	Crystal structure of BBS1N in complex with ARL6DN
4V0O	;	3.351	;	Crystal structure of BBS1N in complex with ARL6DN, soaked with lead
4V0N	;	3.131	;	Crystal structure of BBS1N in complex with ARL6DN, soaked with mercury
4K09	;	2.107	;	Crystal structure of BbTX-II from Bothrops brazili venom
4HD5	;	1.9	;	Crystal Structure of BC0361, a polysaccharide deacetylase from Bacillus cereus
4AOC	;	2.7	;	crystal structure of BC2L-A Lectin from Burkolderia cenocepacia in complex with methyl-heptoside
6CUG	;	2.4	;	Crystal structure of BC8B TCR-CD1b-PC complex
4O2H	;	2.3	;	Crystal structure of BCAM1869 protein (RsaM homolog) from Burkholderia cenocepacia
7E0W	;	2.8	;	Crystal Structure of BCH domain from S. pombe
1G8P	;	2.1	;	CRYSTAL STRUCTURE OF BCHI SUBUNIT OF MAGNESIUM CHELATASE
1X1B	;	2.6	;	Crystal structure of BchU complexed with S-adenosyl-L-homocysteine
1X1D	;	2.7	;	Crystal structure of BchU complexed with S-adenosyl-L-homocysteine and Zn-bacteriopheophorbide d
1X1C	;	2.85	;	Crystal structure of BchU complexed with S-adenosyl-L-homocysteine and Zn2+
1X1A	;	2.6	;	Crystal structure of BchU complexed with S-adenosyl-L-methionine
1X19	;	2.27	;	Crystal structure of BchU involved in bacteriochlorophyll c biosynthesis
5JMX	;	1.44	;	Crystal Structure of BcII metallo-beta-lactamase in complex with DZ-305
6EUM	;	1.18	;	CRYSTAL STRUCTURE OF BCII METALLO-BETA-LACTAMASE IN COMPLEX WITH DZ-307
6EWE	;	1.46	;	Crystal structure of BCII Metallo-beta-lactamase in complex with DZ-308
6F2N	;	1.149	;	Crystal structure of BCII Metallo-beta-lactamase in complex with KDU197
4TYT	;	1.799	;	Crystal Structure of BcII metallo-beta-lactamase in complex with ML302F
8HOI	;	2.25	;	Crystal structure of Bcl-2 D103Y in complex with sonrotoclax
6O0M	;	1.75	;	crystal structure of BCL-2 F104L mutation with venetoclax
6O0P	;	1.8	;	crystal structure of BCL-2 G101A mutation with venetoclax
8HOH	;	1.9	;	Crystal structure of Bcl-2 G101V in complex with sonrotoclax
6O0O	;	1.998	;	crystal structure of BCL-2 G101V mutation with S55746
6O0L	;	2.2	;	crystal structure of BCL-2 G101V mutation with venetoclax
2XA0	;	2.7	;	Crystal structure of BCL-2 in complex with a BAX BH3 peptide
5FCG	;	2.1	;	Crystal structure of Bcl-2 in complex with HBx-BH3 motif
7LHB	;	2.068	;	Crystal structure of Bcl-2 in complex with prodrug ABBV-167
8HOG	;	1.8	;	Crystal structure of Bcl-2 in complex with sonrotoclax
6GL8	;	1.4	;	Crystal structure of Bcl-2 in complex with the novel orally active inhibitor S55746
6O0K	;	1.62	;	crystal structure of BCL-2 with venetoclax
5WHI	;	1.69	;	Crystal Structure of Bcl-2-related protein A1
5WHH	;	2.38	;	Crystal Structure of Bcl-2-related protein A1 in complex with stapled peptide (AQ7)T(0EH)LRRFGD(MK8)INFRQ(NH2)
5MW2	;	2.35	;	CRYSTAL STRUCTURE OF BCL-6 BTB-domain with BI-3802
5C3G	;	2.45	;	Crystal structure of Bcl-xl bound to BIM-MM
3SPF	;	1.7	;	Crystal Structure of Bcl-xL bound to BM501
3SP7	;	1.4	;	Crystal Structure of Bcl-xL bound to BM903
6UVF	;	2.24	;	Crystal structure of BCL-XL bound to compound 12: (R)-2-(3-([1,1'-Biphenyl]-4-carbonyl)-3-(4-methylbenzyl)ureido)-3-((cyclohexylmethyl)sulfonyl)propanoic acid
6UVG	;	2.1	;	Crystal structure of BCL-XL bound to compound 13: (R)-2-(3-([1,1'-Biphenyl]-4-carbonyl)-3-(4-methylbenzyl)ureido)-3-(((3R,5R,7R)-adamantan-1-ylmethyl)sulfonyl)propanoic acid
6UVH	;	2.19	;	Crystal structure of BCL-XL bound to compound 15: (R)-2-(3-(2-((4'-Chloro-[1,1'-biphenyl]-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-6-carbonyl)-3-(4-methylbenzyl)ureido)-3-((cyclohexylmethyl)sulfonyl)propanoic acid
6UVD	;	2.15	;	Crystal structure of BCL-XL bound to compound 2: (2R)-3-(Benzylsulfanyl)-2-({[(4-methylphenyl)methyl] [(4 phenylphenyl)carbonyl] carbamoyl}amino) propanoic acid
6UVE	;	2.87	;	Crystal structure of BCL-XL bound to compound 7: (R)-3-(Benzylthio)-2-(3-(4-chloro-[1,1':2',1'':3'',1'''-quaterphenyl]-4'''-carbonyl)-3-(4-methylbenzyl)ureido)propanoic acid
6UVC	;	1.9	;	Crystal structure of BCL-XL bound to compound 8: (R)-3-(Benzylthio)-2-(3-(2-((4'-chloro-[1,1'-biphenyl]-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-6-carbonyl)-3-(4-methylbenzyl)ureido)propanoic acid
7WJH	;	1.698	;	Crystal structure of Bcl-xL bound to the BH3 domain of human Pxt1
4EHR	;	2.09	;	Crystal structure of Bcl-Xl complex with 4-(5-butyl-3-(hydroxymethyl)-1-phenyl-1h-pyrazol-4-yl)-3-(3,4-dihydro-2(1h)-isoquinolinylcarbonyl)-n-((2-(trimethylsilyl)ethyl)sulfonyl)benzamide
4PPI	;	2.851	;	Crystal structure of Bcl-xL hexamer
7LH7	;	1.409	;	Crystal structure of BCL-XL in complex with a benzothiazole-based inhibitor
3QKD	;	2.02	;	Crystal structure of Bcl-xL in complex with a Quinazoline sulfonamide inhibitor
2YXJ	;	2.2	;	Crystal structure of Bcl-xL in complex with ABT-737
4C52	;	2.049	;	Crystal structure of Bcl-xL in complex with benzoylurea compound (39b)
4C5D	;	2.3	;	Crystal structure of Bcl-xL in complex with benzoylurea compound (42)
4QVE	;	2.05	;	Crystal structure of Bcl-xL in complex with BID BH3 domain
4QVF	;	1.531	;	Crystal structure of Bcl-xL in complex with BIM BH3 domain
3WIZ	;	2.45	;	Crystal structure of Bcl-xL in complex with compound 10
7JGW	;	1.3	;	Crystal structure of BCL-XL in complex with COMPOUND 1620116, CRYSTAL FORM 1
7JGV	;	2.05	;	CRYSTAL STRUCTURE OF BCL-XL IN COMPLEX WITH COMPOUND 1620116, CRYSTAL FORM 2
7XGF	;	1.9	;	Crystal structure of BCL-xL in complex with computationally designed inhibitor protein
7XGG	;	1.9	;	Crystal structure of BCL-xL in complex with computationally designed inhibitor protein
5B1Z	;	2.15	;	Crystal structure of Bcl-xL in complex with HBx-BH3 motif
3ZK6	;	2.48	;	Crystal structure of Bcl-xL in complex with inhibitor (Compound 2).
3ZLN	;	2.288	;	Crystal structure of BCL-XL in complex with inhibitor (Compound 3)
3ZLO	;	2.601	;	Crystal structure of BCL-XL in complex with inhibitor (Compound 6)
3ZLR	;	2.026	;	Crystal structure of BCL-XL in complex with inhibitor (WEHI-539)
6VWC	;	1.604	;	Crystal structure of Bcl-xL in complex with tetrahydroisoquinoline-pyridine based inhibitors
3PL7	;	2.613	;	Crystal structure of Bcl-xL in complex with the BaxBH3 domain
4YJ4	;	2.1	;	Crystal structure of Bcl-xL in complex with the BIM BH3 domain containing Ile155-to-Arg and Glu158-to-phosphoserine mutations
3INQ	;	2.0	;	Crystal structure of BCL-XL in complex with W1191542
1PQ1	;	1.65	;	Crystal structure of Bcl-xl/Bim
6KI6	;	2.5	;	Crystal structure of BCL11A in complex with gamma-globin -115 HPFH region
6C3N	;	2.53171	;	Crystal structure of BCL6 BTB domain in complex with compound 7CC5
6C3L	;	1.46092	;	Crystal structure of BCL6 BTB domain with compound 15f
2VNV	;	1.7	;	Crystal structure of BclA lectin from burkholderia cenocepacia in complex with alpha-methyl-mannoside at 1.7 Angstrom resolution
2R6Q	;	1.43	;	Crystal Structure of BclA-island Construct
6BVG	;	3.2	;	Crystal structure of bcMalT T280C-E54C crosslinked by divalent mercury
8HCU	;	2.2	;	Crystal structure of BCOR/PCGF1/KDM2B complex
7C4H	;	1.83	;	Crystal structure of BCP1 from Saccharomyces Cerevisiae
3RKP	;	2.243	;	Crystal structure of BcpA*(D312A), the major pilin subunit of Bacillus cereus
3KPT	;	2.102	;	Crystal structure of BcpA, the major pilin subunit of Bacillus cereus
8BTN	;	3.1	;	Crystal structure of BcThsB
4RYM	;	2.8	;	Crystal structure of BcTSPO Iodo Type1 monomer
4RYO	;	1.6	;	Crystal structure of BcTSPO type II high resolution monomer
4RYQ	;	1.7	;	Crystal structure of BcTSPO, type 2 at 1.7 Angstrom
4RYR	;	1.704	;	Crystal structure of BcTSPO, type 2 at 1.7 Angstrom with DMSO
4RYN	;	2.01	;	Crystal structure of BcTSPO, type1 monomer
4RYI	;	3.49	;	Crystal structure of BcTSPO/PK11195 complex
7N7X	;	2.097	;	Crystal structure of BCX7353(ORLADEYO) in complex with human plasma kallikrein serine protease domain at 2.1 angstrom resolution
3OF1	;	2.21	;	Crystal Structure of Bcy1, the Yeast Regulatory Subunit of PKA
7Y0C	;	2.94	;	Crystal structure of BD55-1403 and SARS-CoV-2 Omicron RBD
3EU4	;	2.3	;	Crystal Structure of BdbD from Bacillus subtilis (oxidised)
3EU3	;	1.5	;	Crystal Structure of BdbD from Bacillus subtilis (reduced)
5Z2L	;	1.7	;	Crystal structure of BdcA in complex with NADPH
8OML	;	2.56	;	Crystal structure of Bdellovibrio bacteriovorus Bd1334 C-terminal domains
8OKH	;	2.17	;	Crystal structure of Bdellovibrio bacteriovorus Bd1399
8ONF	;	1.53	;	Crystal structure of Bdellovibrio bacteriovorus Bd2439 fibre C-terminal domains with ethylene glycol
8OKW	;	1.84	;	Crystal structure of Bdellovibrio bacteriovorus Bd2734 C-terminal domain
8OKS	;	2.09	;	Crystal structure of Bdellovibrio bacteriovorus Bd2740 C-terminal domain
5TLC	;	2.8	;	Crystal structure of BdsA from Bacillus subtilis WU-S2B
4DDP	;	1.547	;	crystal structure of Beclin 1 evolutionarily conserved domain(ECD)
1FCV	;	2.65	;	CRYSTAL STRUCTURE OF BEE VENOM HYALURONIDASE IN COMPLEX WITH HYALURONIC ACID TETRAMER
1POC	;	2.0	;	CRYSTAL STRUCTURE OF BEE-VENOM PHOSPHOLIPASE A2 IN A COMPLEX WITH A TRANSITION-STATE ANALOGUE
8E7N	;	1.65	;	Crystal structure of beluga whale Gammacoronavirus SW1 Mpro with GC-376 captured in two conformational states
7W27	;	1.49	;	Crystal structure of BEND3-BEN4-DNA complex
3M1E	;	1.8	;	Crystal Structure of BenM_DBD
4IHT	;	3.0	;	Crystal Structure of BenM_DBD/benA site 1 DNA Complex
4IHS	;	3.1	;	Crystal Structure of BenM_DBD/catB site 1 DNA Complex
2AG0	;	2.58	;	Crystal structure of Benzaldehyde lyase (BAL)- native
2AG1	;	2.58	;	Crystal structure of Benzaldehyde lyase (BAL)- SeMet
3D7K	;	2.49	;	Crystal structure of benzaldehyde lyase in complex with the inhibitor MBP
3O50	;	2.0	;	Crystal structure of benzamide 9 bound to AuroraA
3MNR	;	1.9	;	Crystal Structure of Benzamide SNX-1321 bound to Hsp90
3D0B	;	1.74	;	Crystal Structure of Benzamide Tetrahydro-4H-carbazol-4-one bound to Hsp90
1J8A	;	1.21	;	CRYSTAL STRUCTURE OF BENZAMIDINE INHIBITED BOVINE PANCREATIC TRYPSIN AT 105K TO 1.21A RESOLUTION FROM LABORATORY SOURCE WITH HIGH NUMBER OF WATERS MODELLED
2AER	;	1.87	;	Crystal Structure of Benzamidine-Factor VIIa/Soluble Tissue Factor complex.
2AIQ	;	1.54	;	Crystal structure of benzamidine-inhibited protein C activator from the venom of copperhead snake Agkistrodon contortrix contortrix
7CBF	;	2.301	;	Crystal structure of benzophenone synthase from Garcinia mangostana L. pericarps reveals basis for substrate specificity and catalysis
3FSJ	;	1.37	;	Crystal structure of benzoylformate decarboxylase in complex with the inhibitor MBP
3F6E	;	1.34	;	Crystal structure of benzoylformate decarboxylase in complex with the pyridyl inhibitor 3-PKB
3F6B	;	1.34	;	Crystal structure of benzoylformate decarboxylase in complex with the pyridyl inhibitor PAA
4MQ5	;	1.502	;	Crystal Structure of Benzoylformate Decarboxylase Mutant A306F
4MPP	;	1.501	;	Crystal Structure of Benzoylformate Decarboxylase Mutant H281Y/T377P/F397T/A460I
4QEL	;	1.432	;	Crystal Structure of Benzoylformate Decarboxylase Mutant H70A
4JD5	;	1.33	;	Crystal Structure of Benzoylformate Decarboxylase Mutant L403E
4GP9	;	1.07	;	Crystal Structure of Benzoylformate Decarboxylase Mutant L403F
4GM4	;	1.28	;	Crystal Structure of Benzoylformate Decarboxylase Mutant L403I
4GPE	;	1.39	;	Crystal Structure of Benzoylformate Decarboxylase Mutant L403M
4GM0	;	1.07	;	Crystal Structure of Benzoylformate Decarboxylase Mutant L403N
4GM1	;	1.26	;	Crystal Structure of Benzoylformate Decarboxylase Mutant L403S
4GG1	;	1.069	;	Crystal Structure of Benzoylformate Decarboxylase Mutant L403T
4MZX	;	1.558	;	Crystal Structure of Benzoylformate Decarboxylase Mutant T377L/A460Y
1F8F	;	2.2	;	CRYSTAL STRUCTURE OF BENZYL ALCOHOL DEHYDROGENASE FROM ACINETOBACTER CALCOACETICUS
3L00	;	1.7	;	Crystal structure of benzylated SNAP-tag
4NPS	;	1.9	;	Crystal Structure of Bep1 protein (VirB-translocated Bartonella effector protein) from Bartonella clarridgeiae
4WGJ	;	1.7	;	Crystal Structure of BepC protein (VirB-translocated Bartonella effector protein) with bound AMPPNP from Bartonella tribocorum
5XOH	;	2.2	;	Crystal structure of bergaptol o-methyltransferase complex
4DNS	;	2.15	;	Crystal structure of Bermuda grass isoallergen BG60 provides insight into the various cross-allergenicity of the pollen group 4 allergens
2QM0	;	1.84	;	Crystal structure of BES protein from Bacillus cereus
4KKS	;	2.6	;	Crystal Structure of BesA (C2 form)
4KKT	;	2.53	;	Crystal Structure of BesA (P21 form)
2PWN	;	2.04	;	Crystal structure of BET3 homolog (13277653) from Mus musculus at 2.04 A resolution
3LOZ	;	1.8	;	Crystal structure of Beta 2 Microglobulin amyloidogenic segment LSFSKD
3LOW	;	2.3	;	Crystal structure of Beta 2 Microglobulin domain-swapped dimer
6YL7	;	3.17	;	Crystal structure of beta carbonic anhydrase from the pathogenic bacterium Burkholderia pseudomallei
6YJN	;	2.7	;	Crystal structure of beta carbonic anhydrase from the pathogenic bacterium Burkholderia pseudomallei.
5CXK	;	1.9	;	Crystal structure of beta carbonic anhydrase from Vibrio cholerae
4S3I	;	1.946	;	Crystal structure of beta clamp from Helicobacter pylori
1WUW	;	1.9	;	Crystal Structure of beta hordothionin
4GKU	;	1.915	;	Crystal structure of beta lactamase in PET-15B
1BTG	;	2.5	;	CRYSTAL STRUCTURE OF BETA NERVE GROWTH FACTOR AT 2.5 A RESOLUTION IN C2 SPACE GROUP WITH ZN IONS BOUND
3WB5	;	2.501	;	Crystal Structure of beta secetase in complex with (6S)-2-amino-3,6-dimethyl-6-[(1R,2R)-2-phenylcyclopropyl]-3,4,5,6-tetrahydropyrimidin-4-one
3WB4	;	2.25	;	Crystal Structure of beta secetase in complex with 2-amino-3,6-dimethyl-6-(2-phenylethyl)-3,4,5,6-tetrahydropyrimidin-4-one
3VV6	;	2.05	;	Crystal Structure of beta secetase in complex with 2-amino-3-methyl-6-((1S, 2R)-2-phenylcyclopropyl)pyrimidin-4(3H)-one
3VV8	;	2.5	;	Crystal structure of beta secetase in complex with 2-amino-3-methyl-6-((1S,2R)-2-(3'-methylbiphenyl-4-yl)cyclopropyl)pyrimidin-4(3H)-one
3VV7	;	2.1	;	Crystal Structure of beta secetase in complex with 2-amino-6-((1S,2R)-2-(3'-methoxybiphenyl-3-yl)cyclopropyl)-3-methylpyrimidin-4(3H)-one
6WMK	;	2.2	;	Crystal structure of beta sheet heterodimer LHD29
4Q0G	;	2.31	;	Crystal structure of beta subunit of acyl-CoA carboxylase AccD1 from Mycobacterium tuberculosis
3I5V	;	2.8	;	Crystal structure of beta toxin 275-280 from Staphylococcus aureus
3I41	;	1.75	;	Crystal structure of beta toxin from Staphylococcus aureus F277A, P278A mutant
3I46	;	2.6	;	Crystal structure of beta toxin from Staphylococcus aureus F277A, P278A mutant with bound calcium ions
3I48	;	1.8	;	Crystal structure of beta toxin from Staphylococcus aureus F277A, P278A mutant with bound magnesium ions
4J78	;	1.478	;	Crystal structure of beta'-COP/Emp47p complex
4J77	;	1.756	;	Crystal structure of beta'-COP/hWbp1 complex
4J81	;	1.745	;	Crystal structure of beta'-COP/Insig-1 complex
4J82	;	1.461	;	Crystal structure of beta'-COP/Insig-2 complex
4J73	;	1.439	;	Crystal structure of beta'-COP/p25 complex
4J79	;	1.559	;	Crystal structure of beta'-COP/PEDVspike complex
4J84	;	1.473	;	Crystal structure of beta'-COP/Scyl1 complex
4J86	;	1.48	;	Crystal structure of beta'-COP/yWbp1 complex
8ENW	;	1.45	;	Crystal structure of beta'-COPI-WD40 domain in complex with SARS-CoV-2 clientized spike tail heptapeptide.
8ENS	;	1.45	;	Crystal structure of beta'-COPI-WD40 domain in complex with SARS-CoV-2 spike tail hepta-peptide
8ENX	;	1.8	;	Crystal structure of beta'-COPI-WD40 domain Y33A mutant in complex with SARS-CoV-2 clientized spike tail heptapeptide.
5UH7	;	2.199	;	Crystal structure of beta'MtbSI of Mycobacterium tuberculosis RNA polymerase
5Z06	;	2.1	;	Crystal structure of beta-1,2-glucanase from Parabacteroides distasonis
5YSF	;	1.9	;	Crystal structure of beta-1,2-glucooligosaccharide binding protein in complex with sophoropentaose
5YSE	;	1.6	;	Crystal structure of beta-1,2-glucooligosaccharide binding protein in complex with sophorotetraose
5YSD	;	2.1	;	Crystal structure of beta-1,2-glucooligosaccharide binding protein in complex with sophorotriose
5YSB	;	2.2	;	Crystal structure of beta-1,2-glucooligosaccharide binding protein in ligand-free form
7WWC	;	2.20216	;	Crystal structure of beta-1,3(4)-glucanase with Laminaritriose
3EQN	;	1.7	;	Crystal structure of beta-1,3-glucanase from Phanerochaete chrysosporium (Lam55A)
3EQO	;	2.25	;	Crystal structure of beta-1,3-glucanase from Phanerochaete chrysosporium (Lam55A) gluconolactone complex
2DDX	;	0.86	;	Crystal structure of beta-1,3-xylanase from Vibrio sp. AX-4
4OOU	;	2.36	;	Crystal structure of beta-1,4-D-mannanase from Cryptopygus antarcticus
4OOZ	;	2.6	;	Crystal structure of beta-1,4-D-mannanase from Cryptopygus antarcticus in complex with mannopentaose
1FOB	;	1.8	;	CRYSTAL STRUCTURE OF BETA-1,4-GALACTANASE FROM ASPERGILLUS ACULEATUS AT 100K
1FHL	;	2.3	;	CRYSTAL STRUCTURE OF BETA-1,4-GALACTANASE FROM ASPERGILLUS ACULEATUS AT 293K
1YIF	;	1.8	;	CRYSTAL STRUCTURE OF beta-1,4-xylosidase FROM BACILLUS SUBTILIS, NEW YORK STRUCTURAL GENOMICS CONSORTIUM
6V06	;	2.4	;	Crystal structure of Beta-2 glycoprotein I purified from plasma (pB2GPI)
6K7U	;	1.601	;	Crystal structure of beta-2 microglobulin (beta2m) of Bat (Pteropus Alecto)
7NMO	;	1.2	;	Crystal structure of beta-2-microglobulin D76A mutant
7NMC	;	1.2	;	Crystal structure of beta-2-microglobulin D76E mutant
7NMT	;	1.2	;	Crystal structure of beta-2-microglobulin D76G mutant
7NN5	;	1.242	;	Crystal structure of beta-2-microglobulin D76K mutant
7NMV	;	1.51	;	Crystal structure of beta-2-microglobulin D76Q mutant
7NMR	;	1.15	;	Crystal structure of beta-2-microglobulin D76S mutant
7NMY	;	1.25	;	Crystal structure of beta-2-microglobulin D76Y mutant
1R3N	;	2.7	;	Crystal structure of beta-alanine synthase from Saccharomyces kluyveri
1R43	;	2.8	;	Crystal structure of beta-alanine synthase from Saccharomyces kluyveri (selenomethionine substituted protein)
2VL1	;	2.15	;	Crystal structure of beta-alanine synthase from Saccharomyces kluyveri in complex with a gly-gly peptide
2V8G	;	2.5	;	Crystal structure of beta-alanine synthase from Saccharomyces kluyveri in complex with the product beta-alanine
1FA2	;	2.3	;	CRYSTAL STRUCTURE OF BETA-AMYLASE FROM SWEET POTATO
5XFM	;	2.3	;	Crystal structure of beta-arabinopyranosidase
6K3F	;	2.3	;	Crystal Structure of beta-Arrestin 2 in Complex with CXCR7 Phosphopeptide
7CF6	;	2.75	;	Crystal structure of Beta-aspartyl dipeptidase from thermophilic keratin degrading Fervidobacterium islandicum AW-1 in complex with beta-Asp-Leu dipeptide
6NTR	;	2.101	;	Crystal Structure of Beta-barrel-like Protein of Domain of Unknown Function DUF1849 from Brucella abortus
5UC0	;	1.73	;	Crystal Structure of Beta-barrel-like, Uncharacterized Protein of COG5400 from Brucella abortus
5YO8	;	1.64	;	Crystal structure of beta-C25/C30/C35-prene synthase
6Y04	;	2.48	;	Crystal structure of beta-carbonic anhydrase isoform I (TvaCA1) from the Trichomonas vaginalis protozoan.
1Q5N	;	2.3	;	Crystal Structure of beta-carboxy-cis,cis-muconate cycloisomerase (CMLE) from Acinetobacter calcoaceticus sp. ADP1
3PLC	;	2.41	;	Crystal structure of Beta-Cardiotoxin, a novel three-finger cardiotoxin from the venom of Ophiophagus hannah
1JDH	;	1.9	;	CRYSTAL STRUCTURE OF BETA-CATENIN AND HTCF-4
8EIB	;	3.76	;	Crystal structure of beta-catenin and the MDM2 p53-binding domain in complex with H329, a Helicon Polypeptide
8EIC	;	2.62	;	Crystal structure of beta-catenin and the MDM2 p53-binding domain in complex with H330, a Helicon Polypeptide
8EI9	;	3.9	;	Crystal structure of beta-catenin and the MDM2 p53-binding domain in complex with H332, a Helicon Polypeptide
8EIA	;	3.6	;	Crystal structure of beta-catenin and the MDM2 p53-binding domain in complex with H333, a Helicon Polypeptide
2Z6H	;	2.2	;	Crystal Structure of Beta-Catenin Armadillo Repeat Region and Its C-Terminal domain
7ZRB	;	3.434	;	Crystal structure of Beta-catenin Armadillo repeats domain in complex with the inhibitor RS6452
7AR4	;	2.6	;	Crystal structure of beta-catenin in complex with cyclic peptide inhibitor
1T08	;	2.1	;	Crystal structure of beta-catenin/ICAT helical domain/unphosphorylated APC R3
1LJP	;	1.8	;	Crystal Structure of beta-Cinnamomin Elicitin
8OFD	;	2.81	;	Crystal structure of beta-conglutin from Lupinus albus refined to 2.81 A
3VBE	;	2.5	;	Crystal structure of beta-cyanoalanine synthase in soybean
3VC3	;	1.766	;	Crystal structure of beta-cyanoalanine synthase K95A mutant in soybean
4I8D	;	2.48	;	Crystal Structure of Beta-D-glucoside glucohydrolase from Trichoderma reesei
5N6U	;	3.08	;	Crystal structure of Beta-D-Mannosidase from Dictyoglomus thermophilum.
6YYI	;	2.67	;	Crystal structure of beta-D-xylosidase from Dictyoglomus thermophilum bound to beta-D-xylopyranose
6YYH	;	2.72	;	Crystal structure of beta-D-xylosidase from Dictyoglomus thermophilum in ligand-free form
1PX8	;	2.4	;	Crystal structure of beta-D-xylosidase from Thermoanaerobacterium saccharolyticum, a family 39 glycoside hydrolase
1UHV	;	2.1	;	Crystal structure of beta-D-xylosidase from Thermoanaerobacterium saccharolyticum, a family 39 glycoside hydrolase
5HN3	;	1.7	;	Crystal structure of beta-decarboxylating dehydrogenase (TK0280) from Thermococcus kodakarensis (apo form)
5HN6	;	2.5	;	Crystal structure of beta-decarboxylating dehydrogenase (TK0280) from Thermococcus kodakarensis complexed with Mn and 3-isopropylmalate
5HN4	;	2.64	;	Crystal structure of beta-decarboxylating dehydrogenase (TK0280) from Thermococcus kodakarensis complexed with Mn and homoisocitrate
5HN5	;	2.55	;	Crystal structure of beta-decarboxylating dehydrogenase (TK0280) from Thermococcus kodakarensis complexed with Mn and isocitrate
4XT0	;	2.07	;	Crystal Structure of Beta-etherase LigF from Sphingobium sp. strain SYK-6
4MAD	;	1.8	;	Crystal structure of beta-galactosidase C (BgaC) from Bacillus circulans ATCC 31382
4IUG	;	2.6	;	Crystal structure of beta-galactosidase from Aspergillus oryzae in complex with galactose
3TTS	;	2.401	;	Crystal structure of beta-galactosidase from Bacillus circulans sp. alkalophilus
3TTY	;	2.25	;	Crystal structure of beta-galactosidase from Bacillus circulans sp. alkalophilus in complex with galactose
7SF2	;	2.75	;	Crystal Structure of Beta-Galactosidase from Bacteroides cellulosilyticus
3BGA	;	2.1	;	Crystal structure of beta-galactosidase from Bacteroides thetaiotaomicron VPI-5482
5VYM	;	2.456	;	Crystal structure of beta-galactosidase from Bifidobacterium adolescentis
6Y2K	;	1.9	;	Crystal structure of beta-galactosidase from the psychrophilic Marinomonas ef1
7CWI	;	1.95	;	Crystal structure of beta-galactosidase II from Bacillus circulans
7CWD	;	2.0	;	Crystal structure of beta-galactosidase II from Bacillus circulans in complex with beta-D-galactopyranosyl disaccharide
5A8O	;	2.3	;	Crystal structure of beta-glucanase SdGluc5_26A from Saccharophagus degradans in complex with cellotetraose
5A94	;	1.99	;	Crystal structure of beta-Glucanase SdGluc5_26A from Saccharophagus degradans in complex with tetrasaccharide A, form 1
5A95	;	1.35	;	Crystal structure of beta-glucanase SdGluc5_26A from Saccharophagus degradans in complex with tetrasaccharide A, form 2
4IIB	;	1.8	;	Crystal structure of beta-glucosidase 1 from Aspergillus aculeatus
4IID	;	2.3	;	Crystal structure of beta-glucosidase 1 from Aspergillus aculeatus in complex with 1-deoxynojirimycin
4IIE	;	2.0	;	Crystal structure of beta-glucosidase 1 from Aspergillus aculeatus in complex with calystegine B(2)
4IIF	;	2.45	;	Crystal structure of beta-glucosidase 1 from Aspergillus aculeatus in complex with castanospermine
4IIG	;	2.3	;	Crystal structure of beta-glucosidase 1 from Aspergillus aculeatus in complex with D-glucose
4IIC	;	1.9	;	Crystal structure of beta-glucosidase 1 from Aspergillus aculeatus in complex with isofagomine
4IIH	;	2.0	;	Crystal structure of beta-glucosidase 1 from Aspergillus aculeatus in complex with thiocellobiose
3AHY	;	1.63	;	Crystal structure of beta-glucosidase 2 from fungus Trichoderma reesei in complex with Tris
3AHX	;	1.9	;	Crystal structure of beta-glucosidase A from bacterium Clostridium cellulovorans
5NS6	;	1.5	;	Crystal structure of beta-glucosidase BglM-G1 from marine metagenome
5NS7	;	1.54	;	Crystal structure of beta-glucosidase BglM-G1 mutant H75R from marine metagenome
5NS8	;	1.55	;	Crystal structure of beta-glucosidase BglM-G1 mutant H75R from marine metagenome in complex with inhibitor 1-Deoxynojirimycin
3AC0	;	2.54	;	Crystal structure of Beta-glucosidase from Kluyveromyces marxianus in complex with glucose
4ZOE	;	1.8	;	Crystal Structure of beta-glucosidase from Listeria innocua
4ZOB	;	2.4	;	Crystal Structure of beta-glucosidase from Listeria innocua in complex with gluconolactone
4ZOD	;	2.1	;	Crystal Structure of beta-glucosidase from Listeria innocua in complex with glucose
4ZOA	;	2.17	;	Crystal Structure of beta-glucosidase from Listeria innocua in complex with isofagomine
3VIG	;	0.99	;	Crystal structure of beta-glucosidase from termite Neotermes koshunensis in complex with 1-deoxynojirimycin
3VIM	;	1.03	;	Crystal structure of beta-glucosidase from termite Neotermes koshunensis in complex with a new glucopyranosidic product
3VIN	;	1.13	;	Crystal structure of beta-glucosidase from termite Neotermes koshunensis in complex with a new glucopyranosidic product
3VIO	;	1.12	;	Crystal structure of beta-glucosidase from termite Neotermes koshunensis in complex with a new glucopyranosidic product
3VIP	;	1.28	;	Crystal structure of beta-glucosidase from termite Neotermes koshunensis in complex with a new glucopyranosidic product
3VII	;	0.97	;	Crystal structure of beta-glucosidase from termite Neotermes koshunensis in complex with Bis-Tris
3VIK	;	1.1	;	Crystal structure of beta-glucosidase from termite Neotermes koshunensis in complex with cellobiose
3VIF	;	1.0	;	Crystal structure of beta-glucosidase from termite Neotermes koshunensis in complex with gluconolactone
3VIJ	;	1.03	;	Crystal structure of beta-glucosidase from termite Neotermes koshunensis in complex with glucose
3VIH	;	1.03	;	Crystal structure of beta-glucosidase from termite Neotermes koshunensis in complex with glycerol
3AI0	;	1.4	;	Crystal structure of beta-glucosidase from termite Neotermes koshunensis in complex with para-nitrophenyl-beta-D-glucopyranoside
3VIL	;	1.15	;	Crystal structure of beta-glucosidase from termite Neotermes koshunensis in complex with salicin
3AHZ	;	1.34	;	Crystal structure of beta-glucosidase from termite Neotermes koshunensis in complex with Tris
7E5J	;	1.71	;	Crystal structure of beta-glucosidase from Thermoanaerobacterium saccharolyticum
8WFT	;	1.9	;	Crystal structure of beta-glucosidase from Thermoanaerobacterium saccharolyticum (Data 1)
8WFU	;	2.1	;	Crystal structure of beta-glucosidase from Thermoanaerobacterium saccharolyticum (Data 2)
8WFV	;	1.5	;	Crystal structure of beta-glucosidase from Thermoanaerobacterium saccharolyticum (Data 3)
8WFW	;	1.61	;	Crystal structure of beta-glucosidase from Thermoanaerobacterium saccharolyticum (Data 4)
3AIU	;	2.2	;	Crystal structure of beta-glucosidase in rye
3AIW	;	2.4	;	Crystal structure of beta-glucosidase in rye complexed with 2-deoxy-2-fluoroglucoside and dinitrophenol
3AIV	;	2.5	;	Crystal structure of beta-glucosidase in rye complexed with an aglycone DIMBOA
3AIR	;	2.0	;	Crystal structure of beta-glucosidase in wheat complexed with 2-deoxy-2-fluoroglucoside and dinitrophenol
3AIQ	;	1.9	;	Crystal structure of beta-glucosidase in wheat complexed with an aglycone DIMBOA
3VNY	;	1.5	;	Crystal structure of beta-glucuronidase from Acidobacterium capsulatum
7PSH	;	1.24	;	Crystal structure of beta-glucuronidase from Acidobacterium capsulatum at 1.24 Angstrom resolution
3VO0	;	1.9	;	Crystal structure of beta-glucuronidase from Acidobacterium capsulatum covalent-bonded with 2-deoxy-2-fluoro-D-glucuronic acid
8OHT	;	1.05	;	Crystal structure of Beta-glucuronidase from Acidobacterium capsulatum in complex with competitive inhibitor derrived from siastatin B
7PSK	;	1.09	;	Crystal structure of beta-glucuronidase from Acidobacterium capsulatum in complex with covalent inhibitor GR109
7PSI	;	1.25	;	Crystal structure of beta-glucuronidase from Acidobacterium capsulatum in complex with covalent inhibitor ME727
8B0D	;	1.62	;	Crystal structure of beta-glucuronidase from Acidobacterium capsulatum in complex with covalent inhibitor VB151
8B0E	;	1.55	;	Crystal structure of beta-glucuronidase from Acidobacterium capsulatum in complex with covalent inhibitor VB158
7PSJ	;	1.55	;	Crystal structure of beta-glucuronidase from Acidobacterium capsulatum in complex with covalent inhibitor VL166
3VNZ	;	1.8	;	Crystal structure of beta-glucuronidase from Acidobacterium capsulatum in complex with D-glucuronic acid
8OHV	;	1.5	;	Crystal structure of Beta-glucuronidase from Acidobacterium capsulatum in complex with glucuronic acid configured 3-geminal diol iminosugar inhibitor
8OHU	;	1.25	;	Crystal structure of Beta-glucuronidase from Acidobacterium capsulatum in complex with glucuronic acid configured isofagamine
8OHX	;	1.95	;	Crystal structure of Beta-glucuronidase from Escherichia coli in complex with siastatin B derived inhibitor
4R27	;	2.03	;	Crystal structure of beta-glycosidase BGL167
7C71	;	2.1	;	Crystal structure of beta-glycosides-binding protein (E117A) of ABC transporter in an open state
7C6J	;	2.1	;	Crystal structure of beta-glycosides-binding protein (W177X) of ABC transporter in a closed state bound to cellobiose
7C6R	;	1.96	;	Crystal structure of beta-glycosides-binding protein (W177X) of ABC transporter in a closed state bound to cellopentaose
7C6M	;	1.9	;	Crystal structure of beta-glycosides-binding protein (W177X) of ABC transporter in a closed state bound to cellotetraose (Form I)
7C6N	;	2.05	;	Crystal structure of beta-glycosides-binding protein (W177X) of ABC transporter in a closed state bound to cellotetraose (Form II)
7C6K	;	1.77	;	Crystal structure of beta-glycosides-binding protein (W177X) of ABC transporter in a closed state bound to cellotriose (Form I)
7C6L	;	2.4	;	Crystal structure of beta-glycosides-binding protein (W177X) of ABC transporter in a closed state bound to cellotriose (Form II)
7C6W	;	1.88	;	Crystal structure of beta-glycosides-binding protein (W177X) of ABC transporter in a closed state bound to laminaritetraose
7C6T	;	2.3	;	Crystal structure of beta-glycosides-binding protein (W177X) of ABC transporter in a closed state bound to laminaritriose (Form I)
7C6V	;	2.8	;	Crystal structure of beta-glycosides-binding protein (W177X) of ABC transporter in a closed state bound to laminaritriose (Form II)
7C6F	;	1.7	;	Crystal structure of beta-glycosides-binding protein (W177X) of ABC transporter in an open state
7C6G	;	1.9	;	Crystal structure of beta-glycosides-binding protein (W177X) of ABC transporter in an open-liganded state bound to gentiobiose
7C6H	;	1.85	;	Crystal structure of beta-glycosides-binding protein (W177X) of ABC transporter in an open-liganded state bound to laminaribiose
7C6I	;	1.7	;	Crystal structure of beta-glycosides-binding protein (W177X) of ABC transporter in an open-liganded state bound to sophorose
7C6X	;	2.65	;	Crystal structure of beta-glycosides-binding protein (W41A) of ABC transporter in an open state (Form I)
7C6Y	;	1.7	;	Crystal structure of beta-glycosides-binding protein (W41A) of ABC transporter in an open state (Form II)
7C6Z	;	1.63	;	Crystal structure of beta-glycosides-binding protein (W67A) of ABC transporter in an open state
7C70	;	1.63	;	Crystal structure of beta-glycosides-binding protein (W67A) of ABC transporter in an open-liganded state bound to gentiobiose
7C66	;	2.3	;	Crystal structure of beta-glycosides-binding protein of ABC transporter in a closed state bound to cellobiose
7C68	;	2.05	;	Crystal structure of beta-glycosides-binding protein of ABC transporter in a closed state bound to cellotetraose
7C67	;	2.0	;	Crystal structure of beta-glycosides-binding protein of ABC transporter in a closed state bound to cellotriose
7C69	;	2.35	;	Crystal structure of beta-glycosides-binding protein of ABC transporter in a closed state bound to sophorose
7C63	;	1.63	;	Crystal structure of beta-glycosides-binding protein of ABC transporter in an open state (Form I)
7C64	;	1.63	;	Crystal structure of beta-glycosides-binding protein of ABC transporter in an open state (Form II)
4G6C	;	1.38	;	Crystal structure of beta-hexosaminidase 1 from Burkholderia cenocepacia J2315
4GNV	;	1.5	;	Crystal structure of beta-hexosaminidase 1 from Burkholderia cenocepacia J2315 with bound N-Acetyl-D-Glucosamine
3GH4	;	1.8	;	Crystal structure of beta-hexosaminidase from Paenibacillus sp. TS12
3SUS	;	1.8	;	Crystal structure of beta-hexosaminidase from Paenibacillus sp. TS12 in complex with Gal-NAG-thiazoline
3SUU	;	1.6	;	Crystal structure of beta-hexosaminidase from Paenibacillus sp. TS12 in complex with Gal-PUGNAc
3GH7	;	1.9	;	Crystal structure of beta-hexosaminidase from Paenibacillus sp. TS12 in complex with GalNAc
3GH5	;	1.6	;	Crystal structure of beta-hexosaminidase from Paenibacillus sp. TS12 in complex with GlcNAc
3SUR	;	1.9	;	Crystal structure of beta-hexosaminidase from Paenibacillus sp. TS12 in complex with NAG-thiazoline.
3SUW	;	1.9	;	Crystal structure of beta-hexosaminidase from Paenibacillus sp. TS12 in complex with NHAc-CAS
3SUV	;	1.6	;	Crystal structure of beta-hexosaminidase from Paenibacillus sp. TS12 in complex with NHAc-DNJ
3SUT	;	1.9	;	Crystal structure of beta-hexosaminidase from Paenibacillus sp. TS12 in complex with PUGNAc
1Y65	;	1.85	;	Crystal structure of beta-hexosaminidase from Vibrio cholerae in complex with N-acetyl-D-glucosamine to a resolution of 1.85
7L74	;	2.25	;	Crystal structure of Beta-hexosyl transferase from Hamamotoa (Sporobolomyces) singularis bound to TRIS
4ZW0	;	2.9	;	Crystal structure of beta-Hydroxyacyl-acyl carrier protein dehydratase (FabZ) from Candidatus asiaticum
5BUY	;	2.55	;	Crystal Structure of beta-hydroxyacyl-acyl carrier protein dehydratase (FabZ) from Francisella tularensis
1ZHG	;	2.4	;	Crystal structure of Beta-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Plasmodium falciparum
5BUW	;	1.8	;	Crystal Structure of beta-hydroxyacyl-acyl carrier protein dehydratase (FabZ) from Yersinia Pestis
3LRF	;	1.6	;	Crystal structure of beta-ketoacyl synthase from brucella melitensis
3U0E	;	1.6	;	Crystal structure of beta-ketoacyl synthase from Brucella melitensis in complex with fragment 9320
4JV3	;	1.7	;	Crystal structure of beta-ketoacyl synthase from Brucella melitensis in complex with platencin
3MQD	;	1.25	;	Crystal structure of beta-ketoacyl synthase from brucella melitensis with FOL 0758, (1-methyl-1h-indazol-3-yl) methanol
4W61	;	2.01	;	Crystal structure of beta-ketoacyl thiolase B (BktB) from Ralstonia eutropha
1I01	;	2.6	;	CRYSTAL STRUCTURE OF BETA-KETOACYL [ACYL CARRIER PROTEIN] REDUCTASE FROM E. COLI.
4WZU	;	1.88	;	Crystal structure of beta-ketoacyl-(acyl carrier protein) synthase III-2 (FabH2) from Vibrio cholerae
4LS5	;	1.803	;	Crystal structure of beta-ketoacyl-ACP synthase II (FabF) from Bacillus subtilis
4JRM	;	1.75	;	Crystal structure of beta-ketoacyl-ACP synthase II (FabF) from Vibrio Cholerae (space group P212121) at 1.75 Angstrom
4JRH	;	2.2	;	Crystal structure of beta-ketoacyl-ACP synthase II (FabF) from Vibrio Cholerae (space group P43) at 2.2 Angstrom
4R8E	;	2.7	;	Crystal structure of beta-ketoacyl-ACP synthase II (FabF) from Yersinia pestis
4LS6	;	1.56	;	Crystal structure of beta-ketoacyl-ACP synthase II (FabF) I108F mutant from Bacillus subtilis
1HN9	;	2.0	;	CRYSTAL STRUCTURE OF BETA-KETOACYL-ACP SYNTHASE III
4RYB	;	2.45	;	Crystal structure of beta-ketoacyl-ACP synthase III (FabH) from Neisseria meningitidis
4NHD	;	1.78	;	Crystal structure of beta-ketoacyl-ACP synthase III (FabH) from Vibrio Cholerae in complex with Coenzyme A
4YLT	;	2.2	;	Crystal structure of beta-ketoacyl-ACP synthase III (FabH) from Yersinia pestis
4Z19	;	1.8	;	Crystal structure of beta-ketoacyl-ACP synthase III (FabH) from Yersinia pestis with acetylated active site cysteine
1HNH	;	1.9	;	CRYSTAL STRUCTURE OF BETA-KETOACYL-ACP SYNTHASE III + DEGRADED FORM OF ACETYL-COA
1HNJ	;	1.46	;	CRYSTAL STRUCTURE OF BETA-KETOACYL-ACP SYNTHASE III + MALONYL-COA
1MZS	;	2.1	;	CRYSTAL STRUCTURE OF BETA-KETOACYL-ACP SYNTHASE III WITH BOUND dichlorobenzyloxy-indole-carboxylic acid inhibitor
1HNK	;	1.9	;	CRYSTAL STRUCTURE OF BETA-KETOACYL-ACP SYNTHASE III, APO TETRAGONAL FORM
5V0P	;	2.16	;	Crystal Structure of Beta-ketoacyl-ACP synthase III-2 (FabH2) (C113A) from Vibrio Cholerae co-crystallized with octanoyl-CoA
1HND	;	1.6	;	CRYSTAL STRUCTURE OF BETA-KETOACYL-ACP SYNTHASE III-COA COMPLEX
4I08	;	2.063	;	Crystal structure of beta-ketoacyl-acyl carrier protein reductase (FabG) from Vibrio cholerae in complex with NADPH
4WJZ	;	2.4	;	Crystal structure of beta-ketoacyl-acyl carrier protein reductase (FabG)(G141A) from Vibrio cholerae
5END	;	2.55	;	Crystal structure of beta-ketoacyl-acyl carrier protein reductase (FabG)(Q152A) from Vibrio cholerae
1DD8	;	2.3	;	CRYSTAL STRUCTURE OF BETA-KETOACYL-[ACYL CARRIER PROTEIN] SYNTHASE I FROM ESCHERICHIA COLI
6PCA	;	1.81	;	Crystal structure of beta-ketoadipyl-CoA thiolase
6PCD	;	1.37	;	Crystal structure of beta-ketoadipyl-CoA thiolase mutant (C90S-H356A) in complex Octanoyl coenzyme A
6PCC	;	1.96	;	Crystal structure of beta-ketoadipyl-CoA thiolase mutant (H356A) in complex hexanoyl coenzyme A
6PCB	;	1.61	;	Crystal structure of beta-ketoadipyl-CoA thiolase mutant (H356A) in complex with COA
4O99	;	1.96	;	Crystal structure of Beta-ketothiolase (PhaA) from Ralstonia eutropha H16
4O9A	;	1.52	;	Crystal structure of Beta-ketothiolase (PhaA) from Ralstonia eutropha H16
4O9C	;	2.0	;	Crystal structure of Beta-ketothiolase (PhaA) from Ralstonia eutropha H16
4NZS	;	2.29	;	Crystal structure of beta-ketothiolase BktB B from Ralstonia eutropha H16
5VAN	;	2.202	;	Crystal Structure of Beta-Klotho
5VAQ	;	2.606	;	Crystal Structure of Beta-Klotho in Complex with FGF21CT
5VAK	;	1.7	;	Crystal Structure of Beta-Klotho, Domain 1
6LCF	;	1.92	;	Crystal Structure of beta-L-arabinobiose binding protein - native
6LCE	;	1.78	;	Crystal Structure of beta-L-arabinobiose binding protein - selenomethionine derivative
3A23	;	1.9	;	Crystal Structure of beta-L-Arabinopyranosidase complexed with D-galactose
3A22	;	1.9	;	Crystal Structure of beta-L-Arabinopyranosidase complexed with L-arabinose
1JGT	;	1.95	;	CRYSTAL STRUCTURE OF BETA-LACTAM SYNTHETASE
5E2F	;	1.3	;	Crystal Structure of Beta-lactamase class D from Bacillus subtilis
5U8O	;	2.4	;	Crystal Structure of Beta-lactamase domain protein, from Burkholderia multivorans
5VPQ	;	1.4	;	Crystal structure of beta-lactamase from Burkholderia phymatum
5HX9	;	1.8	;	Crystal structure of Beta-lactamase from Burkholderia vietnamiensis
3P09	;	1.898	;	Crystal Structure of Beta-Lactamase from Francisella tularensis
4Q8I	;	1.901	;	Crystal Structure of beta-lactamase from M.tuberculosis covalently complexed with Tebipenem
4QB8	;	1.758	;	Crystal Structure of beta-lactamase from M.tuberculosis forming Michaelis Menten with Tebipenem
6NJK	;	1.55	;	Crystal structure of beta-lactamase from Sulfitobacter sp. EE-36
1JTD	;	2.3	;	Crystal structure of beta-lactamase inhibitor protein-II in complex with TEM-1 beta-lactamase
3BYD	;	1.93	;	Crystal structure of beta-lactamase OXY-1-1 from Klebsiella oxytoca
5ZFL	;	1.5	;	Crystal structure of beta-lactamase PenP mutant E166Y
5GHX	;	1.24	;	Crystal structure of beta-lactamase PenP mutant-E166H
5GHY	;	2.1	;	Crystal structure of beta-lactamase PenP mutant-E166H in complex with cephaloridine as ""post-acylation"" intermediate
5GHZ	;	1.93	;	Crystal structure of beta-lactamase PenP mutant-E166H in complex with cephaloridine as ""pre-deacylation"" intermediate
5ZG6	;	2.0	;	Crystal structure of beta-lactamase PenP mutant-E166Y in complex with cephaloridine as ""post-acylation"" intermediate
5ZFT	;	1.93	;	Crystal structure of beta-lactamase PenP mutant-E166Y in complex with cephaloridine as ""pre-deacylation"" intermediate
5E2E	;	1.9	;	Crystal Structure of Beta-lactamase Precursor BlaA from Yersinia enterocolitica
5E43	;	1.7095	;	Crystal Structure of Beta-lactamase Sros_5706 from Streptosporangium roseum
5EVL	;	1.52	;	Crystal Structure of Beta-Lactamase/D-Alanine Carboxypeptidase from Chromobacterium violaceum
5EVI	;	1.8	;	Crystal Structure of Beta-Lactamase/D-Alanine Carboxypeptidase from Pseudomonas syringae
3OZH	;	1.907	;	Crystal Structure of Beta-Lactamase/D-alanine Carboxypeptidase from Yersinia pestis
3RJU	;	1.5	;	Crystal Structure of Beta-lactamase/D-alanine Carboxypeptidase from Yersinia pestis complexed with citrate
3GMU	;	1.98	;	Crystal Structure of Beta-Lactamse Inhibitory Protein (BLIP) in Apo Form
3GMV	;	1.8	;	Crystal Structure of Beta-Lactamse Inhibitory Protein-I (BLIP-I) in Apo Form
3GMW	;	2.1	;	Crystal Structure of Beta-Lactamse Inhibitory Protein-I (BLIP-I) in Complex with TEM-1 Beta-Lactamase
3GMX	;	1.05	;	Crystal Structure of Beta-Lactamse Inhibitory Protein-Like Protein (BLP) at 1.05 Angstrom Resolution
3GMY	;	1.7	;	Crystal Structure of Beta-Lactamse Inhibitory Protein-Like Protein (BLP), Selenomethionine Derivative
4N92	;	1.93	;	Crystal structure of beta-lactamse PenP_E166S
4N9K	;	1.93	;	crystal structure of beta-lactamse PenP_E166S in complex with cephaloridine
4N9L	;	2.3	;	crystal structure of beta-lactamse PenP_E166S in complex with meropenem
7ER3	;	2.598	;	Crystal structure of beta-lactoglobulin complexed with chloroquine
1NIO	;	2.0	;	Crystal structure of beta-luffin, a ribosome inactivating protein at 2.0A resolution
3WDQ	;	1.3	;	Crystal structure of beta-mannanase from a symbiotic protist of the termite Reticulitermes speratus
3WDR	;	1.4	;	Crystal structure of beta-mannanase from a symbiotic protist of the termite Reticulitermes speratus complexed with gluco-manno-oligosaccharide
3WSU	;	1.6	;	Crystal structure of beta-mannanase from Streptomyces thermolilacinus
4Y7E	;	1.5	;	Crystal structure of beta-mannanase from Streptomyces thermolilacinus with mannohexaose
1KD0	;	1.9	;	Crystal Structure of beta-methylaspartase from Clostridium tetanomorphum. Apo-structure.
1KCZ	;	1.9	;	Crystal Structure of beta-methylaspartase from Clostridium tetanomorphum. Mg-complex.
5IOB	;	2.252	;	Crystal structure of beta-N-acetylglucosaminidase-like protein from Corynebacterium glutamicum
7CBN	;	1.7	;	Crystal structure of beta-N-acetylhexosaminidase Am0868 from Akkermansia muciniphila
7CBO	;	1.5	;	Crystal structure of beta-N-acetylhexosaminidase Am0868 from Akkermansia muciniphila in complex with GlcNAc
3RCN	;	2.514	;	Crystal Structure of Beta-N-Acetylhexosaminidase from Arthrobacter aurescens
5BU9	;	2.255	;	Crystal structure of Beta-N-acetylhexosaminidase from Beutenbergia cavernae DSM 12333
3MW2	;	2.69	;	Crystal structure of beta-neurexin 1 with the splice insert 4
3MW3	;	2.33	;	Crystal structure of beta-neurexin 2 with the splice insert 4
3MW4	;	2.0	;	Crystal structure of beta-neurexin 3 without the splice insert 4
4EDL	;	2.1	;	Crystal structure of beta-parvin CH2 domain
4EDM	;	2.0	;	Crystal structure of beta-parvin CH2 domain
4EDN	;	2.9	;	Crystal structure of beta-parvin CH2 domain in complex with paxillin LD1 motif
4G9B	;	1.7	;	Crystal structure of beta-phosphoglucomutase homolog from escherichia coli, target efi-501172, with bound mg, open lid
3WQ4	;	1.9	;	Crystal structure of beta-primeverosidase
3IXJ	;	2.2	;	Crystal structure of beta-secretase 1 in complex with selective beta-secretase 1 inhibitor
2P4J	;	2.5	;	Crystal structure of beta-secretase bond to an inhibitor with Isophthalamide Derivatives at P2-P3
1XN3	;	2.0	;	Crystal structure of Beta-secretase bound to a long inhibitor with additional upstream residues.
2G94	;	1.86	;	Crystal structure of beta-secretase bound to a potent and highly selective inhibitor.
2FDP	;	2.5	;	Crystal structure of beta-secretase complexed with an amino-ethylene inhibitor
1M4H	;	2.1	;	Crystal Structure of Beta-secretase complexed with Inhibitor OM00-3
7EAD	;	1.74	;	Crystal structure of beta-sheet cytochrome c prime from Thermus thermophilus.
4FSL	;	2.5	;	Crystal structure of beta-site app-cleaving enzyme 1 (BACE-DB-MUT) complex with N-(N-(4- acetamido-3-chloro-5-methylbenzyl)carbamimidoyl)-3-(4- methoxyphenyl)-5-methyl-4-isothiazolecarboxamide
3SKG	;	2.88	;	Crystal structure of beta-site app-cleaving enzyme 1 (BACE-WT) complex with (2S)-2-((3R)-3-acetamido-3-isobutyl-2-oxo-1-pyrrolidinyl)-N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-2-(1,2,3,4-tetrahydro-3-isoquinolinyl)ethyl)-4-phenylbutanamide
3SKF	;	3.0	;	Crystal structure of beta-site app-cleaving enzyme 1 (BACE-WT) complex with (2S)-2-((3S)-3-(acetylamino)-3-(butan-2-yl)-2-oxopyrrolidin-1-yl)-N-((2S,3R)-3-hydroxy-4-((3-methoxybenzyl)amino)-1-phenylbutan-2-yl)-4-phenylbutanamide
3OHF	;	2.1	;	Crystal structure of beta-site app-cleaving enzyme 1 (BACE-WT) complex with bms-655295 aka n~3~-((1s,2r)-1- benzyl-2-hydroxy-3-((3-methoxybenzyl)amino)propyl)-n~1~, n~1~-dibutyl-1h-indole-1,3-dicarboxamide
3OHH	;	2.01	;	Crystal structure of beta-site app-cleaving enzyme 1 (bace-wt) complex with bms-681889 aka n~1~-butyl-5-cyano- n~3~-((1s,2r)-1-(3,5-difluorobenzyl)-2-hydroxy-3-((3- methoxybenzyl)amino)propyl)-n~1~-methyl-1h-indole-1,3- dicarboxamide
3R2F	;	2.53	;	Crystal structure of beta-site app-cleaving enzyme 1 (BACE-WT) complex with BMS-693391 AKA (2S)-2-((3R)-3-acetamido-3-isobutyl-2-oxo-1-pyrrolidinyl)-N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-2-((2R,4R)-4-propoxy-2-pyrrolidinyl)ethyl)-4-phenylbutanamide
4FSE	;	2.65	;	crystal structure of beta-site app-cleaving enzyme 1 (bace-wt) complex with N-(N-(4-amino-3,5- dichlorobenzyl)carbamimidoyl)-3-(4-methoxyphenyl)-5- methyl-4-isothiazolecarboxamide
5TOL	;	2.51	;	CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 COMPLEXED WITH N-(3-((4AS,7AS)-2-AMINO-4,4A,5,6-TETRAHYDRO-7AH-FURO[2,3-D][1,3]THIAZIN-7A-YL)-4-FLUOROPHENYL)-5-BROMO-2-PYRIDINECARBOXAMIDE
1BTY	;	1.5	;	Crystal structure of beta-trypsin in complex with benzamidine
1G9I	;	2.2	;	CRYSTAL STRUCTURE OF BETA-TRYSIN COMPLEX IN CYCLOHEXANE
2BFG	;	2.4	;	crystal structure of beta-xylosidase (fam GH39) in complex with dinitrophenyl-beta-xyloside and covalently bound xyloside
5ZQJ	;	1.73	;	Crystal structure of beta-xylosidase from Bacillus pumilus
7ZDY	;	1.46	;	Crystal structure of beta-xylosidase from Thermotoga maritima in complex with methyl-beta-D-xylopyranoside
7ZGZ	;	1.85	;	Crystal structure of beta-xylosidase from Thermotoga maritima in complex with methyl-beta-D-xylopyranoside hydrolysed to xylose
7ZB3	;	1.51	;	Crystal structure of beta-xylosidase from Thermotoga maritima in complex with xylohexaose hydrolysed to xylobiose
8C7F	;	1.52	;	Crystal structure of beta-xylosidase mutant (D281N, E517Q) from Thermotoga maritima in complex with xylopentaose
5ZQX	;	2.0	;	Crystal structure of beta-xylosidase mutant (E186Q) from Bacillus pumilus
5ZQS	;	1.782	;	Crystal structure of beta-xylosidase mutant (E186Q/F503Y) from Bacillus pumilus
1KWS	;	2.1	;	CRYSTAL STRUCTURE OF BETA1,3-GLUCURONYLTRANSFERASE I IN COMPLEX WITH THE ACTIVE UDP-GLCUA DONOR
1YRO	;	1.9	;	Crystal structure of beta14,-galactosyltransferase mutant ARG228Lys in complex with alpha-lactalbumin in the presence of UDP-galactose and Mn
1FUY	;	2.25	;	CRYSTAL STRUCTURE OF BETAA169L/BETAC170W DOUBLE MUTANT OF TRYPTOPHAN SYNTHASE COMPLEXED WITH 5-FLUORO-INDOLE-PROPANOL PHOSPHATE
7CDH	;	2.6	;	Crystal structure of Betaaspartyl dipeptidase from thermophilic keratin degrading Fervidobacterium islandicum-AW-1
3B1E	;	1.78	;	Crystal structure of betaC-S lyase from Streptococcus anginosus in complex with L-serine: alpha-Aminoacrylate form
3B1D	;	1.66	;	Crystal structure of betaC-S lyase from Streptococcus anginosus in complex with L-serine: External aldimine form
3B1C	;	1.93	;	Crystal structure of betaC-S lyase from Streptococcus anginosus: Internal aldimine form
3QW9	;	2.0	;	Crystal structure of betaglycan ZP-C domain
8UZO	;	2.1	;	Crystal Structure of Betaine aldehyde dehydrogenase (BetB) from Klebsiella aerogenes (ADP bound)
8UZN	;	2.15	;	Crystal Structure of Betaine aldehyde dehydrogenase (BetB) from Klebsiella aerogenes (AMP bound)
8U9B	;	1.9	;	Crystal Structure of Betaine aldehyde dehydrogenase (BetB) from Klebsiella aerogenes (Apo, P21 Form)
8UZI	;	2.05	;	Crystal Structure of Betaine aldehyde dehydrogenase (BetB) from Klebsiella aerogenes (betaine bound)
8VQZ	;	2.05	;	Crystal Structure of Betaine aldehyde dehydrogenase (BetB) from Klebsiella aerogenes (CMP bound)
8VQW	;	2.2	;	Crystal Structure of Betaine aldehyde dehydrogenase (BetB) from Klebsiella aerogenes (CoA bound)
8VR1	;	2.05	;	Crystal Structure of Betaine aldehyde dehydrogenase (BetB) from Klebsiella aerogenes (CTP bound)
8VJ3	;	1.9	;	Crystal Structure of Betaine aldehyde dehydrogenase (BetB) from Klebsiella aerogenes (FAD bound)
8VR0	;	2.25	;	Crystal Structure of Betaine aldehyde dehydrogenase (BetB) from Klebsiella aerogenes (GMP bound)
8SKF	;	1.8	;	Crystal Structure of Betaine aldehyde dehydrogenase (BetB) from Klebsiella aerogenes (Lattice Translocation Disorder)
8UZK	;	1.9	;	Crystal Structure of Betaine aldehyde dehydrogenase (BetB) from Klebsiella aerogenes (NADP+ bound)
8UZM	;	2.2	;	Crystal Structure of Betaine aldehyde dehydrogenase (BetB) from Klebsiella aerogenes (NADPH bound)
3R31	;	2.148	;	Crystal structure of betaine aldehyde dehydrogenase from Agrobacterium tumefaciens
4CAZ	;	2.55	;	CRYSTAL STRUCTURE OF BETAINE ALDEHYDE DEHYDROGENASE FROM Pseudomonas aeruginosa IN COMPLEX WITH NADH
6BPG	;	3.086	;	Crystal structure of betaine aldehyde dehydrogenase from Pseudomonas aeruginosa with bound rubidium ions
4A0M	;	2.3	;	CRYSTAL STRUCTURE OF BETAINE ALDEHYDE DEHYDROGENASE FROM SPINACH IN COMPLEX WITH NAD
4V37	;	2.1	;	Crystal structure of betaine aldehyde dehydrogenase from spinach showing a thiohemiacetal with 3-aminopropionaldehyde
4V3F	;	1.998	;	Crystal structure of betaine aldehyde dehydrogenase from spinach showing a thiohemiacetal with betaine aldehyde
5A2D	;	1.98	;	CRYSTAL STRUCTURE OF BETAINE ALDEHYDE DEHYDROGENASE FROM SPINACH SHOWING A THIOHEMIACETAL WITH BETAINE ALDEHYDE
3K2W	;	1.9	;	CRYSTAL STRUCTURE OF betaine-aldehyde dehydrogenase FROM Pseudoalteromonas atlantica T6c
3L4F	;	2.8	;	Crystal Structure of betaPIX Coiled-Coil Domain and Shank PDZ Complex
4DOJ	;	3.25	;	Crystal structure of BetP in outward-facing conformation
4AIN	;	3.1	;	Crystal structure of BetP with asymmetric protomers.
3P03	;	3.35	;	Crystal structure of BetP-G153D with choline bound
6UEU	;	1.8	;	Crystal structure of BF DNA polymerase F710Y mutant bound to tetrahydrofuran and dATP
3HN5	;	1.7	;	Crystal structure of BF0290 (YP_210027.1) from Bacteroides fragilis NCTC 9343 at 1.70 A resolution
5YVF	;	2.804	;	Crystal structure of BFA1
2WTL	;	2.59	;	Crystal structure of BfrA from M. tuberculosis
8B6A	;	1.77	;	Crystal structure of BfrB protein from Bacteroides fragilis NCTC 9343
8B61	;	1.81	;	Crystal structure of BfrC protein from Bacteroides fragilis NCTC 9343
7UGM	;	1.4	;	Crystal Structure of BG24-iGL CDR3mat Fab
8E1P	;	3.82	;	Crystal structure of BG505 SOSIP.v4.1-GT1.2 trimer in complex with gl-PGV20 and PGT124 Fabs
5W6D	;	3.202	;	Crystal structure of BG505-SOSIP.v4.1-GT1-N137A in complex with Fabs 35022 and 9H/109L
4HZ6	;	1.4	;	crystal structure of BglB
4HZ7	;	2.0	;	Crystal structure of BglB with glucose
4HZ8	;	1.14	;	Crystal structure of BglB with natural substrate
7KF0	;	2.32	;	Crystal structure of bH1 Fab variant (CDR H3 loop design 13_0346) in complex with VEGF
7KF1	;	2.45	;	Crystal structure of bH1 Fab variant (CDR H3 loop design 14_0130) in complex with VEGF
7KEZ	;	2.31	;	Crystal structure of bH1 Fab variant (CDR H3 loop design 16_0325) in complex with VEGF
6D33	;	2.502	;	Crystal structure of BH1352 2-deoxyribose-5-phosphate from Bacillus halodurans
6MSW	;	2.169	;	Crystal structure of BH1352 2-deoxyribose-5-phosphate from Bacillus halodurans, K184L mutant
3O3W	;	2.91	;	Crystal Structure of BH2092 protein (residues 14-131) from Bacillus halodurans, Northeast Structural Genomics Consortium Target BhR228A
3NHV	;	2.5	;	Crystal Structure of BH2092 protein from Bacillus halodurans, Northeast Structural Genomics Consortium Target BhR228F
3NWZ	;	2.566	;	Crystal Structure of BH2602 protein from Bacillus halodurans with CoA, Northeast Structural Genomics Consortium Target BhR199
2OA2	;	1.41	;	Crystal structure of BH2720 (10175341) from Bacillus halodurans at 1.41 A resolution
6Q7N	;	2.02	;	Crystal structure of BH32 alkylated with the mechanistic inhibitor 2-bromoacetophenone
2HH6	;	2.04	;	Crystal structure of BH3980 (10176605) from BACILLUS HALODURANS at 2.04 A resolution
5T4G	;	1.8	;	Crystal structure of BhGH81 in complex with laminarin
5V1W	;	2.15	;	Crystal structure of BhGH81 in complex with laminaro-biose
5T4A	;	2.1	;	Crystal structure of BhGH81 in complex with laminaro-hexaose
5UPI	;	1.65	;	Crystal structure of BhGH81 mutant in complex with laminaro-biose
5T4C	;	1.8	;	Crystal structure of BhGH81 mutant in complex with laminaro-hexaose
5UPO	;	1.7	;	Crystal structure of BhGH81 mutant in complex with laminaro-pentaose
5UPN	;	1.8	;	Crystal structure of BhGH81 mutant in complex with laminaro-tetraose
5UPM	;	1.7	;	Crystal structure of BhGH81 mutant in complex with laminaro-triose
8BP1	;	1.72	;	Crystal structure of BHMeHis1.0, an engineered enzyme for the Morita-Baylis-Hillman reaction
8BP0	;	2.621	;	Crystal structure of BHMeHis1.8, an engineered enzyme for the Morita-Baylis-Hillman reaction
8SM5	;	2.61003	;	Crystal Structure of BHRF1 from Epstein Barr Virus in complex with BID BH3 peptide
2XPX	;	2.05	;	Crystal structure of BHRF1:Bak BH3 complex
6J22	;	2.2	;	Crystal structure of Bi-functional enzyme
6J2L	;	2.17	;	Crystal structure of Bi-functional enzyme
2I4B	;	1.35	;	Crystal structure of Bicarbonate Transport Protein CmpA from Synechocystis sp. PCC 6803 in complex with bicarbonate and calcium
2I4C	;	1.7	;	Crystal structure of Bicarbonate Transport Protein CmpA from Synechocystis sp. PCC 6803 in complex with bicarbonate and calcium
2I48	;	1.6	;	Crystal structure of Bicarbonate Transport Protein CmpA from Synechocystis sp. PCC 6803 in complex with carbonic acid
4MNV	;	1.8	;	Crystal structure of bicyclic peptide UK729 bound as an acyl-enzyme intermediate to urokinase-type plasminogen activator (uPA)
5WAB	;	2.45	;	Crystal Structure of Bifidobacterium adolescentis GH3 beta-glucosidase
4UZS	;	1.74	;	Crystal structure of Bifidobacterium bifidum beta-galactosidase
4UCF	;	1.94	;	Crystal structure of Bifidobacterium bifidum beta-galactosidase in complex with alpha-galactose
6RXD	;	1.65	;	Crystal Structure of Bifidobacterium longum Multiple Inositol Polyphosphate Phosphatase Apo Form
6RXE	;	1.84	;	Crystal Structure of Bifidobacterium longum Multiple Inositol Polyphosphate Phosphatase Complex with Inositol Hexasulfate
6RXG	;	1.71	;	Crystal Structure of Bifidobacterium longum Multiple Inositol Polyphosphate Phosphatase Complex with Phosphate
6RXF	;	2.397	;	Crystal Structure of Bifidobacterium longum Multiple Inositol Polyphosphate Phosphatase Phosphohistidine Intermediate
3AI7	;	2.2	;	Crystal Structure of Bifidobacterium Longum Phosphoketolase
3NGL	;	2.4	;	Crystal structure of bifunctional 5,10-methylenetetrahydrofolate dehydrogenase / cyclohydrolase from Thermoplasma acidophilum
3NGX	;	2.3	;	Crystal structure of bifunctional 5,10-methylenetetrahydrofolate dehydrogenase / cyclohydrolase from Thermoplasma acidophilum
7TM8	;	1.65	;	Crystal structure of Bifunctional adenosylcobalamin biosynthesis protein from Klebsiella pneumoniae
1MJG	;	2.2	;	CRYSTAL STRUCTURE OF BIFUNCTIONAL CARBON MONOXIDE DEHYDROGENASE/ACETYL-COA SYNTHASE(CODH/ACS) FROM MOORELLA THERMOACETICA (F. CLOSTRIDIUM THERMOACETICUM)
2F6R	;	1.7	;	Crystal structure of Bifunctional coenzyme A synthase (CoA synthase): (18044849) from MUS MUSCULUS at 1.70 A resolution
5O15	;	1.174	;	Crystal structure of bifunctional dehydratase-cyclase domain in ambruticin biosynthesis
5O16	;	2.745	;	Crystal structure of bifunctional dehydratase-cyclase domain in ambruticin biosynthesis
6DE8	;	2.104	;	Crystal Structure of Bifunctional Enzyme FolD-Methylenetetrahydrofolate Dehydrogenase/Cyclohydrolase from Campylobacter jejuni
6DEB	;	1.7	;	Crystal Structure of Bifunctional Enzyme FolD-Methylenetetrahydrofolate Dehydrogenase/Cyclohydrolase in the Complex with Methotrexate from Campylobacter jejuni
3PYZ	;	2.1	;	Crystal structure of bifunctional folylpolyglutamate synthase/dihydrofolate synthase complexed with AMPPNP and Mn ion from Yersinia pestis c092
3N2A	;	1.9	;	Crystal structure of bifunctional folylpolyglutamate synthase/dihydrofolate synthase from Yersinia pestis CO92
3QCZ	;	2.0	;	Crystal structure of bifunctional folylpolyglutamate synthase/dihydrofolate synthase with Mn, AMPPNP and L-Glutamate bound
7ETX	;	2.1	;	Crystal structure of bifunctional indole-3-glycerol phosphate synthase / phosphoribosylanthranilate isomerase (TrpC) from corynebacterium glutamicum
7ETY	;	2.21	;	Crystal structure of bifunctional indole-3-glycerol phosphate synthase / phosphoribosylanthranilate isomerase (trpC) from Corynebacterium glutamicum in complex with reduced 1-(O-carboxyphenylamino)-1-deoxyribulose 5-phosphate (rCdRP)
5WVX	;	3.003	;	Crystal Structure of bifunctional Kunitz type Trypsin /amylase inhibitor (AMTIN) from the tubers of Alocasia macrorrhiza
3V97	;	2.2	;	Crystal structure of bifunctional methyltransferase YcbY (RlmLK) from Escherichia coli, SAH binding
3V8V	;	2.6	;	Crystal structure of bifunctional methyltransferase YcbY (RlmLK) from Escherichia coli, SAM binding
7Y47	;	2.5	;	Crystal structure of bifunctional miltiradiene synthase from selaginella moellendorffii that complexed with GGPP
3HAZ	;	2.1	;	Crystal structure of bifunctional proline utilization A (PutA) protein
6APE	;	1.45	;	Crystal Structure of Bifunctional protein FolD from Helicobacter pylori
8CU9	;	2.65	;	Crystal Structure of Bifunctional protein GlmU from Klebsiella pneumoniae subsp. pneumoniae
5B3V	;	2.594	;	Crystal structure of biliverdin reductase in complex with biliverdin and NADP+ from Synechocystis sp. PCC 6803
5B3U	;	2.698	;	Crystal structure of biliverdin reductase in complex with NADP+ from Synechocystis sp. PCC 6803
8PFD	;	2.17	;	Crystal structure of binary complex between Aster yellows witches'-broom phytoplasma effector SAP05 and the von Willebrand Factor Type A domain of the proteasomal ubiquitin receptor Rpn10 from Arabidopsis thaliana
8PFC	;	2.2	;	Crystal structure of binary complex between Aster yellows witches'-broom phytoplasma effector SAP05 and the zinc finger domain of SPL5 from Arabidopsis thaliana
4WWA	;	2.953	;	Crystal structure of binary complex Bud32-Cgi121
4WW9	;	1.951	;	Crystal structure of binary complex Bud32-Cgi121 in complex with ADP
4WW7	;	1.669	;	Crystal structure of binary complex Bud32-Cgi121 in complex with AMP
4WW5	;	1.997	;	Crystal structure of binary complex Bud32-Cgi121 in complex with AMPP
4WX8	;	2.99	;	Crystal structure of binary complex Gon7-Pcc1
4WXA	;	2.44	;	Crystal structure of binary complex Gon7-Pcc1
1EQM	;	1.5	;	CRYSTAL STRUCTURE OF BINARY COMPLEX OF 6-HYDROXYMETHYL-7,8-DIHYDROPTERIN PYROPHOSPHOKINASE WITH ADENOSINE-5'-DIPHOSPHATE
1LRM	;	2.1	;	Crystal structure of binary complex of the catalytic domain of human phenylalanine hydroxylase with dihydrobiopterin (BH2)
3WA1	;	1.75	;	Crystal structure of BinB: A receptor binding component of the binary toxin from Lysinibacillus sphaericus
7MFH	;	2.3	;	Crystal structure of BIO-32546 bound mouse Autotaxin
5UC7	;	1.835	;	Crystal structure of BioA / 7,8-diaminopelargonic acid aminotransferase / DAPA synthase from Citrobacter rodentium, PLP complex
5GNG	;	1.26	;	Crystal Structure of BioG from Haemophilus influenzae at 1.26 Angstroms resolution
4GET	;	2.24	;	Crystal structure of biogenic amine binding protein from Rhodnius prolixus
1M33	;	1.7	;	Crystal Structure of BioH at 1.7 A
6K5E	;	2.257	;	Crystal structure of BioH from Klebsiella pneumonia
7WWF	;	2.27	;	Crystal structure of BioH3 from Mycolicibacterium smegmatis
5YEK	;	2.191	;	Crystal structure of BioQ
5YEJ	;	2.698	;	Crystal structure of BioQ with its naturel double-stranded DNA operator
2RJG	;	2.4	;	Crystal structure of biosynthetic alaine racemase from Escherichia coli
2RJH	;	2.4	;	Crystal structure of biosynthetic alaine racemase in D-cycloserine-bound form from Escherichia coli
6A2F	;	2.5	;	Crystal structure of biosynthetic alanine racemase from Pseudomonas aeruginosa
3NZQ	;	3.1	;	Crystal Structure of Biosynthetic arginine decarboxylase ADC (SpeA) from Escherichia coli, Northeast Structural Genomics Consortium Target ER600
1M1O	;	1.95	;	Crystal structure of biosynthetic thiolase, C89A mutant, complexed with acetoacetyl-CoA
6CK0	;	2.25	;	Crystal Structure of Biotin Acetyl Coenzyme A Carboxylase Synthetase from Helicobacter pylori with bound Biotinylated ATP
4HR7	;	2.495	;	Crystal Structure of Biotin Carboxyl Carrier Protein-Biotin Carboxylase Complex from E.coli
1W93	;	2.5	;	Crystal Structure of Biotin Carboxylase Domain of Acetyl-Coenzyme A Carboxylase from Saccharomyces cerevisiae
1W96	;	1.8	;	Crystal Structure of Biotin Carboxylase Domain of Acetyl-coenzyme A Carboxylase from Saccharomyces cerevisiae in Complex with Soraphen A
4MV7	;	1.73	;	Crystal Structure of Biotin Carboxylase form Haemophilus influenzae in Complex with Phosphonoformate
2W6O	;	2.5	;	Crystal structure of Biotin carboxylase from E. coli in complex with 4-Amino-7,7-dimethyl-7,8-dihydro-quinazolinone fragment
2W6P	;	1.85	;	Crystal structure of Biotin carboxylase from E. coli in complex with 5-Methyl-6-phenyl-quinazoline-2,4-diamine
2W6M	;	2.0	;	Crystal structure of Biotin carboxylase from E. coli in complex with amino-oxazole fragment series
2W6N	;	1.87	;	Crystal structure of Biotin carboxylase from E. coli in complex with amino-oxazole fragment series
2J9G	;	2.05	;	Crystal structure of Biotin carboxylase from E. coli in complex with AMPPNP and ADP
2VR1	;	2.6	;	Crystal structure of Biotin carboxylase from E. coli in complex with ATP analog, ADPCF2P.
3JZI	;	2.31	;	Crystal structure of biotin carboxylase from E. Coli in complex with benzimidazole series
3JZF	;	2.13	;	Crystal structure of biotin carboxylase from E. Coli in complex with benzimidazoles series
2W6Z	;	1.9	;	Crystal structure of Biotin carboxylase from E. coli in complex with the 3-(3-Methyl-but-2-enyl)-3H-purin-6-ylamine fragment
2W70	;	1.77	;	Crystal structure of Biotin carboxylase from E. coli in complex with the amino-thiazole-pyrimidine fragment
2W71	;	1.99	;	Crystal structure of Biotin carboxylase from E. coli in complex with the imidazole-pyrimidine inhibitor
2W6Q	;	2.05	;	Crystal structure of Biotin carboxylase from E. coli in complex with the triazine-2,4-diamine fragment
2V58	;	2.1	;	CRYSTAL STRUCTURE OF BIOTIN CARBOXYLASE FROM E.COLI IN COMPLEX WITH POTENT INHIBITOR 1
2V59	;	2.4	;	CRYSTAL STRUCTURE OF BIOTIN CARBOXYLASE FROM E.COLI IN COMPLEX WITH POTENT INHIBITOR 2
2V5A	;	2.31	;	CRYSTAL STRUCTURE OF BIOTIN CARBOXYLASE FROM E.COLI IN COMPLEX WITH POTENT INHIBITOR 3
4MV1	;	1.91	;	Crystal Structure of Biotin Carboxylase from Haemophilus influenzae in Complex with ADP and Phosphate
4MV3	;	1.69	;	Crystal Structure of Biotin Carboxylase from Haemophilus influenzae in Complex with AMPPCP and Bicarbonate
4MV4	;	1.61	;	Crystal Structure of Biotin Carboxylase from Haemophilus influenzae in Complex with AMPPCP and Mg2
4MV8	;	2.06	;	Crystal Structure of Biotin Carboxylase from Haemophilus influenzae in Complex with AMPPCP and Phosphate
4MV9	;	1.98	;	Crystal Structure of Biotin Carboxylase from Haemophilus influenzae in Complex with Bicarbonate
4MV6	;	1.77	;	Crystal Structure of Biotin Carboxylase from Haemophilus influenzae in Complex with Phosphonoacetamide
2VQD	;	2.41	;	Crystal Structure of Biotin Carboxylase from Pseudomonas aeruginosa complexed with AMPCP
2C00	;	2.5	;	Crystal Structure of Biotin Carboxylase from Pseudomonas aeruginosa in apo form
2VPQ	;	2.1	;	Crystal structure of biotin carboxylase from S. aureus complexed with AMPPNP
3G8C	;	2.0	;	Crystal Structure of Biotin Carboxylase in Complex with Biotin, Bicarbonate, ADP and Mg Ion
3OUZ	;	1.902	;	Crystal Structure of Biotin Carboxylase-ADP complex from Campylobacter jejuni
3OUU	;	2.252	;	Crystal Structure of Biotin Carboxylase-beta-gamma-ATP Complex from Campylobacter jejuni
2CGH	;	1.8	;	crystal structure of biotin ligase from Mycobacterium tuberculosis
4OP0	;	1.7	;	Crystal structure of biotin protein ligase (RV3279C) of Mycobacterium tuberculosis, complexed with biotinyl-5'-AMP
2EAY	;	1.95	;	Crystal Structure Of Biotin Protein Ligase From Aquifex Aeolicus
7DBS	;	2.33	;	Crystal Structure Of Biotin Protein Ligase From Leishmania Major in complex with Biotin
6JHU	;	1.97	;	Crystal Structure Of Biotin Protein Ligase From Leishmania Major in complex with Biotinyl-5-AMP
2EJ9	;	2.0	;	Crystal Structure Of Biotin Protein Ligase From Methanococcus jannaschii
2ZGW	;	1.5	;	Crystal Structure Of Biotin Protein Ligase From Pyrococcus Horikoshii Complexed with Adenosine and Biotin, Mutations R48A and K111A
2DXT	;	1.6	;	Crystal Structure Of Biotin Protein Ligase From Pyrococcus Horikoshii Complexed with ATP and Biotin, Mutation D104A
2DZ9	;	1.84	;	Crystal Structure Of Biotin Protein Ligase From Pyrococcus Horikoshii Complexed with biotinyl-5'-AMP, Mutation D104A
2DXU	;	1.28	;	Crystal Structure Of Biotin Protein Ligase From Pyrococcus Horikoshii Complexed with Biotinyl-5'-AMP, Mutation R48A
2E41	;	1.75	;	Crystal Structure Of Biotin Protein Ligase From Pyrococcus Horikoshii Complexed with the Reaction Product Analog Biotinol-5'-AMP, Mutations R48A and K111A
2DTO	;	1.5	;	Crystal Structure Of Biotin Protein Ligase From Pyrococcus Horikoshii OT3 Complexed with ATP and Biotin
2FYK	;	1.6	;	Crystal Structure Of Biotin Protein Ligase From Pyrococcus Horikoshii OT3 in complex with ADP and Biotin
1X01	;	2.0	;	Crystal Structure Of Biotin Protein Ligase From Pyrococcus Horikoshii Ot3 in complex with ATP
2DJZ	;	1.85	;	Crystal Structure Of Biotin Protein Ligase From Pyrococcus Horikoshii OT3 in complex with Biotinyl-5'-AMP, K111A mutation
2DEQ	;	1.85	;	Crystal Structure Of Biotin Protein Ligase From Pyrococcus Horikoshii OT3 in complex with Biotinyl-5'-AMP, K111G mutation
2DVE	;	1.6	;	Crystal Structure Of Biotin Protein Ligase From Pyrococcus Horikoshii OT3 in Complex with Biotinyl-5'-AMP, Mutation Arg51Ala
2DKG	;	2.0	;	Crystal Structure Of Biotin Protein Ligase From Pyrococcus Horikoshii OT3 in Complex with Biotinyl-5'-AMP, Pyrophosphate and Mg(2+)
2DTI	;	2.2	;	Crystal Structure Of Biotin Protein Ligase From Pyrococcus Horikoshii OT3 in Complex with Biotinyl-5'-AMP, Pyrophosphate and Mn(2+)
1WQW	;	1.45	;	Crystal Structure Of Biotin Protein Ligase From Pyrococcus Horikoshii Ot3 in complex with Biotinyl-5-AMP
2HNI	;	1.9	;	Crystal Structure Of Biotin Protein Ligase From Pyrococcus Horikoshii OT3, K111A mutation
2E1H	;	1.4	;	Crystal Structure Of Biotin Protein Ligase From Pyrococcus Horikoshii OT3, K111G mutation
2E65	;	1.65	;	Crystal Structure Of Biotin Protein Ligase From Pyrococcus Horikoshii OT3, Mutation D104A
2DZC	;	1.45	;	Crystal Structure Of Biotin Protein Ligase From Pyrococcus Horikoshii, Mutation R48A
2E10	;	1.35	;	Crystal Structure Of Biotin Protein Ligase From Pyrococcus Horikoshii, Mutation R51A
2E64	;	1.5	;	Crystal Structure Of Biotin Protein Ligase From Pyrococcus Horikoshii, Mutations R48A and K111A
1WQ7	;	1.6	;	Crystal Structure Of Biotin-(Acetyl-CoA-Carboxylase) ligase From Pyrococcus Horikoshii Ot3
1WNL	;	1.6	;	Crystal Structure Of Biotin-(Acetyl-CoA-Carboxylase) ligase From Pyrococcus Horikoshii Ot3 in complex with ADP
1WPY	;	1.6	;	Crystal Structure Of Biotin-(Acetyl-CoA-Carboxylase) ligase From Pyrococcus Horikoshii Ot3 in complex with biotin
3RUX	;	1.7	;	Crystal structure of biotin-protein ligase BirA from Mycobacterium tuberculosis in complex with an acylsulfamide bisubstrate inhibitor
6K38	;	1.78	;	Crystal structure of BioU (H233A) from Synechocystis sp.PCC6803 conjugated with DAPA
6K37	;	2.5	;	Crystal structure of BioU (K124A) from Synechocystis sp.PCC6803 in complex with NAD+ and the analog of reaction intermediate, 3-(1-aminoethyl)-nonanedioic acid
6ITD	;	2.0	;	Crystal structure of BioU (K124A) from Synechocystis sp.PCC6803 in complex with the analog of reaction intermediate, 3-(1-aminoethyl)-nonanedioic acid
6IR4	;	2.0	;	Crystal structure of BioU from Synechocystis sp.PCC6803 (apo form)
6K36	;	2.3	;	Crystal structure of BioU from Synechocystis sp.PCC6803 conjugated with DAPA
6HAB	;	2.08	;	Crystal structure of BiP V461F (apo)
2GBW	;	1.7	;	Crystal Structure of Biphenyl 2,3-Dioxygenase from Sphingomonas yanoikuyae B1
2GBX	;	2.8	;	Crystal Structure of Biphenyl 2,3-Dioxygenase from Sphingomonas yanoikuyae B1 Bound to Biphenyl
2XR8	;	2.49	;	Crystal structure of biphenyl dioxygenase from Burkholderia xenovorans LB400
2XRX	;	2.42	;	CRYSTAL STRUCTURE OF BIPHENYL DIOXYGENASE IN COMPLEX WITH BIPHENYL FROM BURKHOLDERIA XENOVORANS LB400
2YFI	;	2.15	;	Crystal Structure of Biphenyl dioxygenase variant RR41 (BPDO-RR41)
2YFL	;	2.6	;	Crystal Structure of Biphenyl dioxygenase variant RR41 with 2-chloro dibenzofuran
2YFJ	;	2.15	;	Crystal structure of Biphenyl dioxygenase variant RR41 with dibenzofuran
5WC4	;	1.2	;	Crystal structure of biphenyl synthase from Malus domestic complexed with benzoyl-CoA
5W8Q	;	1.173	;	Crystal structure of biphenyl synthase from Malus domestica
6ORU	;	2.392	;	Crystal structure of Bira from S. aureus in complex with a acylsulfamide analogue of biotinyl-5'-AMP
4A8V	;	1.23	;	Crystal Structure of Birch Pollen Allergen Bet v 1 isoform j in complex with 8-Anilinonaphthalene-1-sulfonate (ANS)
4Z3L	;	2.5	;	CRYSTAL STRUCTURE OF BIRCH POLLEN ALLERGEN BET V 1 MUTANT G26L, D69I, P90L, K97I
8DWN	;	2.15	;	Crystal structure of bis-phosphorylated insulin receptor kinase domain
6JH1	;	3.0	;	Crystal structure of bISG15/NS1B complex
5XP9	;	1.55	;	Crystal structure of Bismuth bound NDM-1
2F90	;	2.0	;	Crystal structure of bisphosphoglycerate mutase in complex with 3-phosphoglycerate and AlF4-
3LVP	;	3.0	;	Crystal structure of bisphosphorylated IGF1-R Kinase domain (2P) in complex with a bis-azaindole inhibitor
8AFD	;	1.633	;	CRYSTAL STRUCTURE OF BIT-BLOCKED KRAS-G12V-S39C IN COMPLEX WITH COMPOUND 20a
1Q7S	;	2.0	;	Crystal structure of bit1
1JWI	;	2.0	;	Crystal Structure of Bitiscetin, a von Willeband Factor-dependent Platelet Aggregation Inducer.
1VBW	;	0.93	;	Crystal Structure of Bitter Gourd Trypsin Inhibitor
8FWH	;	2.833	;	Crystal structure of bivalent antibody Fab fragment of Anti-human LAG3 (22D2)
4XLX	;	2.0	;	Crystal structure of BjKS from Bradyrhizobium japonicum
5NJW	;	1.25	;	Crystal Structure of BJP-1 metallo beta-lactamase in complex with boric acid
2GMN	;	1.4	;	Crystal structure of BJP-1, a subclass B3 metallo-beta-lactamase of Bradyrhizobium japonicum
3LIZ	;	1.8	;	crystal structure of bla g 2 complexed with Fab 4C3
8IWV	;	2.4	;	Crystal structure of BlaA-1 APO
2WUQ	;	1.8	;	Crystal structure of BlaB protein from Streptomyces cacaoi
3IQA	;	2.2	;	Crystal Structure of BlaC covalently bound with Doripenem
5OYO	;	2.1	;	Crystal structure of BlaC from Mycobacterium tuberculosis
5NJ2	;	1.19	;	Crystal structure of BlaC from Mycobacterium tuberculosis bound to phosphate
3N6I	;	2.0	;	Crystal Structure of BlaC-E166A covalently bound with 6-aminopenicillian
3N7W	;	1.7	;	Crystal Structure of BlaC-E166A covalently bound with Amoxicillin
3N8L	;	1.4	;	Crystal Structure of BlaC-E166A covalently bound with Ampicillin
3N8R	;	1.41	;	Crystal Structure of BlaC-E166A covalently bound with Carbenicillin
3N8S	;	2.0	;	Crystal Structure of BlaC-E166A covalently bound with Cefamandole
3NBL	;	2.0	;	Crystal Structure of BlaC-E166A covalently bound with Cefuroxime
3NDE	;	1.7	;	Crystal Structure of BlaC-E166A covalently bound with Cephalotin
3NC8	;	1.5	;	Crystal Structure of BlaC-E166A covalently bound with Mecillinam
3NDG	;	1.9	;	Crystal Structure of BlaC-E166A covalently bound with Methicillin
3NCK	;	2.8	;	Crystal Structure of BlaC-E166A covalently bound with Nafcillin
3NY4	;	1.22	;	Crystal Structure of BlaC-K73A bound with Cefamandole
1GBS	;	1.5	;	CRYSTAL STRUCTURE OF BLACK SWAN GOOSE-TYPE LYSOZYME AT 1.8 ANGSTROMS RESOLUTION
4U56	;	3.45	;	Crystal structure of Blasticidin S bound to the yeast 80S ribosome
4V9Q	;	3.4	;	Crystal Structure of Blasticidin S Bound to Thermus Thermophilus 70S Ribosome.
2Z3G	;	1.5	;	Crystal structure of blasticidin S deaminase (BSD)
1WN5	;	1.8	;	Crystal Structure of Blasticidin S Deaminase (BSD) Complexed with Cacodylic Acid
2Z3H	;	1.5	;	Crystal structure of blasticidin S deaminase (BSD) complexed with deaminohydroxy blasticidin S
1WN6	;	1.8	;	Crystal Structure of Blasticidin S Deaminase (BSD) Complexed with Tetrahedral Intermediate of Blasticidin S
2Z3I	;	1.8	;	Crystal structure of blasticidin S deaminase (BSD) mutant E56Q complexed with substrate
2Z3J	;	1.6	;	Crystal structure of blasticidin S deaminase (BSD) R90K mutant
3OJ6	;	1.7	;	Crystal structure of Blasticidin S Deaminase from Coccidioides Immitis
3G7F	;	2.5	;	Crystal structure of Blastochloris viridis heterodimer mutant reaction center
8BOU	;	2.32	;	Crystal structure of Blautia producta GH94
8U4F	;	2.01	;	Crystal Structure of BlCel9A from Glycoside Hydrolase Family 9 in Complex with Cellohexaose
8U4A	;	1.97	;	Crystal Structure of BlCel9A from Glycoside Hydrolase Family 9 in Complex with Cellotriose
7EV5	;	1.44	;	Crystal structure of BLEG-1 B3 metallo-beta-lactamase
2ZW7	;	2.8	;	Crystal structure of bleomycin N-acetyltransferase complexed with bleomycin A2 and coenzyme A
2ZW4	;	2.7	;	Crystal structure of bleomycin N-acetyltransferase complexed with coenzyme A in the orthorhombic crystal
2ZW5	;	2.4	;	Crystal structure of bleomycin N-acetyltransferase complexed with coenzyme A in the trigonal crystal
2ZW6	;	2.5	;	Crystal structure of bleomycin N-acetyltransferase from bleomycin-producing Streptomyces verticillus ATCC15003
1EWJ	;	2.5	;	CRYSTAL STRUCTURE OF BLEOMYCIN-BINDING PROTEIN COMPLEXED WITH BLEOMYCIN
1JIF	;	1.6	;	Crystal structure of bleomycin-binding protein from bleomycin-producing Streptomyces verticillus complexed with copper(II)-bleomycin
1JIE	;	1.8	;	Crystal structure of bleomycin-binding protein from bleomycin-producing Streptomyces verticillus complexed with metal-free bleomycin
2ZHP	;	1.6	;	Crystal structure of bleomycin-binding protein from Streptoalloteichus hindustanus complexed with bleomycin derivative
6MPA	;	1.9	;	Crystal structure of BlMan5B in complex with GlcNAc (soaking)
6MP2	;	1.98	;	Crystal structure of BlMan5B solved by SIRAS
1P0S	;	2.8	;	Crystal Structure of Blood Coagulation Factor Xa in Complex with Ecotin M84R
3EO8	;	1.74	;	Crystal structure of BluB-like flavoprotein (YP_001089088.1) from CLOSTRIDIUM DIFFICILE 630 at 1.74 A resolution
4ZB1	;	2.25	;	Crystal Structure of Blue Chromoprotein sgBP from Stichodactyla Gigantea
3G5W	;	1.9	;	Crystal structure of Blue Copper Oxidase from Nitrosomonas europaea
6J7H	;	2.309	;	Crystal structure of blue fluorescent protein from metagenomic library
6J7U	;	2.302	;	Crystal structure of blue fluorescent protein from metagenomic library in complex with NADPH
2HRH	;	2.6	;	Crystal Structure of Blue Laccase from Trametes trogii
2HRG	;	1.58	;	Crystal Structure of Blue Laccase from Trametes trogii complexed with p-methylbenzoate
4JQ6	;	2.31	;	Crystal structure of blue light-absorbing proteorhodopsin from Med12 at 2.3 Angstrom
6GPV	;	2.0	;	Crystal structure of blue-light irradiated miniSOG
4YZI	;	2.5	;	Crystal structure of blue-shifted channelrhodopsin mutant (T198G/G202A)
1V4U	;	2.0	;	Crystal structure of bluefin tuna carbonmonoxy-hemoglobin
1V4X	;	1.6	;	Crystal structure of bluefin tuna hemoglobin deoxy form at pH5.0
1V4W	;	1.7	;	Crystal structure of bluefin tuna hemoglobin deoxy form at pH7.5
2OL3	;	2.9	;	crystal structure of BM3.3 ScFV TCR in complex with PBM8-H-2KBM8 MHC class I molecule
3VRL	;	3.2	;	Crystal structure of BMJ4 p24 capsid protein in complex with A10F9 Fab
3GBO	;	1.77	;	Crystal structure of BmooMPalpha-I, a non-hemorrhagic metalloproteinase isolated from Bothrops moojeni snake venom
5I3O	;	2.4	;	Crystal Structure of BMP-2-inducible kinase in complex with an Indazole inhibitor
5I3R	;	2.4	;	Crystal Structure of BMP-2-inducible kinase in complex with an Indazole inhibitor
5IKW	;	2.41	;	Crystal Structure of BMP-2-inducible kinase in complex with an Indazole inhibitor
4W9X	;	2.14	;	Crystal Structure of BMP-2-inducible kinase in complex with baricitinib
4W9W	;	1.72	;	Crystal Structure of BMP-2-inducible kinase in complex with small molecule AZD-7762
1ZKZ	;	2.33	;	Crystal Structure of BMP9
4MPL	;	1.9	;	Crystal structure of BMP9 at 1.90 Angstrom
6R72	;	3.95	;	Crystal structure of BmrA-E504A in an outward-facing conformation
3Q5S	;	3.1	;	Crystal structure of BmrR bound to Acetylcholine
1R8E	;	2.4	;	Crystal Structure of BmrR Bound to DNA at 2.4A Resolution
3Q2Y	;	2.95	;	Crystal Structure of BmrR bound to ethidium
3Q5R	;	3.05	;	Crystal structure of BmrR bound to Kanamycin
3Q3D	;	2.79	;	Crystal structure of BmrR bound to puromycin
3Q5P	;	2.942	;	Crystal structure of BmrR bound to Tetracycline
3Q1M	;	3.2	;	Crystal Structure of BmrR Dimer bound to DNA and the ligand 4-amino-quinaldine
3SXR	;	2.4	;	Crystal structure of BMX non-receptor tyrosine kinase complex with dasatinib
3SXS	;	1.89	;	Crystal structure of BMX non-receptor tyrosine kinase complexed with PP2
3MLM	;	2.21	;	Crystal structure of Bn IV in complex with myristic acid: A Lys49 myotoxic phospholipase A2 from Bothrops neuwiedi venom
3B46	;	2.0	;	Crystal Structure of Bna3p, a Putative Kynurenine Aminotransferase from Saccharomyces cerevisiae
1PC9	;	2.5	;	Crystal Structure of BnSP-6, a Lys49-Phospholipase A2
5VFH	;	1.592	;	Crystal structure of BnSP-7 from Bothrops pauloensis complexed to sulfates
5VFJ	;	2.084	;	Crystal structure of BnSP-7 from bothrops pauloensis complexed with caffeic acid
5VFN	;	2.389	;	Crystal structure of BnSP-7 from Bothrops pauloensis complexed with cinnamic acid
5VFM	;	2.058	;	Crystal structure of BnSP-7 from Bothrops pauloensis complexed with p-coumaric acid
1PA0	;	2.2	;	CRYSTAL STRUCTURE OF BNSP-7, A LYS49-PHOSPHOLIPASE A2
3WCZ	;	1.3	;	Crystal structure of Bombyx mori aldo-keto reductase (AKR2E4) in complex with NADP
3AQX	;	2.05	;	Crystal structure of Bombyx mori beta-GRP/GNBP3 N-terminal domain with laminarihexaoses
5A9B	;	1.883	;	Crystal structure of Bombyx mori CPV1 polyhedra base domain deleted mutant
3P0S	;	3.1	;	Crystal structure of Bombyx mori densovirus 1 capsid
3WD6	;	2.5	;	Crystal structure of Bombyx mori omega-class glutathione transferase in complex with GSH
3VPT	;	1.9	;	Crystal structure of Bombyx mori sigma-class glutathione transferase in apo form
3VPQ	;	1.702	;	Crystal structure of Bombyx mori sigma-class glutathione transferase in complex with glutathione
3VUR	;	1.365	;	Crystal structure of Bombyx mori sigma-class glutathione transferase in complex with glutathionesulfonic acid
3WJM	;	2.8	;	Crystal structure of Bombyx mori Sp2/Sp3 heterohexamer
7E04	;	1.25	;	Crystal structure of Bomgl, a monoacylglycerol lipase from marine Bacillus sp.
3EDG	;	1.27	;	Crystal structure of bone morphogenetic protein 1 protease domain
3EDH	;	1.25	;	Crystal structure of bone morphogenetic protein 1 protease domain in complex with partially bound DMSO
2QCQ	;	2.21	;	Crystal structure of Bone Morphogenetic Protein-3 (BMP-3)
2QCW	;	2.49	;	Crystal Structure of Bone Morphogenetic Protein-6 (BMP-6)
1M4U	;	2.42	;	Crystal structure of Bone Morphogenetic Protein-7 (BMP-7) in complex with the secreted antagonist Noggin
3QIY	;	2.3	;	Crystal Structure of BoNT/A LC complexed with Hydroxamate-based Inhibitor PT-1
3QIZ	;	2.0	;	Crystal Structure of BoNT/A LC complexed with Hydroxamate-based Inhibitor PT-2
3QJ0	;	2.301	;	Crystal Structure of BoNT/A LC complexed with Hydroxamate-based Inhibitor PT-3
3NF3	;	2.4	;	Crystal structure of BoNT/A LC with JTH-NB-7239 peptide
3QIX	;	2.413	;	Crystal Structure of BoNT/A LC with Zinc bound
5L21	;	1.68	;	Crystal structure of BoNT/A receptor binding domain in complex with VHH C2
7L6V	;	2.01	;	Crystal structure of BoNT/A-LC-JPU-A5-JPU-C1-JPU-H7-JPU-D12-ciA-F12
6UI1	;	2.20001	;	Crystal structure of BoNT/A-LCHn domain in complex with VHH ciA-D12, ciA-B5, and ciA-H7
6UL6	;	2.02	;	Crystal Structure of BoNT/A-LCHn domain in complex with VNA ciA-D12/11/ciA-B5 and VHH ciA-H7
6UHT	;	2.20001	;	Crystal structure of BoNT/B receptor-binding domain in complex with VHH JLI-G10
6UC6	;	2.32006	;	Crystal structure of BoNT/B receptor-binding domain in complex with VHH JLI-H11
6UFT	;	2.90008	;	Crystal structure of BoNT/B receptor-binding domain in complex with VHH JLK-G12
6UL4	;	3.18424	;	Crystal structure of BoNT/B receptor-binding domain in complex with VHH JLO-G11
7NA9	;	1.76	;	Crystal structure of BoNT/B-LC-JSG-C1
7K84	;	2.5	;	Crystal structure of BoNT/E LC-HN domain in complex with VHH JLE-E5
7K7Y	;	3.6	;	Crystal structure of BoNT/E LC-HN domain in complex with VHH JLE-E9
7UIA	;	2.59	;	Crystal structure of BoNT/E receptor binding domain in complex with SV2 and VHH
7UIB	;	2.77	;	Crystal structure of BoNT/E receptor binding domain in complex with SV2, VHH, and sialic acid
6LBE	;	2.6	;	Crystal structure of bony fish MHC class I binding beta2M-2 for 2.6 angstrom
5H5Z	;	1.74	;	Crystal structure of bony fish MHC class I, peptide and B2m II
3MPK	;	2.04	;	Crystal Structure of Bordetella pertussis BvgS periplasmic VFT2 domain
3MPL	;	2.1	;	Crystal Structure of Bordetella pertussis BvgS VFT2 domain (Double Mutant F375E/Q461E)
2OWS	;	1.49	;	Crystal structure of Bordetella pertussis holo ferric binding protein bound with two synergistic oxalate anions
2OWT	;	2.4	;	Crystal structure of Bordetella pertussis holo ferric binding protein with bound synergistic carbonate anion
2RAX	;	3.3	;	Crystal structure of Borealin (20-78) bound to Survivin (1-120)
5CHO	;	2.37	;	Crystal Structure of BorF, the Flavin Reductase Component of a Bacterial Two-Component Tryptophan Halogenase
6QO1	;	2.25	;	Crystal structure of Borrelia (Borreliella) burgdorferi outer surface protein BBA69
8Q4K	;	2.4	;	Crystal structure of Borrelia burgdorferi BB0158
4ONR	;	1.6	;	Crystal structure of Borrelia burgdorferi decorin-binding protein DbpA
6ROC	;	2.9	;	Crystal structure of Borrelia burgdorferi outer surface protein BBA69, mutant Leu214Met (Se-Met data)
8CQN	;	2.7	;	Crystal structure of Borrelia burgdorferi paralogous family 12 outer surface protein BBK01
8CQO	;	3.3	;	Crystal structure of Borrelia burgdorferi paralogous family 12 outer surface protein BBK01 (Se-Met data)
6R1G	;	1.55	;	Crystal structure of Borrelia burgdorferi periplasmic protein BB0365 (IPLA7, p22)
3N8B	;	1.9	;	Crystal Structure of Borrelia burgdorferi Pur-alpha
3NM7	;	2.2	;	Crystal Structure of Borrelia burgdorferi Pur-alpha
6HPN	;	2.6	;	Crystal structure of Borrelia spielmanii WP_012665240 (BSA64) - an orthologous protein to B. burgdorferi BBA64
6DEC	;	4.6	;	Crystal structure of Bos taurus Arp2/3 complex binding with C-terminus of Homo sapiens SPIN90
4JD2	;	3.08	;	Crystal structure of Bos taurus Arp2/3 complex binding with Mus musculus GMF
3UKR	;	2.48	;	Crystal structure of Bos taurus Arp2/3 complex with bound inhibitor CK-666
1XB2	;	2.2	;	Crystal Structure of Bos taurus mitochondrial Elongation Factor Tu/Ts Complex
6ORT	;	2.3	;	Crystal Structure of Bos taurus Mxra8 Ectodomain
5TE3	;	2.7	;	Crystal structure of Bos taurus opsin at 2.7 Angstrom
5TE5	;	4.01	;	Crystal structure of Bos taurus opsin regenerated with 6-carbon ring retinal chromophore
1Y4L	;	1.7	;	Crystal structure of Bothrops asper myotoxin II complexed with the anti-trypanosomal drug suramin
8DND	;	2.018	;	Crystal structure of Bothrops pirajai Piratoxin-I (PrTX-I) and synthetic inhibitor Varespladib (LY315920)
6DIK	;	1.93	;	Crystal structure of Bothropstoxin I (BthTX-I) complexed to Chicoric acid
3HZD	;	1.91	;	Crystal structure of bothropstoxin-I (BthTX-I), a PLA2 homologue from Bothrops jararacussu venom
3HZW	;	2.28	;	Crystal structure of bothropstoxin-I chemically modified by p-bromophenacyl bromide (BPB)
3I03	;	1.48	;	Crystal structure of bothropstoxin-I chemically modified by p-bromophenacyl bromide (BPB) - monomeric form at a high resolution
3IQ3	;	1.55	;	Crystal Structure of Bothropstoxin-I complexed with polietilene glicol 4000 - crystallized at 283 K
3I3I	;	1.82	;	Crystal Structure of Bothropstoxin-I crystallized at 283 K
3I3H	;	2.17	;	Crystal structure of Bothropstoxin-I crystallized at 291K
1FVU	;	1.8	;	CRYSTAL STRUCTURE OF BOTROCETIN
7Z5T	;	1.63	;	Crystal Structure of botulinum neurotoxin A2 cell binding domain
7Z5S	;	2.1	;	Crystal Structure of botulinum neurotoxin A2 cell binding domain in complex with GD1a
3BTA	;	3.2	;	CRYSTAL STRUCTURE OF BOTULINUM NEUROTOXIN SEROTYPE A
2VU9	;	1.6	;	CRYSTAL STRUCTURE OF BOTULINUM NEUROTOXIN SEROTYPE A BINDING DOMAIN IN COMPLEX WITH GT1B
3N7K	;	2.5	;	Crystal structure of botulinum neurotoxin serotype C1 binding domain
3N7J	;	2.0	;	Crystal structure of botulinum neurotoxin serotype D binding domain
3OBR	;	1.72	;	Crystal structure of Botulinum neurotoxin serotype D binding domain
3OBT	;	2.0	;	Crystal structure of Botulinum neurotoxin serotype D ligand binding domain in complex with N-Acetylneuraminic acid
3N7L	;	2.0	;	Crystal structure of botulinum neurotoxin serotype D/C VPI 5993 binding domain
3D3X	;	2.25	;	Crystal structure of botulinum neurotoxin serotype E catalytic domain in complex with SNAP-25 substrate peptide
2NZ9	;	3.79	;	Crystal structure of botulinum neurotoxin type A complexed with monoclonal antibody AR2
2NYY	;	2.61	;	Crystal structure of botulinum neurotoxin type A complexed with monoclonal antibody CR1
1S0G	;	2.6	;	Crystal structure of botulinum neurotoxin type B apo form
1S0B	;	2.0	;	Crystal structure of botulinum neurotoxin type B at pH 4.0
1S0C	;	2.2	;	Crystal structure of botulinum neurotoxin type B at pH 5.0
1S0D	;	2.2	;	Crystal structure of botulinum neurotoxin type B at pH 5.5
1S0E	;	1.9	;	Crystal structure of botulinum neurotoxin type B at pH 6.0
1S0F	;	2.3	;	Crystal structure of botulinum neurotoxin type B at pH 7.0
2FPQ	;	1.65	;	Crystal Structure of Botulinum Neurotoxin Type D Light Chain
1ZB7	;	2.35	;	Crystal Structure of Botulinum Neurotoxin Type G Light Chain
5ZL2	;	2.703	;	Crystal structure of Bourbon virus envelope glycoprotein at pH8.0
3DT6	;	2.1	;	Crystal Structure of Bovin Brain Platelet Activating Factor Acetylhydrolase Covalently Inhibited by Paraoxon
3DT8	;	1.85	;	Crystal Structure of Bovin Brain Platelet Activating Factor Acetylhydrolase Covalently Inhibited by Sarin
3DT9	;	1.85	;	Crystal Structure of Bovin Brain Platelet Activating Factor Acetylhydrolase Covalently Inhibited by Soman
4MZZ	;	1.88	;	Crystal structure of Bovine 3 Glu-Osteocalcin.
6Q68	;	3.161	;	Crystal structure of bovine ACBD3 GOLD domain in complex with 3A protein of enterovirus-F2 (fusion protein)
1KRM	;	2.5	;	Crystal structure of bovine adenosine deaminase complexed with 6-hydroxyl-1,6-dihydropurine riboside
1FG5	;	2.8	;	CRYSTAL STRUCTURE OF BOVINE ALPHA-1,3-GALACTOSYLTRANSFERASE CATALYTIC DOMAIN.
6DI8	;	1.859	;	Crystal structure of bovine alpha-chymotrypsin in space group P65
1F6S	;	2.2	;	CRYSTAL STRUCTURE OF BOVINE ALPHA-LACTALBUMIN
1AGI	;	1.5	;	CRYSTAL STRUCTURE OF BOVINE ANGIOGENIN AT 1.5 ANGSTROMS RESOLUTION
4X9P	;	2.01	;	Crystal structure of bovine Annexin A2
4K3D	;	1.85	;	Crystal structure of bovine antibody BLV1H12 with ultralong CDR H3
4K3E	;	2.2	;	Crystal structure of bovine antibody BLV5B8 with ultralong CDR H3
2P9L	;	2.65	;	Crystal Structure of bovine Arp2/3 complex
2P9N	;	2.85	;	Crystal Structure of bovine Arp2/3 complex co-crystallized with ADP
2P9P	;	2.9	;	Crystal Structure of bovine Arp2/3 complex co-crystallized with ADP
2P9I	;	2.46	;	Crystal Structure of bovine Arp2/3 Complex co-crystallized with ADP and crosslinked with gluteraldehyde
2P9U	;	2.75	;	Crystal structure of bovine Arp2/3 complex co-crystallized with AMP-PNP and calcium
2P9K	;	2.59	;	Crystal structure of bovine Arp2/3 complex co-crystallized with ATP and crosslinked with glutaraldehyde
1JSY	;	2.9	;	Crystal structure of bovine arrestin-2
1ZSH	;	2.9	;	Crystal structure of bovine arrestin-2 in complex with inositol hexakisphosphate (IP6)
1G4M	;	1.9	;	CRYSTAL STRUCTURE OF BOVINE BETA-ARRESTIN 1
1G4R	;	2.2	;	CRYSTAL STRUCTURE OF BOVINE BETA-ARRESTIN 1
1TLD	;	1.5	;	CRYSTAL STRUCTURE OF BOVINE BETA-TRYPSIN AT 1.5 ANGSTROMS RESOLUTION IN A CRYSTAL FORM WITH LOW MOLECULAR PACKING DENSITY. ACTIVE SITE GEOMETRY, ION PAIRS AND SOLVENT STRUCTURE
1BMG	;	2.5	;	CRYSTAL STRUCTURE OF BOVINE BETA2-MICROGLOBULIN
1AQL	;	2.8	;	CRYSTAL STRUCTURE OF BOVINE BILE-SALT ACTIVATED LIPASE COMPLEXED WITH TAUROCHOLATE
1PRW	;	1.7	;	Crystal structure of bovine brain Ca++ calmodulin in a compact form
4HH8	;	2.3	;	Crystal structure of bovine butyrophilin
2O51	;	3.0	;	Crystal structure of bovine C-lobe with fructose at 3.0 A resolution
6SKT	;	1.9	;	Crystal structure of bovine carbonic anhydrase II in complex with a benzenesulfonamide-based ligand (SH0)
6SKS	;	1.75	;	Crystal structure of bovine carbonic anhydrase II in complex with a benzenesulfonamide-based ligand (SH1)
6SKV	;	1.75	;	Crystal structure of bovine carbonic anhydrase II in complex with a benzenesulfonamide-based ligand (SH2)
3L9R	;	2.3	;	Crystal structure of bovine CD1b3 with endogenously bound ligands
4F7C	;	2.864	;	Crystal structure of bovine CD1d with bound C12-di-sulfatide
4F7E	;	2.4	;	Crystal structure of bovine CD1d with bound C16:0-alpha-galactosyl ceramide
5EBG	;	1.8	;	Crystal structure of bovine CD8aa homodimer
1EX3	;	3.0	;	CRYSTAL STRUCTURE OF BOVINE CHYMOTRYPSINOGEN A (TETRAGONAL)
3CL4	;	2.1	;	Crystal structure of bovine coronavirus hemagglutinin-esterase
4H14	;	1.55	;	Crystal Structure of Bovine Coronavirus Spike Protein Lectin Domain
3E2J	;	2.9	;	Crystal structure of bovine coupling factor B
3DZE	;	1.15	;	Crystal structure of bovine coupling Factor B bound with cadmium
3E3Z	;	1.7	;	Crystal structure of bovine coupling Factor B bound with phenylarsine oxide
3E4G	;	0.96	;	Crystal structure of bovine coupling Factor B, G28E mutant
4KKN	;	2.253	;	Crystal structure of bovine CTLA-4, PSI-NYSGRC-012704
1E9Q	;	1.75	;	Crystal structure of bovine Cu Zn SOD - (1 of 3)
1E9P	;	1.7	;	Crystal structure of bovine Cu, Zn SOD to 1.7 Angstrom (3 of 3)
6HAW	;	3.45	;	Crystal structure of bovine cytochrome bc1 in complex with 2-pyrazolyl quinolone inhibitor WDH2G7
7R3V	;	3.2	;	Crystal structure of bovine Cytochrome bc1 in complex with inhibitor CK-2-67.
5OKD	;	3.1	;	Crystal structure of bovine Cytochrome bc1 in complex with inhibitor SCR0911.
6ZFT	;	3.3	;	Crystal structure of bovine cytochrome bc1 in complex with quinolone inhibitor CK-2-68
6ZFU	;	3.5	;	Crystal structure of bovine cytochrome bc1 in complex with quinolone inhibitor RKA066
6ZFS	;	3.5	;	Crystal structure of bovine cytochrome bc1 in complex with quinolone inhibitor WDH-1U-4
6XVF	;	3.5	;	Crystal structure of bovine cytochrome bc1 in complex with tetrahydro-quinolone inhibitor JAG021
7LMM	;	2.798	;	Crystal structure of bovine DNMT1 BAH1 domain in complex with H4K20me2
7LMK	;	2.647	;	Crystal structure of bovine DNMT1 BAH1 domain in complex with H4K20me3
6PZV	;	3.01	;	Crystal Structure of Bovine DNMT1 RFTS domain in complex with H3K9me3 and Ubiquitin
5OSN	;	2.3	;	Crystal Structure of Bovine Enterovirus 2 determined with Serial Femtosecond X-ray Crystallography
2XND	;	3.5	;	Crystal structure of bovine F1-c8 sub-complex of ATP Synthase
5ILT	;	2.0	;	Crystal structure of bovine Fab A01
5IHU	;	2.06	;	Crystal structure of bovine Fab B11
5IJV	;	2.2	;	Crystal structure of bovine Fab E03
6OO0	;	2.1	;	Crystal structure of bovine Fab NC-Cow1
6OPA	;	4.084	;	Crystal structure of bovine Fab NC-Cow1 in complex with HIV-1 BG505 SOSIP.664, and human Fabs 35022 and PGT128
1SDD	;	2.8	;	Crystal Structure of Bovine Factor Vai
4WNK	;	2.42	;	Crystal Structure of Bovine G Protein Coupled-Receptor Kinase 5 in Complex with CCG215022
1AB9	;	1.6	;	CRYSTAL STRUCTURE OF BOVINE GAMMA-CHYMOTRYPSIN
1AFQ	;	1.8	;	CRYSTAL STRUCTURE OF BOVINE GAMMA-CHYMOTRYPSIN COMPLEXED WITH A SYNTHETIC INHIBITOR
1M8U	;	1.65	;	Crystal Structure of Bovine gamma-E at 1.65 Ang Resolution
3ETE	;	3.0	;	Crystal structure of bovine glutamate dehydrogenase complexed with hexachlorophene
1NQT	;	3.5	;	Crystal structure of bovine Glutamate dehydrogenase-ADP complex
1TFJ	;	1.61	;	Crystal structure of Bovine Glycolipid transfer protein in complex with a fatty acid
7XMA	;	2.2	;	Crystal structure of Bovine heart cytochrome c oxidase, apo structure with DMSO
7XMB	;	2.2	;	Crystal structure of Bovine heart cytochrome c oxidase, the structure complexed with an allosteric inhibitor T113
2FYU	;	2.26	;	Crystal structure of bovine heart mitochondrial bc1 with jg144 inhibitor
1PNT	;	2.2	;	CRYSTAL STRUCTURE OF BOVINE HEART PHOSPHOTYROSYL PHOSPHATASE AT 2.2 ANGSTROMS RESOLUTION
6LS9	;	2.503	;	Crystal structure of bovine herpesvirus 1 glycoprotein D
1KT3	;	1.4	;	Crystal structure of bovine holo-RBP at pH 2.0
1KT4	;	1.461	;	Crystal structure of bovine holo-RBP at pH 3.0
1KT5	;	1.46	;	Crystal structure of bovine holo-RBP at pH 4.0
1KT7	;	1.274	;	Crystal structure of bovine holo-RBP at pH 7.0
1KT6	;	1.1	;	Crystal structure of bovine holo-RBP at pH 9.0
2QWL	;	1.75	;	Crystal structure of bovine hsc70 (1-394aa)in the ADP state
2QWM	;	1.86	;	Crystal structure of bovine hsc70 (1-394aa)in the ADP*Vi state
2QW9	;	1.85	;	Crystal structure of bovine hsc70 (1-394aa)in the apo state
4FL9	;	1.901	;	Crystal Structure of bovine hsc70(aa1-554)E213A/D214A at 1.9A Resolution
7O6R	;	2.0	;	Crystal structure of bovine Hsc70(aa1-554)E213A/D214A in complex with 1H-Indazole
6H54	;	2.02	;	CRYSTAL STRUCTURE OF BOVINE HSC70(AA1-554)E213A/D214A IN COMPLEX WITH INHIBITOR VER155008
7ODI	;	1.83	;	Crystal structure of bovine Hsc70(aa1-554)E213A/D214A in complex with methanesulfonamide
7ODB	;	1.662	;	Crystal structure of bovine Hsc70(aa1-554)E213A/D214A in complex with triazine-derivative
7ODD	;	1.984	;	Crystal structure of bovine Hsc70(aa1-554)E213A/D214A in complex with tricine
1YUW	;	2.6	;	crystal structure of bovine hsc70(aa1-554)E213A/D214A mutant
2ZP6	;	2.56	;	Crystal structure of Bovine Insulin (Hexameric form)
2HCA	;	2.8	;	Crystal structure of bovine lactoferrin C-lobe liganded with Glucose at 2.8 A resolution
3GC1	;	2.5	;	Crystal structure of bovine lactoperoxidase
2PT3	;	2.34	;	Crystal structure of bovine lactoperoxidase at 2.34 A resolution reveals multiple anion binding sites
2PUM	;	2.7	;	Crystal structure of bovine lactoperoxidase complex with catechol and iodide at 2.7 A resolution
4KSZ	;	1.98	;	Crystal structure of bovine lactoperoxidase complexed with cystiene at 1.98A resolution
3R4X	;	2.01	;	Crystal structure of bovine lactoperoxidase complexed with pyrazine-2-carboxamide at 2 A resolution
3PY4	;	2.42	;	Crystal structure of bovine lactoperoxidase in complex with paracetamol at 2.4A resolution
5B72	;	1.98	;	Crystal structure of bovine lactoperoxidase with a broken covalent bond between Glu258 and heme moiety at 1.98 A resolution.
5WV3	;	2.07	;	Crystal structure of bovine lactoperoxidase with a partial Glu258-heme linkage at 2.07 A resolution.
7DN6	;	1.696	;	Crystal structure of bovine lactoperoxidase with hydrogen peroxide trapped between heme iron and his109 at 1.69 A resolution
2NQX	;	2.95	;	Crystal Structure of bovine lactoperoxidase with iodide ions at 2.9A resolution
6A4Y	;	1.92	;	Crystal structure of bovine lactoperoxidase with partial occupancies of iodide and SCN- ions at the substrate binding site on the distal heme side at 1.92 A resolution
6LCO	;	1.995	;	Crystal structure of bovine lactoperoxidase with substrates thiocynate and iodide bound at the distal heme side at 1.99 A resolution.
2E5A	;	2.1	;	Crystal Structure of Bovine Lipoyltransferase in Complex with Lipoyl-AMP
5JNV	;	1.6	;	Crystal structure of bovine low molecular weight protein tyrosine phosphatase (LMPTP) mutant (W49Y N50E) complexed with HEPES
5JNW	;	1.86	;	Crystal structure of bovine low molecular weight protein tyrosine phosphatase (LMPTP) mutant (W49Y N50E) complexed with vanadate and uncompetitive inhibitor
1DG9	;	1.9	;	CRYSTAL STRUCTURE OF BOVINE LOW MOLECULAR WEIGHT PTPASE COMPLEXED WITH HEPES
1Z13	;	2.2	;	Crystal Structure of Bovine Low Molecular Weight PTPase Complexed with Molybdate
1Z12	;	2.2	;	Crystal Structure of Bovine Low Molecular Weight PTPase Complexed with Vanadate
1FVA	;	1.7	;	CRYSTAL STRUCTURE OF BOVINE METHIONINE SULFOXIDE REDUCTASE
4O8Q	;	2.15	;	Crystal structure of bovine MHD domain of the COPI delta subunit at 2.15 A resolution
1V97	;	1.94	;	Crystal Structure of Bovine Milk Xanthine Dehydrogenase FYX-051 bound form
3UNC	;	1.65	;	Crystal Structure of Bovine Milk Xanthine Dehydrogenase to 1.65A Resolution
3BDJ	;	2.0	;	Crystal Structure of Bovine Milk Xanthine Dehydrogenase with a Covalently Bound Oxipurinol Inhibitor
3UNA	;	1.9	;	Crystal Structure of Bovine Milk Xanthine Dehydrogenase with NAD Bound
3UNI	;	2.2	;	Crystal Structure of Bovine Milk Xanthine Dehydrogenase with NADH Bound
1QCR	;	2.7	;	CRYSTAL STRUCTURE OF BOVINE MITOCHONDRIAL CYTOCHROME BC1 COMPLEX, ALPHA CARBON ATOMS ONLY
4MH2	;	2.2	;	Crystal structure of Bovine Mitochondrial Peroxiredoxin III
4MH3	;	2.4	;	Crystal structure of Bovine Mitochondrial Peroxiredoxin III
2R16	;	1.04	;	Crystal Structure of bovine neurexin 1 alpha LNS/LG domain 4 (with no splice insert)
2BN2	;	2.8	;	CRYSTAL STRUCTURE OF BOVINE NEUROPHYSIN II COMPLEXED WITH THE VASOPRESSIN ANALOGUE PHE-TYR AMIDE
7WBT	;	2.75	;	Crystal structure of bovine NLRP9
5E6T	;	2.27	;	Crystal structure of bovine norovirus P domain
2HKA	;	1.81	;	Crystal structure of bovine NPC2 and cholesterol sulfate complex
1HN2	;	1.8	;	CRYSTAL STRUCTURE OF BOVINE OBP COMPLEXED WITH AMINOANTHRACENE
1G85	;	1.8	;	CRYSTAL STRUCTURE OF BOVINE ODORANT BINDING PROTEIN COMPLEXED WITH IS NATURAL LIGAND
6NWE	;	2.705	;	Crystal structure of bovine opsin with beta octyl glucoside bound
6PEL	;	3.186	;	Crystal structure of bovine opsin with citronellol bound
6PGS	;	2.905	;	Crystal structure of bovine opsin with geraniol bound
6PH7	;	2.902	;	Crystal structure of bovine opsin with nerol bound
1HDU	;	1.75	;	Crystal structure of bovine pancreatic carboxypeptidase A complexed with aminocarbonylphenylalanine at 1.75 A
1HDQ	;	2.3	;	Crystal structure of bovine pancreatic carboxypeptidase A complexed with D-N-hydroxyaminocarbonyl phenylalanine at 2.3 A
1HEE	;	1.75	;	Crystal structure of bovine pancreatic carboxypeptidase A complexed with L-N-hydroxyaminocarbonyl phenylalanine at 2.3 A
3DH5	;	1.6	;	Crystal structure of bovine pancreatic ribonuclease A (wild-type)
8R5V	;	1.8	;	Crystal structure of bovine pancreatic ribonuclease A in complex with [Sp-PS]-mU-dT dinucleotide
3DIB	;	1.4	;	Crystal structure of bovine pancreatic ribonuclease A variant (I106A)
3DI9	;	2.0	;	Crystal structure of bovine pancreatic ribonuclease A variant (I81A)
3DIC	;	1.6	;	Crystal structure of bovine pancreatic ribonuclease A variant (V108A)
3DH6	;	1.6	;	Crystal structure of bovine pancreatic ribonuclease A variant (V47A)
3DI7	;	1.6	;	Crystal structure of bovine pancreatic ribonuclease A variant (V54A)
3DI8	;	1.6	;	Crystal structure of bovine pancreatic ribonuclease A variant (V57A)
3JW1	;	1.6	;	Crystal Structure of Bovine Pancreatic Ribonuclease Complexed with Uridine-5'-monophosphate at 1.60 A Resolution
7WB6	;	1.48	;	Crystal structure of Bovine Pancreatic Trypsin in complex with 4-Bromobenzamidine at Room Temperature
7WA2	;	1.52	;	Crystal structure of Bovine Pancreatic Trypsin in complex with 4-Methoxybenzamidine at Room Temperature
7WB9	;	1.56	;	Crystal structure of Bovine Pancreatic Trypsin in complex with 5-Chlorotryptamine at Room Temperature
7WB8	;	1.38	;	Crystal structure of Bovine Pancreatic Trypsin in complex with 5-Methoxytryptamine at Room Temperature
7WA0	;	1.77	;	Crystal structure of Bovine Pancreatic Trypsin in complex with Benzamidine at Room Temperature
7WB7	;	1.45	;	Crystal structure of Bovine Pancreatic Trypsin in complex with Serotonin at Room Temperature
7WBA	;	1.45	;	Crystal structure of Bovine Pancreatic Trypsin in complex with Tryptamine at Room Temperature
1FVG	;	1.6	;	CRYSTAL STRUCTURE OF BOVINE PEPTIDE METHIONINE SULFOXIDE REDUCTASE
1TU5	;	2.37	;	Crystal structure of bovine plasma copper-containing amine oxidase
2PNC	;	2.4	;	Crystal Structure of Bovine Plasma Copper-Containing Amine Oxidase in Complex with Clonidine
4YX2	;	2.194	;	Crystal structure of Bovine prion protein complexed with POM1 FAB
1FON	;	1.7	;	CRYSTAL STRUCTURE OF BOVINE PROCARBOXYPEPTIDASE A-S6 SUBUNIT III, A HIGHLY STRUCTURED TRUNCATED ZYMOGEN E
1G0W	;	2.3	;	CRYSTAL STRUCTURE OF BOVINE RETINAL CREATINE KINASE
1F88	;	2.8	;	CRYSTAL STRUCTURE OF BOVINE RHODOPSIN
1HZX	;	2.8	;	CRYSTAL STRUCTURE OF BOVINE RHODOPSIN
1U19	;	2.2	;	Crystal Structure of Bovine Rhodopsin at 2.2 Angstroms Resolution
1L9H	;	2.6	;	Crystal structure of bovine rhodopsin at 2.6 angstroms RESOLUTION
3OAX	;	2.6	;	Crystal structure of bovine rhodopsin with beta-ionone
8FD0	;	3.71	;	Crystal structure of bovine rod opsin in complex with a nanobody
3KVC	;	1.9	;	Crystal structure of bovine RPE65 at 1.9 angstrom resolution
7K89	;	2.15	;	Crystal structure of bovine RPE65 in complex with 4-fluoro-emixustat and palmitate
7K8G	;	1.95	;	Crystal structure of bovine RPE65 in complex with 4-fluoro-MB-004 and palmitate
7L0E	;	1.9	;	Crystal structure of bovine RPE65 in complex with gem-difluoro emixustat and palmitate
7K88	;	2.1	;	Crystal structure of bovine RPE65 in complex with hexaethylene glycol monooctyl ether
3V03	;	2.7	;	Crystal structure of Bovine Serum Albumin
4F5S	;	2.47	;	Crystal Structure of Bovine Serum Albumin
4JK4	;	2.653	;	Crystal Structure of Bovine Serum Albumin in complex with 3,5-diiodosalicylic acid
4OR0	;	2.58	;	Crystal Structure of Bovine Serum Albumin in complex with naproxen
1E9O	;	1.85	;	Crystal structure of bovine SOD - 1 of 3
3QZ1	;	3.0	;	Crystal Structure of Bovine Steroid of 21-hydroxylase (P450c21)
1CBJ	;	1.65	;	CRYSTAL STRUCTURE OF BOVINE SUPEROXIDE DISMUTASE CRYSTAL.
8Q5Z	;	1.5	;	Crystal structure of bovine Thiosulfate sulfurtransferase
1ID5	;	2.5	;	CRYSTAL STRUCTURE OF BOVINE THROMBIN COMPLEX WITH PROTEASE INHIBITOR ECOTIN
3WPE	;	2.38	;	Crystal structure of bovine TLR9 in complex with agonistic DNA1668_12mer
5Y3M	;	2.5	;	Crystal structure of bovine TLR9 in complex with two DNAs (CpG DNA and TCGTTT DNA)
6XYK	;	1.5	;	Crystal structure of bovine trypsin at room temperature.
4HGC	;	1.29	;	Crystal structure of bovine trypsin complexed with sfti-1 analog containing a peptoid residue at position p1
1TGB	;	1.8	;	CRYSTAL STRUCTURE OF BOVINE TRYPSINOGEN AT 1.8 ANGSTROMS RESOLUTION. II. CRYSTALLOGRAPHIC REFINEMENT, REFINED CRYSTAL STRUCTURE AND COMPARISON WITH BOVINE TRYPSIN
3NS1	;	2.6	;	Crystal Structure of Bovine Xanthine Oxidase in Complex with 6-Mercaptopurine
3NVV	;	1.82	;	Crystal Structure of Bovine Xanthine Oxidase in Complex with Arsenite
3NVW	;	1.6	;	Crystal Structure of Bovine Xanthine Oxidase in Complex with Guanine
3NRZ	;	1.8	;	Crystal Structure of Bovine Xanthine Oxidase in Complex with Hypoxanthine
3NVZ	;	1.6	;	Crystal Structure of Bovine Xanthine Oxidase in Complex with Indole-3-Aldehyde
3NVY	;	2.0	;	Crystal Structure of Bovine Xanthine Oxidase in Complex with Quercetin
5GIO	;	3.604	;	Crystal structure of box C/D RNP with 12 nt guide regions and 13 nt substrates
5GIN	;	3.308	;	Crystal structure of box C/D RNP with 12 nt guide regions and 9 nt substrates
5GIP	;	3.129	;	Crystal structure of box C/D RNP with 13 nt guide regions and 11 nt substrates
3Q1G	;	2.5	;	Crystal Structure of BoxB crystallized with PEG
3PM5	;	2.3	;	Crystal Structure of BoxB in mixed valent state with bound benzoyl-CoA
3PF7	;	1.903	;	Crystal structure of BoxB with malonate bound to the diiron center
3PER	;	2.1	;	Crystal Structure of BoxB with phosphate bound to the diiron center
6GXR	;	1.7	;	Crystal structure of BP39L lectin from Burkholderia pseudomallei at 1.7 A resolution
4AK7	;	1.8	;	Crystal structure of BpGH117_E303Q in complex with neoagarobiose
5T3B	;	1.4	;	Crystal structure of BpGH50
2E4P	;	2.0	;	Crystal structure of BphA3 (oxidized form)
2E4Q	;	1.8	;	Crystal structure of BphA3 (reduced form)
6L3W	;	2.6	;	Crystal structure of BphC, a halotolerant catechol dioxygenase
1KW8	;	2.0	;	Crystal structure of BphC-2,3-dihydroxybiphenyl-NO complex
2OG1	;	1.6	;	Crystal Structure of BphD, a C-C hydrolase from Burkholderia xenovorans LB400
1BP1	;	2.4	;	CRYSTAL STRUCTURE OF BPI, THE HUMAN BACTERICIDAL PERMEABILITY-INCREASING PROTEIN
4IQG	;	1.85	;	Crystal structure of BPRO0239 oxidoreductase from Polaromonas sp. JS666 in NADP bound form
1I9X	;	2.18	;	CRYSTAL STRUCTURE OF BPS-U2 SNRNA DUPLEX
7VXR	;	1.55	;	Crystal structure of BPSL1038 from Burkholderia pseudomallei
5A4O	;	1.76	;	Crystal structure of BPSL1147, a PC4 homolog from Burkholderia pseudomallei K96243 (orthorhombic crystal form)
5A4N	;	1.96	;	Crystal structure of BPSL1147, a PC4 homolog from Burkholderia pseudomallei K96243 (tetragonal crystal form)
2Y78	;	0.91	;	Crystal structure of BPSS1823, a Mip-like chaperone from Burkholderia pseudomallei
3QZS	;	1.8	;	Crystal Structure of BPTF bromo in complex with histone H4K16ac - Form I
3QZT	;	1.5	;	Crystal Structure of BPTF bromo in complex with histone H4K16ac - Form II
7RWQ	;	1.9	;	Crystal Structure of BPTF bromodomain in complex with 4-chloro-2-methyl-5-[(1,2,3,4-tetrahydroisoquinolin-6-yl)amino]pyridazin-3(2H)-one
7RWO	;	1.58	;	Crystal Structure of BPTF bromodomain in complex with 4-chloro-2-methyl-5-[(1,2,3,4-tetrahydroisoquinolin-7-yl)amino]pyridazin-3(2H)-one
7RWN	;	1.39	;	Crystal Structure of BPTF bromodomain in complex with 4-chloro-5-{4-[(dimethylamino)methyl]anilino}-2-methylpyridazin-3(2H)-one
7RWP	;	1.73	;	Crystal Structure of BPTF bromodomain in complex with 5-[4-(aminomethyl)anilino]-4-chloro-2-methylpyridazin-3(2H)-one
7M2E	;	1.75	;	Crystal structure of BPTF bromodomain in complex with CB02-092
7LRO	;	1.45	;	Crystal structure of BPTF bromodomain in complex with inhibitor HZ-01-105
7LPK	;	1.39	;	Crystal structure of BPTF bromodomain in complex with inhibitor HZ-03-112
7LP0	;	1.66	;	Crystal structure of BPTF bromodomain in complex with inhibitor Pdy-3-077
7LRK	;	1.44	;	Crystal structure of BPTF bromodomain in complex with inhibitor Pdy-3-093
7JT4	;	2.06	;	Crystal Structure of BPTF bromodomain labelled with 5-fluoro-tryptophan
3QZV	;	1.999	;	Crystal Structure of BPTF PHD-linker-bromo in complex with histone H4K12ac peptide
7F5D	;	1.57151	;	Crystal structure of BPTF-BRD with ligand DC-BPi-03 bound
7F5C	;	1.65004	;	Crystal structure of BPTF-BRD with ligand DC-BPi-07 bound
7F5E	;	2.20017	;	Crystal structure of BPTF-BRD with ligand DC-BPi-11 bound
6LU5	;	1.86528	;	Crystal structure of BPTF-BRD with ligand DCBPin5 bound
6LU6	;	1.97006	;	Crystal structure of BPTF-BRD with ligand DCBPin5-2 bound
7VD4	;	1.85659	;	Crystal structure of BPTF-BRD with ligand TP248 bound
5T7A	;	1.6	;	Crystal structure of Br derivative BhCBM56
1UHJ	;	1.8	;	Crystal structure of br-aequorin
3A0B	;	3.7	;	Crystal structure of Br-substituted Photosystem II complex
2Y32	;	1.78	;	Crystal structure of bradavidin
4H2S	;	2.15	;	Crystal structure of Bradyrhizobium japonicum glycine:[carrier protein] ligase complexed with cognate carrier protein and AMP
4H2T	;	2.44	;	Crystal structure of Bradyrhizobium japonicum glycine:[carrier protein] ligase complexed with cognate carrier protein and an analogue of glycyl adenylate
4H2U	;	2.1	;	Crystal structure of Bradyrhizobium japonicum glycine:[carrier protein] ligase complexed with cognate carrier protein and ATP
4H2V	;	2.0	;	Crystal structure of Bradyrhizobium japonicum glycine:[carrier protein] ligase complexed with glycylated carrier protein
4Q73	;	2.3	;	Crystal Structure of Bradyrhizobium japonicum Proline Utilization A (PutA) Mutant D778Y
4Q71	;	2.2	;	Crystal Structure of Bradyrhizobium japonicum Proline Utilization A (PutA) Mutant D779W
4Q72	;	2.3	;	Crystal Structure of Bradyrhizobium japonicum Proline Utilization A (PutA) Mutant D779Y
4WBJ	;	1.3	;	Crystal structure of Bradyrhizobium japonicum ScoI in the oxidized state
4RZW	;	3.493	;	Crystal structure of BRAF (R509H) kinase domain bound to AZ628
8C7X	;	1.65	;	Crystal structure of BRAF in complex with a hybrid compound 6
6XLO	;	2.493	;	Crystal structure of bRaf in complex with inhibitor
7K0V	;	1.93	;	Crystal structure of bRaf in complex with inhibitor GNE-0749
5ITA	;	1.95	;	Crystal Structure of BRAF Kinase Domain Bound to AZ-VEM
6XFP	;	2.0	;	Crystal Structure of BRAF kinase domain bound to Belvarafenib
7SHV	;	2.88	;	Crystal structure of BRAF kinase domain bound to GDC0879
6NSQ	;	3.05	;	Crystal structure of BRAF kinase domain bound to the inhibitor 2l
6UUO	;	3.288	;	Crystal structure of BRAF kinase domain bound to the PROTAC P4B
8C7Y	;	1.65	;	Crystal structure of BRAF V600E in complex with a hybrid compound 6
6V34	;	3.15	;	Crystal structure of BRAF V600E oncogenic mutant in complex with TAK-580
5C9C	;	2.7	;	CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
4MNF	;	2.802	;	Crystal structure of BRAF-V600E bound to GDC0879
6PP9	;	2.59	;	Crystal structure of BRAF:MEK1 complex
6NST	;	2.136	;	Crystal structure of branched chain amino acid aminotransferase from Pseudomonas aeruginosa
6OQ1	;	2.2	;	Crystal Structure of Branched K11/K48-Linked Tri-Ubiquitin
3L60	;	2.0	;	Crystal structure of branched-chain alpha-keto acid dehydrogenase subunit e2 from mycobacterium tuberculosis
4H7Q	;	2.1	;	Crystal structure of branched-chain alpha-ketoacid dehydrogenase kinase in complex with alpha-ketoisocaproic acid and ADP
4H81	;	2.05	;	Crystal structure of branched-chain alpha-ketoacid dehydrogenase kinase/(R)-2-chloro-3-phenylpropanoic acid complex with ADP
4H85	;	2.1	;	Crystal structure of branched-chain alpha-ketoacid dehydrogenase kinase/(R)-alpha-chloroisocaproate complex with ADP
4DZY	;	2.101	;	Crystal structure of branched-chain alpha-ketoacid dehydrogenase kinase/(S)-2-chloro-3-phenylpropanoic acid complex with ADP
4E02	;	2.1547	;	Crystal structure of branched-chain alpha-ketoacid dehydrogenase kinase/(S)-2-chloro-3-phenylpropanoic acid complex with AMPPNP
4E00	;	2.15	;	Crystal structure of branched-chain alpha-ketoacid dehydrogenase kinase/3,6-dichlorobenzo[b]thiophene-2-carboxylic acid complex with ADP
4E01	;	1.97	;	Crystal structure of branched-chain alpha-ketoacid dehydrogenase kinase/3,6-dichlorobenzo[b]thiophene-2-carboxylic acid complex with AMPPNP
3TZ2	;	2.85	;	Crystal structure of branched-chain alpha-ketoacid dehydrogenase kinase/phenylbutyrate complex
3TZ5	;	2.4	;	Crystal structure of branched-chain alpha-ketoacid dehydrogenase kinase/phenylbutyrate complex with ADP
3TZ0	;	2.5	;	Crystal structure of branched-chain alpha-ketoacid dehydrogenase kinase/S-alpha-chloroisocaproate complex
3TZ4	;	2.25	;	Crystal structure of branched-chain alpha-ketoacid dehydrogenase kinase/S-alpha-chloroisocaproate complex with ADP
4DA1	;	2.383	;	Crystal structure of branched-chain alpha-ketoacid dehydrogenase phosphatase with Mg (II) ions at the active site
3U0G	;	1.9	;	Crystal structure of branched-chain amino acid aminotransferase from burkholderia pseudomallei
7LV7	;	2.1	;	Crystal Structure of Branched-chain amino acid aminotransferase from Giardia lamblia ATCC 50803
7NEA	;	2.0	;	Crystal structure of branched-chain amino acid aminotransferase from Thermobaculum terrenum (M3 mutant).
7NEB	;	2.2	;	Crystal structure of branched-chain amino acid aminotransferase from Thermobaculum terrenum (M4 mutant)
6GKR	;	2.19	;	Crystal structure of branched-chain amino acid aminotransferase from Thermobaculum terrenum in PLP-form (holo-form)
6Q8E	;	1.5	;	Crystal structure of branched-chain amino acid aminotransferase from Thermobaculum terrenum in PMP-form
5CM0	;	1.9	;	Crystal structure of branched-chain aminotransferase from thermophilic archaea Geoglobus acetivorans
5E25	;	2.2	;	Crystal structure of branched-chain aminotransferase from thermophilic archaea Geoglobus acetivorans complexed with alpha-ketoglutarate
5CE8	;	2.0	;	Crystal structure of branched-chain aminotransferase from thermophilic archaea Thermoproteus uzoniensis
6THQ	;	2.15	;	Crystal structure of branched-chain aminotransferase from thermophilic archaea Thermoproteus uzoniensis with norvaline
6KLF	;	2.5	;	Crystal structure of branching enzyme D434A mutant from Cyanothece sp. ATCC 51142
5GR0	;	1.95	;	Crystal structure of branching enzyme D501A mutant from Cyanothece sp. ATCC 51142
5GQU	;	1.85	;	Crystal structure of branching enzyme from Cyanothece sp. ATCC 51142
5GQY	;	2.0	;	Crystal structure of branching enzyme from Cyanothece sp. ATCC 51142 in complex with maltoheptaose
5GQV	;	3.0	;	Crystal structure of branching enzyme from Cyanothece sp. ATCC 51142 in complex with maltohexaose
5GR2	;	1.95	;	Crystal structure of branching enzyme L541A mutant from Cyanothece sp. ATCC 51142
5GR4	;	2.0	;	Crystal structure of branching enzyme L541A mutant from Cyanothece sp. ATCC 51142 in complex with maltoheptaose
5GR3	;	2.6	;	Crystal structure of branching enzyme L541A/W655A mutant from Cyanothece sp. ATCC 51142
5GR5	;	2.4	;	Crystal structure of branching enzyme W610A mutant from Cyanothece sp. ATCC 51142
5GQW	;	1.8	;	Crystal structure of branching enzyme W610N mutant from Cyanothece sp. ATCC 51142
5GQX	;	2.3	;	Crystal structure of branching enzyme W610N mutant from Cyanothece sp. ATCC 51142 in complex with maltoheptaose
5GQZ	;	1.85	;	Crystal structure of branching enzyme Y500A mutant from Cyanothece sp. ATCC 51142
5GR6	;	2.0	;	Crystal structure of branching enzyme Y500A/D501A double mutant from Cyanothece sp. ATCC 51142
5GR1	;	2.5	;	Crystal structure of branching enzyme Y500A/D501A mutant from Cyanothece sp. ATCC 51142 in complex with maltoheptaose
4Z8I	;	2.701	;	Crystal structure of Branchiostoma belcheri tsingtauense peptidoglycan recognition protein 3
2Z37	;	1.53	;	Crystal structure of Brassica juncea chitinase catalytic module (Bjchi3)
2Z39	;	1.7	;	Crystal structure of Brassica juncea chitinase catalytic module Glu234Ala mutant (Bjchi3-E234A)
7CQT	;	2.8	;	Crystal structure of Brassica juncea HMG-CoA synthase 1 mutant - S359A in complex with acetyl-CoA
1D7O	;	1.9	;	CRYSTAL STRUCTURE OF BRASSICA NAPUS ENOYL ACYL CARRIER PROTEIN REDUCTASE COMPLEXED WITH NAD AND TRICLOSAN
5EX7	;	2.6	;	Crystal structure of Brat NHL domain in complex with an 8-nt hunchback mRNA
6B4S	;	2.035	;	Crystal Structure of Brazil nut (Bertholletia excelsa) allergen Ber e 2
4HE7	;	1.8	;	Crystal Structure of Brazzein
3K16	;	3.0	;	Crystal Structure of BRCA1 BRCT D1840T in complex with a minimal recognition tetrapeptide with a free carboxy C-terminus
3K15	;	2.8	;	Crystal Structure of BRCA1 BRCT D1840T in complex with a minimal recognition tetrapeptide with an amidated C-terminus
3K0K	;	2.7	;	Crystal Structure of BRCA1 BRCT in complex with a minimal recognition tetrapeptide with a free carboxy C-terminus.
4JLU	;	3.5	;	Crystal structure of BRCA1 BRCT with doubly phosphorylated Abraxas
7CMZ	;	1.695	;	Crystal Structure of BRCT7/8 in Complex with the APS Motif of PHF8
6IN2	;	1.75	;	Crystal structure of BRD1 in complex with 18-Crown-6
4Z02	;	1.87	;	Crystal structure of BRD1 in complex with Isoquinoline-3-carboxylic acid
5BT5	;	1.4	;	Crystal structure of BRD2 second bromodomain in complex with SGC-CBP30 chemical probe
6K05	;	1.935	;	Crystal structure of BRD2(BD1)with ligand BY27 bound
7DPN	;	1.79999	;	Crystal structure of BRD2(BD1)with ligand ZB-BD-224 bound
4QEU	;	1.5	;	Crystal structure of BRD2(BD2) mutant in free form
5DFB	;	1.4	;	Crystal structure of BRD2(BD2) mutant W370F in the free form
4QEW	;	1.7	;	Crystal structure of BRD2(BD2) mutant with ligand ET bound (METHYL (2R)- 2-[(4S)-6-(4-CHLOROPHENYL)-8-METHOXY-1-METHYL-4H-[1,2,4]TRIAZOLO[4,3-A][1, 4]BENZODIAZEPIN-4-YL]BUTANOATE)
4QEV	;	1.8	;	Crystal structure of BRD2(BD2) mutant with ligand ME bound (METHYL (2R)- 2-[(4S)-6-(4-CHLOROPHENYL)-8-METHOXY-1-METHYL-4H-[1,2,4]TRIAZOLO[4,3-A][1, 4]BENZODIAZEPIN-4-YL]PROPANOATE)
5DFD	;	1.5	;	Crystal structure of BRD2(BD2) W370F mutant with ligand 28 bound
5DFC	;	1.5	;	Crystal structure of BRD2(BD2) W370F mutant with ligand I-BET 762 bound
6K04	;	1.251	;	Crystal structure of BRD2(BD2)with ligand BY27 bound
7DPO	;	2.29994	;	Crystal Structure of BRD2(BD2)with Ligand ZB-BD-224 bound
7VRH	;	2.2	;	crystal structure of BRD2-BD1 in complex with guanosine analog
7VRK	;	2.48	;	crystal structure of BRD2-BD1 in complex with purine derivative
7VRO	;	2.35	;	crystal structure of BRD2-BD1 in complex with purine derivative
7VRZ	;	2.05	;	crystal structure of BRD2-BD1 in complex with purine derivative
7VSF	;	2.5	;	crystal structure of BRD2-BD1 in complex with purine derivative
7VRI	;	1.5	;	crystal structure of BRD2-BD2 in complex with guanosine analog
7VRM	;	1.1	;	crystal structure of BRD2-BD2 in complex with purine derivative
7VRQ	;	1.15	;	crystal structure of BRD2-BD2 in complex with purine derivative
7VS0	;	1.25	;	crystal structure of BRD2-BD2 in complex with purine derivative
7VS1	;	1.25	;	crystal structure of BRD2-BD2 in complex with purine derivative
6KEI	;	1.451	;	Crystal structure of BRD4 bromodomain 1 (BD1) in complex with 16-methoxy-11-methyl-6-[(pyridin-2-yl)methoxy]-2-oxa-11-azatetracyclo[8.6.1.03,8.013,17]heptadeca-1(16),3,5,7,9,13(17),14-heptaen-12-one
7YMG	;	1.4	;	Crystal structure of BRD4 bromodomain 1 (BD1) in complex with 2-({3-ethyl-[1,2,4]triazolo[4,3-b]pyridazin-6-yl}amino)-3-(1H-indol-3-yl)propan-1-ol
6KEC	;	1.35	;	Crystal structure of BRD4 bromodomain 1 (BD1) in complex with 4-ethoxy-5,16-dimethoxy-11-methyl-2-oxa-11-azatetracyclo[8.6.1.03,8.013,17]heptadeca-1(17),3,5,7,9,13,15-heptaen-12-one
6KEH	;	1.553	;	Crystal structure of BRD4 bromodomain 1 (BD1) in complex with 6,16-dimethoxy-11-methyl-2-oxa-11-azatetracyclo[8.6.1.03,8.013,17]heptadeca-1(17),3,5,7,9,13,15-heptaen-12-one
6KEK	;	1.553	;	Crystal structure of BRD4 bromodomain 1 (BD1) in complex with 6-hydroxy-16-methoxy-11-methyl-2-oxa-11-azatetracyclo[8.6.1.03,8.013,17]heptadeca-1(16),3,5,7,9,13(17),14-heptaen-12-one
6KEJ	;	1.85	;	Crystal structure of BRD4 bromodomain 1 (BD1) in complex with 6-[2-(diethylamino)ethoxy]-16-methoxy-11-methyl-2-oxa-11-azatetracyclo[8.6.1.03,8.013,17]heptadeca-1(17),3,5,7,9,13,15-heptaen-12-one
8GPZ	;	1.528	;	Crystal structure of BRD4 bromodomain 1 (BD1) in complex with C239-0012
7YQ9	;	1.5	;	Crystal structure of BRD4 bromodomain 1 (BD1) in complex with N-[2-(1H-indol-3-yl)ethyl]-3-(trifluoromethyl)[1,2,4]triazolo[4,3-b]pyridazin-6-amine
7W3D	;	1.98	;	Crystal structure of BRD4 bromodomain 1 (BD1) in complex with N2-(1,2,3-benzotriazol-5-yl)-N3-(dimethylsulfamoyl)-N6-[(2S)-1-methoxypropan-2-yl]pyridine-2,3,6-triamine
8GQ0	;	1.44	;	Crystal structure of BRD4 bromodomain 1 (BD1) in complex with STL233497
4KV1	;	1.5	;	Crystal Structure of Brd4 Bromodomain 1 in Complex with Acetylated Rel Peptide
7TV0	;	2.6	;	Crystal structure of BRD4 bromodomain 1 in complex with dual-acetylated SARS-CoV-2 E
5M39	;	1.38	;	Crystal structure of BRD4 BROMODOMAIN 1 IN COMPLEX WITH LIGAND 1
5M3A	;	1.65	;	Crystal structure of BRD4 BROMODOMAIN 1 IN COMPLEX WITH LIGAND 2
7TUQ	;	2.68	;	Crystal structure of BRD4 bromodomain 1 in complex with monoacetylated SARS-CoV-2 E
3MUL	;	1.65	;	Crystal structure of Brd4 bromodomain 1 with butyrylated histone H3-K(buty)14
6PRT	;	1.3	;	Crystal structure of BRD4 bromodomain 1 with N-methylpyrrolidin-2-one (NMP) derivative 10 (methyl [(3R)-1-methyl-5-oxopyrrolidin-3-yl]acetate)
6VUJ	;	1.48	;	Crystal structure of BRD4 bromodomain 1 with N-methylpyrrolidin-2-one (NMP) derivative 15c (N,N-diethyl-3',4'-dimethoxy-6-(1-methyl-5-oxopyrrolidin-3-yl)-[1,1'-biphenyl]-3-sulfonamide)
6PS9	;	1.21	;	Crystal structure of BRD4 bromodomain 1 with N-methylpyrrolidin-2-one (NMP) derivative 17 (5-{2-[(3R)-1-methyl-5-oxopyrrolidin-3-yl]ethyl}-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one)
6PSB	;	1.59	;	Crystal structure of BRD4 bromodomain 1 with N-methylpyrrolidin-2-one (NMP) derivative 18 (5-{[(3R)-1-methyl-5-oxopyrrolidin-3-yl]methyl}-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one)
6VUB	;	1.5	;	Crystal structure of BRD4 bromodomain 1 with N-methylpyrrolidin-2-one (NMP) derivative 5 (1-methyl-4-phenylpyrrolidin-2-one)
6VUC	;	1.55	;	Crystal structure of BRD4 bromodomain 1 with N-methylpyrrolidin-2-one (NMP) derivative 7b (1-methyl-4-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-one)
6VUF	;	1.59	;	Crystal structure of BRD4 bromodomain 1 with N-methylpyrrolidin-2-one (NMP) derivative 7h (4-(1-methyl-5-oxopyrrolidin-3-yl)-N-propylbenzenesulfonamide)
3MUK	;	1.75	;	Crystal structure of Brd4 bromodomain 1 with propionylated histone H3-K(prop)23
6KEE	;	2.12155	;	Crystal structure of BRD4 Bromodomain1 with an inhibitor
6HOV	;	1.85	;	Crystal Structure of BRD4 first bromodomain in complex with ferulic acid
5BT4	;	1.5	;	Crystal structure of BRD4 first bromodomain in complex with SGC-CBP30 chemical probe
6AJY	;	1.6	;	Crystal structure of BRD4 in complex with 2',4'-dihydroxy-2-methoxychalcone
6AJW	;	1.401	;	Crystal structure of BRD4 in complex with DMSO (Cocktail No. 4)
6AJV	;	1.45	;	Crystal structure of BRD4 in complex with isoliquiritigenin and DMSO (Cocktail No. 3)
6AJX	;	1.887	;	Crystal structure of BRD4 in complex with isoliquiritigenin in the absence of DMSO
6CKR	;	1.62	;	Crystal Structure of BRD4 with QC4956
6CKS	;	1.72	;	Crystal Structure of BRD4 with QC4956
4LYS	;	1.83	;	Crystal Structure of BRD4(1) bound to Colchiceine
4LZR	;	1.85	;	Crystal Structure of BRD4(1) bound to Colchicine
6RWJ	;	1.4	;	Crystal Structure of BRD4(1) bound to inhibitor BUG0 (6)
6S4B	;	1.6	;	Crystal Structure of BRD4(1) bound to inhibitor BUX1 (8)
6SB8	;	1.5	;	Crystal Structure of BRD4(1) bound to inhibitor BUX14 (7)
6S6K	;	1.4	;	Crystal Structure of BRD4(1) bound to inhibitor BUX2 (9)
6SA2	;	1.5	;	Crystal Structure of BRD4(1) bound to inhibitor BUX3 (10)
6SA3	;	1.8	;	Crystal Structure of BRD4(1) bound to inhibitor BUX4 (13)
6SAH	;	1.5	;	Crystal Structure of BRD4(1) bound to inhibitor BUX5 (11)
6SAJ	;	1.5	;	Crystal Structure of BRD4(1) bound to inhibitor BUX6 (12)
4LYW	;	1.95	;	Crystal Structure of BRD4(1) bound to inhibitor XD14
4LZS	;	2.2	;	Crystal Structure of BRD4(1) bound to inhibitor XD46
7AXR	;	1.5	;	Crystal structure of BRD4(1) bound to the dual BET-HDAC inhibitor LSH24
7R5B	;	1.77	;	Crystal structure of BRD4(1) in complex with the inhibitor MPM2
7B1T	;	1.92	;	Crystal structure of BRD4(1) in complex with the inhibitor MPM6
7RXR	;	1.41	;	Crystal Structure of BRD4(D1) with 4-[4-(4-bromophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]-N-(3,5-dimethylphenyl)pyrimidin-2-amine
5YOV	;	1.451	;	Crystal structure of BRD4-BD1 bound with hjp126
5YOU	;	1.503	;	Crystal structure of BRD4-BD1 bound with hjp64
6ZCI	;	1.976	;	Crystal structure of BRD4-BD1 in complex with NVS-BET-1
8PIQ	;	1.117	;	Crystal Structure of BRD4-BD1 with BI894999
6XVC	;	1.098	;	CRYSTAL STRUCTURE OF BRD4-BD1 WITH COMPOUND 1
6XV7	;	1.668	;	CRYSTAL STRUCTURE OF BRD4-BD1 WITH COMPOUND 2
6XV3	;	1.47	;	CRYSTAL STRUCTURE OF BRD4-BD1 WITH COMPOUND 3
6XUZ	;	1.07	;	CRYSTAL STRUCTURE OF BRD4-BD1 WITH COMPOUND 4
6KO2	;	1.5	;	Crystal Structure of BRD4-Brmo2 in complex with H2A.ZK4acK7ac peptide
5TWX	;	2.55	;	Crystal Structure of BRD9 bromodomain
4YY6	;	1.45	;	Crystal structure of BRD9 Bromodomain bound to a butyryllysine peptide
4YYG	;	2.1	;	Crystal structure of BRD9 Bromodomain bound to a butyryllysine peptide
4YYJ	;	1.85	;	Crystal structure of BRD9 Bromodomain bound to a butyryllysine peptide
4YYD	;	1.52	;	Crystal structure of BRD9 Bromodomain bound to a crotonyllysine peptide
4YYH	;	1.74	;	Crystal structure of BRD9 Bromodomain bound to a crotonyllysine peptide
4YYK	;	1.79	;	Crystal structure of BRD9 Bromodomain bound to a crotonyllysine peptide
4YYI	;	1.5	;	Crystal structure of BRD9 Bromodomain bound to an acetylated peptide
4YY4	;	1.47	;	Crystal structure of BRD9 Bromodomain bound to DMSO
4Z6I	;	1.95	;	Crystal structure of BRD9 bromodomain in complex with a substituted valerolactam quinolone ligand
4Z6H	;	1.8	;	Crystal structure of BRD9 bromodomain in complex with a valerolactam quinolone ligand
5E9V	;	1.8	;	Crystal structure of BRD9 bromodomain in complex with an indolizine ligand
8A7I	;	1.76	;	Crystal structure of BRD9 bromodomain in complex with compound EA-89
5EU1	;	1.6	;	CRYSTAL STRUCTURE OF BRD9 IN COMPLEX WITH BI-7273
7L9A	;	2.27	;	Crystal structure of BRDT bromodomain 2 in complex with CDD-1102
7L99	;	1.9	;	Crystal structure of BRDT bromodomain 2 in complex with CDD-1302
3O2K	;	2.4	;	Crystal Structure of Brevianamide F Prenyltransferase Complexed with Brevianamide F and Dimethylallyl S-thiolodiphosphate
4ZST	;	2.011	;	Crystal structure of Brevundimonas diminuta phosphotriesterase mutant L7eP-3a
4ZSU	;	2.011	;	Crystal structure of Brevundimonas diminuta phosphotriesterase mutant L7eP-3aG
4OH4	;	2.25	;	Crystal structure of BRI1 in complex with BKI1
4LSA	;	2.5	;	Crystal structure of BRI1 sud1 (Gly643Glu) bound to brassinolide
7XRZ	;	2.1	;	Crystal structure of BRIL and SRP2070_Fab complex
6CBV	;	1.872	;	Crystal structure of BRIL bound to an affinity matured synthetic antibody.
8J7E	;	2.8	;	Crystal structure of BRIL in complex with 1b3 Fab
4J0M	;	2.5	;	Crystal structure of BRL1 (LRR) in complex with brassinolide
6JOZ	;	1.35	;	Crystal structure of BRLF peptide from EBV in complex with HLA-A1101.
6UUH	;	2.7	;	Crystal structure of broad and potent HIV-1 neutralizing antibody 438-B11
6UUL	;	2.06	;	Crystal structure of broad and potent HIV-1 neutralizing antibody 438-D5
3TWC	;	1.65	;	Crystal structure of broad and potent HIV-1 neutralizing antibody PGT127 in complex with Man9
3TYG	;	3.25	;	Crystal structure of broad and potent HIV-1 neutralizing antibody PGT128 in complex with a glycosylated engineered gp120 outer domain with miniV3 (eODmV3)
3TV3	;	1.29	;	Crystal structure of broad and potent HIV-1 neutralizing antibody PGT128 in complex with Man9
4YDI	;	3.452	;	Crystal structure of broad and potently neutralizing VRC01-class antibody Z258-VRC27.01, isolated from human donor Z258, in complex with HIV-1 gp120 from clade A strain Q23.17
5GHW	;	2.4	;	Crystal structure of broad neutralizing antibody 10E8 with long epitope bound
4JPW	;	2.904	;	Crystal structure of broadly and potently neutralizing antibody 12a21 in complex with hiv-1 strain 93th057 gp120 mutant
4LSV	;	3.0	;	Crystal structure of broadly and potently neutralizing antibody 3BNC117 in complex with HIV-1 clade C C1086 gp120
4JPV	;	2.827	;	Crystal structure of broadly and potently neutralizing antibody 3bnc117 in complex with hiv-1 gp120
4YDJ	;	2.308	;	Crystal structure of broadly and potently neutralizing antibody 44-VRC13.01 in complex with HIV-1 clade AE strain 93TH057 gp120
4YDK	;	2.051	;	Crystal structure of broadly and potently neutralizing antibody C38-VRC16.01 in complex with HIV-1 clade AE strain 93TH057 gp120
4YDL	;	1.8	;	Crystal structure of broadly and potently neutralizing antibody C38-VRC18.02 in complex with HIV-1 clade AE strain 93TH057gp120
4LSP	;	2.15	;	Crystal structure of broadly and potently neutralizing antibody VRC-CH31 in complex with HIV-1 clade A/E gp120 93TH057
4LSQ	;	2.25	;	Crystal structure of broadly and potently neutralizing antibody VRC-CH31 in complex with HIV-1 clade A/E gp120 93TH057 with LOOP D and Loop V5 from clade A strain 3415_v1_c1
4LSR	;	2.28	;	Crystal structure of broadly and potently neutralizing antibody VRC-CH31 in complex with HIV-1 clade A/E stran 93TH057 gp120 with LOOP D and Loop V5 from clade A strain KER_2018_11
3SE9	;	2.0	;	Crystal structure of broadly and potently neutralizing antibody VRC-PG04 in complex with HIV-1 gp120
4LSU	;	2.3	;	Crystal structure of broadly and potently neutralizing antibody VRC-PG20 in complex with HIV-1 clade A/E 93TH057 gp120
4LSS	;	2.59	;	Crystal structure of broadly and potently neutralizing antibody VRC01 in complex with HIV-1 clade A strain KER_2018_11 gp120
4LST	;	2.55	;	Crystal structure of broadly and potently neutralizing antibody VRC01 in complex with HIV-1 clade C strain ZM176.66 gp120
3NGB	;	2.68	;	Crystal structure of broadly and potently neutralizing antibody VRC01 in complex with HIV-1 gp120
3SE8	;	1.895	;	Crystal structure of broadly and potently neutralizing antibody VRC03 in complex with HIV-1 gp120
4XNZ	;	3.389	;	Crystal structure of broadly and potently neutralizing antibody VRC06B in complex with HIV-1 clade A/E strain 93TH057 gp120
4XMP	;	1.7831	;	Crystal structure of broadly and potently neutralizing antibody VRC08 in complex with HIV-1 clade A strain Q842.d12 gp120
4XNY	;	2.3	;	Crystal structure of broadly and potently neutralizing antibody VRC08C in complex with HIV-1 clade A strain Q842.d12 gp120
4J6R	;	1.64	;	Crystal structure of broadly and potently neutralizing antibody VRC23 in complex with HIV-1 gp120
7L77	;	1.543	;	Crystal structure of broadly HIV-1-neutralizing antibody VRC33.01
7L79	;	2.826	;	Crystal structure of broadly HIV-1-neutralizing antibody VRC40.01
4RNR	;	2.758	;	Crystal structure of broadly neutralizing anti-HIV antibody PGT130
5X08	;	1.49	;	Crystal structure of broadly neutralizing anti-HIV-1 antibody 4E10, mutant Npro, with peptide bound
4JAM	;	1.65	;	Crystal structure of broadly neutralizing anti-hiv-1 antibody ch103
6A0X	;	2.3	;	Crystal structure of broadly neutralizing antibody 13D4
6A0Z	;	2.329	;	Crystal structure of broadly neutralizing antibody 13D4 bound to H5N1 influenza hemagglutinin, HA head region
6WF1	;	4.19	;	Crystal Structure of Broadly Neutralizing Antibody 3I14 Bound to the Influenza A H10 Hemagglutinin
6WF0	;	3.46	;	Crystal Structure of Broadly Neutralizing Antibody 3I14 Bound to the Influenza A H3 Hemagglutinin
6WEZ	;	3.21	;	Crystal Structure of Broadly Neutralizing Antibody 3I14-D93N Mutant Bound to the Influenza A H3 Hemagglutinin
6WEX	;	3.49	;	Crystal Structure of Broadly Neutralizing Antibody 3I14-D93N Mutant Bound to the Influenza A H6 Hemagglutinin
4M5Z	;	2.25	;	Crystal structure of broadly neutralizing antibody 5J8 bound to 2009 pandemic influenza hemagglutinin, HA1 subunit
6MEF	;	2.9	;	Crystal structure of broadly neutralizing antibody AR3C
6URH	;	2.2	;	Crystal structure of broadly neutralizing antibody AR3X in complex with Hepatitis C virus envelope glycoprotein E2 ectodomain
4FNL	;	2.297	;	Crystal structure of broadly neutralizing antibody C05
4FQR	;	4.1	;	Crystal structure of broadly neutralizing antibody C05 bound to H3 influenza hemagglutinin
4FP8	;	2.947	;	Crystal structure of broadly neutralizing antibody C05 bound to H3 influenza hemagglutinin, HA1 subunit
5ESV	;	3.105	;	Crystal Structure of Broadly Neutralizing Antibody CH03, Isolated from Donor CH0219, in Complex with Scaffolded Trimeric HIV-1 Env V1V2 Domain from the Clade C Superinfecting Strain of Donor CAP256.
5ESZ	;	4.191	;	Crystal Structure of Broadly Neutralizing Antibody CH04, Isolated from Donor CH0219, in Complex with Scaffolded Trimeric HIV-1 Env V1V2 Domain from the Clade AE Strain A244
4JAN	;	3.15	;	crystal structure of broadly neutralizing antibody CH103 in complex with HIV-1 gp120
3SDY	;	2.85	;	Crystal Structure of Broadly Neutralizing Antibody CR8020 Bound to the Influenza A H3 Hemagglutinin
4NM4	;	2.65	;	Crystal structure of broadly neutralizing antibody CR8043
4NM8	;	4.0041	;	Crystal structure of broadly neutralizing antibody CR8043 bound to H3 influenza hemagglutinin
4FQY	;	5.253	;	Crystal structure of broadly neutralizing antibody CR9114 bound to H3 influenza hemagglutinin
4FQV	;	5.75	;	Crystal structure of broadly neutralizing antibody CR9114 bound to H7 influenza hemagglutinin
4O5L	;	1.5045	;	Crystal structure of broadly neutralizing antibody F045-092
4O58	;	2.7501	;	Crystal structure of broadly neutralizing antibody F045-092 in complex with A/Victoria/3/1975 (H3N2) influenza hemagglutinin
4O5I	;	6.501	;	Crystal structure of broadly neutralizing antibody F045-092 in complex with A/Victoria/361/2011 (H3N2) influenza hemagglutinin
8W0Y	;	3.31	;	Crystal structure of broadly neutralizing antibody hcab17 in complex with Hepatitis C virus envelope glycoprotein E2 ectodomain
8W0X	;	3.12	;	Crystal structure of broadly neutralizing antibody hcab40 in complex with Hepatitis C virus envelope glycoprotein E2 ectodomain
8W0V	;	2.59	;	Crystal structure of broadly neutralizing antibody hcab55 in complex with Hepatitis C virus envelope glycoprotein E2 ectodomain
8W0W	;	2.13	;	Crystal structure of broadly neutralizing antibody hcab64 in complex with Hepatitis C virus envelope glycoprotein E2 ectodomain
6MED	;	2.04	;	Crystal structure of broadly neutralizing antibody HEPC3
6MEI	;	2.9	;	Crystal structure of broadly neutralizing antibody HEPC3 in complex with Hepatitis C virus envelope glycoprotein E2 ectodomain
7U0B	;	2.79	;	Crystal structure of broadly neutralizing antibody HEPC3.1
7U0C	;	3.3	;	Crystal structure of broadly neutralizing antibody HEPC3.4
6MEE	;	1.36	;	Crystal structure of broadly neutralizing antibody HEPC74
6MEH	;	1.99	;	Crystal structure of broadly neutralizing antibody HEPC74 in complex with Hepatitis C virus envelope glycoprotein E2 ectodomain
7RFB	;	2.7	;	Crystal structure of broadly neutralizing antibody mAb1198 in complex with Hepatitis C virus envelope glycoprotein E2 ectodomain
7RFC	;	3.24	;	Crystal structure of broadly neutralizing antibody mAb1382 in complex with Hepatitis C virus envelope glycoprotein E2 ectodomain
6OZ4	;	4.05	;	Crystal structure of broadly neutralizing antibody N49P6 Fab in complex with HIV-1 BG505 SOSIP.664 Env trimer ectodomain.
6BCK	;	2.7	;	Crystal Structure of Broadly Neutralizing Antibody N49P7 in Complex with HIV-1 Clade AE strain 93TH057 gp120 core.
6OZ3	;	3.15	;	Crystal structure of broadly neutralizing antibody N49P9.1 Fab in complex with HIV-1 Clade A/E strain 93TH057 gp120 core
7SX6	;	3.4	;	Crystal structure of broadly neutralizing antibody N49P9.3 Fab in complex with HIV-1 Clade A/E strain 93TH057 gp120 core
7SX7	;	2.15	;	Crystal structure of broadly neutralizing antibody N49P9.3-FR3-3 Fab in complex with HIV-1 Clade A/E strain 93TH057 gp120 core
4M5Y	;	1.55	;	Crystal structure of broadly neutralizing Fab 5J8
5I8E	;	2.655	;	Crystal Structure of Broadly Neutralizing HIV-1 Fusion Peptide-Targeting Antibody VRC34.01 Fab
5KAQ	;	3.514	;	Crystal structure of broadly neutralizing Influenza A antibody 31.a.83 in complex with Hemagglutinin Hong Kong 1968.
6NZ7	;	2.95	;	Crystal structure of broadly neutralizing Influenza A antibody 429 B01 in complex with Hemagglutinin Hong Kong 1968
5F9W	;	2.8911	;	Crystal structure of broadly neutralizing VH1-46 germline-derived CD4-binding site-directed antibody CH235 in complex with HIV-1 clade A/E 93TH057 gp120
5F9O	;	1.86	;	Crystal structure of broadly neutralizing VH1-46 germline-derived CD4-binding site-directed antibody CH235.09 in complex with HIV-1 clade A/E 93TH057 gp120
5F96	;	2.2407	;	Crystal structure of broadly neutralizing VH1-46 germline-derived CD4-binding site-directed antibody CH235.12 in complex with HIV-1 clade A/E 93TH057 gp120
5TE6	;	2.4	;	Crystal Structure of Broadly Neutralizing VRC01-class Antibody N6 in Complex with HIV-1 Clade AE Strain 93TH057 gp120 Core
5TE7	;	2.15	;	Crystal Structure of Broadly Neutralizing VRC01-class Antibody N6 in Complex with HIV-1 Clade C Strain DU172.17 gp120 Core
5TE4	;	2.75	;	Crystal Structure of Broadly Neutralizing VRC01-class Antibody N6 in Complex with HIV-1 Clade G Strain X2088 gp120 Core
7JZ1	;	3.37	;	Crystal structure of broadly Plasmodium RIFIN reactive LAIR1-inserted antibody MGC34
7JZ4	;	2.747	;	Crystal structure of broadly Plasmodium RIFIN reactive LAIR1-inserted antibody MGD21
1D2V	;	1.75	;	CRYSTAL STRUCTURE OF BROMIDE-BOUND HUMAN MYELOPEROXIDASE ISOFORM C AT PH 5.5
3JVK	;	1.8	;	Crystal structure of bromodomain 1 of mouse Brd4 in complex with histone H3-K(ac)14
3JVL	;	1.2	;	Crystal structure of bromodomain 2 of mouse Brd4
3JVM	;	1.2	;	Crystal structure of bromodomain 2 of mouse Brd4
4QNS	;	1.497	;	Crystal structure of bromodomain from Plasmodium faciparum GCN5, PF3D7_0823300
4PY6	;	2.5	;	Crystal Structure of bromodomain of PFA0510w from Plasmodium Falciparum
2DWW	;	1.8	;	Crystal structure of Bromodomain-containing protein 4
3FOB	;	1.74	;	Crystal structure of bromoperoxidase from Bacillus anthracis
3ULY	;	2.6	;	Crystal Structure of BROX Bro1 Domain in Complex with the C-Terminal Tails of CHMP5
5XEP	;	2.6	;	Crystal structure of BRP39, a chitinase-like protein, at 2.6 Angstorm resolution
7LH9	;	2.6	;	Crystal structure of BRPF2 PWWP domain in complex with DNA
4BGD	;	3.1	;	Crystal structure of Brr2 in complex with the Jab1/MPN domain of Prp8
4HVZ	;	3.5	;	Crystal structure of brucella abortus immunogenic BP26 protein
7DSG	;	1.9	;	Crystal structure of Brucella abortus PhiA
4ML7	;	1.8	;	Crystal structure of Brucella abortus PliC in complex with human lysozyme
5U2A	;	2.5	;	Crystal structure of Brucella canis Acyl-CoA Synthetase
4PR3	;	2.606	;	Crystal structure of Brucella melitensis 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase
6W3Z	;	2.3	;	Crystal Structure of Brugia malayi Deoxyhypusine synthase (DHPS)
5T18	;	1.5	;	Crystal structure of Bruton agammabulinemia tyrosine kinase complexed with BMS-986142 aka (2s)-6-fluoro-5-[3-(8-fluoro-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-3-yl)-2-methylphenyl]-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1h-carbazole-8-carboxamide
5JRS	;	1.97	;	CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -3,4-DIHYDROQUINAZOLIN-3-YL)PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
4NWM	;	2.03	;	Crystal structure of Bruton agammaglobulinemia tyrosine kinase complexed with BMS-809959 aka 4-tert-butyl-n-[2-me thyl-3-(6-{[4-(morpholine-4-carbonyl)phenyl]amino}-9h- purin-2-yl)phenyl]benzamide
5BPY	;	2.31	;	Crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with BMS-824171 AKA 6-[(3R)-3-(4-tert-bu tylbenzamido)piperidin-1-yl]-2-{[4-(morpholine-4-carbonyl) phenyl]amino}pyridine-3-carboxamide
5BQ0	;	1.57	;	Crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with BMS-824171 AKA 6-[(3R)-3-(4-tert-bu tylbenzamido)piperidin-1-yl]-2-{[4-(morpholine-4-carbonyl) phenyl]amino}pyridine-3-carboxamide
4ZLY	;	1.65	;	Crystal Structure of Bruton's Tyrosine Kinase bound to a Cinnoline Fragment
1K2P	;	2.1	;	Crystal structure of Bruton's tyrosine kinase domain
4ZLZ	;	2.0	;	Crystal Structure of Bruton's Tyrosine Kinase in complex with a substituted Cinnoline
5ZZ4	;	2.9	;	Crystal structure of bruton's tyrosine kinase in complex with inhibitor 2e
3OCS	;	1.8	;	Crystal structure of bruton's tyrosine kinase in complex with inhibitor CGI1746
6AUA	;	1.66	;	CRYSTAL STRUCTURE OF BRUTON'S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI2625
6AUB	;	1.65	;	CRYSTAL STRUCTURE OF BRUTON'S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI2815
3OCT	;	1.95	;	Crystal structure of bruton's tyrosine kinase mutant V555R in complex with dasatinib
3PF4	;	1.38	;	Crystal structure of Bs-CspB in complex with r(GUCUUUA)
3PF5	;	1.68	;	Crystal structure of Bs-CspB in complex with rU6
4KN8	;	1.502	;	Crystal structure of Bs-TpNPPase
6FZZ	;	2.05	;	Crystal structure of BSE31 (BSPA14S_RS05060 gene product) from Lyme disease agent Borrelia (Borreliella) spielmanii
5D01	;	2.02	;	Crystal structure of BshA from B. subtilis complexed with N-acetylglucosaminyl-malate
5D00	;	2.15	;	Crystal structure of BshA from B. subtilis complexed with N-acetylglucosaminyl-malate and UMP
4BHU	;	1.91	;	Crystal structure of BslA - A bacterial hydrophobin
2D0A	;	2.3	;	Crystal structure of Bst-RNase HIII
2D0B	;	2.1	;	Crystal structure of Bst-RNase HIII in complex with Mg2+
2D0C	;	2.6	;	Crystal structure of Bst-RNase HIII in complex with Mn2+
2XG7	;	3.45	;	Crystal Structure of BST2-Tetherin Ectodomain expressed in HEK293T cells
3NWH	;	2.6	;	Crystal structure of BST2/Tetherin
5Y0Q	;	2.1	;	Crystal structure of BsTmcAL bound with AMPCPP
5I87	;	3.7	;	Crystal structure of BT-CD domains of human acetyl-CoA carboxylase
5LX8	;	1.76	;	Crystal structure of BT1762
5T3R	;	3.1	;	Crystal structure of BT1762-1763
5T4Y	;	3.1	;	Crystal structure of BT1762-1763
3A24	;	2.3	;	Crystal structure of BT1871 retaining glycosidase
2P0V	;	2.1	;	Crystal structure of BT3781 protein from Bacteroides thetaiotaomicron, Northeast Structural Genomics Target BtR58
8UWV	;	1.08	;	Crystal structure of BT3984 SusD-like from Bacteroides thetaiotaomicron VPI-5482 at 1.1 A resolution (Space group P21)
3GGM	;	2.0	;	Crystal Structure of BT9727_2919 from Bacillus thuringiensis subsp. Northeast Structural Genomics Target BuR228B
2VKP	;	1.9	;	Crystal structure of BTB domain from BTBD6
2YY9	;	2.6	;	Crystal structure of BTB domain from mouse HKR3
6I0Q	;	2.3	;	Crystal structure of BTB domain of KCTD16 hexamer
6ER1	;	1.4	;	Crystal structure of BTB-domain of CP190 from D.melanogaster at high resolution
7Y3X	;	2.14	;	Crystal structure of BTG13 mutant (H58F)
7Y3Y	;	1.92	;	Crystal structure of BTG13 mutant (T299V)
2OQD	;	2.19	;	Crystal Structure of BthTX-II
3JR8	;	2.1	;	Crystal Structure of BthTX-II (Asp49-PLA2 from Bothrops jararacussu snake venom) with calcium ions
8FLN	;	1.334	;	Crystal structure of BTK C481S kinase domain in complex with pirtobrutinib
6DI1	;	1.1	;	CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT FRAGMENT LIGAND
6DI5	;	1.42	;	CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT INHIBITOR
6DI9	;	1.25	;	CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT INHIBITOR
6DI0	;	1.3	;	CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH FRAGMENT LIGAND
6DI3	;	2.0	;	CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH FRAGMENT LIGAND
3PIZ	;	2.21	;	Crystal structure of BTK kinase domain complexed with (5-Amino-1-o-tolyl-1H-pyrazol-4-yl)-[3-(1-methanesulfonyl-piperidin-4-yl)-phenyl]-methanone
4OTQ	;	1.55	;	Crystal structure of BTK kinase domain complexed with 1-[5-[3-(7-tert-butyl-4-oxo-quinazolin-3-yl)-2-methyl-phenyl]-1-methyl-2-oxo-3-pyridyl]-3-methyl-urea
6HRT	;	1.36	;	CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 12-(6-tert-butyl-8-fluoro-1-oxo-phthalazin-2-yl)-9-hydroxy-6-methyl-4-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6-azatricyclo[9.4.0.02,7]pentadeca-1(15),2(7),3,11,13-pentaen-5-one
3PIX	;	1.85	;	Crystal structure of BTK kinase domain complexed with 2-Isopropyl-7-(4-methyl-piperazin-1-yl)-4-(5-methyl-2H-pyrazol-3-ylamino)-2H-phthalazin-1-one
3PJ3	;	1.85	;	Crystal structure of BTK kinase domain complexed with 2-Methyl-5-[(E)-(3-phenyl-acryloyl)amino]-N-(2-phenyl-3H-imidazo[4,5-b]pyridin-6-yl)-benzamide
3PJ2	;	1.75	;	Crystal structure of BTK kinase domain complexed with 2-[4-(2-Diethylamino-ethoxy)-phenylamino]-6-(4-fluoro-phenoxy)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
4RG0	;	2.5	;	Crystal structure of BTK kinase domain complexed with 2-[8-fluoro-2-[2-(hydroxymethyl)-3-[1-methyl-5-[[5-(4-methylpiperazin-1-yl)-2-pyridyl]amino]-6-oxo-3-pyridyl]phenyl]-1-oxo-3,4-dihydroisoquinolin-6-yl]-2-methyl-propanenitrile
3PJ1	;	2.0	;	Crystal structure of BTK kinase domain complexed with 3-(2,6-Dichloro-phenyl)-7-[4-(2-diethylamino-ethoxy)-phenylamino]-1-methyl-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one
4OT6	;	2.05	;	Crystal structure of BTK kinase domain complexed with 4-Methanesulfonyl-N-(3-{8-[4-(morpholine-4-carbonyl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-benzamide
4OT5	;	1.55	;	Crystal structure of BTK kinase domain complexed with 4-tert-Butyl-N-(3-{8-[4-(4-methyl-piperazine-1-carbonyl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-benzamide
4RFY	;	1.7	;	Crystal structure of BTK kinase domain complexed with 6-(dimethylamino)-2-[2-(hydroxymethyl)-3-[1-methyl-5-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6-oxo-3-pyridyl]phenyl]-3,4-dihydroisoquinolin-1-one
6HRP	;	1.12	;	CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-(dimethylamino)-2-[2-(hydroxymethyl)-3-[1-methyl-5-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6-oxo-3-pyridyl]phenyl]-3,4-dihydroisoquinolin-1-one
4RFZ	;	1.17	;	Crystal structure of BTK kinase domain complexed with 6-(dimethylamino)-8-fluoro-2-[2-(hydroxymethyl)-3-[1-methyl-5-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6-oxo-3-pyridyl]phenyl]isoquinolin-1-one
4OTR	;	1.95	;	Crystal structure of BTK kinase domain complexed with 6-cyclopropyl-2-[3-[5-[[5-(4-ethylpiperazin-1-yl)-2-pyridyl]amino]-1-methyl-6-oxo-3-pyridyl]-2-(hydroxymethyl)phenyl]-8-fluoro-isoquinolin-1-one
6EP9	;	2.01	;	Crystal structure of BTK kinase domain complexed with N-[2-methyl-3-[4-methyl-6-[4-(4-methylpiperazine-1-carbonyl)anilino]-5-oxo-pyrazin-2-yl]phenyl]-4-(1-piperidyl)benzamide
3PIY	;	2.55	;	Crystal structure of BTK kinase domain complexed with R406
8FLL	;	1.498	;	Crystal structure of BTK kinase domain in complex with pirtobrutinib
3T9T	;	1.65	;	Crystal structure of BTK mutant (F435T,K596R) complexed with Imidazo[1,5-a]quinoxaline
5P9K	;	1.28	;	CRYSTAL STRUCTURE OF BTK with CNX 774
7RU7	;	1.4	;	Crystal structure of BtrK, a decarboxylase involved in butirosin biosynthesis
4M7T	;	1.56	;	Crystal structure of BtrN in complex with AdoMet and 2-DOIA
5O01	;	2.5	;	Crystal structure of BtubC (BKLC) from P. vanneervenii
4JB3	;	1.5	;	Crystal structure of BT_0970, a had family phosphatase from bacteroides thetaiotaomicron VPI-5482, TARGET EFI-501083, with bound sodium and glycerol, closed lid, ordered loop
3HLZ	;	1.5	;	Crystal structure of BT_1490 (NP_810393.1) from BACTEROIDES THETAIOTAOMICRON VPI-5482 at 1.50 A resolution
6JKK	;	1.85	;	Crystal structure of BubR1 kinase domain
6JKM	;	1.95	;	Crystal structure of BubR1 kinase domain
5KQA	;	2.05	;	Crystal structure of buckwheat glutaredoxin-glutathione complex
3RDY	;	1.84	;	Crystal Structure of buckwheat trypsin inhibitor rBTI at 1.84 angstrom resolution
6AAG	;	2.445	;	Crystal structure of budding yeast Atg8 complexed with the helical AIM of Hfl1.
5XW5	;	1.85	;	Crystal structure of budding yeast Cdc14p (C283S) bound to a Swi6p phosphopeptide
5XW4	;	1.85	;	Crystal structure of budding yeast Cdc14p (wild type) in the apo state
6MF5	;	2.7	;	Crystal structure of budding yeast Cdc5 polo-box domain in complex with Spc72 phosphopeptide.
6MF6	;	3.4	;	Crystal structure of budding yeast Cdc5 polo-box domain in complex with the Dbf4 polo-interacting region.
4J4W	;	2.661	;	Crystal structure of BueVN
2GJM	;	2.75	;	Crystal structure of Buffalo lactoperoxidase at 2.75A resolution
4Y55	;	2.1	;	Crystal structure of Buffalo lactoperoxidase with Rhodanide at 2.09 Angstrom resolution
5TA7	;	2.35	;	Crystal structure of BuGH117Bwt
5TA9	;	2.4	;	Crystal structure of BuGH117Bwt in complex with neoagarobiose
5T9X	;	2.5	;	Crystal structure of BuGH16Bwt
5T98	;	2.6	;	Crystal structure of BuGH2Awt
5T99	;	2.4	;	Crystal structure of BuGH2Awt in complex with Galactoisofagomine
5T9A	;	2.5	;	Crystal structure of BuGH2Cwt
5T9G	;	2.4	;	Crystal structure of BuGH2Cwt in complex with Galactoisofagomine
5TA0	;	1.4	;	Crystal structure of BuGH86E322Q in complex with neoagarooctaose
5TA1	;	2.3	;	Crystal structure of BuGH86wt
5TA5	;	1.65	;	Crystal structure of BuGH86wt in complex with neoagarooctaose
4DAS	;	2.56	;	Crystal structure of Bullfrog M ferritin
5SYW	;	1.85	;	Crystal structure of Burkhoderia pseudomallei KatG variant Q233E
5NM7	;	1.72	;	Crystal structure of Burkholderia AP3 phage endolysin
5IXH	;	1.4	;	Crystal Structure of Burkholderia cenocepacia BcnA
5IXG	;	1.6	;	Crystal Structure of Burkholderia cenocepacia BcnB
2Y5S	;	1.95	;	Crystal structure of Burkholderia cenocepacia dihydropteroate synthase complexed with 7,8-dihydropteroate.
2Y5J	;	2.33	;	Crystal structure of Burkholderia cenocepacia dihydropteroate synthase.
4MSS	;	1.8	;	Crystal structure of Burkholderia cenocepacia family 3 glycoside hydrolase (NagZ) bound to (3S,4R,5R,6S)-3-acetamido-4,5,6-trihydroxyazepane
5UTR	;	2.15	;	Crystal structure of Burkholderia cenocepacia family 3 glycoside hydrolase (NagZ) bound to (3S,4R,5R,6S)-3-butyryl-4,5,6-trihydroxyazepane
5UTP	;	2.2	;	Crystal structure of Burkholderia cenocepacia family 3 glycoside hydrolase (NagZ) bound to N-ethylbutyryl-PUGNAc
5UTQ	;	2.2	;	Crystal structure of Burkholderia cenocepacia family 3 glycoside hydrolase (NagZ) bound to PUGNAc
4E84	;	2.6	;	Crystal Structure of Burkholderia cenocepacia HldA
4E8W	;	2.8654	;	Crystal Structure of Burkholderia cenocepacia HldA in Complex with an ATP-competitive Inhibitor
4E8Y	;	2.6	;	Crystal Structure of Burkholderia cenocepacia HldA in Complex with an ATP-competitive Inhibitor
4E8Z	;	3.05	;	Crystal Structure of Burkholderia cenocepacia HldA in Complex with an ATP-competitive Inhibitor
2WR9	;	1.75	;	CRYSTAL STRUCTURE OF BURKHOLDERIA CENOCEPACIA LECTIN (BCLA) COMPLEXED WITH AMAN1-3MAN DISACCHARIDE
5JE6	;	1.571	;	Crystal structure of Burkholderia glumae ToxA
5JDZ	;	1.6	;	Crystal structure of Burkholderia glumae ToxA with bound S-adenosylhomocysteine (SAH)
5JE0	;	1.552	;	Crystal structure of Burkholderia glumae ToxA with bound S-adenosylhomocysteine (SAH) and 1,6-didemethyltoxoflavin
5JE5	;	1.564	;	Crystal structure of Burkholderia glumae ToxA with bound S-adenosylhomocysteine (SAH) and 1-demethyltoxoflavin
5JE1	;	1.95	;	Crystal structure of Burkholderia glumae ToxA with bound S-adenosylhomocysteine (SAH) and toxoflavin
5JE3	;	1.792	;	Crystal structure of Burkholderia glumae ToxA Y7A mutant with bound S-adenosylhomocysteine (SAH)
5JE4	;	1.932	;	Crystal structure of Burkholderia glumae ToxA Y7A mutant with bound S-adenosylhomocysteine (SAH)
5JE2	;	1.519	;	Crystal structure of Burkholderia glumae ToxA Y7F mutant with bound S-adenosylhomocysteine (SAH)
5JDY	;	1.77	;	Crystal structure of Burkholderia glumae ToxA Y7F mutant with bound S-adenosylhomocysteine (SAH) and toxoflavin
7SPQ	;	1.8	;	Crystal structure of Burkholderia glumae toxoflavin biosynthesis protein ToxD
4GU8	;	2.4	;	Crystal Structure of Burkholderia oklahomensis agglutinin (BOA)
4GK9	;	1.9	;	Crystal structure of Burkholderia oklahomensis agglutinin (BOA) bound to 3a,6a-mannopentaose
5NRH	;	1.3	;	Crystal structure of Burkholderia pseudomallei D-alanine-D-alanine ligase in complex with AMP
5NRI	;	1.5	;	Crystal structure of Burkholderia pseudomallei D-alanine-D-alanine ligase in complex with AMP and D-Ala-D-Ala
4K2D	;	1.9	;	Crystal structure of Burkholderia Pseudomallei DsbA
4HCP	;	2.52	;	crystal structure of Burkholderia pseudomallei effector protein chbp in complex with nedd8
4HCN	;	2.6	;	Crystal structure of Burkholderia pseudomallei effector protein CHBP in complex with ubiquitin
7PRB	;	1.31	;	Crystal structure of Burkholderia pseudomallei heparanase in complex with covalent inhibitor GR109
7PR9	;	1.34	;	Crystal structure of Burkholderia pseudomallei heparanase in complex with covalent inhibitor VL166
5SYU	;	1.8	;	Crystal structure of Burkholderia pseudomallei KatG E242Q variant
5SYV	;	1.75	;	Crystal structure of Burkholderia pseudomallei KatG N240D variant
5SYX	;	1.77	;	Crystal structure of Burkholderia pseudomallei KatG variant W139F
5UFM	;	1.77	;	Crystal structure of Burkholderia thailandensis 1,6-didemethyltoxoflavin-N1-methyltransferase with bound 1,6-didemethyltoxoflavin and S-adenosylhomocysteine
5UFN	;	1.39	;	Crystal structure of Burkholderia thailandensis 1,6-didemethyltoxoflavin-N1-methyltransferase with bound S-adenosylhomocysteine
4MWG	;	2.2	;	Crystal structure of Burkholderia xenovorans DmrB apo form: A Cubic Protein Cage for Redox Transfer
3WIS	;	1.901	;	Crystal structure of Burkholderia xenovorans DmrB in complex with FMN: A Cubic Protein Cage for Redox Transfer
8I29	;	2.72	;	Crystal structure of butanol dehydrogenase A (YqdH) in complex with NADH from Fusobacterium nucleatum
7FJG	;	2.72	;	Crystal structure of butanol dehydrogenase A (YqdH) in complex with partial NADH from Fusobacterium nucleatum
5Z3S	;	1.65	;	Crystal structure of butanol modified signaling protein from buffalo (SPB-40) at 1.65 A resolution
3USU	;	2.46	;	Crystal structure of Butea monosperma seed lectin
1L0H	;	2.0	;	CRYSTAL STRUCTURE OF BUTYRYL-ACP FROM E.COLI
1L0I	;	1.2	;	Crystal structure of butyryl-ACP I62M mutant
5WSO	;	2.82	;	crystal structure of BVDV NS3 helicase
5GVU	;	2.82	;	crystal structure of BVDV NS3 helicase domain
5L7R	;	1.85	;	Crystal structure of BvGH123
5L7V	;	2.3	;	Crystal Structure of BvGH123 with bond transition state analog Galthiazoline.
5L7U	;	2.1	;	Crystal structure of BvGH123 with bound GalNAc
6U9I	;	1.777	;	Crystal structure of BvnE pinacolase from Penicillium brevicompactum
3VXB	;	1.85	;	Crystal Structure of BxlE from Streptomyces thermoviolaceus OPC-520
7XT1	;	1.98	;	Crystal structure of Bypass-of-forespore protein C from Bacillus Subtilis
5ZU1	;	3.009	;	Crystal Structure of BZ junction in diverse sequence
5ZUO	;	2.902	;	Crystal Structure of BZ junction in diverse sequence
5ZUP	;	2.9	;	Crystal Structure of BZ junction in diverse sequence
1GD2	;	2.0	;	CRYSTAL STRUCTURE OF BZIP TRANSCRIPTION FACTOR PAP1 BOUND TO DNA
7C7E	;	2.047	;	Crystal structure of C terminal domain of Escherichia coli DgoR
2QUO	;	1.75	;	Crystal Structure of C terminal fragment of Clostridium perfringens enterotoxin
5Z1N	;	1.949	;	Crystal structure of C terminal region of G-protein interacting protein 1 (Gip1) from Dictyostelium discoideum
5Z39	;	2.74	;	Crystal structure of C terminal region of G-protein interacting protein 1 (Gip1) from Dictyostelium discoideum form II
5ZY8	;	2.899	;	Crystal structure of C terminal truncated HadBC (3R-Hydroxyacyl-ACP Dehydratase) complex from Mycobacterium tuberculosis
2ERZ	;	2.2	;	Crystal Structure of c-AMP Dependent Kinase (PKA) bound to hydroxyfasudil
5C68	;	1.4618	;	Crystal structure of C-As lyase at 1.46 Angstroms resolution
5C6X	;	1.5	;	Crystal structure of C-As lyase with Co(II)
5D4F	;	1.72	;	Crystal structure of C-As lyase with Fe(III)
5CB9	;	1.95	;	Crystal structure of C-As lyase with mercaptoethonal
5V0F	;	2.23	;	Crystal structure of C-As lyase with mutation K105A and substrate Roxarsone
6XCK	;	1.62	;	Crystal structure of C-As lyase with mutation K105E
6XA0	;	2.15	;	Crystal structure of C-As lyase with mutation K105R with Ni(II)
5DFG	;	1.9711	;	Crystal structure of C-As lyase with mutations Y100H and V102F
5HCW	;	2.785	;	Crystal structure of C-As lyase with mutations Y100H and V102F (monoclinic form)
3OB2	;	2.1	;	Crystal structure of c-Cbl TKB domain in complex with double phosphorylated EGFR peptide
3OB1	;	2.2	;	Crystal structure of c-Cbl TKB domain in complex with double phosphorylated Spry2 peptide
5HKY	;	1.8	;	Crystal structure of c-Cbl TKBD domain in complex with SPRY2 peptide (36-60, pY55) Refined to 1.8A Resolution (P6 form)
5HKZ	;	1.8	;	Crystal Structure of c-Cbl TKBD in complex with SPRY2 peptide (36-60, pY55) Refined to 1.8 A Resolution (P21 form)
5HL0	;	2.2	;	Crystal Structure of c-Cbl TKBD in complex with SPRY2 peptide (54-60, pY55) Refined to 2.2A Resolution
5HKX	;	1.85	;	Crystal Structure of c-Cbl TKBD-RING domains (Y371E mutant) Refined to 1.85 A Resolution
3BUX	;	1.35	;	Crystal structure of c-Cbl-TKB domain complexed with its binding motif in c-Met
3BUO	;	2.6	;	Crystal structure of c-Cbl-TKB domain complexed with its binding motif in EGF receptor'
3BUM	;	2.0	;	Crystal structure of c-Cbl-TKB domain complexed with its binding motif in Sprouty2
3BUN	;	2.0	;	Crystal structure of c-Cbl-TKB domain complexed with its binding motif in Sprouty4
3BUW	;	1.45	;	Crystal structure of c-Cbl-TKB domain complexed with its binding motif in Syk
6K8S	;	1.8	;	Crystal structure of C-domain of baterial malonyl-CoA reductase
6K8T	;	1.9	;	Crystal structure of C-domain with CoA of baterial malonyl-CoA reductase
6K8U	;	2.0	;	Crystal structure of C-domain with NADP of baterial malonyl-CoA reductase
5WSQ	;	1.05	;	Crystal structure of C-Hg-T pair containing DNA duplex
3UK4	;	1.98	;	Crystal Structure of C-lobe of Bovine lactoferrin Complexed with 1,2,5-Pentanetriol at 1.98 A Resolution
3TOD	;	1.38	;	Crystal Structure of C-lobe of Bovine lactoferrin Complexed with 1-Butyl-1H-Pyrazole-5-carboxylic acid at 1.38 A Resolution
4DXU	;	1.46	;	Crystal Structure of C-lobe of Bovine lactoferrin Complexed with aminocaproic acid at 1.46 A Resolution
4FIM	;	1.8	;	Crystal Structure of C-lobe of Bovine lactoferrin Complexed with celecoxib acid at 1.80 A Resolution
3UGW	;	1.87	;	Crystal Structure of C-lobe of Bovine lactoferrin Complexed with Deoxycytidine at 1.87 A Resolution
3VDF	;	1.46	;	Crystal Structure of C-lobe of Bovine lactoferrin Complexed with diaminopimelic acid at 1.46 A Resolution
4NED	;	2.1	;	Crystal STRUCTURE OF C-LOBE OF BOVINE LACTOFERRIN COMPLEXED WITH FENOPROFEN AT 2.1 ANGSTROM RESOLUTION
4FOR	;	1.58	;	Crystal Structure of C-lobe of Bovine lactoferrin Complexed with Flurbiprofen at 1.58 A Resolution
3V5A	;	1.44	;	Crystal Structure of C-lobe of Bovine Lactoferrin Complexed with Gamma Amino Butyric Acid at 1.44 A Resolution
3USD	;	2.4	;	Crystal Structure of C-lobe of Bovine lactoferrin Complexed with Imidazol (1,2 a) pyridine3-yl-acitic acid at 2.4 A Resolution
3U72	;	2.2	;	Crystal Structure of C-lobe of Bovine lactoferrin Complexed with Isoniazid at 2.2 A Resolution
4GRK	;	1.68	;	Crystal Structure of C-lobe of Bovine lactoferrin Complexed with ketorolac at 1.68 A Resolution
4G8H	;	1.88	;	Crystal structure of C-lobe of bovine lactoferrin complexed with licofelone at 1.88 A resolution
3TTR	;	2.27	;	Crystal structure of C-lobe of bovine lactoferrin complexed with Lidocaine at 2.27 A resolution
3RGY	;	2.0	;	Crystal Structure of C-lobe of Bovine lactoferrin Complexed with Lipopolysaccharide at 2.0 A Resolution
3SDF	;	2.1	;	Crystal Structure of C-lobe of Bovine lactoferrin Complexed with Lipoteichoic acid at 2.1 A Resolution
4N6P	;	1.4	;	Crystal Structure of C-lobe of Bovine lactoferrin complexed with meclofenamic acid at 1.4 A resolution
4G2Z	;	1.9	;	Crystal Structure of C-lobe of Bovine lactoferrin Complexed with Mefenamic acid at 1.90 A Resolution
3TUS	;	2.5	;	Crystal Structure of C-lobe of Bovine lactoferrin Complexed with Meta-hydroxy benzoic acid at 2.5 A Resolution
4DIG	;	1.8	;	Crystal Structure of C-lobe of Bovine lactoferrin Complexed with N-acetylmuramyl l-alanyl d-isoglutamine at 1.8 A Resolution
3TAJ	;	1.7	;	Crystal structure of C-lobe of bovine lactoferrin complexed with Nabumetone at 1.7A resolution
4FJP	;	1.68	;	Crystal Structure of C-lobe of Bovine lactoferrin Complexed with Naproxen at 1.68 A Resolution
3U8Q	;	1.97	;	Crystal Structure of C-lobe of Bovine lactoferrin Complexed with Phenyl-Propanolamine at 1.97 A Resolution
4G77	;	1.98	;	Crystal Structure of C-lobe of Bovine lactoferrin Complexed with tolfenamic acid at 1.98 A Resolution
7B3Q	;	1.75	;	Crystal structure of c-MET bound by compound 1
7B3T	;	2.23	;	Crystal structure of c-MET bound by compound 2
7B3V	;	1.93	;	Crystal structure of c-MET bound by compound 3
7B3W	;	2.02	;	Crystal structure of c-MET bound by compound 4
7B3Z	;	1.8	;	Crystal structure of c-MET bound by compound 5
7B40	;	1.76	;	Crystal structure of c-MET bound by compound 6
7B41	;	1.97	;	Crystal structure of c-MET bound by compound 7
7B42	;	1.8	;	Crystal structure of c-MET bound by compound 8
7B43	;	1.87	;	Crystal structure of c-MET bound by compound 9
7B44	;	1.76	;	Crystal structure of c-MET bound by compound S1
4XMO	;	1.75	;	Crystal structure of c-Met in complex with (R)-5-(8-fluoro-3-(1-fluoro-1-(3-methoxyquinolin-6-yl)ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-3-methylisoxazole
4XYF	;	1.85	;	Crystal structure of c-Met in complex with (S)-5-(8-fluoro-3-(1-(3-(2-methoxyethoxy)quinolin-6-yl)ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-3-methylisoxazole
5EYD	;	1.85	;	Crystal structure of c-Met in complex with AMG 337
4EEV	;	1.8	;	Crystal structure of c-Met in complex with LY2801653
5EYC	;	1.8	;	Crystal structure of c-Met in complex with naphthyridinone inhibitor 5
5YA5	;	1.89	;	CRYSTAL STRUCTURE OF c-MET IN COMPLEX WITH NOVEL INHIBITOR
3U6H	;	2.0	;	Crystal structure of c-Met in complex with pyrazolone inhibitor 26
3U6I	;	2.1	;	Crystal structure of c-Met in complex with pyrazolone inhibitor 58a
4DEG	;	2.0	;	Crystal structure of c-Met in complex with triazolopyridazine inhibitor 2
4DEI	;	2.05	;	Crystal structure of c-Met in complex with triazolopyridinone inhibitor 24
4DEH	;	2.0	;	Crystal structure of c-Met in complex with triazolopyridinone inhibitor 3
4AP7	;	1.8	;	Crystal structure of C-MET kinase domain in complex with 4-((6-(4- fluorophenyl)-(1,2,4)triazolo(4,3-b)(1,2,4)triazin-3-yl)methyl)phenol
4AOI	;	1.9	;	Crystal structure of C-MET kinase domain in complex with 4-(3-((1H- pyrrolo(2,3-b)pyridin-3-yl)methyl)-(1,2,4)triazolo(4,3-b)(1,2,4) triazin-6-yl)benzonitrile
5HTI	;	1.66	;	Crystal structure of c-Met kinase domain in complex with LXM108
3ZZE	;	1.87	;	Crystal structure of C-MET kinase domain in complex with N'-((3Z)-4- chloro-7-methyl-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2-(4- hydroxyphenyl)propanohydrazide
5HOA	;	2.14	;	Crystal structure of c-Met L1195V in complex with SAR125844
5HLW	;	1.97	;	Crystal structure of c-Met mutant Y1230H in complex with compound 14
3I5N	;	2.0	;	Crystal structure of c-Met with triazolopyridazine inhibitor 13
5HOR	;	2.2	;	Crystal structure of c-Met-M1250T in complex with SAR125844.
1GUU	;	1.6	;	CRYSTAL STRUCTURE OF C-MYB R1
1GV5	;	1.58	;	CRYSTAL STRUCTURE OF C-MYB R2
1GVD	;	1.45	;	CRYSTAL STRUCTURE OF C-MYB R2 V103L MUTANT
1GV2	;	1.68	;	CRYSTAL STRUCTURE OF C-MYB R2R3
3BRP	;	1.85	;	Crystal Structure of C-Phycocyanin from Galdieria sulphuraria
4L1E	;	2.61	;	Crystal structure of C-Phycocyanin from Leptolyngbya sp. N62DM
2UUL	;	3.1	;	Crystal structure of C-phycocyanin from Phormidium, Lyngbya spp. (Marine) and Spirulina sp. (Fresh water) shows two different ways of energy transfer between two hexamers.
2UUM	;	3.0	;	Crystal structure of C-phycocyanin from Phormidium, Lyngbya spp. (Marine) and Spirulina sp. (Fresh water) shows two different ways of energy transfer between two hexamers.
2UUN	;	3.0	;	Crystal structure of C-phycocyanin from Phormidium, Lyngbya spp. (Marine) and Spirulina sp. (Fresh water) shows two different ways of energy transfer between two hexamers.
1GH0	;	2.2	;	CRYSTAL STRUCTURE OF C-PHYCOCYANIN FROM SPIRULINA PLATENSIS
3O18	;	1.35	;	Crystal structure of c-phycocyanin from Themosynechococcus vulcanus at 1.35 angstroms resolution
1KTP	;	1.6	;	Crystal structure of c-phycocyanin of synechococcus vulcanus at 1.6 angstroms
1I7Y	;	2.5	;	CRYSTAL STRUCTURE OF C-PHYCOCYANIN OF SYNECHOCOCCUS VULCANUS AT 2.5 ANGSTROMS.
3OMV	;	4.0	;	Crystal structure of c-raf (raf-1)
1GJI	;	2.85	;	Crystal structure of c-Rel bound to DNA
5K9I	;	2.5	;	Crystal structure of c-SRC in complex with a covalent lysine probe
3EL7	;	2.8	;	Crystal structure of c-Src in complex with pyrazolopyrimidine 3
3EL8	;	2.3	;	Crystal structure of c-Src in complex with pyrazolopyrimidine 5
6XVN	;	1.7	;	Crystal structure of c-Src SH3 domain without ATCUN motif: monomer 1
6XVM	;	0.9	;	Crystal structure of c-Src SH3 domain without ATCUN motif: monomer 2
196D	;	1.7	;	CRYSTAL STRUCTURE OF C-T-C-T-C-G-A-G-A-G: IMPLICATIONS FOR THE STRUCTURE OF THE HOLLIDAY JUNCTION
3E0K	;	2.52	;	Crystal structure of C-termianl domain of N-acetylglutamate synthase from Vibrio parahaemolyticus
1F00	;	1.9	;	CRYSTAL STRUCTURE OF C-TERMINAL 282-RESIDUE FRAGMENT OF ENTEROPATHOGENIC E. COLI INTIMIN
1F02	;	2.9	;	CRYSTAL STRUCTURE OF C-TERMINAL 282-RESIDUE FRAGMENT OF INTIMIN IN COMPLEX WITH TRANSLOCATED INTIMIN RECEPTOR (TIR) INTIMIN-BINDING DOMAIN
1KO6	;	3.0	;	Crystal Structure of C-terminal Autoproteolytic Domain of Nucleoporin Nup98
2YW7	;	3.3	;	Crystal structure of C-terminal deletion mutant of Mycobacterium smegmatis Dps
4KC6	;	2.4	;	Crystal structure of C-terminal deletion mutant of ribosome recycling factor from Mycobacterium tuberculosis
1RZQ	;	2.2	;	Crystal Structure of C-Terminal Despentapeptide Nitrite Reductase from Achromobacter Cycloclastes at pH5.0
1RZP	;	1.9	;	Crystal Structure of C-Terminal Despentapeptide Nitrite Reductase from Achromobacter Cycloclastes at pH6.2
2AVF	;	2.6	;	Crystal Structure of C-terminal Desundecapeptide Nitrite Reductase from Achromobacter cycloclastes
6ZCO	;	1.361	;	Crystal Structure of C-terminal Dimerization Domain of Nucleocapsid Phosphoprotein from SARS-CoV-2, crystal form II
6LXL	;	3.56	;	Crystal structure of C-terminal DNA-binding domain of Escherichia coli OmpR
6LXM	;	2.412	;	Crystal structure of C-terminal DNA-binding domain of Escherichia coli OmpR as a domain-swapped dimer
6LXN	;	2.93	;	Crystal structure of C-terminal DNA-binding domain of Escherichia coli OmpR in complex with F1-DNA
5JUH	;	1.35	;	Crystal structure of C-terminal domain (RV) of MpAFP
2QSW	;	1.5	;	Crystal structure of C-terminal domain of ABC transporter / ATP-binding protein from Enterococcus faecalis
5HFS	;	1.97	;	CRYSTAL STRUCTURE OF C-TERMINAL DOMAIN OF CARGO PROTEINS OF TYPE IX SECRETION SYSTEM
8U5E	;	1.4	;	Crystal Structure of C-terminal domain of Clostridium perfringens Enterotoxin in Space Group P 21 21 21
8U5D	;	1.6	;	Crystal Structure of C-terminal domain of Clostridium perfringens Enterotoxin in Space Group P 41 21 2
5VKD	;	1.749	;	Crystal structure of C-terminal domain of Ebola (Bundibugyo) nucleoprotein in complex with Fab fragment
5W2B	;	2.25	;	Crystal structure of C-terminal domain of Ebola (Reston) nucleoprotein in complex with Fab fragment
4A1F	;	2.5	;	Crystal structure of C-terminal domain of Helicobacter pylori DnaB Helicase
2QQ2	;	2.8	;	Crystal structure of C-terminal domain of Human acyl-CoA thioesterase 7
3OJB	;	3.01	;	Crystal structure of C-terminal domain of human galectin-8
5BQK	;	2.0	;	CRYSTAL STRUCTURE OF C-TERMINAL DOMAIN OF ICP27 PROTEIN FROM HSV-1
5DMR	;	2.8	;	Crystal Structure of C-terminal domain of mouse eRF1 in complex with RNase H domain of RT of Moloney Murine Leukemia Virus
7UP4	;	3.0	;	Crystal structure of C-terminal Domain of MSK1 in complex with covalently bound pyrrolopyrimidine compound 20 (co-crystal)
7UP5	;	2.8	;	Crystal structure of C-terminal Domain of MSK1 in complex with covalently bound pyrrolopyrimidine compound 23 (co-crystal)
7UP8	;	2.9	;	Crystal structure of C-terminal Domain of MSK1 in complex with covalently bound pyrrolopyrimidine compound 27 (co-crystal)
7UP7	;	2.8	;	Crystal structure of C-terminal Domain of MSK1 in complex with covalently bound with literature RSK2 inhibitor indazole cyanoacrylamide compound 26 (soak)
7UP6	;	2.6	;	Crystal structure of C-terminal domain of MSK1 in complex with in covalently bound literature RSK2 inhibitor pyrrolopyrimidine cyanoacrylamide compound 25 (co-crystal)
3KUI	;	2.3	;	Crystal structure of C-terminal domain of PABPC1 in complex with binding region of eRF3a
3KUJ	;	1.4	;	Crystal structure of C-terminal domain of PABPC1 in complex with binding region of eRF3a
7BN3	;	1.93	;	Crystal structure of C-terminal domain of PABPC1 in complex with Nucleoprotein from Human Coronavirus 229E
4WHI	;	1.7	;	Crystal structure of C-terminal domain of penicillin binding protein Rv0907
3MSE	;	2.1	;	Crystal structure of C-terminal domain of PF110239.
2PB9	;	2.7	;	Crystal structure of C-terminal domain of phosphomethylpyrimidine kinase
5ZKG	;	3.3	;	Crystal Structure of C-terminal Domain of Plasmodium vivax p43
3NJR	;	2.7	;	Crystal structure of C-terminal domain of precorrin-6Y C5,15-methyltransferase from Rhodobacter capsulatus
8B0V	;	1.7	;	Crystal structure of C-terminal domain of Pseudomonas aeruginosa LexA G91D mutant
4WIW	;	2.637	;	Crystal structure of C-terminal domain of putative chitinase from Desulfitobacterium hafniense DCB-2
3F9U	;	2.2	;	Crystal structure of C-terminal domain of putative exported cytochrome C biogenesis-related protein from Bacteroides fragilis
4EVU	;	1.45	;	Crystal structure of C-terminal domain of putative periplasmic protein ydgH from S. enterica
3BJN	;	1.65	;	Crystal structure of C-terminal domain of putative transcriptional regulator from Vibrio cholerae, targeted domain 79-240
5YDD	;	1.5	;	Crystal structure of C-terminal domain of Rv1828 from Mycobacterium tuberculosis
2IPQ	;	2.2	;	Crystal structure of C-terminal domain of Salmonella Enterica protein STY4665, PFAM DUF1528
5FGS	;	2.0	;	Crystal structure of C-terminal domain of shaft pilin spaA from Lactobacillus rhamnosus GG - P21212 space group
5FGR	;	2.79	;	Crystal structure of C-terminal domain of shaft pilin spaA from Lactobacillus rhamnosus GG - P21212 space group with Yb Heavy atom
5FAA	;	1.6	;	Crystal structure of C-terminal domain of shaft pilin spaA from Lactobacillus rhamnosus GG, - I422 space group
2QKP	;	1.75	;	Crystal structure of C-terminal domain of SMU_1151c from Streptococcus mutans
5F0Q	;	2.21	;	Crystal structure of C-terminal domain of the human DNA primase large subunit with bound DNA template/RNA primer
5F0S	;	3.0	;	Crystal structure of C-terminal domain of the human DNA primase large subunit with bound DNA template/RNA primer and manganese ion
2QSR	;	3.1	;	Crystal structure of C-terminal domain of transcription-repair coupling factor
4ZCK	;	2.48	;	Crystal Structure of C-terminal Fragment of Escherichia coli BipA/TypA
6M7C	;	3.18	;	Crystal structure of C-terminal fragment of pilus adhesin SpaC from Lactobacillus rhamnosus GG
7BVX	;	3.36	;	Crystal structure of C-terminal fragment of pilus adhesin SpaC from Lactobacillus rhamnosus GG-Iodide soaked
5YXG	;	1.48	;	Crystal structure of C-terminal fragment of SpaD from Lactobacillus rhamnosus GG generated by limited proteolysis
4DQZ	;	2.301	;	Crystal Structure of C-terminal Half of Bacterial Hen1
7EVQ	;	2.6	;	Crystal structure of C-terminal half of lactoferrin obtained by limited proteolysis using pepsin at 2.6 A resolution
4Y32	;	1.7	;	Crystal structure of C-terminal modified Tau peptide-hybrid 109B with 14-3-3sigma
4Y5I	;	1.4	;	Crystal structure of C-terminal modified Tau peptide-hybrid 126B with 14-3-3sigma
4Y3B	;	1.8	;	Crystal structure of C-terminal modified Tau peptide-hybrid 201D with 14-3-3sigma
5HF3	;	1.8	;	Crystal structure of C-terminal modified Tau peptide-hybrid 201D with 14-3-3sigma
6FI5	;	1.7	;	Crystal structure of C-terminal modified Tau peptide-hybrid 3.2d with 14-3-3sigma
6FI4	;	2.0	;	Crystal structure of C-terminal modified Tau peptide-hybrid 3.2e with 14-3-3sigma
6FBY	;	1.5	;	Crystal structure of C-terminal modified Tau peptide-hybrid 4.2b with 14-3-3sigma
6FAW	;	1.4	;	Crystal structure of C-terminal modified Tau peptide-hybrid 4.2c-I with 14-3-3sigma
6FAU	;	1.25	;	Crystal structure of C-terminal modified Tau peptide-hybrid 4.2e-I with 14-3-3sigma
6FAV	;	1.4	;	Crystal structure of C-terminal modified Tau peptide-hybrid 4.2f-I with 14-3-3sigma
6FBW	;	1.45	;	Crystal structure of C-terminal modified Tau peptide-hybrid 4.2f-II with 14-3-3sigma
2QZQ	;	1.9	;	Crystal structure of C-terminal of Aida
5H1D	;	1.494	;	Crystal structure of C-terminal of RhoGDI2
5YRY	;	2.698	;	Crystal structure of C-terminal redox domain of APR1 from Arabidopsis thaliana
4TLQ	;	2.503	;	Crystal structure of C-terminal RNA recognition motif of human ELAV type RNA binding protein-3 at 2.5 Angstrom resolution
4LJM	;	3.0	;	Crystal structure of C-terminal RNA recognition motif of human ETR3
2YV4	;	2.0	;	Crystal Structure of C-terminal Sua5 Domain from Pyrococcus horikoshii Hypothetical Sua5 Protein PH0435
4UON	;	1.81	;	Crystal structure of C-terminal truncated (110-265) Aura virus capsid protease.
5DBT	;	2.811	;	Crystal structure of C-terminal truncated 2-deoxyribose-5-phosphate aldolase (1-201) from Streptococcus suis
3DJ3	;	2.4	;	Crystal Structure of C-terminal Truncated TIP-1 (6-113)
3R3I	;	3.57	;	Crystal Structure of C-terminal truncation of UDP-glucose Pyrophosphorylase of Homo sapiens
5DMA	;	1.53	;	Crystal structure of C-terminal tudor domain in PcrA/UvrD helicase
5I6F	;	3.6	;	Crystal structure of C-terminal variant 1 of Chaetomium thermophilum acetyl-CoA carboxylase
5I6G	;	4.5	;	Crystal structure of C-terminal variant 2 of Chaetomium thermophilum acetyl-CoA carboxylase
6D12	;	2.205	;	Crystal structure of C-terminal xRRM domain of human Larp7 bound to 7SK stem-loop 4 RNA
5M1B	;	3.15	;	Crystal structure of C-terminally tagged apo-UbiD from E. coli
4M9Q	;	2.5	;	Crystal structure of C-terminally truncated Arl13B from Chlamydomonas rheinhardtii bound to GppNHp
4J2Q	;	3.0	;	Crystal structure of C-terminally truncated arrestin reveals mechanism of arrestin activation
7OL9	;	2.9	;	Crystal structure of C-terminally truncated Bacillus subtilis nucleoid occlusion protein (Noc) complexed to the Noc-binding site (NBS)
7NFU	;	2.5	;	Crystal structure of C-terminally truncated Geobacillus thermoleovorans nucleoid occlusion protein Noc
4BWE	;	2.46	;	Crystal structure of C-terminally truncated glypican-1 after controlled dehydration to 86 percent relative humidity
4OV2	;	2.6	;	Crystal structure of C-terminally truncated Neuronal Calcium Sensor (NCS-1) from Rattus norvegicus
4YRU	;	2.8	;	Crystal structure of C-terminally truncated Neuronal Calcium Sensor (NCS-1) from Rattus norvegicus
7FAC	;	2.71	;	Crystal Structure of C-terminus of the non-structural protein 2 from SARS coronavirus
4QL7	;	3.75	;	Crystal structure of C-terminus truncated Alkylhydroperoxide Reductase subunit C (AhpC1-172) from E. coli
4QL9	;	3.4	;	Crystal structure of C-terminus truncated Alkylhydroperoxide Reductase subunit C (AhpC1-182) from E. coli
6ONQ	;	2.71	;	Crystal structure of c-type cytochrome XoxG from Methylobacterium extorquens AM1
1WMZ	;	1.7	;	Crystal Structure of C-type Lectin CEL-I complexed with N-acetyl-D-galactosamine
1WMY	;	2.0	;	Crystal Structure of C-type Lectin CEL-I from Cucumaria echinata
3VYJ	;	2.15	;	Crystal structure of C-type lectin domain of murine dendritic cell inhibitory receptor 2 (apo form)
3VYK	;	1.5	;	Crystal structure of C-type lectin domain of murine dendritic cell inhibitory receptor 2 in complex with N-glycan
4ESX	;	2.2	;	Crystal structure of C. albicans Thi5 complexed with PLP
4ESW	;	1.6	;	Crystal structure of C. albicans Thi5 H66G mutant
3WC1	;	4.18	;	Crystal structure of C. albicans tRNA(His) guanylyltransferase (Thg1) with a G-1 deleted tRNA(His)
3WC2	;	3.641	;	Crystal structure of C. albicans tRNA(His) guanylyltransferase (Thg1) with a tRNA(Phe)(GUG)
3WBZ	;	2.392	;	Crystal structure of C. albicans tRNA(His) guanylyltransferase (Thg1) with ATP
3WC0	;	3.03	;	Crystal structure of C. albicans tRNA(His) guanylyltransferase (Thg1) with GTP
6JIR	;	1.95	;	Crystal structure of C. crescentus beta sliding clamp with PEG bound to putative beta-motif tethering region
6JYK	;	2.0	;	Crystal Structure of C. crescentus free GapR
4AM3	;	3.0	;	Crystal structure of C. crescentus PNPase bound to RNA
4AID	;	2.6	;	Crystal structure of C. crescentus PNPase bound to RNase E recognition peptide
4AIM	;	3.3	;	Crystal structure of C. crescentus PNPase bound to RNase E recognition peptide
7L00	;	1.72	;	Crystal Structure of C. difficile Enoyl-Acyl Carrier Protein Reductase (FabK) in Complex with an Inhibitor
7RCX	;	2.85	;	Crystal structure of C. difficile penicillin-binding protein 2 in apo form
7RCW	;	3.0	;	Crystal structure of C. difficile penicillin-binding protein 2 in complex with ampicillin
7RCY	;	3.0	;	Crystal structure of C. difficile penicillin-binding protein 2 in complex with ceftobiprole
7RD0	;	2.4	;	Crystal structure of C. difficile penicillin-binding protein 3 in apo form
7RCZ	;	2.2	;	Crystal structure of C. difficile SpoVD in complex with ampicillin
1KT9	;	1.98	;	Crystal Structure of C. elegans Ap4A Hydrolase
3KRN	;	3.918	;	Crystal Structure of C. elegans cell-death-related nuclease 5(CRN-5)
7O6L	;	1.5	;	Crystal structure of C. elegans ERH-2
7O6N	;	2.17	;	Crystal structure of C. elegans ERH-2 PID-3 complex
1SZH	;	1.5	;	Crystal Structure of C. elegans HER-1
7X4N	;	2.88	;	Crystal Structure of C. elegans kinesin-4 KLP-12 complexed with tubulin and DARPin
5WNO	;	2.386	;	Crystal structure of C. elegans LET-23 kinase domain complexed with AMP-PNP
5E6N	;	2.102	;	Crystal structure of C. elegans LGG-2
5E6O	;	1.8	;	Crystal structure of C. elegans LGG-2 bound to an AIM/LIR motif
8GCI	;	2.42	;	Crystal structure of C. elegans LIN-42 PAS-B domain
6NOD	;	2.547	;	Crystal structure of C. elegans PUF-8 in complex with RNA
5FIR	;	2.836	;	Crystal structure of C. elegans XRN2 in complex with the XRN2-binding domain of PAXT-1
6GY3	;	2.68	;	Crystal Structure of C. glutamicum AmtR bound to glnA operator DNA
3AAG	;	2.8	;	Crystal structure of C. jejuni pglb C-terminal domain
5T2Y	;	1.94	;	Crystal Structure of C. jejuni PglD in complex with 5-methyl-4-(methylamino)-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylic acid
6YUG	;	1.95	;	Crystal structure of C. parvum GNA1 in complex with acetyl-CoA and glucose 6P.
5GTT	;	2.011	;	Crystal structure of C. perfringens iota-like enterotoxin CPILE-a
5WTZ	;	1.803	;	Crystal structure of C. perfringens iota-like enterotoxin CPILE-a with NAD+
5WU0	;	2.251	;	Crystal structure of C. perfringens iota-like enterotoxin CPILE-a with NADH
3LPZ	;	1.98	;	Crystal structure of C. therm. Get4
3TY9	;	3.12	;	Crystal Structure of C. Thermocellum PNKP Ligase Domain AMP-Adenylate
3TY8	;	2.6	;	Crystal Structure of C. Thermocellum PNKP Ligase Domain Apo Form
3TY5	;	2.4	;	Crystal Structure of C. thermocellum PNKP Ligase domain in complex with ATP
7OPK	;	3.0	;	Crystal structure of C. thermophilum Xrn2
3KF8	;	2.4	;	Crystal structure of C. tropicalis Stn1-ten1 complex
4Q3Y	;	1.4	;	Crystal structure of C. violaceum phenylalanine hydroxylase D139A mutation
4Q3W	;	1.4	;	Crystal structure of C. violaceum phenylalanine hydroxylase D139E mutation
4Q3Z	;	1.35	;	Crystal structure of C. violaceum phenylalanine hydroxylase D139K mutation
4Q3X	;	1.35	;	Crystal structure of C. violaceum phenylalanine hydroxylase D139N mutation
6X6R	;	2.02	;	Crystal structure of C.difficile ribosyltransferase CDTa in complex with pCl-phenylthioDADMeImmA
2EF8	;	1.95	;	Crystal structure of C.EcoT38IS
3X0D	;	2.15	;	Crystal structure of C.elegans PRMT7 in complex with SAH (P43212)
3WST	;	2.39	;	Crystal structure of C.elegans PRMT7 in complex with SAH(P31)
4PSG	;	2.8	;	Crystal Structure of C.elegans Thymidylate Synthase in complex with an inhibitor N(4)OHdCMP
4IRR	;	2.48	;	Crystal Structure of C.elegans Thymidylate Synthase in Complex with dUMP
5NOO	;	2.9	;	Crystal Structure of C.elegans Thymidylate Synthase in Complex with dUMP and Tomudex
8K8C	;	2.06	;	Crystal structure of C/EBPalpha BZIP domain bound to a high affinity DNA
1NWQ	;	2.8	;	CRYSTAL STRUCTURE OF C/EBPALPHA-DNA COMPLEX
8K8D	;	2.2	;	Crystal structure of C/EBPbeta BZIP domain bound to a high affinity DNA
1GU5	;	2.1	;	Crystal structure of C/EBPBETA BZIP homodimer bound to a DNA fragment from the MIM-1 promoter
1GTW	;	1.85	;	crystal structure of C/EBPbeta bZip homodimer bound to a DNA fragment from the tom-1A promoter
1GU4	;	1.8	;	Crystal structure of C/EBPBETA BZIP homodimer bound to a high affinity DNA fragment
2E43	;	2.1	;	Crystal structure of C/EBPbeta Bzip homodimer K269A mutant bound to A High Affinity DNA fragment
2E42	;	1.8	;	Crystal structure of C/EBPbeta Bzip homodimer V285A mutant bound to A High Affinity DNA fragment
6D0U	;	3.25	;	Crystal structure of C05 V110P/A117E mutant bound to H3 influenza hemagglutinin, HA1 subunit
5UMN	;	1.97	;	Crystal structure of C05 VPGSGW mutant bound to H3 influenza hemagglutinin, HA1 subunit
3NOO	;	1.03	;	Crystal Structure of C101A Isocyanide Hydratase from Pseudomonas fluorescens
3NOQ	;	1.0	;	Crystal Structure of C101S Isocyanide Hydratase from Pseudomonas fluorescens
4K2H	;	2.2	;	Crystal structure of C103A mutant of DJ-1 superfamily protein STM1931 from Salmonella typhimurium
3ROR	;	2.0	;	Crystal structure of C105S mutant of Mycobacterium tuberculosis methionine aminopeptidase
7EHK	;	2.0	;	Crystal structure of C107S mutant of FfIBP
4FZ8	;	2.66	;	Crystal structure of C11 Fab, an ADCC mediating anti-HIV-1 antibody.
4MKK	;	1.45	;	Crystal structure of C115A mutant L-methionine gamma-lyase from Citrobacter freundii modified by allicine
4QAL	;	1.5	;	Crystal structure of C117A mutant of human acidic fibroblast growth factor
3FJ8	;	2.0	;	Crystal structure of C117I mutant of Human acidic fibroblast growth factor
4QC4	;	1.491	;	Crystal structure of C117S mutant of human acidic fibroblast growth factor
4QBV	;	1.497	;	Crystal structure of C117T mutant of human acidic fibroblast growth factor in sodium citrate buffer
4QBC	;	1.519	;	Crystal structure of C117T mutant of human acidic fibroblast growth factor in sodium formate buffer
2NWR	;	1.5	;	Crystal structure of C11N mutant of KDO8P Synthase in complex with PEP
4G8G	;	2.4	;	Crystal Structure of C12C TCR-HA B2705-KK10
4G9F	;	1.9	;	Crystal Structure of C12C TCR-HLAB2705-KK10-L6M
5IXR	;	2.5	;	Crystal Structure of C139A nostoc H-NOX domain with imidazole
7U09	;	2.1	;	Crystal Structure of C13B8 Fab in complex with SARS-CoV-2 S fusion peptide
7U0E	;	2.1	;	Crystal Structure of C13C9 Fab in complex with SARS-CoV-2 S fusion peptide
4KTI	;	1.839	;	Crystal Structure of C143A Xathomonas campestris OleA
4KTM	;	2.36	;	Crystal Structure of C143S Xanthomonas campestris OleA
4KU3	;	1.97	;	Crystal Structure of C143S Xanthomonas Campestris OleA bound with myristic acid and myrisotoyl-CoA
6UHN	;	1.92	;	Crystal Structure of C148 mGFP-cDNA-1
6UHO	;	1.95	;	Crystal Structure of C148 mGFP-cDNA-2
6UHQ	;	2.85	;	Crystal Structure of C148 mGFP-cDNA-3
6UHP	;	2.9	;	Crystal Structure of C148 mGFP-ncDNA-1
6UHL	;	1.91	;	Crystal Structure of C148 mGFP-scDNA-1
6UHR	;	3.0	;	Crystal Structure of C148 mGFP-scDNA-2
5EIN	;	1.7	;	Crystal structure of C148A mutant of LysY from Thermus thermophilus in complex with NADP+ and LysW-gamma-aminoadipic acid
1GZL	;	1.8	;	Crystal structure of C14linkmid/IQN17: a cross-linked inhibitor of HIV-1 entry bound to the gp41 hydrophobic pocket
7C5J	;	1.98	;	Crystal Structure of C150A mutant of Glyceraldehyde-3-phosphate dehydrogenase1 from Escherichia coli at 1.98 Angstrom resolution
7C5I	;	2.48	;	Crystal Structure of C150A mutant of Glyceraldehyde-3-phosphate-dehydrogenase1 from Escherichia coli complexed with PO4 at 2.49 Angstrom resolution
7C5N	;	1.99	;	Crystal Structure of C150A+H177A mutant of Glyceraldehyde-3-phosphate-dehydrogenase1 from Escherichia coli at 2.0 Angstrom resolution
7C5M	;	1.8	;	Crystal Structure of C150A+H177A mutant of Glyceraldehyde-3-phosphate-dehydrogenase1 from Escherichia coli complexed with G3P at 1.8 Angstrom resolution
7C5R	;	2.31	;	Crystal Structure of C150S mutant Glyceraldehyde-3-phosphate dehydrogenase1 from Escherichia coli complexed with BPG at 2.31 Angstrom resolution
7C5L	;	2.09	;	Crystal Structure of C150S mutant of Glyceraldehyde-3-phosphate-dehydrogenase1 from Escherichia coli at 2.1 Angstrom resolution
7C5K	;	2.68	;	Crystal Structure of C150S mutant of Glyceraldehyde-3-phosphate-dehydrogenase1 from Escherichia coli complexed with G3P at 2.69 Angstrom resolution
7C5G	;	1.98	;	Crystal Structure of C150S mutant of Glyceraldehyde-3-phosphate-dehydrogenase1 from Escherichia coli complexed with PO4 at 1.98 Angstrom resolution
3L4S	;	2.2	;	Crystal structure of C151G mutant of Glyceraldehyde 3-phosphate dehydrogenase 1 (GAPDH1) from methicillin resistant Staphylococcus aureus MRSA252 complexed with NAD and G3P
3K9Q	;	2.5	;	Crystal structure of C151G mutant of Glyceraldehyde 3-phosphate dehydrogenase 1 from Methicillin resistant Staphylococcus aureus (MRSA252) at 2.5 angstrom resolution
3KV3	;	2.5	;	Crystal structure of C151S mutant of Glyceraldehyde-3-phosphate dehydrogenase 1 (GAPDH 1)from methicillin resistant Staphylococcus aureus MRSA252 complexed with NAD and G3P
3HQ4	;	2.2	;	Crystal Structure of C151S mutant of Glyceraldehyde-3-phosphate dehydrogenase 1 (GAPDH1) complexed with NAD from Staphylococcus aureus MRSA252 at 2.2 angstrom resolution
3KSD	;	2.2	;	Crystal Structure of C151S+H178N mutant of Glyceraldehyde-3-phosphate dehydrogenase 1 (GAPDH1) from Staphylococcus aureus MRSA252 complexed with NAD at 2.2 angstrom resolution
3KSZ	;	2.6	;	Crystal Structure of C151S+H178N mutant of Glyceraldehyde-3-phosphate-dehydrogenase 1 (GAPDH 1) from Staphylococcus aureus MRSA252 complexed with NAD and G3P
4QA0	;	2.242	;	Crystal structure of C153F HDAC8 in complex with SAHA
3CIF	;	2.0	;	Crystal Structure of C153S mutant glyceraldehyde 3-phosphate dehydrogenase from Cryptosporidium parvum
5GW9	;	1.65	;	Crystal structure of C163, a backbone circularized G-CSF
5ZO6	;	1.7	;	Crystal structure of C166, a backbone circularized G-CSF
4Q91	;	1.799	;	Crystal structure of C16A/K12V/C117V/P134V mutant of human acidic fibroblast growth factor
4QO3	;	2.047	;	Crystal structure of C16S/N18S/K12V/C117V/P134V mutant of human acidic fibroblast growth factor
4Q9P	;	1.8	;	Crystal structure of C16T/K12V/C117V/P134V mutant of human acidic fibroblast growth factor
8HPC	;	2.52	;	Crystal structure of C171A Mutant of N-carbamyl-D-amino acid amidohydrolase complexed with N-carbamyl-D-Hydroxyphenylglycine
1UF4	;	2.15	;	Crystal structure of C171A/V236A Mutant of N-carbamyl-D-amino acid amidohydrolase
1UF5	;	1.6	;	Crystal structure of C171A/V236A Mutant of N-carbamyl-D-amino acid amidohydrolase complexed with N-carbamyl-D-methionine
1UF8	;	1.8	;	Crystal structure of C171A/V236A Mutant of N-carbamyl-D-amino acid amidohydrolase complexed with N-carbamyl-D-Phenylalanine
1UF7	;	1.9	;	Crystal structure of C171A/V236A Mutant of N-carbamyl-D-amino acid amidohydrolase complexed with N-carbamyl-D-valine
6ZL7	;	1.5	;	CRYSTAL STRUCTURE OF C173S MUTATION IN THE PMGL2 ESTERASE FROM PERMAFROST METAGENOMIC LIBRARY
6UHK	;	1.9	;	Crystal Structure of C176 mGFP
3SZG	;	2.25	;	Crystal structure of C176A glutamine-dependent NAD+ synthetase from M. tuberculosis bound to AMP/PPi and NaAD+
3SDB	;	2.0017	;	Crystal structure of C176A mutant of glutamine-dependent NAD+ synthetase from M. tuberculosis in apo form
3SEQ	;	2.7342	;	Crystal structure of C176A mutant of glutamine-dependent NAD+ synthetase from M. tuberculosis in complex with AMPCPP and NaAD+
3SEZ	;	2.6529	;	Crystal structure of C176A mutant of glutamine-dependent NAD+ synthetase from M. tuberculosis in complex with ATP and NaAD+
2ABZ	;	2.16	;	Crystal structure of C19A/C43A mutant of leech carboxypeptidase inhibitor in complex with bovine carboxypeptidase A
5ZLQ	;	2.0	;	Crystal Structure of C1orf123
4QQ2	;	1.801	;	Crystal structure of C1QL1
4QPY	;	2.384	;	Crystal structure of C1QL2
4QQL	;	2.39	;	Crystal structure of C1QL3 in P1 space group
4QQH	;	1.2	;	Crystal structure of C1QL3 in space group H32
4QQO	;	2.031	;	Crystal structure of C1QL3 mutant D205A
4QQP	;	1.464	;	Crystal structure of C1QL3 mutant D207A
2Z0U	;	2.2	;	Crystal structure of C2 domain of KIBRA protein
4RYU	;	2.04	;	Crystal Structure of C2 form of E112A Mutant of Stationary Phase Survival Protein (SurE) from Salmonella typhimurium
4XER	;	1.97	;	Crystal Structure of C2 form of E112A/H234A Mutant of Stationary Phase Survival Protein (SurE) from Salmonella typhimurium
1TEE	;	2.9	;	Crystal structure of C205F mutant of PKS18 from Mycobacterium tuberculosis
3UGK	;	2.01	;	Crystal Structure of C205S mutant and Saccharopine Dehydrogenase from Saccharomyces cerevisiae.
4YJK	;	1.68	;	Crystal structure of C212S mutant of Shewanella oneidensis MR-1 uridine phosphorylase
6H1D	;	1.94	;	Crystal structure of C21orf127-TRMT112 in complex with SAH
6H1E	;	1.9	;	Crystal structure of C21orf127-TRMT112 in complex with SAH and H4 peptide
5CP1	;	1.801	;	Crystal structure of C239S mutant of a novel disulfide oxidoreductase from Deinococcus radiodurans
4ATN	;	1.95	;	Crystal structure of C2498 2'-O-ribose methyltransferase RlmM from Escherichia coli
4AUK	;	1.9	;	Crystal structure of C2498 2'-O-ribose methyltransferase RlmM from Escherichia coli
4B17	;	2.6	;	Crystal structure of C2498 2'-O-ribose methyltransferase RlmM from Escherichia coli in complex with S-adenosylmethionine
5D2N	;	2.099	;	Crystal structure of C25-NLV-HLA-A2 complex
2Y5D	;	1.4	;	Crystal structure of C296A mutant of the box pathway encoded ALDH from Burkholderia xenovorans LB400
2IPW	;	2.0	;	Crystal Structure of C298A W219Y Aldose Reductase complexed with Dichlorophenylacetic acid
2ISF	;	2.0	;	Crystal Structure of C298A W219Y Aldose Reductase complexed with Phenylacetic Acid
6CFE	;	1.994	;	Crystal structure of C2S5: A computationally designed immunogen to target Carbohydrate-Occluded Epitopes on the HIV envelope
7R80	;	2.9	;	Crystal structure of C3 TCR complex with QW9-bound HLA-B*5301
6Q6U	;	1.81	;	Crystal structure of C39S mutant of thioredoxin h1 from Chlamydomonas reinhardtii
1JQO	;	3.0	;	Crystal structure of C4-form phosphoenolpyruvate carboxylase from maize
1CM5	;	2.3	;	CRYSTAL STRUCTURE OF C418A,C419A MUTANT OF PFL FROM E.COLI
4R4M	;	1.922	;	Crystal structure of C42L cGMP dependent protein kinase I alpha (PKGI alpha) leucine zipper
6VWY	;	1.83	;	Crystal structure of C45G/T50C D. vulgaris carbon monoxide dehydrogenase (anaerobic)
6CBU	;	1.2	;	Crystal structure of C4S3: A computationally designed immunogen to target Carbohydrate-Occluded Epitopes on the HIV envelope
4BWR	;	1.74	;	Crystal structure of c5321: a protective antigen present in uropathogenic Escherichia coli strains displaying an SLR fold
7XI6	;	2.3	;	Crystal structure of C56 from pSSVi
6PDX	;	3.993	;	Crystal structure of C585 Fab in complex with influenza virus hemagglutinin from A/Switzerland/9715293/2013 (H3N2)
4E0S	;	4.21	;	Crystal Structure of C5b-6
4A5W	;	3.5	;	Crystal structure of C5b6
3UBT	;	2.502	;	Crystal Structure of C71S Mutant of DNA Cytosine-5 Methyltransferase M.HaeIII Bound to DNA
2HSH	;	1.35	;	Crystal structure of C73S mutant of human thioredoxin-1 oxidized with H2O2
1OQR	;	1.65	;	Crystal structure of C73S mutant of putidaredoxin, a [2Fe-2S] ferredoxin from Pseudomonas putida, at 1.65A resolution
1OQQ	;	1.47	;	Crystal structure of C73S/C85S mutant of putidaredoxin, a [2Fe-2S] ferredoxin from Pseudomonas putida, at 1.47A resolution
7U0A	;	1.7	;	Crystal Structure of C77G12 Fab in complex with SARS-CoV-2 S fusion peptide
1JS2	;	1.9	;	Crystal structure of C77S HiPIP: a serine ligated [4Fe-4S] cluster
7RL8	;	1.95	;	Crystal Structure of C79A Mutant of Class D beta-lactamase from Clostridium difficile 630
5Y38	;	2.8	;	Crystal structure of C7orf59-HBXIP complex
3FJH	;	1.9	;	Crystal structure of C83A mutant of Human acidic fibroblast growth factor
3FJE	;	2.1	;	Crystal structure of C83S mutant of Human acidic fibroblast growth factor
3FJF	;	1.9	;	Crystal structure of C83T mutant of Human acidic fibroblast growth factor
3FJJ	;	1.9	;	Crystal structure of C83V mutant of Human acidic fibroblast growth factor
7EUL	;	1.45	;	Crystal structure of C86H-H196S mutant of N(omega)-hydroxy-L-arginine hydrolase
7EUQ	;	1.8	;	Crystal structure of C86H-Y124N-G126H-H196S mutant of N(omega)-hydroxy-L-arginine hydrolase
5EW7	;	1.75	;	Crystal structure of C9ORF72 Antisense CCCCGG repeat RNA associated with Lou Gehrig's disease and frontotemporal dementia, crystallized with Ba2+
5EW4	;	1.47	;	Crystal structure of C9ORF72 Antisense CCCCGG repeat RNA associated with Lou Gehrig's disease and frontotemporal dementia, crystallized with Sr2+
6O8L	;	1.36	;	Crystal Structure of C9S apo and reduced Sulfide-responsive transcriptional repressor (SqrR) from Rhodobacter capsulatus.
6O8M	;	1.46	;	Crystal Structure of C9S apo Sulfide-responsive transcriptional repressor (SqrR) from Rhodobacter capsulated bound to diamide (tetramethylazodicarboxamide).
6O8O	;	2.5	;	Crystal Structure of C9S disulfide state of Sulfide-responsive transcriptional repressor (SqrR) from Rhodobacter capsulatus.
6O8N	;	1.95	;	Crystal Structure of C9S tetrasulfide state of Sulfide-responsive transcriptional repressor (SqrR) from Rhodobacter capsulatus.
3RYD	;	2.37	;	Crystal structure of Ca bound IMPase family protein from Staphylococcus aureus
4N1G	;	1.5	;	Crystal Structure of Ca(2+)- discharged F88Y obelin mutant from Obelia longissima at 1.50 Angstrom resolution
4MRY	;	1.299	;	Crystal Structure of Ca(2+)- discharged Y138F obelin mutant from Obelia longissima at 1.30 Angstrom resolution
4NQG	;	1.301	;	Crystal Structure of Ca(2+)-regulated photoprotein mitrocomin from Jellyfish Mitrocoma cellularia at 1.3 Angstrom resolution
1J35	;	1.8	;	Crystal Structure of Ca(II)-bound Gla Domain of Factor IX Complexed with Binding Protein
6K22	;	2.747	;	Crystal structure of Ca-bound human Annexin A5 in low salt condition
6K25	;	2.401	;	Crystal structure of Ca-unbound human Annexin A5 in low salt condition
2ZWO	;	2.07	;	Crystal structure of Ca2 site mutant of Pro-S324A
4O03	;	3.38	;	Crystal structure of Ca2+ bound prothrombin deletion mutant residues 146-167
2ZN9	;	2.4	;	Crystal structure of Ca2+-bound form of des3-20ALG-2
2ZRS	;	3.1	;	Crystal structure of Ca2+-bound form of des3-23ALG-2
3AAJ	;	2.4	;	Crystal structure of Ca2+-bound form of des3-23ALG-2deltaGF122
3SUI	;	1.95	;	Crystal structure of ca2+-calmodulin in complex with a trpv1 c-terminal peptide
8A9S	;	2.1	;	Crystal structure of Ca2+-discharged obelin in complex with coelenteramine-v
2ZND	;	1.7	;	Crystal structure of Ca2+-free form of des3-20ALG-2
4NZQ	;	2.807	;	Crystal structure of Ca2+-free prothrombin deletion mutant residues 146-167
2RGI	;	1.6	;	Crystal structure of Ca2+-free S100A2 at 1.6 A resolution
2HQW	;	1.9	;	Crystal Structure of Ca2+/Calmodulin bound to NMDA Receptor NR1C1 peptide
1L7Z	;	2.3	;	Crystal structure of Ca2+/Calmodulin complexed with myristoylated CAP-23/NAP-22 peptide
3OXQ	;	2.55	;	Crystal Structure of Ca2+/CaM-CaV1.2 pre-IQ/IQ domain complex
3DVM	;	2.6	;	Crystal Structure of Ca2+/CaM-CaV2.1 IQ domain complex
3DVJ	;	2.8	;	Crystal Structure of Ca2+/CaM-CaV2.2 IQ domain (without cloning artifact, HM to TV) complex
3DVE	;	2.35	;	Crystal Structure of Ca2+/CaM-CaV2.2 IQ domain complex
3DVK	;	2.3	;	Crystal Structure of Ca2+/CaM-CaV2.3 IQ domain complex
4GOW	;	2.6	;	Crystal Structure of Ca2+/CaM:Kv7.4 (KCNQ4) B helix complex
2ZWP	;	2.4	;	Crystal structure of Ca3 site mutant of Pro-S324A
8Q40	;	2.21	;	Crystal structure of cA4 activated Can2 in complex with a cleaved DNA substrate
6WXX	;	3.0	;	crystal structure of cA4-activated Card1
6XL1	;	1.95	;	crystal structure of cA4-activated Card1(D294N)
8Q42	;	1.97	;	Crystal structure of cA4-bound Can2 (E341A) in complex with oligo-A DNA
8Q43	;	2.28	;	Crystal structure of cA4-bound Can2 (E341A) in complex with oligo-C DNA
8Q44	;	2.3	;	Crystal structure of cA4-bound Can2 (E364R) in complex with oligo-T DNA
8Q3Z	;	3.15	;	Crystal structure of cA4-bound Can2 from Thermoanaerobacter brockii
4JRX	;	2.3	;	Crystal Structure of CA5 TCR-HLA B*3505-LPEP complex
6WXY	;	2.1	;	crystal structure of cA6-bound Card1
6UJ5	;	1.8	;	Crystal structure of CAB1 Pantothenate Kinase from Saccharomyces cerevisiae
7T1H	;	1.9	;	Crystal structure of CAB1 Pantothenate Kinase from Saccharomyces cerevisiae in complex with compound YU281445
7T1G	;	2.0	;	Crystal structure of CAB1 Pantothenate Kinase from Saccharomyces cerevisiae in complex with compound YU385595
7T1I	;	2.4	;	Crystal structure of CAB1 Pantothenate Kinase from Saccharomyces cerevisiae in complex with compound YU385597
2QA2	;	2.7	;	Crystal structure of CabE, an aromatic hydroxylase from angucycline biosynthesis, determined to 2.7 A resolution
3O4Y	;	2.2	;	Crystal structure of CAD domain of the Plasmodium Vivax CDPK, PVX_11610
3LND	;	2.82	;	Crystal structure of cadherin-6 EC12 W4A
1ZXK	;	2.0	;	Crystal Structure of Cadherin8 EC1 domain
7QC0	;	3.11	;	Crystal structure of Cadmium translocating P-type ATPase
1FE0	;	1.75	;	CRYSTAL STRUCTURE OF CADMIUM-HAH1
6KGE	;	2.0	;	Crystal structure of CaDoc0917(R16D)-CaCohA2 complex at pH 5.5
6KGF	;	2.3	;	Crystal structure of CaDoc0917(R16D)-CaCohA2 complex at pH 8.2
6KGC	;	1.6	;	Crystal structure of CaDoc0917(R49D)-CaCohA2 complex at pH 5.4
6KGD	;	1.65	;	Crystal structure of CaDoc0917(R49D)-CaCohA2 complex at pH 8.0
4Y9L	;	2.27	;	Crystal Structure of Caenorhabditis elegans ACDH-11
4Y9J	;	1.8	;	Crystal Structure of Caenorhabditis elegans ACDH-11 in complex with C11-CoA
6M6S	;	1.6	;	Crystal structure of Caenorhabditis elegans Dicer-related helicase 3 (DRH-3) C-terminal domain with 5'-ppp 12-mer dsRNA
6M6R	;	1.89	;	Crystal structure of Caenorhabditis elegans Dicer-related helicase 3 (DRH-3) C-terminal domain with 5'-ppp 8-mer ssRNA
6M6Q	;	2.8	;	Crystal structure of Caenorhabditis elegans Dicer-related helicase 3 (DRH-3) N-terminal domain
3VV1	;	1.5	;	Crystal Structure of Caenorhabditis elegans galectin LEC-6
8GU3	;	3.01	;	Crystal structure of Caenorhabditis elegans METT-10 methyltransferase domain
1D4X	;	1.75	;	Crystal Structure of Caenorhabditis Elegans Mg-ATP Actin Complexed with Human Gelsolin Segment 1 at 1.75 A resolution.
6N2G	;	3.003	;	Crystal structure of Caenorhabditis elegans NAP1
8HAZ	;	2.66	;	Crystal structure of Caenorhabditis elegans NMAD-1 in complex with ligand I
8HB2	;	3.06	;	Crystal structure of Caenorhabditis elegans NMAD-1 in complex with ligand II
8HBB	;	3.09	;	Crystal structure of Caenorhabditis elegans NMAD-1 in complex with ligand III
8H68	;	2.2	;	Crystal structure of Caenorhabditis elegans NMAD-1 in complex with NOG and Mg(II)
6QIR	;	1.531	;	Crystal structure of CAG repeats with synthetic CMBL3a compound (model I)
6QIS	;	1.99	;	Crystal structure of CAG repeats with synthetic CMBL3a compound (model II)
6QIT	;	1.501	;	Crystal structure of CAG repeats with synthetic CMBL3b compound
2PT7	;	2.4	;	Crystal structure of Cag VirB11 (HP0525) and an inhibitory protein (HP1451)
1S2X	;	1.9	;	Crystal structure of Cag-Z from Helicobacter pylori
3CWX	;	2.3	;	Crystal structure of cagd from helicobacter pylori pathogenicity island
2G3V	;	2.3	;	Crystal structure of CagS (HP0534, Cag13) from Helicobacter pylori
6IQT	;	1.922	;	Crystal Structure of CagV, a VirB8 homolog of T4SS from Helicobacter pylori Strain 26695
5WM5	;	1.797	;	Crystal Structure of CahJ in Complex with 5-Methylsalicyl Adenylate
5WM4	;	1.781	;	Crystal Structure of CahJ in Complex with 6-Methylsalicyl Adenylate
5WM7	;	1.777	;	Crystal Structure of CahJ in Complex with AMP
5WM6	;	2.0	;	Crystal Structure of CahJ in Complex with Benzoyl Adenylate
5WM3	;	1.679	;	Crystal Structure of CahJ in Complex with Salicyl Adenylate
5WM2	;	1.548	;	Crystal Structure of CahJ in Complex with Salicylic Acid and AMP
1XVV	;	2.4	;	Crystal Structure of CaiB mutant D169A in complex with carnitinyl-CoA
1XVU	;	2.4	;	Crystal Structure of CaiB mutant D169A in complex with Coenzyme A
1XA3	;	1.85	;	Crystal structure of CaiB, a type III CoA transferase in carnitine metabolism
1XA4	;	1.9	;	Crystal structure of CaiB, a type III CoA transferase in carnitine metabolism
4M8J	;	3.294	;	Crystal structure of CaiT R262E bound to gamma-butyrobetaine
5X9A	;	1.85	;	Crystal structure of calaxin with calcium
5YPX	;	2.64	;	Crystal structure of calaxin with magnesium
4K6G	;	1.5	;	Crystal structure of CALB from Candida antarctica
4K6K	;	1.6	;	Crystal structure of CALB mutant D223G from Candida antarctica
4K5Q	;	1.49	;	Crystal structure of CALB mutant DGLM from Candida antarctica
4K6H	;	1.6	;	Crystal structure of CALB mutant L278M from Candida antarctica
5B8I	;	1.85	;	Crystal structure of Calcineurin A and Calcineurin B in complex with FKBP12 and FK506 from Coccidioides immitis RS
3LL8	;	2.0	;	Crystal Structure of Calcineurin in Complex with AKAP79 Peptide
4F0Z	;	1.7	;	Crystal Structure of Calcineurin in Complex with the Calcineurin-Inhibiting Domain of the African Swine Fever Virus Protein A238L
1M63	;	2.8	;	Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes
3GVE	;	1.25	;	Crystal structure of calcineurin-like phosphoesterase YfkN from Bacillus subtilis
1Y1A	;	2.3	;	CRYSTAL STRUCTURE OF CALCIUM AND INTEGRIN BINDING PROTEIN
5HLO	;	2.1	;	Crystal structure of calcium and zinc-bound human S100A8 in space group C2221
5HLV	;	2.2	;	Crystal structure of calcium and zinc-bound human S100A8 in space group P212121
2OA0	;	3.4	;	Crystal structure of Calcium ATPase with bound ADP and cyclopiazonic acid
2O9J	;	2.65	;	Crystal structure of calcium atpase with bound magnesium fluoride and cyclopiazonic acid
1SU4	;	2.4	;	Crystal structure of calcium ATPase with two bound calcium ions
3RB5	;	2.35	;	Crystal structure of calcium binding domain CBD12 of CALX1.1
3L19	;	2.14	;	Crystal structure of calcium binding domain of CpCDPK3, cgd5_820
2NXQ	;	2.4	;	Crystal structure of calcium binding protein 1 from Entamoeba histolytica: a novel arrangement of EF hand motifs
4OCI	;	2.009	;	Crystal Structure of Calcium Binding Protein-5 from Entamoeba histolytica and its involvement in initiation of phagocytosis of human erythrocytes
3EVU	;	1.75	;	Crystal structure of Calcium bound dimeric GCAMP2
3EVV	;	2.6	;	Crystal Structure of Calcium bound dimeric GCAMP2 (#2)
1K96	;	1.44	;	CRYSTAL STRUCTURE OF CALCIUM BOUND HUMAN S100A6
1K9K	;	1.76	;	CRYSTAL STRUCTURE OF CALCIUM BOUND HUMAN S100A6
3EVR	;	2.0	;	Crystal structure of Calcium bound monomeric GCAMP2
1K9P	;	1.9	;	CRYSTAL STRUCTURE OF CALCIUM FREE (OR APO) HUMAN S100A6
1UD4	;	2.15	;	Crystal structure of calcium free alpha amylase from Bacillus sp. strain KSM-K38 (AmyK38, in calcium containing solution)
6JCO	;	2.88	;	Crystal structure of calcium free human gelsolin amyloid mutant D187N
6JEH	;	2.95	;	Crystal structure of calcium free human gelsolin amyloid mutant D187Y
6JEG	;	2.975	;	Crystal structure of calcium free human gelsolin amyloid mutant G167R
3ULG	;	3.2	;	Crystal structure of Calcium-Binding Protein-1 from Entamoeba histolytica in complex with barium
4EVH	;	2.6	;	Crystal structure of calcium-bound alpha-1 giardin
4MDV	;	2.5	;	Crystal structure of calcium-bound annexin (Sm)1
3BRX	;	2.5	;	Crystal Structure of calcium-bound cotton annexin Gh1
3ESQ	;	1.7	;	Crystal Structure of Calcium-bound D,D-heptose 1.7-bisphosphate phosphatase from E. Coli
3L1U	;	1.95	;	Crystal structure of Calcium-bound GmhB from E. coli.
5A1M	;	1.81	;	Crystal structure of calcium-bound human adseverin domain A3
1KXR	;	2.07	;	Crystal Structure of Calcium-Bound Protease Core of Calpain I
1MDW	;	1.95	;	Crystal Structure of Calcium-Bound Protease Core of Calpain II Reveals the Basis for Intrinsic Inactivation
1LJ7	;	3.15	;	Crystal structure of calcium-depleted human C-reactive protein from perfectly twinned data
1K8U	;	1.15	;	CRYSTAL STRUCTURE OF CALCIUM-FREE (OR APO) HUMAN S100A6; CYS3MET MUTANT (SELENOMETHIONINE DERIVATIVE)
1UD2	;	2.13	;	Crystal structure of calcium-free alpha-amylase from Bacillus sp. strain KSM-K38 (AmyK38)
5A1K	;	2.9	;	Crystal structure of calcium-free human adseverin domains A1-A3
3FFN	;	3.0	;	Crystal structure of calcium-free human gelsolin
5HYD	;	2.3	;	Crystal structure of calcium-free human S100Z
1JUO	;	2.2	;	Crystal Structure of Calcium-free Human Sorcin: A Member of the Penta-EF-Hand Protein Family
2PKC	;	1.5	;	CRYSTAL STRUCTURE OF CALCIUM-FREE PROTEINASE K AT 1.5 ANGSTROMS RESOLUTION
1SL7	;	2.2	;	Crystal structure of calcium-loaded apo-obelin from Obelia longissima
5K8Q	;	1.739	;	Crystal Structure of Calcium-loaded Calmodulin in complex with STRA6 CaMBP2-site peptide.
5DKR	;	1.742	;	Crystal Structure of Calcium-loaded S100B bound to SBi29
4PDZ	;	1.73	;	Crystal Structure of Calcium-loaded S100B bound to SBi4172
4FQO	;	1.65	;	Crystal Structure of Calcium-Loaded S100B Bound to SBi4211
5DKQ	;	1.591	;	Crystal Structure of Calcium-loaded S100B bound to SBi4214
5DKN	;	1.528	;	Crystal Structure of Calcium-loaded S100B bound to SBi4225
4PE0	;	1.08	;	Crystal Structure of Calcium-loaded S100B bound to SBi4434
5ER4	;	1.813	;	Crystal Structure of Calcium-loaded S100B bound to SC0025
4PE1	;	1.576	;	Crystal Structure of Calcium-loaded S100B bound to SC124
4PE4	;	2.178	;	Crystal Structure of Calcium-loaded S100B bound to SC1475
4PE7	;	1.652	;	Crystal Structure of Calcium-loaded S100B bound to SC1982
5ER5	;	1.26	;	Crystal Structure of Calcium-loaded S100B bound to SC1990
1DTL	;	2.15	;	CRYSTAL STRUCTURE OF CALCIUM-SATURATED (3CA2+) CARDIAC TROPONIN C COMPLEXED WITH THE CALCIUM SENSITIZER BEPRIDIL AT 2.15 A RESOLUTION
3B32	;	1.6	;	Crystal Structure of Calcium-Saturated Calmodulin N-Terminal Domain Fragment, Residues 1-75
3IFK	;	2.03	;	Crystal Structure Of Calcium-Saturated Calmodulin N-terminal Domain Fragment, Residues 1-90
1TCF	;	1.9	;	CRYSTAL STRUCTURE OF CALCIUM-SATURATED RABBIT SKELETAL TROPONIN C
8J8T	;	1.81	;	Crystal structure of calcium-saturated SRCR domain 11 of DMBT1
1HKX	;	2.65	;	Crystal structure of calcium/calmodulin-dependent protein kinase
4G9A	;	2.001	;	Crystal structure of calcium2+-bound wild-type CD23 lectin domain
4G96	;	2.25	;	Crystal structure of calcium2+-free wild-type CD23 lectin domain
4J6J	;	1.9	;	Crystal structure of calcium2+-free wild-type CD23 lectin domain (crystal form A)
4J6K	;	2.3	;	Crystal structure of calcium2+-free wild-type CD23 lectin domain (crystal form B)
4J6L	;	3.15	;	Crystal structure of calcium2+-free wild-type CD23 lectin domain (crystal form C)
4J6M	;	2.48	;	Crystal structure of calcium2+-free wild-type CD23 lectin domain (crystal form D)
4J6N	;	2.85	;	Crystal structure of calcium2+-free wild-type CD23 lectin domain (crystal form E)
4J6P	;	1.9	;	Crystal structure of calcium2+-free wild-type CD23 lectin domain (crystal form F)
4J6Q	;	2.539	;	Crystal structure of calcium2+-free wild-type CD23 lectin domain (crystal form G)
1PMJ	;	1.55	;	Crystal structure of Caldicellulosiruptor saccharolyticus CBM27-1
1PMH	;	1.06	;	Crystal structure of Caldicellulosiruptor saccharolyticus CBM27-1 in complex with mannohexaose
2QPL	;	2.1	;	Crystal structure of calf spleen purine nucleoside phosphorylase complexed to a novel purine analogue
1LV8	;	2.3	;	Crystal structure of calf spleen purine nucleoside phosphorylase in a new space group with full trimer in the asymmetric unit
1LVU	;	2.05	;	Crystal structure of calf spleen purine nucleoside phosphorylase in a new space group with full trimer in the asymmetric unit
3OTH	;	2.301	;	Crystal Structure of CalG1, Calicheamicin Glycostyltransferase, TDP and calicheamicin alpha3I bound form
3OTG	;	2.08	;	Crystal Structure of CalG1, Calicheamicin Glycostyltransferase, TDP bound form
3RSC	;	2.19	;	Crystal Structure of CalG2, Calicheamicin Glycosyltransferase, TDP and calicheamicin T0 bound form
3IAA	;	2.505	;	Crystal Structure of CalG2, Calicheamicin Glycosyltransferase, TDP bound form
3D0Q	;	2.79	;	Crystal structure of calG3 from Micromonospora echinospora determined in space group I222
3D0R	;	1.9	;	Crystal structure of calG3 from Micromonospora echinospora determined in space group P2(1)
3OTI	;	1.597	;	Crystal Structure of CalG3, Calicheamicin Glycostyltransferase, TDP and calicheamicin T0 bound form
3IA7	;	1.91	;	Crystal Structure of CalG4, the Calicheamicin Glycosyltransferase
8DJ8	;	2.0	;	Crystal Structure of Calgreen 1 protein
4GF5	;	2.2	;	Crystal Structure of Calicheamicin Methyltransferase, CalS11
4EHQ	;	1.9005	;	Crystal Structure of Calmodulin Binding Domain of Orai1 in Complex with Ca2+/Calmodulin Displays a Unique Binding Mode
3EWT	;	2.4	;	Crystal Structure of calmodulin complexed with a peptide
3EWV	;	2.6	;	Crystal Structure of calmodulin complexed with a peptide
2BCX	;	2.0	;	Crystal structure of calmodulin in complex with a ryanodine receptor peptide
4AQR	;	1.95	;	Crystal structure of calmodulin in complex with the regulatory domain of a plasma-membrane Ca2+-ATPase
5X2E	;	1.299	;	Crystal structure of Calmodulin like domain of CsTAL3 (1-81aa)
3LST	;	2.4	;	Crystal Structure of CalO1, Methyltransferase in Calicheamicin Biosynthesis, SAH bound form
3BUJ	;	2.47	;	Crystal Structure of CalO2
4OKH	;	2.45	;	Crystal structure of calpain-3 penta-EF-hand domain
7QDA	;	2.1	;	Crystal structure of CalpL
3TOS	;	1.55	;	Crystal Structure of CalS11, Calicheamicin Methyltransferase
4XRR	;	2.55	;	Crystal structure of cals8 from micromonospora echinospora (P294S mutant)
4XR9	;	1.95	;	Crystal structure of CalS8 from Micromonospora echinospora cocrystallized with NAD and TDP-glucose
5XFI	;	1.653	;	Crystal structure of Calsepa lectin in complex with biantennary N-glycan
5AV7	;	1.85	;	Crystal structure of Calsepa lectin in complex with bisected glycan
1A8Y	;	2.4	;	CRYSTAL STRUCTURE OF CALSEQUESTRIN FROM RABBIT SKELETAL MUSCLE SARCOPLASMIC RETICULUM AT 2.4 A RESOLUTION
6VAN	;	1.33	;	Crystal structure of caltubin from the great pond snail
4FPW	;	2.5	;	Crystal Structure of CalU16 from Micromonospora echinospora. Northeast Structural Genomics Consortium Target MiR12.
3E9U	;	2.5	;	Crystal structure of Calx CBD2 domain
3EAD	;	2.25	;	Crystal structure of CALX-CBD1
1OUW	;	1.37	;	Crystal structure of Calystegia sepium agglutinin
7PSZ	;	1.898	;	Crystal structure of CaM in complex with CDZ (form 1)
7PU9	;	2.279	;	Crystal structure of CaM in complex with CDZ (form 2)
6HCS	;	2.0	;	Crystal structure of CaM-peptide complex containing AzF at position 108
3QJ1	;	3.2	;	Crystal structure of camel peptidoglycan recognition protein, PGRP-S with a trapped diethylene glycol in the ligand diffusion channel at 3.2 A resolution
2R90	;	2.8	;	Crystal structure of cameline peptidoglycan recognition protein at 2.8A resolution
2Z9N	;	3.2	;	Crystal structure of cameline peptidoglycan recognition protein at 3.2 A resolution
7B57	;	1.95	;	Crystal structure of CaMKII-actinin complex bound to ADP
7B56	;	1.45	;	Crystal structure of CaMKII-actinin complex bound to AMPPNP
7B55	;	1.6	;	Crystal structure of CaMKII-actinin complex bound to MES
3PNA	;	1.503	;	Crystal Structure of cAMP bound (91-244)RIa Subunit of cAMP-dependent Protein Kinase
3OCP	;	2.49	;	Crystal structure of cAMP bound cGMP-dependent protein kinase(92-227)
3MZH	;	2.9	;	Crystal structure of cAMP receptor protein from mycobacterium tuberculosis in complex with cAMP and its DNA binding element
6YQK	;	1.67	;	Crystal structure of cAMP-dependent Protein Kinase (PKA) in complex with a methylisoquinoline Fasudil-derivative (soaked)
6YNA	;	1.47	;	Crystal structure of cAMP-dependent Protein Kinase (PKA) in complex with Fasudil (M77, soaked)
6YQI	;	1.42	;	Crystal structure of cAMP-dependent Protein Kinase (PKA) in complex with long-chain Fasudil-derivative N-[2-(propylamino)ethyl]isoquinoline-5-sulfonamide (soaked)
6YQJ	;	1.58	;	Crystal structure of cAMP-dependent Protein Kinase (PKA) in complex with open-chain Fasudil-derivative 2-[isoquinolin-5-ylsulfonyl(propyl)amino]ethylazanium (soaked)
6YNB	;	1.72	;	Crystal structure of cAMP-dependent Protein Kinase (PKA) in complex with short-chain Fasudil-derivative N-(2-aminoethyl)isoquinoline-5-sulfonamide (soaked)
6YNC	;	1.4	;	Crystal structure of cAMP-dependent Protein Kinase (PKA) in complex with the methylated Fasudil-derived fragment N-methylisoquinoline-5-sulfonamide (soaked)
6SPU	;	1.39	;	Crystal structure of cAMP-dependent protein kinase A (CHO PKA) in complex with 3-aminobenzoic acid
6SPS	;	1.65	;	Crystal structure of cAMP-dependent protein kinase A (CHO PKA) in complex with 4-(trifluoromethyl)benzamide
6SPM	;	1.37	;	Crystal structure of cAMP-dependent protein kinase A (CHO PKA) in complex with 4-(trifluoromethyl)benzoic acid
6SOX	;	1.38	;	Crystal structure of cAMP-dependent protein kinase A (CHO PKA) in complex with 4-carbamoylbenzoic acid
6Z08	;	1.49	;	Crystal structure of cAMP-dependent protein kinase A (CHO PKA) in complex with 4-Nitrophenol
6SPY	;	1.6	;	Crystal structure of cAMP-dependent protein kinase A (CHO PKA) in complex with 6-(morpholin-4-yl)pyridine-3-carboxamide
6SQ1	;	1.49	;	Crystal structure of cAMP-dependent Protein Kinase A (CHO PKA) in complex with Aminofasudil
6SNX	;	1.4	;	Crystal structure of cAMP-dependent protein kinase A (CHO PKA) in complex with benzamide
6SNN	;	1.817	;	Crystal structure of cAMP-dependent protein kinase A (CHO PKA) in complex with benzoic acid
6ZN0	;	1.59	;	Crystal structure of cAMP-dependent protein kinase A (CHO PKA) in complex with isonicotinamidine
4WIH	;	1.139	;	Crystal structure of cAMP-dependent Protein Kinase A from Cricetulus griseus
3IM4	;	2.285	;	Crystal structure of cAMP-dependent Protein Kinase A Regulatory Subunit I alpha in complex with dual-specific A-Kinase Anchoring Protein 2
6C0U	;	2.65	;	Crystal structure of cAMP-dependent protein kinase Calpha subunit bound with N46
3FJQ	;	1.6	;	Crystal structure of cAMP-dependent protein kinase catalytic subunit alpha in complex with peptide inhibitor PKI alpha (6-25)
1REJ	;	2.2	;	Crystal structure of cAMP-dependent protein kinase complexed with balanol analog 1
1RE8	;	2.1	;	Crystal structure of cAMP-dependent protein kinase complexed with balanol analog 2
1REK	;	2.3	;	Crystal structure of cAMP-dependent protein kinase complexed with balanol analog 8
1RL3	;	2.7	;	Crystal structure of cAMP-free R1a subunit of PKA
2ZWU	;	1.3	;	Crystal Structure of Camphor Soaked Ferric Cytochrome P450cam
3LXI	;	2.2	;	Crystal Structure of Camphor-Bound CYP101D1
3NV6	;	2.2	;	Crystal Structure of Camphor-Bound CYP101D2
3L63	;	1.5	;	Crystal structure of camphor-bound P450cam at low [K+]
2ZUH	;	1.55	;	Crystal Structure of Camphor-soaked Ferric Cytochrome P450cam Mutant (D297A)
2ZUI	;	1.5	;	Crystal Structure of Camphor-soaked Ferric Cytochrome P450cam Mutant (D297N)
2ZUJ	;	1.6	;	Crystal Structure of Camphor-soaked Ferric Cytochrome P450cam Mutant(D297L)
6AYM	;	1.25	;	Crystal structure of Campylobacter jejuni 5'-methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN)
6AYO	;	1.67	;	Crystal structure of Campylobacter jejuni 5'-methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) complexed with 5'-deoxy-5'-Propyl-DADMe-Immucillin-A
6AYR	;	1.95	;	Crystal structure of Campylobacter jejuni 5'-methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) complexed with butylthio-DADMe-Immucillin-A
6AYS	;	1.7	;	Crystal structure of Campylobacter jejuni 5'-methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) complexed with hexylthio-DADMe-Immucillin-A
6AYQ	;	1.42	;	Crystal structure of Campylobacter jejuni 5'-methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) complexed with methylthio-DADMe-Immucillin-A
6AYT	;	1.85	;	Crystal structure of Campylobacter jejuni 5'-methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) complexed with pyrazinylthio-DADMe-Immucillin-A
5X2H	;	2.3	;	Crystal structure of Campylobacter jejuni Cas9 in complex with sgRNA and target DNA (AGAAACA PAM)
5X2G	;	2.4	;	Crystal structure of Campylobacter jejuni Cas9 in complex with sgRNA and target DNA (AGAAACC PAM)
3SWJ	;	2.409	;	Crystal structure of Campylobacter jejuni ChuZ
4GIO	;	1.9	;	Crystal structure of Campylobacter jejuni cj0090
7LAM	;	2.31	;	Crystal structure of Campylobacter jejuni Cj0843c lytic transglycosylase in complex with N,N',N''-triacetylchitotriose
7LAQ	;	2.58	;	Crystal structure of Campylobacter jejuni Cj0843c lytic transglycosylase in complex with N,N'-diacetylchitobiose
7PQ7	;	1.55	;	Crystal structure of Campylobacter jejuni DsbA1
7PQ8	;	1.329	;	Crystal structure of Campylobacter jejuni DsbA1
7PQF	;	1.82	;	Crystal structure of Campylobacter jejuni DsbA2
3D6X	;	2.59	;	Crystal structure of Campylobacter jejuni FabZ
4ETS	;	2.1	;	Crystal structure of Campylobacter jejuni ferric uptake regulator
7RDU	;	2.502	;	Crystal structure of Campylobacter jejuni keto said reductoisomerase in complex with magnesium and oxidixized and reduced NADPH
6DK4	;	2.71	;	Crystal structure of Campylobacter jejuni peroxide stress regulator
5W17	;	2.58	;	Crystal structure of Campylobacter jejuni YCEI protein that crystallizes with large solvent channels for nanotechnology applications
2FGS	;	2.9	;	Crystal structure of Campylobacter jejuni YCEI protein, structural genomics
8Q41	;	2.38	;	Crystal structure of Can2 (E341A) bound to cA4 and TTTAAA ssDNA
4K20	;	3.4	;	Crystal structure of Canavalia boliviana lectin
4K1Y	;	2.5	;	Crystal structure of Canavalia boliviana lectin in complex with Man1-3Man-OMe
4K1Z	;	2.3	;	Crystal structure of Canavalia boliviana lectin in complex with Man1-4Man-OMe
4K21	;	1.6	;	Crystal structure of Canavalia boliviana lectin in complex with Xman
4P14	;	2.0	;	Crystal structure of Canavalia brasiliensis (ConBr) complexed with adenine
4PCR	;	2.15	;	Crystal structure of Canavalia brasiliensis seed lectin (ConBr) complexed with Gamma-Aminobutyric Acid (GABA)
4H55	;	2.15	;	Crystal structure of Canavalia brasiliensis seed lectin (ConBr) in complex with beta-d-ribofuranose
4L8Q	;	2.3	;	Crystal structure of Canavalia grandiflora seed lectin complexed with X-Man.
4TYS	;	3.25	;	Crystal structure of Canavalia maritima lectin (ConM) complexed with a dinucleotide
4TZD	;	3.2	;	Crystal structure of Canavalia maritima lectin (ConM) complexed with interleukin - 1 beta primer
4I30	;	1.89	;	Crystal structure of Canavalia maritima seeds lectin (ConM) co-crystalized with gamma-aminobutyric acid (GABA) and soaked with adenine
5F5Q	;	2.52	;	Crystal structure of Canavalia virosa lectin in complex with alpha-methyl-mannoside
1D6R	;	2.3	;	CRYSTAL STRUCTURE OF CANCER CHEMOPREVENTIVE BOWMAN-BIRK INHIBITOR IN TERNARY COMPLEX WITH BOVINE TRYPSIN AT 2.3 A RESOLUTION. STRUCTURAL BASIS OF JANUS-FACED SERINE PROTEASE INHIBITOR SPECIFICITY
6XLX	;	1.7	;	Crystal structure of cancer-associated G301D mutant of U2AF65 bound to AdML splice site
8JYQ	;	1.75	;	Crystal structure of cancer-specific anti-HER2 antibody H2Mab-214 in complex with epitope peptide
6DEK	;	2.971	;	Crystal structure of Candida albicans acetohydroxyacid synthase catalytic subunit
6DEM	;	2.038	;	Crystal structure of Candida albicans acetohydroxyacid synthase in complex with the herbicide bensulfuron methyl
6DEL	;	2.119	;	Crystal structure of Candida albicans acetohydroxyacid synthase in complex with the herbicide chlorimuron ethyl
6DEN	;	1.806	;	Crystal structure of Candida albicans acetohydroxyacid synthase in complex with the herbicide iodomuron ethyl
6DEO	;	1.971	;	Crystal structure of Candida albicans acetohydroxyacid synthase in complex with the herbicide iodomuron methyl
6DER	;	2.126	;	Crystal structure of Candida albicans acetohydroxyacid synthase in complex with the herbicide metosulam
6DEQ	;	2.127	;	Crystal structure of Candida albicans acetohydroxyacid synthase in complex with the herbicide penoxsulam
6DES	;	2.402	;	Crystal structure of Candida albicans acetohydroxyacid synthase in complex with the herbicide propoxycarbazone
6DEP	;	2.149	;	Crystal structure of Candida albicans acetohydroxyacid synthase in complex with the herbicide sulfometuron methyl
6TZ6	;	2.55	;	Crystal Structure of Candida Albicans Calcineurin A, Calcineurin B, FKBP12 and FK506 (Tacrolimus)
7YVA	;	2.93	;	Crystal structure of Candida albicans Fructose-1,6-bisphosphate aldolase complexed with lipoic acid
5AEZ	;	1.47	;	Crystal structure of Candida albicans Mep2
5AF1	;	1.639	;	Crystal structure of Candida albicans Mep2
1IYK	;	2.3	;	Crystal structure of candida albicans N-myristoyltransferase with myristoyl-COA and peptidic inhibitor
1IYL	;	3.2	;	Crystal Structure of Candida albicans N-myristoyltransferase with Non-peptidic Inhibitor
5NW7	;	1.85	;	Crystal structure of candida albicans phosphomannose isomerase in complex with inhibitor
4YDE	;	2.701	;	CRYSTAL STRUCTURE OF CANDIDA ALBICANS PROTEIN FARNESYLTRANSFERASE BINARY COMPLEX WITH THE ISOPRENOID FARNESYLDIPHOSPHATE
4YDO	;	3.0	;	CRYSTAL STRUCTURE OF CANDIDA ALBICANS PROTEIN FARNESYLTRANSFERASE IN APO FORM
5BTH	;	2.2	;	Crystal structure of Candida albicans Rai1
5BUD	;	1.99	;	Crystal structure of Candida albicans Rai1 in complex with pU5-Mn2+
6J1R	;	1.601	;	Crystal structure of Candida Antarctica Lipase B mutant - RR
6J1Q	;	1.6	;	Crystal structure of Candida Antarctica Lipase B mutant - RS
6J1P	;	1.759	;	Crystal structure of Candida Antarctica Lipase B mutant - SR
6J1S	;	1.83	;	Crystal structure of Candida Antarctica Lipase B mutant - SS
6J1T	;	1.783	;	Crystal structure of Candida Antarctica Lipase B mutant SR with product analogue
5GV5	;	2.89	;	Crystal structure of Candida antarctica Lipase B with active Ser105 modified with a phosphonate inhibitor
3W9B	;	2.9	;	Crystal structure of Candida antarctica lipase B with anion-tag
7ZZX	;	2.4	;	Crystal structure of Candida auris DHFR in apo form
8A0N	;	1.4	;	Crystal structure of Candida auris dihydrofolate reductase complexed with NADPH
8CRH	;	1.3	;	Crystal structure of Candida auris dihydrofolate reductase complexed with NADPH and cycloguanil
8A0Z	;	1.7	;	Crystal structure of Candida auris dihydrofolate reductase complexed with NADPH and pyrimethamine
5DNA	;	1.75	;	Crystal structure of Candida boidinii formate dehydrogenase
5DN9	;	1.5	;	Crystal structure of Candida boidinii formate dehydrogenase complexed with NAD+ and azide
6D4B	;	1.45	;	Crystal structure of Candida boidinii formate dehydrogenase V123A mutant complexed with NAD+ and azide
6D4C	;	1.45	;	Crystal structure of Candida boidinii formate dehydrogenase V123G mutant complexed with NAD+ and azide
3FWK	;	1.2	;	Crystal Structure of Candida glabrata FMN Adenylyltransferase
4KKV	;	1.74	;	Crystal structure of candida glabrata FMN adenylyltransferase D181A Mutant
3G59	;	1.87	;	Crystal Structure of Candida glabrata FMN Adenylyltransferase in complex with ATP
3G6K	;	1.35	;	Crystal Structure of Candida glabrata FMN Adenylyltransferase in complex with FAD and Inorganic Pyrophosphate
3G5A	;	1.95	;	Crystal Structure of Candida glabrata FMN Adenylyltransferase in complex with FMN and ATP analog AMPCPP
7MJF	;	2.2	;	Crystal structure of Candidatus Liberibacter solanacearum dihydrodipicolinate synthase with pyruvate and succinic semi-aldehyde bound in active site
6BXO	;	1.655	;	Crystal structure of Candidatus Methanoperedens nitroreducens Dph2 with 4Fe-4S cluster and SAH
6BXN	;	2.079	;	Crystal structure of Candidatus Methanoperedens nitroreducens Dph2 with 4Fe-4S cluster and SAM
6BXM	;	2.252	;	Crystal structure of Candidatus Methanoperedens nitroreducens Dph2 with 4Fe-4S cluster and SAM/cleaved SAM
1BGC	;	1.7	;	CRYSTAL STRUCTURE OF CANINE AND BOVINE GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF)
1BGD	;	2.3	;	CRYSTAL STRUCTURE OF CANINE AND BOVINE GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF)
1BGE	;	2.2	;	CRYSTAL STRUCTURE OF CANINE AND BOVINE GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF)
7XJW	;	2.75	;	Crystal structure of canine coronavirus main protease in complex with GC376
8IAY	;	3.027	;	Crystal structure of canine distemper virus hemagglutinin
2Z2E	;	2.01	;	Crystal Structure of Canine Milk Lysozyme Stabilized against Non-enzymatic Deamidation
6E07	;	2.6	;	Crystal structure of Canton G6PD in complex with structural NADP
4YRD	;	2.44	;	Crystal structure of CapF with inhibitor 3-isopropenyl-tropolone
7F0A	;	1.95	;	Crystal structure of capreomycin phosphotransferase
7F0B	;	2.14	;	Crystal structure of capreomycin phosphotransferase in complex with ATP
7F0C	;	2.07	;	Crystal structure of capreomycin phosphotransferase in complex with CMN IIA
7F0F	;	2.1	;	Crystal structure of capreomycin phosphotransferase in complex with CMN IIB
7EQS	;	2.1	;	Crystal structure of capsid P domain of norovirus GI.3 DSV
7EQT	;	2.05	;	Crystal structure of capsid P domain of norovirus GI.3 DSV complexed with Gala1-3Galb1-4Glc
7EQW	;	2.15	;	Crystal structure of capsid P domain of norovirus GI.3 DSV complexed with NA2 N-glycan
7ER0	;	2.183	;	Crystal structure of capsid P domain of norovirus GI.3 VA115
7ER1	;	2.2	;	Crystal structure of capsid P domain of norovirus GI.3 VA115 complexed with Gala1-3Galb1-4Glc
4AGK	;	1.81	;	Crystal structure of capsid protein (110-267) from Aura virus
2ZKL	;	2.61	;	Crystal Structure of capsular polysaccharide assembling protein CapF from staphylococcus aureus
3ST7	;	2.45	;	Crystal Structure of capsular polysaccharide assembling protein CapF from staphylococcus aureus
3VHR	;	2.7	;	Crystal Structure of capsular polysaccharide assembling protein CapF from Staphylococcus aureus in space group C2221
7YA2	;	3.2	;	Crystal structure of capsular polysaccharide synthesis enzyme CapG from Staphylococcus aureus
3VVC	;	2.2	;	Crystal Structure of Capsular Polysaccharide Synthesizing Enzyme CapE , K126E, in apo form
3VVB	;	2.8	;	Crystal Structure of Capsular Polysaccharide Synthesizing Enzyme CapE from Staphylococcus aureus in apo form
4G5H	;	1.88	;	Crystal structure of capsular polysaccharide synthesizing enzyme CapE from Staphylococcus aureus in complex with by-product
3W1V	;	2.1	;	Crystal Structure of Capsular Polysaccharide Synthesizing Enzyme CapE from Staphylococcus aureus in complex with inihibitor
3LK3	;	2.68	;	Crystal structure of CapZ bound to the CPI and CSI uncapping motifs from CARMIL
3LK2	;	2.2	;	Crystal structure of CapZ bound to the uncapping motif from CARMIL
3LK4	;	1.99	;	Crystal structure of CapZ bound to the uncapping motif from CD2AP
1XVP	;	2.6	;	crystal structure of CAR/RXR heterodimer bound with SRC1 peptide, fatty acid and CITCO
1XV9	;	2.7	;	crystal structure of CAR/RXR heterodimer bound with SRC1 peptide, fatty acid, and 5b-pregnane-3,20-dione.
1CS0	;	2.0	;	Crystal structure of carbamoyl phosphate synthetase complexed at CYS269 in the small subunit with the tetrahedral mimic l-glutamate gamma-semialdehyde
1C30	;	2.0	;	CRYSTAL STRUCTURE OF CARBAMOYL PHOSPHATE SYNTHETASE: SMALL SUBUNIT MUTATION C269S
2PN1	;	2.0	;	Crystal structure of carbamoylphosphate synthase large subunit (split gene in MJ) (ZP_00538348.1) from Exiguobacterium sp. 255-15 at 2.00 A resolution
4OJ8	;	2.1	;	Crystal structure of carbapenem synthase in complex with (3S,5S)-carbapenam
7TOJ	;	1.3	;	Crystal structure of carbohydrate esterase CspAcXE, apoenzyme
7XMJ	;	2.41067	;	Crystal structure of carbohydrate esterase family 7 acetyl xylan esterase
7TOG	;	1.35	;	Crystal structure of carbohydrate esterase PbeAcXE, apoenzyme
7TOI	;	1.13	;	Crystal structure of carbohydrate esterase PbeAcXE, in complex with acetate
7TOH	;	1.26	;	Crystal structure of carbohydrate esterase PbeAcXE, in complex with MeGlcpA-Xylp
3RJ8	;	2.4	;	Crystal structure of carbohydrate oxidase from Microdochium nivale
3RJA	;	2.1	;	Crystal structure of carbohydrate oxidase from Microdochium nivale in complex with substrate analogue
3WBP	;	1.8	;	Crystal structure of carbohydrate recognition domain of Blood Dendritic Cell Antigen-2 (BDCA2) lectin (crystal form-1)
3WBQ	;	2.3	;	Crystal structure of carbohydrate recognition domain of Blood Dendritic Cell Antigen-2 (BDCA2) lectin (crystal form-2)
3WBR	;	2.2	;	Crystal structure of carbohydrate recognition domain of Blood Dendritic Cell Antigen-2 (BDCA2) lectin (crystal form-3)
4RS3	;	1.4	;	Crystal structure of carbohydrate transporter A0QYB3 from Mycobacterium smegmatis str. MC2 155, target EFI-510969, in complex with xylitol
4RU1	;	1.5	;	Crystal structure of carbohydrate transporter ACEI_1806 from Acidothermus cellulolyticus 11B, TARGET EFI-510965, in complex with myo-inositol
4RSM	;	1.6	;	Crystal structure of carbohydrate transporter msmeg_3599 from mycobacterium smegmatis str. mc2 155, target efi-510970, in complex with d-threitol
4RXT	;	1.35	;	Crystal structure of carbohydrate transporter solute binding protein Arad_9553 from Agrobacterium Radiobacter, Target EFI-511541, in complex with D-arabinose
4RXU	;	1.4	;	Crystal structure of carbohydrate transporter solute binding protein CAUR_1924 from Chloroflexus aurantiacus, Target EFI-511158, in complex with D-glucose
4RY9	;	1.4	;	Crystal structure of carbohydrate transporter solute binding protein VEIS_2079 from Verminephrobacter eiseniae EF01-2, TARGET EFI-511009, a complex with D-TALITOL
4C8X	;	1.998	;	Crystal structure of carbohydrate-binding module CBM3b mutant (Y56S) from the cellulosomal cellobiohydrolase 9A from Clostridium thermocellum
3ACF	;	1.6	;	Crystal Structure of Carbohydrate-Binding Module Family 28 from Clostridium josui Cel5A in a ligand-free form
3ACG	;	1.5	;	Crystal Structure of Carbohydrate-Binding Module Family 28 from Clostridium josui Cel5A in complex with cellobiose
3ACI	;	1.6	;	Crystal Structure of Carbohydrate-Binding Module Family 28 from Clostridium josui Cel5A in complex with cellopentaose
3ACH	;	1.4	;	Crystal Structure of Carbohydrate-Binding Module Family 28 from Clostridium josui Cel5A in complex with cellotetraose
6A6C	;	2.05	;	Crystal structure of carbohydrate-binding module family 56 beta-1,3-glucan binding domain
4O35	;	1.8	;	Crystal structure of carbomonoxy murine neuroglobin mutant F106W
4O2G	;	2.7	;	Crystal structure of carbomonoxy murine neuroglobin mutant V140W
1JQK	;	2.8	;	Crystal structure of carbon monoxide dehydrogenase from Rhodospirillum rubrum
7UD8	;	1.8	;	Crystal structure of carbon monoxy Hemoglobin in complex with 5HMF at 1.8 Angstrom
5V12	;	2.451	;	Crystal structure of Carbon Sulfoxide lyase, Egt2 Y134F with sulfenic acid intermediate
6MG6	;	2.1	;	Crystal structure of carbon-nitrogen hydrolase from Helicobacter pylori G27
7QUG	;	2.6	;	Crystal structure of carbon-sulfur lyase FnaPatB1 from Fusobacterium nucleatum subspecies animalis in complex with allyl-cysteine
3I16	;	2.0	;	Crystal structure of carbon-sulfur lyase involved in aluminum resistance (YP_878183.1) from Clostridium novyi NT at 2.00 A resolution
3GWP	;	2.9	;	Crystal structure of carbon-sulfur lyase involved in aluminum resistance (YP_878183.1) from CLOSTRIDIUM NOVYI NT at 2.90 A resolution
8BZZ	;	1.07	;	Crystal structure of carbonic anhydrase 2 4-(dimethylamino)-N-nitrobenzenesulfonamide
6SYB	;	1.6	;	Crystal structure of carbonic anhydrase 2 with (3aR,4S,9bS)-4-(2-chloro-4-hydroxyphenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide
6SX9	;	1.43	;	Crystal structure of carbonic anhydrase 2 with 4-(2-chlorophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide
8DPC	;	2.41	;	Crystal structure of carbonic anhydrase from Neisseria gonorrhoeae
7O48	;	2.0	;	Crystal structure of carbonic anhydrase from schistosoma mansoni with 4-(2-(3-(4-iodophenyl)thioureido)ethyl)benzenesulfonamide
3LAS	;	1.4	;	Crystal structure of carbonic anhydrase from streptococcus mutans to 1.4 angstrom resolution
3NJ9	;	2.0	;	Crystal structure of carbonic anhydrase II in complex with a Nir inhibitor
3EYX	;	2.04	;	Crystal structure of Carbonic Anhydrase Nce103 from Saccharomyces cerevisiae
1YM3	;	1.75	;	Crystal Structure of carbonic anhydrase RV3588c from Mycobacterium tuberculosis
7PUV	;	1.4	;	Crystal structure of carbonic anhydrase XII with methyl 2-(benzenesulfonyl)-4-chloro-5-sulfamoylbenzoate
7PUW	;	1.42	;	Crystal structure of carbonic anhydrase XII with methyl 2-chloro-4-[(2-phenylethyl)sulfanyl]-5-sulfamoylbenzoate
7PUU	;	1.51	;	Crystal structure of carbonic anhydrase XII with methyl 4-chloro-2-cyclohexylsulfanyl-5-sulfamoylbenzoate
1T1N	;	2.2	;	CRYSTAL STRUCTURE OF CARBONMONOXY HEMOGLOBIN
2Z6N	;	1.86	;	Crystal Structure of Carbonmonoxy Hemoglobin D from the Aldabra Giant Tortoise, Geochelone gigantea
5U3I	;	1.95	;	CRYSTAL STRUCTURE OF CARBONMONOXY HEMOGLOBIN S (LIGANDED SICKLE CELL HEMOGLOBIN) COMPLEXED WITH GBT compound 31
5UFJ	;	2.05	;	Crystal Structure of Carbonmonoxy Hemoglobin S (Liganded Sickle Cell Hemoglobin) Complexed with GBT Compound 6
7UVB	;	2.05	;	CRYSTAL STRUCTURE OF CARBONMONOXY HEMOGLOBIN S (LIGANDED SICKLE CELL HEMOGLOBIN) COMPLEXED WITH GBT021601
5E83	;	1.8	;	CRYSTAL STRUCTURE OF CARBONMONOXY HEMOGLOBIN S (LIGANDED SICKLE CELL HEMOGLOBIN) COMPLEXED WITH GBT440, CO-CRYSTALLIZATION EXPERIMENT
2D5X	;	1.45	;	Crystal structure of carbonmonoxy horse hemoglobin complexed with L35
3AG0	;	2.6	;	Crystal structure of carbonmonoxy human cytoglobin
5E6E	;	1.76	;	Crystal Structure of Carbonmonoxy Sickle Hemoglobin in R-State Conformation
8JQJ	;	1.4	;	Crystal structure of carbonyl reductase SSCR mutant 1 from Sporobolomyces Salmonicolor
3K21	;	1.15	;	Crystal Structure of carboxy-terminus of PFC0420w.
3K5H	;	2.1	;	Crystal structure of carboxyaminoimidazole ribonucleotide synthase from asperigillus clavatus complexed with ATP
6BWU	;	2.0	;	Crystal structure of carboxyhemoglobin in complex with beta Cys93 modifying agent, TD3
5MIF	;	2.141	;	Crystal structure of carboxyl esterase 2 (TmelEST2) from mycorrhizal fungus Tuber melanosporum
5MII	;	2.372	;	Crystal structure of carboxyl esterase 2 (TmelEST2) from mycorrhizal fungus Tuber melanosporum
7RQH	;	3.2	;	Crystal Structure of carboxyl-terminal processing protease A mutant S302A, CtpA_S302A, of Pseudomonas aeruginosa
7RPQ	;	3.3	;	Crystal Structure of carboxyl-terminal processing protease A, CtpA, of Pseudomonas aeruginosa
3B5E	;	1.75	;	Crystal structure of carboxylesterase (NP_108484.1) from Mesorhizobium loti at 1.75 A resolution
4NMW	;	1.496	;	Crystal Structure of Carboxylesterase BioH from Salmonella enterica
4CCY	;	2.04	;	Crystal structure of carboxylesterase CesB (YbfK) from Bacillus subtilis
7W1K	;	1.39	;	Crystal structure of carboxylesterase from Thermobifida fusca
7W1J	;	1.92	;	Crystal structure of carboxylesterase from Thermobifida fusca with J1K
4C89	;	2.05	;	Crystal structure of carboxylesterase LpEst1 from Lactobacillus plantarum: high resolution model
7W1L	;	2.44	;	Crystal structure of carboxylesterase mutant from Thermobifida fusca with C8X
7W1I	;	1.67	;	Crystal structure of carboxylesterase mutant from Thermobifida fusca with C8X and C9C
4F21	;	2.5	;	Crystal structure of carboxylesterase/phospholipase family protein from Francisella tularensis
1VKE	;	1.56	;	Crystal structure of carboxymuconolactone decarboxylase family protein possibly involved in antioxidative response (TM1620) from Thermotoga maritima at 1.56 A resolution
3D7I	;	1.75	;	Crystal structure of carboxymuconolactone decarboxylase family protein possibly involved in oxygen detoxification (1591455) from METHANOCOCCUS JANNASCHII at 1.75 A resolution
3LVY	;	2.1	;	Crystal Structure of Carboxymuconolactone Decarboxylase Family Protein SMU.961 from Streptococcus mutans
3N29	;	1.9	;	Crystal structure of carboxynorspermidine decarboxylase complexed with Norspermidine from Campylobacter jejuni
7EQZ	;	2.2	;	Crystal structure of Carboxypeptidase B complexed with Potato Carboxypeptidase Inhibitor
5WVU	;	2.6	;	Crystal structure of carboxypeptidase from Thermus thermophilus
1WPX	;	2.7	;	Crystal structure of carboxypeptidase Y inhibitor complexed with the cognate proteinase
3H8Y	;	2.51	;	Crystal structure of carboxysome small shell protein CsoS1C from Halothiobacillus neapolitanus
8H50	;	2.9	;	Crystal structure of carboxyspermidine dehydrogenase from Helicobacter pylori in space group C2221
8H4Z	;	2.2	;	Crystal structure of carboxyspermidine dehydrogenase from Helicobacter pylori in space group P21212
4IQD	;	2.0	;	Crystal Structure of Carboxyvinyl-Carboxyphosphonate Phosphorylmutase from Bacillus anthracis
4IQE	;	2.501	;	Crystal Structure of Carboxyvinyl-Carboxyphosphonate Phosphorylmutase from Bacillus anthracis str. Ames Ancestor
3PIS	;	2.0	;	Crystal Structure of Carcinoscorpius rotundicauda Serine Protease Inhibitor Domain 1
6J52	;	2.504	;	Crystal structure of CARD-only protein in frog virus 3
3N71	;	2.3	;	Crystal structure of cardiac specific histone methyltransferase SmyD1
3MA7	;	2.29	;	Crystal structure of Cardiolipin bound to mouse CD1D
5M76	;	2.5	;	Crystal structure of cardiotoxic Bence-Jones light chain dimer H10
5M6A	;	1.64	;	Crystal structure of cardiotoxic Bence-Jones light chain dimer H9
1UG4	;	1.6	;	Crystal Structure of Cardiotoxin VI from Taiwan Cobra (Naja atra) Venom
5AOH	;	1.8	;	Crystal Structure of CarF
4O7J	;	1.8	;	Crystal structure of CarG
5DXJ	;	1.95	;	Crystal structure of CARM1 and sinefungin
6S7A	;	1.86	;	Crystal structure of CARM1 in complex with inhibitor AA175
6S79	;	2.1	;	Crystal structure of CARM1 in complex with inhibitor AA183
6S7C	;	2.3	;	Crystal structure of CARM1 in complex with inhibitor UM079
6S7B	;	2.659	;	Crystal structure of CARM1 in complex with inhibitor UM249
6S70	;	2.3	;	Crystal structure of CARM1 in complex with inhibitor UM251
6S74	;	2.1	;	Crystal structure of CARM1 in complex with inhibitor UM305
6S71	;	2.062	;	Crystal structure of CARM1 in complex with inhibitor WH5C
6S77	;	2.12	;	Crystal structure of CARM1 N265Y mutant in complex with inhibitor AA183
6ARV	;	2.0	;	Crystal structure of CARM1 with Compound 2 and SAH
6ARJ	;	1.92	;	Crystal structure of CARM1 with EPZ022302 and SAH
5DX0	;	2.05	;	Crystal structure of CARM1, sinefungin, and H3 peptide (R17)
5DWQ	;	2.36	;	Crystal structure of CARM1, sinefungin, and methylated H3 peptide (R17)
5DX8	;	1.94	;	Crystal structure of CARM1, sinefungin, and methylated PABP1 peptide (R455)
5DXA	;	2.07	;	Crystal structure of CARM1, sinefungin, and methylated PABP1 peptide (R460)
5DX1	;	1.93	;	Crystal structure of CARM1, sinefungin, and PABP1 peptide (R455)
4I16	;	1.751	;	Crystal structure of CARMA1 CARD
1TW2	;	2.5	;	Crystal structure of Carminomycin-4-O-methyltransferase (DnrK) in complex with S-adenosyl-L-homocystein (SAH) and 4-methoxy-e-rhodomycin T (M-ET)
1TW3	;	2.35	;	Crystal structure of Carminomycin-4-O-methyltransferase (DnrK) in complex with S-adenosyl-L-homocystein (SAH) and 4-methoxy-e-rhodomycin T (M-ET)
5EEH	;	1.82	;	Crystal structure of carminomycin-4-O-methyltransferase DnrK in complex with SAH and 2-chloro-4-nitrophenol
5JR3	;	1.84	;	Crystal structure of carminomycin-4-O-methyltransferase DnrK in complex with SAH and 4-methylumbelliferone
5EEG	;	2.255	;	Crystal structure of carminomycin-4-O-methyltransferase DnrK in complex with tetrazole-SAH
1NDB	;	1.8	;	Crystal structure of Carnitine Acetyltransferase
3HFX	;	3.15	;	Crystal structure of carnitine transporter
2WSX	;	3.5	;	Crystal Structure of Carnitine Transporter from Escherichia coli
2WSW	;	2.294	;	Crystal Structure of Carnitine Transporter from Proteus mirabilis
3R0O	;	2.1	;	Crystal structure of carnitinyl-CoA hydratase from Mycobacterium avium
5YF2	;	2.802	;	Crystal structure of CARNMT1 bound to anserine and SAH
5YF1	;	2.399	;	Crystal structure of CARNMT1 bound to carnosine and SFG
5YF0	;	2.25	;	Crystal structure of CARNMT1 bound to SAM
3UVE	;	1.55	;	Crystal structure of Carveol dehydrogenase ((+)-trans-carveol dehydrogenase) from Mycobacterium avium
3T7C	;	1.95	;	Crystal structure of carveol dehydrogenase from Mycobacterium avium bound to NAD
3PXX	;	2.0	;	Crystal structure of carveol dehydrogenase from Mycobacterium avium bound to nicotinamide adenine dinucleotide
5EJ2	;	2.15	;	Crystal structure of Carveol dehydrogenase from Mycobacterium avium in complex with NAD
3OEC	;	1.95	;	Crystal structure of carveol dehydrogenase from Mycobacterium thermoresistibile
7ENH	;	2.097	;	Crystal structure of cas and anti-cas protein complex
7ENI	;	2.632	;	Crystal structure of cas and anti-cas protein complex
7ENR	;	4.205	;	Crystal structure of cas and anti-cas protein complex
4N77	;	1.999	;	Crystal structure of Cas protein
5DQU	;	4.5	;	Crystal Structure of Cas-DNA-10 complex
5DQT	;	3.1	;	Crystal Structure of Cas-DNA-22 complex
5DLJ	;	2.6	;	Crystal Structure of Cas-DNA-N1 complex
5DQZ	;	2.7	;	Crystal Structure of Cas-DNA-PAM complex
4N06	;	2.4	;	Crystal structure of Cas1 from Archaeoglobus fulgidus and its nucleolytic activity
5FCL	;	2.7	;	Crystal structure of Cas1 from Pectobacterium atrosepticum
8H9D	;	3.1	;	Crystal structure of Cas12a protein
6LTP	;	3.4	;	Crystal structure of Cas12i2 binary complex
6LU0	;	3.22	;	Crystal structure of Cas12i2 ternary complex with 12 nt spacer
6LTU	;	2.57	;	Crystal structure of Cas12i2 ternary complex with double Mg2+ bound in catalytic pocket
6LTR	;	2.51	;	Crystal structure of Cas12i2 ternary complex with single Mg2+ bound in catalytic pocket
6JHZ	;	1.999	;	Crystal structure of cas2
6K2E	;	2.8	;	Crystal structure of cas2
8IA4	;	2.0	;	Crystal structure of Cas2 in complex with AcrVA5-peptide
3I4H	;	2.25	;	Crystal structure of Cas6 in Pyrococcus furiosus
3PKM	;	3.103	;	Crystal structure of Cas6 with its substrate RNA
4Z7L	;	3.503	;	Crystal structure of Cas6b
4UN3	;	2.593	;	Crystal structure of Cas9 bound to PAM-containing DNA target
4UN5	;	2.4	;	Crystal structure of Cas9 bound to PAM-containing DNA target containing mismatches at positions 1-3
4UN4	;	2.371	;	Crystal structure of Cas9 bound to PAM-containing DNA target with mismatches at positions 1-2
5FQ5	;	2.136	;	Crystal structure of Cas9-sgRNA-DNA complex solved by native SAD phasing
4H79	;	1.9	;	Crystal structure of CasB from Thermobifida fusca
4H7A	;	2.6	;	Crystal structure of CasB from Thermus thermophilus
6RCG	;	1.4	;	Crystal structure of Casein kinase 1 delta (CK1 delta) complexed with SR3029 inhibitor
6RU7	;	2.08	;	Crystal structure of Casein Kinase I delta (CK1d) in complex with double phosphorylated p63 PAD2P peptide
6RU6	;	2.05	;	Crystal structure of Casein Kinase I delta (CK1d) in complex with monophosphorylated p63 PAD1P peptide
6RU8	;	1.92	;	Crystal structure of Casein Kinase I delta (CK1d) in complex with triple phosphorylated p63 PAD3P peptide
7P7H	;	2.4	;	Crystal structure of Casein Kinase I delta (CK1d) with alphaG-in conformation
5X18	;	1.8	;	Crystal structure of Casein kinase I homolog 1
6RCH	;	1.45	;	Crystal structure of Casein kinase I isoform delta (CK1 delta) complexed with SR4133 inhibitor
3SV0	;	2.0	;	Crystal structure of casein kinase-1 like protein in plant
6LNM	;	2.4	;	Crystal structure of CASK-CaMK in complex with Mint1-CID
3SEI	;	2.4	;	Crystal Structure of Caskin1 Tandem SAMs
2NSN	;	2.0	;	Crystal structure of Caspace Activation and Recruitment Domain (CARD) of NOD1
6BDV	;	1.938	;	Crystal structure of Caspase 3 S150A
4DCJ	;	1.7	;	Crystal structure of caspase 3, L168D mutant
4DCP	;	1.7	;	Crystal Structure of caspase 3, L168F mutant
4DCO	;	1.7	;	Crystal Structure of caspase 3, L168Y mutant
1M72	;	2.3	;	Crystal Structure of Caspase-1 from Spodoptera frugiperda
6PZP	;	1.94	;	Crystal structure of caspase-1 in complex with VX-765
6KXG	;	2.805	;	Crystal structure of caspase-11-CARD
5IC4	;	2.65	;	Crystal structure of caspase-3 DEVE peptide complex
1RE1	;	2.5	;	CRYSTAL STRUCTURE OF CASPASE-3 WITH A NICOTINIC ACID ALDEHYDE INHIBITOR
2H5I	;	1.69	;	Crystal structure of caspase-3 with inhibitor Ac-DEVD-Cho
7RNG	;	2.55	;	Crystal structure of caspase-3 with inhibitor Ac-ITAKD-CHO
7RNA	;	1.9	;	Crystal structure of caspase-3 with inhibitor Ac-ITV(Dab)D-CHO
3EDQ	;	1.61	;	Crystal structure of Caspase-3 with inhibitor AC-LDESD-CHO
7RN7	;	2.4	;	Crystal structure of caspase-3 with inhibitor Ac-VD(Aly)VD-CHO
7RN8	;	1.88	;	Crystal structure of caspase-3 with inhibitor Ac-VD(Orn)VD-CHO
7RN9	;	1.67	;	Crystal structure of caspase-3 with inhibitor Ac-VDFVD-CHO
7RNF	;	2.11	;	Crystal structure of caspase-3 with inhibitor Ac-VDKVD-CHO
7RND	;	2.15	;	Crystal structure of caspase-3 with inhibitor Ac-VDPVD-CHO
7RNB	;	1.75	;	Crystal structure of caspase-3 with inhibitor Ac-VDRVD-CHO
7RNC	;	1.93	;	Crystal structure of caspase-3 with inhibitor Ac-VDVVD-CHO
7RNE	;	2.73	;	Crystal structure of caspase-3 with inhibitor Ac-YKPVD-CHO
7SEO	;	3.25	;	Crystal Structure of Caspase-3 with Peptide Inhibitor Ac-VDV(DAB)D-CHO
7USQ	;	2.71	;	Crystal Structure of Caspase-3 with Peptide Inhibitor AcDVPD-CHO
7USP	;	2.85	;	Crystal Structure of Caspase-3 with Peptide Inhibitor AcITV(Orn)D-CHO
7USO	;	2.3	;	Crystal Structure of Caspase-3 with Peptide Inhibitor AcITVKD-CHO
3V6L	;	2.2	;	Crystal Structure of caspase-6 inactivation mutation
3NR2	;	2.9	;	Crystal structure of Caspase-6 zymogen
1K86	;	2.6	;	Crystal structure of caspase-7
4FDL	;	2.801	;	Crystal structure of Caspase-7
1I51	;	2.45	;	CRYSTAL STRUCTURE OF CASPASE-7 COMPLEXED WITH XIAP
5IC6	;	2.7	;	Crystal structure of caspase-7 DEVE peptide complex
1F1J	;	2.35	;	CRYSTAL STRUCTURE OF CASPASE-7 IN COMPLEX WITH ACETYL-ASP-GLU-VAL-ASP-CHO
4FEA	;	3.79	;	Crystal structure of CASPASE-7 in Complex with allosteric inhibitor
3IBC	;	2.75	;	Crystal Structure of Caspase-7 incomplex with Acetyl-YVAD-CHO
2QL5	;	2.34	;	Crystal Structure of caspase-7 with inhibitor AC-DMQD-CHO
2QLF	;	2.8	;	Crystal Structure of Caspase-7 with inhibitor AC-DNLD-CHO
2QL9	;	2.14	;	Crystal Structure of Caspase-7 with inhibitor AC-DQMD-CHO
2QLB	;	2.25	;	Crystal Structure of caspase-7 with inhibitor AC-ESMD-CHO
2QL7	;	2.4	;	Crystal Structure of Caspase-7 with inhibitor AC-IEPD-CHO
2QLJ	;	2.6	;	Crystal Structure of Caspase-7 with Inhibitor AC-WEHD-CHO
2C2Z	;	1.95	;	Crystal structure of caspase-8 in complex with aza-peptide Michael acceptor inhibitor
1V0D	;	2.6	;	Crystal Structure of Caspase-activated DNase (CAD)
5JQE	;	3.157	;	Crystal structure of caspase8 tDED
5GS9	;	2.5	;	Crystal structure of CASTOR1-arginine
8AMC	;	2.95	;	Crystal Structure of cat allergen Fel d 4
6SQR	;	2.18	;	Crystal structure of Cat MDM2-S429E RING domain bound to UbcH5B-Ub
6SQP	;	1.21	;	Crystal structure of Cat MDM2-S429E RING domain homodimer
1PYK	;	2.6	;	CRYSTAL STRUCTURE OF CAT MUSCLE PYRUVATE KINASE AT A RESOLUTION OF 2.6 ANGSTROMS
6SQS	;	1.83	;	Crystal structure of cat phospho-Ser429 MDM2 RING domain bound to UbcH5B-Ub
4JG3	;	1.8	;	Crystal structure of catabolite repression control protein (crc) from Pseudomonas aeruginosa
7DOA	;	2.7	;	Crystal structure of Catabolite repressor acivator from E. coli in complex with HEPES
7DOB	;	2.4	;	Crystal structure of Catabolite repressor activator (Apo)
6BY0	;	2.93	;	Crystal structure of catalase HPII from E. coli in space group P1
6ZTV	;	1.78	;	Crystal Structure of catalase HPII from Escherichia coli (serendipitously crystallized)
6ZTW	;	1.84	;	Crystal Structure of catalase HPII from Escherichia coli (serendipitously crystallized)
6ZTX	;	1.3	;	Crystal Structure of catalase HPII from Escherichia coli (serendipitously crystallized)
1GGJ	;	1.92	;	CRYSTAL STRUCTURE OF CATALASE HPII FROM ESCHERICHIA COLI, ASN201ALA VARIANT.
1GGK	;	2.26	;	CRYSTAL STRUCTURE OF CATALASE HPII FROM ESCHERICHIA COLI, ASN201HIS VARIANT.
1GGH	;	2.15	;	CRYSTAL STRUCTURE OF CATALASE HPII FROM ESCHERICHIA COLI, HIS128ALA VARIANT.
1GG9	;	1.89	;	CRYSTAL STRUCTURE OF CATALASE HPII FROM ESCHERICHIA COLI, HIS128ASN VARIANT.
1GGE	;	1.89	;	CRYSTAL STRUCTURE OF CATALASE HPII FROM ESCHERICHIA COLI, NATIVE STRUCTURE AT 1.9 A RESOLUTION.
1GGF	;	2.28	;	CRYSTAL STRUCTURE OF CATALASE HPII FROM ESCHERICHIA COLI, VARIANT HIS128ASN, COMPLEX WITH HYDROGEN PEROXIDE.
4PAE	;	3.206	;	Crystal structure of catalase-peroxidase (KatG) W78F mutant from Synechococcus elongatus PCC7942
1ITK	;	2.0	;	Crystal structure of catalase-peroxidase from Haloarcula marismortui
1UB2	;	2.4	;	Crystal structure of catalase-peroxidase from Synechococcus PCC 7942
5SX7	;	1.95	;	Crystal structure of catalase-peroxidase KatG of B. pseudomallei at pH 8.5
5L05	;	1.7	;	Crystal structure of catalase-peroxidase KATG of burkholderia pseudomallei treated with INH
5SXS	;	1.887	;	Crystal structure of catalase-peroxidase KatG with isonicotinic acid hydrazide and AMP bound
3KKR	;	2.453	;	Crystal structure of catalytic core domain of BIV integrase in crystal form I
3KKS	;	2.2	;	Crystal structure of catalytic core domain of BIV integrase in crystal form II
4PA1	;	1.84	;	Crystal Structure of Catalytic Core domain of FIV Integrase
2GP5	;	2.28	;	Crystal structure of catalytic core domain of jmjd2A complexed with alpha-Ketoglutarate
2XKJ	;	2.2	;	CRYSTAL STRUCTURE OF CATALYTIC CORE OF A. BAUMANNII TOPO IV (PARE- PARC FUSION TRUNCATE)
6SMK	;	2.997	;	Crystal structure of catalytic domain A109H mutant of prophage-encoded M23 protein EnpA from Enterococcus faecalis.
7PJ4	;	1.25	;	Crystal structure of catalytic domain in closed conformation of LytB (E585Q)from Streptococcus pneumoniae
7PL3	;	1.8	;	Crystal structure of catalytic domain in closed conformation of LytB from Streptococcus pneumoniae
7PJ3	;	1.43	;	Crystal structure of catalytic domain in open conformation of LytB from Streptococcus pneumoniae
5XYH	;	1.864	;	Crystal Structure of catalytic domain of 1,4-beta-Cellobiosidase (CbsA) from Xanthomonas oryzae pv. oryzae
7DBT	;	2.3	;	Crystal structure of catalytic domain of Anhydrobiosis-related Mn-dependent Peroxidase (AMNP) from Ramazzottius varieornatus (Mn2+-bound form)
7DBU	;	1.6	;	Crystal structure of catalytic domain of Anhydrobiosis-related Mn-dependent Peroxidase (AMNP) from Ramazzottius varieornatus (Zn2+-bound form)
4KRV	;	2.4	;	Crystal structure of catalytic domain of bovine beta1,4-galactosyltransferase mutant M344H-GalT1 complex with 6-sulfo-GlcNAc
3W6B	;	1.9	;	Crystal structure of catalytic domain of chitinase from Ralstonia sp. A-471
3W6D	;	2.15	;	Crystal structure of catalytic domain of chitinase from Ralstonia sp. A-471 (E141Q) in complex with tetrasaccharide
3W6E	;	2.15	;	Crystal structure of catalytic domain of chitinase from Ralstonia sp. A-471 (E162Q)
3W6F	;	2.1	;	Crystal structure of catalytic domain of chitinase from Ralstonia sp. A-471 (E162Q) in complex with disaccharide
3W6C	;	2.0	;	Crystal structure of catalytic domain of chitinase from Ralstonia sp. A-471 in complex with disaccharide
2A97	;	1.8	;	Crystal structure of catalytic domain of Clostridium botulinum neurotoxin serotype F
4LW6	;	2.4	;	Crystal structure of catalytic domain of Drosophila beta1,4galactosyltransferase 7 complex with xylobiose
2E0T	;	1.67	;	Crystal structure of catalytic domain of dual specificity phosphatase 26, MS0830 from Homo sapiens
2GML	;	2.6	;	Crystal Structure of Catalytic Domain of E.coli RluF
5V9I	;	1.74	;	Crystal structure of catalytic domain of G9a with MS0105
5TTF	;	1.72	;	Crystal structure of catalytic domain of G9a with MS012
5V9J	;	1.74	;	Crystal structure of catalytic domain of GLP with MS0105
5TTG	;	1.66	;	Crystal structure of catalytic domain of GLP with MS012
6KTQ	;	1.98	;	Crystal structure of catalytic domain of homocitrate synthase from Sulfolobus acidocaldarius (SaHCS(dRAM)) in complex with alpha-ketoglutarate/Zn2+/CoA
4IRP	;	2.1	;	Crystal structure of catalytic domain of human beta1,4-galactosyltransferase-7 in open conformation with manganses and UDP
4IRQ	;	2.3	;	Crystal structure of catalytic domain of human beta1,4galactosyltransferase 7 in closed conformation in complex with manganese and UDP
4KP5	;	1.45	;	Crystal structure of catalytic domain of human carbonic anhydrase isozyme XII with 2-Chloro-4-[(pyrimidin-2-ylsulfanyl)acetyl]benzenesulfonamide
4KP8	;	1.8	;	Crystal structure of catalytic domain of human carbonic anhydrase isozyme XII with 3-[(Pyrimidin-2-ylsulfanyl)acetyl]benzenesulfonamide
4Q0L	;	2.0	;	Crystal structure of catalytic domain of human carbonic anhydrase isozyme XII with inhibitor
4QJ0	;	1.55	;	Crystal structure of catalytic domain of human carbonic anhydrase isozyme XII with inhibitor
4QJO	;	1.8	;	Crystal structure of catalytic domain of human carbonic anhydrase isozyme XII with inhibitor
4QJW	;	1.55	;	Crystal structure of catalytic domain of human carbonic anhydrase isozyme XII with inhibitor
2RFI	;	1.59	;	Crystal structure of catalytic domain of human euchromatic histone methyltransferase 1 in complex with SAH and dimethylated H3K9 peptide
3HNA	;	1.5	;	Crystal structure of catalytic domain of human euchromatic histone methyltransferase 1 in complex with SAH and mono-Methylated H3K9 Peptide
3C0Y	;	2.1	;	Crystal structure of catalytic domain of human histone deacetylase HDAC7
3C0Z	;	2.1	;	Crystal structure of catalytic domain of human histone deacetylase HDAC7 in complex with SAHA
3C10	;	2.0	;	Crystal structure of catalytic domain of human histone deacetylase HDAC7 in complex with Trichostatin A (TSA)
1ZZW	;	1.6	;	Crystal Structure of catalytic domain of Human MAP Kinase Phosphatase 5
6U8Z	;	1.799	;	Crystal Structure of Catalytic Domain of Human Phospholipase D1
1WOK	;	3.0	;	Crystal structure of catalytic domain of human poly(ADP-ribose) polymerase complexed with a quinoxaline-type inhibitor
1UK0	;	3.0	;	Crystal structure of catalytic domain of human poly(ADP-ribose) polymerase with a novel inhibitor
2DSK	;	1.5	;	Crystal structure of catalytic domain of hyperthermophilic chitinase from Pyrococcus furiosus
2Z83	;	1.8	;	Crystal Structure of Catalytic Domain of Japanese Encephalitis Virus NS3 Helicase/Nucleoside Triphosphatase at a Resolution 1.8
7POD	;	1.5	;	Crystal structure of catalytic domain of LytB (E585Q) from Streptococcus pneumoniae in complex with NAG-NAM-NAG-NAM tetrasaccharide
7PJ6	;	1.3	;	Crystal structure of catalytic domain of LytB (E585Q) from Streptococcus pneumoniae in complex with NAG-NAM-NAG-NAM-NAG peptidolycan analogue
7PJ5	;	1.55	;	Crystal structure of catalytic domain of LytB from Streptococcus pneumoniae in complex with NAG-NAG-NAG-NAG tetrasaccharide
4L67	;	2.8	;	Crystal Structure of Catalytic Domain of PAK4
5GZ9	;	2.4	;	Crystal structure of catalytic domain of Protein O-mannosyl Kinase in complexes with AMP-PNP, Magnesium ions and glycopeptide
5GZ8	;	2.5	;	Crystal structure of catalytic domain of Protein O-mannosyl Kinase in ligand-free form
1V9F	;	1.7	;	Crystal structure of catalytic domain of pseudouridine synthase RluD from Escherichia coli
4IKC	;	1.56	;	Crystal Structure of catalytic domain of PTPRQ
2II0	;	2.02	;	Crystal Structure of catalytic domain of Son of sevenless (Rem-Cdc25) in the absence of Ras
3O64	;	1.88	;	Crystal structure of catalytic domain of TACE with 2-(2-Aminothiazol-4-yl)pyrrolidine-Based Tartrate Diamides
3LGP	;	1.9	;	Crystal structure of catalytic domain of tace with benzimidazolyl-thienyl-tartrate based inhibitor
3EWJ	;	1.8	;	Crystal structure of catalytic domain of TACE with carboxylate inhibitor
3L0T	;	1.92	;	Crystal structure of catalytic domain of TACE with hydantoin inhibitor
3E8R	;	1.9	;	Crystal structure of catalytic domain of TACE with hydroxamate inhibitor
3EDZ	;	1.9	;	Crystal structure of catalytic domain of TACE with hydroxamate inhibitor
2I47	;	1.9	;	Crystal structure of catalytic domain of TACE with inhibitor
3KME	;	1.85	;	Crystal structure of catalytic domain of TACE with phenyl-pyrrolidinyl-tartrate inhibitor
3KMC	;	1.8	;	Crystal structure of catalytic domain of TACE with tartrate-based inhibitor
3L0V	;	1.75	;	Crystal structure of catalytic domain of TACE with the first hydantoin inhibitor occupying the S1' pocket
2A8H	;	2.3	;	Crystal structure of catalytic domain of TACE with Thiomorpholine Sulfonamide Hydroxamate inhibitor
3BRB	;	1.9	;	Crystal structure of catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with ADP
3BPR	;	2.8	;	Crystal structure of catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with inhibitor C52
1ZXC	;	2.28	;	Crystal structure of catalytic domain of TNF-alpha converting enzyme (TACE) with inhibitor
5Y7F	;	1.35	;	Crystal structure of catalytic domain of UGGT (UDP-bound form) from Thermomyces dupontii
5H18	;	1.4	;	Crystal structure of catalytic domain of UGGT (UDP-glucose-bound form) from Thermomyces dupontii
3CFJ	;	2.6	;	Crystal structure of catalytic elimination antibody 34E4, orthorhombic crystal form
3CFK	;	2.6	;	Crystal structure of catalytic elimination antibody 34E4, triclinic crystal form
3HXZ	;	1.99	;	Crystal Structure of catalytic fragment of E. coli AlaRS G237A in complex with AlaSA
3HY0	;	1.9	;	Crystal Structure of catalytic fragment of E. coli AlaRS G237A in complex with GlySA
3HY1	;	2.79	;	Crystal Structure of catalytic fragment of E. coli AlaRS G237A in complex with SerSA
3HXU	;	2.1	;	Crystal Structure of catalytic fragment of E. coli AlaRS in complex with AlaSA
3HXX	;	2.11	;	Crystal Structure of catalytic fragment of E. coli AlaRS in complex with AMPPCP
3HXY	;	2.27	;	Crystal Structure of catalytic fragment of E. coli AlaRS in complex with AMPPCP, Ala-AMP and PCP
3HXV	;	1.93	;	Crystal Structure of catalytic fragment of E. coli AlaRS in complex with GlySA
3HXW	;	1.93	;	Crystal Structure of catalytic fragment of E. coli AlaRS in complex with SerSA
5V59	;	2.03	;	Crystal structure of catalytic fragment of human AlaRS in complex with Aze-SA
6LCT	;	2.55	;	Crystal structure of catalytic inactive chloroplast resolvase NtMOC1 in complex with Holliday junction
6Z2P	;	2.16	;	Crystal structure of catalytic inactive OgpA from Akkermansia muciniphila in complex with an O-glycopeptide (glycodrosocin) substrate
7ZO0	;	1.95	;	Crystal structure of catalytic inactive unliganded form of FucOB, a GH95 family alpha-1,2-fucosidase from Akkermansia muciniphila
2AU6	;	1.2	;	Crystal structure of catalytic intermediate of inorganic pyrophosphatase
4PI8	;	1.39	;	Crystal structure of catalytic mutant E138A of S. Aureus Autolysin E in complex with disaccharide NAG-NAM
6V0T	;	2.1	;	Crystal Structure of Catalytic Subunit of Bovine Pyruvate Dehydrogenase Phosphatase 1 - Catalytic Domain
3E3B	;	3.2	;	Crystal structure of catalytic subunit of human protein kinase CK2alpha prime with a potent indazole-derivative inhibitor
2R7I	;	3.003	;	Crystal structure of catalytic subunit of protein kinase CK2
2D1Z	;	1.6	;	Crystal structure of catalytic-site mutant xylanase from Streptomyces olivaceoviridis E-86
5GTJ	;	2.0	;	CRYSTAL STRUCTURE OF CATALYTICALLY ACTIVE FORM OF HUMAN DUSP26
3IH7	;	3.1	;	Crystal structure of catalytically active human 8-oxoguanine glycosylase distally crosslinked to guanine-containing DNA
5NFV	;	2.501	;	Crystal structure of catalytically inactive FnCas12 mutant bound to an R-loop structure containing a pre-crRNA mimic and full-length DNA target
6I1K	;	2.65	;	Crystal structure of catalytically inactive FnCas12a in complex with a crRNA guide and a dsDNA target
2Z2P	;	2.8	;	Crystal Structure of catalytically inactive H270A virginiamycin B lyase from Staphylococcus aureus with Quinupristin
4WME	;	1.55	;	Crystal structure of catalytically inactive MERS-CoV 3CL Protease (C148A) in spacegroup C2
4WMD	;	2.585	;	Crystal structure of catalytically inactive MERS-CoV 3CL protease (C148A) in spacegroup C2221
4WMF	;	1.97	;	Crystal structure of catalytically inactive MERS-CoV 3CL protease (C148A) in spacegroup P212121
1ZLB	;	0.97	;	Crystal structure of catalytically-active phospholipase A2 in the absence of calcium
1ZL7	;	1.6	;	Crystal structure of catalytically-active phospholipase A2 with bound calcium
4ZT0	;	2.9	;	Crystal structure of catalytically-active Streptococcus pyogenes Cas9 in complex with single-guide RNA at 2.9 Angstrom resolution
5F9R	;	3.4	;	Crystal structure of catalytically-active Streptococcus pyogenes CRISPR-Cas9 in complex with single-guided RNA and double-stranded DNA primed for target DNA cleavage
8J40	;	1.57	;	Crystal Structure of CATB8 in complex with chloramphenicol
5VXT	;	1.75	;	Crystal structure of catechol 1,2-dioxygenase from Burkholderia ambifaria
5TD3	;	1.75	;	Crystal structure of Catechol 1,2-dioxygenase from Burkholderia vietnamiensis
2AZQ	;	2.65	;	Crystal Structure of Catechol 1,2-Dioxygenase from Pseudomonas arvilla C-1
3HJQ	;	2.0	;	Crystal structure of catechol 1,2-dioxygenase from Rhodococcus opacus 1CP in complex with 3-methylcatechol
3HJS	;	1.8	;	Crystal structure of catechol 1,2-dioxygenase from Rhodococcus opacus 1CP in complex with 4-methylcatechol
3HGI	;	1.94	;	Crystal structure of Catechol 1,2-Dioxygenase from the gram-positive Rhodococcus opacus 1CP
5UMH	;	1.35	;	Crystal Structure of Catechol 1,2-dioxygenase protein from Burkholderia multivorans
2WL3	;	2.2	;	crystal structure of catechol 2,3-dioxygenase
2WL9	;	1.9	;	Crystal structure of catechol 2,3-dioxygenase
7CVU	;	1.75	;	Crystal structure of Catechol o-methyl transferase (COMT) from Niastella koreensis
7CVV	;	2.52	;	Crystal structure of Catechol o-methyl transferase (COMT) from Niastella koreensis
7CVW	;	1.54	;	Crystal structure of Catechol o-methyl transferase (COMT) from Niastella koreensis
7CVX	;	1.7	;	Crystal structure of Catechol o-methyl transferase (COMT) from Niastella koreensis
4J3R	;	2.2	;	Crystal structure of catechol oxidase from Aspergillus oryzae, soaked in 4-tert-butylcatechol
126D	;	2.0	;	CRYSTAL STRUCTURE OF CATGGCCATG AND ITS IMPLICATIONS FOR A-TRACT BENDING MODELS
6EEW	;	2.05002	;	Crystal structure of Catharanthus roseus tryptophan decarboxylase in complex with L-tryptophan
4CI9	;	1.58	;	Crystal structure of cathepsin A, apo-structure
4AZ3	;	2.04	;	crystal structure of cathepsin a, complexed with 15a
4AZ0	;	2.17	;	crystal structure of cathepsin a, complexed with 8a.
4CIA	;	1.98	;	Crystal structure of cathepsin A, complexed with compound 1
4CIB	;	1.89	;	crystal structure of cathepsin a, complexed with compound 2
3HHI	;	1.6	;	Crystal Structure of Cathepsin B from T. brucei in complex with CA074
3MOR	;	2.55	;	Crystal structure of Cathepsin B from Trypanosoma Brucei
1CSB	;	2.0	;	Crystal structure of cathepsin b inhibited with CA030 at 2.1 angstroms resolution: A basis for the design of specific epoxysuccinyl inhibitors
4OEL	;	1.4	;	Crystal structure of Cathepsin C in complex with dipeptide substrates
4OEM	;	1.52	;	Crystal structure of Cathepsin C in complex with dipeptide substrates
5N7N	;	2.3	;	CRYSTAL STRUCTURE OF CATHEPSIN D ZYMOGEN FROM THE TICK IXODES RICINUS (IRCD1)
8D4S	;	1.95	;	Crystal Structure of Cathepsin G Inhibited by Eap1 from S. aureus
8D4V	;	1.85	;	Crystal Structure of Cathepsin G Inhibited by Eap2 from S. aureus
4YV8	;	2.0	;	Crystal structure of cathepsin K bound to the covalent inhibitor lichostatinal
2FTD	;	2.55	;	Crystal structure of Cathepsin K complexed with 7-Methyl-Substituted Azepan-3-one compound
1MEM	;	1.8	;	Crystal structure of Cathepsin K complexed with a potent vinyl sulfone inhibitor
5TDI	;	1.4	;	Crystal structure of Cathepsin K with a covalently-linked inhibitor at 1.4 Angstrom resolution.
6HGY	;	2.2	;	CRYSTAL STRUCTURE OF CATHEPSIN K WITH N-DESMETHYL THALASSOSPIRAMIDE C
3HHA	;	1.27	;	Crystal structure of cathepsin L in complex with AZ12878478
2HXZ	;	1.9	;	Crystal Structure of Cathepsin S in complex with a Nonpeptidic Inhibitor (Hexagonal spacegroup)
2H7J	;	1.5	;	Crystal Structure of Cathepsin S in complex with a Nonpeptidic Inhibitor.
2HH5	;	1.8	;	Crystal Structure of Cathepsin S in complex with a Zinc mediated non-covalent arylaminoethyl amide
8G24	;	1.82	;	Crystal Structure of Cathepsin-G and Neutrophil Elastase Inhibited by S. aureus EapH2 at pH 5.5
8G25	;	1.8	;	Crystal Structure of Cathepsin-G and Neutrophil Elastase Inhibited by S. aureus EapH2 at pH 7.5
8G26	;	1.85	;	Crystal Structure of Cathepsin-G and Neutrophil Elastase Inhibited by S. aureus EapH2 at pH 8.5
5VXB	;	1.69	;	Crystal structure of Caulobacter crescentus ProXp-ala at 1.69 Angstrom
2QAS	;	2.55	;	Crystal structure of Caulobacter crescentus SspB ortholog
3EPM	;	2.793	;	Crystal structure of Caulobacter crescentus ThiC
3EPO	;	2.1	;	Crystal structure of Caulobacter crescentus ThiC complexed with HMP-P
3EPN	;	2.11	;	Crystal structure of Caulobacter crescentus ThiC complexed with imidazole ribonucleotide
4S2A	;	2.93	;	Crystal structure of Caulobacter crescentus ThiC with Fe4S4 cluster at remote site (holo form)
4IRX	;	1.451	;	Crystal structure of Caulobacter myo-inositol binding protein bound to myo-inositol
8G4J	;	2.35	;	Crystal structure of Cavia porcellus (guinea pig) importin-alpha 1 in cargo-free state
7BXB	;	1.72	;	Crystal structure of Ca_00311
7BXC	;	2.25	;	Crystal structure of Ca_00311 form II
7BXD	;	1.18	;	Crystal structure of Ca_00815
2HFF	;	1.95	;	Crystal structure of CB2 Fab
8HFJ	;	2.75	;	Crystal Structure of CbAR mutant (H162F) in complex with NADP+ and a bulky 1,3-cyclodiketone
8HFK	;	2.9	;	Crystal Structure of CbAR mutant (H162F) in complex with NADP+ and halogenated aryl ketone
4NSC	;	3.2	;	Crystal Structure of CBARA1 in the Apo-form
4NSD	;	2.7	;	Crystal Structure of CBARA1 in the Ca2+ Binding Form
4UAV	;	1.3	;	Crystal structure of CbbY (AT3G48420) from Arabidobsis thaliana
4UAT	;	1.3	;	Crystal structure of CbbY (mutant D10N) from Rhodobacter sphaeroides in complex with Xylulose-(1,5)bisphosphate, crystal form I
4UAU	;	1.45	;	Crystal structure of CbbY (mutant D10N) from Rhodobacter sphaeroides in complex with Xylulose-(1,5)bisphosphate, crystal form II
4UAS	;	1.2	;	Crystal structure of CbbY from Rhodobacter sphaeroides in complex with phosphate
3RB7	;	2.9	;	Crystal structure of CBD12 from CALX1.2
8P2B	;	2.6	;	Crystal structure of CbFMN4 domain 1
2E0N	;	2.0	;	Crystal structure of CbiL in complex with S-adenosylhomocysteine, a methyltransferase involved in anaerobic vitamin B12 biosynthesis
2E0K	;	2.1	;	Crystal structure of CbiL, a methyltransferase involved in anaerobic vitamin B12 biosynthesis
8QTJ	;	1.523	;	Crystal structure of Cbl-b in complex with an allosteric inhibitor (compound 30)
8QTK	;	1.873	;	Crystal structure of CBL-b in complex with an allosteric inhibitor (compound 31)
8QTH	;	2.198	;	Crystal structure of CBL-b in complex with an allosteric inhibitor (compound 8)
8QTG	;	1.419	;	Crystal structure of CBL-b in complex with an allosteric inhibitor (compound 9)
5AXI	;	2.5	;	Crystal structure of Cbl-b TKB domain in complex with Cblin
3PFV	;	2.27	;	Crystal structure of Cbl-b TKB domain in complex with EGFR pY1069 peptide
3OP0	;	2.52	;	Crystal structure of Cbl-c (Cbl-3) TKB domain in complex with EGFR pY1069 peptide
5UOS	;	2.51	;	Crystal Structure of CblC (MMACHC) (1-238), a human B12 processing enzyme, complexed with an Antivitamin B12
5H48	;	2.2	;	Crystal structure of Cbln1
5H49	;	2.8	;	Crystal structure of Cbln1
5KC6	;	2.801	;	Crystal structure of Cbln1 (Val55-Gly58 deletion mutant)
5KC7	;	7.035	;	Crystal structure of Cbln1 (Val55-Gly58 deletion mutant)
5H4B	;	2.8	;	Crystal structure of Cbln4
5H4C	;	2.3	;	Crystal structure of Cbln4
7VT5	;	1.46	;	Crystal structure of CBM deleted MtGlu5 from Meiothermus taiwanensis WR-220
7VT6	;	1.53	;	Crystal structure of CBM deleted MtGlu5 in complex with BGC.
7VT7	;	1.53	;	Crystal structure of CBM deleted MtGlu5 in complex with CBI
2Z0B	;	2.0	;	Crystal structure of CBM20 domain of human putative glycerophosphodiester phosphodiesterase 5 (KIAA1434)
2COV	;	1.25	;	Crystal structure of CBM31 from beta-1,3-xylanase
4TXW	;	1.4	;	Crystal structure of CBM32-4 from the Clostridium perfringens NagH
3KMV	;	1.8	;	Crystal structure of CBM42A from Clostridium thermocellum
6B15	;	2.1	;	Crystal structure of CBMbc (family CBM26) from Eubacterium rectale Amy13K
6B3P	;	2.01	;	Crystal structure of CBMbc (family CBM26) from Eubacterium rectale Amy13K in Complex with Maltoheptaose
6AZ5	;	2.2	;	Crystal structure of CBMd (family CBM41) from Eubacterium rectale Amy13K
1IXC	;	2.2	;	Crystal structure of CbnR, a LysR family transcriptional regulator
1IZ1	;	2.5	;	CRYSTAL STRUCTURE OF CBNR, A LYSR FAMILY TRANSCRIPTIONAL REGULATOR
5XXP	;	2.55	;	Crystal structure of CbnR_DBD-DNA complex
4OUF	;	1.4	;	Crystal Structure of CBP bromodomain
7EVJ	;	2.57	;	Crystal structure of CBP bromodomain liganded with 9c
7XH6	;	1.75	;	Crystal structure of CBP bromodomain liganded with CCS1477
7XI0	;	1.62	;	Crystal structure of CBP bromodomain liganded with CCS150
7XHE	;	1.59	;	Crystal structure of CBP bromodomain liganded with CCS151
7KPY	;	1.7	;	Crystal structure of CBP bromodomain liganded with UMB298 (compound 23)
7XNG	;	2.35	;	Crystal structure of CBP bromodomain liganded with Y08092(31g)
7XIJ	;	1.82	;	Crystal structure of CBP bromodomain liganded with Y08175
7XNE	;	2.17	;	Crystal structure of CBP bromodomain liganded with Y08284
5GH9	;	1.451	;	Crystal structure of CBP Bromodomain with H3K56ac peptide
5GT1	;	1.85	;	crystal structure of cbpa from L. salivarius REN
6ZZ9	;	2.644	;	Crystal structure of CbpB from Streptococcus agalactiae
6ZZA	;	2.491	;	Crystal structure of CbpB in complex with c-di-AMP
6XNU	;	1.62	;	CRYSTAL STRUCTURE OF CBPB PROTEIN (LMO1009) FROM LISTERIA MONOCYTOGENES
7BAY	;	2.65	;	Crystal structure of CbpF from Streptococcus pneumoniae complexed with a Ytterbium derivative
2X8P	;	2.27	;	Crystal Structure of CbpF in Complex with Atropine by Co- Crystallization
2X8O	;	2.03	;	Crystal Structure of CbpF in complex with Atropine by soaking
2X8M	;	1.85	;	Crystal Structure of CbpF in complex with ipratropium by soaking
4XSX	;	3.708	;	Crystal structure of CBR 703 bound to Escherichia coli RNA polymerase holoenzyme
4XSY	;	4.007	;	Crystal structure of CBR 9379 bound to Escherichia coli RNA polymerase holoenzyme
4XSZ	;	3.683	;	Crystal structure of CBR 9393 bound to Escherichia coli RNA polymerase holoenzyme
3LV9	;	2.4	;	Crystal structure of CBS domain of a putative transporter from Clostridium difficile 630
7LZG	;	2.81	;	CRYSTAL STRUCTURE OF CBS DOMAIN PROTEIN FROM STREPTOCOCCUS PNEUMONIAE TIGR4
2RC3	;	1.6	;	Crystal structure of CBS domain, NE2398
3LQN	;	1.8	;	Crystal Structure of CBS Domain-containing Protein of Unknown Function from Bacillus anthracis str. Ames Ancestor
1YAV	;	2.1	;	Crystal structure of CBS domain-containing protein ykuL from Bacillus subtilis
4GQW	;	2.201	;	Crystal structure of CBS-pair protein, CBSX1 (loop deletion) from Arabidopsis thaliana
4GQV	;	2.392	;	Crystal structure of CBS-pair protein, CBSX1 from Arabidopsis thaliana
3SL7	;	1.905	;	Crystal structure of CBS-pair protein, CBSX2 from Arabidopsis thaliana
5BZA	;	2.002	;	Crystal structure of CbsA from Thermotoga neapolitana
4GQY	;	2.193	;	Crystal structure of CBSX2 in complex with AMP
4PMD	;	1.7	;	Crystal structure of CbXyn10B from Caldicellulosiruptor bescii and its mutant(E139A) in complex with hydrolyzed xylotetraose
5OFL	;	1.871	;	Crystal structure of CbXyn10C variant E140Q/E248Q complexed with cellohexaose
5OFK	;	1.16	;	Crystal structure of CbXyn10C variant E140Q/E248Q complexed with xyloheptaose
5COY	;	1.443	;	Crystal structure of CC chemokine 5 (CCL5)
5DNF	;	2.549	;	Crystal structure of CC chemokine 5 (CCL5) oligomer in complex with heparin
5UIW	;	2.204	;	Crystal Structure of CC Chemokine Receptor 5 (CCR5) in complex with high potency HIV entry inhibitor 5P7-CCL5
4MHE	;	2.1	;	Crystal structure of CC-chemokine 18
1Q82	;	2.98	;	Crystal Structure of CC-Puromycin bound to the A-site of the 50S ribosomal subunit
5ED9	;	2.009	;	Crystal structure of CC1 of mouse SUN2
5ED8	;	2.5	;	Crystal structure of CC2-SUN of mouse SUN2
4U3N	;	3.2	;	Crystal structure of CCA trinucleotide bound to the yeast 80S ribosome
1Q86	;	3.0	;	Crystal structure of CCA-Phe-cap-biotin bound simultaneously at half occupancy to both the A-site and P-site of the the 50S ribosomal Subunit.
7YN3	;	2.1	;	Crystal structure of CcbD complex with CcbZ carrier protein domain
7YN2	;	2.3	;	Crystal structure of CcbD with methylthiolincosamide
3A64	;	1.6	;	Crystal structure of CcCel6C, a glycoside hydrolase family 6 enzyme, from Coprinopsis cinerea
3PZ7	;	2.441	;	Crystal structure of Ccd1-DIX domain
1Q7Y	;	3.2	;	Crystal Structure of CCdAP-Puromycin bound at the Peptidyl transferase center of the 50S ribosomal subunit
7EOE	;	2.9	;	Crystal structure of CCDC25 homodimer
3NJ2	;	1.59	;	Crystal structure of cce_0566 from the cyanobacterium Cyanothece 51142, a protein associated with nitrogen fixation from the DUF269 family
4PZQ	;	2.24	;	Crystal Structure of CCG DNA repeats
5ZT2	;	1.66002	;	Crystal structure of CCG DNA repeats at 1.66 angstrom resolution
3W8I	;	2.4	;	Crystal structure of CCM3 in complex with the C-terminal regulatory domain of MST4
3W8H	;	2.426	;	Crystal structure of CCM3 in complex with the C-terminal regulatory domain of STK25
3L8I	;	2.5	;	Crystal structure of CCM3, a cerebral cavernous malformation protein critical for vascular integrity
3L8J	;	3.05	;	Crystal structure of CCM3, a cerebral cavernous malformation protein critical for vascular integrity
1KNG	;	1.14	;	Crystal structure of CcmG reducing oxidoreductase at 1.14 A
7D6C	;	2.89	;	Crystal structure of CcmM N-terminal domain in complex with CcmN
8EFZ	;	2.38	;	Crystal structure of CcNikZ-II, apoprotein
5GPL	;	2.1	;	Crystal structure of Ccp1
5GPK	;	2.103	;	Crystal structure of Ccp1 mutant
5Z72	;	2.4	;	Crystal structure of CcpC regulatory domain in complex with citrate from Bacillus amyloliquefaciens
7DMW	;	2.29	;	Crystal structure of CcpC regulatory domain in complex with citrate from Bacillus amyloliquefaciens
5Z7H	;	2.5	;	Crystal structure of CcpE regulatory domain in citrate-bound form from Staphyloccocus aureus
5ZZO	;	2.5	;	Crystal structure of CcpE regulatory domain in complex with citrate from Staphyloccocus aureus
6GPS	;	3.3	;	CRYSTAL STRUCTURE OF CCR2A IN COMPLEX WITH MK-0812
6GPX	;	2.7	;	CRYSTAL STRUCTURE OF CCR2A IN COMPLEX WITH MK-0812
1FA7	;	1.9	;	CRYSTAL STRUCTURE OF CD(II)-BOUND GLYOXALASE I OF ESCHERICHIA COLI
5I6H	;	7.2	;	Crystal structure of CD-CT domains of Chaetomium thermophilum acetyl-CoA carboxylase
6Y8K	;	2.011	;	Crystal structure of CD137 in complex with the cyclic peptide BCY10916
1WWL	;	2.5	;	Crystal structure of CD14
5X0T	;	2.5	;	Crystal structure of CD147 C2 domain in complex with Fab of its monoclonal antibody 6H8
1ONQ	;	2.15	;	Crystal Structure of CD1a in Complex with a Sulfatide
1XZ0	;	2.8	;	Crystal structure of CD1a in complex with a synthetic mycobactin lipopeptide
2PO6	;	3.2	;	Crystal structure of CD1d-lipid-antigen complexed with Beta-2-Microglobulin, NKT15 Alpha-Chain and NKT15 Beta-Chain
8GZJ	;	2.093	;	Crystal structure of Cd2+-bound DNA aptamer
8GZL	;	3.0	;	Crystal structure of Cd2+-bound DNA aptamer
8GZK	;	2.94	;	Crystal structure of Cd2+-bound DNA aptamer T10A mutant
8GZM	;	2.55	;	Crystal structure of Cd2+-bound DNA aptamer T22C mutant
4GJX	;	2.8	;	Crystal structure of CD23 lectin domain mutant D258A
4GK1	;	2.236	;	Crystal structure of CD23 lectin domain mutant D270A
4GI0	;	2.27	;	Crystal structure of CD23 lectin domain mutant E249A
4GJ0	;	1.953	;	Crystal structure of CD23 lectin domain mutant S252A
6YAX	;	2.8	;	Crystal structure of CD32b (Fc Gamma Receptor IIb) in complex with Human IgG1 Fab fragment (5C05)
5OCC	;	2.5	;	Crystal structure of CD32b (Fc Gamma Receptor IIb) in complex with Human IgG1 Fab fragment (6G08)
7DHA	;	2.55	;	crystal structure of CD38 in complex with daratumumab
4CMH	;	1.53	;	Crystal structure of CD38 with a novel CD38-targeting antibody SAR650984
1SY6	;	2.1	;	Crystal Structure of CD3gammaepsilon Heterodimer in Complex with OKT3 Fab Fragment
5WB9	;	2.4	;	Crystal structure of CD4 binding site antibody N60P23 in complex with HIV-1 clade A/E strain 93TH057 gp120 core
3S4S	;	2.4	;	Crystal structure of CD4 mutant bound to HLA-DR1
3S5L	;	2.1	;	Crystal structure of CD4 mutant bound to HLA-DR1
4JZZ	;	1.49	;	Crystal structure of CD4-mimetic miniprotein M48U1 in complex with HIV-1 YU2 gp120 in C2221 space group
4JZW	;	1.784	;	Crystal structure of CD4-mimetic miniprotein M48U1 in complex with HIV-1 YU2 gp120 in P212121 space group
4KA2	;	1.79	;	Crystal structure of CD4-mimetic miniprotein M48U12 in complex with HIV-1 YU2 gp120
4K0A	;	2.13	;	Crystal structure of CD4-mimetic miniprotein M48U7 in complex with HIV-1 YU2 gp120
6PE9	;	3.13	;	Crystal Structure of CD40 complexed to FAB516
6PE8	;	2.84	;	Crystal structure of CD40/ABBV-323 FAB complex
1YYL	;	2.75	;	crystal structure of CD4M33, a scorpion-toxin mimic of CD4, in complex with HIV-1 YU2 gp120 envelope glycoprotein and anti-HIV-1 antibody 17b
2I5Y	;	2.2	;	Crystal structure of CD4M47, a scorpion-toxin mimic of CD4, in complex with HIV-1 YU2 GP120 envelope glycoprotein and anti-HIV-1 antibody 17B
2JA4	;	2.21	;	Crystal structure of CD5 domain III reveals the fold of a group B scavenger cysteine-rich receptor
2OTT	;	2.5	;	Crystal structure of CD5_DIII
7PBY	;	1.13	;	Crystal structure of CD73 in complex with 4-nitrocatechol in the open form
7PCP	;	1.377	;	Crystal structure of CD73 in complex with 5-iodouracil in the open form
7P9N	;	1.55	;	Crystal structure of CD73 in complex with AMP in the open form
7PBB	;	1.47	;	Crystal structure of CD73 in complex with caffeine in the open form
7PA4	;	1.45	;	Crystal structure of CD73 in complex with CMP in the open form
7P9T	;	1.79	;	Crystal structure of CD73 in complex with dCMP in the open form
7P9R	;	1.41	;	Crystal structure of CD73 in complex with GMP in the open form
7PBA	;	1.42	;	Crystal structure of CD73 in complex with IMP in the open form
7PD9	;	1.39	;	Crystal structure of CD73 in complex with riboflavin in the open form
7PB5	;	1.28	;	Crystal structure of CD73 in complex with UMP in the open form
2PKD	;	2.043	;	Crystal structure of CD84: Insite into SLAM family function
3B9K	;	2.7	;	Crystal structure of CD8alpha-beta in complex with YTS 156.7 FAB
6RLR	;	2.0	;	Crystal structure of CD9 large extracellular loop
6ARQ	;	2.88	;	Crystal structure of CD96 (D1) bound to CD155/necl-5 (D1-3)
7DO4	;	3.2	;	Crystal structure of CD97-CD55 complex
6HUW	;	2.8	;	Crystal structure of CdaA from Bacillus subtilis
8OGM	;	1.1	;	Crystal structure of CdaA from Bacillus subtilis
8OGK	;	1.18	;	Crystal structure of CdaA from Bacillus subtilis co-crystallized with DMSO
4LUY	;	2.6	;	Crystal structure of CdALR mutant K 271 T
8FWP	;	2.22	;	Crystal Structure of CDC10 - CDC3 heterocomplex from Saccharomyces cerevisiae
5AR1	;	2.85	;	Crystal structure of Cdc11 from Saccharomyces cerevisiae
6XJ1	;	3.52	;	Crystal Structure of CDC15 F-BAR Domain from Schizosaccharomyces pombe
4N14	;	2.1	;	Crystal structure of Cdc20 and apcin complex
8SGD	;	2.66	;	Crystal Structure of CDC3(G) - CDC10(Delta 1-10) heterocomplex from Saccharomyces cerevisiae
4AW2	;	1.7	;	Crystal structure of CDC42 binding protein kinase alpha (MRCK alpha)
6CC2	;	1.66	;	Crystal Structure of CDC45 from Entamoeba histolytica
1FNN	;	2.0	;	CRYSTAL STRUCTURE OF CDC6P FROM PYROBACULUM AEROPHILUM
5UWR	;	2.24	;	Crystal Structure of CDC7 NES Peptide (extended) in complex with CRM1-Ran-RanBP1
5UWQ	;	2.278	;	Crystal Structure of CDC7 NES Peptide in complex with CRM1-Ran-RanBP1
5AXS	;	1.67	;	Crystal structure of CdCat-Fn
5T87	;	2.4	;	Crystal structure of CDI complex from Cupriavidus taiwanensis LMG 19424
5T86	;	2.0	;	Crystal structure of CDI complex from E. coli A0 34/86
5HKQ	;	2.0	;	Crystal structure of CDI complex from Escherichia coli STEC_O31
5E3E	;	1.7	;	Crystal structure of CdiA-CT/CdiI complex from Y. kristensenii 33638
5FFP	;	2.5	;	Crystal structure of CdiI from Burkholderia dolosa AUO158
8U2O	;	2.15	;	Crystal Structure of Cdk-related protein kinase 6 (PK6) from Plasmodium falciparum in complex with inhibitor TCMDC-123995
5ANK	;	1.9	;	Crystal structure of CDK2 in complex with 2,4,6-trioxo-1-phenyl- hexahydropyrimidine-5-carboxamide processed with the CrystalDirect automated mounting and cryo-cooling technology
5AND	;	2.3	;	Crystal structure of CDK2 in complex with 2-imidazol-1-yl-1H- benzimidazole processed with the CrystalDirect automated mounting and cryo-cooling technology
5ANI	;	1.9	;	Crystal structure of CDK2 in complex with 6-chloro-7H-purine processed with the CrystalDirect automated mounting and cryo-cooling technology
5ANE	;	1.7	;	Crystal structure of CDK2 in complex with 6-methoxy-7H-purine processed with the CrystalDirect automated mounting and cryo-cooling technology
5ANG	;	1.9	;	Crystal structure of CDK2 in complex with 7-hydroxy-4-(morpholinomethyl)chromen-2-one processed with the CrystalDirect automated mounting and cryo-cooling technology
5K4J	;	1.6	;	Crystal Structure of CDK2 in complex with compound 22
8CUR	;	2.2	;	Crystal structure of Cdk2 in complex with Cyclin A inhibitor 6-[(E)-2-(4-chlorophenyl)ethenyl]-2-{[(2R)-3-(4-hydroxyphenyl)-1-methoxy-1-oxopropan-2-yl]carbamoyl}quinoline-4-carboxylic acid
3NS9	;	1.78	;	Crystal structure of CDK2 in complex with inhibitor BS-194
6INL	;	1.75	;	Crystal structure of CDK2 IN complex with Inhibitor CVT-313
5JQ5	;	1.94	;	Crystal structure of CDK2 in complex with inhibitor ICEC0942
5JQ8	;	1.94	;	Crystal structure of CDK2 in complex with inhibitor ICEC0943
6JGM	;	2.3	;	Crystal structure of CDK2 IN complex with Inhibitor NU-6140
2J9M	;	2.5	;	Crystal Structure of CDK2 in complex with Macrocyclic Aminopyrimidine
5ANJ	;	1.6	;	Crystal structure of CDK2 in complex with N-(9H-purin-6-yl)thiophene- 2-carboxamide processed with the CrystalDirect automated mounting and cryo-cooling technology
4BGH	;	1.95	;	Crystal Structure of CDK2 in complex with pan-CDK Inhibitor
3WBL	;	2.0	;	Crystal structure of CDK2 in complex with pyrazolopyrimidine inhibitor
7RWF	;	1.5	;	Crystal structure of CDK2 in complex with TW8672
7S4T	;	1.91	;	Crystal structure of CDK2 liganded with compound EF2252
7S7A	;	1.7	;	Crystal structure of CDK2 liganded with compound EF3019
7SA0	;	1.59	;	Crystal structure of CDK2 liganded with compound EF4195
7RWE	;	1.59	;	Crystal structure of CDK2 liganded with compound GPHR787
7S84	;	2.0	;	Crystal structure of CDK2 liganded with compound TW8972
7S85	;	1.98	;	Crystal structure of CDK2 liganded with compound WN316
7RXO	;	1.38	;	Crystal structure of CDK2 liganded with compound WN333
7S9X	;	1.69	;	Crystal structure of CDK2 liganded with compound WN378
5ANO	;	1.7	;	Crystal structure of CDK2 processed with the CrystalDirect automated mounting and cryo-cooling technology
3S2P	;	2.3	;	Crystal structure of CDK2 with a 2-aminopyrimidine compound
1YKR	;	1.8	;	Crystal structure of cdk2 with an aminoimidazo pyridine inhibitor
1PYE	;	2.0	;	Crystal structure of CDK2 with inhibitor
3LFS	;	2.4	;	Crystal structure of CDK2 with SAR37, an aminoindazole type inhibitor
3LFN	;	2.28	;	Crystal structure of CDK2 with SAR57, an aminoindazole type inhibitor
3LFQ	;	2.03	;	Crystal structure of CDK2 with SAR60, an aminoindazole type inhibitor
7KJS	;	2.187	;	Crystal structure of CDK2/cyclin E in complex with PF-06873600
2W96	;	2.3	;	Crystal Structure of CDK4 in complex with a D-type cyclin
2W99	;	2.8	;	Crystal Structure of CDK4 in complex with a D-type cyclin
2W9F	;	2.85	;	Crystal Structure of CDK4 in complex with a D-type cyclin
2W9Z	;	2.45	;	Crystal Structure of CDK4 in complex with a D-type cyclin
6P8H	;	3.19	;	Crystal structure of CDK4 in complex with CyclinD1 and P21
6P8E	;	2.3	;	Crystal structure of CDK4 in complex with CyclinD1 and P27
6P8F	;	2.89	;	Crystal structure of CDK4 in complex with CyclinD1 and P27
6P8G	;	2.8	;	Crystal structure of CDK4 in complex with CyclinD1 and P27
3G33	;	3.0	;	Crystal structure of CDK4/cyclin D3
3O0G	;	1.95	;	Crystal Structure of Cdk5:p25 in complex with an ATP analogue
6Y0A	;	2.19	;	CRYSTAL STRUCTURE OF CDK8-CycC IN COMPLEX WITH BI00690300
6R3S	;	2.19	;	CRYSTAL STRUCTURE OF CDK8-CycC IN COMPLEX WITH COMPOUND 1
5CEI	;	2.24	;	Crystal structure of CDK8:Cyclin C complex with compound 22
7NWK	;	2.81	;	Crystal structure of CDK9-Cyclin T1 bound by compound 6
2OYN	;	1.85	;	Crystal structure of CDP-bound protein MJ0056 from Methanococcus jannaschii, Pfam DUF120
3Q1P	;	1.8	;	Crystal structure of CDP-Chase
3Q4I	;	2.5	;	Crystal structure of CDP-Chase in complex with Gd3+
6NCH	;	2.0	;	Crystal structure of CDP-Chase: Raster data collection
6NCI	;	2.08	;	Crystal structure of CDP-Chase: Vector data collection
2POF	;	1.4	;	Crystal structure of CDP-diacylglycerol pyrophosphatase
1ORR	;	1.5	;	Crystal Structure of CDP-Tyvelose 2-Epimerase complexed with NAD and CDP
3IS5	;	2.55	;	Crystal structure of CDPK kinase domain from toxoplasma Gondii, TGME49_018720
3HX4	;	1.95	;	Crystal structure of CDPK1 of Toxoplasma gondii, TGME49_101440, in presence of calcium
4QOX	;	2.748	;	Crystal Structure of CDPK4 from Plasmodium Falciparum, PF3D7_0717500
7Y3V	;	2.43	;	Crystal structure of CdpNPT in complex with harmane
7XVJ	;	2.4	;	Crystal structure of CdpNPT in complex with harmol
4E0U	;	2.6	;	Crystal structure of CdpNPT in complex with thiolodiphosphate and (S)-benzodiazependione
4E0T	;	2.25	;	Crystal structure of CdpNPT in its unbound state
3A4C	;	1.889	;	Crystal structure of cdt1 C terminal domain
2ZXX	;	2.8	;	Crystal structure of Cdt1/geminin complex
6V41	;	1.603	;	crystal structure of CDY1 chromodomain bound to H3K9me3
6V3N	;	2.7	;	Crystal structure of CDYL2 in complex with H3K27me3
6V2H	;	2.6	;	Crystal structure of CDYL2 in complex with H3tK27me3
6AW1	;	2.1	;	Crystal structure of CEACAM3
6AW0	;	2.43	;	Crystal structure of CEACAM3 L44Q
6LDU	;	1.701	;	Crystal structure of CeCht1, a nematode I family chitinase from C. elegans
4M9R	;	2.656	;	Crystal structure of CED-3
3S5B	;	1.796	;	Crystal Structure of CED-3 Protease Suppressor-6 (CPS-6) from Caenorhabditis elegans
4M9S	;	3.207	;	crystal structure of CED-4 bound CED-3 fragment
4M9X	;	3.344	;	Crystal structure of CED-4 bound CED-3 fragment
4M9Y	;	4.2	;	Crystal structure of CED-4 bound CED-3 fragment
4M9Z	;	3.405	;	Crystal structure of CED-4 bound CED-3 fragment
3ZG0	;	2.6	;	Crystal structure of ceftaroline acyl-PBP2a from MRSA with non- covalently bound ceftaroline and muramic acid at allosteric site obtained by cocrystallization
3ZFZ	;	2.25	;	Crystal structure of ceftaroline acyl-PBP2a from MRSA with non- covalently bound ceftaroline and muramic acid at allosteric site obtained by soaking
6K03	;	2.857	;	Crystal structure of ceH2A-H2B
3ALS	;	3.0	;	Crystal structure of CEL-IV
3ALT	;	2.5	;	Crystal structure of CEL-IV complexed with Melibiose
3ALU	;	1.65	;	Crystal structure of CEL-IV complexed with Raffinose
2E4T	;	0.96	;	Crystal structure of Cel44A, GH family 44 endoglucanase from Clostridium thermocellum
2EEX	;	2.0	;	Crystal structure of Cel44A, GH family 44 endoglucanase from Clostridium thermocellum
2EJ1	;	1.8	;	Crystal structure of Cel44A, GH family 44 endoglucanase from Clostridium thermocellum
2EO7	;	1.75	;	Crystal structure of Cel44A, GH family 44 endoglucanase from Clostridium thermocellum
2EQD	;	2.8	;	Crystal structure of Cel44A, GH family 44 endoglucanase from Clostridium thermocellum
1LF1	;	1.7	;	Crystal Structure of Cel5 from Alkalophilic Bacillus sp.
3QR3	;	2.05	;	Crystal Structure of Cel5A (EG2) from Hypocrea jecorina (Trichoderma reesei)
3PFJ	;	1.3611	;	Crystal structure of Cel7A from Talaromyces emersonii
3PFX	;	1.2616	;	Crystal structure of Cel7A from Talaromyces emersonii in complex with cellobiose
3PL3	;	1.1804	;	Crystal structure of Cel7A from Talaromyces emersonii in complex with cellopentaose
3PFZ	;	1.0993	;	Crystal structure of Cel7A from Talaromyces emersonii in complex with cellotetraose
8GHX	;	2.46	;	Crystal Structure of CelD Cellulase from the Anaerobic Fungus Piromyces finnis
4CJ0	;	1.1	;	Crystal structure of CelD in complex with affitin E12
4CJ1	;	1.63	;	Crystal structure of CelD in complex with affitin H3
5JW1	;	2.822	;	Crystal structure of Celecoxib bound to S121P murine COX-2 mutant
4DFI	;	1.8	;	Crystal structure of cell adhesion molecule nectin-2/CD112 mutant FAMP
4DFH	;	1.85	;	Crystal structure of cell adhesion molecule nectin-2/CD112 variable domain
5EZ1	;	2.4	;	Crystal Structure of Cell Binding Factor 2 from Helicobacter pylori in complex with I2CA
4IKG	;	1.9318	;	Crystal structure of cell death-inducing DFFA-like effector c
3OP3	;	2.63	;	Crystal Structure of Cell Division Cycle 25C Protein Isoform A from Homo sapiens
5DGO	;	2.1	;	Crystal structure of cell division cycle protein 45 (Cdc45)
1VMA	;	1.6	;	Crystal structure of Cell division protein ftsY (TM0570) from Thermotoga maritima at 1.60 A resolution
5V68	;	3.46	;	Crystal structure of cell division protein FtsZ from Mycobacterium tuberculosis bounded via the T9 loop
2Q1X	;	2.35	;	Crystal Structure of cell division protein FtsZ from Mycobacterium tuberculosis in complex with citrate.
2Q1Y	;	2.3	;	Crystal Structure of cell division protein FtsZ from Mycobacterium tuberculosis in complex with GTP-gamma-S
2VH2	;	3.4	;	Crystal structure of cell divison protein FtsQ from Yersinia enterecolitica
3GQM	;	2.1	;	Crystal structure of Cell Inhibiting Factor (Cif) from Burkholderia pseudomallei (CifBp)
3GQJ	;	1.85	;	Crystal structure of Cell Inhibiting Factor (Cif) from Photorhabdus luminescens
4WCM	;	1.75	;	Crystal Structure of Cell Shape Determinant protein Csd4 Gln46His variant from Helicobacter pylori
7EFT	;	2.1	;	Crystal structure of cell shape-determining protein MreC
6IQV	;	2.13	;	Crystal Structure of Cell Surface Glyceraldehyde-3-Phosphate Dehydrogenase Complexed with Hg2+ from Lactobacillus plantarum
6IQM	;	1.85	;	Crystal Structure of Cell Surface Glyceraldehyde-3-Phosphate Dehydrogenase Complexed with NAD+ from Lactobacillus plantarum
3CG7	;	2.5	;	Crystal structure of cell-death related nuclease 4 (CRN-4)
3CM6	;	2.6	;	Crystal structure of cell-death related nuclease 4 (CRN-4) bound with Er
3CM5	;	2.81	;	Crystal structure of Cell-Death Related Nuclease 4 (CRN-4) bound with Mn
2RFW	;	1.6	;	Crystal Structure of Cellobiohydrolase from Melanocarpus albomyces
2RFY	;	1.7	;	Crystal structure of cellobiohydrolase from Melanocarpus albomyces complexed with cellobiose
2RG0	;	2.1	;	Crystal structure of cellobiohydrolase from Melanocarpus albomyces complexed with cellotetraose
2RFZ	;	1.8	;	Crystal structure of cellobiohydrolase from Melanocarpus albomyces complexed with cellotriose
3WKF	;	1.743	;	Crystal structure of cellobiose 2-epimerase
4Z4J	;	1.542	;	Crystal Structure of cellobiose 2-epimerase from Caldicellulosiruptor saccharolyticus DSM 8903
4Z4L	;	1.671	;	Crystal Structure of cellobiose 2-epimerase from Caldicellulosiruptor saccharolyticus DSM 8903
3WKI	;	2.191	;	Crystal structure of cellobiose 2-epimerase in complex with cellobiitol
3WKH	;	1.644	;	Crystal structure of cellobiose 2-epimerase in complex with epilactose
3WKG	;	1.47	;	Crystal structure of cellobiose 2-epimerase in complex with glucosylmannose
5HZQ	;	1.75	;	Crystal structure of cellular retinoic acid binding protein 2 (CRABP2)-aryl fluorosulfate covalent conjugate
2FR3	;	1.48	;	Crystal Structure of Cellular Retinoic Acid Binding Protein Type II in Complex with All-Trans-Retinoic Acid at 1.48 Angstroms Resolution
1CBQ	;	2.2	;	CRYSTAL STRUCTURE OF CELLULAR RETINOIC-ACID-BINDING PROTEINS I AND II IN COMPLEX WITH ALL-TRANS-RETINOIC ACID AND A SYNTHETIC RETINOID
1CBR	;	2.9	;	CRYSTAL STRUCTURE OF CELLULAR RETINOIC-ACID-BINDING PROTEINS I AND II IN COMPLEX WITH ALL-TRANS-RETINOIC ACID AND A SYNTHETIC RETINOID
1CBS	;	1.8	;	CRYSTAL STRUCTURE OF CELLULAR RETINOIC-ACID-BINDING PROTEINS I AND II IN COMPLEX WITH ALL-TRANS-RETINOIC ACID AND A SYNTHETIC RETINOID
3AMH	;	2.09	;	crystal structure of cellulase 12A from Thermotoga maritima
5H4U	;	2.6	;	Crystal structure of cellulase from Antarctic springtail, Cryptopygus antarcticus
2EA3	;	1.78	;	Crystal Structure Of Cellulomonas Bogoriensis Chymotrypsin
8X39	;	1.7	;	Crystal structure of cellulosomal double-dockerin module of Clo1313_0689 from Clostridium thermocellum
3QG0	;	2.7	;	Crystal Structure of Cellvibrio gilvus Cellobiose Phosphorylase Complexed with Phosphate and 1-Deoxynojirimycin
3QFZ	;	2.39	;	Crystal Structure of Cellvibrio gilvus Cellobiose Phosphorylase Complexed with Sulfate and 1-Deoxynojirimycin
3QFY	;	2.3	;	Crystal Structure of Cellvibrio gilvus Cellobiose Phosphorylase Complexed with Sulfate and Isofagomine
2CQS	;	2.0	;	Crystal Structure of Cellvibrio gilvus Cellobiose Phosphorylase Crystallized from Ammonium Sulfate
2CQT	;	2.1	;	Crystal Structure of Cellvibrio gilvus Cellobiose Phosphorylase Crystallized from Sodium/Potassium Phosphate
3ACT	;	1.85	;	Crystal Structure of Cellvibrio gilvus Cellobiose Phosphorylase Histidine mutant
3AFJ	;	1.9	;	Crystal Structure of Cellvibrio gilvus Cellobiose Phosphorylase triple mutant
3ACS	;	2.51	;	Crystal Structure of Cellvibrio gilvus Cellobiose Phosphorylase W488F mutant
3FW6	;	2.3	;	Crystal structure of CelM2, a bifunctional glucanase-xylanase protein from a metagenome library
6K02	;	2.162	;	Crystal structure of ceNAP1 core
6K0C	;	2.281	;	Crystal structure of ceNAP1-H2A.Z-H2B complex
1HLV	;	2.5	;	CRYSTAL STRUCTURE OF CENP-B(1-129) COMPLEXED WITH THE CENP-B BOX DNA
4X23	;	3.5	;	CRYSTAL STRUCTURE OF CENP-C IN COMPLEX WITH THE NUCLEOSOME CORE PARTICLE
4WAU	;	2.2	;	Crystal structure of CENP-M solved by native-SAD phasing
4OXM	;	1.9	;	CRYSTAL STRUCTURE OF Central Coiled-Coil from Influenza Hemagglutinin HA2 without Heptad Repeat Stutter
4P67	;	1.9	;	CRYSTAL STRUCTURE OF Central Coiled-Coil from Influenza Hemagglutinin HA2 without Heptad Repeat Stutter, spacegroup P3(1)
3CTV	;	2.46	;	Crystal structure of central domain of 3-hydroxyacyl-CoA dehydrogenase from Archaeoglobus fulgidus
6J7E	;	2.4	;	Crystal Structure of Central domain of FleQ in complex with ATPgS and Mg
5Z07	;	2.298	;	Crystal structure of centromere protein Cenp-I
6FLJ	;	1.751	;	Crystal structure of Cep120 C2A_K76A mutant
6FLK	;	1.6	;	Crystal structure of Cep120 C2C domain
6OQA	;	2.2	;	Crystal structure of CEP250 bound to FKBP12 in the presence of FK506-like novel natural product
4ZJ3	;	1.7	;	Crystal structure of cephalexin bound acyl-enzyme intermediate of Val216AcrF mutant TEM1 beta-lactamase from Escherichia coli: E166N and V216AcrF mutant.
2NLZ	;	2.7	;	Crystal structure of cephalosporin acylase from Bacillus halodurans
4HHV	;	1.75	;	Crystal structure of ceramide transfer protein pleckstrin homology domain
3SUJ	;	1.34	;	Crystal structure of cerato-platanin 1 from M. perniciosa (MpCP1)
3SUK	;	1.34	;	Crystal structure of cerato-platanin 2 from M. perniciosa (MpCP2)
3SUL	;	1.63	;	Crystal structure of cerato-platanin 3 from M. perniciosa (MpCP3)
3SUM	;	1.87	;	Crystal structure of cerato-platanin 5 from M. perniciosa (MpCP5)
4YKC	;	2.7	;	Crystal structure of cerebral cavernous malformation 2 C-terminal adaptor domain
3S3L	;	2.0	;	Crystal Structure of CerJ from Streptomyces tendae
3T5Y	;	2.12	;	Crystal structure of CerJ from Streptomyces tendae - malonic acid covalently linked to the catalytic Cystein C116
3T6S	;	2.0	;	Crystal structure of CerJ from Streptomyces tendae in Complex with CoA
3T8E	;	2.1	;	Crystal structure of CerJ from Streptomyces tendae soaked with CerviK
2E3M	;	2.2	;	Crystal structure of CERT START domain
2E3S	;	1.94	;	Crystal structure of CERT START domain co-crystallized with C24-ceramide (P21)
2Z9Y	;	1.8	;	Crystal structure of CERT START domain in complex with C10-diacylglycerol
2E3P	;	1.4	;	Crystal structure of CERT START domain in complex with C16-cearmide (P1)
2E3O	;	1.55	;	Crystal structure of CERT START domain in complex with C16-ceramide (P212121)
2E3R	;	1.65	;	Crystal structure of CERT START domain in complex with C18-ceramide (P1)
2E3Q	;	2.08	;	Crystal structure of CERT START domain in complex with C18-ceramide (P212121)
2E3N	;	1.4	;	Crystal structure of CERT START domain in complex with C6-ceramide (P212121)
6IEZ	;	1.9	;	Crystal structure of CERT START domain in complex with compound B16
5ZYG	;	1.8	;	Crystal structure of CERT START domain in complex with compound B5
6IF0	;	1.8	;	Crystal structure of CERT START domain in complex with compound D16
6J81	;	1.8	;	Crystal structure of CERT START domain in complex with compound E14
5ZYI	;	1.9	;	Crystal structure of CERT START domain in complex with compound E16
5ZYJ	;	1.9	;	Crystal structure of CERT START domain in complex with compound E16A
5ZYK	;	1.55	;	Crystal structure of CERT START domain in complex with compound E25
5ZYL	;	1.8	;	Crystal structure of CERT START domain in complex with compound E25A
5ZYM	;	1.9	;	Crystal structure of CERT START domain in complex with compound E25B
5ZYH	;	1.95	;	Crystal structure of CERT START domain in complex with compound E5
6J0O	;	1.8	;	Crystal structure of CERT START domain in complex with compound SC1
2Z9Z	;	1.74	;	Crystal structure of CERT START domain(N504A mutant), in complex with C10-diacylglycerol
4GF1	;	2.25	;	Crystal Structure of Certhrax
4FK7	;	1.78	;	Crystal structure of Certhrax catalytic domain
5WUV	;	1.952	;	Crystal structure of Certolizumab Fab
3S21	;	1.7001	;	Crystal structure of cerulenin bound Xanthomonas campestri OleA (co-crystal)
3S23	;	1.9484	;	Crystal structure of cerulenin bound Xanthomonas campestri oleA (co-crystal) Xe Derivative
3S20	;	1.8796	;	Crystal structure of cerulenin bound Xanthomonas campestri OleA (soak)
6L7Y	;	2.51	;	Crystal structure of Cet1 from Trypanosoma cruzi in complex with #466 ligand.
6L7X	;	2.39	;	Crystal structure of Cet1 from Trypanosoma cruzi in complex with #951 ligand
6L7W	;	2.6	;	Crystal structure of Cet1 from Trypanosoma cruzi in complex with manganese ion.
6L7V	;	2.2	;	Crystal structure of Cet1 from Trypanosoma cruzi in complex with tripolyphosphate, manganese and iodide ions.
3VWA	;	2.2	;	Crystal structure of Cex1p
8T9O	;	2.7	;	Crystal structure of CF, a heterohexamer of the 4-oxalocrotonate tautomerase (4-OT) family
5ZAB	;	2.147	;	Crystal structure of cf3-aequorin
3FFC	;	2.8	;	Crystal Structure of CF34 TCR in complex with HLA-B8/FLR
2HB0	;	2.3	;	Crystal Structure of CfaE, the Adhesive Subunit of CFA/I Fimbria of Enterotoxigenic Escherichia coli
6B02	;	2.82	;	Crystal structure of CfFPPS2 (apo form), a lepidopteran type-II farnesyl diphosphate synthase
6B06	;	2.6	;	Crystal structure of CfFPPS2, a lepidopteran type-II farnesyl diphosphate synthase, complexed with IPP and [2-(1-methylpyridin-2-yl)-1-phosphono-ethyl]phosphonic acid (inhibitor 1b)
6B07	;	1.98	;	Crystal structure of CfFPPS2, a lepidopteran type-II farnesyl diphosphate synthase, complexed with [1-phosphono-2-(1-propylpyridin-2-yl)ethyl]phosphonic acid (inhibitor 1d)
6B04	;	1.83	;	Crystal structure of CfFPPS2, a lepidopteran type-II farnesyl diphosphate synthase, complexed with [2-(1-methylpyridin-2-yl)-1-phosphono-ethyl]phosphonic acid (inhibitor 1b)
3Q2S	;	2.9	;	Crystal Structure of CFIm68 RRM/CFIm25 complex
3Q2T	;	3.061	;	Crystal Structure of CFIm68 RRM/CFIm25/RNA complex
7JQX	;	2.2	;	Crystal structure of Cfl1 wild-type from Burkholderia cenocepacia
7JQY	;	2.15	;	Crystal structure of Cfl1-D123S from Burkholderia cenocepacia
7JQZ	;	2.2	;	Crystal structure of Cfl2 wild-type from Burkholderia cenocepacia
4E34	;	1.395	;	Crystal structure of CFTR Associated Ligand (CAL) PDZ domain bound to iCAL36 (ANSRWPTSII) peptide
4E35	;	1.4	;	Crystal structure of CFTR Associated Ligand (CAL) PDZ domain bound to iCAL36-L (ANSRWPTSIL) peptide
3N4H	;	2.02	;	Crystal structure of Cg10062 inactivated by (S)-oxirane-2-carboxylate
3N4D	;	2.54	;	Crystal structure of Cg10062 inactivated by(R)-oxirane-2-carboxylate
4DBH	;	1.94	;	Crystal structure of Cg1458 with inhibitor
3MA8	;	2.64	;	Crystal structure of CGD1_2040, a pyruvate kinase from cryptosporidium Parvum
6MF9	;	2.037	;	Crystal structure of CGD4-650 with compound BI2536
3EB0	;	2.65	;	Crystal Structure of cgd4_240 from cryptosporidium Parvum in complex with indirubin E804
6KAW	;	2.01	;	Crystal structure of CghA
6KBC	;	1.99	;	Crystal structure of CghA with Sch210972
3ENH	;	3.6	;	Crystal structure of Cgi121/Bud32/Kae1 complex
3FOK	;	2.5	;	Crystal Structure of Cgl0159 From Corynebacterium glutamicum (Brevibacterium flavum). Northeast Structural Genomics Target CgR115
5ID8	;	1.1	;	Crystal structure of CGL1 from Crassostrea gigas, ligand free form (CGL1/FREE)
8JE9	;	1.0	;	Crystal structure of CGL1 from Crassostrea gigas, mannobiose-bound form (CGL1/Man(alpha)1-2Man)
5IDA	;	1.1	;	Crystal structure of CGL1 from Crassostrea gigas, mannose-bound form (CGL1/MAN)
5IDB	;	1.0	;	Crystal structure of CGL1 from Crassostrea gigas, mannose-bound form (CGL1/MAN2)
8JEB	;	1.3	;	Crystal structure of CGL1 from Crassostrea gigas, mannotetraose-bound form (CGL1/Man(alpha)1-2Man(alpha)1-2Man(alpha)1-6Man)
8JEA	;	0.97	;	Crystal structure of CGL1 from Crassostrea gigas, mannotriose-bound form (CGL1/Man(alpha)1-2Man(alpha)1-2Man)
3OD0	;	2.9	;	Crystal structure of cGMP bound cGMP-dependent protein kinase(92-227)
7MBJ	;	1.26	;	Crystal structure of cGMP dependent protein kinase I alpha (PKG I alpha)CNB-A domain with R177Q mutation
7T4T	;	2.08	;	Crystal Structure of cGMP-dependent Protein Kinase
7T4U	;	1.99	;	Crystal Structure of cGMP-dependent Protein Kinase
7T4V	;	2.28	;	Crystal Structure of cGMP-dependent Protein Kinase
7T4W	;	2.23	;	Crystal Structure of cGMP-dependent Protein Kinase
6C0T	;	1.98	;	Crystal structure of cGMP-dependent protein kinase Ialpha (PKG Ialpha) catalytic domain bound with N46
6BG2	;	1.83	;	Crystal structure of cGMP-dependent protein kinase Ialpha (PKG Ialpha) catalytic domain in AMP-PNP bound state
6BDL	;	1.96	;	Crystal structure of cGMP-dependent protein kinase Ialpha (PKG Ialpha) catalytic domain in apo state
3SHR	;	2.5	;	Crystal Structure of cGMP-dependent Protein Kinase Reveals Novel Site of Interchain Communication
7XLF	;	1.85	;	Crystal structure of CH3-THF complex of methylenetetrahydrofolate reductase from Sphingobium sp. SYK-6
6L7R	;	1.84813	;	Crystal structure of Chaetomium GCP3 N-terminus and Mozart1
6L82	;	2.24104	;	Crystal structure of Chaetomium GCP5 N-terminus and Mozart1
7T6W	;	2.6	;	Crystal structure of Chaetomium Glucosidase I (apo)
7Q5N	;	2.5	;	Crystal structure of Chaetomium thermophilum Ahp1-Urm1 complex
5M59	;	3.2	;	Crystal structure of Chaetomium thermophilum Brr2 helicase core in complex with Prp8 Jab1 domain
7Q6A	;	1.1	;	Crystal structure of Chaetomium thermophilum C30S Ahp1 in post-reaction state
7Q69	;	1.85	;	Crystal structure of Chaetomium thermophilum C30S Ahp1 in the pre-reaction state
6B4G	;	2.648	;	Crystal structure of Chaetomium thermophilum Gle1 CTD-Nup42 GBM complex
6B4H	;	2.17	;	Crystal structure of Chaetomium thermophilum Gle1 CTD-Nup42 GBM-IP6 complex
6ZQ6	;	2.3	;	Crystal structure of Chaetomium thermophilum Glycerol Kinase in complex with glycerol in P21212 space group
6ZQ4	;	2.02	;	Crystal structure of Chaetomium thermophilum Glycerol Kinase in complex with substrate in P1 space group
6ZQ7	;	2.421	;	Crystal structure of Chaetomium thermophilum Glycerol Kinase in I222 space group
6ZQ5	;	2.14	;	Crystal structure of Chaetomium thermophilum Glycerol Kinase in P2221 space group
6ZQ8	;	2.38	;	Crystal structure of Chaetomium thermophilum Glycerol Kinase in P3221 space group
6QP0	;	2.409	;	Crystal structure of Chaetomium thermophilum Kti12 in complex with ADP-AlF3
4BR6	;	2.0	;	Crystal structure of Chaetomium thermophilum MnSOD
6G7E	;	3.2129	;	Crystal structure of Chaetomium thermophilum Mot1 (E1434Q, 1837-1886 deletion mutant)
6ZMP	;	1.57	;	Crystal structure of Chaetomium thermophilum Naa20 in complex with a bisubstrate analogue
5HB2	;	3.3	;	Crystal Structure of Chaetomium thermophilum Nic96 SOL
5HB3	;	2.65	;	Crystal structure of Chaetomium thermophilum Nic96 SOL-Nup53 complex
5HB5	;	1.5	;	Crystal structure of Chaetomium thermophilum Nup145N APD
5HB6	;	1.3	;	Crystal structure of Chaetomium thermophilum Nup145N APD T994A mutant fused to Nup145C N
5HAY	;	2.8	;	Crystal structure of Chaetomium thermophilum Nup170 CTD Y905M L1007M L1183M V1292M mutant
5HB0	;	3.5	;	Crystal structure of Chaetomium thermophilum Nup170 CTD-Nup145N complex
5HAX	;	2.1	;	Crystal structure of Chaetomium thermophilum Nup170 NTD-Nup53 complex
5HB1	;	4.007	;	Crystal structure of Chaetomium thermophilum Nup170 SOL
7MVW	;	2.76	;	Crystal structure of Chaetomium thermophilum Nup188 NTD (residues 1-1134)
5CWU	;	3.35	;	Crystal structure of Chaetomium thermophilum Nup188 TAIL domain
5HB4	;	3.2	;	Crystal structure of Chaetomium thermophilum Nup192
5CWV	;	3.155	;	Crystal structure of Chaetomium thermophilum Nup192 TAIL domain
5HB7	;	0.819	;	Crystal structure of Chaetomium thermophilum Nup53 RRM
5HB8	;	1.7	;	Crystal structure of Chaetomium thermophilum Nup53 RRM (space group P3121)
5CWT	;	2.5	;	Crystal structure of Chaetomium thermophilum Nup57
5EF5	;	4.3	;	Crystal structure of Chaetomium thermophilum Raptor
6ZPN	;	3.5	;	Crystal structure of Chaetomium thermophilum Raptor
5D5W	;	2.35	;	Crystal structure of Chaetomium thermophilum Skn7 with HSE DNA
5D5X	;	2.4	;	Crystal structure of Chaetomium thermophilum Skn7 with SSRE DNA
5WY3	;	3.2	;	Crystal structure of Chaetomium thermophilum Utp10 middle domain
5WY4	;	2.499	;	Crystal structure of Chaetomium thermophilum Utp10 N-terminal domain
5WYL	;	2.638	;	Crystal structure of Chaetomium thermophilum Utp10 N-terminal domain in complex with Utp17 C-terminal helices
6L3Q	;	2.702	;	Crystal structure of Chaetomium thermophilum Utp15 C terminal domain
5W8M	;	1.52	;	Crystal structure of Chaetomium thermophilum Vps29
6XS8	;	1.9501	;	Crystal structure of Chaetomium thermophilum Vps29 complexed with RaPID-derived cyclic peptide RT-D3
7Q68	;	1.75	;	Crystal structure of Chaetomium thermophilum wild-type Ahp1
2NNR	;	1.7	;	Crystal structure of chagasin, cysteine protease inhibitor from Trypanosoma cruzi
2H7W	;	1.7	;	Crystal structure of Chagasin, the endogenous cysteine-protease inhibitor from Trypanosoma cruzi
5WL7	;	1.9	;	Crystal structure of chalcone isomerase engineered from ancestral inference (ancCHI*)
5WL3	;	2.4	;	Crystal structure of chalcone isomerase engineered from ancestral inference (ancR2)
5WL4	;	2.0	;	Crystal structure of chalcone isomerase engineered from ancestral inference (ancR3)
5WL5	;	1.513	;	Crystal structure of chalcone isomerase engineered from ancestral inference (ancR5)
5WL6	;	1.6	;	Crystal structure of chalcone isomerase engineered from ancestral inference (AncR7)
5WL8	;	1.58	;	Crystal structure of chalcone isomerase engineered from ancestral inference (epR4)
5WKR	;	1.4	;	Crystal structure of chalcone isomerase engineered from ancestral inference complexed with naringenin (ancCC)
5WKS	;	1.5	;	Crystal structure of chalcone isomerase engineered from ancestral inference complexed with naringenin (ancR1)
6CJO	;	2.4	;	Crystal Structure of Chalcone Isomerase from Medicago Sativa with the G95S mutation.
6CJN	;	2.4	;	Crystal Structure of Chalcone Isomerase from Medicago Sativa with the G95T mutation
6MS8	;	1.9	;	Crystal Structure of Chalcone Isomerase from Medicago Truncatula Complexed with (2S) Naringenin
6DXB	;	1.549	;	Crystal structure of chalcone synthase from Arabidopsis thaliana
6DXD	;	1.59	;	Crystal structure of chalcone synthase from Arabidopsis thaliana - C347S mutant
6DXE	;	1.608	;	Crystal structure of chalcone synthase from Arabidopsis thaliana - M64I F170S G173A S213G Q217A T270V C347S mutant
6DX9	;	1.5	;	Crystal structure of chalcone synthase from Equisetum arvense
6DX7	;	2.61	;	Crystal structure of chalcone synthase from Physcomitrella patens
6DXA	;	2.01	;	Crystal structure of chalcone synthase from Pinus sylvestris
6DX8	;	1.7	;	Crystal structure of chalcone synthase from Selaginella moellendorffii
6DXF	;	1.55	;	Crystal structure of chalcone synthase from Selaginella moellendorffii - hydrogen peroxide treated
6DXC	;	1.54	;	Crystal structure of chalcone synthase from Selaginella moellendorffii - S340C mutant
8DLD	;	1.85	;	Crystal structure of chalcone-isomerase like protein from Physcomitrella patens (PpCHIL-A)
8DLC	;	1.9	;	Crystal structure of chalcone-isomerase like protein from Vitis vinifera (VvCHIL)
5W63	;	2.436	;	Crystal structure of channel catfish BAX
3G48	;	1.5	;	Crystal structure of chaperone CsaA form Bacillus anthracis str. Ames
5DLB	;	1.77	;	Crystal structure of chaperone EspG3 of ESX-3 type VII secretion system from Mycobacterium marinum M
1N57	;	1.6	;	Crystal Structure of Chaperone Hsp31
3DPA	;	2.5	;	CRYSTAL STRUCTURE OF CHAPERONE PROTEIN PAPD REVEALS AN IMMUNOGLOBULIN FOLD
5DA8	;	3.0	;	Crystal structure of chaperonin GroEL from
1IOK	;	3.2	;	CRYSTAL STRUCTURE OF CHAPERONIN-60 FROM PARACOCCUS DENITRIFICANS
5DHD	;	1.27	;	Crystal structure of ChBD2 from Thermococcus kodakarensis KOD1
5DHE	;	1.6	;	Crystal structure of ChBD3 from Thermococcus kodakarensis KOD1
7VI8	;	1.83	;	Crystal structure of ChbG
3EIR	;	2.101	;	Crystal structure of CHBP, a Cif Homologue from Burkholderia pseudomallei
1B3Q	;	2.6	;	CRYSTAL STRUCTURE OF CHEA-289, A SIGNAL TRANSDUCING HISTIDINE KINASE
3IIC	;	2.13	;	Crystal structure of CheC-like superfamily protein (YP_001095400.1) from Shewanella SP. PV-4 at 2.13 A resolution
2WMQ	;	2.48	;	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors
2WMR	;	2.43	;	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors
2WMS	;	2.7	;	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors
2WMT	;	2.55	;	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors
2WMU	;	2.6	;	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors
2WMV	;	2.009	;	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors
2WMW	;	2.43	;	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors
2WMX	;	2.45	;	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors
2XEY	;	2.7	;	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors
2XEZ	;	2.25	;	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors
2XF0	;	2.4	;	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors
2YM3	;	2.007	;	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors
2YM4	;	2.35	;	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors
2YM5	;	2.03	;	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors
2YM6	;	2.01	;	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors
2YM7	;	1.81	;	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors
2YM8	;	2.07	;	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors
2YCQ	;	2.05	;	Crystal structure of checkpoint kinase 2 in complex with inhibitor PV1115
2YCF	;	1.77	;	Crystal Structure of Checkpoint Kinase 2 in complex with Inhibitor PV1531
2YCR	;	2.2	;	Crystal structure of checkpoint kinase 2 in complex with inhibitor PV976
2YCS	;	2.35	;	Crystal structure of checkpoint kinase 2 in complex with PV788
2HXL	;	1.8	;	crystal structure of Chek1 in complex with inhibitor 1
2QHN	;	1.7	;	Crystal Structure of Chek1 in Complex with Inhibitor 1a
2HXQ	;	2.0	;	crystal structure of Chek1 in complex with inhibitor 2
2HOG	;	1.9	;	crystal structure of Chek1 in complex with inhibitor 20
2HY0	;	1.7	;	crystal structure of chek1 in complex with inhibitor 22
2QHM	;	2.0	;	crystal structure of Chek1 in complex with inhibitor 2a
2R0U	;	1.9	;	Crystal Structure of Chek1 in Complex with Inhibitor 54
8H98	;	2.5	;	Crystal structure of chemically modified E. coli ThrS catalytic domain 1
8H9A	;	1.9	;	Crystal structure of chemically modified E. coli ThrS catalytic domain 2
8H9B	;	2.23	;	Crystal structure of chemically modified E. coli ThrS catalytic domain 3
8H9C	;	2.15	;	Crystal structure of chemically modified E. coli ThrS catalytic domain 4
3HLO	;	1.6	;	Crystal structure of chemically synthesized 'covalent dimer' [Gly51/D-Ala51']HIV-1 protease
3KA2	;	1.4	;	Crystal structure of chemically synthesized 203 amino acid 'covalent dimer' [L-Ala;Gly51']HIV-1 protease molecule complexed with MVT-101 reduced isostere inhibitor at 1.4 A resolution
4GLS	;	1.6	;	Crystal Structure of Chemically Synthesized Heterochiral {D-Protein Antagonist plus VEGF-A} Protein Complex in space group P21
4GLN	;	1.6	;	Crystal Structure of Chemically Synthesized Heterochiral {D-Protein Antagonist plus VEGF-A} Protein Complex in space group P21/n
5HHD	;	2.1	;	Crystal Structure of Chemically Synthesized Heterochiral {RFX037 plus VEGF-A} Protein Complex in space group P21
5HHC	;	2.1	;	Crystal Structure of Chemically Synthesized Heterochiral {RFX037 plus VEGF-A} Protein Complex in space group P21/n
3HAU	;	1.3	;	Crystal structure of chemically synthesized HIV-1 protease with reduced isostere MVT-101 inhibitor
4I6O	;	2.14	;	Crystal structure of chemically synthesized human anaphylatoxin C3a
4HHF	;	1.8	;	Crystal Structure of chemically synthesized scorpion alpha-toxin OD1
3HDK	;	1.8	;	Crystal structure of chemically synthesized [Aib51/51']HIV-1 protease
3HBO	;	1.71	;	Crystal structure of chemically synthesized [D-Ala51/51']HIV-1 protease
2P0B	;	1.74	;	Crystal structure of chemically-reduced E.coli nrfB
1F2L	;	2.0	;	CRYSTAL STRUCTURE OF CHEMOKINE DOMAIN OF FRACTALKINE
8F7N	;	2.7	;	Crystal structure of chemoreceptor McpZ ligand sensing domain
5XLY	;	1.763	;	Crystal structure of CheR1 in complex with c-di-GMP-bound MapZ
1U8T	;	1.5	;	Crystal structure of CheY D13K Y106W alone and in complex with a FliM peptide
3FFT	;	2.21	;	Crystal Structure of CheY double mutant F14E, E89R complexed with BeF3- and Mn2+
2FMF	;	1.998	;	Crystal structure of CheY in complex with CheZ 200-214 solved from a F432 crystal grown in Hepes (pH 7.5)
2FMI	;	2.302	;	Crystal structure of CheY in complex with CheZ 200-214 solved from a F432 crystal grown in Tris (pH 8.4)
2FLK	;	2.1	;	Crystal structure of CheY in complex with CheZ(200-214) solved from a F432 crystal grown in CAPS (pH 10.5)
3H1F	;	2.2	;	Crystal structure of CheY mutant D53A of Helicobacter pylori
3H1G	;	1.7	;	Crystal structure of Chey mutant T84A of helicobacter pylori
3GWG	;	1.8	;	Crystal structure of CheY of Helicobacter pylori
3F7N	;	2.0	;	Crystal Structure of CheY triple mutant F14E, N59M, E89L complexed with BeF3- and Mn2+
3FGZ	;	2.0	;	Crystal Structure of CheY triple mutant F14E, N59M, E89R complexed with BeF3- and Mn2+
3FFX	;	2.01	;	Crystal Structure of CheY triple mutant F14E, N59R, E89H complexed with BeF3- and Mn2+
3FFW	;	2.0	;	Crystal Structure of CheY triple mutant F14Q, N59K, E89Y complexed with BeF3- and Mn2+
1D4Z	;	1.9	;	CRYSTAL STRUCTURE OF CHEY-95IV, A HYPERACTIVE CHEY MUTANT
2PMC	;	2.688	;	Crystal Structure of CheY-Mg(2+) in Complex with CheZ(C15) Peptide solved from a P1 Crystal
2PL9	;	2.6	;	Crystal Structure of CheY-Mg(2+)-BeF(3)(-) in Complex with CheZ(C19) Peptide solved from a P2(1)2(1)2 Crystal
1EM8	;	2.1	;	Crystal structure of chi and psi subunit heterodimer from DNA POL III
1ZVN	;	2.16	;	Crystal structure of chick MN-cadherin EC1
6LHH	;	2.71	;	Crystal structure of chicken 8mer-BF2*1501
1U06	;	1.49	;	crystal structure of chicken alpha-spectrin SH3 domain
6RWC	;	2.143	;	crystal structure of chicken beta-microseminoprotein-like 3 (MSMB3)
5WDD	;	1.799	;	Crystal structure of chicken BOK
1QH4	;	1.41	;	CRYSTAL STRUCTURE OF CHICKEN BRAIN-TYPE CREATINE KINASE AT 1.41 ANGSTROM RESOLUTION
2OIQ	;	2.07	;	Crystal Structure of chicken c-Src kinase domain in complex with the cancer drug imatinib.
4JZ4	;	1.56	;	Crystal structure of chicken c-Src-SH3 domain: monomeric form
6LHG	;	2.8	;	Crystal structure of chicken cCD8aa/pBF2*04:01
6LHF	;	2.7	;	Crystal structure of chicken cCD8aa/pBF2*15:01
3JVG	;	2.2	;	Crystal Structure of chicken CD1-1
5EB9	;	2.006	;	Crystal Structure Of Chicken CD8aa Homodimer
7X85	;	2.639	;	Crystal structure of chicken CENP-C Cupin domain
5E53	;	2.497	;	Crystal structure of chicken CNTN1 FN1-FN3 domains
2WRY	;	1.58	;	Crystal structure of chicken cytokine interleukin 1 beta
7Y6A	;	1.5	;	Crystal structure of Chicken Egg Lysozyme
8H3W	;	2.39	;	Crystal structure of chicken egg lysozyme at ambient temperature
4TUN	;	1.925	;	Crystal structure of Chicken egg white lysozyme adduct with Organophosphorus pesticide Monochrotophos
2YMZ	;	1.75	;	Crystal structure of chicken Galectin 2
5VH1	;	2.3	;	Crystal Structure of Chicken Gamma S Crystallin
3NJ5	;	1.67	;	Crystal structure of chicken IL-1 hydrophobic cavity mutant 157
5JBJ	;	3.58	;	Crystal structure of chicken LGP2 with 5'p 12-mer dsRNA at 3.6 A resolution
5JB2	;	2.2	;	Crystal structure of chicken LGP2 with 5'ppp 10-mer dsRNA and ADP-AlF4-Mg2+ at 2.2 A resolution.
5JBG	;	2.0	;	Crystal structure of chicken LGP2 with 5'ppp 26-mer hairpin RNA with 3' GG overhang and ADP-AlF4-Mg2+ at 2.0 A resolution.
1TW4	;	2.0	;	Crystal Structure of Chicken Liver Basic Fatty Acid Binding Protein (Bile Acid Binding Protein) Complexed With Cholic Acid
3MTX	;	2.0	;	Crystal structure of chicken MD-1
3MU3	;	2.4	;	Crystal structure of chicken MD-1 complexed with lipid IVa
5JC3	;	2.6	;	Crystal structure of chicken MDA5 with 5'p 10-mer dsRNA and ADP-Mg2+ at 2.6 A resolution (monoclinic form, twinned).
5JCF	;	2.6	;	Crystal structure of chicken MDA5 with 5'p 10-mer dsRNA and ADP-Mg2+ at 2.6 A resolution (orthorhombic form).
5JCH	;	2.95	;	Crystal structure of chicken MDA5 with 5'p 10-mer dsRNA and ADP-Mg2+ at 2.95 A resolution (untwinned).
5JC7	;	2.75	;	Crystal structure of chicken MDA5 with 5'p 24-mer dsRNA and ADP-Mg2+ at 2.75 A resolution.
6KVM	;	1.897	;	Crystal structure of Chicken MHC Class II for 1.9 angstrom
4PLM	;	2.801	;	Crystal Structure of Chicken Netrin-1 (LN-LE3)
4PLN	;	3.2	;	Crystal Structure of Chicken Netrin-1 (LN-LE3) complexed with mouse Neogenin (FN4-5)
4PLO	;	2.901	;	Crystal Structure of chicken Netrin-1 (LN-LE3) in complex with mouse DCC (FN4-5)
1PXU	;	2.2	;	Crystal structure of chicken NtA from a eukaryotic source at 2.2A resolution
7QR2	;	1.64	;	Crystal structure of chicken Ovalbumin-related protein X
4PBV	;	2.5	;	Crystal structure of chicken receptor protein tyrosine phosphatase sigma in complex with TrkC
4PBW	;	3.05	;	Crystal structure of chicken receptor protein tyrosine phosphatase sigma in complex with TrkC
6HCE	;	2.5	;	Crystal structure of chicken riboflavin binding protein in ""Apo"" form at 2.5 A resolution
3HC2	;	2.5	;	Crystal Structure of chicken sulfite oxidase mutant Tyr 322 Phe
3K6I	;	1.13	;	Crystal structure of chicken T-cadherin EC1
3K5S	;	2.9	;	Crystal structure of chicken T-cadherin EC1 EC2
6LIR	;	2.091	;	crystal structure of chicken TCR for 2.0
3PPE	;	2.1	;	Crystal structure of chicken VE-cadherin EC1-2
5H23	;	2.2	;	Crystal structure of Chikungunya virus capsid protein
4TU0	;	2.3	;	CRYSTAL STRUCTURE OF CHIKUNGUNYA VIRUS NSP3 MACRO DOMAIN IN COMPLEX WITH A 2'-5' OLIGOADENYLATE TRIMER
5BQ7	;	2.738	;	Crystal structure of chikungunya virus-human Fab 5F-10 fragment
6VUQ	;	1.64	;	Crystal structure of CHIKV nsP3 macrodomain soaked with ADP-ribose
7OA3	;	2.8	;	Crystal structure of Chili RNA aptamer in complex with DMHBO+ (Iridium hexammine co-crystallized form)
7OAV	;	2.99	;	Crystal structure of Chili RNA aptamer in complex with DMHBO+ (Iridium III hexammine soaking crystal form)
2W3L	;	2.1	;	Crystal Structure of Chimaeric Bcl2-xL and Phenyl Tetrahydroisoquinoline Amide Complex
7XL1	;	1.65	;	Crystal structure of chimeric 7D12-Vob nanobody at 1.65 Angstrom
3BKY	;	2.61	;	Crystal Structure of Chimeric Antibody C2H7 Fab in complex with a CD20 Peptide
3MBX	;	1.6	;	Crystal structure of chimeric antibody X836
3MM0	;	2.7	;	Crystal structure of chimeric avidin
4ID4	;	1.05	;	Crystal structure of chimeric beta-lactamase cTEM-17m
4R4S	;	1.1	;	Crystal structure of chimeric beta-lactamase cTEM-19m at 1.1 angstrom resolution
4R4R	;	1.2	;	Crystal structure of chimeric beta-lactamase cTEM-19m at 1.2 angstrom resolution
5OGO	;	0.99	;	Crystal structure of chimeric carbonic anhydrase I with 3-(Benzylamino)-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide
4Q06	;	1.15	;	Crystal structure of chimeric carbonic anhydrase IX with inhibitor
4Q07	;	1.15	;	Crystal structure of chimeric carbonic anhydrase IX with inhibitor
7NZS	;	1.5	;	Crystal structure of chimeric carbonic anhydrase VA with 2,3,5,6-tetrafluoro-4-(propylsulfanyl)benzenesulfonamide
7NZX	;	1.33	;	Crystal structure of chimeric carbonic anhydrase VA with 2,3,5,6-tetrafluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide
7NZR	;	1.284	;	Crystal structure of chimeric carbonic anhydrase VA with 2-(cyclooctylamino)-3,5,6-trifluoro-4-[(2-hydroxyethyl)sulfanyl]benzenesulfonamide
7NZU	;	1.24	;	Crystal structure of chimeric carbonic anhydrase VA with 3-(benzylamino)-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide
7NZT	;	1.35	;	Crystal structure of chimeric carbonic anhydrase VA with 3-(cyclooctylamino)-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide
7NZW	;	1.45	;	Crystal structure of chimeric carbonic anhydrase VA with 4-[(4,6-dimethylpyrimidin-2-yl)thio]-2,3,5,6-tetrafluorobenzenesulfonamide
6QL3	;	1.35	;	Crystal structure of chimeric carbonic anhydrase VI with 3-(cyclooctylamino)-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide
6QL1	;	1.42	;	Crystal structure of chimeric carbonic anhydrase VI with 4-[(4,6-dimethylpyrimidin-2-yl)thio]-2,3,5,6-tetrafluorobenzenesulfonamide
6QL2	;	1.3	;	Crystal structure of chimeric carbonic anhydrase VI with ethoxzolamide.
6YH4	;	1.3	;	Crystal structure of chimeric carbonic anhydrase XII with 2,3,5,6-Tetrafluoro-4-(propylthio)benzenesulfonamide
6YHA	;	1.25	;	Crystal structure of chimeric carbonic anhydrase XII with 2,3,5,6-Tetrafluoro-4-(propylthio)benzenesulfonamide
6YH9	;	1.55	;	Crystal structure of chimeric carbonic anhydrase XII with 2,3,6-trifluoro-5-{[(1R,2S)-2-hydroxy-1,2-diphenylethyl]amino}-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide
6YH6	;	1.4	;	Crystal structure of chimeric carbonic anhydrase XII with 2-(Cyclooctylamino)-3,5,6-trifluorobenzenesulfonamide
6YH5	;	1.2	;	Crystal structure of chimeric carbonic anhydrase XII with 2-Chloro-4-[(pyrimidin-2-ylsulfanyl)acetyl]benzenesulfonamide
6YH8	;	1.2	;	Crystal structure of chimeric carbonic anhydrase XII with 2-[(1S)-1,2,3,4-Tetrahydronapthalen-1-ylamino)-3,5,6-trifluorobenzenesulfonamide
6YHC	;	1.28	;	Crystal structure of chimeric carbonic anhydrase XII with 3-(benzylamino)-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide
6YH7	;	1.12	;	Crystal structure of chimeric carbonic anhydrase XII with 3-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide
6YHB	;	1.65	;	Crystal structure of chimeric carbonic anhydrase XII with 4-[(4,6-dimethylpyrimidin-2-yl)thio]-2,3,5,6-tetrafluorobenzenesulfonamide
4Q08	;	1.07	;	Crystal structure of chimeric carbonic anhydrase XII with inhibitor
4Q09	;	1.2	;	Crystal structure of chimeric carbonic anhydrase XII with inhibitor
6IFW	;	2.95	;	crystal structure of chimeric construct of KsgA with loop 1 from erm
3WYE	;	1.58	;	Crystal Structure of chimeric engineered (2S,3S)-butanediol dehydrogenase complexed with NAD+
4JDT	;	3.26	;	Crystal structure of chimeric germ-line precursor of NIH45-46 Fab in complex with gp120 of 93TH057 HIV-1
6D0X	;	1.849	;	Crystal structure of chimeric H.2140 / K.1210 Fab in complex with circumsporozoite protein NANP3
7U8M	;	5.39	;	Crystal structure of chimeric hemagglutinin cH15/3 in complex with broad protective antibodies 31.a.83 and FluA-20
7U8L	;	4.56	;	Crystal structure of chimeric hemagglutinin cH15/3 in complex with broad protective antibody 31.a.83
7U8J	;	4.9	;	Crystal structure of chimeric hemagglutinin cH4/3 in complex with broad protective antibody 31.a.83
6IFX	;	3.8	;	Crystal structure of chimeric KsgA with loop 12 from Erm
7C0I	;	2.4	;	Crystal structure of chimeric mutant of E3L in complex with Z-DNA
7C0J	;	2.75	;	Crystal structure of chimeric mutant of GH5 in complex with Z-DNA
7U0N	;	2.61	;	Crystal structure of chimeric omicron RBD (strain BA.1) complexed with human ACE2
7UFL	;	2.84	;	Crystal structure of chimeric omicron RBD (strain BA.2) complexed with chimeric mouse ACE2
7UFK	;	2.38	;	Crystal structure of chimeric omicron RBD (strain BA.2) complexed with human ACE2
8SPH	;	2.71	;	Crystal structure of chimeric omicron RBD (strain XBB.1) complexed with human ACE2
8SPI	;	3.06	;	Crystal structure of chimeric omicron RBD (strain XBB.1.5) complexed with human ACE2
3JWR	;	2.994	;	Crystal structure of chimeric PDE5/PDE6 catalytic domain complexed with 3-isobutyl-1-methylxanthine (IBMX) and PDE6 gamma-subunit inhibitory peptide 70-87.
3JWQ	;	2.87	;	Crystal structure of chimeric PDE5/PDE6 catalytic domain complexed with sildenafil
1V6Y	;	2.2	;	Crystal Structure Of chimeric Xylanase between Streptomyces Olivaceoviridis E-86 FXYN and Cellulomonas fimi Cex
2OBE	;	2.1	;	Crystal Structure of Chimpanzee Adenovirus (Type 68/Simian 25) Major Coat Protein Hexon
2VSD	;	1.82	;	crystal structure of CHIR-AB1
3PA0	;	1.6	;	Crystal Structure of Chiral Gamma-PNA with Complementary DNA Strand: Insight Into the Stability and Specificity of Recognition an Conformational Preorganization
2CWR	;	1.7	;	Crystal structure of chitin biding domain of chitinase from Pyrococcus furiosus
8I5K	;	1.219	;	Crystal structure of chitin oligosaccharide binding protein from Vibrio cholera in complex with chitotriose.
8I5J	;	1.602	;	Crystal structure of chitin oligosaccharide binding protein from Vibrio cholera.
4TX7	;	1.55	;	Crystal structure of chitinase (GH19) from Vigna unguiculata
7FBT	;	1.9	;	Crystal structure of chitinase (RmChi1) from Rhizomucor miehei (sp p32 2 1, MR)
5XWF	;	2.581	;	Crystal structure of chitinase (RmChi1) from Rhizomucor miehei (SP3221/SAD)
4W5U	;	2.771	;	Crystal structure of chitinase 40 from thermophilic bacteria Streptomyces thermoviolaceus.
1FFQ	;	1.9	;	CRYSTAL STRUCTURE OF CHITINASE A COMPLEXED WITH ALLOSAMIDIN
1EDQ	;	1.55	;	CRYSTAL STRUCTURE OF CHITINASE A FROM S. MARCESCENS AT 1.55 ANGSTROMS
1EIB	;	1.8	;	CRYSTAL STRUCTURE OF CHITINASE A MUTANT D313A COMPLEXED WITH OCTA-N-ACETYLCHITOOCTAOSE (NAG)8.
1EHN	;	1.9	;	CRYSTAL STRUCTURE OF CHITINASE A MUTANT E315Q COMPLEXED WITH OCTA-N-ACETYLCHITOOCTAOSE (NAG)8.
1FFR	;	1.8	;	CRYSTAL STRUCTURE OF CHITINASE A MUTANT Y390F COMPLEXED WITH HEXA-N-ACETYLCHITOHEXAOSE (NAG)6
1CNS	;	1.91	;	CRYSTAL STRUCTURE OF CHITINASE AT 1.91A RESOLUTION
1WVU	;	2.45	;	Crystal structure of chitinase C from Streptomyces griseus HUT6037
2DBT	;	3.14	;	Crystal structure of chitinase C from Streptomyces griseus HUT6037
1WVV	;	2.0	;	Crystal structure of chitinase C mutant E147Q
5GZT	;	2.1	;	Crystal Structure of Chitinase ChiW from Paenibacillus sp. str. FPU-7 Reveals a Novel Type of Bacterial Cell-Surface-Expressed Multi-Modular Enzyme Machinery
5GZU	;	2.03	;	Crystal Structure of Chitinase ChiW from Paenibacillus sp. str. FPU-7 Reveals a Novel Type of Bacterial Cell-Surface-Expressed Multi-Modular Enzyme Machinery
5GZV	;	2.61	;	Crystal Structure of Chitinase ChiW from Paenibacillus sp. str. FPU-7 Reveals a Novel Type of Bacterial Cell-Surface-Expressed Multi-Modular Enzyme Machinery
4NZC	;	1.45	;	Crystal structure of Chitinase D from Serratia proteamaculans at 1.45 Angstrom resolution
4Q22	;	1.93	;	Crystal structure of Chitinase D from Serratia proteamaculans in complex with N-acetyl glucosamine at 1.93 Angstrom resolution
4PTM	;	1.7	;	Crystal Structure of Chitinase D from Serratia proteamaculans in complex with N-acetyl glucosamine, a hydrolyzed product of hexasaccharide at 1.7 Angstrom resolution
5JH8	;	1.018	;	Crystal structure of chitinase from Chromobacterium violaceum ATCC 12472
5GQB	;	2.7	;	Crystal structure of chitinase-h from O. furnacalis in complex with chitohepatose
7VRG	;	2.4	;	Crystal structure of chitinase-h from O. furnacalis in complex with Lynamicin B
5GPR	;	3.23	;	Crystal structure of chitinase-h from Ostrinia furnacalis
4URI	;	1.85	;	Crystal structure of chitinase-like agglutinin RobpsCRA from Robinia pseudoacacia
7XGQ	;	1.5	;	Crystal structure of chitosanase crystallized by ammonium sulfate with glycan
7BKN	;	2.74	;	Crystal structure of CHK1 complex with adenine
7BKO	;	2.3	;	Crystal structure of CHK1 complex with compound 9
1ZLT	;	1.74	;	Crystal Structure of Chk1 Complexed with a Hymenaldisine Analog
3TKH	;	1.79	;	Crystal structure of Chk1 in complex with inhibitor S01
3TKI	;	1.6	;	Crystal structure of Chk1 in complex with inhibitor S25
7AKO	;	1.8	;	Crystal structure of CHK1 kinase domain in complex with a CLASPIN phosphopeptide
7AKM	;	1.93	;	Crystal structure of CHK1 kinase domain in complex with ATPyS
3F9N	;	1.9	;	Crystal structure of chk1 kinase in complex with inhibitor 38
2YWP	;	2.9	;	Crystal Structure of CHK1 with a Urea Inhibitor
2AYP	;	2.9	;	Crystal Structure of CHK1 with an Indol Inhibitor
7BJE	;	1.8	;	Crystal structure of CHK1-10pt-mutant complex with adenine
7BJM	;	2.3	;	Crystal structure of CHK1-10pt-mutant complex with compound 10
7BJO	;	2.3	;	Crystal structure of CHK1-10pt-mutant complex with compound 13
7BJR	;	1.9	;	Crystal structure of CHK1-10pt-mutant complex with compound 18
7BJX	;	2.4	;	Crystal structure of CHK1-10pt-mutant complex with compound 26
7BJD	;	2.0	;	Crystal structure of CHK1-10pt-mutant complex with compound 3
7BK1	;	2.0	;	Crystal structure of CHK1-10pt-mutant complex with compound 32
7BK2	;	2.0	;	Crystal structure of CHK1-10pt-mutant complex with compound 44
7BK3	;	2.0	;	Crystal structure of CHK1-10pt-mutant complex with compound 45
7BJH	;	1.8	;	Crystal structure of CHK1-10pt-mutant complex with compound 8
7BJJ	;	1.8	;	Crystal structure of CHK1-10pt-mutant complex with compound 9
2WTC	;	3.0	;	CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
2WTD	;	2.75	;	Crystal structure of Chk2 in complex with an inhibitor
2WTI	;	2.5	;	CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
2WTJ	;	2.1	;	CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
2XBJ	;	2.3	;	Crystal Structure of Chk2 in complex with an inhibitor
2W0J	;	2.05	;	Crystal structure of Chk2 in complex with NSC 109555, a specific inhibitor
6MRN	;	2.29	;	Crystal Structure of ChlaDUB2 DUB domain
6OAM	;	2.503	;	Crystal Structure of ChlaDUB2 DUB domain
5KBC	;	2.706	;	Crystal structure of Chlamydia trachomatis DsbA
4Q9N	;	1.795	;	Crystal structure of Chlamydia trachomatis enoyl-ACP reductase (FabI) in complex with NADH and AFN-1252
6WYC	;	1.5	;	Crystal Structure of Chlamydia trachomatis Glyceraldehyde 3-phosphate dehydrogenase
6X2E	;	1.8	;	Crystal Structure of Chlamydia trachomatis mixed (apo/holo) Glyceraldehyde 3-phosphate dehydrogenase
5N4A	;	1.79	;	Crystal structure of Chlamydomonas IFT80
5YXM	;	1.545	;	Crystal structure of Chlamydomonas Outer Arm Dynein Light Chain 1
6A8D	;	2.34	;	Crystal Structure of Chlamydomonas reinhardtii ARF
7B2N	;	2.36	;	Crystal structure of Chlamydomonas reinhardtii chloroplastic Fructose bisphosphate aldolase
7ZY7	;	1.98	;	Crystal structure of Chlamydomonas reinhardtii chloroplastic phosphoglycerate kinase
7B2O	;	3.09	;	Crystal structure of Chlamydomonas reinhardtii chloroplastic sedoheptulose-1,7-bisphosphatase
7ZUV	;	3.11	;	Crystal structure of Chlamydomonas reinhardtii chloroplastic sedoheptulose-1,7-bisphosphatase in reducing conditions
5XFT	;	2.46	;	Crystal structure of Chlamydomonas reinhardtii dehydroascorbate reductase
6E18	;	2.6	;	Crystal structure of Chlamydomonas reinhardtii HAP2 ectodomain provides structural insights of functional loops in green algae.
4J7R	;	2.3	;	Crystal Structure of Chlamydomonas reinhardtii Isoamylase 1 (ISA1)
4OKD	;	2.4	;	Crystal Structure of Chlamydomonas reinhardtii Isoamylase 1 (ISA1) in complex with maltoheptaose
7P9D	;	1.99	;	Crystal structure of Chlamydomonas reinhardtii NADPH Dependent Thioredoxin Reductase 1 domain
2JIG	;	1.85	;	Crystal structure of Chlamydomonas reinhardtii prolyl-4 hydroxylase type I complexed with zinc and pyridine-2,4-dicarboxylate
2VDH	;	2.3	;	Crystal structure of Chlamydomonas reinhardtii Rubisco with a large- subunit C172S mutation
2VDI	;	2.65	;	Crystal structure of Chlamydomonas reinhardtii Rubisco with a large- subunit C192S mutation
2V69	;	2.8	;	Crystal structure of Chlamydomonas reinhardtii Rubisco with a large- subunit mutation D473E
2V67	;	2.0	;	Crystal structure of Chlamydomonas reinhardtii Rubisco with a large- subunit supressor mutation T342I
2V6A	;	1.5	;	Crystal structure of Chlamydomonas reinhardtii Rubisco with large- subunit mutations V331A, G344S
2V68	;	2.3	;	Crystal structure of Chlamydomonas reinhardtii Rubisco with large- subunit mutations V331A, T342I
6CII	;	1.7	;	Crystal structure of Chlamydomonas reinhardtii THB1 in the cyanomet state
6BME	;	1.899	;	Crystal structure of Chlamydomonas reinhardtii THB4
6I1C	;	2.01	;	Crystal structure of Chlamydomonas reinhardtii thioredoxin f2
6I19	;	1.378	;	Crystal structure of Chlamydomonas reinhardtii thioredoxin h1
6MFK	;	1.65	;	Crystal Structure of Chloramphenicol Acetyltransferase from Elizabethkingia anophelis
1Q23	;	2.18	;	Crystal structure of Chloramphenicol acetyltransferase I complexed with Fusidic acid at 2.18 A resolution
3EEV	;	2.61	;	Crystal Structure of Chloramphenicol Acetyltransferase VCA0300 from Vibrio cholerae O1 biovar eltor
6AAE	;	1.641	;	Crystal structure of Chloramphenicol-Metabolizaing Enzyme EstDL136
6IEY	;	2.097	;	Crystal structure of Chloramphenicol-Metabolizaing Enzyme EstDL136-Chloramphenicol complex
1FVI	;	2.0	;	CRYSTAL STRUCTURE OF CHLORELLA VIRUS DNA LIGASE-ADENYLATE
3IM0	;	1.66	;	Crystal structure of Chlorella virus vAL-1 soaked in 200mM D-glucuronic acid, 10% PEG-3350, and 200mM glycine-NaOH (pH 10.0)
2Z38	;	1.8	;	Crystal structure of chloride bound Brassica juncea chitinase catalytic module (Bjchi3)
2QRB	;	2.5	;	Crystal structure of chloride saturated bovine lactoperoxidase at 2.5 A resolution shows multiple halide binding sites
3Q08	;	3.05	;	Crystal Structure of Chlorite Dismutase from D. Aromatica at pH 6.5
3Q09	;	3.0	;	Crystal Structure of Chlorite Dismutase from D. Aromatica at pH 9.0
5A12	;	1.4	;	Crystal structure of Chlorite Dismutase from Magnetospirillum sp. in complex with azide
5A13	;	1.75	;	Crystal structure of Chlorite Dismutase from Magnetospirillum sp. in complex with thiocyanate
3TH1	;	3.4	;	Crystal structure of chlorocatechol 1,2-dioxygenase from Pseudomonas putida
7O0T	;	2.4	;	Crystal structure of Chloroflexus aggregans ene-reductase CaOYE holoenzyme
4L7Z	;	2.502	;	Crystal Structure of Chloroflexus aurantiacus malyl-CoA lyase
4L80	;	2.008	;	Crystal Structure of Chloroflexus aurantiacus malyl-CoA lyase in complex with magnesium, oxalate, and propionyl-CoA
5TBW	;	3.0	;	Crystal structure of chlorolissoclimide bound to the yeast 80S ribosome
3HWC	;	2.5	;	Crystal Structure of Chlorophenol 4-Monooxygenase (TftD) of Burkholderia cepacia AC1100
3V3C	;	3.402	;	Crystal Structure of Chloroplast ATP synthase c-ring from Pisum sativum
1CTM	;	2.3	;	CRYSTAL STRUCTURE OF CHLOROPLAST CYTOCHROME F REVEALS A NOVEL CYTOCHROME FOLD AND UNEXPECTED HEME LIGATION
2OG2	;	2.0	;	Crystal structure of chloroplast FtsY from Arabidopsis thaliana
6KVN	;	2.02	;	Crystal structure of chloroplast resolvase
6KVO	;	2.5	;	Crystal structure of chloroplast resolvase in complex with Holliday junction
6LCM	;	2.5	;	Crystal structure of chloroplast resolvase ZmMOC1 with the magic triangle I3C
4OHQ	;	2.15	;	Crystal structure of chloroplast triose phosphate isomerase from Arabidopsis thaliana
7SKJ	;	1.9	;	Crystal structure of chloroplast triosephosphate isomerase from Cuscuta australis
1IYN	;	1.6	;	Crystal structure of chloroplastic ascorbate peroxidase from tobacco plants and structural insights for its instability
7ASW	;	2.444	;	Crystal structure of chloroplastic thioredoxin z defines a novel type-specific target recognition
4MKN	;	1.1	;	Crystal structure of chloroplastic triosephosphate isomerase from Chlamydomonas reinhardtii at 1.1 A of resolution
7X43	;	1.04	;	Crystal structure of chlorotoxin mutant - M1R
7X44	;	1.04	;	Crystal structure of chlorotoxin mutant - Q11N
7X4D	;	1.55	;	Crystal structure of chlorotoxin mutant - Y29K
7X41	;	1.15	;	Crystal structure of chlorotoxin, a glioma specific scorpion toxin
4HN0	;	2.2	;	Crystal Structure of ChmJ, a 3'-monoepimerase apoenzyme from Streptomyces bikiniensis
4HMZ	;	2.0	;	Crystal Structure of ChmJ, a 3'-monoepimerase from Streptomyces bikiniensis in complex with dTDP-quinovose
4ABM	;	1.8	;	Crystal Structure of CHMP4B hairpin
6X1P	;	1.702	;	Crystal Structure of Choanoflagellate (Monosiga brevicollis) Dlg1 PDZ2 (mbDLG-2) in spacegroup I2
6X1R	;	1.3	;	Crystal Structure of Choanoflagellate (Monosiga brevicollis) Dlg1 PDZ2 (mbDLG-2) in spacegroup P212121
6X1N	;	1.4	;	Crystal Structure of Choanoflagellate (Monosiga brevicollis) Dlg1 PDZ3 (mbDLG-3)
6UR0	;	1.8	;	Crystal structure of ChoE D285N mutant acyl-enzyme
6UQZ	;	1.43	;	Crystal structure of ChoE D285N mutant in complex with acetate and thiocholine
6UQY	;	1.57	;	Crystal structure of ChoE H288N mutant in complex with acetylthiocholine
8D91	;	1.49	;	Crystal structure of ChoE in complex with acetate and tetraethylammonium (TEA)
6UQW	;	1.65	;	Crystal structure of ChoE in complex with acetate and thiocholine
8D8X	;	1.36	;	Crystal structure of ChoE in complex with acetate and thiocholine (crystal form 2)
6UQX	;	1.85	;	Crystal structure of ChoE in complex with propionylthiocholine
8D8Y	;	1.54	;	Crystal structure of ChoE N147A mutant in complex with acetylthiocholine
8D90	;	1.82	;	Crystal structure of ChoE N147A mutant in complex with bromide ions
8D8Z	;	1.38	;	Crystal structure of ChoE N147A mutant in complex with thiocholine and chloride
6UR1	;	1.42	;	Crystal structure of ChoE S38A mutant in complex with acetate and acetylthiocholine
8D8W	;	1.4	;	Crystal structure of ChoE with Ser38 adopting alternative conformations
6UQV	;	1.35	;	Crystal structure of ChoE, a bacterial acetylcholinesterase from Pseudomonas aeruginosa
1COY	;	1.8	;	CRYSTAL STRUCTURE OF CHOLESTEROL OXIDASE COMPLEXED WITH A STEROID SUBSTRATE. IMPLICATIONS FOR FAD DEPENDENT ALCOHOL OXIDASES
3COX	;	1.8	;	CRYSTAL STRUCTURE OF CHOLESTEROL OXIDASE COMPLEXED WITH A STEROID SUBSTRATE. IMPLICATIONS FOR FAD DEPENDENT ALCOHOL OXIDASES
1I19	;	1.7	;	CRYSTAL STRUCTURE OF CHOLESTEROL OXIDASE FROM B.STEROLICUM
2OBD	;	2.1	;	Crystal Structure of Cholesteryl Ester Transfer Protein
4EWS	;	2.59	;	Crystal structure of cholesteryl ester transfer protein in complex with inhibitors
4F2A	;	3.11	;	Crystal structure of cholestryl esters transfer protein in complex with inhibitors
2V04	;	2.1	;	CRYSTAL STRUCTURE OF CHOLINE BINDING PROTEIN F FROM STREPTOCOCCUS PNEUMONIAE
2VYU	;	2.45	;	CRYSTAL STRUCTURE OF CHOLINE BINDING PROTEIN F FROM STREPTOCOCCUS PNEUMONIAE IN THE PRESENCE OF A PEPTIDOGLYCAN ANALOGUE (TETRASACCHARIDE-PENTAPEPTIDE)
2V05	;	1.67	;	CRYSTAL STRUCTURE OF CHOLINE BINDING PROTEIN F FROM STREPTOCOCCUS PNEUMONIAE. CRYSTAL FORM II.
3R6U	;	1.61	;	Crystal structure of choline binding protein OpuBC from Bacillus subtilis
1NW1	;	2.02	;	Crystal Structure of Choline Kinase
5EQY	;	2.5	;	Crystal structure of choline kinase alpha-1 bound by 5-[(4-methyl-1,4-diazepan-1-yl)methyl]-2-[4-[(4-methyl-1,4-diazepan-1-yl)methyl]phenyl]benzenecarbonitrile (compound 65)
5EQP	;	2.35	;	Crystal structure of choline kinase alpha-1 bound by 6-[(4-methyl-1,4-diazepan-1-yl)methyl]quinoline (compound 37)
5EQE	;	2.4	;	Crystal structure of choline kinase alpha-1 bound by [4-[(4-methyl-1,4-diazepan-1-yl)methyl]phenyl]methanamine (compound 11)
3MES	;	2.35	;	Crystal structure of choline kinase from Cryptosporidium parvum Iowa II, cgd3_2030
3FI8	;	2.3	;	Crystal structure of choline kinase from Plasmodium Falciparum, PF14_0020
4R77	;	1.94	;	Crystal structure of choline kinase LicA from Streptococcus pneumoniae
4MJW	;	1.95	;	Crystal Structure of Choline Oxidase in Complex with the Reaction Product Glycine Betaine
2JBV	;	1.86	;	Crystal structure of choline oxidase reveals insights into the catalytic mechanism
3NNE	;	2.47	;	Crystal structure of choline oxidase S101A mutant
3LJP	;	2.2	;	Crystal structure of choline oxidase V464A mutant
7PL5	;	1.99	;	Crystal structure of choline-binding module (R1-R9) of LytB from Streptococcus pneumoniae
7PL2	;	2.98	;	Crystal structure of choline-binding module of LytB from Streptococcus pneumoniae
3DXQ	;	2.55	;	Crystal structure of choline/ethanolamine kinase family protein (NP_106042.1) from MESORHIZOBIUM LOTI at 2.55 A resolution
3HBC	;	2.269	;	Crystal Structure of Choloylglycine Hydrolase from Bacteroides thetaiotaomicron VPI
1HN0	;	1.9	;	CRYSTAL STRUCTURE OF CHONDROITIN ABC LYASE I FROM PROTEUS VULGARIS AT 1.9 ANGSTROMS RESOLUTION
7EIS	;	2.5	;	Crystal structure of chondroitin ABC lyase I in complex with chondroitin disaccharide 0S
7YKE	;	1.88	;	Crystal structure of chondroitin ABC lyase I in complex with chondroitin disaccharide 4,6-sulfate
7EIQ	;	1.8	;	Crystal structure of chondroitin ABC lyase I in complex with chondroitin disaccharide 4S
7EIR	;	1.92	;	Crystal structure of chondroitin ABC lyase I in complex with chondroitin disaccharide 6S
2Z87	;	3.0	;	Crystal structure of chondroitin polymerase from Escherichia coli strain K4 (K4CP) complexed with UDP-GalNAc and UDP
2Z86	;	2.4	;	Crystal structure of chondroitin polymerase from Escherichia coli strain K4 (K4CP) complexed with UDP-GlcUA and UDP
2Q1F	;	2.85	;	Crystal structure of chondroitin sulfate lyase abc from bacteroides thetaiotaomicron wal2926
1DBG	;	1.7	;	CRYSTAL STRUCTURE OF CHONDROITINASE B
1DBO	;	1.7	;	CRYSTAL STRUCTURE OF CHONDROITINASE B
1OFM	;	1.8	;	CRYSTAL STRUCTURE OF CHONDROITINASE B COMPLEXED TO CHONDROITIN 4-SULFATE TETRASACCHARIDE
1OFL	;	1.7	;	CRYSTAL STRUCTURE OF CHONDROITINASE B COMPLEXED TO DERMATAN SULFATE HEXASACCHARIDE
4BPS	;	1.081	;	Crystal structure of Chorismatase at 1.08 Angstrom resolution.
2PV7	;	2.0	;	Crystal structure of chorismate mutase / prephenate dehydrogenase (tyrA) (1574749) from Haemophilus influenzae RD at 2.00 A resolution
3RMI	;	2.4	;	Crystal structure of Chorismate mutase from Bartonella henselae str. Houston-1 in complex with malate
5TS9	;	1.95	;	Crystal structure of Chorismate mutase from Burkholderia phymatum
6CNZ	;	2.15	;	Crystal Structure of Chorismate Mutase from Burkholderia thailandensis
6AL9	;	2.3	;	Crystal structure of chorismate mutase from Helicobacter pylori in complex with prephenate
5GMU	;	1.8	;	Crystal structure of chorismate mutase like domain of bifunctional DAHP synthase of Bacillus subtilis in complex with Chlorogenic acid
5GO2	;	1.907	;	Crystal structure of chorismate mutase like domain of bifunctional DAHP synthase of Bacillus subtilis in complex with Citrate
1Q1L	;	2.05	;	Crystal Structure of Chorismate Synthase
1UMF	;	2.25	;	crystal structure of chorismate synthase
1UM0	;	1.95	;	Crystal structure of chorismate synthase complexed with FMN
1QXO	;	2.0	;	Crystal structure of Chorismate synthase complexed with oxidized FMN and EPSP
4OB9	;	2.5	;	Crystal structure of chorismate synthase from Acinetobacter baumannii at 2.50A resolution
5WUY	;	2.5	;	Crystal structure of chorismate synthase from Acinetobacter baumannii at 2.50A resolution
4O90	;	2.61	;	Crystal structure of chorismate synthase from Acinetobacter baumannii at 2.6A resolution
4LJ2	;	3.15	;	Crystal structure of chorismate synthase from Acinetobacter baumannii at 3.15A resolution
1ZTB	;	2.65	;	Crystal Structure of Chorismate Synthase from Mycobacterium tuberculosis
2G85	;	2.22	;	Crystal structure of chorismate synthase from Mycobacterium tuberculosis at 2.22 angstrons of resolution
5Z9A	;	2.79	;	Crystal structure of chorismate synthase from Pseudomonas aeruginosa
2RF1	;	2.0	;	Crystal structure of ChoX in an unliganded closed conformation
2BEC	;	2.7	;	Crystal structure of CHP2 in complex with its binding region in NHE1 and insights into the mechanism of pH regulation
6MJL	;	2.5	;	Crystal structure of ChREBP NLS peptide bound to importin alpha.
5F74	;	2.35	;	Crystal structure of ChREBP:14-3-3 complex bound with AMP
2Z7C	;	2.8	;	Crystal structure of chromatin protein alba from hyperthermophilic archaeon pyrococcus horikoshii
4QLC	;	3.503	;	Crystal structure of chromatosome at 3.5 angstrom resolution
7Q9X	;	1.6	;	Crystal structure of Chromobacterium violaceum aminotransferase in complex with PLP-pyruvate adduct
7Q9Z	;	1.95	;	Crystal structure of Chromobacterium violaceum aminotransferase in complex with PLP-pyruvate adduct
7WZS	;	3.6	;	Crystal structure of Chromobacterium violaceum effector CopC in complex with host calmodulin and caspase-7
1LTZ	;	1.4	;	CRYSTAL STRUCTURE OF CHROMOBACTERIUM VIOLACEUM PHENYLALANINE HYDROXYLASE, STRUCTURE HAS BOUND IRON (III) AND OXIDIZED COFACTOR 7,8-DIHYDROBIOPTERIN
1LTV	;	2.0	;	CRYSTAL STRUCTURE OF CHROMOBACTERIUM VIOLACEUM PHENYLALANINE HYDROXYLASE, STRUCTURE WITH BOUND OXIDIZED Fe(III)
1LTU	;	1.74	;	CRYSTAL STRUCTURE OF CHROMOBACTERIUM VIOLACEUM, APO (NO IRON BOUND) STRUCTURE
4X3K	;	1.45	;	Crystal structure of chromobox homolog 7 (CBX7) chromodomain with H3K27me3 peptide
5EJW	;	2.6	;	Crystal structure of chromobox homolog 7 (CBX7) chromodomain with MS351
4X3T	;	2.14	;	Crystal structure of chromobox homolog 7 (CBX7) chromodomain with MS37452
4X3U	;	1.63	;	Crystal structure of chromobox homolog 7 (CBX7) chromodomain with Suramin
4X3S	;	1.6	;	Crystal structure of chromobox homology 7 (CBX7) with SETDB1-1170me3 Peptide
7VZ2	;	1.7	;	Crystal structure of chromodomain of Arabidopsis LHP1
5EPK	;	1.8	;	Crystal Structure of chromodomain of CBX2 in complex with inhibitor UNC3866
5EPL	;	1.81	;	Crystal Structure of chromodomain of CBX4 in complex with inhibitor UNC3866
5EPJ	;	1.6	;	Crystal Structure of chromodomain of CBX7 in complex with inhibitor UNC3866
6V2R	;	1.6	;	Crystal Structure of chromodomain of CBX7 mutant V13A in complex with inhibitor UNC3866
5EQ0	;	1.18	;	Crystal Structure of chromodomain of CBX8 in complex with inhibitor UNC3866
7N27	;	1.85	;	Crystal Structure of chromodomain of CDYL in complex with inhibitor UNC6261
6V2D	;	2.1	;	Crystal Structure of chromodomain of CDYL2 in complex with inhibitor UNC3866
6V2S	;	1.6	;	Crystal Structure of chromodomain of MPP8 in complex with inhibitor UNC3866
4QUC	;	1.502	;	Crystal structure of chromodomain of Rhino
4QUF	;	2.501	;	crystal structure of chromodomain of Rhino with H3K9me3
2Z3U	;	2.4	;	Crystal Structure of Chromopyrrolic Acid Bound Cytochrome P450 StaP (CYP245A1)
3CWQ	;	2.47	;	Crystal structure of chromosome partitioning protein (ParA) in complex with ADP from Synechocystis sp. Northeast Structural Genomics Consortium Target SgR89
6U9J	;	1.5	;	Crystal structure of ChuX
3FAN	;	1.9	;	Crystal structure of chymotrypsin-like protease/proteinase (3CLSP/Nsp4) of porcine reproductive and respiratory syndrome virus (PRRSV)
3R6Y	;	3.0	;	Crystal structure of chymotrypsin-treated aspartase from Bacillus sp. YM55-1
1EYG	;	2.8	;	Crystal structure of chymotryptic fragment of E. coli ssb bound to two 35-mer single strand DNAS
7AON	;	1.3	;	Crystal structure of CI2 double mutant L49I,I57V
7AOK	;	1.87	;	Crystal structure of CI2 mutant L49I
8SWD	;	2.45	;	Crystal Structure of CiaD from Campylobacter jejuni (C-terminal fragment)
8UZ8	;	2.45	;	Crystal Structure of CiaD from Campylobacter jejuni (C-terminal fragment, Orthorhombic P form)
6TBN	;	2.0	;	Crystal structure of CIAO1-CIAO2B CIA core complex
3UW4	;	1.79	;	Crystal structure of cIAP1 BIR3 bound to GDC0152
4HY4	;	1.249	;	Crystal structure of cIAP1 BIR3 bound to T3170284
4HY5	;	1.752	;	Crystal structure of cIAP1 BIR3 bound to T3256336
4MTI	;	2.15	;	Crystal structure of cIAP1 BIR3 bound to T3258042
4MU7	;	1.79	;	Crystal structure of cIAP1 BIR3 bound to T3450325
6HPR	;	1.7	;	Crystal structure of cIAP1 RING domain bound to UbcH5B-Ub and a non-covalent Ub
6EXW	;	2.2	;	Crystal structure of cIAP1-BIR3 in complex with a covalently bound SM
1XO5	;	1.99	;	Crystal structure of CIB1, an EF-hand, integrin and kinase-binding protein
1SQK	;	2.5	;	CRYSTAL STRUCTURE OF CIBOULOT IN COMPLEX WITH SKELETAL ACTIN
6JRP	;	3.0	;	Crystal structure of CIC-HMG-ETV5-DNA complex
4MAC	;	2.0	;	Crystal structure of CIDE-N domain of FSP27
1NTF	;	1.8	;	Crystal Structure of Cimex Nitrophorin
4L1Y	;	1.55	;	Crystal structure of Cimex nitrophorin A21V mutant
4L20	;	1.68	;	Crystal structure of Cimex nitrophorin A21V mutant ferrous NO complex
1SI6	;	1.45	;	Crystal structure of cimex nitrophorin complex with CO
4L1Z	;	1.65	;	Crystal structure of Cimex nitrophorin F64V mutant
4L21	;	1.65	;	Crystal structure of Cimex nitrophorin F64V mutant ferrous NO complex
1YJH	;	1.65	;	Crystal Structure of Cimex Nitrophorin Ferrous NO Complex
1Y21	;	1.75	;	Crystal Structure of Cimex Nitrophorin NO Complex
4OXX	;	1.21	;	Crystal Structure of Cindoxin, Surface Entropy reduction Mutant
4QTZ	;	2.0	;	Crystal Structure of Cinnamyl-Alcohol Dehydrogenase 2
4QUK	;	1.9	;	Crystal Structure of Cinnamyl-Alcohol Dehydrogenase 2 Mutant K169A
6OZI	;	2.302	;	Crystal structure of Ciona intestinalis (Ci) Endonuclease V (D234N) in complex with a 23mer DNA containing an inosine followed by a ribo-adenosine
6OZH	;	3.026	;	Crystal structure of Ciona intestinalis (Ci) Endonuclease V in complex with a 24mer DNA containing an inosine followed by a ribo-adenosine
3V0D	;	1.1	;	Crystal structure of Ciona intestinalis voltage sensor-containing phosphatase (Ci-VSP), residues 241-576(C363S)
3V0H	;	1.85	;	Crystal structure of Ciona intestinalis voltage sensor-containing phosphatase (Ci-VSP), residues 241-576(C363S), complexed with D-MYO-inositol-1,4,5-triphosphate
3V0J	;	1.72	;	Crystal structure of Ciona intestinalis voltage sensor-containing phosphatase (Ci-VSP), residues 241-576(C363S), Deletion of 401-405
3V0F	;	1.3	;	Crystal structure of Ciona intestinalis voltage sensor-containing phosphatase (Ci-VSP), residues 241-576(C363S), form II
3V0G	;	1.6	;	Crystal structure of Ciona intestinalis voltage sensor-containing phosphatase (Ci-VSP), residues 241-576(C363S), form III
3V0E	;	1.65	;	Crystal structure of Ciona intestinalis voltage sensor-containing phosphatase (Ci-VSP), residues 256-576(C363S)
3V0I	;	1.95	;	Crystal structure of Ciona intestinalis voltage sensor-containing phosphatase (Ci-VSP), residues 256-576, E411F
7XHS	;	2.11	;	Crystal structure of CipA crystal produced by cell-free protein synthesis
1R8J	;	2.03	;	Crystal Structure of Circadian Clock Protein KaiA from Synechococcus elongatus
4KSO	;	2.622	;	Crystal Structure of Circadian clock protein KaiB from S.Elongatus
1TF7	;	2.8	;	Crystal Structure of Circadian Clock Protein KaiC
4IJM	;	3.352	;	Crystal structure of circadian clock protein KaiC A422V mutant
4DUG	;	3.292	;	Crystal Structure of Circadian Clock Protein KaiC E318A Mutant
1U9I	;	2.8	;	Crystal Structure of Circadian Clock Protein KaiC with Phosphorylation Sites
3RWT	;	3.0	;	Crystal structure of circular permutated Red Fluorescent Protein mKate(cp 154-153)
4EIB	;	1.86	;	Crystal Structure of Circular Permuted CBM21 (CP90) Gives Insight into the Altered Selectivity on Carbohydrate Binding.
3EVP	;	1.453	;	crystal structure of circular-permutated EGFP
3RWA	;	1.67	;	Crystal structure of circular-permutated mKate
6AHW	;	1.56	;	Crystal structure of circular-permutated YibK methyltransferase from Haemophilus influenzae
5YT7	;	1.66	;	crystal structure of circularly permutated Azurin 3
1UN2	;	2.4	;	Crystal structure of circularly permuted CPDSBA_Q100T99: Preserved Global Fold and Local Structural Adjustments
4ET0	;	3.3	;	Crystal structure of circularly permuted human asparaginase-like protein 1
4ZM9	;	2.51	;	Crystal structure of circularly permuted human asparaginase-like protein 1
6UGK	;	2.15	;	CRYSTAL STRUCTURE OF CIRCULARLY PERMUTED HUMAN TASPASE-1
6B0S	;	1.95	;	Crystal structure of circumsporozoite protein aTSR domain in complex with 1710 antibody
3VDL	;	2.04	;	Crystal structure of circumsporozoite protein aTSR domain, P43212 form
3VDJ	;	1.698	;	Crystal structure of circumsporozoite protein aTSR domain, R32 native form
3VDK	;	1.847	;	Crystal structure of circumsporozoite protein aTSR domain, R32 platinum-bound form
1RPU	;	2.5	;	Crystal Structure of CIRV p19 bound to siRNA
7E5N	;	3.2	;	crystal structure of cis assembled TROP-2
7WZD	;	2.8	;	Crystal Structure of cis-4,5-dihydrodiol phthalate dehydrogenase from Comamonas testosteroni KF1
7X1X	;	2.77	;	Crystal Structure of cis-4,5-dihydrodiol phthalate dehydrogenase in complex with NAD+
7X2Y	;	2.48	;	Crystal Structure of cis-4,5-dihydrodiol phthalate dehydrogenase in complex with NAD+ and 3-Hydroxybenzoate
3ZV5	;	2.4	;	CRYSTAL STRUCTURE OF CIS-BIPHENYL-2,3-DIHYDRODIOL-2,3-DEHYDROGENASE (BPHB) FROM PANDORAEA PNOMENUSA STRAIN B-356 COMPLEX WITH CO-ENZYME NAD AND PRODUCT 2,3-DIHYDROXYBIPHENYL
3ZV6	;	2.14	;	CRYSTAL STRUCTURE OF CIS-BIPHENYL-2,3-DIHYDRODIOL-2,3-DEHYDROGENASE (BPHB) FROM PANDORAEA PNOMENUSA STRAIN B-356 COMPLEX WITH CO-ENZYME NAD AND PRODUCT ANALOG 4,4'-DIHYDROXYBIPHENYL
3ZV4	;	1.8	;	CRYSTAL STRUCTURE OF CIS-BIPHENYL-2,3-DIHYDRODIOL-2,3-DEHYDROGENASE (BPHB) FROM PANDORAEA PNOMENUSA STRAIN B-356 IN APO FORM AT 1.8 ANGSTROM
2Y99	;	2.5	;	Crystal Structure of cis-Biphenyl-2,3-dihydrodiol-2,3-dehydrogenase (BphB)from Pandoraea pnomenusa strain B-356 complex with co-enzyme NAD
3ZV3	;	2.9	;	CRYSTAL STRUCTURE OF CIS-BIPHENYL-2,3-DIHYDRODIOL-2,3-DEHYDROGENASE (BPHB)FROM PANDORAEA PNOMENUSA STRAIN B-356 IN INTERMEDIATE STATE OF SUBSTRATE BINDING LOOP
2Y93	;	2.22	;	Crystal Structure of cis-Biphenyl-2,3-dihydrodiol-2,3-dehydrogenase (BphB)from Pandoraea pnomenusa strain B-356.
8WBR	;	2.02	;	Crystal structure of cis-Epoxysuccinate Hydrolases KlCESH[L]
8WBT	;	2.05	;	Crystal structure of cis-Epoxysuccinate Hydrolases KlCESH[L] mutant D48N complexed with L-TA
8WBS	;	2.03	;	Crystal structure of cis-Epoxysuccinate Hydrolases KlCESH[L]-D48N complexed with sulfate ions
8WBK	;	2.15	;	Crystal structure of cis-Epoxysuccinate Hydrolases RhCESH[L]
8WBL	;	1.941	;	Crystal structure of cis-Epoxysuccinate Hydrolases RhCESH[L] complexed with sulfate ions
8WBO	;	1.58	;	Crystal structure of cis-Epoxysuccinate Hydrolases RhCESH[L] mutant D18N complexed with sulfate ions
8WBM	;	2.06	;	Crystal structure of cis-Epoxysuccinate Hydrolases RhCESH[L] mutant D193A complexed with sulfate ions
8WBN	;	2.5	;	Crystal structure of cis-Epoxysuccinate Hydrolases RhCESH[L] mutant D193N
8WBP	;	1.87	;	Crystal structure of cis-Epoxysuccinate Hydrolases RhCESH[L] mutant E212Q
8WBQ	;	2.2	;	Crystal structure of cis-Epoxysuccinate Hydrolases RhCESH[L] mutant E212Q complexed with L-TA.
6JH0	;	2.403	;	Crystal structure of cISG15/NS1B complex
1XTE	;	1.6	;	crystal structure of CISK-PX domain
1XTN	;	2.2	;	crystal structure of CISK-PX domain with sulfates
3IWX	;	2.14	;	Crystal structure of cisplatin bound to a human copper chaperone (dimer)
4YEA	;	2.14	;	Crystal structure of cisplatin bound to a human copper chaperone (dimer) - new refinement
3IWL	;	1.6	;	Crystal structure of cisplatin bound to a human copper chaperone (monomer)
4YDX	;	1.602	;	Crystal structure of cisplatin bound to a human copper chaperone (monomer) - new refinement
4N0Z	;	1.7	;	Crystal structure of cisplatin bound to a plasmodium falciparum glutaredoxin 1 (PfGrx1)
8C62	;	2.31	;	Crystal structure of cisplatin/B-DNA adduct
2AEO	;	1.8	;	Crystal structure of cisplatinated bovine Cu,Zn superoxide dismutase
6LNP	;	2.993	;	Crystal structure of citrate Biosensor
4WLE	;	1.9	;	Crystal structure of citrate bound MDH2
6KCX	;	1.933	;	Crystal structure of citrate complex of alpha-glucuronidase (TM0752)from Thermotoga maritima
1SGJ	;	1.84	;	Crystal structure of citrate lyase beta subunit
6ZU0	;	3.397	;	Crystal structure of citrate synthase (GltA) from Pseudomonas aeruginosa
6ABV	;	1.8	;	Crystal structure of citrate synthase (Msed_0281) from Metallosphaera sedula
6ABW	;	1.72	;	Crystal structure of citrate synthase (Msed_0281) from Metallosphaera sedula in complex with acetyl-CoA
6ABX	;	1.7	;	Crystal structure of citrate synthase (Msed_1522) from Metallosphaera sedula in complex with citrate
6ABY	;	2.0	;	Crystal structure of citrate synthase (Msed_1522) from Metallosphaera sedula in complex with oxaloacetate
3MSU	;	1.843	;	Crystal Structure of Citrate Synthase from Francisella tularensis
5UZQ	;	2.16	;	Crystal structure of citrate synthase from homo sapiens
5UZR	;	2.3	;	Crystal structure of citrate synthase from homo sapiens
2IBP	;	1.6	;	Crystal Structure of Citrate Synthase from Pyrobaculum aerophilum
5UQS	;	1.6	;	Crystal structure of Citrate synthase from Sus scrofa
2P2W	;	1.9	;	Crystal structure of citrate synthase from Thermotoga maritima MSB8
1IOM	;	1.5	;	CRYSTAL STRUCTURE OF CITRATE SYNTHASE FROM THERMUS THERMOPHILUS HB8
1IXE	;	2.3	;	Crystal structure of citrate synthase from Thermus thermophilus HB8
5UZP	;	2.29	;	Crystal structure of citrate synthase mutant A348G from homo sapiens
4TV5	;	1.85	;	Crystal Structure of Citrate Synthase SbnG
4TV6	;	2.6	;	Crystal Structure of Citrate Synthase Variant SbnG E151Q
1HUY	;	2.2	;	CRYSTAL STRUCTURE OF CITRINE, AN IMPROVED YELLOW VARIANT OF GREEN FLUORESCENT PROTEIN
1KKO	;	1.33	;	CRYSTAL STRUCTURE OF CITROBACTER AMALONATICUS METHYLASPARTATE AMMONIA LYASE
1KKR	;	2.1	;	CRYSTAL STRUCTURE OF CITROBACTER AMALONATICUS METHYLASPARTATE AMMONIA LYASE CONTAINING (2S,3S)-3-METHYLASPARTIC ACID
1Y4I	;	1.9	;	Crystal structure of Citrobacter Freundii L-methionine-lyase
5M3Z	;	1.45	;	Crystal structure of Citrobacter freundii methionine gamma-lyase with C115H replacement in the complex with L-norleucine
6EGR	;	1.45	;	Crystal structure of Citrobacter freundii methionine gamma-lyase with V358Y replacement
1CFR	;	2.15	;	CRYSTAL STRUCTURE OF CITROBACTER FREUNDII RESTRICTION ENDONUCLEASE CFR10I AT 2.15 ANGSTROMS RESOLUTION.
6CMK	;	1.732	;	Crystal structure of Citrobacter koseri AztD
8JD8	;	1.86	;	Crystal structure of Citrus limon Cu-Zn superoxide dismutase
5U50	;	2.902	;	Crystal structure of citrus MAF1 in space group C 2 2 21
5U4Z	;	2.85	;	Crystal structure of citrus MAF1 in space group P 31 2 1
7DCM	;	2.495	;	Crystal structure of CITX
6DRR	;	1.599	;	Crystal structure of Cj0485 dehydrogenase
6DS1	;	2.119	;	Crystal structure of Cj0485 dehydrogenase in complex with NADP+
6CF8	;	1.87	;	Crystal structure of Cj0843 lytic transglycosylase of Campylobacter jejuni at 1.87A resolution
3D6L	;	2.59	;	Crystal structure of Cj0915, a hexameric hotdog fold thioesterase of Campylobacter jejuni
3BNV	;	2.6	;	Crystal structure of Cj0977, a sigma28-regulated virulence protein from Campylobacter jejuni.
7RXU	;	2.4	;	Crystal structure of Cj1090c
6VO6	;	1.5	;	Crystal Structure of Cj1427, an Essential NAD-dependent Dehydrogenase from Campylobacter jejuni, in the Presence of NADH and GDP
7M13	;	1.5	;	Crystal structure of CJ1428, a GDP-D-GLYCERO-L-GLUCO-HEPTOSE SYNTHASE from campylobacter jejuni in the presence of NADPH
7M15	;	1.85	;	crystal structure of cj1430 in the presence of GDP-D-glycero-L-gluco-heptose, a GDP-D-glycero-4-keto-D-lyxo-heptose-3,5-epimerase from campylobacter jejuni
5NPB	;	1.9	;	Crystal Structure of cjAgd31B (alpha-transglucosylase from Glycoside Hydrolase Family 31) in complex with alpha Cyclophellitol Cyclosulfate probe ME647
5NPE	;	1.95	;	Crystal Structure of cjAgd31B (alpha-transglucosylase from Glycoside Hydrolase Family 31) in complex with beta Cyclophellitol Aziridine probe KY358
7QRB	;	2.6	;	Crystal structure of CK1 delta in complex with PK-09-129
7QR9	;	2.3	;	Crystal structure of CK1 delta in complex with PK-09-82
7QRA	;	2.4	;	Crystal structure of CK1 delta in complex with VN725
4HNF	;	2.07	;	Crystal structure of ck1d in complex with pf4800567
4HGT	;	1.8	;	Crystal structure of ck1d with compound 13
3UYT	;	2.0	;	crystal structure of ck1d with PF670462 from P1 crystal form
3UZP	;	1.94	;	crystal structure of ck1d with PF670462 from P21 crystal form
4HNI	;	2.74	;	crystal structure of ck1e in complex with PF4800567
4G17	;	2.1	;	Crystal structure of ck1g3 with 2-[(4-TERT-BUTYLPHENYL)AMINO]-1H-BENZIMIDAZOLE-6-CARBONITRILE
4G16	;	2.3	;	Crystal structure of ck1g3 with 2-[(4-{[3-(TRIFLUOROMETHYL)PYRIDIN2-YL]OXY}PHENYL)AMINO]-1H-BENZIMIDAZOLE-6-CARBONITRILE
4HGL	;	2.4	;	Crystal structure of ck1g3 with compound 1
4HGS	;	2.4	;	Crystal structure of ck1gs with compound 13
5KU8	;	2.22	;	Crystal structure of CK2
5KWH	;	2.12	;	Crystal structure of CK2
5T1H	;	2.11	;	Crystal structure of CK2
7AY9	;	2.25	;	Crystal structure of CK2 bound by compound 7
7AYA	;	2.45	;	Crystal structure of CK2 bound by compound 9
5H8B	;	2.55	;	Crystal structure of CK2 with compound 2
5H8G	;	2.0	;	Crystal structure of CK2 with compound 7b
5H8E	;	2.15	;	Crystal structure of CK2 with compound 7h
7X4H	;	1.77	;	Crystal structure of CK2a1 complexed with AG1112
7BU4	;	1.70227	;	Crystal structure of CK2a1 complexed with KY49
6L22	;	2.12318	;	Crystal structure of CK2a1 H115Y with hematein
6L24	;	2.40009	;	Crystal structure of CK2a1 H115Y/V116I with hematein
6L21	;	2.05452	;	Crystal structure of CK2a1 H160A with hematein
6L23	;	1.97449	;	Crystal structure of CK2a1 V116I with hematein
6JWA	;	1.781	;	Crystal structure of CK2a1 with 5-iodotubercidin
6L1Z	;	1.90821	;	Crystal structure of CK2a1 with hematein
7XYH	;	2.04	;	Crystal structure of CK2a2 complexed with AG1112
5Y9M	;	2.006	;	Crystal structure of CK2a2 form 3
5YWM	;	1.939	;	Crystal structure of CK2a2 form-1
5YF9	;	1.89	;	Crystal structure of CK2a2 form-2
6L20	;	3.08735	;	Crystal structure of CK2a2 with hematein
3AT2	;	1.6	;	Crystal structure of CK2alpha
5CU6	;	1.36	;	Crystal Structure of CK2alpha
5CVH	;	1.848	;	Crystal Structure of CK2alpha
5CU3	;	1.787	;	Crystal structure of CK2alpha bound to CAM4066
5CU4	;	1.56	;	Crystal structure of CK2alpha bound to CAM4066
5CX9	;	1.732	;	Crystal structure of CK2alpha with (methyl 4-((3-(3-chloro-4-(phenyl)benzylamino)propyl)amino)-4-oxobutanoate bound
6YPN	;	1.58	;	Crystal Structure of CK2alpha with 2 molecules of ADP bound
5CU2	;	1.705	;	Crystal structure of CK2alpha with 2-hydroxy-5-methylbenzoic acid and (methyl 4-((3-(3-chloro-4-(phenyl)benzylamino)propyl)amino)-4-oxobutanoat bound
5CU0	;	2.18	;	Crystal structure of CK2alpha with 2-hydroxy-5-methylbenzoic acid and N-(3-(3-chloro-4-(phenyl)benzylamino)propyl)acetamide bound
5CLP	;	1.684	;	Crystal Structure of CK2alpha with 3,4-dichlorophenethylamine bound
5CT0	;	2.008	;	Crystal structure of CK2alpha with 3-(3-chloro-4-(phenyl)benzylamino)propan-1-ol bound
5CVG	;	1.25	;	Crystal Structure of CK2alpha with a novel closed conformation of the aD loop
6GIH	;	1.96	;	Crystal Structure of CK2alpha with CAM187 bound
6YPJ	;	1.64	;	Crystal Structure of CK2alpha with Compound 1 bound
6YPH	;	1.67	;	Crystal Structure of CK2alpha with Compound 2 bound
6YPG	;	1.51	;	Crystal Structure of CK2alpha with Compound 2 bound to second crystal form
5CS6	;	1.88	;	Crystal Structure of CK2alpha with Compound 3 bound
5CSH	;	1.59	;	Crystal Structure of CK2alpha with Compound 4 bound
5CSP	;	1.5	;	Crystal Structure of CK2alpha with Compound 5 bound
5CVF	;	1.63	;	Crystal Structure of CK2alpha with Compound 5 bound
5CSV	;	1.375	;	Crystal Structure of CK2alpha with Compound 6 bound
5MMF	;	1.99	;	Crystal Structure of CK2alpha with Compound 7 bound
6YPK	;	1.79	;	Crystal Structure of CK2alpha with GTP bound
5MMR	;	2.0	;	Crystal Structure of CK2alpha with N-((2-chloro-[1,1'-biphenyl]-4-yl)methyl)butane-1,4-diamine bound
5MO5	;	2.04	;	Crystal Structure of CK2alpha with N-(3-(((2-chloro-[1,1'-biphenyl]-4-yl)methyl)amino)propyl)methanesulfonamide bound
5MO6	;	1.825	;	Crystal Structure of CK2alpha with N-(3-(((2-chloro-[1,1'-biphenyl]-4-yl)methyl)amino)propyl)methanesulfonamide bound
5MO7	;	2.15	;	Crystal Structure of CK2alpha with N-(3-(((2-chloro-[1,1'-biphenyl]-4-yl)methyl)amino)propyl)methanesulfonamide bound
5MO8	;	1.82	;	Crystal Structure of CK2alpha with N-(3-(((2-chloro-[1,1'-biphenyl]-4-yl)methyl)amino)propyl)methanesulfonamide bound
5MOD	;	2.08	;	Crystal Structure of CK2alpha with N-(3-(((2-chloro-[1,1'-biphenyl]-4-yl)methyl)amino)propyl)methanesulfonamide bound
5MOE	;	1.89	;	Crystal Structure of CK2alpha with N-(3-(((2-chloro-[1,1'-biphenyl]-4-yl)methyl)amino)propyl)methanesulfonamide bound
5CTP	;	2.033	;	Crystal structure of CK2alpha with N-(3-(3-chloro-4-(phenyl)benzylamino)propyl)acetamide bound
3AT3	;	2.6	;	Crystal structure of CK2alpha with pyradine derivative
3AT4	;	2.2	;	Crystal structure of CK2alpha with pyradine derivertive
5MOW	;	1.86	;	Crystal Structure of CK2alpha with ZT0432 bound
5MP8	;	1.92	;	Crystal Structure of CK2alpha with ZT0432 bound
5MOH	;	1.38	;	Crystal structure of CK2alpha with ZT0583 bound.
5MOT	;	2.09	;	Crystal structure of CK2alpha with ZT0627 bound
5MOV	;	2.2	;	Crystal structure of Ck2alpha with ZT0633 bound
6O6Q	;	2.7	;	Crystal structure of Cka1p, a casein kinase 2 alpha ortholog from Candida albicans
6M84	;	2.81	;	Crystal structure of cKir2.2 force open mutant in complex with PI(4,5)P2
4QLX	;	1.95	;	Crystal structure of CLA-ER with product binding
4QLY	;	2.005	;	Crystal structure of CLA-ER, a novel enone reductase catalyzing a key step of a gut-bacterial fatty acid saturation metabolism, biohydrogenation
2B9W	;	1.95	;	Crystal Structure of CLA-producing fatty acid isomerase from P. acnes
2B9X	;	2.22	;	Crystal Structure of CLA-producing fatty acid isomerase from P. acnes
2B9Y	;	2.21	;	Crystal structure of CLA-producing fatty acid isomerase from P. acnes
2BA9	;	1.95	;	Crystal structure of CLA-producing fatty acid isomerase from P. acnes
2BAB	;	2.0	;	Crystal structure of CLA-producing fatty acid isomerase from P. acnes
2BAC	;	2.3	;	Crystal structure of CLA-producing fatty acid isomerase from P. acnes
7CCG	;	1.85	;	Crystal structure of ClA1, a kind of a chlorinase from soil bacteria
4DVV	;	1.94	;	Crystal structure of clade A/E 93TH057 HIV-1 gp120 core in complex with AS-I-261
4DVT	;	2.4	;	Crystal structure of clade A/E 93TH057 HIV-1 gp120 core in complex with AS-II-37
4DKR	;	1.8	;	Crystal structure of clade A/E 93TH057 HIV-1 gp120 core in complex with AWS-I-169
4DKP	;	1.7978	;	Crystal structure of clade A/E 93TH057 HIV-1 gp120 core in complex with AWS-I-50
4DKQ	;	1.888	;	Crystal structure of clade A/E 93TH057 HIV-1 gp120 core in complex with DMJ-I-228
4DVW	;	2.2	;	Crystal structure of clade A/E 93TH057 HIV-1 gp120 core in complex with MAE-II-167
4DVX	;	2.4	;	Crystal structure of clade A/E 93TH057 HIV-1 gp120 core in complex with MAE-II-188
4DKU	;	2.4902	;	Crystal structure of clade A/E 93TH057 HIV-1 gp120 core in complex with NBD-09027
4DKV	;	2.1847	;	Crystal structure of clade A/E 93TH057 HIV-1 gp120 core in complex with NBD-10007
8F9Z	;	1.94	;	Crystal structure of clade A/E 93TH057 HIV-1 gp120 core in complex with NBD-14204, an HIV-1 gp120 antagonist
8FA0	;	2.09	;	Crystal structure of clade A/E 93TH057 HIV-1 gp120 core in complex with NBD-14208, an HIV-1 gp120 antagonist
4DVS	;	2.1	;	Crystal structure of clade A/E 93TH057 HIV-1 gp120 core in complex with NBD-557
4DKO	;	1.981	;	Crystal structure of clade A/E 93TH057 HIV-1 gp120 core in complex with TS-II-224
4I54	;	2.5	;	Crystal structure of clade A/E 93TH057 HIV-1 gp120 H375S core in complex with DMJ-II-121
5U6E	;	2.095	;	Crystal structure of clade A/E HIV-1 gp120 core in complex with NBD-14010
3LQA	;	3.4	;	Crystal structure of clade C gp120 in complex with sCD4 and 21c Fab
4I53	;	2.5002	;	Crystal structure of clade C1086 HIV-1 gp120 core in complex with DMJ-II-121
4YCU	;	2.1	;	Crystal structure of cladosporin in complex with human lysyl-tRNA synthetase
4YCW	;	2.9	;	Crystal structure of cladosporin in complex with plasmodium like human lysyl-tRNA synthetase mutant
4YCV	;	3.406	;	Crystal structure of cladosporin in complex with plasmodium lysyl-tRNA synthetase
7XSF	;	2.006	;	Crystal structure of ClAgl29A
7XSG	;	1.609	;	Crystal structure of ClAgl29B
7XSH	;	1.708	;	Crystal structure of ClAgl29B bound with L-glucose
4LGU	;	2.0	;	Crystal structure of clAP1 BIR3 bound to T3226692
4LGE	;	1.55	;	Crystal structure of clAP1 BIR3 bound to T3261256
6MQ7	;	1.78	;	Crystal structure of CLASP1 TOG2 domain at 1.78A resolution
3WOY	;	2.1	;	Crystal structure of CLASP2 TOG domain (TOG2)
3WOZ	;	2.2	;	Crystal structure of CLASP2 TOG domain (TOG3)
5NR4	;	1.198	;	Crystal structure of Clasp2 TOG1 domain
4XXL	;	1.47	;	Crystal structure of Class 1 cytochrome MtoD from Sideroxydans lithotrophicus ES-1
4NCD	;	2.037	;	Crystal Structure of Class 5 Fimbriae Chaperone CfaA
6AFO	;	1.399	;	Crystal structure of class A b-lactamase, PenL, variant Asn136Asp, from Burkholderia thailandensis
6AFP	;	1.398	;	Crystal structure of class A b-lactamase, PenL, variant Asn136Asp, from Burkholderia thailandensis, in complex with ceftazidime-like boronic acid
6AFM	;	1.3	;	Crystal structure of class A b-lactamase, PenL, variant Cys69Tyr, from Burkholderia thailandensis
6AFN	;	1.4	;	Crystal structure of class A b-lactamase, PenL, variant Cys69Tyr, from Burkholderia thailandensis, in complex with ceftazidime-like boronic acid
8IXX	;	1.7	;	Crystal structure of Class A beta-lactamase BlaA WT - complex with Ertapenem
8IY4	;	2.0	;	Crystal structure of Class A beta-lactamase BlaA WT - complex with Meropenem
8IX8	;	1.5	;	Crystal structure of Class A beta-lactamase BlaA WT - complex with Tebipenem
6W34	;	1.45	;	Crystal Structure of Class A Beta-lactamase from Bacillus cereus
6W33	;	1.85	;	Crystal Structure of Class A Beta-lactamase from Bacillus cereus in the Complex with the Beta-lactamase Inhibitor Clavulanate
2Y91	;	2.0	;	Crystal structure of class A beta-lactamase from Bacillus licheniformis BS3 with clavulanic acid
4A5R	;	2.1	;	Crystal structure of class A beta-lactamase from Bacillus licheniformis BS3 with tazobactam
6NJ1	;	1.399	;	Crystal structure of class A beta-lactamase from Clostridium kluyveri DSM 555
3B3X	;	2.5	;	Crystal structure of class A beta-lactamase of Bacillus licheniformis BS3 with aminocitrate
1IYS	;	1.65	;	Crystal Structure of Class A beta-Lactamase Toho-1
1WE4	;	1.7	;	Crystal Structure of Class A beta-Lactamase Toho-1 G238C mutant
7MQN	;	2.21	;	Crystal structure of class C beta lactamase from Rhodobacter sphaeroides
5GGW	;	1.762	;	Crystal structure of Class C beta-lactamase
2ZC7	;	2.4	;	Crystal Structure of Class C beta-Lactamase ACT-1
8TTP	;	1.43	;	Crystal structure of class C beta-lactamase from Escherichia coli in complex with avibactam
3W8K	;	1.5	;	Crystal structure of class C beta-lactamase Mox-1
4WBG	;	1.9	;	Crystal structure of class C beta-lactamase Mox-1 covalently complexed with aztorenam
6XJ3	;	1.85	;	Crystal structure of Class D beta-lactamase from Klebsiella quasipneumoniae in complex with avibactam
6N1N	;	1.601	;	Crystal structure of class D beta-lactamase from Sebaldella termitidis ATCC 33386
6ZRJ	;	1.94	;	Crystal structure of class D Beta-lactamase OXA-48 in complex with ertapenem
6ZRP	;	1.74	;	Crystal structure of class D Beta-lactamase OXA-48 in complex with meropenem
6PQI	;	2.05	;	Crystal Structure of Class D Beta-lactamase OXA-48 with Cefotaxime
6PT5	;	2.304	;	Crystal Structure of Class D Beta-lactamase OXA-48 with Cefoxitin
6PSG	;	2.13	;	Crystal Structure of Class D Beta-lactamase OXA-48 with Faropenem
6PTU	;	2.004	;	Crystal Structure of Class D Beta-lactamase OXA-48 with Imipenem
6PT1	;	2.0	;	Crystal Structure of Class D Beta-lactamase OXA-48 with Meropenem
1NP3	;	2.0	;	Crystal structure of class I acetohydroxy acid isomeroreductase from Pseudomonas aeruginosa
1DL2	;	1.54	;	CRYSTAL STRUCTURE OF CLASS I ALPHA-1,2-MANNOSIDASE FROM SACCHAROMYCES CEREVISIAE AT 1.54 ANGSTROM RESOLUTION
2DKV	;	2.0	;	Crystal structure of class I chitinase from Oryza sativa L. japonica
3IWR	;	2.57	;	Crystal structure of class I chitinase from Oryza sativa L. japonica
3HHN	;	2.987	;	Crystal structure of class I ligase ribozyme self-ligation product, in complex with U1A RBD
1IRX	;	2.6	;	Crystal structure of class I lysyl-tRNA synthetase
1I7T	;	2.8	;	CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDE P1049-5V
1I7U	;	1.8	;	CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDE P1049-6V
1I7R	;	2.2	;	CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDE P1058
1ZT7	;	3.0	;	crystal structure of class I MHC H-2Kk in complex with a nonapeptide
1ZT1	;	2.5	;	crystal structure of class I MHC H-2Kk in complex with an octapeptide
7V40	;	1.43	;	Crystal structure of Class I P450 monooxygenase (P450tol) from Rhodococcus coprophilus TC-2
7V42	;	1.69	;	Crystal structure of Class I P450 monooxygenase (P450tol) from Rhodococcus coprophilus TC-2 in complex with benzyl-alcohol.
7V44	;	1.42	;	Crystal structure of Class I P450 monooxygenase (P450tol) from Rhodococcus coprophilus TC-2 in complex with meta-chlorotoluene.
7V46	;	1.8	;	Crystal structure of Class I P450 monooxygenase (P450tol) from Rhodococcus coprophilus TC-2 in complex with ortho-chlorotoluene.
7V45	;	1.45	;	Crystal structure of Class I P450 monooxygenase (P450tol) from Rhodococcus coprophilus TC-2 in complex with para-bromotoluene.
7V43	;	1.4	;	Crystal structure of Class I P450 monooxygenase (P450tol) from Rhodococcus coprophilus TC-2 in complex with para-chlorotoluene.
7V41	;	1.45	;	Crystal structure of Class I P450 monooxygenase (P450tol) from Rhodococcus coprophilus TC-2 in complex with toluene.
6K3C	;	3.074	;	Crystal structure of class I PHA synthase (PhaC) mutant from Chromobacterium sp. USM2 bound to Coenzyme A.
7NE2	;	1.5	;	Crystal structure of class I SFP aldolase YihT from Salmonella enterica with SFP/ DHAP (Schiff base complex with active site Lys193)
5HJL	;	3.0	;	Crystal structure of class I tagatose 1,6-bisphosphate aldolase LacD from Streptococcus porcinus
6LOO	;	1.99	;	Crystal Structure of Class IB terpene synthase bound with geranylcitronellyl diphosphate
6LOP	;	1.91	;	Crystal Structure of Class IB terpene synthase bound with geranylgeraniol
3MF2	;	2.15	;	Crystal structure of class II aaRS homologue (Bll0957) complexed with AMP
3MF1	;	2.2	;	Crystal structure of class II aaRS homologue (Bll0957) complexed with an analogue of glycyl adenylate
3MEY	;	2.5	;	Crystal structure of class II aaRS homologue (Bll0957) complexed with ATP
3PZC	;	2.2	;	Crystal structure of class II aaRS homologue (Bll0957) complexed with Coenzyme A
1RVG	;	2.0	;	crystal structure of class II fructose-bisphosphate aldolase from Thermus aquaticus in complex with Y
5DZT	;	2.2	;	Crystal structure of class II lanthipeptide synthetase CylM in complex with AMP
1LNU	;	2.5	;	CRYSTAL STRUCTURE OF CLASS II MHC MOLECULE IAb BOUND TO EALPHA3K PEPTIDE
1KT2	;	2.8	;	CRYSTAL STRUCTURE OF CLASS II MHC MOLECULE IEK BOUND TO MOTH CYTOCHROME C PEPTIDE
1KTD	;	2.4	;	CRYSTAL STRUCTURE OF CLASS II MHC MOLECULE IEK BOUND TO PIGEON CYTOCHROME C PEPTIDE
7V8T	;	2.48	;	Crystal structure of class II pyruvate aldolase from Pseudomonas aeruginosa.
1EKE	;	2.0	;	CRYSTAL STRUCTURE OF CLASS II RIBONUCLEASE H (RNASE HII) WITH MES LIGAND
8Q57	;	1.7	;	Crystal structure of class II SFP aldolase from Yersinia aldovae (YaSqiA-Zn-SO4) with bound sulfate ions
4TOQ	;	1.6	;	Crystal structure of class III chitinase from pomegranate provides the insight into its metal storage capacity
8SAM	;	2.15	;	Crystal structure of class III lanthipeptide synthetase LP-GS-ThurKC in complex with ATP
8SAP	;	2.52	;	Crystal structure of class III lanthipeptide synthetase ThurKC
8SAO	;	2.502	;	Crystal structure of class III lanthipeptide synthetase ThurKC in complex with ThurA1 leader peptide
3ALG	;	1.8	;	Crystal Structure of Class V Chitinase (E115Q mutant) from Nicotiana tobaccum in complex with NAG4
3ALF	;	1.2	;	Crystal Structure of Class V Chitinase from Nicotiana tobaccum
1DS0	;	1.63	;	CRYSTAL STRUCTURE OF CLAVAMINATE SYNTHASE
1DS1	;	1.08	;	CRYSTAL STRUCTURE OF CLAVAMINATE SYNTHASE IN COMPLEX WITH FE(II) AND 2-OXOGLUTARATE
1DRY	;	1.4	;	CRYSTAL STRUCTURE OF CLAVAMINATE SYNTHASE IN COMPLEX WITH FE(II), 2-OXOGLUTARATE AND N-ALPHA-L-ACETYL ARGININE
1DRT	;	2.1	;	CRYSTAL STRUCTURE OF CLAVAMINATE SYNTHASE IN COMPLEX WITH FE(II), 2-OXOGLUTARATE AND PROCLAVAMINIC ACID
1GVG	;	1.54	;	Crystal Structure of Clavaminate Synthase with Nitric Oxide
4JCW	;	1.75	;	Crystal structure of Clavibacter michiganensis expansin in complex with cellopentaose
2A49	;	1.43	;	Crystal structure of clavulanic acid bound to E166A variant of SHV-1 beta-lactamase
3O3V	;	2.4	;	Crystal structure of ClbP peptidase domain
5UGZ	;	1.983	;	Crystal structure of ClbQ from the colibactin NRPS/PKS pathway
2H2P	;	3.1	;	Crystal structure of CLC-ec1 in complex with Fab fragment in SeCN-
6V2J	;	2.62	;	Crystal structure of ClC-ec1 triple mutant (E113Q, E148Q, E203Q)
3ZNU	;	1.65	;	Crystal structure of ClcF in crystal form 2
3ZO7	;	2.224	;	Crystal structure of ClcFE27A with substrate
6WNI	;	1.66	;	Crystal structure of CldA, the first cyclomaltodextrin glucanotransferase with a three-domain ABC distribution
4H9K	;	1.599	;	Crystal structure of cleavage site mutant of Npro of classical swine fever virus.
1D5S	;	3.0	;	CRYSTAL STRUCTURE OF CLEAVED ANTITRYPSIN POLYMER
1ATT	;	3.2	;	CRYSTAL STRUCTURE OF CLEAVED BOVINE ANTITHROMBIN III AT 3.2 ANGSTROMS RESOLUTION
4BB2	;	2.48	;	Crystal structure of cleaved corticosteroid-binding globulin in complex with progesterone
1HLE	;	1.95	;	CRYSTAL STRUCTURE OF CLEAVED EQUINE LEUCOCYTE ELASTASE INHIBITOR DETERMINED AT 1.95 ANGSTROMS RESOLUTION
4O48	;	2.29	;	Crystal structure of cleaved guinea pig L-asparaginase type III in complex with L-aspartate
2ACH	;	2.7	;	CRYSTAL STRUCTURE OF CLEAVED HUMAN ALPHA1-ANTICHYMOTRYPSIN AT 2.7 ANGSTROMS RESOLUTION AND ITS COMPARISON WITH OTHER SERPINS
7ZAS	;	2.0	;	Crystal structure of cleaved Iripin-4 serpin from tick Ixodes ricinus
6F4V	;	1.8	;	Crystal structure of cleaved Kallistatin complexed with heparin at 1.8 Angstrom resolution
3OUG	;	1.55	;	Crystal structure of cleaved L-aspartate-alpha-decarboxylase from Francisella tularensis
3DY0	;	1.55	;	Crystal Structure of Cleaved PCI Bound to Heparin
1LQ8	;	2.4	;	Crystal structure of cleaved protein C inhibitor
3WSR	;	1.91	;	Crystal structure of CLEC-2 in complex with O-glycosylated podoplanin
3WWK	;	2.98	;	Crystal structure of CLEC-2 in complex with rhodocytin
5JQ6	;	2.4	;	Crystal structure of ClfA in complex with the Fab fragment of Tefibazumab
1YJN	;	3.0	;	Crystal Structure Of Clindamycin Bound To The G2099A Mutant 50S Ribosomal Subunit Of Haloarcula Marismortui
6G33	;	2.05	;	Crystal structure of CLK1 in complex with 5-iodotubercidin
7OPG	;	1.93	;	Crystal structure of CLK1 in complex with compound 2 (CC513)
6KHD	;	2.7	;	Crystal structure of CLK1 in complex with CX-4945
6I5H	;	1.49	;	Crystal structure of CLK1 in complex with furanopyrimidin VN412
6FT9	;	1.87	;	Crystal structure of CLK1 in complex with inhibitor 16
6FT8	;	1.45	;	Crystal structure of CLK1 in complex with inhibitor 8g
6Z50	;	1.6	;	Crystal structure of CLK1 in complex with macrocycle ODS2003208
6Z4Z	;	2.07	;	Crystal structure of CLK1 in complex with macrocycle ODS2004070
6I5I	;	1.6	;	Crystal structure of CLK1 in complexed with furo[3,2-b]pyridine compound 12h
6I5L	;	2.55	;	Crystal structure of CLK1 in complexed with furo[3,2-b]pyridine compound VN316 (derivative of compound 12h)
6I5K	;	2.3	;	Crystal structure of CLK1 in complexed with furo[3,2-b]pyridine compound VN345 (derivative of compound 12h)
6KHE	;	2.8	;	Crystal structure of CLK2 in complex with CX-4945
2EU9	;	1.53	;	Crystal Structure of CLK3
6FT7	;	2.02	;	Crystal structure of CLK3 in complex with compound 8a
6KHF	;	2.598	;	Crystal structure of CLK3 in complex with CX-4945
6Z51	;	1.92	;	Crystal structure of CLK3 in complex with macrocycle ODS2002941
6Z53	;	1.65	;	Crystal structure of CLK3 in complex with macrocycle ODS2003128
6Z52	;	2.12	;	Crystal structure of CLK3 in complex with macrocycle ODS2003136
6Z54	;	1.73	;	Crystal structure of CLK3 in complex with macrocycle ODS2003178
6Z55	;	1.7	;	Crystal structure of CLK3 in complex with macrocycle ODS2004070
6RCT	;	2.32	;	Crystal structure of CLK3 in complex with T3-CLK
4G8E	;	2.2	;	Crystal Structure of clone18 TCR
4G8F	;	2.1	;	Crystal Structure of clone42 TCR
2YX2	;	2.8	;	Crystal structure of cloned trimeric hyluranidase from streptococcus pyogenes at 2.8 A resolution
3WPT	;	2.629	;	Crystal structure of closed dimer of human importin-alpha1 (Rch1)
4LHE	;	1.962	;	Crystal structure of closed form of Monoacylglycerol Lipase
4MT6	;	5.501	;	Crystal structure of closed inactive collybistin
8DCN	;	2.6	;	Crystal structure of Clostridioides difficile binary toxin CDTb D4 fragment in complex with BINTOXB/9 Fab
8DCM	;	2.5	;	Crystal structure of Clostridioides difficile binary toxin proCDTb lacking D4 in complex with BINTOXB/22 Fab
8DHJ	;	1.483	;	Crystal structure of Clostridioides difficile Protein Tyrosine Phosphatase at pH 7.5
8DHI	;	1.588	;	Crystal Structure of Clostridioides difficile Protein Tyrosine Phosphatase at pH 8.5
4EUH	;	2.1	;	Crystal structure of Clostridium acetobutulicum trans-2-enoyl-CoA reductase apo form
4EUF	;	2.7	;	Crystal structure of Clostridium acetobutulicum trans-2-enoyl-CoA reductase in complex with NAD
4EUE	;	2.0	;	Crystal structure of Clostridium acetobutulicum trans-2-enoyl-CoA reductase in complex with NADH
3F10	;	2.3	;	Crystal structure of Clostridium Acetobutylicum 8-oxoguanine DNA glycosylase in complex with 8-oxoguanosine
3I0X	;	1.8	;	Crystal structure of Clostridium acetobutylicum 8-oxoguanine glycosylase/lyase in complex with dsDNA containing adenine opposite to 8-oxoG
3I0W	;	1.73	;	Crystal structure of Clostridium acetobutylicum 8-oxoguanine glycosylase/lyase in complex with dsDNA containing cytosine opposite to 8-oxoG
3F0Z	;	2.2	;	Crystal structure of Clostridium acetobutylicum 8-oxoguanine glycosylase/lyase in its apo-form
3TVI	;	3.0	;	Crystal structure of Clostridium acetobutylicum aspartate kinase (CaAK): An important allosteric enzyme for industrial amino acids production
1F31	;	2.6	;	CRYSTAL STRUCTURE OF CLOSTRIDIUM BOTULINUM NEUROTOXIN B COMPLEXED WITH A TRISACCHARIDE
1G9B	;	2.0	;	CRYSTAL STRUCTURE OF CLOSTRIDIUM BOTULINUM NEUROTOXIN B COMPLEXED WITH AN INHIBITOR (EXPERIMENT 1)
1G9D	;	2.2	;	CRYSTAL STRUCTURE OF CLOSTRIDIUM BOTULINUM NEUROTOXIN B COMPLEXED WITH AN INHIBITOR (EXPERIMENT 2)
1G9A	;	2.1	;	CRYSTAL STRUCTURE OF CLOSTRIDIUM BOTULINUM NEUROTOXIN B COMPLEXED WITH AN INHIBITOR (EXPERIMENT 3)
1G9C	;	2.35	;	CRYSTAL STRUCTURE OF CLOSTRIDIUM BOTULINUM NEUROTOXIN B COMPLEXED WITH AN INHIBITOR (EXPERIMENT 4)
1I1E	;	2.5	;	CRYSTAL STRUCTURE OF CLOSTRIDIUM BOTULINUM NEUROTOXIN B COMPLEXED WITH DOXORUBICIN
3FIE	;	2.1	;	Crystal structure of Clostridium botulinum neurotoxin serotype F catalytic domain with an inhibitor (inh1)
3FII	;	2.17	;	Crystal structure of Clostridium botulinum neurotoxin serotype F catalytic domain with an inhibitor (inh2)
2A8A	;	2.0	;	Crystal structure of Clostridium botulinum neurotoxin serotype F light chain
1T3A	;	2.16	;	Crystal structure of Clostridium botulinum neurotoxin type E catalytic domain
3V3T	;	2.302	;	Crystal structure of Clostridium botulinum phage c-st TubZ
4NBX	;	1.75	;	Crystal Structure of Clostridium difficile Toxin A fragment TcdA-A1 Bound to A20.1 VHH
7LOU	;	1.82	;	Crystal structure of Clostridium difficile Toxin B (TcdB) glucosyltransferase in complex with UDP and isofagomine
7LOV	;	2.5	;	Crystal structure of Clostridium difficile Toxin B (TcdB) glucosyltransferase in complex with UDP and noeuromycin
1NQJ	;	1.0	;	CRYSTAL STRUCTURE OF CLOSTRIDIUM HISTOLYTICUM COLG COLLAGENASE COLLAGEN-BINDING DOMAIN 3B AT 1.0 ANGSTROM RESOLUTION IN ABSENCE OF CALCIUM
2O8O	;	1.35	;	Crystal structure of Clostridium histolyticum colg collagenase collagen-binding domain 3B at 1.35 Angstrom resolution in presence of calcium
4HPK	;	1.35	;	Crystal structure of Clostridium histolyticum colg collagenase collagen-binding domain 3B at 1.35 Angstrom resolution in presence of calcium nitrate
1NQD	;	1.65	;	CRYSTAL STRUCTURE OF CLOSTRIDIUM HISTOLYTICUM COLG COLLAGENASE COLLAGEN-BINDING DOMAIN 3B AT 1.65 ANGSTROM RESOLUTION IN PRESENCE OF CALCIUM
4JRW	;	1.6	;	Crystal structure of Clostridium histolyticum colg collagenase PKD domain 2 at 1.6 Angstrom resolution
4TN9	;	1.4	;	Crystal structure of Clostridium histolyticum ColG collagenase polycystic kidney disease-like domain at 1.4 Angstrom resolution
3JQX	;	2.2	;	Crystal structure of Clostridium histolyticum colH collagenase collagen binding domain 3 at 2.2 Angstrom resolution in the presence of calcium and cadmium
3JQW	;	2.0	;	Crystal structure of Clostridium histolyticum colH collagenase collagen-binding domain 3 at 2 Angstrom resolution in presence of calcium
4JGU	;	1.42	;	Crystal structure of Clostridium histolyticum ColH collagenase polycystic kidney-disease-like domain 2b at 1.4 Angstrom resolution in the presence of calcium
1EPW	;	1.9	;	CRYSTAL STRUCTURE OF CLOSTRIDIUM NEUROTOXIN TYPE B
4JKM	;	2.263	;	Crystal Structure of Clostridium perfringens beta-glucuronidase
6CXS	;	2.8	;	Crystal Structure of Clostridium perfringens beta-glucuronidase bound with a novel, potent inhibitor 4-(8-(piperazin-1-yl)-1,2,3,4-tetrahydro-[1,2,3]triazino[4',5':4,5]thieno[2,3-c]isoquinolin-5-yl)morpholine
7SJY	;	2.0	;	Crystal structure of Clostridium thermocellum RsgI9 S1C-NTF2 bi-domain
5HT8	;	2.01	;	Crystal structure of clostrillin double mutant (S17H,S19H) in complex with nickel
1K6K	;	1.8	;	Crystal Structure of ClpA, an AAA+ Chaperone-like Regulator of ClpAP protease implication to the functional difference of two ATPase domains
1KSF	;	2.6	;	Crystal Structure of ClpA, an HSP100 chaperone and regulator of ClpAP protease: Structural basis of differences in Function of the Two AAA+ ATPase domains
4HSE	;	2.2	;	Crystal structure of ClpB NBD1 in complex with guanidinium chloride and ADP
2Y1Q	;	1.5	;	Crystal Structure of ClpC N-terminal Domain
8AD9	;	1.43	;	Crystal structure of ClpC2 C-terminal domain
8ADA	;	1.996	;	Crystal structure of ClpC2 N-terminal domain
3HLN	;	3.2	;	Crystal structure of ClpP A153C mutant with inter-heptamer disulfide bonds
7P81	;	2.79	;	Crystal structure of ClpP from Bacillus subtilis in complex with ADEP2 (compact state)
7P80	;	2.98	;	Crystal structure of ClpP from Bacillus subtilis in complex with ADEP2 (compressed state)
3QWD	;	2.1	;	Crystal structure of ClpP from Staphylococcus aureus
3V5E	;	2.3	;	Crystal structure of ClpP from Staphylococcus aureus in the active, extended conformation
8QYF	;	2.33	;	Crystal structure of ClpP from Staphylococcus epidermidis in complex with ixazomib
8CJ4	;	1.9	;	Crystal structure of ClpP from Staphylococcus epidermidis, tetradecamer
3ST9	;	2.43	;	Crystal structure of ClpP in heptameric form from Staphylococcus aureus
3STA	;	2.28	;	Crystal structure of ClpP in tetradecameric form from Staphylococcus aureus
6MX2	;	2.5	;	Crystal Structure of ClpP1 from Clostridium difficile 630.
5ZNX	;	2.114	;	Crystal structure of CM14-treated HlyU from Vibrio vulnificus
7FC9	;	2.2	;	Crystal structure of CmABCB1 in lipidic mesophase revealed by LCP-SFX
7VR5	;	3.0	;	Crystal structure of CmABCB1 W114Y/W161Y/W363Y/W364Y/M391W (4WY/M391W) mutant
7CY4	;	2.2	;	Crystal Structure of CMD1 in apo form
7CY6	;	2.1	;	Crystal Structure of CMD1 in complex with 5mC-DNA
7CY8	;	2.4	;	Crystal Structure of CMD1 in complex with 5mC-DNA and vitamin C
7CY7	;	2.15	;	Crystal Structure of CMD1 in complex with DNA
7CY5	;	2.2	;	Crystal Structure of CMD1 in complex with vitamin C
3HGG	;	2.57	;	Crystal Structure of CmeR Bound to Cholic Acid
3HGY	;	2.416	;	Crystal Structure of CmeR Bound to Taurocholic Acid
7V3R	;	1.7	;	Crystal structure of CMET in complex with a novel inhibitor
7V3S	;	1.9	;	Crystal structure of CMET in complex with a novel inhibitor
5HO6	;	1.97	;	CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH CMPD.
4GG5	;	2.423	;	Crystal structure of CMET in complex with novel inhibitor
4GG7	;	2.27	;	Crystal structure of cMET in complex with novel inhibitor
4MXC	;	1.632	;	Crystal structure of CMET in complex with novel inhibitor
5EOB	;	1.75	;	Crystal structure of CMET in complex with novel inhibitor
7Y4T	;	2.16	;	Crystal structure of cMET kinase domain bound by compound 9I
7Y4U	;	2.26	;	Crystal structure of cMET kinase domain bound by compound 9Y
8GVJ	;	2.71	;	Crystal structure of cMET kinase domain bound by D6808
5HNI	;	1.71	;	CRYSTAL STRUCTURE OF CMET WT with compound 3
9AV7	;	2.1	;	Crystal structure of CMGC family protein kinase from Trichomonas vaginalis (AMP-PNP)
9AV6	;	2.0	;	Crystal structure of CMGC family protein kinase from Trichomonas vaginalis (Apo)
6J38	;	2.3	;	Crystal structure of CmiS2
6J39	;	2.45	;	Crystal structure of CmiS2 with inhibitor
5JJP	;	2.3	;	Crystal structure of CmiS6
4JO0	;	2.17	;	Crystal Structure of CmlA, a diiron beta-hydroxylase from Streptomyces venezuelae
3I3L	;	2.2	;	Crystal structure of CmlS, a flavin-dependent halogenase
8IF7	;	2.2	;	Crystal structure of CmnB
7VGL	;	1.67	;	Crystal structure of CmnC
7VGN	;	1.83	;	Crystal structure of CmnC
7Y5P	;	1.7	;	Crystal structure of CmnC in complex with L-arginine and alpha-KG
7Y5F	;	1.52	;	Crystal structure of CmnC in complex with L-homoarginine
7Y5I	;	1.49	;	Crystal structure of CmnC in complex with L-homoarginine
7CXV	;	2.35	;	Crystal structure of CmnK
7CXU	;	2.19	;	Crystal structure of CmnK in complex with NAD+
7CXS	;	1.83	;	Crystal structure of CmnK, a L-Dap formation enzyme in capreomycin biosynthesis
4QNU	;	2.6	;	Crystal structure of CmoB bound with Cx-SAM in P21212
8JOZ	;	2.22	;	Crystal structure of CmoM from E. coli complexed with sinefungin and cellularly expressed tRNA Ser
6I1R	;	2.8	;	Crystal structure of CMP bound CST in an outward facing conformation
3W90	;	1.65	;	Crystal structure of CMP kinase from Thermus thermophilus HB8
3AKC	;	1.65	;	Crystal structure of CMP kinase in complex with CDP and ADP from Thermus thermophilus HB8
3AKD	;	1.6	;	Crystal structure of CMP kinase in complex with CDP from Thermus thermophilus HB8
7CKJ	;	1.5	;	Crystal structure of CMP kinase in complex with CMP from Thermus thermophilus HB8
1VH1	;	2.6	;	Crystal structure of CMP-KDO synthetase
1VH3	;	2.7	;	Crystal structure of CMP-KDO synthetase
1VIC	;	1.8	;	Crystal structure of CMP-KDO synthetase
6IFD	;	2.3	;	Crystal Structure of CMP-N-acetylneuraminate Synthetase from Vibrio cholerae in complex with CDP and Mg2+.
4W8Z	;	2.7	;	Crystal structure of Cmr1 from Pyrococcus furiosus (apo form)
4W8X	;	3.0	;	Crystal Structure of Cmr1 from Pyrococcus furiosus bound to a nucleotide
4RDP	;	2.85	;	Crystal structure of Cmr4
4W8V	;	2.15	;	Crystal structure of Cmr6 from Pyrococcus furiosus
5F1F	;	1.548	;	Crystal structure of CMY-10 adenylylated by acetyl-AMP
6G9T	;	1.6	;	CRYSTAL STRUCTURE OF CMY-136 class C BETA-LACTAMASE
8JB7	;	1.35	;	Crystal structure of CMY-185
8JB8	;	2.4	;	Crystal structure of CMY-185 complex with ceftazidime
1JL7	;	1.4	;	Crystal Structure Of CN-Ligated Component III Glycera Dibranchiata Monomeric Hemoglobin
1JL6	;	1.4	;	Crystal Structure of CN-Ligated Component IV Glycera Dibranchiata Monomeric Hemoglobin
8BDW	;	1.86	;	Crystal structure of CnaB2 domain from Lactobacillus plantarum
6YHL	;	3.277	;	Crystal structure of CNFy from Yersinia pseudotuberculosis - N-terminal fragment comprising residues 1-704
3K03	;	1.62	;	Crystal Structure of CNG mimicking NaK mutant, NaK-DTPP, K+ complex
3K04	;	1.58	;	Crystal Structure of CNG mimicking NaK mutant, NaK-DTPP, Na+ complex
4R6Z	;	2.3	;	Crystal Structure of CNG mimicking NaK mutant, NaK-ETPP, Cs+ complex
3K0D	;	1.95	;	Crystal Structure of CNG mimicking NaK mutant, NaK-ETPP, K+ complex
3K0G	;	1.95	;	Crystal Structure of CNG mimicking NaK mutant, NaK-ETPP, Na+ complex
3K06	;	1.58	;	Crystal Structure of CNG mimicking NaK mutant, NaK-NTPP, K+ complex
3K08	;	1.62	;	Crystal Structure of CNG mimicking NaK mutant, NaK-NTPP, Na+ complex
6FIZ	;	2.63	;	Crystal Structure of CNG mimicking NaK-EAPP mutant (T67A) cocrystallized with K+
4R7C	;	2.3	;	Crystal Structure of CNG mimicking NaK-ETPP mutant cocrystallized with DiMethylammonium
4R50	;	2.85	;	Crystal Structure of CNG mimicking NaK-ETPP mutant cocrystallized with Li+
4RO2	;	2.7	;	Crystal Structure of CNG mimicking NaK-ETPP mutant cocrystallized with Methylammonium
4RAI	;	2.31	;	Crystal Structure of CNG mimicking NaK-ETPP mutant in complex with Na+
4R8C	;	2.5	;	Crystal Structure of CNG mimicking NaK-ETPP mutant in complex with Rb+
6DJ3	;	2.6	;	Crystal structure of CNNM2 cyclic nucleotide-binding homology domain
6DFD	;	1.901	;	Crystal structure of CNNM3 cyclic nucleotide-binding homology domain
7EZN	;	1.8	;	Crystal structure of CnYvh1 complex with vanadate
4JZ2	;	1.95	;	Crystal structure of Co ion substituted SOD2 from Clostridium difficile
5W97	;	2.3	;	Crystal Structure of CO-bound Cytochrome c Oxidase determined by Serial Femtosecond X-Ray Crystallography at Room Temperature
5WAU	;	1.95	;	Crystal Structure of CO-bound Cytochrome c Oxidase determined by Synchrotron X-Ray Crystallography at 100 K
5U8Y	;	2.5	;	Crystal structure of Co-CAO1
5U97	;	1.85	;	Crystal structure of Co-CAO1 in complex with piceatannol
5U90	;	1.9	;	Crystal structure of Co-CAO1 in complex with resveratrol
2RB7	;	1.6	;	Crystal structure of co-catalytic metallopeptidase (YP_387682.1) from Desulfovibrio desulfuricans G20 at 1.60 A resolution
3NX6	;	1.97	;	Crystal Structure of co-chaperonin, GroES (Xoo4289) from Xanthomonas oryzae pv. oryzae KACC10331
8PN6	;	1.61	;	Crystal Structure of co-expressed NS2B-NS3 Protease from Zika Virus
1NWI	;	2.5	;	Crystal structure of CO-HbI transformed to an unligated state
3QZ5	;	2.5	;	Crystal Structure of Co-type Nitrile Hydratase alpha-E168Q from Pseudomonas putida.
3QYG	;	2.3	;	Crystal Structure of Co-type Nitrile Hydratase beta-E56Q from Pseudomonas putida.
3QYH	;	2.0	;	Crystal Structure of Co-type Nitrile Hydratase beta-H71L from Pseudomonas putida.
3QZ9	;	2.4	;	Crystal structure of Co-type nitrile hydratase beta-Y215F from Pseudomonas putida.
1UGP	;	1.63	;	Crystal structure of Co-type nitrile hydratase complexed with n-butyric acid
3QXE	;	2.104	;	Crystal Structure of Co-type Nitrile Hydratase from Pseudomonas putida.
1IRE	;	1.8	;	Crystal Structure of Co-type nitrile hydratase from Pseudonocardia thermophila
7W8M	;	2.6	;	Crystal structure of Co-type nitrile hydratase mutant from Pseudomonas thermophila - A129R
8I6N	;	2.2	;	Crystal structure of Co-type nitrile hydratase mutant from Pseudomonas thermophila - L6T
7W8L	;	2.301	;	Crystal Structure of Co-type nitrile hydratase mutant from Pseudonocardia thermophila - M46R
3AZ4	;	1.62	;	Crystal structure of Co/O-HEWL
3AZ6	;	1.5	;	Crystal structure of Co/T-HEWL
3MZ3	;	3.2	;	Crystal structure of Co2+ HDAC8 complexed with M344
3THE	;	1.97	;	Crystal structure of Co2+2-HAI (pH 8.5)
2Y1W	;	2.1	;	CRYSTAL STRUCTURE OF COACTIVATOR ASSOCIATED ARGININE METHYLTRANSFERASE 1 (CARM1) IN COMPLEX WITH SINEFUNGIN AND INDOLE INHIBITOR
2Y1X	;	2.4	;	CRYSTAL STRUCTURE OF COACTIVATOR ASSOCIATED ARGININE METHYLTRANSFERASE 1 (CARM1) IN COMPLEX WITH SINEFUNGIN AND INDOLE INHIBITOR
2V74	;	2.7	;	Crystal structure of coactivator-associated arginine methyltransferase 1 (CARM1), in complex with S-adenosyl-homocysteine
2V7E	;	2.7	;	Crystal structure of coactivator-associated arginine methyltransferase 1 (CARM1), unliganded
4IKP	;	2.0	;	Crystal structure of coactivator-associated arginine methyltransferase 1 with methylenesinefungin
4LIZ	;	1.499	;	Crystal structure of coactosin from Entamoeba histolytica
1BJ3	;	2.6	;	CRYSTAL STRUCTURE OF COAGULATION FACTOR IX-BINDING PROTEIN (IX-BP) FROM VENOM OF HABU SNAKE WITH A HETERODIMER OF C-TYPE LECTIN DOMAINS
1IXX	;	2.5	;	CRYSTAL STRUCTURE OF COAGULATION FACTORS IX/X-BINDING PROTEIN (IX/X-BP) FROM VENOM OF HABU SNAKE WITH A HETERODIMER OF C-TYPE LECTIN DOMAINS
2YXD	;	2.3	;	Crystal Structure of Cobalamin biosynthesis precorrin 8W decarboxylase (cbiT)
2BB3	;	2.27	;	Crystal Structure of Cobalamin Biosynthesis Precorrin-6Y Methylase (cbiE) from Archaeoglobus fulgidus
3BY5	;	2.52	;	Crystal structure of cobalamin biosynthesis protein chiG from Agrobacterium tumefaciens str. C58
1T7L	;	2.0	;	Crystal Structure of Cobalamin-Independent Methionine Synthase from T. maritima
3KON	;	1.5	;	Crystal structure of cobalt (II) human carbonic anhydrase II at pH 11.0
3KOK	;	1.5	;	Crystal structure of cobalt (II) human carbonic anhydrase II at pH 8.5
3KOI	;	1.64	;	Crystal structure of cobalt (III) human carbonic anhydrase II at pH 6.0
1P24	;	3.02	;	Crystal structure of cobalt(II)-d(GGCGCC)2
1LFM	;	1.5	;	CRYSTAL STRUCTURE OF COBALT(III)-SUBSTITUTED CYTOCHROME C (TUNA)
6XM6	;	1.45	;	Crystal structure of cobalt-bound LSD4 from Sphingobium sp. strain SYK-6
4NUI	;	1.7	;	Crystal structure of cobalt-bound Na-ASP-2
1IQX	;	2.0	;	CRYSTAL STRUCTURE OF COBALT-SUBSTITUTED AMINE OXIDASE FROM ARTHROBACTER GLOBIFORMIS
6BIG	;	2.21	;	Crystal structure of cobalt-substituted Synechocystis ACO
6RXO	;	1.95	;	Crystal structure of CobB Ac2 (A76G, I131C, V162A) in complex with H4K16-Buturyl peptide
6RXM	;	1.92	;	Crystal structure of CobB Ac2 (A76G, I131C, V162G) in complex with H4K16-Acetyl peptide
6RXR	;	1.7	;	Crystal structure of CobB Ac2 (A76G, I131C, V162G) in complex with H4K16Cr-2'OH-ADPr peptide intermediate after co-crystallisation
6RXP	;	1.8	;	Crystal structure of CobB Ac2 (A76G,I131C,V162A) in complex with H4K16-Crotonyl peptide
6RXQ	;	1.7	;	Crystal structure of CobB Ac2 (A76G,I131C,V162A) in complex with H4K16Cr-2'OH-ADPr peptide intermediate after soaking
6RXS	;	1.599	;	Crystal structure of CobB Ac3(A76G,Y92A, I131L, V187Y) in complex with H4K16-Acetyl peptide
6RXJ	;	1.6	;	Crystal structure of CobB wt in complex with H4K16-Acetyl peptide
6RXK	;	1.35	;	Crystal structure of CobB wt in complex with H4K16-Butyryl peptide
6RXL	;	2.3	;	Crystal structure of CobB wt in complex with H4K16-Crotonyl peptide
4AU1	;	1.45	;	Crystal Structure of CobH (precorrin-8x methyl mutase) complexed with C5 desmethyl-HBA
5N0G	;	1.57	;	Crystal Structure of CobH T85A (precorrin-8x methyl mutase) complexed with C5 allyl-HBA
8D9Z	;	1.8	;	Crystal structure of Cobra alpha-neurotoxin in complex with Centi-3FTX-D09 antibody
3FRP	;	2.61	;	Crystal Structure of Cobra Venom Factor, a Co-factor for C3- and C5 convertase CVFBb
1POB	;	2.0	;	CRYSTAL STRUCTURE OF COBRA-VENOM PHOSPHOLIPASE A2 IN A COMPLEX WITH A TRANSITION-STATE ANALOGUE
1V6P	;	0.87	;	Crystal structure of Cobrotoxin
1L4L	;	2.0	;	Crystal Structure of CobT complexed with 2,5-dimethylaniline and nicotinate mononucleotide
1L4M	;	2.0	;	Crystal Structure of CobT complexed with 2-amino-p-cresol and nicotinate mononucleotide
1L4N	;	2.0	;	Crystal Structure of CobT complexed with 2-aminophenol
1L4K	;	2.2	;	Crystal Structure of CobT complexed with 3,4-dimethylaniline and nicotinate mononucleotide
1L5O	;	1.6	;	Crystal Structure of CobT complexed with 3,4-dimethylphenol and nicotinate mononucleotide
1L4G	;	2.1	;	Crystal Structure of CobT complexed with 4-methylcatechol and nicotinate mononucleotide
1L5F	;	1.9	;	Crystal Structure of CobT complexed with benzimidazole
1L5N	;	1.9	;	Crystal Structure of CobT complexed with imidazole
1L4H	;	2.1	;	Crystal Structure of CobT complexed with indole and nicotinate mononucleotide
1L5K	;	2.0	;	Crystal Structure of CobT complexed with N1-(5'-phosphoribosyl)-benzimidazole and nicotinate
1L5M	;	2.0	;	Crystal Structure of CobT complexed with N7-(5'-phosphoribosyl)-2-aminopurine and nicotinate
1L5L	;	2.0	;	Crystal Structure of CobT complexed with N7-(5'-phosphoribosyl)purine and nicotinate
4KQF	;	1.9	;	Crystal structure of CobT E174A complexed with adenine
4KQG	;	1.9	;	Crystal structure of CobT E174A complexed with DMB
4KQH	;	1.9	;	Crystal structure of CobT E317A
4KQI	;	1.4	;	Crystal structure of CobT E317A complexed with its reaction products
6PTF	;	2.203	;	Crystal Structure of CobT from Methanocaldococcus jannaschii in Apo State
6PT8	;	1.4	;	Crystal Structure of CobT from Methanocaldococcus jannaschii in complex with Adenine Alpha-Ribotide and Nicotinic Acid
1J33	;	2.0	;	Crystal structure of CobT from Thermus thermophilus HB8
1L4B	;	1.7	;	Crystal Structure of CobT in apo state
4KQK	;	1.47	;	Crystal structure of CobT S80Y/Q88M/L175M complexed with p-cresol
4KQJ	;	1.95	;	Crystal structure of CobT S80Y/Q88M/L175M complexed with p-cresol and NaMN
4PFS	;	2.3	;	Crystal Structure of Cobyrinic Acid a,c-diamide synthase from Mycobacterium smegmatis
5IHP	;	1.85	;	Crystal Structure of Cobyrinic Acid a,c-diamide synthase from Mycobacterium smegmatis with bound ADP and Magnesium
5IF9	;	1.8	;	Crystal Structure of Cobyrinic Acid a,c-diamide synthase from Mycobacterium smegmatis with bound ATP analog and Magnesium
2PGZ	;	1.76	;	Crystal structure of Cocaine bound to an ACh-Binding Protein
2AK1	;	1.85	;	Crystal Structure of Cocaine catalytic Antibody 7A1 Fab' in Complex with benzoic acid
2AJV	;	1.5	;	Crystal Structure of Cocaine catalytic Antibody 7A1 Fab' in Complex with Cocaine
2AJZ	;	2.3	;	Crystal Structure of Cocaine catalytic Antibody 7A1 Fab' in Complex with ecgonine methyl ester
2AJY	;	2.1	;	Crystal Structure of Cocaine catalytic Antibody 7A1 Fab' in Complex with ecgonine methyl ester and benzoic acid
2AJS	;	1.7	;	Crystal structure of cocaine catalytic antibody 7A1 Fab' in complex with heptaethylene glycol
2AJX	;	1.85	;	Crystal Structure of Cocaine catalytic Antibody 7A1 Fab' in Complex with Transition State Analog
7ZNX	;	1.6	;	Crystal structure of cocaprin 1, inhibitor of cysteine and aspartic proteases from Coprinopsis cinerea
6GKV	;	2.35	;	Crystal structure of Coclaurine N-Methyltransferase (CNMT) bound to N-methylheliamine and SAH
6GKY	;	2.847	;	Crystal structure of Coclaurine N-Methyltransferase (CNMT) bound to N-methylheliamine and SAH
6GKZ	;	2.43	;	Crystal structure of Coclaurine N-Methyltransferase (CNMT) bound to N-methylheliamine and SAH
5WPW	;	1.847	;	Crystal structure of coconut allergen cocosin
3WX7	;	1.349	;	Crystal structure of COD
2VUV	;	1.3	;	Crystal structure of Codakine at 1.3A resolution
2VUZ	;	1.7	;	Crystal structure of Codakine in complex with biantennary nonasaccharide at 1.7A resolution
6X5K	;	2.47	;	Crystal structure of CODH/ACS with carbon monoxide bound to the A-cluster
5FHX	;	2.55	;	CRYSTAL STRUCTURE OF CODV IN COMPLEX WITH IL4 AT 2.55 Ang. RESOLUTION.
5EY2	;	3.0	;	Crystal structure of CodY from Bacillus cereus
5EY0	;	1.6	;	Crystal structure of CodY from Staphylococcus aureus with GTP and Ile
5EY1	;	2.0	;	Crystal structure of CodY from Staphylococcus aureus with GTP and Ile
7OMR	;	1.5	;	Crystal structure of coelenteramide-bound Renilla reniformis luciferase RLuc8-D162A variant
7OMO	;	1.451	;	Crystal structure of coelenteramine-bound Renilla reniformis luciferase RLuc8-D120A variant
2HPS	;	1.72	;	Crystal structure of coelenterazine-binding protein from Renilla Muelleri
2HQ8	;	1.8	;	Crystal structure of coelenterazine-binding protein from renilla muelleri in the ca loaded apo form
2G39	;	2.1	;	Crystal structure of coenzyme A transferase from Pseudomonas aeruginosa
6FRM	;	2.2	;	Crystal Structure of coenzyme F420H2 oxidase (FprA) co-crystallized with 10 mM Tb-Xo4
2OHH	;	1.7	;	Crystal Structure of coenzyme F420H2 oxidase (FprA), a diiron flavoprotein, active oxidized state
2OHJ	;	2.26	;	Crystal Structure of coenzyme F420H2 oxidase (FprA), a diiron flavoprotein, inactive oxidized state
2OHI	;	2.3	;	Crystal Structure of coenzyme F420H2 oxidase (FprA), a diiron flavoprotein, reduced state
4NJO	;	2.22	;	crystal structure of cofactor(NAD+) bound 3-phosphoglycerate dehydrogenase in Entamoeba histolytica
6JCL	;	1.644	;	Crystal structure of cofactor-bound Rv0187 from MTB
4CW0	;	1.5	;	Crystal structure of cofactor-free urate oxidase anaerobically complexed with 9-methyl uric acid
4D12	;	1.4	;	Crystal Structure of Cofactor-free Urate Oxidase Anaerobically Complexed with Uric Acid
4D19	;	1.35	;	Crystal structure of cofactor-free urate oxidase in complex with its 5-peroxoisourate intermediate (X-ray dose, 1.75 MGy)
4D17	;	1.3	;	Crystal structure of cofactor-free urate oxidase in complex with its 5-peroxoisourate intermediate (X-ray dose, 106 kGy)
4D13	;	1.3	;	Crystal structure of cofactor-free urate oxidase in complex with its 5-peroxoisourate intermediate (X-ray dose, 2.2 kGy)
4CW2	;	1.32	;	Crystal structure of cofactor-free urate oxidase in complex with the 5-peroxo derivative of 9-metyl uric acid (X-ray dose, 2.5 kGy)
4CW3	;	1.34	;	Crystal structure of cofactor-free urate oxidase in complex with the 5-peroxo derivative of 9-metyl uric acid (X-ray dose, 665 kGy)
4CW6	;	1.28	;	Crystal structure of cofactor-free urate oxidase in complex with the 5-peroxo derivative of 9-metyl uric acid (X-ray dose, 92 kGy)
4QS4	;	2.0	;	Crystal Structure of CofB from Enterotoxigenic Escherichia coli
4KED	;	1.901	;	Crystal Structure of Cofilin Mutant (cof1-157p)
4KEE	;	1.448	;	Crystal Structure of Cofilin Mutant (cof1-158p)
2OH3	;	2.0	;	Crystal structure of COG1633: Uncharacterized conserved protein (ZP_00055496.1) from Magnetospirillum magnetotacticum MS-1 at 2.00 A resolution
3UL4	;	1.95	;	Crystal structure of Coh-OlpA(Cthe_3080)-Doc918(Cthe_0918) complex: A novel type I Cohesin-Dockerin complex from Clostridium thermocellum ATTC 27405
4DH2	;	1.75	;	Crystal structure of Coh-OlpC(Cthe_0452)-Doc435(Cthe_0435) complex: A novel type I Cohesin-Dockerin complex from Clostridium thermocellum ATTC 27405
4U3S	;	1.64	;	Crystal structure of Coh3ScaB-XDoc_M1ScaA complex: A N-terminal interface mutant of type II Cohesin-X-Dockerin complex from Acetivibrio cellulolyticus
4WI0	;	1.93	;	Crystal structure of Coh3ScaB-XDoc_M2ScaA complex: A C-terminal interface mutant of type II Cohesin-X-Dockerin complex from Acetivibrio cellulolyticus
1ZZB	;	2.3	;	Crystal Structure of CoII HppE in Complex with Substrate
1ZZC	;	1.8	;	Crystal Structure of CoII HppE in Complex with Tris Buffer
2X6P	;	2.15	;	Crystal Structure of Coil Ser L19C
5FIY	;	3.0	;	crystal structure of coiled coil domain of PAWR
6WBE	;	2.1	;	Crystal structure of coiled coil region of human septin 1
6WB3	;	1.35	;	Crystal structure of coiled coil region of human septin 4
6WCU	;	1.8	;	Crystal structure of coiled coil region of human septin 5
6WBP	;	1.8	;	Crystal structure of coiled coil region of human septin 6
6WSM	;	2.451	;	Crystal structure of coiled coil region of human septin 8
7WJT	;	2.3	;	Crystal structure of coiled-coil region of mouse TMEM266
3GR9	;	2.2	;	Crystal structure of ColD H188K S187N
3A0J	;	1.65	;	Crystal structure of cold shock protein 1 from Thermus thermophilus HB8
6T00	;	2.1	;	Crystal structure of Cold Shock Protein B (CSP-B) containing 4-F-Phe modified residues
6SZZ	;	2.05	;	Crystal structure of Cold Shock Protein B (CspB) containing the modified residue 4-F-Trp
3A52	;	2.2	;	Crystal structure of cold-active alkailne phosphatase from psychrophile Shewanella sp.
4NS4	;	2.15	;	Crystal structure of cold-active estarase from Psychrobacter cryohalolentis K5T
7B1X	;	2.3	;	Crystal structure of cold-active esterase PMGL3 from permafrost metagenomic library
1V73	;	1.82	;	Crystal Structure of Cold-Active Protein-Tyrosine Phosphatase of a Psychrophile Shewanella SP.
4HMC	;	2.1	;	Crystal structure of cold-adapted chitinase from Moritella marina
4HMD	;	2.26	;	Crystal structure of cold-adapted chitinase from Moritella marina with a reaction intermediate - oxazolinium ion (NGO)
4HME	;	2.07	;	Crystal structure of cold-adapted chitinase from Moritella marina with a reaction product - NAG2
6F9O	;	1.05	;	Crystal structure of cold-adapted haloalkane dehalogenase DpcA from Psychrobacter cryohalolentis K5
3CIA	;	2.7	;	Crystal structure of cold-aminopeptidase from Colwellia psychrerythraea
2AXC	;	1.7	;	Crystal structure of ColE7 translocation domain
5KJV	;	1.75	;	Crystal structure of Coleus blumei HCT
5KJW	;	1.9	;	Crystal structure of Coleus blumei HCT in complex with 3-hydroxyacetophenone
6MK2	;	3.35	;	Crystal structure of Coleus blumei rosmarinic acid synthase (RAS) in complex with 4-coumaroyl-(R)-3-(4-hydroxyphenyl)lactate
7MTL	;	2.446	;	Crystal structure of colibactin self-resistance protein ClbS in complex with a dsDNA
7MTT	;	1.85	;	Crystal structure of colibactin self-resistance protein ClbS in complex with two molecules of CHES
3EIP	;	1.8	;	CRYSTAL STRUCTURE OF COLICIN E3 IMMUNITY PROTEIN: AN INHIBITOR TO A RIBOSOME-INACTIVATING RNASE
1JCH	;	3.02	;	Crystal Structure of Colicin E3 in Complex with its Immunity Protein
2B5U	;	2.3	;	Crystal Structure Of Colicin E3 V206C Mutant In Complex With Its Immunity Protein
1EMV	;	1.7	;	CRYSTAL STRUCTURE OF COLICIN E9 DNASE DOMAIN WITH ITS COGNATE IMMUNITY PROTEIN IM9 (1.7 ANGSTROMS)
5EW5	;	3.2	;	Crystal Structure of Colicin E9 In Complex with Its Immunity Protein Im9
3DA3	;	2.5	;	Crystal Structure of Colicin M, A Novel Phosphatase Specifically Imported by Escherichia Coli
3DA4	;	1.7	;	Crystal Structure of Colicin M, a Novel Phosphatase Specifically Imported by Escherichia Coli
5NIR	;	1.74	;	Crystal structure of collagen 2A vWC domain
2F68	;	1.95	;	Crystal structure of collagen adhesin (CNA) from S. aureus
8GZO	;	1.23	;	Crystal structure of collagen heterotrimer with K, D, E, R residuesC
8H0E	;	1.76	;	Crystal structure of collagen heterotrimer with KD, ER and KE axial pairs
8H0F	;	1.87	;	Crystal structure of collagen heterotrimer with KD,ER and KE axial pairs
1T61	;	1.5	;	crystal structure of collagen IV NC1 domain from placenta basement membrane
4Z1R	;	1.27	;	Crystal structure of collagen-like peptide at 1.27 Angstrom resolution
3WN8	;	1.45	;	Crystal Structure of Collagen-Model Peptide, (POG)3-PRG-(POG)4
2Y50	;	2.8	;	Crystal Structure of Collagenase G from Clostridium histolyticum at 2. 80 Angstrom Resolution
2Y6I	;	3.25	;	Crystal Structure of Collagenase G from Clostridium histolyticum in complex with Isoamylphosphonyl-Gly-Pro-Ala at 3.25 Angstrom Resolution
456C	;	2.4	;	CRYSTAL STRUCTURE OF COLLAGENASE-3 (MMP-13) COMPLEXED TO A DIPHENYL-ETHER SULPHONE BASED HYDROXAMIC ACID
4MT7	;	3.5	;	Crystal structure of collybistin I
5I36	;	5.123	;	Crystal structure of color device state A
5I6Q	;	4.912	;	Crystal structure of color device state B
5I6T	;	5.283	;	Crystal structure of color device state C
3LVA	;	1.5	;	Crystal structure of colorless GFP-like protein from Aequorea coerulescens
4O1W	;	2.0	;	Crystal Structure of Colwellia psychrerythraea cytochrome c
5XGX	;	2.33	;	Crystal structure of colwellia psychrerythraea strain 34H isoaspartyl dipeptidase E80Q mutant complexed with beta-isoaspartyl lysine
4MQD	;	2.16	;	Crystal structure of ComJ, inhibitor of the DNA degrading activity of NucA, from Bacillus subtilis
8ESD	;	3.33	;	Crystal structure of COMMD7-COMMD9-COMMD5-COMMD10 tetramer
6BP6	;	2.17	;	Crystal structure of Commd9 COMM domain
2DUY	;	1.75	;	Crystal structure of competence protein ComEA-related protein from Thermus thermophilus HB8
6QVI	;	2.72	;	Crystal structure of competence-associated pilin ComZ from Thermus thermophilus
2XWJ	;	4.0	;	Crystal Structure of Complement C3b in Complex with Factor B
2XWB	;	3.49	;	Crystal Structure of Complement C3b in complex with Factors B and D
5JTW	;	3.5	;	Crystal structure of complement C4b re-refined using iMDFF
7OP0	;	2.57	;	Crystal structure of complement C5 in complex with chemically synthesized K92 knob domain.
5B71	;	2.11	;	Crystal structure of complement C5 in complex with SKY59
3RPX	;	2.65	;	Crystal structure of complement component 1, q subcomponent binding protein, C1QBP
2XWA	;	2.8	;	Crystal Structure of Complement Factor D Mutant R202A
4CBN	;	1.8	;	Crystal structure of Complement Factor D mutant R202A after conventional refinement
4CBO	;	1.8	;	Crystal structure of Complement Factor D mutant R202A after ensemble refinement
2XW9	;	1.2	;	Crystal Structure of Complement Factor D mutant S183A
4BG0	;	2.1	;	Crystal structure of complement factors H and FHL-1 binding protein BBH06 or CRASP-2 from Borrelia burgdorferi
4CBE	;	1.83	;	Crystal structure of complement factors H and FHL-1 binding protein BBH06 or CRASP-2 from Borrelia burgdorferi (Native)
2QOS	;	1.81	;	Crystal structure of complement protein C8 in complex with a peptide containing the C8 binding site on C8
5ZCJ	;	2.004	;	Crystal structure of complex
2DYA	;	1.77	;	Crystal structure of complex between Adenine nucleotide and nucleoside diphosphate kinase
3O4X	;	3.2	;	Crystal structure of complex between amino and carboxy terminal fragments of mDia1
1D9K	;	3.2	;	CRYSTAL STRUCTURE OF COMPLEX BETWEEN D10 TCR AND PMHC I-AK/CA
5GTC	;	2.7	;	Crystal structure of complex between DMAP-SH conjugated with a Kaposi's sarcoma herpesvirus LANA peptide (5-15) and nucleosome core particle
3A3P	;	1.9	;	Crystal structure of complex between E201A/SA-subtilisin and Tk-propeptide
3OUR	;	2.2	;	Crystal structure of complex between EIIA and a novel pyruvate decarboxylase
6ZH1	;	2.2	;	Crystal structure of complex between FH19-20 and FhbA protein from Borrelia hermsii
5N1T	;	2.6	;	Crystal structure of complex between flavocytochrome c and copper chaperone CopC from T. paradoxus
6SQC	;	2.28	;	Crystal structure of complex between nuclear coactivator binding domain of CBP and [1040-1086]ACTR containing alpha-methylated Leu1055 and Leu1076
1Z3G	;	3.3	;	Crystal structure of complex between Pvs25 and Fab fragment of malaria transmission blocking antibody 2A8
6OY4	;	2.45	;	Crystal structure of complex between recombinant Der p 2.0103 and Fab fragment of 7A1
3A3O	;	1.9	;	Crystal structure of complex between SA-subtilisin and Tk-propeptide with deletion of the five C-terminal residues
3A3N	;	2.2	;	Crystal structure of complex between SA-subtilisin and Tk-propeptide with deletion of the two C-terminal residues
2H5K	;	3.25	;	Crystal Structure of Complex Between the Domain-Swapped Dimeric Grb2 SH2 Domain and Shc-Derived Ligand, Ac-NH-pTyr-Val-Asn-NH2
2Z30	;	1.65	;	Crystal structure of complex form between mat-Tk-subtilisin and Tk-propeptide
3VV2	;	1.83	;	Crystal structure of complex form between S324A-subtilisin and mutant Tkpro
4QMC	;	1.09	;	Crystal structure of complex formed between phospholipase A2 and Biotin-sulfoxide at 1.09 A Resolution
3RWB	;	1.699	;	Crystal structure of complex of 4PAL (4-Pyridoxolactone) and PLDH (tetrameric pyridoxal 4-dehydrogenase) from Mesorhizobium loti
1ZSF	;	1.98	;	Crystal Structure of Complex of a Hydroxyethylamine Inhibitor with HIV-1 Protease at 2.0A Resolution
6DWH	;	2.0	;	Crystal structure of complex of BBKI and Bovine Trypsin
6DWU	;	3.96	;	Crystal structure of complex of BBKI and Bovine Trypsin
6DWF	;	1.94	;	Crystal structure of complex of BBKI mutant, L55R with Bovine Trypsin
3T0I	;	2.4	;	Crystal structure of complex of BT_2972 and AdoHcy, a methyltransferase from Bacteroides thetaiotaomicron
3SXJ	;	2.5	;	Crystal structure of complex of BT_2972 and AdoMet, a methyltransferase from Bacteroides thetaiotaomicron
7UT3	;	3.0	;	Crystal structure of complex of Fab, G10C with GalNAc-pNP
2GVZ	;	3.27	;	Crystal Structure of Complex of Gs- with The Catalytic Domains of Mammalian Adenylyl Cyclase: Complex with MANT-ATP and Mn
2RGU	;	2.6	;	Crystal structure of complex of human DPP4 and inhibitor
5EIV	;	2.414	;	Crystal structure of complex of osteoclast-associated immunoglobulin-like receptor (OSCAR) and a synthetic collagen consensus peptide
3FVI	;	2.7	;	Crystal Structure of Complex of Phospholipase A2 with Octyl Sulfates
3T7T	;	2.5	;	Crystal structure of complex of SAH and BVU_3255, a methyltransferase from Bacteroides vulgatus ATCC 8482
3T7S	;	2.2	;	Crystal structure of complex of SAM and BVU_3255, a methyltransferase from Bacteroides vulgatus ATCC 8482
3AB0	;	3.09	;	Crystal structure of complex of the Bacillus anthracis major spore surface protein BclA with ScFv antibody fragment
3M61	;	1.68	;	Crystal structure of complex of urokinase and a upain-1 variant(W3A) in pH4.6 condition
6XVD	;	1.4	;	Crystal structure of complex of urokinase and a upain-1 variant(W3F) in pH7.4 condition
4R4J	;	1.51	;	Crystal structure of complex sp_ASADH with 3-carboxypropyl-phthalic acid and Nicotinamide Adenine dinucleotide phosphate
1VBR	;	1.8	;	Crystal structure of complex xylanase 10B from Thermotoga maritima with xylobiose
3W5P	;	1.9	;	Crystal structure of complexes of vitamin D receptor ligand binding domain with lithocholic acid derivatives
3W5Q	;	1.9	;	Crystal structure of complexes of vitamin D receptor ligand binding domain with lithocholic acid derivatives
3W5R	;	2.2	;	Crystal structure of complexes of vitamin D receptor ligand binding domain with lithocholic acid derivatives
3W5T	;	2.29	;	Crystal structure of complexes of vitamin D receptor ligand binding domain with lithocholic acid derivatives
1JF3	;	1.4	;	Crystal Structure Of Component III Glycera Dibranchiata Monomeric Hemoglobin
1JF4	;	1.4	;	Crystal Structure Of Component IV Glycera Dibranchiata Monomeric Hemoglobin
8T4V	;	1.47	;	Crystal structure of compound 1 bound to K-Ras(G12D)
6HKM	;	2.47	;	Crystal structure of Compound 1 with ERK5
6YM3	;	2.05	;	Crystal structure of Compound 1 with PIP4K2A
6ARK	;	1.75	;	Crystal Structure of compound 10 covalently bound to K-Ras G12C
4YDG	;	3.25	;	Crystal structure of compound 10 in complex with HTLV-1 Protease
7Z76	;	1.32	;	Crystal structure of compound 10 in complex with the bromodomain of human SMARCA2 and pVHL:ElonginC:ElonginB
4QOC	;	1.7	;	crystal structure of compound 16 bound to MDM2(17-111), {(3R,5R,6S)-5-(3-CHLOROPHENYL)-6-(4-CHLOROPHENYL)-1-[(1S)-1-CYCLOPROPYL-2-(PYRROLIDIN-1-YLSULFONYL)ETHYL]-3-METHYL-2-OXOPIPERIDIN-3-YL}ACETIC ACID
6UYA	;	1.74	;	Crystal structure of Compound 19 bound to IRAK4
7ZY5	;	1.82	;	Crystal structure of compound 2 bound to CK2alpha
7ZY8	;	1.85	;	Crystal structure of compound 2 bound to CK2alpha
8QW6	;	2.2	;	Crystal Structure of compound 3 in complex with KRAS G12V C118S GDP and pVHL:ElonginC:ElonginB
8SKN	;	2.41	;	Crystal structure of compound 3-bound human Dynamin-1-like protein GTPase-BSE fusion
6HKN	;	2.33	;	Crystal structure of Compound 35 with ERK5
8QW7	;	2.36	;	Crystal Structure of compound 4 in complex with KRAS G12V C118S GDP and pVHL:ElonginC:ElonginB
7Z78	;	1.32	;	Crystal structure of compound 4 in complex with the bromodomain of human SMARCA2 and pVHL:ElonginC:ElonginB
4AU8	;	1.9	;	Crystal structure of compound 4a in complex with cdk5, showing an unusual binding mode to the hinge region via a water molecule
4IO9	;	3.2	;	Crystal structure of compound 4d bound to large ribosomal subunit (50S) from Deinococcus radiodurans
4IOA	;	3.2	;	Crystal structure of compound 4e bound to large ribosomal subunit (50S) from Deinococcus radiodurans
4IOC	;	3.6	;	Crystal structure of compound 4f bound to large ribosomal subunit (50S) from Deinococcus radiodurans
7E47	;	1.38	;	Crystal structure of compound 6 bound to MIF
7Z77	;	1.97	;	Crystal structure of compound 6 in complex with the bromodomain of human SMARCA2 and pVHL:ElonginC:ElonginB
7ZY0	;	1.44	;	Crystal structure of compound 7 bound to CK2alpha
7ZY2	;	1.51	;	Crystal structure of compound 7 bound to CK2alpha
7E45	;	1.433	;	Crystal structure of compound 7 bound to MIF
2YIY	;	2.49	;	Crystal structure of compound 8 bound to TAK1-TAB
4YDF	;	2.804	;	Crystal structure of compound 9 in complex with HTLV-1 Protease
6HHQ	;	3.1	;	Crystal structure of compound C45 bound to the yeast 80S ribosome
4R6J	;	2.9	;	Crystal structure of computaional designed Lucine rich repeats DLRR_H in space group P212121
4R58	;	2.4	;	Crystal structure of computational designed leucine rich repeats DLRR_A in space group P21
4R5C	;	1.93	;	Crystal structure of computational designed leucine rich repeats DLRR_E in space group of P212121
4R5D	;	2.53	;	Crystal structure of computational designed leucine rich repeats DLRR_G3 in space group F222
4R6G	;	2.8	;	Crystal structure of computational designed leucine rich repeats DLRR_K in space group P22121
4R6F	;	1.73	;	Crystal structure of computational designed protein DLRR_I
4D49	;	2.09	;	Crystal structure of computationally designed armadillo repeat proteins for modular peptide recognition.
4D4E	;	2.0	;	Crystal structure of computationally designed armadillo repeat proteins for modular peptide recognition.
6WRX	;	3.07	;	Crystal structure of computationally designed protein 2DS25.1 in complex with the human Transferrin receptor ectodomain
6WRW	;	2.84	;	Crystal structure of computationally designed protein 2DS25.5 in complex with the human Transferrin receptor ectodomain
6WRV	;	2.47	;	Crystal structure of computationally designed protein 3DS18 in complex with the human Transferrin receptor ectodomain
6NX2	;	2.3	;	Crystal structure of computationally designed protein AAA
4DAC	;	2.1	;	Crystal Structure of Computationally Designed Protein P6d
6NZ3	;	2.3	;	Crystal structure of computationally designed protein XAA_GGHN
6NXM	;	2.2	;	Crystal structure of computationally designed protein XAA_GVDQ
6NY8	;	2.3	;	Crystal structure of computationally designed protein XAA_GVDQ with calcium
6NYE	;	1.9	;	Crystal structure of computationally designed protein XAX
6NYK	;	2.8	;	Crystal structure of computationally designed protein XAX_GGDQ
6NYI	;	2.3	;	Crystal structure of computationally designed protein XXA
6NZ1	;	1.9	;	Crystal structure of computationally designed protein XXA_GVDQ
3U3B	;	1.854	;	Crystal Structure of Computationally Redesigned Four-Helix Bundle
3ZY7	;	1.09	;	Crystal structure of computationally redesigned gamma-adaptin appendage domain forming a symmetric homodimer
5JUB	;	2.57	;	Crystal structure of ComR from S.thermophilus in complex with DNA and its signalling peptide ComS.
5FD4	;	2.9	;	Crystal Structure of ComR from Streptococcus suis
5K0B	;	2.36	;	Crystal Structure of COMT in complex with 2,4-dimethyl-5-[3-(1-phenylethyl)-1H-pyrazol-5-yl]-1,3-thiazole
5K0C	;	1.95	;	Crystal Structure of COMT in complex with 2,4-dimethyl-5-[3-(2-phenylpropan-2-yl)-1H-pyrazol-5-yl]-1,3-thiazole
5K0E	;	2.3	;	Crystal Structure of COMT in complex with 2,4-dimethyl-5-[3-(2-phenylpropan-2-yl)-1H-pyrazol-5-yl]-1,3-thiazole
5K03	;	1.81	;	Crystal Structure of COMT in complex with 2,6-dimethyl-3-(1H-pyrazol-3-yl)imidazo[1,2-a]pyridine
5K01	;	1.383	;	Crystal Structure of COMT in complex with 2,7-dimethyl-3-(1H-pyrazol-3-yl)imidazo[1,2-a]pyridine
5LQN	;	1.72	;	Crystal Structure of COMT in complex with 2-[(3-chlorophenoxy)methyl]-4-methyl-5-(1H-pyrazol-5-yl)-1,3-thiazole
5LQJ	;	2.41	;	Crystal Structure of COMT in complex with 3-cyclopropyl-5-methyl-4-phenyl-1,2,4-triazole
5K05	;	2.14	;	Crystal Structure of COMT in complex with 4-methyl-2-(4-methylphenyl)-5-(1H-pyrazol-5-yl)-1,3-thiazole
5K0N	;	1.99	;	Crystal Structure of COMT in complex with 4-[5-[1-(4-methoxyphenyl)cyclopropyl]-1H-pyrazol-3-yl]-1,3-dimethylpyrazole
5K0G	;	1.89	;	Crystal Structure of COMT in complex with 4-[5-[1-(4-methoxyphenyl)ethyl]-1H-pyrazol-3-yl]-1,3-dimethylpyrazole
5K0J	;	1.94	;	Crystal Structure of COMT in complex with 5-[5-[1-(4-methoxyphenyl)cyclopropyl]-1H-pyrazol-3-yl]-2,4-dimethyl-1,3-thiazole
5K0L	;	2.02	;	Crystal Structure of COMT in complex with 5-[5-[1-(4-methoxyphenyl)cyclopropyl]-1H-pyrazol-3-yl]-2,4-dimethyl-1,3-thiazole
5K0F	;	1.81	;	Crystal Structure of COMT in complex with 5-[5-[1-(4-methoxyphenyl)ethyl]-1H-pyrazol-3-yl]-2,4-dimethyl-1,3-thiazole
5K09	;	2.7	;	Crystal Structure of COMT in complex with a thiazole ligand
5LQC	;	1.903	;	Crystal Structure of COMT in complex with N-[(E)-3-[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(methylamino)purin-9-yl]oxolan-2-yl]prop-2-enyl]-5-(4-fluorophenyl)-2,3-dihydroxybenzamide
5LQK	;	2.24	;	Crystal Structure of COMT in complex with N-[(E)-3-[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]prop-2-enyl]-2,3-dihydroxy-5-[(4-methylphenyl)methyl]benzamide
5LQR	;	1.5	;	Crystal Structure of COMT in complex with N-[(E)-3-[(2R,3S,4R,5R)-5-(6-ethylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]prop-2-enyl]-5-(4-fluorophenyl)-2,3-dihydroxybenzamide
5LQU	;	1.8	;	Crystal Structure of COMT in complex with N-[(E)-3-[(2R,3S,4R,5R)-5-[6-(ethylamino)purin-9-yl]-3,4-dihydroxyoxolan-2-yl]prop-2-enyl]-5-(4-fluorophenyl)-2,3-dihydroxybenzamide
5LR6	;	2.3	;	Crystal Structure of COMT in complex with [3-(2,4-dimethyl-1,3-thiazol-5-yl)-1H-pyrazol-5-yl]-(4-phenylpiperazin-1-yl)methanone
5P8W	;	2.03	;	Crystal Structure of COMT in complex with [5-(2,4-dimethyl-1,3-thiazol-5-yl)-1H-pyrazol-3-yl]methanamine
4U5G	;	2.1997	;	Crystal structure of con-ikot-ikot toxin
4U5H	;	1.58	;	crystal structure of con-ikot-ikot toxin
5Z5N	;	2.04	;	Crystal structure of ConA-R1M
5ZAC	;	2.59	;	Crystal structure of ConA-R2M
5Z5P	;	1.4	;	Crystal structure of ConA-R3M
5Z5Y	;	1.89	;	Crystal structure of ConA-R4M
5Z5L	;	2.3	;	Crystal structure of ConA-R5M
3QLQ	;	1.7	;	Crystal structure of Concanavalin A bound to an octa-alpha-mannosyl-octasilsesquioxane cluster
4PF5	;	2.04	;	Crystal structure of Concanavalin A complexed with a synthetic derivative of high-mannose chain
1CNV	;	1.65	;	CRYSTAL STRUCTURE OF CONCANAVALIN B AT 1.65 A RESOLUTION
4PPH	;	2.009	;	Crystal structure of conglutin gamma, a unique basic 7S globulin from lupine seeds
5B74	;	2.039	;	Crystal structure of conjoined Pyrococcus furiosus L-asparaginase with peptide
5CBP	;	2.358	;	Crystal Structure of Conjoint Pyrococcus furiosus L-asparaginase at 37 degree C
4RA9	;	2.049	;	Crystal Structure of Conjoint Pyrococcus Furiosus L-asparaginase with Citrate
2BJF	;	1.67	;	Crystal Structure of Conjugated Bile Acid Hydrolase from Clostridium perfringens in Complex with Reaction Products Taurine and Deoxycholate
2BJG	;	2.1	;	Crystal Structure of Conjugated Bile Acid Hydrolase from Clostridium perfringens in Complex with Reaction Products Taurine and Deoxycholate
3WG6	;	2.2	;	Crystal structure of conjugated polyketone reductase C1 from Candida parapsilosis complexed with NADPH
3VXG	;	1.7	;	Crystal structure of conjugated polyketone reductase C2 from Candida Parapsilosis
4H8N	;	1.8	;	Crystal structure of conjugated polyketone reductase C2 from candida parapsilosis complexed with NADPH
4DPN	;	2.55	;	Crystal Structure of ConM Complexed with Resveratrol
2CY6	;	2.0	;	Crystal structure of ConM in complex with trehalose and maltose
1F9P	;	1.93	;	CRYSTAL STRUCTURE OF CONNECTIVE TISSUE ACTIVATING PEPTIDE-III(CTAP-III) COMPLEXED WITH POLYVINYLSULFONIC ACID
5CDX	;	2.4	;	Crystal structure of conserpin
5CDZ	;	1.449	;	Crystal structure of conserpin in the latent state
5CE0	;	2.3	;	Crystal structure of conserpin with Z-mutation
3LKV	;	2.2	;	Crystal structure of conserved domain protein from vibrio cholerae o1 biovar eltor str. n16961
3CLW	;	2.199	;	Crystal structure of conserved exported protein from Bacteroides fragilis
3DME	;	1.7	;	Crystal structure of conserved exported protein from Bordetella pertussis. NorthEast Structural Genomics target BeR141
2FDR	;	2.0	;	Crystal Structure of Conserved Haloacid Dehalogenase-like Protein of Unknown Function ATU0790 from Agrobacterium tumefaciens str. C58
3IBS	;	2.1	;	Crystal structure of conserved hypothetical protein BatB from Bacteroides thetaiotaomicron
2P9M	;	2.59	;	Crystal structure of conserved hypothetical protein MJ0922 from Methanocaldococcus jannaschii DSM 2661
2CYJ	;	1.5	;	Crystal structure of conserved hypothetical protein PH1505 from Pyrococcus horikoshii OT3
1RFE	;	2.0	;	Crystal structure of conserved hypothetical protein Rv2991 from Mycobacterium tuberculosis
6IY0	;	2.5	;	Crystal structure of conserved hypothetical protein SAV0927 from Staphylococcus aureus subsp. aureus Mu50
1WWM	;	2.61	;	Crystal Structure of Conserved Hypothetical Protein TT2028 from an Extremely Thermophilic Bacterium Thermus thermophilus HB8
2DP9	;	1.9	;	Crystal Structure of Conserved Hypothetical Protein TTHA0113 from Thermus thermophilus HB8
2CWY	;	1.85	;	Crystal structure of conserved hypothetical protein, TTHA0068 from Thermus thermophilus HB8
2CXD	;	2.0	;	Crystal structure of conserved hypothetical protein, TTHA0068 from Thermus thermophilus HB8
2DX6	;	1.78	;	Crystal structure of conserved hypothetical protein, TTHA0132 from Thermus thermophilus HB8
3S93	;	2.28	;	Crystal structure of conserved motif in TDRD5
1NOG	;	1.55	;	Crystal Structure of Conserved Protein 0546 from Thermoplasma Acidophilum
3EWL	;	2.0	;	Crystal Structure of Conserved protein BF1870 of Unknown Function from Bacteroides fragilis
3MQZ	;	1.3	;	Crystal Structure of Conserved Protein DUF1054 from Pink Subaerial Biofilm Microbial Leptospirillum sp. Group II UBA.
7M5H	;	2.15	;	Crystal structure of conserved protein from Enterococcus faecalis V583
2PCS	;	2.4	;	Crystal structure of conserved protein from Geobacillus kaustophilus
2NRK	;	1.65	;	Crystal structure of conserved protein GrpB from Enterococcus faecalis
1YQE	;	1.83	;	Crystal Structure of Conserved Protein of Unknown Function AF0625
3D0J	;	1.53	;	Crystal structure of conserved protein of unknown function CA_C3497 from Clostridium acetobutylicum ATCC 824
3CP3	;	2.0	;	Crystal structure of conserved protein of unknown function DIP1874 from Corynebacterium diphtheriae
3NAT	;	2.925	;	Crystal Structure of Conserved Protein of Unknown Function EF_1977 from Enterococcus faecalis
2HQY	;	1.8	;	Crystal Structure of Conserved Protein of Unknown Function from Bacteroides thetaiotaomicron VPI-5482
2FB0	;	2.1	;	Crystal Structure of Conserved Protein of Unknown Function from Bacteroides thetaiotaomicron VPI-5482 at 2.10 A Resolution, Possible Oxidoreductase
2HV2	;	2.4	;	Crystal Structure of Conserved Protein of Unknown Function from Enterococcus faecalis V583 at 2.4 A Resolution, Probable N-Acyltransferase
2IDL	;	1.7	;	Crystal Structure of Conserved Protein of Unknown Function from Streptococcus pneumoniae
1T07	;	1.8	;	Crystal Structure of Conserved Protein of Unknown Function PA5148 from Pseudomonas aeruginosa
1TLJ	;	2.8	;	Crystal Structure of Conserved Protein of Unknown Function SSO0622 from Sulfolobus solfataricus
2ESH	;	2.3	;	Crystal Structure of Conserved Protein of Unknown Function TM0937- a Potential Transcriptional Factor
3RQB	;	2.8	;	Crystal Structure of Conserved Protein of Unknown Function with Hot dog Fold from Alicyclobacillus acidocaldarius
2CWQ	;	1.9	;	Crystal structure of conserved protein TTHA0727 from Thermus thermophilus HB8
2NRH	;	2.3	;	Crystal structure of conserved putative Baf family transcriptional activator from Campylobacter jejuni
3C2Q	;	2.0	;	Crystal structure of conserved putative LOR/SDH protein from Methanococcus maripaludis S2
1YHF	;	2.0	;	Crystal Structure of Conserved SPY1581 Protein of Unknown Function from Streptococcus pyogenes
3CK2	;	2.3	;	Crystal structure of conserved uncharacterized protein (predicted phosphoesterase COG0622) from Streptococcus pneumoniae TIGR4
3B5M	;	1.21	;	Crystal structure of conserved uncharacterized protein from Rhodopirellula baltica
2PHC	;	2.29	;	Crystal structure of conserved uncharacterized protein PH0987 from Pyrococcus horikoshii
3SJR	;	2.94	;	Crystal structure of conserved unkown function protein CV_1783 from Chromobacterium violaceum ATCC 12472
7SMU	;	1.95	;	Crystal Structure of Consomatin-Ro1 <structure_details=Consomatin-Ro1, a cone snail venom SSTL mimetic
1B3U	;	2.3	;	CRYSTAL STRUCTURE OF CONSTANT REGULATORY DOMAIN OF HUMAN PP2A, PR65ALPHA
1XNX	;	2.9	;	Crystal structure of constitutive androstane receptor
5DS3	;	2.6	;	Crystal structure of constitutively active PARP-1
5DSY	;	2.7	;	Crystal structure of constitutively active PARP-2
4L4U	;	2.2	;	Crystal structure of construct containing A. aeolicus NtrC1 receiver, central and DNA binding domains
3N7D	;	2.149	;	Crystal structure of CopK bound to Cu(I) and Cu(II)
3N7E	;	2.295	;	Crystal structure of CopK bound to Cu(II)
3WA3	;	1.55	;	Crystal structure of copper amine oxidase from arthrobacter globiformis in N2 condition
3X42	;	1.875	;	Crystal structure of copper amine oxidase from Arthrobacter globiformis in the presence of sodium bromide
1IVV	;	2.1	;	Crystal structure of copper amine oxidase from Arthrobacter globiformis: Early intermediate in topaquinone biogenesis
1IVX	;	2.2	;	Crystal structure of copper amine oxidase from Arthrobacter globiformis: Holo form generated by biogenesis in crystal.
1IVU	;	1.9	;	Crystal structure of copper amine oxidase from Arthrobacter globiformis: Initial intermediate in topaquinone biogenesis
1IVW	;	1.8	;	Crystal structure of copper amine oxidase from Arthrobacter globiformis: Late intermediate in topaquinone biogenesis
2ZL8	;	1.73	;	Crystal structure of copper amine oxidase from Arthrobacter globiformis: Substrate Schiff-base intermediate formed with ethylamine
4EV5	;	2.25	;	Crystal structure of copper amine oxidase-1 from Hansenula polymorpha in complex with benzylamine
4EV2	;	2.18	;	Crystal structure of copper amine oxidase-1 from Hansenula polymorpha in complex with ethylamine
5EOI	;	1.8	;	Crystal structure of copper bound human Carbonic anhydrase II
5I6K	;	1.07	;	Crystal Structure of Copper Nitrite Reductase at 100K after 0.69 MGy
5I6N	;	1.22	;	Crystal Structure of Copper Nitrite Reductase at 100K after 11.73 MGy
5I6L	;	1.08	;	Crystal Structure of Copper Nitrite Reductase at 100K after 2.76 MGy
5I6O	;	1.45	;	Crystal Structure of Copper Nitrite Reductase at 100K after 20.70 MGy
5I6P	;	1.56	;	Crystal Structure of Copper Nitrite Reductase at 100K after 27.60 MGy
5I6M	;	1.09	;	Crystal Structure of Copper Nitrite Reductase at 100K after 7.59 MGy
3WI9	;	1.3	;	Crystal structure of copper nitrite reductase from Geobacillus kaustophilus
1CB4	;	2.3	;	CRYSTAL STRUCTURE OF COPPER, ZINC SUPEROXIDE DISMUTASE
1LCF	;	2.0	;	CRYSTAL STRUCTURE OF COPPER-AND OXALATE-SUBSTITUTED HUMAN LACTOFERRIN AT 2.0 ANGSTROMS RESOLUTION
1ZMG	;	2.5	;	Crystal structure of copper-bound engineered maltose binding protein
5Z0M	;	1.7	;	Crystal structure of copper-bound H63F-mutated tyrosinase from Streptomyces castaneoglobisporus in complex with the caddie protein obtained by soaking in the hydroxylamine-containing solution for 12 h at 298 K
4LSY	;	1.895	;	Crystal structure of copper-bound L66S mutant toxin from Helicobacter pylori
8IUW	;	1.5	;	Crystal structure of Copper-bound N(omega)-hydroxy-L-arginine hydrolase with oxidized Cys86
8IUT	;	1.58	;	Crystal structure of Copper-bound N(omega)-hydroxy-L-arginine hydrolase with reduced Cys86
4NUN	;	2.2	;	Crystal structure of copper-bound Na-ASP-2
5Z0I	;	1.32	;	Crystal structure of copper-bound tyrosinase from Streptomyces castaneoglobisporus in complex with the caddie protein obtained by soaking in the hydroxylamine-containing solution for 1 h at 277 K
5Z0F	;	1.16	;	Crystal structure of copper-bound tyrosinase from Streptomyces castaneoglobisporus in complex with the caddie protein obtained by soaking in the hydroxylamine-containing solution for 10 min at 298 K
5Z0J	;	1.35	;	Crystal structure of copper-bound tyrosinase from Streptomyces castaneoglobisporus in complex with the caddie protein obtained by soaking in the hydroxylamine-containing solution for 2 h at 277 K
5Z0H	;	1.18	;	Crystal structure of copper-bound tyrosinase from Streptomyces castaneoglobisporus in complex with the caddie protein obtained by soaking in the hydroxylamine-containing solution for 2 h at 298 K
5Z0G	;	1.32	;	Crystal structure of copper-bound tyrosinase from Streptomyces castaneoglobisporus in complex with the caddie protein obtained by soaking in the hydroxylamine-containing solution for 20 min at 298 K
5Z0K	;	1.28	;	Crystal structure of copper-bound tyrosinase from Streptomyces castaneoglobisporus in complex with the caddie protein obtained by soaking in the hydroxylamine-containing solution for 4 h at 277 K
5Z0L	;	1.17	;	Crystal structure of copper-bound tyrosinase from Streptomyces castaneoglobisporus in complex with the caddie protein obtained by soaking in the hydroxylamine-containing solution for 9 h at 277 K
5Z0E	;	1.16	;	Crystal structure of copper-bound tyrosinase from Streptomyces castaneoglobisporus in complex with the Y98F mutant of the caddie protein obtained by soaking in the hydroxylamine-containing solution for 2 h at 298 K
1FEE	;	1.8	;	CRYSTAL STRUCTURE OF COPPER-HAH1
3NRQ	;	1.7	;	Crystal structure of copper-reconstituted FetP from uropathogenic Escherichia coli strain F11
1TXN	;	1.7	;	Crystal structure of coproporphyrinogen III oxidase
7UDP	;	2.01	;	Crystal structure of COQ8A-CA157 inhibitor complex in space group C2
7UDQ	;	1.9	;	Crystal structure of COQ8A-CA157 inhibitor complex in space group P1
1MOU	;	2.2	;	Crystal structure of Coral pigment
1MOV	;	2.4	;	Crystal structure of Coral protein mutant
4YUF	;	1.54	;	Crystal Structure of CorB
4YUC	;	1.31	;	Crystal Structure of CorB derivatized with S-(2-acetamidoethyl) 4-methyl-3-oxohexanethioate
4LAL	;	2.1	;	Crystal structure of Cordyceps militaris IDCase D323A mutant in complex with 5-carboxyl-uracil
4LAK	;	2.41	;	Crystal structure of Cordyceps militaris IDCase D323N mutant in apo form
4LAM	;	2.1	;	Crystal structure of Cordyceps militaris IDCase D323N mutant in complex with 5-carboxyl-uracil
4LAN	;	1.75	;	Crystal structure of Cordyceps militaris IDCase H195A mutant
4LAO	;	2.0	;	Crystal structure of Cordyceps militaris IDCase H195A mutant (Zn)
4HK5	;	1.9	;	Crystal structure of Cordyceps militaris IDCase in apo form
4HK6	;	2.3	;	Crystal structure of Cordyceps militaris IDCase in complex with 5-nitro-uracil
4HK7	;	2.189	;	Crystal structure of Cordyceps militaris IDCase in complex with uracil
4ZDS	;	1.78	;	Crystal Structure of core DNA binding domain of Arabidopsis Thaliana Transcription Factor Ethylene-Insensitive 3
6THE	;	2.87	;	Crystal structure of core domain of four-domain heme-cupredoxin-Cu nitrite reductase from Bradyrhizobium sp. ORS 375
2Q82	;	1.83	;	Crystal structure of core protein P7 from Pseudomonas phage phi12. Northeast Structural Genomics Target OC1
4BBO	;	1.6	;	Crystal structure of core-bradavidin
7BOO	;	1.95	;	Crystal Structure of Core-mannan synthase A (CmsA/Ktr4) from Aspergillus fumigatus, apo form
7BOP	;	1.9	;	Crystal Structure of Core-mannan synthase A (CmsA/Ktr4) from Aspergillus fumigatus, Mn/GDP-form
4ZIG	;	2.2	;	Crystal Structure of core/latch dimer of Bax in complex with BidBH3mini
4ZIE	;	1.797	;	Crystal Structure of core/latch dimer of Bax in complex with BimBH3
4ZIF	;	2.401	;	Crystal Structure of core/latch dimer of Bax in complex with BimBH3mini
4ZIH	;	2.5	;	Crystal Structure of core/latch dimer of Bax in complex with BimBH3mini
4ZII	;	2.191	;	Crystal Structure of core/latch dimer of BaxI66A in complex with BidBH3
3WR1	;	3.5	;	Crystal structure of Cormorant (Phalacrocorax carbo) hemoglobin
7A9I	;	2.1	;	Crystal structure of Coronafacic Acid Ligase from Pectobacterium brasiliense
6ITQ	;	1.526	;	Crystal structure of cortisol complexed with its nanobody at pH 10.5
6ITP	;	1.572	;	Crystal structure of cortisol complexed with its nanobody at pH 3.5
4P6X	;	2.5	;	Crystal Structure of cortisol-bound glucocorticoid receptor ligand binding domain
6JOO	;	2.9	;	Crystal structure of Corynebacterium diphtheriae Cas9 in complex with sgRNA and target DNA
6D2E	;	2.05	;	Crystal structure of Corynebacterium diphtheriae UDP-galactopyranose mutase in complex with UDP-galactopyranose (open, oxidized)
6D2G	;	2.5	;	Crystal structure of Corynebacterium diphtheriae UDP-galactopyranose mutase in complex with UDP-galactopyranose (open, reduced)
6D99	;	2.15	;	Crystal structure of Corynebacterium diphtheriae UDP-galactopyranose mutase in complex with UDP-GalNAc (open, oxidized)
6D9A	;	2.9	;	Crystal structure of Corynebacterium diphtheriae UDP-galactopyranose mutase in complex with UDP-GalNAc (open, reduced)
6D9D	;	2.2	;	Crystal structure of Corynebacterium diphtheriae UDP-galactopyranose mutase in complex with UDP-GlcNAc (open, oxidized)
6D9E	;	2.85	;	Crystal structure of Corynebacterium diphtheriae UDP-galactopyranose mutase in complex with UDP-GlcNAc (open, reduced)
6D9B	;	2.2	;	Crystal structure of Corynebacterium diphtheriae UDP-galactopyranose mutase in complex with UDP-glucose (open, oxidized)
6D9C	;	3.05	;	Crystal structure of Corynebacterium diphtheriae UDP-galactopyranose mutase in complex with UDP-glucose (open, reduced)
8PR6	;	1.7	;	Crystal structure of Corynebacterium glutamicum mycoredoxin-3 at 1.7 A resolution.
3OKC	;	2.4	;	Crystal structure of Corynebacterium glutamicum PimB' bound to GDP (orthorhombic crystal form)
3OKP	;	2.0	;	Crystal structure of Corynebacterium glutamicum PimB' bound to GDP-Man (orthorhombic crystal form)
3OKA	;	2.2	;	Crystal structure of Corynebacterium glutamicum PimB' in complex with GDP-Man (triclinic crystal form)
4Y83	;	2.89	;	Crystal structure of COT kinase domain in complex with 5-(2-amino-5-(quinolin-3-yl)pyridin-3-yl)-1,3,4-oxadiazole-2(3H)-thione
4Y85	;	2.33	;	Crystal structure of COT kinase domain in complex with 5-(5-(1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3,4-oxadiazol-2-amine
4YVN	;	2.3	;	Crystal structure of CotA laccase complexed with ABTS at a novel binding site
7Y8C	;	2.0	;	Crystal structure of CotA laccase complexed with syringaldehyde
7Y8B	;	2.0	;	Crystal structure of CotA laccase complexed with syringic acid
4YVU	;	2.3	;	Crystal structure of CotA native enzyme in the acid condition, PH5.6
5ZLJ	;	1.96	;	Crystal structure of CotA native enzyme, PH8.0
1GSK	;	1.7	;	Crystal structure of CotA, an endospore coat protein from Bacillus subtilis
5GUC	;	1.8	;	Crystal structure of CotB2 (apo form) from Streptomyces melanosporofaciens
5GUE	;	1.8	;	Crystal structure of CotB2 (GGSPP/Mg2+-Bound Form) from Streptomyces melanosporofaciens
6GGK	;	2.15	;	Crystal structure of CotB2 C-terminal truncation
6GGI	;	1.803	;	Crystal structure of CotB2 in complex with 2-fluoro-3,7,18-dolabellatriene
6GGJ	;	2.1	;	Crystal structure of CotB2 in complex with alendronate
6GGL	;	1.9	;	Crystal structure of CotB2 variant F107A
7AO0	;	1.93	;	Crystal structure of CotB2 variant F107A in complex with alendronate
7AO3	;	1.45	;	Crystal structure of CotB2 variant F149L in complex with alendronate
7AO5	;	2.06	;	Crystal structure of CotB2 variant W288F
7AO1	;	1.8	;	Crystal structure of CotB2 variant W288F in complex with alendronate
7AO4	;	2.2	;	Crystal structure of CotB2 variant W288G
7AO2	;	1.75	;	Crystal structure of CotB2 variant W288G in complex with alendronate
7XC8	;	2.55	;	Crystal structure of cotton alpha-like expansin GhEXLA1
5M58	;	2.05	;	Crystal structure of CouO, a C-methyltransferase from Streptomyces rishiriensis
5CYV	;	1.52	;	Crystal structure of CouR from Rhodococcus jostii RHA1 bound to p-coumaroyl-CoA
7KG3	;	1.45	;	Crystal structure of CoV-2 Nsp3 Macrodomain
7LG7	;	2.3	;	Crystal structure of CoV-2 Nsp3 Macrodomain complex with PARG345
3PX7	;	2.3	;	Crystal Structure of covalent complex of topoisomerase 1A with substrate
3HJ2	;	1.4	;	Crystal structure of covalent dimer of HNP1
2D22	;	1.7	;	Crystal structure of covalent glycosyl-enzyme intermediate of catalytic-site mutant xylanase from Streptomyces olivaceoviridis E-86
5GQD	;	1.8	;	Crystal structure of covalent glycosyl-enzyme intermediate of xylanase mutant (T82A, N127S, and E128H) from Streptomyces olivaceoviridis E-86
8EDE	;	1.799	;	Crystal structure of covalent inhibitor 2-chloro-N'-(N-(4-chlorophenyl)-N-methylglycyl)acetohydrazide bound to Ubiquitin C-terminal Hydrolase-L1
7EHI	;	1.69	;	Crystal structure of covalent maltosyl-alpha-glucosidase intermediate
3I3T	;	2.59	;	Crystal structure of covalent ubiquitin-USP21 complex
2GDG	;	1.45	;	Crystal structure of covalently modified macrophage inhibitory factor
7CM4	;	2.71	;	Crystal Structure of COVID-19 virus spike receptor-binding domain complexed with a neutralizing antibody CT-P59
4PDC	;	1.991	;	Crystal structure of Cowpox virus CPXV018 (OMCP) bound to human NKG2D
3NTG	;	2.19	;	Crystal structure of COX-2 with selective compound 23d-(R)
8CIL	;	1.98	;	Crystal structure of Coxiella burnetii Fic protein 2
4Y2A	;	2.9	;	Crystal Structure of Coxsackie Virus B3 3D polymerase in complex with GPC-N114 inhibitor
5C4W	;	2.65	;	Crystal structure of coxsackievirus A16
4Q4V	;	2.9	;	Crystal structure of Coxsackievirus A24v
4Q4X	;	1.65	;	Crystal structure of Coxsackievirus A24v soaked with 6'-Sialyllactose (6SL)
4Q4Y	;	1.88	;	Crystal structure of Coxsackievirus A24v soaked with Disialyllacto-N-tetraose (DSLNT)
8SP9	;	2.92	;	Crystal Structure of Coxsackievirus B3 (CVB3) Cloverleaf RNA with tRNA scaffold
4Y34	;	2.7	;	Crystal Structure of Coxsackievirus B3 3D polymerase in complex with GPC-N143
8DP3	;	1.91	;	Crystal structure of coxsackievirus B3 cloverleaf RNA replication element
2VB0	;	2.4	;	Crystal structure of coxsackievirus B3 proteinase 3C
3CDU	;	2.1	;	Crystal structure of coxsackievirus B3 RNA-dependent RNA polymerase (3Dpol) in complex with a pyrophosphate
3CDW	;	2.5	;	Crystal structure of coxsackievirus B3 RNA-dependent RNA polymerase (3Dpol) in complex with protein primer VPg and a pyrophosphate
5GLM	;	1.8	;	Crystal structure of CoXyl43, GH43 beta-xylosidase/alpha-arabinofuranosidase from a compost microbial metagenome in complex with xylotriose, calcium-free form.
5GLK	;	1.7	;	Crystal structure of CoXyl43, GH43 beta-xylosidase/alpha-arabinofuranosidase from a compost microbial metagenome, calcium-free form.
5GLR	;	1.7	;	Crystal structure of CoXyl43, GH43 beta-xylosidase/alpha-arabinofuranosidase from a compostmicrobial metagenome in complex with l-arabinose and xylotriose, calcium-bound form
5GLQ	;	1.7	;	Crystal structure of CoXyl43, GH43 beta-xylosidase/alpha-arabinofuranosidase from a compostmicrobial metagenome in complex with l-arabinose and xylotriose, calcium-free form
5GLP	;	1.8	;	Crystal structure of CoXyl43, GH43 beta-xylosidase/alpha-arabinofuranosidase from a compostmicrobial metagenome in complex with l-arabinose, calcium-bound form
5GLO	;	1.8	;	Crystal structure of CoXyl43, GH43 beta-xylosidase/alpha-arabinofuranosidase from a compostmicrobial metagenome in complex with l-arabinose, calcium-free form
5GLN	;	1.7	;	Crystal structure of CoXyl43, GH43 beta-xylosidase/alpha-arabinofuranosidase from a compostmicrobial metagenome in complex with xylotriose, calcium-bound form
5GLL	;	1.8	;	Crystal structure of CoXyl43, GH43 beta-xylosidase/alpha-arabinofuranosidase from a compostmicrobial metagenome, calcium-bound form
1SMM	;	1.36	;	Crystal Structure of Cp Rd L41A mutant in oxidized state
1SMU	;	1.43	;	Crystal Structure of Cp Rd L41A mutant in reduced state 1 (drop-reduced)
1SMW	;	1.38	;	Crystal Structure of Cp Rd L41A mutant in reduced state 2 (soaked)
1UHH	;	1.8	;	Crystal structure of cp-aequorin
3R7F	;	2.101	;	Crystal Structure of CP-bound Aspartate Transcarbamoylase from Bacillus subtilis
7Y8D	;	2.0	;	Crystal structure of cp1 bound BCLxl
1IY7	;	2.0	;	Crystal Structure of CPA and sulfamide-based inhibitor complex
3DPN	;	3.3	;	Crystal Structure of cpaf s499a mutant
3DJA	;	2.9	;	Crystal Structure of cpaf solved with MAD
5EIB	;	2.1	;	Crystal structure of CPAP PN2-3 C-terminal loop-helix in complex with DARPin-tubulin
4LDF	;	2.0	;	Crystal Structure of CpBRD2 from cryptosporidium, cgd3_3190
4IN4	;	2.59	;	Crystal structure of cpd 15 bound to Keap1 Kelch domain
4IQK	;	1.97	;	Crystal structure of cpd 16 bound to Keap1 Kelch domain
3O6U	;	2.5	;	Crystal Structure of CPE2226 protein from Clostridium perfringens. Northeast Structural Genomics Consortium Target CpR195
5DIF	;	2.092	;	Crystal Structure of CPEB4 NES Peptide in complex with CRM1-Ran-RanBP1
5DHA	;	2.95	;	Crystal Structure of CPEB4 NES Reverse Mutant Peptide in complex with CRM1-Ran-RanBP1
8I80	;	2.3	;	Crystal structure of Cph001-D189N
8I85	;	2.17	;	Crystal structure of Cph001-D189N in complex with ATP
8I82	;	1.95	;	Crystal structure of Cph001-D189N in complex with CMN IIA
8I8G	;	3.0	;	Crystal structure of Cph001-D189N in complex with CMN IIA and ATP
8I84	;	2.2	;	Crystal structure of Cph001-D189N in complex with CMN IIB
8I86	;	2.23	;	Crystal structure of Cph001-D189N in complex with GTP
8I89	;	2.0	;	Crystal structure of Cph001-D189N in complex with VIO
8I8H	;	2.02	;	Crystal structure of Cph001-D189N in complex with VIO and ATP
3IOF	;	1.44	;	Crystal structure of CphA N220G mutant with inhibitor 10a
3IOG	;	1.41	;	Crystal structure of CphA N220G mutant with inhibitor 18
6I3B	;	1.0	;	Crystal structure of cPizza6-AYW, a circularly permuted designer protein
7Y0K	;	3.03	;	Crystal structure of CpKR in complex with NADPH complex from Candida parapsilosis
7VFC	;	1.21	;	Crystal structure of cPMO2
3RUS	;	2.338	;	Crystal structure of Cpn-rls in complex with ADP from Methanococcus maripaludis
3RUW	;	2.702	;	Crystal structure of Cpn-rls in complex with ADP-AlFx from Methanococcus maripaludis
3RUV	;	2.242	;	Crystal structure of Cpn-rls in complex with ATP analogue from Methanococcus maripaludis
3RUQ	;	2.798	;	Crystal structure of Cpn-WT in complex with ADP from Methanococcus maripaludis
3Q9D	;	2.0	;	Crystal Structure of Cpn0803 from C. pneumoniae.
3RTK	;	2.8	;	Crystal structure of Cpn60.2 from Mycobacterium tuberculosis at 2.8A
4QOB	;	2.7	;	Crystal structure of cPOP1
3E0R	;	2.3	;	Crystal structure of cppA protein from Streptococcus pneumoniae TIGR4
3E6D	;	2.0	;	Crystal Structure of CprK C200S
4LDG	;	2.31	;	Crystal Structure of CpSET8 from Cryptosporidium, cgd4_370
5E4X	;	2.75	;	Crystal structure of cpSRP43 chromodomain 3
5E4W	;	2.8	;	Crystal structure of cpSRP43 chromodomains 2 and 3 in complex with the Alb3 tail
5J9L	;	2.7515	;	Crystal structure of CPT1691 bound to TAK1-TAB1
5LFK	;	3.094	;	Crystal structure of CpxAHDC (hemiphosphorylated form)
4BIW	;	2.85	;	Crystal structure of CpxAHDC (hexagonal form)
4BIX	;	2.0	;	Crystal structure of CpxAHDC (monoclinic form 1)
4BIY	;	3.3	;	Crystal structure of CpxAHDC (monoclinic form 2)
4BIU	;	3.65	;	Crystal structure of CpxAHDC (orthorhombic form 1)
4BIZ	;	2.65	;	Crystal structure of CpxAHDC (orthorhombic form 2)
4BIV	;	3.4	;	Crystal structure of CpxAHDC (trigonal form)
4CB0	;	3.3	;	Crystal structure of CpxAHDC in complex with ATP (hexagonal form)
6IPV	;	2.2	;	Crystal structure of CqsB2 from Streptomyces exfoliatus 2419-SVT2 (apo form)
6IPW	;	2.1	;	Crystal structure of CqsB2 from Streptomyces exfoliatus in complex with the product, 1-(2-hydroxypropyl)-2-methyl-carbazole-3,4-dione
3O74	;	2.0	;	Crystal structure of Cra transcriptional dual regulator from Pseudomonas putida
3O75	;	2.3	;	Crystal structure of Cra transcriptional dual regulator from Pseudomonas putida in complex with fructose 1-phosphate'
3HY5	;	3.04	;	Crystal structure of CRALBP
3HX3	;	1.69	;	Crystal structure of CRALBP mutant R234W
4IHZ	;	1.5	;	Crystal structure of CrataBL, a trypsin inhibitor from Crataeva tapia
4II0	;	1.75	;	Crystal structure of CrataBL, a trypsin inhibitor from Crataeva tapia
2FHD	;	2.4	;	Crystal structure of Crb2 tandem tudor domains
1MA7	;	2.3	;	Crystal structure of Cre site-specific recombinase complexed with a mutant DNA substrate, LoxP-A8/T27
1I0E	;	3.5	;	CRYSTAL STRUCTURE OF CREATINE KINASE FROM HUMAN MUSCLE
1RL9	;	1.45	;	Crystal structure of Creatine-ADP arginine kinase ternary complex
1Q3K	;	2.1	;	Crystal structure of creatinine amidohydrolase (creatininase)
6FQU	;	1.43	;	Crystal structure of CREBBP bromodomain complexd with DR09
6FQT	;	1.8	;	Crystal structure of CREBBP bromodomain complexd with DR46
6FQO	;	1.35	;	Crystal structure of CREBBP bromodomain complexd with DT29
6FRF	;	2.1	;	Crystal structure of CREBBP bromodomain complexd with PA10
6FR0	;	1.5	;	Crystal structure of CREBBP bromodomain complexd with PB08
5NLK	;	1.8	;	Crystal structure of CREBBP bromodomain complexd with US13A
5MME	;	1.35	;	Crystal structure of CREBBP bromodomain complexd with US46C
5MQE	;	1.65	;	Crystal structure of CREBBP bromodomain complexed with CBP006
5MPZ	;	1.4	;	Crystal structure of CREBBP bromodomain complexed with CBP007
5MQG	;	1.35	;	Crystal structure of CREBBP bromodomain complexed with CBP015
5MQK	;	1.53	;	Crystal structure of CREBBP bromodomain complexed with CBP019
5MPK	;	1.9	;	Crystal structure of CREBBP bromodomain complexed with DK19
5OWK	;	1.25	;	Crystal structure of CREBBP bromodomain complexed with DSPB2A002
5MPN	;	1.23	;	Crystal structure of CREBBP bromodomain complexed with FA26
6SQE	;	1.506	;	Crystal structure of CREBBP bromodomain complexed with KD341
6SQM	;	1.8	;	Crystal structure of CREBBP bromodomain complexed with LA36
6SQF	;	2.006	;	Crystal structure of CREBBP bromodomain complexed with LB32A
5MMG	;	1.23	;	Crystal structure of CREBBP bromodomain complexed with UT07C
6SW3	;	1.2	;	Crystal structure of CREBBP bromodomain L1109W mutant
8OG2	;	2.47	;	Crystal structure of CREBBP histone acetyltransferase domain in complex with Coenzyme A
8CNA	;	2.463	;	Crystal structure of CREBBP-R1446C histone acetyltransferase domain in complex with a bisubstrate inhibitor, Lys-CoA
8CMZ	;	2.252	;	Crystal structure of CREBBP-R1446C histone acetyltransferase domain in complex with Coenzyme A
8CND	;	2.972	;	Crystal structure of CREBBP-Y1482N histone acetyltransferase domain in complex with a bisubstrate inhibitor, Lys-CoA
8CN0	;	2.44	;	Crystal structure of CREBBP-Y1482N histone acetyltransferase domain in complex with Coenzyme A
8CNB	;	1.986	;	Crystal structure of CREBBP-Y1503C histone acetyltransferase domain in complex with Coenzyme A
5XNY	;	2.18	;	Crystal structure of CreD
5XNZ	;	2.3	;	Crystal structure of CreD complex with fumarate
5K07	;	2.0	;	Crystal structure of CREN7-DSDNA (GTAATTGC) complex
5K17	;	2.1	;	Crystal structure of CREN7-DSDNA (GTGATCGC) complex
3LWH	;	1.9	;	Crystal structure of Cren7-dsDNA complex
3LWI	;	2.3	;	Crystal structure of Cren7-dsDNA complex
5VZX	;	2.501	;	Crystal structure of crenezumab Fab
5VZY	;	2.32	;	Crystal structure of crenezumab Fab in complex with Abeta
3S5U	;	2.7	;	Crystal structure of CRISPR associated protein
4Z7K	;	3.0	;	Crystal structure of CRISPR RNA processing endoribonuclease Cas6b
7F84	;	2.6	;	Crystal structure of CRISPR-associated Cas2c of Leptospira interrogans
3VZH	;	1.7	;	Crystal Structure of CRISPR-associated Protein
3VZI	;	2.66	;	Crystal Structure of CRISPR-associated Protein
4F3M	;	1.71	;	Crystal structure of CRISPR-associated protein
4Q2C	;	2.5	;	Crystal structure of CRISPR-associated protein
4ZKJ	;	2.25	;	Crystal structure of CRISPR-associated protein
4H3T	;	2.03	;	Crystal structure of CRISPR-associated protein Cse1 from Acidimicrobium ferrooxidans
4Q2D	;	2.771	;	Crystal Structure of CRISPR-Associated protein in complex with 2'-Deoxyadenosine 5'-Triphosphate
6WXQ	;	2.05	;	Crystal structure of CRISPR-associated transcription factor Csa3 complexed with cA4
4HAV	;	2.0	;	Crystal structure of CRM1 inhibitor Anguinomycin A in complex with CRM1-Ran-RanBP1
4HB4	;	2.05	;	Crystal structure of CRM1 inhibitor Leptomycin B in complex with CRM1(537DLTVK541/GLCEQ)-Ran-RanBP1
4HB0	;	2.2	;	Crystal structure of CRM1 inhibitor Leptomycin B in complex with CRM1(K541Q,K542Q,R543S,K545Q,K548Q,K579Q)-Ran-RanBP1
4HAW	;	1.9	;	Crystal structure of CRM1 inhibitor Leptomycin B in complex with CRM1(K548A)-Ran-RanBP1
4HAY	;	2.3	;	Crystal structure of CRM1 inhibitor Leptomycin B in complex with CRM1(K548E,K579Q)-Ran-RanBP1
4HAZ	;	1.9	;	Crystal structure of CRM1 inhibitor Leptomycin B in complex with CRM1(R543S,K548E,K579Q)-Ran-RanBP1
4HAT	;	1.78	;	Crystal structure of CRM1 inhibitor Leptomycin B in complex with CRM1-Ran-RanBP1
4HAX	;	2.28	;	Crystal structure of CRM1 inhibitor Ratjadone A in complex with CRM1(K579A)-Ran-RanBP1
4HAU	;	2.0	;	Crystal structure of CRM1 inhibitor Ratjadone A in complex with CRM1-Ran-RanBP1
4HB3	;	2.8	;	Crystal structure of CRM1(T539S)-Ran-RanBP1 with weakly bound unmodeled Leptomycin B
4HB2	;	1.8	;	Crystal structure of CRM1-Ran-RanBP1
3GB8	;	2.9	;	Crystal structure of CRM1/Snurportin-1 complex
7C23	;	1.9	;	Crystal structure of CrmE10, a SGNH-hydrolase family esterase
5I1V	;	1.84	;	Crystal structure of CrmK, a flavoenzyme involved in the shunt product recycling mechanism in caerulomycin biosynthesis
5I1W	;	2.15	;	Crystal structure of CrmK, a flavoenzyme involved in the shunt product recycling mechanism in caerulomycin biosynthesis
5DK5	;	2.1	;	Crystal structure of CRN-4-MES complex
1D1M	;	2.05	;	CRYSTAL STRUCTURE OF CRO K56-[DGEVK]-F58W MUTANT
1D1L	;	2.1	;	CRYSTAL STRUCTURE OF CRO-F58W MUTANT
7T9Q	;	1.8	;	Crystal structure of Crocodile defensin CpoBD13
7T9R	;	1.45	;	Crystal structure of Crocodile defensin CpoBD13:phosphatidic acid complex
3QC9	;	2.7	;	Crystal structure of cross-linked bovine GRK1 T8C/N480C double mutant complexed with ADP and Mg
4J7V	;	1.54	;	Crystal structure of cross-linked hen egg white lysozyme soaked with 5mM [Ru(benzene)Cl2]2
4XU6	;	1.898	;	Crystal structure of cross-linked MvINS R77C trimer at 1.9A resolution
3W6A	;	1.77	;	Crystal structure of cross-linked tetragonal hen egg white lysozyme soaked wiht 5mM [Ru(benzene)Cl2]2
5YKY	;	1.88	;	Crystal Structure of Cross-Linked Tetragonal Hen Egg White Lysozyme Soaked with 10 mM Rose Bengal and 10mM H2PtCl6
4W94	;	1.55	;	Crystal structure of cross-linked tetragonal hen egg white lysozyme soaked with 5mM [Ru(CO)3Cl2]2
4W96	;	1.5	;	Crystal structure of cross-linked tetragonal hen egg white lysozyme soaked with 5mM [Ru(CO)3Cl2]2 followed by the reaction in deoxy-myoglobin solution
4WZI	;	2.58	;	Crystal structure of crosslink stabilized long-form PDE4B
4X0F	;	3.22	;	Crystal structure of crosslink stabilized long-form PDE4B in complex with (R)-(-)-rolipram
1FZB	;	2.9	;	CRYSTAL STRUCTURE OF CROSSLINKED FRAGMENT D
3V8F	;	3.8	;	Crystal structure of crosslinked GltPh V216C-M385C mutant
3EUX	;	1.65	;	Crystal Structure of Crosslinked Ribonuclease A
5Z7R	;	2.2	;	Crystal structure of crotonase from Clostridium acetobutylicum
3R0L	;	1.35	;	Crystal structure of crotoxin
3H3U	;	2.9	;	Crystal structure of CRP (cAMP receptor Protein) from Mycobacterium tuberculosis
7ETS	;	2.22	;	Crystal structure of crp protein from Gardnerella Vaginalis
6SXL	;	2.5	;	Crystal structure of CrtE
4L35	;	2.1	;	Crystal structure of cruxrhodopsin-3 at pH5 from Haloarcula vallismortis at 2.1 angstrom resolution
4JR8	;	2.3	;	Crystal structure of cruxrhodopsin-3 from Haloarcula vallismortis at 2.3 angstrom resolution
1U9Q	;	2.3	;	Crystal structure of cruzain bound to an alpha-ketoester
1EWL	;	2.0	;	CRYSTAL STRUCTURE OF CRUZAIN BOUND TO WRR-99
3I06	;	1.1	;	Crystal structure of cruzain covalently bound to a purine nitrile
4KLB	;	2.62	;	Crystal Structure of Cruzain in complex with the non-covalent inhibitor Nequimed176
7S18	;	2.14	;	Crystal structure of cruzain with gallinamide analog from 2-biaryl series
7S19	;	2.08	;	Crystal structure of cruzain with gallinamide analog from 2-indolyl series
4QH6	;	3.13	;	Crystal structure of cruzain with nitrile inhibitor N-(2-AMINOETHYL)-NALPHA-BENZOYL-L-PHENYLALANINAMIDE
4RHZ	;	2.35	;	Crystal structure of Cry23Aa1 and Cry37Aa1 binary protein complex
4JOX	;	2.15	;	Crystal structure of cry34Ab1 protein at 2.15 A resolution
4JP0	;	1.8	;	Crystal structure of Cry35Ab1
4MOA	;	2.0	;	Crystal structure of CRY4BA-R203Q TOXIN
8HHE	;	4.5	;	Crystal structure of Cry5B from Bacillus thuringiensis at 4.5 A resolution
7Y78	;	2.9	;	Crystal structure of Cry78Aa
7Y79	;	2.32	;	Crystal structure of Cry78Aa
7AJK	;	3.1	;	Crystal structure of CRYI-B Rac1 complex
2IJG	;	2.1	;	Crystal Structure of cryptochrome 3 from Arabidopsis thaliana
4AF0	;	2.2	;	Crystal structure of cryptococcal inosine monophosphate dehydrogenase
6TZ8	;	3.3	;	Crystal structure of Cryptococcus neoformans Calceineurin A, Calcineurin B, and FKBP12 with FK-506
5U29	;	2.5	;	Crystal structure of Cryptococcus neoformans H99 Acetyl-CoA Synthetase in complex with Ac-AMS
7LPP	;	2.85	;	Crystal structure of Cryptococcus neoformans sterylglucosidase 1 with hit 1
7LPQ	;	2.32	;	Crystal structure of Cryptococcus neoformans sterylglucosidase 1 with hit 9
7LPO	;	2.13	;	Crystal structure of Cryptococcus neoformans sterylglucosidase 1 with tris
4U55	;	3.2	;	Crystal structure of Cryptopleurine bound to the yeast 80S ribosome
6Q55	;	2.0	;	Crystal structure of Cryptosporidium hominis CPSF3 in complex with Compound 61
6Q5A	;	1.55	;	Crystal structure of Cryptosporidium hominis CPSF3 in the apo form
7ZOG	;	1.8	;	Crystal structure of Cryptosporidium parvum -Plasmodium falciparum mutant lysyl tRNA synthetase in complex with inhibitor
2NPM	;	2.52	;	crystal structure of Cryptosporidium parvum 14-3-3 protein in complex with peptide
3BE4	;	1.6	;	Crystal structure of Cryptosporidium parvum adenylate kinase cgd5_3360
6CW0	;	1.38	;	Crystal structure of Cryptosporidium parvum bromodomain cgd2_2690
3F3Z	;	1.84	;	Crystal structure of Cryptosporidium parvum calcium dependent protein kinase cgd7_1840 in presence of indirubin E804
3IGO	;	2.25	;	Crystal structure of Cryptosporidium parvum CDPK1, cgd3_920
2POE	;	2.01	;	Crystal structure of Cryptosporidium parvum cyclophilin type peptidyl-prolyl cis-trans isomerase cgd2_1660
2QER	;	2.17	;	Crystal structure of Cryptosporidium parvum cyclophilin type peptidyl-prolyl cis-trans isomerase cgd2_1660 in the presence of dipeptide ala-pro
2PLU	;	1.82	;	Crystal structure of Cryptosporidium parvum cyclophilin type peptidyl-prolyl cis-trans isomerase cgd2_4120
3CPS	;	1.9	;	Crystal structure of Cryptosporidium parvum glyceraldehyde-3-phosphate dehydrogenase
2HJR	;	2.2	;	Crystal Structure of Cryptosporidium parvum malate dehydrogenase
8FBT	;	2.2	;	Crystal structure of Cryptosporidium parvum N-myristoyltransferase with bound myristoyl-CoA
8FBU	;	2.0	;	Crystal structure of Cryptosporidium parvum N-myristoyltransferase with bound myristoyl-CoA and Compound-2
8FBM	;	1.9	;	Crystal structure of Cryptosporidium parvum N-myristoyltransferase with bound myristoyl-CoA and inhibitor 1
5XIO	;	2.46	;	Crystal Structure of Cryptosporidium parvum Prolyl-tRNA Synthetase (CpPRS) in complex with Halofuginone
4DRS	;	2.5	;	Crystal structure of Cryptosporidium parvum pyruvate kinase
2RHD	;	2.06	;	Crystal structure of Cryptosporidium parvum small GTPase RAB1A
3PGG	;	2.14	;	Crystal structure of cryptosporidium parvum u6 snrna-associated sm-like protein lsm5
7ACF	;	1.91	;	CRYSTAL STRUCTURE OF CRYSTAL FORM 2 OF AN ACTIVE KRAS G12D (GPPCP) DIMER IN COMPLEX WITH BI-5747
1X9I	;	1.16	;	Crystal structure of Crystal structure of phosphoglucose/phosphomannose phosphoglucose/phosphomannoseisomerase from Pyrobaculum aerophilum in complex with glucose 6-phosphate
2PY0	;	1.35	;	Crystal structure of Cs1 pilin chimera
5ZDI	;	1.7	;	Crystal structure of CsaA chaperone protein from picrophilus torridus
4JCI	;	1.7	;	Crystal structure of csal_2705, a putative hydroxyproline epimerase from CHROMOHALOBACTER SALEXIGENS (TARGET EFI-506486), SPACE GROUP P212121, unliganded
5J1L	;	2.27	;	Crystal structure of Csd1-Csd2 dimer I
5J1M	;	2.35	;	Crystal structure of Csd1-Csd2 dimer II
5J1K	;	1.81	;	Crystal structure of Csd2-Csd2 dimer
1I29	;	2.8	;	CRYSTAL STRUCTURE OF CSDB COMPLEXED WITH L-PROPARGYLGLYCINE
6IG8	;	1.8	;	Crystal structure of CSF-1R kinase domain with a small molecular inhibitor, JTE-952
8JOT	;	1.69	;	Crystal structure of CSF-1R kinase domain with sulfatinib
7MFC	;	2.8	;	Crystal structure of CSF1R in complex with vimseltinib
7TNH	;	2.7	;	Crystal structure of CSF1R kinase domain in complex with DP-6233
5Y6R	;	3.01	;	Crystal structure of CSFV NS5B
1TTU	;	2.85	;	Crystal Structure of CSL bound to DNA
4UW2	;	2.632	;	Crystal structure of Csm1 in T.onnurineus
6O74	;	2.71	;	Crystal structure of Csm1-Csm4 cassette in complex with AMPPNP
6O79	;	3.0	;	Crystal structure of Csm1-Csm4 cassette in complex with cA3
6O7B	;	2.4	;	Crystal structure of Csm1-Csm4 cassette in complex with cA4
6O7D	;	2.81	;	Crystal structure of Csm1-Csm4 cassette in complex with one ATP
6O75	;	2.6	;	Crystal structure of Csm1-Csm4 cassette in complex with pppApA
6O78	;	2.8	;	Crystal structure of Csm1-Csm4 cassette in complex with pppApApA
6MUA	;	2.91	;	Crystal structure of Csm1-Csm4 subcomplex in the type III-A CRISPR-Csm interference complex
6AE1	;	2.405	;	Crystal structure of Csm2 of the type III-A CRISPR-Cas effector complex
6AE2	;	2.701	;	Crystal structure of Csm3 of the type III-A CRISPR-Cas effector complex
4QTS	;	3.105	;	Crystal structure of Csm3-Csm4 subcomplex in the type III-A CRISPR-Cas interference complex
6O6T	;	2.31	;	Crystal structure of Csm6 H132A mutant
6O70	;	2.3	;	Crystal structure of Csm6 H132A mutant in complex with cA4 by cocrystallization of cA4 and Csm6 H132A mutant
6O6Z	;	2.1	;	Crystal structure of Csm6 H381A in complex with cA4 by cocrystallization of cA4 and Csm6
6OV0	;	2.8	;	Crystal structure of Csm6 in complex with A4>p by soaking A4>p into Csm6
6O6V	;	2.35	;	Crystal structure of Csm6 in complex with cA4 by soaking cA4 into Csm6
6O71	;	2.55	;	Crystal structure of Csm6 in complex with cdA4 by soaking cdA4 into Csm6
6O6Y	;	1.96	;	Crystal structure of Csm6 in complex with cyclic-tetraadenylates (cA4) by cocrystallization of Csm6 and cA4
6O6X	;	2.11	;	Crystal structure of Csm6 W14A/E337A mutant in complex with cA4 by cocrystallization
7XH0	;	1.68	;	crystal structure of Csn-PD from Paenibacillus dendritiformis
4F7O	;	2.6	;	Crystal structure of CSN5
5JOH	;	1.99	;	CRYSTAL STRUCTURE OF CSN5(2-257) IN COMPLEX WITH CNS5i-1b
5JOG	;	2.46	;	CRYSTAL STRUCTURE OF CSN5(2-257) IN COMPLEX WITH CNS5i-3
1MJC	;	2.0	;	CRYSTAL STRUCTURE OF CSPA, THE MAJOR COLD SHOCK PROTEIN OF ESCHERICHIA COLI
5Z38	;	2.292	;	Crystal structure of CsrA bound to CesT
2XZ2	;	1.4	;	Crystal structure of CstF-50 homodimerization domain
6B3X	;	2.3	;	Crystal structure of CstF-50 in complex with CstF-77
2UY1	;	2.0	;	CRYSTAL STRUCTURE OF CSTF-77
5D6H	;	2.4	;	Crystal structure of CsuC-CsuA/B chaperone-major subunit pre-assembly complex from Csu biofilm-mediating pili of Acinetobacter baumannii
6FJY	;	2.31	;	Crystal structure of CsuC-CsuE chaperone-tip adhesion subunit pre-assembly complex from archaic chaperone-usher Csu pili of Acinetobacter baumannii
6QZQ	;	3.6	;	Crystal structure of Csx1 from Sulfolobus islandicus monoclinic form
6QZT	;	2.93	;	Crystal structure of Csx1 from Sulfolobus islandicus orthorhombic form
6R7B	;	3.12	;	Crystal structure of Csx1 in complex with cyclic oligoadenylate cOA4 conformation 1
6R9R	;	2.7	;	Crystal structure of Csx1 in complex with cyclic oligoadenylate cOA4 conformation 2
4EOG	;	2.3	;	Crystal structure of Csx1 of Pyrococcus furiosus
3WXY	;	1.706	;	Crystal structure of CsyB complexed with CoA-SH
3GN6	;	1.8	;	Crystal structure of CT0912, ORFan protein from Chlorobium tepidum with a ferredoxin-like domain repeat (NP_661805.1) from CHLOROBIUM TEPIDUM TLS at 1.80 A resolution
3VSZ	;	2.893	;	Crystal structure of Ct1,3Gal43A in complex with galactan
3VT1	;	3.187	;	Crystal structure of Ct1,3Gal43A in complex with galactose
3VT2	;	3.002	;	Crystal structure of Ct1,3Gal43A in complex with isopropy-beta-D-thiogalactoside
3VT0	;	2.913	;	Crystal structure of Ct1,3Gal43A in complex with lactose
1RCW	;	2.5	;	Crystal structure of CT610 from Chlamydia trachomatis
7ZHE	;	2.0	;	Crystal structure of CtaZ from Ruminiclostridium cellulolyticum
7ZHD	;	1.65	;	Crystal structure of CtaZ in complex with Closthioamide
1MX3	;	1.95	;	Crystal structure of CtBP dehydrogenase core holo form
4U3A	;	2.42	;	Crystal structure of CtCel5E
5YEF	;	2.807	;	Crystal structure of CTCF ZFs2-8-Hs5-1aE
5YEH	;	2.328	;	Crystal structure of CTCF ZFs4-8-eCBS
5YEG	;	2.0	;	Crystal structure of CTCF ZFs4-8-Hs5-1a complex
5YEL	;	2.96	;	Crystal structure of CTCF ZFs6-11-gb7CSE
5UND	;	2.549	;	Crystal Structure of CTCF(ZnF 4-10) With 28-mer DNA
7KPQ	;	2.1	;	Crystal structure of CtdE in complex with FAD
7KPT	;	1.91	;	Crystal structure of CtdE in complex with FAD and substrate 4
5MU3	;	2.1	;	Crystal structure of Ctf19-Mcm21 kinetochore assembly bound with Ctf19-Mcm21 binding motif of central kinetochore subunit Okp1
7YP0	;	2.3	;	Crystal structure of CtGST
8K2P	;	2.2	;	Crystal structure of CtGST-F76A
6XY2	;	3.05	;	Crystal structure of CTLA-4 complexed with the Fab of HL32 antibody
6JLI	;	1.778	;	Crystal structure of CTLD7 domain of human PLA2R
1RAA	;	2.5	;	CRYSTAL STRUCTURE OF CTP-LIGATED T STATE ASPARTATE TRANSCARBAMOYLASE AT 2.5 ANGSTROMS RESOLUTION: IMPLICATIONS FOR ATCASE MUTANTS AND THE MECHANISM OF NEGATIVE COOPERATIVITY
1RAB	;	2.5	;	CRYSTAL STRUCTURE OF CTP-LIGATED T STATE ASPARTATE TRANSCARBAMOYLASE AT 2.5 ANGSTROMS RESOLUTION: IMPLICATIONS FOR ATCASE MUTANTS AND THE MECHANISM OF NEGATIVE COOPERATIVITY
1RAC	;	2.5	;	CRYSTAL STRUCTURE OF CTP-LIGATED T STATE ASPARTATE TRANSCARBAMOYLASE AT 2.5 ANGSTROMS RESOLUTION: IMPLICATIONS FOR ATCASE MUTANTS AND THE MECHANISM OF NEGATIVE COOPERATIVITY
1RAD	;	2.5	;	CRYSTAL STRUCTURE OF CTP-LIGATED T STATE ASPARTATE TRANSCARBAMOYLASE AT 2.5 ANGSTROMS RESOLUTION: IMPLICATIONS FOR ATCASE MUTANTS AND THE MECHANISM OF NEGATIVE COOPERATIVITY
1RAE	;	2.5	;	CRYSTAL STRUCTURE OF CTP-LIGATED T STATE ASPARTATE TRANSCARBAMOYLASE AT 2.5 ANGSTROMS RESOLUTION: IMPLICATIONS FOR ATCASE MUTANTS AND THE MECHANISM OF NEGATIVE COOPERATIVITY
1RAF	;	2.5	;	CRYSTAL STRUCTURE OF CTP-LIGATED T STATE ASPARTATE TRANSCARBAMOYLASE AT 2.5 ANGSTROMS RESOLUTION: IMPLICATIONS FOR ATCASE MUTANTS AND THE MECHANISM OF NEGATIVE COOPERATIVITY
1RAG	;	2.5	;	CRYSTAL STRUCTURE OF CTP-LIGATED T STATE ASPARTATE TRANSCARBAMOYLASE AT 2.5 ANGSTROMS RESOLUTION: IMPLICATIONS FOR ATCASE MUTANTS AND THE MECHANISM OF NEGATIVE COOPERATIVITY
1RAH	;	2.5	;	CRYSTAL STRUCTURE OF CTP-LIGATED T STATE ASPARTATE TRANSCARBAMOYLASE AT 2.5 ANGSTROMS RESOLUTION: IMPLICATIONS FOR ATCASE MUTANTS AND THE MECHANISM OF NEGATIVE COOPERATIVITY
1RAI	;	2.5	;	CRYSTAL STRUCTURE OF CTP-LIGATED T STATE ASPARTATE TRANSCARBAMOYLASE AT 2.5 ANGSTROMS RESOLUTION: IMPLICATIONS FOR ATCASE MUTANTS AND THE MECHANISM OF NEGATIVE COOPERATIVITY
2B7L	;	3.0	;	Crystal Structure of CTP:Glycerol-3-Phosphate Cytidylyltransferase from Staphylococcus aureus
4C2G	;	1.9	;	Crystal structure of CtpB(S309A) in complex with a peptide having a Val-Pro-Ala C-terminus
8IAN	;	2.08	;	Crystal structure of CtPL-H210S/F214I mutant
2WQH	;	2.2	;	Crystal structure of CTPR3Y3
3PPZ	;	2.99	;	Crystal structure of CTR1 kinase domain in complex with staurosporine
3P86	;	2.496	;	Crystal structure of CTR1 kinase domain mutant D676N in complex with staurosporine
8HEN	;	1.95	;	Crystal structure of CTSB in complex with 212-148
8HEI	;	1.55	;	Crystal structure of CTSB in complex with E64d
8HE9	;	1.55	;	Crystal structure of CTSB in complex with K777
8HET	;	2.0	;	Crystal structure of CTSL in complex with E64d
8HFV	;	2.1	;	Crystal structure of CTSL in complex with K777
5FBY	;	1.898	;	Crystal structure of ctSPD
3H0D	;	2.4	;	Crystal structure of CtsR in complex with a 26bp DNA duplex
4OM4	;	2.74	;	Crystal structure of CTX A2 from Taiwan Cobra (Naja naja atra)
4OM5	;	2.55	;	Crystal structure of CTX A4 from Taiwan Cobra (Naja naja atra)
7Q0Z	;	1.0	;	Crystal structure of CTX-M-14
6V6P	;	1.55	;	Crystal structure of CTX-M-14 E166A/D240G beta-lactamase
6V7T	;	1.34	;	Crystal structure of CTX-M-14 E166A/D240G beta-lactamase in complex with ceftazidime
7K2X	;	1.8	;	Crystal structure of CTX-M-14 E166A/K234R Beta-lactamase
7K2Y	;	1.62	;	Crystal structure of CTX-M-14 E166A/K234R Beta-lactamase in complex with hydrolyzed ampicillin
7K2W	;	1.4	;	Crystal structure of CTX-M-14 E166A/K234R Beta-lactamase in complex with hydrolyzed cefotaxime
6V6G	;	1.5	;	Crystal structure of CTX-M-14 E166A/P167S/D240G beta-lactamase
6V83	;	1.8	;	Crystal structure of CTX-M-14 E166A/P167S/D240G beta-lactamase in complex with ceftazidime-1
6V8V	;	1.8	;	Crystal structure of CTX-M-14 E166A/P167S/D240G beta-lactamase in complex with ceftazidime-2
6VHS	;	1.28	;	Crystal structure of CTX-M-14 in complex with beta-lactamase inhibitor ETX1317
7Q0Y	;	1.3	;	Crystal structure of CTX-M-14 in complex with Bortezomib
7Q11	;	1.14	;	Crystal structure of CTX-M-14 in complex with Ixazomib
6UNB	;	1.3	;	Crystal structure of CTX-M-14 in complex with temocillin
8DOE	;	1.5	;	Crystal Structure of CTX-M-14 N106A
6V5E	;	2.3	;	Crystal structure of CTX-M-14 P167S/D240G beta-lactamase
4PM6	;	1.56	;	Crystal structure of CTX-M-14 S70G beta-lactamase at 1.56 Angstroms resolution
4PM5	;	1.261	;	Crystal structure of CTX-M-14 S70G beta-lactamase in complex with cefotaxime at 1.26 Angstroms resolution
6CYQ	;	1.698	;	Crystal structure of CTX-M-14 S70G/N106S beta-lactamase in complex with hydrolyzed cefotaxime
6CYU	;	1.82	;	Crystal structure of CTX-M-14 S70G/N106S/D240G beta-lactamase in complex with hydrolyzed cefotaxime
4PM8	;	1.169	;	Crystal structure of CTX-M-14 S70G:S237A beta-lactamase at 1.17 Angstroms resolution
4PM7	;	1.29	;	Crystal structure of CTX-M-14 S70G:S237A in complex with cefotaxime at 1.29 Angstroms resolution
4PMA	;	1.399	;	Crystal structure of CTX-M-14 S70G:S237A:R276A beta-lactamase at 1.39 Angstroms resolution
4PM9	;	1.454	;	Crystal structure of CTX-M-14 S70G:S237A:R276A beta-lactamase in complex with cefotaxime at 1.45 Angstroms resolution
7U70	;	1.36	;	Crystal Structure of CTX-M-14 with compound 2
6MD8	;	1.4	;	Crystal structure of CTX-M-14 with compound 3
6MIA	;	1.399	;	Crystal structure of CTX-M-14 with compound 6
6QW8	;	1.1	;	Crystal structure of CTX-M-15 complexed with relebactam (16 hour soak)
6Z7I	;	0.98	;	Crystal structure of CTX-M-15 E166Q mutant apoenzyme
4HBU	;	1.1	;	Crystal structure of CTX-M-15 extended-spectrum beta-lactamase in complex with avibactam (NXL104)
7R3R	;	1.17	;	Crystal structure of CTX-M-15 G238C mutant apoenzyme
7R3Q	;	1.46	;	Crystal structure of CTX-M-15 G238C/A240 insert mutant apoenzyme
6Z7K	;	1.1	;	Crystal structure of CTX-M-15 in complex with the imine form of hydrolysed tazobactam
5T66	;	1.951	;	Crystal Structure of CTX-M-15 with 1C
6J2O	;	1.9	;	Crystal structure of CTX-M-64 clavulanic acid complex
2HXA	;	2.21	;	Crystal structure of Cu(I) Azurin with the metal-binding loop sequence ""CTFPGHSALM"" replaced with ""CSPHQGAGM"", at pH3.5
2HX9	;	1.7	;	Crystal structure of Cu(I) Azurin with the metal-binding loop sequence ""CTFPGHSALM"" replaced with ""CSPHQGAGM"", at pH4
2HX8	;	1.6	;	Crystal structure of Cu(I) Azurin with the metal-binding loop sequence ""CTFPGHSALM"" replaced with ""CSPHQGAGM"", at pH5
3DSO	;	1.55	;	Crystal structure of Cu(I) bound copper resistance protein CopK
2HH7	;	2.55	;	Crystal Structure of Cu(I) bound CsoR from Mycobacterium tuberculosis.
2GI0	;	1.7	;	Crystal structure of Cu(I) Phe114Pro Azurin mutant
5VDE	;	1.65	;	Crystal Structure of Cu(I)-loaded yeast Atx1: Crystal Form I
5VDF	;	1.93	;	Crystal Structure of Cu(I)-loaded yeast Atx1: Crystal Form II
3K0I	;	4.116	;	Crystal structure of Cu(I)CusA
2VB2	;	1.7	;	Crystal structure of Cu(I)CusF
2HX7	;	1.55	;	Crystal structure of Cu(II) Azurin with the metal-binding loop sequence ""CTFPGHSALM"" replaced with ""CSPHQGAGM""
2EB9	;	1.8	;	Crystal Structure of Cu(II)(Sal-Leu)/apo-Myoglobin
2EB8	;	1.65	;	Crystal Structure of Cu(II)(Sal-Phe)/apo-Myoglobin
2WTP	;	1.5	;	Crystal Structure of Cu-form Czce from C. metallidurans CH34
8IMD	;	1.45	;	Crystal structure of Cu/Zn Superoxide dismutase from Paenibacillus lautus
4OH2	;	2.384	;	Crystal Structure of Cu/Zn Superoxide Dismutase I149T
8HCT	;	2.26	;	Crystal structure of Cu2+ binding to Dendrorhynchus zhejiangensis ferritin
3N30	;	3.0	;	Crystal Structure of cubic Zn3-hUb (human ubiquitin) adduct
4LLF	;	2.8891	;	Crystal structure of Cucumber Necrosis Virus
4YN3	;	1.95	;	Crystal structure of Cucumisin complex with pro-peptide
3VTA	;	2.75	;	Crystal Structure of cucumisin, a subtilisin-like endoprotease from Cucumis melo L
1KV7	;	1.4	;	Crystal Structure of CueO, a multi-copper oxidase from E. coli involved in copper homeostasis
7Y2P	;	1.58	;	Crystal structure of CUG repeat RNA duplex containing A-U base pair and U-U mismatches
7Y2B	;	1.88	;	Crystal structure of CUG repeat RNA duplex containing U-U mismatches
3NMR	;	1.85	;	Crystal Structure of CUGBP1 RRM1/2-RNA Complex
3NNA	;	1.899	;	Crystal Structure of CUGBP1 RRM1/2-RNA Complex
3NNC	;	2.2005	;	Crystal Structure of CUGBP1 RRM1/2-RNA Complex
5J7M	;	2.07	;	Crystal structure of Cupin 2 conserved barrel domain protein from Kribbella flavida DSM 17836
3IBM	;	2.0	;	CRYSTAL STRUCTURE OF cupin 2 domain-containing protein Hhal_0468 FROM Halorhodospira halophila
1SEF	;	2.05	;	Crystal structure of cupin domain protein EF2996 from Enterococcus faecalis
4E2G	;	1.86	;	Crystal structure of Cupin fold protein Sthe2323 from Sphaerobacter thermophilus
5ZXN	;	1.855	;	Crystal structure of CurA from Vibrio vulnificus
5ZXU	;	2.2	;	Crystal structure of CurA in complex with NADPH from Vibrio vulnificus
2DPF	;	1.5	;	Crystal Structure of curculin1 homodimer
3OIT	;	2.0	;	Crystal structure of curcuminoid synthase CUS from Oryza sativa
5THZ	;	2.1	;	Crystal structure of CurJ carbon methyltransferase
5TZ6	;	2.4	;	Crystal Structure of CurJ Dehydratase H978F Inactive Mutant In Complex with Compound 21
5TZ7	;	1.648	;	Crystal Structure of CurK Dehydratase D1169N Inactive Mutant
5TZ5	;	1.428	;	Crystal Structure of CurK Dehydratase H996F Inactive Mutant
5DP1	;	1.85	;	Crystal structure of CurK enoyl reductase
3K07	;	3.521	;	Crystal structure of CusA
7ZP0	;	1.398	;	Crystal structure of CusS histidine kinase catalytic core from Escherichia coli
5KU5	;	2.15	;	Crystal Structure of CusS Sensor Domain with Silver Bound
2NUH	;	1.39	;	Crystal structure of CutA from the phytopathgen bacterium Xylella fastidiosa
1NAQ	;	1.7	;	Crystal structure of CUTA1 from E.coli at 1.7 A resolution
2ZOM	;	3.02	;	Crystal structure of CutA1 from Oryza sativa
1J2V	;	2.0	;	Crystal Structure of CutA1 from Pyrococcus Horikoshii
2E66	;	2.0	;	Crystal Structure Of CutA1 From Pyrococcus Horikoshii OT3, Mutation D60A
6GVB	;	1.8	;	Crystal structure of Cutibacterium acnes exo-beta-1,4-mannosidase
3F7O	;	2.2	;	Crystal structure of Cuticle-Degrading Protease from Paecilomyces lilacinus (PL646)
7QJR	;	1.51	;	Crystal structure of cutinase 1 from Thermobifida fusca DSM44342 (703)
8C65	;	1.491	;	Crystal structure of cutinase AdCut from Acidovorax delafieldii (PBS depolymerase)
3VIS	;	1.76	;	Crystal structure of cutinase Est119 from Thermobifida alba AHK119
8AIT	;	1.24	;	Crystal structure of cutinase PbauzCut from Pseudomonas bauzanensis
8AIS	;	1.56	;	Crystal structure of cutinase PsCut from Pseudomonas saudimassiliensis
8AIR	;	1.08	;	Crystal structure of cutinase RgCutII from Rhizobacter gummiphilus
7RAQ	;	1.74	;	Crystal structure of CV3-25 Fab bound to SARS-CoV-2 spike stem helix peptide
6GXS	;	1.8	;	Crystal structure of CV39L lectin from Chromobacterium violaceum at 1.8 A resolution
3SJI	;	1.798	;	crystal structure of CVA16 3C in complex with Rupintrivir (AG7088)
2ZU1	;	1.38	;	crystal structure of CVB3 3C protease mutant C147A
3QP6	;	2.0	;	Crystal structure of CviR (Chromobacterium violaceum 12472) bound to C6-HSL
3QP8	;	1.6	;	Crystal structure of CviR (Chromobacterium violaceum 12472) ligand-binding domain bound to C10-HSL
3QP5	;	3.249	;	Crystal structure of CviR bound to antagonist chlorolactone (CL)
3QP4	;	1.55	;	Crystal structure of CviR ligand-binding domain bound to C10-HSL
3QP2	;	1.638	;	Crystal structure of CviR ligand-binding domain bound to C8-HSL
3QP1	;	1.55	;	Crystal structure of CviR ligand-binding domain bound to the native ligand C6-HSL
7XN2	;	1.6	;	Crystal structure of CvkR, a novel MerR-type transcriptional regulator
6ISJ	;	2.3	;	Crystal structure of CX-4945 bound CK2 alpha from C. neoformans
6K3L	;	2.09	;	Crystal structure of CX-4945 bound Cka1 from C. neoformans
4QNV	;	2.64	;	Crystal structure of Cx-SAM bound CmoB from E. coli in P6122
7CTA	;	2.9	;	Crystal structure of Cx-SAM bound CmoB from Vibrio vulnificus
3HP3	;	2.2	;	Crystal structure of CXCL12
4UAI	;	1.9	;	Crystal structure of CXCL12 in complex with inhibitor
7JNY	;	1.88	;	Crystal structure of CXCL13
4HSV	;	2.083	;	Crystal Structure of CXCL4L1
4RWS	;	3.1	;	Crystal structure of CXCR4 and viral chemokine antagonist vMIP-II complex (PSI Community Target)
5UK3	;	2.8	;	Crystal structure of cyanase from T. urticae
6XGT	;	2.2	;	Crystal structure of cyanase from the thermophilic fungus Thermomyces lanuginosus
2D0U	;	3.4	;	Crystal structure of cyanide bound form of human indoleamine 2,3-dioxygenase
1N2N	;	2.4	;	Crystal structure of cyanide complex of the oxygenase domain of inducible nitric oxide synthase.
1D5L	;	1.9	;	CRYSTAL STRUCTURE OF CYANIDE-BOUND HUMAN MYELOPEROXIDASE ISOFORM C AT PH 5.5
3VV9	;	2.85	;	Crystal structure of cyanide-insensitive alternative oxidase from Trypanosoma brucei
3VVA	;	2.59	;	Crystal structure of cyanide-insensitive alternative oxidase from Trypanosoma brucei with ascofuranone derivative
5ZDR	;	2.59	;	Crystal structure of cyanide-insensitive alternative oxidase from Trypanosoma brucei with ascofuranone derivative
3W54	;	2.3	;	Crystal structure of cyanide-insensitive alternative oxidase from Trypanosoma brucei with colletochlorin B
5ZDQ	;	2.3	;	Crystal structure of cyanide-insensitive alternative oxidase from Trypanosoma brucei with COLLETOCHLORIN B
5ZDP	;	2.71	;	Crystal structure of cyanide-insensitive alternative oxidase from Trypanosoma brucei with ferulenol
5AZQ	;	1.4	;	Crystal structure of cyano-cobalt(III) tetradehydrocorrin in the heme pocket of horse heart myoglobin
4RC5	;	2.3	;	Crystal structure of cyanobacterial aldehyde-deformylating oxygenase
4RC6	;	2.9	;	Crystal structure of cyanobacterial aldehyde-deformylating oxygenase 122F mutant
4RC8	;	1.71	;	Crystal structure of cyanobacterial aldehyde-deformylating oxygenase bound with fatty acid
4RC7	;	2.2	;	Crystal structure of cyanobacterial aldehyde-deformylating oxygenase F86YF87Y mutant
7DXQ	;	2.8	;	Crystal Structure of Cyanobacterial Circadian Clock Protein KaiC
7DY1	;	2.2	;	Crystal Structure of Cyanobacterial Circadian Clock Protein KaiC
7DY2	;	3.04	;	Crystal Structure of Cyanobacterial Circadian Clock Protein KaiC
7DYE	;	2.6	;	Crystal Structure of Cyanobacterial Circadian Clock Protein KaiC
7DYI	;	2.64	;	Crystal Structure of Cyanobacterial Circadian Clock Protein KaiC
7DYJ	;	2.4	;	Crystal Structure of Cyanobacterial Circadian Clock Protein KaiC
7DYK	;	2.99	;	Crystal Structure of Cyanobacterial Circadian Clock Protein KaiC
7V3X	;	3.1	;	Crystal Structure of Cyanobacterial Circadian Clock Protein KaiC
7WDC	;	2.84	;	Crystal Structure of Cyanobacterial Circadian Clock Protein KaiC
8WV8	;	2.93	;	Crystal Structure of Cyanobacterial Circadian Clock Protein KaiC
8WVE	;	2.729	;	Crystal Structure of Cyanobacterial Circadian Clock Protein KaiC
4V62	;	2.9	;	Crystal Structure of cyanobacterial Photosystem II
4V82	;	3.2	;	Crystal structure of cyanobacterial Photosystem II in complex with terbutryn
3LS0	;	1.8	;	Crystal Structure of Cyanobacterial PsbQ from Synechocystis sp. PCC 6803
3LS1	;	1.85	;	Crystal Structure of Cyanobacterial PsbQ from Synechocystis sp. PCC 6803 complexed with Zn2+
7BW2	;	6.5	;	Crystal Structure of Cyanobacterial PSI Monomer from T.elongatus at 6.5 A Resolution
7CKV	;	1.63	;	Crystal structure of Cyanobacteriochrome GAF domain in Pr state
3VV4	;	2.0	;	Crystal structure of cyanobacteriochrome TePixJ GAF domain
8EIP	;	2.24	;	Crystal structure of cyanophycin dipeptide hydrolase CphZ E251A from Acinetobacter baylyi DSM587 in complex with beta-Asp-Arg
7TA5	;	3.0	;	Crystal structure of cyanophycin synthetase 2 from Gloeothece citriformis
3GXY	;	2.4	;	Crystal structure of cyanovirin-n complexed to a synthetic hexamannoside
3GXZ	;	2.5	;	Crystal structure of cyanovirin-n complexed to oligomannose-9 (man-9)
3CZZ	;	1.36	;	Crystal structure of Cyanovirin-N domain B mutant
3LHC	;	1.34	;	Crystal structure of cyanovirin-n swapping domain b mutant
4NQ3	;	2.702	;	Crystal structure of cyanuic acid hydrolase from A. caulinodans
4LK8	;	1.494	;	Crystal structure of CyaY protein from Psychromonas ingrahamii in complex with Co(II)
4LP1	;	1.803	;	Crystal structure of CyaY protein from Psychromonas ingrahamii in complex with Eu(III)
2B0R	;	2.6	;	Crystal Structure of Cyclase-Associated Protein from Cryptosporidium parvum
7BVT	;	1.47	;	Crystal structure of cyclic alpha-maltosyl-1,6-maltose binding protein from Arthrobacter globiformis
8GUF	;	1.99	;	Crystal structure of cyclic B subunit of type II heat labile enterotoxin
1K6U	;	1.0	;	Crystal Structure of Cyclic Bovine Pancreatic Trypsin Inhibitor
5Z7C	;	2.76	;	crystal structure of cyclic GMP-AMP specifc phosphodiesterases in V.cholerae (V-cGAP3)
1FSI	;	2.5	;	CRYSTAL STRUCTURE OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE OF APPR>P FROM ARABIDOPSIS THALIANA
4RFA	;	2.21	;	Crystal structure of cyclic nucleotide-binding domain containing protein from Listeria monocytogenes EGD-e
2I53	;	1.5	;	Crystal structure of Cyclin K
4LYN	;	2.0	;	Crystal structure of cyclin-dependent kinase 2 (cdk2-wt) complex with (2s)-n-(5-(((5-tert-butyl-1,3-oxazol-2-yl)methyl)sulfanyl)-1,3-thiazol-2-yl)-2-phenylpropanamide
5D1J	;	1.8	;	CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH N-[5-[[[5-(1,1-DIMETHYLETHYL)-2-OXAZOLYL] METHYL]THIO]-2-THIAZOLYL]-4-PIPERIDINECARBOXAMIDE (BMS-387032)
2R3F	;	1.5	;	Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor
2R3G	;	1.55	;	Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor
2R3H	;	1.5	;	Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor
2R3I	;	1.28	;	Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor
2R3J	;	1.65	;	Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor
2R3K	;	1.7	;	Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor
2R3L	;	1.65	;	Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor
2R3M	;	1.7	;	Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor
2R3N	;	1.63	;	Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor
2R3O	;	1.8	;	Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor
2R3P	;	1.66	;	Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor
2R3Q	;	1.35	;	Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor
2R3R	;	1.47	;	Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor
7QHL	;	1.7	;	Crystal structure of Cyclin-dependent kinase 2/cyclin A in complex with 3,5,7-Substituted pyrazolo[4,3-d]pyrimidine inhibitor 24
4Y8D	;	2.1	;	Crystal structure of Cyclin-G associated kinase (GAK) complexed with selective 12i inhibitor
5ERM	;	2.303	;	Crystal structure of cyclization domain of Phomopsis amygdali fusicoccadiene synthase complexed with magnesium ions and pamidronate
5ER8	;	2.5	;	Crystal structure of cyclization domain of Phomopsis amygdali fusicoccadiene synthase complexed with manganese ions and neridronate
4Q24	;	2.9	;	Crystal structure of Cyclo(L-leucyl-L-phenylalanyl) synthase
6VXV	;	1.6	;	Crystal structure of cyclo-L-Trp-L-Pro-bound cytochrome P450 NasF5053 from Streptomyces sp. NRRL F-5053
2ZYM	;	1.8	;	Crystal structure of cyclo/maltodextrin-binding protein complexed with alpha-cyclodextrin
2ZYN	;	1.7	;	Crystal structure of cyclo/maltodextrin-binding protein complexed with beta-cyclodextrin
2ZYK	;	2.5	;	Crystal structure of cyclo/maltodextrin-binding protein complexed with gamma-cyclodextrin
2ZYO	;	1.55	;	Crystal structure of cyclo/maltodextrin-binding protein complexed with maltotetraose
1C58	;	0.99	;	CRYSTAL STRUCTURE OF CYCLOAMYLOSE 26
1UKQ	;	2.0	;	Crystal structure of cyclodextrin glucanotransferase complexed with a pseudo-maltotetraose derived from acarbose
1I75	;	2.0	;	CRYSTAL STRUCTURE OF CYCLODEXTRIN GLUCANOTRANSFERASE FROM ALKALOPHILIC BACILLUS SP.#1011 COMPLEXED WITH 1-DEOXYNOJIRIMYCIN
5HPQ	;	2.05	;	Crystal structure of cyclohexadienyl dehydratase from Pseudomonas aeruginosa bound to acetate
4WJI	;	1.4	;	Crystal structure of cyclohexadienyl dehydrogenase from Sinorhizobium meliloti in complex with NADP and tyrosine
6ER9	;	2.37	;	Crystal structure of cyclohexanone monooxygenase from Rhodococcus sp. Phi1 bound to NADP+
7V8R	;	1.764	;	Crystal structure of cyclohexanone monooxygenase from T. municipale mutant L437T complexed with NADP+ and FAD in space group of C2221
7V8S	;	2.08	;	Crystal structure of cyclohexanone monooxygenase from T. municipale mutant L437T complexed with NADP+ and FAD in space group of P1211
7V8O	;	2.72	;	Crystal structure of cyclohexanone monooxygenase from T. municipale mutant L437T complexed with NADP+ and FAD in space group of P21221
5M10	;	1.22	;	Crystal structure of cyclohexanone monooxygenase from Thermocrispum municipale in the oxidised state with a bound nicotinamide.
6ERA	;	2.49	;	Crystal structure of cyclohexanone monooxygenase mutant (F249A, F280A and F435A) from Rhodococcus sp. Phi1 bound to NADP+
4U3U	;	2.9	;	Crystal structure of Cycloheximide bound to the yeast 80S ribosome
6LQC	;	1.88	;	Crystal structure of Cyclohexylamine Oxidase from Erythrobacteraceae bacterium
3KK6	;	2.75	;	Crystal Structure of Cyclooxygenase-1 in complex with celecoxib
3N8Z	;	2.9	;	Crystal Structure of Cyclooxygenase-1 in Complex with Flurbiprofen
3N8X	;	2.75	;	Crystal Structure of Cyclooxygenase-1 in Complex with Nimesulide
2HAQ	;	1.97	;	Crystal Structure of Cyclophilin A from Leishmania Donovani
3O7T	;	1.85	;	Crystal Structure of Cyclophilin A from Moniliophthora perniciosa
3PMP	;	1.47	;	Crystal Structure of Cyclophilin A from Moniliophthora perniciosa in complex with Cyclosporin A
3ODI	;	2.2	;	Crystal structure of cyclophilin A in complex with Voclosporin E-ISA247
3ODL	;	2.31	;	Crystal structure of cyclophilin A in complex with Voclosporin Z-ISA247
4EYV	;	1.97	;	Crystal structure of Cyclophilin A like protein from Piriformospora indica
2R99	;	1.61	;	Crystal structure of cyclophilin ABH-like domain of human peptidylprolyl isomerase E isoform 1
5EX2	;	1.294	;	Crystal structure of cyclophilin AquaCyp293 from Hirschia baltica
5EX1	;	2.053	;	Crystal structure of cyclophilin AquaCyp300 from Hirschia baltica
3ICH	;	1.2	;	Crystal structure of cyclophilin B at 1.2 A resolution
3ICI	;	1.7	;	Crystal structure of cyclophilin B in complex with calmegin fragment
5A0E	;	1.25	;	Crystal structure of cyclophilin D in complex with CsA analogue, JW47.
3EOV	;	2.6	;	Crystal structure of cyclophilin from Leishmania donovani ligated with cyclosporin A
1Z81	;	2.8	;	Crystal Structure of cyclophilin from Plasmodium yoelii.
1XO7	;	1.61	;	Crystal structure of cyclophilin from Trypanosoma cruzi
6L2B	;	2.65	;	Crystal structure of cyclophilin mutant I164M from Leishmania donovani at 2.65 angstrom resolution
4S1E	;	2.22	;	Crystal structure of cyclophilin mutant L120A from Leishmania donovani at 2.22 angstrom.
4S1J	;	2.3	;	Crystal structure of cyclophilin mutant V33A from Leishmania donovani at 2.3 angstrom.
8B58	;	1.1	;	Crystal Structure of Cyclophilin TgCyp23 from Toxoplasma gondii in complex with Cyclosporin A
3BKX	;	1.85	;	Crystal structure of cyclopropane-fatty-acyl-phospholipid synthase-like protein (YP_807781.1) from Lactobacillus casei ATCC 334 at 1.85 A resolution
7VEY	;	1.9	;	Crystal structure of Cyclosorus parasiticus chalcone synthase 1 (CpCHS1)
7VEZ	;	2.397	;	Crystal structure of Cyclosorus parasiticus chalcone synthase 1 (CpCHS1) complex with naringenin
7VF0	;	2.399	;	Crystal structure of Cyclosorus parasiticus chalcone synthase 1 (CpCHS1) complex with naringenin and CoA
7RMQ	;	1.17	;	Crystal structure of cycloviolacin O2
6I28	;	1.65	;	Crystal Structure of Cydia Pomonella PTP-2 phosphatase
3WXG	;	3.1	;	Crystal structure of CYLD USP domain (C596A) in complex with Lys63-linked diubiquitin
3WXF	;	2.3	;	Crystal structure of CYLD USP domain (C596S E674Q) in complex with Met1-linked diubiquitin
3WXE	;	2.5	;	Crystal structure of CYLD USP domain (C596S) in complex with Met1-linked diubiquitin
4D51	;	2.3	;	Crystal structure of CymA from Klebsiella oxytoca
4D5B	;	1.702	;	Crystal structure of CymA from Klebsiella oxytoca
4D5D	;	1.902	;	Crystal structure of CymA from Klebsiella oxytoca
4V3G	;	2.513	;	Crystal structure of CymA from Klebsiella oxytoca
4V3H	;	1.83	;	Crystal structure of CymA from Klebsiella oxytoca
6OS5	;	1.66	;	Crystal structure of CymD prenyltransferase complexed with L-tryptophan
6OS6	;	1.33	;	Crystal structure of CymD prenyltransferase complexed with L-tryptophan and DMSPP
5KYO	;	1.8	;	Crystal Structure of CYP101J2
4OQS	;	2.04	;	Crystal structure of CYP105AS1
3ABB	;	2.3	;	Crystal structure of CYP105D6
3TYW	;	2.9	;	Crystal Structure of CYP105N1 from Streptomyces coelicolor A3(2)
4FXB	;	2.9	;	Crystal structure of CYP105N1 from Streptomyces coelicolor: a cytochrome P450 oxidase in the coelibactin siderophore biosynthetic pathway
3E5L	;	2.4	;	Crystal structure of CYP105P1 H72A mutant
3ABA	;	1.8	;	Crystal structure of CYP105P1 in complex with filipin I
3E5K	;	2.6	;	Crystal structure of CYP105P1 wild-type 4-phenylimidazole complex
3E5J	;	1.95	;	Crystal structure of CYP105P1 wild-type ligand-free form
7ZZL	;	1.7	;	Crystal structure of CYP106A1
3TKT	;	2.2	;	Crystal structure of CYP108D1 from Novosphingobium aromaticivorans DSM12444
8ABR	;	2.1	;	Crystal structure of CYP109A2 from Bacillus megaterium bound with putative ligands hexanoic acid and octanoic acid
8ABS	;	1.75	;	Crystal structure of CYP109A2 from Bacillus megaterium bound with testosterone and putative ligand 4,6-dimethyloctanoic acid
7Y97	;	2.36	;	Crystal structure of CYP109B4 from Bacillus Sonorensis
7Y98	;	2.27	;	Crystal structure of CYP109B4 from Bacillus Sonorensis in complex with Testosterone
6LDL	;	1.38	;	Crystal structure of CYP116B46-N(20-445) from Tepidiphilus thermophilus in complex with HEME
4WQJ	;	2.7	;	Crystal Structure of CYP119 from Sulfolobus acidocaldarius, Collected at 298K and Complexed with 4-(4-bromophenyl)-1H imidazole
4TT5	;	2.18	;	Crystal Structure of CYP119 from Sulfolobus acidocaldarius, complexed with 4-(4-bromophenyl)-1H imidazole
6T0H	;	1.18	;	Crystal structure of CYP124 in complex with 1-alpha-hydroxy-vitamin D3
6T0F	;	1.65	;	Crystal structure of CYP124 in complex with cholest-4-en-3-one
6T0K	;	1.18	;	Crystal structure of CYP124 in complex with inhibitor carbethoxyhexyl imidazole
7ZB9	;	1.15	;	Crystal structure of CYP124 in complex with inhibitor carbethoxyhexyl imidazole in the absence of glycerol (NoCryo)
6T0L	;	1.8	;	Crystal structure of CYP124 in complex with inhibitor compound 5'
6T0J	;	1.25	;	Crystal structure of CYP124 in complex with SQ109
6T0G	;	1.3	;	Crystal structure of CYP124 in complex with vitamin D3
7QWN	;	1.93	;	Crystal structure of CYP125 from Mycobacterium tuberculosis in complex with an inhibitor
7R1I	;	2.24	;	Crystal structure of CYP125 from Mycobacterium tuberculosis in complex with an inhibitor
7R3U	;	1.86	;	Crystal structure of CYP125 from Mycobacterium tuberculosis in complex with an inhibitor
7YXF	;	1.85	;	Crystal structure of CYP125 from Mycobacterium tuberculosis in complex with an inhibitor
7ZGL	;	2.5	;	Crystal structure of CYP125 from Mycobacterium tuberculosis in complex with an inhibitor
7ZIC	;	1.9	;	Crystal structure of CYP125 from Mycobacterium tuberculosis in complex with an inhibitor
7ZLT	;	1.9	;	Crystal structure of CYP125 from Mycobacterium tuberculosis in complex with an inhibitor
7ZLZ	;	1.89	;	Crystal structure of CYP125 from Mycobacterium tuberculosis in complex with an inhibitor
7ZQR	;	1.79	;	Crystal structure of CYP125 from Mycobacterium tuberculosis in complex with an inhibitor
7ZSU	;	2.2	;	Crystal structure of CYP125 from Mycobacterium tuberculosis in complex with an inhibitor
7ZT0	;	1.99	;	Crystal structure of CYP125 from Mycobacterium tuberculosis in complex with an inhibitor
7ZXD	;	2.09	;	Crystal structure of CYP125 from Mycobacterium tuberculosis in complex with an inhibitor
7QKE	;	2.3	;	Crystal structure of CYP125 from Mycobacterium tuberculosis in complex with inhibitor (surface entropy reduction mutant)
7QNN	;	2.47	;	Crystal structure of CYP125 from Mycobacterium tuberculosis in complex with inhibitor (surface entropy reduction mutant)
2UUQ	;	1.46	;	Crystal structure of CYP130 from Mycobacterium tuberculosis in the ligand-free form
8A9P	;	1.63	;	Crystal structure of CYP142 from Mycobacterium tuberculosis in complex with a fragment
7QJL	;	1.38	;	Crystal structure of CYP142 from Mycobacterium tuberculosis in complex with an inhibitor
7QQ7	;	1.6	;	Crystal structure of CYP142 from Mycobacterium tuberculosis in complex with an inhibitor at partial occupancy with PEG
8A6W	;	2.09	;	Crystal structure of CYP142 from Mycobacterium tuberculosis in complex with cholestenone
7SH5	;	1.83	;	Crystal structure of CYP142A3 from Mycobacterium ulcerans bound to Cholest-4-en-3-one
6L69	;	1.5	;	Crystal structure of CYP154C2 from Streptomyces avermitilis
6TO2	;	2.0	;	Crystal structure of CYP154C5 from Nocardia farcinica in complex with 5alpha-Androstan-3-one
1N97	;	1.8	;	Crystal Structure of CYP175A1 from Thermus thermophillus strain HB27
6IQ5	;	3.7	;	Crystal Structure of CYP1B1 and Inhibitor Having Azide Group
5UDA	;	1.93	;	Crystal structure of CYP2B6 (Y226H/K262R) in complex with a monoterpene bornane
5UAP	;	2.03	;	Crystal Structure of CYP2B6 (Y226H/K262R) in complex with Bornyl Bromide
5UEC	;	2.27	;	Crystal Structure of CYP2B6 (Y226H/K262R) in complex with myrtenyl bromide.
5UFG	;	1.76	;	Crystal Structure of CYP2B6 (Y226H/K262R/I114V) in complex with myrtenyl bromide
5X23	;	2.0	;	Crystal structure of CYP2C9 genetic variant A477T (*30) in complex with multiple losartan molecules
5X24	;	2.48	;	Crystal structure of CYP2C9 genetic variant I359L (*3) in complex with multiple losartan molecules
4NZ2	;	2.45	;	Crystal structure of CYP2C9 in complex with an inhibitor
5XXI	;	2.3	;	Crystal structure of CYP2C9 in complex with multiple losartan molecules
3DL9	;	2.721	;	Crystal structure of CYP2R1 in complex with 1-alpha-hydroxy-vitamin D2
3CZH	;	2.3	;	Crystal structure of CYP2R1 in complex with vitamin D2
3C6G	;	2.8	;	Crystal structure of CYP2R1 in complex with vitamin D3
8EWD	;	2.2	;	Crystal structure of CYP3A4 bound to an inhibitor
8EWE	;	2.3	;	Crystal structure of CYP3A4 bound to an inhibitor
8EWL	;	2.35	;	Crystal structure of CYP3A4 bound to an inhibitor
8EWM	;	2.3	;	Crystal structure of CYP3A4 bound to an inhibitor
8EWN	;	2.1	;	Crystal structure of CYP3A4 bound to an inhibitor
8EWP	;	2.4	;	Crystal structure of CYP3A4 bound to an inhibitor
8EWQ	;	2.25	;	Crystal structure of CYP3A4 bound to an inhibitor
8EWR	;	2.2	;	Crystal structure of CYP3A4 bound to an inhibitor
8EWS	;	2.15	;	Crystal structure of CYP3A4 bound to an inhibitor
8EXB	;	2.05	;	Crystal structure of CYP3A4 bound to an inhibitor
4NY4	;	2.95	;	Crystal structure of CYP3A4 in complex with an inhibitor
4I4G	;	2.718	;	Crystal structure of CYP3A4 ligated to oxazole-substituted desoxyritonavir
4I4H	;	2.9	;	Crystal structure of CYP3A4 ligated to pyridine-substituted desoxyritonavir
6A18	;	2.48	;	Crystal structure of CYP90B1 in complex with 1,6-hexandiol
6A17	;	2.301	;	Crystal structure of CYP90B1 in complex with brassinazole
6A16	;	1.998	;	Crystal structure of CYP90B1 in complex with uniconazole
6J94	;	2.401	;	Crystal structure of CYP97A3
6J95	;	2.002	;	Crystal structure of CYP97A3 in complex with retinal
6L8I	;	1.7	;	Crystal structure of CYP97A3 mutant S290D/W300L/S304V
6L8J	;	2.399	;	Crystal structure of CYP97A3 mutant S290D/W300L/S304V in complex with retinal
6L8H	;	2.0	;	Crystal structure of CYP97C1
7WYR	;	1.75	;	Crystal structure of Cypovirus Polyhedra mutant fused with CLN025
5GQI	;	1.3	;	Crystal structure of Cypovirus Polyhedra mutant with deletion of Ala194
6LEE	;	1.95	;	Crystal structure of Cypovirus Polyhedra mutant with deletion of Ala67-Ala104
5GQK	;	1.5	;	Crystal structure of Cypovirus Polyhedra mutant with deletion of Gly192-Ala194
5GQJ	;	1.5	;	Crystal structure of Cypovirus Polyhedra mutant with deletion of Ser193 and Ala194
5AXU	;	1.6	;	Crystal Structure of Cypovirus Polyhedra R13A Mutant
5YR9	;	1.7	;	Crystal Structure of Cypovirus Polyhedra R13A/E73C/Y83C Mutant
5YR1	;	1.72	;	Crystal Structure of Cypovirus Polyhedra R13A/E73C/Y83C/S193C/A194C Mutant
5YRA	;	1.79	;	Crystal Structure of Cypovirus Polyhedra R13A/S193C/A194C Mutant
5AXV	;	2.04	;	Crystal Structure of Cypovirus Polyhedra R13K Mutant
2H4E	;	1.45	;	Crystal structure of Cys10 sulfonated transthyretin
1GLO	;	2.2	;	Crystal Structure of Cys25Ser mutant of human cathepsin S
2HGX	;	1.8	;	Crystal structure of Cys315Ala mutant of human mitochondrial branched chain aminotransferase
2HG8	;	1.8	;	Crystal Structure of Cys315Ala mutant of human mitochondrial branched chain aminotransferase complexed with its substrate mimic, N-methyl leucine.
2HDK	;	2.4	;	Crystal Structure of Cys315Ala-Cys318Ala Mutant of Human Mitochondrial Branched Chain Aminotransferase
2HGW	;	1.98	;	Crystal structure of Cys318Ala mutant of human mitochondrial branched chain aminotransferase
3B8B	;	1.7	;	Crystal structure of CysQ from Bacteroides thetaiotaomicron, a bacterial member of the inositol monophosphatase family
1C7N	;	1.9	;	CRYSTAL STRUCTURE OF CYSTALYSIN FROM TREPONEMA DENTICOLA CONTAINS A PYRIDOXAL 5'-PHOSPHATE COFACTOR
1C7O	;	2.5	;	CRYSTAL STRUCTURE OF CYSTALYSIN FROM TREPONEMA DENTICOLA CONTAINS A PYRIDOXAL 5'-PHOSPHATE-L-AMINOETHOXYVINYLGLYCINE COMPLEX
8SA7	;	1.4	;	Crystal Structure of Cystathionine beta lyase from Klebsiella aerogenes (C2 form)
8SAC	;	1.8	;	Crystal Structure of Cystathionine beta lyase from Klebsiella aerogenes (P21212 form)
8U98	;	1.4	;	Crystal Structure of Cystathionine beta lyase from Klebsiella aerogenes (PLP-Glycine adduct)
8U99	;	1.8	;	Crystal Structure of Cystathionine beta lyase from Klebsiella aerogenes (PLP-Serine adduct)
8SA8	;	1.3	;	Crystal Structure of Cystathionine beta lyase from Klebsiella aerogenes, Covalently bound and free PLP (I2 form)
8SAB	;	1.6	;	Crystal Structure of Cystathionine beta lyase from Klebsiella aerogenes, PLP adduct with Alanine (C2 form)
8SAE	;	1.5	;	Crystal Structure of Cystathionine beta lyase from Klebsiella aerogenes, PLP and Hepes bound (C2 form)
8SAA	;	1.45	;	Crystal Structure of Cystathionine beta lyase from Klebsiella aerogenes, PLP and phosphate bound (C2 form)
8SA9	;	1.1	;	Crystal Structure of Cystathionine beta lyase from Klebsiella aerogenes, PLP-Oxamate Adduct (C2 form)
8SAD	;	1.4	;	Crystal Structure of Cystathionine beta lyase from Klebsiella aerogenes, PLP/Malonate complex (C2 form)
6VJU	;	1.3	;	Crystal Structure of Cystathionine beta synthase from Legionella pneumophila with LLP, PLP, and homocysteine
1IBJ	;	2.3	;	Crystal structure of cystathionine beta-lyase from Arabidopsis thaliana
8DUY	;	1.9	;	Crystal structure of Cystathionine beta-lyase from Klebsiella pneumoniae
6CJB	;	1.75	;	Crystal structure of Cystathionine beta-lyase from Legionella pneumophila Philadelphia 1 covalently bound to Pyridoxal phosphate
6CJA	;	1.7	;	Crystal structure of Cystathionine beta-lyase from Legionella pneumophila Philadelphia 1 in complex with Alanyl-PLP and Serine
5XW3	;	2.17	;	Crystal structure of cystathionine beta-synthase from Bacillus anthracis
5B1H	;	2.4	;	Crystal structure of cystathionine beta-synthase from Lactobacillus plantarum
4IY7	;	1.7	;	crystal structure of cystathionine gamma lyase (XometC) from Xanthomonas oryzae pv. oryzae in complex with E-site serine, A-site external aldimine structure with serine and A-site external aldimine structure with aminoacrylate intermediates
4IYO	;	1.8	;	Crystal structure of cystathionine gamma lyase from Xanthomonas oryzae pv. oryzae (XometC) in complex with E-site serine, A-site serine, A-site external aldimine structure with aminoacrylate and A-site iminopropionate intermediates
6LD8	;	2.31	;	Crystal structure of cystathionine gamma synthase from Xanthomonas oryzae pv. oryzae in complex with aminoacrylate and cysteine
6LD9	;	2.5	;	Crystal structure of cystathionine gamma synthase from Xanthomonas oryzae pv. oryzae in complex with cystathionine
6LGO	;	2.39	;	Crystal structure of cystathionine gamma synthase from Xanthomonas oryzae pv. oryzae in complex with homolanthionine
7D7O	;	1.98	;	Crystal structure of cystathionine gamma-lyase from Bacillus cereus ATCC 14579
6LE4	;	3.1	;	Crystal structure of cystathionine gamma-lyase from Lactobacillus plantarum complexed with cystathionine
6LDO	;	2.75	;	Crystal structure of cystathionine gamma-lyase from Lactobacillus plantarum complexed with L-serine
7NL1	;	2.331	;	Crystal structure of cystathionine gamma-lyase from Toxoplasma gondii
8BIS	;	2.266	;	Crystal structure of cystathionine gamma-lyase from Toxoplasma gondii in complex with DL-propargylglycine
1N8P	;	2.6	;	Crystal Structure of cystathionine gamma-lyase from yeast
8J6N	;	1.9	;	Crystal structure of Cystathionine gamma-lyase in complex with compound 1
3QI6	;	1.91	;	Crystal Structure of Cystathionine gamma-synthase MetB (Cgs) from Mycobacterium ulcerans Agy99
3QHX	;	1.65	;	Crystal Structure of Cystathionine gamma-synthase MetB (Cgs) from Mycobacterium ulcerans Agy99 bound to HEPES
7YEO	;	1.7	;	Crystal Structure of cystathionine gamma-synthase-like protein C23A1.14c
5VPR	;	2.05	;	Crystal Structure of Cysteine desulfurase from Elizabethkingia anophelis with covalently bound pyridoxal phosphate
6C9E	;	1.55	;	Crystal structure of Cysteine desulfurase from Legionella pneumophila Philadelphia 1
7MHV	;	1.75	;	Crystal Structure of Cysteine desulfurase NifS from Legionella pneumophila Philadelphia 1 in complex with pyridoxal 5'-phosphate
7E6A	;	1.96	;	Crystal structure of cysteine desulfurase SufS C361A from Bacillus subtilis
7CEQ	;	2.0	;	Crystal structure of cysteine desulfurase SufS H121A from Bacillus subtilis
7E6D	;	2.67	;	Crystal structure of cysteine desulfurase SufS R376A from Bacillus subtilis
3G0M	;	1.76	;	Crystal structure of cysteine desulfuration protein SufE from Salmonella typhimurium LT2
3USS	;	2.7	;	Crystal structure of Cysteine dioxygenase from Pseudomonas aeruginosa
3IRV	;	1.6	;	CRYSTAL STRUCTURE OF CYSTEINE HYDROLASE PSPPH_2384 FROM Pseudomonas syringae pv. phaseolicola 1448A
3KW0	;	2.5	;	Crystal structure of Cysteine peptidase (NP_982244.1) from BACILLUS CEREUS ATCC 10987 at 2.50 A resolution
3U8E	;	1.31	;	Crystal Structure of Cysteine Protease from Bulbs of Crocus sativus at 1.3 A Resolution
1AYW	;	2.4	;	CRYSTAL STRUCTURE OF CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT BENZYLOXYBENZOYLCARBOHYDRAZIDE INHIBITOR
1BGO	;	2.3	;	CRYSTAL STRUCTURE OF CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT PEPTIDOMIMETIC INHIBITOR
1AYU	;	2.2	;	CRYSTAL STRUCTURE OF CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT SYMMETRIC BISCARBOHYDRAZIDE INHIBITOR
1AYV	;	2.3	;	CRYSTAL STRUCTURE OF CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT THIAZOLHYDRAZIDE INHIBITOR
2NQD	;	1.75	;	Crystal structure of cysteine protease inhibitor, chagasin, in complex with human cathepsin L
4R9I	;	1.65	;	Crystal structure of cysteine proteinase inhibitor Serpin18 from Bombyx mori
2PQM	;	1.86	;	Crystal structure of Cysteine Synthase (OASS) from Entamoeba histolytica at 1.86 A resolution
2BHS	;	2.67	;	Crystal Structure of Cysteine Synthase B
6N43	;	2.289	;	Crystal structure of cysteine, nitric oxide-bound ferrous form of the crosslinked human cysteine dioxygenase in the anaerobic condition
6BPR	;	1.96	;	Crystal structure of cysteine, nitric oxide-bound ferrous form of the uncrosslinked F2-Tyr157 human cysteine dioxygenase
1XT8	;	2.0	;	Crystal Structure of Cysteine-Binding Protein from Campylobacter jejuni at 2.0 A Resolution
6CDN	;	2.055	;	Crystal structure of cysteine-bound ferrous form of the crosslinked Cl-Tyr157 human cysteine dioxygenase
6BGF	;	2.251	;	Crystal structure of cysteine-bound ferrous form of the crosslinked human cysteine dioxygenase
6N42	;	2.199	;	Crystal structure of cysteine-bound ferrous form of the crosslinked human cysteine dioxygenase in the anaerobic condition
6BPX	;	2.15	;	Crystal structure of cysteine-bound ferrous form of the matured Cl2-Tyr157 human cysteine dioxygenase
6BPV	;	1.95	;	Crystal structure of cysteine-bound ferrous form of the matured F2-Tyr157 human cysteine dioxygenase
6BPS	;	2.1	;	Crystal structure of cysteine-bound ferrous form of the uncrosslinked F2-Tyr157 human cysteine dioxygenase
6UJD	;	2.6	;	Crystal structure of Cysteine-tRNA ligase from Elizabethkingia sp.
6RZ4	;	2.7	;	Crystal structure of cysteinyl leukotriene receptor 1 in complex with pranlukast
1LI5	;	2.3	;	Crystal Structure of Cysteinyl-tRNA Synthetase
3SP1	;	2.55	;	Crystal structure of cysteinyl-tRNA synthetase (cysS) from Borrelia burgdorferi
1U0B	;	2.3	;	Crystal structure of cysteinyl-tRNA synthetase binary complex with tRNACys
1LI7	;	2.6	;	Crystal Structure of Cysteinyl-tRNA Synthetase with Cysteine Substrate Bound
1DBX	;	1.8	;	Crystal structure of cysteinyl-tRNA(Pro) deacylase from H. influenzae (HI1434)
1DBU	;	1.8	;	Crystal structure of cysteinyl-tRNA(Pro) deacylase protein from H. influenzae (HI1434)
4FF9	;	2.5003	;	Crystal Structure of cysteinylated WT SOD1.
7ZK1	;	2.65	;	Crystal structure of cystinosin from Arabidopsis thaliana bound to sybody and nanobody
7ZKZ	;	2.329	;	Crystal structure of cystinosin from Arabidopsis thaliana bound to two nanobodies
7ZKW	;	3.372	;	Crystal structure of cystinosin from Arabidopsis thaliana in complex with Cystine and sybody
4F3W	;	1.8	;	Crystal structure of cytidine deaminase Cdd from Mycobacterium marinum
2D30	;	2.4	;	Crystal Structure of Cytidine Deaminase Cdd-2 (BA4525) from Bacillus Anthracis at 2.40A Resolution
1ALN	;	2.3	;	CRYSTAL STRUCTURE OF CYTIDINE DEAMINASE COMPLEXED WITH 3-DEAZACYTIDINE
1AF2	;	2.3	;	CRYSTAL STRUCTURE OF CYTIDINE DEAMINASE COMPLEXED WITH URIDINE
1JTK	;	2.04	;	Crystal structure of cytidine deaminase from Bacillus subtilis in complex with the inhibitor tetrahydrodeoxyuridine
3R2N	;	2.3	;	Crystal structure of cytidine deaminase from Mycobacterium leprae
3MPZ	;	1.7	;	Crystal structure of CYTIDINE DEAMINASE from Mycobacterium smegmatis
3IJF	;	1.99	;	Crystal structure of cytidine deaminase from Mycobacterium tuberculosis
6KW6	;	1.895	;	Crystal Structure of cytidine deaminase from Streptomyces noursei
5JNH	;	2.202	;	Crystal Structure of cytidine monophosphate hydroxymethylase MilA
5B6D	;	1.65	;	Crystal Structure of cytidine monophosphate hydroxymethylase MilA with CMP
5JP9	;	2.101	;	Crystal Structure of cytidine monophosphate hydroxymethylase MilA with dCMP
5B6E	;	1.8	;	Crystal Structure of cytidine monophosphate hydroxymethylase MilA with hmCMP
3R8C	;	2.2	;	Crystal structure of cytidylate kinase (Cmk) from Mycobacterium abscessus
7L4A	;	1.5	;	Crystal Structure of Cytidylate kinase from Encephalitozoon cuniculi GB-M1 in complex with two CDP molecules
3R20	;	2.0	;	Crystal structure of cytidylate kinase from Mycobacterium smegmatis
3OAM	;	1.75	;	Crystal structure of cytidylyltransferase from Vibrio cholerae
7DUC	;	2.56	;	Crystal Structure of cyto WalK
3ME6	;	3.1	;	Crystal structure of cytochrome 2B4 in complex with the anti-platelet drug clopidogrel
3KW4	;	2.67	;	Crystal structure of cytochrome 2B4 in complex with the anti-platelet drug ticlopidine
6JT6	;	2.0	;	Crystal structure of cytochrome b domain of Pyranose Dehydrogenase from Coprinopsis cinerea
1X3X	;	1.8	;	Crystal Structure of Cytochrome b5 from Ascaris suum
4O6Y	;	1.7	;	Crystal Structure of Cytochrome b561
4ER9	;	1.897	;	Crystal structure of cytochrome b562 from Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S
1VF5	;	3.0	;	Crystal Structure of Cytochrome b6f Complex from M.laminosus
2D2C	;	3.8	;	Crystal Structure Of Cytochrome B6F Complex with DBMIB From M. Laminosus
4I7Z	;	2.803	;	Crystal structure of cytochrome b6f in DOPG, with disordered Rieske Iron-Sulfur Protein soluble domain
5LFT	;	1.249	;	Crystal structure of cytochrome c - Bromo-trisulfonatocalix[4]arene complexes
3TYI	;	1.399	;	Crystal Structure of Cytochrome c - p-Sulfonatocalix[4]arene Complexes
5KPF	;	1.698	;	Crystal structure of cytochrome c - Phenyl-trisulfonatocalix[4]arene complex
2B4Z	;	1.5	;	Crystal structure of cytochrome C from bovine heart at 1.5 A resolution.
7TLX	;	1.9	;	Crystal Structure of cytochrome c from Pseudomonas putida S16
6S8Y	;	2.09	;	Crystal structure of cytochrome c in complex with a sulfonated quinoline-derived foldamer
6EGZ	;	2.17	;	Crystal structure of cytochrome c in complex with di-PEGylated sulfonatocalix[4]arene
6EGY	;	2.7	;	Crystal structure of cytochrome c in complex with mono-PEGylated sulfonatocalix[4]arene
5NCV	;	1.5	;	Crystal Structure of Cytochrome c in complex with p-Methylphosphonatocalix[4]arene
6V0A	;	2.55	;	Crystal structure of cytochrome c nitrite reductase from the bacterium Geobacter lovleyi with bound sulfate
2VR0	;	2.8	;	Crystal structure of cytochrome c nitrite reductase NrfHA complex bound to the HQNO inhibitor
2J7A	;	2.3	;	Crystal structure of cytochrome c nitrite reductase NrfHA complex from Desulfovibrio vulgaris
4JMT	;	1.6	;	Crystal structure of Cytochrome C Peroxidase W191G-Gateless in complex with 1H-pyrrolo[3,2-b]pyridin-6-ylmethanol
4JN0	;	1.864	;	Crystal structure of Cytochrome C Peroxidase W191G-Gateless in complex with 1H-pyrrolo[3,2-b]pyridine-6-carbaldehyde
4JM6	;	1.45	;	Crystal structure of Cytochrome C Peroxidase W191G-Gateless in complex with 2,4-diaminopyrimidine
4JM8	;	1.3	;	Crystal structure of Cytochrome C Peroxidase W191G-Gateless in complex with 2,6-diaminopyridine
4JQK	;	1.36	;	Crystal structure of Cytochrome C Peroxidase W191G-Gateless in complex with 2-(2-aminopyridin-1-ium-1-yl)ethanol
4JM5	;	1.26	;	Crystal structure of Cytochrome C Peroxidase W191G-Gateless in complex with 2-Amino-5-methylthiazole
4JM9	;	1.41	;	Crystal structure of Cytochrome C Peroxidase W191G-Gateless in complex with 3-amino-1-methylpyridinium
4JMA	;	1.6	;	Crystal structure of Cytochrome C Peroxidase W191G-Gateless in complex with 3-Fluorocatechol
4JQM	;	1.41	;	Crystal structure of Cytochrome C Peroxidase W191G-Gateless in complex with 4-Aminoquinazoline
4JQJ	;	1.6	;	Crystal structure of Cytochrome C Peroxidase W191G-Gateless in complex with 4-Aminoquinoline
4JPL	;	1.41	;	Crystal structure of Cytochrome C Peroxidase W191G-Gateless in complex with 4-Azaindole
4JQN	;	1.36	;	Crystal structure of Cytochrome C Peroxidase W191G-Gateless in complex with 4-Hydroxybenzaldehyde
4JMB	;	1.3	;	Crystal structure of Cytochrome C Peroxidase W191G-Gateless in complex with 5,6,7,8-tetrahydrothieno[2,3-b]quinolin-4-amine
4JPU	;	1.41	;	Crystal structure of Cytochrome C Peroxidase W191G-Gateless in complex with Benzamidine
4JMS	;	1.75	;	Crystal structure of Cytochrome C Peroxidase W191G-Gateless in complex with imidazo[1,2-a]pyridin-5-amine
4JMV	;	1.82	;	Crystal structure of Cytochrome C Peroxidase W191G-Gateless in complex with imidazo[1,2-a]pyridin-6-amine
4JMZ	;	1.82	;	Crystal structure of Cytochrome C Peroxidase W191G-Gateless in complex with N-methyl-1H-benzimidazol-2-amine
4JMW	;	1.19	;	Crystal structure of Cytochrome C Peroxidase W191G-Gateless in complex with Phenol
4JPT	;	1.41	;	Crystal structure of Cytochrome C Peroxidase W191G-Gateless in complex with quinazoline-2,4-diamine
3EXB	;	1.6	;	Crystal structure of Cytochrome C Peroxidase with a Proposed Electron Pathway Excised in a Complex with a Peptide Wire
1KXM	;	1.74	;	Crystal structure of Cytochrome c Peroxidase with a Proposed Electron Transfer Pathway Excised to Form a Ligand Binding Channel.
1KXN	;	1.8	;	Crystal Structure of Cytochrome c Peroxidase with a Proposed Electron Transfer Pathway Excised to Form a Ligand Binding Channel.
3E2O	;	1.06	;	Crystal structure of cytochrome c peroxidase, N184R mutant
7S5O	;	1.8	;	Crystal structure of Cytochrome c' beta from Nitrosomonas europaea ATCC 19718
4WGY	;	1.48	;	Crystal Structure of Cytochrome c' from Alcaligenes xylosoxidans NCIMB 11015 at pH 10.4
4WGZ	;	1.11	;	Crystal Structure of Cytochrome c' from Alcaligenes xylosoxidans NCIMB 11015 at pH 6.0
1JAF	;	2.5	;	CRYSTAL STRUCTURE OF CYTOCHROME C' FROM RHODOCYCLUS GELATINOSUS AT 2.5 ANGSTOMS RESOLUTION
6A3K	;	1.71	;	Crystal structure of cytochrome c' from Shewanella benthica DB6705
6A3L	;	2.14	;	Crystal structure of cytochrome c' from Shewanella violacea DSS12
3VRC	;	1.0	;	Crystal structure of cytochrome c' from Thermochromatium tepidum
1VYD	;	2.3	;	Crystal structure of cytochrome C2 mutant G95E
2CY3	;	1.7	;	CRYSTAL STRUCTURE OF CYTOCHROME C3 FROM DESULFOVIBRIO DESULFURICANS NORWAY AT 1.7 ANGSTROMS RESOLUTION
1ETP	;	2.2	;	CRYSTAL STRUCTURE OF CYTOCHROME C4 FROM PSEUDOMONAS STUTZERI
1F1C	;	2.3	;	CRYSTAL STRUCTURE OF CYTOCHROME C549
1MZ4	;	1.8	;	Crystal Structure of Cytochrome c550 from Thermosynechococcus elongatus
6KQ1	;	1.57	;	Crystal structure of cytochrome c551 from Pseudomonas sp. strain MT-1.
3VNW	;	1.97	;	Crystal structure of cytochrome c552 from Thermus thermophilus at pH 5.44
2ZZS	;	1.8	;	Crystal structure of cytochrome c554 from Vibrio parahaemolyticus strain RIMD2210633
2ZXY	;	1.15	;	Crystal Structure of Cytochrome c555 from Aquifex aeolicus
1CTJ	;	1.1	;	CRYSTAL STRUCTURE OF CYTOCHROME C6
1F1F	;	2.7	;	CRYSTAL STRUCTURE OF CYTOCHROME C6 FROM ARTHROSPIRA MAXIMA
1GDV	;	1.57	;	CRYSTAL STRUCTURE OF CYTOCHROME C6 FROM RED ALGA PORPHYRA YEZOENSIS AT 1.57 A RESOLUTION
4EID	;	1.13	;	Crystal structure of cytochrome c6 Q57V mutant from Synechococcus sp. PCC 7002
4KMG	;	1.4	;	Crystal structure of cytochrome c6B from Synechococcus sp. WH8102
4EIE	;	1.03	;	Crystal structure of cytochrome c6C from Synechococcus sp. PCC 7002
4EIF	;	1.04	;	Crystal structure of cytochrome c6C L50Q mutant from Synechococcus sp. PCC 7002
2D0W	;	1.98	;	Crystal structure of cytochrome cL from Hyphomicrobium denitrificans
7C90	;	2.13	;	Crystal structure of Cytochrome CL from the marine methylotrophic bacterium Methylophaga aminisulfidivorans MPT (Ma-CytcL)
8GTL	;	3.2	;	Crystal Structure of Cytochrome P450 (CYP101D5)
3DBG	;	2.6	;	Crystal structure of Cytochrome P450 170A1 (CYP170A1) from Streptomyces coelicolor
7WZL	;	2.27	;	Crystal structure of Cytochrome P450 184A1 from streptomyces avermitilis
7WZM	;	1.68	;	Crystal structure of Cytochrome P450 184A1 from streptomyces avermitilis in complex with Oleic acid
5E58	;	2.4	;	Crystal Structure Of Cytochrome P450 2B35 from Desert Woodrat Neotoma Lepida in complex with 4-(4-chlorophenyl)imidazole
5E0E	;	3.4	;	Crystal Structure of Cytochrome P450 2B37 from Desert Woodrat in complex with 4-(4-chlorophenyl)imidazole
4MGJ	;	2.41	;	Crystal structure of cytochrome P450 2B4 F429H in complex with 4-CPI
3MVR	;	1.76	;	Crystal Structure of cytochrome P450 2B4-H226Y in a closed conformation
4I91	;	2.0	;	Crystal Structure of Cytochrome P450 2B6 (Y226H/K262R) in complex with alpha-Pinene.
5A1R	;	2.45	;	Crystal structure of cytochrome P450 3A4 bound to progesterone
5A1P	;	2.5	;	Crystal structure of cytochrome P450 3A4 bound to progesterone and citrate
7SHI	;	2.00003	;	Crystal Structure of Cytochrome P450 AmphL from Streptomyces nodosus and the Structural Basis for Substrate Selectivity in Macrolide Metabolizing P450s
8TWU	;	1.84	;	Crystal structure of Cytochrome P450 AspB bound to N1-methylated cyclo-L-Trp-L-Pro
4KPA	;	2.0	;	Crystal structure of cytochrome P450 BM-3 in complex with N-palmitoylglycine (NPG)
4KPB	;	2.1	;	Crystal structure of cytochrome P450 BM-3 R47E mutant
5JQU	;	2.162	;	Crystal structure of Cytochrome P450 BM3 heme domain G265F/T269V/L272W/L322I/F405M/A406S (WIVS-FM) variant with iron(III) deuteroporphyrin IX bound
5JQV	;	2.34	;	Crystal structure of Cytochrome P450 BM3 heme domain T269V/L272W/L322I/A406S (WIVS) variant with iron(III) deuteroporphyrin IX bound
8JNQ	;	2.0	;	Crystal structure of cytochrome P450 CftA from Streptomyces torulosus NRRL B-3889, in complex with a substrate compound c
8JNP	;	2.0	;	Crystal structure of cytochrome P450 CftA from Streptomyces torulosus NRRL B-3889, in complex with the substrate ikarugamycin
3OFT	;	1.9	;	Crystal Structure of Cytochrome P450 CYP101C1
3OFU	;	2.8	;	Crystal Structure of Cytochrome P450 CYP101C1
3LXH	;	2.2	;	Crystal Structure of Cytochrome P450 CYP101D1
3NV5	;	2.41	;	Crystal Structure of Cytochrome P450 CYP101D2
4WPZ	;	2.1	;	Crystal structure of cytochrome P450 CYP107W1 from Streptomyces avermitilis
4WQ0	;	2.7	;	Crystal structure of cytochrome P450 CYP107W1 from Streptomyces avermitilis in complex with Oligomycin A
3MZS	;	2.5	;	Crystal Structure of Cytochrome P450 CYP11A1 in complex with 22-hydroxy-cholesterol
3CXX	;	1.9	;	Crystal structure of cytochrome P450 CYP121 F338H from M. tuberculosis
3CXZ	;	1.08	;	Crystal structure of cytochrome P450 CYP121 R386L mutant from M. tuberculosis
3CY0	;	1.9	;	Crystal structure of cytochrome P450 CYP121 S237A mutant from Mycobacterium tuberculosis
2IJ5	;	1.6	;	Crystal structure of cytochrome P450 CYP121, P212121 space group
2FR7	;	2.01	;	Crystal Structure of Cytochrome P450 CYP199A2
6F8A	;	1.35	;	Crystal structure of cytochrome P450 CYP260A1 (S276I) bound with histidine
6F8C	;	1.9	;	Crystal structure of cytochrome P450 CYP260A1 (S276I) bound with progesterone
6F85	;	2.05	;	Crystal structure of cytochrome P450 CYP260A1 (S276N) bound with histidine
6F88	;	1.75	;	Crystal structure of cytochrome P450 CYP260A1 (S276N) bound with progesterone
6GK5	;	1.6	;	Crystal structure of cytochrome P450 CYP267B1 from Sorangium cellulosum So ce56
7UOR	;	3.16	;	Crystal structure of cytochrome P450 enzyme CYP119 in complex with methyliridium(III) mesoporphyrin.
8JNO	;	2.0	;	Crystal structure of cytochrome P450 IkaD from Streptomyces sp. ZJ306, in complex with the substrate 10-epi-deOH-HSAF
8JNC	;	2.0	;	Crystal structure of cytochrome P450 IkaD from Streptomyces sp. ZJ306, in complex with the substrate 10-epi-maltophilin
8JOO	;	2.25	;	Crystal structure of cytochrome P450 IkaD from Streptomyces sp. ZJ306, in complex with the substrate ikarugamycin
2Z36	;	2.8	;	Crystal structure of cytochrome P450 MoxA from Nonomuraea recticatena (CYP105)
8HNY	;	2.1	;	Crystal structure of cytochrome P450 NasF5053 mutant E73S complexed with 5FCWP
8HNZ	;	1.5	;	Crystal structure of cytochrome P450 NasF5053 mutant E73S complexed with 6FCWP
8HO0	;	1.71	;	Crystal structure of cytochrome P450 NasF5053 mutant E73S complexed with 8FCWP
8HO1	;	2.0	;	Crystal structure of cytochrome P450 NasF5053 mutant F387G
6VZA	;	1.47	;	Crystal structure of cytochrome P450 NasF5053 Q65I-A86G mutant variant from Streptomyces sp. NRRL F-5053 in the cyclo-L-Trp-L-Pro-bound state
6VZB	;	1.68	;	Crystal structure of cytochrome P450 NasF5053 S284A-V288A mutant variant from Streptomyces sp. NRRL F-5053 in the cyclo-L-Trp-L-Pro-bound state
5M0P	;	1.95	;	Crystal structure of cytochrome P450 OleT F79A in complex with arachidonic acid
5M0O	;	1.8	;	Crystal structure of cytochrome P450 OleT H85Q in complex with arachidonic acid
5M0N	;	1.44	;	Crystal structure of cytochrome P450 OleT in complex with formate
7XBM	;	2.4	;	Crystal Structure of cytochrome P450 PikC with the unnatural amino acid p-Acetyl-L-Phenylalanine incorporated at position 238
7OQ6	;	2.0	;	Crystal structure of cytochrome P450 Sas16 from Streptomyces asterosporus
1RF9	;	1.8	;	Crystal structure of cytochrome P450-cam with a fluorescent probe D-4-AD (Adamantane-1-carboxylic acid-5-dimethylamino-naphthalene-1-sulfonylamino-butyl-amide)
1LWL	;	2.2	;	Crystal Structure of Cytochrome P450-cam with a Fluorescent Probe D-8-Ad (Adamantane-1-carboxylic acid-5-dimethylamino-naphthalene-1-sulfonylamino-octyl-amide)
1RE9	;	1.45	;	CRYSTAL STRUCTURE OF CYTOCHROME P450-CAM WITH A FLUORESCENT PROBE D-8-AD (ADAMANTANE-1-CARBOXYLIC ACID-5-DIMETHYLAMINO-NAPHTHALENE-1-SULFONYLAMINO-OCTYL-AMIDE)
3P6V	;	2.0	;	Crystal Structure of Cytochrome P450cam crystallized in the presence of a tethered substrate analog 3Et-AdaC1-Etg-Boc
3P6R	;	2.1	;	Crystal Structure of Cytochrome P450cam crystallized in the presence of a tethered substrate analog 3OH-AdaC1-Etg-Boc
3P6P	;	1.9	;	Crystal Structure of Cytochrome P450cam crystallized in the presence of a tethered substrate analog AdaC1-C6-Bio
3P6M	;	2.0	;	Crystal Structure of Cytochrome P450cam crystallized in the presence of a tethered substrate analog AdaC1-C8-Dans
3P6N	;	1.7	;	Crystal Structure of Cytochrome P450cam crystallized in the presence of a tethered substrate analog AdaC1-C8-Dans
3OIA	;	1.65	;	Crystal Structure of Cytochrome P450cam crystallized in the presence of a tethered substrate analog AdaC1-C8GluEtg-Bio
3P6O	;	2.0	;	Crystal Structure of Cytochrome P450cam crystallized in the presence of a tethered substrate analog AdaC1-Etg-Dans
3P6S	;	2.0	;	Crystal Structure of Cytochrome P450cam crystallized in the presence of a tethered substrate analog AdaC2-C8-Dans
3P6T	;	1.9	;	Crystal Structure of Cytochrome P450cam crystallized in the presence of a tethered substrate analog AdaC2-C8-Dans
3P6Q	;	1.95	;	Crystal Structure of Cytochrome P450cam crystallized in the presence of a tethered substrate analog AdaC2-Etg-Boc
3P6U	;	1.7	;	Crystal Structure of Cytochrome P450cam crystallized in the presence of a tethered substrate analog AdaC3-C6-Dans
3P6X	;	1.65	;	Crystal Structure of Cytochrome P450cam crystallized in the presence of a tethered substrate analog AdaC3-C8-Dans
3P6W	;	2.1	;	Crystal Structure of Cytochrome P450cam crystallized in the presence of a tethered substrate analog AdaC3-Etg-Boc
3OL5	;	1.75	;	Crystal Structure of Cytochrome P450cam crystallized with a tethered substrate analog 3OH-AdaC1-C8-Dans
1P2Y	;	2.3	;	CRYSTAL STRUCTURE OF CYTOCHROME P450CAM IN COMPLEX WITH (S)-(-)-NICOTINE
1C8J	;	2.1	;	CRYSTAL STRUCTURE OF CYTOCHROME P450CAM MUTANT (F87W/Y96F)
2GR6	;	2.3	;	Crystal structure of cytochrome p450cam mutant (f87w/y96f/l244a/v247l/c334a)
2GQX	;	2.1	;	Crystal structure of cytochrome p450cam mutant (f87w/y96f/l244a/v247l/c334a) with pentachlorobenzene
2FRZ	;	2.1	;	Crystal Structure of Cytochrome P450cam mutant (F87W/Y96F/V247L/C334A)
1J51	;	2.2	;	CRYSTAL STRUCTURE OF CYTOCHROME P450CAM MUTANT (F87W/Y96F/V247L/C334A) WITH 1,3,5-TRICHLOROBENZENE
4JWS	;	2.15	;	Crystal structure of Cytochrome P450cam-putidaredoxin complex
4JWU	;	2.2	;	Crystal structure of Cytochrome P450cam-putidaredoxin complex
1T2B	;	1.7	;	Crystal Structure of cytochrome P450cin complexed with its substrate 1,8-cineole
7F3H	;	2.5	;	Crystal structure of cytochrome P450DA heme domain
7F3W	;	2.86	;	Crystal structure of cytochrome P450DA mutant (N190F/V356L/A486E) heme domain
6KZS	;	1.601	;	Crystal structure of cytochrome P450mel 107F1 in complex with heme and imidazole
6KZT	;	3.5	;	Crystal structure of cytochrome P450mel 107F1 with biaryl coupling reactivity
3WVS	;	1.4	;	Crystal Structure of Cytochrome P450revI
1URV	;	2.0	;	Crystal structure of cytoglobin: the fourth globin type discovered in man displays heme hexa-coordination
1UT0	;	2.1	;	CRYSTAL STRUCTURE OF CYTOGLOBIN: THE FOURTH GLOBIN TYPE DISCOVERED IN MAN DISPLAYS HEME HEXA-COORDINATION
2FLH	;	1.2	;	Crystal structure of cytokinin-specific binding protein from mung bean in complex with cytokinin
3C0V	;	1.8	;	Crystal structure of cytokinin-specific binding protein in complex with cytokinin and Ta6Br12
2F2F	;	2.4	;	Crystal structure of cytolethal distending toxin (CDT) from Actinobacillus actinomycetemcomitans
1LAY	;	2.5	;	CRYSTAL STRUCTURE OF CYTOMEGALOVIRUS PROTEASE
1YYP	;	2.5	;	Crystal structure of cytomegalovirus UL44 bound to C-terminal peptide from CMV UL54
3B0Z	;	2.45	;	Crystal structure of cytoplasmic domain of FlhB from Salmonella typhimurium
1U4E	;	2.09	;	Crystal Structure of Cytoplasmic Domains of GIRK1 channel
1U4F	;	2.41	;	Crystal Structure of Cytoplasmic Domains of IRK1 (Kir2.1) channel
4IMH	;	1.976	;	Crystal Structure of Cytoplasmic Heme Binding Protein, PhuS, from Pseudomonas aeruginosa
3L8P	;	2.4	;	Crystal structure of cytoplasmic kinase domain of Tie2 complexed with inhibitor CEP11207
6IU8	;	2.7	;	Crystal structure of cytoplasmic metal binding domain with cobalt ions
6IU9	;	3.0	;	Crystal structure of cytoplasmic metal binding domain with iron ions
6IU6	;	2.9	;	Crystal structure of cytoplasmic metal binding domain with nickel ions
6IU5	;	2.25	;	Crystal structure of cytoplasmic metal binding domain with zinc ions
6BLJ	;	2.1	;	Crystal structure of cytoplasmic Serine-tRNA ligase from Naegleria fowleri in complex with AMP
7V03	;	1.78	;	Crystal structure of cytoplasmic triosephosphate isomerase from Cuscuta australis
1FBK	;	3.2	;	CRYSTAL STRUCTURE OF CYTOPLASMICALLY OPEN CONFORMATION OF BACTERIORHODOPSIN
3R0D	;	1.501	;	Crystal structure of Cytosine Deaminase from Escherichia Coli complexed with two zinc atoms in the active site
3RN6	;	2.255	;	Crystal structure of Cytosine Deaminase from Escherichia Coli complexed with zinc and isoguanine
3O7U	;	1.708	;	Crystal structure of Cytosine Deaminase from Escherichia Coli complexed with zinc and phosphono-cytosine
3PEI	;	2.7	;	Crystal Structure of Cytosol Aminopeptidase from Francisella tularensis
3KZW	;	2.7	;	Crystal structure of cytosol aminopeptidase from Staphylococcus aureus COL
4NV0	;	1.65	;	Crystal structure of cytosolic 5'-nucleotidase IIIB (cN-IIIB) bound to 7-methylguanosine
4NWI	;	2.05	;	Crystal structure of cytosolic 5'-nucleotidase IIIB (cN-IIIB) bound to cytidine
6UNZ	;	3.195	;	Crystal structure of cytosolic fumarate hydratase from Leishmania major
6MSN	;	1.591	;	Crystal structure of cytosolic fumarate hydratase from Leishmania major in a complex with inhibitor thiomalate
6UOI	;	1.953	;	Crystal structure of cytosolic fumarate hydratase from Leishmania major in a complex with malonate
6UO0	;	1.85	;	Crystal structure of cytosolic fumarate hydratase from Leishmania major in a complex with S-malate
6UOJ	;	2.35	;	Crystal structure of cytosolic fumarate hydratase from Leishmania major in a complex with succinate
7MPY	;	2.3	;	Crystal structure of cytosolic HPPK-DHPS from A.thaliana
4G63	;	2.7	;	Crystal structure of cytosolic IMP-GMP specific 5'-nucleotidase (lpg0095) in complex with phosphate ions from Legionella pneumophila, Northeast Structural Genomics Consortium Target LgR1
3QVN	;	2.6	;	Crystal Structure of cytosolic MnSOD3 from Candida albicans
4OHF	;	2.53	;	Crystal structure of cytosolic nucleotidase II (LPG0095) in complex with GMP from Legionella pneumophila, NORTHEAST STRUCTURAL GENOMICS CONSORTIUM TARGET LGR1
7QHI	;	2.302	;	Crystal structure of cytotoxin 13 from Naja naja, hexagonal form
7QFC	;	2.6	;	Crystal structure of cytotoxin 13 from Naja naja, orthorhombic form
3HVN	;	2.852	;	Crystal structure of cytotoxin protein suilysin from Streptococcus suis
2A2T	;	3.1	;	crystal structure of d(AAATATTT)
1BQJ	;	2.2	;	CRYSTAL STRUCTURE OF D(ACCCT)
1CN0	;	2.2	;	CRYSTAL STRUCTURE OF D(ACCCT)
3G2R	;	2.15	;	Crystal structure of d(CACGCG).d(CGCGTG) cocrystallized with MnCl2
3G2A	;	2.0	;	Crystal structure of d(CACGCG).d(CGCGTG) grown in presence of 1mM MnCl2
3FQ5	;	2.8	;	Crystal Structure of d(CACGCG).d(CGCGTG) with 10mM MnCl2
2F8W	;	1.2	;	Crystal structure of d(CACGTG)2
4OKL	;	1.65	;	Crystal Structure of d(CCCCGGTACCGGGG)2 at 1.65 Angstrom
4EZ2	;	1.6	;	Crystal Structure of d(CCGGGACCGG)4 as a four-way junction at 1.6 angstrom resolution
8ASH	;	1.837	;	Crystal structure of d(CCGGGGTACCCCGG) with XRB
5WV7	;	1.406	;	Crystal structure of d(CCGGGGTACCCCGG)2 at 1.4A resolution
3IXN	;	2.87	;	Crystal structure of d(CCGGTACCGG) as B-DNA duplex
3R86	;	2.8	;	Crystal structure of d(CCGGTACCGG)2 as B-DNA duplex grown with 5 mM CoCl2
1PRP	;	2.1	;	CRYSTAL STRUCTURE OF D(CGCGAATTCGCG) COMPLEXED WITH PROPAMIDINE, A SHORT-CHAIN HOMOLOGUE OF THE DRUG PENTAMIDIN
4U8B	;	1.31	;	Crystal structure of D(CGCGAATTCGCG)2 complexed with BPH-1358
4U8C	;	1.24	;	Crystal structure of D(CGCGAATTCGCG)2 complexed with BPH-1409
4U8A	;	1.48	;	Crystal structure of D(CGCGAATTCGCG)2 complexed with BPH-1503
2DP7	;	1.55	;	Crystal Structure of D(CGCGAATXCGCG) Where X is 5-(N-aminohexyl)carbamoyl-2'-deoxyuridine
2DPB	;	1.5	;	Crystal Structure of d(CGCGAATXCGCG) Where X is 5-(N-aminohexyl)carbamoyl-2'-deoxyuridine
2DPC	;	1.55	;	Crystal Structure of d(CGCGAATXCGCG) Where X is 5-(N-aminohexyl)carbamoyl-2'-O-methyluridine
3AJJ	;	3.02	;	Crystal Structure of d(CGCGGATf5UCGCG): 5-Formyluridine/Guanosine Base-pair in B-DNA
3AJL	;	2.7	;	Crystal structure of d(CGCGGATf5UCGCG): 5-Formyluridine:guanosine Base-pair in B-DNA with DAPI
3AJK	;	1.95	;	Crystal structure of d(CGCGGATf5UCGCG): 5-Formyluridine:Guanosine Base-pair in B-DNA with Hoechst33258
3QK4	;	2.6	;	Crystal structure of d(CGCGGGTACCCGCG)2 as A-DNA duplex
3T8P	;	2.35	;	Crystal structure of d(CGGGTACCCG)4 as a four-way Holliday junction
2DQO	;	2.3	;	Crystal Structure of d(CXCTXCTTC):r(gaagaagag) Where X is 5-(N-aminohexyl)carbamoyl-2'-O-methyluridine
2DQQ	;	2.0	;	Crystal Structure of d(CXCTXCTTC):r(gaagaagag) Where X is 5-(N-aminohexyl)carbamoyl-2'-O-methyluridine
7ECF	;	1.6	;	Crystal Structure of d(G4C2)2-Ba in C2221 space group
7ECG	;	1.97	;	Crystal Structure of d(G4C2)2-Ba in F222 space group
7ECH	;	2.38	;	Crystal Structure of d(G4C2)2-K in F222 space group
2GWQ	;	2.0	;	Crystal structure of D(G4T4G4) with four quadruplexes in the asymmetric unit.
2GWE	;	2.2	;	Crystal structure of D(G4T4G4) with six quadruplexes in the asymmetric unit.
1UE2	;	1.4	;	Crystal structure of d(GC38GAAAGCT)
8ASK	;	2.955	;	Crystal structure of d(GCCCACCACGGC)
1UE4	;	1.65	;	Crystal structure of d(GCGAAAGC)
1UE3	;	2.15	;	Crystal structure of d(GCGAAAGC) containing hexaamminecobalt
1IXJ	;	2.5	;	Crystal Structure of d(GCGAAAGCT) Containing Parallel-stranded Duplex with Homo Base Pairs and Anti-Parallel Duplex with Watson-Crick Base pairs
2GOT	;	2.602	;	Crystal structure of d(GCGAACGC): two types of bulge-containing duplexes
1UB8	;	1.6	;	Crystal structure of d(GCGAAGC), bending duplex with a bulge-in residue
1UHX	;	2.0	;	Crystal structure of d(GCGAGAGC): the base-intercalated duplex
1V3P	;	2.3	;	Crystal structure of d(GCGAGAGC): the DNA octaplex structure with I-motif of G-quartet
1V3N	;	1.8	;	Crystal structure of d(GCGAGAGC): the DNA quadruplex structure split from the octaplex
1V3O	;	1.7	;	Crystal structure of d(GCGAGAGC): the DNA quadruplex structure split from the octaplex
1UHY	;	1.7	;	Crystal structure of d(GCGATAGC): the base-intercalated duplex
331D	;	1.65	;	CRYSTAL STRUCTURE OF D(GCGCGCG) WITH 5'-OVERHANG G'S
2FZA	;	3.6	;	Crystal structure of d(GCGGGAGC): the base-intercalated duplex
1VT8	;	1.9	;	Crystal structure of D(GGGCGCCC)-hexagonal form
5GUN	;	2.588	;	Crystal structure of d(GTGGAATGGAAC)
6L75	;	1.578	;	Crystal structure of d(GTGGGCCGAC)2 DNA duplex
4PNH	;	2.66	;	Crystal structure of D,D-heptose 1,7-bisphosphate phosphatase from Burkholderia Thailandensis
3L8H	;	1.68	;	Crystal Structure of D,D-heptose 1.7-bisphosphate phosphatase from B. bronchiseptica complexed with magnesium and phosphate
3L8G	;	2.18	;	Crystal Structure of D,D-heptose 1.7-bisphosphate phosphatase from E. Coli complexed with D-glycero-D-manno-heptose 1 ,7-bisphosphate
3L8F	;	1.79	;	Crystal Structure of D,D-heptose 1.7-bisphosphate phosphatase from E. Coli complexed with magnesium and phosphate
2GMW	;	1.5	;	Crystal Structure of D,D-heptose 1.7-bisphosphate phosphatase from E. Coli.
3ESR	;	1.95	;	Crystal Structure of D,D-heptose1.7-bisphosphate phosphatase from E. coli in complex with calcium and phosphate
4MNR	;	1.653	;	Crystal Structure of D,D-Transpeptidase Domain of Peptidoglycan Glycosyltransferase from Eggerthella lenta
3W8E	;	1.24	;	Crystal structure of D-3-hydroxybutyrate dehydrogenase from Alcaligenes faecalis complexed with NAD+ and a substrate D-3-hydroxybutyrate
5B4T	;	1.19	;	Crystal structure of D-3-hydroxybutyrate dehydrogenase from Alcaligenes faecalis complexed with NAD+ and a substrate D-3-hydroxybutyrate
3W8F	;	1.45	;	Crystal structure of D-3-hydroxybutyrate dehydrogenase from Alcaligenes faecalis complexed with NAD+ and an inhibitor malonate
5B4U	;	1.45	;	Crystal structure of D-3-hydroxybutyrate dehydrogenase from Alcaligenes faecalis complexed with NAD+ and an inhibitor malonate
3W8D	;	1.37	;	Crystal structure of D-3-hydroxybutyrate dehydrogenase from Alcaligenes faecalis complexed with NAD+ and an inhibitor methylmalonate
5B4V	;	1.5	;	Crystal structure of D-3-hydroxybutyrate dehydrogenase from Alcaligenes faecalis complexed with NAD+ and an inhibitor methylmalonate
1X1T	;	1.52	;	Crystal Structure of D-3-Hydroxybutyrate Dehydrogenase from Pseudomonas fragi Complexed with NAD+
3VDR	;	3.0	;	Crystal structure of D-3-hydroxybutyrate dehydrogenase, prepared in the presence of the substrate D-3-hydroxybutyrate and NAD(+)
1YGY	;	2.3	;	Crystal Structure of D-3-Phosphoglycerate dehydrogenase From Mycobacterium tuberculosis
1SKV	;	2.6	;	Crystal Structure of D-63 from Sulfolobus Spindle Virus 1
2YZG	;	2.3	;	Crystal structure of D-ALA:D-ALA Ligase from Thermus thermophilus HB8
5E2G	;	1.651	;	Crystal Structure of D-alanine Carboxypeptidase AmpC from Burkholderia cenocepacia
5E2H	;	1.8	;	Crystal Structure of D-alanine Carboxypeptidase AmpC from Mycobacterium smegmatis
3R23	;	2.5	;	Crystal Structure of D-alanine--D-Alanine Ligase from Bacillus anthracis
3R5X	;	2.0	;	Crystal Structure of D-alanine--D-Alanine Ligase from Bacillus anthracis complexed with ATP
4EG0	;	1.65	;	Crystal Structure of D-alanine--D-alanine ligase from Burkholderia ambifaria
7U56	;	1.85	;	Crystal Structure of D-alanine--D-alanine ligase from Klebsiella pneumoniae subsp. pneumoniae in complex with AMP
3RFC	;	2.1	;	Crystal structure of D-alanine-D-alanine ligase A from Xanthomonas oryzae pathovar oryzae with ADP
4ME6	;	2.1	;	Crystal structure of D-alanine-D-alanine ligase A from Xanthomonas oryzae pathovar oryzae with ADP
4EGQ	;	2.2	;	Crystal structure of D-alanine-D-alanine ligase B from Burkholderia pseudomallei
5D8D	;	2.19	;	Crystal structure of D-alanine-D-alanine ligase from Acinetobacter baumannii
5DMX	;	2.81	;	Crystal structure of D-alanine-D-alanine ligase from Acinetobacter baumannii, space group p212121
6LL9	;	2.7	;	Crystal structure of D-alanine-D-alanine ligase from Aeromonas hydrophila
4EGJ	;	2.3	;	Crystal structure of D-alanine-D-alanine ligase from Burkholderia xenovorans
2PVP	;	2.4	;	Crystal structure of D-Alanine-D-Alanine Ligase from Helicobacter pylori
3E5N	;	2.0	;	Crystal structure of D-alanine-D-alanine ligase from Xanthomonas oryzae pv. oryzae KACC10331
4L1K	;	2.3	;	Crystal structure of D-alanine-D-alnine ligase from Xanthomonas oryzae pv. oryzae with AMPPNP
3R5F	;	2.07	;	Crystal structure of D-alanine-D-alnine ligase from Xanthomonas oryzae pv. oryzae with ATP
2ZDH	;	1.9	;	Crystal structure of D-Alanine:D-Alanine Ligase with ADP and D-Alanine from Thermus thermophius HB8
2ZDG	;	2.2	;	Crystal structure of D-Alanine:D-Alanine Ligase with ADP from Thermus thermophius HB8
2YZN	;	2.6	;	Crystal structure of D-alanine:D-Alanine Ligase with AMPPNP from Thermus thermophilus HB8.
2ZDQ	;	2.3	;	Crystal structure of D-Alanine:D-Alanine Ligase with ATP and D-Alanine:D-Alanine from Thermus thermophius HB8
3BMA	;	2.24	;	Crystal structure of D-alanyl-lipoteichoic acid synthetase from Streptococcus pneumoniae R6
1RPJ	;	1.8	;	CRYSTAL STRUCTURE OF D-ALLOSE BINDING PROTEIN FROM ESCHERICHIA COLI
3HTV	;	1.95	;	Crystal structure of D-allose kinase (NP_418508.1) from ESCHERICHIA COLI K12 at 1.95 A resolution
7ERM	;	2.32	;	Crystal structure of D-allulose 3-epimerase from Agrobacterium sp. SUL3
7ERO	;	2.12	;	Crystal structure of D-allulose 3-epimerase with D-allulose from Agrobacterium sp. SUL3
7ERN	;	2.05	;	Crystal structure of D-allulose 3-epimerase with D-fructose from Agrobacterium sp. SUL3
3CT7	;	2.5	;	Crystal structure of D-allulose 6-phosphate 3-epimerase from Escherichia Coli K-12
3CTL	;	2.2	;	Crystal structure of D-Allulose 6-Phosphate 3-Epimerase from Escherichia coli K12 complexed with D-glucitol 6-phosphate and magnesium
8AYJ	;	1.75	;	Crystal structure of D-amino acid aminotransferase from Aminobacterium colombiens complexed with 3-aminooxypropionic acid
8AIE	;	1.9	;	Crystal structure of D-amino acid aminotransferase from Aminobacterium colombiense complexed with D-cycloserine
8AHR	;	1.9	;	Crystal structure of D-amino acid aminotransferase from Aminobacterium colombiense in holo form with PLP
8ONL	;	1.9	;	Crystal structure of D-amino acid aminotransferase from Aminobacterium colombiense point mutant E113A
8ONN	;	2.1	;	Crystal structure of D-amino acid aminotransferase from Aminobacterium colombiense point mutant E113A complexed with 3-aminooxypropionic acid
8ONM	;	1.85	;	Crystal structure of D-amino acid aminotransferase from Aminobacterium colombiense point mutant E113A complexed with D-glutamate
8ONJ	;	1.8	;	Crystal structure of D-amino acid aminotransferase from Aminobacterium colombiense point mutant R88L
8PNY	;	1.8	;	Crystal structure of D-amino acid aminotransferase from Blastococcus saxobsidens complexed with phenylhydrazine and in its apo form
8PNW	;	1.7	;	Crystal structure of D-amino acid aminotransferase from Blastococcus saxobsidens in holo form with PLP
8AYK	;	1.9	;	Crystal structure of D-amino acid aminotrensferase from Aminobacterium colombiense complexed with D-glutamate
8AHU	;	1.41	;	Crystal structure of D-amino acid aminotrensferase from Haliscomenobacter hydrossis complexed with D-cycloserine
7CT4	;	2.0	;	Crystal structure of D-amino acid oxidase from Rasamsonia emersonii strain YA
1C0I	;	1.9	;	CRYSTAL STRUCTURE OF D-AMINO ACID OXIDASE IN COMPLEX WITH TWO ANTHRANYLATE MOLECULES
3WGT	;	1.88	;	Crystal structure of D-amino acid oxidase mutant
7P7X	;	2.0	;	Crystal structure of D-amino acid transaminase from Haliscomenobacter hydrossis (holo form).
8RAF	;	2.0	;	Crystal structure of D-amino acid transaminase from Haliscomenobacter hydrossis point mutant R90I (holo form)
8RAI	;	2.0	;	Crystal structure of D-amino acid transaminase from Haliscomenobacter hydrossis point mutant R90I complexed with phenylhydrazine
7P8O	;	1.95	;	Crystal structure of D-aminoacid transaminase from Haliscomenobacter hydrossis in its intermediate form
1M7J	;	1.5	;	Crystal structure of D-aminoacylase defines a novel subset of amidohydrolases
1RJP	;	1.8	;	Crystal structure of D-aminoacylase in complex with 100mM CuCl2
6JIL	;	2.32	;	Crystal structure of D-cycloserine synthetase DcsG
1VFS	;	1.9	;	Crystal structure of D-cycloserine-bound form of alanine racemase from D-cycloserine-producing Streptomyces lavendulae
7CET	;	2.64	;	Crystal structure of D-cycloserine-bound form of cysteine desulfurase NifS from Helicobacter pylori
7CER	;	2.3	;	Crystal structure of D-cycloserine-bound form of cysteine desulfurase SufS H121A from Bacillus subtilis
7YSK	;	1.8	;	Crystal structure of D-Cysteine desulfhydrase from Pectobacterium atrosepticum
4D8T	;	2.28	;	Crystal structure of D-Cysteine desulfhydrase from Salmonella typhimurium at 2.2 A resolution
4D8U	;	3.3	;	Crystal structure of D-Cysteine desulfhydrase from Salmonella typhimurium at 3.3 A in monoclinic space group with 8 subunits in the asymmetric unit
7YSL	;	2.02	;	Crystal structure of D-Cysteine desulfhydrase with a trapped PLP-pyruvate geminal diamine
2Z4E	;	2.7	;	Crystal Structure of D-Dimer from Human Fibrin Complexed with Gly-His-Arg-Pro-Tyr-amide
3H32	;	3.6	;	Crystal structure of D-dimer from human fibrin complexed with Gly-His-Arg-Pro-Tyr-amide
2Q9I	;	2.8	;	Crystal Structure of D-Dimer from Human Fibrin Complexed with Met-His-Arg-Pro-Tyr-amide.
3GO0	;	1.56	;	Crystal structure of D-enantiomer of human alpha-defensin 1 (D-HNP1)
2O4C	;	2.3	;	Crystal Structure of D-Erythronate-4-phosphate Dehydrogenase Complexed with NAD
4K3Z	;	1.95	;	Crystal structure of D-erythrulose 4-phosphate dehydrogenase from Brucella melitensis, solved by iodide SAD
4EW6	;	2.3	;	Crystal structure of D-galactose-1-dehydrogenase protein from Rhizobium etli
4LFK	;	1.96	;	Crystal Structure of D-galactose-6-phosphate isomerase in a substrate-free form
4LFM	;	1.65	;	Crystal Structure of D-galactose-6-phosphate isomerase in complex with D-psicose
4LFN	;	1.65	;	Crystal Structure of D-galactose-6-phosphate isomerase in complex with D-ribulose
4LFL	;	1.65	;	Crystal Structure of D-galactose-6-phosphate isomerase in complex with D-tagatose-6-phosphate
3VCC	;	1.64	;	CRYSTAL STRUCTURE OF D-Galacturonate Dehydratase from GEOBACILLUS SP. complexed with Mg
4HCD	;	1.7	;	Crystal structure of D-glucarate dehydratase from agrobacterium tumefaciens complexed with magnesium
4HCL	;	1.8	;	CRYSTAL STRUCTURE OF D-GLUCARATE DEHYDRATASE FROM AGROBACTERIUM TUMEFACIENS complexed with magnesium and L-Lyxarohydroxamate
4HCH	;	1.699	;	CRYSTAL STRUCTURE OF D-GLUCARATE DEHYDRATASE FROM AGROBACTERIUM TUMEFACIENS complexed with magnesium and L-tartrate
4MMW	;	1.647	;	Crystal structure of D-glucarate dehydratase from Agrobacterium tumefaciens complexed with magnesium, L-Xylarohydroxamate and L-Lyxarohydroxamate
3P0W	;	1.71	;	Crystal structure of D-Glucarate dehydratase from Ralstonia solanacearum complexed with Mg and D-glucarate
3PFR	;	1.899	;	Crystal structure of D-Glucarate dehydratase related protein from Actinobacillus Succinogenes complexed with D-Glucarate
7QE2	;	2.15	;	Crystal structure of D-glucuronic acid bound to SN243
3A0N	;	1.45	;	Crystal structure of D-glucuronic acid-bound alginate lyase vAL-1 from Chlorella virus
4PW2	;	1.9	;	Crystal structure of D-glucuronyl C5 epimerase
4PXQ	;	2.2	;	Crystal structure of D-glucuronyl C5-epimerase in complex with heparin hexasaccharide
1K1D	;	3.01	;	Crystal structure of D-hydantoinase
4KIR	;	2.8	;	Crystal Structure of D-Hydantoinase from Bacillus sp. AR9 in C2221 space group
3HG7	;	1.8	;	CRYSTAL STRUCTURE OF D-isomer specific 2-hydroxyacid dehydrogenase family protein from Aeromonas salmonicida subsp. salmonicida A449
4N18	;	1.97	;	Crystal structure of D-isomer specific 2-hydroxyacid dehydrogenase family protein from Klebsiella pneumoniae 342
5TX7	;	2.51	;	Crystal structure of D-isomer specific 2-hydroxyacid dehydrogenase from Desulfovibrio vulgaris
2YQ4	;	3.45	;	Crystal Structure of D-isomer specific 2-hydroxyacid dehydrogenase from Lactobacillus delbrueckii ssp. bulgaricus
2YQ5	;	2.75	;	Crystal Structure of D-isomer specific 2-hydroxyacid dehydrogenase from Lactobacillus delbrueckii ssp. bulgaricus: NAD complexed form
4XA8	;	1.9	;	Crystal structure of D-isomer specific 2-hydroxyacid dehydrogenase from Xanthobacter autotrophicus Py2
5VG6	;	2.2	;	Crystal structure of D-isomer specific 2-hydroxyacid dehydrogenase from Xanthobacter autotrophicus Py2 in complex with NADPH and MES.
4PRK	;	2.13	;	Crystal structure of D-lactate dehydrogenase (D-LDH) from Lactobacillus jensenii
3KB6	;	2.12	;	Crystal structure of D-Lactate dehydrogenase from aquifex aeolicus complexed with NAD and Lactic acid
4PRL	;	2.6	;	Crystal structure of D-lactate dehydrogenase with NAD+ from Lactobacillus jensenii
1F0X	;	1.9	;	CRYSTAL STRUCTURE OF D-LACTATE DEHYDROGENASE, A PERIPHERAL MEMBRANE RESPIRATORY ENZYME.
4IL2	;	1.95	;	Crystal structure of D-mannonate dehydratase (rspA) from E. coli CFT073 (EFI TARGET EFI-501585)
3BSM	;	2.2	;	Crystal structure of D-mannonate dehydratase from Chromohalobacter salexigens
3RGT	;	1.9	;	Crystal structure of d-mannonate dehydratase from Chromohalobacter salexigens complexed with D-Arabinohydroxamate
3OW1	;	1.798	;	Crystal structure of D-mannonate dehydratase from Chromohalobacter salexigens complexed with MG
3QKE	;	1.55	;	Crystal structure of D-mannonate dehydratase from Chromohalobacter Salexigens complexed with Mg and D-Gluconate
4KT2	;	1.798	;	Crystal structure of d-mannonate dehydratase from chromohalobacter salexigens complexed with mg and glycerol
4KWS	;	1.642	;	Crystal structure of d-mannonate dehydratase from chromohalobacter salexigens complexed with Mg and glycerol
3P93	;	1.8	;	Crystal structure of D-mannonate dehydratase from Chromohalobacter Salexigens complexed with MG,D-Mannonate and 2-keto-3-deoxy-D-Gluconate
4KPL	;	2.0	;	Crystal structure of d-mannonate dehydratase from chromohalobacter salexigens complexed with Mg,d-mannonate and 2-keto-3-deoxy-d-gluconate
3PK7	;	1.642	;	Crystal structure of D-mannonate dehydratase from Chromohalobacter salexigens with MG and Glycerol bound in the active site
2QJJ	;	1.8	;	Crystal structure of D-Mannonate dehydratase from Novosphingobium aromaticivorans
2QJN	;	2.0	;	Crystal structure of D-mannonate dehydratase from Novosphingobium aromaticivorans complexed with Mg and 2-keto-3-deoxy-D-gluconate
4K8G	;	1.25	;	Crystal structure of D-Mannonate dehydratase from Novosphingobium aromaticivorans mutant (V161A, R163A, K165G, L166A, Y167G, Y168A, E169G)
4F4R	;	1.8	;	Crystal structure of D-mannonate dehydratase homolog from Chromohalobacter salexigens (Target EFI-502114), with bound NA, ordered loop
5X32	;	2.586	;	Crystal structure of D-mannose isomerase
2CY8	;	2.3	;	Crystal structure of D-phenylglycine aminotransferase (D-PhgAT) from Pseudomonas strutzeri ST-201
6G1F	;	2.248	;	Crystal structure of D-phenylglycine aninotransferase (D-PhgAT) from Pseudomonas stutzeri with PLP internal aldimine
8OKY	;	1.17	;	Crystal structure of D-ProB26-DTriA analogue of human insulin
2HK0	;	2.0	;	Crystal structure of D-psicose 3-epimerase (DPEase) in the absence of substrate
2HK1	;	2.3	;	Crystal structure of D-psicose 3-epimerase (DPEase) in the presence of D-fructose
3E7N	;	2.45	;	Crystal structure of d-ribose high-affinity transport system from salmonella typhimurium lt2
3P12	;	2.35	;	Crystal Structure of D-ribose Pyranase Sa240
1LKZ	;	2.5	;	Crystal structure of D-ribose-5-phosphate isomerase (RpiA) from Escherichia coli.
1TQJ	;	1.6	;	Crystal structure of D-ribulose 5-phosphate 3-epimerase from Synechocystis to 1.6 angstrom resolution
3ANU	;	1.9	;	Crystal structure of D-serine dehydratase from chicken kidney
3ANV	;	2.09	;	Crystal structure of D-serine dehydratase from chicken kidney (2,3-DAP complex)
3AWN	;	2.8	;	Crystal structure of D-serine dehydratase from chicken kidney (EDTA treated)
3AWO	;	2.65	;	Crystal structure of D-serine dehydratase in complex with D-serine from chicken kidney (EDTA-treated)
5ITG	;	1.95	;	Crystal structure of D-sorbitol dehydrogenase in substrate-free form
3WWX	;	1.49	;	Crystal structure of D-stereospecific amidohydrolase from Streptomyces sp. 82F2
7EBY	;	2.0	;	Crystal structure of D-Succinylase (DSA) from Cupriavidus sp. P4-10-C
4YTS	;	2.14	;	Crystal structure of D-tagatose 3-epimerase C66S from Pseudomonas cichorii in complex with 1-deoxy 3-keto D-galactitol
4YTQ	;	1.9	;	Crystal structure of D-tagatose 3-epimerase C66S from Pseudomonas cichorii in complex with 1-deoxy D-tagatose
4YTR	;	1.9	;	Crystal structure of D-tagatose 3-epimerase C66S from Pseudomonas cichorii in complex with 1-deoxy L-tagatose
5J8L	;	1.73	;	Crystal structure of D-tagatose 3-epimerase C66S from Pseudomonas cichorii in complex with 1-deoxy L-tagatose, using a crystal grown in microgravity
4YTT	;	1.8	;	Crystal structure of D-tagatose 3-epimerase C66S from Pseudomonas cichorii in complex with 6-deoxy L-psicose
4XSM	;	2.3	;	Crystal structure of D-tagatose 3-epimerase C66S from Pseudomonas cichorii in complex with D-talitol
4YTU	;	2.2	;	Crystal structure of D-tagatose 3-epimerase C66S from Pseudomonas cichorii in complex with L-erythrulose
2OU4	;	2.5	;	Crystal structure of D-tagatose 3-epimerase from Pseudomonas cichorii
2QUL	;	1.79	;	Crystal structure of D-tagatose 3-epimerase from Pseudomonas cichorii at 1.79 A resolution
2QUN	;	2.06	;	Crystal Structure of D-tagatose 3-epimerase from Pseudomonas cichorii in Complex with D-fructose
2QUM	;	2.28	;	Crystal structure of D-tagatose 3-epimerase from Pseudomonas cichorii with D-tagatose
3WQO	;	2.64	;	Crystal structure of D-tagatose 3-epimerase-like protein
2DW7	;	2.5	;	Crystal structure of D-tartrate dehydratase from Bradyrhizobium japonicum complexed with Mg++ and meso-tartrate
4V15	;	1.5	;	Crystal structure of D-threonine aldolase from Alcaligenes xylosoxidans
7YQA	;	1.85	;	Crystal structure of D-threonine aldolase from Chlamydomonas reinhardtii
7DIB	;	2.2	;	Crystal structure of D-threonine aldolase from Filomicrobium marinum
2DBO	;	2.76	;	Crystal structure of D-Tyr-tRNA(Tyr) deacylase from Aquifex aeolicus
3KNF	;	3.0	;	Crystal structure of D-Tyr-tRNA(Tyr) deacylase from Plasmodium falciparum
3KO4	;	2.7	;	Crystal structure of D-Tyr-tRNA(Tyr) deacylase from Plasmodium falciparum in complex with ADP
5OYN	;	2.7	;	Crystal structure of D-xylonate dehydratase in holo-form
3N4A	;	1.94	;	Crystal structure of D-Xylose Isomerase in complex with S-1,2-Propandiol
5Z6U	;	1.95	;	Crystal structure of D-xylose reductase from Scheffersomyces stipitis
5Z6T	;	2.0	;	Crystal structure of D-xylose reductase from Scheffersomyces stipitis in complex with NADPH
4QIQ	;	3.51	;	Crystal structure of D-xylose-proton symporter
1NM1	;	1.8	;	Crystal Structure of D. Dicsoideum Actin Complexed With Gelsolin Segment 1 and Mg ATP at 1.8 A Resolution
1NMD	;	1.9	;	Crystal Structure of D. Discoideum Actin-Gelsolin Segment 1 Complex Crystallized In Presence Of Lithium ATP
1ZM7	;	2.2	;	Crystal structure of D. melanogaster deoxyribonucleoside kinase mutant N64D in complex with dTTP
1ZMX	;	3.1	;	Crystal structure of D. melanogaster deoxyribonucleoside kinase N64D mutant in complex with thymidine
5FGP	;	2.0	;	Crystal structure of D. melanogaster Pur-alpha repeat I-II in complex with DNA.
5FGO	;	2.6	;	Crystal structure of D. melanogaster Pur-alpha repeat III.
2Y8E	;	1.39	;	Crystal structure of D. melanogaster Rab6 GTPase bound to GMPPNP
7VKR	;	2.1	;	Crystal structure of D. melanogaster SAMTOR in complex with SAM
7VKQ	;	2.094	;	Crystal structure of D. melanogaster SAMTOR in the SAH bound form
7VKK	;	3.55	;	Crystal structure of D. melanogaster SAMTOR V66W/E67P mutant
4YGX	;	2.95	;	Crystal Structure of D. melanogaster Ssu72+Symplekin bound to cis peptidomimetic CTD phospho-Ser5 peptide
4O0P	;	3.8	;	Crystal Structure of D. radiodurans Bacteriophytochrome Photosensory Core Module in its Dark Form
4O01	;	3.24	;	Crystal Structure of D. radiodurans Bacteriophytochrome Photosensory Core Module in its Illuminated Form
1J6V	;	2.1	;	CRYSTAL STRUCTURE OF D. RADIODURANS LUXS, C2
1INN	;	1.8	;	CRYSTAL STRUCTURE OF D. RADIODURANS LUXS, P21
4FPV	;	1.73	;	Crystal structure of D. rerio TDP2 complexed with single strand DNA product
2NLK	;	2.4	;	Crystal structure of D1 and D2 catalytic domains of human Protein Tyrosine Phosphatase Gamma (D1+D2 PTPRG)
3MZ7	;	1.9	;	Crystal structure of D101L Co2+ HDAC8 complexed with M344
3MZ6	;	2.0	;	Crystal structure of D101L Fe2+ HDAC8 complexed with M344
3MZ4	;	1.845	;	Crystal structure of D101L Mn2+ HDAC8 complexed with M344
7N96	;	2.38	;	Crystal structure of D103A human Galectin-7 mutant
7RDG	;	3.0	;	Crystal structure of D103A human Galectin-7 mutant in presence of lactose
1CQS	;	1.9	;	CRYSTAL STRUCTURE OF D103E MUTANT WITH EQUILENINEOF KSI IN PSEUDOMONAS PUTIDA
5LNN	;	1.6	;	Crystal structure of D1050A mutant of the receiver domain of the histidine kinase CKI1 from Arabidopsis thaliana
5LNM	;	1.95	;	Crystal structure of D1050E mutant of the receiver domain of the histidine kinase CKI1 from Arabidopsis thaliana
4U5R	;	1.55	;	Crystal structure of D106A mutant of RhCC (YP_702633.1) from Rhodococcus jostii RHA1 at 1.55 Angstrom
7D96	;	2.29	;	Crystal structure of D110G mutant of GATase subunit of Methanocaldococcus jannaschii GMP synthetase
7YC6	;	2.4	;	Crystal structure of D110P mutant of GATase subunit of Methanocaldococcus jannaschii GMP synthetase
8GR1	;	2.5	;	Crystal structure of D110V/K151L mutant of GATase subunit of Methanocaldococcus jannaschii GMP synthetase
6KEQ	;	1.84	;	Crystal structure of D113A mutant of Drosophila melanogaster Noppera-bo, glutathione S-transferase epsilon 14 (DmGSTE14), in apo-form
6KER	;	1.84	;	Crystal structure of D113A mutant of Drosophila melanogaster Noppera-bo, glutathione S-transferase epsilon 14 (DmGSTE14), in glutathione-bound form
3COC	;	2.31	;	Crystal Structure of D115A mutant of Bacteriorhodopsin
7DC7	;	1.77	;	Crystal structure of D12 Fab-ATP complex
8ANS	;	2.01	;	Crystal structure of D1228V c-MET bound by compound 1.
8OV7	;	1.95	;	Crystal structure of D1228V c-MET bound by compound 10
8OUV	;	1.783	;	Crystal structure of D1228V c-MET bound by compound 15
8OVZ	;	2.206	;	Crystal structure of D1228V c-MET bound by compound 16
8OWG	;	2.631	;	Crystal structure of D1228V c-MET bound by compound 2
8OUU	;	1.77	;	Crystal structure of D1228V c-MET bound by compound 29
6SDD	;	1.93	;	Crystal structure of D1228V cMET bound by BMS-777607
6SDC	;	1.67	;	Crystal structure of D1228V cMET bound by foretinib
2JAO	;	2.0	;	Crystal structure of D12N variant of mouse cytosolic 5'(3')- deoxyribonucleotidase (cdN) in complex with deoxyguanosine 5'- monophosphate
2JAR	;	1.94	;	Crystal structure of D12N variant of mouse cytosolic 5'(3')- deoxyribonucleotidase (cdN) in complex with deoxyuridine 5'- monophosphate
3KCC	;	1.66	;	Crystal structure of D138L mutant of Catabolite Gene Activator Protein
2DSO	;	2.1	;	Crystal structure of D138N mutant of Drp35, a 35kDa drug responsive protein from Staphylococcus aureus
5SX1	;	1.8	;	Crystal structure of D141E variant of B. pseudomallei KatG
4YPR	;	2.59	;	Crystal Structure of D144N MutY bound to its anti-substrate
3PNI	;	2.8	;	Crystal structure of D14C [3Fe-4S] Pyrococcus furiosus ferredoxin
2ZJ7	;	2.21	;	Crystal structure of D157A mutant of Pseudomonas sp. MIS38 lipase
6KXM	;	1.95	;	Crystal structure of D157N mutant of Chitiniphilus shinanonensis chitinase ChiL (CsChiL) complexed with N,N'-diacetylchitobiose
5YIY	;	2.504	;	Crystal structure of D175A mutant of Rv3272 from Mycobacterium tuberculosis
5DC7	;	2.3	;	Crystal structure of D176A-Y306F HDAC8 in complex with a tetrapeptide substrate
5DC5	;	1.94	;	Crystal structure of D176N HDAC8 in complex with M344
5DC6	;	1.553	;	Crystal structure of D176N-Y306F HDAC8 in complex with a tetrapeptide substrate
7TB7	;	0.99	;	Crystal structure of D179N KPC-2 beta-lactamase
7TC1	;	1.16	;	Crystal structure of D179N KPC-2 beta-lactamase in complex with vaborbactam
7TBX	;	3.16	;	Crystal structure of D179Y KPC-2 beta-lactamase
3NOV	;	1.05	;	Crystal Structure of D17E Isocyanide Hydratase from Pseudomonas fluorescens
5ZOE	;	1.95	;	Crystal Structure of D181A hFen1 in complex with DNA
5ZOF	;	2.249	;	Crystal Structure of D181A/R192F hFen1 in complex with DNA
3TPO	;	2.1	;	Crystal structure of D192A/E396A mutant of mouse importin alpha2
4KEA	;	1.7	;	Crystal structure of D196N mutant of Monoglyceride lipase from Bacillus sp. H257 in space group P212121
2EU7	;	1.2	;	Crystal structure of D1A mutant of nitrophorin 2 complexed with ammonia
2ASN	;	1.7	;	Crystal structure of D1A mutant of nitrophorin 2 complexed with imidazole
3DAR	;	2.2	;	Crystal structure of D2 domain from human FGFR2
7UNY	;	4.13	;	Crystal structure of D2 nanobody in complex with PfCSS
4GAD	;	2.35	;	Crystal Structure of D230A/H234A Mutant of Stationary Phase Survival Protein (SurE) from Salmonella typhimurium
5D1C	;	1.422	;	Crystal structure of D233G-Y306F HDAC8 in complex with a tetrapeptide substrate
3FHX	;	2.5	;	Crystal structure of D235A mutant of human pyridoxal kinase
3FHY	;	2.3	;	Crystal structure of D235N mutant of human pyridoxal kinase
3U3R	;	2.36	;	Crystal structure of D249G mutated Human SULT1A1 bound to PAP and P-NITROPHENOL
1X08	;	1.9	;	Crystal structure of D26A mutant UPPs in complex with Mg, IPP and FsPP
3BA5	;	1.75	;	Crystal structure of D28A mutant of Human acidic fibroblast growth factor
2YX9	;	1.68	;	Crystal structure of D298K copper amine oxidase from Arthrobacter globiformis
3UMJ	;	2.1	;	Crystal Structure of D311E Lipase
2ZJ6	;	2.25	;	Crystal structure of D337A mutant of Pseudomonas sp. MIS38 lipase
7EXH	;	2.63	;	Crystal structure of D383A mutant from Arabidopsis thaliana complexed with Galactinol.
7EXG	;	2.05	;	Crystal structure of D383A mutant from Arabidopsis thaliana complexed with Galactose.
2B5W	;	1.6	;	Crystal structure of D38C glucose dehydrogenase mutant from Haloferax mediterranei
4LL9	;	2.686	;	Crystal structure of D3D4 domain of the LILRB1 molecule
4LLA	;	2.502	;	Crystal structure of D3D4 domain of the LILRB2 molecule
5NPD	;	1.95	;	Crystal Structure of D412N nucleophile mutant cjAgd31B (alpha-transglucosylase from Glycoside Hydrolase Family 31) in complex with alpha Cyclophellitol Aziridine probe CF021
5NPC	;	1.96	;	Crystal Structure of D412N nucleophile mutant cjAgd31B (alpha-transglucosylase from Glycoside Hydrolase Family 31) in complex with unreacted alpha Cyclophellitol Cyclosulfate probe ME647
2JAU	;	1.8	;	Crystal structure of D41N variant of human mitochondrial 5'(3')- deoxyribonucleotidase (mdN) in complex with 3'-azidothymidine 5'- monophosphate
2JAW	;	1.95	;	Crystal structure of D41N variant of human mitochondrial 5'(3')- deoxyribonucleotidase (mdN) in complex with 5-bromovinyldeoxyuridine 5'-monophosphate
6JTA	;	1.75	;	Crystal Structure of D464A L465A mutant of FGAM Synthetase
6JT9	;	2.1	;	Crystal Structure of D464A mutant of FGAM Synthetase
6C7P	;	2.6	;	Crystal structure of D477G ACO/RPE65 chimera, monoclinic crystal form
6C7O	;	3.15	;	Crystal structure of D477G ACO/RPE65 chimera, trigonal crystal form
4GXD	;	2.1	;	Crystal structure of D48V mutant of human GLTP bound with 12:0 disulfatide
4GVT	;	2.9	;	Crystal structure of D48V mutant of human GLTP bound with 12:0 disulfatide (hexagonal form)
4GH0	;	1.35	;	Crystal structure of D48V mutant of human GLTP bound with 12:0 monosulfatide
2EVT	;	1.99	;	Crystal structure of D48V mutant of human Glycolipid Transfer Protein
3S0I	;	1.5	;	Crystal Structure of D48V mutant of Human Glycolipid Transfer Protein complexed with 3-O-sulfo galactosylceramide containing nervonoyl acyl chain
4GHP	;	1.9	;	Crystal Structure of D48V||A47D mutant of Human GLTP bound with 12:0 monosulfatide
3RIC	;	2.1	;	Crystal Structure of D48V||A47D mutant of Human Glycolipid Transfer Protein complexed with 3-O-sulfo-galactosylceramide containing nervonoyl acyl chain (24:1)
5OPM	;	1.68	;	Crystal structure of D52N/R238W cN-II mutant bound to dATP and free phosphate
5OPK	;	1.74	;	Crystal structure of D52N/R367Q cN-II mutant bound to dATP and free phosphate
3GSI	;	2.0	;	Crystal structure of D552A dimethylglycine oxidase mutant of Arthrobacter globiformis in complex with tetrahydrofolate
4NTG	;	2.5505	;	Crystal structure of D60A mutant of Arabidopsis ACD11 (accelerated-cell-death 11) complexed with C12 ceramide-1-phosphate (d18:1/12:0) at 2.55 Angstrom resolution
4NTO	;	2.152	;	Crystal structure of D60A mutant of Arabidopsis ACD11 (accelerated-cell-death 11) complexed with C2 ceramide-1-phosphate (d18:1/2:0) at 2.15 Angstrom resolution
4NTI	;	2.899	;	Crystal structure of D60N mutant of Arabidopsis ACD11 (accelerated-cell-death 11) complexed with C12 ceramide-1-phosphate (d18:1/12:0) at 2.9 Angstrom resolution
5L6Z	;	1.501	;	Crystal structure of D62A mutant of Thermotoga maritima TmPEP1050 aminopeptidase
6LYM	;	2.46	;	Crystal structure of D657A mutant of formylglycinamidine synthetase
6UBZ	;	1.83	;	Crystal structure of D678A GoxA bound to glycine at pH 5.5
6UBR	;	1.96	;	Crystal structure of D678A GoxA bound to glycine at pH 7.5
6UC1	;	2.19	;	Crystal structure of D678A GoxA soaked in glycine at pH 7.5
6UBN	;	2.15	;	Crystal structure of D678E GoxA bound to glycine
6UFQ	;	2.51	;	Crystal structure of D678N GoxA bound to glycine
7EWO	;	2.4	;	Crystal Structure of D67A, E68P double mutant of O-acetyl-L-serine sulfhydrylase from Haemophilus influenzae
3BAD	;	2.0	;	Crystal structure of D70A/H93G mutant of Human acidic fibroblast growth factor
4JS7	;	2.101	;	Crystal structure of D78N mutant apo form of clavibacter michiganensis expansin
4L48	;	2.1	;	Crystal structure of d78n mutant clavibacter michiganensis expansin in complex with cellohexaose
2ZGJ	;	2.3	;	Crystal Structure of D86N-GzmM Complexed with Its Optimal Synthesized Substrate
7TKY	;	2.53	;	Crystal structure of D94A human Galectin-7 mutant
7TKZ	;	1.83	;	Crystal structure of D94A human Galectin-7 mutant in presence of lactose
5XRF	;	2.2	;	Crystal structure of Da-36, a thrombin-like enzyme from Deinagkistrodon acutus
4YJD	;	2.3	;	Crystal structure of DAAO(Y228L/R283G) variant (apo form)
4YJH	;	2.7	;	Crystal structure of DAAO(Y228L/R283G) variant (R-2-phenylpyrrolidine binding form)
4YJG	;	2.5	;	Crystal structure of DAAO(Y228L/R283G) variant (R-3-amino 1-phenylbutane binding form)
4YJF	;	2.2	;	Crystal structure of DAAO(Y228L/R283G) variant (S-methylbenzylamine binding form)
6GYW	;	1.7	;	Crystal structure of DacA from Staphylococcus aureus
6GYX	;	2.6	;	Crystal structure of DacA from Staphylococcus aureus in complex with ApCpp
6GYY	;	2.77	;	Crystal structure of DacA from Staphylococcus aureus, N166C/T172C double mutant
4D0Y	;	2.0	;	Crystal structure of DacB from Streptococcus pneumoniae D39
5LLV	;	1.7	;	Crystal structure of DACM F87M/L110M Transthyretin mutant
5LLL	;	1.42	;	Crystal structure of DACM wild type Transthyretin
4DNP	;	2.15	;	Crystal Structure of DAD2
6O5J	;	1.63	;	Crystal Structure of DAD2 bound to quinazolinone derivative
6UH9	;	1.52	;	Crystal structure of DAD2 D166A mutant
6AP7	;	1.51	;	Crystal Structure of DAD2 in complex with 2-(2-methyl-3-nitroanilino)benzoic acid
6AP6	;	1.65	;	Crystal Structure of DAD2 in complex with tolfenamic acid
6UH8	;	1.58	;	Crystal structure of DAD2 N242I mutant
4DNQ	;	2.8	;	Crystal Structure of DAD2 S96A mutant
4HSN	;	2.0	;	Crystal structure of DAH7PS from Neisseria meningitidis
5J6F	;	2.75	;	Crystal structure of DAH7PS-CM complex from Geobacillus sp. with prephenate
4DZ1	;	1.9	;	Crystal structure of DalS, an ATP binding cassette transporter for D-alanine from Salmonella enterica
5G0I	;	1.99	;	Crystal structure of Danio rerio HDAC6 CD1 and CD2 (linker cleaved) in complex with Nexturastat A
5G0J	;	2.88	;	Crystal structure of Danio rerio HDAC6 CD1 and CD2 (linker intact) in complex with Nexturastat A
5G0G	;	1.499	;	Crystal structure of Danio rerio HDAC6 CD1 in complex with trichostatin A
5G0H	;	1.6	;	Crystal structure of Danio rerio HDAC6 CD2 in complex with (S)- trichostatin A
8A8Z	;	1.6	;	Crystal structure of Danio rerio HDAC6 CD2 in complex with in situ enzymatically hydrolyzed DFMO-based ITF5924
5G0F	;	1.9	;	Crystal structure of Danio rerio HDAC6 ZnF-UBP domain
7KUT	;	2.05	;	Crystal Structure of Danio rerio Histone Deacetylase 10 H137A Mutant in Complex with N-Acetylputrescine (Tetrahedral Intermediate)
7KUS	;	2.0	;	Crystal Structure of Danio rerio Histone Deacetylase 10 H137A Mutant in Complex with N8-Acetylspermidine (Tetrahedral Intermediate)
7U6A	;	2.25	;	Crystal Structure of Danio rerio Histone Deacetylase 10 in Complex with 3-thienylmethyl Benzhydroxamic Acid Inhibitor
6UII	;	2.65	;	Crystal Structure of Danio rerio Histone Deacetylase 10 in Complex with 5-[(3-aminopropyl)amino]pentane-1-thiol
6UHU	;	2.8	;	Crystal Structure of Danio rerio Histone Deacetylase 10 in Complex with 5-[(3-aminopropyl)amino]pentylboronic acid
6UHV	;	2.53	;	Crystal Structure of Danio rerio Histone Deacetylase 10 in Complex with 6-[(3-aminopropyl)amino]-N-hydroxyhexanamide
6UIL	;	2.85	;	Crystal Structure of Danio rerio Histone Deacetylase 10 in Complex with 7-[(3-aminopropyl)amino]-1,1,1-trifluoroheptan-2-one
6UFO	;	2.68	;	Crystal Structure of Danio rerio Histone Deacetylase 10 in Complex with 7-[(3-aminopropyl)amino]-1-methoxyheptan-2-one
6UFN	;	2.7	;	Crystal Structure of Danio rerio Histone Deacetylase 10 in Complex with 7-[(3-aminopropyl)amino]heptan-2-one
6UIM	;	2.75	;	Crystal Structure of Danio rerio Histone Deacetylase 10 in Complex with 7-{[(3-aminopropyl)amino]-2-oxoheptyl} thioacetate
7KUV	;	2.15	;	Crystal Structure of Danio rerio Histone Deacetylase 10 in Complex with Acetate
6VNQ	;	2.05	;	Crystal Structure of Danio rerio Histone Deacetylase 10 in Complex with Bishydroxamic Acid Based Inhibitor
6WDW	;	2.2	;	Crystal Structure of Danio rerio Histone Deacetylase 10 in Complex with Dimethylaminoethylindole Phenylhydroxamate Inhibitor
6WDV	;	2.4	;	Crystal Structure of Danio rerio Histone Deacetylase 10 in Complex with Dimethylaminomethylindole Phenylhydroxamate Inhibitor
7SGJ	;	2.15	;	Crystal Structure of Danio rerio Histone Deacetylase 10 in Complex with DKFZ-711
7SGK	;	2.2	;	Crystal Structure of Danio rerio Histone Deacetylase 10 in Complex with DKFZ-728
6WDX	;	2.65	;	Crystal Structure of Danio rerio Histone Deacetylase 10 in Complex with Hydroxyethylindole Phenylhydroxamate Inhibitor
6WDY	;	2.65	;	Crystal Structure of Danio rerio Histone Deacetylase 10 in Complex with Indole Phenylhydroxamate Inhibitor
7U6B	;	2.6	;	Crystal Structure of Danio rerio Histone Deacetylase 10 in Complex with Indolethyl Piperidine-4-acrylhydroxamic Acid Inhibitor
7SGI	;	2.15	;	Crystal Structure of Danio rerio Histone Deacetylase 10 in Complex with Inhibitor 14
7U3M	;	2.1	;	Crystal Structure of Danio rerio Histone Deacetylase 10 in Complex with N-methylpiperazine Benzhydroxamic Acid
7U69	;	2.5	;	Crystal Structure of Danio rerio Histone Deacetylase 10 in Complex with Phenethyl Piperidine-4-acrylhydroxamic Acid Inhibitor
7U59	;	2.18	;	Crystal Structure of Danio rerio Histone Deacetylase 10 in Complex with Piperidine-4-hydroxamic acid Inhibitor
6UIJ	;	2.9	;	Crystal Structure of Danio rerio Histone Deacetylase 10 in Complex with S-{5-[(3-aminopropyl)amino]pentyl} thioacetate
7SGG	;	2.1	;	Crystal Structure of Danio rerio Histone Deacetylase 10 in Complex with SAHA
6WBQ	;	2.0	;	Crystal Structure of Danio rerio Histone Deacetylase 10 in Complex with Tubastatin A
7KUR	;	2.1	;	Crystal Structure of Danio rerio Histone Deacetylase 10 Y307F Mutant in Complex with N-Acetylputrescine
7KUQ	;	2.1	;	Crystal Structure of Danio rerio Histone Deacetylase 10 Y307F Mutant in Complex with N8-Acetylspermidine
6UO3	;	1.09	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 1 (CD1) complexed with AR-42
6UO2	;	1.65002	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 1 (CD1) complexed with Trichostatin A
6WYO	;	2.3	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 1 (CD1) H82F F202Y double mutant complexed with Trichostatin A
6WYQ	;	1.90001	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 1 (CD1) K330L mutant complexed with 4-iodo-SAHA
6UO7	;	1.39501	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 1 (CD1) K330L mutant complexed with AR-42
6UOC	;	1.40001	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 1 (CD1) K330L mutant complexed with Givinostat
6UOB	;	1.58001	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 1 (CD1) K330L mutant complexed with Resminostat
6WYP	;	2.40006	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 1 (CD1) K330L mutant complexed with SAHA-BPyne
6UO5	;	1.43934	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 1 (CD1) Y363F mutant complexed with AR-42
6UO4	;	1.26831	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 1 (CD1) Y363F mutant complexed with Trichostatin A
5EEF	;	2.151	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 1 in complex with trichostatin A
5EEM	;	2.0	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2
6VNR	;	1.94301	;	Crystal Structure of Danio rerio Histone Deacetylase 6 Catalytic Domain 2 (CD2) Complexed with Bishydroxamic Acid Inhibitor
7U8Z	;	1.85	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 (CD2) complexed with fluorinated peptoid inhibitor
6V79	;	2.03952	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 (CD2) complexed with NF2376
6V7A	;	2.08742	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 (CD2) complexed with NF2657
5EFN	;	1.804	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 (H574A) in complex with histone H4 Lys6 tripeptide substrate
5EFK	;	1.82	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 (Y745F mutant) in complex with alpha tubulin K40 tripeptide substrate
8TQ0	;	2.4	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 complexed with (R)-Lipoic Acid
6PZU	;	1.74	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 complexed with AP-1-62-A
8EQI	;	2.0	;	Crystal Structure of Danio rerio histone deacetylase 6 catalytic domain 2 complexed with cyclopeptide des4.2.0
6WSJ	;	1.7	;	Crystal Structure of Danio rerio histone deacetylase 6 catalytic domain 2 complexed with cyclopeptide des4.3.1
8GD4	;	2.0	;	Crystal Structure of Danio rerio histone deacetylase 6 catalytic domain 2 complexed with DMFO Inhibitor 6
8D9C	;	1.82	;	Crystal Structure of Danio rerio histone deacetylase 6 catalytic domain 2 complexed with fluorinated inhibitor 10
8D98	;	1.66	;	Crystal Structure of Danio rerio histone deacetylase 6 catalytic domain 2 complexed with fluorinated inhibitor 5
8D99	;	1.79	;	Crystal Structure of Danio rerio histone deacetylase 6 catalytic domain 2 complexed with fluorinated inhibitor 7
8D9A	;	1.75	;	Crystal Structure of Danio rerio histone deacetylase 6 catalytic domain 2 complexed with fluorinated inhibitor 8
8D9B	;	1.63	;	Crystal Structure of Danio rerio histone deacetylase 6 catalytic domain 2 complexed with fluorinated inhibitor 9
8G1Z	;	1.87	;	Crystal Structure of Danio rerio histone deacetylase 6 catalytic domain 2 complexed with inhibitor Mz317
8G20	;	1.766	;	Crystal Structure of Danio rerio histone deacetylase 6 catalytic domain 2 complexed with inhibitor Mz327
6PZS	;	1.79	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 complexed with JR005
6Q0Z	;	1.75	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 complexed with JS28
6CGP	;	2.5	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 complexed with MAIP-032
7UK2	;	1.6	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 complexed with NN-390
6PYE	;	1.48	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 complexed with NR160
6PZR	;	2.3	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 complexed with Resminostat
6CW8	;	1.9	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 complexed with RTS-V5
7JOM	;	1.84	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 complexed with TO-317
6PZO	;	1.5	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 complexed with YX-153
6MR5	;	1.85	;	Crystal Structure of Danio rerio histone deacetylase 6 catalytic domain 2 in complex with a mercaptoacetamide-based inhibitor
5EFG	;	2.25	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 in complex with acetate
5WGM	;	1.75	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 in complex with ACY-1083
6DVO	;	1.98	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 in complex with Bavarostat
5EEN	;	1.861	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 in complex with belinostat
6CSP	;	1.237	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 in complex with cyclohexenylhydroxamate
6CSQ	;	2.031	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 in complex with cyclohexylhydroxamate
6CSS	;	1.7	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 in complex with cyclopentenylhydroxamate
6DVL	;	2.1	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 in complex with DDK-115
6DVM	;	1.47	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 in complex with DDK-122
6DVN	;	2.2	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 in complex with DDK-137
5EFJ	;	1.73	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 in complex with HC toxin
5WGK	;	1.822	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 in complex with HPB
5EF7	;	1.9	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 in complex with HPOB
7O2P	;	1.9	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 in complex with ITF3756
7O2R	;	2.3	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 in complex with ITF3985
5W5K	;	2.7	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 in complex with KV70
5EFB	;	2.543	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 in complex with oxamflatin
5EF8	;	2.6	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 in complex with panobinostat
6CSR	;	1.619	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 in complex with phenylhydroxamate
5WGL	;	1.7	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 in complex with ricolinostat (ACY-1215)
5EEI	;	1.32	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 in complex with SAHA
5EEK	;	1.59	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 in complex with trichostatin A
5EFH	;	2.162	;	Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 in complex with trifluoroketone transition state analogue
6FPT	;	2.6	;	Crystal structure of Danio rerio Lin41 filamin-NHL domains
6FQ3	;	1.901	;	Crystal structure of Danio rerio Lin41 filamin-NHL domains in complex with lin-29A 5'UTR 13mer RNA
6FQL	;	2.349	;	Crystal structure of Danio rerio Lin41 filamin-NHL domains in complex with mab-10 3'UTR 13mer RNA
4HKF	;	1.7	;	Crystal structure of Danio rerio MEC-17 catalytic domain in complex with acetyl-CoA
4JHJ	;	3.25	;	Crystal structure of Danio rerio Slip1 in complex with Dbp5
4JHK	;	2.507	;	Crystal structure of Danio rerio SLIP1 in complex with SLBP
3QZE	;	1.59	;	Crystal Structure of DapA (PA1010) at 1.6 A resolution
5EER	;	2.5	;	Crystal structure of DapB from Corynebacterium glutamicum
5EES	;	2.15	;	Crystal structure of DapB in complex with NADP+ from Corynebacterium glutamicum
5E3P	;	2.01	;	Crystal structure of DapD from Corynebacterium glutamicum
5E3R	;	1.85	;	Crystal structure of DapD in complex with 2-aminopimelate from Corynebacterium glutamicum
5E3Q	;	1.8	;	Crystal structure of DapD in complex with succinyl-CoA from Corynebacterium glutamicum
5VO3	;	1.954	;	Crystal structure of DapE in complex with the products (succinic acid and diaminopimelic acid)
5M47	;	2.59	;	Crystal structure of DapF from Corynebacterium glutamicum in complex with D,L-diaminopimelate
4YPD	;	1.4	;	Crystal Structure of DAPK1 catalytic domain in complex with the hinge binding fragment 4-methylpyridazine
4YO4	;	1.6	;	Crystal Structure of DAPK1 catalytic domain in complex with the hinge binding fragment phthalazine
5AV0	;	1.85	;	Crystal structure of DAPK1 in complex with 7,3',4'-trihydroxyisoflavone.
5AUT	;	1.7	;	Crystal structure of DAPK1 in complex with ANS.
5AUV	;	1.5	;	Crystal structure of DAPK1 in complex with apigenin.
5AUZ	;	1.6	;	Crystal structure of DAPK1 in complex with genistein.
8IE8	;	1.75	;	Crystal structure of DAPK1 in complex with isorhapontigenin
5AUX	;	1.5	;	Crystal structure of DAPK1 in complex with kaempferol.
5AUU	;	1.7	;	Crystal structure of DAPK1 in complex with luteolin.
5AUY	;	2.0	;	Crystal structure of DAPK1 in complex with morin.
8IE5	;	1.803	;	Crystal structure of DAPK1 in complex with oxyresveratrol
8IE6	;	1.701	;	Crystal structure of DAPK1 in complex with pinostilbene
8IE7	;	1.849	;	Crystal structure of DAPK1 in complex with pterostilbene
6AAR	;	1.95	;	Crystal structure of DAPK1 in complex with purpurin
5AUW	;	1.5	;	Crystal structure of DAPK1 in complex with quercetin.
5AV1	;	1.5	;	Crystal structure of DAPK1 in the presence of bromide ions.
4TXC	;	1.951	;	Crystal Structure of DAPK1 kinase domain in complex with a small molecule inhibitor
5AV4	;	1.4	;	Crystal structure of DAPK1-genistein complex in the presence of bromide ions.
5AV2	;	1.502	;	Crystal structure of DAPK1-kaempferol complex in the presence of bromide ions.
5AV3	;	1.9	;	Crystal structure of DAPK1-kaempferol complex in the presence of iodide ions.
6PAW	;	2.953	;	Crystal structure of DAPK2 S308A Calcium/Calmodulin complex
3GUB	;	1.71	;	Crystal structure of DAPKL93G complexed with N6-(2-Phenylethyl)adenosine
3GU8	;	1.6	;	Crystal structure of DAPKL93G with N6-cyclopentyladenosine
3GU6	;	1.49	;	Crystal structure of DAPKQ23V-ADP
3GU7	;	1.9	;	Crystal structure of DAPKQ23V-ADP-Mg2+
3GU4	;	1.35	;	Crystal structure of DAPKQ23V-AMPPNP
3GU5	;	1.65	;	Crystal structure of DAPKQ23V-AMPPNP-Mg2+
7DUO	;	2.81	;	Crystal structure of daratumumab fab and CD38 complex
7BTG	;	2.188	;	Crystal structure of DARP, drosophila arginine phosphatase
4YDY	;	2.0	;	CRYSTAL STRUCTURE OF DARPIN 44C12V5 IN COMPLEX WITH HUMAN IL-4
5LW2	;	1.75	;	Crystal structure of DARPin 5m3_D12
5KNH	;	1.6	;	CRYSTAL STRUCTURE OF DARPIN 6G9 IN COMPLEX WITH CYNO IL-13
5LEB	;	2.3	;	Crystal structure of DARPin-DARPin rigid fusion, variant DDD_D12_06_D12_06_D12
5LEC	;	2.506	;	Crystal structure of DARPin-DARPin rigid fusion, variant DDD_D12_12_D12_12_D12
5LED	;	2.6	;	Crystal structure of DARPin-DARPin rigid fusion, variant DDD_D12_12_D12_12_D12
5LEE	;	2.401	;	Crystal structure of DARPin-DARPin rigid fusion, variant DDD_D12_12_D12_12_D12
5LE2	;	2.4	;	Crystal structure of DARPin-DARPin rigid fusion, variant DDD_D12_15_D12_15_D12
5LW1	;	3.2	;	Crystal structure of DARPin-DARPin rigid fusion, variant DD_232_11_D12 in complex JNK1a1 and JIP1 peptide
5LE3	;	3.5	;	Crystal structure of DARPin-DARPin rigid fusion, variant DD_D12_09_D12
5LE6	;	1.8	;	Crystal structure of DARPin-DARPin rigid fusion, variant DD_D12_09_D12
6F5E	;	2.7	;	Crystal structure of DARPin-DARPin rigid fusion, variant DD_D12_10_47 in complex JNK1a1 and JIP1 peptide
5LE4	;	2.35	;	Crystal structure of DARPin-DARPin rigid fusion, variant DD_D12_11_D12
5LE7	;	2.104	;	Crystal structure of DARPin-DARPin rigid fusion, variant DD_D12_13_D12
5LE8	;	1.78	;	Crystal structure of DARPin-DARPin rigid fusion, variant DD_D12_15_D12
5LE9	;	1.85	;	Crystal structure of DARPin-DARPin rigid fusion, variant DD_Off7_09_3G124
5LEL	;	3.1	;	Crystal structure of DARPin-DARPin rigid fusion, variant DD_Off7_10_3G124 in complex with Maltose-binding Protein and Green Fluorescent Protein
5LEM	;	2.98	;	Crystal structure of DARPin-DARPin rigid fusion, variant DD_Off7_11_3G124 in complex with Maltose-binding Protein and Green Fluorescent Protein
5LEA	;	2.4	;	Crystal structure of DARPin-DARPin rigid fusion, variant DD_Off7_12_3G124
7YK3	;	2.2	;	Crystal structure of DarTG toxin-antitoxin complex from Mycobacterium tuberculosis
6POP	;	2.147	;	Crystal structure of DauA in complex with NADP+
7XKC	;	2.56	;	Crystal structure of Daucus Carrot hypoglycemic peptide (DCHP)
3USF	;	2.463	;	Crystal structure of DAVA-4
5Y18	;	2.202	;	Crystal structure of DAXX helical bundle domain in complex with ATRX
5Y6O	;	3.1	;	Crystal structure of DAXX N-terminal four-helix bundle domain (4HB) in complex with ATRX
3U05	;	1.27	;	Crystal structure of DB1804-D(CGCGAATTCGCG)2 complex
3U08	;	1.25	;	Crystal structure of DB1963-D(CGCGAATTCGCG)2 complex at 1.25 A resolution
2B3E	;	1.36	;	Crystal structure of DB819-D(CGCGAATTCGCG)2 complex.
2GYX	;	1.86	;	Crystal structure of DB884- D(CGCGAATTCGCG)2 complex at 1.86 A resolution.
8GN1	;	2.1	;	Crystal structure of DBBQ-bound photosystem II complex
7C4P	;	1.995	;	Crystal structure of DBD plasma treated zebrafish TRF2 myb-domain complexed with DNA
7C4Q	;	2.5	;	Crystal structure of DBD plasma treated zebrafish TRF2 myb-domain complexed with DNA
3AFI	;	1.75	;	Crystal structure of DBJA (HIS-DBJA)
3A2L	;	1.78	;	Crystal structure of DBJA (mutant dbja delta)
3A2M	;	1.84	;	CRYSTAL STRUCTURE OF DBJA (WILD TYPE Type I)
3A2N	;	1.89	;	Crystal structure of DBJA (Wild Type Type II P21)
5F3J	;	4.001	;	Crystal structure of DBP in complex with inhibitory monoclonal antibody 2D10
5DXX	;	1.45	;	Crystal structure of Dbr2
5DXY	;	1.77	;	Crystal structure of Dbr2
5DY3	;	1.82	;	Crystal structure of Dbr2
5DY2	;	1.57	;	Crystal structure of Dbr2 with mutation M27L
1SL5	;	1.8	;	Crystal Structure of DC-SIGN carbohydrate recognition domain complexed with LNFP III (Dextra L504).
1SL4	;	1.55	;	Crystal Structure of DC-SIGN carbohydrate recognition domain complexed with Man4
7NL6	;	2.2	;	Crystal Structure of DC-SIGN in complex with a triazole-based glycomimetic ligand
7NL7	;	2.1	;	Crystal Structure of DC-SIGN in complex with a triazole-based glycomimetic ligand
5MUQ	;	2.62	;	Crystal structure of DC8E8 Fab at pH 7.0 containing a Zn atom
5MP5	;	2.31	;	Crystal structure of DC8E8 Fab in the complex with a 14-mer tau peptide at pH 6.5
5MP1	;	3.1	;	Crystal structure of DC8E8 Fab in the complex with a 14-mer tau peptide at pH 7.5
5MO3	;	1.69	;	Crystal structure of DC8E8 Fab in the complex with a 14-mer tau peptide at pH 8.5
5MP3	;	2.75	;	Crystal structure of DC8E8 Fab in the complex with a 30-mer tau peptide at pH 6.5
6XM7	;	1.45	;	Crystal structure of DCA-S bound to Co-LSD4 from Sphingobium sp. strain SYK-6
4Z8L	;	2.6	;	Crystal structure of DCAF1/SIV-MND VPX/MND SAMHD1 NTD ternary complex
6K57	;	2.98	;	Crystal structure of dCas9 in complex with sgRNA and DNA (CGA PAM)
6K3Z	;	3.2	;	Crystal structure of dCas9 in complex with sgRNA and DNA (TGA PAM)
8GN0	;	2.15	;	Crystal structure of DCBQ-bound photosystem II complex
4RI3	;	2.7	;	Crystal structure of DCCD-modified PsbS from spinach
8OOJ	;	2.1	;	Crystal structure of dCK C4S-S74E mutant in complex with EdC and UDP
7ZI1	;	1.85	;	Crystal structure of dCK C4S-S74E mutant in complex with UDP and the dCKi1 inhibitor
7ZI2	;	2.18	;	Crystal structure of dCK C4S-S74E mutant in complex with UDP and the dCKi2 inhibitor
7ZI5	;	2.0	;	Crystal structure of dCK C4S-S74E mutant in complex with UDP and the OR0274 inhibitor
7ZI6	;	2.1	;	Crystal structure of dCK C4S-S74E mutant in complex with UDP and the OR0325 inhibitor
7ZI7	;	1.8	;	Crystal structure of dCK C4S-S74E mutant in complex with UDP and the OR0345 inhibitor
7ZI8	;	1.99	;	Crystal structure of dCK C4S-S74E mutant in complex with UDP and the OR0602 inhibitor
7ZI9	;	1.8	;	Crystal structure of dCK C4S-S74E mutant in complex with UDP and the OR0624 inhibitor
7ZIA	;	1.7	;	Crystal structure of dCK C4S-S74E mutant in complex with UDP and the OR0634 inhibitor
7ZIB	;	1.95	;	Crystal structure of dCK C4S-S74E mutant in complex with UDP and the OR0635 inhibitor
7ZI3	;	1.9	;	Crystal structure of dCK C4S-S74E mutant in complex with UDP and the OR0642 inhibitor
5MQJ	;	3.7	;	Crystal structure of dCK mutant C3S
5MQT	;	3.2	;	Crystal structure of dCK mutant C3S in complex with imatinib and UDP
5MQL	;	3.25	;	Crystal structure of dCK mutant C3S in complex with masitinib and UDP
6KYQ	;	2.141	;	Crystal structure of DCLK1 Autoinhibited Kinase Domain
7F3G	;	2.1	;	Crystal structure of DCLK1 kinase domain in complex with ruxolitinib
6KYR	;	2.206	;	Crystal structure of DCLK1 mutant (P675L) Autoinhibited Kinase Domain
7KX8	;	3.1	;	Crystal structure of DCLK1-Cter in complex with FMF-03-055-1
5JZJ	;	1.71	;	Crystal structure of DCLK1-KD in complex with AMPPN
7KXW	;	3.002	;	Crystal structure of DCLK1-KD in complex with DCLK1-IN-1
5JZN	;	2.85	;	Crystal structure of DCLK1-KD in complex with NVP-TAE684
7KX6	;	2.5	;	Crystal structure of DCLK1-KD in complex with XMD8-85
6TT5	;	1.5	;	Crystal structure of DCLRE1C/Artemis
2HVV	;	3.0	;	Crystal structure of dCMP deaminase from Streptococcus mutans
2HVW	;	1.67	;	Crystal structure of dCMP deaminase from Streptococcus mutans
4P9E	;	2.6	;	Crystal structure of dCMP deaminase from the cyanophage S-TIM5 in apo form
4P9C	;	2.6	;	Crystal structure of dCMP deaminase from the cyanophage S-TIM5 in complex with dCMP and dUMP
4P9D	;	2.9	;	Crystal structure of dCMP deaminase from the cyanophage S-TIM5 in complex with dTMP and dTTP.
1DCH	;	3.0	;	CRYSTAL STRUCTURE OF DCOH, A BIFUNCTIONAL, PROTEIN-BINDING TRANSCRIPTION COACTIVATOR
3HXA	;	1.8	;	Crystal Structure of DCoH1Thr51Ser
4WIL	;	1.36	;	Crystal structure of DCoH2 S51T
1RU0	;	1.6	;	Crystal structure of DCoH2, a paralog of DCoH, the Dimerization Cofactor of HNF-1
1Q67	;	2.3	;	Crystal structure of Dcp1p
5QPC	;	1.66	;	Crystal Structure of DCP2 (NUDT20) after initial refinement with no ligand modelled (structure $n)
3MHD	;	2.901	;	Crystal structure of DCR3
3K51	;	2.45	;	Crystal Structure of DcR3-TL1A complex
6E8A	;	1.92	;	Crystal structure of DcrB from Salmonella enterica at 1.92 Angstroms resolution
2IT6	;	1.95	;	Crystal Structure of DCSIGN-CRD with man2
2IT5	;	2.4	;	Crystal Structure of DCSIGN-CRD with man6
2GRL	;	3.0	;	Crystal structure of dCT/iCF10 complex
2YZJ	;	1.66	;	Crystal structure of dCTP deaminase from Sulfolobus tokodaii
2PFZ	;	1.8	;	Crystal structure of DctP6, a Bordetella pertussis extracytoplasmic solute receptor binding pyroglutamic acid
2PFY	;	1.95	;	Crystal structure of DctP7, a Bordetella pertussis extracytoplasmic solute receptor binding pyroglutamic acid
4NX2	;	2.0	;	Crystal structure of DCYRS complexed with DCY
2B5M	;	2.92	;	Crystal Structure of DDB1
6DSZ	;	3.093	;	Crystal structure of DDB1 in complex with DET1- and DDB1-associated protein 1 (DDA1)
2B5L	;	2.85	;	Crystal Structure of DDB1 In Complex with Simian Virus 5 V Protein
3I7L	;	2.8	;	Crystal Structure of DDB1 in Complex with the H-Box Motif of DDB2
3I7H	;	2.9	;	Crystal Structure of DDB1 in Complex with the H-Box Motif of HBX
3I7O	;	2.8	;	Crystal Structure of DDB1 in Complex with the H-Box Motif of IQWD1
7UKN	;	2.9	;	Crystal Structure of DDB1 in Complex with the H-Box Motif of pUL145
3I8C	;	2.8	;	Crystal Structure of DDB1 in Complex with the H-Box Motif of WDR21A
3I89	;	3.0	;	Crystal Structure of DDB1 in Complex with the H-Box Motif of WDR22
3I7P	;	3.0	;	Crystal Structure of DDB1 in Complex with the H-Box Motif of WDR40A
3I8E	;	3.4	;	Crystal Structure of DDB1 in Complex with the H-Box Motif of WDR42A
3I7N	;	2.8	;	Crystal Structure of DDB1 in Complex with the H-Box Motif of WDTC1
3I7K	;	2.8	;	Crystal Structure of DDB1 in Complex with the H-Box Motif of WHX
7LPS	;	3.78	;	Crystal structure of DDB1-CRBN-ALV1 complex bound to Helios (IKZF2 ZF2)
6BN7	;	3.501	;	Crystal structure of DDB1-CRBN-BRD4(BD1) complex bound to dBET23 PROTAC.
6BN8	;	3.99004	;	Crystal structure of DDB1-CRBN-BRD4(BD1) complex bound to dBET55 PROTAC.
6BNB	;	6.343	;	Crystal structure of DDB1-CRBN-BRD4(BD1) complex bound to dBET57 PROTAC
6BOY	;	3.33	;	Crystal structure of DDB1-CRBN-BRD4(BD1) complex bound to dBET6 PROTAC.
6BN9	;	4.382	;	Crystal structure of DDB1-CRBN-BRD4(BD1) complex bound to dBET70 PROTAC
6A53	;	2.0	;	Crystal structure of DddK
6A55	;	1.6	;	Crystal structure of DddK mutant Y122A
6A54	;	2.3	;	Crystal structure of DddK mutant Y64A
8HLF	;	1.62	;	Crystal structure of DddK-DMSOP complex
5Y4K	;	2.0	;	Crystal structure of DddY mutant Y260A
5XKY	;	2.303	;	Crystal structure of DddY Se derivative
4NOE	;	2.2	;	Crystal structure of DdrB bound to 30b ssDNA
4HQB	;	2.301	;	Crystal structure of DdrB from Deinococcus radiodurans bound to ssDNA
6JQ1	;	2.3	;	Crystal Structure of DdrO from Deinococcus geothermalis
8DBB	;	1.3	;	Crystal structure of DDT with the selective inhibitor 2,5-Pyridinedicarboxylic Acid
7YMF	;	2.3	;	Crystal Structure of DDX3X449_450ET>DP
3IUY	;	2.4	;	Crystal structure of DDX53 DEAD-box domain
8KCA	;	1.97	;	Crystal structure of DDX53 helicase domain
3VJF	;	2.2	;	Crystal structure of de novo 4-helix bundle protein WA20
3U13	;	1.6	;	Crystal Structure of de Novo design of cystein esterase ECH13 at the resolution 1.6A, Northeast Structural Genomics Consortium Target OR51
4GVV	;	2.895	;	Crystal Structure of de novo design serine hydrolase OSH55.27, Northeast Structural Genomics Consortium (NESG) Target OR246
4E88	;	2.0	;	CRYSTAL STRUCTURE OF DE NOVO DESIGNED CYSTEINE ESTERASE ECH13, Northeast Structural Genomics Consortium Target OR51
3UAK	;	3.232	;	Crystal Structure of De Novo designed cysteine esterase ECH14, Northeast Structural Genomics Consortium Target OR54
5CW9	;	3.108	;	Crystal structure of De novo designed ferredoxin-ferredoxin domain insertion protein
5HKR	;	2.35	;	Crystal structure of de novo designed fullerene organising protein complex with fullerene
5ET3	;	1.671	;	Crystal Structure of De novo Designed Fullerene organizing peptide
3S0R	;	2.453	;	Crystal Structure of De novo Designed helical assembly protein
5CWG	;	1.2	;	Crystal structure of de novo designed helical repeat protein DHR10
5CWH	;	1.3	;	Crystal structure of de novo designed helical repeat protein DHR14
5CWI	;	1.75	;	Crystal structure of de novo designed helical repeat protein DHR18
5CWB	;	1.55	;	Crystal structure of de novo designed helical repeat protein DHR4
5CWJ	;	1.7	;	Crystal structure of de novo designed helical repeat protein DHR49
5CWC	;	1.25	;	Crystal structure of de novo designed helical repeat protein DHR5
5CWK	;	1.9	;	Crystal structure of de novo designed helical repeat protein DHR53
5CWL	;	1.5	;	Crystal structure of de novo designed helical repeat protein DHR54
5CWM	;	2.9	;	Crystal structure of de novo designed helical repeat protein DHR64
5CWD	;	2.61	;	Crystal structure of de novo designed helical repeat protein DHR7
5CWN	;	1.7	;	Crystal structure of de novo designed helical repeat protein DHR71
5CWO	;	3.35	;	Crystal structure of de novo designed helical repeat protein DHR76
5CWP	;	1.9	;	Crystal structure of de novo designed helical repeat protein DHR79
5CWF	;	1.8	;	Crystal structure of de novo designed helical repeat protein DHR8
5CWQ	;	2.05	;	Crystal structure of de novo designed helical repeat protein DHR81
6NLA	;	1.34	;	Crystal structure of de novo designed metal-controlled dimer of B1 immunoglobulin-binding domain of Streptococcal Protein G (L12H, E15V, T16L, T18I, V29H, Y33H, N37L)-zinc
6NLB	;	2.3	;	Crystal structure of de novo designed metal-controlled dimer of mutant B1 immunoglobulin-binding domain of Streptococcal Protein G (L12H, E15V, T16L, T18I, V29H, Y33H, N37L)-apo
6NL9	;	1.7	;	Crystal structure of de novo designed metal-controlled dimer of mutant B1 immunoglobulin-binding domain of Streptococcal Protein G (L12H, T16L, V29H, Y33H, N37L)-apo
6NL8	;	1.5	;	Crystal structure of de novo designed metal-controlled dimer of mutant B1 immunoglobulin-binding domain of Streptococcal Protein G (L12H, T16L, V29H, Y33H, N37L)-zinc
3V1A	;	0.98	;	Crystal structure of de novo designed MID1-apo1
3V1B	;	1.28	;	Crystal structure of de novo designed MID1-apo2
3V1D	;	1.239	;	Crystal structure of de novo designed MID1-cobalt
3V1C	;	1.129	;	Crystal structure of de novo designed MID1-zinc
3V1E	;	1.073	;	Crystal structure of de novo designed MID1-zinc H12E mutant
3V1F	;	1.151	;	Crystal structure of de novo designed MID1-zinc H35E mutant
5E6G	;	2.09	;	Crystal Structure of De Novo Designed Protein CA01
7TJL	;	1.87	;	Crystal structure of de novo designed protein, SEWN0.1
4N3P	;	2.501	;	Crystal Structure of De Novo designed Serine Hydrolase OSH18, Northeast Structural Genomics Consortium (NESG) Target OR396
3V45	;	2.6	;	Crystal Structure of de novo designed serine hydrolase OSH55, Northeast Structural Genomics Consortium Target OR130
4KYB	;	2.909	;	Crystal Structure of de novo designed serine hydrolase OSH55.14_E3, Northeast Structural Genomics Consortium Target OR342
4F2V	;	2.493	;	Crystal Structure of de novo designed serine hydrolase, Northeast Structural Genomics Consortium (NESG) Target OR165
6IIY	;	1.29	;	Crystal structure of deacetylase triple mutant (Orf2*T) that involving in teicoplanin biosynthetic pathway
2X9L	;	1.732	;	Crystal structure of deacetylase-bog complex in biosynthesis pathway of teicoplanin.
2XAD	;	1.7	;	Crystal structure of deacetylase-teicoplanin complex in biosynthesis pathway of teicoplanin
2VAX	;	2.6	;	Crystal structure of deacetylcephalosporin C acetyltransferase (Cephalosporin C-soak)
2VAV	;	2.5	;	Crystal structure of deacetylcephalosporin C acetyltransferase (DAC-Soak)
2VAT	;	2.2	;	Crystal structure of deacetylcephalosporin C acetyltransferase in complex with coenzyme A
6Z21	;	1.3	;	Crystal structure of deacylation mutant KPC-2 (E166Q)
6Z22	;	1.4	;	Crystal structure of deacylation mutant KPC-4 (E166Q)
8ARK	;	3.22	;	Crystal structure of DEAD-box protein Dbp2 in apo form
8ARP	;	3.05	;	Crystal structure of DEAD-box protein Dbp2 in complex with ADP
6O5F	;	2.504	;	Crystal structure of DEAD-box RNA helicase DDX3X at pre-unwound state
5UWW	;	2.152	;	Crystal Structure of DEAF1 Peptide in complex with CRM1 K579A mutant-Ran-RanBP1
4AQA	;	1.96	;	CRYSTAL STRUCTURE OF DEAFNESS ASSOCIATED MUTANT MOUSE CADHERIN-23 EC1- 2D124G AND PROTOCADHERIN-15 EC1-2 FORM I
4AQE	;	2.27	;	CRYSTAL STRUCTURE OF DEAFNESS ASSOCIATED MUTANT MOUSE CADHERIN-23 EC1- 2S70P AND PROTOCADHERIN-15 EC1-2 FORM I
6I3O	;	3.25	;	Crystal structure of DEAH-box ATPase Prp22
6I3P	;	2.75	;	Crystal structure of DEAH-box ATPase Prp22 with bound ssRNA
6QIC	;	2.7	;	Crystal structure of DEAH-box ATPase Prp22-S837A with bound ssRNA
6QID	;	2.204	;	Crystal structure of DEAH-box ATPase Prp43-S387A
6QIE	;	2.7	;	Crystal structure of DEAH-box ATPase Prp43-S387G
6IZH	;	1.754	;	Crystal structure of deaminase AmnE from Pseudomonas sp. AP-3
6H9V	;	1.52	;	Crystal structure of deaminated P domain from norovirus strain Saga GII-4 in complex with Fuc
3EH9	;	1.7	;	Crystal structure of death associated protein kinase complexed with ADP
3EHA	;	1.6	;	Crystal structure of death associated protein kinase complexed with AMPPNP
3F5G	;	1.85	;	Crystal structure of death associated protein kinase in complex with ADP and Mg2+
4ZBW	;	2.2	;	Crystal structure of death effector domain of Caspase8 in Homo Sapiens
5CIR	;	3.0	;	Crystal structure of death receptor 4 (DR4; TNFFRSF10A) bound to TRAIL (TNFSF10)
1D0G	;	2.4	;	CRYSTAL STRUCTURE OF DEATH RECEPTOR 5 (DR5) BOUND TO APO2L/TRAIL
7CCV	;	1.753	;	Crystal structure of death-associated protein kinase 1 in complex with piceatannol
7CCU	;	1.649	;	Crystal structure of death-associated protein kinase 1 in complex with resveratrol
7CCW	;	1.4	;	Crystal structure of death-associated protein kinase 1 in complex with resveratrol and MES
4TL0	;	2.7	;	Crystal structure of death-associated protein kinase 1 with a crucial phosphomimicking mutation
2GRE	;	2.65	;	Crystal structure of Deblocking aminopeptidase from Bacillus cereus
2WCS	;	2.8	;	Crystal Structure of Debranching enzyme from Nostoc punctiforme (NPDE)
1TSU	;	2.1	;	CRYSTAL STRUCTURE OF DECAMER NCP1 SUBSTRATE PEPTIDE IN COMPLEX WITH WILD-TYPE D25N HIV-1 PROTEASE VARIANT
5J09	;	2.0	;	Crystal structure of decameric BFDV Capsid Protein
3ZTL	;	3.0	;	Crystal structure of decameric form of Peroxiredoxin I from Schistosoma mansoni
5MAC	;	2.6	;	Crystal structure of decameric Methanococcoides burtonii Rubisco complexed with 2-carboxyarabinitol bisphosphate
1HHC	;	1.13	;	Crystal structure of Decaplanin - space group P21, second form
8IH6	;	2.519	;	Crystal structure of decarboxylase-hydratase complex from Pseudomonas species AP-3
8I75	;	1.33	;	Crystal structure of decarboxylated osteocalcin at pH 2.0
8I76	;	1.381	;	Crystal structure of decarboxylated osteocalcin at pH 2.0 without glycerol
8I74	;	1.36	;	Crystal structure of decarboxylated osteocalcin at pH 8.5
8X38	;	2.0	;	Crystal Structure of Decarboxylative Vanillate 1-Hydroxylase from Phanerochaete chrysosporium
7K3H	;	3.0	;	Crystal structure of deep network hallucinated protein 0217
7M0Q	;	2.4	;	Crystal structure of deep network hallucinated protein 0738_mod
5H12	;	2.502	;	Crystal structure of Deep Vent DNA Polymerase
5H0O	;	1.53	;	Crystal structure of deep-sea thermophilic bacteriophage GVE2 HNH endonuclease with manganese ion
5H0M	;	1.52	;	Crystal structure of deep-sea thermophilic bacteriophage GVE2 HNH endonuclease with zinc ion
4YXH	;	2.7	;	Crystal structure of Deer prion protein complexed with POM1 FAB
1DFN	;	1.9	;	CRYSTAL STRUCTURE OF DEFENSIN HNP-3, AN AMPHIPHILIC DIMER: MECHANISMS OF MEMBRANE PERMEABILIZATION
4IC5	;	2.607	;	Crystal structure of Deg5
4IC6	;	2.0	;	Crystal structure of Deg8
5IL9	;	2.2	;	Crystal structure of Deg9
5Y09	;	2.449	;	Crystal structure of Deg9 at 295 K
6E7O	;	3.0	;	Crystal structure of deglycosylated human EPDR1
4D2N	;	2.7	;	Crystal structure of deglycosylated serum-derived human IgG4 Fc
1KY9	;	2.8	;	Crystal Structure of DegP (HtrA)
3CS0	;	3.0	;	Crystal structure of DegP24
1VCW	;	3.05	;	Crystal structure of DegS after backsoaking the activating peptide
3GDV	;	2.489	;	Crystal structure of DegS H198P/D320A mutant modified by DFP and in complex with YQF peptide
3GDU	;	3.0	;	Crystal structure of DegS H198P/D320A mutant modified by DFP and in complex with YRF peptide
3GCO	;	2.798	;	Crystal structure of DegS H198P/D320A mutant modified by DFP in complex with DNRDGNVYQF OMP peptide
3GDS	;	2.85	;	Crystal structure of DegS H198P/D320A mutant modified by DFP in complex with DNRDGNVYYF peptide
3GCN	;	3.002	;	Crystal structure of DegS H198P/D320A mutant modified by DFP in complex with OMP peptide (YQF)
1SOZ	;	2.4	;	Crystal Structure of DegS protease in complex with an activating peptide
6EW9	;	2.2	;	CRYSTAL STRUCTURE OF DEGS STRESS SENSOR PROTEASE IN COMPLEX WITH ACTIVATING DNRLGLVYQF PEPTIDE
3EGL	;	2.41	;	Crystal Structure of DegV Family Protein Cg2579 from Corynebacterium glutamicum
3FYS	;	2.5	;	Crystal Structure of DegV, a fatty acid binding protein from Bacillus subtilis
4W7H	;	3.11	;	Crystal Structure of DEH Reductase A1-R Mutant
4W7I	;	1.98	;	Crystal structure of DEH reductase A1-R' mutant
4KYV	;	1.796	;	Crystal Structure of dehalogenase HaloTag2 with HALTS at the resolution 1.8A. Northeast Structural Genomics Consortium (NESG) Target OR150
3IXF	;	1.58	;	Crystal Structure of Dehaloperoxidase B at 1.58 and Structural Characterization of the AB Dimer from Amphitrite ornata
7T9E	;	1.57	;	Crystal structure of dehaloperoxidase B in complex with +(-)-limonene oxide
7T9D	;	1.66	;	Crystal structure of dehaloperoxidase B in complex with -(-) limonene oxide
7M1J	;	1.554	;	Crystal structure of dehaloperoxidase B in complex with 2,6-dibromophenol
7M1I	;	1.66	;	Crystal structure of dehaloperoxidase B in complex with 2,6-dichlorophenol
7M1K	;	1.795	;	Crystal structure of dehaloperoxidase B in complex with 2,6-difluorophenol
7SJB	;	1.718	;	Crystal structure of dehaloperoxidase B in complex with alpha-terpinene
6VDS	;	1.97	;	Crystal Structure of Dehaloperoxidase B in Complex with cofactor Iron(III) Deuteroporphyrin IX and Substrate 4-bromo-ortho-cresol
6VDR	;	1.87	;	Crystal Structure of Dehaloperoxidase B in Complex with cofactor Iron(III) Deuteroporphyrin IX and Substrate 4-bromophenol
6VDT	;	1.978	;	Crystal Structure of Dehaloperoxidase B in Complex with cofactor Iron(III) Deuteroporphyrin IX and Substrate 4-nitrophenol
6VDU	;	1.98	;	Crystal Structure of Dehaloperoxidase B in Complex with cofactor Iron(III) Deuteroporphyrin IX and Substrate Trichlorophenol
6VD4	;	1.954	;	Crystal Structure of Dehaloperoxidase B in Complex with cofactor Iron(III) Mesoporphyrin IX and Substrate 4-bromo-ortho-cresol
6VD3	;	1.67	;	Crystal Structure of Dehaloperoxidase B in Complex with cofactor Iron(III) Mesoporphyrin IX and Substrate 4-bromophenol
6VD6	;	1.563	;	Crystal Structure of Dehaloperoxidase B in Complex with cofactor Iron(III) Mesoporphyrin IX and Substrate 4-nitrophenol
6VD5	;	1.64	;	Crystal Structure of Dehaloperoxidase B in Complex with cofactor Iron(III) Mesoporphyrin IX and Substrate Trichlorophenol
6VDW	;	1.5	;	Crystal Structure of Dehaloperoxidase B in Complex with cofactor Manganese(III) Porphyrin and Substrate 4-nitrophenol
6VDV	;	1.88	;	Crystal Structure of Dehaloperoxidase B in Complex with cofactor Manganese(III)- Porphyrin and Substrate 4-bromophenol
6VDX	;	1.53	;	Crystal Structure of Dehaloperoxidase B in Complex with cofactor Manganese(III)- Porphyrin and Substrate Trichlorophenol
7SJC	;	1.7	;	Crystal structure of dehaloperoxidase B in complex with gamma-terpinene
7SJE	;	1.72	;	Crystal structure of dehaloperoxidase B in complex with p-cymene
7SJI	;	1.76	;	Crystal structure of dehaloperoxidase B in complex with R-(+)-limonene
7SJH	;	1.87	;	Crystal structure of dehaloperoxidase B in complex with S-(-)-limonene
7SJD	;	1.703	;	Crystal structure of dehaloperoxidase B in complex with terpinolene
7T9C	;	1.73	;	Crystal structure of dehaloperoxidase B in complex with thymol
6VDY	;	1.7	;	Crystal Structure of Dehaloperoxidase B wild type in Complex with Substrate Trichlorophenol
8E5W	;	2.15	;	Crystal structure of dehydroalanine Hip1
5D9T	;	1.9	;	Crystal structure of dehydroascorbate reductase (OsDHAR) from Oryza sativa L. japonica
5O0X	;	2.2	;	Crystal structure of dehydrogenase domain of Cylindrospermum stagnale NADPH-Oxidase 5 (NOX5)
8CAO	;	2.3	;	Crystal structure of dehydrogenase domain of Cylindrospermum stagnale NADPH-Oxidase 5 (NOX5) in complex with CA24
8CAP	;	3.0	;	Crystal structure of dehydrogenase domain of Cylindrospermum stagnale NADPH-Oxidase 5 (NOX5) in complex with CB28
8CAL	;	2.41	;	Crystal structure of dehydrogenase domain of Cylindrospermum stagnale NADPH-Oxidase 5 (NOX5) in complex with M34
8CAK	;	2.67	;	Crystal structure of dehydrogenase domain of Cylindrospermum stagnale NADPH-Oxidase 5 (NOX5) in complex with M41
8CB0	;	2.5	;	Crystal structure of dehydrogenase domain of Cylindrospermum stagnale NADPH-Oxidase 5 (NOX5) in complex with M41 and NADP+
5F1P	;	2.099	;	Crystal Structure of Dehydrogenase from Streptomyces platensis
7E1Q	;	1.7	;	Crystal structure of dehydrogenase/isomerase FabX from Helicobacter pylori
7E1R	;	2.795	;	Crystal structure of Dehydrogenase/isomerase FabX from Helicobacter pylori in complex with holo-ACP
7E1S	;	2.31	;	Crystal structure of dehydrogenase/isomerase FabX from Helicobacter pylori in complex with octanoyl-ACP
5X47	;	2.54	;	Crystal structure of dehydroquinate dehydratase from Acinetobacter baumannii at 2.5 Angstrom resolution
5YHM	;	1.91	;	Crystal structure of dehydroquinate dehydratase with tris induced oligomerisation at 1.907 Angstrom resolution
1DQS	;	1.8	;	CRYSTAL STRUCTURE OF DEHYDROQUINATE SYNTHASE (DHQS) COMPLEXED WITH CARBAPHOSPHONATE, NAD+ AND ZN2+
1UJN	;	1.8	;	Crystal structure of dehydroquinate synthase from Thermus thermophilus HB8
4EA2	;	2.05	;	Crystal structure of dehydrosqualene synthase (Crtm) aureus complexed with SQ-109
4E9U	;	2.1	;	Crystal structure of dehydrosqualene synthase (Crtm) from S. aureus complexed with a thiocyanate inhibitor
4F6V	;	2.3	;	Crystal structure of dehydrosqualene synthase (crtm) from s. aureus complexed with bph-1034, mg2+ and fmp.
4F6X	;	1.98	;	Crystal structure of dehydrosqualene synthase (crtm) from s. aureus complexed with bph-1112
3TFV	;	3.0	;	Crystal structure of dehydrosqualene synthase (crtm) from s. aureus complexed with bph-1154
3TFP	;	2.0	;	Crystal Structure of Dehydrosqualene Synthase (CrtM) from S. aureus Complexed with BPH-1162
3TFN	;	2.07	;	Crystal structure of dehydrosqualene synthase (crtm) from s. aureus complexed with bph-1183
4EA0	;	2.12	;	Crystal structure of dehydrosqualene synthase (Crtm) from S. aureus complexed with diphosphate and quinuclidine BPH-651
4E9Z	;	2.06	;	Crystal structure of dehydrosqualene synthase (Crtm) from S. aureus complexed with quinuclidine BPH-651 in the S1 site
3LGZ	;	2.41	;	Crystal structure of dehydrosqualene synthase Y129A from S. aureus complexed with presqualene pyrophosphate
8SLM	;	2.81	;	Crystal structure of Deinococcus geothermalis PprI
8SLN	;	2.2	;	Crystal structure of Deinococcus geothermalis PprI complexed with ssDNA
4UNF	;	2.15	;	Crystal structure of Deinococcus radiodurans Endonuclease III-1
8A5F	;	1.38	;	Crystal structure of Deinococcus radiodurans Endonuclease III-1 R61Q variant
8A5C	;	1.951	;	Crystal structure of Deinococcus radiodurans Endonuclease III-1 Y100L variant
4UOB	;	1.31	;	Crystal structure of Deinococcus radiodurans Endonuclease III-3
8A5G	;	1.89	;	Crystal structure of Deinococcus radiodurans Endonuclease III-3 double mutant
2BHU	;	1.1	;	Crystal structure of Deinococcus radiodurans maltooligosyltrehalose trehalohydrolase
2BHZ	;	1.2	;	Crystal structure of Deinococcus radiodurans maltooligosyltrehalose trehalohydrolase in complex with maltose
2BHY	;	1.5	;	Crystal structure of Deinococcus radiodurans maltooligosyltrehalose trehalohydrolase in complex with trehalose
5KTE	;	3.941	;	Crystal structure of Deinococcus radiodurans MntH, an Nramp-family transition metal transporter
6D9W	;	3.941	;	Crystal structure of Deinococcus radiodurans MntH, an Nramp-family transition metal transporter, in the inward-open apo state
2A1V	;	2.15	;	Crystal structure of Deinococcus radiodurans protein DR2400, Pfam domain DUF419
8IOO	;	2.0	;	Crystal structure of Deinococcus radiodurans RecJ-like protein in complex with Mg2+
4ABX	;	2.041	;	Crystal structure of Deinococcus radiodurans RecN coiled-coil domain
4ABY	;	3.0	;	Crystal structure of Deinococcus radiodurans RecN head domain
2NVO	;	1.89	;	Crystal structure of Deinococcus radiodurans RO (RSR) protein
2Q7V	;	1.9	;	Crystal Structure of Deinococcus Radiodurans Thioredoxin Reductase
2F4Q	;	1.75	;	Crystal Structure of Deinococcus radiodurans topoisomerase IB
4C2U	;	2.55	;	Crystal structure of Deinococcus radiodurans UvrD in complex with DNA, Form 1
4C30	;	3.0	;	Crystal structure of Deinococcus radiodurans UvrD in complex with DNA, form 2
4D90	;	2.601	;	Crystal Structure of Del-1 EGF domains
4YLC	;	3.1	;	Crystal Structure of Del-C4 mutant of hsp14.1 from Sulfolobus solfatataricus P2
2IHF	;	1.9	;	Crystal structure of deletion mutant delta 228-252 R190A of the single-stranded DNA binding protein from Thermus aquaticus
2PEY	;	1.88	;	Crystal structure of deletion mutant of APS-kinase domain of human PAPS-synthetase 1
5MC5	;	1.9	;	Crystal Structure of delGlu452 mutant of Human Prolidase with Mn ions and GlyPro ligand
7G0N	;	1.12	;	Crystal Structure of delipidated apo human FABP4
5YD2	;	2.35	;	Crystal Structure of Delta 4 mutant of EhPSAT (Phosphoserine aminotransferase of Entamoeba histolytica)
5Z3R	;	2.42	;	Crystal Structure of Delta 5-3-Ketosteroid Isomerase from Mycobacterium sp.
7TCE	;	3.85	;	Crystal structure of delta sub IV Rhodobacter Sphaeroides bc1 with the antimalarial drug atovaquone.
3BV7	;	1.79	;	Crystal structure of Delta(4)-3-ketosteroid 5-beta-reductase in complex with NADP and glycerol. Resolution: 1.79 A.
3BUR	;	1.62	;	Crystal structure of Delta(4)-3-ketosteroid 5-beta-reductase in complex with NADP and TESTOSTERONE. RESOLUTION: 1.62 A.
3OBK	;	2.5	;	Crystal structure of delta-aminolevulinic acid dehydratase (porphobilinogen synthase) from toxoplasma gondii ME49 in complex with the reaction product porphobilinogen
3VK9	;	2.001	;	Crystal structure of delta-class glutathione transferase from silkmoth
4L27	;	3.391	;	Crystal structure of delta1-39 and delta516-525 human cystathionine beta-synthase D444N mutant containing C-terminal 6xHis tag
2CWF	;	1.8	;	Crystal Structure of delta1-piperideine-2-carboxylate reductase from Pseudomonas syringae complexed with NADPH
2CWH	;	1.7	;	Crystal Structure of delta1-piperideine-2-carboxylate reductase from Pseudomonas syringae complexed with NADPH and pyrrole-2-carboxylate
1WTJ	;	1.55	;	Crystal Structure of delta1-piperideine-2-carboxylate reductase from Pseudomonas syringae pvar.tomato
3FG4	;	2.31	;	Crystal structure of Delta413-417:GS I805A LOX
3FG3	;	1.9	;	Crystal structure of Delta413-417:GS I805W LOX
3FG1	;	1.85	;	Crystal structure of Delta413-417:GS LOX
6Y21	;	3.6	;	Crystal structure of delta466-491 cystathionine beta-synthase from Toxoplasma gondii with L-Cystathionine
6ZS7	;	3.5	;	Crystal structure of delta466-491 cystathionine beta-synthase from Toxoplasma gondii with L-cysteine
6XYL	;	3.151	;	Crystal structure of delta466-491 cystathionine beta-synthase from Toxoplasma gondii with L-serine
6Z3S	;	3.048	;	Crystal structure of delta466-491 cystathionine beta-synthase from Toxoplasma gondii with O-Acetylserine
4K1U	;	2.0	;	Crystal structure of delta5-3-ketosteroid isomerase containing Y16F and Y32F mutations
4K1V	;	1.8	;	Crystal structure of delta5-3-ketosteroid isomerase containing Y16F and Y57F mutations
8CHO	;	2.3	;	CRYSTAL STRUCTURE OF DELTA5-3-KETOSTEROID ISOMERASE FROM PSEUDOMONAS TESTOSTERONI
1QJG	;	2.3	;	Crystal structure of delta5-3-ketosteroid isomerase from Pseudomonas testosteroni in complex with equilenin
4PCU	;	3.578	;	Crystal structure of delta516-525 E201S human cystathionine beta-synthase with AdoMet
4L3V	;	3.628	;	Crystal structure of delta516-525 human cystathionine beta-synthase
4L0D	;	2.97	;	Crystal structure of delta516-525 human cystathionine beta-synthase containing C-terminal 6xHis-tag
4L28	;	2.626	;	Crystal structure of delta516-525 human cystathionine beta-synthase D444N mutant containing C-terminal 6xHis tag
4FBZ	;	2.7	;	Crystal structure of deltarhodopsin from Haloterrigena thermotolerans
5MC0	;	1.56	;	Crystal Structure of delTyr231 mutant of Human Prolidase with Mn ions and GlyPro ligand
1CN1	;	3.2	;	CRYSTAL STRUCTURE OF DEMETALLIZED CONCANAVALIN A. THE METAL-BINDING REGION
1XT9	;	2.2	;	Crystal Structure of Den1 in complex with Nedd8
4X42	;	2.78	;	Crystal structure of DEN4 ED3 mutant with epitope two residues substituted from DEN3 ED3
5B1C	;	2.003	;	Crystal structure of DEN4 ED3 mutant with L387I
2E1U	;	2.2	;	Crystal structure of Dendranthema morifolium DmAT
2E1T	;	2.1	;	Crystal structure of Dendranthema morifolium DmAT complexed with malonyl-CoA
2E1V	;	1.8	;	Crystal structure of Dendranthema morifolium DmAT, seleno-methionine derivative
5DU1	;	1.8	;	Crystal structure of Dendroaspis polylepis mambalgin-1 wild-type in P21 space group.
5DZ5	;	1.95	;	Crystal structure of Dendroaspis polylepis mambalgin-1 wild-type in P41212 space group
5DO6	;	1.697	;	Crystal structure of Dendroaspis polylepis venom mambalgin-1 T23A mutant
7A3R	;	3.6	;	Crystal structure of dengue 1 virus envelope glycoprotein
7A3O	;	2.8	;	Crystal structure of dengue 1 virus envelope glycoprotein in complex with the scFv fragment of the broadly neutralizing human antibody EDE1 C10
4UTC	;	3.08	;	Crystal structure of dengue 2 virus envelope glycoprotein
4UT9	;	3.2	;	Crystal structure of dengue 2 virus envelope glycoprotein dimer in complex with the ScFv fragment of the broadly neutralizing human antibody EDE1 C10
4UTA	;	3.0	;	Crystal structure of dengue 2 virus envelope glycoprotein in complex with the Fab fragment of the broadly neutralizing human antibody EDE1 C8
4UTB	;	3.85	;	Crystal structure of dengue 2 virus envelope glycoprotein in complex with the Fab fragment of the broadly neutralizing human antibody EDE2 A11
4UT6	;	3.2	;	Crystal structure of dengue 2 virus envelope glycoprotein in complex with the Fab fragment of the broadly neutralizing human antibody EDE2 B7
7A3S	;	2.8	;	Crystal structure of dengue 3 virus envelope glycoprotein
7A3T	;	2.65	;	Crystal structure of dengue 3 virus envelope glycoprotein in complex with the Fab fragment of the broadly neutralizing human antibody EDE1 C8
7A3P	;	3.19	;	Crystal structure of dengue 3 virus envelope glycoprotein in complex with the scFv fragment of the broadly neutralizing human antibody EDE1 C10
3WE1	;	2.278	;	Crystal structure of Dengue 4 Envelope protein domain III (ED3)
7A3Q	;	2.7	;	Crystal structure of dengue 4 virus envelope glycoprotein in complex with the scFv fragment of the broadly neutralizing human antibody EDE1 C10
2P3O	;	2.756	;	Crystal Structure of Dengue Methyltransferase in Complex with 7MeGpppA and S-Adenosyl-L-homocysteine
2P40	;	2.701	;	Crystal Structure of Dengue Methyltransferase in Complex with 7MeGpppG
2P41	;	1.801	;	Crystal Structure of Dengue Methyltransferase in Complex with 7MeGpppG2'OMe and S-Adenosyl-L-homocysteine
2P3L	;	2.2	;	Crystal Structure of Dengue Methyltransferase in Complex with GpppA and S-Adenosyl-L-Homocysteine
2P3Q	;	2.75	;	Crystal Structure of Dengue Methyltransferase in Complex with GpppG and S-Adenosyl-L-homocysteine
2P1D	;	2.9	;	Crystal structure of dengue methyltransferase in complex with GTP and S-Adenosyl-L-homocysteine
7VMV	;	3.351	;	Crystal structure of Dengue NS2B-NS3 Protease after secondary cleavage
3L6P	;	2.2	;	Crystal Structure of Dengue Virus 1 NS2B/NS3 protease
3LKW	;	2.0	;	Crystal Structure of Dengue Virus 1 NS2B/NS3 protease active site mutant
6KR2	;	3.06	;	Crystal structure of Dengue virus nonstructural protein NS5 (form 1)
6KR3	;	2.931	;	Crystal structure of Dengue virus nonstructural protein NS5 (form 2)
7XD9	;	2.58	;	Crystal Structure of Dengue Virus serotype 2 (DENV2) Polymerase Elongation Complex (CTP Form)
7XD8	;	2.85	;	Crystal Structure of Dengue Virus Serotype 2 (DENV2) Polymerase Elongation Complex (Native Form)
5IQ6	;	3.0	;	Crystal structure of Dengue virus serotype 3 RNA dependent RNA polymerase bound to HeE1-2Tyr, a new pyridobenzothizole inhibitor
3G7T	;	3.5	;	Crystal structure of dengue virus type 1 envelope protein in the postfusion conformation
3EVG	;	2.2	;	Crystal structure of Dengue-2 virus methyltransferase complexed with S-adenosyl-L-homocysteine
6YQX	;	1.638	;	Crystal structure of DeNovoTIM13, a de novo designed TIM barrel
6Z2I	;	2.901	;	Crystal structure of DeNovoTIM6, a de novo designed TIM barrel
4L5F	;	2.45	;	Crystal Structure of DENV1-E106 Fab bound to DENV-1 Envelope protein DIII
4FFZ	;	3.8	;	Crystal Structure of DENV1-E111 fab fragment bound to DENV-1 DIII (Western Pacific-74 strain).
4FFY	;	2.5	;	Crystal structure of DENV1-E111 single chain variable fragment bound to DENV-1 DIII, strain 16007.
4LKR	;	2.4	;	Crystal structure of deoD-3 gene product from Shewanella oneidensis MR-1, NYSGRC target 029437
1J7S	;	2.2	;	Crystal Structure of deoxy HbalphaYQ, a mutant of HbA
1J7W	;	2.0	;	Crystal structure of deoxy HbbetaYQ, a site directed mutant of HbA
2H8F	;	1.3	;	Crystal structure of deoxy hemoglobin from Trematomus bernacchii at pH 6.2
2H8D	;	1.78	;	Crystal structure of deoxy hemoglobin from Trematomus bernacchii at pH 8.4
6BWP	;	1.7	;	Crystal structure of Deoxy Hemoglobin in complex with beta Cys93 modifying agent, TD3
2D60	;	1.7	;	Crystal structure of deoxy human hemoglobin complexed with two L35 molecules
1F63	;	1.8	;	CRYSTAL STRUCTURE OF DEOXY SPERM WHALE MYOGLOBIN MUTANT Y(B10)Q(E7)R(E10)
1R1Y	;	1.8	;	Crystal structure of deoxy-human hemoglobin Bassett at 1.8 angstrom
6HBW	;	2.0	;	Crystal structure of deoxy-human hemoglobin beta6 glu->trp
7UD7	;	1.8	;	Crystal structure of deoxygenated hemoglobin in complex with 5HMF-NO at 1.8 Angstrom
5E29	;	1.85	;	Crystal Structure of Deoxygenated Hemoglobin in Complex with an Allosteric Effector and Nitric Oxide
5KSJ	;	2.4	;	Crystal structure of deoxygenated hemoglobin in complex with Sphingosine phosphate
5KSI	;	1.8	;	Crystal structure of deoxygenated hemoglobin in complex with sphingosine phosphate and 2,3-Bisphosphoglycerate
1LLA	;	2.18	;	CRYSTAL STRUCTURE OF DEOXYGENATED LIMULUS POLYPHEMUS SUBUNIT II HEMOCYANIN AT 2.18 ANGSTROMS RESOLUTION: CLUES FOR A MECHANISM FOR ALLOSTERIC REGULATION
3BG2	;	1.95	;	Crystal structure of deoxyguanosinetriphosphate triphosphohydrolase from Flavobacterium sp. MED217
7CMC	;	2.2	;	CRYSTAL STRUCTURE OF DEOXYHYPUSINE SYNTHASE FROM PYROCOCCUS HORIKOSHII
4U53	;	3.3	;	Crystal structure of Deoxynivalenol bound to the yeast 80S ribosome
7E37	;	2.09	;	Crystal structure of deoxypodophyllotoxin synthase from Sinopodophyllum hexandrum in complex with 2-oxoglutarate
7E38	;	2.05	;	Crystal structure of deoxypodophyllotoxin synthase from Sinopodophyllum hexandrum in complex with yatein and succinate
3BWV	;	1.55	;	Crystal structure of deoxyribonucleotidase-like protein (NP_764060.1) from Staphylococcus epidermidis ATCC 12228 at 1.55 A resolution
3NG3	;	2.15	;	Crystal structure of deoxyribose phosphate aldolase from mycobacterium avium 104 in a schiff base with an unknown aldehyde
3NDO	;	1.25	;	Crystal structure of deoxyribose phosphate aldolase from mycobacterium smegmatis
6BTG	;	1.698	;	Crystal structure of deoxyribose-phosphate aldolase bound with DHAP from Bacillus Thuringiensis
6BTD	;	1.551	;	Crystal structure of deoxyribose-phosphate aldolase from Bacillus Thuringiensis involved in dispatching the ubiquitous radical SAM enzyme byproduct 5-deoxyribose
5C5Y	;	2.1	;	Crystal structure of deoxyribose-phosphate aldolase from Colwellia psychrerythraea (hexagonal form)
5C2X	;	2.11	;	Crystal structure of deoxyribose-phosphate aldolase from Colwellia psychrerythraea (tetragonal form)
5EKY	;	1.1	;	Crystal structure of deoxyribose-phosphate aldolase from Escherichia coli (K58E-Y96W mutant)
5EL1	;	1.25	;	Crystal structure of deoxyribose-phosphate aldolase from Escherichia coli (K58E-Y96W mutant) after acetaldehyde treatment
5EMU	;	1.5	;	Crystal structure of deoxyribose-phosphate aldolase from Escherichia coli (K58E-Y96W mutant) after acetaldehyde treatment and heating
5C6M	;	1.76	;	Crystal structure of deoxyribose-phosphate aldolase from Shewanella halifaxensis
6MAI	;	1.8	;	Crystal structure of Deoxyuridine 5'-triphosphate nucleotidohydrolase from Legionella pneumophila Philadelphia 1
6MAO	;	1.95	;	Crystal structure of Deoxyuridine 5'-triphosphate nucleotidohydrolase from Legionella pneumophila Philadelphia 1 in complex with dUMP (Deoxyuridine 5'-monophosphate)
7N56	;	2.15	;	Crystal Structure of deoxyuridine 5'-triphosphate nucleotidohydrolase from Rickettsia prowazekii str. Madrid E
7N6S	;	1.75	;	Crystal Structure of deoxyuridine 5'-triphosphate nucleotidohydrolase from Rickettsia prowazekii str. Madrid E in complex with 2'-deoxyuridine 5'-monophoephate (dUMP)
3MBQ	;	2.1	;	Crystal structure of deoxyuridine 5-triphosphate nucleotidohydrolase from Brucella melitensis, orthorhombic crystal form
3MDX	;	1.45	;	Crystal structure of deoxyuridine 5-triphosphate nucleotidohydrolase from Brucella melitensis, rhombohedral crystal form
3LQW	;	1.3	;	Crystal structure of deoxyuridine 5-triphosphate nucleotidohydrolase from Entamoeba histolytica
4NTE	;	1.9	;	Crystal structure of DepH
1VIY	;	1.89	;	Crystal structure of dephospho-CoA kinase
2GRJ	;	2.6	;	Crystal structure of Dephospho-CoA kinase (EC 2.7.1.24) (Dephosphocoenzyme A kinase) (tm1387) from THERMOTOGA MARITIMA at 2.60 A resolution
8U94	;	1.4	;	Crystal Structure of Dephospho-CoA kinase from Klebsiella aerogenes (ADP Bound)
8U97	;	1.5	;	Crystal Structure of Dephospho-CoA kinase from Klebsiella aerogenes (AMP-PNP bound)
8U96	;	1.5	;	Crystal Structure of Dephospho-CoA kinase from Klebsiella aerogenes (ATP bound)
8SBN	;	1.15	;	Crystal Structure of Dephospho-CoA kinase from Klebsiella aerogenes (P21 Form 1)
8SBO	;	1.4	;	Crystal Structure of Dephospho-CoA kinase from Klebsiella aerogenes (P21 Form 2)
1VHL	;	1.65	;	Crystal structure of dephospho-CoA kinase with adenosine-5'-diphosphate
1VHT	;	1.59	;	Crystal structure of dephospho-coA kinase with bis(adenosine)-5'-triphosphate
1N3B	;	1.8	;	Crystal Structure of Dephosphocoenzyme A kinase from Escherichia coli
1CQJ	;	2.9	;	CRYSTAL STRUCTURE OF DEPHOSPHORYLATED E. COLI SUCCINYL-COA SYNTHETASE
1EUC	;	2.1	;	CRYSTAL STRUCTURE OF DEPHOSPHORYLATED PIG HEART, GTP-SPECIFIC SUCCINYL-COA SYNTHETASE
7OY3	;	1.78	;	Crystal structure of depupylase Dop in complex with phosphorylated Pup and ADP
7OYH	;	1.75	;	Crystal structure of depupylase Dop in complex with Pup and ADP/tetrafluoromagnesate
7OYF	;	1.88	;	Crystal structure of depupylase Dop in complex with Pup and ADP/trifluoromagnesate
7OXY	;	1.65	;	Crystal structure of depupylase Dop in complex with Pup and AMP-PCP
7OXV	;	1.394	;	Crystal structure of depupylase Dop in the Dop-loop-inserted state
5VPL	;	1.9	;	CRYSTAL STRUCTURE OF DER F 1 COMPLEXED WITH FAB 4C1
5VPG	;	1.95	;	CRYSTAL STRUCTURE OF DER P 1 COMPLEXED WITH FAB 4C1
5VPH	;	2.5	;	CRYSTAL STRUCTURE OF DER P 1 COMPLEXED WITH FAB 4C1
1K94	;	1.7	;	Crystal structure of des(1-52)grancalcin with bound calcium
1K95	;	1.9	;	Crystal structure of des(1-52)grancalcin with bound calcium
3WR8	;	2.25	;	Crystal structure of DesB from Sphingobium sp. strain SYK-6
7NHU	;	1.4	;	Crystal structure of desB30 insulin produced by cell free protein synthesis
2OQ5	;	1.61	;	Crystal structure of DESC1, a new member of the type II transmembrane serine proteinases family
7TGJ	;	2.85	;	Crystal structure of DesD, the desferrioxamine synthetase from the Streptomyces griseoflavus ferrimycin biosynthetic pathway
7TGN	;	2.3	;	Crystal structure of DesD, the desferrioxamine synthetase from the Streptomyces violaceus salmycin biosynthetic pathway
2X4L	;	1.5	;	Crystal structure of DesE, a ferric-siderophore receptor protein from Streptomyces coelicolor
3VV3	;	1.76	;	Crystal structure of deseasin MCP-01 from Pseudoalteromonas sp. SM9913
5IWB	;	1.764	;	Crystal structure of design pentatricopeptide repeat complex with MORF protein
4PJS	;	2.6	;	Crystal structure of designed (SeMet)-cPPR-NRE protein
3PG0	;	1.62	;	Crystal structure of designed 3-fold symmetric protein, ThreeFoil
4PJR	;	2.0	;	Crystal structure of designed cPPR-NRE protein
4WN4	;	3.85	;	Crystal structure of designed cPPR-polyA protein
4WSL	;	3.7	;	Crystal structure of designed cPPR-polyC protein
4PJQ	;	3.353	;	Crystal structure of designed cPPR-polyG protein
5ORM	;	2.08	;	Crystal structure of designed cPPR-Telo1
5ORQ	;	1.95	;	Crystal structure of designed cPPR-Telo1 in complex with ssDNA
7UDO	;	2.5	;	Crystal structure of designed helical repeat protein RPB_LRP2_R4 (proteolysis fragment?), forming pseudopolymeric filaments
7UDK	;	3.18	;	Crystal structure of designed helical repeat protein RPB_LRP2_R4 bound to LRPx4 peptide
7UDJ	;	2.7	;	Crystal structure of designed helical repeat protein RPB_PEW3_R4 bound to PAWx4 peptide
7UDL	;	2.15	;	Crystal structure of designed helical repeat protein RPB_PLP1_R6 bound to PLPx6 peptide
7UDM	;	2.65	;	Crystal structure of designed helical repeat protein RPB_PLP1_R6 in alternative conformation 1 (with peptide)
7UDN	;	2.45	;	Crystal structure of designed helical repeat protein RPB_PLP1_R6 in alternative conformation 2
7UE2	;	2.68	;	Crystal structure of designed helical repeat protein RPB_PLP3_R6 bound to PLPx6 peptide
7UPO	;	2.1	;	Crystal structure of designed heterotrimeric assembly DHT03
7UPQ	;	3.35	;	Crystal structure of designed heterotrimeric assembly DHT03_1arm_A21/B/C
7UPP	;	3.35	;	Crystal structure of designed heterotrimeric assembly DHT03_2arm_A21/B21/C long
5I9F	;	2.194	;	Crystal structure of designed pentatricopeptide repeat protein dPPR-U10 in complex with its target RNA U10
5I9D	;	2.596	;	Crystal structure of designed pentatricopeptide repeat protein dPPR-U8A2 in complex with its target RNA U8A2
5I9G	;	2.288	;	Crystal structure of designed pentatricopeptide repeat protein dPPR-U8C2 in complex with its target RNA U8C2
5I9H	;	2.504	;	Crystal structure of designed pentatricopeptide repeat protein dPPR-U8G2 in complex with its target RNA U8G2
7ZP5	;	1.54	;	Crystal structure of designed photoenzyme EnT1.0
5IM6	;	5.588	;	Crystal structure of designed two-component self-assembling icosahedral cage I32-28
5IM4	;	3.5	;	Crystal structure of designed two-component self-assembling icosahedral cage I52-32
5IM5	;	3.699	;	Crystal structure of designed two-component self-assembling icosahedral cage I53-40
1R66	;	1.44	;	Crystal Structure of DesIV (dTDP-glucose 4,6-dehydratase) from Streptomyces venezuelae with NAD and TYD bound
1R6D	;	1.35	;	Crystal Structure of DesIV double mutant (dTDP-glucose 4,6-dehydratase) from Streptomyces venezuelae with NAD and DAU bound
3EHF	;	3.1	;	Crystal structure of DesKC in complex with AMP-PCP
3EHH	;	2.1	;	Crystal structure of DesKC-H188V in complex with ADP
3EHJ	;	2.5	;	Crystal structure of DesKC-H188V in complex with AMP-PCP
3GIF	;	2.7	;	Crystal structure of DesKC_H188E in complex with ADP
3GIE	;	2.65	;	Crystal structure of DesKC_H188E in complex with AMP-PCP
4I3G	;	1.4	;	Crystal Structure of DesR, a beta-glucosidase from Streptomyces venezuelae in complex with D-glucose.
3LSP	;	2.66	;	Crystal Structure of DesT bound to desCB promoter and oleoyl-CoA
3LSR	;	2.55	;	Crystal structure of DesT in complex with duplex DNA
3LSJ	;	2.3	;	Crystal structure of DesT in complex with palmitoyl-CoA
1HTV	;	1.9	;	CRYSTAL STRUCTURE OF DESTRIPEPTIDE (B28-B30) INSULIN
3EUB	;	2.6	;	Crystal Structure of Desulfo-Xanthine Oxidase with Xanthine
1DXG	;	1.8	;	CRYSTAL STRUCTURE OF DESULFOREDOXIN FROM DESULFOVIBRIO GIGAS AT 1.8 A RESOLUTION
6DC2	;	1.992	;	Crystal structure of Desulfovibrio vulgaris carbon monoxide dehydrogenase C301S variant
6ONC	;	1.5	;	Crystal structure of Desulfovibrio vulgaris carbon monoxide dehydrogenase produced without CooC, as-isolated
6OND	;	1.723	;	Crystal structure of Desulfovibrio vulgaris carbon monoxide dehydrogenase produced without CooC, reduced
6ONS	;	2.485	;	Crystal structure of Desulfovibrio vulgaris carbon monoxide dehydrogenase with the D-cluster ligating cysteines mutated to alanines, coexpressed with CooC, as-isolated
6B6V	;	2.5	;	Crystal structure of Desulfovibrio vulgaris carbon monoxide dehydrogenase, as-isolated (protein batch 1), canonical C-cluster
6B6W	;	1.72	;	Crystal structure of Desulfovibrio vulgaris carbon monoxide dehydrogenase, as-isolated (protein batch 2), oxidized C-cluster
6B6X	;	1.84	;	Crystal structure of Desulfovibrio vulgaris carbon monoxide dehydrogenase, dithionite-reduced (protein batch 2), canonical C-cluster
6B6Y	;	2.6	;	Crystal structure of Desulfovibrio vulgaris carbon monoxide dehydrogenase, dithionite-reduced then oxygen-exposed (protein batch 2), oxidized C-cluster
1LKO	;	1.63	;	Crystal structure of Desulfovibrio vulgaris rubrerythrin all-iron(II) form
1LKP	;	1.64	;	Crystal structure of Desulfovibrio vulgaris rubrerythrin all-iron(II) form, azide adduct
1LKM	;	1.69	;	Crystal structure of Desulfovibrio vulgaris rubrerythrin all-iron(III) form
2DE2	;	1.8	;	Crystal structure of desulfurization enzyme DSZB
2WP7	;	1.9	;	Crystal structure of deSUMOylase(DUF862)
2QMO	;	1.47	;	Crystal structure of dethiobiotin synthetase (bioD) from Helicobacter pylori
3MLE	;	2.8	;	Crystal structure of dethiobiotin synthetase (BioD) from Helicobacter pylori cocrystallized with ATP
3QXH	;	1.36	;	Crystal structure of dethiobiotin synthetase (BioD) from Helicobacter pylori complexed with ADP and 8-aminocaprylic acid
3QXS	;	1.35	;	Crystal structure of dethiobiotin synthetase (BioD) from Helicobacter pylori complexed with ANP
3QXC	;	1.34	;	Crystal structure of dethiobiotin synthetase (BioD) from Helicobacter pylori complexed with ATP
3QY0	;	1.6	;	Crystal structure of dethiobiotin synthetase (BioD) from Helicobacter pylori complexed with GDP
3QXX	;	1.36	;	Crystal structure of dethiobiotin synthetase (BioD) from Helicobacter pylori complexed with GDP and 8-aminocaprylic acid
3QXJ	;	1.38	;	Crystal structure of dethiobiotin synthetase (BioD) from Helicobacter pylori complexed with GTP
6NKB	;	2.0	;	Crystal structure of Dethiobiotin Synthetase from Mycobacterium tuberculosis in complex with 2'-deoxycytidine diphosphate
3FGN	;	1.85	;	Crystal structure of dethiobiotin synthetase in Mycobacterium tuberculosis
6F7D	;	1.634	;	Crystal structure of Dettilon tailspike protein (gp208)
6F7K	;	2.1	;	Crystal structure of Dettilon tailspike protein (gp208)
5JKN	;	3.0	;	Crystal structure of deubiquitinase MINDY-1
5JQS	;	2.65	;	Crystal structure of deubiquitinase MINDY-1 in complex with Ubiquitin
6Z49	;	2.0	;	Crystal structure of deubiquitinase Mindy2
5R47	;	1.1	;	Crystal Structure of deuterated gamma-Chymotrypsin at pH 5.6, cryo temperature
5R46	;	1.05	;	Crystal Structure of deuterated gamma-Chymotrypsin at pH 5.6, room temperature
5R43	;	1.0	;	Crystal Structure of deuterated gamma-Chymotrypsin at pH 7.5, cryo temperature
5R42	;	1.05	;	Crystal Structure of deuterated gamma-Chymotrypsin at pH 7.5, room temperature
5R4B	;	1.05	;	Crystal Structure of deuterated gamma-Chymotrypsin at pH 9, cryo temperature
5R4A	;	1.2	;	Crystal Structure of deuterated gamma-Chymotrypsin at pH 9, room temperature
1Y89	;	2.0	;	Crystal Structure of devB protein
2ZID	;	2.2	;	Crystal structure of dextran glucosidase E236Q complex with isomaltotriose
3VMN	;	1.6	;	Crystal structure of dextranase from Streptococcus mutans
3VMP	;	1.88	;	Crystal structure of dextranase from Streptococcus mutans in complex with 4,5-epoxypentyl alpha-D-glucopyranoside
3VMO	;	1.9	;	Crystal structure of dextranase from Streptococcus mutans in complex with isomaltotriose
8HSN	;	1.69	;	Crystal structure of DFA I-forming Inulin Lyase from Streptomyces peucetius subsp. caesius ATCC 27952
8HUI	;	1.44	;	Crystal structure of DFA I-forming Inulin Lyase from Streptomyces peucetius subsp. caesius ATCC 27952 in complex with GF4, DFA I, and fructose
5ZKS	;	2.0	;	Crystal structure of DFA-IIIase from Arthrobacter chlorophenolicus A6
5ZKU	;	2.32	;	Crystal structure of DFA-IIIase from Arthrobacter chlorophenolicus A6 in complex with DFA-III
5ZKW	;	1.86	;	Crystal structure of DFA-IIIase from Arthrobacter chlorophenolicus A6 in complex with GF2
5ZL4	;	3.0	;	Crystal structure of DFA-IIIase from Arthrobacter chlorophenolicus A6 wihout its lid in complex with GF2
5ZKY	;	2.1	;	Crystal structure of DFA-IIIase from Arthrobacter chlorophenolicus A6 without its lid
5ZL5	;	1.65	;	Crystal structure of DFA-IIIase mutant C387A from Arthrobacter chlorophenolicus A6
2ZE3	;	1.65	;	Crystal Structure of DFA0005 Complexed with alpha-Ketoglutarate: A Novel Member of the ICL/PEPM Superfamily from Alkali-tolerant Deinococcus ficus
6RY0	;	1.05	;	Crystal structure of Dfg5 from Chaetomium thermophilum
6RY2	;	1.3	;	Crystal structure of Dfg5 from Chaetomium thermophilum in complex with alpha-1,2-mannobiose
6RY5	;	1.3	;	Crystal structure of Dfg5 from Chaetomium thermophilum in complex with alpha-1,6-mannobiose
6RY6	;	1.3	;	Crystal structure of Dfg5 from Chaetomium thermophilum in complex with glucosamine
6RY7	;	1.3	;	Crystal structure of Dfg5 from Chaetomium thermophilum in complex with laminaribiose
6RY1	;	1.3	;	Crystal structure of Dfg5 from Chaetomium thermophilum in complex with mannose
5DTJ	;	2.71	;	Crystal Structure of dfp-inhibited mouse acetylcholinesterase in complex with the reactivator SP-134
1E1A	;	1.8	;	Crystal structure of DFPase from Loligo vulgaris
2FIR	;	2.0	;	Crystal structure of DFPR-VIIa/sTF
7MYL	;	2.15	;	Crystal structure of DfrA1 dihydrofolate reductase in complex with TRIMETHOPRIM
7R6G	;	2.61	;	Crystal structure of DfrA5 dihydrofolate reductase in complex with TRIMETHOPRIM and NADPH
7XRE	;	2.76	;	Crystal structure of DgpA
7XR9	;	2.42	;	Crystal structure of DgpA with glucose
2Z0Q	;	1.79	;	Crystal structure of DH-PH domain of RhoGEF3(Xpln)
8GDO	;	1.95	;	Crystal structure of DH1010 Fab
5U0U	;	3.428	;	Crystal Structure of DH270.1 (unliganded, single-chain Fv) from the DH270 Broadly Neutralizing N332-glycan Dependent Lineage
5TPL	;	2.5	;	Crystal Structure of DH270.3 (unliganded) from the DH270 Broadly Neutralizing N332-glycan Dependent Lineage
6CBJ	;	2.85	;	Crystal Structure of DH270.3 Fab in complex with Man9
5TPP	;	1.85	;	Crystal Structure of DH270.5 (unliganded) from the DH270 Broadly Neutralizing N332-glycan Dependent Lineage
5TQA	;	2.723	;	Crystal Structure of DH270.6 (unliganded) from the DH270 Broadly Neutralizing N332-Glycan Dependent Lineage
5U0R	;	3.295	;	Crystal Structure of DH270.UCA1 (unliganded) from the DH270 Broadly Neutralizing N332-glycan Dependent Lineage
5U15	;	2.26	;	Crystal Structure of DH270.UCA3 (unliganded) from the DH270 Broadly Neutralizing N332-glycan Dependent Lineage
8D3A	;	2.9	;	Crystal Structure of DH475 Fab in complex with Man9
5U3J	;	2.74	;	Crystal Structure of DH511.1 Fab in Complex with HIV-1 gp41 MPER Peptide
5U3M	;	2.418	;	Crystal Structure of DH511.11P Fab in Complex with HIV-1 gp41 MPER Peptide
5U3N	;	2.0	;	Crystal Structure of DH511.12P Fab in Complex with HIV-1 gp41 MPER Peptide
5U3K	;	2.637	;	Crystal Structure of DH511.2 Fab in Complex with HIV-1 gp41 MPER 662-683 Peptide
5U3L	;	2.165	;	Crystal Structure of DH511.2 Fab in Complex with HIV-1 gp41 MPER 670-683 Peptide
5U3O	;	1.761	;	Crystal Structure of DH511.2_K3 Fab in Complex with HIV-1 gp41 MPER Peptide
5U3P	;	1.5	;	Crystal Structure of DH511.4 Fab
6XCJ	;	2.8	;	Crystal Structure of DH650 Fab from a Rhesus Macaque in Complex with HIV-1 gp120 Core
5Y5C	;	2.61	;	Crystal structure of dha bind to bovine beta-lactoglobulin
2BTD	;	2.6	;	Crystal structure of DhaL from E. coli
3CT6	;	1.1	;	Crystal structure of DhaM of L. lactis
5GRQ	;	1.584	;	Crystal Structure of DHB domain of Daxx in complex with an ATRX peptide
1MDF	;	2.5	;	CRYSTAL STRUCTURE OF DhbE IN ABSENCE OF SUBSTRATE
1MD9	;	2.8	;	CRYSTAL STRUCTURE OF DhbE IN COMPLEX WITH DHB AND AMP
1MDB	;	2.15	;	CRYSTAL STRUCTURE OF DhbE IN COMPLEX WITH DHB-ADENYLATE
3MGZ	;	2.07	;	Crystal structure of DHBPS domain of bi-functional DHBPS/GTP cyclohydrolase II from Mycobacterium tuberculosis at pH 4.0
2FWT	;	1.85	;	Crystal structure of DHC purified from Rhodobacter sphaeroides
5UI3	;	2.0	;	Crystal structure of DHDPS from chlamydomonas reinhardtii
5UD6	;	2.4	;	Crystal structure of DHDPS from Cyanidioschyzon merolae with lysine bound
5EAJ	;	1.701	;	Crystal structure of DHFR in 0% Isopropanol
5E8Q	;	1.8	;	Crystal structure of DHFR in 20% Isopropanol
5UJX	;	1.8	;	Crystal structure of DHFR in 20% Isopropanol
1QZF	;	2.8	;	Crystal structure of DHFR-TS from Cryptosporidium hominis
3N1G	;	1.9	;	Crystal structure of DhhN bound to BOCFn3
3N1Q	;	2.89	;	Crystal Structure of DhhN bound to CDOFn3
6AJE	;	3.65	;	Crystal structure of DHODH in complex with ferulenol from Eimeria tenella
6SFE	;	1.08	;	CRYSTAL STRUCTURE OF DHQ1 FROM SALMONELLA TYPHI COVALENTLY MODIFIED BY COMPOUND 7
6SFG	;	1.23	;	CRYSTAL STRUCTURE OF DHQ1 FROM SALMONELLA TYPHI COVALENTLY MODIFIED BY COMPOUND 9
6H5C	;	1.14	;	Crystal structure of DHQ1 from Salmonella typhi covalently modified by ligand 1
6H5D	;	1.25	;	Crystal structure of DHQ1 from Salmonella typhi covalently modified by ligand 2
6H5G	;	1.04	;	Crystal structure of DHQ1 from Salmonella typhi covalently modified by ligand 3
6H5J	;	1.4	;	Crystal structure of DHQ1 from Salmonella typhi covalently modified by ligand 4
6SFH	;	1.73	;	CRYSTAL STRUCTURE OF DHQ1 FROM Staphylococcus aureus COVALENTLY MODIFIED BY LIGAND 7
3L3X	;	1.55	;	Crystal structure of DHT-bound androgen receptor in complex with the first motif of steroid receptor coactivator 3
3L3Z	;	2.0	;	Crystal structure of DHT-bound androgen receptor in complex with the third motif of steroid receptor coactivator 3
6HYU	;	3.22	;	Crystal structure of DHX8 helicase bound to single stranded poly-adenine RNA
6HYT	;	2.33	;	Crystal structure of DHX8 helicase domain bound to ADP at 2.3 Angstrom
6HYS	;	2.6	;	Crystal structure of DHX8 helicase domain bound to ADP at 2.6 angstrom
3PUD	;	2.8	;	Crystal structure of Dhydrodipicolinate synthase from Acinetobacter baumannii at 2.8A resolution
7AE6	;	1.65	;	Crystal structure of di-AMPylated HEPN(R102A) toxin
1IQC	;	1.8	;	Crystal structure of Di-Heme Peroxidase from Nitrosomonas europaea
3CHH	;	2.0	;	Crystal Structure of Di-iron AurF
3CHU	;	2.2	;	Crystal Structure of Di-iron Aurf
3CHI	;	2.1	;	Crystal Structure of Di-iron AurF (Monoclinic form)
3CHT	;	2.0	;	Crystal Structure of Di-iron AurF with partially bound Ligand
7FFP	;	1.8	;	Crystal structure of di-peptidase-E from Xenopus laevis
6R8J	;	1.75	;	Crystal structure of di-phosphorylated human CLK1 in complex with 4-(1-methyl-1H-indol-3-yl)pyrimidin-2-amine
7O9Y	;	1.66	;	Crystal structure of di-phosphorylated human CLK1 in complex with 4-(1H-indol-3-yl)pyrimidin-2-amine
6R3D	;	1.85	;	Crystal structure of di-phosphorylated human CLK1 in complex with 4-(6,7-dichloro-1H-indol-3-yl)pyrimidin-2-amine
6R6X	;	2.05	;	Crystal structure of di-phosphorylated human CLK1 in complex with 5-(1-methyl-1H-indol-3-yl)pyrimidin-4-amine
6R6E	;	2.25	;	Crystal structure of di-phosphorylated human CLK1 in complex with 5-(6,7-dichloro-1-methyl-1H-indol-3-yl)pyrimidin-4-amine
7OA0	;	1.81	;	Crystal structure of di-phosphorylated human CLK1 in complex with 5-(6,7-dichloro-1H-indol-3-yl)pyrimidin-4-amine
2VAG	;	1.8	;	Crystal structure of di-phosphorylated human CLK1 in complex with a novel substituted indole inhibitor
5N5G	;	1.292	;	Crystal structure of di-zinc metallo-beta-lactamase VIM-1
5GS3	;	1.698	;	Crystal structure of diabody
5GS2	;	3.592	;	Crystal structure of diabody complex with repebody and MBP
3WE7	;	1.55	;	Crystal Structure of Diacetylchitobiose Deacetylase from Pyrococcus horikoshii
2QVL	;	2.4	;	Crystal Structure of Diacylglycerol Kinase
4WER	;	2.05	;	Crystal structure of diacylglycerol kinase catalytic domain protein from Enterococcus faecalis V583
2QV7	;	2.3	;	Crystal Structure of Diacylglycerol Kinase DgkB in complex with ADP and Mg
1ZOD	;	1.8	;	Crystal structure of dialkylglycine decarboxylase bound with cesium ion
1ZOB	;	2.75	;	Crystal structure of dialkylglycine decarboxylases bound with calcium ion
6ERK	;	1.6	;	Crystal structure of diaminopelargonic acid aminotransferase from Psychrobacter cryohalolentis
1KNW	;	2.1	;	Crystal structure of diaminopimelate decarboxylase
3C5Q	;	2.4	;	Crystal structure of diaminopimelate decarboxylase (I148L mutant) from Helicobacter pylori complexed with L-lysine
3VAB	;	2.1	;	Crystal structure of Diaminopimelate decarboxylase from Brucella melitensis bound to PLP
2QGH	;	2.3	;	Crystal structure of diaminopimelate decarboxylase from Helicobacter pylori complexed with L-lysine
1TUF	;	2.4	;	Crystal structure of Diaminopimelate Decarboxylase from m. jannaschi
1TWI	;	2.0	;	Crystal structure of Diaminopimelate Decarboxylase from m. jannaschii in co-complex with L-lysine
3EKM	;	2.3	;	Crystal structure of diaminopimelate epimerase form arabidopsis thaliana in complex with irreversible inhibitor DL-AziDAP
3EJX	;	1.95	;	Crystal structure of diaminopimelate epimerase from Arabidopsis thaliana in complex with LL-AziDAP
4IJZ	;	2.0	;	Crystal structure of diaminopimelate epimerase from Escherichia coli
2GKJ	;	1.7	;	Crystal structure of diaminopimelate epimerase in complex with an irreversible inhibitor DL-AZIDAP
2GKE	;	1.35	;	Crystal structure of diaminopimelate epimerase in complex with an irreversible inhibitor LL-AziDAP
3FVE	;	2.6	;	Crystal structure of diaminopimelate epimerase Mycobacterium tuberculosis DapF
4IK0	;	2.05	;	Crystal structure of diaminopimelate epimerase Y268A mutant from Escherichia coli
4D9M	;	2.5	;	Crystal structure of Diaminopropionate ammonia lyase from Escherichia coli in complex with aminoacrylate-PLP azomethine reaction intermediate
4D9N	;	2.5	;	Crystal structure of Diaminopropionate ammonia lyase from Escherichia coli in complex with D-serine
5Y9V	;	2.841	;	Crystal structure of diamondback moth ryanodine receptor N-terminal domain
6J6O	;	1.848	;	Crystal structure of diamondback moth ryanodine receptor phosphorylation domain(2836-3050)
6J6P	;	1.53	;	Crystal structure of diamondback moth ryanodine receptor phosphorylation domain(2836-3050) mutant S2946D
6KIM	;	2.057	;	Crystal structure of diamondback moth ryanodine receptor SPRY2 domain
1SE0	;	1.75	;	Crystal structure of DIAP1 BIR1 bound to a Grim peptide
1SDZ	;	1.78	;	Crystal structure of DIAP1 BIR1 bound to a Reaper peptide
1JD4	;	2.7	;	Crystal Structure of DIAP1-BIR2
1JD5	;	1.9	;	Crystal Structure of DIAP1-BIR2/GRIM
1JD6	;	2.7	;	Crystal Structure of DIAP1-BIR2/Hid Complex
4DOY	;	1.789	;	Crystal structure of Dibenzothiophene desulfurization enzyme C
5XB8	;	1.795	;	Crystal structure of dibenzothiophene monooxygenase (TdsC) from Paenibacillus sp. A11-2
5XKC	;	2.209	;	Crystal structure of dibenzothiophene sulfone monooxygenase BdsA at 2.2 angstrome
5XKD	;	2.393	;	Crystal structure of dibenzothiophene sulfone monooxygenase BdsA in complex with FMN at 2.4 angstrom
3GKE	;	1.75	;	Crystal Structure of Dicamba Monooxygenase
3GL0	;	1.75	;	Crystal structure of dicamba monooxygenase bound to 3,6 dichlorosalicylic acid (DCSA)
3GL2	;	2.1	;	Crystal structure of dicamba monooxygenase bound to dicamba
3GOB	;	2.05	;	Crystal Structure of Dicamba Monooxygenase with Non-heme Cobalt and DCSA
3GB4	;	2.05	;	Crystal Structure of Dicamba Monooxygenase with Non-heme Cobalt and Dicamba
3GTE	;	1.95	;	Crystal Structure of Dicamba Monooxygenase with Non-heme Iron
3GTS	;	2.2	;	Crystal Structure of Dicamba Monooxygenase with Non-heme Iron and Dicamba
2FFL	;	3.33	;	Crystal Structure of Dicer from Giardia intestinalis
4PWM	;	1.95	;	Crystal structure of Dickerson Drew Dodecamer with 5-carboxycytosine
1PXX	;	2.9	;	CRYSTAL STRUCTURE OF DICLOFENAC BOUND TO THE CYCLOOXYGENASE ACTIVE SITE OF COX-2
1C0F	;	2.4	;	CRYSTAL STRUCTURE OF DICTYOSTELIUM CAATP-ACTIN IN COMPLEX WITH GELSOLIN SEGMENT 1
1NLV	;	1.8	;	Crystal Structure Of Dictyostelium Discoideum Actin Complexed With Ca ATP And Human Gelsolin Segment 1
1YKQ	;	3.5	;	Crystal structure of Diels-Alder ribozyme
8GX4	;	1.97008	;	Crystal structure of Diels-Alderase ApiI in complex with SAM
7Y3H	;	1.97	;	Crystal Structure of Diels-Alderase ApiI in complex with SAM and product
4O5S	;	1.8	;	Crystal structure of Diels-Alderase CE11
4O5T	;	2.9	;	Crystal structure of Diels-Alderase CE20 in complex with a product analog
7YAV	;	2.1	;	Crystal structure of Diels-Alderase MaDA1
7X2N	;	1.72	;	Crystal structure of Diels-Alderase PycR1
5BU3	;	1.897	;	Crystal Structure of Diels-Alderase PyrI4 in complex with its product
4U2B	;	1.7	;	Crystal structure of dienelactone hydrolase (C123S) at 1.70 A resolution
2O2G	;	1.92	;	Crystal structure of Dienelactone hydrolase (YP_324580.1) from Anabaena variabilis ATCC 29413 at 1.92 A resolution
4U2C	;	1.95	;	Crystal structure of dienelactone hydrolase A-6 variant (S7T, A24V, Q35H, F38L, Q110L, C123S, Y145C, E199G and S208G) at 1.95 A resolution
4U2F	;	1.8	;	Crystal structure of dienelactone hydrolase B-1 variant (Q35H, F38L, Y64H, Q110L, C123S, Y137C, Y145C, N154D, E199G, S208G and G211D) at 1.80 A resolution
4U2G	;	1.8	;	Crystal structure of dienelactone hydrolase B-4 variant (Q35H, F38L, Y64H, Q76L, Q110L, C123S, Y137C, A141V, Y145C, N154D, E199G, S208G, G211D, S233G and 237Q) at 1.80 A resolution
4P92	;	1.65	;	Crystal structure of dienelactone hydrolase C123S mutant at 1.65 A resolution
4U2D	;	1.67	;	Crystal structure of dienelactone hydrolase S-2 variant (Q35H, F38L, Q110L, C123S, Y137C, Y145C, N154D, E199G, S208G and G211D) at 1.67 A resolution
4U2E	;	1.7	;	Crystal structure of dienelactone hydrolase S-3 variant (Q35H, F38L, Q110L, C123S, Y137C, Y145C, N154D, E199G, S208G, G211D and K234N) at 1.70 A resolution
4ZI5	;	1.702	;	Crystal Structure of Dienelactone Hydrolase-like Promiscuous Phospotriesterase P91 from Metagenomic Libraries
3PXS	;	2.22	;	Crystal Structure of Diferrous MauG in Complex with Pre-Methylamine Dehydrogenase:
3OGF	;	2.864	;	Crystal structure of Difoil-4P homo-trimer: de novo designed dimeric trefoil-fold sub-domain which forms homo-trimer assembly
7E6G	;	2.65	;	Crystal structure of diguanylate cyclase SiaD in complex with its activator SiaC from Pseudomonas aeruginosa
1FE2	;	3.0	;	CRYSTAL STRUCTURE OF DIHOMO-GAMMA-LINOLEIC ACID BOUND IN THE CYCLOOXYGENASE CHANNEL OF PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE-1.
1VM6	;	2.27	;	Crystal structure of Dihydrodipicolinate reductase (TM1520) from Thermotoga maritima at 2.27 A resolution
5WOL	;	1.7	;	Crystal structure of dihydrodipicolinate reductase DapB from Coxiella burnetii
8D57	;	2.65	;	Crystal Structure of dihydrodipicolinate reductase from Acinetobacter baumannii
3IJP	;	2.3	;	Crystal structure of dihydrodipicolinate reductase from bartonella henselae at 2.0A resolution
1XXX	;	2.28	;	Crystal structure of Dihydrodipicolinate Synthase (DapA, Rv2753c) from Mycobacterium tuberculosis
6XGS	;	2.2	;	Crystal Structure of Dihydrodipicolinate synthase (DHDPS) from Brucella suis 1330
1O5K	;	1.8	;	Crystal structure of Dihydrodipicolinate synthase (TM1521) from Thermotoga maritima at 1.80 A resolution
1XKY	;	1.94	;	Crystal Structure of Dihydrodipicolinate Synthase DapA-2 (BA3935) from Bacillus Anthracis at 1.94A Resolution.
1XL9	;	2.23	;	Crystal Structure of Dihydrodipicolinate Synthase DapA-2 (BA3935) from Bacillus Anthracis.
4DXV	;	1.8	;	Crystal structure of Dihydrodipicolinate synthase from Acinetobacter baumannii complexed with Mg and Cl ions at 1.80 A resolution
3UQN	;	1.94	;	Crystal structure of dihydrodipicolinate synthase from Acinetobacter baumannii complexed with Oxamic acid at 1.9 Angstrom resolution
3B4U	;	1.2	;	Crystal structure of dihydrodipicolinate synthase from Agrobacterium tumefaciens str. C58
2EHH	;	1.9	;	Crystal structure of dihydrodipicolinate synthase from aquifex aeolicus
3HIJ	;	2.15	;	Crystal structure of dihydrodipicolinate synthase from Bacillus anthracis in complex with its substrate, pyruvate
3E96	;	1.8	;	Crystal structure of dihydrodipicolinate synthase from bacillus clausii
3SI9	;	2.1	;	Crystal structure of Dihydrodipicolinate Synthase from Bartonella Henselae
3M5V	;	1.8	;	Crystal Structure of Dihydrodipicolinate Synthase from Campylobacter jejuni
3LER	;	1.84	;	Crystal Structure of Dihydrodipicolinate Synthase from Campylobacter jejuni subsp. jejuni NCTC 11168
2RFG	;	1.5	;	Crystal structure of dihydrodipicolinate synthase from Hahella chejuensis at 1.5A resolution
6UE0	;	1.892	;	Crystal structure of dihydrodipicolinate synthase from Klebsiella pneumoniae bound to pyruvate
3DAQ	;	1.45	;	Crystal structure of dihydrodipicolinate synthase from methicillin-resistant Staphylococcus aureus
5J5D	;	2.4	;	Crystal structure of Dihydrodipicolinate Synthase from Mycobacterium tuberculosis in complex with alpha-ketopimelic acid
3D0C	;	1.9	;	Crystal structure of dihydrodipicolinate synthase from Oceanobacillus iheyensis at 1.9 A resolution
3NOE	;	2.95	;	Crystal Structure of Dihydrodipicolinate synthase from Pseudomonas aeruginosa
3PUO	;	2.65	;	Crystal structure of dihydrodipicolinate synthase from Pseudomonas aeruginosa(PsDHDPS)complexed with L-lysine at 2.65A resolution
3DZ1	;	1.87	;	Crystal structure of Dihydrodipicolinate Synthase from Rhodopseudomonas palustris at 1.87A resolution
3EB2	;	2.04	;	Crystal structure of Dihydrodipicolinate Synthase from Rhodopseudomonas palustris at 2.0A resolution
3DI0	;	2.38	;	Crystal Structure of Dihydrodipicolinate synthase from Staphylococcus aureus
3FLU	;	2.0	;	Crystal structure of dihydrodipicolinate synthase from the pathogen Neisseria meningitidis
7K6C	;	2.0	;	Crystal Structure of Dihydrofolate reductase (DHFR) from Mycobacterium abscessus ATCC 19977 / DSM 44196 with NADP and inhibitor P218
8F80	;	1.1	;	Crystal Structure of Dihydrofolate reductase (DHFR) from Mycobacterium ulcerans Agy99 in complex with NADP and inhibitor MAM738
8F81	;	1.3	;	Crystal Structure of Dihydrofolate reductase (DHFR) from Mycobacterium ulcerans Agy99 in complex with NADP and inhibitor MAM777
8F84	;	1.1	;	Crystal Structure of Dihydrofolate reductase (DHFR) from Mycobacterium ulcerans Agy99 in complex with NADP and inhibitor MAM787
8F82	;	1.2	;	Crystal Structure of Dihydrofolate reductase (DHFR) from Mycobacterium ulcerans Agy99 in complex with NADP and inhibitor MAM845
8F83	;	1.32	;	Crystal Structure of Dihydrofolate reductase (DHFR) from Mycobacterium ulcerans Agy99 in complex with NADP and inhibitor MAM846
8F85	;	1.15	;	Crystal Structure of Dihydrofolate reductase (DHFR) from Mycobacterium ulcerans Agy99 in complex with NADP and inhibitor MAM851
7K68	;	1.45	;	Crystal Structure of Dihydrofolate reductase (DHFR) from Mycobacterium ulcerans Agy99 in complex with NADP and inhibitor SDDC-0001565
7K69	;	1.6	;	Crystal Structure of Dihydrofolate reductase (DHFR) from Mycobacterium ulcerans Agy99 in complex with NADP and inhibitor SDDC-0001574
7K6A	;	1.6	;	Crystal Structure of Dihydrofolate reductase (DHFR) from Mycobacterium ulcerans Agy99 in complex with NADP and inhibitor SDDC-0001575
7KI8	;	1.25	;	Crystal Structure of Dihydrofolate reductase (DHFR) from Mycobacterium ulcerans Agy99 in complex with NADP and inhibitor SDDC-0001580
7KI9	;	1.25	;	Crystal Structure of Dihydrofolate reductase (DHFR) from Mycobacterium ulcerans Agy99 in complex with NADP and inhibitor SDDC-0001912
7KM9	;	1.95	;	Crystal Structure of Dihydrofolate reductase (DHFR) from Mycobacterium ulcerans Agy99 in complex with NADP and inhibitor SDDC-0001913, tetragonal crystal from
7KM8	;	1.55	;	Crystal Structure of Dihydrofolate reductase (DHFR) from Mycobacterium ulcerans Agy99 in complex with NADP and inhibitor SDDC-0001914, orthorhombic crystal from
7KM7	;	1.8	;	Crystal Structure of Dihydrofolate reductase (DHFR) from Mycobacterium ulcerans Agy99 in complex with NADP and inhibitor SDDC-0001914, tetragonal crystal from
8E4F	;	2.47	;	Crystal structure of dihydrofolate reductase (DHFR) from the filarial nematode W. bancrofti in complex with NADPH and folate
5SD9	;	2.1	;	Crystal Structure of Dihydrofolate Reductase from Homo sapiens bound to NADP and SDDC Inhibitor SDDC-1096
5SD8	;	2.05	;	Crystal Structure of Dihydrofolate Reductase from Homo sapiens bound to NADP and SDDC Inhibitor SDDC-1190 (racemic mixture)
5SD7	;	1.8	;	Crystal Structure of Dihydrofolate Reductase from Homo sapiens bound to NADP and SDDC Inhibitor SDDC-735
5SDA	;	2.45	;	Crystal Structure of Dihydrofolate Reductase from Homo sapiens bound to NADP and SDDC Inhibitor SDDC-774
5SD6	;	2.15	;	Crystal Structure of Dihydrofolate Reductase from Homo sapiens bound to NADP and SDDC Inhibitor SDDC-892
7K62	;	2.05	;	Crystal Structure of Dihydrofolate reductase from Mycobacterium kansasii in complex with NADP and inhibitor P218
5SD3	;	1.3	;	Crystal Structure of Dihydrofolate Reductase from Mycobacterium tuberculosis bound to NADP and SDDC Inhibitor SDDC-1088
5SCX	;	1.3	;	Crystal Structure of Dihydrofolate Reductase from Mycobacterium tuberculosis bound to NADP and SDDC Inhibitor SDDC-1190 (racemic mixture)
5SCY	;	1.4	;	Crystal Structure of Dihydrofolate Reductase from Mycobacterium tuberculosis bound to NADP and SDDC Inhibitor SDDC-1198
5SD4	;	1.25	;	Crystal Structure of Dihydrofolate Reductase from Mycobacterium tuberculosis bound to NADP and SDDC Inhibitor SDDC-1218
5SCZ	;	1.75	;	Crystal Structure of Dihydrofolate Reductase from Mycobacterium tuberculosis bound to NADP and SDDC Inhibitor SDDC-1224
5SD0	;	1.75	;	Crystal Structure of Dihydrofolate Reductase from Mycobacterium tuberculosis bound to NADP and SDDC Inhibitor SDDC-1225
5SD5	;	1.2	;	Crystal Structure of Dihydrofolate Reductase from Mycobacterium tuberculosis bound to NADP and SDDC Inhibitor SDDC-1230
5SD1	;	2.0	;	Crystal Structure of Dihydrofolate Reductase from Mycobacterium tuberculosis bound to NADP and SDDC Inhibitor SDDC-1235 (enantiomer)
5SD2	;	2.0	;	Crystal Structure of Dihydrofolate Reductase from Mycobacterium tuberculosis bound to NADP and SDDC Inhibitor SDDC-1236 (enantiomer)
5SCM	;	1.65	;	Crystal Structure of Dihydrofolate Reductase from Mycobacterium tuberculosis bound to NADP and SDDC Inhibitor SDDC-22
5SCP	;	1.8	;	Crystal Structure of Dihydrofolate Reductase from Mycobacterium tuberculosis bound to NADP and SDDC Inhibitor SDDC-23
5SCN	;	1.45	;	Crystal Structure of Dihydrofolate Reductase from Mycobacterium tuberculosis bound to NADP and SDDC Inhibitor SDDC-25
5SCQ	;	1.65	;	Crystal Structure of Dihydrofolate Reductase from Mycobacterium tuberculosis bound to NADP and SDDC Inhibitor SDDC-614
5SCR	;	1.95	;	Crystal Structure of Dihydrofolate Reductase from Mycobacterium tuberculosis bound to NADP and SDDC Inhibitor SDDC-735
5SCS	;	1.55	;	Crystal Structure of Dihydrofolate Reductase from Mycobacterium tuberculosis bound to NADP and SDDC Inhibitor SDDC-781
5SCT	;	1.55	;	Crystal Structure of Dihydrofolate Reductase from Mycobacterium tuberculosis bound to NADP and SDDC Inhibitor SDDC-783
5SCU	;	1.65	;	Crystal Structure of Dihydrofolate Reductase from Mycobacterium tuberculosis bound to NADP and SDDC Inhibitor SDDC-888
5SCV	;	1.55	;	Crystal Structure of Dihydrofolate Reductase from Mycobacterium tuberculosis bound to NADP and SDDC Inhibitor SDDC-889
5SCW	;	1.75	;	Crystal Structure of Dihydrofolate Reductase from Mycobacterium tuberculosis bound to NADP and SDDC Inhibitor SDDC-916
5SCO	;	1.3	;	Crystal Structure of Dihydrofolate Reductase from Mycobacterium tuberculosis bound to NADP and SDDC Inhibitor SDDC-M7
4KM2	;	1.4	;	Crystal structure of Dihydrofolate reductase from Mycobacterium tuberculosis in an open conformation in complex with trimethoprim
4KLX	;	1.23	;	Crystal structure of dihydrofolate reductase from Mycobacterium tuberculosis in an open conformation.
4KNE	;	2.0	;	Crystal structure of dihydrofolate reductase from Mycobacterium tuberculosis in complex with cycloguanil
6NNE	;	1.595	;	Crystal structure of Dihydrofolate reductase from Mycobacterium tuberculosis in complex with diaverdine
4KM0	;	1.3	;	Crystal structure of dihydrofolate reductase from Mycobacterium tuberculosis in complex with pyrimethamine
4KL9	;	1.39	;	Crystal structure of dihydrofolate reductase from Mycobacterium tuberculosis in the space group C2
6UWW	;	0.92	;	Crystal structure of dihydrofolate reductase from Mycobacterium ulcerans with P218 inhibitor
6UWQ	;	1.5	;	Crystal structure of dihydrofolate reductase from Mycobacterium ulcerans with SDDC-0001565 inhibitor
7L9T	;	1.8	;	Crystal Structure of Dihydrofolate reductase from Mycolicibacterium smegmatis in complex with SDDC-0001565 inhibitor
6E4E	;	1.9	;	Crystal structure of dihydrofolate reductase from Staphylococcus aureus MW2 bound to NADP and p218
3Q1H	;	1.804	;	Crystal Structure of Dihydrofolate Reductase from Yersinia pestis
4QI9	;	2.297	;	Crystal structure of dihydrofolate reductase from Yersinia pestis complexed with methotrexate
1SEJ	;	2.87	;	Crystal Structure of Dihydrofolate Reductase-Thymidylate Synthase from Cryptosporidium hominis Bound to 1843U89/NADPH/dUMP
3KJR	;	1.95	;	Crystal structure of dihydrofolate reductase/thymidylate synthase from Babesia bovis determined using SlipChip based microfluidics
6UZI	;	2.8	;	Crystal structure of Dihydrolipoyl dehydrogenase from Elizabethkingia anophelis NUHP1
3V9O	;	1.451	;	Crystal structure of Dihydroneopterin aldolase (BTH_I0291) from Burkholderia thailendensis bound to guanine.
5FAR	;	2.0	;	Crystal structure of dihydroneopterin aldolase from Bacillus anthracis complex with 9-METHYLGUANINE
5F3M	;	1.498	;	Crystal structure of dihydroneopterin aldolase from Bacillus anthracis complexed with L-neopterin at 1.5 Angstroms resolution .
2NM2	;	1.7	;	Crystal structure of dihydroneopterin aldolase from S. aureus in complex with (1S,2R)-neopterin at 1.50 Angstrom resolution
2NM3	;	1.68	;	Crystal structure of dihydroneopterin aldolase from S. aureus in complex with (1S,2S)-monapterin at 1.68 angstrom resolution
2Z00	;	2.42	;	Crystal structure of dihydroorotase from Thermus thermophilus
6L0F	;	3.26	;	Crystal structure of dihydroorotase in complex with 5-Aminouracil from Saccharomyces cerevisiae
7CA0	;	2.5	;	Crystal structure of dihydroorotase in complex with 5-fluoroorotic acid from Saccharomyces cerevisiae
6L0B	;	2.7	;	Crystal structure of dihydroorotase in complex with fluorouracil from Saccharomyces cerevisiae
6L0G	;	2.053	;	Crystal structure of dihydroorotase in complex with malate at pH6 from Saccharomyces cerevisiae
6L0I	;	2.2	;	Crystal structure of dihydroorotase in complex with malate at pH6.5 from Saccharomyces cerevisiae
6L0A	;	1.79	;	Crystal structure of dihydroorotase in complex with malate at pH7 from Saccharomyces cerevisiae
6L0H	;	2.054	;	Crystal structure of dihydroorotase in complex with malate at pH7 from Saccharomyces cerevisiae
6L0J	;	1.933	;	Crystal structure of Dihydroorotase in complex with malate at pH7.5 from Saccharomyces cerevisiae
6L0K	;	3.3	;	Crystal structure of dihydroorotase in complex with malate at pH9 from Saccharomyces cerevisiae
7CA1	;	3.6	;	Crystal structure of dihydroorotase in complex with plumbagin from Saccharomyces cerevisiae
5VGM	;	1.95	;	Crystal structure of dihydroorotase pyrC from Vibrio cholerae in complex with zinc at 1.95 A resolution.
6CTY	;	2.41	;	Crystal structure of dihydroorotase pyrC from Yersinia pestis in complex with zinc and malate at 2.4 A resolution
6B8S	;	2.25	;	Crystal Structure of Dihydroorotate Dehydrogenase from Helicobacter pylori with bound FMN
3C61	;	1.8	;	Crystal structure of dihydroorotate dehydrogenase from Leishmania donovani
4EF9	;	1.6	;	Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with 4-Nitrophenyl isothiocyanate
3MJY	;	1.96	;	Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with 5-Aminoorotic acid
3MHU	;	1.85	;	Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with 5-Nitroorotic acid
4EF8	;	1.56	;	Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with Phenyl isothiocyanate
7S87	;	2.75	;	Crystal Structure of Dihydroorotate dehydrogenase from Plasmodium falciparum in complex with Orotate, FMN, and inhibitor NCGC00600348-01
6UY4	;	2.796	;	Crystal structure of dihydroorotate dehydrogenase from Schistosoma mansoni
3C3N	;	2.2	;	Crystal structure of dihydroorotate dehydrogenase from Trypanosoma cruzi strain Y
4XQ6	;	2.0	;	CRYSTAL STRUCTURE OF DIHYDROOROTATE DEHYDROGENSE from MYCOBACTERIUM TUBERCULOSIS
3ORF	;	2.16	;	Crystal Structure of Dihydropteridine Reductase from Dictyostelium discoideum
8DOR	;	1.35	;	Crystal structure of Dihydropteridine reductase/oxygen-insensitive NAD(P)H nitroreductase from Klebsiella pneumoniae
2DQW	;	1.65	;	Crystal Structure of Dihydropteroate Synthase (FolP) from Thermus thermophilus HB8
8D5H	;	1.72	;	Crystal structure of dihydropteroate synthase (folP-SMZ_B27) from soil uncultured bacterium in complex with 6-hydroxymethyl-7,8-dihydropterin
8D5G	;	2.78	;	Crystal structure of dihydropteroate synthase (folP-SMZ_B27) from soil uncultured bacterium in complex with 6-hydroxymethyl-7,8-dihydropterin pyrophosphate
6UCZ	;	2.0	;	Crystal structure of dihydropteroate synthase from Anaplasma phagocytophilum with bound 6-hydroxymethylpterin-monophosphate
5UMG	;	2.601	;	Crystal structure of dihydropteroate synthase from Klebsiella pneumoniae subsp.
6OMZ	;	1.85	;	Crystal Structure of Dihydropteroate synthase from Mycobacterium smegmatis with bound 6-hydroxymethylpterin-monophosphate
7L6P	;	2.35	;	Crystal structure of dihydropteroate synthase from Stenotrophomonas maltophilia with active site-bound imidazole
2DZA	;	1.9	;	Crystal Structure of Dihydropteroate Synthase from Thermus thermophilus HB8 in Complex with 4-aminobenzoate
2DZB	;	1.9	;	Crystal Structure of Dihydropteroate Synthase from Thermus thermophilus HB8 in complex with 6HMPPP
8D5I	;	1.82	;	Crystal structure of dihydropteroate synthase H182G mutant (folP-SMZ_B27) from soil uncultured bacterium in complex with pteroic acid and pyrophosphate
3TYU	;	2.7	;	Crystal Structure of Dihydropteroate synthetase with Product1
8WQ9	;	1.97	;	Crystal structure of dihydropyrimidinase complexed with gamma-aminobutyric acid
3SFW	;	1.73	;	Crystal structure of dihydropyrimidinase from Brevibacillus agri NCHU1002
4TQT	;	2.15	;	Crystal structure of Dihydropyrimidinase from Brucella suis
2FTW	;	2.05	;	Crystal structure of dihydropyrimidinase from dictyostelium discoideum
5E5C	;	2.1	;	Crystal structure of dihydropyrimidinase from Pseudomonas aeruginosa PAO1
5YKD	;	2.17	;	Crystal structure of dihydropyrimidinase from Pseudomonas aeruginosa PAO1 at 2.17 angstrom resolution
2FTY	;	2.4	;	Crystal structure of dihydropyrimidinase from Saccharomyces kluyveri
2FVM	;	2.45	;	Crystal structure of dihydropyrimidinase from Saccharomyces kluyveri in complex with the reaction product N-carbamyl-beta-alanine
2FVK	;	2.4	;	Crystal structure of dihydropyrimidinase from Saccharomyces kluyveri in complex with the substrate dihydrouracil
3DC8	;	1.85	;	Crystal structure of dihydropyrimidinase from Sinorhizobium meliloti
7WJR	;	2.0	;	Crystal structure of dihydroxybenzoate decarboxylase mutant A63S from Aspergillus oryzae in complex with catechol
7WKL	;	1.88	;	Crystal structure of dihydroxybenzoate decarboxylase mutant F296Y from Aspergillus oryzae in complex with catechol
4QRO	;	1.65	;	CRYSTAL STRUCTURE of DIHYDROXYBENZOIC ACID DECARBBOXYLASE BPRO_2061 (TARGET EFI-500288) FROM POLAROMONAS SP. JS666 WITH BOUND MANGANESE AND AN INHIBITOR, 2-NITRORESORCINOL
2IEX	;	2.2	;	Crystal structure of dihydroxynapthoic acid synthetase (GK2873) from Geobacillus kaustophilus HTA426
2YXG	;	2.2	;	Crystal structure of Dihyrodipicolinate Synthase (dapA)
3T81	;	2.63	;	Crystal Structure of diiron adenine deaminase
2GVU	;	2.0	;	Crystal structure of diisopropyl fluorophosphatase (DFPase), mutant D229N / N120D
2WFV	;	1.85	;	Crystal structure of DILP5 variant C4
2WFU	;	1.85	;	Crystal structure of DILP5 variant DB
4WD6	;	2.2	;	Crystal Structure of DIM-1 metallo-beta-lactamase
4ZEJ	;	1.79	;	Crystal Structure of DIM-1 Metallo-beta-Lactamase exposed to Ceftazidime
3FYC	;	2.15	;	Crystal Structure of Dim1 from the thermophilic archeon, Methanocaldococcus jannaschi
3FYD	;	1.75	;	Crystal Structure of Dim1 from the thermophilic archeon, Methanocaldococcus jannaschi
3VHH	;	2.26	;	Crystal structure of DiMe-biotin-avidin complex
3W6K	;	2.374	;	Crystal structure of dimer of ScpB N-terminal domain complexed with ScpA peptide
3K3K	;	1.7	;	Crystal structure of dimeric abscisic acid (ABA) receptor pyrabactin resistance 1 (PYR1) with ABA-bound closed-lid and ABA-free open-lid subunits
3JU5	;	1.75	;	Crystal Structure of Dimeric Arginine Kinase at 1.75-A Resolution
3JU6	;	2.45	;	Crystal Structure of Dimeric Arginine Kinase in Complex with AMPPNP and Arginine
2GN0	;	1.7	;	Crystal structure of dimeric biodegradative threonine deaminase (TdcB) from Salmonella typhimurium at 1.7 A resolution (Triclinic form with one complete subunit built in alternate conformation)
2GN1	;	2.2	;	Crystal structure of dimeric biodegradative threonine deaminase (TdcB) from Salmonella typhimurium at 2.2A resolution (Triclinic form with one dimer of TdcB in the asymmetric unit)
5MAU	;	1.3	;	Crystal structure of dimeric chlorite dismutase from Cyanothece sp. PCC7425 (pH 6.5)
5K8Z	;	1.55	;	Crystal structure of dimeric chlorite dismutase from Cyanothece sp. PCC7425 (pH 8.5)
5NKV	;	2.0	;	Crystal structure of dimeric chlorite dismutase from Cyanothece sp. PCC7425 at pH 9.0 and 293 K.
5K91	;	1.18	;	Crystal structure of dimeric chlorite dismutase from Cyanothece sp. PCC7425 in complex with fluoride
5K90	;	1.28	;	Crystal structure of dimeric chlorite dismutase from Cyanothece sp. PCC7425 in complex with isothiocyanate
7OU5	;	1.9	;	Crystal structure of dimeric chlorite dismutase from Cyanothece sp. PCC7425 in complex with nitrite
7ASB	;	1.4	;	Crystal structure of dimeric chlorite dismutase variant Q74E (CCld Q74E) from Cyanothece sp. PCC7425
7OU9	;	2.42	;	Crystal structure of dimeric chlorite dismutase variant Q74E (CCld Q74E) from Cyanothece sp. PCC7425 in complex with nitrite
7ATI	;	1.51	;	Crystal structure of dimeric chlorite dismutase variant Q74V (CCld Q74V) from Cyanothece sp. PCC7425
7OU7	;	1.63	;	Crystal structure of dimeric chlorite dismutase variant Q74V (CCld Q74V) from Cyanothece sp. PCC7425 in complex with nitrite
7OWI	;	1.7	;	Crystal structure of dimeric chlorite dismutase variant R127A (CCld R127A) from Cyanothece sp. PCC7425
7OUY	;	1.5	;	Crystal structure of dimeric chlorite dismutase variant R127A (CCld R127A) from Cyanothece sp. PCC7425 in complex with nitrite
7OUA	;	2.09	;	Crystal structure of dimeric chlorite dismutase variant R127K (CCld R127K) from Cyanothece sp. PCC7425
3QPI	;	2.1	;	Crystal Structure of Dimeric Chlorite Dismutases from Nitrobacter winogradskyi
3NBS	;	2.2	;	Crystal structure of dimeric cytochrome c from horse heart
6I7I	;	2.33	;	Crystal structure of dimeric FICD mutant K256A complexed with MgATP
6I7H	;	2.25	;	Crystal structure of dimeric FICD mutant K256S
5W2J	;	2.5	;	Crystal structure of dimeric form of mouse Glutaminase C
4KL6	;	2.2	;	Crystal structure of dimeric form of NpuDnaE intein
2OKI	;	2.7	;	Crystal structure of dimeric form of PfFabZ in crystal form2
2OKH	;	3.0	;	Crystal structure of dimeric form of PfFabZ in crystal form3
3SG6	;	1.7	;	Crystal Structure of Dimeric GCaMP2-LIA(linker 1)
3SG5	;	1.9	;	Crystal Structure of Dimeric GCaMP3-D380Y, QP(linker 1), LP(linker 2)
3WLC	;	2.49	;	Crystal structure of dimeric GCaMP6m
2CH9	;	2.1	;	Crystal structure of dimeric human cystatin F
3DSH	;	2.0	;	Crystal structure of dimeric interferon regulatory factor 5 (IRF-5) transactivation domain
6XNK	;	2.08	;	Crystal structure of dimeric K72A human cytochrome c alkaline conformer
6A1Z	;	2.58	;	Crystal Structure of dimeric Kinesin-3 KIF13B
3O08	;	2.0	;	Crystal structure of dimeric KlHxk1 in crystal form I
3O1B	;	2.8	;	CRYSTAL STRUCTURE OF DIMERIC KLHXK1 IN CRYSTAL FORM II
3O1W	;	1.66	;	Crystal structure of dimeric KlHxk1 in crystal form III
3O4W	;	1.61	;	Crystal structure of dimeric KlHxk1 in crystal form IV
3O5B	;	1.97	;	Crystal structure of dimeric KlHxk1 in crystal form VII with glucose bound (open state)
4JAX	;	2.26	;	Crystal structure of dimeric KlHxk1 in crystal form X
6ZA2	;	3.35	;	Crystal structure of dimeric latent PorU from Porphyromonas gingivalis
6S1U	;	1.9	;	Crystal structure of dimeric M-PMV protease C7A/D26N/C106A mutant in complex with inhibitor
6S1W	;	1.98	;	Crystal structure of dimeric M-PMV protease D26N mutant
6S1V	;	1.64	;	Crystal structure of dimeric M-PMV protease D26N mutant in complex with inhibitor
7C02	;	2.91	;	Crystal structure of dimeric MERS-CoV receptor binding domain
8W6P	;	1.91	;	Crystal structure of dimeric murine SMPDL3A
5YN4	;	1.47	;	Crystal structure of dimeric peptidyl tRNA hydrolase from Acinetobacter baumannii with occluded substrate binding site at 1.47 A resolution
7PV7	;	2.41	;	Crystal structure of dimeric Porphyromonas gingivalis PorX, a type 9 secretion system response regulator.
3FMB	;	1.85	;	Crystal structure of dimeric protein of unknown function and ferredoxin-like fold (YP_212648.1) from Bacteroides fragilis NCTC 9343 at 1.85 A resolution
4HI3	;	2.09	;	Crystal structure of dimeric R298A mutant of SARS coronavirus main protease
6LB5	;	2.4	;	Crystal structure of dimeric RXR-LBD complexed with full agonist NEt-3IB and TIF2 co-activator
6LB4	;	1.5	;	Crystal structure of dimeric RXR-LBD complexed with NEt-3ME and TIF2 co-activator
6LB6	;	2.4	;	Crystal structure of dimeric RXR-LBD complexed with partial agonist NEt-4IB and TIF2 co-activator
6L6K	;	1.8	;	Crystal structure of dimeric RXRalpha-LBD complexed with partial agonist CBt-PMN and SRC1
4RAH	;	1.4	;	Crystal structure of dimeric S33C beta-2 microglobulin mutant at 1.4 Angstrom resolution
4R9H	;	1.9	;	Crystal structure of dimeric S33C beta-2 microglobulin mutant at 1.9 Angstrom resolution
4RA3	;	2.8	;	Crystal structure of dimeric S33C beta-2 microglobulin mutant in complex with Thioflavin (ThT) at 2.8 Angstrom resolution
4LD8	;	1.83	;	Crystal Structure of Dimeric Sudan Virus VP40
5NE6	;	2.0	;	Crystal structure of dimeric TmPep1050 aminopeptidase
6I7G	;	2.7	;	Crystal structure of dimeric wild type FICD complexed with ATP
1K8C	;	2.1	;	Crystal structure of dimeric xylose reductase in complex with NADP(H)
5T7H	;	2.003	;	Crystal structure of dimeric yeast iso-1-cytochrome C with CYMAL6
1JB6	;	1.7	;	Crystal Structure of Dimerization Domain (1-33) of HNF-1alpha
2Q2G	;	1.9	;	Crystal structure of dimerization domain of HSP40 from Cryptosporidium parvum, cgd2_1800
3NFG	;	2.51	;	Crystal structure of Dimerization module of RNA polymerase I subcomplex A49/A34.5
4L1C	;	2.28	;	Crystal structure of Dimerized N-terminal Domain of MinC
2CI3	;	1.7	;	Crystal Structure of Dimethylarginine dimethylaminohydrolase crystal form I
2CI6	;	2.0	;	Crystal Structure of Dimethylarginine dimethylaminohydrolase I bound with Zinc low pH
2CI4	;	1.7	;	Crystal Structure of Dimethylarginine dimethylaminohydrolase I crystal form II
2C6Z	;	1.2	;	crystal structure of dimethylarginine dimethylaminohydrolase I in complex with citrulline
2CI5	;	1.79	;	Crystal structure of Dimethylarginine Dimethylaminohydrolase I in complex with L-homocysteine
2CI1	;	1.08	;	Crystal Structure of dimethylarginine dimethylaminohydrolase I in complex with S-nitroso-Lhomocysteine
2CI7	;	1.6	;	Crystal structure of Dimethylarginine Dimethylaminohydrolase I in complex with Zinc, high pH
3I4A	;	1.898	;	Crystal structure of dimethylarginine dimethylaminohydrolase-1 (DDAH-1) in complex with N5-(1-iminopropyl)-L-ornithine
6F7W	;	1.28	;	Crystal structure of dimethylated RSL - cucurbit[7]uril complex, C2221 Form
6F7X	;	2.42	;	Crystal structure of dimethylated RSL - cucurbit[7]uril complex, F432 form
6GL5	;	1.6	;	Crystal Structure of dimethylated RSL - sulfonatocalix[4]arene complex
6ZUL	;	1.62	;	Crystal structure of dimethylated RSL in complex with cucurbit[7]uril and zinc
6F7Y	;	1.6	;	Crystal structure of dimethylated RSL, cucurbituril-free form
6ZUM	;	1.589	;	Crystal structure of dimethylated RSL-N23H (RSL-B3) in complex with cucurbit[7]uril and zinc
6ZUK	;	2.03	;	Crystal structure of dimethylated RSL-N23H/G68H (RSL-B6) in complex with cucurbit[7]uril and zinc
6STZ	;	1.14	;	Crystal structure of dimethylated RSLex - cucurbituril free form
6SU0	;	1.98	;	Crystal structure of dimethylated RSLex in complex with cucurbit[7]uril
1PJ5	;	1.61	;	Crystal structure of dimethylglycine oxidase of Arthrobacter globiformis in complex with acetate
1PJ6	;	1.65	;	Crystal structure of dimethylglycine oxidase of Arthrobacter globiformis in complex with folic acid
4N0J	;	1.9	;	Crystal structure of dimethyllysine hen egg-white lysozyme in complex with sclx4 at 1.9 A resolution
4PRU	;	2.2	;	Crystal structure of dimethyllysine hen egg-white lysozyme in complex with sclx4 at 2.2 A resolution
4LA2	;	1.6	;	Crystal structure of dimethylsulphoniopropionate (DMSP) lyase DddQ
4LA3	;	2.701	;	Crystal structure of dimethylsulphoniopropionate (DMSP) lyase DddQ Y131A in complex with DMSP
6MFZ	;	6.0	;	Crystal structure of dimodular LgrA in a condensation state
1K1S	;	2.8	;	Crystal Structure of DinB from Sulfolobus solfataricus
6IZ2	;	2.069	;	Crystal structure of DinB/YfiT protein DR0053 from D. radiodurans R1
3W9W	;	1.35	;	Crystal structure of DING protein
1H9P	;	2.0	;	Crystal Structure of Dioclea guianensis Seed Lectin
5UUY	;	1.88	;	Crystal structure of Dioclea lasiocarpa lectin (DLL) complexed with X-MAN
5TG3	;	1.765	;	Crystal Structure of Dioclea reflexa seed lectin (DrfL) in complex with X-Man
2ZBJ	;	2.05	;	Crystal structure of Dioclea rostrata lectin
4NOT	;	2.35	;	Crystal structure of Dioclea sclerocarpa lectin complexed with X-man
2GDF	;	2.4	;	Crystal structure of Dioclea violacea seed lectin
1IWB	;	1.85	;	Crystal structure of diol dehydratase
1EGM	;	1.85	;	CRYSTAL STRUCTURE OF DIOL DEHYDRATASE-CYANOCOBALAMIN COMPLEX AT 100K.
5A24	;	1.5	;	Crystal structure of Dionain-1, the major endopeptidase in the Venus flytrap digestive juice
4TWL	;	2.11	;	Crystal structure of dioscorin complexed with ascorbate
4TWM	;	2.11	;	Crystal structure of dioscorin from Dioscorea japonica
6KUN	;	2.002	;	Crystal structure of dioxygenase for auxin oxidation (DAO) in rice
6BDJ	;	2.15	;	Crystal structure of dioxygenase Tetur07g02040
6EFY	;	2.9	;	Crystal Structure of DIP-Alpha Ig1-3
6NRX	;	1.9	;	Crystal structure of DIP-eta IG1 homodimer
6NS1	;	1.85	;	Crystal structure of DIP-gamma IG1+IG2
6EFZ	;	3.499	;	Crystal Structure of DIP-Theta Ig1-3
1WN1	;	2.25	;	Crystal Structure of Dipeptiase from Pyrococcus Horikoshii OT3
3K5X	;	1.4	;	Crystal structure of dipeptidase from Streptomics coelicolor complexed with phosphinate pseudodipeptide L-Ala-D-Asp at 1.4A resolution.
3S2J	;	1.297	;	Crystal structure of dipeptidase from Streptomyces coelicolor complexed with phosphinate pseudodipeptide L-Leu-D-Ala
3S2L	;	1.399	;	Crystal structure of dipeptidase from Streptomyces coelicolor complexed with phosphinate pseudodipeptide L-Leu-D-Glu
3S2M	;	1.399	;	Crystal structure of dipeptidase from Streptomyces coelicolor complexed with phosphinate pseudodipeptide L-Phe-D-Asp
3S2N	;	1.4	;	Crystal structure of dipeptidase from Streptomyces coelicolor complexed with phosphinate pseudodipeptide L-Tyr-D-Asp
4EGE	;	2.2	;	Crystal Structure of Dipeptidase PepE from Mycobacterium ulcerans
7C9B	;	1.4	;	Crystal structure of dipeptidase-E from Xenopus laevis
4QFK	;	2.288	;	Crystal structure of dipeptide binding protein from pseudoalteromonas sp. SM9913
4QFL	;	1.749	;	Crystal structure of dipeptide binding protein from pseudoalteromonas sp. SM9913 in complex with Ala-Phe
4QFN	;	2.297	;	Crystal structure of dipeptide binding protein from pseudoalteromonas sp. SM9913 in complex with Gly-Glu
4QFO	;	2.304	;	Crystal structure of dipeptide binding protein from pseudoalteromonas sp. SM9913 in complex with Met-Leu
4QFP	;	1.903	;	Crystal structure of dipeptide binding protein from pseudoalteromonas sp. SM9913 in complex with Val-Thr
3Q4D	;	3.0	;	Crystal structure of dipeptide epimerase from Cytophaga hutchinsonii complexed with Mg and dipeptide D-Ala-L-Ala
3Q45	;	3.0	;	Crystal structure of Dipeptide Epimerase from Cytophaga hutchinsonii complexed with Mg and dipeptide D-Ala-L-Val
3JVA	;	1.7	;	Crystal structure of Dipeptide Epimerase from Enterococcus faecalis V583
3KUM	;	1.9	;	Crystal structure of Dipeptide Epimerase from Enterococcus faecalis V583 complexed with Mg and dipeptide L-Arg-L-Tyr
3JW7	;	1.8	;	Crystal structure of Dipeptide Epimerase from Enterococcus faecalis V583 complexed with Mg and dipeptide L-Ile-L-Tyr
3JZU	;	2.0	;	Crystal structure of Dipeptide Epimerase from Enterococcus faecalis V583 complexed with Mg and dipeptide L-Leu-L-Tyr
3K1G	;	2.0	;	Crystal structure of Dipeptide Epimerase from Enterococcus faecalis V583 complexed with Mg and dipeptide L-Ser-L-Tyr
3RIT	;	2.701	;	Crystal structure of Dipeptide Epimerase from Methylococcus capsulatus complexed with Mg and dipeptide L-Arg-D-Lys
3RO6	;	2.2	;	Crystal structure of Dipeptide Epimerase from Methylococcus capsulatus complexed with Mg ion
3DEQ	;	2.1	;	Crystal structure of dipeptide epimerase from Thermotoga maritima complexed with L-Ala-L-Leu dipeptide
3DER	;	1.9	;	Crystal structure of dipeptide epimerase from Thermotoga maritima complexed with L-Ala-L-Lys dipeptide
3DES	;	2.3	;	Crystal structure of dipeptide epimerase from Thermotoga maritima complexed with L-Ala-L-Phe dipeptide
2ECF	;	2.8	;	Crystal Structure of Dipeptidyl Aminopeptidase IV from Stenotrophomonas maltophilia
4XZY	;	2.7	;	Crystal structure of dipeptidyl peptidase 11 (DPP11) from Porphyromonas gingivalis
4Y01	;	2.46	;	Crystal structure of dipeptidyl peptidase 11 (DPP11) from Porphyromonas gingivalis
4Y02	;	1.96	;	Crystal structure of dipeptidyl peptidase 11 (DPP11) from Porphyromonas gingivalis (Ground)
4Y04	;	1.66	;	Crystal structure of dipeptidyl peptidase 11 (DPP11) from Porphyromonas gingivalis (Space)
6JTB	;	1.5	;	Crystal structure of dipeptidyl peptidase 11 (DPP11) with citrate from Porphyromonas gingivalis (Space)
6JTC	;	2.39	;	Crystal structure of dipeptidyl peptidase 11 (DPP11) with SH-5 from Porphyromonas gingivalis (Space)
5YP1	;	2.47	;	Crystal structure of dipeptidyl peptidase IV (DPP IV) from Pseudoxanthomonas mexicana WO24
5YP2	;	2.13	;	Crystal structure of dipeptidyl peptidase IV (DPP IV) with DPP4 inhibitor from Pseudoxanthomonas mexicana WO24
5YP3	;	2.44	;	Crystal structure of dipeptidyl peptidase IV (DPP IV) with Ile-Pro from Pseudoxanthomonas mexicana
5YP4	;	1.9	;	Crystal structure of dipeptidyl peptidase IV (DPP IV) with Lys-Pro from Pseudoxanthomonas mexicana WO24
4FFV	;	2.4	;	Crystal Structure of Dipeptidyl Peptidase IV (DPP4, DPP-IV, CD26) in Complex with 11A19 Fab
4FFW	;	2.9	;	Crystal Structure of Dipeptidyl Peptidase IV (DPP4, DPP-IV, CD26) in Complex with Fab + sitagliptin
1W1I	;	3.03	;	Crystal structure of dipeptidyl peptidase IV (DPPIV or CD26) in complex with adenosine deaminase
3G0C	;	2.69	;	Crystal structure of dipeptidyl peptidase IV in complex with a pyrimidinedione inhibitor 1
3G0D	;	2.39	;	Crystal structure of dipeptidyl peptidase IV in complex with a pyrimidinedione inhibitor 2
3G0G	;	2.45	;	Crystal structure of dipeptidyl peptidase IV in complex with a pyrimidinone inhibitor 3
3F8S	;	2.43	;	Crystal structure of dipeptidyl peptidase IV in complex with inhibitor
3QBJ	;	2.21	;	Crystal structure of dipeptidyl peptidase IV in complex with inhibitor
5KBY	;	2.24	;	Crystal structure of dipeptidyl peptidase IV in complex with SYR-472
3G0B	;	2.25	;	Crystal structure of dipeptidyl peptidase IV in complex with TAK-322
4JH0	;	2.35	;	Crystal structure of dipeptidyl-peptidase 4 (CD26, adenosine deaminase complexing protein 2) (DPP-IV-WT) complex with bms-767778 AKA 2-(3-(aminomethyl)-4-(2,4- dichlorophenyl)-2-methyl-5-oxo-5,7-dihydro-6h-pyrrolo[3,4- b]pyridin-6-yl)-n,n-dimethylacetamide
6XR5	;	1.7	;	Crystal Structure of Diphosphomevalonate decarboxylase (MVD1) Cryptococcus neoformans var. grubii serotype A
6NFZ	;	2.966	;	Crystal structure of diphosphorylated HPK1 kinase domain in complex with sunitinib in the active state.
4OW6	;	2.8	;	Crystal structure of Diphtheria Toxin at acidic pH
7K7B	;	2.05	;	Crystal structure of diphtheria toxin from crystals obtained at pH 5.0
7K7C	;	2.05	;	Crystal structure of diphtheria toxin from crystals obtained at pH 5.5
7K7D	;	2.1	;	Crystal structure of diphtheria toxin from crystals obtained at pH 6.0
7K7E	;	2.3	;	Crystal structure of diphtheria toxin from crystals obtained at pH 7.0
8G0G	;	2.1	;	Crystal structure of diphtheria toxin H223Q/H257Q double mutant (pH 4.5)
8G0F	;	2.25	;	Crystal structure of diphtheria toxin H223Q/H257Q double mutant (pH 5.5)
4AE0	;	1.996	;	Crystal structure of diphtheria toxin mutant CRM197
4AE1	;	2.078	;	Crystal structure of diphtheria toxin mutant CRM197 in complex with nicotinamide
7O4W	;	2.03002	;	Crystal structure of diphtheria toxin mutant CRM197 with a disulphide bond replaced by a Cys-Acetone-Cys bridge
2H09	;	2.1	;	Crystal structure of diphtheria toxin repressor like protein from E. coli
1VHV	;	1.75	;	Crystal structure of diphthine synthase
3D4O	;	2.1	;	Crystal structure of dipicolinate synthase subunit A (NP_243269.1) from BACILLUS HALODURANS at 2.10 A resolution
3LQK	;	2.1	;	Crystal structure of dipicolinate synthase subunit B from Bacillus halodurans C
2RIR	;	2.79	;	Crystal structure of dipicolinate synthase, A chain, from Bacillus subtilis
6NAZ	;	3.081	;	Crystal structure of DIRAS 2/3 chimera in complex with GDP
2ERX	;	1.65	;	Crystal Structure of DiRas2 in Complex With GDP and Inorganic Phosphate
2WN3	;	1.59	;	Crystal structure of Discoidin I from Dictyostelium discoideum in complex with the disaccharide GalNAc beta 1-3 galactose, at 1.6 A resolution.
3OR1	;	1.76	;	Crystal structure of dissimilatory sulfite reductase I (DsrI)
3OR2	;	2.05	;	Crystal structure of dissimilatory sulfite reductase II (DsrII)
3HSM	;	2.5	;	Crystal structure of distal N-terminal beta-trefoil domain of Ryanodine Receptor type 1
4JRR	;	1.88	;	Crystal structure of disulfide bond oxidoreductase DsbA1 from Legionella pneumophila
5HD8	;	3.15	;	Crystal structure of disulfide cross-linked D417C ClC-ec1
1Y6P	;	2.25	;	Crystal structure of disulfide engineered porcine pancratic phospholipase a2 to group-x isozyme
1Y6O	;	2.0	;	Crystal structure of disulfide engineered porcine pancreatic phospholipase A2 to group-X isozyme in complex with inhibitor MJ33 and phosphate ions
3GV1	;	2.0	;	Crystal structure of disulfide interchange protein from Neisseria gonorrhoeae
4MCU	;	1.99	;	Crystal structure of disulfide oxidoreductase from Klebsiella pneumoniae in reduced state
4K6X	;	1.972	;	Crystal structure of disulfide oxidoreductase from Mycobacterium tuberculosis
2QWN	;	2.4	;	Crystal structure of disulfide-bond-crosslinked complex of bovine hsc70 (1-386aa)R171C and bovine Auxilin (810-910aa)D876C in the ADP*Pi state
2QWO	;	1.7	;	Crystal structure of disulfide-bond-crosslinked complex of bovine hsc70 (1-394aa)R171C and bovine Auxilin (810-910aa)D876C in the ADP*Pi form #1
2QWP	;	1.75	;	Crystal structure of disulfide-bond-crosslinked complex of bovine hsc70 (1-394aa)R171C and bovine Auxilin (810-910aa)D876C in the ADP*Pi form #2
2QWQ	;	2.21	;	Crystal structure of disulfide-bond-crosslinked complex of bovine hsc70 (1-394aa)R171C and bovine Auxilin (810-910aa)D876C in the AMPPNP hydrolyzed form
2QWR	;	2.21	;	Crystal structure of disulfide-bond-crosslinked complex of bovine hsc70 (1-394aa)R171C and bovine Auxilin (810-910aa)D876C in the AMPPNP intact form
5GRX	;	2.002	;	Crystal structure of disulfide-bonded diabody
5GRY	;	1.639	;	Crystal structure of disulfide-bonded diabody
5GRZ	;	2.7	;	Crystal structure of disulfide-bonded diabody
2D31	;	3.2	;	Crystal structure of disulfide-linked HLA-G dimer
6RMT	;	2.0	;	Crystal structure of disulphide-linked human C3d dimer
6RMU	;	2.4	;	Crystal structure of disulphide-linked human C3d dimer in complex with Staphylococcus aureus complement subversion protein Sbi-IV
7Y9H	;	2.03	;	Crystal structure of diterpene synthase VenA from Streptomyces venezuelae ATCC 15439
7Y9G	;	2.18	;	Crystal structure of diterpene synthase VenA from Streptomyces venezuelae ATCC 15439 in complex with pyrophosphate
2VNZ	;	1.3	;	Crystal structure of dithinonite reduced soybean ascorbate peroxidase mutant W41A.
2IUP	;	1.8	;	CRYSTAL STRUCTURE OF DITHIONITE-REDUCED AROMATIC AMINE DEHYDROGENASE (AADH) FROM ALCALIGENES FAECALIS
2IUQ	;	1.5	;	CRYSTAL STRUCTURE OF DITHIONITE-REDUCED AROMATIC AMINE DEHYDROGENASE (AADH) FROM ALCALIGENES FAECALIS IN COMPLEX WITH TRYPTAMINE
5X3N	;	1.649	;	Crystal structure of DiUb-K6
4IYQ	;	2.55	;	Crystal structure of divalent ion tolerance protein CutA1 from Ehrlichia chaffeensis
3OPK	;	1.9	;	Crystal structure of divalent-cation tolerance protein CutA from Salmonella enterica subsp. enterica serovar Typhimurium str. LT2
3FYY	;	1.8	;	Crystal structure of divergent enolase from Oceanobacillus iheyensis complexed with Mg
3ES7	;	1.9	;	Crystal structure of divergent enolase from Oceanobacillus Iheyensis complexed with Mg and L-malate.
3ES8	;	2.2	;	Crystal structure of divergent enolase from Oceanobacillus Iheyensis complexed with Mg and L-malate.
3GD6	;	1.6	;	Crystal structure of divergent enolase from Oceanobacillus iheyensis complexed with phosphate
4RKW	;	1.5	;	Crystal structure of DJ-1
4P34	;	1.55	;	Crystal structure of DJ-1 in sulfenic acid form (fresh crystal)
4P2G	;	1.35	;	Crystal structure of DJ-1 in sulfinic acid form (aged crystal)
4RKY	;	1.5	;	Crystal structure of DJ-1 isoform X1
4P35	;	1.75	;	Crystal structure of DJ-1 with Zinc(II) bound (crystal I)
4P36	;	1.182	;	Crystal structure of DJ-1 With Zn(II) bound (crystal 2)
1Q2U	;	1.6	;	Crystal structure of DJ-1/RS and implication on familial Parkinson's disease
5H7O	;	2.8	;	Crystal structure of DJ-101 in complex with tubulin protein
1WLZ	;	1.6	;	Crystal structure of DJBP fragment which was obtained by limited proteolysis
8YDO	;	2.0	;	Crystal structure of dKeima570
4N2X	;	1.7	;	Crystal Structure of DL-2-haloacid dehalogenase
3WJ8	;	2.7	;	Crystal Structure of DL-2-haloacid dehalogenase mutant with 2-bromo-2-methylpropionate
5X2D	;	2.6	;	Crystal structure of DLC like domain of CsTAL3 (83-177aa)
7Y8W	;	2.4	;	Crystal structure of DLC-1/SAO-1 complex
7CNU	;	2.0	;	Crystal structure of DLC2 in complex with BMF peptide
7K3L	;	1.79	;	Crystal structure of dLC8 in complex with Panoramix TQ peptide
7K3K	;	1.415	;	Crystal structure of dLC8 in complex with Panoramix TQT peptide
7K3J	;	2.5	;	Crystal structure of dLC8 in complex with Panoramix TQT+TQ peptide
3WP0	;	2.039	;	Crystal structure of Dlg GK in complex with a phosphor-Lgl2 peptide
5CEN	;	1.7	;	Crystal structure of DLK (kinase domain)
8OUR	;	1.95	;	CRYSTAL STRUCTURE OF DLK IN COMPLEX WITH COMPOUND 16
8OUS	;	2.2	;	CRYSTAL STRUCTURE OF DLK IN COMPLEX WITH COMPOUND 19
8OUT	;	1.935	;	CRYSTAL STRUCTURE OF DLK IN COMPLEX WITH COMPOUND 22
8DEG	;	2.79	;	Crystal structure of DLK in complex with inhibitor DN0011197
5DI0	;	1.7	;	Crystal structure of Dln1
4ZNQ	;	1.9	;	Crystal structure of Dln1 complexed with Man(alpha1-2)Man
4ZNR	;	2.1	;	Crystal structure of Dln1 complexed with Man(alpha1-3)Man
4ZNO	;	1.86	;	Crystal structure of Dln1 complexed with sucrose
3FCC	;	2.32	;	CRYSTAL STRUCTURE OF DLTA PROTEIN IN COMPLEX WITH ATP and MAGNESIUM
3DHV	;	2.0	;	Crystal structure of DltA protein in complex with D-alanine adenylate
3E7W	;	2.28	;	Crystal structure of DLTA: Implications for the reaction mechanism of non-ribosomal peptide synthetase (NRPS) adenylation domains
3E7X	;	2.6	;	Crystal structure of DLTA: implications for the reaction mechanism of non-ribosomal peptide synthetase (NRPS) adenylation domains
7DXM	;	2.96	;	Crystal structure of DltD
8AKH	;	1.4	;	Crystal structure of DltE from L. plantarum soaked with LTA
8AGR	;	1.86	;	Crystal structure of DltE from L. plantarum, apo form
8AIK	;	1.95	;	Crystal structure of DltE from L. plantarum, tartare bound form
8AJI	;	1.94	;	Crystal structure of DltE from L. plantarum, TCEP form
5VNY	;	1.101	;	Crystal structure of DM14-3 domain of Lgd
8DB0	;	2.26	;	Crystal structure of DMATS1 prenyltransferase in complex with L-Trp and DMSPP
8DAZ	;	2.49	;	Crystal structure of DMATS1 prenyltransferase in complex with L-Trp and GSPP
8DAY	;	2.55	;	Crystal Structure of DMATS1 prenyltransferase in complex with L-Tyr and DMSPP
7Q4I	;	2.4	;	Crystal structure of DmC1GalT1 in complex with UDP-Mn2+ and the APD-TGalNAc-RP
5I8J	;	1.75	;	Crystal structure of Dmd from phage RB69
4IZD	;	1.8	;	Crystal structure of DmdD E121A in complex with MMPA-CoA
4IZC	;	1.8	;	Crystal structure of DmdD E121A in complex with MTA-CoA
4IZB	;	1.504	;	Crystal structure of DmdD, a crotonase superfamily enzyme that catalyzes the hydration and hydrolysis of methylthioacryloyl-CoA
6AMU	;	2.151	;	Crystal structure of DMF5 TCR bound to HLA-A2 presenting synthetic peptide MMWDRGLGMM
6AM5	;	2.394	;	Crystal structure of DMF5 TCR bound to HLA-A2 presenting synthetic peptide SMLGIGIVPV
6MRK	;	2.8	;	Crystal structure of dmNxf2 NTF2-like domain in complex with Nxt1/p15
6OPF	;	2.0	;	Crystal structure of dmNxf2 UBA domain fused with Panoramix helix
6AK1	;	2.284	;	Crystal structure of DmoA from Hyphomicrobium sulfonivorans
3M20	;	2.37	;	Crystal structure of DmpI from Archaeoglobus fulgidus determined to 2.37 Angstroms resolution
3M21	;	1.9	;	Crystal structure of DmpI from Helicobacter pylori Determined to 1.9 Angstroms resolution
5CU1	;	2.3	;	Crystal structure of DMSP lyase DddQ from Ruegeria pomeroyi DSS-3
4B28	;	2.15	;	Crystal structure of DMSP lyase RdDddP from Roseobacter denitrificans
6I0V	;	1.851	;	Crystal structure of DmTailor in complex with CACAGU RNA
6I0T	;	2.0	;	Crystal structure of DmTailor in complex with GpU
6I0U	;	2.001	;	Crystal structure of DmTailor in complex with U6 RNA
6I0S	;	1.9	;	Crystal structure of DmTailor in complex with UMPNPP
4ONH	;	3.008	;	Crystal Structure of DN6 TCR
4P55	;	2.504	;	Crystal structure of DNA binding domain of K11 from KSHV
3IHU	;	1.92	;	Crystal structure of DNA binding protein (YP_298823.1) from Ralstonia eutropha JMP134 at 1.92 A resolution
6IFM	;	2.804	;	Crystal structure of DNA bound VapBC from Salmonella typhimurium
5NZY	;	1.551	;	Crystal structure of DNA cross-link repair protein 1A in complex with Cefotaxime
5NZW	;	2.7	;	Crystal structure of DNA cross-link repair protein 1A in complex with ceftriaxone
5NZX	;	1.47	;	Crystal structure of DNA cross-link repair protein 1A in complex with Ceftriaxone (alternative site)
3E0C	;	2.41	;	Crystal Structure of DNA Damage-Binding protein 1(DDB1)
8HIS	;	2.01	;	Crystal structure of DNA decamer containing GuNA[Me,tBu]
6CQ3	;	1.3	;	Crystal structure of DNA dodecamer D(CGCGAATTCGCG)
5XUV	;	1.9	;	Crystal structure of DNA duplex containing 4-thiothymine-2Ag(I)-4-thiothymine base pairs
4L25	;	1.1	;	Crystal structure of DNA duplex containing consecutive T-T mispairs
4L26	;	1.4	;	Crystal structure of DNA duplex containing consecutive T-T mispairs (Br-derivative)
4R6M	;	2.357	;	Crystal Structure of DNA Duplex Containing Two Consecutive Mercury-mediated Base Pairs
5LJ4	;	2.17	;	Crystal structure of DNA duplex containing ZP base pair
2ZJT	;	2.8	;	Crystal structure of dna gyrase B' domain sheds lights on the mechanism for T-segment navigation
1NLF	;	1.95	;	Crystal Structure of DNA Helicase RepA in complex with sulfate at 1.95 A resolution
4EFB	;	2.2	;	Crystal structure of DNA ligase
4EFE	;	2.0	;	crystal structure of DNA ligase
3SGI	;	3.5	;	Crystal structure of DNA ligase A BRCT domain deleted mutant of Mycobacterium tuberculosis
8I50	;	0.95	;	Crystal structure of DNA octamer containing GuNA[Me,Me]
8HU5	;	0.93	;	Crystal structure of DNA octamer containing GuNA[Me,tBu]
1IQR	;	2.1	;	Crystal structure of DNA photolyase from Thermus thermophilus
7N2M	;	2.9	;	Crystal structure of DNA polymerase alpha catalytic core in complex with dCTP and template/primer having T-C mismatch at the post-insertion site
1HUO	;	2.6	;	CRYSTAL STRUCTURE OF DNA POLYMERASE BETA COMPLEXED WITH DNA AND CR-TMPPCP
7S9K	;	1.97	;	Crystal Structure of DNA Polymerase Beta with Fapy-dG base-paired with a dA
7S9J	;	1.91	;	Crystal Structure of DNA Polymerase Beta with Fapy-dG base-paired with a dC
7S9M	;	2.31	;	Crystal Structure of DNA Polymerase Beta with Ring open intermediate Fapy-dG base-paired with a dA
7S9L	;	2.05	;	Crystal Structure of DNA Polymerase Beta with Ring open intermediate Fapy-dG base-paired with a dC
1HUZ	;	2.6	;	CRYSTAL STRUCTURE OF DNA POLYMERASE COMPLEXED WITH DNA AND CR-PCP
2XHB	;	2.72	;	Crystal structure of DNA polymerase from Thermococcus gorgonarius in complex with hypoxanthine-containing DNA
8DT6	;	2.35	;	Crystal Structure of DNA Polymerase III beta subunit from Elizabethkingia anophelis
3P16	;	2.89	;	Crystal structure of DNA polymerase III sliding clamp
6DLY	;	2.1	;	Crystal structure of DNA polymerase III subunit beta from Mycobacterium marinum in complex with a natural product
5W7Z	;	1.7	;	Crystal structure of DNA polymerase III subunit beta from Rickettsia conorii
6DLK	;	2.0	;	Crystal structure of DNA polymerase III subunit beta from Rickettsia rickettsii
2AWA	;	2.5	;	Crystal structure of DNA polymerase III, beta chain (EC 2.7.7.7) (np_344555.1) from STREPTOCOCCUS PNEUMONIAE TIGR4 at 2.50 A resolution
1VPK	;	2.0	;	Crystal structure of DNA polymerase III, beta subunit (TM0262) from Thermotoga maritima at 2.00 A resolution
1RZT	;	2.1	;	Crystal structure of DNA polymerase lambda complexed with a two nucleotide gap DNA molecule
4TR6	;	1.5	;	Crystal structure of DNA polymerase sliding clamp from Bacillus subtilis
6IZO	;	1.94	;	Crystal structure of DNA polymerase sliding clamp from Caulobacter crescentus
4TR7	;	2.29	;	Crystal structure of DNA polymerase sliding clamp from Mycobaterium tuberculosis
4TR8	;	1.8	;	Crystal structure of DNA polymerase sliding clamp from Pseudomonas aeruginosa
4TSZ	;	2.0	;	Crystal structure of DNA polymerase sliding clamp from Pseudomonas aeruginosa with ligand
1V33	;	1.8	;	Crystal structure of DNA primase from Pyrococcus horikoshii
1L8Q	;	2.7	;	CRYSTAL STRUCTURE OF DNA REPLICATION INITIATION FACTOR
1EV7	;	2.38	;	CRYSTAL STRUCTURE OF DNA RESTRICTION ENDONUCLEASE NAEI
1D8X	;	1.2	;	CRYSTAL STRUCTURE OF DNA SHEARED TANDEM G A BASE PAIRS
1D9R	;	1.5	;	CRYSTAL STRUCTURE OF DNA SHEARED TANDEM G-A BASE PAIRS
1DCR	;	1.6	;	CRYSTAL STRUCTURE OF DNA SHEARED TANDEM G-A BASE PAIRS
3W2X	;	1.6	;	Crystal structure of DNA uridine endonuclease Mth212
3W2Y	;	1.9	;	Crystal structure of DNA uridine endonuclease Mth212 mutant W205S
3U2N	;	1.25	;	Crystal structure of DNA(CGCGAATTCGCG)2 at 1.25 angstroms
2H56	;	2.55	;	Crystal structure of DNA-3-methyladenine glycosidase (10174367) from Bacillus halodurans at 2.55 A resolution
7XKM	;	2.79	;	Crystal structure of DNA-Ag(I) rod comprising a one-dimensional array of 11 silver ions
2D1V	;	2.4	;	Crystal structure of DNA-binding domain of Bacillus subtilis YycF
6ZWT	;	2.2	;	Crystal structure of DNA-binding domain of OmpR of two-component system of Acinetobacter baumannii
5WFY	;	1.4	;	Crystal structure of DNA-binding domain of the bacteriophage T4 ligase
3B2N	;	2.04	;	Crystal structure of DNA-binding response regulator, LuxR family, from Staphylococcus aureus
3MKL	;	2.15	;	Crystal structure of DNA-binding transcriptional dual regulator from Escherichia coli K-12
7C9O	;	2.55	;	Crystal structure of DNA-bound CCT/NF-YB/YC complex (HD1CCT/GHD8/OsNF-YC2)
5Z2T	;	2.623	;	Crystal structure of DNA-bound DUX4-HD2
4QJU	;	2.16	;	Crystal structure of DNA-bound nucleoid associated protein, SAV1473
2JGU	;	2.6	;	crystal structure of DNA-directed DNA polymerase
6I5F	;	2.6	;	Crystal structure of DNA-free E.coli MutS P839E dimer mutant
3VK7	;	2.1	;	Crystal structure of DNA-glycosylase bound to DNA containing 5-Hydroxyuracil
3VK8	;	2.0	;	Crystal structure of DNA-glycosylase bound to DNA containing Thymine glycol
4U6K	;	1.5	;	Crystal structure of DNA/RNA duplex containing 2'-4'-BNA-NC
4U6M	;	1.9	;	Crystal structure of DNA/RNA duplex obtained in the presence of Spermine
4U6L	;	1.9	;	Crystal structure of DNA/RNA duplex obtained in the presence of [Co(NH3)6]Cl3 and SrCl2
5EAN	;	2.36	;	Crystal structure of Dna2 in complex with a 5' overhang DNA
5EAX	;	3.05	;	Crystal structure of Dna2 in complex with an ssDNA
5EAW	;	3.0	;	Crystal structure of Dna2 nuclease-helicase
5WSP	;	1.502	;	Crystal structure of DNA3 duplex
1J1V	;	2.1	;	Crystal structure of DnaA domainIV complexed with DnaAbox DNA
2I5U	;	1.5	;	Crystal structure of DnaD domain protein from Enterococcus faecalis. Structural genomics target APC85179
2ZC2	;	2.1	;	Crystal structure of DnaD-like replication protein from Streptococcus mutans UA159, gi 24377835, residues 127-199
3NZM	;	1.55	;	Crystal structure of DNAE intein with N-extein in redox trap
7CIZ	;	1.8	;	Crystal structure of DNAJC9 HBD helix2 in complex with H3.3-H4 dimer and MCM2 HBD
7CJ0	;	2.5	;	Crystal structure of DNAJC9 HBD in complex with H3.3-H4 dimer and MCM2 HBD
7RZM	;	2.15	;	Crystal Structure of dnaN DNA polymerase III beta subunit from Stenotrophomonas maltophilia K279a
8H2F	;	1.448	;	Crystal structure of DnaQ domain in complex witn TMP of Streptococcus thermophilus strain DGCC 7710
8H18	;	1.499	;	Crystal structure of DnaQ domain of Streptococcus thermophilus strain DGCC 7710
6X2D	;	1.85	;	Crystal Structure of DNase I Domain of Ribonuclease E from Vibrio cholerae
4OU6	;	1.96	;	Crystal structure of DnaT84-153-dT10 ssDNA complex form 1
4OU7	;	2.83	;	Crystal structure of DnaT84-153-dT10 ssDNA complex reveals a novel single-stranded DNA binding mode
3VAX	;	2.4	;	Crystal structure of DndA from streptomyces lividans
4LRV	;	2.5	;	Crystal structure of DndE from Escherichia coli B7A involved in DNA phosphorothioation modification
5WTU	;	2.9	;	Crystal structure of DndE G21/24K mutant involved in DNA phosphorothioation
4Z96	;	2.85	;	Crystal structure of DNMT1 in complex with USP7
5WVO	;	1.997	;	Crystal structure of DNMT1 RFTS domain in complex with K18/K23 mono-ubiquitylated histone H3
6BRR	;	2.97	;	Crystal structure of DNMT3A (R836A)-DNMT3L in complex with DNA containing two CpG sites
4QBQ	;	2.406	;	Crystal structure of DNMT3a ADD domain bound to H3 peptide
4QBS	;	1.8	;	Crystal structure of DNMT3a ADD domain E545R mutant bound to H3T3ph peptide
4QBR	;	1.902	;	Crystal structure of DNMT3a ADD domain G550D mutant bound to H3 peptide
4U7P	;	3.821	;	Crystal structure of DNMT3A-DNMT3L complex
5YX2	;	2.653	;	Crystal structure of DNMT3A-DNMT3L in complex with DNA containing two CpG sites
4U7T	;	2.9	;	Crystal structure of DNMT3A-DNMT3L in complex with histone H3
6F57	;	3.098	;	Crystal structure of DNMT3A-DNMT3L in complex with single CpG-containing DNA
6U8W	;	2.94892	;	Crystal structure of DNMT3B(K777A)-DNMT3L in complex with CpGpT DNA
6U90	;	3.00082	;	Crystal structure of DNMT3B(N779A)-DNMT3L in complex with CpGpT DNA
6U91	;	2.99999	;	Crystal structure of DNMT3B(Q772R)-DNMT3L in complex with CpGpT DNA
6U8X	;	2.95064	;	Crystal structure of DNMT3B-DNMT3L in complex with CpApG DNA
6U8P	;	3.05	;	Crystal structure of DNMT3B-DNMT3L in complex with CpGpA DNA
6U8V	;	3.0	;	Crystal structure of DNMT3B-DNMT3L in complex with CpGpT DNA
3VAT	;	2.1	;	Crystal structure of DNPEP, ZnMg form
3VAR	;	2.25	;	Crystal structure of DNPEP, ZnZn form
4KXL	;	1.69	;	Crystal structure of DNPH1 (RCL) with 6-CYCLOPENTYL-AMP
4KXN	;	1.9	;	Crystal structure of DNPH1 (RCL) with kinetine riboside monophosphate
4KXM	;	2.24	;	Crystal structure of DNPH1 (RCL) WITH N6-ISOPENTENYL-AMP
3DKW	;	3.6	;	Crystal Structure of DNR from Pseudomonas aeruginosa.
2DQB	;	2.2	;	Crystal structure of dNTP triphosphohydrolase from Thermus thermophilus HB8, which is homologous to dGTP triphosphohydrolase
8HYL	;	2.0	;	Crystal structure of DO1 Fv-clasp fragment
4LCV	;	2.0	;	Crystal Structure of DOC2B C2A domain
4LDC	;	1.264	;	Crystal Structure of DOC2B C2B domain
7XIN	;	2.0	;	Crystal structure of DODC from Pseudomonas
3W80	;	1.4	;	Crystal structure of dodecamer human insulin with double C-axis length of the hexamer 2 Zn insulin cell
5YL5	;	1.9	;	Crystal structure of dodecameric Dehydroquinate dehydratase from Acinetobacter baumannii at 1.9A resolution
1SBZ	;	2.0	;	Crystal Structure of dodecameric FMN-dependent Ubix-like Decarboxylase from Escherichia coli O157:H7
4RB4	;	3.88	;	Crystal structure of dodecameric iron-containing heptosyltransferase TibC in complex with ADP-D-beta-D-heptose at 3.9 angstrom resolution
8DBA	;	3.5	;	Crystal structure of dodecameric KaiC
5WRF	;	2.51	;	Crystal structure of dodecameric type II dehydroquinate dehydratase from Acinetobacter baumannii with unexplained connecting electron density between free cysteine residues of molecular pairs
7CPM	;	2.6	;	CRYSTAL STRUCTURE OF DODECAPRENYL DIPHOSPHATE SYNTHASE FROM THERMOBIFIDA FUSCA
7CPN	;	2.28	;	CRYSTAL STRUCTURE OF DODECAPRENYL DIPHOSPHATE SYNTHASE FROM THERMOBIFIDA FUSCA
4CLV	;	3.12	;	Crystal Structure of dodecylphosphocholine-solubilized NccX from Cupriavidus metallidurans 31A
3GOU	;	3.0	;	Crystal structure of dog (Canis familiaris) hemoglobin
1K8Q	;	2.7	;	CRYSTAL STRUCTURE OF DOG GASTRIC LIPASE IN COMPLEX WITH A PHOSPHONATE INHIBITOR
5MZF	;	2.0	;	Crystal structure of dog MTH1 protein
1P5T	;	2.35	;	Crystal Structure of Dok1 PTB Domain
1UEF	;	2.5	;	Crystal Structure of Dok1 PTB Domain Complex
6GPM	;	1.73	;	Crystal structure of domain 2 from TmArgBP
1EJ8	;	1.55	;	CRYSTAL STRUCTURE OF DOMAIN 2 OF THE YEAST COPPER CHAPERONE FOR SUPEROXIDE DISMUTASE (LYS7) AT 1.55 A RESOLUTION
2XHA	;	1.906	;	Crystal Structure of Domain 2 of Thermotoga maritima N-utilization Substance G (NusG)
1WVN	;	2.1	;	Crystal Structure of domain 3 of human alpha polyC binding protein
7VZO	;	1.75	;	crystal structure of Domain 5-6 of filamin C from Scylla paramamosain
6XKS	;	2.4	;	Crystal structure of domain A from the periplasmic Lysine-, Arginine-, Ornithine-binding protein (LAO) of Salmonella typhimurium
353D	;	2.4	;	CRYSTAL STRUCTURE OF DOMAIN A OF THERMUS FLAVUS 5S RRNA AND THE CONTRIBUTION OF WATER MOLECULES TO ITS STRUCTURE
361D	;	3.0	;	CRYSTAL STRUCTURE OF DOMAIN E OF THERMUS FLAVUS 5S RRNA: A HELICAL RNA-STRUCTURE INCLUDING A TETRALOOP
3UC0	;	2.71	;	Crystal structure of domain I of the envelope glycoprotein ectodomain from dengue virus serotype 4 in complex with the fab fragment of the chimpanzee monoclonal antibody 5H2
4QEG	;	2.0	;	Crystal structure of domain I10 from titin (space group P41)
5JDJ	;	1.738	;	Crystal structure of domain I10 from titin in space group P212121
2Z4R	;	3.05	;	Crystal structure of domain III from the Thermotoga maritima replication initiation protein DnaA
2Z4S	;	3.0	;	Crystal structure of domain III from the Thermotoga maritima replication initiation protein DnaA
3B31	;	2.4	;	Crystal structure of domain III of the Cricket Paralysis Virus IRES RNA
3LNO	;	2.1	;	Crystal Structure of Domain of Unknown Function DUF59 from Bacillus anthracis
8GDW	;	2.35	;	Crystal structure of Domain Related to Iron (DRI) from cyanobacteria
8GF4	;	3.0	;	Crystal structure of Domain Related to Iron (DRI) in complex with heme
5QU3	;	1.02	;	Crystal Structure of domain swapped human Nck SH3.1, 1.01A, monoclinic
1MI7	;	2.5	;	Crystal Structure of Domain Swapped trp Aporepressor in 30%(v/v) Isopropanol
6ST6	;	2.05	;	Crystal Structure of Domain Swapped Trp Repressor V58I Variant
6ST7	;	2.45	;	Crystal Structure of Domain Swapped Trp Repressor V58I Variant with bound L-trp
7OS9	;	2.45	;	Crystal Structure of Domain Swapped Trp Repressor V58I Variant with purification tag
3TBD	;	1.8	;	Crystal Structure of domain VI and LE1 of human Netrin-G2
5E4R	;	1.94	;	Crystal structure of domain-duplicated synthetic class II ketol-acid reductoisomerase 2Ia_KARI-DD
6FNZ	;	2.23	;	Crystal Structure of domain-swapped C-terminal domain of human doublecortin
5ZYO	;	1.75	;	Crystal Structure of domain-swapped Circular-Permuted YbeA (CP74) from Escherichia coli
7DNS	;	2.327	;	Crystal structure of domain-swapped dimer of H5_Fold-0 Elsa; de novo designed protein with an asymmetric all-alpha topology
3UX2	;	1.8	;	Crystal Structure of Domain-Swapped Fam96a Major dimer
3UX3	;	1.8	;	Crystal Structure of Domain-Swapped Fam96a minor dimer
3DAK	;	2.25	;	Crystal Structure of Domain-Swapped OSR1 kinase domain
4DG6	;	2.9	;	Crystal structure of domains 1 and 2 of LRP6
1CID	;	2.8	;	CRYSTAL STRUCTURE OF DOMAINS 3 & 4 OF RAT CD4 AND THEIR RELATIONSHIP TO THE NH2-TERMINAL DOMAINS
6YHN	;	1.8	;	Crystal structure of domains 4-5 of CNFy from Yersinia pseudotuberculosis
2NZI	;	2.9	;	Crystal structure of domains A168-A170 from titin
5CS0	;	2.5	;	Crystal structure of domains AC1-AC2 of yeast acetyl-CoA carboxylase
5CS4	;	3.19	;	Crystal structure of domains AC3-AC5 of yeast acetyl-CoA carboxylase
5CSA	;	3.0	;	Crystal structure of domains BT-BCCP-AC1-AC5 of yeast acetyl-CoA carboxylase
5E7H	;	1.57	;	Crystal structure of domains CD (residues 230-489) of Bacova_02650
4HSQ	;	1.87	;	Crystal Structure of Domains D2 and D3 of the Major Pilin SpaD from Corynebacterium diphtheriae
1JS6	;	2.6	;	Crystal Structure of DOPA decarboxylase
1JS3	;	2.25	;	Crystal structure of dopa decarboxylase in complex with the inhibitor carbidopa
7JOZ	;	3.8	;	Crystal structure of dopamine D1 receptor in complex with G protein and a non-catechol agonist
3TE4	;	1.46	;	Crystal structure of dopamine N Acetyltransferase in complex with acetyl-COA from Drosophila Melanogaster
6IQL	;	3.5	;	Crystal structure of dopamine receptor D4 bound to the subtype-selective ligand, L745870
6IN3	;	2.3	;	Crystal structure of DOT1L in complex with 18-Crown-6
3UWP	;	2.05	;	Crystal structure of Dot1l in complex with 5-iodotubercidin
3SX0	;	2.28	;	Crystal structure of Dot1l in complex with a brominated SAH analog
5MVS	;	2.18	;	Crystal structure of Dot1L in complex with adenosine and inhibitor CPD1 [N6-(2,6-dichlorophenyl)-N6-(pent-2-yn-1-yl)quinoline-4,6-diamine]
6TEL	;	2.19	;	Crystal structure of Dot1L in complex with an inhibitor (compound 10).
6TEN	;	2.21	;	Crystal structure of Dot1L in complex with an inhibitor (compound 11).
6TE6	;	1.98	;	Crystal structure of Dot1L in complex with an inhibitor (compound 3).
4HRA	;	3.15	;	Crystal Structure of DOT1L in Complex with EPZ-5676
4EK9	;	2.5	;	Crystal structure of DOT1L in complex with EPZ000004
4EKG	;	2.8	;	Crystal Structure of DOT1L in Complex with EPZ003696
4EKI	;	2.85	;	Crystal Structure of DOT1L in complex with EPZ004777
5DTM	;	2.2	;	Crystal structure of Dot1L in complex with inhibitor CPD1 [4-(2,6-dichlorobenzoyl)-N-methyl-1H-pyrrole-2-carboxamide]
5MW3	;	2.09	;	Crystal structure of Dot1L in complex with inhibitor CPD1 [N6-(2,6-dichlorophenyl)-N6-(pent-2-yn-1-yl)quinoline-4,6-diamine] and inhibitor CPD2 [(R)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-amine]
5DSX	;	2.41	;	Crystal structure of Dot1L in complex with inhibitor CPD10 [6'-chloro-1,4-dimethyl-5'-(2-methyl-6-((4-(methylamino)pyrimidin-2-yl)amino)-1H-indol-1-yl)-[3,3'-bipyridin]-2(1H)-one]
5DT2	;	2.3	;	Crystal structure of Dot1L in complex with inhibitor CPD11 [N4-methyl-N2-(2-methyl-1-(2-phenoxyphenyl)-1H-indol-6-yl)pyrimidine-2,4-diamine]
5DRT	;	2.69	;	Crystal structure of Dot1L in complex with inhibitor CPD2 [2-(2-(5-((2-chlorophenoxy)methyl)-1H-tetrazol-1-yl)acetyl)-N-(4-chlorophenyl)hydrazinecarboxamide]
5DTQ	;	2.61	;	Crystal structure of Dot1L in complex with inhibitor CPD3 [(2,6-dichlorophenyl)(quinolin-6-yl)methanone]
5DRY	;	2.41	;	Crystal structure of Dot1L in complex with inhibitor CPD3 [N-(1-(2-chlorophenyl)-1H-indol-6-yl)-2-(2-(5-(2-chlorophenyl)-1H-tetrazol-1-yl)acetyl)hydrazinecarboxamide]
5DTR	;	2.34	;	Crystal structure of Dot1L in complex with inhibitor CPD5 [N-(2,6-dichlorophenyl)-4-methoxy-N-methylquinolin-6-amine]
5MW4	;	2.19	;	Crystal structure of Dot1L in complex with inhibitor CPD7 [N-(3-(((R)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-yl)(methyl)amino)propyl)-2-(3-(2-chloro-3-(2-methylpyridin-3-yl)benzo[b]thiophen-5-yl)ureido)acetamide]
3ADY	;	2.0	;	Crystal structure of DotD from Legionella
6EXD	;	2.14	;	Crystal structure of DotM cytoplasmic domain (residues 153-380) SeMet derivative
6EXA	;	1.79	;	Crystal structure of DotM cytoplasmic domain (residues 153-380), double mutant R196E/R197E
6EXB	;	1.84	;	Crystal structure of DotM cytoplasmic domain (residues 153-380), native form
6EXE	;	2.0	;	Crystal structure of DotM cytoplasmic domain (residues 153-380),R217E
6EXC	;	2.16	;	Crystal structure of DotM cytoplasmic domain (residues 153-380),R314E/R315E
4KGO	;	3.194	;	Crystal Structure of double Leucine to Methionine mutant human splunc1 lacking the secretion signal sequence
4P0K	;	1.7	;	Crystal Structure of Double Loop-Swapped Interleukin-36Ra
4P0L	;	1.55	;	Crystal Structure of Double Loop-Swapped Interleukin-36Ra With Additional Point Mutations
5JJC	;	2.01	;	Crystal Structure of double mutant (Q96A-Y125A) O-Acetyl Serine Sulfhydralase from Brucella abortus
4TTA	;	2.0	;	Crystal structure of double mutant E. Coli purine nucleoside phosphorylase with 2 FMC molecules
4TTI	;	1.89	;	Crystal structure of double mutant E. Coli purine nucleoside phosphorylase with 4 FMC molecules
4TTJ	;	1.874	;	Crystal structure of double mutant E. Coli purine nucleoside phosphorylase with 6 FMC molecules
6O69	;	2.081	;	Crystal Structure of Double Mutant L380R/F535K of Human Acetylcholinesterase
1KEB	;	1.8	;	Crystal Structure of Double Mutant M37L,P40S E.coli Thioredoxin
5DSU	;	1.93	;	Crystal structure of double mutant of N-domain of human calmodulin
3CZO	;	2.2	;	Crystal Structure of Double Mutant Phenylalanine Ammonia-Lyase From Anabaena Variabilis
5F7Z	;	1.8	;	Crystal structure of Double Mutant S12T and N87T of Adenosine/Methylthioadenosine Phosphorylase from Schistosoma mansoni in APO Form
5FAK	;	1.87	;	Crystal structure of Double Mutant S12T and N87T of Adenosine/Methylthioadenosine Phosphorylase from Schistosoma mansoni in complex with Adenine
4IFT	;	1.995	;	Crystal structure of double mutant thermostable NPPase from Geobacillus stearothermophilus
4YU9	;	2.1	;	Crystal Structure of double mutant Y115E Y117E human Glutaminyl Cyclase
4YWY	;	1.95	;	Crystal Structure of double mutant Y115E Y117E human Glutaminyl Cyclase in complex with inhibitor PBD-150
7CP0	;	1.7	;	Crystal Structure of double mutant Y115E Y117E human Secretory Glutaminyl Cyclase
7D8E	;	2.0	;	Crystal Structure of double mutant Y115E Y117E human Secretory Glutaminyl Cyclase in complex with LSB-09
7COZ	;	1.85	;	Crystal Structure of double mutant Y115E Y117E human Secretory Glutaminyl Cyclase in complex with LSB-41
1TDW	;	2.1	;	Crystal structure of double truncated human phenylalanine hydroxylase BH4-responsive PKU mutant A313T.
1DMW	;	2.0	;	CRYSTAL STRUCTURE OF DOUBLE TRUNCATED HUMAN PHENYLALANINE HYDROXYLASE WITH BOUND 7,8-DIHYDRO-L-BIOPTERIN
5D6W	;	1.992	;	Crystal structure of double tudor domain of human lysine demethylase KDM4A
5D6X	;	2.153	;	Crystal structure of double tudor domain of human lysine demethylase KDM4A
5D6Y	;	2.287	;	Crystal structure of double tudor domain of human lysine demethylase KDM4A complexed with histone H3K23me3
4RF6	;	1.95	;	Crystal structure of double-domain arginine kinase from Anthopleura japonicas
4RF8	;	2.17	;	Crystal structure of double-domain arginine kinase from Anthopleura japonicas in complex with ADP
4RF9	;	2.35	;	Crystal structure of double-domain arginine kinase from Anthopleura japonicas in complex with L-arginine and ATPgS
4RF7	;	2.1	;	Crystal structure of double-domain arginine kinase from Anthopleura japonicas in complex with substrate L-arginine
4KQ0	;	2.1	;	Crystal structure of double-helical CGG-repetitive RNA 19mer complexed with RSS p19
4KTG	;	1.92	;	Crystal structure of double-helical GGC-repetitive RNA 19mer complexed with RSS p19
6ZQS	;	1.95	;	Crystal structure of double-phosphorylated p38alpha with ATF2(83-102)
6DY5	;	1.26	;	Crystal structure of double-stranded DNA AGGGATCCCT in complex with Zn2+
8E5E	;	2.62	;	Crystal structure of double-stranded DNA deaminase toxin DddA in complex with DNA with the target cytosine flipped into the active site
8E5D	;	2.39	;	Crystal structure of double-stranded DNA deaminase toxin DddA in complex with DNA with the target cytosine parked in the major groove
6DWT	;	1.6	;	Crystal structure of double-stranded DNA GAGGCCTC, crystals grown in Mg2+
6DXJ	;	1.65	;	Crystal structure of double-stranded DNA GAGGCCTC; crystals grown in Zn2+
6DY9	;	2.3	;	Crystal structure of double-stranded DNA GGGATCCC; crystals grown in Zn2+
4PCO	;	1.32	;	Crystal structure of double-stranded RNA with four terminal GU wobble base pairs
8CI4	;	2.01	;	Crystal structure of doubly S-methanethiolated rabbit M-type creatine kinase
5LTC	;	2.101	;	Crystal structure of doubly spin labelled VcSiaP R125
3DMK	;	4.19	;	Crystal structure of Down Syndrome Cell Adhesion Molecule (DSCAM) isoform 1.30.30, N-terminal eight Ig domains
4ZQF	;	2.2	;	Crystal structure of DOX-P Reductoisomerase fosmidomycin and magnesium
4ZQE	;	1.98	;	Crystal structure of DOX-P Reductoisomerase in complex with magnesium
4ZQH	;	2.4	;	Crystal structure of DOX-P Reductoisomerase in complex with NADPH, fosmidomycin and magnesium
7CK9	;	1.602	;	Crystal structure of Doxorubicin loaded human ferritin heavy chain
8IKR	;	2.9	;	Crystal structure of DpaA
6LSB	;	2.0	;	Crystal Structure of DPF domain of MOZ in complex with H3K14bz peptide
5B79	;	2.601	;	Crystal structure of DPF2 double PHD finger
4YLH	;	2.58	;	Crystal structure of DpgC with bound substrate analog and Xe on oxygen diffusion pathway
3LZC	;	2.261	;	Crystal structure of Dph2 from Pyrococcus horikoshii
3LZD	;	2.1	;	Crystal structure of Dph2 from Pyrococcus horikoshii with 4Fe-4S cluster
6K34	;	2.5	;	Crystal Structure of DphMB1
6VKP	;	2.54	;	Crystal structure of DPO4 extension past 8-oxoadenine (oxoA) and dG
6VNP	;	2.42	;	Crystal structure of DPO4 extension past 8-oxoadenine (oxoA) and dT
3M9M	;	2.9	;	Crystal Structure of Dpo4 in complex with DNA containing the major cisplatin lesion
3M9N	;	1.93	;	Crystal Structure of Dpo4 in complex with DNA containing the major cisplatin lesion
3M9O	;	2.0	;	Crystal Structure of Dpo4 in complex with DNA containing the major cisplatin lesion
4G3I	;	2.5	;	Crystal structure of Dpo4 in complex with DNA duplex
4GC6	;	2.895	;	Crystal structure of Dpo4 in complex with N-MC-dAMP opposite dT
4GC7	;	2.89	;	Crystal structure of Dpo4 in complex with S-MC-dADP opposite dT
4QWB	;	1.8	;	CRYSTAL STRUCTURE of DPO4 LINKER REGION P236A MUTANT WITH AN INCOMING D-dCDP
6VG6	;	3.08	;	Crystal structure of DPO4 with 8-oxoadenine (oxoA) and dGTP*
6VGM	;	2.84	;	Crystal structure of DPO4 with 8-oxoadenine (oxoA) and dTTP*
2OGZ	;	2.1	;	Crystal structure of DPP-IV complexed with Lilly aryl ketone inhibitor
4DSA	;	3.25	;	Crystal Structure of DPP-IV with Compound C1
4DSZ	;	3.2	;	Crystal Structure of DPP-IV with Compound C2
4J3J	;	3.2	;	Crystal Structure of DPP-IV with Compound C3
4DTC	;	3.0	;	Crystal Structure of DPP-IV with Compound C5
6TRX	;	3.2	;	Crystal structure of DPP8 in complex with 1G244
7A3G	;	2.8	;	Crystal structure of DPP8 in complex with a 4-oxo-b-lactam based inhibitor, 91
7A3L	;	2.8	;	Crystal structure of DPP8 in complex with a 4-oxo-b-lactam based inhibitor, A241
7A3J	;	3.0	;	Crystal structure of DPP8 in complex with a 4-oxo-b-lactam based inhibitor, A272
7AYQ	;	2.45	;	Crystal structure of DPP8 in complex with a 4-oxo-b-lactam based inhibitor, B114
7AYR	;	2.69	;	Crystal structure of DPP8 in complex with a 4-oxo-b-lactam based inhibitor, B115
7OR4	;	2.44	;	Crystal structure of DPP8 in complex with a 4-oxo-b-lactam based inhibitor, B142
7OZ7	;	2.6	;	Crystal structure of DPP8 in complex with a 4-oxo-b-lactam based inhibitor, L84
7A3I	;	2.8	;	Crystal structure of DPP8 in complex with a 4-oxo-b-lactam based inhibitor, LMC375
7A3K	;	2.65	;	Crystal structure of DPP8 in complex with a b-lactam based inhibitor, A296.1
6TRW	;	3.0	;	Crystal structure of DPP8 in complex with the EIL peptide (SLRFLFEGQRIADNH)
6HP8	;	2.5	;	Crystal structure of DPP8 in complex with Val-BoroPro
7ZXS	;	1.81	;	Crystal structure of DPP9 in complex with a 4-oxo-b-lactam based inhibitor, A295
6NRW	;	2.4	;	Crystal structure of Dpr1 IG1 bound to DIP-eta IG1
6NRQ	;	1.8	;	Crystal structure of Dpr10 IG1 bound to DIP-alpha IG1
6NRR	;	2.5	;	Crystal structure of Dpr11 IG1 bound to DIP-gamma IG+IG2
6EG1	;	2.95	;	Crystal structure of Dpr2 Ig1-Ig2 in complex with DIP-Theta Ig1-Ig3
6EG0	;	2.9	;	Crystal structure of Dpr4 Ig1-Ig2 in complex with DIP-Eta Ig1-Ig3
2D5K	;	1.85	;	Crystal structure of Dps from Staphylococcus aureus
3IQ1	;	1.67	;	Crystal structure of DPS protein from Vibrio cholerae O1, a member of a broad superfamily of ferritin-like diiron-carboxylate proteins
1UMN	;	1.95	;	Crystal structure of Dps-like peroxide resistance protein (Dpr) from Streptococcus suis
6LKP	;	2.9	;	Crystal structure of Dps1 from the thermophilic non-heterocystous filamentous cyanobacterium Thermoleptolyngbya sp. O-77
4RIQ	;	2.231	;	Crystal structure of DPY-30 dimerization/docking domain in complex with Ash2L Sdc1-DPY-30 Interacting region (SDI)
4RT4	;	1.997	;	Crystal structure of Dpy30 complexed with Bre2
6DIG	;	2.0	;	Crystal structure of DQA1*01:02/DQB1*06:02 in complex with a hypocretin peptide
2O5F	;	1.9	;	Crystal Structure of DR0079 from Deinococcus radiodurans at 1.9 Angstrom Resolution
6CQJ	;	2.75	;	Crystal structure of DR1 presenting the RQ13 peptide
6CPL	;	2.45	;	Crystal structure of DR11 presenting the gag293 epitope
6CPN	;	2.0	;	Crystal structure of DR11 presenting the RQ13 peptide
6CPO	;	2.4	;	Crystal structure of DR15 presenting the RQ13 peptide
5HVA	;	2.1	;	Crystal structure of DR2231 in complex with dUMPNPP and magnesium.
2YF4	;	1.7	;	Crystal structure of DR2231, the MazG-like protein from Deinococcus radiodurans, Apo structure
2YF3	;	2.0	;	Crystal structure of DR2231, the MazG-like protein from Deinococcus radiodurans, complex with manganese
5HX1	;	1.799	;	Crystal structure of DR2231_E46A mutant in complex with dUMP and magnesium
5HWU	;	2.1	;	Crystal Structure of DR2231_E46A mutant in complex with dUMPNPP and Manganese
5I0J	;	1.8	;	Crystal structure of DR2231_E47A mutant in complex with dUMP
5HZZ	;	1.801	;	Crystal structure of DR2231_E47A mutant in complex with dUMP and manganese
5HYL	;	1.8	;	Crystal structure of DR2231_E47A mutant in complex with dUMPNPP and magnesium
5I0M	;	2.15	;	Crystal structure of DR2231_E79A mutant in complex with dUMP
3P1X	;	1.9	;	Crystal structure of DRBM 2 domain of Interleukin enhancer-binding factor 3 from Homo sapiens, Northeast Structural Genomics Consortium Target HR4527E
4D2K	;	2.302	;	Crystal structure of DREP2 CIDE domain
5XPC	;	1.902	;	Crystal Structure of Drep4 CIDE domain
3SIR	;	2.68	;	Crystal Structure of drICE
3SIP	;	3.496	;	Crystal structure of drICE and dIAP1-BIR1 complex
5HZS	;	2.17	;	Crystal structure of Dronpa-Co2+
5HZT	;	2.84	;	Crystal structure of Dronpa-Cu2+
5HZU	;	1.89	;	Crystal structure of Dronpa-Ni2+
3MJ0	;	2.306	;	Crystal Structure of Drosophia Ago-PAZ domain in complex with 3'-end 2'-O-methylated RNA
3K40	;	1.75	;	Crystal structure of Drosophila 3,4-dihydroxyphenylalanine decarboxylase
6JRL	;	2.2	;	Crystal structure of Drosophila alpha methyldopa-resistant protein/3,4-dihydroxyphenylacetaldehyde synthase
1J36	;	2.4	;	Crystal Structure of Drosophila AnCE
1J37	;	2.4	;	Crystal Structure of Drosophila AnCE
1J38	;	2.6	;	Crystal Structure of Drosophila AnCE
3LW6	;	1.81	;	Crystal Structure of Drosophila beta1,4-galactosyltransferase-7
6XWS	;	4.36	;	Crystal Structure of Drosophila CAL1 1-160 bound to CENP-A/H4
4K03	;	3.2	;	Crystal structure of Drosophila Cryprochrome
4ZBM	;	1.9	;	Crystal structure of Drosophila cyclic nucleotide gated channel pore mimicking NaK mutant
1J90	;	2.56	;	Crystal Structure of Drosophila Deoxyribonucleoside Kinase
1OE0	;	2.4	;	CRYSTAL STRUCTURE OF DROSOPHILA DEOXYRIBONUCLEOSIDE KINASE IN COMPLEX WITH DTTP
1OT3	;	2.5	;	Crystal structure of Drosophila deoxyribonucleotide kinase complexed with the substrate deoxythymidine
5N96	;	2.716	;	Crystal Structure of Drosophila DHX36 helicase in complex with AGGGTTTTTT
5N8Z	;	3.477	;	Crystal Structure of Drosophila DHX36 helicase in complex with CTCTCCCTT
5N8U	;	2.62	;	Crystal Structure of Drosophila DHX36 helicase in complex with CTCTCCT
5N9D	;	2.71	;	Crystal Structure of Drosophila DHX36 helicase in complex with GGGTTAGGGT
5N9A	;	3.036	;	Crystal Structure of Drosophila DHX36 helicase in complex with GTTAGGGTT
5N8S	;	2.88	;	Crystal Structure of Drosophila DHX36 helicase in complex with polyT
5N94	;	2.428	;	Crystal Structure of Drosophila DHX36 helicase in complex with polyU
5N9F	;	2.969	;	Crystal Structure of Drosophila DHX36 helicase in complex with ssDNA CpG_A
5N98	;	2.756	;	Crystal Structure of Drosophila DHX36 helicase in complex with TAGGGTTTT
5N9E	;	3.007	;	Crystal Structure of Drosophila DHX36 helicase in complex with TGGGGATTT
5N90	;	3.069	;	Crystal Structure of Drosophila DHX36 helicase in complex with TTGTGGTGT
5WRO	;	2.015	;	Crystal structure of Drosophila enolase
4BY4	;	2.3	;	Crystal structure of Drosophila Frq2
4BY5	;	2.22	;	Crystal structure of Drosophila Frq2
2XXL	;	1.8	;	Crystal structure of drosophila Grass clip serine protease of Toll pathway
3RIU	;	3.4	;	Crystal structure of Drosophila hexameric C3PO formed by truncated Translin and Trax
1MG5	;	1.63	;	Crystal structure of Drosophila melanogaster alcohol dehydrogenase complexed with NADH and acetate at 1.6 A
8OR6	;	2.5	;	Crystal structure of Drosophila melanogaster alpha-amylase
8ORP	;	2.0	;	Crystal structure of Drosophila melanogaster alpha-amylase in complex with the inhibitor acarbose
6XWV	;	2.27	;	Crystal structure of drosophila melanogaster CENP-C bound to CAL1
6XWU	;	1.82	;	Crystal structure of drosophila melanogaster CENP-C cumin domain
4E08	;	2.0	;	Crystal structure of Drosophila melanogaster DJ-1beta
5GI5	;	1.45	;	Crystal Structure of Drosophila melanogaster Dopamine N-Acetyltransferase Bound to CoA
5GI6	;	1.65	;	Crystal Structure of Drosophila melanogaster Dopamine N-Acetyltransferase Bound to CoA and Phenylethylamine
6K80	;	1.28	;	Crystal Structure of Drosophila melanogaster Dopamine N-Acetyltransferase in Complex with CoA and Tryptophol
5GI8	;	1.3	;	Crystal Structure of Drosophila melanogaster Dopamine N-Acetyltransferase in Ternary Complex with CoA and Acetyl-dopamine
5GI7	;	1.201	;	Crystal Structure of Drosophila melanogaster Dopamine N-Acetyltransferase in Ternary Complex with CoA and Acetyl-phenylethylamine
5GI9	;	1.4	;	Crystal Structure of Drosophila melanogaster Dopamine N-Acetyltransferase in Ternary Complex with CoA and Acetyl-Tryptamine
5GIF	;	1.3	;	Crystal Structure of Drosophila melanogaster E47D Dopamine N-Acetyltransferase in Binary Complex with Acetyl-CoA
5GIG	;	1.3	;	Crystal Structure of Drosophila melanogaster E47D Dopamine N-Acetyltransferase in Ternary Complex with CoA and Acetyl-dopamine
5GIH	;	1.392	;	Crystal Structure of Drosophila melanogaster E47D Dopamine N-Acetyltransferase in Ternary Complex with CoA and Acetyl-phenylethylamine
5GII	;	1.294	;	Crystal Structure of Drosophila melanogaster E47N Dopamine N-Acetyltransferase in Ternary Complex with CoA and Acetyl-phenylethylamine
6T2T	;	1.3	;	Crystal structure of Drosophila melanogaster glutathione S-transferase epsilon 14 in complex with glutathione and 2-methyl-2,4-pentanediol
2Y5W	;	2.7	;	Crystal structure of Drosophila melanogaster kinesin-1 motor domain dimer
2Y65	;	2.2	;	Crystal structure of Drosophila melanogaster kinesin-1 motor domain dimer-tail complex
6KEP	;	1.55	;	Crystal structure of Drosophila melanogaster Noppera-bo, glutathione S-transferase epsilon 14 (DmGSTE14), in 17beta-estradiol- and glutathione-bound form
6KEO	;	1.7	;	Crystal structure of Drosophila melanogaster Noppera-bo, glutathione S-transferase epsilon 14 (DmGSTE14), in 17beta-estradiol-bound form
6KEL	;	1.4	;	Crystal structure of Drosophila melanogaster Noppera-bo, glutathione S-transferase epsilon 14 (DmGSTE14), in apo-form
6KEM	;	1.5	;	Crystal structure of Drosophila melanogaster Noppera-bo, glutathione S-transferase epsilon 14 (DmGSTE14), in apo-form 2
7DB1	;	1.83	;	Crystal structure of Drosophila melanogaster Noppera-bo, glutathione S-transferase epsilon 14 (DmGSTE14), in dimedone- and glutathione-bound form
7DB0	;	1.66	;	Crystal structure of Drosophila melanogaster Noppera-bo, glutathione S-transferase epsilon 14 (DmGSTE14), in dimedone-bound form
6KEN	;	1.75	;	Crystal structure of Drosophila melanogaster Noppera-bo, glutathione S-transferase epsilon 14 (DmGSTE14), in glutathione-bound form
7DB2	;	1.4	;	Crystal structure of Drosophila melanogaster Noppera-bo, glutathione S-transferase epsilon 14 (DmGSTE14), in GS-dimedone-bound form
7DB3	;	1.7	;	Crystal structure of Drosophila melanogaster Noppera-bo, glutathione S-transferase epsilon 14 (DmGSTE14), in TDP011-bound form
7DB4	;	1.54	;	Crystal structure of Drosophila melanogaster Noppera-bo, glutathione S-transferase epsilon 14 (DmGSTE14), in TDP012- and glutathione-bound form
7DAY	;	1.48	;	Crystal structure of Drosophila melanogaster Noppera-bo, glutathione S-transferase epsilon 14 (DmGSTE14), in TDP013-, and GSH-bound form
7DAX	;	1.70001	;	Crystal structure of Drosophila melanogaster Noppera-bo, glutathione S-transferase epsilon 14 (DmGSTE14), in TDP013-bound form
7DAZ	;	1.64	;	Crystal structure of Drosophila melanogaster Noppera-bo, glutathione S-transferase epsilon 14 (DmGSTE14), in TDP015- and GSH-bound form
5YGC	;	2.0	;	Crystal structure of Drosophila melanogaster Papi extended Tudor domain
5YGF	;	1.698	;	Crystal structure of Drosophila melanogaster Papi extended Tudor domain (D287A) in complex with Piwi N-terminal R10-unme peptide
5YGD	;	1.551	;	Crystal structure of Drosophila melanogaster Papi extended Tudor domain (D287A) in complex with Piwi N-terminal R10me2s peptide
5YGB	;	1.4	;	Crystal structure of drosophila melanogaster Papi extended Tudor domain mutant - D287A
8CT8	;	2.5	;	Crystal structure of Drosophila melanogaster PRL/CBS-pair domain complex
3K44	;	2.1	;	Crystal Structure of Drosophila melanogaster Pur-alpha
5XYV	;	2.1	;	Crystal structure of drosophila melanogaster Rhino chromoshadow domain in complex with Deadlock N-terminal domain
5WOU	;	1.55	;	Crystal Structure of drosophila melanogaster Scribble PDZ1 domain in complex with Guk-Holder
6F4I	;	1.49	;	Crystal structure of Drosophila melanogaster SNF
6F4J	;	1.42	;	Crystal structure of Drosophila melanogaster SNF/U2A' complex
2QRX	;	3.6	;	Crystal structure of Drosophila melanogaster Translin protein
2QVA	;	3.4	;	Crystal structure of Drosophila melanogaster Translin protein
4HKA	;	2.7	;	Crystal structure of Drosophila melanogaster tryptophan 2,3-dioxygenase in complex with HEME
4C0K	;	2.801	;	Crystal structure of Drosophila Miro EF hand and cGTPase domains bound to one calcium ion (Ca-MiroS)
4C0L	;	3.0	;	Crystal structure of Drosophila Miro EF hand and cGTPase domains bound to one magnesium ion and Mg:GDP (MgGDP-MiroS)
4C0J	;	2.82	;	Crystal structure of Drosophila Miro EF hand and cGTPase domains in the apo state (Apo-MiroS)
3UBF	;	2.5	;	Crystal structure of Drosophila N-cadherin EC1-3, I
3UBG	;	2.502	;	Crystal structure of Drosophila N-cadherin EC1-3, II
3UBH	;	2.7	;	Crystal structure of Drosophila N-cadherin EC1-4
5G08	;	1.52	;	Crystal structure of Drosophila NCS-1 bound to chlorpromazine
5FYX	;	1.8	;	Crystal structure of Drosophila NCS-1 bound to penothiazine FD16
5AAN	;	1.6	;	Crystal structure of Drosophila NCS-1 bound to penothiazine FD44
6FF3	;	2.57	;	Crystal structure of Drosophila neural ectodermal development factor Imp-L1 with Human IGF-I
6FEY	;	3.48	;	Crystal structure of Drosophila neural ectodermal development factor Imp-L2 with Drosophila DILP5 insulin
7JW6	;	1.5	;	Crystal structure of Drosophila Nibbler EXO domain
5YI7	;	1.7	;	Crystal structure of drosophila Numb PTB domain and Pon peptide complex
5YI8	;	2.001	;	Crystal structure of drosophila Numb PTB domain and Pon peptide complex
6IHJ	;	2.7	;	Crystal structure of Drosophila Nxf1 NTF2 domain in complex with Nxt1/p15
7MKK	;	2.5	;	Crystal structure of Drosophila Panoramix in complex with Sov NTD
2RKQ	;	1.5	;	Crystal structure of drosophila peptidoglycan recognition protein SD (PGRP-SD)
6KR6	;	2.9	;	Crystal structure of Drosophila Piwi
5F84	;	2.5	;	Crystal structure of Drosophila Poglut1 (Rumi) complexed with its glycoprotein product (glucosylated EGF repeat) and UDP
5F86	;	1.9	;	Crystal structure of Drosophila Poglut1 (Rumi) complexed with its substrate protein (EGF repeat)
5F85	;	2.15	;	Crystal structure of Drosophila Poglut1 (Rumi) complexed with its substrate protein (EGF repeat) and UDP
5F87	;	3.2	;	Crystal structure of Drosophila Poglut1 (Rumi) complexed with UDP
3ZPV	;	2.68	;	Crystal structure of Drosophila Pygo PHD finger in complex with Legless HD1 domain
5XYW	;	2.705	;	Crystal structure of drosophila simulans Rhino chromoshadow domain in complex with N-terminal domain
4XHV	;	1.23	;	Crystal structure of Drosophila Spinophilin-PDZ and a C-terminal peptide of Neurexin
4KMA	;	2.68	;	Crystal structure of Drosophila Suppressor of Fused
3DGH	;	1.745	;	Crystal Structure of Drosophila Thioredoxin Reductase, C-terminal 8-residue truncation
3DH9	;	2.25	;	Crystal Structure of Drosophila Thioredoxin Reductase, wild-type
4KRR	;	2.124	;	Crystal structure of Drosophila WntD N-terminal domain-linker (residues 31-240)
5N8R	;	2.2	;	Crystal Structure of Drosophilia DHX36 helicase in complex with GAGCACTGC
2DG0	;	2.4	;	Crystal structure of Drp35, a 35kDa drug responsive protein from Staphylococcus aureus
2DG1	;	1.72	;	Crystal structure of Drp35, a 35kDa drug responsive protein from Staphylococcus aureus, complexed with Ca2+
2QI8	;	2.32	;	Crystal structure of drug resistant SRC kinase domain
2QQ7	;	2.38	;	Crystal structure of drug resistant SRC kinase domain with irreversible inhibitor
4QLH	;	2.45	;	Crystal structure of drug resistant V82S/V1082S HIV-1 Protease
6KKL	;	2.654	;	Crystal structure of Drug:Proton Antiporter-1 (DHA1) Family SotB, in the inward conformation (H115N mutant)
6KKJ	;	3.385	;	Crystal structure of Drug:Proton Antiporter-1 (DHA1) Family SotB, in the inward open conformation
6KKK	;	3.5	;	Crystal structure of Drug:Proton Antiporter-1 (DHA1) Family SotB, in the inward open conformation (H115A mutant)
6KKI	;	3.064	;	Crystal structure of Drug:Proton Antiporter-1 (DHA1) Family SotB, in the inward-occluded conformation
3C4N	;	2.4	;	Crystal structure of DR_0571 protein from Deinococcus radiodurans in complex with ADP. Northeast Structural Genomics Consortium Target DrR125
4H5B	;	2.0	;	Crystal Structure of DR_1245 from Deinococcus radiodurans
3GGN	;	2.0	;	Crystal structure of DR_A0006 from Deinococcus radiodurans. Northeast Structural Genomics Consortium Target DrR147D
4JR6	;	1.902	;	Crystal structure of DsbA from Mycobacterium tuberculosis (reduced)
4PWO	;	1.52	;	Crystal structure of DsbA from the Gram positive bacterium Corynebacterium diphtheriae
4PWP	;	1.803	;	Crystal structure of DsbA from the Gram positive bacterium Corynebacterium diphtheriae
2HI7	;	3.7	;	Crystal structure of DsbA-DsbB-ubiquinone complex
7DKA	;	1.56	;	Crystal structure of DsbA-like protein DR2335 from Deinococcus radiodurans R1, C24S mutant protein
7DK9	;	1.72	;	Crystal structure of DsbA-like protein DR2335 from Deinococcus radiodurans R1, native protein
3FEU	;	1.758	;	Crystal Structure of DsbA-like thioredoxin domain VF_A0457 from Vibrio fischeri
2ZUQ	;	3.3	;	Crystal structure of DsbB-Fab complex
4ILF	;	1.999	;	Crystal structure of DsbC R125A from Salmonella enterica serovar Typhimurium
1JPE	;	1.9	;	Crystal structure of DsbD-alpha; the N-terminal domain of DsbD
1UC7	;	1.9	;	Crystal structure of DsbDgamma
2H0H	;	1.8	;	Crystal Structure of DsbG K113E mutant
2H0G	;	2.3	;	Crystal Structure of DsbG T200M mutant
2H0I	;	2.4	;	Crystal Structure of DsbG V216M mutant
4WVR	;	1.948	;	Crystal structure of Dscam1 Ig7 domain, isoform 5
4X5L	;	2.374	;	Crystal structure of Dscam1 Ig7 domain, isoform 9
4X8X	;	2.5	;	Crystal structure of Dscam1 isoform 1.9, N-terminal four Ig domains
4XB7	;	4.004	;	Crystal structure of Dscam1 isoform 4.4, N-terminal four Ig domains
4X9B	;	2.2	;	Crystal structure of Dscam1 isoform 4.44, N-terminal four Ig domains
4X9G	;	3.403	;	Crystal structure of Dscam1 isoform 6.44, N-terminal four Ig domains
4X9F	;	2.35	;	Crystal structure of Dscam1 isoform 6.9, N-terminal four Ig domains
4X83	;	1.902	;	Crystal structure of Dscam1 isoform 7.44, N-terminal four Ig domains
4X9H	;	2.95	;	Crystal structure of Dscam1 isoform 8.4, N-terminal four Ig domains
4X9I	;	2.904	;	Crystal structure of Dscam1 isoform 9.44, N-terminal four Ig domains
4XB8	;	3.202	;	Crystal structure of Dscam1 isoform 9.44, N-terminal four Ig domains (with zinc)
1I8K	;	1.8	;	CRYSTAL STRUCTURE OF DSFV MR1 IN COMPLEX WITH THE PEPTIDE ANTIGEN OF THE MUTANT EPIDERMAL GROWTH FACTOR RECEPTOR, EGFRVIII, AT LIQUID NITROGEN TEMPERATURE
1I8I	;	2.4	;	CRYSTAL STRUCTURE OF DSFV MR1 IN COMPLEX WITH THE PEPTIDE ANTIGEN OF THE MUTANT EPIDERMAL GROWTH FACTOR RECEPTOR, EGFRVIII, AT ROOM TEMPERATURE
3MC3	;	1.49	;	Crystal structure of DsrE/DsrF-like family protein (NP_342589.1) from SULFOLOBUS SOLFATARICUS at 1.49 A resolution
1G7K	;	2.0	;	CRYSTAL STRUCTURE OF DSRED, A RED FLUORESCENT PROTEIN FROM DISCOSOMA SP. RED
8WGP	;	2.9	;	Crystal structure of DsRed-Monomer
2HY5	;	1.72	;	Crystal structure of DsrEFH
6F3H	;	2.703	;	Crystal structure of Dss1 exoribonuclease active site mutant D477N from Candida glabrata
6CCA	;	1.75	;	Crystal structure of DszA carbon methyltransferase
2DE3	;	1.6	;	Crystal structure of DSZB C27S mutant in complex with 2'-hydroxybiphenyl-2-sulfinic acid
2DE4	;	1.8	;	Crystal structure of DSZB C27S mutant in complex with biphenyl-2-sulfinic acid
3KNP	;	3.3	;	Crystal structure of DTD from Plasmodium falciparum
3LMT	;	2.75	;	Crystal structure of DTD from Plasmodium falciparum
3LMU	;	3.3	;	Crystal structure of DTD from Plasmodium falciparum
3EJK	;	1.95	;	Crystal structure of dTDP Sugar Isomerase (YP_390184.1) from DESULFOVIBRIO DESULFURICANS G20 at 1.95 A resolution
6C46	;	1.95	;	Crystal structure of dTDP-4-dehydrorhamnose 3,5-epimerase from Elizabethkingia anophelis NUHP1
2B9U	;	2.07	;	Crystal structure of dTDP-4-dehydrorhamnose 3,5-epimerase from sulfolobus tokodaii
1WLT	;	1.9	;	Crystal Structure of dTDP-4-dehydrorhamnose 3,5-epimerase homologue from Sulfolobus tokodaii
8CTR	;	1.65	;	Crystal Structure of dTDP-4-dehydrorhamnose reductase from Klebsiella pneumoniae with bound NADP
6NDR	;	1.6	;	Crystal structure of dTDP-6-deoxy-D-glucose-3,5-epimerase RmlC from Legionella pneumophila Philadelphia 1 in complex with dTDP-4-KETO-L-RHAMNOSE
1EPZ	;	1.75	;	CRYSTAL STRUCTURE OF DTDP-6-DEOXY-D-XYLO-4-HEXULOASE 3,5-EPIMERASE FROM METHANOBACTERIUM THERMOAUTOTROPHICUM WITH BOUND LIGAND.
1N2S	;	2.0	;	CRYSTAL STRUCTURE OF DTDP-6-DEOXY-L-LYXO-4-HEXULOSE REDUCTASE (RMLD) IN COMPLEX WITH NADH
1KC1	;	2.6	;	Crystal structure of dTDP-6-deoxy-L-lyxo-4-hexulose reductase (RmlD) in complex with NADPH
1KC3	;	2.7	;	Crystal structure of dTDP-6-deoxy-L-lyxo-4-hexulose reductase (RmlD) in complex with NADPH and dTDP-L-rhamnose
7W74	;	2.84	;	Crystal structure of DTG rhodopsin from Pseudomonas putida
2PLR	;	1.6	;	Crystal structure of dTMP kinase (st1543) from Sulfolobus Tokodaii Strain7
5CFD	;	2.5	;	Crystal Structure of DTT treated Human Cardiovirus SAFV-3
2QQ9	;	1.71	;	Crystal Structure of DtxR(D6A C102D) Complexed with Nickel(II)
2QQA	;	2.1	;	Crystal Structure of DtxR(E9A C102D) Complexed with Nickel(II)
2QQB	;	1.92	;	Crystal Structure of DtxR(M10A C102D) Complexed with Nickel(II)
4UA1	;	2.56	;	Crystal structure of dual function transcriptional regulator MerR form Bacillus megaterium MB1 in complex with mercury (II) ion
4UA2	;	2.61	;	Crystal structure of dual function transcriptional regulator MerR from Bacillus megaterium MB1
5GRG	;	1.94	;	Crystal structure of dual peptide from EBV in complex with HLA-A*11:01
5F24	;	2.5	;	Crystal structure of dual specific IMPase/NADP phosphatase bound with D-inositol-1-phosphate
6EMS	;	1.996	;	Crystal Structure of dual specific Trm10 construct from Thermococcus kodakaraensis.
6EMT	;	1.794	;	Crystal Structure of dual specific Trm10 construct from Thermococcus kodakaraensis.
6EMU	;	2.29745	;	Crystal Structure of dual specific Trm10 construct from Thermococcus kodakaraensis.
6EMV	;	2.90001	;	Crystal Structure of dual specific Trm10 construct from Thermococcus kodakaraensis.
2PQ5	;	2.3	;	Crystal structure of Dual specificity protein phosphatase 13 (DUSP13)
2IMG	;	1.93	;	Crystal structure of dual specificity protein phosphatase 23 from Homo sapiens in complex with ligand malate ion
3TMH	;	3.8	;	Crystal structure of dual-specific A-kinase anchoring protein 2 in complex with cAMP-dependent protein kinase A type II alpha and PDZK1
3K2L	;	2.36	;	Crystal Structure of dual-specificity tyrosine phosphorylation regulated kinase 2 (DYRK2)
3KVW	;	2.28	;	Crystal Structure of dual-specificity tyrosine phosphorylation regulated kinase 2 (DYRK2) in complex with an indirubin ligand
5GJY	;	1.71	;	Crystal structure of DUCK MHC CLASS I for 1.71 angstrom
5GJX	;	2.06	;	Crystal structure of DUCK MHC I for 2.06 angstrom
4OFI	;	2.3	;	Crystal Structure of Duf (Kirre) D1
8ITS	;	1.94	;	Crystal structure of DUF-3268 k-junction
3LM7	;	1.9	;	Crystal Structure of DUF1341 representative, from Yersinia enterocolitica subsp. enterocolitica 8081
6ZNS	;	3.32	;	Crystal Structure of DUF1998 helicase MrfA
6ZNP	;	3.16	;	Crystal Structure of DUF1998 helicase MrfA bound to DNA
6ZNQ	;	3.34	;	Crystal Structure of DUF1998 helicase MrfA bound to DNA and AMPPNP
3BT5	;	1.35	;	Crystal structure of DUF305 fragment from Deinococcus radiodurans
3AI9	;	1.55	;	Crystal structure of DUF358 protein reveals a putative SPOUT-class rRNA methyltransferase
3AIA	;	1.4	;	Crystal structure of DUF358 reveals a putative SPOUT-class methltransferase
7Y7N	;	1.764	;	Crystal structure of DUF371 domain-containing protein from Methanobrevibacter ruminantium
3D7A	;	1.9	;	Crystal structure of DUF54 family protein PH1010 from hyperthermophilic archaea Pyrococcus horikoshii OT3
5GSK	;	1.05	;	Crystal structure of duplex DNA3 in complex with Hg(II) and Sr(II)
3W9Z	;	2.1	;	Crystal structure of DusC
7Y4C	;	1.87	;	Crystal structure of DUSP10
7Y4B	;	1.86	;	Crystal structure of DUSP10 mutant_D59A
7Y4E	;	1.93	;	Crystal structure of DUSP10 mutant_N130A
7Y4D	;	2.18	;	Crystal structure of DUSP10 mutant_S95A
1YZ4	;	2.4	;	Crystal structure of DUSP15
6L1S	;	1.3611	;	Crystal structure of DUSP22 mutant_C88S
6LMY	;	1.5	;	Crystal structure of DUSP22 mutant_C88S/S93A
6LOU	;	1.5301	;	Crystal structure of DUSP22 mutant_C88S/S93N
7C8S	;	1.31	;	Crystal structure of DUSP22 mutant_N128A
6LOT	;	1.69	;	Crystal structure of DUSP22 mutant_N128D
6LVQ	;	1.38	;	Crystal structure of DUSP22_VO4
3MQ1	;	2.8	;	Crystal Structure of Dust Mite Allergen Der p 5
3F4F	;	2.0	;	Crystal structure of dUT1p, a dUTPase from Saccharomyces cerevisiae
5VJY	;	2.0	;	Crystal Structure of dUTP pyrophosphatase protein, from Naegleria fowleri
6MJK	;	1.45	;	Crystal Structure of dUTP pyrophosphatase protein, from Naegleria fowleri in complex with deoxyuridine
1RN8	;	1.93	;	Crystal structure of dUTPase complexed with substrate analogue imido-dUTP
2HRM	;	1.7	;	Crystal structure of dUTPase complexed with substrate analogue methylene-dUTP
1MQ7	;	1.95	;	CRYSTAL STRUCTURE OF DUTPASE FROM MYCOBACTERIUM TUBERCULOSIS (RV2697C)
3H6X	;	1.7	;	Crystal structure of dUTPase from Streptococcus mutans
2ZDC	;	2.0	;	Crystal structure of dUTPase from Sulfolobus tokodaii
3HZA	;	1.2	;	Crystal structure of dUTPase H145W mutant
2HR6	;	1.84	;	Crystal structure of dUTPase in complex with substrate analogue dUDP and manganese
7C21	;	1.95	;	Crystal structure of Duvenhage virus phosphoprotein C-terminal domain
7DW5	;	2.83	;	Crystal structure of DUX4 HD1-HD2 domain complexed with ERG sites
6A8R	;	1.6	;	Crystal structure of DUX4 HD2 domain associated with ERG DNA binding site
5Z2S	;	1.5	;	Crystal structure of DUX4-HD2 domain
3PZ8	;	2.873	;	Crystal structure of Dvl1-DIX(Y17D) mutant
4LXG	;	2.22	;	Crystal structure of DxnB2, a carbon - carbon bond hydrolase from Sphingomonas wittichii RW1
6AIY	;	1.902	;	Crystal structure of DXO (E234A mutant) in complex with adenosine 3', 5' bisphosphate and two magnesium ions
6AIX	;	1.8	;	Crystal structure of DXO in complex with adenosine 3', 5' bisphosphate and two magnesium ions
3A06	;	2.0	;	Crystal structure of DXR from Thermooga maritia, in complex with fosmidomycin and NADPH
3A14	;	2.0	;	Crystal structure of DXR from Thermotoga maritima, in complex with NADPH
1Q0L	;	2.65	;	Crystal structure of DXR in complex with fosmidomycin
1Q0Q	;	1.9	;	Crystal structure of DXR in complex with the substrate 1-deoxy-D-xylulose-5-phosphate
6KMN	;	2.44	;	Crystal Structure of Dye Decolorizing peroxidase from Bacillus subtilis
7E5Q	;	1.9	;	Crystal Structure of Dye Decolorizing peroxidase from Bacillus subtilis at acidic pH
3ZVR	;	3.1	;	Crystal structure of Dynamin
3RJS	;	1.5	;	Crystal structure of Dynein Light Chain 8a (DLC8) from Toxoplasma gondii at 1.5 A resolution
2P2T	;	3.0	;	Crystal structure of dynein light chain LC8 bound to residues 123-138 of intermediate chain IC74
3E2B	;	2.0	;	Crystal structure of Dynein Light chain LC8 in complex with a peptide derived from Swallow
5WI4	;	2.0	;	CRYSTAL STRUCTURE OF DYNLT1/TCTEX-1 IN COMPLEX WITH ARHGEF2
7D8M	;	2.0	;	Crystal structure of DyP
4GRC	;	2.0	;	Crystal structure of DyP-type peroxidase (SCO2276) from Streptomyces coelicolor
4GT2	;	1.8	;	Crystal structure of DyP-type peroxidase (SCO3963) from Streptomyces coelicolor
4GU7	;	3.1	;	Crystal structure of DyP-type peroxidase (SCO7193) from Streptomyces coelicolor
6QZO	;	2.4	;	Crystal structure of DyP-type peroxidase from Cellulomonas bogoriensis
7O9J	;	1.7	;	Crystal structure of DyP-type peroxidase from Dictyostelium discoideum in complex with an activated form of oxygen
4GS1	;	1.7	;	Crystal structure of DyP-type peroxidase from Thermobifida cellulosilytica
6QU2	;	2.9	;	Crystal structure of DYRK1A complexed with FC162 inhibitor
6T6A	;	2.8	;	Crystal structure of DYRK1A complexed with KuFal319 (compound 11)
4YLK	;	1.4	;	Crystal structure of DYRK1A in complex with 10-Chloro-substituted 11H-indolo[3,2-c]quinolone-6-carboxylic acid inhibitor 5s
4YLJ	;	2.58	;	Crystal structure of DYRK1A in complex with 10-Iodo-substituted 11H-indolo[3,2-c]quinoline-6-carboxylic acid inhibitor 5j
8C3G	;	2.08	;	Crystal structure of DYRK1A in complex with AZ191
7Z5N	;	2.77	;	Crystal structure of DYRK1A in complex with CX-4945
8C3R	;	2.06	;	Crystal structure of DYRK1A in complex with gossypin
7FHS	;	2.42	;	Crystal structure of DYRK1A in complex with RD0392
7FHT	;	2.68	;	Crystal structure of DYRK1A in complex with RD0448
8C3Q	;	2.32	;	Crystal structure of DYRK1A in complex with rutin
4YU2	;	2.9	;	Crystal structure of DYRK1A with harmine-derivatized AnnH-75 inhibitor
6S11	;	2.445	;	Crystal Structure of DYRK1A with small molecule inhibitor
6S14	;	1.05	;	Crystal Structure of DYRK1A with small molecule inhibitor
6S17	;	1.1	;	Crystal Structure of DYRK1A with small molecule inhibitor
6S1B	;	1.3	;	Crystal Structure of DYRK1A with small molecule inhibitor
6S1H	;	1.05	;	Crystal Structure of DYRK1A with small molecule inhibitor
6S1I	;	2.38	;	Crystal Structure of DYRK1A with small molecule inhibitor
6S1J	;	1.408	;	Crystal Structure of DYRK1A with small molecule inhibitor
4YLL	;	1.4	;	Crystal structure of DYRK1AA in complex with 10-Bromo-substituted 11H-indolo[3,2-c]quinolone-6-carboxylic acid inhibitor 5t
8C2Z	;	1.91	;	Crystal structure of DYRK1B in complex with AZ191
5LXD	;	2.58	;	Crystal structure of DYRK2 in complex with EHT 1610 (compound 2)
5LXC	;	2.15	;	Crystal structure of DYRK2 in complex with EHT 5372 (Compound 1)
7SEV	;	2.3	;	Crystal structure of E coli contaminant protein YadF co-purified with a plant protein
7SEU	;	2.5	;	Crystal structure of E coli contaminant protein YncE co-purified with a plant protein
4JXX	;	2.3	;	Crystal structure of E coli E. coli glutaminyl-tRNA synthetase bound to tRNA(Gln)(CUG) and ATP from novel cryostabilization conditions
1C14	;	2.0	;	CRYSTAL STRUCTURE OF E COLI ENOYL REDUCTASE-NAD+-TRICLOSAN COMPLEX
2GMU	;	1.9	;	Crystal structure of E coli GDP-4-keto-6-deoxy-D-mannose-3-dehydratase complexed with PLP-glutamate ketimine intermediate
4RCB	;	1.63	;	Crystal structure of E Coli Hfq
4RCC	;	1.981	;	Crystal structure of E Coli Hfq
4HT8	;	1.9	;	Crystal structure of E coli Hfq bound to poly(A) A7
4HT9	;	1.8	;	Crystal structure of E coli Hfq bound to two RNAs
3RES	;	2.0	;	Crystal structure of E coli Hfq in complex with ADP
4QR8	;	1.999	;	Crystal Structure of E coli pepQ
3KXP	;	2.26	;	Crystal Structure of E-2-(Acetamidomethylene)succinate Hydrolase
6JW9	;	3.5	;	Crystal structure of E-64 inhibited falcipain 2 from Plasmodium falciparum, strain 3D7
3QRB	;	1.8	;	crystal structure of E-cadherin EC1-2 P5A P6A
3LNG	;	2.7	;	Crystal structure of E-cadherin EC12 AA extension
3LNI	;	2.3	;	Crystal structure of E-cadherin EC12 E89A
3LNE	;	2.0	;	Crystal structure of E-cadherin EC12 K14E
3LNF	;	2.5	;	Crystal structure of E-cadherin EC12 K14EW2A
3LNH	;	2.6	;	Crystal structure of E-cadherin EC12 W2A
4I63	;	5.709	;	Crystal Structure of E-R ClpX Hexamer
1G1T	;	1.5	;	CRYSTAL STRUCTURE OF E-SELECTIN LECTIN/EGF DOMAINS COMPLEXED WITH SLEX
5O3N	;	2.05	;	Crystal structure of E. cloacae 3,4-dihydroxybenzoic acid decarboxylase (AroY) reconstituted with prFMN
1KZN	;	2.3	;	Crystal Structure of E. coli 24kDa Domain in Complex with Clorobiocin
1DIZ	;	2.5	;	CRYSTAL STRUCTURE OF E. COLI 3-METHYLADENINE DNA GLYCOSYLASE (ALKA) COMPLEXED WITH DNA
2BH2	;	2.15	;	Crystal Structure of E. coli 5-methyluridine methyltransferase RumA in complex with ribosomal RNA substrate and S-adenosylhomocysteine.
1L5J	;	2.4	;	CRYSTAL STRUCTURE OF E. COLI ACONITASE B.
5EJE	;	1.9	;	Crystal structure of E. coli Adenylate kinase G56C/T163C double mutant in complex with Ap5a
4X8H	;	2.5	;	Crystal structure of E. coli Adenylate kinase P177A mutant
4X8L	;	1.7	;	Crystal structure of E. coli Adenylate kinase P177A mutant in complex with inhibitor Ap5a
6RZE	;	1.69	;	Crystal structure of E. coli Adenylate kinase R119A mutant
6S36	;	1.6	;	Crystal structure of E. coli Adenylate kinase R119K mutant
4X8M	;	2.6	;	Crystal structure of E. coli Adenylate kinase Y171W mutant
4X8O	;	2.1	;	Crystal structure of E. coli Adenylate kinase Y171W mutant in complex with inhibitor Ap5a
5L6V	;	2.667	;	Crystal structure of E. coli ADP-glucose pyrophosphorylase (AGPase) in complex with a negative allosteric regulator adenosine monophosphate (AMP) - AGPase*AMP
5L6S	;	3.04	;	Crystal structure of E. coli ADP-glucose pyrophosphorylase (AGPase) in complex with a positive allosteric regulator beta-fructose-1,6-diphosphate (FBP) - AGPase*FBP
4YR1	;	2.24	;	Crystal Structure of E. Coli Alkaline Phosphatase D101A/D153A in complex with inorganic phosphate
3E74	;	2.1	;	Crystal structure of E. coli allantoinase with iron ions at the metal center
1D6U	;	2.4	;	CRYSTAL STRUCTURE OF E. COLI AMINE OXIDASE ANAEROBICALLY REDUCED WITH BETA-PHENYLETHYLAMINE
1LVN	;	2.4	;	CRYSTAL STRUCTURE OF E. COLI AMINE OXIDASE COMPLEXED WITH TRANYLCYPROMINE
3B2P	;	2.0	;	Crystal structure of E. coli Aminopeptidase N in complex with arginine
4XN9	;	2.8	;	Crystal Structure of E. coli Aminopeptidase N in complex with Beta Alanine
4XN7	;	2.22	;	Crystal Structure of E. coli Aminopeptidase N in complex with L-2,3-Diaminopropionic acid
4XN8	;	1.89	;	Crystal Structure of E. coli Aminopeptidase N in complex with L-Alanine
4XNA	;	2.4	;	Crystal Structure of E. coli Aminopeptidase N in complex with L-Beta Homolysine
4XNB	;	1.95	;	Crystal Structure of E. coli Aminopeptidase N in complex with L-Beta Homophenylalanine
4XND	;	1.93	;	Crystal Structure of E. coli Aminopeptidase N in complex with L-Beta Homotryptophan
4XO5	;	1.98	;	Crystal Structure of E. coli Aminopeptidase N in complex with L-Glutamate
4XO3	;	2.0	;	Crystal Structure of E. coli Aminopeptidase N in complex with L-Leucine
4XO4	;	2.18	;	Crystal Structure of E. coli Aminopeptidase N in complex with L-Methionine
3QJX	;	1.45	;	Crystal Structure of E. coli Aminopeptidase N in complex with L-Serine
3B2X	;	1.5	;	Crystal Structure of E. coli Aminopeptidase N in complex with Lysine
3B34	;	1.3	;	Crystal structure of E. coli Aminopeptidase N in complex with Phenylalanine
3B3B	;	1.85	;	Crystal structure of E. coli Aminopeptidase N in complex with tryptophan
3B37	;	1.7	;	Crystal structure of E. coli Aminopeptidase N in complex with Tyrosine
1T8R	;	2.7	;	Crystal Structure of E. coli AMP Nucleosidase
1T8W	;	2.8	;	Crystal Structure of E. coli AMP Nucleosidase
2DH6	;	3.0	;	Crystal structure of E. coli Apo-TrpB
3A7L	;	1.3	;	Crystal structure of E. coli apoH-protein
1K97	;	2.0	;	Crystal Structure of E. coli Argininosuccinate Synthetase in complex with Aspartate and Citrulline
1KP2	;	2.0	;	Crystal Structure of E. coli Argininosuccinate Synthetase in Complex with ATP
1KP3	;	2.0	;	Crystal Structure of E. coli Argininosuccinate Synthetase in Complex with ATP and Citrulline
1U9J	;	2.4	;	Crystal Structure of E. coli ArnA (PmrI) Decarboxylase Domain
1Z73	;	2.5	;	Crystal Structure of E. coli ArnA dehydrogenase (decarboxylase) domain, S433A mutant
8E9D	;	1.37	;	Crystal structure of E. coli aspartate aminotransferase mutant AIFS bound to maleic acid at 100 K
8E9C	;	2.18	;	Crystal structure of E. coli aspartate aminotransferase mutant AIFS in the ligand-free form at 100 K
8E9Q	;	1.8	;	Crystal structure of E. coli aspartate aminotransferase mutant HEX bound to maleic acid at 278 K
8E9J	;	2.09	;	Crystal structure of E. coli aspartate aminotransferase mutant HEX in the ligand-free form at 278 K
8E9U	;	1.94	;	Crystal structure of E. coli aspartate aminotransferase mutant HEX in the ligand-free form at 303 K
8E9S	;	2.0	;	Crystal structure of E. coli aspartate aminotransferase mutant VFCS bound to maleic acid at 278 K
8E9R	;	1.9	;	Crystal structure of E. coli aspartate aminotransferase mutant VFCS in the ligand-free form at 278 K
8E9M	;	1.76	;	Crystal structure of E. coli aspartate aminotransferase mutant VFIT bound to maleic acid at 278 K
8E9L	;	2.31	;	Crystal structure of E. coli aspartate aminotransferase mutant VFIT in the ligand-free form at 278 K
8E9V	;	2.01	;	Crystal structure of E. coli aspartate aminotransferase mutant VFIT in the ligand-free form at 303 K
8E9O	;	1.96	;	Crystal structure of E. coli aspartate aminotransferase mutant VFIY bound to maleic acid at 278 K
8E9N	;	1.88	;	Crystal structure of E. coli aspartate aminotransferase mutant VFIY in the ligand-free form at 278 K
4E2F	;	2.8	;	Crystal Structure of E. coli Aspartate Transcarbamoylase K164E/E239K Mutant in an intermediate state
1F1B	;	2.3	;	CRYSTAL STRUCTURE OF E. COLI ASPARTATE TRANSCARBAMOYLASE P268A MUTANT IN THE R-STATE IN THE PRESENCE OF N-PHOSPHONACETYL-L-ASPARTATE
1EZZ	;	2.7	;	CRYSTAL STRUCTURE OF E. COLI ASPARTATE TRANSCARBAMOYLASE P268A MUTANT IN THE T-STATE
2J0W	;	2.5	;	Crystal structure of E. coli aspartokinase III in complex with aspartate and ADP (R-state)
2J0X	;	2.8	;	CRYSTAL STRUCTURE OF E. COLI ASPARTOKINASE III IN COMPLEX WITH LYSINE AND ASPARTATE (T-STATE)
3E1N	;	2.8	;	Crystal structure of E. coli Bacterioferritin (BFR) after a 65 minute (aerobic) exposure to FE(II) revealing a possible MU-OXO bridge/MU-Hydroxy bridged DIIRON intermediate at the ferroxidase centre. (FE(III)-O-FE(III)-BFR).
3E1P	;	2.4	;	Crystal structure of E. coli Bacterioferritin (BFR) in which the Ferroxidase centre is inhibited with ZN(II) and high occupancy iron is bound within the cavity.
3E1M	;	2.7	;	Crystal structure of E. coli Bacterioferritin (BFR) obtained after soaking APO-BFR crystals for 2.5 minutes in FE2+ (2.5M FE(II)-BFR)
3E1L	;	2.5	;	Crystal structure of E. coli Bacterioferritin (BFR) soaked in phosphate with an alternative conformation of the unoccupied Ferroxidase centre (APO-BFR II).
3E1J	;	2.7	;	Crystal structure of E. coli Bacterioferritin (BFR) with an unoccupied ferroxidase centre (APO-BFR).
3E1O	;	2.95	;	Crystal structure of E. coli Bacterioferritin (BFR) with two ZN(II) ION sites at the Ferroxidase centre (ZN-BFR).
6AIT	;	2.598	;	Crystal structure of E. coli BepA
1I6O	;	2.2	;	CRYSTAL STRUCTURE OF E. COLI BETA CARBONIC ANHYDRASE (ECCA)
1I6P	;	2.0	;	CRYSTAL STRUCTURE OF E. COLI BETA CARBONIC ANHYDRASE (ECCA)
7PR6	;	1.99	;	Crystal structure of E. coli beta-glucuronidase in complex with covalent inhibitor ME727
3K4D	;	2.393	;	Crystal structure of E. coli beta-glucuronidase with the glucaro-d-lactam inhibitor bound
6OI9	;	2.06	;	Crystal Structure of E. coli Biotin Carboxylase Complexed with 7-[3-(aminomethyl)pyrrolidin-1-yl]-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-2-amine
1HXD	;	2.4	;	CRYSTAL STRUCTURE OF E. COLI BIOTIN REPRESSOR WITH BOUND BIOTIN
1T36	;	2.1	;	Crystal structure of E. coli carbamoyl phosphate synthetase small subunit mutant C248D complexed with uridine 5'-monophosphate
5H9E	;	3.21	;	Crystal structure of E. coli Cascade bound to a PAM-containing dsDNA target (32-nt spacer) at 3.20 angstrom resolution.
5H9F	;	2.45	;	Crystal structure of E. coli Cascade bound to a PAM-containing dsDNA target at 2.45 angstrom resolution.
3K8N	;	2.3	;	Crystal structure of E. Coli CCMG
2B1K	;	1.9	;	Crystal structure of E. coli CcmG protein
4CIU	;	3.5	;	Crystal structure of E. coli ClpB
2FZS	;	1.9	;	Crystal structure of E. coli ClpP with a Peptide Chloromethyl Ketone Covalently Bound at the Active Site
1D6Y	;	2.4	;	CRYSTAL STRUCTURE OF E. COLI COPPER-CONTAINING AMINE OXIDASE ANAEROBICALLY REDUCED WITH BETA-PHENYLETHYLAMINE AND COMPLEXED WITH NITRIC OXIDE.
5EEP	;	2.4	;	Crystal structure of E. coli CsdE
1S1M	;	2.3	;	Crystal Structure of E. Coli CTP Synthetase
2BC5	;	2.25	;	Crystal structure of E. coli cytochrome b562 with engineered c-type heme linkages
2YJT	;	2.9	;	Crystal structure of E. coli DEAD-box protein SrmB bound to regulator of ribonuclease activity A (RraA)
2FAE	;	1.55	;	Crystal structure of E. coli decanoyl-ACP
6EUD	;	2.4	;	Crystal structure of E. coli DExH-box NTPase HrpB
4EOU	;	2.3	;	Crystal structure of E. coli dihydrodipicolinate synthase with pyruvate and succinic semi-aldehyde bound in active site
4BFA	;	1.65	;	Crystal structure of E. coli dihydrouridine synthase C (DusC)
4BF9	;	2.6	;	Crystal structure of E. coli dihydrouridine synthase C (DusC) (selenomethionine derivative)
4GOM	;	2.45	;	Crystal Structure of E. coli DNA Adenine Methyltransferase in Complex with Aza-SAM
4GOO	;	2.7	;	Crystal Structure of E. coli DNA Adenine Methyltransferase in Complex with Benzothiophene Aza-SAM
4GON	;	2.72	;	Crystal Structure of E. coli DNA Adenine Methyltransferase in Complex with Indole Aza-SAM
4GOL	;	2.57	;	Crystal Structure of E. coli DNA Adenine Methyltransferase in Complex with Methylated Aza-SAM
4GBE	;	2.66	;	Crystal Structure of E. coli DNA Adenine Methyltransferase in Complex with SAH
1WBB	;	2.5	;	Crystal structure of E. coli DNA mismatch repair enzyme MutS, E38A mutant, in complex with a G.T mismatch
1WBD	;	2.4	;	Crystal structure of E. coli DNA mismatch repair enzyme MutS, E38Q mutant, in complex with a G.T mismatch
1WB9	;	2.1	;	Crystal Structure of E. coli DNA Mismatch Repair enzyme MutS, E38T mutant, in complex with a G.T mismatch
1D6M	;	3.0	;	CRYSTAL STRUCTURE OF E. COLI DNA TOPOISOMERASE III
7AQS	;	2.8	;	Crystal structure of E. coli DPS in space group P1
1SEH	;	1.47	;	Crystal structure of E. coli dUTPase complexed with the product dUMP
3H8A	;	1.9	;	Crystal structure of E. coli enolase bound to its cognate RNase E recognition domain
2FYM	;	1.6	;	Crystal structure of E. coli enolase complexed with the minimal binding segment of RNase E.
1QG6	;	1.9	;	CRYSTAL STRUCTURE OF E. COLI ENOYL ACYL CARRIER PROTEIN REDUCTASE IN COMPLEX WITH NAD AND TRICLOSAN
1LXC	;	2.4	;	Crystal Structure of E. Coli Enoyl Reductase-NAD+ with a Bound Acrylamide Inhibitor
1LX6	;	2.4	;	Crystal Structure of E. Coli Enoyl Reductase-NAD+ with a Bound Benzamide Inhibitor
2FWM	;	2.0	;	Crystal Structure of E. coli EntA, a 2,3-dihydrodihydroxy benzoate dehydrogenase
4JRQ	;	3.0	;	Crystal structure of E. coli Exonuclease I in complex with a 5cy-dA13 oligonucleotide
4JS4	;	3.1	;	Crystal structure of E. coli Exonuclease I in complex with a dA16 oligonucleotide
4JS5	;	3.5	;	Crystal structure of E. coli Exonuclease I in complex with a dT13 oligonucleotide
3I8P	;	1.9	;	Crystal structure of E. coli FabF(C163A) in complex with Platensimycin A1
5CG1	;	2.07	;	Crystal structure of E. coli FabI bound to the carbamoylated benzodiazaborine inhibitor 14b.
5CG2	;	2.11	;	Crystal structure of E. coli FabI bound to the thiocarbamoylated benzodiazaborine inhibitor 35b.
5CFZ	;	1.97	;	Crystal structure of E. coli FabI in apo form
7UM8	;	1.7	;	Crystal structure of E. Coli FabI in complex with NAD and (R,E)-3-(7-amino-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)acrylamide
4D46	;	2.0	;	Crystal structure of E. coli FabI in complex with NAD and 5-bromo-2-(4-chloro-2-hydroxyphenoxy)benzonitrile
7UMW	;	1.54	;	Crystal structure of E. Coli FabI in complex with NAD and Fabimycin ((S,E)-3-(7-amino-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)acrylamide)
4CV2	;	1.8	;	Crystal structure of E. coli FabI in complex with NADH and CG400549
4CV3	;	1.95	;	Crystal structure of E. coli FabI in complex with NADH and PT166
7QP5	;	1.92	;	Crystal Structure of E. coli FhuF
1FW4	;	1.7	;	CRYSTAL STRUCTURE OF E. COLI FRAGMENT TR2C FROM CALMODULIN TO 1.7 A RESOLUTION
6NZ9	;	1.528	;	Crystal structure of E. coli fumarase C bound to citrate at 1.53 angstrom resolution
6NZA	;	1.406	;	Crystal structure of E. coli fumarase C K324A variant with closed SS Loop at 1.41 angstrom resolution
6NZC	;	1.403	;	Crystal structure of E. coli fumarase C N326A variant with closed SS Loop at 1.40 angstrom resolution
6NZB	;	1.37	;	Crystal structure of E. coli fumarase C S318A variant with closed SS Loop at 1.37 angstrom resolution
5O0V	;	2.4	;	crystal structure of E. coli GAP-DH by fortuitous crystallization as an impurity from a solution of human liver FBPase
1SZ2	;	2.2	;	Crystal structure of E. coli glucokinase in complex with glucose
2E3D	;	1.95	;	Crystal structure of E. coli glucose-1-phosphate uridylyltransferase
4JYZ	;	2.5	;	Crystal structure of E. coli glutaminyl-tRNA synthetase bound to ATP and native tRNA(Gln) containing the cmnm5s2U34 anticodon wobble base
2PAN	;	2.7	;	Crystal structure of E. coli glyoxylate carboligase
8BEO	;	1.96	;	Crystal structure of E. coli glyoxylate carboligase mutant I393A with MAP
7DKP	;	1.45	;	Crystal structure of E. coli Grx2 in complex with GSH at 1.45 A resolution
7D9L	;	1.61	;	Crystal structure of E. coli Grx2: Enzyme inhibited state in complex with Zinc and glutathione sulfinic acid
2BZ0	;	2.6	;	Crystal Structure of E. coli GTP cyclohydrolase II in complex with GTP analogue, GMPcPP, and Zinc
6VWO	;	1.78	;	Crystal structure of E. coli guanosine kinase
6VWP	;	3.45	;	Crystal structure of E. coli guanosine kinase in complex with ppGpp
3G7E	;	2.2	;	Crystal structure of E. coli Gyrase B co-complexed with PROP-2-YN-1-YL {[5-(4-PIPERIDIN-1-YL-2-PYRIDIN-3-YL-1,3-THIAZOL-5-YL)-1H-PYRAZOL-3-YL]METHYL}CARBAMATE inhibitor
6F86	;	1.9	;	Crystal Structure of E. coli GyraseB 24kDa in complex with 4-(4-bromo-1H-pyrazol-1-yl)-6-[(ethylcarbamoyl)amino]-N-(pyridin-3-yl)pyridine-3-carboxamide
6F8J	;	1.95	;	Crystal Structure of E. coli GyraseB 24kDa in complex with 6-[(ethylcarbamoyl)amino]-4-(1H-pyrazol-1-yl)-N-(pyridin-3-yl)pyridine-3-carboxamide
6F94	;	2.35	;	Crystal Structure of E. coli GyraseB 24kDa in complex with 6-[(ethylcarbamoyl)amino]-4-[(3-methyphenyl)amino]-N-(3-methyphenyl)pyridine-3-carboxamide
6F96	;	2.5	;	Crystal Structure of E. coli GyraseB 24kDa in complex with 6-[(ethylcarbamoyl)amino]-4-[(4-methoxyphenyl)amino]-N-(pyridin-3-yl)pyridine-3-carboxamide
2FAD	;	1.6	;	Crystal structure of E. coli heptanoyl-ACP
7YSE	;	2.907	;	Crystal structure of E. coli heterotetrameric GlyRS in complex with tRNA
2FAC	;	1.76	;	Crystal structure of E. coli hexanoyl-ACP
3RER	;	1.7	;	Crystal structure of E. coli Hfq in complex with AU6A RNA and ADP
2DH5	;	2.9	;	Crystal structure of E. coli Holo-TrpB
5BV2	;	1.53	;	Crystal structure of E. coli HPII catalase variant
3UD5	;	2.0	;	Crystal structure of E. coli HPPK in complex with bisubstrate analogue inhibitor J1A
3UDE	;	1.881	;	Crystal structure of E. coli HPPK in complex with bisubstrate analogue inhibitor J1B
3UDV	;	1.88	;	Crystal structure of E. coli HPPK in complex with bisubstrate analogue inhibitor J1C
4F7V	;	1.73	;	Crystal structure of E. coli HPPK in complex with bisubstrate analogue inhibitor J1D (HP26)
3IP0	;	0.89	;	Crystal structure of E. coli HPPK in complex with MgAMPCPP and 6-hydroxymethylpterin/6-carboxypterin
3ILI	;	1.45	;	Crystal structure of E. coli HPPK(D95A)
3ILJ	;	1.65	;	Crystal structure of E. coli HPPK(D95A) in complex with MgAMPCPP
3ILL	;	1.73	;	Crystal structure of E. coli HPPK(D97A)
3ILO	;	1.1	;	Crystal structure of E. coli HPPK(D97A) in complex with MgAMPCPP and 6-hydroxymethyl-7,8-dihydropterin
3KUE	;	1.538	;	Crystal structure of E. coli HPPK(E77A)
3HSZ	;	1.4	;	Crystal structure of E. coli HPPK(F123A)
3HT0	;	1.4	;	Crystal structure of E. coli HPPK(F123A) in complex with MgAMPCPP
3KUG	;	1.996	;	Crystal structure of E. coli HPPK(H115A)
3KUH	;	1.35	;	Crystal structure of E. coli HPPK(H115A) in complex with AMPCPP and HP
3HCX	;	1.75	;	Crystal structure of E. coli HPPK(N10A)
3HD1	;	1.3	;	Crystal structure of E. coli HPPK(N10A) in complex with MgAMPCPP
3HSJ	;	1.18	;	Crystal structure of E. coli HPPK(N55A)
3HD2	;	1.1	;	Crystal structure of E. coli HPPK(Q50A) in complex with MgAMPCPP and pterin
3HSD	;	1.652	;	Crystal structure of E. coli HPPK(Y53A)
3HSG	;	1.14	;	Crystal structure of E. coli HPPK(Y53A) in complex with MgAMPCPP
7ACL	;	2.049	;	Crystal structure of E. coli HTH-type transcriptional regulator RcdA at 2.05 A resolution
7ACM	;	1.763	;	Crystal structure of E. coli HTH-type transcriptional regulator RcdA in complex with TMAO at 1.76 A resolution
7ACO	;	1.798	;	Crystal structure of E. coli HTH-type transcriptional regulator RcdA in complex with Tris at 1.80 A resolution
2O97	;	2.45	;	Crystal Structure of E. coli HU heterodimer
3USC	;	2.0	;	Crystal Structure of E. coli hydrogenase-1 in a ferricyanide-oxidized form
3USE	;	1.67	;	Crystal Structure of E. coli hydrogenase-1 in its as-isolated form
2I6R	;	2.51	;	Crystal structure of E. coli HypE, a hydrogenase maturation protein
3TSP	;	2.05	;	Crystal structure of E. coli HypF
3TTC	;	1.86	;	Crystal structure of E. coli HypF with ADP and carbamoyl phosphate
3TTF	;	1.92	;	Crystal structure of E. coli HypF with AMP and carbamoyl phosphate
3TTD	;	2.2	;	Crystal structure of E. coli HypF with AMP-CPP and carbamoyl phosphate
3TSU	;	1.92	;	Crystal structure of E. coli HypF with AMP-PNP and carbamoyl phosphate
3TSQ	;	2.4	;	Crystal structure of E. coli HypF with ATP and Carbamoyl phosphate
1NXU	;	1.8	;	CRYSTAL STRUCTURE OF E. COLI HYPOTHETICAL OXIDOREDUCTASE YIAK NORTHEAST STRUCTURAL GENOMICS CONSORTIUM TARGET ER82.
5KNT	;	2.55	;	Crystal structure of E. coli hypoxanthine phosphoribosyltransferase in complexed with 2-((2,3-Dihydroxypropyl)(2-(hypoxanthin-9-yl)ethyl)amino)ethylphosphonic acid
5KNU	;	2.808	;	Crystal structure of E. coli hypoxanthine phosphoribosyltransferase in complexed with 9-[N,N-(Bis-3-phosphonopropyl)aminomethyl]-9-deazahypoxanthine
5KNX	;	2.4	;	Crystal structure of E. coli hypoxanthine phosphoribosyltransferase in complexed with {[(2-[(Hypoxanthin-9H-yl)methyl]propane-1,3-diyl)bis(oxy)]bis- (methylene)}diphosphonic Acid
2ZAL	;	1.9	;	Crystal structure of E. coli isoaspartyl aminopeptidase/L-asparaginase in complex with L-aspartate
2AQO	;	1.95	;	Crystal structure of E. coli Isoaspartyl Dipeptidase Mutant E77Q
2AQV	;	1.95	;	Crystal Structure of E. coli Isoaspartyl Dipeptidase mutant Y137F
1W8G	;	2.0	;	CRYSTAL STRUCTURE OF E. COLI K-12 YGGS
1O89	;	2.25	;	Crystal structure of E. COLI K-12 yhdH
1O8C	;	2.6	;	CRYSTAL STRUCTURE OF E. COLI K-12 YHDH WITH BOUND NADPH
6EOK	;	2.5	;	Crystal structure of E. coli L-asparaginase II
4RJY	;	2.1	;	Crystal structure of E. coli L-Threonine Aldolase in complex with a non-covalently uncleaved bound L-serine substrate
4OAA	;	3.5	;	Crystal structure of E. coli lactose permease G46W,G262W bound to sugar
4ZYR	;	3.312	;	Crystal structure of E. coli Lactose permease G46W/G262W bound to p-nitrophenyl alpha-D-galactopyranoside (alpha-NPG)
2GQQ	;	3.2	;	Crystal Structure of E. coli Leucine-responsive regulatory protein (Lrp)
3A7R	;	2.05	;	Crystal structure of E. coli lipoate-protein ligase A in complex with lipoyl-AMP.
3A7A	;	3.1	;	Crystal structure of E. coli lipoate-protein ligase A in complex with octyl-amp and apoH-protein
3K8E	;	2.51	;	Crystal structure of E. coli lipopolysaccharide specific CMP-KDO synthetase
3K8D	;	1.9	;	Crystal structure of E. coli lipopolysaccharide specific CMP-KDO synthetase in complex with CTP and 2-deoxy-Kdo
6DR3	;	2.101	;	Crystal structure of E. coli LpoA amino terminal domain
8GAK	;	1.9	;	Crystal Structure of E. coli LptA in complex with Chinavia Ubica Thanatin
8GAJ	;	2.43	;	Crystal Structure of E. coli LptA in complex with Podisus maculiventris Thanatin
4P32	;	1.55	;	Crystal structure of E. coli LptB in complex with ADP-magnesium
4P33	;	1.65	;	Crystal structure of E. coli LptB-E163Q in complex with ATP-sodium
3GKF	;	2.9	;	Crystal Structure of E. coli LsrF
3GLC	;	2.5	;	Crystal Structure of E. coli LsrF in complex with Ribose-5-phosphate
3GND	;	2.9	;	Crystal Structure of E. coli LsrF in complex with Ribulose-5-phosphate
3QMQ	;	1.8	;	Crystal Structure of E. coli LsrG
1JRL	;	1.95	;	Crystal structure of E. coli Lysophospholiase L1/Acyl-CoA Thioesterase I/Protease I L109P mutant
1Q1B	;	2.8	;	Crystal structure of E. coli MalK in the nucleotide-free form
4JBW	;	3.913	;	Crystal structure of E. coli maltose transporter MalFGK2 in complex with its regulatory protein EIIAglc
3H5A	;	2.8	;	Crystal structure of E. coli MccB
3H9J	;	2.3	;	Crystal structure of E. coli MccB + AMPCPP + SeMeT MccA
3H5N	;	1.9	;	Crystal structure of E. coli MccB + ATP
3H9G	;	2.2	;	Crystal structure of E. coli MccB + MccA-N7isoASN
3H9Q	;	2.63	;	Crystal structure of E. coli MccB + SeMet MccA
3H5R	;	2.1	;	Crystal structure of E. coli MccB + Succinimide
6J0A	;	14.2	;	Crystal structure of E. coli methionine aminopeptidase enzyme and chaperone trigger factor fitted into the cryo-EM density map of the complex
6XGY	;	2.9	;	Crystal structure of E. coli MlaFB ABC transport subunits in the dimeric state
6XGZ	;	2.6	;	Crystal structure of E. coli MlaFB ABC transport subunits in the monomeric state
2PI8	;	2.25	;	Crystal structure of E. coli MltA with bound chitohexaose
4HJV	;	2.3	;	Crystal structure of E. coli MltE with bound bulgecin and murodipeptide
1D5N	;	1.55	;	CRYSTAL STRUCTURE OF E. COLI MNSOD AT 100K
1JYS	;	1.9	;	Crystal Structure of E. coli MTA/AdoHcy Nucleosidase
1NC1	;	2.0	;	Crystal structure of E. coli MTA/AdoHcy nucleosidase complexed with 5'-methylthiotubercidin (MTH)
1NC3	;	2.2	;	Crystal structure of E. coli MTA/AdoHcy nucleosidase complexed with formycin A (FMA)
3O4V	;	1.75	;	Crystal structure of E. coli MTA/SAH nucleosidase in complex with (4-Chlorophenyl)thio-DADMe-ImmA
3DF9	;	1.95	;	Crystal structure of E. coli MTA/SAH nucleosidase in complex with BnT-DADMeImmA
4ZOW	;	2.45	;	Crystal structure of E. coli multidrug transporter MdfA in complex with chloramphenicol
4ZP0	;	2.0	;	Crystal structure of E. coli multidrug transporter MdfA in complex with deoxycholate
4ZP2	;	2.2	;	Crystal structure of E. coli multidrug transporter MdfA in complex with n-dodecyl-N,N-dimethylamine-N-oxide
2Q85	;	2.51	;	Crystal Structure of E. Coli Mur B bound to a Naphthyl Tetronic Acid inihibitor
3JZ4	;	2.3	;	Crystal structure of E. coli NADP dependent enzyme
7X32	;	1.829	;	Crystal structure of E. coli NfsB in complex with berberine
1K4K	;	2.0	;	Crystal structure of E. coli Nicotinic acid mononucleotide adenylyltransferase
5IW4	;	2.6	;	Crystal structure of E. coli NudC in complex with NAD
5IW5	;	2.7	;	Crystal structure of E. coli NudC in complex with NMN
3SQV	;	3.3	;	Crystal Structure of E. coli O157:H7 E3 ubiquitin ligase, NleL, with a human E2, UbcH7
3NAW	;	2.5	;	Crystal structure of E. coli O157:H7 effector protein NleL
3NB2	;	2.1	;	Crystal structure of E. coli O157:H7 effector protein NleL
2IGI	;	1.7	;	Crystal Structure of E. coli Oligoribonuclease
4GCP	;	1.98	;	Crystal Structure of E. coli OmpF porin in complex with Ampicillin
4GCQ	;	2.2	;	Crystal Structure of E. coli OmpF porin in complex with Carbenicillin
4GCS	;	1.87	;	Crystal Structure of E. coli OmpF porin in complex with Ertapenem
3TCF	;	2.0	;	Crystal structure of E. coli OppA complexed with endogenous ligands
3TCG	;	2.0	;	Crystal structure of E. coli OppA complexed with the tripeptide KGE
3TCH	;	1.98	;	Crystal structure of E. coli OppA in an open conformation
1DUV	;	1.7	;	CRYSTAL STRUCTURE OF E. COLI ORNITHINE TRANSCARBAMOYLASE COMPLEXED WITH NDELTA-L-ORNITHINE-DIAMINOPHOSPHINYL-N-SULPHONIC ACID (PSORN)
1QWI	;	1.8	;	Crystal Structure of E. coli OsmC
1SQ5	;	2.2	;	Crystal Structure of E. coli Pantothenate kinase
5J8X	;	2.53	;	CRYSTAL STRUCTURE OF E. COLI PBP5 WITH 2C
6NTZ	;	2.2	;	Crystal structure of E. coli PBP5-meropenem
4BJP	;	2.5	;	Crystal structure of E. coli penicillin binding protein 3
4BJQ	;	2.1	;	Crystal structure of E. coli penicillin binding protein 3, domain V88- S165
3BEC	;	1.6	;	Crystal structure of E. coli penicillin-binding protein 5 in complex with a peptide-mimetic cephalosporin
3BEB	;	2.0	;	Crystal structure of E. coli penicillin-binding protein 5 in complex with a peptide-mimetic penicillin
2HPT	;	2.3	;	Crystal Structure of E. coli PepN (Aminopeptidase N)in complex with Bestatin
6IZI	;	11.8	;	Crystal structure of E. coli peptide deformylase and methionine aminopeptidase fitted into the cryo-EM density map of the complex
6J45	;	12.2	;	Crystal structure of E. coli peptide deformylase enzyme and chaperone trigger factor fitted into the cryo-EM density map of the complex
1DJ8	;	2.0	;	CRYSTAL STRUCTURE OF E. COLI PERIPLASMIC PROTEIN HDEA
4WHE	;	1.8	;	Crystal structure of E. coli phage shock protein A (PspA 1-144)
3PCO	;	3.02	;	crystal structure of E. coli phenylalanine-tRNA synthetase complexed with phenylalanine and AMP
3HYC	;	3.06	;	Crystal structure of E. coli phosphatase YrbI, with Mg, tetragonal form
2PY7	;	2.2	;	Crystal structure of E. coli phosphoenolpyruvate carboxykinase mutant Lys213Ser complexed with ATP-Mg2+-Mn2+
6V2N	;	1.65	;	Crystal structure of E. coli phosphoenolpyruvate carboxykinase mutant Lys254Ser
4HN7	;	2.352	;	Crystal structure of E. coli PmrD
3UT6	;	1.895	;	Crystal structure of E. Coli PNP complexed with PO4 and formycin A
3CDI	;	2.6	;	Crystal structure of E. coli PNPase
3GCM	;	2.5	;	Crystal Structure of E. coli polynucleotide phosphorylase bound to RNA and RNase E
2CCZ	;	2.7	;	Crystal structure of E. coli primosomol protein PriB bound to ssDNA
2AB0	;	1.1	;	Crystal Structure of E. coli protein YajL (ThiJ)
1QYA	;	2.0	;	CRYSTAL STRUCTURE OF E. COLI PROTEIN YDDE
2OLW	;	1.6	;	Crystal Structure of E. coli pseudouridine synthase RluE
2OML	;	1.2	;	crystal structure of E. coli pseudouridine synthase RluE
1QCZ	;	1.5	;	CRYSTAL STRUCTURE OF E. COLI PURE, AN UNUSUAL MUTASE THAT CATALYZES THE CONVERSION OF N5-CARBOXYAMINOIMIDAZOLE RIBONUCLEOTIDE (N5-CAIR) TO 4-CARBOXYAMINOIMIDAZOLE RIBONUCLEOTIDE (CAIR) IN THE PURINE BIOSYNTHETIC PATHWAY
1D7A	;	2.5	;	CRYSTAL STRUCTURE OF E. COLI PURE-MONONUCLEOTIDE COMPLEX.
3OPV	;	2.4	;	Crystal structure of E. Coli purine nucleoside phosphorylase Arg24Ala mutant
1PKE	;	2.3	;	Crystal Structure of E. coli purine nucleoside phosphorylase complexed with 2-fluoro-2'-deoxyadenosine and sulfate/phosphate
1PK9	;	1.9	;	Crystal Structure of E. coli purine nucleoside phosphorylase complexed with 2-fluoroadenosine and sulfate/phosphate
1PW7	;	2.0	;	Crystal Structure of E. coli purine nucleoside phosphorylase complexed with 9-beta-D-arabinofuranosyladenine and sulfate/phosphate
1PK7	;	2.5	;	Crystal Structure of E. coli purine nucleoside phosphorylase complexed with adenosine and sulfate/phosphate
6XZ2	;	1.65	;	Crystal structure of E. Coli purine nucleoside phosphorylase mutant Y160W with SO4 and Formycin A
3OOE	;	2.0	;	Crystal structure of E. Coli purine nucleoside phosphorylase with PO4
3OOH	;	2.9	;	Crystal structure of E. Coli purine nucleoside phosphorylase with PO4
3ONV	;	1.893	;	Crystal structure of E. Coli purine nucleoside phosphorylase with SO4
3ETH	;	1.6	;	Crystal structure of E. coli Purk in complex with MgATP
1TJ0	;	2.1	;	Crystal structure of E. coli PutA proline dehydrogenase domain (residues 86-669) co-crystallized with L-lactate
1TJ2	;	2.05	;	Crystal structure of E. coli PutA proline dehydrogenase domain (residues 86-669) complexed with acetate
1TJ1	;	2.0	;	Crystal structure of E. coli PutA proline dehydrogenase domain (residues 86-669) complexed with L-lactate
1TIW	;	2.0	;	Crystal structure of E. coli PutA proline dehydrogenase domain (residues 86-669) complexed with L-Tetrahydro-2-furoic acid
3NBX	;	2.91	;	Crystal structure of E. coli RavA (Regulatory ATPase variant A) in complex with ADP
2OWL	;	2.4	;	Crystal structure of E. coli RdgC
1U94	;	1.9	;	Crystal Structure of E. Coli RecA in a Compressed Helical Filament Form 2
1U98	;	2.0	;	Crystal Structure of E. coli RecA in a Compressed Helical Filament Form3
3H4R	;	2.8	;	Crystal structure of E. coli RecE exonuclease
2YJV	;	2.8	;	Crystal structure of E. coli regulator of ribonuclease activity A (RraA) bound to fragment of DEAD-box protein RhlB
3KGD	;	1.68	;	Crystal structure of E. coli RNA 3' cyclase
6ZWX	;	2.7	;	Crystal structure of E. coli RNA helicase HrpA
6ZWW	;	3.16	;	Crystal structure of E. coli RNA helicase HrpA in complex with RNA
7AKP	;	2.59	;	Crystal structure of E. coli RNA helicase HrpA-D305A
3K4G	;	2.05	;	Crystal structure of E. coli RNA polymerase alpha subunit C-terminal domain
4JKR	;	4.2	;	Crystal Structure of E. coli RNA Polymerase in complex with ppGpp
2VMK	;	3.3	;	Crystal Structure of E. coli RNase E Apoprotein - Catalytic Domain
2VRT	;	3.5	;	Crystal Structure of E. coli RNase E possessing M1 RNA fragments - Catalytic Domain
6D1Q	;	2.15	;	Crystal structure of E. coli RppH-DapF complex, monomer
6D1V	;	1.81	;	Crystal structure of E. coli RppH-DapF complex, monomer bound to RNA
7W6X	;	3.2	;	Crystal structure of E. coli RseP in complex with batimastat
1QY9	;	2.05	;	Crystal structure of E. coli Se-MET protein YDDE
1LRR	;	2.65	;	CRYSTAL STRUCTURE OF E. COLI SEQA COMPLEXED WITH HEMIMETHYLATED DNA
6R1O	;	2.6	;	Crystal structure of E. coli seryl-tRNA synthetase complexed to a seryl sulfamoyl adenosine derivative
6R1M	;	1.5	;	Crystal structure of E. coli seryl-tRNA synthetase complexed to seryl sulfamoyl adenosine
7AGK	;	2.97	;	Crystal structure of E. coli SF kinase (YihV) in complex with product sulfofructose phosphate (SFP)
7AG1	;	2.0	;	Crystal structure of E. coli SFP aldolase (YihT) from sulfo-EMP pathway
3D1E	;	1.9	;	Crystal structure of E. coli sliding clamp (beta) bound to a polymerase II peptide
3D1F	;	2.0	;	Crystal structure of E. coli sliding clamp (beta) bound to a polymerase III peptide
2UYN	;	1.6	;	Crystal structure of E. coli TdcF with bound 2-ketobutyrate
2UYJ	;	2.35	;	Crystal structure of E. coli TdcF with bound ethylene glycol
2UYP	;	2.44	;	Crystal structure of E. coli TdcF with bound propionate
2UYK	;	1.6	;	Crystal structure of E. coli TdcF with bound serine
3DYR	;	2.0	;	Crystal structure of E. coli thioredoxin mutant I76T in its oxidized form
8OU8	;	2.05	;	Crystal structure of E. coli threonyl tRNA synthetase in complex with a TM84 analogue
4HWO	;	1.907	;	Crystal structure of E. coli Threonyl-tRNA synthetase bound to a novel inhibitor
4HWP	;	1.807	;	Crystal structure of E. coli Threonyl-tRNA synthetase bound to a novel inhibitor
4HWR	;	1.9	;	Crystal structure of E. coli Threonyl-tRNA synthetase bound to a novel inhibitor
4HWS	;	1.7	;	Crystal structure of E. coli Threonyl-tRNA synthetase bound to a novel inhibitor
1KOG	;	3.5	;	Crystal structure of E. coli threonyl-tRNA synthetase interacting with the essential domain of its mRNA operator
8H99	;	1.94	;	Crystal structure of E. coli ThrS catalytic domain mutant
1F4D	;	2.15	;	CRYSTAL STRUCTURE OF E. COLI THYMIDYLATE SYNTHASE C146S, L143C COVALENTLY MODIFIED AT C143 WITH N-[TOSYL-D-PROLINYL]AMINO-ETHANETHIOL
1F4F	;	2.0	;	CRYSTAL STRUCTURE OF E. COLI THYMIDYLATE SYNTHASE COMPLEXED WITH SP-722
1F4G	;	1.75	;	CRYSTAL STRUCTURE OF E. COLI THYMIDYLATE SYNTHASE COMPLEXED WITH SP-876
1F4E	;	1.9	;	CRYSTAL STRUCTURE OF E. COLI THYMIDYLATE SYNTHASE COMPLEXED WITH TOSYL-D-PROLINE
1F4C	;	2.0	;	CRYSTAL STRUCTURE OF E. COLI THYMIDYLATE SYNTHASE COVALENTLY MODIFIED AT C146 WITH N-[TOSYL-D-PROLINYL]AMINO-ETHANETHIOL
3FV5	;	1.8	;	Crystal Structure of E. coli Topoisomerase IV co-complexed with inhibitor
1S16	;	2.1	;	Crystal Structure of E. coli Topoisomerase IV ParE 43kDa subunit complexed with ADPNP
7D8O	;	2.097	;	Crystal structure of E. coli ToxIN type III toxin-antitoxin complex
1X13	;	1.9	;	Crystal structure of E. coli transhydrogenase domain I
1X14	;	1.94	;	Crystal structure of E. coli transhydrogenase domain I with bound NAD
1X15	;	2.04	;	Crystal structure of E. coli transhydrogenase domain I with bound NADH
5HHT	;	1.5	;	Crystal structure of E. coli transketolase triple variant Ser385Tyr/Asp469Thr/Arg520Gln
3ERS	;	1.87	;	Crystal Structure of E. coli Trbp111
4RDH	;	2.1	;	Crystal structure of E. coli tRNA N6-threonylcarbamoyladenosine dehydratase, TcdA
4RDI	;	1.95	;	Crystal structure of E. coli tRNA N6-threonylcarbamoyladenosine dehydratase, TcdA
4D7A	;	1.801	;	Crystal structure of E. coli tRNA N6-threonylcarbamoyladenosine dehydratase, TcdA, in complex with AMP at 1.801 Angstroem resolution
4D79	;	1.768	;	Crystal structure of E. coli tRNA N6-threonylcarbamoyladenosine dehydratase, TcdA, in complex with ATP at 1.768 Angstroem resolution
1SZW	;	2.0	;	Crystal structure of E. coli tRNA pseudouridine synthase TruD
6EI9	;	2.55	;	Crystal structure of E. coli tRNA-dihydrouridine synthase B (DusB)
2C44	;	2.8	;	Crystal Structure of E. coli Tryptophanase
7AP3	;	2.0	;	Crystal structure of E. coli tyrosyl-tRNA synthetase in complex with TyrS7HMDDA
6I5Y	;	1.9	;	Crystal structure of E. coli tyrRS in complex with 5'-O-(N-L-tyrosyl)sulfamoyl-adenosine
6HB5	;	1.88	;	Crystal structure of E. coli tyrRS in complex with 5'-O-(N-L-tyrosyl)sulfamoyl-cytidine
6HB7	;	1.9	;	Crystal structure of E. coli tyrRS in complex with 5'-O-(N-L-tyrosyl)sulfamoyl-N3-methyluridine
6HB6	;	1.92	;	Crystal structure of E. coli tyrRS in complex with 5'-O-(N-L-tyrosyl)sulfamoyl-uridine
1LRJ	;	1.9	;	Crystal Structure of E. coli UDP-Galactose 4-Epimerase Complexed with UDP-N-Acetylglucosamine
5CQB	;	2.2	;	Crystal structure of E. coli undecaprenyl pyrophosphate synthase
3SH0	;	1.84	;	Crystal Structure of E. coli undecaprenyl pyrophosphate synthase in complex with BPH-1065
3SGX	;	2.45	;	Crystal Structure of E. coli undecaprenyl pyrophosphate synthase in complex with BPH-1100
3SGV	;	1.61	;	Crystal Structure of E. coli undecaprenyl pyrophosphate synthase in complex with BPH-1290
3SGT	;	1.85	;	Crystal Structure of E. coli undecaprenyl pyrophosphate synthase in complex with BPH-1299
5CQJ	;	2.15	;	Crystal structure of E. coli undecaprenyl pyrophosphate synthase in complex with clomiphene
3LFU	;	1.8	;	Crystal Structure of E. coli UvrD
7EQJ	;	2.043	;	crystal structure of E. coli Valine tRNA
3GHQ	;	2.7	;	Crystal Structure of E. coli W35F BFR mutant
2RG1	;	1.85	;	Crystal structure of E. coli WrbA apoprotein
4YQE	;	1.33	;	Crystal structure of E. coli WrbA in complex with benzoquinone
2R96	;	2.6	;	Crystal structure of E. coli WrbA in complex with FMN
2R97	;	2.0	;	Crystal structure of E. coli WrbA in complex with FMN
4JLS	;	2.2	;	Crystal Structure of E. coli XGPRT in complex with (3R,4S)-4-(Guanin-9-yl)-3-hydroxypyrrolidin-1-N-ylacetylphosphonic acid
4JIT	;	2.8	;	Crystal Structure of E. coli XGPRT in complex with (S)-3-(Guanin-9-yl)pyrrolidin-N-ylacetylphosphonic acid
5CAJ	;	1.65	;	Crystal structure of E. coli YaaA, a member of the DUF328/UPF0246 family
3QOU	;	1.8	;	Crystal Structure of E. coli YbbN
5DUD	;	2.8	;	Crystal structure of E. coli YbgJK
6NTW	;	2.76	;	Crystal structure of E. coli YcbB
1KK9	;	2.1	;	CRYSTAL STRUCTURE OF E. COLI YCIO
2IGL	;	1.8	;	Crystal Structure of E. coli YEDX, a transthyretin related protein
4LR3	;	2.5	;	Crystal structure of E. coli YfbU at 2.5 A resolution
4PDN	;	1.448	;	Crystal structure of E. coli YfcM
3WTR	;	1.96	;	Crystal structure of E. coli YfcM bound to Co(II)
4YDU	;	2.33	;	Crystal structure of E. coli YgjD-YeaZ heterodimer in complex with ADP
3W7X	;	2.7	;	Crystal structure of E. coli YgjK D324N complexed with melibiose
3W7W	;	2.0	;	Crystal structure of E. coli YgjK E727A complexed with 2-O-alpha-D-glucopyranosyl-alpha-D-galactopyranose
1LN4	;	1.5	;	CRYSTAL STRUCTURE OF E. COLI YHBY
6AL2	;	2.8	;	Crystal structure of E. coli YidC at 2.8 A resolution
1X8D	;	1.8	;	Crystal structure of E. coli YiiL protein containing L-rhamnose
3VGZ	;	1.7	;	Crystal structure of E. coli YncE
3VH0	;	2.9	;	Crystal structure of E. coli YncE complexed with DNA
2EVC	;	1.6	;	Crystal structure of E. Coli. methionine amino peptidase in complex with 5-(2-(trifluoromethyl)phenyl)furan-2-carboxylic acid
1SI8	;	2.3	;	Crystal structure of E. faecalis catalase
4WUH	;	2.294	;	Crystal structure of E. faecalis DNA binding domain LiaR wild type complexed with 22bp DNA
4WU4	;	2.3	;	Crystal structure of E. faecalis DNA binding domain LiaRD191N complexed with 22bp DNA
4WUL	;	2.4	;	Crystal structure of E. faecalis DNA binding domain LiaRD191N complexed with 26bp DNA
4EEQ	;	2.1	;	Crystal structure of E. faecalis DNA ligase with inhibitor
7X5N	;	1.9	;	Crystal structure of E. faecium SHMT in complex with (+)-SHIN-1 and PLP-Ser
7X5O	;	2.62	;	Crystal structure of E. faecium SHMT in complex with Me-THF and PLP-Gly
4DVG	;	2.604	;	Crystal structure of E. histolytica Formin1 bound to EhRho1-GTPgammaS
4MIT	;	2.35	;	Crystal structure of E. histolytica RacC bound to the EhPAK4 PBD
7R0P	;	1.6	;	CRYSTAL STRUCTURE OF E.coli ALCOHOL DEHYDROGENASE - FucO MUTANT F254I COMPLEXED WITH FE, NAD+, AND ETHYLENE GLYCOL
7QNJ	;	1.66	;	CRYSTAL STRUCTURE OF E.coli ALCOHOL DEHYDROGENASE - FucO MUTANT F254I COMPLEXED WITH FE, NAD+, AND GLYCEROL
7R5T	;	1.85	;	CRYSTAL STRUCTURE OF E.coli ALCOHOL DEHYDROGENASE - FucO MUTANT F254I COMPLEXED WITH FE, NADH, AND GLYCEROL
7QNI	;	1.73	;	CRYSTAL STRUCTURE OF E.coli ALCOHOL DEHYDROGENASE - FucO MUTANT L259V
7QLG	;	2.0	;	CRYSTAL STRUCTURE OF E.coli ALCOHOL DEHYDROGENASE - FucO MUTANT L259V COMPLEXED WITH FE, NADH, AND GLYCEROL
7QNF	;	2.14	;	CRYSTAL STRUCTURE OF E.coli ALCOHOL DEHYDROGENASE - FucO MUTANT N151G, L259V COMPLEXED WITH FE, NAD+, AND ETHYLENE GLYCOL
7QLQ	;	2.6	;	CRYSTAL STRUCTURE OF E.coli ALCOHOL DEHYDROGENASE - FucO MUTANT N151G, L259V COMPLEXED WITH FE, NAD, AND DIMETHOXYPHENYL ACETAMIDE
7QLS	;	2.4	;	CRYSTAL STRUCTURE OF E.coli ALCOHOL DEHYDROGENASE - FucO MUTANT N151G, L259V COMPLEXED WITH FE, NADH, AND DIMETHOXYPHENYL ACETAMIDE
7QNH	;	2.2	;	CRYSTAL STRUCTURE OF E.coli ALCOHOL DEHYDROGENASE - FucO MUTANT N151G, L259V COMPLEXED WITH FE, NADH, AND GLYCEROL
7R3D	;	1.4	;	CRYSTAL STRUCTURE OF E.coli ALCOHOL DEHYDROGENASE - FucO MUTANT N151G, L259V COMPLEXED WITH FE, NADH, AND GLYCEROL (Absence of Nicotinamide ring)
4Q4E	;	1.9	;	Crystal structure of E.coli aminopeptidase N in complex with actinonin
4Q4I	;	2.31	;	Crystal structure of E.coli aminopeptidase N in complex with amastatin
5YQ1	;	1.58	;	Crystal structure of E.coli aminopeptidase N in complex with O-Methyl-L-tyrosine
5YQB	;	1.56	;	Crystal structure of E.coli aminopeptidase N in complex with Puromycin
5YQ2	;	1.6	;	Crystal structure of E.coli aminopeptidase N in complex with Puromycin aminonucleoside
1T8S	;	2.6	;	Crystal Structure of E.coli AMP Nucleosidase complexed with formicin 5'-monophosphate
1T8Y	;	3.0	;	Crystal Structure of E.coli AMP Nucleosidase complexed with phosphate
1RTZ	;	1.33	;	CRYSTAL STRUCTURE OF E.COLI APO-HPPK(V83G/DEL84-89) AT 1.33 ANGSTROM RESOLUTION
1TMJ	;	1.45	;	Crystal structure of E.coli apo-HPPK(W89A) at 1.45 Angstrom resolution
4OBY	;	2.574	;	Crystal Structure of E.coli Arginyl-tRNA Synthetase and Ligand Binding Studies Revealed Key Residues in Arginine Recognition
1Z7B	;	2.31	;	Crystal structure of E.coli ArnA dehydrogenase (decarboxylase) domain, R619E mutant
1Z74	;	2.7	;	Crystal Structure of E.coli ArnA dehydrogenase (decarboxylase) domain, R619Y mutant
1YRW	;	1.7	;	Crystal Structure of E.coli ArnA Transformylase Domain
1X29	;	2.2	;	Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid
1X2A	;	2.2	;	Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-D-glutamic acid
1X28	;	2.4	;	Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-L-glutamic acid
7NRE	;	2.3	;	Crystal structure of E.coli BamA beta-barrel in complex with darobactin (crystal form 1)
7NRF	;	2.2	;	Crystal structure of E.coli BamA beta-barrel in complex with darobactin (crystal form 2)
7P1C	;	2.5	;	Crystal structure of E.coli BamA beta-barrel in complex with darobactin B
7R1V	;	2.5	;	Crystal structure of E.coli BamA beta-barrel in complex with dynobactin A
6QGY	;	2.509	;	Crystal structure of E.coli BamA beta-barrel in complex with nanobody B12
6QGW	;	1.938	;	Crystal structure of E.coli BamA beta-barrel in complex with nanobody E6
6QGX	;	2.2	;	Crystal structure of E.coli BamA beta-barrel in complex with nanobody F7
6FSU	;	2.6	;	Crystal structure of E.coli BamA beta-barrel with a C-terminal extension
2XHY	;	2.3	;	Crystal Structure of E.coli BglA
3RV3	;	1.91	;	Crystal structure of E.coli biotin carboxylase in complex with two ADP and one Mg ion
3RUP	;	1.99	;	Crystal structure of E.coli biotin carboxylase in complex with two ADP and two Ca ions
3RV4	;	1.98	;	Crystal structure of E.coli biotin carboxylase R16E mutant in complex with Mg-ADP and bicarbonate
5E6Y	;	2.6	;	Crystal structure of E.Coli branching enzyme in complex with alpha cyclodextrin
8SDB	;	3.0	;	Crystal Structure of E.Coli Branching Enzyme in complex with malto-octose
4LPC	;	2.39	;	Crystal Structure of E.Coli Branching Enzyme in complex with maltoheptaose
4LQ1	;	2.55	;	Crystal Structure of E.Coli Branching Enzyme in complex with maltohexaose
4QDL	;	2.7	;	Crystal structure of E.coli Cas1-Cas2 complex
7EPG	;	1.631	;	Crystal structure of E.coli CcdB mutant S12G
7EPI	;	1.931	;	Crystal structure of E.coli CcdB mutant S60E
7EPJ	;	1.354	;	Crystal structure of E.coli CcdB mutant V46L
1PD5	;	2.5	;	Crystal structure of E.coli chloramphenicol acetyltransferase type I at 2.5 Angstrom resolution
4Y65	;	1.7	;	Crystal structure of E.coli CutA1 C16A/C39A/C79A mutation
4Y6I	;	1.7	;	Crystal structure of E.coli CutA1 E61V/C16A/C39A/C79A mutation
8K6G	;	1.5	;	Crystal structure of E.coli Cyanase
8K6S	;	1.6	;	Crystal structure of E.coli Cyanase complex with bicarbonate
8K6H	;	1.5	;	Crystal structure of e.coli cyanase complex with cyanate
8K6X	;	1.8	;	Crystal structure of E.coli Cyanase complex with cyanate and bicarbonate
3PNK	;	2.21	;	Crystal Structure of E.coli Dha kinase DhaK
3PNM	;	2.55	;	Crystal Structure of E.coli Dha kinase DhaK (H56A)
3PNO	;	1.97	;	Crystal Structure of E.coli Dha kinase DhaK (H56N)
3PNQ	;	2.2	;	Crystal Structure of E.coli Dha kinase DhaK (H56N) complex with Dha
3PNL	;	2.2	;	Crystal Structure of E.coli Dha kinase DhaK-DhaL complex
2ANQ	;	2.13	;	Crystal Structure of E.coli DHFR in complex with NADPH and the inhibitor compound 10a.
2ANO	;	2.68	;	Crystal structure of E.coli dihydrofolate reductase in complex with NADPH and the inhibitor MS-SH08-17
4ML0	;	2.1	;	Crystal structure of E.coli DinJ-YafQ complex
6KZV	;	2.4	;	Crystal structure of E.coli DNA gyrase B in complex with 2-oxo-1,2-dihydroquinoline derivative
6KZX	;	2.1	;	Crystal structure of E.coli DNA gyrase B in complex with 2-oxo-1,2-dihydroquinoline derivative
6KZZ	;	2.0	;	Crystal structure of E.coli DNA gyrase B in complex with 2-oxo-1,2-dihydroquinoline derivative
6L01	;	2.6	;	Crystal structure of E.coli DNA gyrase B in complex with 2-oxo-1,2-dihydroquinoline derivative
7C7N	;	2.3	;	Crystal structure of E.coli DNA gyrase B in complex with 6-fluoro-8-(methylamino)-2-oxo-1,2-dihydroquinoline derivative
7C7O	;	1.8	;	Crystal structure of E.coli DNA gyrase B in complex with 6-fluoro-8-(methylamino)-2-oxo-1,2-dihydroquinoline derivative
3K0S	;	2.2	;	Crystal structure of E.coli DNA mismatch repair protein MutS, D693N mutant, in complex with GT mismatched DNA
4WF4	;	1.7	;	Crystal structure of E.Coli DsbA co-crystallised in complex with compound 4
6XSP	;	2.3	;	Crystal structure of E.coli DsbA in complex with 2-(2,6-bis(3-methoxyphenyl)benzofuran-3-yl)acetic acid
4ZIJ	;	1.78	;	Crystal structure of E.Coli DsbA in complex with 2-(4-iodophenylsulfonamido) benzoic acid
6XSQ	;	2.3	;	Crystal structure of E.coli DsbA in complex with 2-(6-(3-methoxyphenyl)-2-(4-methoxyphenyl)benzofuran-3-yl)acetic acid
6XT3	;	1.99	;	Crystal structure of E.coli DsbA in complex with 3-(3-(carboxymethyl)-6-(3-methoxyphenyl)benzofuran-2-yl)benzoic acid
7LSM	;	1.786	;	Crystal structure of E.coli DsbA in complex with bile salt taurocholate
4WET	;	1.63	;	Crystal structure of E.Coli DsbA in complex with compound 16
4WEY	;	1.55	;	Crystal structure of E.Coli DsbA in complex with compound 17
7S1D	;	1.59	;	Crystal structure of E.coli DsbA in complex with compound MIPS-0001877 (compound 39)
7S1F	;	1.76	;	Crystal structure of E.coli DsbA in complex with compound MIPS-0001886 (compound 38)
7S1L	;	1.623	;	Crystal structure of E.coli DsbA in complex with compound MIPS-0001896 (compound 72)
7S1C	;	1.949	;	Crystal structure of E.coli DsbA in complex with compound MIPS-0001897 (compound 1)
6WHD	;	1.99	;	Crystal structure of E.coli DsbA in complex with diaryl ether analogue 2
8EQR	;	2.29	;	Crystal structure of E.coli DsbA mutant E24A
8EQP	;	2.3	;	Crystal structure of E.coli DsbA mutant E24A/E37A/K58A
8EOC	;	1.47	;	Crystal structure of E.coli DsbA mutant E24A/K58A
8EQQ	;	2.13	;	Crystal structure of E.coli DsbA mutant E37A
8EQO	;	1.62	;	Crystal structure of E.coli DsbA mutant K58A
4WF5	;	1.45	;	Crystal structure of E.Coli DsbA soaked with compound 4
4JX8	;	3.2	;	Crystal Structure of E.coli Enoyl Reductase in Complex with NAD and AEA16
4JQC	;	2.8	;	Crystal Structure of E.coli Enoyl Reductase in Complex with NAD and AFN-1252
3M8J	;	1.4	;	Crystal structure of E.coli FocB at 1.4 A resolution
1K82	;	2.1	;	Crystal structure of E.coli formamidopyrimidine-DNA glycosylase (Fpg) covalently trapped with DNA
4NJN	;	2.4	;	Crystal Structure of E.coli GlpG at pH 4.5
1Q18	;	2.36	;	Crystal structure of E.coli glucokinase (Glk)
3D1J	;	3.0	;	Crystal Structure of E.coli GS mutant dmGS(C7S;C408S)
3COP	;	2.3	;	Crystal Structure of E.coli GS mutant E377A in complex with ADP and acceptor analogue HEPPSO
3CX4	;	2.29	;	Crystal Structure of E.coli GS mutant E377A in complex with ADP and oligosaccharides
2F3R	;	2.5	;	Crystal Structure Of E.coli Guanylate Kinase In Complex With Ap5G
2F3T	;	3.16	;	Crystal Structure Of E.coli Guanylate Kinase In Complex With Ganciclovir monophosphate
2EL9	;	2.7	;	Crystal structure of E.coli Histidyl-tRNA synthetase complexed with a histidyl-adenylate analogue
1G9T	;	2.8	;	CRYSTAL STRUCTURE OF E.COLI HPRT-GMP COMPLEX
2RB9	;	2.0	;	Crystal structure of E.coli HypE
2NYB	;	1.1	;	Crystal structure of E.Coli Iron Superoxide Dismutase Q69E at 1.1 Angstrom resolution
3LVM	;	2.05	;	Crystal Structure of E.coli IscS
3LVL	;	3.0	;	Crystal Structure of E.coli IscS-IscU complex
3LVJ	;	2.435	;	Crystal Structure of E.coli IscS-TusA complex (form 1)
3LVK	;	2.442	;	Crystal Structure of E.coli IscS-TusA complex (form 2)
1HX3	;	2.1	;	CRYSTAL STRUCTURE OF E.COLI ISOPENTENYL DIPHOSPHATE:DIMETHYLALLYL DIPHOSPHATE ISOMERASE
7ZRA	;	2.8	;	Crystal structure of E.coli LexA in complex with nanobody NbSOS1(Nb14497)
7OCJ	;	2.7	;	Crystal structure of E.coli LexA in complex with nanobody NbSOS2(Nb14509)
7B5G	;	2.4	;	Crystal structure of E.coli LexA in complex with nanobody NbSOS3(Nb14527)
5LDM	;	2.46	;	Crystal structure of E.coli LigT complexed with 2'-AMP
5LDO	;	2.752	;	Crystal structure of E.coli LigT complexed with 3'-AMP
5LDK	;	2.099	;	Crystal structure of E.coli LigT complexed with ATP
5LDP	;	1.8	;	Crystal structure of E.coli LigT complexed with ATP
5LDQ	;	1.7	;	Crystal structure of E.coli LigT complexed with NADP+
5LDJ	;	2.802	;	Crystal structure of E.coli LigT complexed with phosphate
5LDI	;	2.1	;	Crystal structure of E.coli LigT in apo form
1RRE	;	1.75	;	Crystal structure of E.coli Lon proteolytic domain
5YZX	;	3.2	;	Crystal structure of E.coli LysU T146D mutant
3FPP	;	2.99	;	Crystal structure of E.coli MacA
3NFC	;	2.0	;	Crystal structure of E.coli MazF Toxin
2JLC	;	2.5	;	Crystal structure of E.coli MenD, 2-succinyl-5-enolpyruvyl-6-hydroxy- 3-cyclohexadiene-1-carboxylate synthase - native protein
2JLA	;	2.81	;	Crystal structure of E.coli MenD, 2-succinyl-5-enolpyruvyl-6-hydroxy- 3-cyclohexadiene-1-carboxylate synthase - SeMet protein
4GDM	;	2.75	;	Crystal Structure of E.coli MenH
4GEC	;	2.5	;	Crystal Structure of E.coli MenH R124A Mutant
4GEG	;	2.49	;	Crystal Structure of E.coli MenH Y85F Mutant
3CES	;	2.412	;	Crystal Structure of E.coli MnmG (GidA), a Highly-Conserved tRNA Modifying Enzyme
6GV1	;	3.4	;	Crystal structure of E.coli Multidrug/H+ antiporter MdfA in outward open conformation with bound Fab fragment
7B6P	;	1.68	;	Crystal structure of E.coli MurE - C269S C340S C450S in complex with Ellman's reagent
7B6O	;	1.86	;	Crystal structure of E.coli MurE mutant - C269S C340S C450S
4YZE	;	2.2	;	Crystal structure of E.coli NemR reduced form
1K4M	;	1.9	;	Crystal structure of E.coli nicotinic acid mononucleotide adenylyltransferase complexed to deamido-NAD
2OZY	;	1.74	;	Crystal structure of E.coli nrfB
3POU	;	2.8	;	Crystal structure of E.coli OmpF porin in lipidic cubic phase: space group H32, large unit cell
3POQ	;	1.9	;	Crystal structure of E.coli OmpF porin in lipidic cubic phase: space group H32, small unit cell
3POX	;	2.0	;	Crystal Structure of E.coli OmpF porin in lipidic cubic phase: space group P1
1PS6	;	2.25	;	Crystal structure of E.coli PdxA
1PS7	;	2.47	;	Crystal structure of E.coli PdxA
1PTM	;	1.96	;	Crystal structure of E.coli PdxA
1LRU	;	2.1	;	Crystal Structure of E.coli Peptide Deformylase Complexed with Antibiotic Actinonin
1JQN	;	2.35	;	Crystal structure of E.coli phosphoenolpyruvate carboxylase in complex with Mn2+ and DCDP
6CCN	;	1.87	;	Crystal structure of E.coli Phosphopantetheine Adenylyltransferase (PPAT/CoaD) in complex with (R)-2,4-dihydroxy-N-(2-(4-hydroxy-1H-benzo[d]imidazol-2-yl)ethyl)-3,3-dimethylbutanamide
6B7F	;	2.562	;	Crystal structure of E.coli Phosphopantetheine Adenylyltransferase (PPAT/CoaD) in complex with (R)-3,3-dimethyl-4-(5-vinyl-1H-imidazol-1-yl)isochroman-1-one
6CCK	;	1.61	;	Crystal structure of E.coli Phosphopantetheine Adenylyltransferase (PPAT/CoaD) in complex with (R)-3-(3-chlorophenyl)-3-((5-methyl-7-oxo-4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)amino)propanenitrile
6B7E	;	2.104	;	Crystal structure of E.coli Phosphopantetheine Adenylyltransferase (PPAT/CoaD) in complex with (R)-4-(5-(difluoromethyl)-1H-imidazol-1-yl)-3,3-dimethylisochroman-1-one
6CCL	;	1.77	;	Crystal structure of E.coli Phosphopantetheine Adenylyltransferase (PPAT/CoaD) in complex with 1-benzyl-1H-imidazo[4,5-b]pyridine
6CCM	;	1.79	;	Crystal structure of E.coli Phosphopantetheine Adenylyltransferase (PPAT/CoaD) in complex with 2-((3-bromobenzyl)amino)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one
6CCQ	;	1.92	;	Crystal structure of E.coli Phosphopantetheine Adenylyltransferase (PPAT/CoaD) in complex with 2-(3-chlorophenethyl)-1H-benzo[d]imidazol-4-ol
6CCS	;	2.06	;	Crystal structure of E.coli Phosphopantetheine Adenylyltransferase (PPAT/CoaD) in complex with 2-(trifluoromethyl)-1H-benzo[d]imidazol-4-ol
6B7A	;	1.991	;	Crystal structure of E.coli Phosphopantetheine Adenylyltransferase (PPAT/CoaD) in complex with 2-methyl-1H-benzo[d]imidazol-4-ol
6CCO	;	1.82	;	Crystal structure of E.coli Phosphopantetheine Adenylyltransferase (PPAT/CoaD) in complex with 3-((1S,2S)-2-(4-hydroxy-1H-benzo[d]imidazol-2-yl)cyclopentyl)benzoic acid
6B7D	;	1.8	;	Crystal structure of E.coli Phosphopantetheine Adenylyltransferase (PPAT/CoaD) in complex with 3-(4-chlorophenyl)-6-methoxy-4,5-dimethylpyridazine
6B7B	;	1.981	;	Crystal structure of E.coli Phosphopantetheine Adenylyltransferase (PPAT/CoaD) in complex with 5-methoxy-2-methyl-1H-indole
6B7C	;	1.564	;	Crystal structure of E.coli Phosphopantetheine Adenylyltransferase (PPAT/CoaD) in complex with N-((1,3-dimethyl-1H-pyrazol-5-yl)methyl)-5-methyl-1H-imidazo[4,5-b]pyridin-2-amine
3K5O	;	2.2	;	Crystal structure of E.coli Pol II
3K5N	;	3.15	;	Crystal structure of E.coli Pol II-abasic DNA binary complex
3K5L	;	2.7	;	Crystal structure of E.coli Pol II-abasic DNA-dATP Lt(0, 3) ternary complex
3K5M	;	2.04	;	Crystal structure of E.coli Pol II-abasic DNA-ddGTP Lt(-2, 2) ternary complex
3K57	;	2.08	;	Crystal structure of E.coli Pol II-normal DNA-dATP ternary complex
3K59	;	1.92	;	Crystal structure of E.coli Pol II-normal DNA-dCTP ternary complex
3MAQ	;	2.4	;	Crystal structure of E.coli Pol II-normal DNA-dGTP ternary complex
3K58	;	2.05	;	Crystal structure of E.coli Pol II-normal DNA-dTTP ternary complex
1G27	;	2.1	;	CRYSTAL STRUCTURE OF E.COLI POLYPEPTIDE DEFORMYLASE COMPLEXED WITH THE INHIBITOR BB-3497
2H5E	;	2.8	;	Crystal structure of E.coli polypeptide release factor RF3
7VKP	;	2.3	;	Crystal structure of E.coli pseudouridine kinase PsuK
7W93	;	1.9	;	Crystal structure of E.coli pseudouridine kinase PsuK complexed with N1-methyl-pseudouridine
7VSK	;	2.31	;	Crystal structure of E.coli pseudouridine kinase PsuK complexed with pseudouridine.
4RJ2	;	0.99	;	Crystal structure of E.coli purine nucleoside phosphorylase at 0.99 A resolution
5IU6	;	2.51	;	Crystal structure of E.coli purine nucleoside phosphorylase with 7-deazahypoxanthine
5I3C	;	2.32	;	Crystal structure of E.coli purine nucleoside phosphorylase with acycloguanosine
2XOV	;	1.65	;	Crystal Structure of E.coli rhomboid protease GlpG, native enzyme
1DFU	;	1.8	;	CRYSTAL STRUCTURE OF E.COLI RIBOSOMAL PROTEIN L25 COMPLEXED WITH A 5S RRNA FRAGMENT AT 1.8 A RESOLUTION
4TOI	;	2.3	;	Crystal structure of E.coli ribosomal protein S2 in complex with N-terminal domain of S1
1WSH	;	1.9	;	Crystal structure of E.coli RNase HI active site mutant (E48A/K87A)
1WSI	;	2.0	;	Crystal structure of E.coli RNase HI active site mutant (E48A/K87A/D134N)
1WSJ	;	2.0	;	Crystal structure of E.coli RNase HI active site mutant (K87A/H124A)
2Z1G	;	2.1	;	Crystal structure of E.coli RNase HI surface charged mutant(Q4R/T40E/Q72H/Q76K/Q80E/T92K/Q105K)
2Z1I	;	2.0	;	Crystal structure of E.coli RNase HI surface charged mutant(Q4R/T40E/Q72H/Q76K/Q80E/T92K/Q105K/Q113R/Q115K)
2Z1J	;	2.38	;	Crystal structure of E.coli RNase HI surface charged mutant(Q4R/T40E/Q72H/Q76K/Q80E/T92K/Q105K/Q113R/Q115K/N143K/T145K)
2Z1H	;	2.6	;	Crystal structure of E.coli RNase HI surface charged mutant(Q4R/T92K/Q105K/Q113R/Q115K/N143K/T145K)
6VCR	;	1.6	;	Crystal structure of E.coli RppH in complex with CTP
6VCQ	;	1.6	;	Crystal structure of E.coli RppH in complex with GTP
6VCO	;	1.7	;	Crystal structure of E.coli RppH in complex with ppcpA
6VCN	;	1.9	;	Crystal structure of E.coli RppH in complex with ppcpG
6VCP	;	1.7	;	Crystal structure of E.coli RppH in complex with UTP
6D13	;	3.06	;	Crystal structure of E.coli RppH-DapF complex
6VCK	;	2.69	;	Crystal structure of E.coli RppH-DapF in complex with GDP, Mg2+ and F-
6VCM	;	2.35	;	Crystal structure of E.coli RppH-DapF in complex with GTP, Mg2+ and F-
6VCL	;	2.06	;	Crystal structure of E.coli RppH-DapF in complex with pppGpp, Mg2+ and F-
2P4B	;	2.4	;	Crystal structure of E.coli RseB
4LTY	;	1.8	;	Crystal Structure of E.coli SbcD at 1.8 A Resolution
4LU9	;	2.5	;	Crystal structure of E.coli SbcD at 2.5 angstrom resolution
4M0V	;	1.83	;	Crystal structure of E.coli SbcD with Mn2+
4ISK	;	1.752	;	Crystal structure of E.coli thymidylate synthase with dUMP and the BGC 945 inhibitor
1XNF	;	1.98	;	Crystal structure of E.coli TPR-protein NlpI
2G2N	;	1.65	;	Crystal Structure of E.coli transthyretin-related protein with bound Zn
2G2P	;	2.1	;	Crystal Structure of E.coli transthyretin-related protein with bound Zn and Br
4CND	;	1.5	;	Crystal structure of E.coli TrmJ
4CNE	;	1.9	;	Crystal structure of E.coli TrmJ in complex with S-adenosyl-L- homocysteine
1T0U	;	2.2	;	Crystal structure of E.coli uridine phosphorylase at 2.2 A resolution (Type-A Native)
1QOJ	;	3.0	;	Crystal Structure of E.coli UvrB C-terminal domain, and a model for UvrB-UvrC interaction.
3C0U	;	2.7	;	Crystal structure of E.coli yaeQ protein
1FUX	;	1.81	;	CRYSTAL STRUCTURE OF E.COLI YBCL, A NEW MEMBER OF THE MAMMALIAN PEBP FAMILY
1FJJ	;	1.66	;	CRYSTAL STRUCTURE OF E.COLI YBHB PROTEIN, A NEW MEMBER OF THE MAMMALIAN PEBP FAMILY
1KON	;	2.2	;	CRYSTAL STRUCTURE OF E.COLI YEBC
4XJ7	;	1.6	;	Crystal Structure of E112A Mutant of Stationary Phase Survival Protein (SurE) from Salmonella typhimurium soaked with AMP
4XH8	;	3.56	;	Crystal Structure of E112A/D230A Mutant of Stationary Phase Survival Protein (SurE) from Salmonella typhimurium
4XGP	;	1.9	;	Crystal Structure of E112A/H234A Mutant of Stationary Phase Survival Protein (SurE) from Salmonella typhimurium co-crystallized and soaked with AMP.
4XGB	;	2.23	;	Crystal Structure of E112A/H234A Mutant of Stationary Phase Survival Protein (SurE) from Salmonella typhimurium co-crystallized with AMP
1SO5	;	1.8	;	Crystal structure of E112Q mutant of 3-keto-L-gulonate 6-phosphate decarboxylase with bound L-threonohydroxamate 4-phosphate
1SO6	;	1.902	;	Crystal structure of E112Q/H136A double mutant of 3-keto-L-gulonate 6-phosphate decarboxylase with bound L-threonohydroxamate 4-phosphate
7MS9	;	2.2	;	Crystal structure of E114D mutant of Cg10062 with a covalent intermediate of the hydration of acetylenecarboxylic acid
1L7G	;	1.85	;	Crystal structure of E119G mutant influenza virus neuraminidase in complex with BCX-1812
2P7Q	;	2.4	;	Crystal structure of E126Q mutant of genomically encoded fosfomycin resistance protein, FosX, from Listeria monocytogenes complexed with MN(II) and 1S,2S-dihydroxypropylphosphonic acid
5ZT5	;	1.9	;	Crystal structure of E134A mutant of phosphomannose isomerase from Salmonella typhimurium
5ZUY	;	2.0	;	Crystal structure of E134H mutant of phosphomannose isomerase from Salmonella typhimurium
6KQC	;	1.7	;	Crystal structure of E136F mutant of Xanthine-guanine phosphoribosyltransferase from Yersinia pestis
2HNY	;	2.5	;	Crystal Structure of E138K Mutant HIV-1 Reverse Transcriptase in Complex with Nevirapine
2HNZ	;	3.0	;	Crystal Structure of E138K Mutant HIV-1 Reverse Transcriptase in Complex with PETT-2
6BNZ	;	1.45	;	Crystal structure of E144Q-glyoxalase I mutant from Zea mays in space group P4(1)2(1)2
2H2S	;	3.1	;	Crystal Structure of E148A mutant of CLC-ec1 in SeCN-
4MB4	;	1.481	;	Crystal structure of E153Q mutant of cold-adapted chitinase from Moritella complex with Nag4
4MB5	;	1.639	;	Crystal structure of E153Q mutant of cold-adapted chitinase from Moritella complex with Nag5
4MB3	;	1.55	;	Crystal structure of E153Q mutant of cold-adapted chitinase from Moritella marina
4DBL	;	3.493	;	Crystal structure of E159Q mutant of BtuCDF
1RCJ	;	1.63	;	Crystal structure of E166A mutant of SHV-1 beta-lactamase with the trans-enamine intermediate of tazobactam
2Y51	;	1.6	;	Crystal structure of E167A mutant of the box pathway encoded ALDH from Burkholderia xenovorans LB400
3NH5	;	2.094	;	Crystal structure of E177A-mutant murine aminoacylase 3
3HCE	;	2.85	;	Crystal Structure of E185D hPNMT in Complex With Octopamine and AdoHcy
3HCA	;	2.4	;	Crystal Structure of E185Q hPNMT in Complex With Octopamine and AdoHcy
4OQ4	;	1.49	;	Crystal Structure of E18A Human DJ-1
3CZA	;	1.2	;	Crystal Structure of E18D DJ-1
3F71	;	1.2	;	Crystal structure of E18D DJ-1 with oxidized C106
3CZ9	;	1.15	;	Crystal Structure of E18L DJ-1
3CYF	;	1.6	;	Crystal Structure of E18N DJ-1
3CY6	;	1.35	;	Crystal Structure of E18Q DJ-1
3EZG	;	1.15	;	Crystal structure of E18Q DJ-1 with oxidized C106
7C6D	;	1.451	;	Crystal structure of E19A mutant chitosanase from Bacillus subtilis MY002 complexed with 6 GlcN.
3PMR	;	2.11	;	Crystal Structure of E2 domain of Human Amyloid Precursor-Like Protein 1
3Q7G	;	2.3	;	Crystal Structure of E2 domain of Human Amyloid Precursor-Like Protein 1 in complex with SOS (sucrose octasulfate)
1SYK	;	2.8	;	Crystal structure of E230Q mutant of cAMP-dependent protein kinase reveals unexpected apoenzyme conformation
1N8F	;	1.75	;	Crystal structure of E24Q mutant of phenylalanine-regulated 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase (DAHP synthase) from Escherichia Coli in complex with Mn2+ and PEP
3D70	;	2.8	;	Crystal structure of E253A mutant of BMRR bound to 22-bp oligonucleotide
3D71	;	2.8	;	Crystal structure of E253Q BMRR bound to 22 base pair promoter site
6MPC	;	1.8	;	Crystal structure of E257A mutant of BlMan5B
2Y53	;	1.4	;	Crystal structure of E257Q mutant of the box pathway encoded ALDH from Burkholderia xenovorans LB400
5ZV0	;	2.1	;	Crystal structure of E264A mutant of phosphomannose isomerase from Salmonella typhimurium
6EV5	;	1.28	;	Crystal structure of E282Q A. niger Fdc1 with prFMN in the hydroxylated form
6XKC	;	2.03	;	Crystal structure of E3 ligase
7JYA	;	2.46	;	Crystal structure of E3 ligase in complex with peptide
5C7M	;	3.03	;	CRYSTAL STRUCTURE OF E3 LIGASE ITCH WITH A UB VARIANT
6DAU	;	2.26	;	Crystal structure of E33Q and E41Q mutant forms of the spermidine/spermine N-acetyltransferase SpeG from Vibrio cholerae
2JKC	;	2.3	;	Crystal Structure of E346D of Tryptophan 7-Halogenase (PrnA)
5JX4	;	1.8	;	Crystal structure of E36-G37del mutant of the Bacillus caldolyticus cold shock protein.
2E6H	;	2.1	;	Crystal structure of E37A mutant of the stationary phase survival protein SurE from Thermus thermophilus HB8 cocrystallized with manganese and AMP
4AI4	;	1.73	;	crystal structure of E38Q mutant of 3-methyladenine DNA glycosylase I from Staphylococcus aureus
2BKG	;	1.9	;	Crystal structure of E3_19 a designed ankyrin repeat protein
4HF2	;	2.99	;	Crystal Structure of E43A IscR mutant bound to its promoter
6KS9	;	2.001	;	Crystal Structure of E447A Acyl-CoA Dehydrogenase FadE5 mutant from Mycobacteria smegmatis
6LQ2	;	1.9	;	Crystal Structure of E447A Acyl-CoA Dehydrogenase FadE5 mutant from Mycobacteria smegmatis in complex with C10CoA
6LQ3	;	2.5	;	Crystal Structure of E447A Acyl-CoA Dehydrogenase FadE5 mutant from Mycobacteria smegmatis in complex with C12CoA
6LQ4	;	2.4	;	Crystal Structure of E447A Acyl-CoA Dehydrogenase FadE5 mutant from Mycobacteria smegmatis in complex with C14CoA
6LQ5	;	1.9	;	Crystal Structure of E447A Acyl-CoA Dehydrogenase FadE5 mutant from Mycobacteria smegmatis in complex with C16CoA
6LQ7	;	1.9	;	Crystal Structure of E447A Acyl-CoA Dehydrogenase FadE5 mutant from Mycobacteria smegmatis in complex with C17CoA
6KSA	;	1.768	;	Crystal Structure of E447A Acyl-CoA Dehydrogenase FadE5 mutant from Mycobacteria smegmatis in complex with C18CoA
6LQ6	;	2.0	;	Crystal Structure of E447A Acyl-CoA Dehydrogenase FadE5 mutant from Mycobacteria smegmatis in complex with C20CoA
6LQ8	;	1.85	;	Crystal Structure of E447A Acyl-CoA Dehydrogenase FadE5 mutant from Mycobacteria smegmatis in complex with C22CoA
6LPY	;	1.9	;	Crystal Structure of E447A Acyl-CoA Dehydrogenase FadE5 mutant from Mycobacteria smegmatis in complex with C4CoA
6LQ0	;	2.2	;	Crystal Structure of E447A Acyl-CoA Dehydrogenase FadE5 mutant from Mycobacteria smegmatis in complex with C6CoA
6LQ1	;	2.8	;	Crystal Structure of E447A Acyl-CoA Dehydrogenase FadE5 mutant from Mycobacteria smegmatis in complex with C8CoA
6KSE	;	1.998	;	Crystal Structure of E447A Acyl-CoA Dehydrogenase FadE5 mutant from Mycobacteria tuberculosisin complex with C18CoA
6KSB	;	1.973	;	Crystal Structure of E447A M130G Acyl-CoA Dehydrogenase FadE5 mutant from Mycobacteria smegmatis in complex with C16CoA
1M2M	;	1.8	;	Crystal structure of E44A/E48A/E56A/D60A mutant of cytochrome b5
1M2I	;	1.8	;	Crystal structure of E44A/E56A mutant of cytochrome b5
3GIN	;	2.4	;	Crystal structure of E454K-CBD1
4WIG	;	1.758	;	Crystal structure of E47D mutant cytidine deaminase from Mycobacterium tuberculosis (MtCDA E47D)
4WIF	;	1.8	;	Crystal structure of E47Q mutant cytidine deaminase from Mycobacterium tuberculosis (MtCDA E47Q)
2Y52	;	1.65	;	Crystal structure of E496A mutant of the box pathway encoded ALDH from Burkholderia xenovorans LB400
1PY0	;	2.0	;	Crystal structure of E51C/E54C Psaz from A.faecalis with CLaNP probe
2VGS	;	2.0	;	Crystal structure of E53QbsSHMT internal aldimine
2VGW	;	1.86	;	Crystal structure of E53QbsSHMT obtained in the presence of glycine and 5-fomyl tetrahydrofolate
2VGV	;	2.3	;	Crystal structure of E53QbsSHMT obtained in the presence of L-allo- Threonine
2VGT	;	1.86	;	Crystal structure of E53QbsSHMT with glycine
2VGU	;	1.8	;	Crystal structure of E53QbsSHMT with L-serine
3FLL	;	1.5	;	Crystal structure of E55Q mutant of nitrophorin 4
4HGQ	;	2.28	;	Crystal structure of E56A mutant of 2-keto-3-deoxy-D-glycero-D-galactonononate-9-phosphate phosphohydrolase from Bacteroides thetaiotaomicron
4HGR	;	2.05	;	Crystal structure of E56A/K67A mutant of 2-keto-3-deoxy-D-glycero-D-galactonononate-9-phosphate phosphohydrolase from Bacteroides thetaiotaomicron
2PPO	;	1.29	;	Crystal structure of E60A mutant of FKBP12
2PPP	;	0.94	;	Crystal structure of E60Q mutant of FKBP12
6KGB	;	1.3	;	Crystal structure of E61K mutated transthyretin
5JTH	;	1.84	;	Crystal structure of E67A calmodulin - CaM:RM20 analog complex
4ETK	;	2.7	;	Crystal Structure of E6A/L130D/A155H variant of de novo designed serine hydrolase, Northeast Structural Genomics Consortium (NESG) Target OR186
4ESS	;	1.9971	;	Crystal Structure of E6D/L155R variant of de novo designed serine hydrolase OSH55, Northeast Structural Genomics Consortium (NESG) Target OR187
4ETJ	;	2.203	;	Crystal Structure of E6H variant of de novo designed serine hydrolase OSH55, Northeast Structural Genomics Consortium (NESG) Target OR185
5KKG	;	2.608	;	Crystal structure of E72A mutant of ancestral protein ancMT of ADP-dependent sugar kinases family
5DPQ	;	1.775	;	Crystal Structure of E72A mutant of domain swapped dimer Human Cellular Retinol Binding Protein
3I95	;	1.4	;	Crystal structure of E76Q mutant PcyA-biliverdin complex
3FPG	;	2.0	;	Crystal Structure of E81Q mutant of MtNAS
3FPH	;	1.8	;	Crystal Structure of E81Q mutant of MtNAS in complex with L-Glutamate
3FPJ	;	1.8	;	Crystal Structure of E81Q mutant of MtNAS in complex with S-ADENOSYLMETHIONINE
4WPU	;	2.26	;	Crystal Structure of E83A mutant of Mtb PEPCK in complex with PEP and GDP
4WPV	;	1.672	;	Crystal Structure of E83A mutant of Mtb PEPCK in complex with Zn2+ and phosphate ion
7C9K	;	2.75	;	Crystal Structure of E84Q mutant of CntL in complex with SAM
7XTJ	;	2.5	;	Crystal structure of E88A mutant of GH3 beta-xylosidase from Aspergillus niger (AnBX)
1TR1	;	2.2	;	CRYSTAL STRUCTURE OF E96K MUTATED BETA-GLUCOSIDASE A FROM BACILLUS POLYMYXA, AN ENZYME WITH INCREASED THERMORESISTANCE
6XNO	;	1.9	;	Crystal structure of E99A mutant of human CEACAM1
8I3G	;	2.4	;	Crystal structure of Eaf3-Eaf7 complex
4HU4	;	2.4	;	Crystal structure of EAL domain of the E. coli DosP - dimeric form
4HU3	;	3.301	;	Crystal structure of EAL domain of the E. coli DosP - monomeric form
4Q6J	;	1.369	;	Crystal Structure of EAL domain Protein from Listeria monocytogenes EGD-e
3TLQ	;	1.91	;	Crystal structure of EAL-like domain protein YdiV
1M9U	;	2.3	;	Crystal Structure of Earthworm Fibrinolytic Enzyme Component A from Eisenia fetida
1YM0	;	2.06	;	Crystal Structure of Earthworm Fibrinolytic Enzyme Component B: a Novel, Glycosylated Two-chained Trypsin
4QNW	;	1.8	;	Crystal structure of EasA, an old yellow enzyme from Aspergillus fumigatus
4NAO	;	1.649	;	Crystal structure of EasH
1ZRL	;	2.3	;	Crystal structure of EBA-175 Region II (RII)
1ZRO	;	2.25	;	Crystal structure of EBA-175 Region II (RII) crystallized in the presence of (alpha)2,3-sialyllactose
2DGJ	;	2.35	;	Crystal structure of EbhA (756-1003 domain) from Staphylococcus aureus
4GAI	;	1.49	;	Crystal structure of EBI-005, a chimera of human IL-1beta and IL-1Ra
4GAF	;	2.15	;	Crystal structure of EBI-005, a chimera of human IL-1beta and IL-1Ra, bound to human Interleukin-1 receptor type 1
7EWY	;	2.01	;	Crystal structure of Ebinur Lake virus cap snatching endonuclease (D79A mutant)
7EWZ	;	2.05	;	Crystal structure of Ebinur Lake virus cap snatching endonuclease (D92A mutant)
7EWV	;	2.61	;	Crystal structure of Ebinur Lake virus cap snatching endonuclease (H34A mutant)
7EX0	;	2.07	;	Crystal structure of Ebinur Lake virus cap snatching endonuclease (K108A mutant)
7EWW	;	2.34	;	Crystal structure of Ebinur Lake virus cap snatching endonuclease (N52A mutant)
7EWX	;	1.95	;	Crystal structure of Ebinur Lake virus cap snatching endonuclease (P78A mutant)
7EWU	;	2.11	;	Crystal structure of Ebinur Lake virus cap snatching endonuclease (WT)
7EX1	;	2.3	;	Crystal structure of Ebinur Lake virus cap snatching endonuclease (Y109A mutant)
7EX6	;	2.18	;	Crystal structure of Ebinur Lake virus cap snatching endonuclease in complex with inhibitor 11
7EX7	;	2.3	;	Crystal structure of Ebinur Lake virus cap snatching endonuclease in complex with inhibitor 16
7EX8	;	1.97	;	Crystal structure of Ebinur Lake virus cap snatching endonuclease in complex with inhibitor 27
7EX9	;	1.75	;	Crystal structure of Ebinur Lake virus cap snatching endonuclease in complex with inhibitor 28
7EX3	;	2.25	;	Crystal structure of Ebinur Lake virus cap snatching endonuclease in complex with inhibitor 3
7EX4	;	2.0	;	Crystal structure of Ebinur Lake virus cap snatching endonuclease in complex with inhibitor 5
7EX2	;	3.1	;	Crystal structure of Ebinur Lake virus cap snatching endonuclease in complex with L-742,001 (methyl ester form)
5JQ3	;	2.23	;	Crystal structure of Ebola glycoprotein
5JQB	;	2.68	;	Crystal structure of Ebola glycoprotein in complex with ibuprofen
5JQ7	;	2.69	;	Crystal structure of Ebola glycoprotein in complex with toremifene
4Z9P	;	1.792	;	Crystal structure of Ebola virus nucleoprotein core domain at 1.8A resolution
6E5X	;	1.5	;	Crystal structure of Ebola virus VP30 C-terminus/RBBP6 peptide complex
4LDB	;	3.1	;	Crystal Structure of Ebola Virus VP40 Dimer
4LDD	;	3.498	;	Crystal Structure of Ebola virus VP40 Hexamer
7M2D	;	2.7	;	Crystal Structure of Ebola zaire Envelope glycoprotein GP in complex with compound ARN0074953
7SSR	;	2.5	;	Crystal Structure of Ebola zaire Envelope glycoprotein GP in complex with compound ARN0075093
7LYD	;	2.35	;	Crystal Structure of Ebola zaire Envelope glycoprotein GP in complex with compound ARN0075146
7LYY	;	2.75	;	Crystal Structure of Ebola zaire Envelope glycoprotein GP in complex with compound ARN0075164
7SSQ	;	2.25	;	Crystal Structure of Ebola zaire Envelope glycoprotein GP in complex with compound ARN0075231
8F87	;	2.6	;	Crystal structure of Ebola Zaire envelope glycoprotein GP in complex with compound ARN75092
6NAE	;	2.75	;	Crystal Structure of Ebola zaire GP protein with bound ARN0074898
6F6S	;	2.29	;	CRYSTAL STRUCTURE OF EBOLAVIRUS GLYCOPROTEIN IN COMPLEX WITH benztropine
6F5U	;	2.07	;	CRYSTAL STRUCTURE OF EBOLAVIRUS GLYCOPROTEIN IN COMPLEX WITH BEPRIDIL
6G9I	;	2.19	;	Crystal structure of Ebolavirus glycoprotein in complex with clomipramine
6G9B	;	2.26	;	Crystal structure of Ebolavirus glycoprotein in complex with imipramine
6HS4	;	2.05	;	Crystal structure of Ebolavirus glycoprotein in complex with inhibitor 118
6HRO	;	2.3	;	Crystal structure of Ebolavirus glycoprotein in complex with inhibitor 118a
6F6I	;	2.4	;	CRYSTAL STRUCTURE OF EBOLAVIRUS GLYCOPROTEIN IN COMPLEX WITH PAROXETINE
6F6N	;	2.15	;	CRYSTAL STRUCTURE OF EBOLAVIRUS GLYCOPROTEIN IN COMPLEX WITH SERTRALINE
6G95	;	2.31	;	Crystal structure of Ebolavirus glycoprotein in complex with thioridazine
7JPH	;	3.195	;	Crystal structure of EBOV glycoprotein with modified HR1c and HR2 stalk at 3.2 A resolution
7JPI	;	2.28	;	Crystal structure of EBOV glycoprotein with modified HR2 stalk at 2.3A resolution
7BFB	;	2.05	;	Crystal structure of ebselen covalently bound to the main protease (3CLpro/Mpro) of SARS-CoV-2.
7D5Z	;	4.2	;	Crystal structure of EBV gH/gL bound with neutralizing antibody 1D8
5W0K	;	3.1	;	Crystal structure of EBV gHgL/CL40/gp42 N-domain
5T1D	;	3.1	;	Crystal structure of EBV gHgL/gp42/E1D1 complex
5KDM	;	3.5	;	Crystal structure of EBV tegument protein BNRF1 in complex with histone chaperone DAXX and histones H3.3-H4
2Z0L	;	2.9	;	Crystal structure of EBV-DNA polymerase accessory protein BMRF1
1K77	;	1.63	;	Crystal Structure of EC1530, a Putative Oxygenase from Escherichia coli
3MEP	;	2.3	;	Crystal Structure of ECA2234 protein from Erwinia carotovora, Northeast Structural Genomics Consortium Target EwR44
2QHD	;	1.95	;	Crystal structure of ecarpholin S (ser49-PLA2) complexed with fatty acid
3BJW	;	2.3	;	Crystal Structure of ecarpholin S complexed with suramin
3X3N	;	2.0	;	Crystal structure of EccB1 of Mycobacterium tuberculosis in spacegroup P21
5EBC	;	3.0	;	Crystal structure of EccB1 of Mycobacterium tuberculosis in spacegroup P21 (state III)
5EBD	;	2.6	;	Crystal structure of EccB1 of Mycobacterium tuberculosis in spacegroup P21 (state IV)
3X3M	;	1.9	;	Crystal structure of EccB1 of Mycobacterium tuberculosis in spacegroup P212121
8D10	;	1.6	;	Crystal Structure of EcDsbA in a complex with (1-methyl-1H-pyrazol-5-yl)methanamine
8D12	;	1.6	;	Crystal Structure of EcDsbA in a complex with 1-methyl-1H-pyrazol-4-amine
8D11	;	1.85	;	Crystal Structure of EcDsbA in a complex with 1-methyl-1H-pyrazol-5-amine
8CXE	;	1.47	;	Crystal Structure of EcDsbA in a complex with 1H-imidazole
8CZN	;	1.7	;	Crystal Structure of EcDsbA in a complex with 1H-pyrrole-3-carboxylic acid
7L7C	;	1.8	;	Crystal Structure of EcDsbA in a complex with 2-(6-(3-Methoxyphenyl)benzofuran-3-yl)acetic acid
7L76	;	1.83	;	Crystal Structure of EcDsbA in a complex with 2-(6-Phenylbenzofuran-3-yl)acetic acid
8CZM	;	1.8	;	Crystal Structure of EcDsbA in a complex with 4-bromo-1H-pyrazole
8DG1	;	1.95	;	Crystal Structure of EcDsbA in a complex with DMSO
8DG2	;	1.95	;	Crystal Structure of EcDsbA in a complex with DMSO
7LHP	;	1.9	;	Crystal Structure of EcDsbA in a complex with methyl 2-(6-bromo-2-phenylbenzofuran-3-yl)acetate
8CXD	;	1.8	;	Crystal Structure of EcDsbA in a complex with phenylmethanol
6PC9	;	2.3	;	Crystal Structure of EcDsbA in a complex with purified methylpiperazinone 6
6PBI	;	1.9	;	Crystal Structure of EcDsbA in a complex with purified morpholine 8
6PD7	;	1.92	;	Crystal Structure of EcDsbA in a complex with purified morpholine carboxylic acid 7
6PLI	;	1.93	;	Crystal Structure of EcDsbA in a complex with purified oxadiazole 11
6PDH	;	1.96	;	Crystal Structure of EcDsbA in a complex with purified pyrazole 9
6PGJ	;	1.9	;	Crystal Structure of EcDsbA in a complex with unpurified reaction product A5 (Morpholine carboxylic acid 7)
6PG1	;	2.01	;	Crystal Structure of EcDsbA in a complex with unpurified reaction product F1 (methylpiperazinone 6)
6PIQ	;	2.1	;	Crystal Structure of EcDsbA in a complex with unpurified reaction product G6 (pyrazole 9)
6PG2	;	1.91	;	Crystal Structure of EcDsbA in a complex with unpurified reaction product H5 (morpholine 8)
8DG0	;	2.5	;	Crystal Structure of EcDsbA in a complex with Urea
6POH	;	1.67	;	Crystal Structure of EcDsbA in complex alkyl ether 21
6PML	;	2.0	;	Crystal Structure of EcDsbA in complex benzyl ether 23
6POI	;	1.77	;	Crystal Structure of EcDsbA in complex phenyl ether 25
6PMF	;	1.95	;	Crystal Structure of EcDsbA in complex with aniline 15
6POQ	;	1.8	;	Crystal Structure of EcDsbA in complex with anisidine 16
6FNP	;	3.4	;	Crystal structure of ECF-CbrT, a cobalamin transporter
4ZIR	;	3.0	;	Crystal structure of EcfAA' heterodimer bound to AMPPNP
4PPL	;	2.2	;	Crystal structure of eCGP123 H193Q variant at pH 7.5
4PPK	;	2.0	;	Crystal structure of eCGP123 T69V variant at pH 7.5
4TZG	;	2.1	;	Crystal structure of eCGP123, an extremely thermostable green fluorescent protein
6WYI	;	1.915	;	Crystal structure of EchA19, enoyl-CoA hydratase from Mycobacterium tuberculosis
1OZ7	;	2.4	;	Crystal structure of Echicetin from the venom of Indian saw-scaled viper (Echis carinatus) at 2.4 resolution
2ADW	;	1.6	;	Crystal structure of Echinomycin-(ACGTACGT)2 solved by SAD
5YTY	;	1.58	;	Crystal structure of echinomycin-d(ACGACGT/ACGTCGT) complex
5YTZ	;	1.55	;	Crystal structure of echinomycin-d(ACGTCGT)2 complex
6LSQ	;	1.8	;	Crystal structure of Echistatin, an RGD-containing short disintegrin
5VM2	;	1.983	;	Crystal structure of ECK1772, an oxidoreductase/dehydrogenase of unknown specificity involved in membrane biogenesis from Escherichia coli
7V09	;	2.0	;	Crystal structure of ECL_RS08780, putative sugar transport system periplasmic sugar-binding protein
6WL5	;	1.4	;	Crystal structure of EcmrR C-terminal domain
5E6Z	;	1.878	;	Crystal structure of Ecoli Branching Enzyme with beta cyclodextrin
5E70	;	2.33	;	Crystal structure of Ecoli Branching Enzyme with gamma cyclodextrin
7YQN	;	1.6	;	Crystal structure of Ecoli malate synthase G
2UVN	;	3.0	;	Crystal structure of econazole-bound CYP130 from Mycobacterium tuberculosis
1EZS	;	2.3	;	CRYSTAL STRUCTURE OF ECOTIN MUTANT M84R, W67A, G68A, Y69A, D70A BOUND TO RAT ANIONIC TRYPSIN II
8W7D	;	2.81	;	Crystal structure of EcPPAT-FR901483 complex
6NA5	;	1.75	;	Crystal Structure of ECR in complex with NADP+
4MHR	;	2.1	;	Crystal structure of EctD from S. alaskensis in its apoform
4Q5O	;	2.64	;	Crystal structure of EctD from S. alaskensis with 2-oxoglutarate and 5-hydroxyectoine
4MHU	;	2.56	;	Crystal structure of EctD from S. alaskensis with bound Fe
4HWB	;	2.61	;	Crystal structure of ectodomain 3 of the IL-13 receptor alpha 1 in complex with a human neutralizing monoclonal antibody fragment
4HWE	;	2.43	;	Crystal structure of ectodomain 3 of the IL-13 receptor alpha1 in complex with a human neutralizing monoclonal antibody fragment
3MQ7	;	2.28	;	Crystal Structure of Ectodomain Mutant of BST-2/Tetherin/CD317
3MQ9	;	2.8	;	Crystal Structure of Ectodomain Mutant of BST-2/Tetherin/CD317 Fused to MBP
3MQB	;	3.2	;	Crystal Structure of Ectodomain of BST-2/Tetherin/CD317 (C2)
3MQC	;	2.8	;	Crystal Structure of Ectodomain of BST-2/Tetherin/CD317 (P21)
5ONM	;	1.52	;	Crystal Structure of Ectoine Synthase from P. lautus
5ONN	;	1.4	;	Crystal Structure of Ectoine Synthase from P. lautus
5ONO	;	2.5	;	Crystal Structure of Ectoine Synthase from P. lautus
6F2T	;	2.4	;	Crystal structure of ectonucleotide phosphodiesterase/pyrophosphatase-3 (NPP3)
6F2V	;	2.5	;	Crystal structure of ectonucleotide phosphodiesterase/pyrophosphatase-3 (NPP3) in complex with AMP
6F33	;	3.0	;	Crystal structure of ectonucleotide phosphodiesterase/pyrophosphatase-3 (NPP3) in complex with AMPNPP
6F2Y	;	2.4	;	Crystal structure of ectonucleotide phosphodiesterase/pyrophosphatase-3 (NPP3) in complex with Ap4A
6F30	;	2.3	;	Crystal structure of ectonucleotide phosphodiesterase/pyrophosphatase-3 (NPP3) in complex with UDPGlcNAc
3DXX	;	2.05	;	Crystal structure of EcTrmB
3DXZ	;	1.58	;	Crystal structure of EcTrmB in complex with SAH
3DXY	;	1.5	;	Crystal structure of EcTrmB in complex with SAM
2GRK	;	2.6	;	Crystal structure of ectromelia virus EVM1 chemokine binding protein
1KZJ	;	2.6	;	Crystal Structure of EcTS W80G/dUMP/CB3717 Complex
1KZI	;	1.75	;	Crystal Structure of EcTS/dUMP/THF Complex
3HB1	;	2.51	;	Crystal structure of ed-eya2 complexed with Alf3
1RJ7	;	2.3	;	Crystal structure of EDA-A1
6G3E	;	1.9	;	Crystal structure of EDDS lyase in complex with formate
6G3F	;	2.222	;	Crystal structure of EDDS lyase in complex with fumarate
6G3I	;	2.41	;	Crystal structure of EDDS lyase in complex with N-(2-aminoethyl)aspartic acid (AEAA)
6G3H	;	2.269	;	Crystal structure of EDDS lyase in complex with SS-EDDS
6G3G	;	2.606	;	Crystal structure of EDDS lyase in complex with succinate
4U4N	;	3.1	;	Crystal structure of Edeine bound to the yeast 80S ribosome
3GEB	;	2.4	;	Crystal Structure of edeya2
3VLA	;	0.95	;	Crystal structure of edgp
3GH9	;	1.69	;	Crystal structure of EDTA-treated BdbD (Oxidised)
5U5K	;	2.33	;	Crystal structure of EED in complex with 3-(3-methoxybenzyl)piperidine hydrochloride
5U5H	;	1.8	;	Crystal structure of EED in complex with 6-(2-fluoro-5-methoxybenzyl)-1-isopropyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3-amine 6-(2-fluoro-5-methoxybenzyl)-1-isopropyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3-amine
3IIY	;	2.65	;	Crystal structure of Eed in complex with a trimethylated histone H1K26 peptide
3IIW	;	1.8	;	Crystal structure of Eed in complex with a trimethylated histone H3K27 peptide
3IJ0	;	2.45	;	Crystal structure of Eed in complex with a trimethylated histone H3K9 peptide
3IJ1	;	2.1	;	Crystal structure of Eed in complex with a trimethylated histone H4K20 peptide
4X3E	;	2.3	;	Crystal structure of EED in complex with a trimethylated Jarid2 peptide
5WP3	;	2.55	;	Crystal Structure of EED in complex with EB22
6LO2	;	2.21	;	Crystal structure of EED in complex with EZH2 peptide and compound 11#
5U5T	;	1.6	;	Crystal structure of EED in complex with H3K27Me3 peptide and 3-(benzo[d][1,3]dioxol-4-ylmethyl)piperidine-1-carboximidamide
5U62	;	1.9	;	Crystal structure of EED in complex with H3K27Me3 peptide and 6-(benzo[d][1,3]dioxol-4-ylmethyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3-amine
3IJC	;	1.95	;	Crystal structure of Eed in complex with NDSB-195
6V3Y	;	1.63	;	Crystal structure of EED in complex with PALI1-K1219me3 peptide
6V3X	;	1.7	;	Crystal structure of EED in complex with PALI1-K1241me3 peptide
5TTW	;	1.74	;	Crystal Structure of EED in Complex with UNC4859
7SI5	;	1.75	;	CRYSTAL STRUCTURE OF EED WITH MRTX-1919
7SI4	;	1.9	;	CRYSTAL STRUCTURE OF EED WITH MRTX-2219
5WUK	;	2.03	;	Crystal structure of EED [G255D] in complex with EZH2 peptide and EED226 compound
2DY1	;	1.6	;	Crystal structure of EF-G-2 from Thermus thermophilus
5H0P	;	1.862	;	Crystal structure of EF-hand protein mutant
3WND	;	1.55	;	Crystal structure of EF-Pyl
3WNC	;	1.9	;	Crystal structure of EF-Pyl in complex with GDP
3WNB	;	1.7	;	Crystal structure of EF-Pyl in complex with GMPPNP
6MIJ	;	1.955	;	Crystal structure of EF-Tu from Acinetobacter baumannii in complex with Mg2+ and GDP
7VMC	;	3.413	;	Crystal structure of EF-Tu/CdiA/CdiI
3HRA	;	1.693	;	Crystal Structure of EF0377 an Ankyrin Repeat Protein
3D5R	;	2.1	;	Crystal Structure of Efb-C (N138A) / C3d Complex
3D5S	;	2.3	;	Crystal Structure of Efb-C (R131A) / C3d Complex
2GOX	;	2.2	;	Crystal structure of Efb-C / C3d Complex
2GOM	;	1.25	;	Crystal structure of Efb-C from Staphylococcus aureus
3I2W	;	2.67	;	Crystal structure of EFC/F-BAR domain of Drosophila Syndapin/PACSIN
3O72	;	1.95	;	Crystal structure of EfeB in complex with heme
6JBO	;	1.88	;	Crystal structure of EfeO-like protein Algp7 containing samarium ion
5Y4C	;	2.701	;	Crystal structure of EfeO-like protein Algp7 in complex with a metal ion
3HGK	;	3.3	;	crystal structure of effect protein AvrptoB complexed with kinase Pto
3BXE	;	1.8	;	Crystal structure of effector binding domain of central glycolytic gene regulator (CggR) from Bacillus subtilis in complex with dihydroxyacetone phosphate
3BXF	;	1.7	;	Crystal structure of effector binding domain of central glycolytic gene regulator (CggR) from Bacillus subtilis in complex with effector fructose-1,6-bisphosphate
3BXH	;	1.85	;	Crystal structure of effector binding domain of central glycolytic gene regulator (CggR) from Bacillus subtilis in complex with fructose-6-phosphate
3BXG	;	1.8	;	Crystal structure of effector binding domain of central glycolytic gene regulator (CggR) from Bacillus subtilis in complex with glucose-6-phosphate
6BWS	;	1.65	;	Crystal structure of Efga from Methylobacterium extorquens
6C0Z	;	1.83	;	Crystal structure of Efga from Methylobacterium extorquens in complex with formaldehyde
6AGH	;	2.742	;	Crystal structure of EFHA1 in Apo-State
6AGJ	;	2.999	;	Crystal Structure of EFHA2 in Apo State
6AGI	;	2.799	;	Crystal Structure of EFHA2 in Ca-binding State
3RCM	;	2.05	;	crystal structure of EFI target 500140:TatD family hydrolase from Pseudomonas putida
4GFI	;	1.9	;	Crystal structure of EFI-502318, an enolase family member from Agrobacterium tumefaciens with homology to dipeptide epimerases (bound sodium, L-Ala-L-Glu with ordered loop)
4N5A	;	3.204	;	Crystal structure of Efr3
3PM7	;	2.001	;	Crystal Structure of EF_3132 protein from Enterococcus faecalis at the resolution 2A, Northeast Structural Genomics Consortium Target EfR184
4L1I	;	1.2	;	Crystal structure of EGFP-based Calcium Sensor CatchER complexed with Ca
4L12	;	1.78	;	Crystal structure of EGFP-based Calcium Sensor CatchER complexed with Gd
5ZWJ	;	2.9	;	Crystal structure of EGFR 675-1022 T790M/C797S/V948R in complex with EAI045
6JWL	;	2.551	;	Crystal structure of EGFR 696-1022 L858R in complex with AZD9291
5XDL	;	2.7	;	Crystal structure of EGFR 696-1022 L858R in complex with CO-1686
4R5S	;	3.001	;	Crystal structure of EGFR 696-1022 L858R in complex with FIIN-3
5X26	;	2.951	;	Crystal structure of EGFR 696-1022 L858R in complex with SKLB(3)
5X27	;	2.952	;	Crystal structure of EGFR 696-1022 L858R in complex with SKLB(5)
5X28	;	2.952	;	Crystal structure of EGFR 696-1022 L858R in complex with SKLB(6)
6JX0	;	2.53	;	Crystal structure of EGFR 696-1022 T790M in complex with AZD9291 prepared by co-crystallization
6JX4	;	2.531	;	Crystal structure of EGFR 696-1022 T790M in complex with AZD9291 prepared by soaking
5XDK	;	2.346	;	Crystal structure of EGFR 696-1022 T790M in complex with CO-1686
5XGM	;	2.952	;	Crystal structure of EGFR 696-1022 T790M in complex with Go6976
5YU9	;	1.95	;	Crystal structure of EGFR 696-1022 T790M in complex with Ibrutinib
5GTZ	;	2.999	;	Crystal structure of EGFR 696-1022 T790M in complex with JTS-1-39
5GTY	;	3.14	;	Crystal structure of EGFR 696-1022 T790M in complex with LXX-6-26
4WD5	;	3.3	;	Crystal structure of EGFR 696-1022 T790M in complex with QL-X138
5X2K	;	3.201	;	Crystal structure of EGFR 696-1022 T790M in complex with WZ4003
5GMP	;	2.797	;	Crystal structure of EGFR 696-1022 T790M in complex with XTF-262
3IKA	;	2.9	;	Crystal Structure of EGFR 696-1022 T790M Mutant Covalently Binding to WZ4002
5ZTO	;	2.649	;	Crystal structure of EGFR 696-1022 T790M/C797S in complex with D3003
5XGN	;	3.0	;	Crystal structure of EGFR 696-1022 T790M/C797S in complex with Go6976
7ER2	;	2.662	;	Crystal structure of EGFR 696-1022 T790M/C797S in complex with LS_2_40
5X2A	;	1.85	;	Crystal structure of EGFR 696-1022 T790M/V948R in complex with SKLB(3)
5X2C	;	2.05	;	Crystal structure of EGFR 696-1022 T790M/V948R in complex with SKLB(5)
5X2F	;	2.2	;	Crystal structure of EGFR 696-1022 T790M/V948R in complex with SKLB(6)
4ZSE	;	1.97	;	Crystal structure of EGFR 696-1022 T790M/V948R, crystal form II
6JXT	;	2.307	;	Crystal structure of EGFR 696-1022 WT in complex with AZD9291 prepared by cocrystallization
5GNK	;	1.796	;	Crystal structure of EGFR 696-988 T790M in complex with LXX-6-34
7OXB	;	2.56	;	Crystal structure of EGFR double mutant (T790M/L858R) in complex with compound 6.
6P1L	;	2.8	;	Crystal structure of EGFR in complex with EAI045
5UWD	;	3.06	;	Crystal structure of EGFR kinase domain (L858R, T790M, V948R) in complex with the covalent inhibitor CO-1686
2ITP	;	2.74	;	Crystal structure of EGFR kinase domain G719S mutation in complex with AEE788
2ITQ	;	2.68	;	Crystal structure of EGFR kinase domain G719S mutation in complex with AFN941
2ITN	;	2.47	;	Crystal structure of EGFR kinase domain G719S mutation in complex with AMP-PNP
2ITO	;	3.25	;	Crystal structure of EGFR kinase domain G719S mutation in complex with Iressa
5U8L	;	1.6	;	Crystal structure of EGFR kinase domain in complex with a sulfonyl fluoride probe XO44
2J6M	;	3.1	;	Crystal structure of EGFR kinase domain in complex with AEE788
2ITW	;	2.88	;	Crystal structure of EGFR kinase domain in complex with AFN941
2ITX	;	2.98	;	Crystal structure of EGFR kinase domain in complex with AMP-PNP
2J5E	;	3.1	;	Crystal structure of EGFR kinase domain in complex with an irreversible inhibitor 13-jab
2J5F	;	3.0	;	Crystal structure of EGFR kinase domain in complex with an irreversible inhibitor 34-jab
4JQ7	;	2.73	;	Crystal structure of EGFR kinase domain in complex with compound 2a
4JR3	;	2.7	;	Crystal structure of EGFR kinase domain in complex with compound 3g
4JQ8	;	2.83	;	Crystal structure of EGFR kinase domain in complex with compound 4b
4JRV	;	2.8	;	Crystal structure of EGFR kinase domain in complex with compound 4c
6JZ0	;	2.86	;	Crystal structure of EGFR kinase domain in complex with compound 78
2ITY	;	3.42	;	Crystal structure of EGFR kinase domain in complex with Iressa
4ZJV	;	2.7	;	crystal structure of EGFR kinase domain in complex with Mitogen-inducible gene 6 protein
2ITT	;	2.73	;	Crystal structure of EGFR kinase domain L858R mutation in complex with AEE788
2ITU	;	2.8	;	Crystal structure of EGFR kinase domain L858R mutation in complex with AFN941
2ITV	;	2.47	;	Crystal structure of EGFR kinase domain L858R mutation in complex with AMP-PNP
2ITZ	;	2.8	;	Crystal structure of EGFR kinase domain L858R mutation in complex with Iressa
2JIT	;	3.1	;	Crystal structure of EGFR kinase domain T790M mutation
2JIV	;	3.5	;	Crystal structure of EGFR kinase domain T790M mutation in compex with HKI-272
2JIU	;	3.05	;	Crystal structure of EGFR kinase domain T790M mutation in complex with AEE788
8DSW	;	2.39	;	Crystal structure of EGFR kinase domain, Exon20 Insertion FQEA mutant
4G5J	;	2.8	;	Crystal structure of EGFR kinase in complex with BIBW2992
4G5P	;	3.17	;	Crystal structure of EGFR kinase T790M in complex with BIBW2992
8D76	;	2.4	;	Crystal Structure of EGFR LRTM with compound 24
8D73	;	2.17	;	Crystal Structure of EGFR LRTM with compound 7
5Y9T	;	3.25	;	Crystal Structure of EGFR T790M mutant in complex with naquotinib
8H7X	;	3.404	;	Crystal structure of EGFR T790M/C797S mutant in complex with brigatinib
6TFU	;	2.0	;	Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 14d
6TFV	;	1.5	;	Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 18b
6TFY	;	1.7	;	Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 18c
6TFW	;	2.0	;	Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 18d
6TFZ	;	1.8	;	Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 19
6TG0	;	1.5	;	Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 21a
6TG1	;	1.6	;	Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 21b
5JEB	;	3.298	;	Crystal structure of EGFR tyrosine kinase domain with novel inhibitor of active state of HER2
6P1D	;	2.4	;	Crystal structure of EGFR with mutant-selective dihydrodibenzodiazepinone allosteric inhibitor
6LUB	;	2.315	;	Crystal Structure of EGFR(L858R/T790M/C797S) in complex with CH7233163
6LUD	;	2.05	;	Crystal Structure of EGFR(L858R/T790M/C797S) in complex with Osimertinib
6WA2	;	2.4	;	Crystal structure of EGFR(T790M/V948R) in complex with LN3753
7ZYM	;	2.5	;	Crystal Structure of EGFR-T790M/C797S in Complex with Brigatinib
6S89	;	2.701	;	Crystal Structure of EGFR-T790M/C797S in Complex with Covalent Pyrrolopyrimidine 19g
6S8A	;	2.6	;	Crystal Structure of EGFR-T790M/C797S in Complex with Covalent Pyrrolopyrimidine 19h
7ZYP	;	2.8	;	Crystal Structure of EGFR-T790M/C797S in Complex with Reversible Aminopyrimidine 9
7ZYN	;	2.3	;	Crystal Structure of EGFR-T790M/C797S in Complex with WZ4002
7A6I	;	2.4	;	Crystal Structure of EGFR-T790M/V948R in Complex with LDC8201
6Z4D	;	2.0	;	Crystal Structure of EGFR-T790M/V948R in Complex with Mavelertinib and EAI001
6Z4B	;	2.5	;	Crystal Structure of EGFR-T790M/V948R in Complex with Osimertinib and EAI045
7A6J	;	2.0	;	Crystal Structure of EGFR-T790M/V948R in Complex with Poziotinib
7ZYQ	;	2.1	;	Crystal Structure of EGFR-T790M/V948R in Complex with Reversible Aminopyrimidine 13
7A2A	;	1.9	;	Crystal Structure of EGFR-T790M/V948R in Complex with Spebrutinib and EAI001
7A6K	;	2.0	;	Crystal Structure of EGFR-T790M/V948R in Complex with TAK-788
7B85	;	2.5	;	Crystal Structure of EGFR-WT in Complex with TAK-788
7T4J	;	2.2	;	Crystal Structure of EGFR_D770_N771insNPG/V948R in complex with TAK-788
8HV5	;	2.2	;	Crystal structure of EGFR_DMX in complex with compound 7
8HV1	;	2.4	;	Crystal structure of EGFR_DMX in complex with covalently bound fragment 1
8HV3	;	2.4	;	Crystal structure of EGFR_DMX in complex with covalently bound fragment 4
8HVA	;	2.77	;	Crystal structure of EGFR_TMX in complex with covalently bound compound 14
8HV8	;	2.4	;	Crystal structure of EGFR_TMX in complex with covalently bound fragment 10
8HV9	;	2.5	;	Crystal structure of EGFR_TMX in complex with covalently bound fragment 12
8HV4	;	2.2	;	Crystal structure of EGFR_TMX in complex with covalently bound fragment 4
8HV6	;	2.2	;	Crystal structure of EGFR_TMX in complex with covalently bound fragment 8
8HV7	;	2.69	;	Crystal structure of EGFR_TMX in complex with covalently bound fragment 9
8HV2	;	2.8	;	Crystal structure of EGFR_wt in complex with covalently bound fragment 4
4XPM	;	2.4	;	Crystal structure of EGO-TC
4FTX	;	2.1	;	Crystal structure of Ego3 homodimer
4FUW	;	2.6	;	Crystal structure of Ego3 mutant
6JWP	;	3.2	;	crystal structure of EGOC
6RFK	;	1.6	;	Crystal structure of EGRCK-inhibited Gla-domainless fIXa (K148Q, R150Q variant)
7TXK	;	1.78	;	Crystal structure of EgtU solute binding domain from Streptococcus pneumoniae D39 in complex with L-ergothioneine
7TXL	;	2.44	;	Crystal structure of EgtU solute binding domain from Streptococcus pneumoniae D39 in complex with L-ergothioneine
1QU1	;	1.9	;	CRYSTAL STRUCTURE OF EHA2 (23-185)
3NCW	;	2.8	;	Crystal structure of EHEC O157:H7 intimin
3NCX	;	2.6	;	Crystal structure of EHEC O157:H7 intimin mutant
6BY9	;	2.3	;	Crystal structure of EHMT1
7DCF	;	1.8	;	Crystal structure of EHMT2 SET domain in complex with compound 10
7BUC	;	2.6	;	Crystal structure of EHMT2 SET domain in complex with compound 13
7BTV	;	2.0	;	Crystal structure of EHMT2 SET domain in complex with compound 5.
2NOJ	;	2.7	;	Crystal structure of Ehp / C3d complex
3REG	;	1.801	;	Crystal structure of EhRho1 bound to a GTP analog and Magnesium
3REF	;	1.95	;	Crystal structure of EhRho1 bound to GDP and Magnesium
5F3O	;	2.05	;	Crystal structure of EhRNaseIII229 from Entamoeba histolytica complexed with Mn2+
2Q88	;	1.9	;	Crystal structure of EhuB in complex with ectoine
2Q89	;	2.3	;	Crystal structure of EhuB in complex with hydroxyectoine
4GPR	;	1.6	;	Crystal structure of EhUbc5, a ubiquitin conjugating enzyme from Entamoeba histolytica
1P72	;	2.1	;	Crystal structure of EHV4-TK complexed with Thy and ADP
1P6X	;	2.0	;	Crystal structure of EHV4-TK complexed with Thy and SO4
1P73	;	2.7	;	Crystal structure of EHV4-TK complexed with TP4A
1P75	;	3.02	;	Crystal structure of EHV4-TK complexed with TP5A
3WMJ	;	1.998	;	Crystal structure of EIAV vaccine gp45
3WMI	;	1.9	;	Crystal structure of EIAV wild type gp45
1IGX	;	3.1	;	Crystal Structure of Eicosapentanoic Acid Bound in the Cyclooxygenase Channel of Prostaglandin Endoperoxide H Synthase-1.
1ZXE	;	2.6	;	Crystal Structure of eIF2alpha Protein Kinase GCN2: D835N Inactivating Mutant in Apo Form
1ZY5	;	2.0	;	Crystal Structure of eIF2alpha Protein Kinase GCN2: R794G Hyperactivating Mutant Complexed with AMPPNP.
1ZY4	;	1.95	;	Crystal Structure of eIF2alpha Protein Kinase GCN2: R794G Hyperactivating Mutant in Apo Form.
1ZYD	;	2.75	;	Crystal Structure of eIF2alpha Protein Kinase GCN2: Wild-Type Complexed with ATP.
1ZYC	;	3.0	;	Crystal Structure of eIF2alpha Protein Kinase GCN2: Wild-Type in Apo Form.
4ZEM	;	2.55	;	Crystal structure of eIF2B beta from Chaetomium thermophilum
4ZEO	;	2.55	;	Crystal structure of eIF2B delta from Chaetomium thermophilum
7KMA	;	2.7	;	Crystal structure of eif2Balpha with a ligand.
6XKI	;	2.87	;	Crystal structure of eIF4A-I in complex with RNA bound to des-MePateA, a pateamine A analog
4C9B	;	2.0	;	Crystal structure of eIF4AIII-CWC22 complex
2W97	;	2.29	;	Crystal Structure of eIF4E Bound to Glycerol and eIF4G1 peptide
5ME7	;	2.2	;	Crystal Structure of eiF4E from C. melo
5ME6	;	2.9	;	Crystal Structure of eiF4E from C. melo bound to a CAP analog
5ME5	;	1.9	;	Crystal Structure of eiF4E from C. melo bound to a eIF4G peptide
4BEA	;	2.57	;	Crystal Structure of eIF4E in Complex with a Stapled Peptide Derivative
8SX4	;	1.986	;	Crystal Structure of eIF4e in complex with Compound 7n
2IU1	;	1.8	;	Crystal structure of eIF5 C-terminal domain
4GQX	;	3.0	;	Crystal structure of EIIA(NTR) from Burkholderia pseudomallei
3BP3	;	1.65	;	Crystal structure of EIIB
5VLM	;	3.403	;	Crystal structure of EilR in complex with crystal violet
5VL9	;	2.16	;	Crystal structure of EilR in complex with eilO DNA element
5VLG	;	2.932	;	Crystal structure of EilR in complex with malachite green
2PTG	;	2.6	;	Crystal structure of Eimeria tenella enoyl reductase
5XIP	;	3.1	;	Crystal Structure of Eimeria tenella Prolyl-tRNA Synthetase (EtPRS) in complex with Halofuginone
3UY5	;	2.5	;	crystal structure of Eis from Mycobacterium tuberculosis
6VUU	;	2.6	;	Crystal structure of Eis from Mycobacterium tuberculosis in complex with inhibitor SGT1347
6VV2	;	2.95	;	Crystal structure of Eis from Mycobacterium tuberculosis in complex with inhibitor SGT1348
6VV0	;	3.0	;	Crystal structure of Eis from Mycobacterium tuberculosis in complex with inhibitor SGT1354
6VV3	;	2.4	;	Crystal structure of Eis from Mycobacterium tuberculosis in complex with inhibitor SGT1358
6P3U	;	2.55	;	Crystal structure of Eis from Mycobacterium tuberculosis in complex with inhibitor SGT335
6VUZ	;	2.65	;	Crystal structure of Eis from Mycobacterium tuberculosis in complex with inhibitor SGT353
6VUY	;	2.7	;	Crystal structure of Eis from Mycobacterium tuberculosis in complex with inhibitor SGT358
6VUR	;	2.2	;	Crystal structure of Eis from Mycobacterium tuberculosis in complex with inhibitor SGT366
6VUW	;	2.87	;	Crystal structure of Eis from Mycobacterium tuberculosis in complex with inhibitor SGT368
6VUS	;	2.28	;	Crystal structure of Eis from Mycobacterium tuberculosis in complex with inhibitor SGT379
6VV1	;	2.45	;	Crystal structure of Eis from Mycobacterium tuberculosis in complex with inhibitor SGT384
6VUX	;	1.97	;	Crystal structure of Eis from Mycobacterium tuberculosis in complex with inhibitor SGT388
6VUT	;	2.73	;	Crystal structure of Eis from Mycobacterium tuberculosis in complex with inhibitor SGT392
6P3V	;	2.5	;	Crystal structure of Eis from Mycobacterium tuberculosis in complex with inhibitor SGT416
6P3T	;	2.5	;	Crystal structure of Eis from Mycobacterium tuberculosis in complex with inhibitor SGT449
5IV0	;	2.1	;	Crystal structure of Eis from Mycobacterium tuberculosis in complex with sulfonamide inhibitor 39 and coenzyme A
6YCA	;	2.9	;	Crystal structure of Eis1 from Mycobacterium abscessus
6RFY	;	2.2	;	Crystal structure of Eis2 form Mycobacterium abscessus
6RFX	;	1.9	;	Crystal structure of Eis2 from Mycobacterium abscessus
6RFT	;	2.3	;	Crystal structure of Eis2 from Mycobacterium abscessus bound to Acetyl-CoA
7E9Y	;	2.25	;	Crystal structure of eLACCO1
1FLE	;	1.9	;	CRYSTAL STRUCTURE OF ELAFIN COMPLEXED WITH PORCINE PANCREATIC ELASTASE
7YP4	;	3.1	;	Crystal structure of elaiophylin glycosyltransferase in apo-form
7YP3	;	2.1	;	Crystal structure of elaiophylin glycosyltransferase in complex with elaiophylin
7YP5	;	2.33	;	Crystal structure of elaiophylin glycosyltransferase in complex with TDP
7YP6	;	2.6	;	Crystal structure of elaiophylin glycosyltransferase in complex with UDP
2ZON	;	1.7	;	Crystal structure of electron transfer complex of nitrite reductase with cytochrome c
3IH5	;	2.6	;	Crystal Structure of Electron Transfer Flavoprotein alpha-subunit from Bacteroides thetaiotaomicron
4EK1	;	1.97	;	Crystal Structure of Electron-Spin Labeled Cytochrome P450cam
4YXK	;	2.805	;	Crystal structure of Elk prion protein complexed with POM1 FAB
8I3E	;	2.7	;	Crystal structure of ELKS1 in complex with Piccolo
6IE1	;	2.48	;	Crystal Structure of ELMO2(Engulfment and cell motility protein 2)
8VLB	;	2.9	;	Crystal structure of EloBC-VHL-CDO1 complex bound to compound 4 molecular glue
8VL9	;	2.5	;	Crystal structure of EloBC-VHL-CDO1 complex bound to compound 8 molecular glue
4X67	;	4.1	;	Crystal structure of elongating yeast RNA polymerase II stalled at oxidative Cyclopurine DNA lesions.
5ERN	;	2.434	;	Crystal structure of elongation domain of Phomopsis amygdali fusicoccadiene synthase
5ERO	;	2.55	;	Crystal structure of elongation domain of Phomopsis amygdali fusicoccadiene synthase complexed with cobalt ions and pamidronate
1N0V	;	2.85	;	Crystal structure of elongation factor 2
5H7J	;	2.3	;	Crystal structure of Elongation factor 2
5H7K	;	1.599	;	Crystal structure of Elongation factor 2 GDP-form
5J8B	;	2.6	;	Crystal structure of Elongation Factor 4 (EF-4/LepA) in complex with GDPCP bound to the Thermus thermophilus 70S ribosome
4W2E	;	2.9	;	Crystal structure of Elongation Factor 4 (EF4/LepA) bound to the Thermus thermophilus 70S ribosome
4M1K	;	2.952	;	Crystal structure of elongation factor G (EFG)
4MYT	;	3.505	;	Crystal structure of elongation factor G (EFG)
1KTV	;	3.8	;	Crystal Structure of Elongation Factor G Dimer Without Nucleotide
4MYU	;	3.004	;	Crystal structure of elongation factor G mutant(EFG)
1D8T	;	2.35	;	CRYSTAL STRUCTURE OF ELONGATION FACTOR, TU (EF-TU-MGGDP) COMPLEXED WITH GE2270A, A THIAZOLYL PEPTIDE ANTIBIOTIC
5M2N	;	2.812	;	Crystal Structure of Elongator subunit Elp2
4XFV	;	3.2	;	Crystal Structure of Elp2
5L7J	;	2.15	;	Crystal Structure of Elp3 from Dehalococcoides mccartyi
5L7L	;	2.593	;	Crystal Structure of Elp3 from Dehalococcoides mccartyi (390-407 GSGSG)
2NW2	;	1.4	;	Crystal structure of ELS4 TCR at 1.4A
2NX5	;	2.7	;	Crystal structure of ELS4 TCR bound to HLA-B*3501 presenting EBV peptide EPLPQGQLTAY at 1.7A
6MTM	;	3.0	;	Crystal Structure of EM2 TCR in complex with HLA-B*37:01-NP338
2A6W	;	1.75	;	Crystal structure of Emp46p carbohydrate recognition domain (CRD), metal-free form
2A6V	;	1.52	;	Crystal structure of Emp46p carbohydrate recognition domain (CRD), potassium-bound form
2A6X	;	1.55	;	Crystal structure of Emp46p carbohydrate recognition domain (CRD), Y131F mutant
2A6Z	;	1.0	;	Crystal structure of Emp47p carbohydrate recognition domain (CRD), monoclinic crystal form 1
2A70	;	1.1	;	Crystal structure of Emp47p carbohydrate recognition domain (CRD), monoclinic crystal form 2
2A71	;	2.7	;	Crystal structure of Emp47p carbohydrate recognition domain (CRD), orthorhombic crystal form
2A6Y	;	1.42	;	Crystal structure of Emp47p carbohydrate recognition domain (CRD), tetragonal crystal form
5C9A	;	2.7	;	Crystal structure of empty coxsackievirus A16 particle
4QPG	;	3.5	;	Crystal structure of empty hepatitis A virus
3VBU	;	4.0	;	Crystal structure of empty human Enterovirus 71 particle
2GXG	;	1.45	;	Crystal structure of EmrR homolog from hyperthermophilic archaea Sulfolobus tokodaii strain7
1UKM	;	1.9	;	Crystal structure of EMS16, an Antagonist of collagen receptor integrin alpha2beta1 (GPIa/IIa)
2FMM	;	1.8	;	Crystal Structure of EMSY-HP1 complex
3WTG	;	2.3	;	Crystal structure of Emu (dromaius novaehollandiae) hemoglobin at 2.3 angstrom resolution
6T9F	;	2.24847	;	CRYSTAL STRUCTURE OF EN ENDOGLUCANASE S308P FROM PENICILLIUM VERRUCULOSUM
7JJU	;	2.604	;	Crystal structure of en exoribonuclease-resistant RNA (xrRNA) from Potato leafroll virus (PLRV)
5N5E	;	2.026	;	Crystal structure of encapsulated ferritin domain from Pyrococcus furiosus PFC_05175
6I9G	;	2.5	;	Crystal structure of encapsulin from Mycolicibacterium hassiacum
2J4B	;	2.5	;	Crystal structure of Encephalitozoon cuniculi TAF5 N-terminal domain
4XLO	;	1.67	;	Crystal Structure of EncM (crystallized with 4 mM NADPH)
3WC3	;	1.5	;	Crystal structure of endo-1,4-beta-glucanase from Eisenia fetida
5Y6T	;	1.7	;	Crystal structure of endo-1,4-beta-mannanase from Eisenia fetida
3KST	;	1.7	;	Crystal structure of Endo-1,4-beta-xylanase (NP_811807.1) from BACTEROIDES THETAIOTAOMICRON VPI-5482 at 1.70 A resolution
5Y3X	;	2.1	;	Crystal structure of endo-1,4-beta-xylanase from Caldicellulosiruptor owensensis
5M0K	;	2.59	;	CRYSTAL STRUCTURE of endo-1,4-beta-xylanase from Cellulomonas flavigena
5MRJ	;	2.7	;	Crystal structure of Endo-1,4-beta-xylanase-like protein from Acremonium chrysogenum
4KCA	;	1.9	;	Crystal Structure of Endo-1,5-alpha-L-arabinanase from a Bovine Ruminal Metagenomic Library
4KC7	;	1.75	;	Crystal Structure of Endo-1,5-alpha-L-arabinanase from Thermotoga petrophila RKU-1
4KC8	;	1.76	;	Crystal Structure of Endo-1,5-alpha-L-arabinanase from Thermotoga petrophila RKU-1 in complex with TRIS
2ZXQ	;	2.0	;	Crystal structure of endo-alpha-N-acetylgalactosaminidase from Bifidobacterium longum (EngBF)
6A8I	;	1.9	;	Crystal structure of endo-arabinanase ABN-TS D147N mutant in complex with arabinohexaose
6A8H	;	1.65	;	Crystal structure of endo-arabinanase ABN-TS D27A mutant in complex with arabinotriose
2ZZJ	;	1.8	;	Crystal structure of endo-beta-1,4-glucuronan lyase from fungus Trichoderma reesei
3JUG	;	1.6	;	Crystal structure of endo-beta-1,4-mannanase from the alkaliphilic Bacillus sp. N16-5
4IXL	;	1.49	;	Crystal structure of endo-beta-1,4-xylanase from the alkaliphilic Bacillus sp. SN5
2EBN	;	2.0	;	CRYSTAL STRUCTURE OF ENDO-BETA-N-ACETYLGLUCOSAMINIDASE F1, AN ALPHA(SLASH)BETA-BARREL ENZYME ADAPTED FOR A COMPLEX SUBSTRATE
1EOK	;	1.8	;	CRYSTAL STRUCTURE OF ENDO-BETA-N-ACETYLGLUCOSAMINIDASE F3
6KPN	;	2.1	;	Crystal Structure of endo-beta-N-acetylglucosaminidase from Cordyceps militaris D154N/E156Q mutant in complex with fucosyl-N-acetylglucosamine
6KPO	;	2.36	;	Crystal Structure of endo-beta-N-acetylglucosaminidase from Cordyceps militaris D154N/E156Q mutant in complex with fucosyl-N-acetylglucosamine-Asn
6KPL	;	1.75	;	Crystal Structure of endo-beta-N-acetylglucosaminidase from Cordyceps militaris in apo form
6KPM	;	1.8	;	Crystal Structure of endo-beta-N-acetylglucosaminidase from Cordyceps militaris in complex with L-fucose
1EDT	;	1.9	;	CRYSTAL STRUCTURE OF ENDO-BETA-N-ACETYLGLUCOSAMINIDASE H AT 1.9 ANGSTROMS RESOLUTION: ACTIVE SITE GEOMETRY AND SUBSTRATE RECOGNITION
6VE1	;	2.1	;	Crystal structure of endo-beta-N-acetylglucosaminidase H at high pH
6JBY	;	1.6	;	Crystal structure of endo-deglycosylated hydroxynitrile lyase isozyme 5 of Prunus communis
3GVK	;	1.84	;	Crystal structure of endo-neuraminidase NF mutant
3GVL	;	1.41	;	Crystal Structure of endo-neuraminidaseNF
4C2L	;	1.75	;	Crystal structure of endo-xylogalacturonan hydrolase from Aspergillus tubingensis
6JYZ	;	1.35	;	Crystal structure of endogalactoceramidase
2FVG	;	2.01	;	Crystal structure of Endoglucanase (tm1049) from THERMOTOGA MARITIMA at 2.01 A resolution
3ISX	;	1.4	;	Crystal structure of Endoglucanase (TM1050) from THERMOTOGA MARITIMA at 1.40 A resolution
1VJZ	;	2.05	;	Crystal structure of Endoglucanase (TM1752) from Thermotoga maritima at 2.05 A resolution
3MMU	;	2.201	;	Crystal structure of endoglucanase Cel5A from the hyperthermophilic Thermotoga maritima
3MMW	;	1.85	;	Crystal structure of endoglucanase Cel5A from the hyperthermophilic Thermotoga maritima
3EZ8	;	2.302	;	Crystal Structure of endoglucanase Cel9A from the thermoacidophilic Alicyclobacillus acidocaldarius
5GXZ	;	2.05	;	Crystal structure of endoglucanase CelQ from Clostridium thermocellum complexed with cellobiose and cellotriose
5GXY	;	1.7	;	Crystal structure of endoglucanase CelQ from Clostridium thermocellum complexed with cellobiose and Tris
5GY0	;	1.74	;	Crystal structure of endoglucanase CelQ from Clostridium thermocellum complexed with cellotetraose
5GY1	;	1.99	;	Crystal structure of endoglucanase CelQ from Clostridium thermocellum complexed with cellotriose
5GXX	;	1.5	;	Crystal structure of endoglucanase CelQ from Clostridium thermocellum complexed with Tris
4ZG8	;	1.39	;	Crystal structure of Endoglucanase from Perinereis brevicirris
4ZH5	;	1.35	;	Crystal structure of Endoglucanase from Perinereis brevicirris with Cellobiose
6TPC	;	1.52219	;	Crystal structure of Endoglucanase N194A from Penicillium verruculosum
6YON	;	2.6	;	Crystal structure of Endoglucanase S127C/A165C from Penicillium verruculosum
3H7L	;	2.3	;	CRYSTAL STRUCTURE OF ENDOGLUCANASE-RELATED PROTEIN FROM Vibrio parahaemolyticus
5CCU	;	2.11	;	Crystal structure of endoglycoceramidase I from Rhodococ-cus equi
5J7Z	;	2.15	;	Crystal structure of endoglycoceramidase I from Rhodococ-cus equi in complex with GM1
5J14	;	1.915	;	Crystal structure of endoglycoceramidase I from Rhodococ-cus equi in complex with GM3
7PUJ	;	1.752	;	Crystal structure of Endoglycosidase E GH18 domain from Enterococcus faecalis
7PUK	;	2.69	;	Crystal structure of Endoglycosidase E GH18 domain from Enterococcus faecalis in complex with Man5 product
7PUL	;	1.4	;	Crystal structure of Endoglycosidase E GH20 domain from Enterococcus faecalis
1XP3	;	2.57	;	Crystal Structure of Endonuclease IV (BA4508) from Bacillus anthracis at 2.57A Resolution.
3AAL	;	1.6	;	Crystal Structure of endonuclease IV from Geobacillus kaustophilus
3AAM	;	1.58	;	Crystal structure of endonuclease IV from Thermus thermophilus HB8
7K32	;	3.11	;	Crystal structure of Endonuclease Q complex with 27-mer duplex substrate with an abasic lesion at the active site
7K33	;	3.11	;	Crystal structure of Endonuclease Q complex with 27-mer duplex substrate with an abasic lesion at the active site
7K31	;	2.88	;	Crystal structure of Endonuclease Q complex with 27-mer duplex substrate with dI at the active site
7K30	;	2.34	;	Crystal structure of Endonuclease Q complex with 27-mer duplex substrate with dU at the active site
3MPR	;	1.899	;	Crystal Structure of endonuclease/exonuclease/phosphatase family protein from Bacteroides thetaiotaomicron, Northeast Structural Genomics Consortium Target BtR318A
6TAV	;	4.2	;	Crystal structure of endopeptidase-induced alpha2-macroglobulin
1X03	;	3.1	;	Crystal structure of endophilin BAR domain
1X04	;	2.9	;	Crystal structure of endophilin BAR domain (mutant)
1ZWW	;	2.3	;	Crystal structure of endophilin-A1 BAR domain
7SH0	;	3.2	;	CRYSTAL STRUCTURE OF ENDOPLASMIC RETICULUM AMINOPEPTIDASE 2 (ERAP2) COMPLEX WITH A HIGHLY SELECTIVE AND POTENT SMALL MOLECULE
5K1V	;	2.897	;	Crystal structure of Endoplasmic Reticulum aminopeptidase 2 (ERAP2) in complex with a diaminobenzoic acid derivative ligand.
5J6S	;	2.8	;	Crystal structure of Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) in complex with a hydroxamic derivative ligand
3TLM	;	2.95	;	Crystal Structure of Endoplasmic Reticulum Ca2+-ATPase (SERCA) From Bovine Muscle
4NUY	;	2.609	;	Crystal structure of EndoS, an endo-beta-N-acetyl-glucosaminidase from Streptococcus pyogenes
1NIW	;	2.05	;	Crystal structure of endothelial nitric oxide synthase peptide bound to calmodulin
5QBQ	;	1.697	;	Crystal structure of Endothiapepsin
5QBR	;	1.418	;	Crystal structure of Endothiapepsin
5QB5	;	1.2	;	Crystal structure of Endothiapepsin-FRG056 complex
5QB6	;	1.538	;	Crystal structure of Endothiapepsin-FRG062 complex
5QB7	;	1.5	;	Crystal structure of Endothiapepsin-FRG075 complex
5QB8	;	1.24	;	Crystal structure of Endothiapepsin-FRG080 complex
5QB9	;	1.478	;	Crystal structure of Endothiapepsin-FRG081 complex
5QBA	;	1.338	;	Crystal structure of Endothiapepsin-FRG134 complex
5QBB	;	1.759	;	Crystal structure of Endothiapepsin-FRG140 complex
5QBC	;	1.449	;	Crystal structure of Endothiapepsin-FRG164 complex
5QBD	;	1.419	;	Crystal structure of Endothiapepsin-FRG166 complex
5QBE	;	1.498	;	Crystal structure of Endothiapepsin-FRG175 complex
5QBF	;	1.268	;	Crystal structure of Endothiapepsin-FRG203 complex
5QBG	;	1.697	;	Crystal structure of Endothiapepsin-FRG245 complex
5QBH	;	1.469	;	Crystal structure of Endothiapepsin-FRG270 complex
5QBI	;	1.624	;	Crystal structure of Endothiapepsin-FRG274 complex
5QBJ	;	1.699	;	Crystal structure of Endothiapepsin-FRG283 complex
5QBN	;	1.403	;	Crystal structure of Endothiapepsin-NAT14-350193 complex
5QBS	;	1.528	;	Crystal structure of Endothiapepsin-NAT17-346976 complex
5QBT	;	1.299	;	Crystal structure of Endothiapepsin-NAT17-346985 complex
5QBK	;	1.279	;	Crystal structure of Endothiapepsin-NAT17-347144 complex
5QBL	;	1.619	;	Crystal structure of Endothiapepsin-NAT17-347147 complex
5QBM	;	1.569	;	Crystal structure of Endothiapepsin-NAT17-347151 complex
5QBO	;	1.123	;	Crystal structure of Endothiapepsin-NAT17-347283 complex
5QBP	;	1.297	;	Crystal structure of Endothiapepsin-NAT17-347290a complex
3LZY	;	1.8	;	Crystal structure of Endothiapesin in complex with Xenon
6S32	;	1.35	;	Crystal structure of ene-reductase CtOYE from Chroococcidiopsis thermalis.
6S0G	;	1.45	;	Crystal structure of ene-reductase GsOYE from Galdieria sulphuraria
6S31	;	1.63	;	Crystal structure of ene-reductase GsOYE from Galdieria sulphuraria in complex with 4-Hydroxybenzaldehyde
7BO0	;	1.63	;	Crystal structure of ene-reductase GsOYE from Galdieria sulphuraria in complex with alpha-angelica lactone
6S23	;	2.38	;	Crystal structure of ene-reductase GsOYE from Galleria sulphuraria in complex with 2-methyl-cyclopenten-1-one
7BN7	;	2.45	;	Crystal structure of ene-reductase OYE2 from S. cerevisiae
7BLF	;	2.15	;	Crystal structure of ene-reductase OYE4 from Botryotinia fuckeliana (BfOYE4)
7WNS	;	1.799	;	Crystal structure of ENF peptide binding protein from Silkworm
4NKD	;	3.303	;	Crystal structure of engineered anti-EE scFv antibody fragment
4NKM	;	3.71	;	Crystal structure of engineered anti-EE scFv antibody fragment
4NKO	;	3.496	;	Crystal structure of engineered anti-EE scFv antibody fragment
3NN8	;	3.1	;	Crystal structure of engineered antibody fragment based on 3D5
2C4I	;	1.95	;	Crystal structure of engineered avidin
3CMJ	;	1.6	;	Crystal Structure of engineered Beta-Glucosidase from Soil metagenome
4H2W	;	1.95	;	Crystal structure of engineered Bradyrhizobium japonicum glycine:[carrier protein] ligase complexed with carrier protein from Agrobacterium tumefaciens and AMP
4H2X	;	2.15	;	Crystal structure of engineered Bradyrhizobium japonicum glycine:[carrier protein] ligase complexed with carrier protein from Agrobacterium tumefaciens and an analogue of glycyl adenylate
4H2Y	;	2.1	;	Crystal structure of engineered Bradyrhizobium japonicum glycine:[carrier protein] ligase complexed with carrier protein from Agrobacterium tumefaciens and ATP
5UR7	;	2.0004	;	Crystal structure of engineered CCL20 disulfide locked dimer
7T97	;	2.144	;	Crystal structure of engineered CYS-CYS fab dimer CH1-207 (HC4)
7T99	;	2.65	;	Crystal structure of engineered CYS-CYS fab dimer CL-205 (LC25)
7T98	;	2.97	;	Crystal structure of engineered CYS-CYS fab dimer VL-108 (LC33)
4PFH	;	1.9	;	Crystal structure of engineered D-tagatose 3-epimerase PcDTE-IDF8
4PGL	;	2.1	;	Crystal structure of engineered D-tagatose 3-epimerase PcDTE-ILS6
8HP8	;	2.397	;	Crystal Structure of Engineered Endolysin EC340 derived from Gram-Negative Bacteria targeted Bacteriophage
5UWO	;	2.347	;	Crystal Structure of Engineered FMRP-1b NES Peptide in complex with CRM1-Ran-RanBP1
4OSN	;	1.76	;	Crystal structure of engineered HCMV glycoprotein B Domain II
8JYJ	;	2.01	;	Crystal structure of engineered HIV-1 Reverse Transcriptase RNase H domain complexed with laccaic acid A
8JYH	;	2.21	;	Crystal structure of engineered HIV-1 Reverse Transcriptase RNase H domain complexed with laccaic acid C
8JYI	;	1.92	;	Crystal structure of engineered HIV-1 Reverse Transcriptase RNase H domain complexed with laccaic acid E
7XIS	;	1.88	;	Crystal structure of engineered HIV-1 Reverse Transcriptase RNase H domain complexed with nitrofuran methoxy(methoxycarbonyl)phenyl ester
7XIT	;	2.18	;	Crystal structure of engineered HIV-1 Reverse Transcriptase RNase H domain complexed with nitrofuran methoxy(methoxycarbonyl)phenyl ester
7XIU	;	2.09	;	Crystal structure of engineered HIV-1 Reverse Transcriptase RNase H domain complexed with nitrofuran methoxy(methoxycarbonyl)phenyl ester
7XJ4	;	1.8	;	Crystal structure of engineered HIV-1 Reverse Transcriptase RNase H domain complexed with nitrofuran methoxy(methoxycarbonyl)phenyl ester
7XJ5	;	1.75	;	Crystal structure of engineered HIV-1 Reverse Transcriptase RNase H domain complexed with nitrofuran methoxy(methoxycarbonyl)phenyl ester
7XJ7	;	1.8	;	Crystal structure of engineered HIV-1 Reverse Transcriptase RNase H domain complexed with nitrofuran methoxy(methoxycarbonyl)phenyl ester
5MHH	;	2.0	;	Crystal structure of engineered human lipocalin 2 carrying p-boronophenylalanine at position 36
4NE7	;	2.497	;	Crystal Structure of engineered Kumamolisin-As from Alicyclobacillus sendaiensis, Northeast Structural Genomics Consortium (NESG) Target OR367
3NDS	;	1.2	;	Crystal structure of engineered Naja Nigricollis toxin alpha
2O3E	;	2.2	;	Crystal structure of engineered neurolysin with thimet oligopeptidase specificity for neurotensin cleavage site.
8CTP	;	1.9	;	Crystal structure of engineered phospholipase D mutant superPLD 2-23
8CTQ	;	1.85	;	Crystal structure of engineered phospholipase D mutant superPLD 2-48
3TP4	;	1.979	;	Crystal Structure of engineered protein at the resolution 1.98A, Northeast Structural Genomics Consortium Target OR128
3UW6	;	2.3	;	Crystal Structure of Engineered Protein, Northeast Structural Genomics Consortium Target OR120
4IJB	;	1.739	;	Crystal Structure of Engineered Protein, Northeast Structural Genomics Consortium Target OR288
4LT9	;	2.15	;	Crystal Structure of Engineered Protein, Northeast Structural Genomics Consortium Target OR404
4LNY	;	1.929	;	Crystal Structure of Engineered Protein, Northeast Structural Genomics Consortium Target OR422
3VB8	;	2.9	;	Crystal Structure of Engineered Protein, Northeast Structural Genomics Consortium Target OR43
4PQ8	;	1.833	;	Crystal Structure of Engineered Protein, Northeast Structural Genomics Consortium Target OR465
4RZP	;	2.804	;	Crystal Structure of Engineered Protein. Northeast Structural Genomics Consortium (NESG) Target OR366.
4PSJ	;	1.992	;	Crystal Structure of Engineered Protein. Northeast Structural Genomics Consortium (NESG) Target OR464.
4RV1	;	2.573	;	Crystal Structure of Engineered Protein. Northeast Structural Genomics Consortium (NESG) Target OR497.
4ILS	;	2.5	;	Crystal structure of engineered protein. northeast structural genomics Consortium target or117
4J29	;	2.1	;	Crystal Structure of Engineered Protein. Northeast Structural Genomics Consortium Target OR258.
4GPM	;	2.002	;	Crystal Structure of Engineered Protein. Northeast Structural Genomics Consortium Target OR264.
4HQD	;	2.433	;	Crystal Structure of Engineered Protein. Northeast Structural Genomics Consortium Target OR265.
4GMR	;	2.377	;	Crystal Structure of Engineered Protein. Northeast Structural Genomics Consortium Target OR266.
4HB5	;	2.294	;	Crystal Structure of Engineered Protein. Northeast Structural Genomics Consortium Target OR267.
4HHU	;	2.0	;	Crystal Structure of Engineered Protein. Northeast Structural Genomics Consortium Target OR280.
4HXT	;	1.95	;	Crystal Structure of Engineered Protein. Northeast Structural Genomics Consortium Target OR329
3U26	;	1.59	;	Crystal Structure of Engineered Protein. Northeast Structural Genomics Consortium Target OR48
4FFD	;	2.31	;	Crystal structure of engineered protein. northeast structural genomics consortium target or48
4PWW	;	1.471	;	Crystal Structure of Engineered Protein. Northeast Structural Genomics Consortium Target OR494.
3TC7	;	1.5	;	Crystal Structure of Engineered Protein. Northeast Structural Genomics Consortium Target OR62.
3TC6	;	1.6	;	Crystal Structure of Engineered Protein. Northeast Structural Genomics Consortium Target OR63.
3SXW	;	1.801	;	Crystal Structure of Engineered Protein. Northeast Structural Genomics Consortium Target OR69.
3SY1	;	1.465	;	Crystal Structure of Engineered Protein. Northeast Structural Genomics Consortium Target OR70
4DIU	;	2.0	;	Crystal Structure of Engineered Protein. Northeast Structural Genomics Consortium Target OR94
7QPJ	;	1.54	;	Crystal structure of engineered TCR (756) complexed to HLA-A*02:01 presenting MAGE-A10 9-mer peptide
7PBC	;	2.04	;	Crystal structure of engineered TCR (796) complexed to HLA-A*02:01 presenting MAGE-A10 9-mer peptide
4YIV	;	1.93	;	Crystal structure of engineered TgAMA1 lacking the DII loop
4YIZ	;	2.2	;	Crystal structure of engineered TgAMA1 lacking the DII loop in complex with an Eimeria tenella RON2D3 peptide
4Q7I	;	1.8	;	Crystal structure of engineered thermostable D-tagatose 3-epimerase PcDTE-Var8
2O36	;	1.95	;	Crystal structure of engineered thimet oligopeptidase with neurolysin specificity in neurotensin cleavage site
5BYW	;	2.6	;	Crystal structure of engineered trifunctional CtCEL5E
4J4A	;	1.6499	;	Crystal Structure of Engineered Trimeric Cortexillin-1 Coiled-Coil Variant
5VOH	;	2.302	;	Crystal structure of engineered water-forming NADPH oxidase (TPNOX) bound to NADPH. The G159A, D177A, A178R, M179S, P184R mutant of LbNOX.
1P7I	;	2.1	;	CRYSTAL STRUCTURE OF ENGRAILED HOMEODOMAIN MUTANT K52A
1P7J	;	2.1	;	Crystal structure of engrailed homeodomain mutant K52E
1CV7	;	2.5	;	Crystal structure of enhanced cyan-emission variant of GFP
4EUL	;	1.35	;	Crystal structure of enhanced Green Fluorescent Protein to 1.35A resolution reveals alternative conformations for Glu222
3RYO	;	2.8	;	Crystal Structure of Enhanced Intracellular Survival (Eis) Protein from Mycobacterium tuberculosis with Acetyl CoA
3OW2	;	2.7	;	Crystal Structure of Enhanced Macrolide Bound to 50S Ribosomal Subunit
1WZ7	;	2.1	;	Crystal structure of enhancer of rudimentary homologue (ERH)
1VHQ	;	1.65	;	Crystal structure of enhancing lycopene biosynthesis protein 2
6HPZ	;	2.3	;	Crystal structure of ENL (MLLT1) in complex with acetyllysine
6HPY	;	2.0	;	Crystal structure of ENL (MLLT1) in complex with compound 12
6HPX	;	2.3	;	Crystal structure of ENL (MLLT1) in complex with compound 19
6HPW	;	1.9	;	Crystal structure of ENL (MLLT1) in complex with compound 20
6HQ0	;	1.81	;	Crystal structure of ENL (MLLT1), apo form
7X8B	;	2.3	;	Crystal structure of ENL T1 mutant YEATS domain in complex with histone H3 acetylation at K27
7X8G	;	1.91	;	Crystal structure of ENL T1(H116P) mutant YEATS domain in complex with histone H3 acetylation at K27
7X8F	;	2.44	;	Crystal structure of ENL T4 mutant YEATS domain in complex with histone H3 acetylation at K27
7E7C	;	1.84	;	Crystal structure of ENL YEATS domain T1 mutant in complex with histone H3 acetylation at K27
7X88	;	2.25	;	Crystal structure of ENL YEATS domain T2 mutant in complex with histone H3 acetylation at K27
7E74	;	2.9	;	Crystal structure of ENL YEATS domain T3 mutant in complex with histone H3 acetylation at K27
1RVK	;	1.7	;	Crystal structure of enolase AGR_L_2751 from Agrobacterium Tumefaciens
3TTE	;	2.0	;	Crystal structure of enolase brado_4202 (target EFI-501651) from Bradyrhizobium complexed with magnesium and mandelic acid
3TOY	;	1.8	;	CRYSTAL STRUCTURE OF ENOLASE BRADO_4202 (TARGET EFI-501651) FROM Bradyrhizobium sp. ORS278 WITH CALCIUM AND ACETATE BOUND
4HNL	;	1.48	;	Crystal structure of ENOLASE EGBG_01401 (TARGET EFI-502226) from Enterococcus gallinarum EG2
7UGH	;	1.95	;	Crystal Structure of enolase family protein from Naegleria fowleri with bound 2-phosphoglyceric acid
3VA8	;	2.0	;	Crystal structure of enolase FG03645.1 (target EFI-502278) from Gibberella zeae PH-1 complexed with magnesium, formate and sulfate
4A3R	;	2.2	;	Crystal structure of Enolase from Bacillus subtilis.
6O4N	;	1.8	;	Crystal Structure of Enolase from Chlamydia trachomatis
8W21	;	2.25	;	Crystal Structure of Enolase from Chlamydia trachomatis (P43212 Form)
6BFZ	;	2.21	;	Crystal structure of enolase from E. coli with a mixture of apo form, substrate, and product form
1IYX	;	2.8	;	Crystal structure of enolase from Enterococcus hirae
6BFY	;	1.81	;	Crystal structure of enolase from Escherichia coli with bound 2-phosphoglycerate substrate
4MKS	;	2.079	;	Crystal structure of enolase from Lactobacillus gasseri
6NB2	;	1.85	;	CRYSTAL STRUCTURE OF ENOLASE FROM LEGIONELLA PNEUMOPHILA BOUND TO 2-PHOSPHOGLYCERIC ACID AND MAGNESIUM
6NBM	;	1.9	;	CRYSTAL STRUCTURE OF ENOLASE FROM LEGIONELLA PNEUMOPHILA BOUND TO PHOSPHATE AND MAGNESIUM
8UEL	;	2.49	;	Crystal structure of enolase from Litopenaeus vannamei
4ROP	;	2.05	;	Crystal structure of enolase from Synechococcus elongatus
5J04	;	2.3	;	Crystal structure of Enolase from Synechococcus elongatus, complex with phosphoenolpyruvate
4G7F	;	2.4	;	Crystal Structure of Enolase from Trypanosoma Cruzi
3VDG	;	1.9	;	Crystal structure of enolase MSMEG_6132 (TARGET EFI-502282) from Mycobacterium smegmatis str. MC2 155 complexed with formate and acetate
3VFC	;	2.0	;	Crystal structure of enolase MSMEG_6132 (TARGET EFI-502282) from Mycobacterium smegmatis str. MC2 155 complexed with tartrate
4E4F	;	2.0	;	Crystal structure of enolase PC1_0802 (TARGET EFI-502240) from Pectobacterium carotovorum subsp. carotovorum PC1
4IT1	;	2.2	;	Crystal structure of enolase pfl01_3283 (target efi-502286) from pseudomonas fluorescens pf0-1 with bound magnesium, potassium and tartrate
3RR1	;	1.95	;	Crystal structure of enolase PRK14017 (target EFI-500653) from Ralstonia pickettii 12J
3RRA	;	2.3	;	Crystal structure of enolase PRK14017 (target EFI-500653) from Ralstonia pickettii 12J with magnesium bound
3SJN	;	1.9	;	Crystal structure of enolase Spea_3858 (target EFI-500646) from Shewanella pealeana with magnesium bound
3OZY	;	1.2994	;	Crystal structure of enolase superfamily member from Bordetella bronchiseptica complexed with Mg and m-Xylarate
3OZM	;	1.6	;	Crystal structure of enolase superfamily member from Bordetella bronchiseptica complexed with Mg, m-Xylarate and L-Lyxarate
3S47	;	1.7	;	Crystal structure of enolase superfamily member from Clostridium beijerincki complexed with Mg
3R25	;	1.603	;	Crystal structure of enolase superfamily member from Vibrionales bacterium complexed with Mg and Glycerol in the active site
3VC6	;	1.64	;	Crystal structure of enolase Tbis_1083(TARGET EFI-502310) FROM Thermobispora bispora DSM 43833 complexed with magnesium and formate
3VC5	;	1.5	;	Crystal structure of enolase Tbis_1083(TARGET EFI-502310) FROM Thermobispora bispora DSM 43833 complexed with phosphate
4DHG	;	1.9	;	Crystal structure of enolase TBIS_1083(TARGET EFI-502310) from Thermobispora bispora dsm 43833, an open loop conformation
2PSN	;	2.2	;	Crystal structure of enolase1
7V67	;	2.0	;	Crystal Structure of Enolase1 from Candida albicans
7VRD	;	1.7	;	Crystal structure of Enolase1 from Candida albicans complexed with 2'-phosphoglyceric acid sodium
3ISS	;	2.5	;	Crystal structure of enolpyruvyl-UDP-GlcNAc synthase (MurA):UDP-N-acetylmuramic acid:phosphite from Escherichia coli
4RLH	;	2.26	;	Crystal structure of enoyl ACP reductase from Burkholderia pseudomallei in complex with AFN-1252
7MKU	;	2.648	;	Crystal Structure of ENOYL COA-HYDRATASE2 from Arabidopsis thaliana
4Z38	;	2.8	;	Crystal structure of enoyl reductase domain of MlnA from the macrolactin biosynthesis cluster from Bacillus amyloliquefaciens
1QSG	;	1.75	;	CRYSTAL STRUCTURE OF ENOYL REDUCTASE INHIBITION BY TRICLOSAN
5TF4	;	1.95	;	Crystal structure of enoyl-(acyl carrier protein) reductase from Bartonella henselae in complext with NAD
5TRT	;	1.85	;	Crystal Structure of enoyl-(acyl carrier protein) reductase from Burkholderia pseudomallei 1710b bound to NAD
3K2E	;	1.9	;	Crystal structure of enoyl-(acyl-carrier-protein) reductase from Anaplasma phagocytophilum at 1.9A resolution
8JFJ	;	1.8	;	Crystal structure of enoyl-ACP reductase FabI from Helicobacter pylori
8JFN	;	2.41	;	Crystal structure of enoyl-ACP reductase FabI in complex with NAD+ and crotonyl-ACP from Helicobacter pylori
8JFM	;	2.21	;	Crystal structure of enoyl-ACP reductase FabI in complex with NADH from Helicobacter pylori
6AHE	;	2.29	;	Crystal structure of enoyl-ACP reductase from Acinetobacter baumannii in complex with NAD and AFN-1252
6AH9	;	1.74	;	Crystal structure of enoyl-ACP reductase from Acinetobacter baumannii in complex with NAD and Triclosan
1UH5	;	2.2	;	Crystal Structure of Enoyl-ACP Reductase with Triclosan at 2.2angstroms
3OIG	;	1.25	;	Crystal Structure of Enoyl-ACP Reductases I (FabI) from B. subtilis (complex with NAD and INH)
3OIF	;	2.6	;	Crystal Structure of Enoyl-ACP Reductases I (FabI) from B. subtilis (complex with NAD and TCL)
3OIC	;	2.2	;	Crystal Structure of Enoyl-ACP Reductases III (FabL) from B. subtilis (apo form)
3OID	;	1.8	;	Crystal Structure of Enoyl-ACP Reductases III (FabL) from B. subtilis (complex with NADP and TCL)
4M86	;	2.15	;	Crystal Structure of Enoyl-Acyl Carrier Protein Reductase (FabI) from Neisseria meningitidis
4M87	;	2.25	;	Crystal Structure of Enoyl-Acyl Carrier Protein Reductase (FabI) from Neisseria meningitidis in complex with NAD+
4M89	;	1.9	;	Crystal Structure of Enoyl-Acyl Carrier Protein Reductase (FabI) from Neisseria meningitidis in complex with NAD+ and Triclosan
6IUM	;	2.0	;	Crystal structure of enoyl-CoA hydratase (ECH) from Ralstonia eutropha H16
6IUN	;	2.38	;	Crystal structure of enoyl-CoA hydratase (ECH) from Ralstonia eutropha H16 in complex with NAD
3QXI	;	2.2	;	Crystal structure of enoyl-CoA hydratase EchA1 from Mycobacterium marinum
3QK8	;	1.6	;	Crystal structure of enoyl-coA hydratase EchA15 from Mycobacterium marinum in complex with an unknown ligand
7M3W	;	2.9	;	Crystal Structure of enoyl-CoA hydratase EchA15 protein from Mycolicibacterium paratuberculosis
3QYR	;	2.45	;	Crystal structure of enoyl-coA hydratase EchA16_2 Mycobacterium paratuberculosis ATCC BAA-968 / K-10
4DI1	;	2.25	;	Crystal structure of enoyl-CoA hydratase EchA17 from Mycobacterium marinum
3QKA	;	2.15	;	Crystal structure of enoyl-CoA hydratase EchA5 from Mycobacterium marinum
3QMJ	;	2.2	;	Crystal structure of Enoyl-CoA hydratase EchA8_6 from Mycobacterium marinum
3PEA	;	1.817	;	Crystal structure of enoyl-CoA hydratase from Bacillus anthracis str. 'Ames Ancestor'
3LKE	;	1.7	;	Crystal structure of enoyl-CoA hydratase from Bacillus halodurans
3Q1T	;	2.35	;	Crystal structure of enoyl-coA hydratase from Mycobacterium avium
3NJD	;	1.75	;	Crystal structure of enoyl-coa hydratase from mycobacterium smegmatis
3PE8	;	1.6	;	Crystal structure of Enoyl-CoA hydratase from Mycobacterium smegmatis
3NJB	;	2.2	;	Crystal structure of enoyl-coa hydratase from Mycobacterium smegmatis, iodide soak
3H81	;	1.8	;	Crystal structure of enoyl-CoA hydratase from Mycobacterium tuberculosis
3HE2	;	2.3	;	Crystal structure of enoyl-CoA hydratase from Mycobacterium tuberculosis
5KJP	;	1.8	;	Crystal structure of enoyl-CoA hydratase from Mycobacterium tuberculosis H37Rv
7MCM	;	2.05	;	Crystal Structure of Enoyl-CoA hydratase from Mycolicibacterium smegmatis
3LAO	;	2.4	;	Crystal Structure of Enoyl-CoA Hydratase from Pseudomonas aeruginosa PA01
4JYL	;	2.37	;	Crystal structure of enoyl-CoA hydratase from Thermoplasma volcanium GSS1
1UIY	;	2.85	;	Crystal Structure of Enoyl-CoA Hydratase from Thermus Thermophilus HB8
3MYB	;	1.55	;	Crystal structure of enoyl-coa hydratase mycobacterium smegmatis
6C7C	;	2.1	;	Crystal structure of Enoyl-CoA hydratase, EchA3, from Mycobacterium ulcerans Agy99
3JU1	;	2.301	;	Crystal Structure of Enoyl-CoA Hydratase/Isomerase Family Protein
4JCS	;	1.77	;	Crystal structure of Enoyl-CoA hydratase/isomerase from Cupriavidus metallidurans CH34
5VE2	;	2.3	;	Crystal structure of enoyl-CoA hydratase/isomerase from Pseudoalteromonas atlantica T6c at 2.3 A resolution.
2PPY	;	2.16	;	Crystal structure of Enoyl-CoA hydrates (gk_1992) from Geobacillus Kaustophilus HTA426
2PBP	;	1.8	;	Crystal structure of ENOYL-CoA hydrates subunit I (gk_2039) from geobacillus kaustophilus HTA426
2QQ3	;	1.95	;	Crystal Structure Of Enoyl-CoA Hydrates Subunit I (gk_2039) Other Form From Geobacillus Kaustophilus HTA426
4JOT	;	1.94	;	Crystal structure of enoyl-CoA hydrotase from Deinococcus radiodurans R1
2P91	;	2.0	;	Crystal structure of Enoyl-[acyl-carrier-protein] reductase (NADH) from Aquifex aeolicus VF5
6Q1Y	;	1.65	;	Crystal Structure of Enoyl-[acyl-carrier-protein] reductase from Mycobacterium avium with bound NAD
7L6C	;	1.85	;	Crystal Structure of Enoyl-[acyl-carrier-protein] reductase InhA from Mycobacterium abscessus in complex with NAD
7KLI	;	1.75	;	Crystal Structure of Enoyl-[acyl-carrier-protein] reductase [NADH] (InhA) from Mycobacterium abscessus
6UDF	;	1.95	;	Crystal structure of Enoyl-[acyl-carrier-protein] reductase [NADH] (InhA) from Mycobacterium kansasii
7KXA	;	1.8	;	Crystal structure of Enoyl-[acyl-carrier-protein] reductase [NADH] (InhA) from Mycobacterium kansasii in complex with NAD
5WWO	;	2.4	;	Crystal structure of Enp1
7F0G	;	2.67	;	Crystal Structure of EnPKS1
7F0E	;	2.62	;	Crystal Structure of EnPKS2
6AEL	;	1.9	;	Crystal structure of ENPP1 in complex with 3'3'-cGAMP
6AEK	;	1.8	;	Crystal structure of ENPP1 in complex with pApG
5ZX1	;	2.31	;	Crystal structure of ENT domain from T. brucei
3PYA	;	2.25	;	Crystal structure of ent-copalyl diphosphate synthase from Arabidopsis thaliana in complex with (S)-15-aza-14,15-dihydrogeranylgeranyl thiolodiphosphate
4LIX	;	1.548	;	Crystal structure of ent-copalyl diphosphate synthase from Arabidopsis thaliana in complex with (S)-15-aza-14,15-dihydrogeranylgeranyl thiolodiphosphate at 1.55 A resolution
3PYB	;	2.759	;	Crystal structure of ent-copalyl diphosphate synthase from Arabidopsis thaliana in complex with 13-aza-13,14-dihydrocopalyl diphosphate
4W4R	;	1.92	;	Crystal structure of ent-kaurene synthase BJKS from bradyrhizobium japonicum
4W4S	;	2.0	;	Crystal structure of ent-kaurene synthase BJKS from bradyrhizobium japonicum in complex with BPH-629
5ZEF	;	2.01	;	Crystal structure of Entamoeba histolytica Arginase in complex with L- Norvaline at 2.01 A
5ZEH	;	2.36	;	Crystal structure of Entamoeba histolytica Arginase in complex with L- Ornithine at 2.35 A
5ZEE	;	1.74	;	Crystal structure of Entamoeba histolytica Arginase in complex with N(omega)-hydroxy-L-arginine (NOHA) at 1.74 A
4UP8	;	2.896	;	Crystal structure of Entamoeba histolytica lysyl-tRNA synthetase apo form
4UPA	;	2.901	;	Crystal structure of Entamoeba histolytica lysyl-tRNA synthetase in complex with AMPPNP
4UP9	;	3.047	;	Crystal structure of Entamoeba histolytica lysyl-tRNA synthetase in complex with ATP
4UP7	;	2.789	;	Crystal structure of Entamoeba histolytica lysyl-tRNA synthetase in complex with lysyl-adenylate
3NV9	;	2.25	;	Crystal structure of Entamoeba histolytica Malic Enzyme
3ACZ	;	1.97	;	Crystal structure of Entamoeba histolytica methionine gamma-lyase 1
3P47	;	1.78	;	Crystal structure of Entamoeba histolytica Serine acetyltransferase 1 in complex with L-cysteine
3Q1X	;	1.59	;	Crystal structure of Entamoeba histolytica serine acetyltransferase 1 in complex with L-serine
7VLJ	;	1.83	;	Crystal structure of Entamoeba histolytica serine protease inhibitor, Histopin, in the cleaved conformation
3NX1	;	2.4	;	Crystal structure of Enterobacter sp. Px6-4 Ferulic Acid Decarboxylase
1Q9Y	;	2.8	;	CRYSTAL STRUCTURE OF ENTEROBACTERIA PHAGE RB69 GP43 DNA POLYMERASE COMPLEXED WITH 8-OXOGUANOSINE CONTAINING DNA
1Q9X	;	2.69	;	Crystal structure of Enterobacteria phage RB69 gp43 DNA polymerase complexed with tetrahydrofuran containing DNA
3UWL	;	2.07	;	Crystal structure of Enteroccocus faecalis thymidylate synthase (EfTS) in complex with 5-formyl tetrahydrofolate
6QYA	;	1.76	;	Crystal structure of Enteroccocus faecalis thymidylate synthase (EfTS) in complex with dUMP
6QXS	;	2.88	;	Crystal structure of Enteroccocus faecalis thymidylate synthase (EfTS) in complex with FdUMP
2B20	;	2.95	;	Crystal Structure of Enterochelin Esterase from Shigella flexneri Enterochelin Esterase
5Y63	;	2.87	;	Crystal structure of Enterococcus faecalis AhpC
2JFO	;	2.5	;	Crystal structure of Enterococcus faecalis glutamate racemase in complex with D- and L-Glutamate
2JFP	;	1.98	;	Crystal structure of Enterococcus faecalis glutamate racemase in complex with D- Glutamate
5IJ6	;	2.0	;	Crystal structure of Enterococcus faecalis lipoate-protein ligase A (lplA-1) in complex with lipoic acid
5IDH	;	1.55	;	Crystal structure of Enterococcus faecalis lipoate-protein ligase A (lplA-2) in complex with 8-bromooctanoic acid
5ICH	;	1.85	;	Crystal structure of Enterococcus faecalis lipoate-protein ligase A (lplA-2) in complex with 8BO-AMP
5IBY	;	1.85	;	Crystal structure of Enterococcus faecalis lipoate-protein ligase A (lplA-2) in complex with lipoic acid
5ICL	;	1.8	;	Crystal structure of Enterococcus faecalis lipoate-protein ligase A (lplA-2) in complex with lipoyl-AMP
4MZY	;	1.95	;	Crystal structure of enterococcus faecalis nicotinate phosphoribosyltransferase with malonate and phosphate bound
2F7F	;	2.0	;	Crystal structure of Enterococcus faecalis putative nicotinate phosphoribosyltransferase, NEW YORK STRUCTURAL GENOMICS CONSORTIUM
6LOI	;	2.503	;	Crystal structure of Enterococcus faecalis Undecaprenyl pyrophosphate synthase(EfaUPPS)
6G0K	;	2.9	;	Crystal structure of Enterococcus faecium D63r Penicillin-Binding protein 5 (PBP5fm)
6G88	;	3.3	;	Crystal structure of Enterococcus Faecium D63r Penicillin-Binding protein 5 (PBP5fm)
8U55	;	1.9	;	Crystal structure of Enterococcus faecium EnGen25 Penicillin-binding protein 5 (PBP5)
2JFV	;	1.8	;	Crystal structure of Enterococcus faecium glutamate racemase in complex with citrate
2JFU	;	1.8	;	Crystal structure of Enterococcus faecium glutamate racemase in complex with phosphate
2JFW	;	2.0	;	Crystal structure of Enterococcus faecium glutamate racemase in complex with tartrate
2HKL	;	2.6	;	Crystal structure of Enterococcus faecium L,D-transpeptidase C442S mutant
8AIH	;	1.9	;	Crystal Structure of Enterococcus faecium Nicotinate Nucleotide Adenylyltransferase at 1.9 Angstroms Resolution
6M73	;	1.7	;	Crystal structure of Enterococcus hirae L-lactate oxidase in complex with D-lactate form ligand
6M74	;	1.52	;	Crystal structure of Enterococcus hirae L-lactate oxidase M207L in complex with D-lactate form ligand
3VR4	;	2.172	;	Crystal structure of Enterococcus hirae V1-ATPase [eV1]
3UJZ	;	2.5	;	Crystal structure of enterohemorrhagic E. coli StcE
4DNY	;	1.61	;	Crystal structure of enterohemorrhagic E. coli StcE(132-251)
3QK1	;	2.08	;	Crystal Structure of Enterokinase-like Trypsin Variant
1YJ7	;	1.8	;	Crystal structure of enteropathogenic E.coli (EPEC) type III secretion system protein EscJ
8FL5	;	1.8	;	Crystal Structure of Enterovirus 68 3C Protease inactive mutant C147A at 1.8 Angstroms.
6KWR	;	2.5	;	Crystal structure of enterovirus 71 polymerase elongation complex (ddCTP form)
6KWQ	;	1.76	;	Crystal structure of enterovirus 71 polymerase elongation complex (native form)
4GMP	;	3.9	;	Crystal structure of enterovirus 71 strain 1095 procapsid
6L4R	;	2.147	;	Crystal structure of Enterovirus D68 RdRp
7ROA	;	1.82	;	Crystal structure of EntV136 from Enterococcus faecalis
2EDM	;	2.2	;	Crystal Structure of Envelope Protein VP26 from White Spot Syndrome Virus (WSSV)
2ED6	;	2.0	;	Crystal Structure of Envelope Protein VP28 from White Spot Syndrome Virus (WSSV)
2VGD	;	1.8	;	Crystal structure of environmental isolated GH11 in complex with xylobiose and feruloyl-arabino-xylotriose
5GY9	;	1.94	;	Crystal structure of ENZbleach xylanase A74C+G84C mutant
5GYC	;	1.4	;	Crystal structure of ENZbleach xylanase K73R+K185R and T28C+T60C mutant
5GYE	;	1.9	;	Crystal structure of ENZbleach xylanase T28C+T60C and T77C+E249C mutant
5GY8	;	1.8	;	Crystal structure of ENZbleach xylanase T28C+T60C mutant
5GYG	;	1.74	;	Crystal structure of ENZbleach xylanase T28C+T60C mutant with three N-teminal residue truncation
5GYF	;	1.94	;	Crystal structure of ENZbleach xylanase T28C+T60C+L59F mutant
5GYH	;	1.86	;	Crystal structure of ENZbleach xylanase T28C+T60C+T48F+L59F mutant
5GYI	;	1.97	;	Crystal structure of ENZbleach xylanase V176C+E220C mutant
5GYB	;	1.65	;	Crystal structure of ENZbleach xylanase V5N+V6N+K7R+K223R+K227R and T28C+T60C mutant
5GYA	;	1.93	;	Crystal structure of ENZbleach xylanase V5N+V6N+K7R+K223R+K227R mutant
5GV1	;	1.5	;	Crystal structure of ENZbleach xylanase wild type
6X6X	;	1.71	;	Crystal structure of enzymatic binary toxin component from Clostridium difficile in complex with
2WQD	;	2.4	;	Crystal structure of enzyme I of the phosphoenolpyruvate:sugar phosphotransferase system in the dephosphorylated state
5K7Y	;	1.79	;	Crystal structure of enzyme in purine metabolism
5L4Z	;	1.84	;	Crystal structure of enzyme in purine metabolism
5L50	;	1.643	;	Crystal structure of enzyme in purine metabolism
3EK2	;	1.9	;	Crystal structure of eonyl-(acyl carrier protein) reductase from burkholderia pseudomallei 1719b
3K31	;	1.8	;	Crystal structure of eonyl-(acyl-carrier-protein) reductase from anaplasma phagocytophilum in complex with nad at 1.9a resolution
1H1H	;	2.0	;	Crystal Structure of Eosinophil Cationic Protein in Complex with 2',5'-ADP at 2.0 A resolution Reveals the Details of the Ribonucleolytic Active site
5E13	;	1.34	;	Crystal structure of Eosinophil-derived neurotoxin in complex with the triazole double-headed ribonucleoside 11c
3KM3	;	2.1	;	Crystal structure of eoxycytidine triphosphate deaminase from anaplasma phagocytophilum at 2.1A resolution
1V35	;	2.5	;	Crystal Structure of Eoyl-ACP Reductase with NADH
2D23	;	1.95	;	Crystal structure of EP complex of catalytic-site mutant xylanase from Streptomyces olivaceoviridis E-86
6M9T	;	2.5	;	Crystal structure of EP3 receptor bound to misoprostol-FA
5BT3	;	1.05	;	Crystal structure of EP300 bromodomain in complex with SGC-CBP30 chemical probe
7VHY	;	2.3	;	Crystal structure of EP300 HAT domain in complex with compound (+)-3
8GZC	;	2.0	;	Crystal structure of EP300 HAT domain in complex with compound 10
7VI0	;	2.1	;	Crystal structure of EP300 HAT domain in complex with compound 11
7VHZ	;	2.0	;	Crystal structure of EP300 HAT domain in complex with compound 7
6I07	;	2.35	;	Crystal structure of EpCAM in complex with scFv
6ACI	;	1.87	;	Crystal structure of EPEC effector NleB in complex with FADD death domain
3CKH	;	2.8	;	Crystal structure of Eph A4 receptor
4ET7	;	2.6	;	Crystal structure of Eph receptor 5
3GXU	;	2.5	;	Crystal structure of Eph receptor and ephrin complex
3MX0	;	3.506	;	Crystal Structure of EphA2 ectodomain in complex with ephrin-A5
6B9L	;	3.2	;	Crystal structure of EphA2 with peptide 135E2
5ZRX	;	1.5	;	Crystal Structure of EphA2/SHIP2 Complex
6IN0	;	1.501	;	Crystal structure of EphA3 in complex with 18-Crown-6
4M4P	;	2.081	;	Crystal structure of EPHA4 ectodomain
2Y6M	;	1.7	;	Crystal structure of EphA4 kinase domain
2Y6O	;	1.543	;	Crystal structure of EphA4 kinase domain in complex with Dasatinib.
2XYU	;	2.117	;	Crystal structure of EphA4 kinase domain in complex with VUF 12058
5ZRZ	;	1.89	;	Crystal Structure of EphA5/SAMD5 Complex
5ZRY	;	1.3	;	Crystal Structure of EphA6/Odin Complex
7EED	;	3.05	;	Crystal structure of EphA7 mutant D751H
7EEF	;	2.6	;	Crystal structure of EphA7 mutant G656E
7EEC	;	3.1	;	Crystal structure of EphA7 mutant G656R
8J1I	;	1.6	;	Crystal Structure of EphA8/SASH1 Complex
3ZFX	;	2.5	;	Crystal structure of EphB1
3ZFM	;	2.27	;	Crystal structure of EphB2
3ZFY	;	2.2	;	Crystal structure of EphB3
3ZEW	;	2.5	;	Crystal structure of EphB4 in complex with staurosporine
1MQB	;	2.3	;	Crystal Structure of Ephrin A2 (ephA2) Receptor Protein Kinase
5I9U	;	1.889	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase
6FNH	;	1.379	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with a pyrazolo[3,4-d]pyrimidine fragment of NVP-BHG712
5I9V	;	1.458	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with AGS
5IA0	;	1.948	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with alisertib (MLN8237)
6FNG	;	1.038	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with an isomer of NVP-BHG712
5I9W	;	1.359	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with ANP
5I9X	;	1.427	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with bosutinib (SKI-606)
8BOK	;	2.02	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 11
8BOF	;	1.82	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 12
8BOM	;	1.12	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 14
8BOC	;	1.9	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 19
5NJZ	;	1.768	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 1g
5NK0	;	1.597	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 1j
5NK1	;	1.548	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 1k
5NK3	;	1.586	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 1l
5NK5	;	1.329	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 1m
8BOD	;	1.5	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 20
5NK7	;	1.889	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2a
5NK2	;	1.649	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2b
5NK4	;	1.45	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2c
5NK6	;	1.267	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2d
5NK9	;	1.588	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2e
5NK8	;	1.761	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2f
5NKA	;	1.377	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2g
5NKC	;	1.448	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2h
5NKD	;	1.408	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2i
5NKE	;	1.39	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 3a
5NKF	;	1.099	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 3b
5NKG	;	1.1	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 3d
5NKH	;	1.29	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 3e
5NKB	;	1.5	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 4a
5NKI	;	1.675	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 4b
5IA2	;	1.619	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with compound 66
8BOG	;	1.47	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 7
8BOH	;	1.42	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 8
8BOI	;	1.63	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 9
5I9Z	;	1.698	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with danusertib (PHA739358)
5I9Y	;	1.228	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with dasatinib
5IA4	;	1.797	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with foretinib (XL880)
5IA5	;	1.776	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with golvatinib (E7050)
5IA1	;	2.036	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with MLN8054
6FNF	;	1.556	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with NVP-BHG712
5IA3	;	1.788	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with PD173955
6HES	;	1.128	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative AT050
6HET	;	1.208	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative AT055
6HEU	;	1.719	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative AT058
6HEV	;	1.28	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative AT061
6HEW	;	1.268	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative AT069
6Q7B	;	1.009	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative ATDL09
6Q7C	;	1.049	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative ATDL11
6Q7D	;	0.978	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative ATDL13
6Q7E	;	1.059	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative ATDL14
6Q7F	;	1.204	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative ATDL18
6Q7G	;	1.047	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative ATHA01
6HEX	;	1.413	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative ATMM006
6HEY	;	1.367	;	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative ATNK002
6FNL	;	1.269	;	Crystal Structure of Ephrin B4 (EphB4) Receptor Protein Kinase
6FNK	;	1.049	;	Crystal Structure of Ephrin B4 (EphB4) Receptor Protein Kinase with a pyrazolo[3,4-d]pyrimidine fragment of NVP-BHG712
6FNJ	;	1.239	;	Crystal Structure of Ephrin B4 (EphB4) Receptor Protein Kinase with an isomer of NVP-BHG712
6FNM	;	1.157	;	Crystal Structure of Ephrin B4 (EphB4) Receptor Protein Kinase with Dasatinib
6FNI	;	1.468	;	Crystal Structure of Ephrin B4 (EphB4) Receptor Protein Kinase with NVP-BHG712
4LTV	;	2.403	;	Crystal structure of epi-isozizaene synthase from Streptomyces coelicolor A3(2)
1QDA	;	1.6	;	Crystal structure of epidoxorubicin-formaldehyde virtual crosslink of DNA
7EKA	;	1.2	;	crystal structure of epigallocatechin binding with alpha-lactalbumin
7MP4	;	2.43	;	Crystal structure of Epiphyas postvittana antennal carboxylesterase 24
6VQ5	;	2.6	;	Crystal Structure of Epiphyas postvittana Pheromone Binding Protein 3
3E8T	;	1.3	;	Crystal Structure of Epiphyas postvittana Takeout 1
3E8W	;	2.5	;	Crystal Structure of Epiphyas postvittana Takeout 1
4G0S	;	2.191	;	Crystal Structure of Epiphyas postvittana Takeout 1 expressed in Sf9 cells
4AF9	;	1.5	;	Crystal Structure of Epithelial Adhesin 1 A domain (Epa1A) from Candida glabrata in complex with Galb1-3Glc
4D3W	;	1.5	;	Crystal Structure of Epithelial Adhesin 1 A domain (Epa1A) from Candida glabrata in complex with the T-antigen (Galb1-3GalNAc)
4COV	;	1.5	;	Crystal Structure of Epithelial Adhesin 6 A domain (Epa6A) from Candida glabrata in complex with Gala1-3Gal
4COZ	;	2.3	;	Crystal Structure of Epithelial Adhesin 6 A domain (Epa6A) from Candida glabrata in complex with Galb1-3GlcNAc
4COY	;	1.8	;	Crystal Structure of Epithelial Adhesin 6 A domain (Epa6A) from Candida glabrata in complex with Galb1-4GlcNAc
4COU	;	1.48	;	Crystal Structure of Epithelial Adhesin 6 A domain (Epa6A) from Candida glabrata in complex with Lactose
4COW	;	2.15	;	Crystal Structure of Epithelial Adhesin 6 A domain (Epa6A) from Candida glabrata in complex with the T-antigen (Galb1-3GalNAc)
4CP1	;	2.5	;	Crystal Structure of Epithelial Adhesin 9 A domain (Epa9A) from Candida glabrata in complex with Galb1-3GlcNAc
4CP2	;	2.6	;	Crystal Structure of Epithelial Adhesin 9 A domain (Epa9A) from Candida glabrata in complex with Galb1-4GlcNAc
4CP0	;	2.15	;	Crystal Structure of Epithelial Adhesin 9 A domain (Epa9A) from Candida glabrata in complex with Lactose
1PKF	;	2.1	;	Crystal Structure of Epothilone D-bound Cytochrome P450epoK
5CW2	;	2.0	;	Crystal structure of Epoxide Hydrolase A from Mycobacterium thermoresistibile
3RGA	;	1.59	;	Crystal structure of epoxide hydrolase for polyether lasalocid A biosynthesis
4NZZ	;	1.75	;	Crystal structure of epoxide hydrolase from bacillus megaterium
3WMD	;	1.999	;	Crystal structure of epoxide hydrolase MonBI
5XMD	;	2.0	;	Crystal structure of epoxide hydrolase VrEH1 from Vigna radiata
1G65	;	2.25	;	Crystal structure of epoxomicin:20s proteasome reveals a molecular basis for selectivity of alpha,beta-epoxyketone proteasome inhibitors
7LC5	;	1.5	;	Crystal structure of epoxyqueuosine reductase QueH from Thermotoga maritima
7LC7	;	1.58	;	Crystal structure of epoxyqueuosine reductase QueH in complex with GMP from Thermotoga maritima
5D0B	;	2.645	;	Crystal structure of epoxyqueuosine reductase with a tRNA-TYR epoxyqueuosine-modified tRNA stem loop
5D0A	;	2.1	;	Crystal structure of epoxyqueuosine reductase with cleaved RNA stem loop
7CZE	;	3.0	;	Crystal structure of Epstein-Barr virus (EBV) gHgL and in complex with the ligand binding domian (LBD) of EphA2
7S0J	;	2.15	;	Crystal structure of Epstein-Barr virus gH/gL targeting antibody 769B10
7S08	;	2.42	;	Crystal structure of Epstein-Barr virus gH/gL targeting antibody 770F7
8TNT	;	3.15	;	Crystal structure of Epstein-Barr virus gH/gL/gp42 in complex with antibodies F-2-1 and 769C2
8TNN	;	3.36	;	Crystal structure of Epstein-Barr virus gH/gL/gp42 in complex with gp42 antibody A10
7S07	;	3.29	;	Crystal structure of Epstein-Barr virus glycoprotein gH/gL/gp42-peptide in complex with human neutralizing antibodies 769B10 and 769C2
7S1B	;	3.03	;	Crystal structure of Epstein-Barr virus glycoproteins gH/gL/gp42-peptide in complex with human neutralizing antibodies 769C2 and 770F7
8TOO	;	2.6	;	Crystal structure of Epstein-Barr virus gp42 in complex with antibody 4C12
3FD4	;	2.4	;	Crystal Structure of Epstein-Barr virus gp42 protein
1Y6M	;	2.8	;	Crystal structure of Epstein-Barr virus IL-10 complexed with the soluble IL-10R1 chain
1Y6N	;	2.7	;	Crystal structure of Epstein-Barr virus IL-10 mutant (A87I) complexed with the soluble IL-10R1 chain
6VH6	;	1.3	;	Crystal structure of Epstein-Barr Virus Nuclear Antigen-1, EBNA1, bound to fragment
6NPI	;	1.501	;	Crystal structure of Epstein-Barr Virus Nuclear Antigen-1, EBNA1, bound to fragments
6NPM	;	1.603	;	Crystal structure of Epstein-Barr Virus Nuclear Antigen-1, EBNA1, bound to fragments
6NPP	;	1.35	;	Crystal structure of Epstein-Barr Virus Nuclear Antigen-1, EBNA1, bound to fragments
1HEK	;	2.8	;	Crystal structure of equine infectious anaemia virus matrix antigen (EIAV MA)
4ZUW	;	2.6	;	Crystal structure of Equine MHC I(Eqca-N*00601) in complexed with equine infectious anaemia virus (EIAV) derived peptide Gag-GW12
4ZUV	;	2.3	;	Crystal structure of Equine MHC I(Eqca-N*00602) in complexed with equine infectious anaemia virus (EIAV) derived peptide Env-RW12
4ZUU	;	2.2	;	Crystal structure of Equine MHC I(Eqca-N*00602) in complexed with equine infectious anaemia virus (EIAV) derived peptide Gag-CF9
4ZUT	;	2.6	;	Crystal structure of Equine MHC I(Eqca-N*00602) in complexed with equine infectious anaemia virus (EIAV) derived peptide Gag-GW12
4ZUS	;	2.6	;	Crystal structure of Equine MHC I(Eqca-N*00602) in complexed with equine infectious anaemia virus (EIAV) derived peptide REV-QW11
3V08	;	2.45	;	Crystal structure of Equine Serum Albumin
4F5T	;	2.32	;	Crystal Structure of Equine Serum Albumin
5HOZ	;	2.15	;	Crystal structure of Equine Serum Albumin (ESA) at pH 9.0
4F5U	;	2.04	;	Crystal structure of Equine Serum Albumin at 2.04 resolution
6U5A	;	2.65	;	Crystal structure of Equine Serum Albumin complex with 6-MNA
5V0V	;	2.45	;	Crystal structure of Equine Serum Albumin complex with etodolac
6U4X	;	2.25	;	Crystal structure of Equine Serum Albumin complex with ibuprofen
6U4R	;	2.45	;	Crystal structure of Equine Serum Albumin complex with ketoprofen
4J2V	;	2.12	;	Crystal Structure of Equine Serum Albumin in complex with 3,5-diiodosalicylic acid
7Q4X	;	2.12	;	Crystal Structure of Equine Serum Albumin in Complex with Cefaclor
7MBL	;	2.7	;	Crystal structure of Equine Serum Albumin in complex with Cobalt (II)
4ZBQ	;	1.92	;	Crystal Structure of Equine Serum Albumin in complex with Diclofenac
4ZBR	;	2.19	;	Crystal Structure of Equine Serum Albumin in complex with Diclofenac and Naproxen
5DBY	;	2.35	;	Crystal Structure of Equine Serum Albumin in Complex with Diclofenac and Naproxen Obtained in Displacement Experiment
6OCI	;	2.54	;	Crystal Structure of Equine Serum Albumin in Complex with Ibuprofen
6CI6	;	2.8	;	Crystal structure of equine serum albumin in complex with nabumetone
4OT2	;	2.42	;	Crystal Structure of Equine Serum Albumin in complex with Naproxen
5ID9	;	2.48	;	Crystal structure of equine serum albumin in complex with phosphorodithioate derivative of myristoyl cyclic phosphatidic acid (cPA)
6OCJ	;	2.5	;	Crystal Structure of Equine Serum Albumin in Complex with Suprofen
6MDQ	;	2.15	;	Crystal structure of equine serum albumin in complex with testosterone
5IIU	;	2.3	;	Crystal structure of Equine Serum Albumin in the presence of 10 mM zinc at pH 6.9
5IIX	;	2.2	;	Crystal structure of Equine Serum Albumin in the presence of 15 mM zinc at pH 6.5
5IIH	;	2.4	;	Crystal structure of Equine Serum Albumin in the presence of 2.5 mM zinc at pH 7.4
5IJE	;	2.4	;	Crystal structure of Equine Serum Albumin in the presence of 30 mM zinc at pH 7.4
5IJ5	;	2.55	;	Crystal structure of Equine Serum Albumin in the presence of 50 mM zinc at pH 4.5
6ZJ9	;	2.2	;	Crystal structure of Equus ferus caballus glutathione transferase A3-3 in complex with glutathione
6ZJC	;	2.2	;	Crystal structure of Equus ferus caballus glutathione transferase A3-3 in complex with glutathione and triethyltin
5TOA	;	2.5	;	Crystal Structure of ER beta bound to Estradiol
5JQP	;	2.2	;	Crystal structure of ER glucosidase II heterodimeric complex consisting of catalytic subunit and the binding domain of regulatory subunit
3IEU	;	2.8	;	Crystal Structure of ERA in Complex with GDP
3R9W	;	2.05	;	Crystal structure of Era in complex with MgGDPNP and nucleotides 1506-1542 of 16S ribosomal RNA
3R9X	;	2.8	;	Crystal structure of Era in complex with MgGDPNP, nucleotides 1506-1542 of 16S ribosomal RNA, and KsgA
3IEV	;	1.9	;	Crystal Structure of ERA in Complex with MgGNP and the 3' End of 16S rRNA
4DMA	;	2.3	;	Crystal structure of ERa LBD in complex with RU100132
3RJO	;	2.3	;	Crystal Structure of ERAP1 Peptide Binding Domain
7PFS	;	2.7	;	Crystal structure of ERAP2 aminopeptidase in complex with phosphinic pseudotripeptide ((1R)-1-Amino-3-phenylpropyl){2-([1,1:3,1-terphenyl]-5-ylmethyl)-3-[((2S)-1-amino-1-oxo-3-phenylpropan-2-yl)-amino]-3-oxopropyl}phosphinic acid
7P7P	;	3.0	;	Crystal structure of ERAP2 aminopeptidase in complex with phosphinic pseudotripeptide((1R)-1-Amino-3-phenylpropyl){(2S)-3-[((2S)-1-amino-1-oxo-3-phenylpropan-2-yl)amino]-2-{[3-(2-hydroxyphenyl)-isoxazol-5-yl]methyl}-3-oxopropyl}phosphinic acid
5CU5	;	3.02	;	Crystal structure of ERAP2 without catalytic Zn(II) atom
2A91	;	2.5	;	Crystal structure of ErbB2 domains 1-3
2V6C	;	2.5	;	Crystal structure of ErbB3 binding protein 1 (Ebp1)
6KBI	;	3.0	;	Crystal structure of ErbB3 N418Q mutant
2AHX	;	2.396	;	Crystal structure of ErbB4/HER4 extracellular domain
2H3L	;	1.0	;	Crystal Structure of ERBIN PDZ
5AYK	;	2.25	;	Crystal structure of ERdj5 form I
5AYL	;	2.4	;	Crystal structure of ERdj5 form II
5M87	;	3.3	;	Crystal structure of Eremococcus coleocola manganese transporter
6TL2	;	3.8	;	Crystal structure of Eremococcus coleocola manganese transporter in complex with an aromatic bis-isothiourea substituted compound
5M8A	;	3.9	;	Crystal structure of Eremococcus coleocola manganese transporter mutant E129A
5M8K	;	3.6	;	Crystal structure of Eremococcus coleocola manganese transporter mutant E129Q
5M8J	;	3.7	;	Crystal structure of Eremococcus coleocola manganese transporter mutant H236A
6UMG	;	2.7	;	Crystal structure of erenumab Fab bound to the extracellular domain of CGRP receptor
6UMH	;	2.15	;	Crystal structure of erenumab Fab-a
6UMI	;	2.4	;	Crystal structure of erenumab Fab-b
6UMJ	;	2.7	;	Crystal structure of erenumab Fab-c
3WHT	;	1.8	;	Crystal structure of ERGIC-53/MCFD2, Calcium-free form
3WHU	;	2.6	;	Crystal structure of ERGIC-53/MCFD2, Calcium/Man2-bound form
3WNX	;	2.75	;	Crystal structure of ERGIC-53/MCFD2, Calcium/Man3-bound form
4YGC	;	2.4	;	Crystal structure of ERGIC-53/MCFD2, monoclinic calcium-bound form 1
4YGD	;	2.51	;	Crystal structure of ERGIC-53/MCFD2, monoclinic calcium-bound form 2
4YGB	;	1.6	;	Crystal structure of ERGIC-53/MCFD2, monoclinic calcium-free form
4YGE	;	3.05	;	Crystal structure of ERGIC-53/MCFD2, trigonal calcium-bound form 2
6S7Q	;	2.7	;	Crystal structure of ergothioneine degrading enzyme Ergothionase from Treponema denticola in complex with desmethyl-ergothioneine sulfonic acid
7N8W	;	2.35	;	Crystal structure of ERI2 nuclease bound to rAMP
4F5E	;	2.601	;	Crystal structure of ERIS/STING
3C9W	;	2.5	;	Crystal Structure of ERK-2 with hypothemycin covalently bound
6GES	;	2.07	;	Crystal structure of ERK1 covalently bound to SM1-71
4S32	;	1.34	;	Crystal structure of ERK2 AMP-PNP complex
3I60	;	2.5	;	Crystal structure of ERK2 bound to (S)-4-(2-(2-chlorophenylamino)-5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-2-carboxamide
3I5Z	;	2.2	;	Crystal structure of ERK2 bound to (S)-N-(2-hydroxy-1-phenylethyl)-4-(5-methyl-2-(phenylamino)pyrimidin-4-yl)-1H-pyrrole-2-carboxamide
2FYS	;	2.5	;	Crystal structure of Erk2 complex with KIM peptide derived from MKP3
5AX3	;	2.984	;	Crystal structure of ERK2 complexed with allosteric and ATP-competitive inhibitors.
6G54	;	2.05	;	Crystal structure of ERK2 covalently bound to SM1-71
6D5Y	;	2.86	;	Crystal structure of ERK2 G169D mutant
4QP3	;	2.599	;	Crystal Structure of ERK2 in complex with (S)-2-((9H-purin-6-yl)amino)-3-phenylpropan-1-ol
2OJJ	;	2.4	;	Crystal structure of ERK2 in complex with (S)-N-(1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl)-4-(4-(3-chlorophenyl)-1H-pyrazol-3-yl)-1H-pyrrole-2-carboxamide
4QP7	;	2.249	;	Crystal Structure of ERK2 in complex with 2-(1H-pyrazol-4-yl)-5H-pyrrolo[2,3-b]pyrazine
4QP8	;	2.446	;	Crystal Structure of ERK2 in complex with 2-(1H-pyrazol-4-yl)-7-(pyridin-3-yl)-5H-pyrrolo[2,3-b]pyrazine
4QP6	;	3.1	;	Crystal Structure of ERK2 in complex with 5H-pyrrolo[2,3-b]pyrazine
4QPA	;	2.85	;	Crystal Structure of ERK2 in complex with 7-(1-benzyl-1H-pyrazol-4-yl)-2-(pyridin-4-yl)-5H-pyrrolo[2,3-b]pyrazine
4QP9	;	2.001	;	Crystal Structure of ERK2 in complex with 7-(1-propyl-1H-pyrazol-4-yl)-2-(pyridin-4-yl)-5H-pyrrolo[2,3-b]pyrazine
6FI3	;	1.52	;	Crystal structure of ERK2 in complex with an adenosine derivative
6FI6	;	1.65	;	Crystal structure of ERK2 in complex with an adenosine derivative
6FJ0	;	1.659	;	Crystal structure of ERK2 in complex with an adenosine derivative
6FJB	;	1.85	;	Crystal structure of ERK2 in complex with an adenosine derivative
6FJZ	;	1.864	;	Crystal structure of ERK2 in complex with an adenosine derivative
6FLE	;	1.48	;	Crystal structure of ERK2 in complex with an adenosine derivative
6FLV	;	1.91	;	Crystal structure of ERK2 in complex with an adenosine derivative
6FMA	;	1.667	;	Crystal structure of ERK2 in complex with an adenosine derivative
6FN5	;	1.932	;	Crystal structure of ERK2 in complex with an adenosine derivative
6FQ7	;	1.6	;	Crystal structure of ERK2 in complex with an adenosine derivative
6FR1	;	1.561	;	Crystal structure of ERK2 in complex with an adenosine derivative
6FRP	;	1.53	;	Crystal structure of ERK2 in complex with an adenosine derivative
6FXV	;	1.53	;	Crystal structure of ERK2 in complex with an adenosine derivative
3QYW	;	1.5	;	Crystal structure of ERK2 in complex with an inhibitor
3QYZ	;	1.46	;	Crystal structure of ERK2 in complex with an inhibitor
4XNE	;	1.8	;	Crystal structure of ERK2 in complex with an inhibitor
4XOY	;	2.1	;	Crystal structure of ERK2 in complex with an inhibitor
4XOZ	;	1.95	;	Crystal structure of ERK2 in complex with an inhibitor
4XP0	;	1.46	;	Crystal structure of ERK2 in complex with an inhibitor
4XP2	;	1.748	;	Crystal structure of ERK2 in complex with an inhibitor
4XP3	;	1.782	;	Crystal structure of ERK2 in complex with an inhibitor
4XRJ	;	1.69	;	Crystal structure of ERK2 in complex with an inhibitor
4XJ0	;	2.58	;	Crystal structure of ERK2 in complex with an inhibitor 14K
5K4I	;	1.76	;	Crystal Structure of ERK2 in complex with compound 22
2OJG	;	2.0	;	Crystal structure of ERK2 in complex with N,N-dimethyl-4-(4-phenyl-1H-pyrazol-3-yl)-1H-pyrrole-2-carboxamide
2OJI	;	2.6	;	Crystal structure of ERK2 in complex with N-benzyl-4-(4-(3-chlorophenyl)-1H-pyrazol-3-yl)-1H-pyrrole-2-carboxamide
4QP1	;	2.7	;	Crystal structure of ERK2 in complex with N-cyclohexyl-9H-purin-6-amine
4QP4	;	2.2	;	Crystal Structure of ERK2 in complex with N-cyclohexyl-9H-purin-6-amine
7W5O	;	2.35	;	Crystal structure of ERK2 with an allosteric inhibitor
7X4U	;	1.98	;	Crystal structure of ERK2 with an allosteric inhibitor 2
7XC1	;	2.09	;	Crystal structure of ERK2 with an allosteric inhibitor 3
3O71	;	1.95	;	Crystal structure of ERK2/DCC peptide complex
4QP2	;	2.23	;	Crystal Structure of ERKs in complex with 5-chlorobenzo[d]oxazol-2-amine
2ERC	;	3.03	;	CRYSTAL STRUCTURE OF ERMC' A RRNA-METHYL TRANSFERASE
5V8Z	;	2.105	;	Crystal structure of ERp29 D-domain in complex with the P-domain of calmegin
5V90	;	3.255	;	Crystal structure of ERp29 D-domain in complex with the P-domain of calreticulin
3WGD	;	2.5	;	Crystal structure of ERp46 Trx1
3WGE	;	0.95	;	Crystal structure of ERp46 Trx2
3WGX	;	0.92	;	Crystal structure of ERp46 Trx2 in a complex with Prx4 C-term
1JR8	;	1.5	;	Crystal Structure of Erv2p
1JRA	;	2.0	;	Crystal Structure of Erv2p
3ZLC	;	1.999	;	Crystal Structure of Erv41p
7DUD	;	1.95	;	Crystal Structure of erWalK
1JSL	;	1.7	;	Crystal structure of Erwinia chrysanthemi L-asparaginase complexed with 6-HYDROXY-D-NORLEUCINE
1JSR	;	1.7	;	CRYSTAL STRUCTURE OF ERWINIA CHRYSANTHEMI L-ASPARAGINASE COMPLEXED WITH 6-HYDROXY-L-NORLEUCINE
8FIB	;	1.68	;	Crystal Structure of Erwinia tracheiphila CYP114
8FIC	;	1.7	;	Crystal Structure of Erwinia tracheiphila CYP114 in complex with ent-kaurenoic acid (Crystal Form 1)
8FID	;	1.83	;	Crystal Structure of Erwinia tracheiphila CYP114 in complex with ent-kaurenoic acid (Crystal Form 2)
8FIE	;	2.26	;	Crystal Structure of Erwinia tracheiphila CYP114 mutant - A261D
1FYU	;	2.6	;	Crystal structure of erythrina corallodendron lectin in hexagonal crystal form
1YI2	;	2.65	;	Crystal Structure Of Erythromycin Bound To The G2099A Mutant 50S Ribosomal Subunit Of Haloarcula Marismortui
2D24	;	1.85	;	Crystal structure of ES complex of catalytic-site mutant xylanase from Streptomyces olivaceoviridis E-86
8GUP	;	2.29872	;	Crystal structure of EsaG from Staphylococcus aureus
1IYD	;	2.15	;	CRYSTAL STRUCTURE OF ESCHELICHIA COLI BRANCHED-CHAIN AMINO ACID AMINOTRANSFERASE
1IYE	;	1.82	;	CRYSTAL STRUCTURE OF ESCHELICHIA COLI BRANCHED-CHAIN AMINO ACID AMINOTRANSFERASE
1I1K	;	2.1	;	CRYSTAL STRUCTURE OF ESCHELICHIA COLI BRANCHED-CHAIN AMINO ACID AMINOTRANSFERASE.
1I1L	;	2.4	;	CRYSTAL STRUCTURE OF ESCHELICHIA COLI BRANCHED-CHAIN AMINO ACID AMINOTRANSFERASE.
4PDX	;	1.75	;	Crystal structure of Escherchia coli uncharacterized protein YjcS
5YGU	;	2.298	;	Crystal structure of Escherichia coli (strain K12) mRNA Decapping Complex RppH-DapF
1NR9	;	2.7	;	Crystal Structure of Escherichia coli 1262 (APC5008), Putative Isomerase
5HW4	;	2.211	;	Crystal structure of Escherichia coli 16S rRNA methyltransferase RsmI in complex with AdoMet
4BLU	;	1.85	;	Crystal structure of Escherichia coli 23S rRNA (A2030-N6)- methyltransferase RlmJ
4BLW	;	1.95	;	Crystal structure of Escherichia coli 23S rRNA (A2030-N6)- methyltransferase RlmJ in complex with S-adenosylhomocysteine (AdoHcy) and Adenosine monophosphate (AMP)
4BLV	;	2.0	;	Crystal structure of Escherichia coli 23S rRNA (A2030-N6)- methyltransferase RlmJ in complex with S-adenosylmethionine (AdoMet)
4YML	;	1.75	;	Crystal structure of Escherichia coli 5'-methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) complexed with (3S,4R)-methylthio-DADMe-Immucillin-A
4WKC	;	1.64	;	Crystal structure of Escherichia coli 5'-methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) complexed with butylthio-DADMe-Immucillin-A
7Y94	;	1.5	;	Crystal structure of Escherichia coli Adenine Phosphoribosyltransferase (APRT) in complex with Adenine
8IZJ	;	1.6	;	Crystal structure of Escherichia coli Adenine Phosphoribosyltransferase (APRT) in complex with AMP
7XI2	;	1.65	;	Crystal structure of Escherichia coli Adenine Phosphoribosyltransferase (APRT) in complex with phosphate
2PTR	;	1.85	;	Crystal structure of Escherichia coli adenylosuccinate lyase mutant H171A with bound adenylosuccinate substrate
2PTQ	;	2.0	;	Crystal structure of Escherichia coli adenylosuccinate lyase mutant H171N with bound AMP and fumarate
3B8U	;	3.0	;	Crystal structure of Escherichia coli alaine racemase mutant E221A
3B8V	;	2.6	;	Crystal structure of Escherichia coli alaine racemase mutant E221K
3B8W	;	2.7	;	Crystal structure of Escherichia coli alaine racemase mutant E221P
3B8T	;	3.0	;	Crystal structure of Escherichia coli alaine racemase mutant P219A
1M41	;	2.3	;	Crystal structure of Escherichia coli alkanesulfonate monooxygenase SsuD at 2.3 A resolution
3KHC	;	2.2	;	Crystal Structure of Escherichia coli AlkB in complex with ssDNA containing a 1-methylguanine lesion
3KHB	;	2.9	;	Crystal structure of Escherichia coli AlkB with Co(II) and 2-OG
6EZZ	;	1.8	;	Crystal structure of Escherichia coli amine oxidase mutant E573Q
6GRR	;	1.7	;	Crystal structure of Escherichia coli amine oxidase mutant I342F/E573Q
7U9H	;	2.0	;	Crystal Structure of Escherichia coli apo Pyridoxal 5'-phosphate homeostasis protein (YGGS)
1T4D	;	1.95	;	Crystal structure of Escherichia coli aspartate beta-semialdehyde dehydrogenase (EcASADH), at 1.95 Angstrom resolution
4U3G	;	2.0	;	Crystal structure of Escherichia coli bacterioferritin mutant D132F
3Q54	;	2.004	;	Crystal structure of Escherichia coli BamB
3P1L	;	2.6	;	Crystal structure of Escherichia coli BamB, a lipoprotein component of the beta-barrel assembly machinery complex, native crystals.
3Q5M	;	2.604	;	Crystal structure of Escherichia coli BamD
1T75	;	2.5	;	Crystal structure of Escherichia coli beta carbonic anhydrase
1I1M	;	2.4	;	CRYSTAL STRUCTURE OF ESCHERICHIA COLI BRANCHED-CHAIN AMINO ACID AMINOTRANSFERASE.
4ZNZ	;	2.7	;	Crystal structure of Escherichia coli carbonic anhydrase (YadF) in complex with Zn - artifact of purification
3CHY	;	1.66	;	CRYSTAL STRUCTURE OF ESCHERICHIA COLI CHEY REFINED AT 1.7-ANGSTROM RESOLUTION
7MK5	;	2.95	;	Crystal structure of Escherichia coli ClpP covalently inhibited by clipibicyclene
6NB1	;	1.9	;	Crystal structure of Escherichia coli ClpP protease complexed with small molecule activator, ACP1-06
1EW4	;	1.4	;	CRYSTAL STRUCTURE OF ESCHERICHIA COLI CYAY PROTEIN REVEALS A NOVEL FOLD FOR THE FRATAXIN FAMILY
6HEG	;	3.019	;	Crystal structure of Escherichia coli DEAH/RHA helicase HrpB
2YVA	;	1.85	;	Crystal structure of Escherichia coli DiaA
4U6N	;	1.91	;	Crystal structure of Escherichia coli DiaA
4D9K	;	2.19	;	Crystal structure of Escherichia coli Diaminopropionate ammonia lyase in apo form
6NVA	;	2.16	;	Crystal structure of Escherichia coli dihydrodipicolinate synthase and propionate covalently bound to K161.
7NAE	;	2.35	;	Crystal structure of Escherichia coli dihydrofolate reductase in complex with TRIMETHOPRIM
7MYM	;	3.04	;	Crystal structure of Escherichia coli dihydrofolate reductase in complex with TRIMETHOPRIM and NADPH
3U41	;	2.5	;	Crystal structure of Escherichia coli DmsD in space group P212121
1Q8I	;	2.0	;	Crystal structure of ESCHERICHIA coli DNA Polymerase II
4XJ6	;	2.31	;	Crystal structure of Escherichia coli DncV 3'-deoxy GTP bound form
6BQX	;	1.992	;	Crystal structure of Escherichia coli DsbA in complex with N-methyl-1-(4-phenoxyphenyl)methanamine
6BR4	;	1.99	;	Crystal structure of Escherichia coli DsbA in complex with {N}-methyl-1-(3-thiophen-2-ylphenyl)methanamine
5Z6N	;	2.6	;	Crystal structure of Escherichia coli ElaA
2NQJ	;	2.45	;	Crystal structure of Escherichia coli endonuclease IV (Endo IV) E261Q mutant bound to damaged DNA
1QUM	;	1.55	;	CRYSTAL STRUCTURE OF ESCHERICHIA COLI ENDONUCLEASE IV IN COMPLEX WITH DAMAGED DNA
6D3Q	;	2.24	;	Crystal structure of Escherichia coli enolase complexed with a natural inhibitor SF2312.
3HWO	;	2.3	;	Crystal structure of Escherichia coli enterobactin-specific isochorismate synthase EntC in complex with isochorismate
4XGV	;	1.883	;	Crystal structure of Escherichia coli Flavin trafficking protein, an FMN transferase
4XGW	;	1.747	;	Crystal structure of Escherichia coli Flavin trafficking protein, an FMN transferase, E169K mutant
4XGX	;	1.9	;	Crystal structure of Escherichia coli Flavin trafficking protein, an FMN transferase, Y60N mutant, ADP-inhibited
1PMM	;	2.0	;	Crystal structure of Escherichia coli GadB (low pH)
1PMO	;	2.3	;	Crystal structure of Escherichia coli GadB (neutral pH)
2DGL	;	3.15	;	Crystal structure of Escherichia coli GadB in complex with bromide
2DGM	;	1.95	;	Crystal structure of Escherichia coli GadB in complex with iodide
2Z8K	;	1.65	;	Crystal Structure of Escherichia coli gamma-Glutamyltranspeptidase in Complex with Acivicin
2Z8I	;	1.65	;	Crystal Structure of Escherichia coli Gamma-Glutamyltranspeptidase in Complex with Azaserine
2Z8J	;	2.05	;	Crystal Structure of Escherichia coli gamma-Glutamyltranspeptidase in Complex with Azaserine prepared in the dark
5B5T	;	1.7	;	Crystal Structure of Escherichia coli Gamma-Glutamyltranspeptidase in Complex with peptidyl phosphonate inhibitor 1b
1J2R	;	1.3	;	Crystal structure of Escherichia coli gene product Yecd at 1.3 A resolution
3A5Z	;	2.5	;	Crystal structure of Escherichia coli GenX in complex with elongation factor P
2JFN	;	1.9	;	Crystal structure of Escherichia coli glutamate racemase in complex with L- Glutamate and activator UDP-MurNAc-ala
4KX4	;	1.6	;	Crystal structure of Escherichia coli glutaredoxin 2 complex with glutathione
4KSM	;	2.4	;	Crystal structure of Escherichia coli glutraredoxin 2 C9S/C12S mutant without glutathione
2R45	;	2.3	;	Crystal structure of Escherichia coli Glycerol-3-phosphate Dehydrogenase in complex with 2-phospho-d-glyceric acid
2R46	;	2.1	;	Crystal structure of Escherichia coli Glycerol-3-phosphate Dehydrogenase in complex with 2-phosphopyruvic acid.
2R4E	;	2.1	;	Crystal structure of Escherichia coli Glycerol-3-phosphate Dehydrogenase in complex with DHAP
6RZ0	;	1.1	;	Crystal structure of Escherichia coli Glyoxalase II
6S0I	;	1.803	;	Crystal structure of Escherichia coli Glyoxalase II with L-Tartrate in the active site
8I01	;	2.15	;	Crystal structure of Escherichia coli glyoxylate carboligase
8I05	;	2.09	;	Crystal structure of Escherichia coli glyoxylate carboligase double mutant
8I07	;	1.99	;	Crystal structure of Escherichia coli glyoxylate carboligase double mutant in complex with glycolaldehyde
8I08	;	1.91	;	Crystal structure of Escherichia coli glyoxylate carboligase quadruple mutant
6PBZ	;	2.475	;	Crystal structure of Escherichia coli GppA
4ZCI	;	2.627	;	Crystal Structure of Escherichia coli GTPase BipA/TypA
4ZCL	;	3.06	;	Crystal Structure of Escherichia coli GTPase BipA/TypA Complexed with GDP
4ZCM	;	3.31	;	Crystal Structure of Escherichia coli GTPase BipA/TypA Complexed with ppGpp
1ONS	;	2.2	;	Crystal structure of Escherichia coli heat shock protein YedU
4JUV	;	2.19	;	Crystal Structure of Escherichia coli Hfq Distal Face 1 Mutant
4JRI	;	1.829	;	Crystal Structure of Escherichia coli Hfq Proximal Edge Mutant
4JLI	;	1.79	;	Crystal Structure of Escherichia coli Hfq Proximal Pore Mutant
4JRK	;	1.894	;	Crystal Structure of Escherichia coli Hfq Surface Mutant
3QO3	;	2.15	;	Crystal structure of Escherichia coli Hfq, in complex with ATP
5XU7	;	1.84	;	Crystal structure of Escherichia coli holo-[acyl-carrier-protein] synthase (AcpS)
5XUH	;	2.02	;	Crystal structure of Escherichia coli holo-[acyl-carrier-protein] synthase (AcpS) D9A mutant in complex with CoA
6AN4	;	1.47	;	Crystal structure of Escherichia coli HPPK in complex with bisubstrate analogue inhibitor HP-39 (J1F)
6AN6	;	2.3	;	Crystal structure of Escherichia coli HPPK in complex with bisubstrate analogue inhibitor HP-72
7KDO	;	1.6	;	Crystal structure of Escherichia coli HPPK in complex with bisubstrate inhibitor HP-73
7KDR	;	1.488	;	Crystal structure of Escherichia coli HPPK in complex with bisubstrate inhibitor HP-75
1YBQ	;	2.0	;	Crystal structure of Escherichia coli isoaspartyl dipeptidase mutant D285N complexed with beta-aspartylhistidine
2OFP	;	2.3	;	Crystal structure of Escherichia coli ketopantoate reductase in a ternary complex with NADP+ and pantoate
4F2D	;	2.3	;	Crystal Structure of Escherichia coli L-arabinose Isomerase (ECAI) complexed with Ribitol
3ECA	;	2.4	;	CRYSTAL STRUCTURE OF ESCHERICHIA COLI L-ASPARAGINASE, AN ENZYME USED IN CANCER THERAPY (ELSPAR)
5AZC	;	1.902	;	Crystal structure of Escherichia coli Lgt in complex with phosphatidylglycerol
5AZB	;	1.6	;	Crystal structure of Escherichia coli Lgt in complex with phosphatidylglycerol and the inhibitor palmitic acid
7OKC	;	1.84	;	Crystal structure of Escherichia coli LpxA in complex with compound 1
3CRA	;	2.1	;	Crystal Structure of Escherichia coli MazG, the Regulator of Nutritional Stress Response
3CRC	;	3.0	;	Crystal Structure of Escherichia coli MazG, the Regulator of Nutritional Stress Response
3T88	;	1.998	;	Crystal structure of Escherichia coli MenB in complex with substrate analogue, OSB-NCoA
3T89	;	1.949	;	Crystal structure of Escherichia coli MenB, the 1,4-dihydroxy-2-naphthoyl-CoA synthase in vitamin K2 biosynthesis
3FSU	;	1.7	;	Crystal Structure of Escherichia coli Methylenetetrahydrofolate Reductase Double Mutant Phe223LeuGlu28Gln complexed with methyltetrahydrofolate
3FST	;	1.65	;	Crystal Structure of Escherichia coli Methylenetetrahydrofolate Reductase Mutant Phe223Leu at pH 7.4
1NP6	;	1.9	;	Crystal structure of Escherichia coli MobB
1P9N	;	2.8	;	Crystal structure of Escherichia coli MobB.
1G8L	;	1.95	;	CRYSTAL STRUCTURE OF ESCHERICHIA COLI MOEA
4HWA	;	4.37	;	Crystal Structure of Escherichia coli MscS Wildtype (Open State)
6SYM	;	1.6302	;	Crystal structure of Escherichia coli MsrB (reduced form)
2WTU	;	3.4	;	Crystal structure of Escherichia coli MutS in complex with a 16 basepair oligo containing an A.A mismatch.
3X22	;	2.001	;	Crystal structure of Escherichia coli nitroreductase NfsB mutant N71S/F123A/F124W
3X21	;	3.002	;	Crystal structure of Escherichia coli nitroreductase NfsB mutant T41L/N71S/F124W
3TOR	;	2.0	;	Crystal structure of Escherichia coli NrfA with Europium bound
1TXK	;	2.5	;	Crystal structure of Escherichia coli OpgG
6TAJ	;	1.6	;	Crystal structure of Escherichia coli Orotate Phosphoribosyltransferase in complex with Orotic acid 1.60 Angstrom resolution
6TAK	;	1.25	;	Crystal structure of Escherichia coli Orotate Phosphoribosyltransferase in complex with Orotic acid and Sulfate at 1.25 Angstrom resolution
6TAI	;	1.551	;	Crystal structure of Escherichia coli Orotate Phosphoribosyltransferase with an empty active site at 1.55 Angstrom resolution
1NT4	;	2.4	;	Crystal structure of Escherichia coli periplasmic glucose-1-phosphatase H18A mutant complexed with glucose-1-phosphate
6RMR	;	2.50005	;	Crystal structure of Escherichia coli periplasmic glucose-1-phosphatase H18D mutant
3QK6	;	2.4	;	Crystal structure of Escherichia coli PhnD
3P7I	;	1.71	;	Crystal structure of Escherichia coli PhnD in complex with 2-aminoethyl phosphonate
6L06	;	2.6	;	Crystal structure of Escherichia coli phosphatidylserine decarboxylase (apo-form)
6L07	;	3.6	;	Crystal structure of Escherichia coli phosphatidylserine decarboxylase (PE-bound form)
2OLR	;	1.6	;	Crystal structure of Escherichia coli phosphoenolpyruvate carboxykinase complexed with carbon dioxide, Mg2+, ATP
2I2W	;	1.95	;	Crystal Structure of Escherichia Coli Phosphoheptose Isomerase
2I22	;	2.8	;	Crystal structure of Escherichia coli phosphoheptose isomerase in complex with reaction substrate sedoheptulose 7-phosphate
1DKL	;	2.3	;	CRYSTAL STRUCTURE OF ESCHERICHIA COLI PHYTASE AT PH 4.5 (NO LIGAND BOUND)
1DKN	;	2.4	;	CRYSTAL STRUCTURE OF ESCHERICHIA COLI PHYTASE AT PH 5.0 WITH HG2+ CATION ACTING AS AN INTERMOLECULAR BRIDGE
1DKM	;	2.25	;	CRYSTAL STRUCTURE OF ESCHERICHIA COLI PHYTASE AT PH 6.6 WITH HG2+ CATION ACTING AS AN INTERMOLECULAR BRIDGE
4G9S	;	0.95	;	Crystal structure of Escherichia coli PliG in complex with Atlantic salmon g-type lysozyme
4DY3	;	1.8	;	crystal structure of Escherichia coli PliG, a periplasmic lysozyme inhibitor of g-type lysozyme
1XDO	;	3.0	;	Crystal Structure of Escherichia coli Polyphosphate Kinase
7EYJ	;	1.38	;	Crystal structure of Escherichia coli ppnP
7EYK	;	1.38	;	Crystal structure of Escherichia coli ppnP-Selenomethionine derived
4TNN	;	1.951	;	Crystal structure of Escherichia coli protein YodA in complex with Ni - artifact of purification.
2AA4	;	2.2	;	Crystal structure of Escherichia coli putative N-ACETYLMANNOSAMINE KINASE, New York Structural Genomics Consortium
6K0K	;	2.68	;	Crystal structure of Escherichia coli pyruvate kinase II
1QOR	;	2.2	;	CRYSTAL STRUCTURE OF ESCHERICHIA COLI QUINONE OXIDOREDUCTASE COMPLEXED WITH NADPH
4NUB	;	2.7	;	Crystal structure of Escherichia coli ribosomal oxygenase YcfD
5NWT	;	3.76	;	Crystal Structure of Escherichia coli RNA polymerase - Sigma54 Holoenzyme complex
4MEY	;	3.948	;	Crystal structure of Escherichia coli RNA polymerase holoenzyme
4ZH2	;	4.204	;	Crystal structure of Escherichia coli RNA polymerase in complex with CBR703
4ZH3	;	4.082	;	Crystal structure of Escherichia coli RNA polymerase in complex with CBRH16-Br
4ZH4	;	3.993	;	Crystal structure of Escherichia coli RNA polymerase in complex with CBRP18
4MEX	;	3.902	;	Crystal structure of Escherichia coli RNA polymerase in complex with salinamide A
1YT3	;	1.6	;	Crystal Structure of Escherichia coli RNase D, an exoribonuclease involved in structured RNA processing
1RDD	;	2.8	;	CRYSTAL STRUCTURE OF ESCHERICHIA COLI RNASE HI IN COMPLEX WITH MG2+ AT 2.8 ANGSTROMS RESOLUTION: PROOF FOR A SINGLE MG2+ SITE
2IS3	;	3.1	;	Crystal Structure of Escherichia coli RNase T
4LFU	;	2.26	;	Crystal structure of Escherichia coli SdiA in the space group C2
4LGW	;	2.7	;	Crystal structure of Escherichia coli SdiA in the space group P6522
2R4J	;	1.96	;	Crystal structure of Escherichia coli SeMet substituted Glycerol-3-phosphate Dehydrogenase in complex with DHAP
2H27	;	2.3	;	Crystal Structure of Escherichia coli SigmaE Region 4 Bound to its-35 Element DNA
1OR7	;	2.0	;	Crystal Structure of Escherichia coli sigmaE with the Cytoplasmic Domain of its Anti-sigma RseA
3BF0	;	2.55	;	Crystal structure of Escherichia coli Signal peptide peptidase (SppA), Native crystals
3BEZ	;	2.76	;	Crystal structure of Escherichia coli Signal peptide peptidase (SppA), SeMet crystals
2D2A	;	2.7	;	Crystal Structure of Escherichia coli SufA Involved in Biosynthesis of Iron-sulfur Clusters
2D3W	;	2.5	;	Crystal Structure of Escherichia coli SufC, an ATPase compenent of the SUF iron-sulfur cluster assembly machinery
1BTL	;	1.8	;	CRYSTAL STRUCTURE OF ESCHERICHIA COLI TEM1 BETA-LACTAMASE AT 1.8 ANGSTROMS RESOLUTION
1QXH	;	2.2	;	Crystal Structure of Escherichia coli Thiol Peroxidase in the Oxidized State
1TDE	;	2.1	;	CRYSTAL STRUCTURE OF ESCHERICHIA COLI THIOREDOXIN REDUCTASE REFINED AT 2 ANGSTROM RESOLUTION: IMPLICATIONS FOR A LARGE CONFORMATIONAL CHANGE DURING CATALYSIS
1TDF	;	2.3	;	CRYSTAL STRUCTURE OF ESCHERICHIA COLI THIOREDOXIN REDUCTASE REFINED AT 2 ANGSTROM RESOLUTION: IMPLICATIONS FOR A LARGE CONFORMATIONAL CHANGE DURING CATALYSIS
1F4B	;	1.75	;	CRYSTAL STRUCTURE OF ESCHERICHIA COLI THYMIDYLATE SYNTHASE
1JG0	;	2.0	;	Crystal structure of Escherichia coli thymidylate synthase complexed with 2'-deoxyuridine-5'-monophosphate and N,O-didansyl-L-tyrosine
1S14	;	2.0	;	Crystal structure of Escherichia coli Topoisomerase IV ParE 24kDa subunit
5HY3	;	3.1	;	Crystal structure of Escherichia coli toxin LsoA in complex with T4 phage antitoxin Dmd
1I2P	;	2.05	;	CRYSTAL STRUCTURE OF ESCHERICHIA COLI TRANSALDOLASE B MUTANT D17A
1I2O	;	2.05	;	CRYSTAL STRUCTURE OF ESCHERICHIA COLI TRANSALDOLASE B MUTANT E96A
1I2N	;	2.05	;	CRYSTAL STRUCTURE OF ESCHERICHIA COLI TRANSALDOLASE B MUTANT N35A
1I2R	;	2.1	;	CRYSTAL STRUCTURE OF ESCHERICHIA COLI TRANSALDOLASE B MUTANT S176A
1I2Q	;	2.05	;	CRYSTAL STRUCTURE OF ESCHERICHIA COLI TRANSALDOLASE B MUTANT T156A
2EYQ	;	3.2	;	Crystal structure of Escherichia coli transcription-repair coupling factor
4W1Y	;	3.2	;	Crystal structure of Escherichia coli Tryptophanase in 'semi-holo' form
4UP2	;	2.78	;	Crystal structure of Escherichia coli tryptophanase purified from alkaline stressed bacterial culture.
1T7D	;	2.47	;	Crystal structure of Escherichia coli type I signal peptidase in complex with a lipopeptide inhibitor
3S04	;	2.44	;	Crystal structure of Escherichia coli type I signal peptidase in complex with an Arylomycin Lipoglycopeptide Antibiotic
1LRK	;	1.75	;	Crystal Structure of Escherichia coli UDP-Galactose 4-Epimerase Mutant Y299C Complexed with UDP-N-acetylglucosamine
1GG4	;	2.3	;	CRYSTAL STRUCTURE OF ESCHERICHIA COLI UDPMURNAC-TRIPEPTIDE D-ALANYL-D-ALANINE-ADDING ENZYME (MURF) AT 2.3 ANGSTROM RESOLUTION
6CB2	;	2.0	;	Crystal structure of Escherichia coli UppP
1EUG	;	1.6	;	CRYSTAL STRUCTURE OF ESCHERICHIA COLI URACIL DNA GLYCOSYLASE AND ITS COMPLEXES WITH URACIL AND GLYCEROL: STRUCTURE AND GLYCOSYLASE MECHANISM REVISITED
2EUG	;	1.5	;	CRYSTAL STRUCTURE OF ESCHERICHIA COLI URACIL DNA GLYCOSYLASE AND ITS COMPLEXES WITH URACIL AND GLYCEROL: STRUCTURE AND GLYCOSYLASE MECHANISM REVISITED
3EUG	;	1.43	;	CRYSTAL STRUCTURE OF ESCHERICHIA COLI URACIL DNA GLYCOSYLASE AND ITS COMPLEXES WITH URACIL AND GLYCEROL: STRUCTURE AND GLYCOSYLASE MECHANISM REVISITED
3GRH	;	1.7	;	Crystal structure of escherichia coli ybhc
3CA8	;	1.8	;	Crystal structure of Escherichia coli YdcF, an S-adenosyl-L-methionine utilizing enzyme
4XXJ	;	1.9	;	Crystal Structure of Escherichia coli-Expressed Halobacterium salinarum Bacteriorhodopsin in the Trimeric Form
3B5W	;	5.3	;	Crystal Structure of Eschericia coli MsbA
8URN	;	2.01	;	Crystal structure of EscI(51-87)-linker-EtgA(18-152) fusion protein
3BZS	;	1.48	;	Crystal structure of EscU C-terminal domain with N262D mutation, Space group P 21 21 21
3BZR	;	1.646	;	Crystal structure of EscU C-terminal domain with N262D mutation, Space group P 41 21 2
4WJ1	;	2.415	;	Crystal structure of EspB from the ESX-1 type VII secretion system
4W4J	;	2.803	;	Crystal structure of EspG3 from the ESX-3 type VII secretion system of M. smegmatis
4W4I	;	2.85	;	Crystal structure of EspG3 from the ESX-3 type VII secretion system of M. tuberculosis
4W4L	;	2.45	;	Crystal structure of EspG5 in complex with PE25 and PPE41 from the ESX-5 type VII secretion system of M. tuberculosis
3QF3	;	2.41	;	Crystal structure of EspR transcription factor from mycobacterium tuberculosis
3QWG	;	1.992	;	Crystal structure of EspRdelta10, C-terminal 10 amino acids deletion mutant of EspR transcription factor from Mycobacterium tuberculosis
4P85	;	2.0	;	Crystal structure of Est-Y29, a novel penicillin-binding protein/beta-lactamase homolog from a metagenomic library
4P87	;	1.999	;	Crystal structure of Est-Y29, a novel penicillin-binding protein/beta-lactamase homolog from a metagenomic library
4P6B	;	1.7	;	Crystal structure of Est-Y29,a novel penicillin-binding protein/beta-lactamase homolog from a metagenomic library
5Y5A	;	2.206	;	Crystal structure of Est1 and Cdc13
4J7A	;	1.492	;	Crystal Structure of Est25 - a Bacterial Homolog of Hormone-Sensitive Lipase from a Metagenomic Library
8ILT	;	2.42	;	Crystal structure of Est30
3L1I	;	2.2	;	Crystal structure of EstE5, was soaked by CuSO4
3H1A	;	2.5	;	Crystal structure of EstE5, was soaked by ethyl alcohol
3L1H	;	2.4	;	Crystal structure of EstE5, was soaked by FeCl3
3H1B	;	2.1	;	Crystal structure of EstE5, was soaked by isopropyl alcohol
3H19	;	2.3	;	Crystal structure of EstE5, was soaked by methyl alcohol
3G9U	;	2.2	;	Crystal structure of EstE5, was soaked by p-nitrophenyl butyrate for 5min
3G9T	;	1.96	;	Crystal structure of EstE5, was soaked by p-nitrophenyl butyrate for 5sec
3G9Z	;	2.2	;	Crystal structure of EstE5, was soaked by p-nitrophenyl caprylate
3L1J	;	2.0	;	Crystal structure of EstE5, was soaked by ZnSO4
3H17	;	2.5	;	Crystal structure of EstE5-PMSF (I)
3H18	;	2.4	;	Crystal structure of EstE5-PMSF (II)
4ROT	;	1.8	;	Crystal structure of esterase A from Streptococcus pyogenes
4N5H	;	1.71	;	Crystal structure of ESTERASE B from Lactobacillus Rhamnosis (HN001)
5JKF	;	2.393	;	Crystal structure of esterase E22
5JKJ	;	1.55	;	Crystal structure of esterase E22 L374D mutant
3QH4	;	1.75	;	Crystal structure of esterase LipW from Mycobacterium marinum
5IQ0	;	1.799	;	Crystal structure of Esterase mutant - F72G
5IQ3	;	1.75	;	Crystal structure of Esterase mutant - F72G/L255W
5IQ2	;	1.78	;	Crystal structure of Esterase mutant - L255W
5DWD	;	1.66	;	Crystal structure of esterase PE8
4OU4	;	2.4	;	Crystal structure of esterase rPPE mutant S159A complexed with (S)-Ac-CPA
4OU5	;	1.99	;	Crystal structure of esterase rPPE mutant S159A/W187H
4OB7	;	1.65	;	Crystal structure of esterase rPPE mutant W187H
3V9A	;	2.07	;	Crystal structure of Esterase/Lipase from uncultured bacterium
3WJ2	;	1.61	;	Crystal structure of ESTFA (FE-lacking apo form)
7U1B	;	2.62	;	Crystal structure of EstG in complex with tantalum cluster
2YAT	;	2.602	;	Crystal structure of estradiol derived metal chelate and estrogen receptor-ligand binding domain complex
2Q6J	;	2.7	;	Crystal Structure of Estrogen Receptor alpha Complexed to a B-N Substituted Ligand
1X7R	;	2.0	;	CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA COMPLEXED WITH GENISTEIN
1X7E	;	2.8	;	CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA COMPLEXED WITH WAY-244
5GS4	;	2.4	;	Crystal structure of estrogen receptor alpha in complex with a stabilized peptide antagonist
6DFN	;	2.1	;	Crystal structure of estrogen receptor alpha in complex with receptor degrader 16aa
6DF6	;	2.5	;	Crystal structure of estrogen receptor alpha in complex with receptor degrader 16ab
6WOK	;	2.309	;	Crystal structure of estrogen receptor alpha in complex with receptor degrader 6
2QAB	;	1.89	;	Crystal Structure of Estrogen Receptor Alpha Ligand Binding Domain Mutant 537S Complexed with an Ethyl Indazole Compound
2QA6	;	2.6	;	Crystal Structure of Estrogen Receptor Alpha mutant 537S Complexed with 4-(6-hydroxy-1H-indazol-3-yl)benzene-1,3-diol
2OUZ	;	2.0	;	Crystal Structure of Estrogen Receptor alpha-lasofoxifene complex
1YY4	;	2.7	;	Crystal structure of estrogen receptor beta complexed with 1-chloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol
1ZAF	;	2.2	;	Crystal structure of estrogen receptor beta complexed with 3-Bromo-6-hydroxy-2-(4-hydroxy-phenyl)-inden-1-one
1U3Q	;	2.4	;	Crystal Structure of Estrogen Receptor beta complexed with CL-272
1X7B	;	2.3	;	CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH ERB-041
1X7J	;	2.3	;	CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH GENISTEIN
1YYE	;	2.03	;	Crystal structure of estrogen receptor beta complexed with way-202196
1X78	;	2.3	;	CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-244
1U3R	;	2.21	;	Crystal Structure of Estrogen Receptor beta complexed with WAY-338
1U9E	;	2.4	;	CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-397
2NV7	;	2.1	;	Crystal Structure of Estrogen Receptor Beta Complexed with WAY-555
1X76	;	2.2	;	CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-697
1U3S	;	2.5	;	Crystal Structure of Estrogen Receptor beta complexed with WAY-797
3OLS	;	2.2	;	Crystal structure of estrogen receptor beta ligand binding domain
2P7A	;	2.3	;	Crystal Structure of Estrogen Related Receptor g in complex with 3-methyl phenol
5YSO	;	2.501	;	Crystal structure of Estrogen Related Receptor-3 (ERR-gamma) ligand binding domain with DN200434
2EWP	;	2.3	;	Crystal structure of Estrogen Related Receptor-3 (ERR-gamma) ligand binding domaind with tamoxifen analog GSK5182
8IFO	;	2.2	;	Crystal structure of estrogen related receptor-gamma DNA binding domain complexed with Pla2g12b promoter
6KNR	;	2.804	;	Crystal structure of Estrogen-related receptor gamma ligand-binding domain with DN200699
6A6K	;	2.9	;	Crystal structure of Estrogen-related Receptor-3 (ERR-gamma) ligand binding domain with DN201000
3A8J	;	1.98	;	Crystal Structure of ET-EHred complex
3A8I	;	1.99	;	Crystal Structure of ET-EHred-5-CH3-THF complex
3A8K	;	1.95	;	Crystal Structure of ETD97N-EHred complex
3GHA	;	1.4	;	Crystal Structure of ETDA-treated BdbD (Reduced)
3ABS	;	2.25	;	Crystal structure of ethanolamine ammonia-lyase from Escherichia coli complexed with adeninylpentylcobalamin and ethanolamine
3ABR	;	2.1	;	Crystal structure of ethanolamine ammonia-lyase from Escherichia coli complexed with CN-Cbl (substrate-free form)
3ANY	;	2.1	;	Crystal structure of ethanolamine ammonia-lyase from escherichia coli complexed with CN-CBL and (R)-2-amino-1-propanol
3AO0	;	2.25	;	Crystal structure of ethanolamine ammonia-lyase from Escherichia coli complexed with CN-CBL and (S)-2-amino-1-propanol
3ABQ	;	2.05	;	Crystal structure of ethanolamine ammonia-lyase from Escherichia coli complexed with CN-Cbl and 2-amino-1-propanol
3ABO	;	2.1	;	Crystal structure of ethanolamine ammonia-lyase from Escherichia coli complexed with CN-Cbl and ethanolamine
2QEZ	;	2.15	;	Crystal structure of ethanolamine ammonia-lyase heavy chain (YP_013784.1) from Listeria monocytogenes 4b F2365 at 2.15 A resolution
3H1Q	;	2.8	;	Crystal structure of ethanolamine utilization protein EutJ from Carboxydothermus hydrogenoformans
3U27	;	1.852	;	Crystal structure of ethanolamine utilization protein EutL from Leptotrichia buccalis C-1013-b
4YSB	;	2.5015	;	Crystal structure of ETHE1 from Myxococcus xanthus
4GBG	;	2.9	;	Crystal structure of Ethyl acetoacetate treated lipase from Thermomyces lanuginosa at 2.9 A resolution
6H19	;	1.89	;	Crystal structure of ethyl-paraoxon inhibited recombinant human bile salt activated lipase (aged form)
8CPK	;	1.76	;	Crystal structure of EtpA secretion domain from Enterotoxigenic Escherichia coli
3WTZ	;	2.61	;	Crystal structure of ETS-1 DNA binding and autoinhibitory domains (276-441)
4FIN	;	2.4	;	Crystal Structure of EttA (formerly YjjK) - an E. coli ABC-type ATPase
3IO0	;	3.0	;	Crystal structure of EtuB from Clostridium kluyveri
4MHG	;	2.199	;	Crystal structure of ETV6 bound to a specific DNA sequence
5FXF	;	1.9	;	Crystal structure of eugenol oxidase in complex with benzoate
5FXE	;	1.9	;	Crystal structure of eugenol oxidase in complex with coniferyl alcohol
5FXD	;	1.7	;	Crystal structure of eugenol oxidase in complex with isoeugenol
5FXP	;	2.6	;	Crystal structure of eugenol oxidase in complex with vanillin
6DI6	;	1.39	;	Crystal structure of eukaryotic DNA primase large subunit iron-sulfur cluster domain
6DTV	;	1.12	;	Crystal structure of eukaryotic DNA primase large subunit iron-sulfur cluster domain Y395F mutant
6DU0	;	1.82	;	Crystal structure of eukaryotic DNA primase large subunit iron-sulfur cluster domain Y395L mutant
6DI2	;	1.32	;	Crystal structure of eukaryotic DNA primase large subunit iron-sulfur cluster domain Y397L mutant
6DTZ	;	1.36	;	Crystal structure of eukaryotic DNA primase large subunit iron-sulfur cluster domain, Y397F mutant
6ZDT	;	1.71	;	Crystal structure of eukaryotic Fibrillarin with Nop56 N-terminal domain
4HNZ	;	2.393	;	Crystal structure of eukaryotic HslV from Trypanosoma brucei
4HO7	;	2.601	;	Crystal structure of eukaryotic HslV from Trypanosoma brucei
5TKE	;	2.481	;	Crystal Structure of Eukaryotic Hydrolase
1IPB	;	2.0	;	CRYSTAL STRUCTURE OF EUKARYOTIC INITIATION FACTOR 4E COMPLEXED WITH 7-METHYL GPPPA
1IPC	;	2.0	;	CRYSTAL STRUCTURE OF EUKARYOTIC INITIATION FACTOR 4E COMPLEXED WITH 7-METHYL GTP
2WMC	;	2.2	;	Crystal structure of eukaryotic initiation factor 4E from Pisum sativum
5Y50	;	2.6	;	Crystal structure of eukaryotic MATE transporter AtDTX14
4YKE	;	2.783	;	Crystal structure of eukaryotic Mre11 catalytic domain from Chaetomium thermophilum
6R45	;	1.784	;	Crystal structure of eukaryotic O-GlcNAcase HAT-like domain
5CJH	;	1.6	;	Crystal Structure of Eukaryotic Oxoiron MagKatG2 at pH 8.5
4N7Q	;	1.6	;	Crystal structure of eukaryotic THIC from A. thaliana
3HKS	;	2.3	;	Crystal structure of eukaryotic translation initiation factor eIF-5A2 from Arabidopsis thaliana
4NCF	;	3.015	;	Crystal structure of eukaryotic translation initiation factor eIF5B (399-852) from Saccharomyces cerevisiae in complex with GDP
4N3S	;	1.832	;	Crystal structure of eukaryotic translation initiation factor eIF5B (399-852) from Saccharomyces cerevisiae, apo form
4N3N	;	2.752	;	Crystal structure of eukaryotic translation initiation factor eIF5B (517-1116) from Chaetomium thermophilum, apo form
4NCN	;	1.87	;	Crystal structure of eukaryotic translation initiation factor eIF5B (517-858) from Chaetomium thermophilum in complex with GTP
4NCL	;	2.115	;	Crystal structure of eukaryotic translation initiation factor eIF5B (517-970) from Chaetomium thermophilum in complex with GDP
4N3G	;	3.203	;	Crystal structure of eukaryotic translation initiation factor eIF5B (870-1116) from Chaetomium thermophilum, domains III and IV
4QIW	;	3.5	;	Crystal structure of euryarchaeal RNA polymerase from Thermococcus kodakarensis
4TM6	;	1.9002	;	Crystal Structure of EutL from Clostridium Perfringens at 298K
4TME	;	1.7	;	Crystal Structure of EutL from Clostridium Perfringens bound to ethanolamine
3GFH	;	2.2	;	Crystal structure of EUTL shell protein of the bacterial ethanolamine micrompartment
6WW6	;	3.8	;	Crystal structure of EutV bound to RNA
6WSH	;	2.12	;	Crystal structure of EutV from Enterococcus faecalis
7MG0	;	3.5	;	Crystal structure of EV-D68 2A protease
7JRE	;	2.5	;	Crystal structure of EV-D68 2A protease C107A mutant
7LW2	;	2.57	;	Crystal structure of EV-D68 2A protease N84T mutant
5XE0	;	2.3	;	Crystal structure of EV-D68-3Dpol in complex with GTP
4FVB	;	1.9	;	Crystal structure of EV71 2A proteinase C110A mutant
4FVD	;	1.66	;	Crystal structure of EV71 2A proteinase C110A mutant in complex with substrate
5GSW	;	3.19	;	Crystal structure of EV71 3C in complex with N69S 1.8k
4GHQ	;	2.2	;	Crystal structure of EV71 3C proteinase
7DNC	;	1.17	;	Crystal structure of EV71 3C proteinase in complex with a novel inhibitor
4GHT	;	1.96	;	Crystal structure of EV71 3C proteinase in complex with AG7088
5C1Y	;	1.97	;	Crystal structure of EV71 3C Proteinase in complex with Compound 1
5C20	;	2.75	;	Crystal structure of EV71 3C Proteinase in complex with Compound 2
5DP3	;	2.05	;	Crystal Structure of EV71 3C Proteinase in complex with compound 2
5DP4	;	2.21	;	Crystal Structure of EV71 3C Proteinase in complex with compound 3
5DP5	;	2.03	;	Crystal Structure of EV71 3C Proteinase in complex with compound 4
5DP7	;	2.08	;	Crystal Structure of EV71 3C Proteinase in complex with compound 5
5DPA	;	2.06	;	Crystal Structure of EV71 3C Proteinase in complex with compound 6
5DP6	;	3.01	;	Crystal Structure of EV71 3C Proteinase in complex with compound 7
5DP8	;	2.4	;	Crystal Structure of EV71 3C Proteinase in complex with compound 8
5DP9	;	1.9	;	Crystal Structure of EV71 3C Proteinase in complex with compound 9
5C1X	;	1.86	;	Crystal structure of EV71 3C Proteinase in complex with Compound VIII
5C1U	;	1.49	;	Crystal structure of EV71 3C Proteinase in complex with Compound Xb
5BPE	;	2.7	;	Crystal structure of EV71 3Cpro in complex with a potent and selective Inhibitor
4IKA	;	2.7	;	Crystal structure of EV71 3Dpol-VPg
3N6N	;	2.9	;	crystal structure of EV71 RdRp in complex with Br-UTP
3N6M	;	2.5	;	Crystal structure of EV71 RdRp in complex with GTP
6LKA	;	2.033	;	Crystal Structure of EV71-3C protease with a Novel Macrocyclic Compounds
4J7H	;	1.69	;	Crystal structure of EvaA, a 2,3-dehydratase in complex with dTDP-benzene and dTDP-rhamnose
4J7G	;	1.7	;	Crystal structure of EvaA, a 2,3-dehydratase in complex with dTDP-fucose and dTDP-rhamnose
3FPR	;	1.63	;	Crystal Structure of Evasin-1
6EC3	;	3.35	;	Crystal Structure of EvdMO1
4XBZ	;	2.3	;	Crystal Structure of EvdO1 from Micromonospora carbonacea var. aurantiaca
4XAB	;	1.75	;	Crystal Structure of EvdO2 from Micromonospora carbonacea var. aurantiaca
4XAC	;	1.87	;	Crystal Structure of EvdO2 from Micromonospora carbonacea var. aurantiaca complexed with 2-oxoglutarate
8SK0	;	1.51	;	Crystal structure of EvdS6 decarboxylase in ligand bound state
8SHH	;	1.93	;	Crystal structure of EvdS6 decarboxylase in ligand free state
7ZP6	;	1.9	;	Crystal structure of evolved photoenzyme EnT1.3
7ZP7	;	1.7	;	Crystal structure of evolved photoenzyme EnT1.3 (truncated) with bound product
5VAO	;	2.56	;	Crystal structure of eVP30 C-terminus and eNP peptide
5VAP	;	1.85	;	Crystal structure of eVP30 C-terminus and eNP peptide
6K17	;	1.602	;	Crystal structure of EXD2 exonuclease domain
6K19	;	2.202	;	Crystal structure of EXD2 exonuclease domain soaked in Mg
6K1C	;	2.45	;	Crystal structure of EXD2 exonuclease domain soaked in Mg and dGMP
6K1E	;	2.9	;	Crystal structure of EXD2 exonuclease domain soaked in Mg and GMP
6K18	;	2.303	;	Crystal structure of EXD2 exonuclease domain soaked in Mn
6K1B	;	2.605	;	Crystal structure of EXD2 exonuclease domain soaked in Mn and dGMP
6K1D	;	3.0	;	Crystal structure of EXD2 exonuclease domain soaked in Mn and GMP
6K1A	;	2.602	;	Crystal structure of EXD2 exonuclease domain soaked in Mn and Mg
1DUA	;	2.0	;	CRYSTAL STRUCTURE OF EXFOLIATIVE TOXIN A
1DUE	;	2.0	;	CRYSTAL STRUCTURE OF EXFOLIATIVE TOXIN A S195A MUTANT
1DT2	;	2.8	;	CRYSTAL STRUCTURE OF EXFOLIATIVE TOXIN B
1QTF	;	2.4	;	CRYSTAL STRUCTURE OF EXFOLIATIVE TOXIN B
4HYJ	;	2.3	;	Crystal structure of Exiguobacterium sibiricum rhodopsin
1H4P	;	1.75	;	Crystal structure of exo-1,3-beta glucanse from Saccharomyces cerevisiae
3UT0	;	2.3	;	Crystal structure of exo-1,3/1,4-beta-glucanase (EXOP) from Pseudoalteromonas sp. BB1
4KCB	;	2.9	;	Crystal Structure of Exo-1,5-alpha-L-arabinanase from Bovine Ruminal Metagenomic Library
3AKF	;	2.2	;	Crystal structure of exo-1,5-alpha-L-arabinofuranosidase
3AKG	;	1.8	;	Crystal structure of exo-1,5-alpha-L-arabinofuranosidase complexed with alpha-1,5-L-arabinofuranobiose
3AKH	;	1.7	;	Crystal structure of exo-1,5-alpha-L-arabinofuranosidase complexed with alpha-1,5-L-arabinofuranotriose
3AKI	;	2.0	;	Crystal structure of exo-1,5-alpha-L-arabinofuranosidase complexed with alpha-L-arabinofuranosyl azido
7BYS	;	1.4	;	Crystal structure of exo-beta-1,3-galactanase from Phanerochaete chrysosporium Pc1,3Gal43A apo form
7BYX	;	2.3	;	Crystal structure of exo-beta-1,3-galactanase from Phanerochaete chrysosporium Pc1,3Gal43A E208A with beta-1,3-galactotriose
7BYV	;	2.5	;	Crystal structure of exo-beta-1,3-galactanase from Phanerochaete chrysosporium Pc1,3Gal43A E208Q with beta-1,3-galactotriose
7BYT	;	1.5	;	Crystal structure of exo-beta-1,3-galactanase from Phanerochaete chrysosporium Pc1,3Gal43A with galactose
6GDT	;	3.17	;	Crystal structure of exo-glucosidase/glucosaminidase VC0615 from Vibrio Cholerae
1Y9G	;	1.87	;	Crystal structure of exo-inulinase from Aspergillus awamori complexed with fructose
1Y4W	;	1.55	;	Crystal structure of exo-inulinase from Aspergillus awamori in spacegroup P21
1Y9M	;	1.89	;	Crystal structure of exo-inulinase from Aspergillus awamori in spacegroup P212121
1KFQ	;	2.4	;	Crystal Structure of Exocytosis-Sensitive Phosphoprotein, pp63/parafusin (Phosphoglucomutse) from Paramecium. OPEN FORM
1VP7	;	2.4	;	Crystal structure of Exodeoxyribonuclease VII small subunit (NP_881400.1) from Bordetella pertussis at 2.40 A resolution
7SPT	;	2.1	;	Crystal structure of exofacial state human glucose transporter GLUT3
6LJA	;	1.978	;	Crystal Structure of exoHep from Bacteroides intestinalis DSM 17393 complexed with disaccharide product
6LJL	;	1.73	;	Crystal Structure of exoHep-Y390A/H555A complexed with a tetrasaccharide substrate
5EWT	;	1.8	;	Crystal structure of ExoIII endonuclease from Sulfolobus islandicus
7R0T	;	2.194	;	Crystal structure of exonuclease ExnV1
3HL8	;	1.55	;	Crystal structure of exonuclease I in complex with inhibitor BCBP
1IR6	;	2.9	;	Crystal structure of exonuclease RecJ bound to manganese
2FLO	;	2.2	;	Crystal structure of exopolyphosphatase (PPX) from E. coli O157:H7
7EPQ	;	2.2	;	Crystal structure of exopolyphosphatase (PPX) from Porphyromonas gingivalis in complex with sulfate and magnesium ions
8GTY	;	1.8	;	Crystal structure of exopolyphosphatase (PPX) from Zymomonas mobilis in complex with magnesium ions
8GTZ	;	1.56	;	Crystal structure of exopolyphosphatase (PPX) mutant E137A from Zymomonas mobilis in complex with magnesium ions
3RF0	;	1.8	;	Crystal Structure of Exopolyphosphatase from Yersinia pestis
4JMF	;	2.099	;	Crystal structure of ExoT (residues 28 -77)- SpcS complex from Pseudomonas aeruginosa at 2.1 angstrom
3AFL	;	2.99	;	Crystal structure of exotype alginate lyase Atu3025 H531A complexed with alginate trisaccharide
2ZUY	;	1.65	;	Crystal structure of exotype rhamnogalacturonan lyase YesX
5XNW	;	2.201	;	Crystal structure of ExoY, a unique nucleotidyl cyclase toxin from Pseudomonas aeruginosa
2HCZ	;	2.75	;	Crystal structure of EXPB1 (Zea m 1), a beta-expansin and group-1 pollen allergen from maize
5YU7	;	3.301	;	CRYSTAL STRUCTURE OF EXPORTIN-5
5YU6	;	2.997	;	CRYSTAL STRUCTURE OF EXPORTIN-5:RANGTP COMPLEX
3A6P	;	2.92	;	Crystal structure of Exportin-5:RanGTP:pre-miRNA complex
7R1M	;	1.64	;	Crystal structure of ExsFA, a Bacillus cereus spore exosporium protein
3NFF	;	3.24	;	Crystal structure of extended Dimerization module of RNA polymerase I subcomplex A49/A34.5
5EOO	;	1.48	;	Crystal structure of extended-spectrum beta-lactamase BEL-1 (monoclinic form)
5EOE	;	1.6	;	Crystal structure of extended-spectrum beta-lactamase BEL-1 (orthorhombic form)
5EPH	;	1.79	;	Crystal structure of extended-spectrum beta-lactamase BEL-1 in complex with Imipenem
5EUA	;	1.85	;	Crystal structure of extended-spectrum beta-lactamase BEL-1 in complex with Moxalactam
4Q5Y	;	3.0	;	Crystal structure of extended-Tudor 10-11 of Drosophila melanogaster
4Q5W	;	1.801	;	Crystal structure of extended-Tudor 9 of Drosophila melanogaster
3F95	;	1.8	;	Crystal Structure of Extra C-terminal Domain (X) of Exo-1,3/1,4-beta-glucanase (ExoP) from Pseudoalteromonas sp. BB1
5IN2	;	1.55	;	Crystal structure of extra cellular Cu/Zn Superoxide Dismutase from Onchocerca volvulus at 1.5 Angstrom; Insight into novel binding site and new inhibitors
6HE6	;	2.0	;	Crystal structure of Extracellular Domain 1 (ECD1) of FtsX from S. pneumonie in complex with dodecane-trimethylamine
6HFX	;	2.16	;	Crystal structure of Extracellular Domain 1 (ECD1) of FtsX from S. pneumonie in complex with n-decyl-B-D-maltoside
6HEE	;	2.3	;	Crystal structure of Extracellular Domain 1 (ECD1) of FtsX from S. pneumonie in complex with undecyl-maltoside
8GK6	;	2.7	;	Crystal structure of extracellular domain of CNNM4 from Echinococcus granulosus
5KWG	;	4.3	;	Crystal structure of extracellular domain of HER2 in complex with Fcab H10-03-6
5K33	;	3.3	;	Crystal structure of extracellular domain of HER2 in complex with Fcab STAB19
3U9U	;	3.42	;	Crystal Structure of Extracellular Domain of Human ErbB4/Her4 in complex with the Fab fragment of mAb1479
1N8Z	;	2.52	;	Crystal structure of extracellular domain of human HER2 complexed with Herceptin Fab
4WCO	;	2.46	;	Crystal structure of extracellular domain of human lectin-like transcript 1 (LLT1), the ligand for natural killer receptor-P1A
3M9Z	;	1.7	;	Crystal Structure of extracellular domain of mouse NKR-P1A
3QBQ	;	2.5	;	Crystal structure of extracellular domains of mouse RANK-RANKL complex
3UKJ	;	1.6	;	Crystal structure of extracellular ligand-binding receptor from Rhodopseudomonas palustris HaA2
4M88	;	1.762	;	Crystal structure of extracellular ligand-binding receptor from Verminephrobacter eiseniae ef01-2
2Z8X	;	1.48	;	Crystal structure of extracellular lipase from Pseudomonas sp. MIS38
2QUB	;	1.8	;	Crystal structure of extracellular lipase LipA from Serratia marcescens
4MZV	;	1.865	;	Crystal structure of extracellular part of human EpCAM
7PEE	;	2.81	;	Crystal structure of extracellular part of human Trop2
3U7U	;	3.03	;	Crystal structure of extracellular region of human epidermal growth factor receptor 4 in complex with neuregulin-1 beta
5IXP	;	1.73	;	Crystal structure of Extracellular solute-binding protein family 1
3OMB	;	2.1	;	Crystal structure of extracellular solute-binding protein from Bifidobacterium longum subsp. infantis
5MAL	;	1.708	;	Crystal structure of extracelular lipase from Streptomyces rimosus at 1.7A resolution
3LV0	;	1.85	;	Crystal structure of extragenic suppressor protein suhB from Bartonella henselae, native
3LUZ	;	2.05	;	Crystal structure of extragenic suppressor protein suhB from Bartonella henselae, via combined iodide SAD molecular replacement
4K7B	;	1.55	;	Crystal structure of Extrinsic protein in photosystem II
6VIO	;	3.6	;	Crystal structure of eYFP His148Ser
8GRF	;	2.53	;	Crystal structure of F-box protein in the ternary complex with adaptor protein Skp1(DL) and its substrate
3B2S	;	1.92	;	Crystal Structure of F. graminearum TRI101 complexed with Coenzyme A and Deoxynivalenol
2RKV	;	1.6	;	Crystal Structure of F. graminearum TRI101 complexed with Coenzyme A and T-2 mycotoxin
3B30	;	1.97	;	Crystal Structure of F. graminearum TRI101 complexed with Ethyl Coenzyme A
2ZBA	;	2.0	;	Crystal Structure of F. sporotrichioides TRI101 complexed with Coenzyme A and T-2
2QWU	;	1.65	;	Crystal structure of F. tularensis pathogenicity island protein C
8SIJ	;	2.6	;	Crystal structure of F. varium tryptophanase
1XQX	;	2.1	;	Crystal structure of F1-mutant S105A complex with PCK
1XQW	;	2.0	;	Crystal structure of F1-mutant S105A complex with PHE-LEU
1XQY	;	3.2	;	Crystal structure of F1-mutant S105A complex with PRO-LEU-GLY-GLY
4JTE	;	1.9	;	Crystal structure of F114A mutant of 3-deoxy-D-manno-octulosonate 8-phosphate synthase (KDO8PS) from Neisseria meningitidis
4JTF	;	1.8	;	Crystal structure of F114R mutant of 3-deoxy-D-manno-octulosonate 8-phosphate synthase (KDO8PS) from Neisseria meningitidis
4JTG	;	1.85	;	Crystal structure of F114R/R117A mutant of 3-deoxy-D-manno-octulosonate 8-phosphate synthase (KDO8PS) from Neisseria meningitidis
4JTH	;	2.0	;	Crystal structure of F114R/R117Q mutant of 3-deoxy-D-manno-octulosonate 8-phosphate synthase (KDO8PS) from Neisseria meningitidis
4JTI	;	1.75	;	Crystal structure of F114R/R117Q/F139G mutant of 3-deoxy-D-manno-octulosonate 8-phosphate synthase (KDO8PS) from Neisseria meningitidis
1EIC	;	1.4	;	CRYSTAL STRUCTURE OF F120A MUTANT OF BOVINE PANCREATIC RIBONUCLEASE A
1EID	;	1.4	;	CRYSTAL STRUCTURE OF F120G MUTANT OF BOVINE PANCREATIC RIBONUCLEASE A
1EIE	;	1.4	;	CRYSTAL STRUCTURE OF F120W MUTANT OF BOVINE PANCREATIC RIBONUCLEASE A
4IO0	;	2.9	;	Crystal structure of F128A mutant of an epoxide hydrolase from Bacillus megaterium complexed with its product (R)-3-[1]naphthyloxy-propane-1,2-diol
3FJA	;	1.95	;	Crystal structure of F132W mutant of Human acidic fibroblast growth factor
4JTL	;	2.1	;	Crystal structure of F139G mutant of 3-deoxy-D-manno-octulosonate 8-phosphate synthase (KDO8PS) from Neisseria meningitidis
4D2J	;	1.75	;	Crystal structure of F16BP Aldolase from Toxoplasma gondii (TgALD1)
4X45	;	1.75	;	Crystal Structure of F173G Mutant of Human APRT
2BS7	;	2.1	;	Crystal structure of F17b-G in complex with chitobiose
2BS8	;	2.25	;	Crystal structure of F17b-G in complex with N-acetyl-D-glucosamine
6QLL	;	1.56	;	Crystal structure of F181H UbiX in complex with FMN and dimethylallyl monophosphate
6QLK	;	1.78	;	Crystal structure of F181H UbiX in complex with prFMN
6QLJ	;	1.77	;	Crystal structure of F181Q UbiX in complex with an oxidised N5-C1' adduct derived from DMAP
6QLI	;	1.99	;	Crystal structure of F181Q UbiX in complex with FMN and dimethylallyl monophosphate
8G35	;	2.0	;	Crystal structure of F182L-CYP199A4 in complex with (S)-4-(2-hydroxy-3-oxobutan-2-yl)benzoic acid
8G36	;	2.1	;	Crystal structure of F182L-CYP199A4 in complex with terephthalic acid
1UKS	;	1.9	;	Crystal structure of F183L/F259L mutant cyclodextrin glucanotransferase complexed with a pseudo-maltotetraose derived from acarbose
4DC0	;	2.813	;	Crystal Structure of F189W Actinorhodin Polyketide Ketoreductase with NADPH
7Z99	;	1.92	;	Crystal structure of F191M variant of Variovorax paradoxus indole monooxygenase (VpIndA1) in complex with methyl phenyl sulfoxide
7Z98	;	1.73	;	Crystal structure of F191M variant Variovorax paradoxus indole monooxygenase (VpIndA1) in complex with methyl phenyl sulfide
4RYT	;	2.09	;	Crystal Structure of F222 form of E112A Mutant of Stationary Phase Survival Protein (SurE) from Salmonella typhimurium
4XEP	;	1.5	;	Crystal Structure of F222 form of E112A/H234A Mutant of Stationary Phase Survival Protein (SurE) from Salmonella typhimurium
1YYM	;	2.2	;	crystal structure of F23, a scorpion-toxin mimic of CD4, in complex with HIV-1 YU2 gp120 envelope glycoprotein and anti-HIV-1 antibody 17b
6CQR	;	3.04	;	Crystal structure of F24 TCR -DR1-RQ13 peptide complex
6CQL	;	2.4	;	Crystal structure of F24 TCR -DR11-RQ13 peptide complex
6CQQ	;	2.8	;	Crystal structure of F24 TCR -DR15-RQ13 peptide complex
1F5C	;	1.75	;	CRYSTAL STRUCTURE OF F25H FERREDOXIN 1 MUTANT FROM AZOTOBACTER VINELANDII AT 1.75 ANGSTROM RESOLUTION
1V3J	;	2.0	;	Crystal structure of F283L mutant cyclodextrin glycosyltransferase
1V3L	;	2.1	;	Crystal structure of F283L mutant cyclodextrin glycosyltransferase complexed with a pseudo-tetraose derived from acarbose
1V3K	;	2.0	;	Crystal structure of F283Y mutant cyclodextrin glycosyltransferase
1V3M	;	2.0	;	Crystal structure of F283Y mutant cyclodextrin glycosyltransferase complexed with a pseudo-tetraose derived from acarbose
8OKK	;	1.63	;	Crystal structure of F2F-2020184-00X bound to the main protease (3CLpro/Mpro) of SARS-CoV-2.
8OKL	;	1.5	;	Crystal structure of F2F-2020185-01X bound to the main protease (3CLpro/Mpro) of SARS-CoV-2.
8OKM	;	1.66	;	Crystal structure of F2F-2020197-00X bound to the main protease (3CLpro/Mpro) of SARS-CoV-2.
8OKN	;	1.35	;	Crystal structure of F2F-2020198-00X bound to the main protease (3CLpro/Mpro) of SARS-CoV-2.
7Q5E	;	1.67	;	Crystal structure of F2F-2020209-00X bound to the main protease (3CLpro/Mpro) of SARS-CoV-2.
7Q5F	;	1.72	;	Crystal structure of F2F-2020216-01X bound to the main protease (3CLpro/Mpro) of SARS-CoV-2.
1F5B	;	1.62	;	CRYSTAL STRUCTURE OF F2H FERREDOXIN 1 MUTANT FROM AZOTOBACTER VINELANDII AT 1.75 ANGSTROM RESOLUTION
4HJR	;	2.5	;	Crystal structure of F2YRS
4HJX	;	2.91	;	Crystal structure of F2YRS complexed with F2Y
2QUR	;	2.5	;	Crystal Structure of F327A/K285P Mutant of cAMP-dependent Protein Kinase
2VMZ	;	1.7	;	Crystal structure of F351GbsSHMT in complex with Gly
2VMY	;	2.7	;	Crystal structure of F351GbsSHMT in complex with Gly and FTHF
2VMX	;	1.82	;	Crystal structure of F351GbsSHMT in complex with L-allo-Thr
2VMW	;	1.73	;	Crystal structure of F351GbsSHMT in complex with L-Ser
2VMV	;	1.7	;	Crystal structure of F351GbsSHMT internal aldimine
1M20	;	1.8	;	Crystal Structure of F35Y Mutant of Trypsin-solubilized Fragment of Cytochrome b5
4HI5	;	3.6	;	crystal structure of F37A mutant of borna disease virus matrix protein
4HNT	;	2.8	;	crystal structure of F403A mutant of S. aureus Pyruvate carboxylase
1IO1	;	2.0	;	CRYSTAL STRUCTURE OF F41 FRAGMENT OF FLAGELLIN
2E2Y	;	1.6	;	Crystal Structure of F43W/H64D/V68I Myoglobin
4QAU	;	1.597	;	Crystal structure of F43Y mutant of sperm whale myoglobin
3IBX	;	2.4	;	Crystal structure of F47Y variant of TenA (HP1287) from Helicobacter pylori
6CQN	;	2.5	;	Crystal structure of F5 TCR -DR11-RQ13 peptide complex
7MGO	;	1.85	;	Crystal structure of F501H variant of 2-ketopropyl coenzyme M oxidoreductase/carboxylase (2-KPCC) from Xanthobacter autotrophicus
7MGN	;	1.8	;	Crystal structure of F501H/H506E variant of 2-ketopropyl coenzyme M oxidoreductase/carboxylase (2-KPCC) from Xanthobacter autotrophicus
1U9M	;	2.0	;	Crystal structure of F58W mutant of cytochrome b5
1U9U	;	1.86	;	Crystal structure of F58Y mutant of cytochrome b5
1KEQ	;	1.88	;	Crystal Structure of F65A/Y131C Carbonic Anhydrase V, covalently modified with 4-chloromethylimidazole
3FJ9	;	1.9	;	Crystal structure of F85W mutant of Human acidic fibroblast growth factor
3DGI	;	1.95	;	Crystal structure of F87A/T268A mutant of CYP BM3
4N1F	;	2.087	;	Crystal Structure of F88Y obelin mutant from Obelia longissima at 2.09 Angstrom resolution
4DTA	;	2.35	;	Crystal Structure of F95M Aminoglycoside-2''-Phosphotransferase Type IVa in Complex with Adenosine
4DTB	;	2.1	;	Crystal Structure of F95Y Aminoglycoside-2''-Phosphotransferase Type IVa in Complex with Guanosine
2VFE	;	2.2	;	Crystal structure of F96S mutant of Plasmodium falciparum triosephosphate isomerase with 3- phosphoglycerate bound at the dimer interface
3WW0	;	2.5	;	Crystal structure of F97A mutant, a new nuclear transport receptor of Hsp70
4HBP	;	2.91	;	Crystal Structure of FAAH in complex with inhibitor
3WWQ	;	1.9	;	Crystal structure of FAAP20 UBZ domain in complex with Lys63-linked diubiquitin
1RIH	;	2.5	;	Crystal Structure of Fab 14F7, a unique anti-tumor antibody specific for N-glycolyl GM3
2R69	;	3.8	;	Crystal structure of Fab 1A1D-2 complexed with E-DIII of Dengue virus at 3.8 angstrom resolution
3LZF	;	2.8	;	Crystal Structure of Fab 2D1 in Complex with the 1918 Influenza Virus Hemagglutinin
4HG4	;	3.2	;	Crystal structure of Fab 2G1 in complex with a H2N2 influenza virus hemagglutinin
4PY7	;	2.7	;	Crystal Structure of Fab 3.1
4PY8	;	2.91	;	Crystal structure of Fab 3.1 in complex with the 1918 influenza virus hemagglutinin
5CEX	;	2.105	;	Crystal Structure of Fab 32H+109L, a putative precursor of the PGT121 family of potent HIV-1 antibodies
4KVN	;	3.1	;	Crystal structure of Fab 39.29 in complex with Influenza Hemagglutinin A/Perth/16/2009 (H3N2)
6WIY	;	1.65	;	Crystal structure of Fab 54-1G05
6WIZ	;	4.2	;	Crystal structure of Fab 54-1G05 bound to H1 influenza hemagglutinin
6WJ0	;	1.802	;	Crystal structure of Fab 54-4H03
6WJ1	;	3.503	;	Crystal structure of Fab 54-4H03 bound to H1 influenza hemagglutinin
4NJA	;	2.204	;	Crystal structure of Fab 6C8 in complex with MPTS
4NJ9	;	1.95	;	Crystal structure of Fab 8B10 in complex with MPTS
4HF5	;	3.004	;	Crystal structure of Fab 8F8 in complex a H2N2 influenza virus hemagglutinin
4HFU	;	3.106	;	Crystal structure of Fab 8M2 in complex with a H2N2 influenza virus hemagglutinin
5CEY	;	2.387	;	Crystal Structure of Fab 9H+3L, a putative precursor of the PGT121 family of potent HIV-1 antibodies
7LUD	;	2.9	;	Crystal structure of Fab ADI-14442
4HLZ	;	2.9	;	Crystal Structure of Fab C179 in Complex with a H2N2 influenza virus hemagglutinin
5EOC	;	1.98	;	Crystal structure of Fab C2 in complex with a Cyclic variant of Hepatitis C Virus E2 epitope I
3QPX	;	2.0	;	Crystal structure of Fab C2507
7SEN	;	2.09	;	Crystal structure of Fab containing a fluorescent noncanonical amino acid with blocked excited state proton transfer
7T86	;	1.9	;	Crystal Structure of Fab CR5133 / Phospho-SD Peptide Complex
4EVN	;	2.851	;	Crystal Structure of Fab CR6261 (somatic heavy chain with germline-reverted light chain)
3GBM	;	2.7	;	Crystal Structure of Fab CR6261 in Complex with a H5N1 influenza virus hemagglutinin.
3GBN	;	2.2	;	Crystal Structure of Fab CR6261 in Complex with the 1918 H1N1 influenza virus hemagglutinin
4FQH	;	2.05	;	Crystal Structure of Fab CR9114
4FQI	;	1.71	;	Crystal Structure of Fab CR9114 in Complex with a H5N1 influenza virus hemagglutinin
1JPT	;	1.85	;	Crystal Structure of Fab D3H44
3QHF	;	1.655	;	Crystal Structure of Fab del2D1, a deletion variant of anti-influenza antibody 2D1
4PUB	;	1.75	;	Crystal structure of Fab DX-2930
4OGY	;	2.1	;	Crystal structure of Fab DX-2930 in complex with human plasma kallikrein at 2.1 Angstrom resolution
4OGX	;	2.4	;	Crystal structure of Fab DX-2930 in complex with human plasma kallikrein at 2.4 Angstrom resolution
3GGW	;	1.7	;	Crystal Structure of FAB F22-4 in complex with a Carbohydrate-mimetic peptide
3BZ4	;	1.8	;	Crystal structure of Fab F22-4 in complex with a Shigella flexneri 2a O-Ag decasaccharide
3C6S	;	1.8	;	Crystal structure of Fab F22-4 in complex with a Shigella flexneri 2a O-Ag pentadecasaccharide
6YHQ	;	1.89	;	Crystal Structure of Fab F5.18.6, anti-Plasmodium vivax AMA1
1KFA	;	2.8	;	Crystal structure of Fab fragment complexed with gibberellin A4
3HI5	;	2.5	;	Crystal structure of Fab fragment of AL-57
4A6Y	;	2.9	;	CRYSTAL STRUCTURE OF FAB FRAGMENT OF ANTI-(4-HYDROXY-3-NITROPHENYL) -ACETYL MURINE GERMLINE ANTIBODY BBE6.12H3
5X4G	;	1.45	;	Crystal structure of Fab fragment of anti-CD147 monoclonal antibody 6H8
5VKK	;	2.014	;	Crystal structure of Fab fragment of anti-CD22 Epratuzumab
2Z93	;	2.4	;	Crystal structure of Fab fragment of anti-ciguatoxin antibody 10C9 in complex with CTX3C-ABCD
5WHJ	;	2.15	;	Crystal structure of Fab fragment of anti-FcRn antibody DX-2507
6X9X	;	1.8	;	Crystal structure of Fab fragment of Anti-HCV E2 antibody (HC84.26)
3QQ9	;	1.64	;	Crystal structure of FAB fragment of anti-human RSV (RESPIRATORY SYNCYTIAL VIRUS) F Protein MAB 101F
7VSU	;	3.1	;	Crystal structure of Fab fragment of anti-mesothelin antibody
3MXV	;	1.9	;	Crystal structure of fab fragment of anti-Shh 5E1 chimera
5VH4	;	2.0	;	Crystal structure of Fab fragment of anti-TNFa antibody infliximab in an I-centered orthorhombic crystal form
5WHK	;	2.5	;	Crystal structure of Fab fragment of antibody DX-2507 bound to FcRn-B2M
1NDM	;	2.1	;	Crystal structure of Fab fragment of antibody HyHEL-26 complexed with lysozyme
1NDG	;	1.9	;	Crystal structure of Fab fragment of antibody HyHEL-8 complexed with its antigen lysozyme
7V5N	;	1.7	;	Crystal structure of Fab fragment of bevacizumab bound to DNA aptamer
7DUN	;	1.607	;	Crystal structure of Fab fragment of Daratumumab
4S2S	;	2.1	;	Crystal Structure of Fab fragment of monoclonal antibody RoAb13
5VH3	;	2.0	;	Crystal structure of Fab fragment of the anti-TNFa antibody infliximab in a C-centered orthorhombic crystal form
3RPI	;	2.648	;	Crystal Structure of Fab from 3BNC60, Highly Potent anti-HIV Antibody
4MHJ	;	6.98	;	Crystal structure of Fab H5M9 in complex with influenza virus hemagglutinin from A/goose/Guangdong/1/96 (H5N1)
4MHH	;	3.564	;	Crystal structure of Fab H5M9 in complex with influenza virus hemagglutinin from A/Viet Nam/1203/2004 (H5N1)
5V2A	;	4.656	;	Crystal structure of Fab H7.167 in complex with influenza virus hemagglutinin from A/Shanghai/02/2013 (H7N9)
1DQD	;	2.1	;	CRYSTAL STRUCTURE OF FAB HGR-2 F6, A COMPETITIVE ANTAGONIST OF THE GLUCAGON RECEPTOR
7S7I	;	2.4	;	Crystal structure of Fab in complex with MICA alpha3 domain
7S13	;	2.12	;	Crystal structure of Fab in complex with mouse CD96 dimer
7S11	;	2.58	;	Crystal structure of Fab in complex with mouse CD96 monomer
6JJP	;	2.9	;	Crystal structure of Fab of a PD-1 monoclonal antibody MW11-h317 in complex with PD-1
4XML	;	2.68	;	Crystal structure of Fab of HIV-1 gp120 V3-specific human monoclonal antibody 2424
4XMK	;	3.179	;	Crystal structure of Fab of HIV-1 gp120 V3-specific human monoclonal antibody 2424 in complex with JR-FL V3 peptide
3Q6F	;	3.192	;	Crystal structure of Fab of human mAb 2909 specific for quaternary neutralizing epitope of HIV-1 gp120
6FG1	;	2.03	;	CRYSTAL STRUCTURE OF FAB OF NATALIZUMAB IN COMPLEX WITH FAB OF NAA32.
6FG2	;	2.788	;	CRYSTAL STRUCTURE OF FAB OF NATALIZUMAB IN COMPLEX WITH FAB OF NAA84.
5EZI	;	1.61	;	Crystal Structure of Fab of parasite invasion inhibitory antibody c1 - hexagonal form
5EZL	;	2.43	;	Crystal Structure of Fab of parasite invasion inhibitory antibody c1 - monoclinic form
5EZJ	;	1.95	;	Crystal Structure of Fab of parasite invasion inhibitory antibody c1 - orthorhombic form
3Q6G	;	1.902	;	Crystal structure of Fab of rhesus mAb 2.5B specific for quaternary neutralizing epitope of HIV-1 gp120
6CA9	;	2.702	;	Crystal structure of Fab PCT64_LMCA (SAR), the least mutated common ancestor of the HIV-1 broadly neutralizing antibody lineage PCT64
7WC0	;	2.705	;	Crystal structure of Fab region of TAU-2212 neutralizing SARS-CoV-2
6YIO	;	1.83	;	CRYSTAL STRUCTURE OF FAB RG6292 IN COMPLEX WITH CD25 ECD
6W5D	;	2.0	;	Crystal Structure of Fab RSB1
5XHV	;	3.35	;	Crystal Structure Of Fab S40 In Complex With Influenza Hemagglutinin, HA1 subunit.
3V0W	;	1.73	;	Crystal structure of Fab WN1 222-5 in complex with LPS
3BKJ	;	1.59	;	Crystal structure of Fab wo2 bound to the n terminal domain of amyloid beta peptide (1-16)
3BAE	;	1.593	;	Crystal structure of Fab WO2 bound to the N terminal domain of Amyloid beta peptide (1-28)
2F5A	;	2.05	;	CRYSTAL STRUCTURE OF FAB' FROM THE HIV-1 NEUTRALIZING ANTIBODY 2F5
2PR4	;	2.05	;	Crystal Structure of Fab' from the HIV-1 Neutralizing Antibody 2F5
2F5B	;	2.0	;	CRYSTAL STRUCTURE OF FAB' FROM THE HIV-1 NEUTRALIZING ANTIBODY 2F5 IN COMPLEX WITH ITS GP41 EPITOPE
1JN6	;	2.7	;	Crystal Structure of Fab-Estradiol Complexes
1JNH	;	2.85	;	Crystal Structure of Fab-Estradiol Complexes
1JNL	;	3.0	;	Crystal Structure of Fab-Estradiol Complexes
1JNN	;	3.2	;	Crystal Structure of Fab-Estradiol Complexes
8TUI	;	2.75	;	Crystal structure of Fab-Lirilumab bound to KIR2DL3
8TQA	;	2.6	;	Crystal structure of Fab.28.14.8 in complex with MHC-I (H2-Db)
8TQ7	;	2.8	;	Crystal structure of Fab.34.2.12 in complex with MHC-I (H2-Dd)
8TQ8	;	2.69	;	Crystal structure of Fab.34.5.8 in complex with MHC-I (H2-Dd)
8TQ9	;	2.9	;	Crystal structure of Fab.S19.8 in complex with MHC-I (H2-Dd)
7BM5	;	2.95	;	Crystal structure of Fab1, the Fab fragment of the anti-BamA monoclonal antibody MAB1
3ULS	;	2.495	;	Crystal structure of Fab12
1E6O	;	1.8	;	Crystal structure of Fab13B5 against HIV-1 capsid protein p24
3NA9	;	1.7	;	Crystal structure of Fab15
3NAA	;	1.7	;	Crystal structure of Fab15 Mut5
3NAB	;	2.32	;	Crystal Structure of fab15 Mut6
3NAC	;	1.8	;	Crystal structure of Fab15 Mut7
3NCJ	;	1.6	;	Crystal structure of Fab15 Mut8
1FN4	;	2.8	;	CRYSTAL STRUCTURE OF FAB198, AN EFFICIENT PROTECTOR OF ACETYLCHOLINE RECEPTOR AGAINST MYASTHENOGENIC ANTIBODIES
7TE4	;	2.456	;	Crystal structure of Fab2 anti-GluN2B antibody
6WFY	;	1.226	;	Crystal structure of Fab224 in complex with NPNA4 peptide from circumsporozoite protein
8FYM	;	2.45	;	Crystal structure of Fab235 in complex with MPER peptide
6W00	;	1.853	;	Crystal structure of Fab239 in complex with NPNA2 peptide from circumsporozoite protein
6WG2	;	2.534	;	Crystal structure of Fab239 in complex with NPNA4 peptide from circumsporozoite protein
6AXK	;	2.103	;	Crystal structure of Fab311 complex
6AXL	;	2.4	;	Crystal structure of Fab317 complex
6W05	;	2.516	;	Crystal structure of Fab356 in complex with NPNA2 peptide from circumsporozoite protein
6WFW	;	2.093	;	Crystal structure of Fab364 in complex with NPNA2 peptide from circumsporozoite protein
6WG0	;	1.599	;	Crystal structure of Fab366 in complex with NPNA3 peptide from circumsporozoite protein
6WFX	;	2.59	;	Crystal structure of Fab395 in complex with NPNA2 peptide from circumsporozoite protein
6WFZ	;	1.84	;	Crystal structure of Fab399 in complex with NPNA3 peptide from circumsporozoite protein
6WG1	;	2.086	;	Crystal structure of Fab399 in complex with NPNA6 peptide from circumsporozoite protein
5A16	;	2.5	;	Crystal structure of Fab4201 raised against Human Erythrocyte Anion Exchanger 1
8FXJ	;	2.0	;	Crystal structure of Fab460
8FZ2	;	3.5	;	Crystal structure of Fab460 in complex with MPER peptide
6PBW	;	2.058	;	Crystal structure of Fab667 complex
6PBV	;	1.566	;	Crystal structure of Fab668 complex
5YPV	;	1.67	;	Crystal structure of FabD from Acinetobacter baumannii
4NBT	;	1.48	;	Crystal structure of FabG from Acholeplasma laidlawii
4NBU	;	1.34	;	Crystal structure of FabG from Bacillus sp
4NBV	;	1.645	;	Crystal structure of FabG from Cupriavidus taiwanensis
4NBW	;	2.0	;	Crystal structure of FabG from Plesiocystis pacifica
4RZH	;	2.2	;	Crystal structure of FabG from Synechocystis sp. PCC 6803
3Q6I	;	2.59	;	Crystal structure of FabG4 and coenzyme binary complex
4FW8	;	2.79	;	Crystal structure of FABG4 complexed with Coenzyme NADH
4EWP	;	2.198	;	Crystal structure of FabH from Micrococcus luteus
6VLX	;	1.72	;	Crystal structure of FabI from Alistipes finegoldii
4NK4	;	1.7	;	Crystal structure of FabI from Candidatus Liberibacter asiaticus
4J4T	;	2.34	;	Crystal Structure of FabI from F. tularensis in complex with novel inhibitors based on the benzimidazole scaffold
4J3F	;	1.85	;	Crystal Structure of FabI from F. tularensis in complex with novel inhibitors based on the benzimidazole scaffold.
4NZ9	;	2.3	;	Crystal Structure of FabI from S. aureus in complex with a novel benzimidazole inhibitor
3UIC	;	2.5	;	Crystal Structure of FabI, an Enoyl Reductase from F. tularensis, in complex with a Novel and Potent Inhibitor
4NK5	;	2.7	;	Crystal structure of FabI-NAD complex from Candidatus Liberibacter asiaticus
6VLY	;	1.86	;	Crystal structure of FabI-NADH complex from Alistipes finegoldii
3DGG	;	2.3	;	Crystal structure of FabOX108
3DIF	;	2.4	;	Crystal structure of FabOX117
5D4A	;	1.7	;	Crystal Structure of FABP4 in complex with 3-(2-phenyl-1H-indol-1-yl)propanoic acid
5D45	;	1.65	;	Crystal Structure of FABP4 in complex with 3-(5-cyclopropyl-2,3-diphenyl-1H-indol-1-yl)propanoic acid
5D47	;	1.7	;	Crystal Structure of FABP4 in complex with 3-[5-cyclopropyl-3-(3-methoxypyridin-4-yl)-2-phenyl-1H-indol-1-yl] propanoic acid
5D48	;	1.81	;	Crystal Structure of FABP4 in complex with 3-{5-cyclopropyl-3-(3,5-dimethyl-1H-pyrazol-4-yl)-2-[3-(propan-2-yloxy) phenyl]-1H-indol-1-yl}propanoic acid
4NNS	;	1.53	;	Crystal structure of FABP4 in complex with novel inhibitor
4NNT	;	1.53	;	Crystal structure of FABP4 in complex with novel inhibitor
6L9O	;	1.42	;	Crystal structure of FABP7 apo
5XI0	;	2.087	;	Crystal structure of FabV, a new class of enyl-acyl carrier protein reductase from Vibrio fischeri
3OD4	;	2.2	;	Crystal Structure of Factor Inhibiting HIF-1 Alpha Complexed with Inhibitor
5JB9	;	1.3	;	Crystal structure of factor IXa K98T variant in complex with PPACK
5JB8	;	1.45	;	Crystal structure of factor IXa variant K98T in complex with EGR-chloromethylketone
5JBA	;	1.4	;	Crystal structure of factor IXa variant V16I K98T Y177T I212V in complex with PPACK
5JBB	;	1.56	;	Crystal structure of factor IXa variant V16I K98T Y177T I213V in complex with EGR-chloromethylketone
5JBC	;	1.9	;	Crystal structure of factor IXa variant V16I K98T Y177T I213V in complex with PPACK
2C4F	;	1.72	;	crystal structure of factor VII.stf complexed with pd0297121
5PAG	;	1.36	;	Crystal Structure of Factor VIIa in complex with (2R)-2-hydroxy-N-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]-3-methylbutanamide;hydrobromide
5PAO	;	1.4	;	Crystal Structure of Factor VIIa in complex with (2S)-2,3-dihydroxy-N-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]propanamide;hydrobromide
5PAS	;	1.48	;	Crystal Structure of Factor VIIa in complex with (2S)-2-hydroxy-N-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]-3-phenylpropanamide
5PAE	;	1.45	;	Crystal Structure of Factor VIIa in complex with (2S)-2-hydroxy-N-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]propanamide
5PAJ	;	1.7	;	Crystal Structure of Factor VIIa in complex with 1-(1-aminoisoquinolin-6-yl)-3-benzylurea
5PAX	;	1.36	;	Crystal Structure of Factor VIIa in complex with 1-(2,6-difluorophenyl)-3-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]urea
5PAB	;	1.99	;	Crystal Structure of Factor VIIa in complex with 1-[[3-[2-hydroxy-3-(1H-pyrrolo[3,2-c]pyridin-2-yl)phenyl]phenyl]methyl]-3-phenylurea
5PB3	;	1.9	;	Crystal Structure of Factor VIIa in complex with 1-[[3-[4-(5-amino-1H-pyrrolo[3,2-b]pyridin-2-yl)-5-hydroxypyrazol-1-yl]phenyl]methyl]-3-phenylurea
5PAY	;	1.66	;	Crystal Structure of Factor VIIa in complex with 1-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]-3-phenylurea
5PAR	;	2.1	;	Crystal Structure of Factor VIIa in complex with 1H-benzimidazol-2-amine
5PB0	;	1.98	;	Crystal Structure of Factor VIIa in complex with 2-(4-ethoxy-3-methoxyphenyl)-2-(isoquinolin-6-ylamino)acetic acid
5PB2	;	1.45	;	Crystal Structure of Factor VIIa in complex with 2-phenyl-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-3-ol
5PAQ	;	1.59	;	Crystal Structure of Factor VIIa in complex with 2-[(1-aminoisoquinolin-6-yl)amino]-2-(3-ethoxy-4-propan-2-yloxyphenyl)-1-(2-phenylpyrrolidin-1-yl)ethanone
5PAM	;	1.6	;	Crystal Structure of Factor VIIa in complex with 2-[(1-aminoisoquinolin-6-yl)amino]-2-(5-ethoxy-2-fluorophenyl)-1-(2-phenylpyrrolidin-1-yl)ethanone
5PAN	;	1.62	;	Crystal Structure of Factor VIIa in complex with 5-hydroxy-N-(3-oxo-1,2-dihydroisoindol-5-yl)-1-[3-[(phenylcarbamoylamino)methyl]phenyl]pyrazole-4-carboxamide
5PB1	;	1.9	;	Crystal Structure of Factor VIIa in complex with benzenecarboximidamide
5PA8	;	1.98	;	Crystal Structure of Factor VIIa in complex with cyclohexanamine
5PAA	;	1.98	;	Crystal Structure of Factor VIIa in complex with cyclohexylmethanamine
5PAW	;	2.2	;	Crystal Structure of Factor VIIa in complex with isoquinoline-1,6-diamine
5PAT	;	1.6	;	Crystal Structure of Factor VIIa in complex with N-(2-amino-1H-benzimidazol-5-yl)-2-(3-chlorophenyl)acetamide
5PAF	;	1.5	;	Crystal Structure of Factor VIIa in complex with N-(2-amino-1H-benzimidazol-5-yl)-2-[3-[(2-amino-2-oxoethyl)-methylsulfonylamino]-5-chlorophenyl]acetamide;2,2,2-trifluoroacetic acid
5PAU	;	1.55	;	Crystal Structure of Factor VIIa in complex with N-(2-amino-1H-benzimidazol-5-yl)-2-[3-[(2-amino-2-oxoethyl)-methylsulfonylamino]phenyl]acetamide;2,2,2-trifluoroacetic acid
5PAV	;	1.4	;	Crystal Structure of Factor VIIa in complex with N-(6-aminopyridin-3-yl)-5-hydroxy-1-phenylpyrazole-4-carboxamide
5PB6	;	1.9	;	Crystal Structure of Factor VIIa in complex with N-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]pentanamide
5PAK	;	1.56	;	Crystal Structure of Factor VIIa in complex with N-[[4-(aminomethyl)-2-(2-amino-2-oxoethoxy)phenyl]methyl]-2-(4-hydroxyphenyl)-2-methoxyacetamide;hydrochloride
5PA9	;	1.55	;	Crystal Structure of Factor VIIa in complex with phenylmethanamine;hydrochloride
2BQ6	;	3.0	;	Crystal structure of factor Xa in complex with 21
2BQ7	;	2.2	;	Crystal structure of factor Xa in complex with 43
2BMG	;	2.7	;	Crystal structure of factor Xa in complex with 50
2BOH	;	2.2	;	Crystal structure of factor Xa in complex with compound ""1""
2BQW	;	2.95	;	CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH COMPOUND 45
3BG8	;	1.6	;	Crystal structure of Factor XIa in complex with Clavatadine A
4E0H	;	2.0	;	Crystal structure of FAD binding domain of Erv1 from Saccharomyces cerevisiae
4QOG	;	1.4	;	Crystal structure of fad quinone reductase 2 in complex with melatonin at 1.4A
4QOH	;	1.6	;	Crystal structure of fad quinone reductase 2 in complex with resveratrol at 1.6A
8CT0	;	2.45	;	Crystal structure of FAD reductase CtcQ from Kitasatospora aureofaciens in complex with FAD and NAD
6RR3	;	1.69	;	CRYSTAL STRUCTURE OF FAD-CONTAINING FERREDOXIN-NADP REDUCTASE FROM BRUCELLA OVIS
4B4D	;	1.5	;	Crystal structure of FAD-containing ferredoxin-NADP reductase from Xanthomonas axonopodis pv. citri
7DVE	;	2.4	;	Crystal structure of FAD-dependent C-glycoside oxidase
6CXT	;	1.9	;	Crystal structure of FAD-dependent dehydrogenase
6CY8	;	2.729	;	Crystal structure of FAD-dependent dehydrogenase
7XLY	;	2.9	;	Crystal structure of FadA2 (Rv0243) from the fatty acid metabolic pathway of Mycobacterium tuberculosis
3WHB	;	2.15	;	Crystal structure of FadR from Bacillus subtilis, a transcriptional regulator involved in the regulation of fatty acid degradation
3E21	;	1.73	;	Crystal structure of FAF-1 UBA Domain
3QX1	;	1.6	;	Crystal structure of FAF1 UBX domain
3QC8	;	2.2	;	Crystal Structure of FAF1 UBX Domain In Complex with p97/VCP N Domain Reveals The Conserved FcisP Touch-Turn Motif of UBX Domain Suffering Conformational Change
3QCA	;	2.9	;	Crystal Structure of FAF1 UBX Domain In Complex with p97/VCP N Domain Reveals The Conserved FcisP Touch-Turn Motif of UBX Domain Suffering Conformational Change
3QWZ	;	2.0	;	Crystal structure of FAF1 UBX-p97N-domain complex
6LLG	;	2.1	;	Crystal Structure of Fagopyrum esculentum M UGT708C1
6LLW	;	2.256	;	Crystal Structure of Fagopyrum esculentum M UGT708C1 complexed with UDP
6LLZ	;	2.006	;	Crystal Structure of Fagopyrum esculentum M UGT708C1 complexed with UDP-glucose
2R7N	;	2.4	;	Crystal structure of FAICAR synthetase (PurP) from M. jannaschii complexed with ADP and FAICAR
2R7M	;	2.3	;	Crystal structure of FAICAR synthetase (PurP) from M. jannaschii complexed with AMP
2R7K	;	2.1	;	Crystal structure of FAICAR synthetase (PurP) from M. jannaschii complexed with AMPPCP and AICAR
2R7L	;	2.1	;	Crystal structure of FAICAR synthetase (PurP) from M. jannaschii complexed with ATP and AICAR
7EI0	;	3.4	;	Crystal structure of falcipain 2 from 3D7 strain
2GHU	;	3.1	;	Crystal structure of falcipain-2 from Plasmodium falciparum
3BPF	;	2.9	;	Crystal Structure of Falcipain-2 with Its inhibitor, E64
3BWK	;	2.42	;	Crystal Structure of Falcipain-3 with Its inhibitor, K11017
3BPM	;	2.5	;	Crystal Structure of Falcipain-3 with Its inhibitor, Leupeptin
1P1V	;	1.4	;	Crystal Structure of FALS-associated human Copper-Zinc Superoxide Dismutase (CuZnSOD) Mutant D125H to 1.4A
7FB5	;	2.84	;	Crystal structure of FAM134B/GABARAP complex
5WRR	;	2.506	;	Crystal structure of Fam20A
5WRS	;	2.75	;	Crystal Structure of Fam20A in complex with ATP
7ECQ	;	1.381	;	Crystal structure of FAM3A
6JYJ	;	2.6932	;	Crystal structure of FAM46B (TENT5B)
6W36	;	2.854	;	Crystal structure of FAM46C
1OZU	;	1.3	;	Crystal Structure of Familial ALS Mutant S134N of human Cu,Zn Superoxide Dismutase (CuZnSOD) to 1.3A resolution
2UWF	;	2.1	;	Crystal structure of family 10 xylanase from Bacillus halodurans
6LPS	;	2.21357	;	Crystal structure of family 10 xylanase from Bacillus halodurans
1TE1	;	2.5	;	Crystal structure of family 11 xylanase in complex with inhibitor (XIP-I)
1WMX	;	2.0	;	Crystal Structure of Family 30 Carbohydrate Binding Module
1WZX	;	3.52	;	Crystal Structure of Family 30 Carbohydrate Binding Module.
5F7C	;	2.6	;	Crystal structure of Family 31 alpha-glucosidase (BT_0339) from Bacteroides thetaiotaomicron
5DJW	;	2.7	;	Crystal structure of Family 31 alpha-glucosidase (BT_3299) from Bacteroides thetaiotaomicron
5NE5	;	1.05	;	Crystal structure of family 47 alpha-1,2-mannosidase from Caulobacter K31 strain in complex with kifunensine
2Z42	;	1.6	;	Crystal Structure of Family 7 Alginate Lyase A1-II' from Sphingomonas sp. A1
2ZAA	;	1.8	;	Crystal Structure of Family 7 Alginate Lyase A1-II' H191N/Y284F in Complex with Substrate (GGMG)
2ZAB	;	1.66	;	Crystal Structure of Family 7 Alginate Lyase A1-II' Y284F in Cmplex with Product (GGG)
2ZAC	;	1.5	;	Crystal Structure of Family 7 Alginate Lyase A1-II' Y284F in Complex with Product (MMG)
1WNS	;	3.0	;	Crystal structure of family B DNA polymerase from hyperthermophilic archaeon pyrococcus kodakaraensis KOD1
4R5E	;	1.5	;	Crystal Structure of Family GH18 Chitinase from Cycas revoluta a Complex with Allosamidin
4MCK	;	1.5	;	Crystal structure of Family GH19, Class IV chitinase from Zea mays
2HAW	;	1.75	;	Crystal structure of family II Inorganic pyrophosphatase in complex with PNP
3K1L	;	3.2	;	Crystal Structure of FANCL
6YRV	;	1.94	;	Crystal structure of FAP after illumination at 100K
6YRZ	;	1.824	;	Crystal structure of FAP et pH 8.5 after illumination at 150K
6YRU	;	1.78	;	Crystal structure of FAP in the dark at 100K
6YS2	;	1.97	;	Crystal structure of FAP R451A in the dark at 100K
6YS1	;	1.64	;	Crystal structure of FAP R451K mutant in the dark at 100K
2F3X	;	3.1	;	Crystal structure of FapR (in complex with effector)- a global regulator of fatty acid biosynthesis in B. subtilis
2F41	;	2.5	;	Crystal structure of FapR- a global regulator of fatty acid biosynthesis in B. subtilis
4EDO	;	1.8	;	Crystal structure of far-red fluorescent protein eqFP650
4EDS	;	1.6	;	Crystal structure of far-red fluorescent protein eqFP670
3PJ5	;	1.6	;	Crystal structure of far-red fluorescent protein Katushka crystallized at pH 5.0
3PJ7	;	1.85	;	Crystal structure of far-red fluorescent protein Katushka crystallized at pH 8.5
6UVB	;	3.0	;	Crystal structure of far-red-light absorbing cyanobacteriochrome at 100K
6HL0	;	1.66	;	Crystal Structure of Farnesoid X receptor (FXR) with bound NCoA-2 peptide
6HL1	;	1.599	;	Crystal Structure of Farnesoid X receptor (FXR) with bound NCoA-2 peptide and CDCA
7TRB	;	2.15	;	CRYSTAL STRUCTURE OF FARNESOID X-ACTIVATED RECEPTOR COMPLEXED WITH COMPOUND-32 AKA (1S,3S)-N-({4-[5-(2-FLUOROPR OPAN-2-YL)-1,2,4-OXADIAZOL-3-YL]BICYCLO[2.2.2]OCTAN-1-YL}M ETHYL)-3-HYDROXY-N-[4'-(2-HYDROXYPROPAN-2-YL)-[1,1'-BIPHEN YL]-3-YL]-3-(TRIFLUOROMETHYL)CYCLOBUTANE-1-CARBOXAMIDE
7W61	;	1.6	;	Crystal structure of farnesol dehydrogenase from Helicoverpa armigera
3TS7	;	1.94	;	CRYSTAL STRUCTURE OF FARNESYL DIPHOSPHATE SYNTHASE (TARGET EFI-501951) FROM Methylococcus capsulatus
3LVS	;	2.15	;	Crystal structure of farnesyl diphosphate synthase from rhodobacter capsulatus sb1003
4KPJ	;	1.95	;	Crystal Structure of Farnesyl Pyrophosphate Synthase (Y204A) Mutant complexed with Mg, Pamidronate
4KQS	;	1.97	;	Crystal Structure of Farnesyl Pyrophosphate Synthase Mutant (Y204A) Complexed with Mg, Risedronate and Isopentenyl Pyrophosphate
4KQU	;	2.07	;	Crystal Structure of Farnesyl Synthase Mutant (Y204A) Complexed with Mg, Alendronate and Isopentenyl Pyrophosphate
5TAR	;	1.9	;	Crystal structure of farnesylated and methylated kras4b in complex with PDE-delta (crystal form II - with ordered hypervariable region)
6K1Z	;	2.307	;	Crystal structure of farnesylated hGBP1
3TJE	;	1.93	;	Crystal structure of Fas receptor extracellular domain in complex with Fab E09
3THM	;	2.1	;	Crystal structure of Fas receptor extracellular domain in complex with Fab EP6b_B01
5N86	;	1.484	;	Crystal structure of FAS1 domain of hyaluronic acid receptor stabilin-2
1FSC	;	2.0	;	Crystal Structure of Fasciculin 2 from Green Mamba Snake Venom: Evidence for Unusual Loop Flexibility
6I18	;	1.49	;	CRYSTAL STRUCTURE OF FASCIN IN COMPLEX WITH BDP-13176
6I0Z	;	1.77	;	CRYSTAL STRUCTURE OF FASCIN IN COMPLEX WITH COMPOUND 1
6I15	;	1.91	;	CRYSTAL STRUCTURE OF FASCIN IN COMPLEX WITH COMPOUND 11
6I16	;	2.0	;	CRYSTAL STRUCTURE OF FASCIN IN COMPLEX WITH COMPOUND 15
6I10	;	2.1	;	CRYSTAL STRUCTURE OF FASCIN IN COMPLEX WITH COMPOUND 2
6I17	;	1.56	;	CRYSTAL STRUCTURE OF FASCIN IN COMPLEX WITH COMPOUND 24
6I11	;	1.67	;	CRYSTAL STRUCTURE OF FASCIN IN COMPLEX WITH COMPOUND 3
6I12	;	1.65	;	CRYSTAL STRUCTURE OF FASCIN IN COMPLEX WITH COMPOUND 5
6I13	;	1.79	;	CRYSTAL STRUCTURE OF FASCIN IN COMPLEX WITH COMPOUND 7
6I14	;	1.73	;	CRYSTAL STRUCTURE OF FASCIN IN COMPLEX WITH COMPOUND 9
4MSV	;	2.5	;	Crystal structure of FASL and DcR3 complex
3LF3	;	1.15	;	Crystal Structure of Fast Fluorescent Timer Fast-FT
7RRK	;	1.929	;	Crystal structure of fast switching M159E mutant of fluorescent protein Dronpa (Dronpa2)
7RRJ	;	2.2	;	Crystal structure of fast switching M159Q mutant of fluorescent protein Dronpa (Dronpa2)
6NQJ	;	2.0	;	Crystal structure of fast switching M159T mutant of fluorescent protein Dronpa (Dronpa2)
6NQQ	;	2.6	;	Crystal structure of fast switching M159T mutant of fluorescent protein Dronpa (Dronpa2), Y63(2,3,5-F3Y)
6NQP	;	2.2	;	Crystal structure of fast switching M159T mutant of fluorescent protein Dronpa (Dronpa2), Y63(2,3-F2Y)
6NQN	;	2.1	;	Crystal structure of fast switching M159T mutant of fluorescent protein Dronpa (Dronpa2), Y63(3-BrY)
6NQV	;	2.7	;	Crystal structure of fast switching M159T mutant of fluorescent protein Dronpa (Dronpa2), Y63(3-CH3Y)
6NQL	;	2.147	;	Crystal structure of fast switching M159T mutant of fluorescent protein Dronpa (Dronpa2), Y63(3-ClY)
6NQK	;	2.0	;	Crystal structure of fast switching M159T mutant of fluorescent protein Dronpa (Dronpa2), Y63(3-FY)
6NQO	;	2.1	;	Crystal structure of fast switching M159T mutant of fluorescent protein Dronpa (Dronpa2), Y63(3-IY)
6NQR	;	2.9	;	Crystal structure of fast switching M159T mutant of fluorescent protein Dronpa (Dronpa2)- Y63(3-NO2Y)
6NQS	;	2.5	;	Crystal structure of fast switching M159T mutant of fluorescent protein Dronpa (Dronpa2)- Y63(3-OMeY)
7RRH	;	1.747	;	Crystal structure of fast switching R66M/M159T mutant of fluorescent protein Dronpa (Dronpa2)
7RRI	;	2.643	;	Crystal structure of fast switching S142A/M159T mutant of fluorescent protein Dronpa (Dronpa2)
5F28	;	2.9	;	Crystal structure of FAT domain of Focal Adhesion Kinase (FAK) bound to the transcription factor MEF2C
4HHR	;	1.51	;	Crystal Structure of fatty acid alpha-dioxygenase (Arabidopsis thaliana)
4HHS	;	1.7	;	Crystal Structure of fatty acid alpha-dioxygenase (Arabidopsis thaliana)
1MT5	;	2.8	;	CRYSTAL STRUCTURE OF FATTY ACID AMIDE HYDROLASE
3QJ8	;	2.9	;	Crystal structure of fatty acid amide hydrolase
2VYA	;	2.75	;	Crystal Structure of fatty acid amide hydrolase conjugated with the drug-like inhibitor PF-750
3QKV	;	3.1	;	Crystal structure of fatty acid amide hydrolase with small molecule compound
3QJ9	;	2.3	;	Crystal structure of fatty acid amide hydrolase with small molecule inhibitor
3QK5	;	2.2	;	Crystal structure of fatty acid amide hydrolase with small molecule inhibitor
3LUP	;	2.65	;	Crystal structure of fatty acid binding DegV family protein SAG1342 from Streptococcus agalactiae
6ZH7	;	2.0	;	Crystal structure of fatty acid photodecarboxylase in the dark state determined by serial femtosecond crystallography at room temperature
4V59	;	3.1	;	Crystal structure of fatty acid synthase complexed with nadp+ from thermomyces lanuginosus at 3.1 angstrom resolution.
4V58	;	3.1	;	Crystal structure of fatty acid synthase from thermomyces lanuginosus at 3.1 angstrom resolution.
5GKB	;	2.04	;	Crystal Structure of Fatty Acid-Binding Protein in Brain Tissue of Drosophila melanogaster without citrate inside
3BDR	;	2.8	;	Crystal structure of fatty acid-binding protein-like Ycf58 from Thermosynecoccus elongatus. Northeast Structural Genomics Consortium target TeR13.
2G04	;	2.7	;	Crystal structure of fatty acid-CoA racemase from Mycobacterium tuberculosis H37Rv
8SJ7	;	2.09	;	Crystal structure of FBF-2 (RBD+CT) in complex with compact FBE RNA
3V6Y	;	2.5	;	crystal structure of FBF-2 in complex with a mutant gld-1 FBEa13 RNA
3V74	;	2.3	;	crystal structure of FBF-2 in complex with gld-1 FBEa13 RNA
7RZZ	;	2.39	;	Crystal structure of FBF-2 in complex with LST-1 site A peptide and compact FBE RNA
7S02	;	2.34	;	Crystal structure of FBF-2 in complex with LST-1 site A peptide and FBE RNA
3QGB	;	2.4	;	Crystal structure of FBF-2 R288Y mutant in complex with gld-1 FBEa
3QGC	;	1.9	;	Crystal structure of FBF-2 R288Y mutant in complex with gld-1 FBEa A7U mutant
6NOC	;	2.849	;	Crystal structure of FBF-2 repeat 5 mutant (C363A, R364Y) in complex with 8-nt RNA
6NOF	;	2.251	;	Crystal structure of FBF-2 repeat 5 mutant (C363A, R364Y, Q367S) in complex with 8-nt RNA
6NOH	;	2.249	;	Crystal structure of FBF-2 repeat 5 mutant (C363S, R364Y, Q367S) in complex with 8-nt RNA
3K5Q	;	2.2	;	Crystal structure of FBF-2/FBE complex
3K64	;	2.0	;	Crystal structure of FBF-2/fem-3 PME complex
3K61	;	2.21	;	Crystal structure of FBF-2/fog-1 FBEa complex
3QG9	;	2.25	;	crystal structure of FBF-2/gld-1 FBEa A7U mutant complex
3K5Y	;	2.3	;	Crystal structure of FBF-2/gld-1 FBEa complex
3K5Z	;	2.4	;	Crystal structure of FBF-2/gld-1 FBEa G4A mutant complex
3K62	;	1.9	;	Crystal structure of FBF-2/gld-1 FBEb complex
5TK3	;	1.83	;	Crystal structure of FBP aldolase from Toxoplasma gondii, burst-phase ternary complex
5TKL	;	1.751	;	Crystal structure of FBP aldolase from Toxoplasma gondii, condensation intermediate
5TKP	;	2.09	;	Crystal structure of FBP aldolase from Toxoplasma gondii, equilibrium Schiff base FBP complex
5TJS	;	1.78	;	Crystal structure of FBP aldolase from Toxoplasma gondii, native form
5TKN	;	1.92	;	Crystal structure of FBP aldolase from Toxoplasma gondii, Schiff base FBP complex
5TKC	;	1.779	;	Crystal structure of FBP aldolase from Toxoplasma gondii, ternary complex
5VH5	;	1.75	;	Crystal Structure of Fc fragment of anti-TNFa antibody infliximab
6S5A	;	1.72	;	CRYSTAL STRUCTURE OF FC P329G LALA WITH ANTI FC P329G FAB
3RJD	;	2.65	;	Crystal structure of Fc RI and its implication to high affinity immunoglobulin G binding
4HAG	;	3.4	;	Crystal structure of fc-fragment of human IgG2 antibody (centered crystal form)
4HAF	;	2.04	;	Crystal structure of fc-fragment of human IgG2 antibody (primitive crystal form)
4L4J	;	1.92	;	Crystal structure of fc-fragment of human IgG2-Sigma antibody
7Q15	;	3.301	;	Crystal structure of FcRn and beta-2-microglobulin in complex with IgG1-Fc-MST-HN (efgartigimod)
6C97	;	2.0	;	Crystal structure of FcRn at pH3
6C99	;	2.0	;	Crystal structure of FcRn bound to UCB-303
6C98	;	1.85	;	Crystal structure of FcRn bound to UCB-84
7CYV	;	3.13	;	Crystal structure of FD20, a neutralizing single-chain variable fragment (scFv) in complex with SARS-CoV-2 Spike receptor-binding domain (RBD)
4PDE	;	2.8	;	Crystal structure of FdhD in complex with GDP
6TUK	;	1.9	;	Crystal structure of Fdr9
4MZU	;	2.2	;	Crystal structure of FdtD, a bifunctional ketoisomerase/N-acetyltransferase from Shewanella denitrificans
4KAR	;	2.03	;	Crystal structure of FDTS (TM0449) mutant (H53D) with FAD
4KAS	;	1.85	;	Crystal structure of FDTS from T. maritima mutant (H53D) with FAD and dUMP
4KAT	;	2.14	;	Crystal structure of FDTS from T. maritima mutant (R174K) with FAD and dUMP
2NVM	;	2.19	;	Crystal structure of fdxN element excision controlling factor XisI (YP_321976.1) from Anabaena Variabilis ATCC 29413 at 2.19 A resolution
5JRX	;	1.95	;	Crystal structure of Fe(II) CO-bound H-NOX protein from C. subterraneus
5JRV	;	1.953	;	Crystal structure of Fe(II) NO-bound H-NOX protein from C. subterraneus
5JRU	;	2.305	;	Crystal structure of Fe(II) unliganded H-NOX protein from C. subterraneus
6BDD	;	1.901	;	Crystal structure of Fe(II) unliganded H-NOX protein from K. algicida
6BDE	;	1.641	;	Crystal structure of Fe(II) unliganded H-NOX protein mutant A71G from K. algicida
4J1W	;	2.72	;	Crystal Structure of Fe(II)-HppE with alternative substrate (R)-1-HPP
4J1X	;	2.8	;	Crystal Structure of Fe(II)-HppE with alternative substrate (S)-1-HPP
6NSI	;	2.00006	;	Crystal structure of Fe(III)-bound YtgA from Chlamydia trachomatis
5U8X	;	2.17	;	Crystal structure of Fe-CAO1
4JJF	;	2.2	;	Crystal structure of FE-hydrogenase from methanothermobacter marburgensis in complex with 2-naphthylisocyanide
4JJG	;	2.5	;	Crystal structure of FE-hydrogenase from methanothermobacter marburgensis in complex with toluenesulfonylmethylisocyanide
8EJ0	;	2.59	;	Crystal structure of Fe-S cluster-dependent dehydratase from Paralcaligenes ureilyticus in complex with Mg
8EPZ	;	2.6	;	Crystal structure of Fe-S cluster-dependent dehydratase from Paralcaligenes ureilyticus in complex with Mn
2QDY	;	1.3	;	Crystal Structure of Fe-type NHase from Rhodococcus erythropolis AJ270
5GGX	;	3.4	;	Crystal Structure of Fe3+ - Desferal bound siderophore binding protein FhuD from Vibrio cholerae
5CZU	;	1.6	;	Crystal structure of FeCat-Fn
3AB4	;	2.47	;	Crystal structure of feedback inhibition resistant mutant of aspartate kinase from Corynebacterium glutamicum in complex with lysine and threonine
1ZZ9	;	2.4	;	Crystal Structure of FeII HppE
1ZZ7	;	2.1	;	Crystal Structure of FeII HppE in Complex with Substrate form 1
1ZZ8	;	2.3	;	Crystal Structure of FeII HppE in Complex with Substrate Form 2
1PUO	;	1.85	;	Crystal structure of Fel d 1- the major cat allergen
2FIV	;	2.0	;	Crystal structure of feline immunodeficiency virus protease complexed with a substrate
3FIV	;	1.85	;	CRYSTAL STRUCTURE OF FELINE IMMUNODEFICIENCY VIRUS PROTEASE COMPLEXED WITH A SUBSTRATE
5XMF	;	2.1	;	Crystal structure of feline MHC class I for 2,1 angstrom
4QUZ	;	2.35	;	Crystal structure of Feline Norovirus P Domain
6LBF	;	3.252	;	Crystal structure of FEM1B
6SNR	;	1.62	;	Crystal structure of FemX
5UJV	;	2.7	;	Crystal structure of FePYR1 in complex with abscisic acid
8ITO	;	2.1	;	Crystal structure of FeRlp from Desulfovibrio vulgaris (Hildenborough)
4NY0	;	2.8	;	Crystal structure of FERM domain of human focal adhesion kinase
4EKU	;	3.25	;	Crystal Structure of FERM Domain of Proline-rich Tyrosine Kinase 2
6VGU	;	2.78	;	Crystal structure of FERM-folded talin head domain bound to the NPLY motif of beta3-integrin
8DOS	;	1.872	;	Crystal structure of Ferredoxin (flavodoxin):NADP(+) oxidoreductase from Klebsiella pneumoniae
1D3W	;	1.7	;	Crystal structure of ferredoxin 1 d15e mutant from azotobacter vinelandii at 1.7 angstrom resolution.
1VCK	;	1.9	;	Crystal structure of ferredoxin component of carbazole 1,9a-dioxygenase of Pseudomonas resinovorans strain CA10
4LTU	;	2.31	;	Crystal Structure of Ferredoxin from Rhodopseudomonas palustris HaA2
5AUI	;	1.499	;	Crystal structure of Ferredoxin from Thermosynechococcus elongatus
1WRI	;	1.2	;	Crystal Structure of Ferredoxin isoform II from E. arvense
3AB1	;	2.39	;	Crystal Structure of Ferredoxin NADP+ Oxidoreductase
5YGQ	;	2.4	;	Crystal Structure of Ferredoxin NADP+ Oxidoreductase from Rhodopseudomonas palustris
3LXD	;	2.5	;	Crystal Structure of Ferredoxin Reductase ArR from Novosphingobium aromaticivorans
2YVF	;	1.6	;	Crystal structure of ferredoxin reductase BPHA4 (hydroquinone)
3FG2	;	2.2	;	Crystal Structure of Ferredoxin Reductase for the CYP199A2 System from Rhodopseudomonas palustris
2YVG	;	1.6	;	crystal structure of ferredoxin reductase, BPHA4 (blue-semiquinone)
2GR1	;	1.8	;	Crystal structure of Ferredoxin reductase, BphA4 (hydroquinone)
2GQW	;	1.4	;	Crystal structure of Ferredoxin reductase, BphA4 (oxidized form)
2GR2	;	1.85	;	Crystal structure of Ferredoxin reductase, BphA4 (oxidized form)
2GR3	;	1.5	;	Crystal structure of Ferredoxin reductase, BphA4 (oxidized form)
2GR0	;	1.7	;	Crystal structure of Ferredoxin reductase, BphA4 (oxidized form, NAD+ complex)
4H4X	;	1.5	;	Crystal Structure of Ferredoxin reductase, BphA4 E175A/T176R/Q177G mutant (oxidized form)
4H4Y	;	1.9	;	Crystal Structure of Ferredoxin reductase, BphA4 E175A/T176R/Q177G mutant (reduced form)
4H4R	;	1.4	;	Crystal Structure of Ferredoxin reductase, BphA4 E175C/Q177G mutant (oxidized form)
4H4S	;	1.65	;	Crystal Structure of Ferredoxin reductase, BphA4 E175C/Q177G mutant (reduced form)
4H4V	;	1.4	;	Crystal Structure of Ferredoxin reductase, BphA4 E175C/T176R/Q177G mutant (oxidized form)
4H4W	;	1.7	;	Crystal Structure of Ferredoxin reductase, BphA4 E175C/T176R/Q177G mutant (reduced form)
4H4Q	;	1.95	;	Crystal Structure of Ferredoxin reductase, BphA4 E175Q/Q177K (reduced form)
4H4P	;	1.502	;	Crystal Structure of Ferredoxin reductase, BphA4 E175Q/Q177K mutant (oxidized form)
4H4Z	;	1.95	;	Crystal Structure of Ferredoxin reductase, BphA4 E175Q/T176R/Q177G mutant (oxidized form)
4H50	;	2.65	;	Crystal Structure of Ferredoxin reductase, BphA4 E175Q/T1776R/Q177G mutant (reduced form)
4H4T	;	1.5	;	Crystal Structure of Ferredoxin reductase, BphA4 T176R mutant (oxidized form)
4H4U	;	1.6	;	Crystal Structure of Ferredoxin reductase, BphA4 T176R mutant (reduced form)
1DJ7	;	1.6	;	CRYSTAL STRUCTURE OF FERREDOXIN THIOREDOXIN REDUCTASE
4TPU	;	2.355	;	CRYSTAL STRUCTURE OF FERREDOXIN-DEPENDENT DISULFIDE REDUCTASE FROM METHANOSARCINA ACETIVORANS
4F7D	;	2.35	;	Crystal structure of ferredoxin-NADP reductase from burkholderia thailandensis E264
4FK8	;	2.1	;	Crystal structure of FERREDOXIN-NADP REDUCTASE from burkholderia thailandensis E264 with bound FAD
3FPK	;	1.7	;	Crystal Structure of Ferredoxin-NADP Reductase from Salmonella typhimurium
3LZW	;	1.8	;	Crystal structure of ferredoxin-NADP+ oxidoreductase from bacillus subtilis (form I)
3LZX	;	1.9	;	Crystal structure of ferredoxin-NADP+ oxidoreductase from Bacillus subtilis (FORM II)
8C3M	;	2.6	;	Crystal structure of ferredoxin/flavodoxin NADP+ oxidoreductase 1 (FNR1) V329H mutant from Bacillus cereus
7C2B	;	1.7949	;	Crystal structure of ferredoxin: thioredoxin reductase and thioredoxin f2 complex
7C3F	;	2.3986	;	Crystal structure of ferredoxin: thioredoxin reductase and thioredoxin m2 complex
7BZK	;	1.5935	;	Crystal structure of ferredoxin: thioredoxin reductase and thioredoxin y1 complex
4ZF7	;	1.893	;	Crystal structure of ferret interleukin-2
1PO3	;	3.4	;	Crystal structure of ferric citrate transporter FecA in complex with ferric citrate
1PO0	;	2.15	;	Crystal structure of ferric citrate transporter FecA in complex with iron-free citrate
1PNZ	;	2.5	;	Crystal structure of ferric citrate transporter FecA in the unliganded form
1GDI	;	1.8	;	CRYSTAL STRUCTURE OF FERRIC COMPLEXES OF THE YELLOW LUPIN LEGHEMOGLOBIN WITH ISOQUINOLINE AT 1.8 ANGSTROMS RESOLUTION (RUSSIAN)
1GDJ	;	1.7	;	CRYSTAL STRUCTURE OF FERRIC COMPLEXES OF THE YELLOW LUPIN LEGHEMOGLOBIN WITH ISOQUINOLINE AT 1.8 ANGSTROMS RESOLUTION (RUSSIAN)
1GDK	;	1.8	;	CRYSTAL STRUCTURE OF FERRIC COMPLEXES OF THE YELLOW LUPIN LEGHEMOGLOBIN WITH ISOQUINOLINE AT 1.8 ANGSTROMS RESOLUTION (RUSSIAN)
1GDL	;	1.8	;	CRYSTAL STRUCTURE OF FERRIC COMPLEXES OF THE YELLOW LUPIN LEGHEMOGLOBIN WITH ISOQUINOLINE AT 1.8 ANGSTROMS RESOLUTION (RUSSIAN)
2ZAX	;	1.6	;	Crystal Structure of Ferric Cytochrome P450cam
2ZWT	;	1.35	;	Crystal Structure of Ferric Cytochrome P450cam
2ZAW	;	1.55	;	Crystal Structure of Ferric Cytochrome P450cam Reconstituted with 6-Methyl-6-depropionated Hemin
2Z97	;	1.8	;	Crystal Structure of Ferric Cytochrome P450cam Reconstituted with 7-Methyl-7-depropionated Hemin
4HLT	;	1.7	;	Crystal structure of ferric E32V Pirin
2QBL	;	1.8	;	Crystal structure of ferric G248T cytochrome P450cam
2QBN	;	1.75	;	Crystal structure of ferric G248V cytochrome P450cam
7OHD	;	1.8	;	CRYSTAL STRUCTURE OF FERRIC MURINE NEUROGLOBIN CDLESS MUTANT
6HK2	;	1.55	;	Crystal structure of ferric R-state human methemoglobin bound to maleimide-deferoxamine bifunctional chelator (DFO)
1I0R	;	1.5	;	CRYSTAL STRUCTURE OF FERRIC REDUCTASE FROM ARCHAEOGLOBUS FULGIDUS
1IO3	;	1.9	;	CRYSTAL STRUCTURE OF FERRICYTOCHROME C2 FROM RHODOPSEUDOMONAS VIRIDIS
8B43	;	2.49	;	Crystal structure of ferrioxamine transporter
3FVB	;	1.806	;	Crystal structure of ferritin (bacterioferritin) from Brucella melitensis
1VLG	;	2.0	;	Crystal structure of Ferritin (TM1128) from Thermotoga maritima at 2.00 A resolution
7USN	;	1.789	;	Crystal structure of ferritin 1 from Caenorhabditis elegans, FTN-1
7URH	;	1.468	;	Crystal structure of Ferritin 2 from Caenorhabditis elegans, FTN-2
5V5K	;	3.08	;	Crystal structure of ferritin E65R mutant from hyperthermophilic archaeon Archaeoglobus fulgidus
3VNX	;	2.4	;	Crystal structure of ferritin from multicellular green algae, Ulva pertusa.
4ISM	;	2.0	;	Crystal structure of ferritin from Pseudo-nitzschia multiseries soaked with zinc
7XZ4	;	2.2	;	Crystal structure of ferritin from Setaria italica
7VP8	;	2.002	;	Crystal structure of ferritin from Ureaplasma urealyticum
7RZN	;	1.97	;	Crystal Structure of Ferritin grown by microbatch method in presence of agarose and electric field 2.1KV
7RZX	;	2.44	;	Crystal Structure of Ferritin grown by microbatch method in presence of agarose and electric field 4.3KV
7RYW	;	2.09	;	Crystal structure of Ferritin grown by the microbatch method in the presence of Agarose
2QQY	;	2.0	;	Crystal structure of ferritin like, diiron-carboxylate proteins from Bacillus anthracis str. Ames
3E6S	;	1.95	;	Crystal structure of ferritin soaked with iron from Pseudo-nitzschia multiseries
3GE4	;	1.7	;	Crystal structure of ferritin:DNA-binding protein DPS from Brucella Melitensis
1DOZ	;	1.8	;	CRYSTAL STRUCTURE OF FERROCHELATASE
1L8X	;	2.7	;	Crystal Structure of Ferrochelatase from the Yeast, Saccharomyces cerevisiae, with Cobalt(II) as the Substrate Ion
2C8J	;	2.1	;	CRYSTAL STRUCTURE OF ferrochelatase HemH-1 from Bacillus anthracis, str. Ames
1N0I	;	2.0	;	Crystal Structure of Ferrochelatase with Cadmium bound at active site
1SHR	;	1.88	;	Crystal structure of ferrocyanide bound human hemoglobin A2 at 1.88A resolution
1CO6	;	1.6	;	CRYSTAL STRUCTURE OF FERROCYTOCHROME C2 FROM RHODOPSEUDOMONAS VIRIDIS
2IMQ	;	1.3	;	Crystal structure of ferrous cimex nitrophorin
3PXT	;	2.16	;	Crystal Structure of Ferrous CO Adduct of MauG in Complex with Pre-Methylamine Dehydrogenase
2V1K	;	1.25	;	Crystal structure of ferrous deoxymyoglobin at pH 6.8
2A1N	;	1.9	;	Crystal structure of ferrous dioxygen complex of D251N cytochrome P450cam
2A1O	;	1.55	;	Crystal structure of ferrous dioxygen complex of T252A cytochrome P450cam
2A1M	;	2.1	;	Crystal structure of ferrous dioxygen complex of wild-type cytochrome P450cam
6CDH	;	1.821	;	Crystal structure of ferrous form of the Cl-Tyr157 human cysteine dioxygenase with both uncrosslinked and crosslinked cofactor
6BPW	;	2.43	;	Crystal structure of ferrous form of the Cl2-Tyr157 human cysteine dioxygenase with both uncrosslinked and crosslinked cofactor
6BGM	;	2.206	;	Crystal structure of ferrous form of the crosslinked human cysteine dioxygenase
6E87	;	1.952	;	Crystal structure of ferrous form of the crosslinked human cysteine dioxygenase in the anaerobic condition
6BPU	;	1.8	;	Crystal structure of ferrous form of the F2-Tyr157 human cysteine dioxygenase with both uncrosslinked and crosslinked cofactor
6BPT	;	2.402	;	Crystal structure of ferrous form of the uncrosslinked F2-Tyr157 human cysteine dioxygenase
3PXW	;	2.11	;	Crystal Structure of Ferrous NO Adduct of MauG in Complex with Pre-Methylamine Dehydrogenase
1R65	;	1.95	;	Crystal structure of ferrous soaked Ribonucleotide Reductase R2 subunit (wildtype) at pH 5 from E. coli
1USW	;	2.5	;	Crystal Structure of Ferulic Acid Esterase from Aspergillus niger
3WMT	;	1.5	;	Crystal structure of feruloyl esterase B from Aspergillus oryzae
8BBP	;	1.07	;	Crystal structure of feruloyl esterase wtsFae1B
8BF3	;	1.19	;	Crystal structure of feruloyl esterase wtsFae1B in complex with xylobiose
7XWT	;	1.76	;	Crystal structure of Feruoyl-CoA hydratase/lyase complexed with CoA from Sphingomonas paucimobilis
1R6V	;	1.7	;	Crystal structure of fervidolysin from Fervidobacterium pennivorans, a keratinolytic enzyme related to subtilisin
1ZPU	;	2.8	;	Crystal Structure of Fet3p, a Multicopper Oxidase that Functions in Iron Import
2ZNZ	;	2.39	;	Crystal structure of FFRP
2E1A	;	2.5	;	crystal structure of FFRP-DM1
2Z4P	;	1.95	;	Crystal structure of FFRP-DM1
4LHO	;	2.224	;	Crystal Structure of FG41Malonate Semialdehyde Decarboxylase inhibited by 3-bromopropiolate
3MLC	;	2.224	;	Crystal structure of FG41MSAD inactivated by 3-chloropropiolate
4QQJ	;	1.682	;	Crystal Structure of FGF Receptor (FGFR) 4 Kinase Domain Harboring the V550L Gate-Keeper Mutation
4QQC	;	2.4	;	Crystal Structure of FGF Receptor (FGFR) 4 Kinase Domain in Complex with FIIN-2, an Irreversible Tyrosine Kinase Inhibitor Capable of Overcoming FGFR Kinase Gate-Keeper Mutations
4QQ5	;	2.203	;	Crystal Structure of FGF Receptor (FGFR) 4 Kinase Harboring the V550L Gate-Keeper Mutation in Complex With FIIN-2, an Irreversible Tyrosine Kinase Inhibitor Capable of Overcoming FGFR Kinase Gate-Keeper Mutations
4R6V	;	2.353	;	Crystal Structure of FGF Receptor (FGFR) 4 Kinase Harboring the V550L Gate-Keeper Mutation in Complex with FIIN-3, an Irreversible Tyrosine Kinase Inhibitor Capable of Overcoming FGFR kinase Gate-Keeper Mutations
4QQT	;	1.501	;	Crystal Structure of FGF Receptor (FGFR) 4 Tyrosine Kinase Domain
4J98	;	2.3067	;	Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Gain-of-Function K659Q Mutation.
4J99	;	1.8474	;	Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Gain-of-Function K659T Mutation.
2Q0B	;	2.9	;	Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic E565A Mutation Responsible for Pfeiffer Syndrome
2PY3	;	2.3	;	Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic E565G Mutation Responsible for Pfeiffer Syndrome
4J97	;	2.5482	;	Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659E Mutation Identified in Endometrial Cancer.
4J96	;	2.2972	;	Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659M Mutation Identified in Cervical Cancer.
2PZP	;	2.4	;	Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K526E Mutation Responsible for Crouzon Syndrome
2PZR	;	3.0	;	Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K641R Mutation Responsible for Pfeiffer Syndrome
4J95	;	2.3767	;	Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K659N Mutation Responsible for an Unclassified Craniosynostosis Syndrome in Space Group C2.
2PVY	;	2.2	;	Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K659N Mutation Responsible for an Unclassified Craniosynostosis Syndrome.
2PWL	;	2.4	;	Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic N549H Mutation Responsible for Crouzon Syndrome.
2PZ5	;	2.4	;	Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic N549T Mutation Responsible for Pfeiffer Syndrome
3CLY	;	2.0	;	Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domains Trapped in Trans-Phosphorylation Reaction
5UGL	;	1.861	;	Crystal Structure of FGF Receptor 2 Tyrosine Kinase Domain Harboring the D650V Activating Mutation
4K33	;	2.3405	;	Crystal Structure of FGF Receptor 3 (FGFR3) Kinase Domain Harboring the K650E Mutation, a Gain-of-Function Mutation Responsible for Thanatophoric Dysplasia Type II and Spermatocytic Seminoma
2AQZ	;	1.85	;	Crystal structure of FGF-1, S17T/N18T/G19 deletion mutant
1Q04	;	1.8	;	Crystal structure of FGF-1, S50E/V51N
1Q03	;	2.05	;	Crystal structure of FGF-1, S50G/V51G mutant
1PZZ	;	2.0	;	Crystal structure of FGF-1, V51N mutant
3OJV	;	2.6	;	Crystal Structure of FGF1 complexed with the ectodomain of FGFR1c exhibiting an ordered ligand specificity-determining betaC'-betaE loop
3OJM	;	2.1	;	Crystal Structure of FGF1 complexed with the ectodomain of FGFR2b harboring P253R Apert mutation
3OJ2	;	2.2	;	Crystal structure of FGF1 complexed with the ectodomain of FGFR2b harboring the A172F Pfeiffer syndrome mutation
1EVT	;	2.8	;	CRYSTAL STRUCTURE OF FGF1 IN COMPLEX WITH THE EXTRACELLULAR LIGAND BINDING DOMAIN OF FGF RECEPTOR 1 (FGFR1)
1EV2	;	2.2	;	CRYSTAL STRUCTURE OF FGF2 IN COMPLEX WITH THE EXTRACELLULAR LIGAND BINDING DOMAIN OF FGF RECEPTOR 2 (FGFR2)
4L0R	;	2.49	;	Crystal structure of FGF2-interacting protein from Homo sapiens. Northeast Structural Genomics Consortium Target HR9027A.
8OM6	;	1.31	;	Crystal structure of FGF2-STAB, a stable variant of human fibroblast growth factor 2
3F1R	;	2.5	;	Crystal structure of FGF20 dimer
6JPJ	;	2.638	;	Crystal structure of FGF401 in complex of FGFR4
4RWL	;	2.193	;	Crystal structure of FGFR1 (C488A, C584C) in complex with 6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide (E3810)
4RWJ	;	2.489	;	Crystal Structure of FGFR1 (C488A, C584S) in complex with AZD4547 (N-{3-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R,5S)-3,5-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
4ZSA	;	2.0	;	Crystal structure of FGFR1 kinase domain in complex with 7n
5Z0S	;	2.45	;	Crystal structure of FGFR1 kinase domain in complex with a novel inhibitor
6ITJ	;	1.994	;	Crystal structure of FGFR1 kinase domain in complex with compound 3
7WCL	;	2.495	;	Crystal structure of FGFR1 kinase domain with Pemigatinib
6P69	;	2.2	;	Crystal structure of FGFR1-Y563C (FGFR4 surrogate) covalently bound to compound 11.
6P68	;	2.9	;	Crystal structure of FGFR1-Y563C (FGFR4 surrogate) covalently bound to compound 22.
5VND	;	2.2	;	Crystal structure of FGFR1-Y563C (FGFR4 surrogate) covalently bound to H3B-6527
6LVK	;	2.29	;	Crystal structure of FGFR2 in complex with 1,3,5-triazine derivative
6LVL	;	2.98	;	Crystal structure of FGFR2 in complex with 1,3,5-triazine derivative
7KIA	;	2.22	;	Crystal structure of FGFR2 kinase domain gatekeeper mutant V564F in complex with covalent compound 19
7KIE	;	2.47	;	Crystal structure of FGFR2 kinase domain gatekeeper mutant V564F in complex with covalent compound 3
6LVM	;	2.53	;	Crystal structure of FGFR3 in complex with pyrimidine derivative
7DHL	;	2.57	;	Crystal structure of FGFR3 in complex with pyrimidine derivative
7N1J	;	2.99	;	Crystal structure of FGFR4 domain 3 in complex with a de novo-designed mini-binder
7TYD	;	2.86	;	Crystal structure of FGFR4 domain 3 in complex with a de novo-designed mini-binder in P21 space group
6IUO	;	2.3	;	Crystal structure of FGFR4 kinase domain in complex with a covalent inhibitor
6IUP	;	2.0	;	Crystal structure of FGFR4 kinase domain in complex with compound 5
6V9C	;	1.9	;	Crystal structure of FGFR4 kinase domain in complex with covalent inhibitor
7YC1	;	2.535	;	Crystal structure of FGFR4 kinase domain with 10d
7YC3	;	1.987	;	Crystal structure of FGFR4 kinase domain with 10t
7YBO	;	2.307	;	Crystal structure of FGFR4 kinase domain with 10z
7WCT	;	2.106	;	Crystal structure of FGFR4 kinase domain with 7v
6JPE	;	1.601	;	Crystal structure of FGFR4 kinase domain with irreversible inhibitor 1
7F3M	;	2.289	;	Crystal structure of FGFR4 kinase domain with PRN1371
7V29	;	1.983	;	Crystal structure of FGFR4 with a dual-warhead covalent inhhibitor
4XCU	;	1.71	;	Crystal Structure of FGFR4 with an Irreversible Inhibitor
7YBP	;	2.243	;	Crystal structure of FGFR4(V550L) kinase domain with 10z
7WCW	;	2.317	;	Crystal structure of FGFR4(V550L) kinase domain with 7v
7YBX	;	2.233	;	Crystal structure of FGFR4(V550M) kinase domain with 10z
7WCX	;	2.175	;	Crystal structure of FGFR4(V550M) kinase domain with 7v
7RDW	;	3.55	;	Crystal Structure of FH1 Fab bound to HXb2 HIV-1 gp120 core
5W7W	;	1.348	;	Crystal Structure of FHA domain of human APLF
5W7X	;	2.005	;	Crystal Structure of FHA domain of human APLF in complex with XRCC1 bisphospho peptide
5W7Y	;	2.1	;	Crystal Structure of FHA domain of human APLF in complex with XRCC1 monophosphorylated mutated peptide
7YOC	;	2.41	;	Crystal structure of Fhb7
8K2O	;	2.01	;	Crystal structure of Fhb7-M10
7P8P	;	2.34	;	Crystal structure of Fhit covalently bound to a nucleotide
8A60	;	3.37	;	Crystal structure of FhuA in complex with the superinfection exclusion lipoprotein Llp
5GM3	;	1.59	;	Crystal structure of FI-CMCase from Aspergillus aculeatus F-50
5GM5	;	1.73	;	Crystal structure of FI-CMCase from Aspergillus aculeatus F-50 in complex with cellobiose
5GM4	;	1.92	;	Crystal structure of FI-CMCase from Aspergillus aculeatus F-50 in complex with cellotetrose
3TEU	;	1.002	;	Crystal structure of fibcon
1NT2	;	2.9	;	CRYSTAL STRUCTURE OF FIBRILLARIN/NOP5P COMPLEX
2W86	;	1.8	;	Crystal structure of fibrillin-1 domains cbEGF9hyb2cbEGF10, calcium saturated form
1FZA	;	2.9	;	CRYSTAL STRUCTURE OF FIBRINOGEN FRAGMENT D
966C	;	1.9	;	CRYSTAL STRUCTURE OF FIBROBLAST COLLAGENASE-1 COMPLEXED TO A DIPHENYL-ETHER SULPHONE BASED HYDROXAMIC ACID
2FDB	;	2.28	;	Crystal Structure of Fibroblast growth factor (FGF)8b in complex with FGF Receptor (FGFR) 2c
1PWA	;	1.3	;	Crystal structure of Fibroblast Growth Factor 19
6KTR	;	2.59776	;	Crystal structure of fibroblast growth factor 19 in complex with Fab
1IJT	;	1.8	;	Crystal Structure of Fibroblast Growth Factor 4 (FGF4)
1IHK	;	2.2	;	CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR 9 (FGF9)
3KY2	;	2.7	;	Crystal structure of Fibroblast Growth Factor Receptor 1 kinase domain
1SLM	;	1.9	;	CRYSTAL STRUCTURE OF FIBROBLAST STROMELYSIN-1: THE C-TRUNCATED HUMAN PROENZYME
7YPL	;	1.63	;	Crystal structure of fibronectin type III domain variant, a VEGFR2-specific antagonist
5ZXA	;	1.77	;	Crystal structure of fibronectin-binding protein Apa mutant from Mycobacterium tuberculosis
3LET	;	1.802	;	Crystal Structure of Fic domain containing AMPylator, VopS
8GYH	;	1.8	;	Crystal structure of Fic25 (apo form) from Streptomyces ficellus
8GYI	;	1.93	;	Crystal structure of Fic25 (holo form) from Streptomyces ficellus
8GYJ	;	1.82	;	Crystal structure of Fic25 complexed with PLP-(5S,6S)-N2-acetyl-DADH adduct from Streptomyces ficellus
8HK0	;	2.29	;	Crystal structure of Fic32-33 complex from Streptomyces ficellus NRRL 8067
4L15	;	2.6	;	Crystal structure of FIGL-1 AAA domain
4L16	;	2.8	;	Crystal structure of FIGL-1 AAA domain in complex with ADP
1RWR	;	1.72	;	Crystal structure of filamentous hemagglutinin secretion domain
2BP3	;	2.32	;	Crystal structure of Filamin A domain 17 and GPIb alpha cytoplasmic domain complex
3ISW	;	2.8	;	Crystal structure of filamin-A immunoglobulin-like repeat 21 bound to an N-terminal peptide of CFTR
7D1B	;	1.24	;	Crystal structure of Fimbriiglobus ruber glutaminyl cyclase
5JR4	;	2.596	;	Crystal structure of FimH A27V/V163A from E. coli UTI89 bound to FimG N-terminal extension
5JQI	;	1.962	;	Crystal structure of FimH A62S from E. coli UTI89 bound to FimG N-terminal extension
4CST	;	1.1	;	Crystal structure of FimH in complex with 3'-Chloro-4'-(alpha-D-mannopyranosyloxy)-biphenyl-4-carbonitrile
4X5Q	;	1.12	;	Crystal structure of FimH in complex with 5-nitro-indolinylphenyl alpha-D-mannopyranoside
4X5P	;	0.997	;	Crystal structure of FimH in complex with a benzoyl-amidophenyl alpha-D-mannopyranoside
6G2S	;	2.2	;	Crystal structure of FimH in complex with a pentaflourinated biphenyl alpha D-mannoside
4X5R	;	1.65	;	Crystal structure of FimH in complex with a squaryl-phenyl alpha-D-mannopyranoside derivative
4CSS	;	1.069	;	Crystal structure of FimH in complex with a sulfonamide biphenyl alpha D-mannoside
6G2R	;	2.1	;	Crystal structure of FimH in complex with a tetraflourinated biphenyl alpha D-mannoside
4X50	;	2.0	;	Crystal structure of FimH in complex with biphenyl alpha-D-mannopyranoside
5CGB	;	1.6	;	Crystal structure of FimH in complex with heptyl alpha-D-septanoside
4LOV	;	1.5	;	Crystal structure of FimH in complex with Heptylmannoside
3MCY	;	2.9	;	Crystal structure of FimH lectin domain bound to biphenyl mannoside meta-methyl ester.
5L4T	;	1.9	;	Crystal structure of FimH lectin domain in complex with 2-Deoxy-Heptylmannoside
5L4U	;	2.1	;	Crystal structure of FimH lectin domain in complex with 2-Fluoro-Heptylmannoside
5L4V	;	2.99	;	Crystal structure of FimH lectin domain in complex with 3-Deoxy-Heptylmannoside
5L4W	;	1.9	;	Crystal structure of FimH lectin domain in complex with 3-Fluoro-Heptylmannoside
5L4X	;	1.9	;	Crystal structure of FimH lectin domain in complex with 4-Deoxy-Heptylmannoside
5L4Y	;	1.9	;	Crystal structure of FimH lectin domain in complex with 4-Fluoro-Heptylmannoside
4CA4	;	2.84	;	Crystal structure of FimH lectin domain with the Tyr48Ala mutation, in complex with heptyl alpha-D-mannopyrannoside
5MCA	;	1.604	;	Crystal structure of FimH-LD R60P variant in the apo state
4AG0	;	2.304	;	Crystal structure of FimX EAL domain
3HV9	;	2.298	;	Crystal structure of FimX EAL domain from Pseudomonas aeruginosa
3HV8	;	1.445	;	Crystal structure of FimX EAL domain from Pseudomonas aeruginosa bound to c-di-GMP
3HVA	;	2.042	;	Crystal structure of FimX GGDEF domain from Pseudomonas aeruginosa
5ECH	;	2.14	;	Crystal Structure of FIN219-FIP1 complex with JA and ATP
5ECM	;	1.6	;	Crystal Structure of FIN219-FIP1 complex with JA and Leu
5ECI	;	1.56	;	Crystal Structure of FIN219-FIP1 complex with JA, ATP and Mg
5ECK	;	1.54	;	Crystal Structure of FIN219-FIP1 complex with JA, Ile and ATP
5ECL	;	1.85	;	Crystal Structure of FIN219-FIP1 complex with JA, Ile and Mg
5ECN	;	1.72	;	Crystal Structure of FIN219-FIP1 complex with JA, Leu and ATP
5ECO	;	1.8	;	Crystal Structure of FIN219-FIP1 complex with JA, Leu and Mg
5ECP	;	2.25002	;	Crystal Structure of FIN219-FIP1 complex with JA, MET and ATP
5ECQ	;	1.66	;	Crystal Structure of FIN219-FIP1 complex with JA, VAL and ATP
5ECR	;	1.72	;	Crystal Structure of FIN219-FIP1 complex with JA, VAL and Mg
5GZZ	;	2.386	;	Crystal Structure of FIN219-SjGST complex with JA
1OSY	;	1.7	;	Crystal structure of FIP-Fve fungal immunomodulatory protein
5ECS	;	1.65	;	Crystal Structure of FIP1 with GSH
7CZG	;	1.8	;	Crystal structure of FIP200 Claw domain apo form
7D0E	;	1.4	;	Crystal structure of FIP200 Claw/p-CCPG1 FIR2
7CZM	;	2.0	;	Crystal structure of FIP200 Claw/p-OPtineurin LIR complex
7Z3X	;	1.65	;	Crystal structure of FIR RRM1-2 Y115F mutant bound to FUSE ssDNA
1EQ9	;	1.7	;	CRYSTAL STRUCTURE OF FIRE ANT CHYMOTRYPSIN COMPLEXED TO PMSF
2YGU	;	2.6	;	Crystal structure of fire ant venom allergen, Sol I 2
3UUL	;	1.95	;	Crystal Structure of first N-terminal utrophin spectrin repeat
3ILX	;	2.0	;	Crystal structure of First ORF in transposon ISC1904 from Sulfolobus solfataricus P2
2QFJ	;	2.1	;	Crystal Structure of First Two RRM Domains of FIR Bound to ssDNA from a Portion of FUSE
4IHX	;	2.8	;	Crystal structure of Fis bound to 27 bp 2-Aminopurine substituted DNA F28-2AP (AAATTTGTTTGA2T2TTGAGCAAATTT)
3JRB	;	3.1	;	Crystal structure of Fis bound to 27 bp DNA F24 containing T-tract at center
3JRD	;	3.1	;	Crystal structure of Fis bound to 27 bp DNA F25 containing T2A3 sequence at center
3JRE	;	3.17	;	Crystal structure of Fis bound to 27 bp DNA F26 containing A-tract at center
3JRF	;	3.05	;	Crystal structure of Fis bound to 27 bp DNA F27 containing a C/G at center
3JRC	;	3.08	;	Crystal structure of Fis bound to 27 bp DNA F29 containing 5 G/Cs at center
4IHW	;	2.7	;	Crystal structure of Fis bound to 27 bp Inosine substituted DNA F28-dI (AAATTTGTTTGAICITTGAGCAAATTT)
3JRG	;	3.11	;	Crystal structure of Fis bound to 27 bp non consensus sequence DNA F18
3JRH	;	2.88	;	Crystal structure of Fis bound to 27 bp non consensus sequence DNA F21
3JRI	;	3.11	;	Crystal structure of Fis bound to 27 bp non consensus sequence DNA F23
3IV5	;	2.9	;	Crystal structure of Fis bound to 27 bp optimal binding sequence F1
3JR9	;	2.9	;	Crystal structure of Fis bound to 27 bp optimal binding sequence F2
4IHV	;	2.716	;	Crystal structure of Fis bound to 27 bp sequence DNA F28 (AAATTTGTTTGAGCGTTGAGCAAATTT)
5DS9	;	2.561	;	Crystal structure of Fis bound to 27bp DNA F1-8A (AAATTAGTTTGAATTTTGAGCTAATTT)
5DTD	;	2.642	;	Crystal structure of Fis bound to 27bp DNA F1-8C (AAATTCGTTTGAATTTTGAGCGAATTT)
5E3L	;	2.66	;	Crystal structure of Fis bound to 27bp DNA F1-8G (AAATTGGTTTGAATTTTGAGCCAATTT)
5E3N	;	2.66	;	Crystal structure of Fis bound to 27bp DNA F31 (AAATTTGTAGGAATTTTCTGCAAATTT)
5E3O	;	2.78	;	Crystal structure of Fis bound to 27bp DNA F32 (AAATTTGGAGGAATTTTCTCCAAATTT)
5E3M	;	2.886	;	Crystal structure of Fis bound to 27bp DNA F35 (AAATTAGTTTGAATCTCGAGCTAATTT)
4IHY	;	2.9	;	Crystal structure of Fis bound to 27bp Inosine substituted DNA F29-dI (AAATTTGTTTGIICICTGAGCAAATTT)
3JRA	;	3.11	;	Crystal structure of Fis bound to 27bp non consensus sequence DNA F6
7YKA	;	2.3	;	Crystal structure of Fis1 (Mitochondrial fission 1 protein)
4IZZ	;	2.502	;	Crystal Structure of Fischerella Transcription Factor HetR complexed with 21mer DNA target
4J00	;	3.004	;	Crystal Structure of Fischerella Transcription Factor HetR complexed with 24mer DNA target
4J01	;	3.246	;	Crystal Structure of Fischerella Transcription Factor HetR complexed with 29mer DNA target
5W4T	;	2.65	;	Crystal Structure of Fish Cadherin-23 EC1-3
3O48	;	1.75	;	Crystal structure of fission protein Fis1 from Saccharomyces cerevisiae
3DWL	;	3.78	;	Crystal Structure of Fission Yeast Arp2/3 Complex Lacking the Arp2 Subunit
6AAF	;	2.197	;	Crystal structure of fission yeast Atg8 complexed with the helical AIM of Hfl1.
7CUJ	;	2.4	;	Crystal structure of fission yeast Ccq1 and Tpz1
7YO8	;	1.805	;	Crystal structure of fission yeast Hfl1 LIR fused to human GABARAPL2
6A6W	;	2.601	;	Crystal structure of fission yeast inner membrane protein Bqt4 in complex with Sad1
7CUH	;	3.0	;	Crystal structure of fission yeast Pot1 and ssDNA
7CUI	;	2.6	;	Crystal structure of fission yeast Pot1 and Tpz1
2H1C	;	1.8	;	Crystal Structure of FitAcB from Neisseria gonorrhoeae
3BE5	;	2.2	;	Crystal structure of FitE (crystal form 1), a group III periplasmic siderophore binding protein
3BE6	;	1.82	;	Crystal structure of FitE (crystal form 2), a group III periplasmic siderophore binding protein
5DCK	;	2.29	;	Crystal Structure of FIV Capsid C-Terminal Domain
5OVN	;	2.942	;	Crystal Structure of FIV Reverse Transcriptase
4V4G	;	11.5	;	Crystal structure of five 70s ribosomes from Escherichia Coli in complex with protein Y.
2R39	;	2.02	;	Crystal structure of FixG-related protein from Vibrio parahaemolyticus
1DBW	;	1.6	;	CRYSTAL STRUCTURE OF FIXJ-N
6RCY	;	2.3	;	CRYSTAL STRUCTURE OF FK1 DOMAIN OF FKBP52 IN COMPLEX WITH A BIO-INSPIRED HYBRID FLUORESCENT LIGAND
4J4N	;	2.75	;	Crystal structure of FK506 binding domain of plasmodium falciparum FKBP35 in complex with D44
4J4O	;	1.73	;	Crystal structure of FK506 binding domain of plasmodium VIVAX FKBP35 in complex with D44
4MGV	;	1.72	;	Crystal structure of FK506 binding domain of plasmodium VIVAX FKBP35 In complex with inhibitor D5
7U0S	;	1.7	;	Crystal Structure of FK506-binding protein 1A from Aspergillus fumigatus Bound to Ascomycin
3PA7	;	2.61	;	Crystal structure of FKBP from plasmodium vivax in complex with tetrapeptide ALPF
6M4U	;	2.2	;	Crystal structure of FKBP-FRB T2098L mutant in complex with rapamycin
2PPN	;	0.92	;	Crystal structure of FKBP12
6VSI	;	1.87	;	Crystal structure of FKBP12 of Candida auris
5I7Q	;	1.9	;	Crystal structure of Fkbp12-IF(SlpA), a chimeric protein of human Fkbp12 and the insert in flap domain of Ecoli SlpA
5I7P	;	2.002	;	Crystal structure of Fkbp12-IF(SlyD), a chimeric protein of human Fkbp12 and the insert in flap domain of Ecoli SlyD
1C9H	;	2.0	;	CRYSTAL STRUCTURE OF FKBP12.6 IN COMPLEX WITH RAPAMYCIN
4JYS	;	1.9	;	Crystal structure of FKBP25 from Plasmodium Vivax
1P5Q	;	2.8	;	Crystal Structure of FKBP52 C-terminal Domain
1QZ2	;	3.0	;	Crystal Structure of FKBP52 C-terminal Domain complex with the C-terminal peptide MEEVD of Hsp90
1Q6U	;	2.45	;	Crystal structure of FkpA from Escherichia coli
6KAJ	;	2.2249	;	Crystal structure of FKRP in complex with Ba ion
6KAN	;	2.251	;	Crystal structure of FKRP in complex with Ba ion
6L7U	;	2.24	;	Crystal structure of FKRP in complex with Ba ion, Ba-SAD data
6KAM	;	2.46	;	Crystal structure of FKRP in complex with Ba ion, CDP-ribtol, and sugar acceptor
6KAK	;	2.056	;	Crystal structure of FKRP in complex with Mg ion
6KAL	;	2.6	;	Crystal structure of FKRP in complex with Mg ion and CMP
6L7T	;	2.41	;	Crystal structure of FKRP in complex with Mg ion, Zinc low remote data
6L7S	;	2.41	;	Crystal structure of FKRP in complex with Mg ion, Zinc peak data
4WIA	;	2.2	;	Crystal structure of flagellar accessory protein FlaH from Methanocaldococcus jannaschii
5XEF	;	2.0	;	Crystal structure of flagellar chaperone from bacteria
5YTI	;	2.75	;	Crystal structure of flagellar hook associated protein-3 (HAP-3: Q5ZW61_LEGPH) from Legionella pneumophila
5XRW	;	2.5	;	Crystal structure of flagellar motor switch complex from H. pylori
3FRN	;	2.05	;	CRYSTAL STRUCTURE OF flagellar protein FlgA FROM Thermotoga maritima MSB8
3H3M	;	2.5	;	Crystal structure of flagellar protein FliT from Bordetella bronchiseptica
5GNA	;	2.3	;	Crystal Structure of flagellin assembly related protein
3ORY	;	2.0	;	Crystal structure of Flap endonuclease 1 from hyperthermophilic archaeon Desulfurococcus amylolyticus
1MC8	;	3.1	;	Crystal Structure of Flap Endonuclease-1 R42E mutant from Pyrococcus horikoshii
8J50	;	1.9	;	Crystal structure of Flavihumibacter petaseus GH31 alpha-galactosidase
8J51	;	2.15	;	Crystal structure of Flavihumibacter petaseus GH31 alpha-galactosidase in complex with galactose
8J52	;	1.9	;	Crystal structure of Flavihumibacter petaseus GH31 alpha-galactosidase mutant D304A in complex with alpha-1,4-galactobiose
1S4M	;	2.1	;	Crystal structure of flavin binding to FAD synthetase from Thermotoga maritina
3AH5	;	2.5	;	Crystal Structure of flavin dependent thymidylate synthase ThyX from helicobacter pylori complexed with FAD and dUMP
6ASL	;	1.9	;	Crystal Structure of Flavin monooxygenase CmoJ (earlier YtnJ) bound with FMN
2ECU	;	1.3	;	Crystal structure of flavin reductase component (HpaC) of 4-hydroxyphenylacetate 3-monooxygenase
2QCK	;	1.9	;	Crystal structure of flavin reductase domain protein (YP_831077.1) from Arthrobacter sp. FB24 at 1.90 A resolution
2ED4	;	1.85	;	Crystal structure of flavin reductase HpaC complexed with FAD and NAD
2GV8	;	2.1	;	Crystal structure of flavin-containing monooxygenase (FMO) from S.pombe and NADPH cofactor complex
2GVC	;	2.22	;	Crystal structure of flavin-containing monooxygenase (FMO)from S.pombe and substrate (methimazole) complex
2RGJ	;	2.4	;	Crystal structure of flavin-containing monooxygenase PhzS
3D1C	;	2.4	;	Crystal structure of Flavin-containing Putative Monooxygenase (NP_373108.1) from STAPHYLOCOCCUS AUREUS MU50 at 2.40 A resolution
6JHM	;	2.3	;	Crystal structure of Flavin-dependent Monooxygenase HadA
3G4A	;	1.95	;	Crystal structure of flavine dependant thymidylate synthase S88A mutant from Thermotoga maritima at 1.95 angstrom resolution
5JXF	;	2.1	;	Crystal structure of Flavobacterium psychrophilum DPP11 in complex with dipeptide Arg-Asp
1C3A	;	2.5	;	CRYSTAL STRUCTURE OF FLAVOCETIN-A FROM THE HABU SNAKE VENOM, A NOVEL CYCLIC TETRAMER OF C-TYPE LECTIN-LIKE HETERODIMERS
3VRD	;	1.5	;	Crystal structure of flavocytochrome c from Thermochromatium tepidum
5YOE	;	1.35	;	Crystal Structure of flavodoxin with engineered disulfide bond A43C-L74C
5YOC	;	1.5	;	Crystal Structure of flavodoxin with engineered disulfide bond C102-R125C
5YOG	;	1.42	;	Crystal Structure of flavodoxin with engineered disulfide bond N14C-C93
5YOB	;	1.142	;	Crystal Structure of flavodoxin without engineered disulfide bond
6O0A	;	1.7	;	Crystal structure of flavohemoglobin from Malassezia yamatoensis with bound FAD and heme determined by iron SAD phasing
1VME	;	1.8	;	Crystal structure of Flavoprotein (TM0755) from Thermotoga maritima at 1.80 A resolution
2GQF	;	2.7	;	Crystal structure of flavoprotein HI0933 from Haemophilus influenzae Rd
3EDO	;	1.2	;	Crystal structure of Flavoprotein in Complex with FMN (YP_193882.1) from Lactobacillus acidophilus NCFM at 1.20 A resolution
2XOD	;	0.96	;	Crystal structure of flavoprotein NrdI from Bacillus anthracis in the oxidised form
2XOE	;	1.4	;	Crystal structure of flavoprotein NrdI from Bacillus anthracis in the semiquinone form
3NIX	;	2.6	;	Crystal structure of flavoprotein/dehydrogenase from Cytophaga hutchinsonii. Northeast Structural Genomics Consortium Target ChR43.
7EJW	;	1.98	;	Crystal structure of FleN in complex with FleQ AAA+ doamain
4MN8	;	3.062	;	Crystal structure of flg22 in complex with the FLS2 and BAK1 ectodomains
3C12	;	2.51	;	Crystal Structure of FlgD from Xanthomonas campestris: Insights into the Hook Capping Essential for Flagellar Assembly
1WLG	;	1.8	;	Crystal structure of FlgE31, a major fragment of the hook protein
3OPC	;	2.09	;	Crystal structure of FlgN chaperone from Bordetella pertussis
1G8E	;	1.8	;	CRYSTAL STRUCTURE OF FLHD FROM ESCHERICHIA COLI
4QXL	;	1.512	;	Crystal Structure of FLHE
2PX0	;	3.0	;	Crystal structure of FlhF complexed with GMPPNP/Mg(2+)
2PX3	;	3.2	;	Crystal structure of FlhF complexed with GTP/Mg(2+)
3SYN	;	3.063	;	Crystal structure of FlhF in complex with its activator
8ERM	;	1.475	;	Crystal structure of FliC D2/D3 domains from Pseudomonas aeruginosa PAO1
5FHY	;	2.201	;	Crystal structure of FliD (HAP2) from Pseudomonas aeruginosa PAO1
5WUJ	;	2.3	;	Crystal structure of FliF-FliG complex from H. pylori
3USY	;	2.706	;	Crystal structure of Flig (residue 116-343) from H. Pylori
3USW	;	2.601	;	Crystal structure of FliG (residues 86-343) from H. pylori
4FQ0	;	2.82	;	Crystal structure of FliG-FliM complex from H. pylori
7DMA	;	1.44	;	Crystal structure of FliM middle domain (46-231) with R49P substitution from Vibro alginolyticus
7DM9	;	1.71	;	Crystal structure of FliM middle domain (51-229) from Vibro alginolyticus
4GC8	;	2.2	;	Crystal structure of FliM middle domain from H. pylori
5X0Z	;	2.7	;	Crystal structure of FliM-SpeE complex from H. pylori
3IQC	;	2.7	;	Crystal structure of FliS from H. pylori
3LOB	;	3.6	;	Crystal Structure of Flock House Virus calcium mutant
1RJB	;	2.1	;	Crystal Structure of FLT3
7ZV9	;	4.507	;	Crystal structure of FLT3 in complex with a monomeric FLT3 Ligand variant
6JQR	;	2.2	;	Crystal structure of FLT3 in complex with gilteritinib
7QDP	;	3.691	;	Crystal structure of FLT3 T343I in complex with the canonical ligand FL
4RT7	;	3.1	;	Crystal Structure of FLT3 with a small molecule inhibitor
4YVQ	;	2.401	;	Crystal Structure of FLU-TPR in Complex with the C-terminal Region of GluTR
6OBZ	;	1.73	;	Crystal structure of FluA-20 Fab
6OC3	;	2.85	;	Crystal structure of FluA-20 Fab in complex with the head domain of H1 (A/Solomon Islands/3/2006)
6OCB	;	2.1	;	Crystal structure of FluA-20 Fab in complex with the head domain of H3 (A/Hong Kong/1/1968)
7QEA	;	2.28	;	Crystal structure of fluorescein-di-Beta-D-glucuronide bound to a mutant of SN243 (D415A)
3M2K	;	3.5	;	Crystal Structure of fluorescein-labeled Class A -beta lactamase PenP in complex with cefotaxime
3M2J	;	1.8	;	Crystal Structure of fluorescein-labeled Class A -lactamase PenP
8SXC	;	1.5	;	Crystal Structure of Fluorescent Protein Fusion Red 2
6U1A	;	1.09	;	Crystal Structure of Fluorescent Protein FusionRed
8GOS	;	1.01	;	Crystal structure of fluorescent protein RasM
4I3D	;	2.298	;	Crystal structure of fluorescent protein UnaG N57A mutant
4I3C	;	2.001	;	Crystal structure of fluorescent protein UnaG N57Q mutant
4I3B	;	1.199	;	Crystal structure of fluorescent protein UnaG wild type
3LF4	;	1.808	;	Crystal Structure of Fluorescent Timer Precursor Blue102
6B2A	;	2.65	;	Crystal structure of fluoride channel Fluc Ec2 F80M Mutant
6B24	;	2.75	;	Crystal structure of fluoride channel Fluc Ec2 F80Y Mutant
6B2B	;	2.6	;	Crystal structure of fluoride channel Fluc Ec2 F83M Mutant
6B2D	;	3.01	;	Crystal structure of fluoride channel Fluc Ec2 T114S Mutant
4ENC	;	2.272	;	Crystal structure of fluoride riboswitch
4ENB	;	2.302	;	Crystal structure of fluoride riboswitch, bound to Iridium
4ENA	;	2.85	;	Crystal structure of fluoride riboswitch, soaked in Cs+
3VRS	;	2.603	;	Crystal structure of fluoride riboswitch, soaked in Mn2+
4EN5	;	2.957	;	Crystal structure of fluoride riboswitch, Tl-Acetate soaked
3IPN	;	1.21	;	Crystal Structure of fluorine and methyl modified collagen: (mepFlpgly)7
8SDC	;	1.86	;	Crystal structure of fluoroacetate dehalogenase Daro3835 apoenzyme
8SDD	;	2.0	;	Crystal structure of fluoroacetate dehalogenase Daro3835 H274N mutant with D107-glycolyl intermediate
5AAO	;	2.6	;	Crystal structure of fluorogen-activating designed ankyrin repeat protein (DARPin) dimer in complex with malachite green
3SH7	;	2.5	;	Crystal structure of fluorophore-labeled beta-lactamase PenP
3SH9	;	1.9	;	Crystal structure of fluorophore-labeled beta-lactamase PenP in complex with cefotaxime
3SH8	;	2.0	;	Crystal structure of fluorophore-labeled beta-lactamase PenP in complex with cephaloridine
3LY4	;	1.8	;	Crystal Structure of fluorophore-labeled Class A -lactamase PenP-E166Cb in complex with penicillin G
3LY3	;	1.8	;	Crystal Structure of fluorophore-labeled Class A Beta-lactamase PenP
5JVZ	;	2.62	;	Crystal structure of flurbiprofen bound to S121P murine COX-2 mutant
5I76	;	1.922	;	Crystal structure of FM318, a recombinant Fab adopted from cetuximab
5GZ0	;	1.7	;	Crystal structure of FM329, a recombinant Fab adopted from cetuximab
7DP0	;	2.10004	;	Crystal structure of FMN and NADPH-dependent nitroreductase NfnB from sphigopyxis sp. strain HMH
7DP1	;	2.0035	;	Crystal structure of FMN and NADPH-dependent nitroreductase NfnB mutant Y88A derived from sphigopyxis sp. strain HMH
7DP2	;	2.40009	;	Crystal structure of FMN and NADPH-dependent nitroreductase NfnB mutant Y88F derived from sphigopyxis sp. strain HMH
4QOF	;	1.55	;	Crystal structure of fmn quinone reductase 2 AT 1.55A
4QOI	;	1.55	;	Crystal structure of FMN quinone reductase 2 in complex with melatonin at 1.55A
4QOJ	;	1.85	;	CRYSTAL STRUCTURE OF FMN QUINONE REDUCTASE 2 IN COMPLEX WITH RESVERATROL AT 1.85A
6MVF	;	2.55	;	Crystal structure of FMN-binding beta-glucuronidase from Facaelibacterium prausnitzii L2-6
6MVH	;	2.4	;	Crystal structure of FMN-binding beta-glucuronidase from Roseburia hominis
6MVG	;	2.8	;	Crystal structure of FMN-binding beta-glucuronidase from Ruminococcus gnavus
2R6V	;	1.25	;	Crystal structure of FMN-binding protein (NP_142786.1) from Pyrococcus horikoshii at 1.35 A resolution
3ZOG	;	1.75	;	Crystal structure of FMN-binding protein (NP_142786.1) from Pyrococcus horikoshii with bound 1-Cyclohex-2-enone
3ZOD	;	1.68	;	Crystal structure of FMN-binding protein (NP_142786.1) from Pyrococcus horikoshii with bound benzene-1,4-diol
3ZOC	;	2.1	;	Crystal structure of FMN-binding protein (NP_142786.1) from Pyrococcus horikoshii with bound p-hydroxybenzaldehyde
3ZOH	;	1.65	;	Crystal structure of FMN-binding protein (YP_005476) from Thermus thermophilus with bound 1-Cyclohex-2-enone
3ZOF	;	2.15	;	Crystal structure of FMN-binding protein (YP_005476) from Thermus thermophilus with bound benzene-1,4-diol
3ZOE	;	1.85	;	Crystal structure of FMN-binding protein (YP_005476) from Thermus thermophilus with bound p-hydroxybenzaldehyde
3X0Y	;	2.3	;	Crystal structure of FMN-bound DszC from Rhodococcus erythropolis D-1
2NR4	;	1.85	;	Crystal structure of FMN-bound protein MM1853 from Methanosarcina mazei, Pfam DUF447
5XDB	;	1.811	;	Crystal structure of FMN-bound TdsC from Paenibacillus sp. A11-2
2HPV	;	2.0	;	Crystal structure of FMN-Dependent azoreductase from Enterococcus faecalis
7CFU	;	2.15	;	Crystal Structure of FMN-dependent Cysteine Decarboxylases SpaF
6JLS	;	2.24	;	Crystal Structure of FMN-dependent Cysteine Decarboxylases TvaF from Thioviridamide Biosynthesis
7F76	;	1.57	;	Crystal Structure of FMN-dependent NADPH-quinone reductase (azoR) from Bacillus cohnii
3HOI	;	1.55	;	Crystal structure of FMN-dependent nitroreductase BF3017 from Bacteroides fragilis NCTC 9343 (YP_212631.1) from Bacteroides fragilis NCTC 9343 at 1.55 A resolution
7OH2	;	1.9	;	Crystal structure of FMNH2-dependent monooxygenase for oxidative desulfurization of sulfoquinovose
7OLF	;	3.4	;	Crystal structure of FMNH2-dependent monooxygenase from Agrobacterium tumefaciens for oxidative desulfurization of sulfoquinovose
8ACS	;	2.5	;	Crystal structure of FMO from Janthinobacterium svalbardensis
5UWJ	;	2.221	;	Crystal Structure of FMRP NES Peptide in complex with CRM1-Ran-RanBP1
4R7I	;	2.75	;	Crystal structure of FMS kinase domain with a small molecular inhibitor, GLEEVEC
4R7H	;	2.8001	;	Crystal structure of FMS KINASE domain with a small molecular inhibitor, PLX3397
6N33	;	2.25	;	Crystal structure of fms kinase domain with a small molecular inhibitor, PLX5622
4HW7	;	2.9001	;	Crystal structure of FMS kinase domain with a small molecular inhibitor, PLX647-OME
1Z6L	;	2.5	;	crystal structure of Fms1 in complex with its substrate
3CND	;	2.5	;	Crystal structure of fms1 in complex with N1-AcSpermine
3CNT	;	2.7	;	Crystal structure of fms1 in complex with R-Bz-MeSpermidine
3CNS	;	2.4	;	Crystal structure of fms1 in complex with S-Bz-MeSpermidine
3CNP	;	2.5	;	Crystal structure of fms1 in complex with S-N1-AcMeSpermidine
3CN8	;	2.4	;	Crystal structure of fms1 in complex with spermidine
1XPQ	;	2.51	;	Crystal structure of fms1, a polyamine oxidase from yeast
1YY5	;	2.3	;	Crystal structure of Fms1, a polyamine oxidase from Yeast
5ZH8	;	2.6	;	Crystal Structure of FmtA from Staphylococcus aureus at 2.58 A
8AXF	;	2.54	;	Crystal structure of FMV N bound to 42-mer ssRNA
8AX4	;	2.28	;	Crystal structure of FMV N in its RNA-free form
5KF4	;	2.5	;	Crystal structure of FN3 domain (Residues P368-P466) of Human collagen XX
4U3H	;	1.98	;	Crystal structure of FN3con
7JGT	;	1.9	;	Crystal Structure of FN3tt
5NG6	;	3.342	;	Crystal structure of FnCas12a bound to a crRNA
6I1L	;	2.98	;	Crystal structure of FnCas12a in complex with a crRNA guide and ssDNA target
3NCO	;	1.5	;	Crystal structure of FnCel5A from F. nodosum Rt17-B1
3L5I	;	1.9	;	Crystal structure of FnIII domains of human GP130 (Domains 4-6)
3L5J	;	3.042	;	Crystal structure of FnIII domains of human GP130 (Domains 4-6)
5CVR	;	2.6	;	Crystal structure of FNR of A. fischeri in a partially degraded form
1MP8	;	1.6	;	Crystal structure of Focal Adhesion Kinase (FAK)
2ETM	;	2.3	;	Crystal Structure of Focal Adhesion Kinase Domain Complexed with 7H-Pyrrolo [2,3-d] pyrimidine Derivative
2IJM	;	2.187	;	Crystal Structure of Focal Adhesion Kinase Domain with 2 molecules in the Asymmetric Unit Complexed with ADP and ATP
4DJE	;	3.504	;	Crystal structure of folate-bound corrinoid iron-sulfur protein (CFeSP) in complex with its methyltransferase (MeTr), co-crystallized with folate
4DJF	;	3.03	;	Crystal structure of folate-bound corrinoid iron-sulfur protein (CFeSP) in complex with its methyltransferase (MeTr), co-crystallized with folate and Ti(III) citrate reductant
4DJD	;	2.38	;	Crystal structure of folate-free corrinoid iron-sulfur protein (CFeSP) in complex with its methyltransferase (MeTr)
3P2O	;	2.227	;	Crystal Structure of FolD Bifunctional Protein from Campylobacter jejuni
5TVL	;	2.55	;	Crystal structure of foldase protein PrsA from Streptococcus pneumoniae str. Canada MDR_19A
2GHJ	;	2.9	;	Crystal structure of folded and partially unfolded forms of Aquifex aeolicus ribosomal protein L20
5Y7O	;	3.1	;	Crystal structure of folding sensor region of UGGT from Thermomyces dupontii
5JWR	;	2.61	;	Crystal structure of foldswitch-stabilized KaiB in complex with the N-terminal CI domain of KaiC and a dimer of KaiA C-terminal domains from Thermosynechococcus elongatus
5JWO	;	1.8	;	Crystal structure of foldswitch-stabilized KaiB in complex with the N-terminal CI domain of KaiC from Thermosynechococcus elongatus
5BT9	;	1.5	;	Crystal Structure of FolM Alternative dihydrofolate reductase 1 from Brucella canis complexed with NADP
5TGD	;	1.7	;	Crystal structure of FolM Alternative dihydrofolate reductase 1 from Brucella suis in complex with NADP
6PZ2	;	2.0	;	Crystal Structure of FolP (dihydropteroate synthase) from Colstridium difficile in the presence of pteroic acid
4Z7F	;	3.194	;	Crystal structure of FolT bound with folic acid
4AEY	;	3.0	;	Crystal structure of FolX from Pseudomonas aeruginosa
1O5Z	;	2.1	;	Crystal structure of Folylpolyglutamate synthase (TM0166) from Thermotoga maritima at 2.10 A resolution
4GH4	;	3.0	;	Crystal Structure of Foot and Mouth Disease Virus A22 Serotype
5NE4	;	2.3	;	Crystal Structure of Foot and Mouth Disease Virus O PanAsia
2WV4	;	2.5	;	Crystal structure of foot-and-mouth disease virus 3C protease in complex with a decameric peptide corresponding to the VP1-2A cleavage junction
2WV5	;	2.7	;	Crystal structure of foot-and-mouth disease virus 3C protease in complex with a decameric peptide corresponding to the VP1-2A cleavage junction with a GLN to Glu substitution at P1
6NKO	;	2.403	;	Crystal structure of ForH
1WAV	;	2.5	;	CRYSTAL STRUCTURE OF FORM B MONOCLINIC CRYSTAL OF INSULIN
1KOL	;	1.65	;	Crystal structure of formaldehyde dehydrogenase
4JLW	;	2.7	;	Crystal structure of formaldehyde dehydrogenase from Pseudomonas aeruginosa
2DPH	;	2.27	;	Crystal Structure of Formaldehyde dismutase
3VBO	;	2.88	;	Crystal structure of formaldehyde treated empty human Enterovirus 71 particle (cryo at 100K)
3VBR	;	3.8	;	Crystal structure of formaldehyde treated empty human Enterovirus 71 particle (room temperature)
3VBF	;	2.6	;	Crystal structure of formaldehyde treated human Enterovirus 71 (space group I23)
3VBH	;	2.3	;	Crystal structure of formaldehyde treated human enterovirus 71 (space group R32)
6T9W	;	2.15	;	Crystal structure of formate dehydrogenase FDH2 D222A/Q223R enzyme from Granulicella mallensis MP5ACTX8 in complex with NADP and azide.
6T9X	;	2.2	;	Crystal structure of formate dehydrogenase FDH2 D222Q/Q223R mutant enzyme from Granulicella mallensis MP5ACTX8 in complex with NADP and Azide.
6TB6	;	1.98	;	Crystal structure of formate dehydrogenase FDH2 D222S/Q223R enzyme from Granulicella mallensis MP5ACTX8 in complex with NADP and azide.
8BXX	;	1.97	;	Crystal structure of formate dehydrogenase FDH2 enzyme from Granulicella mallensis MP5ACTX8 in complex with NAD and azide.
6T8C	;	1.97	;	Crystal structure of formate dehydrogenase FDH2 enzyme from Granulicella mallensis MP5ACTX8 in the apo form.
8J83	;	2.4	;	Crystal structure of formate dehydrogenase from Methylorubrum extorquens AM1
6JWG	;	2.081	;	Crystal structure of Formate dehydrogenase mutant C256I/E261P/S381I from Pseudomonas sp. 101
6JUK	;	2.293	;	Crystal structure of Formate dehydrogenase mutant C256I/E261P/S381I from Pseudomonas sp. 101 in complex with non-natural cofactor Nicotinamide Cytosine Dinucleotide
6JX1	;	2.233	;	Crystal structure of Formate dehydrogenase mutant V198I/C256I/P260S/E261P/S381N/S383F from Pseudomonas sp. 101
6JUJ	;	2.183	;	Crystal structure of Formate dehydrogenase mutant V198I/C256I/P260S/E261P/S381N/S383F from Pseudomonas sp. 101in complex with non-natural cofactor Nicotinamide Cytosine Dinucleotide
1O5H	;	2.8	;	Crystal structure of formiminotetrahydrofolate cyclodeaminase (TM1560) from Thermotoga maritima at 2.80 A resolution
1P5H	;	2.2	;	Crystal structure of Formyl-CoA Transferase (apoenzyme) from Oxalobacter formigenes
1PQY	;	2.35	;	Crystal structure of formyl-coA transferase yfdW from E. coli
2ZW2	;	1.55	;	Crystal Structure of Formylglycinamide Ribonucleotide Amidotransferase III from SULFOLOBUS TOKODAII (STPURS)
2FHJ	;	2.0	;	Crystal structure of formylmethanofuran: tetrahydromethanopterin formyltransferase in complex with its coenzymes
2FHK	;	2.0	;	Crystal structure of formylmethanofuran: tetrahydromethanopterin formyltransferase in complex with its coenzymes
3LOU	;	1.9	;	Crystal structure of Formyltetrahydrofolate deformylase (YP_105254.1) from BURKHOLDERIA MALLEI ATCC 23344 at 1.90 A resolution
3W7B	;	2.71	;	Crystal structure of formyltetrahydrofolate deformylase from Thermus thermophilus HB8
5XVV	;	2.25	;	Crystal Structure of Forward Inhibited Aspergillus niger Glutamate Dehydrogenase With Both Apo- and Alpha Ketoglutarate Bound Subunits
4JH5	;	1.77	;	Crystal Structure of FosB from Bacillus cereus with Cobalt and Fosfomycin
4JH9	;	1.77	;	Crystal Structure of FosB from Bacillus cereus with Maganese and Potential BSH-Fosfomycin Product
4JH6	;	1.32	;	Crystal Structure of FosB from Bacillus cereus with Manganese and Fosfomycin
4JH7	;	1.55	;	Crystal Structure of FosB from Bacillus cereus with Manganese and L-Cysteine-Fosfomycin Product
4JH4	;	1.9	;	Crystal Structure of FosB from Bacillus cereus with Nickel and Fosfomycin
8G7G	;	2.23	;	Crystal Structure of FosB from Bacillus cereus with Zinc and (1-hydroxy-2-methylpropyl)phosphonic acid
8G7H	;	1.81	;	Crystal Structure of FosB from Bacillus cereus with Zinc and (1-hydroxypropan-2-yl)phosphonic acid
8G7F	;	2.04	;	Crystal Structure of FosB from Bacillus cereus with Zinc and 1-hydroxypropylphosphonic acid
8E7Q	;	1.9	;	Crystal Structure of FosB from Bacillus cereus with Zinc and 2-Phosphonopropionic acid
4JH3	;	1.5	;	Crystal Structure of FosB from Bacillus cereus with Zinc and Fosfomycin
4JH8	;	1.41	;	Crystal Structure of FosB from Bacillus cereus with Zinc and L-Cysteine-Fosfomycin Ternary Complex
8E7R	;	1.975	;	Crystal Structure of FosB from Bacillus cereus with Zinc and Phosphonoacetate
8DTD	;	1.95	;	Crystal Structure of FosB from Bacillus cereus with Zinc and Phosphonoformate
8G7I	;	1.83	;	Crystal Structure of FosB from Bacillus cereus with Zinc and Sulfate
4JH2	;	1.27	;	Crystal Structure of FosB from Bacillus cereus with Zinc and Sulfate at 1.27 A Resolution
4JH1	;	1.55	;	Crystal Structure of FosB from Bacillus cereus with Zinc and Sulfate at 1.55 A Resolution -SAD Phasing
7N7G	;	2.0	;	Crystal Structure of FosB from Enterococcus faecium with Fosfomycin
4NB1	;	1.8	;	Crystal Structure of FosB from Staphylococcus aureus at 1.80 Angstrom Resolution with L-Cysteine-Cys9 Disulfide
4NB2	;	1.89	;	Crystal Structure of FosB from Staphylococcus aureus at 1.89 Angstrom Resolution - Apo structure
4NB0	;	1.62	;	Crystal Structure of FosB from Staphylococcus aureus with BS-Cys9 disulfide at 1.62 Angstrom Resolution
4NAZ	;	1.15	;	Crystal Structure of FosB from Staphylococcus aureus with Zn and Sulfate at 1.15 Angstrom Resolution
4NAY	;	1.42	;	Crystal Structure of FosB from Staphylococcus aureus with Zn and Sulfate at 1.42 Angstrom Resolution - SAD Phasing
3QVH	;	1.85	;	Crystal structure of fosfomycin resistance kinase FomA from Streptomyces wedmorensis complexed with ADP
3QUO	;	1.58	;	Crystal structure of fosfomycin resistance kinase FomA from Streptomyces wedmorensis complexed with ATP and fosfomycin
3D40	;	1.53	;	Crystal structure of fosfomycin resistance kinase FomA from Streptomyces wedmorensis complexed with diphosphate
3QUR	;	1.57	;	Crystal structure of fosfomycin resistance kinase FomA from Streptomyces wedmorensis complexed with MgADP and fosfomycin monophosphate
3QVF	;	1.85	;	Crystal structure of fosfomycin resistance kinase FomA from Streptomyces wedmorensis complexed with MgADP and fosfomycin vanadate
3D41	;	2.2	;	Crystal structure of fosfomycin resistance kinase FomA from Streptomyces wedmorensis complexed with MgAMPPNP and fosfomycin
3QUN	;	1.87	;	Crystal structure of fosfomycin resistance kinase FomA from Streptomyces wedmorensis complexed with MgATP
5VB0	;	2.689	;	Crystal structure of fosfomycin resistance protein FosA3
5WEP	;	3.502	;	Crystal structure of fosfomycin resistance protein FosA3 with inhibitor (ANY1) bound
1R9C	;	1.83	;	Crystal Structure of Fosfomycin Resistance Protein FosX from Mesorhizobium Loti
5V91	;	1.3	;	Crystal structure of fosfomycin resistance protein from Klebsiella pneumoniae
5V3D	;	1.539	;	Crystal structure of fosfomycin resistance protein from Klebsiella pneumoniae with bound fosfomycin
215D	;	1.7	;	CRYSTAL STRUCTURE OF FOUR MORPHOLINO-DOXORUBICIN ANTICANCER DRUGS COMPLEXED WITH D(CGTACG) AND D(CGATCG): IMPLICATIONS IN DRUG-DNA CROSSLINK
234D	;	1.8	;	CRYSTAL STRUCTURE OF FOUR MORPHOLINO-DOXORUBICIN ANTICANCER DRUGS COMPLEXED WITH D(CGTACG) AND D(CGATCG): IMPLICATIONS IN DRUG-DNA CROSSLINK
235D	;	1.8	;	CRYSTAL STRUCTURE OF FOUR MORPHOLINO-DOXORUBICIN ANTICANCER DRUGS COMPLEXED WITH D(CGTACG) AND D(CGATCG): IMPLICATIONS IN DRUG-DNA CROSSLINK
236D	;	1.8	;	CRYSTAL STRUCTURE OF FOUR MORPHOLINO-DOXORUBICIN ANTICANCER DRUGS COMPLEXED WITH D(CGTACG) AND D(CGATCG): IMPLICATIONS IN DRUG-DNA CROSSLINK
1EC5	;	2.5	;	CRYSTAL STRUCTURE OF FOUR-HELIX BUNDLE MODEL
1JM0	;	1.7	;	CRYSTAL STRUCTURE OF FOUR-HELIX BUNDLE MODEL
1JMB	;	2.2	;	CRYSTAL STRUCTURE OF FOUR-HELIX BUNDLE MODEL
1MFT	;	2.5	;	Crystal Structure Of Four-Helix Bundle Model
1OVU	;	3.1	;	CRYSTAL STRUCTURE OF FOUR-HELIX BUNDLE MODEL di-Co(II)-DF1-L13A (form I)
1OVV	;	2.9	;	CRYSTAL STRUCTURE OF FOUR-HELIX BUNDLE MODEL di-Co(II)-DF1-L13A (form II)
1OVR	;	2.99	;	CRYSTAL STRUCTURE OF FOUR-HELIX BUNDLE MODEL di-Mn(II)-DF1-L13
3Q5C	;	2.501	;	Crystal structure of four-way junction with sticky end
6Y24	;	1.86	;	Crystal structure of fourth KH domain of FUBP1
6P7B	;	3.317	;	Crystal structure of Fowlpox virus resolvase and substrate Holliday junction DNA complex
5CGS	;	1.634	;	CRYSTAL STRUCTURE OF Fox-4 cephamycinase
5CHM	;	1.9	;	CRYSTAL STRUCTURE OF Fox-4 cephamycinase complexed with ceftazidime BATSI (LP06)
5CHJ	;	1.358	;	CRYSTAL STRUCTURE OF Fox-4 cephamycinase complexed with cephalothin BATSI (SM23)
5CHU	;	1.1	;	CRYSTAL STRUCTURE OF Fox-4 cephamycinase complexed with sulfate
5CGW	;	1.4	;	CRYSTAL STRUCTURE OF Fox-4 cephamycinase mutant Y150F
5CGX	;	1.21	;	CRYSTAL STRUCTURE OF Fox-4 cephamycinase mutant Y150F complexed with cefoxitin
5X07	;	2.796	;	Crystal structure of FOXA2 DNA binding domain bound to a full consensus DNA site
6AKO	;	2.396	;	Crystal Structure of FOXC2 DBD Bound to DBE2 DNA
6LBM	;	2.841	;	Crystal Structure of FOXC2-DBD bound to a palindromic DNA sequence
3CO6	;	2.1	;	Crystal Structure of FoxO1 DBD Bound to DBE1 DNA
3CO7	;	2.91	;	Crystal Structure of FoxO1 DBD Bound to DBE2 DNA
3COA	;	2.2	;	Crystal Structure of FoxO1 DBD Bound to IRE DNA
6LBI	;	3.067	;	Crystal Structure of FOXO1-DBD homodimer bound to a palindromic DNA sequence
2A07	;	1.9	;	Crystal Structure of Foxp2 bound Specifically to DNA.
6KDC	;	1.85	;	crystal structure of Fpglu1 from fervidobacterium pennivoraus
2F8C	;	2.2	;	Crystal structure of FPPS in complex with Zoledronate
5TZP	;	1.35	;	Crystal structure of FPV039:Bik BH3 complex
5TZQ	;	1.65	;	Crystal Structure of FPV039:Bmf BH3 complex
7CP6	;	2.2	;	Crystal structure of FqzB
7CP7	;	2.4	;	Crystal structure of FqzB, native proteins
4TSO	;	2.3	;	Crystal structure of FraC with DHPC bound (crystal form I)
4TSP	;	2.15	;	Crystal structure of FraC with DHPC bound (crystal form II)
4TSQ	;	1.6	;	Crystal structure of FraC with DHPC bound (crystal form III)
4TSY	;	3.14	;	Crystal structure of FraC with lipids
4TSL	;	1.6	;	Crystal structure of FraC with POC bound (crystal form I)
4TSN	;	1.57	;	Crystal structure of FraC with POC bound (crystal form II)
5KH3	;	1.6	;	Crystal structure of fragment (3-(5-Chloro-1,3-benzothiazol-2-yl)propanoic acid) bound in the ubiquitin binding pocket of the HDAC6 zinc-finger domain
5KH7	;	1.7	;	Crystal structure of fragment (3-[6-Oxo-3-(3-pyridinyl)-1(6H)-pyridazinyl]propanoic acid) bound in the ubiquitin binding pocket of the HDAC6 zinc-finger domain
3EQ5	;	2.45	;	Crystal structure of fragment 137 to 238 of the human Ski-like protein
4TT0	;	2.599	;	Crystal structure of fragment 1600-1733 of HSV1 UL36 in the presence of 1M potassium iodide
4TT1	;	2.75	;	Crystal structure of fragment 1600-1733 of HSV1 UL36, native
6CE8	;	1.55	;	Crystal structure of fragment 2-(Benzo[d]thiazol-2-yl)acetic acid bound in the ubiquitin binding pocket of the HDAC6 zinc-finger domain
6CEF	;	1.8	;	Crystal structure of fragment 3-(1,3-Benzothiazol-2-yl)propanoic acid bound in the ubiquitin binding pocket of the HDAC6 zinc-finger domain
6CEE	;	1.55	;	Crystal structure of fragment 3-(1-Methyl-2-oxo-1,2-dihydroquinoxalin-3-yl)propionic acid bound in the ubiquitin binding pocket of the HDAC6 zinc-finger domain
5WPB	;	1.55	;	Crystal structure of fragment 3-(3-(pyridin-2-ylmethoxy)quinoxalin-2-yl)propanoic acid bound in the ubiquitin binding pocket of the HDAC6 zinc-finger domain
5WBN	;	1.64	;	Crystal structure of fragment 3-(3-Benzyl-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazolin-6-yl)propanoic acid bound in the ubiquitin binding pocket of the HDAC6 zinc-finger domain
6CEC	;	1.55	;	Crystal structure of fragment 3-(3-Methoxy-2-quinoxalinyl)propanoic acid bound in the ubiquitin binding pocket of the HDAC6 zinc-finger domain
6CED	;	1.7	;	Crystal structure of fragment 3-(3-Methyl-4-oxo-3,4-dihydroquinazolin-2-yl)propanoic acid bound in the ubiquitin binding pocket of the HDAC6 zinc-finger domain
6CEA	;	1.6	;	Crystal structure of fragment 3-(quinolin-2-yl)propanoic acid bound in the ubiquitin binding pocket of the HDAC6 zinc-finger domain
5HQ5	;	1.6	;	Crystal structure of fragment bound with Brd4
5HQ6	;	1.95	;	Crystal structure of fragment bound with Brd4
5HQ7	;	1.9	;	Crystal structure of fragment bound with Brd4
2HOD	;	2.9	;	Crystal Structure of Fragment D from Human Fibrinogen Complexed with Gly-hydroxyPro-Arg-Pro-amide
2HPC	;	2.9	;	Crystal structure of fragment D from Human Fibrinogen Complexed with Gly-Pro-Arg-Pro-amide.
1FZG	;	2.5	;	CRYSTAL STRUCTURE OF FRAGMENT D FROM HUMAN FIBRINOGEN WITH THE PEPTIDE LIGAND GLY-HIS-ARG-PRO-AMIDE
1LWU	;	2.8	;	Crystal structure of fragment D from lamprey fibrinogen complexed with the peptide Gly-His-Arg-Pro-amide
1RE4	;	2.7	;	Crystal Structure of Fragment D of BbetaD398A Fibrinogen
1RE3	;	2.45	;	Crystal Structure of Fragment D of BbetaD398A Fibrinogen with the Peptide Ligand Gly-His-Arg-Pro-Amide
2OYH	;	2.4	;	Crystal Structure of Fragment D of gammaD298,301A Fibrinogen with the Peptide Ligand Gly-His-Arg-Pro-Amide
2OYI	;	2.7	;	Crystal Structure of Fragment D of gammaD298,301A Fibrinogen with the Peptide Ligand Gly-Pro-Arg-Pro-Amide
1RF0	;	2.81	;	Crystal Structure of Fragment D of gammaE132A Fibrinogen
1RF1	;	2.53	;	Crystal Structure of Fragment D of gammaE132A Fibrinogen with the Peptide Ligand Gly-His-Arg-Pro-amide
2HLO	;	2.6	;	Crystal Structure of Fragment D-dimer from Human Fibrin Complexed with Gly-hydroxyPro-Arg-Pro-amide
3HP6	;	1.81	;	Crystal structure of fragment DNA polymerase I from Bacillus stearothermophilus F710Y mutant bound to G:T mismatch
3HT3	;	1.7	;	Crystal structure of fragment DNA polymerase I from Bacillus stearothermophilus V713P mutant bound to G:dCTP
4O0I	;	2.203	;	Crystal structure of fragment DNA polymerase I from Bacillus stearothermophilus with 2'-MeSe-arabino-guanosine derivatized DNA
4DSL	;	2.45	;	Crystal structure of fragment DNA polymerase I from Bacillus stearothermophilus with duplex DNA and Calcium
4DSJ	;	2.86	;	Crystal structure of fragment DNA polymerase I from Bacillus stearothermophilus with duplex DNA, dGTP and Calcium
4DSK	;	2.18	;	Crystal structure of fragment DNA polymerase I from Bacillus stearothermophilus with duplex DNA, PPi and Calcium
4DSI	;	2.05	;	Crystal structure of fragment DNA polymerase I from Bacillus stearothermophilus with duplex DNA, Se-dGTP and Calcium
4DWI	;	1.85	;	Crystal structure of fragment DNA polymerase I from Bacillus stearothermophilus with self complementary DNA, Se-dGTP and Calcium
3HPO	;	1.75	;	Crystal structure of fragment DNA polymerase I from Bacillus stearothermophilus Y714S mutant bound to G:T mismatch
1FZE	;	3.0	;	CRYSTAL STRUCTURE OF FRAGMENT DOUBLE-D FROM HUMAN FIBRIN
1FZF	;	2.7	;	CRYSTAL STRUCTURE OF FRAGMENT DOUBLE-D FROM HUMAN FIBRIN WITH THE PEPTIDE LIGAND GLY-HIS-ARG-PRO-AMIDE
1FZC	;	2.3	;	CRYSTAL STRUCTURE OF FRAGMENT DOUBLE-D FROM HUMAN FIBRIN WITH TWO DIFFERENT BOUND LIGANDS
1Z7L	;	2.8	;	Crystal structure of fragment of mouse ubiquitin-activating enzyme
5D6G	;	3.3	;	CRYSTAL STRUCTURE OF FRAGMENT OF RIBOSOMAL PROTEIN P0 IN COMPLEX WITH 74NT 23S RNA FROM METHANOCOCCUS JANNASCHII
7YNE	;	2.7	;	Crystal structure of fragmin domain-1 (1-160) in complex with G-form actin
7W52	;	2.001	;	Crystal structure of fragmin domain-1 (15-160) in complex with actin
7W51	;	1.2	;	Crystal structure of fragmin domain-1 in complex with actin (ADP-form)
7W50	;	1.15	;	Crystal structure of fragmin domain-1 in complex with actin (ADP-Pi-form)
7W4Z	;	1.15	;	Crystal structure of fragmin domain-1 in complex with actin (AMPPNP-form)
6LJC	;	1.85	;	Crystal structure of fragmin F2-F3 domains (calcium and magnesium condition)
6LJD	;	2.15	;	Crystal structure of fragmin F2-F3 domains (calcium condition)
6KWZ	;	1.551	;	Crystal structure of fragmin F3 domain with calcium ion
4L71	;	3.9	;	Crystal Structure of Frameshift Suppressor tRNA SufA6 Bound to Codon CCC-A on the Ribosome
1VVJ	;	3.44	;	Crystal Structure of Frameshift Suppressor tRNA SufA6 bound to Codon CCC-G on the Ribosome
4LFZ	;	3.92	;	Crystal Structure of Frameshift Suppressor tRNA SufA6 Bound to Codon CCC-U in the Absence of Paromomycin
4L47	;	3.22	;	Crystal Structure of Frameshift Suppressor tRNA SufA6 Bound to Codon CCC-U on the Ribosome
4LEL	;	3.9	;	Crystal Structure of Frameshift Suppressor tRNA SufA6 Bound to Codon CCG-G on the Ribosome
5B2P	;	1.7	;	Crystal structure of Francisella novicida Cas9 in complex with sgRNA and target DNA (TGA PAM)
5B2O	;	1.7	;	Crystal structure of Francisella novicida Cas9 in complex with sgRNA and target DNA (TGG PAM)
5B2Q	;	1.7	;	Crystal structure of Francisella novicida Cas9 RHA in complex with sgRNA and target DNA (TGG PAM)
4MYB	;	2.4	;	Crystal Structure of Francisella tularensis 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase (IspD)
2JJY	;	2.9	;	Crystal structure of Francisella tularensis enoyl reductase (ftFabI) with bound NAD
4PZV	;	1.704	;	Crystal structure of Francisella tularensis HPPK-DHPS in complex with bisubstrate analog HPPK inhibitor J1D
4OKO	;	2.053	;	Crystal structure of Francisella tularensis REP34 (Rapid Encystment Phenotype Protein 34 KDa)
1EQR	;	2.7	;	CRYSTAL STRUCTURE OF FREE ASPARTYL-TRNA SYNTHETASE FROM ESCHERICHIA COLI
1ES8	;	2.3	;	Crystal structure of free BglII
4FGV	;	2.941	;	Crystal structure of free CRM1 (crystal form 1)
4HZK	;	3.1	;	Crystal structure of free CRM1 (crystal form 2)
7N8V	;	2.1	;	Crystal structure of free ERI2 nuclease
6MYF	;	1.6	;	Crystal structure of free human Scribble PDZ1 domain
3KZD	;	1.3	;	Crystal Structure of Free T-cell Lymphoma Invasion and Metastasis-1 PDZ Domain
4NXP	;	2.3	;	Crystal Structure of Free T-cell Lymphoma Invasion and Metastasis-1 PDZ Domain Quadruple Mutant (QM)
5K16	;	2.599	;	Crystal structure of free Ubiquitin-specific protease 12
5HCG	;	2.68	;	CRYSTAL STRUCTURE OF FREE-CODV.
4HKG	;	1.3002	;	Crystal Structure of Free-Standing Peptidyl Carrier Protein from Uncharacterized Acinetobacter baumannii Secondary Metabolic Pathway
6BB8	;	3.49	;	Crystal Structure of Frequency-Interacting RNA helicase (FRH)
7ROO	;	1.52	;	Crystal structure of Friedel-Crafts alkylating enzyme CylK from Cylindospermum licheniforme with bromide
5CH6	;	3.26	;	Crystal Structure of FRIGIDA Flowering-time Regulator
5URZ	;	2.202	;	Crystal structure of Frizzled 5 CRD in complex with BOG
6O39	;	1.8	;	Crystal structure of Frizzled 5 CRD in complex with F2.I Fab
5URY	;	2.098	;	Crystal structure of Frizzled 5 CRD in complex with PAM
5T44	;	1.9944	;	Crystal structure of Frizzled 7 CRD
5URV	;	2.2	;	Crystal structure of Frizzled 7 CRD in complex with C24 fatty acid
6O3B	;	2.5	;	Crystal structure of Frizzled 7 CRD in complex with F6 Fab
6O3A	;	2.1	;	Crystal structure of Frizzled 7 CRD in complex with F7.B Fab
5WBS	;	2.88	;	Crystal structure of Frizzled-7 CRD with an inhibitor peptide Fz7-21
4E5R	;	1.9	;	Crystal Structure of Frog DGCR8 Dimerization Domain
4P18	;	1.91	;	Crystal Structure of frog M ferritin mutant D80K
5XHI	;	1.26	;	Crystal structure of Frog M-ferritin D38A mutant
5XHM	;	1.7	;	Crystal structure of Frog M-ferritin D40A mutant
5XHO	;	1.73	;	Crystal structure of Frog M-ferritin E135K mutant
5XHN	;	1.63	;	Crystal structure of Frog M-ferritin K104E mutant
8A90	;	2.574	;	Crystal structure of FrsH
4GWU	;	3.0	;	Crystal Structure of Fru 2,6-bisphosphate complexes of Porcine Liver Fructose-1,6-bisphosphatase with Filled Central Cavity
2AEZ	;	3.05	;	Crystal structure of fructan 1-exohydrolase IIa (E201Q) from Cichorium intybus in complex with 1-kestose
1ST8	;	2.35	;	Crystal structure of fructan 1-exohydrolase IIa from Cichorium intybus
2AEY	;	3.27	;	Crystal structure of fructan 1-exohydrolase IIa from Cichorium intybus in complex with 2,5 dideoxy-2,5-immino-D-mannitol
2ADE	;	2.65	;	Crystal structure of fructan 1-exohydrolase IIa from Cichorium intybus in complex with fructose
2ADD	;	2.5	;	Crystal structure of fructan 1-exohydrolase IIa from Cichorium intybus in complex with sucrose
2QHP	;	1.8	;	Crystal structure of fructokinase (NP_810670.1) from Bacteroides thetaiotaomicron VPI-5482 at 1.80 A resolution
5YGG	;	1.671	;	Crystal structure of Fructokinase Double-Mutant (T261C-H108C) from Vibrio cholerae O395 in fructose, ADP and potassium ion bound form
3OHR	;	1.66	;	Crystal structure of fructokinase from bacillus subtilis complexed with ADP
4U7X	;	2.1	;	Crystal structure of Fructokinase from Brucella abortus 2308
4WJM	;	1.7	;	Crystal structure of Fructokinase from Brucella abortus 2308 with bound AMPPNP
5EY7	;	2.461	;	Crystal structure of Fructokinase from Vibrio cholerae O395 in apo form
5F11	;	2.3	;	Crystal structure of Fructokinase from Vibrio cholerae O395 in fructose bound form
5F0Z	;	1.75	;	Crystal structure of Fructokinase from Vibrio cholerae O395 in fructose, ADP and calcium ion bound form
5EYN	;	1.289	;	Crystal structure of Fructokinase from Vibrio cholerae O395 in fructose, ADP, Beryllium trifluoride and calcium ion bound form
3LJS	;	1.97	;	Crystal structure of Fructokinase from Xylella fastidiosa
3LM9	;	2.45	;	Crystal structure of fructokinase with ADP and Fructose bound in the active site
3LKI	;	2.04	;	Crystal Structure of Fructokinase with bound ATP from Xylella fastidiosa
3MMT	;	2.35	;	Crystal structure of fructose bisphosphate aldolase from Bartonella henselae, bound to fructose bisphosphate
3MBF	;	2.37	;	Crystal structure of fructose bisphosphate aldolase from Encephalitozoon cuniculi, bound to fructose 1,6-bisphosphate
3QRH	;	2.0	;	Crystal structure of fructose bisphosphate aldolase from Encephalitozoon Cuniculi, bound to glyceraldehyde 3-phosphate
3MBD	;	2.0	;	Crystal structure of fructose bisphosphate aldolase from Encephalitozoon cuniculi, bound to phosphate
7X7H	;	2.0	;	Crystal structure of Fructose regulator/Histidine phosphocarrier protein complex from Vibrio cholerae
1UMG	;	1.8	;	Crystal structure of fructose-1,6-bisphosphatase
1FBP	;	2.5	;	CRYSTAL STRUCTURE OF FRUCTOSE-1,6-BISPHOSPHATASE COMPLEXED WITH FRUCTOSE 6-PHOSPHATE, AMP, AND MAGNESIUM
1FRP	;	2.0	;	CRYSTAL STRUCTURE OF FRUCTOSE-1,6-BISPHOSPHATASE COMPLEXED WITH FRUCTOSE-2,6-BISPHOSPHATE, AMP AND ZN2+ AT 2.0 ANGSTROMS RESOLUTION. ASPECTS OF SYNERGISM BETWEEN INHIBITORS
3BIH	;	2.1	;	Crystal structure of fructose-1,6-bisphosphatase from E.coli GlpX
6AYV	;	2.3	;	Crystal structure of fructose-1,6-bisphosphatase T84A from Mycobacterium tuberculosis
6AYU	;	2.2	;	Crystal structure of fructose-1,6-bisphosphatase T84S from Mycobacterium tuberculosis
7K74	;	2.2	;	Crystal Structure of Fructose-1,6-bisphosphatase, type I, from Stenotrophomonas maltophilia K279a
3KX6	;	2.1	;	Crystal structure of fructose-1,6-bisphosphate aldolase from Babesia bovis at 2.1A resolution
2FJK	;	2.2	;	Crystal structure of Fructose-1,6-Bisphosphate Aldolase in Thermus caldophilus
2ABQ	;	2.1	;	Crystal structure of fructose-1-phosphate kinase from Bacillus halodurans
7NCC	;	2.0	;	Crystal structure of fructose-bisphosphate aldolase FBAP from Bacillus methanolicus
2PC4	;	2.4	;	Crystal structure of fructose-bisphosphate aldolase from Plasmodium falciparum in complex with TRAP-tail determined at 2.4 angstrom resolution
2EPH	;	2.7	;	Crystal structure of fructose-bisphosphate aldolase from Plasmodium falciparum in complex with TRAP-tail determined at 2.7 angstrom resolution
2IQT	;	2.46	;	Crystal Structure of Fructose-Bisphosphate Aldolase, Class I from Porphyromonas gingivalis
7NC7	;	2.2	;	Crystal structure of fructose-bisphosphate aldolases FBAC from Bacillus methanolicus
6IWE	;	1.939	;	Crystal structure of fructosyl peptide oxidase thermally stable mutant
3LIG	;	1.8	;	Crystal structure of fructosyltransferase (D191A) from A. japonicus
3LDR	;	2.1	;	Crystal structure of fructosyltransferase (D191A) from A. japonicus in complex with 1-Kestose
3LEM	;	2.1	;	Crystal structure of fructosyltransferase (D191A) from A. japonicus in complex with Nystose
3LIH	;	2.2	;	Crystal structure of fructosyltransferase (D191A) from A. japonicus in complex with raffinose
3LF7	;	2.0	;	Crystal structure of fructosyltransferase (wild-type) from A. japonicus
3LFI	;	2.0	;	Crystal structure of fructosyltransferase (wild-type) from A. japonicus in complex with glucose
4IM7	;	1.9	;	Crystal structure of fructuronate reductase (ydfI) from E. coli CFT073 (EFI TARGET EFI-506389) complexed with NADH and D-mannonate
4WOG	;	1.813	;	Crystal Structure of Frutalin from Artocarpus incisa
5BN6	;	1.6499	;	Crystal Structure of Frutalin from Artocarpus incisa in complex with galactose
2PE3	;	2.0	;	Crystal structure of Frv operon protein FRVX (PH1821)from pyrococcus horikoshii OT3
1LR8	;	2.1	;	Crystal structure of Fs1, the heparin-binding domain of follistatin, complexed with the heparin analogue D-myo-inositol hexasulphate (Ins6S)
1LR7	;	1.5	;	Crystal structure of Fs1, the heparin-binding domain of follistatin, complexed with the heparin analogue sucrose octasulphate (SOS)
7E5T	;	2.16978	;	Crystal structure of Fsa2
6IGG	;	1.0	;	Crystal structure of FT condition 1
6IGI	;	1.33	;	Crystal structure of FT condition 2
6IGJ	;	1.501	;	Crystal structure of FT condition 4
6IGH	;	1.01	;	Crystal structure of FT condition3
3EU5	;	2.8	;	Crystal structure of FTase(ALPHA-subunit; BETA-subunit DELTA C10) in complex with BiotinGPP
3PZ4	;	2.1	;	Crystal structure of FTase(ALPHA-subunit; BETA-subunit DELTA C10) in complex with BMS3 and lipid substrate FPP
3EUV	;	2.75	;	Crystal structure of FTase(ALPHA-subunit; BETA-subunit DELTA C10, W102T, Y154T) in complex with BiotinGPP
5A4J	;	2.15	;	Crystal structure of FTHFS1 from T.acetoxydans Re1
5A5G	;	2.3	;	Crystal structure of FTHFS2 from T.acetoxydans Re1
7DE0	;	2.4	;	Crystal structure of FtmOx1 Y224F mutation
4QKN	;	2.2	;	Crystal structure of FTO bound to a selective inhibitor
5ZMD	;	3.3	;	Crystal structure of FTO in complex with m6dA modified ssDNA
5DAB	;	2.1	;	Crystal structure of FTO-IN115
1ZU5	;	2.4	;	Crystal structure of FtsY from Mycoplasma mycoides- space group H32
1ZU4	;	1.95	;	Crystal structure of FtsY from Mycoplasma mycoides- space group P21212
4U39	;	3.194	;	Crystal Structure of FtsZ:MciZ Complex from Bacillus subtilis
7KZW	;	1.34	;	Crystal structure of FTT_1639c from Francisella tularensis str. tularensis SCHU S4
8EQW	;	1.76	;	Crystal structure of Fub7
8ERJ	;	2.16	;	Crystal structure of Fub7 in complex with E-2-aminocrotonate
8ERB	;	1.98	;	Crystal structure of Fub7 in complex with vinylglycine ketimine
4UOU	;	2.4	;	Crystal Structure of Fucose binding lectin from Aspergillus Fumigatus (AFL) - apo-form
4C1Y	;	2.23	;	Crystal Structure of Fucose binding lectin from Aspergillus Fumigatus (AFL) in complex with b-methylfucoside
4AH4	;	1.75	;	Crystal Structure of Fucose binding lectin from Aspergillus Fumigatus (AFL) in complex with BGA Oligosaccharide.
4AGT	;	2.0	;	Crystal Structure of Fucose binding lectin from Aspergillus Fumigatus (AFL) in complex with Fuc1-6GlcNAc.
4AHA	;	2.2	;	Crystal Structure of Fucose binding lectin from Aspergillus Fumigatus (AFL) in complex with fucosylated monosaccharides (Fuc1-2Gal, Fuc1- 3GlcNAc, Fuc1-4GlcNAc and Fuc1-6GlcNAc)
4D52	;	1.76	;	CRYSTAL STRUCTURE OF FUCOSE BINDING LECTIN FROM ASPERGILLUS FUMIGATUS (AFL) IN COMPLEX WITH L-GALACTOPYRANOSE.
4D4U	;	1.99	;	Crystal Structure of Fucose binding lectin from Aspergillus Fumigatus (AFL) in complex with LewisY tetrasaccharide.
4AGI	;	1.6	;	Crystal Structure of Fucose binding lectin from Aspergillus Fumigatus (AFL) in complex with seleno fucoside.
7LL6	;	2.25	;	Crystal structure of fucose synthetase family protein from Brucella suis ATCC 23445
5XJF	;	2.5	;	Crystal structure of fucosylated IgG Fc Y296W mutant complexed with bis-glycosylated soluble form of Fc gamma receptor IIIa
5XJE	;	2.4	;	Crystal structure of fucosylated IgG1 Fc complexed with bis-glycosylated soluble form of Fc gamma receptor IIIa
2HHC	;	1.54	;	Crystal structure of fucosyltransferase NodZ from Bradyrhizobium
2HLH	;	1.95	;	Crystal structure of fucosyltransferase NodZ from Bradyrhizobium
6A2W	;	1.8	;	Crystal structure of fucoxanthin chlorophyll a/c complex from Phaeodactylum tricornutum
6P3Z	;	2.844	;	Crystal Structure of Full Length APOBEC3G E/Q (pH 5.2)
6P3X	;	2.402	;	Crystal Structure of Full Length APOBEC3G E/Q (pH 7.0)
6P3Y	;	2.57	;	Crystal Structure of Full Length APOBEC3G E/Q (pH 7.4)
6P40	;	2.452	;	Crystal Structure of Full Length APOBEC3G FKL
1U04	;	2.25	;	Crystal structure of full length Argonaute from Pyrococcus furiosus
1Z7E	;	3.0	;	Crystal structure of full length ArnA
2ETF	;	2.29	;	Crystal structure of full length botulinum neurotoxin (Type B) light chain
3FEH	;	1.9	;	Crystal structure of full length centaurin alpha-1
3FM8	;	2.3	;	Crystal structure of full length centaurin alpha-1 bound with the FHA domain of KIF13B (CAPRI target)
3LJU	;	1.702	;	Crystal structure of full length centaurin alpha-1 bound with the head group of PIP3
3DVL	;	2.8	;	Crystal Structure of Full Length Circadian Clock Protein KaiC with Correct Geometry at Phosphorylation Sites
2GBL	;	2.8	;	Crystal Structure of Full Length Circadian Clock Protein KaiC with Phosphorylation Sites
3LIJ	;	1.9	;	Crystal structure of full length CpCDPK3 (cgd5_820) in complex with Ca2+ and AMPPNP
5KUD	;	2.7	;	Crystal structure of full length Cry6Aa
4C2T	;	3.997	;	Crystal structure of full length Deinococcus radiodurans UvrD in complex with DNA
1SRU	;	3.3	;	Crystal structure of full length E. coli SSB protein
4XBO	;	2.6	;	Crystal structure of full length E.coli TrmJ in complex with SAH
6EN3	;	2.903	;	Crystal structure of full length EndoS from Streptococcus pyogenes in complex with G2 oligosaccharide.
6LN2	;	3.2	;	Crystal structure of full length human GLP1 receptor in complex with Fab fragment (Fab7F38)
5D3O	;	2.791	;	Crystal structure of full length human glutaminase C expressed in E.coli
6J04	;	1.899	;	Crystal structure of full length human LC3B delta G120 mutant (2_125)
7UED	;	3.0	;	Crystal structure of full length mesothelin bound with MORAb-009 Fab
4ABN	;	2.05	;	Crystal structure of full length mouse Strap (TTC5)
5XAZ	;	2.3	;	Crystal structure of full length native tylp, a tetr regulator from streptomyces fradiae
5YVJ	;	2.508	;	Crystal structure of full length NS2B47-NS3 (gD4NS2BNS3) from Dengue virus 4 in open conformation
5YVW	;	3.1	;	Crystal structure of full length NS3 protein (eD4NS2BNS3) from DENV4 in closed conformation
5YW1	;	2.6	;	Crystal structure of full length NS3 protein (eD4NS2BNS3) in complex with Bovine Pancreatic Trypsin Inhibitor
5YVV	;	3.097	;	Crystal structure of full length NS3 protein (gD4NS2BNS3) from DENV4 in closed conformation
4G56	;	2.95	;	Crystal Structure of full length PRMT5/MEP50 complexes from Xenopus laevis
3IB7	;	1.6	;	Crystal structure of full length Rv0805
3IB8	;	1.8	;	Crystal structure of full length Rv0805 in complex with 5'-AMP
4GO1	;	3.0	;	Crystal Structure of full length transcription repressor LsrR from E. coli.
5XAY	;	2.58	;	Crystal structure of full length tylp, a tetr regulator from streptomyces fradiae
4WWC	;	2.903	;	Crystal structure of full length YvoA in complex with palindromic operator DNA
1ZP9	;	2.0	;	Crystal Structure of full-legnth A.fulgidus Rio1 Serine Kinase bound to ATP and Mn2+ ions.
5MZ4	;	3.048	;	Crystal Structure of full-lengh CSFV NS3/4A
1ZBU	;	2.998	;	crystal structure of full-length 3'-exonuclease
7ZBR	;	3.0	;	Crystal Structure of full-length Bartonella Effector protein 1
3K1N	;	2.99	;	Crystal Structure of full-length BenM
3K1P	;	3.0	;	Crystal Structure of full-length BenM E226K mutant
3K1M	;	2.29	;	Crystal Structure of full-length BenM, R156H mutant
3PY7	;	2.288	;	Crystal structure of full-length Bovine Papillomavirus oncoprotein E6 in complex with LD1 motif of paxillin at 2.3A resolution
4IYR	;	2.697	;	Crystal structure of full-length caspase-6 zymogen
4J3P	;	2.5	;	Crystal structure of full-length catechol oxidase from Aspergillus oryzae
7D98	;	3.6	;	Crystal structure of full-length CbnR complexed with the target DNA complex
4EC9	;	3.21	;	Crystal structure of full-length cdk9 in complex with cyclin t
6YHK	;	2.7	;	Crystal structure of full-length CNFy (C866S) from Yersinia pseudotuberculosis
6LAA	;	2.13	;	Crystal structure of full-length CYP116B46 from Tepidiphilus thermophilus
3HYI	;	2.34	;	Crystal structure of full-length DUF199/WhiA from Thermatoga maritima
3K46	;	2.5	;	Crystal structure of full-length E. coli beta-glucuronidase
5A60	;	1.82	;	Crystal structure of full-length E. coli ygiF in complex with tripolyphosphate and two magnesium ions
5A61	;	1.5	;	Crystal structure of full-length E. coli ygiF in complex with tripolyphosphate and two manganese ions.
3ZLJ	;	3.1	;	CRYSTAL STRUCTURE OF FULL-LENGTH E.COLI DNA MISMATCH REPAIR PROTEIN MUTS D835R MUTANT IN COMPLEX WITH GT MISMATCHED DNA
4RUL	;	2.9	;	Crystal structure of full-length E.Coli topoisomerase I in complex with ssDNA
3HDE	;	1.95	;	Crystal structure of full-length endolysin R21 from phage 21
3APO	;	2.4	;	Crystal structure of full-length ERdj5
5TB5	;	2.0	;	Crystal structure of full-length farnesylated and methylated KRAS4b in complex with PDE-delta (crystal form I - with partially disordered hypervariable region)
5XSO	;	1.778	;	Crystal structure of full-length FixJ from B. japonicum crystallized in space group C2221
4YWT	;	2.38	;	Crystal structure of full-length glypican-1 core protein after controlled crystal dehydration to 87% relative humidity
3QHS	;	2.85	;	Crystal structure of full-length Hfq from Escherichia coli
6SLM	;	2.8	;	Crystal structure of full-length HPV31 E6 oncoprotein in complex with LXXLL peptide of ubiquitin ligase E6AP
2IOQ	;	3.5	;	Crystal Structure of full-length HTPG, the Escherichia coli HSP90
2IOP	;	3.55	;	Crystal Structure of Full-length HtpG, the Escherichia coli Hsp90, Bound to ADP
4HM9	;	3.1001	;	Crystal structure of full-length human catenin-beta-like 1
6UD7	;	2.3	;	Crystal structure of full-length human DCAF15-DDB1(deltaBPB)-DDA1-RBM39 in complex with indisulam
6UE5	;	2.61	;	Crystal structure of full-length human DCAF15-DDB1-deltaPBP-DDA1-RBM39 in complex with 4-(aminomethyl)-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide
4HOQ	;	2.07	;	Crystal Structure of Full-Length Human IFIT5
4HOT	;	2.501	;	Crystal Structure of Full-Length Human IFIT5 with 5`-triphosphate Oligoadenine
4HOR	;	1.861	;	Crystal Structure of Full-Length Human IFIT5 with 5`-triphosphate Oligocytidine
4HOS	;	2.0	;	Crystal Structure of Full-Length Human IFIT5 with 5`-triphosphate Oligouridine
6FXK	;	2.7	;	Crystal Structure of full-length Human Lysyl Hydroxylase LH3
8ONE	;	2.3	;	Crystal Structure of full-length Human Lysyl Hydroxylase LH3 - Asp190Ser mutant - Cocrystal with Fe2+, Mn2+, UDP-Glucose
6TE3	;	2.3	;	Crystal Structure of full-length Human Lysyl Hydroxylase LH3 - Cocrystal with Fe2+, Mn2+, UDP
6FXR	;	2.1	;	Crystal Structure of full-length Human Lysyl Hydroxylase LH3 - Cocrystal with Fe2+, Mn2+, UDP-Gal
6FXY	;	2.138	;	Crystal Structure of full-length Human Lysyl Hydroxylase LH3 - Cocrystal with Fe2+, Mn2+, UDP-Gal - Structure from long-wavelength S-SAD
6FXX	;	3.0	;	Crystal Structure of full-length Human Lysyl Hydroxylase LH3 - Cocrystal with Fe2+, Mn2+, UDP-Gal, Hg2+ Soak
6FXT	;	2.5	;	Crystal Structure of full-length Human Lysyl Hydroxylase LH3 - Cocrystal with Fe2+, Mn2+, UDP-Glc
6TES	;	2.2	;	Crystal Structure of full-length Human Lysyl Hydroxylase LH3 - Cocrystal with Fe2+, Mn2+, UDP-Glucuronic Acid
6TEC	;	2.4	;	Crystal Structure of full-length Human Lysyl Hydroxylase LH3 - Cocrystal with Fe2+, Mn2+, UDP-Xylose
6FXM	;	2.1	;	Crystal Structure of full-length Human Lysyl Hydroxylase LH3 - Cocrystal with Mn2+
6TEU	;	3.0	;	Crystal Structure of full-length Human Lysyl Hydroxylase LH3 - Val80Lys mutant - Cocrystal with Fe2+, Mn2+
6TEX	;	2.3	;	Crystal Structure of full-length Human Lysyl Hydroxylase LH3 - Val80Lys mutant - Cocrystal with Fe2+, Mn2+, UDP-Glucose
6TEZ	;	2.7	;	Crystal Structure of full-length Human Lysyl Hydroxylase LH3 - Val80Lys mutant - Cocrystal with Fe2+, Mn2+, UDP-Glucuronic Acid
3BA0	;	3.0	;	Crystal structure of full-length human MMP-12
4GIZ	;	2.55	;	Crystal structure of full-length human papillomavirus oncoprotein E6 in complex with LXXLL peptide of ubiquitin ligase E6AP at 2.55 A resolution
3TKP	;	2.49	;	Crystal structure of full-length human peroxiredoxin 4 in the reduced form
3TKS	;	2.4	;	Crystal structure of full-length human peroxiredoxin 4 in three different redox states
3TKQ	;	2.22	;	Crystal structure of full-length human peroxiredoxin 4 with mixed conformation
3TKR	;	2.1	;	Crystal structure of full-length human peroxiredoxin 4 with T118E mutation
5XQI	;	2.8	;	Crystal structure of full-length human Rogdi
2PQA	;	2.5	;	Crystal Structure of Full-length Human RPA 14/32 Heterodimer
2Z6K	;	3.0	;	Crystal structure of full-length human RPA14/32 heterodimer
4BL8	;	3.04	;	Crystal structure of full-length human Suppressor of fused (SUFU)
4BL9	;	2.8	;	Crystal structure of full-length human Suppressor of fused (SUFU) mutant lacking a regulatory subdomain (crystal form I)
4BLA	;	3.5	;	Crystal structure of full-length human Suppressor of fused (SUFU) mutant lacking a regulatory subdomain (crystal form II)
3VTH	;	2.0	;	Crystal structure of full-length HypF in the phosphate- and nucleotide-bound form
7WRG	;	3.16	;	Crystal structure of full-length kinesin-3 KLP-6
5VCH	;	2.35	;	Crystal structure of full-length Kluyveromyces lactis Kap123
5VE8	;	2.7	;	Crystal structure of full-length Kluyveromyces lactis Kap123 with histone H3 1-28
5W0V	;	2.821	;	Crystal structure of full-length Kluyveromyces lactis Kap123 with histone H4 1-34
5KCN	;	1.965	;	Crystal Structure of full-length LpoA from Haemophilus influenzae at 1.97 angstrom resolution
5VBG	;	2.8	;	Crystal Structure of full-length LpoA, Monoclinic form 1, from Haemophilus influenzae
8CX3	;	3.609	;	Crystal structure of full-length mesothelin
4K1N	;	6.5	;	Crystal structure of full-length mouse alphaE-catenin
3SFZ	;	3.0	;	Crystal structure of full-length murine Apaf-1
3TB8	;	3.71	;	Crystal structure of full-length myristoylated HIV-1 Nef
4AD7	;	2.945	;	Crystal structure of full-length N-glycosylated human glypican-1
5CCV	;	3.6	;	Crystal structure of full-length NS5 from dengue virus type 3
7WT6	;	1.94	;	Crystal structure of full-length peptidyl-tRNA hydrolase from Mycobacterium tuberculosis
7V53	;	2.1	;	Crystal structure of full-length phospholipase D from Pseudomonas aeruginosa PAO1
3NK4	;	2.0	;	Crystal structure of full-length sperm receptor ZP3 at 2.0 A resolution
3NK3	;	2.6	;	Crystal structure of full-length sperm receptor ZP3 at 2.6 A resolution
4W6R	;	3.471	;	Crystal Structure of Full-Length Split GFP Mutant D102C Disulfide Dimer, P 1 Space Group
4W6P	;	3.085	;	Crystal Structure of Full-Length Split GFP Mutant D102C Disulfide Dimer, P 21 21 21 Space Group
4W6N	;	3.375	;	Crystal Structure of Full-Length Split GFP Mutant D117C Disulfide Dimer, C 1 2 1 Space Group
4W6L	;	2.45	;	Crystal Structure of Full-Length Split GFP Mutant D117C Disulfide Dimer, I 41 2 2 Space Group
4W6J	;	1.702	;	Crystal Structure of Full-Length Split GFP Mutant D117C Disulfide Dimer, P 31 2 1 Space Group
4W6K	;	2.877	;	Crystal Structure of Full-Length Split GFP Mutant D117C Disulfide Dimer, P 41 21 2 Space Group
4W6M	;	2.794	;	Crystal Structure of Full-Length Split GFP Mutant D117C Disulfide Dimer, P 63 Space Group
4W6O	;	2.6	;	Crystal Structure of Full-Length Split GFP Mutant D117C Disulfide Dimer, P 64 2 2 Space Group
4W6I	;	2.625	;	Crystal Structure of Full-Length Split GFP Mutant D190C Disulfide Dimer, P 21 21 21 Space Group
4W6G	;	3.024	;	Crystal Structure of Full-Length Split GFP Mutant D190C Disulfide Dimer, P 61 Space Group
4W6H	;	1.953	;	Crystal Structure of Full-Length Split GFP Mutant D190C Disulfide Dimer, P 65 Space Group
4W7C	;	2.5	;	Crystal Structure of Full-Length Split GFP Mutant D21H/K26C Disulfide and Metal-Mediated Dimer, C 2 Space Group
4W75	;	3.473	;	Crystal Structure of Full-Length Split GFP Mutant D21H/K26C Disulfide and Metal-Mediated Dimer, P 21 21 21 Space Group, Form 1
4W76	;	2.35	;	Crystal Structure of Full-Length Split GFP Mutant D21H/K26C Disulfide and Metal-Mediated Dimer, P 21 21 21 Space Group, Form 2
4W77	;	3.1	;	Crystal Structure of Full-Length Split GFP Mutant D21H/K26C Disulfide and Metal-Mediated Dimer, P 21 21 21 Space Group, Form 3
4W7A	;	3.603	;	Crystal Structure of Full-Length Split GFP Mutant D21H/K26C Disulfide and Metal-Mediated Dimer, P 21 21 21 Space Group, Form 4
4W7D	;	1.8	;	Crystal Structure of Full-Length Split GFP Mutant D21H/K26H With Copper Mediated Crystal Contacts, P 21 21 21 Space Group
4W7X	;	2.8	;	Crystal Structure of Full-Length Split GFP Mutant E115C Disulfide Dimer, P 1 21 1 Space Group
4W73	;	2.79	;	Crystal Structure of Full-Length Split GFP Mutant E115C/T118H Disulfide Dimer P 21 21 21
4W72	;	2.0	;	Crystal Structure of Full-Length Split GFP Mutant E115C/T118H Disulfide Dimer With Copper Mediated Crystal Contacts, P 21 21 21, Form 1
4W74	;	2.1	;	Crystal Structure of Full-Length Split GFP Mutant E115C/T118H With Metal Mediated Crystal Contacts, P 1 21 1 Space Group
4W6T	;	1.604	;	Crystal Structure of Full-Length Split GFP Mutant E115H/T118H With Copper Mediated Crystal Contacts, P 43 21 2 Space Group
4W6U	;	2.28	;	Crystal Structure of Full-Length Split GFP Mutant E115H/T118H With Nickel Mediated Crystal Contacts, P 21 21 21 Space Group
4W7R	;	1.8	;	Crystal Structure of Full-Length Split GFP Mutant E124H/K126H Copper Mediated Dimer, P 21 Space Group
4W7F	;	2.9	;	Crystal Structure of Full-Length Split GFP Mutant E124H/K126H With Copper Mediated Crystal Contacts, C 2 2 21 Space Group
4W7E	;	2.592	;	Crystal Structure of Full-Length Split GFP Mutant E124H/K126H With Copper Mediated Crystal Contacts, P 41 21 2 Space Group
4W6S	;	3.1	;	Crystal Structure of Full-Length Split GFP Mutant K126C Disulfide Dimer, P 43 21 2 Space Group
4W6C	;	2.4924	;	Crystal Structure of Full-Length Split GFP Mutant K26C Disulfide Dimer, P 21 21 21 Space Group
4W6D	;	3.45	;	Crystal Structure of Full-Length Split GFP Mutant K26C Disulfide Dimer, P 32 2 1 Space Group, Form 1
4W6F	;	2.7	;	Crystal Structure of Full-Length Split GFP Mutant K26C Disulfide Dimer, P 32 2 1 Space Group, Form 2
4W6A	;	2.991	;	Crystal Structure of Full-Length Split GFP Mutant Q157C Disulfide Dimer, P 32 2 1 Space Group
4W69	;	3.975	;	Crystal Structure of Full-Length Split GFP Mutant Q157C Disulfide Dimer, P 43 21 2 Space Group
6X3M	;	3.581	;	Crystal structure of full-length Streptococcal bacteriophage hyaluronidase in complex with unsaturated hyaluronan octa-saccharides
4MD7	;	3.1	;	Crystal Structure of full-length symmetric CK2 holoenzyme
4MD8	;	3.3	;	Crystal Structure of full-length symmetric CK2 holoenzyme with mutated alpha subunit (F121E)
6W4Q	;	1.9	;	Crystal structure of full-length tailspike protein 2 (TSP2, ORF211) ) from Escherichia coli O157:H7 bacteriophage CAB120
5C8D	;	2.8	;	Crystal structure of full-length Thermus thermophilus CarH bound to adenosylcobalamin (dark state)
4HL0	;	2.0	;	Crystal structure of full-length Toxascaris leonina galectin
3I5A	;	2.796	;	Crystal structure of full-length WpsR from Pseudomonas syringae
3ELV	;	2.4	;	Crystal Structure of Full-Length Yeast Pml1p
8P5R	;	4.562	;	Crystal structure of full-length, homohexameric 2-oxoglutarate dehydrogenase KGD from Mycobacterium smegmatis in complex with GarA
4RQS	;	4.493	;	Crystal structure of fully glycosylated HIV-1 gp120 core bound to CD4 and 17b Fab
4AQD	;	2.5	;	Crystal structure of fully glycosylated human butyrylcholinesterase
4X95	;	3.08	;	Crystal structure of fully glycosylated Lysosomal Phospholipase A2 in complex with methyl arachidonyl fluorophosphonate (MAFP)
5X9S	;	2.5	;	Crystal structure of fully modified H-Ras-GppNHp
3W2G	;	1.68	;	Crystal structure of fully reduced form of NADH-cytochrome b5 reductase from pig liver
4PVS	;	1.84	;	Crystal structure of fully-cleaved human l-asparaginase protein in complex with l-aspartate
1VDK	;	1.8	;	Crystal structure of fumarase from thermus thermophilus HB8
3QBP	;	1.85	;	Crystal structure of fumarase Fum from Mycobacterium marinum
2ISB	;	1.66	;	Crystal structure of Fumarase of FUM-1 (NP_069927.1) from Archaeoglobus Fulgidus at 1.66 A resolution
7C1A	;	2.144	;	Crystal structure of FumaraseC (S319C) from Mannheimia succiniciproducens in complex with malate
7C1C	;	1.5	;	Crystal structure of FumaraseC from Mannheimia succiniciproducens
7C18	;	2.12	;	Crystal structure of FumaraseC from Mannheimia succiniciproducens in complex with Fumarate
7MIW	;	1.25	;	Crystal Structure of Fumarate hydratase class II from Elizabethkingia anophelis NUHP1
6N1M	;	1.55	;	Crystal structure of Fumarate hydratase class II from Legionella pneumophila Philadelphia 1
7T93	;	1.65	;	Crystal Structure of Fumarate hydratase class II from Mycobacterium ulcerans in complex with L-Malate
3RD8	;	2.2	;	Crystal structure of fumarate hydratase class II Mycobacterium smegmatis
5L2R	;	2.054	;	Crystal structure of fumarate hydratase from Leishmania major
3RRP	;	2.3	;	Crystal structure of fumarate hydratase Fum from Mycobacterium abscessus with malate bound
3C8T	;	2.2	;	Crystal structure of fumarate lyase from Mesorhizobium sp. BNC1
3OCE	;	2.58	;	Crystal structure of fumarate lyase:delta crystallin from Brucella melitensis bound to cobalt
3OCF	;	2.1	;	Crystal structure of fumarate lyase:delta crystallin from Brucella melitensis in native form
6N56	;	2.35	;	Crystal structure of fumarate reductase, flavo protein subunit, from Helicobacter pylori G27
1QCN	;	1.9	;	CRYSTAL STRUCTURE OF FUMARYLACETOACETATE HYDROLASE
1HYO	;	1.3	;	CRYSTAL STRUCTURE OF FUMARYLACETOACETATE HYDROLASE COMPLEXED WITH 4-(HYDROXYMETHYLPHOSPHINOYL)-3-OXO-BUTANOIC ACID
1QCO	;	1.9	;	CRYSTAL STRUCTURE OF FUMARYLACETOACETATE HYDROLASE COMPLEXED WITH FUMARATE AND ACETOACETATE
5TI1	;	2.0	;	Crystal Structure of Fumarylacetoacetate hydrolase from Burkholderia xenovorans LB400
6J57	;	2.01	;	Crystal structure of fumarylpyruvate hydrolase from Corynebacterium glutamicum
6J5X	;	1.79	;	Crystal structure of fumarylpyruvate hydrolase from Corynebacterium glutamicum in complex with Mn2+ and pyruvate
6J5Y	;	1.98	;	Crystal structure of fumarylpyruvate hydrolase from Pseudomonas aeruginosa in complex with Mn2+ and pyruvate
3IRP	;	1.5	;	Crystal structure of functional region of UafA from Staphylococcus saprophyticus at 1.50 angstrom resolution
3IS1	;	2.45	;	Crystal structure of functional region of UafA from Staphylococcus saprophyticus in C2 form at 2.45 angstrom resolution
3IRZ	;	1.7	;	Crystal structure of functional region of UafA from Staphylococcus saprophyticus in P212121 form
3IS0	;	1.75	;	Crystal structure of functional region of UafA from Staphylococcus saprophyticus in the presence of cholesterol
3KKL	;	2.03	;	Crystal structure of functionally unknown HSP33 from Saccharomyces cerevisiae
7DC5	;	1.54	;	Crystal structure of fungal antifreeze protein with intermediate activity
7DDB	;	1.72	;	Crystal structure of fungal antifreeze protein with intermediate activity
7ZTN	;	1.45	;	Crystal structure of fungal CE16 acetyl xylan esterase
1OFZ	;	1.5	;	Crystal structure of fungal lectin : six-bladed beta-propeller fold and novel fucose recognition mode for aleuria aurantia lectin
4EA6	;	2.3	;	Crystal structure of Fungal lipase from Thermomyces(Humicola) lanuginosa at 2.30 Angstrom resolution.
6NS4	;	2.4	;	Crystal structure of fungal lipoxygenase from Fusarium graminearum. C2 crystal form.
6NS3	;	2.84	;	Crystal structure of fungal lipoxygenase from Fusarium graminearum. I222 crystal form.
6NS6	;	3.3	;	Crystal structure of fungal lipoxygenase from Fusarium graminearum. P21 crystal form.
6NS2	;	2.79	;	Crystal structure of fungal lipoxygenase from Fusarium graminearum. P212121 crystal form.
6NS5	;	2.79	;	Crystal structure of fungal lipoxygenase from Fusarium graminearum. Second C2 crystal form.
3UT2	;	1.549	;	Crystal Structure of Fungal MagKatG2
5JHX	;	1.4	;	Crystal Structure of Fungal MagKatG2 at pH 3.0
5JHY	;	1.4	;	Crystal Structure of Fungal MagKatG2 at pH 5.5
5JHZ	;	1.7	;	Crystal Structure of Fungal MagKatG2 at pH 7.0
5U32	;	2.191	;	Crystal Structure of Fungal RNA Kinase
6TZM	;	1.714	;	Crystal Structure of Fungal RNA Kinase
6TZO	;	1.69	;	Crystal Structure of Fungal RNA Kinase
6TZX	;	1.529	;	Crystal Structure of Fungal RNA Kinase
6U00	;	1.981	;	Crystal Structure of Fungal RNA Kinase
6U03	;	1.849	;	Crystal Structure of Fungal RNA Kinase
6U05	;	1.948	;	Crystal Structure of Fungal RNA Kinase
5FNB	;	1.792	;	CRYSTAL STRUCTURE OF FUNGAL VERSATILE PEROXIDASE FROM PLEUROTUS ERYNGII SEPTUPLE MUTANT E37K, H39R, V160A, T184M, Q202L, D213A & G330R
5FNE	;	1.499	;	CRYSTAL STRUCTURE OF FUNGAL VERSATILE PEROXIDASE FROM PLEUROTUS ERYNGII TRIPLE MUTANT E37K, H39R & G330R
4BLK	;	1.049	;	Crystal Structure of Fungal Versatile Peroxidase I from Pleurotus ostreatus - Crystal Form I
4BLL	;	1.099	;	Crystal Structure of Fungal Versatile Peroxidase I from Pleurotus ostreatus - Crystal Form II
4BLN	;	1.149	;	CRYSTAL STRUCTURE OF FUNGAL VERSATILE PEROXIDASE I FROM PLEUROTUS OSTREATUS - CRYSTAL FORM III
4BLX	;	1.249	;	CRYSTAL STRUCTURE OF FUNGAL VERSATILE PEROXIDASE I FROM PLEUROTUS OSTREATUS - CRYSTAL FORM IV
4BLY	;	1.794	;	CRYSTAL STRUCTURE OF FUNGAL VERSATILE PEROXIDASE I FROM PLEUROTUS OSTREATUS - CRYSTAL FORM V
4BLZ	;	2.0	;	CRYSTAL STRUCTURE OF FUNGAL VERSATILE PEROXIDASE I FROM PLEUROTUS OSTREATUS - CRYSTAL FORM VI
4BM0	;	2.199	;	CRYSTAL STRUCTURE OF FUNGAL VERSATILE PEROXIDASE I FROM PLEUROTUS OSTREATUS - CRYSTAL FORM VII
7RH8	;	1.69	;	Crystal structure of Fur1p from Candida albicans, in complex with UTP
2OF4	;	2.7	;	crystal structure of furanopyrimidine 1 bound to lck
2OF2	;	2.0	;	crystal structure of furanopyrimidine 8 bound to lck
2O03	;	2.699	;	Crystal structure of FurB from M. tuberculosis- a Zinc uptake regulator
3S2E	;	1.763	;	Crystal Structure of FurX NADH Complex 1
3S2G	;	2.3	;	Crystal Structure of FurX NADH+:Furfuryl alcohol I
3S2I	;	2.0	;	Crystal Structure of FurX NADH+:Furfuryl alcohol II
3S2F	;	2.0	;	Crystal Structure of FurX NADH:Furfural
5XRR	;	1.503	;	Crystal structure of FUS (54-59) SYSSYG
4IED	;	1.5	;	Crystal Structure of FUS-1 (OXA-85), a Class D beta-lactamase from Fusobacterium nucleatum subsp. polymorphum
2F49	;	1.9	;	Crystal structure of Fus3 in complex with a Ste5 peptide
2F9G	;	2.1	;	Crystal structure of Fus3 phosphorylated on Tyr182
2B9J	;	2.3	;	Crystal structure of Fus3 with a docking motif from Far1
2B9I	;	2.5	;	Crystal structure of Fus3 with a docking motif from Msg5
2B9H	;	1.55	;	Crystal structure of Fus3 with a docking motif from Ste7
2FA2	;	2.85	;	Crystal structure of Fus3 without a peptide from Ste5
5AJH	;	1.9	;	Crystal structure of Fusarium oxysporum cutinase
3F5H	;	1.75	;	Crystal structure of fused docking domains from PikAIII and PikAIV of the pikromycin polyketide synthase
8T9Q	;	2.29	;	Crystal structure of fused YR, an asymmetric 4-OT trimer
4XXT	;	1.77	;	Crystal structure of Fused Zn-dependent amidase/peptidase/peptodoglycan-binding domain-containing protein from Clostridium acetobutylicum ATCC 824
6K97	;	2.5	;	Crystal structure of fusion DH domain
6EAG	;	3.302	;	CRYSTAL STRUCTURE OF FUSION INHIBITOR JNJ-2408068 IN COMPLEX WITH HUMAN RESPIRATORY SYNCYTIAL VIRUS FUSION GLYCOPROTEIN ESCAPE VARIANT G143S STABILIZED IN THE PREFUSION STATE
6EAK	;	2.6	;	CRYSTAL STRUCTURE OF FUSION INHIBITOR JNJ-2408068 IN COMPLEX WITH HUMAN RESPIRATORY SYNCYTIAL VIRUS FUSION GLYCOPROTEIN ESCAPE VARIANT T400A STABILIZED IN THE PREFUSION STATE
7YO9	;	1.75	;	Crystal structure of fusion protein of human TP53INP2 LIR and human GABARAP
3E0M	;	2.4	;	Crystal structure of fusion protein of MsrA and MsrB
6OHL	;	1.85	;	Crystal structure of Fusobacterium nucleatum flavodoxin bound to flavin mononucleotide
6OHK	;	1.2	;	Crystal structure of Fusobacterium nucleatum flavodoxin mutant K13G bound to flavin mononucleotide
8AXG	;	2.04	;	Crystal structure of Fusobacterium nucleatum fusolisin protease
6YQ4	;	2.399	;	Crystal structure of Fusobacterium nucleatum tannase
8OGG	;	1.76	;	Crystal structure of FutA after an accumulated dose of 5 kGy
8OEM	;	1.7	;	Crystal structure of FutA bound to Fe(II)
8RK1	;	2.095	;	Crystal structure of FutA bound to Fe(III) solved by neutron diffraction
2E27	;	1.7	;	Crystal structure of Fv fragment of anti-ciguatoxin antibody complexed with ABC-ring of ciguatoxin
2OTU	;	1.68	;	Crystal structure of Fv polyglutamine complex
2OTW	;	2.35	;	Crystal structure of Fv polyglutamine complex
4R1A	;	2.0	;	Crystal Structure of FVO strain Plasmodium falciparum AMA1
4Z0F	;	2.3	;	Crystal structure of FVO strain Plasmodium falciparum AMA1 in complex with the RON2hp [Phe2038(6CW)] peptide
4Z0E	;	1.9	;	Crystal structure of FVO strain Plasmodium falciparum AMA1 in complex with the RON2hp [Phe2038TRN] peptide
4Z0D	;	2.1	;	Crystal structure of FVO strain Plasmodium falciparum AMA1 in complex with the RON2hp [Phe2038Trp] peptide
4Z09	;	2.0	;	Crystal structure of FVO strain Plasmodium falciparum AMA1 in complex with the RON2hp [Thr2040Ala] peptide
1LPK	;	2.2	;	CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 125.
2W3K	;	2.05	;	Crystal Structure of FXa in complex with 4,4-disubstituted pyrrolidine-1,2-dicarboxamide inhibitor 1
2W3I	;	1.9	;	Crystal Structure of FXa in complex with 4,4-disubstituted pyrrolidine-1,2-dicarboxamide inhibitor 2
1LPZ	;	2.4	;	CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 41.
1LQD	;	2.7	;	CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 45.
1LPG	;	2.0	;	CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 79.
2H9E	;	2.2	;	Crystal Structure of FXa/selectide/NAPC2 ternary complex
6ITM	;	2.5	;	Crystal structure of FXR in complex with agonist XJ034
5CX3	;	2.3	;	Crystal structure of FYCO1 LIR in complex with LC3A
7BQI	;	1.3	;	Crystal structure of FYCO1 RUN domain
2DQ7	;	2.8	;	Crystal Structure of Fyn kinase domain complexed with staurosporine
1G83	;	2.6	;	CRYSTAL STRUCTURE OF FYN SH3-SH2
1ZCA	;	2.9	;	Crystal structure of G alpha 12 in complex with GDP, Mg2+ and AlF4-
1ZCB	;	2.0	;	Crystal structure of G alpha 13 in complex with GDP
3C4Z	;	1.84	;	Crystal structure of G protein coupled receptor kinase 1 bound to ADP and magnesium chloride at 1.84A
3C50	;	2.6	;	Crystal Structure of G protein coupled receptor kinase 1 bound to ADP and magnesium chloride at 2.6A
3C51	;	3.55	;	Crystal structure of G protein coupled receptor kinase 1 bound to ADP and magnesium chloride at 3.55A
3C4W	;	2.7	;	Crystal Structure of G protein coupled receptor kinase 1 bound to ATP and magnesium chloride at 2.7A
3C4X	;	2.9	;	Crystal Structure of G protein coupled receptor kinase 1 bound to ATP and magnesium chloride at 2.9A
2ACX	;	2.6	;	Crystal Structure of G protein coupled receptor kinase 6 bound to AMPPNP
4MK0	;	2.4	;	Crystal structure of G protein-coupled receptor kinase 2 in complex with a a rationally designed paroxetine derivative
2BCJ	;	3.061	;	Crystal Structure of G Protein-Coupled Receptor Kinase 2 in Complex with Galpha-q and Gbetagamma Subunits
6PJX	;	1.96	;	Crystal Structure of G Protein-Coupled Receptor Kinase 5 (GRK5) in Complex with Calmodulin (CaM)
4TND	;	1.802	;	Crystal Structure of G Protein-Coupled Receptor Kinase 5 in Complex with AMP-PNP
4TNB	;	2.113	;	Crystal Structure of G Protein-Coupled Receptor Kinase 5 in Complex with Sangivamycin
3NYO	;	2.92	;	Crystal Structure of G Protein-Coupled Receptor Kinase 6 in Complex with AMP
3NYN	;	2.72	;	Crystal Structure of G Protein-Coupled Receptor Kinase 6 in Complex with Sangivamycin
5MWI	;	1.51	;	Crystal structure of G(CUG)8G duplex
6FRG	;	1.535	;	Crystal structure of G-1F mutant of Ssp DnaB Mini-Intein variant M86
6FRE	;	1.22	;	Crystal structure of G-1F/H73A mutant of Ssp DnaB Mini-Intein variant M86
6JKN	;	1.401	;	Crystal Structure of G-quadruplex Formed by Bromo-substituted Human Telomeric DNA
7BN6	;	1.5	;	Crystal structure of G. sulphuraria ene-reductase GsOYE in complex with b-angelica lactone
6BG7	;	2.54	;	Crystal structure of G107A mutant of human macrophage migration inhibitory factor
5D1B	;	2.9	;	Crystal structure of G117E HDAC8 in complex with TSA
2PWX	;	2.5	;	Crystal structure of G11A mutant of SARS-CoV 3C-like protease
6NTC	;	2.9	;	Crystal Structure of G12V HRas-GppNHp bound in complex with the engineered RBD variant 1 of CRAF Kinase protein
6NTD	;	3.15	;	Crystal Structure of G12V HRas-GppNHp bound in complex with the engineered RBD variant 12 of CRAF Kinase protein
6OB3	;	2.1	;	Crystal structure of G13D-KRAS (GMPPNP-bound) in complex with GAP-related domain (GRD) of neurofibromin (NF1)
6VTP	;	2.3	;	Crystal structure of G16C human Galectin-7 mutant
6VTQ	;	1.95	;	Crystal structure of G16C human Galectin-7 mutant in complex with lactose
6VTR	;	2.3	;	Crystal structure of G16S human Galectin-7 mutant
6VTS	;	1.9	;	Crystal structure of G16S human Galectin-7 mutant in complex with lactose
4RFL	;	2.2	;	Crystal structure of G1PDH with NADPH from Methanocaldococcus jannaschii
3H2H	;	2.1	;	Crystal structure of G231F mutant of the rice cell wall degrading esterase LipA from Xanthomonas oryzae
1JWV	;	1.85	;	Crystal structure of G238A mutant of TEM-1 beta-lactamase in complex with a boronic acid inhibitor (sefb4)
1IL1	;	2.2	;	Crystal structure of G3-519, an anti-HIV monoclonal antibody
5THS	;	1.9	;	Crystal Structure of G302A HDAC8 in complex with M344
5THT	;	2.407	;	Crystal Structure of G303A HDAC8 in complex with M344
5THU	;	1.95	;	Crystal Structure of G304A HDAC8 in complex with M344
5THV	;	1.868	;	Crystal Structure of G305A HDAC8 in complex with M344
2P9E	;	2.6	;	Crystal Structure of G336V mutant of E.coli phosphoglycerate dehydrogenase
2X9A	;	2.47	;	crystal structure of g3p from phage IF1 in complex with its coreceptor, the C-terminal domain of TolA
3N3I	;	2.501	;	Crystal Structure of G48V/C95F tethered HIV-1 Protease/Saquinavir complex
3VVM	;	1.7	;	Crystal structure of G52A-P55G mutant of L-serine-O-acetyltransferase found in D-cycloserine biosynthetic pathway
2Z57	;	1.8	;	Crystal structure of G56E-propeptide:S324A-subtilisin complex
2Z56	;	1.9	;	Crystal structure of G56S-propeptide:S324A-subtilisin complex
2Z58	;	1.88	;	Crystal structure of G56W-propeptide:S324A-subtilisin complex
3FGS	;	1.8	;	Crystal structure of G65R/K206E double mutant of the N-lobe human transferrin
6E08	;	1.9	;	Crystal structure of G6PD in complex with structural NADP
2VR6	;	1.3	;	Crystal Structure of G85R ALS mutant of Human Cu,Zn Superoxide Dismutase (CuZnSOD) at 1.3 A resolution
2VR8	;	1.36	;	Crystal Structure of G85R ALS mutant of Human Cu,Zn Superoxide Dismutase (CuZnSOD) at 1.36 A resolution
2VR7	;	1.58	;	Crystal Structure of G85R ALS mutant of Human Cu,Zn Superoxide Dismutase (CuZnSOD) at 1.58 A resolution
2R6S	;	2.1	;	Crystal structure of Gab protein
1JR7	;	2.0	;	CRYSTAL STRUCTURE OF GAB REVEALS OXIDOREDUCTASE FOLD
6B6G	;	1.95	;	Crystal Structure of GABA Aminotransferase bound to (S)-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, an Potent Inactivatorfor the Treatment of Addiction
7VEC	;	3.0	;	Crystal structure of GABARAP complexed with the TEX264 LIR phosphorylated at Ser271 and Ser272
7VED	;	2.02	;	Crystal structure of GABARAP fused to TEX264 LIR with S272D mutation
4XC2	;	1.9	;	Crystal structure of GABARAP in complex with KBTBD6 LIR peptide
8T2N	;	1.88	;	Crystal structure of GABARAP in complex with the LIR of NSs3
8T2M	;	1.27	;	Crystal structure of GABARAP in complex with the LIR of NSs4
4I9O	;	2.0	;	Crystal Structure of GACKIX L664C Tethered to 1-10
7QZO	;	1.45	;	Crystal structure of GacS D1 domain
7QZ2	;	1.87	;	Crystal structure of GacS D1 domain in complex with BeF3-
3HBX	;	2.672	;	Crystal structure of GAD1 from Arabidopsis thaliana
3CG6	;	1.7	;	Crystal structure of Gadd45 gamma
5C6I	;	1.9	;	Crystal Structure of Gadolinium derivative of HEWL solved using Free-Electron Laser radiation
5C6J	;	2.1	;	Crystal Structure of Gadolinium derivative of HEWL solved using Free-Electron Laser radiation
5C6L	;	2.1	;	Crystal Structure of Gadolinium derivative of HEWL solved using intense Free-Electron Laser radiation
3MNM	;	1.73	;	Crystal structure of GAE domain of GGA2p from Saccharomyces cerevisiae
4QPR	;	1.55	;	CRYSTAL STRUCTURE OF GAF DOMAIN of POTASSIUM SENSOR HISTIDINE KINASE KDPD FROM ESCHERICHIA COLI
8DGD	;	1.9	;	Crystal Structure of GAF domain-containing protein, from Klebsiella pneumoniae
2VKS	;	2.1	;	Crystal structure of GAF-B domain of DevS from Mycobacterium smegmatis
2XSS	;	2.5	;	Crystal structure of GAFb from the human phosphodiesterase 5
1GA8	;	2.0	;	CRYSTAL STRUCTURE OF GALACOSYLTRANSFERASE LGTC IN COMPLEX WITH DONOR AND ACCEPTOR SUGAR ANALOGS.
4A2C	;	1.87	;	Crystal structure of galactitol-1-phosphate dehydrogenase from Escherichia coli
2ZUS	;	2.11	;	Crystal structure of Galacto-N-biose/Lacto-N-biose I phosphorylase
3WFZ	;	2.6	;	Crystal structure of Galacto-N-Biose/Lacto-N-Biose I Phosphorylase C236Y Mutant
2ZUT	;	1.9	;	Crystal structure of Galacto-N-biose/Lacto-N-biose I phosphorylase in complex with GalNAc
2ZUU	;	2.3	;	Crystal structure of Galacto-N-biose/Lacto-N-biose I phosphorylase in complex with GlcNAc
2ZUW	;	2.11	;	Crystal structure of Galacto-N-biose/Lacto-N-biose I phosphorylase in complex with GlcNAc and sulfate
2ZUV	;	1.85	;	Crystal structure of Galacto-N-biose/Lacto-N-biose I phosphorylase in complex with GlcNAc, Ethylene glycol, and nitrate
2CZ9	;	1.5	;	Crystal Structure of galactokinase from Pyrococcus horikoshi
7M3K	;	2.3	;	Crystal Structure of Galactonate dehydratase from Brucella melitensis biovar Abortus 2308
3IMH	;	1.76	;	CRYSTAL STRUCTURE OF GALACTOSE 1-EPIMERASE FROM Lactobacillus acidophilus NCFM
5KWS	;	1.316	;	Crystal Structure of Galactose Binding Protein from Yersinia pestis in the Complex with beta D Glucose
3IKN	;	1.6	;	Crystal structure of galactose bound trimeric human lung surfactant protein D
5DVJ	;	1.8	;	Crystal structure of galactose complexed periplasmic glucose binding protein (ppGBP) from P. putida CSV86
1MMX	;	1.8	;	Crystal structure of galactose mutarotase from Lactococcus lactis complexed with D-fucose
1MMU	;	1.8	;	Crystal structure of galactose mutarotase from Lactococcus lactis complexed with D-glucose
1MMY	;	1.85	;	Crystal structure of galactose mutarotase from Lactococcus lactis complexed with D-quinovose
1MN0	;	1.9	;	Crystal structure of galactose mutarotase from lactococcus lactis complexed with D-xylose
1MMZ	;	1.8	;	Crystal structure of galactose mutarotase from Lactococcus lactis complexed with L-arabinose
1NSM	;	1.85	;	Crystal structure of galactose mutarotase from Lactococcus lactis mutant D243A complexed with galactose
1NSS	;	1.85	;	Crystal structure of galactose mutarotase from Lactococcus lactis mutant D243A complexed with glucose
1NS8	;	1.8	;	Crystal structure of galactose mutarotase from Lactococcus lactis mutant D243N complexed with galactose
1NSR	;	1.8	;	Crystal structure of galactose mutarotase from Lactococcus lactis mutant D243N complexed with glucose
1NS2	;	1.95	;	Crystal structure of galactose mutarotase from Lactococcus lactis mutant E304A complexed with galactose
1NS7	;	1.85	;	Crystal structure of galactose mutarotase from Lactococcus lactis mutant E304A complexed with glucose
1NS0	;	1.85	;	Crystal structure of galactose mutarotase from Lactococcus lactis mutant E304Q complexed with galactose
1NS4	;	1.85	;	Crystal structure of galactose mutarotase from Lactococcus lactis mutant E304Q complexed with glucose
1NSX	;	1.75	;	Crystal structure of galactose mutarotase from Lactococcus lactis mutant H170N complexed with galactose
1NSZ	;	1.75	;	Crystal structure of galactose mutarotase from Lactococcus lactis mutant H170N complexed with glucose
1NSU	;	1.8	;	Crystal structure of galactose mutarotase from Lactococcus lactis mutant H96N complexed with galactose
1NSV	;	1.8	;	Crystal structure of galactose mutarotase from Lactococcus lactis mutant H96N complexed with glucose
4BZE	;	2.0	;	Crystal structure of galactose mutarotase GalM from Bacillus subtilis
4BZG	;	2.13	;	Crystal structure of galactose mutarotase GalM from Bacillus subtilis in complex with maltose
4BZH	;	2.6	;	Crystal structure of galactose mutarotase GalM from Bacillus subtilis in complex with maltose and trehalose
4BZF	;	1.9	;	Crystal structure of galactose mutarotase GalM from Bacillus subtilis with trehalose
2EIE	;	1.8	;	Crystal Structure of Galactose Oxidase complexed with Azide
2EIC	;	2.8	;	Crystal Structure of Galactose Oxidase mutant W290F
2EIB	;	2.1	;	Crystal Structure of Galactose Oxidase, W290H mutant
5U2K	;	1.38	;	Crystal structure of Galactoside O-acetyltransferase complex with CoA (H3 space group)
5V0Z	;	1.26	;	Crystal structure of Galactoside O-acetyltransferase complex with CoA (P32 space group).
1G9R	;	2.0	;	CRYSTAL STRUCTURE OF GALACTOSYLTRANSFERASE LGTC IN COMPLEX WITH MN AND UDP-2F-GALACTOSE
3QPE	;	1.796	;	Crystal structure of Galacturonate Dehydratase from GEOBACILLUS SP. complexed with D-Galacturonate and 5-keto-4-deoxy-D-Galacturonate
3P3B	;	1.651	;	CRYSTAL STRUCTURE OF Galacturonate DEHYDRATASE FROM GEOBACILLUS SP. COMPLEXED WITH D-TARTRATE
2DEJ	;	1.5	;	Crystal Structure of galaktokinase from Pyrococcus horikoshii with AMP-PN and galactose
2DEI	;	1.7	;	Crystal Structure of galaktokinase from Pyrococcus horikoshii with AMP-PNP and galactose
5CGZ	;	2.103	;	Crystal structure of GalB, the 4-carboxy-2-hydroxymuconate hydratase, from Pseuodomonas putida KT2440
4HAN	;	2.551	;	Crystal structure of Galectin 8 with NDP52 peptide
4Q26	;	1.399	;	Crystal Structure of Galectin-1 in Complex with N-Acetyllactosamine
3W58	;	1.58	;	Crystal structure of Galectin-1 in the lactose-unbound state(P21)
3W59	;	2.1	;	Crystal structure of Galectin-1 in the lactose-unbound state(P212121)
4NO4	;	1.399	;	Crystal Structure of Galectin-1 L11A mutant
3AYC	;	1.8	;	Crystal structure of galectin-3 CRD domian complexed with GM1 pentasaccharide
3AYE	;	2.0	;	Crystal structure of galectin-3 CRD domian complexed with lactose
3AYD	;	1.9	;	Crystal structure of galectin-3 CRD domian complexed with TFN
3AYA	;	2.0	;	Crystal structure of galectin-3 CRD domian complexed with Thomsen-Friedenreich antigen
6F6Y	;	1.41	;	Crystal structure of galectin-3 CRD in complex with galactopentaose
8HL9	;	1.6	;	Crystal structure of Galectin-8 C-CRD with part of linker
5GZC	;	1.08	;	Crystal structure of Galectin-8 N-CRD with part of linker
5T7U	;	1.58	;	Crystal structure of galectin-8N in complex with Glycerol
5T7S	;	1.9	;	Crystal structure of galectin-8N in complex with Lactose
5T7I	;	2.0	;	Crystal structure of galectin-8N in complex with LNnT
4HGU	;	0.98	;	Crystal Structure of Galleria mellonella Silk Protease Inhibitor 2
6W54	;	1.5	;	Crystal Structure of Gallic Acid Decarboxylase from Arxula adeninivorans
7KD9	;	1.94	;	Crystal Structure of Gallic Acid Decarboxylase from Arxula adeninivorans
3FS7	;	1.9539	;	Crystal structure of Gallus gallus beta-parvalbumin (avian thymic hormone)
5FV9	;	2.07	;	Crystal structure of GalNAc-T2 in complex with compound 16d
5NQA	;	1.9	;	Crystal structure of GalNAc-T4 in complex with the monoglycopeptide 3
6IWQ	;	2.95	;	Crystal structure of GalNAc-T7 with Mn2+
6IWR	;	2.604	;	Crystal structure of GalNAc-T7 with UDP, GalNAc and Mn2+
4GNK	;	4.0	;	Crystal structure of Galphaq in complex with full-length human PLCbeta3
8D3T	;	2.37	;	Crystal structure of GalS1 from Populus trichocarpas
8D3Z	;	2.56	;	Crystal structure of GalS1 in complex with Manganese from Populus trichocarpas
5HWK	;	1.344	;	Crystal structure of gama glutamyl cyclotransferease specific to glutathione from yeast
1GGD	;	1.5	;	CRYSTAL STRUCTURE OF GAMMA CHYMOTRYPSIN WITH N-ACETYL-LEUCIL-PHENYLALANINE ALDEHYDE BOUND AT THE ACTIVE SITE
1GG6	;	1.4	;	CRYSTAL STRUCTURE OF GAMMA CHYMOTRYPSIN WITH N-ACETYL-PHENYLALANINE TRIFLUOROMETHYL KETONE BOUND AT THE ACTIVE SITE
4L95	;	2.34	;	Crystal structure of gamma glutamyl hydrolase (H218N) from zebrafish
4L8W	;	2.39	;	Crystal structure of gamma glutamyl hydrolase (H218N) from zebrafish complex with MTX polyglutamate
4L7Q	;	2.1	;	Crystal structure of gamma glutamyl hydrolase (wild-type) from zebrafish
6A2U	;	2.6	;	Crystal structure of gamma-alpha subunit complex from Burkholderia cepacia FAD glucose dehydrogenase
8GRJ	;	2.95	;	Crystal structure of gamma-alpha subunit complex from Burkholderia cepacia FAD glucose dehydrogenase in complex with gluconolactone
6WOP	;	1.85	;	Crystal structure of gamma-aminobutyrate aminotransferase PuuE from Acinetobacter baumannii
6WJ8	;	2.59	;	Crystal structure of gamma-aminobutyrate aminotransferase PuuE from Klebsiella pneumoniae in complex with PLP
4W9B	;	1.279	;	Crystal structure of Gamma-B Crystallin expressed in E. coli based on mRNA variant 1
4W9A	;	1.38	;	Crystal structure of Gamma-B Crystallin expressed in E. coli based on mRNA variant 2
1UI5	;	2.4	;	Crystal structure of gamma-butyrolactone receptor (ArpA like protein)
1UI6	;	2.4	;	Crystal structure of gamma-butyrolactone receptor (ArpA-like protein)
3OTZ	;	1.6	;	Crystal structure of gamma-carbonic anhydrase W19A mutant from Metanosarcina thermophila
3OU9	;	1.8	;	Crystal structure of gamma-carbonic anhydrase W19F mutant from Methanosarcina thermophila
4REP	;	1.97	;	Crystal Structure of gamma-carotenoid desaturase
4JCM	;	1.65	;	Crystal structure of Gamma-CGTASE from Alkalophilic bacillus clarkii at 1.65 Angstrom resolution
5R49	;	1.05	;	Crystal Structure of gamma-Chymotrypsin at pH 5.6, cryo temperature
5R48	;	1.05	;	Crystal Structure of gamma-Chymotrypsin at pH 5.6, room temperature
5R45	;	1.05	;	Crystal Structure of gamma-Chymotrypsin at pH 7.5, cryo temperature
5R44	;	1.05	;	Crystal Structure of gamma-Chymotrypsin at pH 7.5, room temperature
5R4D	;	1.05	;	Crystal Structure of gamma-Chymotrypsin at pH 9, cryo temperature
5R4C	;	1.15	;	Crystal Structure of gamma-Chymotrypsin at pH 9, room temperature
1K2I	;	1.8	;	Crystal Structure of Gamma-Chymotrypsin in Complex with 7-Hydroxycoumarin
4L8F	;	1.97	;	Crystal structure of gamma-glutamyl hydrolase (C108A) complex with MTX
4L8Y	;	1.97	;	Crystal structure of gamma-glutamyl hydrolase (C108A) from zebrafish
1O20	;	2.0	;	Crystal structure of Gamma-glutamyl phosphate reductase (TM0293) from Thermotoga maritima at 2.00 A resolution
1VLU	;	2.29	;	Crystal structure of Gamma-glutamyl phosphate reductase (yor323c) from Saccharomyces cerevisiae at 2.40 A resolution
2V36	;	1.85	;	Crystal structure of gamma-glutamyl transferase from Bacillus subtilis
2I3O	;	2.03	;	Crystal structure of gamma-glutamyl transferase related protein from Thermoplasma acidophilum
2DG5	;	1.6	;	Crystal Structure of Gamma-glutamyl transpeptidase from Escherichia coli in complex with hydrolyzed Glutathione
2D33	;	2.6	;	Crystal Structure of gamma-Glutamylcysteine Synthetase Complexed with Aluminum Fluoride
1V4G	;	2.5	;	Crystal Structure of gamma-Glutamylcysteine Synthetase from Escherichia coli B
1VA6	;	2.1	;	Crystal structure of Gamma-glutamylcysteine synthetase from Escherichia Coli B complexed with Transition-state analogue
3WHQ	;	1.85	;	Crystal structure of gamma-glutamyltranspeptidase from Bacillus subtilis (crystal soaked for 0 min. in acivicin soln. )
3WHR	;	1.58	;	Crystal structure of gamma-glutamyltranspeptidase from Bacillus subtilis (crystal soaked for 3min. in acivicin soln. )
2DBU	;	1.95	;	Crystal Structure of Gamma-glutamyltranspeptidase from Escherichia coli
2E0X	;	1.95	;	Crystal Structure of Gamma-glutamyltranspeptidase from Escherichia coli (monoclinic form)
2DBW	;	1.8	;	Crystal Structure of Gamma-glutamyltranspeptidase from Escherichia coli Acyl-Enzyme Intermediate
2DBX	;	1.7	;	Crystal Structure of Gamma-glutamyltranspeptidase from Escherichia coli Complexed with L-Glutamate
3PEF	;	2.07	;	Crystal structure of gamma-hydroxybutyrate dehydrogenase from Geobacter metallireducens in complex with NADP+
3PDU	;	1.89	;	Crystal structure of gamma-hydroxybutyrate dehydrogenase from Geobacter sulfurreducens in complex with NADP+
5C05	;	1.65	;	Crystal Structure of Gamma-terpinene Synthase from Thymus vulgaris
1Z5W	;	3.0	;	Crystal Structure of gamma-tubulin bound to GTP
5C3M	;	3.059	;	Crystal structure of Gan4C, a GH4 6-phospho-glucosidase from Geobacillus stearothermophilus
4UML	;	1.9	;	Crystal structure of ganglioside induced differentiation associated protein 2 (GDAP2) macro domain
3KCW	;	2.0	;	Crystal structure of Ganoderma fungal immunomodulatory protein, GMI
6GQ0	;	1.94	;	Crystal structure of GanP, a glucose-galactose binding protein from Geobacillus stearothermophilus
6GT9	;	1.894	;	Crystal structure of GanP, a glucose-galactose binding protein from Geobacillus stearothermophilus, in complex with galactose
6GUQ	;	2.385	;	Crystal structure of GanP, a glucose-galactose binding protein from Geobacillus stearothermophilus, in complex with glucose
5CSZ	;	1.8	;	CRYSTAL STRUCTURE OF GANTENERUMAB FAB FRAGMENT IN COMPLEX WITH ABETA 1-11
6IQ6	;	2.29	;	Crystal structure of GAPDH
8HMN	;	2.16	;	Crystal structure of GAPDH complexed with arsenate from Lactiplantibacillus plantarum
6KEZ	;	3.5	;	Crystal structure of GAPDH/CP12/PRK complex from Arabidopsis thaliana
2YYA	;	2.4	;	Crystal structure of GAR synthetase from Aquifex aeolicus
2YW2	;	1.8	;	Crystal structure of GAR synthetase from Aquifex aeolicus in complex with ATP
2YRW	;	2.2	;	Crystal structure of GAR synthetase from Geobacillus kaustophilus
2YRX	;	1.9	;	Crystal structure of GAR synthetase from Geobacillus kaustophilus
2YS6	;	2.21	;	Crystal structure of GAR synthetase from Geobacillus kaustophilus
2YS7	;	2.21	;	Crystal structure of GAR synthetase from Geobacillus kaustophilus
2YWR	;	1.77	;	Crystal structure of GAR transformylase from Aquifex aeolicus
2Y44	;	1.65	;	Crystal structure of GARP from Trypanosoma congolense
4QSG	;	2.7	;	Crystal structure of gas vesicle protein GvpF from Microcystis aeruginosa
5O9P	;	1.75	;	Crystal structure of Gas2 in complex with compound 10
5Y8V	;	2.61	;	Crystal structure of GAS41
5XTZ	;	2.105	;	Crystal structure of GAS41 YEATS bound to H3K27ac peptide
7EIF	;	1.58	;	Crystal structure of GAS41 YEATS domain
8IJ0	;	1.52	;	Crystal structure of GAS41 YEATS domain in complex with H3K9ac peptide
8I60	;	2.3	;	Crystal structure of GAS41 YEATS domain in complex with histone H3K27cr
5D4Q	;	2.39	;	Crystal structure of GASDALIE IgG1 Fc
5D6D	;	3.13	;	Crystal structure of GASDALIE IgG1 Fc in complex with FcgRIIIa
8UFO	;	1.46	;	Crystal Structure of Gastrointestinal HAstV VA1 capsid spike domain at 1.46 A resolution
7D40	;	1.67	;	Crystal structure of GATase subunit of Methanocaldococcus jannaschii GMP synthetase
5N9M	;	1.85	;	Crystal structure of GatD - a glutamine amidotransferase from Staphylococcus aureus involved in peptidoglycan amidation
1EO6	;	1.8	;	CRYSTAL STRUCTURE OF GATE-16
4M34	;	2.05	;	Crystal structure of gated-pore mutant D138H of second DNA-Binding protein under starvation from Mycobacterium smegmatis
4M32	;	1.86	;	Crystal structure of gated-pore mutant D138N of second DNA-Binding protein under starvation from Mycobacterium smegmatis
4M35	;	2.05	;	Crystal structure of gated-pore mutant H126/141D of second DNA-Binding protein under starvation from Mycobacterium smegmatis
4M33	;	2.22	;	Crystal structure of gated-pore mutant H141D of second DNA-Binding protein under starvation from Mycobacterium smegmatis
7YYG	;	1.95	;	Crystal structure of gatekeeper of type III secretion system in Bordetella BopN
5H6I	;	2.45	;	Crystal Structure of GBS CAMP Factor
5Y37	;	1.36	;	Crystal structure of GBS GAPDH
3O9O	;	2.0	;	Crystal Structure of GBS1074, an Esat-6 homologue from Group B Streptococcus
3PHS	;	1.8	;	Crystal Structure of GBS52, the minor pilin in gram-positive pathogen Streptococcus agalactiae
3R1E	;	0.972	;	Crystal structure of GC(8BrG)GCGGC duplex
3R1D	;	1.45	;	Crystal structure of GC(8BrG)GCGGCGGC duplex
3SG2	;	2.0	;	Crystal Structure of GCaMP2-T116V,D381Y
3SG3	;	2.1	;	Crystal Structure of GCaMP3-D380Y
3SG4	;	2.4	;	Crystal Structure of GCaMP3-D380Y, LP(linker 2)
3SG7	;	1.9	;	Crystal Structure of GCaMP3-KF(linker 1)
4E58	;	1.952	;	Crystal structure of GCC(LCG)CCGC duplex containing LNA residue
4E59	;	1.54	;	Crystal structure of GCCGCCGC duplex
8IE4	;	2.1	;	Crystal structure of GcCGT
3R1C	;	2.0531	;	Crystal structure of GCGGCGGC duplex
7CT6	;	2.1	;	Crystal structure of GCL from Deinococcus metallilatus
1PIQ	;	1.8	;	CRYSTAL STRUCTURE OF GCN4-PIQ, A TRIMERIC COILED COIL WITH BURIED POLAR RESIDUES
7BY1	;	1.8	;	Crystal structure of GCN5 PCAF N-terminal domain
2Q0Y	;	1.8	;	Crystal structure of GCN5-related N-acetyltransferase (YP_295895.1) from Ralstonia eutropha JMP134 at 1.80 A resolution
2OZG	;	2.0	;	Crystal structure of GCN5-related N-acetyltransferase (YP_325469.1) from Anabaena variabilis ATCC 29413 at 2.00 A resolution
8HEH	;	1.4	;	Crystal structure of GCN5-related N-acetyltransferase 05790
4MY0	;	2.101	;	Crystal Structure of GCN5-related N-acetyltransferase from Kribbella flavida
4MY3	;	2.57	;	Crystal Structure of GCN5-related N-acetyltransferase from Kribbella flavida
3TT2	;	2.73	;	Crystal Structure of GCN5-related N-Acetyltransferase from Sphaerobacter thermophilus
3G3S	;	1.8	;	Crystal structure of GCN5-related N-acetyltransferase-like protein (ZP_00874857) (ZP_00874857.1) from Streptococcus suis 89/1591 at 1.80 A resolution
6HQK	;	1.57	;	Crystal structure of GcoA F169A bound to guaiacol
6YCN	;	1.83	;	Crystal structure of GcoA F169A bound to o-vanillin
6HQQ	;	1.66	;	Crystal structure of GcoA F169A bound to syringol
6YCT	;	2.39	;	Crystal structure of GcoA F169A_T296S bound to p-vanillin
6HQL	;	1.49	;	Crystal structure of GcoA F169H bound to guaiacol
6HQR	;	1.79	;	Crystal structure of GcoA F169H bound to syringol
6HQM	;	1.85	;	Crystal structure of GcoA F169I bound to guaiacol
6HQN	;	1.87	;	Crystal structure of GcoA F169L bound to guaiacol
6HQO	;	1.7	;	Crystal structure of GcoA F169S bound to guaiacol
6YCO	;	1.8	;	Crystal structure of GcoA F169S bound to o-vanillin
6HQS	;	2.17	;	Crystal structure of GcoA F169S bound to syringol
6HQP	;	1.62	;	Crystal structure of GcoA F169V bound to guaiacol
6YCP	;	1.8	;	Crystal structure of GcoA F169V bound to o-vanillin
6HQT	;	1.85	;	Crystal structure of GcoA F169V bound to syringol
6YCH	;	1.88	;	Crystal structure of GcoA T296A bound to guaiacol
6YCK	;	1.8	;	Crystal structure of GcoA T296A bound to p-vanillin
6YCI	;	1.8	;	Crystal structure of GcoA T296G bound to guaiacol
6YCL	;	1.7	;	Crystal structure of GcoA T296G bound to p-vanillin
6YCJ	;	1.64	;	Crystal structure of GcoA T296S bound to guaiacol
6YCM	;	1.6	;	Crystal structure of GcoA T296S bound to p-vanillin
7DOH	;	1.45	;	Crystal Structure of GD-26 Fab in Complex with TD Peptide from Haloarcula Marismortui Bacteriorhodopsin I
4RHS	;	1.9211	;	Crystal structure of GD2 bound PltB
6PFM	;	2.84	;	Crystal structure of GDC-0927 bound to estrogen receptor alpha
5JI1	;	2.25	;	Crystal Structure of GDF8
3FUB	;	2.35	;	Crystal structure of GDNF-GFRalpha1 complex
8DQ9	;	2.8	;	Crystal structure of GDP bound 3-dehydroquinate dehydratase I from Klebsiella oxytoca
6G0Z	;	2.15	;	Crystal structure of GDP bound RbgA from S. aureus
6KX2	;	1.454	;	Crystal structure of GDP bound RhoA protein
1BWS	;	2.2	;	CRYSTAL STRUCTURE OF GDP-4-KETO-6-DEOXY-D-MANNOSE EPIMERASE/REDUCTASE FROM ESCHERICHIA COLI A KEY ENZYME IN THE BIOSYNTHESIS OF GDP-L-FUCOSE
3B8X	;	1.7	;	Crystal structure of GDP-4-keto-6-deoxymannose-3-dehydratase (ColD) H188N mutant with bound GDP-perosamine
2R0T	;	1.9	;	Crystal structure of GDP-4-keto-6-deoxymannose-3-dehydratase with a trapped PLP-glutamate geminal diamine
4NON	;	2.5	;	Crystal structure of GDP-bound A143S mutant of the S. thermophilus FeoB G-domain
5FG3	;	1.9	;	Crystal structure of GDP-bound aIF5B from Aeropyrum pernix
3WYA	;	2.35	;	Crystal structure of GDP-bound EF1alpha from Pyrococcus horikoshii
7E5E	;	1.95	;	Crystal structure of GDP-bound GNAS in complex with the cyclic peptide inhibitor GD20
2XTM	;	1.7	;	Crystal structure of GDP-bound human GIMAP2, amino acid residues 1- 234
2XTO	;	2.8	;	Crystal structure of GDP-bound human GIMAP2, amino acid residues 21- 260
6Z3E	;	2.80039	;	Crystal structure of GDP-bound human GIMAP5, amino acid residues 1-276
6AU6	;	1.7	;	Crystal structure of GDP-bound human GNAS R201C mutant
4OBE	;	1.24	;	Crystal Structure of GDP-bound Human KRas
6P0J	;	1.31	;	Crystal structure of GDP-bound human RalA
6P0O	;	1.54	;	Crystal structure of GDP-bound human RalA
6P0I	;	1.18	;	Crystal structure of GDP-bound human RalA in a covalent complex with aryl sulfonyl fluoride compounds.
6P0K	;	1.49	;	Crystal structure of GDP-bound human RalA in a covalent complex with aryl sulfonyl fluoride compounds.
6P0L	;	1.3	;	Crystal structure of GDP-bound human RalA in a covalent complex with aryl sulfonyl fluoride compounds.
6P0M	;	1.5	;	Crystal structure of GDP-bound human RalA in a covalent complex with aryl sulfonyl fluoride compounds.
6P0N	;	1.63	;	Crystal structure of GDP-bound human RalA in a covalent complex with aryl sulfonyl fluoride compounds.
6PQ3	;	1.75	;	Crystal structure of GDP-bound KRAS with ten residues long internal tandem duplication in the switch II region
2YWH	;	2.24	;	Crystal structure of GDP-bound LepA from Aquifex aeolicus
3W5J	;	1.932	;	Crystal structure of GDP-bound NfeoB from Gallionella capsiferriformans
3LX8	;	2.9	;	Crystal structure of GDP-bound NFeoB from S. thermophilus
6WGH	;	1.65	;	Crystal structure of GDP-bound NRAS with ten residues long internal tandem duplication in the switch II region
7EQ2	;	1.5509	;	Crystal structure of GDP-bound Rab1a-T75D
4LI0	;	3.3	;	Crystal structure of GDP-bound Rab8:GRAB
4LHY	;	3.1	;	Crystal structure of GDP-bound Rab8:Rabin8
7T1F	;	2.2	;	Crystal structure of GDP-bound T50I mutant of human KRAS4B
1RPN	;	2.15	;	Crystal Structure of GDP-D-mannose 4,6-dehydratase in complexes with GDP and NADPH
2Z1M	;	2.0	;	Crystal Structure of GDP-D-Mannose Dehydratase from Aquifex aeolicus VF5
2Z95	;	2.6	;	Crystal Structure of GDP-D-Mannose Dehydratase from Aquifex aeolicus VF5
2XKB	;	3.0	;	Crystal structure of GDP-form protofilaments of Bacillus thuringiensis serovar israelensis TubZ
8SKB	;	2.58	;	Crystal Structure of GDP-mannose 3,5 epimerase de Myrciaria dubia in complex with NAD
5IN4	;	1.6	;	Crystal Structure of GDP-mannose 4,6 dehydratase bound to a GDP-fucose based inhibitor
5IN5	;	1.9	;	Crystal Structure of GDP-mannose 4,6 dehydratase in complex with natural inhibitor GDP-Fucose
7KF3	;	2.35	;	Crystal structure of GDP-mannose 4,6-dehydratase from Brucella abortus (strain 2308) in complex with Guanosine-diphosphate-rhamnose
1N7H	;	1.8	;	Crystal Structure of GDP-mannose 4,6-dehydratase ternary complex with NADPH and GDP
8SG0	;	1.25	;	Crystal Structure of GDP-manose 3,5 epimerase de Myrciaria dubia in complex with substrate, product and NAD
3BN1	;	1.8	;	Crystal structure of GDP-perosamine synthase
7E16	;	2.62	;	crystal structure of GDSL esterase from Geobacillus thermodenitrificans
5XTU	;	1.38	;	Crystal Structure of GDSL Esterase of Photobacterium sp. J15
6WK5	;	3.5	;	Crystal structure of Gdx-Clo from Small Multidrug Resistance family of transporters
8TGY	;	2.18	;	Crystal structure of Gdx-Clo from Small Multidrug Resistance family of transporters in complex with guanylurea
6WK9	;	2.32	;	Crystal structure of Gdx-Clo from Small Multidrug Resistance family of transporters in complex with octylguanidinium
6WK8	;	2.53	;	Crystal structure of Gdx-Clo from Small Multidrug Resistance family of transporters in complex with phenylguanidinium
7SZT	;	2.32	;	Crystal structure of Gdx-Clo from Small Multidrug Resistance family of transporters in low pH (protonated state)
3NKG	;	2.0	;	Crystal Structure of GEBA250068378 from Sulfurospirillum deleyianum
6EKK	;	1.82	;	Crystal structure of GEF domain of DENND 1A in complex with Rab GTPase Rab35-GDP bound state.
1QIB	;	2.8	;	CRYSTAL STRUCTURE OF GELATINASE A CATALYTIC DOMAIN
2FF6	;	2.05	;	Crystal structure of Gelsolin domain 1:ciboulot domain 2 hybrid in complex with actin
2FF3	;	2.0	;	Crystal structure of Gelsolin domain 1:N-wasp V2 motif hybrid in complex with actin
1RGI	;	3.0	;	Crystal structure of gelsolin domains G1-G3 bound to actin
6LJE	;	1.4	;	Crystal structure of gelsolin G3 domain (calcium and magnesium condition)
6LJF	;	1.5	;	Crystal structure of gelsolin G3 domain (calcium condition)
5L2K	;	3.2	;	Crystal structure of GEM42 TCR-CD1b-GMM complex
5C9N	;	2.2	;	Crystal structure of GEMC1 coiled-coil domain
5TEE	;	1.65	;	Crystal structure of Gemin5 WD40 repeats in apo form
5TEF	;	1.95	;	Crystal structure of Gemin5 WD40 repeats in complex with m7GpppG
1UII	;	2.0	;	Crystal structure of Geminin coiled-coil domain
5Z8A	;	1.398	;	Crystal structure of GenB1 from Micromonospora echinospora in complex with JI-20A and PLP (external aldimine)
5Z83	;	1.7	;	Crystal structure of GenB1 from Micromonospora echinospora in complex with PLP (internal aldimine)
7LM0	;	2.09	;	Crystal structure of GenB3 in complex with PLP
7LLD	;	1.4	;	Crystal structure of GenB4 in complex with external aldimine of PLP-sisomicin
7LLE	;	1.704	;	Crystal structure of GenB4 in complex with PLP
6NOR	;	2.402	;	Crystal structure of GenD2 from gentamicin A biosynthesis in complex with NAD
3H2T	;	3.2	;	Crystal structure of gene product 6, baseplate protein of bacteriophage T4
3GAN	;	2.0	;	Crystal structure of gene product from Arabidopsis thaliana At3g22680 with bound suramin
1VJH	;	2.1	;	Crystal structure of gene product of At1g24000 from Arabidopsis thaliana
2R6U	;	1.5	;	Crystal structure of gene product RHA04853 from Rhodococcus sp. RHA1
2OX6	;	1.7	;	Crystal structure of gene product SO3848 from Shewanella oneidensis MR-1
1PT5	;	2.0	;	Crystal structure of gene yfdW of E. coli
2FHQ	;	1.87	;	Crystal Structure of General Stress Protein from Bacteroides thetaiotaomicron
6RO0	;	2.13	;	CRYSTAL STRUCTURE OF GENETICALLY DETOXIFIED PERTUSSIS TOXIN GDPT.
5NDG	;	3.7	;	Crystal structure of geneticin (G418) bound to the yeast 80S ribosome
1MWL	;	2.4	;	Crystal structure of geneticin bound to the eubacterial 16S rRNA A site
4K32	;	2.5	;	Crystal structure of geneticin bound to the leishmanial rRNA A-site
4U4O	;	3.6	;	Crystal structure of Geneticin bound to the yeast 80S ribosome
4XKB	;	1.501	;	Crystal Structure of GENOMES UNCOUPLED 4 (GUN4) in Complex with Deuteroporphyrin IX
4XKC	;	2.0	;	Crystal Structure of GENOMES UNCOUPLED 4 (GUN4) in Complex with Magnesium Deuteroporphyrin IX
2P7K	;	3.3	;	Crystal structure of genomically encoded fosfomycin resistance protein, FosX, from Listeria monocytogenes (hexagonal form)
2P7O	;	1.44	;	Crystal structure of genomically encoded fosfomycin resistance protein, FosX, from Listeria monocytogenes (tetragonal form)
2P7P	;	2.17	;	Crystal structure of genomically encoded fosfomycin resistance protein, FosX, from Listeria monocytogenes complexed with MN(II) and sulfate ion
1T1J	;	1.7	;	Crystal structure of genomics APC5043
1YOC	;	1.7	;	Crystal Structure of genomics APC5556
1YNB	;	1.76	;	crystal structure of genomics APC5600
5OBM	;	3.4	;	Crystal structure of Gentamicin bound to the yeast 80S ribosome
4B52	;	1.76	;	Crystal structure of Gentlyase, the neutral metalloprotease of Paenibacillus polymyxa
4GER	;	1.59	;	Crystal structure of Gentlyase, the neutral metalloprotease of Paenibacillus polymyxa
3A5Y	;	1.9	;	Crystal structure of GenX from Escherichia coli in complex with lysyladenylate analog
5YTL	;	1.401	;	Crystal structure of Geobacillus thermodenitrificans copper-containing nitrite reductase determined with an anaerobically manipulated crystal
2YNQ	;	2.4	;	Crystal Structure of Geobacillus thermodenitrificans EssB extracellular fragment
5H93	;	2.176	;	Crystal structure of Geobacter metallireducens SMUG1
5H98	;	2.04	;	Crystal structure of Geobacter metallireducens SMUG1
5H99	;	2.5	;	Crystal structure of Geobacter metallireducens SMUG1 mutant N58D
5H9I	;	1.501	;	Crystal structure of Geobacter metallireducens SMUG1 with xanthine
3DP5	;	1.86	;	Crystal structure of Geobacter sulfurreducens OmcF with N-terminal Strep-tag II
5AVP	;	2.9	;	Crystal structure of Geodermatophilus obscurus L-ribose isomerase
5TWA	;	1.85	;	Crystal structure of Geodia cydonium BHP2 in complex with Lubomirskia baicalensis Bak-2
3QWM	;	2.39	;	Crystal Structure of GEP100, the plextrin homology domain of IQ motif and SEC7 domain-containing protein 1 isoform a
6FGD	;	1.5	;	Crystal structure of Gephyrin E domain in complex with Artemether
6FGC	;	1.5	;	Crystal structure of Gephyrin E domain in complex with Artesunate
2FU3	;	2.7	;	Crystal structure of gephyrin E-domain
5GP0	;	1.702	;	Crystal structure of geraniol-NUDX1 complex
1WMW	;	1.55	;	Crystal structure of geranulgeranyl diphosphate synthase from Thermus thermophilus
3VC2	;	2.046	;	Crystal structure of geranyl diphosphate C-methyltransferase from Streptomyces coelicolor A3(2) in complex with Mg2+, geranyl diphosphate, and S-adenosyl-L-homocysteine
3VC1	;	1.82	;	Crystal structure of geranyl diphosphate C-methyltransferase from Streptomyces coelicolor A3(2) in complex with Mg2+, geranyl-S-thiolodiphosphate, and S-adenosyl-L-homocysteine
3QKC	;	2.2	;	CRYSTAL STRUCTURE OF geranyl diphosphate synthase small subunit from Antirrhinum majus
5E8H	;	2.3	;	Crystal structure of geranylfarnesyl pyrophosphate synthases 2 from Arabidopsis thaliana
4LFG	;	1.76	;	Crystal structure of geranylgeranyl diphosphate synthase sub1274 (target efi-509455) from streptococcus uberis 0140j with bound magnesium and isopentyl diphosphate, fully liganded complex;
4LFE	;	1.95	;	Crystal structure of geranylgeranyl diphosphate synthase sub1274 (target efi-509455) from streptococcus uberis 0140j with bound magnesium and isopentyl diphosphate, partially liganded complex;
6KD7	;	2.0	;	Crystal structure of geranylgeranyl pyrophosphate synthase
5E8L	;	2.807	;	Crystal structure of geranylgeranyl pyrophosphate synthase 11 from Arabidopsis thaliana
3RMG	;	2.3	;	Crystal structure of geranylgeranyl pyrophosphate synthase from bacteroides thetaiotaomicron
3LMD	;	1.9	;	Crystal structure of geranylgeranyl pyrophosphate synthase from corynebacterium glutamicum atcc 13032
3Q2Q	;	1.9	;	Crystal structure of geranylgeranyl pyrophosphate synthase from Corynebacterium glutamicum complexed with calcium and isoprenyl diphosphate
3QQV	;	2.0	;	Crystal structure of geranylgeranyl pyrophosphate synthase from corynebacterium glutamicum complexed with isoprenyl diphosphate and magnesium
3M9U	;	1.77	;	Crystal structure of geranylgeranyl pyrophosphate synthase from lactobacillus brevis atcc 367
3N3D	;	2.4	;	Crystal structure of geranylgeranyl pyrophosphate synthase from lactobacillus brevis atcc 367
3PKO	;	1.98	;	Crystal structure of geranylgeranyl pyrophosphate synthase from lactobacillus brevis atcc 367 complexed with citrate
3PDE	;	1.75	;	Crystal structure of geranylgeranyl pyrophosphate synthase from Lactobacillus brevis atcc 367 complexed with isoprenyl diphosphate and magnesium
1WY0	;	2.2	;	Crystal structure of geranylgeranyl pyrophosphate synthetase from Pyrococcus horikoshii Ot3
4F38	;	2.8	;	Crystal structure of geranylgeranylated RhoA in complex with RhoGDI in its active GPPNHP-bound form
3LLW	;	2.3	;	Crystal structure of geranyltransferase from helicobacter pylori 26695
3Q1O	;	2.4	;	Crystal structure of geranyltransferase from helicobacter pylori complexed with magnesium and isoprenyl diphosphate
3LOM	;	2.3	;	CRYSTAL STRUCTURE OF GERANYLTRANSFERASE FROM Legionella pneumophila
2FTZ	;	1.9	;	Crystal structure of Geranyltranstransferase (EC 2.5.1.10) (tm0161) from THERMOTOGA MARITIMA at 1.90 A resolution
5F7E	;	1.9	;	Crystal structure of germ-line precursor of 3BNC60 Fab
4JDV	;	1.65	;	Crystal structure of germ-line precursor of NIH45-46 Fab
5I1U	;	1.5	;	Crystal structure of germacradien-4-ol synthase from Streptomyces citricolor
1FI2	;	1.6	;	CRYSTAL STRUCTURE OF GERMIN (OXALATE OXIDASE)
7C4X	;	2.5	;	Crystal structure of germination protease from the spore-forming bacterium Paenisporosarcina sp. TG-20 in its inactive form
4BH8	;	2.4	;	CRYSTAL STRUCTURE OF GERMLINE ANTIBODY 36-65 IN COMPLEX WITH PEPTIDE GDPRPSYISHLL
4BH7	;	2.89	;	CRYSTAL STRUCTURE OF GERMLINE ANTIBODY 36-65 IN COMPLEX WITH PEPTIDE PPYPAWHAPGNI
4FQQ	;	2.42	;	Crystal Structure of Germline Antibody PGT121-GL Fab
4NPY	;	1.796	;	Crystal structure of germline Fab PGT121, a putative precursor of the broadly reactive and potent HIV-1 neutralizing antibody
3V3R	;	1.898	;	Crystal Structure of GES-11
3TSG	;	1.9	;	Crystal structure of GES-14
3V3S	;	1.9	;	Crystal structure of GES-18
6Q35	;	1.4	;	Crystal structure of GES-5 beta-lactamase in complex with boronic inhibitor cpd 3
4GNU	;	1.09	;	Crystal structure of GES-5 carbapenemase
6TS9	;	1.55	;	Crystal structure of GES-5 carbapenemase
3H84	;	2.3	;	Crystal structure of GET3
3UG6	;	3.3	;	Crystal Structure of Get3 from Methanocaldococcus jannaschii
3UG7	;	2.901	;	Crystal Structure of Get3 from Methanocaldococcus jannaschii
4OGS	;	2.21	;	Crystal structure of GFP S205A/T203V at 2.2 A resolution
4GF6	;	1.1	;	crystal structure of GFP with cuprum bound at the Incorporated metal Chelating Amino Acid PYZ151
6RUL	;	2.2	;	Crystal structure of GFP-LAMA-F98 - a GFP enhancer nanobody with cpDHFR insertion and TMP and NADPH
6RUM	;	1.6	;	Crystal structure of GFP-LAMA-G97 - a GFP enhancer nanobody with cpDHFR insertion and TMP and NADPH
3LVC	;	1.14	;	Crystal structure of GFP-like protein aceGFP_G222E (A. coerulescens). Colorless form.
3LVD	;	1.751	;	Crystal structure of GFP-like protein aceGFP_G222E (A. coerulescens). UV-photoconverted green form.
4Z4K	;	2.8	;	Crystal structure of GFP-TAX1BP1 UBZ1+2 domain fusion protein
4Z4M	;	2.15	;	Crystal structure of GFP-TAX1BP1 UBZ2 domain fusion protein
4GES	;	1.23	;	crystal structure of GFP-TYR151PYZ with an unnatural amino acid incorporation
3VHT	;	2.4	;	Crystal structure of GFP-Wrnip1 UBZ domain fusion protein in complex with ubiquitin
6LR7	;	1.67	;	Crystal structure of GFPuv complexed with the nanobody LaG16 at 1.67 Angstron resolution
1J2J	;	1.6	;	Crystal structure of GGA1 GAT N-terminal region in complex with ARF1 GTP form
1P4U	;	2.2	;	CRYSTAL STRUCTURE OF GGA3 GAE DOMAIN IN COMPLEX WITH RABAPTIN-5 PEPTIDE
1WR6	;	2.6	;	Crystal structure of GGA3 GAT domain in complex with ubiquitin
1IH2	;	2.8	;	Crystal Structure of GGBr5CGBr5CC
6L7H	;	1.8	;	crystal structure of GgCGT in complex with UDP and Nothofagin
6L5Q	;	2.894	;	crystal structure of GgCGT in complex with UDP-Gal
6L5P	;	2.603	;	crystal structure of GgCGT in complex with UDP-Glu
6L5R	;	2.89	;	crystal structure of GgCGT in complex with UDP-Glu
6L5S	;	1.914	;	crystal structure of GgCGT in complex with UDP-Glu
4URQ	;	2.5	;	Crystal Structure of GGDEF domain (I site mutant) from T.maritima
4URS	;	2.27	;	Crystal Structure of GGDEF domain from T.maritima
4URG	;	1.9	;	Crystal Structure of GGDEF domain from T.maritima (active-like dimer)
4ZVE	;	1.2	;	Crystal structure of GGDEF domain of the E. coli DosC - form I (apo-form)
4ZVF	;	1.15	;	Crystal structure of GGDEF domain of the E. coli DosC - form II (GTP-alpha-S-bound)
4ZVG	;	2.2	;	Crystal structure of GGDEF domain of the E. coli DosC - form III
4ZVH	;	3.301	;	Crystal structure of GGDEF domain of the E. coli DosC - form IV
6O60	;	2.503	;	Crystal structure of GGTase3-FBXL2-SKP1 complex
3CQL	;	1.5	;	Crystal Structure of GH family 19 chitinase from Carica papaya
7VTL	;	2.07038	;	Crystal structure of GH family 64 beta-1,3-glucanase complexed with Laminaritriose
5H9X	;	1.91	;	Crystal structure of GH family 64 laminaripentaose-producing beta-1,3-glucanase from Paenibacillus barengoltzii
5H9Y	;	1.969	;	Crystal structure of GH family 64 laminaripentaose-producing beta-1,3-glucanase from Paenibacillus barengoltzii complexed with laminarihexaose.
5XC2	;	2.7	;	Crystal structure of GH family 81 beta-1,3-glucanase from Rhizomucr miehei complexed with laminarihexaose
5XBZ	;	2.7	;	Crystal structure of GH family 81 beta-1,3-glucanase from Rhizomucr miehei complexed with laminaripentaose
5U0H	;	1.7	;	Crystal structure of GH family 9 endoglucanase J30
3WH5	;	1.6	;	Crystal structure of GH1 beta-glucosidase Td2F2
3WH6	;	1.6	;	Crystal structure of GH1 beta-glucosidase Td2F2 glucose complex
3WH8	;	1.9	;	Crystal structure of GH1 beta-glucosidase Td2F2 isofagomine complex
3WH7	;	1.1	;	Crystal structure of GH1 beta-glucosidase Td2F2 L-fucose complex
5AYB	;	1.8	;	Crystal structure of GH1 Beta-Glucosidase TD2F2 N223G mutant
5AYI	;	1.85	;	Crystal structure of GH1 Beta-glucosidase TD2F2 N223Q mutant
4PMZ	;	1.401	;	Crystal structure of GH10 endo-b-1,4-xylanase (XynB) from Xanthomonas axonopodis pv citri complexed with xylobiose
4PMY	;	1.601	;	Crystal structure of GH10 endo-b-1,4-xylanase (XynB) from Xanthomonas axonopodis pv citri complexed with xylose
4PN2	;	1.42	;	Crystal structure of GH10 endo-b-1,4-xylanase (XynB) from Xanthomonas axonopodis pv citri complexed with xylotriose
4PMX	;	1.304	;	Crystal structure of GH10 endo-b-1,4-xylanase (XynB) from Xanthomonas axonopodis pv citri in the native form
6JDT	;	1.68	;	Crystal structure of GH10 family xylanase XynAF1 from Aspergillus fumigatus Z5
5XZU	;	1.7	;	Crystal structure of GH10 xylanase from Bispora. sp MEY-1 with xylobiose
5XZO	;	1.5	;	Crystal structure of GH10 xylanase XYL10C from Bispora. sp MEY-1
8IH0	;	1.5	;	Crystal structure of GH11 from Thermoanaerobacterium saccharolyticum
8X1D	;	1.95	;	Crystal structure of GH11 from Thermoanaerobacterium saccharolyticum (pH8.5)
6NPS	;	1.99	;	Crystal structure of GH115 enzyme AxyAgu115A from Amphibacillus xylanus
6M5A	;	1.85	;	Crystal structure of GH121 beta-L-arabinobiosidase HypBA2 from Bifidobacterium longum
6RQK	;	1.85	;	Crystal structure of GH125 1,6-alpha-mannosidase from Clostridium perfringens in complex with mannoimidazole
5M7I	;	2.1	;	Crystal structure of GH125 1,6-alpha-mannosidase mutant from Clostridium perfringens in complex with 1,6-alpha-mannobiose
5M7Y	;	1.55	;	Crystal structure of GH125 1,6-alpha-mannosidase mutant from Clostridium perfringens in complex with 1,6-alpha-mannotriose
3WKX	;	2.0	;	Crystal structure of GH127 beta-L-arabinofuranosidase HypBA1 from Bifidobacterium longum arabinose complex form
3WKW	;	2.2	;	Crystal structure of GH127 beta-L-arabinofuranosidase HypBA1 from Bifidobacterium longum ligand free form
6KQT	;	2.0	;	Crystal Structure of GH136 lacto-N-biosidase from Eubacterium ramulus - native protein
6KQS	;	1.4	;	Crystal Structure of GH136 lacto-N-biosidase from Eubacterium ramulus - selenomethionine derivative
8K7Y	;	1.7	;	Crystal structure of GH146 beta-L-arabinofuranosidase Bll3HypBA1 (amino acids 380-1051), ligand-free form
8K7X	;	1.75	;	Crystal structure of GH146 beta-L-arabinofuranosidase Bll3HypBA1 (amino acids 380-1223) in complex with Tris
4MNL	;	1.6	;	Crystal Structure of GH18 Chitinase (G77W/E119Q mutant) from Cycas revoluta in complex with (GlcNAc)4
4MNM	;	1.8	;	Crystal Structure of GH18 Chitinase (G77W/E119Q mutant) from Cycas revoluta in complex with (GlcNAc)4
4MNJ	;	1.58	;	Crystal Structure of GH18 Chitinase from Cycad, Cycas revoluta
4MNK	;	1.29	;	Crystal Structure of GH18 Chitinase from Cycas revoluta in complex with (GlcNAc)3
7F88	;	1.6	;	Crystal structure of GH19 chitinase lacking the third loop structure
6NCX	;	2.25	;	Crystal structure of GH2 beta-galacturonidase from Eisenbergiella tayi bound to galacturonate
6EZT	;	2.6	;	Crystal structure of GH20 Exo beta-N-Acetylglucosaminidase D437A inactive mutant from Vibrio harveyi
6EZR	;	2.37	;	Crystal structure of GH20 Exo beta-N-Acetylglucosaminidase from Vibrio harveyi
6EZS	;	2.5	;	Crystal structure of GH20 Exo beta-N-Acetylglucosaminidase from Vibrio harveyi in complex with N-acetylglucosamine
6K35	;	2.36	;	Crystal structure of GH20 exo beta-N-acetylglucosaminidase from Vibrio harveyi in complex with NAG-thiazoline
4NI3	;	1.3993	;	Crystal Structure of GH29 family alpha-L-fucosidase from Fusarium graminearum in the closed form
4PSP	;	1.561	;	Crystal Structure of GH29 family alpha-L-fucosidase from Fusarium graminearum in the open form
5XXL	;	1.6	;	Crystal structure of GH3 beta-glucosidase from Bacteroides thetaiotaomicron
5XXM	;	1.7	;	Crystal structure of GH3 beta-glucosidase from Bacteroides thetaiotaomicron in complex with gluconolactone
7VI6	;	2.0	;	Crystal structure of GH3 beta-N-acetylhexosaminidase Amuc_2109 from Akkermansia muciniphila
7VI7	;	2.0	;	Crystal structure of GH3 beta-N-acetylhexosaminidase Amuc_2109 from Akkermansia muciniphila in complex with GlcNAc
4L39	;	2.81	;	Crystal structure of GH3.12 from Arabidopsis thaliana in complex with AMPCPP and salicylate
4EQL	;	1.8	;	Crystal Structure of GH3.12 in complex with AMP and salicylate
4EWV	;	2.897	;	Crystal structure of GH3.12 in complex with AMPCPP
5KOD	;	2.202	;	Crystal Structure of GH3.5 Acyl Acid Amido Synthetase from Arabidopsis thaliana
7VKA	;	2.401	;	Crystal Structure of GH3.6 in complex with an inhibitor
7NCX	;	1.36	;	Crystal structure of GH30 (double mutant EE) from Thermothelomyces thermophila.
7O0E	;	1.85	;	Crystal structure of GH30 (mutant E188A) complexed with aldotriuronic acid from Thermothelomyces thermophila.
6IUJ	;	2.25	;	Crystal structure of GH30 xylanase B from Talaromyces cellulolyticus
6KRL	;	1.601	;	Crystal structure of GH30 xylanase B from Talaromyces cellulolyticus expressed by Pichia pastoris
6KRN	;	1.653	;	Crystal structure of GH30 xylanase B from Talaromyces cellulolyticus expressed by Pichia pastoris in complex with aldotriuronic acid
5ZN6	;	1.8	;	Crystal structure of GH31 alpha-xylosidase from a soil metagenome
5ZN7	;	2.1	;	Crystal structure of GH31 alpha-xylosidase from a soil metagenome complexed with xylose
4FNU	;	3.6	;	Crystal structure of GH36 alpha-galactosidase AgaA A355E D478A from Geobacillus stearothermophilus in complex with stachyose
4FNT	;	2.6	;	Crystal structure of GH36 alpha-galactosidase AgaA A355E D548N from Geobacillus stearothermophilus in complex with raffinose
4FNP	;	2.803	;	Crystal structure of GH36 alpha-galactosidase AgaA A355E from Geobacillus stearothermophilus
4FNS	;	2.6	;	Crystal structure of GH36 alpha-galactosidase AgaA A355E from Geobacillus stearothermophilus in complex with 1-deoxygalactonojirimycin
4FNR	;	3.2	;	Crystal structure of GH36 alpha-galactosidase AgaA from Geobacillus stearothermophilus
4FNQ	;	1.8	;	Crystal structure of GH36 alpha-galactosidase AgaB from Geobacillus stearothermophilus
8IBS	;	1.9	;	Crystal structure of GH42 beta-galactosidase BiBga42A from Bifidobacterium longum subspecies infantis E160A/E318A mutant in complex with galactose
8IBT	;	2.2	;	Crystal structure of GH42 beta-galactosidase BiBga42A from Bifidobacterium longum subspecies infantis E318S mutant in complex with lacto-N-tetraose
8IBR	;	1.7	;	Crystal structure of GH42 beta-galactosidase BiBga42A from Bifidobacterium longum subspecies infantis in complex with glycerol
6XN0	;	1.709	;	Crystal structure of GH43_1 enzyme from Xanthomonas citri
5XC4	;	1.42	;	Crystal structure of GH45 endoglucanase EG27II at pH4.0, in complex with cellobiose
5XC8	;	1.45	;	Crystal structure of GH45 endoglucanase EG27II at pH5.5, in complex with cellobiose
5XC9	;	1.28	;	Crystal structure of GH45 endoglucanase EG27II at pH8.0, in complex with cellobiose
5XCA	;	1.35	;	Crystal structure of GH45 endoglucanase EG27II D137A mutant in complex with cellobiose
5XBU	;	1.0	;	Crystal structure of GH45 endoglucanase EG27II in apo-form
5XBX	;	1.04	;	Crystal structure of GH45 endoglucanase EG27II in complex with cellobiose
8B5M	;	0.97	;	Crystal structure of GH47 alpha-1,2-mannosidase from Caulobacter K31 strain in complex with cyclosulfamidate inhibitor
5WU7	;	2.31	;	Crystal structure of GH57-type branching enzyme from hyperthermophilic archaeon Pyrococcus horikoshii
7LR1	;	1.8	;	Crystal structure of GH5_18 from Bifidobacterium longum subsp. longum ATCC 55813
7LR2	;	2.4	;	Crystal structure of GH5_18 from Bifidobacterium longum subsp. longum ATCC 55813 in complex with GlcNAc
7LR7	;	1.95	;	Crystal structure of GH5_18 from Streptomyces cattleya in complex with GlcNAc
7LR6	;	2.3	;	Crystal structure of GH5_18-E140A from Bifidobacterium longum subsp. longum ATCC 55813 in complex with Manb1-4GlcNAc
7LR8	;	1.6	;	Crystal structure of GH5_18-E153A from Streptomyces cattleya in complex with Manb1-4GlcNAc
4PVA	;	1.23	;	Crystal structure of GH62 hydrolase from thermophilic fungus Scytalidium thermophilum
4PVI	;	1.48	;	Crystal structure of GH62 hydrolase in complex with xylotriose
4WVB	;	1.77	;	Crystal structure of GH63 mannosylglycerate hydrolase from Thermus thermophilus HB8 in complex with glucose
4WVA	;	1.67	;	Crystal structure of GH63 mannosylglycerate hydrolase from Thermus thermophilus HB8 in complex with Tris
4WVC	;	2.1	;	Crystal structure of GH63 mannosylglycerate hydrolase from Thermus thermophilus HB8 in complex with Tris and D-glycerate
7FE3	;	1.54	;	Crystal structure of GH65 alpha-1,2-glucosidase from Flavobacterium johnsoniae
7FE4	;	1.4	;	Crystal structure of GH65 alpha-1,2-glucosidase from Flavobacterium johnsoniae in complex with glucose
8IUC	;	1.56	;	Crystal structure of GH65 alpha-1,2-glucosidase from Flavobacterium johnsoniae in complex with isomaltose
8IU8	;	1.85	;	Crystal structure of GH66 endodextranase from Flavobacterium johnsoniae
8IU9	;	1.8	;	Crystal structure of GH66 endodextranase from Flavobacterium johnsoniae in complex with glucose
8IUA	;	1.8	;	Crystal structure of GH66 endodextranase from Flavobacterium johnsoniae in complex with isomaltose
8IUB	;	1.18	;	Crystal structure of GH66 endodextranase from Flavobacterium johnsoniae in complex with isomaltotriose
2OKX	;	1.9	;	Crystal structure of GH78 family rhamnosidase of Bacillus SP. GL1 AT 1.9 A
5B4S	;	1.75	;	Crystal Structure of GH80 chitosanase from Mitsuaria chitosanitabida
5DGQ	;	1.9	;	Crystal structure of GH9 exo-beta-D-glucosaminidase PBPRA0520
5DGR	;	1.9	;	Crystal structure of GH9 exo-beta-D-glucosaminidase PBPRA0520, glucosamine complex
7FE1	;	1.72	;	Crystal structure of GH92 alpha-1,2-mannosidase from Enterococcus faecalis ATCC 10100 in complex with methyl alpha-1,2-C-mannobioside
4ZQ0	;	3.1	;	crystal structure of Giardia 14-3-3 in complex with the phosphopeptide A8Ap
1DQN	;	1.75	;	CRYSTAL STRUCTURE OF GIARDIA GUANINE PHOSPHORIBOSYLTRANSFERASE COMPLEXED WITH A TRANSITION STATE ANALOGUE
1DQP	;	1.75	;	CRYSTAL STRUCTURE OF GIARDIA GUANINE PHOSPHORIBOSYLTRANSFERASE COMPLEXED WITH IMMUCILLING
4Y66	;	3.2	;	Crystal structure of Giardia lamblia Hop2-Mnd1 complex
6KU3	;	2.15	;	Crystal structure of gibberellin 2-oxidase3 (GA2ox3)in rice
7EKD	;	1.899	;	Crystal structure of gibberellin 3-oxidase 2 (GA3ox2) in rice
7SLZ	;	1.97	;	CRYSTAL STRUCTURE OF GID4 IN COMPLEX WITH BPF023596
8V1P	;	2.21	;	CRYSTAL STRUCTURE OF GID4 IN COMPLEX WITH UBF9092
3CP8	;	3.2	;	Crystal structure of GidA from Chlorobium tepidum
3CP2	;	2.9	;	Crystal structure of GidA from E. coli
7WA4	;	3.5	;	Crystal structure of GIGANTEA in complex with LKP2
4Z4S	;	1.8	;	Crystal structure of GII.10 P domain in complex with 150mM fucose
4Z4V	;	1.8	;	Crystal structure of GII.10 P domain in complex with 19mM fucose
5HZB	;	1.553	;	Crystal structure of GII.10 P domain in complex with 2-fucosyllactose (2'FL)
5HZA	;	1.35	;	Crystal structure of GII.10 P domain in complex with 3-fucosyllactose (3 FL)
4Z4R	;	1.801	;	Crystal structure of GII.10 P domain in complex with 300mM fucose
4Z4Z	;	1.801	;	Crystal structure of GII.10 P domain in complex with 30mM B antigen (trisaccharide)
4Z4U	;	1.89	;	Crystal structure of GII.10 P domain in complex with 37.5mM fucose
4Z4W	;	1.8	;	Crystal structure of GII.10 P domain in complex with 4.7mM fucose
4Z4Y	;	1.797	;	Crystal structure of GII.10 P domain in complex with 7.5mM B antigen (trisaccharide)
4Z4T	;	1.8	;	Crystal structure of GII.10 P domain in complex with 75mM fucose
5BSX	;	1.78	;	Crystal structure of GII.10 P domain in complex with disinfectant Puregreen24
5BSY	;	1.6	;	Crystal structure of GII.10 P domain in complex with lemon juice
6N81	;	2.579	;	Crystal structure of GII.4 2002 norovirus P domain in complex with cross-reactive human antibody A1227
6N8D	;	3.1	;	Crystal structure of GII.4 2002 norovirus P domain in complex with neutralizing human antibody A1431
6EWB	;	2.78	;	Crystal structure of GII.4 UNSW 2012 P domain in complex with Fab 10E9
6N7O	;	1.7	;	Crystal structure of GIL01 gp7
3A2E	;	2.38	;	Crystal structure of ginkbilobin-2, the novel antifungal protein from Ginkgo biloba seeds
7VCM	;	1.85	;	crystal structure of GINKO1
4REH	;	1.5	;	Crystal structure of ginseng major latex-like protein 151 (GLP) from Panax ginseng. (crystal-1)
4REI	;	1.49	;	Crystal structure of ginseng major latex-like protein 151 (GLP) from Panax ginseng. (crystal-2)
4REJ	;	1.69	;	Crystal structure of ginseng major latex-like protein 151 (GLP) from Panax ginseng. (crystal-3)
5V6B	;	1.9	;	Crystal structure of GIPC1
6JMT	;	2.8	;	Crystal structure of GIT/PIX complex
6IUH	;	1.8	;	Crystal structure of GIT1 PBD domain in complex with Liprin-alpha2
6IUI	;	2.6	;	Crystal structure of GIT1 PBD domain in complex with Paxillin LD4 motif
6JMU	;	2.0	;	Crystal structure of GIT1/Paxillin complex
7LAW	;	2.752	;	crystal structure of GITR complex with GITR-L
4G4F	;	1.847	;	Crystal structure of GITRL from Bushbaby
2P17	;	1.52	;	Crystal structure of GK1651 from Geobacillus kaustophilus
2EJ5	;	2.0	;	Crystal structure of GK2038 protein (enoyl-CoA hydratase subunit II) from Geobacillus kaustophilus
3TN3	;	1.6	;	Crystal structure of GkaP from Geobacillus kaustophilus HTA426
3TN4	;	1.5	;	Crystal structure of GkaP mutant G209D from Geobacillus kaustophilus HTA426
3TNB	;	1.6	;	Crystal structure of GkaP mutant G209D/R230H from Geobacillus kaustophilus HTA426
3TN6	;	1.6	;	Crystal structure of GkaP mutant R230H from Geobacillus kaustophilus HTA426
3TN5	;	1.75	;	Crystal structure of GkaP mutant Y99L from Geobacillus kaustophilus HTA426
6VRQ	;	2.57	;	Crystal structure of gl12A21 Fab in complex with anti-idiotypic iv12 Fab
8X6V	;	1.797	;	Crystal structure of GlacPETase
7QWJ	;	1.65	;	Crystal structure of Glc7 phosphatase
8A8F	;	1.85	;	Crystal structure of Glc7 phosphatase in complex with the regulatory region of Ref2
6AKZ	;	1.69	;	Crystal structure of GlcNAc Inducible Gene 2, GIG2 (DUF1479) from Candida albicans
3RIO	;	1.99	;	Crystal structure of GlcT CAT-PRDI
1OXS	;	1.65	;	Crystal structure of GlcV, the ABC-ATPase of the glucose ABC transporter from Sulfolobus solfataricus
1OXT	;	2.1	;	Crystal structure of GlcV, the ABC-ATPase of the glucose ABC transporter from Sulfolobus solfataricus
1OXU	;	2.1	;	Crystal structure of GlcV, the ABC-ATPase of the glucose ABC transporter from Sulfolobus solfataricus
1OXV	;	1.95	;	Crystal structure of GlcV, the ABC-ATPase of the glucose ABC transporter from Sulfolobus solfataricus
1OXX	;	1.45	;	Crystal structure of GlcV, the ABC-ATPase of the glucose ABC transporter from Sulfolobus solfataricus
4FIX	;	2.45	;	Crystal Structure of GlfT2
4FIY	;	3.1	;	Crystal Structure of GlfT2 Complexed with UDP
1VKK	;	1.35	;	Crystal structure of Glia maturation factor-gamma (GMFG) from Mus musculus at 1.50 A resolution
5J0Z	;	3.25	;	Crystal structure of GLIC in complex with DHA
4IRE	;	3.19	;	Crystal structure of GLIC with mutations at the loop C region
4NTC	;	1.9	;	Crystal structure of GliT
6GYZ	;	3.0	;	Crystal structure of GlmM from Staphylococcus aureus
2W0V	;	1.99	;	Crystal structure of Glmu from Haemophilus influenzae in complex with quinazoline inhibitor 1
2W0W	;	2.59	;	Crystal structure of Glmu from Haemophilus influenzae in complex with quinazoline inhibitor 2
3SPT	;	2.33	;	Crystal structure of GlmU from Mycobacterium tuberculosis in complex with ACETYL COENZYME A and URIDINE-DIPHOSPHATE-N-ACETYLGLUCOSAMINE
3ST8	;	1.98	;	Crystal structure of GlmU from Mycobacterium tuberculosis in complex with COENZYME A, GLUCOSAMINE 1-PHOSPHATE and URIDINE-DIPHOSPHATE-N-ACETYLGLUCOSAMINE
4HCQ	;	2.6	;	Crystal structure of GLMU from mycobacterium tuberculosis in complex with glucosamine-1-phosphate
3D8V	;	2.55	;	Crystal structure of GlmU from Mycobacterium tuberculosis in complex with uridine-diphosphate-N-acetylglucosamine
4G3S	;	2.04	;	Crystal structure of GlmU from Mycobacterium tuberculosis in complex with uridine-diphosphate-n-acetylglucosamine and pyrophosphate Snapshot 2
3DJ4	;	2.38	;	Crystal Structure of GlmU from Mycobacterium tuberculosis in complex with URIDINE-DIPHOSPHATE-N-ACETYLGLUCOSAMINE.
4G87	;	2.03	;	Crystal structure of GLMU from Mycobacterium tuberculosis snapshot 1
4G3P	;	2.47	;	Crystal structure of GlmU from Mycobacterium tuberculosis Snapshot 3
4G3Q	;	1.9	;	Crystal structure of GlmU from Mycobacterium tuberculosis Snapshot 4
3D98	;	2.5	;	Crystal structure of GlmU from Mycobacterium tuberculosis, ligand-free form
4K6R	;	1.98	;	Crystal structure of GlmU in complex with ATP
4ZVA	;	2.0	;	Crystal structure of globin domain of the E. coli DosC - form I (ferric)
4ZVB	;	2.4	;	Crystal structure of globin domain of the E. coli DosC - form II (ferrous)
1HST	;	2.6	;	CRYSTAL STRUCTURE OF GLOBULAR DOMAIN OF HISTONE H5 AND ITS IMPLICATIONS FOR NUCLEOSOME BINDING
5UZG	;	1.541	;	Crystal structure of Glorund qRRM1 domain
5UZM	;	1.552	;	Crystal structure of Glorund qRRM2 domain
5UZN	;	1.99	;	Crystal structure of Glorund qRRM3 domain
2IC8	;	2.1	;	Crystal structure of GlpG
3B45	;	1.9	;	Crystal structure of GlpG at 1.9A resolution
3TXT	;	2.3	;	Crystal structure of GlpG in complex with inhibitor DFP
6VJ9	;	2.3	;	Crystal structure of GlpG in complex with peptide boronate inhibitor
6XRO	;	2.3	;	Crystal structure of GlpG in complex with peptide boronate inhibitor, Ac-KRFRSMQYSA-B(OH)2
6VJ8	;	2.3	;	Crystal structure of GlpG in complex with peptide chloromethylketone inhibitor
6XRP	;	2.4	;	Crystal structure of GlpG in complex with peptide ketoamide inhibitor, Ac-RVWHA-ketoamide-phenylbutyl
3B44	;	1.7	;	Crystal structure of GlpG W136A mutant
2NRF	;	2.6	;	Crystal Structure of GlpG, a Rhomboid family intramembrane protease
2IRV	;	2.3	;	Crystal structure of GlpG, a rhomboid intramembrane serine protease
2NR9	;	2.2	;	Crystal structure of GlpG, Rhomboid Peptidase from Haemophilus influenzae
2BV7	;	1.79	;	Crystal structure of GLTP with bound GM3
6CTF	;	4.05	;	Crystal structure of GltPh fast mutant - R276S/M395R
2NWL	;	2.96	;	Crystal structure of GltPh in complex with L-Asp
2NWX	;	3.29	;	Crystal structure of GltPh in complex with L-aspartate and sodium ions
2NWW	;	3.2	;	Crystal structure of GltPh in complex with TBOA
3KBC	;	3.51	;	Crystal structure of GltPh K55C-A364C mutant crosslinked with divalent mercury
4IZM	;	4.5	;	Crystal structure of GltPh L66C-S300C mutant crosslinked with divalent mercury
4OYE	;	4.0	;	Crystal structure of GltPh R397A in apo
5CFY	;	3.5	;	CRYSTAL STRUCTURE OF GLTPH R397A IN COMPLEX WITH NA+ AND L-ASP
4OYF	;	3.41	;	Crystal structure of GLTPH R397A IN Sodium-bound state
6BAU	;	3.8	;	Crystal Structure of GltPh R397C in complex with L-Cysteine
6BMI	;	3.9	;	Crystal Structure of GltPh R397C in complex with L-Serine
6BAV	;	3.7	;	Crystal Structure of GltPh R397C in complex with S-Benzyl-L-Cysteine
2B8O	;	2.8	;	Crystal Structure of Glu-Gly-Arg-Chloromethyl Ketone-Factor VIIa/Soluble Tissue Factor Complex
2D6F	;	3.15	;	Crystal structure of Glu-tRNA(Gln) amidotransferase in the complex with tRNA(Gln)
1UBZ	;	2.0	;	Crystal structure of Glu102-mutant human lysozyme doubly labeled with 2',3'-epoxypropyl beta-glycoside of N-acetyllactosamine
2W25	;	2.15	;	Crystal structure of Glu104Ala mutant
3PUU	;	2.15	;	Crystal Structure of Glu121Gln mutant of E. coli Aminopeptidase N
2E16	;	2.0	;	Crystal structure of Glu140 to Arg mutant of Diphthine synthase
2EGB	;	1.9	;	Crystal structure of Glu140 to Asn mutant of Diphthine synthase
2E08	;	2.0	;	Crystal structure of Glu140 to Lys mutant of Diphthine synthase
1ZKX	;	2.52	;	Crystal structure of Glu158Ala/Thr159Ala/Asn160Ala- a triple mutant of Clostridium botulinum neurotoxin E catalytic domain
2DSI	;	2.2	;	Crystal structure of Glu171 to Arg mutant of Diphthine synthase
2EGL	;	1.8	;	Crystal structure of Glu171 to Lys mutant of Diphthine synthase
3QAM	;	1.92	;	Crystal Structure of Glu208Ala mutant of catalytic subunit of cAMP-dependent protein kinase
1ZN3	;	2.6	;	Crystal structure of Glu335Ala mutant of Clostridium botulinum neurotoxin type E
1ZL5	;	2.6	;	Crystal structure of Glu335Gln mutant of Clostridium botulinum neurotoxin E catalytic domain
5MC3	;	1.52	;	Crystal Structure of Glu412Lys mutant of Human Prolidase with Mn ions and GlyPro ligand
2E7R	;	1.8	;	Crystal structure of Glu54 to Arg mutant of Diphthine synthase
2DXV	;	1.9	;	Crystal structure of Glu54 to His mutant of Diphthine synthase
2DXW	;	1.8	;	Crystal structure of Glu54 to Lys mutant of Diphthine synthase
1Z2V	;	1.9	;	Crystal Structure of Glu60 deletion Mutant of Human Acidic Fibroblast Growth Factor
4U5B	;	3.5037	;	Crystal structure of GluA2 A622T, con-ikot-ikot snail toxin, partial agonist KA and postitive modulator (R,R)-2b complex
6XSR	;	4.25	;	Crystal structure of GluA2 AMPA receptor in complex with trans-4-butylcyclohexane carboxylic acid (4-BCCA) inhibitor
4U5E	;	3.5073	;	Crystal structure of GluA2 T625G, con-ikot-ikot snail toxin, partial agonist KA and postitive modulator (R,R)-2b complex
4U5C	;	3.6883	;	Crystal structure of GluA2, con-ikot-ikot snail toxin, partial agonist FW and postitive modulator (R,R)-2b complex
4U5D	;	3.5757	;	Crystal structure of GluA2, con-ikot-ikot snail toxin, partial agonist KA and postitive modulator (R,R)-2b complex
4U5F	;	3.7	;	Crystal structure of GluA2, con-ikot-ikot snail toxin, partial agonist KA and postitive modulator (R,R)-2b complex, GluA2cryst2 construct
6PHN	;	1.33	;	Crystal structure of glucagon analog composed of D-amino acids with mono-stereoinversion at position 23 (L-Val23) in space group I41 at 1.33 A resolution
6PHM	;	1.1	;	Crystal structure of glucagon analog fully composed of D-amino acids in space group I41 at 1.1 A resolution
6PHQ	;	1.32	;	Crystal structure of glucagon analog fully composed of D-amino acids with 4-bromo-D-phenylalanine substitutions at position 6 and 22 in space group I41 at 1.1 A resolution
6PHP	;	1.65	;	Crystal structure of glucagon analog with 4-bromo-phenylalanine substitutions at position 6 and 22 in space group I41 at 1.65 A resolution
6PHK	;	1.18	;	Crystal structure of glucagon analog with mono-stereoinversion at position 21 (D-Asp21) in space group I41 at 1.18 A resolution
6PHL	;	1.443	;	Crystal structure of glucagon analog with mono-stereoinversion at position 23 (D-Val23) in space group I41 at 1.44 A resolution
6PHO	;	1.42	;	Crystal structure of glucagon analog with selenomethionine substitutions at position 1 and 27 in space group I41 at 1.42 A resolution
3IOL	;	2.1	;	Crystal structure of Glucagon-Like Peptide-1 in complex with the extracellular domain of the Glucagon-Like Peptide-1 Receptor
3AIB	;	3.09	;	Crystal Structure of Glucansucrase
3AIC	;	3.11	;	Crystal Structure of Glucansucrase from Streptococcus mutans
3AIE	;	2.1	;	Crystal Structure of glucansucrase from Streptococcus mutans
3NXL	;	1.885	;	Crystal structure of Glucarate dehydratase from Burkholderia cepacia complexed with magnesium
4IL0	;	2.8	;	Crystal structure of GlucDRP from E. coli K-12 MG1655 (EFI target EFI-506058)
1AYX	;	1.7	;	CRYSTAL STRUCTURE OF GLUCOAMYLASE FROM SACCHAROMYCOPSIS FIBULIGERA AT 1.7 ANGSTROMS
6T13	;	1.85	;	CRYSTAL STRUCTURE OF GLUCOCEREBROSIDASE IN COMPLEX WITH A PYRROLOPYRAZINE
8P3E	;	1.75	;	Crystal structure of glucocerebrosidase in complex with allosteric activator
8P41	;	1.83	;	Crystal structure of glucocerebrosidase in complex with allosteric activator
5LVX	;	2.2	;	Crystal structure of glucocerebrosidase with an inhibitory quinazoline modulator
8VKZ	;	2.133	;	Crystal structure of Glucocorticoid Receptor in complex with an inhibitor
1ULV	;	2.42	;	Crystal Structure of Glucodextranase Complexed with Acarbose
1UG9	;	2.5	;	Crystal Structure of Glucodextranase from Arthrobacter globiformis I42
3MCP	;	3.0	;	Crystal structure of Glucokinase (BDI_1628) from Parabacteroides distasonis ATCC 8503 at 3.00 A resolution
7T79	;	2.4	;	CRYSTAL STRUCTURE OF GLUCOKINASE (HEXOKINASE 4) COMPLEXED WITH LIGAND AKA DIETHYL {[3-(3-{[5-(AZETIDINE-1-CARBON YL)PYRAZIN-2-YL]OXY}-5-(PROPAN-2-YLOXY)BENZAMIDO)-1H- PYRAZOL-1-YL]METHYL}PHOSPHONATE
7T78	;	2.4	;	CRYSTAL STRUCTURE OF GLUCOKINASE (HEXOKINASE 4) COMPLEXED WITH LIGAND DIETHYL ({2-[3-(4-METHANESULFONYLPHENO XY)-5-{[(2S)-1-METHOXYPROPAN-2-YL]OXY}BENZAMIDO]-1,3-THIAZ OL-4-YL}METHYL)PHOSPHONATE
6DA0	;	2.2	;	Crystal structure of glucokinase (NfHK) from Naegleria fowleri
3VPZ	;	1.69	;	Crystal structure of glucokinase from Antarctic psychrotroph at 1.69A
6VZZ	;	2.65	;	Crystal structure of glucokinase from Balamuthia mandrillaris in complex with glucose
2QM1	;	2.02	;	Crystal structure of glucokinase from Enterococcus faecalis
6E0E	;	2.7	;	Crystal structure of Glucokinase in complex with compound 6
6E0I	;	1.9	;	Crystal structure of Glucokinase in complex with compound 72
4BB9	;	1.47	;	Crystal structure of glucokinase regulatory protein complexed to fructose-1-phosphate
4BBA	;	1.92	;	Crystal structure of glucokinase regulatory protein complexed to phosphate
8DTC	;	2.25	;	Crystal Structure of Glucokinase with bound glucose from Acanthamoeba castellanii
4L3Q	;	2.7	;	Crystal structure of glucokinase-activator complex
3CXR	;	2.0	;	Crystal structure of gluconate 5-dehydrogase from streptococcus suis type 2
1VL8	;	2.07	;	Crystal structure of Gluconate 5-dehydrogenase (TM0441) from Thermotoga maritima at 2.07 A resolution
6LE3	;	2.1	;	Crystal structure of gluconate 5-dehydrogenase from Lentibacter algarum
3TW9	;	1.7	;	Crystal structure of gluconate dehydratase (TARGET EFI-501679) from Salmonella enterica subsp. enterica serovar Enteritidis str. P125109
3TWB	;	1.76	;	Crystal structure of gluconate dehydratase (TARGET EFI-501679) from Salmonella enterica subsp. enterica serovar Enteritidis str. P125109 complexed with magnesium and gluconic acid
3TWA	;	1.8	;	Crystal structure of gluconate dehydratase (TARGET EFI-501679) from Salmonella enterica subsp. enterica serovar Enteritidis str. P125109 complexed with magnesium and glycerol
1KNQ	;	2.0	;	Crystal structure of gluconate kinase
1KO1	;	2.09	;	Crystal structure of gluconate kinase
1KO4	;	2.5	;	Crystal structure of gluconate kinase
1KO5	;	2.28	;	Crystal structure of gluconate kinase
1KO8	;	2.4	;	Crystal structure of gluconate kinase
1KOF	;	2.8	;	Crystal structure of gluconate kinase
3GBT	;	2.4	;	Crystal structure of gluconate kinase from Lactobacillus acidophilus
2AXR	;	1.98	;	Crystal structure of glucooligosaccharide oxidase from Acremonium strictum: a novel flavinylation of 6-S-cysteinyl, 8alpha-N1-histidyl FAD
2RI0	;	1.6	;	Crystal Structure of glucosamine 6-phosphate deaminase (NagB) from S. mutans
2RI1	;	2.03	;	Crystal Structure of glucosamine 6-phosphate deaminase (NagB) with GlcN6P from S. mutans
2CB0	;	1.8	;	Crystal structure of glucosamine 6-phosphate deaminase from Pyrococcus furiosus
7K47	;	2.9	;	Crystal Structure of Glucosamine-1-phosphate N-acetyltransferase from Stenotrophomonas maltophilia K279a
1J5X	;	1.8	;	Crystal structure of Glucosamine-6-phosphate deaminase (TM0813) from Thermotoga maritima at 1.8 A resolution
3HN6	;	2.2	;	Crystal structure of glucosamine-6-phosphate deaminase from Borrelia burgdorferi
4R7T	;	2.1	;	Crystal structure of glucosamine-6-phosphate deaminase from Vibrio cholerae
7KQA	;	1.65	;	Crystal Structure of Glucosamine-6-phosphate deanimase from Strenotrophomonas maltophilia
3T90	;	1.5	;	Crystal structure of glucosamine-6-phosphate N-acetyltransferase from Arabidopsis thaliana
4HO0	;	1.9	;	Crystal structure of glucose 1-phosphate thymidylyltransferase from Aneurinibacillus thermoaerophilus
4HO5	;	1.7	;	Crystal structure of glucose 1-phosphate thymidylyltransferase from Aneurinibacillus thermoaerophilus complexed with TDP-glucose
4HO2	;	1.84	;	Crystal structure of glucose 1-phosphate thymidylyltransferase from Aneurinibacillus thermoaerophilus complexed with thymidine
4HO4	;	1.64	;	Crystal structure of glucose 1-phosphate thymidylyltransferase from Aneurinibacillus thermoaerophilus complexed with thymidine and glucose-1-phosphate
4HO3	;	1.8	;	Crystal structure of glucose 1-phosphate thymidylyltransferase from Aneurinibacillus thermoaerophilus complexed with thymidine triphosphate
4HO9	;	1.8	;	Crystal structure of glucose 1-phosphate thymidylyltransferase from Aneurinibacillus thermoaerophilus complexed with UDP-galactose and UTP
4HO8	;	2.6	;	Crystal structure of glucose 1-phosphate thymidylyltransferase from Aneurinibacillus thermoaerophilus complexed with UDP-glucose and thymidine
4HO6	;	1.92	;	Crystal structure of glucose 1-phosphate thymidylyltransferase from Aneurinibacillus thermoaerophilus complexed with UDP-glucose and UTP
4HOC	;	2.2	;	Crystal structure of glucose 1-phosphate thymidylyltransferase from Aneurinibacillus thermoaerophilus complexed with UDP-N-acetylglucosamine
7CDY	;	1.329	;	Crystal structure of glucose dehydrogenase
1GCO	;	1.7	;	CRYSTAL STRUCTURE OF GLUCOSE DEHYDROGENASE COMPLEXED WITH NAD+
2B5V	;	2.0	;	Crystal structure of glucose dehydrogenase from Haloferax mediterranei
1G6K	;	2.0	;	Crystal structure of glucose dehydrogenase mutant E96A complexed with NAD+
1GEE	;	1.6	;	Crystal structure of glucose dehydrogenase mutant Q252L complexed with NAD+
1SPX	;	2.1	;	Crystal Structure of Glucose Dehydrogenase of Caenorhabditis Elegans in the Apo-Form
4J4K	;	1.9	;	Crystal structure of glucose isomerase
8WDH	;	1.7	;	Crystal structure of glucose isomerase by fixed-target pink-beam serial synchrotron crystallography
6IRK	;	1.75	;	Crystal structure of glucose isomerase by fixed-target serial femtosecond crystallography
6LL2	;	1.75	;	Crystal structure of glucose isomerase by fixed-target serial femtosecond crystallography
7CVK	;	1.7	;	Crystal structure of glucose isomerase by fixed-target serial synchrotron crystallography (100 ms)
7CVM	;	2.0	;	Crystal structure of glucose isomerase by fixed-target serial synchrotron crystallography (500 ms)
7DFJ	;	1.5	;	Crystal structure of glucose isomerase by serial millisecond crystallography
7BVN	;	2.0	;	Crystal structure of glucose isomerase delivered in alginate
7BVL	;	2.0	;	Crystal structure of glucose isomerase delivered in wheat starch
6OQZ	;	1.6	;	Crystal structure of Glucose Isomerase from Non-merohedrally twinned crystals
5VR0	;	1.7	;	Crystal structure of glucose isomerase from Streptomyces rubiginosus
5Y4I	;	1.91	;	Crystal structure of glucose isomerase in complex with glycerol in one metal binding mode
5Y4J	;	1.4	;	Crystal structure of glucose isomerase in complex with xylitol inhibitor in one metal binding mode
5ZYD	;	1.4	;	Crystal Structure of Glucose Isomerase Soaked with Glucose
5ZYC	;	1.75	;	Crystal Structure of Glucose Isomerase Soaked with Mn2+
5ZYE	;	1.4	;	Crystal Structure of Glucose Isomerase Soaked with Mn2+ and Glucose
3QVP	;	1.2	;	Crystal structure of glucose oxidase for space group C2221 at 1.2 A resolution
3QVR	;	1.3	;	Crystal structure of glucose oxidase for space group P3121 at 1.3 A resolution.
1GAL	;	2.3	;	CRYSTAL STRUCTURE OF GLUCOSE OXIDASE FROM ASPERGILLUS NIGER: REFINED AT 2.3 ANGSTROMS RESOLUTION
3NTL	;	1.88	;	Crystal Structure of Glucose-1-phosphatase (AgpE) from Enterobacter cloacae
5IN3	;	1.73	;	Crystal structure of glucose-1-phosphate bound nucleotidylated human galactose-1-phosphate uridylyltransferase
5IFY	;	2.25	;	Crystal structure of Glucose-1-phosphate thymidylyltransferase from Burkholderia vietnamiensis in complex with 2 -Deoxyuridine-5'-monophosphate and 2'-Deoxy-Thymidine-B-L-Rhamnose
2GGO	;	1.8	;	Crystal Structure of glucose-1-phosphate thymidylyltransferase from Sulfolobus tokodaii
1LVW	;	1.7	;	Crystal structure of glucose-1-phosphate thymidylyltransferase, RmlA, complex with dTDP
4D48	;	2.46	;	Crystal Structure of glucose-1-phosphate uridylyltransferase GalU from Erwinia amylovora.
8H1K	;	1.6	;	Crystal structure of glucose-2-epimerase from Runella slithyformis Runsl_4512
8H1L	;	2.33	;	Crystal structure of glucose-2-epimerase in complex with D-Glucitol from Runella slithyformis Runsl_4512
8H1M	;	1.6	;	Crystal structure of glucose-2-epimerase mutant_D254A from Runella slithyformis Runsl_4512
8H1N	;	2.67	;	Crystal structure of glucose-2-epimerase mutant_D254A in complex with D-Glucitol from Runella slithyformis Runsl_4512
6VA8	;	3.95	;	Crystal structure of glucose-6-phosphate dehydrogenase F381L mutant in complex with catalytic NADP+
6VA7	;	3.07	;	Crystal structure of glucose-6-phosphate dehydrogenase P396L mutant in complex with catalytic NADP+
6VA9	;	3.95	;	Crystal structure of glucose-6-phosphate dehydrogenase R393H mutant in complex with catalytic NADP+
6VAQ	;	2.95	;	Crystal structure of glucose-6-phosphate dehydrogenase V394L mutant in complex with catalytic NADP+
6VA0	;	3.1	;	Crystal structure of glucose-6-phosphate dehydrogenase W509A mutant in complex with catalytic NADP+
2Q8N	;	1.82	;	Crystal structure of Glucose-6-phosphate isomerase (EC 5.3.1.9) (TM1385) from Thermotoga maritima at 1.82 A resolution
3QKI	;	1.92	;	Crystal structure of Glucose-6-Phosphate Isomerase (PF14_0341) from Plasmodium falciparum 3D7
6BZB	;	1.6	;	Crystal Structure of Glucose-6-phosphate Isomerase from Elizabethkingia anophelis
6BZC	;	2.05	;	Crystal Structure of Glucose-6-phosphate Isomerase from Elizabethkingia anophelis with bound Glucose-6-phosphate
1EVJ	;	2.7	;	CRYSTAL STRUCTURE OF GLUCOSE-FRUCTOSE OXIDOREDUCTASE (GFOR) DELTA1-22 S64D
1RYD	;	2.2	;	Crystal Structure of Glucose-Fructose Oxidoreductase from Zymomonas mobilis
5Z3K	;	1.802	;	Crystal structure of glucosidase from Croceicoccus marinus at 1.8 Angstrom resolution
5DKZ	;	2.4	;	Crystal structure of glucosidase II alpha subunit (alpha3-Glc2-bound from)
5DKY	;	1.6	;	Crystal structure of glucosidase II alpha subunit (DNJ-bound from)
5DL0	;	2.3	;	Crystal structure of glucosidase II alpha subunit (Glc1Man2-bound from)
5DKX	;	1.4	;	Crystal structure of glucosidase II alpha subunit (Tris-bound from)
7VTM	;	2.05153	;	Crystal structure of Glucoside hydrolase family 64 beta-1,3-glucanase complexed with Laminaritetraose
4DDZ	;	2.6	;	Crystal structure of glucosyl-3-phosphoglycerate synthase from Mycobacterium tuberculosis
5JQQ	;	2.6	;	Crystal structure of glucosyl-3-phosphoglycerate synthase from Mycobacterium tuberculosis - apo form
4DE7	;	3.0	;	Crystal structure of glucosyl-3-phosphoglycerate synthase from Mycobacterium tuberculosis in complex with Mg2+ and uridine-diphosphate (UDP)
5JSX	;	2.81	;	Crystal structure of glucosyl-3-phosphoglycerate synthase from Mycobacterium tuberculosis in complex with Mn2+ and uridine-diphosphate-glucose (UDP-Glc)
5JT0	;	2.8	;	Crystal structure of glucosyl-3-phosphoglycerate synthase from Mycobacterium tuberculosis in complex with Mn2+, uridine-diphosphate (UDP) and glucosyl-3-phosphoglycerate (GPG) - GpgS*GPG*UDP*Mn2+
5JUC	;	2.8	;	Crystal structure of glucosyl-3-phosphoglycerate synthase from Mycobacterium tuberculosis in complex with Mn2+, uridine-diphosphate (UDP) and glucosyl-3-phosphoglycerate (GPG) - GpgS*GPG*UDP*Mn2+_2
4DEC	;	1.98	;	Crystal structure of glucosyl-3-phosphoglycerate synthase from Mycobacterium tuberculosis in complex with Mn2+, uridine-diphosphate (UDP) and phosphoglyceric acid (PGA)
4Y7F	;	3.231	;	Crystal structure of glucosyl-3-phosphoglycerate synthase from Mycobacterium tuberculosis in complex with Mn2+, uridine-diphosphate-glucose (UDP-Glc) and 3-(phosphonooxy)propanoic acid (PPA) - GpgS Mn2+ UDP-Glc PPA
4Y7G	;	2.59	;	Crystal structure of glucosyl-3-phosphoglycerate synthase from Mycobacterium tuberculosis in complex with Mn2+, uridine-diphosphate-glucose (UDP-Glc) and glycerol 3-phosphate (G3P) - GpgS Mn2+ UDP-Glc G3P
4Y6N	;	2.348	;	Crystal structure of glucosyl-3-phosphoglycerate synthase from Mycobacterium tuberculosis in complex with Mn2+, uridine-diphosphate-glucose (UDP-Glc) and phosphoglyceric acid (PGA) - GpgS Mn2+ UDP-Glc PGA-1
4Y9X	;	2.637	;	Crystal structure of glucosyl-3-phosphoglycerate synthase from Mycobacterium tuberculosis in complex with Mn2+, uridine-diphosphate-glucose (UDP-Glc) and phosphoglyceric acid (PGA) - GpgS Mn2+ UDP-Glc PGA-3
5JQX	;	2.82	;	Crystal structure of glucosyl-3-phosphoglycerate synthase from Mycobacterium tuberculosis in complex with phosphoglyceric acid (PGA) - GpgS*PGA
5JUD	;	2.59	;	Crystal structure of glucosyl-3-phosphoglycerate synthase from Mycobacterium tuberculosis in complex with uridine-diphosphate (UDP) - GpgS*UDP
2Q6E	;	2.4	;	Crystal structure of glucuronate isomerase from Bacillus halodurans complexed with Zn
2Q01	;	2.34	;	Crystal structure of glucuronate isomerase from Caulobacter crescentus
3AY3	;	2.1	;	Crystal structure of glucuronic acid dehydrogeanse from Chromohalobacter salexigens
6RU2	;	1.96	;	Crystal Structure of Glucuronoyl Esterase from Cerrena unicolor
6RV8	;	1.85	;	Crystal Structure of Glucuronoyl Esterase from Cerrena unicolor covalent complex with the aldouronic acid UXXR
6RTV	;	1.46	;	Crystal Structure of Glucuronoyl Esterase from Cerrena unicolor inactive S270A variant
6RU1	;	1.39	;	Crystal Structure of Glucuronoyl Esterase from Cerrena unicolor inactive S270A variant in complex with the aldouronic acid Um4X
6RV7	;	1.73	;	Crystal Structure of Glucuronoyl Esterase from Cerrena unicolor inactive S270A variant in complex with the aldouronic acid UXXR
6RV9	;	1.64	;	Crystal Structure of Glucuronoyl Esterase from Cerrena unicolor inactive S270A variant in complex with the aldouronic acid XUXXR
4G4I	;	1.9	;	Crystal structure of glucuronoyl esterase S213A mutant from Sporotrichum thermophile determined at 1.9 A resolution
4G4J	;	2.35	;	Crystal structure of glucuronoyl esterase S213A mutant from Sporotrichum thermophile in complex with methyl 4-O-methyl-beta-D-glucopyranuronate determined at 2.35 A resolution
4NF4	;	2.0	;	Crystal structure of GluN1/GluN2A ligand-binding domain in complex with DCKA and glutamate
4NF5	;	1.903	;	Crystal structure of GluN1/GluN2A ligand-binding domain in complex with glycine and D-AP5
4NF8	;	1.856	;	Crystal structure of GluN1/GluN2A ligand-binding domain in complex with glycine and glutamate in PEG2000MME
6UZR	;	1.87	;	Crystal structure of GLUN1/GLUN2A ligand-binding domain in complex with glycine and homoquinolinic acid
5U8C	;	1.598	;	CRYSTAL STRUCTURE OF GLUN1/GLUN2A LIGAND-BINDING DOMAIN IN COMPLEX WITH GLYCINE AND NVP-AAM077
4NF6	;	2.1	;	Crystal structure of GluN1/GluN2A ligand-binding domain in complex with glycine and PPDA
6USV	;	2.304	;	Crystal structure of GluN1/GluN2A ligand-binding domain in complex with glycine and SDZ 220-040
6UZW	;	2.13	;	Crystal structure of GLUN1/GLUN2A ligand-binding domain in complex with glycine and UBP791
6USU	;	2.092	;	Crystal structure of GluN1/GluN2A ligand-binding domain in complex with L689,560 and glutamate
6OVD	;	2.102	;	Crystal structure of GluN1/GluN2A NMDA receptor agonist binding domains with glycine and antagonist, 3-ethylphenyl-ACEPC
5VII	;	1.951	;	Crystal structure of GluN1/GluN2A NMDA receptor agonist binding domains with glycine and antagonist, 4-(3-fluoropropyl)phenyl-ACEPC
5VIJ	;	2.105	;	Crystal structure of GluN1/GluN2A NMDA receptor agonist binding domains with glycine and antagonist, 4-bromophenyl-ACEPC
5VIH	;	2.4	;	Crystal structure of GluN1/GluN2A NMDA receptor agonist binding domains with glycine and antagonist, 4-fluorophenyl-ACEPC
6OVE	;	2.0	;	Crystal structure of GluN1/GluN2A NMDA receptor agonist binding domains with glycine and antagonist, 4-propylphenyl-ACEPC
5DEX	;	2.4	;	Crystal structure of GluN1/GluN2A NMDA receptor agonist binding domains with glycine and antagonist, phenyl-ACEPC
6UZ6	;	1.66	;	Crystal structure of GLUN1/GLUN2A-4M mutant ligand-binding domain in complex with glycine and glutamate
6UZG	;	1.94	;	Crystal structure of GLUN1/GLUN2A-4M mutant ligand-binding domain in complex with glycine and homoquinolinic acid
6UZX	;	2.41	;	Crystal structure of GLUN1/GLUN2A-4M mutant ligand-binding domain in complex with glycine and UBP791
5UN1	;	3.6	;	Crystal structure of GluN1/GluN2B delta-ATD NMDA receptor
4TLL	;	3.59	;	Crystal structure of GluN1/GluN2B NMDA receptor, structure 1
4TLM	;	3.77	;	Crystal structure of GluN1/GluN2B NMDA receptor, structure 2
4PE5	;	3.96	;	Crystal Structure of GluN1a/GluN2B NMDA Receptor Ion Channel
7TE6	;	4.55	;	Crystal structure of GluN1b-2B ATD complexed to Fab5 anti-GluN2B antibody
6ODL	;	2.3	;	Crystal structure of GluN2A agonist binding domain with 4-butyl-(S)-CCG-IV
3OEL	;	1.9	;	Crystal structure of GluN2D ligand-binding core in complex with D-glutamate
3OEK	;	1.9	;	Crystal structure of GluN2D ligand-binding core in complex with L-aspartate
3OEN	;	1.8	;	Crystal structure of GluN2D ligand-binding core in complex with L-glutamate
3OEM	;	1.9	;	Crystal structure of GluN2D ligand-binding core in complex with N-methyl-D-aspartate
1LBC	;	1.8	;	Crystal structure of GluR2 ligand binding core (S1S2J-N775S) in complex with cyclothiazide (CTZ) as well as glutamate at 1.8 A resolution
4X48	;	1.89	;	Crystal structure of GluR2 ligand-binding core
3C36	;	1.68	;	Crystal structure of GluR5 ligand-binding core in complex with ammonium ions at 1.68 Angstrom resolution
3C35	;	1.97	;	Crystal structure of GluR5 ligand-binding core in complex with cesium at 1.97 Angstrom resolution
3C31	;	1.49	;	Crystal structure of GluR5 ligand-binding core in complex with lithium at 1.49 Angstrom resolution
3C33	;	1.72	;	Crystal structure of GluR5 ligand-binding core in complex with potassium at 1.78 Angstrom resolution
3C34	;	1.82	;	Crystal structure of GluR5 ligand-binding core in complex with rubidium at 1.82 Angstrom resolution
3C32	;	1.72	;	Crystal structure of GluR5 ligand-binding core in complex with sodium at 1.72 Angstrom resolution
1POI	;	2.5	;	CRYSTAL STRUCTURE OF GLUTACONATE COENZYME A-TRANSFERASE FROM ACIDAMINOCOCCUS FERMENTANS TO 2.55 ANGSTOMS RESOLUTION
4G9H	;	2.1	;	Crystal structure of glutahtione s-transferase homolog from yersinia pestis, target EFI-501894, with bound glutathione
4GCI	;	1.5	;	Crystal structure of glutahtione s-transferase homolog from yersinia pestis, target EFI-501894, with bound glutathione, monoclinic form
4GF0	;	1.75	;	Crystal structure of glutahtione transferase homolog from sulfitobacter, TARGET EFI-501084, with bound glutathione
3BS8	;	2.3	;	Crystal structure of Glutamate 1-Semialdehyde Aminotransferase complexed with pyridoxamine-5'-phosphate From Bacillus subtilis
2AKO	;	2.2	;	Crystal structure of Glutamate 5-kinase from Campylobacter jejuni
4NGM	;	1.84	;	Crystal Structure of Glutamate Carboxypeptidase II in a complex with urea-based inhibitor
4NGN	;	1.64	;	Crystal Structure of Glutamate Carboxypeptidase II in a complex with urea-based inhibitor
4NGP	;	1.63	;	Crystal Structure of Glutamate Carboxypeptidase II in a complex with urea-based inhibitor
4NGQ	;	2.08	;	Crystal Structure of Glutamate Carboxypeptidase II in a complex with urea-based inhibitor
4NGR	;	1.9	;	Crystal Structure of Glutamate Carboxypeptidase II in a complex with urea-based inhibitor
4NGS	;	1.68	;	Crystal Structure of Glutamate Carboxypeptidase II in a complex with urea-based inhibitor
4NGT	;	2.31	;	Crystal Structure of Glutamate Carboxypeptidase II in a complex with urea-based inhibitor
3A75	;	1.95	;	Crystal structure of glutamate complex of halotolerant &gamma;-glutamyltranspeptidase from Bacillus subtilis
3FZ6	;	2.82	;	Crystal structure of glutamate decarboxylase beta from Escherichia coli: complex with xenon
3FZ8	;	3.0	;	Crystal structure of glutamate decarboxylase beta from Escherichia coli: reduced Schiff base with PLP
2QMA	;	1.81	;	Crystal structure of glutamate decarboxylase domain of diaminobutyrate-pyruvate transaminase and L-2,4-diaminobutyrate decarboxylase from Vibrio parahaemolyticus
3AOG	;	2.1	;	Crystal structure of glutamate dehydrogenase (GdhB) from Thermus thermophilus (Glu bound form)
8OWM	;	1.7	;	Crystal structure of glutamate dehydrogenase 2 from Arabidopsis thaliana binding Ca, NAD and 2,2-dihydroxyglutarate
7F77	;	3.086	;	Crystal structure of glutamate dehydrogenase 3 from Candida albicans
7F79	;	2.7	;	Crystal structure of glutamate dehydrogenase 3 from Candida albicans in complex with alpha-ketoglutarate and NADPH
4XGI	;	2.0	;	Crystal structure of Glutamate dehydrogenase from Burkholderia thailandensis
2YFQ	;	2.94	;	Crystal structure of Glutamate dehydrogenase from Peptoniphilus asaccharolyticus
5IJZ	;	2.29	;	Crystal structure of glutamate dehydrogenase(GDH) from Corynebacterium glutamicum
5FTW	;	1.8	;	Crystal structure of glutamate O-methyltransferase in complex with S- adenosyl-L-homocysteine (SAH) from Bacillus subtilis
3UHF	;	1.83	;	Crystal Structure of Glutamate Racemase from Campylobacter jejuni subsp. jejuni
3UHO	;	2.2	;	Crystal Structure of Glutamate Racemase from Campylobacter jejuni subsp. jejuni
3UHP	;	2.794	;	Crystal Structure of Glutamate Racemase from Campylobacter jejuni subsp. jejuni
3OUT	;	1.65	;	Crystal structure of glutamate racemase from Francisella tularensis subsp. tularensis SCHU S4 in complex with D-glutamate.
8EB3	;	2.2	;	Crystal structure of glutamate racemase from Helicobacter pylori in complex with a fragment
7UJ5	;	1.75	;	Crystal structure of glutamate racemase from Helicobacter pylori in complex with D-glutamate
3HFR	;	2.3	;	Crystal structure of glutamate racemase from Listeria monocytogenes
3ISV	;	1.85	;	Crystal structure of glutamate racemase from Listeria monocytogenes in complex with acetate ion
3IST	;	1.65	;	Crystal structure of glutamate racemase from Listeria monocytogenes in complex with succinic acid
6DLI	;	2.7	;	Crystal structure of glutamate racemase from Thermus thermophilus in complex with Beta-chloro-D-alanine
5W16	;	1.909	;	Crystal structure of glutamate racemase from Thermus thermophilus in complex with D-glutamate
2DWU	;	1.6	;	Crystal Structure of Glutamate Racemase Isoform RacE1 from Bacillus anthracis
3SAJ	;	2.5	;	Crystal Structure of glutamate receptor GluA1 Amino Terminal Domain
1MY3	;	1.75	;	crystal structure of glutamate receptor ligand-binding core in complex with bromo-willardiine in the Zn crystal form
1MY4	;	1.9	;	crystal structure of glutamate receptor ligand-binding core in complex with iodo-willardiine in the Zn crystal form
5I92	;	1.75	;	Crystal structure of Glutamate-1-semialdehyde 2,1- aminomutase (GSA) from Pseudomonas aeruginosa
2EPJ	;	1.7	;	Crystal structure of glutamate-1-semialdehyde 2,1-aminomutase from Aeropyrum pernix
2ZSL	;	1.7	;	Crystal structure of glutamate-1-semialdehyde 2,1-aminomutase from Aeropyrum pernix
2ZSM	;	2.3	;	Crystal structure of glutamate-1-semialdehyde 2,1-aminomutase from Aeropyrum pernix, hexagonal form
6W80	;	1.4	;	Crystal structure of Glutamate-1-semialdehyde 2,1-aminomutase from Stenotrophomonas maltophilia K279a in complex with PLP
2E7U	;	1.9	;	Crystal structure of glutamate-1-semialdehyde 2,1-aminomutase from Thermus thermophilus HB8
4GSA	;	2.5	;	CRYSTAL STRUCTURE OF GLUTAMATE-1-SEMIALDEHYDE AMINOMUTASE (AMINOTRANSFERASE) REDUCED WITH CYANOBOROHYDRATE
2GSA	;	2.4	;	CRYSTAL STRUCTURE OF GLUTAMATE-1-SEMIALDEHYDE AMINOMUTASE (AMINOTRANSFERASE, WILD-TYPE FORM)
3GSB	;	3.0	;	CRYSTAL STRUCTURE OF GLUTAMATE-1-SEMIALDEHYDE AMINOMUTASE IN COMPLEX WITH GABACULINE
6B1Z	;	1.6	;	Crystal Structure of Glutamate-tRNA Synthetase from Elizabethkingia anophelis
6B1P	;	2.5	;	Crystal Structure of Glutamate-tRNA Synthetase from Helicobacter pylori
8JUE	;	2.39	;	Crystal structure of glutaminase C in complex with compound 11
8JUB	;	2.01	;	Crystal structure of glutaminase C in complex with compound 27
5WJ6	;	2.445	;	Crystal structure of glutaminase C in complex with inhibitor 2-phenyl-N-{5-[4-({5-[(phenylacetyl)amino]-1,3,4-thiadiazol-2-yl}amino)piperidin-1-yl]-1,3,4-thiadiazol-2-yl}acetamide (UPGL-00004)
5HL1	;	2.4	;	Crystal structure of glutaminase C in complex with inhibitor CB-839
3M3P	;	1.3	;	Crystal structure of glutamine amido transferase from Methylobacillus Flagellatus
2YWD	;	1.9	;	Crystal structure of glutamine amidotransferase
5DM3	;	2.6	;	Crystal Structure of Glutamine Synthetase from Chromohalobacter salexigens DSM 3043(Csal_0679, TARGET EFI-550015) with bound ADP
5ZLI	;	2.8	;	Crystal structure of glutamine synthetase from helicobacter pylori
5ZLP	;	2.93	;	Crystal structure of glutamine synthetase from helicobacter pylori
1F52	;	2.49	;	CRYSTAL STRUCTURE OF GLUTAMINE SYNTHETASE FROM SALMONELLA TYPHIMURIUM CO-CRYSTALLIZED WITH ADP
1FPY	;	2.89	;	CRYSTAL STRUCTURE OF GLUTAMINE SYNTHETASE FROM SALMONELLA TYPHIMURIUM WITH INHIBITOR PHOSPHINOTHRICIN
1F1H	;	2.67	;	CRYSTAL STRUCTURE OF GLUTAMINE SYNTHETASE FROM SALMONELLA TYPHIMURIUM WITH THALLIUM IONS
4BAX	;	2.55	;	Crystal structure of glutamine synthetase from Streptomyces coelicolor
3NG0	;	2.8	;	Crystal Structure of Glutamine Synthetase from Synechocystis sp. PCC 6803
4G4P	;	1.5	;	Crystal structure of glutamine-binding protein from Enterococcus faecalis at 1.5 A
3SYT	;	2.6511	;	Crystal structure of glutamine-dependent NAD+ synthetase from M. tuberculosis bound to AMP/PPi, NAD+, and glutamate
5BNZ	;	1.9	;	Crystal structure of Glutamine-tRNA ligase /Glutaminyl-tRNA synthetase (GlnRS) from Pseudomonas aeruginosa
4FWU	;	2.0	;	Crystal structure of glutaminyl cyclase from drosophila melanogaster in space group I4
1EUQ	;	3.1	;	CRYSTAL STRUCTURE OF GLUTAMINYL-TRNA SYNTHETASE COMPLEXED WITH A TRNA-GLN MUTANT AND AN ACTIVE-SITE INHIBITOR
3OJ0	;	1.648	;	Crystal structure of glutamyl-tRNA reductase from Thermoplasma volcanium (nucleotide binding domain)
7K86	;	2.05	;	Crystal Structure of Glutamyl-tRNA synthetase (gltX) from Stenotrophomonas maltophilia
2O5R	;	2.34	;	Crystal structure of Glutamyl-tRNA synthetase 1 (EC 6.1.1.17) (Glutamate-tRNA ligase 1) (GluRS 1) (TM1351) from Thermotoga maritima at 2.5 A resolution
8VC5	;	2.3	;	Crystal structure of glutamyl-tRNA synthetase GluRS from Pseudomonas aeruginosa (Zinc bound)
2GI3	;	1.8	;	Crystal structure of Glutamyl-tRNA(Gln) amidotransferase subunit A (tm1272) from THERMOTOGA MARITIMA at 1.80 A resolution
3LGC	;	2.77	;	Crystal Structure of Glutaredoxin 1 from Francisella tularensis
3MSZ	;	2.053	;	Crystal Structure of Glutaredoxin 1 from Francisella tularensis Complexed with Cacodylate
4HJM	;	1.5462	;	Crystal structure of Glutaredoxin 1 from Plasmodium falciparum (PfGrx1) solved by S-SAD
3H8Q	;	2.21	;	Crystal structure of glutaredoxin domain of human thioredoxin reductase 3
4F2I	;	1.67	;	Crystal structure of glutaredoxin-like NrdH from Mycobacterium tuberculosis
2YWM	;	2.3	;	Crystal structure of glutaredoxin-like protein from Aquifex aeolicus
1J08	;	2.3	;	Crystal structure of glutaredoxin-like protein from Pyrococcus horikoshii
3II9	;	1.74	;	Crystal structure of glutaryl-coa dehydrogenase from Burkholderia pseudomallei at 1.73 Angstrom
3GQT	;	1.99	;	Crystal structure of glutaryl-CoA dehydrogenase from Burkholderia pseudomallei with fragment (1,4-dimethyl-1,2,3,4-tetrahydroquinoxalin-6-yl)methylamine
3GNC	;	2.15	;	Crystal structure of Glutaryl-COA dehydrogenase from Burkholderia Pseudomallei with fragment 6421
3SF6	;	1.7	;	Crystal structure of Glutaryl-CoA dehydrogenase from Mycobacterium smegmatis
3O0H	;	1.9	;	Crystal structure of glutathione reductase from Bartonella henselae
2HQM	;	2.4	;	Crystal Structure of Glutathione Reductase Glr1 from the Yeast Saccharomyces cerevisiae
3LXT	;	1.76	;	Crystal structure of Glutathione S Transferase from Pseudomonas fluorescens
3M0F	;	1.6	;	Crystal structure of Glutathione S Transferase in complex with glutathione from Pseudomonas fluorescens
1U3I	;	1.89	;	Crystal structure of glutathione S-tranferase from Schistosoma mansoni
3BBY	;	1.85	;	Crystal structure of glutathione S-transferase (NP_416804.1) from Escherichia coli K12 at 1.85 A resolution
4JBB	;	1.48	;	Crystal structure of Glutathione S-transferase A6TBY7(Target EFI-507184) from Klebsiella pneumoniae MGH 78578, GSH complex
4HZ4	;	1.62	;	Crystal structure of glutathione s-transferase b4xh91 (target efi-501787) from actinobacillus pleuropneumoniae
4Q5R	;	2.249	;	Crystal Structure of Glutathione S-transferase Bla g 5
6JI6	;	1.5	;	Crystal structure of glutathione S-transferase complexed and modified with glutathione
4W66	;	2.36	;	Crystal structure of Glutathione S-transferase domain protein from Haliangium ochraceum DSM 14365
3LQ7	;	2.3	;	Crystal structure of glutathione s-transferase from agrobacterium tumefaciens str. c58
1A0F	;	2.1	;	CRYSTAL STRUCTURE OF GLUTATHIONE S-TRANSFERASE FROM ESCHERICHIA COLI COMPLEXED WITH GLUTATHIONESULFONIC ACID
3M3M	;	1.75	;	Crystal structure of glutathione S-transferase from Pseudomonas fluorescens [Pf-5]
3LSZ	;	1.7	;	Crystal structure of glutathione s-transferase from Rhodobacter sphaeroides
7SO8	;	2.2	;	Crystal structure of Glutathione S-Transferase from Shrimp Litopenaeus vannamei in complex with silver ions and a molecules of Glutathione binding in G-site and H-site
4MDC	;	1.78	;	Crystal structure of glutathione S-transferase from Sinorhizobium meliloti 1021, NYSGRC target 021389
4EXJ	;	1.64	;	Crystal structure of glutathione s-transferase like protein lelg_03239 (target efi-501752) from lodderomyces elongisporus
4GLT	;	2.2	;	Crystal structure of glutathione s-transferase MFLA_2116 (target EFI-507160) from methylobacillus flagellatus kt with gsh bound
4IW9	;	1.76	;	Crystal structure of glutathione s-transferase mha_0454 (target efi-507015) from mannheimia haemolytica, gsh complex
4IQ1	;	1.85	;	Crystal structure of glutathione s-transferase MHA_0454 (TARGET EFI-507015) FROM Mannheimia haemolytica, SUBSTRATE-FREE
4JED	;	1.1	;	Crystal structure of glutathione s-transferase mrad2831_1084 (target efi-507060) from methylobacterium radiotolerans jcm 2831, complex with glutathione sulfonate
3RBT	;	2.2	;	Crystal structure of glutathione S-transferase Omega 3 from the silkworm Bombyx mori
6TUM	;	1.48	;	Crystal structure of glutathione s-transferase PA1623 from Pseudomonas aeruginosa PACS2 complexed with tartrate
4ECI	;	1.8	;	Crystal structure of glutathione s-transferase prk13972 (target efi-501853) from pseudomonas aeruginosa pacs2 complexed with acetate
4ECJ	;	1.76	;	Crystal structure of glutathione s-transferase prk13972 (target efi-501853) from pseudomonas aeruginosa pacs2 complexed with glutathione
4HZ2	;	1.5	;	Crystal structure of glutathione s-transferase xaut_3756 (target efi-507152) from xanthobacter autotrophicus py2
3TOT	;	1.76	;	Crystal structure of GLUTATHIONE TRANSFERASE (TARGET EFI-501058) from Ralstonia solanacearum GMI1000
3TOU	;	1.75	;	Crystal structure of GLUTATHIONE TRANSFERASE (TARGET EFI-501058) from Ralstonia solanacearum GMI1000 with GSH bound
3UBK	;	1.95	;	Crystal structure of glutathione transferase (TARGET EFI-501770) from leptospira interrogans
3UBL	;	2.0	;	Crystal structure of glutathione transferase (TARGET EFI-501770) from leptospira interrogans with gsh bound
3UAP	;	2.8	;	Crystal structure of glutathione transferase (TARGET EFI-501774) from methylococcus capsulatus str. bath
3UAR	;	2.6	;	Crystal structure of glutathione transferase (TARGET EFI-501774) from methylococcus capsulatus str. bath with gsh bound
4MF7	;	1.8	;	Crystal structure of glutathione transferase BBTA-3750 from Bradyrhizobium sp., Target EFI-507290
4NHZ	;	1.901	;	Crystal structure of glutathione transferase BBTA-3750 from Bradyrhizobium sp., Target EFI-507290, with one glutathione bound
4MF5	;	1.11	;	Crystal structure of glutathione transferase BgramDRAFT_1843 from Burkholderia graminis, Target EFI-507289, with traces of one GSH bound
4MF6	;	1.2	;	Crystal structure of glutathione transferase BgramDRAFT_1843 from Burkholderia graminis, Target EFI-507289, with two glutathione molecules bound per one protein subunit
8AI8	;	1.7	;	Crystal structure of glutathione transferase Chi 1 from Synechocystis sp. PCC 6803 in complex with glutathione
3MAK	;	1.8	;	Crystal structure of Glutathione transferase dmGSTD1 from Drosophila melanogaster, in complex with glutathione
3F6F	;	1.6	;	Crystal Structure of Glutathione Transferase dmGSTD10 from Drosophila melanogaster
3GH6	;	1.65	;	Crystal Structure of Glutathione Transferase dmgstd10 from Drosophila melanogaster, in complex with glutathione
5EY6	;	1.9	;	CRYSTAL STRUCTURE OF GLUTATHIONE TRANSFERASE F2 FROM POPULUS TRICHOCARPA
5F05	;	1.7	;	Crystal structure of glutathione transferase F5 from Populus trichocarpa
5F06	;	1.8	;	Crystal structure of glutathione transferase F7 from Populus trichocarpa
5F07	;	1.5	;	Crystal structure of glutathione transferase F8 from Populus trichocarpa
4LMV	;	3.204	;	Crystal structure of glutathione transferase GSTFuA2 from Phanerochaete chrysosporium
4LMW	;	2.099	;	Crystal structure of glutathione transferase GSTFuA3 from Phanerochaete chrysosporium
4ISD	;	2.65	;	Crystal structure of GLUTATHIONE TRANSFERASE homolog from BURKHOLDERIA GL BGR1, TARGET EFI-501803, with bound glutathione
4HI7	;	1.25	;	Crystal structure of glutathione transferase homolog from drosophilia mojavensis, TARGET EFI-501819, with bound glutathione
4IVF	;	2.2	;	Crystal structure of glutathione transferase homolog from Lodderomyces elongisporus, target EFI-501753, with two GSH per subunit
4HOJ	;	1.4	;	Crystal structure of glutathione transferase homolog from Neisseria Gonorrhoeae, target EFI-501841, with bound glutathione
4PQH	;	1.4	;	Crystal structure of glutathione transferase lambda1 from Populus trichocarpa
4PQI	;	1.95	;	Crystal structure of glutathione transferase lambda3 from Populus trichocarpa
6HJS	;	1.612	;	Crystal structure of glutathione transferase Omega 1C from Trametes versicolor
6SR8	;	1.94	;	Crystal structure of glutathione transferase Omega 2C from Trametes versicolor
6SRA	;	2.206	;	Crystal structure of glutathione transferase Omega 2C from Trametes versicolor in complex with naringenin
6SR9	;	1.845	;	Crystal structure of glutathione transferase Omega 2C from Trametes versicolor in complex with oxyresveratrol
6GIB	;	2.194	;	Crystal structure of glutathione transferase Omega 2S from Trametes versicolor
6HT6	;	2.671	;	Crystal structure of glutathione transferase Omega 2S from Trametes versicolor in complex with 2,4-dihydroxybenzophenone
6GIC	;	2.304	;	Crystal structure of glutathione transferase Omega 2S from Trametes versicolor in complex with oxyresveratrol
6SRB	;	1.65	;	Crystal structure of glutathione transferase Omega 3C from Trametes versicolor
6F69	;	1.803	;	Crystal structure of glutathione transferase Omega 3S from Trametes versicolor in complex with 2,3,4-Trihydroxybenzophenone
6F66	;	1.749	;	Crystal structure of glutathione transferase Omega 3S from Trametes versicolor in complex with 2,4-Dihydroxybenzophenone
6F67	;	2.398	;	Crystal structure of glutathione transferase Omega 3S from Trametes versicolor in complex with 3,4-Dihydroxybenzophenone
6F6A	;	1.7	;	Crystal structure of glutathione transferase Omega 3S from Trametes versicolor in complex with dihydrowogonin from wild-cherry extract
6F4B	;	1.55	;	Crystal structure of Glutathione Transferase Omega 3S from Trametes versicolor in complex with glutathione
6F51	;	1.92	;	Crystal structure of glutathione transferase Omega 3S from Trametes versicolor in complex with glutathionyl-phenylacetophenone
6F4F	;	1.75	;	Crystal structure of glutathione transferase Omega 3S from Trametes versicolor in complex with glutathionyl-S-dinitrobenzene
6F4K	;	1.55	;	Crystal structure of glutathione transferase Omega 3S from Trametes versicolor in complex with hexyl-glutathione
6HPE	;	1.45	;	Crystal structure of glutathione transferase Omega 3S from Trametes versicolor in complex with the glutathione adduct of phenethyl-isothiocyanate
6F70	;	1.48	;	Crystal structure of glutathione transferase Omega 6S from Trametes versicolor
6F71	;	2.301	;	Crystal structure of glutathione transferase Omega 6S from Trametes versicolor in complex with naringenin
2A2R	;	1.4	;	Crystal Structure of Glutathione Transferase Pi in complex with S-nitrosoglutathione
3CSH	;	1.55	;	Crystal Structure of Glutathione Transferase Pi in complex with the Chlorambucil-Glutathione Conjugate
3HKR	;	1.8	;	Crystal Structure of Glutathione Transferase Pi Y108V Mutant
3HJO	;	1.95	;	Crystal Structure of Glutathione Transferase Pi Y108V Mutant in Complex with the Glutathione Conjugate of Ethacrynic Acid
4NAX	;	1.301	;	Crystal structure of glutathione transferase PPUT_1760 from Pseudomonas putida, target EFI-507288, with one glutathione disulfide bound per one protein subunit
4NHW	;	2.0	;	Crystal structure of glutathione transferase SMc00097 from Sinorhizobium meliloti, target EFI-507275, with one glutathione bound per one protein subunit
4ZB6	;	1.801	;	Crystal structure of glutathione transferase URE2P4 from Phanerochaete chrysosporium in complex with oxidized glutathione.
6GC9	;	3.2	;	Crystal structure of glutathione transferase Xi 1 from Trametes versicolor
6GCA	;	2.282	;	Crystal structure of glutathione transferase Xi 3 from Trametes versicolor
6GCB	;	1.795	;	Crystal structure of glutathione transferase Xi 3 from Trametes versicolor in complex with glutathione
6HTA	;	1.85	;	Crystal structure of glutathione transferase Xi 3 mutant C56S from Trametes versicolor
6GCC	;	1.9	;	Crystal structure of glutathione transferase Xi 3 mutant C56S from Trametes versicolor in complex with dextran-sulfate
4PUA	;	1.708	;	Crystal Structure Of glutathione transferase YghU from Streptococcus pneumoniae ATCC 700669, complexed with glutathione, Target EFI-507284
2CZ2	;	1.4	;	Crystal structure of glutathione transferase zeta 1-1 (maleylacetoacetate isomerase) from Mus musculus (form-1 crystal)
2CZ3	;	2.3	;	Crystal structure of glutathione transferase zeta 1-1 (maleylacetoacetate isomerase) from Mus musculus (form-2 crystal)
4DEJ	;	2.9	;	Crystal structure of glutathione transferase-like protein IL0419 (Target EFI-501089) from Idiomarina loihiensis L2TR
3M8U	;	1.85	;	Crystal structure of glutathione-binding protein A (GbpA) from Haemophilus parasuis SH0165 in complex with glutathione disulfide (GSSG)
3CMI	;	2.02	;	Crystal structure of glutathione-dependent phospholipid peroxidase Hyr1 from the yeast Saccharomyces cerevisiae
1PA3	;	2.7	;	Crystal Structure of Glutathione-S-transferase from Plasmodium falciparum
6QUQ	;	2.993	;	Crystal structure of glutathionylated glycolytic glyceraldehyde-3- phosphate dehydrogenase from Arabidopsis thaliana (AtGAPC1)
1U8X	;	2.05	;	CRYSTAL STRUCTURE OF GLVA FROM BACILLUS SUBTILIS, A METAL-REQUIRING, NAD-DEPENDENT 6-PHOSPHO-ALPHA-GLUCOSIDASE
7JLK	;	1.99	;	Crystal structure of glVRC01 Fab in complex with anti-idiotype iv1 scFv
7JLN	;	2.57	;	Crystal structure of glVRC01 Fab in complex with anti-idiotype iv9 Fab
6XOC	;	2.45	;	Crystal structure of glVRC01 Fab in complex with anti-idiotypic iv4 Fab
6OL7	;	2.419	;	Crystal structure of glVRC01 scFv in complex with anti-idiotype iv8 scFv
3R6S	;	2.38	;	Crystal structure of GlxR transcription factor from Corynebacterium glutamicum with cAMP
3DRU	;	3.2	;	Crystal Structure of Gly117Phe Alpha1-Antitrypsin
1Z4S	;	2.6	;	Crystal Structure of Gly19 and Glu60 deletion mutant of Human Acidic Fibroblast Growth Factor
1YTO	;	2.1	;	Crystal Structure of Gly19 deletion Mutant of Human Acidic Fibroblast Growth Factor
5MC2	;	1.7	;	Crystal Structure of Gly278Asp mutant of Human Prolidase with Mn ions and GlyPro ligand
5MC4	;	1.8	;	Crystal Structure of Gly448Arg mutant of Human Prolidase with Mn ions and GlyPro ligand
7DC4	;	0.95	;	Crystal structure of glycan-bound Pseudomonas taiwanensis lectin
7DC0	;	1.88	;	Crystal structure of glycan-free Pseudomonas taiwanensis lectin
3B75	;	2.3	;	Crystal Structure of Glycated Human Haemoglobin
8I7E	;	2.05	;	Crystal structure of Glyceraldehyde 3-phosphate dehydrogenase from Salmonella typhi at 2.05A
1VC2	;	2.6	;	Crystal structure of Glyceraldehyde 3-Phosphate Dehydrogenase from Thermus thermophilus HB8
4ZOH	;	2.2	;	Crystal structure of glyceraldehyde oxidoreductase
2YYY	;	1.85	;	Crystal structure of Glyceraldehyde-3-phosphate dehydrogenase
6OK4	;	2.4	;	Crystal Structure of Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) from Chlamydia trachomatis with bound NAD
7JWK	;	2.2	;	Crystal Structure of Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH) from Mycoplasma genitalium with bound NAD
4IQ8	;	2.49	;	Crystal structure of glyceraldehyde-3-phosphate dehydrogenase 3 from Saccharomyces cerevisiae
3B1K	;	3.302	;	Crystal structure of Glyceraldehyde-3-Phosphate Dehydrogenase complexed with CP12 in the absence of copper from Synechococcus elongatus
3B1J	;	2.2	;	Crystal structure of Glyceraldehyde-3-Phosphate Dehydrogenase complexed with CP12 in the presence of copper from Synechococcus elongatus
3B20	;	2.398	;	Crystal structure of Glyceraldehyde-3-Phosphate Dehydrogenase complexed with NADfrom Synechococcus elongatus""
3L0D	;	2.5	;	Crystal structure of glyceraldehyde-3-phosphate dehydrogenase from Bartonella henselae with bound NAD
3HJA	;	2.2	;	Crystal structure of glyceraldehyde-3-phosphate dehydrogenase from Borrelia burgdorferi
8HRQ	;	2.09	;	Crystal structure of glyceraldehyde-3-phosphate dehydrogenase from Corynebacterium glutamicum ATCC13032 (L36S/T37K) in complex with NAD
8HRR	;	2.0	;	Crystal structure of glyceraldehyde-3-phosphate dehydrogenase from Corynebacterium glutamicum ATCC13032 (L36S/T37K/F100V) in complex with NADP
8HRT	;	1.99	;	Crystal structure of glyceraldehyde-3-phosphate dehydrogenase from Corynebacterium glutamicum ATCC13032 (L36S/T37K/F100V/P192S) in complex with NADP
8HRS	;	2.0	;	Crystal structure of glyceraldehyde-3-phosphate dehydrogenase from Corynebacterium glutamicum ATCC13032 (L36S/T37K/P192S) in complex with NADP
8HRO	;	2.59	;	Crystal structure of glyceraldehyde-3-phosphate dehydrogenase from Corynebacterium glutamicum ATCC13032 in complex with NAD
8HRP	;	1.99	;	Crystal structure of glyceraldehyde-3-phosphate dehydrogenase from Corynebacterium glutamicum ATCC13032 in complex with NAD and G3P
8JB1	;	2.44	;	Crystal structure of glyceraldehyde-3-phosphate dehydrogenase from Corynebacterium glutamicum ATCC13032 in complex with NADP
6NLX	;	1.8	;	Crystal Structure of Glyceraldehyde-3-phosphate Dehydrogenase from Naegleria fowleri with bound NAD
5DDI	;	2.4	;	Crystal structure of glyceraldehyde-3-phosphate dehydrogenase from pig muscle - holo enzyme - at 2.40 Angstrom resolution
5TSO	;	1.9	;	CRYSTAL STRUCTURE OF GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE FROM PIG MUSCLE COMPLEXED WITH ORTHOPHENANTHROLINE AT 1.90 ANGSTROM RESOLUTION
2B4R	;	2.25	;	Crystal structure of glyceraldehyde-3-phosphate dehydrogenase from Plasmodium falciparum at 2.25 Angstrom Resolution reveals intriguing extra electron density in the active site
2B4T	;	2.5	;	Crystal structure of glyceraldehyde-3-phosphate dehydrogenase from Plasmodium falciparum at 2.25 Angstrom resolution reveals intriguing extra electron density in the active site
2CZC	;	2.0	;	Crystal structure of glyceraldehyde-3-phosphate dehydrogenase from Pyrococcus horikoshii OT3
4QX6	;	2.46	;	CRYSTAL STRUCTURE OF GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE FROM STREPTOCOCCUS AGALACTIAE NEM316 at 2.46 ANGSTROM RESOLUTION
3STH	;	2.25	;	Crystal structure of glyceraldehyde-3-phosphate dehydrogenase from Toxoplasma gondii
7D1G	;	1.58	;	Crystal structure of Glyceraldehyde-3-Phosphate Dehydrogenase GAPDH from Clostridium beijerinckii
3PQA	;	1.5	;	Crystal structure of glyceraldehyde-3-phosphate dehydrogenase GapN from Methanocaldococcus jannaschii DSM 2661
3RHD	;	2.2	;	Crystal structure of glyceraldehyde-3-phosphate dehydrogenase GapN from Methanocaldococcus jannaschii DSM 2661 complexed with NADP
2I5P	;	2.3	;	Crystal structure of glyceraldehyde-3-phosphate dehydrogenase isoform 1 from K. marxianus
3GNQ	;	2.4	;	Crystal structure of glyceraldehyde-3-phosphate dehydrogenase, type I from Burkholderia pseudomallei
7C5F	;	1.88	;	Crystal Structure of Glyceraldehyde-3-phosphate dehydrogenase1 from Escherichia coli at 1.88 Angstrom resolution
7C5H	;	2.09	;	Crystal Structure of Glyceraldehyde-3-phosphate dehydrogenase1 from Escherichia coli at 2.09 Angstrom resolution
3GVX	;	2.2	;	Crystal structure of Glycerate dehydrogenase related protein from Thermoplasma acidophilum
2B8N	;	2.53	;	Crystal structure of Glycerate kinase (EC 2.7.1.31) (tm1585) from THERMOTOGA MARITIMA at 2.70 A resolution
3CE9	;	2.37	;	Crystal structure of glycerol dehydrogenase (NP_348253.1) from Clostridium acetobutylicum at 2.37 A resolution
1TA9	;	1.9	;	Crystal structure of glycerol dehydrogenase from Schizosaccharomyces pombe
4MCA	;	1.9	;	Crystal Structure of Glycerol Dehydrogenase from Serratia to 1.9A
8GOA	;	2.9	;	Crystal Structure of Glycerol Dehydrogenase in the absence of NAD+
8GOB	;	2.6	;	Crystal Structure of Glycerol Dehydrogenase in the presence of NAD+
8X6M	;	2.0	;	Crystal Structure of Glycerol Dehydrogenase in the Presence of NAD+ and Glycerol
2D4W	;	2.3	;	Crystal structure of glycerol kinase from Cellulomonas sp. NT3060
6UDE	;	1.95	;	Crystal structure of Glycerol kinase from Elizabethkingia anophelis NUHP1 in complex with ADP and glycerol
5AZI	;	2.45	;	Crystal structure of glycerol kinase from Trypanosoma brucei gambiense complexed with 4NP
5AZJ	;	2.61	;	Crystal structure of glycerol kinase from Trypanosoma brucei gambiense complexed with 4NP (with disulfide bridge)
5GN5	;	2.85	;	Crystal structure of glycerol kinase from Trypanosoma brucei gambiense complexed with cumarin derivative-17
5GN6	;	2.5	;	Crystal structure of glycerol kinase from Trypanosoma brucei gambiense complexed with cumarin derivative-17b
4E1J	;	2.33	;	Crystal structure of glycerol kinase in complex with glycerol from Sinorhizobium meliloti 1021
4I9F	;	2.21	;	Crystal structure of glycerol phosphate phosphatase Rv1692 from Mycobacterium tuberculosis in complex with calcium
4I9G	;	3.25	;	Crystal structure of glycerol phosphate phosphatase Rv1692 from Mycobacterium tuberculosis in complex with magnesium
4JIQ	;	2.49	;	Crystal structure of glycerol trinitrate reductase NerA from Agrobacterium radiobacter in complex with 1-nitro-2-phenylpropene
4JIP	;	2.29	;	Crystal structure of glycerol trinitrate reductase NerA from Agrobacterium radiobacter in complex with 4-hydroxybenzaldehyde
5EPD	;	2.1	;	Crystal structure of Glycerol Trinitrate Reductase XdpB from Agrobacterium sp. R89-1 (Apo form)
3KTS	;	2.75	;	CRYSTAL STRUCTURE OF GLYCEROL UPTAKE OPERON ANTITERMINATOR REGULATORY PROTEIN FROM LISTERIA MONOCYTOGENES STR. 4b F2365
3RF6	;	1.695	;	Crystal structure of glycerol-3 phosphate bound HAD-like phosphatase from Saccharomyces cerevisiae
1Z82	;	2.0	;	Crystal structure of glycerol-3-phosphate dehydrogenase (TM0378) from THERMOTOGA MARITIMA at 2.00 A resolution
2QCU	;	1.75	;	Crystal structure of Glycerol-3-phosphate Dehydrogenase from Escherichia coli
1O1Z	;	1.6	;	Crystal structure of glycerophosphodiester phosphodiesterase (GDPD) (TM1621) from Thermotoga maritima at 1.60 A resolution
2PZ0	;	1.91	;	Crystal structure of Glycerophosphodiester Phosphodiesterase (GDPD) from T. tengcongensis
1ZCC	;	2.5	;	Crystal structure of glycerophosphodiester phosphodiesterase from Agrobacterium tumefaciens str.C58
4OEC	;	1.9	;	Crystal structure of glycerophosphodiester phosphodiesterase from Thermococcus kodakarensis KOD1
3CH0	;	1.5	;	Crystal structure of glycerophosphoryl diester phosphodiesterase (YP_677622.1) from Cytophaga hutchinsonii ATCC 33406 at 1.50 A resolution
1VD6	;	1.3	;	Crystal Structure of Glycerophosphoryl Diester Phosphodiesterase complexed with Glycerol
5VUG	;	1.5	;	Crystal Structure of Glycerophosphoryl Diester Phosphodiesterase Domain of Uncharacterized Protein Rv2277c from Mycobacterium tuberculosis
2OOG	;	2.2	;	Crystal structure of glycerophosphoryl diester phosphodiesterase from Staphylococcus aureus
1V8E	;	1.5	;	Crystal Structure of Glycerophosphoryl Diester Phosphodiesterase from Thermus thermophilus HB8
3DCJ	;	2.2	;	Crystal structure of glycinamide formyltransferase (PurN) from Mycobacterium tuberculosis in complex with 5-methyl-5,6,7,8-tetrahydrofolic acid derivative
2IP4	;	2.8	;	Crystal Structure of Glycinamide Ribonucleotide Synthetase from Thermus thermophilus HB8
3AV3	;	1.7	;	Crystal structure of glycinamide ribonucleotide transformylase 1 from Geobacillus kaustophilus
3AUF	;	2.07	;	Crystal structure of glycinamide ribonucleotide transformylase 1 from Symbiobacterium toebii
1GRC	;	3.0	;	CRYSTAL STRUCTURE OF GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE FROM ESCHERICHIA COLI AT 3.0 ANGSTROMS RESOLUTION: A TARGET ENZYME FOR CHEMOTHERAPY
1KJQ	;	1.05	;	Crystal structure of glycinamide ribonucleotide transformylase in complex with Mg-ADP
1KJI	;	1.6	;	Crystal structure of glycinamide ribonucleotide transformylase in complex with Mg-AMPPCP
3TMG	;	1.9	;	Crystal structure of Glycine betaine, L-proline ABC transporter, glycine/betaine/L-proline-binding protein (ProX) from Borrelia burgdorferi
3O66	;	1.86	;	Crystal structure of glycine betaine/carnitine/choline ABC transporter
5OBH	;	2.4	;	Crystal structure of glycine binding protein in complex with bicuculline
5OBG	;	2.0	;	Crystal structure of glycine binding protein in complex with strychnine
5A35	;	1.5	;	Crystal structure of Glycine Cleavage Protein H-Like (GcvH-L) from Streptococcus pyogenes
3GIR	;	1.6	;	Crystal structure of glycine cleavage system aminomethyltransferase T from Bartonella henselae
1ZKO	;	1.65	;	Crystal structure of Glycine cleavage system H protein (tm0212) from Thermotoga maritima at 1.65 A resolution
3MXU	;	1.8	;	Crystal structure of glycine cleavage system protein H from Bartonella henselae
3HGB	;	1.75	;	Crystal structure of glycine cleavage system protein H from Mycobacterium tuberculosis
3IFT	;	2.0	;	Crystal structure of glycine cleavage system protein H from Mycobacterium tuberculosis, using X-rays from the Compact Light Source.
1WYT	;	2.4	;	Crystal structure of glycine decarboxylase (P-protein) of the glycine cleavage system, in apo form
1WYU	;	2.1	;	Crystal structure of glycine decarboxylase (P-protein) of the glycine cleavage system, in holo form
1WYV	;	2.4	;	Crystal structure of glycine decarboxylase (P-protein) of the glycine cleavage system, in inhibitor-bound form
4LGL	;	2.0004	;	Crystal Structure of Glycine Decarboxylase P-protein from Synechocystis sp. PCC 6803, apo form
1KIA	;	2.8	;	Crystal structure of glycine N-methyltransferase complexed with S-adenosylmethionine and acetate
4YSH	;	2.2	;	Crystal structure of glycine oxidase from Geobacillus kaustophilus
3IF9	;	2.6	;	Crystal structure of Glycine Oxidase G51S/A54R/H244A mutant in complex with inhibitor glycolate
3OXB	;	2.947	;	Crystal structure of glycine riboswitch with single mutation
3OXD	;	2.999	;	Crystal structure of glycine riboswitch with two mutations
3OXE	;	2.899	;	crystal structure of glycine riboswitch, Mn2+ soaked
3OXJ	;	3.2	;	crystal structure of glycine riboswitch, soaked in Ba2+
3OWZ	;	2.949	;	Crystal structure of glycine riboswitch, soaked in Iridium
3OXM	;	2.95	;	crystal structure of glycine riboswitch, Tl-Acetate soaked
3OX0	;	3.049	;	Crystal structure of glycine riboswitch, unbound state
5HII	;	1.9	;	Crystal structure of glycine sarcosine N-methyltransferase (GSMT) from Methanohalophilus portucalensis (apo form)
5HIJ	;	1.93	;	Crystal structure of glycine sarcosine N-methyltransferase from Methanohalophilus portucalensis in complex with betaine
5HIM	;	2.338	;	Crystal structure of glycine sarcosine N-methyltransferase from Methanohalophilus portucalensis in complex with S-adenosylhomocysteine and dimethylglycine
5HIL	;	2.471	;	Crystal structure of glycine sarcosine N-methyltransferase from Methanohalophilus portucalensis in complex with S-adenosylhomocysteine and sarcosine
5HIK	;	2.354	;	Crystal structure of glycine sarcosine N-methyltransferase from Methanohalophilus portucalensis in complex with S-adenosylmethionine
5GWX	;	2.205	;	Crystal structure of glycine sarcosine N-methyltransferase from Methanohalophilus portucalensis in complex with S-adenosylmethionine and sarcosine
8SLF	;	2.9	;	Crystal Structure of Glycine tRNA ligase from Mycobacterium thermoresistibile (AMP bound)
8SLH	;	3.05	;	Crystal Structure of Glycine tRNA ligase from Mycobacterium thermoresistibile (AMP bound, hexagonal form)
8SLD	;	2.85	;	Crystal Structure of Glycine tRNA ligase from Mycobacterium thermoresistibile (Apo)
8SLG	;	1.95	;	Crystal Structure of Glycine tRNA ligase from Mycobacterium thermoresistibile (glycyl adenylate bound)
8U2Q	;	2.45	;	Crystal Structure of Glycine--tRNA ligase active site chimera from Mycobacterium thermoresistibile/tuberculosis (G5A bound)
8T5N	;	1.65	;	Crystal Structure of Glycine--tRNA ligase from Mycobacterium tuberculosis (AMP-Mg bound)
8U2P	;	2.25	;	Crystal Structure of Glycine--tRNA ligase from Mycobacterium tuberculosis (G5A bound)
1OD5	;	2.1	;	Crystal structure of glycinin A3B4 subunit homohexamer
1KJJ	;	1.75	;	Crystal structure of glycniamide ribonucleotide transformylase in complex with Mg-ATP-gamma-S
3K1D	;	2.33	;	Crystal structure of glycogen branching enzyme synonym: 1,4-alpha-D-glucan:1,4-alpha-D-GLUCAN 6-glucosyl-transferase from mycobacterium tuberculosis H37RV
2WSK	;	2.25	;	Crystal structure of Glycogen Debranching Enzyme GlgX from Escherichia coli K-12
2VNC	;	3.0	;	Crystal structure of Glycogen Debranching enzyme TreX from Sulfolobus solfataricus
2VUY	;	3.0	;	Crystal structure of Glycogen Debranching exzyme TreX from Sulfolobus solfatarius
3DD1	;	2.57	;	Crystal structure of glycogen phophorylase complexed with an anthranilimide based inhibitor GSK254
1P2D	;	1.94	;	Crystal Structure of Glycogen Phosphorylase B in complex with Beta Cyclodextrin
1P4H	;	2.06	;	Crystal structure of glycogen phosphorylase b in complex with C-(1-acetamido-alpha-D-glucopyranosyl) formamide
1P4G	;	2.1	;	Crystal structure of glycogen phosphorylase b in complex with C-(1-azido-alpha-D-glucopyranosyl)formamide
1P4J	;	2.0	;	Crystal structure of glycogen phosphorylase b in complex with C-(1-hydroxy-beta-D-glucopyranosyl)formamide
1P2G	;	2.3	;	Crystal Structure of Glycogen Phosphorylase B in complex with Gamma Cyclodextrin
5LRD	;	1.8	;	Crystal structure of Glycogen Phosphorylase b in complex with KS242
5LRE	;	1.8	;	Crystal structure of Glycogen Phosphorylase b in complex with KS382
5LRF	;	1.75	;	Crystal structure of Glycogen Phosphorylase b in complex with KS389
1P2B	;	2.2	;	Crystal Structure of Glycogen Phosphorylase B in Complex with Maltoheptaose
1P29	;	2.2	;	Crystal Structure of glycogen phosphorylase b in complex with maltopentaose
3CUT	;	2.3	;	Crystal structure of glycogen phosphorylase b in complex with N-(-D-glucopyranosyl)-N'-(2-naphthyl)oxamide
3CUU	;	2.3	;	Crystal structure of glycogen phosphorylase b in complex with N-(-D-glucopyranosyl)-N'-(2-naphthyl)oxamides
3CUW	;	2.0	;	Crystal structure of glycogen phosphorylase b in complex with N-(-D-glucopyranosyl)-N'-(2-naphthyl)oxamides
3DDW	;	1.9	;	Crystal structure of glycogen phosphorylase complexed with an anthranilimide based inhibitor GSK055
3DDS	;	1.8	;	Crystal structure of glycogen phosphorylase complexed with an anthranilimide based inhibitor GSK261
3L79	;	1.86	;	Crystal Structure of Glycogen Phosphorylase DK1 complex
3L7A	;	1.9	;	Crystal Structure of Glycogen Phosphorylase DK2 complex
3L7B	;	2.0	;	Crystal Structure of Glycogen Phosphorylase DK3 complex
3L7C	;	1.93	;	Crystal Structure of Glycogen Phosphorylase DK4 complex
3L7D	;	2.0	;	Crystal Structure of Glycogen Phosphorylase DK5 complex
2PYI	;	1.88	;	Crystal structure of Glycogen Phosphorylase in complex with glucosyl triazoleacetamide
5LRC	;	2.0	;	Crystal structure of Glycogen Phosphorylase in complex with KS114
8DJC	;	2.463	;	CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH (4S)-N-{4-[(2S)-2-methylmorpholin-4-yl] pyridin-3-yl}-2-phenylimidazo[1,2-b]pyridazine-8-carboxamide
8FF8	;	2.33	;	CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 2-[(4-CYANOPHENYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIMIDINE-4-CARBOXAMIDE
8DJD	;	2.205	;	CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 3-[(CYCLOPROPYLMETHYL)AMINO] -N-(4-PHENYLPYRIDIN-3-YL)IMIDAZO[1,2-B]PYRIDAZINE-8-CARBOX AMIDE
8DJE	;	2.374	;	CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 3-[(CYCLOPROPYLMETHYL)AMINO] -N-(4-PHENYLPYRIDIN-3-YL)IMIDAZO[1,2-B]PYRIDAZINE-8-CARBOX AMIDE
1Q5K	;	1.94	;	crystal structure of Glycogen synthase kinase 3 in complexed with inhibitor
6GN1	;	2.6	;	Crystal Structure of Glycogen synthase kinase-3 beta (GSK3B) in Complex with PIK-75
6GJO	;	2.91	;	Crystal Structure of Glycogen Synthase Kinase-3 beta in Complex with BI-91BS
2YVS	;	2.0	;	Crystal structure of glycolate oxidase subunit GlcE from Thermus thermophilus HB8
5OWP	;	1.85	;	Crystal structure of glycopeptide ""GVTSAfPDT*RPAP"" in complex with scFv-SM3
5FXC	;	2.05	;	Crystal structure of glycopeptide 22 in complex with scFv-SM3
5AWV	;	1.93	;	Crystal structure of glycopeptide hexose oxidase DBV29 complexed with teicoplanin
5V2S	;	3.6	;	Crystal structure of glycoprotein B from Herpes Simplex Virus type I
6BM8	;	4.1	;	Crystal structure of glycoprotein B from Herpes Simplex Virus type I
5J81	;	1.8	;	Crystal structure of Glycoprotein C from Puumala virus in the post-fusion conformation (pH 6.0)
5J9H	;	2.5	;	Crystal structure of Glycoprotein C from Puumala virus in the post-fusion conformation (pH 8.0)
4HJ1	;	1.9	;	Crystal structure of glycoprotein C from Rift Valley Fever Virus (glycosylated)
4HJC	;	4.15	;	Crystal structure of glycoprotein C from Rift Valley Fever Virus (non-glycosylated)
6SQJ	;	2.245	;	Crystal structure of glycoprotein D of Equine Herpesvirus Type 1
6TM8	;	1.9	;	Crystal structure of glycoprotein D of Equine Herpesvirus Type 4
2A6A	;	2.5	;	Crystal structure of Glycoprotein endopeptidase (tm0874) from THERMOTOGA MARITIMA at 2.50 A resolution
3RFE	;	1.245	;	Crystal structure of glycoprotein GPIb ectodomain
5OU9	;	2.5	;	Crystal structure of Glycoprotein VI in complex with collagen-peptide (GPO)3
5OU8	;	2.5	;	Crystal structure of Glycoprotein VI in complex with collagen-peptide (GPO)5
7DFM	;	2.4	;	Crystal structure of glycoside hydrolase family 11 beta-xylanase from Streptomyces olivaceoviridis E-86
7DFO	;	2.0	;	Crystal structure of glycoside hydrolase family 11 beta-xylanase from Streptomyces olivaceoviridis E-86 in complex with 4-O-methyl-alpha-D-glucuronopyranosyl xylotetraose
7DFN	;	2.0	;	Crystal structure of glycoside hydrolase family 11 beta-xylanase from Streptomyces olivaceoviridis E-86 in complex with alpha-L-arabinofuranosyl xylotetraose
4WTP	;	1.3	;	Crystal structure of glycoside hydrolase family 17 beta-1,3-glucanosyltransferase from Rhizomucor miehei
3C7H	;	2.0	;	Crystal structure of glycoside hydrolase family 43 arabinoxylan arabinofuranohydrolase from Bacillus subtilis in complex with AXOS-4-0.5.
4NRS	;	2.57	;	Crystal Structure of Glycoside Hydrolase Family 5 Mannosidase (E202A mutant) from Rhizomucor miehei in complex with mannobiose
4NRR	;	2.4	;	Crystal Structure of Glycoside Hydrolase Family 5 Mannosidase (E202A mutant) from Rhizomucor miehei in complex with mannosyl-fructose
4LYP	;	1.28	;	Crystal Structure of Glycoside Hydrolase Family 5 Mannosidase from Rhizomucor miehei
4LYQ	;	2.0	;	Crystal Structure of Glycoside Hydrolase Family 5 Mannosidase from Rhizomucor miehei, E202A mutant
3SQL	;	2.25	;	Crystal Structure of Glycoside Hydrolase from Synechococcus
3SQM	;	2.703	;	Crystal Structure of Glycoside Hydrolase from Synechococcus Complexed with N-acetyl-D-glucosamine
7VTK	;	1.90697	;	Crystal structure of Glycoside Hydrolases family 64 beta-1,3-glucanase
8HKG	;	2.56	;	Crystal structure of glycosidic hydrolase family 10 (GH10) xylanase XynA contains an additional proline-rich sequence in the C-terminus
5TF0	;	2.2021	;	Crystal Structure of Glycosil Hydrolase Family 3 N-Terminal Domain Protein from Bacteroides intestinalis
1GYQ	;	3.4	;	CRYSTAL STRUCTURE OF GLYCOSOMAL GLYCERALDEHYDE FROM LEISHMANIA MEXICANA IN COMPLEX WITH N6-BENZYL-NAD
1GYP	;	2.8	;	CRYSTAL STRUCTURE OF GLYCOSOMAL GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE FROM LEISHMANIA MEXICANA: IMPLICATIONS FOR STRUCTURE-BASED DRUG DESIGN AND A NEW POSITION FOR THE INORGANIC PHOSPHATE BINDING SITE
3KZS	;	2.1	;	Crystal structure of glycosyl hydrolase family 5 (NP_809925.1) from BACTEROIDES THETAIOTAOMICRON VPI-5482 at 2.10 A resolution
4W65	;	1.38	;	Crystal Structure of Glycosyl hydrolase family protein from Mycobacterium fortuitum
7P6J	;	1.75	;	Crystal structure of glycosyl-enzyme intermediate of RBcel1 Y201F
2GL9	;	2.0	;	Crystal Structure of Glycosylasparaginase-Substrate Complex
6MFT	;	2.315	;	Crystal structure of glycosylated 426c HIV-1 gp120 core G459C in complex with glVRC01 A60C heavy chain
6E8N	;	3.2	;	Crystal structure of glycosylated human EPDR1
3FIR	;	2.0	;	Crystal structure of Glycosylated K135E PEB3
4DYH	;	2.0	;	Crystal structure of glycosylated Lipase from Humicola lanuginosa at 2 Angstrom resolution
6NYQ	;	1.85	;	Crystal structure of glycosylated lysosomal membrane protein (GLMP) luminal domain bound to a Fab fragment
5LFR	;	2.12	;	Crystal structure of glycosylated Myelin-associated glycoprotein (MAG) Ig1-3
5LFV	;	2.3	;	Crystal structure of glycosylated Myelin-associated glycoprotein (MAG) Ig1-3 with soaked trisaccharide ligand
7MI0	;	2.9	;	Crystal Structure of Glycosyltransferase from Rickettsia africae ESF-5
3WAG	;	2.1	;	Crystal structure of glycosyltransferase VinC in complex with DTDP
3WAD	;	2.0	;	Crystal structure of glycosyltransferase VinC involved in the biosynthesis of vicenistatin
3VGE	;	2.7	;	Crystal structure of glycosyltrehalose trehalohydrolase (D252S)
3VGF	;	2.3	;	Crystal structure of glycosyltrehalose trehalohydrolase (D252S) complexed with maltotriosyltrehalose
3VGG	;	2.66	;	Crystal structure of glycosyltrehalose trehalohydrolase (E283Q) complexed with maltoheptaose
3VGH	;	2.6	;	Crystal structure of glycosyltrehalose trehalohydrolase (E283Q) complexed with maltotriosyltrehalose
3VGB	;	2.65	;	Crystal structure of glycosyltrehalose trehalohydrolase (GTHase) from Sulfolobus solfataricus KM1
1EHA	;	3.0	;	CRYSTAL STRUCTURE OF GLYCOSYLTREHALOSE TREHALOHYDROLASE FROM SULFOLOBUS SOLFATARICUS
2Y8N	;	1.75	;	Crystal structure of glycyl radical enzyme
6XS4	;	2.33	;	Crystal structure of glycyl radical enzyme ECL_02896 from Enterobacter cloacae subsp. cloacae
2YAJ	;	1.813	;	CRYSTAL STRUCTURE OF GLYCYL RADICAL ENZYME with bound substrate
1J5W	;	1.95	;	Crystal structure of Glycyl-tRNA synthetase alpha chain (TM0216) from Thermotoga maritima at 1.95 A resolution
1ATI	;	2.75	;	CRYSTAL STRUCTURE OF GLYCYL-TRNA SYNTHETASE FROM THERMUS THERMOPHILUS
8FI4	;	1.8	;	Crystal Structure of Glycylpeptide N-tetradecanoyltransferase (N-myristoyl transferase) (NMT) from Leishmania major Friedlin bound to tetradecanoyl-CoA (Orthorhombic P Form 1)
8FI5	;	2.25	;	Crystal Structure of Glycylpeptide N-tetradecanoyltransferase (N-myristoyl transferase) (NMT) from Leishmania major Friedlin bound to tetradecanoyl-CoA (Orthorhombic P Form 2)
8FI6	;	1.8	;	Crystal Structure of Glycylpeptide N-tetradecanoyltransferase (N-myristoyl transferase) (NMT) from Leishmania major Friedlin bound to tetradecanoyl-CoA (Orthorhombic P Form 3)
6NXG	;	1.6	;	Crystal structure of glycylpeptide N-tetradecanoyltransferase from Plasmodium vivax in complex with inhibitor 303a
5V0W	;	1.8	;	Crystal structure of glycylpeptide N-tetradecanoyltransferase from Plasmodium vivax in complex with inhibitor IMP-0001088
5V0X	;	2.1	;	Crystal structure of glycylpeptide N-tetradecanoyltransferase from Plasmodium vivax in complex with inhibitor IMP-0001114
6B1L	;	2.3	;	Crystal structure of glycylpeptide N-tetradecanoyltransferase from Plasmodium vivax in complex with inhibitor IMP-0001173
7C2X	;	1.89	;	Crystal Structure of Glycyrrhiza uralensis UGT73P12 complexed with glycyrrhetinic acid 3-O-monoglucuronide
5D7Z	;	1.73	;	Crystal structure of glyoxalase I from Zea mays
4LRU	;	1.6	;	Crystal structure of glyoxalase III (Orf 19.251) from Candida albicans
4G6X	;	1.73	;	Crystal structure of glyoxalase/bleomycin resistance protein from Catenulispora acidiphila.
3RRI	;	1.5	;	Crystal structure of glyoxalase/bleomycin resistance protein/dioxygenase from Alicyclobacillus acidocaldarius
4GYM	;	1.56	;	Crystal structure of Glyoxalase/bleomycin resistance protein/dioxygenase from Conexibacter woesei DSM 14684
2RK0	;	2.04	;	Crystal structure of glyoxylase/bleomycin resistance protein/dioxygenase domain from Frankia sp. EAN1pec
2DBQ	;	1.7	;	Crystal Structure of Glyoxylate Reductase (PH0597) from Pyrococcus horikoshii OT3, Complexed with NADP (I41)
2DBR	;	2.61	;	Crystal Structure of Glyoxylate Reductase (PH0597) from Pyrococcus horikoshii OT3, Complexed with NADP (P1)
2DBZ	;	2.45	;	Crystal Structure of Glyoxylate Reductase (PH0597) from Pyrococcus horikoshii OT3, Complexed with NADP (P61)
6WJL	;	3.3	;	Crystal structure of Glypican-2 core protein in complex with D3 Fab
5TGT	;	2.45	;	Crystal structure of glytamyl-tRNA synthetase GluRS from Pseudomonas aeruginosa
2X3Y	;	2.4	;	Crystal structure of GmhA from Burkholderia pseudomallei
2XBL	;	1.62	;	Crystal structure of GmhA from Burkholderia pseudomallei in complex with product
3L1V	;	1.954	;	Crystal structure of GmhB from E. coli in complex with calcium and phosphate.
6JL8	;	2.804	;	Crystal structure of GMP reductase C318A from Trypanosoma brucei
6JIG	;	1.903	;	Crystal structure of GMP reductase C318A from Trypanosoma brucei in complex with guanosine 5'-monophosphate
7R50	;	2.5	;	Crystal structure of GMP reductase from mycobacterium smegmatis in complex with GMP.
7OY9	;	2.8	;	Crystal structure of GMP reductase from mycobacterium smegmatis.
6LK4	;	2.503	;	Crystal structure of GMP reductase from Trypanosoma brucei in complex with guanosine 5'-triphosphate
2YWB	;	2.1	;	Crystal structure of GMP synthetase from Thermus thermophilus
2YWC	;	2.2	;	Crystal structure of GMP synthetase from Thermus thermophilus in complex with XMP
3A4I	;	1.79	;	Crystal structure of GMP synthetase PH1347 from Pyrococcus horikoshii OT3
6G12	;	1.929	;	Crystal structure of GMPPNP bound RbgA from S. aureus
6CU6	;	1.5	;	Crystal structure of GMPPNP-bound G12R mutant of human KRAS4b
3ZJC	;	3.15	;	Crystal structure of GMPPNP-bound human GIMAP7 L100Q variant
8EBZ	;	1.2	;	Crystal Structure of GMPPNP-bound KRAS-G13D mutant at 1.2 Ang resolution
2YWF	;	2.24	;	Crystal structure of GMPPNP-bound LepA from Aquifex aeolicus
6F8P	;	1.6	;	Crystal structure of Gn from Rift Valley fever virus
2JJA	;	1.3	;	Crystal structure of GNA with synthetic copper base pair
3GXA	;	2.25	;	Crystal structure of GNA1946
3T9Y	;	2.0	;	Crystal structure of GNAT family acetyltransferase Staphylococcus aureus subsp. aureus USA300_TCH1516
3OWC	;	1.9	;	Crystal structure of GNAT superfamily protein PA2578 from Pseudomonas aeruginosa
7RP3	;	2.0	;	Crystal structure of GNE-1952 alkylated KRAS G12C in complex with 2H11 CLAMP
6FBM	;	2.5	;	Crystal structure of GNIP1Aa from Chromobacterium piscinae
4XRE	;	2.597	;	Crystal structure of Gnk2 complexed with mannose
3CNL	;	2.0	;	Crystal structure of GNP-bound YlqF from T. maritima
2HUZ	;	2.67	;	Crystal structure of GNPNAT1
2O28	;	1.8	;	Crystal Structure of GNPNAT1
4XO2	;	1.952	;	crystal structure of GnsA from E.coli
4OMW	;	2.3	;	Crystal structure of goat beta-lactoglobulin (orthorhombic form)
4OMX	;	2.3	;	Crystal structure of goat beta-lactoglobulin (trigonal form)
3RKE	;	2.3	;	Crystal Structure of goat Lactoperoxidase complexed with a tightly bound inhibitor, 4-aminophenyl-4H-imidazole-1-yl methanone at 2.3 A resolution
2EHA	;	3.3	;	Crystal structure of goat lactoperoxidase complexed with formate anion at 3.3 A resolution
4QJQ	;	2.1	;	Crystal structure of goat lactoperoxidase in complex with octopamine at 2.1 Angstrom resolution
5F0U	;	1.68	;	Crystal structure of Gold binding protein
6LHE	;	1.206	;	Crystal Structure of Gold-bound NDM-1
8HTG	;	2.91	;	Crystal structure of Golf in complex with GTP-gamma S and Mg
3BLB	;	1.3	;	Crystal structure of Golgi Mannosidase II in complex with swainsonine at 1.3 Angstrom resolution
3KN1	;	2.9	;	Crystal Structure of Golgi Phosphoprotein 3 N-term Truncation Variant
1SMB	;	1.55	;	Crystal Structure of Golgi-Associated PR-1 protein
3WTB	;	2.2	;	Crystal structure of Gox0525
3WBX	;	2.4	;	Crystal structure of Gox0644 at apoform
3WBY	;	3.2	;	Crystal structure of Gox0644 D53A mutant in complex with NADPH
3WBW	;	1.85	;	Crystal structure of Gox0644 in complex with NADPH
3WTC	;	1.65	;	Crystal structure of Gox2036
3AWD	;	1.8	;	Crystal structure of gox2181
3WJ7	;	2.6	;	Crystal structure of gox2253
4ZJF	;	2.595	;	Crystal structure of GP1 - the receptor binding domain of Lassa virus
6GH8	;	2.44	;	Crystal structure of GP1 domain of Lujo virus in complex with the first CUB domain of neuropilin-2
5NFF	;	2.615	;	Crystal structure of GP1 receptor binding domain from Morogoro virus
7CNB	;	2.32	;	Crystal structure of Gp16 C-terminal domain from Bacillus virus phi29
5OMI	;	2.56	;	Crystal structure of GP2 from Lassa virus in a post fusion conformation
1JE5	;	1.9	;	Crystal Structure of gp2.5, a Single-Stranded DNA Binding Protein Encoded by Bacteriophage T7
5FT0	;	2.2	;	Crystal structure of gp37(Dip) from bacteriophage phiKZ
5FT1	;	2.75	;	Crystal structure of gp37(Dip) from bacteriophage phiKZ bound to RNase E of Pseudomonas aeruginosa
3MA9	;	2.05	;	Crystal structure of gp41 derived protein complexed with fab 8066
4KHX	;	2.921	;	Crystal structure of gp41 helix complexed with antibody 8062
6QAZ	;	1.02	;	Crystal structure of gp41-1 intein
6RIZ	;	1.85	;	Crystal structure of gp41-1 intein (C1A, F65W, D107C)
3O3X	;	1.45	;	Crystal structure of gp41-5, a single-chain 5-helix-bundle based on HIV gp41
3MAC	;	2.5	;	crystal structure of GP41-derived protein complexed with fab 8062
1WTH	;	2.8	;	Crystal structure of gp5-S351L mutant and gp27 complex
4YI3	;	1.8	;	Crystal structure of Gpb in complex with 4a
4YI5	;	1.8	;	Crystal structure of Gpb in complex with 4b
5JTT	;	1.85	;	Crystal structure of GPb in complex with 8a
5JTU	;	1.85	;	Crystal structure of GPb in complex with 8b
4EJ2	;	2.65	;	Crystal structure of GPb in complex with DK10
4EKE	;	2.6	;	Crystal structure of GPb in complex with DK11
4EL5	;	2.0	;	Crystal structure of GPb in complex with DK12
4EKY	;	2.45	;	Crystal structure of GPb in complex with DK15
4EL0	;	2.4	;	Crystal structure of GPb in complex with DK16
4MRA	;	2.34	;	Crystal structure of Gpb in complex with QUERCETIN
4MHO	;	2.0	;	Crystal structure of Gpb in complex with S3, SUGAR (N-[(BIPHENYL-4-YLOXY)ACETYL]-BETA-D-GLUCOPYRANOSYLAMINE)
4MHS	;	2.0	;	Crystal structure of Gpb in complex with SUGAR (N-[(2E)-3-(BIPHENYL-4-YL)PROP-2-ENOYL]-BETA-D-GLUCOPYRANOSYLAMINE
4MI9	;	1.85	;	Crystal structure of Gpb in complex with SUGAR (N-[(3R)-3-(4-ETHYLPHENYL)BUTANOYL]-BETA-D-GLUCOPYRANOSYLAMINE) (S20)
4MI6	;	1.9	;	Crystal structure of Gpb in complex with SUGAR (N-[4-(5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)BUTANOYL]-BETA-D-GLUCOPYRANOSYLAMINE)
4MIC	;	2.45	;	Crystal structure of Gpb in complex with SUGAR (N-{(2E)-3-[4-(PROPAN-2-YL)PHENYL]PROP-2-ENOYL}-BETA-D-GLUCOPYRANOSYLAMINE) (S6)
4MI3	;	2.15	;	Crystal structure of Gpb in complex with SUGAR (N-{(2R)-2-METHYL-3-[4-(PROPAN-2-YL)PHENYL]PROPANOYL}-BETA-D-GLUCOPYRANOSYLAMINE) (S21)
7BPH	;	1.57	;	Crystal structure of GppNHp-bound GNAS in complex with the cyclic peptide inhibitor GN13
3EVE	;	1.7	;	Crystal structure of GpppA complex of yellow fever virus methyltransferase and S-adenosyl-L-homocysteine
6LI0	;	2.2	;	Crystal structure of GPR52 in complex with agonist c17
6LI1	;	2.9	;	Crystal structure of GPR52 ligand free form with flavodoxin fusion
6LI2	;	2.8	;	Crystal structure of GPR52 ligand free form with rubredoxin fusion
7FC2	;	2.0	;	Crystal Structure of GPX6
6NAL	;	2.3	;	Crystal Structure of Gram Negative Toxin
1J77	;	1.5	;	Crystal Structure of Gram-negative Bacterial Heme Oxygenase Complexed with Heme
1XDZ	;	1.6	;	Crystal Structure of Gram_Positive Bacillus subtilis Glucose inhibited Division protein B (gidB), Structural genomics, MCSG
1F4O	;	2.5	;	CRYSTAL STRUCTURE OF GRANCALCIN WITH BOUND CALCIUM
5H3J	;	1.33	;	Crystal structure of Grasp domain of Grasp55 complexed with the Golgin45 C-terminus
5GML	;	2.546	;	Crystal Structure of GRASP Domain of GRASP55 with N terminal extra residues
3RLE	;	1.649	;	Crystal Structure of GRASP55 GRASP domain (residues 7-208)
5GMJ	;	2.986	;	Crystal Structure of GRASP55 GRASP domain in complex with JAM-B C-terminus
5GMI	;	2.71	;	Crystal Structure of GRASP55 GRASP domain in complex with JAM-C C-terminus
7WQY	;	1.95	;	Crystal structure of grass carp ARF1-GDP complex
3GBL	;	2.1	;	Crystal structure of grass carp Beta2-microglobulin
5Z11	;	2.35	;	Crystal Structure of Grass Carp CD8 alpha alpha Homodimers
4J4X	;	2.51	;	Crystal structure of GraVN
6KWS	;	2.8	;	Crystal structure of Gre2 from Candida albicans
6KWT	;	3.02	;	Crystal structure of Gre2 in complex with NADPH complex from Candida albicans
2F23	;	1.6	;	Crystal structure of GreA factor homolog 1 (Gfh1) protein of Thermus thermophilus
1GAK	;	1.85	;	CRYSTAL STRUCTURE OF GREEN ABALONE SP18
4KW4	;	1.746	;	Crystal Structure of Green Fluorescent Protein
4KW8	;	2.459	;	Crystal Structure of Green Fluorescent Protein
4KW9	;	1.8	;	Crystal Structure of Green Fluorescent Protein
6OG8	;	1.599	;	Crystal structure of Green Fluorescent Protein (GFP); S65T, H148D with globally incorporated 3-F1Y; circular permutant (50-51)
4ZF3	;	1.9	;	Crystal structure of Green Fluorescent Protein (GFP); S65T, H148D; circular permutant ( 50-51)
6OFN	;	1.649	;	Crystal structure of green fluorescent protein (GFP); S65T, T203(3-OMeY); ih circular permutant (50-51)
6UN5	;	1.36	;	Crystal structure of green fluorescent protein (GFP); S65T, Y66(2,3,5-F3Y); ih circular permutant (50-51)
6OGC	;	1.178	;	Crystal structure of Green Fluorescent Protein (GFP); S65T, Y66(2,3-F2Y), H148D; circular permutant (50-51)
6OG9	;	1.798	;	Crystal structure of Green Fluorescent Protein (GFP); S65T, Y66(3,5-F2Y), H148D; circular permutant (50-51)
6OGA	;	1.6	;	Crystal structure of Green Fluorescent Protein (GFP); S65T, Y66(3-Br1Y), H148D; circular permutant (50-51)
6OFM	;	1.48	;	Crystal structure of green fluorescent protein (GFP); S65T, Y66(3-CH3Y); ih circular permutant (50-51)
6OFL	;	1.25	;	Crystal structure of green fluorescent protein (GFP); S65T, Y66(3-ClY); ih circular permutant (50-51)
6OGB	;	1.65	;	Crystal structure of Green Fluorescent Protein (GFP); S65T, Y66(3-I1Y), H148D; circular permutant (50-51)
6UN6	;	1.5	;	Crystal structure of green fluorescent protein (GFP); S65T, Y66(3-NO2Y); ih circular permutant (50-51)
6UN7	;	1.5	;	Crystal structure of green fluorescent protein (GFP); S65T, Y66(3-OMeY); ih circular permutant (50-51)
4ZF4	;	1.823	;	Crystal structure of Green Fluorescent Protein (GFP); S65T, Y66(Cl1Y), H148D; circular permutant (50-51)
4ZF5	;	1.7	;	Crystal structure of Green Fluorescent Protein (GFP); S65T, Y66(Cl2Y), H148D; circular permutant ( 50-51)
6OFK	;	1.15	;	Crystal structure of green fluorescent protein (GFP); S65T; ih circular permutant (50-51)
5WJ3	;	1.351	;	Crystal structure of green fluorescent protein Clover mutant S147C/Q204C
2OJK	;	2.2	;	Crystal Structure of Green Fluorescent Protein from Zoanthus sp at 2.2 A Resolution
4HVF	;	1.7	;	Crystal structure of green fluorescent protein lanGFP(Branchiostoma Lanceolatum)
2ZPO	;	1.6	;	Crystal Structure of Green Turtle Egg White Ribonuclease
4GI3	;	1.75	;	Crystal structure of Greglin in complex with subtilisin
2P3X	;	2.2	;	Crystal structure of Grenache (Vitis vinifera) Polyphenol Oxidase
2QT5	;	2.3	;	Crystal Structure of GRIP1 PDZ12 in Complex with the Fras1 Peptide
2VKM	;	2.05	;	Crystal structure of GRL-8234 bound to BACE (Beta-secretase)
1PCQ	;	2.808	;	Crystal structure of groEL-groES
1SVT	;	2.808	;	Crystal structure of GroEL14-GroES7-(ADP-AlFx)7
8FCZ	;	3.7	;	Crystal structure of ground-state rhodopsin in complex with a nanobody
8WKH	;	2.0	;	Crystal structure of group 13 allergen from Blomia tropicalis
6S92	;	1.93	;	Crystal structure of group A of Usutu virus envelope protein domain III
6ITE	;	1.739	;	Crystal structure of group A Streptococcal surface dehydrogenase (SDH)
5ESC	;	2.0	;	Crystal structure of Group A Streptococcus HupZ
2AU1	;	2.4	;	Crystal Structure of group A Streptococcus MAC-1 orthorhombic form
7RSW	;	1.32	;	Crystal structure of group B human rotavirus VP8*
6S93	;	1.67	;	Crystal structure of group B of Usutu virus envelope protein domain III
4UZG	;	1.06	;	Crystal structure of group B streptococcus pilus 2b backbone protein SAK_1440
5M63	;	2.74	;	Crystal structure of group B Streptococcus type III DP2 oligosaccharide bound to Fab NVS-1-19-5
6S94	;	1.79	;	Crystal structure of group D of Usutu virus envelope protein domain III
6S95	;	1.19	;	Crystal structure of group I of Usutu virus envelope protein domain III
3Q4Y	;	2.3	;	Crystal structure of group I phospholipase A2 at 2.3 A resolution in 40% ethanol revealed the critical elements of hydrophobicity of the substrate-binding site
5X9V	;	3.003	;	Crystal structure of group III chaperonin in the Closed state
5X9U	;	4.001	;	Crystal structure of group III chaperonin in the open state
2IG3	;	2.15	;	Crystal structure of group III truncated hemoglobin from Campylobacter jejuni
3MWS	;	1.09	;	Crystal Structure of Group N HIV-1 Protease
5VMN	;	1.65	;	Crystal structure of grouper iridovirus GIV66
5VMO	;	1.7	;	Crystal structure of grouper iridovirus GIV66:Bim complex
3KHS	;	2.38	;	Crystal structure of grouper iridovirus purine nucleoside phosphorylase
4WIZ	;	3.6	;	Crystal structure of Grouper nervous necrosis virus-like particle at 3.6A
5VT2	;	2.3	;	Crystal structure of growth differentiation factor
6ZYH	;	1.88	;	Crystal structure of GRP78 (70kDa heat shock protein 5 / BiP) ATPase domain in complex with ADP and calcium
5TTZ	;	2.707	;	Crystal structure of Grp94 bound to isoform-selective inhibitor methyl 2-(2-(1-(4-bromobenzyl)-1H-imidazol-2-yl)ethyl)-3-chloro-4,6-dihydroxybenzoate
5IN9	;	2.6	;	Crystal structure of Grp94 bound to methyl 3-chloro-2-(2-(1-((5-chlorofuran-2-yl)methyl)-1H-imidazol-2-yl)ethyl)-4,6-dihydroxybenzoate, an inhibitor based on the BnIm and Radamide scaffolds.
3A6M	;	3.23	;	Crystal structure of GrpE from Thermus thermophilus HB8
5Y4U	;	1.7	;	Crystal structure of Grx domain of Grx3 from Saccharomyces cerevisiae
4MZB	;	1.038	;	Crystal structure of Grx1 from Plasmodium falciparum
3C1S	;	2.5	;	Crystal structure of GRX1 in glutathionylated form
5B5R	;	1.902	;	Crystal structure of GSDMA3
7WJQ	;	2.7	;	Crystal structure of GSDMB in complex with Ipah7.8
4TR1	;	1.582	;	Crystal structure of GSH-bound cGrx2/C15S
3GX0	;	2.3	;	Crystal Structure of GSH-dependent Disulfide bond Oxidoreductase
3DU8	;	2.2	;	Crystal structure of GSK-3 beta in complex with NMS-869553A
4NM3	;	2.1	;	Crystal structure of GSK-3/Axin complex bound to phosphorylated N-terminal auto-inhibitory pS9 peptide
4NM5	;	2.3	;	Crystal structure of GSK-3/Axin complex bound to phosphorylated Wnt receptor LRP6 c-motif
4NM7	;	2.3	;	Crystal structure of GSK-3/Axin complex bound to phosphorylated Wnt receptor LRP6 e-motif
6HK4	;	2.5	;	Crystal structure of GSK-3B in complex with pyrazine inhibitor C22
6HK3	;	2.35	;	Crystal structure of GSK-3B in complex with pyrazine inhibitor C44
6HK7	;	3.2	;	Crystal structure of GSK-3B in complex with pyrazine inhibitor C50
6Y9R	;	2.08	;	Crystal structure of GSK-3b in complex with the 1H-indazole-3-carboxamide inhibitor 2
6Y9S	;	2.03	;	Crystal structure of GSK-3b in complex with the imidazo[1,5-a]pyridine-3-carboxamide inhibitor 16
5K5N	;	2.2	;	Crystal structure of GSK-3beta complexed with PF-04802367, a highly selective brain-penetrant kinase inhibitor
8AV1	;	2.15	;	Crystal structure of GSK3 beta (GSK3b) in complex with CD7.
8AUZ	;	2.66	;	Crystal structure of GSK3 beta (GSK3b) in complex with FL291.
3I4B	;	2.3	;	Crystal structure of GSK3b in complex with a pyrimidylpyrrole inhibitor
5F94	;	2.51	;	Crystal structure of GSK3b in complex with Compound 15: 2-[(cyclopropylcarbonyl)amino]-N-(4-methoxypyridin-3-yl)pyridine-4-carboxamide
5F95	;	2.525	;	Crystal structure of GSK3b in complex with Compound 18: 2-[(cyclopropylcarbonyl)amino]-N-(4-phenylpyridin-3-yl)pyridine-4-carboxamide
7Z1F	;	3.0	;	Crystal structure of GSK3b in complex with CX-4945
4J1R	;	2.702	;	Crystal Structure of GSK3b in complex with inhibitor 15R
4J71	;	2.31	;	Crystal Structure of GSK3b in complex with inhibitor 1R
6AE3	;	2.14	;	Crystal structure of GSK3beta complexed with Morin
2O5K	;	3.2	;	Crystal Structure of GSK3beta in complex with a benzoimidazol inhibitor
4DIT	;	2.6	;	Crystal Structure of GSK3beta in complex with a Imidazopyridine inhibitor
7OY5	;	2.57	;	Crystal structure of GSK3Beta in complex with ARN25068
4M7I	;	2.34	;	Crystal Structure of GSK6157 Bound to PERK (R587-R1092, delete A660-T867) at 2.34A Resolution
4G31	;	2.28	;	Crystal Structure of GSK6414 Bound to PERK (R587-R1092, delete A660-T867) at 2.28 A Resolution
4G34	;	2.7	;	Crystal Structure of GSK6924 Bound to PERK (R587-R1092, delete A660-T867) at 2.70 A Resolution
4TR0	;	1.951	;	Crystal structure of GSSG-bound cGrx2
4WR4	;	1.6	;	Crystal Structure of GST Mutated with Halogenated Tyrosine (7bGST-1)
4WR5	;	1.93	;	Crystal Structure of GST Mutated with Halogenated Tyrosine (7cGST-1)
4GSN	;	2.3	;	Crystal Structure of GSTe2 ZAN/U variant from Anopheles gambiae
8EML	;	2.21	;	Crystal Structure of Gsx2 Homeodomain in Complex with DNA
5TJL	;	1.89	;	Crystal structure of GTA + A trisaccharide (mercury derivative)
5TJK	;	1.45	;	Crystal structure of GTA + A trisaccharide (native)
5BXC	;	1.4	;	Crystal structure of GTA + UDP + DI
5C36	;	1.55	;	Crystal structure of GTA + UDP-C-Gal + DI
5C4B	;	1.54	;	Crystal structure of GTA + UDP-Glc + DI
5TJO	;	1.57	;	Crystal structure of GTB + B trisaccharide (mercury derivative)
5TJN	;	1.47	;	Crystal structure of GTB + B trisaccharide (native)
5C48	;	1.46	;	Crystal structure of GTB + UDP-C-Gal + DI
5C49	;	1.49	;	Crystal structure of GTB + UDP-C-Gal + H-antigen
5C1L	;	1.4	;	Crystal structure of GTB + UDP-Gal + DI
5C4D	;	1.4	;	Crystal structure of GTB + UDP-Glc + DI
5C4E	;	1.55	;	Crystal structure of GTB + UDP-Glc + H-antigen acceptor
3I0G	;	1.4	;	Crystal structure of GTB C80S/C196S + DA + UDP-Gal
3I0E	;	1.81	;	Crystal structure of GTB C80S/C196S + H-antigen
3I0D	;	1.9	;	Crystal structure of GTB C80S/C196S + UDP
3I0F	;	1.56	;	Crystal structure of GTB C80S/C196S + UDP + H antigen
3I0C	;	1.55	;	Crystal structure of GTB C80S/C196S unliganded
3I0L	;	1.6	;	Crystal structure of GTB C80S/C196S/C209S + DA + UDP-Gal
3I0J	;	1.48	;	Crystal structure of GTB C80S/C196S/C209S + H antigen
3I0I	;	1.9	;	Crystal structure of GTB C80S/C196S/C209S + UDP
3I0K	;	2.2	;	Crystal structure of GTB C80S/C196S/C209S + UDP + H antigen
3I0H	;	2.0	;	Crystal structure of GTB C80S/C196S/C209S unliganded
5E9T	;	2.92	;	Crystal structure of GtfA/B complex
5E9U	;	3.84	;	Crystal structure of GtfA/B complex bound to UDP and GlcNAc
5JGJ	;	1.66	;	Crystal structure of GtmA
5JGL	;	2.28	;	Crystal structure of GtmA in complex with S-Adenosylmethionine
5JGK	;	1.33	;	Crystal structure of GtmA in complex with SAH
1WXQ	;	2.6	;	Crystal Structure of GTP binding protein from Pyrococcus horikoshii OT3
1VR8	;	1.75	;	Crystal structure of GTP binding regulator (TM1622) from Thermotoga Maritima at 1.75 A resolution
3EVC	;	1.6	;	Crystal structure of GTP complex of yellow fever virus methyltransferase and S-adenosyl-L-homocysteine
3EVD	;	1.5	;	Crystal structure of GTP complex of yellow fever virus methyltransferase and S-adenosyl-L-homocysteine
4DU6	;	2.106	;	Crystal structure of GTP cyclohydrolase I from Yersinia pestis complexed with GTP
4RL4	;	2.199	;	Crystal structure of GTP cyclohydrolase II from Helicobacter pylori 26695
5K95	;	2.77	;	Crystal Structure of GTP Cyclohydrolase-IB with 8-oxo-GTP
5K9G	;	1.9	;	Crystal Structure of GTP Cyclohydrolase-IB with Tris
1WF3	;	1.88	;	Crystal structure of GTP-binding protein TT1341 from Thermus thermophilus HB8
7EB6	;	3.014	;	Crystal structure of GTP-binding protein-like domain of AGAP1
1R4A	;	2.3	;	Crystal Structure of GTP-bound ADP-ribosylation Factor Like Protein 1 (Arl1) and GRIP Domain of Golgin245 COMPLEX
2XTN	;	1.9	;	Crystal structure of GTP-bound human GIMAP2, amino acid residues 1- 234
7VEX	;	1.51	;	Crystal Structure of GTP-bound Irgb6
8H4M	;	1.68	;	Crystal Structure of GTP-bound Irgb6_T95D mutant
2YWG	;	2.94	;	Crystal structure of GTP-bound LepA from Aquifex aeolicus
2HV8	;	1.86	;	Crystal structure of GTP-bound Rab11 in complex with FIP3
4LHZ	;	3.2	;	Crystal structure of GTP-bound Rab8:Rabin8
6MQK	;	2.19	;	Crystal Structure of GTPase Domain of Human Septin 12 in complex with GDP
6MQ9	;	1.86	;	Crystal Structure of GTPase Domain of Human Septin 12 in complex with GMPPNP
6MQB	;	2.12	;	Crystal Structure of GTPase Domain of Human Septin 12 in complex with GMPPNP in Space Group C2221
6MQL	;	2.17	;	Crystal Structure of GTPase Domain of Human Septin 12 Mutant T89M
6UPQ	;	1.86	;	Crystal Structure of GTPase Domain of Human Septin 2 / Septin 11 Heterocomplex
6UPR	;	2.299	;	Crystal Structure of GTPase Domain of Human Septin 2 / Septin 8 Heterocomplex
6UPA	;	2.51	;	Crystal Structure of GTPase Domain of Human Septin 2/Septin 6 Heterocomplex
6UQQ	;	2.75	;	Crystal Structure of GTPase Domain of Human Septin 7 / Septin 3 T282Y Heterocomplex
3R7W	;	2.773	;	Crystal Structure of Gtr1p-Gtr2p complex
3ERF	;	2.23	;	Crystal structure of Gtt2 from Saccharomyces cerevisiae
3ERG	;	2.2	;	Crystal structure of Gtt2 from Saccharomyces cerevisiae in complex with glutathione sulfnate
1YPF	;	1.8	;	Crystal Structure of GuaC (BA5705) from Bacillus anthracis at 1.8 A Resolution
2A1Y	;	2.27	;	Crystal Structure of GuaC-GMP complex from Bacillus anthracis at 2.26 A Resolution.
4C53	;	4.14	;	Crystal Structure of Guanarito virus GP2 in the post-fusion conformation
8C0H	;	1.58	;	Crystal structure of guanidinase from Nitrospira inopinata
1KHH	;	2.5	;	Crystal Structure of Guanidinoacetate Methyltransferase from Rat Liver: A Template Structure of Protein Arginine Methyltransferase
2OOD	;	2.62	;	Crystal structure of guanine deaminase from Bradyrhizobium japonicum
2I9U	;	2.05	;	Crystal Structure of Guanine Deaminase from C. acetobutylicum with bound guanine in the active site
3G4M	;	2.4	;	Crystal structure of guanine riboswitch bound to 2-aminopurine
3FO6	;	1.9	;	Crystal structure of guanine riboswitch bound to 6-O-methylguanine
3RKF	;	2.5	;	Crystal structure of guanine riboswitch C61U/G37A double mutant bound to thio-guanine
3FO4	;	1.9	;	Crystal structure of guanine riboswitch C74U mutant bound to 6-chloroguanine
3RNT	;	1.8	;	CRYSTAL STRUCTURE OF GUANOSINE-FREE RIBONUCLEASE T1, COMPLEXED WITH VANADATE(V), SUGGESTS CONFORMATIONAL CHANGE UPON SUBSTRATE BINDING
3LNC	;	1.95	;	Crystal structure of guanylate kinase from Anaplasma phagocytophilum
7LUY	;	2.3	;	Crystal Structure of guanylate kinase from Bartonella henselae str. Houston-1
1S4Q	;	2.16	;	Crystal Structure of Guanylate Kinase from Mycobacterium tuberculosis (Rv1389)
1Z6G	;	2.18	;	Crystal structure of guanylate kinase from Plasmodium falciparum
7U5F	;	2.0	;	Crystal structure of guanylate kinase from Pseudomonas aeruginosa PAO1 in complex with GMP
8EGL	;	2.35	;	Crystal Structure of Guanylate kinase from Pseudomonas aeruginosa PAO1 in complex with GMP and ADP
3K8Z	;	2.4	;	Crystal Structure of Gudb1 a decryptified secondary glutamate dehydrogenase from B. subtilis
1XSE	;	2.5	;	Crystal Structure of Guinea Pig 11beta-Hydroxysteroid Dehydrogenase Type 1
2Q6V	;	2.28	;	Crystal Structure of GumK in complex with UDP
3CUY	;	2.3	;	Crystal Structure of GumK mutant D157A
3CV3	;	2.25	;	Crystal Structure of GumK mutant D157A in complex with UDP
2HY7	;	1.9	;	Crystal Structure of GumK, a beta-glucuronosyltransferase from Xanthomonas campestris
5OLL	;	1.45	;	Crystal structure of gurmarin, a sweet taste suppressing polypeptide
3WJS	;	3.3	;	Crystal structure of GYE (old yellow enzyme)
2G77	;	2.26	;	Crystal Structure of Gyp1 TBC domain in complex with Rab33 GTPase bound to GDP and AlF3
3LPX	;	2.6	;	Crystal structure of GyrA
4TMA	;	3.3	;	Crystal structure of gyrase bound to its inhibitor YacG
5ZTJ	;	2.4	;	Crystal Structure of GyraseA C-Terminal Domain from Salmonella typhi at 2.4A Resolution
5ZXM	;	1.938	;	Crystal Structure of GyraseB N-terminal at 1.93A Resolution
6J90	;	2.2	;	Crystal Structure of GyraseB N-Terminal Domain complex with ATP from Salmonella Typhi at 2.2A Resolution
3KZA	;	2.0	;	Crystal structure of Gyuba, a patched chimera of b-lactglobulin
1YM8	;	1.55	;	crystal structure of GZZ shows up puckering of the proline ring in the Xaa position.
4KPP	;	2.3	;	Crystal Structure of H+/Ca2+ Exchanger CAX
3WS6	;	1.98	;	Crystal Structure of H-2D in complex with a mimotopic peptide
3WS3	;	2.335	;	Crystal Structure of H-2D in complex with an insulin derived peptide
3CPL	;	2.5	;	Crystal Structure of H-2Db in complex with a variant M6A of the NP366 peptide from influenza A virus
3CH1	;	2.3	;	Crystal structure of H-2Db in complex with chimeric gp100
2ZOK	;	2.1	;	Crystal structure of H-2Db in complex with JHMV epitope S510
5JWD	;	2.5	;	Crystal structure of H-2Db in complex with the LCMV-derived GP392-401 peptide
5JWE	;	2.4	;	Crystal structure of H-2Db in complex with the LCMV-derived GP92-101 peptide
2ZOL	;	2.7	;	Crystal structure of H-2Db in complex with the W513S variant of JHMV epitope S510
5WLG	;	2.1	;	Crystal Structure of H-2Db with the GAP501 peptide (SQL)
5WLI	;	2.2	;	Crystal Structure of H-2Db with the GAP501 peptide (SQL)
4IHO	;	2.8	;	Crystal structure of H-2Db Y159F in complex with chimeric gp100
6NPR	;	2.37	;	Crystal structure of H-2Dd with C84-C139 disulfide in complex with gp120 derived peptide P18-I10
1LEG	;	1.75	;	Crystal Structure of H-2Kb bound to the dEV8 peptide
2ZSV	;	1.8	;	Crystal structure of H-2Kb in complex with JHMV epitope S598
2ZSW	;	2.8	;	Crystal structure of H-2Kb in complex with the Q600Y variant of JHMV epitope S598
4HS3	;	2.1	;	Crystal structure of H-2Kb with a disulfide stabilized F pocket in complex with the LCMV derived peptide GP34
7WCY	;	2.36	;	Crystal Structure of H-2Kb with Cryptosporidium parvum gp40/15 epitope
1LEK	;	2.15	;	Crystal Structure of H-2Kbm3 bound to dEV8
6DXI	;	2.6	;	Crystal structure of H-NOX protein from Nostoc sp V52W/L67W double-mutant.
6MX5	;	2.35	;	Crystal structure of H-NOX protein from Nostoc sp.
4L9S	;	1.606	;	Crystal Structure of H-Ras G12C, GDP-bound
4L9W	;	1.952	;	Crystal Structure of H-Ras G12C, GMPPNP-bound
4EFM	;	1.9	;	Crystal structure of H-Ras G12V in complex with GppNHp (state 1)
4EFN	;	2.3	;	Crystal structure of H-Ras Q61L in complex with GppNHp (state 1)
3KKM	;	1.7	;	Crystal structure of H-Ras T35S in complex with GppNHp
3KKN	;	2.09	;	Crystal structure of H-Ras T35S in complex with GppNHp
3I3S	;	1.36	;	Crystal Structure of H-Ras with Thr50 replaced by Isoleucine
4EFL	;	1.9	;	Crystal structure of H-Ras WT in complex with GppNHp (state 1)
2RGE	;	1.4	;	Crystal structure of H-Ras-GppNHp
2RGA	;	1.9	;	Crystal structure of H-RasQ61I-GppNHp
2RGG	;	1.45	;	Crystal structure of H-RasQ61I-GppNHp, trigonal crystal form
2RGB	;	1.35	;	Crystal structure of H-RasQ61K-GppNHp
2RGD	;	2.0	;	Crystal structure of H-RasQ61L-GppNHp
2RGC	;	1.6	;	Crystal structure of H-RasQ61V-GppNHp
3ODJ	;	2.84	;	Crystal structure of H. influenzae rhomboid GlpG with disordered loop 4, helix 5 and loop 5
1FX3	;	2.5	;	CRYSTAL STRUCTURE OF H. INFLUENZAE SECB
4YVG	;	1.549	;	Crystal Structure of H. influenzae TrmD in complex with AdoMet
8APT	;	1.8	;	Crystal Structure of H. influenzae TrmD in complex with Compound 13
8APU	;	1.9	;	Crystal Structure of H. influenzae TrmD in complex with Compound 14
8APV	;	2.4	;	Crystal Structure of H. influenzae TrmD in complex with Compound 27
8APW	;	1.8	;	Crystal Structure of H. influenzae TrmD in complex with Compound 30
4YVH	;	1.6	;	Crystal Structure of H. influenzae TrmD in complex with sinefungin
4YVI	;	3.01	;	Crystal Structure of H. influenzae TrmD in complex with sinefungin and tRNA
4YVK	;	3.002	;	Crystal Structure of H. influenzae TrmD in complex with sinefungin and tRNA variant (G36C)
4YVJ	;	2.9	;	Crystal Structure of H. influenzae TrmD in complex with sinefungin and tRNA variant (G36U)
5NKZ	;	2.85	;	Crystal structure of H. polymorpha ubiquitin conjugating enzyme Pex4p in complex with soluble domain of Pex22p
5Y2D	;	3.7001	;	Crystal structure of H. pylori HtrA
5Y28	;	3.08607	;	Crystal structure of H. pylori HtrA with PDZ2 deletion
8WNF	;	1.9	;	Crystal structure of H. pylori isoleucyl-tRNA synthetase (HpIleRS) in apo form
8WNG	;	1.92	;	Crystal structure of H. pylori isoleucyl-tRNA synthetase (HpIleRS) in complex with Ile
8WNJ	;	1.78	;	Crystal structure of H. pylori isoleucyl-tRNA synthetase (HpIleRS) in complex with Ile-AMP
8WO3	;	2.2	;	Crystal structure of H. pylori isoleucyl-tRNA synthetase (HpIleRS) in complex with Mupirocin
8WNI	;	1.95	;	Crystal structure of H. pylori isoleucyl-tRNA synthetase (HpIleRS) in complex with Val
8WO2	;	2.34	;	Crystal structure of H. pylori isoleucyl-tRNA synthetase (HpIleRS) in complex with Val-AMP
6F5A	;	2.201	;	Crystal structure of H. pylori purine nucleoside phosphorylase
6F5I	;	2.298	;	Crystal structure of H. pylori purine nucleoside phosphorylase
5MX4	;	2.31	;	Crystal structure of H. pylori purine nucleoside phosphorylase from clinical isolate HpPNP-1
5MX6	;	2.41	;	Crystal structure of H. pylori purine nucleoside phosphorylase from clinical isolate HpPNP-2
5MX8	;	2.4	;	Crystal structure of H. pylori purine nucleoside phosphorylase from clinical isolate HpPNP-3
6F4W	;	2.293	;	Crystal structure of H. pylori purine nucleoside phosphorylase in complex with formycin A
6F4X	;	1.694	;	Crystal structure of H. pylori purine nucleoside phosphorylase in complex with PO4 and formycin A
6F52	;	2.0	;	Crystal structure of H. pylori purine nucleoside phosphorylase in complex with PO4 and formycin A
6G7X	;	1.762	;	Crystal structure of H. pylori purine nucleoside phosphorylase soaked in PO4
5LU0	;	1.73	;	Crystal structure of H. pylori referent strain in complex with PO4
1MOG	;	1.7	;	Crystal structure of H. salinarum dodecin
4HRO	;	1.15	;	Crystal structure of H. volcanii small archaeal modifier protein 1
4HRS	;	2.3	;	Crystal structure of H. volcanii small archaeal modifier protein 2
4QI1	;	1.85	;	Crystal structure of H. walsbyi bacteriorhodopsin
1PU6	;	1.64	;	Crystal structure of H.pylori 3-methyladenine DNA glycosylase (MagIII)
1PU8	;	2.13	;	Crystal structure of H.pylori 3-methyladenine DNA glycosylase (MagIII) bound to 1,N6-ethenoadenine
1PU7	;	1.93	;	Crystal structure of H.pylori 3-methyladenine DNA glycosylase (MagIII) bound to 3,9-dimethyladenine
2ZL0	;	2.6	;	Crystal structure of H.pylori ClpP
2ZL2	;	2.5	;	Crystal structure of H.pylori ClpP in complex with the peptide NVLGFTQ
2ZL3	;	2.81	;	Crystal structure of H.pylori ClpP S99A
2ZL4	;	2.5	;	Crystal structure of H.pylori ClpP S99A in complex with the peptide AAAA
6MRJ	;	2.8	;	Crystal structure of H.pylori NikR in complex with DNA
3NV7	;	1.75	;	Crystal structure of H.pylori phosphopantetheine adenylyltransferase mutant I4V/N76Y
5GJS	;	2.9	;	Crystal structure of H1 hemagglutinin from A/California/04/2009 in complex with a neutralizing antibody 3E1
5GJT	;	3.1	;	Crystal structure of H1 hemagglutinin from A/Washington/05/2011 in complex with a neutralizing antibody 3E1
5TGO	;	2.35	;	Crystal structure of H10 hemagglutinin mutant (K158aA-D193T-Q226L-G228S) from Jiangxi-Donghu (2013) H10N8 influenza virus
5TGV	;	2.974	;	Crystal structure of H10 hemagglutinin mutant (K158aA-D193T-Q226L-G228S) from Jiangxi-Donghu (2013) H10N8 influenza virus in complex with 3'-SLN
5TGU	;	2.35	;	Crystal structure of H10 hemagglutinin mutant (K158aA-D193T-Q226L-G228S) from Jiangxi-Donghu (2013) H10N8 influenza virus in complex with 6'-SLNLN
5TH0	;	2.25	;	Crystal structure of H10 hemagglutinin mutant (K158aA-Q226L-G228S) from Jiangxi-Donghu (2013) H10N8 influenza virus
5TH1	;	2.191	;	Crystal structure of H10 hemagglutinin mutant (K158aA-Q226L-G228S) from Jiangxi-Donghu (2013) H10N8 influenza virus in complex with 6'-SLNLN
5THB	;	2.41	;	Crystal structure of H10 hemagglutinin mutant (T193D-Q226L-G228S) from Jiangxi-Donghu (2013) H10N8 influenza virus
5THC	;	2.792	;	Crystal structure of H10 hemagglutinin mutant (T193D-Q226L-G228S) from Jiangxi-Donghu (2013) H10N8 influenza virus in complex with 6'-SLNLN
6CNI	;	1.7	;	Crystal structure of H105A PGAM5 dimer
6CNL	;	2.6	;	Crystal Structure of H105A PGAM5 Dodecamer
5WJA	;	2.3	;	Crystal structure of H107A peptidylglycine alpha-hydroxylating monooxygenase (PHM) in complex with citrate
6ALV	;	3.5	;	Crystal structure of H107A-peptidylglycine alpha-hydroxylating monooxygenase (PHM) mutant (no CuH bound)
3T3A	;	2.3	;	Crystal structure of H107R mutant of extracellular domain of mouse receptor NKR-P1A
6AO6	;	2.98	;	Crystal structure of H108A peptidylglycine alpha-hydroxylating monooxygenase (PHM)
6NCK	;	2.7	;	Crystal structure of H108A peptidylglycine alpha-hydroxylating monooxygenase (PHM)
6ALA	;	2.59	;	Crystal structure of H108A peptidylglycine alpha-hydroxylating monooxygenase (PHM) in complex with citrate
6AY0	;	2.6	;	Crystal structure of H108A peptidylglycine alpha-hydroxylating monooxygenase (PHM) soaked with peptide
5B4D	;	1.75	;	Crystal structure of H10N mutant of LpxH
5B4C	;	1.96	;	Crystal structure of H10N mutant of LpxH with manganese
4HI6	;	2.2	;	Crystal structure of H112W mutant of borna disease virus matrix protein
4HIT	;	2.4	;	Crystal structure of H112W mutant of borna disease virus matrix protein
1R38	;	2.2	;	Crystal structure of H114A mutant of Candida tenuis xylose reductase
4R2K	;	1.97	;	Crystal structure of H119A mutant of YdaA (Universal Stress Protein E) from Salmonella typhimurium
7A9D	;	2.7	;	Crystal structure of H12 Haemagglutinin
1WAE	;	1.95	;	Crystal structure of H129V Mutant of Alcaligenes Xylosoxidans Nitrite Reductase
1SO3	;	1.9	;	Crystal structure of H136A mutant of 3-keto-L-gulonate 6-phosphate decarboxylase with bound L-threonohydroxamate 4-phosphate
7WVD	;	3.39	;	Crystal structure of H14 complexed with SIA28
5DC8	;	1.3	;	Crystal structure of H142A-Y306F HDAC8 in complex with a tetrapeptide substrate
1NPJ	;	1.9	;	Crystal structure of H145A mutant of nitrite reductase from Alcaligenes faecalis
5TG8	;	3.1	;	Crystal structure of H15 hemagglutinin from A/shearwater/WA/2576/1979 H15N9 influenza virus
5TG9	;	2.749	;	Crystal structure of H15 hemagglutinin from A/shearwater/WA/2576/1979 H15N9 influenza virus in complex with 3'-SLN
3Q9E	;	2.5	;	Crystal structure of H159A APAH complexed with acetylspermine
3Q9C	;	2.3	;	Crystal Structure of H159A APAH complexed with N8-acetylspermidine
2ZE9	;	2.3	;	Crystal structure of H168A mutant of phospholipase D from Streptomyces antibioticus, as a complex with phosphatidylcholine
6AMP	;	2.48	;	Crystal structure of H172A PHM (CuH absent, CuM present)
6AN3	;	2.05	;	Crystal structure of H172A-peptidylglycine alpha-hydroxylating monooxygenase (PHM) mutant soaked with peptide (no CuH bound, no peptide bound)
2AZT	;	2.7	;	Crystal structure of H176N mutant of human Glycine N-Methyltransferase
7C5Q	;	2.13	;	Crystal Structure of H177A mutant Glyceraldehyde-3-phosphate dehydrogenase1 from Escherichia coli complexed with BPG at 2.13 Angstrom resolution
7C5O	;	1.981	;	Crystal Structure of H177A mutant of Glyceraldehyde-3-phosphate-dehydrogenase1 from Escherichia coli complexed with NAD at 1.98 Angstrom resolution.
3LC1	;	2.0	;	Crystal Structure of H178N mutant of Glyceraldehyde-3-phosphate-dehydrogenase 1 (GAPDH 1) from Staphylococcus aureus MRSA252 complexed with NAD at 2.0 angstrom resolution.
7WVG	;	2.6	;	Crystal structure of H18 complexed with SIA28
2Q2O	;	2.1	;	Crystal structure of H183C Bacillus subtilis ferrochelatase in complex with deuteroporphyrin IX 2,4-disulfonic acid dihydrochloride
4J18	;	2.35	;	Crystal structure of H191L mutant of UDP-glucose pyrophosphorylase from Leishmania major
3M6S	;	2.8	;	Crystal structure of H1N1pdm Hemagglutinin
7UNZ	;	2.03	;	Crystal structure of H2 nanobody in complex with PfCSS
5WEU	;	1.584	;	Crystal Structure of H2-Dd with disulfide-linked 10mer peptide
5WET	;	2.64	;	Crystal Structure of H2-Dd with disulfide-linked 6mer peptide
6JQ3	;	2.5	;	Crystal Structure of H2-Kb in complex with a DPAGT1 mutant peptide
6JQ2	;	2.4	;	Crystal Structure of H2-Kb in complex with a DPAGT1 self-peptide
3PAB	;	2.2	;	Crystal Structure of H2-Kb in complex with a mutant of the chicken ovalbumin epitope OVA-E1
3P9M	;	2.0	;	Crystal Structure of H2-Kb in complex with a mutant of the chicken ovalbumin epitope OVA-G4
7JI2	;	1.95	;	Crystal Structure of H2-Kb in complex with a OVA mutant peptide
3P9L	;	2.0	;	Crystal Structure of H2-Kb in complex with the chicken ovalbumin epitope OVA
3P4O	;	2.3	;	Crystal Structure of H2-Kb in complex with the mutant NP205-LCMV-V3A epitope YTAKYPNL, an 8-mer modified peptide from the LCMV
3P4M	;	2.5	;	Crystal Structure of H2-Kb in complex with the NP205-LCMV epitope YTVKYPNL, an 8-mer peptide from the LCMV
3P4N	;	2.5	;	Crystal Structure of H2-Kb in complex with the NP205-PV epitope YTVKFPNM, an 8-mer peptide from PV
1WNI	;	2.2	;	Crystal Structure of H2-Proteinase
2R7P	;	2.8	;	Crystal Structure of H225A NSP2 and AMPPNP complex
2R8F	;	2.8	;	Crystal structure of H225A NSP2 and ATP-gS complex
4G9O	;	2.12	;	Crystal Structure of H234A Mutant of Stationary Phase Survival Protein (SurE) from Salmonella typhimurium
1GS7	;	1.85	;	Crystal structure of H254F mutant of Alcaligenes xylosoxidans Nitrite Reductase
5ZT6	;	2.5	;	Crystal structure of H255A mutant of phosphomannose isomerase from Salmonella typhimurium
7MS1	;	2.95	;	Crystal structure of H28A mutant of Cg10062 with a covalent intermediate of the hydration of acetylenecarboxylic acid
6LYO	;	1.87	;	Crystal Structure of H296A mutant of Formylglycinamidine Synthetase
7DLX	;	2.395	;	crystal structure of H2AM4>Z-H2B
7N9J	;	1.74	;	Crystal structure of H2DB in complex with HSF2 melanoma neoantigen
3FTG	;	2.6	;	Crystal Structure of H2Db in complex with NP366-N3A variant peptide from influenza
4HUX	;	2.2	;	Crystal Structure of H2Db-H155A-NP
4HV8	;	2.0	;	Crystal Structure of H2Db-H155A-NPM6I
4HUU	;	2.0	;	Crystal Structure of H2Db-NPM6I
4HUW	;	3.16	;	Crystal Structure of H2Db-NPM6T
4HUV	;	2.5	;	Crystal Structure of H2Db-NPM6W
4PV8	;	2.31	;	Crystal Structure of H2Kb-Q600F complex
4PV9	;	2.0	;	Crystal Structure of H2Kb-Q600V complex
2Z7U	;	2.1	;	Crystal Structure of H2O2 treated Cu,Zn-SOD
2Z7W	;	1.8	;	Crystal Structure of H2O2 treated Cu,Zn-SOD
2Z7Y	;	1.55	;	Crystal Structure of H2O2 treated Cu,Zn-SOD
2Z7Z	;	1.85	;	Crystal Structure of H2O2 treated Cu,Zn-SOD
2ZOW	;	1.45	;	Crystal Structure of H2O2 treated Cu,Zn-SOD
5THF	;	2.59	;	Crystal structure of H3 hemagglutinin with insertion of two amino acids in the 150-loop from the A/Hong Kong/1/1968 (H3N2) influenza virus
7D8A	;	2.0	;	Crystal Structure of H3(1-13)/PHF14-PZP fusion protein
5NE8	;	1.75	;	Crystal structure of H307A mutant of Thermotoga maritima TmPEP1050 aminopeptidase
1WA1	;	1.65	;	Crystal Structure Of H313Q Mutant Of Alcaligenes Xylosoxidans Nitrite Reductase
1WA2	;	1.72	;	Crystal Structure Of H313Q Mutant Of Alcaligenes Xylosoxidans Nitrite Reductase with nitrite bound
6UPO	;	3.113	;	Crystal structure of H334A variant of cytosolic fumarate hydratase from Leishmania major in a complex with S-malate
4QA4	;	1.98	;	Crystal structure of H334R HDAC8 in complex with M344
4QA7	;	2.31	;	Crystal structure of H334R/Y306F HDAC8 in complex with a tetrapeptide substrate
1MW9	;	1.67	;	Crystal Structure of H365R mutant of 67 kDA N-terminal fragment of E. coli DNA Topoisomerase I
2E01	;	1.73	;	Crystal structure of H369A mutant of yeast bleomycin hydrolase
2E02	;	2.2	;	Crystal structure of H369L mutant of yeast bleomycin hydrolase
3IE1	;	2.85	;	Crystal structure of H380A mutant TTHA0252 from Thermus thermophilus HB8 complexed with RNA
6DZR	;	2.4	;	Crystal structure of h38C2 K99R mutation
2IPJ	;	1.8	;	Crystal structure of h3alpha-hydroxysteroid dehydrogenase type 3 mutant Y24A in complex with NADP+ and epi-testosterone
6D3N	;	2.7	;	Crystal structure of h4-1BB ligand
3IE2	;	2.8	;	Crystal Structure of H400V mutant TTHA0252 from Thermus thermophilus HB8
8JDD	;	1.55	;	Crystal structure of H405A mLDHD in apo form
8JDR	;	1.64	;	Crystal structure of H405A mLDHD in complex with D-2-hydroxy-3-methyl-valeric acid
8JDG	;	1.31	;	Crystal structure of H405A mLDHD in complex with D-2-hydroxybutanoic acid
8JDO	;	1.72	;	Crystal structure of H405A mLDHD in complex with D-2-hydroxyhexanoic acid
8JDQ	;	1.39	;	Crystal structure of H405A mLDHD in complex with D-2-hydroxyisocaproic acid
8JDP	;	1.6	;	Crystal structure of H405A mLDHD in complex with D-2-hydroxyisovaleric acid
8JDB	;	1.75	;	Crystal structure of H405A mLDHD in complex with D-2-hydroxyoctanoic acid
8JDN	;	1.56	;	Crystal structure of H405A mLDHD in complex with D-2-hydroxyvaleric acid
8JDF	;	1.69	;	Crystal structure of H405A mLDHD in complex with D-lactate
6X8N	;	1.6	;	Crystal Structure of H49A ABLE mutant
4CQV	;	2.86	;	Crystal structure of H5 (tyTy) Del133/Ile155Thr Mutant Haemagglutinin
4BGZ	;	2.68	;	Crystal Structure of H5 (tyTy) Influenza Virus Haemagglutinin
4CR0	;	2.65	;	Crystal Structure of H5 (VN1194) Asn186Lys/Gly143Arg Mutant Haemagglutinin
4CQZ	;	2.7	;	Crystal Structure of H5 (VN1194) Gln196Arg Mutant Haemagglutinin
4BGW	;	2.48	;	Crystal Structure of H5 (VN1194) Influenza Haemagglutinin
4CQP	;	2.65	;	Crystal Structure of H5 (VN1194) Ser227Asn/Gln196Arg Mutant Haemagglutinin
5YKC	;	2.823	;	crystal structure of H5 hemagglutinin from A/chicken/Taiwan/0502/2012
5YT9	;	2.766	;	Crystal structure of H5 hemagglutinin G228S mutant from A/chicken/Taiwan/0502/2012
5Z88	;	3.0	;	Crystal structure of H5 hemagglutinin G228S mutant with 3SLN from A/chicken/Taiwan/0502/2012
4N5Y	;	3.1615	;	Crystal structure of H5 hemagglutinin mutant (N158D, N224K and Q226L) from the influenza virus A/Viet Nam/1203/2004 (H5N1)
5E32	;	2.7	;	Crystal structure of H5 hemagglutinin mutant (N224K, Q226L, N158D and L133a deletion) from the influenza virus A/chicken/Vietnam/NCVD-093/2008 (H5N1)
5E34	;	2.7	;	Crystal structure of H5 hemagglutinin mutant (N224K, Q226L, N158D and L133a deletion) from the influenza virus A/chicken/Vietnam/NCVD-093/2008 (H5N1) with LSTa
5E35	;	2.7	;	Crystal structure of H5 hemagglutinin mutant (N224K, Q226L, N158D and L133a deletion) from the influenza virus A/chicken/Vietnam/NCVD-093/2008 (H5N1) with LSTc
6E7G	;	3.094	;	Crystal structure of H5 hemagglutinin mutant Y161A from A/Viet Nam/1203/2004 H5N1 influenza virus
6E7H	;	3.3	;	Crystal structure of H5 hemagglutinin mutant Y161A from A/Viet Nam/1203/2004 H5N1 influenza virus in complex with 3'-GcLN
5E2Y	;	2.6	;	Crystal structure of H5 hemagglutinin Q226L mutant from the influenza virus A/duck/Egypt/10185SS/2010 (H5N1)
5E2Z	;	2.624	;	Crystal structure of H5 hemagglutinin Q226L mutant from the influenza virus A/duck/Egypt/10185SS/2010 (H5N1) with LSTa
5E30	;	2.7	;	Crystal structure of H5 hemagglutinin Q226L mutant from the influenza virus A/duck/Egypt/10185SS/2010 (H5N1) with LSTc
5YT8	;	2.765	;	Crystal structure of H5 hemagglutinin with G228S Q226L mutants from A/chicken/Taiwan/0502/2012
4JUK	;	2.7502	;	Crystal structure of H5N1 influenza virus hemagglutinin, clade 2.3.2.1
4JUL	;	2.7927	;	Crystal structure of H5N1 influenza virus hemagglutinin, clade 2.3.4
4JUM	;	1.997	;	Crystal structure of H5N1 influenza virus hemagglutinin, clade 4
4JUN	;	2.3398	;	Crystal structure of H5N1 influenza virus hemagglutinin, clade 5
3S11	;	2.5	;	Crystal structure of H5N1 influenza virus hemagglutinin, strain 437-10
3S12	;	3.1	;	Crystal structure of H5N1 influenza virus hemagglutinin, strain YU562 crystal form 1
3S13	;	2.96	;	Crystal structure of H5N1 influenza virus hemagglutinin, strain YU562 crystal form 2
6KCJ	;	2.46	;	Crystal structure of H5N2 hemagglutinin Apo-Q226L mutant from A/chicken/Taiwan/0502/2012
6IIG	;	3.208	;	crystal structure of H5N2 hemagglutinin G228S mutant With 6SLN from A/chicken/Taiwan/0502/2012
6IN5	;	2.916	;	Crystal structure of H5N2 hemagglutinin G228S Q226L mutant with 3SLN from A/chicken/Taiwan/0502/2012
6IJT	;	2.9	;	Crystal structure of H5N2 hemagglutinin G228S Q226L mutant with 6SLN from A/chicken/Taiwan/0502/2012
5T08	;	2.1895	;	Crystal structure of H6 hemagglutinin G225D mutant from Taiwan (2013) H6N1 influenza virus
5T0D	;	2.864	;	Crystal structure of H6 hemagglutinin G225D mutant from Taiwan (2013) H6N1 influenza virus in complex with 3'-SLN
5T0B	;	2.001	;	Crystal structure of H6 hemagglutinin G225D mutant from Taiwan (2013) H6N1 influenza virus in complex with 6'-SLN
5T0E	;	2.089	;	Crystal structure of H6 hemagglutinin G225D mutant from Taiwan (2013) H6N1 influenza virus in complex with LSTa
5NE9	;	2.374	;	Crystal structure of H60A H307A mutant of Thermotoga maritima TmPEP1050 aminopeptidase
5NE7	;	1.84	;	Crystal structure of H60A mutant of Thermotoga maritima TmPEP1050 aminopeptidase
4HN1	;	1.6	;	Crystal Structure of H60N/Y130F double mutant of ChmJ, a 3'-monoepimerase from Streptomyces bikiniensis in complex with dTDP
3A4Y	;	2.5	;	Crystal Structure of H61A mutant TTHA0252 from Thermus thermophilus HB8
5UMJ	;	1.61	;	Crystal structure of H62A mutant of human macrophage migration inhibitory factor
6OYG	;	1.55	;	Crystal structure of H62F mutant of human macrophage migration inhibitory factor
6OYB	;	1.53	;	Crystal structure of H62G mutant of human macrophage migration inhibitory factor
5UMK	;	1.73	;	Crystal structure of H62Y mutant of human macrophage migration inhibitory factor
8C6O	;	2.2	;	Crystal Structure of H64F obelin mutant from Obelia longissima at 2.2 Angstrom resolution
6II9	;	3.5	;	Crystal structure of H7 hemagglutinin from A/Anhui/1/2013 in complex with a human neutralizing antibody L3A-44
6II4	;	3.3	;	Crystal structure of H7 hemagglutinin from A/Anhui/1/2013 in complex with a human neutralizing antibody L4A-14
6II8	;	3.32	;	Crystal structure of H7 hemagglutinin from A/Anhui/1/2013 in complex with a human neutralizing antibody L4B-18
4R8W	;	2.795	;	Crystal structure of H7 hemagglutinin from A/Anhui/1/2013 in complex with a neutralizing antibody CT149
5VJK	;	2.593	;	Crystal structure of H7 hemagglutinin mutant (V186K, K193T, G228S) from the influenza virus A/Shanghai/2/2013 (H7N9)
5VJM	;	2.909	;	Crystal structure of H7 hemagglutinin mutant (V186K, K193T, G228S) from the influenza virus A/Shanghai/2/2013 (H7N9) with LSTa
5VJL	;	2.597	;	Crystal structure of H7 hemagglutinin mutant (V186K, K193T, G228S) from the influenza virus A/Shanghai/2/2013 (H7N9) with LSTc
6ICX	;	2.399	;	Crystal structure of H7 hemagglutinin mutant AH-AGPL (V186G) from the influenza virus A/Anhui/1/2013 (H7N9)
6ICW	;	2.6	;	Crystal structure of H7 hemagglutinin mutant AH-SGTQ (A138S, V186G, P221T and L226Q) from the influenza virus A/Anhui/1/2013 (H7N9)
6ICY	;	2.403	;	Crystal structure of H7 hemagglutinin mutant H7-AGTL ( V186G, P221T) from the influenza virus A/Anhui/1/2013 (H7N9)
6ID2	;	2.705	;	Crystal structure of H7 hemagglutinin mutant H7-AVTL (P221T) from the influenza virus A/Anhui/1/2013 (H7N9)
6ID3	;	2.6	;	Crystal structure of H7 hemagglutinin mutant H7-SGPL ( A138S, V186G) from the influenza virus A/Anhui/1/2013 (H7N9)
6ID9	;	2.7	;	Crystal structure of H7 hemagglutinin mutant H7-SGTL ( A138S, V186G, P221T) from the influenza virus A/Anhui/1/2013 (H7N9)
6ID5	;	2.6	;	Crystal structure of H7 hemagglutinin mutant H7-SVPL ( A138S) from the influenza virus A/Anhui/1/2013 (H7N9)
6ID8	;	2.902	;	Crystal structure of H7 hemagglutinin mutant H7-SVTL ( A138S, P221T) from the influenza virus A/Anhui/1/2013 (H7N9)
6IDA	;	3.104	;	Crystal structure of H7 hemagglutinin mutant H7-SVTQ ( A138S, P221T, L226Q) from the influenza virus A/Anhui/1/2013 (H7N9)
6IDZ	;	2.707	;	Crystal structure of H7 hemagglutinin mutant H7-SVTQ ( A138S, P221T, L226Q) with 3'SLN
6IDB	;	2.502	;	Crystal structure of H7 hemagglutinin mutant H7-SVTQ ( A138S, P221T, L226Q) with 6'SLN
6IDD	;	2.383	;	Crystal structure of H7 hemagglutinin mutant SH1-AVPL ( S138A, G186V, T221P, Q226L) from the influenza virus A/Shanghai/1/2013 (H7N9)
5VAG	;	1.9	;	Crystal structure of H7-specific antibody m826 in complex with the HA1 domain of hemagglutinin from H7N9 influenza virus
3PHT	;	2.04	;	Crystal structure of H74A mutant of Helicobacter Pylori NikR
4EOE	;	1.2	;	Crystal structure of H74A synechocystis sp. pcya
4EOD	;	1.3	;	Crystal structure of H74E synechocystis sp. pcya sp. PCYA
4EOC	;	1.49	;	Crystal structure of h74q Synechocystis sp. PCYA
6ZRK	;	2.0	;	Crystal structure of H8 haemagglutinin
5H0V	;	1.58	;	Crystal structure of H88A mutated human transthyretin
5H0W	;	1.904	;	Crystal structure of H88F mutated human transthyretin
5H0X	;	1.573	;	Crystal structure of H88S mutated human transthyretin
5H0Y	;	1.8	;	Crystal structure of H88Y mutated human transthyretin
1JSI	;	2.4	;	CRYSTAL STRUCTURE OF H9 HAEMAGGLUTININ BOUND TO LSTC RECEPTOR ANALOG
1JSH	;	2.4	;	CRYSTAL STRUCTURE OF H9 HAEMAGGLUTININ COMPLEXED WITH LSTA RECEPTOR ANALOG
5ZT4	;	1.7	;	Crystal structure of H99A mutant of phosphomannose isomerase from Salmonella typhimurium
5ZUW	;	2.1	;	Crystal structure of H99Q mutant of phosphomannose isomerase from Salmonella typhimurium
3D25	;	1.3	;	Crystal structure of HA-1 minor histocompatibility antigen bound to human class I MHC HLA-A2
5BP5	;	2.18	;	Crystal structure of HA17-HA33-IPT
5BQU	;	2.38	;	Crystal structure of HA17-HA33-Lactulose
3QQO	;	2.9	;	Crystal structure of HA2 R106H mutant of H2 hemagglutinin, acidic pH form
3QQB	;	1.97	;	Crystal structure of HA2 R106H mutant of H2 hemagglutinin, neutral pH form
3QQE	;	2.1	;	Crystal structure of HA2 R106H mutant of H2 hemagglutinin, re-neutralized form
4S1X	;	1.9	;	Crystal structure of HA2-Del-L2seM, Central Coiled-Coil from Influenza Hemagglutinin HA2 without Heptad Repeat Stutter
5B2H	;	2.2	;	Crystal structure of HA33 from Clostridium botulinum serotype C strain Yoichi
1YBI	;	1.5	;	Crystal structure of HA33A, a neurotoxin-associated protein from Clostridium botulinum type A
4OUJ	;	1.46	;	Crystal structure of HA33B-Lac
4EN7	;	2.68	;	Crystal structure of HA70 (HA3) subcomponent of Clostridium botulinum type C progenitor toxin in complex with alpha 2-3-sialyllactosamine
4EN6	;	2.56	;	Crystal structure of HA70 (HA3) subcomponent of Clostridium botulinum type C progenitor toxin in complex with alpha 2-3-sialyllactose
4EN9	;	2.64	;	Crystal structure of HA70 (HA3) subcomponent of Clostridium botulinum type C progenitor toxin in complex with alpha 2-6-sialyllactosamine
4EN8	;	2.6	;	Crystal structure of HA70 (HA3) subcomponent of Clostridium botulinum type C progenitor toxin in complex with alpha 2-6-sialyllactose
1X2T	;	1.72	;	Crystal Structure of Habu IX-bp at pH 6.5
4F72	;	2.4	;	Crystal structure of had family enzyme bt-2542 (target efi-501088) from Bacteroides thetaiotaomicron, asp12ala mutant, complex with magnesium and inorganic phosphate
4DFD	;	2.0	;	Crystal structure of had family enzyme bt-2542 (target efi-501088) from bacteroides thetaiotaomicron, magnesium complex
4F71	;	2.27	;	Crystal structure of had family enzyme bt-2542 (target efi-501088) from Bacteroides thetaiotaomicron, wild-type protein, complex with magnesium and inorganic phosphate
4DCC	;	1.65	;	Crystal structure of had family enzyme bt-2542 from bacteroides thetaiotaomicron (target efi-501088)
4EEL	;	1.75	;	Crystal structure of HAD FAMILY HYDROLASE DR_1622 from Deinococcus radiodurans R1 (TARGET EFI-501256) with bound citrate and sodium
4EEN	;	1.65	;	crystal structure of HAD FAMILY HYDROLASE DR_1622 from Deinococcus radiodurans R1 (TARGET EFI-501256) with bound magnesium
4EEK	;	1.6	;	Crystal structure of HAD FAMILY HYDROLASE DR_1622 from Deinococcus radiodurans R1 (TARGET EFI-501256) With bound phosphate and sodium
4EZE	;	2.27	;	Crystal structure of had family hydrolase t0658 from Salmonella enterica subsp. enterica serovar Typhi (Target EFI-501419)
6W04	;	1.95	;	Crystal structure of HAD hydrolase, family IA, variant 3 from Entamoeba histolytica HM-1:IMSS
4YGQ	;	2.0	;	Crystal structure of HAD phosphatase from Thermococcus onnurineus
4YGR	;	1.703	;	Crystal structure of HAD phosphatase from Thermococcus onnurineus
4YGS	;	1.7	;	Crystal structure of HAD phosphatase from Thermococcus onnurineus
1RKQ	;	1.4	;	Crystal structure of HAD-like phosphatase yidA from E. coli
7QXV	;	1.67	;	Crystal Structure of Haem-Binding Protein HemS Mutant F104A F199A, from Yersinia enterocolitica
6TJY	;	2.82	;	Crystal structure of haemagglutinin from (A/seal/Germany/1/2014) seal H10N7 influenza virus
5ON6	;	3.1	;	Crystal structure of haemanthamine bound to the 80S ribosome
3D5H	;	2.0	;	Crystal structure of haementhin from Haemanthus multiflorus at 2.0A resolution: Formation of a novel loop on a TIM barrel fold and its functional significance
4E52	;	1.7	;	Crystal structure of Haemophilus Eagan 4A polysaccharide bound human lung surfactant protein D
6XXY	;	2.09	;	Crystal structure of Haemophilus influenzae 3-isopropylmalate dehydrogenase in complex with O-isobutenyl oxalylhydroxamate.
6J09	;	3.0	;	Crystal structure of Haemophilus Influenzae BamA POTRA1-4
6IZT	;	2.03	;	Crystal structure of Haemophilus Influenzae BamA POTRA3-5
6IZS	;	2.03	;	Crystal structure of Haemophilus influenzae BamA POTRA4
6OJH	;	2.05	;	Crystal Structure of Haemophilus Influenzae Biotin Carboxylase Complexed with (R)-7-(3-aminopyrrolidin-1-yl)-6-(naphthalen-1-yl)pyrido[2,3-d]pyrimidin-2-amine
6OI8	;	2.5	;	Crystal Structure of Haemophilus Influenzae Biotin Carboxylase Complexed with 7-((1R,5S,6s)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl)-6-(2-chloro-6-(pyridin-3-yl)phenyl)pyrido[2,3-d]pyrimidin-2-amine
1QVS	;	2.1	;	Crystal Structure of Haemophilus influenzae H9A mutant Holo Ferric ion-Binding Protein A
3EMF	;	2.0	;	Crystal structure of Haemophilus influenzae HiaBD2
1J6W	;	2.1	;	CRYSTAL STRUCTURE OF HAEMOPHILUS INFLUENZAE LUXS
7L5S	;	2.089	;	Crystal Structure of Haemophilus influenzae MtsZ at pH 5.5
7L5I	;	1.733	;	Crystal Structure of Haemophilus influenzae MtsZ at pH 7.0
1QW0	;	1.9	;	Crystal Structure of Haemophilus influenzae N175L mutant Holo Ferric ion-Binding Protein A
2O69	;	2.0	;	Crystal Structure of Haemophilus influenzae N193L mutant FbpA
6DQQ	;	1.85	;	Crystal structure of Haemophilus influenzae OppA complex with endogenous peptide
6DQU	;	1.65	;	Crystal structure of Haemophilus influenzae OppA complex with GIINTL
6DTF	;	1.75	;	Crystal structure of Haemophilus influenzae OppA complex with KKK
6DQT	;	1.95	;	Crystal structure of Haemophilus influenzae OppA complex with LGG
6DQR	;	2.08	;	Crystal structure of Haemophilus influenzae OppA complex with MGG
6DTH	;	1.96	;	Crystal structure of Haemophilus influenzae OppA complex with RPPGFSPFR
6DTG	;	1.9	;	Crystal structure of Haemophilus influenzae OppA complex with YLGANGRGGGS
1VHY	;	1.9	;	Crystal structure of Haemophilus influenzae protein HI0303, Pfam DUF558
1YZY	;	2.1	;	Crystal structure of Haemophilus influenzae protein HI1011, Pfam DUF1537
2O68	;	1.7	;	Crystal Structure of Haemophilus influenzae Q58L mutant FbpA
3AXZ	;	2.25	;	Crystal structure of Haemophilus influenzae TrmD in complex with adenosine
3KN7	;	1.71	;	Crystal Structure of Haemophilus influenzae Y195A mutant Holo Ferric ion-Binding Protein A
3KN8	;	1.89	;	Crystal Structure of Haemophilus influenzae Y196A mutant Holo Ferric ion-Binding Protein A
7RIL	;	1.8	;	Crystal structure of hairpin polyamide Py-Im 1 bound to 5' CCTGACCAGG
6EOA	;	2.18	;	Crystal Structure of HAL3 from Cryptococcus neoformans
5N5F	;	2.057	;	Crystal structure of Haliangium ochraceum encapsulated ferritin
5KO7	;	2.248	;	Crystal structure of haliscomenobacter hydrossis iodotyrosine deiodinase (IYD) bound to FMN
5KRD	;	2.103	;	Crystal structure of haliscomenobacter hydrossis iodotyrosine deiodinase (IYD) bound to FMN and 2-iodophenol (2IP)
5KO8	;	2.15	;	Crystal structure of haliscomenobacter hydrossis iodotyrosine deiodinase (IYD) bound to FMN and mono-iodotyrosine (I-Tyr)
8CYK	;	1.65	;	Crystal structure of hallucinated protein HALC1_878
4OVY	;	1.8	;	Crystal structure of Haloacid dehalogenase domain protein hydrolase from Planctomyces limnophilus DSM 3776
8HVQ	;	1.73	;	Crystal structure of haloacid dehalogenase-like hydrolase family enzyme from Staphylococcus lugdunensis
2PKE	;	1.81	;	Crystal structure of haloacid delahogenase-like family hydrolase (NP_639141.1) from Xanthomonas campestris at 1.81 A resolution
5ESR	;	1.476	;	Crystal structure of haloalkane dehalogenase (DccA) from Caulobacter crescentus
4K2A	;	2.2	;	Crystal structure of haloalkane dehalogenase DbeA from Bradyrhizobium elkani USDA94
6XY9	;	2.2	;	Crystal structure of haloalkane dehalogenase DbeA-M1 loop variant from Bradyrhizobium elkanii
4KAF	;	1.496	;	Crystal Structure of Haloalkane dehalogenase HaloTag7 at the resolution 1.5A, Northeast Structural Genomics Consortium (NESG) Target OR151
4WDR	;	2.5	;	Crystal structure of haloalkane dehalogenase LinB 140A+143L+177W+211L mutant (LinB86) from Sphingobium japonicum UT26
5LKA	;	1.298	;	Crystal structure of haloalkane dehalogenase LinB 140A+143L+177W+211L mutant (LinB86) from Sphingobium japonicum UT26 at 1.3 A resolution
6S06	;	1.15	;	Crystal structure of haloalkane dehalogenase LinB D147C+L177C mutant (LinB73) from Sphingobium japonicum UT26
4H77	;	1.6	;	Crystal structure of haloalkane dehalogenase LinB from Sphingobium sp. MI1205
4H7J	;	1.8	;	Crystal structure of haloalkane dehalogenase LinB H247A mutant from Sphingobium sp. MI1205
4H7K	;	1.75	;	Crystal structure of haloalkane dehalogenase LinB I253M mutant from Sphingobium sp. MI1205
4H7I	;	1.8	;	Crystal structure of haloalkane dehalogenase LinB L138I mutant from Sphingobium sp. MI1205
4H7H	;	2.1	;	Crystal structure of haloalkane dehalogenase LinB T135A mutant from Sphingobium sp. MI1205
4H7D	;	1.95	;	Crystal structure of haloalkane dehalogenase LinB T81A mutant from Sphingobium sp. MI1205
4H7E	;	1.8	;	Crystal structure of haloalkane dehalogenase LinB V112A mutant from Sphingobium sp. MI1205
4H7F	;	1.8	;	Crystal structure of haloalkane dehalogenase LinB V134I mutant from Sphingobium sp. MI1205
4WDQ	;	1.58	;	Crystal structure of haloalkane dehalogenase LinB32 mutant (L177W) from Sphingobium japonicum UT26
7NFZ	;	1.551	;	Crystal structure of haloalkane dehalogenase LinB57 mutant (H272F) from Sphingobium japonicum UT26
2QVB	;	1.19	;	Crystal Structure of Haloalkane Dehalogenase Rv2579 from Mycobacterium tuberculosis
2O2H	;	1.6	;	Crystal structure of haloalkane dehalogenase Rv2579 from Mycobacterium tuberculosis complexed with 1,2-dichloroethane
2O2I	;	1.5	;	Crystal structure of haloalkane dehalogenase Rv2579 from Mycobacterium tuberculosis complexed with 1,3-propandiol
6TY7	;	1.5	;	Crystal structure of haloalkane dehalogenase variant DhaA115 domain-swapped dimer type-1
6XT8	;	1.7	;	Crystal structure of haloalkane dehalogenase variant DhaA115 domain-swapped dimer type-2
6XTC	;	2.543	;	Crystal structure of haloalkane dehalogenase variant DhaA177 domain-swapped dimer type-3
2HAD	;	1.9	;	CRYSTAL STRUCTURE OF HALOALKANE DEHALOGENASE: AN ENZYME TO DETOXIFY HALOGENATED ALKANES
4PXK	;	2.5	;	Crystal structure of Haloarcula marismortui bacteriorhodopsin I D94N mutant
7ESG	;	2.53	;	Crystal structure of Haloarcula marismortui CheB with Glutathione S-transferase expression tag
8AJP	;	1.8	;	Crystal structure of Halogen methyl transferase from Paraburkholderia xenovorans at 1.8 A in complex with SAH
7V0D	;	2.6	;	Crystal structure of halogenase CtcP from Kitasatospora aureofaciens
7V0B	;	2.15	;	Crystal structure of halogenase CtcP from Kitasatospora aureofaciens in complex with FAD
5DBJ	;	2.75	;	Crystal structure of halogenase PltA
6BZN	;	1.8	;	Crystal structure of halogenase PltM
6BZI	;	2.4	;	Crystal structure of halogenase PltM in complex with ethyl mercury and mercury
6BZQ	;	2.75	;	Crystal structure of halogenase PltM in complex with FAD
6BZZ	;	2.05	;	Crystal structure of halogenase PltM in complex with partially bound FAD
6BZA	;	2.6	;	Crystal structure of halogenase PltM in complex with phloroglucinol and FAD
6BZT	;	2.1	;	Crystal structure of halogenase PltM L111Y mutant in complex with FAD
7WKQ	;	2.89	;	Crystal Structure of halohydrin dehalogenase from Acidimicrobiia bacterium
4QID	;	2.57	;	Crystal structure of Haloquadratum walsbyi bacteriorhodopsin
4WAV	;	2.8	;	Crystal Structure of Haloquadratum walsbyi bacteriorhodopsin mutant D93N
3A7K	;	2.0	;	Crystal structure of halorhodopsin from Natronomonas pharaonis
5Y2Y	;	2.27	;	Crystal structure of HaloTag (M175C) complexed with dansyl-PEG2-HaloTag ligand
6U32	;	1.8	;	Crystal structure of HaloTag bound to tetramethylrhodamine-HaloTag ligand
7WAN	;	2.284	;	Crystal structure of HaloTag complexed with UL2
7WAM	;	1.49	;	Crystal structure of HaloTag complexed with VL1
6ICE	;	1.8	;	Crystal structure of Hamster MIF
2OQE	;	1.6	;	Crystal Structure of Hansenula polymorpha amine oxidase in complex with Xe to 1.6 Angstroms
2OOV	;	1.7	;	Crystal Structure of Hansenula polymorpha amine oxidase to 1.7 Angstroms
4KFD	;	1.69	;	Crystal structure of Hansenula polymorpha copper amine oxidase-1 reduced by methylamine at pH 6.0
4KFE	;	2.1	;	Crystal structure of Hansenula polymorpha copper amine oxidase-1 reduced by methylamine at pH 7.0
4KFF	;	2.15	;	Crystal structure of Hansenula polymorpha copper amine oxidase-1 reduced by methylamine at pH 8.5
6W45	;	1.7	;	Crystal structure of HAO1 in complex with biaryl acid inhibitor - compound 3
6W44	;	1.64	;	Crystal structure of HAO1 in complex with indazole acid inhibitor - compound 4
6W4C	;	1.75	;	Crystal structure of HAO1 in complex with indazole acid inhibitor - compound 5
2JDJ	;	2.0	;	crystal structure of HapK from Hahella chejuensis
3FO1	;	2.2	;	Crystal structure of hapten complex of catalytic elimination antibody 13G5 (Glu(L39)Ala mutant)
3FO2	;	2.18	;	Crystal structure of hapten complex of catalytic elimination antibody 13G5 (Glu(L39)Gln mutant)
3FO0	;	2.5	;	Crystal structure of hapten complex of catalytic elimination antibody 13G5 (wild-type)
4KKJ	;	3.0	;	Crystal Structure of Haptocorrin in Complex with Cbi
4KKI	;	2.35	;	Crystal Structure of Haptocorrin in Complex with CNCbl
5F3X	;	2.649	;	Crystal structure of Harmonin NPDZ1 in complex with ANKS4B SAM-PBM
7WU8	;	1.599	;	Crystal structure of Harmonin-homology domain 2 (HHD2) of human RTEL1
4Y1Q	;	3.1	;	Crystal Structure of HasA mutant Y75A monomer from Yersinia pseudotuberculosis
7EMP	;	1.5	;	Crystal Structure of HasAp Capturing Chromium Tetraphenylporphyrin
7EMR	;	1.55	;	Crystal Structure of HasAp Capturing Cobalt Tetraphenylporphyrin
7VM1	;	2.0	;	Crystal Structure of HasAp Capturing Iron Tetra(4-pyridyl)porphyrin
7EMO	;	1.5	;	Crystal Structure of HasAp Capturing Iron Tetraphenylporphyrin
7EMQ	;	1.5	;	Crystal Structure of HasAp Capturing Manganese Tetraphenylporphyrin
5XIE	;	2.05	;	Crystal Structure of HasAp with 5-ethynyl-10,20-diphenylporphyrin
7VF8	;	1.35	;	Crystal Structure of HasAp with Co-5-octaethyloxaporphyrinium cation
6JLG	;	2.5	;	Crystal Structure of HasAp with Co-9,10,19,20-Tetraphenylporphycene
7VF7	;	1.35	;	Crystal Structure of HasAp with Co-octaethylporphyrin
5XIC	;	1.45	;	Crystal Structure of HasAp with Fe-5,10,15-triphenylporphyrin
5XKB	;	1.9	;	Crystal Structure of HasAp with Fe-5,15-bisethynyl-10,20-diphenylporphyrin
5XA4	;	1.3	;	Crystal Structure of HasAp with Fe-5,15-Diazaporphyrin
5XIB	;	2.3	;	Crystal Structure of HasAp with Fe-5,15-Diphenylporphyrin
5XHL	;	2.5	;	Crystal Structure of HasAp with Gallium Phthalocyanine
3WAH	;	1.54	;	Crystal Structure of HasAp with Iron MesoporphyrinIX
3W8O	;	1.85	;	Crystal Structure of HasAp with Iron Phthalocyanine
3W8M	;	1.46	;	Crystal Structure of HasAp with Iron Salophen
5HTB	;	1.7	;	Crystal structure of haspin (GSG2) in complex with bisubstrate inhibitor ARC-3353
5HTC	;	1.5	;	Crystal structure of haspin (GSG2) in complex with bisubstrate inhibitor ARC-3372
6Z5A	;	1.55	;	Crystal structure of haspin (GSG2) in complex with macrocycle ODS2002941
6Z5B	;	1.9	;	Crystal structure of haspin (GSG2) in complex with macrocycle ODS2003128
6Z56	;	1.9	;	Crystal structure of haspin (GSG2) in complex with macrocycle ODS2003208
6Z58	;	1.8	;	Crystal structure of haspin (GSG2) in complex with macrocycle ODS2003791
6Z59	;	2.0	;	Crystal structure of haspin (GSG2) in complex with macrocycle ODS2003816
6Z5C	;	1.75	;	Crystal structure of haspin (GSG2) in complex with macrocycle ODS2004070
6Z57	;	1.5	;	Crystal structure of haspin (GSG2) in complex with macrocycle ODS2004078
6Z5D	;	1.75	;	Crystal structure of haspin (GSG2) in complex with macrocycle ODS2004082
6Z5E	;	1.5	;	Crystal structure of haspin (GSG2) in complex with macrocycle ODS2004093
6G3A	;	1.43	;	Crystal structure of haspin F605T mutant in complex with 5-iodotubercidin
6G39	;	1.45	;	Crystal structure of haspin F605Y mutant in complex with 5-iodotubercidin
6G35	;	1.55	;	Crystal structure of haspin in complex with 5-bromotubercidin
6G36	;	1.46	;	Crystal structure of haspin in complex with 5-chlorotubercidin
6G37	;	1.48	;	Crystal structure of haspin in complex with 5-fluorotubercidin
6G34	;	1.76	;	Crystal structure of haspin in complex with 5-iodotubercidin
7AVQ	;	1.65	;	Crystal structure of haspin in complex with disubstituted imidazo[1,2- b]pyridazine inhibitor (compound 12)
6G38	;	1.47	;	Crystal structure of haspin in complex with tubercidin
7OPS	;	2.38	;	Crystal structure of haspin in complex with ZW282 (compound 2a)
2WB8	;	2.15	;	Crystal structure of Haspin kinase
5JPZ	;	3.045	;	Crystal structure of HAT domain of human Squamous Cell Carcinoma Antigen Recognized By T Cells 3, SART3 (TIP110)
2OOE	;	3.0	;	Crystal structure of HAT domain of murine CstF-77
4E85	;	3.0	;	crystal STRUCTURE OF HAT DOMAIN OF RNA14
7XAY	;	3.3	;	Crystal structure of Hat1-Hat2-Asf1-H3-H4
2F1Z	;	3.2	;	Crystal structure of HAUSP
3FPV	;	2.2	;	Crystal Structure of HbpS
3FPW	;	1.6	;	Crystal Structure of HbpS with bound iron
2HFG	;	2.61	;	Crystal structure of hBR3 bound to CB3s-Fab
4I1Q	;	2.53	;	Crystal Structure of hBRAP1 N-BAR domain
4ZW1	;	1.75	;	Crystal structure of hBRD4 in complex with BL-BI06 reveals a novel synthesized inhibitor that induces Beclin1-independent/ATG5-dependent autophagic cell death in breast cancer
3KXS	;	2.25	;	Crystal structure of HBV capsid mutant dimer (oxy form), strain adyw
7K5M	;	2.65	;	CRYSTAL STRUCTURE OF HBV CAPSID Y132A MUTANT IN COMPLEX WITH N-(3-chloro-4-fluorophenyl)-3-phenyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide AT 2.65A RESOLUTION
6RVK	;	1.58	;	Crystal structure of hCA II in complex with Urea, N-(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-6-yl)-N'-(phenylmethyl)-
6RW1	;	1.7	;	Crystal structure of hCA II in complex with Urea, N-(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-6-yl)-N'-(phenylmethyl)-
6RVF	;	2.07	;	Crystal structure of hCA II in complex with Urea, N-(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-6-yl)-N'-phenyl
6RVL	;	1.72	;	Crystal structure of hCA II with Urea, N-(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-6-yl)-?N'-phenyl-
7N67	;	2.5	;	Crystal structure of HCAN_0198, a 3,4-ketoisomerase from Helicobacter canadensis
7UIE	;	3.23	;	Crystal structure of HcE-JLE-G6
4GO6	;	2.7	;	Crystal structure of HCF-1 self-association sequence 1
1HJW	;	2.3	;	Crystal structure of hcgp-39 in complex with chitin octamer
1HJV	;	2.75	;	Crystal structure of hcgp-39 in complex with chitin tetramer
3VS7	;	3.001	;	Crystal structure of HCK complexed with a pyrazolo-pyrimidine inhibitor 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
3VS6	;	2.373	;	Crystal structure of HCK complexed with a pyrazolo-pyrimidine inhibitor tert-butyl {4-[4-amino-1-(propan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl}carbamate
5H0E	;	2.1	;	Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor (S)-2-(((1r,4S)-4-(4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyl)amino)-4-methylpentanamide
5H0B	;	1.651	;	Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor (S)-2-(((1r,4S)-4-(4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyl)amino)-4-methylpentanoic acid
5H0G	;	1.8	;	Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor (S)-2-(((1r,4S)-4-(4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyl)amino)-N,4-dimethylpentanamide
5H0H	;	1.72	;	Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor (S)-2-(((1r,4S)-4-(4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyl)amino)-N,N,4-trimethylpentanamide
5H09	;	1.945	;	Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor (S)-ethyl2-(((1r,4S)-4-(4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyl)amino)-4-methylpentanoate
3VRZ	;	2.218	;	Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor 1-[4-(4-amino-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl]-3-benzylurea
3VS1	;	2.464	;	Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor 1-[4-(4-amino-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl]-3-phenylurea
3VRY	;	2.481	;	Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-cyclopentane
3VS4	;	2.747	;	Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor 5-(4-phenoxyphenyl)-7-(tetrahydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
3VS5	;	2.851	;	Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor 7-(1-methylpiperidin-4-yl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
3VS2	;	2.609	;	Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor 7-[cis-4-(4-methylpiperazin-1-yl)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
3VS3	;	2.17	;	Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor 7-[trans-4-(4-methylpiperazin-1-yl)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
3VS0	;	2.934	;	Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor N-[4-(4-amino-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl]benzamide
4LUE	;	3.04	;	Crystal Structure of HCK in complex with 7-[trans-4-(4-methylpiperazin-1-yl)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (resulting from displacement of SKF86002)
1QCF	;	2.0	;	CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH A SRC FAMILY-SELECTIVE TYROSINE KINASE INHIBITOR
4LUD	;	2.85	;	Crystal Structure of HCK in complex with the fluorescent compound SKF86002
5ZJ6	;	1.696	;	Crystal structure of HCK kinase complexed with a pyrrolo-pyrimidine inhibitor 7-[trans-4-(4-methylpiperazin-1-yl)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
4OSU	;	1.87	;	Crystal structure of HCMV gB-neutralizing SM5-1 Fab fragment
5C6T	;	3.6	;	Crystal structure of HCMV glycoprotein B in complex with 1G2 Fab
5VOB	;	3.02	;	Crystal structure of HCMV Pentamer in complex with neutralizing antibody 8I21
5VOC	;	3.99	;	Crystal structure of HCMV Pentamer in complex with neutralizing antibody 8I21 - Low resolution dataset for initial phasing by SAD
5VOD	;	5.9	;	Crystal structure of HCMV Pentamer in complex with neutralizing antibody 9I6
3BS5	;	2.0	;	Crystal Structure of hCNK2-SAM/dHYP-SAM Complex
8IM6	;	2.01	;	Crystal structure of HCoV 229E main protease in complex with PF07304814
7YRZ	;	1.79	;	Crystal structure of HCoV 229E main protease in complex with PF07321332
3EJG	;	1.78	;	Crystal structure of HCoV-229E X-domain
8DGW	;	2.81	;	Crystal structure of HCoV-HKU1 spike stem helix peptide in complex with Fab of broadly neutralizing antibody CC95.108 isolated from a vaccinated COVID-19 convalescent
3TLO	;	1.6	;	Crystal structure of HCoV-NL63 3C-like protease
7EO7	;	2.24917	;	Crystal structure of HCoV-NL63 3C-like protease in complex with an inhibitor Shikonin
7E6L	;	1.78037	;	Crystal structure of HCoV-NL63 3C-like protease,pH5.0
7E6N	;	1.8413	;	Crystal structure of HCoV-NL63 3C-like protease,pH5.2
7E6R	;	1.9	;	Crystal structure of HCoV-NL63 3C-like protease,pH5.6
7WQH	;	2.32	;	Crystal structure of HCoV-NL63 main protease with PF07304814
8HUU	;	1.71	;	Crystal structure of HCoV-NL63 main protease with S217622
4LI4	;	1.71	;	Crystal structure of HCoV-OC43 N-NTD complexed with AMP
4LMC	;	1.742	;	Crystal structure of HCoV-OC43 N-NTD complexed with CMP
4LM9	;	1.601	;	Crystal structure of HCoV-OC43 N-NTD complexed with GMP
4KXJ	;	2.65	;	Crystal structure of HCoV-OC43 N-NTD complexed with PJ34
4LM7	;	1.72	;	Crystal structure of HCoV-OC43 N-NTD complexed with UMP
6A2V	;	2.588	;	Crystal structure of Hcp protein
5XHH	;	2.1	;	crystal structure of Hcp1 from Salmonella typhimurium
5XEU	;	3.0	;	crystal structure of Hcp2 from Salmonella typhimurium
3RMX	;	2.75	;	Crystal structure of HCR/D F1240A mutant
3RMY	;	2.3	;	Crystal structure of HCR/D W1238A mutant
4FVV	;	2.7	;	Crystal structure of HCR/D-Sa-GBL1/C
3HMY	;	2.0	;	Crystal structure of HCR/T complexed with GT2
3HN1	;	2.1	;	Crystal structure of HCR/T complexed with GT2 and lactose
4IQP	;	2.3	;	Crystal Structure of HCRA-W1266A
1RTL	;	2.75	;	CRYSTAL STRUCTURE OF HCV NS3 PROTEASE DOMAIN: NS4A PEPTIDE COMPLEX WITH COVALENTLY BOUND PYRROLIDINE-5,5-TRANSLACTAM INHIBITOR
1N1L	;	2.6	;	CRYSTAL STRUCTURE OF HCV NS3 PROTEASE DOMAIN:NS4A PEPTIDE COMPLEX WITH COVALENTLY BOUND INHIBITOR (GW472467X)
2XCF	;	2.48	;	Crystal structure of HCV NS3 protease with a boronate inhibitor
2XCN	;	3.02	;	Crystal structure of HCV NS3 protease with a boronate inhibitor
2OIN	;	2.5	;	crystal structure of HCV NS3-4A R155K mutant
2QV1	;	2.4	;	Crystal structure of HCV NS3-4A V36M mutant
7L7P	;	1.58	;	Crystal structure of HCV NS3/4A D168A protease in complex with CH-24
7MME	;	1.56	;	Crystal structure of HCV NS3/4A D168A protease in complex with JZ01-15
7MMD	;	1.89	;	Crystal structure of HCV NS3/4A D168A protease in complex with JZ01-19
7MMC	;	2.001	;	Crystal structure of HCV NS3/4A D168A protease in complex with NR01-115
7MMB	;	1.99	;	Crystal structure of HCV NS3/4A D168A protease in complex with NR01-127
7L7L	;	1.88	;	Crystal structure of HCV NS3/4A D168A protease in complex with NR01-129
7MML	;	1.701	;	Crystal structure of HCV NS3/4A D168A protease in complex with NR01-145
7MMK	;	1.89	;	Crystal structure of HCV NS3/4A D168A protease in complex with NR01-149
7MMJ	;	1.992	;	Crystal structure of HCV NS3/4A D168A protease in complex with NR02-08
7MMI	;	1.8	;	Crystal structure of HCV NS3/4A D168A protease in complex with NR02-23
7MMH	;	1.75	;	Crystal structure of HCV NS3/4A D168A protease in complex with NR02-49
7MMG	;	1.95	;	Crystal structure of HCV NS3/4A D168A protease in complex with NR02-58
7L7N	;	1.59	;	Crystal structure of HCV NS3/4A D168A protease in complex with NR02-59
7MMF	;	1.891	;	Crystal structure of HCV NS3/4A D168A protease in complex with NR02-60
7L7O	;	1.72	;	Crystal structure of HCV NS3/4A D168A protease in complex with NR04-49
6DIW	;	1.8	;	Crystal structure of HCV NS3/4A D168A protease in complex with P4-1 (AJ-71)
6PIZ	;	1.89	;	Crystal structure of HCV NS3/4A D168A protease in complex with P4-1 (NR02-24)
6PIY	;	1.862	;	Crystal structure of HCV NS3/4A D168A protease in complex with P4-2 (NR02-61)
6PJ1	;	1.89	;	Crystal structure of HCV NS3/4A D168A protease in complex with P4-4(AJ-74)
6PJ0	;	2.05	;	Crystal structure of HCV NS3/4A D168A protease in complex with P4-5 (NR01-97)
6PIW	;	1.9	;	Crystal structure of HCV NS3/4A D168A protease in complex with P4-6 (NR03-67)
6PIV	;	2.14	;	Crystal structure of HCV NS3/4A D168A protease in complex with P4-7 (NR03-77)
6DIV	;	1.83	;	Crystal structure of HCV NS3/4A D168A protease in complex with P4-P5-2 (AJ-67)
6PJ2	;	2.1	;	Crystal structure of HCV NS3/4A D168A protease in complex with P4-P5-4 (AJ-65)
6PIX	;	1.87	;	Crystal structure of HCV NS3/4A D168A protease in complex with P4-P5-5 (WK-25)
6PIU	;	2.28	;	Crystal structure of HCV NS3/4A D168A protease in complex with P4-P5-6 (NR03-68)
6UE3	;	1.56	;	Crystal structure of HCV NS3/4A D168A protease in complex with PC (JZ01-15)
4I32	;	2.3001	;	Crystal structure of HCV NS3/4A D168V protease complexed with compound 4
6C2N	;	1.802	;	Crystal structure of HCV NS3/4A double mutant variant Y56H/D168A in complex with danoprevir
5ETX	;	2.35	;	Crystal structure of HCV NS3/4A protease A156T variant in complex with 5172-Linear (MK-5172 linear analogue)
5EPY	;	2.3	;	Crystal structure of HCV NS3/4A protease A156T variant in complex with 5172-mcP1P3 (MK-5172 P1-P3 macrocyclic analogue)
4K8B	;	2.8	;	Crystal structure of HCV NS3/4A protease complexed with inhibitor
5EPN	;	2.3	;	Crystal structure of HCV NS3/4A protease in complex with 5172-mcP1P3 (MK-5172 P1-P3 macrocyclic analogue)
5VP9	;	1.859	;	Crystal structure of HCV NS3/4A protease in complex with AM-07, an analogue of 5172-mcP1P3
4WH8	;	2.703	;	Crystal Structure of HCV NS3/4A protease in complex with an Asunaprevir P1-P3 macrocyclic analog.
6NZV	;	1.55	;	Crystal structure of HCV NS3/4A protease in complex with compound 12
3M5L	;	1.25	;	Crystal structure of HCV NS3/4A protease in complex with ITMN-191
5VOJ	;	1.799	;	Crystal structure of HCV NS3/4A protease in complex with JZ01-15, an analogue of 5172-mcP1P3
3M5N	;	1.9	;	Crystal structure of HCV NS3/4A protease in complex with N-terminal product 4B5A
3M5O	;	1.6	;	Crystal structure of HCV NS3/4A protease in complex with N-terminal product 5A5B
7MM4	;	1.89	;	Crystal structure of HCV NS3/4A protease in complex with NR01-115
7MM3	;	1.78	;	Crystal structure of HCV NS3/4A protease in complex with NR01-127
7MMA	;	1.65	;	Crystal structure of HCV NS3/4A protease in complex with NR01-145
7MM9	;	2.11	;	Crystal structure of HCV NS3/4A protease in complex with NR01-149
7MM8	;	1.43	;	Crystal structure of HCV NS3/4A protease in complex with NR02-08
7MM7	;	1.862	;	Crystal structure of HCV NS3/4A protease in complex with NR02-23
7MM6	;	2.0	;	Crystal structure of HCV NS3/4A protease in complex with NR02-49
7MM5	;	1.86	;	Crystal structure of HCV NS3/4A protease in complex with NR02-60
7MM2	;	1.891	;	Crystal structure of HCV NS3/4A protease in complex with NR02-61
6DIS	;	1.921	;	Crystal structure of HCV NS3/4A protease in complex with P4-1 (AJ-71)
6DIT	;	1.789	;	Crystal structure of HCV NS3/4A protease in complex with P4-2 (JZ01-19)
6DIU	;	1.868	;	Crystal structure of HCV NS3/4A protease in complex with P4-3(AJ-74)
6DIQ	;	1.579	;	Crystal structure of HCV NS3/4A protease in complex with P4-P5-1 (WK-23)
6DIR	;	1.751	;	Crystal structure of HCV NS3/4A protease in complex with P4-P5-2 (AJ-67)
6NZT	;	1.4	;	Crystal structure of HCV NS3/4A protease in complex with voxilaprevir
4WH6	;	1.99	;	Crystal structure of HCV NS3/4A protease variant R155K in complex with Asunaprevir
6C2O	;	1.179	;	Crystal structure of HCV NS3/4A protease variant Y56H in complex with danoprevir
6C2M	;	1.859	;	Crystal structure of HCV NS3/4A protease variant Y56H in complex with MK-5172
4I33	;	1.9001	;	Crystal structure of HCV NS3/4A R155K protease complexed with compound 4
5EQQ	;	1.65	;	Crystal structure of HCV NS3/4A WT protease in complex with 5172-Linear (MK-5172 linear analogue)
6CVY	;	1.798	;	Crystal structure of HCV NS3/4A WT protease in complex with AJ-21 (MK-5172 linear analogue)
6CVX	;	1.779	;	Crystal structure of HCV NS3/4A WT protease in complex with AJ-50 (MK-5172 linear analogue)
6CVW	;	1.78	;	Crystal structure of HCV NS3/4A WT protease in complex with AJ-52 (MK-5172 linear analogue)
3P8N	;	1.9	;	Crystal structure of HCV NS3/NS4A protease complexed with BI 201335
4I31	;	1.9301	;	Crystal structure of HCV NS3/NS4A protease complexed with compound 4
4JMY	;	1.95	;	Crystal structure of HCV NS3/NS4A protease complexed with DDIVPC peptide
3P8O	;	2.3	;	Crystal structure of HCV NS3/NS4A protease complexed with des-bromine analogue of BI 201335
3H98	;	1.9	;	Crystal structure of HCV NS5b 1b with (1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl) azolo[1,5-a]pyrimidine derivative
4WTD	;	2.7	;	CRYSTAL STRUCTURE OF HCV NS5B GENOTYPE 2A JFH-1 ISOLATE WITH S15G E86Q E87Q C223H V321I MUTATIONS AND DELTA8 BETA HAIRPIN LOOP DELETION IN COMPLEX WITH ADP, MN2+ AND SYMMETRICAL PRIMER TEMPLATE 5'-AUAAAUUU
4WTC	;	2.75	;	CRYSTAL STRUCTURE OF HCV NS5B GENOTYPE 2A JFH-1 ISOLATE WITH S15G E86Q E87Q C223H V321I MUTATIONS AND DELTA8 BETA HAIRPIN LOOP DELETION IN COMPLEX WITH CDP, MN2+ AND SYMMETRICAL PRIMER TEMPLATE 5'-AGAAAUUU
4WTE	;	2.9	;	CRYSTAL STRUCTURE OF HCV NS5B GENOTYPE 2A JFH-1 ISOLATE WITH S15G E86Q E87Q C223H V321I MUTATIONS AND DELTA8 BETA HAIRPIN LOOP DELETION IN COMPLEX WITH GDP, MN2+ AND SYMMETRICAL PRIMER TEMPLATE 5'-ACAAAUUU
4WTF	;	2.65	;	CRYSTAL STRUCTURE OF HCV NS5B GENOTYPE 2A JFH-1 ISOLATE WITH S15G E86Q E87Q C223H V321I MUTATIONS AND DELTA8 BETA HAIRPIN LOOP DELETION IN COMPLEX WITH GS-639475, MN2+ AND SYMMETRICAL PRIMER TEMPLATE 5'-CAAAAUUU
4WTG	;	2.9	;	CRYSTAL STRUCTURE OF HCV NS5B GENOTYPE 2A JFH-1 ISOLATE WITH S15G E86Q E87Q C223H V321I MUTATIONS AND DELTA8 BETA HAIRPIN LOOP DELETION IN COMPLEX WITH SOFOSBUVIR DIPHOSPHATE GS-607596, MN2+ AND SYMMETRICAL PRIMER TEMPLATE 5'-CAAAAUUU
4WTA	;	2.8	;	CRYSTAL STRUCTURE OF HCV NS5B GENOTYPE 2A JFH-1 ISOLATE WITH S15G E86Q E87Q C223H V321I MUTATIONS AND DELTA8 BETA HAIRPIN LOOP DELETION IN COMPLEX WITH UDP, MN2+ AND SYMMETRICAL PRIMER TEMPLATE 5'-CAAAAUUU
5UJ2	;	2.9	;	Crystal structure of HCV NS5B genotype 2A JFH-1 isolate with S15G E86Q E87Q C223H V321I mutations and Delta8 neta hairpoin loop deletion in complex with GS-639476 (diphsohate version of GS-9813), Mn2+ and symmetrical primer template 5'-AUAAAUUU
4WTI	;	2.8	;	CRYSTAL STRUCTURE OF HCV NS5B GENOTYPE 2A JFH-1 ISOLATE WITH S15G E86Q E87Q C223H V321I MUTATIONS IN COMPLEX WITH RNA TEMPLATE 5'-ACGG, RNA PRIMER 5'-PCC, MN2+, AND GDP
4WTK	;	2.5	;	CRYSTAL STRUCTURE OF HCV NS5B GENOTYPE 2A JFH-1 ISOLATE WITH S15G E86Q E87Q C223H V321I MUTATIONS IN COMPLEX WITH RNA TEMPLATE 5'-AGCC, RNA PRIMER 5'-PGG, MN2+, AND CDP
4WTJ	;	2.2	;	CRYSTAL STRUCTURE OF HCV NS5B GENOTYPE 2A JFH-1 ISOLATE WITH S15G E86Q E87Q C223H V321I MUTATIONS IN COMPLEX WITH RNA TEMPLATE 5'-AUCC, RNA PRIMER 5'-PGG, MN2+, AND ADP
4WTL	;	2.0	;	CRYSTAL STRUCTURE OF HCV NS5B GENOTYPE 2A JFH-1 ISOLATE WITH S15G E86Q E87Q C223H V321I MUTATIONS IN COMPLEX WITH RNA TEMPLATE 5'-UACC, RNA PRIMER 5'-PGG, MN2+, AND UDP
4WTM	;	2.15	;	CRYSTAL STRUCTURE OF HCV NS5B GENOTYPE 2A JFH-1 ISOLATE WITH S15G E86Q E87Q C223H V321I MUTATIONS IN COMPLEX WITH RNA TEMPLATE 5'-UAGG, RNA PRIMER 5'-PCC, MN2+, AND UDP
3MWV	;	2.2	;	Crystal structure of HCV NS5B polymerase
3MWW	;	2.8	;	Crystal structure of HCV NS5B polymerase
4IZ0	;	2.22	;	Crystal structure of HCV NS5B polymerase in complex with 2,4,5-trichloro-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide
4J0A	;	2.4	;	Crystal structure of hcv ns5b polymerase in complex with 2-{[(4-METHYLPHENYL)SULFONYL]AMINO}-4-PHENOXYBENZOIC ACID
4J08	;	2.1	;	Crystal structure of hcv ns5b polymerase in complex with 2-{[(4-METHYLPHENYL)SULFONYL]AMINO}-5-PHENOXYBENZOIC ACID
4J06	;	2.0	;	Crystal structure of hcv ns5b polymerase in complex with 2-{[(5-BROMOTHIOPHEN-2-YL)SULFONYL]AMINO}-4-CHLOROBENZOIC ACID
4J04	;	2.0	;	Crystal structure of hcv ns5b polymerase in complex with 4-CHLORO-2-{[(2,4,5-TRICHLOROPHENYL)SULFONYL]AMINO}BENZOIC ACID
3H2L	;	1.9	;	Crystal structure of HCV NS5B polymerase in complex with a novel bicyclic dihydro-pyridinone inhibitor
4GMC	;	2.7	;	Crystal structure of HCV NS5B polymerase in complex with a thumb inhibitor
4JU2	;	2.7	;	Crystal structure of hcv ns5b polymerase in complex with compound 12
4JJS	;	2.2	;	Crystal structure of HCV NS5B polymerase in complex with COMPOUND 2
4JU4	;	2.4	;	Crystal structure of hcv ns5b polymerase in complex with compound 22
4JU6	;	2.2	;	Crystal structure of hcv ns5b polymerase in complex with compound 24
4JU7	;	2.2	;	Crystal structure of hcv ns5b polymerase in complex with compound 24
4JJU	;	1.91	;	Crystal structure of HCV NS5B polymerase in complex with COMPOUND 29
4JY0	;	2.2	;	Crystal structure of hcv ns5b polymerase in complex with compound 3
4JTZ	;	2.8	;	Crystal structure of hcv ns5b polymerase in complex with compound 4
4JY1	;	2.6	;	CRYSTAL STRUCTURE OF HCV NS5B POLYMERASE IN COMPLEX WITH COMPOUND 5
4JU1	;	2.9	;	Crystal structure of hcv ns5b polymerase in complex with compound 6
4JU3	;	2.0	;	Crystal structure of hcv ns5b polymerase in complex with compound 8
4JVQ	;	2.4	;	Crystal structure of hcv ns5b polymerase in complex with compound 9
4JTW	;	3.0	;	Crystal structure of HCV NS5B polymerase in complex with coupound 1
4J02	;	2.0	;	Crystal structure of hcv ns5b polymerase in complex with [(1R)-5,8-DICHLORO-1-PROPYL-1,3,4,9-TETRAHYDROPYRANO[3,4-B]INDOL-1-YL]ACETIC ACID
3D28	;	2.3	;	Crystal structure of hcv ns5b polymerase with a novel benzisothiazole inhibitor
3IGV	;	2.6	;	Crystal structure of HCV NS5B polymerase with a novel monocyclic dihydro-pyridinone inhibitor
3GYN	;	2.15	;	Crystal structure of HCV NS5B polymerase with a novel monocyclic dihydropyridinone inhibitor
3BR9	;	2.3	;	Crystal Structure of HCV NS5B Polymerase with a Novel Pyridazinone Inhibitor
3BSA	;	2.3	;	Crystal Structure of HCV NS5B Polymerase with a Novel Pyridazinone Inhibitor
3BSC	;	2.65	;	Crystal Structure of HCV NS5B Polymerase with a Novel Pyridazinone Inhibitor
3CDE	;	2.1	;	Crystal structure of HCV NS5B polymerase with a novel Pyridazinone inhibitor
3CO9	;	2.1	;	Crystal structure of HCV NS5B polymerase with a novel pyridazinone inhibitor
3CVK	;	2.31	;	Crystal structure of HCV NS5B polymerase with a novel pyridazinone inhibitor
3CWJ	;	2.4	;	Crystal structure of hcv ns5b polymerase with a novel pyridazinone inhibitor
3D5M	;	2.2	;	Crystal structure of HCV NS5B polymerase with a novel pyridazinone inhibitor
3E51	;	1.9	;	Crystal structure of HCV NS5B polymerase with a novel pyridazinone inhibitor
4JTY	;	2.6	;	Crystal structure of HCV NS5B polymerase with COMPOUND 2
1OS5	;	2.2	;	Crystal structure of HCV NS5B RNA polymerase complexed with a novel non-competitive inhibitor.
2DXS	;	2.2	;	Crystal structure of HCV NS5B RNA polymerase complexed with a tetracyclic inhibitor
2HAI	;	1.58	;	Crystal structure of HCV NS5B RNA polymerase in complex with novel class of dihydropyrone-containing inhibitor.
3FRZ	;	1.86	;	Crystal Structure of HCV NS5B RNA polymerase in complex with PF868554
3VQS	;	1.9	;	Crystal structure of HCV NS5B RNA polymerase with a novel piperazine inhibitor
4OBC	;	2.5	;	Crystal structure of HCV polymerase NS5b genotype 2a JFH-1 isolate with the S15G, C223H, V321I resistance mutations against the guanosine analog GS-0938 (PSI-3529238)
5LM2	;	2.54	;	Crystal Structure of HD-PTP phosphatase
5LM1	;	2.55	;	Crystal Structure of HD-PTP phosphatase in complex with UBAP1
6J6T	;	2.36	;	Crystal Structure of HDA15 HD domain
5LI3	;	2.4	;	Crystal structure of HDAC-like protein from P. aeruginosa in complex with a photo-switchable inhibitor.
5UWI	;	2.143	;	Crystal Structure of HDAC5 NES Peptide in complex with CRM1-Ran-RanBP1
6ODA	;	2.88	;	Crystal structure of HDAC8 in complex with compound 2
6ODB	;	2.7	;	Crystal structure of HDAC8 in complex with compound 3
6ODC	;	2.8	;	Crystal structure of HDAC8 in complex with compound 30
2V5X	;	2.25	;	Crystal structure of HDAC8-inhibitor complex
2V5W	;	2.0	;	Crystal structure of HDAC8-substrate complex
5XHW	;	2.0	;	Crystal structure of HddC from Yersinia pseudotuberculosis
6JQ8	;	1.546	;	Crystal structure of HddC from Yersinia pseudotuberculosis complexed with GMP-PN
7KHM	;	2.88	;	Crystal structure of hDHHS20 bound to palmitoyl CoA
3RL7	;	2.3	;	Crystal structure of hDLG1-PDZ1 complexed with APC
3RL8	;	2.2	;	Crystal structure of hDLG1-PDZ2 complexed with APC
6HFA	;	1.79	;	Crystal structure of hDM2 in complex with a C-terminal triurea capped peptide chimera foldamer.
7QDQ	;	1.26	;	Crystal Structure of HDM2 in complex with Caylin-1
5C5A	;	1.146	;	Crystal Structure of HDM2 in complex with Nutlin-3a
3FEA	;	1.33	;	Crystal Structure of HdmX bound to the p53-peptidomimetic Ac-Phe-Met-Aib-Pmp-6-Cl-Trp-Glu-Ac3c-Leu-NH2 at 1.33A
3FE7	;	1.35	;	Crystal Structure of HdmX bound to the p53-peptidomimetic Ac-Phe-Met-Aib-Pmp-Trp-Glu-Ac3c-Leu-NH2 at 1.35A
3HC1	;	1.9	;	Crystal structure of HDOD domain protein with unknown function (NP_953345.1) from GEOBACTER SULFURREDUCENS at 1.90 A resolution
1NM3	;	2.8	;	Crystal structure of Heamophilus influenza hybrid-Prx5
7WN7	;	1.9	;	Crystal structure of HearNPV P26
3RSW	;	2.599	;	Crystal Structure of Heart Fatty Acid Binding Protein (FABP3)
1M5N	;	2.9	;	Crystal structure of HEAT repeats (1-11) of importin b bound to the non-classical NLS(67-94) of PTHrP
5HDG	;	1.7	;	crystal structure of heat shock factor 1-DBD
5HDK	;	1.32	;	Crystal structure of heat shock factor 2-DBD
6J6V	;	1.2	;	Crystal structure of heat shock factor 4-DBD
5HDN	;	1.68	;	Crystal structure of heat shock factor1-DBD complex with ds-DNA and TtT
3CQB	;	1.86	;	Crystal structure of heat shock protein HtpX domain from Vibrio parahaemolyticus RIMD 2210633
2P4W	;	2.6	;	Crystal structure of heat shock regulator from Pyrococcus furiosus
2IGP	;	1.8	;	Crystal Structure of Hec1 CH domain
2IBG	;	2.2	;	Crystal Structure of Hedgehog Bound to the FNIII Domains of Ihog
3HO3	;	2.9	;	Crystal structure of Hedgehog-interacting protein (HHIP)
3HO4	;	3.1	;	Crystal structure of Hedgehog-interacting protein (HHIP)
3HO5	;	3.01	;	Crystal structure of Hedgehog-interacting protein (HHIP) and Sonic hedgehog (SHH) complex
2NML	;	1.55	;	Crystal structure of HEF2/ERH at 1.55 A resolution
1OHQ	;	2.0	;	Crystal structure of HEL4, a soluble human VH antibody domain resistant to aggregation
1C3K	;	2.0	;	CRYSTAL STRUCTURE OF HELIANTHUS TUBEROSUS LECTIN
1C3N	;	2.45	;	CRYSTAL STRUCTURE OF HELIANTHUS TUBEROSUS LECTIN COMPLEXED TO MAN(1-2)MAN
3WRX	;	2.5	;	Crystal structure of helicase complex 1
3WRY	;	2.3	;	Crystal structure of helicase complex 2
6S3E	;	3.787	;	Crystal structure of helicase Pif1 from Thermus oshimai in apo form
6S3P	;	1.926	;	Crystal structure of helicase Pif1 from Thermus oshimai in complex with (dT)18
6S3H	;	2.06	;	Crystal structure of helicase Pif1 from Thermus oshimai in complex with ADP-AlF4 and (dT)7ds11bp
7BIL	;	2.21	;	Crystal structure of helicase Pif1 from Thermus oshimai in complex with oligo GGTTTGGTTTGGTT
7OAR	;	2.58	;	Crystal structure of helicase Pif1 from Thermus oshimai in complex with parallel G-quadruplex
6S3O	;	1.974	;	Crystal structure of helicase Pif1 from Thermus oshimai in complex with ssDNA (dT)18 and ADP
6S3M	;	2.113	;	Crystal structure of helicase Pif1 from Thermus oshimai in complex with ssDNA (dT)18 and ADP-AlF4
6S3I	;	2.455	;	Crystal structure of helicase Pif1 from Thermus oshimai in complex with ssDNA (dT)18 and ADP-MgF4
6S3N	;	2.533	;	Crystal structure of helicase Pif1 from Thermus oshimai in complex with ssDNA (dT)18 and ADP-VO4
6XZT	;	3.341	;	Crystal structure of helicase Pif1 from Thermus oshimai mutant G110C-E410C
7ADA	;	3.34	;	Crystal structure of helicase Pif1 from Thermus oshimai mutant Q164C-E409C
5LBH	;	2.553	;	Crystal structure of Helicobacter cinaedi CAIP
4YO8	;	2.1	;	Crystal structure of Helicobacter pylori 5'-methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) complexed with (((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)(hexyl)amino)methanol
6DYW	;	1.45	;	Crystal structure of Helicobacter pylori 5'-methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) complexed with (3R,4S)-1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-(((3-(1-benzyl-1H-1,2,3-triazol-4-yl)propyl)thio)methyl)pyrrolidin-3-ol
6DYY	;	1.61	;	Crystal structure of Helicobacter pylori 5'-methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) complexed with (3R,4S)-1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-(((3-(1-butyl-1H-1,2,3-triazol-4-yl)propyl)thio)methyl)pyrrolidin-3-ol
6DYV	;	1.62	;	Crystal structure of Helicobacter pylori 5'-methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) complexed with (3R,4S)-1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-((pent-4-yn-1-ylthio)methyl)pyrrolidin-3-ol
6DYU	;	1.6	;	Crystal structure of Helicobacter pylori 5'-methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) complexed with (3R,4S)-1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-((prop-2-yn-1-ylthio)methyl)pyrrolidin-3-ol
4WKP	;	1.58	;	Crystal structure of Helicobacter pylori 5'-methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) complexed with 2-(2-hydroxyethoxy)ethylthiomethyl-DADMe-Immucillin-A
4WKO	;	1.9	;	Crystal structure of Helicobacter pylori 5'-methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) complexed with hydroxybutylthio-DADMe-Immucillin-A
4WKN	;	2.0	;	Crystal structure of Helicobacter pylori 5'-methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) complexed with methylthio-DADMe-Immucillin-A
4YNB	;	2.0	;	Crystal structure of Helicobacter pylori 5'-methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) complexed with pyrazinylthio-DADMe-Immucillin-A
6GMM	;	2.06	;	Crystal structure of Helicobacter pylori adhesin LabA
3SXP	;	2.55	;	Crystal Structure of Helicobacter pylori ADP-L-glycero-D-manno-heptose-6-epimerase (rfaD, HP0859)
7LKJ	;	2.79	;	Crystal structure of Helicobacter pylori aminofutalosine deaminase (AFLDA)
7LKK	;	1.89	;	Crystal structure of Helicobacter pylori aminofutalosine deaminase (AFLDA) in complex with Methylthio-coformycin
4G3H	;	2.2	;	Crystal structure of helicobacter pylori arginase
2R62	;	3.3	;	Crystal structure of Helicobacter pylori ATP dependent protease, FtsH
2R65	;	3.3	;	Crystal structure of Helicobacter pylori ATP dependent protease, FtsH ADP complex
5FRQ	;	2.9	;	Crystal Structure of Helicobacter pylori beta clamp bound to DNA ligase peptide
5FVE	;	2.07	;	Crystal Structure of Helicobacter pylori beta clamp in complex with 3, 4-Difluorobenzamide
5FXT	;	1.97	;	Crystal Structure of Helicobacter pylori beta clamp in complex with Carprofen
8H52	;	3.1	;	Crystal structure of Helicobacter pylori carboxyspermidine dehydrogenase in complex with NADP
2IQF	;	1.86	;	Crystal structure of Helicobacter pylori catalase compound I
1UM8	;	2.6	;	Crystal structure of helicobacter pylori ClpX
7P0H	;	2.499	;	Crystal structure of Helicobacter pylori ComF fused to an artificial alphaREP crystallization helper(named B2)
8EVK	;	1.49	;	Crystal structure of Helicobacter pylori dihydroneopterin aldolase (DHNA)
4EHS	;	1.78	;	Crystal structure of Helicobacter pylori DnaG Primase C terminal domain
8DP6	;	1.3	;	Crystal structure of Helicobacter pylori EgtU
5NPY	;	2.292	;	Crystal structure of Helicobacter pylori flagellar hook protein FlgE2
6K8C	;	1.95175	;	Crystal structure of Helicobacter pylori folylpolyglutamate synthetase
2NQO	;	1.9	;	Crystal Structure of Helicobacter pylori gamma-Glutamyltranspeptidase
2QM6	;	1.6	;	Crystal Structure of Helicobacter Pylori Gamma-Glutamyltranspeptidase in Complex with Glutamate
2QMC	;	1.55	;	Crystal Structure of Helicobacter Pylori Gamma-Glutamyltranspeptidase T380A Mutant
2JFX	;	2.3	;	Crystal structure of Helicobacter pylori glutamate racemase in complex with D-Glutamate
2JFY	;	1.9	;	Crystal structure of Helicobacter pylori glutamate racemase in complex with D-Glutamate
2JFZ	;	1.86	;	Crystal structure of Helicobacter pylori glutamate racemase in complex with D-Glutamate and an inhibitor
2W4I	;	1.87	;	Crystal structure of Helicobacter pylori glutamate racemase in complex with D-Glutamate and an inhibitor
3GAS	;	1.8	;	Crystal Structure of Helicobacter pylori Heme Oxygenase Hugz in Complex with Heme
5XUK	;	2.3	;	Crystal structure of Helicobacter pylori holo-[acyl-carrier-protein] synthase (AcpS) in complex with coenzyme A
4TSD	;	1.53	;	Crystal structure of Helicobacter pylori HP1029
7XFP	;	1.87	;	Crystal structure of Helicobacter pylori IceA2
8XHU	;	2.4	;	Crystal structure of Helicobacter pylori IspDF
8XKF	;	2.5	;	Crystal structure of Helicobacter pylori IspDF with substrate CTP
1J6X	;	2.38	;	CRYSTAL STRUCTURE OF HELICOBACTER PYLORI LUXS
3KU7	;	2.8	;	Crystal structure of Helicobacter pylori MinE, a cell division topological specificity factor
3MCD	;	3.2	;	Crystal structure of Helicobacter pylori MinE, a cell division topological specificity factor
4HW9	;	4.14	;	Crystal Structure of Helicobacter pylori MscS (Closed State)
2EW7	;	2.2	;	Crystal Structure of Helicobacter Pylori peptide deformylase
6PC0	;	1.7	;	Crystal structure of Helicobacter pylori PPX/GppA
6PC1	;	2.76	;	Crystal structure of Helicobacter pylori PPX/GppA (E143A) in complex with ppGpp
6PC2	;	2.9	;	Crystal structure of Helicobacter pylori PPX/GppA in complex with GNP
6PC3	;	2.1	;	Crystal structure of Helicobacter pylori PPX/GppA in complex with GSP
2I9I	;	1.8	;	Crystal Structure of Helicobacter pylori protein HP0492
4RI1	;	2.3	;	Crystal structure of Helicobacter pylori pseudaminic acid biosynthesis N -acetyltransferase PseH complex with acetyl-coA
3ZCI	;	2.201	;	Crystal structure of Helicobacter pylori T4SS protein CagL in a cubic crystal form with a distorted helical conformation of the RGD-motif
3ZCJ	;	3.25	;	Crystal structure of Helicobacter pylori T4SS protein CagL in a tetragonal crystal form with a helical RGD-motif (6 Mol per ASU)
3ISH	;	2.43	;	Crystal structure of Helicobacter pylori thioredoxin reductase
6DTM	;	2.5	;	Crystal Structure of Helicobacter pylori TlpA Chemoreceptor Ligand Binding Domain
6E09	;	2.3	;	Crystal Structure of Helicobacter pylori TlpA Chemoreceptor Ligand Binding Domain
6E0A	;	2.43	;	Crystal Structure of Helicobacter pylori TlpA Chemoreceptor Ligand Binding Domain
2D2R	;	1.88	;	Crystal structure of Helicobacter pylori Undecaprenyl Pyrophosphate Synthase
2DTN	;	2.5	;	Crystal structure of Helicobacter pylori undecaprenyl pyrophosphate synthase complexed with pyrophosphate
1E9Z	;	3.0	;	Crystal structure of Helicobacter pylori urease
3SF5	;	2.495	;	Crystal Structure of Helicobacter pylori Urease Accessory Protein UreF/H complex
4HI0	;	2.35	;	Crystal Structure of Helicobacter pylori Urease Accessory Protein UreF/H/G complex
1E9Y	;	3.0	;	Crystal structure of Helicobacter pylori urease in complex with acetohydroxamic acid
3TJ8	;	1.591	;	Crystal structure of Helicobacter pylori UreE bound to Ni2+
3TJ9	;	2.521	;	Crystal structure of Helicobacter pylori UreE bound to Zn2+
3TJA	;	2.0	;	Crystal structure of Helicobacter pylori UreE in the apo form
3N2E	;	2.53	;	Crystal structure of Helicobactor pylori shikimate kinase in complex with NSC162535
2WGL	;	2.0	;	Crystal structure of Helicobactor pylori UreF
3S6P	;	2.5	;	Crystal Structure of Helicoverpa Armigera Stunt Virus
1DQF	;	2.2	;	CRYSTAL STRUCTURE OF HELIX II OF THE X. LAEVIS SOMATIC 5S RRNA WITH A CYTOSINE BULGE IN TWO CONFORMATIONS
1DQH	;	1.7	;	CRYSTAL STRUCTURE OF HELIX II OF THE X. LAEVIS SOMATIC 5S RRNA WITH A CYTOSINE BULGE IN TWO CONFORMATIONS
4NK2	;	1.96	;	Crystal structure of Hell's gate globin IV
1C3M	;	2.0	;	CRYSTAL STRUCTURE OF HELTUBA COMPLEXED TO MAN(1-3)MAN
3A5P	;	1.82	;	Crystal structure of hemagglutinin
4N5J	;	2.702	;	Crystal structure of hemagglutinin from an H7N9 influenza virus
4N64	;	2.7014	;	Crystal structure of hemagglutinin from an H7N9 influenza virus in complex with a biantennary glycan receptor
4N62	;	2.5026	;	Crystal structure of hemagglutinin from an H7N9 influenza virus in complex with a sulfated receptor analog
4N63	;	2.7522	;	Crystal structure of hemagglutinin from an H7N9 influenza virus in complex with an O-linked glycan receptor
4N5K	;	2.7053	;	Crystal structure of hemagglutinin from an H7N9 influenza virus in complex with LSTa
4N61	;	2.6023	;	Crystal structure of hemagglutinin from an H7N9 influenza virus in complex with LSTa, extended soaking
4N60	;	2.9032	;	Crystal structure of hemagglutinin from an H7N9 influenza virus in complex with LSTc
6ML8	;	2.92	;	Crystal structure of hemagglutinin from H1N1 Influenza A virus A/Denver/57 bound to the C05 antibody
6N08	;	1.916	;	Crystal structure of hemagglutinin from influenza virus A/Netherlands/209/1980 (H3N2)
6MZK	;	2.5	;	Crystal structure of hemagglutinin from influenza virus A/Pennsylvania/14/2010 (H3N2)
6MYM	;	2.45	;	Crystal structure of hemagglutinin from influenza virus A/Phillipines/2/1982 (H3N2)
6P6P	;	2.31	;	Crystal structure of hemagglutinin from influenza virus A/Sichuan/2/1987 (H3N2)
6MXU	;	1.85	;	Crystal structure of hemagglutinin from influenza virus A/Texas/1/1977 (H3N2)
4XQU	;	3.25	;	Crystal structure of hemagglutinin from Jiangxi-Donghu (2013) H10N8 influenza virus in complex with 3'-SLN
4XQO	;	2.85	;	Crystal structure of hemagglutinin from Jiangxi-Donghu (2013) H10N8 influenza virus in complex with 6'-SLN
4XKD	;	2.482	;	Crystal structure of hemagglutinin from Taiwan (2013) H6N1 influenza virus
4XKE	;	2.356	;	Crystal structure of hemagglutinin from Taiwan (2013) H6N1 influenza virus in complex with 3'-SLN
4XKG	;	2.25	;	Crystal structure of hemagglutinin from Taiwan (2013) H6N1 influenza virus in complex with 6'-SLN
4XKF	;	2.446	;	Crystal structure of hemagglutinin from Taiwan (2013) H6N1 influenza virus in complex with LSTa
5XKU	;	1.78	;	Crystal structure of hemagglutinin globular head from an H7N9 influenza virus in complex with a neutralizing antibody HNIgGA6
5BNY	;	2.66	;	Crystal structure of hemagglutinin of A/Chicken/Guangdong/S1311/2010 (H6N6)
5BQY	;	2.78	;	Crystal structure of hemagglutinin of A/Chicken/Guangdong/S1311/2010 (H6N6) in complex with avian-like receptor LSTa
5BQZ	;	2.89	;	Crystal structure of hemagglutinin of A/Chicken/Guangdong/S1311/2010 (H6N6) in complex with human-like receptor LSTc
5BR0	;	2.39	;	Crystal structure of hemagglutinin of A/Taiwan/2/2013 (H6N1)
5BR3	;	2.55	;	Crystal structure of hemagglutinin of A/Taiwan/2/2013 (H6N1) in complex with LSTa
5BR6	;	2.43	;	Crystal structure of hemagglutinin of A/Taiwan/2/2013 (H6N1) in complex with LSTc
4M40	;	3.54	;	Crystal structure of hemagglutinin of influenza virus B/Yamanashi/166/1998
4M44	;	2.5	;	Crystal structure of hemagglutinin of influenza virus B/Yamanashi/166/1998 in complex with avian-like receptor LSTa
2E4M	;	1.85	;	Crystal structure of hemagglutinin subcomponent complex (HA-33/HA-17) from Clostridium botulinum serotype D strain 4947
1OR4	;	2.15	;	Crystal Structure of HemAT sensor domain from B.subtilis in the cyano-liganded form
1OR6	;	2.71	;	Crystal Structure of HemAT sensor domain from B.subtilis in the unliganded form
1IYH	;	1.7	;	Crystal structure of hematopoietic prostaglandin D synthase
1IYI	;	1.8	;	Crystal structure of hematopoietic prostaglandin D synthase
5YWE	;	1.68	;	Crystal structure of hematopoietic prostaglandin D synthase apo form
1PD2	;	2.3	;	CRYSTAL STRUCTURE OF HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE COMPLEX WITH GLUTATHIONE
5YWX	;	1.74	;	Crystal structure of hematopoietic prostaglandin D synthase in complex with F092
5YX1	;	1.39	;	Crystal structure of hematopoietic prostaglandin D synthase in complex with U004
4ES6	;	2.22	;	Crystal structure of HemD (PA5259) from Pseudomonas aeruginosa (PAO1) at 2.22 A resolution
6A2J	;	2.2	;	Crystal structure of heme A synthase from Bacillus subtilis
6IED	;	3.0	;	Crystal structure of heme A synthase from Bacillus subtilis
5AZ3	;	1.423	;	Crystal structure of heme binding protein HmuT
5B4Z	;	1.3	;	Crystal structure of heme binding protein HmuT H141A mutant
5B51	;	1.3	;	Crystal structure of heme binding protein HmuT R242A mutant
5B50	;	1.65	;	Crystal structure of heme binding protein HmuT Y240A
6JSB	;	1.699	;	Crystal structure of Heme binding protein HtaB from Corynebacterium glutamicum
5EXV	;	2.901	;	Crystal structure of heme binding protein HutX from Vibrio cholerae
1WXR	;	2.2	;	Crystal structure of Heme Binding protein, an autotransporter hemoglobine protease from pathogenic Escherichia coli
1S66	;	1.8	;	Crystal structure of heme domain of direct oxygen sensor from E. coli
1S67	;	1.5	;	Crystal structure of heme domain of direct oxygen sensor from E. coli
6EWM	;	1.4	;	Crystal structure of heme free PORPHYROMONAS GINGIVALIS HEME-BINDING PROTEIN HMUY
4RAJ	;	1.84	;	Crystal structure of heme oxygenase 2 from Chlamydomonas reinhardtii without heme.
1WE1	;	2.5	;	Crystal structure of heme oxygenase-1 from cyanobacterium Synechocystis sp. PCC6803 in complex with heme
1WOW	;	2.2	;	Crystal structure of heme oxygenase-2 from Synechocystis sp. PCC 6803 complexed with heme in ferrous form
1WOV	;	1.75	;	Crystal structure of heme oxygenase-2 from Synechocystis sp. PCC 6803 in complex with heme
1WOX	;	2.1	;	Crystal structure of heme oxygenase-2 from Synechocystis sp. PCC 6803 in complex with heme and NO
7DVR	;	1.7	;	Crystal structure of heme sensor protein PefR from Streptococcus agalactiae in complex with heme
7DVT	;	2.09	;	Crystal structure of heme sensor protein PefR in complex with heme and carbon monoxide
7DVU	;	2.1	;	Crystal structure of heme sensor protein PefR in complex with heme and cyanide
5VJ0	;	1.93	;	Crystal Structure of heme-containing DyP Type Peroxidase from Enterobacter lignolyticus
5UQ4	;	2.201	;	Crystal structure of Heme-Degrading Protein Rv3592 from Mycobacterium tuberculosis - heme free with cleaved protein
8VC8	;	1.8	;	Crystal structure of heme-loaded design: HEM_3.C9
4XPY	;	1.13	;	Crystal structure of hemerythrin : L114Y mutant
6U3L	;	1.75	;	Crystal structure of Hemerythrin HHE cation binding domain-containing protein: Rv2633c homolog from Mycobacterium kansasii
4XQ1	;	1.4	;	Crystal structure of hemerythrin: L114A mutant
4XPX	;	1.03	;	Crystal structure of hemerythrin:wild-type
6PED	;	2.3	;	Crystal structure of HEMK2-TRMT112 complex
6KHS	;	1.895	;	Crystal structure of HEMK2/TRMT112 in complex with SAH and MEQ
1V75	;	2.02	;	Crystal structure of hemoglobin D from the Aldabra giant tortoise (Geochelone gigantea) at 2.0 A resolution
1WMU	;	1.65	;	Crystal Structure of Hemoglobin D from the Aldabra Giant Tortoise, Geochelone gigantea, at 1.65 A resolution
2QLS	;	3.5	;	crystal structure of hemoglobin from dog (Canis familiaris) at 3.5 Angstrom resolution
3HRW	;	2.8	;	Crystal structure of hemoglobin from mouse (Mus musculus)at 2.8
6ZMY	;	1.655	;	Crystal structure of hemoglobin from turkey (Meleagiris gallopova) crystallized in monoclinic form at 1.66 Angstrom resolution
6ZMX	;	1.389	;	Crystal structure of hemoglobin from turkey (Meleagiris gallopova) crystallized in orthorhombic form at 1.4 Angstrom resolution
1UC3	;	2.3	;	Crystal Structure of hemoglobin I from river lamprey
3WKY	;	1.801	;	Crystal structure of hemolymph type prophenoloxidase (proPOb) from crustacean
4W8R	;	1.519	;	Crystal structure of hemolysin A Y134F from P. mirabilis at 1.5 Angstroms resolution
2NRJ	;	2.03	;	Crystal Structure of Hemolysin binding component from Bacillus cereus
1VCL	;	1.7	;	Crystal Structure of Hemolytic Lectin CEL-III
2Z48	;	1.7	;	Crystal Structure of Hemolytic Lectin CEL-III Complexed with GalNac
2Z49	;	1.95	;	Crystal Structure of Hemolytic Lectin CEL-III Complexed with methyl-alpha-D-galactopylanoside
4RM6	;	1.6	;	Crystal structure of Hemopexin Binding Protein
3OYO	;	2.1	;	Crystal structure of hemopexin fold protein CP4 from cow pea
2HPD	;	2.0	;	CRYSTAL STRUCTURE OF HEMOPROTEIN DOMAIN OF P450BM-3, A PROTOTYPE FOR MICROSOMAL P450'S
3A8Z	;	1.4	;	Crystal structure of hen egg white lysozyme
7D0W	;	1.8	;	Crystal structure of Hen Egg White Lysozyme
7S27	;	1.6	;	Crystal structure of hen egg white lysozyme
7S28	;	1.6	;	Crystal structure of hen egg white lysozyme
7S29	;	1.6	;	Crystal structure of hen egg white lysozyme
7S2A	;	1.6	;	Crystal structure of hen egg white lysozyme
7S2B	;	1.6	;	Crystal structure of hen egg white lysozyme
7S2C	;	1.6	;	Crystal structure of hen egg white lysozyme
7S2D	;	1.6	;	Crystal structure of hen egg white lysozyme
7S2E	;	1.6	;	Crystal structure of hen egg white lysozyme
7S2F	;	1.58	;	Crystal structure of hen egg white lysozyme
7S2G	;	1.6	;	Crystal structure of hen egg white lysozyme
7S2Q	;	1.6	;	Crystal structure of hen egg white lysozyme
7S2U	;	1.6	;	Crystal structure of hen egg white lysozyme
7S2V	;	1.6	;	Crystal structure of hen egg white lysozyme
7S2W	;	1.6	;	Crystal structure of hen egg white lysozyme
7S30	;	1.6	;	Crystal structure of hen egg white lysozyme
7S31	;	1.6	;	Crystal structure of hen egg white lysozyme
7S32	;	1.6	;	Crystal structure of hen egg white lysozyme
7S33	;	1.6	;	Crystal structure of hen egg white lysozyme
7S34	;	1.6	;	Crystal structure of hen egg white lysozyme
7S35	;	1.6	;	Crystal structure of hen egg white lysozyme
8FP6	;	1.6	;	Crystal structure of hen egg white lysozyme
8FP7	;	1.6	;	Crystal structure of hen egg white lysozyme
8FP8	;	1.6	;	Crystal structure of hen egg white lysozyme
8FPB	;	1.6	;	Crystal structure of hen egg white lysozyme
8FPD	;	1.6	;	Crystal structure of hen egg white lysozyme
8FPM	;	1.6	;	Crystal structure of hen egg white lysozyme
8FPN	;	1.6	;	Crystal structure of hen egg white lysozyme
8FPP	;	1.6	;	Crystal structure of hen egg white lysozyme
8FPR	;	1.6	;	Crystal structure of hen egg white lysozyme
8FPU	;	1.6	;	Crystal structure of hen egg white lysozyme
8FRY	;	1.6	;	Crystal structure of hen egg white lysozyme
8FS0	;	1.6	;	Crystal structure of hen egg white lysozyme
8FS9	;	1.6	;	Crystal structure of hen egg white lysozyme
8FSA	;	1.6	;	Crystal structure of hen egg white lysozyme
8FSC	;	1.6	;	Crystal structure of hen egg white lysozyme
8FSF	;	1.6	;	Crystal structure of hen egg white lysozyme
8FSG	;	1.6	;	Crystal structure of hen egg white lysozyme
8FSH	;	1.6	;	Crystal structure of hen egg white lysozyme
8FSM	;	1.6	;	Crystal structure of hen egg white lysozyme
8FSN	;	1.6	;	Crystal structure of hen egg white lysozyme
8FST	;	1.6	;	Crystal structure of hen egg white lysozyme
8FSU	;	1.6	;	Crystal structure of hen egg white lysozyme
8FSV	;	1.6	;	Crystal structure of hen egg white lysozyme
8FSW	;	1.6	;	Crystal structure of hen egg white lysozyme
8FSX	;	1.6	;	Crystal structure of hen egg white lysozyme
8FSY	;	1.6	;	Crystal structure of hen egg white lysozyme
8FT0	;	1.6	;	Crystal structure of hen egg white lysozyme
8FT1	;	1.6	;	Crystal structure of hen egg white lysozyme
8FT2	;	1.6	;	Crystal structure of hen egg white lysozyme
8FT3	;	1.6	;	Crystal structure of hen egg white lysozyme
1G7I	;	1.8	;	CRYSTAL STRUCTURE OF HEN EGG WHITE LYSOZYME (HEL) COMPLEXED WITH THE MUTANT ANTI-HEL MONOCLONAL ANTIBODY D1.3 (VLW92F)
1G7J	;	1.75	;	CRYSTAL STRUCTURE OF HEN EGG WHITE LYSOZYME (HEL) COMPLEXED WITH THE MUTANT ANTI-HEL MONOCLONAL ANTIBODY D1.3 (VLW92H)
1G7L	;	2.0	;	CRYSTAL STRUCTURE OF HEN EGG WHITE LYSOZYME (HEL) COMPLEXED WITH THE MUTANT ANTI-HEL MONOCLONAL ANTIBODY D1.3 (VLW92S)
1G7M	;	1.9	;	CRYSTAL STRUCTURE OF HEN EGG WHITE LYSOZYME (HEL) COMPLEXED WITH THE MUTANT ANTI-HEL MONOCLONAL ANTIBODY D1.3 (VLW92V)
1G7H	;	1.85	;	CRYSTAL STRUCTURE OF HEN EGG WHITE LYSOZYME (HEL) COMPLEXED WITH THE MUTANT ANTI-HEL MONOCLONAL ANTIBODY D1.3(VLW92A)
8F2G	;	1.84	;	Crystal structure of Hen Egg White Lysozyme at 0.44 GPa
8D5S	;	1.5	;	Crystal structure of hen egg white lysozyme at 100 Kelvin
8D5T	;	1.5	;	Crystal structure of hen egg white lysozyme at 100 Kelvin (Duplicate)
8D5U	;	1.498	;	Crystal structure of hen egg white lysozyme at 100 Kelvin (Triplicate)
8D5W	;	1.499	;	Crystal structure of hen egg white lysozyme at 125 Kelvin
8D5X	;	1.5	;	Crystal structure of hen egg white lysozyme at 125 Kelvin (Duplicate)
8D5Z	;	1.5	;	Crystal structure of hen egg white lysozyme at 125 Kelvin (Triplicate)
8D60	;	1.5	;	Crystal structure of hen egg white lysozyme at 150 Kelvin
8D61	;	1.5	;	Crystal structure of hen egg white lysozyme at 150 Kelvin (Duplicate)
8D62	;	1.5	;	Crystal structure of hen egg white lysozyme at 150 Kelvin (Triplicate)
8D69	;	1.5	;	Crystal structure of hen egg white lysozyme at 175 Kelvin
8D6B	;	1.5	;	Crystal structure of hen egg white lysozyme at 175 Kelvin (Duplicate)
8D6I	;	1.5	;	Crystal structure of hen egg white lysozyme at 175 Kelvin (Triplicate)
8D75	;	1.5	;	Crystal structure of hen egg white lysozyme at 200 Kelvin
8D77	;	1.5	;	Crystal structure of hen egg white lysozyme at 200 Kelvin (Duplicate)
8D7A	;	1.5	;	Crystal structure of hen egg white lysozyme at 200 Kelvin (Triplicate)
8D7B	;	1.5	;	Crystal structure of hen egg white lysozyme at 225 Kelvin
8D7C	;	1.5	;	Crystal structure of hen egg white lysozyme at 225 Kelvin (Duplicate)
8D7D	;	1.5	;	Crystal structure of hen egg white lysozyme at 225 Kelvin (Triplicate)
8D7J	;	1.5	;	Crystal structure of hen egg white lysozyme at 250 Kelvin
8D7L	;	1.5	;	Crystal structure of hen egg white lysozyme at 250 Kelvin (Duplicate)
8D7Q	;	1.5	;	Crystal structure of hen egg white lysozyme at 250 Kelvin (Triplicate)
8D7S	;	1.5	;	Crystal structure of hen egg white lysozyme at 275 Kelvin
8D8A	;	1.5	;	Crystal structure of hen egg white lysozyme at 275 Kelvin (Duplicate)
8D8B	;	1.5	;	Crystal structure of hen egg white lysozyme at 275 Kelvin (Triplicate)
8D8C	;	1.5	;	Crystal structure of hen egg white lysozyme at 300 Kelvin
8D8D	;	1.5	;	Crystal structure of hen egg white lysozyme at 300 Kelvin (Duplicate)
8D8E	;	1.5	;	Crystal structure of hen egg white lysozyme at 300 Kelvin (Triplicate)
8D8F	;	1.5	;	Crystal structure of hen egg white lysozyme at 325 Kelvin
8D8G	;	1.5	;	Crystal structure of hen egg white lysozyme at 325 Kelvin (Duplicate)
8D8H	;	1.5	;	Crystal structure of hen egg white lysozyme at 325 Kelvin (Triplicate)
4HPI	;	1.19	;	Crystal Structure of Hen Egg White Lysozyme complex with GN2-M
4E3U	;	1.5	;	Crystal Structure of Hen Egg White Lysozyme Cryoprotected in Proline
6A10	;	1.13	;	Crystal structure of hen egg white lysozyme crystallized by ammonium sulfate
4B0D	;	1.1	;	CRYSTAL STRUCTURE OF HEN EGG WHITE LYSOZYME FROM AN AUTO HARVESTED CRYSTAL
4AXT	;	1.1	;	CRYSTAL STRUCTURE OF HEN EGG WHITE LYSOZYME FROM AN AUTO HARVESTED CRYSTAL, Control Experiment
4XAD	;	1.25	;	Crystal structure of hen egg white lysozyme in complex with Galf-GlcNAc
4HP0	;	1.19	;	Crystal Structure of Hen Egg White Lysozyme in complex with GN3-M
6PBB	;	1.89151	;	Crystal structure of Hen Egg White Lysozyme in complex with I3C
7YNU	;	1.44	;	Crystal structure of Hen Egg white LYSOZYME introduced with O-(2-nitrobenzyl)-L-tyrosine
3WW6	;	1.53	;	Crystal Structure of hen egg white lysozyme mutant N46D/D52S
3WW5	;	1.53	;	Crystal Structure of hen egg white lysozyme mutant N46E/D52S
5AMY	;	1.8	;	Crystal Structure of Hen egg white lysozyme processed with the CrystalDirect automated mounting and cryo-cooling technology
3A94	;	1.55	;	Crystal structure of hen egg white lysozyme soaked with 100mM RhCl3
3A96	;	1.75	;	Crystal structure of hen egg white lysozyme soaked with 100mM RhCl3 at pH2.2
3A95	;	1.5	;	Crystal structure of hen egg white lysozyme soaked with 100mM RhCl3 at pH3.8
3A92	;	1.5	;	Crystal structure of hen egg white lysozyme soaked with 10mM RhCl3
3A90	;	1.45	;	Crystal structure of hen egg white lysozyme soaked with 1mM RhCl3
3A93	;	1.55	;	Crystal structure of hen egg white lysozyme soaked with 30mM RhCl3
3A91	;	1.55	;	Crystal structure of hen egg white lysozyme soaked with 5mM RhCl3
7BHL	;	1.45	;	Crystal structure of hen egg white lysozyme using drop-on-drop SFX method - 0.2 s mixing with N-acetyl-D-glucosamine.
7BHM	;	1.45	;	Crystal structure of hen egg white lysozyme using drop-on-drop SFX method - 0.7 s mixing with N-acetyl-D-glucosamine.
7BHN	;	1.45	;	Crystal structure of hen egg white lysozyme using drop-on-drop SFX method - 2 s mixing with N-acetyl-D-glucosamine.
7BHK	;	1.45	;	Crystal structure of hen egg white lysozyme using drop-on-drop SFX method.
4Z98	;	1.55	;	Crystal Structure of Hen Egg White Lysozyme using Serial X-ray Diffraction Data Collection
1AVE	;	2.8	;	CRYSTAL STRUCTURE OF HEN EGG-WHITE APO-AVIDIN IN RELATION TO ITS THERMAL STABILITY PROPERTIES
3WUL	;	2.0	;	Crystal structure of hen egg-white lysozyme
3WUM	;	2.0	;	Crystal structure of hen egg-white lysozyme
3WUN	;	2.4	;	Crystal structure of hen egg-white lysozyme
3WXT	;	2.0	;	Crystal structure of hen egg-white lysozyme
3WXU	;	2.0	;	Crystal structure of hen egg-white lysozyme
4YM8	;	2.1	;	Crystal structure of hen egg-white lysozyme
4YOP	;	2.1	;	CRYSTAL STRUCTURE OF HEN EGG-WHITE LYSOZYME
5B1F	;	2.3	;	Crystal structure of hen egg-white lysozyme
5B1G	;	2.3	;	Crystal structure of hen egg-white lysozyme
5WR9	;	1.8	;	Crystal structure of hen egg-white lysozyme
5WRA	;	1.45	;	Crystal structure of hen egg-white lysozyme
5WRB	;	2.013	;	Crystal structure of hen egg-white lysozyme
2LYM	;	2.0	;	CRYSTAL STRUCTURE OF HEN EGG-WHITE LYSOZYME AT A HYDROSTATIC PRESSURE OF 1000 ATMOSPHERES
3LYM	;	2.0	;	CRYSTAL STRUCTURE OF HEN EGG-WHITE LYSOZYME AT A HYDROSTATIC PRESSURE OF 1000 ATMOSPHERES
6F2I	;	1.2	;	Crystal structure of Hen Egg-White Lysozyme co-crystallized in presence of 100 mM Tb-Xo4
6FRO	;	1.42	;	Crystal structure of Hen Egg-White Lysozyme co-crystallized in presence of 100 mM Tb-Xo4 and 100 mM potassium iodide.
6F2K	;	1.5	;	Crystal structure of Hen Egg-White Lysozyme co-crystallized in presence of 100 mM Tb-Xo4 and 100 mM potassium phosphate monobasic.
6F2J	;	1.3	;	Crystal structure of Hen Egg-White Lysozyme co-crystallized in presence of 100 mM Tb-Xo4 and 100 mM sodium sulfate
4PRQ	;	1.72	;	CRYSTAL STRUCTURE OF HEN EGG-WHITE LYSOZYME IN COMPLEX WITH SCLX4 AT 1.72 A RESOLUTION
3WMK	;	1.46	;	Crystal structure of Hen egg-white lysozyme in pH 4.5 Sodium Acetatewith 1M NaCl at 277K
4NHI	;	1.34	;	Crystal structure of Hen egg-white lysozyme in Tris buffer at pH 7.5 with Magnesium formate
1RYX	;	3.5	;	Crystal structure of hen serum transferrin in apo- form
6VY6	;	2.6	;	Crystal structure of Hendra receptor binding protein head domain in complex with human neutralizing antibody HENV-26
6VY4	;	2.0	;	Crystal structure of Hendra receptor binding protein head domain in complex with human neutralizing antibody HENV-32
6PD4	;	2.2	;	Crystal Structure of Hendra Virus Attachment G Glycoprotein
6PDL	;	2.7	;	Crystal Structure of Hendra Virus Attachment G Glycoprotein in Complex with Receptor Ephrin-B2
1WP8	;	2.2	;	crystal structure of Hendra Virus fusion core
6BK6	;	2.5	;	Crystal structure of Hendra virus matrix protein
5X3D	;	1.93	;	Crystal structure of HEP-CMP-bound form of cytidylyltransferase (CyTase) domain of Fom1 from Streptomyces wedmorensis
3F5F	;	2.65	;	Crystal structure of heparan sulfate 2-O-sulfotransferase from gallus gallus as a maltose binding protein fusion.
1VKJ	;	2.5	;	Crystal structure of heparan sulfate 3-O-sulfotransferase isoform 1 in the presence of PAP
5T03	;	2.1	;	Crystal structure of heparan sulfate 6-O-sulfotransferase with bound PAP and glucuronic acid containing hexasaccharide substrate
5T0A	;	1.95	;	Crystal Structure of Heparan Sulfate 6-O-Sulfotransferase with bound PAP and heptasaccharide substrate
5T05	;	1.952	;	Crystal structure of heparan sulfate 6-O-sulfotransferase with bound PAP and IdoA2S containing hexasaccharide substrate
4MMH	;	2.2	;	Crystal structure of heparan sulfate lyase HepC from Pedobacter heparinus
4MMI	;	2.4	;	Crystal structure of heparan sulfate lyase HepC mutant from Pedobacter heparinus
8OHW	;	1.27	;	Crystal structure of heparanase from Burkholderia pseudomallei in complex with siastatin B derived inhibitor
1FNH	;	2.8	;	CRYSTAL STRUCTURE OF HEPARIN AND INTEGRIN BINDING SEGMENT OF HUMAN FIBRONECTIN
3IN9	;	2.0	;	Crystal structure of heparin lyase I complexed with disaccharide heparin
3IMN	;	1.81	;	Crystal structure of heparin lyase I from Bacteroides thetaiotaomicron
3INA	;	1.9	;	Crystal structure of heparin lyase I H151A mutant complexed with a dodecasaccharide heparin
2FUQ	;	2.15	;	Crystal Structure of Heparinase II
2FUT	;	2.3	;	Crystal Structure of Heparinase II Complexed with a Disaccharide Product
4FNV	;	1.6	;	Crystal Structure of Heparinase III
4NWK	;	1.62	;	Crystal structure of hepatis c virus protease (ns3) complexed with bms-605339 aka n-(tert-butoxycarbonyl)-3-me thyl-l-valyl-(4r)-n-((1r,2s)-1-((cyclopropylsulfonyl)carba moyl)-2-vinylcyclopropyl)-4-((6-methoxy-1-isoquinolinyl)ox y)-l-prolinamide
4NWL	;	2.2	;	Crystal structure of hepatis c virus protease (ns3) complexed with bms-650032 aka n-(tert-butoxycarbonyl)-3-me thyl-l-valyl-(4r)-4-((7-chloro-4-methoxy-1-isoquinolinyl)o xy)-n-((1r,2s)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylc yclopropyl)-l-prolinamide
6BQJ	;	1.69	;	CRYSTAL STRUCTURE OF HEPATIS C VIRUS PROTEASE (NS3) COMPLEXED WITH TRIPEPTIDIC ACYL SULFONAMIDE INHIBITOR (COMPOUND 16)
6BQK	;	1.97	;	CRYSTAL STRUCTURE OF HEPATIS C VIRUS PROTEASE (NS3) COMPLEXED WITH TRIPEPTIDIC ACYL SULFONAMIDE INHIBITOR (COMPOUND 18)
4QPI	;	3.01	;	Crystal structure of hepatitis A virus
6MWN	;	2.838	;	Crystal structure of hepatitis A virus IRES domain V in complex with Fab HAVx
3V6Z	;	3.34	;	Crystal Structure of Hepatitis B Virus e-antigen
5D7Y	;	3.894	;	Crystal structure of Hepatitis B virus T=4 capsid in complex with the allosteric modulator HAP18
3MS6	;	2.085	;	Crystal structure of Hepatitis B X-Interacting Protein (HBXIP)
3MSH	;	1.51	;	Crystal structure of Hepatitis B X-Interacting Protein at high resolution
6MEK	;	3.1	;	Crystal structure of Hepatitis C virus envelope glycoprotein E2 core in complex with human antibodies HEPC3 and HEPC46
6MEJ	;	2.8	;	Crystal structure of Hepatitis C virus envelope glycoprotein E2 ectodomain in complex with human antibodies HEPC3 and HEPC46
6U8D	;	1.807	;	Crystal structure of hepatitis C virus IRES junction IIIabc in complex with Fab HCV2
6U8K	;	2.75	;	Crystal structure of hepatitis C virus IRES junction IIIabc in complex with Fab HCV3
2PN3	;	2.9	;	Crystal Structure of Hepatitis C Virus IRES Subdomain IIa
2PN4	;	2.32	;	Crystal Structure of Hepatitis C Virus IRES Subdomain IIa
4OK6	;	2.4	;	Crystal Structure of Hepatitis C Virus NS3 Helicase Inhibitor Co-complex with Compound 13 [[1-(2-methoxy-5-nitrobenzyl)-1H-indol-3-yl]acetic acid]
4OKS	;	2.25	;	Crystal Structure of Hepatitis C Virus NS3 Helicase Inhibitor Co-complex with Compound 19 [[6-(3,5-diaminophenyl)-1-(2-methoxy-5-nitrobenzyl)-1H-indol-3-yl]acetic acid]
4OK3	;	2.3	;	Crystal Structure of Hepatitis C Virus NS3 Helicase Inhibitor Co-complex with Compound 7 [[1-(3-chlorobenzyl)-1H-indol-3-yl]acetic acid]
4OK5	;	2.15	;	Crystal Structure of Hepatitis C Virus NS3 Helicase Inhibitor Co-complex with Compound 9 [1-(3-ethynylbenzyl)-1H-indol-3-yl]acetic acid]
4OJQ	;	2.25	;	Crystal Structure of Hepatitis C Virus NS3 Helicase Inhibitor Co-complex with Fragment 1 [(5-bromo-1H-indol-3-yl)acetic acid]
2ZJO	;	2.5	;	Crystal structure of hepatitis C virus NS3 helicase with a novel inhibitor
2P59	;	2.9	;	Crystal Structure of Hepatitis C Virus NS3.4A protease
2WHO	;	2.0	;	CRYSTAL STRUCTURE OF HEPATITIS C VIRUS NS5B POLYMERASE FROM 1B GENOTYPE IN COMPLEX WITH A NON-NUCLEOSIDE INHIBITOR
2WCX	;	2.0	;	Crystal Structure of Hepatitis C Virus NS5B Polymerase in Complex with Thienopyrrole-Based Finger-Loop Inhibitors
2BRK	;	2.3	;	Crystal structure of Hepatitis C virus polymerase in complex with an allosteric inhibitor (compound 1)
2BRL	;	2.4	;	Crystal structure of Hepatitis C virus polymerase in complex with an allosteric inhibitor (compound 2)
2JC0	;	2.2	;	CRYSTAL STRUCTURE OF HEPATITIS C VIRUS POLYMERASE IN COMPLEX WITH INHIBITOR SB655264
2JC1	;	2.0	;	CRYSTAL STRUCTURE OF HEPATITIS C VIRUS POLYMERASE IN COMPLEX WITH INHIBITOR SB698223
3CJ2	;	1.75	;	Crystal structure of hepatitis c virus rna-dependent rna polymerase ns5b in complex with optimized small molecule fragments
3CJ3	;	1.87	;	Crystal structure of hepatitis c virus rna-dependent rna polymerase ns5b in complex with optimized small molecule fragments
3CJ4	;	2.07	;	Crystal structure of hepatitis c virus rna-dependent rna polymerase ns5b in complex with optimized small molecule fragments
3CJ5	;	1.92	;	Crystal structure of hepatitis c virus rna-dependent rna polymerase ns5b in complex with optimized small molecule fragments
3CIZ	;	1.87	;	Crystal structure of hepatitis c virus rna-dependent rna polymerase ns5b in complex with small molecule fragments
3CJ0	;	1.9	;	Crystal structure of hepatitis c virus rna-dependent rna polymerase ns5b in complex with small molecule fragments
7XT3	;	2.15	;	Crystal Structure of Hepatitis virus A 2C protein 128-335 aa
3CBB	;	2.0	;	Crystal Structure of Hepatocyte Nuclear Factor 4alpha in complex with DNA: Diabetes Gene Product
8EK7	;	1.65	;	Crystal structure of Hepes and Mg bound 2,3-diketo-5-methylthiopentyl-1-phosphate enolase-phosphatase from Klebsiella aerogenes
6KMM	;	1.93	;	Crystal Structure of HEPES bound Dye Decolorizing peroxidase from Bacillus subtilis
7JHX	;	1.91	;	Crystal structure of hEPG5 LIR/GABARAPL1 complex
7KPM	;	1.608	;	Crystal structure of hEphB1 bound with ADP
6UMW	;	1.982	;	Crystal structure of hEphB1 bound with chlortetracycline
7KPL	;	2.705	;	Crystal structure of hEphB1 in apo form
4NQF	;	2.7	;	Crystal structure of HEPN domain protein
7AE2	;	2.0	;	Crystal structure of HEPN(H107A-Y109F) toxin in complex with MNT antitoxin
7AE8	;	2.0	;	Crystal structure of HEPN(R102A) toxin
5H9D	;	2.68	;	Crystal structure of Heptaprenyl Diphosphate Synthase from Staphylococcus aureus
3D44	;	1.9	;	Crystal structure of HePTP in complex with a dually phosphorylated Erk2 peptide mimetic
3D42	;	2.46	;	Crystal structure of HePTP in complex with a monophosphorylated Erk2 peptide
3O4S	;	1.9	;	Crystal Structure of HePTP with a Closed WPD Loop and an Ordered E-Loop
3O4U	;	2.25	;	Crystal Structure of HePTP with an Atypically Open WPD Loop
3O4T	;	2.6	;	Crystal Structure of HePTP with an Open WPD Loop and Partially Depleted Active Site
5JIK	;	1.82	;	Crystal structure of HER2 binding IgG1-Fc (Fcab H10-03-6)
5JIH	;	1.663	;	Crystal structure of HER2 binding IgG1-Fc (Fcab STAB19)
6LBX	;	2.03	;	Crystal structure of HER2 Domain IV and Rb-H2
3UUC	;	2.1	;	Crystal structure of hERa-LBD (wt) in complex with bisphenol-C
4MGA	;	1.8	;	Crystal structure of hERa-LBD (Y537S) in complex with 4-tert-octylphenol
4MG8	;	1.85	;	Crystal structure of hERa-LBD (Y537S) in complex with alpha-zearalanol
4TUZ	;	1.9	;	Crystal structure of hERa-LBD (Y537S) in complex with alpha-zearalenol
4MGC	;	2.15	;	Crystal structure of hERa-LBD (Y537S) in complex with benzophenone-2
4MG6	;	2.1	;	Crystal structure of hERa-LBD (Y537S) in complex with benzylbutylphtalate
5JMM	;	2.1	;	Crystal structure of hERa-LBD (Y537S) in complex with biochanin A
3UU7	;	2.196	;	Crystal structure of hERa-LBD (Y537S) in complex with bisphenol-A
3UUA	;	2.05	;	Crystal structure of hERa-LBD (Y537S) in complex with bisphenol-AF
4MG9	;	2.0	;	Crystal structure of hERa-LBD (Y537S) in complex with butylparaben
4MG5	;	2.05	;	Crystal structure of hERa-LBD (Y537S) in complex with chlordecone
3UUD	;	1.6	;	Crystal structure of hERa-LBD (Y537S) in complex with estradiol
4MG7	;	2.15	;	Crystal structure of hERa-LBD (Y537S) in complex with ferutinine
4MGD	;	1.9	;	Crystal structure of hERa-LBD (Y537S) in complex with HPTE
4TV1	;	1.85	;	Crystal structure of hERa-LBD (Y537S) in complex with propylparaben
4MGB	;	1.85	;	Crystal structure of hERa-LBD (Y537S) in complex with TCBPA
7WWX	;	1.36	;	Crystal structure of Herbaspirillum huttiense L-arabinose 1-dehydrogenase (NAD bound form)
5JRJ	;	1.7	;	Crystal Structure of Herbaspirillum seropedicae RecA
7RGW	;	1.99	;	Crystal structure of HERC2 DOC domain
6WW4	;	2.252	;	Crystal structure of HERC2 ZZ domain in complex with histone H3 tail
6WW3	;	2.096	;	Crystal structure of HERC2 ZZ domain in complex with SUMO1 tail
1DML	;	2.7	;	CRYSTAL STRUCTURE OF HERPES SIMPLEX UL42 BOUND TO THE C-TERMINUS OF HSV POL
6T5A	;	1.83	;	Crystal structure of herpes simplex virus 1 pUL7:pUL51 complex
3KV0	;	1.9	;	Crystal structure of HET-C2: A FUNGAL GLYCOLIPID TRANSFER PROTEIN (GLTP)
7X36	;	1.92	;	Crystal Structure of hetero-Diels-Alderase EupfF
7X2X	;	1.58	;	Crystal Structure of hetero-Diels-Alderase PycR1 in complex with 10-hydroxy-8E-humulene
7X2S	;	1.92	;	Crystal Structure of hetero-Diels-Alderase PycR1 in complex with Neosetophomone B and tropolone o-quinone methide
3AOE	;	2.6	;	Crystal structure of hetero-hexameric glutamate dehydrogenase from Thermus thermophilus (Leu bound form)
5Y3T	;	2.4	;	Crystal structure of hetero-trimeric core of LUBAC: HOIP double-UBA complexed with HOIL-1L UBL and SHARPIN UBL
4JJN	;	3.09	;	Crystal structure of heterochromatin protein Sir3 in complex with a silenced yeast nucleosome
3QOD	;	3.38	;	Crystal Structure of Heterocyst Differentiation Protein, HetR from Fischerella mv11
3QOE	;	3.004	;	Crystal Structure of Heterocyst Differentiation Protein, HetR from Fischerella mv11
8QZO	;	2.29	;	Crystal structure of heterodimeric complex of CdpB1 and CdpB2 from A. fulgidus
1R0N	;	2.6	;	Crystal Structure of Heterodimeric Ecdsyone receptor DNA binding complex
2B9S	;	2.27	;	Crystal Structure of heterodimeric L. donovani topoisomerase I-vanadate-DNA complex
3MAS	;	3.2	;	Crystal structure of heterodimeric R132H mutant of human cytosolic NADP(+)-dependent isocitrate dehydrogenase in complex with NADP and isocitrate
7V6W	;	2.55	;	Crystal structure of heterohexameric Sa2YoeB-Sa2YefM complex bound to 26bp-DNA
2D1P	;	2.15	;	crystal structure of heterohexameric TusBCD proteins, which are crucial for the tRNA modification
6L8E	;	2.35	;	Crystal structure of heterohexameric YoeB-YefM complex bound to 26bp-DNA
4GMT	;	2.05	;	Crystal structure of heterosubtypic Fab S139/1
4GMS	;	2.95	;	Crystal structure of heterosubtypic Fab S139/1 in complex with influenza A H3 hemagglutinin
7V5Z	;	1.99	;	Crystal structure of heterotetrameric complex of Sa2YoeB-Sa2YefM toxin-antitoxin from Staphylococcus aureus
6L8F	;	2.4	;	Crystal structure of heterotetrameric complex of YoeB-YefM toxin-antitoxin from Staphylococcus aureus.
4CQL	;	2.85	;	Crystal structure of heterotetrameric human ketoacyl reductase complexed with NAD
4CQM	;	2.339	;	Crystal structure of heterotetrameric human ketoacyl reductase complexed with NAD and NADP
1X31	;	2.15	;	Crystal Structure of Heterotetrameric Sarcosine Oxidase from Corynebacterium sp. U-96
1VRQ	;	2.2	;	Crystal Structure of Heterotetrameric Sarcosine Oxidase from Corynebacterium sp. U-96 in complex with Folinic Acid
8SZY	;	2.31	;	Crystal Structure of Heterotrimeric Anti-TIGIT Fabs in complex with human TIGIT
6NE6	;	1.7	;	Crystal Structure of heterotrimeric G-protein alpha subunit Galpha7 from Naegleria fowleri
4HRI	;	2.954	;	Crystal structure of HetR in complex with a 21-bp palindromic DNA at the upstream of the hetP promoter from Anabaena
1QTK	;	2.03	;	CRYSTAL STRUCTURE OF HEW LYSOZYME UNDER PRESSURE OF KRYPTON (55 BAR)
1C10	;	2.03	;	CRYSTAL STRUCTURE OF HEW LYSOZYME UNDER PRESSURE OF XENON (8 BAR)
6AC2	;	1.23	;	Crystal Structure of HEWL at pH 2.2
6ABN	;	1.17	;	Crystal Structure of HEWL at pH 8.6
4CJ2	;	1.5	;	Crystal structure of HEWL in complex with affitin H4
6AHL	;	1.8	;	Crystal Structure of HEWL in complex with Cinnamaldehyde (in the aroma form) after 5 hours under fibrillation conditions
6AHH	;	2.1	;	Crystal Structure of HEWL in complex with Phenylethyl alcohol (in the aroma form) after 5 hours under fibrillation conditions
6AD5	;	1.75	;	Crystal Structure of HEWL in complex with TEMED (in the aroma form) after 24 hours under fibrillation conditions
6AEA	;	1.4	;	Crystal Structure of HEWL in complex with TEMED (in the aroma form) after 5 hours under fibrillation conditions
6ABZ	;	1.7	;	Crystal Structure of HEWL in deionized water
4PHI	;	1.811	;	Crystal structure of HEWL with hexatungstotellurate(VI)
1KHI	;	1.78	;	CRYSTAL STRUCTURE OF HEX1
8BYU	;	1.85	;	Crystal Structure of HexaBody-CD38 Fab in complex with CD38
5ZIQ	;	1.5	;	Crystal structure of hexacoordinated heme protein from anhydrobiotic tardigrade at pH 4
5ZM9	;	2.7	;	Crystal structure of hexacoordinated heme protein from anhydrobiotic tardigrade at pH 7
4ZV7	;	2.0	;	Crystal structure of hexagonal form of lipase B from Candida antarctica
2DGA	;	1.8	;	Crystal structure of hexameric beta-glucosidase in wheat
5NVD	;	2.5	;	Crystal structure of hexameric CBS-CP12 protein from bloom-forming cyanobacteria at 2.5 A resolution in P6322 crystal form
5NPL	;	2.79	;	Crystal structure of hexameric CBS-CP12 protein from bloom-forming cyanobacteria, Yb-derivative at 2.8 A resolution
7V5Y	;	2.25	;	Crystal structure of hexameric complex of Sa2YoeB-Sa2YefM toxin-antitoxin from Staphylococcus aureus
2HYB	;	2.5	;	Crystal Structure of Hexameric DsrEFH
1HC1	;	3.2	;	CRYSTAL STRUCTURE OF HEXAMERIC HAEMOCYANIN FROM PANULIRUS INTERRUPTUS REFINED AT 3.2 ANGSTROMS RESOLUTION
1HCY	;	3.2	;	CRYSTAL STRUCTURE OF HEXAMERIC HAEMOCYANIN FROM PANULIRUS INTERRUPTUS REFINED AT 3.2 ANGSTROMS RESOLUTION
4BMG	;	3.0	;	Crystal structure of hexameric HBc149 Y132A
4QIV	;	2.3	;	Crystal structure of hexameric microcomparment shell protein from Aeromonas hydrophila
7EFW	;	1.65	;	Crystal structure of hexameric state of C-phycocyanin from Thermoleptolyngbya sp. O-77
3IXC	;	1.61	;	Crystal structure of hexapeptide transferase family protein from Anaplasma phagocytophilum
3NZ2	;	2.35	;	Crystal Structure of Hexapeptide-Repeat containing-Acetyltransferase VCA0836 Complexed with Acetyl Co Enzyme A from Vibrio cholerae O1 biovar eltor
6KRJ	;	1.72	;	Crystal structure of Hexokinase
6KSR	;	1.37	;	Crystal structure of Hexokinase from Eimeria tenella
7AL0	;	2.2	;	Crystal Structure of Heymonin, a Novel Frog-derived Peptide
5VYG	;	2.2	;	Crystal structure of hFA9 EGF repeat with O-glucose trisaccharide
5ZOD	;	1.9	;	Crystal Structure of hFen1 in apo form
3CAF	;	1.96	;	Crystal Structure of hFGFR2 D2 Domain
4J5Y	;	2.0953	;	Crystal structure of Hfq from Pseudomonas aeruginosa in complex with ATP
4J6W	;	1.8	;	Crystal structure of HFQ from Pseudomonas aeruginosa in complex with CTP
4J6X	;	2.222	;	Crystal structure of Hfq from Pseudomonas aeruginosa in complex with UTP
4V2S	;	3.48	;	Crystal structure of Hfq in complex with the sRNA RydC
2YHT	;	2.9	;	Crystal structure of Hfq riboregulator from E. coli (P1 space group)
2Y90	;	2.252	;	Crystal structure of Hfq riboregulator from E. coli (P6 space group)
5AWG	;	4.278	;	Crystal structure of Hg-bound SufB-SufC-SufD complex from Escherichia coli
3K2U	;	2.35	;	Crystal structure of HGFA in complex with the allosteric inhibitory antibody Fab40
2WUB	;	2.9	;	Crystal structure of HGFA in complex with the allosteric non- inhibitory antibody Fab40.deltaTrp
2WUC	;	2.7	;	Crystal structure of HGFA in complex with the allosteric non- inhibitory antibody Fab40.deltaTrp and Ac-KQLR-chloromethylketone
3OHP	;	2.04	;	Crystal structure of HGPRT from Vibrio cholerae
1PZM	;	2.1	;	Crystal structure of HGPRT-ase from Leishmania tarentolae in complex with GMP
6ATO	;	1.55	;	Crystal structure of hGSTA1-1 complexed with GSH and MPD in each subunit
6ATR	;	1.29	;	Crystal structure of hGSTA1-1 complexed with two GSH analogues in each subunit
5JCU	;	1.93	;	Crystal Structure of hGSTA1-1 with Glutathione Adduct of Phenethyl Isothiocyanate and Cystein Adduct of Phenethyl Isothiocyanate
1TDI	;	2.4	;	Crystal Structure of hGSTA3-3 in Complex with Glutathione
5L6X	;	2.0	;	CRYSTAL STRUCTURE OF HGSTP1-1 COMPLEXED WITH FERROCENE-GLUTATHIONE CONJUGATE
5JCW	;	1.945	;	Crystal Structure of hGSTP1-1 with Glutathione Adduct of Phenethyl Isothiocyanate
6AP9	;	1.55	;	Crystal Structure of hGSTP1-1 with S-nitrosation of Cys101
3PGT	;	2.14	;	CRYSTAL STRUCTURE OF HGSTP1-1[I104] COMPLEXED WITH THE GSH CONJUGATE OF (+)-ANTI-BPDE
4PGT	;	2.1	;	CRYSTAL STRUCTURE OF HGSTP1-1[V104] COMPLEXED WITH THE GSH CONJUGATE OF (+)-ANTI-BPDE
4EC0	;	1.85	;	Crystal structure of hH-PGDS with water displacing inhibitor
4EDY	;	1.72	;	Crystal structure of hH-PGDS with water displacing inhibitor
4EDZ	;	2.0	;	Crystal structure of hH-PGDS with water displacing inhibitor
4EE0	;	1.75	;	Crystal structure of hH-PGDS with water displacing inhibitor
5LOD	;	1.9	;	Crystal structure of HhaI DNA methyltransferase in APO form
3AY5	;	2.5	;	Crystal structure of HHM (human homologue of murine maternal Id-like molecule)
5T7X	;	2.35	;	Crystal structure of HHV-4 EBNA1 DNA binding domain (patient-derived, nasopharyngeal carcinoma) bound to DNA
1YLI	;	1.95	;	Crystal structure of HI0827, a hexameric broad specificity acyl-coenzyme A thioesterase
3BJK	;	1.9	;	Crystal structure of HI0827, a hexameric broad specificity acyl-coenzyme A thioesterase: The Asp44Ala mutant enzyme
3EMI	;	1.8	;	Crystal structure of Hia 307-422 non-adhesive domain
1S7M	;	2.1	;	Crystal Structure of HiaBD1
7CUD	;	1.8	;	Crystal structure of HID in the unbound form
7CUE	;	2.75	;	Crystal structure of HID2 bound to human Hemoglobin
2HBT	;	1.6	;	Crystal structure of HIF prolyl hydroxylase EGLN-1 in complex with a biologically active inhibitor
2HBU	;	1.85	;	Crystal structure of HIF prolyl hydroxylase EGLN-1 in complex with a biologically active inhibitor
6BVB	;	2.002	;	Crystal structure of HIF-2alpha-pVHL-elongin B-elongin C
6D0C	;	1.5	;	Crystal structure of HIF2a-B*:ARNT-B* complex
6IRP	;	1.954	;	Crystal structure of HigA from Shigella flexneri
5IFG	;	2.702	;	Crystal structure of HigA-HigB complex from E. Coli
5YCL	;	3.101	;	Crystal structure of HigBA complex from Shigella flexneri
1MQA	;	2.5	;	Crystal structure of high affinity alphaL I domain in the absence of ligand or metal
1MQ9	;	2.0	;	Crystal structure of high affinity alphaL I domain with ligand mimetic crystal contact
2AIF	;	1.895	;	Crystal Structure of High Mobility Like Protein, NHP2, putative from Cryptosporidium parvum
3ZVJ	;	3.0	;	Crystal structure of high molecular weight (HMW) form of Peroxiredoxin I from Schistosoma mansoni
4C29	;	2.202	;	Crystal Structure of High-Affinity von Willebrand Factor A1 domain with Disulfide Mutation
4C2B	;	2.8	;	Crystal Structure of High-Affinity von Willebrand Factor A1 domain with Disulfide Mutation in Complex with High Affinity GPIb alpha
4C2A	;	2.081	;	Crystal Structure of High-Affinity von Willebrand Factor A1 domain with R1306Q and I1309V Mutations in Complex with High Affinity GPIb alpha
2CVC	;	2.0	;	Crystal structure of High-Molecular Weight Cytochrome c from Desulfovibrio vulgaris (Hildenborough)
2E84	;	2.7	;	Crystal structure of High-Molecular Weight Cytochrome c from Desulfovibrio vulgaris (Miyazaki F) in the presence of zinc ion
1EYT	;	1.5	;	CRYSTAL STRUCTURE OF HIGH-POTENTIAL IRON-SULFUR PROTEIN FROM THERMOCHROMATIUM TEPIDUM
3A38	;	0.7	;	Crystal structure of high-potential iron-sulfur protein from Thermochromatium tepidum at 0.7 angstrom resolution
3A39	;	0.72	;	Crystal Structure of High-Potential Iron-Sulfur Protein from Thermochromatium tepidum at 0.72 angstrom resolution
5Y52	;	1.63	;	Crystal Structure of Highly Active BTUO Mutant P287G Improved by Humidity Control at 83% RH
5Z2B	;	1.901	;	Crystal structure of highly active BTUO mutant P287G Improved by Humidity Control at 86% RH
5YJA	;	1.65	;	Crystal structure of highly active BTUO mutant P287G without dehydration
5Z27	;	1.6	;	Crystal structure of highly active BTUO mutant P287G without dehydration
4XFP	;	1.66	;	Crystal Structure of Highly Active Mutant of Bacillus sp. TB-90 Urate Oxidase
6F5M	;	2.7	;	Crystal structure of highly glycosylated human leukocyte elastase in complex with a thiazolidinedione inhibitor
3HDL	;	1.85	;	Crystal Structure of Highly Glycosylated Peroxidase from Royal Palm Tree
2Q9X	;	1.7	;	Crystal structure of highly stable mutant Q40P/S47I/H93G of human fibroblast growth factor-1
2ZF5	;	2.4	;	Crystal Structure of highly thermostable glycerol kinase from a hyperthermophilic archaeon
3WVZ	;	1.88	;	Crystal structure of Hikeshi, a new nuclear transport receptor of Hsp70
5NNS	;	2.1	;	Crystal structure of HiLPMO9B
1YF8	;	2.8	;	Crystal structure of Himalayan mistletoe RIP reveals the presence of a natural inhibitor and a new functionally active sugar-binding site
6J85	;	2.2	;	Crystal structure of HinD apo
6J88	;	2.35	;	Crystal structure of HinD with benzo[b]thiophen analog
6J86	;	2.6	;	Crystal structure of HinD with NMFT
6J87	;	2.3	;	Crystal structure of HinD with NMFT and NO
6M5F	;	2.75	;	Crystal structure of HinK, a LysR family transcriptional regulator from Pseudomonas aeruginosa
5E01	;	2.3	;	Crystal structure of HiNmlR, a MerR family regulator lacking the sensor domain, bound to palyndromic promoter DNA
5D8C	;	2.25	;	Crystal structure of HiNmlR, a MerR family regulator lacking the sensor domain, bound to promoter DNA
5D90	;	2.3	;	Crystal structure of HiNmlR, a MerR family regulator lacking the sensor domain, bound to promoter DNA
8JMQ	;	2.0	;	Crystal structure of hinokiresinol synthase
8JMR	;	2.2	;	Crystal structure of hinokiresinol synthase in complex with 1,7-bis(4-hydroxyphenyl)hepta-1,6-dien-3-one
5UGQ	;	2.609	;	Crystal Structure of Hip1 (Rv2224c)
5UNO	;	2.603	;	Crystal Structure of Hip1 (Rv2224c)
5BKM	;	2.703	;	Crystal Structure of Hip1 (Rv2224c) mutant - S228DHA (dehydroalanine)
7M7C	;	2.3	;	Crystal Structure of Hip1 (Rv2224c) mutant - T466A/S228DHA (dehydroalanine)
5UOH	;	2.609	;	Crystal Structure of Hip1 (Rv2224c) T466A mutant
8EZT	;	2.06	;	Crystal structure of HipB(Lp) from Legionella pneumophila
7NCF	;	2.72	;	Crystal structure of HIPK2 in complex with MU135 (compound 21e)
5YJE	;	2.45	;	Crystal structure of HIRA(644-1017)
6KCS	;	2.1	;	Crystal structure of HIRAN domain of HLTF in complex with duplex DNA
4XZG	;	2.4	;	Crystal structure of HIRAN domain of human HLTF
4XZF	;	1.38	;	Crystal structure of HIRAN domain of human HLTF in complex with DNA
6QXH	;	2.04	;	Crystal structure of His-tag human thymidylate synthase (HT-hTS) in complex with dUMP
6QXG	;	2.08	;	Crystal structure of His-tag human thymidylate synthase (HT-hTS) in complex with FdUMP
3KKW	;	1.41	;	Crystal structure of His-tagged form of PA4794 protein
6ZXO	;	2.6	;	Crystal structure of His-tagged human thymidylate synthase (HT-hTS) in complex with FdUMP and Raltitrexed (Tomudex)
4KPW	;	2.03	;	Crystal structure of His-tagged human thymidylate synthase R175A mutant
2G9G	;	2.0	;	Crystal structure of His-tagged mouse PNGase C-terminal domain
2CCG	;	2.3	;	Crystal structure of His-tagged S. aureus thymidylate kinase complexed with thymidine monophosphate (TMP)
2CAL	;	1.1	;	Crystal structure of His143Met rusticyanin
4JUF	;	2.148	;	Crystal Structure of His281Ala mutant of Benzoylformate Decarboxylase from Pseudomonas putida
1KSS	;	1.8	;	Crystal Structure of His505Ala Mutant Flavocytochrome c3 from Shewanella frigidimarina
1KSU	;	2.0	;	Crystal Structure of His505Tyr Mutant Flavocytochrome c3 from Shewanella frigidimarina
5Z02	;	1.35	;	Crystal structure of HIS6-tagged Mdm2 with nutlin-3a
4WD0	;	1.5	;	Crystal structure of HisAp form Arthrobacter aurescens
4W9T	;	1.57	;	Crystal structure of HisAP from Streptomyces sp. Mg1
4X9S	;	1.6	;	CRYSTAL STRUCTURE OF HISAP FROM STREPTOMYCES SP. MG1
4TX9	;	1.6	;	Crystal structure of HisAp from Streptomyces sviceus with degraded ProFAR
4GQU	;	2.02	;	Crystal structure of HisB from Mycobacterium tuberculosis
6KHH	;	1.65	;	Crystal Structure of HisB from Mycobacterium tuberculosis
7TQR	;	2.1	;	Crystal Structure of histidine ammonia lyase from Thermoplasma acidophilum
6V6H	;	2.55	;	Crystal structure of histidine ammonia-lyase from Trypanosoma cruzi
4UY6	;	2.04	;	Crystal structure of Histidine and SAH bound Histidine-specific methyltransferase EgtD from Mycobacterium smegmatis
4UY7	;	2.306	;	Crystal structure of Histidine bound Histidine-specific methyltransferase EgtD from Mycobacterium smegmatis
6NB0	;	1.9	;	Crystal structure of Histidine kinase from Burkholderia phymatum STM815
3A0R	;	3.8	;	Crystal structure of histidine kinase ThkA (TM1359) in complex with response regulator protein TrrA (TM1360)
2OOC	;	1.52	;	Crystal structure of Histidine Phosphotransferase ShpA (NP_419930.1) from Caulobacter crescentus at 1.52 A resolution
4EQG	;	1.52	;	Crystal structure of histidine triad nucleotide-binding protein 1 (HINT1) from human complexed with Ala-AMS
4EQE	;	1.52	;	Crystal structure of histidine triad nucleotide-binding protein 1 (HINT1) from human complexed with Lys-AMS
4EQH	;	1.668	;	Crystal structure of histidine triad nucleotide-binding protein 1 (HINT1) from human complexed with Trp-AMS
6IQ1	;	2.485	;	Crystal structure of histidine triad nucleotide-binding protein from Candida albicans
3I4S	;	1.75	;	CRYSTAL STRUCTURE OF HISTIDINE TRIAD PROTEIN blr8122 FROM Bradyrhizobium japonicum
6NHI	;	2.1	;	Crystal structure of Histidine--tRNA ligase from Elizabethkingia sp. CCUG 26117
3RAC	;	2.301	;	Crystal Structure of Histidine--tRNA ligase subunit from Alicyclobacillus acidocaldarius subsp. acidocaldarius DSM 446.
4PAC	;	2.53	;	Crystal Structure of Histidine-containing Phosphotransfer Protein AHP2 from Arabidopsis thaliana
7C1I	;	1.58	;	Crystal structure of histidine-containing phosphotransfer protein B (HptB) from Pseudomonas aeruginosa PAO1
3US6	;	1.446	;	Crystal Structure of Histidine-containing Phosphotransfer Protein MtHPt1 from Medicago truncatula
1WN0	;	2.2	;	Crystal Structure of Histidine-containing Phosphotransfer Protein, ZmHP2, from maize
4CCV	;	1.93	;	Crystal structure of histidine-rich glycoprotein N2 domain reveals redox activity at an interdomain disulfide bridge: Implications for the regulation of angiogenesis
4UY5	;	1.997	;	Crystal structure of Histidine-specific methyltransferase EgtD from Mycobacterium smegmatis
3N5G	;	2.27	;	Crystal Structure of histidine-tagged human thymidylate synthase
6AN0	;	1.85	;	Crystal Structure of Histidinol Dehydrogenase from Elizabethkingia anophelis
4GK8	;	1.933	;	Crystal structure of histidinol phosphate phosphatase (HISK) from Lactococcus lactis subsp. lactis Il1403 complexed with ZN and L-histidinol arsenate
4GYF	;	1.647	;	Crystal structure of histidinol phosphate phosphatase (HISK) from Lactococcus lactis subsp. lactis Il1403 complexed with ZN, L-histidinol and phosphate
2F8J	;	2.4	;	Crystal structure of Histidinol-phosphate aminotransferase (EC 2.6.1.9) (Imidazole acetol-phosphate transferase) (tm1040) from Thermotoga maritima at 2.40 A resolution
3EUC	;	2.05	;	Crystal structure of histidinol-phosphate aminotransferase (YP_297314.1) from RALSTONIA EUTROPHA JMP134 at 2.05 A resolution
1GEX	;	2.2	;	CRYSTAL STRUCTURE OF HISTIDINOL-PHOSPHATE AMINOTRANSFERASE COMPLEXED WITH HISTIDINOL-PHOSPHATE
1GEY	;	2.3	;	CRYSTAL STRUCTURE OF HISTIDINOL-PHOSPHATE AMINOTRANSFERASE COMPLEXED WITH N-(5'-PHOSPHOPYRIDOXYL)-L-GLUTAMATE
1GEW	;	2.0	;	CRYSTAL STRUCTURE OF HISTIDINOL-PHOSPHATE AMINOTRANSFERASE COMPLEXED WITH PYRIDOXAL 5'-PHOSPHATE
7SZP	;	1.8	;	Crystal Structure of Histidinol-phosphate aminotransferase from Klebsiella pneumoniae subsp. pneumoniae (strain HS11286)
4WBT	;	1.6	;	Crystal structure of histidinol-phosphate aminotransferase from Sinorhizobium meliloti in complex with pyridoxal-5'-phosphate
3NET	;	2.7	;	Crystal structure of histidyl-tRNA synthetase from Nostoc sp. PCC 7120
1WU7	;	2.4	;	Crystal structure of histidyl-tRNA synthetase from Thermoplasma acidophilum
3FNS	;	2.5	;	Crystal structure of histo-aspartic protease (HAP) from Plasmodium Falciparum
3QVC	;	2.1	;	Crystal structure of histo-aspartic protease (HAP) zymogen from Plasmodium falciparum
4PSW	;	2.101	;	Crystal structure of histone acetyltransferase complex
4PSX	;	2.509	;	Crystal structure of histone acetyltransferase complex
2QEC	;	1.9	;	Crystal structure of histone acetyltransferase HPA2 and related acetyltransferase (NP_600742.1) from Corynebacterium glutamicum ATCC 13032 at 1.90 A resolution
6YN1	;	2.35	;	Crystal structure of histone chaperone APLF acidic domain bound to the histone H2A-H2B-H3-H4 octamer
2DZE	;	1.8	;	Crystal structure of histone chaperone Asf1 in complex with a C-terminus of histone H3
2CU9	;	1.8	;	Crystal structure of Histone chaperone cia1
5TD7	;	2.85	;	Crystal structure of histone deacetylase 10
5ZOO	;	1.85	;	Crystal structure of histone deacetylase 4 (HDAC4) in complex with a SMRT corepressor SP1 fragment
5ZOP	;	2.698	;	Crystal structure of histone deacetylase 4 (HDAC4) in complex with a SMRT corepressor SP2 fragment
5VI6	;	1.237	;	Crystal structure of histone deacetylase 8 in complex with trapoxin A
4QXH	;	2.2	;	Crystal structure of histone demethylase KDM2A-H3K36ME1 with NOG
4QX7	;	2.34	;	Crystal structure of histone demethylase kdm2a-h3k36me2 with alpha-kg
4QXC	;	1.75	;	Crystal structure of histone demethylase KDM2A-H3K36ME2 with NOG
4QX8	;	1.65	;	Crystal structure of histone demethylase kdm2a-h3k36me3 complex with alpha-kg
4QXB	;	1.6	;	crystal structure of histone demethylase KDM2A-H3K36ME3 with NOG
4E4H	;	2.28	;	Crystal structure of Histone Demethylase NO66
6A7U	;	2.6	;	Crystal structure of histone H2A.Bbd-H2B dimer
8HKR	;	2.4	;	Crystal Structure of Histone H3 Lysine 79 (H3K79) Methyltransferase Rv2067c from Mycobacterium tuberculosis
1U2Z	;	2.2	;	Crystal structure of histone K79 methyltransferase Dot1p from yeast
5FBM	;	1.9	;	Crystal Structure of Histone Like Protein (HLP) from Streptococcus mutans Refined to 1.9 A Resolution
7DYQ	;	1.998	;	Crystal structure of histone lysine demethylase 4D (KDM4D) in complex with the inhibitor 5-hydroxy-2-methylpyrazolo[1,5-a]pyrido[3,2-e]pyrimidine-3-carbonitrile
3RJW	;	2.56	;	Crystal structure of histone lysine methyltransferase g9a with an inhibitor
6N3G	;	2.43	;	Crystal structure of histone lysine methyltransferase SmyD2 in complex with polyethylene glycol
3QWV	;	2.03	;	Crystal structure of histone lysine methyltransferase SmyD2 in complex with the cofactor product AdoHcy
3QWW	;	1.8	;	Crystal structure of histone lysine methyltransferase SmyD2 in complex with the methyltransferase inhibitor sinefungin
3VUZ	;	2.5	;	Crystal structure of histone methyltransferase SET7/9 in complex with AAM-1
3VV0	;	2.001	;	Crystal structure of histone methyltransferase SET7/9 in complex with DAAM-3
3GFC	;	2.3	;	Crystal Structure of Histone-binding protein RBBP4
6D6J	;	1.35	;	Crystal structure of HIT family hydrolase from Legionella pneumophila Philadelphia 1
3LB5	;	1.9	;	Crystal structure of Hit-like protein involved in cell-cycle regulation from Bartonella henselae with unknown ligand
6IWF	;	1.70662	;	Crystal structure of HitA from Pseudomonas aeruginosa
7DQ6	;	2.6	;	Crystal structure of HitB in complex with (S)-beta-3-Br-phenylalanine sulfamoyladenosine
7DQ5	;	2.45	;	Crystal structure of HitB in complex with (S)-beta-phenylalanine sulfamoyladenosine
3H3P	;	2.7	;	Crystal structure of HIV epitope-scaffold 4E10 Fv complex
3LH2	;	2.65	;	Crystal structure of HIV epitope-scaffold 4E10_1VI7A_S0_002_N 4E10 Fv complex
3LF6	;	1.9	;	Crystal structure of HIV epitope-scaffold 4E10_1XIZA_S0_001_N
3T43	;	1.95	;	Crystal Structure of HIV Epitope-Scaffold 4E10_1XIZA_S0_006_C
3LF9	;	2.0	;	Crystal structure of HIV epitope-scaffold 4E10_D0_1IS1A_001_C
3LHP	;	2.7	;	Crystal structure of HIV epitope-scaffold 4E10_D0_1ISEA_004_N 4E10 Fv complex
3LG7	;	2.5	;	Crystal structure of HIV epitope-scaffold 4E10_S0_1EZ3A_002_C
3LEF	;	2.3	;	Crystal structure of HIV epitope-scaffold 4E10_S0_1Z6NA_001
3K9A	;	2.1	;	Crystal Structure of HIV gp41 with MPER
4JMU	;	2.0	;	Crystal structure of HIV matrix residues 1-111 in complex with inhibitor
3TKG	;	1.36	;	crystal structure of HIV model protease precursor/saquinavir complex
4RBP	;	1.85	;	Crystal structure of HIV neutralizing antibody 2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomanose
6B36	;	1.63	;	Crystal Structure of HIV Protease complexed with (S)-N-(3-fluoro-2-(2-(1-(phenylsulfonyl)piperazin-2-yl)ethyl)phenyl)-3,3-bis(4-fluorophenyl)propanamide
1T7K	;	2.1	;	Crystal Structure of HIV Protease complexed with Arylsulfonamide azacyclic urea
1NPW	;	2.0	;	Crystal structure of HIV protease complexed with LGZ479
5IVQ	;	1.57	;	Crystal Structure of HIV Protease complexed with methyl N-[(1S)-1-benzhydryl-2-(3-morpholin-4-ium-2-ylpropylamino)-2-oxo-ethyl]carbamate
5IVS	;	1.46	;	Crystal Structure of HIV Protease complexed with methyl N-[(1S)-1-benzhydryl-2-[2-[2-[(2R,5S)-5-(benzylcarbamoyloxymethyl)morpholin-2-yl]ethyl]anilino]-2-oxo-ethyl]carbamate
5IVR	;	1.5	;	Crystal Structure of HIV Protease complexed with methyl N-[(1S)-1-[[2-[(3S)-3-[(4-aminophenyl)methylamino]-4-hydroxy-butyl]phenyl]carbamoyl]-2,2-diphenyl-ethyl]carbamate
6B3H	;	1.62	;	Crystal Structure of HIV Protease complexed with N-(2-(2-((6R,9S)-2,2-dioxido-2-thia-1,7-diazabicyclo[4.3.1]decan-9-yl)ethyl)-3-fluorophenyl)-3,3-bis(4-fluorophenyl)propanamide
6B3F	;	1.46	;	Crystal Structure of HIV Protease complexed with N-(3-fluoro-2-(2-((2S,5S)-5-methyl-1-(phenylsulfonyl)piperazin-2-yl)ethyl)phenyl)-3,3-bis(4-fluorophenyl)propanamide
6B38	;	1.48	;	Crystal Structure of HIV Protease complexed with N-(3-fluoro-2-(2-((2S,6R)-6-methyl-1-(phenylsulfonyl)piperazin-2-yl)ethyl)phenyl)-3,3-bis(4-fluorophenyl)propanamide
6B3C	;	1.6	;	Crystal Structure of HIV Protease complexed with N-(3-fluoro-2-(2-((2S,6R)-6-methyl-1-(phenylsulfonyl)piperazin-2-yl)ethyl)phenyl)-3,3-bis(4-fluorophenyl)propanamide
6B3G	;	1.5	;	Crystal Structure of HIV Protease complexed with N-(3-fluoro-2-(2-((2S,6S)-6-methyl-1-(phenylsulfonyl)piperazin-2-yl)ethyl)phenyl)-3,3-bis(4-fluorophenyl)propanamide
5IVT	;	1.15	;	Crystal Structure of HIV Protease complexed with [(1S)-1-[(S)-(4-chlorophenyl)-(3,5-difluorophenyl)methyl]-2-[[5-fluoro-4-[2-[(2R,5S)-5-(2,2,2-trifluoroethylcarbamoyloxymethyl)morpholin-4-ium-2-yl]ethyl]pyridin-1-ium-3-yl]amino]-2-oxo-ethyl]ammonium
2FDD	;	1.58	;	Crystal structure of HIV protease D545701 bound with GW0385
3TKW	;	1.55	;	Crystal structure of HIV protease model precursor/Darunavir complex
3TL9	;	1.32	;	crystal structure of HIV protease model precursor/Saquinavir complex
1ZTZ	;	2.15	;	Crystal structure of HIV protease- metallacarborane complex
3C6T	;	2.7	;	Crystal Structure of HIV Reverse Transcriptase in complex with inhibitor 14
3C6U	;	2.7	;	Crystal Structure of HIV Reverse Transcriptase in complex with inhibitor 22
3I0R	;	2.98	;	crystal structure of HIV reverse transcriptase in complex with inhibitor 3
3I0S	;	2.7	;	crystal structure of HIV reverse transcriptase in complex with inhibitor 7
4KV8	;	2.3	;	Crystal structure of HIV RT in complex with BILR0355BS
4XVT	;	1.69	;	Crystal structure of HIV-1 93TH057 coreE gp120 with antibody 45-VRC01.H01+07.O-863513/45-VRC01.L01+07.O-110653 (VRC07_1995)
6MUG	;	2.954	;	Crystal Structure of HIV-1 B41 SOSIP.664 Prefusion Env Trimer Bound to Small Molecule HIV-1 Entry Inhibitor BMS-386150 in Complex with Human Antibodies 3H109L and 35O22 at 3.8 Angstrom
6MUF	;	2.91	;	Crystal Structure of HIV-1 B41 SOSIP.664 Prefusion Env Trimer in Complex with Human Antibodies 3H109L and 35O22 at 3.4 Angstrom
6W03	;	2.4	;	Crystal Structure of HIV-1 BG505 DS-SOSIP.3mut Prefusion Env Trimer in Complex with Human Antibodies 3H109L and 35O22 at 3.3 Angstrom
6NNJ	;	2.6	;	Crystal Structure of HIV-1 BG505 SOSIP.664 Prefusion Env Trimer Bound to CH31 scFv in Complex with Crystallization Chaperones 3H109L Fab and 35O22 scFv at 3.1 Angstrom
6NM6	;	2.739	;	Crystal Structure of HIV-1 BG505 SOSIP.664 Prefusion Env Trimer Bound to N6 FR3-03 scFv in Complex with Crystallization Chaperones 3H109L Fab and 35O22 scFv at 3.2 Angstrom
6MTJ	;	2.336	;	Crystal Structure of HIV-1 BG505 SOSIP.664 Prefusion Env Trimer Bound to Small Molecule HIV-1 Entry Inhibitor BMS-378806 in Complex with Human Antibodies 3H109L and 35O22 at 2.9 Angstrom
5U7M	;	3.025	;	Crystal Structure of HIV-1 BG505 SOSIP.664 Prefusion Env Trimer Bound to Small Molecule HIV-1 Entry Inhibitor BMS-378806 in Complex with Human Antibodies PGT122 and 35O22 at 3.8 Angstrom
6MU8	;	2.993	;	Crystal Structure of HIV-1 BG505 SOSIP.664 Prefusion Env Trimer Bound to Small Molecule HIV-1 Entry Inhibitor BMS-386150 in Complex with Human Antibodies 3H109L and 35O22 at 3.5 Angstrom
5U7O	;	3.031	;	Crystal Structure of HIV-1 BG505 SOSIP.664 Prefusion Env Trimer Bound to Small Molecule HIV-1 Entry Inhibitor BMS-626529 in Complex with Human Antibodies PGT122 and 35O22 at 3.8 Angstrom
6MU6	;	2.551	;	Crystal Structure of HIV-1 BG505 SOSIP.664 Prefusion Env Trimer Bound to Small Molecule HIV-1 Entry Inhibitor BMS-814508 in Complex with Human Antibodies 3H109L and 35O22 at 3.2 Angstrom
6MU7	;	2.501	;	Crystal Structure of HIV-1 BG505 SOSIP.664 Prefusion Env Trimer Bound to Small Molecule HIV-1 Entry Inhibitor BMS-818251 in Complex with Human Antibodies 3H109L and 35O22 at 3.1 Angstrom
6MTN	;	2.5	;	Crystal Structure of HIV-1 BG505 SOSIP.664 Prefusion Env Trimer Bound to Small Molecule HIV-1 Entry Inhibitor Compound 484 in Complex with Human Antibodies 3H109L and 35O22 at 3.0 Angstrom
6NNF	;	2.762	;	Crystal Structure of HIV-1 BG505 SOSIP.664 Prefusion Env Trimer Bound to VRC01 FR3-03 scFv in Complex with Crystallization Chaperones 3H109L Fab and 35O22 scFv at 3.5 Angstrom
5I8H	;	4.301	;	Crystal Structure of HIV-1 BG505 SOSIP.664 Prefusion Env Trimer in Complex with V3 Loop-targeting Antibody PGT122 Fab and Fusion Peptide-targeting Antibody VRC34.01 Fab
8D0Y	;	4.7	;	Crystal Structure of HIV-1 BG505 SOSIPv8 Trimer in Complex with CD4bs targeting antibody 21N13 and interface targeting antibody 35O22 at 4.7 Angstrom
6NCP	;	2.76	;	Crystal structure of HIV-1 broadly neutralizing antibody ACS202
4NUG	;	1.8617	;	Crystal structure of HIV-1 broadly neutralizing antibody PGT151
4NUJ	;	1.827	;	Crystal structure of HIV-1 broadly neutralizing antibody PGT152
2PWO	;	1.45	;	Crystal Structure of HIV-1 CA146 A92E Psuedo Cell
2PWM	;	1.9	;	Crystal Structure of HIV-1 CA146 A92E real cell
2PXR	;	1.5	;	Crystal Structure of HIV-1 CA146 in the Presence of CAP-1
6VZI	;	2.716	;	Crystal Structure of HIV-1 CAP256 RnS-3mut-2G-SOSIP.664 Prefusion Env Trimer in Complex with Human Antibodies 3H109L and 35O22 at 3.5 Angstrom
7ZUD	;	2.93	;	Crystal structure of HIV-1 capsid IP6-CPSF6 complex
4LQW	;	1.95	;	Crystal structure of HIV-1 capsid N-terminal domain in complex with NUP358 cyclophilin
1E6J	;	3.0	;	Crystal structure of HIV-1 capsid protein (p24) in complex with Fab13B5
5I8C	;	1.54	;	Crystal Structure of HIV-1 Clade A BG505 Fusion Peptide (residue 512-520) in Complex with Broadly Neutralizing Antibody VRC34.01 Fab
6BF4	;	2.382	;	Crystal Structure of HIV-1 Clade AE Strain CNE55 gp120 Core in Complex with Neutralizing Antibody VRC-PG05 that Targets the Center of the Silent Face on the Outer Domain of gp120
3TGS	;	2.7	;	Crystal structure of HIV-1 clade C strain C1086 gp120 core in complex with NBD-556
6CK9	;	2.714	;	Crystal Structure of HIV-1 ConC_Base0 Prefusion Env Trimer in Complex with Human Antibody Fragment 3H109L and 35O22 variants at 3.5 Angstrom
3D3T	;	2.8	;	Crystal Structure of HIV-1 CRF01_AE in complex with the substrate p1-p6
3LZS	;	1.95	;	Crystal Structure of HIV-1 CRF01_AE Protease in Complex with Darunavir
4XVS	;	1.9	;	Crystal structure of HIV-1 donor 45 d45-01dG5 coreE gp120 with antibody 45-VRC01.H01+07.O-863513/45-VRC01.L01+07.O-110653 (VRC07_1995)
6C0P	;	2.05	;	Crystal structure of HIV-1 E138K mutant reverse transcriptase in complex with non-nucleoside inhibitor 25a
6C0L	;	1.95	;	Crystal structure of HIV-1 E138K mutant reverse transcriptase in complex with non-nucleoside inhibitor K-5a2
6IEQ	;	3.9	;	Crystal Structure of HIV-1 Env ConM SOSIP.v7 in Complex with bNAb PGT124 and 35O22
5UM8	;	3.935	;	Crystal structure of HIV-1 envelope trimer 16055 NFL TD CC (T569G) in complex with Fabs 35022 and PGT124
5H0N	;	2.8	;	Crystal structure of HIV-1 fusion inhibitor MT-WQ-IDL bound to gp41 NHR
5Z0W	;	1.896	;	Crystal structure of HIV-1 fusion inhibitor SC29EK complexed with gp41 NHR (N36)
6J5E	;	2.33	;	Crystal structure of HIV-1 fusion inhibitor SC29EK complexed with gp41 NHR (N44)
4RZ8	;	1.9	;	Crystal structure of HIV-1 gp120 core in complex with NBD-11021, a small molecule CD4-antagonist
3OXV	;	1.75	;	Crystal Structure of HIV-1 I50V, A71 Protease in Complex with the protease inhibitor amprenavir.
3OXX	;	1.65	;	Crystal Structure of HIV-1 I50V, A71V Protease in Complex with the Protease Inhibitor Atazanavir
3OXW	;	1.95	;	Crystal Structure of HIV-1 I50V, A71V Protease in Complex with the Protease Inhibitor Darunavir
6L0C	;	2.101	;	Crystal structure of HIV-1 Integrase catalytic core domain (A128T/K173Q/F185K)
7WCE	;	1.85	;	Crystal structure of HIV-1 integrase catalytic core domain in complex with (2S)-2-(tert-Butoxy)-2-(10-fluoro-2-(2-hydroxy-4-methylphenyl)-1,4-dimethyl-5-(methylsulfonyl)-5,6-dihydrophenanthridin-3-yl)acetic acid
7D83	;	2.43	;	Crystal structure of HIV-1 integrase catalytic core domain in complex with 2-(tert-butoxy)-2-(2-(3-cyclohexylureido)-3,6-dimethyl-5-(5-methylchroman-6-yl)pyridin-4-yl)acetic acid
6LMQ	;	2.1	;	Crystal structure of HIV-1 integrase catalytic core domain in complex with 2-(tert-butoxy)-2-[3-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)-6-methanesulfonamido-2,3',4',5-tetramethyl-[1,1'-biphenyl]-4-yl]acetic acid
6LMI	;	2.5	;	Crystal structure of HIV-1 integrase catalytic core domain in complex with 2-(tert-butoxy)-2-[3-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-methanesulfonamido-2,3',4',5-tetramethyl-[1,1'-biphenyl]-4-yl]acetic acid
6EX9	;	2.014	;	Crystal Structure of HIV-1 Integrase Catalytic Core Domain with Inhibitor Peptide
5EU7	;	2.64	;	Crystal structure of HIV-1 integrase catalytic core in complex with Fab
7UOQ	;	1.8867	;	CRYSTAL STRUCTURE OF HIV-1 INTEGRASE COMPLEXED WITH (2S)-2-(TERT-BUTOXY)-2-(5-{2-[(2-CHLORO-6-M ETHYLPHENYL)METHYL]-1,2,3,4-TETRAHYDROISOQUINOLIN-6-YL}-4- (4,4-DIMETHYLPIPERIDIN-1-YL)-2-METHYLPYRIDIN-3-YL)ACETIC ACID
7U2U	;	1.839	;	CRYSTAL STRUCTURE OF HIV-1 INTEGRASE COMPLEXED WITH Compound-2a AKA (2S)-2-(TERT-BUTOXY)-2-[7-(4,4-DIMETHYLPIPE RIDIN-1-YL)-8-{4-[2-(4-FLUOROPHENYL)ETHOXY]PHENYL}-2,5-DIM ETHYLIMIDAZO[1,2-A]PYRIDIN-6-YL]ACETIC ACID
4E1M	;	1.9	;	Crystal Structure of HIV-1 Integrase with a non-catayltic site inhibitor
4E1N	;	2.0	;	Crystal Structure of HIV-1 Integrase with a non-catayltic site inhibitor
2B4C	;	3.3	;	Crystal structure of HIV-1 JR-FL gp120 core protein containing the third variable region (V3) complexed with CD4 and the X5 antibody
3DM2	;	3.1	;	Crystal structure of HIV-1 K103N mutant reverse transcriptase in complex with GW564511.
6C0O	;	1.901	;	Crystal structure of HIV-1 K103N mutant reverse transcriptase in complex with non-nucleoside inhibitor 25a
6C0K	;	1.958	;	Crystal structure of HIV-1 K103N mutant reverse transcriptase in complex with non-nucleoside inhibitor K-5a2
7SO6	;	2.79	;	Crystal Structure of HIV-1 K103N, Y181C mutant Reverse Transcriptase in Complex with 5-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)-7-fluoro-2-naphthonitrile (JLJ635), a Non-nucleoside Inhibitor
6C0R	;	2.049	;	Crystal structure of HIV-1 K103N/Y181C mutant reverse transcriptase in complex with non-nucleoside inhibitor 25a
3OY4	;	1.76	;	Crystal Structure of HIV-1 L76V Protease in Complex with the Protease Inhibitor Darunavir.
6USW	;	2.5	;	CRYSTAL STRUCTURE OF HIV-1 LM/HS CLADE A/E CRF01 GP120 CORE IN COMPLEX WITH (S)-MCG-IV-210
6UT1	;	2.65	;	CRYSTAL STRUCTURE OF HIV-1 LM/HS CLADE A/E CRF01 GP120 CORE IN COMPLEX WITH BNM-III-170
6ONV	;	3.253	;	Crystal structure of HIV-1 LM/HT Clade A/E CRF01 gp120 core in complex with (S)-MCG-III-027-D05.
6ONE	;	2.2	;	Crystal structure of HIV-1 LM/HT Clade A/E CRF01 gp120 core in complex with (S)-MCG-III-188-A01.
6ONF	;	1.842	;	Crystal structure of HIV-1 LM/HT Clade A/E CRF01 gp120 core in complex with (S)-MCG-III-188-A02.
6ONH	;	2.244	;	Crystal structure of HIV-1 LM/HT Clade A/E CRF01 gp120 core in complex with (S)-MCG-IV-031-A05.
6P9N	;	2.65	;	CRYSTAL STRUCTURE OF HIV-1 LM/HT CLADE A/E CRF01 GP120 CORE IN COMPLEX WITH (S)-MCG-IV-210.
6OOO	;	2.4	;	Crystal structure of HIV-1 LM/HT Clade A/E CRF01 gp120 core in complex with (S)-MCG-IV-226.
8GD3	;	2.19	;	Crystal Structure of HIV-1 LM/HT Clade A/E CRF01 GP120 Core in Complex with DL-I-101
8GD5	;	2.6	;	Crystal Structure of HIV-1 LM/HT Clade A/E CRF01 GP120 Core in Complex with DL-I-102
8GD0	;	2.4	;	Crystal Structure of HIV-1 LM/HT Clade A/E CRF01 GP120 Core in Complex with TFH-I-070-A6
8GJT	;	3.5	;	Crystal Structure of HIV-1 LM/HT Clade A/E CRF01 GP120 Core in Complex with TFH-I-116-D1
8GDJ	;	2.42	;	Crystal Structure of HIV-1 LM/HT CLADE A/E CRF01 GP120 Core in Complex with TFH-II-128
8GDK	;	2.65	;	Crystal Structure of HIV-1 LM/HT CLADE A/E CRF01 GP120 Core in Complex with TFH-II-151
8DCQ	;	3.2	;	CRYSTAL STRUCTURE OF HIV-1 LM/HT CLADE A/E CRF01 GP120 CORE IN COMPLEX WITH YIR-821
8GCZ	;	2.4	;	Crystal Structure of HIV-1 LM/HT Clade A/E CRF01 GP120 Core in Complex with ZXC-I-090
8GD1	;	2.85	;	Crystal Structure of HIV-1 LM/HT Clade A/E CRF01 GP120 Core in Complex with ZXC-I-092
6WIX	;	2.67	;	Crystal Structure of HIV-1 MI369 RnS-DS.SOSIP Prefusion Env Trimer in Complex with Human Antibodies 3H109L and 35O22 at 3.5 Angstrom
3CYX	;	1.2	;	Crystal structure of HIV-1 mutant I50V and inhibitor saquinavira
3D1Z	;	1.3	;	Crystal structure of HIV-1 mutant I54M and inhibitor DARUNAVIR
3D1X	;	1.05	;	Crystal structure of HIV-1 mutant I54M and inhibitor saquinavir
3D20	;	1.05	;	Crystal structure of HIV-1 mutant I54V and inhibitor DARUNAVIA
3D1Y	;	1.05	;	Crystal structure of HIV-1 mutant I54V and inhibitor SAQUINA
4D8D	;	2.5201	;	Crystal structure of HIV-1 NEF Fyn-SH3 R96W variant
4U5W	;	1.86	;	Crystal Structure of HIV-1 Nef-SF2 Core Domain in Complex with the Src Family Kinase Hck SH3-SH2 Tandem Regulatory Domains
3TCL	;	1.906	;	Crystal Structure of HIV-1 Neutralizing Antibody CH04
4NRY	;	3.14	;	Crystal Structure of HIV-1 Neutralizing Antibody m66
4NRX	;	2.21	;	Crystal Structure of HIV-1 Neutralizing Antibody m66 in complex with gp41 MPER peptide
4NRZ	;	2.42	;	Crystal Structure of HIV-1 Neutralizing Antibody m66.6
1TZG	;	2.2	;	Crystal structure of HIV-1 neutralizing human Fab 4E10 in complex with a 13-residue peptide containing the 4E10 epitope on gp41
2FX7	;	1.76	;	Crystal structure of hiv-1 neutralizing human fab 4e10 in complex with a 16-residue peptide encompassing the 4e10 epitope on gp41
2FX9	;	2.1	;	Crystal structure of hiv-1 neutralizing human fab 4e10 in complex with a thioether-linked peptide encompassing the 4e10 epitope on gp41
2FX8	;	2.2	;	Crystal structure of hiv-1 neutralizing human fab 4e10 in complex with an aib-induced peptide encompassing the 4e10 epitope on gp41
3FN0	;	1.8	;	Crystal structure of HIV-1 neutralizing human Fab Z13e1 in complex with a 12-residue peptide containing the Z13e1 epitope on gp41
3O2D	;	2.19	;	Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibody
2O4K	;	1.6	;	Crystal Structure of HIV-1 Protease (Q7K) in Complex with Atazanavir
2O4S	;	1.54	;	Crystal Structure of HIV-1 Protease (Q7K) in Complex with Lopinavir
2O4P	;	1.8	;	Crystal Structure of HIV-1 Protease (Q7K) in Complex with Tipranavir
2O4L	;	1.33	;	Crystal Structure of HIV-1 Protease (Q7K, I50V) in Complex with Tipranavir
2PK5	;	1.9	;	Crystal Structure of HIV-1 Protease (Q7K, L33I, L63I ) in Complex with KNI-10075
3KDB	;	1.66	;	Crystal Structure of HIV-1 Protease (Q7K, L33I, L63I) in Complex with KNI-10006
2PK6	;	1.45	;	Crystal Structure of HIV-1 Protease (Q7K, L33I, L63I) in Complex with KNI-10033
3KDC	;	2.2	;	Crystal Structure of HIV-1 Protease (Q7K, L33I, L63I) in Complex with KNI-10074
3KDD	;	1.8	;	Crystal Structure of HIV-1 Protease (Q7K, L33I, L63I) in Complex with KNI-10265
2O4N	;	2.0	;	Crystal Structure of HIV-1 Protease (TRM Mutant) in Complex with Tipranavir
1IIQ	;	1.83	;	CRYSTAL STRUCTURE OF HIV-1 PROTEASE COMPLEXED WITH A HYDROXYETHYLAMINE PEPTIDOMIMETIC INHIBITOR
1SP5	;	1.8	;	Crystal structure of HIV-1 protease complexed with a product of autoproteolysis
3A2O	;	0.88	;	Crystal Structure of HIV-1 Protease Complexed with KNI-1689
1NPV	;	2.0	;	Crystal structure of HIV-1 protease complexed with LDC271
1MUI	;	2.8	;	Crystal structure of HIV-1 protease complexed with Lopinavir.
2QMP	;	1.8	;	Crystal Structure of HIV-1 protease complexed with PL-100
4FE6	;	2.0	;	Crystal Structure of HIV-1 Protease in Complex with an enamino-oxindole inhibitor
1G35	;	1.8	;	CRYSTAL STRUCTURE OF HIV-1 PROTEASE IN COMPLEX WITH INHIBITOR, AHA024
3NLS	;	1.7	;	Crystal Structure of HIV-1 Protease in Complex with KNI-10772
7WCQ	;	2.011	;	Crystal structure of HIV-1 protease in complex with lactam derivative 1
7WBS	;	1.85	;	Crystal structure of HIV-1 protease in complex with lactam derivative 2
7YF6	;	2.01	;	Crystal structure of HIV-1 protease in complex with macrocyclic peptide
1HPV	;	1.9	;	CRYSTAL STRUCTURE OF HIV-1 PROTEASE IN COMPLEX WITH VX-478, A POTENT AND ORALLY BIOAVAILABLE INHIBITOR OF THE ENZYME
5DGW	;	1.62	;	Crystal Structure of HIV-1 Protease Inhibitor GRL-105-11A Containing Substituted fused-Tetrahydropyranyl Tetrahydrofuran as P2-Ligand
3MXD	;	1.95	;	Crystal structure of HIV-1 protease inhibitor KC53 in complex with wild-type protease
3MXE	;	1.85	;	Crystal structure of HIV-1 protease inhibitor, KC32 complexed with wild-type protease
5DGU	;	1.22	;	Crystal Structure of HIV-1 Protease Inhibitors Containing Substituted fused-Tetrahydropyranyl Tetrahydrofuran as P2-Ligand GRL-004-11A
4NPU	;	1.5	;	Crystal Structure of HIV-1 Protease Multiple Mutant P51
4NPT	;	1.66	;	Crystal Structure of HIV-1 Protease Multiple Mutant P51 Complexed with Darunavir
7N6X	;	1.47	;	Crystal structure of HIV-1 Protease multiple mutants PRS17 bound to inhibitor Amprenavir
7N6V	;	1.39	;	Crystal structure of HIV-1 Protease multiple mutants PRS17 with Revertant mutation V48G bound to inhibitor Amprenavir
3VF5	;	1.25	;	Crystal Structure of HIV-1 Protease Mutant I47V with novel P1'-Ligands GRL-02031
3NU5	;	1.29	;	Crystal Structure of HIV-1 Protease Mutant I50V with Antiviral Drug Amprenavir
3NU6	;	1.16	;	Crystal Structure of HIV-1 Protease Mutant I54M with Antiviral Drug Amprenavir
3NUJ	;	1.5	;	Crystal Structure of HIV-1 Protease Mutant I54V with Antiviral Drug Amprenavir
3NU9	;	1.85	;	Crystal Structure of HIV-1 Protease Mutant I84V with Antiviral Drug Amprenavir
3VF7	;	1.3	;	Crystal Structure of HIV-1 Protease Mutant L76V with novel P1'-Ligands GRL-02031
3NUO	;	1.35	;	Crystal Structure of HIV-1 Protease Mutant L90M with Antiviral Drug Amprenavir
3VFB	;	1.55	;	Crystal Structure of HIV-1 Protease Mutant N88D with novel P1'-Ligands GRL-02031
3TH9	;	1.34	;	Crystal Structure of HIV-1 Protease Mutant Q7K V32I L63I with a cyclic sulfonamide inhibitor
3NU4	;	1.2	;	Crystal Structure of HIV-1 Protease Mutant V32I with Antiviral Drug Amprenavir
3VFA	;	1.43	;	Crystal Structure of HIV-1 Protease Mutant V82A with novel P1'-Ligands GRL-02031
4HDB	;	1.49	;	Crystal Structure of HIV-1 protease mutants D30N complexed with inhibitor GRL-0519
4HDP	;	1.22	;	Crystal Structure of HIV-1 protease mutants I50V complexed with inhibitor GRL-0519
4HE9	;	1.06	;	Crystal Structure of HIV-1 protease mutants I54M complexed with inhibitor GRL-0519
4HEG	;	1.46	;	Crystal Structure of HIV-1 protease mutants R8Q complexed with inhibitor GRL-0519
4HDF	;	1.29	;	Crystal Structure of HIV-1 protease mutants V82A complexed with inhibitor GRL-0519
6DH6	;	1.97	;	Crystal structure of HIV-1 Protease NL4-3 I50V Mutant in complex with darunavir
6DH7	;	1.997	;	Crystal structure of HIV-1 Protease NL4-3 I50V Mutant in complex with UMass1
6DH8	;	1.951	;	Crystal structure of HIV-1 Protease NL4-3 I50V Mutant in complex with UMass6
6DH0	;	1.899	;	Crystal structure of HIV-1 Protease NL4-3 I84V Mutant in complex with darunavir
6DH1	;	1.971	;	Crystal structure of HIV-1 Protease NL4-3 I84V Mutant in complex with UMass1
6DH2	;	1.978	;	Crystal structure of HIV-1 Protease NL4-3 I84V Mutant in complex with UMass6
6OOU	;	2.127	;	Crystal structure of HIV-1 Protease NL4-3 L89V Mutant in complex with darunavir
6DH3	;	1.908	;	Crystal structure of HIV-1 Protease NL4-3 V82I Mutant in complex with darunavir
6DH4	;	1.943	;	Crystal structure of HIV-1 Protease NL4-3 V82I Mutant in complex with UMass1
6DH5	;	2.008	;	Crystal structure of HIV-1 Protease NL4-3 V82I Mutant in complex with UMass6
6DGX	;	2.001	;	Crystal structure of HIV-1 Protease NL4-3 WT in complex with darunavir
6DGY	;	1.954	;	Crystal structure of HIV-1 Protease NL4-3 WT in complex with UMass1
6DGZ	;	1.994	;	Crystal structure of HIV-1 Protease NL4-3 WT in complex with UMass6
8VB1	;	1.3	;	Crystal structure of HIV-1 protease with GS-9770
1NPA	;	2.0	;	crystal structure of HIV-1 protease-hup
7MYY	;	1.5	;	Crystal Structure of HIV-1 PRS17 with GRL-142
7MYP	;	1.65	;	Crystal Structure of HIV-1 PRS17 with GRL-44-10A
6CF2	;	3.0	;	Crystal structure of HIV-1 Rev (residues 1-93)-RNA aptamer complex
5C42	;	3.5	;	Crystal Structure of HIV-1 Reverse Transcriptase (K101P) Variant in Complex with 8-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)indolizine-2-carbonitrile (JLJ555), a non-nucleoside inhibitor
3T1A	;	2.4	;	Crystal Structure of HIV-1 Reverse Transcriptase (K103N mutant) in Complex with Inhibitor M05
3TAM	;	2.51	;	Crystal structure of HIV-1 reverse transcriptase (K103N mutant) in complex with inhibitor M06
4RW7	;	3.014	;	Crystal Structure of HIV-1 Reverse Transcriptase (K103N, Y181C) variant in complex with (E)-3-(3-chloro-5-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)phenyl)acrylonitrile (JLJ532), a non-nucleoside inhibitor
5VQZ	;	2.23	;	Crystal Structure of HIV-1 Reverse Transcriptase (K103N, Y181C) Variant in Complex with 2-chloro-N-(6-cyano-3-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)-4-methylnaphthalen-1-yl)-N-methylacetamide (JLJ686), a Non-nucleoside Inhibitor
5VQY	;	2.35	;	Crystal Structure of HIV-1 Reverse Transcriptase (K103N, Y181C) Variant in Complex with N-(6-cyano-3-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)-4-methylnaphthalen-1-yl)-N-methylacrylamide (JLJ684), a Non-nucleoside Inhibitor
4RW4	;	2.674	;	Crystal Structure of HIV-1 Reverse Transcriptase (K103N,Y181C) variant in complex with (E)-3-(3-chloro-5-(4-chloro-2-(2-(2,4-dioxo-3,4- dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)phenyl)acrylonitrile (JLJ494), a Non-nucleoside Inhibitor
3V6D	;	2.7048	;	Crystal structure of HIV-1 reverse transcriptase (RT) cross-linked with AZT-terminated DNA
4H4O	;	2.9	;	Crystal Structure of HIV-1 Reverse Transcriptase (RT) in Complex with (E)-3-(3-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)- 4-fluorophenoxy)-5-fluorophenyl)acrylonitrile (JLJ506), A Non-nucleoside inhibitor
6UL5	;	2.23	;	Crystal structure of HIV-1 reverse transcriptase (RT) in complex with 4-[(4-{4-[(E)-2-cyanoethenyl]-2,6-dimethylphenoxy}thieno[3,2-d]pyrimidin-2-yl)amino]-2-fluorobenzonitrile (24b), a non-nucleoside RT inhibitor
2YKM	;	2.9	;	Crystal structure of HIV-1 Reverse Transcriptase (RT) in complex with a Difluoromethylbenzoxazole (DFMB) Pyrimidine Thioether derivative, a non-nucleoside RT inhibitor (NNRTI)
2YKN	;	2.12	;	Crystal structure of HIV-1 Reverse Transcriptase (RT) in complex with a Difluoromethylbenzoxazole (DFMB) Pyrimidine Thioether derivative, a non-nucleoside RT inhibitor (NNRTI)
6HAK	;	3.95	;	Crystal structure of HIV-1 reverse transcriptase (RT) in complex with a double stranded RNA represents the RT transcription initiation complex prior to nucleotide incorporation
2RKI	;	2.3	;	Crystal Structure of HIV-1 Reverse Transcriptase (RT) in Complex with a triazole derived NNRTI
4KO0	;	1.95	;	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) IN COMPLEX WITH an anilinylpyrimidine derivative (JLJ-135)
2I5J	;	3.15	;	Crystal structure of HIV-1 reverse transcriptase (RT) in complex with DHBNH, an RNASE H inhibitor
1S9G	;	2.8	;	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) IN COMPLEX WITH JANSSEN-R120394.
1S9E	;	2.6	;	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) IN COMPLEX WITH JANSSEN-R129385
1S6Q	;	3.0	;	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) IN COMPLEX WITH JANSSEN-R147681
2BAN	;	2.95	;	Crystal structure of HIV-1 reverse transcriptase (RT) in complex with JANSSEN-R157208
2B5J	;	2.9	;	Crystal structure of HIV-1 reverse transcriptase (RT) in complex with JANSSEN-R165481
1SUQ	;	3.0	;	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) IN COMPLEX WITH JANSSEN-R185545
2BE2	;	2.43	;	Crystal structure of HIV-1 reverse transcriptase (RT) in complex with R221239
4G1Q	;	1.51	;	Crystal structure of HIV-1 reverse transcriptase (RT) in complex with Rilpivirine (TMC278, Edurant), a non-nucleoside rt-inhibiting drug
3IRX	;	2.8	;	Crystal Structure of HIV-1 reverse transcriptase (RT) in complex with the Non-nucleoside RT Inhibitor (E)-S-Methyl 5-(1-(3,7-Dimethyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)-5-(5-methyl-1,3,4-oxadiazol-2-yl)pent-1-enyl)-2-methoxy-3-methylbenzothioate.
2B6A	;	2.65	;	Crystal structure of HIV-1 reverse transcriptase (RT) in complex with THR-50
2ZD1	;	1.8	;	Crystal Structure of HIV-1 Reverse Transcriptase (RT) in Complex with TMC278 (Rilpivirine), A Non-nucleoside RT Inhibitor
3QO9	;	2.6	;	Crystal structure of HIV-1 Reverse Transcriptase (RT) in complex with TSAO-T, a non-nucleoside RT inhibitor (NNRTI)
7TAZ	;	2.4	;	Crystal structure of HIV-1 reverse transcriptase (RT) in complex with VM-1500A, a non-nucleoside RT inhibitor
4R5P	;	2.894	;	Crystal structure of HIV-1 reverse transcriptase (RT) with DNA and a nucleoside triphosphate mimic alpha-carboxy nucleoside phosphonate inhibitor
3V4I	;	2.7983	;	Crystal structure of HIV-1 reverse transcriptase (RT) with DNA and AZTTP
3V81	;	2.8503	;	Crystal structure of HIV-1 reverse transcriptase (RT) with DNA and the nonnucleoside inhibitor nevirapine
4DG1	;	2.15	;	Crystal structure of HIV-1 reverse transcriptase (RT) with polymorphism mutation K172A and K173A
3T19	;	2.6	;	Crystal structure of HIV-1 reverse transcriptase (wild type) in complex with inhibitor M05
4RW9	;	2.986	;	Crystal Structure of HIV-1 Reverse Transcriptase (Y181C) variant in complex with (E)-3-(3-chloro-5-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)phenyl)acrylonitrile (JLJ532), a non-nucleoside inhibitor
4RW6	;	2.631	;	Crystal Structure of HIV-1 Reverse Transcriptase (Y181C) variant in complex with (E)-3-(3-chloro-5-(4-chloro-2-(2-(2,4-dioxo-3,4- dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)phenyl)acrylonitrile (JLJ494), a Non-nucleoside Inhibitor
5VQX	;	2.4	;	Crystal Structure of HIV-1 Reverse Transcriptase (Y181C) Variant in Complex with 2-chloro-N-(6-cyano-3-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)-4-methylnaphthalen-1-yl)-N-methylacetamide (JLJ686), a Non-nucleoside Inhibitor
6X4A	;	2.537	;	Crystal Structure of HIV-1 Reverse Transcriptase (Y181C) Variant in Complex with 5-chloro-7-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)-8-methyl-2-naphthonitrile (JLJ651), a Non-nucleoside Inhibitor
6X49	;	2.745	;	Crystal Structure of HIV-1 Reverse Transcriptase (Y181C) Variant in Complex with 7-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)-2-naphthonitrile (JLJ649), a Non-nucleoside Inhibitor
6X4F	;	2.72	;	Crystal Structure of HIV-1 Reverse Transcriptase (Y181C) Variant in Complex with methyl 2-(6-cyano-3-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)-4-methylnaphthalen-1-yl)acetate (JLJ681), a Non-nucleoside Inhibitor
5VQU	;	2.6	;	Crystal Structure of HIV-1 Reverse Transcriptase (Y181C) Variant in Complex with N-(6-cyano-3-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)-4-methylnaphthalen-1-yl)-2-fluoro-N-methylacetamide (JLJ683), a Non-nucleoside Inhibitor
5VQV	;	2.58	;	Crystal Structure of HIV-1 Reverse Transcriptase (Y181C) Variant in Complex with N-(6-cyano-3-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)-4-methylnaphthalen-1-yl)-N-methylacrylamide (JLJ684), a Non-nucleoside Inhibitor
5VQW	;	2.5	;	Crystal Structure of HIV-1 Reverse Transcriptase (Y181C) Variant in Complex with N-(6-cyano-3-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)-4-methylnaphthalen-1-yl)acrylamide (JLJ685), a Non-nucleoside Inhibitor
8STR	;	2.77	;	Crystal Structure of HIV-1 Reverse Transcriptase (Y181C) varient in Complex with 5-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)-4-fluorophenoxy)-7-fluoro-2-naphthonitrile (JLJ636), a non-nucleoside inhibitor
8STQ	;	2.955	;	Crystal Structure of HIV-1 Reverse Transcriptase (Y181C) varient in Complex with 5-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)-2-naphthonitrile (JLJ600), a non-nucleoside inhibitor
8STP	;	3.09	;	Crystal Structure of HIV-1 Reverse Transcriptase (Y181C) varient in Complex with 8-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)indolizine-2-carbonitrile (JLJ555), a non-nucleoside inhibitor
8STV	;	2.78	;	Crystal Structure of HIV-1 Reverse Transcriptase (Y181C, V106A) variant in Complex with 5-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)-2-naphthonitrile (JLJ600), a non-nucleoside inhibitor
8STU	;	2.76	;	Crystal Structure of HIV-1 Reverse Transcriptase (Y181C, V106A) variant in Complex with 8-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)-4-fluorophenoxy)-6-fluoroindolizine-2-carbonitrile (JLJ578), a non-nucleoside inhibitor
8STS	;	3.02	;	Crystal Structure of HIV-1 Reverse Transcriptase (Y181C, V106A) varient in Complex with 5-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)-4-fluorophenoxy)-7-fluoro-2-naphthonitrile (JLJ636), a non-nucleoside inhibitor
8STT	;	2.62	;	Crystal Structure of HIV-1 Reverse Transcriptase (Y181C, V106A) varient in Complex with 8-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)indolizine-2-carbonitrile (JLJ555), a non-nucleoside inhibitor
1RT1	;	2.55	;	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE COMPLEXED WITH MKC-442
1RT2	;	2.55	;	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE COMPLEXED WITH TNK-651
1R0A	;	2.8	;	Crystal structure of HIV-1 reverse transcriptase covalently tethered to DNA template-primer solved to 2.8 angstroms
4LSL	;	2.69	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with (E)-3-(3-(4-chloro-2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)phenyl)acrylonitrile (JLJ476), a non-nucleoside inhibitor
4LSN	;	3.1	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with (E)-3-(3-bromo-5-(4-chloro-2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)phenyl)acrylonitrile (JLJ518), a non-nucleoside inhibitor
7SNP	;	2.89	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with (E)-3-(3-chloro-5-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)-4-(2-morpholinoethoxy)phenoxy)phenyl)acrylonitrile (JLJ530)
4RW8	;	2.878	;	Crystal Structure of HIV-1 Reverse Transcriptase in complex with (E)-3-(3-chloro-5-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)phenyl)acrylonitrile (JLJ532), a non-nucleoside inhibitor'
4H4M	;	2.85	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with (E)-3-(3-chloro-5-(4-chloro-2-(2-(2,4-dioxo-3,4- dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)phenyl)acrylonitrile (JLJ494), a Non-nucleoside Inhibitor
7SO1	;	2.727	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with (E)-4-((4-((4-(2-cyanovinyl)-2,6-dimethylphenyl)amino)-6-(3-morpholinopropoxy)-1,3,5-triazin-2-yl)amino)benzonitrile (JLJ564)
7KRF	;	2.6	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with (E)-4-(3-(2-cyanovinyl)-5-fluorophenoxy)-3-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenyl sulfurofluoridate (JLJ710)
7KRC	;	2.65	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with (E)-4-(3-chloro-5-(2-cyanovinyl)phenoxy)-3-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenyl sulfurofluoridate (JLJ709)
8U6A	;	2.37	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with (JLJ729), a non-nucleoside inhibitor
8U6C	;	2.7	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 2-chloro-N-(4-chloro-3-(3-chloro-5-cyanophenoxy)phenethyl)acetamide (JLJ732), a non-nucleoside inhibitor
5VQT	;	2.556	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 2-chloro-N-(6-cyano-3-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)-4-methylnaphthalen-1-yl)-N-methylacetamide (JLJ686), a Non-nucleoside Inhibitor
8U6P	;	2.81	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 3-(2-((2-cyanoindolizin-8-yl)oxy)phenoxy)-N,N-dimethylpropanamide (JLJ754), a non-nucleoside inhibitor
8U6R	;	2.87	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 3-(2-((2-cyanoindolizin-8-yl)oxy)phenoxy)-N-(2,2-difluoroethyl)propanamide (JLJ756), a non-nucleoside inhibitor
8U6N	;	2.74	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 3-(2-((6-cyanonaphthalen-1-yl)oxy)phenoxy)-N,N-dimethylpropanamide (JLJ752), a non-nucleoside inhibitor
8U6G	;	2.77	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 3-(2-(2-(3-acryloyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)ethoxy)-4-chlorophenoxy)-5-chlorobenzonitrile (JLJ744), a non-nucleoside inhibitor
8U6H	;	2.99	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 3-(2-(2-(3-acryloyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)ethoxy)-4-chlorophenoxy)-5-chlorobenzonitrile (JLJ744), a non-nucleoside inhibitor
8U69	;	2.45	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 3-chloro-5-(4-chloro-2-(2-(5-chloro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)benzonitrile (JLJ334), a non-nucleoside inhibitor
4O4G	;	2.712	;	Crystal Structure of HIV-1 Reverse Transcriptase in complex with 4-((4-(mesitylamino)-1,3,5-triazin-2-yl)amino)benzonitrile (JLJ527), a non-nucleoside inhibitor
4O44	;	2.889	;	Crystal Structure of HIV-1 Reverse Transcriptase in complex with 4-((4-(mesitylamino)-6-(3-morpholinopropoxy)-1,3,5-triazin-2-yl)amino)benzonitrile (JLJ529), a non-nucleoside inhibitor
4KKO	;	2.89	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 4-((4-methoxy-6-(2-morpholinoethoxy)-1,3,5-triazin-2-yl)amino)-2-((3-methylbut-2-en-1-yl)oxy)benzonitrile (JLJ513), a non-nucleoside inhibitor
7KRE	;	2.728	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 4-((6-cyanonaphthalen-1-yl)oxy)-3-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenyl sulfurofluoridate (JLJ704)
7KRD	;	2.7	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 4-(3-chloro-5-cyanophenoxy)-3-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenyl sulfurofluoridate (JLJ702)
5TW3	;	2.853	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 5-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)-4-fluorophenoxy)-7-fluoro-2-naphthonitrile (JLJ636), a Non-nucleoside Inhibitor
4WE1	;	2.491	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 5-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)-2-naphthonitrile (JLJ600)
6OE3	;	2.9	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 5-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)-7-fluoro-2-naphthonitrile (JLJ635), a Non-nucleoside Inhibitor
8U6T	;	2.25	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 5-(2-(2-(3-acryloyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)ethoxy)phenoxy)-2-naphthonitrile (JLJ758), a non-nucleoside inhibitor
6X4D	;	2.65	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 5-(cyclopropylmethyl)-7-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)-8-methyl-2-naphthonitrile (JLJ678), a Non-nucleoside Inhibitor
5TER	;	2.7	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 5-chloro-7-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)-8-methyl-2-naphthonitrile (JLJ651), a Non-nucleoside Inhibitor
7SNZ	;	2.368	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 6-((2-((4-cyanophenyl)amino)pyrimidin-4-yl)amino)-5,7-dimethylindolizine-2-carbonitrile (JLJ604)
5C25	;	2.841	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 6-((4-((4-cyanophenyl)amino)-1,3,5-triazin-2-yl)amino)-5,7-dimethyl-2-naphthonitrile (JLJ639), a Non-nucleoside Inhibitor
5C24	;	2.6	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 7-((4-((4-cyanophenyl)amino)-1,3,5-triazin-2-yl)amino)-6,8-dimethylindolizine-2-carbonitrile (JLJ605), a non-nucleoside inhibitor
6X4C	;	2.861	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 7-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)-4-fluorophenoxy)-5,8-dimethyl-2-naphthonitrile (JLJ658), a Non-nucleoside Inhibitor
6X47	;	2.767	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 7-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)-2-naphthonitrile (JLJ649), a Non-nucleoside Inhibitor
6X4B	;	2.5	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 7-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)-5-fluoro-8-methyl-2-naphthonitrile (JLJ655), a Non-nucleoside Inhibitor
1JLQ	;	3.0	;	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH 739W94
4MFB	;	2.88	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 8-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)indolizine-2-carbonitrile (JLJ555), a non-nucleoside inhibitor
8U6S	;	2.99	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 8-(2-(3-morpholino-3-oxopropoxy)phenoxy)indolizine-2-carbonitrile (JLJ757), a non-nucleoside inhibitor
8U6Q	;	2.55	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 8-(2-(3-oxo-3-(pyrrolidin-1-yl)propoxy)phenoxy)indolizine-2-carbonitrile (JLJ755), a non-nucleoside inhibitor
1HYS	;	3.0	;	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH A POLYPURINE TRACT RNA:DNA
1C0T	;	2.7	;	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH BM+21.1326
1C0U	;	2.52	;	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH BM+50.0934
4PWD	;	3.0	;	Crystal structure of HIV-1 reverse transcriptase in complex with bulge-RNA/DNA and Nevirapine
1FK9	;	2.5	;	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH DMP-266(EFAVIRENZ)
4Q0B	;	3.3	;	Crystal structure of HIV-1 reverse transcriptase in complex with gap-RNA/DNA and Nevirapine
1C1B	;	2.5	;	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH GCA-186
3DLE	;	2.5	;	Crystal structure of hiv-1 reverse transcriptase in complex with GF128590.
2OPP	;	2.55	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with GW420867X.
1TKT	;	2.6	;	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH GW426318
1TKZ	;	2.81	;	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH GW429576
1TL3	;	2.8	;	Crystal structure of hiv-1 reverse transcriptase in complex with gw450557
1TL1	;	2.9	;	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH GW451211
1TKX	;	2.85	;	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH GW490745
3DLG	;	2.2	;	Crystal structure of hiv-1 reverse transcriptase in complex with GW564511.
7U5Z	;	2.3	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with JLJ353
6X4E	;	2.6	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with methyl 2-(6-cyano-3-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)-4-methylnaphthalen-1-yl)acetate (JLJ681), a Non-nucleoside Inhibitor
8U6I	;	2.46	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with N-(2-(2-((2-cyanoindolizin-8-yl)oxy)phenoxy)ethyl)-N-methylacrylamide (JLJ745), a non-nucleoside inhibitor
8U6M	;	2.62	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with N-(2-(2-((6-chloro-2-cyanoindolizin-8-yl)oxy)phenoxy)ethyl)-N-methylacrylamide (JLJ751), a non-nucleoside inhibitor
8U6K	;	2.72	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with N-(2-(2-((6-cyanonaphthalen-1-yl)oxy)phenoxy)ethyl)-N-methylacrylamide (JLJ747), a non-nucleoside inhibitor
8U6D	;	2.33	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with N-(2-(4-chloro-3-(3-chloro-5-cyanophenoxy)phenoxy)ethyl)-N-methylacrylamide (JLJ736), a non-nucleoside inhibitor
8U6J	;	2.64	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with N-(2-(5-chloro-2-((2-cyanoindolizin-8-yl)oxy)phenoxy)ethyl)-N-methylacrylamide (JLJ746), a non-nucleoside inhibitor
8U6L	;	2.486	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with N-(2-(5-chloro-2-((6-cyanonaphthalen-1-yl)oxy)phenoxy)ethyl)-N-methylacrylamide (JLJ748), a non-nucleoside inhibitor
8U6F	;	2.69	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with N-(2-(5-chloro-2-(3-chloro-5-cyanophenoxy)phenoxy)ethyl)-N-methylacrylamide (JLJ742), a non-nucleoside inhibitor
8U6E	;	2.31	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with N-(4-chloro-3-(3-chloro-5-cyanophenoxy)phenethyl)-N-methylacrylamide (JLJ738), a non-nucleoside inhibitor
8U6B	;	2.35	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with N-(4-chloro-3-(3-chloro-5-cyanophenoxy)phenethyl)acrylamide (JLJ731), a non-nucleoside inhibitor
5VQQ	;	2.55	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with N-(6-cyano-3-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)-4-methylnaphthalen-1-yl)-2-fluoro-N-methylacetamide (JLJ683), a Non-nucleoside Inhibitor
5VQR	;	2.55	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with N-(6-cyano-3-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)-4-methylnaphthalen-1-yl)-N-methylacrylamide (JLJ684), a Non-nucleoside Inhibitor
5VQS	;	2.504	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with N-(6-cyano-3-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)-4-methylnaphthalen-1-yl)acrylamide (JLJ685), a Non-nucleoside Inhibitor
3LAN	;	2.55	;	Crystal structure of HIV-1 reverse transcriptase in complex with N1-butyl pyrimidinedione non-nucleoside inhibitor
3LAL	;	2.51	;	Crystal structure of HIV-1 reverse transcriptase in complex with N1-ethyl pyrimidinedione non-nucleoside inhibitor
3LAK	;	2.3	;	Crystal structure of HIV-1 reverse transcriptase in complex with N1-heterocycle pyrimidinedione non-nucleoside inhibitor
3LAM	;	2.76	;	Crystal structure of HIV-1 reverse transcriptase in complex with N1-propyl pyrimidinedione non-nucleoside inhibitor
8FFX	;	2.42	;	Crystal structure of HIV-1 reverse transcriptase in complex with non-nucleoside inhibitor 19980
6C0N	;	2.001	;	Crystal structure of HIV-1 reverse transcriptase in complex with non-nucleoside inhibitor 25a
6C0J	;	1.92	;	Crystal structure of HIV-1 reverse transcriptase in complex with non-nucleoside inhibitor K-5a2
1DTQ	;	2.8	;	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH PETT-1 (PETT131A94)
1DTT	;	3.0	;	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH PETT-2 (PETT130A94)
4I2P	;	2.2964	;	Crystal structure of HIV-1 reverse transcriptase in complex with rilpivirine (TMC278) based analogue
4PQU	;	2.508	;	Crystal structure of HIV-1 Reverse Transcriptase in complex with RNA/DNA and dATP
4PUO	;	2.901	;	Crystal structure of HIV-1 reverse transcriptase in complex with RNA/DNA and Nevirapine
1EP4	;	2.5	;	Crystal structure of HIV-1 reverse transcriptase in complex with S-1153
1C1C	;	2.5	;	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH TNK-6123
8U6O	;	2.48	;	Crystal Structure of HIV-1 Reverse Transcriptase in Complex with5-(2-(3-oxo-3-(pyrrolidin-1-yl)propoxy)phenoxy)-2-naphthonitrile (JLJ753), a non-nucleoside inhibitor
6DUG	;	2.225	;	Crystal structure of HIV-1 reverse transcriptase K101P mutant in complex with non-nucleoside inhibitor 25a
7SO3	;	2.767	;	Crystal Structure of HIV-1 Reverse Transcriptase K103N/Y181C Variant in Complex with (E)-4-((4-((4-(2-cyanovinyl)-2,6-dimethylphenyl)amino)-6-(3-morpholinopropoxy)-1,3,5-triazin-2-yl)amino)benzonitrile (JLJ564)
6DUF	;	1.963	;	Crystal structure of HIV-1 reverse transcriptase V106A/F227L mutant in complex with non-nucleoside inhibitor 25a
7OXQ	;	3.3	;	Crystal structure of HIV-1 reverse transcriptase with a double stranded DNA in complex with fragment 048 at the transient P-pocket.
7OZ5	;	3.37	;	Crystal structure of HIV-1 reverse transcriptase with a double stranded DNA in complex with fragment 166 at the transient P-pocket.
7OZ2	;	2.85	;	Crystal structure of HIV-1 reverse transcriptase with a double stranded DNA showing a transient P-pocket
7SO2	;	3.089	;	Crystal Structure of HIV-1 Reverse Transcriptase Y181C Variant in Complex with (E)-4-((4-((4-(2-cyanovinyl)-2,6-dimethylphenyl)amino)-6-(3-morpholinopropoxy)-1,3,5-triazin-2-yl)amino)benzonitrile (JLJ564)
6DUH	;	2.003	;	Crystal structure of HIV-1 reverse transcriptase Y181I mutant in complex with non-nucleoside inhibitor 25a
1FIR	;	3.3	;	CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTION PRIMER TRNA(LYS3)
3HYF	;	1.7	;	Crystal structure of HIV-1 RNase H p15 with engineered E. coli loop and active site inhibitor
3QIN	;	1.6967	;	Crystal Structure of HIV-1 RNase H p15 with engineered E. coli loop and pyrimidinol carboxylic acid inhibitor
3QIO	;	1.4011	;	Crystal Structure of HIV-1 RNase H with engineered E. coli loop and N-hydroxy quinazolinedione inhibitor
3ISN	;	2.5	;	Crystal structure of HIV-1 RT bound to A 6-vinylpyrimidine inhibitor
7KWU	;	2.02	;	Crystal Structure of HIV-1 RT in Complex with 16c (K07-15)
7LQU	;	2.6	;	Crystal Structure of HIV-1 RT in Complex with NBD-14075
7LPW	;	2.32	;	Crystal Structure of HIV-1 RT in Complex with NBD-14189
7LPX	;	2.45	;	Crystal Structure of HIV-1 RT in Complex with NBD-14270
8FE8	;	2.5	;	Crystal Structure of HIV-1 RT in Complex with the non-nucleoside inhibitor 18b1
3C5D	;	1.8	;	Crystal structure of HIV-1 subtype F DIS extended duplex RNA bound to lividomycin
3C7R	;	1.7	;	Crystal Structure of HIV-1 subtype F DIS extended duplex RNA bound to neomycin
3C44	;	2.0	;	Crystal structure of HIV-1 subtype F DIS extended duplex RNA bound to paromomycin
3C3Z	;	1.5	;	Crystal structure of HIV-1 subtype F DIS extended duplex RNA bound to ribostamycin
3DVV	;	2.0	;	Crystal structure of HIV-1 subtype F DIS extended duplex RNA bound to ribostamycin (U267OMe)
3MIA	;	3.0	;	Crystal structure of HIV-1 Tat complexed with ATP-bound human P-TEFb
3MI9	;	2.1	;	Crystal structure of HIV-1 Tat complexed with human P-TEFb
4OR5	;	2.9	;	Crystal structure of HIV-1 Tat complexed with human P-TEFb and AFF4
2BGR	;	2.0	;	Crystal structure of HIV-1 Tat derived nonapeptides Tat(1-9) bound to the active site of Dipeptidyl peptidase IV (CD26)
3DMJ	;	2.6	;	CRYSTAL STRUCTURE OF HIV-1 V106A and Y181C MUTANT REVERSE TRANSCRIPTASE IN COMPLEX WITH GW564511.
5B56	;	2.3	;	Crystal structure of HIV-1 VPR C-Terminal domain and DIBB-M-Importin-Alpha2 complex
7SO4	;	2.95	;	Crystal Structure of HIV-1 Y181C mutant Reverse Transcriptase in Complex with 5-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)-7-fluoro-2-naphthonitrile (JLJ635), a Non-nucleoside Inhibitor
6CGF	;	1.94	;	Crystal structure of HIV-1 Y188L mutant reverse transcriptase in complex with non-nucleoside inhibitor K-5a2
4LAJ	;	2.14	;	Crystal structure of HIV-1 YU2 envelope gp120 glycoprotein in complex with CD4-mimetic miniprotein, M48U1, and llama single-domain, broadly neutralizing, co-receptor binding site antibody, JM4
6K6M	;	2.072	;	Crystal structure of HIV-2 Nef protein
1MU2	;	2.35	;	CRYSTAL STRUCTURE OF HIV-2 REVERSE TRANSCRIPTASE
3IDX	;	2.5	;	Crystal structure of HIV-gp120 core in complex with CD4-binding site antibody b13, space group C222
3IDY	;	3.2	;	Crystal structure of HIV-gp120 core in complex with CD4-binding site antibody b13, space group C2221
2NPH	;	1.65	;	Crystal structure of HIV1 protease in situ product complex
2YU1	;	2.7	;	Crystal structure of hJHDM1A complexed with a-ketoglutarate
2YU2	;	2.7	;	Crystal structure of hJHDM1A without a-ketoglutarate
3E8K	;	3.65	;	Crystal structure of HK97 Prohead II
8OME	;	2.0	;	Crystal structure of hKHK-A in complex with compound-4
8OMF	;	2.14	;	Crystal structure of hKHK-C in complex with compound-4
6KR0	;	2.3	;	Crystal structure of HL homo-diabody
3MJ8	;	2.94	;	Crystal structure of HL4E10 Fab, a hamster Ab stimulatory for gammadelta T cells
4NQV	;	2.39	;	Crystal Structure of HLA A*0101 in complex with NP44, an 9-mer influenza epitope
4NQX	;	2.0	;	Crystal Structure of HLA A*0101 in complex with NP44-S7N, an 9-mer influenza epitope
3OX8	;	2.16	;	Crystal Structure of HLA A*02:03 Bound to HBV Core 18-27
3OXR	;	1.7	;	Crystal Structure of HLA A*02:06 Bound to HBV Core 18-27
3OXS	;	1.75	;	Crystal Structure of HLA A*02:07 Bound to HBV Core 18-27
7UC5	;	1.95	;	Crystal Structure of HLA A*0301 in complex with ILRGSVAHK, a 9-mer epitope from Influenza A
7S8Q	;	2.08	;	Crystal Structure of HLA A*1101 in complex with KTNGNAFIGK, an 10-mer epitope from Influenza B
7S8S	;	1.87	;	Crystal Structure of HLA A*1101 in complex with RVLVNGTFLK, an 10-mer epitope from Influenza B
7S8R	;	2.95	;	Crystal Structure of HLA A*1101 in complex with SALEWIKNK, an 9-mer epitope from Influenza B
7JYW	;	2.9	;	Crystal Structure of HLA A*2402 in complex with TYQWIIRNW, an 9-mer influenza epitope
7JYX	;	2.95	;	Crystal Structure of HLA A*2402 in complex with TYQWIIRNWET, an 11-mer epitope from Influenza
6XQA	;	2.16	;	Crystal Structure of HLA A*2402 in complex with TYQWVLKNL, an 9-mer epitope from Influenza B virus
7JYV	;	1.51	;	Crystal Structure of HLA A*2402 in complex with YFSPIRVTF, an 9-mer influenza epitope
6TRN	;	1.35	;	Crystal structure of HLA A2*01-AVYDGREHTV
4QRS	;	1.4	;	Crystal Structure of HLA B*0801 in complex with ELK_IYM, ELKRKMIYM
4QRT	;	1.4	;	Crystal Structure of HLA B*0801 in complex with ELN_YYM, ELNRKMIYM
4QRU	;	1.6	;	Crystal Structure of HLA B*0801 in complex with ELR_MYM, ELRRKMMYM
4QRQ	;	1.7	;	Crystal Structure of HLA B*0801 in complex with HSKKKCDEL
4QRP	;	2.9	;	Crystal Structure of HLA B*0801 in complex with HSKKKCDEL and DD31 TCR
3LKN	;	2.0	;	Crystal Structure of HLA B*3501 in complex with influenza NP418 epitope from 1918 strain
3LKO	;	1.8	;	Crystal Structure of HLA B*3501 in complex with influenza NP418 epitope from 1934 strain
3LKP	;	1.8	;	Crystal Structure of HLA B*3501 in complex with influenza NP418 epitope from 1972 strain
3LKQ	;	1.8	;	Crystal Structure of HLA B*3501 in complex with influenza NP418 epitope from 1977 strain
3LKS	;	1.9	;	Crystal Structure of HLA B*3501 in complex with influenza NP418 epitope from 1980 strain
3LKR	;	2.0	;	Crystal Structure of HLA B*3501 in complex with influenza NP418 epitope from 2009 H1N1 swine origin strain
7SIG	;	1.741	;	Crystal Structure of HLA B*3501 in complex with NPDIVIYQY, an 9-mer epitope from HIV-I
4QRR	;	3.0	;	Crystal Structure of HLA B*3501-IPS in complex with a Delta-Beta TCR, clone 12 TCR
7SIH	;	1.9	;	Crystal Structure of HLA B*3503 in complex with NPDIVIYQY, an 9-mer epitope from HIV-I
7SIF	;	1.73	;	Crystal Structure of HLA B*3505 in complex with NPDIVIYQY, an 9-mer epitope from HIV-I
3BW9	;	1.75	;	Crystal Structure of HLA B*3508 in complex with a HCMV 12-mer peptide from the pp65 protein
3BWA	;	1.3	;	Crystal Structure of HLA B*3508 in complex with a HCMV 8-mer peptide from the pp65 protein
3VFW	;	2.3	;	crystal structure of HLA B*3508 LPEP-P10Ala, peptide mutant P10-ala
3VFU	;	1.65	;	crystal structure of HLA B*3508 LPEP-P7Ala, peptide mutant P7-ala
3VFV	;	1.55	;	crystal structure of HLA B*3508 LPEP-P9Ala, peptide mutant P9-ala
3VFM	;	1.9	;	crystal structure of HLA B*3508 LPEP155A, HLA mutant Ala155
3VFO	;	1.7	;	crystal structure of HLA B*3508 LPEP157A, HLA mutant Ala157
3VFP	;	1.85	;	crystal structure of HLA B*3508 LPEP158G, HLA mutant Gly158
3VFR	;	1.85	;	crystal structure of HLA B*3508LPEP-P4Ala, peptide mutant P4-ala
3VFS	;	1.85	;	crystal structure of HLA B*3508LPEP-P5Ala , peptide mutant P5-ala
3VFT	;	1.947	;	crystal structure of HLA B*3508LPEP-P6Ala, peptide mutant P6-ala
3VFN	;	1.5	;	crystal structure of HLA B*3508LPEP151A, HLA mutant Ala151
3KPM	;	1.6	;	Crystal Structure of HLA B*4402 in complex with EEYLKAWTF, a mimotope
3KPL	;	1.96	;	Crystal Structure of HLA B*4402 in complex with EEYLQAFTY a self peptide from the ABCD3 protein
1M6O	;	1.6	;	Crystal Structure of HLA B*4402 in complex with HLA DPA*0201 peptide
3KPO	;	2.3	;	Crystal Structure of HLA B*4403 in complex with EEYLKAWTF, a mimotope
3KPN	;	2.0	;	Crystal Structure of HLA B*4403 in complex with EEYLQAFTY a self peptide from the ABCD3 protein
3KPQ	;	1.84	;	Crystal Structure of HLA B*4405 in complex with EEYLKAWTF, a mimotope
3KPP	;	1.9	;	Crystal Structure of HLA B*4405 in complex with EEYLQAFTY a self peptide from the ABCD3 protein
4G9D	;	1.6	;	Crystal Structure of HLA B2705-KK10
4G8I	;	1.6	;	Crystal Structure of HLA B2705-KK10-L6M
5XS3	;	2.5	;	Crystal structure of HLA Class I antigen
3C5J	;	1.8	;	Crystal structure of HLA DR52c
7DUU	;	2.51	;	Crystal structure of HLA molecule with an KIR receptor
1SYS	;	2.4	;	Crystal structure of HLA, B*4403, and peptide EEPTVIKKY
1B0R	;	2.9	;	CRYSTAL STRUCTURE OF HLA-A*0201 COMPLEXED WITH A PEPTIDE WITH THE CARBOXYL-TERMINAL GROUP SUBSTITUTED BY A METHYL GROUP
4U6X	;	1.68	;	Crystal Structure of HLA-A*0201 in complex with ALQDA, a 15 mer self-peptide
4U6Y	;	1.467	;	Crystal Structure of HLA-A*0201 in complex with FLNDK, a 15 mer self-peptide
5HHN	;	2.03	;	Crystal Structure of HLA-A*0201 in complex with M1-F5L
5HHP	;	1.9	;	Crystal Structure of HLA-A*0201 in complex with M1-G4E
5HHQ	;	2.1	;	Crystal Structure of HLA-A*0201 in complex with M1-L3W
5SWQ	;	2.0	;	Crystal Structure of HLA-A*0201 in complex with NA231, an influenza epitope
7KGS	;	1.58	;	Crystal Structure of HLA-A*0201 in complex with SARS-CoV-2 N138-146
7KGT	;	1.9	;	Crystal Structure of HLA-A*0201 in complex with SARS-CoV-2 N226-234
7KGP	;	1.396	;	Crystal Structure of HLA-A*0201 in complex with SARS-CoV-2 N316-324
1I4F	;	1.4	;	CRYSTAL STRUCTURE OF HLA-A*0201/MAGE-A4-PEPTIDE COMPLEX
1DUY	;	2.15	;	CRYSTAL STRUCTURE OF HLA-A*0201/OCTAMERIC TAX PEPTIDE COMPLEX
7KGR	;	1.55	;	Crystal Structure of HLA-A*0201in complex with SARS-CoV-2 N159-167
7KGQ	;	1.34	;	Crystal Structure of HLA-A*0201in complex with SARS-CoV-2 N222-230
7KGO	;	2.15	;	Crystal Structure of HLA-A*0201in complex with SARS-CoV-2 N351-359
7M8S	;	2.35	;	Crystal Structure of HLA-A*02:01 in complex with KLNDLCFTNV, an 10-mer epitope from SARS-CoV-2 Spike (S386-395)
7L1C	;	1.96	;	Crystal structure of HLA-A*03:01 in complex with a mutant PIK3CA peptide
7L1B	;	2.04	;	Crystal structure of HLA-A*03:01 in complex with a wild-type PIK3CA peptide
7MLE	;	2.2	;	Crystal Structure of HLA-A*03:01 in complex with VVRPSVASK, an 9-mer epitope from Influenza B virus
4MJ5	;	2.401	;	Crystal Structure of HLA-A*1101 in complex with H1-22, an influenza A(H1N1) virus epitope
4MJ6	;	2.57	;	Crystal Structure of HLA-A*1101 in complex with H7-22, an influenza A(H7N9) virus epitope
1X7Q	;	1.45	;	Crystal structure of HLA-A*1101 with sars nucleocapsid peptide
7OW4	;	1.81	;	Crystal structure of HLA-A*11:01 in complex with KRAS G12D peptide (VVVGADGVGK)
8I5E	;	2.2	;	Crystal structure of HLA-A*11:01 in complex with KRAS peptide (VVGAGGVGK)
7OW3	;	2.46	;	Crystal structure of HLA-A*11:01 in complex with KRAS peptide (VVVGAGGVGK)
7M8T	;	1.5	;	Crystal Structure of HLA-A*11:01 in complex with NSASFSTFK, an 9-mer epitope from SARS-CoV-2 spike (S370-378)
5WJL	;	3.15	;	Crystal Structure of HLA-A*11:01 with GTS1 peptide
5WJN	;	2.85	;	Crystal Structure of HLA-A*11:01-GTS3
7WT3	;	1.88766	;	Crystal structure of HLA-A*2402 complexed with 4-mer lipopeptide
7WT4	;	1.89459	;	Crystal structure of HLA-A*2402 complexed with 8-mer Influenza PB1 peptide
4F7M	;	2.4	;	Crystal Structure of HLA-A*2402 Complexed with a Newly Identified Peptide from 2009 H1N1 PA (649-658)
4F7T	;	1.7	;	Crystal Structure of HLA-A*2402 Complexed with a Newly Identified Peptide from 2009 H1N1 PB1 (498-505)
4F7P	;	1.9	;	Crystal Structure of HLA-A*2402 Complexed with a Newly Identified Peptide from 2009H1N1 PB1 (496-505)
2BCK	;	2.8	;	Crystal Structure of HLA-A*2402 Complexed with a telomerase peptide
5WWU	;	2.794	;	Crystal Structure of HLA-A*2402 in complex with 2009 pandemic influenza A(H1N1) virus and avian influenza A(H5N1) virus-derived peptide H1-25
5WWI	;	3.194	;	Crystal Structure of HLA-A*2402 in complex with avian influenza A(H7N9) virus-derived peptide H7-25 (data set 1)
5WWJ	;	2.29	;	Crystal Structure of HLA-A*2402 in complex with avian influenza A(H7N9) virus-derived peptide H7-25 (data set 1)
5WXD	;	3.295	;	Crystal Structure of HLA-A*2402 in complex with avian influenza A(H7N9) virus-derived peptide H7-25 (data set 1)
5WXC	;	2.295	;	Crystal Structure of HLA-A*2402 in complex with avian influenza A(H7N9) virus-derived peptide H7-25 (data set 2)
7JYU	;	2.75	;	Crystal Structure of HLA-A*2402 in complex with IYFSPIRVTF, an 10-mer epitope from Influenza B virus
7WT5	;	2.09508	;	Crystal structure of HLA-A*2450 complexed with 8-mer model peptide
6PBH	;	1.89	;	Crystal Structure of HLA-A*68:01 in complex with NP145-156, a 12 mer influenza peptide
4UQ3	;	2.1	;	Crystal structure of HLA-A0201 in complex with an azobenzene- containing peptide
4UQ2	;	2.43	;	Crystal structure of HLA-A1101 in complex with an azobenzene- containing peptide
1W72	;	2.15	;	Crystal structure of HLA-A1:MAGE-A1 in complex with Fab-Hyb3
1P7Q	;	3.4	;	Crystal Structure of HLA-A2 Bound to LIR-1, a Host and Viral MHC Receptor
6EWA	;	2.39	;	Crystal structure of HLA-A2 in complex with LILRB1
1JF1	;	1.85	;	Crystal structure of HLA-A2*0201 in complex with a decameric altered peptide ligand from the MART-1/Melan-A
1JHT	;	2.15	;	Crystal structure of HLA-A2*0201 in complex with a nonameric altered peptide ligand (ALGIGILTV) from the MART-1/Melan-A.
7BBG	;	2.64	;	CRYSTAL STRUCTURE OF HLA-A2-WT1-RMF AND FAB 11D06
6O9C	;	2.45	;	Crystal structure of HLA-A3*01 in complex with a mutant beta-catenin peptide
6O9B	;	2.2	;	Crystal structure of HLA-A3*01 in complex with a wild-type beta-catenin peptide
6EI2	;	1.61	;	Crystal Structure of HLA-A68 presenting a C-terminally extended peptide
6AT5	;	1.5	;	Crystal structure of HLA-B*07:02 in complex with an NY-ESO-1 peptide
7RZD	;	1.82	;	CRYSTAL STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH MLL(747-755) PEPTIDE
7RZJ	;	1.8	;	CRYSTAL STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH MLL(747-755) PHOSPHOPEPTIDE
6UJ7	;	1.9	;	Crystal structure of HLA-B*07:02 with R140Q mutant IDH2 peptide
6UJ9	;	2.9	;	Crystal structure of HLA-B*07:02 with R140Q mutant IDH2 peptide in complex with Fab
6UJ8	;	2.25	;	Crystal structure of HLA-B*07:02 with wild-type IDH2 peptide
3X13	;	1.8	;	Crystal structure of HLA-B*0801.N80I
3X14	;	2.0	;	Crystal structure of HLA-B*0801.N80I.R82L.G83R
7NUI	;	2.0	;	Crystal structure of HLA-B*08:01 in complex with ELRSRYWAI viral peptide
7YG3	;	1.5	;	Crystal structure of HLA-B*13:01
8ELG	;	1.65	;	Crystal Structure of HLA-B*15:01 in complex with spike derived peptide NQKLIANAF from OC43 virus
8ELH	;	1.85	;	Crystal Structure of HLA-B*15:01 in complex with spike derived peptide NQKLIANQF from SARS-CoV-2 virus
6MT3	;	1.21	;	Crystal Structure of HLA-B*18:01 in complex with NP338 influenza peptide
6PYL	;	1.52	;	Crystal Structure of HLA-B*2703 in complex with KK10, an HIV peptide
6PZ5	;	1.53	;	Crystal Structure of HLA-B*2703 in complex with LRN, a self-peptide
6PYV	;	1.45	;	Crystal Structure of HLA-B*2703-P47G in complex with LRN, a self-peptide
3LV3	;	1.94	;	Crystal structure of HLA-B*2705 complexed with a peptide derived from the human voltage-dependent calcium channel alpha1 subunit (residues 513-521)
3B6S	;	1.8	;	Crystal Structure of hla-b*2705 Complexed with the Citrullinated Vasoactive Intestinal Peptide Type 1 Receptor (vipr) Peptide (residues 400-408)
3DTX	;	2.1	;	Crystal structure of HLA-B*2705 complexed with the double citrullinated vasoactive intestinal peptide type 1 receptor (VIPR) peptide (residues 400-408)
2A83	;	1.4	;	Crystal structure of hla-b*2705 complexed with the glucagon receptor (gr) peptide (residues 412-420)
1UXS	;	1.55	;	CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2)OF EPSTEIN-BARR VIRUS
1W0V	;	2.27	;	Crystal Structure Of HLA-B*2705 Complexed With the self-Peptide TIS from EGF-response factor 1
1OGT	;	1.47	;	CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (VIPR) PEPTIDE (RESIDUES 400-408)
6PYJ	;	1.44	;	Crystal Structure of HLA-B*2705 in complex with LRN, a self-peptide
6PYW	;	1.38	;	Crystal Structure of HLA-B*2705-W60A in complex with LRN, a self-peptide
3D18	;	1.74	;	Crystal structure of HLA-B*2709 complexed with a variant of the latent membrane protein 2 peptide (LMP2(L)) of epstein-barr virus
3HCV	;	1.95	;	Crystal structure of HLA-B*2709 complexed with the double citrullinated vasoactive intestinal peptide type 1 receptor (VIPR) peptide (residues 400-408)
3CZF	;	1.2	;	Crystal structure of HLA-B*2709 complexed with the glucagon receptor (GR) peptide (residues 412-420)
1UXW	;	1.71	;	CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2) OF EPSTEIN-BARR VIRUS
1W0W	;	2.11	;	Crystal Structure Of HLA-B*2709 Complexed With the self-Peptide TIS from EGF-response factor 1
1OF2	;	2.2	;	Crystal structure of HLA-B*2709 complexed with the vasoactive intestinal peptide type 1 receptor (VIPR) peptide (residues 400-408)
5IB2	;	1.44	;	Crystal structure of HLA-B*27:05 complexed with the self-peptide pVIPR
5IB3	;	1.91	;	Crystal structure of HLA-B*27:05 complexed with the self-peptide pVIPR and Copper
5IB4	;	1.95	;	Crystal structure of HLA-B*27:05 complexed with the self-peptide pVIPR and Nickel
5IB1	;	1.91	;	Crystal structure of HLA-B*27:05 complexed with the self-peptide pVIPR measured at 295 K
5IB5	;	2.49	;	Crystal structure of HLA-B*27:09 complexed with the self-peptide pVIPR and Copper
1ZHK	;	1.6	;	Crystal structure of HLA-B*3501 presenting 13-mer EBV antigen LPEPLPQGQLTAY
1ZSD	;	1.7	;	Crystal Structure Of HLA-B*3501 Presenting an 11-Mer EBV Antigen EPLPQGQLTAY
2H6P	;	1.9	;	Crystal structure of HLA-B*3501 presenting the human cytochrome P450 derived peptide, KPIVVLHGY
1ZHL	;	1.5	;	Crystal structure of HLA-B*3508 presenting 13-mer EBV antigen LPEPLPQGQLTAY
2NW3	;	1.7	;	Crystal structure of HLA-B*3508 presenting EBV peptide EPLPQGQLTAY at 1.7A
7M8U	;	1.45	;	Crystal Structure of HLA-B*35:01 in complex with IPFAMQMAY, an 9-mer epitope from SARS-CoV-2 spike (S896-904)
8EMK	;	1.66523	;	Crystal structure of HLA-B*35:01-NP3 epitope from 1957 H2N2 influenza strain
8EMJ	;	1.75003	;	Crystal structure of HLA-B*35:01-NP9 epitope from 2006 H1N1 influenza strain
6MT6	;	1.31	;	Crystal Structure of HLA-B*37:01 in complex with NP338 influenza peptide
6MT4	;	1.55	;	Crystal Structure of HLA-B*37:01 in complex with NP338-L7S influenza peptide
6MT5	;	1.55	;	Crystal Structure of HLA-B*37:01 in complex with NP338-V6L influenza peptide
6IEX	;	2.314	;	Crystal structure of HLA-B*4001 in complex with SARS-CoV derived peptide N216-225 GETALALLLL
3LN4	;	1.296	;	Crystal structure of HLA-B*4103 in complex with a 16mer self-peptide derived from heterogeneous nuclear ribonucleoproteins C1/C2
3LN5	;	1.9	;	Crystal structure of HLA-B*4104 in complex with a 11mer self-peptide derived from S-methyl-5-thioadenosine phosphorylase
3L3D	;	1.8	;	Crystal structure of HLA-B*4402 in complex with the F3A mutant of a self-peptide derived from DPA*0201
3L3J	;	2.4	;	Crystal structure of HLA-B*4402 in complex with the F3A/R5A double mutant of a self-peptide derived from DPA*0201
3L3I	;	1.7	;	Crystal structure of HLA-B*4402 in complex with the F7A mutant of a self-peptide derived from DPA*0201
3L3G	;	2.1	;	Crystal structure of HLA-B*4402 in complex with the R5A mutant of a self-peptide derived from DPA*0201
3L3K	;	2.6	;	Crystal structure of HLA-B*4402 in complex with the R5A/F7A double mutant of a self-peptide derived from DPA*0201
3DX7	;	1.6	;	Crystal Structure of HLA-B*4403 presenting 10mer EBV antigen
7TUD	;	1.45	;	Crystal structure of HLA-B*44:05 (T73C) with 6mer EEFGRC and dipeptide GL
7TUC	;	1.25	;	Crystal structure of HLA-B*44:05 (T73C) with 9mer EEFGRAFSF
6MTL	;	1.35	;	Crystal Structure of HLA-B*44:05 in complex with NP338 influenza peptide
3W39	;	3.1	;	Crystal structure of HLA-B*5201 in complexed with HIV immunodominant epitope (TAFTIPSI)
7R7V	;	1.6	;	Crystal structure of HLA-B*5301 complex with an HIV-1 Gag-derived epitope QW9
7R7W	;	1.17	;	Crystal structure of HLA-B*5301 complex with an HIV-1 Gag-derived epitope QW9 S3T variant
7R7X	;	2.099	;	Crystal structure of HLA-B*5701 complex with an HIV-1 Gag-derived epitope QW9
7R7Y	;	1.601	;	Crystal structure of HLA-B*5701 complex with an HIV-1 Gag-derived epitope QW9 S3T variant
5V5M	;	2.878	;	Crystal structure of HLA-B*5701 complex with HIV-1 gag derived peptide TW10
2RFX	;	2.5	;	Crystal Structure of HLA-B*5701, presenting the self peptide, LSSPVTKSF
6BXP	;	1.45	;	Crystal Structure of HLA-B*57:01 with a modified HIV peptide RKV-Kyn
6BXQ	;	1.58	;	Crystal Structure of HLA-B*57:01 with an HIV peptide RKV
3X12	;	1.8	;	Crystal structure of HLA-B*57:01.I80N
3X11	;	2.15	;	Crystal structure of HLA-B*57:01.I80N.L82R.R83G
5V5L	;	2.002	;	Crystal structure of HLA-B*5801 complex with HIV-1 gag derived peptide TW10
5EO0	;	1.7	;	Crystal Structure of HLA-B0702-RFL9
5EO1	;	1.85	;	Crystal Structure of HLA-B0702-RL9
6Y26	;	1.2	;	Crystal structure of HLA-B2705 complexed with the nona-peptide mA
6Y28	;	1.69	;	Crystal structure of HLA-B2705 complexed with the nona-peptide mE
6Y2A	;	1.25	;	Crystal structure of HLA-B2705 complexed with the nona-peptide mQ
6Y27	;	1.38	;	Crystal structure of HLA-B2709 complexed with the nona-peptide mA
6Y29	;	1.28	;	Crystal structure of HLA-B2709 complexed with the nona-peptide mE
6Y2B	;	1.37	;	Crystal structure of HLA-B2709 complexed with the nona-peptide mQ
5XOS	;	1.697	;	Crystal structure of HLA-B35 in complex with a pepetide antigen
4LCY	;	1.6	;	Crystal structure of HLA-b46 at 1.6 angstrom resolution
2HJK	;	1.85	;	Crystal Structure of HLA-B5703 and HIV-1 peptide
2HJL	;	1.5	;	Crystal Structure of HLA-B5703 and HIV-1 peptide
5IM7	;	2.502	;	Crystal structure of HLA-B5801, a protective HLA allele for HIV-1 infection
5INC	;	2.881	;	Crystal structure of HLA-B5801, a protective HLA allele for HIV-1 infection
5IND	;	2.132	;	Crystal structure of HLA-B5801, a protective HLA allele for HIV-1 infection
5WMO	;	1.62	;	Crystal Structure of HLA-B7 in complex with RPP, an EBV peptide
5WMN	;	1.82	;	Crystal Structure of HLA-B7 in complex with SPI, an influenza peptide
5WMP	;	1.6	;	Crystal Structure of HLA-B7 in complex with TPR, a CMV peptide
3VCL	;	1.7	;	Crystal Structure of HLA-B7 with the HCMV pp65 peptide RPHERNGFTVL
5WMQ	;	1.4	;	Crystal Structure of HLA-B8 in complex with ELR, an Influenza A virus peptide
5WMR	;	1.58	;	Crystal Structure of HLA-B8 in complex with QIK, a CMV peptide
5VGD	;	2.32	;	Crystal Structure of HLA-C*0501 in complex with SAE
5VGE	;	2.6	;	Crystal structure of HLA-C*07:02 in complex with RYR peptide
7WJ3	;	1.56344	;	Crystal structure of HLA-C*1402 complexed with 4-mer lipopeptide
7WJ2	;	1.28	;	Crystal structure of HLA-C*1402 complexed with 8-mer HIV gag peptide
6JTO	;	1.7	;	Crystal structure of HLA-C05 in complex with a tumor mut10m peptide
6JTN	;	1.9	;	Crystal structure of HLA-C08 in complex with a tumor mut10m peptide
6JTP	;	1.9	;	Crystal structure of HLA-C08 in complex with a tumor mut9m peptide
1QQD	;	2.7	;	CRYSTAL STRUCTURE OF HLA-CW4, A LIGAND FOR THE KIR2D NATURAL KILLER CELL INHIBITORY RECEPTOR
2BC4	;	2.27	;	Crystal structure of HLA-DM
4FQX	;	2.599	;	Crystal structure of HLA-DM bound to HLA-DR1
7ZAK	;	1.62	;	Crystal structure of HLA-DP (DPA1*02:01-DPB1*01:01) in complex with a peptide
7ZFR	;	2.9	;	Crystal structure of HLA-DP (DPA1*02:01-DPB1*01:01) in complex with a peptide bound in the reverse direction
7T6I	;	2.3	;	Crystal structure of HLA-DP1 in complex with pp65 peptide in reverse orientation
3LQZ	;	3.25	;	Crystal Structure of HLA-DP2
7T2A	;	3.04	;	Crystal structure of HLA-DP4 in complex with Ply
3WEX	;	2.4	;	Crystal structure of HLA-DP5 in complex with Cry j 1-derived peptide (residues 214-222)
1UVQ	;	1.8	;	Crystal structure of HLA-DQ0602 in complex with a hypocretin peptide
1S9V	;	2.22	;	Crystal structure of HLA-DQ2 complexed with deamidated gliadin peptide
5KSU	;	2.73	;	Crystal structure of HLA-DQ2.5-CLIP1 at 2.73 resolution
5KSV	;	2.195	;	Crystal structure of HLA-DQ2.5-CLIP2
3PDO	;	1.95	;	Crystal Structure of HLA-DR1 with CLIP102-120
3PGD	;	2.72	;	Crystal Structure of HLA-DR1 with CLIP106-120, canonical peptide orientation
3PGC	;	2.66	;	Crystal Structure of HLA-DR1 with CLIP106-120, flipped peptide orientation
1KLU	;	1.93	;	Crystal structure of HLA-DR1/TPI(23-37) complexed with staphylococcal enterotoxin C3 variant 3B2 (SEC3-3B2)
1KLG	;	2.4	;	Crystal structure of HLA-DR1/TPI(23-37, Thr28-->Ile mutant) complexed with staphylococcal enterotoxin C3 variant 3B2 (SEC3-3B2)
1BX2	;	2.6	;	CRYSTAL STRUCTURE OF HLA-DR2 (DRA*0101,DRB1*1501) COMPLEXED WITH A PEPTIDE FROM HUMAN MYELIN BASIC PROTEIN
4IS6	;	2.5	;	Crystal structure of HLA-DR4 bound to GP100 peptide
1D6E	;	2.45	;	CRYSTAL STRUCTURE OF HLA-DR4 COMPLEX WITH PEPTIDOMIMETIC AND SEB
7NZH	;	2.831	;	Crystal structure of HLA-DR4 in complex with a citrullinated cilp peptide
7O00	;	2.24	;	Crystal structure of HLA-DR4 in complex with a HSP70 peptide
7NZE	;	2.05	;	Crystal structure of HLA-DR4 in complex with a human collagen type II peptide
7NZF	;	1.9	;	Crystal structure of HLA-DR4 in complex with a mutated human collagen type II peptide
8EUQ	;	3.09	;	Crystal structure of HLA-DRA*01:01/HLA-DRB1*04:01 in complex with c44H10 Fab
5JLZ	;	1.99	;	Crystal structure of HLA-DRB1*04:01 in complex with modified alpha-enolase peptide 26-40 with citrulline at the position 32
5NIG	;	1.35	;	Crystal structure of HLA-DRB1*04:01 with modified alpha-enolase peptide 326-340 (arginine 327 to citrulline)
5NI9	;	1.33	;	Crystal structure of HLA-DRB1*04:01 with the alpha-enolase peptide 326-340
3KYN	;	2.4	;	Crystal structure of HLA-G presenting KGPPAALTL peptide
3KYO	;	1.7	;	Crystal structure of HLA-G presenting KLPAQFYIL peptide
5LAX	;	2.6	;	Crystal structure of HLA_DRB1*04:01 in complex with alpha-enolase peptide 26-40
5X9Q	;	2.4	;	Crystal structure of HldC from Burkholderia pseudomallei
4NTD	;	1.6	;	Crystal structure of HlmI
4S0N	;	1.501	;	Crystal Structure of HLTF HIRAN Domain bound to DNA
2FX0	;	2.4	;	Crystal Structure of HlyIIR, a Hemolysin II transcriptional Regulator
3HA7	;	2.35	;	Crystal structure of HMA (MMAA4) from mycobacterium tuberculosis complexed with S-adenosyl-N-decyl-aminoethyl (SADAE)
3HA3	;	2.2	;	Crystal structure of HMA (MMAA4) from mycobacterium tuberculosis complexed with S-adenosylhomocysteine
2FK8	;	2.0	;	Crystal structure of Hma (MmaA4) from Mycobacterium tuberculosis complexed with S-adenosylmethionine
3HA5	;	2.3	;	Crystal structure of HMA (MMAA4) from mycobacterium tuberculosis complexed with sinefungin
2FK7	;	2.1	;	Crystal structure of Hma (MmaA4) from Mycobacterium tuberculosis, apo-form
6P9V	;	2.051	;	Crystal Structure of hMAT Mutant K289L
6OE7	;	2.2	;	Crystal structure of HMCES cross-linked to DNA abasic site
6OEB	;	2.1	;	Crystal structure of HMCES SRAP domain in complex with 3' overhang DNA
6OEA	;	2.1	;	Crystal structure of HMCES SRAP domain in complex with longer 3' overhang DNA
6OOV	;	2.2	;	Crystal structure of HMCES SRAP domain in complex with palindromic 3' overhang DNA
6DU4	;	1.7	;	Crystal structure of hMettl16 catalytic domain in complex with MAT2A 3'UTR hairpin 1
6DU5	;	3.006	;	Crystal structure of hMettl16 catalytic domain in complex with MAT2A 3'UTR hairpin 6
4S2Q	;	2.7	;	Crystal Structure of HMG domain of the chondrogenesis master regulator, Sox9 in complex with ChIP-Seq identified DNA element
4A3N	;	2.4	;	Crystal Structure of HMG-BOX of Human SOX17
1X9E	;	2.4	;	Crystal structure of HMG-CoA synthase from Enterococcus faecalis
1YSL	;	1.9	;	Crystal structure of HMG-CoA synthase from Enterococcus faecalis with AcetoAcetyl-CoA ligand.
1CKT	;	2.5	;	CRYSTAL STRUCTURE OF HMG1 DOMAIN A BOUND TO A CISPLATIN-MODIFIED DNA DUPLEX
3SQZ	;	1.2	;	Crystal structure of HMG_CoA synthase complexed with CoA
1J7D	;	1.85	;	Crystal Structure of hMms2-hUbc13
5WQ6	;	1.648	;	Crystal Structure of hMNDA-PYD with MBP tag
4H67	;	2.7	;	Crystal structure of HMP synthase Thi5 from S. cerevisiae
5H5M	;	2.4	;	Crystal structure of HMP-1 M domain
5XA5	;	1.6	;	Crystal structure of HMP-1-HMP-2 complex
3RAM	;	2.7	;	Crystal structure of HmrA
6GLU	;	1.7	;	Crystal structure of hMTH1 D120N in complex with LW14 in the presence of acetate
6GLV	;	1.601	;	Crystal structure of hMTH1 D120N in complex with TH scaffold 1 in the absence of acetate
6GLT	;	1.596	;	Crystal structure of hMTH1 D120N in the presence of acetate
6GLH	;	1.201	;	Crystal structure of hMTH1 F27A in complex with LW14 in the absence of acetate
6GLG	;	1.313	;	Crystal structure of hMTH1 F27A in complex with LW14 in the presence of acetate
6GLJ	;	1.301	;	Crystal structure of hMTH1 F27A in complex with TH scaffold 1 in the absence of acetate
6GLI	;	1.6	;	Crystal structure of hMTH1 F27A in complex with TH scaffold 1 in the presence of acetate
6GLF	;	2.0	;	Crystal structure of hMTH1 F27A in the presence of acetate
6GLE	;	1.402	;	Crystal structure of hMTH1 in complex with TH scaffold 1 in the presence of acetate
6GLM	;	1.6	;	Crystal structure of hMTH1 N33A in complex with LW14 in the absence of acetate
6GLL	;	1.395	;	Crystal structure of hMTH1 N33A in complex with LW14 in the presence of acetate
6GLN	;	1.401	;	Crystal structure of hMTH1 N33A in complex with TH scaffold 1 in the absence of acetate
6GLK	;	1.5	;	Crystal structure of hMTH1 N33A in the presence of acetate
6GLQ	;	1.601	;	Crystal structure of hMTH1 N33G in complex with LW14 in the absence of acetate
6GLP	;	1.5	;	Crystal structure of hMTH1 N33G in complex with LW14 in the presence of acetate
6GLS	;	1.501	;	Crystal structure of hMTH1 N33G in complex with TH scaffold 1 in the absence of acetate
6GLR	;	1.601	;	Crystal structure of hMTH1 N33G in complex with TH scaffold 1 in the presence of acetate
6GLO	;	1.701	;	Crystal structure of hMTH1 N33G in the presence of acetate
4GGV	;	2.331	;	Crystal Structure of HmtT Involved in Himastatin Biosynthesis
4M91	;	1.1	;	crystal structure of hN33/Tusc3-peptide 1
4M92	;	1.6	;	Crystal structure of hN33/Tusc3-peptide 2
2D5V	;	2.0	;	Crystal structure of HNF-6alpha DNA-binding domain in complex with the TTR promoter
8C1L	;	2.0	;	Crystal structure of HNF4 alpha LBD in complexes with palmitic acid and GRIP-1 peptide
3FS1	;	2.2	;	Crystal structure of HNF4a LBD in complex with the ligand and the coactivator PGC-1a fragment
1PZL	;	2.1	;	Crystal structure of HNF4a LBD in complex with the ligand and the coactivator SRC-1 peptide
7EVR	;	1.8	;	Crystal structure of hnRNP L RRM2 in complex with SETD2
7EVS	;	1.6	;	Crystal structure of hnRNP LL RRM2 in complex with SETD2
5HO4	;	1.85	;	Crystal structure of hnRNPA2B1 in complex with 10-mer RNA
5WWG	;	2.03	;	Crystal structure of hnRNPA2B1 in complex with AAGGACUUGC
5EN1	;	2.58	;	Crystal structure of hnRNPA2B1 in complex with RNA
5WWE	;	2.4	;	Crystal structure of hnRNPA2B1 in complex with RNA
5WWF	;	2.15	;	Crystal structure of hnRNPA2B1 in complex with RNA
2UVP	;	1.7	;	Crystal structure of HobA (HP1230)from Helicobacter pylori
4I66	;	1.3	;	Crystal structure of Hoch_4089 protein from Haliangium ochraceum
4WPE	;	2.7	;	Crystal Structure of Hof1p F-BAR domain
1M3Q	;	1.9	;	Crystal Structure of hogg1 D268E Mutant with Base-Excised DNA and 8-aminoguanine
1M3H	;	2.05	;	Crystal Structure of Hogg1 D268E Mutant with Product Oligonucleotide
7YUI	;	2.599	;	Crystal structure of HOIL-1L(195-423) in complex with the linear tetra-ubiquitin
7YUJ	;	1.865	;	Crystal structure of HOIL-1L(365-510)
4DBG	;	2.71	;	Crystal structure of HOIL-1L-UBL complexed with a HOIP-UBA derivative
4P09	;	1.7	;	Crystal structure of HOIP PUB domain
4P0B	;	2.7005	;	Crystal structure of HOIP PUB domain in complex with OTULIN PIM
4P0A	;	2.3001	;	Crystal structure of HOIP PUB domain in complex with p97 PIM
7V8G	;	2.75	;	Crystal structure of HOIP RING1 domain bound to IpaH1.4 LRR domain
2EO0	;	2.4	;	Crystal Structure of Holliday Junction Resolvase ST1444
5DSB	;	1.4959	;	Crystal structure of Holliday junctions stabilized by 5-hydroxymethylcytosine in GCC junction core
5DSA	;	1.6896	;	Crystal structure of Holliday junctions stabilized by 5-methylcytosine in GCC junction core
3SS7	;	1.55	;	Crystal structure of holo D-serine dehydratase from Escherichia coli at 1.55 A resolution
3SS9	;	1.97	;	Crystal structure of holo D-serine dehydratase from Escherichia coli at 1.97 A resolution
4D9I	;	2.0	;	Crystal structure of holo Diaminopropionate ammonia lyase from Escherichia coli
3TLK	;	1.853	;	Crystal structure of holo FepB
2ZTH	;	2.6	;	Crystal structure of holo form of rat catechol-o-methyltransferase
3LVF	;	1.7	;	Crystal Structure of holo Glyceraldehyde-3-phosphate dehydrogenase 1 (GAPDH1) from methicillin resistant Staphylococcus aureus MRSA252 at 1.7 Angstrom resolution
5LJB	;	1.263	;	Crystal structure of holo human CRBP1
5LJC	;	1.433	;	Crystal structure of holo human CRBP1
5LJG	;	1.146	;	Crystal structure of holo human CRBP1
5LJD	;	1.61	;	Crystal structure of holo human CRBP1/K40L mutant
5LJE	;	1.4	;	Crystal structure of holo human CRBP1/K40L,Q108L mutant
2VHZ	;	2.04	;	Crystal structure of holo L-alanine dehydrogenase from Mycobacterium tuberculosis in the closed conformation
2VHW	;	2.0	;	Crystal structure of holo L-alanine dehydrogenase from Mycobacterium tuberculosis in the open and closed conformation
3MVI	;	1.6	;	Crystal structure of holo mADA at 1.6 A resolution
7LI1	;	1.75	;	Crystal structure of holo Moraxella catarrhalis ferric binding protein A in an open conformation
5EA2	;	2.01	;	Crystal Structure of Holo NAD(P)H dehydrogenase, quinone 1
3GZL	;	2.55	;	Crystal Structure of holo PfACP Disulfide-Linked Dimer
3GZM	;	1.8	;	Crystal Structure of holo PfACP Reduced Monomer
6R4Y	;	1.452	;	Crystal structure of holo PPEP-1(E143A/Y178F) in complex with product peptide Ac-EVNP-CO2 (substrate peptide: Ac-EVNPAVP-CONH2)
6R4Z	;	1.052	;	Crystal structure of holo PPEP-1(E143A/Y178F) in complex with product peptide Ac-EVNP-CO2 (substrate peptide: Ac-EVNPPVP-CONH2)
6R50	;	1.807	;	Crystal structure of holo PPEP-1(E143A/Y178F) in complex with substrate peptide Ac-EVNAPVP-CONH2
6MCV	;	3.3	;	Crystal Structure of Holo Retinal-Bound Domain-Swapped Dimer of Wild Type Human Cellular Retinol Binding Protein II
6E5S	;	2.061	;	Crystal structure of holo retinal-bound domain-swapped dimer Q108K:T51D mutant of human Cellular Retinol Binding Protein II
7DH8	;	1.85	;	Crystal structure of holo XcZur
5VCB	;	4.1	;	Crystal structure of holo-(acyl-carrier-protein) synthase:holo(acyl-carrier-protein) complex from Escherichia Coli.
4ZXI	;	2.9	;	Crystal Structure of holo-AB3403 a four domain nonribosomal peptide synthetase bound to AMP and Glycine
4ZXH	;	2.7	;	Crystal Structure of holo-AB3403 a four domain nonribosomal peptide synthetase from Acinetobacter Baumanii
2BDD	;	2.28	;	Crystal Structure of Holo-ACP-synthase from Plasmodium yoelii
1KQW	;	1.38	;	Crystal structure of holo-CRBP from zebrafish
5T3D	;	2.8	;	Crystal structure of holo-EntF a nonribosomal peptide synthetase in the thioester-forming conformation
7O87	;	1.5	;	Crystal structure of holo-F210W mutant of Hydroxy ketone aldolase (SwHKA) from Sphingomonas wittichii RW1 in complex with hydroxypyruvate
7OBU	;	1.2	;	Crystal structure of holo-F210W mutant of Hydroxy ketone aldolase (SwHKA) from Sphingomonas wittichii RW1, with the active site in the resting and the active state
7O5W	;	1.2	;	Crystal structure of holo-F210W mutant of Hydroxy ketone aldolase (SwHKA)from Sphingomonas wittichii RW1
5E44	;	2.65	;	Crystal structure of holo-FNR of A. fischeri
1VSV	;	2.0	;	Crystal Structure of holo-glyceraldehyde 3-phosphate dehydrogenase from Cryptosporidium parvum
7O9R	;	1.85	;	Crystal structure of holo-H44A mutant of Hydroxy ketone aldolase (SwHKA) from Sphingomonas wittichii RW1
7O5V	;	1.95	;	Crystal structure of holo-H44A mutant of Hydroxy ketone aldolase (SwHKA) from Sphingomonas wittichii RW1, in complex with Hydroxypyruvate
8QTO	;	2.4	;	CRYSTAL STRUCTURE OF HOLO-L28H-FNR OF A. FISCHERI
6N8E	;	3.0	;	Crystal structure of holo-ObiF1, a five domain nonribosomal peptide synthetase from Burkholderia diffusa
4MF9	;	1.95	;	Crystal structure of holo-PhuS, a heme-binding protein from Pseudomonas aeruginosa
7NR1	;	2.3	;	Crystal structure of holo-S116A mutant of Hydroxy ketone aldolase (SwHKA) from Sphingomonas wittichii RW1
7NUJ	;	1.9	;	Crystal structure of holo-SwHPA-Mg (hydroxy ketone aldolase) from Sphingomonas wittichii RW1
8ADQ	;	1.6	;	Crystal structure of holo-SwHPA-Mg (hydroxy ketone aldolase) from Sphingomonas wittichii RW1 in complex with hydroxypyruvate and D-Glyceraldehyde
7O5R	;	1.65	;	Crystal structure of holo-SwHPA-Mn (hydroxyketoacid aldolase) from Sphingomonas wittichii RW1
3W36	;	1.97	;	Crystal structure of holo-type bacterial Vanadium-dependent chloroperoxidase
3R5T	;	1.45	;	Crystal structure of holo-ViuP
5VBX	;	2.05	;	Crystal structure of holo-[acyl-carrier-protein] synthase (AcpS) from Escherichia coli
5CMO	;	2.0	;	Crystal structure of holo-[acyl-carrier-protein] synthase (AcpS) from Neisseria meningitidis
5SUV	;	1.75	;	Crystal structure of holo-[acyl-carrier-protein] synthase (AcpS) from Neisseria meningitidis in complex with Coenzyme A
2X88	;	1.8	;	Crystal Structure of HoloCotA
4ENL	;	1.9	;	CRYSTAL STRUCTURE OF HOLOENZYME REFINED AT 1.9 ANGSTROMS RESOLUTION: TRIGONAL-BIPYRAMIDAL GEOMETRY OF THE CATION BINDING SITE
5ZZ9	;	2.3	;	Crystal structure of Homer2 EVH1/Drebrin PPXXF complex
7QST	;	2.49	;	Crystal structure of homing endonuclease-associated PhoVMA intein (C1A)
7QSS	;	1.56	;	Crystal structure of homing endonuclease-associated TliVMA intein (C1A)
7QSU	;	1.9	;	Crystal structure of homing endonuclease-associated TliVMA intein (C1A, d333-339)
7CJ4	;	2.08	;	Crystal structure of homo dimeric D-allulose 3-epimerase from Methylomonas sp.
7CJ6	;	1.8	;	Crystal structure of homo dimeric D-allulose 3-epimerase from Methylomonas sp. in complex with D-allulose
7CJ5	;	1.8	;	Crystal structure of homo dimeric D-allulose 3-epimerase from Methylomonas sp. in complex with D-fructose
7CJ7	;	1.695	;	Crystal structure of homo dimeric D-allulose 3-epimerase from Methylomonas sp. in complex with L-tagatose
6M33	;	3.29435	;	Crystal structure of Homo Sapian GCP6 N-terminus and Mozart1
1X0V	;	2.3	;	Crystal Structure of Homo Sapien Glycerol-3-Phosphate Dehydrogenase 1
3FY7	;	1.95	;	Crystal structure of homo sapiens CLIC3
3HR0	;	1.9	;	Crystal structure of Homo sapiens Conserved Oligomeric Golgi subunit 4
3L4G	;	3.3	;	Crystal structure of Homo Sapiens cytoplasmic Phenylalanyl-tRNA synthetase
6L81	;	2.19651	;	Crystal structure of Homo sapiens GCP5 N-terminus and Mozart1
4PVF	;	2.6	;	Crystal structure of Homo sapiens holo serine hydroxymethyltransferase 2 (mitochondrial) (SHMT2), isoform 3, transcript variant 5, 483 aa, at 2.6 ang. resolution
4TTB	;	2.447	;	Crystal structure of homo sapiens IODOTYROSINE DEIODINASE (IYD) bound to FMN
4TTC	;	2.65	;	Crystal structure of homo sapiens IODOTYROSINE DEIODINASE bound to FMN and mono-iodotyrosine (MIT)
2HZP	;	2.0	;	Crystal Structure of Homo Sapiens Kynureninase
3E9K	;	1.7	;	Crystal structure of Homo sapiens kynureninase-3-hydroxyhippuric acid inhibitor complex
7MW0	;	2.0	;	Crystal structure of Homo sapiens NUP93 solenoid (residues 174-819)
5V7I	;	2.47	;	Crystal structure of homo sapiens serine hydroxymethyltransferase 2 (mitochondrial) (SHMT2), in complex with glycine, PLP and folate-competitive pyrazolopyran inhibitor: 6-amino-4-isopropyl-3-methyl-4-(3-(pyrrolidin-1-yl)-5-(trifluoromethyl)phenyl)-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile
2H9S	;	1.75	;	Crystal Structure of Homo-DNA and Nature's Choice of Pentose over Hexose in the Genetic System
5GRV	;	2.3	;	Crystal structure of homo-specific diabody
5GRW	;	2.8	;	Crystal structure of homo-specific diabody
5GS1	;	2.0	;	Crystal structure of homo-specific diabody
4KP2	;	2.504	;	Crystal structure of homoaconitase large subunit from methanococcus jannaschii (MJ1003)
2ZTJ	;	1.8	;	Crystal structure of homocitrate synthase from Thermus thermophilus complexed with alpha-ketoglutarate
2ZTK	;	1.96	;	Crystal structure of homocitrate synthase from Thermus thermophilus complexed with homocitrate
3A9I	;	1.8	;	Crystal structure of homocitrate synthase from Thermus thermophilus complexed with Lys
2ZYF	;	2.15	;	Crystal structure of homocitrate synthase from Thermus thermophilus complexed with magnesuim ion and alpha-ketoglutarate
1PFF	;	2.5	;	Crystal Structure of Homocysteine alpha-, gamma-lyase at 1.8 Angstroms
5JJM	;	2.15	;	Crystal Structure of Homodimeric Androgen Receptor Ligand-Binding Domain bound to DHT and LxxLL peptide
3MAR	;	3.41	;	Crystal structure of homodimeric R132H mutant of human cytosolic NADP(+)-dependent isocitrate dehydrogenase in complex with NADP
3MAP	;	2.8	;	Crystal structure of homodimeric R132H mutant of human cytosolic NADP(+)-dependent isocitrate dehydrogenase in complex with NADP and isocitrate
4U4Q	;	3.0	;	Crystal structure of Homoharringtonine bound to the yeast 80S ribosome
3TY4	;	1.55	;	Crystal structure of homoisocitrate dehydrogenase from Schizosaccharomyces pombe
3TY3	;	1.85	;	Crystal structure of homoisocitrate dehydrogenase from Schizosaccharomyces pombe bound to glycyl-glycyl-glycine
4YB4	;	2.5	;	Crystal structure of homoisocitrate dehydrogenase from Thermus thermophilus in complex with homoisocitrate, magnesium ion (II) and NADH
3ASJ	;	2.6	;	Crystal structure of homoisocitrate dehydrogenase in complex with a designed inhibitor
2G9I	;	2.5	;	Crystal structure of homolog of F420-0:gamma-Glutamyl Ligase from Archaeoglobus fulgidus Reveals a Novel Fold.
3BW1	;	2.5	;	Crystal structure of homomeric yeast Lsm3 exhibiting novel octameric ring organisation
1F1U	;	1.5	;	CRYSTAL STRUCTURE OF HOMOPROTOCATECHUATE 2,3-DIOXYGENASE FROM ARTHROBACTER GLOBIFORMIS (NATIVE, LOW TEMPERATURE)
1F1R	;	1.8	;	CRYSTAL STRUCTURE OF HOMOPROTOCATECHUATE 2,3-DIOXYGENASE FROM ARTHROBACTER GLOBIFORMIS (NATIVE, NON-CRYO)
1F1X	;	1.6	;	CRYSTAL STRUCTURE OF HOMOPROTOCATECHUATE 2,3-DIOXYGENASE FROM BREVIBACTERIUM FUSCUM
1Q0O	;	2.3	;	CRYSTAL STRUCTURE OF HOMOPROTOCATECHUATE 2,3-DIOXYGENASE FROM BREVIBACTERIUM FUSCUM (FULL LENGTH PROTEIN)
3ING	;	1.95	;	Crystal structure of Homoserine dehydrogenase (NP_394635.1) from THERMOPLASMA ACIDOPHILUM at 1.95 A resolution
3C8M	;	1.9	;	Crystal structure of homoserine dehydrogenase from Thermoplasma volcanium
5X9D	;	2.1	;	Crystal structure of homoserine dehydrogenase in complex with L-cysteine and NAD
1FWL	;	2.25	;	CRYSTAL STRUCTURE OF HOMOSERINE KINASE
1FWK	;	2.1	;	CRYSTAL STRUCTURE OF HOMOSERINE KINASE COMPLEXED WITH ADP
1H72	;	1.8	;	CRYSTAL STRUCTURE OF HOMOSERINE KINASE COMPLEXED WITH HSE
1H74	;	1.9	;	CRYSTAL STRUCTURE OF HOMOSERINE KINASE COMPLEXED WITH ILE
1H73	;	2.0	;	CRYSTAL STRUCTURE OF HOMOSERINE KINASE COMPLEXED WITH THREONINE
4P52	;	2.6	;	Crystal structure of homoserine kinase from Cytophaga hutchinsonii ATCC 33406, NYSGRC Target 032717.
4RPF	;	2.3	;	Crystal structure of homoserine kinase from Yersinia pestis Nepal516, NYSGRC target 032715
2VDJ	;	2.0	;	Crystal Structure of Homoserine O-acetyltransferase (metA) from Bacillus Cereus with Homoserine
2PL5	;	2.2	;	Crystal Structure of Homoserine O-acetyltransferase from Leptospira interrogans
6IOG	;	1.55	;	Crystal structure of Homoserine O-acetyltransferase from Mycobacterium smegmatis ATCC 19420
4QLO	;	2.45	;	Crystal Structure of homoserine o-acetyltransferase from Staphylococcus aureus
6IOI	;	1.6	;	Crystal structure of Homoserine O-acetyltransferase in complex with CoA from Mycobacterium smegmatis ATCC 19420
6IOH	;	2.0	;	Crystal structure of Homoserine O-acetyltransferase in complex with Homoserine from Mycobacterium smegmatis ATCC 19420
2H2W	;	2.52	;	Crystal structure of Homoserine O-succinyltransferase (EC 2.3.1.46) (Homoserine O-transsuccinylase) (HTS) (tm0881) from THERMOTOGA MARITIMA at 2.52 A resolution
2GHR	;	2.4	;	Crystal structure of homoserine o-succinyltransferase (NP_981826.1) from Bacillus cereus ATCC 10987 at 2.40 A resolution
7CBE	;	1.7	;	Crystal structure of Homoserine O-succinyltransferase from Escherichia coli K-12
2B61	;	1.65	;	Crystal Structure of Homoserine Transacetylase
7RHP	;	1.54	;	Crystal Structure of Honeybee (Apis mellifera) glutathione S-transferase AmGSTD1
6LQK	;	2.499	;	Crystal structure of honeybee RyR NTD
4TPV	;	1.6	;	Crystal Structure of Hookworm Platelet Inhibitor
4JC8	;	2.6	;	Crystal Structure of HOPS component Vps33 from Chaetomium thermophilum
5KLP	;	2.002	;	Crystal structure of HopZ1a in complex with IP6
5KLQ	;	3.4	;	Crystal structure of HopZ1a in complex with IP6 and CoA
8J69	;	2.67	;	Crystal structure of HORMA domain-containing protein 1 (HORMAD1) from Homo sapiens
1JDN	;	2.9	;	Crystal Structure of Hormone Receptor
1JDP	;	2.0	;	Crystal Structure of Hormone/Receptor Complex
1IWH	;	1.55	;	Crystal Structure of Horse Carbonmonoxyhemoglobin-Bezafibrate Complex at 1.55A Resolution: A Novel Allosteric Binding Site in R-State Hemoglobin
4NS2	;	1.18	;	Crystal structure of Horse heart ferric myoglobin; D44K/D60K/E85K mutant
3RJ6	;	1.23	;	Crystal Structure of Horse heart ferric myoglobin; K45E/K63E/K96E mutant
3WFU	;	1.35	;	Crystal structure of horse heart myoglobin reconstituted with cobalt(I) tetradehydrocorrin
3WFT	;	1.3	;	Crystal structure of horse heart myoglobin reconstituted with cobalt(II) tetradehydrocorrin
3WI8	;	2.2	;	Crystal structure of horse heart myoglobin reconstituted with manganese porphycene
5YL3	;	1.5	;	Crystal structure of horse heart myoglobin reconstituted with manganese porphycene in resting state at pH 8.5
6TRZ	;	2.02	;	Crystal structure of horse L ferritin (HoLf) Fe(III)-loaded for 15 minutes
6TSX	;	2.021	;	Crystal structure of horse L ferritin (HoLf) Fe(III)-loaded for 30 minutes
6TSS	;	2.18	;	Crystal structure of horse L ferritin (HoLf) Fe(III)-loaded for 60 minutes
4O9L	;	1.944	;	crystal structure of horse MAVS card domain mutant E26R
4O9F	;	2.348	;	crystal structure of horse MAVS card domain mutant R64C
5ZZE	;	1.423	;	Crystal structure of horse myoglobin crystallized by ammonium sulfate
8I81	;	1.5	;	Crystal structure of horse spleen L-ferritin A115G mutant at -180deg Celsius.
8J0U	;	1.5	;	Crystal structure of horse spleen L-ferritin A115T mutant at -180deg Celsius.
8I77	;	1.5	;	Crystal structure of horse spleen L-ferritin A115V mutant at -180deg Celsius.
8J0V	;	1.6	;	Crystal structure of horse spleen L-ferritin at -100deg Celsius.
8J10	;	1.6	;	Crystal structure of horse spleen L-ferritin at -180deg Celsius cooled from -20deg Celsius.
8J0Z	;	1.6	;	Crystal structure of horse spleen L-ferritin at -180deg Celsius cooled from -40deg Celsius.
8I6L	;	1.5	;	Crystal structure of horse spleen L-ferritin at -180deg Celsius.
8J0X	;	1.6	;	Crystal structure of horse spleen L-ferritin at -20deg Celsius.
8J0W	;	1.6	;	Crystal structure of horse spleen L-ferritin at -40deg Celsius.
8J16	;	1.6	;	Crystal structure of horse spleen L-ferritin at -80deg Celsius.
8J11	;	1.6	;	Crystal structure of horse spleen L-ferritin at 0deg Celsius.
8J0Y	;	1.6	;	Crystal structure of horse spleen L-ferritin at 20deg Celsius.
8I8Q	;	1.5	;	Crystal structure of horse spleen L-ferritin H114A mutant at -180deg Celsius.
8I8U	;	1.6	;	Crystal structure of horse spleen L-ferritin S118A mutant at -180deg Celsius.
3WPB	;	2.4	;	Crystal structure of horse TLR9 (unliganded form)
3WPC	;	1.6	;	Crystal structure of horse TLR9 in complex with agonistic DNA1668_12mer
3WPD	;	2.75	;	Crystal structure of horse TLR9 in complex with inhibitory DNA4084
5Y3L	;	2.6	;	Crystal structure of horse TLR9 in complex with two DNAs (CpG DNA and CCGCAC DNA)
5Y3K	;	2.7	;	Crystal structure of horse TLR9 in complex with two DNAs (CpG DNA and GCGCAC DNA)
5Y3J	;	1.81	;	Crystal structure of horse TLR9 in complex with two DNAs (CpG DNA and TCGCAC DNA)
4FRU	;	1.1	;	Crystal structure of horse wild-type cyclophilin B
8KH2	;	2.0	;	Crystal structure of horse-spleen L-ferritin fused with amyloid beta peptide (1-42).
6MIG	;	1.7	;	Crystal structure of host-guest complex with PB hachimoji DNA
6MIH	;	1.6	;	Crystal structure of host-guest complex with PC hachimoji DNA
6MIK	;	1.7	;	Crystal structure of host-guest complex with PP hachimoji DNA
5HJ3	;	3.3	;	Crystal structure of host-primed Ebola virus GP, GPcl.
3QOO	;	1.25	;	Crystal structure of hot-dog-like Taci_0573 protein from Thermanaerovibrio acidaminovorans
7F87	;	1.69	;	Crystal structure of housekeeping sortase SrtA bound with self derived tripeptide from Lactobacillus rhamnosus GG
7CFJ	;	2.64	;	Crystal structure of housekeeping sortase SrtA from Lactobacillus rhamnosus GG
3A03	;	1.54	;	Crystal structure of Hox11L1 homeodomain
1PUF	;	1.9	;	Crystal Structure of HoxA9 and Pbx1 homeodomains bound to DNA
4FZ4	;	2.44	;	Crystal structure of HP0197-18kd
4FZQ	;	2.5	;	Crystal structure of HP0197-G5
2BO3	;	2.27	;	Crystal Structure of HP0242, a Hypothetical Protein from Helicobacter pylori
3LWG	;	1.8	;	Crystal structure of HP0420-homologue C46A from helicobacter felis
3LW3	;	1.6	;	Crystal structure of HP0420-homologue from Helicobacter felis
3K1H	;	1.74	;	Crystal structure of HP1076 from H.pylori
8IGI	;	1.84	;	Crystal structure of HP1526 (XthA)- a base excision DNA repair protein in Helicobacter pylori
5YB3	;	2.043	;	Crystal structure of HP23L/N36
5YB4	;	2.5	;	Crystal structure of HP23LN36KR
3MYC	;	1.7	;	Crystal Structure of HP67 H41F - P212121
3MYA	;	2.5	;	Crystal Structure of HP67 H41F - P61
3NKJ	;	1.6	;	Crystal Structure of HP67 L61G
3MYE	;	1.799	;	Crystal Structure of HP67 L61GL
8HNW	;	3.41	;	Crystal structure of HpaCas9-sgRNA surveillance complex bound to double-stranded DNA
7EL3	;	1.7	;	Crystal structure of HpaR-DNA complex from Acinetobacter baumannii
1GTT	;	1.7	;	CRYSTAL STRUCTURE OF HPCE
1I7O	;	1.7	;	CRYSTAL STRUCTURE OF HPCE
2EB6	;	1.69	;	Crystal structure of HpcG complexed with Mg ion
2EB5	;	1.7	;	Crystal structure of HpcG complexed with oxalate
1U7B	;	1.88	;	Crystal structure of hPCNA bound to residues 331-350 of the flap endonuclease-1 (FEN1)
1U76	;	2.6	;	Crystal structure of hPCNA bound to residues 452-466 of the DNA polymerase-delta-p66 subunit
4V8H	;	3.1	;	Crystal structure of HPF bound to the 70S ribosome.
6M3I	;	1.98	;	Crystal structure of HPF1/PARP1 complex
1XQZ	;	2.1	;	Crystal Structure of hPim-1 kinase at 2.1 A resolution
1XR1	;	2.1	;	Crystal structure of hPim-1 kinase in complex with AMP-PNP at 2.1 A Resolution
5B3W	;	2.4	;	Crystal structure of hPin1 WW domain (5-15) fused with maltose-binding protein in C2221 form
5B3X	;	2.4	;	Crystal structure of hPin1 WW domain (5-15) fused with maltose-binding protein in P41212 form
5BMY	;	2.001	;	Crystal structure of hPin1 WW domain (5-21) fused with maltose-binding protein
5B3Y	;	1.901	;	Crystal structure of hPin1 WW domain (5-23) fused with maltose-binding protein
5B3Z	;	2.3	;	Crystal structure of hPin1 WW domain (5-39) fused with maltose-binding protein
4MZA	;	1.653	;	Crystal structure of hPIV3 hemagglutinin-neuraminidase
4MZE	;	1.8	;	Crystal structure of hPIV3 hemagglutinin-neuraminidase, H552Q/Q559R mutant
7SIU	;	1.786	;	Crystal structure of HPK1 (MAP4K1) complex with inhibitor A-745
7KAC	;	1.85	;	Crystal structure of HPK1 (MAP4K1) kinase in complex with 5-{[4-{[(1S)-2-HYDROXY-1-PHENYLETHYL]AMINO}-5-(1,3,4-OXADIAZOL-2-YL)PYRIMIDIN-2-YL]AMINO}-3,3-DIMETHYL-2-BENZOFURAN-1(3H)-ONE
8EEC	;	2.5	;	Crystal structure of HPK1 citron-homology domain
6CQF	;	2.246	;	Crystal structure of HPK1 in complex an inhibitor G1858
6CQD	;	2.12	;	Crystal structure of HPK1 in complex with ATP analogue (AMPPNP)
7R9P	;	2.27	;	Crystal structure of HPK1 in complex with compound 14
7R9T	;	2.0	;	Crystal structure of HPK1 in complex with compound 17
7R9L	;	2.332	;	Crystal structure of HPK1 in complex with compound 2
7R9N	;	1.5	;	Crystal structure of HPK1 in complex with GNE1858
6CQE	;	1.886	;	Crystal structure of HPK1 kinase domain S171A mutant
8FH4	;	1.827	;	Crystal structure of HPK1 kinase domain T165E,S171E phosphomimetic mutant in complex with 3-[6-chloro-4-(9-methyl-1-oxa-4,9-diazaspiro[5.5]undec-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile
8FKO	;	2.104	;	Crystal structure of HPK1 kinase domain T165E,S171E phosphomimetic mutant in complex with 3-{4-[(2S,5R)-5-Amino-2-methylpiperidin-1-yl]-6-chloro-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzonitrile
8FJZ	;	1.897	;	Crystal structure of HPK1 kinase domain T165E,S171E phosphomimetic mutant in complex with 3-{4-[(3R,5S)-3-Amino-5-methylpiperidin-1-yl]-6-chloro-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzonitrile
8XN7	;	2.65	;	Crystal structure of HPK1 kinase domain T165E,S171E phosphomimetic mutant in complex with compound 9f
6NG0	;	2.05	;	Crystal structure of HPK1 kinase domain T165E,S171E phosphomimetic mutant in complex with sunitinib in the inactive state.
3KPW	;	2.4	;	Crystal Structure of hPNMT in Complex AdoHcy and 1-Aminoisoquinoline
3KQT	;	2.399	;	Crystal Structure of hPNMT in Complex AdoHcy and 2-Amino-1-methylbenzimidazole
3KR0	;	2.6	;	Crystal Structure of hPNMT in Complex AdoHcy and 2-amino-1H-benzo[d]imidazol-6-ol
3KQY	;	2.2	;	Crystal Structure of hPNMT in Complex AdoHcy and 2-amino-1H-benzo[d]imidazol-7-ol
3KQS	;	2.005	;	Crystal Structure of hPNMT in Complex AdoHcy and 2-Aminobenzimidazole
3KQQ	;	2.5	;	Crystal Structure of hPNMT in Complex AdoHcy and 2-Hydroxynicotinic acid
3KQM	;	2.4	;	Crystal Structure of hPNMT in Complex AdoHcy and 4-Bromo-1H-imidazole
3KPU	;	2.4	;	Crystal Structure of hPNMT in Complex AdoHcy and 4-quinolinol
3KR1	;	2.3	;	Crystal Structure of hPNMT in Complex AdoHcy and 5-chloro-1H-benzo[d]imidazol-2-amine
3KQW	;	2.486	;	Crystal Structure of hPNMT in Complex AdoHcy and 5-Chlorobenzimidazole
3KR2	;	2.3	;	Crystal Structure of hPNMT in Complex AdoHcy and 5-fluoro-1H-benzo[d]imidazol-2-amine
3KQP	;	2.4	;	Crystal Structure of hPNMT in Complex AdoHcy and 6-Aminoquinoline
3KPY	;	2.4	;	Crystal Structure of hPNMT in Complex AdoHcy and 6-Chlorooxindole
3KQO	;	2.4	;	Crystal Structure of hPNMT in Complex AdoHcy and 6-Chloropurine
3KPV	;	2.4	;	Crystal Structure of hPNMT in Complex AdoHcy and Adenine
3KPJ	;	2.5	;	Crystal Structure of hPNMT in Complex AdoHcy and Bound Phosphate
3KQV	;	2.3	;	Crystal Structure of hPNMT in Complex AdoHcy and Formanilide
3HCF	;	2.702	;	Crystal Structure of hPNMT in Complex With 3-trifluoromethyl phenylethanolamine and AdoHcy
3HCC	;	2.3	;	Crystal Structure of hPNMT in Complex With anti-9-amino-5-(trifluromethyl) benzonorbornene and AdoHcy
4MIK	;	1.9506	;	Crystal Structure of hPNMT in Complex with bisubstrate inhibitor (2R,3R,4S,5S)-2-(6-amino-9H-purin-9-yl)-5-(((2-(((7-nitro-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)amino)ethyl)thio)methyl)tetrahydrofuran-3,4-diol
4MQ4	;	2.2042	;	Crystal Structure of hPNMT in Complex with bisubstrate inhibitor N-(3-((((2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)thio)propyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
3HCD	;	2.392	;	Crystal Structure of hPNMT in Complex With Noradrenaline and AdoHcy
3HCB	;	2.4	;	Crystal Structure of hPNMT in Complex With Noradrenochrome and AdoHcy
3KJO	;	1.8	;	Crystal Structure of hPOT1V2-dTrUd(AGGGTTAG)
3KJP	;	1.8	;	Crystal Structure of hPOT1V2-GGTTAGGGTTAG
5AZV	;	2.7	;	Crystal structure of hPPARgamma ligand binding domain complexed with 17-oxoDHA
7EFQ	;	2.3	;	Crystal structure of hPPARgamma ligand binding domain complexed with rosiglitazone-based fluorescence probe
7V6X	;	1.8	;	Crystal structure of HPPD complexed with Y18556
3LE5	;	2.0	;	Crystal structure of HPr dimer from Thermoanaerobacter tengcongensis
3LFG	;	1.58	;	Crystal structure of HPr-C-His from Thermoanaerobacter tengcongensis
6IGS	;	2.16	;	Crystal structure of HPRT from F. tularensis with Zinc
8E08	;	1.93	;	Crystal structure of HPSE P6 in complex with tetraose pentosan inhibitor
8E07	;	1.8	;	Crystal structure of HPSE P6 in complex with triose pentosan inhibitor
6LON	;	2.2	;	Crystal structure of HPSG
2B9D	;	1.6	;	Crystal Structure of HPV E7 CR3 domain
7MYT	;	2.1	;	Crystal Structure of HPV L1-directed B25.M05 Fab
7MU4	;	1.83	;	Crystal Structure of HPV L1-directed D24.M01Fab
7MX8	;	2.02	;	Crystal Structure of HPV L1-directed E7M03 Fab
5W1O	;	2.8	;	Crystal Structure of HPV16 L1 Pentamer Bound to Heparin Oligosaccharides
5Y9E	;	2.042	;	Crystal structure of HPV58 pentamer
5Y9C	;	3.443	;	Crystal structure of HPV58 pentamer in complex with the Fab fragment of antibody A12A3
6IGD	;	2.5	;	Crystal structure of HPV58/33 chimeric L1 pentamer
6IGC	;	3.5	;	Crystal structure of HPV58/33/52 chimeric L1 pentamer
5Y9F	;	3.35	;	Crystal structure of HPV59 pentamer in complex with the Fab fragment of antibody 28F10
7F8I	;	3.366	;	Crystal structure of HPV6 L1 pentamer
2AYB	;	3.2	;	Crystal structure of HPV6a E2 DNA Binding Domain bound to a 16 base pair DNA target
2AYG	;	3.1	;	Crystal structure of HPV6a E2 DNA binding domain bound to an 18 base pair DNA target
5WEE	;	1.99	;	Crystal structure of HpVAL4
6HJ2	;	2.28	;	Crystal structure of hPXR in complex with dabrafenib
5HFT	;	2.646	;	Crystal structure of HpxW
5BNQ	;	2.8	;	Crystal structure of hRANKL-mRANK complex
6ZL3	;	2.031	;	CRYSTAL STRUCTURE OF HRAS IN COMPLEX WITH COMPOUND 18 and GDP
7JHP	;	2.766	;	Crystal structure of HRas in complex with the Ras-binding and cysteine-rich domains of CRaf-kinase
2VH5	;	2.7	;	CRYSTAL STRUCTURE OF HRAS(G12V) - ANTI-RAS FV (disulfide free mutant) COMPLEX
2UZI	;	2.0	;	Crystal structure of HRAS(G12V) - anti-RAS Fv complex
7VV9	;	1.6	;	Crystal Structure of HRas(GMPPNP-bound) in complex with the Ras-binding domain(RBD) of SIN1
6ZJ0	;	1.763	;	CRYSTAL STRUCTURE OF HRAS-G12D IN COMPLEX WITH GCP AND COMPOUND 18
7VVG	;	1.7	;	Crystal Structure of HRasG12V(GMPPNP-bound) in complex with the Ras-binding domain(RBD) of SIN1
4Q95	;	2.2	;	Crystal structure of HRASLS3/LRAT chimeric protein
7VV8	;	1.7	;	Crystal Structure of HRasQ61L(GMPPNP-bound) in complex with the Ras-binding domain(RBD) of SIN1
6JTZ	;	2.797	;	Crystal Structure of hRecQ1_D2-Zn-WH containing mutation on beta-hairpin
5DHF	;	2.285	;	Crystal Structure of hRio2 NES Peptide in complex with CRM1-Ran-RanBP1
5DI9	;	2.28	;	Crystal Structure of hRio2 NES Reverse Mutant Peptide in complex with CRM1-Ran-RanBP1
3OVP	;	1.695	;	Crystal Structure of hRPE
3OVQ	;	1.999	;	Crystal Structure of hRPE and D-Ribulose-5-Phospate Complex
3OVR	;	1.948	;	Crystal Structure of hRPE and D-Xylulose 5-Phosphate Complex
8FTQ	;	2.1	;	Crystal structure of hRpn13 Pru domain in complex with Ubiquitin and XL44
7WOK	;	2.9	;	Crystal structure of HSA soaked with cisplatin for one week
7WOJ	;	2.89	;	Crystal structure of HSA-Myr complex soaked with cisplatin for one week
5JZ9	;	2.68	;	Crystal structure of HsaD bound to 3,5-dichloro-4-hydroxybenzenesulphonic acid
5JZB	;	2.102	;	Crystal structure of HsaD bound to 3,5-dichlorobenzene sulphonamide
7ZJT	;	1.96	;	Crystal structure of HsaD from Mycobacterium tuberculosis at 1.96 A resolution
7ZM3	;	1.81	;	Crystal structure of HsaD from Mycobacterium tuberculosis in complex with Cyclipostin-like inhibitor CyC17
7ZM4	;	1.62	;	Crystal structure of HsaD from Mycobacterium tuberculosis in complex with Cyclipostin-like inhibitor CyC31
7ZM1	;	2.15	;	Crystal structure of HsaD from Mycobacterium tuberculosis in complex with Cyclophostin-like inhibitor CyC7b
7ZM2	;	2.2	;	Crystal structure of HsaD from Mycobacterium tuberculosis in complex with Cyclophostin-like inhibitor CyC8b
7EPU	;	3.5	;	Crystal structure of HsALC1
7KSP	;	2.8	;	Crystal structure of hSAMD9_DBD with DNA
3TDP	;	2.99	;	Crystal structure of HSC at pH 4.5
3TDR	;	3.2	;	Crystal structure of HSC at pH 7.5
3TDO	;	2.197	;	Crystal structure of HSC at pH 9.0
3TDS	;	1.975	;	Crystal structure of HSC F194I
3TE0	;	2.09	;	Crystal structure of HSC K148E
3TE2	;	2.3	;	Crystal structure of HSC K16S
3TDX	;	2.5	;	Crystal structure of HSC L82V
3TE1	;	2.39	;	Crystal structure of HSC T84A
7TGM	;	2.5	;	Crystal structure of HSC-AMS bound DesD, the desferrioxamine synthetase from the Streptomyces griseoflavus ferrimycin biosynthetic pathway
6ZYJ	;	1.85	;	Crystal structure of Hsc70 ATPase domain in complex with ADP and calcium
3FZF	;	2.2	;	Crystal Structure of Hsc70/Bag1 in complex with ATP
3LDQ	;	1.9	;	Crystal structure of HSC70/BAG1 in complex with small molecule inhibitor
3M3Z	;	2.1	;	Crystal structure of HSC70/BAG1 in complex with small molecule inhibitor
2EXX	;	2.4	;	Crystal structure of HSCARG from Homo sapiens in complex with NADP
6VCJ	;	2.34	;	Crystal structure of hsDHFR in complex with NADP+, DAP, and R-naproxen
3OKG	;	1.95	;	Crystal structure of HsdS subunit from Thermoanaerobacter tengcongensis
1ZKK	;	1.45	;	Crystal structure of hSET8 in ternary complex with H4 peptide (16-24) and AdoHcy
5TEG	;	1.3	;	Crystal structure of hSETD8 in complex with histone H4K20 norleucine mutant peptide and S-Adenosylmethionine
5LNL	;	3.3	;	Crystal structure of Hsf 1608-1749 putative domain 1
7DCJ	;	2.004	;	Crystal structure of HSF1 DNA-binding domain in complex with 2-site HSE DNA in the head-to-head orientation
7DCS	;	2.4	;	Crystal structure of HSF1 DNA-binding domain in complex with 3-site HSE DNA (23 bp)
7DCT	;	2.36	;	Crystal structure of HSF1 DNA-binding domain in complex with 3-site HSE DNA (24 bp)
7DCI	;	1.7	;	Crystal structure of HSF2 DNA-binding domain in complex with 2-site HSE DNA in the head-to-head orientation
7DCU	;	1.75	;	Crystal structure of HSF2 DNA-binding domain in complex with 3-site HSE DNA (21 bp)
8A50	;	1.484	;	Crystal structure of HSF2BP-ALPHA1 tetramer
8A51	;	1.9	;	Crystal structure of HSF2BP-BRME1 complex
5H4D	;	3.21	;	Crystal structure of hSIRT3 in complex with a specific agonist Amiodarone hydrochloride
1G41	;	2.3	;	CRYSTAL STRUCTURE OF HSLU HAEMOPHILUS INFLUENZAE
1NED	;	3.8	;	CRYSTAL STRUCTURE OF HSLV (CLPQ) AT 3.8 ANGSTROMS RESOLUTION
1M4Y	;	2.1	;	Crystal structure of HslV from Thermotoga maritima
6B09	;	3.2	;	Crystal structure of HsNUDT16 in complex with diADPR (soaked)
5D4W	;	3.7	;	Crystal structure of Hsp104
5ZUI	;	2.701	;	Crystal Structure of HSP104 from Chaetomium thermophilum
6AMN	;	2.816	;	Crystal Structure of Hsp104 N Domain
6AZY	;	2.7	;	Crystal structure of Hsp104 R328M/R757M mutant from Calcarisporiella thermophila
1IZY	;	2.8	;	Crystal structure of Hsp31
1IZZ	;	2.31	;	Crystal structure of Hsp31
4AU4	;	2.97	;	Crystal Structure of Hsp47
6ZYI	;	1.52	;	Crystal structure of HSP70 ATPase domain in complex with ADP and calcium
5LRL	;	1.33	;	CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH A003492875
5LR1	;	1.44	;	CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH A003498614A.
5LRZ	;	2.0	;	CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH A003643501
5T21	;	2.1	;	CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH SAR148019.
5LS1	;	1.85	;	CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH SAR166475
5LQ9	;	1.9	;	CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH SAR200323.
5LR7	;	1.86	;	CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH SAR567530
3HYY	;	1.9	;	Crystal structure of Hsp90 with fragment 37-D04
3HYZ	;	2.3	;	Crystal structure of Hsp90 with fragment 42-C03
3HZ5	;	1.9	;	Crystal structure of Hsp90 with fragment Z064
3HZ1	;	2.3	;	Crystal structure of Hsp90 with fragments 37-D04 and 42-C03
3OW6	;	1.8	;	Crystal Structure of HSP90 with N-Aryl-benzimidazolone I
3OWD	;	1.63	;	Crystal Structure of HSP90 with N-Aryl-benzimidazolone II
3OWB	;	2.05	;	Crystal Structure of HSP90 with VER-49009
5J2V	;	1.59	;	Crystal Structure of Hsp90-alpha Apo N-domain
4U93	;	1.55	;	Crystal Structure of Hsp90-alpha N-domain Bound to the Inhibitor NVP-HSP990
4W7T	;	1.8	;	Crystal Structure of Hsp90-alpha N-domain Bound to the Inhibitor NVP-HSP990
5J82	;	2.17	;	Crystal Structure of Hsp90-alpha N-domain in complex 5-[4-(2-Fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-2,4-dihydroxy-N-isopropyl-N-methyl-benzenesulfonamide
5J86	;	1.87	;	Crystal Structure of Hsp90-alpha N-domain in complex with 2,4-Dihydroxy-N-methyl-5-(5-oxo-4-o-tolyl-4,5-dihydro-1H-[1,2,4]triazol-3-yl)-N-thiophen-2-ylmethyl-benzamide
5J64	;	1.38	;	Crystal Structure of Hsp90-alpha N-domain in complex with 5-(2,4-Dihydroxy-phenyl)-4-(2-fluoro-phenyl)-2,4-dihydro-[1,2,4]triazol-3-one
5J2X	;	1.22	;	Crystal Structure of Hsp90-alpha N-domain in complex with 5-(5-Bromo-2,4-dihydroxy-phenyl)-4-(2-fluoro-phenyl)-2,4-dihydro-[1,2,4]triazol-3-one
5NYH	;	1.65	;	Crystal Structure of Hsp90-alpha N-Domain in complex with Indazole derivative
5ODX	;	1.82	;	Crystal Structure of Hsp90-alpha N-Domain in complex with Indazole derivative
5J6L	;	1.75	;	Crystal Structure of Hsp90-alpha N-domain in complex with N-Butyl-5-[4-(2-fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-2,4-dihydroxy-N-methyl-benzamide
5NYI	;	1.44	;	Crystal Structure of Hsp90-alpha N-Domain in complex with Resorcinol derivative
5J6M	;	1.64	;	Crystal Structure of Hsp90-alpha N-domain L107 mutant in complex with 5-[4-(2-Fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-N-furan-2-ylmethyl-2,4-dihydroxy-N-methyl-benzamide
5J8U	;	1.75	;	Crystal Structure of Hsp90-alpha N-domain L107A mutant in complex with 5-(2,4-Dihydroxy-phenyl)-4-(2-fluoro-phenyl)-2,4-dihydro-[1,2,4]triazol-3-one
5J8M	;	1.9	;	Crystal Structure of Hsp90-alpha N-domain L107A mutant in complex with 5-(5-Bromo-2,4-dihydroxy-phenyl)-4-(2-fluoro-phenyl)-2,4-dihydro-[1,2,4]triazol-3-one
5J6N	;	1.9	;	Crystal Structure of Hsp90-alpha N-domain L107A mutant in complex with 5-[4-(2-Fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-2,4-dihydroxy-N-methyl-N-propyl-benzenesulfonamide
3WQ9	;	1.8	;	Crystal structure of Hsp90-alpha N-terminal domain in complex with 2-(4-Hydroxy-cyclohexylamino)-4-[5-(4-phenyl-imidazol-1-yl)-isoquinolin-1-yl]-benzamide
5ZR3	;	2.5	;	Crystal structure of Hsp90-alpha N-terminal domain in complex with 4-(3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3-methylbenzamide
7F51	;	1.98	;	Crystal structure of Hst2 in complex with 2'-O-Benzoyl ADP Ribose
7F4E	;	1.78	;	Crystal structure of Hst2 in complex with H3K9bz peptide
7SHO	;	2.25	;	Crystal structure of hSTING in complex with c[2',3'-(ara-2'-G, ribo-3'-A)-MP] (RJ242)
7SHP	;	2.2	;	Crystal structure of hSTING in complex with c[2',3'-(ribo-2'-G, xylo-3'-A)-MP](RJ244)
7T9U	;	2.46	;	Crystal structure of hSTING with an agonist (SHR169224)
7T9V	;	2.68	;	Crystal structure of hSTING with the agonist, SHR171032
4QXP	;	2.51	;	Crystal structure of hSTING(G230I) in complex with DMXAA
4QXO	;	1.88	;	Crystal structure of hSTING(group2) in complex with DMXAA
4LOI	;	1.89	;	Crystal structure of hSTING(H232) in complex with c[G(2',5')pA(2',5')p]
4LOH	;	2.25	;	Crystal structure of hSTING(H232) in complex with c[G(2',5')pA(3',5')p]
4QXR	;	2.37	;	Crystal structure of hSTING(S162A/G230I/Q266I) in complex with DMXAA
4QXQ	;	2.42	;	Crystal structure of hSTING(S162A/Q266I) in complex with DMXAA
3U3J	;	2.7	;	Crystal structure of hSULT1A1 bound to PAP
3U3K	;	2.36	;	Crystal structure of hSULT1A1 bound to PAP and 2-Naphtol
5ED7	;	2.72	;	Crystal Structure of HSV-1 UL21 C-terminal Domain
4U4H	;	2.05	;	Crystal Structure of HSV-1 UL21 N-terminal Domain
1P7C	;	2.1	;	Crystal Structure of HSV1-TK complexed with TP5A
5KCI	;	1.833	;	Crystal Structure of HTC1
6VBN	;	3.18	;	Crystal Structure of hTDO2 bound to inhibitor GNE1
3WEW	;	2.4	;	Crystal structure of HtdX (Rv0241c) of Mycobacterium tuberculosis at 2.4 A resolution
4OOB	;	2.3	;	Crystal structure of HtdX(Rv0241c) from Mycobacterium tuberculosis
5FOG	;	2.3	;	Crystal structure of hte Cryptosporidium muris cytosolic leucyl-tRNA synthetase editing domain complex with a post-transfer editing analogue of norvaline (Nv2AA)
3NS6	;	1.25	;	Crystal structure of hte RNA recognition motif of yeast eIF3b residues 76-170
8E1O	;	2.25	;	Crystal structure of hTEAD2 bound to a methoxypyridine lipid pocket binder
6S60	;	2.0	;	Crystal structure of hTEAD2 in complex with a trisubstituted pyrazole inhibitor
6S64	;	2.22	;	Crystal structure of hTEAD2 in complex with a trisubstituted pyrazole inhibitor
6S66	;	2.2	;	Crystal structure of hTEAD2 in complex with a trisubstituted pyrazole inhibitor
6S69	;	2.15	;	Crystal structure of hTEAD2 in complex with a trisubstituted pyrazole inhibitor
6S6J	;	2.1	;	Crystal structure of hTEAD2 in complex with a trisubstituted pyrazole inhibitor
7OYJ	;	1.91	;	Crystal structure of hTEAD2 in complex with fragment at the interface 2
2GFN	;	1.9	;	Crystal structure of HTH-type transcriptional regulator pksA related protein from Rhodococcus sp. RHA1
7CLA	;	2.5	;	Crystal structure of HTH-type transcriptional regulator SkgA from Caulobacter crescentus
3F5O	;	1.7	;	Crystal Structure of hTHEM2(undecan-2-one-CoA) complex
1Y9Q	;	1.9	;	Crystal Structure of HTH_3 family Transcriptional Regulator from Vibrio cholerae
3LIY	;	1.86	;	crystal structure of HTLV protease complexed with Statine-containing peptide inhibitor
3LIV	;	2.59	;	crystal structure of HTLV protease complexed with the inhibitor KNI-10683
3LIX	;	2.7	;	crystal structure of htlv protease complexed with the inhibitor KNI-10729
3LIN	;	1.96	;	crystal structure of HTLV protease complexed with the inhibitor, KNI-10562
3LIQ	;	2.29	;	Crystal Structure of HTLV protease complexed with the inhibitor, KNI-10673
2AV1	;	1.95	;	Crystal structure of HTLV-1 TAX peptide Bound to Human Class I MHC HLA-A2 with the E63Q and K66A mutations in the heavy chain.
2AV7	;	2.05	;	Crystal structure of HTLV-1 TAX peptide Bound to Human Class I MHC HLA-A2 with the K66A mutation in the heavy chain.
5UGJ	;	2.7	;	Crystal structure of HTPA Reductase from neisseria meningitidis
6WGT	;	3.4	;	Crystal structure of HTR2A with hallucinogenic agonist
6WH4	;	3.4	;	Crystal structure of HTR2A with inverse agonist
5ZVJ	;	2.7	;	Crystal structure of HtrA1 from Mycobacterium tuberculosis
4FEC	;	3.0	;	Crystal Structure of Htt36Q3H
4FED	;	2.807	;	Crystal Structure of Htt36Q3H
4FE8	;	3.0	;	Crystal Structure of Htt36Q3H-EX1-X1-C1(Alpha)
4FEB	;	2.8	;	Crystal Structure of Htt36Q3H-EX1-X1-C2(Beta)
5NN0	;	2.1	;	Crystal structure of huBChE with N-((1-(2,3-dihydro-1H-inden-2-yl)piperidin-3-yl)methyl)-N-(2-(dimethylamino)ethyl)-2-naphthamide.
1FXL	;	1.8	;	CRYSTAL STRUCTURE OF HUD AND AU-RICH ELEMENT OF THE C-FOS RNA
1G2E	;	2.3	;	CRYSTAL STRUCTURE OF HUD AND AU-RICH ELEMENT OF THE TUMOR NECROSIS FACTOR ALPHA RNA
7RRG	;	2.12	;	Crystal structure of human 0606T1-2 TCR bound to HLA-A*03:01 in complex with a mutant PIK3CA peptide
3V9G	;	2.5	;	Crystal structure of human 1-pyrroline-5-carboxylate dehydrogenase
3V9H	;	2.4	;	Crystal structure of human 1-pyrroline-5-carboxylate dehydrogenase mutant S352A
3V9I	;	2.85	;	Crystal structure of human 1-pyrroline-5-carboxylate dehydrogenase mutant S352L
3BWY	;	1.3	;	Crystal Structure of Human 108M Catechol O-methyltransferase bound with S-adenosylmethionine and inhibitor dinitrocatechol
3CZR	;	2.35	;	Crystal Structure of Human 11-beta-Hydroxysteroid Dehydrogenase (HSD1) in Complex with Arylsulfonylpiperazine Inhibitor
3D3E	;	2.6	;	Crystal Structure of Human 11-beta-Hydroxysteroid Dehydrogenase (HSD1) in Complex with Benzamide Inhibitor
3D4N	;	2.5	;	Crystal Structure of Human 11-beta-Hydroxysteroid Dehydrogenase (HSD1) in Complex with Sulfonamide Inhibitor
3PDJ	;	2.3	;	Crystal Structure of Human 11-beta-Hydroxysteroid Dehydrogenase 1 (11b-HSD1) in Complex with 4,4-Disubstituted Cyclohexylbenzamide Inhibitor
3BZU	;	2.25	;	Crystal structure of human 11-beta-hydroxysteroid dehydrogenase(HSD1) in complex with NADP and thiazolone inhibitor
3H6K	;	2.187	;	Crystal Structure of Human 11-beta-hydroxysteroid-dehydrogenase Bound to an Ortho-chlro-sulfonyl-piperazine Inhibitor
3HFG	;	2.3	;	Crystal Structure of Human 11-beta-hydroxysteroid-dehydrogenase Bound to an Sulfonyl-piperazine Inhibitor
6HEP	;	1.86	;	Crystal structure of human 14-3-3 beta in complex with CFTR R-domain peptide pS753-pS768
6Y6B	;	3.08	;	Crystal structure of human 14-3-3 gamma in complex with CaMKK2 14-3-3 binding motif Ser100 and 16-OMe-Fusicoccin H
6Y4K	;	3.0	;	Crystal structure of human 14-3-3 gamma in complex with CaMKK2 14-3-3 binding motif Ser100 and Fusicoccin A
5D3E	;	2.75	;	Crystal structure of human 14-3-3 gamma in complex with CFTR R-domain peptide pS768-pS795
7QI1	;	1.76	;	Crystal structure of human 14-3-3 protein beta in complex with CFTR peptide pS753pS768 and PPI stabilizer CY007424
3P1P	;	1.95	;	Crystal structure of human 14-3-3 sigma C38N/N166H in complex with TASK-3 peptide
3P1Q	;	1.7	;	Crystal structure of human 14-3-3 sigma C38N/N166H in complex with TASK-3 Peptide and stabilizer fusicoccin A
3P1S	;	1.65	;	Crystal structure of human 14-3-3 sigma C38N/N166H in complex with TASK-3 peptide and stabilizer fusicoccin A
3SML	;	1.9	;	Crystal structure of human 14-3-3 sigma C38N/N166H in complex with TASK-3 peptide and stabilizer Fusicoccin A aglycone
3SMN	;	2.0	;	Crystal structure of human 14-3-3 sigma C38N/N166H in complex with task-3 peptide and stabilizer Fusicoccin A-THF
3SMM	;	2.0	;	Crystal structure of human 14-3-3 sigma C38N/N166H in complex with task-3 peptide and stabilizer Fusicoccin J aglycone
3P1R	;	1.7	;	Crystal structure of human 14-3-3 sigma C38V/N166H in complex with TASK-3 peptide
3SMK	;	2.1	;	Crystal structure of human 14-3-3 sigma C38V/N166H in complex with TASK-3 peptide and stabilizer Cotylenin A
3SP5	;	1.8	;	Crystal structure of human 14-3-3 sigma C38V/N166H in complex with TASK-3 peptide and stabilizer Cotylenol
3SPR	;	1.99	;	Crystal structure of human 14-3-3 sigma C38V/N166H in complex with TASK-3 peptide and stabilizer FC-THF
3SMO	;	1.8	;	Crystal structure of human 14-3-3 sigma C38V/N166H in complex with TASK-3 peptide and stabilizer Fusicoccin J aglycone
4FL5	;	1.9	;	Crystal structure of human 14-3-3 sigma in complex with a Tau-protein peptide surrounding pS214
5BTV	;	1.7	;	Crystal structure of human 14-3-3 sigma in complex with a Tau-protein peptide surrounding pS324
5MYC	;	1.459	;	Crystal structure of human 14-3-3 sigma in complex with LRRK2 peptide pS910
5MY9	;	1.327	;	Crystal structure of human 14-3-3 sigma in complex with LRRK2 peptide pS935
3IQJ	;	1.15	;	Crystal Structure of human 14-3-3 sigma in Complex with Raf1 peptide (10mer)
3IQU	;	1.05	;	Crystal Structure of human 14-3-3 sigma in Complex with Raf1 peptide (6mer)
3IQV	;	1.2	;	Crystal Structure of human 14-3-3 sigma in Complex with Raf1 peptide (6mer) and stabilisator Fusicoccin
3P1N	;	1.4	;	Crystal structure of human 14-3-3 sigma in complex with TASK-3 peptide
3P1O	;	1.9	;	Crystal structure of human 14-3-3 sigma in complex with TASK-3 peptide and stabilisator Fusicoccin A
4FR3	;	1.9	;	Crystal structure of human 14-3-3 sigma in complex with TASK-3 peptide and stabilizer 16-O-Me-FC-H
3UX0	;	1.75	;	Crystal structure of human 14-3-3 sigma in complex with TASK-3 peptide and stabilizer Fusicoccin H
8AH2	;	2.9	;	Crystal structure of human 14-3-3 zeta fused to the NPM1 peptide including phosphoserine-48
5D2D	;	2.1	;	Crystal structure of human 14-3-3 zeta in complex with CFTR R-domain peptide pS753-pS768
5D3F	;	2.74	;	Crystal structure of human 14-3-3 zeta in complex with CFTR R-domain peptide pS753-pS768 and stabilizer fusicoccin-A
5NAS	;	2.08	;	Crystal structure of human 14-3-3 zeta in complex with PI4KIIIB peptide
2ZB4	;	1.63	;	Crystal structure of human 15-ketoprostaglandin delta-13-reductase in complex with NADP and 15-keto-PGE2
2ZB8	;	2.0	;	Crystal structure of human 15-ketoprostaglandin delta-13-reductase in complex with NADP and indomethacin
2ZB7	;	1.8	;	Crystal structure of human 15-ketoprostaglandin delta-13-reductase in complex with NADPH and nicotinamide
1ZBQ	;	2.19	;	Crystal Structure Of Human 17-Beta-Hydroxysteroid Dehydrogenase Type 4 In Complex With NAD
1YB1	;	1.95	;	Crystal structure of human 17-beta-hydroxysteroid dehydrogenase type XI
2FGB	;	1.35	;	Crystal structure of human 17bet a-hydroxysteroid dehydrogenase type 5 in complexes with PEG and NADP
6CGC	;	2.1	;	Crystal structure of human 17beta-HSD type 1 in ternary complex with 2-MeO-CC-156 and NADP+
6CGE	;	2.2	;	Crystal structure of human 17beta-HSD type 1 in ternary complex with PBRM and NADP+
6DTP	;	2.0	;	CRYSTAL STRUCTURE OF HUMAN 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 COMPLEXED WITH EM139
6MNC	;	2.4	;	CRYSTAL STRUCTURE OF HUMAN 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 COMPLEXED WITH ESTRONE
7X3Z	;	2.25	;	Crystal structure of human 17beta-hydroxysteroid dehydrogenase type 1 complexed with estrone and NAD
6MNE	;	1.86	;	CRYSTAL STRUCTURE OF HUMAN 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 COMPLEXED WITH ESTRONE AND NADP+
1XF0	;	2.0	;	Crystal structure of human 17beta-hydroxysteroid dehydrogenase type 5 (AKR1C3) complexed with delta4-androstene-3,17-dione and NADP
4DBW	;	1.802	;	Crystal structure of human 17beta-hydroxysteroid dehydrogenase type 5 (AKR1C3) in complex with NADP+ and 2'-desmethyl-indomethacin
4DBS	;	1.852	;	Crystal structure of human 17beta-hydroxysteroid dehydrogenase type 5 (AKR1C3) in complex with NADP+ and 3'-[(4-nitronaphthalen-1-yl)amino]benzoic acid
4DBU	;	2.528	;	Crystal structure of human 17beta-hydroxysteroid dehydrogenase type 5 (AKR1C3) in complex with NADP+ and 3-((4 -(trifluoromethyl)phenyl)amino)benzoic acid
4HMN	;	2.4	;	Crystal structure of human 17beta-hydroxysteroid dehydrogenase type 5 in complex with (4-(4-Chlorophenyl)piperazin-1-yl)(morpholino)methanone (24)
4FA3	;	2.2	;	Crystal structure of human 17beta-hydroxysteroid dehydrogenase type 5 in complex with (R)-1-(naphthalen-2-ylsulfonyl)piperidine-3-carboxylic acid (86)
4H7C	;	1.97	;	Crystal structure of human 17beta-hydroxysteroid dehydrogenase type 5 in complex with 1-{4-[(2-methyl-1-piperidinyl)sulfonyl]phenyl}-2-pyrrolidinone
4FAL	;	2.0	;	Crystal structure of human 17beta-hydroxysteroid dehydrogenase type 5 in complex with 3-((3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)-N-methylbenzamide (80)
4FAM	;	2.0	;	Crystal structure of human 17beta-hydroxysteroid dehydrogenase type 5 in complex with 3-((3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)benzoic acid (17)
6Q20	;	2.45	;	Crystal structure of human 1E01 Fab in complex with influenza virus neuraminidase from A/Japan/305/1957 (H2N2)
6Q23	;	3.27	;	Crystal structure of human 1G01 Fab in complex with influenza virus neuraminidase from A/California/04/2009 (H1N1)
6Q1Z	;	3.446	;	Crystal structure of human 1G04 Fab in complex with influenza virus neuraminidase from A/Hunan/02650/2016 (H7N9)
1MRQ	;	1.59	;	Crystal structure of human 20alpha-HSD in ternary complex with NADP and 20alpha-hydroxy-progesterone
7L1D	;	3.11	;	Crystal structure of human 21LT2-2 TCR bound to HLA-A*03:01 in complex with a mutant PIK3CA peptide
3PIQ	;	3.325	;	Crystal structure of human 2909 Fab, a quaternary structure-specific antibody against HIV-1
4XO6	;	1.2	;	Crystal structure of human 3-alpha hydroxysteroid dehydrogenase type 3 in complex with NADP+, 5alpha-androstan-3,17-dione and (3beta, 5alpha)-3-hydroxyandrostan-17-one
4XO7	;	1.75	;	Crystal structure of human 3-alpha hydroxysteroid dehydrogenase type 3 in complex with NADP+, 5alpha-androstan-3,17-dione and (3beta, 5alpha)-3-hydroxyandrostan-17-one
2FVL	;	2.4	;	Crystal structure of human 3-alpha hydroxysteroid/dihydrodiol dehydrogenase (AKR1C4) complexed with NADP+
2P8U	;	2.0	;	Crystal structure of human 3-hydroxy-3-methylglutaryl CoA synthase I
3IR3	;	1.99	;	Crystal structure of human 3-hydroxyacyl-thioester dehydratase 2 (HTD2)
2QNK	;	1.6	;	Crystal structure of human 3-hydroxyanthranilate 3,4-dioxygenase
1T8T	;	1.85	;	Crystal Structure of human 3-O-Sulfotransferase-3 with bound PAP
1T8U	;	1.95	;	Crystal Structure of human 3-O-Sulfotransferase-3 with bound PAP and tetrasaccharide substrate
3DLX	;	2.2	;	Crystal structure of human 3-oxoacid CoA transferase 1
2G76	;	1.7	;	Crystal structure of human 3-phosphoglycerate dehydrogenase
5NZO	;	1.29	;	Crystal structure of human 3-phosphoglycerate dehydrogenase in complex with 1-methyl-3-phenyl-1H-pyrazol-5-amine
5NZQ	;	1.5	;	Crystal structure of human 3-phosphoglycerate dehydrogenase in complex with 3-(1,3-oxazol-5-yl)aniline.
5OFW	;	1.5	;	Crystal structure of human 3-phosphoglycerate dehydrogenase in complex with 3-Chloro-4-fluorobenzamide
5NZP	;	1.3	;	Crystal structure of human 3-phosphoglycerate dehydrogenase in complex with 3-Hydroxybenzisoxazole
5OFM	;	1.5	;	Crystal structure of human 3-phosphoglycerate dehydrogenase in complex with 5-amino-1-methyl-1H-indole
5OFV	;	1.5	;	Crystal structure of human 3-phosphoglycerate dehydrogenase in complex with 5-fluoro-2-methylbenzoic acid
7VA1	;	1.74	;	Crystal structure of human 3-phosphoglycerate dehydrogenase in complex with GDD-04-35
5N53	;	1.48	;	Crystal structure of human 3-phosphoglycerate dehydrogenase in complex with N-(3-chloro-4-methoxyphenyl) acetamide
5N6C	;	2.3	;	Crystal structure of human 3-phosphoglycerate dehydrogenase in complex with NAD and L-Tartrate
5TK5	;	1.88	;	Crystal structure of human 3HAO with iron bound in the active site
5TKQ	;	1.75	;	Crystal structure of human 3HAO with zinc bound in the active site
3S5N	;	2.5	;	Crystal Structure of Human 4-hydroxy-2-oxoglutarate Aldolase
3S5O	;	1.97	;	Crystal Structure of Human 4-hydroxy-2-oxoglutarate Aldolase Bound to Pyruvate
3ISQ	;	1.75	;	Crystal structure of human 4-Hydroxyphenylpyruvate dioxygenase
4XCE	;	2.93	;	Crystal structure of human 4E10 Fab crystalized in the presence of Phosphatidylcholine (06:0 PC); C2 space group
4XCC	;	2.81	;	Crystal structure of human 4E10 Fab crystalized in the presence of Phosphatidylcholine (06:0 PC); I422 space group
4XBP	;	2.94	;	Crystal structure of human 4E10 Fab crystalized in the presence of Phosphatidylethanolamine (06:0 PE)
4XAW	;	1.47	;	Crystal structure of human 4E10 Fab in complex with its peptide epitope on HIV-1 gp41: Crystals cryoprotected with phosphatidic acid (08:0 PA)
4XC1	;	1.63	;	Crystal structure of human 4E10 Fab in complex with its peptide epitope on HIV-1 GP41: crystals cryoprotected with sn-Glycerol 3-phosphate
4XBE	;	1.756	;	Crystal structure of human 4E10 Fab in complex with its peptide epitope on HIV-1 gp41: crystals cryoprotected with sphingomyelin (02:0 SM (d18:1/2:0)).
4XCF	;	1.43	;	Crystal structure of human 4E10 Fab in complex with its peptide epitope on HIV-1 gp41; crystals cryoprotected with phosphatidylcholine (03:0 PC)
4XC3	;	1.63	;	Crystal structure of human 4E10 Fab in complex with its peptide epitope on HIV-1 gp41; crystals cryoprotected with rac-glycerol 1-phosphate
4XBG	;	2.73	;	Crystal structure of human 4E10 Fab in complex with phosphatidic acid (06:0 PA): 2.73 A resolution
4XCN	;	2.9	;	Crystal structure of human 4E10 Fab in complex with phosphatidic acid (06:0 PA); 2.9 A resolution
4XCY	;	3.96	;	Crystal structure of human 4E10 Fab in complex with phosphatidylglycerol (06:0 PG)
5AHO	;	2.16	;	Crystal structure of human 5' exonuclease Apollo
7B9B	;	2.8	;	Crystal structure of human 5' exonuclease Appollo APO form
7B2X	;	3.1	;	Crystal structure of human 5' exonuclease Appollo H61Y variant
7A1F	;	1.8	;	Crystal structure of human 5' exonuclease Appollo in complex with 5'dAMP
3OZE	;	2.0	;	Crystal Structure of human 5'-deoxy-5'-methyladenosine phosphorylase
3OZC	;	1.93	;	Crystal Structure of human 5'-deoxy-5'-methyladenosine phosphorylase in complex with pCl-phenylthioDADMeImmA
3OZD	;	2.1	;	Crystal Structure of human 5'-deoxy-5'-methyladenosine phosphorylase in complex with pCl-phenylthioDADMeImmA
6DZ2	;	1.99	;	Crystal structure of human 5'-deoxy-5'-methylthioadenosine phosphorylase in complex with (3R,4S)-1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-(((3-(1-benzyl-1H-1,2,3-triazol-4-yl)propyl)thio)methyl)pyrrolidin-3-ol
6DZ3	;	1.91	;	Crystal structure of human 5'-deoxy-5'-methylthioadenosine phosphorylase in complex with (3R,4S)-1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-(((3-(1-butyl-1H-1,2,3-triazol-4-yl)propyl)thio)methyl)pyrrolidin-3-ol
6DZ0	;	1.62	;	Crystal structure of human 5'-deoxy-5'-methylthioadenosine phosphorylase in complex with (3R,4S)-1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-((pent-4-yn-1-ylthio)methyl)pyrrolidin-3-ol
6DYZ	;	1.62	;	Crystal structure of human 5'-deoxy-5'-methylthioadenosine phosphorylase in complex with (3R,4S)-1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-((prop-2-yn-1-ylthio)methyl)pyrrolidin-3-ol
5EUB	;	1.81	;	Crystal structure of human 5'-deoxy-5'-methylthioadenosine phosphorylase in complex with 2-amino-MTA and sulfate
5TC7	;	1.75	;	Crystal structure of human 5'-deoxy-5'-methylthioadenosine phosphorylase in complex with 5'-methylthiotubercidin at 1.75 angstrom
5TC5	;	1.96	;	Crystal structure of human 5'-deoxy-5'-methylthioadenosine phosphorylase in complex with butylthio-DADMe-Immucillin-A and chloride
5TC8	;	1.8	;	Crystal structure of human 5'-deoxy-5'-methylthioadenosine phosphorylase in complex with methylthio-DADMe-Immucillin-A
5TC6	;	1.48	;	Crystal structure of human 5'-deoxy-5'-methylthioadenosine phosphorylase in complex with propylthio-immucillin-A
4CCZ	;	2.7	;	Crystal structure of human 5-methyltetrahydrofolate-homocysteine methyltransferase, the homocysteine and folate binding domains
4CNC	;	1.77	;	Crystal structure of human 5T4 (Wnt-activated inhibitory factor 1, Trophoblast glycoprotein)
4CNM	;	1.75	;	Crystal structure of human 5T4 (Wnt-activated inhibitory factor 1, Trophoblast glycoprotein)
3Q93	;	1.8	;	Crystal Structure of Human 8-oxo-dGTPase (MTH1)
1QRN	;	2.8	;	CRYSTAL STRUCTURE OF HUMAN A6 TCR COMPLEXED WITH HLA-A2 BOUND TO ALTERED HTLV-1 TAX PEPTIDE P6A
3BTY	;	2.35	;	Crystal structure of human ABH2 bound to dsDNA containing 1meA through cross-linking away from active site
3BTZ	;	3.0	;	Crystal structure of human ABH2 cross-linked to dsDNA
3BU0	;	2.5	;	crystal structure of human ABH2 cross-linked to dsDNA with cofactors
2IUW	;	1.5	;	Crystal structure of human ABH3 in complex with iron ion and 2- oxoglutarate
4ASI	;	2.8	;	Crystal structure of human ACACA C-terminal domain
5LZ1	;	2.0	;	Crystal structure of human ACBD3 GOLD domain
5LZ3	;	3.0	;	Crystal structure of human ACBD3 GOLD domain in complex with 3A protein of Aichivirus A
5LZ6	;	2.6	;	Crystal structure of human ACBD3 GOLD domain in complex with 3A protein of Aichivirus B
6HLW	;	2.728	;	Crystal structure of human ACBD3 GOLD domain in complex with 3A protein of enterovirus-A71 (fusion protein)
6HLN	;	2.1	;	Crystal structure of human ACBD3 GOLD domain in complex with 3A protein of enterovirus-D68
6HM8	;	2.277	;	Crystal structure of human ACBD3 GOLD domain in complex with 3A protein of enterovirus-D68 (fusion protein)
6HMV	;	2.244	;	Crystal structure of human ACBD3 GOLD domain in complex with 3A protein of enterovirus-D68 (fusion protein, LVVY mutant)
6HLV	;	2.5	;	Crystal structure of human ACBD3 GOLD domain in complex with 3A protein of poliovirus-1 (L24A mutant)
6HLT	;	2.815	;	Crystal structure of human ACBD3 GOLD domain in complex with 3A protein of rhinovirus-14 (HRV14)
5KKN	;	2.6	;	Crystal structure of human ACC2 BC domain in complex with ND-646, the primary amide of ND-630
7VIB	;	3.2	;	Crystal structure of human ACE2 and GX/P2V RBD
7PKI	;	2.94234	;	Crystal structure of human ACE2 bound to the spike receptor-binding domain from a cave bat sarbecovirus closely related to SARS-CoV-2.
2YL2	;	2.3	;	Crystal structure of human acetyl-CoA carboxylase 1, biotin carboxylase (BC) domain
3TDC	;	2.41	;	Crystal Structure of Human Acetyl-CoA carboxylase 2
4PQE	;	2.9	;	Crystal Structure of Human Acetylcholinesterase
7E3D	;	2.5	;	Crystal structure of human acetylcholinesterase
6ZWE	;	3.0	;	Crystal structure of human acetylcholinesterase in complex with ((6-((2E,4E)-5-(benzo[d][1,3]dioxol-5-yl)penta-2,4-dienamido)hexyl)triphenylphosphonium bromide)
7P1N	;	2.95	;	Crystal structure of human acetylcholinesterase in complex with (2R,3R,4S,5S,6R)-2-{4-[1-(4-{5-hydroxy-6-[(E)-(hydroxyimino)methyl]pyridin-2-yl}butyl)-1H-1,2,3-triazol-4-yl]butoxy}-6-(hydroxymethyl)oxane-3,4,5-triol oxime
7P1P	;	3.03	;	Crystal structure of human acetylcholinesterase in complex with (E)-3-hydroxy-6-(3-(4-(4-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)butyl)-1H-1,2,3-triazol-1-yl)propyl)picolinaldehyde oxime
6F25	;	3.052	;	Crystal structure of human acetylcholinesterase in complex with C35.
7E3H	;	2.45	;	Crystal structure of human acetylcholinesterase in complex with donepezil
5HF8	;	2.8	;	Crystal structure of human acetylcholinesterase in complex with paraoxon (alternative acyl loop conformation)
5HFA	;	2.201	;	Crystal structure of human acetylcholinesterase in complex with paraoxon and 2-PAM
5HF9	;	2.2	;	Crystal structure of human acetylcholinesterase in complex with paraoxon and HI6
5HF6	;	2.3	;	Crystal structure of human acetylcholinesterase in complex with paraoxon in the aged state
5HF5	;	2.152	;	Crystal structure of human acetylcholinesterase in complex with paraoxon in the unaged state (predominant acyl loop conformation)
7XN1	;	2.85	;	Crystal structure of human acetylcholinesterase in complex with tacrine
2X8B	;	2.95	;	Crystal structure of human acetylcholinesterase inhibited by aged tabun and complexed with fasciculin-II
6MHM	;	2.743	;	Crystal structure of human acid ceramidase in covalent complex with carmofur
5JG8	;	2.8	;	Crystal structure of human acid sphingomyelinase
2YBT	;	2.22	;	Crystal structure of human acidic chitinase in complex with bisdionin C
2YBU	;	2.25	;	Crystal structure of human acidic chitinase in complex with bisdionin F
6G6S	;	1.65	;	Crystal structure of human Acinus RNA recognition motif domain
3F6U	;	2.8	;	Crystal structure of human Activated Protein C (APC) complexed with PPACK
4C02	;	2.17	;	Crystal structure of human ACVR1 (ALK2) in complex with FKBP12.6 and dorsomorphin
2WH5	;	2.6	;	Crystal structure of human acyl-CoA binding domain 4 complexed with stearoyl-CoA
3EPY	;	2.005	;	Crystal Structure of human acyl-CoA binding domain 7 complexed with palmitoyl-Coa
2WBI	;	2.8	;	Crystal structure of human acyl-CoA dehydrogenase 11
3GPC	;	1.9	;	Crystal structure of human Acyl-CoA synthetase medium-chain family member 2A (L64P mutation) in a complex with CoA
3EQ6	;	2.4	;	Crystal structure of human acyl-CoA synthetase medium-chain family member 2A (L64P mutation) in a ternary complex with products
2VZE	;	2.45	;	Crystal structure of human acyl-CoA synthetase medium-chain family member 2A (L64P mutation) in complex with AMP
3DAY	;	1.95	;	Crystal structure of human acyl-CoA synthetase medium-chain family member 2A (L64P mutation) in complex with AMP-CPP
3C5E	;	1.6	;	Crystal structure of human acyl-CoA synthetase medium-chain family member 2A (L64P mutation) in complex with ATP
2WD9	;	2.6	;	CRYSTAL STRUCTURE OF HUMAN ACYL-COA SYNTHETASE MEDIUM-CHAIN FAMILY MEMBER 2A (L64P MUTATION) IN COMPLEX WITH IBUPROFEN
3B7W	;	2.0	;	Crystal structure of human acyl-CoA synthetase medium-chain family member 2A, with L64P mutation
8HQ2	;	2.93	;	Crystal structure of human ADAM22 in complex with human LGI1 mutant
2V4B	;	2.0	;	Crystal Structure of Human ADAMTS-1 catalytic Domain and Cysteine- Rich Domain (apo-form)
2JIH	;	2.1	;	Crystal Structure of Human ADAMTS-1 catalytic Domain and Cysteine- Rich Domain (complex-form)
4WK7	;	1.24	;	Crystal structure of human ADAMTS-4 in complex with inhibitor (compound 1, 2-(4-chlorophenoxy)-N-{[(4R)-4-methyl-2,5-dioxoimidazolidin-4-yl]methyl} acetamide)
4WKE	;	1.62	;	Crystal structure of human ADAMTS-4 in complex with inhibitor 5-chloro-N-{[(4R)-2,5-dioxo-4-(1,3-thiazol-2-yl)imidazolidin-4-yl]methyl}-1-benzofuran-2-carboxamide (compound 10)
4WKI	;	1.6	;	Crystal structure of human ADAMTS-4 in complex with inhibitor 5-CHLORO-N-{[(4S)-4-(1-METHYL-1H-IMIDAZOL-2-YL)-2,5-DIOXOIMIDAZOLIDIN-4-YL]METHYL}-1-BENZOFURAN-2-CARBOXAMIDE (compound 11)
8GNE	;	2.3	;	Crystal structure of human adenosine A2A receptor in complex with an insurmountable inverse agonist, KW-6356.
8GNG	;	3.2	;	Crystal structure of human adenosine A2A receptor in complex with istradefylline.
3VG9	;	2.7	;	Crystal structure of human adenosine A2A receptor with an allosteric inverse-agonist antibody at 2.7 A resolution
3VGA	;	3.1	;	Crystal structure of human adenosine A2A receptor with an allosteric inverse-agonist antibody at 3.1 A resolution
3LGD	;	2.0	;	Crystal structure of human adenosine deaminase growth factor, adenosine deaminase type 2 (ADA2)
3LGG	;	2.5	;	Crystal structure of human adenosine deaminase growth factor, adenosine deaminase type 2 (ADA2) complexed with transition state analogue, coformycin
4PIE	;	1.94	;	Crystal structure of human adenovirus 2 protease a substrate based nitrile inhibitor
4PID	;	1.59	;	Crystal structure of human adenovirus 2 protease with a weak pyrimidine nitrile inhibitor
1NLN	;	1.6	;	CRYSTAL STRUCTURE OF HUMAN ADENOVIRUS 2 PROTEINASE WITH ITS 11 AMINO ACID COFACTOR AT 1.6 ANGSTROM RESOLUTION
4XL8	;	1.65	;	Crystal Structure of Human Adenovirus 52 Short Fiber Knob in Complex with 2-O-Methyl-5-N-Acetylneuraminic Acid
6G47	;	1.497	;	Crystal Structure of Human Adenovirus 52 Short Fiber Knob in Complex with alpha-(2,8)-Trisialic Acid (DP3)
7AJP	;	1.38202	;	Crystal Structure of Human Adenovirus 56 Fiber Knob
4PIS	;	2.1	;	Crystal structure of human adenovirus 8 protease in complex with a nitrile inhibitor
4PIQ	;	2.07	;	Crystal structure of human adenovirus 8 protease with a nitrile inhibitor
4WX6	;	2.15	;	Crystal structure of human adenovirus 8 protease with an irreversible vinyl sulfone inhibitor
6ZJE	;	1.48	;	Crystal structure of human adenylate kinase 3, AK3, in complex with inhibitor Ap5A
6ZJD	;	1.75	;	Crystal structure of human adenylate kinase 3, AK3, in complex with inhibitor ATP
6ZJB	;	1.822	;	Crystal structure of human adenylate kinase 3, AK3, in complex with inhibitor Gp5A
2BBW	;	2.05	;	Crystal structure of human adenylate kinase 4 (AK4) in complex with diguanosine pentaphosphate
2AR7	;	2.15	;	Crystal structure of human adenylate kinase 4, AK4
2J91	;	1.8	;	Crystal structure of Human Adenylosuccinate Lyase in complex with AMP
3Q6L	;	1.4	;	Crystal Structure of Human Adipocyte Fatty Acid Binding Protein (FABP4) at 1.4 Ang. Resolution
2NNQ	;	1.8	;	Crystal structure of human adipocyte fatty acid binding protein in complex with ((2'-(5-ethyl-3,4-diphenyl-1H-pyrazol-1-yl)-3-biphenylyl)oxy)acetic acid
1TOW	;	2.0	;	Crystal structure of human adipocyte fatty acid binding protein in complex with a carboxylic acid ligand
1TOU	;	2.0	;	Crystal structure of human adipocyte fatty acid binding protein in complex with a non-covalent ligand
5LX9	;	2.4	;	CRYSTAL STRUCTURE OF HUMAN ADIPONECTIN RECEPTOR 2 IN COMPLEX WITH A C18 FREE FATTY ACID AT 2.4 ANGSTROM RESOLUTION
5LXA	;	3.0	;	CRYSTAL STRUCTURE OF HUMAN ADIPONECTIN RECEPTOR 2 IN COMPLEX WITH A C18 FREE FATTY ACID AT 3.0 ANGSTROM RESOLUTION
2DSB	;	2.5	;	Crystal structure of human ADP-ribose pyrophosphatase NUDT5
2DSC	;	2.0	;	Crystal structure of human ADP-ribose pyrophosphatase NUDT5 in complex with magnesium and ADP-ribose
2DSD	;	2.6	;	Crystal structure of human ADP-ribose pyrophosphatase NUDT5 in complex with magnesium and AMP
3BM4	;	2.0	;	Crystal Structure of Human ADP-ribose Pyrophosphatase NUDT5 In complex with magnesium and AMPcpr
1Q33	;	1.81	;	Crystal structure of human ADP-ribose pyrophosphatase NUDT9
2H57	;	2.0	;	Crystal structure of human ADP-ribosylation factor-like 6
3HFW	;	1.92	;	Crystal Structure of human ADP-ribosylhydrolase 1 (hARH1)
4FA0	;	2.65	;	Crystal structure of human AdPLA to 2.65 A resolution
7MJU	;	2.1	;	Crystal structure of human AF10 PZP bound to histone H3 tail
6K7P	;	2.4	;	Crystal structure of human AFF4-THD domain
2CLP	;	3.0	;	Crystal structure of human aflatoxin B1 aldehyde reductase member 3
1JV3	;	2.2	;	CRYSTAL STRUCTURE OF HUMAN AGX1 COMPLEXED WITH UDPGALNAC
1JV1	;	1.9	;	CRYSTAL STRUCTURE OF HUMAN AGX1 COMPLEXED WITH UDPGLCNAC
6Z2F	;	1.7	;	Crystal structure of human AGX1 mutant complexed with UDPGLCNAC
1JVG	;	2.3	;	CRYSTAL STRUCTURE OF HUMAN AGX2 COMPLEXED WITH UDPGALNAC
1JVD	;	2.4	;	CRYSTAL STRUCTURE OF HUMAN AGX2 COMPLEXED WITH UDPGLCNAC
3VD8	;	2.0685	;	Crystal structure of human AIM2 PYD domain with MBP fusion
1Z83	;	1.9	;	Crystal structure of human AK1A in complex with AP5A
3NDP	;	2.3	;	Crystal structure of human AK4(L171P)
5OU0	;	0.94	;	Crystal structure of human AKR1B1 complexed with NADP+ and compound 37
5OUJ	;	0.96	;	Crystal structure of human AKR1B1 complexed with NADP+ and compound 39
5OUK	;	0.959	;	Crystal structure of human AKR1B1 complexed with NADP+ and compound 41
4XZL	;	1.7	;	Crystal structure of human AKR1B10 complexed with NADP+ and JF0049
4ICC	;	1.752	;	Crystal structure of human AKR1B10 complexed with NADP+ and JF0064
4WEV	;	1.453	;	Crystal structure of human AKR1B10 complexed with NADP+ and sulindac
5LIU	;	1.75	;	Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor IDD388
5LIK	;	2.05	;	Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor MK181
5LIX	;	1.95	;	Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor MK184
5LIY	;	2.05	;	Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor MK204
5LIW	;	1.75	;	Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor MK319
5M2F	;	1.503	;	Crystal structure of human AKR1B10 complexed with NADP+ and the synthetic retinoid UVI2008
3O96	;	2.7	;	Crystal Structure of Human AKT1 with an Allosteric Inhibitor
3D0E	;	2.0	;	Crystal structure of human Akt2 in complex with GSK690693
5F9S	;	1.7	;	Crystal structure of human Alanine:Glyoxylate Aminotransferase major allele (AGT-Ma) at 1.7 Angstrom; internal aldimine with PLP in the active site
5OG0	;	2.5	;	Crystal structure of human Alanine:Glyoxylate Aminotransferase major allele (AGT-Ma) at 2.5 Angstrom; internal aldimine with PLP in the active site
4XEO	;	1.38	;	Crystal Structure of human AlaRS catalytic domain with R329H mutation
1U3T	;	2.49	;	Crystal Structure of Human Alcohol Dehydrogenase Alpha-Alpha Isoform Complexed with N-Cyclopentyl-N-Cyclobutylformamide Determined to 2.5 Angstrom Resolution
1U3U	;	1.6	;	Crystal Structure of Human Alcohol Dehydrogenase Beta-1-Beta-1 Isoform Complexed with N-Benzylformamide Determined to 1.6 Angstrom Resolution
1U3V	;	1.65	;	Crystal Structure of Human Alcohol Dehydrogenase Beta-1-Beta-1 Isoform Complexed with N-Heptylformamide Determined to 1.65 Angstrom Resolution
1U3W	;	1.45	;	Crystal Structure of Human Alcohol Dehydrogenase Gamma-2-Gamma-2 Isoform Complexed with N-1-Methylheptylformamide Determined to 1.45 Angstrom Resolution
6TGW	;	2.8	;	Crystal structure of human Aldehyde dehydrogenase 1A3 in complex with a selective inhibitor
6TE5	;	3.25	;	Crystal structure of human Aldehyde dehydrogenase 1A3 in complex with LQ43 inhibitor compound
6TRY	;	2.9	;	Crystal structure of human Aldehyde dehydrogenase 1A3 in complex with MF13 inhibitor compound
7A6Q	;	2.95	;	Crystal structure of human aldehyde dehydrogenase 1A3 in complex with selective NR6 inhibitor compound
8BB8	;	1.8	;	Crystal structure of human aldehyde dehydrogenase ALDH3A1 in complex with octanal
4X2Q	;	2.94	;	Crystal Structure of Human Aldehyde Dehydrogenase, ALDH1a2
4FR8	;	2.2	;	Crystal structure of human aldehyde dehydrogenase-2 in complex with nitroglycerin
7JWS	;	1.6	;	Crystal structure of human ALDH1A1 bound to compound (R)-28
7JWT	;	1.8	;	Crystal structure of human ALDH1A1 bound to compound (R)-28
7JWU	;	1.9	;	Crystal structure of human ALDH1A1 bound to compound (R)-28
7JWV	;	1.6	;	Crystal structure of human ALDH1A1 bound to compound (R)-28
7JWW	;	1.6	;	Crystal structure of human ALDH1A1 bound to compound (R)-28
6S6W	;	3.25	;	Crystal Structure of human ALDH1A3 in complex with 2,6-diphenylimidazo[1,2-a]pyridine (compound GA11) and NAD+
8DR9	;	1.5	;	Crystal structure of human ALDH2 in complex with NAD+ and PEG MME 550
3SZ9	;	2.1	;	Crystal structure of human ALDH2 modified with the beta-elimination product of Aldi-3; 1-(4-ethylbenzene)prop-2-en-1-one
3SZA	;	1.48	;	Crystal structure of human ALDH3A1 - apo form
3SZB	;	1.51	;	Crystal structure of human ALDH3A1 modified with the beta-elimination product of Aldi-1; 1-phenyl- 2-propen-1-one
4L1O	;	2.3	;	Crystal structure of human ALDH3A1 with inhibitor 1-{[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]methyl}-1H-indole-2,3-dione
4H80	;	2.5	;	Crystal structure of human ALDH3A1 with its isozyme selective inhibitor - N-[4-(4-methylsulfonyl-2-nitroanilino)phenyl]acetamide
4L2O	;	1.937	;	Crystal structure of human ALDH3A1 with its selective inhibitor 1-(4-fluorophenyl)sulfonyl-2-methylbenzimidazole
1PWM	;	0.92	;	Crystal structure of human Aldose Reductase complexed with NADP and Fidarestat
1T41	;	1.05	;	Crystal structure of human aldose reductase complexed with NADP and IDD552
1T40	;	1.8	;	Crystal structure of human aldose reductase complexed with NADP and IDD552 at ph 5
1PWL	;	1.1	;	Crystal structure of human Aldose Reductase complexed with NADP and Minalrestat
4XZH	;	1.0	;	Crystal structure of human Aldose Reductase complexed with NADP+ and JF0048
4XZI	;	2.45	;	Crystal structure of human Aldose Reductase complexed with NADP+ and JF0049
4IGS	;	0.85	;	Crystal structure of human Aldose Reductase complexed with NADP+ and JF0064
3RX3	;	1.9	;	Crystal Structure of Human Aldose Reductase Complexed with Sulindac
3RX4	;	2.0	;	Crystal Structure of Human Aldose Reductase complexed with Sulindac Sulfide
3RX2	;	1.9	;	Crystal Structure of Human Aldose Reductase Complexed with Sulindac Sulfone
1IEI	;	2.5	;	CRYSTAL STRUCTURE OF HUMAN ALDOSE REDUCTASE COMPLEXED WITH THE INHIBITOR ZENARESTAT.
3S3G	;	1.8	;	Crystal Structure of Human Aldose Reductase Complexed with Tolmetin
2DUX	;	1.6	;	Crystal structure of human Aldose Reductase complexed with zopolrestat after 3 days soaking (3days_soaked_1)
4TT7	;	2.1	;	Crystal structure of human ALK with a covalent modification
7C3G	;	1.802	;	Crystal structure of human ALK2 kinase domain with R206H mutation in complex with a bicyclic pyrazole inhibitor RK-73134
6ACR	;	2.01	;	Crystal structure of human ALK2 kinase domain with R206H mutation in complex with RK-59638
6JUX	;	1.75	;	Crystal structure of human ALK2 kinase domain with R206H mutation in complex with RK-71807
6G7O	;	2.7	;	Crystal structure of human alkaline ceramidase 3 (ACER3) at 2.7 Angstrom resolution
8JNR	;	3.66	;	Crystal structure of human ALKBH3 bound to 3mC containing ssDNA through distal crosslink
8JNK	;	2.69	;	Crystal structure of human ALKBH3 bound to ssDNA through active site crosslink
4NJ4	;	2.02	;	Crystal Structure of Human ALKBH5
4OCT	;	2.28	;	Crystal structure of human ALKBH5 crystallized in the presence of Mn^{2+} and 2-oxoglutarate
7WKV	;	2.1	;	Crystal structure of human ALKBH5 in complex with 2-oxoglutarate (2OG) and m6A-containing ssRNA
4NRO	;	2.3	;	Crystal structure of human ALKBH5 in complex with alpha-ketoglutarate
4NRM	;	2.17	;	Crystal structure of human ALKBH5 in complex with citrate and acetate
7V4G	;	2.1	;	Crystal structure of human ALKBH5 in complex with m6A-containing ssRNA
4O7X	;	1.78	;	Crystal structure of human ALKBH5 in complex with Mn2+
4NRP	;	1.8	;	Crystal structure of human ALKBH5 in complex with N-oxalylglycine
7WL0	;	2.5	;	Crystal structure of human ALKBH5 in complex with N-oxalylglycine (NOG) and m6A-containing ssRNA
4NRQ	;	2.5	;	Crystal structure of human ALKBH5 in complex with pyridine-2,4-dicarboxylate
4QKD	;	1.35	;	Crystal structure of human ALKBH7 in complex with alpha-ketoglutarate and Mn(II)
4QKF	;	1.99	;	Crystal structure of human ALKBH7 in complex with N-oxalylglycine and Mn(II)
3UBY	;	2.0	;	Crystal structure of human alklyadenine DNA glycosylase in a lower and higher-affinity complex with DNA
3QI5	;	2.2	;	Crystal structure of human alkyladenine DNA glycosylase in complex with 3,N4-ethenocystosine containing duplex DNA
3REV	;	2.2	;	Crystal structure of human alloreactive tcr nb20
2DE0	;	2.61	;	Crystal structure of human alpha 1,6-fucosyltransferase, FUT8
6VLD	;	2.28	;	Crystal structure of human alpha 1,6-fucosyltransferase, FUT8 bound to GDP and A2SGP
6VLE	;	2.28	;	Crystal structure of human alpha 1,6-fucosyltransferase, FUT8 in its Apo-form
5UBB	;	2.0	;	Crystal structure of human alpha N-terminal protein methyltransferase 1B
1D4P	;	2.07	;	CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH 5-AMIDINOINDOLE-4-BENZYLPIPERIDINE INHIBITOR
4I7Y	;	2.4	;	Crystal Structure of Human Alpha Thrombin in Complex with a 27-mer Aptamer Bound to Exosite II
1D3D	;	2.04	;	CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZOTHIOPHENE INHIBITOR 4
1D3T	;	3.0	;	CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 1
1D3Q	;	2.9	;	CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 2
4B5O	;	1.05	;	Crystal structure of human alpha tubulin acetyltransferase catalytic domain
4B5P	;	1.6	;	Crystal structure of human alpha tubulin acetyltransferase catalytic domain Q58A variant
3LOE	;	1.56	;	Crystal structure of human alpha-defensin 1 (F28A mutant)
3GNY	;	1.56	;	Crystal structure of human alpha-defensin 1 (HNP1)
4LBB	;	1.719	;	Crystal structure of human alpha-defensin 1 (HNP1) I20A mutant
4LBF	;	1.7	;	Crystal structure of HUMAN ALPHA-DEFENSIN 1 (HNP1) I20A/L25A mutant
4LB1	;	2.0	;	Crystal structure of human alpha-defensin 1 (HNP1) Y16A/F28A mutant
4LB7	;	1.902	;	Crystal structure of human alpha-defensin 1 (HNP1) Y16A/I20A/L25A/F28A mutant.
3LVX	;	1.63	;	Crystal structure of human alpha-defensin 1 (I6A mutant)
3H6C	;	1.63	;	Crystal structure of human alpha-defensin 1 (Mutant Gln22Ala)
3LO4	;	1.75	;	Crystal structure of human alpha-defensin 1 (R24A mutant)
3LO6	;	1.56	;	Crystal structure of human alpha-defensin 1 (W26Aba mutant)
3LO9	;	1.56	;	Crystal structure of human alpha-defensin 1 (W26Ahp mutant)
3LO1	;	1.6	;	Crystal structure of human alpha-defensin 1 (Y16A mutant)
3LO2	;	1.56	;	Crystal structure of human alpha-defensin 1 (Y21A mutant)
4DU0	;	1.9	;	Crystal structure of human alpha-defensin 1, HNP1 (G17A mutant)
3I5W	;	1.63	;	Crystal structure of human alpha-defensin 5 (mutant R13H)
4RBX	;	1.1	;	Crystal structure of human alpha-defensin 5, HD5 (Glu21Arg mutant)
4E86	;	2.75	;	Crystal structure of human alpha-defensin 5, HD5 (Leu29Aba mutant)
4E83	;	1.9	;	Crystal structure of human alpha-defensin 5, HD5 (Leu29NLe mutant)
4RBW	;	1.5	;	Crystal structure of human alpha-defensin 5, HD5 (Thr7Arg Glu21Arg mutant)
3QTE	;	1.949	;	Crystal structure of human alpha-defensin 6 (H27W mutant)
1ZMK	;	1.3	;	Crystal structure of human alpha-defensin-2 (variant Gly16-> D-ALA), P 42 21 2 space group
1ZMM	;	1.6	;	Crystal structure of human alpha-defensin-4
1ZMQ	;	2.1	;	Crystal structure of human alpha-defensin-6
5LLK	;	1.8	;	Crystal structure of human alpha-dystroglycan
4NXS	;	2.5493	;	Crystal structure of human alpha-galactosidase A in complex with 1-deoxygalactonojirimycin-pFPhT
6IBT	;	2.04	;	Crystal structure of human alpha-galactosidase A in complex with alpha-galactose configured cyclophellitol aziridine ME737
6IBR	;	2.02	;	Crystal structure of human alpha-galactosidase A in complex with alpha-galactose configured cyclophellitol epoxide LWA481
6IBK	;	1.99	;	Crystal structure of human alpha-galactosidase A in complex with alpha-galactose configured cyclosulfamidate ME763
6IBM	;	2.07	;	Crystal structure of human alpha-galactosidase A in complex with alpha-galactose configured cyclosulfate ME776
3OVU	;	2.83	;	Crystal Structure of Human Alpha-Haemoglobin Complexed with AHSP and the First NEAT Domain of IsdH from Staphylococcus aureus
4KH2	;	2.36	;	Crystal structure of human alpha-L-iduronidase complex with 2-deoxy-2-fluoro-alpha-L-idopyranosyluronic acid fluoride
4KGJ	;	2.99	;	Crystal structure of human alpha-L-iduronidase complex with 5-fluoro-alpha-L-idopyranosyluronic acid fluoride
4OBR	;	2.46	;	Crystal structure of human alpha-L-iduronidase complex with alpha-L-iduronic acid
4KGL	;	2.701	;	Crystal structure of human alpha-L-iduronidase complex with [2R,3R,4R,5S]-2-carboxy-3,4,5-trihydroxy-piperidine
4OBS	;	2.26	;	Crystal structure of human alpha-L-iduronidase in the P212121 form
3H53	;	2.01	;	Crystal Structure of human alpha-N-acetylgalactosaminidase
3H55	;	1.91	;	Crystal Structure of human alpha-N-acetylgalactosaminidase, Complex with Galactose
3IGU	;	2.15	;	Crystal structure of human alpha-N-acetylgalactosaminidase, covalent intermediate
3H54	;	2.2	;	Crystal Structure of human alpha-N-acetylgalactosaminidase,complex with GalNAc
3Q25	;	1.9	;	Crystal structure of human alpha-synuclein (1-19) fused to maltose binding protein (MBP)
1G37	;	2.0	;	CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN COMPLEXED WITH BCH-10556 AND EXOSITE-DIRECTED PEPTIDE
1AHT	;	1.6	;	CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN COMPLEXED WITH HIRUGEN AND P-AMIDINOPHENYLPYRUVATE AT 1.6 ANGSTROMS RESOLUTION
2H9T	;	2.4	;	Crystal structure of human alpha-thrombin in complex with suramin
7KME	;	2.1	;	CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN INHIBITED WITH SEL2711.
8KME	;	2.1	;	CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN INHIBITED WITH SEL2770.
1DOJ	;	1.7	;	Crystal structure of human alpha-thrombin*RWJ-51438 complex at 1.7 A
1R5L	;	1.5	;	Crystal Structure of Human Alpha-Tocopherol Transfer Protein Bound to its Ligand
6U3V	;	2.96	;	Crystal structure of human alpha/epsilon-COP of the COPI vesicular coat bound to alpha-COP STM1
6TZT	;	3.065	;	Crystal structure of human alpha/epsilon-COP of the COPI vesicular coat bound to alpha-COP STM2
3KQ0	;	1.8	;	Crystal structure of human alpha1-acid glycoprotein
6KUW	;	2.8	;	Crystal structure of human alpha2C adrenergic G protein-coupled receptor.
1ZMI	;	1.15	;	Crystal structure of human alpha_defensin-2 (variant GLY16->D-ALA), P 32 2 1 space group )
3U2M	;	2.0	;	Crystal structure of human ALR mutant C142/145S
3U2L	;	1.95	;	Crystal structure of human ALR mutant C142S.
7NUU	;	1.836	;	Crystal structure of human AMDHD2 in complex with Zn
7NUT	;	1.898	;	Crystal structure of human AMDHD2 in complex with Zn and GlcN6P
8DDA	;	2.4	;	Crystal structure of human aminoadipate semialdehyde synthase (AASS), lysine ketoglutarate reductase (LKR) domain
5L76	;	2.57	;	Crystal structure of human aminoadipate semialdehyde synthase, saccharopine dehydrogenase domain (in apo form)
5L78	;	2.68	;	Crystal structure of human aminoadipate semialdehyde synthase, saccharopine dehydrogenase domain (in NAD+ bound form)
5O1N	;	2.28	;	Crystal structure of human aminoadipate semialdehyde synthase, saccharopine dehydrogenase domain with N-[(2S)-2-Pyrrolidinylmethyl]-trifluoromethanesulfonamide bound
5O1O	;	2.48	;	Crystal structure of human aminoadipate semialdehyde synthase, saccharopine dehydrogenase domain with proline bound.
5O1P	;	1.9	;	Crystal structure of human aminoadipate semialdehyde synthase, saccharopine dehydrogenase.
4KX7	;	2.15	;	Crystal structure of human aminopeptidase A
4KX8	;	2.4	;	Crystal structure of human aminopeptidase A complexed with amastatin
4KX9	;	2.25	;	Crystal structure of human aminopeptidase A complexed with arginine
4KXA	;	2.4	;	Crystal structure of human aminopeptidase A complexed with aspartate and calcium
4KXB	;	2.4	;	Crystal structure of human aminopeptidase A complexed with bestatin
4KXC	;	2.4	;	Crystal structure of human aminopeptidase A complexed with glutamate
4KXD	;	2.15	;	Crystal structure of human aminopeptidase A complexed with glutamate and calcium
4RED	;	2.95	;	Crystal structure of human AMPK alpha1 KD-AID with K43A mutation
2ZNV	;	1.6	;	Crystal structure of human AMSH-LP DUB domain in complex with Lys63-linked ubiquitin dimer
4JOA	;	2.7	;	Crystal Structure of Human Anaplastic Lymphoma Kinase in complex with 7-azaindole based inhibitor
4DCE	;	2.03	;	Crystal structure of human anaplastic lymphoma kinase in complex with a piperidine-carboxamide inhibitor
4FOB	;	1.9	;	Crystal structure of human anaplastic lymphoma kinase in complex with acyliminobenzimidazole inhibitor 1
4FOC	;	1.7	;	Crystal structure of human anaplastic lymphoma kinase in complex with acyliminobenzimidazole inhibitor 2
4FOD	;	2.0	;	Crystal structure of human anaplastic lymphoma kinase in complex with acyliminobenzimidazole inhibitor 36
4FNZ	;	2.6	;	Crystal structure of human anaplastic lymphoma kinase in complex with piperidine-carboxamide inhibitor 2
5OGS	;	2.503	;	Crystal structure of human AND-1 SepB domain
2AMA	;	1.9	;	Crystal structure of human androgen receptor ligand binding domain in complex with dihydrotestosterone
2AM9	;	1.64	;	Crystal structure of human androgen receptor ligand binding domain in complex with testosterone
2AMB	;	1.75	;	Crystal structure of human androgen receptor ligand binding domain in complex with tetrahydrogestrinone
2PNU	;	1.65	;	Crystal structure of human androgen receptor ligand-binding domain in complex with EM-5744
1ZQ5	;	1.3	;	Crystal structure of human androgenic 17beta-hydroxysteroid dehydrogenase type 5 in complexed with a potent inhibitor EM1404
1B1I	;	1.8	;	CRYSTAL STRUCTURE OF HUMAN ANGIOGENIN
8AF0	;	2.43	;	Crystal structure of human angiogenin and RNA duplex
5EOP	;	1.35	;	Crystal structure of human Angiogenin at 1.35 Angstroms resolution
1K5A	;	2.33	;	Crystal structure of human angiogenin double variant I119A/F120A
1H0D	;	2.0	;	Crystal structure of Human Angiogenin in complex with Fab fragment of its monoclonal antibody mAb 26-2F
2ANG	;	2.0	;	CRYSTAL STRUCTURE OF HUMAN ANGIOGENIN OF THE MET(-1) FORM
1ANG	;	2.4	;	CRYSTAL STRUCTURE OF HUMAN ANGIOGENIN REVEALS THE STRUCTURAL BASIS FOR ITS FUNCTIONAL DIVERGENCE FROM RIBONUCLEASE
1K58	;	2.7	;	Crystal Structure of Human Angiogenin Variant D116H
1K5B	;	1.8	;	Crystal Structure of Human Angiogenin Variant des(121-123)
1B1J	;	2.0	;	CRYSTAL STRUCTURE OF HUMAN ANGIOGENIN VARIANT H13A.
1B1E	;	2.0	;	CRYSTAL STRUCTURE OF HUMAN ANGIOGENIN VARIANT K40Q
1K59	;	1.8	;	Crystal Structure of Human Angiogenin Variant Q117G
1UN3	;	1.7	;	CRYSTAL STRUCTURE OF HUMAN ANGIOGENIN VARIANT T44D
1UN4	;	2.1	;	CRYSTAL STRUCTURE OF HUMAN ANGIOGENIN VARIANT T80A
4B36	;	1.76	;	Crystal Structure of Human Angiogenin with an Engineered Loop Exhibits Conformational Flexibility at the Functional Regions of the Molecule
1O8A	;	2.0	;	Crystal Structure of Human Angiotensin Converting Enzyme (Native).
1O86	;	2.0	;	Crystal Structure of Human Angiotensin Converting Enzyme in complex with lisinopril.
5M3X	;	2.63	;	Crystal structure of human angiotensin I-deleted angiotensinogen
4ZUD	;	2.8	;	Crystal Structure of Human Angiotensin Receptor in Complex with Inverse Agonist Olmesartan at 2.8A resolution.
6H5W	;	1.37	;	Crystal structure of human Angiotensin-1 converting enzyme C-domain in complex with Omapatrilat.
6QS1	;	1.8	;	Crystal structure of human Angiotensin-1 converting enzyme N-domain in complex with BPPb
6H5X	;	1.8	;	Crystal structure of human Angiotensin-1 converting enzyme N-domain in complex with Omapatrilat.
6F9R	;	1.85	;	Crystal structure of human Angiotensin-1 converting enzyme N-domain in complex with Sampatrilat-Asp.
6F9V	;	1.69	;	Crystal structure of human Angiotensin-1 converting enzyme N-domain in complex with Sampatrilat.
2WXW	;	3.3	;	Crystal structure of human angiotensinogen
2X0B	;	4.33	;	Crystal structure of human angiotensinogen complexed with renin
4O6X	;	2.103	;	Crystal structure of human Ankyrin G death domain
7ZVN	;	1.87	;	Crystal structure of human Annexin A2 in complex with full phosphorothioate 5-10 2'-methoxyethyl DNA gapmer antisense oligonucleotide solved at 1.87 A resolution
7ZVX	;	2.4	;	Crystal structure of human Annexin A2 in complex with full phosphorothioate 5-10 2'-methoxyethyl DNA gapmer antisense oligonucleotide solved at 2.4 A resolution
1AIN	;	2.5	;	CRYSTAL STRUCTURE OF HUMAN ANNEXIN I AT 2.5 ANGSTROMS RESOLUTION
2D7T	;	1.7	;	Crystal structure of human anti polyhydroxybutyrate antibody Fv
6P9J	;	2.2	;	crystal structure of human anti staphylococcus aureus antibody STAU-229 Fab
6P9H	;	3.003	;	Crystal structure of human anti staphylococcus aureus antibody STAU-281 Fab in complex with IsdB NEAT2 domain
6P9I	;	2.4	;	crystal structure of human anti staphylococcus aureus antibody STAU-399 Fab
5AWN	;	1.887	;	Crystal structure of Human anti-HIV-1 broadly neutralizing antibody 3BC176 Fab
5CCK	;	1.95	;	Crystal structure of Human anti-HIV-1 broadly neutralizing antibody 3BC315 Fab
8GPK	;	3.34	;	Crystal structure of human anti-HIV-1 broadly neutralizing antibody F6 Fab
1RZG	;	2.0	;	Crystal structure of Human anti-HIV-1 GP120 reactive antibody 412d
1RZ8	;	2.3	;	CRYSTAL STRUCTURE OF HUMAN ANTI-HIV-1 GP120-REACTIVE ANTIBODY 17B
1RZI	;	2.9	;	Crystal structure of human anti-HIV-1 gp120-reactive antibody 47e fab
1RZ7	;	2.0	;	CRYSTAL STRUCTURE OF HUMAN ANTI-HIV-1 GP120-REACTIVE ANTIBODY 48D
1RZF	;	1.7	;	Crystal structure of Human anti-HIV-1 GP120-reactive antibody E51
3QHZ	;	1.55	;	Crystal Structure of human anti-influenza Fab 2D1
8EQA	;	2.55	;	Crystal structure of human anti-N1 neuraminidase 2H08 Fab
8EQC	;	2.2	;	Crystal structure of human anti-N1 neuraminidase 3H03 Fab
3KDM	;	1.5	;	Crystal Structure of Human Anti-steroid Fab 5F2 in Complex with Testosterone
5ZIA	;	2.603	;	Crystal structure of human anti-tau antibody CBTAU-24.1 in complex with its phosphorylated tau peptide
6DCV	;	1.9	;	Crystal structure of human anti-tau antibody CBTAU-27.1
6DCW	;	2.0	;	Crystal structure of human anti-tau antibody CBTAU-27.1 Fab in complex with a human tau peptide
5ZV3	;	2.093	;	Crystal structure of human anti-tau antibody CBTAU-28.1 in complex with its tau peptide
3U53	;	2.705	;	Crystal structure of human Ap4A hydrolase
4ICK	;	2.1	;	Crystal structure of human AP4A hydrolase E58A mutant
4IJX	;	2.1	;	Crystal structure of human Ap4A hydrolase E58A mutant complexed with DPO
1DEW	;	2.65	;	CRYSTAL STRUCTURE OF HUMAN APE1 BOUND TO ABASIC DNA
1D3P	;	2.1	;	CRYSTAL STRUCTURE OF HUMAN APLHA-THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 3
2RCQ	;	1.2	;	Crystal structure of human apo Cellular Retinol Binding Protein II (CRBP-II)
5LJK	;	1.7	;	Crystal structure of human apo CRBP1
5LJH	;	1.52	;	Crystal structure of human apo CRBP1/K40L mutant
3ECU	;	1.9	;	Crystal structure of human apo Cu,Zn Superoxide Dismutase (SOD1)
3RE0	;	2.28	;	Crystal structure of human apo Cu,Zn superoxide dismutase (SOD1) complexed with cisplatin
1PFQ	;	1.9	;	crystal structure of human apo dipeptidyl peptidase IV / CD26
1TK3	;	2.0	;	Crystal Structure Of Human Apo Dipeptidyl Peptidase IV/CD26
6JVF	;	1.73	;	Crystal structure of human apo MTH1
2HXY	;	3.3	;	Crystal structure of human apo-eIF4AIII
6BD4	;	2.4	;	Crystal structure of human apo-Frizzled4 receptor
4KWV	;	2.797	;	Crystal Structure of human apo-QPRT
4XXO	;	2.843	;	Crystal Structure of Human APOBEC3A
5SWW	;	3.151	;	Crystal Structure of Human APOBEC3A complexed with ssDNA
5TKM	;	1.9	;	Crystal structure of human APOBEC3B N-terminal Domain
5TD5	;	1.718	;	Crystal Structure of Human APOBEC3B variant complexed with ssDNA
6B0B	;	3.28006	;	Crystal structure of human APOBEC3H
6BBO	;	3.428	;	Crystal structure of human APOBEC3H/RNA complex
1AV1	;	4.0	;	CRYSTAL STRUCTURE OF HUMAN APOLIPOPROTEIN A-I
2HZR	;	1.8	;	Crystal structure of human apolipoprotein D (ApoD)
2HZQ	;	1.8	;	Crystal structure of human apolipoprotein D (ApoD) in complex with progesterone
2WEX	;	2.0	;	Crystal structure of human apoM in complex with glycerol 1- myristic acid
2WEW	;	1.95	;	Crystal structure of human apoM in complex with myristic acid
3VW6	;	2.4	;	Crystal structure of human apoptosis signal-regulating kinase 1 (ASK1) with imidazopyridine inhibitor
8D3J	;	2.4	;	Crystal structure of human Apoptosis-Inducing Factor (AIF) complexed with 6-fluoro-2-methylquinolin-4-amine
8D3N	;	2.25	;	Crystal structure of human Apoptosis-Inducing Factor (AIF) complexed with 7-chloroquinolin-4-amine
8D3K	;	2.3	;	Crystal structure of human Apoptosis-Inducing Factor (AIF) complexed with 8-fluoro-2-methylquinolin-4-amine
8D3O	;	2.25	;	Crystal structure of human Apoptosis-Inducing Factor (AIF) complexed with 8-methoxyquinolin-4-amine
8D3G	;	2.58	;	Crystal structure of human Apoptosis-Inducing Factor (AIF) W196A mutant complexed with 6-chloroquinolin-4-amine
8D3E	;	2.38	;	Crystal structure of human Apoptosis-Inducing Factor (AIF) W196A mutant complexed with 6-fluoroquinolin-4-amine
8D3H	;	2.51	;	Crystal structure of human Apoptosis-Inducing Factor (AIF) W196A mutant complexed with 7-chloroquinolin-4-amine
8D3I	;	2.65	;	Crystal structure of human Apoptosis-Inducing Factor (AIF) W196A mutant complexed with quinolin-4-amine
5KVH	;	2.273	;	Crystal structure of human apoptosis-inducing factor with W196A mutation
5C5B	;	2.9	;	Crystal Structure of Human APPL BAR-PH Heterodimer
4H8S	;	3.5	;	Crystal structure of human APPL2BARPH domain
6FCI	;	1.94	;	Crystal Structure of Human APRT wild type in complex with Adenine, PRPP and Mg2+
6FCL	;	1.5	;	Crystal Structure of Human APRT wild type in complex with AMP
6HGS	;	1.55	;	Crystal Structure of Human APRT wild type in complex with GMP
6HGQ	;	1.9	;	Crystal Structure of Human APRT wild type in complex with Hypoxanthine, PRPP and Mg2+
6HGR	;	1.52	;	Crystal Structure of Human APRT wild type in complex with IMP
6HGP	;	1.7	;	Crystal Structure of Human APRT wild type in complex with Phosphate ion.
6FCH	;	1.45	;	Crystal Structure of Human APRT wild type in complex with PRPP and Mg2+
6FD5	;	1.55	;	Crystal Structure of Human APRT-Tyr105Phe variant in complex with Adenine, PRPP and Mg2+, 14 days post crystallization (with AMP and PPi products partially generated)
6FD4	;	1.5	;	Crystal Structure of Human APRT-Tyr105Phe variant in complex with Adenine, PRPP and Mg2+, 14 hours post crystallization
6FD6	;	1.8	;	Crystal Structure of Human APRT-Tyr105Phe variant in complex with Adenine, PRPP and Mg2+, 30 days post crystallization (with AMP and PPi products fully generated)
3U8U	;	2.15	;	Crystal structure of Human Apurinic/Apyridinimic Endonuclease, Ape1 in a new crystal form
4LND	;	1.92	;	Crystal structure of human apurinic/apyrimidinic endonuclease 1 with essential Mg2+ cofactor
6F7H	;	2.304	;	Crystal structure of human AQP10
8GHJ	;	3.9	;	Crystal structure of human AQP2 T125M mutant
8OEE	;	3.15	;	Crystal structure of human AQP2 T126M mutant
3GD8	;	1.8	;	Crystal Structure of Human Aquaporin 4 at 1.8 and its Mechanism of Conductance
6QZI	;	1.9	;	Crystal structure of human Aquaporin 7 at 1.9 A resolution
6QZJ	;	2.2	;	Crystal structure of human Aquaporin 7 at 2.2 A resolution
6KXW	;	3.7	;	Crystal structure of human aquaporin AQP7 in bound to glycerol
4QXI	;	0.867	;	Crystal structure of human AR complexed with NADP+ and AK198
4LB4	;	0.8	;	Crystal structure of human AR complexed with NADP+ and {2-[(4-bromo-2,3,5,6-tetrafluorobenzyl)carbamoyl]-5-chlorophenoxy}acetic acid
4LBS	;	0.76	;	Crystal structure of human AR complexed with NADP+ and {2-[(4-bromo-2,6-difluorobenzyl)carbamoyl]-5-chlorophenoxy}acetic acid
4LAU	;	0.843	;	Crystal structure of human AR complexed with NADP+ and {2-[(4-bromobenzyl)carbamoyl]-5-chlorophenoxy}acetic acid
4LBR	;	0.8	;	Crystal structure of human AR complexed with NADP+ and {5-chloro-2-[(2,6-difluoro-4-iodobenzyl)carbamoyl]phenoxy}acetic acid
4LB3	;	0.8	;	Crystal structure of human AR complexed with NADP+ and {5-chloro-2-[(2-fluoro-4-iodobenzyl)carbamoyl]phenoxy}acetic acid
4LAZ	;	0.85	;	Crystal structure of human AR complexed with NADP+ and {5-chloro-2-[(4-iodobenzyl)carbamoyl]phenoxy}acetic acid
7R23	;	2.77	;	Crystal structure of human Arc CTD in complex with two anti-Arc nanobodies
5YZ1	;	1.97	;	Crystal structure of human Archease
5YZL	;	3.4	;	Crystal structure of human Archease D178A
5YZJ	;	2.79	;	Crystal structure of human Archease mutant D51A
2AEB	;	1.29	;	Crystal structure of human arginase I at 1.29 A resolution and exploration of inhibition in immune response.
2PHO	;	1.95	;	Crystal structure of human arginase I complexed with thiosemicarbazide at 1.95 resolution
1WVA	;	1.94	;	Crystal structure of human arginase I from twinned crystal
3MFV	;	1.9	;	Crystal structure of human arginase I in complex with 2-aminohomohistidine
3MJL	;	1.9	;	Crystal structure of human arginase I in complex with 2-aminoimidazole. Resolution 1.90 A.
3GN0	;	1.7	;	Crystal structure of human arginase I in complex with difluoromethylornithine (DFMO)
3LP7	;	2.04	;	Crystal structure of Human Arginase I in complex with inhibitor N(omega)-hydroxy-L-arginine (NOHA), 2.04A Resolution
3MFW	;	1.47	;	Crystal structure of human arginase I in complex with L-2-aminohistidine and sulphate
3LP4	;	1.9	;	Crystal structure of human arginase I in complex with L-LYSINE, 1.90A Resolution.
3SKK	;	1.701	;	Crystal structure of human arginase I in complex with the inhibitor FABH, Resolution 1.70 A, twinned structure
3SJT	;	1.597	;	Crystal structure of human arginase I in complex with the inhibitor Me-ABH, Resolution 1.60 A, twinned structure
1WVB	;	2.3	;	Crystal structure of human arginase I: the mutant E256Q
6Q92	;	1.5	;	Crystal structure of human Arginase-1 at pH 7.0 in complex with ABH
6Q9P	;	1.66	;	Crystal structure of human Arginase-1 at pH 9.0 in complex with ABH
6QAF	;	1.61	;	Crystal structure of human Arginase-1 at pH 9.0 in complex with CB-1158/INCB001158
4HXQ	;	1.45	;	Crystal structure of human Arginase-1 complexed with inhibitor 14
4IE1	;	2.0006	;	Crystal structure of human Arginase-1 complexed with inhibitor 1h
4HWW	;	1.298	;	Crystal structure of human Arginase-1 complexed with inhibitor 9
4IE3	;	2.3522	;	Crystal structure of human Arginase-2 complexed with inhbitor 1o
4IXU	;	1.9	;	Crystal structure of human Arginase-2 complexed with inhibitor 11d: {(5R)-5-amino-5-carboxy-5-[(3-endo)-8-(3,4-dichlorobenzyl)-8-azabicyclo[3.2.1]oct-3-yl]pentyl}(trihydroxy)borate(1-)
4I06	;	1.8	;	Crystal structure of human Arginase-2 complexed with inhibitor 14
4IE2	;	2.2082	;	Crystal structure of human Arginase-2 complexed with inhibitor 1h
4IXV	;	2.3	;	Crystal structure of human Arginase-2 complexed with inhibitor 2d: {(5R)-5-amino-5-carboxy-5-[1-(4-chlorobenzyl)piperidin-4-yl]pentyl}(trihydroxy)borate(1-)
4HZE	;	1.602	;	Crystal structure of human Arginase-2 complexed with inhibitor 9
2NZ2	;	2.4	;	Crystal structure of human argininosuccinate synthase in complex with aspartate and citrulline
4OLA	;	2.3	;	Crystal Structure of Human Argonaute2
6CBD	;	2.203	;	Crystal Structure of Human Argonaute2 Bound to Three Tryptophans
4OLB	;	2.899	;	Crystal Structure of Human Argonaute2 Bound to Tryptophan
4R3Z	;	4.033	;	Crystal structure of human ArgRS-GlnRS-AIMP1 complex
7L9F	;	1.75	;	Crystal structure of human ARH3 bound to calcium and ADP-ribose
7L9I	;	1.8	;	Crystal structure of human ARH3-D314A bound to magnesium and ADP-ribose
7L9H	;	1.85	;	Crystal structure of human ARH3-D77A bound to magnesium and ADP-ribose
1ZJ6	;	2.0	;	Crystal structure of human ARL5
3RBF	;	2.9	;	Crystal structure of Human aromatic L-amino acid decarboxylase (AADC) in the apo form
3RBL	;	3.24	;	Crystal structure of Human aromatic L-amino acid decarboxylase (AADC) in the apo form
3RCH	;	2.8	;	Crystal structure of Human aromatic L-amino acid decarboxylase (AADC) in the open conformation with LLP and PLP bound to Chain-A and Chain-B respectively
6F7P	;	3.7	;	Crystal structure of Human ARS2 residues 147-270 + 408-763
6F7S	;	3.37	;	Crystal structure of Human ARS2 residues 147-270 + 408-763 with deletion of loop B
6F7J	;	3.22	;	Crystal structure of Human ARS2 residues 171-270 + 408-763
6F8D	;	3.48	;	Crystal structure of Human ARS2 residues 171-270 + 408-763 (P65 form)
2GYR	;	2.6	;	Crystal structure of human artemin
2GYZ	;	1.76	;	Crystal structure of human artemin
4UUC	;	1.8	;	Crystal structure of human ASB11 ankyrin repeat domain
6KI0	;	2.0	;	Crystal Structure of Human ASC-CARD
6INE	;	2.6	;	Crystal Structure of human ASH1L-MRG15 complex
6E2H	;	2.236	;	Crystal structure of human Ash2L (SPRY domain and SDI motif) in complex with full length DPY-30
3TKJ	;	2.3	;	Crystal Structure of Human Asparaginase-like Protein 1 Thr168Ala
5APA	;	2.05	;	Crystal structure of human aspartate beta-hydroxylase isoform a
4DYO	;	2.2	;	Crystal Structure of Human Aspartyl Aminopeptidase (DNPEP) in complex with Aspartic acid Hydroxamate
5IBV	;	2.15	;	Crystal Structure of Human Astrovirus capsid protein
5A5N	;	1.95	;	Crystal structure of human ATAD2 bromodomain in complex with (2S)-2,6- diacetamido-N-methylhexanamide
5A5O	;	2.04	;	Crystal structure of human ATAD2 bromodomain in complex with 3-methyl- 1,2-dihydroquinolin-2-one
5A5Q	;	1.97	;	Crystal structure of human ATAD2 bromodomain in complex with 3-methyl- 8-piperidin-4-ylamino-1,2-dihydro-1,7-naphthyridin-2-one hydrochloride
6HDN	;	1.9	;	Crystal structure of human ATAD2 bromodomain in complex with 3-methyl-8-((8-methyl-8-azabicyclooctan-3-yl)amino)-1,7-naphthyridin-2(1H)-one
5A83	;	2.09	;	Crystal structure of human ATAD2 bromodomain in complex with 4-((3R, 4R)-4-3-methyl-5-(5-methylpyridin-3-yl)-2-oxo-1,2-dihydroquinolin-8- yl-aminopiperidin-3-yloxymethyl)-1-thiane-1,1-dione
5A82	;	1.86	;	Crystal structure of human ATAD2 bromodomain in complex with 4-(3R,4R) -4-(3-methyl-2-oxo-1,2-dihydro-1,7-naphthyridin-8-yl)aminopiperidin-3- yloxymethyl)-1-thiane-1,1-dione
5A5R	;	2.01	;	Crystal structure of human ATAD2 bromodomain in complex with 5-5- methoxypyridin-3-yl-3-methyl-8-piperidin-4-ylamino-1,2-dihydro-1,7- naphthyridin-2-one
6HDO	;	2.61	;	Crystal structure of human ATAD2 bromodomain in complex with 8-(((1R,2R,3R,5S)-2-(2-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)ethyl)-8-azabicyclo[3.2.1]octan-3-yl)amino)-3-methyl-5-(5-methylpyridin-3-yl)quinolin-2(1H)-one
5LJ0	;	1.82	;	Crystal structure of human ATAD2 bromodomain in complex with 8-(((3R,4R,5S)-3-((4,4-difluorocyclohexyl)methoxy)-5-methoxypiperidin-4-yl)amino)-3-methyl-5-(5-methylpyridin-3-yl)-1,7-naphthyridin-2(1H)-one
5A81	;	2.03	;	Crystal structure of human ATAD2 bromodomain in complex with 8-(3R,4R) -3-(cyclohexylmethoxy)piperidin-4-yl-amino-3-methyl-1,2-dihydro-1,7- naphthyridin-2-one
5A5P	;	2.03	;	Crystal structure of human ATAD2 bromodomain in complex with 8-2-(dimethylamino)ethylamino-3-methyl-1,2-dihydroquinolin-2-one
6S55	;	2.09	;	Crystal structure of human ATAD2 bromodomain in complex with N-(4-bromo-3-((3-methylpiperidin-1-yl)sulfonyl)phenyl)-2-(2,5-dioxoimidazolidin-1-yl)acetamide
6YB4	;	1.85	;	Crystal structure of human ATAD2 bromodomain in complex with N-(4-bromo-3-(3-methylpyrrolidin-1-yl)sulfonyl)phenyl)-2-(-4-cyclopropyl-4-methyl-2,5-dioxoimidazolidin-1-yl)acetamide
6S56	;	2.01	;	Crystal structure of human ATAD2 bromodomain in complex with N-(4-chloro-3-(N,N-dimethylsulfamoyl)phenyl)-2-(2,5-dioxo-3',4'-dihydro-2'H-spiro[imidazolidine-4,1'-naphthalen]-1-yl)acetamide
6S57	;	1.82	;	Crystal structure of human ATAD2 bromodomain in complex withN-(3-(azepan-1-ylsulfonyl)-4-methylphenyl)-2-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)acetamide
4GDK	;	2.7	;	Crystal Structure of Human Atg12~Atg5 Conjugate in Complex with an N-terminal Fragment of Atg16L1
4GDL	;	2.875	;	Crystal Structure of Human Atg12~Atg5 Conjugate in Complex with an N-terminal Fragment of Atg16L1
4NAW	;	2.195	;	Crystal Structure of Human ATG12~ATG5-ATG16N in complex with a fragment of ATG3
7W36	;	3.0	;	Crystal structure of human Atg5 complexed with a stapled peptide
4TQ0	;	2.697	;	Crystal structure of human ATG5-ATG16N69
4TQ1	;	1.802	;	Crystal structure of human ATG5-TECAIR
1P4R	;	2.55	;	Crystal Structure of Human ATIC in complex with folate-based inhibitor BW1540U88UD
1PL0	;	2.6	;	Crystal structure of human ATIC in complex with folate-based inhibitor, BW2315U89UC
1PKX	;	1.9	;	Crystal Structure of human ATIC in complex with XMP
3Q5D	;	2.699	;	crystal structure of human Atlastin-1 (residues 1-447) bound to GDP, crystal form 1
3Q5E	;	3.013	;	crystal structure of human Atlastin-1 (residues 1-447) bound to GDP, crystal form 2
6A71	;	1.6	;	Crystal Structure of Human ATP7B and TM Complex
3MBG	;	1.85	;	Crystal Structure of Human Augmenter of Liver Regeneration (ALR)
2ZQQ	;	2.2	;	Crystal structure of human AUH (3-methylglutaconyl-coa hydratase) mixed with (AUUU)24A RNA
1HZD	;	2.2	;	CRYSTAL STRUCTURE OF HUMAN AUH PROTEIN, AN RNA-BINDING HOMOLOGUE OF ENOYL-COA HYDRATASE
1JIQ	;	1.9	;	Crystal Structure of Human Autocrine Motility Factor
1IRI	;	2.4	;	Crystal structure of human autocrine motility factor complexed with an inhibitor
3SDX	;	3.12	;	Crystal structure of human autoreactive-Valpha24 NKT TCR in complex with CD1d-beta-galactosylceramide
1YFK	;	2.7	;	Crystal structure of human B type phosphoglycerate mutase
1YJX	;	2.8	;	Crystal structure of human B type phosphoglycerate mutase
4GPI	;	2.0817	;	Crystal structure of human B type phosphoglycerate mutase
4GPZ	;	1.65	;	Crystal structure of human B type phosphoglycerate mutase H11 phosphorylated form
3E9V	;	1.7	;	Crystal structure of human B-cell Translocation Gene 2 (BTG2)
1XWW	;	1.63	;	Crystal Structure of Human B-form Low Molecular Weight Phosphotyrosyl Phosphatase at 1.6 Angstrom Resolution
4KSQ	;	3.3	;	Crystal Structure of Human B-raf bound to a DFG-out Inhibitor 5B
4KSP	;	2.93	;	Crystal Structure of Human B-raf bound to a DFG-out Inhibitor TAK-632
3PRF	;	2.9	;	Crystal Structure of Human B-Raf Kinase Domain in Complex with a Non-Oxime Furopyridine Inhibitor
3PRI	;	3.5	;	Crystal Structure of Human B-Raf Kinase in Complex with a Non-Oxime Furopyridine Inhibitor
4GOS	;	1.59	;	Crystal structure of human B7-H4 IgV-like domain
4WY1	;	1.98	;	Crystal structure of human BACE-1 bound to Compound 24B
4WY6	;	2.1	;	Crystal structure of human BACE-1 bound to Compound 36
4X2L	;	2.55	;	Crystal structure of human BACE-1 bound to Compound 6
2NTR	;	1.8	;	Crystal structure of Human Bace-1 bound to inhibitor
6FGY	;	1.54	;	Crystal Structure of Human BACE-1 in Complex with amino-1,4-oxazine compound 4
6EQM	;	1.35	;	Crystal Structure of Human BACE-1 in Complex with CNP520
7B1P	;	1.77	;	Crystal Structure of Human BACE-1 in Complex with Compound 38a (NB-854)
7B1Q	;	1.94	;	Crystal Structure of Human BACE-1 in Complex with Compound NB-360 (compound 54)
2EWY	;	3.1	;	Crystal structure of human BACE2 in complex with a hydroxyethylenamine transition-state inhibitor
7CYU	;	2.55	;	Crystal structure of human BAF57 HMG domain
6FXN	;	2.9	;	Crystal structure of human BAFF in complex with Fab fragment of anti-BAFF antibody belimumab
7M5B	;	1.85	;	Crystal Structure of human BAK in complex with M3W5_BID
8GSV	;	2.2	;	Crystal structure of human BAK in complex with the Pxt1 BH3 domain
7M5A	;	1.5	;	Crystal Structure of human BAK in complex with W3W5_BID
7M5C	;	3.06	;	Crystal Structure of human BAK in complex with WT BAK BH3 peptide
7MWI	;	1.8	;	Crystal structure of human BAZ2A
4QBM	;	1.65	;	Crystal structure of human BAZ2A bromodomain in complex with a diacetylated histone 4 peptide (H4K16acK20ac)
6FAP	;	2.7	;	Crystal structure of human BAZ2A PHD zinc finger in complex with Fr23
5T8R	;	2.4	;	Crystal structure of human BAZ2A PHD zinc finger in complex with unmodified H3 10-mer
4Q6F	;	1.91	;	Crystal structure of human BAZ2A PHD zinc finger in complex with unmodified H3K4 histone peptide
4QF2	;	1.7	;	Crystal structure of human BAZ2A PHD zinc finger in the free form
4QC3	;	1.6	;	Crystal structure of human BAZ2B bromodomain in complex with a diacetylated histone 4 peptide (H4K8acK12ac)
4QC1	;	1.99	;	Crystal structure of human BAZ2B bromodomain in complex with an acetylated histone 3 peptide (H3K14ac)
4CUP	;	1.88	;	Crystal structure of human BAZ2B in complex with fragment-1 N09421
4CUQ	;	2.11	;	Crystal structure of human BAZ2B in complex with fragment-2 N09594
4CUR	;	1.842	;	Crystal structure of human BAZ2B in complex with fragment-3 N09555
4CUS	;	1.783	;	Crystal structure of human BAZ2B in complex with fragment-4 N09496
4CUT	;	1.835	;	Crystal structure of human BAZ2B in complex with fragment-5 N09428
4CUU	;	1.801	;	Crystal structure of human BAZ2B in complex with fragment-6 N09645
6FHQ	;	1.95	;	Crystal structure of human BAZ2B PHD zinc finger in complex with Fr 21
6FI1	;	2.7	;	Crystal structure of human BAZ2B PHD zinc finger in complex with Fr23
4QF3	;	1.6	;	Crystal structure of human BAZ2B PHD zinc finger in the free form
7KYQ	;	3.06	;	Crystal structure of human BCCIP beta (Native1)
7KYS	;	2.2	;	Crystal structure of human BCCIP beta (Native2)
6L8U	;	2.925	;	Crystal structure of human BCDIN3D in complex with SAH
2YV6	;	2.5	;	Crystal structure of human Bcl-2 family protein Bak
4IEH	;	2.1	;	Crystal Structure of human Bcl-2 in complex with a small molecule inhibitor targeting Bcl-2 BH3 domain interactions
6YLI	;	1.9	;	Crystal structure of human bcl-xL bound to trichoplax adhaerens trBak BH3
7ZWN	;	2.05	;	Crystal structure of human BCL6 BTB domain in complex with a WVIP peptide
6TOM	;	1.9	;	Crystal structure of human BCL6 BTB domain in complex with compound 1
7Q7R	;	1.7	;	Crystal structure of human BCL6 BTB domain in complex with compound 1
7ZWQ	;	1.65	;	Crystal structure of human BCL6 BTB domain in complex with compound 10
7ZWR	;	1.47	;	Crystal structure of human BCL6 BTB domain in complex with compound 11
6TOO	;	1.53	;	Crystal structure of human BCL6 BTB domain in complex with compound 11a
6TOI	;	1.58	;	Crystal structure of human BCL6 BTB domain in complex with compound 11f
7Q7V	;	1.81	;	Crystal structure of human BCL6 BTB domain in complex with compound 12a
7QK0	;	1.96	;	Crystal structure of human BCL6 BTB domain in complex with compound 12a
7OKI	;	1.61	;	Crystal structure of human BCL6 BTB domain in complex with compound 12b
7OKJ	;	1.43	;	Crystal structure of human BCL6 BTB domain in complex with compound 12c and its enantiomer 12b
7OKK	;	2.05	;	Crystal structure of human BCL6 BTB domain in complex with compound 12e
7ZWS	;	1.53	;	Crystal structure of human BCL6 BTB domain in complex with compound 13
7OKL	;	1.2	;	Crystal structure of human BCL6 BTB domain in complex with compound 13e
7OKM	;	1.48	;	Crystal structure of human BCL6 BTB domain in complex with compound 13g
7ZWT	;	1.94	;	Crystal structure of human BCL6 BTB domain in complex with compound 14
7ZWU	;	1.56	;	Crystal structure of human BCL6 BTB domain in complex with compound 15
7ZWV	;	1.52	;	Crystal structure of human BCL6 BTB domain in complex with compound 17
6TOJ	;	1.85	;	Crystal structure of human BCL6 BTB domain in complex with compound 17a
7ZWW	;	1.67	;	Crystal structure of human BCL6 BTB domain in complex with compound 18
7ZWX	;	1.38	;	Crystal structure of human BCL6 BTB domain in complex with compound 19
7OKE	;	1.48	;	Crystal structure of human BCL6 BTB domain in complex with compound 2
7ZWO	;	1.39	;	Crystal structure of human BCL6 BTB domain in complex with compound 2
7ZWY	;	1.65	;	Crystal structure of human BCL6 BTB domain in complex with compound 21
7ZWZ	;	1.4	;	Crystal structure of human BCL6 BTB domain in complex with compound 22
6TOK	;	1.43	;	Crystal structure of human BCL6 BTB domain in complex with compound 23d
7OKD	;	1.94	;	Crystal structure of human BCL6 BTB domain in complex with compound 25
6TOL	;	1.64	;	Crystal structure of human BCL6 BTB domain in complex with compound 25a
6TON	;	2.36	;	Crystal structure of human BCL6 BTB domain in complex with compound 25b
6TOF	;	1.67	;	Crystal structure of human BCL6 BTB domain in complex with compound 4
7Q7S	;	1.44	;	Crystal structure of human BCL6 BTB domain in complex with compound 4
6TOG	;	1.69	;	Crystal structure of human BCL6 BTB domain in complex with compound 5
6TOH	;	1.58	;	Crystal structure of human BCL6 BTB domain in complex with compound 6
7Q7T	;	1.46	;	Crystal structure of human BCL6 BTB domain in complex with compound 7
7ZWP	;	1.85	;	Crystal structure of human BCL6 BTB domain in complex with compound 7
7OKF	;	1.6	;	Crystal structure of human BCL6 BTB domain in complex with compound 8c
7OKG	;	1.32	;	Crystal structure of human BCL6 BTB domain in complex with compound 8e
7OKH	;	1.52	;	Crystal structure of human BCL6 BTB domain in complex with compound 8f
7Q7U	;	1.78	;	Crystal structure of human BCL6 BTB domain in complex with compound 9a
8C78	;	1.8	;	Crystal structure of human BCL6 BTB domain in complex with compound CCT374705
6J7W	;	2.6	;	Crystal Structure of Human BCMA in complex with UniAb(TM) VH
7YUL	;	1.82	;	Crystal structure of human BEND6 BEN domain in complex with DNA
7YUN	;	2.13	;	Crystal structure of human BEND6 BEN domain in complex with methylated DNA
1SZ7	;	1.55	;	Crystal structure of Human Bet3
2XSX	;	1.7	;	Crystal structure of human beta enolase ENOB
2QZK	;	1.8	;	Crystal structure of human Beta Secretase complexed with I21
1TQF	;	1.8	;	Crystal structure of human Beta secretase complexed with inhibitor
2B8L	;	1.7	;	Crystal structure of human beta secretase complexed with inhibitor
2OAH	;	1.8	;	Crystal Structure of Human Beta Secretase Complexed with inhibitor
2P8H	;	1.8	;	Crystal structure of human beta secretase complexed with inhibitor
2PH6	;	2.0	;	Crystal Structure of Human Beta Secretase Complexed with inhibitor
2PH8	;	1.7	;	Crystal Structure of Human Beta Secretase Complexed with inhibitor
2QZL	;	1.8	;	Crystal Structure of human Beta Secretase complexed with IXS
1YM4	;	2.25	;	Crystal structure of human beta secretase complexed with NVP-AMK640
1YM2	;	2.05	;	Crystal structure of human beta secretase complexed with NVP-AUR200
3FKT	;	1.9	;	Crystal Structure of Human Beta Secretase Complexed with Spiropiperdine Iminohydantoin Inhibitor
3PI5	;	2.4	;	Crystal Structure of Human Beta Secretase in Complex with BFG356
4LXA	;	1.95	;	Crystal Structure of Human Beta Secretase in Complex with Compound 11a
4LXK	;	2.05	;	Crystal Structure of Human Beta Secretase in Complex with compound 11d
4LXM	;	2.3	;	Crystal Structure of Human Beta Secretase in Complex with compound 12a
3VEU	;	1.52	;	Crystal Structure of Human Beta Secretase in Complex with NVP-AVI326
3VF3	;	1.48	;	Crystal Structure of Human Beta Secretase in Complex with NVP-BQQ711
4D83	;	2.4	;	Crystal Structure of Human Beta Secretase in Complex with NVP-BUR436, derived from a co-crystallization experiment
3VG1	;	1.77	;	Crystal Structure of Human Beta Secretase in Complex with NVP-BUR436, derived from a soaking experiment
4D85	;	2.65	;	Crystal Structure of Human Beta Secretase in Complex with NVP-BVI151
4D8C	;	2.07	;	Crystal Structure of Human Beta Secretase in Complex with NVP-BXD552, derived from a co-crystallization experiment
4D89	;	1.65	;	Crystal Structure of Human Beta Secretase in Complex with NVP-BXD552, derived from a soaking experiment
4D88	;	1.7	;	Crystal Structure of Human Beta Secretase in Complex with NVP-BXQ490
1C1Z	;	2.87	;	CRYSTAL STRUCTURE OF HUMAN BETA-2-GLYCOPROTEIN-I (APOLIPOPROTEIN-H)
8AS4	;	2.3	;	Crystal structure of human beta-arrestin-1
3LWK	;	1.7	;	Crystal structure of human Beta-crystallin A4 (CRYBA4)
3QK3	;	1.95	;	Crystal structure of human beta-crystallin B3
6CS9	;	1.85	;	Crystal structure of human beta-defensin 2 in complex with PIP2
5KI9	;	1.6	;	Crystal structure of human beta-defensin 4 (HBD4)
3THD	;	1.79	;	Crystal structure of human beta-galactosidase in complex with 1-deoxygalactonojirimycin
3WF0	;	2.2	;	Crystal structure of human beta-galactosidase in complex with 6S-NBI-DGJ
3WF1	;	2.0	;	Crystal structure of human beta-galactosidase in complex with 6S-NBI-GJ
3THC	;	1.8	;	Crystal structure of human beta-galactosidase in complex with galactose
3WF2	;	2.3	;	Crystal structure of human beta-galactosidase in complex with NBT-DGJ
3WEZ	;	2.11	;	Crystal structure of human beta-galactosidase in complex with NOEV
3WF4	;	2.3	;	Crystal structure of human beta-galactosidase mutant I51T in complex with 6S-NBI-DGJ
3WF3	;	2.15	;	Crystal structure of human beta-galactosidase mutant I51T in complex with Galactose
4JS2	;	2.3	;	Crystal structure of human Beta-galactoside alpha-2,6-sialyltransferase 1 in complex with CMP
4JS1	;	2.09	;	crystal structure of human Beta-galactoside alpha-2,6-sialyltransferase 1 in complex with cytidine and phosphate
3BPT	;	1.5	;	Crystal structure of human beta-hydroxyisobutyryl-CoA hydrolase in complex with quercetin
2HIZ	;	2.5	;	Crystal Structure of human beta-secretase (BACE) in the presence of an inhibitor
2HM1	;	2.2	;	Crystal Structure of human beta-secretase (BACE) in the presence of an inhibitor (2)
2IRZ	;	1.8	;	Crystal structure of human Beta-secretase complexed with inhibitor
2IS0	;	2.2	;	Crystal structure of human Beta-secretase complexed with inhibitor
2B8V	;	1.8	;	Crystal structure of human Beta-secretase complexed with L-L000430,469
3DUY	;	1.97	;	Crystal structure of human beta-secretase in complex with NVP-AFJ144
3DV1	;	2.1	;	Crystal structure of human beta-secretase in complex with NVP-ARV999
3DV5	;	2.1	;	Crystal structure of human beta-secretase in complex with NVP-BAV544
3V7T	;	2.09	;	Crystal Structure of Human Beta-Tryptase Complexed with a Synthetic Inhibitor with a Tropanylamide Scaffold
6FTQ	;	2.08	;	Crystal structure of human beta-ureidopropionase (beta-alanine synthase) - mutant T299C
5N11	;	2.45	;	Crystal structure of Human beta1-coronavirus OC43 NL/A/2005 Hemagglutinin-Esterase
6MXT	;	2.95934	;	Crystal structure of human beta2 adrenergic receptor bound to salmeterol and Nb71
7CCL	;	2.7	;	Crystal structure of human BFK
3I1H	;	2.2	;	Crystal structure of human BFL-1 in complex with BAK BH3 peptide
3MQP	;	2.24	;	Crystal Structure of human BFL-1 in complex with NOXA BH3 peptide, Northeast Structural Genomics Consortium Target HR2930
4ZEQ	;	1.8	;	Crystal Structure of human BFL-1 in complex with tBid BH3 peptide, Northeast Structural Genomics Consortium Target HX9247
4C4Y	;	2.41	;	Crystal structure of human bifunctional epoxide hydroxylase 2 complexed with A4
4C4Z	;	2.06	;	Crystal structure of human bifunctional epoxide hydroxylase 2 complexed with A8
4C4X	;	2.17	;	Crystal structure of human bifunctional epoxide hydroxylase 2 complexed with C9
3LTL	;	2.2	;	Crystal structure of human BIG1 Sec7 domain
7ER6	;	1.6	;	Crystal structure of human Biliverdin IX-beta reductase B
7ERB	;	1.5	;	Crystal structure of human Biliverdin IX-beta reductase B with Ataluren (PTC)
7ERC	;	1.5	;	Crystal structure of human Biliverdin IX-beta reductase B with Deferasirox (ICL)
7ER9	;	1.45	;	Crystal structure of human Biliverdin IX-beta reductase B with Febuxostat (TEI)
7ERD	;	2.0	;	Crystal structure of human Biliverdin IX-beta reductase B with Flunixin Meglumin (FMG)
7ERA	;	1.35	;	Crystal structure of human Biliverdin IX-beta reductase B with Olsalazine Sodium (OSS)
7ERE	;	1.6	;	Crystal structure of human Biliverdin IX-beta reductase B with Pyrantel Pamoate (PPA)
7ER8	;	1.45	;	Crystal structure of human Biliverdin IX-beta reductase B with Sulfasalazine (SAS)
2H63	;	2.7	;	Crystal Structure of Human Biliverdin Reductase A
4DWN	;	1.581	;	Crystal Structure of Human BinCARD CARD
4FH0	;	1.4	;	Crystal Structure of Human BinCARD CARD, double mutant F16M/L66M SeMet form
7TRL	;	1.74	;	Crystal structure of human BIRC2 BIR3 domain in complex with histone H3
7TRM	;	2.4	;	Crystal structure of human BIRC2 BIR3 domain in complex with inhibitor LCL-161
2H52	;	2.0	;	Crystal structure of human bisphosphoglycerate mutase complex with 3-phosphoglycerate (18 days)
4URJ	;	2.68	;	Crystal structure of human BJ-TSA-9
7V5L	;	1.74	;	Crystal structure of human bleomycin hydrolase
7V5S	;	3.02	;	Crystal structure of human bleomycin hydrolase C73A mutant
7V5T	;	3.25	;	Crystal structure of human bleomycin hydrolase C73S mutant
7XF9	;	3.2	;	Crystal structure of human bleomycin hydrolase H372A mutant
5I05	;	1.87	;	Crystal structure of human BMP9 at 1.87 A resolution
6F59	;	2.151	;	Crystal structure of human Brachyury (T) G177D variant in complex with DNA
6F58	;	2.253	;	Crystal structure of human Brachyury (T) in complex with DNA
8A7N	;	1.9	;	Crystal Structure of human Brachyury G177D variant in complex with (S)-N-(3-aminopropyl)-3-((1-(2-fluorophenyl)-2-oxopyrrolidin-3-yl)amino)-N-methylbenzamide (CF-2-125)
6ZU8	;	1.95	;	Crystal structure of human Brachyury G177D variant in complex with Afatinib
7ZKF	;	1.49	;	Crystal Structure of human Brachyury G177D variant in complex with CF-5-86
7ZK2	;	1.6	;	Crystal Structure of human Brachyury G177D variant in complex with CSC027898502
8A10	;	1.88	;	Crystal Structure of human Brachyury G177D variant in complex with Molpolrt-020-049-143
7ZL2	;	1.8	;	Crystal Structure of human Brachyury G177D variant in complex with Molpolrt-039-246-810
8FMU	;	2.03	;	Crystal structure of human Brachyury G177D variant in complex with SJF-4601
8CDN	;	2.55	;	Crystal structure of human Brachyury in complex with a single T box binding element DNA
1FDQ	;	2.1	;	CRYSTAL STRUCTURE OF HUMAN BRAIN FATTY ACID BINDING PROTEIN
1FE3	;	2.8	;	CRYSTAL STRUCTURE OF HUMAN BRAIN FATTY ACID BINDING PROTEIN OLEIC ACID
5IKO	;	2.5	;	Crystal structure of human brain glycogen phosphorylase
5IKP	;	3.4	;	Crystal structure of human brain glycogen phosphorylase bound to AMP
3B6R	;	2.0	;	Crystal structure of Human Brain-type Creatine Kinase
3DRB	;	2.0	;	Crystal structure of Human Brain-type Creatine Kinase
3DRE	;	2.2	;	Crystal structure of Human Brain-type Creatine Kinase
1EKP	;	2.5	;	CRYSTAL STRUCTURE OF HUMAN BRANCHED CHAIN AMINO ACID AMINOTRANSFERASE (MITOCHONDRIAL) COMPLEXED WITH PYRIDOXAL-5'-PHOSPHATE AT 2.5 ANGSTROMS (MONOCLINIC FORM).
2ABJ	;	2.2	;	Crystal structure of human branched chain amino acid transaminase in a complex with an inhibitor, C16H10N2O4F3SCl, and pyridoxal 5' phosphate.
4OFB	;	3.05	;	Crystal structure of human BRCA1 BRCT in complex with nonphosphopeptide inhibitor
5OVB	;	1.95	;	Crystal structure of human BRD4(1) bromodomain in complex with DR46
5O97	;	1.3	;	Crystal structure of human BRD4(1) bromodomain in complex with JRMBR4106
5OWW	;	1.5	;	Crystal structure of human BRD4(1) bromodomain in complex with UT22B
5OWM	;	1.5	;	Crystal structure of human BRD4(1) bromodomain in complex with UT48
4YH3	;	1.6	;	Crystal structure of human BRD4(1) in complex with 4-[(2E)-3-(4-methoxyphenyl)-2-phenylprop-2-enoyl]-3,4-dihydroquinoxalin-2(1H)-one (compound 19a)
4YH4	;	1.33	;	Crystal structure of human BRD4(1) in complex with 4-[(5-phenylpyridin-3-yl)carbonyl]-3,4-dihydroquinoxalin-2(1H)-one (compound 19d)
6MAU	;	2.11	;	Crystal structure of human BRD4(1) in complex with CN210 (compound 19)
6E4A	;	1.26	;	Crystal structure of human BRD4(1) in complex with CN750
6HM0	;	2.4	;	Crystal structure of human BRD9 bromodomain in complex with a PROTAC
5IGN	;	1.7	;	Crystal structure of human BRD9 bromodomain in complex with LP99 chemical probe
6EG3	;	2.84	;	Crystal structure of human BRM in complex with compound 15
6EG2	;	2.98	;	Crystal structure of human BRM in complex with compound 16
3G0L	;	2.03	;	Crystal Structure of Human Bromodomain Adjacent to Zinc finger domain 2B (BAZ2B)
3HME	;	2.23	;	Crystal structure of human bromodomain containing 9 isoform 1 (BRD9)
2NXB	;	1.4	;	Crystal structure of human Bromodomain containing protein 3 (BRD3)
6QJU	;	1.202	;	Crystal structure of human Bromodomain containing protein 3 (BRD3) in complex with 3-bromo-1H-indazol-5-amine
7RJN	;	1.95	;	Crystal structure of human bromodomain containing protein 3 (BRD3) in complex with BCLTF1
7RJK	;	1.85	;	Crystal structure of human Bromodomain containing protein 3 (BRD3) in complex with hnRNPK
7RJM	;	2.1	;	Crystal structure of human Bromodomain containing protein 3 (BRD3) in complex with ILF3
7RJL	;	1.5	;	Crystal structure of human Bromodomain containing protein 3 (BRD3) in complex with SHMT
7RJR	;	1.45	;	Crystal structure of human Bromodomain containing protein 4 (BRD4) in complex with BCLTF1
7RJO	;	1.38	;	Crystal structure of human Bromodomain containing protein 4 (BRD4) in complex with hnRNPK
7RJQ	;	1.72	;	Crystal structure of human Bromodomain containing protein 4 (BRD4) in complex with ILF3
7RJP	;	1.25	;	Crystal structure of human Bromodomain containing protein 4 (BRD4) in complex with SHMT
2YYN	;	2.5	;	Crystal structure of human bromodomain protein
6DJC	;	1.46	;	Crystal structure of human Bromodomain-containing protein 4 (BRD4) bromodomain with MS645
6DNE	;	2.958	;	Crystal structure of human Bromodomain-containing protein 4 (BRD4) bromodomain with MS660
6U04	;	2.2	;	Crystal structure of human BRPF1 PZP bound to histone H3 tail
5URM	;	2.8	;	Crystal structure of human BRR2 in complex with T-1206548
5URJ	;	2.75	;	Crystal structure of human BRR2 in complex with T-3905516
5URK	;	2.95	;	Crystal structure of human BRR2 in complex with T-3935799
4KIT	;	3.598	;	Crystal structure of human Brr2 in complex with the Prp8 Jab1/MPN domain
4NS5	;	1.9	;	Crystal structure of human BS69 Bromo-Zinc finger-PWWP
3DJU	;	2.26	;	Crystal structure of human BTG2
6HTF	;	2.102	;	Crystal structure of human Btk SH2 domain bound to rF10 repebody
8DFY	;	3.552	;	Crystal structure of Human BTN2A1 Ectodomain
8DFW	;	2.1	;	Crystal Structure of Human BTN2A1 in Complex With Vgamma9-Vdelta2 T Cell Receptor
8DFX	;	5.55	;	Crystal structure of Human BTN2A1-BTN3A1 Ectodomain Complex
1P0I	;	2.0	;	Crystal structure of human butyryl cholinesterase
1P0M	;	2.38	;	Crystal structure of human butyryl cholinesterase in complex with a choline molecule
7AWG	;	2.0	;	Crystal structure of human butyrylcholinesterase in complex with (2-((1-(benzenesulfonyl)-1H-indol-4-yl)oxy)ethyl)(benzyl)amine
7AIY	;	2.937	;	Crystal structure of human butyrylcholinesterase in complex with 2-{1-[4-(12-Amino-3-chloro-6,7,10,11-tetrahydro-7,11-methanocycloocta[b]quinolin-9-yl)butyl]-1H-1,2,3-triazol-4-yl}-N-[4-hydroxy-3-methoxybenzyl]acetamide
5DYW	;	2.5	;	Crystal structure of human butyrylcholinesterase in complex with N-((1-benzylpiperidin-3-yl)methyl)-N-(2-methoxyethyl)naphthalene-2-sulfonamide
5DYT	;	2.55	;	Crystal structure of human butyrylcholinesterase in complex with N-((1-benzylpiperidin-3-yl)methyl)-N-methylnaphthalene-2-sulfonamide
5DYY	;	2.65	;	Crystal structure of human butyrylcholinesterase in complex with N-((1-benzylpiperidin-3-yl)methyl)naphthalene-2-sulfonamide
7AMZ	;	2.25	;	Crystal structure of human Butyrylcholinesterase in complex with N-((2S,3R)-4-((2,2-dimethylpropyl)amino)-3-hydroxy-1-phenylbutan-2-yl)-2,2-diphenylacetamide
7Q1N	;	2.35	;	Crystal structure of human butyrylcholinesterase in complex with N-[(2R)-3-[(cyclohexylmethyl)amino]-2-hydroxypropyl]-2,2-diphenylacetamide
7Q1P	;	2.35	;	Crystal structure of human butyrylcholinesterase in complex with N-[(2R)-3-[(cyclohexylmethyl)amino]-2-hydroxypropyl]-3,3-diphenylpropanamide
7Q1M	;	2.79	;	Crystal structure of human butyrylcholinesterase in complex with N-[(2S)-3-[(cyclohexylmethyl)amino]-2-hydroxypropyl]-2,2-diphenylacetamide
7Q1O	;	2.65	;	Crystal structure of human butyrylcholinesterase in complex with N-[(2S)-3-[(cyclohexylmethyl)amino]-2-hydroxypropyl]-3,3-diphenylpropanamide
7AWH	;	2.3	;	Crystal structure of human butyrylcholinesterase in complex with tert-butyl 3-(((2-((1-(benzenesulfonyl)-1H-indol-4-yl)oxy)ethyl)amino)methyl)piperidine-1-carboxylate
7AWI	;	2.3	;	Crystal structure of human butyrylcholinesterase in complex with tert-butyl 3-(((2-((1-benzyl-1H-indol-4-yl)oxy)ethyl)amino)methyl]piperidine-1-carboxylate
6GQM	;	2.0	;	Crystal structure of human c-KIT kinase domain in complex with a small molecule inhibitor, AZD3229
6GQJ	;	2.33	;	Crystal structure of human c-KIT kinase domain in complex with AZD3229-analogue (compound 18)
6GQK	;	2.31	;	Crystal structure of human c-KIT kinase domain in complex with AZD3229-analogue (compound 23)
6GQL	;	2.01	;	Crystal structure of human c-KIT kinase domain in complex with AZD3229-analogue (compound 35)
6KLA	;	2.109	;	Crystal structure of human c-KIT kinase domain in complex with compound 15a
3VW8	;	2.1	;	Crystal structure of human c-Met kinase domain with its inhibitor
4H7W	;	1.1	;	Crystal Structure of Human C16orf57
5ZRT	;	1.9	;	Crystal structure of human C1ORF123 protein
8GMN	;	2.6	;	Crystal structure of human C1s in complex with inhibitor
5UBM	;	2.5	;	Crystal structure of human C1s in complex with inhibitor gigastasin
3PJA	;	3.0	;	Crystal structure of human C3PO complex
6IOM	;	2.594	;	Crystal structure of human C4.4A
4MTC	;	1.47	;	Crystal structure of human C53A DJ-1
4N0M	;	1.95	;	Crystal structure of human C53A DJ-1 in complex with Cu
6C1R	;	2.2	;	Crystal structure of human C5a receptor in complex with an orthosteric antagonist PMX53 and an allosteric antagonist avacopan
6C1Q	;	2.9	;	Crystal structure of human C5a receptor in complex with an orthosteric antagonist PMX53 and an allosteric antagonist NDT9513727
6YQU	;	1.478	;	CRYSTAL STRUCTURE OF HUMAN CA II IN COMPLEX WITH 2-MERCAPTOBENZOXAZOLE
6YQT	;	1.5	;	CRYSTAL STRUCTURE OF HUMAN CA II IN COMPLEX WITH A SULFONAMIDE DERIVATIVE OF 2-MERCAPTOBENZOXAZOLE
8AHS	;	2.48	;	Crystal structure of human Ca2+/Calmodulin in complex with melittin
3MHC	;	1.698	;	Crystal structure of human cabonic anhydrase II in adduct with an adamantyl analogue of acetazolamide in a novel hydrophobic binding pocket
6ULM	;	2.15	;	Crystal structure of human cadherin 17 EC1-2
5WJ8	;	1.86	;	Crystal Structure of Human Cadherin-23 EC13-14
5TFM	;	2.92	;	Crystal Structure of Human Cadherin-23 EC6-8
7Y5L	;	3.42	;	Crystal structure of human CAF-1 core complex in spacegroup C2
7Y5K	;	3.48	;	Crystal structure of human CAF-1 core complex in spacegroup C2221
7Y5O	;	3.57	;	Crystal structure of human CAF-1 core complex in spacegroup P21
4OR9	;	2.23	;	Crystal structure of human calcineurin
1MF8	;	3.1	;	Crystal Structure of human calcineurin complexed with cyclosporin A and human cyclophilin
2P6B	;	2.3	;	Crystal Structure of Human Calcineurin in Complex with PVIVIT Peptide
2VN9	;	2.3	;	Crystal Structure of Human Calcium Calmodulin dependent Protein Kinase II delta isoform 1, CAMKD
5K89	;	2.249	;	Crystal Structure of Human Calcium-Bound S100A1
2V7O	;	2.25	;	Crystal structure of human calcium-calmodulin-dependent protein kinase II gamma
4FG7	;	2.7	;	Crystal structure of human calcium/calmodulin-dependent protein kinase I 1-293 in complex with ATP
4FG8	;	2.2	;	Crystal structure of human calcium/calmodulin-dependent protein kinase I 1-315 in complex with ATP
4FG9	;	2.4	;	Crystal structure of human calcium/calmodulin-dependent protein kinase I 1-320 in complex with ATP
4FGB	;	2.6	;	Crystal structure of human calcium/calmodulin-dependent protein kinase I apo form
3BHH	;	2.4	;	Crystal structure of human calcium/calmodulin-dependent protein kinase IIB isoform 1 (CAMK2B)
2ZV2	;	2.4	;	Crystal structure of human calcium/calmodulin-dependent protein kinase kinase 2, beta, CaMKK2 kinase domain in complex with STO-609
2Y4V	;	1.8	;	CRYSTAL STRUCTURE OF HUMAN CALMODULIN IN COMPLEX WITH A DAP KINASE-1 MUTANT (W305Y) PEPTIDE
2JC6	;	2.3	;	Crystal structure of human calmodulin-dependent protein kinase 1D
6T29	;	1.484	;	Crystal structure of human calmodulin-dependent protein kinase 1D (CAMK1D) bound to compound 18 (CS587)
6T28	;	1.55	;	Crystal structure of human calmodulin-dependent protein kinase 1D (CAMK1D) bound to compound 19 (CS640)
6T6F	;	1.97	;	Crystal structure of human calmodulin-dependent protein kinase 1D (CAMK1D) bound to compound 8 (CS275)
8BFS	;	1.95	;	Crystal structure of human calmodulin-dependent protein kinase 1D (CAMK1D) in complex with FZ326
8BFM	;	1.7	;	Crystal structure of human calmodulin-dependent protein kinase 1D (CAMK1D) in complex with FZ331
2JAM	;	1.7	;	Crystal structure of human calmodulin-dependent protein kinase I G
6BJD	;	2.8	;	Crystal Structure of Human Calpain-3 Protease Core in Complex with E-64
6BKJ	;	3.2	;	Crystal Structure of Human Calpain-3 Protease Core in Complex with Leupeptin
6BGP	;	2.75	;	Crystal Structure of Human Calpain-3 Protease Core Mutant-C129A
6BDT	;	2.3	;	Crystal Structure of Human Calpain-3 Protease Core Mutant-C129S
7QUV	;	1.85	;	Crystal structure of human Calprotectin (S100A8/S100A9) in complex with Peptide 3
1XK4	;	1.8	;	Crystal structure of human calprotectin(S100A8/S100A9)
2W4O	;	2.17	;	Crystal structure of Human CAMK4 in complex with 4-Amino(sulfamoyl- phenylamino)-triazole-carbothioic acid (2,6-difluoro-phenyl)-amide)
6VZK	;	2.55	;	Crystal structure of human CaMKII-alpha (CAMK2A)kinase domain
4WB5	;	1.641	;	Crystal structure of human cAMP-dependent protein kinase A (catalytic alpha subunit)
4WB8	;	1.55	;	Crystal structure of human cAMP-dependent protein kinase A (catalytic alpha subunit), exon 1 deletion
4F9K	;	2.8	;	Crystal Structure of human cAMP-dependent protein kinase type I-beta regulatory subunit (fragment 11-73), Northeast Structural Genomics Consortium (NESG) Target HR8613A
6IGX	;	2.995	;	Crystal structure of human CAP-G in complex with CAP-H
4OZ0	;	2.2	;	Crystal structure of human CAPERalpha U2AF homology motif (apo-state)
4OZ1	;	1.74	;	Crystal structure of human CAPERalpha UHM bound to SF3b155 ULM5
4OUL	;	1.949	;	Crystal structure of human Caprin-2 C1q domain
4OUM	;	1.491	;	Crystal structure of human Caprin-2 C1q domain
5DOT	;	2.4	;	Crystal Structure of Human Carbamoyl phosphate synthetase I (CPS1), apo form
5DOU	;	2.6	;	Crystal Structure of Human Carbamoyl phosphate synthetase I (CPS1), ligand-bound form
6XZE	;	1.54	;	crystal structure of human carbonic anhydrase I in complex with 4-(3-(2-((2-fluorobenzyl)amino)ethyl)ureido) benzenesulfonamide
6XZX	;	1.55	;	crystal structure of human carbonic anhydrase I in complex with 4-(3-(2-((2-fluorobenzyl)amino)ethyl)ureido) benzenesulfonamide
6XZY	;	1.66	;	crystal structure of human carbonic anhydrase I in complex with 4-(3-(2-((2-fluorobenzyl)amino)ethyl)ureido) benzenesulfonamide
6Y00	;	1.37	;	crystal structure of human carbonic anhydrase I in complex with 4-(3-(2-((2-fluorobenzyl)amino)ethyl)ureido) benzenesulfonamide
6XZO	;	1.44	;	Crystal structure of human carbonic anhydrase I in complex with 4-(3-(2-((4-bromo-2-hydroxybenzyl)amino)ethyl)ureido) benzenesulfonamide
6XZS	;	1.53	;	Crystal structure of human carbonic anhydrase I in complex with 4-(3-(2-((4-fluorobenzyl)amino)ethyl)ureido) benzenesulfonamide
5GMM	;	2.003	;	Crystal structure of human Carbonic anhydrase I in complex with polmacoxib
6FAG	;	1.79	;	Crystal structure of human carbonic anhydrase I in complex with the 1-(2-hydroxy-5-sulfamoylphenyl)-3-(2-methoxyphenyl)urea inhibitor
6F3B	;	1.4	;	Crystal structure of human carbonic anhydrase I in complex with the 1-(2-hydroxy-5-sulfamoylphenyl)-3-[(4-methylphenyl)methyl]urea inhibitor
6I0L	;	1.4	;	Crystal structure of human carbonic anhydrase I in complex with the 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[2-(4-sulfamoylphenyl)ethyl]urea inhibitor
6FAF	;	1.99	;	Crystal structure of human carbonic anhydrase I in complex with the 3-(2,5-dimethylphenyl)-1-(2-hydroxy-5-sulfamoylphenyl)urea inhibitor
6EVR	;	1.5	;	Crystal structure of human carbonic anhydrase I in complex with the 4-(4 acetyl-3-benzylpiperazine-1 carbonyl)benzene-1-sulfonamide inhibitor
6I0J	;	1.35	;	Crystal structure of human carbonic anhydrase I in complex with the 4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenyl sulfamate inhibitor
6EX1	;	1.6	;	Crystal structure of human carbonic anhydrase I in complex with the 4-[(3S)-3 benzyl-4-(4-sulfamoylbenzoyl)piperazine -1-carbonyl]benzene-1-sulfonamide inhibitor
6G3V	;	1.69	;	Crystal structure of human carbonic anhydrase I in complex with the inhibitor famotidine
1XEG	;	1.81	;	Crystal structure of human carbonic anhydrase II complexed with an acetate ion
1EOU	;	2.1	;	CRYSTAL STRUCTURE OF HUMAN CARBONIC ANHYDRASE II COMPLEXED WITH AN ANTICONVULSANT SUGAR SULFAMATE
5ZXW	;	1.316	;	Crystal structure of human carbonic anhydrase II crystallized by ammonium sulfate
1XEV	;	2.2	;	Crystal structure of human carbonic anhydrase II in a new crystal form
6RG4	;	1.25	;	Crystal structure of human Carbonic anhydrase II in complex with (R)-4-(2-benzyl-4-methylpiperazin-1-yl)benzenesulfonamide
6RG3	;	1.32	;	Crystal structure of human Carbonic anhydrase II in complex with (R)-4-(2-benzylpiperazin-1-yl)benzenesulfonamide
8BJX	;	1.283	;	Crystal structure of human Carbonic anhydrase II in complex with (R)-4-(3-(1-(6-nitropyridin-2-yl)pyrrolidin-3-yl)thioureido)benzenesulfonamide
5N0D	;	1.7	;	Crystal structure of human carbonic anhydrase II in complex with (R)-4-(6,7-dihydroxy-1-phenyl-3,4-tetrahydroisoquinoline-1H-2-carbonyl)benzenesulfonamide.
5N0E	;	1.75	;	Crystal structure of human carbonic anhydrase II in complex with (S)-4-(6,7-dihydroxy-1-phenyl-3,4-tetrahydroisoquinoline-1H-2-carbonyl)benzenesulfonamide.
4RH2	;	1.3	;	Crystal structure of human carbonic anhydrase II in complex with 2-(6-hydroxy-3-Oxo-3H-xanthen-9-yl)-5-{3-1-(4-sulfamoyl-phenyl)-1h-[1,2,3]triazol-4-ylmethyl-thioureido}-benzoic acid
7ORP	;	1.43	;	crystal structure of human carbonic anhydrase II in complex with 4-((2-hydroxy-3-((3,4,5-trimethoxyphenyl)tellanyl)propyl)selanyl)benzenesulfonamide
7ORQ	;	1.43	;	crystal structure of human carbonic anhydrase II in complex with 4-((3-(butylselanyl)-2-hydroxypropyl)selanyl)benzenesulfonamide
4RUX	;	1.14	;	Crystal structure of human Carbonic Anhydrase II in complex with 4-(allyloxy)benzenesulfonamide
4RUZ	;	1.63	;	Crystal structure of human Carbonic Anhydrase II in complex with 4-ethoxybenzenesulfonamide
4RUY	;	1.14	;	Crystal structure of human Carbonic Anhydrase II in complex with 4-propoxybenzenesulfonamide
3MMF	;	1.5	;	Crystal structure of human carbonic anhydrase II in complex with a 1,3,5-triazine-substituted benzenesulfonamide inhibitor
3N0N	;	1.5	;	Crystal structure of human carbonic anhydrase II in complex with a benzenesulfonamide inhibitor
3N2P	;	1.648	;	Crystal structure of human carbonic anhydrase II in complex with a benzenesulfonamide inhibitor
3N3J	;	1.5	;	Crystal structure of human carbonic anhydrase II in complex with a benzenesulfonamide inhibitor
3N4B	;	1.6	;	Crystal structure of human carbonic anhydrase II in complex with a benzenesulfonamide inhibitor
8C0Q	;	1.67	;	Crystal structure of human carbonic anhydrase II in complex with a coumarin derivative.
8C0R	;	1.56	;	Crystal structure of human carbonic anhydrase II in complex with a coumarin derivative.
6B4D	;	1.196	;	Crystal structure of human carbonic anhydrase II in complex with a heteroaryl-pyrazole carboxylic acid derivative.
4LP6	;	2.15	;	Crystal Structure of Human Carbonic Anhydrase II in complex with a quinoline oligoamide foldamer
5L3O	;	1.98	;	Crystal Structure of Human Carbonic Anhydrase II in Complex with a Quinoline Oligoamide Foldamer
5L6K	;	1.7	;	Crystal Structure of Human Carbonic Anhydrase II in Complex with a Quinoline Oligoamide Foldamer
5L6T	;	2.65	;	CRYSTAL STRUCTURE OF HUMAN CARBONIC ANHYDRASE II IN COMPLEX WITH A QUINOLINE OLIGOAMIDE FOLDAMER
5L70	;	2.2	;	CRYSTAL STRUCTURE OF HUMAN CARBONIC ANHYDRASE II IN COMPLEX WITH A QUINOLINE OLIGOAMIDE FOLDAMER
5L9E	;	2.9	;	CRYSTAL STRUCTURE OF HUMAN CARBONIC ANHYDRASE II IN COMPLEX WITH A QUINOLINE OLIGOAMIDE FOLDAMER
8CR0	;	1.22	;	Crystal structure of human carbonic anhydrase II in complex with a triazolyl benzoxaborole inhibitor
5JQT	;	1.36	;	Crystal structure of human carbonic anhydrase II in complex with Benzoxaborole at pH 7.4
5JQ0	;	1.4	;	Crystal structure of human carbonic anhydrase II in complex with Benzoxaborole at pH=8.7
4YVY	;	1.45	;	Crystal structure of human carbonic anhydrase II in complex with hydroxylamine-O-sulfonamide, a molecule incorporating two zinc-binding groups.
5GMN	;	1.8	;	Crystal structure of human carbonic anhydrase II in complex with polmacoxib
3C7P	;	1.7	;	Crystal structure of human carbonic anhydrase II in complex with STX237
5LJT	;	1.0	;	Crystal structure of human carbonic anhydrase II in complex with the 4-((1-phenyl-1H-1,2,3-triazol-4-yl)methoxy)benzenesulfonamide inhibitor
5E2S	;	1.5	;	Crystal structure of human carbonic anhydrase II in complex with the 4-(2-iso-propylphenyl)benzenesulfonamide inhibitor
5E2K	;	1.4	;	Crystal structure of human carbonic anhydrase II in complex with the 4-(3-aminophenyl)benzenesulfonamide inhibitor
5LJQ	;	1.05	;	Crystal structure of human carbonic anhydrase II in complex with the 4-(4-(phenoxymethyl)-1H-1,2,3-triazol-1-yl)benzenesulfonamide inhibitor
5E28	;	1.3	;	Crystal structure of human carbonic anhydrase II in complex with the 4-(4-aminophenyl)benzenesulfonamide inhibitor
6H3Q	;	1.31	;	Crystal structure of human carbonic anhydrase II in complex with the 4-(5-(chloromethyl)-1,3-selenazol-2-yl)benzenesulfonamide
3V5G	;	1.5	;	Crystal structure of human carbonic anhydrase II in complex with the 4-sulfamido-benzenesulfonamide inhibitor
4KUV	;	1.35	;	Crystal structure of human carbonic anhydrase II in complex with the 5-(3-(4-chlorophenylsulfonyl)ureido)pyridine-2-sulfonamide inhibitor
4KUW	;	1.55	;	Crystal structure of human carbonic anhydrase II in complex with the 5-(3-(4-fluorophenylsulfonyl)ureido)pyridine-2-sulfonamide inhibitor
4KUY	;	1.65	;	Crystal structure of human carbonic anhydrase II in complex with the 5-(3-(o-tolylsulfonyl)ureido)pyridine-2-sulfonamide inhibitor
4KV0	;	1.55	;	Crystal structure of human carbonic anhydrase II in complex with the 5-(3-tosylureido)pyridine-2-sulfonamide inhibitor
4WL4	;	1.1	;	Crystal structure of human carbonic anhydrase II in complex with the 6-hydroxy-chromene-2-thione inhibitor
5FDC	;	1.75	;	Crystal structure of Human Carbonic Anhydrase II in complex with the anticonvulsant sulfamide JNJ-26990990 and its S,S-dioxide analog.
5N1R	;	1.3	;	Crystal structure of human carbonic anhydrase II in complex with the inhibitor 4'-Pyrazol-1-ylmethyl-biphenyl-4-sulfonamide
5N1S	;	1.3	;	Crystal structure of human carbonic anhydrase II in complex with the inhibitor 4-(1H-Indol-2-yl)-benzenesulfonamide
5NEA	;	1.3	;	Crystal structure of human carbonic anhydrase II in complex with the inhibitor 4-(2-methyl-1,3-oxazol-5-yl)benzene-1-sulfonammide
6GOT	;	1.56	;	Crystal structure of human carbonic anhydrase II in complex with the inhibitor 4-(phenethylthio)benzenesulfonamide
5N25	;	1.4	;	Crystal structure of human carbonic anhydrase II in complex with the inhibitor 4-Pyridin-3-yl-benzenesulfonamide
5NEE	;	1.7	;	Crystal structure of human carbonic anhydrase II in complex with the inhibitor 5-[2-(morpholine-4-carbonyl)1,3-oxazol-5-yl)]thiophene-2-sulfonammide
5N24	;	1.5	;	Crystal structure of human carbonic anhydrase II in complex with the inhibitor b4'-Cyano-biphenyl-4-sulfonic acid amide
6G3Q	;	1.01	;	Crystal structure of human carbonic anhydrase II in complex with the inhibitor famotidine
8IGF	;	2.6	;	Crystal Structure of Human Carbonic Anhydrase II In-complex with 4-Acetylphenylboronic acid at 2.6 A Resolution
7NH6	;	1.28	;	Crystal structure of human carbonic anhydrase II with 3-(3-((1-(2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl)-1H-1,2,3-triazol-4-yl)methyl)ureido)benzenesulfonamide
7OK8	;	1.43	;	Crystal structure of human carbonic anhydrase II with 4-((2-hydroxy-3-(phenylselanyl)propyl)thio)benzenesulfonamide
3PO6	;	1.47	;	Crystal structure of human carbonic anhydrase II with 6,7-Dimethoxy-1-methyl-3,4-dihydroisoquinoline-2(1H)-sulfonamide
7NH8	;	1.369	;	Crystal structure of human carbonic anhydrase II with N-((1-(6-((3aR,7R,7aS)-7-hydroxy-2,2-dimethyltetrahydro-[1,3]dioxolo[4,5-c]pyridin-5(4H)-yl)hexyl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide
5FDI	;	1.85	;	Crystal structure of Human Carbonic Anhydrase II with the anticonvulsant sulfamide JNJ-26990990 and its S,S-dioxide analog.
4WR7	;	1.5	;	Crystal structure of human carbonic anhydrase isozyme I with 2,3,5,6-Tetrafluoro-4-(propylthio)benzenesulfonamide.
4WUQ	;	1.75	;	Crystal structure of human carbonic anhydrase isozyme I with 2,3,5,6-Tetrafluoro-4-piperidin-1-ylbenzenesulfonamide
5E2M	;	1.41	;	Crystal structure of human carbonic anhydrase isozyme I with 3-(cyclooctylamino)-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide
4WUP	;	1.75	;	Crystal structure of human carbonic anhydrase isozyme I with 4-[(2-Hydroxyethyl)thio]benzenesulfonamide
4WW6	;	1.06	;	Crystal structure of human carbonic anhydrase isozyme II with 2,3,5,6-Tetrafluoro-4-(propylthio)benzenesulfonamide
4PZH	;	1.06	;	Crystal structure of human carbonic anhydrase isozyme II with 2,3,5,6-tetrafluoro-4[(2-hydroxyethyl)sulfonyl]benzenesulfonamide
6R6J	;	1.55	;	Crystal structure of human carbonic anhydrase isozyme II with 2-(benzenesulfonyl)-4-chloro-N-(2-hydroxyethyl)-5-sulfamoyl-benzamide
5DOG	;	1.7	;	Crystal structure of human carbonic anhydrase isozyme II with 2-(Benzylamino)-3,5,6-trifluoro-4-[(2-phenylethyl)thio]benzene- sulfonamide
4KNJ	;	2.0	;	Crystal structure of human carbonic anhydrase isozyme II with 2-Chloro-4-[(pyrimidin-2-ylsulfanyl)acetyl]benzenesulfonamide
4KNI	;	1.8	;	Crystal structure of human carbonic anhydrase isozyme II with 2-Chloro-4-{[(4,6-dimethylpyrimidin-2-yl)sulfanyl]acetyl}benzenesulfonamide
4QSA	;	1.501	;	Crystal structure of human carbonic anhydrase isozyme II with 2-chloro-4-{[(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)thio]acetyl}benzenesulfonamide
3MYQ	;	1.35	;	Crystal structure of human carbonic anhydrase isozyme II with 2-chloro-5-[(1H-imidazo[4,5-c]quinolin-2-ylsulfanyl)acetyl]benzenesulfonamide
3M67	;	1.8	;	Crystal structure of human carbonic anhydrase isozyme II with 2-chloro-5-[(6,7-dihydro-1H-[1,4]dioxino[2,3-f]benzimidazol-2-ylsulfanyl)acetyl]benzenesulfonamide
3S9T	;	1.3	;	Crystal structure of human carbonic anhydrase isozyme II with 2-chloro-5-{[(4,6-dimethyl-2-pyrimidinyl)sulfanyl]acetyl}benzenesulfonamide
3SAX	;	1.1	;	Crystal structure of human carbonic anhydrase isozyme II with 2-chloro-5-{[(5-ethyl-2-pyrimidinyl)sulfanyl]acetyl}benzenesulfonamide
5DOH	;	1.05	;	Crystal structure of human carbonic anhydrase isozyme II with 2-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]-3,5,6-trifluoro-4-[(2-hydroxyethyl)thio]benzenesulfonamide
5EHE	;	1.5	;	Crystal structure of human carbonic anhydrase isozyme II with 3-(benzylamino)-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide
5LLC	;	1.1	;	Crystal structure of human carbonic anhydrase isozyme II with 3-(Methylamino)-2,5,6-trifluoro-4-[(2-phenylethyl)sulfonyl]benzenesulfonamide
3HLJ	;	1.44	;	Crystal structure of human carbonic anhydrase isozyme II with 3-methylthiobenzimidazo[1,2-c][1,2,3]thiadiazol-7-sulfonamide
4QSB	;	1.4	;	Crystal structure of human carbonic anhydrase isozyme II with 3-{[(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)thio]acetyl}benzenesulfonamide
5LLH	;	1.9	;	Crystal structure of human carbonic anhydrase isozyme II with 4-(1,3-Benzothiazol-2-ylthio)-2,3,5,6-tetrafluorobenzenesulfonamide
5LLE	;	1.9	;	Crystal structure of human carbonic anhydrase isozyme II with 4-(1-Adamantylamino)-2,3,5,6-tetrafluorobenzenesulfonamide
5LL4	;	1.12	;	Crystal structure of human carbonic anhydrase isozyme II with 4-(1H-benzimidazol-1-ylacetyl)benzenesulfonamide
6RHJ	;	1.44	;	Crystal structure of human carbonic anhydrase isozyme II with 4-(4-benzyl-1,4-diazepane-1-carbonyl)benzenesulfonamide
6R6F	;	1.2	;	Crystal structure of human carbonic anhydrase isozyme II with 4-chloro-2-cyclohexylsulfanyl-N-(2-hydroxyethyl)-5-sulfamoyl-benzamide
5LLG	;	1.12	;	Crystal structure of human carbonic anhydrase isozyme II with 4-Propylthiobenzenesulfonamide
3SBI	;	1.4	;	Crystal structure of human carbonic anhydrase isozyme II with 4-[(2-pyrimidinylsulfanyl)acetyl]benzenesulfonamide
4Q6D	;	1.12	;	Crystal structure of human carbonic anhydrase isozyme II with 4-[(Z)-azepan-1-yldiazenyl]benzenesulfonamide
3MHO	;	1.15	;	Crystal structure of human carbonic anhydrase isozyme II with 4-[N-(6-chloro-5-formyl-2-methylthiopyrimidin-4-yl)amino]benzenesulfonamide
3M40	;	1.6	;	Crystal structure of human carbonic anhydrase isozyme II with 4-[N-(6-chloro-5-nitropyrimidin-4-yl)amino]benzenesulfonamide
3M2N	;	1.65	;	Crystal structure of human carbonic anhydrase isozyme II with 4-{2-[N-(6-chloro-5-nitropyrimidin-4-yl)amino]ethyl}benzenesulfonamide
3M3X	;	1.68	;	Crystal structure of human carbonic anhydrase isozyme II with 4-{2-[N-(6-methoxy-5-nitropyrimidin-4-yl)amino]ethyl}benzenesulfonamide
3SBH	;	1.65	;	Crystal structure of human carbonic anhydrase isozyme II with 4-{[(4,6-dimethyl-2-pyrimidinyl)sulfanyl]acetyl}benzenesulfonamide
3S8X	;	1.3	;	Crystal structure of human carbonic anhydrase isozyme II with 4-{[(4-methyl-6-oxo-1,6-dihydro-2-pyrimidinyl)sulfanyl]acetyl}benzenesulfonamide
3SAP	;	1.75	;	Crystal structure of human carbonic anhydrase isozyme II with 4-{[(5-butyl-2-pyrimidinyl)sulfanyl]acetyl}benzenesulfonamide
3MHI	;	1.7	;	Crystal structure of human carbonic anhydrase isozyme II with 4-{[(5-nitro-6-oxo-1,6-dihydro-4-pyrimidinyl)amino]methyl}benzenesulfonamide
4Q6E	;	1.12	;	Crystal structure of human carbonic anhydrase isozyme II with 4-{[3-(3,5-Dimethyl-1H-pyrazol-1-yl)-3-oxopropyl]amino}benzene-1-sulfonamide
3MHM	;	1.5	;	Crystal structure of human carbonic anhydrase isozyme II with 4-{[N-(6-benzylamino-5-nitropyrimidin-4-yl)amino]methyl}benzenesulfonamide
3M5E	;	1.7	;	Crystal structure of human carbonic anhydrase isozyme II with 4-{[N-(6-chloro-5-formyl-2-methylthiopyrimidin-4-yl)amino]methyl}benzenesulfonamide
3MHL	;	1.9	;	Crystal structure of human carbonic anhydrase isozyme II with 4-{[N-(6-methoxy-5-nitropyrimidin-4-yl)amino]methyl}benzenesulfonamide
3M98	;	1.5	;	Crystal structure of human carbonic anhydrase isozyme II with 5-(1H-benzimidazol-1-ylacetyl)-2-chlorobenzenesulfonamide
4LHI	;	1.6	;	Crystal structure of human carbonic anhydrase isozyme II with 5-(phenylsulfonyl)thiophene-2-sulfonamide
4QSI	;	1.95	;	Crystal structure of human carbonic anhydrase isozyme II with 5-{[(4-tert-buthyl-6-oxo-1,6-dihydropyrimidin-2-yl)thio]acetyl}-2-chlorobenzenesulfonamide
3M96	;	1.4	;	Crystal structure of human carbonic anhydrase isozyme II with 5-{[(5-bromo-1H-benzimidazol-2-yl)sulfanyl]acetyl}-2-chlorobenzenesulfonamide
4PYX	;	1.8	;	Crystal structure of human carbonic anhydrase isozyme II with inhibitor
4PYY	;	1.75	;	Crystal structure of human carbonic anhydrase isozyme II with inhibitor
4QIY	;	1.3	;	Crystal structure of human carbonic anhydrase isozyme II with inhibitor
4QJM	;	1.75	;	Crystal structure of human carbonic anhydrase isozyme II with inhibitor
4QTL	;	1.8	;	Crystal structure of human carbonic anhydrase isozyme II with inhibitor
6G6T	;	1.12	;	Crystal structure of human carbonic anhydrase isozyme II with N-butyl-2,4-dichloro-5-sulfamoyl-benzamide
4HT0	;	1.6	;	Crystal structure of human carbonic anhydrase isozyme II with the inhibitor.
5IPZ	;	2.1	;	Crystal structure of human carbonic anhydrase isozyme IV with 5-(2-amino-1,3-thiazol-4-yl)-2-chlorobenzenesulfonamide
6G7A	;	1.42	;	Crystal structure of human carbonic anhydrase isozyme XII 2-(benzylamino)-4-chloro-N-(2-hydroxyethyl)-5-sulfamoyl-benzamide
5MSA	;	1.2	;	Crystal structure of human carbonic anhydrase isozyme XII with 2,3,5,6-Tetrafluoro-4-(propylthio)benzenesulfonamide
5MSB	;	1.3	;	Crystal structure of human carbonic anhydrase isozyme XII with 2,3,5,6-tetrafluoro-4[(2-hydroxyethyl)sulfonyl]benzenesulfonamide
6R71	;	2.0	;	Crystal structure of human carbonic anhydrase isozyme XII with 2-(benzenesulfonyl)-4-chloro-N-(2-hydroxyethyl)-5-sulfamoyl-benzamide
5LLP	;	1.48	;	Crystal structure of human carbonic anhydrase isozyme XII with 3-[(1S)-1,2,3,4-Tetrahydronapthalen-1-ylamino)-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide
5LLO	;	1.6	;	Crystal structure of human carbonic anhydrase isozyme XII with 3-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]-2,5,6-trifluoro-4-[(2-hy-droxyethyl)sulfonyl]benzenesulfonamide
5LL9	;	1.45	;	Crystal structure of human carbonic anhydrase isozyme XII with 4-(1H-benzimidazol-1-ylacetyl)-2-chlorobenzenesulfonamide
5LL5	;	1.42	;	Crystal structure of human carbonic anhydrase isozyme XII with 4-(1H-benzimidazol-1-ylacetyl)benzenesulfonamide
6G5L	;	1.21	;	Crystal structure of human carbonic anhydrase isozyme XII with 4-chloro-2-(cyclohexylamino)-N-(2-hydroxyethyl)-5-sulfamoyl-benzamide
6R6Y	;	1.38	;	Crystal structure of human carbonic anhydrase isozyme XII with 4-chloro-2-cyclohexylsulfanyl-N-(2-hydroxyethyl)-5-sulfamoyl-benzamide
4WW8	;	1.42	;	Crystal structure of human carbonic anhydrase isozyme XII with 4-Propylthiobenzenesulfonamide
4HT2	;	1.45	;	Crystal structure of human carbonic anhydrase isozyme XII with the inhibitor.
5LLN	;	1.6	;	Crystal structure of human carbonic anhydrase isozyme XIII with 2,3,5,6-Tetrafluoro-4-(propylthio)benzenesulfonamide
5OGJ	;	1.06	;	Crystal structure of human carbonic anhydrase isozyme XIII with 2-(Cyclooctylamino)-3,5,6-trifluoro-4-[(2-hydroxyethyl)thio]benzenesulfonamide
4KNN	;	1.404	;	Crystal structure of human carbonic anhydrase isozyme XIII with 2-Chloro-4-[(pyrimidin-2-ylsulfanyl)acetyl]benzenesulfonamide
4KNM	;	1.9	;	Crystal structure of human carbonic anhydrase isozyme XIII with 2-Chloro-4-{[(4,6-dimethylpyrimidin-2-yl)sulfanyl]acetyl}benzenesulfonamide
4QSJ	;	1.7	;	Crystal structure of human carbonic anhydrase isozyme XIII with 2-chloro-4-{[(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)thio]acetyl}benzenesulfonamide
5OHH	;	1.42	;	Crystal structure of human carbonic anhydrase isozyme XIII with 2-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]-3,5,6-trifluoro-4-[(2-hydroxyethyl)thio]benzenesulfonamide
5E2N	;	1.53	;	Crystal structure of human carbonic anhydrase isozyme XIII with 3-(cyclooctylamino)-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide
5LLA	;	1.5	;	Crystal structure of human carbonic anhydrase isozyme XIII with 4-(1H-benzimidazol-1-ylacetyl)-2-chlorobenzenesulfonamide
4QIZ	;	1.55	;	Crystal structure of human carbonic anhydrase isozyme XIII with inhibitor
4QJP	;	1.62	;	Crystal structure of human carbonic anhydrase isozyme XIII with inhibitor
4QJX	;	1.95	;	Crystal structure of human carbonic anhydrase isozyme XIII with inhibitor
6G5U	;	1.7	;	Crystal structure of human carbonic anhydrase isozyme XIII with N-butyl-2,4-dichloro-5-sulfamoyl-benzamide
4HU1	;	1.95	;	Crystal structure of human carbonic anhydrase isozyme XIII with the inhibitor.
3FE4	;	1.9	;	Crystal Structure of Human Carbonic Anhydrase vi
7NC4	;	1.6	;	Crystal structure of human carbonic anhydrase VII (hCA VII) in complex with a 4-(4-aroylpiperazine-1-carbonyl)benzenesulfonamide derivative.
3MDZ	;	2.32	;	Crystal Structure of Human Carbonic Anhydrase VII [isoform 1], CA7
7NTB	;	1.7	;	Crystal structure of human carbonic anhydrase with a benzophenone-derivative
3D0N	;	1.55	;	Crystal structure of human carbonic anhydrase XIII
5DRS	;	1.1	;	Crystal structure of human carbonic anhydraseisozyme II with 3-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide
1LJW	;	2.16	;	Crystal Structure of Human Carbonmonoxy Hemoglobin at 2.16 A: A Snapshot of the Allosteric Transition
1IRD	;	1.25	;	Crystal Structure of Human Carbonmonoxy-Haemoglobin at 1.25 A Resolution
3BHJ	;	1.77	;	Crystal structure of human Carbonyl Reductase 1 in complex with glutathione
3BHI	;	2.27	;	Crystal structure of human Carbonyl Reductase 1 in complex with NADP
3BHM	;	1.8	;	Crystal structure of human Carbonyl Reductase 1 in complex with S-hydroxymethylglutathione
2HRB	;	1.9	;	Crystal Structure of human Carbonyl Reductase 3, complexed with NADP+
2Q5E	;	2.51	;	Crystal structure of human carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 2
2DQY	;	3.0	;	Crystal structure of human carboxylesterase in complex with cholate and palmitate
2H7C	;	2.0	;	Crystal structure of human carboxylesterase in complex with Coenzyme A
2DQZ	;	2.8	;	Crystal structure of human carboxylesterase in complex with homatropine, coenzyme A, and palmitate
2DR0	;	3.2	;	Crystal structure of human carboxylesterase in complex with taurocholate
2V77	;	1.603	;	Crystal Structure of Human Carboxypeptidase A1
1UWY	;	3.0	;	Crystal structure of human carboxypeptidase M
5MRV	;	1.854	;	Crystal structure of human carboxypeptidase O in complex with NvCI
8GSU	;	1.5	;	Crystal structure of human cardiac alpha actin (WT_ADP-Pi) in complex with fragmin F1 domain
8GT1	;	1.35	;	Crystal structure of human cardiac alpha actin A108G mutant (ADP-Pi state) in complex with fragmin F1 domain
8GSW	;	1.4	;	Crystal structure of human cardiac alpha actin A108G mutant (AMPPNP state) in complex with fragmin F1 domain
8GT3	;	1.5	;	Crystal structure of human cardiac alpha actin P109A mutant (ADP-Pi state) in complex with fragmin F1 domain
8GT2	;	1.5	;	Crystal structure of human cardiac alpha actin P109A mutant (AMPPNP state) in complex with fragmin F1 domain
8GT5	;	1.4	;	Crystal structure of human cardiac alpha actin Q137A mutant (ADP-Pi state) in complex with fragmin F1 domain
8GT4	;	1.55	;	Crystal structure of human cardiac alpha actin Q137A mutant (AMPPNP state) in complex with fragmin F1 domain
2VAF	;	3.8	;	Crystal structure of Human Cardiac Calsequestrin
7F05	;	2.298	;	Crystal structure of human cardiac calsequestrin bound with calcium
3RV5	;	2.2	;	Crystal structure of human cardiac troponin C regulatory domain in complex with cadmium and deoxycholic acid
5CFC	;	2.5	;	Crystal Structure of Human Cardiovirus SAFV-3
6DVR	;	1.54	;	Crystal structure of human CARM1 with (R)-SKI-72
6D2L	;	2.0	;	Crystal structure of human CARM1 with (S)-SKI-72
4RUH	;	2.25	;	Crystal structure of Human Carnosinase-2 (CN2) in complex with inhibitor, Bestatin at 2.25 A
3DLJ	;	2.26	;	Crystal structure of human carnosine dipeptidase 1
1NWR	;	2.7	;	Crystal structure of human cartilage gp39 (HC-gp39)
1NWS	;	2.7	;	Crystal structure of human cartilage gp39 (HC-gp39) in complex with chitobiose
1NWT	;	2.5	;	Crystal structure of human cartilage gp39 (HC-gp39) in complex with chitopentaose
1NWU	;	2.2	;	Crystal structure of human cartilage gp39 (HC-gp39) in complex with chitotetraose
5MQV	;	2.154	;	Crystal structure of human Casein Kinase I delta in complex with 4-(2,5-Dimethoxyphenyl)-N-(4-(5-(4-fluorphenyl)-2-(methylthio)-1H-imidazol-4-yl)-pyridin-2-yl)-1-methyl-1H-pyrrole-2-carboxamide
6HMP	;	2.039	;	Crystal structure of human Casein Kinase I delta in complex with a photoswitchable 2-Azoimidazole-based Inhibitor (compound 3)
6HMR	;	1.782	;	Crystal structure of human Casein Kinase I delta in complex with a photoswitchable 2-Azothiazole-based inhibitor (compound 2)
7NZY	;	1.85	;	Crystal structure of human Casein Kinase I delta in complex with CGS-15943
6F1W	;	1.864	;	Crystal structure of human Casein Kinase I delta in complex with compound 31a
6F26	;	1.83	;	Crystal structure of human Casein Kinase I delta in complex with compound 31b
5OKT	;	2.13	;	Crystal structure of human Casein Kinase I delta in complex with IWP-2
8QWY	;	2.6	;	Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with 4-(6-((5-isopropoxy-2-methoxyphenyl)amino)pyrazin-2-yl)benzoic acid
8QWZ	;	2.6	;	Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with 4-(6-(6-isopropoxy-1H-indol-1-yl)pyrazin-2-yl)benzoic acid
8P06	;	2.4	;	Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with 5-((2-(4H-1,2,4-triazol-4-yl)pyridin-4-yl)amino)-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidine-3-carbonitrile
8P07	;	2.4	;	Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with 5-((3-(4H-1,2,4-triazol-4-yl)phenyl)amino)-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidine-3-carbonitrile
8PVO	;	2.25	;	Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with allosteric compound FG5
8PVP	;	2.6	;	Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with allosteric compound FGJG18
8BGC	;	2.8	;	Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with compound 2 (AA-CS-9-003)
8P05	;	2.45	;	Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with Leucettinib-92
2HBR	;	2.2	;	Crystal structure of human caspase-1 (Arg286->Ala) in complex with 3-[2-(2-benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-4-oxo-pentanoic acid (z-VAD-FMK)
2HBZ	;	1.9	;	Crystal structure of human caspase-1 (Arg286->Ala, Glu390->Ala) in complex with 3-[2-(2-benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-4-oxo-pentanoic acid (z-VAD-FMK)
2H4Y	;	1.9	;	Crystal structure of human caspase-1 (Arg286->Lys) in complex with 3-[2-(2-benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-4-oxo-pentanoic acid (z-VAD-FMK)
2FQQ	;	3.3	;	Crystal structure of human caspase-1 (Cys285->Ala, Cys362->Ala, Cys364->Ala, Cys397->Ala) in complex with 1-methyl-3-trifluoromethyl-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (2-mercapto-ethyl)-amide
2H48	;	2.2	;	Crystal structure of human caspase-1 (Cys362->Ala, Cys364->Ala, Cys397->Ala) in complex with 3-[2-(2-benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-4-oxo-pentanoic acid (z-VAD-FMK)
2HBY	;	2.1	;	Crystal structure of human caspase-1 (Glu390->Ala) in complex with 3-[2-(2-benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-4-oxo-pentanoic acid (z-VAD-FMK)
2H51	;	2.1	;	Crystal structure of human caspase-1 (Glu390->Asp and Arg286->Lys) in complex with 3-[2-(2-benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-4-oxo-pentanoic acid (z-VAD-FMK)
2H4W	;	2.0	;	Crystal structure of human caspase-1 (Glu390->Asp) in complex with 3-[2-(2-benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-4-oxo-pentanoic acid (z-VAD-FMK)
2H54	;	1.8	;	Crystal structure of human caspase-1 (Thr388->Ala) in complex with 3-[2-(2-benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-4-oxo-pentanoic acid (z-VAD-FMK)
1RWK	;	2.3	;	Crystal structure of human caspase-1 in complex with 3-(2-mercapto-acetylamino)-4-oxo-pentanoic acid
1RWN	;	2.0	;	Crystal structure of human caspase-1 in complex with 3-{2-ethyl-6-[4-(quinoxalin-2-ylamino)-benzoylamino]-hexanoylamino}-4-oxo-butyric acid
1RWP	;	2.2	;	Crystal structure of human caspase-1 in complex with 3-{6-[(8-hydroxy-quinoline-2-carbonyl)-amino]-2-thiophen-2-yl-hexanoylamino}-4-oxo-butyric acid
1RWW	;	2.8	;	Crystal structure of human caspase-1 in complex with 4-oxo-3-[(6-{[4-(quinoxalin-2-ylamino)-benzoylamino]-methyl}-pyridine-3-carbonyl)-amino]-butyric acid
1RWM	;	2.7	;	Crystal structure of human caspase-1 in complex with 4-oxo-3-[2-(5-{[4-(quinoxalin-2-ylamino)-benzoylamino]-methyl}-thiophen-2-yl)-acetylamino]-pentanoic acid
1RWO	;	2.1	;	Crystal structure of human caspase-1 in complex with 4-oxo-3-{6-[4-(quinoxalin-2-ylamino)-benzoylamino]-2-thiophen-2-yl-hexanoylamino}-pentanoic acid
1RWX	;	1.85	;	Crystal structure of human caspase-1 in complex with 4-oxo-3-{6-[4-(quinoxalin-2-yloxy)-benzoylamino]-2-thiophen-2-yl-hexanoylamino}-butyric acid
1RWV	;	2.1	;	Crystal structure of human caspase-1 in complex with 5-[5-(1-carboxymethyl-2-oxo-propylcarbamoyl)-5-phenyl-pentylsulfamoyl]-2-hydroxy-benzoic acid
6BZ9	;	1.796	;	Crystal structure of human caspase-1 in complex with Ac-FLTD-CMK
5MTK	;	2.53	;	Crystal structure of human Caspase-1 with (3S,6S,10aS)-N-((2S,3S)-2-hydroxy-5-oxotetrahydrofuran-3-yl)-6-(isoquinoline-1-carboxamido)-5-oxodecahydropyrrolo[1,2-a]azocine-3-carboxamide (PGE-3935199)
5MMV	;	2.15	;	Crystal structure of human Caspase-1 with 2-((2-naphthoyl)-L-valyl)-4-hydroxy-N-((3S)-2-hydroxy-5-oxotetrahydrofuran-3-yl)-2-azabicyclo[2.2.2]octane-3-carboxamide (Compound 1)
3D6F	;	1.9	;	Crystal structure of human caspase-1 with a naturally-occurring Arg240->Gln substitution in complex with 3-[2-(2-benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-4-oxo-pentanoic acid (z-VAD-FMK)
3D6H	;	2.0	;	Crystal structure of human caspase-1 with a naturally-occurring Asn263->Ser substitution in complex with 3-[2-(2-benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-4-oxo-pentanoic acid (z-VAD-FMK)
3D6M	;	1.8	;	Crystal structure of human caspase-1 with a naturally-occurring Lys319->Arg substitution in complex with 3-[2-(2-benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-4-oxo-pentanoic acid (z-VAD-FMK)
6F6R	;	1.8	;	Crystal structure of human Caspase-1 with N-{3-[1-((S)-2-Hydroxy-5-oxo-tetrahydro-furan-3-ylcarbamoyl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl}-4-(quinoxalin-2-ylamino)-benzamide
1PYO	;	1.65	;	Crystal Structure of Human Caspase-2 in Complex with Acetyl-Leu-Asp-Glu-Ser-Asp-cho
6NRY	;	2.184	;	Crystal structure of human caspase-4
5V6U	;	2.8	;	Crystal structure of human caspase-7 soaked with allosteric inhibitor 2-[(2-acetylphenyl)sulfanyl]benzoic acid
5V6Z	;	2.6	;	Crystal structure of human caspase-7 soaked with allosteric inhibitor 2-{[2-(4-chlorophenyl)-2-oxoethyl]sulfanyl}benzoic acid
3BWM	;	1.98	;	Crystal Structure of Human Catechol O-Methyltransferase with bound SAM and DNC
2AVD	;	1.7	;	Crystal Structure of Human Catechol-O-methyltransferase domain containing 1
4HNM	;	2.9001	;	Crystal structure of human catenin-beta-like 1 56 kDa fragment
6QBG	;	1.8	;	Crystal structure of human cathepsin D in complex with macrocyclic inhibitor 14
6QBH	;	1.85	;	Crystal structure of human cathepsin D in complex with macrocyclic inhibitor 33
6QCB	;	1.55	;	Crystal structure of human cathepsin D in complex with macrocyclic inhibitor 9
1M6D	;	1.7	;	Crystal structure of human cathepsin F
2ATO	;	2.0	;	Crystal structure of Human Cathepsin K in complex with myocrisin
6ASH	;	1.423	;	Crystal structure of human Cathepsin K with a non-active site inhibitor at 1.42 Angstrom resolution
7QKC	;	1.69	;	Crystal structure of human Cathepsin L after incubation with Sulfo-Calpeptin
8PRX	;	1.8	;	Crystal structure of human cathepsin L after reaction with the bound ketoamide inhibitor 13b
8B4F	;	1.9	;	Crystal structure of human cathepsin L forming a thiohemiacetal with N-Boc-2-aminoacetaldehyde
8AHV	;	1.7	;	Crystal structure of human cathepsin L in complex with calpain inhibitor XII
7Z58	;	1.35	;	Crystal structure of human Cathepsin L in complex with covalently bound Calpeptin
7ZVF	;	1.6	;	Crystal structure of human cathepsin L in complex with covalently bound CLIK148
7QKB	;	1.8	;	Crystal structure of human Cathepsin L in complex with covalently bound GC376
8A5B	;	1.8	;	Crystal structure of human cathepsin L in complex with covalently bound MG-101
7QKD	;	1.5	;	Crystal structure of human Cathepsin L in complex with covalently bound MG132
8QKB	;	1.6	;	Crystal structure of human cathepsin L in complex with the vinyl sulfone inhibitor K777
8OFA	;	1.9	;	Crystal structure of human cathepsin L interacting with tosyl phenylalanyl chloromethyl ketone (TPCK)
8A4U	;	1.9	;	Crystal structure of human cathepsin L with CAA0225
7ZXA	;	1.6	;	Crystal structure of human cathepsin L with covalently bound aloxistatin (E-64D)
8A4X	;	1.8	;	Crystal structure of human Cathepsin L with covalently bound Calpain inhibitor III
7ZS7	;	1.6	;	Crystal structure of human cathepsin L with covalently bound calpain inhibitor VI
8A4W	;	1.4	;	Crystal structure of human cathepsin L with covalently bound Cathepsin L inhibitor IV
8A4V	;	1.65	;	Crystal structure of human cathepsin L with covalently bound E-64
4P6E	;	1.8	;	Crystal Structure of Human Cathepsin S Bound to a Non-covalent Inhibitor
4P6G	;	1.58	;	Crystal Structure of Human Cathepsin S Bound to a Non-covalent Inhibitor.
1FH0	;	1.6	;	CRYSTAL STRUCTURE OF HUMAN CATHEPSIN V COMPLEXED WITH AN IRREVERSIBLE VINYL SULFONE INHIBITOR
1EF7	;	2.67	;	CRYSTAL STRUCTURE OF HUMAN CATHEPSIN X
5QBU	;	2.78	;	Crystal structure of human Cathepsin-S with bound ligand
5QBV	;	1.796	;	Crystal structure of human Cathepsin-S with bound ligand
5QBW	;	3.01	;	Crystal structure of human Cathepsin-S with bound ligand
5QBX	;	2.1	;	Crystal structure of human Cathepsin-S with bound ligand
5QBY	;	2.25	;	Crystal structure of human Cathepsin-S with bound ligand
5QBZ	;	2.8	;	Crystal structure of human Cathepsin-S with bound ligand
5QC0	;	1.9	;	Crystal structure of human Cathepsin-S with bound ligand
5QC1	;	2.082	;	Crystal structure of human Cathepsin-S with bound ligand
5QC2	;	2.26	;	Crystal structure of human Cathepsin-S with bound ligand
5QC3	;	1.998	;	Crystal structure of human Cathepsin-S with bound ligand
5QC4	;	2.0	;	Crystal structure of human Cathepsin-S with bound ligand
5QC5	;	2.4	;	Crystal structure of human Cathepsin-S with bound ligand
5QC6	;	2.1	;	Crystal structure of human Cathepsin-S with bound ligand
5QC7	;	1.9	;	Crystal structure of human Cathepsin-S with bound ligand
5QC8	;	1.74	;	Crystal structure of human Cathepsin-S with bound ligand
5QC9	;	2.0	;	Crystal structure of human Cathepsin-S with bound ligand
5QCA	;	2.29	;	Crystal structure of human Cathepsin-S with bound ligand
5QCB	;	2.2	;	Crystal structure of human Cathepsin-S with bound ligand
5QCC	;	1.8	;	Crystal structure of human Cathepsin-S with bound ligand
5QCD	;	1.95	;	Crystal structure of human Cathepsin-S with bound ligand
5QCE	;	2.78	;	Crystal structure of human Cathepsin-S with bound ligand
5QCF	;	2.1	;	Crystal structure of human Cathepsin-S with bound ligand
5QCG	;	2.7	;	Crystal structure of human Cathepsin-S with bound ligand
5QCH	;	2.2	;	Crystal structure of human Cathepsin-S with bound ligand
5QCI	;	2.179	;	Crystal structure of human Cathepsin-S with bound ligand
5QCJ	;	2.0	;	Crystal structure of human Cathepsin-S with bound ligand
2PFG	;	1.54	;	Crystal structure of human CBR1 in complex with BiGF2.
1WMA	;	1.24	;	Crystal structure of human CBR1 in complex with Hydroxy-PP
1OU5	;	3.4	;	Crystal structure of human CCA-adding enzyme
6AEZ	;	1.63	;	Crystal structure of human CCL5 trimer
6LOG	;	2.55	;	Crystal structure of human CCL5-12AAA14 mutant
8CE9	;	2.11	;	Crystal structure of human Cd11b I domain in C121 space group
8CE6	;	1.582	;	Crystal structure of human Cd11b I domain in P212121 space group
6RHW	;	2.75	;	Crystal structure of human CD11b I-domain (CD11b-I) in complex with Staphylococcus aureus octameric bi-component leukocidin LukGH
6NG9	;	1.954	;	Crystal structure of human CD160
6NG3	;	2.88	;	Crystal structure of human CD160 and HVEM complex
6NGG	;	1.95	;	Crystal structure of human CD160 V58M mutant
5L2J	;	1.65	;	Crystal Structure of human CD1b in complex with C36-GMM
8GLH	;	1.83	;	Crystal Structure of Human CD1b in Complex with Endogenous PC C40:5
8GLE	;	1.85	;	Crystal Structure of Human CD1b in Complex with Lysosulfatide
8GLI	;	2.1	;	Crystal Structure of Human CD1b in Complex with Mycobacterial C85-GMM
5WKG	;	2.06	;	Crystal Structure of Human CD1b in Complex with PA
5WL1	;	1.38	;	Crystal Structure of Human CD1b in Complex with PG
8GLG	;	1.6	;	Crystal Structure of Human CD1b in Complex with Phosphatidylethanolamine C34:1
6D64	;	1.7	;	Crystal Structure of Human CD1b in Complex with POPC
5WKE	;	1.69	;	Crystal Structure of Human CD1b in Complex with PS
8GLF	;	2.0	;	Crystal Structure of Human CD1b in Complex with Sphingomyelin C34:2
3T8X	;	1.9	;	Crystal structure of human CD1b in complex with synthetic antigenic diacylsulfoglycolipid SGL12 and endogenous spacer
8DV3	;	1.9	;	Crystal structure of human CD1b presenting Phosphatidylinositol C34:1
6V80	;	3.53	;	Crystal structure of human CD1d presenting alpha-Galactosylceramide in complex with NKT12 TCR and VHH nanobody 1D12
3HUJ	;	2.5	;	Crystal structure of human CD1d-alpha-Galactosylceramide in complex with semi-invariant NKT cell receptor
3U0P	;	2.8	;	Crystal structure of human CD1d-lysophosphatidylcholine
5VKJ	;	2.12	;	Crystal structure of human CD22 Ig domains 1-3
5VKM	;	2.2	;	Crystal structure of human CD22 Ig domains 1-3 in complex with alpha 2-6 sialyllactose
6ISB	;	2.5	;	crystal structure of human CD226
6Y0M	;	1.5	;	Crystal structure of human CD23 lectin domain N225D, K229E, S252N, T251N mutant
6Y0L	;	1.65	;	Crystal structure of human CD23 lectin domain N225D, K229E, S252N, T251N, R253G, S254G mutant
1YJD	;	2.7	;	Crystal structure of human CD28 in complex with the Fab fragment of a mitogenic antibody (5.11A1)
1XIW	;	1.9	;	Crystal structure of human CD3-e/d dimer in complex with a UCHT1 single-chain antibody fragment
3I9M	;	1.75	;	Crystal structure of human CD38 complexed with an analog ara-2'F-ADPR
3I9N	;	2.01	;	Crystal structure of human CD38 complexed with an analog ribo-2'F-ADP ribose
4F45	;	2.1	;	Crystal structure of human CD38 E226Q mutant in complex with NAADP
7VKE	;	1.9	;	Crystal structure of human CD38 ECD in complex with UniDab(TM) F11A
1YH3	;	1.91	;	Crystal structure of human CD38 extracellular domain
3DZF	;	2.01	;	Crystal structure of human CD38 extracellular domain complexed with a covalent intermediate, ara-F-ribose-5'-phosphate
3DZJ	;	1.9	;	Crystal structure of human CD38 extracellular domain E226Q mutant, NMN complex
3DZG	;	1.65	;	Crystal structure of human CD38 extracellular domain, ara-F-ribose-5'-phosphate/nicotinamide complex
3DZH	;	1.6	;	Crystal structure of human CD38 extracellular domain, GTP complex
3DZK	;	1.81	;	Crystal structure of human CD38 extracellular domain, NMN complex
3DZI	;	1.73	;	Crystal structure of human CD38 extracellular domain, ribose-5'-phosphate intermediate/GTP complex
6EDR	;	2.4	;	Crystal Structure of Human CD38 in Complex with 4'-Thioribose NAD+
3ROK	;	1.65	;	Crystal structure of human CD38 in complex with compound CZ-27
3ROQ	;	2.1	;	Crystal structure of human CD38 in complex with compound CZ-46
3ROM	;	2.04	;	Crystal structure of human CD38 in complex with compound CZ-48
3ROP	;	1.94	;	Crystal structure of human CD38 in complex with compound CZ-50b
4TMF	;	2.05	;	Crystal structure of human CD38 in complex with hydrolysed compound JMS713
3RAJ	;	3.044	;	Crystal structure of human CD38 in complex with the Fab fragment of antibody HB7
1ZVM	;	2.2	;	Crystal structure of human CD38: cyclic-ADP-ribosyl synthetase/NAD+ glycohydrolase
1ALY	;	2.0	;	CRYSTAL STRUCTURE OF HUMAN CD40 LIGAND
7P3I	;	2.29	;	Crystal structure of human CD40/TNFRSF5 in complex with the anti-CD40 DARPin protein
5FN7	;	2.3	;	Crystal structure of human CD45 extracellular region, domains d1-d2
5FN6	;	3.3	;	Crystal structure of human CD45 extracellular region, domains d1-d3
5FMV	;	2.9	;	Crystal structure of human CD45 extracellular region, domains d1-d4
5TZU	;	2.1	;	Crystal structure of human CD47 ECD bound to Fab of B6H12.2
5TZT	;	2.89	;	Crystal structure of human CD47 ECD bound to Fab of C47B161
5TZ2	;	2.302	;	Crystal structure of human CD47 ECD bound to Fab of C47B222
7YGG	;	2.76	;	Crystal structure of human CD47 in complex with engineered SIRPa.D1(N80A)
2OFS	;	2.12	;	Crystal structure of human CD59
1FM5	;	2.27	;	CRYSTAL STRUCTURE OF HUMAN CD69
1G8Q	;	1.6	;	CRYSTAL STRUCTURE OF HUMAN CD81 EXTRACELLULAR DOMAIN, A RECEPTOR FOR HEPATITIS C VIRUS
6U9S	;	2.4	;	Crystal structure of human CD81 large extracellular loop in complex with 5A6 Fab
5DFV	;	2.8	;	CRYSTAL STRUCTURE OF HUMAN CD81 LARGE EXTRACELLULAR LOOP IN COMPLEX WITH MURINE FAB FRAGMENT K04
6EK2	;	2.65	;	CRYSTAL STRUCTURE OF HUMAN CD81 LARGE EXTRACELLULAR LOOP IN COMPLEX WITH SINGLE CHAIN FV FRAGMENT 10
6EJG	;	2.82	;	CRYSTAL STRUCTURE OF HUMAN CD81 LARGE EXTRACELLULAR LOOP IN COMPLEX WITH SINGLE CHAIN FV FRAGMENT 4
6EJM	;	2.15	;	CRYSTAL STRUCTURE OF HUMAN CD81 LARGE EXTRACELLULAR LOOP IN COMPLEX WITH SINGLE CHAIN FV FRAGMENT 5
5DFW	;	2.33	;	CRYSTAL STRUCTURE OF HUMAN CD81 LARGE EXTRACELLULAR LOOP IN COMPLEX WITH SINGLE CHAIN FV FRAGMENT K13
7UMG	;	2.4	;	Crystal structure of human CD8aa-MR1-Ac-6-FP complex
7DF1	;	2.806	;	Crystal structure of human CD98 heavy chain extracellular domain in complex with S1-F4 scFv
3RAW	;	2.09	;	Crystal Structure of human CDC-like kinase 3 isoform in complex with leucettine L41
5VVM	;	3.54	;	Crystal structure of human CDH23 EC21-23
4NST	;	2.2	;	Crystal structure of human Cdk12/Cyclin K in complex with ADP-aluminum fluoride
8P81	;	2.68	;	Crystal structure of human Cdk12/Cyclin K in complex with inhibitor SR-4835
7NXK	;	3.0	;	Crystal structure of human Cdk12/Cyclin K in complex with the inhibitor BSJ-01-175
6B3E	;	3.06	;	Crystal structure of human CDK12/CyclinK in complex with an inhibitor
5EFQ	;	2.0	;	Crystal structure of human Cdk13/Cyclin K in complex with ADP-aluminum fluoride
7NXJ	;	2.36	;	Crystal structure of human Cdk13/Cyclin K in complex with the inhibitor THZ531
1JVP	;	1.53	;	Crystal structure of human CDK2 (unphosphorylated) in complex with PKF049-365
1Y8Y	;	1.996	;	Crystal structure of human CDK2 complexed with a pyrazolo[1,5-a]pyrimidine inhibitor
1Y91	;	2.15	;	Crystal structure of human CDK2 complexed with a pyrazolo[1,5-a]pyrimidine inhibitor
2UZB	;	2.7	;	Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor
2UZD	;	2.72	;	Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor
2UZE	;	2.4	;	Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor
2UZL	;	2.4	;	Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor
2UZN	;	2.3	;	Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor
2UZO	;	2.3	;	Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor
2V0D	;	2.2	;	Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor
1W0X	;	2.2	;	Crystal structure of human CDK2 in complex with the inhibitor olomoucine.
5UQ1	;	3.201	;	Crystal structure of human Cdk2-Spy1 complex
5UQ2	;	2.7	;	Crystal structure of human Cdk2-Spy1 complex
5UQ3	;	3.6	;	Crystal structure of human Cdk2-Spy1-P27 ternary complex
1UA2	;	3.02	;	Crystal Structure of Human CDK7
4CRL	;	2.4	;	Crystal structure of human CDK8-Cyclin C in complex with cortistatin A
3RGF	;	2.2	;	Crystal Structure of human CDK8/CycC
6QTJ	;	2.48	;	Crystal structure of human CDK8/CYCC in complex with BI 919811
6QTG	;	2.7	;	Crystal structure of human CDK8/CYCC in complex with BI-1347
4F6W	;	2.39	;	Crystal structure of human CDK8/CYCC in complex with compound 1 (N-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-4-[2-({[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]carbamoyl}amino)ethyl]piperazine-1-carboxamide)
4F7N	;	2.65	;	Crystal structure of human CDK8/CYCC in complex with compound 11 (1-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-3-(5-hydroxypentyl)urea)
4F7L	;	2.9	;	Crystal structure of human CDK8/CYCC in complex with compound 2 (tert-butyl [3-({[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]carbamoyl}amino)propyl]carbamate)
4F7J	;	2.6	;	Crystal structure of human CDK8/CYCC in complex with compound 3 (1-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-3-(2-hydroxyethyl)urea)
4F70	;	3.0	;	Crystal structure of human CDK8/CYCC in complex with compound 4 (1-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-3-[2-(morpholin-4-yl)ethyl]urea)
4F6U	;	2.1	;	Crystal structure of human CDK8/CYCC in complex with compound 5 (1-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-3-[3-(morpholin-4-yl)propyl]urea)
4F6S	;	2.6	;	Crystal structure of human CDK8/CYCC in complex with compound 7 (1-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]urea)
4F7S	;	2.2	;	Crystal structure of human CDK8/CYCC in the DMG-in conformation
4G6L	;	2.7	;	Crystal structure of human CDK8/CYCC in the DMG-in conformation
3BLH	;	2.48	;	Crystal Structure of Human CDK9/cyclinT1
3BLQ	;	2.9	;	Crystal Structure of Human CDK9/cyclinT1 in Complex with ATP
3BLR	;	2.8	;	Crystal Structure of Human CDK9/cyclinT1 in complex with Flavopiridol
6W9E	;	3.1	;	Crystal Structure of Human CDK9/cyclinT1 in complex with MC180295
6GZH	;	3.17	;	Crystal Structure of Human CDK9/cyclinT1 with A86
7RPP	;	2.2	;	Crystal structure of human CEACAM1 with GFCC' and ABED face
8GEV	;	1.85	;	Crystal structure of human cellular retinol binding protein 1 in complex with 1-{[3-(diphenylmethyl)-1,2,4-oxadiazol-5-yl]methyl}-4-(methoxymethyl)piperidine
8GEY	;	1.3	;	Crystal structure of human cellular retinol binding protein 1 in complex with 4-(hydroxymethyl)-1-[(4-methoxy-5,6,7,8-tetrahydronaphthalen-1-yl)sulfonyl]piperidin-4-ol
6E5L	;	1.17	;	Crystal structure of human cellular retinol binding protein 1 in complex with abnormal-cannabidiol (abn-CBD)
6E5T	;	1.55	;	Crystal structure of human cellular retinol binding protein 1 in complex with abnormal-cannabidiorcin (Abn-CBDO)
5H8T	;	1.21	;	Crystal structure of human cellular retinol binding protein 1 in complex with all-trans-retinol
5HBS	;	0.89	;	Crystal structure of human cellular retinol binding protein 1 in complex with all-trans-retinol at 0.89 angstrom.
8GEU	;	1.47	;	Crystal structure of human cellular retinol binding protein 1 in complex with methyl({3-[1-(4-methylphenyl)cyclopentyl]-1,2,4-oxadiazol-5-yl}methyl)[(1-methylpyrazol-4-yl)methyl]amine
8GEM	;	1.55	;	Crystal structure of human cellular retinol binding protein 1 in complex with N-ethyl-N-({3-[1-(4-methylphenyl)cyclopentyl]-1,2,4-oxadiazol-5-yl}methyl)-2-(1H-pyrazol-1-yl)ethanamine
8GD2	;	1.13	;	Crystal structure of human cellular retinol binding protein 1 in complex with N-methyl-1-{3-[1-(4-methylphenyl)cyclopentyl]-1,2,4-oxadiazol-5-yl}-N-(2-thienylmethyl)methanamine
5HA1	;	1.35	;	Crystal structure of human cellular retinol binding protein 1 in complex with retinylamine
8GDM	;	1.8	;	Crystal structure of human cellular retinol binding protein 1 in complex with {[3-(diphenylmethyl)-1,2,4-oxadiazol-5-yl]methyl}(methyl)[1-(thiophen-2-yl)ethyl]amine
6BTH	;	1.35	;	Crystal structure of human cellular retinol binding protein 2 (CRBP2) in complex with 2-arachidonoylglycerol (2-AG)
6BTI	;	1.45	;	Crystal structure of human cellular retinol binding protein 2 (CRBP2) in complex with N-arachidonoylethanolamine (AEA)
6E5W	;	2.5	;	Crystal structure of human cellular retinol binding protein 3 in complex with abnormal-cannabidiol (abn-CBD)
6E6M	;	1.55	;	Crystal structure of human cellular retinol-binding protein 1 in complex with cannabidiorcin (CBDO)
6E6K	;	1.3	;	Crystal structure of human cellular retinol-binding protein 4 in complex with abnormal-cannabidiol (abn-CBD)
8D40	;	3.554	;	Crystal structure of human CELSR1 EC1-4
7SZ8	;	2.337	;	Crystal structure of human CELSR1 EC4-7
4P0T	;	1.493	;	Crystal structure of human centromere protein M
4K85	;	1.901	;	Crystal structure of human ceramide-1-phosphate transfer protein (CPTP) in complex with 12:0 Ceramide-1-Phosphate (12:0-C1P)
4KBS	;	1.898	;	Crystal structure of human ceramide-1-phosphate transfer protein (CPTP) in complex with 12:0 phosphatidic acid (12:0 PA)
4K84	;	1.897	;	Crystal structure of human ceramide-1-phosphate transfer protein (CPTP) in complex with 16:0 ceramide-1-phosphate (16:0-C1P)
4K8N	;	3.102	;	Crystal structure of human ceramide-1-phosphate transfer protein (CPTP) in complex with 18:1 Ceramide-1-Phosphate (18:1-C1P)
4K80	;	2.051	;	Crystal structure of human ceramide-1-phosphate transfer protein (CPTP) in complex with 2:0 ceramide-1-phosphate (2:0-C1P)
4KF6	;	3.195	;	Crystal structure of human ceramide-1-phosphate transfer protein (CPTP) in complex with 8:0 Ceramide-1-Phosphate (8:0-C1P)
4TZ4	;	3.01	;	Crystal Structure of Human Cereblon in Complex with DDB1 and Lenalidomide
4MKP	;	1.953	;	Crystal structure of human cGAS apo form
3ENP	;	2.48	;	Crystal structure of human cgi121
7S5A	;	1.37	;	Crystal structure of human chemokine CCL8
3CXL	;	2.6	;	Crystal structure of human chimerin 1 (CHN1)
1HKI	;	2.55	;	Crystal structure of human chitinase in complex with glucoallosamidin B
1HKJ	;	2.6	;	Crystal structure of human chitinase in complex with methylallosamidin
1LQ0	;	2.2	;	CRYSTAL STRUCTURE OF HUMAN CHITOTRIOSIDASE AT 2.2 ANGSTROM RESOLUTION
1LG1	;	2.78	;	CRYSTAL STRUCTURE OF HUMAN CHITOTRIOSIDASE IN COMPLEX WITH CHITOBIOSE
1LG2	;	2.1	;	CRYSTAL STRUCTURE OF HUMAN CHITOTRIOSIDASE IN COMPLEX WITH ETHYLENE GLYCOL
6JK6	;	1.571	;	Crystal structure of human chitotriosidase-1 (hCHIT) catalytic domain in complex with compound 2-8-s2
5NR8	;	1.349	;	Crystal structure of human chitotriosidase-1 (hCHIT) catalytic domain in complex with compound 7a
5NRA	;	1.267	;	Crystal structure of human chitotriosidase-1 (hCHIT) catalytic domain in complex with compound 7g
5NRF	;	1.447	;	Crystal structure of human chitotriosidase-1 (hCHIT) catalytic domain in complex with compound 7i
6ZE8	;	1.5	;	Crystal structure of human chitotriosidase-1 (hCHIT) catalytic domain in complex with compound OATD-01
6JJR	;	1.834	;	Crystal structure of human chitotriosidase-1 (hChit1) catalytic domain in complex with compound 2-8-14
4WKA	;	0.95	;	Crystal structure of human chitotriosidase-1 catalytic domain at 0.95 A resolution
4WJX	;	1.0	;	Crystal structure of human chitotriosidase-1 catalytic domain at 1.0 A resolution
4WK9	;	1.102	;	Crystal structure of human chitotriosidase-1 catalytic domain in complex with chitobiose (0.3mM) at 1.10 A resolution
4WKH	;	1.05	;	Crystal structure of human chitotriosidase-1 catalytic domain in complex with chitobiose (1mM) at 1.05 A resolution
4WKF	;	1.101	;	Crystal structure of human chitotriosidase-1 catalytic domain in complex with chitobiose (2.5mM) at 1.10 A resolution
2CN5	;	2.25	;	Crystal structure of human Chk2 in complex with ADP
4A9R	;	2.85	;	CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4A9S	;	2.66	;	CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4A9T	;	2.7	;	CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4A9U	;	2.48	;	CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
2CN8	;	2.7	;	Crystal structure of human Chk2 in complex with debromohymenialdisine
2PER	;	2.0	;	Crystal Structure of Human Chloride Intracellular Channel protein 2
1Q22	;	2.5	;	Crystal structure of human cholesterol sulfotransferase (SULT2B1b) in the presence of DHEA and PAP
1Q1Z	;	2.4	;	Crystal structure of human cholesterol sulfotransferase (SULT2B1b) in the presence of PAP
1Q20	;	2.3	;	Crystal Structure of human cholesterol sulfotransferase (SULT2B1b) in the presence of PAP and pregnenolone
7NB1	;	2.3	;	Crystal structure of human choline alpha in complex with an inhibitor
7NB2	;	2.4	;	Crystal structure of human choline alpha in complex with an inhibitor
7NB3	;	2.0	;	Crystal structure of human choline alpha in complex with an inhibitor
2I7Q	;	1.9	;	Crystal structure of Human Choline Kinase A
8BI6	;	2.4	;	Crystal structure of human Choline Kinase A in complex with UNC0638
8BI5	;	2.5	;	Crystal structure of human Choline Kinase A in complex with UNC0737
2CKO	;	2.15	;	Crystal structure of Human Choline Kinase alpha 2
2CKQ	;	2.4	;	Crystal structure of Human Choline Kinase alpha 2 in complex with Phosphocholine
3F2R	;	2.35	;	Crystal structure of human choline kinase alpha in complex with hemicholinium-3
3G15	;	1.7	;	Crystal structure of human choline kinase alpha in complex with hemicholinium-3 and ADP
2CKP	;	3.1	;	Crystal structure of Human Choline Kinase alpha-2 in complex with ADP
2IG7	;	1.8	;	Crystal structure of Human Choline Kinase B
3FEG	;	1.302	;	Crystal structure of human choline kinase beta in complex with phosphorylated hemicholinium-3 and adenosine nucleotide
3LQ3	;	1.42	;	Crystal structure of human choline kinase beta in complex with phosphorylated hemicholinium-3 and adenosine nucleotide
5LFN	;	2.1	;	Crystal structure of human chondroadherin
5MX1	;	2.17	;	Crystal structure of human chondroadherin
1HRP	;	3.0	;	CRYSTAL STRUCTURE OF HUMAN CHORIONIC GONADOTROPIN
3F2U	;	1.8	;	Crystal structure of human chromobox homolog 1 (CBX1)
3I8Z	;	1.51	;	Crystal structure of human chromobox homolog 4 (CBX4)
3I90	;	2.0	;	Crystal structure of human chromobox homolog 6 (CBX6) with H3K27 peptide
3GV6	;	1.76	;	Crystal Structure of human chromobox homolog 6 (CBX6) with H3K9 peptide
3I91	;	1.55	;	Crystal structure of human chromobox homolog 8 (CBX8) with H3K9 peptide
4K60	;	1.5	;	Crystal Structure of Human Chymase in Complex with Fragment 6-bromo-1,3-dihydro-2H-indol-2-one
4K2Y	;	2.3	;	Crystal Structure of Human Chymase in Complex with Fragment Inhibitor 6-chloro-1,3-dihydro-2H-indol-2-one
4K5Z	;	1.8	;	Crystal Structure of Human Chymase in Complex with Fragment Inhibitor 6-chloro-2,3-dihydro-1H-isoindol-1-one
4K69	;	1.5	;	Crystal Structure of Human Chymase in Complex with Fragment Linked Benzimidazolone Inhibitor: (3S)-3-{3-[(6-bromo-2-oxo-2,3-dihydro-1H-indol-4-yl)methyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}hexanoic acid
3S0N	;	1.95	;	Crystal Structure of Human Chymase with Benzimidazolone Inhibitor
4H4F	;	1.9	;	Crystal structure of human chymotrypsin C (CTRC) bound to inhibitor eglin c from Hirudo medicinalis
6R6U	;	1.705	;	Crystal structure of human cis-aconitate decarboxylase
3AMY	;	2.3	;	Crystal structure of human CK2 alpha complexed with apigenin
2ZJW	;	2.4	;	Crystal structure of human CK2 alpha complexed with Ellagic acid
3Q9X	;	2.2	;	Crystal structure of human CK2 alpha in complex with emodin at pH 6.5
3Q9W	;	1.7	;	Crystal structure of human CK2 alpha in complex with emodin at pH 8.5
3Q9Z	;	2.2	;	Crystal structure of human CK2 alpha in complex with Quinalizarin at pH 6.5
3Q9Y	;	1.8	;	Crystal structure of human CK2 alpha in complex with Quinalizarin at pH 8.5
3W8L	;	2.4	;	Crystal structure of human CK2 in complex with inositol hexakisphosphate
4KWP	;	1.25	;	Crystal Structure of Human CK2-alpha in complex with a benzimidazole inhibitor (K164) at 1.25 A resolution
3WAR	;	1.04	;	Crystal structure of human CK2a
3WOW	;	2.5	;	Crystal structure of human CK2a with AMPPNP
3AXW	;	2.5	;	Crystal structure of human CK2alpha complexed with a potent inhibitor
4RLL	;	1.85	;	Crystal structure of human CK2alpha in complex with the ATP-competitive inhibitor 4-[(E)-(fluoren-9-ylidenehydrazinylidene)-methyl] benzoate
6GZM	;	1.59	;	Crystal Structure of Human CKIdelta with A86
1X9D	;	1.41	;	Crystal Structure Of Human Class I alpha-1,2-Mannosidase In Complex With Thio-Disaccharide Substrate Analogue
1FMI	;	1.9	;	CRYSTAL STRUCTURE OF HUMAN CLASS I ALPHA1,2-MANNOSIDASE
1FO2	;	2.38	;	CRYSTAL STRUCTURE OF HUMAN CLASS I ALPHA1,2-MANNOSIDASE IN COMPLEX WITH 1-DEOXYMANNOJIRIMYCIN
1FO3	;	1.75	;	CRYSTAL STRUCTURE OF HUMAN CLASS I ALPHA1,2-MANNOSIDASE IN COMPLEX WITH KIFUNENSINE
1I1F	;	2.8	;	Crystal structure of human class i mhc (hla-a2.1) complexed with beta 2-microglobulin and hiv-rt variant peptide i1y
1I1Y	;	2.2	;	CRYSTAL STRUCTURE OF HUMAN CLASS I MHC (HLA-A2.1) COMPLEXED WITH BETA 2-MICROGLOBULIN AND HIV-RT VARIANT PEPTIDE I1Y
3COS	;	2.1	;	Crystal structure of human class II alcohol dehydrogenase (ADH4) in complex with NAD and Zn
1HNA	;	1.85	;	CRYSTAL STRUCTURE OF HUMAN CLASS MU GLUTATHIONE TRANSFERASE GSTM2-2: EFFECTS OF LATTICE PACKING ON CONFORMATIONAL HETEROGENEITY
1HNB	;	3.5	;	CRYSTAL STRUCTURE OF HUMAN CLASS MU GLUTATHIONE TRANSFERASE GSTM2-2: EFFECTS OF LATTICE PACKING ON CONFORMATIONAL HETEROGENEITY
1HNC	;	3.0	;	CRYSTAL STRUCTURE OF HUMAN CLASS MU GLUTATHIONE TRANSFERASE GSTM2-2: EFFECTS OF LATTICE PACKING ON CONFORMATIONAL HETEROGENEITY
5B2G	;	3.5	;	Crystal structure of human claudin-4 in complex with C-terminal fragment of Clostridium perfringens enterotoxin
7KP4	;	3.37	;	Crystal structure of human claudin-4 in complex with Clostridium perfringens enterotoxin C-terminal domain
6OV2	;	3.2	;	Crystal structure of human claudin-9 in complex with Clostridium perfringens entertoxin C-terminal domain in closed form
6OV3	;	3.25	;	Crystal structure of human claudin-9 in complex with Clostridium perfringens entertoxin C-terminal domain in open form
2CL3	;	1.9	;	Crystal structure of human Cleavage and Polyadenylation Specificity Factor 5 (CPSF5)
2J8Q	;	2.3	;	Crystal structure of human cleavage and polyadenylation specificity factor 5 (CPSF5) in complex with a sulphate ion.
2C6U	;	1.6	;	Crystal structure of human CLEC-2 (CLEC1B)
8JAH	;	2.58	;	Crystal structure of human CLEC12A C-type lectin domain
8W8T	;	2.3	;	Crystal structure of human CLEC12A CRD
8W9J	;	3.5	;	Crystal structure of human CLEC12A ectodomain complexed with 50C1 Fab
4K0N	;	1.25	;	Crystal structure of human CLIC1 C24A mutant
4JZQ	;	1.35	;	Crystal structure of human CLIC1 C24D mutant
4K0G	;	1.4	;	Crystal structure of human CLIC1 C24S mutant
1Z57	;	1.7	;	Crystal structure of human CLK1 in complex with 10Z-Hymenialdisine
5X8I	;	1.902	;	Crystal structure of human CLK1 in complex with compound 25
8P08	;	2.4	;	Crystal structure of human CLK1 in complex with Leucettinib-21
8P04	;	2.6	;	Crystal structure of human CLK1 in complex with Leucettinib-92
5J1V	;	2.52	;	Crystal structure of human CLK1 in complex with pyrido[3,4-g]quinazoline derivative ZW29 (compound 13)
5J1W	;	2.42	;	Crystal structure of human CLK1 in complex with pyrido[3,4-g]quinazoline derivative ZW31 (compound 14)
6R99	;	2.7	;	Crystal Structure of Human CLN protein 5 (Ceroid Lipofuscinosis Neuronal Protein 5)
7VP9	;	2.552	;	Crystal structure of human ClpP in complex with ZG111
7WH5	;	2.13	;	Crystal structure of human ClpP in complex with ZG180
8I7X	;	1.99	;	Crystal structure of human ClpP in complex with ZG36
8HGK	;	1.9	;	Crystal structure of human ClpP in complex with ZK53
7UVU	;	3.24	;	Crystal structure of human ClpP protease in complex with TR-107
7UW0	;	2.8	;	Crystal structure of human ClpP protease in complex with TR-133
7UVM	;	2.19	;	Crystal structure of human ClpP protease in complex with TR-27
7UVN	;	3.11	;	Crystal structure of human ClpP protease in complex with TR-57
7UVR	;	2.86	;	Crystal structure of human ClpP protease in complex with TR-65
7ZET	;	2.8	;	Crystal structure of human Clusterin, crystal form I
7ZEU	;	3.5	;	Crystal structure of human Clusterin, crystal form II
4J8S	;	1.55	;	Crystal structure of human CNOT1 MIF4G domain in complex with a TTP peptide
5DV2	;	2.07	;	Crystal structure of human CNOT6L in complex with cytidine-5'-monophosphate
5DV4	;	1.8	;	Crystal structure of human CNOT6L in complex with neomycin
5E52	;	2.685	;	Crystal structure of human CNTN5 FN1-FN3 domains
3BVO	;	3.0	;	Crystal structure of human co-chaperone protein HscB
6MV4	;	1.37	;	CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR IXa
1KSN	;	2.1	;	Crystal Structure of Human Coagulation Factor XA Complexed with FXV673
1EZQ	;	2.2	;	CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR128515
1NFU	;	2.05	;	CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR132747
1NFY	;	2.1	;	CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR200095
1F0S	;	2.1	;	Crystal Structure of Human Coagulation Factor XA Complexed with RPR208707
1F0R	;	2.1	;	CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR208815
1NFX	;	2.15	;	CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR208944
1NFW	;	2.1	;	CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR209685
3HON	;	3.0	;	Crystal Structure of Human Collagen XVIII Trimerization Domain (cubic form)
3HSH	;	1.8	;	Crystal structure of human collagen XVIII trimerization domain (Tetragonal crystal form)
2VH7	;	1.45	;	Crystal structure of human common-type acylphosphatase
5FO7	;	2.8	;	Crystal Structure of Human Complement C3b at 2.8 Angstrom resolution
5FO9	;	3.3	;	Crystal Structure of Human Complement C3b in Complex with CR1 (CCP15- 17)
5FOA	;	4.188	;	Crystal Structure of Human Complement C3b in complex with DAF (CCP2-4)
5FO8	;	2.4	;	Crystal Structure of Human Complement C3b in Complex with MCP (CCP1-4)
5FOB	;	2.6	;	Crystal Structure of Human Complement C3b in complex with Smallpox Inhibitor of Complement (SPICE)
7AD7	;	2.3	;	Crystal structure of human complement C5 in complex with the K8 bovine knob domain peptide.
7AD6	;	2.75	;	Crystal structure of human complement C5 in complex with the K92 bovine knob domain peptide.
3T5O	;	2.869	;	Crystal Structure of human Complement Component C6
3OJY	;	2.51	;	Crystal Structure of Human Complement Component C8
6VMJ	;	2.95	;	Crystal structure of human Complement Factor D with anti-Factor D Fab 20D12
6VMK	;	3.01	;	Crystal structure of human Complement Factor D with anti-Factor D Fab 20D12
2UWN	;	2.35	;	Crystal structure of Human Complement Factor H, SCR domains 6-8 (H402 risk variant), in complex with ligand.
2V8E	;	2.5	;	Crystal structure of Human Complement Factor H, SCR domains 6-8 (H402 risk variant), in complex with ligand.
1LF7	;	1.2	;	Crystal Structure of Human Complement Protein C8gamma at 1.2 A Resolution
2OVD	;	1.8	;	Crystal Structure of Human Complement Protein C8gamma with Laurate
3A7E	;	2.8	;	Crystal structure of human COMT complexed with SAM and 3,5-dinitrocatechol
7ZC3	;	1.9	;	Crystal structure of human copper chaperone Atox1 bound to zinc ion by CxxC motif
4QOT	;	2.2	;	Crystal structure of human copper chaperone bound to the platinum ion
3IWP	;	2.5	;	Crystal structure of human copper homeostasis protein CutC
5F0W	;	2.7	;	Crystal structure of human copper homeostatic proteins atox1
7DC1	;	1.75	;	Crystal structure of human copper homeostatic proteins atox1
6AWL	;	2.0	;	Crystal structure of human Coq9
4RHP	;	2.393	;	Crystal structure of human COQ9 in complex with a phospholipid, Northeast Structural Genomics Consortium Target HR5043
7STY	;	2.0	;	Crystal structure of human CORO1C
7KYX	;	1.63	;	Crystal structure of human CORO6
7VN9	;	4.49	;	Crystal structure of human coronavirus 229E spike protein receptor-binding domain in complex with C04 Fab
7VNG	;	3.8	;	Crystal structure of human coronavirus 229E spike protein receptor-binding domain in complex with S11 Fab
7E6M	;	1.83445	;	Crystal structure of Human coronavirus NL63 3C-like protease
4K5Y	;	2.977	;	Crystal structure of human corticotropin-releasing factor receptor 1 (CRF1R) in complex with the antagonist CP-376395
4Z9G	;	3.183	;	Crystal structure of human corticotropin-releasing factor receptor 1 (CRF1R) in complex with the antagonist CP-376395 in a hexagonal setting with translational non-crystallographic symmetry
4JGZ	;	3.0	;	Crystal structure of human coxsackievirus A16 uncoating intermediate (space group I222)
4JGY	;	3.0	;	Crystal structure of human coxsackievirus A16 uncoating intermediate (space group P4232)
7OJ7	;	1.78	;	Crystal structure of human coxsackievirus A24v in complex with a pentavalent N-acetylneuraminic acid conjugate
6TSD	;	1.81	;	Crystal structure of human coxsackievirus A24v in complex with pentavalent inhibitor ME0752
7K95	;	1.9	;	Crystal structure of human CPSF30 in complex with hFip1
7ZYH	;	2.2	;	Crystal structure of human CPSF30 in complex with hFip1
8T1Q	;	1.7	;	Crystal structure of human CPSF73 catalytic segment in complex with compound 1
8T1R	;	2.2	;	Crystal structure of human CPSF73 catalytic segment in complex with compound 2
8OJH	;	2.72	;	Crystal structure of human CRBN-DDB1 in complex with compound 4
8OIZ	;	2.5	;	Crystal structure of human CRBN-DDB1 in complex with Pomalidomide
3N96	;	2.75	;	Crystal structure of human CRFR2 alpha extracellular domain in complex with Urocortin 1
3N95	;	2.72	;	Crystal structure of human CRFR2 alpha extracellular domain in complex with Urocortin 2
3N93	;	2.5	;	Crystal structure of human CRFR2 alpha extracellular domain in complex with Urocortin 3
3AQQ	;	2.798	;	Crystal structure of human CRHSP-24
7B51	;	2.58	;	Crystal structure of human CRM1 covalently modified by 2-mercaptoethanol at Cys528
5X1A	;	1.821	;	Crystal Structure of Human CRMP-2
5YZA	;	2.3	;	Crystal Structure of Human CRMP-2 with S522D mutation
5YZB	;	2.8	;	Crystal Structure of Human CRMP-2 with S522D-T509D-T514D-S518D mutations crystallized with GSK3b
5YZ5	;	1.8	;	Crystal Structure of Human CRMP-2 with T509D-T514D-S518D-S522D mutations
5X1C	;	2.101	;	Crystal Structure of Human CRMP-2 without C-terminal Tail
6JVB	;	2.0	;	Crystal Structure of Human CRMP2 1-532, AGE-modified
6JV9	;	2.26	;	Crystal Structure of Human CRMP2 1-532, unmodified
4D0P	;	1.6	;	Crystal structure of human CSN4
4R14	;	2.601	;	Crystal structure of human CSN6 MPN domain
6GZD	;	2.28	;	Crystal structure of Human CSNK1A1 with A86
7ZY4	;	2.55	;	Crystal structure of human CstF77 in complex with hFip1
2OME	;	2.8	;	Crystal structure of human CTBP2 dehydrogenase complexed with NAD(H)
3OSK	;	1.8	;	Crystal structure of human CTLA-4 apo homodimer
4MFV	;	2.92	;	Crystal structure of human CTNNBL1(residues 33~563)
4MFU	;	2.744	;	Crystal structure of human CTNNBL1(residues 77~563)
7FB9	;	2.7	;	Crystal Structure of Human Cu, Zn Superoxide Dismutase (SOD1)
2ZKX	;	2.72	;	Crystal structure of human Cu-Zn superoxide dismutase mutant G85R in space group I212121
2ZKW	;	1.9	;	Crystal structure of human Cu-Zn superoxide dismutase mutant G85R in space group P21
2ZKY	;	2.4	;	Crystal structure of human Cu-Zn superoxide dismutase mutant G93A
3KH3	;	3.5	;	Crystal structure of human Cu/Zn superoxide dismutase recombinantly produced in Leishmania tarantolae; P212121 crystal form containing 12 chains in the asymmetric unit
3KH4	;	3.5	;	Crystal structure of human Cu/Zn superoxide dismutase recombinantly produced in Leishmania tarantolae; P6522 crystal form containing 6 chains in the asymmetric unit
5NLB	;	3.45	;	Crystal structure of human CUL3 N-terminal domain bound to KEAP1 BTB and 3-box
7W3O	;	2.46	;	Crystal structure of human CYB5R3
7FU5	;	2.18	;	Crystal Structure of human cyclic GMP-AMP synthase
7FU7	;	2.24	;	Crystal Structure of human cyclic GMP-AMP synthase
7FUI	;	1.74	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with (Z)-2-cyano-N-[4-(3-fluorophenyl)-5-methylsulfonylpyrimidin-2-yl]-3-hydroxy-3-(5-methyl-1,2-oxazol-4-yl)prop-2-enamide
7FUJ	;	1.79	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with (Z)-2-cyano-N-[4-(3-fluorophenyl)-5-methylsulfonylpyrimidin-2-yl]-3-hydroxy-3-(5-methyl-1,2-oxazol-4-yl)prop-2-enamide
7FTR	;	1.64	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with (Z)-N-(4-acetylphenyl)-2-cyano-3-hydroxy-3-(5-methyl-1,2-oxazol-4-yl)prop-2-enamide
7FTU	;	1.65	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with (Z)-N-[4-(4-chlorophenyl)sulfonylphenyl]-2-cyano-3-hydroxy-3-(5-methyl-1,2-oxazol-4-yl)prop-2-enamide
7FUR	;	1.7	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 1-[9-(6-aminopyridin-3-yl)-6,7-dichloro-1,3,4,5-tetrahydropyrido[4,3-b]indol-2-yl]-2-hydroxyethanone
7FU6	;	2.37	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 2-benzyl-6-(2-chloro-4-methylphenyl)indazole-4-carboxylic acid
7FU8	;	1.718	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 2-[(2-chloro-5-pyridin-4-ylphenyl)methylamino]-5-propyl-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one
7FU9	;	1.668	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 2-[(2-chloro-5-pyridin-4-ylphenyl)methylamino]-5-propyl-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one
7FUO	;	1.81	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 2-[(2-chlorophenyl)methylamino]-5-[(2-fluoroanilino)methyl]-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one
7FU4	;	1.926	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 2-[(2-fluoro-4-phenylphenyl)methylamino]-5-propyl-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one
7FUM	;	2.06	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 2-[(4-benzylpiperazin-1-yl)methyl]-6-(2-chloro-4-methylphenyl)-1H-benzimidazole-4-carboxylic acid
7FUN	;	2.07	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 2-[(4-benzylpiperazin-1-yl)methyl]-6-(2-chloro-4-methylphenyl)-1H-benzimidazole-4-carboxylic acid
7FU0	;	1.969	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 2-[(4-phenylphenyl)methylamino]-5-(trifluoromethyl)-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one
7FTY	;	2.3	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 2-[(4-phenylphenyl)methylamino]-5-propyl-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one:2,2,2-trifluoroacetic acid
7FTM	;	1.698	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 2-[2-(4-fluoroanilino)-1,3-thiazol-4-yl]acetic acid
7FTZ	;	2.5	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 2-[2-[3-[[(5-bromo-2-hydroxybenzoyl)amino]methyl]anilino]-1,3-thiazol-4-yl]acetic acid
7FUE	;	2.169	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 2-[[2-chloro-5-(1-methylpyrazol-3-yl)phenyl]methylamino]-5-(2-phenylethyl)-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one
7FTI	;	2.0	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 5-(4-fluorophenyl)-2-methylpyrazole-3-carboxylic acid
7FUD	;	2.026	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 5-benzyl-2-[[2-chloro-5-(1-methylpyrazol-3-yl)phenyl]methylamino]-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one
7FUF	;	1.919	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 5-benzyl-2-[[2-chloro-5-(1-methylpyrazol-3-yl)phenyl]methylamino]-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one
7FUG	;	2.106	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 5-benzyl-2-[[2-chloro-5-(1-methylpyrazol-3-yl)phenyl]methylamino]-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one
7FTV	;	1.875	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 5-bromo-2-hydroxy-N-(quinolin-6-ylmethyl)benzamide
7FTW	;	2.208	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 5-bromo-2-hydroxy-N-[[3-(1-methylpyrazol-4-yl)phenyl]methyl]benzamide
7FTS	;	2.215	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 5-bromo-N-[[2-fluoro-5-(1-methylpyrazol-4-yl)phenyl]methyl]-2-hydroxybenzamide
7FTT	;	2.235	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 5-bromo-N-[[2-fluoro-5-(1-methylpyrazol-4-yl)phenyl]methyl]-2-hydroxybenzamide
7FU1	;	2.074	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 5-[3-[[(5-bromo-2-hydroxybenzoyl)amino]methyl]phenyl]-2-methylpyrazole-3-carboxylic acid
7FUC	;	2.52	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 6-(2-chloro-4-methylphenyl)-2-(morpholin-4-ylmethyl)-1H-benzimidazole-4-carboxylic acid
7FUK	;	1.606	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 6-(2-chloro-4-methylphenyl)-3-(2-phenylethyl)benzimidazole-4-carboxylic acid
7FUB	;	1.981	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 6-(2-chloro-4-methylphenyl)-3-(pyridin-4-ylmethyl)benzimidazole-4-carboxylic acid
7FUQ	;	1.757	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 6-(2-chloro-4-methylphenyl)-3-phenylbenzimidazole-4-carboxylic acid
7FUL	;	2.296	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 6-(2-chloro-4-methylphenyl)-3-[3-(methanesulfonamido)propyl]benzimidazole-4-carboxylic acid
7FTO	;	2.4	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 6-(2-chloro-5-fluoro-4-methylphenyl)-1H-benzimidazole-4-carboxylic acid
7FTQ	;	2.08	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 6-(2-chloro-5-fluoro-4-methylphenyl)-1H-benzimidazole-4-carboxylic acid
7FU2	;	2.3	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 6-(2-chloro-5-fluoro-4-methylphenyl)-1H-benzimidazole-4-carboxylic acid
7FTP	;	2.48	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 6-(4-chlorophenyl)-10,11-dimethoxy-7-methyl-2,4,6-triazatricyclo[7.3.1.05,13]trideca-1(12),2,4,7,9(13),10-hexaene
7FTL	;	2.2	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 8-chloro-2-(2-hydroxyphenyl)quinoline-4-carboxylic acid
7FU3	;	1.822	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with 8-chloro-2-(2-hydroxyphenyl)quinoline-4-carboxylic acid
7FTG	;	1.73	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with cGAMP
7FTH	;	2.55	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with cGAMP
7FUP	;	2.411	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with methyl 1-benzoyl-3-methyl-5-(1,2-oxazol-5-yl)pyrazole-4-carboxylate
7FUA	;	1.444	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with phosphate
7FUH	;	1.944	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with phosphate
7FTN	;	2.001	;	Crystal Structure of human cyclic GMP-AMP synthase in complex with propanedioic acid
2B9R	;	2.9	;	Crystal Structure of Human Cyclin B1
1G5S	;	2.61	;	CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH THE INHIBITOR H717
2IVX	;	1.8	;	Crystal structure of human cyclin T2 at 1.8 A resolution
1PF8	;	2.51	;	Crystal Structure of Human Cyclin-Dependent Kinase 2 Complexed with a Nucleoside Inhibitor
8EJX	;	1.65	;	Crystal structure of human cyclophilin D (CypD) with in complex with the covalently bound Ebselen inhibitor
3QYU	;	1.54	;	Crystal structure of human cyclophilin D at 1.54 A resolution at room temperature
2BIT	;	1.71	;	Crystal structure of human cyclophilin D at 1.7 A resolution
2BIU	;	1.71	;	Crystal structure of human cyclophilin D at 1.7 A resolution, DMSO complex
2Z6W	;	0.96	;	Crystal structure of human cyclophilin D in complex with cyclosporin A
3NA0	;	2.5	;	Crystal structure of human CYP11A1 in complex with 20,22-dihydroxycholesterol
3NA1	;	2.25	;	Crystal structure of human CYP11A1 in complex with 20-hydroxycholesterol
3N9Z	;	2.17	;	Crystal structure of human CYP11A1 in complex with 22-hydroxycholesterol
3N9Y	;	2.1	;	Crystal structure of human CYP11A1 in complex with cholesterol
6BCZ	;	2.23	;	Crystal structure of human CYP3A4 bound to an inhibitor
6BD5	;	2.5	;	Crystal structure of human CYP3A4 bound to an inhibitor
6BD6	;	2.5	;	Crystal structure of human CYP3A4 bound to an inhibitor
6BD7	;	2.42	;	Crystal structure of human CYP3A4 bound to an inhibitor
6BD8	;	2.38	;	Crystal structure of human CYP3A4 bound to an inhibitor
6BDH	;	2.25	;	Crystal structure of human CYP3A4 bound to an inhibitor
6BDI	;	2.57	;	Crystal structure of human CYP3A4 bound to an inhibitor
6BDK	;	2.67	;	Crystal structure of human CYP3A4 bound to an inhibitor
6BDM	;	2.6	;	Crystal structure of human CYP3A4 bound to an inhibitor
5VCC	;	1.7	;	Crystal structure of human CYP3A4 bound to glycerol
5G5J	;	2.6	;	Crystal structure of human CYP3A4 bound to metformin
5VC0	;	2.7	;	Crystal structure of human CYP3A4 bound to ritonavir
7LXL	;	2.75	;	Crystal structure of human CYP3A4 bound to the testosterone dimer
4I3Q	;	2.602	;	Crystal structure of human CYP3A4 coordinated to a water molecule
7KS8	;	2.5	;	Crystal structure of human CYP3A4 with the caged inhibitor
7KSA	;	2.5	;	Crystal structure of human CYP3A4 with the caged inhibitor
7UAY	;	2.78	;	Crystal structure of human CYP3A4 with the caged inhibitor
7UAZ	;	2.65	;	Crystal structure of human CYP3A4 with the caged inhibitor
4FIA	;	2.1	;	Crystal Structure of Human CYP46A1 P450 with bicalutamide Bound
3DAX	;	2.15	;	Crystal structure of human CYP7A1
3V8D	;	1.9	;	Crystal structure of human CYP7A1 in complex with 7-ketocholesterol
3SN5	;	2.75	;	Crystal structure of human CYP7A1 in complex with cholest-4-en-3-one
7LYX	;	2.6	;	Crystal structure of human CYP8B1 in complex with (S)-tioconazole
2ALF	;	1.9	;	crystal structure of human CypA mutant K131A
3COG	;	2.0	;	Crystal structure of human cystathionase (Cystathionine gamma lyase) in complex with DL-propargylglycine
4COO	;	2.0	;	Crystal structure of human cystathionine beta-synthase (delta516-525) at 2.0 angstrom resolution
7QGT	;	2.691	;	Crystal structure of human cystathionine beta-synthase (delta516-525) in complex with AOAA.
2NMP	;	2.6	;	Crystal structure of human Cystathionine gamma lyase
6NBA	;	2.495	;	Crystal structure of Human Cystathionine gamma lyase with S-3-Carboxpropyl-L-Cysteine
4N6L	;	1.952	;	Crystal structure of human cystatin E/M
4N6M	;	2.9	;	Crystal structure of human cystatin E/M produced in LEXSY
2IC1	;	2.7	;	Crystal Structure of Human Cysteine Dioxygenase in Complex with Substrate Cysteine
8DYP	;	3.4	;	Crystal structure of human cystine transporter cystinosin
1MQ0	;	2.4	;	Crystal Structure of Human Cytidine Deaminase
5VBU	;	3.31	;	Crystal Structure of Human Cytochrome P450 21A2 Hydroxyprogesterone Complex
4Y8W	;	2.64	;	Crystal Structure of Human Cytochrome P450 21A2 Progesterone Complex
5WBG	;	2.99	;	Crystal Structure of human Cytochrome P450 2B6 (Y226H/K262R) in complex with an analog of a drug Efavirenz
2F9Q	;	3.002	;	Crystal Structure of Human Cytochrome P450 2D6
1W0E	;	2.8	;	Crystal structure of human cytochrome P450 3A4
1W0F	;	2.65	;	Crystal structure of human cytochrome P450 3A4
1W0G	;	2.73	;	Crystal structure of human cytochrome P450 3A4
2Q9G	;	2.4	;	Crystal structure of human cytochrome P450 46A1
2Q9F	;	1.9	;	Crystal structure of human cytochrome P450 46A1 in complex with cholesterol-3-sulphate
8EOH	;	2.65	;	crystal structure of human Cytochrome P450 8B1 in complex with a C12-Pyridine Containing Steroid
4ENH	;	2.5	;	Crystal Structure of Human Cytochrome P450 CYP46A1 with Fluvoxamine Bound
4J14	;	2.5	;	Crystal Structure of Human Cytochrome P450 CYP46A1 with Posaconazole Bound
3NXU	;	2.0	;	Crystal structure of human cytochrome P4503A4 bound to an inhibitor ritonavir
1V5H	;	2.4	;	Crystal Structure of Human Cytoglobin (Ferric Form)
2DC3	;	1.68	;	Crystal structure of human cytoglobin at 1.68 angstroms resolution
4B3W	;	2.8	;	Crystal structure of human cytoglobin H(E7)Q mutant
4I9X	;	2.1	;	Crystal structure of human cytomegalovirus glycoprotein UL141 targeting the death receptor TRAIL-R2
1LQS	;	2.7	;	CRYSTAL STRUCTURE OF HUMAN CYTOMEGALOVIRUS IL-10 BOUND TO SOLUBLE HUMAN IL-10R1
3WZF	;	2.991	;	Crystal structure of human cytoplasmic aspartate aminotransferase
4RH7	;	3.41	;	Crystal structure of human cytoplasmic dynein 2 motor domain in complex with ADP.Vi
6G2N	;	1.4	;	Crystal structure of human cytosolic 5'(3')-deoxyribonucleotidase in complex with the inhibitor PB-PAU
4YIH	;	1.82	;	Crystal structure of human cytosolic 5'(3')-deoxyribonucleotidase in complex with the inhibitor PB-PVU
4YIK	;	1.483	;	Crystal structure of human cytosolic 5'(3')-deoxyribonucleotidase in complex with the inhibitor PB-PVU
2J2C	;	2.2	;	Crystal structure of Human Cytosolic 5'-Nucleotidase II (NT5C2, cN-II)
2JC9	;	1.5	;	Crystal structure of Human Cytosolic 5'-Nucleotidase II in complex with adenosine
2JCM	;	2.15	;	Crystal structure of Human Cytosolic 5'-Nucleotidase II in complex with beryllium trifluoride
2VKQ	;	2.5	;	Crystal structure of human cytosolic 5'-nucleotidase III (cN-III, NT5C3) in complex with beryllium trifluoride
2CN1	;	2.67	;	Crystal structure of Human Cytosolic 5'-Nucleotidase III (NT5C3)
2JGA	;	3.01	;	Crystal structure of human cytosolic 5'-nucleotidase III in complex with phosphate and magnesium
6IY6	;	3.6	;	Crystal structure of human cytosolic aspartyl-tRNA synthetase (DRS) in complex with glutathion-S transferase (GST) domains from Aminoacyl tRNA synthase complex-interacting multifunctional protein 2 (AIMP2) and glutamyl-prolyl-tRNA synthetase (EPRS)
4J15	;	2.24	;	Crystal structure of human cytosolic aspartyl-tRNA synthetase, a component of multi-tRNA synthetase complex
7YH4	;	2.03	;	Crystal structure of human cytosolic beta-alanyl lysine dipeptidase (PM20D2)
7NWA	;	1.59	;	CRYSTAL STRUCTURE OF HUMAN CYTOSOLIC BRANCHED-CHAIN AMINOTRANSFERASE (BCAT1) IN COMPLEX WITH PLP AND COMPOUND A
7NWB	;	2.64	;	CRYSTAL STRUCTURE OF HUMAN CYTOSOLIC BRANCHED-CHAIN AMINOTRANSFERASE (BCAT1) IN COMPLEX WITH PLP AND INHIBITOR COMPOUND 1
7NWE	;	2.54	;	CRYSTAL STRUCTURE OF HUMAN CYTOSOLIC BRANCHED-CHAIN AMINOTRANSFERASE (BCAT1) IN COMPLEX WITH PLP AND INHIBITOR COMPOUND 10
7NWM	;	2.15	;	CRYSTAL STRUCTURE OF HUMAN CYTOSOLIC BRANCHED-CHAIN AMINOTRANSFERASE (BCAT1) IN COMPLEX WITH PLP AND INHIBITOR COMPOUND 12
7NWC	;	2.38	;	CRYSTAL STRUCTURE OF HUMAN CYTOSOLIC BRANCHED-CHAIN AMINOTRANSFERASE (BCAT1) IN COMPLEX WITH PLP AND INHIBITOR COMPOUND 2
7NYA	;	1.85	;	CRYSTAL STRUCTURE OF HUMAN CYTOSOLIC BRANCHED-CHAIN AMINOTRANSFERASE (BCAT1) IN COMPLEX WITH PLP AND SMALL MOLECULE INHIBITOR BAY-069 (COMPOUND 36)
7NXN	;	1.7	;	CRYSTAL STRUCTURE OF HUMAN CYTOSOLIC BRANCHED-CHAIN AMINOTRANSFERASE (BCAT1) IN COMPLEX WITH PLP AND SMALL MOLECULE INHIBITOR COMPOUND 21(5-F)
7NXO	;	1.71	;	CRYSTAL STRUCTURE OF HUMAN CYTOSOLIC BRANCHED-CHAIN AMINOTRANSFERASE (BCAT1) IN COMPLEX WITH PLP AND SMALL MOLECULE INHIBITOR COMPOUND 24(5-F)
7NY2	;	2.31	;	CRYSTAL STRUCTURE OF HUMAN CYTOSOLIC BRANCHED-CHAIN AMINOTRANSFERASE (BCAT1) IN COMPLEX WITH PLP AND SMALL MOLECULE INHIBITOR COMPOUND 35
7NY9	;	1.6	;	CRYSTAL STRUCTURE OF HUMAN CYTOSOLIC BRANCHED-CHAIN AMINOTRANSFERASE (BCAT1) IN COMPLEX WITH PLP AND SMALL MOLECULE INHIBITOR COMPOUND 38
7NTR	;	2.23	;	CRYSTAL STRUCTURE OF HUMAN CYTOSOLIC BRANCHED-CHAIN AMINOTRANSFERASE (BCAT1) IN COMPLEX WITH PLP AND SUBSTRATE MIMIC 3-PHENYLPROPIONATE
6VEI	;	2.1	;	Crystal Structure of Human Cytosolic Isocitrate Dehydrogenase (IDH1) R132H Mutant in Complex with NADPH and AG-881 (Vorasidenib) Inhibitor
6VG0	;	2.66	;	CRYSTAL STRUCTURE OF HUMAN CYTOSOLIC ISOCITRATE DEHYDROGENASE (IDH1) R132H MUTANT IN COMPLEX WITH NADPH and AGI-15056
1T09	;	2.7	;	Crystal structure of human cytosolic NADP(+)-dependent isocitrate dehydrogenase in complex NADP
1T0L	;	2.41	;	Crystal structure of human cytosolic NADP(+)-dependent isocitrate dehydrogenase in complex with NADP, isocitrate, and calcium(2+)
3INM	;	2.1	;	Crystal structure of human cytosolic NADP(+)-dependent isocitrate dehydrogenase R132H mutant in complex with NADPH, ALPHA-KETOGLUTARATE and CALCIUM(2+)
2E9M	;	1.8	;	Crystal Structure of human Cytosolic Neutral beta-Glycosylceramidase (Klotho-related Prote:KLrP) complex with Galactose and fatty acids
2E9L	;	1.6	;	Crystal Structure of human Cytosolic Neutral beta-Glycosylceramidase (Klotho-related Prote:KLrP) complex with Glucose and fatty acids
1NUR	;	2.15	;	CRYSTAL STRUCTURE OF HUMAN CYTOSOLIC NMN/NaMN ADENYLYLTRANSFERASE
1NUP	;	1.9	;	CRYSTAL STRUCTURE OF HUMAN CYTOSOLIC NMN/NaMN ADENYLYLTRANSFERASE COMPLEX WITH NMN
1NUT	;	1.9	;	CRYSTAL STRUCTURE OF HUMAN CYTOSOLIC NMN/NaMN ADENYLYLTRANSFERASE COMPLEXED WITH ATP ANALOG
1NUS	;	2.2	;	CRYSTAL STRUCTURE OF HUMAN CYTOSOLIC NMN/NaMN ADENYLYLTRANSFERASE COMPLEXED WITH ATP ANALOG AND NMN
1NUQ	;	1.9	;	CRYSTAL STRUCTURE OF HUMAN CYTOSOLIC NMN/NaMN ADENYLYLTRANSFERASE COMPLEXED WITH NaAD
1NUU	;	1.9	;	CRYSTAL STRUCTURE OF HUMAN CYTOSOLIC NMN/NaMN ADENYLYLTRANSFERASE COMPLEXED WITH NAD
3CKL	;	2.0	;	Crystal structure of human cytosolic sulfotransferase SULT1B1 in complex with PAP and resveratrol
3F3Y	;	2.2	;	Crystal structure of human cytosolic sulfotransferase SULT2A1 in complex with PAP and lithocholic acid
6LPN	;	2.206	;	Crystal structure of human D-2-hydroxyglutarate dehydrogenase in apo form
6LPX	;	2.8	;	Crystal structure of human D-2-hydroxyglutarate dehydrogenase in complex with 2-oxoglutarate (2-OG)
6LPP	;	2.65	;	Crystal structure of human D-2-hydroxyglutarate dehydrogenase in complex with D-2-hydroxyglutarate (D-2-HG)
6LPT	;	2.621	;	Crystal structure of human D-2-hydroxyglutarate dehydrogenase in complex with D-lactate (D-LAC)
6LPQ	;	2.8	;	Crystal structure of human D-2-hydroxyglutarate dehydrogenase in complex with D-malate (D-MAL)
6LPU	;	2.923	;	Crystal structure of human D-2-hydroxyglutarate dehydrogenase in complex with L-2-hydroxyglutarate (L-2-HG)
2DU8	;	2.5	;	Crystal structure of human D-amino acid oxidase
2E82	;	2.7	;	Crystal structure of human D-amino acid oxidase complexed with imino-DOPA
3G3E	;	2.2	;	Crystal structure of human D-amino acid oxidase in complex with hydroxyquinolin-2(1H)
2E49	;	3.2	;	Crystal Structure of Human D-Amino Acid Oxidase in Complex with Imino-Serine
7U9S	;	2.1	;	Crystal structure of human D-amino acid oxidase in complex with inhibitor
7U9U	;	1.66	;	Crystal structure of human D-amino acid oxidase in complex with inhibitor
2E4A	;	2.6	;	Crystal Structure of Human D-Amino Acid Oxidase in complex with o-aminobenzoate
6KBP	;	2.25	;	Crystal structure of human D-amino acid oxidase mutant (P219L) complexed with benzoate
3CUK	;	2.49	;	Crystal structure of human D-amino acid oxidase: bound to an inhibitor
2E48	;	2.9	;	Crystal Structure of Human D-Amino Acid Oxidase: Substrate-Free Holoenzyme
1N86	;	3.2	;	Crystal structure of human D-dimer from cross-linked fibrin complexed with GPR and GHRPLDK peptide ligands.
4BC3	;	1.68	;	Crystal structure of human D-xylulokinase
4BC4	;	1.79	;	Crystal structure of human D-xylulokinase in complex with D-xylulose
4BC2	;	1.97	;	Crystal structure of human D-xylulokinase in complex with D-xylulose and adenosine diphosphate
4BC5	;	1.98	;	Crystal structure of human D-xylulokinase in complex with inhibitor 5- deoxy-5-fluoro-D-xylulose
2Z6E	;	2.8	;	Crystal Structure of Human DAAM1 FH2
3W4J	;	2.74	;	Crystal Structure of human DAAO in complex with coumpound 12
3W4K	;	2.86	;	Crystal Structure of human DAAO in complex with coumpound 13
3W4I	;	2.5	;	Crystal Structure of human DAAO in complex with coumpound 8
3FHT	;	2.2	;	Crystal structure of human Dbp5 in complex with AMPPNP and RNA
3FHC	;	2.8	;	Crystal structure of human Dbp5 in complex with Nup214
4PXW	;	1.72	;	Crystal structure of human DCAF1 WD40 repeats (Q1250L)
8OG5	;	2.2	;	Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 1
8OG6	;	2.245	;	Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 1
8OGC	;	2.09	;	Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 11
8OO5	;	2.25	;	Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 13
8OOD	;	1.497	;	Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 15
8OG7	;	2.64	;	Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 2
8OG8	;	2.11	;	Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 3
8OG9	;	2.945	;	Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 4
8OGA	;	2.2	;	Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 6
8OGB	;	2.27	;	Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 8
2A7Q	;	2.55	;	Crystal structure of human dCK complexed with clofarabine and ADP
3HP1	;	2.31	;	Crystal structure of human dCK R104M/D133A in complex with L-dT and ADP
6SZQ	;	2.412	;	Crystal structure of human DDAH-1
6ZUE	;	3.094	;	Crystal structure of human DDB1 bound to human DCAF1 (amino acid residues 1046-1396)
7FEH	;	1.61	;	Crystal structure of human DDR1 in complex with CH5541127
6FER	;	2.87	;	Crystal Structure of human DDR2 kinase in complex with 2-[4,5-difluoro-2-oxo-1'-(1H-pyrazolo[3,4-b]pyridine-5-carbonyl)spiro[indole-3,4'-piperidine]-1-yl]-N-(2,2,2-trifluoroethyl)acetamide
8TBX	;	2.71	;	Crystal structure of human DDX1 helicase in complex with ADP
6B4K	;	2.2	;	Crystal structure of human DDX19B(AMPPNP)
6L5L	;	3.1	;	Crystal structure of human DEAD-box RNA helicase DDX21 at apo state
6L5O	;	1.8	;	Crystal structure of human DEAD-box RNA helicase DDX21 at post-hydrolysis state
6L5N	;	2.242	;	Crystal structure of human DEAD-box RNA helicase DDX21 at post-unwound state
6L5M	;	2.7	;	Crystal structure of human DEAD-box RNA helicase DDX21 in complex with AMP
2I4I	;	2.2	;	Crystal Structure of human DEAD-box RNA helicase DDX3X
8EJM	;	1.8	;	Crystal structure of human DEAH-box helicase DHX15 in complex with SUGP1 G-patch
5XDR	;	2.0	;	Crystal structure of human DEAH-box RNA helicase DHX15 in complex with ADP
3BHY	;	1.24	;	Crystal structure of human death associated protein kinase 3 (DAPK3) in complex with a beta-carboline ligand
3BQR	;	1.75	;	Crystal structure of human death associated protein kinase 3 (DAPK3) in complex with an imidazo-pyridazine ligand
5A6N	;	1.7	;	Crystal structure of human death associated protein kinase 3 (DAPK3) in complex with compound 2
3B6E	;	1.6	;	Crystal structure of human DECH-box RNA Helicase MDA5 (Melanoma differentiation-associated protein 5), DECH-domain
1ZMP	;	1.65	;	Crystal structure of human defensin-5
5CUI	;	2.403	;	Crystal structure of Human Defensin-5 R28A mutant.
5CUM	;	1.752	;	Crystal structure of Human Defensin-5 Y27A mutant crystal form 1.
5CUJ	;	2.08	;	Crystal structure of Human Defensin-5 Y27A mutant crystal form 2.
6W2L	;	2.306	;	Crystal structure of human dehydrodolichyl diphosphate synthase (NgBR/DHDDS) in complex with Mg and IPP
1J99	;	1.99	;	CRYSTAL STRUCTURE OF HUMAN DEHYDROEPIANDROSTERONE SULFOTRANSFERASE IN COMPLEX WITH SUBSTRATE
3O4R	;	1.7	;	Crystal Structure of Human Dehydrogenase/Reductase (SDR family) member 4 (DHRS4)
6VFW	;	3.6	;	Crystal structure of human delta protocadherin 10 EC1-EC4
6VFT	;	3.71	;	Crystal structure of human delta protocadherin 17 EC1-EC4
3BUV	;	1.35	;	Crystal structure of human Delta(4)-3-ketosteroid 5-beta-reductase in complex with NADP and HEPES. Resolution: 1.35 A.
1XMJ	;	2.3	;	Crystal structure of human deltaF508 human NBD1 domain with ATP
5B1X	;	2.902	;	Crystal structure of human dendritic cell inhibitory receptor (DCIR) C-type lectin domain in complex with biantennary glycan
5B1W	;	3.05	;	Crystal structure of human dendritic cell inhibitory receptor (DCIR) C-type lectin domain in ligand-free form
2A30	;	3.02	;	Crystal structure of human deoxycytidine kinase in complex with deoxycytidine
2A2Z	;	3.02	;	Crystal Structure of human deoxycytidine kinase in complex with deoxycytidine and uridine diphosphate
2OCP	;	2.8	;	Crystal Structure of Human Deoxyguanosine Kinase
1KD2	;	1.87	;	Crystal Structure of Human Deoxyhemoglobin in Absence of Any Anions
6XXH	;	1.52	;	Crystal Structure of Human Deoxyhypusine Synthase in apo form
6XXI	;	1.679	;	Crystal Structure of Human Deoxyhypusine Synthase in complex with NAD
6XXM	;	1.67	;	Crystal Structure of Human Deoxyhypusine Synthase in complex with putrescine
6XXK	;	1.65	;	Crystal Structure of Human Deoxyhypusine Synthase in complex with spermidine
6XXJ	;	1.41	;	Crystal Structure of Human Deoxyhypusine Synthase in complex with spermidine and NAD
6XXL	;	1.69	;	Crystal Structure of Human Deoxyhypusine Synthase in complex with spermine
8A0F	;	1.64	;	Crystal structure of human deoxyhypusine synthase variant K329A in complex with NAD and SPD
3VJM	;	2.1	;	Crystal structure of human depiptidyl peptidase IV (DPP-4) in complex with a prolylthiazolidine inhibitor #1
3VJL	;	2.393	;	Crystal structure of human depiptidyl peptidase IV (DPP-4) in complex with a prolylthiazolidine inhibitor #2
3VJK	;	2.49	;	Crystal structure of human depiptidyl peptidase IV (DPP-4) in complex with MP-513
3W2T	;	2.36	;	Crystal structure of human depiptidyl peptidase IV (DPP-4) in complex with vildagliptin
6HZN	;	2.41	;	Crystal structure of human dermatan sulfate epimerase 1
3HQA	;	2.586	;	Crystal structure of human desarg-C5A
3HQB	;	3.299	;	Crystal structure of human desarg-C5A
5IRY	;	3.095	;	Crystal structure of human Desmocollin-1 ectodomain
5ERP	;	2.7	;	Crystal structure of human Desmocollin-2 ectodomain fragment EC2-5
5ERD	;	2.9	;	Crystal structure of human Desmoglein-2 ectodomain
5EQX	;	3.05	;	Crystal structure of human Desmoglein-3 ectodomain
2YT4	;	2.6	;	Crystal structure of human DGCR8 core
1OV4	;	2.7	;	Crystal structure of human DHEA-ST complexed with androsterone
5SDB	;	1.55	;	Crystal Structure of Human DHFR complexed with NADP and N10-formyl-tetrahydrofolate
6DAV	;	1.55	;	Crystal Structure of Human DHFR complexed with NADP and N10formyltetrahydrofolate
6QU7	;	1.52	;	Crystal structure of human DHODH in complex with BAY 2402234
6IDJ	;	1.9	;	Crystal structure of human DHODH in complex with ferulenol
6LP7	;	1.802	;	Crystal structure of human DHODH in complex with inhibitor 0944
6JME	;	1.8	;	Crystal structure of human DHODH in complex with inhibitor 0946
6LP6	;	1.795	;	Crystal structure of human DHODH in complex with inhibitor 1214
6JMD	;	1.781	;	Crystal structure of human DHODH in complex with inhibitor 1223
6LP8	;	1.79	;	Crystal structure of human DHODH in complex with inhibitor 1243
6J3B	;	1.6	;	Crystal structure of human DHODH in complex with inhibitor 1289
6J3C	;	1.851	;	Crystal structure of human DHODH in complex with inhibitor 1291
5H73	;	1.58	;	Crystal structure of human DHODH with 18F
6OC0	;	1.4	;	Crystal structure of human DHODH with OSU-03012
6OC1	;	2.7	;	Crystal structure of human DHODH with TAK-632
2AG5	;	1.84	;	Crystal Structure of Human DHRS6
6IIE	;	2.142	;	Crystal structure of human diacylglycerol kinase alpha EF-hand domains bound to Ca2+
3HI7	;	1.799	;	Crystal structure of human diamine oxidase
3HIG	;	2.09	;	Crystal structure of human diamine oxidase in complex with the inhibitor berenil
3HII	;	2.149	;	Crystal structure of human diamine oxidase in complex with the inhibitor pentamidine
3K5T	;	2.11	;	Crystal structure of human diamine oxidase in space group C2221
4M6L	;	1.7	;	Crystal structure of human dihydrofolate reductase (DHFR) bound to NADP+ and 5,10-dideazatetrahydrofolic acid
4M6K	;	1.396	;	Crystal structure of human dihydrofolate reductase (DHFR) bound to NADP+ and folate
4M6J	;	1.201	;	Crystal structure of human dihydrofolate reductase (DHFR) bound to NADPH
4QHV	;	1.61	;	Crystal structure of human dihydrofolate reductase as complex with pyridopyrimidine 22 (N~6~-METHYL-N~6~-[4-(PROPAN-2-YL)PHENYL]PYRIDO[2,3-D]PYRIMIDINE-2,4,6-TRIAMINE)
1DRF	;	2.0	;	CRYSTAL STRUCTURE OF HUMAN DIHYDROFOLATE REDUCTASE COMPLEXED WITH FOLATE
4KAK	;	1.8	;	Crystal structure of human dihydrofolate reductase complexed with NADPH and 6-ethyl-5-[(3S)-3-[3-methoxy-5-(pyridine-4-yl)phenyl]but-1-yn-1-yl]pyrimidine-2,4-diamine (UCP1006)
2F5Z	;	2.18	;	Crystal Structure of Human Dihydrolipoamide Dehydrogenase (E3) Complexed to the E3-Binding Domain of Human E3-Binding Protein
1ZMC	;	2.53	;	Crystal Structure of Human dihydrolipoamide dehydrogenase complexed to NAD+
1ZMD	;	2.08	;	Crystal Structure of Human dihydrolipoamide dehydrogenase complexed to NADH
4JS3	;	2.0	;	Crystal structure of human dihydroorotate dehydrogenase (DHODH) with 057
4JTT	;	2.1	;	Crystal structure of human dihydroorotate dehydrogenase (DHODH) with 066
4JTS	;	2.206	;	Crystal structure of human dihydroorotate dehydrogenase (DHODH) with 072
5HIN	;	1.6	;	Crystal structure of human dihydroorotate dehydrogenase (DHODH) with 18L compound
4ZL1	;	1.86	;	Crystal structure of human dihydroorotate dehydrogenase (DHODH) with 18X at 1.86 A resolution
5H2Z	;	1.58	;	Crystal structure of Human Dihydroorotate Dehydrogenase (DHODH) with 7GF
3KVJ	;	1.94	;	Crystal Structure of Human Dihydroorotate Dehydrogenase (DHODH) with Amino-Benzoic Acid Inhibitor 105 at 1.94A Resolution
3KVK	;	2.05	;	Crystal structure of human dihydroorotate dehydrogenase (DHODH) with amino-benzoic acid inhibitor 641 at 2.05A resolution
3KVL	;	1.85	;	Crystal structure of human dihydroorotate dehydrogenase (DHODH) with amino-benzoic acid inhibitor 715 at 1.85A resolution
3KVM	;	2.0	;	Crystal structure of human dihydroorotate dehydrogenase (DHODH) with amino-benzoic acid inhibitor 951 at 2.00A resolution
4JTU	;	1.9	;	Crystal structure of human dihydroorotate dehydrogenase (DHODH) with brequinar analogue
5HQE	;	1.62	;	Crystal structure of human dihydroorotate dehydrogenase (DHODH) with compound 18T
4LS0	;	2.07	;	Crystal structure of human dihydroorotate dehydrogenase (DHODH) with DH01B0033
4JGD	;	2.05	;	Crystal structure of human dihydroorotate dehydrogenase (DHODH) with DH03A016
4RLI	;	2.5	;	Crystal structure of human dihydroorotate dehydrogenase (DHODH) with DH03A048
4LS1	;	2.2	;	Crystal structure of human dihydroorotate dehydrogenase (DHODH) with DH03A312
4LS2	;	2.27	;	Crystal structure of human dihydroorotate dehydrogenase (DHODH) with DH03A313
4ZMG	;	1.9	;	Crystal structure of Human Dihydroorotate Dehydrogenase (DHODH) with DH03A338
4RKA	;	2.71	;	Crystal structure of human dihydroorotate dehydrogenase (DHODH) with DH03A347
4RK8	;	2.22	;	Crystal structure of human dihydroorotate dehydrogenase (DHODH) with DH03A356
4RR4	;	2.38	;	Crystal structure of human dihydroorotate dehydrogenase (DHODH) with DH03A367
4YLW	;	1.79	;	Crystal structure of human dihydroorotate dehydrogenase (DHODH) with No.33 compound
6LZL	;	1.98	;	Crystal structure of human dihydroorotate dehydrogenase (DHODH) with Piperine
6M2B	;	1.76	;	Crystal structure of human dihydroorotate dehydrogenase (DHODH) with S416
5K9D	;	1.7	;	Crystal structure of human dihydroorotate dehydrogenase at 1.7 A resolution
7Z6C	;	1.85	;	Crystal structure of human Dihydroorotate Dehydrogenase in complex with the inhibitor 2-Hydroxy-N-(2-ispropyl-5-methyl-4-phenoxyphenyl)pyrazolo[1,5-a]pyridine-3-carboxamide.
5K9C	;	1.66	;	Crystal structure of human dihydroorotate dehydrogenase with ML390
2GSE	;	2.4	;	Crystal Structure of Human Dihydropyrimidinease-like 2
5MLE	;	2.48	;	Crystal Structure of Human Dihydropyrimidinease-like 2 (DPYSL2A)/Collapsin Response Mediator Protein (CRMP2 13-516) Mutant Y479E/Y499E
5MKV	;	1.8	;	Crystal Structure of Human Dihydropyrimidinease-like 2 (DPYSL2A)/Collapsin Response Mediator Protein (CRMP2) residues 13-516
1XBS	;	2.5	;	Crystal structure of human dim2: a dim1-like protein
1ZQ9	;	1.9	;	Crystal structure of human Dimethyladenosine transferase
3P8E	;	2.4946	;	Crystal structure of human DIMETHYLARGININE DIMETHYLAMINOHYDROLASE-1 (DDAH-1) covalently bound with N5-(1-iminopentyl)-L-ornithine
3P8P	;	2.5	;	Crystal Structure of Human Dimethylarginine Dimethylaminohydrolase-1 (DDAH-1) variant C274S bound with N5-(1-iminopentyl)-L-ornithine
3I2E	;	2.03	;	Crystal structure of human dimethylarginine dymethylaminohydrolase-1 (DDAH-1)
5L46	;	3.09	;	Crystal structure of human dimethylglycine-dehydrogenase
6VGO	;	1.82	;	Crystal Structure of Human Dipeptidase 3
6VGR	;	2.84	;	Crystal Structure of Human Dipeptidase 3 in Complex with Fab of SC-003
2I03	;	2.4	;	Crystal structure of human dipeptidyl peptidase 4 (DPP IV) with potent alkynyl cyanopyrrolidine (ABT-279)
2DJF	;	2.0	;	Crystal Structure of human dipeptidyl peptidase I (Cathepsin C) in complex with the inhibitor Gly-Phe-CHN2
1K3B	;	2.15	;	Crystal Structure of Human Dipeptidyl Peptidase I (Cathepsin C): Exclusion Domain Added to an Endopeptidase Framework Creates the Machine for Activation of Granular Serine Proteases
3FVY	;	1.9	;	Crystal structure of human Dipeptidyl Peptidase III
1J2E	;	2.6	;	Crystal structure of Human Dipeptidyl peptidase IV
2BUB	;	2.66	;	Crystal Structure Of Human Dipeptidyl Peptidase IV (CD26) in Complex with a Reversed Amide Inhibitor
3H0C	;	2.66	;	Crystal Structure of Human Dipeptidyl Peptidase IV (CD26) in Complex with a Reversed Amide Inhibitor
2I78	;	2.5	;	Crystal structure of human dipeptidyl peptidase IV (DPP IV) complexed with ABT-341, a cyclohexene-constrained phenethylamine inhibitor
1NU6	;	2.1	;	Crystal structure of human Dipeptidyl Peptidase IV (DPP-IV)
1NU8	;	2.5	;	Crystal structure of human dipeptidyl peptidase IV (DPP-IV) in complex with Diprotin A (IPI)
2OLE	;	2.4	;	Crystal Structure Of Human Dipeptidyl Peptidase IV (DPPIV) Complex With Cyclic Hydrazine Derivatives
1WCY	;	2.2	;	Crystal Structure Of Human Dipeptidyl Peptidase IV (DPPIV) Complex With Diprotin A
2G5P	;	2.4	;	Crystal structure of human dipeptidyl peptidase IV (DPPIV) complexed with cyanopyrrolidine (C5-pro-pro) inhibitor 21ac
2G5T	;	2.3	;	Crystal structure of human dipeptidyl peptidase IV (DPPIV) complexed with cyanopyrrolidine (C5-pro-pro) inhibitor 21ag
2G63	;	2.0	;	Crystal structure of human dipeptidyl peptidase IV (DPPIV) complexed with cyanopyrrolidine (C5-pro-pro) inhibitor 24b
2OAG	;	2.3	;	Crystal structure of human dipeptidyl peptidase IV (DPPIV) with pyrrolidine-constrained phenethylamine 29g
1R9M	;	2.1	;	Crystal Structure of Human Dipeptidyl Peptidase IV at 2.1 Ang. Resolution.
1R9N	;	2.3	;	Crystal Structure of human dipeptidyl peptidase IV in complex with a decapeptide (tNPY) at 2.3 Ang. Resolution
4G1F	;	2.9	;	Crystal Structure of human Dipeptidyl Peptidase IV in complex with a pyridopyrimidinedione analogue
6PCK	;	1.2	;	Crystal structure of human diphosphoinositol polyphosphate phosphohydrolase 1 in complex with 1-IP7
6PCL	;	1.3	;	Crystal structure of human diphosphoinositol polyphosphate phosphohydrolase 1 in complex with 5-IP7
3MCF	;	2.0	;	Crystal structure of human diphosphoinositol polyphosphate phosphohydrolase 3-alpha
6LCA	;	2.4	;	Crystal structure of human Dishevelled1 PDZ domain homotrimer
6LCB	;	1.4	;	Crystal structure of human Dishevelled1 PDZ domain with its inhibitor NPL3009
4BKG	;	2.11	;	crystal structure of human diSUMO-2
1J42	;	2.5	;	Crystal Structure of Human DJ-1
1P5F	;	1.1	;	Crystal Structure of Human DJ-1
4MNT	;	1.584	;	Crystal structure of human DJ-1 in complex with Cu
6E5Z	;	1.35	;	Crystal structure of human DJ-1 with a natural modification on Cys-106
4OGF	;	1.6	;	Crystal Structure of Human DJ-1 with glyoxylate as substrate analog
6M8Z	;	1.83	;	Crystal structure of human DJ-1 without a modification on Cys-106
1PDW	;	2.2	;	Crystal structure of human DJ-1, P 1 21 1 space group
1PDV	;	1.8	;	Crystal structure of human DJ-1, P 31 2 1 space group
3W6P	;	1.7	;	Crystal structure of human Dlp1 in complex with GDP.AlF4
3W6O	;	1.9	;	Crystal structure of human Dlp1 in complex with GMP-PCP
3W6N	;	2.0	;	Crystal structure of human Dlp1 in complex with GMP-PN.Pi
6R3P	;	2.05	;	Crystal structure of human DMC1 ATPase domain
4B87	;	2.16	;	Crystal structure of human DNA cross-link repair 1A
8CG9	;	1.68	;	Crystal structure of human DNA cross-link repair 1A in complex with a cyclic N-hydroxyurea inhibitor
8C8S	;	1.8	;	Crystal structure of human DNA cross-link repair 1A in complex with hydroxamic acid inhibitor (compound 21).
8C8D	;	1.46	;	Crystal structure of human DNA cross-link repair 1A in complex with hydroxamic acid inhibitor (compound 44).
8C8B	;	1.46	;	Crystal structure of human DNA cross-link repair 1A in complex with hydroxamic acid inhibitor (compound 48).
8CEW	;	1.53	;	Crystal structure of human DNA cross-link repair 1A in complex with N-hydroxyimide inhibitor H1
8CF0	;	1.76	;	Crystal structure of human DNA cross-link repair 1A in complex with quinoxalinedione inhibitor H2
5AHR	;	2.19	;	Crystal structure of human DNA cross-link repair 1A, crystal form B
1X9N	;	3.0	;	Crystal Structure of Human DNA Ligase I bound to 5'-adenylated, nicked DNA
3W5O	;	2.84	;	Crystal Structure of Human DNA ligase IV
3W1B	;	2.4	;	Crystal Structure of Human DNA ligase IV-Artemis Complex (Mercury Derivative)
3W1G	;	2.55	;	Crystal Structure of Human DNA ligase IV-Artemis Complex (Native)
5VBN	;	2.35	;	Crystal Structure of human DNA polymerase epsilon B-subunit in complex with C-terminal domain of catalytic subunit
6V5K	;	2.69	;	Crystal structure of human DNA polymerase eta complexed with N7-nitrogen half-mustard guanine (NHMG) and dCTP*
5DGB	;	1.79	;	CRYSTAL STRUCTURE OF HUMAN DNA POLYMERASE ETA EXTENDING AN 1,N6-ETHENODEOXYADENOSINE : dA PAIR BY INSERTING dTMPNPP OPPOSITE TEMPLATE dA
5DGA	;	2.3	;	CRYSTAL STRUCTURE OF HUMAN DNA POLYMERASE ETA EXTENDING AN 1,N6-ETHENODEOXYADENOSINE : dT PAIR BY INSERTING dTMPNPP OPPOSITE TEMPLATE dA
5DQI	;	2.3	;	Crystal Structure of Human DNA Polymerase Eta Extending an O4-Ethylthymidine : dA Pair By Inserting dCTP Opposite dG
4EEY	;	2.32	;	Crystal structure of human DNA polymerase eta in ternary complex with a cisplatin DNA adduct
4O3N	;	1.579	;	Crystal structure of human dna polymerase eta in ternary complex with native dna and incoming nucleotide (dcp)
8GKR	;	2.784	;	Crystal structure of human DNA polymerase eta incorporating 5F-dUTP across dA
8GML	;	2.567	;	Crystal structure of human DNA polymerase eta incorporating 5F-dUTP across dG
8SKI	;	2.163	;	Crystal structure of human DNA polymerase eta incorporating 5F-dUTP across HX
8FN3	;	2.17	;	Crystal structure of human DNA polymerase eta incorporating dITP across dC
8FOG	;	2.29	;	Crystal structure of human DNA polymerase eta incorporating dITP across dT
8G8H	;	1.64	;	Crystal structure of human DNA polymerase eta incorporating ITP across dC
8G8J	;	1.74	;	Crystal structure of human DNA polymerase eta incorporating ITP across dT
8GBF	;	2.11	;	Crystal structure of human DNA polymerase eta incorporating syn-ITP across dT
5F9L	;	2.592	;	CRYSTAL STRUCTURE OF HUMAN DNA POLYMERASE ETA INSERTING dAMPNPP ACROSS A DNA TEMPLATE CONTAINING 1,N2-ETHENODEOXYGUANOSINE LESION
5DG8	;	2.12	;	CRYSTAL STRUCTURE OF HUMAN DNA POLYMERASE ETA INSERTING dAMPNPP ACROSS A DNA TEMPLATE CONTAINING 1,N6-ETHENODEOXYADENOSINE LESION
5DQG	;	2.29	;	Crystal Structure of Human DNA Polymerase Eta Inserting dAMPNPP Opposite O4-Ethylthymidine
5DLF	;	1.97	;	Crystal Structure of Human DNA Polymerase Eta Inserting dATP Opposite O4-Methylhymidine
5F9N	;	2.23	;	CRYSTAL STRUCTURE OF HUMAN DNA POLYMERASE ETA INSERTING dCMPNPP ACROSS A DNA TEMPLATE CONTAINING 1,N2-ETHENODEOXYGUANOSINE LESION
4RU9	;	2.65	;	Crystal structure of human DNA polymerase eta inserting dCMPNPP opposite a MeFapy-dG adducted DNA template
5JUM	;	2.6	;	Crystal Structure of Human DNA Polymerase Eta Inserting dCTP Opposite N-(2'-deoxyguanosin-8- yl)-3-aminobenzanthrone (C8-dG-ABA)
5L1I	;	2.78	;	Crystal Structure of Human DNA Polymerase Eta Inserting dCTP Opposite O6-Methyl-2'-deoxyguanosine
5DG9	;	2.15	;	CRYSTAL STRUCTURE OF HUMAN DNA POLYMERASE ETA INSERTING dGMPNPP ACROSS A DNA TEMPLATE CONTAINING 1,N6-ETHENODEOXYADENOSINE LESION
5DQH	;	1.99	;	Crystal Structure of Human DNA Polymerase Eta Inserting dGMPNPP Opposite O4-Ethylthymidine
5DLG	;	2.351	;	Crystal Structure of Human DNA Polymerase Eta Inserting dGMPNPP Opposite O4-Methylhymidine
5L1J	;	1.94	;	Crystal Structure of Human DNA Polymerase Eta Inserting dTMPNPP Opposite O6-Methyl-2'-deoxyguanosine
5DG7	;	2.26	;	CRYSTAL STRUCTURE OF HUMAN DNA POLYMERASE ETA INSERTING dTTP ACROSS A DNA TEMPLATE CONTAINING 1,N6-ETHENODEOXYADENOSINE LESION
2G4C	;	3.15	;	Crystal Structure of human DNA polymerase gamma accessory subunit
6BRX	;	2.8	;	Crystal Structure of Human DNA polymerase kappa in complex with DNA containing the major cisplatin lesion
6BS1	;	3.15	;	Crystal Structure of Human DNA polymerase kappa in complex with DNA containing the major cisplatin lesion
1XSL	;	2.3	;	Crystal Structure of human DNA polymerase lambda in complex with a one nucleotide DNA gap
1XSN	;	1.95	;	Crystal Structure of human DNA polymerase lambda in complex with a one nucleotide DNA gap and ddTTP
1XSP	;	2.2	;	Crystal Structure of human DNA polymerase lambda in complex with nicked DNA and pyrophosphate
5CWR	;	2.5	;	Crystal Structure of human DNA polymerase lambda L431A mutant in complex with a one nucleotide DNA gap and dCTP
2GWS	;	2.4	;	Crystal Structure of human DNA Polymerase lambda with a G/G mismatch in the primer terminus
3KGV	;	6.6	;	Crystal Structure of Human DNA-dependent Protein Kinase Catalytic Subunit (DNA-PKcs)
5LUQ	;	4.3	;	Crystal Structure of Human DNA-dependent Protein Kinase Catalytic Subunit (DNA-PKcs)
4YOC	;	2.916	;	Crystal Structure of human DNMT1 and USP7/HAUSP complex
3PTA	;	3.6	;	Crystal structure of human DNMT1(646-1600) in complex with DNA
6KDT	;	2.87	;	Crystal structure of human DNMT3B (Q772R)-DNMT3L complex
6KDL	;	3.274	;	Crystal structure of human DNMT3B-DNMT3L complex (I)
6KDP	;	2.93	;	Crystal structure of human DNMT3B-DNMT3L complex (II)
6KDA	;	2.909	;	Crystal structure of human DNMT3B-DNMT3L in complex with DNA containing CpGpG site
6KDB	;	2.862	;	Crystal structure of human DNMT3B-DNMT3L in complex with DNA containing CpGpT site
4P5E	;	1.35	;	CRYSTAL STRUCTURE OF HUMAN DNPH1 (RCL) WITH 6-NAPHTHYL-PURINE-RIBOSIDE-MONOPHOSPHATE
8QHQ	;	1.78	;	Crystal structure of human DNPH1 bound to hmdUMP
4ER5	;	2.57	;	Crystal structure of human DOT1L in complex with 2 molecules of EPZ004777
3SR4	;	2.5	;	Crystal Structure of Human DOT1L in Complex with a Selective Inhibitor
4ER3	;	2.4	;	Crystal Structure of Human DOT1L in complex with inhibitor EPZ004777
4ER0	;	2.5	;	Crystal Structure of human DOT1L in complex with inhibitor FED1
4EQZ	;	2.15	;	Crystal structure of human DOT1L in complex with inhibitor FED2
4ER6	;	2.3	;	Crystal structure of human DOT1L in complex with inhibitor SGC0946
4ER7	;	2.2	;	Crystal Structure of human DOT1L in complex with inhibitor SGC0947
4M8V	;	1.951	;	Crystal structure of Human double mutant beta2-microglobulin Q8H-L65T
2ONC	;	2.55	;	Crystal structure of human DPP-4
3BJM	;	2.35	;	Crystal structure of human DPP-IV in complex with (1S,3S, 5S)-2-[(2S)-2-AMINO-2-(3-HYDROXYTRICYCLO[3.3.1.13,7]DEC-1- YL)ACETYL]-2-AZABICYCLO[3.1.0]HEXANE-3-CARBONITRILE (CAS), (1S,3S,5S)-2-((2S)-2-AMINO-2-(3-HYDROXYADAMANTAN-1- YL)ACETYL)-2-AZABICYCLO[3.1.0]HEXANE-3-CARBONITRILE (IUPAC), OR BMS-477118
3WQH	;	2.85	;	Crystal Structure of human DPP-IV in complex with Anagliptin
4LKO	;	2.43	;	Crystal structure of human DPP-IV in complex with BMS-744891
5J3J	;	2.75	;	Crystal Structure of human DPP-IV in complex with HL1
5ZID	;	3.0	;	Crystal Structure of human DPP-IV in complex with HL2
3NOX	;	2.338	;	Crystal structure of human DPP-IV in complex with Sa-(+)-(6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidin-2-yl)(morpholino)methanone
3SWW	;	2.0	;	Crystal structure of human dpp-iv in complex with sa-(+)-3-(aminomethyl)-4-(2,4-dichlorophenyl)-6-(2-methoxyphenyl)- 2-methyl-5h-pyrrolo[3,4-b]pyridin-7(6h)-one
3SX4	;	2.6	;	Crystal structure of human dpp-iv in complex with sa-(+)-3-(aminomethyl)-4-(2,4-dichlorophenyl)-6-(2-methoxyphenyl)- 2-methyl-5h-pyrrolo[3,4-b]pyridin-7(6h)-one
3Q0T	;	2.401	;	Crystal structure of human dpp-iv in complex withsa-(+)- methyl2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl- 7-oxo-5h-pyrrolo[3,4-b]pyridin-6(7h)-yl)acetate
3O95	;	2.85	;	Crystal Structure of Human DPP4 Bound to TAK-100
3OPM	;	2.72	;	Crystal Structure of Human DPP4 Bound to TAK-294
3O9V	;	2.75	;	Crystal Structure of Human DPP4 Bound to TAK-986
3CCB	;	2.49	;	Crystal Structure of Human DPP4 in complex with a benzimidazole derivative
3CCC	;	2.71	;	Crystal Structure of Human DPP4 in complex with a benzimidazole derivative
4A5S	;	1.62	;	CRYSTAL STRUCTURE OF HUMAN DPP4 IN COMPLEX WITH A NOVAL HETEROCYCLIC DPP4 INHIBITOR
5Y7K	;	2.512	;	Crystal structure of human DPP4 in complex with inhibitor1
5Y7J	;	2.521	;	Crystal structure of human DPP4 in complex with inhibitor2
5Y7H	;	3.0	;	Crystal structure of human DPP4 in complex with inhibitor3
1PQ2	;	2.7	;	Crystal Structure of Human Drug Metabolizing Cytochrome P450 2C8
1QBG	;	2.3	;	CRYSTAL STRUCTURE OF HUMAN DT-DIAPHORASE (NAD(P)H OXIDOREDUCTASE)
6APX	;	2.491	;	Crystal structure of human dual specificity phosphatase 1 catalytic domain (C258S) as a maltose binding protein fusion in complex with the monobody YSX1
2WGP	;	1.88	;	Crystal structure of human dual specificity phosphatase 14
3CEK	;	2.3	;	Crystal structure of human dual specificity protein kinase (TTK)
3H9F	;	2.6	;	Crystal Structure of Human Dual Specificity Protein Kinase (TTK) in complex with a pyrimido-diazepin ligand
3GFW	;	2.74	;	Crystal Structure of Human Dual Specificity Protein Kinase (TTK) in complex with a pyrolo-pyridin ligand
2ESB	;	2.0	;	Crystal structure of human DUSP18
5Y15	;	2.1	;	Crystal structure of human DUSP28
5Y16	;	2.399	;	Crystal structure of human DUSP28(Y102H)
2G6Z	;	2.7	;	Crystal structure of human DUSP5
5H4J	;	1.8	;	Crystal structure of Human dUTPase in complex with N-[(1R)-1-[3-(Cyclopentyloxy)-phenyl]-ethyl]-3-[(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)methoxy]-1-propanesulfonamide
5ZFW	;	2.103	;	Crystal structure of human DUX4 homeodomains bound to A11G DNA mutant
5ZFY	;	2.3	;	Crystal structure of human DUX4 homeodomains bound to A12C DNA mutant
5ZFZ	;	1.9	;	Crystal structure of human DUX4 homeodomains bound to A12T DNA mutant
5Z6Z	;	2.301	;	Crystal structure of human DUX4 homeodomains bound to DNA
2HZ5	;	2.1	;	Crystal structure of human dynein light chain Dnlc2A
7OY6	;	2.38	;	Crystal structure of human DYRK1A in complex with ARN25068
6A1F	;	1.5	;	Crystal structure of human DYRK1A in complex with compound 14
6A1G	;	2.15	;	Crystal structure of human DYRK1A in complex with compound 32
4ZTE	;	2.13	;	Crystal structure of human E-Cadherin (residues 3-213) in complex with a peptidomimetic inhibitor
4ZT1	;	1.92	;	Crystal structure of human E-Cadherin (residues 3-213) in x-dimer conformation
6VEL	;	2.65	;	Crystal Structure of Human E-cadherin bound by mouse monoclonal antibody 66E8Fab
6CXY	;	2.2	;	Crystal Structure of Human E-cadherin bound by mouse monoclonal antibody Fab mAb-1_19A11
7STZ	;	2.95	;	Crystal Structure of Human E-cadherin EC1-5 bound by mouse monoclonal antibody Fab mAb-1_19A11
4N12	;	1.478	;	Crystal structure of human E18D DJ-1 in complex with Cu
3GJO	;	2.5	;	Crystal structure of human EB1 in complex with microtubule Tip localization signal peptide of MACF
2DH2	;	2.1	;	Crystal Structure of human ED-4F2hc
2DH3	;	2.8	;	Crystal Structure of human ED-4F2hc
7X9G	;	2.8	;	Crystal structure of human EDA and EDAR
3D3J	;	2.8	;	Crystal structure of human Edc3p
3D3K	;	2.2	;	Crystal structure of human Edc3p
7KXT	;	2.15	;	Crystal structure of human EED
8QZZ	;	3.35	;	Crystal structure of human eIF2 alpha-gamma complexed with PPP1R15A_420-452
3ECS	;	2.65	;	Crystal structure of human eIF2B alpha
1RZ4	;	2.1	;	Crystal Structure of Human eIF3k
7Y4A	;	1.6	;	Crystal structure of human ELMO1 RBD-RhoG complex
6Y7F	;	2.052	;	Crystal structure of human ELOVL fatty acid elongase 7 (ELOVL7)
1Y4M	;	1.6	;	Crystal structure of human endogenous retrovirus HERV-FRD envelope protein (syncitin-2)
1TDH	;	2.1	;	Crystal structure of human endonuclease VIII-like 1 (NEIL1)
5Y7D	;	1.71	;	Crystal structure of human Endothelial-overexpressed LPS associated factor 1
6LRY	;	3.0	;	Crystal structure of human endothelin ETB receptor in complex with sarafotoxin S6b
4NSP	;	2.3	;	Crystal structure of human ENDOV
3B97	;	2.2	;	Crystal Structure of human Enolase 1
1ZS9	;	1.7	;	Crystal structure of human enolase-phosphatase E1
1YNS	;	1.7	;	Crystal Structure Of Human Enolase-phosphatase E1 and its complex with a substrate analog
2VX2	;	2.3	;	Crystal structure of human enoyl Coenzyme A hydratase domain- containing protein 3 (ECHDC3)
4LR2	;	1.5	;	Crystal Structure of Human ENPP4 (apo)
4LQY	;	1.54	;	Crystal Structure of Human ENPP4 with AMP
3VBS	;	3.0	;	Crystal structure of human Enterovirus 71
4AED	;	3.8	;	Crystal structure of Human enterovirus 71
4CEW	;	2.75	;	Crystal structure of human Enterovirus 71 in complex with the uncoating inhibitor ALD
4CDX	;	2.8	;	Crystal structure of human Enterovirus 71 in complex with the uncoating inhibitor GPP12
4CDQ	;	2.65	;	Crystal structure of human Enterovirus 71 in complex with the uncoating inhibitor GPP2
4CDU	;	2.8	;	Crystal structure of human Enterovirus 71 in complex with the uncoating inhibitor GPP3
4CDW	;	2.8	;	Crystal structure of human Enterovirus 71 in complex with the uncoating inhibitor GPP4
4CEY	;	2.75	;	Crystal structure of human Enterovirus 71 in complex with the uncoating inhibitor NLD
4WM8	;	2.0	;	Crystal Structure of Human Enterovirus D68
5BNP	;	2.15	;	Crystal structure of human enterovirus D68 in complex with 3'SLN
5BNN	;	2.32	;	Crystal structure of human enterovirus D68 in complex with 6'SL
5BNO	;	2.15	;	Crystal structure of human enterovirus D68 in complex with 6'SLN
4WM7	;	2.32	;	Crystal Structure of Human Enterovirus D68 in Complex with Pleconaril
5ZIT	;	3.196	;	Crystal structure of human Enterovirus D68 RdRp in complex with NADPH
5ZIU	;	2.147	;	Crystal structure of human Entervirus D68 RdRp
4QMD	;	1.601	;	Crystal structure of human envoplakin plakin repeat domain
8F5X	;	1.7	;	Crystal structure of human eosinophil-derived neurotoxin (EDN, ribonuclease 2) in complex with 5'-adenosine monophosphate (AMP)
8QQY	;	1.8	;	Crystal structure of human Ephrin type-A receptor 2 (EPHA2) Kinase domain in complex with JG165
8BK0	;	1.7	;	Crystal structure of human Ephrin type-A receptor 2 (EPHA2) Kinase domain in complex with LDN-211904
8BIN	;	1.5	;	Crystal structure of human Ephrin type-A receptor 2 (EPHA2) Kinase domain in complex with MR21
8BIO	;	1.6	;	Crystal structure of human Ephrin type-A receptor 2 (EPHA2) Kinase domain in complex with MRAL5
4LKT	;	2.57	;	Crystal Structure of Human Epidermal Fatty Acid Binding Protein (FABP5) in Complex with Linoleic Acid
1JL9	;	3.0	;	Crystal Structure of Human Epidermal Growth Factor
1MOX	;	2.5	;	Crystal Structure of Human Epidermal Growth Factor Receptor (residues 1-501) in complex with TGF-alpha
4B4O	;	2.7	;	Crystal Structure of human epimerase family protein SDR39U1 (isoform2) with NADPH
5E8D	;	2.5	;	Crystal structure of human epiregulin in complex with the Fab fragment of murine monoclonal antibody 9E5
4N40	;	3.106	;	Crystal structure of human Epithelial cell-transforming sequence 2 protein
2QY7	;	2.0	;	Crystal structure of human epsinR ENTH domain
6Y4L	;	2.2	;	Crystal structure of human ER membrane protein complex subunits EMC2 and EMC9
3E1Y	;	3.8	;	Crystal structure of human eRF1/eRF3 complex
2XRI	;	2.15	;	Crystal structure of human ERI1 exoribonuclease 3
2Y9Q	;	1.55	;	Crystal structure of human ERK2 complexed with a MAPK docking peptide
3TEI	;	2.404	;	Crystal structure of human ERK2 complexed with a MAPK docking peptide
4FMQ	;	2.098	;	Crystal structure of human ERK2 complexed with a MAPK docking peptide
4H3P	;	2.3	;	Crystal structure of human ERK2 complexed with a MAPK docking peptide
4H3Q	;	2.2	;	Crystal structure of human ERK2 complexed with a MAPK docking peptide
1WZY	;	2.5	;	Crystal structure of human ERK2 complexed with a pyrazolopyridazine derivative
7E75	;	2.481	;	Crystal structure of human ERK2 mutant (G37C)
7E73	;	2.28	;	Crystal structure of human ERK2 mutant (Y36H)
4F9Z	;	2.2	;	Crystal Structure of human ERp27
2R2J	;	2.6	;	crystal structure of human ERp44
5GU6	;	2.0	;	Crystal structure of Human ERp44 form I
5GU7	;	2.05	;	Crystal Structure of human ERp44 form II
6I65	;	1.5	;	Crystal structure of human ERRg LBD in complex with 4-iso-propylphenol
6I66	;	1.6	;	Crystal structure of human ERRg LBD in complex with 4-sec-butylphenol
6I63	;	2.229	;	Crystal structure of human ERRg LBD in complex with bisphenol-A
6I61	;	1.65	;	Crystal structure of human ERRg LBD in complex with bisphenol-B
6I64	;	1.91	;	Crystal structure of human ERRg LBD in complex with bisphenol-E
6I62	;	1.65	;	Crystal structure of human ERRg LBD in complex with HPTE
6I67	;	1.75	;	Crystal structure of human ERRg LBD in complex with tetrahydro-2-naphtol
1T8P	;	2.5	;	Crystal structure of Human erythrocyte 2,3-bisphosphoglycerate mutase
1QQW	;	2.75	;	CRYSTAL STRUCTURE OF HUMAN ERYTHROCYTE CATALASE
3F57	;	2.9	;	Crystal structure of human erythroid beta spectrin repeats 14 and 15 (ankyrin binding domain)
1EER	;	1.9	;	CRYSTAL STRUCTURE OF HUMAN ERYTHROPOIETIN COMPLEXED TO ITS RECEPTOR AT 1.9 ANGSTROMS
3FCX	;	1.5	;	Crystal structure of human esterase D
3Q95	;	2.05	;	Crystal structure of human estrogen receptor alpha LBD in complex with GRIP peptide and estriol
3HLV	;	3.0	;	Crystal structure of human Estrogen Receptor Alpha Ligand-Binding Domain in complex with a Glucocorticoid Receptor Interacting Protein 1 Nr Box II Peptide and 16-alpha-hydroxy-estrone ((8S,9R,13S,14R,16R)-3,16-dihydroxy-13-methyl-7,8,9,11,12,14,15, 16-octahydro-6H-cyclopenta[a]phenanthren-17-one
3L03	;	1.896	;	Crystal Structure of human Estrogen Receptor alpha Ligand-Binding Domain in complex with a Glucocorticoid Receptor Interacting Protein 1 Nr Box II peptide and Estetrol (Estra-1,3,5(10)-triene-3,15 alpha,16alpha,17beta-tetrol)
3HM1	;	2.33	;	Crystal structure of human Estrogen Receptor Alpha Ligand-Binding Domain in complex with a Glucocorticoid Receptor Interacting Protein 1 Nr Box II Peptide and estrone ((8R,9S,13S,14S)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one)
4JVM	;	1.994	;	Crystal structure of human estrogen sulfotransferase (SULT1E1) in complex with inactive cofactor PAP and brominated flame retardant TBBPA (tetrabromobisphenol A)
4JVL	;	1.943	;	Crystal structure of human estrogen sulfotransferase (SULT1E1) in complex with inactive cofactor PAP and estradiol (E2)
4JVN	;	2.05	;	Crystal structure of human estrogen sulfotransferase (SULT1E1) in complex with inactive cofactor PAP and metabolite of brominated flame retardant 3OH BDE47 (3-hydroxyl bromodiphenyl ether)
1G3M	;	1.7	;	CRYSTAL STRUCTURE OF HUMAN ESTROGEN SULFOTRANSFERASE IN COMPLEX WITH IN-ACTIVE COFACTOR PAP AND 3,5,3',5'-TETRACHLORO-BIPHENYL-4,4'-DIOL
1HY3	;	1.8	;	CRYSTAL STRUCTURE OF HUMAN ESTROGEN SULFOTRANSFERASE V269E MUTANT IN THE PRESENCE OF PAPS
2PJL	;	2.3	;	Crystal Structure of Human Estrogen-Related Receptor alpha in Complex with a Synthetic Inverse Agonist reveals its Novel Molecular Mechanism
2ZBS	;	1.8	;	Crystal structure of human estrogen-related receptor gamma ligand binding domain apo form
2ZAS	;	2.0	;	Crystal structure of human estrogen-related receptor gamma ligand binding domain complex with 4-alpha-cumylphenol, a bisphenol A derivative
2E2R	;	1.6	;	Crystal structure of human estrogen-related receptor gamma ligand binding domain complex with bisphenol A
2ZKC	;	1.7	;	Crystal structure of human estrogen-related receptor gamma ligand binding domain complex with bisphenol Z
6K3N	;	1.97	;	Crystal structure of human estrogen-related receptor gamma ligand binding domain complex with BPA-monoF
1QYW	;	1.63	;	Crystal structure of human estrogenic 17beta-hydroxysteroid dehydrogenase complex with androstanedione and NADP
1QYX	;	1.89	;	Crystal structure of human estrogenic 17beta-hydroxysteroid dehydrogenase complex with androstenedione and NADP
1QYV	;	1.81	;	Crystal structure of human estrogenic 17beta-hydroxysteroid dehydrogenase complex with NADP
6IGK	;	2.0	;	Crystal Structure of human ETB receptor in complex with Endothelin-3
6IGL	;	2.7	;	Crystal Structure of human ETB receptor in complex with IRL1620
8DYS	;	1.8	;	Crystal structure of human Eukaryotic translation initiation factor 2A (eIF2A)
3CPF	;	2.5	;	Crystal structure of human eukaryotic translation initiation factor EIF5A
5V07	;	2.15	;	Crystal structure of human exonuclease 1 Exo1 (D173A) in complex with 5' recessed-end DNA (rV)
5V08	;	2.812	;	Crystal structure of human exonuclease 1 Exo1 (D173A) in complex with 5' recessed-end DNA (rVI)
3QE9	;	2.51	;	Crystal structure of human exonuclease 1 Exo1 (D173A) in complex with DNA (complex I)
5V09	;	2.75	;	Crystal structure of human exonuclease 1 Exo1 (D225A) in complex with 5' recessed-end DNA (rVII)
5V0A	;	2.38	;	Crystal structure of human exonuclease 1 Exo1 (D225A) in complex with 5' recessed-end DNA (rVIII)
7MXX	;	2.85	;	Crystal structure of human exonuclease 1 Exo1 (R92A) in complex with 5' flap DNA (uf4)
7MXU	;	3.042	;	Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' flap DNA (cf2)
5V0C	;	2.58	;	Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' flap DNA (f2I)
5V0D	;	2.63	;	Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' flap DNA (f2II)
5V0E	;	2.744	;	Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' flap DNA (f5I)
7MXW	;	2.836	;	Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' flap DNA (uf1)
7MXT	;	3.048	;	Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' recessed-end DNA (cmr)
7MXS	;	2.798	;	Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' recessed-end DNA (cr)
7MXQ	;	3.23	;	Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' recessed-end DNA (r-1)
7MXR	;	3.101	;	Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' recessed-end DNA (r-2)
5UZV	;	2.45	;	Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' recessed-end DNA (rI)
5V04	;	2.65	;	Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' recessed-end DNA (rII)
5V05	;	2.902	;	Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' recessed-end DNA (rIII)
5V06	;	2.75	;	Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' recessed-end DNA (rIV)
5V0B	;	2.63	;	Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' recessed-end DNA (rIX)
7MXV	;	2.211	;	Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' recessed-end DNA (ur)
3QEA	;	3.1	;	Crystal structure of human exonuclease 1 Exo1 (WT) in complex with DNA (complex II)
3QEB	;	3.0	;	Crystal structure of human exonuclease 1 Exo1 (WT) in complex with DNA and Mn2+ (complex III)
2JLP	;	1.7	;	Crystal structure of human extracellular copper-zinc superoxide dismutase.
4RM9	;	2.0	;	Crystal structure of human ezrin in space group C2221
4RM8	;	1.9	;	Crystal structure of human ezrin in space group P21
2ZOT	;	2.7	;	Crystal structure of human F-spondin reeler domain (fragment 1)
2ZOU	;	1.45	;	Crystal structure of human F-spondin reeler domain (fragment 2)
1XMI	;	2.25	;	Crystal structure of human F508A NBD1 domain with ATP
5J3D	;	4.077	;	Crystal structure of human Fab 14N4 in complex with post-fusion RSV F
7T1X	;	2.6	;	Crystal structure of human Fab A194-01 in complex with its synthetic heptasaccharide Ara6-Man epitope (BSI110888)
7T1W	;	2.45	;	Crystal structure of human Fab A194-01 in complex with its synthetic tetrasaccharide Ara4 epitope (BSI110886)
4OCR	;	1.895	;	Crystal structure of human Fab CAP256-VRC26.01, a potent V1V2-directed HIV-1 neutralizing antibody
4OD1	;	2.69	;	Crystal structure of human Fab CAP256-VRC26.03, a potent V1V2-directed HIV-1 neutralizing antibody
4ORG	;	3.121	;	Crystal structure of human Fab CAP256-VRC26.04, a potent V1V2-directed HIV-1 neutralizing antibody
4OCW	;	3.001	;	Crystal structure of human Fab CAP256-VRC26.06, a potent V1V2-directed HIV-1 neutralizing antibody
4OD3	;	2.616	;	Crystal structure of human Fab CAP256-VRC26.07, a potent V1V2-directed HIV-1 neutralizing antibody
4OCS	;	1.901	;	Crystal structure of human Fab CAP256-VRC26.10, a potent V1V2-directed HIV-1 neutralizing antibody
5DT1	;	1.954	;	Crystal structure of human Fab CAP256-VRC26.25, a potent V1V2-directed HIV-1 broadly neutralizing antibody
4ODH	;	2.894	;	Crystal structure of human Fab CAP256-VRC26.UCA, a potent V1V2-directed HIV-1 neutralizing antibody
6P3S	;	4.0	;	Crystal structure of human Fab H5.28 in complex with influenza A H5N1 Vietnam hemagglutinin head domain
6P3R	;	3.0	;	crystal structure of human Fab H5.31 in complex with influenza A H5N1 Vietnam hemagglutinin head domain
3MUG	;	2.49	;	Crystal structure of human Fab PG16, a broadly reactive and potent HIV-1 neutralizing antibody
4RQQ	;	3.1	;	Crystal structure of human Fab PGDM1400, a broadly reactive and potent HIV-1 neutralizing antibody
4JY4	;	2.8	;	Crystal structure of human Fab PGT121, a broadly reactive and potent HIV-1 neutralizing antibody
4JY5	;	1.75	;	Crystal structure of human Fab PGT122, a broadly reactive and potent HIV-1 neutralizing antibody
4JY6	;	2.5	;	Crystal structure of human Fab PGT123, a broadly reactive and potent HIV-1 neutralizing antibody
4R26	;	2.4969	;	Crystal structure of human Fab PGT124, a broadly neutralizing and potent HIV-1 neutralizing antibody
5UY3	;	2.9	;	Crystal structure of human Fab PGT144, a broadly reactive and potent HIV-1 neutralizing antibody
3U1S	;	2.3	;	Crystal structure of human Fab PGT145, a broadly reactive and potent HIV-1 neutralizing antibody
7STR	;	1.5	;	Crystal Structure of Human Fab S24-1063 in the Complex with the N-teminal Domain of Nucleocapsid Protein from SARS CoV-2
7STS	;	2.16	;	Crystal Structure of Human Fab S24-1379 in the Complex with the N-teminal Domain of Nucleocapsid Protein from SARS CoV-2
7N3D	;	1.53	;	Crystal Structure of Human Fab S24-1564 in the complex with the N-terminal Domain of Nucleocapsid protein from SARS CoV-2
7SUE	;	2.9	;	Crystal Structure of Human Fab S24-188 in the complex with the N-teminal Domain of Nucleocapsid protein from SARS CoV-2
7N3C	;	1.82	;	Crystal Structure of Human Fab S24-202 in the complex with the N-terminal Domain of Nucleocapsid protein from SARS CoV-2
7G00	;	2.6	;	Crystal Structure of human FABP1 in complex with 2-[[3-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl]cyclopentene-1-carboxylic acid
7FY8	;	2.23	;	Crystal Structure of human FABP1 in complex with 2-[[4-cyclopropyl-5-methyl-3-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]thiophen-2-yl]carbamoyl]cyclopentene-1-carboxylic acid
7FZQ	;	1.597	;	Crystal Structure of human FABP3 in complex with myristate
7G10	;	1.26	;	Crystal Structure of human FABP4 binding site mutated to that of FABP3 in complex with 1-[(4-chloro-2-phenoxyphenyl)methyl]-4-hydroxypyridin-2-one
7FWM	;	1.17	;	Crystal Structure of human FABP4 binding site mutated to that of FABP3 in complex with 1-[(4-chloro-2-phenylphenyl)methyl]-4-hydroxypyridin-2-one
7FW8	;	1.16	;	Crystal Structure of human FABP4 binding site mutated to that of FABP3 in complex with 6-chloro-2-methyl-4-phenylquinoline-3-carboxylic acid
7FWQ	;	1.2	;	Crystal Structure of human FABP4 binding site mutated to that of FABP3 in complex with 6-chloro-4-(2-chlorophenoxy)-2-methylquinoline-3-carboxylic acid
7FXX	;	1.29	;	Crystal Structure of human FABP4 binding site mutated to that of FABP3 in complex with 6-cyclopentyl-N,5-dimethyl-4-phenyl-N-propan-2-yl-3-(1H-tetrazol-5-yl)pyridin-2-amine
7FZK	;	1.12	;	Crystal Structure of human FABP4 binding site mutated to that of FABP3 in complex with myristate
7FWX	;	1.13	;	Crystal Structure of human FABP4 binding site mutated to that of FABP5
7FZU	;	1.25	;	Crystal Structure of human FABP4 binding site mutated to that of FABP5 in complex with 2-(indole-1-carbonylamino)benzoic acid
7FY4	;	1.51	;	Crystal Structure of human FABP4 binding site mutated to that of FABP5 in complex with 2-benzyl-6-tert-butyl-3-methyl-4-phenyl-5-(1H-tetrazol-5-yl)pyridine
7FY9	;	1.74	;	Crystal Structure of human FABP4 binding site mutated to that of FABP5 in complex with 2-cyclopentyl-4-(4-fluorophenyl)-6-[1-(methoxymethyl)cyclopentyl]-3-methyl-5-(1H-tetrazol-5-yl)pyridine
7G0C	;	1.14	;	Crystal Structure of human FABP4 binding site mutated to that of FABP5 in complex with 2-[2,3-bis[(2-chlorophenyl)methoxy]phenyl]-2-methoxyacetic acid
7G0O	;	1.32	;	Crystal Structure of human FABP4 binding site mutated to that of FABP5 in complex with 2-[[3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dimethylthiophen-2-yl]carbamoyl]cyclohexene-1-carboxylic acid
7FX2	;	1.47	;	Crystal Structure of human FABP4 binding site mutated to that of FABP5 in complex with 2-[[6,6-difluoro-3-(4-methyl-1,3-thiazol-2-yl)-5,7-dihydro-4H-1-benzothiophen-2-yl]carbamoyl]cyclohexene-1-carboxylic acid
7G13	;	1.15	;	Crystal Structure of human FABP4 binding site mutated to that of FABP5 in complex with 4-[[3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl]-3,6-dihydro-2H-pyran-5-carboxylic acid
7G1W	;	1.34	;	Crystal Structure of human FABP4 binding site mutated to that of FABP5 in complex with 5-(3,5-dichloroanilino)-3,3-dimethyl-5-oxopentanoic acid
7FYM	;	1.21	;	Crystal Structure of human FABP4 binding site mutated to that of FABP5 in complex with 5-(3-bromo-4-methylphenyl)-3,3-dimethyl-5-oxopentanoic acid
7FWF	;	1.24	;	Crystal Structure of human FABP4 binding site mutated to that of FABP5 in complex with 5-cyclohexyl-6-(2,2,2-trifluoroethoxy)-2-(trifluoromethyl)pyridine-3-carboxylic acid
7FXS	;	1.25	;	Crystal Structure of human FABP4 binding site mutated to that of FABP5 in complex with 5-phenoxy-6-(2,2,2-trifluoroethoxy)-2-(trifluoromethyl)pyridine-3-carboxylic acid
7G0Z	;	0.84	;	Crystal Structure of human FABP4 binding site mutated to that of FABP5 in complex with 5-[[3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl]-3,6-dihydro-2H-pyran-4-carboxylic acid
7G1P	;	1.28	;	Crystal Structure of human FABP4 binding site mutated to that of FABP5 in complex with 6-chloro-5-fluoro-1H-benzimidazole
7FWV	;	1.45	;	Crystal Structure of human FABP4 binding site mutated to that of FABP5 in complex with 6-cyclopentyl-N,5-dimethyl-4-phenyl-N-propan-2-yl-3-(1H-tetrazol-5-yl)pyridin-2-amine
7FYH	;	1.34	;	Crystal Structure of human FABP4 binding site mutated to that of FABP5 in complex with 6-fluoro-1,3-benzothiazol-2-amine
7G0X	;	1.48	;	Crystal Structure of human FABP4 binding site mutated to that of FABP5 in complex with isoquinolin-3-amine
7FXL	;	1.12	;	Crystal Structure of human FABP4 binding site mutated to that of FABP5 in complex with myristic acid
7G12	;	1.64	;	Crystal Structure of human FABP4 binding site mutated to that of FABP5 in complex with N-methyl-6-(3-methylthiophen-2-yl)-4-phenyl-N-propan-2-yl-3-(1H-tetrazol-5-yl)pyridin-2-amine
7G1M	;	1.34	;	Crystal Structure of human FABP4 binding site mutated to that of FABP5 in complex with rac-(1R,2R)-2-[[3-(3-methyl-1,2,4-oxadiazol-5-yl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl]cyclohexane-1-carboxylic acid
7FZT	;	1.4	;	Crystal Structure of human FABP4 binding site mutated to that of FABP5 in complex with rac-(1R,2S)-2-[(3,4-dichlorobenzoyl)amino]cyclohexane-1-carboxylic acid
7G15	;	1.28	;	Crystal Structure of human FABP4 binding site mutated to that of FABP5 in complex with rac-(1R,2S)-2-[(3,4-dichlorophenoxy)methyl]cyclohexane-1-carboxylic acid
8WDX	;	1.65	;	Crystal structure of human FABP4 complexed with C3
8WE3	;	1.82	;	Crystal structure of human FABP4 complexed with C7
5Y0X	;	1.604	;	Crystal structure of human FABP4 complexed with ligand 2-fluoro-3-((4-methoxynaphthalene)-1-sulfonamido)benzoic acid
5Y0F	;	1.54	;	Crystal structure of human FABP4 complexed with ligand 2-fluoro-5-((4-methoxynaphthalene)-1-sulfonamido) benzoic acid
5Y0G	;	1.542	;	Crystal structure of human FABP4 complexed with ligand 4-Fluoro-3-((4-methoxynaphthalene)-1-sulfonamido) benzoic acid
5Y13	;	1.75	;	Crystal structure of human FABP4 complexed with ligand 5-((4-bromonaphthalene)-1-sulfonamido)pentanoic acid
5Y12	;	1.75	;	Crystal structure of human FABP4 complexed with ligand 5-((4-methoxynaphthalene)-1-sulfonamido)pentanoic acid
7FWS	;	1.1	;	Crystal Structure of human FABP4 covalently modified with 1,2-benzothiazol-3-one
7FVV	;	1.08	;	Crystal Structure of human FABP4 in complex with (1S,2R)-2-[(5-carbamoyl-3-ethoxycarbonyl-4-methyl-2-thienyl)carbamoyl]cyclohexanecarboxylic acid
7FYP	;	1.12	;	Crystal Structure of human FABP4 in complex with (1S,2S)-2-[(1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexyl]oxycarbonylcyclopropane-1-carboxylic acid
7FZN	;	1.12	;	Crystal Structure of human FABP4 in complex with (1S,2S,5R)-3-(2-thiophen-3-ylacetyl)-3-azabicyclo[3.1.0]hexane-2-carboxylic acid
7FYC	;	1.08	;	Crystal Structure of human FABP4 in complex with (2R)-1-[(2-phenylphenyl)carbamoyl]pyrrolidine-2-carboxylic acid
7G0K	;	1.13	;	Crystal Structure of human FABP4 in complex with (2R)-1-[(3,5-dichloro-2-phenylphenyl)carbamoyl]pyrrolidine-2-carboxylic acid
7G0H	;	1.46	;	Crystal Structure of human FABP4 in complex with (2R,3S)-2-(phenoxymethyl)-1-phenyl-pyrrolidine-3-carboxylic acid
7FZX	;	1.07	;	Crystal Structure of human FABP4 in complex with (2S)-6-(4-chlorophenoxy)-2-(4-methylphenoxy)hexanoic acid
7FWW	;	1.05	;	Crystal Structure of human FABP4 in complex with (3-bromophenyl)-[(2Z)-2-phenylimino-1,3-thiazepan-3-yl]methanone
7FXY	;	1.13	;	Crystal Structure of human FABP4 in complex with (4-chlorophenyl)methyl 5-fluoro-2,4-dioxo-1H-pyrimidine-6-carboxylate
7FVZ	;	1.12	;	Crystal Structure of human FABP4 in complex with (E)-6-(5-methoxy-3,6,7-trimethyl-1,2-benzoxazol-4-yl)-4-methyl-hex-4-enoic acid
7FXP	;	1.05	;	Crystal Structure of human FABP4 in complex with (Z)-4-(4-bromo-2-chloroanilino)-4-oxobut-2-enoic acid
7G1F	;	0.91	;	Crystal Structure of human FABP4 in complex with 1-(4-methylphenyl)sulfonyl-3-(8-tricyclo[5.2.1.02,6]decanyl)urea
7FZV	;	2.55	;	Crystal Structure of human FABP4 in complex with 1-[(2,4-dichlorophenyl)methyl]-4-hydroxy-3-[(E)-3-phenylprop-2-enyl]pyridin-2-one
7FWK	;	0.95	;	Crystal Structure of human FABP4 in complex with 1-[(2-chlorophenyl)methyl]pyrrole-2-carboxamide
7FWG	;	1.13	;	Crystal Structure of human FABP4 in complex with 1-[(4-chloro-3-phenoxyphenyl)methyl]-4-hydroxypyridin-2-one
7FXJ	;	1.03	;	Crystal Structure of human FABP4 in complex with 1-[(4-chlorophenyl)methyl]-3,4-dihydroxy-2H-pyrrol-5-one
7FYE	;	1.25	;	Crystal Structure of human FABP4 in complex with 1-[(4-chlorophenyl)methyl]-4-hydroxypyridin-2-one
7G20	;	1.12	;	Crystal Structure of human FABP4 in complex with 1-[(4-methoxyphenyl)methyl]-5-propan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
7G0T	;	1.65	;	Crystal Structure of human FABP4 in complex with 1-[[4-chloro-2-(trifluoromethyl)phenyl]carbamoylamino]cyclopentane-1-carboxylic acid
7G0S	;	1.02	;	Crystal Structure of human FABP4 in complex with 2,3-bis(phenylmethoxy)benzoic acid
7G11	;	1.12	;	Crystal Structure of human FABP4 in complex with 2,4,6-triisopropylbenzenesulfonic acid
7FY5	;	1.12	;	Crystal Structure of human FABP4 in complex with 2,5,5-trimethyl-6,7,8,9-tetrahydrobenzo[7]annulene-3-carboxylic acid
7G05	;	0.95	;	Crystal Structure of human FABP4 in complex with 2,6-dichloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenol
7G17	;	1.05	;	Crystal Structure of human FABP4 in complex with 2-(1H-indol-7-yloxymethyl)-1,3-thiazole-4-carboxylic acid
7G1G	;	1.03	;	Crystal Structure of human FABP4 in complex with 2-(2-hydroxy-3,5,5,8,8-pentamethyl-3,4,4a,6,7,8a-hexahydro-1H-naphthalen-2-yl)acetic acid
7G0Y	;	0.99	;	Crystal Structure of human FABP4 in complex with 2-(2-methoxyanilino)benzoic acid
7FYQ	;	1.12	;	Crystal Structure of human FABP4 in complex with 2-(3,5-ditert-butyl-2-hydroxyphenyl)-3,3,3-trifluoro-2-hydroxypropanoic acid
7G1H	;	1.12	;	Crystal Structure of human FABP4 in complex with 2-(3,5-ditert-butyl-2-hydroxyphenyl)-3,3,3-trifluoro-2-hydroxypropanoic acid
7G08	;	0.99	;	Crystal Structure of human FABP4 in complex with 2-(3-chloro-2-methylanilino)benzoic acid
7FX9	;	1.1	;	Crystal Structure of human FABP4 in complex with 2-(3-cyanoanilino)benzoic acid
7FX1	;	0.99	;	Crystal Structure of human FABP4 in complex with 2-(3-phenyl-4-piperidin-1-ylphenyl)acetic acid
7FXQ	;	1.12	;	Crystal Structure of human FABP4 in complex with 2-(5,6,7,8,9,10-hexahydrobenzo[8]annulen-3-yl)acetic acid
7FZF	;	1.09	;	Crystal Structure of human FABP4 in complex with 2-(6-methyl-4-oxo-5-phenylthieno[2,3-d]pyrimidin-3-yl)butanoic acid
7FXE	;	1.04	;	Crystal Structure of human FABP4 in complex with 2-(9-benzyl-6-methyl-1,2,3,4-tetrahydrocarbazol-1-yl)acetic acid
7FWU	;	1.01	;	Crystal Structure of human FABP4 in complex with 2-(fluoren-9-ylidenemethyl)-4-hydroxy-2,3-dihydropyran-6-one
7FY7	;	1.05	;	Crystal Structure of human FABP4 in complex with 2-(indole-1-carbonylamino)benzoic acid
7FYU	;	1.17	;	Crystal Structure of human FABP4 in complex with 2-benzyl-6-tert-butyl-3-methyl-4-phenyl-5-(1H-tetrazol-5-yl)pyridine
7FXG	;	1.12	;	Crystal Structure of human FABP4 in complex with 2-chloro-4,6-bis(trifluoromethylsulfanyl)phenol
7FY2	;	1.12	;	Crystal Structure of human FABP4 in complex with 2-chloro-5-pyrrol-1-ylbenzoic acid
7FWO	;	1.12	;	Crystal Structure of human FABP4 in complex with 2-cyclohexyl-6-hydroxy-1-benzofuran-3-one
7FW1	;	1.26	;	Crystal Structure of human FABP4 in complex with 2-cyclopentyl-4-(4-fluorophenyl)-6-[1-(methoxymethyl)cyclopentyl]-3-methyl-5-(1H-tetrazol-5-yl)pyridine
7FXB	;	1.12	;	Crystal Structure of human FABP4 in complex with 2-methyl-2-(2,3,4,5,6-pentachlorophenoxy)propanoic acid
7FZ0	;	1.02	;	Crystal Structure of human FABP4 in complex with 2-tert-butyl-6-ethyl-4,5-diphenyl-3-(1H-tetrazol-5-yl)pyridine
7G0M	;	1.05	;	Crystal Structure of human FABP4 in complex with 2-tert-butylsulfanyl-6-phenyl-1H-1,3,5-triazine-4-thione
7FXF	;	0.95	;	Crystal Structure of human FABP4 in complex with 2-[(2-chlorophenoxy)methyl]-1,3-thiazole-4-carboxylic acid
7FXH	;	1.02	;	Crystal Structure of human FABP4 in complex with 2-[(2R)-oxolan-2-yl]-4-phenyl-3-(1H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine
7FXN	;	1.02	;	Crystal Structure of human FABP4 in complex with 2-[(2S)-oxolan-2-yl]-4-phenyl-3-(1H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine
7FW7	;	1.06	;	Crystal Structure of human FABP4 in complex with 2-[(3-chloro-4-fluorophenyl)carbamoyl]cyclohexane-1-carboxylic acid
7FWY	;	1.12	;	Crystal Structure of human FABP4 in complex with 2-[(3-chloro-5,6-dihydrobenzo[b][1]benzothiepin-6-yl)sulfanyl]acetic acid
7FW6	;	1.04	;	Crystal Structure of human FABP4 in complex with 2-[(3-chlorophenoxy)methyl]-4-phenoxycyclohexane-1-carboxylic acid
7FVY	;	1.0	;	Crystal Structure of human FABP4 in complex with 2-[(3-chlorophenyl)methyl]-1,3-thiazole-4-carboxylic acid
7FW9	;	1.0	;	Crystal Structure of human FABP4 in complex with 2-[(3-ethoxycarbonyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)carbamoyl]cyclopentene-1-carboxylic acid
7G1R	;	0.93	;	Crystal Structure of human FABP4 in complex with 2-[(3-ethoxycarbonylthiophen-2-yl)carbamoyl]cyclopentene-1-carboxylic acid
7G1Y	;	0.95	;	Crystal Structure of human FABP4 in complex with 2-[(3-methoxyphenyl)sulfanylmethyl]-1,3-thiazole-4-carboxylic acid
7FYX	;	1.4	;	Crystal Structure of human FABP4 in complex with 2-[(3-phenylthiophen-2-yl)carbamoyl]cyclopentene-1-carboxylic acid
7G1A	;	1.12	;	Crystal Structure of human FABP4 in complex with 2-[(3S)-oxolan-3-yl]oxy-4-phenyl-3-(1H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine
8S1K	;	1.22	;	Crystal Structure of human FABP4 in complex with 2-[1-(methoxymethyl)cyclopentyl]-6-pentyl-4-phenyl-3-(1H-tetrazol-5-yl)-5,6,7,8-tetrahydroquinoline
7G1B	;	1.17	;	Crystal Structure of human FABP4 in complex with 2-[1-[(3-chlorophenyl)methyl]indol-2-yl]cyclopropane-1-carboxylic acid
7FYZ	;	1.13	;	Crystal Structure of human FABP4 in complex with 2-[2,3-bis[(2-chlorophenyl)methoxy]phenyl]-2-methoxyacetic acid
7FVW	;	1.04	;	Crystal Structure of human FABP4 in complex with 2-[2-(3-chlorophenyl)ethyl]-1,3-thiazole-4-carboxylic acid
7FVU	;	1.24	;	Crystal Structure of human FABP4 in complex with 2-[2-(benzothiophen-3-yl)-2,3-dihydrobenzothiophene-3-carbonyl]benzoic acid
7FZ7	;	1.12	;	Crystal Structure of human FABP4 in complex with 2-[2-[(2-chlorophenyl)methyl]-1-hydroxycyclohexyl]acetic acid
7G0J	;	1.08	;	Crystal Structure of human FABP4 in complex with 2-[3-(4-chloro-2-phenoxyphenyl)phenyl]acetic acid
7FZB	;	1.08	;	Crystal Structure of human FABP4 in complex with 2-[5-methyl-2-(1-methylcyclohexyl)-1,3-oxazol-4-yl]acetic acid
7FXR	;	0.99	;	Crystal Structure of human FABP4 in complex with 2-[rac-(9R,10S)-10-benzyl-3,3-dimethyl-1,5-dioxaspiro[5.5]undecan-9-yl]acetic acid
7FZI	;	1.07	;	Crystal Structure of human FABP4 in complex with 2-[[2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid
7G1J	;	1.11	;	Crystal Structure of human FABP4 in complex with 2-[[3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dimethylthiophen-2-yl]carbamoyl]cyclohexene-1-carboxylic acid
7FXU	;	1.96	;	Crystal Structure of human FABP4 in complex with 2-[[3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dimethylthiophen-2-yl]carbamoyl]cyclopentene-1-carboxylic acid
7FZW	;	1.24	;	Crystal Structure of human FABP4 in complex with 2-[[5-bromo-2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid
7G1U	;	1.14	;	Crystal Structure of human FABP4 in complex with 2-[[5-chloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid
7G1S	;	1.08	;	Crystal Structure of human FABP4 in complex with 3-(3,4-dichlorophenyl)-3,7a-dihydro-1H-imidazo[1,5-c][1,3]thiazole-5,7-dione
7FZL	;	1.12	;	Crystal Structure of human FABP4 in complex with 3-(3-chlorophenyl)-4-prop-2-enyl-1H-1,2,4-triazole-5-thione
7FZD	;	1.02	;	Crystal Structure of human FABP4 in complex with 3-(4-chlorophenyl)-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,2]oxazole-5-carboxylic acid
7FWE	;	1.05	;	Crystal Structure of human FABP4 in complex with 3-(4-chlorophenyl)sulfanylbutanoic acid
7FWN	;	1.12	;	Crystal Structure of human FABP4 in complex with 3-(5-methyl-2,3-diphenylindol-1-yl)propanoic acid
7FZJ	;	1.25	;	Crystal Structure of human FABP4 in complex with 3-cyclohexyl-2-ethylsulfanyl-6-hydroxypyrimidin-4-one
7FWP	;	1.03	;	Crystal Structure of human FABP4 in complex with 3-hydroxy-4-[3-(3-methoxyphenyl)propyl]-2-(2-phenylethyl)-2H-furan-5-one
7FW0	;	1.12	;	Crystal Structure of human FABP4 in complex with 3-methyl-2-(2,4,5-trichlorophenyl)sulfanylbutanoic acid
7FZZ	;	1.12	;	Crystal Structure of human FABP4 in complex with 3-[(2,4-dichloro-5-methylphenyl)sulfonylamino]thiophene-2-carboxamide
7G1E	;	1.21	;	Crystal Structure of human FABP4 in complex with 3-[(2-phenylphenoxy)methyl]benzoic acid
7G1V	;	1.02	;	Crystal Structure of human FABP4 in complex with 3-[(2-sulfanylphenyl)carbamoyl]bicyclo[2.2.1]heptane-2-carboxylic acid
7FWR	;	1.12	;	Crystal Structure of human FABP4 in complex with 3-[(3,4-dichlorophenyl)methylsulfanyl]-1,2,4-triazin-5-ol
7G0L	;	1.18	;	Crystal Structure of human FABP4 in complex with 3-[(4-methyl-3-phenoxyphenyl)methyl]-1H-pyrazol-5-ol
7G0P	;	1.02	;	Crystal Structure of human FABP4 in complex with 3-[(4-phenyl-5-sulfanylidene-1,3,4-thiadiazol-2-yl)sulfanyl]propane-1-sulfonic acid
7FZ1	;	0.99	;	Crystal Structure of human FABP4 in complex with 3-[(E)-anilino-(2-oxo-1H-indol-3-ylidene)methyl]sulfanylpropanoic acid
7FWD	;	1.12	;	Crystal Structure of human FABP4 in complex with 3-[1-(4-carbamoylphenyl)-5-(4-fluorophenyl)pyrrol-2-yl]propanoic acid
7FWH	;	1.12	;	Crystal Structure of human FABP4 in complex with 3-[5-(3,5-dichlorophenyl)tetrazol-2-yl]propanoic acid
7FVX	;	1.05	;	Crystal Structure of human FABP4 in complex with 4-(1-methyl-2-phenylindol-3-yl)cyclohexane-1-carboxylic acid
7FX8	;	1.12	;	Crystal Structure of human FABP4 in complex with 4-(2-methylpropyl)-2-phenyl-3-(1H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine
7G18	;	1.12	;	Crystal Structure of human FABP4 in complex with 4-(4-chloro-3-fluorophenoxy)-2-(3,4-dichlorophenyl)-2-methylbutanoic acid
7FZ3	;	1.1	;	Crystal Structure of human FABP4 in complex with 4-(4-chlorophenoxy)benzenesulfinic acid:sodium hydride
7FYF	;	1.02	;	Crystal Structure of human FABP4 in complex with 4-(4-fluorophenyl)-2-piperidin-1-yl-3-(1H-tetrazol-5-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine
7G1K	;	1.12	;	Crystal Structure of human FABP4 in complex with 4-(4-fluorophenyl)sulfanyl-6-methyl-2-phenylpyrimidine-5-carboxylic acid
7G1O	;	1.12	;	Crystal Structure of human FABP4 in complex with 4-chloro-2,5-dimethyl-N-(2-methylpyrazol-3-yl)benzenesulfonamide
7FXZ	;	1.03	;	Crystal Structure of human FABP4 in complex with 4-hexylsulfanyl-1-(3-pyridylmethyl)-6-sulfanyl-1,3,5-triazin-2-one
7G21	;	1.12	;	Crystal Structure of human FABP4 in complex with 4-hydroxy-2-[(E)-2-(2-phenylcyclohexyl)ethenyl]-2,3-dihydropyran-6-one
7FZR	;	1.12	;	Crystal Structure of human FABP4 in complex with 4-hydroxy-6-(2-naphthalen-1-ylethyl)pyran-2-one
7G0R	;	1.03	;	Crystal Structure of human FABP4 in complex with 4-methoxy-1,2-benzoxazol-3-amine
7FZO	;	0.99	;	Crystal Structure of human FABP4 in complex with 4-oxo-3-(2-phenylethyl)-10-oxa-3-azatricyclo[5.2.1.01,5]dec-8-ene-6-carboxylic acid
7G0Q	;	1.02	;	Crystal Structure of human FABP4 in complex with 4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]butanoic acid
7FWZ	;	1.12	;	Crystal Structure of human FABP4 in complex with 4-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-4H-cyclohepta[c]pyrazol-1-yl]butanoic acid
7G07	;	1.61	;	Crystal Structure of human FABP4 in complex with 4-[[3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl]-3,6-dihydro-2H-pyran-5-carboxylic acid
7FZH	;	1.12	;	Crystal Structure of human FABP4 in complex with 4-[[3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-6,6-difluoro-5,7-dihydro-4H-1-benzothiophen-2-yl]carbamoyl]-3,6-dihydro-2H-pyran-5-carboxylic acid
7FXW	;	1.18	;	Crystal Structure of human FABP4 in complex with 5,6-dichloro-3-(2-chlorophenyl)-1H-indole-2-carboxylic acid
7FYY	;	1.12	;	Crystal Structure of human FABP4 in complex with 5,7-bis(trifluoromethylsulfanyl)quinolin-8-ol
7FYR	;	1.05	;	Crystal Structure of human FABP4 in complex with 5-(3,4-dichlorophenyl)-5-methyl-2-sulfanylidene-1,3-diazinane-4,6-dione
7FYO	;	1.12	;	Crystal Structure of human FABP4 in complex with 5-(3,5-dichloroanilino)-3,3-dimethyl-5-oxopentanoic acid
7G0G	;	1.12	;	Crystal Structure of human FABP4 in complex with 5-(3-bromo-4-methylphenyl)-3,3-dimethyl-5-oxopentanoic acid
7FWC	;	1.12	;	Crystal Structure of human FABP4 in complex with 5-(4-chlorophenyl)-2-(hydroxymethylene)cyclohexane-1,3-dione
7G1I	;	1.53	;	Crystal Structure of human FABP4 in complex with 5-(4-chlorophenyl)-6-(2,2,2-trifluoroethoxy)-2-(trifluoromethyl)pyridine-3-carboxylic acid
7FYV	;	0.97	;	Crystal Structure of human FABP4 in complex with 5-(4-chlorophenyl)-9-methyl-3-oxa-4-azatricyclo[5.2.1.02,6]dec-4-ene-8-carboxylic acid
7G0A	;	1.12	;	Crystal Structure of human FABP4 in complex with 5-(6-chloro-4-phenyl-2-piperidin-1-ylquinolin-3-yl)-3H-1,3,4-oxadiazol-2-one
7G06	;	1.26	;	Crystal Structure of human FABP4 in complex with 5-(chloromethyl)-2-phenyl-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one
7FXK	;	1.03	;	Crystal Structure of human FABP4 in complex with 5-benzyl-4-(2,5-dimethylpyrrol-1-yl)-1,2,4-triazole-3-thiol
7FXM	;	1.19	;	Crystal Structure of human FABP4 in complex with 5-cyclohexyl-2-hydroxybenzoic acid
7FWJ	;	1.08	;	Crystal Structure of human FABP4 in complex with 5-cyclohexyl-6-(2,2,2-trifluoroethoxy)-2-(trifluoromethyl)pyridine-3-carboxylic acid
7G1D	;	1.12	;	Crystal Structure of human FABP4 in complex with 5-ethyl-6-(3-methoxyphenyl)-3-methyl-2-sulfanylidene-1H-pyrimidin-4-one
7G0I	;	1.07	;	Crystal Structure of human FABP4 in complex with 5-phenoxy-6-(2,2,2-trifluoroethoxy)-2-(trifluoromethyl)pyridine-3-carboxylic acid
7FYK	;	1.12	;	Crystal Structure of human FABP4 in complex with 5-phenylmethoxy-4-prop-2-enyl-1,2,4-triazole-3-thiol
7FX0	;	1.03	;	Crystal Structure of human FABP4 in complex with 5-[(2-chloroanilino)methyl]-4-ethyl-1,2,4-triazole-3-thiol
7FZC	;	1.12	;	Crystal Structure of human FABP4 in complex with 5-[(2-chlorophenoxy)methyl]-4-propan-2-yl-1,2,4-triazole-3-thiol
7FWL	;	1.12	;	Crystal Structure of human FABP4 in complex with 5-[(3,4-dichlorophenyl)methyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one
7FYJ	;	2.6	;	Crystal Structure of human FABP4 in complex with 5-[(3-chloro-2-methylphenoxy)methyl]-2-phenyl-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one
7FYT	;	1.24	;	Crystal Structure of human FABP4 in complex with 5-[(3-chloro-2-methylphenoxy)methyl]-2-phenyl-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one
7G0U	;	1.12	;	Crystal Structure of human FABP4 in complex with 5-[(3-chlorophenyl)methyl]-6-hydroxy-1-methyl-4-morpholin-4-ylpyrimidin-2-one
7G1Z	;	1.12	;	Crystal Structure of human FABP4 in complex with 5-[(4-chloro-3-phenoxyphenyl)methyl]-1H-tetrazole
7FWA	;	1.07	;	Crystal Structure of human FABP4 in complex with 5-[(4-chloroanilino)methyl]-2-phenyl-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one
7FW2	;	1.12	;	Crystal Structure of human FABP4 in complex with 5-[(4-chlorophenoxy)methyl]-4-prop-2-enyl-1,2,4-triazole-3-thiol
7FYI	;	1.14	;	Crystal Structure of human FABP4 in complex with 5-[(4-chlorophenyl)sulfanylmethyl]-2-methylpyrazol-3-ol
7G19	;	1.04	;	Crystal Structure of human FABP4 in complex with 5-[2-(1H-tetrazol-5-yl)ethyl]-6,7,8,9,10,11-hexahydrocycloocta[b]indole
7FWB	;	1.12	;	Crystal Structure of human FABP4 in complex with 5-[2-(2,4-dichlorophenoxy)phenyl]-1H-tetrazole
7FX5	;	1.12	;	Crystal Structure of human FABP4 in complex with 5-[[3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-6,6-difluoro-5,7-dihydro-4H-1-benzothiophen-2-yl]carbamoyl]-3,6-dihydro-2H-pyran-4-carboxylic acid
7G1L	;	0.98	;	Crystal Structure of human FABP4 in complex with 6-(1,3-benzodioxol-5-ylmethyl)-3-sulfanyl-1,2,4-triazin-5-ol
7FYL	;	1.07	;	Crystal Structure of human FABP4 in complex with 6-(4-chlorophenyl)sulfanyl-2-(4-methylphenyl)sulfanylhexanoic acid
7FZ4	;	1.01	;	Crystal Structure of human FABP4 in complex with 6-(difluoromethyl)-4-isobutyl-5-methoxycarbonyl-2-(trifluoromethyl)pyridine-3-carboxylic acid
7FYG	;	0.94	;	Crystal Structure of human FABP4 in complex with 6-benzyl-2H-1,2,4-triazine-3,5-dithione
7G16	;	1.1	;	Crystal Structure of human FABP4 in complex with 6-bromo-3-hexyl-2-oxo-3,4-dihydro-1H-quinoline-4-carboxylic acid
7FXA	;	1.12	;	Crystal Structure of human FABP4 in complex with 6-bromo-4-hexyl-2-oxo-1,3-dihydroquinoline-4-carboxylic acid
7FZY	;	1.17	;	Crystal Structure of human FABP4 in complex with 6-chloro-4-phenyl-2-piperidin-1-yl-3-(1H-tetrazol-5-yl)quinoline
7FZS	;	1.04	;	Crystal Structure of human FABP4 in complex with 6-chloro-4-[(2-chlorophenyl)methyl]-2-methylquinoline-3-carboxylic acid
7G14	;	1.2	;	Crystal Structure of human FABP4 in complex with 6-cyclopentyl-N,5-dimethyl-4-phenyl-N-propan-2-yl-3-(1H-tetrazol-5-yl)pyridin-2-amine
7G03	;	1.27	;	Crystal Structure of human FABP4 in complex with 6-fluoro-1,3-benzothiazol-2-amine
7G1T	;	1.1	;	Crystal Structure of human FABP4 in complex with 6-methyl-3-phenyl-1,2,4-triazin-5-ol
7FY6	;	1.12	;	Crystal Structure of human FABP4 in complex with 6-phenyl-11H-pyrimido[4,5-c][2]benzazepin-3-amine
7FXC	;	1.12	;	Crystal Structure of human FABP4 in complex with 6-[(3,4-dichlorophenyl)methyl]-5-methyl-1,1-dioxo-1,2,6-thiadiazin-3-one
7G0F	;	1.12	;	Crystal Structure of human FABP4 in complex with 6-[(3-methoxycarbonyl-4-thiophen-2-ylthiophen-2-yl)carbamoyl]cyclohex-3-ene-1-carboxylic acid
7FZP	;	1.12	;	Crystal Structure of human FABP4 in complex with 6-[(4-chlorophenyl)methylsulfanylmethyl]-2-sulfanylidene-1H-pyrimidin-4-one
7FXV	;	0.88	;	Crystal Structure of human FABP4 in complex with 6-[(4-methoxyphenyl)methyl]-2H-1,2,4-triazine-3,5-dithione
7FW3	;	1.08	;	Crystal Structure of human FABP4 in complex with 7-(4-chlorophenyl)-1,2,3,4-tetrahydronaphthalene-1-carboxylic acid
7FYS	;	1.05	;	Crystal Structure of human FABP4 in complex with 7-(4-methoxyphenyl)-1,8-dithia-3-azaspiro[4.5]dec-6-ene-2,4-dione
7G02	;	1.03	;	Crystal Structure of human FABP4 in complex with 7-methoxy-1-(3-methoxyphenyl)naphthalene-2-carboxylic acid
7G09	;	1.05	;	Crystal Structure of human FABP4 in complex with 8-(3-bromophenyl)-7,9-dioxa-1-thia-3-azaspiro[4.5]decane-2,4-dione
6LJS	;	1.75	;	Crystal structure of human FABP4 in complex with a novel inhibitor
6LJT	;	1.45	;	Crystal structure of human FABP4 in complex with a novel inhibitor
6LJU	;	1.5	;	Crystal structure of human FABP4 in complex with a novel inhibitor
6LJV	;	1.401	;	Crystal structure of human FABP4 in complex with a novel inhibitor
6LJW	;	1.4	;	Crystal structure of human FABP4 in complex with a novel inhibitor
6LJX	;	1.75	;	Crystal structure of human FABP4 in complex with a novel inhibitor
7FX6	;	1.05	;	Crystal Structure of human FABP4 in complex with N,N-diethyl-4-pyridin-4-yl-3-(1H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-2-amine
7FXT	;	1.07	;	Crystal Structure of human FABP4 in complex with N-(2,1,3-benzothiadiazol-4-yl)-2,5-dichlorothiophene-3-sulfonamide
7FZM	;	1.05	;	Crystal Structure of human FABP4 in complex with N-(2,4-dichlorophenyl)-2-(2,6-dihydroxypyrimidin-4-yl)acetamide
7FZ9	;	0.96	;	Crystal Structure of human FABP4 in complex with N-methyl-6-(3-methylthiophen-2-yl)-4-phenyl-N-propan-2-yl-3-(1H-tetrazol-5-yl)pyridin-2-amine
7G1N	;	1.55	;	Crystal Structure of human FABP4 in complex with rac-(1R,2R)-2-[[3-(3-methyl-1,2,4-oxadiazol-5-yl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl]cyclohexane-1-carboxylic acid
7FZ6	;	1.09	;	Crystal Structure of human FABP4 in complex with rac-(1R,2S)-2-(phenoxymethyl)cyclohexane-1-carboxylic acid
7FX4	;	1.02	;	Crystal Structure of human FABP4 in complex with rac-(1R,2S)-2-[(3,4-dichlorophenoxy)methyl]cyclohexane-1-carboxylic acid
7G1C	;	1.08	;	Crystal Structure of human FABP4 in complex with rac-(1R,2S)-2-[(3-methylphenoxy)methyl]cyclohexane-1-carboxylic acid
7G0V	;	1.06	;	Crystal Structure of human FABP4 in complex with rac-(1R,2S)-2-[[3-(trifluoromethyl)phenoxy]methyl]cyclohexane-1-carboxylic acid
7FYB	;	1.05	;	Crystal Structure of human FABP4 in complex with rac-(1R,2S,4R)-2-[(3-chlorobenzoyl)amino]-4-phenoxycyclohexane-1-carboxylic acid
7FXI	;	1.51	;	Crystal Structure of human FABP4 in complex with rac-(1R,3S)-2,2-dimethyl-3-[(2-phenylphenyl)carbamoyl]cyclopropane-1-carboxylic acid
7FZ5	;	1.25	;	Crystal Structure of human FABP4 in complex with rac-(2R)-1-[[3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl]pyrrolidine-2-carboxylic acid
7FY3	;	1.12	;	Crystal Structure of human FABP4 in complex with sulfate
7FZ8	;	1.22	;	Crystal Structure of human FABP4 in complex with thieno[2,3-d]pyrimidine-2,4-diamine
7FZ2	;	1.12	;	Crystal Structure of human FABP4 in complex with [3-oxo-5-[4-(trifluoromethyl)phenyl]cyclohexen-1-yl] acetate
7FW4	;	1.44	;	Crystal Structure of human FABP4 soaked with glycerol
7FW5	;	1.15	;	Crystal Structure of human FABP4 with active site mutated to that of FABP3 in complex with palmitate
7FX7	;	1.12	;	Crystal Structure of human FABP4 with binding site mutated to FABP5 in complex with 5-methylsulfanyl-2-[(4-phenylmethoxy-1H-indazol-3-yl)methylsulfanyl]pyrimidin-4-ol
7G1Q	;	1.24	;	Crystal Structure of human FABP5 in complex with (1S,2R)-2-[(5-carbamoyl-3-ethoxycarbonyl-4-methyl-2-thienyl)carbamoyl]cyclohexanecarboxylic acid
7FY0	;	1.34	;	Crystal Structure of human FABP5 in complex with (2R)-1-[(3,5-dichloro-2-phenylphenyl)carbamoyl]pyrrolidine-2-carboxylic acid
7FWI	;	2.0	;	Crystal Structure of human FABP5 in complex with 2-(indole-1-carbonylamino)benzoic acid
7FXD	;	2.44	;	Crystal Structure of human FABP5 in complex with 2-(indole-1-carbonylamino)benzoic acid
7G0E	;	1.11	;	Crystal Structure of human FABP5 in complex with 2-[(3-ethoxycarbonyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)carbamoyl]cyclopentene-1-carboxylic acid
7G01	;	1.17	;	Crystal Structure of human FABP5 in complex with 6-chloro-4-phenyl-2-piperidin-1-ylquinoline-3-carboxylic acid
7FYD	;	1.45	;	Crystal Structure of human FABP5 in complex with 6-chloro-4-phenyl-2-propan-2-ylquinoline-3-carboxylic acid
7G04	;	1.4	;	Crystal Structure of human FABP5 in complex with 7-(4-chlorophenyl)-1,2,3,4-tetrahydronaphthalene-1-carboxylic acid
7G0B	;	1.47	;	Crystal Structure of human FABP5 in complex with 7-bromo-1-methyl-5-phenyl-2,3,4,5-tetrahydro-1-benzazepine-4-carboxylic acid
5L8I	;	1.88	;	crystal structure of human FABP6 apo-protein
5L8O	;	2.39	;	crystal structure of human FABP6 in complex with cholate
5L8N	;	2.12	;	crystal structure of human FABP6 protein with fragment 1
7E25	;	1.6	;	Crystal structure of human FABP7 complexed with palmitic acid
4Z2N	;	1.923	;	Crystal structure of human FACT SPT16 middle domain
1NL0	;	2.2	;	Crystal structure of human factor IX Gla domain in complex of an inhibitory antibody, 10C12
3CDZ	;	3.98	;	Crystal structure of human factor VIII
2P3T	;	1.92	;	Crystal structure of human factor XA complexed with 3-Chloro-4-(2-methylamino-imidazol-1-ylmethyl)-thiophene-2-carboxylic acid [4-chloro-2-(5-chloro-pyridin-2-ylcarbamoyl)-6-methoxy-phenyl]-amide
2P3U	;	1.62	;	Crystal structure of human factor XA complexed with 3-chloro-N-(4-chloro-2-{[(5-chloropyridin-2-yl)amino]carbonyl}-6-methoxyphenyl)-4-[(1-methyl-1H-imidazol-2-yl)methyl]thiophene-2-carboxamide {Pfizer 320663}
8ROM	;	1.69	;	Crystal structure of human FAD synthase PAPS domain in complex with FAD
8RON	;	2.6	;	Crystal structure of human FAD synthase, isoform 2
3O55	;	1.9	;	Crystal structure of human FAD-linked augmenter of liver regeneration (ALR)
7CTP	;	1.8	;	Crystal Structure of Human FAM129B/MINERVA/NIBAN2
7BRQ	;	1.404	;	Crystal structure of human FAM134B LIR fused to human GABARAP
8EXF	;	3.22	;	Crystal structure of human FAM46A-BCCIPa complex at 3.2 angstrom resolution
8EXE	;	3.5	;	Crystal structure of human FAM46A-BCCIPa complex at 3.5 angstrom resolution
8FZB	;	3.35	;	Crystal structure of human FAM86A
2IQC	;	2.4	;	Crystal structure of Human FancF Protein that Functions in the Assembly of a DNA Damage Signaling Complex
2ILR	;	2.0	;	Crystal structure of human Fanconi Anemia protein E C-terminal domain
4RY3	;	2.802	;	Crystal structure of human Fanconi-associated nuclease 1
3CP6	;	1.95	;	Crystal structure of human farnesyl diphosphate synthase (T201A mutant) complexed with Mg and biphosphonate inhibitor
4N1Z	;	2.35	;	Crystal Structure of Human Farnesyl Diphosphate Synthase in Complex with BPH-1222
4GA3	;	2.39	;	Crystal Structure of Human Farnesyl Diphosphate Synthase in Complex with BPH-1260
4RXA	;	2.2	;	Crystal structure of human farnesyl diphosphate synthase in complex with BPH-1358
4P0V	;	2.4	;	Crystal structure of human farnesyl diphosphoate synthase in complex with zoledronate and taxodione
4KFA	;	1.98	;	Crystal structure of human farnesyl pyrophosphate synthase (t201a mutant) complexed with mg and zoledronate
4KPD	;	1.96	;	Crystal Structure of Human Farnesyl Pyrophosphate Synthase (Y204F) Mutant Complexed with Mg, Risedronate and Isopentenyl Pyrophosphate
4KQ5	;	2.4	;	Crystal Structure of Human Farnesyl Pyrophosphate Synthase Mutant (Y204A) Complexed with Mg and Zoledronate
2QIS	;	1.8	;	Crystal structure of human farnesyl pyrophosphate synthase T210S mutant bound to risedronate
1DFC	;	2.9	;	CRYSTAL STRUCTURE OF HUMAN FASCIN, AN ACTIN-CROSSLINKING PROTEIN
2F73	;	2.5	;	Crystal structure of human fatty acid binding protein 1 (FABP1)
4W4N	;	1.8	;	Crystal structure of human Fc at 1.80 A
1OVZ	;	3.0	;	Crystal structure of human FcaRI
1OW0	;	3.1	;	Crystal structure of human FcaRI bound to IgA1-Fc
7YTE	;	3.0	;	crystal structure of human FcmR-D1 bound to IgM C4-domain
3M1B	;	3.1	;	Crystal structure of human FcRn with a dimeric peptide inhibitor
3M17	;	2.6	;	Crystal structure of human FcRn with a monomeric peptide inhibitor
5BJT	;	3.2	;	Crystal structure of human FcRn with a peptide inhibitor at multiple sites
2IDH	;	2.28	;	Crystal Structure of human FE65 WW domain
2OEI	;	1.35	;	Crystal structure of human FE65-WW domain in complex with human Mena peptide
3BKB	;	1.78	;	Crystal structure of human Feline Sarcoma Viral Oncogene Homologue (v-FES)
3CBL	;	1.75	;	Crystal structure of human feline sarcoma viral oncogene homologue (v-FES) in complex with staurosporine and a consensus peptide
4E93	;	1.84	;	Crystal structure of human Feline Sarcoma Viral Oncogene Homologue (v-FES)in complex with TAE684
6KC4	;	1.37	;	Crystal structure of human Fer SH2 domain bound to a phosphopeptide (DEpYENVD)
3P1M	;	2.54	;	Crystal structure of human ferredoxin-1 (FDX1) in complex with iron-sulfur cluster
3KXU	;	1.85	;	Crystal structure of human ferritin FTL498InsTC pathogenic mutant
2Z6M	;	2.72	;	Crystal structure of Human Ferritin H8 as biotemplate for noble metal nanoparticle synthesis
7CK8	;	1.8	;	Crystal structure of human ferritin heavy chain mutant C90S/C102S/C130S
4V6B	;	2.85	;	Crystal structure of human ferritin Phe167SerfsX26 mutant.
1HRK	;	2.0	;	CRYSTAL STRUCTURE OF HUMAN FERROCHELATASE
2PO5	;	2.2	;	Crystal structure of human ferrochelatase mutant with His 263 replaced by Cys
2PO7	;	2.2	;	Crystal structure of human ferrochelatase mutant with His 341 replaced by Cys
2PNJ	;	2.35	;	Crystal structure of human ferrochelatase mutant with Phe 337 replaced by Ala
4CJM	;	2.7	;	Crystal structure of human FGF18
2P23	;	1.8	;	Crystal structure of human FGF19
2P39	;	1.5	;	Crystal structure of human FGF23
7UY0	;	2.55	;	Crystal structure of human Fgr tyrosine kinase in complex with A-419259
7UY3	;	2.99	;	Crystal structure of human Fgr tyrosine kinase in complex with TL02-59
1Q1U	;	1.7	;	Crystal structure of human FHF1b (FGF12b)
5K31	;	2.2	;	Crystal structure of Human fibrillar procollagen type I C-propeptide Homo-trimer
4AE2	;	1.68	;	Crystal structure of Human fibrillar procollagen type III C- propeptide trimer
4AEJ	;	2.21	;	Crystal structure of Human fibrillar procollagen type III C- propeptide trimer
4AK3	;	3.5	;	Crystal structure of Human fibrillar procollagen type III C- propeptide trimer
7SE9	;	1.75	;	Crystal structure of human Fibrillarin in complex with compound 1 from single soak
7SEC	;	1.9	;	Crystal structure of human Fibrillarin in complex with compound 1a
7SEA	;	1.91	;	Crystal structure of human Fibrillarin in complex with compound 2 from cocktail soak
7SEB	;	1.81	;	Crystal structure of human Fibrillarin in complex with compound 2 from single soak
7SED	;	1.9	;	Crystal structure of human Fibrillarin in complex with compound 2a
7SE8	;	1.75	;	Crystal structure of human Fibrillarin in complex with fragment 1 from cocktail soak
7SE7	;	1.75	;	Crystal structure of human Fibrillarin in complex with S-adenosyl-L-methionine
7SE6	;	1.99	;	Crystal structure of human Fibrillarin in ligand-free state
3GHG	;	2.9	;	Crystal Structure of Human Fibrinogen
1Z68	;	2.6	;	Crystal Structure Of Human Fibroblast Activation Protein alpha
3HBW	;	1.9	;	Crystal Structure of Human Fibroblast Growth Factor Homologous Factor 2A (FHF2A), also referred to as Fibroblast Growth Factor 13A (FGF13A)
4F63	;	2.55	;	Crystal structure of Human Fibroblast Growth Factor Receptor 1 Kinase domain in complex with compound 1
4F64	;	2.05	;	Crystal structure of Human Fibroblast Growth Factor Receptor 1 Kinase domain in complex with compound 6
4F65	;	2.26	;	Crystal structure of Human Fibroblast Growth Factor Receptor 1 Kinase domain in complex with compound 8
4NK9	;	2.57	;	Crystal structure of human fibroblast growth factor receptor 1 kinase domain in complex with pyrazolaminopyrimidine 1
4NKA	;	2.19	;	Crystal structure of human fibroblast growth factor receptor 1 kinase domain in complex with pyrazolaminopyrimidine 2
4NKS	;	2.5	;	Crystal structure of human fibroblast growth factor receptor 1 kinase domain in complex with pyrazolaminopyrimidine 3
3CQA	;	1.8	;	Crystal structure of human fibroblast growth factor-1 with mutations Glu81Ala and Lys101Ala
3CRG	;	1.85	;	Crystal structure of human fibroblast growth factor-1 with mutations Glu81Ala, Glu82Asn and Lys101Ala
3CRH	;	2.15	;	Crystal structure of human fibroblast growth factor-1 with mutations Glu81Ser and Lys101Ala
3CRI	;	2.1	;	Crystal structure of human fibroblast growth factor-1 with mutations Glu81Ser, Glu82Asn and Lys101Ala
5MX0	;	2.21	;	Crystal structure of human fibromodulin
3D8B	;	2.0	;	Crystal structure of human fidgetin-like protein 1 in complex with ADP
5JWP	;	2.1	;	Crystal structure of human FIH D201E variant in complex with Zn, alpha-ketoglutarate, and HIF1 alpha peptide.
2WA5	;	1.9	;	Crystal structure of human filamin B actin binding domain at 1.9 Angstroms resolution
4B7L	;	2.05	;	Crystal Structure of Human Filamin B Actin Binding Domain with 1st Filamin Repeat
7OUU	;	1.47	;	Crystal structure of human filamin C domains 14-15
7P0E	;	1.6	;	Crystal structure of human filamin C domains 14-15 cardiovascular disease causing mutation G1676R
7OUV	;	1.8	;	Crystal structure of human filamin C domains 14-15 cardiovascular disease causing mutation S1624L
4MGX	;	3.16	;	Crystal structure of human filamin C domains 4-5 and GPIB alpha cytoplasmic domain complex
3B7X	;	2.1	;	Crystal structure of human FK506-Binding Protein 6
5D75	;	1.83	;	Crystal structure of Human FKBD25 in complex with FK506
6TX7	;	1.13	;	CRYSTAL STRUCTURE OF HUMAN FKBP51 FK1 DOMAIN A19T MUTANT IN COMPLEX WITH 2-PIPERIDONE
6TX4	;	1.06	;	CRYSTAL STRUCTURE OF HUMAN FKBP51 FK1 DOMAIN A19T MUTANT IN COMPLEX WITH 2-PYRIDONE
6TX5	;	1.08	;	CRYSTAL STRUCTURE OF HUMAN FKBP51 FK1 DOMAIN A19T MUTANT IN COMPLEX WITH 4-METHYLIMIDAZOLE
6TX9	;	1.42	;	CRYSTAL STRUCTURE OF HUMAN FKBP51 FK1 DOMAIN A19T MUTANT IN COMPLEX WITH HYDANTOIN
6TX8	;	1.2	;	CRYSTAL STRUCTURE OF HUMAN FKBP51 FK1 DOMAIN A19T MUTANT IN COMPLEX WITH IMIDAZOLE
6TX6	;	0.98	;	CRYSTAL STRUCTURE OF HUMAN FKBP51 FK1 DOMAIN A19T MUTANT IN COMPLEX WITH NICOTINAMIDE
6TXX	;	2.1	;	CRYSTAL STRUCTURE OF HUMAN FKBP51 FK1 DOMAIN A19T MUTANT IN COMPLEX WITH SAFit2
3Q8M	;	2.6	;	Crystal Structure of Human Flap Endonuclease FEN1 (D181A) in complex with substrate 5'-flap DNA and K+
3Q8K	;	2.2001	;	Crystal Structure of Human Flap Endonuclease FEN1 (WT) in complex with product 5'-flap DNA, SM3+, and K+
3Q8L	;	2.319	;	Crystal Structure of Human Flap Endonuclease FEN1 (WT) in complex with substrate 5'-flap DNA, SM3+, and K+
2Q7R	;	4.0	;	Crystal structure of human FLAP with an iodinated analog of MK-591
2Q7M	;	4.25	;	Crystal structure of human FLAP with MK-591
6ANO	;	2.61	;	Crystal structure of human FLASH N-terminal domain
6AOZ	;	2.1	;	Crystal structure of human FLASH N-terminal domain C54S/C83A (Crystal form 1)
6AP0	;	2.581	;	Crystal structure of human FLASH N-terminal domain C54S/C83A (Crystal form 2)
4YC7	;	2.5	;	Crystal structure of human FMNL2 GBD-FH3 Domains bound to Cdc42-GppNHp
4Q9S	;	2.07	;	Crystal Structure of human Focal Adhesion Kinase (Fak) bound to Compound1 (3,5-DIHYDRO[1,2,4]TRIAZINO[3,4-C][1,4]BENZOXAZIN-2(1H)-ONE)
7W7Z	;	2.15	;	Crystal Structure of human Focal Adhesion Targeting (FAT) domain of the Focal Adhesion Kinase
7W8B	;	2.093	;	Crystal Structure of human Focal Adhesion Targeting (FAT) domain of the Focal Adhesion Kinase
4LRH	;	2.8	;	Crystal structure of human folate receptor alpha in complex with folic acid
5IZQ	;	3.6	;	Crystal structure of human folate receptor alpha in complex with novel antifolate AGF183
1XWD	;	2.92	;	Crystal Structure of Human Follicle Stimulating Hormone Complexed with its Receptor
5SSY	;	1.29	;	Crystal Structure of human formylglycine generating enzyme
8ARU	;	1.08	;	Crystal Structure of human formylglycine generating enzyme
2F92	;	2.15	;	Crystal structure of human FPPS in complex with alendronate
5KSX	;	2.65	;	Crystal structure of human FPPS in complex with an allosteric inhibitor AM-02-072
5JUZ	;	2.4	;	Crystal structure of human FPPS in complex with an allosteric inhibitor CL-06-057
5JV0	;	2.4	;	Crystal structure of human FPPS in complex with an allosteric inhibitor CL-08-038
5JV1	;	2.3	;	Crystal structure of human FPPS in complex with an allosteric inhibitor CL-08-066
5JV2	;	2.3	;	Crystal structure of human FPPS in complex with an allosteric inhibitor MIT-01-055
6N7Y	;	2.0	;	Crystal structure of human FPPS in complex with an allosteric inhibitor MIT-01-102
6OAH	;	2.2	;	Crystal structure of human FPPS in complex with an allosteric inhibitor YF-02-78
6OAG	;	2.3	;	Crystal structure of human FPPS in complex with an allosteric inhibitor YF-02-82
6N7Z	;	2.55	;	Crystal structure of human FPPS in complex with an allosteric inhibitor YF-02037
6N82	;	2.0	;	Crystal structure of human FPPS in complex with an allosteric inhibitor YF-02037
6N83	;	2.0	;	Crystal structure of human FPPS in complex with an allosteric inhibitor YF-02037
5YGI	;	2.177	;	Crystal structure of human FPPS in complex with an inhibitor THZ93
5DJP	;	2.4	;	Crystal structure of human FPPS in complex with biaryl compound 5
5DJR	;	2.4	;	Crystal structure of human FPPS in complex with biaryl compound 6
5DJV	;	2.3	;	Crystal structure of human FPPS in complex with biaryl compound 8e
4LPG	;	2.35	;	Crystal structure of human FPPS in complex with CL01131
4LPH	;	2.3	;	Crystal structure of human FPPS in complex with CL03093
5DGN	;	2.08	;	Crystal structure of human FPPS in complex with compound 13
2F94	;	1.94	;	Crystal structure of human FPPS in complex with ibandronate
4NFI	;	1.85	;	Crystal structure of human FPPS in complex with magnesium and JDS05120
4JVJ	;	2.8	;	Crystal structure of human FPPS in complex with magnesium, CL01131, and sulfate
4L2X	;	2.55	;	Crystal structure of human FPPS in complex with magnesium, CL02134, and inorganic pyrophosphate
4NFJ	;	2.05	;	Crystal structure of human FPPS in complex with magnesium, JDS05120, and sulfate
5DGM	;	2.86	;	Crystal structure of human FPPS in complex with monophosphonate compound 7
4NFK	;	1.85	;	Crystal structure of human FPPS in complex with nickel, JDS05120, and sulfate
4XQS	;	2.3	;	Crystal structure of human FPPS in complex with one magnesium ion
2F89	;	2.6	;	Crystal structure of human FPPS in complex with pamidronate
5DIQ	;	2.1	;	Crystal structure of human FPPS in complex with salicylic acid derivative 3a
5DGS	;	2.62	;	Crystal structure of human FPPS in complex with the monophosphonate compound 15
4XQT	;	2.1	;	Crystal structure of human FPPS in complex with three magnesium ions
4QXS	;	1.9	;	Crystal structure of human FPPS in complex with WC01088
4LFV	;	2.0	;	Crystal structure of human FPPS in complex with YS0470 and two molecules of inorganic phosphate
4DEM	;	1.85	;	Crystal structure of human FPPS in complex with YS_04_70
2F8Z	;	2.6	;	Crystal structure of human FPPS in complex with zoledronate and isopentenyl diphosphate
2F9K	;	2.06	;	Crystal structure of human FPPS in complex with Zoledronate and Zn2+
4PVX	;	2.18	;	Crystal structure of human FPPS in complex with [({4-[4-(cyclopropyloxy)phenyl]pyridin-2-yl}amino)methanediyl]bis(phosphonic acid)
4PVY	;	2.05	;	Crystal structure of human FPPS in complex with [({5-[4-(propan-2-yloxy)phenyl]pyridin-3-yl}amino)methanediyl]bis(phosphonic acid)
4H5C	;	2.02	;	Crystal structure of human FPPS in ternary complex with YS0470 and inorganic phosphate
4H5D	;	2.02	;	Crystal structure of human FPPS in ternary complex with YS0470 and inorganic pyrophosphate
4H5E	;	2.04	;	Crystal structure of human FPPS in ternary complex with YS0470 and isopentenyl pyrophosphate
5JA0	;	1.9	;	Crystal structure of human FPPS with allosterically bound FPP
2H43	;	2.7	;	Crystal Structure of Human Fragment D Complexed with Ala-His-Arg-Pro-amide
3S5D	;	1.5	;	Crystal structure of human frataxin variant W155A
3S5F	;	1.5	;	Crystal structure of human frataxin variant W155F
3S5E	;	1.31	;	Crystal structure of human frataxin variant W155R, one of the Friedreich's ataxia point mutations
1G8I	;	1.9	;	CRYSTAL STRUCTURE OF HUMAN FREQUENIN (NEURONAL CALCIUM SENSOR 1)
5CM4	;	2.4	;	Crystal structure of human Frizzled 4 Cysteine-Rich Domain (CRD)
4CXX	;	2.76	;	Crystal structure of human FTO in complex with acylhydrazine inhibitor 16
4CXY	;	2.65	;	Crystal structure of human FTO in complex with acylhydrazine inhibitor 21
6AEJ	;	2.8	;	Crystal structure of human FTO in complex with small-molecule inhibitors
6AK4	;	2.8	;	Crystal structure of human FTO in complex with small-molecule inhibitors
4CXW	;	3.1	;	Crystal structure of human FTO in complex with subfamily-selective inhibitor 12
2NYU	;	1.76	;	Crystal Structure of Human FtsJ homolog 2 (E.coli) protein in complex with S-adenosylmethionine
5HBF	;	1.95	;	Crystal structure of human full-length chitotriosidase (CHIT1)
1TR2	;	2.9	;	Crystal structure of human full-length vinculin (residues 1-1066)
6FUY	;	3.0	;	Crystal structure of human full-length vinculin-T12-A974K (residues 1-1066)
3E04	;	1.95	;	Crystal structure of human fumarate hydratase
5UPP	;	1.8	;	Crystal structure of human fumarate hydratase
3HPT	;	2.19	;	Crystal structure of human FxA in complex with (S)-2-cyano-1-(2-methylbenzofuran-5-yl)-3-(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-yl)guanidine
3ENS	;	2.3	;	Crystal structure of human FXA in complex with methyl (2Z)-3-[(3-chloro-1H-indol-7-yl)amino]-2-cyano-3-{[(3S)-2-oxo-1-(2-oxo-2-pyrrolidin-1-ylethyl)azepan-3-yl]amino}acrylate
3OKI	;	2.0	;	Crystal structure of human FXR in complex with (2S)-2-[2-(4-chlorophenyl)-1H-benzimidazol-1-yl]-N,2-dicyclohexylethanamide
3OMK	;	1.9	;	Crystal structure of human FXR in complex with (2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexyl-N-(2-methylphenyl)ethanamide
3OKH	;	2.5	;	Crystal structure of human FXR in complex with 2-(4-chlorophenyl)-1-[(1S)-1-cyclohexyl-2-(cyclohexylamino)-2-oxoethyl]-1H-benzimidazole-6-carboxylic acid
3OOK	;	2.29	;	Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3,5-difluorobenzoic acid
3OMM	;	2.1	;	Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3-fluorobenzoic acid
3OLF	;	1.9	;	Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3-methylbenzoic acid
3OOF	;	2.29	;	Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)benzoic acid
5Y1J	;	2.0	;	Crystal structure of human FXR in complex with a functional drug ligand
6A60	;	3.05	;	Crystal structure of human FXR/RXR-LBD heterodimer bound to GW4064 and 9cRA and SRC1
6A5Y	;	2.1	;	Crystal structure of human FXR/RXR-LBD heterodimer bound to HNC143 and 9cRA and SRC1
6A5Z	;	2.95	;	Crystal structure of human FXR/RXR-LBD heterodimer bound to HNC180 and 9cRA and SRC1
2XNS	;	3.41	;	Crystal Structure Of Human G alpha i1 Bound To A Designed Helical Peptide Derived From The Goloco Motif Of RGS14
5ZTY	;	2.8	;	Crystal structure of human G protein coupled receptor
8UAP	;	2.5	;	Crystal Structure of Human G Protein-Coupled Receptor Kinase 5 D311N in Complex with CCG273441
8UAQ	;	2.8	;	Crystal Structure of Human G Protein-Coupled Receptor Kinase 5 in Complex with GRL018-21
5FW5	;	1.92	;	Crystal structure of human G3BP1 in complex with Semliki Forest Virus nsP3-25 comprising two FGDF motives
6TA7	;	1.93	;	CRYSTAL STRUCTURE OF HUMAN G3BP1-NTF2 IN COMPLEX WITH HUMAN CAPRIN1-DERIVED SOLOMON MOTIF
7S17	;	2.36	;	Crystal structure of human G3BP1-NTF2 with three mutations- F15W, F33W, and F124W
6JYU	;	1.89	;	Crystal structure of Human G6PD Canton
5KZW	;	2.0	;	Crystal structure of human GAA
5KZX	;	2.0	;	Crystal structure of human GAA
3UNW	;	2.56	;	Crystal Structure of Human GAC in Complex with Glutamate
3UO9	;	2.3	;	Crystal Structure of Human GAC in Complex with Glutamate and BPTES
6UJG	;	3.0	;	Crystal structure of human GAC in complex with inhibitor UPGL00012
6UKB	;	3.0	;	Crystal structure of human GAC in complex with inhibitor UPGL00012
6ULA	;	2.95	;	Crystal structure of human GAC in complex with inhibitor UPGL00012
6ULJ	;	2.69	;	Crystal structure of human GAC in complex with inhibitor UPGL00012
6UMC	;	2.75	;	Crystal structure of human GAC in complex with inhibitor UPGL00012
6UMD	;	2.7	;	Crystal structure of human GAC in complex with inhibitor UPGL00012
6UME	;	2.9	;	Crystal structure of human GAC in complex with inhibitor UPGL00012
6UMF	;	2.68	;	Crystal structure of human GAC in complex with inhibitor UPGL00012
6UJM	;	2.5	;	Crystal structure of human GAC in complex with inhibitor UPGL00013
6UK6	;	2.9	;	Crystal structure of human GAC in complex with inhibitor UPGL00018
6UL9	;	2.5	;	Crystal structure of human GAC in complex with inhibitor UPGL00023
5FI2	;	2.5	;	Crystal structure of human GAC in complex with inhibitor UPGL_00009: 2-phenyl-~{N}-[5-[[(3~{R})-1-[5-(2-phenylethanoylamino)-1,3,4-thiadiazol- 2-yl]pyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]ethanamide
5FI6	;	2.52	;	Crystal structure of human GAC in complex with inhibitor UPGL_00011: 2-phenyl-~{N}-[5-[[(3~{S})-1-[5-(2-phenylethanoylamino)-1,3,4-thiadiazol-2-yl]pyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]ethanamide
5FI7	;	2.5	;	Crystal structure of human GAC in complex with inhibitor UPGL_00015: 2-phenyl-~{N}-[5-[(3~{S})-3-[[5-(2-phenylethanoylamino)-1,3,4-thiadiazol-2-yl]oxy]pyrrolidin-1-yl]-1,3,4-thiadiazol-2-yl]ethanamide
2WAL	;	2.4	;	Crystal Structure of human GADD45gamma
1WUU	;	2.5	;	crystal structure of human galactokinase complexed with MgAMPPNP and galactose
1SO0	;	2.3	;	Crystal structure of human galactose mutarotase complexed with galactose
2A8U	;	1.69	;	Crystal Structure of Human Galactosyltransferase (GTB) Complexed with Beta-Methyl Lactoside
1ZIZ	;	1.49	;	Crystal Structure of Human Galactosyltransferase (GTB) Complexed with Galactose
1ZJP	;	1.59	;	Crystal Structure of Human Galactosyltransferase (GTB) Complexed with Galactose-grease
1ZJ2	;	1.69	;	Crystal Structure of Human Galactosyltransferase (GTB) Complexed with H type I Trisaccharide
1ZJ3	;	1.69	;	Crystal Structure of Human Galactosyltransferase (GTB) Complexed with H type II Trisaccharide
1ZJ0	;	1.67	;	Crystal Structure of Human Galactosyltransferase (GTB) Complexed with Lactose
1ZJ1	;	1.65	;	Crystal Structure of Human Galactosyltransferase (GTB) Complexed with N-acetyllactosamine
3OY8	;	2.19	;	Crystal structure of human galectin-1 in complex with lactobionic acid
6B94	;	1.8	;	Crystal structure of Human galectin-1 in complex with Lactulose
3T2T	;	1.9	;	Crystal structure of human galectin-1 in complex with methyl 2-O-acetyl-3-O-toluoyl-beta-D-talopyranoside
6F83	;	2.2	;	Crystal Structure of Human Galectin-1 in Complex With Thienyl-1,2, 3-triazolyl Thiodigalactoside Inhibitor
3OYW	;	2.5	;	Crystal structure of human galectin-1 in complex with thiodigalactoside
4XBL	;	1.931	;	Crystal Structure of Human Galectin-1 in Complex with Type 1 N-acetyllactosamine
6LJP	;	2.0	;	Crystal structure of human galectin-16
3T1M	;	1.55	;	Crystal structure of human galectin-3 carbohydrate recognition domain in complex with methyl 3-deoxy-2-O-toluoyl-3-N-toluoyl-beta-D-talopyranoside
2NMN	;	2.45	;	Crystal structure of human galectin-3 carbohydrate-recognising domain at 2.45 angstrom resolution
2NMO	;	1.35	;	Crystal structure of human galectin-3 carbohydrate-recognition domain at 1.35 angstrom resolution
2NN8	;	1.35	;	Crystal structure of human galectin-3 carbohydrate-recognition domain with lactose bound, at 1.35 angstrom resolution
5E89	;	1.5	;	Crystal structure of Human galectin-3 CRD in complex with 3-fluophenyl-1,2,3-triazolyl thiodigalactoside inhibitor
5E8A	;	1.5	;	Crystal structure of Human galectin-3 CRD in complex with 4-fluophenyl-1,2,3-triazolyl thiodigalactoside inhibitor
4LBO	;	1.65	;	Crystal structure of Human galectin-3 CRD in complex with a-GM3
7RDO	;	1.99	;	Crystal structure of human galectin-3 CRD in complex with diselenodigalactoside
4R9B	;	1.2	;	Crystal structure of Human galectin-3 CRD in complex with lactose (pH 7.0, PEG 6000)
4R9A	;	1.197	;	Crystal structure of Human galectin-3 CRD in complex with lactose (pH 7.0, PEG4000)
4R9C	;	1.19	;	Crystal structure of Human galectin-3 CRD in complex with lactose (pH 7.5, PEG6000)
4RL7	;	2.0	;	Crystal structure of Human galectin-3 CRD in complex with lactose (pH 7.5, PEG6000)
4R9D	;	1.239	;	Crystal structure of Human galectin-3 CRD in complex with lactose (pH 7.9, PEG6000)
3ZSJ	;	0.86	;	Crystal structure of Human Galectin-3 CRD in complex with Lactose at 0.86 angstrom resolution
6B8K	;	1.28	;	Crystal structure of Human galectin-3 CRD in complex with Lactulose
4LBN	;	1.7	;	Crystal structure of Human galectin-3 CRD in complex with LNnT
4LBM	;	1.55	;	Crystal structure of Human galectin-3 CRD in complex with LNT
7RGY	;	1.337	;	Crystal structure of human galectin-3 CRD in complex with Methyl 2-O-(2-nitro-4-chloro)-benzoyl-3-O-toluoyl-b-D-talopyranoside
7RGZ	;	1.485	;	Crystal structure of human galectin-3 CRD in complex with Methyl 2-O-(2-nitro-4-fluoro)-benzoyl-3-O-toluoyl-b-D-talopyranoside
7RH0	;	1.487	;	Crystal structure of human galectin-3 CRD in complex with Methyl 2-O-(2-nitro-4-trifluoromethyl-benzoyl)-3-O-toluoyl-b-D-talopyranoside
7RGX	;	1.58	;	Crystal structure of human galectin-3 CRD in complex with Methyl 2-O-(2-nitrobenzoyl)-3-O-(4-methylbenzoyl)-b-D-talopyranoside
7RH1	;	1.444	;	Crystal structure of human galectin-3 CRD in complex with Methyl 2-O-(3-nitro-benzoyl)-3-toluoyl-b-D-talopyranoside
5EXO	;	1.502	;	Crystal structure of Human galectin-3 CRD in complex with methyl 2-O-acetyl-3-O-(2H-chromene-3-yl-methyl)-a-D-galactopyranoside inhibitor
6Q0Q	;	1.98601	;	Crystal structure of Human galectin-3 CRD in complex with Methyl 3-O-(1-{3-O-[1-(b-D-galactopyranosyl)-1,2,3-triazol-4-yl]-methyl-b-D-galactopyranosyl}-1,2,3-triazol-4-yl)-methyl-b-D-galactopyranoside
6Q17	;	1.98	;	Crystal structure of Human galectin-3 CRD in complex with Methyl 3-O-[1-(b-D-galactopyranosyl)-1,2,3-triazol-4-yl]-methyl-b-D-galactopyranoside
7RDP	;	1.96	;	Crystal structure of human galectin-3 CRD in complex with selenodigalactoside
5H9R	;	1.58	;	Crystal Structure of Human Galectin-3 CRD in Complex with TAZTDG
5H9P	;	2.04	;	Crystal Structure of Human Galectin-3 CRD in Complex with TD139
5E88	;	1.6	;	Crystal structure of Human galectin-3 CRD in complex with thienyl-1,2,3-triazolyl thiodigalactoside inhibitor
4XBN	;	2.208	;	Crystal Structure of Human Galectin-3 CRD in Complex with Type 1 N-acetyllactosamine
4LBL	;	1.58	;	Crystal structure of Human galectin-3 CRD K176L mutant in complex with a-GM3
4LBK	;	1.6	;	Crystal structure of Human galectin-3 CRD K176L mutant in complex with LNnT
4LBJ	;	1.8	;	Crystal structure of Human galectin-3 CRD K176L mutant in complex with LNT
3ZSK	;	0.9	;	Crystal structure of Human Galectin-3 CRD with glycerol bound at 0.90 angstrom resolution
3T1L	;	1.6	;	Crystal structure of human Galectin-3 in complex with methyl 2-O-acetyl-3-O-toluoyl-beta-D-talopyranoside
8ITX	;	1.12	;	Crystal structure of human Galectin-3 in complex with small molecule inhibitor
8ITZ	;	1.22	;	Crystal structure of human Galectin-3 in complex with small molecule inhibitor
6WAB	;	2.28	;	Crystal structure of human galectin-4 C-terminal carbohydrate recognition domain in complex with galactose derivative
1BKZ	;	1.9	;	CRYSTAL STRUCTURE OF HUMAN GALECTIN-7
6VTO	;	1.69	;	Crystal structure of human Galectin-7 in complex with 4-O-beta-D-Galactopyranosyl-D-glucose
3ZXE	;	1.67	;	Crystal structure of Human Galectin-7 in complex with a galactose- benzylphosphate inhibitor
3GAL	;	1.9	;	CRYSTAL STRUCTURE OF HUMAN GALECTIN-7 IN COMPLEX WITH GALACTOSAMINE
2GAL	;	2.0	;	CRYSTAL STRUCTURE OF HUMAN GALECTIN-7 IN COMPLEX WITH GALACTOSE
4GAL	;	1.95	;	CRYSTAL STRUCTURE OF HUMAN GALECTIN-7 IN COMPLEX WITH LACTOSE
5GAL	;	2.0	;	CRYSTAL STRUCTURE OF HUMAN GALECTIN-7 IN COMPLEX WITH N-ACETYLLACTOSAMINE
5H9S	;	1.821	;	Crystal Structure of Human Galectin-7 in Complex with TAZTDG
5H9Q	;	1.931	;	Crystal Structure of Human Galectin-7 in Complex with TD139
4XBQ	;	2.234	;	Crystal Structure of Human Galectin-7 in Complex with Type 1 N-acetyllactosamine
3NV1	;	1.5	;	Crystal structure of human galectin-9 C-terminal CRD
3NV3	;	1.57	;	Crystal structure of human galectin-9 C-terminal CRD in complex with biantennary oligosaccharide
3NV2	;	2.34	;	Crystal structure of human galectin-9 C-terminal CRD in complex with N-acetyllactosamine
3NV4	;	1.99	;	Crystal structure of human galectin-9 C-terminal CRD in complex with Sialyllactose
2EAL	;	1.85	;	Crystal structure of human galectin-9 N-terminal CRD in complex with Forssman pentasaccharide
2EAK	;	1.97	;	Crystal structure of human galectin-9 N-terminal CRD in complex with lactose
2ZHK	;	1.8	;	Crystal structure of human galectin-9 N-terminal CRD in complex with N-acetyllactosamine dimer (crystal 1)
2ZHL	;	1.75	;	Crystal structure of human galectin-9 N-terminal CRD in complex with N-acetyllactosamine dimer (crystal 2)
2ZHM	;	1.84	;	Crystal structure of human galectin-9 N-terminal CRD in complex with N-acetyllactosamine trimer (crystal 1)
2ZHN	;	1.3	;	Crystal structure of human galectin-9 N-terminal CRD in complex with N-acetyllactosamine trimer (crystal 2)
3WLU	;	1.4	;	Crystal Structure of human galectin-9 NCRD with Selenolactose
6PXU	;	2.007	;	Crystal structure of human GalNAc-T12 bound to a diglycosylated peptide, Mn2+, and UDP
2R2Q	;	1.65	;	Crystal structure of human Gamma-Aminobutyric Acid Receptor-Associated Protein-like 1 (GABARAP1), Isoform CRA_a
3N6W	;	2.0	;	Crystal structure of human gamma-butyrobetaine hydroxylase
3MS5	;	1.82	;	Crystal Structure of Human gamma-butyrobetaine,2-oxoglutarate dioxygenase 1 (BBOX1)
3O2G	;	1.78	;	Crystal Structure of Human gamma-butyrobetaine,2-oxoglutarate dioxygenase 1 (BBOX1)
4CWD	;	1.899	;	CRYSTAL STRUCTURE OF HUMAN GAMMA-BUTYROBETAINE,2-OXOGLUTARATE IN COMPLEX WITH 449, A NOVEL SUBSTRATE
6ETA	;	2.198	;	Crystal Structure of Human Gamma-D crystallin Mutant P23T+R36S at Room Temperature
7P53	;	1.57	;	Crystal Structure of Human gamma-D-crystallin mutant C110M at 1.57 Angstroms resolution
6ETC	;	1.197	;	Crystal Structure of Human gamma-D-crystallin Mutant P23T+R36S at 1.2 Angstroms Resolution
4GDX	;	1.67	;	Crystal Structure of Human Gamma-Glutamyl Transpeptidase--Glutamate complex
3CB2	;	2.303	;	Crystal structure of human gamma-tubulin bound to GDP
1Z5V	;	2.71	;	Crystal structure of human gamma-tubulin bound to GTPgammaS
3RIP	;	2.3	;	Crystal Structure of human gamma-tubulin complex protein 4 (GCP4)
1IU1	;	1.8	;	Crystal structure of human gamma1-adaptin ear domain
7Z1X	;	1.86	;	Crystal structure of human Gasdermin D complexed with nanobodies VHH-2 and VHH-6
1HLG	;	3.0	;	CRYSTAL STRUCTURE OF HUMAN GASTRIC LIPASE
7W41	;	2.952	;	Crystal Structure of Human Gastrin Releasing Peptide Receptor in complex with the antagonist PD176252
4CO7	;	2.0	;	Crystal structure of human GATE-16
5TRL	;	2.299	;	Crystal structure of human GCN5 histone acetyltransferase domain
5TRM	;	2.9	;	Crystal structure of human GCN5 histone acetyltransferase domain
8E6O	;	2.37	;	Crystal structure of human GCN5 histone acetyltransferase domain
8H65	;	3.0	;	Crystal structure of human GCN5 histone acetyltransferase domain bound with butyryl-CoA
8H6D	;	3.26	;	Crystal structure of human GCN5 histone acetyltransferase domain bound with glutaryl-CoA
8H6C	;	2.5	;	Crystal structure of human GCN5 histone acetyltransferase domain bound with malonyl-CoA
8H66	;	2.8	;	Crystal structure of human GCN5 histone acetyltransferase domain bound with propionyl-CoA
7ALM	;	2.8	;	Crystal structure of human GDAP1 at 2.8 Angstrom resolution.
1T2A	;	1.84	;	Crystal structure of human GDP-D-mannose 4,6-dehydratase
6GPK	;	1.47	;	Crystal structure of human GDP-D-mannose 4,6-dehydratase (E157Q) in complex with GDP-Man
6Q94	;	2.8	;	Crystal structure of human GDP-D-mannose 4,6-dehydratase (S156D) in complex with GDP-Man
6GPJ	;	1.94	;	Crystal structure of human GDP-D-mannose 4,6-dehydratase in complex with GDP-4F-Man
6GPL	;	1.76	;	Crystal structure of human GDP-D-mannose 4,6-dehydratase in complex with GDP-4k6d-Man
4BKP	;	2.7	;	Crystal structure of human GDP-L-fucose synthase with bound NADP
4B8Z	;	2.75	;	Crystal structure of human GDP-L-fucose synthase with bound NADP and GDP, rhombohedral crystal form
4B8W	;	2.75	;	Crystal structure of human GDP-L-fucose synthase with bound NADP and GDP, tetragonal crystal form
4BL5	;	2.6	;	Crystal structure of human GDP-L-fucose synthase with bound NADP and product GDP-L-fucose
7P2B	;	3.0	;	Crystal structure of human gelsolin amyloid mutant A551P
3FFK	;	3.0	;	Crystal structure of human Gelsolin domains G1-G3 bound to Actin
2HT6	;	2.4	;	Crystal structure of Human Gem G-domain bound to GDP
5T9J	;	3.00013	;	Crystal Structure of human GEN1 in complex with Holliday junction DNA in the upper interface
6R4V	;	2.202	;	Crystal structure of human geranylgeranyl diphosphate synthase bound to ibandronate
6G32	;	3.281	;	Crystal structure of human geranylgeranyl diphosphate synthase mutant D188Y
6G31	;	3.0	;	Crystal structure of human geranylgeranyl diphosphate synthase mutant D188Y bound to zoledronate
2Q80	;	2.7	;	Crystal structure of human geranylgeranyl pyrophosphate synthase bound to GGPP
4KMT	;	2.1	;	Crystal structure of human germline antibody 5-51/O12
5I15	;	2.6	;	CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV1-69/IGKV1-39
5I16	;	1.9	;	CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV1-69/IGKV3-11
5I17	;	3.3	;	CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV1-69/IGKV3-20
5I18	;	1.92	;	CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV1-69/IGKV4-1
5I19	;	2.8	;	CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV3-23/IGKV1-39
5I1A	;	2.0	;	CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV3-23/IGKV3-11
5I1C	;	2.25	;	CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV3-23/IGKV3-20
5I1D	;	2.0	;	CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV3-23/IGKV4-1
5I1E	;	2.7	;	CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV3-53/IGKV1-39
5I1G	;	2.3	;	CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV3-53/IGKV3-11
5I1H	;	2.222	;	CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV3-53/IGKV3-20
5I1I	;	2.5	;	CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV3-53/IGKV4-1
5I1J	;	2.5	;	CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV5-51/IGKV3-11
5I1K	;	1.65	;	CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV5-51/IGKV3-20
5I1L	;	1.95	;	CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV5-51/IGKV4-1
6R4H	;	2.244	;	Crystal structure of human GFAT-1 G451E
6R4J	;	2.42	;	Crystal structure of human GFAT-1 G451E in complex with UDP-GlcNAc
6R4I	;	2.586	;	Crystal structure of human GFAT-1 G461E
6SVQ	;	2.717	;	Crystal structure of human GFAT-1 G461E after UDP-GlcNAc soaking
6SVO	;	2.328	;	Crystal structure of human GFAT-1 in complex with Glucosamine-6-Phosphate and L-Glu
6R4F	;	2.501	;	Crystal structure of human GFAT-1 in complex with Glucose-6-Phosphate
6R4E	;	2.353	;	Crystal structure of human GFAT-1 in complex with Glucose-6-Phosphate and L-Glu
6SVM	;	2.481	;	Crystal structure of human GFAT-1 in complex with Glucose-6-Phosphate, L-Glu, and UDP-GalNAc
6SVP	;	2.531	;	Crystal structure of human GFAT-1 in complex with Glucose-6-Phosphate, L-Glu, and UDP-GlcNAc
6R4G	;	2.501	;	Crystal structure of human GFAT-1 in complex with UDP-GlcNAc
6ZMK	;	2.382	;	Crystal structure of human GFAT-1 L405R
6ZMJ	;	2.774	;	Crystal structure of human GFAT-1 R203H
7NDL	;	2.223	;	Crystal structure of human GFAT-1 S205D
1O3X	;	2.1	;	Crystal structure of human GGA1 GAT domain
1X79	;	2.41	;	Crystal structure of human GGA1 GAT domain complexed with the GAT-binding domain of Rabaptin5
1JWF	;	2.1	;	Crystal Structure of human GGA1 VHS domain.
1MHQ	;	2.2	;	Crystal Structure Of Human GGA2 VHS Domain
4Z9O	;	2.3	;	Crystal Structure of human GGT1
5V4Q	;	2.2	;	Crystal Structure of human GGT1 in complex with DON
4ZBK	;	2.18	;	Crystal Structure of human GGT1 in complex with GGsTop inhibitor
4ZCG	;	2.22	;	Crystal Structure of human GGT1 in complex with Glutamate (with all atoms of glutamate)
4ZC6	;	2.1	;	Crystal Structure of human GGT1 in complex with Serine Borate
2EHO	;	3.0	;	Crystal structure of human GINS complex
2Q1M	;	2.3	;	Crystal Structure of human GITRL
3B93	;	2.2	;	crystal structure of human GITRL
3B94	;	2.5	;	Crystal structure of human GITRL
2R30	;	3.2	;	Crystal Structure of human GITRL mutant
2R32	;	1.95	;	Crystal Structure of human GITRL variant
1V82	;	1.85	;	Crystal structure of human GlcAT-P apo form
1V84	;	1.82	;	Crystal structure of human GlcAT-P in complex with N-acetyllactosamine, Udp, and Mn2+
1V83	;	1.9	;	Crystal structure of human GlcAT-P in complex with Udp and Mn2+
2D0J	;	2.0	;	Crystal Structure of Human GlcAT-S Apo Form
6B4F	;	2.811	;	Crystal structure of human Gle1 CTD-Nup42 GBM complex
6B4I	;	3.619	;	Crystal structure of human Gle1 CTD-Nup42 GBM-DDX19B(ADP) complex
6B4J	;	3.4	;	Crystal structure of human Gle1 CTD-Nup42 GBM-DDX19B(AMPPNP) complex
4GIX	;	1.8	;	Crystal structure of human GLTP bound with 12:0 disulfatide
4GHS	;	3.2	;	Crystal structure of human GLTP bound with 12:0 disulfatide (orthorombic form; two subunits in asymmetric unit)
4H2Z	;	1.45	;	Crystal structure of human GLTP bound with 12:0 monosulfatide
4GXG	;	2.4	;	Crystal structure of human GLTP bound with 12:0 monosulfatide (orthorhombic form; four subunits in asymmetric unit)
4GJQ	;	2.0	;	Crystal structure of human GLTP bound with 12:0 monosulfatide (orthorhombic form;two subunits in asymmetric unit)
1V4S	;	2.3	;	Crystal structure of human glucokinase
1V4T	;	3.4	;	Crystal structure of human glucokinase
4IXC	;	2.0	;	Crystal structure of Human Glucokinase in complex with a small molecule activator.
3IMX	;	2.0	;	Crystal Structure of human glucokinase in complex with a synthetic activator
4DHY	;	2.38	;	Crystal structure of human glucokinase in complex with glucose and activator
3CXQ	;	2.3	;	Crystal structure of human glucosamine 6-phosphate N-acetyltransferase 1 bound to GlcN6P
3CXP	;	2.01	;	Crystal structure of human glucosamine 6-phosphate N-acetyltransferase 1 mutant E156A
5UKW	;	2.65	;	Crystal structure of human Glucose 6-phosphate Dehydrogenase mutant (A277C) complexed with G6P
7CRZ	;	2.3	;	Crystal structure of human glucose transporter GLUT3 bound with C3361
7SPS	;	2.3	;	Crystal structure of human glucose transporter GLUT3 bound with exofacial inhibitor SA47
3QXM	;	1.65	;	Crystal Structure of Human GluK2 Ligand-Binding Core in Complex with Novel Marine-Derived Toxins, Neodysiherbaine A
4ZW9	;	1.502	;	Crystal structure of human GLUT3 bound to D-glucose in the outward-occluded conformation at 1.5 angstrom
3IWW	;	2.3	;	Crystal structure of human glutamate carboxypeptidase II (GCPII) in a complex with DBIBzL, a urea-based inhibitor
3FEC	;	1.49	;	Crystal structure of human Glutamate Carboxypeptidase III (GCPIII/NAALADase II), pseudo-unliganded
3II0	;	2.05	;	Crystal structure of human Glutamate oxaloacetate transaminase 1 (GOT1)
6LIG	;	2.62	;	Crystal structure of human Glutamate oxaloacetate transaminase 1 (GOT1) in complex with AH
5I94	;	2.983	;	Crystal structure of human glutaminase C in complex with the inhibitor UPGL-00019
3VOY	;	2.2	;	Crystal structure of human glutaminase in apo form
4O7D	;	2.3	;	Crystal structure of human glutaminase in complex DON
3VOZ	;	2.4	;	Crystal structure of human glutaminase in complex with BPTES
3VP2	;	2.7	;	Crystal structure of human glutaminase in complex with inhibitor 2
3VP3	;	2.7	;	Crystal structure of human glutaminase in complex with inhibitor 3
3VP4	;	2.45	;	Crystal structure of human glutaminase in complex with inhibitor 4
3CZD	;	2.4	;	Crystal structure of human glutaminase in complex with L-glutamate
3VP1	;	2.3	;	Crystal structure of human glutaminase in complex with L-glutamate and BPTES
3VP0	;	2.4	;	Crystal structure of human glutaminase in complex with L-glutamine
6LOX	;	3.2	;	Crystal Structure of human glutaminase with macrocyclic inhibitor
2QC8	;	2.6	;	Crystal structure of human glutamine synthetase in complex with ADP and methionine sulfoximine phosphate
2OJW	;	2.05	;	Crystal structure of human glutamine synthetase in complex with ADP and phosphate
6OFB	;	2.84	;	Crystal structure of human glutamine-dependent NAD+ synthetase complexed with NaAD+, AMP, pyrophosphate, and Mg2+
2AFM	;	1.66	;	Crystal structure of human glutaminyl cyclase at pH 6.5
2AFO	;	2.35	;	Crystal structure of human glutaminyl cyclase at pH 8.0
2AFX	;	1.64	;	Crystal structure of human glutaminyl cyclase in complex with 1-benzylimidazole
2AFZ	;	1.68	;	Crystal structure of human glutaminyl cyclase in complex with 1-vinylimidazole
6YI1	;	1.92	;	Crystal structure of human glutaminyl cyclase in complex with Glu(gamma-hydrazide)-Phe-Ala
2AFU	;	2.22	;	Crystal structure of human glutaminyl cyclase in complex with glutamine t-butyl ester
2AFW	;	1.56	;	Crystal structure of human glutaminyl cyclase in complex with N-acetylhistamine
6YJY	;	1.67	;	Crystal structure of human glutaminyl cyclase in complex with neurotensin 1-5
6GBX	;	1.72	;	Crystal structure of human glutaminyl cyclase variant Y115E-Y117E in complex with SEN177
2FLS	;	2.05	;	Crystal structure of Human Glutaredoxin 2 complexed with glutathione
4RQR	;	1.08	;	Crystal Structure of Human Glutaredoxin with MESNA
2R37	;	1.85	;	Crystal structure of human glutathione peroxidase 3 (selenocysteine to glycine mutant)
2I3Y	;	2.0	;	Crystal structure of human glutathione peroxidase 5
2P31	;	2.0	;	Crystal structure of human glutathione peroxidase 7
2GH5	;	1.7	;	Crystal Structure of human Glutathione Reductase complexed with a Fluoro-Analogue of the Menadione Derivative M5
1YJ6	;	2.5	;	crystal structure of human glutathione S-transferase M1A-1A complexed with glutathionyl-zinc-trihydroxide
2PGT	;	1.9	;	CRYSTAL STRUCTURE OF HUMAN GLUTATHIONE S-TRANSFERASE P1-1[V104] COMPLEXED WITH (9R,10R)-9-(S-GLUTATHIONYL)-10-HYDROXY-9,10-DIHYDROPHENANTHRENE
1PGT	;	1.8	;	CRYSTAL STRUCTURE OF HUMAN GLUTATHIONE S-TRANSFERASE P1-1[V104] COMPLEXED WITH S-HEXYLGLUTATHIONE
1PKZ	;	2.1	;	Crystal structure of human glutathione transferase (GST) A1-1
1PL1	;	1.75	;	Crystal structure of human glutathione transferase (GST) A1-1 in complex with a decarboxy-glutathione
1PKW	;	2.0	;	Crystal structure of human glutathione transferase (GST) A1-1 in complex with glutathione
1PL2	;	1.8	;	Crystal structure of human glutathione transferase (GST) A1-1 T68E mutant in complex with decarboxy-glutathione
2A2S	;	1.7	;	Crystal Structure of Human Glutathione Transferase in complex with S-nitrosoglutathione in the absence of reducing agent
3LFL	;	2.1	;	Crystal Structure of human Glutathione Transferase Omega 1, delta 155
6Y1E	;	1.402	;	Crystal structure of human glutathione transferase P1-1 (hGSTP1-1) that was co-crystallised in the presence of indanyloxyacetic acid-94 (IAA-94)
5DAK	;	2.11	;	Crystal Structure of human Glutathione Transferase Pi complexed with a metalloid in the absence of Glutathione
5DAL	;	1.5	;	Crystal Structure of human Glutathione Transferase Pi complexed with a metalloid in the presence of Glutathione
3HJM	;	2.1	;	Crystal structure of human Glutathione Transferase Pi Y108V mutant
4MPG	;	1.951	;	Crystal structure of human glutathione transferase theta-2, complex with glutathione and unknown ligand, target EFI-507257
4MPF	;	2.1	;	Crystal structure of human glutathione transferase theta-2, complex with inorganic phosphate, GSH free, target EFI-507257
2J9H	;	2.4	;	Crystal structure of human glutathione-S-transferase P1-1 cys-free mutant in complex with S-hexylglutathione at 2.4 A resolution
2PLA	;	2.51	;	Crystal structure of human glycerol-3-phosphate dehydrogenase 1-like protein
6I33	;	2.3	;	Crystal structure of human glycine decarboxylase (P-protein)
6I35	;	2.0	;	Crystal structure of human glycine decarboxylase (P-protein) bound with pyridoxyl-glycine-5'-monophosphate
1R74	;	2.55	;	Crystal Structure of Human Glycine N-Methyltransferase
5TIO	;	3.25	;	Crystal Structure of Human Glycine Receptor alpha-3 Bound to AM-3607
5VDH	;	2.85	;	Crystal Structure of Human Glycine Receptor alpha-3 Bound to AM-3607, Glycine, and Ivermectin
5CFB	;	3.04	;	Crystal Structure of Human Glycine Receptor alpha-3 Bound to Strychnine
5TIN	;	2.61	;	Crystal Structure of Human Glycine Receptor alpha-3 Mutant N38Q Bound to AM-3607
5VDI	;	3.1	;	Crystal Structure of Human Glycine Receptor alpha-3 Mutant N38Q Bound to AM-3607, Glycine, and Ivermectin
4BZY	;	2.75	;	Crystal structure of human glycogen branching enzyme (GBE1)
5CLT	;	2.79	;	Crystal structure of human glycogen branching enzyme (GBE1) in complex with acarbose
5CLW	;	2.8	;	Crystal structure of human glycogen branching enzyme (GBE1) in complex with maltoheptaose
3SAY	;	2.231	;	Crystal structure of human glycogen synthase kinase 3 beta (GSK3b) in complex with inhibitor 142
3U2T	;	2.05	;	Crystal Structure of Human Glycogenin-1 (GYG1) complexed with manganese
3U2W	;	1.68	;	Crystal Structure of Human Glycogenin-1 (GYG1) complexed with manganese and glucose or a glucal species
3QVB	;	2.26	;	Crystal Structure of Human Glycogenin-1 (GYG1) complexed with manganese and UDP
3T7N	;	1.98	;	Crystal Structure of Human Glycogenin-1 (GYG1) complexed with manganese and UDP, in a monoclinic closed form
3T7M	;	1.8	;	Crystal Structure of Human Glycogenin-1 (GYG1) complexed with manganese and UDP, in a triclinic closed form
3U2X	;	1.77	;	Crystal Structure of Human Glycogenin-1 (GYG1) complexed with manganese, UDP and 1'-deoxyglucose
3U2V	;	1.5	;	Crystal Structure of Human Glycogenin-1 (GYG1) complexed with manganese, UDP and maltohexaose
3U2U	;	1.45	;	Crystal Structure of Human Glycogenin-1 (GYG1) complexed with manganese, UDP and maltotetraose
3T7O	;	1.85	;	Crystal Structure of Human Glycogenin-1 (GYG1) complexed with manganese, UDP-Glucose and glucose
3RMV	;	1.82	;	Crystal Structure of Human Glycogenin-1 (GYG1) T83M mutant complexed with manganese and UDP
3RMW	;	1.93	;	Crystal Structure of Human Glycogenin-1 (GYG1) T83M mutant complexed with manganese and UDP-glucose
6EQL	;	2.38	;	Crystal Structure of Human Glycogenin-1 (GYG1) Tyr195pIPhe mutant complexed with manganese and UDP
6EQJ	;	2.18	;	Crystal Structure of Human Glycogenin-1 (GYG1) Tyr195pIPhe mutant, apo form
3Q4S	;	1.98	;	Crystal Structure of Human Glycogenin-1 (GYG1), apo form
4UEG	;	1.93	;	Crystal structure of human glycogenin-2 catalytic domain
2RDT	;	1.95	;	Crystal Structure of Human Glycolate Oxidase (GO) in Complex with CDST
2RDU	;	1.65	;	Crystal Structure of Human Glycolate Oxidase in Complex with Glyoxylate
2RDW	;	1.95	;	Crystal Structure of Human Glycolate Oxidase in Complex with Sulfate
2W0U	;	2.84	;	CRYSTAL STRUCTURE OF HUMAN GLYCOLATE OXIDASE IN COMPLEX WITH THE INHIBITOR 5-[(4-CHLOROPHENYL)SULFANYL]- 1,2,3-THIADIAZOLE-4-CARBOXYLATE.
7M2O	;	2.07	;	Crystal structure of Human Glycolate Oxidase with Inhibitor Compound 15
2EVD	;	2.0	;	Crystal structure of human Glycolipid Transfer Protein complexed with 12:0 Lactosylceramide
2EVL	;	2.2	;	Crystal structure of human Glycolipid Transfer Protein complexed with 18:2 Galactosylceramide
2EUK	;	1.85	;	Crystal Structure of Human Glycolipid Transfer Protein complexed with 24:1 Galactosylceramide
3RZN	;	1.1	;	Crystal Structure of Human Glycolipid Transfer Protein complexed with 3-O-sulfo-galactosylceramide containing nervonoyl acyl chain (24:1)
2EUM	;	2.3	;	Crystal structure of human Glycolipid Transfer Protein complexed with 8:0 Lactosylceramide
3S0K	;	1.4	;	Crystal Structure of Human Glycolipid Transfer Protein complexed with glucosylceramide containing oleoyl acyl chain (18:1)
2EVS	;	2.2	;	Crystal structure of human Glycolipid Transfer Protein complexed with n-hexyl-beta-D-glucoside
1SX6	;	1.95	;	Crystal structure of human Glycolipid Transfer protein in lactosylceramide-bound form
5M3Y	;	2.3	;	Crystal structure of human glycosylated angiotensinogen
6F02	;	3.0	;	Crystal structure of human glycosylated kallistatin at 3.0 Angstrom resolution
2ZT6	;	3.08	;	Crystal structure of human Glycyl-tRNA synthetase (GlyRS) in complex with AMPCPP
2ZXF	;	3.4	;	Crystal structure of human glycyl-trna synthetase (GLYRS) in complex with AP4A (cocrystallized with AP4A)
2ZT5	;	2.5	;	Crystal structure of human glycyl-trna synthetase (GLYRS) in complex with AP4A (cocrystallized with ATP)
2ZT8	;	3.35	;	Crystal structure of human Glycyl-tRNA synthetase (GlyRS) in complex with Gly-AMP analog
2ZT7	;	2.7	;	Crystal structure of human Glycyl-tRNA synthetase (GlyRS) in complex with Glycine and ATP
3ZI1	;	1.9	;	Crystal structure of human glyoxalase domain-containing protein 4 (GLOD4)
2WWR	;	2.82	;	Crystal Structure of Human Glyoxylate Reductase Hydroxypyruvate Reductase
3CXS	;	2.7	;	Crystal structure of human GNA1
5ZIB	;	1.9	;	Crystal structure of human GnT-V luminal domain in apo form
5ZIC	;	2.1	;	Crystal structure of human GnT-V luminal domain in complex with acceptor sugar
7ZL9	;	2.7	;	Crystal structure of human GPCR Niacin receptor (HCA2)
7ZLY	;	2.7	;	Crystal structure of human GPCR Niacin receptor (HCA2) expressed from Spodoptera frugiperda
4PHU	;	2.332	;	Crystal structure of Human GPR40 bound to allosteric agonist TAK-875
5H5Q	;	1.1	;	Crystal structure of human GPX4 in complex with GXpep-1
5H5R	;	1.2	;	Crystal structure of human GPX4 in complex with GXpep-2
5H5S	;	1.85	;	Crystal structure of human GPX4 in complex with GXpep-3
7L8K	;	1.38	;	Crystal structure of human GPX4-U46C
7U4M	;	1.93	;	Crystal structure of human GPX4-U46C in complex with LOC1886
7U4L	;	2.25	;	Crystal structure of human GPX4-U46C in complex with MAC-5576
7U4N	;	1.6	;	Crystal structure of human GPX4-U46C in complex with RSL3
7L8R	;	1.52	;	Crystal structure of human GPX4-U46C mutant K48A
7L8M	;	2.07	;	Crystal structure of human GPX4-U46C mutant K48L
7L8Q	;	1.48	;	Crystal structure of human GPX4-U46C with oxidized Cys-46
7U4I	;	1.97	;	Crystal structure of human GPX4-U46C-R152H in complex with CDS9
7U4K	;	1.69	;	Crystal structure of human GPX4-U46C-R152H in complex with ML162
7U4J	;	1.81	;	Crystal structure of human GPX4-U46C-R152H in complex with TMT10
6GN5	;	1.41	;	CRYSTAL STRUCTURE OF HUMAN GRAMD1C START DOMAIN
1OP8	;	2.5	;	Crystal Structure of Human Granzyme A
1FQ3	;	3.1	;	CRYSTAL STRUCTURE OF HUMAN GRANZYME B
3TK9	;	2.2	;	Crystal structure of human granzyme H
3TJV	;	2.4	;	Crystal structure of human granzyme H with a peptidyl substrate
3TJU	;	2.7	;	Crystal structure of human granzyme H with an inhibitor
5AEJ	;	1.904	;	Crystal structure of human Gremlin-1
8B7H	;	1.95	;	Crystal structure of human Gremlin-1 in complex with Fab
4MF3	;	3.0	;	Crystal Structure of Human GRIK1 complexed with a 6-(tetrazolyl)aryl decahydroisoquinoline antagonist
1WAQ	;	2.28	;	Crystal structure of human Growth and Differentiation Factor 5 (GDF-5)
2BHK	;	2.4	;	Crystal structure of human growth and differentiation factor 5 (GDF5)
5E4G	;	1.5	;	Crystal structure of human growth differentiation factor 11 (GDF-11)
3B9C	;	1.9	;	Crystal Structure of Human GRP CRD
3LDN	;	2.2	;	Crystal structure of human GRP78 (70kDa heat shock protein 5 / BIP) ATPase domain in apo form
5F0X	;	1.6	;	Crystal structure of human GRP78 (70kDa heat shock protein 5 / BIP) ATPase domain in complex with 2'-deoxy-ADP and inorganic phosphate
5EY4	;	1.86	;	Crystal structure of human GRP78 (70kDa heat shock protein 5 / BIP) ATPase domain in complex with 2'-deoxy-ATP
5EX5	;	1.9	;	Crystal structure of human GRP78 (70kDa heat shock protein 5 / BIP) ATPase domain in complex with 7-deaza-ADP and inorganic phosphate
5EXW	;	1.9	;	Crystal structure of human GRP78 (70kDa heat shock protein 5 / BIP) ATPase domain in complex with 7-deaza-ATP
5EVZ	;	1.85	;	Crystal structure of human GRP78 (70kDa heat shock protein 5 / BIP) ATPase domain in complex with ADP and inorganic phosphate
5F2R	;	2.15	;	Crystal structure of human GRP78 (70kDa heat shock protein 5 / BIP) ATPase domain in complex with AMP-PCP
3LDO	;	1.95	;	Crystal structure of human GRP78 (70kDa heat shock protein 5 / BIP) ATPase domain in complex with AMPPNP
3LDL	;	2.3	;	Crystal structure of human GRP78 (70kDa heat shock protein 5 / BIP) ATPase domain in complex with ATP
5F1X	;	1.9	;	Crystal structure of human GRP78 (70kDa heat shock protein 5 / BIP) ATPase domain in complex with ATP
3LDP	;	2.2	;	Crystal structure of human GRP78 (70kDa heat shock protein 5 / BIP) ATPase domain in complex with small molecule inhibitor
6DWS	;	1.9	;	Crystal structure of human GRP78 in complex with (2R,3R,4S,5R)-2-(6-amino-8-((2-chlorobenzyl)amino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
6DO2	;	1.7	;	Crystal structure of human GRP78 in complex with 7-deaza-2'-C-methyladenosine
6DFM	;	2.14	;	Crystal structure of human GRP78 in complex with 8-aminoadenosine
6DFO	;	2.54	;	Crystal structure of human GRP78 in complex with 8-bromoadenosine
6N9O	;	3.5	;	Crystal structure of human GSDMD
7U36	;	2.75	;	Crystal structure of human GSK3B in complex with ARN1484
7U33	;	2.6	;	Crystal structure of human GSK3B in complex with ARN9133
7U2Z	;	2.21	;	Crystal structure of human GSK3B in complex with G12
7U31	;	2.38	;	Crystal structure of human GSK3B in complex with G5
7BIC	;	2.46	;	Crystal structure of human GSTA1-1 bound to allyl-isothiocyanate
6YAW	;	2.19	;	Crystal structure of human GSTA1-1 bound to the glutathione adduct of cinnamaldehyde
7BIB	;	2.03	;	Crystal structure of human GSTA1-1 bound to the glutathione adduct of hexyl-isothiocyanate
7BIA	;	1.73	;	Crystal structure of human GSTP1 bound to iberin
1FB1	;	3.1	;	CRYSTAL STRUCTURE OF HUMAN GTP CYCLOHYDROLASE I
3V70	;	2.206	;	Crystal Structure of Human GTPase IMAP family member 1
3P1J	;	2.58	;	Crystal structure of human GTPase IMAP family member 2 in the nucleotide-free state
3LXX	;	2.15	;	Crystal structure of human GTPase IMAP family member 4
2A7R	;	3.0	;	Crystal structure of human Guanosine Monophosphate reductase 2 (GMPR2)
2BZN	;	2.15	;	Crystal structure of human guanosine monophosphate reductase 2 GMPR2 in complex with IMP
2C6Q	;	1.7	;	Crystal structure of human guanosine monophosphate reductase 2 GMPR2 in complex with IMP and NADPH
2GGZ	;	3.0	;	Crystal Structure of Human Guanylate Cyclase Activating Protein-3
7M1S	;	2.91	;	Crystal structure of human guanylate-binding protein 2 (hGBP2) K51A mutant
1KJY	;	2.7	;	Crystal Structure of Human G[alpha]i1 Bound to the GoLoco Motif of RGS14
2OM2	;	2.2	;	Crystal Structure Of Human G[alpha]i1 Bound To The Goloco Motif Of Rgs14
3AJP	;	1.901	;	Crystal structure of human H ferritin E140A mutant
3AJQ	;	1.58	;	Crystal structure of human H ferritin E140Q mutant
6WYG	;	2.27	;	Crystal structure of Human H-chain Ferritin variant 157C Delta C-star Modified with a RAFT agent
6WYF	;	1.25	;	Crystal structure of Human H-chain Ferritin variant 157C Delta C-star Modified with a RAFT Agent Soaked in an Acrylate Solution
6WYH	;	2.22	;	Crystal structure of Human H-chain Ferritin variant 157C Delta C-star Modified with a RAFT Agent Soaked in an Acrylate Solution
7K26	;	2.7	;	Crystal structure of Human H-chain Ferritin variant infused with Sodium Acrylate
8JAI	;	2.56	;	Crystal Structure of Human H-Ferritin variant 123F assembling in solution 1
8J9L	;	2.5	;	Crystal Structure of Human H-Ferritin variant 123F assembling in solution2
8J9M	;	2.9	;	Crystal Structure of Human H-Ferritin variant 123F assembling in solution3
5UJJ	;	2.1	;	Crystal structure of human H130R tryptophanyl-tRNA synthetase in complex with TrpAMP
3K1Z	;	1.55	;	Crystal Structure of Human Haloacid Dehalogenase-like Hydrolase Domain containing 3 (HDHD3)
8RDK	;	2.0	;	Crystal structure of human Haspin (GSG2) kinase bound to MD420
3IQ7	;	2.0	;	Crystal Structure of human Haspin in complex with 5-Iodotubercidin
3DLZ	;	1.85	;	Crystal structure of human haspin in complex with AMP
3E7V	;	2.0	;	Crystal Structure of Human Haspin with a pyrazolo-pyrimidine ligand
3F2N	;	1.8	;	Crystal Structure of Human Haspin with an Imidazo-pyridazine ligand
3FMD	;	2.0	;	Crystal Structure of Human Haspin with an Isoquinoline ligand
5GK9	;	2.4	;	Crystal structure of human HBO1 in complex with BRPF2
7D0O	;	2.51	;	Crystal structure of human HBO1-BRPF2 in apo form
7D0Q	;	2.21	;	Crystal structure of human HBO1-BRPF2 in complex with butyryl-coenzyme A
7D0R	;	1.95	;	Crystal structure of human HBO1-BRPF2 in complex with crotonoyl-coenzyme A
7D0P	;	1.8	;	Crystal structure of human HBO1-BRPF2 in complex with propionyl-coenzyme A
7D0S	;	2.3	;	Crystal structure of human HBO1-BRPF2 in complex with succinyl-coenzyme A
3MAX	;	2.05	;	Crystal Structure of Human HDAC2 complexed with an N-(2-aminophenyl)benzamide
6G3O	;	2.27	;	Crystal structure of human HDAC2 in complex with (R)-6-[3,4-Dioxo-2-(4-trifluoromethoxy-phenylamino)-cyclobut-1-enylamino]-heptanoic acid hydroxyamide
3PHD	;	3.0	;	Crystal structure of human HDAC6 in complex with ubiquitin
3C5K	;	1.55	;	Crystal structure of human HDAC6 zinc finger domain
3GV4	;	1.72	;	Crystal structure of human HDAC6 zinc finger domain and ubiquitin C-terminal peptide RLRGG
1VKG	;	2.2	;	Crystal Structure of Human HDAC8 complexed with CRA-19156
1T67	;	2.31	;	Crystal Structure of Human HDAC8 complexed with MS-344
1T69	;	2.91	;	Crystal Structure of human HDAC8 complexed with SAHA
1T64	;	1.9	;	Crystal Structure of human HDAC8 complexed with Trichostatin A
3SFF	;	2.0	;	Crystal Structure of Human HDAC8 Inhibitor Complex, an Amino Acid Derived Inhibitor
3SFH	;	2.7	;	Crystal Structure of Human HDAC8 Inhibitor Complex, an Amino Acid Derived Inhibitor
2O2L	;	2.53	;	Crystal structure of human heat-labile enterotoxin in complex with a blood group A antigen analog
1ZC0	;	1.85	;	Crystal structure of human hematopoietic tyrosine phosphatase (HePTP) catalytic domain
1N3U	;	2.58	;	Crystal structure of human heme oxygenase 1 (HO-1) in complex with its substrate heme, crystal form B
5BTQ	;	2.08	;	Crystal structure of human heme oxygenase 1 H25R with biliverdin bound
1S8C	;	2.19	;	Crystal structure of human heme oxygenase in a complex with biliverdine
3CZY	;	1.54	;	Crystal Structure of Human Heme Oxygenase-1 in Complex with 1-(Adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone
5UC8	;	2.0	;	Crystal structure of human Heme Oxygenase-2
2Q32	;	2.4	;	Crystal structure of human heme oxygenase-2 C127A (HO-2)
2QPP	;	2.61	;	Crystal structure of human heme oxygenase-2 C127A (HO-2) with bound heme
5UCA	;	2.117	;	Crystal structure of human Heme Oxygenase-2 in complex with Laurate
5UC9	;	1.903	;	Crystal structure of human Heme Oxygenase-2 in complex with Myristate
1SI4	;	2.2	;	Crystal structure of Human hemoglobin A2 (in R2 state) at 2.2 A resolution
1NQP	;	1.73	;	Crystal structure of Human hemoglobin E at 1.73 A resolution
1ZRH	;	2.1	;	Crystal structure of Human heparan sulfate glucosamine 3-O-sulfotransferase 1 in complex with PAP
5E8M	;	1.75	;	Crystal structure of human heparanase
6ZDM	;	1.714	;	Crystal structure of human heparanase in complex with a N',6O'-bis-sulfated 4-methylumbelliferyl heparan sulfate disaccharide
8OHQ	;	1.7	;	Crystal structure of human heparanase in complex with competitive inhibitor derrived from siastatin B
8BAC	;	2.05	;	Crystal structure of human heparanase in complex with competitive inhibitor GD05
7PRT	;	1.7	;	Crystal structure of human heparanase in complex with covalent inhibitor CB678
7PR8	;	1.66	;	Crystal structure of human heparanase in complex with covalent inhibitor GR109
8B0B	;	1.95	;	Crystal structure of human heparanase in complex with covalent inhibitor VB151
8B0C	;	2.1	;	Crystal structure of human heparanase in complex with covalent inhibitor VB158
7PR7	;	1.52	;	Crystal structure of human heparanase in complex with covalent inhibitor VL166
8OHR	;	1.8	;	Crystal structure of human heparanase in complex with glucuronic acid configured 3-geminal diol iminosugar inhibitor
5E9C	;	1.73	;	Crystal structure of human heparanase in complex with heparin tetrasaccharide dp4
5E98	;	1.63	;	Crystal structure of human heparanase in complex with HepMer M04S02a
5E9B	;	1.88	;	Crystal structure of human heparanase in complex with HepMer M09S05a
5L9Z	;	1.57	;	Crystal structure of human heparanase nucleophile mutant (E343Q), in complex with unreacted glucuronic acid configured aziridine probe JJB355
5L9Y	;	1.88	;	Crystal structure of human heparanase, in complex with glucuronic acid configured aziridine probe JJB355
5X6V	;	2.02	;	Crystal structure of human heteroheptameric complex
5X6U	;	2.4	;	Crystal structure of human heteropentameric complex
5HG1	;	2.76	;	Crystal Structure of Human Hexokinase 2 with cmpd 1, a C-2-substituted glucosamine
5HFU	;	2.923	;	Crystal Structure of Human Hexokinase 2 with cmpd 27, a 2-amido-6-benzenesulfonamide glucosamine
5HEX	;	2.734	;	Crystal Structure of Human Hexokinase 2 with cmpd 30, a 2-amino-6-benzenesulfonamide glucosamine
2NZT	;	2.45	;	Crystal structure of human hexokinase II
3O7X	;	2.9248	;	Crystal structure of human Hili PAZ domain
6J58	;	1.521	;	Crystal structure of human HINT1 complexing with AP4A
5ED3	;	1.309	;	crystal structure of human Hint1 complexing with AP5A
6J53	;	1.52	;	Crystal structure of human HINT1 complexing with ATP
5ED6	;	1.52	;	crystal structure of human Hint1 H114A mutant complexing with ATP
6J5Z	;	1.3	;	Crystal structure of human HINT1 mutant complexing with AP3A
6J64	;	0.95	;	Crystal structure of human HINT1 mutant complexing with AP4A
6J65	;	1.42	;	Crystal structure of human HINT1 mutant complexing with AP4A II
6J5S	;	1.02	;	Crystal structure of human HINT1 mutant complexing with AP5A
5G4P	;	2.42	;	Crystal structure of human hippocalcin at 2.4 A resolution
4G84	;	2.4	;	Crystal structure of human HisRS
4G85	;	3.11	;	Crystal structure of human HisRS
7F61	;	2.6	;	Crystal structure of human histamine receptor H3R in complex with antagonist PF03654746
5O9L	;	1.75	;	Crystal structure of human Histamine-Releasing Factor (HRF/TCTP)
5O9M	;	1.4	;	Crystal structure of human Histamine-Releasing Factor (HRF/TCTP)containing a disulphide-linked dimer
4ZKL	;	2.34	;	Crystal structure of human histidine triad nucleotide-binding protein 1 (hHINT1) complexed with JB419 (AP4A analog)
5O8I	;	1.27	;	Crystal structure of human histidine triad nucleotide-binding protein 1 (hHINT1) crystallized at P212121 space group, and refined to 1.27 A
6G9Z	;	1.43	;	Crystal structure of human histidine triad nucleotide-binding protein 1 (hHINT1) crystallized at P212121 space group, with visible extended fragment of N-terminus
4ZKV	;	1.92	;	Crystal structure of human histidine triad nucleotide-binding protein 1 (hHINT1) refined to 1.92A at P21 space group
8PA6	;	1.58	;	Crystal structure of human Histidine Triad Nucleotide-Binding Protein 1 in complex with 5'-O-[(3-Indolyl)-1-Ethyl]Carbamoyl 2-aminoethenoadenosine
8P8P	;	1.9	;	Crystal structure of human Histidine Triad Nucleotide-Binding Protein 1 in complex with 5'-O-[(3-Indolyl)-1-Ethyl]Carbamoyl Ethenoadenosine
8PA9	;	1.5	;	Crystal structure of human Histidine Triad Nucleotide-Binding Protein 1 in complex with 5'-O-[(3-Indolyl)-1-Ethyl]Carbamoyl N2-methyl-2-aminoethenoadenosine
8PAF	;	2.1	;	Crystal structure of human Histidine Triad Nucleotide-Binding Protein 1 in complex with 5'-O-[N-(3-Indolepropionic acid)sulfamoyl] 2-aminoethenoadenosine
8PAI	;	1.8	;	Crystal structure of human Histidine Triad Nucleotide-Binding Protein 1 in complex with 5'-O-[N-(3-Indolepropionic acid)sulfamoyl] N2-methyl-2-aminoethenoadenosine
6VO5	;	1.6	;	Crystal structure of Human histone acetytransferas 1 (HAT1) in complex with isobutryl-COA and K12A mutant variant of histone H4
5EDU	;	2.79	;	Crystal structure of human histone deacetylase 6 catalytic domain 2 in complex with trichostatin A
7JVV	;	1.84	;	Crystal structure of human histone deacetylase 8 (HDAC8) E66D/Y306F double mutation complexed with a tetrapeptide substrate
7JVW	;	2.40302	;	Crystal structure of human histone deacetylase 8 (HDAC8) G320R mutation complexed with M344
7JVU	;	1.50048	;	Crystal structure of human histone deacetylase 8 (HDAC8) I45T mutation complexed with SAHA
3OOI	;	1.75	;	Crystal Structure of Human Histone-Lysine N-methyltransferase NSD1 SET domain in Complex with S-adenosyl-L-methionine
3MEK	;	2.1	;	Crystal Structure of Human Histone-Lysine N-methyltransferase SMYD3 in Complex with S-adenosyl-L-methionine
3O7V	;	2.1	;	Crystal Structure of human Hiwi1 (V361M) PAZ domain (residues 277-399) in complex with 14-mer RNA (12-bp + 2-nt overhang) containing 2'-OCH3 at its 3'-end
3O6E	;	2.904	;	Crystal Structure of human Hiwi1 PAZ domain (residues 277-399) in complex with 14-mer RNA (12-bp + 2-nt overhang) containing 2'-OCH3 at its 3'-end
3O3I	;	2.801	;	Crystal Structure of human Hiwi1 PAZ domain (residues 277-399) in complex with 14-mer RNA (12-bp + 2-nt overhang) containing 2'-OH at its 3'-end
5UJT	;	1.94	;	Crystal structure of human HLA-DQ8 in complex with insulin mimotope binding in register 3
3QVE	;	2.04	;	Crystal structure of human HMG box-containing protein 1, HBP1
2CW6	;	2.1	;	Crystal Structure of Human HMG-CoA Lyase: Insights into Catalysis and the Molecular Basis for Hydroxymethylglutaric Aciduria
4WD4	;	2.95	;	Crystal structure of human HO1 H25R
2RCT	;	1.2	;	Crystal structure of human holo cellular retinol-binding protein II (CRBP-II)
7L1T	;	2.25	;	Crystal structure of human holo SepSecS
2P8V	;	1.85	;	Crystal structure of human Homer3 EVH1 domain
5J8E	;	1.7	;	Crystal structure of human Hook3's conserved Hook domain
6M3G	;	1.57	;	Crystal structure of human HPF1
8CIJ	;	2.821	;	CRYSTAL STRUCTURE OF HUMAN HPK1 (MAP4K1) COMPLEX WITH 2-[8-Amino-7-fluoro-6-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)-isoquinolin-3-ylamino]-6-isopropyl-5,6-dihydro-4H-1,6,8a-triaza-azulen-7-one
8CDW	;	1.941	;	CRYSTAL STRUCTURE OF HUMAN HPK1 (MAP4K1) COMPLEX WITH 7-(1-methyl-1H-pyrazol-4-yl)-N-[4-(1-methylpiperidin-4-yl)phenyl]quinazolin-2-amine
8IM3	;	2.78	;	Crystal structure of human HPPD complexed with compound a10
8IM2	;	2.81	;	Crystal structure of human HPPD complexed with NTBC
7YI7	;	2.8	;	Crystal structure of Human HPSE1 in complex with inhibitor
7YJC	;	2.3	;	Crystal structure of Human HPSE1 in complex with inhibitor
8JYG	;	2.0	;	Crystal structure of Human HPSE1 in complex with inhibitor
4DPZ	;	1.25	;	Crystal structure of human HRASLS2
4DOT	;	1.96	;	Crystal structure of human HRASLS3.
5D5U	;	2.91	;	Crystal structure of human Hsf1 with HSE DNA
5D5V	;	2.55	;	Crystal structure of human Hsf1 with Satellite III repeat DNA
3AGX	;	1.85	;	Crystal structure of human Hsp40 Hdj1 peptide-binding domain
3AGY	;	1.85	;	Crystal structure of human Hsp40 Hdj1 peptide-binding domain complexed with a C-terminal peptide of Hsp70
3AGZ	;	2.51	;	Crystal structure of human Hsp40 Hdj1 peptide-binding domain complexed with a C-terminal peptide of Hsp70
4IO8	;	2.58	;	Crystal structure of human HSP70 complexed with 4-{(2R,3S,4R)-5-[(R)-6-Amino-8-(3,4-dichloro-benzylamino)-purin-9-yl]-3,4-dihydroxy-tetrahydro-furan-2-ylmethoxymethyl}-benzonitrile
3ATU	;	1.65	;	Crystal structure of human Hsp70 NBD in the ADP- and Mg ion-bound state
3AY9	;	1.75	;	Crystal structure of human Hsp70 NBD in the ADP-, Mg ion-, and K ion-bound state
3ATV	;	1.58	;	Crystal structure of human Hsp70 NBD in the ADP-bound and Mg ion-free state
7Q4R	;	1.79	;	Crystal structure of human HSP72-NBD in complex with fragment 1
5XQD	;	1.6	;	Crystal structure of Human Hsp90 with FS2
5XQE	;	1.699	;	Crystal structure of Human Hsp90 with FS3
5XR5	;	1.6	;	Crystal structure of Human Hsp90 with FS4
5XR9	;	1.501	;	Crystal structure of Human Hsp90 with FS6
4R3M	;	1.8	;	Crystal structure of Human Hsp90 with JR9
4L8Z	;	1.703	;	Crystal structure of Human Hsp90 with RL1
4L90	;	2.001	;	Crystal structure of Human Hsp90 with RL3
4L93	;	1.845	;	Crystal structure of Human Hsp90 with S36
4L94	;	1.649	;	Crystal structure of Human Hsp90 with S46
4L91	;	1.75	;	Crystal structure of Human Hsp90 with X29
1YC3	;	2.12	;	Crystal Structure of human HSP90alpha complexed with dihydroxyphenylpyrazoles
1YC4	;	1.81	;	Crystal structure of human HSP90alpha complexed with dihydroxyphenylpyrazoles
6PFL	;	2.1	;	Crystal structure of Human HUWE1 WWE domain in complex with ADPR
2NZL	;	1.35	;	Crystal structure of human hydroxyacid oxidase 1
2GF2	;	2.38	;	Crystal structure of human hydroxyisobutyrate dehydrogenase
2I9P	;	2.55	;	Crystal structure of human hydroxyisobutyrate dehydrogenase complexed with NAD+
7SAN	;	2.58156	;	Crystal structure of human hypoxanthine guanine phosphoribzosyltransferase in complex with (4S,7S)-7-hydroxy-4-((guanin-9-yl)methyl)-2,5-dioxaheptan-1,7-diphosphonate
4KN6	;	2.728	;	Crystal structure of human hypoxanthine-guanine phosphoribosyltransferase in complex with 6-fluoro-3-hydroxy-2-pyrazinecarboxamide (T-705) ribose-5'-monophosphate
2JJZ	;	2.15	;	Crystal Structure of Human Iba2, orthorhombic crystal form
2VTG	;	2.45	;	Crystal Structure of Human Iba2, trigonal crystal form
5DE1	;	2.25	;	Crystal structure of human IDH1 in complex with GSK321A
5LGE	;	2.7	;	Crystal Structure of human IDH1 mutant (R132H) in complex with NADP+ and an Inhibitor related to BAY 1436032
8HB9	;	2.8	;	Crystal Structure of Human IDH1 R132H Mutant in Complex with NADPH and Compound IHMT-IDH1-053
7CE3	;	3.472	;	Crystal structure of human IDH3 holoenzyme in APO form.
6O3I	;	2.69	;	Crystal Structure of Human IDO1 bound to navoximod (NLG-919)
8FUR	;	2.285	;	Crystal structure of human IDO1 with compound 11
3KG5	;	3.2	;	Crystal structure of human Ig-beta homodimer
7MLH	;	2.1	;	Crystal structure of human IgE (2F10) in complex with Der p 2.0103
5MOI	;	2.2	;	Crystal structure of human IgE-Fc epsilon 3-4
5MOK	;	2.0	;	Crystal structure of human IgE-Fc epsilon 3-4
2VXV	;	1.49	;	Crystal structure of human IgG ABT-325 Fab Fragment
4B7I	;	2.36	;	Crystal Structure of Human IgG Fc Bearing Hybrid-type Glycans
5YC5	;	2.71	;	Crystal structure of human IgG-Fc in complex with aglycan and optimized Fc gamma receptor IIIa
5VME	;	3.1	;	Crystal structure of human IgG1 Fc K248E, T437R mutant
5JII	;	1.79	;	Crystal structure of human IgG1-Fc
5W5L	;	1.9	;	Crystal structure of human IgG1-Sigma Fc fragment
5W5M	;	1.9	;	Crystal structure of human IgG4-Sigma1 Fc fragment
5W5N	;	1.85	;	Crystal structure of human IgG4-Sigma2 Fc fragment
5EBZ	;	4.5	;	Crystal structure of human IKK1
2H24	;	2.0	;	Crystal structure of human IL-10
1Y6K	;	2.52	;	Crystal structure of human IL-10 complexed with the soluble IL-10R1 chain
8CDG	;	2.9	;	Crystal structure of human IL-17A cytokine in complex with macrocycle
7ZAN	;	5.061	;	Crystal Structure of human IL-17A in complex with IL-17RA and IL-17RC
5N92	;	2.3	;	Crystal Structure of Human IL-17AF
5NAN	;	3.3	;	Crystal Structure of human IL-17AF in complex with human IL-17RA
6HGO	;	2.1	;	Crystal Structure of human IL-17F
2VXT	;	1.49	;	Crystal structure of human IL-18 complexed to murine reference antibody 125-2H Fab
3F62	;	2.0	;	Crystal Structure of Human IL-18 in complex with Ectromelia virus IL-18 Binding Protein
8C3U	;	1.945	;	Crystal Structure of human IL-1beta in complex with a low molecular weight antagonist
7CHY	;	2.65	;	Crystal Structure Of Human Il-1beta In Complex With Antibody Binding Fragment Of IgG26
7CHZ	;	2.5	;	Crystal Structure Of Human Il-1beta In Complex With Antibody Binding Fragment Of IgG26A
4G6J	;	2.03	;	Crystal structure of human IL-1beta in complex with the therapeutic antibody binding fragment of canakinumab
4G6M	;	1.81	;	Crystal structure of human IL-1beta in complex with therapeutic antibody binding fragment of gevokizumab
1M48	;	1.95	;	Crystal Structure of Human IL-2 Complexed with (R)-N-[2-[1-(Aminoiminomethyl)-3-piperidinyl]-1-oxoethyl]-4-(phenylethynyl)-L-phenylalanine methyl ester
2MIP	;	2.2	;	CRYSTAL STRUCTURE OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) TYPE 2 PROTEASE IN COMPLEX WITH A REDUCED AMIDE INHIBITOR AND COMPARISON WITH HIV-1 PROTEASE STRUCTURES
1S6P	;	2.9	;	CRYSTAL STRUCTURE OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REVERSE TRANSCRIPTASE (RT) IN COMPLEX WITH JANSSEN-R100943
7FAB	;	2.0	;	CRYSTAL STRUCTURE OF HUMAN IMMUNOGLOBULIN FRAGMENT FAB NEW REFINED AT 2.0 ANGSTROMS RESOLUTION
5TBK	;	3.45	;	Crystal structure of human importin a3 bound to RCC1
8FUB	;	2.75	;	Crystal structure of human Importin alpha 3 in complex with Hendra virus matrix protein NLS1
2P8Q	;	2.35	;	Crystal Structure of human Importin beta bound to the Snurportin1 IBB-domain
2Q5D	;	3.2	;	Crystal Structure of Human Importin Beta bound to the Snurportin1 IBB-domain second crystal form
2QNA	;	2.84	;	Crystal structure of human Importin-beta (127-876) in complex with the IBB-domain of Snurportin1 (1-65)
5XAH	;	3.004	;	Crystal structure of human Importin4
5XBK	;	3.223	;	Crystal structure of human Importin4
6E35	;	2.411	;	Crystal structure of human indoleamime 2,3-dioxygenase (IDO1) in complex with L-Trp and cyanide, Northeast Structural Genomics Target HR6160
7E0T	;	2.137	;	Crystal Structure of Human Indoleamine 2,3-dioxygenagse 1 (hIDO1) Complexed with (1R,2S)-2-(((5-bromo-1H-indazol-4-yl)amino)methyl)Cyclohexan-1-ol (36)
7E0S	;	2.712	;	Crystal Structure of Human Indoleamine 2,3-dioxygenagse 1 (hIDO1) Complexed with (1R,2S)-2-(((6-Bromo-1H-indazol-4-yl)amino)methyl)cyclohexan-1-ol (23)
7E0Q	;	2.462	;	Crystal Structure of Human Indoleamine 2,3-dioxygenagse 1 (hIDO1) Complexed with (1S,2R)-2-(((6-Bromo-1H-indazol-4-yl)amino)methyl)cyclohexan-1-ol (22)
7E0P	;	2.635	;	Crystal Structure of Human Indoleamine 2,3-dioxygenagse 1 (hIDO1) Complexed with 4-(((6-Bromo-1H-indazol-4-yl)amino)methyl)phenol (2)
7E0O	;	3.337	;	Crystal Structure of Human Indoleamine 2,3-dioxygenagse 1 (hIDO1) Complexed with 6-Bromo-1H-indazol-4-amine (1)
7E0U	;	2.278	;	Crystal Structure of Human Indoleamine 2,3-dioxygenagse 1 (hIDO1) Complexed with 6-Bromo-N-(((1S,2S)-2-chlorocyclohexyl)methyl)-1H-indazol-4-amine (39)
6E44	;	1.903	;	CRYSTAL STRUCTURE OF HUMAN INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) free enzyme in the ferric state
6E45	;	2.0	;	CRYSTAL STRUCTURE OF HUMAN INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) free enzyme in the ferrous state
6E43	;	1.705	;	Crystal structure of human indoleamine 2,3-dioxygenase 1 (IDO1) in complex with a BMS-978587 analog
6E42	;	2.103	;	CRYSTAL STRUCTURE OF HUMAN INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) in complex with ferric heme and 4-Chlorophenyl imidazole
6E41	;	2.291	;	CRYSTAL STRUCTURE OF HUMAN INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) in complex with ferric heme and an Epacadostat analog
6E46	;	2.09	;	CRYSTAL STRUCTURE OF HUMAN INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) in complex with ferrous heme and tryptophan
6PZ1	;	2.65	;	Crystal Structure of human Indoleamine 2,3-Dioxygenase 1 in complex with PF-06840003 in Active Site and Si site
6F0A	;	2.26	;	Crystal structure of human indoleamine 2,3-dioxygenase bound to a triazole inhibitor and alanine molecule.
7YXT	;	2.48	;	Crystal structure of human Indoleamine-2,3-dioxygenase 1 (hIDO1) with different conformations for G261-G265 fragment
2A14	;	1.7	;	Crystal Structure of Human Indolethylamine N-methyltransferase with SAH
8I3J	;	2.69	;	Crystal structure of human inner-arm dynein heavy chain d stalk and microtubule binding domain
7CMO	;	3.4	;	Crystal structure of human inorganic pyrophosphatase
6C45	;	2.388	;	Crystal structure of human inorganic pyrophosphatase in the P212121 space group
7BTN	;	2.382	;	Crystal structure of human inorganic pyrophosphatase with metal ions
2CAR	;	1.09	;	Crystal Structure Of Human Inosine Triphosphatase
2I5D	;	1.63	;	Crystal Structure of Human Inosine Triphosphate Pyrophosphatase
4F95	;	2.07	;	Crystal structure of human inosine triphosphate pyrophosphatase P32T variant
2QB5	;	1.8	;	Crystal Structure of Human Inositol 1,3,4-Trisphosphate 5/6-Kinase (ITPK1) in Complex with ADP and Mn2+
2Q7D	;	1.6	;	Crystal Structure of Human Inositol 1,3,4-Trisphosphate 5/6-kinase (ITPK1) in complex with AMPPNP and Mn2+
6E7F	;	2.5	;	Crystal Structure of Human Inositol Polyphosphate Multikinase (IPMK) Catalytic Core Domain
2XSW	;	1.9	;	Crystal structure of human INPP5E
4CXN	;	1.7	;	Crystal structure of human insulin analogue (NMe-AlaB8)-insulin crystal form I
4CY7	;	1.4	;	Crystal structure of human insulin analogue (NMe-AlaB8)-insulin crystal form II
3IR0	;	2.2	;	Crystal Structure of Human Insulin complexed with Cu+2 metal ion
4RE9	;	2.908	;	Crystal structure of human insulin degrading enzyme (IDE) in complex with compound 71290
4IFH	;	3.286	;	Crystal structure of human insulin degrading enzyme (IDE) in complex with compound BDM44619
7K1D	;	3.0	;	Crystal structure of human insulin degrading enzyme (IDE) in complex with compound BDM_77291
7K1F	;	2.6	;	Crystal structure of human insulin degrading enzyme (IDE) in complex with compound BDM_88558
7K1E	;	2.8	;	Crystal structure of human insulin degrading enzyme (IDE) in complex with compound BDM_88646
4DTT	;	3.22	;	Crystal structure of human insulin degrading enzyme (ide) in complex with compund 41367
4QIA	;	3.202	;	Crystal structure of human insulin degrading enzyme (ide) in complex with inhibitor N-benzyl-N-(carboxymethyl)glycyl-L-histidine
2JBU	;	3.0	;	Crystal structure of human insulin degrading enzyme complexed with co- purified peptides.
3E4Z	;	2.28	;	Crystal structure of human insulin degrading enzyme in complex with insulin-like growth factor II
2WC0	;	2.8	;	crystal structure of human insulin degrading enzyme in complex with iodinated insulin
3E50	;	2.3	;	Crystal structure of human insulin degrading enzyme in complex with transforming growth factor-alpha
8PJC	;	2.14	;	Crystal structure of human insulin desB30 precursor with an Alanine-Alanine-Lysine C-peptide in dimer (T2) conformation
8PI4	;	1.25	;	Crystal structure of human insulin desB30 precursor with an Alanine-Methionine-Lysine C-peptide in dimer (T2) conformation
8PI5	;	1.66	;	Crystal structure of human insulin desB30 precursor with an Alanine-Methionine-Lysine C-peptide in hexamer (T3R3) conformation
8PJH	;	1.5	;	Crystal structure of human insulin desB30 precursor with an Aspartate-Glycine-Lysine C-peptide in dimer (T2) conformation
4NIB	;	1.4	;	Crystal structure of human insulin mutant B20 D-ala, B23 D-ala
4P8Q	;	3.02	;	Crystal Structure of Human Insulin Regulated Aminopeptidase with Alanine in Active Site
4PJ6	;	2.96	;	Crystal Structure of Human Insulin Regulated Aminopeptidase with Lysine in Active Site
8ONR	;	1.88	;	Crystal structure of human insulin trans-HypB26-DTI analogue
3INC	;	1.85	;	Crystal structure of human insulin with Ni+2 complex
7Z5L	;	1.4	;	Crystal structure of human insulin, crystallised in the presence of macrophage migration inhibitory factor (MIF) and dimethyl sulfoxide (DMSO)
7Z5Q	;	1.8	;	Crystal structure of human insulin, crystallised in the presence of macrophage migration inhibitory factor (MIF) and p-Hydroxyphenylpyruvate (HPP)
3N57	;	3.03	;	Crystal Structure of human Insulin-degrading enzyme (IDE) in complex with human atrial natriuretic peptide (ANP)
3N56	;	3.102	;	Crystal Structure of human Insulin-degrading enzyme (IDE) in complex with human B-type natriuretic peptide (BNP)
2G48	;	2.6	;	crystal structure of human insulin-degrading enzyme in complex with amylin
3HGZ	;	2.91	;	Crystal structure of human insulin-degrading enzyme in complex with amylin
2G47	;	2.1	;	Crystal structure of human insulin-degrading enzyme in complex with amyloid-beta (1-40)
2WK3	;	2.59	;	Crystal structure of human insulin-degrading enzyme in complex with amyloid-beta (1-42)
2G49	;	2.5	;	Crystal structure of human insulin-degrading enzyme in complex with glucagon
2WBY	;	2.6	;	Crystal structure of human insulin-degrading enzyme in complex with insulin
2G56	;	2.2	;	crystal structure of human insulin-degrading enzyme in complex with insulin B chain
3OFI	;	2.35	;	Crystal structure of human insulin-degrading enzyme in complex with ubiquitin
4ZYO	;	3.25	;	Crystal Structure of Human Integral Membrane Stearoyl-CoA Desaturase with Substrate
5V8W	;	2.1	;	Crystal structure of human Integrator IntS9-IntS11 CTD complex
3ZGQ	;	2.203	;	Crystal structure of human interferon-induced protein IFIT5
6KN9	;	3.302	;	Crystal structure of human interleukin 18 receptor beta extracellular domain in complex with an antagonistic scFv
4NI7	;	2.4	;	Crystal structure of human interleukin 6 in complex with a modified nucleotide aptamer (SOMAMER SL1025)
4NI9	;	2.55	;	Crystal structure of human interleukin 6 in complex with a modified nucleotide aptamer (SOMAMER SL1025), FORM 2
6MOM	;	2.1	;	Crystal structure of human Interleukin-1 receptor associated Kinase 4 (IRAK 4, CID 100300) in complex with compound NCC00371481 (BSI 107591)
2ILK	;	1.6	;	CRYSTAL STRUCTURE OF HUMAN INTERLEUKIN-10 AT 1.6 ANGSTROMS RESOLUTION
3WO2	;	2.33	;	Crystal structure of human interleukin-18
1N1F	;	1.95	;	Crystal Structure of Human Interleukin-19
1M47	;	1.99	;	Crystal Structure of Human Interleukin-2
1M4C	;	2.4	;	Crystal Structure of Human Interleukin-2
1M49	;	2.0	;	Crystal Structure of Human Interleukin-2 Complexed with SP-1985
1M4B	;	2.15	;	Crystal Structure of Human Interleukin-2 K43C Covalently Modified at C43 with 2-[2-(2-Cyclohexyl-2-guanidino-acetylamino)-acetylamino]-N-(3-mercapto-propyl)-propionamide
1M4A	;	2.18	;	Crystal Structure of Human Interleukin-2 Y31C Covalently Modified at C31 with (1H-Indol-3-yl)-(2-mercapto-ethoxyimino)-acetic acid
1NBP	;	2.2	;	Crystal Structure Of Human Interleukin-2 Y31C Covalently Modified At C31 With 3-Mercapto-1-(1,3,4,9-tetrahydro-B-carbolin-2-yl)-propan-1-one
4DKC	;	1.85	;	Crystal Structure of Human Interleukin-34
4DKE	;	3.0	;	Crystal Structure of Human Interleukin-34 Bound to FAb1.1
4DKF	;	2.61	;	Crystal Structure of Human Interleukin-34 Bound to FAb2
4DKD	;	3.0	;	Crystal Structure of Human Interleukin-34 Bound to Human CSF-1R
3VA2	;	2.703	;	Crystal structure of human Interleukin-5 in complex with its alpha receptor
3JZY	;	1.56	;	Crystal structure of human Intersectin 2 C2 domain
3GF9	;	2.5	;	Crystal structure of human Intersectin 2 RhoGEF domain
2PMV	;	2.6	;	Crystal Structure of Human Intrinsic Factor- Cobalamin Complex at 2.6 A Resolution
8HPP	;	3.0	;	Crystal structure of human INTS3 with SAGE1
2DHO	;	1.6	;	Crystal structure of human IPP isomerase I in space group P212121
2VGQ	;	2.1	;	Crystal Structure of Human IPS-1 CARD
6BFN	;	2.26	;	Crystal structure of human IRAK1
4U6R	;	2.5	;	Crystal structure of human IRE1 cytoplasmic domains in complex with a sulfonamide inhibitor.
4Z7G	;	2.6	;	Crystal structure of human IRE1 cytoplasmic kinase-RNase region - apo
4Z7H	;	2.9	;	Crystal structure of human IRE1 cytoplasmic kinase-RNase region - complex with imidazopyridine compound 3
6SHC	;	3.55	;	Crystal structure of human IRE1 luminal domain Q105C
3SDL	;	2.29	;	Crystal structure of human ISG15 in complex with NS1 N-terminal region from influenza B virus, Northeast Structural Genomics Consortium Target IDs HX6481, HR2873, and OR2
3R66	;	2.3	;	Crystal structure of human ISG15 in complex with NS1 N-terminal region from influenza virus B, Northeast Structural Genomics Consortium Target IDs HX6481, HR2873, and OR2
4CVH	;	2.39	;	Crystal structure of human isoprenoid synthase domain-containing protein
5JK9	;	2.1	;	Crystal structure of human IZUMO1
5JKC	;	2.9	;	Crystal structure of human IZUMO1-JUNO complex (crystal form 1)
5JKD	;	2.9	;	Crystal structure of human IZUMO1-JUNO complex (crystal form 2)
5JKE	;	2.86	;	Crystal structure of human IZUMO1-JUNO complex (crystal form 3)
5FV3	;	2.37	;	Crystal structure of human JARID1B construct c2 in complex with N- Oxalylglycine.
5FUP	;	2.15	;	Crystal structure of human JARID1B in complex with 2-oxoglutarate.
5FPL	;	2.35	;	Crystal structure of human JARID1B in complex with CCT363901
5FUN	;	2.3	;	Crystal structure of human JARID1B in complex with GSK467
5FPU	;	2.24	;	Crystal structure of human JARID1B in complex with GSKJ1
5LW9	;	2.3	;	Crystal structure of human JARID1B in complex with S40563a
5LWB	;	2.39	;	Crystal structure of human JARID1B in complex with S40650a
5FWJ	;	2.1	;	Crystal structure of human JARID1C in complex with KDM5-C49
5F5I	;	2.63	;	Crystal Structure of human JMJD2A complexed with KDOOA011340
4URA	;	2.23	;	Crystal structure of human JMJD2A in complex with compound 14a
5A7Q	;	2.0	;	Crystal structure of human JMJD2A in complex with compound 30
5A7W	;	2.27	;	Crystal structure of human JMJD2A in complex with compound 35
5A7P	;	2.28	;	Crystal structure of human JMJD2A in complex with compound 36
5A80	;	2.28	;	Crystal structure of human JMJD2A in complex with compound 40
5A7O	;	2.15	;	Crystal structure of human JMJD2A in complex with compound 42
5A7N	;	2.39	;	Crystal structure of human JMJD2A in complex with compound 43
5A7S	;	2.2	;	Crystal structure of human JMJD2A in complex with compound 44
5FPV	;	2.44	;	Crystal structure of human JMJD2A in complex with compound KDOAM20A
5FY8	;	2.343	;	Crystal structure of human JMJD2A in complex with D-threo-isocitrate
5FYH	;	2.348	;	Crystal structure of human JMJD2A in complex with fumarate
5FYI	;	2.096	;	Crystal structure of human JMJD2A in complex with pyruvate
5FYC	;	2.261	;	Crystal structure of human JMJD2A in complex with succinate
2XML	;	2.55	;	Crystal structure of human JMJD2C catalytic domain
5FJK	;	1.66	;	Crystal structure of human JMJD2C catalytic domain in complex 6-ethyl- 5-methyl-7-oxo-4,7-dihydropyrazolo(1,5-a)pyrimidine-3-carbonitrile
5FJH	;	2.1	;	Crystal structure of human JMJD2C catalytic domain in complex with epitherapuetic compound 2-(((2-((2-(dimethylamino)ethyl) (ethyl)amino) -2-oxoethyl)amino)methyl)isonicotinic acid
5F5A	;	1.41	;	Crystal Structure of human JMJD2D complexed with KDOAM16
5F5C	;	1.88	;	Crystal Structure of human JMJD2D complexed with KDOPP7
4D6Q	;	1.292	;	crystal structure of human JMJD2D in complex with 2,4-PDCA
4D6S	;	1.4	;	crystal structure of human JMJD2D in complex with N-OXALYLGLYCINE and bound 5,6-Dimethylbenzimidazole
4D6R	;	1.398	;	crystal structure of human JMJD2D in complex with N-OXALYLGLYCINE and bound o-toluenesulfonamide
4HOO	;	2.495	;	Crystal structure of human JMJD2D/KDM4D apoenzyme
4HON	;	1.799	;	Crystal structure of human JMJD2D/KDM4D in complex with an H3K9me3 peptide and 2-oxoglutarate
4QU1	;	1.57	;	Crystal structure of human JMJD5 jmj-c domain
2WAJ	;	2.4	;	Crystal structure of human Jnk3 complexed with a 1-aryl-3,4- dihydroisoquinoline inhibitor
2ZDT	;	2.0	;	Crystal Structure of human JNK3 complexed with an isoquinolone inhibitor
2ZDU	;	2.5	;	Crystal Structure of human JNK3 complexed with an isoquinolone inhibitor
2O2U	;	2.45	;	Crystal structure of human JNK3 complexed with N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-fluorobenzamide
3DA6	;	2.0	;	Crystal Structure of human JNK3 complexed with N-(3-methyl-4-(3-(2-(methylamino)pyrimidin-4-yl)pyridin-2-yloxy)naphthalen-1-yl)-1H-benzo[d]imidazol-2-amine
2O0U	;	2.1	;	Crystal structure of human JNK3 complexed with N-{3-cyano-6-[3-(1-piperidinyl)propanoyl]-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl}-1-naphthalenecarboxamide
4U79	;	2.23	;	Crystal structure of human JNK3 in complex with a benzenesulfonamide inhibitor.
1NBQ	;	2.9	;	Crystal Structure of Human Junctional Adhesion Molecule Type 1
5JKA	;	2.0	;	Crystal structure of human JUNO (crystal form 1)
5JKB	;	3.23	;	Crystal structure of human JUNO (crystal form 2)
5XCO	;	1.25	;	Crystal structure of human K-Ras G12D Mutant in complex with GDP and Cyclic Inhibitory Peptide
6QFE	;	1.67	;	Crystal Structure of Human Kallikrein 5 in complex with GSK144
2PSX	;	2.3	;	Crystal Structure of Human Kallikrein 5 in complex with Leupeptin
2PSY	;	2.3	;	Crystal Structure of Human Kallikrein 5 in complex with Leupeptin and Zinc
6QFG	;	1.68	;	Crystal Structure of Human Kallikrein 6 (I218Y) in complex with GSK144
6SKD	;	2.26	;	Crystal Structure of Human Kallikrein 6 (I218Y) in complex with GSK3397892A
6SKC	;	2.18	;	Crystal Structure of Human Kallikrein 6 (I218Y) in complex with GSK3448330A
6QFH	;	1.65	;	Crystal Structure of Human Kallikrein 6 (N217D/I218Y/K224R) in complex with GSK144.
6SKB	;	1.84	;	Crystal Structure of Human Kallikrein 6 (N217D/I218Y/K224R) in complex with GSK3496783A
6QFF	;	1.64	;	Crystal Structure of Human Kallikrein 6 in complex with GSK144
6QHA	;	1.82	;	Crystal Structure of Human Kallikrein 6 in complex with GSK3205388B
6QH9	;	2.27	;	Crystal Structure of Human Kallikrein 6 in complex with GSK3239861A
6QHC	;	1.87	;	Crystal Structure of Human Kallikrein 6 in complex with GSK358180B
6QHB	;	1.84	;	Crystal Structure of Human Kallikrein 6 in complex with GSK578724A
2QXG	;	2.6	;	Crystal Structure of Human Kallikrein 7 in Complex with Ala-Ala-Phe-chloromethylketone
2QXH	;	2.0	;	Crystal Structure of Human Kallikrein 7 in Complex with Suc-Ala-Ala-Pro-Phe-chloromethylketone
2QXJ	;	2.1	;	Crystal Structure of Human Kallikrein 7 in Complex with Suc-Ala-Ala-Pro-Phe-chloromethylketone and Copper
3BSQ	;	2.8	;	Crystal structure of human kallikrein 7 produced as a secretion protein in E.coli
4OO6	;	2.7	;	Crystal structure of human KAP-beta2 bound to the NLS of HCC1 (Hepato Cellular Carcinoma protein 1)
1YZX	;	1.93	;	Crystal structure of human kappa class glutathione transferase
3RPP	;	1.8	;	Crystal structure of human kappa class glutathione transferase in apo form
3RPN	;	1.9	;	Crystal structure of human kappa class glutathione transferase in complex with S-hexylglutathione
5J3V	;	3.05	;	Crystal structure of human Karyopherin-beta2 bound to the histone H3 tail
4JLQ	;	3.05	;	Crystal structure of human Karyopherin-beta2 bound to the PY-NLS of Saccharomyces cerevisiae NAB2
2XH1	;	2.1	;	Crystal structure of human KAT II-inhibitor complex
5TF5	;	1.807	;	CRYSTAL STRUCTURE OF HUMAN KAT-2 IN COMPLEX WITH A REVERSIBLE INHIBITOR
5ZQL	;	3.007	;	crystal structure of human katanin AAA ATPase domain
5ZQM	;	2.9	;	Crystal structure of human katanin AAA ATPase domain complex with ATPgammaS
6OCR	;	2.28	;	Crystal structure of human KCTD16 T1 domain
6OCT	;	2.8	;	Crystal structure of human KCTD16 T1 domain
5VMP	;	2.48	;	Crystal Structure of Human KDM4 with Small Molecule Inhibitor QC5714
6HGT	;	2.33	;	Crystal structure of human KDM4A complexed with co-substrate analog NOG and histone H3 peptide with K9R mutation
5F2S	;	2.08	;	Crystal structure of human KDM4A in complex with compound 15
5F2W	;	2.6	;	Crystal structure of human KDM4A in complex with compound 16
6H4P	;	2.19	;	Crystal structure of human KDM4A in complex with compound 16a
6H4S	;	2.45	;	Crystal structure of human KDM4A in complex with compound 16m
6H4X	;	2.34	;	Crystal structure of human KDM4A in complex with compound 17b
6H4Y	;	2.38	;	Crystal structure of human KDM4A in complex with compound 17e
6H4R	;	2.14	;	Crystal structure of human KDM4A in complex with compound 17f
6H4O	;	2.25	;	Crystal structure of human KDM4A in complex with compound 18a
6H4T	;	2.38	;	Crystal structure of human KDM4A in complex with compound 19a
6H4W	;	2.81	;	Crystal structure of human KDM4A in complex with compound 19d
6H4Q	;	2.31	;	Crystal structure of human KDM4A in complex with compound 34a
6H4U	;	2.21	;	Crystal structure of human KDM4A in complex with compound 34b
6H4V	;	2.15	;	Crystal structure of human KDM4A in complex with compound 34g
5F39	;	2.65	;	Crystal structure of human KDM4A in complex with compound 37
5F32	;	2.05	;	Crystal structure of human KDM4A in complex with compound 40
5F3C	;	2.06	;	Crystal structure of human KDM4A in complex with compound 52d
5F3G	;	2.5	;	Crystal structure of human KDM4A in complex with compound 53a
5F3E	;	2.16	;	Crystal structure of human KDM4A in complex with compound 54a
5F3I	;	2.24	;	Crystal structure of human KDM4A in complex with compound 54j
5F37	;	2.22	;	Crystal structure of human KDM4A in complex with compound 58
4XDP	;	2.07	;	Crystal structure of human KDM4C catalytic domain bound to tris
4XDO	;	1.97	;	Crystal structure of human KDM4C catalytic domain with OGA
5FPB	;	1.91	;	Crystal structure of human KDM4D in complex with 2-1H-pyrazol-4-yloxy- 3H,4H-pyrido-3,4-d-pyrimidin-4-one
5FP4	;	2.0	;	Crystal structure of human KDM4D in complex with 3-(4- phenylbutanamido)pyridine-4-carboxylic acid
5FP7	;	2.0	;	Crystal structure of human KDM4D in complex with 3-4-methylthiophen-2- yl methylaminopyridine-4-carboxylic acid
5FP8	;	1.98	;	Crystal structure of human KDM4D in complex with 3-4-methylthiophen-2- ylmethylaminopyridine-4-carboxylic acid
5FP9	;	2.0	;	Crystal structure of human KDM4D in complex with 3-aminopyridine-4- carboxylic acid
5FPA	;	1.96	;	Crystal structure of human KDM4D in complex with 3H,4H-pyrido-3,4-d- pyrimidin-4-one
6H4Z	;	2.3	;	Crystal structure of human KDM5B in complex with compound 16a
6H50	;	2.19	;	Crystal structure of human KDM5B in complex with compound 34a
6H51	;	2.21	;	Crystal structure of human KDM5B in complex with compound 34f
6H52	;	2.14	;	Crystal structure of human KDM5B in complex with compound 34g
6GQO	;	1.87	;	Crystal structure of human KDR (VEGFR2) kinase domain in complex with AZD3229-analogue (compound 18)
6GQP	;	2.09	;	Crystal structure of human KDR (VEGFR2) kinase domain in complex with AZD3229-analogue (compound 23)
6GQQ	;	1.52	;	Crystal structure of human KDR (VEGFR2) kinase domain in complex with AZD3229-analogue (compound 35)
6FFM	;	2.2	;	Crystal Structure of Human KEAP1 BTB Domain in Complex with isoxazoline-based inhibitor
5DAD	;	2.61	;	Crystal Structure of Human KEAP1 BTB Domain in Complex with Small Molecule TX64014
5DAF	;	2.37	;	Crystal Structure of Human KEAP1 BTB Domain in Complex with Small Molecule TX64063
2HLZ	;	1.85	;	Crystal Structure of human ketohexokinase
2HQQ	;	1.86	;	Crystal structure of human ketohexokinase complexed to different sugar molecules
2HW1	;	2.1	;	Crystal structure of human ketohexokinase complexed to different sugar molecules
4FC0	;	2.95	;	Crystal Structure of Human Kinase Domain of B-raf with a DFG-out Inhibitor
2X2R	;	2.2	;	Crystal structure of human kinesin Eg5 in complex with (R)-2-amino-3-((4-chlorophenyl)diphenylmethylthio)propanoic acid
2XAE	;	2.6	;	Crystal structure of human kinesin Eg5 in complex with (R)-2-amino-3-((S)-2-methyl-1,1-diphenylbutylthio)propanoic acid
2X7E	;	2.4	;	Crystal structure of human kinesin Eg5 in complex with (R)-fluorastrol
2IEH	;	2.7	;	Crystal structure of human kinesin Eg5 in complex with (R)-mon97, a new monastrol-based inhibitor that binds as (R)-enantiomer
2X7D	;	2.3	;	Crystal structure of human kinesin Eg5 in complex with (S)-dimethylenastron
2X7C	;	1.9	;	Crystal structure of human kinesin Eg5 in complex with (S)-enastron
4A51	;	2.75	;	Crystal structure of human kinesin Eg5 in complex with 1-(3-(((2-Aminoethyl)thio)diphenylmethyl)phenyl)ethanone hydrochloride
4A50	;	2.75	;	Crystal structure of human kinesin Eg5 in complex with 2-Amino-5-(3-methylphenyl)-5,5-diphenylpentanoic acid
4BBG	;	2.75	;	Crystal structure of human kinesin Eg5 in complex with 3-(((2-Aminoethyl)sulfanyl)(3-ethylphenyl) phenylmethyl)phenol
6VTX	;	2.14	;	Crystal structure of human KLF4 zinc finger DNA binding domain in complex with NANOG DNA
6KBR	;	2.0	;	Crystal structure of Human KLK4 and SPINK2 derived KLK4 inhibitor complex
6O21	;	1.15	;	Crystal Structure of Human KLK4 in Complex With Cleaved SFTI-FCQR(Asn14)[1,14] Inhibitor
5X68	;	2.1	;	Crystal Structure of Human KMO
6BP1	;	2.001	;	Crystal structure of human KRAS A59G mutant in complex with GCP
8FMI	;	1.12	;	Crystal structure of human KRAS at 1.12 A
5VP7	;	1.7	;	Crystal structure of human KRAS G12A mutant in complex with GDP
5VQ0	;	2.3	;	Crystal structure of human KRAS G12A mutant in complex with GDP (EDTA soaked)
5VPY	;	2.0	;	Crystal structure of human KRAS G12A mutant in complex with GppNHp
5VPI	;	1.62	;	Crystal structure of human KRAS G12A mutant in complex with GTP
5VPZ	;	1.85	;	Crystal structure of human KRAS G12A mutant in complex with GTP-gamma-S
6PGO	;	1.6	;	Crystal structure of human KRAS G12C covalently bound to a phthalazine inhibitor
6PGP	;	1.5	;	Crystal structure of human KRAS G12C covalently bound to a quinazolinone inhibitor
6OIM	;	1.65	;	Crystal Structure of human KRAS G12C covalently bound to AMG 510
6P8Z	;	1.65	;	Crystal structure of human KRAS G12C covalently bound to an acryloylazetidine acetamide inhibitor
6P8W	;	2.1	;	Crystal structure of human KRAS G12C covalently bound to an acryloylazetidine acetamide inhibitor.
6P8X	;	2.11	;	Crystal structure of human KRAS G12C covalently bound to an acryloylazetidine acetamide inhibitor.
6P8Y	;	2.31	;	Crystal structure of human KRAS G12C covalently bound to an acryloylazetidine acetamide inhibitor.
8DNI	;	1.5	;	Crystal structure of human KRAS G12C covalently bound with Araxes WO2020/028706A1 compound I-1
8DNJ	;	1.81	;	Crystal structure of human KRAS G12C covalently bound with AstraZeneca WO2020/178282A1 compound 76
8DNK	;	2.23	;	Crystal structure of human KRAS G12C covalently bound with Taiho WO2020/085493A1 compound 6
5US4	;	1.83	;	Crystal structure of human KRAS G12D mutant in complex with GDP
5USJ	;	1.94	;	Crystal Structure of human KRAS G12D mutant in complex with GDPNP
5UQW	;	1.5	;	Crystal structure of human KRAS G12V mutant in complex with GDP
8FMJ	;	1.33	;	Crystal structure of human KRAS in space group R32
6O36	;	2.0	;	Crystal structure of human KRAS P34R mutant in complex with GNP
6O46	;	1.9	;	Crystal structure of human KRAS P34R mutant in complex with GNP and Phosphate
5VQ1	;	1.78	;	Crystal structure of human KRAS Q61A mutant in complex with GDP
8FMK	;	1.48	;	Crystal structure of human KRAS with extended switch I loop
1W7L	;	2.0	;	Crystal structure of human kynurenine aminotransferase I
3FVU	;	1.55	;	Crystal Structure of Human Kynurenine Aminotransferase I in Complex with Indole-3-acetic Acid
1W7M	;	2.7	;	Crystal structure of human kynurenine aminotransferase I in complex with L-Phe
1W7N	;	2.9	;	Crystal structure of human kynurenine aminotransferase I in PMP form
2QLR	;	2.3	;	Crystal structure of human kynurenine aminotransferase II
2VGZ	;	2.3	;	CRYSTAL STRUCTURE OF HUMAN KYNURENINE AMINOTRANSFERASE II
4WP0	;	3.0	;	Crystal structure of human kynurenine aminotransferase-I with a C-terminal V5-hexahistidine tag
6TSJ	;	2.3	;	Crystal structure of human L ferritin (HuLf) Fe(III)-loaded for 15 minutes
6TSA	;	2.18	;	Crystal structure of human L ferritin (HuLf) Fe(III)-loaded for 30 minutes
6TSF	;	2.09	;	Crystal structure of human L ferritin (HuLf) Fe(III)-loaded for 60 minutes
6TR9	;	2.46	;	Crystal structure of human L ferritin (HuLf) triple variant E60A-E61A-E64A
6TS0	;	2.2	;	Crystal structure of human L ferritin (HuLf) triple variant E60A-E61A-E64A Fe(III)-loaded for 30 minutes
6TS1	;	2.2	;	Crystal structure of human L ferritin (HuLf) triple variant E60A-E61A-E64A Fe(III)-loaded for 60 minutes
3RQS	;	2.001	;	Crystal Structure of human L-3- Hydroxyacyl-CoA dehydrogenase (EC1.1.1.35) from mitochondria at the resolution 2.0 A, Northeast Structural Genomics Consortium Target HR487, Mitochondrial Protein Partnership
9JDW	;	2.5	;	CRYSTAL STRUCTURE OF HUMAN L-ARGININE:GLYCINE AMIDINOTRANSFERASE IN COMPLEX WITH ALPHA-AMINO BUTYRIC ACID
7JDW	;	2.37	;	CRYSTAL STRUCTURE OF HUMAN L-ARGININE:GLYCINE AMIDINOTRANSFERASE IN COMPLEX WITH DELTA-AMINO VALERIC ACID
6JDW	;	2.5	;	CRYSTAL STRUCTURE OF HUMAN L-ARGININE:GLYCINE AMIDINOTRANSFERASE IN COMPLEX WITH GAMMA-AMINO BUTYRIC ACID
5JDW	;	2.6	;	CRYSTAL STRUCTURE OF HUMAN L-ARGININE:GLYCINE AMIDINOTRANSFERASE IN COMPLEX WITH GLYCINE
8JDW	;	2.3	;	CRYSTAL STRUCTURE OF HUMAN L-ARGININE:GLYCINE AMIDINOTRANSFERASE IN COMPLEX WITH L-ALANINE
1JDX	;	2.4	;	CRYSTAL STRUCTURE OF HUMAN L-ARGININE:GLYCINE AMIDINOTRANSFERASE IN COMPLEX WITH L-NORVALINE
2JDX	;	2.9	;	CRYSTAL STRUCTURE OF HUMAN L-ARGININE:GLYCINE AMIDINOTRANSFERASE, DELETIONMUTANT ATDELTAM302
4O0H	;	1.97	;	Crystal structure of human L-asparaginase protein with covalently linked substrate L-asparagine
1KR5	;	2.1	;	Crystal structure of human L-isoaspartyl methyltransferase
7M2N	;	2.5	;	Crystal structure of Human Lactate Dehydrogenase A with Inhibitor Compound 15
4AD9	;	2.6	;	Crystal structure of human LACTB2.
3RP1	;	2.6	;	Crystal structure of Human LAIR-1 in C2 space group
3TYY	;	2.399	;	Crystal Structure of Human Lamin-B1 Coil 2 Segment
3E6U	;	2.6	;	Crystal structure of Human LanCL1
3E73	;	2.8	;	Crystal Structure of Human LanCL1 complexed with GSH
3JUV	;	3.12	;	Crystal structure of human lanosterol 14alpha-demethylase (CYP51)
3JUS	;	2.9	;	Crystal structure of human lanosterol 14alpha-demethylase (CYP51) in complex with econazole
3LD6	;	2.8	;	Crystal structure of human lanosterol 14alpha-demethylase (CYP51) in complex with ketoconazole
3WAL	;	2.0	;	Crystal structure of human LC3A_2-121
3VTU	;	1.6	;	Crystal structure of human LC3B_2-119
3WAM	;	1.75	;	Crystal structure of human LC3C_8-125
5BV7	;	2.45	;	Crystal structure of human LCAT (L4F, N5D) in complex with Fab of an agonistic antibody
7DBK	;	1.802	;	Crystal structure of human LDHB in complex with NADH
7DBJ	;	1.551	;	Crystal structure of human LDHB in complex with NADH, oxamate, and AXKO-0046
1YXJ	;	1.78	;	Crystal structure of human lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1) at low pH
1YXK	;	2.4	;	Crystal structure of human lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1) disulfide-linked dimer
5LUB	;	2.1	;	Crystal structure of human legumain (AEP) in complex with compound 11
5LUA	;	2.0	;	Crystal structure of human legumain (AEP) in complex with compound 11b
7FQI	;	1.45	;	Crystal Structure of human Legumain in complex with (2S)-N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-[1-[4-[(2,4-difluorophenyl)methoxy]phenyl]cyclopropanecarbonyl]pyrrolidine-2-carboxamide
7FQJ	;	1.7	;	Crystal Structure of human Legumain in complex with (2S)-N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-[1-[4-[(2,4-difluorophenyl)methoxy]phenyl]cyclopropanecarbonyl]pyrrolidine-2-carboxamide
7FQL	;	2.53	;	Crystal Structure of human Legumain in complex with (2S)-N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-[1-[4-[(2,4-difluorophenyl)methoxy]phenyl]cyclopropanecarbonyl]pyrrolidine-2-carboxamide
7FQK	;	1.97	;	Crystal Structure of human Legumain in complex with (2S)-N-[(3S)-5-amino-1-(1,3-oxazol-2-yl)-5-oxopent-1-yn-3-yl]-1-[1-[4-(trifluoromethoxy)phenyl]cyclopropanecarbonyl]pyrrolidine-2-carboxamide
7FQH	;	2.18	;	Crystal Structure of human Legumain in complex with (2S)-N-[(3S)-5-amino-5-oxopent-1-yn-3-yl]-1-[1-[4-(cyclopropylmethoxy)phenyl]cyclopropanecarbonyl]pyrrolidine-2-carboxamide
8AE4	;	1.79	;	Crystal structure of human legumain in complex with Clitocypin 2
7O50	;	1.9	;	Crystal structure of human legumain in complex with Gly-Ser-Asn peptide
8AE5	;	2.29	;	Crystal structure of human legumain in complex with macrocypin 1a
3IEI	;	1.9	;	Crystal structure of human leucine carboxylmethyltransferase-1 in complex with S-adenosyl homocysteine
6KID	;	3.15	;	Crystal structure of human leucyl-tRNA synthetase, ATP-bound form
6KIE	;	3.15	;	Crystal structure of human leucyl-tRNA synthetase, Leu-AMS-bound form
6KQY	;	3.3	;	Crystal structure of human leucyl-tRNA synthetase, Leucine-bound form
1EMR	;	3.5	;	CRYSTAL STRUCTURE OF HUMAN LEUKEMIA INHIBITORY FACTOR (LIF)
5B0H	;	1.94	;	CRYSTAL STRUCTURE OF HUMAN LEUKOCYTE CELL-DERIVED CHEMOTAXIN 2
2Y05	;	2.2	;	Crystal structure of human leukotriene B4 12-hydroxydehydrogenase in complex with NADP and raloxifene
2PNO	;	3.3	;	Crystal structure of human leukotriene C4 synthase
2UUI	;	2.0	;	Crystal structure of Human Leukotriene C4 Synthase
2UUH	;	2.15	;	Crystal structure of Human Leukotriene C4 Synthase in complex with substrate glutathione
3STK	;	1.55	;	Crystal Structure of human LFABP complex with two molecules of palmitic acid (holo-LFABP)
5Y2Z	;	2.67	;	Crystal structure of human LGI1 EPTP-ADAM22 complex
5Y31	;	7.125	;	Crystal structure of human LGI1-ADAM22 complex
8HPY	;	5.87	;	Crystal structure of human LGI1-ADAM22 complex
8HQ1	;	4.17	;	Crystal Structure Of Human Lgi1-Adam22 Complex In Space Group C2
3EQT	;	2.0	;	Crystal structure of human LGP2 C-terminal domain in complex with dsRNA
4QXF	;	2.25	;	crystal structure of human LGR4 and Rspo1
4KNG	;	2.5	;	Crystal structure of human LGR5-RSPO1-RNF43
3K7E	;	3.0	;	Crystal structure of human ligand-free mature caspase-6
3NKF	;	2.9	;	Crystal structure of human ligand-free mature caspase-6 with intersubunit linker attached
7SUM	;	2.9	;	Crystal structure of human ligase I with nick duplexes containing cognate A:T
2V1W	;	1.9	;	Crystal structure of human LIM protein RIL (PDLIM4) PDZ domain bound to the C-terminal peptide of human alpha-actinin-1
8GI4	;	2.06	;	Crystal structure of human LIMK2 PDZ domain
5LP1	;	1.91	;	CRYSTAL STRUCTURE OF HUMAN LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN COMPLEX WITH A [1.1.1]BICYCLOPENTANE-CONTAINING INHIBITOR AT 1.91A RESOLUTION.
1QDD	;	1.3	;	CRYSTAL STRUCTURE OF HUMAN LITHOSTATHINE TO 1.3 A RESOLUTION
3CMF	;	1.9	;	Crystal structure of human liver 5beta-reductase (AKR1D1) in complex with NADP and CORTISONE. Resolution 1.90 A.
3G1R	;	1.701	;	Crystal structure of human liver 5beta-reductase (AKR1D1) in complex with NADP and Finasteride. Resolution 1.70 A
1K6M	;	2.4	;	Crystal Structure of Human Liver 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase
3K9B	;	3.1	;	Crystal structure of human liver carboxylesterase 1 (hCE1) in covalent complex with the nerve agent Cyclosarin (GF)
2HRQ	;	2.7	;	Crystal structure of Human Liver Carboxylesterase 1 (hCE1) in covalent complex with the nerve agent Soman (GD)
2HRR	;	2.7	;	Crystal structure of Human Liver Carboxylesterase 1 (hCE1) in covalent complex with the nerve agent Tabun (GA)
1YA4	;	3.2	;	Crystal Structure of Human Liver Carboxylesterase 1 in complex with tamoxifen
1YAH	;	3.0	;	Crystal Structure of Human Liver Carboxylesterase complexed to Etyl Acetate; A Fatty Acid Ethyl Ester Analogue
1YAJ	;	3.2	;	Crystal Structure of Human Liver Carboxylesterase in complex with benzil
1YA8	;	3.0	;	Crystal Structure of Human Liver Carboxylesterase in complex with cleavage products of Mevastatin
1MX1	;	2.4	;	Crystal Structure of Human Liver Carboxylesterase in complex with tacrine
1MX5	;	2.8	;	Crystal Structure of Human Liver Carboxylesterase in complexed with homatropine, a cocaine analogue
1MX9	;	2.9	;	Crystal Structure of Human Liver Carboxylesterase in complexed with naloxone methiodide, a heroin analogue
3COT	;	2.03	;	Crystal structure of human liver delta(4)-3-ketosteroid 5beta-reductase (akr1d1) in complex with progesterone and nadp. Resolution: 2.03 A.
7WJV	;	1.724	;	Crystal structure of human liver FBPase complexed with an covalent inhibitor
3A29	;	2.6	;	Crystal structure of human liver FBPase in complex with tricyclic inhibitor
3KC0	;	2.8	;	Crystal structure of human liver FBPase in complex with tricyclic inhibitor 10b
3KC1	;	2.25	;	Crystal structure of human liver FBPase in complex with tricyclic inhibitor 19a
3KBZ	;	2.45	;	Crystal structure of human liver FBPase in complex with tricyclic inhibitor 6
5ZWK	;	2.104	;	Crystal structure of Human liver fructose-1,6-bisphoaphatase complex with fructose-1,6-bisphophate and AMP
7C9Q	;	1.878	;	Crystal structure of Human liver fructose-1,6-bisphoaphatase complex with Mg2+ and AMP
1ZNQ	;	2.5	;	Crystal Structure of Human Liver GAPDH
4BQM	;	2.18	;	Crystal structure of human liver-type glutaminase, catalytic domain
4NFT	;	2.61	;	Crystal structure of human lnkH2B-h2A.Z-Anp32e
5JNR	;	2.0	;	Crystal structure of human low molecular weight protein tyrosine phosphatase (LMPTP) type A
5JNT	;	1.45	;	Crystal structure of human low molecular weight protein tyrosine phosphatase (LMPTP) type A complexed with MES
5JNS	;	1.8	;	Crystal structure of human low molecular weight protein tyrosine phosphatase (LMPTP) type A complexed with phosphate
1YOK	;	2.5	;	crystal structure of human LRH-1 bound with TIF-2 peptide and phosphatidylglycerol
5Z8X	;	3.15	;	Crystal structure of human LRRTM2
5Z8Y	;	3.4	;	Crystal structure of human LRRTM2 in complex with Neurexin 1beta
6NQM	;	2.9	;	Crystal structure of Human LSD1
2DW4	;	2.3	;	Crystal structure of human LSD1 at 2.3 A resolution
5NI6	;	1.54	;	Crystal structure of human LTA4H mutant D375N in complex with LTA4
5NIA	;	1.764	;	Crystal structure of human LTA4H mutant D375N in open conformation (crystal form I)
5NID	;	1.568	;	Crystal structure of human LTA4H mutant D375N in open conformation (crystal form II)
5NI2	;	1.501	;	Crystal structure of human LTA4H mutant E271A in complex with LTA4 (crystal form I)
5NI4	;	1.895	;	Crystal structure of human LTA4H mutant E271A in complex with LTA4 (crystal form II)
5NIE	;	2.603	;	Crystal structure of human LTA4H mutant R563A in open conformation
5OXS	;	1.65	;	Crystal structure of human lung surfactant protein D trimeric fragment with bound ligand Salmonella enterica Minnesota R5 oligosaccharide
5OXR	;	1.75	;	Crystal structure of human lung surfactant protein D trimeric fragment with bound ligand Salmonella enterica Minnesota R7 oligosaccharide
3MP3	;	2.4	;	Crystal Structure of Human Lyase in complex with inhibitor HG-CoA
3MP5	;	2.25	;	Crystal Structure of Human Lyase R41M in complex with HMG-CoA
3MP4	;	2.2	;	Crystal structure of Human lyase R41M mutant
4JOB	;	2.171	;	Crystal structure of human lysophosphatidic acid phosphatase type 6 complexed with L-(+)-tartrate
4JOC	;	2.208	;	Crystal structure of human lysophosphatidic acid phosphatase type 6 complexed with Malonate
4JOD	;	2.21	;	Crystal structure of human lysophosphatidic acid phosphatase type 6 complexed with Tris
4Z36	;	2.9	;	Crystal Structure of Human Lysophosphatidic Acid Receptor 1 in complex with ONO-3080573
4Z35	;	2.9	;	Crystal Structure of Human Lysophosphatidic Acid Receptor 1 in complex with ONO-9910539
4Z34	;	3.0	;	Crystal Structure of Human Lysophosphatidic Acid Receptor 1 in complex with ONO9780307
5NN3	;	1.9	;	Crystal structure of human lysosomal acid-alpha-glucosidase, GAA
5NN5	;	2.0	;	Crystal structure of human lysosomal acid-alpha-glucosidase, GAA, in complex with 1-deoxynojirimycin
5NN8	;	2.45	;	Crystal structure of human lysosomal acid-alpha-glucosidase, GAA, in complex with acarbose
7P2Z	;	1.85	;	Crystal structure of human lysosomal acid-alpha-glucosidase, GAA, in complex with cyclosulfamidate 4
7P32	;	1.82	;	Crystal structure of human lysosomal acid-alpha-glucosidase, GAA, in complex with cyclosulfamidate 6
5NN4	;	1.83	;	Crystal structure of human lysosomal acid-alpha-glucosidase, GAA, in complex with N-acetyl-cysteine
5NN6	;	2.0	;	Crystal structure of human lysosomal acid-alpha-glucosidase, GAA, in complex with N-hydroxyethyl-1-deoxynojirimycin
8CB1	;	1.75	;	Crystal structure of human lysosomal acid-alpha-glucosidase, GAA, in complex with N-PNT-DNM 15
8CB6	;	1.9	;	Crystal structure of human lysosomal acid-alpha-glucosidase, GAA, in covalent complex with TAMRA tagged 1,6-Epi-cylcophellitol aziridine activity based probe
8K7J	;	2.01	;	Crystal structure of human lysosomal alpha-galactosidase A in complex with (2R,3R,4S,5R)-2-((dimethylamino)methyl)-5-(hydroxymethyl)pyrrolidine-3,4-diol
8K7L	;	2.0	;	Crystal structure of human lysosomal alpha-galactosidase A in complex with (2R,3R,4S,5R)-2-(aminomethyl)-5-(hydroxymethyl)-1-methylpyrrolidine-3,4-diol
8K7D	;	2.61	;	Crystal structure of human lysosomal alpha-galactosidase A in complex with (2R,3R,4S,5R)-2-(aminomethyl)-5-(hydroxymethyl)pyrrolidine-3,4-diol
8K7E	;	2.2	;	Crystal structure of human lysosomal alpha-galactosidase A in complex with (2R,3R,4S,5R)-2-(aminomethyl)-5-(hydroxymethyl)pyrrolidine-3,4-diol
8K7H	;	2.28	;	Crystal structure of human lysosomal alpha-galactosidase A in complex with (2R,3S,4R)-2-(hydroxymethyl)-1-methylpyrrolidine-3,4-diol
8K7K	;	2.0	;	Crystal structure of human lysosomal alpha-galactosidase A in complex with (2R,3S,4R,5R)-2,5-bis(hydroxymethyl)-1-methylpyrrolidine-3,4-diol
8K7F	;	1.98	;	Crystal structure of human lysosomal alpha-galactosidase A in complex with (2R,3S,4R,5R)-2,5-bis(hydroxymethyl)pyrrolidine-3,4-diol
8K7G	;	2.32	;	Crystal structure of human lysosomal alpha-galactosidase A in complex with (2R,3S,4R,5R)-2,5-bis(hydroxymethyl)pyrrolidine-3,4-diol
8K7I	;	2.12	;	Crystal structure of human lysosomal alpha-galactosidase A in complex with (2R,3S,4R,5R)-2-(hydroxymethyl)-5-((methylamino)methyl)pyrrolidine-3,4-diol
7XF6	;	1.3	;	Crystal Structure of Human Lysozyme
1JWR	;	1.4	;	Crystal structure of human lysozyme at 100 K
7XF7	;	1.55	;	Crystal Structure of Human Lysozyme Complexed with N-Acetyl-alpha-D-Glucosamine
7XF8	;	1.6	;	Crystal Structure of Human Lysozyme Complexed with N-Acetyl-alpha-D-Glucosamine
2ZIJ	;	1.9	;	Crystal Structure of Human Lysozyme Expressed in E. coli.
2ZIK	;	1.81	;	Crystal Structure of Human Lysozyme from Pichia pastoris
2ZIL	;	1.8	;	Crystal Structure of Human Lysozyme from Urine
4DPG	;	2.844	;	Crystal Structure of Human LysRS: P38/AIMP2 Complex I
6ILD	;	1.882	;	Crystal Structure of Human LysRS: P38/AIMP2 Complex II
5ZE3	;	2.4	;	Crystal structure of human lysyl oxidase-like 2 (hLOXL2) in a precursor state
6CHD	;	2.5	;	Crystal Structure of Human Lysyl-tRNA Synthetase complexed with L-Lysylsulfamoyl Adenosine
6ILH	;	2.501	;	Crystal Structure of human lysyl-tRNA synthetase L350H mutant
7EA9	;	2.5	;	Crystal Structure of human lysyl-tRNA synthetase Y145H mutant
1KFX	;	3.15	;	Crystal Structure of Human m-Calpain Form I
1KFU	;	2.5	;	Crystal Structure of Human m-Calpain Form II
1PJL	;	2.9	;	Crystal structure of human m-NAD-ME in ternary complex with NAD and Lu3+
5CCB	;	2.0	;	Crystal structure of human m1A58 methyltransferase in a complex with tRNA3Lys and SAH
4EEG	;	2.2	;	Crystal structure of human M340H-beta-1,4-galactosyltransferase-1 (M340H-B4GAL-T1) in complex with GLCNAC-BETA1,6-Gal-Beta
4EEA	;	2.0	;	Crystal structure of human M340H-beta-1,4-galactosyltransferase-1 (M340H-B4GAL-T1) in complex with GLCNAC-BETA1,6-Gal-Beta1,4-Glc-BETA
4EEO	;	2.3	;	Crystal structure of human M340H-beta-1,4-galactosyltransferase-1 (M340H-B4GAL-T1) in complex with GLCNAC-BETA1,6-GlcNAc-ALPHA-benzyl
4EEM	;	2.2	;	Crystal structure of human M340H-beta-1,4-galactosyltransferase-1 (M340H-B4GAL-T1) in complex with GLCNAC-BETA1,6-MAN-ALPHA-methyl
4EE3	;	2.3	;	Crystal structure of human M340H-beta-1,4-galactosyltransferase-1 (M340H-B4GAL-T1) in complex with pentasaccharide
4EE4	;	1.95	;	Crystal structure of human M340H-beta-1,4-galactosyltransferase-1 (M340H-B4GAL-T1) in complex with tetrasaccharide from Lacto-N-neohexose
4EE5	;	2.2	;	Crystal structure of human M340H-beta-1,4-galactosyltransferase-1 (M340H-B4GAL-T1) in complex with trisaccharide from Lacto-N-neotetraose
2AH9	;	2.0	;	Crystal Structure of Human M340H-Beta-1,4-Galactosyltransferase-I (M340H-B4Gal-T1) in Complex with Chitotriose
2AGD	;	1.9	;	Crystal Structure of Human M340H-Beta-1,4-Galactosyltransferase-I(M340H-B4Gal-T1) in Complex with GlcNAc-beta1,4-Man-alpha1,3-Man-beta-OR
2AES	;	2.0	;	Crystal Structure of Human M340H-Beta1,4-Galactosyltransferase-I (M340H-B4Gal-T1) in Complex with GlcNAc-beta1,2-Man-alpha1,3-Man-beta-OR
2AEC	;	2.0	;	Crystal Structure of Human M340H-Beta1,4-Galactosyltransferase-I (M340H-B4GAL-T1) in Complex with GlcNAc-beta1,2-Man-alpha1,6-Man-beta-OR
3EE5	;	2.2	;	Crystal structure of human M340H-Beta1,4-Galactosyltransferase-I (M340H-B4GAL-T1) in complex with GLCNAC-Beta1,3-Gal-Beta-Naphthalenemethanol
2AE7	;	2.0	;	Crystal Structure of Human M340H-Beta1,4-Galactosyltransferase-I (M340H-B4GAL-T1) in Complex with Pentasaccharide
2X47	;	1.7	;	Crystal structure of human MACROD1
4HCR	;	2.3	;	Crystal structure of human MAdCAM-1 D1D2 complexed with Fab PF-547659
3NR5	;	1.55	;	Crystal structure of human Maf1
2WM8	;	1.75	;	Crystal structure of human magnesium-dependent phosphatase 1 of the haloacid dehalogenase superfamily (MGC5987)
6J08	;	2.9	;	Crystal structure of human MAJIN and TERB2
2DFD	;	1.9	;	Crystal Structure of Human Malate Dehydrogenase Type 2
4F0X	;	3.29	;	Crystal structure of human Malonyl-CoA Decarboxylase (Peroxisomal Isoform)
7ZW3	;	2.0	;	Crystal Structure of human MAO B in complex with (Z)-N-benzyl-1-(8-hydroxyquinolin-2-yl)methanimine oxide (inhibitor 19)
6FW2	;	1.78	;	Crystal Structure of human mARC1
7P41	;	1.6	;	Crystal Structure of human mARC1 A165T Variant
8QDZ	;	1.16	;	Crystal structure of human MAT2a bound to S-Adenosylmethionine and Compound 11
8QE0	;	1.12	;	Crystal structure of human MAT2a bound to S-Adenosylmethionine and Compound 12
8QE1	;	1.095	;	Crystal structure of human MAT2a bound to S-Adenosylmethionine and Compound 15
8QE2	;	1.109	;	Crystal structure of human MAT2a bound to S-Adenosylmethionine and Compound 21
8QE3	;	1.089	;	Crystal structure of human MAT2a bound to S-Adenosylmethionine and Compound 31
8QDY	;	1.19	;	Crystal structure of human MAT2a bound to S-Adenosylmethionine and Compound 8
8OOG	;	1.384	;	Crystal structure of human MAT2a with S-Adenosylmethionine and a fragment bound in a novel pocket
1L6J	;	2.5	;	Crystal structure of human matrix metalloproteinase MMP9 (gelatinase B).
4GWN	;	3.0	;	Crystal structure of human mature meprin beta
7AQ1	;	2.413	;	Crystal structure of human mature meprin beta in complex with the specific inhibitor MWT-S-270
3Q6M	;	3.0	;	Crystal Structure of Human MC-HSP90 in C2221 Space Group
3Q6N	;	3.05	;	Crystal Structure of Human MC-HSP90 in P21 space group
2YGW	;	2.8	;	Crystal structure of human MCD
4OQ5	;	2.86	;	Crystal Structure of Human MCL-1 Bound to Inhibitor 4-(4-methylnaphthalen-1-yl)-2-{[(4-phenoxyphenyl)sulfonyl]amino}benzoic acid
4OQ6	;	1.81	;	Crystal Structure of Human MCL-1 Bound to Inhibitor 4-hydroxy-4'-propylbiphenyl-3-carboxylic acid
8QSO	;	2.106	;	Crystal structure of human Mcl-1 in complex with compound 1
5W8F	;	1.85	;	Crystal structure of human Mcl-1 in complex with modified Bim BH3 peptide SAH-MS1-14
5W89	;	1.42	;	Crystal structure of human Mcl-1 in complex with modified Bim BH3 peptide SAH-MS1-18
5BO0	;	2.906	;	Crystal structure of Human MCM2 HBD and ASF1b chaperoning a histone H3.2-H4 dimer
5BNX	;	2.305	;	Crystal structure of Human MCM2 HBD and ASF1b chaperoning a histone H3.3-H4 dimer
5BNV	;	2.795	;	Crystal structure of Human MCM2 HBD chaperoning a histone H3-H4 tetramer
7WI7	;	6.6	;	Crystal structure of human MCM8/9 complex
2BDN	;	2.53	;	Crystal structure of human MCP-1 bound to a blocking antibody, 11K2
3SHT	;	1.95	;	Crystal structure of human MCPH1 tandem BRCT domains
3SHV	;	2.1	;	Crystal structure of human MCPH1 tandem BRCT domains-gamma H2AX complex
2E56	;	2.0	;	Crystal structure of human MD-2
2E59	;	2.21	;	Crystal structure of human MD-2 in complex with lipid IVa
5XEQ	;	3.136	;	Crystal Structure of human MDGA1 and human neuroligin-2 complex
3IWY	;	1.93	;	Crystal structure of human MDM2 complexed with D-peptide (12 residues)
5UMM	;	1.65	;	CRYSTAL STRUCTURE OF HUMAN MDM2 IN COMPLEX WITH 12-MER PEPTIDE INHIBITOR M3
5VK0	;	1.8	;	Crystal structure of human MDM2 in complex with a 12-mer lysine-cysteine side chain dithiocarbamate stapled peptide inhibitor PMI
3EQS	;	1.65	;	Crystal structure of human MDM2 in complex with a 12-mer peptide inhibitor
3IUX	;	1.65	;	Crystal structure of human MDM2 in complex with a potent miniature protein inhibitor (18-residues)
3TPX	;	1.8	;	Crystal structure of human MDM2 in complex with a trifluoromethylated D-peptide inhibitor
3LNJ	;	2.4	;	Crystal structure of human MDM2 in complex with D-peptide inhibitor (DPMI-alpha)
7KJM	;	1.4	;	CRYSTAL STRUCTURE OF HUMAN MDM2 IN COMPLEX WITH D-PEPTIDE INHIBITOR (DPMI-OMEGA)
6SQO	;	1.41	;	Crystal structure of human MDM2 RING domain homodimer bound to UbcH5B-Ub
3LNZ	;	1.95	;	Crystal structure of human MDM2 with a 12-mer peptide inhibitor PMI (N8A mutant)
3VZV	;	2.8	;	Crystal structure of human mdm2 with a dihydroimidazothiazole inhibitor
3W69	;	1.9	;	Crystal structure of human mdm2 with a dihydroimidazothiazole inhibitor
1RV1	;	2.3	;	CRYSTAL STRUCTURE OF HUMAN MDM2 WITH AN IMIDAZOLINE INHIBITOR
7AI0	;	1.559	;	Crystal structure of human MDM2-G443T RING domain homodimer bound to UbcH5B-Ub (Crystal form 1)
7AI1	;	2.07	;	Crystal structure of human MDM2-G443T RING domain homodimer bound to UbcH5B-Ub (Crystal form 2)
4XXB	;	2.4	;	Crystal structure of human MDM2-RPL11
5VK1	;	2.69	;	Crystal structure of human MDM4 in complex with a 12-mer lysine-cysteine side chain dithiocarbamate stapled peptide inhibitor PMI
5UML	;	3.0	;	CRYSTAL STRUCTURE OF HUMAN MDMX IN COMPLEX WITH 12-MER PEPTIDE INHIBITOR M3
3EQY	;	1.63	;	Crystal structure of human MDMX in complex with a 12-mer peptide inhibitor
7KJN	;	2.8	;	CRYSTAL STRUCTURE OF HUMAN MDMX IN COMPLEX WITH D-PEPTIDE INHIBITOR (DPMI-OMEGA)
7BSJ	;	2.48	;	Crystal structure of human ME2 R484W
7BSL	;	2.55	;	Crystal Structure of human ME2 R67A mutant
7BSK	;	2.55	;	Crystal structure of human ME2 R67Q mutant
6H02	;	2.8	;	Crystal structure of human Mediator subunit MED23
3E6P	;	2.1	;	Crystal structure of human meizothrombin desF1
6PX5	;	2.4	;	CRYSTAL STRUCTURE OF HUMAN MEIZOTHROMBIN DESF1 MUTANT S195A bound with PPACK
3SLS	;	2.3	;	Crystal Structure of human MEK-1 kinase in complex with UCB1353770 and AMPPNP
6R7T	;	2.682	;	Crystal Structure of human Melanoma-associated antigen B1 (MAGEB1) in complex with nanobody
6XR0	;	3.064	;	Crystal Structure of Human Melanotransferrin in complex with SC57.32 Fab
3U84	;	2.5	;	Crystal Structure of Human Menin
7O9T	;	2.159	;	Crystal structure of Human Menin in apo form
4I80	;	3.1	;	Crystal structure of human menin in complex with a high-affinity macrocyclic peptidomimetics
7O9Z	;	1.979	;	Crystal structure of Human Menin in complex with BD-08
7OA9	;	2.098	;	Crystal structure of Human Menin in complex with Fragment 21
3U86	;	2.843	;	Crystal structure of human menin in complex with JunD
3U85	;	3.0	;	Crystal structure of human menin in complex with MLL1
3U88	;	3.0	;	Crystal structure of human menin in complex with MLL1 and LEDGF
7O9X	;	2.299	;	Crystal structure of Human Menin with fragment 16
5WB0	;	2.601	;	Crystal structure of human metapneumovirus fusion glycoprotein stabilized in the prefusion state
3SZK	;	3.01	;	Crystal Structure of Human metHaemoglobin Complexed with the First NEAT Domain of IsdH from Staphylococcus aureus
4FC3	;	2.26	;	Crystal Structure of Human Methaemoglobin Complexed with the Second NEAT Domain of IsdH from Staphylococcus aureus
8P1W	;	1.15	;	Crystal structure of human methionine adenosyltransferase 2A (MAT2A) in complex with allosteric compound STL232591
8AXZ	;	1.154	;	Crystal structure of human methionine adenosyltransferase 2A (MAT2A) in complex with S-adenosylmethionine, adenosin and diphosphono-aminophosphonic acid.
8P1V	;	1.54	;	Crystal structure of human methionine adenosyltransferase 2A (MAT2A) in complex with SAM and allosteric compound 2
8P4H	;	1.71	;	Crystal structure of human methionine adenosyltransferase 2A (MAT2A) in complex with SAM and allosteric compound IDEAYA cmpd A
7KCC	;	1.32	;	Crystal structure of human methionine adenosyltransferase 2A (MAT2A) in complex with SAM and allosteric inhibitor AG-270
7KCF	;	1.1	;	Crystal structure of human methionine adenosyltransferase 2A (MAT2A) in complex with SAM and allosteric inhibitor AGI-24512
7RWH	;	1.17	;	Crystal structure of human methionine adenosyltransferase 2A (MAT2A) in complex with SAM and allosteric inhibitor AGI-41998
7RW5	;	2.48	;	Crystal structure of human methionine adenosyltransferase 2A (MAT2A) in complex with SAM and allosteric inhibitor Compound 1
7KCE	;	1.14	;	Crystal structure of human methionine adenosyltransferase 2A (MAT2A) in complex with SAM and allosteric inhibitor compound 2
7KDA	;	1.24	;	Crystal structure of human methionine adenosyltransferase 2A (MAT2A) in complex with SAM and allosteric inhibitor compound 34
7KDB	;	1.24	;	Crystal structure of human methionine adenosyltransferase 2A (MAT2A) in complex with SAM and allosteric inhibitor compound 35
7RW7	;	1.19	;	Crystal structure of human methionine adenosyltransferase 2A (MAT2A) in complex with SAM and allosteric inhibitor Compound 9
8P1T	;	1.442	;	Crystal structure of human methionine adenosyltransferase 2A (MAT2A) in complex with SAM and allosteric inhibitor Z237451470
6LZB	;	1.29	;	crystal structure of Human Methionine aminopeptidase (HsMetAP1b) in complex with AN-P2-5H-06
6LZC	;	1.35	;	crystal structure of Human Methionine aminopeptidase (HsMetAP1b) in complex with KV-P2-4H-05
8KHN	;	1.51	;	Crystal structure of human methionine aminopeptidase 12 (MAP12) in complex with two cobalt ions
8KHO	;	1.45	;	Crystal structure of human methionine aminopeptidase 12 (MAP12) in complex with two Cobalt ions and Methionine
8KHM	;	1.39	;	Crystal structure of human methionine aminopeptidase 12 (MAP12) in the unbound form
2NQ6	;	1.5	;	Crystal structure of human methionine aminopeptidase type 1 in complex with 3-tert-Butoxycarbonylaminopyridine-2-carboxylic acid thiazole-2-ylamide
2B3K	;	1.55	;	Crystal structure of Human Methionine Aminopeptidase Type I in the holo form
2B3H	;	1.1	;	Crystal structure of Human Methionine Aminopeptidase Type I with a third cobalt in the active site
8OXG	;	1.731	;	Crystal structure of human methionine aminopeptidase-2 complexed with (3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl]-1-oxaspiro[2.5]oct-6-yl N-(trans-4-aminocyclohexyl)carbamate
6QEF	;	1.79	;	CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX WITH AN INHIBITOR (S)-3-Hydroxy-2-oxo-1-phenyl-pyrrolidine-3-carboxylic acid 3-chloro-5-fluoro-benzylamide
6QEG	;	2.08	;	CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX WITH AN INHIBITOR 2-Oxo-1-phenyl-pyrrolidine-3-carboxylic acid (2-thiophen-2-yl-ethyl)-amide
6QEI	;	1.8	;	CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX WITH AN INHIBITOR 5,6-Difluoro-3-(2-isopropoxy-4-piperazin-1-yl-phenyl)-1H-indole-2-carboxylic acid amide
6QEH	;	2.17	;	CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX WITH AN INHIBITOR 5-Chloro-quinolin-8-ol
7A13	;	2.04	;	CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX WITH AN INHIBITOR GSK1978537A (COMPOUND 27)
7A14	;	2.14	;	CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX WITH AN INHIBITOR GSK2218325A (COMPOUND 32)
7A15	;	2.15	;	CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX WITH AN INHIBITOR GSK2224863A (COMPOUND 42)
7A16	;	1.9	;	CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX WITH AN INHIBITOR GSK2229238A (COMPOUND 43)
7A12	;	2.0	;	CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX WITH AN INHIBITOR GW557358X (COMPOUND 9)
6QEJ	;	1.62	;	CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX WITH AN INHIBITOR Thiophene-2-sulfonic acid (4-fluoro-benzyl)-(4H-[1,2,4]triazol-3-ylmethyl)-amide
6QED	;	1.8	;	CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX; WITH AN INHIBITOR (S)-3-Hydroxy-2-oxo-1-(2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyrrolidine-3-carboxylic acid 3-chloro-5-fluoro-benzylamide
5LYX	;	1.9	;	CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX; WITH AN INHIBITOR 5-((R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-yl-pyrrolidin-2-ylmethoxy)-isoquinoline
5LYW	;	1.69	;	CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX; WITH AN INHIBITOR 6-((R)-2-o-Tolyloxymethyl-pyrrolidin-1-yl)-9H-purine
3MAO	;	1.42	;	Crystal Structure of Human Methionine-R-Sulfoxide Reductase B1 (MsrB1)
6QH4	;	1.922	;	Crystal structure of human Methylmalonyl-CoA epimerase (MCEE) p.Arg143Cys variant
3RMU	;	1.8	;	Crystal structure of human Methylmalonyl-CoA epimerase, MCEE
3BIC	;	2.6	;	Crystal structure of human methylmalonyl-CoA mutase
8GJU	;	2.79	;	Crystal structure of human methylmalonyl-CoA mutase (MMUT) in complex with methylmalonic acidemia type A protein (MMAA), coenzyme A, and GDP
8DYL	;	1.9	;	Crystal structure of human methylmalonyl-CoA mutase bound to aquocobalamin
2XIJ	;	1.95	;	Crystal structure of human methylmalonyl-CoA mutase in complex with adenosylcobalamin
2XIQ	;	1.95	;	Crystal structure of human methylmalonyl-CoA mutase in complex with adenosylcobalamin and malonyl-CoA
8DYJ	;	2.2	;	Crystal structure of human methylmalonyl-CoA mutase in complex with ADP and cob(II)alamin
2EX4	;	1.75	;	Crystal Structure of Human methyltransferase AD-003 in complex with S-adenosyl-L-homocysteine
3CKK	;	1.55	;	Crystal structure of human methyltransferase-like protein 1
5WCJ	;	1.7	;	Crystal Structure of Human Methyltransferase-like protein 13 in complex with SAH
4QPN	;	1.25	;	Crystal Structure of Human Methyltransferase-Like Protein 21B
7U20	;	3.1	;	Crystal structure of human METTL1 and WDR4 complex
7PL1	;	1.85	;	Crystal structure of human METTL1 bound to Sinefungin
7OGJ	;	1.59	;	Crystal structure of human METTL1 in complex with SAH
8D5B	;	1.93	;	Crystal structure of human METTL1 in complex with SAH
8D59	;	2.26	;	Crystal structure of human METTL1 in complex with SAM
8D58	;	2.47	;	Crystal structure of human METTL1-WDR4 complex
6H2U	;	1.6	;	Crystal structure of human METTL5-TRMT112 complex, the 18S rRNA m6A1832 methyltransferase at 1.6A resolution
6H2V	;	2.49	;	Crystal structure of human METTL5-TRMT112 complex, the 18S rRNA m6A1832 methyltransferase at 2.5A resolution
8GZE	;	3.4	;	Crystal Structure of human METTL9-SAH-SLC39A7 peptide complex
3D4J	;	2.4	;	Crystal structure of Human mevalonate diphosphate decarboxylase
5ZYT	;	2.702	;	Crystal structure of human MGME1 with 3' overhang double strand DNA3
5ZYV	;	2.72	;	Crystal structure of human MGME1 with single strand DNA2 and Ca2+
1HYR	;	2.7	;	CRYSTAL STRUCTURE OF HUMAN MICA IN COMPLEX WITH NATURAL KILLER CELL RECEPTOR NKG2D
7FI5	;	2.39	;	Crystal structure of human MICA mutants in complex with natural killer cell receptor NKG2D
7FI6	;	2.9	;	Crystal structure of human MICA mutants in complex with natural killer cell receptor NKG2D
7FI7	;	2.78	;	Crystal structure of human MICA mutants in complex with natural killer cell receptor NKG2D
7FI8	;	2.8	;	Crystal structure of human MICA mutants in complex with natural killer cell receptor NKG2D
7FI9	;	2.16	;	Crystal structure of human MICA mutants in complex with natural killer cell receptor NKG2D
6ICI	;	2.3	;	Crystal structure of human MICAL3
7E50	;	1.95	;	Crystal structure of human microplasmin in complex with kazal-type inhibitor AaTI
6SSS	;	2.498	;	Crystal structure of Human Microsomal Glutathione S-Transferase 2
6SSR	;	3.8	;	Crystal structure of Human Microsomal Glutathione S-Transferase 2 at 3.8 Angstroms resolution
6SSW	;	3.0	;	Crystal structure of Human Microsomal Glutathione S-Transferase 2 in complex with an Inhibitor Glutathione sulfonic acid
6SSU	;	2.499	;	Crystal structure of Human Microsomal Glutathione S-Transferase 2 in complex with co-substrate Glutathione
2HI4	;	1.95	;	Crystal Structure of Human Microsomal P450 1A2 in complex with alpha-naphthoflavone
2PG6	;	2.53	;	Crystal Structure of Human Microsomal P450 2A6 L240C/N297Q
2PG5	;	1.95	;	Crystal Structure of Human Microsomal P450 2A6 N297Q
2PG7	;	2.8	;	Crystal Structure of Human Microsomal P450 2A6 N297Q/I300V
1Z10	;	1.9	;	Crystal Structure of Human Microsomal P450 2A6 with Coumarin Bound
1Z11	;	2.05	;	Crystal Structure of Human Microsomal P450 2A6 with Methoxsalen Bound
2FDW	;	2.05	;	Crystal Structure Of Human Microsomal P450 2A6 with the inhibitor (5-(Pyridin-3-yl)furan-2-yl)methanamine bound
1TQN	;	2.05	;	Crystal Structure of Human Microsomal P450 3A4
1FV9	;	3.0	;	Crystal structure of human microurokinase in complex with 2-amino-5-hydroxy-benzimidazole
7SFY	;	2.5	;	Crystal structure of human Mis18ab_cc
7AYC	;	2.02	;	Crystal Structure of human mitochondrial 2-Enoyl Thioester Reductase (MECR) with single mutation G165Q
2WYA	;	1.7	;	CRYSTAL STRUCTURE OF HUMAN MITOCHONDRIAL 3-HYDROXY-3-METHYLGLUTARYL- COENZYME A SYNTHASE 2 (HMGCS2)
4C2K	;	2.0	;	Crystal structure of human mitochondrial 3-ketoacyl-CoA thiolase
4C2J	;	2.0	;	Crystal structure of human mitochondrial 3-ketoacyl-CoA thiolase in complex with CoA
4MWO	;	1.67	;	Crystal structure of human mitochondrial 5'(3')-deoxyribonucleotidase in complex with the inhibitor CPB-T
4NFL	;	1.375	;	Crystal structure of human mitochondrial 5'(3')-deoxyribonucleotidase in complex with the inhibitor NPB-T
6G2M	;	1.37	;	Crystal structure of human mitochondrial 5'(3')-deoxyribonucleotidase in complex with the inhibitor PB-PAU
6G22	;	1.85	;	Crystal structure of human mitochondrial 5'(3')-deoxyribonucleotidase in complex with the inhibitor PB-PEU
6G2L	;	1.48	;	Crystal structure of human mitochondrial 5'(3')-deoxyribonucleotidase in complex with the inhibitor PB-PMTMU
3HLK	;	2.1	;	Crystal structure of human mitochondrial acyl-CoA thioesterase (ACOT2)
6BBA	;	2.796	;	Crystal structure of human mitochondrial ClpP complex with acyldepsipeptide ADEP-28
1SG4	;	1.3	;	Crystal structure of human mitochondrial delta3-delta2-enoyl-CoA isomerase
1Q91	;	1.6	;	Crystal structure of human mitochondrial deoxyribonucleotidase in complex with the inhibitor DPB-T
4L6C	;	1.8	;	Crystal structure of human mitochondrial deoxyribonucleotidase in complex with the inhibitor pib-t
1Q92	;	1.4	;	Crystal structure of human mitochondrial deoxyribonucleotidase in complex with the inhibitor PMcP-U
3IKM	;	3.24	;	Crystal structure of human mitochondrial DNA polymerase holoenzyme
4A35	;	1.74	;	Crystal structure of human Mitochondrial enolase superfamily member 1 (ENOSF1)
7O64	;	1.96	;	Crystal structure of human mitochondrial ferritin (hMTF) Fe(II)-loaded for 1 minute.
7O68	;	1.68	;	Crystal structure of human mitochondrial ferritin (hMTF) Fe(II)-loaded for 120 minutes showing either a dioxygen or a superoxide anion coordinated to iron ions in the ferroxidase site.
7O67	;	1.86	;	Crystal structure of human mitochondrial ferritin (hMTF) Fe(II)-loaded for 15 minutes showing either a dioxygen or a superoxide anion coordinated to iron ions in the ferroxidase site
7O6C	;	1.2	;	Crystal structure of human mitochondrial ferritin (hMTF) Fe(II)-loaded for 15 minutes under anaerobic environment
7OWY	;	1.55	;	Crystal structure of human mitochondrial ferritin (hMTF) Fe(II)-loaded for 3 minutes showing a peroxide anion as bridging species of iron ions in the ferroxidase site
7O6D	;	1.47	;	Crystal structure of human mitochondrial ferritin (hMTF) Fe(II)-loaded for 3 minutes under anaerobic environment
7O69	;	1.35	;	Crystal structure of human mitochondrial ferritin (hMTF) Fe(II)-loaded for 5 minutes showing a peroxide anion as bridging species of iron ions in the ferroxidase site
7O6A	;	1.4	;	Crystal structure of human mitochondrial ferritin (hMTF) Fe(II)-loaded for 5 minutes under anaerobic environment
7O66	;	1.6	;	Crystal structure of human mitochondrial ferritin (hMTF) Fe(II)-loaded for 60 minutes showing either a dioxygen or a superoxide anion coordinated to iron ions in the ferroxidase site
7O65	;	1.7	;	Crystal structure of human mitochondrial ferritin (hMTF) Fe(II)-loaded for 90 minutes showing either a dioxygen or a superoxide anion coordinated to iron ions in the ferroxidase site
6AVJ	;	1.9	;	Crystal structure of human Mitochondrial inner NEET protein (MiNT)/CISD3
5I96	;	1.55	;	Crystal Structure of Human Mitochondrial Isocitrate Dehydrogenase (IDH2) R140Q Mutant Homodimer in Complex with AG-221 (Enasidenib) Inhibitor.
6VFZ	;	1.99	;	Crystal Structure of Human Mitochondrial Isocitrate Dehydrogenase (IDH2) R140Q Mutant Homodimer in Complex with NADPH and AG-881 (Vorasidenib) Inhibitor.
5I95	;	1.54	;	Crystal Structure of Human Mitochondrial Isocitrate Dehydrogenase R140Q Mutant Homodimer bound to NADPH and alpha-Ketoglutaric acid
5TC4	;	1.89	;	Crystal structure of human mitochondrial methylenetetrahydrofolate dehydrogenase-cyclohydrolase (MTHFD2) in complex with LY345899 and cofactors
3N7Q	;	2.4	;	Crystal structure of human mitochondrial mTERF fragment (aa 99-399) in complex with a 12-mer DNA encompassing the tRNALeu(UUR) binding sequence
3N6S	;	3.1	;	Crystal structure of human mitochondrial mTERF in complex with a 15-mer DNA encompassing the tRNALeu(UUR) binding sequence
7R4J	;	2.95	;	Crystal structure of human mitochondrial NAD kinase
7R4K	;	3.33	;	Crystal structure of human mitochondrial NAD kinase
7R4L	;	2.6	;	Crystal structure of human mitochondrial NAD kinase
1PJ4	;	2.3	;	Crystal structure of human mitochondrial NAD(P)+-dependent malic enzyme in a pentary complex with natural substrate malate, ATP, Mn++, and allosteric activator fumarate.
1PJ2	;	2.3	;	Crystal structure of human mitochondrial NAD(P)+-dependent malic enzyme in a pentary complex with natural substrate malate, cofactor NADH, Mn++, and allosteric activator fumarate
1PJ3	;	2.1	;	Crystal structure of human mitochondrial NAD(P)+-dependent malic enzyme in a pentary complex with natural substrate pyruvate, cofactor NAD+, Mn++, and allosteric activator fumarate.
8EYN	;	1.94	;	Crystal Structure of Human Mitochondrial NADP+ Malic Enzyme 3 in Apo Form
8EYO	;	2.49	;	Crystal Structure of Human Mitochondrial NADP+ Malic Enzyme 3 with NADP bound
3CMQ	;	2.2	;	Crystal structure of human mitochondrial phenylalanine tRNA synthetase
3HFV	;	2.6	;	Crystal structure of human mitochondrial phenylalanyl-tRNA synthetase complexed with m-tyrosine
3TUP	;	3.05	;	Crystal structure of human mitochondrial PheRS complexed with tRNAPhe in the active open state
3PQ1	;	3.1	;	Crystal structure of human mitochondrial poly(A) polymerase (PAPD1)
3SPA	;	2.5	;	Crystal Structure of Human Mitochondrial RNA Polymerase
2DUD	;	2.7	;	Crystal structure of human mitochondrial single-stranded DNA-binding protein(hmtSSB)
3TQ6	;	2.45	;	Crystal structure of human mitochondrial transcription factor A, TFAM or mtTFA, bound to the light strand promoter LSP
3M66	;	1.6	;	Crystal structure of human Mitochondrial Transcription Termination Factor 3
6DV2	;	3.6	;	Crystal Structure of Human Mitochondrial Trifunctional Protein
3ZXI	;	2.75	;	Crystal structure of human mitochondrial tyrosyl-tRNA synthetase in complex with a tyrosyl-adenylate analog
2PID	;	2.2	;	Crystal structure of human mitochondrial tyrosyl-tRNA synthetase in complex with an adenylate analog
5X49	;	1.65	;	Crystal Structure of Human mitochondrial X-prolyl Aminopeptidase (XPNPEP3)
3GP0	;	1.9	;	Crystal Structure of Human Mitogen Activated Protein Kinase 11 (p38 beta) in complex with Nilotinib
7AQB	;	2.25	;	Crystal structure of human mitogen activated protein kinase 6 (MAPK6)
3FME	;	2.26	;	Crystal Structure of Human Mitogen-Activated Protein Kinase Kinase 6 (MEK6) Activated Mutant (S207D, T211D)
2DYL	;	2.45	;	Crystal structure of human mitogen-activated protein kinase kinase 7 activated mutant (S287D, T291D)
2C60	;	1.25	;	crystal structure of human mitogen-activated protein kinase kinase kinase 3 isoform 2 phox domain at 1.25 A resolution
2R13	;	1.8	;	Crystal structure of human mitoNEET reveals a novel [2Fe-2S] cluster coordination
2ZMC	;	3.14	;	Crystal structure of human mitotic checkpoint kinase Mps1 catalytic domain apo form
1I7K	;	1.95	;	CRYSTAL STRUCTURE OF HUMAN MITOTIC-SPECIFIC UBIQUITIN-CONJUGATING ENZYME, UBCH10
2RF0	;	2.0	;	Crystal structure of human mixed lineage kinase MAP3K10 SH3 domain
3EZZ	;	2.9	;	Crystal Structure of human MKP-2
4P7A	;	2.3	;	Crystal Structure of human MLH1
3SOM	;	2.4	;	crystal structure of human MMACHC
1JK3	;	1.09	;	Crystal structure of human MMP-12 (Macrophage Elastase) at true atomic resolution
2HU6	;	1.32	;	Crystal structure of human MMP-12 in complex with acetohydroxamic acid and a bicyclic inhibitor
3KEJ	;	2.3	;	Crystal Structure of Human MMP-13 complexed with a (pyridin-4-yl)-2H-tetrazole compound
3KEK	;	1.97	;	Crystal Structure of Human MMP-13 complexed with a (pyridin-4-yl)-2H-tetrazole compound
3KEC	;	2.05	;	Crystal Structure of Human MMP-13 complexed with a phenyl-2H-tetrazole compound
3LJZ	;	2.0	;	Crystal Structure of Human MMP-13 complexed with an Amino-2-indanol compound
7XGJ	;	2.8	;	Crystal structure of human MMP-2 catalytic domain in complex with inhibitor
7XJO	;	2.0	;	Crystal structure of human MMP-2 catalytic domain in complex with inhibitor
8H78	;	2.4	;	Crystal structure of human MMP-2 catalytic domain in complex with inhibitor
7WXX	;	1.5	;	Crystal structure of human MMP-7 in complex with inhibitor
8JUD	;	1.5	;	Crystal structure of human MMP-7 in complex with inhibitor
8JUF	;	1.39	;	Crystal structure of human MMP-7 in complex with inhibitor
8JUG	;	1.3	;	Crystal structure of human MMP-7 in complex with inhibitor
3SHI	;	2.2	;	Crystal structure of human MMP1 catalytic domain at 2.2 A resolution
4ONN	;	1.5	;	Crystal structure of human Mms2/Ubc13 - BAY 11-7082
4ONM	;	1.35	;	Crystal structure of human Mms2/Ubc13 - NSC697923
4ONL	;	1.35	;	Crystal structure of human Mms2/Ubc13_D81N, R85S, A122V, N123P
5H7Q	;	1.451	;	Crystal structure of human MNDA PYD domain with MBP tag
1PM9	;	1.7	;	CRYSTAL STRUCTURE OF HUMAN MNSOD H30N, Y166F MUTANT
1PL4	;	1.47	;	Crystal Structure of human MnSOD Y166F mutant
3I2V	;	1.25	;	Crystal structure of human MOCS3 rhodanese-like domain
4DNC	;	2.05	;	Crystal structure of human MOF in complex with MSL1
4AP8	;	2.78	;	Crystal structure of human Molybdopterin synthase catalytic subunit (MOCS2B)
5MPO	;	2.43	;	Crystal structure of human molybdopterin synthase complex
3JW8	;	2.1	;	Crystal structure of human mono-glyceride lipase
4UUQ	;	2.36	;	Crystal structure of human mono-glyceride lipase in complex with SAR127303
3JWE	;	2.7	;	Crystal structure of human mono-glyceride lipase in complex with SAR629
7OTS	;	1.792	;	Crystal structure of human Monoacylglycerol Lipase ABHD6 in complex with oleic acid and octyl glucoside
7L4T	;	2.2	;	Crystal structure of human monoacylglycerol lipase in complex with compound 1
7L4U	;	2.25	;	Crystal structure of human monoacylglycerol lipase in complex with compound 1h
7L4W	;	2.2	;	Crystal structure of human monoacylglycerol lipase in complex with compound 2d
5ZUN	;	1.35	;	Crystal structure of human monoacylglycerol lipase in complex with compound 3l
7L50	;	2.3	;	Crystal structure of human monoacylglycerol lipase in complex with compound 4f
2Z5Y	;	2.17	;	Crystal Structure of Human Monoamine Oxidase A (G110A) with Harmine
2Z5X	;	2.2	;	Crystal Structure of Human Monoamine Oxidase A with Harmine
6FW0	;	1.6	;	Crystal structure of human monoamine oxidase B (MAO B) in complex with chlorophenyl-chromone-carboxamide
6FVZ	;	1.8	;	Crystal structure of human monoamine oxidase B (MAO B) in complex with dimethylphenyl-chromone-carboxamide
6FWC	;	1.7	;	Crystal structure of human monoamine oxidase B (MAO B) in complex with fluorophenyl-chromone-carboxamide
5MRL	;	2.42	;	Crystal structure of human monoamine oxidase B (MAO B) in complex with N(Furan2ylmethyl)Nmethylprop2yn1amine (F2MPA)
4A79	;	1.89	;	Crystal structure of human monoamine oxidase B (MAO B) in complex with pioglitazone
4A7A	;	1.7	;	Crystal structure of human monoamine oxidase B (MAO B) in complex with rosiglitazone
7B0V	;	2.3	;	Crystal Structure of human monoamine oxidase B in complex with (E)-3-phenyl-1-(3-(trifluoromethyl)phenyl)prop-2-en-1-one
7B0Z	;	2.1	;	Crystal Structure of human monoamine oxidase B in complex with (E)-3-phenyl-1-(4-(trifluoromethyl)phenyl)prop-2-en-1-one
6YT2	;	1.8	;	Crystal Structure of human monoamine oxidase B in complex with Diphenylene iodonium (DPI)
3ZYX	;	2.2	;	Crystal structure of human monoamine oxidase B in complex with methylene blue and bearing the double mutation I199A-Y326A
6RKB	;	2.3	;	Crystal structure of human monoamine oxidase B in complex with styrylpiperidine analogue 1
6RKP	;	1.7	;	Crystal structure of human monoamine oxidase B in complex with styrylpiperidine analogue 84
6RLE	;	2.3	;	Crystal structure of human monoamine oxidase B in complex with styrylpiperidine analogue 97
4CRT	;	1.8	;	Crystal structure of human monoamine oxidase B in complex with the multi-target inhibitor ASS234
5XRQ	;	2.6	;	Crystal structure of human monoclonal antibody H3v-47
5W42	;	3.569	;	Crystal structure of human monoclonal antibody H3v-47 in complex with influenza virus hemagglutinin from A/Minnesota/11/2010 (H3N2)
6UIG	;	3.2	;	Crystal structure of human monoclonal antibody H7.200 in complex with H7N9 hemagglutinin HA1
6MEG	;	1.41	;	Crystal structure of human monoclonal antibody HEPC46
2RA4	;	1.7	;	Crystal Structure of Human Monocyte Chemoattractant Protein 4 (MCP-4/CCL13)
1ESR	;	2.0	;	CRYSTAL STRUCTURE OF HUMAN MONOCYTE CHEMOTACTIC PROTEIN-2
3HJU	;	2.2	;	Crystal structure of human monoglyceride lipase
7PRM	;	1.65	;	CRYSTAL STRUCTURE OF HUMAN MONOGLYCERIDE LIPASE WITH COMPOUND 13
8AQF	;	1.55	;	CRYSTAL STRUCTURE OF HUMAN MONOGLYCERIDE LIPASE WITH COMPOUND LEI-515
7ZPG	;	1.16	;	CRYSTAL STRUCTURE OF HUMAN MONOGLYCERIDE LIPASE WITH LIGAND
5OF9	;	1.807	;	Crystal structure of human MORC2 (residues 1-603)
5OFB	;	2.02	;	Crystal structure of human MORC2 (residues 1-603) with spinal muscular atrophy mutation S87L
5OFA	;	2.57	;	Crystal structure of human MORC2 (residues 1-603) with spinal muscular atrophy mutation T424R
7K7T	;	2.94	;	Crystal structure of human MORC4 ATPase-CW in complex with AMPPNP
7M5U	;	2.02	;	Crystal structure of human MPP8 chromodomain in complex with peptidomimetic ligand UNC5246
5O91	;	3.2	;	Crystal structure of human Mps1 (TTK) C604W mutant in complex with Cpd-5
5NTT	;	2.75	;	Crystal structure of human Mps1 (TTK) C604Y mutant in complex with NMS-P715
5MRB	;	2.2	;	Crystal structure of human Mps1 (TTK) in complex with Cpd-5
5LJJ	;	3.0	;	Crystal structure of human Mps1 (TTK) in complex with Reversine
3WYY	;	3.05	;	CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH (E)-3-(4-((6-(((3s,5s,7s)-adamantan-1-yl)amino)-4-amino-5-cyanopyridin-2-yl)amino)-2-(cyanomethoxy)phenyl)-N-(2-methoxyethyl)acrylamide
3WZJ	;	2.75	;	CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(6-(cyclohexylamino)-8-(((tetrahydro-2H-pyran-4-yl)methyl)amino)imidazo[1,2-b]pyridazin-3-yl)-N-cyclopropylbenzamide
3VQU	;	2.4	;	CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4-[(4-amino-5-cyano-6-ethoxypyridin-2- yl)amino]benzamide
3W1F	;	2.7	;	Crystal structure of Human MPS1 catalytic domain in complex with 5-(5-ethoxy-6-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-2-methylbenzenesulfonamide
3WYX	;	2.9	;	CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 6-((3-(cyanomethoxy)-4-(1-methyl-1H-pyrazol-4-yl)phenyl)amino)-2-(cyclohexylamino)nicotinonitrile
3HMP	;	2.3	;	Crystal structure of human Mps1 catalytic domain in complex with a quinazolin ligand Compound 4
3HMN	;	2.7	;	Crystal structure of human Mps1 catalytic domain in complex with ATP
3WZK	;	2.3	;	CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH N-cyclopropyl-4-(8-((thiophen-2-ylmethyl)amino)imidazo[1,2-a]pyrazin-3-yl)benzamide
3HMO	;	2.4	;	Crystal structure of human Mps1 catalytic domain in complex with the inhibitor staurosporine
2ZMD	;	2.88	;	Crystal structure of human Mps1 catalytic domain T686A mutant in complex with SP600125 inhibitor
4B94	;	2.2	;	Crystal structure of human Mps1 TPR domain
3T1I	;	3.0	;	Crystal Structure of Human Mre11: Understanding Tumorigenic Mutations
3S24	;	3.0137	;	Crystal structure of human mRNA guanylyltransferase
6AO5	;	2.955	;	Crystal structure of human MST2 in complex with SAV1 SARAH domain
4HKD	;	1.503	;	Crystal structure of human MST2 SARAH domain
3MVA	;	2.2	;	Crystal structure of human MTERF1 bound to the termination sequence
3ZR1	;	1.9	;	Crystal structure of human MTH1
3ZR0	;	1.8	;	Crystal structure of human MTH1 in complex with 8-oxo-dGMP
6JVH	;	2.04	;	Crystal structure of human MTH1 in complex with compound MI0320
6JVG	;	1.844	;	Crystal structure of human MTH1 in complex with compound MI0639
6JVI	;	2.249	;	Crystal structure of human MTH1 in complex with compound MI0861
6JVJ	;	2.297	;	Crystal structure of human MTH1 in complex with compound MI1006
6JVK	;	2.1	;	Crystal structure of human MTH1 in complex with compound MI1012
6JVL	;	1.9	;	Crystal structure of human MTH1 in complex with compound MI1014
6JVM	;	2.098	;	Crystal structure of human MTH1 in complex with compound MI1016
6JVN	;	2.102	;	Crystal structure of human MTH1 in complex with compound MI1020
6JVO	;	1.902	;	Crystal structure of human MTH1 in complex with compound MI1022
6JVP	;	2.206	;	Crystal structure of human MTH1 in complex with compound MI1024
6JVQ	;	2.197	;	Crystal structure of human MTH1 in complex with compound MI1025
6JVR	;	2.295	;	Crystal structure of human MTH1 in complex with compound MI1026
6JVS	;	2.1	;	Crystal structure of human MTH1 in complex with compound MI1029
6JVT	;	1.801	;	Crystal structure of human MTH1 in complex with compound MI1030
5NGR	;	2.2	;	Crystal structure of human MTH1 in complex with fragment inhibitor 8-(methylsulfanyl)-7H-purin-6-amine
5NGS	;	1.85	;	Crystal structure of human MTH1 in complex with inhibitor 6-[(2-phenylethyl)sulfanyl]-7H-purin-2-amine
5NGT	;	1.54	;	Crystal structure of human MTH1 in complex with inhibitor 7-(furan-2-yl)-5-methyl-1,3-benzoxazol-2-amine
6QVO	;	2.45	;	Crystal structure of human MTH1 in complex with N6-methyl-dAMP
5OTM	;	1.8	;	Crystal structure of human MTH1 in complex with O6-methyl-dGMP
8I8T	;	1.22	;	Crystal structure of human MTH1(G2K mutant) in complex with 2-oxo-dAMP and Mn2+
5GHJ	;	1.2	;	Crystal structure of human MTH1(G2K mutant) in complex with 2-oxo-dATP
8I1D	;	1.2	;	Crystal structure of human MTH1(G2K mutant) in complex with 2-oxo-dATP at pH 7.7
8I1E	;	1.1	;	Crystal structure of human MTH1(G2K mutant) in complex with 2-oxo-dATP at pH 8.0
8I1F	;	1.05	;	Crystal structure of human MTH1(G2K mutant) in complex with 2-oxo-dATP at pH 8.6
8I1G	;	1.18	;	Crystal structure of human MTH1(G2K mutant) in complex with 2-oxo-dATP at pH 9.1
8I1H	;	1.18	;	Crystal structure of human MTH1(G2K mutant) in complex with 2-oxo-dATP at pH 9.7
8I8S	;	1.42	;	Crystal structure of human MTH1(G2K mutant) in complex with 8-oxo-dGMP and Mn2+
5GHI	;	1.211	;	Crystal structure of human MTH1(G2K mutant) in complex with 8-oxo-dGTP
8I18	;	1.1	;	Crystal structure of human MTH1(G2K mutant) in complex with 8-oxo-dGTP at pH 7.7
8I19	;	1.48	;	Crystal structure of human MTH1(G2K mutant) in complex with 8-oxo-dGTP at pH 8.0
8I1A	;	1.4	;	Crystal structure of human MTH1(G2K mutant) in complex with 8-oxo-dGTP at pH 8.6
8I1C	;	1.4	;	Crystal structure of human MTH1(G2K mutant) in complex with 8-oxo-dGTP at pH 9.1
5WS7	;	1.0	;	Crystal structure of human MTH1(G2K/C87A/C104S mutant) in complex with 2-oxo-dATP
6IJY	;	1.04	;	Crystal structure of human MTH1(G2K/C87A/C104S mutant) in complex with 8-oxo-dGTP determined using a crystal obtained under microgravity
5GHP	;	1.192	;	Crystal structure of human MTH1(G2K/D120A mutant) in complex with 2-oxo-dATP
5GHQ	;	1.181	;	Crystal structure of human MTH1(G2K/D120A mutant) in complex with 2-oxo-dATP under high concentrations of 2-oxo-dATP
5GHO	;	1.191	;	Crystal structure of human MTH1(G2K/D120A mutant) in complex with 8-oxo-dGTP
5GHN	;	1.391	;	Crystal structure of human MTH1(G2K/D120N mutant) in complex with 2-oxo-dATP
8I1I	;	1.2	;	Crystal structure of human MTH1(G2K/D120N mutant) in complex with 2-oxo-dATP at pH 7.7
8I1J	;	1.08	;	Crystal structure of human MTH1(G2K/D120N mutant) in complex with 2-oxo-dATP at pH 9.7
6ILI	;	1.45	;	Crystal structure of human MTH1(G2K/D120N mutant) in complex with 8-oxo-dGTP at pH 6.5
5GHM	;	1.5	;	Crystal structure of human MTH1(G2K/D120N mutant) in complex with 8-oxo-dGTP at pH 7.0
6IEG	;	3.55	;	Crystal structure of human MTR4
6OAE	;	1.9	;	Crystal Structure of Human Mucin-like Protocadherin EC1-2
4P0Q	;	2.851	;	Crystal structure of Human Mus81-Eme1 in complex with 5'-flap DNA
4P0P	;	2.8	;	Crystal structure of Human Mus81-Eme1 in complex with 5'-flap DNA, and Mg2+
7F6L	;	3.2	;	Crystal structure of human MUS81-EME2 complex
4HE0	;	2.69	;	Crystal structure of human muscle fructose-1,6-bisphosphatase
4HE2	;	1.6	;	Crystal structure of human muscle fructose-1,6-bisphosphatase Q32R mutant complex with AMP
4HE1	;	2.23	;	Crystal structure of human muscle fructose-1,6-bisphosphatase Q32R mutant complex with fructose-6-phosphate and phosphate
1Z8D	;	2.3	;	Crystal Structure of Human Muscle Glycogen Phosphorylase a with AMP and Glucose
4OJN	;	2.4	;	Crystal structure of human muscle L-lactate dehydrogenase
4QT0	;	3.2	;	Crystal structure of human muscle L-lactate dehydrogenase in complex with inhibitor 1, 3-{[3-CARBAMOYL-7-(2,4-DIMETHOXYPYRIMIDIN-5-YL)QUINOLIN-4-YL]AMINO}BENZOIC ACID
4QSM	;	3.0	;	Crystal structure of human muscle L-lactate dehydrogenase in complex with inhibitor 2, 3-{[7-(2,4-dimethoxypyrimidin-5-yl)-3-sulfamoylquinolin-4-yl]amino}benzoic acid
4OKN	;	2.1	;	Crystal structure of human muscle L-lactate dehydrogenase, ternary complex with NADH and oxalate
4OMT	;	6.0	;	Crystal structure of human muscle phosphofructokinase (dissociated homodimer)
2I99	;	2.6	;	Crystal structure of human Mu_crystallin at 2.6 Angstrom
4X0R	;	2.905	;	Crystal structure of human MxB stalk domain
7O60	;	2.4	;	Crystal structure of human myelin protein P2 at room temperature from joint X-ray and neutron refinement.
7O60	;	2.0	;	Crystal structure of human myelin protein P2 at room temperature from joint X-ray and neutron refinement.
2WUT	;	1.85	;	Crystal structure of human myelin protein P2 in complex with palmitate
5FIW	;	1.7	;	CRYSTAL STRUCTURE OF HUMAN MYELOPEROXIDASE AT 1.7 ANGSTROMS RESOLUTION
1D7W	;	1.9	;	CRYSTAL STRUCTURE OF HUMAN MYELOPEROXIDASE ISOFORM C COMPLEXED WITH CYANIDE AND BROMIDE AT PH 4.0
1MHL	;	2.25	;	CRYSTAL STRUCTURE OF HUMAN MYELOPEROXIDASE ISOFORM C CRYSTALLIZED IN SPACE GROUP P2(1) AT PH 5.5 AND 20 DEG C
4DL1	;	2.0	;	Crystal Structure of human Myeloperoxidase with covalent thioxanthine analog
2DDK	;	2.7	;	Crystal structure of human myo-inositol monophosphatase 2 (IMPA2) (orthorhombic form)
2CZK	;	2.9	;	Crystal structure of human myo-inositol monophosphatase 2 (IMPA2) (trigonal form)
2CZI	;	3.0	;	Crystal structure of human myo-inositol monophosphatase 2 (IMPA2) with calcium and phosphate ions
2CZH	;	2.7	;	Crystal structure of human myo-inositol monophosphatase 2 (IMPA2) with phosphate ion (orthorhombic form)
2IBN	;	1.5	;	Crystal structure of Human myo-Inositol Oxygenase (MIOX)
3RGK	;	1.65	;	Crystal Structure of Human Myoglobin Mutant K45R
4BYF	;	2.74	;	Crystal structure of human Myosin 1c in complex with calmodulin in the pre-power stroke state
4LLI	;	2.2	;	Crystal Structure of human Myosin 5a globular domain
4LNZ	;	3.11	;	Crystal structure of human Myosin 5b globular domain
5C5S	;	2.2	;	Crystal Structure of human Myosin 9b RhoGAP domain at 2.2 angstrom
1RXT	;	3.0	;	Crystal structure of human myristoyl-CoA:protein N-myristoyltransferase.
2OZU	;	2.3	;	Crystal structure of human MYST histone acetyltransferase 3 in complex with acetylcoenzyme A
5VD3	;	1.8	;	CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN (de-phosphorylated) IN COMPLEX WITH SARACATINIB
5VCX	;	2.7	;	CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN (UNTREATED) IN COMPLEX WITH SARACATINIB
8D6C	;	2.2	;	Crystal Structure of Human Myt1 Kinase domain Bounded with compound 28
8D6D	;	2.35	;	Crystal Structure of Human Myt1 Kinase domain Bounded with compound 39
8D6F	;	2.49	;	Crystal Structure of Human Myt1 Kinase domain Bounded with Eph receptor inhibitor / compound 41
8D6E	;	2.15	;	Crystal Structure of Human Myt1 Kinase domain Bounded with RP-6306
5VCY	;	1.56	;	CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB
5VCZ	;	1.5	;	CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH Bosutinib isomer
5VCV	;	1.92	;	CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH Dasatinib
5VD0	;	2.13	;	CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH MK1775
5VCW	;	2.25	;	CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH Pelitinib
5VD1	;	1.7	;	CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PHA-848125
2A8W	;	1.59	;	Crystal Structure of Human N-acetylgalactosaminyltransferase (GTA) Complexed with Beta-Methyllactoside
1ZHJ	;	1.59	;	Crystal Structure of human N-acetylgalactosaminyltransferase (GTA) Complexed with Galactose
1ZJO	;	1.64	;	Crystal Structure of Human N-acetylgalactosaminyltransferase (GTA) Complexed with Galactose-grease
1ZI5	;	1.55	;	Crystal Structure of Human N-acetylgalactosaminyltransferase (GTA) Complexed with H type I Trisaccharide
1ZI4	;	1.85	;	Crystal Structure of Human N-acetylgalactosaminyltransferase (GTA) Complexed with H type II Trisaccharide
1ZI1	;	1.57	;	Crystal Structure of Human N-acetylgalactosaminyltransferase (GTA) Complexed with Lactose
1ZI3	;	1.69	;	Crystal Structure of Human N-acetylgalactosaminyltransferase (GTA) Complexed with N-acetyllactosamine
2CH6	;	2.72	;	Crystal structure of human N-acetylglucosamine kinase in complex with ADP and glucose
2CH5	;	1.9	;	Crystal structure of human N-acetylglucosamine kinase in complex with N-acetylglucosamine
4A6D	;	2.4	;	Crystal structure of human N-acetylserotonin methyltransferase (ASMT) in complex with SAM
4A6E	;	2.7	;	Crystal structure of human N-acetylserotonin methyltransferase (ASMT) in complex with SAM and N-acetylserotonin
6XI5	;	2.61	;	Crystal structure of human N-acetylserotonin O-methyltransferase-like protein soaked with PDHPTAO
7RK3	;	2.05	;	Crystal structure of human N-myristoyltransferase 1 fragment (residues 109-496) bound to diacylated human Arf6 octapeptide and Coenzyme A
3QEH	;	2.59	;	Crystal structure of human N12-i15, an ADCC and non-neutralizing anti-HIV-1 Env antibody
3QEG	;	1.95	;	Crystal structure of human N12-i2 Fab, an ADCC and neutralizing anti-HIV-1 Env antibody
6Q3V	;	1.882	;	Crystal structure of Human N4BP1 KH domains
6KMS	;	3.2	;	Crystal structure of human N6amt1-Trm112 in complex with SAM (space group I422)
6KMR	;	2.0	;	Crystal structure of human N6amt1-Trm112 in complex with SAM (space group P6122)
6PZH	;	2.3	;	Crystal structure of human NA-22 Fab
6PZE	;	2.3	;	Crystal structure of human NA-45 Fab in complex with neuraminidase Y169aH mutant from A/Shanghai/2/2013 (H7N9)
6PZF	;	2.8	;	Crystal structure of human NA-63 Fab in complex with neuraminidase from A/Hunan/02650/2016(H7N9)
6PZG	;	1.59	;	Crystal structure of human NA-80 Fab
6WF3	;	2.291	;	Crystal structure of human Naa50 in complex with a cofactor derived inhibitor (compound 1)
6WF5	;	2.04	;	Crystal structure of human Naa50 in complex with a truncated cofactor derived inhibitor (compound 2)
6WFN	;	1.07	;	Crystal structure of human Naa50 in complex with AcCoA and an inhibitor (compound 4a) identified using DNA encoded library technology
6WFO	;	1.85	;	Crystal structure of human Naa50 in complex with AcCoA and an inhibitor (compound 4b) identified using DNA encoded library technology
6WFG	;	2.16	;	Crystal structure of human Naa50 in complex with an inhibitor (compound 3) identified using DNA encoded library technology
6WFK	;	1.87	;	Crystal structure of human Naa50 in complex with CoA and an inhibitor (compound 4a) identified using DNA encoded library technology
5HGZ	;	1.383	;	Crystal structure of human Naa60 in complex with acetyl-CoA
5HH0	;	1.6	;	Crystal structure of human Naa60 in complex with CoA
5HH1	;	1.803	;	Crystal structure of human Naa60 mutant - F34A in complex with CoA
3PFN	;	2.7	;	Crystal Structure of human NAD kinase
7THG	;	2.9	;	Crystal Structure Of Human NADH-Cytochrome B5 Reductase
7TSW	;	2.4	;	Crystal Structure Of Human NADH-Cytochrome B5 Reductase T117D Mutant
7TNV	;	1.93	;	Crystal Structure Of Human NADH-Cytochrome B5 Reductase T117S Mutant
1ZSV	;	2.3	;	Crystal structure of human NADP-dependent leukotriene B4 12-hydroxydehydrogenase
3QFC	;	1.8	;	Crystal Structure of Human NADPH-Cytochrome P450 (V492E mutant)
3QE2	;	1.75	;	Crystal Structure of Human NADPH-Cytochrome P450 Reductase
3QFR	;	2.4	;	Crystal Structure of Human NADPH-Cytochrome P450 Reductase (R457H Mutant)
5EMN	;	2.2	;	Crystal Structure of Human NADPH-Cytochrome P450 Reductase(A287P mutant)
1D4A	;	1.7	;	CRYSTAL STRUCTURE OF HUMAN NAD[P]H-QUINONE OXIDOREDUCTASE AT 1.7 A RESOLUTION
1DXO	;	2.5	;	Crystal structure of human NAD[P]H-QUINONE oxidoreductase CO with 2,3,5,6,tetramethyl-P-benzoquinone (duroquinone) at 2.5 Angstrom resolution
1H69	;	1.86	;	CRYSTAL STRUCTURE OF HUMAN NAD[P]H-QUINONE OXIDOREDUCTASE CO WITH 2,3,5,6,TETRAMETHYL-P-BENZOQUINONE (DUROQUINONE) AT 2.5 ANGSTROM RESOLUTION
1H66	;	2.0	;	CRYSTAL STRUCTURE OF HUMAN NAD[P]H-QUINONE OXIDOREDUCTASE CO WITH 2,5-diaziridinyl-3-hydroxyl-6-methyl-1,4-benzoquinone
6ARH	;	1.6	;	Crystal structure of Human NAL at a resolution of 1.6 Angstrom
3DGR	;	2.1	;	Crystal structure of human NAMPT complexed with ADP analogue
3DKJ	;	2.0	;	Crystal structure of human NAMPT complexed with benzamide and phosphoribosyl pyrophosphate
3DHD	;	2.0	;	Crystal structure of human NAMPT complexed with nicotinamide mononucleotide and pyrophosphate
8IVU	;	2.09001	;	Crystal Structure of Human NAMPT in complex with A4276
7ENQ	;	2.20497	;	Crystal structure of human NAMPT in complex with compound NAT
6ATB	;	2.53	;	Crystal Structure of human NAMPT in complex with NVP-LOD812
6B75	;	2.53	;	Crystal Structure of human NAMPT in complex with NVP-LOQ594
6AZJ	;	2.53	;	Crystal Structure of human NAMPT in complex with NVP-LQN520
6PEB	;	2.46	;	Crystal Structure of human NAMPT in complex with NVP-LTM976
6B76	;	2.44	;	Crystal Structure of human NAMPT in complex with NVP-LVR596
5U2M	;	1.89	;	Crystal structure of human NAMPT with A-1293201
5U2N	;	1.73	;	Crystal structure of human NAMPT with A-1326133
5WI0	;	2.05	;	Crystal structure of human NAMPT with fragment 2: 2-[(2-fluorophenyl)amino]-6-propylpyrimidin-4(3H)-one
5WI1	;	1.99	;	Crystal structure of human NAMPT with fragment 5: (3E)-3-[(phenylamino)methylidene]oxan-2-one
5UPE	;	1.93	;	Crystal structure of human NAMPT with isoindoline urea inhibitor compound 5
5UPF	;	1.69	;	Crystal structure of human NAMPT with isoindoline urea inhibitor compound 53
7KD7	;	1.44	;	Crystal structure of human NatD (NAA40) bound to a bisubstrate analogue
7KPU	;	1.43	;	Crystal structure of human NatD (NAA40) bound to a bisubstrate analogue with a C-3 linker
5ICV	;	1.53	;	Crystal structure of human NatF (hNaa60) bound to a bisubstrate analogue
5ICW	;	1.951	;	Crystal structure of human NatF (hNaa60) homodimer bound to Coenzyme A
4WO2	;	1.82	;	CRYSTAL STRUCTURE OF HUMAN NATIVE CKIT PROTO-ONCOGENE PROMOTER QUADRUPLEX DNA
2HI9	;	2.3	;	Crystal Structure of human native protein C inhibitor
6MC9	;	3.3	;	Crystal Structure of Human Nav1.4 C-Terminal (1599-1754) domain in complex with calcium-bound calmodulin
6MBA	;	1.799	;	Crystal Structure of Human Nav1.4 CTerminal Domain in Complex with apo Calmodulin
3GD7	;	2.7	;	Crystal structure of human NBD2 complexed with N6-Phenylethyl-ATP (P-ATP)
5AEA	;	1.9	;	Crystal structure of human NCAM domain 1
5QU2	;	1.04	;	Crystal Structure of human Nck SH3.1 in complex with peptide PPPVPNPDY
6ZMM	;	2.96	;	Crystal structure of human NDRG1
2XMQ	;	2.81	;	Crystal structure of human NDRG2 protein provides insight into its role as a tumor suppressor
2XMR	;	2.0	;	Crystal structure of human NDRG2 protein provides insight into its role as a tumor suppressor
2XMS	;	2.15	;	Crystal structure of human NDRG2 protein provides insight into its role as a tumor suppressor
6L4H	;	3.4	;	Crystal structure of human NDRG3 C30S mutant
6L4G	;	3.304	;	Crystal structure of human NDRG3 I171M/S176H mutant
4FMF	;	3.2	;	Crystal structure of human nectin-1 full ectodomain (D1-D3)
4FOM	;	3.93	;	Crystal structure of human nectin-3 full ectodomain (D1-D3)
4FRW	;	3.5	;	Crystal structure of human nectin-4 extracellular fragment D1-D2
4FQP	;	3.6	;	Crystal structure of human Nectin-like 5 full ectodomain (D1-D3)
8FTJ	;	2.3	;	Crystal structure of human NEIL1 (P2G (242K) C(delta)100) glycosylase bound to DNA duplex containing urea
5ITT	;	2.53	;	Crystal Structure of Human NEIL1 bound to duplex DNA containing THF
5ITU	;	2.41	;	Crystal Structure of Human NEIL1(242K) bound to duplex DNA containing THF
6LWM	;	2.67	;	Crystal structure of human NEIL1(K242) bound to duplex DNA containing 2'-fluoro-2'-deoxy-5,6-dihydrouridine
6LWR	;	2.9	;	Crystal structure of human NEIL1(K242) bound to duplex DNA containing a cleaved C:T mismatch
5ITX	;	2.65	;	Crystal Structure of Human NEIL1(P2G R242K) bound to duplex DNA containing Thymine Glycol
5ITR	;	2.46	;	Crystal Structure of Human NEIL1(P2G) bound to duplex DNA containing THF
5ITY	;	2.48	;	Crystal Structure of Human NEIL1(P2G) bound to duplex DNA containing Thymine Glycol
6LWA	;	2.76	;	Crystal structure of human NEIL1(P2G, E3Q, K242) bound to duplex DNA containing 5-hydroxyuracil (5-OHU)
6LWH	;	2.78	;	Crystal structure of human NEIL1(P2G, E3Q, K242) bound to duplex DNA containing dihydrothymine (DHT)
6LWJ	;	2.83	;	Crystal structure of human NEIL1(P2G, E3Q, K242) bound to duplex DNA containing dihydrouracil (DHU)
6LWF	;	2.79	;	Crystal structure of human NEIL1(P2G, E3Q, K242) bound to duplex DNA containing guanidinohydantoin (Gh)
6LWC	;	2.91	;	Crystal structure of human NEIL1(P2G, E3Q, K242) bound to duplex DNA containing spiroiminodihydantoin (Sp)
6LWB	;	2.55	;	Crystal structure of human NEIL1(P2G, E3Q, R242) bound to duplex DNA containing 5-hydroxyuracil (5-OHU)
6LWI	;	2.72	;	Crystal structure of human NEIL1(P2G, E3Q, R242) bound to duplex DNA containing dihydrothymine (DHT)
6LWK	;	2.88	;	Crystal structure of human NEIL1(P2G, E3Q, R242) bound to duplex DNA containing dihydrouracil (DHU)
6LWG	;	2.53	;	Crystal structure of human NEIL1(P2G, E3Q, R242) bound to duplex DNA containing guanidinohydantoin (Gh)
6LWD	;	2.41	;	Crystal structure of human NEIL1(P2G, E3Q, R242) bound to duplex DNA containing spiroiminodihydantoin (Sp)
6LWL	;	2.55	;	Crystal structure of human NEIL1(R242) bound to duplex DNA containing 2'-fluoro-2'-deoxy-5,6-dihydrouridine
6LWQ	;	2.89	;	Crystal structure of human NEIL1(R242) bound to duplex DNA containing a C:T mismatch
6LWN	;	2.74	;	Crystal structure of human NEIL1(R242, G249P) bound to duplex DNA containing 2'-fluoro-2'-deoxy-5,6-dihydrouridine
6LWO	;	2.51	;	Crystal structure of human NEIL1(R242, Y244H) bound to duplex DNA containing 2'-fluoro-2'-deoxy-5,6-dihydrouridine
6LWP	;	2.64	;	Crystal structure of human NEIL1(R242, Y244R) bound to duplex DNA containing 2'-fluoro-2'-deoxy-5,6-dihydrouridine
5ITQ	;	1.48	;	Crystal Structure of Human NEIL1, Free Protein
7JL5	;	2.6	;	Crystal structure of human NEIL3 tandem zinc finger GRF domains
6S76	;	3.38	;	Crystal structure of human Nek7
6YEK	;	3.2	;	Crystal structure of human NEMO apo form
3FX0	;	3.2	;	Crystal structure of Human NEMO CC2_LZ domain
1Y8J	;	2.25	;	Crystal Structure of human NEP complexed with an imidazo[4,5-c]pyridine inhibitor
6SH2	;	2.6	;	Crystal structure of human neprilysin E584D in complex with C-type natriuretic peptide.
1TE6	;	1.8	;	Crystal Structure of Human Neuron Specific Enolase at 1.8 angstrom
7O1N	;	1.56	;	Crystal Structure of Human Neuropilin-1 b1 Domain mutant - Y297A
4WGK	;	2.582	;	Crystal structure of human neutral ceramidase with Zn-bound phosphate
2YB9	;	2.4	;	Crystal Structure of Human Neutral Endopeptidase complexed with a heteroarylalanine diacid.
7NAB	;	2.15	;	Crystal structure of human neutralizing mAb CV3-25 binding to SARS-CoV-2 S MPER peptide 1140-1165
6SMA	;	2.59	;	Crystal structure of Human Neutrophil Elastase (HNE) in complex with the 3-Oxo-beta-Sultam inhibitor LMC249
1H1B	;	2.0	;	Crystal structure of human neutrophil elastase complexed with an inhibitor (GW475151)
5A09	;	1.81	;	Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor
5A0A	;	1.78	;	Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor
5A0B	;	2.23	;	Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor
5A0C	;	2.1	;	Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor
5A8X	;	2.23	;	Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor
5A8Y	;	1.9	;	Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor
5A8Z	;	2.0	;	Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor
1B0F	;	3.0	;	CRYSTAL STRUCTURE OF HUMAN NEUTROPHIL ELASTASE WITH MDL 101, 146
1DFV	;	2.6	;	CRYSTAL STRUCTURE OF HUMAN NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN MONOMER
1ZMH	;	1.5	;	Crystal structure of human neutrophil peptide 2, HNP-2 (variant Gly16-> D-Ala)
4G3D	;	2.9	;	Crystal structure of human NF-kappaB inducing kinase (NIK)
1S9K	;	3.1	;	Crystal Structure of Human NFAT1 and Fos-Jun on the IL-2 ARRE1 Site
1OWR	;	3.0	;	CRYSTAL STRUCTURE OF HUMAN NFAT1 BOUND MONOMERICALLY TO DNA
5USR	;	3.09	;	Crystal structure of human NFS1-ISD11 in complex with E. coli acyl-carrier protein at 3.09 angstroms
6RMJ	;	2.65	;	Crystal structure of human NGR-TNF
1GZU	;	2.9	;	Crystal Structure of Human Nicotinamide Mononucleotide Adenylyltransferase in Complex with NMN
2QG6	;	1.5	;	Crystal structure of human nicotinamide riboside kinase (NRK1) in complex with nicotinamide mononucleotide (NMN)
4YUB	;	2.9	;	Crystal structure of human Nicotinic Acid Phosphoribosyltransferase
5U73	;	3.348	;	Crystal structure of human Niemann-Pick C1 protein
4APC	;	2.1	;	Crystal Structure of Human NIMA-related Kinase 1 (NEK1)
4B9D	;	1.9	;	Crystal Structure of Human NIMA-related Kinase 1 (NEK1) with inhibitor.
8ESF	;	2.56	;	Crystal structure of human Nischarin PX and LRR domains with engineered mutations
5Y3S	;	2.451	;	Crystal structure of human NLRP1 leucine rich repeat domain
4XHS	;	1.7	;	Crystal structure of human NLRP12 PYD domain and implication in homotypic interaction
5H7N	;	1.849	;	Crystal structure of human NLRP12-PYD with a MBP tag
6NDJ	;	2.27	;	Crystal structure of human NLRP6 PYD domain with MBP fusion
6Z2G	;	1.95	;	Crystal structure of human NLRP9 PYD
3L7U	;	2.1	;	Crystal structure of human NM23-H1
1KR2	;	2.3	;	CRYSTAL STRUCTURE OF HUMAN NMN/NAMN ADENYLYL TRANSFERASE COMPLEXED WITH TIAZOFURIN ADENINE DINUCLEOTIDE (TAD)
2GVG	;	2.2	;	Crystal Structure of human NMPRTase and its complex with NMN
2E5B	;	2.0	;	Crystal structure of Human NMPRTase as free-form
2E5C	;	2.2	;	Crystal structure of Human NMPRTase complexed with 5'-phosphoribosyl-1'-pyrophosphate
2E5D	;	2.0	;	Crystal structure of Human NMPRTase complexed with nicotinamide
2GVJ	;	2.1	;	Crystal Structure of Human NMPRTase in complex with FK866
4DIQ	;	2.4	;	Crystal Structure of human NO66
3ALN	;	2.3	;	Crystal Structure of human non-phosphorylated MKK4 kinase domain complexed with AMP-PNP
3ALO	;	2.6	;	Crystal structure of human non-phosphorylated MKK4 kinase domain ternary complex with AMP-PNP and p38 peptide
5I4E	;	2.25	;	Crystal Structure of Human Nonmuscle Myosin 2C motor domain
8G0W	;	2.87	;	Crystal structure of human norovirus GII.4 P domain in complex with Nanobody M4
4LQ3	;	2.6	;	Crystal structure of human norovirus RNA-dependent RNA-polymerase bound to the inhibitor PPNDS
4LQ9	;	2.04	;	Crystal structure of human norovirus RNA-dependent RNA-polymerase in complex with NAF2
4GML	;	2.9	;	Crystal structure of human NOT1 MIF4G domain
2F8Y	;	1.55	;	Crystal structure of human Notch1 ankyrin repeats to 1.55A resolution.
7WWP	;	2.99	;	Crystal structure of human Npl4
8C9J	;	2.7	;	Crystal structure of human NQO1 by serial femtosecond crystallography
8OK0	;	1.6	;	Crystal structure of human NQO1 in complex with the inhibitor PMSF
4XAJ	;	3.551	;	Crystal structure of human NR2E1/TLX
5CVD	;	1.3	;	Crystal structure of human NRMT1 in complex with alpha-N-dimethylated human CENP-A peptide
6KDQ	;	1.499	;	Crystal structure of human NRMT1 in complex with alpha-N-monomethylated human CENP-A peptide
5CVE	;	1.5	;	Crystal Structure of human NRMT1 in complex with dimethylated fly H2B peptide and SAH
6KDS	;	1.844	;	Crystal structure of human NRMT2 in complex with alpha-N-monomethylated human CENP-A peptide
6KDR	;	2.112	;	Crystal structure of human NRMT2 in complex with human centromere protein B peptide
5WWQ	;	2.815	;	Crystal structure of human NSun6
5WWT	;	3.197	;	Crystal structure of human NSun6/tRNA
5WWS	;	3.247	;	Crystal structure of human NSun6/tRNA/SAM
5WWR	;	3.096	;	Crystal structure of human NSun6/tRNA/SFG
3QOR	;	1.753	;	Crystal structure of human nuclear migration protein NudC
4QJR	;	2.4	;	Crystal structure of human nuclear receptor sf-1 (nr5a1) bound to its hormone pip3 at 2.4 a resolution
4QK4	;	2.81	;	Crystal structure of human nuclear receptor sf-1 (nr5a1) bound to pip2 at 2.8 a resolution
2P1B	;	2.75	;	Crystal structure of human nucleophosmin-core
5EHD	;	2.55	;	Crystal structure of human nucleophosmin-core in complex with cytochrome c
1JXV	;	2.2	;	Crystal Structure of Human Nucleoside Diphosphate Kinase A
6KVD	;	2.21	;	Crystal structure of human nucleosome containing H2A.J
5AY8	;	2.8	;	Crystal structure of human nucleosome containing H3.Y
2CV5	;	2.5	;	Crystal structure of human nucleosome core particle
3AZG	;	2.4	;	Crystal Structure of Human Nucleosome Core Particle Containing H3K115Q mutation
3AZH	;	3.49	;	Crystal Structure of Human Nucleosome Core Particle Containing H3K122Q mutation
3AYW	;	2.9	;	Crystal Structure of Human Nucleosome Core Particle Containing H3K56Q mutation
3AZE	;	3.0	;	Crystal Structure of Human Nucleosome Core Particle Containing H3K64Q mutation
3AZF	;	2.7	;	Crystal Structure of Human Nucleosome Core Particle Containing H3K79Q mutation
3AZI	;	2.7	;	Crystal Structure of Human Nucleosome Core Particle Containing H4K31Q mutation
3AZJ	;	2.89	;	Crystal Structure of Human Nucleosome Core Particle Containing H4K44Q mutation
3AZK	;	3.2	;	Crystal Structure of Human Nucleosome Core Particle Containing H4K59Q mutation
3AZL	;	2.7	;	Crystal Structure of Human Nucleosome Core Particle Containing H4K77Q mutation
3AZM	;	2.89	;	Crystal Structure of Human Nucleosome Core Particle Containing H4K79Q mutation
3AZN	;	3.0	;	Crystal Structure of Human Nucleosome Core Particle Containing H4K91Q mutation
3W96	;	3.0	;	Crystal Structure of Human Nucleosome Core Particle lacking H2A N-terminal region
3W97	;	3.2	;	Crystal Structure of Human Nucleosome Core Particle lacking H2B N-terminal region
3W98	;	3.42	;	Crystal Structure of Human Nucleosome Core Particle lacking H3.1 N-terminal region
3W99	;	3.0	;	Crystal Structure of Human Nucleosome Core Particle lacking H4 N-terminal region
3COU	;	1.8	;	Crystal structure of human Nudix motif 16 (NUDT16)
2XSQ	;	1.72	;	Crystal structure of human Nudix motif 16 (NUDT16) in complex with IMP and magnesium
5BON	;	1.799	;	Crystal structure of human Nudt15 (MTH2)
3MGM	;	1.801	;	Crystal structure of human NUDT16
5LF9	;	1.45	;	Crystal structure of human NUDT22
6GRU	;	1.93	;	Crystal structure of human NUDT5
3ACA	;	2.05	;	Crystal structure of human NUDT5 complexed with 8-oxo-dADP and manganese
3AC9	;	2.1	;	Crystal structure of human NUDT5 complexed with 8-oxo-dGDP and manganese
3L85	;	2.301	;	Crystal structure of human NUDT5 complexed with 8-oxo-dGMP
4I79	;	1.75	;	Crystal structure of human NUP43
3V3Q	;	2.22	;	Crystal Structure of Human Nur77 Ligand-binding Domain in Complex with Ethyl 2-[2,3,4 trimethoxy-6(1-octanoyl)phenyl]acetate
4JGV	;	3.01	;	Crystal Structure of Human Nur77 Ligand-binding Domain in Complex with THPN
8FE7	;	2.98	;	Crystal structure of human O-GlcNAc transferase (OGT) in complex with an exosite-binding peptide (SMG9) and UDP-GlcNAc
8FUF	;	3.69	;	Crystal structure of human O-GlcNAc transferase (OGT) in complex with an exosite-binding peptide (ZNF831) and UDP-GlcNAc
8FE6	;	3.06	;	Crystal structure of human O-GlcNAc transferase (OGT) in complex with an exosite-binding peptide and UDP-GlcNAc
4N3A	;	1.88	;	Crystal Structure of human O-GlcNAc transferase bound to a peptide from HCF-1 pro-repeat 2 (1-26)E10A
4N39	;	1.76	;	Crystal structure of human O-GlcNAc transferase bound to a peptide from HCF-1 pro-repeat 2 (11-26)
6MA5	;	2.0	;	Crystal structure of human O-GlcNAc transferase bound to a peptide from HCF-1 pro-repeat 2 (11-26) and inhibitor 1a
6MA3	;	2.0	;	Crystal structure of human O-GlcNAc transferase bound to a peptide from HCF-1 pro-repeat 2 (11-26) and inhibitor 2a
6MA4	;	2.0	;	Crystal structure of human O-GlcNAc transferase bound to a peptide from HCF-1 pro-repeat 2 (11-26) and inhibitor 3a
6MA1	;	2.75	;	Crystal structure of human O-GlcNAc transferase bound to a peptide from HCF-1 pro-repeat 2 (11-26) and inhibitor 4a
6MA2	;	2.1	;	Crystal structure of human O-GlcNAc transferase bound to a peptide from HCF-1 pro-repeat 2 (11-26) and inhibitor ent-1a
4N3C	;	2.55	;	Crystal Structure of human O-GlcNAc Transferase bound to a peptide from HCF-1 pro-repeat2(1-26) and UDP-GlcNAc
4N3B	;	2.17	;	Crystal Structure of human O-GlcNAc Transferase bound to a peptide from HCF-1 pro-repeat2(1-26)E10Q and UDP-5SGlcNAc
6TKA	;	1.91	;	Crystal structure of human O-GlcNAc transferase bound to substrate 7 and a peptide from HCF-1 pro-repeat 2 (11-26)
4GYW	;	1.7	;	Crystal structure of human O-GlcNAc Transferase in complex with UDP and a glycopeptide
4GZ3	;	1.9	;	Crystal structure of human O-GlcNAc Transferase with UDP and a thioglycopeptide
4GZ6	;	2.98	;	Crystal structure of human O-GlcNAc Transferase with UDP-5SGlcNAc
4GYY	;	1.85	;	Crystal structure of human O-GlcNAc Transferase with UDP-5SGlcNAc and a peptide substrate
4GZ5	;	3.075	;	Crystal structure of human O-GlcNAc Transferase with UDP-GlcNAc
8P0L	;	2.5	;	Crystal structure of human O-GlcNAcase in complex with an S-linked CKII peptide
5UN8	;	2.13	;	Crystal Structure of human O-GlcNAcase in complex with glycopeptide p53
4S3N	;	2.0	;	Crystal structure of human OAS3 domain I in complex with dsRNA
5NNZ	;	2.651	;	Crystal structure of human ODA16
4RUN	;	2.6	;	Crystal structure of human odorant binding protein OBPIIa
4NHX	;	2.105	;	Crystal structure of human OGFOD1, 2-oxoglutarate and iron-dependent oxygenase domain containing 1, in complex with N-oxalylglycine (NOG)
4NHY	;	2.603	;	Crystal structure of human OGFOD1, 2-oxoglutarate and iron-dependent oxygenase domain containing 1, in complex with pyridine-2,4-dicarboxylic acid (2,4-PDCA)
2OHF	;	2.7	;	Crystal structure of human OLA1 in complex with AMPPCP
1EVS	;	2.2	;	CRYSTAL STRUCTURE OF HUMAN ONCOSTATIN M
5UV6	;	2.65002	;	Crystal structure of human Opioid Binding Protein/Cell Adhesion Molecule Like (OPCML)
3M03	;	2.5	;	Crystal structure of human Orc6 fragment
5WQC	;	1.96	;	Crystal structure of human orexin 2 receptor bound to the selective antagonist EMPA determined by the synchrotron light source at SPring-8.
1D7K	;	2.1	;	CRYSTAL STRUCTURE OF HUMAN ORNITHINE DECARBOXYLASE AT 2.1 ANGSTROMS RESOLUTION
1OTH	;	1.85	;	CRYSTAL STRUCTURE OF HUMAN ORNITHINE TRANSCARBAMOYLASE COMPLEXED WITH N-PHOSPHONACETYL-L-ORNITHINE
1FVO	;	2.6	;	CRYSTAL STRUCTURE OF HUMAN ORNITHINE TRANSCARBAMYLASE COMPLEXED WITH CARBAMOYL PHOSPHATE
3BK0	;	1.6	;	Crystal Structure of Human Orotidine 5'-monophosphate Decarboxylase Complexed with 5-CN-UMP
3MW7	;	2.32	;	Crystal structure of human orotidine 5'-monophosphate decarboxylase complexed with 5-fluoro-UMP(produced from 5-fluoro-6-amino-UMP)
3DBP	;	1.5	;	Crystal Structure of Human Orotidine 5'-Monophosphate Decarboxylase Complexed with 6-NH2-UMP
3BGG	;	1.93	;	Crystal structure of Human Orotidine 5'-monophosphate Decarboxylase complexed with BMP
4HKP	;	1.75	;	Crystal structure of human orotidine 5'-monophosphate decarboxylase complexed with CMP-N3-oxide
4HIB	;	1.8	;	Crystal structure of human orotidine 5'-monophosphate decarboxylase complexed with CMP-N4-OH
3BVJ	;	1.8	;	Crystal Structure of Human Orotidine 5'-monophosphate Decarboxylase Complexed with XMP
3MO7	;	1.35	;	Crystal structure of human orotidine 5'-monophosphate decarboxylase covalently modified by 2'-fluoro-6-iodo-UMP
3G3D	;	1.7	;	Crystal Structure of Human Orotidine 5'-monophosphate Decarboxylase Covalently Modified by 5-fluoro-6-azido-UMP
3G3M	;	1.4	;	Crystal Structure of Human Orotidine 5'-monophosphate Decarboxylase Covalently Modified by 5-fluoro-6-iodo-UMP
3BGJ	;	2.0	;	Crystal Structure of Human Orotidine 5'-monophosphate Decarboxylase Covalently Modified by 6-iodo-UMP
3MI2	;	1.2	;	Crystal structure of human orotidine-5'-monophosphate decarboxylase complexed with pyrazofurin monophosphate
5ZM5	;	2.6	;	Crystal structure of human ORP1-ORD in complex with cholesterol at 2.6 A resolution
7V62	;	3.25	;	Crystal structure of human OSBP ORD in complex with cholesterol
3EHQ	;	2.57	;	Crystal Structure of Human Osteoclast Stimulating Factor
3EHR	;	1.95	;	Crystal Structure of Human Osteoclast Stimulating Factor
5YQ5	;	2.17	;	Crystal structure of human osteomodulin
4DDG	;	3.2987	;	Crystal structure of human OTUB1/UbcH5b~Ub/Ub
4DDI	;	3.802	;	Crystal structure of human OTUB1/UbcH5b~Ub/Ub
2ZFY	;	1.69	;	Crystal structure of human Otubain 1
4FJV	;	2.047	;	Crystal Structure of Human Otubain2 and Ubiquitin Complex
4ZMW	;	2.3	;	Crystal structure of human P-cadherin (enc-X-dimer)
4ZMX	;	3.1	;	Crystal structure of human P-cadherin (int-X-dimer)
4ZMY	;	1.5	;	Crystal structure of human P-cadherin (monomer 1)
4ZMZ	;	2.05	;	Crystal structure of human P-cadherin (monomer 2)
4ZMO	;	2.48	;	Crystal structure of human P-cadherin (ss-dimer K14E)
4ZMN	;	2.6	;	Crystal structure of human P-cadherin (ss-dimer long)
4ZMP	;	2.15	;	Crystal structure of human P-cadherin (ss-dimer Q101L)
4ZML	;	1.85	;	Crystal structure of human P-cadherin (ss-dimer)
4ZMV	;	2.4	;	Crystal structure of human P-cadherin (ss-X-dimer pocket I)
4ZMQ	;	2.2	;	Crystal structure of human P-cadherin (ss-X-dimer)
4ZMT	;	2.7	;	Crystal structure of human P-cadherin (ss-X-dimer-long)
4OY9	;	1.62	;	Crystal structure of human P-Cadherin EC1-EC2 in closed conformation
6ZTB	;	1.4	;	Crystal Structure of human P-Cadherin EC1_EC2
8HYI	;	2.85	;	Crystal structure of human P-cadherin MEC12 (X dimer) in complex with 2-(2-methyl-5-phenyl-1H-indole-3-yl)ethan-1-amine
7CME	;	2.45	;	Crystal structure of human P-cadherin MEC12 (X dimer) in complex with 2-(5-chloro-2-methyl-1H-indol-3-yl)ethan-1-amine (inhibitor)
7CMF	;	2.3	;	Crystal structure of human P-cadherin REC12 (monomer) in complex with 2-(5-chloro-2-methyl-1H-indol-3-yl)ethan-1-amine (inhibitor)
2O4X	;	2.0	;	Crystal structure of human P100 tudor domain
2HQX	;	1.42	;	Crystal structure of human P100 tudor domain conserved region
2HQE	;	2.0	;	Crystal structure of human P100 Tudor domain: Large fragment
5YVE	;	3.4	;	Crystal structure of human P2X3 receptor in complex with the AF-219 negative allosteric modulator
1P32	;	2.25	;	CRYSTAL STRUCTURE OF HUMAN P32, A DOUGHNUT-SHAPED ACIDIC MITOCHONDRIAL MATRIX PROTEIN
3ROC	;	1.7	;	Crystal structure of human p38 alpha complexed with a pyrimidinone compound
2Y8O	;	1.95	;	Crystal structure of human p38alpha complexed with a MAPK docking peptide
3HP2	;	2.15	;	Crystal Structure of Human p38alpha complexed with a pyridinone compound
3HP5	;	2.3	;	Crystal Structure of Human p38alpha complexed with a pyrimidopyridazinone compound
3KF7	;	2.0	;	Crystal Structure of Human p38alpha Complexed With a Triazolopyrimidine compound
3HLL	;	1.95	;	Crystal Structure of Human p38alpha complexed with PH-797804
3HL7	;	1.88	;	Crystal Structure of Human p38alpha complexed with SD-0006
3HVC	;	2.1	;	Crystal structure of human p38alpha MAP kinase
6VLT	;	3.12	;	Crystal Structure of Human P450 2C9*2 Genetic Variant in Complex with Losartan
2J0D	;	2.75	;	Crystal structure of human P450 3A4 in complex with erythromycin
2V0M	;	2.8	;	Crystal structure of human P450 3A4 in complex with ketoconazole
2J8Z	;	2.5	;	Crystal Structure of human P53 inducible oxidoreductase (TP53I3,PIG3)
2OBY	;	3.0	;	Crystal structure of Human P53 inducible oxidoreductase (TP53I3,PIG3)
3HF1	;	2.6	;	Crystal structure of human p53R2
2Y4U	;	3.2	;	Crystal structure of human P58(IPK) in space group P312
4A9Z	;	2.29	;	CRYSTAL STRUCTURE OF HUMAN P63 TETRAMERIZATION DOMAIN
3B4D	;	2.001	;	Crystal Structure of Human PABPN1 RRM
3B4M	;	2.82	;	Crystal Structure of Human PABPN1 RRM
6JPT	;	0.96	;	Crystal structure of human PAC3 homodimer (trigonal form)
3Q84	;	2.8	;	Crystal structure of human PACSIN 1 F-BAR domain
3QNI	;	2.8	;	Crystal structure of human PACSIN 1 F-BAR domain
3Q0K	;	2.6	;	Crystal structure of Human PACSIN 2 F-BAR
3HAH	;	2.77	;	Crystal structure of human PACSIN1 F-BAR domain (C2 lattice)
3HAI	;	2.881	;	Crystal structure of human PACSIN1 F-BAR domain (P21 lattice)
3HAJ	;	2.78	;	Crystal structure of human PACSIN2 F-BAR domain (p212121 lattice)
7ALE	;	2.95	;	Crystal structure of human PAICS in complex with inhibitor 69
2H31	;	2.8	;	Crystal structure of human PAICS, a bifunctional carboxylase and synthetase in purine biosynthesis
5XOF	;	1.963	;	Crystal structure of human paired immunoglobulin-like type 2 receptor alpha with synthesized glycopeptide I
5XO2	;	2.201	;	Crystal structure of human paired immunoglobulin-like type 2 receptor alpha with synthesized glycopeptide II
6Q42	;	1.9	;	Crystal Structure of Human Pancreatic Phospholipase A2
3ELO	;	1.55	;	Crystal Structure of Human Pancreatic Prophospholipase A2
3AQG	;	2.75	;	Crystal structure of human pancreatic secretory protein ZG16b
3APA	;	1.65	;	Crystal structure of human pancreatic secretory protein ZG16p
3VZE	;	1.9	;	Crystal structure of human pancreatic secretory protein ZG16p with alpha1,3-mannobiose
3VY6	;	2.0	;	Crystal structure of human pancreatic secretory protein ZG16p with laminaribiose
3VZF	;	2.8	;	Crystal structure of human pancreatic secretory protein ZG16p with methyl alpha-D-mannopyranoside
3VY7	;	2.14	;	Crystal structure of human pancreatic secretory protein ZG16p with O-(alpha-D-mannosyl)-L-serine
3VZG	;	2.7	;	Crystal structure of human pancreatic secretory protein ZG16p with O-(alpha-D-mannosyl)-L-threonine
2I7N	;	1.9	;	Crystal structure of human PANK1 alpha: the catalytic core domain in complex with AcCoA
5E26	;	2.14	;	Crystal structure of human PANK2: the catalytic core domain in complex with pantothenate and adenosine diphosphate
2I7P	;	2.05	;	Crystal structure of human PANK3 in complex with AcCoA
6IGE	;	2.9	;	Crystal structure of Human Papillomavirus type 33 pentamer
6IGF	;	2.751	;	Crystal structure of Human Papillomavirus type 52 pentamer
5J6R	;	4.011	;	Crystal structure of Human Papillomavirus Type 59 L1 pentamer
1ET1	;	0.9	;	CRYSTAL STRUCTURE OF HUMAN PARATHYROID HORMONE 1-34 AT 0.9 A RESOLUTION
7ZTW	;	1.93	;	Crystal Structure of Human Parechovirus 1 2A protein
7ZU3	;	1.74	;	Crystal Structure of Human Parechovirus 1 2A protein lacking the C-terminal oligomerisation helix
7ZU4	;	2.1	;	Crystal Structure of Human Parechovirus 1 2A protein lacking the C-terminal oligomerisation helix
8A2E	;	2.29	;	Crystal Structure of Human Parechovirus 3 2A protein
6NRH	;	1.5	;	Crystal Structure of human PARP-1 ART domain bound inhibitor UTT63
6NTU	;	1.8	;	Crystal Structure of human PARP-1 ART domain bound to inhibitor UKTT-15
6NRF	;	2.0	;	Crystal Structure of human PARP-1 ART domain bound to inhibitor UTT103
6NRG	;	1.7	;	Crystal Structure of human PARP-1 ART domain bound to inhibitor UTT57
6NRI	;	2.2	;	Crystal Structure of human PARP-1 ART domain bound to inhibitor UTT83
6NRJ	;	1.65	;	Crystal Structure of human PARP-1 ART domain bound to inhibitor UTT93
6VKQ	;	2.9	;	Crystal Structure of human PARP-1 CAT domain bound to inhibitor EB-47
6VKK	;	2.1	;	Crystal Structure of human PARP-1 CAT domain bound to inhibitor rucaparib
6VKO	;	2.8	;	Crystal Structure of human PARP-1 CAT domain bound to inhibitor UKTT15
8FYZ	;	3.4	;	Crystal structure of human PARP1 ART domain bound to inhibitor UKTT10 (compound 13)
8FZ1	;	2.7	;	Crystal structure of human PARP1 ART domain bound to inhibitor UKTT22 (compound 14)
8FYY	;	2.8	;	Crystal structure of human PARP1 ART domain bound to inhibitor UKTT5 (compound 10)
5V7W	;	2.65	;	Crystal structure of human PARP14 bound to 2-{[(1-methylpiperidin-4-yl)methyl]amino}-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one inhibitor
3UI5	;	1.4	;	Crystal structure of human Parvulin 14
3DLS	;	2.3	;	Crystal structure of human PAS kinase bound to ADP
4XGZ	;	2.5	;	Crystal structure of human paxillin LD2 motif in complex with Fab fragment
4XH2	;	2.0	;	Crystal structure of human paxillin LD4 motif in complex with Fab fragment
5FE0	;	2.3	;	Crystal structure of human PCAF bromodomain in complex with acetyllysine
5FDZ	;	2.4	;	Crystal structure of human PCAF bromodomain in complex with compound BDOMB00091a (compound 14)
5FE9	;	2.35	;	Crystal structure of human PCAF bromodomain in complex with compound SL1122 (compound 13)
5FE8	;	2.1	;	Crystal structure of human PCAF bromodomain in complex with compound SL1126 (compound 12)
5LVQ	;	2.05	;	Crystal structure of human PCAF bromodomain in complex with compound-D (CPD-D), N-methyl-2-(tetrahydro-2H-pyran-4-yloxy)benzamide
5LVR	;	2.05	;	Crystal structure of human PCAF bromodomain in complex with compound-E (CPD-E)
5FE1	;	2.22	;	Crystal structure of human PCAF bromodomain in complex with fragment BR004 (fragment 1)
5FE2	;	2.25	;	Crystal structure of human PCAF bromodomain in complex with fragment BR013 (fragment 3)
5FE5	;	2.12	;	Crystal structure of human PCAF bromodomain in complex with fragment MB093 (fragment 7)
5FE3	;	2.12	;	Crystal structure of human PCAF bromodomain in complex with fragment MB360 (fragment 4)
5FE4	;	2.15	;	Crystal structure of human PCAF bromodomain in complex with fragment MB364 (fragment 5)
5FE6	;	1.77	;	Crystal structure of human PCAF bromodomain in complex with fragment ZB1916 (fragment 10)
5FE7	;	2.08	;	Crystal structure of human PCAF bromodomain in complex with fragment ZB2216 (fragment 11)
6FCM	;	2.8	;	Crystal structure of human PCNA
4ZTD	;	2.199	;	Crystal Structure of Human PCNA in complex with a TRAIP peptide
5YD8	;	2.3	;	Crystal structure of human PCNA in complex with APIM of human ZRANB3
6K3A	;	2.3	;	Crystal structure of human PCNA in complex with DNMT1 PIP box motif.
8COB	;	2.73	;	Crystal structure of human PCNA in complex with ERCC6L2 PIP box peptide
4D2G	;	2.65	;	Crystal structure of human PCNA in complex with p15 peptide
5MAV	;	2.575	;	Crystal structure of human PCNA in complex with PARG (poly(ADP-ribose) glycohydrolase) peptide.
5IY4	;	2.945	;	Crystal structure of human PCNA in complex with the PIP box of DVC1
8F5Q	;	1.9	;	Crystal structure of human PCNA in complex with the PIP box of FBH1
6GWS	;	2.9	;	Crystal structure of human PCNA in complex with three p15 peptides
6HVO	;	2.1	;	Crystal structure of human PCNA in complex with three peptides of p12 subunit of human polymerase delta
5MLW	;	2.45	;	Crystal structure of human PCNA in complex with ZRANB3 APIM motif peptide
5MLO	;	1.96	;	Crystal structure of human PCNA in complex with ZRANB3 PIP box peptide
6FCN	;	3.22	;	Crystal structure of human PCNA soaked with p47phox(106-127) peptide
6U6V	;	1.9	;	Crystal structure of human PD-1H / VISTA
4Z18	;	1.952	;	CRYSTAL STRUCTURE OF HUMAN PD-L1
5IUS	;	2.889	;	Crystal structure of human PD-L1 in complex with high affinity PD-1 mutant
5GRJ	;	3.206	;	Crystal structure of human PD-L1 with monoclonal antibody avelumab
5UWF	;	1.87	;	Crystal structure of human PDE10A in complex with inhibitor 16d
4NPW	;	1.9	;	Crystal structure of human PDE1B bound to inhibitor 19A (7,8-dimethoxy-N-[(2S)-1-(3-methyl-1H-pyrazol-5-yl)propan-2-yl]quinazolin-4-amine)
4NPV	;	2.4	;	Crystal structure of human PDE1B bound to inhibitor 7A (6,7,8-trimethoxy-N-(pentan-3-yl)quinazolin-4-amine)
5UOY	;	1.82	;	Crystal structure of human PDE1B catalytic domain in complex with inhibitor 16j (6-(4-Methoxybenzyl)-9-((tetrahydro-2H-pyran-4-yl)methyl)-8,9,10,11-tetrahydropyrido[4',3':4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one)
5UP0	;	2.04	;	Crystal structure of human PDE1B catalytic domain in complex with inhibitor 3 (6-(4-chlorobenzyl)-8,9,10,11-tetrahydrobenzo[4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one)
5B25	;	1.9	;	Crystal structure of human PDE1B with inhibitor 3
5TZC	;	2.36	;	Crystal Structure of human PDE2a in complex with (5S)-1-[(3-bromo-4-fluorophenyl)carbonyl]-3,3-difluoro-5-{5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}piperidine
3I8V	;	2.25	;	Crystal structure of human PDE4a with 4-(3-butoxy-4-methoxyphenyl)methyl-2-imidazolidone
3KKT	;	2.48	;	Crystal structure of human PDE4b with 5-[3-[(1S,2S,4R)-Bicyclo[2.2.1]hept-2-yloxy]-4-methoxyp henyl]tetrahydro-2(1H)-pyrimidinone reveals ordering of the C-terminal helix residues 502-509.
4HQX	;	2.3	;	CRYSTAL STRUCTURE OF HUMAN PDGF-BB IN COMPLEX WITH A Modified nucleotide aptamer (SOMAmer SL4)
4HQU	;	2.2	;	Crystal structure of human PDGF-BB in complex with a modified nucleotide aptamer (SOMAmer SL5)
5K5X	;	2.168	;	Crystal structure of human PDGFRA
3UEM	;	2.29	;	Crystal structure of human PDI bb'a' domains
3HRF	;	1.9	;	Crystal structure of Human PDK1 kinase domain in complex with an allosteric activator bound to the PIF-pocket
6LIL	;	1.93	;	Crystal structure of human PDK2 complexed with an allosteric inhibitor compound 8c
6LIN	;	2.67	;	Crystal structure of human PDK2 complexed with GM10030
6LIO	;	1.76	;	Crystal structure of human PDK2 complexed with GM67520
2ZKJ	;	2.0	;	Crystal structure of human PDK4-ADP complex
1YCK	;	1.7	;	Crystal structure of human peptidoglycan recognition protein (PGRP-S)
4DIP	;	1.82	;	Crystal structure of human Peptidyl-prolyl cis-trans isomerase FKBP14
4MSP	;	1.9	;	Crystal structure of human peptidyl-prolyl cis-trans isomerase FKBP22 (aka FKBP14) containing two EF-hand motifs
2DEX	;	2.1	;	Crystal structure of human peptidylarginine deiminase 4 in complex with histone H3 N-terminal peptide including Arg17
2DEW	;	2.1	;	Crystal structure of human peptidylarginine deiminase 4 in complex with histone H3 N-terminal tail including Arg8
2DEY	;	2.25	;	Crystal structure of human peptidylarginine deiminase 4 in complex with histone H4 N-terminal tail including Arg3
4DKT	;	2.98	;	Crystal structure of human peptidylarginine deiminase 4 in complex with N-acetyl-L-threonyl-L-alpha-aspartyl-N5-[(1E)-2-fluoroethanimidoyl]-L-ornithinamide
2DW5	;	2.3	;	Crystal structure of human peptidylarginine deiminase 4 in complex with N-alpha-benzoyl-N5-(2-fluoro-1-iminoethyl)-L-ornithine amide
3B1T	;	2.5	;	Crystal structure of human peptidylarginine deiminase 4 in complex with o-Cl-amidine
3B1U	;	2.1	;	Crystal structure of human peptidylarginine deiminase 4 in complex with o-F-amidine
1WDA	;	2.3	;	Crystal structure of human peptidylarginine deiminase type4 (PAD4) in complex with benzoyl-L-arginine amide
4X8C	;	3.1	;	Crystal structure of human peptidylarginine deiminase type4 (PAD4) in complex with GSK147
4X8G	;	3.29	;	Crystal structure of human peptidylarginine deiminase type4 (PAD4) in complex with GSK199
3NR3	;	1.95	;	Crystal Structure of Human Peripheral Myelin Protein 2
2PN8	;	1.8	;	Crystal structure of human peroxiredoxin 4 (thioredoxin peroxidase)
4RQX	;	2.256	;	Crystal structure of human peroxiredoxin 4(THIOREDOXIN PEROXIDASE) with MESNA
5B6M	;	2.496	;	Crystal structure of human peroxiredoxin 6 in reduced state
2RII	;	2.6	;	Crystal Structure of Human Peroxiredoxin I in complex with Sulfiredoxin
3TJK	;	2.09	;	Crystal Structure of human peroxiredoxin IV C245A mutant in reduced form
3TJJ	;	1.91	;	Crystal structure of human peroxiredoxin IV C245A mutant in sulfenylated form
3TJG	;	2.24	;	Crystal Structure of human peroxiredoxin IV C51A mutant in oxidized form
3TJF	;	2.04	;	Crystal Structure of human peroxiredoxin IV C51A mutant in reduced form
2IIK	;	2.55	;	Crystal Structure of human peroxisomal acetyl-CoA acyl transferase 1 (ACAA1)
7Q84	;	2.0	;	Crystal structure of human peroxisomal acyl-Co-A oxidase 1a, apo-form
7Q86	;	2.09	;	Crystal structure of human peroxisomal acyl-Co-A oxidase 1a, FAD-bound-form
5T3P	;	2.03	;	Crystal structure of Human Peroxisomal coenzyme A diphosphatase NUDT7
2VRE	;	1.95	;	crystal structure of human peroxisomal delta3,5,delta2,4-dienoyl coa isomerase
4U18	;	2.64	;	Crystal structure of human peroxisomal delta3,delta2, enoyl-CoA isomerase (ISO-ECI2)
4U1A	;	2.85	;	Crystal structure of human peroxisomal delta3,delta2, enoyl-CoA isomerase helix-10 deletion mutant (ISOB-ECI2)
4U19	;	1.88	;	Crystal structure of human peroxisomal delta3,delta2, enoyl-CoA isomerase V349A mutant (ISOA-ECI2)
3AJB	;	2.5	;	Crystal Structure of human Pex3p in complex with N-terminal Pex19p peptide
4O33	;	2.1	;	Crystal Structure of human PGK1 3PG and terazosin(TZN) ternary complex
4X8Y	;	1.95	;	Crystal structure of human PGRMC1 cytochrome b5-like domain
2APH	;	2.1	;	Crystal structure of human PGRP-IalphaC in complex with muramyl pentapeptide
2EAX	;	2.1	;	Crystal structure of human PGRP-IBETAC in complex with glycosamyl muramyl pentapeptide
4ANP	;	2.11	;	Crystal structure of human phenylalanine hydroxylase in complex with a pharmacological chaperone
6WS1	;	2.76	;	Crystal structure of human phenylethanolamine N-methyltransferase (PNMT) in complex with (2S)-2-amino-4-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(3-(7,8-dichloro-1,2,3,4-tetrahydroisoquinolin-4-yl)propyl)amino)butanoic acid and AdoHcy (SAH)
7TX2	;	2.43	;	Crystal structure of human phenylethanolamine N-methyltransferase (PNMT) in complex with (2S)-2-amino-4-(((5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(4-(7,8-dichloro-1,2,3,4-tetrahydroisoquinolin-4-yl)butyl)amino)butanoic acid
7TWU	;	2.1	;	Crystal structure of human phenylethanolamine N-methyltransferase (PNMT) in complex with (2S)-2-amino-4-(((5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(4-(7,8-dichloro-1,2,3,4-tetrahydroisoquinolin-4-yl)butyl)amino)butanoic acid and AdoHcy (SAH)
5SYB	;	1.82	;	Crystal structure of human PHF5A
4DO0	;	2.55	;	Crystal Structure of human PHF8 in complex with Daminozide
6PLF	;	1.7	;	Crystal structure of human PHGDH complexed with Compound 1
6PLG	;	2.93	;	Crystal structure of human PHGDH complexed with Compound 15
7EWH	;	2.99	;	Crystal structure of human PHGDH in complex with Homoharringtonine
5K25	;	3.05	;	Crystal structure of human phosphatase PRL-2 in complex with the ADP-bound Bateman domain of human magnesium transporter CNNM3
5BZZ	;	2.2	;	Crystal structure of human phosphatase PTEN in its reduced state
5BUG	;	2.4	;	Crystal structure of human phosphatase PTEN oxidized by H2O2
5BZX	;	2.5	;	Crystal structure of human phosphatase PTEN treated with a bisperoxovanadium complex
1LN1	;	2.4	;	Crystal Structure of Human Phosphatidylcholine Transfer Protein in Complex with Dilinoleoylphosphatidylcholine
1LN2	;	2.9	;	Crystal Structure of Human Phosphatidylcholine Transfer Protein in Complex with Dilinoleoylphosphatidylcholine (Seleno-Met Protein)
7U9D	;	2.18	;	Crystal Structure of Human Phosphatidylcholine Transfer Protein in Complex with PC(16:0/20:4)
6GL3	;	2.77	;	Crystal structure of human Phosphatidylinositol 4-kinase III beta (PI4KIIIbeta) in complex with ligand 44
2YBX	;	2.56	;	Crystal Structure of Human Phosphatidylinositol-5-phosphate 4-kinase type-2 alpha
1WOJ	;	1.8	;	Crystal structure of human phosphodiesterase
5SJH	;	2.1	;	Crystal Structure of human phosphodiesterase 10
5SFC	;	2.18	;	Crystal Structure of human phosphodiesterase 10 in complex with
5SHW	;	2.19	;	Crystal Structure of human phosphodiesterase 10 in complex with (2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)methanol
5SJR	;	2.1	;	Crystal Structure of human phosphodiesterase 10 in complex with (2R)-2-[[3-cyano-2-[4-(2-ethoxyphenyl)phenyl]-6-fluoroquinolin-4-yl]amino]propanoic acid
5SIA	;	2.27	;	Crystal Structure of human phosphodiesterase 10 in complex with 1-(2,3-dimethylquinoxalin-6-yl)-3-(3-methoxyphenyl)urea
5SF7	;	2.08	;	Crystal Structure of human phosphodiesterase 10 in complex with 1-(2-chlorophenyl)-8-methoxy-3,4-dimethylimidazo[1,5-a]quinazolin-5-one
5SII	;	2.18	;	Crystal Structure of human phosphodiesterase 10 in complex with 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine
5SHV	;	1.95	;	Crystal Structure of human phosphodiesterase 10 in complex with 1-(6-fluoropyridin-2-yl)piperidin-4-one
5SGV	;	2.0	;	Crystal Structure of human phosphodiesterase 10 in complex with 1-benzyl-3-(2-phenylpyrazol-3-yl)pyridazin-4-one
5SI3	;	2.4	;	Crystal Structure of human phosphodiesterase 10 in complex with 1-methyl-5-[(2-phenylimidazo[1,2-a]pyrimidin-7-yl)carbamoyl]pyrazole-4-carboxylic acid
5SJ4	;	2.77	;	Crystal Structure of human phosphodiesterase 10 in complex with 1-methyl-6-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]-5H-pyrazolo[3,4-d]pyrimidin-4-one
5SKR	;	1.99	;	Crystal Structure of human phosphodiesterase 10 in complex with 1-methyl-N-(2-methyl-5-pyridin-2-ylpyrazol-3-yl)-4-pyridin-4-ylpyrazole-3-carboxamide
5SIG	;	2.03	;	Crystal Structure of human phosphodiesterase 10 in complex with 1-[(4-methoxyphenyl)methyl]-1-[(4-oxo-3H-quinazolin-2-yl)methyl]-3-phenylurea
5SG5	;	2.17	;	Crystal Structure of human phosphodiesterase 10 in complex with 1-[(4-methoxyphenyl)methyl]-3-(4-methylphenyl)-1-[(4-oxo-3H-quinazolin-2-yl)methyl]urea
5SJD	;	2.16	;	Crystal Structure of human phosphodiesterase 10 in complex with 1-[2-(3,5-dimethylpyrazol-1-yl)ethyl]-3-(2-phenylpyrazol-3-yl)urea
5SHC	;	2.33	;	Crystal Structure of human phosphodiesterase 10 in complex with 1-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethyl]-2-oxo-N-pyrimidin-5-ylpyridine-3-carboxamide
5SG0	;	2.06	;	Crystal Structure of human phosphodiesterase 10 in complex with 1-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethyl]-3-(2-phenylpyrazol-3-yl)imidazolidin-2-one
5SFZ	;	2.16	;	Crystal Structure of human phosphodiesterase 10 in complex with 1-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethyl]-3-(2-phenylpyrazol-3-yl)urea
5SJG	;	1.97	;	Crystal Structure of human phosphodiesterase 10 in complex with 1-[2-[2-(5,8-dimethyl-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)ethyl]-1-methylimidazol-4-yl]pyrrolidin-2-one
5SGU	;	2.14	;	Crystal Structure of human phosphodiesterase 10 in complex with 12-methoxy-5,7-dimethyl-3-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(13),3,5,7,9,11-hexaene
5SJ8	;	2.49	;	Crystal Structure of human phosphodiesterase 10 in complex with 12-methoxy-5-methyl-3-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(13),3,5,7,9,11-hexaene-7-carbonitrile
5SHI	;	2.1	;	Crystal Structure of human phosphodiesterase 10 in complex with 2,3,5-trimethyl-6-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]imidazo[1,2-a]pyridine
5SEV	;	2.31	;	Crystal Structure of human phosphodiesterase 10 in complex with 2,3,5-trimethyl-6-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]pyrazine
5SJ2	;	1.99	;	Crystal Structure of human phosphodiesterase 10 in complex with 2,3-dichloro-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyridine-4-carboxamide
5SE9	;	1.94	;	Crystal Structure of human phosphodiesterase 10 in complex with 2,3-dimethyl-6-[(1-methyl-4-phenylimidazol-2-yl)methoxy]imidazo[1,2-b]pyridazine
5SF5	;	1.98	;	Crystal Structure of human phosphodiesterase 10 in complex with 2,3-dimethyl-6-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]imidazo[1,2-b]pyridazine
5SGN	;	2.07	;	Crystal Structure of human phosphodiesterase 10 in complex with 2,3-dimethyl-6-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-7-(trifluoromethyl)imidazo[1,2-b]pyridazine
5SH3	;	1.98	;	Crystal Structure of human phosphodiesterase 10 in complex with 2,3-dimethyl-6-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-8-methylsulfonylimidazo[1,2-b]pyridazine
5SHE	;	2.19	;	Crystal Structure of human phosphodiesterase 10 in complex with 2,3-dimethylquinoxalin-6-amine
5SE6	;	1.95	;	Crystal Structure of human phosphodiesterase 10 in complex with 2,9-dimethyl-6-[(1-methyl-4-phenylimidazol-2-yl)methoxy]purine
5SK2	;	2.14	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-(4-fluorophenyl)-4-(2-isoquinolin-3-yloxyethyl)-5-methyl-1,3-oxazole
5SF1	;	2.11	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-(difluoromethyl)-3-methyl-6-[2-(1-methyl-4-phenylimidazol-2-yl)ethynyl]imidazo[1,2-b]pyridazine
5SH5	;	2.3	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-amino-4-cyclohexyloxyquinoline-3-carbonitrile
5SI7	;	2.1	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-benzyl-6,6-dimethyl-1H-imidazo[4,5-h]isoquinoline-7,9-dione
5SGR	;	2.04	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-chloro-3-[(1-methyl-4-phenylimidazol-2-yl)methoxy]quinoxaline
5SK9	;	2.82	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-chloro-5-methoxy-3-methylquinoxaline
5SKG	;	2.03	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-chloro-6-(cyclopropylamino)-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyridine-4-carboxamide
5SEZ	;	1.99	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-chloro-6-ethyl-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyridine-4-carboxamide
5SE3	;	2.14	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-chloro-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyridine-4-carboxamide
5SIQ	;	1.97	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-ethyl-3-[4-(4-methylphenyl)sulfonylpiperazin-1-yl]quinoxaline
5SF3	;	2.15	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-3-N-(2-phenylimidazo[1,2-a]pyrimidin-7-yl)-4-N-(1H-pyrazol-5-ylmethyl)pyrazole-3,4-dicarboxamide
5SFJ	;	2.41	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-3-N-(2-phenylimidazo[1,2-a]pyrimidin-7-yl)-4-N-(pyridin-2-ylmethyl)pyrazole-3,4-dicarboxamide
5SHX	;	2.16	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-3-pyrrolidin-1-ylquinoxaline
5SF9	;	2.37	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-3-[(1-methyl-4-phenylimidazol-2-yl)methoxy]quinoxaline
5SEK	;	2.15	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-3-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]quinoxaline
5SGS	;	2.03	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-3-[2-(1-pyridin-2-ylpyrrolidin-3-yl)ethyl]quinoxaline
5SEB	;	2.28	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-3-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]quinoxaline
5SIM	;	1.75	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-4-(2-methylpyrrolidine-1-carbonyl)-N-(2-phenylimidazo[1,2-a]pyridin-7-yl)pyrazole-3-carboxamide
5SIO	;	2.2	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-4-(2-methylpyrrolidine-1-carbonyl)-N-(2-phenylimidazo[1,2-a]pyridin-7-yl)pyrazole-3-carboxamide
5SFM	;	2.16	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-4-(morpholine-4-carbonyl)-N-(2-phenyl-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)pyrazole-3-carboxamide
5SK5	;	1.95	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-4-(morpholine-4-carbonyl)-N-(2-phenylimidazo[1,2-a]pyridin-7-yl)pyrazole-3-carboxamide, space group H3
5SI1	;	1.75	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-4-(morpholine-4-carbonyl)-N-(2-phenylimidazo[1,2-a]pyridin-7-yl)pyrazole-3-carboxamide, space group I23
5SJZ	;	2.19	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-4-(morpholine-4-carbonyl)-N-(2-pyrrolidin-1-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3-carboxamide
5SHN	;	2.03	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-4-N-(1,3-oxazol-2-ylmethyl)-3-N-(2-phenylimidazo[1,2-a]pyrimidin-7-yl)pyrazole-3,4-dicarboxamide
5SDV	;	2.15	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-4-N-(1,3-oxazol-4-ylmethyl)-3-N-(2-phenylimidazo[1,2-a]pyrimidin-7-yl)pyrazole-3,4-dicarboxamide
5SGW	;	1.9	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-phenyl-6-(2-phenylpyrazol-3-yl)-3,4-dihydropyridazin-5-one
5SKE	;	2.2	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-tert-butyl-5-(pyrimidin-5-ylamino)-N-[3-(trifluoromethoxy)phenyl]pyrimidine-4-carboxamide
5SGG	;	2.09	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-[(4-chloro-3,5-dimethylpyridin-2-yl)methylsulfanyl]-6,7-dihydro-3H-furo[3,2-f]benzimidazole
5SHU	;	1.98	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfanyl]-3,5,6,7-tetrahydropyrrolo[3,2-f]benzimidazole
5SJB	;	2.2	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfanyl]-3H-imidazo[4,5-f]quinoline
5SHP	;	2.18	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfanyl]-3H-imidazo[4,5-h]quinoline
5SG9	;	2.13	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-[(E)-2-(4-methyl-6-pyrrolidin-1-ylpyrimidin-2-yl)ethenyl]quinoline
5SEC	;	2.03	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-[2-(1,4-diphenylimidazol-2-yl)ethyl]-3-methylquinoxaline
5SE2	;	2.2	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]quinoline
5SEU	;	2.09	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-6-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine
5SG1	;	2.41	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]triazolo[1,5-a]quinoline
5SEP	;	2.1	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-[2-(4-cyclopentyl-1-methylimidazol-2-yl)ethyl]-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine
5SEO	;	2.1	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-[2-(5-methyl-2-phenyl-1H-imidazol-4-yl)ethyl]isoindole-1,3-dione
5SGT	;	2.26	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-[2-[3-(4-methoxyphenyl)-4-oxoquinazolin-2-yl]ethyl]isoindole-1,3-dione
5SH9	;	2.06	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-[2-[5-[(3R)-3-fluoropyrrolidin-1-yl]-2-methyl-1,2,4-triazol-3-yl]ethyl]-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine
5SHA	;	2.24	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-[2-[5-[3-(difluoromethyl)pyrrolidin-1-yl]-2-methyl-1,2,4-triazol-3-yl]ethyl]-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine
5SJX	;	2.06	;	Crystal Structure of human phosphodiesterase 10 in complex with 2-[[4-(1-methyl-4-pyridin-4-ylpyrazol-3-yl)phenoxy]methyl]quinoline
5SIR	;	2.5	;	Crystal Structure of human phosphodiesterase 10 in complex with 3,6-dimethyl-N-(2-phenylimidazo[1,2-a]pyrimidin-7-yl)pyridine-2-carboxamide
5SHF	;	2.28	;	Crystal Structure of human phosphodiesterase 10 in complex with 3,6-dimethyl-N-(2-phenylpyrazolo[1,5-a]pyridin-6-yl)pyridine-2-carboxamide
5SGZ	;	2.2	;	Crystal Structure of human phosphodiesterase 10 in complex with 3-(2-chlorophenyl)-12-methoxy-5-methyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(13),3,5,9,11-pentaen-7-one
5SHG	;	2.12	;	Crystal Structure of human phosphodiesterase 10 in complex with 3-(2-chlorophenyl)-12-methoxy-5-methyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaen-7-amine
5SI4	;	2.39	;	Crystal Structure of human phosphodiesterase 10 in complex with 3-(2-naphthalen-1-ylpyrazol-3-yl)-1-[3-(trifluoromethoxy)phenyl]pyridazin-4-one
5SJM	;	2.3	;	Crystal Structure of human phosphodiesterase 10 in complex with 3-(2-phenylethyl)-5-pyridin-4-yl-1H-pyridin-2-one
5SJF	;	2.05	;	Crystal Structure of human phosphodiesterase 10 in complex with 3-(2-quinolin-4-ylpyrazol-3-yl)-1-[3-(trifluoromethoxy)phenyl]pyridazin-4-one
5SHS	;	2.3	;	Crystal Structure of human phosphodiesterase 10 in complex with 3-(naphthalen-1-ylmethyl)-7-piperidin-1-yltriazolo[4,5-d]pyrimidine
5SEM	;	2.1	;	Crystal Structure of human phosphodiesterase 10 in complex with 3-methyl-6-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]-2-(trifluoromethyl)imidazo[1,2-b]pyridazine
5SIB	;	2.54	;	Crystal Structure of human phosphodiesterase 10 in complex with 3-methyl-6-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-2-(trifluoromethyl)imidazo[1,2-b]pyridazine
5SG2	;	2.15	;	Crystal Structure of human phosphodiesterase 10 in complex with 3-methylimidazo[4,5-f]quinolin-2-amine
5SG4	;	2.3	;	Crystal Structure of human phosphodiesterase 10 in complex with 3-N-[2-(3-chlorophenyl)-1H-benzimidazol-5-yl]-2-methylpyrazole-3,4-dicarboxamide
5SFE	;	1.86	;	Crystal Structure of human phosphodiesterase 10 in complex with 3-N-[2-(3-fluorophenyl)imidazo[1,2-a]pyrimidin-7-yl]-4-N,4-N,2-trimethylpyrazole-3,4-dicarboxamide
5SGM	;	2.2	;	Crystal Structure of human phosphodiesterase 10 in complex with 3-N-[2-(4-fluorophenyl)imidazo[1,2-a]pyridin-7-yl]-4-N,4-N,2-trimethylpyrazole-3,4-dicarboxamide
5SJE	;	2.1	;	Crystal Structure of human phosphodiesterase 10 in complex with 3-[2-(2,2-difluoro-1,3-benzodioxol-4-yl)pyrazol-3-yl]-1-(3-methylsulfonylphenyl)pyridazin-4-one
5SJO	;	2.1	;	Crystal Structure of human phosphodiesterase 10 in complex with 3-[2-(2,4-difluorophenyl)pyrazol-3-yl]-1-[3-(trifluoromethoxy)phenyl]pyridazin-4-one
5SIF	;	2.2	;	Crystal Structure of human phosphodiesterase 10 in complex with 3-[2-(2,5-difluorophenyl)pyrazol-3-yl]-1-(3-methylsulfonylphenyl)pyridazin-4-one
5SKD	;	2.3	;	Crystal Structure of human phosphodiesterase 10 in complex with 3-[2-(2,5-difluorophenyl)pyrazol-3-yl]-1-[3-(trifluoromethoxy)phenyl]pyridazin-4-one
5SG7	;	2.3	;	Crystal Structure of human phosphodiesterase 10 in complex with 3-[2-(2-fluorophenyl)pyrazol-3-yl]-1-[3-(trifluoromethyl)phenyl]pyridazin-4-one
5SHB	;	1.95	;	Crystal Structure of human phosphodiesterase 10 in complex with 3-[2-(3-bromophenyl)pyrazol-3-yl]-1-pyridin-4-ylpyridazin-4-one
5SHZ	;	2.55	;	Crystal Structure of human phosphodiesterase 10 in complex with 3-[2-(3-ethynylphenyl)pyrazol-3-yl]-1-phenylpyridazin-4-one
5SKH	;	2.1	;	Crystal Structure of human phosphodiesterase 10 in complex with 3-[2-(3-fluorophenyl)pyrazol-3-yl]-1-[3-(trifluoromethoxy)phenyl]pyridazin-4-one
5SIU	;	2.01	;	Crystal Structure of human phosphodiesterase 10 in complex with 3-[2-(6,8-dichloro-5-methyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)ethyl]-1H-quinoxalin-2-one
5SKU	;	2.2	;	Crystal Structure of human phosphodiesterase 10 in complex with 3-[4-[2-[2-(2-ethoxy-4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]ethoxy]naphthalen-1-yl]-2-methoxypropanoic acid
5SKF	;	2.1	;	Crystal Structure of human phosphodiesterase 10 in complex with 3-[5-[1-(2,2-difluoro-1,3-benzodioxol-4-yl)-4-oxopyridazin-3-yl]pyrazol-1-yl]benzonitrile
5SJ6	;	2.15	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-(2-chloroquinazolin-4-yl)morpholine
5SEN	;	2.04	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-(1-quinolin-2-ylimidazol-4-yl)pyrazole-3-carboxamide
5SEL	;	2.2	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-(2-methyl-5-pyridin-2-ylpyrazol-3-yl)pyrazole-3-carboxamide
5SH2	;	2.19	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-(2-morpholin-4-yl-1,3-benzothiazol-5-yl)pyrazole-3-carboxamide
5SEH	;	2.1	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-(2-morpholin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3-carboxamide
5SGC	;	2.09	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-(2-morpholin-4-yl-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)pyrazole-3-carboxamide
5SES	;	2.11	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-(2-phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-7-yl)pyrazole-3-carboxamide
5SE7	;	2.17	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3-carboxamide
5SIP	;	2.03	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-(2-phenylimidazo[1,2-a]pyrimidin-7-yl)pyrazole-3-carboxamide
5SF0	;	2.1	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-(3-pyridin-2-yl-1H-pyrazol-5-yl)pyrazole-3-carboxamide
5SGK	;	2.13	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-[(7R)-2-(2-methylphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-7-yl]pyrazole-3-carboxamide
5SFO	;	1.96	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]pyrazole-3-carboxamide
5SFN	;	2.02	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-[2-(1-methylbenzimidazol-2-yl)ethyl]pyrazole-3-carboxamide
5SE8	;	1.99	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-[2-(2-methyl-5-phenyl-1,2,4-triazol-3-yl)ethyl]pyrazole-3-carboxamide
5SF8	;	2.15	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-[2-(5-phenyl-2-pyridin-2-yl-1,2,4-triazol-3-yl)ethyl]pyrazole-3-carboxamide
5SHJ	;	2.3	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-[3-(phenylcarbamoyl)phenyl]pyrazole-3-carboxamide
5SFV	;	2.41	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-N-(1-cyclopentylpyrazol-3-yl)-2-methylpyrazole-3-carboxamide
5SI6	;	2.0	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-N-(6-cyano-2-phenylimidazo[1,2-a]pyridin-7-yl)-2-methylpyrazole-3-carboxamide
5SFQ	;	2.21	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-N-[1-(2,2-difluoroethyl)pyrazol-3-yl]-2-methylpyrazole-3-carboxamide
5SK6	;	2.2	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-N-[3-(1,3-benzoxazol-2-yl)phenyl]-2-methylpyrazole-3-carboxamide
5SGD	;	2.54	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-(methoxymethyl)-2-methyl-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3-carboxamide
5SJY	;	2.2	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-bromo-2,5-dimethyl-N-(2-phenylimidazo[1,2-a]pyrimidin-7-yl)pyrazole-3-carboxamide
5SJC	;	2.08	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-chloro-2,5-dimethyl-N-(2-phenylimidazo[1,2-a]pyrimidin-7-yl)pyrazole-3-carboxamide
5SJW	;	1.95	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-chloro-2-(2-methylpropyl)-N-(2-phenyl-1H-benzimidazol-5-yl)pyrazole-3-carboxamide
5SGY	;	2.36	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-chloro-2-(2-methylpropyl)-N-(2-phenylimidazo[1,2-a]pyrimidin-7-yl)pyrazole-3-carboxamide
5SJI	;	1.98	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-chloro-2-methyl-N-(2-phenyl-1H-benzimidazol-5-yl)pyrazole-3-carboxamide
5SK8	;	2.3	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-chloro-N-(2-phenyl-1H-benzimidazol-5-yl)-2-propylpyrazole-3-carboxamide
5SIL	;	2.5	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-chloro-N-[2-(3,5-dimethylphenyl)-1H-benzimidazol-5-yl]-2-methylpyrazole-3-carboxamide
5SK1	;	2.3	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-N,2-dimethyl-3-N-(2-phenylimidazo[1,2-a]pyrimidin-7-yl)pyrazole-3,4-dicarboxamide
5SIS	;	1.85	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-N,2-dimethyl-4-N-[2-(methylamino)ethyl]-3-N-(2-phenylimidazo[1,2-a]pyridin-7-yl)pyrazole-3,4-dicarboxamide
5SDW	;	2.35	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-N,4-N,2-trimethyl-3-N-(2-phenyl-1H-benzimidazol-5-yl)pyrazole-3,4-dicarboxamide
5SJT	;	2.1	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-N,4-N,2-trimethyl-3-N-(2-phenylimidazo[1,2-a]pyridin-7-yl)pyrazole-3,4-dicarboxamide
5SER	;	2.25	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-N-(2-fluoroethyl)-4-N,2-dimethyl-3-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3,4-dicarboxamide
5SI9	;	2.01	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-N-(2-hydroxyethyl)-2-methyl-3-N-(2-phenylimidazo[1,2-a]pyrimidin-7-yl)pyrazole-3,4-dicarboxamide
5SGP	;	1.95	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-N-(2-methoxyethyl)-4-N,2-dimethyl-3-N-(2-phenylimidazo[1,2-a]pyridin-7-yl)pyrazole-3,4-dicarboxamide
5SHO	;	1.9	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-N-cyclopropyl-2-methyl-3-N-(2-phenylimidazo[1,2-a]pyridin-7-yl)pyrazole-3,4-dicarboxamide
5SFR	;	2.04	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-N-ethyl-3-N-[2-[3-(2-fluoroethoxy)phenyl]imidazo[1,2-a]pyrimidin-7-yl]-4-N,2-dimethylpyrazole-3,4-dicarboxamide
5SJJ	;	2.1	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-N-ethyl-5-[3-(trifluoromethyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
5SHQ	;	2.08	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-pyrrolidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine
5SGH	;	1.97	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-[1-methyl-6-[(1-methyl-4-phenylimidazol-2-yl)methoxy]pyrazolo[3,4-d]pyrimidin-4-yl]morpholine
5SH6	;	1.98	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-[2-(1-methylbenzimidazol-2-yl)ethyl]-2,3-dihydro-1,4-benzoxazepin-5-one
5SED	;	2.32	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-[6-chloro-2-[(1-methyl-4-phenylimidazol-2-yl)methoxy]quinazolin-4-yl]morpholine
5SDX	;	2.19	;	Crystal Structure of human phosphodiesterase 10 in complex with 4-[6-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]pyridin-2-yl]morpholine
5SEQ	;	2.18	;	Crystal Structure of human phosphodiesterase 10 in complex with 5,6,8-trimethyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]triazolo[1,5-a]pyrazine
5SEF	;	2.29	;	Crystal Structure of human phosphodiesterase 10 in complex with 5,7,8-trimethyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]triazolo[1,5-c]pyrimidine
5SJK	;	2.24	;	Crystal Structure of human phosphodiesterase 10 in complex with 5,8-dichloro-2,3,4,9-tetrahydropyrido[3,4-b]indol-1-one
5SFY	;	2.08	;	Crystal Structure of human phosphodiesterase 10 in complex with 5,8-dimethyl-2-[(E)-2-[2-methyl-5-(1H-pyrazol-4-yl)-1,2,4-triazol-3-yl]ethenyl]-[1,2,4]triazolo[1,5-a]pyrazine
5SIJ	;	2.55	;	Crystal Structure of human phosphodiesterase 10 in complex with 5,8-dimethyl-2-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]-[1,2,4]triazolo[1,5-a]pyrazine
5SFT	;	2.32	;	Crystal Structure of human phosphodiesterase 10 in complex with 5,8-dimethyl-2-[2-(1-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]triazolo[1,5-a]pyrazine
5SFD	;	2.05	;	Crystal Structure of human phosphodiesterase 10 in complex with 5,8-dimethyl-2-[2-(2-methyl-5-piperidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]triazolo[1,5-a]pyrazine
5SG6	;	1.96	;	Crystal Structure of human phosphodiesterase 10 in complex with 5,8-dimethyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]triazolo[1,5-a]pyrazine
5SFI	;	2.01	;	Crystal Structure of human phosphodiesterase 10 in complex with 5,8-dimethyl-2-[2-[2-methyl-5-(2-methylpyrrolidin-1-yl)-1,2,4-triazol-3-yl]ethyl]-[1,2,4]triazolo[1,5-a]pyrazine
5SGX	;	1.93	;	Crystal Structure of human phosphodiesterase 10 in complex with 5,8-dimethyl-2-[2-[2-methyl-5-[(2R)-2-(trifluoromethyl)pyrrolidin-1-yl]-1,2,4-triazol-3-yl]ethyl]-[1,2,4]triazolo[1,5-c]pyrimidine
5SFS	;	2.24	;	Crystal Structure of human phosphodiesterase 10 in complex with 5,8-dimethyl-2-[2-[2-methyl-5-[(3S)-3-methylpyrrolidin-1-yl]-1,2,4-triazol-3-yl]ethyl]-[1,2,4]triazolo[1,5-a]pyrazine
5SGB	;	2.39	;	Crystal Structure of human phosphodiesterase 10 in complex with 5-(4-chloronaphthalen-1-yl)oxythiadiazole
5SIK	;	2.1	;	Crystal Structure of human phosphodiesterase 10 in complex with 5-(cyclopentylmethoxy)pyrimidin-2-amine
5SG8	;	2.16	;	Crystal Structure of human phosphodiesterase 10 in complex with 5-butoxy-4-ethoxypyrimidin-2-amine
5SID	;	1.98	;	Crystal Structure of human phosphodiesterase 10 in complex with 5-chloro-2-[2-(6,8-dichloro-5-methyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)ethyl]-1,3-benzothiazole
5SIE	;	2.12	;	Crystal Structure of human phosphodiesterase 10 in complex with 5-chloro-8-hydroxy-2-methyl-1,4-dihydropyrrolo[3,4-b]indol-3-one
5SE4	;	2.5	;	Crystal Structure of human phosphodiesterase 10 in complex with 5-cyclopropyl-7-methyl-2-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]-[1,2,4]triazolo[1,5-a]pyrimidine
5SFW	;	2.15	;	Crystal Structure of human phosphodiesterase 10 in complex with 5-ethyl-8-methyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]triazolo[1,5-c]pyrimidine
5SH1	;	2.2	;	Crystal Structure of human phosphodiesterase 10 in complex with 5-methyl-2-phenyl-4-(2-quinolin-8-yloxyethyl)-1,3-oxazole
5SDU	;	2.15	;	Crystal Structure of human phosphodiesterase 10 in complex with 5-methyl-4-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]-2-phenyl-1,3-oxazole
5SIX	;	2.29	;	Crystal Structure of human phosphodiesterase 10 in complex with 5-[(3R)-3-fluoropyrrolidin-1-yl]-2-(3-methylquinoxalin-2-yl)-N-(oxan-4-yl)pyrazolo[1,5-a]pyrimidin-7-amine
5SIY	;	2.03	;	Crystal Structure of human phosphodiesterase 10 in complex with 5-[(3R)-3-fluoropyrrolidin-1-yl]-N-methyl-2-(3-methylquinoxalin-2-yl)-N-(oxan-4-yl)pyrazolo[1,5-a]pyrimidin-7-amine
5SJV	;	1.94	;	Crystal Structure of human phosphodiesterase 10 in complex with 5-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]quinoxaline
5SF6	;	2.03	;	Crystal Structure of human phosphodiesterase 10 in complex with 6,7-dimethyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-N-propan-2-ylimidazo[2,1-f][1,2,4]triazin-4-amine
5SJN	;	2.05	;	Crystal Structure of human phosphodiesterase 10 in complex with 6,8-dichloro-2-[2-(6,7-dimethyl-1H-benzimidazol-2-yl)ethyl]-5-methyl-[1,2,4]triazolo[1,5-a]pyridine
5SGI	;	1.97	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-(3-methylphenoxy)-2-(4-pyridin-2-ylpiperazin-1-yl)-9H-purine
5SIH	;	1.9	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-(3-methylphenyl)sulfanyl-2-(4-pyridin-2-ylpiperazin-1-yl)-9H-purine
5SHL	;	2.35	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-chloro-2,3-dimethyl-8-pyrrolidin-1-ylimidazo[1,2-b]pyridazine
5SJQ	;	2.12	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-chloro-2,3-dimethylquinoxaline
5SEI	;	2.37	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-chloro-2-[(E)-2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethenyl]-[1,2,4]triazolo[1,5-a]pyridine
5SEJ	;	2.44	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-chloro-2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]triazolo[1,5-a]pyridine
5SKM	;	1.91	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-chloro-N,N-dimethyl-2-[2-(1-pyridin-2-ylpyrrolidin-3-yl)ethyl]quinazolin-4-amine
5SJ5	;	2.49	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-chloroquinoxalin-2-amine
5SFK	;	2.33	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-3-(pyrimidin-5-ylamino)-N-[1-(2,2,2-trifluoroethyl)pyrazol-3-yl]pyridine-2-carboxamide
5SFU	;	2.4	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-3-(pyrimidin-5-ylamino)-N-[4-(pyrrolidine-1-carbonyl)pyridin-3-yl]pyridine-2-carboxamide
5SGQ	;	2.04	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-3-(pyrimidin-5-ylamino)pyrazine-2-carboxylic acid
5SIZ	;	2.1	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-3-methoxy-N-[2-(3-pyridin-3-yl-1H-1,2,4-triazol-5-yl)ethyl]pyrazine-2-carboxamide
5SFA	;	2.32	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-3-[(1-methyl-4-phenylimidazol-2-yl)methoxy]-N-(oxolan-3-yl)pyrazine-2-carboxamide
5SI2	;	2.4	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-(1-pyridin-2-ylpyrrolidin-3-yl)-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SET	;	2.4	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-(2-methyl-5-pyridin-2-ylpyrazol-3-yl)-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SEA	;	2.0	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-(2-phenylpyrazol-3-yl)-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SEE	;	2.35	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-(2-pyridin-2-ylpyrazol-3-yl)-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SF2	;	2.02	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-(3-oxo-1,2-dihydroisoindol-5-yl)-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SEW	;	2.3	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-[1-(2-methoxyethyl)-5-(methylcarbamoyl)pyrazol-4-yl]-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SE5	;	2.08	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-[1-methyl-5-(methylcarbamoyl)pyrazol-4-yl]-3-(pyrimidin-5-ylamino)pyrazine-2-carboxamide
5SE0	;	2.01	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-[2-(2-hydroxyethyl)-5-pyridin-2-ylpyrazol-3-yl]-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SF4	;	2.25	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-[2-[2-(dimethylamino)ethyl]-5-pyridin-2-ylpyrazol-3-yl]-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SKJ	;	2.74	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-[2-[2-(methylamino)-2-oxoethyl]phenyl]-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SE1	;	2.3	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-[3-(dimethylcarbamoyl)-1-methylpyrazol-4-yl]-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SKV	;	2.6	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-[3-[(2-hydroxy-2-methylpropyl)carbamoyl]-1-methylpyrazol-4-yl]-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SDZ	;	2.35	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-[3-[2,3-dihydroxypropyl(methyl)carbamoyl]-1-methylpyrazol-4-yl]-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SJS	;	2.7	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-[4-(dimethylcarbamoyl)pyridin-3-yl]-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SHD	;	2.6	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-[4-(methylcarbamoyl)pyridin-3-yl]-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SJU	;	1.97	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-[4-(piperidin-1-ylmethyl)-1,3-thiazol-2-yl]-3-(pyrimidin-5-ylamino)pyrazine-2-carboxamide
5SJL	;	2.64	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-[4-[(2-hydroxy-2-methylpropyl)carbamoyl]pyridin-3-yl]-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SDY	;	2.2	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-[5-(dimethylcarbamoyl)-1-(2-methoxyethyl)pyrazol-4-yl]-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SFL	;	2.13	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-[5-[(2-hydroxy-2-methylpropyl)carbamoyl]-1-methylpyrazol-4-yl]-3-(pyrimidin-5-ylamino)pyrazine-2-carboxamide
5SK4	;	2.0	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-methyl-3-(2-phenylpyrazol-3-yl)-1-[3-(trifluoromethoxy)phenyl]pyridazin-4-one
5SKC	;	2.6	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-methyl-N-(1-propan-2-ylpyrazol-3-yl)-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SIT	;	1.99	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-methyl-N-(4-methylphenyl)pyrimidin-4-amine
5SH8	;	2.0	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-methyl-N-(5-methyl-2-phenylpyrazol-3-yl)-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SGJ	;	2.66	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-[(3,6-dimethylpyridine-2-carbonyl)amino]-N-methyl-2-phenyl-3H-benzimidazole-5-carboxamide
5SEG	;	2.29	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-[(5-bromo-1-methyl-2-oxopyridine-3-carbonyl)amino]-N-(oxetan-3-yl)-2-phenyl-3H-benzimidazole-5-carboxamide
5SH7	;	2.66	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-[(5-cyclopropyl-2-oxo-1H-pyridine-3-carbonyl)amino]-N-(oxetan-3-yl)-2-phenyl-3H-benzimidazole-5-carboxamide
5SH4	;	2.22	;	Crystal Structure of human phosphodiesterase 10 in complex with 6-[(5-methoxy-3,4,6-trimethylpyridin-2-yl)methylsulfanyl]-5H-[1,3]dioxolo[4,5-f]benzimidazole
5SGE	;	2.2	;	Crystal Structure of human phosphodiesterase 10 in complex with 6H-imidazo[1,2-c]quinazolin-5-one
5SKT	;	2.02	;	Crystal Structure of human phosphodiesterase 10 in complex with 7-(cyclopropylmethoxy)-2-methyl-4-pyrrolidin-1-ylquinazoline:hydrochloride
5SK7	;	2.29	;	Crystal Structure of human phosphodiesterase 10 in complex with 7-bromo-N,N-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-2-amine
5SI0	;	2.27	;	Crystal Structure of human phosphodiesterase 10 in complex with 7-methyl-2,5-bis[2-(1-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]triazolo[1,5-c]pyrimidine
5SJ1	;	2.16	;	Crystal Structure of human phosphodiesterase 10 in complex with 7-[(3,5-dimethyl-4-propan-2-yloxypyridin-2-yl)methylsulfinyl]-6H-imidazo[4,5-g][1,3]benzothiazole
5SKA	;	2.21	;	Crystal Structure of human phosphodiesterase 10 in complex with 7-[(4-ethoxy-5-methylpyridin-2-yl)methylsulfanyl]-6H-imidazo[4,5-g][1,3]benzothiazole
5SHH	;	2.15	;	Crystal Structure of human phosphodiesterase 10 in complex with 7-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfanyl]-6H-imidazo[4,5-g][1,3]benzothiazole
5SJ7	;	2.14	;	Crystal Structure of human phosphodiesterase 10 in complex with 7-[(5-methyl-4-propan-2-yloxypyridin-2-yl)methylsulfanyl]-6H-imidazo[4,5-g][1,3]benzothiazole
5SHT	;	2.27	;	Crystal Structure of human phosphodiesterase 10 in complex with 8-chloro-5,7-dimethyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]triazolo[1,5-c]pyrimidine
5SKB	;	2.35	;	Crystal Structure of human phosphodiesterase 10 in complex with 9-methoxy-3,5-dihydropyrimido[5,4-b]indol-4-one
5SGF	;	2.3	;	Crystal Structure of human phosphodiesterase 10 in complex with ethyl 1-methyl-5-(propylcarbamoyl)pyrazole-4-carboxylate
5SKS	;	2.31	;	Crystal Structure of human phosphodiesterase 10 in complex with ethyl 1-[3-[3-(4-ethoxycarbonyl-5-methyl-imidazol-1-yl)phenoxy]phenyl]-5-methyl-imidazole-4-carboxylate
5SJP	;	2.25	;	Crystal Structure of human phosphodiesterase 10 in complex with ethyl N-[[4-[[4-(azetidine-1-carbonyl)-2-methylpyrazole-3-carbonyl]amino]-6-methylpyridin-2-yl]carbamothioyl]carbamate
5SFB	;	1.98	;	Crystal Structure of human phosphodiesterase 10 in complex with N,2,3-trimethyl-6-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]imidazo[1,2-b]pyridazine-8-carboxamide
5SH0	;	2.29	;	Crystal Structure of human phosphodiesterase 10 in complex with N-(1,3-dimethyl-2-oxobenzimidazol-5-yl)-2-[methylsulfonyl(naphthalen-1-yl)amino]acetamide
5SI5	;	2.27	;	Crystal Structure of human phosphodiesterase 10 in complex with N-(12-methoxy-5-methyl-3-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(13),3,5,7,9,11-hexaen-7-yl)methanesulfonamide
5SFX	;	2.04	;	Crystal Structure of human phosphodiesterase 10 in complex with N-(2-acetamido-1,3-benzothiazol-5-yl)-4-(azetidine-1-carbonyl)-2-methylpyrazole-3-carboxamide
5SFP	;	2.0	;	Crystal Structure of human phosphodiesterase 10 in complex with N-(2-chloropyridin-4-yl)-2-phenylpyrazolo[1,5-a]pyridine-6-carboxamide
5SJA	;	2.13	;	Crystal Structure of human phosphodiesterase 10 in complex with N-(2-tert-butyl-5-methylpyrazol-3-yl)-1-phenyl-3-(pyridin-2-yloxymethyl)thieno[2,3-c]pyrazole-5-carboxamide
5SKO	;	2.1	;	Crystal Structure of human phosphodiesterase 10 in complex with N-(3-imidazo[1,2-a]pyridin-2-ylphenyl)-1-methyl-3-(pyrimidin-5-ylamino)pyrazole-4-carboxamide
5SIN	;	2.4	;	Crystal Structure of human phosphodiesterase 10 in complex with N-(3-methyl-1-pyridin-2-ylthieno[2,3-c]pyrazol-5-yl)benzamide
5SI8	;	2.1	;	Crystal Structure of human phosphodiesterase 10 in complex with N-(6-cyano-2-phenylimidazo[1,2-a]pyridin-7-yl)-1-methyl-4-(morpholine-4-carbonyl)pyrazole-3-carboxamide
5SKL	;	2.2	;	Crystal Structure of human phosphodiesterase 10 in complex with N-(6-cyano-2-phenylimidazo[1,2-a]pyridin-7-yl)-2-methyl-4-(morpholine-4-carbonyl)pyrazole-3-carboxamide
5SHK	;	2.0	;	Crystal Structure of human phosphodiesterase 10 in complex with N-(6-methylpyridin-2-yl)-5-pyridin-3-yl-1,7-naphthyridin-8-amine
5SIV	;	2.2	;	Crystal Structure of human phosphodiesterase 10 in complex with N-(thiophen-2-ylmethyl)quinoxaline-6-carboxamide
5SJ0	;	2.35	;	Crystal Structure of human phosphodiesterase 10 in complex with N-cyclohexyl-N-methyl-9H-purin-6-amine
5SFH	;	2.29	;	Crystal Structure of human phosphodiesterase 10 in complex with N-cyclopropyl-5-[2-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)ethyl]-N,1-dimethyl-1,2,4-triazol-3-amine
5SKQ	;	2.0	;	Crystal Structure of human phosphodiesterase 10 in complex with N-ethyl-6-(4-fluorophenyl)sulfanyl-N-methyl-9H-purin-2-amine
5SEX	;	1.99	;	Crystal Structure of human phosphodiesterase 10 in complex with N-methyl-6-[(6-methylpyridine-2-carbonyl)amino]-2-phenyl-3H-benzimidazole-5-carboxamide
5SK0	;	2.02	;	Crystal Structure of human phosphodiesterase 10 in complex with N-[(3R)-1-(5-chloropyridin-2-yl)pyrrolidin-3-yl]-1-methyl-4-pyridin-4-ylpyrazole-3-carboxamide
5SFG	;	2.31	;	Crystal Structure of human phosphodiesterase 10 in complex with N-[(3R)-1-(5-chloropyridin-2-yl)pyrrolidin-3-yl]-6-cyclopropyl-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SHM	;	2.26	;	Crystal Structure of human phosphodiesterase 10 in complex with N-[(3R)-1-(5-chloropyridin-2-yl)pyrrolidin-3-yl]-6-cyclopropyl-3-methoxypyrazine-2-carboxamide
5SKI	;	2.16	;	Crystal Structure of human phosphodiesterase 10 in complex with N-[(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)methyl]-2-methyl-5-phenyl-1,2,4-triazol-3-amine
5SHR	;	1.98	;	Crystal Structure of human phosphodiesterase 10 in complex with N-[(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)methyl]-N,2-dimethyl-5-phenyl-1,2,4-triazol-3-amine
5SG3	;	1.98	;	Crystal Structure of human phosphodiesterase 10 in complex with N-[(E)-(4-bromo-3,5-dimethoxyphenyl)methylideneamino]-2-ethoxy-2-(4-morpholin-4-ylphenyl)acetamide
5SGL	;	2.28	;	Crystal Structure of human phosphodiesterase 10 in complex with N-[(E)-(4-bromo-3,5-dimethoxyphenyl)methylideneamino]-2-ethoxy-2-(4-pyrazol-1-ylphenyl)acetamide
5SKK	;	2.15	;	Crystal Structure of human phosphodiesterase 10 in complex with N-[1-methyl-5-(methylcarbamoyl)pyrazol-4-yl]-6-[(3S)-oxolan-3-yl]-3-(pyrimidin-5-ylamino)pyrazine-2-carboxamide
5SJ9	;	2.39	;	Crystal Structure of human phosphodiesterase 10 in complex with N-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]-3-propan-2-yl-[1,2,4]triazolo[4,3-a]pyridine-8-carboxamide
5SKN	;	1.9	;	Crystal Structure of human phosphodiesterase 10 in complex with N-[3-[3-[2-(2-fluorophenyl)pyrazol-3-yl]-4-oxopyridazin-1-yl]phenyl]acetamide
5SGO	;	2.3	;	Crystal Structure of human phosphodiesterase 10 in complex with N-[3-[3-[5-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxypropoxy]phenyl]acetamide
5SJ3	;	2.1	;	Crystal Structure of human phosphodiesterase 10 in complex with [1-(4-chlorophenyl)-3-methylthieno[2,3-c]pyrazol-5-yl]-piperidin-1-ylmethanone
5SK3	;	2.32	;	Crystal Structure of human phosphodiesterase 10 in complex with [2-cyclopropyl-6-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]imidazo[1,2-b]pyridazin-3-yl]methanol
5SEY	;	2.29	;	Crystal Structure of human phosphodiesterase 10 in complex with [2-cyclopropyl-6-[2-(1-methyl-4-phenylimidazol-2-yl)ethynyl]imidazo[1,2-b]pyridazin-3-yl]methanol
5SFF	;	2.16	;	Crystal Structure of human phosphodiesterase 10 in complex with [2-methyl-6-[2-(1-methyl-4-phenylimidazol-2-yl)ethynyl]imidazo[1,2-b]pyridazin-3-yl]methanol
5SKP	;	2.0	;	Crystal Structure of human phosphodiesterase 10 in complex with [4-(2-methoxyphenyl)piperazin-1-yl]-(3-methyl-1-phenylthieno[2,3-c]pyrazol-5-yl)methanone
5SHY	;	2.3	;	Crystal Structure of human phosphodiesterase 10 in complex with [8-[(2-methyl-1,3-thiazol-4-yl)amino]-5-pyridin-3-yl-1,7-naphthyridin-2-yl]methanol
4ZKF	;	1.82	;	Crystal structure of human phosphodiesterase 12
5TZW	;	1.59	;	CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3,4-difluorophenyl)carbonyl]-3,3-difluoro-5-{5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}piperidine
5TZZ	;	1.6	;	CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3-bromo-4-fluorophenyl)carbonyl]-3,3-difluoro-5-{5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}piperidine
5TZX	;	1.9	;	CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3-chloro-4-fluorophenyl)carbonyl]-3,3-difluoro-5-{5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}piperidine
5U00	;	1.41	;	CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 3,3-difluoro-1-[(4-fluoro-3-iodophenyl)carbonyl]-5-{5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}piperidine
5TZH	;	1.6	;	CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 3,3-difluoro-1-[(4-fluorophenyl)carbonyl]-5-{5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}piperidine
5XKM	;	2.16	;	Crystal structure of human phosphodiesterase 2A in complex with 6-methyl-N-(1-(4-(trifluoromethoxy)phenyl)propyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
5TZ3	;	1.72	;	CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX with [1,2,4]triazolo[1,5-a]pyrimidin-7-yl}-N-(naphthalene-2-yl)piperidine-3-carboxamide
6C7F	;	1.82	;	Crystal structure of human phosphodiesterase 2A with 1-(2-chloro-5-isobutoxy-phenyl)-N,4-dimethyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide
6C7I	;	1.713	;	Crystal structure of human phosphodiesterase 2A with 1-(2-chloro-5-methoxy-phenyl)-N-isobutyl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide
6C7E	;	1.43	;	Crystal structure of human phosphodiesterase 2A with 1-(2-chlorophenyl)-N,4-dimethyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide
6C7J	;	1.85	;	Crystal structure of human phosphodiesterase 2A with 1-(5-tert-butoxy-2-chloro-phenyl)-N-isobutyl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide
5TZA	;	1.7	;	CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A WITH 3-{5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl-1-[(naphthalene-2-yl)carbonyl]piperidine
6C7G	;	1.68	;	Crystal structure of human phosphodiesterase 2A with N-(1-adamantyl)-1-(2-chloro-5-isobutoxy-phenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide
6C7D	;	1.79	;	Crystal structure of human phosphodiesterase 2A with N-(1-adamantyl)-1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide
4KP6	;	1.5	;	Crystal structure of human phosphodiesterase 4B (PDE4B) in complex with a [1,3,5]triazine derivative
5LAQ	;	2.4	;	Crystal structure of human phosphodiesterase 4B catalytic domain with inhibitor NPD-001
3G45	;	2.63	;	Crystal structure of human phosphodiesterase 4b with regulatory domain and d155988
3IAK	;	2.8	;	Crystal structure of human phosphodiesterase 4d (PDE4d) with papaverine.
5TKB	;	2.16	;	CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH A TETRAFLUORANLINE COMPOUND
3IAD	;	2.65	;	Crystal structure of human phosphodiesterase 4D with bound allosteric modulator
3G4I	;	1.9	;	Crystal structure of human phosphodiesterase 4d with d155871
3G58	;	2.05	;	Crystal structure of human phosphodiesterase 4d with d155988/pmnpq
3G4G	;	2.3	;	Crystal structure of human phosphodiesterase 4d with regulatory domain and d155871
3G4L	;	2.5	;	Crystal structure of human phosphodiesterase 4d with roflumilast
3G4K	;	1.95	;	Crystal structure of human phosphodiesterase 4d with rolipram
5LBO	;	2.25	;	Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-001
6FW3	;	1.78	;	Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-007
6FTW	;	2.16	;	Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-048
6RCW	;	2.08	;	Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-053
6FEB	;	1.93	;	Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-1086
6HWO	;	1.99	;	Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-1335
7ABJ	;	2.11	;	Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-1361
6FET	;	1.88	;	Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-1439
6FDI	;	1.9	;	Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-226
6FTA	;	2.34	;	Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-3098
6FE7	;	2.0	;	Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-356
6IBF	;	2.31	;	Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-417
6FT0	;	2.1	;	Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-425
7AAG	;	1.79	;	Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-617
7A9V	;	2.17	;	Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-635
6IAG	;	2.0	;	Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-637
7A8Q	;	2.24	;	Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-654
7AB9	;	2.19	;	Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-656
7ABD	;	2.41	;	Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-768
7ABE	;	1.83	;	Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-769
1UDT	;	2.3	;	Crystal structure of Human Phosphodiesterase 5 complexed with Sildenafil(Viagra)
1UDU	;	2.83	;	Crystal structure of Human Phosphodiesterase 5 complexed with tadalafil(Cialis)
1UHO	;	2.5	;	Crystal structure of Human Phosphodiesterase 5 complexed with Vardenafil(Levitra)
4XYK	;	3.4	;	Crystal structure of human phosphofructokinase-1 in complex with ADP, Northeast Structural Genomics Consortium Target HR9275
4XYJ	;	3.1	;	Crystal structure of human phosphofructokinase-1 in complex with ATP and Mg, Northeast Structural Genomics Consortium Target HR9275
6XUH	;	2.38	;	Crystal structure of human phosphoglucose isomerase in complex with inhibitor
6XUI	;	1.95	;	Crystal structure of human phosphoglucose isomerase in complex with inhibitor
1IAT	;	1.62	;	CRYSTAL STRUCTURE OF HUMAN PHOSPHOGLUCOSE ISOMERASE/NEUROLEUKIN/AUTOCRINE MOTILITY FACTOR/MATURATION FACTOR
3C39	;	1.85	;	Crystal Structure of human phosphoglycerate kinase bound to 3-phosphoglycerate
3C3A	;	2.3	;	Crystal Structure of human phosphoglycerate kinase bound to 3-phosphoglycerate and L-ADP
3C3C	;	2.4	;	Crystal Structure of human phosphoglycerate kinase bound to 3-phosphoglycerate and L-CDP
2ZGV	;	2.0	;	Crystal Structure of human phosphoglycerate kinase bound to D-ADP
3C3B	;	1.8	;	Crystal Structure of human phosphoglycerate kinase bound to D-CDP
3O0T	;	1.9	;	Crystal structure of human phosphoglycerate mutase family member 5 (PGAM5) in complex with phosphate
5MUF	;	3.1	;	Crystal structure of human phosphoglycerate mutase family member 5 (PGAM5) in its enzymatically active dodecameric form induced by the presence of the N-terminal WDPNWD motif
2HW4	;	1.9	;	Crystal structure of human phosphohistidine phosphatase
2NMM	;	2.7	;	Crystal structure of human phosphohistidine phosphatase. Northeast Structural Genomics Consortium target HR1409
2PE2	;	2.13	;	CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 3-{5-[2-Oxo-5-ureido-1,2-dihydro-indol-(3Z)-ylidenemethyl]-1H-pyrrol-3-yl}-N-(2-piperidin-1-yl-ethyl)-benzamide COMPLEX
2PE0	;	2.35	;	CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 5-Hydroxy-3-[1-(1H-pyrrol-2-yl)-eth-(Z)-ylidene]-1,3-dihydro-indol-2-one COMPLEX
2PE1	;	2.14	;	CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) {2-Oxo-3-[1-(1H-pyrrol-2-yl)-eth-(Z)-ylidene]-2,3-dihydro-1H-indol-5-yl}-urea {BX-517} COMPLEX
2X4D	;	1.92	;	Crystal structure of human phospholysine phosphohistidine inorganic pyrophosphate phosphatase LHPP
1QZU	;	2.91	;	crystal structure of human phosphopantothenoylcysteine decarboxylase
2H06	;	2.2	;	Crystal structure of human phosphoribosyl pyrophosphate synthetase 1
3EFH	;	2.6	;	Crystal structure of human phosphoribosyl pyrophosphate synthetase 1
2HCR	;	2.2	;	crystal structure of human phosphoribosyl pyrophosphate synthetase 1 in complex with AMP(ATP), cadmium and sulfate ion
2H07	;	2.2	;	crystal structure of human phosphoribosyl pyrophosphate synthetase 1 mutant S132A
2H08	;	2.5	;	crystal structure of human phosphoribosyl pyrophosphate synthetase 1 mutant Y146M
2C4K	;	2.65	;	Crystal structure of human phosphoribosylpyrophosphate synthetase- associated protein 39 (PAP39)
4YZ9	;	2.463	;	Crystal Structure of human phosphorylated IRE1alpha in complex with a type III kinase inhibitor (GSK2850163A)
4YZD	;	3.102	;	Crystal Structure of human phosphorylated IRE1alpha in complex with ADP-Mg
7JFL	;	1.68	;	Crystal structure of human phosphorylated IRF-3 bound to CBP
1NNL	;	1.53	;	Crystal structure of Human Phosphoserine Phosphatase
2OPW	;	1.9	;	Crystal structure of human phytanoyl-CoA dioxygenase PHYHD1 (apo)
3OBZ	;	2.15	;	Crystal structure of human phytanoyl-COA dioxygenase phyhd1 2-oxoglutarate and iron complex
4WWN	;	2.7	;	Crystal structure of human PI3K-gamma in complex with (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine AMG319 inhibitor
4DK5	;	2.95	;	Crystal structure of human PI3K-gamma in complex with a pyridyl-triazine inhibitor
4F1S	;	3.0	;	Crystal structure of human PI3K-gamma in complex with a pyridyl-triazine-sulfonamide inhibitor
4FLH	;	2.6	;	Crystal structure of human PI3K-gamma in complex with AMG511
5EDS	;	2.8	;	Crystal structure of human PI3K-gamma in complex with benzimidazole inhibitor 5
3APF	;	2.82	;	Crystal structure of human PI3K-gamma in complex with CH5039699
3APD	;	2.55	;	Crystal structure of human PI3K-gamma in complex with CH5108134
3APC	;	2.544	;	Crystal structure of human PI3K-gamma in complex with CH5132799
6XRN	;	2.96	;	Crystal structure of human PI3K-gamma in complex with Compound 17
6XRM	;	2.88	;	Crystal structure of human PI3K-gamma in complex with Compound 4
6XRL	;	2.99	;	Crystal structure of human PI3K-gamma in complex with inhibitor IPI-549
4WWO	;	2.3	;	Crystal structure of human PI3K-gamma in complex with phenylquinoline inhibitor N-{(1S)-1-[8-chloro-2-(3-fluorophenyl)quinolin-3-yl]ethyl}-9H-purin-6-amine
4WWP	;	2.4	;	Crystal structure of human PI3K-gamma in complex with pyridinylquinoline inhibitor N-{(1S)-1-[8-chloro-2-(2-methylpyridin-3-yl)quinolin-3-yl]ethyl}-9H-purin-6-amine
5KAE	;	2.65	;	Crystal structure of human PI3K-gamma in complex with quinoline-containing inhibitor 5g
7MLK	;	2.91	;	Crystal structure of human PI3Ka (p110a subunit) with MMV085400 bound to the active site determined at 2.9 angstroms resolution
2A4Z	;	2.9	;	Crystal Structure of human PI3Kgamma complexed with AS604850
2A5U	;	2.7	;	Crystal Structure of human PI3Kgamma complexed with AS605240
6HPU	;	3.96	;	Crystal structure of human Pif1 helicase in complex with ADP-AlF4
6HPH	;	1.13	;	Crystal structure of human Pif1 helicase in complex with AMP-PNP
6HPQ	;	1.43	;	Crystal structure of human Pif1 helicase in complex with AMP-PNP, brominated crystal form.
6HPT	;	1.44	;	Crystal structure of human Pif1 helicase, apoform.
3LS8	;	2.25	;	Crystal structure of human PIK3C3 in complex with 3-[4-(4-Morpholinyl)thieno[3,2-d]pyrimidin-2-yl]-phenol
3F2A	;	1.9	;	Crystal structure of human Pim-1 in complex with DAPPA
5N52	;	2.252	;	Crystal structure of human Pim-1 kinase in complex with a consensus peptide and fragment like molecule (E)-3-(2,3-dimethoxyphenyl)acrylic acid
5NDT	;	1.985	;	Crystal structure of human Pim-1 kinase in complex with a consensus peptide and fragment like molecule (E)-3-(2-(thiophen-2-yl)vinyl)-3,4-dihydroquinoxalin-2(1H)-one
5N4Z	;	2.257	;	Crystal structure of human Pim-1 kinase in complex with a consensus peptide and fragment like molecule (E)-4-(4-hydroxyphenyl)but-3-en-2-one
5N4Y	;	2.56	;	Crystal structure of human Pim-1 kinase in complex with a consensus peptide and fragment like molecule 2,5-dihydro-1H-isothiochromeno[3,4-d]pyrazol-3-one
5N50	;	1.92	;	Crystal structure of human Pim-1 kinase in complex with a consensus peptide and fragment like molecule 2-(4-chlorophenyl)sulfanylacetohydrazide
5N4R	;	2.13	;	Crystal structure of human Pim-1 kinase in complex with a consensus peptide and fragment like molecule 2-(azepan-1-yl)-1-(1H-indol-3-yl)propan-1-one
5N51	;	2.118	;	Crystal structure of human Pim-1 kinase in complex with a consensus peptide and fragment like molecule 3,4-Dibromothiophene-2-carboxylic acid
5N4N	;	2.09	;	Crystal structure of human Pim-1 kinase in complex with a consensus peptide and fragment like molecule 3,4-dimethyl-5-(1H-1,2,4-triazol-3-yl)thiophene-2-carbonitrile
5N5M	;	2.21	;	Crystal structure of human Pim-1 kinase in complex with a consensuspeptide and (R)-3-(2-((isoquinolin-5-ylmethyl)(methyl)carbamoyl)phenyl)pyrrolidin-1-ium
5N4O	;	2.22	;	Crystal structure of human Pim-1 kinase in complex with a consensuspeptide and fragment like molekule (E)-3-(p-tolyl)acrylic acid
5N4V	;	1.85	;	Crystal structure of human Pim-1 kinase in complex with a consensuspeptide and fragment like molekule 2-cyclopropyl-4,5-dimethylthieno[5,4-d]pyrimidine-6-carboxylic acid
5N4X	;	2.2	;	Crystal structure of human Pim-1 kinase in complex with a consensuspeptide and fragment like molekule 4,5-dibromothiophene-2-carbohydrazide
5N4U	;	2.202	;	Crystal structure of human Pim-1 kinase in complex with a consensuspeptide and fragment like molekule 5-(2-amino-1,3-thiazol-4-yl)-1,3-dihydrobenzimidazol-2-one
5MZL	;	1.955	;	Crystal structure of human Pim-1 kinase in complex with a consensuspeptide and fragment like molekule N-quinolin-5-ylpyridine-3-carboxamide
5N5L	;	1.97	;	Crystal structure of human Pim-1 kinase in complex with a consensuspeptide and [2-oxo-2-(1H-pyrrol-2-yl)ethyl] 5-bromo-1H-indole-3-carboxylate
5EOL	;	2.2	;	Crystal structure of human Pim-1 kinase in complex with a macrocyclic quinoxaline-pyrrolodihydropiperidinone inhibitor
6MT0	;	2.2	;	Crystal structure of human Pim-1 kinase in complex with a quinazolinone-pyrrolodihydropyrrolone inhibitor
5IPJ	;	2.1	;	Crystal structure of human Pim-1 kinase in complex with a quinazolinone-pyrrolopyrrolone inhibitor.
4WT6	;	2.3	;	Crystal structure of human Pim-1 kinase in complex with a thiadiazolamine-indole inhibitor.
4WSY	;	2.3	;	Crystal structure of human Pim-1 kinase in complex with a thiazolamine-indazole inhibitor.
4TY1	;	2.7	;	Crystal structure of human Pim-1 kinase in complex with an aminooxadiazole-indole inhibitor.
4WRS	;	2.2	;	Crystal structure of human Pim-1 kinase in complex with an azaspiro pyrazinyl-indazole inhibitor.
5KZI	;	2.1	;	Crystal structure of human Pim-1 kinase in complex with an imidazopyridazine inhibitor.
2OBJ	;	2.5	;	Crystal structure of human PIM-1 Kinase in complex with inhibitor
2OI4	;	2.2	;	Crystal structure of human PIM1 in complex with fluorinated ruthenium pyridocarbazole
2C3I	;	1.9	;	CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH IMIDAZOPYRIDAZIN I
3DCV	;	2.7	;	Crystal structure of human Pim1 kinase complexed with 4-(4-hydroxy-3-methyl-phenyl)-6-phenylpyrimidin-2(1H)-one
7EKV	;	1.95	;	Crystal Structure of human Pin1 complexed with a covalent inhibitor
7F0M	;	1.9	;	Crystal Structure of human Pin1 complexed with a potent covalent inhibitor
7EFX	;	2.41	;	Crystal Structure of human PIN1 complexed with covalent inhibitor
5JCT	;	1.73	;	Crystal Structure of Human Pirin in complex with a Chemical Probe pyrrolidine 24
6H1I	;	1.69	;	Crystal structure of human Pirin in complex with bisamide compound 2
6H1H	;	1.54	;	Crystal structure of human Pirin in complex with compound 7 (PLX4720)
3ACL	;	2.35	;	Crystal Structure of Human Pirin in complex with Triphenyl Compound
1J1L	;	2.1	;	Crystal structure of human Pirin: a Bcl-3 and Nuclear factor I interacting protein and a cupin superfamily member
3N94	;	1.8	;	Crystal structure of human pituitary adenylate cyclase 1 Receptor-short N-terminal extracellular domain
6V74	;	2.32	;	Crystal Structure of Human PKM2 in Complex with L-asparagine
6V75	;	2.85	;	Crystal Structure of Human PKM2 in Complex with L-aspartate
6NU1	;	2.25	;	Crystal Structure of Human PKM2 in Complex with L-cysteine
6V76	;	2.75	;	Crystal Structure of Human PKM2 in Complex with L-valine
3KEU	;	2.1	;	Crystal Structure of Human PL Kinase with bound PLP and ATP
4EOH	;	2.1	;	Crystal Structure of Human PL Kinase with bound Theophylline
3S7S	;	3.21	;	Crystal structure of human placental aromatase complexed with breast cancer drug exemestane
3EQM	;	2.9	;	Crystal structure of human placental aromatase cytochrome P450 in complex with androstenedione
1U8F	;	1.75	;	Crystal Structure Of Human Placental Glyceraldehyde-3-Phosphate Dehydrogenase At 1.75 Resolution
1Z7C	;	2.0	;	Crystal Structure of Human Placental Lactogen
3D59	;	1.5	;	Crystal structure of human plasma platelet activating factor acetylhydrolase
3F9C	;	2.3	;	Crystal structure of human plasma platelet activating factor acetylhydrolase covalently inhibited by diisopropylfluorophosphate
3D5E	;	2.1	;	Crystal structure of human plasma platelet activating factor acetylhydrolase covalently inhibited by paraoxon
3F96	;	2.1	;	Crystal structure of human plasma platelet activating factor acetylhydrolase covalently inhibited by sarin
3F97	;	1.7	;	Crystal structure of human plasma platelet activating factor acetylhydrolase covalently inhibited by soman
3F98	;	1.7	;	Crystal structure of human plasma platelet activating factor acetylhydrolase covalently inhibited by tabun
1DDJ	;	2.0	;	CRYSTAL STRUCTURE OF HUMAN PLASMINOGEN CATALYTIC DOMAIN
2GI7	;	2.4	;	Crystal structure of human platelet Glycoprotein VI (GPVI)
7NMU	;	2.5	;	Crystal structure of human platelet glycoprotein VI in complex with an inhibitory nanobody.
7TFF	;	3.6	;	Crystal structure of human platelet phosphofructokinase-1 mutant- D564N
7MT1	;	1.3	;	Crystal structure of Human Platelet-activating factor acetylhydrolase IB subunit beta (PAFAH1B1)
1PDG	;	3.0	;	CRYSTAL STRUCTURE OF HUMAN PLATELET-DERIVED GROWTH FACTOR BB
8V08	;	3.0	;	Crystal structure of human PLD4 co-crystallized with 5'Pi-ssDNA
8B3K	;	2.685	;	Crystal structure of human Plexin-B1 (20-535) in the unbound state
6GY2	;	3.11	;	Crystal structure of human Plk1-PBD in complex with WSSSLATPPTLSSpTVLI phosphopeptide from BRCA2
4N7V	;	2.758	;	Crystal structure of human Plk4 cryptic polo box (CPB) in complex with a Cep152 N-terminal fragment
4N7Z	;	2.85	;	Crystal structure of human Plk4 cryptic polo box (CPB) in complex with a Cep192 N-terminal fragment
4YYP	;	2.6	;	Crystal structure of human PLK4-PB3 in complex with STIL-CC
5A3T	;	1.9	;	Crystal structure of human PLU-1 (JARID1B) in complex with KDM5-C49 (2-(((2-((2-(dimethylamino)ethyl)(ethyl)amino)-2-oxoethyl)amino)methyl) isonicotinic acid).
5A3N	;	2.0	;	Crystal structure of human PLU-1 (JARID1B) in complex with KDOAM25a
5A3W	;	2.0	;	Crystal structure of human PLU-1 (JARID1B) in complex with Pyridine-2, 6-dicarboxylic Acid (PDCA)
1HNN	;	2.4	;	CRYSTAL STRUCTURE OF HUMAN PNMT COMPLEXED WITH SK&F 29661 AND ADOHCY(SAH)
4DM3	;	2.4001	;	Crystal structure of human PNMT in complex adohcy, resorcinol and imidazole
1M73	;	2.3	;	CRYSTAL STRUCTURE OF HUMAN PNP AT 2.3A RESOLUTION
3D1V	;	2.7	;	Crystal structure of human PNP complexed with 2-mercapto(3H) quinazolinone
1V45	;	2.86	;	Crystal Structure of human PNP complexed with 3-deoxyguanosine
1V41	;	2.85	;	Crystal structure of human PNP complexed with 8-Azaguanine
1PWY	;	2.8	;	CRYSTAL STRUCTURE OF HUMAN PNP COMPLEXED WITH ACYCLOVIR
1V2H	;	2.7	;	Crystal structure of human PNP complexed with guanine
1PF7	;	2.6	;	CRYSTAL STRUCTURE OF HUMAN PNP COMPLEXED WITH IMMUCILLIN H
1YRY	;	2.8	;	Crystal structure of human PNP complexed with MESG
3U1K	;	2.13	;	Crystal structure of human PNPase
4AP5	;	3.003	;	Crystal structure of human POFUT2
4AP6	;	3.401	;	Crystal structure of human POFUT2 E54A mutant in complex with GDP- fucose
4Y97	;	2.51	;	Crystal Structure of human Pol alpha B-subunit in complex with C-terminal domain of catalytic subunit
4LT6	;	2.79	;	Crystal Structure of human poly(A) polymerase gamma
4PY4	;	2.76	;	Crystal structure of human poly(ADP-ribose) polymerase 14, catalytic domain in complex with an inhibitor XL2
3GOY	;	2.8	;	Crystal structure of human poly(adp-ribose) polymerase 14, catalytic fragment in complex with an inhibitor 3-aminobenzamide
3BLJ	;	2.2	;	Crystal structure of human poly(ADP-ribose) polymerase 15, catalytic fragment
3GEY	;	2.2	;	Crystal structure of human poly(ADP-ribose) polymerase 15, catalytic fragment in complex with an inhibitor Pj34
1UK1	;	3.0	;	Crystal structure of human poly(ADP-ribose) polymerase complexed with a potent inhibitor
3L9Q	;	1.698	;	Crystal structure of human polymerase alpha-primase p58 iron-sulfur cluster domain
6W5X	;	2.59	;	Crystal structure of human polymerase eta complexed with N7-benzylguanine and dCTP*
7LCD	;	1.98	;	Crystal structure of human polymerase eta complexed with syn N7-acetophenoneguanine
7L69	;	1.91	;	Crystal structure of human polymerase eta complexed with syn N7-benzylguanine
6WK6	;	2.35	;	Crystal structure of human polymerase eta complexed with Xanthine containing DNA
4O3R	;	1.62	;	Crystal structure of human polymerase eta extending an 8-oxog dna lesion: post insertion of 8-oxog-da pair
4O3S	;	1.717	;	Crystal structure of human polymerase eta extending an 8-oxog dna lesion: post insertion of 8-oxog-dc pair
4RNO	;	2.82	;	Crystal structure of human polymerase eta extending an abasic site-dA pair by inserting dCTP opposite template G
4RNM	;	2.144	;	Crystal structure of human polymerase eta inserting dAMPnPP opposite DNA template containing an abasic site
4O3O	;	1.698	;	Crystal structure of human polymerase eta inserting datp opposite an 8-oxog containing dna template
4O3P	;	1.72	;	Crystal structure of human polymerase eta inserting dctp opposite an 8-oxog containing dna template
4RNN	;	1.808	;	Crystal structure of human polymerase eta inserting dGMPnPP opposite DNA template containing an abasic site
4O3Q	;	1.72	;	Crystal structure of human polymerase eta inserting dgtp opposite an 8-oxog containing dna template
8UJT	;	2.31	;	Crystal structure of human polymerase eta with incoming dAMPnPP nucleotide opposite urea lesion
8UJV	;	2.23	;	Crystal structure of human polymerase eta with incoming dCMPnPP nucleotide opposite urea lesion
8UJX	;	2.17	;	Crystal structure of human polymerase eta with incoming dGMPnPP nucleotide opposite urea lesion
8UK4	;	3.02	;	Crystal structure of human polymerase eta with incoming dTMPnPP nucleotide opposite urea lesion
5H65	;	2.1	;	Crystal structure of human POT1 and TPP1
1XJV	;	1.73	;	Crystal structure of human POT1 bound to telomeric single-stranded DNA (TTAGGGTTAG)
1ZSX	;	1.9	;	Crystal Structure Of Human Potassium Channel Kv Beta-subunit (KCNAB2)
3NOA	;	1.98	;	Crystal structure of human PPAR-gamma ligand binding domain complex with a potency improved agonist
3GBK	;	2.3	;	Crystal Structure of Human PPAR-gamma Ligand Binding Domain Complexed with a Potent and Selective Agonist
1ZEO	;	2.5	;	Crystal Structure of Human PPAR-gamma Ligand Binding Domain Complexed with an Alpha-Aryloxyphenylacetic Acid Agonist
2P4Y	;	2.25	;	Crystal structure of human PPAR-gamma-ligand binding domain complexed with an indole-based modulator
6VZO	;	2.27	;	Crystal structure of human PPARgamma ligand binding domain (Protein delipidated by denature and refold)
6MCZ	;	2.1	;	Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Arachidonic Acid
6DGQ	;	2.45	;	Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with CAY10506
6DGR	;	2.15	;	Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with CAY10638
6O68	;	2.78	;	Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Ciglitazone
6DGL	;	1.95	;	Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Darglitazone
5UGM	;	2.1	;	Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Edaglitazone
6VZL	;	2.07	;	Crystal structure of human PPARgamma ligand binding domain in complex with GW1929
6MD2	;	2.2	;	Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with GW9662 and Arachidonic acid
6AVI	;	2.29	;	Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with GW9662 and Nonanoic acid
6MD1	;	2.2	;	Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with GW9662 and Oleic acid
6DHA	;	1.88	;	Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Hydroxy Pioglitazone (M-IV)
6O67	;	2.52	;	Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Mitoglitazone
6DH9	;	2.7	;	Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with MSDC-0602
6MD0	;	1.95	;	Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Oleic Acid
6MD4	;	2.24	;	Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Rosiglitazone and Oleic acid
6AUG	;	2.73	;	Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with SR16832
6C1I	;	2.26	;	Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with T0070907
6DGP	;	3.1	;	Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with TRAP220 Coactivator Peptide
6DGO	;	3.1	;	Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Troglitazone
6VZN	;	2.3	;	Crystal structure of human PPARgamma ligand binding domain Y473E mutant
6VZM	;	2.4	;	Crystal structure of human PPARgamma ligand binding domain Y473E mutant in complex with Darglitazone
7JQG	;	2.15	;	Crystal structure of human PPARgamma ligand binding domain Y473E mutant in complex with GW1929
4MWS	;	2.8	;	Crystal structure of human PPCA (trigonal crystal form 1)
4MWT	;	3.85	;	Crystal structure of human PPCA (trigonal crystal form 2)
7EDZ	;	1.95	;	Crystal Structure of human PPCS in complex with P-HoPan and AMPPNP
2FFU	;	1.64	;	Crystal Structure of Human ppGalNAcT-2 complexed with UDP and EA2
2IQ1	;	2.25	;	Crystal structure of human PPM1K
3EBQ	;	1.9	;	Crystal structure of human PPPDE1
1ILH	;	2.76	;	Crystal Structure of Human Pregnane X Receptor Ligand Binding Domain Bound to SR12813
1Q1Q	;	2.91	;	Crystal structure of human pregnenolone sulfotransferase (SULT2B1a) in the presence of PAP
4NGE	;	2.704	;	Crystal Structure of Human Presequence Protease in Complex with Amyloid-beta (1-40)
4RPU	;	2.265	;	Crystal Structure of Human Presequence Protease in Complex with Inhibitor MitoBloCK-60
3NXP	;	2.2	;	Crystal structure of human prethrombin-1
6V5T	;	2.1	;	Crystal structure of human prethrombin-2 with tryptophans replaced by 5-F-tryptophan
4RR2	;	2.65	;	Crystal structure of human primase
4BPW	;	3.003	;	Crystal structure of human primase bound to UTP
4MHQ	;	2.2	;	Crystal structure of human primase catalytic subunit
4BPX	;	3.4	;	Crystal structure of human primase in complex with the primase- binding motif of DNA polymerase alpha
4BPU	;	2.7	;	Crystal structure of human primase in heterodimeric form, comprising PriS and truncated PriL lacking the C-terminal Fe-S domain.
5EXR	;	3.6	;	Crystal structure of human primosome
5L2X	;	2.2	;	Crystal structure of human PrimPol ternary complex
6DU9	;	2.33	;	Crystal Structure of Human Prion Protein 90-231
7Y1G	;	2.3	;	Crystal structure of human PRKACA complexed with DS01080522
1XM2	;	2.7	;	Crystal structure of Human PRL-1
4HSG	;	2.3	;	Crystal structure of human PRMT3 in complex with an allosteric inhibitor (PRMT3- KTD)
6P7I	;	2.0	;	Crystal structure of Human PRMT6 in complex with S-Adenosyl-L-Homocysteine and YS17-117 Compound
5DST	;	2.963	;	Crystal structure of human PRMT8 in complex with SAH
6CZS	;	1.66	;	Crystal structure of human pro-cathepsin H C26S mutant
1MZA	;	2.23	;	crystal structure of human pro-granzyme K
1MZD	;	2.9	;	crystal structure of human pro-granzyme K
5NTU	;	2.58	;	Crystal Structure of human Pro-myostatin Precursor at 2.6 A Resolution
5NXS	;	4.19	;	Crystal Structure of Human Pro-myostatin Precursor at 4.2 A Resolution with Experimental Phases from SeMet labelling
5VQP	;	2.9	;	Crystal structure of human pro-TGF-beta1
8FXS	;	3.15	;	Crystal structure of human pro-TGF-beta2 in complex with Nb9
1GQF	;	2.9	;	Crystal structure of human procaspase-7
2PBH	;	3.3	;	CRYSTAL STRUCTURE OF HUMAN PROCATHEPSIN B AT 3.3 ANGSTROM RESOLUTION
1DEU	;	1.7	;	CRYSTAL STRUCTURE OF HUMAN PROCATHEPSIN X: A CYSTEINE PROTEASE WITH THE PROREGION COVALENTLY LINKED TO THE ACTIVE SITE CYSTEINE
1D1J	;	2.2	;	CRYSTAL STRUCTURE OF HUMAN PROFILIN II
5LA7	;	1.94	;	Crystal structure of human proheparanase, in complex with glucuronic acid configured aziridine probe JJB355
4I18	;	3.238	;	Crystal structure of human prolactin receptor complexed with Fab fragment
2IW2	;	1.82	;	Crystal structure of human Prolidase
6SRF	;	1.847	;	Crystal Structure of Human Prolidase G278N variant expressed in the presence of chaperones
6SRG	;	2.558	;	Crystal Structure of Human Prolidase G448R variant expressed in the presence of chaperones
6SRE	;	1.39	;	Crystal Structure of Human Prolidase S202F variant expressed in the presence of chaperones
4K86	;	2.4	;	Crystal structure of human prolyl-tRNA synthetase (apo form)
4K88	;	2.619	;	Crystal structure of human prolyl-tRNA synthetase (halofuginone bound form)
5VAD	;	2.36	;	Crystal structure of human Prolyl-tRNA synthetase (PRS) in complex with inhibitor
4K87	;	2.301	;	Crystal structure of human prolyl-tRNA synthetase (substrate bound form)
5V58	;	2.59	;	Crystal structure of human prolyl-tRNA synthetase in complex with Aze-SA
4HVC	;	2.0	;	Crystal structure of human prolyl-tRNA synthetase in complex with halofuginone and ATP analogue
7BBU	;	2.19	;	Crystal Structure of human Prolyl-tRNA synthetase in complex with NCP26 and L-Proline
4GWM	;	1.85	;	Crystal structure of human promeprin beta
8K5V	;	1.7	;	Crystal structure of human proMMP-9 catalytic domain in complex with inhibitor
8K5W	;	2.0	;	Crystal structure of human proMMP-9 catalytic domain in complex with inhibitor
8K5X	;	1.9	;	Crystal structure of human proMMP-9 catalytic domain in complex with inhibitor
8K5Y	;	1.52	;	Crystal structure of human proMMP-9 catalytic domain in complex with inhibitor
5MFA	;	1.2	;	Crystal structure of human promyeloperoxidase (proMPO)
3VCM	;	2.93	;	Crystal structure of human prorenin
2IAG	;	2.15	;	Crystal structure of human prostacyclin synthase
3B6H	;	1.62	;	Crystal structure of human prostacyclin synthase in complex with inhibitor minoxidil
3DFJ	;	1.45	;	Crystal structure of human Prostasin
3DFL	;	2.0	;	Crystal structure of human Prostasin complexed to 4-guanidinobenzoic acid
3QUM	;	3.2	;	Crystal structure of human prostate specific antigen (PSA) in Fab sandwich with a high affinity and a PCa selective antibody
2ZCH	;	2.83	;	Crystal structure of human prostate specific antigen complexed with an activating antibody
2ZCL	;	3.25	;	Crystal structure of human prostate specific antigen complexed with an activating antibody
1CVI	;	3.2	;	CRYSTAL STRUCTURE OF HUMAN PROSTATIC ACID PHOSPHATASE
3VW7	;	2.2	;	Crystal structure of human protease-activated receptor 1 (PAR1) bound with antagonist vorapaxar at 2.2 angstrom
5DSV	;	3.75	;	Crystal structure of human proteasome alpha7 tetradecamer
5WTQ	;	1.9	;	Crystal structure of human proteasome-assembling chaperone PAC4
6WIA	;	2.21	;	CRYSTAL STRUCTURE OF HUMAN PROTECTIVE PROTEIN/CATHEPSIN A, DFP-INHIBITED (AGED)
6PDM	;	2.45	;	Crystal structure of Human Protein Arginine Methyltransferase 9 (PRMT9)
4Y2H	;	2.37	;	Crystal structure of human protein arginine methyltransferase PRMT6 bound to SAH and an aryl pyrazole inhibitor
4Y30	;	2.1	;	Crystal structure of human protein arginine methyltransferase PRMT6 bound to SAH and EPZ020411
6WAD	;	2.45	;	Crystal Structure of Human Protein arginine N-methyltransferase 6 (PRMT6) in complex with MT2739 inhibitor
6W6D	;	1.91	;	Crystal Structure of Human Protein arginine N-methyltransferase 6 (PRMT6) in complex with SGC6870 inhibitor
8CPQ	;	1.8	;	Crystal structure of human protein disulfide isomerase PDIA6 domain b
5XF7	;	2.381	;	Crystal structure of human protein disulfide isomerase-like protein of the testis
2F0Y	;	2.7	;	Crystal Structure Of Human Protein Farnesyltransferase Complexed With Farnesyl Diphosphate and hydantoin derivative
1JCQ	;	2.3	;	CRYSTAL STRUCTURE OF HUMAN PROTEIN FARNESYLTRANSFERASE COMPLEXED WITH FARNESYL DIPHOSPHATE AND THE PEPTIDOMIMETIC INHIBITOR L-739,750
4RA4	;	2.63	;	Crystal Structure of Human Protein Kinase C Alpha in Complex with Compound 28 ((R)-6-((3S,4S)-1,3-Dimethyl-piperidin-4-yl)-7-(2-fluoro-phenyl)-4-methyl-2,10-dihydro-9-oxa-1,2,4a-triaza-phenanthren-3-one)
3PE1	;	1.6	;	Crystal structure of human protein kinase CK2 alpha subunit in complex with the inhibitor CX-4945
3R0T	;	1.75	;	Crystal structure of human protein kinase CK2 alpha subunit in complex with the inhibitor CX-5279
5N9L	;	1.79	;	Crystal structure of human Protein kinase CK2 catalytic subunit in complex with the ATP-competitive dibenzofuran inhibitor TF (4b)
5N9K	;	1.643	;	Crystal structure of human Protein kinase CK2 catalytic subunit in complex with the ATP-competitive, tight-binding dibenzofuran inhibitor TF107 (5)
5N9N	;	1.841	;	Crystal structure of human Protein kinase CK2 catalytic subunit in complex with the ATP-competitive, tight-binding dibenzofuran inhibitor TF85 (4a)
1JWH	;	3.1	;	Crystal Structure of Human Protein Kinase CK2 Holoenzyme
3PE2	;	1.9	;	Crystal structure of human protein kinase CK2 in complex with the inhibitor CX-5011
3EED	;	2.8	;	Crystal structure of human protein kinase CK2 regulatory subunit (CK2beta; mutant 1-193)
6TEI	;	1.756	;	Crystal structure of human protein kinase CK2alpha (CSNK2A1 gene product) in complex with the 2-aminothiazole-type inhibitor 17
7A4C	;	2.502	;	Crystal structure of human protein kinase CK2alpha (CSNK2A1 gene product) in complex with the ATP-competitive inhibitor 5,6,7-tribromo-1H-triazolo[4,5-b]pyridine
7A4B	;	2.06	;	Crystal structure of human protein kinase CK2alpha (CSNK2A1 gene product) in complex with the ATP-competitive inhibitor 5,6-dibromo-1H-triazolo[4,5-b]pyridine
7A49	;	2.03	;	Crystal structure of human protein kinase CK2alpha (CSNK2A1 gene product) in complex with the ATP-competitive inhibitor 6-bromo-5-chloro-1H-triazolo[4,5-b]pyridine
6TE2	;	0.922	;	Crystal structure of human protein kinase CK2alpha' (CSNK2A2 gene product) in complex with the 2-aminothiazole-type inhibitor 17
6TEW	;	1.082	;	Crystal structure of human protein kinase CK2alpha' (CSNK2A2 gene product) in complex with the 2-aminothiazole-type inhibitor 27
7A2H	;	1.01	;	Crystal structure of human protein kinase CK2alpha' (CSNK2A2 gene product) in complex with the ATP-competitive inhibitor 5,6,7-tribromo-1H-imidazo[4,5-b]pyridine
7A22	;	1.01	;	Crystal structure of human protein kinase CK2alpha' (CSNK2A2 gene product) in complex with the ATP-competitive inhibitor 5,6,7-tribromo-1H-triazolo[4,5-b]pyridine
7A1B	;	1.287	;	Crystal structure of human protein kinase CK2alpha' (CSNK2A2 gene product) in complex with the ATP-competitive inhibitor 5,6-dibromo-1H-triazolo[4,5-b]pyridine
7A1Z	;	1.024	;	Crystal structure of human protein kinase CK2alpha' (CSNK2A2 gene product) in complex with the ATP-competitive inhibitor 6-bromo-5-chloro-1H-triazolo[4,5-b]pyridine
6TGU	;	0.833	;	Crystal structure of human protein kinase CK2alpha'(CSNK2A2 gene product) in complex with the 2-aminothiazole-type inhibitor Cl-OH-3
7LV3	;	2.41	;	Crystal structure of human protein kinase G (PKG) R-C complex in inhibited state
6A0E	;	1.947	;	Crystal structure of human protein N-terminal asparagine amidohydrolase (NTAN1)
6A0I	;	1.996	;	Crystal structure of human protein N-terminal asparagine amidohydrolase (NTAN1) C75S mutant
6A0H	;	3.185	;	Crystal structure of human protein N-terminal asparagine amidohydrolase (NTAN1) C75S mutant with Asn-Leu-Ala-Ala-Arg peptide
6A0F	;	2.384	;	Crystal structure of human protein N-terminal asparagine amidohydrolase (NTAN1) C75S mutant with Asn-Phe-Ala-Ala-Arg peptide
4W79	;	1.5	;	Crystal Structure of Human Protein N-terminal Glutamine Amidohydrolase
5GGG	;	3.0	;	Crystal structure of human protein O-mannose beta-1,2-N-acetylglucosaminyltransferase form I
5GGF	;	2.49	;	Crystal structure of human protein O-mannose beta-1,2-N-acetylglucosaminyltransferase form II
5GGI	;	2.6	;	Crystal structure of human protein O-mannose beta-1,2-N-acetylglucosaminyltransferase in complex with Mn, UDP and Mannosyl-peptide
3FXL	;	2.3	;	Crystal Structure of Human Protein phosphatase 1A (PPM1A) Bound with Citrate at 1 mM of Mn2+
3FXM	;	2.5	;	Crystal Structure of Human Protein phosphatase 1A (PPM1A) Bound with Citrate at 10 mM of Mn2+
3FXO	;	2.5	;	Crystal Structure of Human Protein phosphatase 1A (PPM1A) Bound with Phosphate at 1 mM of Mn2+
3FXK	;	2.1	;	Crystal Structure of Human Protein phosphatase 1A (PPM1A) Bound with Phosphate at 10 mM of Mn2+
3FXJ	;	2.5	;	Crystal Structure of Human Protein phosphatase 1A (PPM1A) Bound with Phosphate at 3 mM of Mn2+
5UI1	;	1.96	;	Crystal Structure of Human Protein Phosphatase 5C (PP5C) in complex with a triazole inhibitor
3KVH	;	1.7	;	Crystal structure of human protein syndesmos (NUDT16-like protein)
2HNP	;	2.85	;	CRYSTAL STRUCTURE OF HUMAN PROTEIN TYROSINE PHOSPHATASE 1B
2HNQ	;	2.85	;	CRYSTAL STRUCTURE OF HUMAN PROTEIN TYROSINE PHOSPHATASE 1B
1RXD	;	1.9	;	Crystal structure of human protein tyrosine phosphatase 4A1
2C7S	;	1.95	;	Crystal structure of human protein tyrosine phosphatase kappa at 1.95A resolution
2I75	;	2.45	;	Crystal Structure of Human Protein Tyrosine Phosphatase N4 (PTPN4)
2PA5	;	1.6	;	Crystal structure of human protein tyrosine phosphatase PTPN9
4GE2	;	1.8	;	Crystal structure of human protein tyrosine phosphatase PTPN9 (MEG2) complex with compound 3
4GE5	;	2.0	;	Crystal structure of human protein tyrosine phosphatase PTPN9 (MEG2) complex with compound 5
4GE6	;	1.4	;	Crystal structure of human protein tyrosine phosphatase PTPN9 (MEG2) complex with compound 7
2CFV	;	2.5	;	Crystal structure of human protein tyrosine phosphatase receptor type J
8FXV	;	2.2	;	Crystal structure of human proTGF-beta2 in complex with Nb18
6C2W	;	4.12	;	Crystal structure of human prothrombin mutant S101C/A470C
3CXW	;	2.1	;	Crystal structure of human proto-oncogene serine threonine kinase (PIM1) in complex with a consensus peptide and a beta carboline ligand I
3CY2	;	2.01	;	Crystal structure of human proto-oncogene serine threonine kinase (PIM1) in complex with a consensus peptide and a beta carboline ligand II
3QF9	;	2.2	;	Crystal structure of human proto-oncogene serine threonine kinase (PIM1) in complex with a consensus peptide and a furan-thiazolidinedione ligand
3MA3	;	2.3	;	Crystal structure of human proto-oncogene serine threonine kinase (PIM1) in complex with a consensus peptide and a naphtho-difuran ligand
3JPV	;	2.35	;	Crystal structure of human proto-oncogene serine threonine kinase (PIM1) in complex with a consensus peptide and a pyrrolo[2,3-a]carbazole ligand
3CY3	;	2.15	;	Crystal structure of human proto-oncogene serine threonine kinase (PIM1) in complex with a consensus peptide and the JNK inhibitor V
7DUA	;	1.64	;	Crystal structure of human Proto-oncogene tyrosine-protein kinase receptor Ret in complex with 4-amino-7-(1-methylcyclopropyl)-N-(5-methyl-1H-pyrazol-3-yl)pyrrolo[2,3-d]pyrimidine-5-carboxamide
7DU9	;	2.31	;	Crystal structure of human Proto-oncogene tyrosine-protein kinase receptor Ret in complex with Pralsetinib
7DU8	;	2.75	;	Crystal structure of human Proto-oncogene tyrosine-protein kinase receptor Ret in complex with Selpercatinib
6VFP	;	3.2	;	Crystal structure of human protocadherin 1 EC1-EC4
6VFR	;	2.79	;	Crystal structure of human protocadherin 18 EC1-EC4
6VFU	;	3.5	;	Crystal structure of human protocadherin 19 EC1-EC4
6VFV	;	2.9	;	Crystal structure of human protocadherin 8 EC5-EC6
6BX7	;	2.85	;	Crystal Structure of Human Protocadherin-1 EC1-4
6MGA	;	3.15	;	Crystal Structure of Human Protocadherin-1 EC1-4 with glycosylation
6PIM	;	3.05	;	Crystal Structure of Human Protocadherin-1 EC3-4
6MFO	;	3.15	;	Crystal Structure of Human Protocadherin-15 EC1-3 G16D N369D Q370N
6N2E	;	2.9	;	Crystal Structure of Human Protocadherin-15 EC1-3 G16D N369D Q370N and Mouse Cadherin-23 EC1-2 T15E
5ULY	;	2.64	;	Crystal Structure of Human Protocadherin-15 EC2-3
6EB5	;	2.6	;	Crystal Structure of Human Protocadherin-15 EC2-3 V250N
5T4M	;	2.24	;	Crystal Structure of Human Protocadherin-15 EC3-5
6E8F	;	2.99	;	Crystal Structure of Human Protocadherin-15 EC3-5 CD2-1
5T4N	;	2.701	;	Crystal Structure of Human Protocadherin-15 EC3-5 D414A Variant
4XHZ	;	2.803	;	Crystal Structure of Human Protocadherin-15 EC8-10
5CZR	;	2.3	;	Crystal Structure of Human Protocadherin-24 EC1-2
7N86	;	3.175	;	Crystal Structure of Human Protocadherin-24 EC1-2 Form II
3E9L	;	1.95	;	Crystal Structure of Human Prp8, Residues 1755-2016
4IJP	;	2.25	;	Crystal Structure of Human PRPF4B kinase domain in complex with 4-{5-[(2-Chloro-pyridin-4-ylmethyl)-carbamoyl]-thiophen-2-yl}-benzo[b]thiophene-2-carboxylic acid amine
4LZO	;	3.31	;	Crystal structure of human PRS1 A87T mutant
4F8E	;	2.27	;	Crystal structure of human PRS1 D52H mutant
4LZN	;	2.14	;	Crystal structure of human PRS1 D65N mutant
4LYG	;	3.0	;	Crystal structure of human PRS1 E43T mutant
4M0P	;	2.11	;	Crystal structure of human PRS1 M115T mutant
4M0U	;	2.74	;	crystal structure of human PRS1 Q133P mutant
4AL0	;	1.16	;	Crystal structure of Human PS-1
4AL1	;	1.95	;	Crystal structure of Human PS-1 GSH-analog complex
3ZRT	;	3.398	;	Crystal structure of human PSD-95 PDZ1-2
5KKP	;	2.26	;	Crystal Structure of Human Pseudouridylate Synthase 7
4C45	;	1.45	;	Crystal structure of human pterin-4-alpha-carbinolamine dehydratase 2 (PCBD2)
3SQD	;	2.153	;	Crystal structure of human PTIP BRCT5/6-gamma H2AX complex
2G62	;	1.6	;	Crystal structure of human PTPA
4RCA	;	2.9908	;	Crystal structure of human PTPdelta and human Slitrk1 complex
7UAD	;	2.044	;	Crystal structure of human PTPN2 with inhibitor ABBV-CLS-484
5AWX	;	1.86	;	Crystal structure of Human PTPRZ D1 domain
4WZR	;	2.154	;	Crystal structure of human Puf-A
4WZW	;	2.9516	;	Crystal structure of human Puf-A in complex with DNA
3BSX	;	2.32	;	Crystal Structure of Human Pumilio 1 in complex with Puf5 RNA
3BSB	;	2.8	;	Crystal Structure of Human Pumilio1 in Complex with CyclinB reverse RNA
8CHT	;	1.95	;	Crystal structure of human PURA (fragment Glu57-Glu212, PUR repeat I and II)
8CHV	;	2.15	;	Crystal structure of human PURA (fragment Glu57-Glu212, PUR repeat I and II) R140P mutant
8CHW	;	1.7	;	Crystal structure of human PURA (fragment Pro216-Lys280, PUR repeat III)
8CHU	;	2.45	;	Crystal structure of human PURA repeat I-II K97E mutant
5UGF	;	2.2	;	Crystal structure of human purine nucleoside phosphorylase (F159Y) mutant complexed with DADMe-ImmG and phosphate
1RFG	;	2.9	;	Crystal Structure of Human Purine Nucleoside Phosphorylase Complexed with Guanosine
1RCT	;	2.8	;	Crystal structure of Human purine nucleoside phosphorylase complexed with INOSINE
3INY	;	2.75	;	Crystal structure of human purine nucleoside phosphorylase in complex with 7-deazaguanine
3PHB	;	2.3	;	Crystal Structure of human purine nucleoside phosphorylase in complex with DADMe-ImmG
3K8O	;	2.4	;	Crystal structure of human purine nucleoside phosphorylase in complex with DATMe-ImmH
3K8Q	;	2.5	;	Crystal structure of human purine nucleoside phosphorylase in complex with SerMe-Immucillin H
2OC4	;	2.592	;	Crystal structure of human purine nucleoside phosphorylase mutant H257D with Imm-H
2ON6	;	2.503	;	Crystal structure of human purine nucleoside phosphorylase mutant H257F with Imm-H
2OC9	;	2.59	;	Crystal structure of human purine nucleoside phosphorylase mutant H257G with Imm-H
2BQ8	;	2.2	;	Crystal structure of human purple acid phosphatase with an inhibitory conformation of the repression loop
2V9K	;	2.0	;	Crystal structure of human PUS10, a novel pseudouridine synthase.
2CFR	;	2.4	;	crystal structure of human pyridoxal 5'-phosphate phosphatase
2CFS	;	2.4	;	crystal structure of human pyridoxal 5'-phosphate phosphatase
5GYN	;	1.995	;	Crystal structure of human pyridoxal 5'-phosphate phosphatase (Chronophin) mutant - C221S
2CFT	;	1.8	;	Crystal structure of human pyridoxal 5'-phosphate phosphatase with its substrate
2F7K	;	2.8	;	Crystal Structure of Human Pyridoxal Kinase
8WR2	;	1.94	;	Crystal Structure of Human Pyridoxal Kinase with bound Luteolin
2OYC	;	1.72	;	Crystal structure of human pyridoxal phosphate phosphatase
2P27	;	1.9	;	Crystal Structure of Human Pyridoxal Phosphate Phosphatase with Mg2+ at 1.9 A resolution
2P69	;	2.25	;	Crystal Structure of Human Pyridoxal Phosphate Phosphatase with PLP
3HY8	;	2.5	;	Crystal Structure of Human Pyridoxine 5'-Phosphate Oxidase R229W Mutant
6H00	;	1.66	;	Crystal structure of human pyridoxine 5-phophate oxidase, R116Q variant
6ZK7	;	3.2	;	Crystal Structure of human PYROXD1/FAD complex
2IZZ	;	1.95	;	Crystal structure of human pyrroline-5-carboxylate reductase
2GRA	;	3.1	;	crystal structure of Human Pyrroline-5-carboxylate Reductase complexed with nadp
2H5G	;	2.25	;	Crystal structure of human pyrroline-5-carboxylate synthetase
3BG3	;	2.8	;	Crystal Structure of Human Pyruvate Carboxylase (missing the biotin carboxylase domain at the N-terminus)
3BG9	;	3.0	;	Crystal Structure of Human Pyruvate Carboxylase (missing the biotin carboxylase domain at the N-terminus) F1077A Mutant
7EA0	;	2.34	;	Crystal structure of human pyruvate dehydrogenase kinase 2 in complex with compound 1
7EBH	;	1.96	;	Crystal structure of human pyruvate dehydrogenase kinase 2 in complex with compound 13
7EAS	;	1.97	;	Crystal structure of human pyruvate dehydrogenase kinase 2 in complex with compound 2
7VBX	;	2.6	;	Crystal structure of human pyruvate dehydrogenase kinase 2 in complex with compound 20
7VBU	;	1.89	;	Crystal structure of human pyruvate dehydrogenase kinase 2 in complex with compound 5
7VBV	;	2.21	;	Crystal structure of human pyruvate dehydrogenase kinase 2 in complex with compound 7
2E0A	;	1.86	;	Crystal structure of human pyruvate dehydrogenase kinase 4 in complex with AMPPNP
7EAT	;	2.1	;	Crystal structure of human pyruvate dehydrogenase kinase 4 in complex with compound 1
7EBB	;	1.9	;	Crystal structure of human pyruvate dehydrogenase kinase 4 in complex with compound 2
7EBG	;	1.95	;	Crystal structure of human pyruvate dehydrogenase kinase 4 in complex with compound 7
6JFB	;	2.12	;	Crystal structure of human pyruvate kinase M2 isoform
5AYX	;	2.8	;	Crystal structure of Human Quinolinate Phosphoribosyltransferase
5AYZ	;	2.6	;	CRYSTAL STRUCTURE OF HUMAN QUINOLINATE PHOSPHORIBOSYLTRANSFERASE IN COMPLEX WITH THE PRODUCT NICOTINATE MONONUCLEOTIDE
5AYY	;	3.09	;	CRYSTAL STRUCTURE OF HUMAN QUINOLINATE PHOSPHORIBOSYLTRANSFERASE IN COMPLEX WITH THE REACTANT QUINOLINATE
8BQ3	;	2.66	;	Crystal structure of human R13 mutant of the c-Src SH3 domain in complex with VSL12-peptide
7L8L	;	1.61	;	Crystal structure of human R152H GPX4-U46C
6HX7	;	1.8	;	Crystal structure of human R180T variant of ORNITHINE AMINOTRANSFERASE at 1.8 Angstrom
2D7C	;	1.75	;	Crystal structure of human Rab11 in complex with FIP3 Rab-binding domain
4UJ3	;	3.0	;	Crystal structure of human Rab11-Rabin8-FIP3
4UJ4	;	4.2	;	Crystal structure of human Rab11-Rabin8-FIP3
4UJ5	;	2.604	;	Crystal structure of human Rab11-Rabin8-FIP3
4DRZ	;	2.3	;	Crystal structure of human RAB14
1X3S	;	1.32	;	Crystal structure of human Rab18 in complex with Gppnhp
2FOL	;	2.631	;	Crystal structure of human RAB1A in complex with GDP
4HLQ	;	3.3	;	Crystal structure of human rab1b bound to GDP and BEF3 in complex with the GAP domain of TBC1D20 from homo sapiens
5O74	;	2.5	;	Crystal structure of human Rab1b covalently bound to the GEF domain of DrrA/SidM from Legionella pneumophila in the presence of GDP
3JZA	;	1.8	;	Crystal structure of human Rab1b in complex with the GEF domain of DrrA/SidM from Legionella pneumophila
2OIL	;	2.3	;	Crystal structure of human RAB25 in complex with GDP
2G6B	;	2.0	;	Crystal structure of human RAB26 in complex with a GTP analogue
2A5J	;	1.501	;	Crystal Structure of Human RAB2B
2FG5	;	2.801	;	Crystal structure of human RAB31 in complex with a GTP analogue
6HDU	;	1.793	;	Crystal structure of human Rab38 in complex with GTP
3DZ8	;	1.9	;	Crystal structure of human Rab3B GTPase bound with GDP
2GF9	;	1.53	;	Crystal structure of human RAB3D in complex with GDP
2HUP	;	2.05	;	Crystal structure of human RAB43 in complex with GDP
2O52	;	2.2	;	Crystal structure of human RAB4B in complex with GDP
1N6H	;	1.51	;	Crystal Structure of Human Rab5a
1N6P	;	1.54	;	Crystal Structure of Human Rab5a A30E mutant complex with GppNHp
1N6O	;	1.8	;	Crystal Structure of Human Rab5a A30K mutant complex with GppNHp
1N6R	;	1.55	;	Crystal Structure of Human Rab5a A30L mutant complex with GppNHp
1N6I	;	1.6	;	Crystal Structure of Human Rab5a A30P mutant Complex with GDP
1N6K	;	1.55	;	Crystal Structure of Human Rab5a A30P mutant complex with GDP and aluminum fluoride
1N6L	;	1.6	;	Crystal Structure of Human Rab5a A30P mutant complex with GTP
1N6N	;	1.6	;	Crystal Structure of Human Rab5a A30R mutant complex with GppNHp
1R2Q	;	1.05	;	Crystal Structure of Human Rab5a GTPase Domain at 1.05 A resolution
3MJH	;	2.03	;	Crystal Structure of Human Rab5A in complex with the C2H2 Zinc Finger of EEA1
2HEI	;	1.55	;	Crystal structure of human RAB5B in complex with GDP
2OCB	;	2.2	;	Crystal structure of human RAB9B in complex with a GTP analogue
2IC5	;	1.9	;	Crystal structure of human RAC3 grown in the presence of Gpp(NH)p.
2QME	;	1.75	;	Crystal structure of human RAC3 in complex with CRIB domain of human p21-activated kinase 1 (PAK1)
2DPX	;	1.8	;	Crystal Structure of human Rad GTPase
3CJJ	;	1.85	;	Crystal structure of human rage ligand-binding domain
2GRN	;	1.8	;	Crystal Structure of human RanGAP1-Ubc9
2GRQ	;	1.7	;	Crystal Structure of human RanGAP1-Ubc9-D127A
2GRR	;	1.3	;	Crystal Structure of human RanGAP1-Ubc9-D127S
2GRO	;	1.7	;	Crystal Structure of human RanGAP1-Ubc9-N85Q
2GRP	;	2.05	;	Crystal Structure of human RanGAP1-Ubc9-Y87A
3GJ0	;	1.48	;	Crystal structure of human RanGDP
3GJ6	;	2.7	;	Crystal structure of human RanGDP-Nup153ZnF1 complex
3GJ7	;	1.93	;	Crystal structure of human RanGDP-Nup153ZnF12 complex
3GJ3	;	1.79	;	Crystal structure of human RanGDP-Nup153ZnF2 complex
3GJ4	;	2.15	;	Crystal structure of human RanGDP-Nup153ZnF3 complex
3GJ8	;	1.82	;	Crystal structure of human RanGDP-Nup153ZnF34 complex
3GJ5	;	1.79	;	Crystal structure of human RanGDP-Nup153ZnF4 complex
1U4R	;	2.2	;	Crystal Structure of human RANTES mutant 44-AANA-47
1U4P	;	1.7	;	Crystal Structure of human RANTES mutant K45E
5MLB	;	3.22	;	Crystal structure of human RAS in complex with darpin K27
5MLA	;	2.19	;	Crystal structure of human RAS in complex with darpin K55
3C5C	;	1.85	;	Crystal structure of human Ras-like, family 12 protein in complex with GDP
3V53	;	2.9	;	Crystal structure of human RBM25
5GWN	;	1.309	;	Crystal structure of human RCC2
3O3U	;	1.497	;	Crystal Structure of Human Receptor for Advanced Glycation Endproducts (RAGE)
6V08	;	2.58	;	Crystal structure of human recombinant Beta-2 glycoprotein I (hrB2GPI)
6V09	;	2.99	;	Crystal structure of human recombinant Beta-2 glycoprotein I short tag (ST-B2GPI)
1RCB	;	2.25	;	CRYSTAL STRUCTURE OF HUMAN RECOMBINANT INTERLEUKIN-4 AT 2.25 ANGSTROMS RESOLUTION
1PBH	;	3.2	;	CRYSTAL STRUCTURE OF HUMAN RECOMBINANT PROCATHEPSIN B AT 3.2 ANGSTROM RESOLUTION
2D8N	;	2.2	;	Crystal structure of human recoverin at 2.2 A resolution
2V1X	;	2.0	;	Crystal structure of human RECQ-like DNA helicase
7ZML	;	2.79	;	Crystal structure of human RECQL5 helicase APO form in complex with engineered nanobody (Gluebody) G1-001
7ZMQ	;	2.7	;	Crystal structure of human RECQL5 helicase APO form in complex with engineered nanobody (Gluebody) G2*-006
7ZMR	;	3.3	;	Crystal structure of human RECQL5 helicase APO form in complex with engineered nanobody (Gluebody) G2*-011
7ZMM	;	2.5	;	Crystal structure of human RECQL5 helicase APO form in complex with engineered nanobody (Gluebody) G2-001
7ZMN	;	3.2	;	Crystal structure of human RECQL5 helicase APO form in complex with engineered nanobody (Gluebody) G3-048
7ZMO	;	3.75	;	Crystal structure of human RECQL5 helicase APO form in complex with engineered nanobody (Gluebody) G3-052
7ZMP	;	3.626	;	Crystal structure of human RECQL5 helicase APO form in complex with engineered nanobody (Gluebody) G3-055
7ZMS	;	2.7	;	Crystal structure of human RECQL5 helicase APO form in complex with engineered nanobody (Gluebody) G4-043
7ZMT	;	2.3	;	Crystal structure of human RECQL5 helicase APO form in complex with engineered nanobody (Gluebody) G5-006
7ZMV	;	2.002	;	Crystal structure of human RECQL5 helicase APO form in complex with engineered nanobody (Gluebody) G5-006
5LB8	;	3.4	;	Crystal structure of human RECQL5 helicase APO form.
5LB5	;	2.0	;	Crystal structure of human RECQL5 helicase in complex with ADP/Mg (tricilinc form).
5LB3	;	1.8	;	Crystal structure of human RECQL5 helicase in complex with ADP/Mg.
5LBA	;	2.5	;	Crystal structure of human RECQL5 helicase in complex with DSPL fragment(1-cyclohexyl-3-(oxolan-2-ylmethyl)urea, SGC - Diamond XChem I04-1 fragment screening.
3LQ9	;	2.0	;	Crystal structure of human REDD1, a hypoxia-induced regulator of mTOR
2IHD	;	1.7	;	Crystal structure of Human Regulator of G-protein signaling 8, RGS8
3QJ4	;	2.5	;	Crystal structure of Human Renalase (isoform 1)
3GW5	;	2.0	;	Crystal structure of human renin complexed with a novel inhibitor
2IKO	;	1.9	;	Crystal Structure of Human Renin Complexed with Inhibitor
2IL2	;	2.24	;	Crystal Structure of Human Renin Complexed with Inhibitor
2IKU	;	2.6	;	Crystal Structure of Human Renin Complexed with Inhibitors
5V8V	;	2.6	;	Crystal Structure of Human Renin in Complex with a biphenylpipderidinylcarbinol
5VPM	;	2.9	;	Crystal Structure of Human Renin in Complex with a biphenylpipderidinylcarbinol
5VRP	;	3.22	;	Crystal Structure of Human Renin in Complex with a biphenylpipderidinylcarbinol
7UJ3	;	3.5	;	Crystal structure of Human respiratory syncytial virus F variant (construct pXCS847A)
6EAL	;	2.751	;	CRYSTAL STRUCTURE OF HUMAN RESPIRATORY SYNCYTIAL VIRUS FUSION GLYCOPROTEIN INHIBITOR ESCAPE VARIANT D486N STABILIZED IN THE PREFUSION STATE
6EAM	;	2.739	;	CRYSTAL STRUCTURE OF HUMAN RESPIRATORY SYNCYTIAL VIRUS FUSION GLYCOPROTEIN INHIBITOR ESCAPE VARIANT E487D STABILIZED IN THE PREFUSION STATE
6EAD	;	2.8	;	CRYSTAL STRUCTURE OF HUMAN RESPIRATORY SYNCYTIAL VIRUS FUSION GLYCOPROTEIN INHIBITOR ESCAPE VARIANT F140I STABILIZED IN THE PREFUSION STATE
6EAN	;	2.9	;	CRYSTAL STRUCTURE OF HUMAN RESPIRATORY SYNCYTIAL VIRUS FUSION GLYCOPROTEIN INHIBITOR ESCAPE VARIANT F488I STABILIZED IN THE PREFUSION STATE
6EAF	;	3.0	;	CRYSTAL STRUCTURE OF HUMAN RESPIRATORY SYNCYTIAL VIRUS FUSION GLYCOPROTEIN INHIBITOR ESCAPE VARIANT G143S STABILIZED IN THE PREFUSION STATE
6EAH	;	3.0	;	CRYSTAL STRUCTURE OF HUMAN RESPIRATORY SYNCYTIAL VIRUS FUSION GLYCOPROTEIN INHIBITOR ESCAPE VARIANT K394R-S398L STABILIZED IN THE PREFUSION STATE
6EAE	;	2.9	;	CRYSTAL STRUCTURE OF HUMAN RESPIRATORY SYNCYTIAL VIRUS FUSION GLYCOPROTEIN INHIBITOR ESCAPE VARIANT L141W STABILIZED IN THE PREFUSION STATE
6EAI	;	2.8	;	CRYSTAL STRUCTURE OF HUMAN RESPIRATORY SYNCYTIAL VIRUS FUSION GLYCOPROTEIN INHIBITOR ESCAPE VARIANT S398L STABILIZED IN THE PREFUSION STATE
6EAJ	;	2.851	;	CRYSTAL STRUCTURE OF HUMAN RESPIRATORY SYNCYTIAL VIRUS FUSION GLYCOPROTEIN INHIBITOR ESCAPE VARIANT T400A STABILIZED IN THE PREFUSION STATE
2VN8	;	2.1	;	Crystal structure of human Reticulon 4 interacting protein 1 in complex with NADPH
1YDE	;	2.4	;	Crystal Structure of Human Retinal Short-Chain Dehydrogenase/Reductase 3
3OZJ	;	2.1	;	Crystal structure of human retinoic X receptor alpha complexed with bigelovin and coactivator SRC-1
3PCU	;	2.0	;	Crystal structure of human retinoic X receptor alpha ligand-binding domain complexed with LX0278 and SRC1 peptide
4RMD	;	1.9	;	Crystal structure of human Retinoid X receptor alpha ligand binding domain complex with 9cUAB110 and coactivator peptide GRIP-1
4RME	;	2.3	;	Crystal structure of human Retinoid X receptor alpha ligand binding domain complex with 9cUAB111 and coactivator peptide GRIP-1
7UW4	;	2.1	;	Crystal structure of human Retinoid X receptor alpha ligand binding domain complex with UAB113 and coactivator peptide GRIP-1
7UW2	;	1.88	;	Crystal structure of human Retinoid X receptor alpha ligand binding domain complex with UAB116 and coactivator peptide GRIP-1
4M8H	;	2.2	;	CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH (R)4-METHYL 9cUAB30 AND COACTIVATOR PEPTIDE GRIP-1
4M8E	;	2.4	;	CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH (S) 4-Methyl 9cUAB30 COACTIVATOR PEPTIDE GRIP-1
4PP5	;	2.0	;	Crystal structure of human Retinoid X Receptor alpha-ligand binding domain complex with 5-methyl UAB30 and the coactivator peptide GRIP-1
4PP3	;	2.0	;	Crystal structure of human Retinoid X Receptor alpha-ligand binding domain complex with 6-methyl UAB30 and the coactivator peptide GRIP-1
4POJ	;	2.0	;	Crystal structure of human Retinoid X Receptor alpha-ligand binding domain complex with 7-methyl UAB30 and the coactivator peptide GRIP-1
4POH	;	2.3	;	Crystal structure of human Retinoid X Receptor alpha-ligand binding domain complex with 8-methyl UAB30 and the coactivator peptide GRIP-1
3OAP	;	2.05	;	Crystal structure of human Retinoid X Receptor alpha-ligand binding domain complex with 9-cis retinoic acid and the coactivator peptide GRIP-1
4K4J	;	2.0	;	Crystal structure of human Retinoid X Receptor alpha-ligand binding domain complex with 9cUAB30 and the coactivator peptide GRIP-1
4RFW	;	2.4	;	Crystal structure of human retinoid X Receptor alpha-ligand binding domain complex with 9cUAB70 and the coactivator peptide GRIP-1
4RMC	;	2.7	;	Crystal Structure of human retinoid X receptor alpha-ligand binding domain complex with 9cUAB76 and the coactivator peptide GRIP-1
4K6I	;	2.1	;	Crystal structure of human retinoid X receptor alpha-ligand binding domain complex with Targretin and the coactivator peptide GRIP-1
6WMQ	;	2.55	;	Crystal Structure of Human REV-ERBbeta Ligand Binding Domain Co-Bound to Heme and NCoR ID1 Peptide
6WMS	;	2.0	;	Crystal Structure of Human REV-ERBbeta Ligand Binding Domain Co-Bound to Heme and NCoR ID2 Peptide
4GK0	;	2.7	;	Crystal structure of human Rev3-Rev7-Rev1 complex
4GK5	;	3.21	;	Crystal structure of human Rev3-Rev7-Rev1-Polkappa complex
6WW9	;	2.7	;	Crystal structure of human REV7(R124A)-SHLD3(35-58) complex
6NIF	;	2.002	;	crystal structure of human REV7-RAN complex
1R1A	;	3.2	;	CRYSTAL STRUCTURE OF HUMAN RHINOVIRUS SEROTYPE 1A (HRV1A)
3BYI	;	2.25	;	Crystal structure of human Rho GTPase activating protein 15 (ARHGAP15)
2J1L	;	2.5	;	Crystal Structure of Human Rho-related GTP-binding protein RhoD
1CXZ	;	2.2	;	CRYSTAL STRUCTURE OF HUMAN RHOA COMPLEXED WITH THE EFFECTOR DOMAIN OF THE PROTEIN KINASE PKN/PRK1
1XCG	;	2.5	;	Crystal Structure of Human RhoA in complex with DH/PH fragment of PDZRHOGEF
4XH9	;	2.0	;	CRYSTAL STRUCTURE OF HUMAN RHOA IN COMPLEX WITH DH/PH FRAGMENT OF THE GUANINE NUCLEOTIDE EXCHANGE FACTOR NET1
6HXU	;	1.19	;	Crystal structure of Human RHOB Q63L in complex with GTP
6SGE	;	1.5	;	Crystal structure of Human RHOB-GTP in complex with nanobody B6
5M70	;	2.2	;	Crystal Structure of human RhoGAP mutated in its arginin finger (R85A) in complex with RhoA.GDP.AlF4- human
5M6X	;	2.4	;	Crystal Structure of human RhoGAP mutated in its arginine finger (R85A) in complex with RhoA.GDP.MgF3- human
1NB0	;	1.7	;	Crystal Structure of Human Riboflavin Kinase
2FV7	;	2.1	;	Crystal structure of human ribokinase
5BYC	;	1.95	;	Crystal structure of human ribokinase in C2 spacegroup
5BYF	;	2.0	;	Crystal structure of human ribokinase in complex with AMP
6WJZ	;	1.8	;	Crystal structure of human ribokinase in complex with AMPCP
6WK0	;	2.0	;	Crystal structure of human ribokinase in complex with AMPPCP and ribose
5C3Z	;	1.9	;	Crystal structure of human ribokinase in complex with AMPPCP in C2 spacegroup
5C40	;	1.5	;	Crystal structure of human ribokinase in complex with AMPPCP in P21 spacegroup
5C41	;	1.95	;	Crystal structure of human ribokinase in complex with AMPPCP in P21 spacegroup and with 4 protomers
5BYD	;	2.1	;	Crystal structure of human ribokinase in P21 spacegroup
5BYE	;	1.75	;	Crystal structure of human ribokinase in P212121 spacegroup
6CWX	;	2.25	;	Crystal structure of human ribonuclease P/MRP proteins Rpp20/Rpp25
4X3V	;	3.7	;	Crystal structure of human ribonucleotide reductase 1 bound to inhibitor
3HNC	;	2.41	;	Crystal structure of human ribonucleotide reductase 1 bound to the effector TTP
3HND	;	3.21	;	Crystal structure of human ribonucleotide reductase 1 bound to the effector TTP and substrate GDP
3HNE	;	3.11	;	Crystal structure of human ribonucleotide reductase 1 bound to the effectors TTP and ATP
3HNF	;	3.16	;	Crystal structure of human ribonucleotide reductase 1 bound to the effectors TTP and dATP
3OLJ	;	2.1	;	Crystal structure of human ribonucleotide reductase subunit M2 (hRRM2)
3VPM	;	2.7	;	Crystal structure of human ribonucleotide reductase subunit M2 (hRRM2) mutant
3VPN	;	2.25	;	Crystal structure of human ribonucleotide reductase subunit M2 (hRRM2) mutant
3VPO	;	2.3	;	Crystal structure of human ribonucleotide reductase subunit M2 (hRRM2) mutant
2UW2	;	2.8	;	Crystal structure of human ribonucleotide reductase subunit R2
2PA2	;	2.5	;	Crystal structure of human Ribosomal protein L10 core domain
3VI6	;	1.59	;	Crystal Structure of human ribosomal protein L30e
3LRR	;	2.15	;	Crystal structure of human RIG-I CTD bound to a 12 bp AU rich 5' ppp dsRNA
3LRN	;	2.6	;	Crystal structure of human RIG-I CTD bound to a 14 bp GC 5' ppp dsRNA
3OG8	;	2.4	;	Crystal structure of human RIG-I CTD bound to a 14-bp blunt-ended dsRNA
7FCZ	;	2.21	;	Crystal Structure of human RIPK1 kinase domain in complex with a novel inhibitor
7FD0	;	2.0	;	Crystal Structure of human RIPK1 kinase domain in complex with a novel inhibitor
7YDX	;	2.642	;	Crystal structure of human RIPK1 kinase domain in complex with compound RI-962
7XMK	;	2.376	;	Crystal structure of human RIPK1 kinase domain in complex with compound SKLB923
7MX3	;	3.23	;	Crystal structure of human RIPK3 complexed with GSK'843
3NBI	;	2.0	;	Crystal structure of human RMI1 N-terminus
3NBH	;	2.0	;	Crystal structure of human RMI1C-RMI2 complex
2EK6	;	2.38	;	Crystal structure of Human RNA-Binding Protein 12
3PUF	;	3.1	;	Crystal structure of human RNase H2 complex
3V3L	;	1.65	;	Crystal structure of human RNF146 WWE domain in complex with iso-ADPRibose
6L5H	;	1.3	;	Crystal structure of human rootletin 1108-1200
6L5J	;	2.77	;	Crystal structure of human rootletin 1108-1317
4ZLD	;	1.6	;	Crystal structure of human Roquin-2 ROQ domain in complex with Roquin CDE RNA
6SLZ	;	2.2	;	Crystal structure of human ROR gamma LBD in complex with a (quinolinoxymethyl)benzamide inverse agonist
6Q2W	;	1.99	;	Crystal structure of human ROR gamma LBD in complex with a quinoline sulfonamide inverse agonist
7XQE	;	2.57	;	Crystal Structure of human RORgamma (C455E) LBD in complex with compound XY039
2GU0	;	2.8	;	Crystal Structure of Human Rotavirus NSP2 (Group C / Bristol Strain)
3B2D	;	2.8	;	Crystal structure of human RP105/MD-1 complex
6LT7	;	2.7	;	Crystal structure of human RPP20-RPP25 proteins in complex with the P3 domain of lncRNA RMRP
6AHV	;	2.6	;	Crystal structure of human RPP40
4FLA	;	2.2	;	Crystal structure of human RPRD1B, carboxy-terminal domain
7XC0	;	1.56	;	Crystal structure of Human RPTPH
3RNY	;	2.7	;	Crystal structure of human RSK1 C-terminal kinase domain
4L1P	;	2.12	;	Crystal Structure of Human Rtf1 Plus3 domain
4L1U	;	2.424	;	Crystal Structure of Human Rtf1 Plus3 Domain in Complex with Spt5 CTR Phosphopeptide
7BRU	;	2.149	;	Crystal structure of human RTN3 LIR fused to human GABARAP
2YW8	;	3.0	;	Crystal structure of human RUN and FYVE domain-containing protein
7CFO	;	2.15	;	Crystal structure of human RXRalpha ligand binding domain complexed with CBTF-EE.
7NKE	;	2.35	;	Crystal structure of human RXRalpha ligand binding domain in complex with 2,4-di-tert-butylphenol and a coactivator fragment
4ERV	;	1.75	;	Crystal structure of human ryanodine receptor 3 (2597-2800)
6UHH	;	3.138	;	Crystal Structure of Human RYR Receptor 3 ( 848-1055) in Complex with ATP
6UHB	;	2.504	;	Crystal Structure of Human RYR Receptor 3 (848-1055)
3MTG	;	2.64	;	Crystal structure of human S-adenosyl homocysteine hydrolase-like 1 protein
2YDX	;	2.8	;	Crystal structure of human S-adenosylmethionine synthetase 2, beta subunit
2YDY	;	2.25	;	Crystal structure of human S-adenosylmethionine synthetase 2, beta subunit in Orthorhombic crystal form
1DCY	;	2.7	;	CRYSTAL STRUCTURE OF HUMAN S-PLA2 IN COMPLEX WITH INDOLE 3 ACTIVE SITE INHIBITOR
2EGD	;	1.8	;	Crystal structure of human S100A13 in the Ca2+-bound state
3HCM	;	2.0	;	Crystal structure of human S100B in complex with S45
1XV8	;	3.0	;	Crystal Structure of Human Salivary Alpha-Amylase Dimer
5AO1	;	2.545	;	Crystal structure of human SAMHD1 (amino acid residues 115-583) bound to ddGTP
5AO2	;	2.966	;	Crystal structure of human SAMHD1 (amino acid residues 115-583) R164A variant bound to dGTP
5AO3	;	3.004	;	Crystal structure of human SAMHD1 (amino acid residues 115-626) bound to GTP
5AO0	;	3.731	;	Crystal structure of human SAMHD1 (amino acid residues 41-583) bound to ddGTP
4CC9	;	2.473	;	Crystal structure of human SAMHD1 (amino acid residues 582-626) bound to Vpx isolated from sooty mangabey and human DCAF1 (amino acid residues 1058-1396)
2DOB	;	2.0	;	Crystal Structure of Human Saposin A
1N69	;	2.2	;	Crystal structure of human saposin B
2GTG	;	2.4	;	Crystal Structure of Human Saposin C
2Z9A	;	2.5	;	Crystal Structure of Human Saposin C Dimer in Open Conformation
2RB3	;	2.1	;	Crystal Structure of Human Saposin D
3BQP	;	1.3	;	Crystal Structure of Human Saposin D (orthorhombic)
3BQQ	;	2.0	;	Crystal Structure of Human Saposin D (triclinic)
2R0R	;	2.5	;	Crystal Structure of Human Saposin D variant SapD K9E
2GAO	;	2.0	;	Crystal Structure of Human SAR1a in Complex With GDP
8DZN	;	2.107	;	Crystal structure of human Sar1a in complex with GDP
8DZM	;	1.648	;	Crystal structure of human Sar1a in complex with ppGpp and Magnesium
8E0H	;	2.0	;	Crystal structure of human Sar1aD104/D140A double mutant
8DZT	;	1.8	;	Crystal structure of human Sar1aH79G mutant
8E0A	;	1.797	;	Crystal structure of human Sar1b
8E0D	;	1.981	;	Crystal structure of human Sar1bE140D
8E0C	;	1.993	;	Crystal structure of human Sar1bH79G
8E0B	;	2.212	;	Crystal structure of human Sar1bT39N
8DZO	;	1.8	;	Crystal structure of human Sar1T39N mutant
4Z9M	;	2.1	;	Crystal structure of human sarcomeric mitochondrial creatine kinase
7YDF	;	2.8	;	Crystal structure of human SARS2 catalytic domain
7YDG	;	3.2	;	Crystal structure of human SARS2 catalytic domain with a disease related mutation
5CTR	;	3.012	;	Crystal structure of human SART3 HAT-C domain-human USP4 DUSP-UBL domain complex
5CTQ	;	2.6	;	Crystal structure of human SART3/TIP110 half-a TPR (HAT) domain
5CTT	;	1.7	;	Crystal structure of human SART3/TIP110 NLS-mouse importin alpha complex
7CUX	;	3.29477	;	Crystal structure of human Schlafen 5 N'-terminal domain (SLFN5-N) involved in ssRNA cleaving and DNA binding
2GGT	;	2.4	;	Crystal structure of human SCO1 complexed with nickel.
4YGY	;	2.36	;	Crystal Structure of Human Scp1 bound to trans-proline peptidomimetic CTD phospho-Ser5 peptide
5VWC	;	1.911	;	Crystal structure of human Scribble PDZ1 domain
8CD3	;	1.9	;	Crystal structure of human Scribble PDZ1 domain in complex with human TMIGD1
6MYE	;	1.1	;	Crystal structure of human Scribble PDZ1 domain in complex with internal PDZ binding motif of Src homology 3 domain-containing guanine nucleotide exchange factor (SGEF)
5VWI	;	1.75	;	Crystal structure of human Scribble PDZ1:Beta-PIX complex
5VWK	;	2.35	;	Crystal structure of human Scribble PDZ1:Beta-PIX complex
6MTV	;	2.597	;	Crystal structure of human Scribble PDZ1:MCC complex
6MTU	;	2.141	;	Crystal structure of human Scribble PDZ1:pMCC complex
6XA8	;	2.2	;	Crystal Structure of Human Scribble PDZ1:Vangl2 complex
7JO7	;	2.44	;	Crystal Structure of Human Scribble PDZ2
6XA7	;	2.5	;	Crystal Structure of Human Scribble PDZ2:Vangl2 complex
6XA6	;	1.95	;	Crystal Structure of Human Scribble PDZ3:Vangl2 Complex
6EEY	;	1.145	;	Crystal structure of human Scribble PDZ4 R1110G Mutant
6VAX	;	2.59	;	Crystal structure of human SDHA-SDHAF2 assembly intermediate
8DYD	;	1.52	;	Crystal structure of human SDHA-SDHAF2-SDHAF4 assembly intermediate
8DYE	;	1.44	;	Crystal structure of human SDHA-SDHAF4 assembly intermediate
2QQ5	;	1.8	;	Crystal structure of human SDR family member 1
6HKW	;	3.09	;	Crystal structure of human SDS22
5WZM	;	2.0	;	Crystal structure of human secreted phospholipase A2 group IIE
5WZT	;	2.4	;	Crystal structure of human secreted phospholipase A2 group IIE with Compound 14
5WZU	;	2.2	;	Crystal structure of human secreted phospholipase A2 group IIE with Compound 24
5WZS	;	2.3	;	Crystal structure of human secreted phospholipase A2 group IIE with Compound 8
5WZW	;	1.95	;	Crystal structure of human secreted phospholipase A2 group IIE with LY311727
5WZV	;	2.2	;	Crystal structure of human secreted phospholipase A2 group IIE with Me-indoxam
5WZO	;	1.9	;	Crystal structure of human secreted phospholipase A2 group IIE, crystallized with calcium
3PBB	;	1.95	;	Crystal structure of human secretory glutaminyl cyclase in complex with PBD150
3A3A	;	3.1	;	Crystal structure of human selenocystine tRNA
3FD6	;	1.95	;	Crystal structure of human selenophosphate synthetase 1 complex with ADP and phosphate
3FD5	;	1.9	;	Crystal structure of human selenophosphate synthetase 1 complex with AMPCP
1N76	;	3.4	;	CRYSTAL STRUCTURE OF HUMAN SEMINAL LACTOFERRIN AT 3.4 A RESOLUTION
3IX0	;	2.3	;	Crystal structure of human seminal plasma protein PSP94
3G4H	;	1.92	;	Crystal structure of Human Senescence Marker Protein-30 (Zinc Bound)
3G4E	;	1.42	;	Crystal structure of human senescence marker protein-30(SMP30)(Calcium bound)
2G4D	;	2.8	;	Crystal structure of human SENP1 mutant (C603S) in complex with SUMO-1
2XPH	;	2.4	;	Crystal structure of human SENP1 with the bound cobalt
2IO0	;	2.3	;	Crystal structure of human Senp2 in complex with preSUMO-2
2IO1	;	2.6	;	Crystal structure of human Senp2 in complex with preSUMO-3
2IO2	;	2.9	;	Crystal structure of human Senp2 in complex with RanGAP1-SUMO-1
2IO3	;	3.2	;	Crystal structure of human Senp2 in complex with RanGAP1-SUMO-2
4XWY	;	2.35	;	Crystal structure of human sepiapterin reductase in complex with an N-acetylserotinin analogue
1Z6Z	;	2.5	;	Crystal Structure of Human Sepiapterin Reductase in complex with NADP+
4HWK	;	2.4	;	Crystal structure of human sepiapterin reductase in complex with sulfapyridine
4J7X	;	2.6	;	Crystal structure of human sepiapterin reductase in complex with sulfasalazine
4J7U	;	2.44	;	Crystal structure of human sepiapterin reductase in complex with sulfathiazole
3SOP	;	2.885	;	Crystal Structure Of Human Septin 3 GTPase Domain
3TW4	;	3.35	;	Crystal Structure of Human Septin 7 GTPase Domain
2QAG	;	4.0	;	Crystal structure of human septin trimer 2/6/7
4I41	;	2.7	;	Crystal Structure of human Ser/Thr kinase Pim1 in complex with mitoxantrone
5X2L	;	1.806	;	Crystal Structure of Human Serine Racemase
7NBF	;	1.6	;	Crystal structure of human serine racemase in complex with DSiP fragment Z126932614, XChem fragment screen.
7NBD	;	1.865	;	Crystal structure of human serine racemase in complex with DSiP fragment Z235449082, XChem fragment screen.
7NBH	;	1.77	;	Crystal structure of human serine racemase in complex with DSiP fragment Z26781964, XChem fragment screen.
7NBC	;	1.71	;	Crystal structure of human serine racemase in complex with DSiP fragment Z2856434779, XChem fragment screen.
7NBG	;	1.53	;	Crystal structure of human serine racemase in complex with DSiP fragment Z52314092, XChem fragment screen.
4AOT	;	2.33	;	Crystal Structure of Human Serine Threonine Kinase-10 (LOK) Bound to GW830263A
4BC6	;	2.2	;	Crystal structure of human serine threonine kinase-10 bound to novel Bosutinib Isoform 1, previously thought to be Bosutinib
2J7T	;	2.0	;	Crystal structure of human serine threonine kinase-10 bound to SU11274
3LM0	;	2.35	;	Crystal Structure of human Serine/Threonine Kinase 17B (STK17B)
3LM5	;	2.29	;	Crystal Structure of human Serine/Threonine Kinase 17B (STK17B) in complex with Quercetin
1F3M	;	2.3	;	CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1
4FR4	;	2.29	;	Crystal structure of human serine/threonine-protein kinase 32A (YANK1)
3GGF	;	2.35	;	Crystal structure of human Serine/threonine-protein kinase MST4 in complex with an quinazolin
4GA7	;	2.9	;	Crystal structure of human serpinB1 mutant
1AO6	;	2.5	;	CRYSTAL STRUCTURE OF HUMAN SERUM ALBUMIN
1BM0	;	2.5	;	CRYSTAL STRUCTURE OF HUMAN SERUM ALBUMIN
1E78	;	2.6	;	Crystal structure of human serum albumin
6YG9	;	1.89	;	CRYSTAL STRUCTURE OF HUMAN SERUM ALBUMIN (HSA) IN COMPLEX WITH GN-07.
7DL4	;	2.4	;	Crystal structure of human serum albumin and nitrosylruthenium complex adduct
8H0O	;	2.479	;	Crystal structure of human serum albumin and ruthenium PZA complex adduct
7VR9	;	2.3	;	Crystal structure of human serum albumin complex with aripiprazole and myristic acid
6WUW	;	2.2	;	Crystal structure of Human Serum Albumin complex with JMS-053
3JQZ	;	3.3	;	Crystal Structure of Human serum albumin complexed with Lidocaine
3CX9	;	2.8	;	Crystal Structure of Human serum albumin complexed with Myristic acid and lysophosphatidylethanolamine
1E7B	;	2.38	;	Crystal structure of human serum albumin complexed with the general anesthetic halothane
1E7A	;	2.2	;	Crystal structure of human serum albumin complexed with the general anesthetic propofol
6JE7	;	3.9	;	Crystal structure of human serum albumin crystallized by ammonium sulfate
8CKS	;	2.6	;	Crystal structure of Human Serum Albumin in complex with FESAN
7QFE	;	2.2	;	Crystal structure of Human Serum albumin in complex with Gemfibrozil
7JWN	;	2.6	;	Crystal structure of Human Serum Albumin in complex with ketoprofen
7AAE	;	2.27	;	Crystal structure of Human serum albumin in complex with myristic acid at 2.27 Angstrom Resolution
7AAI	;	2.1	;	Crystal structure of Human serum albumin in complex with perfluorooctanoic acid (PFOA) at 2.10 Angstrom Resolution
5ID7	;	2.26	;	Crystal structure of human serum albumin in complex with phosphorodithioate derivative of myristoyl cyclic phosphatidic acid (cPA)
7Z57	;	2.2	;	Crystal structure of Human Serum Albumin in complex with surfactant GenX (2,3,3,3-tetrafluoro-2-(heptafluoropropoxy) propanoate)
6ZL1	;	3.272	;	Crystal structure of human serum albumin in complex with the MCL-1 neutralizing Alphabody CMPX-383B
5IJF	;	2.65	;	Crystal structure of Human Serum Albumin in the presence of 0.5 mM zinc at pH 9.0
1N7W	;	2.2	;	Crystal Structure of Human Serum Transferrin, N-Lobe L66W mutant
6CBX	;	1.94	;	Crystal structure of human SET and MYND Domain Containing protein 2 with MTF1497
6CBY	;	2.55	;	Crystal structure of human SET and MYND Domain Containing protein 2 with MTF9975
3SMT	;	2.04	;	Crystal structure of human SET domain-containing protein3
5V22	;	2.4	;	Crystal structure of human SETD2 SET-domain in complex with H3K36M peptide and SAH
5V21	;	2.415	;	Crystal structure of human SETD2 SET-domain in complex with H3K36M peptide and SAM
7P0V	;	1.56	;	Crystal structure of human SF3A1 ubiquitin-like domain in complex with U1 snRNA stem-loop 4
7SP0	;	1.83	;	Crystal structure of human SFPQ L534I mutant in complex with zinc
6WMZ	;	2.85	;	Crystal structure of human SFPQ/NONO complex
7LRQ	;	2.3	;	Crystal structure of human SFPQ/NONO heterodimer, conserved DBHS region
3NR8	;	2.8	;	Crystal structure of human SHIP2
6SRR	;	2.45	;	Crystal structure of human SHIP2 catalytic domain
6SQU	;	2.27	;	Crystal structure of human SHIP2 catalytic domain in complex with 1,2,4 Dimer
4A9C	;	2.1	;	Crystal structure of human SHIP2 in complex with biphenyl 2,3',4,5',6- pentakisphosphate
5OKM	;	1.96	;	Crystal structure of human SHIP2 Phosphatase-C2
5OKN	;	2.65	;	Crystal structure of human SHIP2 Phosphatase-C2 D607A mutant
5OKO	;	1.94	;	Crystal structure of human SHIP2 Phosphatase-C2 double mutant F593D/L597D
5OKP	;	1.85	;	Crystal structure of human SHIP2 Phosphatase-C2 double mutant F593D/L597D
6WWA	;	3.8	;	Crystal structure of human SHLD2-SHLD3-REV7 complex
6KTO	;	3.44976	;	Crystal structure of human SHLD3-C-REV7-O-REV7-SHLD2 complex
7T7A	;	1.79	;	Crystal Structure of Human SHOC2: A Leucine-Rich Repeat Protein
2VIG	;	1.9	;	Crystal structure of human short-chain acyl CoA dehydrogenase
7Y0A	;	2.317	;	Crystal structure of human short-chain acyl-CoA dehydrogenase
7Y0B	;	2.076	;	Crystal structure of human short-chain acyl-CoA dehydrogenase
5DY4	;	1.77	;	Crystal structure of human Sirt2 in complex with a brominated 2nd generation SirReal inhibitor and NAD+
5DY5	;	1.95	;	Crystal structure of human Sirt2 in complex with a SirReal probe fragment
8OWZ	;	1.65	;	Crystal structure of human Sirt2 in complex with a triazole-based SirReal
5D7Q	;	2.01	;	Crystal structure of human Sirt2 in complex with ADPR and CHIC35
5D7P	;	1.76	;	Crystal structure of human Sirt2 in complex with ADPR and EX-243
3GLS	;	2.7	;	Crystal Structure of Human SIRT3
5D7N	;	1.83	;	Crystal structure of human Sirt3 at an improved resolution
8BBK	;	3.27	;	Crystal structure of human Sirt3 in complex with a fragment of the human AROS protein
5BWO	;	2.376	;	Crystal Structure of Human SIRT3 in Complex with a Palmitoyl H3K9 Peptide
8CCW	;	1.65	;	Crystal structure of human Sirt3 in complex with an acetylated HIV1 Tat-46-54 substrate peptide
8CCZ	;	1.95	;	Crystal structure of human Sirt3 in complex with an inhibiting HIV1 Tat-37-59 peptide
4O8Z	;	2.0	;	Crystal structure of human SIRT3 in complex with compound (2-butylbenzofuran-3-yl)(4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl)methanone
4HD8	;	2.3	;	Crystal structure of human Sirt3 in complex with Fluor-de-Lys peptide and piceatannol
4BVG	;	2.5	;	CRYSTAL STRUCTURE OF HUMAN SIRT3 IN COMPLEX WITH NATIVE ALKYLIMIDATE FORMED FROM ACETYL-LYSINE ACS2-PEPTIDE CRYSTALLIZED IN PRESENCE OF THE INHIBITOR EX-527
4BVH	;	1.9	;	CRYSTAL STRUCTURE OF HUMAN SIRT3 IN COMPLEX WITH THE INHIBITOR EX-527 AND 2'-O-ACETYL-ADP-RIBOSE
4BVB	;	2.0	;	CRYSTAL STRUCTURE OF HUMAN SIRT3 IN COMPLEX WITH THE INHIBITOR EX-527 AND ADP-RIBOSE
4BVE	;	2.05	;	CRYSTAL STRUCTURE OF HUMAN SIRT3 IN COMPLEX WITH THIOALKYLIMIDATE FORMED FROM THIO-ACETYL-LYSINE ACS2-PEPTIDE
4BVF	;	2.7	;	CRYSTAL STRUCTURE OF HUMAN SIRT3 IN COMPLEX WITH THIOALKYLIMIDATE FORMED FROM THIO-ACETYL-LYSINE ACS2-PEPTIDE CRYSTALLIZED IN PRESENCE OF THE INHIBITOR EX-527
3GLU	;	2.5	;	Crystal Structure of Human SIRT3 with AceCS2 peptide
3GLR	;	1.8	;	Crystal Structure of human SIRT3 with acetyl-lysine AceCS2 peptide
3GLT	;	2.1	;	Crystal Structure of Human SIRT3 with ADPR bound to the AceCS2 peptide containing a thioacetyl lysine
4JSR	;	1.7	;	Crystal Structure of human SIRT3 with ELT inhibitor 11c [N-{2-[1-(6-carbamoylthieno[3,2-d]pyrimidin-4-yl)piperidin-4-yl]ethyl}-N'-ethylthiophene-2,5-dicarboxamide]
4JT8	;	2.26	;	Crystal Structure of human SIRT3 with ELT inhibitor 28 [4-(4-{2-[(2,2-dimethylpropanoyl)amino]ethyl}piperidin-1-yl)thieno[3,2-d]pyrimidine-6-carboxamide[
4JT9	;	2.24	;	Crystal Structure of human SIRT3 with ELT inhibitor 3 [14-(4-{2-[(methylsulfonyl)amino]ethyl}piperidin-1-yl)thieno[3,2-d]pyrimidine-6-carboxamide]
6LJK	;	1.394	;	Crystal structure of human Sirt5 in complex with an internally quenched fluorescent substrate GluIQF
7X3P	;	1.56	;	Crystal structure of human SIRT5 in complex with diazirine inhibitor 9
4HDA	;	2.601	;	Crystal structure of human Sirt5 in complex with Fluor-de-Lys peptide and resveratrol
6LJM	;	1.78	;	Crystal structure of human Sirt5 in complex with the fluorogenic tetrapeptide substrate P13
6LJN	;	1.8	;	Crystal structure of human Sirt5 in complex with the fluorogenic tetrapeptide substrate P15
3K35	;	2.0	;	Crystal Structure of Human SIRT6
7CL0	;	2.53	;	Crystal structure of human SIRT6
5Y5N	;	2.3	;	Crystal structure of human Sirtuin 2 in complex with a selective inhibitor
2B4Y	;	1.9	;	Crystal Structure of Human Sirtuin homolog 5
2NYR	;	2.06	;	Crystal Structure of Human Sirtuin Homolog 5 in Complex with Suramin
4RCW	;	3.1925	;	Crystal structure of human Slitrk1
7BU5	;	1.8	;	Crystal Structure of Human SLX4 and MUS81
5ZOK	;	2.85	;	Crystal structure of human SMAD1-MAN1 complex.
5ZOJ	;	2.794	;	Crystal structure of human SMAD2-MAN1 complex
5XOD	;	1.851	;	Crystal structure of human Smad2-Ski complex
5XOC	;	2.4	;	Crystal structure of human Smad3-FoxH1 complex
3PGL	;	2.35	;	Crystal structure of human small C-terminal domain phosphatase 1 (Scp1) bound to rabeprazole
1T91	;	1.9	;	crystal structure of human small GTPase Rab7(GTP)
3FAU	;	1.9	;	Crystal Structure of human small-MutS related domain
6WG6	;	3.54	;	Crystal structure of human SMC1-SMC3 hinge domain heterodimer in north-open conformation
6WG4	;	2.31	;	Crystal structure of human SMC1-SMC3 hinge domain heterodimer in south-open conformation
4GLI	;	1.903	;	Crystal Structure of Human SMN YG-Dimer
3PYC	;	1.96	;	Crystal structure of human SMURF1 C2 domain
6MON	;	2.711	;	Crystal structure of human SMYD2 in complex with Nle-peptide inhibitor
5EX0	;	2.7	;	Crystal structure of human SMYD3 in complex with a MAP3K2 peptide
5EX3	;	2.408	;	Crystal structure of human SMYD3 in complex with a VEGFR1 peptide
7V6P	;	2.9	;	Crystal structure of human sNASP TPR domain
5M9O	;	1.45	;	Crystal structure of human SND1 extended Tudor domain in complex with a symmetrically dimethylated E2F peptide
4PQP	;	3.0	;	Crystal structure of human SNX14 PX domain in space group P43212
4OYW	;	1.7	;	Crystal Structure of Human Soluble Adenylate Cyclase
4CLF	;	1.7	;	Crystal structure of human soluble Adenylyl Cyclase (Apo form)
8CO7	;	1.9	;	Crystal structure of human soluble adenylyl cyclase (sAC) in complex with inhibitor TDI-09066
8CNH	;	2.0	;	Crystal structure of human soluble adenylyl cyclase (sAC) in complex with inhibitor TDI-10512
8COJ	;	2.1	;	Crystal structure of human soluble adenylyl cyclase catalytic domain in complex with the inhibitor TDI-10228
4CLP	;	1.9	;	Crystal structure of human soluble Adenylyl Cyclase complex with adenosine-3',5'-cyclic-monophosphate
4CLK	;	2.2	;	Crystal structure of human soluble Adenylyl Cyclase in complex with alpha,beta-methyleneadenosine-5'-triphosphate
4USU	;	1.95	;	Crystal structure of human soluble Adenylyl Cyclase in complex with alpha,beta-methyleneadenosine-5'-triphosphate
5IV3	;	1.86	;	Crystal structure of human soluble adenylyl cyclase in complex with alpha,beta-methyleneadenosine-5'-triphosphate and the allosteric inhibitor LRE1
4CLW	;	2.15	;	Crystal structure of human soluble Adenylyl Cyclase in complex with alpha,beta-methyleneadenosine-5'-triphosphate soaked with bisulfite
4CLL	;	1.7	;	Crystal structure of human soluble Adenylyl Cyclase in complex with bicarbonate
8B75	;	1.82	;	CRYSTAL STRUCTURE OF HUMAN SOLUBLE ADENYLYL CYCLASE IN COMPLEX WITH THE INHIBITOR TDI-011861
4CLY	;	2.05	;	Crystal structure of human soluble Adenylyl Cyclase soaked with biselenite
4CM2	;	1.8	;	Crystal structure of human soluble Adenylyl Cyclase soaked with bisulfite
4CLT	;	1.95	;	Crystal structure of human soluble Adenylyl Cyclase with adenosine-3', 5'-cyclic-monophosphate and pyrophosphate
4CM0	;	3.2	;	Crystal structure of human soluble Adenylyl Cyclase with alpha,beta- methyleneadenosine-5'-triphosphate soaked with bicarbonate
4USW	;	2.05	;	Crystal structure of human soluble Adenylyl Cyclase with ATP
4CLZ	;	1.9	;	Crystal structure of human soluble Adenylyl Cyclase with Inhibitor 4, 4'-Diisothiocyano-2,2'-stilbenedisulfonic acid
4CLS	;	1.85	;	Crystal structure of human soluble Adenylyl Cyclase with Pyrophosphate
4CLU	;	1.9	;	Crystal structure of human soluble Adenylyl Cyclase with pyrophosphate
4USV	;	2.0	;	Crystal structure of human soluble Adenylyl Cyclase with pyrophosphate resulting from soaking with ATP and Calcium
4UST	;	1.9	;	Crystal structure of human soluble Adenylyl Cyclase with pyrophosphate resulting from soaking with GTP and Magnesium
5D0R	;	2.24	;	Crystal structure of human soluble Adenylyl Cyclase with the inhibitor bithionol
2H2N	;	2.3	;	Crystal structure of human soluble calcium-activated nucleotidase (SCAN) with calcium ion
6I3C	;	1.336	;	Crystal structure of Human soluble catechol O-methyltransferase in complex with 3,5-dinitrocatechol and S-adensoyl-L-methionine
6I3D	;	1.45	;	Crystal structure of Human soluble catechol O-methyltransferase in complex with 3,5-dinitrocatechol and Sinefungin
7F8R	;	2.51	;	Crystal structure of human soluble CLIC1 with catalytic cysteine (Cys24) in sulphonic acid form.
4OCZ	;	2.94	;	Crystal structure of human soluble epoxide hydrolase complexed with 1-(1-isobutyrylpiperidin-4-yl)-3-(4-(trifluoromethyl)phenyl)urea
4OD0	;	2.92	;	Crystal structure of human soluble epoxide hydrolase complexed with 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea
4J03	;	2.92	;	Crystal structure of human soluble epoxide hydrolase complexed with fulvestrant
4HAI	;	2.55	;	Crystal structure of human soluble epoxide hydrolase complexed with N-cycloheptyl-1-(mesitylsulfonyl)piperidine-4-carboxamide.
6AUM	;	2.95	;	Crystal structure of human soluble epoxide hydrolase complexed with trans-4-[4-(3-trifluoromethoxyphenyl-l-ureido)-cyclohexyloxy]-benzoic acid.
3M1N	;	1.85	;	Crystal structure of Human Sonic Hedgehog N-terminal domain
4ON3	;	2.6	;	Crystal structure of human sorting nexin 10 (SNX10)
4PZG	;	2.8	;	Crystal structure of human sorting nexin 10 (SNX10)
4AKV	;	2.651	;	Crystal structure of human sorting nexin 33 (SNX33)
3R85	;	1.95	;	Crystal structure of human SOUL BH3 domain in complex with Bcl-xL
3R8K	;	2.85	;	Crystal structure of human SOUL protein (hexagonal form)
3R8J	;	1.6	;	Crystal structure of human SOUL protein (orthorhombic form)
6G5P	;	1.35	;	Crystal structure of human SP100 in complex with bromodomain-focused fragment FM009493b 2,3-Dimethoxy-2,3-dimethyl-2,3-dihydro-1,4-benzodioxin-6-amine
6G5N	;	1.765	;	Crystal structure of human SP100 in complex with bromodomain-focused fragment XS039818e 1-(3-Phenyl-1,2,4-oxadiazol-5-yl)methanamine
4PTB	;	1.6	;	Crystal structure of human SP100 PHD-Bromodomain in the free state
3H9E	;	1.72	;	Crystal structure of human sperm-specific glyceraldehyde-3-phosphate dehydrogenase (GAPDS) complex with NAD and phosphate
3PFW	;	2.15	;	Crystal structure of human sperm-specific glyceraldehyde-3-phosphate dehydrogenase (GAPDS) complex with NAD, a binary form
3RW9	;	2.0	;	Crystal Structure of human Spermidine Synthase in Complex with decarboxylated S-adenosylhomocysteine
2G3T	;	1.8	;	Crystal structure of human spermidine/spermine N1-acetyltransferase (hSSAT)
7OXL	;	2.4	;	Crystal structure of human Spermine Oxidase
3C6K	;	1.95	;	Crystal structure of human spermine synthase in complex with spermidine and 5-methylthioadenosine
3C6M	;	2.45	;	Crystal structure of human spermine synthase in complex with spermine and 5-methylthioadenosine
2JEV	;	2.3	;	Crystal structure of human spermine,spermidine acetyltransferase in complex with a bisubstrate analog (N1-acetylspermine-S-CoA).
8AYF	;	1.84	;	Crystal structure of human Sphingosine-1-phosphate lyase 1
4Q6R	;	2.4	;	Crystal structure of human sphingosine-1-phosphate lyase in complex with inhibitor 6-[(2R)-4-(4-benzyl-7-chlorophthalazin-1-yl)-2-methylpiperazin-1-yl]pyridine-3-carbonitrile
5LUG	;	1.7	;	Crystal structure of human Spindlin-2B protein in complex with ART(M3L)QTA(2MR)KS peptide
4MZF	;	2.098	;	Crystal structure of human Spindlin1 bound to histone H3(K4me3-R8me2a) peptide
4MZH	;	2.204	;	Crystal structure of human Spindlin1 bound to histone H3(K4me3-R8me2s) peptide
4MZG	;	1.698	;	Crystal structure of human Spindlin1 bound to histone H3K4me3 peptide
4H75	;	2.098	;	Crystal structure of human Spindlin1 in complex with a histone H3K4(me3) peptide
5Y5W	;	3.3	;	Crystal structure of human Spindlin1 in complex with a histone H4K20(me3) peptide
8GTX	;	1.8	;	Crystal Structure of human Spindlin1-HBx complex
5A1H	;	2.0	;	Crystal structure of human Spindlin3
3F2O	;	2.05	;	Crystal Structure of human splA/ryanodine receptor domain and SOCS box containing 1 (SPSB1) in complex with a 20-residue VASA peptide
3EMW	;	1.8	;	Crystal Structure of human splA/ryanodine receptor domain and SOCS box containing 2 (SPSB2) in complex with a 20-residue VASA peptide
3CW1	;	5.493	;	Crystal Structure of Human Spliceosomal U1 snRNP
3GIX	;	1.33	;	Crystal structure of human splicing factor dim2
4IN0	;	1.327	;	Crystal Structure of human splicing factor dim2/TXNL4B
5I7J	;	2.544	;	Crystal Structure of Human SPLUNC1 Disulfide Mutant M3 (I76C, V214C)
5I7K	;	2.552	;	Crystal Structure of Human SPLUNC1 Dolphin Mutant D1 (G58A, S61A, G62E, G63D, G66D, I67T)
4KGH	;	2.806	;	Crystal Structure of human splunc1 lacking the secretion signal sequence
2YYO	;	2.0	;	Crystal structure of human SPRY domain
6JKJ	;	1.9	;	Crystal structure of human SPSB2 in the apo-state
4Z2M	;	2.981	;	Crystal structure of human SPT16 Mid-AID/H3-H4 tetramer FACT Histone complex
5E5B	;	1.84	;	Crystal structure of Human Spt16 N-terminal domain
1EZF	;	2.15	;	CRYSTAL STRUCTURE OF HUMAN SQUALENE SYNTHASE
2ZV6	;	2.7	;	Crystal structure of human squamous cell carcinoma antigen 1
5MXX	;	1.75	;	Crystal structure of human SR protein kinase 1 (SRPK1) in complex with compound 1
4WUA	;	2.0	;	Crystal structure of human SRPK1 complexed to an inhibitor SRPIN340
6APJ	;	3.1	;	Crystal Structure of human ST6GALNAC2
6APL	;	2.35	;	Crystal Structure of human ST6GALNAC2 in complex with CMP
6B25	;	2.39	;	Crystal structure of human STAC1 Tandem SH3 Domains (288-402)
6B26	;	1.2	;	Crystal structure of human STAC2 Tandem SH3 Domains (296-411)
6B27	;	1.73	;	Crystal structure of human STAC2 Tandem SH3 Domains (296-411) in complex with a CaV1.1 II-III loop peptide
6B28	;	2.55	;	Crystal structure of human STAC2 Tandem SH3 Domains Q347I (296-411)
3LDZ	;	2.6	;	Crystal structure of human STAM1 VHS domain in complex with ubiquitin
6SER	;	2.299	;	Crystal structure of human STARD10
8D3F	;	2.97	;	Crystal structure of human STAT1 in complex with the repeat region from Toxoplasma protein TgIST
2JFL	;	2.2	;	CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE (DIPHOSPHORYLATED FORM) BOUND TO 5- AMINO-3-((4-(AMINOSULFONYL)PHENYL)AMINO)-N-(2,6- DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE
2JFM	;	2.85	;	CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE (UNLIGANDED FORM)
8A5J	;	2.123	;	Crystal structure of Human STE20-like kinase 1, MST1 in complex with compound XMU-MP-1
2UV2	;	2.3	;	Crystal Structure Of Human Ste20-Like Kinase Bound To 4-(4-(5- Cyclopropyl-1H-pyrazol-3-ylamino)-quinazolin-2-ylamino)-phenyl)- acetonitrile
2J51	;	2.1	;	Crystal structure of Human STE20-like kinase bound to 5-Amino-3-((4-(aminosulfonyl)phenyl)amino) -N-(2,6-difluorophenyl)-1H-1,2,4-triazole- 1-carbothioamide
8SLS	;	1.71	;	Crystal structure of human STEP (PTPN5) at cryogenic temperature (100 K) and ambient pressure (0.1 MPa)
8SLU	;	1.84	;	Crystal structure of human STEP (PTPN5) at cryogenic temperature (100 K) and high pressure (205 MPa)
8SLT	;	1.96	;	Crystal structure of human STEP (PTPN5) at physiological temperature (310 K) and ambient pressure (0.1 MPa)
6Z1W	;	2.48	;	Crystal structure of human steroid carrier protein SL (SCP-2L) mutant A100C
6Z1X	;	2.09	;	Crystal structure of human steroid carrier protein SL (SCP-2L) mutant V83C
8SBI	;	2.73	;	Crystal structure of human sterol 14 alpha-demethylase (CYP51) in the ligand-free state
6MX3	;	1.362	;	Crystal structure of human STING (G230A, H232R, R293Q) in complex with Compound 1
6MXE	;	2.47	;	Crystal structure of human STING (G230A, H232R, R293Q) in complex with Compound 18
6MX0	;	1.73	;	Crystal structure of human STING apoprotein (G230A, H232R, R293Q)
4EMT	;	1.5	;	Crystal Structure of human STING bound to c-di-GMP
7X9Q	;	2.4	;	Crystal structure of human STING complexed with compound BSP16
7X9P	;	2.7	;	Crystal structure of human STING complexed with compound BSP17
4F5Y	;	2.396	;	Crystal structure of human STING CTD complex with C-di-GMP
6XNP	;	1.77	;	Crystal Structure of Human STING CTD complex with SR-717
8P01	;	2.094	;	Crystal structure of human STING ectodomain in complex with BI 7446, a potent cyclic dinucleotide STING agonist with broad-spectrum variant activity for the treatment of cancer
7ZXB	;	3.0	;	Crystal structure of human STING in complex with 3',3'-c-(2'dAMP-2'F,2'd<carba>AMP)
8A2X	;	3.0	;	Crystal structure of human STING in complex with 3',3'-c-(2'F,2'dAMP(S)-2'F,2'd<carba>AMP(S))
7ZKU	;	1.7	;	Crystal structure of human STING in complex with 3',3'-c-(2'F,2'dAMP-2'd<carba>GMP)
7ZV0	;	2.31	;	Crystal structure of human STING in complex with 3',3'-c-(2'F,2'dAMP-2'F,2'd<carba>AMP)
7ZVK	;	2.83	;	Crystal structure of human STING in complex with 3',3'-c-(2'F,2'dAMP-<carba>IMP)
7ZWL	;	2.0	;	Crystal structure of human STING in complex with 3',3'-c-di-(2'F,2'd<carba>AMP)
5BQX	;	2.0	;	Crystal structure of human STING in complex with 3'2'-cGAMP
7Q3B	;	2.55734	;	Crystal structure of human STING in complex with 3'3'-c-(2'F,2'dA-isonucA)MP
8B2J	;	2.174	;	Crystal structure of human STING in complex with ADU-S100
7Q85	;	2.359	;	Crystal structure of human STING in complex with MD1193
8P45	;	3.23	;	Crystal structure of human STING in complex with the agonist MD1202D
8ORW	;	2.95	;	Crystal structure of human STING in complex with the agonist MD1203
7SSM	;	1.96	;	Crystal structure of human STING R232 in complex with compound 11
4N6J	;	2.001	;	Crystal structure of human Striatin-3 coiled coil domain
4PJU	;	3.05	;	crystal structure of human Stromal Antigen 2 (SA2) in complex with Sister Chromatid Cohesion protein 1 (Scc1)
4PK7	;	2.95	;	crystal structure of human Stromal Antigen 2 (SA2) in complex with Sister Chromatid Cohesion protein 1 (Scc1) with bound MES, native proteins
4PJW	;	2.85	;	crystal structure of human Stromal Antigen 2 (SA2) in complex with Sister Chromatid Cohesion protein 1 (Scc1), with bound MES
6THA	;	2.4	;	Crystal structure of human sugar transporter GLUT1 (SLC2A1) in the inward conformation
6OI5	;	2.811	;	Crystal structure of human Sulfide Quinone Oxidoreductase
6OIB	;	2.03	;	Crystal structure of human Sulfide Quinone Oxidoreductase in complex with coenzyme Q
6WH6	;	2.25	;	Crystal structure of human sulfide quinone oxidoreductase in complex with coenzyme Q (cyanide soaked)
6OI6	;	2.56	;	Crystal structure of human Sulfide Quinone Oxidoreductase in complex with coenzyme Q (sulfide soaked)
6OIC	;	2.21	;	Crystal structure of human Sulfide Quinone Oxidoreductase in complex with coenzyme Q (sulfite soaked)
8DHK	;	2.3	;	Crystal structure of human Sulfide Quinone Oxidoreductase K207E
1XW3	;	1.65	;	Crystal Structure of Human Sulfiredoxin (Srx)
1XW4	;	2.0	;	Crystal Structure of Human Sulfiredoxin (Srx) in Complex with ADP
3CYI	;	1.8	;	Crystal Structure of Human Sulfiredoxin (Srx) in Complex with ATP:Mg2+
2REO	;	2.651	;	Crystal structure of human sulfotransferase 1C3 (Sult1C3) in complex with PAP
2A3R	;	2.6	;	Crystal Structure of Human Sulfotransferase SULT1A3 in Complex with Dopamine and 3-Phosphoadenosine 5-Phosphate
3BFX	;	1.8	;	Crystal structure of human sulfotransferase SULT1C1 in complex with PAP
3U3M	;	2.3	;	Crystal structure of Human SULT1A1 bound to PAP and 3-Cyano-7-hydroxycoumarin
3U3O	;	2.0	;	Crystal structure of Human SULT1A1 bound to PAP and two 3-Cyano-7-hydroxycoumarin
5FQ2	;	2.201	;	Crystal structure of human SUMO E1 UFD domain in complex with Ubc9 in a P422 space group.
4W5V	;	2.5	;	Crystal structure of Human SUMO E2-conjugating enzyme (Ubc9) in complex with E1-activating enzyme (Uba2) ubiquitin fold domain (Ufd)
1WM2	;	1.6	;	Crystal structure of human SUMO-2 protein
1WM3	;	1.2	;	Crystal structure of human SUMO-2 protein
7XX3	;	1.9	;	Crystal structure of human Superoxide Dismutase (SOD1) in complex with a fungal metabolite molecule, Phialomustin B (PB)
5YTO	;	1.9	;	Crystal Structure of human Superoxide Dismutase I (hSOD1) in complex with a napthalene-catechol linked compound.
4KM9	;	3.19	;	Crystal structure of human Suppressor of Fused
3UEF	;	2.45	;	Crystal structure of human Survivin bound to histone H3 (C2 space group).
3UED	;	2.7	;	Crystal structure of human Survivin bound to histone H3 phosphorylated on threonine-3 (C2 space group).
3UEC	;	2.18	;	Crystal structure of human Survivin bound to histone H3 phosphorylated on threonine-3.
7LBO	;	2.5	;	Crystal structure of human Survivin bound to histone H3 T3phK4me1 peptide
7LBQ	;	2.69	;	Crystal structure of human Survivin bound to histone H3 T3phK4me2 peptide
7LBK	;	2.7	;	Crystal structure of human Survivin bound to histone H3 T3phK4me3 peptide
7LBP	;	2.6	;	Crystal structure of human Survivin bound to histone H3T3phK4ac peptide
3UEI	;	2.7	;	Crystal structure of human Survivin E65A mutant
3UEH	;	2.6	;	Crystal structure of human Survivin H80A mutant
3UII	;	2.6	;	crystal structure of human Survivin in complex with H3(1-10) peptide
3UIH	;	2.4	;	crystal structure of human Survivin in complex with Smac/DIABLO(1-15) peptide
3UIG	;	2.4	;	crystal structure of human Survivin in complex with T3 phosphorylated H3(1-15) peptide
3UEG	;	2.8	;	Crystal structure of human Survivin K62A mutant
3UEE	;	2.61	;	Crystal structure of human Survivin K62A mutant bound to N-terminal histone H3
3UIJ	;	2.705	;	Crystal structure of human Survivin K62Y/H80W mutant in complex with Smac/DIABLO(1-15) peptide
3UIK	;	2.701	;	crystal structure of human Survivin mutant K62Y/H80W in complex with H3(1-10) peptide
7W1R	;	3.2	;	Crystal structure of human Suv3 monomer
4A27	;	2.1	;	Crystal structure of human synaptic vesicle membrane protein VAT-1 homolog-like protein
4CPC	;	2.24	;	Crystal structure of human synaptonemal complex protein SYCP3
6TZ3	;	1.17	;	Crystal Structure of Human Synaptotagmin 1 C2B without Ca2+
5H4Y	;	1.9	;	Crystal structure of human synaptotagmin 5 C2A domain
6RX1	;	2.1	;	Crystal structure of human syncytin 1 in post-fusion conformation
6RX3	;	2.2	;	Crystal structure of human syncytin 2 in post-fusion conformation
5HA6	;	2.0006	;	Crystal structure of human syncytin-1 fusion subunit
5DZO	;	1.301	;	Crystal structure of human T-cell immunoglobulin and mucin domain protein 1
2B7F	;	2.6	;	Crystal structure of human T-cell leukemia virus protease, a novel target for anti-cancer design
1WSR	;	2.0	;	Crystal Structure of Human T-protein of Glycine Cleavage System
1WSV	;	2.6	;	Crystal Structure of Human T-protein of Glycine Cleavage System
8AM0	;	2.818	;	Crystal structure of human T1061E PI3Kalpha in complex with its regulatory subunit and the inhibitor GDC-0077 (Inavolisib)
5UJI	;	2.79	;	Crystal structure of human T2-Tryptophanyl-tRNA synthetase with H130R mutation
8GW3	;	2.05	;	Crystal structure of human TAK1 kinase domain fused with TAB1
5JGB	;	2.8	;	Crystal structure of human TAK1/TAB1 fusion protein in complex with ligand 10
5JGA	;	2.0	;	Crystal structure of human TAK1/TAB1 fusion protein in complex with ligand 11c
5JGD	;	3.101	;	Crystal structure of human TAK1/TAB1 fusion protein in complex with ligand 12
5GJD	;	2.79	;	Crystal structure of human TAK1/TAB1 fusion protein in complex with ligand 2
5GJF	;	2.89	;	Crystal structure of human TAK1/TAB1 fusion protein in complex with ligand 3
5GJG	;	2.61	;	Crystal structure of human TAK1/TAB1 fusion protein in complex with ligand 4
2RF5	;	2.3	;	Crystal structure of human tankyrase 1- catalytic PARP domain
3U9Y	;	2.3	;	Crystal structure of human tankyrase 2 catalytic domain in complex with olaparib
4BUU	;	1.6	;	Crystal structure of human tankyrase 2 in complex with (4-(4-oxo-3,4- dihydroquinazolin-2-yl)phenyl)methanesulfonamide
4PNT	;	1.6	;	Crystal Structure of human Tankyrase 2 in complex with 1,5-IQD.
4UVU	;	1.95	;	Crystal structure of human tankyrase 2 in complex with 1-((4-(5- methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)phenyl)methyl)pyrrolidin-1- ium
4UX4	;	1.8	;	Crystal structure of human tankyrase 2 in complex with 1-methyl-7-(4- methylphenyl)-5-oxo-5,6-dihydro-1,6-naphthyridin-1-ium
4W5I	;	1.95	;	Crystal structure of human tankyrase 2 in complex with 1-methyl-7-phenyl-1,2,3,4,5,6-hexahydro-1,6- naphthyridin-5-one
4BUF	;	2.5	;	Crystal structure of human tankyrase 2 in complex with 2-(4- acetylphenyl)-3,4-dihydroquinazolin-4-one
4BU6	;	1.8	;	Crystal structure of human tankyrase 2 in complex with 2-(4- aminophenyl)-3,4-dihydroquinazolin-4-one
4BU7	;	2.05	;	Crystal structure of human tankyrase 2 in complex with 2-(4- bromophenyl)-3,4-dihydroquinazolin-4-one
4BU5	;	1.8	;	Crystal structure of human tankyrase 2 in complex with 2-(4- hydroxyphenyl)-3,4-dihydroquinazolin-4-one
4BU9	;	1.65	;	Crystal structure of human tankyrase 2 in complex with 2-(4- methoxyphenyl)-3,4-dihydroquinazolin-4-one
4BUW	;	1.85	;	Crystal structure of human tankyrase 2 in complex with 2-(4-(2-oxo-1, 3-oxazolidin-3-yl)phenyl)-3,4-dihydroquinazolin-4-one
4BUS	;	1.9	;	Crystal structure of human tankyrase 2 in complex with 2-(4-(4-oxo-3, 4-dihydroquinazolin-2-yl)phenoxy)acetic acid
4BUA	;	1.85	;	Crystal structure of human tankyrase 2 in complex with 2-(4-(methylsulfanyl)phenyl)-3,4-dihydroquinazolin-4-one
4BUD	;	2.5	;	Crystal structure of human tankyrase 2 in complex with 2-(4-tert- butylphenyl)-1,4-dihydroquinazolin-4-one
4BU3	;	2.15	;	Crystal structure of human tankyrase 2 in complex with 2-phenyl-3,4- dihydroquinazolin-4-one
4TJU	;	1.57	;	Crystal Structure of human Tankyrase 2 in complex with 3,4-CPQ-5-C.
4BUX	;	1.95	;	Crystal structure of human tankyrase 2 in complex with 3-((4-(4-oxo-3, 4-dihydroquinazolin-2-yl)phenyl)methyl)imidazolidine-2,4-dione
4UVX	;	1.95	;	Crystal structure of human tankyrase 2 in complex with 3-(4- chlorophenyl)-5-fluoro-1,2-dihydroisoquinolin-1-one
4UVY	;	1.95	;	Crystal structure of human tankyrase 2 in complex with 3-(4- chlorophenyl)-5-methoxy-1,2- dihydroisoquinolin-1-one
4UVV	;	1.9	;	Crystal structure of human tankyrase 2 in complex with 3-(4- chlorophenyl)-5-methyl-1,2-dihydroisoquinolin-1-one
4PML	;	1.87	;	Crystal Structure of human Tankyrase 2 in complex with 3-amino-benzamide.
4BUE	;	1.6	;	Crystal structure of human tankyrase 2 in complex with 3-methyl-N-(4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)butanamide
4KZU	;	2.1	;	Crystal structure of human tankyrase 2 in complex with 4' -bromo flavone
4KZQ	;	2.25	;	Crystal structure of human tankyrase 2 in complex with 4' -hydroxy flavone
4KZL	;	2.0	;	Crystal structure of human tankyrase 2 in complex with 4'-fluoro flavone
4BS4	;	1.89	;	Crystal structure of human tankyrase 2 in complex with 4'-isopropylflavone
4UVW	;	2.1	;	Crystal structure of human tankyrase 2 in complex with 4,5-dimethyl-3- phenyl-1,2-dihydroisoquinolin-1-one
4BU8	;	1.85	;	Crystal structure of human tankyrase 2 in complex with 4-(4-oxo-1,4- dihydroquinazolin-2-yl)benzonitrile
4BUT	;	1.9	;	Crystal structure of human tankyrase 2 in complex with 4-(4-oxo-3,4- dihydroquinazolin-2-yl)benzene-1-sulfonamide
4L09	;	2.05	;	Crystal structure of human tankyrase 2 in complex with 4-(4-oxo-4H-chromen-2-yl)benzoic acid
4PNN	;	1.65	;	Crystal Structure of human Tankyrase 2 in complex with 4HQN.
4UVL	;	2.0	;	Crystal structure of human tankyrase 2 in complex with 5-amino-1,2- dihydroisoquinolin-1-one
4UVP	;	1.75	;	Crystal structure of human tankyrase 2 in complex with 5-amino-3- ethyl-1,2-dihydroisoquinolin-1-one
4UVS	;	2.0	;	Crystal structure of human tankyrase 2 in complex with 5-amino-3- pentyl-1,2-dihydroisoquinolin-1-one
4UVZ	;	1.6	;	Crystal structure of human tankyrase 2 in complex with 5-amino-3- phenyl-1,2-dihydroisoquinolin-1-one
4UVN	;	2.2	;	Crystal structure of human tankyrase 2 in complex with 5-amino-3-(4- chlorophenyl)-1,2-dihydroisoquinolin-1-one
4UVO	;	1.85	;	Crystal structure of human tankyrase 2 in complex with 5-amino-3-(4- methoxyphenyl)-1,2-dihydroisoquinolin-1-one
4UVT	;	1.95	;	Crystal structure of human tankyrase 2 in complex with 5-amino-4- methyl-1,2-dihydroisoquinolin-1-one
4BUY	;	1.9	;	Crystal structure of human tankyrase 2 in complex with 5-methyl-5-(4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)imidazolidine-2,4-dione
4PNQ	;	1.85	;	Crystal Structure of human Tankyrase 2 in complex with 5AIQ.
4AVU	;	2.4	;	Crystal structure of human tankyrase 2 in complex with 6(5H)- phenanthridinone
3UA9	;	2.15	;	Crystal structure of human tankyrase 2 in complex with a selective inhibitor
4TJY	;	1.9	;	Crystal Structure of human Tankyrase 2 in complex with ABT-888.
4TKG	;	1.95	;	Crystal Structure of human Tankyrase 2 in complex with AZD2281.
4TKI	;	2.15	;	Crystal Structure of human Tankyrase 2 in complex with BSI-201.
4TK0	;	1.65	;	Crystal Structure of human Tankyrase 2 in complex with DPQ.
4BJ9	;	2.05	;	Crystal structure of human tankyrase 2 in complex with EB-47
4TK5	;	2.02	;	Crystal Structure of human Tankyrase 2 in complex with EB47.
4PNS	;	1.65	;	Crystal Structure of human Tankyrase 2 in complex with INH2BP.
4TKF	;	2.6	;	Crystal Structure of human Tankyrase 2 in complex with IWR-1.
5ADQ	;	2.1	;	Crystal structure of human tankyrase 2 in complex with JW55
4BUI	;	1.95	;	Crystal structure of human tankyrase 2 in complex with methyl 4-(4- oxo-3,4-dihydroquinazolin-2-yl)benzoate
4BUV	;	1.8	;	Crystal structure of human tankyrase 2 in complex with N-(4-(4-oxo-3, 4-dihydroquinazolin-2-yl)phenyl)thiophene-2-carboxamide
4PNM	;	2.19	;	Crystal Structure of human Tankyrase 2 in complex with Nu1025.
5AEH	;	1.85	;	Crystal structure of human tankyrase 2 in complex with OD332
5NOB	;	1.85	;	Crystal structure of human tankyrase 2 in complex with OD336
5ADR	;	2.1	;	Crystal structure of human tankyrase 2 in complex with OD38
5ADS	;	1.8	;	Crystal structure of human tankyrase 2 in complex with OD39
5ADT	;	2.15	;	Crystal structure of human tankyrase 2 in complex with OD73
4BJB	;	2.3	;	Crystal structure of human tankyrase 2 in complex with PJ-34
4TJW	;	1.7	;	Crystal Structure of human Tankyrase 2 in complex with PJ-34.
4BJC	;	2.2	;	Crystal structure of human tankyrase 2 in complex with Rucaparib
4UFU	;	2.1	;	Crystal structure of human tankyrase 2 in complex with TA-12
4UFY	;	1.7	;	Crystal structure of human tankyrase 2 in complex with TA-13
4UHG	;	1.7	;	Crystal structure of human tankyrase 2 in complex with TA-21
4UI3	;	2.0	;	Crystal structure of human tankyrase 2 in complex with TA-26
4UI4	;	2.4	;	Crystal structure of human tankyrase 2 in complex with TA-29
4UI5	;	1.65	;	Crystal structure of human tankyrase 2 in complex with TA-41
4UI6	;	1.8	;	Crystal structure of human tankyrase 2 in complex with TA-47
4UI7	;	1.8	;	Crystal structure of human tankyrase 2 in complex with TA-49
4UI8	;	2.05	;	Crystal structure of human tankyrase 2 in complex with TA-55
5FPF	;	2.6	;	Crystal structure of human tankyrase 2 in complex with TA-91
5FPG	;	2.75	;	Crystal structure of human tankyrase 2 in complex with TA-92
4AVW	;	2.15	;	Crystal structure of human tankyrase 2 in complex with TIQ-A
4PNR	;	1.71	;	Crystal Structure of human Tankyrase 2 in complex with TIQ-A.
4BFP	;	2.4	;	Crystal structure of human tankyrase 2 in complex with WIKI4
5ETY	;	2.9	;	Crystal Structure of human Tankyrase-1 bound to K-756
5C5P	;	1.75	;	CRYSTAL STRUCTURE OF HUMAN TANKYRASE-2 IN COMPLEX WITH A PYRANOPYRIDONE INHIBITOR
5C5Q	;	2.0	;	CRYSTAL STRUCTURE OF HUMAN TANKYRASE-2 IN COMPLEX WITH A PYRANOPYRIDONE INHIBITOR
5C5R	;	1.55	;	CRYSTAL STRUCTURE OF HUMAN TANKYRASE-2 IN COMPLEX WITH A PYRANOPYRIDONE INHIBITOR
6BDN	;	1.5	;	Crystal structure of human TAO3 kinase binding ADP
2A8I	;	2.0	;	Crystal Structure of human Taspase1
2A8J	;	1.9	;	Crystal Structure of human Taspase1 (acivated form)
2A8L	;	2.0	;	Crystal structure of Human Taspase1 (T234A mutant)
2A8M	;	2.6	;	Crystal Structure of Human Taspase1 (T234S mutant)
8EFG	;	1.5	;	Crystal structure of human TATDN1 bound to dAMP and two zinc ions
2QFZ	;	2.1	;	Crystal structure of human TBC1 domain family member 22A
3QWL	;	1.9	;	Crystal structure of human TBC1 domain family member 7
3QYE	;	2.2	;	Crystal Structure of Human TBC1D1 RabGAP domain
2X6V	;	2.2	;	Crystal structure of human TBX5 in the DNA-bound and DNA-free form
2X6U	;	1.9	;	Crystal structure of human TBX5 in the DNA-free form
4WWK	;	3.1	;	Crystal structure of human TCR Alpha Chain-TRAV12-3, Beta Chain-TRBV6-5, Antigen-presenting molecule CD1d, and Beta-2-microglobulin
4WW1	;	1.38	;	Crystal structure of human TCR Alpha Chain-TRAV21-TRAJ8 and Beta Chain-TRBV7-8
4WW2	;	2.48	;	Crystal structure of human TCR Alpha Chain-TRAV21-TRAJ8, Beta Chain-TRBV7-8, Antigen-presenting glycoprotein CD1d, and Beta-2-microglobulin
5TI9	;	2.5	;	Crystal structure of human TDO in complex with Trp and dioxygen, Northeast Structural Genomics Consortium Target HR6161
5TIA	;	2.441	;	Crystal structure of human TDO in complex with Trp, Northeast Structural Genomics Consortium Target HR6161
6A4I	;	2.65	;	Crystal Structure of human TDO inhibitor complex
8QV7	;	2.66	;	Crystal structure of human TDO with alpha-methyl-L-tryptophan
6T4B	;	2.55	;	CRYSTAL STRUCTURE OF HUMAN TDP-43 N-TERMINAL DOMAIN AT 2.55 A RESOLUTION
4IUF	;	2.752	;	Crystal Structure of Human TDP-43 RRM1 Domain in Complex with a Single-stranded DNA
4Y0F	;	2.648	;	Crystal Structure of Human TDP-43 RRM1 Domain in Complex with an Unmodified Single-stranded DNA
4Y00	;	3.0	;	Crystal Structure of Human TDP-43 RRM1 Domain with D169G Mutation in Complex with an Unmodified Single-stranded DNA
5M9N	;	1.95	;	Crystal structure of human TDRD1 extended Tudor domain in complex with a symmetrically dimethylated E2F peptide
4RE1	;	2.2	;	Crystal structure of human TEAD1 and disulfide-engineered YAP
8CUH	;	2.4	;	Crystal structure of human TEAD2 complexed with its inhibitor TM2.
6VAH	;	2.11	;	Crystal structure of human TEAD2 transcription factor in complex with Flufenamic acid derivative
6E5G	;	2.43	;	Crystal structure of human TEAD2-Yap binding domain covalently bound to an allosteric regulator
1XKI	;	1.8	;	Crystal structure of human tear lipocalin/von Ebners gland protein
6XCL	;	2.7	;	Crystal Structure of human telomeric DNA G-quadruplex in complex with a novel platinum(II) complex.
6J07	;	3.298	;	Crystal structure of human TERB2 and TERB1
6F9U	;	1.9	;	Crystal structure of human testis Angiotensin-1 converting enzyme in complex with Sampatrilat-Asp.
6F9T	;	1.6	;	Crystal structure of human testis Angiotensin-1 converting enzyme in complex with Sampatrilat.
4C2O	;	1.8	;	Crystal structure of human testis angiotensin-I converting enzyme mutant D465T
4C2N	;	2.59	;	Crystal structure of human testis angiotensin-I converting enzyme mutant E403R
4C2Q	;	2.4	;	Crystal structure of human testis angiotensin-I converting enzyme mutant R522K
4C2P	;	1.99	;	Crystal structure of human testis angiotensin-I converting enzyme mutant R522K in complex with captopril
4C2R	;	2.3	;	Crystal structure of human testis angiotensin-I converting enzyme mutant R522Q
4A60	;	1.53	;	Crystal structure of human testis-specific fatty acid binding protein 9 (FABP9)
4NPN	;	1.633	;	Crystal structure of human tetra-SUMO-2
5TCX	;	2.955	;	Crystal structure of human tetraspanin CD81
7BPR	;	1.95	;	Crystal structure of human TEX101
8J0K	;	2.1	;	Crystal structure of human TFAP2A in complex with DNA
7Y62	;	2.0	;	Crystal structure of human TFEB HLHLZ domain
1M9Z	;	1.05	;	CRYSTAL STRUCTURE OF HUMAN TGF-BETA TYPE II RECEPTOR LIGAND BINDING DOMAIN
7RCO	;	2.9	;	Crystal structure of human TGF-beta-2 bound to 4A11.V2 Fab
4AE8	;	1.594	;	Crystal structure of human THEM4
4AE7	;	1.45	;	Crystal structure of human THEM5
3S4Y	;	1.8	;	Crystal structure of human thiamin pyrophosphokinase 1
3BHD	;	1.5	;	Crystal structure of human thiamine triphosphatase (THTPA)
1S4B	;	2.0	;	Crystal structure of human thimet oligopeptidase.
4XJV	;	2.8	;	Crystal structure of human thioesterase 2
2H4U	;	2.2	;	Crystal Structure of Human Thioesterase Superfamily Member 2
3M9J	;	1.1	;	Crystal structure of human thioredoxin C69/73S double mutant, reduced form
3M9K	;	1.5	;	Crystal structure of human thioredoxin C69/73S double-mutant, oxidized form
4OO4	;	0.97	;	Crystal Structure of Human Thioredoxin Mutant
2CFY	;	2.7	;	Crystal structure of human thioredoxin reductase 1
2ZZ0	;	2.8	;	Crystal structure of human thioredoxin reductase I (SeCys 498 Cys)
2ZZB	;	3.2	;	Crystal structure of human thioredoxin reductase I and terpyridine platinum(II)
8AGF	;	3.4	;	Crystal structure of human Thiosulfate sulfurtransferase amino acids 2-297
4HWT	;	2.3	;	Crystal structure of human Threonyl-tRNA synthetase bound to a novel inhibitor
6V64	;	2.29	;	Crystal structure of human thrombin bound to ppack with tryptophans replaced by 5-F-tryptophan
6PXQ	;	2.8	;	Crystal structure of human thrombin mutant D194A
6PXJ	;	1.7	;	Crystal structure of human thrombin mutant I16T
3JZ2	;	2.4	;	Crystal structure of human thrombin mutant N143P in E* form
3JZ1	;	1.6	;	Crystal structure of human thrombin mutant N143P in E:Na+ form
3LU9	;	1.8	;	Crystal structure of human thrombin mutant S195A in complex with the extracellular fragment of human PAR1
6P9U	;	3.3	;	Crystal structure of human thrombin mutant W215A
3HKJ	;	2.6	;	Crystal structure of human thrombin mutant W215A/E217A in complex with the extracellular fragment of human PAR1
4TTV	;	2.8	;	Crystal structure of human ThrRS complexing with a bioengineered macrolide BC194
1XBT	;	2.4	;	Crystal Structure of Human Thymidine Kinase 1
1UOU	;	2.11	;	Crystal structure of human thymidine phosphorylase in complex with a small molecule inhibitor
3EGY	;	2.18	;	Crystal Structure of Human Thymidyalte Synthase A191K with Loop 181-197 stabilized in the inactive conformation
3EHI	;	2.0	;	Crystal Structure of Human Thymidyalte Synthase M190K with Loop 181-197 stabilized in the inactive conformation
1NN3	;	1.55	;	Crystal structure of human thymidylate kinase with d4TMP + ADP
1NN5	;	1.5	;	Crystal structure of human thymidylate kinase with d4TMP + AppNHp
1NN0	;	1.6	;	Crystal structure of human thymidylate kinase with ddTMP and ADP
1NN1	;	1.9	;	Crystal structure of human thymidylate kinase with ddTMP and AppNHp
1NMX	;	1.7	;	Crystal structure of human thymidylate kinase with FLTMP and ADP
1NMY	;	1.6	;	Crystal structure of human thymidylate kinase with FLTMP and AppNHp
1NMZ	;	1.75	;	Crystal structure of human thymidylate kinase with NH2TMP and AppNHp
1HZW	;	2.0	;	CRYSTAL STRUCTURE OF HUMAN THYMIDYLATE SYNTHASE
6QYQ	;	2.25	;	Crystal structure of human thymidylate synthase (hTS) variant R175C
3N5E	;	2.26	;	Crystal Structure of human thymidylate synthase bound to a peptide inhibitor
6PF5	;	2.39	;	Crystal structure of human thymidylate synthase Delta (7-29) in complex with dUMP and 2-(2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-4-methoxyphenyl)acetic acid
6PF4	;	2.854	;	Crystal structure of human thymidylate synthase Delta (7-29) in complex with dUMP and 2-(2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)phenyl)acetic acid
6PF3	;	2.391	;	Crystal structure of human thymidylate synthase Delta (7-29) in complex with dUMP and 2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-4-chlorobenzoic acid
6OJU	;	2.884	;	Crystal structure of human thymidylate synthase Delta (7-29) in complex with dUMP and 2-amino-4-oxo-4,7-dihydro-pyrrolo[2,3-d]pyrimidine-methyl-phenyl-D-glutamic acid
6OJV	;	2.593	;	Crystal structure of human thymidylate synthase delta(7-29) in complex with dUMP and 2-amino-4-oxo-4,7-dihydro-pyrrolo[2,3-d]pyrimidine-methyl-phenyl-L-glutamic acid
4O1X	;	2.32	;	Crystal structure of human thymidylate synthase double mutant C195S-Y202C
4O1U	;	2.26	;	Crystal structure of human thymidylate synthase mutant Y202C
4JEF	;	2.311	;	Crystal structure of human thymidylate synthase Y202A in inactive conformation.
1I00	;	2.5	;	CRYSTAL STRUCTURE OF HUMAN THYMIDYLATE SYNTHASE, TERNARY COMPLEX WITH DUMP AND TOMUDEX
3UO7	;	3.002	;	Crystal structure of Human Thymine DNA Glycosylase Bound to Substrate 5-carboxylcytosine
3UOB	;	3.011	;	Crystal structure of Human Thymine DNA Glycosylase Bound to Substrate Analog 2'-deoxy-2'-beta-fluoro-cytidine
5J3E	;	2.6	;	Crystal Structure of Human THYN1 protein in complex with 5-methylcytosine containing DNA
1Q4X	;	2.8	;	Crystal Structure of Human Thyroid Hormone Receptor beta LBD in complex with specific agonist GC-24
4X30	;	1.55	;	Crystal structure of human Thyroxine-binding globulin complexed with thyroine at 1.55 Angstrom resolution
7VYT	;	1.53	;	Crystal structure of human TIGIT(23-129) in complex with the scFv fragment of anti-TIGIT antibody MG1131
2CW9	;	1.9	;	Crystal structure of human Tim44 C-terminal domain
4FZ5	;	3.6	;	Crystal Structure of Human TIRAP TIR-domain
3Q5O	;	2.05	;	Crystal structure of human titin domain M10
2QE3	;	2.5	;	Crystal structure of human tl1a extracellular domain
2RJK	;	2.3	;	Crystal Structure of Human TL1A Extracellular Domain C95S Mutant
2RJL	;	2.05	;	Crystal structure of human TL1A extracellular domain C95S/C135S mutant
4OM3	;	2.855	;	Crystal structure of human TLE1 Q-domain residues 20-156
6NIH	;	2.3	;	Crystal structure of human TLR1
4G8A	;	2.4	;	Crystal structure of human TLR4 polymorphic variant D299G and T399I in complex with MD-2 and LPS
3W3G	;	2.3	;	Crystal structure of human TLR8 (unliganded form)
6V9U	;	2.65	;	Crystal structure of human TLR8 ectodomain bound to small molecule antagonist 14c
7RC9	;	2.76	;	Crystal structure of human TLR8 ectodomain bound to small molecule antagonist 21
6KYA	;	2.89	;	Crystal structure of human TLR8 in complex TH1027
3W3K	;	2.3	;	Crystal structure of human TLR8 in complex with CL075
3W3J	;	2.0	;	Crystal structure of human TLR8 in complex with CL097
6TY5	;	2.793	;	Crystal structure of human TLR8 in complex with Compound 11
7R53	;	3.121	;	Crystal structure of human TLR8 in complex with Compound 15
7R52	;	2.943	;	Crystal structure of human TLR8 in complex with Compound 2
8PFI	;	2.785	;	Crystal structure of human TLR8 in complex with compound 34
7R54	;	2.836	;	Crystal structure of human TLR8 in complex with Compound 4
7CRF	;	2.89	;	Crystal structure of human TLR8 in complex with CU-CPD107
5WYX	;	2.4	;	Crystal structure of human TLR8 in complex with CU-CPT8m
5Z14	;	2.8	;	Crystal structure of human TLR8 in complex with CU-CPT9a
5WYZ	;	2.3	;	Crystal structure of human TLR8 in complex with CU-CPT9b
5Z15	;	2.9	;	Crystal structure of human TLR8 in complex with CU-CPT9c
4QBZ	;	2.0	;	Crystal structure of human TLR8 in complex with DS-802
3WN4	;	1.81	;	Crystal structure of human TLR8 in complex with DS-877
4R6A	;	2.1	;	Crystal structure of human TLR8 in complex with Hybrid-2
5AZ5	;	2.4	;	Crystal structure of human TLR8 in complex with MB-343
5AWC	;	2.5	;	Crystal structure of human TLR8 in complex with MB-564
5AWA	;	2.2	;	Crystal structure of human TLR8 in complex with MB-568
5AWB	;	2.1	;	Crystal structure of human TLR8 in complex with N1-3-aminomethylbenzyl (meta-amine)
5AWD	;	2.05	;	Crystal structure of human TLR8 in complex with N1-4-aminomethylbenzyl (IMDQ)
4R07	;	2.0	;	Crystal structure of human TLR8 in complex with ORN06
4R09	;	2.62	;	Crystal structure of human TLR8 in complex with ORN06S
3W3L	;	2.33	;	Crystal structure of human TLR8 in complex with Resiquimod (R848) crystal form 1
3W3M	;	2.7	;	Crystal structure of human TLR8 in complex with Resiquimod (R848) crystal form 2
3W3N	;	2.1	;	Crystal structure of human TLR8 in complex with Resiquimod (R848) crystal form 3
4R08	;	2.4	;	Crystal structure of human TLR8 in complex with ssRNA40
4R0A	;	1.9	;	Crystal structure of human TLR8 in complex with uridine mononucleoside
4QC0	;	2.1	;	Crystal structure of human TLR8 in complex with XG-1-236
5HDH	;	2.6	;	Crystal structure of human TLR8 with an uncleaved Z-loop
5OC9	;	3.2	;	Crystal Structure of human TMEM16K / Anoctamin 10
6R65	;	3.5	;	Crystal Structure of human TMEM16K / Anoctamin 10 (Form 2)
7MEQ	;	1.95	;	Crystal structure of human TMPRSS2 in complex with Nafamostat
8DS8	;	1.84	;	Crystal structure of human TNRC18 BAH domain in complex with H3K9me3 peptide
5CI8	;	2.328	;	Crystal structure of human Tob in complex with inhibitor fragment 1
5CI9	;	2.3	;	Crystal structure of human Tob in complex with inhibitor fragment 6
2Z15	;	2.3	;	Crystal structure of human Tob1 protein
5JA4	;	2.424	;	Crystal structure of human TONSL and MCM2 HBDs binding to a histone H3-H4 tetramer
1EJ9	;	2.6	;	CRYSTAL STRUCTURE OF HUMAN TOPOISOMERASE I DNA COMPLEX
5ZRF	;	2.3	;	Crystal structure of human topoisomerase II beta in complex with 5-iodouridine-containing-DNA and etoposide in space group p21
5ZQF	;	3.873	;	Crystal structure of human topoisomerase II beta in complex with 5-iodouridine-containing-DNA in space group P3221
5ZEN	;	2.75	;	Crystal structure of human topoisomerase II beta in complex with DNA: a new quaternary conformation showing opening of the protein-linked DNA-gate
2I46	;	2.7	;	Crystal structure of human TPP1
2H77	;	2.33	;	Crystal structure of human TR alpha bound T3 in monoclinic space group
2H79	;	1.87	;	Crystal Structure of human TR alpha bound T3 in orthorhombic space group
1N46	;	2.2	;	CRYSTAL STRUCTURE OF HUMAN TR BETA LIGAND-BINDING DOMAIN COMPLEXED WITH A POTENT SUBTYPE-SELECTIVE THYROMIMETIC
1D2Q	;	2.8	;	CRYSTAL STRUCTURE OF HUMAN TRAIL
7QPO	;	3.0	;	Crystal structure of human trans-3-Hydroxy-L-proline dehydratase
1F05	;	2.45	;	CRYSTAL STRUCTURE OF HUMAN TRANSALDOLASE
5DQE	;	2.183	;	Crystal structure of human transcription factor TEAD2 in complex with bromo-fenamic acid
5DQ8	;	2.305	;	Crystal structure of human transcription factor TEAD2 in complex with flufenamic acid
5HGU	;	2.046	;	Crystal structure of human transcription factor TEAD2 in complex with palmitate
6CTC	;	2.6	;	Crystal structure of human transferrin bound to Triferic FPC iron pyrophosphate
6OKD	;	1.85	;	Crystal Structure of human transferrin receptor in complex with a cystine-dense peptide
3LY6	;	3.14	;	Crystal structure of human transglutaminase 2 complex with adenosine 5' Triphosphate
3OOY	;	2.05	;	Crystal structure of human Transketolase (TKT)
3BPJ	;	1.85	;	Crystal structure of human translation initiation factor 3, subunit 1 alpha
1YZ1	;	2.0	;	Crystal structure of human translationally controlled tumour associated protein
3EBM	;	2.6	;	Crystal structure of human translationally controlled tumour associated protein (hTCTP) mutant E12V
1J1J	;	2.2	;	Crystal Structure of human Translin
4WYV	;	3.0	;	Crystal Structure of Human Translin in Open Conformation
6TP5	;	2.25	;	Crystal structure of human Transmembrane prolyl 4-hydroxylase
1DVQ	;	2.0	;	CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN
4N85	;	1.6	;	Crystal structure of human transthyretin
4TLT	;	1.7	;	Crystal structure of human transthyretin
3A4E	;	1.7	;	Crystal structure of Human Transthyretin (E54G)
3A4F	;	1.99	;	Crystal Structure of Human Transthyretin (E54K)
3D7P	;	1.72	;	Crystal structure of human Transthyretin (TTR) at pH 4.0
3CBR	;	1.7	;	Crystal structure of human Transthyretin (TTR) at pH3.5
5DWP	;	1.2	;	Crystal Structure of human transthyretin (TTR) processed with the CrystalDirect automated mounting and cryo-cooling technology
3A4D	;	2.0	;	Crystal structure of Human Transthyretin (wild-type)
3I9P	;	1.9	;	Crystal structure of human transthyretin - wild type
4TLU	;	1.75	;	Crystal Structure of Human Transthyretin Ala108Trp Mutant
8AWI	;	1.15	;	Crystal structure of Human Transthyretin at 1.15 Angstrom resolution
1F41	;	1.3	;	CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN AT 1.5A RESOLUTION
2G4G	;	1.85	;	Crystal structure of human transthyretin at pH 4.6
4N86	;	2.001	;	Crystal structure of human transthyretin complexed with glabridin
6FZL	;	1.446	;	Crystal structure of human transthyretin double mutant K35T/T119M
6FWD	;	1.576	;	Crystal structure of human transthyretin double mutant R34G/T119M at pH 5.5
4TLS	;	1.35	;	Crystal Structure of Human Transthyretin Glu92Pro Mutant
3CFT	;	1.87	;	Crystal structure of human transthyretin in complex with 1-amino-5-naphthalene sulfonate
3CFN	;	1.87	;	Crystal structure of human transthyretin in complex with 1-anilino-8-naphthalene sulfonate
5JIQ	;	1.45	;	Crystal Structure of Human Transthyretin in Complex with 2,2',4,4'-tetrahydroxybenzophenone (BP2)
6GR7	;	1.4	;	Crystal Structure Of Human Transthyretin in complex with 2,4,5-trichlorophenoxyacetic acid (2,4,5-T)
5L4F	;	1.48	;	Crystal Structure of Human Transthyretin in Complex with 2,6-Dinitro-p-cresol (DNPC)
6GRP	;	1.6	;	Crystal Structure Of Human Transthyretin in complex with 3,5,6-trichloro-2-pyridinol (TC2P)
5L4M	;	1.581	;	Crystal Structure of Human Transthyretin in Complex with 3,5,6-Trichloro-2-pyridinyloxyacetic acid (Triclopyr)
8C85	;	1.19	;	Crystal structure of human transthyretin in complex with 3-O-methyltolcapone analogue 1
8C86	;	1.1	;	Crystal structure of human transthyretin in complex with 3-O-methyltolcapone analogue 2
6SUH	;	1.26	;	Crystal structure of human transthyretin in complex with 3-O-methyltolcapone, a tolcapone analogue
5L4J	;	1.62	;	Crystal Structure of Human Transthyretin in Complex with 4,4'-Dihydroxydiphenyl sulfone (Bisphenol S, BPS)
7DT3	;	1.198	;	Crystal structure of human transthyretin in complex with 4-chloro-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid
7DT5	;	1.25	;	Crystal structure of human transthyretin in complex with 4-chloro-9-oxo-9H-xanthene-2-carboxylic acid
7EJQ	;	1.15	;	Crystal structure of human transthyretin in complex with 8-chloro-9-oxo-9H-xanthene-3-carboxylic acid
7ACU	;	1.541	;	Crystal structure of human transthyretin in complex with Benzbromarone
5L4I	;	1.45	;	Crystal Structure of Human Transthyretin in Complex with Clonixin
1DVU	;	1.9	;	CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH DIBENZOFURAN-4,6-DICARBOXYLIC ACID
1DVX	;	2.0	;	CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH DICLOFENAC
1DVT	;	1.9	;	CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH FLURBIPROFEN
5BOJ	;	1.75	;	Crystal Structure of Human Transthyretin in Complex with Gemfibrozil
4IK7	;	2.1	;	Crystal structure of human transthyretin in complex with indomethacin
4IK6	;	2.0	;	Crystal structure of human transthyretin in complex with lumiracoxib
4QXV	;	1.12	;	CRYSTAL STRUCTURE of HUMAN TRANSTHYRETIN IN COMPLEX WITH LUTEOLIN AT 1.1 A RESOLUTION
5EN3	;	1.25	;	Crystal structure of human transthyretin in complex with luteolin-Cl at 1.25 A resolution
5IHH	;	1.35	;	Crystal structure of human transthyretin in complex with luteolin-MeO at 1.35 A resolution
1DVZ	;	1.9	;	CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH O-TRIFLUOROMETHYLPHENYL ANTHRANILIC ACID
5JIM	;	1.26	;	Crystal Structure of Human Transthyretin in Complex with Perfluoroktansulfonsyra (PFOS)
5JID	;	1.2	;	Crystal Structure of Human Transthyretin in Complex with Perfluorooctanoic acid (PFOA)
1DVS	;	2.0	;	CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH RESVERATROL
5HJG	;	1.4	;	Crystal Structure of Human Transthyretin in Complex with Tetrabromobisphenol A (TBBPA)
4TKW	;	1.8	;	Crystal Structure of Human Transthyretin Leu55Pro Mutant
4TNF	;	1.6	;	Crystal Structure of Human Transthyretin Lys15Trp Mutant
6FXU	;	1.359	;	Crystal structure of human transthyretin mutant T119M at pH 5.5
4TL5	;	1.44	;	Crystal Structure of Human Transthyretin Ser85Pro Mutant
4TLK	;	1.44	;	Crystal Structure of Human Transthyretin Ser85Pro/Glu92Pro Mutant
4TNG	;	1.6	;	Crystal Structure of Human Transthyretin Thr119Met Mutant
4TM9	;	1.7	;	Crystal Structure of Human Transthyretin Thr119Trp Mutant
4TNE	;	1.55	;	Crystal Structure of Human Transthyretin Thr119Tyr Mutant
4TL4	;	1.75	;	Crystal Structure of Human Transthyretin Val30Met Mutant
3I9A	;	1.65	;	Crystal structure of human transthyretin variant A25T - #1
3I9I	;	1.8	;	Crystal structure of human transthyretin variant A25T - #2
3OZL	;	1.9	;	Crystal structure of human transthyretin variant A25T in complex with flufenamic acid.
3OZK	;	1.9	;	Crystal structure of human transthyretin variant A25T in complex with thyroxine (T4)
7Y6J	;	1.38	;	Crystal structure of human transthyretin variant A97S at pH 5.4
8HY4	;	1.53	;	Crystal structure of human transthyretin variant A97S at pH 7.6
7YCQ	;	1.99	;	Crystal structure of human transthyretin variant A97S complexed with Diflunisal
7YBR	;	1.71	;	Crystal structure of human transthyretin variant A97S complexed with Tolcapone
7THA	;	1.75	;	Crystal structure of human transthyretin variant C10A/M13V
4QYA	;	1.7	;	Crystal structure of human transthyretin variant V30M in complex with luteolin
1ZD6	;	1.9	;	Crystal structure of human transthyretin with bound chloride
1ZCR	;	1.8	;	Crystal structure of human Transthyretin with bound iodide
4Z1I	;	3.3	;	Crystal structure of human Trap1 with AMPPNP
4Z1G	;	3.1	;	Crystal structure of human Trap1 with BIIB-021
7C04	;	1.7	;	Crystal structure of human Trap1 with DN203492
7C05	;	2.59	;	Crystal structure of human Trap1 with DN203495
4Z1F	;	2.703	;	Crystal structure of human Trap1 with PU-H71
7C7B	;	1.5	;	Crystal structure of human TRAP1 with SJT009
7C7C	;	3.0	;	Crystal structure of human TRAP1 with SJT104
4Z1H	;	2.9	;	Crystal structure of human Trap1 with SMTIN-P01
6V1D	;	2.4	;	Crystal structure of human trefoil factor 1
6V1C	;	1.55	;	Crystal structure of human trefoil factor 3 in complex with its cognate ligand
1SMO	;	1.47	;	Crystal Structure of Human Triggering Receptor Expressed on Myeloid Cells 1 (TREM-1) at 1.47 .
8R5D	;	1.8	;	Crystal structure of human TRIM7 PRYSPRY domain
8R5C	;	1.6	;	Crystal structure of human TRIM7 PRYSPRY domain bound to (2-(1-oxoisoindolin-2-yl)-3-phenylpropanoyl)-L-glutamine
8R5B	;	1.6	;	Crystal structure of human TRIM7 PRYSPRY domain bound to (3-phenoxybenzoyl)-L-glutamine
4UNK	;	2.0	;	Crystal structure of human triosephosphate isomerase (mutant N15D)
6F00	;	2.163	;	Crystal Structure of human tRNA dihydrouridine synthase (20) dsRBD E423A mutant
4XP7	;	1.9	;	Crystal structure of Human tRNA dihydrouridine synthase 2
6EI8	;	2.25	;	Crystal structure of human tRNA-dihydrouridine (20) synthase dsRBD F359A mutant
6EZA	;	2.0	;	Crystal Structure of human tRNA-dihydrouridine(20) synthase catalytic domain E294K mutant
6EZC	;	2.0	;	Crystal Structure of human tRNA-dihydrouridine(20) synthase catalytic domain E294K Q305K double mutant
6EZB	;	2.25	;	Crystal Structure of human tRNA-dihydrouridine(20) synthase catalytic domain Q305K mutant
5OC6	;	3.2	;	Crystal structure of human tRNA-dihydrouridine(20) synthase dsRBD in complex with a 22 nucleotide dsRNA
5OC5	;	1.893	;	Crystal structure of human tRNA-dihydrouridine(20) synthase dsRBD K419A-K420A mutant
5OC4	;	1.71	;	Crystal structure of human tRNA-dihydrouridine(20) synthase dsRBD R361A-R362A mutant
3DH1	;	2.8	;	Crystal structure of human tRNA-specific adenosine-34 deaminase subunit ADAT2
3OTB	;	2.95	;	Crystal structure of human tRNAHis guanylyltransferase (Thg1) - dGTP complex
3OTD	;	2.28	;	Crystal structure of human tRNAHis guanylyltransferase (Thg1)- NaI derivative
3OTE	;	2.56	;	Crystal structure of human tRNAHis guanylyltransferase (Thg1)- Native I
3OTC	;	3.01	;	Crystal structure of human tRNAHis guanylyltransferase (Thg1)- Native II
3ZWF	;	1.7	;	Crystal structure of Human tRNase Z, short form (ELAC1).
1WOU	;	1.8	;	Crystal Structure of human Trp14
3HF8	;	1.85	;	Crystal structure of human tryoptophan hydroxylase type 1 with bound LP-533401 and Fe
3HFB	;	1.92	;	Crystal structure of human tryoptophan hydroxylase type 1 with LP-534193
1TRN	;	2.2	;	CRYSTAL STRUCTURE OF HUMAN TRYPSIN 1: UNEXPECTED PHOSPHORYLATION OF TYROSINE 151
2ZA5	;	2.3	;	Crystal Structure of human tryptase with potent non-peptide inhibitor
6UD5	;	2.05	;	Crystal structure of human tryptophan 2,3-dioxygenase in complex with carbon monoxide and tryptophan
6PYZ	;	2.02	;	Crystal Structure of human Tryptophan 2,3-dioxygenase in complex with PF-06840003 in Active Site
6PYY	;	2.4	;	Crystal Structure of human Tryptophan 2,3-dioxygenase in complex with PF-06840003 in Active Site and Exo site
7ZIH	;	1.46891	;	Crystal structure of human tryptophan hydroxylase 1 in complex with inhibitor AG-01-128
7ZIG	;	1.80888	;	Crystal structure of human tryptophan hydroxylase 1 in complex with inhibitor KM-05-060
7ZIJ	;	1.94678	;	Crystal structure of human tryptophan hydroxylase 1 in complex with inhibitor KM-05-080
7ZII	;	1.628	;	Crystal structure of human tryptophan hydroxylase 1 in complex with inhibitor KM-05-193
8CJO	;	1.86634	;	Crystal structure of human tryptophan hydroxylase 1 in complex with inhibitor KM-06-004
8CJJ	;	1.66416	;	Crystal structure of human tryptophan hydroxylase 1 in complex with inhibitor KM-06-057
8CJN	;	1.68081	;	Crystal structure of human tryptophan hydroxylase 1 in complex with inhibitor KM-06-070
8CJK	;	1.45915	;	Crystal structure of human tryptophan hydroxylase 1 in complex with inhibitor KM-06-098
8CJM	;	1.9	;	Crystal structure of human tryptophan hydroxylase 1 in complex with inhibitor KM-07-047
8CJI	;	1.65	;	Crystal structure of human tryptophan hydroxylase 1 in complex with inhibitor KM-07-052
7ZIF	;	1.8686	;	Crystal structure of human tryptophan hydroxylase 1 in complex with inhibitor KM-480
7ZIK	;	2.58926	;	Crystal structure of human tryptophan hydroxylase 1 in complex with inhibitor LP533401
8CJL	;	1.83	;	Crystal structure of human tryptophan hydroxylase 1 in complex with inhibitor TPT-004
4V06	;	2.63	;	Crystal structure of human tryptophan hydroxylase 2 (TPH2), catalytic domain
3HF6	;	1.8	;	Crystal structure of human tryptophan hydroxylase type 1 with bound LP-521834 and FE
1MLW	;	1.71	;	Crystal structure of human tryptophan hydroxylase with bound 7,8-dihydro-L-biopterin cofactor and Fe(III)
1R6T	;	2.1	;	crystal structure of human tryptophanyl-tRNA synthetase
2XVS	;	1.8	;	Crystal structure of human TTC5 (Strap) C-terminal OB domain
5WU2	;	2.95	;	Crystal structure of human Tut1 bound with BaUTP, form I
5WU4	;	2.8	;	Crystal structure of human Tut1 bound with MgATP, form II
5WU3	;	2.703	;	Crystal structure of human Tut1 bound with MgUTP, form II
8IDF	;	3.7	;	Crystal structure of human TUT1 complexed with U6 snRNA
4TWK	;	2.6	;	Crystal structure of human two pore domain potassium ion channel TREK1 (K2P2.1)
4BW5	;	3.2	;	Crystal structure of human two pore domain potassium ion channel TREK2 (K2P10.1)
4XDJ	;	3.8	;	Crystal structure of human two pore domain potassium ion channel TREK2 (K2P10.1) in an alternate conformation (FORM 2)
4XDL	;	3.5	;	Crystal structure of human two pore domain potassium ion channel TREK2 (K2P10.1) in complex with a brominated fluoxetine derivative.
4XDK	;	3.6	;	Crystal structure of human two pore domain potassium ion channel TREK2 (K2P10.1) in complex with norfluoxetine
2HDJ	;	2.0	;	Crystal structure of human type 3 3alpha-hydroxysteroid dehydrogenase in complex with NADP(H)
1XJB	;	1.9	;	Crystal structure of human type 3 3alpha-hydroxysteroid dehydrogenase in complex with NADP(H), citrate and acetate molecules
2I6K	;	2.0	;	Crystal structure of human type I IPP isomerase complexed with a substrate analog
1IHI	;	3.0	;	Crystal Structure of Human Type III 3-alpha-Hydroxysteroid Dehydrogenase/Bile Acid Binding Protein (AKR1C2) Complexed with NADP+ and Ursodeoxycholate
3DMW	;	2.3	;	Crystal structure of human type III collagen G982-G1023 containing C-terminal cystine knot
2GEE	;	2.01	;	Crystal Structure of Human Type III Fibronectin Extradomain B and Domain 8
3IU1	;	1.42	;	Crystal Structure of human type-I N-myristoyltransferase with bound myristoyl-CoA
3IWE	;	1.79	;	Crystal Structure of human type-I N-myristoyltransferase with bound myristoyl-CoA and inhibitor DDD85646
3JTK	;	1.61	;	Crystal Structure of human type-I N-myristoyltransferase with bound myristoyl-CoA and inhibitor DDD90055
3IU2	;	1.73	;	Crystal Structure of human type-I N-myristoyltransferase with bound myristoyl-CoA and inhibitor DDD90096
1RHF	;	1.96	;	Crystal Structure of human Tyro3-D1D2
5M8L	;	2.35	;	Crystal structure of human tyrosinase related protein 1
5M8R	;	2.4	;	Crystal structure of human tyrosinase related protein 1 (T391V-R374S-Y362F) in complex with mimosine
5M8T	;	2.35	;	Crystal structure of human tyrosinase related protein 1 (T391V-R374S-Y362F) in complex with tropolone
5M8M	;	2.65	;	Crystal structure of human tyrosinase related protein 1 in complex with kojic acid
5M8N	;	2.6	;	Crystal structure of human tyrosinase related protein 1 in complex with mimosine
5M8O	;	2.5	;	Crystal structure of human tyrosinase related protein 1 in complex with tropolone
5M8P	;	2.8	;	Crystal structure of human tyrosinase related protein 1 in complex with tyrosine
5M8Q	;	2.85	;	Crystal structure of human tyrosinase related protein 1 mutant (T391V-R374S-Y362F) in complex with kojic acid
5M8S	;	2.2	;	Crystal structure of human tyrosinase related protein 1 mutant (T391V-R374S-Y362F) in complex with phenylthiourea (PTU)
2XSN	;	2.68	;	Crystal Structure of Human Tyrosine Hydroxylase Catalytic Domain
2P6X	;	1.9	;	Crystal structure of human tyrosine phosphatase PTPN22
2B3O	;	2.8	;	Crystal structure of human tyrosine phosphatase SHP-1
2R0B	;	1.6	;	Crystal structure of human tyrosine phosphatase-like serine/threonine/tyrosine-interacting protein
1FMK	;	1.5	;	CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC
2SRC	;	1.5	;	CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC, IN COMPLEX WITH AMP-PNP
6JMF	;	2.0	;	Crystal structure of human tyrosine-protein kinase Fes/Fps in complex with compound 4
1JY1	;	1.69	;	CRYSTAL STRUCTURE OF HUMAN TYROSYL-DNA PHOSPHODIESTERASE (TDP1)
1NOP	;	2.3	;	Crystal structure of human tyrosyl-DNA phosphodiesterase (Tdp1) in complex with vanadate, DNA and a human topoisomerase I-derived peptide
1RFF	;	1.7	;	Crystal structure of human Tyrosyl-DNA Phosphodiesterase complexed with vanadate, octapeptide KLNYYDPR, and tetranucleotide AGTT.
1RH0	;	2.3	;	Crystal structure of human Tyrosyl-DNA Phosphodiesterase complexed with vanadate, octopamine and trinucleotide GTT
1RG2	;	2.1	;	Crystal structure of human Tyrosyl-DNA Phosphodiesterase complexed with vanadate, octopamine, and tetranucleotide AGTA
1RGT	;	2.0	;	Crystal structure of human Tyrosyl-DNA Phosphodiesterase complexed with vanadate, octopamine, and tetranucleotide AGTC
1RG1	;	2.1	;	Crystal structure of human Tyrosyl-DNA Phosphodiesterase complexed with vanadate, octopamine, and tetranucleotide AGTT
1RFI	;	2.2	;	Crystal structure of human Tyrosyl-DNA Phosphodiesterase complexed with vanadate, pentapeptide KLNYK, and tetranucleotide AGTC
5WRI	;	1.6	;	Crystal structure of human tyrosylprotein sulfotransferase-1 complexed with PAP and C4 peptide
5WRJ	;	2.31	;	Crystal structure of human tyrosylprotein sulfotransferase-1 complexed with PAP and gastrin peptide
3AP3	;	3.5	;	Crystal structure of human tyrosylprotein sulfotransferase-2 complexed with PAP
3AP1	;	1.9	;	Crystal structure of human tyrosylprotein sulfotransferase-2 complexed with PAP and C4 peptide
3AP2	;	2.4	;	Crystal structure of human tyrosylprotein sulfotransferase-2 complexed with PAP,C4 peptide, and phosphate ion
3AL5	;	2.503	;	Crystal structure of Human TYW5
3AL6	;	2.8	;	Crystal structure of Human TYW5
3PGW	;	4.4	;	Crystal structure of human U1 snRNP
5IAA	;	1.85	;	Crystal structure of human UBA5 in complex with UFM1
5L95	;	2.1	;	Crystal structure of human UBA5 in complex with UFM1 and AMP
7PVN	;	2.71	;	Crystal Structure of Human UBA6 in Complex with ATP
7PYV	;	3.27	;	Crystal structure of human UBA6 in complex with the ubiquitin-like modifier FAT10
3L1Y	;	1.6	;	Crystal structure of human UBC4 E2 conjugating enzyme
5F6E	;	1.12	;	Crystal Structure of human Ubc9 (K48A/K49A/E54A)
6CYO	;	1.85	;	Crystal structure of human UBE2A (RAD6A)
6R75	;	2.0	;	Crystal structure of human Ube2T E54R mutant
6DC6	;	3.14	;	Crystal structure of human ubiquitin activating enzyme E1 (Uba1) in complex with ubiquitin
3ONS	;	1.8	;	Crystal structure of Human Ubiquitin in a new crystal form
3BZH	;	1.6	;	Crystal structure of human ubiquitin-conjugating enzyme E2 E1
2C4P	;	2.35	;	Crystal structure of human ubiquitin-conjugating enzyme UbcH5A
2CLW	;	1.945	;	Crystal structure of human ubiquitin-conjugating enzyme UbcH5B
5EGG	;	1.76	;	Crystal structure of human ubiquitin-conjugating enzyme UBCH5C
8HM1	;	1.29	;	crystal structure of human ubiquitin-like protein from Bacteroides fragilis
8HM2	;	1.34	;	Crystal structure of human ubiquitin-like protein from bacteroides fragilis c terminal cysteine mutant
1QK1	;	2.7	;	CRYSTAL STRUCTURE OF HUMAN UBIQUITOUS MITOCHONDRIAL CREATINE KINASE
7YV4	;	1.58	;	Crystal structure of human UCHL3 in complex with Farrerol
2B69	;	1.21	;	Crystal Structure of Human UDP-glucoronic acid decarboxylase
3TDK	;	2.8	;	Crystal Structure of Human UDP-Glucose Dehydrogenase
3KHU	;	2.3	;	Crystal structure of human UDP-glucose dehydrogenase Glu161Gln, in complex with thiohemiacetal intermediate
2QG4	;	2.1	;	Crystal structure of human UDP-glucose dehydrogenase product complex with UDP-glucuronate
3ITK	;	2.4	;	Crystal structure of human UDP-glucose dehydrogenase Thr131Ala, apo form.
6FM9	;	3.6	;	Crystal structure of human UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosaminephosphotransferase (DPAGT1)
5LEV	;	3.2	;	Crystal structure of human UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosaminephosphotransferase (DPAGT1) (V264G mutant)
5O5E	;	3.4	;	Crystal structure of human UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosaminephosphotransferase (DPAGT1) (V264G mutant) in complex with tunicamycin
6FWZ	;	3.1	;	Crystal structure of human UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosaminephosphotransferase (DPAGT1) (V264G mutant) in complex with UDP-GlcNAc
4LK3	;	2.64	;	Crystal structure of Human UDP-xylose synthase R236A substitution
4M55	;	2.86	;	Crystal structure of Human UDP-xylose synthase R236H substitution
4GLL	;	2.5	;	Crystal structure of human UDP-xylose synthase.
7WWQ	;	2.72	;	Crystal structure of human Ufd1-Npl4 complex
6IIW	;	1.699	;	Crystal structure of human UHRF1 PHD finger in complex with PAF15
7FB7	;	1.45	;	Crystal structure of human UHRF1 TTD in complex with 5-amino-2,4-dimethylpyridine
7CGA	;	3.15	;	Crystal structure of human unphosphorylated p38gamma
4QTI	;	3.0	;	Crystal structure of human uPAR in complex with anti-uPAR Fab 8B12
1EMH	;	1.8	;	CRYSTAL STRUCTURE OF HUMAN URACIL-DNA GLYCOSYLASE BOUND TO UNCLEAVED SUBSTRATE-CONTAINING DNA
3TKB	;	1.5	;	crystal structure of human uracil-DNA glycosylase D183G/K302R mutant
1UGH	;	1.9	;	CRYSTAL STRUCTURE OF HUMAN URACIL-DNA GLYCOSYLASE IN COMPLEX WITH A PROTEIN INHIBITOR: PROTEIN MIMICRY OF DNA
3Q91	;	2.7	;	Crystal Structure of Human Uridine Diphosphate Glucose Pyrophosphatase (NUDT14)
2XRF	;	2.3	;	Crystal structure of human uridine phosphorylase 2
2JEO	;	2.5	;	Crystal structure of human uridine-cytidine kinase 1
2UVQ	;	3.0	;	Crystal structure of human uridine-cytidine kinase 1 in complex with ADP
6PWZ	;	3.0	;	Crystal structure of human uridine-cytidine kinase 2 complexed with 2'-azidocytidine
6N54	;	2.424	;	Crystal structure of human uridine-cytidine kinase 2 complexed with 2'-azidocytidine monophosphate
6N55	;	3.085	;	Crystal structure of human uridine-cytidine kinase 2 complexed with 2'-azidouridine
6N53	;	2.7	;	Crystal structure of human uridine-cytidine kinase 2 complexed with 2'-azidouridine monophosphate
1UDW	;	2.6	;	Crystal structure of human uridine-cytidine kinase 2 complexed with a feedback-inhibitor, CTP
1UEI	;	2.6	;	Crystal structure of human uridine-cytidine kinase 2 complexed with a feedback-inhibitor, UTP
1UEJ	;	2.61	;	Crystal structure of human uridine-cytidine kinase 2 complexed with a substrate, cytidine
7SQL	;	2.4	;	Crystal structure of human uridine-cytidine kinase 2 complexed with a weak small molecule inhibitor
1UJ2	;	1.8	;	Crystal structure of human uridine-cytidine kinase 2 complexed with products, CMP and ADP
7ZRR	;	1.64	;	Crystal structure of human Urokinase-type plasminogen activator in complex with bicycle peptide inhibitor UK965
7ZRT	;	1.8	;	Crystal structure of human Urokinase-type plasminogen activator in complex with bicycle peptide inhibitor UK970
1FLH	;	2.45	;	CRYSTAL STRUCTURE OF HUMAN UROPEPSIN AT 2.45 A RESOLUTION
8IA3	;	3.5	;	Crystal structure of human USF2 bHLHLZ domain in complex with DNA
5XVE	;	1.24	;	Crystal structure of human USP2 C276S mutant in complex with ubiquitin
5XU8	;	1.81	;	Crystal structure of human USP2 in complex with ubiquitin and 6-thioguanine
5O71	;	3.283	;	Crystal structure of human USP25
8D1T	;	2.94	;	Crystal structure of human USP30 in complex with a covalent inhibitor 552 and a Fab
8D0A	;	3.19	;	Crystal structure of human USP30 in complex with a covalent inhibitor 829 and a Fab
6JLQ	;	3.101	;	Crystal structure of human USP46-WDR48-WDR20 complex
7RUO	;	1.8	;	Crystal structure of human UTP15
7DF7	;	2.3	;	Crystal structure of human V-1 in the apo form
6AC9	;	2.07	;	Crystal structure of human Vaccinia-related kinase 1 (VRK1) in complex with AMP-PNP
5UU1	;	2.0	;	Crystal Structure of Human Vaccinia-related kinase 2 (VRK-2) bound to BI-D1870
8Q1Z	;	1.85	;	Crystal Structure of Human Vaccinia-related kinase 2 (VRK-2) bound to JA-296
6NCG	;	2.45	;	Crystal Structure of Human Vaccinia-related kinase 2 (VRK-2) bound to pyridin-benzenesulfonamide inhibitor
2OCG	;	1.75	;	Crystal structure of human valacyclovir hydrolase
8HL6	;	1.8	;	Crystal structure of human valosin-containing protein methyltransferase
1PU4	;	3.2	;	Crystal structure of human vascular adhesion protein-1
1US1	;	2.9	;	Crystal structure of human vascular adhesion protein-1
4BTW	;	2.8	;	Crystal structure of human vascular adhesion protein-1 in complex with pyridazinone inhibitors
4BTX	;	2.78	;	Crystal structure of human vascular adhesion protein-1 in complex with pyridazinone inhibitors
4BTY	;	3.1	;	Crystal structure of human vascular adhesion protein-1 in complex with pyridazinone inhibitors
2C7W	;	2.48	;	Crystal Structure of human vascular endothelial growth factor-B: Identification of amino acids important for angiogeninc activity
6K81	;	2.28	;	Crystal structure of human VASH1-SVBP complex
6K9Y	;	2.2	;	Crystal structure of human VAT-1
4KZN	;	1.7114	;	crystal structure of human VEGF-A receptor binding domain
3VHE	;	1.55	;	Crystal structure of human VEGFR2 kinase domain with a novel pyrrolopyrimidine inhibitor.
3VID	;	2.3	;	Crystal structure of human VEGFR2 kinase domain with Compound A.
2UXW	;	1.45	;	Crystal structure of human very long chain acyl-CoA dehydrogenase (ACADVL)
4EHP	;	2.66	;	Crystal Structure of human vinculin head domain (residues 1-252) in complex with alpha-catenin (residues 277-382)
6OIL	;	1.85	;	Crystal structure of human VISTA extracellular domain
5V39	;	2.2	;	Crystal structure of human vitamin D receptor ligand binding domain in complex with a VDRM
1KXP	;	2.1	;	CRYSTAL STRUCTURE OF HUMAN VITAMIN D-BINDING PROTEIN IN COMPLEX WITH SKELETAL ACTIN
5XDO	;	3.1	;	Crystal structure of human voltage-dependent anion channel 1 (hVDAC1) in C222 space group
5XDN	;	3.15	;	Crystal structure of human voltage-dependent anion channel 1 (hVDAC1) in P22121 space group
4NT5	;	3.281	;	Crystal structure of human von Willebrand factor CTCK domain
2FAU	;	2.1	;	Crystal structure of human vps26
1W24	;	2.1	;	Crystal Structure Of human Vps29
8ESE	;	1.35	;	Crystal structure of human Vps29 bound to a peptide from Vps35L
6XS5	;	2.01	;	Crystal structure of human Vps29 complexed with RaPID-derived cyclic peptide RT-D1
6XS7	;	1.58	;	Crystal structure of human Vps29 complexed with RaPID-derived cyclic peptide RT-D2
6XS9	;	2.69	;	Crystal structure of human Vps29 complexed with RaPID-derived cyclic peptide RT-L1
6XSA	;	1.83	;	Crystal structure of human Vps29 complexed with RaPID-derived cyclic peptide RT-L2
5XGS	;	2.0	;	Crystal structure of human WBSCR16
4IA9	;	1.66	;	Crystal structure of human WD REPEAT DOMAIN 5 in complex with 2-chloro-4-fluoro-3-methyl-N-[2-(4-methylpiperazin-1-yl)-5-nitrophenyl]benzamide
3SMR	;	1.82	;	Crystal structure of human WD repeat domain 5 with compound
3UR4	;	1.8	;	Crystal structure of human WD repeat domain 5 with compound
4GM3	;	3.393	;	Crystal structure of human WD repeat domain 5 with compound MM-101
4GM8	;	2.601	;	Crystal structure of human WD repeat domain 5 with compound MM-102
4GM9	;	2.1	;	Crystal structure of human WD repeat domain 5 with compound MM-401
4GMB	;	2.781	;	Crystal structure of human WD repeat domain 5 with compound MM-402
8UJY	;	2.01	;	Crystal structure of human WD repeat-containing protein 5 in complex with 4-(3,5-dimethoxybenzyl)-9-(4-fluoro-2-methylphenyl)-7-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one (compound 8)
8W3V	;	2.2	;	Crystal structure of human WDR41
6OFZ	;	1.85	;	Crystal structure of human WDR5
8G3E	;	1.33	;	Crystal structure of human WDR5 in complex with (1M)-N-[(3,5-difluoro[1,1'-biphenyl]-4-yl)methyl]-6-methyl-4-oxo-1-(pyridin-3-yl)-1,4-dihydropyridazine-3-carboxamide (compound 2, WDR5-MYC inhibitor)
7WVK	;	1.42	;	Crystal structure of human WDR5 in complex with compound 19
5EAR	;	1.8	;	Crystal structure of human WDR5 in complex with compound 9d
5EAP	;	1.73	;	Crystal structure of human WDR5 in complex with compound 9e
5EAL	;	1.8	;	Crystal structure of human WDR5 in complex with compound 9h
5EAM	;	1.8	;	Crystal structure of human WDR5 in complex with compound 9o
4QL1	;	1.5	;	Crystal structure of human WDR5 in complex with compound OICR-9429
8F1G	;	2.14	;	Crystal structure of human WDR5 in complex with compound WM662
6OI0	;	1.92	;	Crystal structure of human WDR5 in complex with L-arginine
6OI3	;	1.66	;	Crystal structure of human WDR5 in complex with monomethyl H3R2 peptide
6OI1	;	1.68	;	Crystal structure of human WDR5 in complex with monomethyl L-arginine
8T5I	;	1.7	;	Crystal structure of human WDR5 in complex with MR4397
8G3C	;	1.8	;	Crystal structure of human WDR5 in complex with N-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-3-hydroxy-6-methyl-4-oxo-4H-pyran-2-carboxamide (compound 1, WDR5-MYC PPI inhibitor)
6OI2	;	1.68	;	Crystal structure of human WDR5 in complex with symmetric dimethyl-L-arginine
7KQQ	;	1.8	;	Crystal structure of human WDR55
5VC3	;	1.97	;	CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB
5VC4	;	2.1	;	Crystal structure of HUMAN WEE1 KINASE domain in complex with Bosutinib-isomer
5V5Y	;	1.9	;	CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH MK1775
5VC5	;	1.93	;	Crystal structure of human WEE1 kinase domain in complex with PD-166285
5VD2	;	2.05	;	crystal structure of human WEE1 kinase domain in complex with PF-03814735
5VC6	;	2.0	;	crystal structure of human WEE1 kinase domain in complex with PHA-848125
5VD4	;	2.02	;	CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV-016, a MK1775 analougue
5VD5	;	2.05	;	CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV-050, a MK1775 analougue
5VD9	;	1.87	;	Crystal structure of human WEE1 kinase domain in complex with RAC-IV-097, a MK1775 analogue
5VD7	;	2.08	;	CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV-098, a MK1775 analogue
5VD8	;	1.85	;	Crystal structure of human WEE1 kinase domain in complex with RAC-IV-099, a MK1775 analogue
5VDA	;	2.1	;	Crystal structure of human WEE1 kinase domain in complex with RAC-IV-101, a MK1775 analogue
7N3U	;	2.65	;	Crystal structure of human WEE1 kinase domain in complex with ZN-c3
5VDK	;	2.7	;	Crystal structure of human WEE2 kinase domain in complex with MK1775
6FWU	;	2.35	;	Crystal structure of human wild type beta-1,4-galactosyltransferase-1 (B4GalT1) in apo-closed dimeric form
6FWT	;	1.845	;	Crystal structure of human wild type beta-1,4-galactosyltransferase-1 (B4GalT1) in apo-open monomeric form
5E6M	;	2.927	;	Crystal structure of human wild type GlyRS bound with tRNAGly
6S26	;	2.05	;	Crystal structure of human wild type STING in complex with 2'-3'-cyclic-GMP-7-deaza-AMP
6S27	;	2.802	;	Crystal structure of human wild type STING in complex with 2'3'-cyclic-GMP-2'F-2'dAMP
7QC5	;	1.2	;	Crystal structure of human wild type transthyretin in complex with (3,4-dihydroxy-5-nitrophenyl)-(3-fluoro-5-hydroxyphenyl)methanone compound
6LK0	;	2.6	;	Crystal structure of human wild type TRIP13
4WNC	;	1.99	;	Crystal structure of human wild-type GAPDH at 1.99 angstroms resolution
3CFQ	;	2.09	;	Crystal structure of human wild-type transthyretin in complex with diclofenac
6KLR	;	2.21	;	Crystal structure of human WIPI3 in complex with the WIR-peptide from ATG2A
6IYY	;	1.796	;	Crystal structure of human WIPI3,loop deletion mutant
6L4B	;	2.2	;	Crystal structure of human WT NDRG3
5W22	;	1.762	;	Crystal structure of human WT-KRAS in complex with GDP
5VQ8	;	2.3	;	Crystal structure of human WT-KRAS in complex with GDP (EDTA soaked)
5VQ2	;	1.96	;	Crystal structure of human WT-KRAS in complex with GTP
5VQ6	;	1.99	;	Crystal structure of human WT-KRAS in complex with GTP-gamma-S
7YFJ	;	2.4	;	Crystal structure of human WTAP
2E1Q	;	2.6	;	Crystal Structure of Human Xanthine Oxidoreductase mutant, Glu803Val
2R9A	;	2.5	;	Crystal structure of human XLF
3SR2	;	3.9708	;	Crystal Structure of Human XLF-XRCC4 Complex
2QM4	;	2.3	;	Crystal structure of human XLF/Cernunnos, a non-homologous end-joining factor
1FU1	;	2.7	;	CRYSTAL STRUCTURE OF HUMAN XRCC4
3KYS	;	2.8	;	Crystal structure of human YAP and TEAD complex
7F3J	;	1.95	;	Crystal structure of human YBX2 CSD in complex with m5C RNA in space group P1
7F3K	;	1.76	;	Crystal structure of human YBX2 CSD in complex with m5C RNA in space group P21212
7F3I	;	2.25	;	Crystal structure of human YBX2 CSD in complex with m5C RNA in space group P212121
7F3L	;	1.88	;	Crystal structure of human YBX2 CSD in complex with m5C RNA in space group P62
5VNA	;	2.1	;	Crystal structure of human YEATS domain
8DKB	;	2.58	;	Crystal Structure of human YEATS4 in complex with Pfizer small molecule compound 3b
6LXJ	;	2.903	;	Crystal structure of human Z2B3 Fab in complex with influenza virus neuraminidase from A/Anhui/1/2013 (H7N9)
6UCA	;	3.103	;	Crystal structure of human ZCCHC4 in complex with SAH
1YB5	;	1.85	;	Crystal structure of human Zeta-Crystallin with bound NADP
3FKC	;	1.7	;	Crystal Structure of Human Zinc finger and BTB domain containing 33
6UEI	;	2.51	;	Crystal structure of human zinc finger antiviral protein
6UEJ	;	2.21	;	Crystal structure of human zinc finger antiviral protein bound to RNA
5CNY	;	1.7	;	Crystal Structure of human zinc insulin at pH 5.5
5CO6	;	1.8	;	Crystal structure of human zinc insulin at pH 6.5
5CO9	;	1.92	;	Crystal structure of human zinc insulin at pH 6.5
2W4Q	;	2.0	;	Crystal structure of human zinc-binding alcohol dehydrogenase 1 (ZADH1) in ternary complex with NADP and 18beta-glycyrrhetinic acid
2W98	;	1.85	;	CRYSTAL STRUCTURE OF HUMAN ZINC-BINDING ALCOHOL DEHYDROGENASE 1 (ZADH1) IN TERNARY COMPLEX WITH NADP AND PHENYLBUTAZONE
2J90	;	2.0	;	Crystal structure of human ZIP kinase in complex with a tetracyclic pyridone inhibitor (Pyridone 6)
5VJA	;	2.46	;	Crystal Structure of human zipper-interacting protein kinase (ZIPK, alias DAPK3) in complex with a pyrazolo[3,4-d]pyrimidinone ligand (HS38)
5B73	;	1.8	;	Crystal structure of human ZMYND8 PHD-Bromo-PWWP domain
6FGE	;	1.74	;	Crystal structure of human ZUFSP/ZUP1 in complex with ubiquitin
4WYO	;	2.89	;	Crystal structure of human-yeast chimera acetyl coA carboxylase CT domain bound to Compound 1
4WZ8	;	2.23	;	Crystal structure of human-yeast chimera acetyl coA carboxylase CT domain bound to Compound 6
2X29	;	2.3	;	Crystal structure of human4-1BB ligand ectodomain
6CA4	;	1.623	;	Crystal structure of humanized D. rerio TDP2 by 14 mutations
2YSS	;	2.4	;	Crystal structure of Humanized HYHEL-10 FV mutant(HQ39KW47Y)-HEN lysozyme complex
2EIZ	;	1.9	;	Crystal structure of humanized HYHEL-10 fv mutant(HW47Y)-hen lysozyme complex
2EKS	;	2.0	;	Crystal structure of humanized HyHEL-10 FV-HEN lysozyme complex
2EH7	;	2.5	;	Crystal structure of humanized KR127 FAB
5W1X	;	3.374	;	Crystal Structure of Humanpapillomavirus18 (HPV18) Capsid L1 Pentamers Bound to Heparin Oligosaccharides
3ILG	;	1.9	;	Crystal structure of humnan insulin Sr+2 complex
2QA7	;	2.8	;	Crystal structure of Huntingtin-interacting protein 1 (HIP1) coiled-coil domain with a basic surface suitable for HIP-protein interactor (HIPPI)
1WPS	;	2.8	;	Crystal Structure of HutP, an RNA binding anti-termination protein
1WPT	;	2.7	;	Crystal Structure of HutP, an RNA binding anti-termination protein
1VEA	;	2.8	;	Crystal Structure of HutP, an RNA binding antitermination protein
1WRQ	;	2.2	;	Crystal Structure of HutP-Antitermination complex
7CEA	;	2.55	;	Crystal structure of HUTS-4 Fv-clasp fragment
3TGV	;	1.999	;	Crystal structure of HutZ,the heme storsge protein from Vibrio cholerae
5FV2	;	3.45	;	Crystal structure of hVEGF in complex with VH domain antibody
5FV1	;	2.7	;	Crystal structure of hVEGF in complex with VK domain antibody
4FHQ	;	2.251	;	Crystal Structure of HVEM
5UWT	;	2.342	;	Crystal Structure of Hxk2 Peptide in complex with CRM1 K579A mutant-Ran-RanBP1
2OQQ	;	2.0	;	Crystal structure of HY5 leucine zipper homodimer from Arabidopsis thaliana
3RMR	;	2.3	;	Crystal structure of Hyaloperonospora arabidopsidis ATR1 effector domain
8FYG	;	2.05	;	Crystal structure of Hyaluronate lyase A from Cutibacterium acnes
8FNX	;	2.1	;	Crystal structure of Hyaluronate lyase B from Cutibacterium acnes
6WGZ	;	2.2	;	Crystal structure of HyBcl-2-4 with HyBak1 BH3
6WH0	;	1.99	;	Crystal structure of HyBcl-2-4 with HyBax BH3
7CHL	;	3.4	;	Crystal structure of hybrid Arabinose isomerase AI-10
6NCY	;	2.05	;	Crystal structure of hybrid beta-glucuronidase/beta-galacturonidase from Fusicatenibacter saccharivorans
6NCZ	;	2.2	;	Crystal structure of hybrid beta-glucuronidase/beta-galacturonidase from Fusicatenibacter saccharivorans bound to phenyl-thio-beta-D-glucuronide
6FSH	;	2.5	;	Crystal structure of hybrid P450 OxyBtei(BC/FGvan)
4UC4	;	2.5612	;	Crystal structure of hybrid tudor domain of human lysine demethylase KDM4B
2EQ5	;	2.2	;	Crystal structure of hydantoin racemase from Pyrococcus horikoshii OT3
5KH0	;	2.8	;	Crystal Structure of HydF from thermosipho melanesiensis in complex with a [4Fe-4S] cluster
4WCX	;	1.59	;	Crystal structure of HydG: A maturase of the [FeFe]-hydrogenase
3L2Z	;	2.8	;	Crystal structure of hydrated Biotin Protein Ligase from M. tuberculosis
5H6T	;	1.6	;	Crystal structure of Hydrazidase from Microbacterium sp. strain HM58-2
5H6S	;	1.8	;	Crystal structure of Hydrazidase S179A mutant complexed with a substrate
6KMK	;	2.3	;	Crystal structure of hydrogen peroxide bound bovine lactoperoxidase at 2.3 A resolution
7C4R	;	2.44	;	Crystal structure of hydrogen peroxide treated zebrafish TRF2 complexed with DNA
8IQ0	;	1.88	;	Crystal structure of hydrogen sulfide-bound superoxide dismutase in oxidized state
8IQ1	;	1.8	;	Crystal structure of hydrogen sulfide-bound superoxide dismutase in reduced state
5B55	;	2.14	;	Crystal structure of hydrogen sulfide-producing enzyme (Fn1055) D232N mutant in complexed with alpha-aminoacrylate intermediate: lysine-dimethylated form
5B53	;	2.91	;	Crystal structure of hydrogen sulfide-producing enzyme (Fn1055) from Fusobacterium nucleatum
5Z5C	;	2.07	;	Crystal structure of hydrogen sulfide-producing enzyme (Fn1055) from Fusobacterium nucleatum: lysine-dimethylated form
5TTX	;	2.401	;	Crystal structure of hydrogenase 2 maturation peptidase from Thaumarchaeota archaeon SCGC_AB-539-E09
2WSM	;	2.3	;	Crystal structure of Hydrogenase Maturation Factor HypB From Archaeoglobus Fulgidus
2Z1T	;	2.6	;	Crystal Structure of Hydrogenase Maturation Protein HypE
2Z1U	;	2.0	;	Crystal Structure of Hydrogenase Maturation Protein HypE in complex with ATP
2QGV	;	2.7	;	Crystal structure of hydrogenase-1 operon protein hyaE from Shigella flexneri. Northeast Structural Genomics Consortium Target SfR170
4XUK	;	2.0	;	Crystal structure of hydrolase AbOPH in beta lactamase superfamily
3PDC	;	2.6	;	Crystal structure of hydrolase domain of human soluble epoxide hydrolase complexed with a benzoxazole inhibitor
3FDK	;	2.1	;	Crystal structure of hydrolase DR0930 with promiscuous catalytic activity
2HCF	;	1.8	;	Crystal structure of hydrolase haloacid dehalogenase-like family (np_662590.1) from Chlorobium tepidum TLS at 1.80 A resolution
3IPW	;	1.95	;	Crystal structure of hydrolase TatD family protein from Entamoeba histolytica
1VLA	;	1.8	;	Crystal structure of Hydroperoxide resistance protein OsmC (TM0919) from Thermotoga maritima at 1.80 A resolution
1HYP	;	1.8	;	CRYSTAL STRUCTURE OF HYDROPHOBIC PROTEIN FROM SOYBEAN; A MEMBER OF A NEW CYSTINE-RICH FAMILY
2FZ6	;	2.1	;	Crystal structure of hydrophobin HFBI
2GVM	;	2.3	;	Crystal structure of hydrophobin HFBI with detergent
7S86	;	2.0	;	Crystal structure of hydrophobin SC16, C2221
7S7S	;	2.2	;	Crystal structure of hydrophobin SC16, P21212
5M22	;	2.4	;	Crystal structure of hydroquinone 1,2-dioxygenase from Sphingomonas sp. TTNP3
5M4O	;	2.1	;	Crystal structure of hydroquinone 1,2-dioxygenase from Sphingomonas sp. TTNP3 in complex with 4-nitrophenol
5M26	;	1.9	;	Crystal structure of hydroquinone 1,2-dioxygenase from Sphingomonas sp. TTNP3 in complex with methylhydroquinone
5M21	;	1.99	;	Crystal structure of hydroquinone 1,2-dioxygenase from Sphingomonas sp. TTNP3 with 4-hydroxybenzoate bound
4ZXD	;	3.052	;	Crystal Structure of hydroquinone 1,2-dioxygenase PnpCD
4ZXA	;	2.488	;	Crystal Structure of hydroquinone 1,2-dioxygenase PnpCD in complex with Cd2+ and 4-hydroxybenzonitrile
4ZXC	;	3.05	;	Crystal Structure of hydroquinone 1,2-dioxygenase PnpCD in complex with Fe3+
7L0B	;	1.65	;	Crystal structure of hydroxyacyl glutathione hydrolase (GloB) from Staphylococcus aureus, apoenzyme
2J5I	;	1.8	;	Crystal Structure of Hydroxycinnamoyl-CoA Hydratase-Lyase
2IQG	;	1.7	;	Crystal Structure of Hydroxyethyl Secondary Amine-based Peptidomimetic Inhibitor of Human Beta-Secretase (BACE)
1EKQ	;	1.5	;	CRYSTAL STRUCTURE OF HYDROXYETHYLTHIAZOLE KINASE IN R3 SPACE GROUP
1EKK	;	2.0	;	CRYSTAL STRUCTURE OF HYDROXYETHYLTHIAZOLE KINASE IN THE R3 FORM WITH HYDROXYETHYLTHIAZOLE
8UW4	;	2.15	;	Crystal structure of hydroxyisourate hydrolase from Herbaspirillum seropedicae
2FTP	;	2.4	;	Crystal Structure of hydroxymethylglutaryl-CoA lyase from Pseudomonas aeruginosa
7N7S	;	2.4	;	Crystal Structure of Hydroxymethylglutaryl-CoA reductase from Elizabethkingia anophelis NUHP1
7VB3	;	1.48	;	Crystal structure of hydroxynitrile lyase from Linum usitatissimum
7VB5	;	1.58	;	Crystal structure of hydroxynitrile lyase from Linum usitatissimum complexed with acetone cyanohydrin
7VB6	;	1.74	;	Crystal structure of hydroxynitrile lyase from Linum usitatissium complexed with (R)-2-hydroxy-2-methylbutanenitrile
1DWP	;	2.2	;	Crystal Structure of Hydroxynitrile Lyase from Manihot esculenta at 2.2 Angstrom Resolution
1DWO	;	2.2	;	Crystal Structure of Hydroxynitrile Lyase from Manihot esculenta in Complex with Substrates Acetone and Chloroacetone:Implications for the Mechanism of Cyanogenesis
1DWQ	;	2.2	;	Crystal Structure of Hydroxynitrile Lyase from Manihot esculenta in Complex with Substrates Acetone and Chloroacetone:Implications for the Mechanism of Cyanogenesis
1GXS	;	2.3	;	Crystal Structure of Hydroxynitrile Lyase from Sorghum bicolor in Complex with Inhibitor Benzoic Acid: a novel cyanogenic enzyme
6VXC	;	2.05	;	Crystal structure of hydroxyproline dehydratase (HypD) from Clostridioides difficile
6VXE	;	2.464	;	Crystal structure of hydroxyproline dehydratase (HypD) from Clostridioides difficile with substrate trans-4-hydroxy-L-proline bound
3DDN	;	2.4	;	Crystal structure of hydroxypyruvic acid phosphate bound D-3-phosphoglycerate dehydrogenase in mycobacterium tuberculosis
1TMX	;	1.75	;	Crystal structure of hydroxyquinol 1,2-dioxygenase from Nocardioides Simplex 3E
7ENY	;	2.703	;	Crystal structure of hydroxysteroid dehydrogenase from Escherichia coli
4ZPI	;	2.504	;	Crystal Structure of HygX from Streptomyces hygroscopicus with iron bound
4XCA	;	2.295	;	Crystal Structure of HygX from Streptomyces hygroscopicus with nickel and 2-oxoglutarate bound
4XCB	;	1.6	;	Crystal Structure of HygX from Streptomyces hygroscopicus with nickel, 2-oxoglutarate, and hygromycin B bound
5AYU	;	1.8	;	Crystal structure of HyHEL-10 Fv
2DQJ	;	1.8	;	Crystal structure of hyhel-10 FV (wild-type) complexed with hen egg lysozyme at 1.8A resolution
2DQD	;	1.8	;	Crystal structure of hyhel-10 FV mutant (Hy50f) complexed with hen egg lysozyme
2DQE	;	1.9	;	Crystal structure of hyhel-10 FV mutant (Hy53a) complexed with hen egg lysozyme
2DQG	;	2.3	;	Crystal structure of hyhel-10 FV mutant (Hy53f) complexed with hen egg lysozyme
2DQH	;	2.3	;	Crystal structure of hyhel-10 FV mutant (Hy58a) complexed with hen egg lysozyme
2DQI	;	2.0	;	Crystal structure of hyhel-10 FV mutant (Ly50a) complexed with hen egg lysozyme
2DQF	;	2.5	;	Crystal structure of hyhel-10 FV mutant (y33ay53a) complexed with hen egg lysozyme
3A67	;	1.8	;	Crystal Structure of HyHEL-10 Fv mutant LN31D complexed with hen egg white lysozyme
3A6B	;	1.8	;	Crystal Structure of HyHEL-10 Fv mutant LN32D complexed with hen egg white lysozyme
3A6C	;	1.8	;	Crystal Structure of HyHEL-10 Fv mutant LN92D complexed with hen egg white lysozyme
1J1P	;	1.8	;	Crystal structure of HyHEL-10 Fv mutant LS91A complexed with hen egg white lysozyme
1J1X	;	1.8	;	Crystal Structure of HyHEL-10 Fv mutant LS93A complexed with hen egg white lysozyme
1J1O	;	1.8	;	Crystal Structure of HyHEL-10 Fv mutant LY50F complexed with hen egg white lysozyme
1UA6	;	1.9	;	Crystal structure of HYHEL-10 FV MUTANT SFSF complexed with HEN EGG WHITE LYSOZYME complex
1UAC	;	1.7	;	Crystal Structure of HYHEL-10 FV MUTANT SFSF Complexed with TURKEY WHITE LYSOZYME
1IC4	;	2.5	;	CRYSTAL STRUCTURE OF HYHEL-10 FV MUTANT(HD32A)-HEN LYSOZYME COMPLEX
1IC7	;	2.1	;	CRYSTAL STRUCTURE OF HYHEL-10 FV MUTANT(HD32A99A)-HEN LYSOZYME COMPLEX
1IC5	;	2.3	;	CRYSTAL STRUCTURE OF HYHEL-10 FV MUTANT(HD99A)-HEN LYSOZYME COMPLEX
2DQC	;	1.8	;	Crystal structure of hyhel-10 FV mutant(Hy33f) complexed with hen egg lysozyme
1C08	;	2.3	;	CRYSTAL STRUCTURE OF HYHEL-10 FV-HEN LYSOZYME COMPLEX
1NBY	;	1.8	;	Crystal Structure of HyHEL-63 complexed with HEL mutant K96A
1NBZ	;	1.85	;	Crystal Structure of HyHEL-63 complexed with HEL mutant K97A
2YVV	;	2.6	;	Crystal structure of hyluranidase complexed with lactose at 2.6 A resolution reveals three specific sugar recognition sites
2YW0	;	2.6	;	Crystal structure of hyluranidase trimer at 2.6 A resolution
7ER7	;	1.7	;	Crystal structure of hyman Biliverdin IX-beta reductase B with Tamibarotene (A80)
2PQ0	;	2.6	;	Crystal structure of Hyopthetical protein (gk_1056) from geobacillus Kaustophilus HTA426
8II9	;	2.17	;	crystal structure of Hyp mutant from Hypoxylon sp. E7406B
8IJT	;	2.56	;	crystal structure of Hyp N135A mutant from Hypoxylon sp. E7406B
3IE5	;	1.688	;	Crystal structure of Hyp-1 protein from Hypericum perforatum (St John's wort) involved in hypericin biosynthesis
4N3E	;	2.43	;	Crystal structure of Hyp-1, a St John's wort PR-10 protein, in complex with 8-anilino-1-naphthalene sulfonate (ANS)
3A43	;	2.3	;	Crystal structure of HypA
3A44	;	3.31	;	Crystal structure of HypA in the dimeric form
4LPS	;	2.0	;	Crystal structure of HypB from Helicobacter pylori in complex with nickel
2HF9	;	1.9	;	Crystal structure of HypB from Methanocaldococcus jannaschii in the triphosphate form
2HF8	;	2.1	;	Crystal structure of HypB from Methanocaldococcus jannaschii in the triphosphate form, in complex with zinc
2Z1C	;	1.8	;	Crystal structure of HypC from Thermococcus kodakaraensis KOD1
5CZJ	;	1.92	;	Crystal structure of HypD, a 1-pyrroline-4-hydroxy-2-carboxylate deaminase from Sinorhizobium meliloti
6ZMD	;	2.64	;	Crystal structure of HYPE covalently tethered to BiP bound to AMP-PNP
2Z1F	;	1.7	;	Crystal structure of HypE from Thermococcus kodakaraensis (inward form)
2Z1E	;	1.55	;	Crystal structure of HypE from Thermococcus kodakaraensis (outward form)
3WJR	;	1.864	;	crystal structure of HypE in complex with a nucleotide
3VTI	;	2.56	;	Crystal structure of HypE-HypF complex
5FM2	;	3.3	;	Crystal structure of hyper-phosphorylated RET kinase domain with (proximal) juxtamembrane segment
5FM3	;	2.95	;	Crystal structure of hyper-phosphorylated RET kinase domain with (proximal) juxtamembrane segment
7UGT	;	1.21	;	Crystal structure of hyperfolder fluorescent protein FOLD6
7UGR	;	1.74	;	Crystal structure of hyperfolder YFP
2EHG	;	1.6	;	Crystal structure of hyperthermophilic archaeal RNase HI
3APG	;	2.35	;	Crystal structure of hyperthermophilic beta-glucosidase from pyrococcus furiosus
3RJX	;	2.4	;	Crystal Structure of Hyperthermophilic Endo-Beta-1,4-glucanase
3RJY	;	2.2	;	Crystal Structure of Hyperthermophilic Endo-beta-1,4-glucanase in complex with substrate
3IVZ	;	1.57	;	Crystal structure of hyperthermophilic nitrilase
3IW3	;	1.8	;	Crystal structure of hyperthermophilic nitrilase
3KI8	;	1.6	;	Crystal structure of hyperthermophilic nitrilase
3KLC	;	1.76	;	Crystal structure of hyperthermophilic nitrilase
5B7Y	;	1.32	;	Crystal Structure of Hyperthermophilic Thermotoga maritima L-Ketose-3-Epimerase with Co2+
5B80	;	1.7	;	Crystal Structure of Hyperthermophilic Thermotoga maritima L-Ketose-3-Epimerase with Cu2+
5H1W	;	1.631	;	Crystal Structure of Hyperthermophilic Thermotoga maritima L-Ketose-3-Epimerase with Mn2+ and L(+)-Erythrulose
5B7Z	;	1.5	;	Crystal Structure of Hyperthermophilic Thermotoga maritima L-Ketose-3-Epimerase with Ni2+
5H6H	;	1.446	;	Crystal Structure of Hyperthermophilic Thermotoga maritima L-Ribulose 3-Epimerase with Mn2+
2D7U	;	2.5	;	Crystal structure of hypothetical adenylosuccinate synthetase, PH0438 from Pyrococcus horikoshii OT3
2Z0M	;	1.9	;	Crystal structure of hypothetical ATP-dependent RNA helicase from Sulfolobus tokodaii
2GGS	;	1.7	;	crystal structure of hypothetical dTDP-4-dehydrorhamnose reductase from sulfolobus tokodaii
2E87	;	2.35	;	Crystal structure of hypothetical GTP-binding protein PH1320 from Pyrococcus horikoshii OT3, in complex with GDP
2EO4	;	1.8	;	Crystal structure of hypothetical histidine triad nucleotide-binding protein ST2152 from Sulfolobus tokodaii strain7
2YR0	;	1.9	;	Crystal Structure of Hypothetical Methyltransferase TTHA0223 from Thermus thermophilus HB8
2YQZ	;	1.8	;	Crystal Structure of Hypothetical Methyltransferase TTHA0223 from Thermus thermophilus HB8 complexed with S-adenosylmethionine
2OHD	;	2.2	;	Crystal structure of hypothetical molybdenum cofactor biosynthesis protein C from Sulfolobus tokodaii
2EGT	;	2.0	;	Crystal Structure of Hypothetical protein (AQ1549) from Aquifex aeolicus
3VNP	;	2.4	;	Crystal structure of hypothetical protein (GK2848) from Geobacillus Kaustophilus
5YIT	;	2.79	;	Crystal Structure of Hypothetical protein (Rv3272) from Mycobacterium tuberculosis
2IDG	;	2.69	;	Crystal Structure of hypothetical protein AF0160 from Archaeoglobus fulgidus
1TJN	;	2.01	;	Crystal structure of hypothetical protein af0721 from Archaeoglobus fulgidus
2P6H	;	1.95	;	Crystal structure of hypothetical protein APE1520 from Aeropyrum pernix K1
1WDV	;	1.7	;	Crystal structure of hypothetical protein APE2540
2P6C	;	2.0	;	Crystal structure of hypothetical protein aq_2013 from Aquifex aeolicus VF5.
3OA4	;	1.94	;	CRYSTAL STRUCTURE OF hypothetical protein BH1468 from Bacillus halodurans C-125
1S5U	;	1.7	;	Crystal Structure of Hypothetical Protein EC709 from Escherichia coli
2DVK	;	1.8	;	Crystal Structure of Hypothetical protein from Aeropyrum pernix
3KBY	;	1.8	;	Crystal structure of hypothetical protein from Staphylococcus aureus
2I5T	;	2.01	;	Crystal Structure of hypothetical protein LOC79017 from Homo sapiens
3Q4N	;	2.88	;	Crystal structure of hypothetical protein MJ0754 from Methanococcus jannaschii DSM 2661
2EKY	;	1.8	;	Crystal Structure of hypothetical protein MJ1052 from Methanocaldococcus jannaschii (Form 1)
2DB7	;	1.9	;	Crystal structure of hypothetical protein MS0332
3FX7	;	1.65	;	Crystal structure of hypothetical protein of HP0062 from Helicobacter pylori
1V96	;	1.75	;	Crystal structure of hypothetical protein of unknown function from pyrococcus horikoshii OT3
1YE5	;	2.0	;	Crystal structure of hypothetical protein of unknown function from pyrococcus horikoshii OT3
4IX1	;	2.8	;	Crystal structure of hypothetical protein OPAG_01669 from Rhodococcus Opacus PD630, Target 016205
2X5C	;	1.8	;	Crystal structure of hypothetical protein ORF131 from Pyrobaculum Spherical Virus
2X3M	;	1.45	;	Crystal Structure of Hypothetical Protein ORF239 from Pyrobaculum Spherical Virus
4B7C	;	2.1	;	Crystal structure of hypothetical protein PA1648 from Pseudomonas aeruginosa.
4B7X	;	2.2	;	Crystal structure of hypothetical protein PA1648 from Pseudomonas aeruginosa.
2HDW	;	2.0	;	Crystal structure of hypothetical protein PA2218 from Pseudomonas Aeruginosa
4PGO	;	2.3	;	Crystal structure of hypothetical protein PF0907 from Pyrococcus furiosus solved by sulfur SAD using Swiss Light Source data
4PII	;	2.17	;	Crystal structure of hypothetical protein PF0907 from pyrococcus furiosus solved by sulfur SAD using Swiss light source data
2P62	;	2.5	;	Crystal structure of hypothetical protein PH0156 from Pyrococcus horikoshii OT3
2Z0T	;	1.8	;	Crystal structure of hypothetical protein PH0355
2HUN	;	2.07	;	Crystal structure of hypothetical protein PH0414 from Pyrococcus horikoshii OT3
1J31	;	1.6	;	Crystal Structure of Hypothetical Protein PH0642 from Pyrococcus horikoshii
3D79	;	1.73	;	Crystal structure of hypothetical protein PH0734.1 from hyperthermophilic archaea Pyrococcus horikoshii OT3
2GJU	;	2.0	;	Crystal structure of hypothetical protein PH1004 from Pyrococcus horikoshii OT3
2HVB	;	2.5	;	Crystal structure of hypothetical protein PH1083 from Pyrococcus horikoshii OT3
2E6U	;	1.8	;	Crystal structure of hypothetical protein PH1109 from Pyrococcus horikoshii
1WR8	;	1.6	;	Crystal structure of hypothetical protein PH1421 from Pyrococcus horikoshii.
1ZJJ	;	1.85	;	Crystal structure of hypothetical protein PH1952 from Pyrococcus horikoshii OT3
2CVI	;	1.5	;	Crystal structure of hypothetical protein PHS023 from Pyrococcus horikoshii
2VXZ	;	1.7	;	Crystal Structure of hypothetical protein PyrSV_gp04 from Pyrobaculum spherical virus
4M20	;	2.0	;	Crystal Structure of hypothetical protein SAV0944 from Staphylococcus aureus subsp. aureus Mu50
4ITQ	;	2.7	;	Crystal structure of hypothetical protein SCO1480 bound to DNA
4DNH	;	2.5	;	Crystal structure of hypothetical protein SMc04132 from Sinorhizobium meliloti 1021
2IVY	;	1.4	;	Crystal structure of hypothetical protein sso1404 from Sulfolobus solfataricus P2
2X5Q	;	2.05	;	Crystal Structure of Hypothetical protein sso1986 from Sulfolobus solfataricus P2
1ZZG	;	1.95	;	Crystal structure of hypothetical protein TT0462 from Thermus thermophilus HB8
2Z0R	;	2.3	;	Crystal structure of hypothetical protein TTHA0547
1WV8	;	2.2	;	Crystal structure of hypothetical protein TTHA1013 from an extremely thermophilic bacterium thermus thermophilus HB8
3VG8	;	2.2	;	Crystal structure of hypothetical protein TTHB210 from Thermus thermophilus HB8
4H3U	;	1.15	;	Crystal structure of hypothetical protein with ketosteroid isomerase-like protein fold from Catenulispora acidiphila DSM 44928
4HVN	;	1.95	;	Crystal structure of hypothetical protein with ketosteroid isomerase-like protein fold from Catenulispora acidiphila DSM 44928 in complex with Trimethylamine.
4NAV	;	2.69	;	Crystal structure of hypothetical protein XCC2798 from Xanthomonas campestris, Target EFI-508608
2ICU	;	1.6	;	Crystal Structure of Hypothetical Protein YedK From Escherichia coli
1ZYL	;	2.8	;	Crystal Structure of Hypothetical Protein YihE from Escherichia coli
1U5W	;	2.3	;	Crystal structure of hypothetical protein yjjX from Escherichia coli
1SGM	;	2.0	;	Crystal Structure of Hypothetical Protein YXAF
1WY6	;	2.2	;	Crystal Structure of Hypothetical Protein [ST1625p] from Hyperthermophilic Archaeon Sulfolobus tokodaii
2EGJ	;	1.8	;	Crystal Structure of Hypothetical Protein(AQ1494) from Aquifex aeolicus
2EGR	;	1.8	;	Crystal Structure of Hypothetical Protein(AQ1494) from Aquifex aeolicus
2RBG	;	1.75	;	Crystal structure of hypothetical protein(ST0493) from sulfolobus tokodaii
2EI5	;	1.88	;	Crystal Structure of Hypothetical protein(TTHA0061) from Thermus thermophilus
2DUM	;	2.75	;	Crystal structure of hypothetical protein, PH0823
2ZG6	;	2.4	;	Crystal structure of Hypothetical protein; probable 2-haloalkanoic acid dehalogenase from Sulfolobus tokodaii
4I82	;	2.5	;	Crystal Structure of Hypothetical Thioesterase Protein SP_1851 from Streptococcus pneumoniae TIGR4
4ZRF	;	1.86	;	Crystal Structure of Hypothetical Thioesterase Protein SP_1851 from Streptococcus pneumoniae TIGR4
4ZRB	;	2.2	;	Crystal Structure of Hypothetical Thioesterase Protein SP_1851 with Coenzyme A from Streptococcus pneumoniae TIGR4
3VK0	;	1.88	;	Crystal Structure of hypothetical transcription factor NHTF from Neisseria
2CWE	;	2.7	;	Crystal structure of hypothetical transcriptional regulator protein, PH1932 from Pyrococcus horikoshii OT3
2ZKI	;	2.9	;	Crystal structure of hypothetical Trp repressor binding protein from Sul folobus tokodaii (ST0872)
4PFQ	;	2.1	;	Crystal structure of hypoxanthine phosphoribosyltransferase from Brachybacterium faecium DSM 4810, NYSGRC Target 029763.
4LYY	;	1.86	;	Crystal structure of hypoxanthine phosphoribosyltransferase from Shewanella pealeana ATCC 700345, NYSGRC Target 029677.
5ESX	;	2.71	;	Crystal structure of hypoxanthine-guanine phosphoribosyltransferase complexed with GMP from Legionella pneumophila
5IPF	;	2.8	;	Crystal structure of Hypoxanthine-guanine phosphoribosyltransferase from Schistosoma mansoni in complex with IMP
1R3U	;	2.5	;	Crystal Structure of Hypoxanthine-Guanine Phosphoribosyltransferase from Thermoanaerobacter tengcongensis
3ACB	;	2.06	;	Crystal structure of hypoxanthine-guanine phosphoribosyltransferase from Thermus thermophilus HB8
3ACC	;	2.16	;	Crystal structure of hypoxanthine-guanine phosphoribosyltransferase with GMP from Thermus thermophilus HB8
3ACD	;	1.89	;	Crystal structure of hypoxanthine-guanine phosphoribosyltransferase with IMP from Thermus thermophilus HB8
6AR9	;	2.28	;	Crystal structure of hypoxanthine-guanine-xanthine phosphorybosyltranferase in complex with [(2-{[2-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)ethyl][(E)-2-phosphonoethenyl]amino}ethoxy)methyl]phosphonic acid
6AQO	;	2.64	;	Crystal structure of hypoxanthine-guanine-xanthine phosphorybosyltranferase in complex with {[(2S)-3-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)propane-1,2-diyl]bis(oxyethane-2,1-diyl)}bis(phosphonic acid)
4KBZ	;	2.15	;	Crystal Structure of Hypoxia-Inducible Factor Prolyl Hydroxylase (PHD2) with (S)-{2-[2-(5-Cyano-3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetylamino}-phenyl-acetic acid
1XKF	;	1.9	;	Crystal structure of Hypoxic Response Protein I (HRPI) with two coordinated zinc ions
6J0P	;	1.79	;	Crystal structure of HypX from Aquifex aeolicus (Crystal Form I)
6J1E	;	2.4	;	Crystal structure of HypX from Aquifex aeolicus (Crystal Form II)
6J1F	;	2.1	;	Crystal structure of HypX from Aquifex aeolicus in complex with Tetrahydrofolic acid
6J1I	;	2.29	;	Crystal structure of HypX from Aquifex aeolicus, A392F-I419F variant
6J1J	;	2.0	;	Crystal structure of HypX from Aquifex aeolicus, A392F-I419F variant in complex with Tetrahydrofolic acid
6J1H	;	2.101	;	Crystal structure of HypX from Aquifex aeolicus, Q15A-R131A-S194A-Q195A-N306A-R542A variant
6J1G	;	2.5	;	Crystal structure of HypX from Aquifex aeolicus, R9A-Q15A-R131A-R542A variant
6PQN	;	3.01	;	Crystal structure of HzTransib transposase
1UHI	;	1.8	;	Crystal structure of i-aequorin
1N3E	;	2.5	;	Crystal structure of I-CreI bound to a palindromic DNA sequence I (palindrome of left side of wildtype DNA target sequence)
1N3F	;	2.0	;	Crystal structure of I-CreI bound to a palindromic DNA sequence II (palindrome of right side of wildtype DNA target sequence)
4AQU	;	2.3	;	Crystal structure of I-CreI complexed with its target methylated at position plus 2 (in the b strand) in the presence of calcium
4AQX	;	2.2	;	Crystal structure of I-CreI complexed with its target methylated at position plus 2 (in the b strand) in the presence of magnesium
4EFJ	;	2.8	;	Crystal structure of I-GzeII LAGLIDADG homing endonuclease in complex with DNA target site
2YXM	;	1.51	;	Crystal structure of I-set domain of human Myosin Binding ProteinC
3A0H	;	4.0	;	Crystal structure of I-substituted Photosystem II complex
7KYR	;	1.71	;	Crystal structure of I107E CuB myoglobin (I107E L29H F43H sperm whale myoglobin)
7L3U	;	1.47	;	Crystal structure of I107E F33Y CuB myoglobin (I107E F33Y L29H F43H sperm whale myoglobin)
2ZBM	;	1.5	;	Crystal Structure of I115M Mutant Cold-Active Protein Tyrosine Phosphatase
6LTV	;	1.87	;	Crystal Structure of I122A/I330A variant of S-adenosylmethionine synthetase from Cryptosporidium hominis in complex with ONB-SAM (2-nitro benzyme S-adenosyl-methionine)
6I45	;	1.8	;	Crystal structure of I13V/I62V/V77I South African HIV-1 subtype C protease containing a D25A mutation
4QLE	;	1.35	;	Crystal structure of I14A DHFR mutant complexed with folate and NADP+
4QLF	;	1.44	;	Crystal structure of I14G DHFR mutant complexed with folate and NADP+
4QLG	;	1.5	;	Crystal structure of I14V DHFR mutant complexed with folate and NADP+
3VAD	;	2.602	;	Crystal structure of I170F mutant branched-chain alpha-ketoacid dehydrogenase kinase in complex with 3,6-dichlorobenzo[b]thiophene-2-carboxylic acid
4QA2	;	2.377	;	Crystal structure of I243N HDAC8 in complex with SAHA
4QA6	;	2.053	;	Crystal structure of I243N/Y306F HDAC8 in complex with a tetrapeptide substrate
3EM6	;	2.1	;	Crystal structure of I50L/A71V mutant of hiv-1 protease in complex with inhibitor darunavir
7WL6	;	1.41801	;	Crystal structure of I73L mutated human transthyretin
5JOE	;	2.0	;	Crystal structure of I81 from titin
5U5M	;	1.88	;	CRYSTAL STRUCTURE OF I83E MEDITOPE-ENABLED TRASTUZUMAB WITH AZIDO-MEDITOPE
5U6A	;	1.736	;	CRYSTAL STRUCTURE OF I83E MEDITOPE-ENABLED TRASTUZUMAB WITH AZIDO-PEG3-MEDITOPE
5B4H	;	1.11	;	Crystal structure of I86D mutant of phycocyanobilin:ferredoxin oxidoreductase in complex with biliverdin (data 1)
5B4I	;	1.11	;	Crystal structure of I86D mutant of phycocyanobilin:ferredoxin oxidoreductase in complex with biliverdin (data 2)
5B4J	;	1.05	;	Crystal structure of I86D mutant of phycocyanobilin:ferredoxin oxidoreductase in complex with biliverdin (data 3)
4QRV	;	1.978	;	Crystal structure of I86F mutant of papain
4QRG	;	2.497	;	Crystal structure of I86L mutant of papain
7YOG	;	2.3	;	Crystal Structure of I88L single mutant of O-acetyl-L-serine sulfhydrylase from Haemophilus influenzae at 2.3 A
7YOH	;	2.5	;	Crystal structure of I88L single mutant of O-acetylserine sulfhydrylase from Haemophilus influenzae in complex with high-affinity inhibitory peptide from serine acetyltransferase of Haemophilus influenzae at 2.5 A
7YOI	;	2.14	;	Crystal structure of I88L single mutant of O-acetylserine sulfhydrylase from Haemophilus influenzae in complex with high-affinity inhibitory peptide from serine acetyltransferase of Salmonella typhimurium at 2.14 A
5JDE	;	1.9	;	Crystal structure of I9-I11 tandem from titin (P1)
5JDD	;	1.53	;	Crystal structure of I9-I11 tandem from titin (P212121)
6XNT	;	3.1	;	Crystal structure of I91A mutant of human CEACAM1
4H0T	;	2.2	;	Crystal structure of Ia-ADPR-actin complex
3BUZ	;	2.81	;	Crystal structure of ia-bTAD-actin complex
7S80	;	1.4	;	Crystal structure of iAChSnFR Acetylcholine Sensor precursor binding protein
7S7Z	;	1.55	;	Crystal structure of iAChSnFR Acetylcholine Sensor precursor binding protein with choline bound
6V1R	;	1.64	;	Crystal structure of iAChSnFR Fluorescent Acetylcholine Sensor precursor binding protein
6BLQ	;	1.8	;	Crystal Structure of IAg7 in complex with insulin mimotope p8E9E
6BLR	;	1.96	;	Crystal Structure of IAg7 in complex with insulin mimotope p8E9E6SS
6BLX	;	2.323	;	Crystal structure of IAg7 in complex with insulin mimotope p8G9E
5DMK	;	2.45	;	Crystal Structure of IAg7 in complex with RLGL-WE14
7Z3H	;	2.4	;	Crystal structure of Iba57 from Chaetomium thermophilum
1WCD	;	3.0	;	Crystal structure of IBDV T1 virus-like particle reveals a missing link in icosahedral viruses evolution
3N3U	;	1.846	;	Crystal Structure of IbpAFic2
6SIU	;	2.49	;	Crystal structure of IbpAFic2 covalently tethered to Cdc42
4ITR	;	2.3	;	Crystal Structure of IbpAFic2-H3717A in complex with adenylylated Cdc42
7F52	;	2.559	;	Crystal Structure of IBV Nsp2
3LD1	;	2.498	;	Crystal Structure of IBV Nsp2a
5BZ0	;	2.1	;	Crystal structure of IBV papain-like protease PLpro C101S mutant in complex with ubiquitin
3EKE	;	2.1	;	Crystal structure of IBV X-domain at pH 5.6
3EJF	;	1.6	;	Crystal structure of IBV X-domain at pH 8.5
4OI9	;	2.5	;	Crystal Structure of ICAM-5 D1-D4 ectodomain fragment, Space Group P21
4OIA	;	3.7	;	Crystal Structure of ICAM-5 D1-D4 ectodomain fragment, Space Group P4322
4OIB	;	3.503	;	Crystal Structure of ICAM-5 D1-D4 ectodomain fragment, Space Group R3
3BN3	;	2.099	;	crystal structure of ICAM-5 in complex with aL I domain
3GEU	;	1.9	;	Crystal Structure of IcaR from Staphylococcus aureus, a member of the tetracycline repressor protein family
2ZCM	;	1.33	;	Crystal structure of IcaR, a repressor of the TetR family
2ZCN	;	1.9	;	Crystal structure of IcaR, a repressor of the TetR family
6IDN	;	1.5	;	Crystal structure of ICChI chitinase from ipomoea carnea
5UYT	;	1.75	;	Crystal structure of ice binding protein from an Antarctic bacterium Flavobacteriaceae
6A8K	;	1.4	;	Crystal structure of Ice-binding Protein from a Sea-Ice Microalga
7BWX	;	1.904	;	Crystal structure of ice-binding protein from an Antarctic ascomycete, Antarctomyces psychrotrophicus.
7BWY	;	2.02	;	Crystal structure of ice-binding protein from an Antarctic ascomycete, Antarctomyces psychrotrophicus.
5TJJ	;	2.5	;	Crystal structure of IcIR transcriptional regulator from Alicyclobacillus acidocaldarius
5WHM	;	1.95	;	Crystal Structure of IclR Family Transcriptional Regulator from Brucella abortus
7JOO	;	2.4	;	Crystal structure of ICOS in complex with antibody STIM003 and anti-kappa VHH domain
6X4G	;	3.5	;	Crystal structure of ICOS in complex with ICOS-L and an anti ICOS-L VNAR domain
6X4T	;	3.15	;	Crystal structure of ICOS-L in complex with Prezalumab and VNAR domain
6A9V	;	2.9	;	Crystal structure of Icp55 from Saccharomyces cerevisiae (N-terminal 42 residues deletion)
6A9T	;	2.15	;	Crystal structure of Icp55 from Saccharomyces cerevisiae (N-terminal 58 residues deletion)
7S7Y	;	1.3	;	Crystal structure of iCytSnFR Cytisine Sensor precursor binding protein
7S7X	;	1.7	;	Crystal structure of iCytSnFR Cytisine Sensor precursor binding protein with varenicline bound
4AYA	;	2.103	;	Crystal structure of ID2 HLH homodimer at 2.1A resolution
3CWW	;	1.96	;	Crystal Structure of IDE-bradykinin complex
6QG9	;	2.05	;	Crystal structure of Ideonella sakaiensis MHETase
6QGB	;	2.2	;	Crystal structure of Ideonella sakaiensis MHETase bound to benzoic acid
6QGA	;	2.1	;	Crystal structure of Ideonella sakaiensis MHETase bound to the non-hydrolyzable ligand MHETA
6ANE	;	2.02	;	Crystal Structure of Ideonella sakaiensis PET Hydrolase
6Q6F	;	3.3	;	Crystal structure of IDH1 R132H in complex with HMS101
6O2Y	;	2.8	;	Crystal structure of IDH1 R132H mutant in complex with compound 24
6O2Z	;	2.5	;	Crystal structure of IDH1 R132H mutant in complex with compound 32
6U4J	;	2.11	;	Crystal structure of IDH1 R132H mutant in complex with FT-2102
8BAY	;	2.35	;	Crystal Structure of IDH1 variant R132C S280F in complex with NADPH, Ca2+ and 3-butyl-2-oxoglutarate
6HNM	;	2.0	;	Crystal structure of IdmH 96-104 loop truncation variant
5JJQ	;	2.6	;	Crystal structure of IdnL1
6AKD	;	2.1	;	Crystal structure of IdnL7
6LNH	;	2.34	;	Crystal structure of IDO from Bacillus thuringiensis
8ABX	;	1.65	;	Crystal structure of IDO1 in complex with Apoxidole-1
3N77	;	1.86	;	Crystal structure of Idp01880, putative NTP pyrophosphohydrolase of Salmonella typhimurium LT2
4LNQ	;	2.0	;	Crystal structure of Ifi202 HINa domain in complex with 20bp dsDNA
4J0U	;	1.969	;	Crystal structure of IFIT5/ISG58
4LVP	;	2.323	;	Crystal structure of IFT81 N-terminal domain
4LVR	;	2.6	;	Crystal structure of IFT81 N-terminal domain
3BFO	;	1.15	;	Crystal structure of Ig-like C2-type 2 domain of the human Mucosa-associated lymphoid tissue lymphoma translocation protein 1
2NQC	;	2.05	;	Crystal structure of ig-like domain 23 from human filamin C
3M45	;	2.21	;	Crystal structure of Ig1 domain of mouse SynCAM 2
4GRG	;	4.24	;	Crystal structure of IgE complexed with E2_79, an anti-IgE inhibitor
5ANM	;	2.85	;	Crystal structure of IgE Fc in complex with a neutralizing antibody
5MOJ	;	2.26	;	Crystal structure of IgE-Fc epsilon 3-4
3KR3	;	2.2	;	Crystal structure of IGF-II antibody complex
4BM7	;	1.95	;	Crystal Structure of IgG Fc F241A mutant with native glycosylation
5GSQ	;	1.85	;	Crystal structure of IgG Fc with a homogeneous glycoform and Antibody-Dependent Cellular Cytotoxicity
7Q3P	;	2.1	;	Crystal structure of IgG1-Fc-MST-HN (efgartigimod)
4B3F	;	2.5	;	crystal structure of Ighmbp2 helicase
4B3G	;	2.85	;	crystal structure of Ighmbp2 helicase in complex with RNA
6DLE	;	3.994	;	Crystal structure of IgLON5 homodimer
6DLD	;	3.3	;	Crystal structure of IgLON5/NEGR1 heterodimer
3RN8	;	1.7	;	Crystal Structure of iGluR2 Ligand Binding Domain and Symmetrical Carboxyl Containing Potentiator
3RNN	;	1.75	;	Crystal Structure of iGluR2 Ligand Binding Domain with Symmetric Sulfonamide Containing Potentiator
6QSS	;	1.892	;	Crystal Structure of Ignicoccus islandicus malate dehydrogenase co-crystallized with 10 mM Tb-Xo4
5DNX	;	1.8	;	Crystal structure of IGPD from Pyrococcus furiosus in complex with (R)-C348
5DNL	;	1.53	;	Crystal structure of IGPD from Pyrococcus furiosus in complex with (S)-C348
3N1O	;	2.55	;	Crystal structure of IhhN
3N1M	;	1.69	;	Crystal Structure of IhhN bound to BOCFn3
3N1P	;	2.7	;	Crystal Structure of IhhN bound to BOCFn3
3N1F	;	1.6	;	Crystal Structure of IhhN bound to CDOFn3
5AEU	;	2.49	;	Crystal structure of II9 variant of Biphenyl dioxygenase from Burkholderia xenovorans LB400
5AEW	;	1.88	;	Crystal structure of II9 variant of Biphenyl dioxygenase from Burkholderia xenovorans LB400 in complex with biphenyl
1A3A	;	1.8	;	CRYSTAL STRUCTURE OF IIA MANNITOL FROM ESCHERICHIA COLI
3WJJ	;	2.6	;	Crystal structure of IIb selective Fc variant, Fc(P238D), in complex with FcgRIIb
3WJL	;	2.86	;	Crystal structure of IIb selective Fc variant, Fc(V12), in complex with FcgRIIb
1IIB	;	1.8	;	CRYSTAL STRUCTURE OF IIBCELLOBIOSE FROM ESCHERICHIA COLI
1TPZ	;	2.0	;	Crystal Structure of IIGP1: a paradigm for interferon inducible p47 resistance GTPases
1TQ2	;	2.7	;	Crystal Structure of IIGP1: a paradigm for interferon inducible p47 resistance GTPases
1TQ4	;	1.95	;	Crystal Structure of IIGP1: a paradigm for interferon inducible p47 resistance GTPases
1TQ6	;	2.7	;	Crystal Structure of IIGP1: a paradigm for interferon inducible p47 resistance GTPases
1TQD	;	2.3	;	Crystal structure of IIGP1: a paradigm for interferon inducible p47 resistance GTPases
7REW	;	2.1	;	Crystal Structure of IL-13 in complex with MMAb3 Fab
3VBC	;	1.8	;	Crystal Structure of iL-17 receptor B SEFIR domain
4QHU	;	2.2	;	Crystal Structure of IL-17A/Fab6785 complex
1JPY	;	2.85	;	Crystal structure of IL-17F
3WO3	;	3.1	;	Crystal structure of IL-18 in complex with IL-18 receptor alpha
3QWR	;	3.25	;	Crystal structure of IL-23 in complex with an adnectin
3D85	;	1.9	;	Crystal structure of IL-23 in complex with neutralizing FAB
4IZE	;	2.0	;	Crystal Structure of IL-36gamma
6P9E	;	2.0	;	Crystal structure of IL-36gamma complexed to A-552
5BOW	;	1.31	;	CRYSTAL STRUCTURE OF IL-38
6PPG	;	2.75	;	Crystal structure of IL17FF bound to Fab fragments of MCAF5352A
4YH6	;	3.0	;	Crystal structure of IL1RAPL1 ectodomain
7KQ7	;	2.203	;	Crystal structure of IL21R in complex with an antibody Fab fragment
6UIB	;	2.74	;	Crystal structure of IL23 bound to peptide 23-652
1U3Y	;	1.901	;	Crystal structure of ILAC mutant of dimerisation domain of NF-kB p50 transcription factor
4WF0	;	1.95	;	Crystal Structure of iLID - an Improved Light-Inducible Dimer
6PTB	;	2.15	;	Crystal Structure of ILNAMIAKI peptide bound to HLA-A2
6PTE	;	1.901	;	Crystal Structure of ILNAMITKI peptide bound to HLA-A2
6OPD	;	1.791	;	Crystal Structure of ILNAMIVKI peptide bound to HLA-A2
4EES	;	1.805	;	Crystal structure of iLOV
4EET	;	1.2	;	Crystal structure of iLOV
4NXE	;	2.103	;	Crystal structure of iLOV-I486(2LT) at pH 6.5
4NXB	;	2.561	;	Crystal structure of iLOV-I486(2LT) at pH 7.0
4NXF	;	1.766	;	Crystal structure of iLOV-I486(2LT) at pH 8.0
4NXG	;	2.09	;	Crystal structure of iLOV-I486z(2LT) at pH 9.0
7ABY	;	1.45	;	Crystal structure of iLOV-Q489K mutant
6OVT	;	1.88	;	Crystal Structure of IlvD from Mycobacterium tuberculosis
3HT5	;	1.9	;	Crystal Structure of IlvE a Branched Chain Amino Acid Transaminase from Mycobacterium tuberculosis
5YPY	;	1.966	;	Crystal structure of IlvN. Val-1c
5YPP	;	1.9	;	Crystal structure of IlvN.Val-1a
5YPW	;	2.3	;	Crystal structure of IlvN.Val-1b
4UDM	;	2.96	;	Crystal structure of Im3 in complex with Y52A mutant of E3RNase
1JND	;	1.3	;	Crystal structure of imaginal disc growth factor-2
1JNE	;	1.7	;	Crystal structure of imaginal disc growth factor-2
2Q73	;	1.8	;	Crystal structure of iMazG from Vibrio DAT 722: Ctag-iMazG (P41212)
2Q9L	;	2.2	;	Crystal structure of iMazG from Vibrio DAT 722: Ctag-iMazG (P43212)
2Q5Z	;	2.3	;	Crystal structure of iMazG from Vibrio DAT 722: Ntag-iMazG (P43212)
2ZM1	;	2.1	;	Crystal structure of imidazo pyrazin 1 bound to the kinase domain of human LCK, (auto-phosphorylated on TYR394)
3ACJ	;	2.2	;	Crystal structure of imidazo pyrimidine derivative bound to the kinase domain of human LCK, (Auto-phosphorylated on TYR394)
2ZM4	;	2.7	;	Crystal structure of imidazo quinoxaline 1 bound to the kinase domain of human LCK, activated form (auto-phosphorylated on TYR394)
1RHY	;	2.3	;	Crystal structure of Imidazole Glycerol Phosphate Dehydratase
6YJH	;	1.61	;	Crystal structure of Imidazole Glycerol Phosphate Dehydratase from Mycobacterium tuberculosis at 1.61 A resolution
2A0N	;	1.64	;	Crystal structure of Imidazole glycerol phosphate synthase subunit hisF (EC 4.1.3.-) (tm1036) from Thermotoga maritima at 1.64 A resolution
1JVN	;	2.1	;	CRYSTAL STRUCTURE OF IMIDAZOLE GLYCEROL PHOSPHATE SYNTHASE: A TUNNEL THROUGH A (BETA/ALPHA)8 BARREL JOINS TWO ACTIVE SITES
1DP9	;	2.6	;	CRYSTAL STRUCTURE OF IMIDAZOLE-BOUND FIXL HEME DOMAIN
2AE8	;	2.01	;	Crystal Structure of Imidazoleglycerol-phosphate Dehydratase from Staphylococcus aureus subsp. aureus N315
2G3F	;	2.0	;	Crystal Structure of imidazolonepropionase complexed with imidazole-4-acetic acid sodium salt, a substrate homologue
2PUZ	;	1.83	;	Crystal structure of Imidazolonepropionase from Agrobacterium tumefaciens with bound product N-formimino-L-Glutamate
2Q09	;	1.97	;	Crystal structure of Imidazolonepropionase from environmental sample with bound inhibitor 3-(2,5-Dioxo-imidazolidin-4-yl)-propionic acid
7WNN	;	1.53	;	Crystal structure of Imine Reductase from Actinoalloteichus hymeniacidonis in complex with NADPH
7WXE	;	2.5	;	Crystal Structure of Imine Reductase from Paenibacillus mucilaginosus
7XE8	;	1.72	;	Crystal structure of imine reductase from Streptomyces albidoflavus
7WNW	;	2.13	;	Crystal structure of Imine Reductase Mutant(M5) from Actinoalloteichus hymeniacidonis in complex with NADPH
7XR5	;	1.58	;	Crystal structure of imine reductase with NAPDH from Streptomyces albidoflavus
6PXS	;	2.836	;	Crystal structure of iminodiacetate oxidase (IdaA) from Chelativorans sp. BNC1
2HP0	;	1.5	;	Crystal structure of iminodisuccinate epimerase
2HP3	;	1.71	;	Crystal structure of iminodisuccinate epimerase
4IT3	;	2.495	;	Crystal Structure of Iml3 from S. cerevisiae
2Z35	;	2.2	;	Crystal structure of immune receptor
6NIX	;	2.1	;	Crystal structure of Immune Receptor
2Z31	;	2.7	;	Crystal structure of immune receptor complex
5JKP	;	2.106	;	Crystal structure of immunity protein Pa5087 from Pseudomonas aeruginosa
3K2D	;	2.6	;	Crystal structure of Immunogenic lipoprotein A from Vibrio vulnificus
1JGL	;	2.15	;	Crystal structure of immunoglobulin Fab fragment complexed with 17-beta-estradiol
8HT3	;	2.5	;	Crystal structure of immunoglobulin new antigen receptor variable domain from Okamejei kenojei
2IEP	;	2.205	;	Crystal structure of immunoglobulin-like domains 1 and 2 of the receptor tyrosine kinase MuSK
2OTP	;	2.6	;	Crystal Structure of Immunoglobulin-Like Transcript 1 (ILT1/LIR7/LILRA2)
6G9E	;	2.69	;	Crystal structure of immunomodulatory active chitinase from Trichuris suis - TsES1 - 6 molecules in ASU
6G9C	;	1.74	;	Crystal structure of immunomodulatory active chitinase from Trichuris suis, TsES1
2QR6	;	1.5	;	Crystal structure of IMP dehydrogenase/GMP reductase-like protein (NP_599840.1) from Corynebacterium glutamicum ATCC 13032 Kitasato at 1.50 A resolution
7YHA	;	2.135	;	Crystal structure of IMP-1 MBL in complex with (3-(4-(p-tolyl)-1H-1,2,3-triazol-1-yl)benzyl)phosphonic acid
7YH9	;	2.39	;	Crystal structure of IMP-1 MBL in complex with 3-(4-benzyl-1H-1,2,3-triazol-1-yl)phthalic acid
1DDK	;	3.1	;	CRYSTAL STRUCTURE OF IMP-1 METALLO BETA-LACTAMASE FROM PSEUDOMONAS AERUGINOSA
5Y5B	;	1.7	;	Crystal Structure Of IMP-1 Metallo-beta-lactamase
3WXC	;	2.1	;	Crystal Structure of IMP-1 metallo-beta-lactamase complexed with a 3-aminophtalic acid inhibitor
6JED	;	1.57	;	Crystal structure of IMP-1 metallo-beta-lactamase in a complex with MCR
6LBL	;	1.68	;	Crystal structure of IMP-1 metallo-beta-lactamase in complex with NO9 inhibitor
4UBQ	;	2.3	;	Crystal Structure of IMP-2 Metallo-beta-Lactamase from Acinetobacter spp.
6GX6	;	2.0	;	Crystal structure of IMP3 RRM12 in complex with RNA (ACAC)
6FQR	;	2.1	;	Crystal structure of IMP3 RRM12 in complex with RNA (CCCC)
4G61	;	2.3	;	Crystal structure of IMPase/NADP phosphatase complexed with Mg2+ and phosphate
5EYG	;	2.2	;	Crystal structure of IMPase/NADP phosphatase complexed with NADP and Ca2+
5EYH	;	2.5	;	Crystal Structure of IMPase/NADP phosphatase complexed with NADP and Ca2+ at pH 7.0
3ZJY	;	3.6	;	Crystal Structure of Importin 13 - RanGTP - eIF1A complex
2XWU	;	2.8	;	CRYSTAL STRUCTURE OF IMPORTIN 13 - UBC9 COMPLEX
7JJM	;	2.06	;	Crystal structure of Importin alpha 2 in complex with LSD1 NLS
7JK7	;	1.96	;	Crystal structure of Importin alpha 2 in complex with LSD1 NLS S111E mutant
7JJL	;	2.6	;	Crystal structure of Importin Alpha 3 in complex with human LSD1 NLS
4XRK	;	3.25	;	Crystal Structure of Importin Beta in a Polyethylene Glycol Condition
4XRI	;	2.05	;	Crystal Structure of Importin Beta in an Ammonium Sulfate Condition
6K06	;	1.75	;	Crystal structure of Importin-alpha and phosphomimetic GM130
6IWA	;	2.4	;	Crystal structure of Importin-alpha and phosphoserine GM130
6IW8	;	2.8	;	Crystal structure of Importin-alpha and wild-type GM130
3OQS	;	2.0	;	Crystal structure of importin-alpha bound to a CLIC4 NLS peptide
4ZDU	;	2.3	;	Crystal structure of importin-alpha bound to a non-classical nuclear localization signal of the influenza A virus nucleoprotein
4RXH	;	1.7553	;	Crystal Structure of Importin-alpha from Neurospora crassa complexed with SV40NLS
6IUA	;	1.7	;	Crystal structure of importin-alpha1 bound to the 53BP1 nuclear localization signal (S1678D)
6IU7	;	1.9	;	Crystal structure of importin-alpha1 bound to the 53BP1 nuclear localization signal (wild-type)
8HE3	;	1.9	;	Crystal structure of importin-alpha1 bound to the HIF-1alpha nuclear localization signal (delta 724-751)
8HE0	;	1.8	;	Crystal structure of importin-alpha1 bound to the HIF-1alpha nuclear localization signal (wild-type)
8HKW	;	1.9	;	Crystal structure of importin-alpha3 bound to the 53BP1 nuclear localization signal
5XZX	;	3.0	;	Crystal structure of importin-alpha3 bound to the nuclear localization signal of Ran-binding protein 3
1UKL	;	3.0	;	Crystal structure of Importin-beta and SREBP-2 complex
2X1G	;	3.35	;	Crystal structure of Importin13 - Mago-Y14 complex
2X19	;	2.8	;	Crystal structure of Importin13 - RanGTP complex
5GQN	;	1.55	;	Crystal structure of in cellulo Cypovirus Polyhedra mutant with deletion of Gly192-Ala194
4OTV	;	1.7	;	Crystal structure of in cellulo Operophtera brumata CPV18
5EXY	;	1.55	;	Crystal structure of in cellulo recombinant CPV1 Polyhedra
5GQM	;	1.68	;	Crystal structure of in cellulo Wild Type Cypovirus Polyhedra
4B6X	;	2.2	;	Crystal structure of in planta processed AvrRps4
7P8K	;	2.65	;	Crystal structure of in planta processed AvrRps4 in complex with the WRKY domain of RRS1
6FX7	;	1.82	;	Crystal structure of in vitro evolved Af1521
5ZJU	;	2.8	;	Crystal structure of in vitro expressed and assembled PCV2 Virus-like Particle
5MDO	;	1.95	;	Crystal structure of in vitro folded Chitoporin VhChip from Vibrio harveyi (crystal form I)
5MDP	;	3.08	;	Crystal structure of in vitro folded Chitoporin VhChip from Vibrio harveyi (crystal form II)
5MDR	;	1.9	;	Crystal structure of in vitro folded Chitoporin VhChip from Vibrio harveyi in complex with chitohexaose
5AO4	;	3.7	;	Crystal structure of in vitro phosphorylated human SAMHD1 (amino acid residues 115-626) bound to GTP
3KU2	;	2.3	;	Crystal Structure of inactivated form of CDPK1 from toxoplasma gondii, TGME49.101440
4ATF	;	1.9	;	Crystal structure of inactivated mutant beta-agarase B in complex with agaro-octaose
7UM4	;	2.8	;	Crystal structure of inactive 5-HT5AR in complex with AS2674723
2HIW	;	2.2	;	Crystal Structure of Inactive Conformation Abl Kinase Catalytic Domain Complexed with Type II Inhibitor
5BUT	;	5.97	;	Crystal structure of inactive conformation of KtrAB K+ transporter
6X41	;	2.36	;	Crystal structure of inactive enzymatic binary toxin component from Clostridium difficile
6X6W	;	1.89	;	Crystal structure of inactive enzymatic binary toxin component from Clostridium difficile
6X6V	;	2.42	;	Crystal structure of inactive enzymatic binary toxin component from Clostridium difficile in complex with NADPH
7AT2	;	1.44	;	Crystal structure of inactive EstD11 S144A
1XQV	;	2.3	;	Crystal structure of inactive F1-mutant G37A
7CJU	;	1.74	;	Crystal structure of inactive form of chitosanase crystallized by ammonium sulfate
4QJA	;	1.54	;	Crystal structure of inactive HIV-1 protease in complex with p1-p6 substrate variant (P453L)
4QJ9	;	1.83	;	Crystal structure of inactive HIV-1 protease in complex with p1-p6 substrate variant (R452S)
4OBH	;	1.85	;	Crystal Structure of Inactive HIV-1 Protease in Complex with the p1-p6 substrate variant (L449F)
4OBK	;	1.65	;	Crystal structure of inactive HIV-1 protease in complex with the P1-P6 substrate variant (L449F/S451N)
4OBJ	;	1.75	;	Crystal Structure of Inactive HIV-1 Protease in Complex with the p1-p6 substrate variant (S451N)
4QJ6	;	1.5	;	Crystal structure of inactive HIV-1 protease variant (I50V/A71V) in complex with p1-p6 substrate variant (L449F)
4QJ8	;	2.0	;	Crystal structure of inactive HIV-1 protease variant (I50V/A71V) in complex with p1-p6 substrate variant (P453L)
4QJ7	;	1.67	;	Crystal structure of inactive HIV-1 protease variant (I50V/A71V) in complex with p1-p6 substrate variant (R452S)
4QJ2	;	2.13	;	Crystal structure of inactive HIV-1 protease variant (I50V/A71V) in complex with WT p1-p6 substrate
7ACQ	;	1.86	;	CRYSTAL STRUCTURE OF INACTIVE KRAS G12D (GDP) IN COMPLEX WITH THE SOAKED DIMERIC INHIBITOR BI-5747
1RNJ	;	1.7	;	Crystal structure of inactive mutant dUTPase complexed with substrate analogue imido-dUTP
1SYL	;	1.95	;	Crystal structure of inactive mutant dUTPase complexed with substrate dUTP
3B9E	;	1.7	;	Crystal structure of inactive mutant E315M chitinase A from Vibrio harveyi
7VVC	;	1.82	;	Crystal structure of inactive mutant of leaf-branch compost cutinase variant
1N5I	;	1.85	;	CRYSTAL STRUCTURE OF INACTIVE MYCOBACTERIUM TUBERCULOSIS THYMIDYLATE KINASE COMPLEXED WITH THYMIDINE MONOPHOSPHATE (TMP) AT PH 4.6 (RESOLUTION 1.85 A)
6UNA	;	2.554	;	Crystal structure of inactive p38gamma
2PQG	;	2.38	;	Crystal structure of inactive ribosome inactivating protein from maize (b-32)
2R5T	;	1.9	;	Crystal Structure of Inactive Serum and Glucocorticoid- Regulated Kinase 1 in Complex with AMP-PNP
4EQ0	;	1.7	;	Crystal Structure of inactive single chain variant of HIV-1 Protease in Complex with the substrate p2-NC
4EQJ	;	1.8	;	Crystal Structure of inactive single chain variant of HIV-1 Protease in Complex with the substrate RT-RH
4EP3	;	1.81	;	Crystal Structure of inactive single chain wild-type HIV-1 Protease in Complex with the substrate CA-p2
4EPJ	;	1.69	;	Crystal Structure of inactive single chain wild-type HIV-1 Protease in Complex with the substrate p2-NC
4EP2	;	1.9	;	Crystal Structure of inactive single chain wild-type HIV-1 Protease in Complex with the substrate RT-RH
6IGQ	;	2.3	;	Crystal structure of inactive state of S9 peptidase from Deinococcus radiodurans R1 (PMSF treated)
8P1G	;	1.42	;	Crystal structure of inactive TtCE16 in complex with acetate
7VM7	;	1.87	;	Crystal structure of inactive uPA in complex with nafamostat
4LZK	;	1.89	;	Crystal structure of inclusion body protein (PixA pfam12306) from Burkholderia cenocepacia J2315
6JXS	;	1.95	;	Crystal Structure of Indigo reductase (Y151F) from Bacillus smithii type strain DSM 4216
6JXN	;	1.97	;	Crystal Structure of Indigo reductase from Bacillus smithii type strain DSM 4216
2OJY	;	1.6	;	Crystal structure of indol-3-acetaldehyde derived TTQ-amide adduct of aromatic amine dehydrogenase
7P9Q	;	2.53	;	Crystal structure of Indole 3-Carboxylic acid decarboxylase from Arthrobacter nicotianae FI1612 in complex with co-factor prFMN.
7W8U	;	2.25	;	Crystal Structure of Indole Prenyltransferase IptA
5IUU	;	2.09	;	Crystal Structure of Indole-3-acetaldehyde Dehydrogenase in Apo form
5IUV	;	1.928	;	Crystal Structure of Indole-3-acetaldehyde Dehydrogenase in complexed with NAD+
5IUW	;	2.093	;	Crystal Structure of Indole-3-acetaldehyde Dehydrogenase in complexed with NAD+ and IAA
3B5I	;	2.75	;	Crystal structure of Indole-3-acetic Acid Methyltransferase
1LBF	;	2.05	;	CRYSTAL STRUCTURE OF INDOLE-3-GLYCEROL PHOSPHATE SYNTASE (IGPS)WITH REDUCED 1-(O-CABOXYPHENYLAMINO)-1-DEOXYRIBULOSE 5-PHOSPHATE (RCDRP)
1LBL	;	2.4	;	Crystal structure of indole-3-glycerol phosphate synthase (IGPS) in complex with 1-(o-carboxyphenylamino)-1-deoxyribulose 5'-phosphate (CdRP)
1J5T	;	3.0	;	Crystal structure of indole-3-glycerol phosphate synthase (TM0140) from Thermotoga maritima at 3.0 A resolution
1VC4	;	1.8	;	Crystal Structure of Indole-3-Glycerol Phosphate Synthase (TrpC) from Thermus Thermophilus At 1.8 A Resolution
3TSM	;	2.15	;	Crystal structure of Indole-3-glycerol phosphate synthase from Brucella melitensis
5XDC	;	1.5785	;	Crystal structure of Indole-bound TdsC from Paenibacillus sp. A11-2
8I7L	;	2.8	;	Crystal structure of indoleamine 2,3-dioxygenagse 1 (IDO1) complexed with a novel inhibitor
6KW7	;	3.02	;	Crystal structure of indoleamine 2,3-dioxygenagse 1 (IDO1) in complex with compound 12
6KPS	;	2.249	;	Crystal structure of indoleamine 2,3-dioxygenagse 1 (IDO1) in complex with compound 36
6KOF	;	2.263	;	Crystal structure of indoleamine 2,3-dioxygenagse 1 (IDO1) in complex with compound 47
6R63	;	2.894	;	Crystal structure of indoleamine 2,3-dioxygenase 1 (IDO1) in complex with ferric heme and MMG-0358
7AH4	;	2.401	;	Crystal structure of indoleamine 2,3-dioxygenase 1 (IDO1) in complex with ferric heme and MMG-0363
7ZV3	;	2.551	;	Crystal structure of indoleamine 2,3-dioxygenase 1 (IDO1) in complex with ferric heme and MMG-0472
7AH5	;	2.9	;	Crystal structure of indoleamine 2,3-dioxygenase 1 (IDO1) in complex with ferric heme and MMG-0706
7AH6	;	2.998	;	Crystal structure of indoleamine 2,3-dioxygenase 1 (IDO1) in complex with ferric heme and MMG-0752
1I4N	;	2.5	;	CRYSTAL STRUCTURE OF INDOLEGLYCEROL PHOSPHATE SYNTHASE FROM THERMOTOGA MARITIMA
1OVM	;	2.65	;	Crystal structure of Indolepyruvate decarboxylase from Enterobacter cloacae
7U9B	;	1.95	;	Crystal structure of indoline 7 with KPC-2
7UA7	;	2.247	;	Crystal structure of indoline 9 with KPC-2
3NQS	;	2.2	;	Crystal Structure of Inducible Nitric Oxide Synthase with N-Nitrosated-pterin
6APC	;	1.7	;	Crystal Structure of Infant Antibody ADI-19425
8UA5	;	2.45	;	Crystal Structure of infected cell protein 0 (ICP0) from herpes simplex virus 1 (A636-Q776)
8UA2	;	2.65	;	Crystal Structure of infected cell protein 0 (ICP0) from herpes simplex virus 1 (proteolyzed fragment)
3JVB	;	2.17	;	Crystal structure of infectious baculovirus polyhedra
2Q6D	;	2.35	;	Crystal structure of infectious bronchitis virus (IBV) main protease
2Q6F	;	2.0	;	Crystal structure of infectious bronchitis virus (IBV) main protease in complex with a Michael acceptor inhibitor N3
2QJ1	;	3.48	;	Crystal structure of infectious bursal disease virus VP1 polymerase incubated with an oligopeptide mimicking the VP3 C-terminus
2R70	;	2.7	;	Crystal structure of infectious bursal disease virus VP1 polymerase, cocrystallized with an oligopeptide mimicking the VP3 C-terminus.
2R72	;	3.15	;	Crystal structure of infectious bursal disease virus VP1 polymerase, incubated with Mg2+ ion.
2DF7	;	2.6	;	Crystal structure of infectious bursal disease virus VP2 subviral particle
2F3C	;	2.5	;	Crystal structure of infestin 1, a Kazal-type serineprotease inhibitor, in complex with trypsin
2ERW	;	1.4	;	Crystal Structure of Infestin 4, a factor XIIa inhibitor
4HZW	;	1.701	;	Crystal structure of influenza A neuraminidase N3 complexed with laninamivir
4HZX	;	2.2	;	Crystal structure of influenza A neuraminidase N3 complexed with oseltamivir
4HZY	;	1.598	;	Crystal structure of influenza A neuraminidase N3-H274Y
4I00	;	1.6	;	Crystal structure of influenza A neuraminidase N3-H274Y complexed with zanamivir
2RHK	;	1.95	;	Crystal structure of influenza A NS1A protein in complex with F2F3 fragment of human cellular factor CPSF30, Northeast Structural Genomics Targets OR8C and HR6309A
6IUV	;	2.332	;	Crystal structure of influenza A virus H5 hemagglutinin globular head in complex with the Fab of antibody 3C11
5DUM	;	3.003	;	Crystal structure of influenza A virus H5 hemagglutinin globular head in complex with the Fab of antibody 65C6
6IUT	;	2.3	;	Crystal structure of influenza A virus H5 hemagglutinin globular head in complex with the Fab of antibody AVFluIgG01
6A67	;	2.33	;	Crystal structure of influenza A virus H5 hemagglutinin globular head in complex with the Fab of antibody FLD21.140
2Q06	;	3.3	;	Crystal structure of Influenza A Virus H5N1 Nucleoprotein
6UYN	;	2.85	;	Crystal structure of influenza A virus hemagglutinin from A/Ohio/09/2015 bound to the stalk-binding CR6261 antibody Fab
6I3H	;	1.9	;	Crystal structure of influenza A virus M1 N-terminal domain (G18A mutation)
4PUS	;	2.2	;	Crystal Structure of Influenza A Virus Matrix Protein M1
5V7B	;	2.5	;	Crystal structure of Influenza A virus matrix protein M1 (NLS-88E)
5V7S	;	2.5	;	Crystal structure of Influenza A virus matrix protein M1 (NLS-88E, pH 6.2)
5V8A	;	3.0	;	Crystal structure of Influenza A virus matrix protein M1 (NLS-88R, pH 7.3)
5V6G	;	2.0	;	Crystal structure of Influenza A virus Matrix Protein M1(NLS-88R)
3SAL	;	1.5	;	Crystal Structure of Influenza A Virus Neuraminidase N5
7E6Q	;	2.2	;	Crystal structure of influenza A virus neuraminidase N5 complexed with 4'-phenyl-1,2,3-triazolylated oseltamivir carboxylate
3TI8	;	1.601	;	Crystal structure of influenza A virus neuraminidase N5 complexed with laninamivir
3SAN	;	1.6	;	Crystal structure of influenza A virus neuraminidase N5 complexed with Zanamivir
3RO5	;	2.66	;	Crystal structure of influenza A virus nucleoprotein with ligand
3TG6	;	3.0	;	Crystal Structure of Influenza A Virus nucleoprotein with Ligand
4WSA	;	3.4	;	Crystal structure of Influenza B polymerase bound to the vRNA promoter (FluB1 form)
6QCW	;	2.88	;	Crystal structure of influenza B polymerase initiation state with capped 14-mer RNA primer
6QCV	;	3.24	;	Crystal structure of influenza B polymerase initiation state with capped 14-mer RNA primer and CTP
6QCX	;	3.08	;	Crystal structure of influenza B polymerase initiation state with capped 15-mer RNA primer
5EPI	;	4.1	;	CRYSTAL STRUCTURE OF INFLUENZA B POLYMERASE WITH BOUND 5' CRNA EXHIBITS A NOVEL DOMAIN ARRANGEMENT
5FMZ	;	3.4	;	Crystal structure of Influenza B polymerase with bound 5' vRNA
4WRT	;	2.7	;	Crystal structure of Influenza B polymerase with bound vRNA promoter (form FluB2)
3BT6	;	2.8	;	Crystal Structure of Influenza B Virus Hemagglutinin
2RFT	;	2.8	;	Crystal structure of influenza B virus hemagglutinin in complex with LSTa receptor analog
2RFU	;	2.8	;	Crystal structure of influenza B virus hemagglutinin in complex with LSTc receptor analog
3TJ0	;	3.233	;	Crystal Structure of Influenza B Virus Nucleoprotein
3FKU	;	3.2	;	Crystal structure of influenza hemagglutinin (H5) in complex with a broadly neutralizing antibody F10
6ONA	;	1.95	;	Crystal structure of Influenza hemagglutinin from strain A/Hickox/JY2/1940
6OSR	;	2.55	;	Crystal structure of Influenza hemagglutinin from strain A/Melbourne/1/1946(H1N1)
4HZZ	;	1.601	;	Crystal structure of influenza neuraminidase N3-H274Y complexed with oseltamivir
7XGC	;	1.6	;	Crystal structure of influenza polymerase acidic subunit N-terminal domain crystallized by ammonium sulfate with glycan
1L7F	;	1.8	;	Crystal structure of influenza virus neuraminidase in complex with BCX-1812
2G6Q	;	2.0	;	Crystal structure of ING2 PHD finger in complex with H3K4Me3 peptide
3FNF	;	2.3	;	Crystal structure of InhA bound to triclosan derivative
3FNG	;	1.97	;	Crystal structure of InhA bound to triclosan derivative
3FNH	;	2.8	;	Crystal structure of InhA bound to triclosan derivative
3FNE	;	1.98	;	Crystal structure of InhA bound to triclosan derivative 17
7E48	;	2.5	;	Crystal structure of InhA in complex with 3-nitropropanoic acid inhibitor
6R9W	;	1.75	;	Crystal structure of InhA in complex with AP-124 inhibitor
4BGI	;	2.09	;	Crystal structure of InhA(S94A) mutant in complex with OH-141
4BGE	;	2.25	;	Crystal structure of InhA(S94A) mutant in complex with pyridomycin
6ZKZ	;	2.3	;	Crystal structure of InhA:01 TCR in complex with HLA-E (F116C) bound to InhA (53-61 H4C)
6ZKY	;	2.65	;	Crystal structure of InhA:01 TCR in complex with HLA-E (S147C) bound to InhA (53-61 H3C)
6ZKX	;	2.17	;	Crystal structure of InhA:01 TCR in complex with HLA-E (Y84C) bound to InhA (53-61 GCG)
6ZKW	;	2.26	;	Crystal structure of InhA:01 TCR in complex with HLA-E bound to InhA (53-61)
3OF2	;	2.0	;	Crystal structure of InhA_T266D:NADH complex
3OEY	;	2.0	;	Crystal structure of InhA_T266E:NADH complex
1W22	;	2.5	;	Crystal structure of inhibited human HDAC8
1IBC	;	2.73	;	CRYSTAL STRUCTURE OF INHIBITED INTERLEUKIN-1BETA CONVERTING ENZYME
1T7J	;	2.2	;	crystal structure of inhibitor amprenavir in complex with a multi-drug resistant variant of HIV-1 protease (L63P/V82T/I84V)
5EA7	;	2.851	;	Crystal Structure of Inhibitor BMS-433771 in Complex with Prefusion RSV F Glycoprotein
3AYQ	;	1.77	;	Crystal structure of inhibitor bound lysozyme from Meretrix lusoria
5EA6	;	2.75	;	Crystal Structure of Inhibitor BTA-9881 in Complex with Prefusion RSV F Glycoprotein
1MXF	;	2.3	;	Crystal Structure of Inhibitor Complex of Putative Pteridine Reductase 2 (PTR2) from Trypanosoma cruzi
5EA3	;	2.75	;	Crystal Structure of Inhibitor JNJ-2408068 in Complex with Prefusion RSV F Glycoprotein
6VKD	;	2.5	;	Crystal Structure of Inhibitor JNJ-36689282 in Complex with Prefusion RSV F Glycoprotein
6VKC	;	2.6	;	Crystal Structure of Inhibitor JNJ-36811054 in Complex with Prefusion RSV F Glycoprotein
6VKE	;	2.1	;	Crystal Structure of Inhibitor JNJ-40012665 in Complex with Prefusion RSV F Glycoprotein
5EA4	;	2.3	;	Crystal Structure of Inhibitor JNJ-49153390 in Complex with Prefusion RSV F Glycoprotein
5KWW	;	2.5	;	Crystal Structure of Inhibitor JNJ-53718678 In Complex with Prefusion RSV F Glycoprotein
3QA8	;	3.6	;	Crystal Structure of inhibitor of kappa B kinase beta
3RZF	;	4.0	;	Crystal Structure of Inhibitor of kappaB kinase beta (I4122)
3EL4	;	2.0	;	Crystal structure of inhibitor saquinavir (SQV) complexed with the multidrug HIV-1 protease variant L63P/V82T/I84V
3EKQ	;	2.2	;	Crystal structure of inhibitor saquinavir (SQV) in complex with multi-drug resistant HIV-1 protease (L63P/V82T/I84V) (referred to as ACT in paper)
5EA5	;	3.05	;	Crystal Structure of Inhibitor TMC-353121 in Complex with Prefusion RSV F Glycoprotein
7S49	;	2.2	;	Crystal Structure of Inhibitor-bound Galactokinase
7S4C	;	2.2	;	Crystal Structure of Inhibitor-bound Galactokinase
3NN6	;	2.19	;	Crystal structure of inhibitor-bound in active centre 6-hydroxy-L-nicotine oxidase from Arthrobacter nicotinovorans
4JS6	;	1.55	;	Crystal structure of inhibitor-free hCAII H94D
7N6T	;	1.32	;	Crystal structure of inhibitor-free HIV-1 PRS17 revertant mutant PRS17 V48G
2YMX	;	1.9	;	Crystal structure of inhibitory anti-AChE Fab408
6C7Y	;	2.499	;	Crystal structure of inhibitory protein SOCS1 in complex with JAK1 kinase domain
4GL9	;	3.9	;	Crystal structure of inhibitory protein SOCS3 in complex with JAK2 kinase domain and fragment of GP130 intracellular domain
7CD1	;	1.89	;	Crystal structure of inhibitory Smad, Smad7
6J73	;	3.211	;	Crystal structure of IniA from Mycobacterium smegmatis
6J72	;	2.2	;	Crystal structure of IniA from Mycobacterium smegmatis with GTP bound
6EFR	;	2.4	;	Crystal Structure of iNicSnFR 1.0
7S7V	;	2.5	;	Crystal structure of iNicSnFR3a Fluorescent Nicotine Sensor
7S7U	;	2.95	;	Crystal structure of iNicSnFR3a Fluorescent Nicotine Sensor with nicotine bound
7S7W	;	1.1	;	Crystal structure of iNicSnFR3a Nicotine Sensor precursor binding protein
1HR0	;	3.2	;	CRYSTAL STRUCTURE OF INITIATION FACTOR IF1 BOUND TO THE 30S RIBOSOMAL SUBUNIT
2OMU	;	1.8	;	Crystal structure of InlA G194S+S Y369S/hEC1 complex
2OMT	;	2.0	;	Crystal structure of InlA G194S+S/hEC1 complex
2OMX	;	1.7	;	Crystal structure of InlA S192N G194S+S/hEC1 complex
2OMV	;	1.9	;	Crystal structure of InlA S192N Y369S/hEC1 complex
2OMW	;	1.85	;	Crystal structure of InlA S192N Y369S/mEC1 complex
2OMY	;	1.7	;	Crystal structure of InlA S192N/hEC1 complex
2OMZ	;	1.6	;	Crystal structure of InlA Y369A/hEC1 complex
5YCA	;	1.57	;	Crystal structure of inner membrane protein Bqt4 in complex with LEM2
5YC2	;	2.704	;	Crystal structure of inner membrane protein Bqt4 in complex with telomeric protein Rap1
7YBF	;	2.15	;	Crystal structure of inner membrane protein Sad1 in complex with histone H2A-H2B
3LD3	;	1.75	;	Crystal structure of inorganic phosphatase from anaplasma phagocytophilum at 1.75a resolution
3FQ3	;	1.9	;	Crystal structure of inorganic phosphatase from brucella melitensis
1WOQ	;	1.8	;	Crystal Structure of Inorganic Polyphosphate/ATP-Glucomannokinase From Arthrobacter sp. strain KM At 1.8 A Resolution
1Y3H	;	2.8	;	Crystal Structure of Inorganic Polyphosphate/ATP-NAD kinase from Mycobacterium tuberculosis
4HAO	;	2.551	;	Crystal Structure of Inorganic Polyphosphate/ATP-NAD Kinase from Yersinia pestis CO92
4XEL	;	2.0	;	Crystal structure of Inorganic pyrophosphatase (PPase) from Pseudomonas aeruginosa
3SW5	;	2.0	;	Crystal structure of inorganic pyrophosphatase from Bartonella henselae
3D63	;	2.3	;	Crystal structure of inorganic pyrophosphatase from Burkholderia pseudomallei
3EJ2	;	2.12	;	Crystal structure of inorganic pyrophosphatase from burkholderia pseudomallei with bound 5-amino-1-(4-chlorophenyl)-1h-pyrazole-4-carbonitrile, H32 crystal form
3EJ0	;	1.96	;	Crystal structure of inorganic pyrophosphatase from burkholderia pseudomallei with bound N-(pyridin-3-ylmethyl) aniline, H32 crystal form
3EIY	;	2.1	;	Crystal structure of inorganic pyrophosphatase from burkholderia pseudomallei with bound pyrophosphate
3EIZ	;	1.88	;	Crystal structure of inorganic pyrophosphatase from burkholderia pseudomallei, H32 crystal form
3LO0	;	1.95	;	Crystal structure of inorganic pyrophosphatase from Ehrlichia chaffeensis
1YGZ	;	2.6	;	Crystal Structure of Inorganic Pyrophosphatase from Helicobacter pylori
6N1C	;	2.0	;	Crystal structure of Inorganic pyrophosphatase from Legionella pneumophila Philadelphia 1
6MT2	;	2.89	;	Crystal structure of Inorganic Pyrophosphatase from Medicago truncatula (I23 crystal form)
6MT1	;	1.84	;	Crystal structure of Inorganic Pyrophosphatase from Medicago truncatula (R3 crystal form)
4Z73	;	3.3	;	Crystal structure of inorganic pyrophosphatase from Mycobacterium tuberculosis in complex with a phosphate ion and an inorganic pyrophosphate
4Z70	;	1.95	;	Crystal structure of inorganic pyrophosphatase from Mycobacterium tuberculosis in complex with Ca ions
4Z74	;	2.55	;	Crystal structure of inorganic pyrophosphatase from Mycobacterium tuberculosis in complex with inorganic pyrophosphate
4Z71	;	1.85	;	Crystal structure of inorganic pyrophosphatase from Mycobacterium tuberculosis in complex with Mg ions
4Z72	;	2.352	;	Crystal structure of inorganic pyrophosphatase from Mycobacterium tuberculosis in complex with two phosphate ions
4RPA	;	2.1	;	Crystal structure of inorganic pyrophosphatase from Staphylococcus aureus in complex with Mn2+
2PRD	;	2.0	;	CRYSTAL STRUCTURE OF INORGANIC PYROPHOSPHATASE FROM THERMUS THERMOPHILUS
4LUG	;	1.93	;	Crystal structure of Inorganic Pyrophosphatase PPA1 from Arabidopsis thaliana
5LS0	;	1.83	;	Crystal structure of Inorganic Pyrophosphatase PPA1 from Arabidopsis thaliana
3R2G	;	1.941	;	Crystal structure of Inosine 5' monophosphate dehydrogenase from Legionella pneumophila
4Q33	;	2.885	;	Crystal Structure of Inosine 5'-monophosphate Dehydrogenase from Clostridium perfringens Complexed with IMP and A110
4Q32	;	2.788	;	Crystal Structure of Inosine 5'-monophosphate Dehydrogenase from Clostridium perfringens Complexed with IMP and C91
5UWX	;	1.85	;	Crystal Structure of Inosine 5'-monophosphate Dehydrogenase from Clostridium perfringens Complexed with IMP and P176
5UXE	;	2.1	;	Crystal Structure of Inosine 5'-monophosphate Dehydrogenase from Clostridium perfringens Complexed with IMP and P178
5UZE	;	2.27	;	Crystal Structure of Inosine 5'-monophosphate Dehydrogenase from Clostridium perfringens Complexed with IMP and P182
5UZS	;	2.367	;	Crystal Structure of Inosine 5'-monophosphate Dehydrogenase from Clostridium perfringens Complexed with IMP and P200
5UZC	;	1.85	;	Crystal Structure of Inosine 5'-monophosphate Dehydrogenase from Clostridium perfringens Complexed with IMP and P221
5VSV	;	2.205	;	Crystal Structure of Inosine 5'-monophosphate Dehydrogenase from Clostridium perfringens Complexed with IMP and P225
4R7J	;	2.1172	;	Crystal Structure of Inosine 5'-monophosphate Dehydrogenase with the Internal Deletion Containing CBS Domain from Campylobacter jejuni
1JR1	;	2.6	;	Crystal structure of Inosine Monophosphate Dehydrogenase in complex with Mycophenolic Acid
1VRD	;	2.18	;	Crystal structure of Inosine-5'-monophosphate dehydrogenase (TM1347) from THERMOTOGA MARITIMA at 2.18 A resolution
3TSB	;	2.595	;	Crystal Structure of Inosine-5'-monophosphate Dehydrogenase from Bacillus anthracis str. Ames
3TSD	;	2.653	;	Crystal Structure of Inosine-5'-monophosphate Dehydrogenase from Bacillus anthracis str. Ames complexed with XMP
2CU0	;	2.1	;	Crystal structure of inosine-5'-monophosphate dehydrogenase from Pyrococcus horikoshii OT3
5W1Z	;	1.55	;	Crystal Structure of inosine-substituted decamer duplex DNA (I4)
5W20	;	1.36	;	Crystal Structure of inosine-substituted duplex DNA
2C40	;	2.2	;	CRYSTAL STRUCTURE OF INOSINE-URIDINE PREFERRING NUCLEOSIDE HYDROLASE FROM BACILLUS ANTHRACIS AT 2.2A RESOLUTION
5XU6	;	2.35	;	Crystal structure of inositol 1,3,4,5,6-pentakisphosphate 2-kinase (IPK1) from Cryptococcus neoformans
4LV7	;	2.6	;	Crystal structure of inositol 1,3,4,5,6-pentakisphosphate 2-kinase E82C/S142C
5XA0	;	5.812	;	Crystal structure of inositol 1,4,5-trisphosphate receptor cytosolic domain
5XA1	;	6.204	;	Crystal structure of inositol 1,4,5-trisphosphate receptor cytosolic domain with inositol 1,4,5-trisphosphate
5X9Z	;	7.311	;	Crystal structure of inositol 1,4,5-trisphosphate receptor large cytosolic domain
5GUG	;	7.399	;	Crystal structure of inositol 1,4,5-trisphosphate receptor large cytosolic domain with inositol 1,4,5-trisphosphate
7D5M	;	1.75	;	Crystal structure of inositol dehydrogenase homolog complexed with NAD+ from Azotobacter vinelandii
7D5N	;	1.8	;	Crystal structure of inositol dehydrogenase homolog complexed with NADH and myo-inositol from Azotobacter vinelandii
3T0J	;	2.59	;	Crystal structure of inositol monophosphatase - II from Staphylococcus aureus MSSA476
5J16	;	2.4	;	Crystal structure of Inositol monophosphate bound SaIMPase-II
3IKP	;	1.75	;	Crystal structure of inositol phosphate bound trimeric human lung surfactant protein D
2IEW	;	2.0	;	Crystal structure of Inositol Phosphate Multikinase Ipk2 from S. cerevisiae
2IF8	;	2.4	;	Crystal structure of Inositol Phosphate Multikinase Ipk2 in complex with ADP and Mn2+ from S. cerevisiae
7KIO	;	2.4	;	Crystal structure of inositol polyphosphate 1-phosphatase (INPP1) D54A mutant
7KIR	;	2.6	;	Crystal structure of inositol polyphosphate 1-phosphatase (INPP1) D54A mutant in complex with inositol (1,4)-bisphosphate
1INP	;	2.3	;	CRYSTAL STRUCTURE OF INOSITOL POLYPHOSPHATE 1-PHOSPHATASE AT 2.3 ANGSTROMS RESOLUTION
4QXD	;	2.55	;	Crystal structure of Inositol Polyphosphate 1-Phosphatase from Entamoeba histolytica
6X25	;	3.2	;	CRYSTAL STRUCTURE OF INOSITOL POLYPHOSPHATE 1-PHOSPHATASE INPP1 IN COMPLEX GADOLINIUM AFTER ADDITION OF INOSITOL 1,3,4-TRISPHOSPHATE AND LITHIUM AT 3.2 ANGSTROM RESOLUTION
6WRY	;	2.8	;	CRYSTAL STRUCTURE OF INOSITOL POLYPHOSPHATE 1-PHOSPHATASE INPP1 IN COMPLEX GADOLINIUM AFTER ADDITION OF INOSITOL 1,3,4-TRISPHOSPHATE AT 2.5 ANGSTROM RESOLUTION
6WRR	;	2.5	;	CRYSTAL STRUCTURE OF INOSITOL POLYPHOSPHATE 1-PHOSPHATASE INPP1 IN COMPLEX GADOLINIUM AND LITHIUM AT 2.5 ANGSTROM RESOLUTION
6WRO	;	3.0	;	CRYSTAL STRUCTURE OF INOSITOL POLYPHOSPHATE 1-PHOSPHATASE INPP1 IN COMPLEX GADOLINIUM BUT NO LITHIUM AT 3 ANGSTROM RESOLUTION
1I9Y	;	2.0	;	CRYSTAL STRUCTURE OF INOSITOL POLYPHOSPHATE 5-PHOSPHATASE DOMAIN (IPP5C) OF SPSYNAPTOJANIN
1I9Z	;	1.8	;	CRYSTAL STRUCTURE OF INOSITOL POLYPHOSPHATE 5-PHOSPHATASE DOMAIN (IPP5C) OF SPSYNAPTOJANIN IN COMPLEX WITH INOSITOL (1,4)-BISPHOSPHATE AND CALCIUM ION
1VKO	;	2.3	;	Crystal structure of inositol-3-phosphate synthase (ce21227) from Caenorhabditis elegans at 2.30 A resolution
3N9V	;	2.65	;	Crystal Structure of INPP5B
5A7J	;	2.9	;	Crystal structure of INPP5B in complex with benzene 1,2,4,5- tetrakisphosphate
5A7I	;	2.89	;	Crystal structure of INPP5B in complex with biphenyl 3,3',4,4',5,5'- hexakisphosphate
4CML	;	2.3	;	Crystal Structure of INPP5B in complex with Phosphatidylinositol 3,4- bisphosphate
3MTC	;	2.4	;	Crystal Structure of INPP5B in complex with phosphatidylinositol 4-phosphate
5Y1B	;	2.207	;	Crystal Structure of insect beta-N-acetyl-D-hexosaminidase OfHex1 complexed with a berberine derivative (SYSU-00679)
5Y0V	;	2.423	;	Crystal Structure of insect beta-N-acetyl-D-hexosaminidase OfHex1 complexed with berberine
3WMB	;	2.7	;	Crystal structure of insect beta-N-acetyl-D-hexosaminidase OfHex1 complexed with naphthalimide derivative Q1
3WMC	;	2.095	;	Crystal structure of insect beta-N-acetyl-D-hexosaminidase OfHex1 complexed with naphthalimide derivative Q2
3OZO	;	2.0	;	Crystal Structure of insect beta-N-acetyl-D-hexosaminidase OfHex1 complexed with NGT
3OZP	;	2.0	;	Crystal Structure of insect beta-N-acetyl-D-hexosaminidase OfHex1 complexed with PUGNAc
3NSN	;	2.1	;	Crystal Structure of insect beta-N-acetyl-D-hexosaminidase OfHex1 complexed with TMG-chitotriomycin
3VTR	;	2.5	;	Crystal Structure of insect beta-N-acetyl-D-hexosaminidase OfHex1 E328A complexed with TMG-chitotriomycin
3NSM	;	2.1	;	Crystal Structure of insect beta-N-acetyl-D-hexosaminidase OfHex1 from Ostrinia furnacalis
3S6T	;	2.3	;	Crystal Structure of insect beta-N-acetyl-D-hexosaminidase OfHex1 V327G complexed with PUGNAc
1YKB	;	2.6	;	Crystal Structure of Insect Cell Expressed IL-22
1TBQ	;	3.1	;	CRYSTAL STRUCTURE OF INSECT DERIVED DOUBLE DOMAIN KAZAL INHIBITOR RHODNIIN IN COMPLEX WITH THROMBIN
1TBR	;	2.6	;	CRYSTAL STRUCTURE OF INSECT DERIVED DOUBLE DOMAIN KAZAL INHIBITOR RHODNIIN IN COMPLEX WITH THROMBIN
4FD7	;	1.8	;	Crystal structure of insect putative arylalkylamine N-Acetyltransferase 7 from the yellow fever mosquito Aedes aegypt
5DBQ	;	1.95	;	Crystal structure of insect thioredoxin at 1.95 Angstroms
3EB7	;	2.3	;	Crystal Structure of Insecticidal Delta-Endotoxin Cry8Ea1 from Bacillus Thuringiensis at 2.2 Angstroms Resolution
1DLC	;	2.5	;	CRYSTAL STRUCTURE OF INSECTICIDAL DELTA-ENDOTOXIN FROM BACILLUS THURINGIENSIS AT 2.5 ANGSTROMS RESOLUTION
8HGZ	;	1.7	;	Crystal structure of insulin
4PF7	;	2.33	;	Crystal structure of insulin degrading enzyme complexed with inhibitor
4PF9	;	2.5	;	Crystal structure of insulin degrading enzyme complexed with inhibitor
4PFC	;	2.21	;	Crystal structure of insulin degrading enzyme complexed with inhibitor
4PES	;	2.21	;	Crystal structure of insulin degrading enzyme complexed with inhibitor tert-butyl [(2S)-2-(2,5-difluorophenyl)-3-(quinolin-3-yl)propyl]carbamate
4NXO	;	2.73	;	Crystal Structure of Insulin Degrading Enzyme in complex with BDM44768
3H44	;	3.0	;	Crystal Structure of Insulin Degrading Enzyme in Complex with macrophage inflammatory protein 1 alpha
4RAL	;	3.148	;	Crystal structure of insulin degrading enzyme in complex with macrophage inflammatory protein 1 beta
8IPZ	;	1.4	;	Crystal structure of insulin detemir
6OR0	;	1.55	;	Crystal structure of Insulin from Non-merohedrally twinned crystals
6JR3	;	14.5	;	Crystal structure of insulin hexamer fitted into cryo EM density map where each dimer was kept as rigid body
4IBM	;	1.8	;	Crystal structure of insulin receptor kinase domain in complex with an inhibitor Irfin-1
5HHW	;	1.79	;	Crystal structure of insulin receptor kinase domain in complex with cis-(R)-7-(3-(azetidin-1-ylmethyl)cyclobutyl)-5-(3-((tetrahydro-2H-pyran-2-yl)methoxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine.
4Z7I	;	3.31	;	Crystal structure of insulin regulated aminopeptidase in complex with ligand
3NW6	;	2.2	;	Crystal structure of insulin-like growth factor 1 receptor (IGF-1R-WT) complex with a carbon-linked proline isostere inhibitor (11A)
3NW5	;	2.14	;	Crystal structure of insulin-like growth factor 1 receptor (IGF-1R-WT) complex with a carbon-linked proline isostere inhibitor (11B)
3NW7	;	2.11	;	Crystal structure of insulin-like growth factor 1 receptor (IGF-1R-WT) complex with a carbon-linked proline isostere inhibitor (34)
3I81	;	2.08	;	Crystal structure of insulin-like growth factor 1 receptor (IGF-1R-WT) complex with BMS-754807 [1-(4-((5-cyclopropyl-1H-pyrazol-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N-(6-fluoro-3-pyridinyl)-2-methyl-L-prolinamide]
3TUV	;	2.27	;	Crystal structure of insulysin with bound ATP
1HYU	;	2.0	;	CRYSTAL STRUCTURE OF INTACT AHPF
1YZ6	;	3.37	;	Crystal structure of intact alpha subunit of aIF2 from Pyrococcus abyssi
7S3C	;	1.51	;	Crystal structure of intact U2AF65 RRM-region bound to AdML-A5 oligonucleotide
7S3A	;	1.48	;	Crystal structure of intact U2AF65 RRM-region bound to AdML-C5 oligonucleotide
7S3B	;	1.89	;	Crystal structure of intact U2AF65 RRM-region bound to AdML-G5 oligonucleotide
2F2B	;	1.68	;	Crystal structure of integral membrane protein Aquaporin AqpM at 1.68A resolution
3NKH	;	2.502	;	Crystal Structure of Integrase from MRSA strain Staphylococcus aureus
4G1E	;	3.0	;	Crystal structure of integrin alpha V beta 3 with coil-coiled tag.
5FFG	;	2.25	;	Crystal structure of integrin alpha V beta 6 head
5XAU	;	1.8	;	Crystal structure of integrin binding fragment of laminin-511
3F6Q	;	1.6	;	Crystal structure of integrin-linked kinase ankyrin repeat domain in complex with PINCH1 LIM1 domain
2CW7	;	2.7	;	Crystal structure of intein homing endonuclease II
2CW8	;	2.5	;	Crystal structure of intein homing endonuclease II
2G9F	;	1.9	;	Crystal structure of intein-tagged mouse PNGase C-terminal domain
3KCP	;	1.94	;	Crystal structure of interacting Clostridium thermocellum multimodular components
3FXD	;	2.1	;	Crystal structure of interacting domains of IcmR and IcmQ
3FXE	;	2.2	;	Crystal structure of interacting domains of IcmR and IcmQ (seleno-derivative)
191D	;	1.4	;	CRYSTAL STRUCTURE OF INTERCALATED FOUR-STRANDED D(C3T)
5OEM	;	1.9	;	Crystal Structure of Interferon Regulatory Factor 9 IAD Domain
4G1T	;	2.8	;	Crystal structure of interferon-stimulated gene 54
1L2H	;	1.54	;	Crystal structure of Interleukin 1-beta F42W/W120F mutant
2PSM	;	2.19	;	Crystal structure of Interleukin 15 in complex with Interleukin 15 receptor alpha
3IL8	;	2.0	;	CRYSTAL STRUCTURE OF INTERLEUKIN 8: SYMBIOSIS OF NMR AND CRYSTALLOGRAPHY
2C6Y	;	2.4	;	Crystal structure of interleukin enhancer-binding factor 1 bound to DNA
6VQL	;	2.069	;	CRYSTAL STRUCTURE OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK4-WT) COMPLEX WITH A NICOTINAMIDE INHIBITOR
3V5J	;	2.59	;	Crystal Structure of Interleukin-2 Inducible T-cell Kinase Itk Catalytic Domain with Thienopyrazolylindole Inhibitor 090
3V8W	;	2.27	;	Crystal Structure of Interleukin-2 Inducible T-cell Kinase Itk Catalytic Domain with Thienopyrazolylindole Inhibitor 469
3V8T	;	2.0	;	Crystal Structure of Interleukin-2 Inducible T-cell Kinase Itk Catalytic Domain with Thienopyrazolylindole Inhibitor 477
3V5L	;	1.86	;	Crystal Structure of Interleukin-2 Inducible T-cell Kinase Itk Catalytic Domain with Thienopyrazolylindole Inhibitor 542
3D87	;	2.9	;	Crystal structure of Interleukin-23
5HN1	;	2.25	;	Crystal structure of Interleukin-37
3HI6	;	2.3	;	Crystal structure of intermediate affinity I domain of integrin LFA-1 with the Fab fragment of its antibody AL-57
5HAD	;	2.238	;	Crystal structure of intermembrane space region of chloroplast protein ARC6
5GTB	;	2.871	;	crystal structure of intermembrane space region of the ARC6-PDV2 complex
3FP9	;	2.0	;	Crystal structure of Intern Domain of proteasome-associated ATPase, Mycobacterium tuberculosis
1RY6	;	1.6	;	Crystal Structure of Internal Kinesin Motor Domain
8H62	;	1.91	;	Crystal structure of Internalin A from Listeria monocytogenes with human E-cadherin EC12
8H63	;	1.53	;	Crystal structure of Internalin A from Listeria monocytogenes with nanobody VHH10 bound
8H64	;	2.35	;	Crystal structure of Internalin A from Listeria monocytogenes with nanobody VHH24 bound
1M9S	;	2.65	;	Crystal structure of Internalin B (InlB), a Listeria monocytogenes virulence protein containing SH3-like domains.
1XEU	;	2.05	;	Crystal Structure of Internalin C from Listeria monocytogenes
4L3A	;	2.591	;	Crystal structure of Internalin K (InlK) from Listeria monocytogenes
4L3F	;	2.39	;	Crystal structure of Internalin K (InlK) from Listeria monocytogenes
2ZQK	;	2.8	;	Crystal structure of intimin-Tir68 complex
2ZWK	;	3.1	;	Crystal structure of intimin-Tir90 complex
8IGT	;	1.56	;	Crystal Structure of Intracellular B30.2 Domain of BTN2A1
8IH4	;	2.12	;	Crystal Structure of Intracellular B30.2 Domain of BTN2A2 Mutant
8IXV	;	1.72	;	Crystal structure of intracellular B30.2 domain of BTN3A in complex with 2Cl-HMBPP
4N7I	;	1.4015	;	Crystal Structure of Intracellular B30.2 Domain of BTN3A1
8JYC	;	2.29	;	Crystal Structure of Intracellular B30.2 Domain of BTN3A1 and BTN2A1 in Complex with DMAPP
8JYE	;	2.18	;	Crystal Structure of Intracellular B30.2 Domain of BTN3A1 and BTN2A1 in Complex with HMBPP
5LYK	;	1.7	;	CRYSTAL STRUCTURE OF INTRACELLULAR B30.2 DOMAIN OF BTN3A1 BOUND TO CITRATE
5LYG	;	1.6	;	CRYSTAL STRUCTURE OF INTRACELLULAR B30.2 DOMAIN OF BTN3A1 BOUND TO MALONATE
8IZE	;	1.4	;	Crystal structure of intracellular B30.2 domain of BTN3A1 in complex with 4-HMBPP
8IZG	;	1.6	;	Crystal structure of intracellular B30.2 domain of BTN3A1 in complex with 5-HMBPP
4N7U	;	1.4598	;	Crystal Structure of Intracellular B30.2 Domain of BTN3A1 in Complex with CHDMAPP
5ZXK	;	1.96	;	Crystal structure of intracellular B30.2 domain of BTN3A1 in complex with HMBPP
6J06	;	2.65	;	Crystal structure of intracellular B30.2 domain of BTN3A1 in complex with HMBPP-08
6ISM	;	1.25	;	Crystal structure of intracellular B30.2 domain of BTN3A1 mutant
6ITA	;	1.2	;	Crystal structure of intracellular B30.2 domain of BTN3A1 mutant
5ZZ3	;	3.0	;	Crystal structure of intracellular B30.2 domain of BTN3A3
6J0G	;	1.6	;	Crystal structure of intracellular B30.2 domain of BTN3A3 mutant in complex with HMBPP
6J0K	;	2.0	;	Crystal structure of intracellular B30.2 domain of BTN3A3 mutant in complex with HMBPP
6J0L	;	1.95	;	Crystal structure of intracellular B30.2 domain of BTN3A3 mutant in complex with sulfate ion
8JYB	;	1.91	;	Crystal Structure of Intracellular B30.2 Domain of VpBTN3
8HJT	;	2.91	;	Crystal Structure of Intracellular B30.2 Domain of VpBTN3 and VpBTN2 in Complex with HMBPP
8JYF	;	1.8	;	Crystal Structure of Intracellular B30.2 Domain of VpBTN3 in Complex with DMAPP
8JY9	;	1.83	;	Crystal Structure of Intracellular B30.2 Domain of VpBTN3 in Complex with HMBPP
8JYA	;	1.5	;	Crystal Structure of Intracellular B30.2 Domain of VpBTN3 in Complex with IPP
2QBV	;	2.0	;	Crystal Structure of Intracellular Chorismate Mutase from Mycobacterium Tuberculosis
2E40	;	1.9	;	Crystal structure of intracellular family 1 beta-glucosidase BGL1A from the basidiomycete Phanerochaete chrysosporium in complex with gluconolactone
2E3Z	;	1.5	;	Crystal structure of intracellular family 1 beta-glucosidase BGL1A from the basidiomycete Phanerochaete chrysosporium in substrate-free form
2INU	;	1.8	;	Crystal structure of Inulin fructotransferase in the absence of substrate
2INV	;	1.8	;	Crystal structure of Inulin fructotransferase in the presence of di-fructose
2YFR	;	1.75	;	Crystal structure of inulosucrase from Lactobacillus johnsonii NCC533
2YFT	;	1.85	;	Crystal structure of inulosucrase from Lactobacillus johnsonii NCC533 in complex with 1-kestose
2YFS	;	2.6	;	Crystal structure of inulosucrase from Lactobacillus johnsonii NCC533 in complex with sucrose
1CWV	;	2.3	;	CRYSTAL STRUCTURE OF INVASIN: A BACTERIAL INTEGRIN-BINDING PROTEIN
3DTD	;	2.35	;	Crystal structure of invasion associated protein b from bartonella henselae
6D8W	;	2.35	;	Crystal structure of InvbI.18715.a.KN11: Influenza hemagglutinin from strain A/Jiangsu/ALSI/2011
6N41	;	2.5	;	Crystal structure of InvbM.18715.a.KN11: Influenza hemagglutinin from strain A/Netherlands/002P1/1951
6MYA	;	2.05	;	Crystal structure of InvbP.18715.a.KN11: Influenza hemagglutinin from strain A/Almaty/32/1998
6M86	;	3.6	;	Crystal Structure of Inward Rectifier Kir2.2 Force Open Mutant
6M85	;	2.71	;	Crystal Structure of Inward Rectifier Kir2.2 in a different salt condition
5KUK	;	2.0	;	Crystal Structure of Inward Rectifier Kir2.2 K62W Mutant
5KUM	;	2.8	;	Crystal Structure of Inward Rectifier Kir2.2 K62W Mutant In Complex with PIP2
2R1Q	;	2.5	;	Crystal Structure of Iodinated Human Saposin D in Space Group C2221
6TYK	;	1.35	;	Crystal structure of iodotyrosine deiodinase (IYD) in the semiquinone form bound to FMN and 3-iodo-L-tyrosine
3UPS	;	1.75	;	Crystal structure of iojap-like protein from Zymomonas mobilis
7TQG	;	2.07	;	Crystal Structure of IOMA Fab inferred germline
6D2P	;	2.6	;	Crystal structure of IOMA-class CLK31 Fab from an HIV-1 naive donor in complex with a germline-targeting gp120 engineered outer domain eOD-GT8 at 2.6 A
3LMW	;	2.6	;	Crystal structure of iota-carrageenase family GH82 from A. fortis in absence of chloride ions
1O80	;	2.0	;	Crystal structure of IP-10 H-Form
1O7Y	;	3.0	;	Crystal structure of IP-10 M-form
1O7Z	;	1.92	;	Crystal structure of IP-10 T-form
5V3S	;	1.8	;	Crystal structure of IP-1A from Alcaligenes faecalis at 1.8A resolution
4UPU	;	2.34	;	Crystal structure of IP3 3-K calmodulin binding region in complex with Calmodulin
7V8E	;	1.9	;	Crystal structure of IpaH1.4 LRR domain bound to HOIL-1L UBL domain.
8GTK	;	3.1	;	Crystal structure of IpaH7.8-LRR and GSDMB isoform-1 complex
8GTJ	;	2.7	;	Crystal structure of IpaH7.8-LRR and GSDMB isoform-4 complex
7EAP	;	1.42	;	Crystal structure of IpeA-XXXG complex
3LYQ	;	2.3	;	Crystal structure of IpgB2 from Shigella flexneri
3GYZ	;	2.15	;	Crystal structure of IpgC from Shigella flexneri
7P42	;	1.5	;	Crystal structure of IpgC in complex with a follow-up compound based on J2
7OWV	;	1.59	;	Crystal structure of IpgC in complex with a follow-up compound based on J20
8QH6	;	1.8	;	Crystal structure of IpgC in complex with a follow-up compound based on J20
3GZ2	;	2.65	;	Crystal structure of IpgC in complex with an IpaB peptide
7PEF	;	1.54	;	Crystal structure of IpgC in complex with DMSO
7PE0	;	1.5	;	Crystal structure of IpgC in complex with J52
3GZ1	;	2.15	;	Crystal structure of IpgC in complex with the chaperone binding region of IpaB
6RP8	;	2.6	;	Crystal Structure of Ipilimumab Fab complexed with CTLA-4 at 2.6A resolution
4KP1	;	1.8	;	Crystal structure of IPM isomerase large subunit from methanococcus jannaschii (MJ0499)
1WPW	;	2.8	;	Crystal Structure of IPMDH from Sulfolobus tokodaii
3U1H	;	2.8	;	Crystal structure of IPMDH from the last common ancestor of Bacillus
1VCF	;	2.6	;	Crystal Structure of IPP isomerase at I422
1VCG	;	3.02	;	Crystal Structure of IPP isomerase at P43212
4EL6	;	1.71	;	Crystal structure of IPSE/alpha-1 from Schistosoma mansoni eggs
2Q5U	;	1.5	;	Crystal structure of IQN17
2Q7C	;	2.0	;	Crystal structure of IQN17
7VMB	;	1.99777	;	Crystal structure of IQSEC1-IQ motif, Sec7PH tandem in complex with calmodulin
2NRU	;	2.0	;	Crystal structure of IRAK-4
2NRY	;	2.15	;	Crystal structure of IRAK-4
4RMZ	;	2.2	;	Crystal Structure of IRAK-4
5W84	;	2.9	;	CRYSTAL STRUCTURE OF IRAK-4 WITH A 4,6-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 4)
5W85	;	2.25	;	CRYSTAL STRUCTURE OF IRAK-4 WITH A 4,6-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 9)
5UIR	;	2.64	;	Crystal structure of IRAK4 in complex with compound 11
5UIS	;	2.5	;	Crystal structure of IRAK4 in complex with compound 12
5UIT	;	1.84	;	Crystal structure of IRAK4 in complex with compound 14
6O8U	;	1.8	;	Crystal structure of IRAK4 in complex with compound 23
5UIU	;	2.02	;	Crystal structure of IRAK4 in complex with compound 30
5UIQ	;	2.64	;	Crystal structure of IRAK4 in complex with compound 9
2OIB	;	2.0	;	Crystal structure of IRAK4 kinase domain apo form
2OID	;	2.3	;	Crystal structure of IRAK4 kinase domain complexed with AMPPNP
2OIC	;	2.4	;	Crystal structure of IRAK4 kinase domain complexed with staurosporine
4Y73	;	2.14	;	Crystal structure of IRAK4 kinase domain with inhibitor
7C2W	;	3.2	;	Crystal Structure of IRAK4 kinase in complex with a small molecule inhibitor
7C2V	;	2.44	;	Crystal Structure of IRAK4 kinase in complex with the inhibitor CA-4948
7EMM	;	1.25	;	Crystal structure of IrCp* immobilized apo-R52H-rHLFr
7W7J	;	1.5	;	Crystal structure of IrCp* immobilized apo-R52H-rHLFr (25 equiv)
5E1U	;	1.56	;	Crystal structure of IrCp*-apo-Fr
5HQO	;	1.81	;	Crystal structure of IrCp*/I-Pd(allyl)-apo-rHLFr
5E2D	;	1.87	;	Crystal structure of IrCp*/Pd(allyl)-apo-Fr
2H7Z	;	1.5	;	Crystal structure of irditoxin
6XDD	;	2.4	;	Crystal structure of IRE1 in complex with G-3053
6URC	;	2.2	;	Crystal structure of IRE1a in complex with compound 18
6XDF	;	2.54	;	Crystal structure of IRE1a in complex with G-4100
6XDB	;	2.45	;	Crystal structure of IRE1a in complex with G-6904
2O6G	;	3.1	;	Crystal structure of IRF-3 bound to the interferon-b enhancer
2PI0	;	2.31	;	Crystal Structure of IRF-3 bound to the PRDIII-I regulatory element of the human interferon-B enhancer
3QU6	;	2.3	;	Crystal structure of IRF-3 DBD free form
3QU3	;	1.3	;	Crystal structure of IRF-7 DBD apo form
8E51	;	2.594	;	Crystal Structure of Iridescent Shark Catfish Cadherin-23 EC1-2 and Protocadherin-15 EC1-2
5COA	;	2.2	;	Crystal structure of iridoid synthase at 2.2-angstrom resolution
5DBG	;	1.95	;	Crystal Structure of Iridoid Synthase from Cantharanthus roseus in complex with NAD+
5DBI	;	2.2	;	Crystal Structure of Iridoid Synthase from Cantharanthus roseus in complex with NAD+ and 10-oxogeranial
5EMH	;	2.1	;	Crystal structure of Iridoid Synthase from Cantharanthus roseus in complex with NADP+
5DBF	;	2.0	;	Crystal Structure of Iridoid Synthase from Cantharanthus roseus in complex with NADPH
5COB	;	2.65	;	Crystal structure of iridoid synthase in complex with NADP+ and 8-oxogeranial at 2.65-angstrom resolution
7QTZ	;	2.1	;	Crystal structure of Iripin-1 serpin from tick Ixodes ricinus
7B2T	;	1.5	;	Crystal structure of Iripin-5 serpin from Ixodes ricinus
5O46	;	1.76	;	Crystal structure of Iristatin, a secreted salivary cystatin from the hard tick Ixodes ricinus
3GFF	;	2.12	;	Crystal structure of IroE-like serine hydrolase (NP_718593.1) from SHEWANELLA ONEIDENSIS at 2.12 A resolution
4HN9	;	1.85	;	Crystal structure of iron ABC transporter solute-binding protein from Eubacterium eligens
8FFC	;	1.85	;	Crystal structure of iron bound Dps protein (PA0962) from Pseudomonas aeruginosa (cubic form)
8FFB	;	2.25	;	Crystal structure of iron bound Dps protein (PA0962) from Pseudomonas aeruginosa (orthorhombic form)
3VSG	;	2.4	;	Crystal structure of iron free 1,6-APD, 2-Animophenol-1,6-Dioxygenase
4IWJ	;	1.95	;	Crystal structure of iron soaked (45 min) ferritin from Pseudo-nitzschia multiseries
4ISP	;	2.2	;	Crystal structure of iron soaked (4h) ferritin from Pseudo-nitzschia multiseries
4ITT	;	2.1	;	Crystal structure of iron soaked (5 min) ferritin from Pseudo-nitzschia multiseries
4IWK	;	1.65	;	Crystal structure of iron soaked (overnight) ferritin from Pseudo-nitzschia multiseries
3JS4	;	1.95	;	Crystal structure of iron superoxide dismutase from Anaplasma phagocytophilum
4F2N	;	1.85	;	Crystal structure of iron superoxide dismutase from Leishmania major
6IU4	;	3.5	;	Crystal structure of iron transporter VIT1 with cobalt ion
6IU3	;	2.7	;	Crystal structure of iron transporter VIT1 with zinc ions
4H59	;	1.658	;	Crystal structure of iron uptake ABC transporter substrate-binding protein PiaA from Streptococcus pneumoniae Canada MDR_19A bound to Bis-tris propane
5JJ5	;	2.3	;	Crystal structure of iron uptake ABC transporter substrate-binding protein PiaA from Streptococcus pneumoniae Canada MDR_19A bound to hydroxymate siderophore ferrioxamine E and iron(III)
4HMP	;	2.7	;	Crystal structure of iron uptake ABC transporter substrate-binding protein PiaA from Streptococcus pneumoniae TIGR4
4JCC	;	1.133	;	Crystal structure of iron uptake ABC transporter substrate-binding protein PiuA from Streptococcus pneumoniae Canada MDR_19A
3E19	;	2.0	;	Crystal Structure of Iron Uptake Regulatory Protein (FeoA) Solved by Sulfur SAD in a Monoclinic Space Group
6Q09	;	1.75	;	Crystal structure of iron-bound Hemerythrin HHE cation binding domain-containing protein: Rv2633c homolog from Mycobacterium kansasii
6IVY	;	2.0	;	Crystal structure of iron-bound HitA from Pseudomonas aeruginosa
6XMA	;	1.45	;	Crystal structure of iron-bound LSD4 from Sphingobium sp. strain SYK-6
8X3H	;	0.93	;	Crystal structure of iron-bound recombinant ovotransferrin N-lobe at 0.93 angstrom resolution
3IV7	;	2.07	;	Crystal structure of Iron-containing alcohol dehydrogenase (NP_602249.1) from Corynebacterium glutamicum ATCC 13032 KITASATO at 2.07 A resolution
1XVY	;	1.74	;	Crystal Structure of iron-free Serratia marcescens SfuA
1XVX	;	1.53	;	Crystal Structure of iron-loaded Yersinia enterocolitica YfuA
2O1A	;	1.6	;	Crystal structure of iron-regulated surface determinant protein A from Staphylococcus aureus- targeted domain 47...188
7ENU	;	2.322	;	Crystal structure of iron-saturated C-terminal half of lactoferrin produced proteolytically using pepsin at 2.32A resolution
3RN4	;	1.79	;	Crystal structure of iron-substituted Sod2 from Saccharomyces cerevisiae
2QQ4	;	1.85	;	Crystal structure of Iron-sulfur cluster biosynthesis protein IscU (TTHA1736) from thermus thermophilus HB8
5LFA	;	2.5	;	Crystal structure of iron-sulfur cluster containing bacterial (6-4) photolyase PhrB - Y424F mutant with impaired DNA repair activity
5KCM	;	2.149	;	Crystal structure of iron-sulfur cluster containing photolyase PhrB mutant I51W
2PHZ	;	2.15	;	Crystal structure of Iron-uptake system-binding protein FeuA from Bacillus subtilis. Northeast Structural Genomics target SR580.
7SPN	;	2.92	;	Crystal structure of IS11, a thermophilic esterase
2F4F	;	1.8	;	Crystal structure of IS200 transposase
2F5G	;	1.7	;	Crystal structure of IS200 transposase
1R94	;	2.3	;	Crystal Structure of IscA (MERCURY DERIVATIVE)
1R95	;	2.65	;	Crystal Structure of IscA (native)
1X0G	;	2.5	;	Crystal Structure of IscA with the [2Fe-2S] cluster
4HF1	;	2.222	;	Crystal Structure of IscR bound to its promoter
7ZPN	;	1.94	;	Crystal Structure of IscR from Dinoroseobacter shibae
4ISY	;	2.59	;	Crystal structure of IscS from Mycobacterium tuberculosis
7C8O	;	1.84	;	Crystal structure of IscU D40A/H106A variant
7C8N	;	1.5	;	Crystal structure of IscU H106A variant
7CNV	;	2.23	;	Crystal structure of IscU H106C variant
7C8M	;	3.5	;	Crystal structure of IscU wild-type
7XLI	;	1.7	;	Crystal structure of IsdB linker-NEAT2 bound to a nanobody (VHH)
8AVH	;	1.9	;	Crystal structure of IsdG from Bacillus cereus
8AVI	;	2.0	;	Crystal structure of IsdG from Bacillus cereus in complex with heme
2ZDO	;	1.8	;	Crystal structure of IsdG-N7A in complex with hemin
7XLD	;	1.65	;	Crystal structure of IsdH linker-NEAT3 bound to a nanobody (VHH)
2ZDP	;	1.5	;	Crystal structure of IsdI in complex with Cobalt protoporphyrin IX
3LGN	;	1.5	;	Crystal structure of IsdI in complex with heme
3QGP	;	1.8	;	Crystal structure of IsdI in complex with heme and cyanide
4FNH	;	1.9	;	Crystal structure of IsdI-W66Y in complex with heme
4FNI	;	1.8	;	Crystal structure of IsdI-W66Y in complex with heme and cyanide
1Z2M	;	2.5	;	Crystal Structure of ISG15, the Interferon-Induced Ubiquitin Cross Reactive Protein
3MTT	;	3.3	;	Crystal structure of iSH2 domain of human p85beta, Northeast Structural Genomics Consortium Target HR5531C
4JCJ	;	3.0	;	Crystal structure of Isl1 LIM domains with Ldb1 LIM-interaction domain
5L58	;	3.04	;	Crystal structure of Iso-citrate Dehydrogenase 1 [IDH1 (R132H)] in complex with a novel inhibitor (Compound 2)
5L57	;	2.695	;	Crystal structure of Iso-citrate Dehydrogenase R132H in complex with a novel inhibitor (compound 13a)
3MIL	;	1.6	;	Crystal structure of isoamyl acetate-hydrolyzing esterase from Saccharomyces cerevisiae
8DQM	;	2.7	;	Crystal structure of isoaspartyl aminopeptidase from Roseivivax halodurans DSM 15395
1POK	;	2.7	;	Crystal structure of Isoaspartyl Dipeptidase
1ONW	;	1.65	;	Crystal structure of Isoaspartyl Dipeptidase from E. coli
1ONX	;	2.1	;	Crystal structure of isoaspartyl dipeptidase from escherichia coli complexed with aspartate
8DQN	;	1.8	;	Crystal structure of isoaspartyl dipeptidase from Leucothrix mucor DSM2157
1RX0	;	1.77	;	Crystal structure of isobutyryl-CoA dehydrogenase complexed with substrate/ligand.
2A67	;	2.0	;	Crystal structure of Isochorismatase family protein
3HU5	;	1.5	;	CRYSTAL STRUCTURE OF isochorismatase family protein from Desulfovibrio vulgaris subsp. vulgaris str. Hildenborough
6LKZ	;	2.8	;	Crystal structure of isocitrate dehydrogenase 1 from Phaeodactylum tricornutum
7E3N	;	1.9	;	Crystal structure of Isocitrate dehydrogenase D252N mutant from Trypanosoma brucei in complexed with NADP+, alpha-ketoglutarate, and ca2+
1V94	;	2.28	;	Crystal structure of isocitrate dehydrogenase from Aeropyrum pernix
1HQS	;	1.55	;	CRYSTAL STRUCTURE OF ISOCITRATE DEHYDROGENASE FROM BACILLUS SUBTILIS
7Y1U	;	2.5	;	Crystal structure of isocitrate dehydrogenase from Campylobacter corcagiensis
6C0E	;	1.7	;	Crystal Structure of Isocitrate Dehydrogenase from Legionella pneumophila with bound NADPH with an alpha-ketoglutarate adduct
6LKY	;	2.2	;	Crystal structure of isocitrate dehydrogenase from Methylococcus capsulatus
6IXL	;	1.75	;	Crystal structure of isocitrate dehydrogenase from Ostreococcus tauri
7E2W	;	1.8	;	Crystal structure of isocitrate dehydrogenase from Ostreococcus tauri in complex with isocitrate and magnesium(II)
6IXN	;	1.87	;	Crystal structure of isocitrate dehydrogenase from Ostreococcus tauri in complex with NAD+ and citrate
6IXT	;	1.78	;	Crystal structure of isocitrate dehydrogenase from Ostreococcus tauri in complex with NAD+ and Mg2+
2E5M	;	2.4	;	Crystal structure of isocitrate dehydrogenase from Sulfolobus tokodaii strain 7
2DHT	;	2.5	;	Crystal structure of isocitrate dehydrogenase from Sulfolobus tokodaii strain7
2E0C	;	2.0	;	crystal structure of isocitrate dehydrogenase from Sulfolobus tokodaii strain7 at 2.0 A resolution
4ZDA	;	2.8	;	Crystal structure of isocitrate dehydrogenase in complex with isocitrate and Mn from M. smegmatis
1CW1	;	2.1	;	CRYSTAL STRUCTURE OF ISOCITRATE DEHYDROGENASE MUTANT K230M BOUND TO ISOCITRATE AND MN2+
5KVU	;	2.66	;	Crystal structure of isocitrate dehydrogenase-2 in complex with NADP(+) from Mycobacterium tuberculosis
6LRT	;	2.9	;	Crystal structure of isocitrate lyase (Caur_3889) from Chloroflexus aurantiacus in complex with isocitrate and manganese ion
6LRP	;	2.05	;	Crystal structure of isocitrate lyase (Caur_3889) from Chloroflexus aurantiacus in complex with manganese ion
7RBX	;	1.8	;	Crystal structure of isocitrate lyase and phosphorylmutase:isocitrate lyase from Brucella melitensis biovar Abortus 2308 bound to itaconic acid
3P0X	;	2.35	;	Crystal structure of isocitrate lyase from Brucella melitensis, bound to magnesium isocitrate
3OQ8	;	2.25	;	Crystal structure of isocitrate lyase from Brucella melitensis, bound to the product mimic malonate
3I4E	;	2.69	;	Crystal structure of Isocitrate Lyase from Burkholderia pseudomallei
1F61	;	2.0	;	CRYSTAL STRUCTURE OF ISOCITRATE LYASE FROM MYCOBACTERIUM TUBERCULOSIS
7CP1	;	2.58	;	Crystal structure of isocitrate lyase in complex with succinate and itaconate
7EBE	;	2.69	;	Crystal structure of Isocitrate lyase-1 from Candida albicans
7EBC	;	2.3	;	Crystal structure of Isocitrate lyase-1 from Saccaromyces cervisiae
1F8I	;	2.25	;	CRYSTAL STRUCTURE OF ISOCITRATE LYASE:NITROPROPIONATE:GLYOXYLATE COMPLEX FROM MYCOBACTERIUM TUBERCULOSIS
3NON	;	1.05	;	Crystal Structure of Isocyanide Hydratase from Pseudomonas fluorescens
1ZGA	;	2.35	;	Crystal structure of isoflavanone 4'-O-methyltransferase complexed with (+)-6a-hydroxymaackiain
1ZGJ	;	2.5	;	Crystal structure of isoflavanone 4'-O-methyltransferase complexed with (+)-pisatin
2QYO	;	1.95	;	Crystal structure of isoflavone O-methyltransferase homolog in complex with biochanin A and SAH
2GAS	;	1.6	;	Crystal Structure of Isoflavone Reductase
5TBS	;	1.9	;	Crystal Structure of Isoform 2 of Purine Nucleoside Phosphorylase complexed with adenine
5TBT	;	2.101	;	Crystal Structure of Isoform 2 of Purine Nucleoside Phosphorylase complexed with Cytidine
5TBU	;	2.1	;	Crystal Structure of Isoform 2 of Purine Nucleoside Phosphorylase complexed with Hypoxanthine
5CXS	;	1.75	;	Crystal Structure of Isoform 2 of Purine Nucleoside Phosphorylase complexed with MES
5TBV	;	1.95	;	Crystal Structure of Isoform 2 of Purine Nucleoside Phosphorylase complexed with tubercidin
5CXQ	;	1.57	;	Crystal Structure of Isoform 2 of Purine Nucleoside Phosphorylase from Schistosoma mansoni in APO form
5KO5	;	1.36	;	Crystal Structure of Isoform 2 of Purine Nucleoside Phosphorylase from Schistosoma mansoni in complex with cytosine
5KO6	;	1.42	;	Crystal Structure of Isoform 2 of Purine Nucleoside Phosphorylase from Schistosoma mansoni in complex with cytosine and ribose-1-phosphate
5CYG	;	2.017	;	Crystal Structure of isoform 2 of uridine phosphorylase from Schistosoma mansoni APO form
5CYF	;	1.983	;	Crystal structure of isoform 2 of uridine phosphorylase from Schistosoma mansoni in complex with citrate
6TMY	;	1.8	;	Crystal structure of isoform CBd of the basic phospholipase A2 subunit of crotoxin from Crotalus durissus terrificus
3DHX	;	2.1	;	Crystal structure of isolated C2 domain of the methionine uptake transporter
3B2U	;	2.58	;	Crystal structure of isolated domain III of the extracellular region of the epidermal growth factor receptor in complex with the Fab fragment of IMC-11F8
4OTS	;	1.704	;	Crystal Structure of isolated Operophtera brumata CPV18
1WY5	;	2.42	;	Crystal structure of isoluecyl-tRNA lysidine synthetase
3A47	;	1.59	;	Crystal structure of isomaltase from Saccharomyces cerevisiae
3A4A	;	1.6	;	Crystal structure of isomaltase from Saccharomyces cerevisiae
3AJ7	;	1.3	;	Crystal Structure of isomaltase from Saccharomyces cerevisiae
3AXH	;	1.8	;	Crystal structure of isomaltase in complex with isomaltose
3AXI	;	1.4	;	Crystal structure of isomaltase in complex with maltose
1M53	;	2.2	;	CRYSTAL STRUCTURE OF ISOMALTULOSE SYNTHASE (PALI) FROM KLEBSIELLA SP. LX3
7F13	;	2.15	;	Crystal structure of isomerase Dcr3
7F14	;	2.4	;	Crystal structure of isomerase Dcr3 complex with substrate analogue 3
7F0Y	;	1.6	;	Crystal structure of isomerase NsrQ F58A in complex with substrate analogue
6SLA	;	2.55	;	Crystal structure of isomerase PaaG mutant - D136N with Oxepin-CoA
6SLB	;	1.88	;	Crystal structure of isomerase PaaG with trans-3,4-didehydroadipyl-CoA
3WXO	;	2.12	;	Crystal structure of isoniazid bound KatG catalase peroxidase from Synechococcus elongatus PCC7942
2AQH	;	2.01	;	Crystal structure of Isoniazid-resistant I21V Enoyl-ACP(CoA) reductase mutant enzyme from Mycobacterium tuberculosis in complex with NADH
2IE0	;	2.2	;	Crystal Structure of Isoniazid-resistant I21V Enoyl-ACP(COA) Reductase Mutant Enzyme From MYCOBACTERIUM TUBERCULOSIS in Complex with NADH-INH
2AQI	;	2.2	;	Crystal structure of Isoniazid-resistant I47T Enoyl-ACP(CoA) reductase mutant enzyme from Mycobacterium tuberculosis in complex with NADH
2AQK	;	2.3	;	Crystal structure of Isoniazid-resistant S94A Enoyl-ACP(CoA) reductase mutant enzyme from Mycobacterium tuberculosis in complex with NADH
2IEB	;	2.2	;	Crystal Structure of Isoniazid-resistant S94A ENOYL-ACP(COA) Reductase Mutant Enzyme from MYCOBACTERIUM TUBERCULOSIS in Complex with NADH-INH
2IED	;	2.14	;	CRYSTAL STRUCTURE of ISONIAZID-RESISTANT S94A ENOYL-ACP(COA) REDUCTASE MUTANT ENZYME FROM MYCOBACTERIUM TUBERCULOSIS UNCOMPLEXED
3K52	;	2.7	;	Crystal Structure of Isopentenyl Phosphate Kinase from M. jannaschii in complex with IP
3K4Y	;	2.54	;	Crystal Structure of Isopentenyl Phosphate Kinase from M. jannaschii in complex with IPP
3K56	;	2.34	;	Crystal Structure of Isopentenyl Phosphate Kinase from M. jannaschii in complex with IPP beta-S
3K4O	;	2.05	;	Crystal Structure of Isopentenyl Phosphate Kinase from Methanocaldococcus jannaschii
8U0M	;	2.54	;	Crystal structure of isopentenyl phosphate kinase from Thermococcus paralvinellae bound to (E)-2-methylbut-2-en-1-yl monophosphate and ATP
8U0L	;	2.8	;	Crystal structure of isopentenyl phosphate kinase from Thermococcus paralvinellae bound to (E)-But-2-en-1-yl monophosphate and ADP
8U0N	;	2.5	;	Crystal structure of isopentenyl phosphate kinase from Thermococcus paralvinellae bound to 2-cyclopentylideneethyl monophosphate and ADP
8U0K	;	2.5	;	Crystal structure of isopentenyl phosphate kinase from Thermococcus paralvinellae bound to DMAP and ADP
3HYQ	;	1.525	;	Crystal Structure of Isopentenyl-Diphosphate delta-Isomerase from Salmonella entericase
7DJS	;	1.7	;	Crystal structure of isopiperitenol dehydrogenase from Pseudomonas aeruginosa complexed with NAD
3N0F	;	2.7	;	Crystal Structure of Isoprene Synthase from Grey Poplar Leaves (Populus x canescens)
3N0G	;	2.8	;	Crystal Structure of Isoprene Synthase from Grey Poplar Leaves (Populus x canescens) in complex with three Mg2+ ions and dimethylallyl-S-thiolodiphosphate
3L3B	;	1.9	;	Crystal structure of isoprenoid biosynthesis protein with amidotransferase-like domain from Ehrlichia Chaffeensis at 1.90A resolution
3UCA	;	2.0	;	Crystal structure of isoprenoid synthase (target EFI-501974) from clostridium perfringens
4DHD	;	1.65	;	Crystal structure of isoprenoid synthase A3MSH1 (TARGET EFI-501992) from Pyrobaculum calidifontis
4GP1	;	1.94	;	Crystal structure of ISOPRENOID SYNTHASE A3MSH1 (TARGET EFI-501992) from pyrobaculum calidifontis complexed with DMAPP
4GP2	;	2.0	;	Crystal structure of ISOPRENOID SYNTHASE A3MSH1 (TARGET EFI-501992) from pyrobaculum calidifontis complexed with DMAPP and Magnesium
4FP4	;	2.0	;	Crystal structure of isoprenoid synthase a3mx09 (target efi-501993) from pyrobaculum calidifontis
1WMR	;	2.4	;	Crystal Structure of Isopullulanase from Aspergillus niger ATCC 9642
5XK7	;	1.911	;	Crystal structure of Isosesquilavandulyl Diphosphate Synthase from Streptomyces sp. strain CNH-189 in complex with DMAPP
5XK8	;	2.304	;	Crystal structure of Isosesquilavandulyl Diphosphate Synthase from Streptomyces sp. strain CNH-189 in complex with GPP
5XK9	;	2.137	;	Crystal structure of Isosesquilavandulyl Diphosphate Synthase from Streptomyces sp. strain CNH-189 in complex with GSPP and DMAPP
5HS2	;	1.9	;	Crystal structure of IspD complexed with CTP and Mg2+ from Bacillus subtilis at 1.90 Angstroms resolution
5DDT	;	1.8	;	Crystal structure of IspD from Bacillus subtilis at 1.80 Angstroms resolution, crystal form I
5DDV	;	2.3	;	Crystal structure of IspD from Bacillus subtilis at 2.30 Angstroms resolution, crystal form II
7KMW	;	2.35	;	Crystal structure of IspD from Mycobacterium paratuberculosis
2XWM	;	1.8	;	Crystal structure of IspD from Mycobacterium smegmatis in complex with CMP
2XWL	;	1.49	;	Crystal structure of IspD from Mycobacterium smegmatis in complex with CTP and Mg
2XWN	;	2.9	;	Crystal structure of IspD from Mycobacterium tuberculosis in complex with CTP and Mg
4ED4	;	1.75	;	Crystal structure of IspE (4-diphosphocytidyl-2-C-methyl-D-erythritol kinase) from Mycobacterium abcessus, bound to ATP
4EMD	;	1.75	;	Crystal structure of IspE (4-diphosphocytidyl-2-C-methyl-D-erythritol kinase) from Mycobacterium abcessus, bound to CMP and SO4
4DXL	;	2.0	;	Crystal structure of IspE (4-diphosphocytidyl-2-C-methyl-D-erythritol kinase) from Mycobacterium abscessus, bound to CMP and ATP
8CKH	;	1.8	;	Crystal structure of IspE from Klebsiella pneumoniae
8J17	;	1.97	;	Crystal structure of IsPETase variant
3NOY	;	2.7	;	Crystal structure of IspG (gcpE)
4EB3	;	1.9	;	Crystal structure of IspH in complex with iso-HMBPP
3KEF	;	1.7	;	Crystal structure of IspH:DMAPP-complex
3KE8	;	1.7	;	Crystal structure of IspH:HMBPP-complex
3KE9	;	1.9	;	Crystal structure of IspH:Intermediate-complex
3KEM	;	2.0	;	Crystal structure of IspH:IPP complex
3KEL	;	1.8	;	Crystal Structure of IspH:PP complex
5CDC	;	4.0	;	Crystal Structure of Israel acute Paralysis Virus
5CDD	;	2.7	;	Crystal Structure of Israel acute Paralysis Virus Pentamer
8IIC	;	3.25	;	Crystal structure of Israeli acute paralysis virus RNA-dependent RNA polymerase delta40 mutant (residues 41-546)
8IIB	;	2.69	;	Crystal structure of Israeli acute paralysis virus RNA-dependent RNA polymerase delta85 mutant (residues 86-546)
6XPP	;	1.55	;	Crystal structure of itaconate modified Mycobaterium tuberculosis isocitrate lyase
5DWS	;	1.65	;	Crystal Structure of ITCH WW3 domain in complex with TXNIP peptide
4M0Y	;	1.7	;	Crystal structure of ITK in complex with compound 1 [4-(carbamoylamino)-1-(naphthalen-1-yl)-1H-pyrazole-3-carboxamide]
4M0Z	;	2.0	;	Crystal structure of ITK in complex with compound 5 {4-(carbamoylamino)-1-(7-methoxynaphthalen-1-yl)-1H-pyrazole-3-carboxamide}
4HCT	;	1.48	;	Crystal structure of ITK in complex with compound 52
4HCV	;	1.48	;	Crystal structure of ITK in complex with compound 53
4M12	;	2.15	;	Crystal structure of ITK in complex with compound 7 [4-(carbamoylamino)-1-(7-ethoxynaphthalen-1-yl)-1H-pyrazole-3-carboxamide]
4M13	;	1.85	;	Crystal structure of ITK in complex with compound 8 [4-(carbamoylamino)-1-(7-propoxynaphthalen-1-yl)-1H-pyrazole-3-carboxamide]
4M14	;	1.55	;	Crystal structure of ITK in complex with compound 9 [4-(carbamoylamino)-1-[7-(propan-2-yloxy)naphthalen-1-yl]-1H-pyrazole-3-carboxamide]
4M15	;	1.52	;	Crystal structure of ITK in complex with compound 9 [4-(carbamoylamino)-1-[7-(propan-2-yloxy)naphthalen-1-yl]-1H-pyrazole-3-carboxamide] and ADP
4HCU	;	1.43	;	Crystal structure of ITK in complext with compound 40
3QGY	;	2.1	;	Crystal structure of ITK inhibitor complex
3QGW	;	2.1	;	Crystal Structure of ITK kinase bound to an inhibitor
5TSQ	;	1.53	;	Crystal structure of IUnH from Leishmania braziliensis in complex with D-Ribose
7PJM	;	2.1	;	Crystal Structure of Ivosidenib-resistant IDH1 variant R132C S280F in complex with NADPH and Ca2+/2-Oxoglutarate
7PJN	;	2.45	;	Crystal Structure of Ivosidenib-resistant IDH1 variant R132C S280F in complex with NADPH and inhibitor DS-1001B
2XPL	;	2.25	;	Crystal structure of Iws1(Spn1) conserved domain from Encephalitozoon cuniculi
7AHP	;	1.95	;	Crystal structure of Ixodes ricinus serpin - Iripin-3
7D2J	;	1.6	;	Crystal structure of Ixodes scapularis glutaminyl cyclase with a Cd ion bound to the active site
7D2I	;	1.85	;	Crystal structure of Ixodes scapularis glutaminyl cyclase with a Fe ion bound to the active site
7D2D	;	1.8	;	Crystal structure of Ixodes scapularis glutaminyl cyclase with a Mn ion bound to the active site
7D2B	;	1.99	;	Crystal structure of Ixodes scapularis glutaminyl cyclase with a Ni ion bound to the active site
7D1H	;	1.69	;	Crystal structure of Ixodes scapularis glutaminyl cyclase with D238A mutation
7D23	;	1.4	;	Crystal structure of Ixodes scapularis glutaminyl cyclase with one K ion bound to the active site
7D1P	;	2.36	;	Crystal structure of Ixodes scapularis glutaminyl cyclase with three Cd ions bound to the active site
7D1N	;	2.26	;	Crystal structure of Ixodes scapularis glutaminyl cyclase with three Cu ions bound to the active site
7D1Y	;	1.95	;	Crystal structure of Ixodes scapularis glutaminyl cyclase with two Co ions bound to the active site
7D21	;	1.97	;	Crystal structure of Ixodes scapularis glutaminyl cyclase with two Zn ions bound to the active site
5B5K	;	2.5	;	Crystal structure of Izumo1, the mammalian sperm ligand for egg Juno
2QSA	;	1.68	;	Crystal structure of J-domain of DnaJ homolog dnj-2 precursor from C.elegans.
3APQ	;	1.84	;	Crystal structure of J-Trx1 fragment of ERdj5
2V4X	;	1.5	;	Crystal Structure of Jaagsiekte Sheep Retrovirus Capsid N-terminal domain
1KU8	;	1.75	;	Crystal structure of Jacalin
1KUJ	;	2.0	;	Crystal structure of Jacalin complexed with 1-O-methyl-alpha-D-mannose
1UGW	;	1.7	;	Crystal structure of jacalin- Gal complex
1UH1	;	2.8	;	Crystal structure of jacalin- GalNAc-beta(1-3)-Gal-alpha-O-Me complex
1UH0	;	2.8	;	Crystal structure of jacalin- Me-alpha-GalNAc complex
1WS4	;	1.9	;	Crystal structure of Jacalin- Me-alpha-Mannose complex: Promiscuity vs Specificity
1UGX	;	1.6	;	Crystal structure of jacalin- Me-alpha-T-antigen (Gal-beta(1-3)-GalNAc-alpha-o-Me) complex
1UGY	;	2.4	;	Crystal structure of jacalin- mellibiose (Gal-alpha(1-6)-Glc) complex
1WS5	;	1.9	;	Crystal structure of Jacalin-Me-alpha-Mannose complex: Promiscuity vs Specificity
1M26	;	1.62	;	Crystal structure of jacalin-T-antigen complex
4GOA	;	2.2	;	Crystal structure of jack bean urease inhibited with fluoride
8GDX	;	2.74	;	Crystal structure of JADE1 PZP domain
8GE0	;	2.4	;	Crystal structure of JADE1 PZP domain in complex with Histone H3
5KHW	;	2.47	;	Crystal structure of JAK1 in complex with ADP
6BBU	;	2.08	;	Crystal Structure of JAK1 in complex with compound 25
6AAH	;	1.83	;	Crystal structure of JAK1 in complex with peficitinib
5KHX	;	2.4	;	Crystal structure of JAK1 in complex with PF-4950736
6W8L	;	2.11	;	Crystal structure of JAK1 kinase with compound 10
3LPB	;	2.0	;	Crystal structure of Jak2 complexed with a potent 2,8-diaryl-quinoxaline inhibitor
3KRR	;	1.8	;	Crystal Structure of JAK2 complexed with a potent quinoxaline ATP site inhibitor
6BBV	;	1.8	;	Crystal Structure of JAK2 in complex with compound 25
6AAJ	;	2.37	;	Crystal structure of JAK2 in complex with peficitinib
8BX6	;	1.5	;	Crystal structure of JAK2 JH1 in complex with cerdulatinib
8BM2	;	1.5	;	Crystal structure of JAK2 JH1 in complex with gandotinib
8BX9	;	1.4	;	Crystal structure of JAK2 JH1 in complex with ilginatinib
8BXC	;	1.9	;	Crystal structure of JAK2 JH1 in complex with itacitinib
8BPW	;	1.8	;	Crystal structure of JAK2 JH1 in complex with lestaurtinib
8BXH	;	1.3	;	Crystal structure of JAK2 JH1 in complex with momelotinib
8BPV	;	1.7	;	Crystal structure of JAK2 JH1 in complex with pacritinib
7TEU	;	1.45	;	Crystal structure of JAK2 JH1 with type II inhibitor YLIU-04-105-1
8EX0	;	1.85	;	Crystal structure of JAK2 JH2 (pseudokinase domain) in complex with CDK2-IV
8EX2	;	1.9	;	Crystal structure of JAK2 JH2 (pseudokinase domain) in complex with HTSA3
8EX1	;	1.5	;	Crystal structure of JAK2 JH2 (pseudokinase domain) in complex with Reversine
8BA3	;	1.4	;	Crystal structure of JAK2 JH2 in complex with Bemcentinib
8B9H	;	1.5	;	Crystal structure of JAK2 JH2 in complex with Z902-A3
8C09	;	1.9	;	Crystal structure of JAK2 JH2-I559F
8C08	;	2.2	;	Crystal structure of JAK2 JH2-K539L
8C0A	;	1.7	;	Crystal structure of JAK2 JH2-R683S
8BA4	;	2.1	;	Crystal structure of JAK2 JH2-V617F in complex with Bemcentinib
8BAB	;	1.55	;	Crystal structure of JAK2 JH2-V617F in complex with CB76
8B8N	;	2.0	;	Crystal structure of JAK2 JH2-V617F in complex with Cdk2 inhibitor IV
8B8U	;	1.5	;	Crystal structure of JAK2 JH2-V617F in complex with HTS-A3
8B99	;	1.6	;	Crystal structure of JAK2 JH2-V617F in complex with JNJ-7706621
8BAK	;	1.65	;	Crystal structure of JAK2 JH2-V617F in complex with Reversine
8BA2	;	1.5	;	Crystal structure of JAK2 JH2-V617F in complex with Z902-A1
8B9E	;	1.5	;	Crystal structure of JAK2 JH2-V617F in complex with Z902-A3
7UYW	;	2.51	;	Crystal structure of JAK2 kinase domain in complex with compound 30
6X8E	;	1.75	;	Crystal structure of JAK2 with Compound 11
6G3C	;	1.6	;	Crystal Structure of JAK2-V617F pseudokinase domain in complex with Compound 2
4QPS	;	1.8	;	Crystal structure of Jak3 complexed to N-[3-(6-Phenylamino-pyrazin-2-yl)-3H-benzoimidazol-5-yl]-acrylamide
3PJC	;	2.2	;	Crystal structure of JAK3 complexed with a potent ATP site inhibitor showing high selectivity within the Janus kinase family
6GL9	;	1.7	;	Crystal structure of JAK3 in complex with Compound 10 (FM475)
6GLA	;	1.92	;	Crystal structure of JAK3 in complex with Compound 11 (FM481)
6GLB	;	2.0	;	Crystal structure of JAK3 in complex with Compound 20 (FM484)
5LWM	;	1.55	;	Crystal structure of JAK3 in complex with Compound 4 (FM381)
5LWN	;	1.6	;	Crystal structure of JAK3 in complex with Compound 5 (FM409)
7C3N	;	1.98	;	Crystal structure of JAK3 in complex with Delgocitinib
7APG	;	2.4	;	Crystal structure of JAK3 in complex with FM587 (compound 9a)
7APF	;	1.95	;	Crystal structure of JAK3 in complex with FM601 (compound 10a)
6AAK	;	2.67	;	Crystal structure of JAK3 in complex with peficitinib
3ZEP	;	2.35	;	Crystal Structure of JAK3 Kinase Domain in Complex with a Pyrrolopyrazine-2-phenyl Ether Inhibitor
4RIO	;	2.69	;	Crystal structure of JAK3 kinase domain in complex with a pyrrolopyridazine carboxamide inhibitor
6NY4	;	2.33	;	Crystal structure of JAK3 kinase domain in complex with a pyrrolopyridazine carboxamide inhibitor
5VO6	;	2.65	;	CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE INHIBITOR
3ZC6	;	2.42	;	Crystal structure of JAK3 kinase domain in complex with an indazole substituted pyrrolopyrazine inhibitor
7UYV	;	2.15	;	Crystal structure of JAK3 kinase domain in complex with compound 25
5W86	;	2.61	;	CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 4,6-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
5DOV	;	1.8	;	Crystal structure of JamJ enoyl reductase (apo form)
5DOZ	;	2.26	;	Crystal structure of JamJ enoyl reductase (NADPH bound)
3MJ9	;	2.95	;	Crystal structure of JAML in complex with the stimulatory antibody HL4E10
4ZIM	;	2.65	;	CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1-CARBOXAMIDE INHIBITOR
5CF4	;	2.38	;	CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-3,5,8,10-TETRAAZATRICYCLO[7.3.0.0,6] DODECA-1(9),2(6),4,7,11-PENTAENE-11-CARBOXAMIDE
5CF8	;	1.8	;	CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-3,5,8,10-TETRAAZATRICYCLO[7.3.0.0,6] DODECA-1(9),2(6),4,7,11-PENTAENE-11-CARBOXAMIDE
5CF6	;	2.5	;	CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-10-[(2S)-2,3-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-3,5,8,10-TETRAAZATRICYCLO [7.3.0.02,6]DODECA-1(9),2(6),4,7,11-PENTAENE-11-CARBOXAMIDE
5CF5	;	2.45	;	CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-7-[(DIMETHYL-1,3-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-3,5,8,10-TETRAAZATRICYCLO[7.3.0.02,6] DODECA-1(9),2(6),4,7,11-PENTAENE-11-CARBOXAMIDE
1IQQ	;	1.5	;	Crystal Structure of Japanese pear S3-RNase
5C11	;	2.803	;	Crystal Structure of Jarid1a PHD finger bound to histone H3C4me3 peptide
3GL6	;	1.9	;	Crystal structure of JARID1A-PHD3 complexed with H3(1-9)K4me3 peptide
7PB2	;	3.41	;	Crystal structure of JDI TCR in complex with HLA-A*11:01 bound to KRAS G12D peptide (VVVGADGVGK)
4O8S	;	2.1	;	Crystal structure of JHP933 from Helicobacter pylori
8WIM	;	1.84	;	Crystal structure of Jingmen tick virus RNA-dependent RNA polymerase (D307 construct)
8WIL	;	2.1	;	Crystal structure of Jingmen tick virus RNA-dependent RNA polymerase (D55 construct)
4ZDH	;	2.0984	;	Crystal structure of JKA6 TCR
2Q8D	;	2.29	;	Crystal structure of JMJ2D2A in ternary complex with histone H3-K36me2 and succinate
4C8D	;	2.18	;	Crystal structure of JmjC domain of human histone 3 Lysine-specific demethylase 3B (KDM3B)
3ZLI	;	1.8	;	Crystal structure of JmjC domain of human histone demethylase UTY
5FXZ	;	1.98	;	Crystal structure of JmjC domain of human histone demethylase UTY in complex with citrate
5FYM	;	2.0	;	Crystal structure of JmjC domain of human histone demethylase UTY in complex with D-2-hydroxyglutarate
4UF0	;	1.78	;	Crystal structure of JmjC domain of human histone demethylase UTY in complex with epitherapuetic compound 2-(((2-((2-(dimethylamino)ethyl) (ethyl)amino)-2-oxoethyl)amino)methyl)isonicotinic acid.
5FXW	;	2.09	;	Crystal structure of JmjC domain of human histone demethylase UTY in complex with fumarate
5FY0	;	2.14	;	Crystal structure of JmjC domain of human histone demethylase UTY in complex with L-malate
5FXV	;	1.91	;	Crystal structure of JmjC domain of human histone demethylase UTY in complex with N05859b
5FY1	;	1.78	;	Crystal structure of JmjC domain of human histone demethylase UTY in complex with N08619b
5FXX	;	1.99	;	Crystal structure of JmjC domain of human histone demethylase UTY in complex with oxaloacetate
5FY7	;	1.86	;	Crystal structure of JmjC domain of human histone demethylase UTY in complex with succinate
3ZPO	;	2.0	;	Crystal structure of JmjC domain of human histone demethylase UTY with bound GSK J1
5A1L	;	2.0	;	Crystal structure of JmjC domain of human histone demethylase UTY with S21056a
7EQV	;	2.6	;	Crystal structure of JMJD2A complexed with 3,4-dihydroxybenzoic acid
3NJY	;	2.6	;	Crystal structure of JMJD2A complexed with 5-carboxy-8-hydroxyquinoline
3PDQ	;	1.989	;	Crystal structure of JMJD2A complexed with bipyridyl inhibitor
2OX0	;	1.95	;	Crystal structure of JMJD2A complexed with histone H3 peptide dimethylated at Lys9
2OT7	;	2.135	;	Crystal structure of JMJD2A complexed with histone H3 peptide monomethylated at Lys9
2OS2	;	2.3	;	Crystal structure of JMJD2A complexed with histone H3 peptide trimethylated at Lys36
2OQ6	;	2.0	;	Crystal structure of JMJD2A complexed with histone H3 peptide trimethylated at Lys9
3RVH	;	2.251	;	Crystal Structure of JMJD2A Complexed with Inhibitor
4GD4	;	2.33	;	Crystal Structure of JMJD2A Complexed with Inhibitor
2VD7	;	2.25	;	Crystal Structure of JMJD2A complexed with inhibitor Pyridine-2,4- dicarboxylic acid
2Q8C	;	2.047	;	Crystal structure of JMJD2A in ternary complex with an histone H3K9me3 peptide and 2-oxoglutarate
4LXL	;	1.87	;	Crystal structure of JMJD2B complexed with pyridine-2,4-dicarboxylic acid and H3K9me3
2XUE	;	2.0	;	CRYSTAL STRUCTURE OF JMJD3
4ASK	;	1.86	;	CRYSTAL STRUCTURE OF JMJD3 WITH GSK-J1
3UYJ	;	2.351	;	Crystal structure of JMJD5 catalytic core domain in complex with nickle and alpha-KG
4AAP	;	2.6	;	Crystal structure of JMJD5 domain of human Lysine-specific demethylase 8 (KDM8) in complex with N-oxalylglycine (NOG)
4YR8	;	2.4	;	Crystal structure of JNK in complex with a regulator protein
4UX9	;	2.34	;	Crystal structure of JNK1 bound to a MKK7 docking motif
6ZR5	;	2.699	;	Crystal structure of JNK1 in complex with ATF2(19-58)
4HYS	;	2.415	;	Crystal structure of JNK1 in complex with JIP1 peptide and 4-(4-Indazol-1-yl-pyrimidin-2-ylamino)-cyclohexan
4HYU	;	2.152	;	Crystal structure of JNK1 in complex with JIP1 peptide and 4-{4-[4-(3-Methanesulfonyl-propoxy)-indazol-1-yl]-pyrimidin-2-ylamino}-cyclohexan
4IZY	;	2.3	;	Crystal structure of JNK1 in complex with JIP1 peptide and 4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexan
4G1W	;	2.45	;	Crystal structure of JNK1 in complex with JIP1 peptide and 7-Fluoro-3-[4-(2-hydroxy-ethanesulfonyl)-benzyl]-4-oxo-1-phenyl-1,4-dihydro-quinoline-2-carboxylic acid methyl ester
3O17	;	3.0	;	Crystal Structure of JNK1-alpha1 isoform
3O2M	;	2.7	;	Crystal Structure of JNK1-alpha1 isoform complex with a biaryl tetrazol (A-82118)
4E73	;	2.27	;	Crystal structure of JNK1beta-JIP in complex with an azaquinolone inhbitor
3E7O	;	2.14	;	Crystal Structure of JNK2
3NPC	;	2.35	;	Crystal structure of JNK2 complexed with BIRB796
2OK1	;	2.4	;	Crystal structure of JNK3 bound to N-benzyl-4-(4-(3-chlorophenyl)-1H-pyrazol-3-yl)-1H-pyrrole-2-carboxamide
3TTJ	;	2.1	;	Crystal Structure of JNK3 complexed with CC-359, a JNK inhibitor for the prevention of ischemia-reperfusion injury
3TTI	;	2.2	;	Crystal Structure of JNK3 complexed with CC-930, an orally active anti-fibrotic JNK inhibitor
7YL1	;	2.48	;	Crystal structure of JNK3 in complex with a fragment molecule
6EKD	;	2.1	;	Crystal structure of JNK3 in complex with a pyridinylimidazole inhibitor
6EMH	;	1.76	;	Crystal structure of JNK3 in complex with a pyridinylimidazole inhibitor
6EQ9	;	1.83	;	Crystal structure of JNK3 in complex with AMP-PCP
1PMN	;	2.2	;	Crystal structure of JNK3 in complex with an imidazole-pyrimidine inhibitor
4H36	;	3.0	;	Crystal Structure of JNK3 in Complex with ATF2 Peptide
7ORF	;	1.7	;	Crystal structure of JNK3 in complex with FMU-001-367 (compound 1)
4H39	;	1.992	;	Crystal Structure of JNK3 in Complex with JIP1 Peptide
7ORE	;	2.18	;	Crystal structure of JNK3 in complex with light-activated covalent inhibitor MR-II-249 with both non-covalent and covalent binding modes (compound 4)
4H3B	;	2.08	;	Crystal Structure of JNK3 in Complex with SAB Peptide
3FI2	;	2.28	;	Crystal structure of JNK3 with amino-pyrazole inhibitor, SR-3451
3FI3	;	2.2	;	Crystal structure of JNK3 with indazole inhibitor, SR-3737
6LSV	;	2.651	;	Crystal structure of JOX2 in complex with 2OG, Fe, and JA
1WRM	;	1.5	;	Crystal structure of JSP-1
1PW3	;	1.9	;	Crystal structure of JtoR68S
6I9K	;	2.145	;	Crystal structure of Jumping Spider Rhodopsin-1 bound to 9-cis retinal
2NPZ	;	3.35	;	Crystal structure of junctioned hairpin ribozyme incorporating synthetic propyl linker
7RW4	;	1.31	;	Crystal structure of junctophilin-1
7RXE	;	2.35	;	Crystal structure of junctophilin-2
7RXQ	;	2.03	;	Crystal structure of junctophilin-2 in complex with a CaV1.1 peptide
4K7E	;	2.2	;	Crystal structure of Junin virus nucleoprotein
5EJN	;	2.703	;	Crystal structure of Juno, the mammalian egg receptor for sperm Izumo1
7EBS	;	2.95	;	Crystal structure of juvenile hormone acid methyltransferase JHAMT from silkworm
7EC0	;	2.494	;	Crystal structure of juvenile hormone acid methyltransferase JHAMT in complex with S-Adenosyl homocysteine and methyl farnesoate
7EBX	;	2.89	;	Crystal structure of juvenile hormone acid methyltransferase JHAMT in complex with S-adenosyl-L-homocysteine.
7V2S	;	2.133	;	Crystal structure of juvenile hormone acid methyltransferase JHAMT isoform3 from silkworm
7EJB	;	2.85	;	Crystal structure of juvenile hormone acid methyltransferase JHAMT mutant Q15E
7VEO	;	2.53	;	Crystal structure of juvenile hormone acid methyltransferase silkworm JHAMT isoform3 complex with S-Adenosyl-L-homocysteine
2RCK	;	2.44	;	Crystal structure of juvenile hormone binding protein from Galleria mellonella hemolymph
3A1Z	;	2.59	;	Crystal structure of juvenile hormone binding protein from silkworm
3AOS	;	2.2	;	Crystal structure of juvenile hormone binding protein from silkworm in complex with JH II
3AOT	;	2.2	;	Crystal structure of juvenile hormone binding protein from silkworm in its apo form
6KTH	;	1.22	;	Crystal structure of Juvenile hormone diol kinase JHDK-L2 from silkworm, Bombyx mori
4QLA	;	2.3	;	Crystal structure of juvenile hormone epoxide hydrolase from the silkworm Bombyx mori
2FJ0	;	2.7	;	Crystal Structure of Juvenile Hormone Esterase from Manduca sexta, with OTFP covalently attached
1WD6	;	2.9	;	crystal structure of JW1657 from Escherichia coli
2HIQ	;	2.0	;	Crystal structure of JW1657 from Escherichia coli
6CNU	;	1.05	;	Crystal Structure of JzTX-V
4PDM	;	1.58	;	Crystal Structure of K+ selective NaK mutant in rubidium
4LRW	;	2.151	;	Crystal Structure of K-Ras G12C (cysteine-light), GDP-bound
4L8G	;	1.521	;	Crystal Structure of K-Ras G12C, GDP-bound
4LPK	;	1.5	;	Crystal Structure of K-Ras WT, GDP-bound
6WGN	;	1.601	;	Crystal structure of K-Ras(G12D) GppNHp bound to cyclic peptide ligand KD2
7TLK	;	1.71102	;	Crystal Structure of K-Ras(G12S)
5OMC	;	2.38	;	Crystal structure of K. lactis Ddc2 N-terminus in complex with S. cerevisiae Rfa1 (K45E mutant) N-OB domain
5OMB	;	1.94	;	Crystal structure of K. lactis Ddc2 N-terminus in complex with S. cerevisiae Rfa1 N-OB domain
4GPS	;	2.4	;	Crystal Structure of K. lactis Dxo1 (YDR370C)
4GPU	;	2.8	;	Crystal structure of K. lactis Dxo1 (YDR370C) in complex with manganese
6AM0	;	2.84	;	Crystal structure of K. lactis Edc1-Dcp1-Dcp2-Edc3 decapping complex with synthetic cap substrate analog
4G89	;	2.1	;	Crystal structure of k. pneumoniae mta/adohcy nucleosidase in complex with fragmented s-adenosyl-l-homocysteine
3RV0	;	2.29	;	Crystal structure of K. polysporus Dcr1 without the C-terminal dsRBD
4M3O	;	2.1	;	Crystal structure of K.lactis Rtr1 NTD
2OPR	;	2.9	;	Crystal Structure of K101E Mutant HIV-1 Reverse Transcriptase in Complex with GW420867X.
2HND	;	2.5	;	Crystal Structure of K101E Mutant HIV-1 Reverse Transcriptase in Complex with Nevirapine
3A2G	;	1.75	;	Crystal Structure of K102C-Myoglobin conjugated with Fluorescein
1SV5	;	2.9	;	CRYSTAL STRUCTURE OF K103N MUTANT HIV-1 REVERSE TRANSCRIPTASE (RT) IN COMPLEX WITH JANSSEN-R165335
3DOK	;	2.9	;	Crystal structure of K103N mutant HIV-1 reverse transcriptase in complex with GW678248.
2IAJ	;	2.5	;	Crystal Structure of K103N/Y181C Mutant HIV-1 Reverse Transcriptase (RT) in Complex with ATP
5FDL	;	3.1	;	Crystal Structure of K103N/Y181C Mutant HIV-1 Reverse Transcriptase (RT) in Complex with IDX899
2IC3	;	3.0	;	Crystal Structure of K103N/Y181C Mutant HIV-1 Reverse Transcriptase (RT) in Complex with Nonnucleoside Inhibitor HBY 097
3BGR	;	2.1	;	Crystal structure of K103N/Y181C mutant HIV-1 reverse transcriptase (RT) in complex with TMC278 (Rilpivirine), a non-nucleoside RT inhibitor
4I2Q	;	2.7004	;	Crystal structure of K103N/Y181C mutant of HIV-1 reverse transcriptase in complex with rilpivirine (TMC278) analogue
2XEW	;	2.2	;	Crystal structure of K11-linked diubiquitin
3BAH	;	1.65	;	Crystal structure of K112N mutant of Human acidic fibroblast growth factor
3BAG	;	1.75	;	Crystal structure of K112N/N114A mutant of Human acidic fibroblast growth factor
4Q9G	;	1.554	;	Crystal structure of K12V/C16S/C117V/P134V mutant of human acidic fibroblast growth factor
3FJI	;	2.55	;	Crystal structure of K12V/C83I/C117V mutant of Human acidic fibroblast growth factor
3BAU	;	1.6	;	Crystal structure of K12V/L26D/D28A mutant of Human acidic fibroblast growth factor
5ZVU	;	2.2	;	Crystal structure of K132A mutant of phosphomannose isomerase from Salmonella typhimurium
8GR3	;	2.4	;	Crystal structure of K151L/Y158F mutant of GATase subunit of Methanocaldococcus jannaschii GMP synthetase
3Q7Y	;	1.45	;	Crystal structure of K15R/E18D/Y22W/H41G/F44W/E51D/E53P/K57R/E60D/Y64W/H82G/F85W/E90D/E94P/K98R/E101D/Y108W/H129G/F132W/E137D Symfoil-4P: de novo designed beta-trefoil architecture with symmetric primary structure
3NNT	;	1.6	;	Crystal Structure of K170M Mutant of Type I 3-Dehydroquinate Dehydratase (aroD) from Salmonella typhimurium LT2 in Non-Covalent Complex with Dehydroquinate.
2O84	;	2.6	;	Crystal structure of K206E mutant of N-lobe human transferrin
2O7U	;	2.8	;	Crystal structure of K206E/K296E mutant of the N-terminal half molecule of human transferrin
2HXU	;	1.8	;	Crystal structure of K220A mutant of L-Fuconate Dehydratase from Xanthomonas campestris liganded with Mg++ and L-fuconate
1CW4	;	2.1	;	CRYSTAL STRUCTURE OF K230M ISOCITRATE DEHYDROGENASE IN COMPLEX WITH ALPHA-KETOGLUTARATE
4MBK	;	1.46	;	Crystal structure of K234R inhibitor-resistant variant of SHV beta-lactamase in complex with SA2-13
5OPL	;	1.8	;	Crystal structure of K25E cN-II mutant
3EIB	;	1.85	;	Crystal structure of K270N variant of LL-diaminopimelate aminotransferase from Arabidopsis thaliana
3EI9	;	1.55	;	Crystal structure of K270N variant of LL-diaminopimelate aminotransferase from Arabidopsis thaliana complexed with L-Glu: External aldimine form
3EI8	;	1.6	;	Crystal structure of K270N variant of LL-diaminopimelate aminotransferase from Arabidopsis thaliana complexed with LL-DAP: External aldimine form
3EIA	;	1.85	;	Crystal structure of K270Q variant of LL-diaminopimelate aminotransferase from Arabidopsis thaliana complexed with L-Glu: External aldimine form
4S22	;	2.3	;	Crystal structure of K29 linked di-Ubiquitin
7KEO	;	2.9	;	Crystal structure of K29-linked di-ubiquitin in complex with synthetic antigen binding fragment
4XYZ	;	1.65	;	Crystal structure of K33 linked di-Ubiquitin
4Y1H	;	1.4	;	Crystal structure of K33 linked tri-Ubiquitin
6UYX	;	1.7	;	Crystal structure of K37-acetylated SUMO1 in complex with phosphorylated DAXX
6V7S	;	1.47	;	Crystal structure of K37-acetylated SUMO1 in complex with phosphorylated PIAS-SIM2
6UYS	;	1.59	;	Crystal structure of K37-acetylated SUMO1 in complex with phosphorylated PML-SIM
6V7R	;	1.549	;	Crystal structure of K37-acetylated SUMO1 in complex with PIAS-SIM2
6UYO	;	1.639	;	Crystal structure of K37-acetylated SUMO1 in complex with PML-SIM
6UYY	;	1.599	;	Crystal structure of K39-acetylated SUMO1 in complex with phosphorylated DAXX
6UYT	;	1.662	;	Crystal structure of K39-acetylated SUMO1 in complex with phosphorylated PML-SIM
6UYP	;	1.418	;	Crystal structure of K39-acetylated SUMO1 in complex with PML-SIM
5B1I	;	3.3	;	Crystal structure of K42A mutant of cystathionine beta-synthase from Lactobacillus plantarum in a complex with L-methionine
4HNU	;	3.0	;	crystal structure of K442E mutant of S. aureus Pyruvate carboxylase
8AZF	;	1.41	;	Crystal structure of K449E variant of S-adenosyl-L-homocysteine hydrolase from Pseudomonas aeruginosa in complex with adenosine
6UYU	;	1.66	;	Crystal structure of K45-acetylated SUMO1 in complex with phosphorylated PML-SIM
6UYQ	;	1.501	;	Crystal structure of K45-acetylated SUMO1 in complex with PML-SIM
6UYZ	;	1.4	;	Crystal structure of K46-acetylated SUMO1 in complex with phosphorylated DAXX
6UYV	;	1.401	;	Crystal structure of K46-acetylated SUMO1 in complex with phosphorylated PML-SIM
6UYR	;	1.3	;	Crystal structure of K46-acetylated SUMO1 in complex with PML-SIM
5EMZ	;	1.66	;	Crystal structure of K48-linked diubiquitin with F45W mutation in the proximal unit
2E0Q	;	1.49	;	Crystal structure of K53E thioredoxin from Sulfolobus tokodaii strain7
2XK5	;	3.0	;	Crystal structure of K6-linked diubiquitin
3H7P	;	1.9	;	Crystal structure of K63-linked di-ubiquitin
3DVG	;	2.6	;	Crystal structure of K63-specific fab Apu.3A8 bound to K63-linked di-ubiquitin
3DVN	;	2.7	;	Crystal structure of K63-specific fab Apu2.16 bound to K63-linked di-ubiquitin
1SO4	;	1.7	;	Crystal structure of K64A mutant of 3-keto-L-gulonate 6-phosphate decarboxylase with bound L-threonohydroxamate 4-phosphate
5BSC	;	1.89	;	Crystal structure of K66A mutant of human macrophage migration inhibitory factor
5TY3	;	1.25	;	Crystal structure of K72A variant of Human Cytochrome c
7YIA	;	2.428	;	Crystal structure of K74A mutant of Cap4 SAVED domain-containing receptor from Enterobacter cloacae
7F08	;	3.16	;	Crystal Structure of K8
7RLR	;	1.88	;	Crystal Structure of K83A Mutant of Class D beta-lactamase from Clostridium difficile 630
5ZVX	;	1.7	;	Crystal structure of K86A mutant of phosphomannose isomerase from Salmonella typhimurium
3NTO	;	1.9124	;	Crystal structure of K97V mutant myo-inositol dehydrogenase from Bacillus subtilis
3NTQ	;	2.6004	;	Crystal structure of K97V mutant myo-inositol dehydrogenase from Bacillus subtilis with bound cofactor NAD
3NTR	;	2.6503	;	Crystal structure of K97V mutant of myo-inositol dehydrogenase from Bacillus subtilis with bound cofactor NAD and inositol
6C9D	;	2.499	;	Crystal structure of KA1-autoinhibited MARK1 kinase
7KZ3	;	1.55	;	Crystal structure of KabA from Bacillus cereus UW85 in complex with the internal aldimine
7KZ5	;	1.6	;	Crystal structure of KabA from Bacillus cereus UW85 in complex with the plp external aldimine adduct with kanosamine-6-phosphate
7KZD	;	1.9	;	Crystal structure of KabA from Bacillus cereus UW85 in complex with the reduced internal aldimine and with bound Glutarate
7KZ6	;	1.65	;	Crystal structure of KabA from Bacillus cereus UW85 with bound cofactor PMP
4HRX	;	2.11	;	Crystal structure of KAI2
5Z9G	;	1.49	;	Crystal structure of KAI2
4JYP	;	1.3	;	crystal Structure of KAI2 Apo form
4JYM	;	1.35	;	crystal Structure of KAI2 in complex with 3-methyl-2H-furo[2,3-c]pyran-2-one
5DNW	;	2.02	;	Crystal structure of KAI2-like protein from Striga (apo state 1)
5DNV	;	2.65	;	Crystal structure of KAI2-like protein from Striga (apo state 2)
5Z9H	;	1.49	;	Crystal structure of KAI2_ply2(A219V)
1WWJ	;	1.9	;	crystal structure of KaiB from Synechocystis sp.
5JWQ	;	3.871	;	Crystal structure of KaiC S431E in complex with foldswitch-stabilized KaiB from Thermosynechococcus elongatus
8DB3	;	2.9	;	Crystal structure of KaiC with truncated C-terminal coiled-coil domain
2ZTS	;	2.07	;	Crystal structure of KaiC-like protein PH0186 from hyperthermophilic archaea Pyrococcus horikoshii OT3
4F6M	;	2.4	;	Crystal structure of Kaiso zinc finger DNA binding domain in complex with Kaiso binding site DNA
4F6N	;	2.8	;	Crystal structure of Kaiso zinc finger DNA binding protein in complex with methylated CpG site DNA
4KGA	;	2.32	;	Crystal structure of kallikrein-related peptidase 4
7W6Y	;	3.1	;	Crystal structure of Kangiella koreensis RseP orthologue in complex with batimastat in space group P1
7W6Z	;	3.15	;	Crystal structure of Kangiella koreensis RseP orthologue in complex with batimastat in space group P21
7DDX	;	2.5	;	Crystal structure of KANK1 S1179F mutant in complex wtih eIF4A1
5YAY	;	1.55	;	Crystal structure of KANK1/KIF21A complex
4HBD	;	1.72	;	Crystal structure of KANK2 ankyrin repeats
6TMD	;	1.5	;	Crystal structure of KANK2 ankyrin repeats mutant (A670V)
4FDD	;	2.3	;	Crystal structure of KAP beta2-PY-NLS
6AHO	;	2.502	;	Crystal structure of Kap114p
3W3T	;	2.9	;	Crystal structure of Kap121p
3W3Y	;	2.8	;	Crystal structure of Kap121p bound to Nup53p
3W3X	;	2.9	;	Crystal structure of Kap121p bound to Pho4p
3W3Z	;	2.7	;	Crystal structure of Kap121p bound to RanGTP
3W3W	;	2.2	;	Crystal structure of Kap121p bound to Ste12p
3W3V	;	3.2	;	Crystal structure of Kap121p mutant D353K/E396K/D438K
3W3U	;	2.6	;	Crystal structure of Kap121p mutant R349A/Q350A/D353A/E396A/N430K/D438A/N477A
5T94	;	2.631	;	Crystal structure of Kap60 bound to yeast RCC1 (Prp20)
7CZF	;	3.2	;	Crystal structure of Kaposi Sarcoma associated herpesvirus (KSHV ) gHgL in complex with the ligand binding domian (LBD) of EphA2
4P2T	;	2.15	;	Crystal structure of Kaposi's sarcoma-associated herpesvirus (KSHV) protease in complex with a dimer disruptor
4P3H	;	1.45	;	Crystal structure of Kaposi's sarcoma-associated herpesvirus (KSHV) protease in complex with dimer disruptor
3NJQ	;	2.0	;	Crystal structure of Kaposi's sarcoma-associated herpesvirus protease in complex with dimer disruptor
3DVI	;	1.53	;	Crystal structure of kappa 1 amyloidogenic light chain variable domain
1KBA	;	2.3	;	CRYSTAL STRUCTURE OF KAPPA-BUNGAROTOXIN AT 2.3-ANGSTROM RESOLUTION
4IH1	;	1.55	;	Crystal structure of Karrikin Insensitive 2 (KAI2) from Arabidopsis thaliana
5YVH	;	3.15	;	Crystal structure of Karyopherin beta2 in complex with FUS(371-526)
5YVI	;	2.9	;	Crystal structure of Karyopherin beta2 in complex with FUS(456-526)
5YVG	;	4.05	;	Crystal structure of Karyopherin beta2 in complex with FUS(full length)
7CYL	;	2.7	;	Crystal structure of Karyopherin-beta2 in complex with FUS PY-NLS(P525L)
7RP2	;	2.2	;	Crystal structure of Kas G12C in complex with 2H11 CLAMP
5YO9	;	2.002	;	Crystal structure of KAS III from Acinetobacter baumannii
5YOA	;	2.33	;	Crystal structure of KAS III from Acinetobacter baumannii
5YZU	;	2.122	;	Crystal structure of KAS III from Acinetobacter baumannii
6A9N	;	2.099	;	Crystal structure of KAS III from Propionibacterium acnes
2WGD	;	2.01	;	Crystal structure of KasA of Mycobacterium tuberculosis
2WGE	;	1.8	;	Crystal structure of KasA of Mycobacterium tuberculosis with bound TLM
2HHH	;	3.35	;	Crystal structure of kasugamycin bound to the 30S ribosomal subunit
8DD5	;	2.58	;	Crystal structure of KAT6A in complex with inhibitor CTx-648 (PF-9363)
4R42	;	1.902	;	Crystal structure of KatB, a manganese catalase from Anabaena PCC7120
6LFK	;	2.1	;	Crystal structure of KatE from atypical E. coli
2I0A	;	1.8	;	Crystal Structure of KB-19 complexed with wild type HIV-1 protease
2Q54	;	1.85	;	Crystal structure of KB73 bound to HIV-1 protease
2P7T	;	2.05	;	Crystal Structure of KcsA mutant
2HVJ	;	2.75	;	Crystal structure of KcsA-Fab-TBA complex in low K+
2DWE	;	2.5	;	Crystal structure of KcsA-FAB-TBA complex in Rb+
2DWD	;	2.6	;	crystal structure of KcsA-FAB-TBA complex in Tl+
2R91	;	2.0	;	Crystal Structure of KD(P)GA from T.tenax
2R94	;	2.2	;	Crystal Structure of KD(P)GA from T.tenax
3NTC	;	1.55	;	Crystal structure of KD-247 Fab, an anti-V3 antibody that inhibits HIV-1 Entry
1SQW	;	1.9	;	Crystal structure of KD93, a novel protein expressed in the human pro
7UVA	;	1.98	;	Crystal structure of KDM2A histone demethylase catalytic domain in complex with an H3C36 peptide modified by UNC8015
6RBJ	;	2.093	;	Crystal structure of KDM3B in complex with 5-(1H-tetrazol-5-yl)quinolin-8-ol
5VGI	;	2.07	;	Crystal Structure of KDM4 with the Small Molecule Inhibitor QC6352
5VAR	;	1.83	;	Crystal structure of KDM4A tandem TUDOR domain in complex with a tri-methyl lysine competitive inhibitor
6CG1	;	2.16	;	Crystal Structure of KDM4A with Compound 14
6CG2	;	2.34	;	Crystal Structure of KDM4A with Compound 8
6G5X	;	1.78	;	Crystal Structure of KDM4A with compound YP-02-145
6G5W	;	1.83	;	Crystal Structure of KDM4A with compound YP-03-038
7JM5	;	2.7	;	Crystal structure of KDM4B in complex with QC6352
6F5Q	;	1.43	;	Crystal Structure of KDM4D with GF026 ligand
6F5R	;	1.607	;	Crystal Structure of KDM4D with GF028 ligand
6ETT	;	1.257	;	Crystal structure of KDM4D with tetrazole compound 4
6F5S	;	1.48	;	Crystal Structure of KDM4D with tetrazole ligand GF049
6F5T	;	1.58	;	Crystal Structure of KDM4D with tetrazole ligand GF057
6ETS	;	1.333	;	Crystal structure of KDM4D with tetrazolhydrazide compound 1
6ETV	;	1.18	;	Crystal structure of KDM4D with tetrazolhydrazide compound 2
6ETW	;	1.35	;	Crystal structure of KDM4D with tetrazolhydrazide compound 3
6ETE	;	1.468	;	Crystal structure of KDM4D with tetrazolhydrazide compound 5
6ETG	;	1.279	;	Crystal structure of KDM4D with tetrazolhydrazide compound 6
6ETU	;	1.33	;	Crystal structure of KDM4D with tetrazolhydrazide compound 7
6H11	;	1.516	;	Crystal Structure of KDM4D with tetrazolylhydrazide ligand AA028
6H0X	;	1.64	;	Crystal Structure of KDM4D with tetrazolylhydrazide ligand AA040
6H0Z	;	1.34	;	Crystal Structure of KDM4D with tetrazolylhydrazide ligand NR067
6H10	;	1.104	;	Crystal Structure of KDM4D with tetrazolylhydrazide ligand NR073
6H0Y	;	1.212	;	Crystal Structure of KDM4D with tetrazolylhydrazide ligand NS022
6H0W	;	1.23	;	Crystal Structure of KDM4D with tetrazolylhydrazide ligand NS035
5K4L	;	3.179	;	Crystal structure of KDM5A in complex with a naphthyridone inhibitor
6RBI	;	2.21	;	Crystal structure of KDM5B in complex with 5-(1H-tetrazol-5-yl)quinolin-8-ol
6EIY	;	2.15	;	Crystal structure of KDM5B in complex with KDOPZ000034a.
6EJ0	;	2.06	;	Crystal structure of KDM5B in complex with KDOPZ000049a.
6EIU	;	1.88	;	Crystal structure of KDM5B in complex with KDOPZ29a
6EJ1	;	2.07	;	Crystal structure of KDM5B in complex with KDOPZ48a.
6EK6	;	2.05	;	Crystal structure of KDM5B in complex with S49195a.
6EIN	;	2.11	;	Crystal structure of KDM5B in complex with S49365a.
1O60	;	1.8	;	Crystal structure of KDO-8-phosphate synthase
1PHW	;	2.36	;	Crystal structure of KDO8P synthase in its binary complex with substrate analog 1-deoxy-A5P
1PHQ	;	2.7	;	Crystal structure of KDO8P synthase in its binary complex with substrate analog E-FPEP
1PL9	;	2.9	;	Crystal structure of KDO8P synthase in its binary complex with substrate analog Z-FPEP
1Q3N	;	2.7	;	Crystal structure of KDO8P synthase in its binary complex with substrate PEP
1FWR	;	2.7	;	CRYSTAL STRUCTURE OF KDPG ALDOLASE DOUBLE MUTANT K133Q/T161K
6OVI	;	1.6	;	Crystal Structure of KDPG Aldolase from Legionella Pneumophila with pyruvate captured at low pH as a covalent carbinolamine intermediate
7X4W	;	3.209	;	Crystal structure of Keap1 BTB domain in complex with dimethyl fumarate (DMF)
2Z32	;	2.0	;	Crystal structure of Keap1 complexed with Prothymosin alpha
4ZY3	;	1.8	;	Crystal Structure of Keap1 in Complex with a small chemical compound, K67
6LRZ	;	1.54	;	Crystal structure of Keap1 in complex with dimethyl fumarate (DMF)
7C5E	;	1.75	;	Crystal structure of Keap1 in complex with fumarate (FUM)
7C60	;	1.95	;	Crystal structure of Keap1 in complex with monoethyl fumarate (MEF)
3WDZ	;	2.6	;	Crystal Structure of Keap1 in Complex with phosphorylated p62
3ADE	;	2.8	;	Crystal Structure of Keap1 in Complex with Sequestosome-1/p62
3VNG	;	2.1	;	Crystal Structure of Keap1 in Complex with Synthetic Small Molecular based on a co-crystallization
3WN7	;	1.57	;	Crystal Structure of Keap1 in Complex with the N-terminal region of the Nrf2 transcription factor
7XM4	;	2.7	;	Crystal structure of Keap1 Kelch domain (residues 322-609) in complex with 6e
7XM3	;	2.8	;	Crystal structure of Keap1 Kelch domain (residues 322-609) in complex with 6k
7XM2	;	2.3	;	Crystal structure of Keap1 Kelch domain (residues 322-609) in complex with NXPZ-2
3VNH	;	2.1	;	Crystal Structure of Keap1 Soaked with Synthetic Small Molecular
7XOT	;	2.7	;	Crystal structure of Keap1_6k
5YQ4	;	1.58	;	Crystal structure of kelch domain of KLHL20
6N3H	;	2.6	;	Crystal structure of Kelch domain of the human NS1 binding protein
8FMC	;	2.36	;	Crystal Structure of Kemp Eliminase 1A53-core in unbound state
8FOQ	;	1.6	;	Crystal Structure of Kemp Eliminase 1A53-core with bound transition state analogue
3NYD	;	1.23	;	Crystal Structure of Kemp Eliminase HG-2 Complexed with Transition State Analog 5-Nitro Benzotriazole
8USK	;	1.6	;	Crystal Structure of Kemp Eliminase HG185 in unbound state, 280 K
8USL	;	1.55	;	Crystal Structure of Kemp Eliminase HG185 with bound transition state analogue, 280 K
8USI	;	1.9	;	Crystal Structure of Kemp Eliminase HG198 in unbound state, 280 K
8USJ	;	1.6	;	Crystal Structure of Kemp Eliminase HG198 with bound transition state analogue, 280 K
7K4P	;	1.08	;	Crystal structure of Kemp Eliminase HG3
7K4Q	;	1.28	;	Crystal structure of Kemp Eliminase HG3 in complex with the transition state analog 6-nitrobenzotriazole
5RG4	;	1.99	;	Crystal Structure of Kemp Eliminase HG3 in unbound state, 277K
7K4R	;	1.57	;	Crystal structure of Kemp Eliminase HG3 K50Q
7K4U	;	1.3	;	Crystal structure of Kemp Eliminase HG3 K50Q in complex with the transition state analog 6-nitrobenzotriazole
5RGA	;	1.86	;	Crystal Structure of Kemp Eliminase HG3 with bound transition state analogue, 277K
8FME	;	1.44	;	Crystal Structure of Kemp Eliminase HG3-shell in unbound state
8FOS	;	1.56	;	Crystal Structure of Kemp Eliminase HG3-shell with bound transition state analogue
5RG7	;	1.47	;	Crystal Structure of Kemp Eliminase HG3.14 in unbound state, 277K
5RGD	;	1.6	;	Crystal Structure of Kemp Eliminase HG3.14 with bound transition state analogue, 277K
7K4T	;	0.999	;	Crystal structure of Kemp Eliminase HG3.17
7K4V	;	1.3	;	Crystal structure of Kemp Eliminase HG3.17
7K4Y	;	1.8	;	Crystal structure of Kemp Eliminase HG3.17 at 343 K
4BS0	;	1.09	;	Crystal Structure of Kemp Eliminase HG3.17 E47N,N300D Complexed with Transition State Analog 6-Nitrobenzotriazole
7K4Z	;	1.08	;	Crystal structure of Kemp Eliminase HG3.17 in complex with the transition state analog 6-nitrobenzotriazole
7K4W	;	1.9	;	Crystal structure of Kemp Eliminase HG3.17 in the inactive state
5RG8	;	1.73	;	Crystal Structure of Kemp Eliminase HG3.17 in unbound state, 277K
5RGE	;	1.77	;	Crystal Structure of Kemp Eliminase HG3.17 with bound transition state analog, 277K
5RG5	;	1.62	;	Crystal Structure of Kemp Eliminase HG3.3b in unbound state, 277K
5RGB	;	1.42	;	Crystal Structure of Kemp Eliminase HG3.3b with bound transition state analogue, 277K
7K4S	;	2.0	;	Crystal structure of Kemp Eliminase HG3.7
7K4X	;	1.6	;	Crystal structure of Kemp Eliminase HG3.7 in complex with the transition state analog 6-nitrobenzotriazole
5RG6	;	1.35	;	Crystal Structure of Kemp Eliminase HG3.7 in unbound state, 277K
5RGC	;	1.39	;	Crystal Structure of Kemp Eliminase HG3.7 with bound transition state analogue, 277K
5RG9	;	1.47	;	Crystal Structure of Kemp Eliminase HG4 in unbound state, 277K
5RGF	;	1.46	;	Crystal Structure of Kemp Eliminase HG4 with bound transition state analogue, 277K
8USG	;	1.37	;	Crystal Structure of Kemp Eliminase HG630 in unbound state, 280 K
8USH	;	1.32	;	Crystal Structure of Kemp Eliminase HG630 with bound transition state analogue, 280 K
8USE	;	1.55	;	Crystal Structure of Kemp Eliminase HG649 in unbound state, 280 K
8USF	;	1.45	;	Crystal Structure of Kemp Eliminase HG649 with bound transition state analogue, 280 K
8FMD	;	2.2	;	Crystal Structure of Kemp Eliminase KE70-core in unbound state
8FOR	;	2.2	;	Crystal Structure of Kemp Eliminase KE70-core with bound transition state analogue
3NYZ	;	1.514	;	Crystal Structure of Kemp Elimination Catalyst 1A53-2
3NZ1	;	1.56	;	Crystal Structure of Kemp Elimination Catalyst 1A53-2 Complexed with Transition State Analog 5-Nitro Benzotriazole
4RMB	;	1.7	;	Crystal structure of keratin 4 binding domain of surface adhesin Srr-1 of S.agalactiae
7LTB	;	0.95	;	Crystal Structure of Keratinicyclin B
7LKC	;	0.95	;	Crystal Structure of Keratinimicin A
5HWJ	;	1.648	;	Crystal structure of keto-deoxy-D-galactarate dehydratase
4UR8	;	2.097	;	Crystal structure of keto-deoxy-D-galactarate dehydratase complexed with 2-oxoadipic acid
5HWM	;	2.097	;	Crystal structure of keto-deoxy-D-galactarate dehydratase complexed with 2-oxoadipic acid
4UR7	;	1.499	;	Crystal structure of keto-deoxy-D-galactarate dehydratase complexed with pyruvate
5HWN	;	1.499	;	Crystal structure of keto-deoxy-D-galactarate dehydratase complexed with pyruvate
4XIY	;	2.5	;	Crystal structure of ketol-acid reductoisomerase from Azotobacter
6JX2	;	2.6	;	Crystal structure of Ketol-acid reductoisomerase from Corynebacterium glutamicum
1M3U	;	1.8	;	Crystal Structure of Ketopantoate Hydroxymethyltransferase complexed the Product Ketopantoate
5ZIK	;	2.45	;	Crystal structure of Ketopantoate reductase from Pseudomonas aeruginosa
5ZIX	;	2.57	;	Crystal structure of Ketopantoate reductase from Pseudomonas aeruginosa bound to NADP+
6K1R	;	2.55	;	Crystal structure of Ketopantoate reductase from Pseudomonas aeruginosa in complex with NAD+ and ketopantoate
5HWS	;	2.3	;	Crystal structure of ketopantoate reductase from Thermococcus kodakarensis complexed with NADP+
1YJQ	;	2.09	;	Crystal structure of ketopantoate reductase in complex with NADP+
5B6K	;	1.701	;	Crystal structure of Ketoreductase 1 from Candida glabrata
4RF4	;	2.201	;	Crystal structure of ketoreductase from Lactobacillus kefir
4RF5	;	1.596	;	Crystal structure of ketoreductase from Lactobacillus kefir, E145S mutant
4RF3	;	1.694	;	Crystal Structure of ketoreductase from Lactobacillus kefir, mutant A94F
1OH0	;	1.1	;	CRYSTAL STRUCTURE OF KETOSTEROID ISOMERASE COMPLEXED WITH EQUILENIN
5G2G	;	1.599	;	Crystal structure of ketosteroid isomerase containing M116K mutation in the equilenin-bound form
5AI1	;	2.103	;	Crystal structure of ketosteroid isomerase containing Y32F, D40N, Y57F and Y119F mutations in the equilenin-bound form
4L7K	;	2.1	;	Crystal Structure of Ketosteroid Isomerase D38E from Pseudomonas Testosteroni (tKSI)
3MKI	;	2.0	;	Crystal Structure of Ketosteroid Isomerase D38ED99N from Pseudomonas Testosteroni (tKSI)
3NM2	;	1.887	;	Crystal Structure of Ketosteroid Isomerase D38EP39GV40GS42G from Pseudomonas Testosteroni (tKSI)
5UGI	;	1.8	;	Crystal Structure of Ketosteroid Isomerase D38GF54A mutant from Pseudomonas Testosteroni (tKSI) bound to Equilenin
5DRE	;	2.151	;	Crystal Structure of Ketosteroid Isomerase D38GP39GD99N mutant from Pseudomonas Testosteroni (tKSI)
3MYT	;	1.961	;	Crystal structure of Ketosteroid Isomerase D38HD99N from Pseudomonas testosteroni (tKSI)
6P44	;	1.251	;	Crystal Structure of Ketosteroid Isomerase D38N mutant from Mycobacterium hassiacum (mhKSI) bound to 3,4-dinitrophenol
3NUV	;	1.76	;	Crystal structure of ketosteroid isomerase D38ND99N from Pseudomonas testosteroni (tKSI) with 4-Androstene-3,17-dione Bound
3NBR	;	1.73	;	Crystal Structure of Ketosteroid Isomerase D38NP39GD99N from Pseudomonas Testosteroni (tKSI) with 4-Androstene-3,17-dione Bound
2INX	;	1.5	;	Crystal Structure of Ketosteroid Isomerase D40N from Pseudomonas putida (pKSI) with bound 2,6-difluorophenol
3VGN	;	1.3	;	Crystal Structure of Ketosteroid Isomerase D40N from Pseudomonas putida (pKSI) with bound 3-fluoro-4-nitrophenol
2PZV	;	1.25	;	Crystal Structure of Ketosteroid Isomerase D40N from Pseudomonas Putida (pksi) with bound Phenol
6C17	;	1.1	;	Crystal Structure of Ketosteroid Isomerase D40N mutant from Pseudomonas Putida (pKSI) bound to 3,4-dinitrophenol
3CPO	;	1.24	;	Crystal structure of ketosteroid isomerase D40N with bound 2-fluorophenol
3FZW	;	1.32	;	Crystal Structure of Ketosteroid Isomerase D40N-D103N from Pseudomonas putida (pKSI) with bound equilenin
3OX9	;	2.0	;	Crystal Structure of Ketosteroid Isomerase D40N/C69S/C81S/C97S/F86C-CN from P. putida
3OWU	;	1.7	;	Crystal Structure of Ketosteroid Isomerase D40N/C69S/C81S/C97S/F86C-CN from P. putida with Bound Equilenin
3OWY	;	2.3	;	Crystal Structure of Ketosteroid Isomerase D40N/C69S/C81S/C97S/M105C-CN from P. putida with Bound Equilenin
3OXA	;	1.89	;	Crystal Structure of Ketosteroid Isomerase D40N/C69S/C81S/C97S/M116C-CN from P. putida
3OWS	;	1.71	;	Crystal Structure of Ketosteroid Isomerase D40N/C69S/C81S/C97S/M116C-CN from P. putida with Bound Equilenin
6C1X	;	1.05	;	Crystal Structure of Ketosteroid Isomerase D40N/D103N mutant from Pseudomonas Putida (pKSI) bound to 3,4-dinitrophenol
3NXJ	;	1.966	;	Crystal Structure of Ketosteroid Isomerase D99N from Pseudomonas Testosteroni (tKSI)
3NHX	;	1.59	;	Crystal Structure of Ketosteroid Isomerase D99N from Pseudomonas Testosteroni (tKSI) with 4-Androstene-3,17-dione Bound
3M8C	;	2.1	;	Crystal Structure of Ketosteroid Isomerase D99N from Pseudomonas Testosteroni (tKSI) with Equilenin Bound
6F50	;	2.0	;	CRYSTAL STRUCTURE OF KETOSTEROID ISOMERASE DOUBLE VARIANT V88I/L99V
3UNL	;	2.52	;	Crystal structure of ketosteroid isomerase F54G from Pseudomonas testosteroni
4KVH	;	1.61	;	Crystal structure of ketosteroid isomerase fold protein Hmuk_0747
4MJD	;	1.28	;	Crystal structure of ketosteroid isomerase fold protein Hmuk_0747
6P3L	;	1.571	;	Crystal Structure of Ketosteroid Isomerase from Mycobacterium hassiacum (mhKSI)
1E3V	;	2.0	;	Crystal structure of ketosteroid isomerase from Psedomonas putida complexed with deoxycholate
6U1Z	;	1.5005	;	Crystal Structure of Ketosteroid Isomerase from Pseudomonas Putida (pKSI) at 280 K
5KP4	;	1.706	;	Crystal Structure of Ketosteroid Isomerase from Pseudomonas putida (pKSI) bound to 19-nortestosterone
6UBQ	;	1.2991	;	Crystal Structure of Ketosteroid Isomerase from Pseudomonas Putida (pKSI) bound to 4-Androstenedione at 100 K
6TZD	;	1.4507	;	Crystal Structure of Ketosteroid Isomerase from Pseudomonas Putida (pKSI) bound to 4-Androstenedione at 280 K
6UFS	;	1.47	;	Crystal structure of ketosteroid isomerase from Pseudomonas putida (pKSI) bound to 5 alpha-dihydronandrolone
6U4I	;	1.55	;	Crystal Structure of Ketosteroid Isomerase from Pseudomonas Putida (pKSI) bound to Equilenin at 280 K
5KP1	;	1.218	;	Crystal Structure of Ketosteroid Isomerase from Pseudomonas putida (pKSI) bound to Equilenin; D40N, Y16(Cl-Y)
5KP3	;	1.7	;	Crystal Structure of Ketosteroid Isomerase from Pseudomonas putida (pKSI) bound to Equilenin; D40N, Y57(Cl-Y)
5D82	;	1.37	;	Crystal Structure of Ketosteroid Isomerase from Pseudomonas putida (pKSI); D40N, Y16(Cl-Y)
5D83	;	1.7	;	Crystal Structure of Ketosteroid Isomerase from Pseudomonas putida (pKSI); D40N, Y32(Cl-Y)
5D81	;	1.39	;	Crystal Structure of Ketosteroid Isomerase from Pseudomonas putida (pKSI); D40N, Y57(Cl-Y)
1E97	;	2.0	;	Crystal structure of ketosteroid isomerase from Pseudomonas putida ; triple mutant y16f/y32f/y57f
3RGR	;	1.594	;	Crystal structure of ketosteroid isomerase M116A from Pseudomonas putida
1E3R	;	2.5	;	Crystal structure of ketosteroid isomerase mutant D40N (D38N TI numbering) from Pseudomonas putida complexed with androsten-3beta-ol-17-one
3MHE	;	1.722	;	Crystal Structure of Ketosteroid Isomerase P39A from Pseudomonas Testosteroni (tKSI)
3OV4	;	1.83	;	Crystal Structure of Ketosteroid Isomerase P39GV40GS42G from Pseudomonas Testosteroni (tKSI) bound to Equilenin
6F53	;	1.49	;	CRYSTAL STRUCTURE OF KETOSTEROID ISOMERASE QUADRUPLE VARIANT V88I/L99V/D103S/V101A
6F54	;	1.08	;	CRYSTAL STRUCTURE OF KETOSTEROID ISOMERASE TRIPLE VARIANT V88I/L99VD103S
6F4Y	;	1.92	;	CRYSTAL STRUCTURE OF KETOSTEROID ISOMERASE VARIANT D103S
3SED	;	1.302	;	Crystal Structure of Ketosteroid Isomerase Variant M105A from Pseudomonos putida
3T8U	;	2.5	;	Crystal structure of ketosteroid isomerase Y14AY55FD99A from Pseudomonas testosteroni
3T8N	;	1.47	;	Crystal structure of ketosteroid isomerase Y16AD103A from Pseudomonas putida
1OHO	;	1.9	;	CRYSTAL STRUCTURE OF KETOSTEROID ISOMERASE Y16F/D40N mutant COMPLEXED WITH EQUILENIN
3IPT	;	1.632	;	Crystal Structure of Ketosteroid Isomerase Y16S/D40N from Pseudomonas putida with Bound Equilenin
6C1J	;	1.063	;	Crystal Structure of Ketosteroid Isomerase Y32F/Y57F/D40N mutant from Pseudomonas Putida (pKSI) bound to 3,4-dinitrophenol
3D9R	;	2.4	;	Crystal structure of ketosteroid isomerase-like protein (YP_049581.1) from ERWINIA CAROTOVORA ATROSEPTICA SCRI1043 at 2.40 A resolution
6MHK	;	1.93	;	Crystal structure of ketosynthase nine from bacillaene polyketide synthase in Bacillus amyloliquefaciens
6MHL	;	1.82	;	Crystal structure of ketosynthase twelve from bacillaene polyketide synthase in Bacillus amyloliquefaciens
1AC5	;	2.4	;	CRYSTAL STRUCTURE OF KEX1(DELTA)P, A PROHORMONE-PROCESSING CARBOXYPEPTIDASE FROM SACCHAROMYCES CEREVISIAE
4GB5	;	1.55	;	Crystal structure of Kfla4162 protein from Kribbella flavida
3EXR	;	1.7	;	Crystal structure of KGPDC from Streptococcus mutans
3EXT	;	2.0	;	Crystal structure of KGPDC from Streptococcus mutans
3EXS	;	2.5	;	Crystal structure of KGPDC from Streptococcus mutans in complex with D-R5P
2PQU	;	2.12	;	Crystal structure of KH1 domain of human PCBP2 complexed to single-stranded 12-mer telomeric dna
2AXY	;	1.7	;	Crystal Structure of KH1 domain of human Poly(C)-binding protein-2 with C-rich strand of human telomeric DNA
7BJS	;	2.28	;	Crystal structure of Khc/atypical Tm1 complex
8UG1	;	1.99	;	Crystal structure of KHK-C and compound 13
8UG3	;	2.02	;	Crystal structure of KHK-C and compound 23
6JJX	;	2.0	;	Crystal Structure of KIBRA and Angiomotin complex
6JJY	;	2.298	;	Crystal Structure of KIBRA and beta-Dystroglycan
6JJW	;	2.4	;	Crystal Structure of KIBRA and PTPN14 complex
7A0Q	;	1.5	;	Crystal structure of kievitone hydratase from Nectria haematococca (C2 SG)
7A0T	;	2.0	;	Crystal structure of kievitone hydratase from Nectria haematococca (P21 SG)
4EJQ	;	1.893	;	Crystal structure of KIF1A C-CC1-FHA
4EGX	;	2.51	;	Crystal structure of KIF1A CC1-FHA tandem
7EOB	;	1.76	;	Crystal structure of KIF1A Motor-Neck domain E239K mutant with ADP-Mg-AlFx
7EO9	;	2.57	;	Crystal structure of KIF1A Motor-Neck domain with ADP-Mg-AlFx
3RC2	;	1.8	;	Crystal Structure of KijD10, a 3-ketoreductase from Actinomadura kijaniata in complex with TDP-benzene and NADP; open conformation
3RBV	;	1.9	;	Crystal Structure of KijD10, a 3-ketoreductase from Actinomadura kijaniata incomplex with NADP
3RC1	;	1.71	;	Crystal Structure of KijD10, a 3-ketoreductase from Actinomadura kijaniata incomplex with NADP and TDP-benzene
3WYR	;	2.8	;	Crystal structure of Killer cell immunoglobulin-like receptor 2DL4
4N8V	;	2.5	;	Crystal structure of killer cell immunoglobulin-like receptor KIR2DS2 in complex with HLA-A
7YTB	;	3.0	;	Crystal structure of Kin4B8
5C01	;	2.15	;	Crystal Structure of kinase
5C03	;	1.9	;	Crystal Structure of kinase
5Y86	;	1.9	;	Crystal structure of kinase
1FQ1	;	3.0	;	CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2
3DFA	;	2.45	;	Crystal structure of kinase domain of calcium-dependent protein kinase cgd3_920 from Cryptosporidium parvum
2YZA	;	3.02	;	Crystal structure of kinase domain of Human 5'-AMP-activated protein kinase alpha-2 subunit mutant (T172D)
4OW8	;	2.03	;	Crystal structure of kinase domain of PknA from Mtb
3CC6	;	1.6	;	Crystal structure of kinase domain of protein tyrosine kinase 2 beta (PTK2B)
3MA6	;	2.5	;	Crystal structure of kinase domain of TgCDPK1 in presence of 3BrB-PP1
4IZO	;	1.85	;	Crystal structure of kinase Phosphoribosylaminoimidazole carboxylase, ATPase subunit from Burkholderia thailandensis
1YXX	;	2.0	;	Crystal Structure of Kinase Pim1 in complex with (3E)-3-[(4-HYDROXYPHENYL)IMINO]-1H-INDOL-2(3H)-ONE
1YXV	;	2.0	;	Crystal Structure of Kinase Pim1 in complex with 3,4-Dihydroxy-1-methylquinolin-2(1H)-one
1YXU	;	2.24	;	Crystal Structure of Kinase Pim1 in Complex with AMP
1YXT	;	2.0	;	Crystal Structure of Kinase Pim1 in complex with AMPPNP
1YXS	;	2.2	;	Crystal Structure of Kinase Pim1 with P123M mutation
5ZBR	;	2.0	;	Crystal Structure of Kinesin-3 KIF13B motor domain in AMPPNP form
5ZBS	;	2.203	;	Crystal Structure of Kinesin-3 KIF13B motor Y73C mutant
1SDM	;	2.3	;	Crystal structure of kinesin-like calmodulin binding protein
4IGV	;	1.5	;	Crystal structure of kirola (Act d 11)
4IGX	;	2.35	;	Crystal structure of kirola (Act d 11) - triclinic form
4IGY	;	2.92	;	Crystal structure of kirola (Act d 11) - triclinic form
4IH2	;	2.0	;	Crystal structure of kirola (Act d 11) from crystal soaked with 2-aminopurine
4IH0	;	1.75	;	Crystal structure of kirola (Act d 11) from crystal soaked with serotonin
4IGW	;	2.55	;	Crystal structure of kirola (Act d 11) in P6122 space group
4K9E	;	2.7	;	Crystal structure of KIT D4D5 fragment in complex with anti-Kit antibodies Fab79D
4K94	;	2.4	;	Crystal structure of KIT D4D5 fragment in complex with anti-Kit antibody Fab19
4U0I	;	2.0	;	Crystal structure of KIT in complex with ponatinib
7KHG	;	2.15	;	Crystal structure of KIT kinase domain with a small molecule inhibitor, PLX3397
4HVS	;	1.9	;	Crystal structure of KIT kinase domain with a small molecule inhibitor, PLX647
7KHJ	;	2.8	;	Crystal structure of KIT kinase domain with a small molecule inhibitor, PLX8512 in the DFG-in state
7KHK	;	2.34	;	Crystal structure of KIT kinase domain with a small molecule inhibitor, PLX9486 (bezuclastinib) in the DFG-in state
6MOB	;	1.8	;	Crystal structure of KIT1 in complex with DP2976 via co-crystallization
4PMK	;	2.05	;	Crystal structure of kiwellin
4BCT	;	0.98	;	Crystal structure of kiwi-fruit allergen Act d 2
2Q55	;	1.9	;	Crystal structure of KK44 bound to HIV-1 protease
4RLD	;	2.9	;	Crystal structure of kkf mutant of bla G 2 protein
4R9Y	;	4.11	;	Crystal structure of KKOFab in complex with platelet factor 4
5WI9	;	2.7	;	Crystal structure of KL with an agonist Fab
6F9I	;	3.993	;	Crystal structure of KLC2 bound to the second tryptophan-acidic motif peptide from calsyntenin-1
5OJF	;	3.4	;	Crystal Structure of KLC2-TPR domain (fragment [A1-B6]
1KRA	;	2.3	;	CRYSTAL STRUCTURE OF KLEBSIELLA AEROGENES UREASE, ITS APOENZYME AND TWO ACTIVE SITE MUTANTS
1KRB	;	2.5	;	CRYSTAL STRUCTURE OF KLEBSIELLA AEROGENES UREASE, ITS APOENZYME AND TWO ACTIVE SITE MUTANTS
1KRC	;	2.5	;	CRYSTAL STRUCTURE OF KLEBSIELLA AEROGENES UREASE, ITS APOENZYME AND TWO ACTIVE SITE MUTANTS
7SS7	;	1.73	;	Crystal structure of Klebsiella LpxH in complex with JH-LPH-50
6JVU	;	2.8	;	Crystal structure of Klebsiella pneumoniae CysE in complex with L-cysteine
6T77	;	1.75	;	Crystal structure of Klebsiella pneumoniae FabG(NADPH-dependent) NADP-complex at 1.75 A resolution
6T6P	;	1.57	;	Crystal structure of Klebsiella pneumoniae FabG2(NADH-dependent) at 1.57 A resolution
6T6N	;	2.5	;	Crystal structure of Klebsiella pneumoniae FabG2(NADH-dependent) in complex with NADH at 2.5 A resolution
5WEW	;	3.178	;	Crystal structure of Klebsiella pneumoniae fosfomycin resistance protein (FosAKP) with inhibitor (ANY1) bound
6C3U	;	1.85	;	Crystal structure of Klebsiella pneumoniae fosfomycin resistance protein (FosAKP) with inhibitor (ANY2) bound
3RP6	;	2.2	;	Crystal Structure of Klebsiella pneumoniae HpxO complexed with FAD
3RP7	;	2.042	;	Crystal Structure of Klebsiella pneumoniae HpxO complexed with FAD and uric acid
7W1D	;	2.78	;	Crystal structure of Klebsiella pneumoniae K1 capsule-specific polysaccharide lyase in a C2 crystal form
7W1C	;	1.48	;	Crystal structure of Klebsiella pneumoniae K1 capsule-specific polysaccharide lyase in a P1 crystal form
7W1E	;	1.46	;	Crystal structure of Klebsiella pneumoniae K1 capsule-specific polysaccharide lyase in complex with products
4GI7	;	1.95	;	Crystal structure of Klebsiella pneumoniae pantothenate kinase in complex with a pantothenate analogue
4F7W	;	2.1	;	Crystal structure of Klebsiella pneumoniae pantothenate kinase in complex with N-pentylpantothenamide
4S04	;	3.2	;	Crystal structure of Klebsiella pneumoniae PmrA in complex with PmrA box DNA
4S05	;	3.8	;	Crystal structure of Klebsiella pneumoniae PmrA in complex with PmrA box DNA
2A2L	;	2.2	;	Crystal structure of Klebsiella pneumoniae protein ORFY, Pfam DUF336
3RP8	;	1.968	;	Crystal Structure of Klebsiella pneumoniae R204Q HpxO complexed with FAD
4NIC	;	3.18	;	Crystal structure of Klebsiella pneumoniae RstA BeF3-activated N-terminal receiver domain
4NHJ	;	2.701	;	Crystal structure of Klebsiella pneumoniae RstA DNA-binding domain in complex with RstA box
6IDO	;	3.748	;	Crystal structure of Klebsiella pneumoniae sigma4 of sigmaS fusing with the RNA polymerase beta-flap-tip-helix in complex with -35 element DNA
3PLR	;	1.7	;	Crystal structure of Klebsiella pneumoniae UDP-glucose 6-dehydrogenase complexed with NADH and UDP-glucose
3PLN	;	1.5	;	Crystal structure of Klebsiella pneumoniae UDP-glucose 6-dehydrogenase complexed with UDP-glucose
5O7T	;	1.8	;	Crystal structure of KlenTaq mutant M747K in a closed ternary complex with a dG:dCTP base pair
5OXJ	;	2.0	;	Crystal structure of KlenTaq mutant M747K in a closed ternary complex with a O6-MeG:BenziTP base pair
6R2N	;	2.596	;	Crystal structure of KlGlk1 glucokinase from Kluyveromyces lactis
4HXI	;	3.513	;	Crystal structure of KLHL3/Cul3 complex
7QFT	;	1.47	;	Crystal structure of KLK6 in complex with compound 16a
7QFV	;	1.56	;	Crystal structure of KLK6 in complex with compound 17a
7QHZ	;	1.5	;	Crystal structure of KLK6 in complex with compound DKFZ917
7QI0	;	1.88	;	Crystal structure of KLK6 in complex with compound DKFZ918
3VU4	;	2.6	;	Crystal structure of Kluyvelomyces marxianus Hsv2
3E1K	;	3.0	;	Crystal structure of Kluyveromyces lactis Gal80p in complex with the acidic activation domain of Gal4p
3VQI	;	2.5	;	Crystal structure of Kluyveromyces marxianus Atg5
3VX6	;	2.6	;	Crystal structure of Kluyveromyces marxianus Atg7NTD
3VX7	;	3.2	;	Crystal structure of Kluyveromyces marxianus Atg7NTD-Atg10 complex
5ZED	;	2.199	;	Crystal structure of Kluyveromyces polyspora ADH (KpADH) mutant (E214V/T215S)
5ZEC	;	1.779	;	Crystal structure of Kluyveromyces polyspora ADH (KpADH) mutant (Q136N/F161V/S196G/E214G/S237C)
7C1E	;	1.75	;	Crystal structure of Kluyveromyces polyspora ADH (KpADH) mutant (Y127W)
4F1N	;	3.187	;	Crystal structure of Kluyveromyces polysporus Argonaute with a guide RNA
3BHB	;	2.2	;	Crystal Structure of KMD Phosphopeptide Bound to Human Class I MHC HLA-A2
7F0K	;	3.5	;	Crystal structure of Kmp11
3FNU	;	3.0	;	Crystal structure of KNI-10006 bound histo-aspartic protease (HAP) from Plasmodium falciparum
3QS1	;	3.1	;	Crystal structure of KNI-10006 complex of Plasmepsin I (PMI) from Plasmodium falciparum
5YIC	;	1.9	;	Crystal Structure of KNI-10333 bound Plasmepsin II (PMII) from Plasmodium falciparum
5YIA	;	2.0	;	Crystal Structure of KNI-10343 bound Plasmepsin II (PMII) from Plasmodium falciparum
3QVI	;	2.5	;	Crystal structure of KNI-10395 bound histo-aspartic protease (HAP) from Plasmodium falciparum
5YID	;	2.1	;	Crystal Structure of KNI-10395 bound Plasmepsin II (PMII) from Plasmodium falciparum
5YIE	;	2.1	;	Crystal Structure of KNI-10742 bound Plasmepsin II (PMII) from Plasmodium falciparum
5YIB	;	2.15	;	Crystal Structure of KNI-10743 bound Plasmepsin II (PMII) from Plasmodium falciparum
5EVH	;	1.852	;	Crystal structure of known function protein from Kribbella flavida DSM 17836
7OM3	;	1.92	;	Crystal structure of KOD DNA Polymerase in a binary complex with Hypoxanthine containing template
7OMB	;	2.01	;	Crystal structure of KOD DNA Polymerase in a ternary complex with a p/t duplex containing an extended 5' single stranded template overhang
7OMG	;	2.1	;	Crystal structure of KOD DNA Polymerase in a ternary complex with an Uracil containing template
3WIR	;	2.05	;	Crystal structure of kojibiose phosphorylase complexed with glucose
3WIQ	;	2.8	;	Crystal structure of kojibiose phosphorylase complexed with kojibiose
2W7N	;	1.85	;	Crystal Structure of KorA Bound to Operator DNA: Insight into Repressor Cooperation in RP4 Gene Regulation
5CKT	;	2.0	;	Crystal Structure of KorA, a plasmid-encoded, global transcription regulator
5CM3	;	2.302	;	Crystal Structure of KorA, a plasmid-encoded, global transcription regulator
5CLV	;	2.5	;	Crystal Structure of KorA-operator DNA complex (KorA-OA)
4ZBE	;	1.8	;	Crystal structure of KPC-2 beta-lactamase complexed with avibactam
7VQN	;	2.34	;	Crystal structure of KPC-2 beta-lactamase complexed with hydrolyzed EXW-1
5EEC	;	1.87	;	Crystal structure of KPC-2 beta-lactamase in complex with the S02030 boronic acid inhibitor
5LL7	;	1.4	;	Crystal structure of KPC-2 carbapenemase in complex with a phenyl boronic inhibitor.
5MGI	;	1.5	;	Crystal structure of KPC-2 carbapenemase in complex with a phenyl boronic inhibitor.
6D15	;	1.3	;	Crystal structure of KPC-2 complexed with compound 1
6D16	;	1.4	;	Crystal structure of KPC-2 complexed with compound 2
6D17	;	1.45	;	Crystal structure of KPC-2 complexed with compound 3
6D18	;	1.35	;	Crystal structure of KPC-2 complexed with compound 6
6D19	;	1.45	;	Crystal structure of KPC-2 complexed with compound 9
6QW9	;	1.04	;	Crystal structure of KPC-2 complexed with relebactam (16 hour soak)
7E9A	;	2.25	;	Crystal structure of KPC-2 in complex with (S)-2-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-3-yl)acrylic acid (4a-(S))
7LNL	;	1.82	;	Crystal structure of KPC-2 S70G/T215P mutant with hydrolyzed imipenem
7LR9	;	1.47	;	Crystal structure of KPC-2 S70G/T215P mutant with hydrolyzed imipenem
7LLB	;	1.67	;	Crystal structure of KPC-2 S70G/T215P mutant with hydrolyzed meropenem
7LK8	;	1.43	;	Crystal structure of KPC-2 T215P mutant
7U8S	;	1.6	;	Crystal Structure of KPC-2 with compound 2
6M7I	;	1.701	;	Crystal structure of KPC-2 with compound 3
6MNP	;	2.202	;	Crystal structure of KPC-2 with compound 6
6MLL	;	1.86	;	Crystal structure of KPC-2 with compound 7
6MEY	;	1.42	;	Crystal structure of KPC-2 with compound 9
7A61	;	1.25	;	Crystal structure of KPC-2 with hydrolyzed faropenem (ring-open form)
6QWD	;	1.2	;	Crystal structure of KPC-3
6QWA	;	1.06	;	Crystal structure of KPC-3 complexed with relebactam (16 hour soak)
6QWE	;	1.4	;	Crystal structure of KPC-4
6QWC	;	1.3	;	Crystal structure of KPC-4 complexed with relebactam (1 hour soak)
6QWB	;	1.04	;	Crystal structure of KPC-4 complexed with relebactam (16 hour soak)
8TJM	;	1.28	;	Crystal structure of KPC-44 carbapenemase
8TMR	;	1.37	;	Crystal structure of KPC-44 carbapenemase complexed with avibactam
8TMT	;	1.7	;	Crystal structure of KPC-44 carbapenemase in complex with vaborbactam
8TN0	;	1.31	;	Crystal structure of KPC-44 carbapenemase w/o cryoprotectant
6LL5	;	1.75	;	Crystal structure of KpFtsZ (residues 11-316)
6XJP	;	2.802	;	Crystal Structure of KPT-185 bound to CRM1 (537-DLTVK-541 to GLCEQ)
6XJR	;	1.941	;	Crystal Structure of KPT-185 bound to CRM1 (E582K, 537-DLTVK-541 to GLCEQ)
7L5E	;	1.944	;	Crystal Structure of KPT-330 bound to CRM1 (537-DLTVK-541 to GLCEQ)
6XJS	;	1.942	;	Crystal Structure of KPT-330 bound to CRM1 (E582K, 537-DLTVK-541 to GLCEQ)
6XJT	;	2.406	;	Crystal Structure of KPT-8602 bound to CRM1 (537-DLTVK-541 to GLCEQ)
6XJU	;	2.193	;	Crystal Structure of KPT-8602 bound to CRM1 (E582K, 537-DLTVK-541 to GLCEQ)
4GMX	;	2.1	;	Crystal structure of KPT185 in complex with CRM1-Ran-RanBP1
4GPT	;	2.22	;	Crystal structure of KPT251 in complex with CRM1-Ran-RanBP1
4WVF	;	1.8	;	Crystal structure of KPT276 in complex with CRM1-Ran-RanBP1
5JLJ	;	2.5	;	Crystal Structure of KPT8602 in complex with CRM1-Ran-RanBP1
7Q36	;	2.6	;	Crystal structure of KR2 sodium pump rhodopsin pressurized with krypton
8DA1	;	2.67	;	Crystal structure of Krait alpha-neurotoxin in complex with Centi-3FTX-D09 antibody
1TC8	;	2.7	;	Crystal structure of Krait-venom phospholipase A2 in a complex with a natural fatty acid tridecanoic acid
6BOF	;	1.401	;	Crystal structure of KRAS A146T-GDP demonstrating open switch 1 conformation
7RP4	;	2.15	;	Crystal structure of KRAS G12C in complex with GNE-1952
6GJ5	;	1.499	;	CRYSTAL STRUCTURE OF KRAS G12D (GPPCP) IN COMPLEX WITH 15
6GJ6	;	1.761	;	CRYSTAL STRUCTURE OF KRAS G12D (GPPCP) IN COMPLEX WITH 18
6GJ7	;	1.67	;	CRYSTAL STRUCTURE OF KRAS G12D (GPPCP) IN COMPLEX WITH 22
6GJ8	;	1.65	;	CRYSTAL STRUCTURE OF KRAS G12D (GPPCP) IN COMPLEX WITH BI 2852
8TXH	;	1.2	;	Crystal structure of KRAS G12D in complex with GDP and compound 14
8TXE	;	1.35	;	Crystal structure of KRAS G12D in complex with GDP and compound 5
8TXG	;	1.5	;	Crystal structure of KRAS G12D in complex with GDP and compound 8
7RT1	;	1.27	;	Crystal Structure of KRAS G12D with compound 15 (4-(4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-8-fluoro-2-{[(2S)-1-methylpyrrolidin-2-yl]methoxy}pyrido[4,3-d]pyrimidin-7-yl)naphthalen-2-ol) bound
7RT3	;	1.56	;	Crystal Structure of KRAS G12D with compound 24 (4-(4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-8-fluoro-2-{[(2S,4S,7aR)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}pyrido[4,3-d]pyrimidin-7-yl)naphthalen-2-ol) bound
7RT2	;	1.59	;	Crystal Structure of KRAS G12D with compound 25 (4-(4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-8-fluoro-2-{[(2R,4R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}pyrido[4,3-d]pyrimidin-7-yl)naphthalen-2-ol) bound
7RT5	;	1.29	;	Crystal structure of KRAS G12D with compound 36 (4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-7-(8-ethynyl-7-fluoronaphthalen-1-yl)-8-fluoro-2-{[(4s,7as)-tetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}pyrido[4,3-d]pyrimidine) bound
5WHD	;	1.641	;	Crystal structure of KRas G12V/D38P, bound to GDP
6MQN	;	1.6	;	Crystal structure of KRAS V14I-GDP demonstrating disorder switch 1 conformation - Form 2
6MQG	;	1.5	;	Crystal structure of KRAS V14I-GDP demonstrating open switch 1 conformation - Form 1
6V65	;	2.763	;	Crystal structure of KRAS(GMPPNP)-NF1(GRD)-SPRED1 complex
8AFC	;	2.41	;	CRYSTAL STRUCTURE OF KRAS-G12C IN COMPLEX WITH COMPOUND 12
8AFB	;	1.12	;	CRYSTAL STRUCTURE OF KRAS-G12C IN COMPLEX WITH COMPOUND 23 (BI-0474)
7F0W	;	1.39	;	Crystal structure of KRAS-G12D bound to GDP with switch 1 open conformation
6ZLI	;	1.73	;	CRYSTAL STRUCTURE OF KRAS-G12D IN COMPLEX WITH COMPOUND 13 AND GCP
6QUU	;	1.477	;	Crystal Structure of KRAS-G12D in complex with GMP-PCP
6QUV	;	1.475	;	Crystal Structure of KRAS-G12D in complex with GMP-PCP and compound 15R
6QUX	;	1.62	;	Crystal Structure of KRAS-G12D in Complex with Natural Product-Like Compound 15
6QUW	;	1.242	;	Crystal Structure of KRAS-G12D in Complex with Natural Product-Like Compound 9b
6ZL5	;	1.645	;	CRYSTAL STRUCTURE OF KRAS-G12D(C118S) IN COMPLEX WITH BI-2852 AND GDP
8STN	;	2.03	;	Crystal structure of KRAS-G12D/G75A mutant, GDP-bound
6WS4	;	1.84	;	Crystal structure of KRAS-G12D/K104Q mutant, GDP-bound
6XHA	;	2.87	;	Crystal Structure of KRAS-G12V (GMPPNP-bound) in complex with RAS-binding domain (RBD) and cysteine-rich domain (CRD) of RAF1/CRAF
6XGV	;	2.11	;	Crystal Structure of KRAS-G13D (GMPPNP-bound) in complex with RAS-binding domain (RBD) and cysteine-rich domain (CRD) of RAF1/CRAF
8STM	;	2.0	;	Crystal structure of KRAS-G75A mutant, GDP-bound
6WS2	;	1.59	;	Crystal structure of KRAS-K104Q mutant, GDP-bound
6XGU	;	2.7	;	Crystal Structure of KRAS-Q61R (GMPPNP-bound) in complex with RAS-binding domain (RBD) and cysteine-rich domain (CRD) of RAF1/CRAF
8T74	;	1.65	;	Crystal structure of KRAS4a (GMPPNP) in complex with RAF1 (RBD)
8T75	;	2.65	;	Crystal Structure of KRAS4a (GMPPNP) in complex with RAF1 (RBD-CRD)
7VVB	;	1.7	;	Crystal Structure of KRas4A(GMPPNP-bound) in complex with the Ras-binding domain(RBD) of SIN1
8T73	;	1.5	;	Crystal structure of KRAS4a-R151G with bound GDP and Mg ion
7LC1	;	2.35	;	Crystal Structure of KRAS4b (GMPPNP-bound) in complex with the RBD-PH domains of SIN1
8EPW	;	2.0	;	Crystal Structure of KRAS4b-G13D (GMPPNP-bound) in complex with RAS-binding domain (RBD) of RAF1/CRAF
7LC2	;	2.7	;	Crystal Structure of KRAS4b-Q61R (GMPPNP-bound) in complex with the RAS-binding domain (RBD) of SIN1
8BE3	;	1.85	;	Crystal structure of KRasG12V-Nanobody84
7OK4	;	1.7	;	Crystal Structure of KRasG13C in Complex with Nucleotide-based covalent Inhibitor bdaGDP
7OK3	;	1.6	;	Crystal Structure of KRasG13C in Complex with Nucleotide-based Covalent Inhibitor edaGDP
7VDO	;	1.85572	;	Crystal structure of KRED F147L/L153Q/Y190P variant
7EJJ	;	1.80001	;	Crystal structure of KRED F147L/L153Q/Y190P variant and methyl methacrylate complex
7EJI	;	1.56002	;	Crystal structure of KRED F147L/L153Q/Y190P/L199A/M205F/M206F variant and methyl methacrylate complex
7VE7	;	1.72001	;	Crystal structure of KRED mutant-F147L/L153Q/Y190P/L199A/M205F/M206F
7EJH	;	1.72884	;	Crystal structure of KRED mutant-F147L/L153Q/Y190P/L199A/M205F/M206F and 2-hydroxyisoindoline-1,3-dione complex
6YC8	;	1.77	;	Crystal structure of KRED1-Pglu enzyme
5D68	;	2.908	;	Crystal structure of KRIT1 ARD-FERM
4PG3	;	2.696	;	Crystal structure of KRS complexed with inhibitor
4QEP	;	3.1	;	crystal structure of KRYPTONITE in complex with mCHG DNA and SAH
4QEN	;	2.002	;	crystal structure of KRYPTONITE in complex with mCHH DNA and SAH
4QEO	;	2.0	;	crystal structure of KRYPTONITE in complex with mCHH DNA, H3(1-15) peptide and SAH
7TDQ	;	2.5	;	Crystal structure of KSHV KicGAS/ORF52
6XF9	;	2.22	;	Crystal structure of KSHV ORF68
2PBK	;	1.73	;	Crystal structure of KSHV protease in complex with hexapeptide phosphonate inhibitor
1K41	;	2.2	;	Crystal structure of KSI Y57S mutant
2PG2	;	1.849	;	Crystal structure of KSP in complex with ADP and thiophene containing inhibitor 15
2UYI	;	2.1	;	Crystal structure of KSP in complex with ADP and thiophene containing inhibitor 33
2UYM	;	2.11	;	Crystal structure of KSP in complex with ADP and thiophene containing inhibitor 37
1YRS	;	2.5	;	Crystal structure of KSP in complex with inhibitor 1
2Q2Y	;	2.5	;	Crystal Structure of KSP in complex with Inhibitor 1
2FKY	;	2.3	;	crystal structure of KSP in complex with inhibitor 13
2FL2	;	2.5	;	crystal structure of KSP in complex with inhibitor 19
2Q2Z	;	3.0	;	Crystal Structure of KSP in Complex with Inhibitor 22
3CJO	;	2.28	;	Crystal structure of KSP in complex with inhibitor 30
2FL6	;	2.5	;	crystal structure of KSP in complex with inhibitor 6
2G1Q	;	2.51	;	crystal structure of KSP in complex with inhibitor 9h
7JUW	;	2.88	;	Crystal Structure of KSR1:MEK1 in complex with AMP-PNP
7JV1	;	3.62	;	Crystal Structure of KSR1:MEK1 in complex with AMP-PNP, and allosteric MEK inhibitor APS-9-95-1
7JUY	;	3.096	;	Crystal Structure of KSR1:MEK1 in complex with AMP-PNP, and allosteric MEK inhibitor Cobimetinib
7JV0	;	3.63	;	Crystal Structure of KSR1:MEK1 in complex with AMP-PNP, and allosteric MEK inhibitor PD0325901
7JUZ	;	3.21	;	Crystal Structure of KSR1:MEK1 in complex with AMP-PNP, and allosteric MEK inhibitor Selumetinib
7JUX	;	3.34	;	Crystal Structure of KSR1:MEK1 in complex with AMP-PNP, and allosteric MEK inhibitor Trametinib
7JUQ	;	3.22	;	Crystal Structure of KSR2:MEK1 in complex with ADP
7JUV	;	3.36	;	Crystal Structure of KSR2:MEK1 in complex with AMP-PNP, and allosteric MEK inhibitor APS-9-95-1
7JUS	;	2.99	;	Crystal Structure of KSR2:MEK1 in complex with AMP-PNP, and allosteric MEK inhibitor Cobimetinib
7JUU	;	3.19	;	Crystal Structure of KSR2:MEK1 in complex with AMP-PNP, and allosteric MEK inhibitor PD0325901
7JUR	;	2.82	;	Crystal Structure of KSR2:MEK1 in complex with AMP-PNP, and allosteric MEK inhibitor Trametinib
7JUT	;	3.09	;	Crystal Structure of KSR2:MEK1 in complex with ANP-PNP, and allosteric MEK inhibitor Selumetinib
4D4Q	;	2.395	;	Crystal Structure of Kti13/AtS1
4RGI	;	1.732	;	Crystal Structure of KTSC Domain Protein YPO2434 from Yersinia pestis
5Y58	;	2.8	;	Crystal structure of Ku70/80 and TLC1
5Y59	;	2.402	;	Crystal structure of Ku80 and Sir4
1ZR0	;	1.802	;	Crystal Structure of Kunitz Domain 1 of Tissue Factor Pathway Inhibitor-2 with Bovine Trypsin
2QEQ	;	3.1	;	Crystal structure of kunjin virus ns3 helicase
2ZO6	;	1.4	;	Crystal Structure of Kusabira-Cyan (KCY), a Cyan-Emitting GFP-Like Protein
5M6Q	;	1.98	;	Crystal Structure of Kutzneria albida transglutaminase
1S1E	;	2.3	;	Crystal Structure of Kv Channel-interacting protein 1 (KChIP-1)
4JTA	;	2.5	;	Crystal structure of Kv1.2-2.1 paddle chimera channel in complex with Charybdotoxin
4JTC	;	2.56	;	Crystal structure of Kv1.2-2.1 paddle chimera channel in complex with Charybdotoxin in Cs+
4JTD	;	2.54	;	Crystal structure of Kv1.2-2.1 paddle chimera channel in complex with Lys27Met mutant of Charybdotoxin
1S1G	;	2.6	;	Crystal Structure of Kv4.3 T1 Domain
2A0L	;	3.9	;	Crystal structure of KvAP-33H1 Fv complex
8FAN	;	2.9	;	Crystal structure of Ky15.1 Fab in complex with circumsporozoite protein KQPA peptide
8FA6	;	2.6	;	Crystal structure of Ky15.10 Fab in complex with circumsporozoite protein DND peptide
8FB6	;	2.15	;	Crystal structure of Ky15.10 Fab in complex with circumsporozoite protein KQPA peptide
8FB7	;	1.75	;	Crystal structure of Ky15.10 Fab in complex with circumsporozoite protein NPDP peptide
8FB8	;	1.69	;	Crystal structure of Ky15.10-Y100EK Fab in complex with circumsporozoite protein KQPA peptide
8FA7	;	1.8	;	Crystal structure of Ky15.11 Fab in complex with circumsporozoite protein KQPA peptide
8FA8	;	1.8	;	Crystal structure of Ky15.11 Fab in complex with circumsporozoite protein NDN peptide
8FB5	;	2.9	;	Crystal structure of Ky15.11-S100IK Fab in complex with circumsporozoite protein KQPA peptide
8F95	;	2.45	;	Crystal structure of Ky15.2 Fab in complex with circumsporozoite protein DND peptide
8F9E	;	2.95	;	Crystal structure of Ky15.2 Fab in complex with circumsporozoite protein KQPA peptide
8F9F	;	2.2	;	Crystal structure of Ky15.2 Fab in complex with circumsporozoite protein NANP3 peptide
8F9S	;	2.1	;	Crystal structure of Ky15.2 Fab in complex with circumsporozoite protein NDN peptide
8F9T	;	1.85	;	Crystal structure of Ky15.2 Fab in complex with circumsporozoite protein NPDP peptide
8FDD	;	1.54	;	Crystal structure of Ky15.3 Fab in complex with circumsporozoite protein NPDP peptide
8FA9	;	2.45	;	Crystal structure of Ky15.5 Fab in complex with circumsporozoite protein NPDP peptide
8F9U	;	1.7	;	Crystal structure of Ky15.7 Fab in complex with circumsporozoite protein NPDP peptide
8F9V	;	2.25	;	Crystal structure of Ky15.8 Fab in complex with circumsporozoite protein KQPA peptide
8F9W	;	2.4	;	Crystal structure of Ky15.8 Fab in complex with circumsporozoite protein NPDP peptide
8FAT	;	2.95	;	Crystal structure of Ky224 Fab in complex with circumsporozoite protein NPDP peptide
8FAS	;	1.55	;	Crystal structure of Ky230 Fab in complex with circumsporozoite protein NANP5 peptide
8FDC	;	1.8	;	Crystal structure of Ky311 Fab in complex with circumsporozoite protein KQPA peptide
8FBA	;	1.96	;	Crystal structure of Ky315 Fab in complex with circumsporozoite protein DND peptide
4J33	;	1.82	;	Crystal Structure of kynurenine 3-monooxygenase (KMO-394)
4J31	;	2.4	;	Crystal Structure of kynurenine 3-monooxygenase (KMO-396Prot)
4J2W	;	2.6	;	Crystal Structure of kynurenine 3-monooxygenase (KMO-396Prot-Se)
4J34	;	2.03	;	Crystal Structure of kynurenine 3-monooxygenase - truncated at position 394 plus HIS tag cleaved.
3DC1	;	2.5	;	Crystal structure of kynurenine aminotransferase II complex with alpha-ketoglutarate
6D0A	;	1.46809	;	Crystal structure of Kynurenine Aminotransferase-II in apo-form, at 1.47 A resolution
4E15	;	1.5	;	Crystal structure of kynurenine formamidase conjugated with an inhibitor
4E14	;	1.64	;	Crystal structure of kynurenine formamidase conjugated with phenylmethylsulfonyl fluoride
4CO9	;	1.95	;	Crystal structure of kynurenine formamidase from Bacillus anthracis
4CZ1	;	2.24	;	Crystal structure of kynurenine formamidase from Bacillus anthracis complexed with 2-aminoacetophenone.
4COG	;	1.6	;	Crystal structure of kynurenine formamidase from Burkholderia cenocepacia
4E11	;	2.0	;	Crystal structure of kynurenine formamidase from Drosophila melanogaster
5BMQ	;	2.05	;	Crystal structure of L,D-transpeptidase (Yku) from Stackebrandtia nassauensis
6D4K	;	1.32	;	Crystal structure of L,D-transpeptidase 3 from Mycobacterium tuberculosis at 1.32 A resolution
6D51	;	1.83	;	Crystal structure of L,D-transpeptidase 3 from Mycobacterium tuberculosis in complex with a faropenem-derived adduct
6D5A	;	2.622	;	Crystal structure of L,D-transpeptidase 5 from Mycobacterium tuberculosis in apo form
6OXM	;	2.25	;	Crystal structure of L,L-diaminopimelate aminotransferase (DapL) from Verrucomicrobium spinosum
3A28	;	2.0	;	Crystal structure of L-2,3-butanediol dehydrogenase
3D3S	;	1.87	;	Crystal structure of L-2,4-diaminobutyric acid acetyltransferase from Bordetella parapertussis
8GSR	;	1.73	;	Crystal structure of L-2,4-diketo-3-deoxyrhamnonate hydrolase from Sphingomonas sp. (apo-form)
8GST	;	1.71	;	Crystal structure of L-2,4-diketo-3-deoxyrhamnonate hydrolase from Sphingomonas sp. (pyruvate bound-form)
1HYH	;	2.2	;	CRYSTAL STRUCTURE OF L-2-HYDROXYISOCAPROATE DEHYDROGENASE FROM LACTOBACILLUS CONFUSUS AT 2.2 ANGSTROMS RESOLUTION-AN EXAMPLE OF STRONG ASYMMETRY BETWEEN SUBUNITS
1ZH0	;	1.9	;	Crystal Structure of L-3-(2-napthyl)alanine-tRNA synthetase in complex with L-3-(2-napthyl)alanine
3AJR	;	1.77	;	Crystal structure of L-3-Hydroxynorvaline bound L-Threonine dehydrogenase (Y137F) from Hyperthermophilic Archaeon Thermoplasma volcanium
2FM1	;	2.25	;	Crystal structure of L-ALLO-threonine aldolase (tm1744) from Thermotoga maritima at 2.25 A resolution
3VOT	;	1.8	;	Crystal structure of L-amino acid ligase from Bacillus licheniformis
5TS5	;	2.3	;	Crystal structure of L-amino acid oxidase from Bothrops atrox
1F8R	;	2.0	;	CRYSTAL STRUCTURE OF L-AMINO ACID OXIDASE FROM CALLOSELASMA RHODOSTOMA COMPLEXED WITH CITRATE
1F8S	;	2.0	;	CRYSTAL STRUCTURE OF L-AMINO ACID OXIDASE FROM CALLOSELASMA RHODOSTOMA, COMPLEXED WITH THREE MOLECULES OF O-AMINOBENZOATE.
5Z2G	;	2.676	;	Crystal Structure of L-amino acid oxidase from venom of Naja atra
5J83	;	3.001	;	Crystal structure of L-arabinonate dehydratase in apo-form
5J84	;	2.4	;	Crystal structure of L-arabinonate dehydratase in holo-form
2AJT	;	2.6	;	Crystal structure of L-Arabinose Isomerase from E.coli
4LQL	;	3.232	;	Crystal structure of L-arabinose isomerase from Lactobacillus fermentum CGMCC2921
2OCD	;	2.45	;	Crystal structure of L-asparaginase I from Vibrio cholerae O1 biovar eltor str. N16961
3NTX	;	1.9	;	Crystal Structure of L-asparaginase I from Yersinia pestis
1WLS	;	2.16	;	Crystal structure of L-asparaginase I homologue protein from Pyrococcus horikoshii
2DC1	;	1.9	;	Crystal Structure Of L-Aspartate Dehydrogenase From Hyperthermophilic Archaeon Archaeoglobus fulgidus
2E5V	;	2.09	;	Crystal structure of L-Aspartate Oxidase from hyperthermophilic archaeon Sulfolobus tokodaii
5KXJ	;	1.87	;	Crystal Structure of L-Aspartate Oxidase from Salmonella typhimurium in the Complex with Substrate L-Aspartate
1VC3	;	1.5	;	Crystal Structure of L-Aspartate-alpha-Decarboxylase
5ELM	;	2.0	;	Crystal structure of L-aspartate/glutamate specific racemase in complex with L-glutamate
5ELL	;	1.801	;	Crystal structure of L-aspartate/glutamate-specific racemase from Escherichia coli
1VFT	;	2.3	;	Crystal structure of L-cycloserine-bound form of alanine racemase from D-cycloserine-producing Streptomyces lavendulae
7CEU	;	2.9	;	Crystal structure of L-cycloserine-bound form of cysteine desulfurase NifS from Helicobacter pylori
7E6C	;	1.73	;	Crystal structure of L-cycloserine-bound form of cysteine desulfurase SufS C361A from Bacillus subtilis
7CEP	;	2.05	;	Crystal structure of L-cycloserine-bound form of cysteine desulfurase SufS from Bacillus subtilis
7CES	;	2.2	;	Crystal structure of L-cycloserine-bound form of cysteine desulfurase SufS H121A from Bacillus subtilis
4IP4	;	2.128	;	Crystal structure of l-fuconate dehydratase from Silicibacter sp. tm1040 liganded with Mg
4IP5	;	2.13	;	Crystal structure of l-fuconate dehydratase from Silicibacter sp. tm1040 liganded with Mg and d-erythronohydroxamate
2HXT	;	1.7	;	Crystal structure of L-Fuconate Dehydratase from Xanthomonas campestris liganded with Mg++ and D-erythronohydroxamate
1YEY	;	2.34	;	Crystal Structure of L-fuconate Dehydratase from Xanthomonas campestris pv. campestris str. ATCC 33913
2HNE	;	2.0	;	Crystal structure of l-fuconate dehydratase from xanthomonas campestris pv. campestris str. ATCC 33913
2OPI	;	2.5	;	Crystal Structure of L-fuculose-1-phosphate aldolase from Bacteroides thetaiotaomicron
2FK5	;	1.9	;	Crystal structure of l-fuculose-1-phosphate aldolase from Thermus thermophilus HB8
2FLF	;	2.7	;	Crystal structure of l-fuculose-1-phosphate aldolase from Thermus Thermophilus HB8
7SML	;	2.1	;	Crystal Structure of L-GALACTONO-1,4-LACTONE DEHYDROGENASE de Myrciaria dubia
8SCC	;	2.09	;	Crystal Structure of L-galactose 1-dehydrogenase de Myrciaria dubia
8USU	;	2.97	;	Crystal Structure of L-galactose 1-dehydrogenase of Myrciaria dubia in complex with NAD
7SMI	;	1.4	;	Crystal Structure of L-galactose dehydrogenase from Spinacia oleracea
7SVQ	;	1.75	;	Crystal Structure of L-galactose dehydrogenase from Spinacia oleracea in complex with NAD+
1O0C	;	2.7	;	CRYSTAL STRUCTURE OF L-GLUTAMATE AND AMPCPP BOUND TO GLUTAMINE AMINOACYL TRNA SYNTHETASE
2E1M	;	2.8	;	Crystal Structure of L-Glutamate Oxidase from Streptomyces sp. X-119-6
1O0B	;	2.7	;	CRYSTAL STRUCTURE OF L-GLUTAMINE AND AMPCPP BOUND TO GLUTAMINE AMINOACYL TRNA SYNTHETASE
7ERU	;	2.85	;	Crystal structure of L-histidine decarboxylase (C57S mutant) from Photobacterium phosphoreum
7ERV	;	2.5	;	Crystal structure of L-histidine decarboxylase (C57S/C101V/C282V mutant) from Photobacterium phosphoreum
1FG3	;	2.2	;	CRYSTAL STRUCTURE OF L-HISTIDINOL PHOSPHATE AMINOTRANSFERASE COMPLEXED WITH L-HISTIDINOL
1IJI	;	2.2	;	Crystal Structure of L-Histidinol Phosphate Aminotransferase with PLP
1FG7	;	1.5	;	CRYSTAL STRUCTURE OF L-HISTIDINOL PHOSPHATE AMINOTRANSFERASE WITH PYRIDOXAL-5'-PHOSPHATE
4GC3	;	1.32	;	Crystal structure of L-HISTIDINOL PHOSPHATE PHOSPHATASE (HISK) from Lactococcus lactis subsp. lactis Il1403 complexed with ZN and sulfate
1JG2	;	1.5	;	Crystal Structure of L-isoaspartyl (D-aspartyl) O-methyltransferase with adenosine
1JG3	;	2.1	;	Crystal Structure of L-isoaspartyl (D-aspartyl) O-methyltransferase with adenosine & VYP(ISP)HA substrate
1JG1	;	1.2	;	Crystal Structure of L-isoaspartyl (D-aspartyl) O-methyltransferase with S-ADENOSYL-L-HOMOCYSTEINE
1JG4	;	1.5	;	Crystal Structure of L-isoaspartyl (D-aspartyl) O-methyltransferase with S-adenosylmethionine
2YXE	;	2.0	;	Crystal structure of L-isoaspartyl protein carboxyl methyltranferase
7Z2L	;	2.56	;	Crystal structure of L-Kynurenine in the active site of human Indoleamine-2,3-dioxygenase 1 (hIDO1)
4LN1	;	1.9	;	CRYSTAL STRUCTURE OF L-lactate dehydrogenase from Bacillus cereus ATCC 14579 complexed with calcium, NYSGRC Target 029452
4LMR	;	2.45	;	Crystal structure of L-lactate dehydrogenase from Bacillus cereus ATCC 14579, NYSGRC Target 029452
4M1Q	;	1.6	;	Crystal structure of L-lactate dehydrogenase from Bacillus selenitireducens MLS10, NYSGRC Target 029814.
3PQD	;	2.376	;	Crystal structure of L-lactate dehydrogenase from Bacillus subtilis complexed with FBP and NAD+
3PQF	;	2.49	;	Crystal structure of L-lactate dehydrogenase from Bacillus subtilis mutation H171C complexed with NAD+
3PQE	;	2.2	;	Crystal structure of L-lactate dehydrogenase from Bacillus subtilis with H171C mutation
1V6A	;	2.3	;	Crystal Structure of L-lactate dehydrogenase from Cyprinus carpio
2E77	;	1.9	;	Crystal structure of L-lactate oxidase with pyruvate complex
5CQF	;	2.28	;	Crystal structure of L-lysine 6-monooxygenase from Pseudomonas syringae
3ABI	;	2.44	;	Crystal Structure of L-Lysine Dehydrogenase from Hyperthermophilic Archaeon Pyrococcus horikoshii
3MTW	;	1.7	;	Crystal structure of L-Lysine, L-Arginine carboxypeptidase Cc2672 from Caulobacter Crescentus CB15 complexed with N-methyl phosphonate derivative of L-Arginine
4WLU	;	2.14	;	Crystal structure of L-malate and NAD bound MDH2
4WLF	;	2.2	;	Crystal structure of L-malate bound MDH2
1PG8	;	2.68	;	Crystal Structure of L-methionine alpha-, gamma-lyase
7CIF	;	1.8	;	Crystal structure of L-methionine decarboxylase from Streptomyces sp.590 (internal aldimine form).
7CIJ	;	1.61	;	Crystal structure of L-methionine decarboxylase from Streptomyces sp.590 in complexed with 3-methlythiopropylamine (external aldimine form).
7CIM	;	1.8	;	Crystal structure of L-methionine decarboxylase from Streptomyces sp.590 in complexed with 3-methlythiopropylamine (geminal diamine form).
7CII	;	1.51	;	Crystal structure of L-methionine decarboxylase from Streptomyces sp.590 in complexed with L- methionine methyl ester (external aldimine form).
7CIG	;	1.45	;	Crystal structure of L-methionine decarboxylase Q64A mutant from Streptomyces sp.590 in complexed with L- methionine methyl ester (geminal diamine form).
4MKJ	;	1.849	;	Crystal structure of L-methionine gamma-lyase from Citrobacter freundii modified by allicine
4HF8	;	2.45	;	Crystal structure of L-methionine gamma-lyase from Citrobacter freundii with glycine
3JWA	;	1.45	;	Crystal structure of L-methionine gamma-lyase from Citrobacter freundii with methionine phosphinate
3JWB	;	1.63	;	Crystal structure of L-methionine gamma-lyase from Citrobacter freundii with norleucine
3JW9	;	1.8	;	Crystal structure of L-methionine gamma-lyase from Citrobacter freundii with S-ethyl-cysteine
3VK4	;	2.61	;	Crystal Structure of L-Methionine gamma-Lyase from Pseudomonas putida C116H Mutant complexed with L-homocysteine
3VK3	;	2.1	;	Crystal Structure of L-Methionine gamma-Lyase from Pseudomonas putida C116H Mutant Complexed with L-methionine
3VK2	;	2.3	;	Crystal Structure of L-Methionine gamma-Lyase from Pseudomonas putida C116H Mutant.
2O7C	;	1.7	;	Crystal structure of L-methionine-lyase from Pseudomonas
3N5F	;	2.75	;	Crystal Structure of L-N-carbamoylase from Geobacillus stearothermophilus CECT43
8AQ0	;	2.3	;	Crystal structure of L-N-Carbamoylase from Sinorhizobium meliloti mutant L217G/F329C
2YR4	;	1.7	;	Crystal structure of L-phenylalanine oxiase from Psuedomonas sp. P-501
2YR5	;	1.25	;	Crystal structure of L-phenylalanine oxidase from Psuedomonas sp.P501
2YR6	;	1.35	;	Crystal structure of L-phenylalanine oxidase from Psuedomonas sp.P501
3FJ7	;	1.7	;	Crystal structure of L-phospholactate Bound PEB3
1Y56	;	2.86	;	Crystal structure of L-proline dehydrogenase from P.horikoshii
3R0P	;	1.9	;	Crystal structure of L-PSP putative endoribonuclease from uncultured organism
2OZ3	;	2.0	;	Crystal structure of L-Rhamnonate dehydratase from Azotobacter vinelandii
3EKG	;	1.6	;	CRYSTAL STRUCTURE OF L-RHAMNONATE DEHYDRATASE FROM AZOTOBACTER VINELANDII complexed with Mg and L-TARTRATE
2P0I	;	2.1	;	Crystal structure of L-rhamnonate dehydratase from Gibberella zeae
2GSH	;	2.393	;	Crystal structure of L-rhamnonate dehydratase from Salmonella typhimurium
2P3Z	;	1.8	;	Crystal structure of L-Rhamnonate dehydratase from Salmonella typhimurium
3BOX	;	1.8	;	Crystal structure of L-rhamnonate dehydratase from Salmonella typhimurium complexed with Mg
3CXO	;	2.0	;	Crystal structure of L-rhamnonate dehydratase from Salmonella typhimurium complexed with Mg and 3-deoxy-L-rhamnonate
3D47	;	1.8	;	Crystal structure of L-rhamnonate dehydratase from Salmonella typhimurium complexed with Mg and D-malate
3D46	;	1.9	;	Crystal structure of L-rhamnonate dehydratase from Salmonella typhimurium complexed with Mg and L-tartrate
3UU0	;	2.7	;	Crystal structure of L-rhamnose isomerase from Bacillus halodurans in complex with Mn
8JQ3	;	1.9	;	Crystal structure of L-rhamnose isomerase from Lactobacillus rhamnosus
2I57	;	1.97	;	Crystal Structure of L-Rhamnose Isomerase from Pseudomonas stutzeri in Complex with D-Allose
2I56	;	1.97	;	Crystal structure of L-Rhamnose Isomerase from Pseudomonas stutzeri with L-Rhamnose
2HCV	;	2.0	;	Crystal structure of L-rhamnose isomerase from Pseudomonas stutzeri with metal ion
3UVA	;	2.69	;	Crystal structure of L-rhamnose isomerase mutant W38F from Bacillus halodurans in complex with Mn
3UXI	;	2.73	;	Crystal structure of L-rhamnose isomerase W38A mutant from Bacillus halodurans
3P14	;	2.51	;	Crystal structure of L-rhamnose isomerase with a novel high thermo-stability from Bacillus halodurans
6HHN	;	1.47	;	Crystal structure of L-rhamnose mutarotase FA22100 from Formosa agariphila
2CGK	;	2.46	;	Crystal Structure of L-rhamnulose kinase from Escherichia coli in an open uncomplexed conformation.
2CGJ	;	2.26	;	Crystal Structure of L-rhamnulose kinase from Escherichia coli in complex with L-fructose and ADP.
2CGL	;	1.88	;	Crystal Structure of L-rhamnulose kinase from Escherichia coli in complex with L-fructose, ADP and a modeled ATP gamma phosphate.
1JDI	;	2.4	;	CRYSTAL STRUCTURE OF L-RIBULOSE-5-PHOSPHATE 4-EPIMERASE
1K0W	;	2.1	;	CRYSTAL STRUCTURE OF L-RIBULOSE-5-PHOSPHATE 4-EPIMERASE
5VC1	;	1.94	;	Crystal structure of L-selectin lectin/EGF domains
4RQO	;	2.25	;	Crystal structure of L-Serine Dehydratase from Legionella pneumophila
4WXG	;	2.0	;	Crystal structure of L-Serine Hydroxymethyltransferase in complex with a mixture of L-Threonine and Glycine
4WXF	;	2.4	;	Crystal structure of L-Serine Hydroxymethyltransferase in complex with glycine
3VVL	;	1.81	;	Crystal structure of L-serine-O-acetyltransferase found in D-cycloserine biosynthetic pathway
3CB3	;	2.0	;	Crystal structure of L-Talarate dehydratase from Polaromonas sp. JS666 complexed with Mg and L-glucarate
2PP0	;	2.2	;	Crystal structure of L-talarate/galactarate dehydratase from Salmonella typhimurium LT2
2PP1	;	2.2	;	Crystal structure of L-talarate/galactarate dehydratase from Salmonella typhimurium LT2 liganded with Mg and L-lyxarohydroxamate
2PP3	;	2.2	;	Crystal structure of L-talarate/galactarate dehydratase mutant K197A liganded with Mg and L-glucarate
5KIA	;	2.1	;	Crystal structure of L-threonine 3-dehydrogenase from Burkholderia thailandensis
7YVR	;	2.8	;	Crystal Structure of L-Threonine Aldolase from Neptunomonas marina
5VYE	;	2.275	;	Crystal Structure of L-Threonine Aldolase from Pseudomonas putida
3A9W	;	1.85	;	Crystal structure of L-Threonine bound L-Threonine dehydrogenase (Y137F) from Hyperthermophilic Archaeon Thermoplasma volcanium
3A1N	;	2.07	;	Crystal structure of L-Threonine dehydrogenase from Hyperthermophilic Archaeon Thermoplasma volcanium
6JYG	;	2.31	;	Crystal Structure of L-threonine dehydrogenase from Phytophthora infestans
7K34	;	1.66	;	Crystal structure of L-threonine transaldolase from Pseudomonas fluorescens in internal aldimine state
1LC7	;	1.8	;	Crystal Structure of L-Threonine-O-3-phosphate Decarboxylase from S. enterica complexed with a substrate
1LC8	;	1.8	;	Crystal Structure of L-Threonine-O-3-phosphate Decarboxylase from S. enterica complexed with its reaction intermediate
1LC5	;	1.46	;	Crystal Structure of L-Threonine-O-3-phosphate Decarboxylase from S. enterica in its apo state
1LKC	;	1.8	;	Crystal Structure of L-Threonine-O-3-Phosphate Decarboxylase from Salmonella enterica
7NGE	;	2.3	;	Crystal structure of L-Trp/Indoleamine 2,3-dioxygenagse 1 (hIDO1) complex with the JK-loop refined in the closed conformation
7P0N	;	2.5	;	Crystal structure of L-Trp/Indoleamine 2,3-dioxygenagse 1 (hIDO1) complex with the JK-loop refined in the open conformation
7P0R	;	2.5	;	Crystal structure of L-Trp/Indoleamine 2,3-dioxygenase (hIDO1) complex with the JK-loop refined in the intermediate conformation
5B37	;	3.4	;	Crystal structure of L-tryptophan dehydrogenase from Nostoc punctiforme
6ESD	;	2.6	;	Crystal structure of L-tryptophan oxidase VioA from Chromobacterium violaceum
6FW7	;	3.0	;	Crystal structure of L-tryptophan oxidase VioA from Chromobacterium violaceum in complex with 4-Fluoro-L-Tryptophan
6FW8	;	2.4	;	Crystal structure of L-tryptophan oxidase VioA from Chromobacterium violaceum in complex with 5-Methyl-L-Tryptophan
6FW9	;	2.739	;	Crystal structure of L-tryptophan oxidase VioA from Chromobacterium violaceum in complex with 6-Fluoro-L-Tryptophan
6FWA	;	2.846	;	Crystal structure of L-tryptophan oxidase VioA from Chromobacterium violaceum in complex with 7-Methyl-L-Tryptophan
6G2P	;	2.6	;	Crystal structure of L-tryptophan oxidase VioA from Chromobacterium violaceum in complex with L-tryptophan
3F9T	;	2.11	;	Crystal structure of L-tyrosine decarboxylase MfnA (EC 4.1.1.25) (NP_247014.1) from METHANOCOCCUS JANNASCHII at 2.11 A resolution
3CQI	;	2.1	;	Crystal Structure of L-xylulose-5-phosphate 3-epimerase UlaE (form B) complex with sulfate
3CQJ	;	2.04	;	Crystal Structure of L-xylulose-5-phosphate 3-epimerase UlaE (form B) complex with Zn2+
3CQK	;	2.33	;	Crystal Structure of L-xylulose-5-phosphate 3-epimerase UlaE (form B) complex with Zn2+ and sulfate
3CQH	;	2.08	;	Crystal Structure of L-xylulose-5-phosphate 3-epimerase UlaE from the Anaerobic L-ascorbate Utilization Pathway of Escherichia coli
4NDS	;	0.997	;	Crystal structure of L. decastes alpha-galactosyl-binding lectin
4NDU	;	1.301	;	Crystal structure of L. decastes alpha-galactosyl-binding lectin in complex with alpha-methylgalactoside
4NDV	;	1.3	;	Crystal structure of L. decastes alpha-galactosyl-binding lectin in complex with globotriose
4NDT	;	1.03	;	Crystal structure of L. decastes alpha-galactosyl-binding lectin, orthorhombic crystal form
2BSL	;	2.3	;	Crystal structure of L. lactis dihydroorotate dehydrogense A in complex with 3,4-dihydroxybenzoate
2BX7	;	2.04	;	Crystal structure of L. lactis dihydroorotate dehydrogense A in complex with 3,5-dihydroxybenzoate
2HFS	;	1.75	;	Crystal structure of L. major mevalonate kinase
2HFU	;	2.0	;	Crystal structure of L. major mevalonate kinase in complex with R-mevalonate
4S1C	;	2.398	;	Crystal Structure of L. monocytogenes phosphodiesterase PgpH HD domain
4S1B	;	2.099	;	Crystal Structure of L. monocytogenes phosphodiesterase PgpH HD domain in complex with Cyclic-di-AMP
4RWX	;	2.9	;	Crystal Structure of L. monocytogenes PstA
4RWW	;	1.6	;	Crystal Structure of L. monocytogenes PstA in complex with cyclic-di-AMP
4QSH	;	2.51	;	Crystal Structure of L. monocytogenes Pyruvate Carboxylase in complex with Cyclic-di-AMP
4QSK	;	2.7	;	Crystal Structure of L. monocytogenes Pyruvate Carboxylase in complex with Cyclic-di-AMP
3QR1	;	3.2	;	Crystal Structure of L. pealei PLC21
7CMJ	;	2.76	;	Crystal structure of L.donovani Hypoxanthine-guanine phosphoribosyl transferase (HGPRT)
5MRS	;	1.9	;	Crystal structure of L1 protease Lysobacter sp. XL1 in complex with AEBSF
6QOY	;	1.9	;	Crystal structure of L1 protease Lysobacter sp. XL1 in complex with AEBSF
5MRR	;	1.35	;	Crystal structure of L1 protease of Lysobacter sp. XL1
1I2A	;	1.85	;	CRYSTAL STRUCTURE OF L1 RIBOSOMAL PROTEIN FROM METHANOCOCCUS JANNASCHII WITH 1.85A RESOLUTION.
7A63	;	1.57	;	Crystal structure of L1 with hydrolyzed faropenem (imine, ring-closed form)
5ML7	;	3.3	;	CRYSTAL STRUCTURE OF L1-STALK FRAGMENT OF 23S rRNA FROM HALOARCULA MARISMORTUI
2OPQ	;	2.8	;	Crystal Structure of L100I Mutant HIV-1 Reverse Transcriptase in Complex with GW420867X.
3DOL	;	2.5	;	Crystal structure of L100I mutant HIV-1 reverse transcriptase in complex with GW695634.
1S1U	;	3.0	;	Crystal structure of L100I mutant HIV-1 reverse transcriptase in complex with nevirapine
1S1V	;	2.6	;	Crystal structure of L100I mutant HIV-1 reverse transcriptase in complex with TNK-651
1S1T	;	2.4	;	Crystal structure of L100I mutant HIV-1 reverse transcriptase in complex with UC-781
2ZE2	;	2.9	;	Crystal structure of L100I/K103N mutant HIV-1 reverse transcriptase (RT) in complex with TMC278 (rilpivirine), a non-nucleoside RT inhibitor
5N09	;	3.9	;	Crystal structure of L107C/A313C covalently linked dengue 2 virus envelope glycoprotein dimer in complex with the Fab fragment of the broadly neutralizing human antibody EDE2 A11
2ALL	;	1.47	;	Crystal structure of L122V/L132V mutant of nitrophorin 2
2AMM	;	1.9	;	Crystal structure of L122V/L132V mutant of nitrophorin 2
5BRL	;	2.003	;	Crystal Structure of L124D STARD4
3TGA	;	1.3	;	Crystal structure of L130R mutant of Nitrophorin 4 from Rhodnius prolixus at pH 7.4
3TGB	;	1.35	;	Crystal structure of L130R mutant of Nitrophorin 4 from Rhodnius prolixus complexed with imidazole at pH 7.4
3TGC	;	1.4	;	Crystal structure of L130R mutant of Nitrophorin 4 from Rhodnius prolixus complexed with nitrite at pH 7.4
7P8M	;	1.71	;	Crystal structure of L147A/I351A variant of S-adenosylmethionine synthetase from Methanocaldococcus jannaschii in complex with DMNB-SAM (4,5-dimethoxy-2-nitro benzyme S-adenosyl-methionine)
7P84	;	2.054	;	Crystal structure of L147A/I351A variant of S-adenosylmethionine synthetase from Methanocaldococcus jannaschii in complex with ONB-SAM (2-nitro benzyme S-adenosyl-methionine)
7EA4	;	1.95	;	Crystal Structure of L182E D-Succinylase (DSA) from Cupriavidus sp. P4-10-C
6QW7	;	1.78	;	Crystal structure of L2 complexed with relebactam (16 hour soak)
1I4J	;	1.8	;	CRYSTAL STRUCTURE OF L22 RIBOSOMAL PROTEIN MUTANT
3BAQ	;	1.8	;	Crystal structure of L26A mutant of Human acidic fibroblast growth factor
3BAV	;	1.62	;	Crystal structure of L26A/D28N mutant of Human acidic fibroblast growth factor
3BA4	;	1.8	;	Crystal structure of L26D mutant of Human acidic fibroblast growth factor
3BB2	;	1.5	;	Crystal structure of L26D/D28N mutant of Human acidic fibroblast growth factor
3BAO	;	1.55	;	Crystal structure of L26N mutant of Human acidic fibroblast growth factor
3BA7	;	1.6	;	Crystal structure of L26N/D28A mutant of Human acidic fibroblast growth factor
3B9U	;	1.55	;	Crystal structure of L26N/D28N/H93G mutant of Human acidic fibroblast growth factor
4M2B	;	2.2	;	Crystal structure of L281D mutant of udp-glucose pyrophosphorylase from leishmania major in complex with udp-glc
3CPQ	;	1.9	;	Crystal Structure of L30e a ribosomal protein from Methanocaldococcus jannaschii DSM2661 (MJ1044)
6CDA	;	2.0	;	Crystal structure of L34A CzrA in the Zn(II)bound state
3P8H	;	2.55	;	Crystal structure of L3MBTL1 (MBT repeat) in complex with a nicotinamide antagonist
2RJF	;	2.05	;	Crystal structure of L3MBTL1 in complex with H4K20Me2 (residues 12-30), orthorhombic form I
2RJE	;	1.86	;	Crystal structure of L3MBTL1 in complex with H4K20Me2 (residues 17-25), orthorhombic form II
2PQW	;	2.0	;	Crystal structure of L3MBTL1 in complex with H4K20Me2 (residues 17-25), trigonal form
6BYB	;	1.74	;	Crystal structure of L3MBTL1 MBT Domain with MBK14970
2RJD	;	1.65	;	Crystal structure of L3MBTL1 protein
2RJC	;	2.0	;	Crystal structure of L3MBTL1 protein in complex with MES
3CEY	;	2.2	;	Crystal structure of L3MBTL2
3F70	;	2.1	;	Crystal structure of L3MBTL2-H4K20me1 complex
2HQZ	;	1.2	;	Crystal structure of L42H design intermediate for GFP metal ion reporter
2HRS	;	1.4	;	Crystal structure of L42H V224H design intermediate for GFP metal ion reporter
3FGM	;	1.95	;	Crystal structure of L44F/C83T/C117V/F132W mutant of Human acidic fibroblast growth factor
3FJD	;	1.9	;	Crystal structure of L44F/F132W mutant of Human acidic fibroblast growth factor
3FJC	;	2.0	;	Crystal structure of L44W mutant of Human acidic fibroblast growth factor
5MRT	;	1.6	;	Crystal structure of L5 protease Lysobacter sp. XL1
8UFM	;	1.65	;	Crystal Structure of L516C/Y647C Mutant of SARS-Unique Domain (SUD) from SARS-CoV-2
4LS4	;	1.66	;	Crystal structure of L66S mutant toxin from Helicobacter pylori
3PS8	;	2.55	;	Crystal structure of L68V mutant of human cystatin C
3QRD	;	2.19	;	Crystal structure of L68V mutant of human cystatin C
2XSV	;	1.8	;	Crystal structure of L69A mutant Acinetobacter radioresistens catechol 1,2 dioxygenase
1PXW	;	1.94	;	Crystal structure of L7Ae sRNP core protein from Pyrococcus abyssii
4I21	;	3.37	;	Crystal structure of L858R + T790M EGFR kinase domain in complex with MIG6 peptide
4BGP	;	1.8	;	Crystal structure of La Crosse virus nucleoprotein
3EOT	;	1.9	;	Crystal structure of LAC031, an engineered anti-VLA1 Fab
4F7K	;	2.2	;	Crystal structure of Lac15 from a marine microbial metagenome
3KW7	;	3.44	;	Crystal structure of LacB from Trametes sp. AH28-2
2AWD	;	2.0	;	Crystal structure of LacC from Enterococcus faecalis
2F02	;	1.9	;	Crystal Structure of LacC from Enterococcus Faecalis in complex with ATP
5ANH	;	2.492	;	CRYSTAL STRUCTURE OF LACCASE FROM BASIDIOMYCETE PM1 (CECT 2971)
3SQR	;	1.67	;	Crystal structure of laccase from Botrytis aclada at 1.67 A resolution
3DIV	;	1.76	;	Crystal structure of laccase from Cerrena maxima at 1.76A resolution
2H5U	;	1.9	;	Crystal structure of laccase from Cerrena maxima at 1.9A resolution
5Z1X	;	1.38	;	Crystal Structure of Laccase from Cerrena sp. RSD1
5Z22	;	1.5	;	Crystal Structure of Laccase from Cerrena sp. RSD1
4A2H	;	2.3	;	Crystal Structure of Laccase from Coriolopsis gallica pH 7.0
2HZH	;	2.6	;	Crystal structure of laccase from Coriolus zonatus at 2.6 A resolution
3X1B	;	1.8	;	Crystal structure of laccase from Lentinus sp. at 1.8 A resolution
1GW0	;	2.4	;	Crystal Structure of Laccase from Melanocarpus albomyces in Four Copper Form
6F5K	;	1.62	;	Crystal structure of laccase from Myceliophthora thermophila
6Z0J	;	2.5	;	Crystal structure of laccase from Pediococcus acidilactici Pa5930 (Tris-HCl pH 8.5)
6Z0K	;	2.0	;	Crystal structure of laccase from Pediococcus acidilactici Pp5930 (Hepes pH 7.5)
3T6V	;	2.0	;	Crystal Structure of Laccase from Steccherinum ochraceum
2XU9	;	1.501	;	Crystal structure of Laccase from Thermus thermophilus HB27
5K0D	;	1.824	;	Crystal structure of laccase from Thermus thermophilus HB27 (Cu(II)-cyclophanes, 3 min)
5JX9	;	1.599	;	Crystal structure of laccase from Thermus thermophilus HB27 (Cu(II)-cyclophanes, 5 min)
5K15	;	1.55	;	Crystal structure of laccase from Thermus thermophilus HB27 (Cu2PO, 8 min)
5K3K	;	1.644	;	Crystal structure of laccase from Thermus thermophilus HB27 (CuSO4, 20 min)
5K84	;	1.78	;	Crystal structure of laccase from Thermus thermophilus HB27 (sodium nitrate 10 min)
5AFA	;	2.193	;	Crystal structure of Laccase from Thermus thermophilus HB27 complexed with Ag, crystal of the holoenzyme soaked for 30 m in 5 mM AgNO3 at 278 K.
4AI7	;	1.7	;	Crystal structure of Laccase from Thermus thermophilus HB27 complexed with Hg, crystal of the apoenzyme soaked for 2 h in 5 mM HgCl2 at 278 K.
2XVB	;	1.7	;	Crystal structure of Laccase from Thermus thermophilus HB27 complexed with Hg, crystal of the apoenzyme soaked for 5 min. in 5 mM HgCl2 at 278 K.
6W2K	;	2.0	;	Crystal structure of laccase from Thermus thermophilus HB27 in reducing conditions (Na2,S2,O2, 20 min)
6TYR	;	1.813	;	Crystal structure of Laccase from Thermus thermophilus HB27 with a close conformation of its beta-hairpin
6WCG	;	1.7	;	Crystal structure of Laccase from Thermus thermophilus HB27 with an open conformation of beta-hairpin (Average deposited dose 10.33 MGy)
6WCL	;	1.7	;	Crystal structure of Laccase from Thermus thermophilus HB27 with an open conformation of beta-hairpin (Average deposited dose 12.91 MGy)
6WCM	;	1.7	;	Crystal structure of Laccase from Thermus thermophilus HB27 with an open conformation of beta-hairpin (Average deposited dose 15.50 MGy)
6WCN	;	1.7	;	Crystal structure of Laccase from Thermus thermophilus HB27 with an open conformation of beta-hairpin (Average deposited dose 18.08 MGy)
6WCP	;	1.7	;	Crystal structure of Laccase from Thermus thermophilus HB27 with an open conformation of beta-hairpin (Average deposited dose 20.67 MGy)
6W9X	;	1.7	;	Crystal structure of Laccase from Thermus thermophilus HB27 with an open conformation of beta-hairpin (Average deposited dose 5.1 MGy)
6WCH	;	1.7	;	Crystal structure of Laccase from Thermus thermophilus HB27 with an open conformation of beta-hairpin (Average deposited dose 7.75 MGy)
6Q29	;	1.702	;	Crystal structure of Laccase from Thermus thermophilus HB27 with an open conformation of beta-hairpin (Average deposted dose 2.5 MGy)
5K7A	;	1.5	;	Crystal structure of laccase fron Thermus thermophilus HB27 (sodium nitrate 1.5 min)
7ZN6	;	1.9	;	Crystal structure of laccase-like multicopper oxidase (LMCO) from Thermothelomyces thermophilus
5NQ7	;	2.75	;	Crystal structure of laccases from Pycnoporus sanguineus, izoform I
5NQ8	;	2.0	;	Crystal structure of laccases from Pycnoporus sanguineus, izoform II
5NQ9	;	2.72	;	Crystal structure of laccases from Pycnoporus sanguineus, izoform II, monoclinic
5K5K	;	1.796	;	Crystal structure of laccasse from Thermus thermophilus HB27 (ascorbic acid 10 min)
5XUZ	;	2.4	;	Crystal structure of Lachnospiraceae bacterium ND2006 Cpf1 in complex with crRNA and target DNA (CCCA PAM)
5XUU	;	2.5	;	Crystal structure of Lachnospiraceae bacterium ND2006 Cpf1 in complex with crRNA and target DNA (TCCA PAM)
5XUT	;	2.4	;	Crystal structure of Lachnospiraceae bacterium ND2006 Cpf1 in complex with crRNA and target DNA (TCTA PAM)
5XUS	;	2.5	;	Crystal structure of Lachnospiraceae bacterium ND2006 Cpf1 in complex with crRNA and target DNA (TTTA PAM)
5VGL	;	1.4	;	Crystal structure of lachrymatory factor synthase from Allium cepa
5VGS	;	1.9	;	Crystal structure of lachrymatory factor synthase from Allium cepa in complex with crotyl alcohol
3GV0	;	2.35	;	Crystal structure of LacI family transcription regulator from Agrobacterium tumefaciens
3G85	;	1.84	;	Crystal structure of LacI family transcription regulator from Clostridium acetobutylicum
4RK6	;	1.76	;	Crystal structure of LacI family transcriptional regulator CCPA from Weissella paramesenteroides, Target EFI-512926, with bound glucose
4RK7	;	1.8	;	Crystal structure of LacI family transcriptional regulator CCPA from Weissella paramesenteroides, Target EFI-512926, with bound sucrose
4RKQ	;	1.903	;	Crystal structure of LacI family transcriptional regulator from Arthrobacter sp. FB24, target EFI-560007
4RKR	;	2.2	;	Crystal structure of LacI family transcriptional regulator from Arthrobacter sp. FB24, target EFI-560007, complex with lactose
4RK0	;	1.8	;	Crystal structure of LacI family transcriptional regulator from Enterococcus faecalis V583, Target EFI-512923, with bound ribose
4RK1	;	1.9	;	Crystal structure of LacI family transcriptional regulator from Enterococcus faecium, Target EFI-512930, with bound ribose
4RK4	;	1.32	;	Crystal structure of LacI family transcriptional regulator from Lactobacillus casei, Target EFI-512911, with bound glucose
4RK5	;	1.35	;	Crystal structure of LacI family transcriptional regulator from Lactobacillus casei, Target EFI-512911, with bound sucrose
6CHK	;	1.8	;	Crystal structure of LacI family transcriptional regulator from Lactobacillus casei, Target EFI-512911, with bound TRIS
3JY6	;	1.97	;	Crystal structure of LacI Transcriptional regulator from Lactobacillus brevis
3K9C	;	2.14	;	Crystal structure of LacI Transcriptional regulator from Rhodococcus species.
2ILU	;	2.7	;	Crystal structure of lactaldehyde dehydrogenase from E. coli: the binary complex with NADPH
2IMP	;	2.1	;	Crystal structure of lactaldehyde dehydrogenase from E. coli: the ternary complex with lactate (occupancy 0.5) and NADH. Crystals soaked with (L)-Lactate.
2OPX	;	2.53	;	Crystal Structure of Lactaldehyde Dehydrogenase from Escherichia coli
1RRM	;	1.6	;	Crystal Structure of Lactaldehyde reductase
1V6T	;	1.7	;	Crystal Structure of Lactam Utilization Protein from Pyrococcus horikoshii Ot3
2DFA	;	1.9	;	Crystal Structure of Lactam Utilization Protein from Thermus thermophilus HB8
5W8H	;	1.8	;	Crystal Structure of Lactate Dehydrogenase A in complex with inhibitor compound 11
5W8I	;	1.95	;	Crystal Structure of Lactate Dehydrogenase A in complex with inhibitor compound 23 and Zinc
5W8J	;	1.55	;	Crystal Structure of Lactate Dehydrogenase A in complex with inhibitor compound 29
5W8K	;	1.6	;	Crystal Structure of Lactate Dehydrogenase A in complex with inhibitor compound 29 and NADH
5W8L	;	1.95	;	Crystal Structure of Lactate Dehydrogenase A in complex with inhibitor compound 59 and NADH
2V6B	;	2.5	;	Crystal structure of lactate dehydrogenase from Deinococcus Radiodurans (apo form)
6CT6	;	1.705	;	Crystal structure of lactate dehydrogenase from Eimeria maxima with NADH and oxamate
2A92	;	2.04	;	Crystal structure of lactate dehydrogenase from Plasmodium vivax: complex with NADH
7NAY	;	1.84	;	Crystal structure of lactate dehydrogenase from Selenomonas ruminantium with NADH.
3D0O	;	1.8	;	Crystal structure of Lactate Dehydrogenase from Staphylococcus Aureus
3D4P	;	1.8	;	Crystal structure of Lactate Dehydrogenase from Staphylococcus Aureus complexed with NAD and pyruvate
2V6M	;	2.2	;	Crystal structure of lactate dehydrogenase from Thermus Thermophilus HB8 (Apo form)
2V7P	;	2.1	;	Crystal structure of lactate dehydrogenase from Thermus Thermophilus HB8 (Holo form)
3H3J	;	1.8	;	Crystal structure of lactate dehydrogenase mutant (A85R) from staphylococcus aureus complexed with NAD and pyruvate
3GVH	;	2.3	;	Crystal structure of Lactate/malate dehydrogenase from Brucella melitensis
3GVI	;	2.25	;	Crystal structure of Lactate/malate dehydrogenase from Brucella melitensis in complex with ADP
4U4R	;	2.801	;	Crystal structure of Lactimidomycin bound to the yeast 80S ribosome
8IE2	;	3.6	;	Crystal structure of Lactiplantibacillus plantarum GlyRS
7V6I	;	2.51	;	Crystal structure of lacto-N-biosidase BsaX from Bifidobacterium saguini, lacto-N-biose complex
4JAW	;	1.8	;	Crystal Structure of Lacto-N-Biosidase from Bifidobacterium bifidum complexed with LNB-thiazoline
5GQG	;	2.7	;	Crystal structure of lacto-N-biosidase LnbX from Bifidobacterium longum subsp. longum, galacto-N-biose complex
5GQF	;	1.82	;	Crystal structure of lacto-N-biosidase LnbX from Bifidobacterium longum subsp. longum, lacto-N-biose complex
5GQC	;	2.36	;	Crystal structure of lacto-N-biosidase LnbX from Bifidobacterium longum subsp. longum, ligand-free form
8HVC	;	1.58	;	Crystal structure of lacto-N-biosidase StrLNBase from Streptomyces sp. strain 142, galacto-N-biose complex 1
8HVD	;	1.41	;	Crystal structure of lacto-N-biosidase StrLNBase from Streptomyces sp. strain 142, galacto-N-biose complex 2
8HVB	;	1.6	;	Crystal structure of lacto-N-biosidase StrLNBase from Streptomyces sp. strain 142, lacto-N-biose complex
7V6M	;	1.92	;	Crystal structure of lacto-N-biosidase TnX from Tynzenella nexilis, lacto-N-biose complex
6L9I	;	2.79	;	Crystal Structure of Lactobacillus farciminis Oxalate Decarboxylase Formate Complex
4MEJ	;	2.1	;	Crystal structure of Lactobacillus helveticus purine deoxyribosyl transferase (PDT) with the tricyclic purine 8,9-dihydro-9-oxoimidazo[2,1-b]purine (N2,3-ethenoguanine)
4AMC	;	3.6	;	Crystal structure of Lactobacillus reuteri 121 N-terminally truncated glucansucrase GTFA
3KLK	;	1.65	;	Crystal structure of Lactobacillus reuteri N-terminally truncated glucansucrase GTF180 in triclinic apo- form
3KLL	;	2.0	;	Crystal structure of Lactobacillus reuteri N-terminally truncated glucansucrase GTF180-maltose complex
7VGK	;	3.1	;	Crystal structure of Lactobacillus rhamnosus 4-deoxy-L-threo-5-hexosulose-uronate ketol-isomerase KduI
7E4S	;	2.79	;	Crystal structure of Lactobacillus rhamnosus 4-deoxy-L-threo-5-hexosulose-uronate ketol-isomerase KduI complexed with HEPES
7YE3	;	2.553	;	Crystal structure of Lactobacillus rhamnosus 4-deoxy-L-threo-5-hexosulose-uronate ketol-isomerase KduI complexed with MES
7YRS	;	2.802	;	Crystal structure of Lactobacillus rhamnosus 4-deoxy-L-threo-5-hexosulose-uronate ketol-isomerase KduI complexed with MOPS
8JQ6	;	1.71	;	Crystal structure of Lactobacillus rhamnosus L-rhamnose isomerase in complex with D-allose
8JQ5	;	1.73	;	Crystal structure of Lactobacillus rhamnosus L-rhamnose isomerase in complex with D-allulose
8JQ4	;	1.61	;	Crystal structure of Lactobacillus rhamnosus L-rhamnose isomerase in complex with L-rhamnose
3DRI	;	1.8	;	Crystal structure of Lactococcal OppA co-crystallized with an octamer peptide in an open conformation
3DRH	;	1.7	;	Crystal structure of Lactococcal OppA co-crystallized with Leu-enkephalin in an open conformation
3DRK	;	1.8	;	Crystal structure of Lactococcal OppA co-crystallized with Neuropeptide S in an open conformation
3DRJ	;	1.5	;	Crystal structure of Lactococcal OppA co-crystallized with pTH-related peptide in an open conformation
3L6H	;	2.3	;	Crystal structure of lactococcal OpuAC in its closed-liganded conformation complexed with glycine betaine
3L6G	;	1.9	;	Crystal structure of lactococcal OpuAC in its open conformation
4EEX	;	2.2	;	Crystal Structure of Lactococcus lactis Alcohol Dehydrogenase
4EEZ	;	1.9	;	Crystal Structure of Lactococcus lactis Alcohol Dehydrogenase variant RE1
1EP1	;	2.2	;	CRYSTAL STRUCTURE OF LACTOCOCCUS LACTIS DIHYDROOROTATE DEHYDROGENASE B
1EP2	;	2.4	;	CRYSTAL STRUCTURE OF LACTOCOCCUS LACTIS DIHYDROOROTATE DEHYDROGENASE B COMPLEXED WITH OROTATE
1EP3	;	2.1	;	CRYSTAL STRUCTURE OF LACTOCOCCUS LACTIS DIHYDROOROTATE DEHYDROGENASE B. DATA COLLECTED UNDER CRYOGENIC CONDITIONS.
1KFV	;	2.55	;	Crystal Structure of Lactococcus lactis Formamido-pyrimidine DNA Glycosylase (alias Fpg or MutM) Non Covalently Bound to an AP Site Containing DNA.
1PIE	;	2.1	;	Crystal Structure of Lactococcus lactis Galactokinase Complexed with Galactose
4KQP	;	0.95	;	Crystal structure of Lactococcus lactis GlnP substrate binding domain 2 (SBD2) in complex with glutamine at 0.95 A resolution
4KR5	;	1.5	;	Crystal structure of Lactococcus lactis GlnP substrate binding domain 2 (SBD2) in open conformation
5VYW	;	3.1	;	Crystal structure of Lactococcus lactis pyruvate carboxylase
5VZ0	;	2.0	;	Crystal structure of Lactococcus lactis pyruvate carboxylase G746A mutant in complex with cyclic-di-AMP
5VYZ	;	2.3	;	Crystal structure of Lactococcus lactis pyruvate carboxylase in complex with cyclic-di-AMP
7WJB	;	2.0	;	Crystal structure of Lactococcus lactis subsp. cremoris GH31 alpha-1,3-glucosidase in complex with glucose
7WJF	;	1.8	;	Crystal structure of Lactococcus lactis subsp. cremoris GH31 alpha-1,3-glucosidase mutant D394A in complex with kojibiose
7WJC	;	1.75	;	Crystal structure of Lactococcus lactis subsp. cremoris GH31 alpha-1,3-glucosidase mutant D394A in complex with nigerose
7WJE	;	1.8	;	Crystal structure of Lactococcus lactis subsp. cremoris GH31 alpha-1,3-glucosidase mutant D394A in complex with nigerotetraose
7WJD	;	1.8	;	Crystal structure of Lactococcus lactis subsp. cremoris GH31 alpha-1,3-glucosidase mutant D394A in complex with nigerotriose
7WJ9	;	1.75	;	Crystal structure of Lactococcus lactis subsp. cremoris GH31 alpha-1,3-glucosidase, P21 space group
7WJA	;	1.85	;	Crystal structure of Lactococcus lactis subsp. cremoris GH31 alpha-1,3-glucosidase, P6322 space group
5MJK	;	2.0	;	Crystal Structure of Lactococcus lactis Thioredoxin Reductase (FO conformation)
5MH4	;	2.14	;	Crystal Structure of Lactococcus lactis Thioredoxin Reductase (FR conformation)
5MIR	;	2.0	;	Crystal Structure of Lactococcus lactis Thioredoxin Reductase Exposed to Visible Light (120 min)
5MIS	;	1.81	;	Crystal Structure of Lactococcus lactis Thioredoxin Reductase Exposed to Visible Light (180 min)
5MIT	;	1.8	;	Crystal Structure of Lactococcus lactis Thioredoxin Reductase Exposed to Visible Light (240 min)
5MIP	;	2.0	;	Crystal Structure of Lactococcus lactis Thioredoxin Reductase Exposed to Visible Light (30 min)
5MIQ	;	1.92	;	Crystal Structure of Lactococcus lactis Thioredoxin Reductase Exposed to Visible Light (60 min)
2R5L	;	2.4	;	Crystal structure of lactoperoxidase at 2.4A resolution
3FAQ	;	2.7	;	Crystal structure of lactoperoxidase complex with cyanide
1PV6	;	3.5	;	Crystal structure of lactose permease
1PV7	;	3.6	;	Crystal structure of lactose permease with TDG
1NHE	;	2.5	;	Crystal structure of Lactose synthase complex with UDP
1NKH	;	2.0	;	Crystal structure of Lactose synthase complex with UDP and Manganese
1O23	;	2.32	;	CRYSTAL STRUCTURE OF LACTOSE SYNTHASE IN THE PRESENCE OF UDP-GLUCOSE
1NQI	;	2.0	;	crystal structure of lactose synthase, a 1:1 complex between beta1,4-galactosyltransferase and alpha-lactalbumin in the presence of GlcNAc
1NF5	;	2.0	;	Crystal Structure of Lactose Synthase, Complex with Glucose
3R4Q	;	2.51	;	Crystal structure of Lactoylglutathione lyase from Agrobacterium tumefaciens
2Y5Y	;	3.38	;	Crystal structure of LacY in complex with an affinity inactivator
5JD3	;	2.3	;	Crystal structure of LAE5, an alpha/beta hydrolase enzyme from the metagenome of Lake Arreo, Spain
5JD4	;	2.05	;	Crystal structure of LAE6 Ser161Ala mutant, an alpha/beta hydrolase enzyme from the metagenome of Lake Arreo, Spain
7SAH	;	1.6	;	Crystal Structure of LaG16 Nanobody bound to eGFP
7SAI	;	2.23	;	Crystal Structure of Lag30 Nanobody bound to eGFP
4Z1X	;	2.8	;	Crystal structure of LAGLIDADG homing endonuclease I-GzeII in complex with DNA target
4YIT	;	3.24	;	Crystal Structure of LAGLIDADG Meganuclease I-AabMI Bound to Uncleaved DNA
4YIS	;	2.89	;	Crystal Structure of LAGLIDADG Meganuclease I-CpaMI Bound to Uncleaved DNA
4YHX	;	2.15	;	Crystal Structure of LAGLIDADG Meganuclease I-GpeMI Bound to Uncleaved DNA
5ESP	;	2.995	;	Crystal Structure of LAGLIDADG Meganuclease I-PanMI with coordinated Calcium ions
7JZK	;	2.457	;	Crystal structure of LAIR1 ectodomain (from MGD21) in complex with Plasmodium RIFIN (PF3D7_0401300) V2 domain
7JZI	;	2.707	;	Crystal structure of LAIR1 ectodomain (from MGD21) in complex with Plasmodium RIFIN (PF3D7_1040300) V2 domain
7SAJ	;	2.37	;	Crystal Structure of LaM2 Nanobody bound to mCherry
7SAK	;	1.15	;	Crystal Structure of LaM4 Nanobody bound to mCherry
7SAL	;	1.93	;	Crystal Structure of LaM6 Nanobody bound to mCherry
4BOW	;	1.35	;	Crystal structure of LamA_E269S from Z. galactanivorans in complex with laminaritriose and laminaritetraose
4BPZ	;	1.13	;	Crystal structure of lamA_E269S from Zobellia galactanivorans in complex with a trisaccharide of 1,3-1,4-beta-D-glucan.
3SLP	;	2.3	;	Crystal Structure of Lambda Exonuclease in Complex with a 12 BP Symmetric DNA Duplex
4WUZ	;	2.38	;	Crystal structure of lambda exonuclease in complex with DNA and Ca2+
6M9K	;	2.3	;	Crystal structure of lambda exonuclease in complex with the Red beta C-terminal domain
5ZCA	;	1.801	;	Crystal structure of lambda repressor (1-20) fused with maltose-binding protein
3WOA	;	2.0	;	Crystal structure of lambda repressor (1-45) fused with maltose-binding protein
6CRO	;	3.0	;	CRYSTAL STRUCTURE OF LAMBDA-CRO BOUND TO A CONSENSUS OPERATOR AT 3.0 ANGSTROM RESOLUTION
6SNZ	;	2.6	;	Crystal structure of lamin A coil1b tetramer
6JLB	;	3.205	;	Crystal structure of lamin A/C fragment and assembly mechanisms of intermediate filaments
7DTG	;	3.6	;	Crystal structure of lamin B1 Ig-like domain from human
3UMN	;	2.0	;	Crystal Structure of Lamin-B1
5WUT	;	1.6	;	Crystal structure of laminarinase from Flavobacterium sp. UMI-01
3GD0	;	1.62	;	Crystal structure of laminaripentaose-producing beta-1,3-glucanase
3GD9	;	1.8	;	Crystal structure of laminaripentaose-producing beta-1,3-glucanase in complex with laminaritetraose
5LF2	;	1.85	;	Crystal structure of laminin beta2 LE5-LF-LE6
8ATH	;	2.366	;	CRYSTAL STRUCTURE OF LAMP1 IN COMPLEX WITH FAB-B.
4PO4	;	2.5	;	Crystal Structure of Lampetra planeri VLRC
5ZU4	;	2.39	;	Crystal structure of Lamprey immune protein
6IUL	;	2.25	;	Crystal structure of Lamprey immune protein
2R9U	;	2.1	;	Crystal Structure of Lamprey Variable Lymphocyte Receptor 2913 Ectodomain
8YNJ	;	2.48	;	Crystal structure of Langat virus helicase
5G6U	;	1.844	;	Crystal structure of langerin carbohydrate recognition domain with GlcNS6S
8K80	;	3.37	;	Crystal structure of Langya Virus attachment (G) glycoprotein
5EQB	;	2.19	;	Crystal structure of lanosterol 14-alpha demethylase with intact transmembrane domain bound to itraconazole
6ZCV	;	1.7	;	Crystal structure of lanthanide-dependent alcohol dehydrogenase PedH from Pseudomonas putida KT2440
6ZCW	;	1.65	;	Crystal structure of lanthanide-dependent alcohol dehydrogenase PedH from Pseudomonas putida KT2440
6DAM	;	1.85	;	Crystal structure of lanthanide-dependent methanol dehydrogenase XoxF from Methylomicrobium buryatense 5G
6IP9	;	1.85	;	Crystal Structure of Lanthanum ion (La3+) bound bovine alpha-lactalbumin
3NXS	;	2.3	;	Crystal structure of LAO/AO transport system from Mycobacterium smegmatis bound to GDP
2P67	;	1.8	;	Crystal structure of LAO/AO transport system kinase
5GNE	;	2.5	;	Crystal structure of LapB from Legionella pneumophila
4Q7R	;	1.4	;	Crystal structure of large Stokes shift fluorescent protein LSSmOrange
8DHU	;	2.295	;	Crystal structure of LARP-DM15 from Drosophila melanogaster bound to m7GpppC
8DIO	;	2.3	;	Crystal structure of LARP1-DM15 from Danio rerio bound to m7GpppC
4ZC4	;	1.86	;	Crystal structure of LARP1-unique domain DM15
5V7C	;	2.59	;	Crystal structure of LARP1-unique domain DM15 bound 5'TOP RNA sequence
5V87	;	1.692	;	Crystal structure of LARP1-unique domain DM15 bound to m7GpppC
5V4R	;	1.77	;	Crystal structure of LARP1-unique domain DM15 bound to m7GTP
4NG2	;	2.413	;	Crystal structure of LasR LBD-QslA complex from Pseudomonas aeruginosa
6V7W	;	3.0	;	Crystal structure of LasR-Aqs1 complex from Pseudomonas aeruginosa
3MWT	;	1.982	;	Crystal structure of Lassa fever virus nucleoprotein in complex with Mn2+
8GQ9	;	2.3	;	Crystal structure of lasso peptide epimerase MslH
8GQB	;	2.41	;	Crystal structure of lasso peptide epimerase MslH D11A mutant
8ITH	;	2.55	;	Crystal structure of lasso peptide epimerase MslH H295N
8GQA	;	2.29	;	Crystal structure of lasso peptide epimerase MslH in complexed with precursor peptide analog MslAdeltaW21
8ITG	;	2.25	;	Crystal structure of lasso peptide epimerase MslH in complexed with precursor peptide variant MslAW21G
6JGY	;	3.389	;	Crystal structure of LASV-GP2 in a post fusion conformation
6P7J	;	3.501	;	Crystal structure of Latency Associated Peptide unbound to TGF-beta1
2OAY	;	2.35	;	Crystal structure of latent human C1-inhibitor
4KDS	;	1.6682	;	Crystal structure of latent rainbow trout plasminogen activator inhibitor 1 (PAI-1)
4OZK	;	2.038	;	Crystal structure of Laterosporulin, a broad spectrum leaderless bacteriocin produced by Brevibacillus laterosporus strain GI-9
6LWZ	;	2.2	;	Crystal structure of Laterosporulin10, bacteriocin produced by Brevibacillus sp. strain SKDU10
6LWY	;	2.3	;	Crystal structure of Laterosporulin3, bacteriocin produced by Brevibacillus sp. strain SKR3
5HC6	;	2.15	;	Crystal structure of lavandulyl diphosphate synthase from Lavandula x intermedia in apo form
5HC8	;	1.87	;	Crystal structure of lavandulyl diphosphate synthase from Lavandula x intermedia in complex with dimethylallyl diphosphate
5HC7	;	2.05	;	Crystal structure of lavandulyl diphosphate synthase from Lavandula x intermedia in complex with S-thiolo-isopentenyldiphosphate
5W1I	;	2.2	;	Crystal structure of LbaCas13a (C2c2) bound to mature crRNA (20-nt spacer)
5W1H	;	1.99	;	Crystal structure of LbaCas13a (C2c2) bound to mature crRNA (24-nt spacer)
5WLH	;	1.80001	;	Crystal structure of LbaCas13a H328A (C2c2) bound to pre-crRNA (24-nt spacer)
7RQF	;	3.5	;	Crystal Structure of LbcA (lipoprotein binding partner of CtpA) of Pseudomonas aeruginosa
8ODW	;	3.07	;	Crystal structure of LbmA Ox-ACP didomain in complex with NADP and ethyl glycinate from the lobatamide PKS (Gynuella sunshinyii)
5XWP	;	3.086	;	Crystal structure of LbuCas13a-crRNA-target RNA ternary complex
7M1H	;	2.78	;	Crystal structure of LC/A-JPU-C10-JPU-D12-JPU-B8-JPU-G3-ciA-F12-ciA-D12
4H8K	;	2.3	;	Crystal structure of LC11-RNase H1 in complex with RNA/DNA hybrid
1UGM	;	2.05	;	Crystal Structure of LC3
4ZDV	;	1.8	;	Crystal structure of LC3 in complex with FAM134B LIR
5DCN	;	2.0	;	Crystal structure of LC3 in complex with TECPR2 LIR
5D94	;	1.53	;	Crystal structure of LC3-LIR peptide complex
2ZJD	;	1.56	;	Crystal Structure of LC3-p62 complex
8T2L	;	2.24	;	Crystal structure of LC3A in complex with the LIR of NSs4
5WRD	;	1.9	;	Crystal structure of LC3B in complex with FYCO1 LIR
3BRL	;	1.9	;	Crystal Structure of LC8 S88E / Swa
4IBN	;	1.62	;	Crystal structure of LC9-RNase H1, a type 1 RNase H with the type 2 active-site motif
4XWG	;	2.65	;	Crystal Structure of LCAT (C31Y) in complex with Fab1
1IJR	;	2.2	;	Crystal structure of LCK SH2 complexed with nonpeptide phosphotyrosine mimetic
1X27	;	2.7	;	Crystal Structure of Lck SH2-SH3 with SH2 binding site of p130Cas
4JMN	;	2.2	;	Crystal structure of LD transpeptidase LdtMt1 from M. tuberculosis
8D5N	;	1.8	;	Crystal structure of Ld-HF10
6BYA	;	2.26	;	Crystal structure of LdBPK_091320 with inhibitor bound
6Q0D	;	2.05	;	CRYSTAL STRUCTURE OF LDHA IN COMPLEX WITH COMPOUND NCGC00384414-01 AT 2.05 A RESOLUTION
6Q13	;	2.0	;	CRYSTAL STRUCTURE OF LDHA IN COMPLEX WITH COMPOUND NCGC00420737-09 AT 2.00 A RESOLUTION
6BOI	;	2.102	;	Crystal Structure of LdtMt2 (56-408) with a panipenem adduct at the active site cysteine-354
5DU7	;	1.79	;	Crystal structure of ldtMt2 at 1.79 Angstrom resolution
6RLG	;	1.51	;	Crystal structure of LdtMt2 from Mycobacterium tuberculosis
6RRM	;	1.64	;	Crystal structure of LdtMt2 from Mycobacterium tuberculosis bound to Ebselen
5DUJ	;	2.17	;	Crystal structure of ldtMt2 in complex with Faropenem adduct
4HU2	;	1.46	;	Crystal structure of LdtMt2, a L,D-transpeptidase from Mycobacterium tuberculosis: domain A and B
4HUC	;	1.86	;	Crystal structure of LdtMt2, a L,D-transpeptidase from Mycobacterium tuberculosis: domain B and C
4EB0	;	1.5	;	Crystal structure of Leaf-branch compost bacterial cutinase homolog
4CPB	;	1.57	;	CRYSTAL STRUCTURE OF LECA IN COMPLEX WITH A DIVALENT GALACTOSIDE AT 1. 57 ANGSTROM IN MAGNESIUM
4CP9	;	1.65	;	Crystal structure OF lecA lectin complexed with a divalent galactoside at 1.65 angstrom
5TXF	;	3.1	;	Crystal structure of Lecithin:cholesterol acyltransferase (LCAT) in a closed conformation
6MVD	;	3.1	;	Crystal structure of Lecithin:cholesterol acyltransferase (LCAT) in complex with isopropyl dodec-11-enylfluorophosphonate (IDFP) and a small molecule activator
6AOW	;	1.6	;	Crystal structure of lectin domain of F9 pilus adhesin FmlH from E. coli UTI89
7LJG	;	2.21	;	Crystal Structure of Lectin from Dioclea altissima
6CJ9	;	1.7	;	Crystal structure of lectin from Dioclea lasiophylla seeds (DlyL) complexed with X-Man
6LIK	;	2.4	;	Crystal Structure of Lectin from Pleurotus ostreatus in complex with Galactose
6LI7	;	2.098	;	Crystal Structure of Lectin from Pleurotus ostreatus in complex with GalNAc
6KBQ	;	2.299	;	Crystal Structure of Lectin from Pleurotus ostreatus in complex with Glycerol
6KC2	;	2.246	;	Crystal Structure of Lectin from Pleurotus ostreatus in complex with Rhamnose
6TLA	;	2.16	;	CRYSTAL STRUCTURE OF LECTIN-LIKE OX-LDL RECEPTOR 1 (C 1 2 1)
6TL7	;	1.11	;	CRYSTAL STRUCTURE OF LECTIN-LIKE OX-LDL RECEPTOR 1 (P212121)
6TL9	;	2.734	;	CRYSTAL STRUCTURE OF LECTIN-LIKE OX-LDL RECEPTOR 1 IN COMPLEX WITH BI-0115
1I8N	;	2.2	;	CRYSTAL STRUCTURE OF LEECH ANTI-PLATELET PROTEIN
7EYO	;	1.85	;	Crystal structure of leech hyaluronidase
2DFL	;	2.9	;	Crystal structure of left-handed RadA filament
2ZUC	;	3.3	;	Crystal structure of left-handed RadA filament
2ZUD	;	3.2	;	Crystal Structure of Left-handed RadA Filament
5CZY	;	2.2	;	Crystal structure of LegAS4
8SWI	;	3.0	;	Crystal structure of legAS4 from Legionella pneumophila subsp. pneumophila with histone H3 (1-12)peptide
8SR6	;	2.22	;	Crystal structure of legAS4 from Legionella pneumophila subsp. pneumophila with histone H3 (3-17)peptide
6B7Q	;	2.2	;	Crystal structure of Legionella effector protein sdeA (lpg2157) aa. 211-910
6B7P	;	1.51	;	Crystal structure of Legionella effector sdeD (lpg2509)
6B7O	;	1.85	;	Crystal structure of Legionella effector sdeD (lpg2509) H67A in complex with ADP-ribosylated Ubiquitin
6B7M	;	1.7	;	Crystal structure of Legionella effector sdeD (lpg2509) in complex with Ubiquitin
5ZI5	;	2.6	;	Crystal structure of Legionella pneumophila aminopeptidase A
5ZIE	;	2.0	;	Crystal structure of Legionella pneumophila aminopeptidase A in complex with aspartic acid
5ZI7	;	1.86	;	Crystal structure of Legionella pneumophila aminopeptidase A in complex with glutamic acid
4TTP	;	2.2	;	Crystal structure of Legionella pneumophila dephospho-CoA kinase in apo-form
4TTQ	;	2.2	;	Crystal structure of Legionella pneumophila dephospho-CoA kinase in complex with ATP
4TTR	;	2.1	;	Crystal structure of Legionella pneumophila dephospho-CoA kinase in complex with Bu2
6KS5	;	2.8	;	Crystal structure of Legionella pneumophila deubiquitinase Ceg23
5VRQ	;	3.205	;	Crystal structure of Legionella pneumophila effector AnkC
6AOK	;	1.88	;	Crystal structure of Legionella pneumophila effector Ceg4 with N-terminal TEV protease cleavage sequence
6AOJ	;	1.902	;	Crystal structure of Legionella pneumophila effector Ceg4 with N-terminal yeast Hog1p sequence
5WD8	;	1.944	;	Crystal structure of Legionella pneumophila effector lpg2328
5WD9	;	1.4	;	Crystal structure of Legionella pneumophila effector lpg2328
7WBK	;	2.74	;	Crystal structure of Legionella pneumophila effector protein Lpg0081
7WBM	;	2.7	;	Crystal structure of Legionella pneumophila effector protein Lpg0081
4KUN	;	1.95	;	Crystal structure of Legionella pneumophila Lpp1115 / KaiB
8DMP	;	2.17	;	Crystal structure of Legionella pneumophila macrodomain effector MavL
8DMQ	;	2.195	;	Crystal structure of Legionella pneumophila macrodomain MavL in complex with ubiquitin vinyl methyl ester
8DMS	;	2.15	;	Crystal structure of Legionella pneumophila macrodomain MavL in complex with ubiquitin vinyl methyl ester soaked with ADP-ribose
4C7P	;	3.1	;	Crystal structure of Legionella pneumophila RalF F255K mutant
4Q63	;	1.953	;	Crystal Structure of Legionella Uncharacterized Protein Lpg0364
5CKW	;	2.49	;	Crystal structure of LegK4_AMPPNP Kinase
5CLR	;	3.706	;	Crystal structure of LegK4_APO Kinase
6EDI	;	1.85	;	Crystal structure of Leishmania braziliensis glucokinase
8C79	;	3.1	;	Crystal structure of Leishmania donovani 6-Phosphogluconate Dehydrogenase complexed with NADPH
4P4P	;	2.2973	;	Crystal structure of Leishmania infantum polymerase beta: Nick complex
4P4O	;	2.3001	;	Crystal structure of Leishmania infantum polymerase beta: Ternary gap complex
4P4M	;	1.9185	;	Crystal structure of Leishmania infantum polymerase beta: Ternary P/T complex
4ADW	;	3.61	;	CRYSTAL STRUCTURE OF LEISHMANIA INFANTUM TRYPANOTHIONE REDUCTASE IN COMPLEX WITH NADPH AND TRYPANOTHIONE
2X77	;	2.1	;	Crystal Structure of Leishmania major ADP ribosylation factor-like 1.
3TQ0	;	1.9	;	Crystal structure of Leishmania major dihydroorotate dehydrogenase in complex with fumarate
3TRO	;	1.86	;	Crystal Structure of Leishmania major dihydroorotate dehydrogenase mutant D171A
3TJX	;	1.64	;	Crystal Structure of Leishmania major dihydroorotate dehydrogenase mutant H174A
6EBS	;	2.05	;	Crystal structure of Leishmania major dihydroorotate dehydrogenase mutant H174A in complex with orotate
6DWG	;	1.9	;	Crystal structure of Leishmania major dihydroorotate dehydrogenase mutant Q139A
6DGS	;	1.75	;	Crystal Structure of Leishmania major dihydroorotate dehydrogenase mutant Y142A
5OEZ	;	2.41	;	Crystal structure of Leishmania major fructose-1,6-bisphosphatase in apo form.
5OEY	;	2.8	;	Crystal structure of Leishmania major fructose-1,6-bisphosphatase in holo form.
5OFU	;	2.62	;	Crystal structure of Leishmania major fructose-1,6-bisphosphatase in T-state.
3FWU	;	1.8	;	Crystal structure of Leishmania major MIF1
3FWT	;	1.9	;	Crystal structure of Leishmania major MIF2
5AG7	;	2.6	;	CRYSTAL STRUCTURE OF LEISHMANIA MAJOR N-MYRISTOYLTRANSFERASE (NMT) WITH BOUND MYRISTOYL-COA AND A BENZOMORPHOLINE LIGAND
5AGE	;	2.0	;	CRYSTAL STRUCTURE OF LEISHMANIA MAJOR N-MYRISTOYLTRANSFERASE (NMT) WITH BOUND MYRISTOYL-COA AND A BENZOMORPHOLINONE LIGAND
4UCM	;	2.32	;	CRYSTAL STRUCTURE OF LEISHMANIA MAJOR N-MYRISTOYLTRANSFERASE (NMT) WITH BOUND MYRISTOYL-COA AND A FRAGMENT
4UCN	;	1.8	;	CRYSTAL STRUCTURE OF LEISHMANIA MAJOR N-MYRISTOYLTRANSFERASE (NMT) WITH BOUND MYRISTOYL-COA AND A FRAGMENT
4UCP	;	1.5	;	CRYSTAL STRUCTURE OF LEISHMANIA MAJOR N-MYRISTOYLTRANSFERASE (NMT) WITH BOUND MYRISTOYL-COA AND A FRAGMENT
6GNV	;	2.2	;	Crystal Structure of Leishmania major N-Myristoyltransferase (NMT) With Bound Myristoyl-CoA and a isopropyl methyl indole aryl sulphonamide ligand
4A2Z	;	2.31	;	CRYSTAL STRUCTURE OF LEISHMANIA MAJOR N-MYRISTOYLTRANSFERASE (NMT) WITH BOUND MYRISTOYL-COA AND A PYRAZOLE SULPHONAMIDE LIGAND
4A30	;	1.5	;	CRYSTAL STRUCTURE OF LEISHMANIA MAJOR N-MYRISTOYLTRANSFERASE (NMT) WITH BOUND MYRISTOYL-COA AND A PYRAZOLE SULPHONAMIDE LIGAND
4A31	;	2.09	;	CRYSTAL STRUCTURE OF LEISHMANIA MAJOR N-MYRISTOYLTRANSFERASE (NMT) WITH BOUND MYRISTOYL-COA AND A PYRAZOLE SULPHONAMIDE LIGAND
4A32	;	2.2	;	CRYSTAL STRUCTURE OF LEISHMANIA MAJOR N-MYRISTOYLTRANSFERASE (NMT) WITH BOUND MYRISTOYL-COA AND A PYRAZOLE SULPHONAMIDE LIGAND
4A33	;	2.4	;	CRYSTAL STRUCTURE OF LEISHMANIA MAJOR N-MYRISTOYLTRANSFERASE (NMT) WITH BOUND MYRISTOYL-COA AND A PYRAZOLE SULPHONAMIDE LIGAND
2WSA	;	1.6	;	Crystal Structure of Leishmania major N-myristoyltransferase (NMT) with bound myristoyl-CoA and a pyrazole sulphonamide ligand (DDD85646)
6GNT	;	1.6	;	Crystal Structure of Leishmania major N-Myristoyltransferase (NMT) With Bound Myristoyl-CoA and a Quionlinyl aryl sulphonamide ligand
6GNU	;	1.54	;	Crystal Structure of Leishmania major N-Myristoyltransferase (NMT) With Bound Myristoyl-CoA and a Quionlinyl aryl sulphonamide ligand
5AG4	;	1.99	;	CRYSTAL STRUCTURE OF LEISHMANIA MAJOR N-MYRISTOYLTRANSFERASE (NMT) WITH BOUND MYRISTOYL-COA AND A THIAZOLIDINONE LIGAND
5AG5	;	2.0	;	CRYSTAL STRUCTURE OF LEISHMANIA MAJOR N-MYRISTOYLTRANSFERASE (NMT) WITH BOUND MYRISTOYL-COA AND A THIAZOLIDINONE LIGAND
5AG6	;	2.0	;	CRYSTAL STRUCTURE OF LEISHMANIA MAJOR N-MYRISTOYLTRANSFERASE (NMT) WITH BOUND MYRISTOYL-COA AND A THIAZOLIDINONE LIGAND
6GNH	;	1.89	;	Crystal Structure of Leishmania major N-Myristoyltransferase (NMT) With Bound Myristoyl-CoA and an Azepanyl Phenyl Benzylsulphonamide Ligand
6GNS	;	1.8	;	Crystal Structure of Leishmania major N-Myristoyltransferase (NMT) With Bound Myristoyl-CoA and an Azepanyl Phenyl Benzylsulphonamide Ligand
3H5Z	;	1.49	;	Crystal Structure of Leishmania major N-myristoyltransferase with bound myristoyl-CoA
5XIL	;	1.9	;	Crystal Structure of Leishmania major Prolyl-tRNA Synthetase (LmPRS)
3G1U	;	2.2	;	Crystal structure of Leishmania major S-adenosylhomocysteine hydrolase
4ITY	;	1.8	;	Crystal structure of Leishmania mexicana arginase
4IU5	;	1.95	;	Crystal structure of Leishmania mexicana arginase in complex with catalytic product L-ornithine
4IU0	;	1.77	;	Crystal structure of Leishmania mexicana arginase in complex with inhibitor ABH
5HJA	;	1.65	;	Crystal structure of Leishmania mexicana arginase in complex with inhibitor ABHDP
5HJ9	;	1.28	;	Crystal structure of Leishmania mexicana arginase in complex with inhibitor ABHPE
4IU4	;	1.8	;	Crystal structure of Leishmania mexicana arginase in complex with inhibitor BEC
4IU1	;	1.95	;	Crystal structure of Leishmania mexicana arginase in complex with inhibitor nor-NOHA
1EVY	;	1.75	;	CRYSTAL STRUCTURE OF LEISHMANIA MEXICANA GLYCEROL-3-PHOSPHATE DEHYDROGENASE
1N1E	;	1.9	;	Crystal structure of Leishmania mexicana Glycerol-3-phosphate dehydrogenase complexed with DHAP and NAD
1JDJ	;	2.2	;	CRYSTAL STRUCTURE OF LEISHMANIA MEXICANA GLYCEROL-3-PHOSPHATE DEHYDROGENASE IN COMPLEX WITH 2-FLUORO-6-CHLOROPURINE
1EVZ	;	2.8	;	CRYSTAL STRUCTURE OF LEISHMANIA MEXICANA GLYCEROL-3-PHOSPHATE DEHYDROGENASE IN COMPLEX WITH NAD
1N1G	;	2.5	;	Crystal structure of Leishmania mexicana Glycerol-3-phosphate dehydrogenase with inhibitor BCP
1M66	;	1.9	;	Crystal Structure of Leishmania mexicana GPDH Complexed with Inhibitor 2-bromo-6-chloro-purine
1M67	;	2.5	;	Crystal Structure of Leishmania mexicana GPDH Complexed with Inhibitor 2-bromo-6-hydroxy-purine
3HQP	;	2.3	;	Crystal structure of Leishmania mexicana pyruvate kinase (LmPYK) in complex with ATP, Oxalate and fructose 2,6 bisphosphate
3HQQ	;	5.07	;	Crystal structure of Leishmania mexicana pyruvate kinase (LmPYK) in complex with Fructose 2,6 bisphosphate
3IS4	;	2.1	;	Crystal structure of Leishmania mexicana pyruvate kinase (LmPYK)in complex with 1,3,6,8-pyrenetetrasulfonic acid
3KTX	;	2.1	;	Crystal structure of Leishmania mexicana pyruvate kinase (LmPYK)in complex with 1,3,6,8-pyrenetetrasulfonic acid
3PP7	;	2.35	;	Crystal structure of Leishmania mexicana pyruvate kinase in complex with the drug suramin, an inhibitor of glycolysis.
3QV6	;	2.85	;	Crystal structure of Leishmania mexicana pyruvate kinase(LmPYK)in complex with acid blue 80.
3QV8	;	2.45	;	Crystal structure of Leishmania mexicana pyruvate kinase(LmPYK)in complex with benzothiazole-2,5-disulfonic acid.
3QV7	;	2.7	;	Crystal structure of Leishmania mexicana pyruvate kinase(LmPYK)in complex with ponceau S and acid blue 25.
3NGR	;	2.95	;	Crystal structure of Leishmania nucleoside diphosphate kinase b with unordered nucleotide-binding loop.
2Y63	;	1.97	;	Crystal structure of Leishmanial E65Q-TIM complexed with Bromohydroxyacetone phosphate
2Y62	;	1.08	;	Crystal structure of Leishmanial E65Q-TIM complexed with R-Glycidol phosphate
2Y61	;	0.99	;	Crystal structure of Leishmanial E65Q-TIM complexed with S-Glycidol phosphate
7U1H	;	2.5	;	Crystal structure of Lens culinaris vicilin
2YWE	;	2.05	;	Crystal structure of LepA from Aquifex aeolicus
4IRU	;	3.2	;	Crystal Structure of lepB GAP core in a transition state mimetic complex with Rab1A and ALF3
4JVS	;	2.783	;	Crystal structure of LepB GAP domain from Legionella drancourtii in complex with Rab1-GDP and AlF3
4F5V	;	2.27	;	Crystal Structure of Leporine Serum Albumin
6OCK	;	1.9	;	Crystal Structure of Leporine Serum Albumin in Complex with Ketoprofen
4PO0	;	2.73	;	Crystal Structure of Leporine Serum Albumin in complex with naproxen
6OCL	;	2.35	;	Crystal Structure of Leporine Serum Albumin in Complex with Suprofen
8OHA	;	2.37	;	Crystal structure of Leptospira interrogans GAPDH
4X22	;	2.084	;	Crystal structure of Leptospira Interrogans Triosephosphate Isomerase (LiTIM)
4JZB	;	1.9	;	Crystal Structure of Leshmaniasis major Farnesyl diphosphate synthase in complex with 1-(2-HYDROXY-2,2-DIPHOSPHONOETHYL)-3-PHENYLPYRIDINIUM, IPP and Ca2+
4JZX	;	1.8	;	Crystal Structure of Leshmaniasis major Farnesyl diphosphate synthase in complex with 3-BUTYL-1-(2,2-DIPHOSPHONOETHYL)PYRIDINIUM, IPP and Ca2+
4K10	;	2.3	;	Crystal Structure of Leshmaniasis major Farnesyl diphosphate synthase in complex with 3-FLUORO-1-(2-HYDROXY-2,2-DIPHOSPHONOETHYL)PYRIDINIUM and Mg2+
2EGS	;	1.9	;	Crystal structure of Leu261 to Met mutant of Diphthine synthase
2ER8	;	2.85	;	Crystal Structure of Leu3 DNA-binding domain complexed with a 12mer DNA duplex
2ERG	;	3.15	;	Crystal Structure of Leu3 DNA-binding domain with a single H50C mutation complexed with a 15mer DNA duplex
2DV5	;	2.2	;	Crystal structure of Leu65 to Ala mutant of Diphthine synthase
2DV3	;	1.9	;	Crystal structure of Leu65 to Arg mutant of Diphthine synthase
2DV4	;	2.2	;	Crystal structure of Leu65 to Gln mutant of Diphthine synthase
1SR9	;	2.0	;	Crystal Structure of LeuA from Mycobacterium tuberculosis
4MM8	;	3.31	;	Crystal structure of LeuBAT (delta13 mutant) in complex with (R)-fluoxetine
4MM6	;	3.1	;	Crystal structure of LeuBAT (delta13 mutant) in complex with (S)-duloxetine
4MMA	;	3.3	;	Crystal structure of LeuBAT (delta13 mutant) in complex with clomipramine
4MM7	;	2.85	;	Crystal structure of LeuBAT (delta13 mutant) in complex with desvenlafaxine
4MM9	;	2.9	;	Crystal structure of LeuBAT (delta13 mutant) in complex with fluvoxamine
4MM4	;	2.886	;	Crystal structure of LeuBAT (delta13 mutant) in complex with paroxetine
4MM5	;	3.2	;	Crystal structure of LeuBAT (delta13 mutant) in complex with sertraline
4MMF	;	2.7	;	Crystal structure of LeuBAT (delta5 mutant) in complex with mazindol
4MMD	;	2.3	;	Crystal structure of LeuBAT (delta6 mutant) in complex with (S)-duloxetine
4MMC	;	2.3	;	Crystal structure of LeuBAT (delta6 mutant) in complex with desvenlafaxine
4MME	;	2.5	;	Crystal structure of LeuBAT (delta6 mutant) in complex with mazindol
4MMB	;	2.25	;	Crystal structure of LeuBAT (delta6 mutant) in complex with sertraline
4ZI6	;	2.0	;	Crystal structure of leucine aminopeptidase from Helicobacter pylori
8HPE	;	3.22	;	Crystal structure of Leucine dehydrogenase
3VPX	;	2.55	;	Crystal structure of leucine dehydrogenase from a psychrophilic bacterium Sporosarcina psychrophila.
4XFK	;	1.3	;	Crystal structure of Leucine-, Isoleucine-, Valine-, Threonine-, and Alanine-binding protein from Brucella ovis
7JFN	;	1.7	;	Crystal Structure of Leucine-, isoleucine-, valine-, threonine-, and alanine-binding protein from Brucella ovis, closed conformation
3FIG	;	2.3	;	Crystal Structure of Leucine-bound LeuA from Mycobacterium tuberculosis
5V5T	;	2.15	;	Crystal structure of leucine-rich protein regulator, ElrR, from Enterococcus faecalis
5V5U	;	2.278	;	Crystal structure of leucine-rich protein regulator, ElrR, from Enterococcus faecalis
4XGO	;	1.74	;	Crystal structure of leucine-rich repeat domain of APL1B
4Q62	;	1.898	;	Crystal Structure of Leucine-rich repeat- and Coiled coil-containing Protein from Legionella pneumophila
5NGY	;	3.7	;	Crystal structure of Leuconostoc citreum NRRL B-1299 dextransucrase DSR-M
5LFC	;	3.2	;	Crystal structure of Leuconostoc citreum NRRL B-1299 N-terminally truncated dextransucrase DSR-M
6HTV	;	3.9	;	Crystal structure of Leuconostoc citreum NRRL B-1299 N-terminally truncated dextransucrase DSR-M in complex with isomaltotetraose
5O8L	;	3.6	;	Crystal structure of Leuconostoc citreum NRRL B-1299 N-terminally truncated dextransucrase DSR-M in complex with sucrose
3TTQ	;	1.9	;	Crystal structure of Leuconostoc mesenteroides NRRL B-1299 N-terminally truncated dextransucrase DSR-E in orthorhombic apo-form at 1.9 angstrom resolution
3TTO	;	3.3	;	Crystal structure of Leuconostoc mesenteroides NRRL B-1299 N-terminally truncated dextransucrase DSR-E in triclinic form
4Q1L	;	1.9	;	Crystal structure of Leucurolysin-a complexed with an endogenous tripeptide (QSW).
3JRU	;	2.6	;	Crystal structure of Leucyl Aminopeptidase (pepA) from Xoo0834,Xanthomonas oryzae pv. oryzae KACC10331
1WKB	;	2.05	;	Crystal Structure of Leucyl-tRNA Synthetase from the Archaeon Pyrococcus horikoshii Reveals a Novel Editing Domain Orientation
2CXA	;	1.6	;	Crystal structure of Leucyl/phenylalanyl-tRNA protein transferase from Escherichia coli
1PVH	;	2.5	;	Crystal structure of leukemia inhibitory factor in complex with gp130
2Q7N	;	4.0	;	Crystal structure of Leukemia inhibitory factor in complex with LIF receptor (domains 1-5)
6XLV	;	1.4	;	Crystal structure of leukemia-associated N196K mutant of U2AF65 bound to AdML splice site
7T87	;	3.0	;	CRYSTAL STRUCTURE OF LEUKOCIDIN AB/CENTYRIN S17/FAB 214F COMPLEX
7T82	;	3.5	;	Crystal Structure of LEUKOCIDIN E/CENTYRIN S26/FAB B438
2D3V	;	1.85	;	Crystal Structure of Leukocyte Ig-like Receptor A5 (LILRA5/LIR9/ILT11)
3P2T	;	1.699	;	Crystal Structure of Leukocyte Ig-like Receptor LILRB4 (ILT3/LIR-5/CD85k)
3ROH	;	3.2	;	Crystal Structure of Leukotoxin (LukE) from Staphylococcus aureus subsp. aureus COL.
7P8T	;	1.459	;	Crystal Structure of leukotoxin LukE from Staphylococcus aureus at 1.5 Angstrom resolution
7P8S	;	1.9	;	Crystal Structure of leukotoxin LukE from Staphylococcus aureus at 1.9 Angstrom resolution
7P8X	;	1.4	;	Crystal Structure of leukotoxin LukE from Staphylococcus aureus in complex with a doubly sulfated CCR2 N-terminal peptide
7P93	;	1.55	;	Crystal Structure of leukotoxin LukE from Staphylococcus aureus in complex with a sulfated ACKR1 N-terminal peptide
7P8U	;	1.6	;	Crystal Structure of leukotoxin LukE from Staphylococcus aureus in complex with p-cresyl sulfate
3CHS	;	2.55	;	Crystal structure of leukotriene A4 hydrolase in complex with (2S)-2-amino-5-[[4-[(2S)-2-hydroxy-2-phenyl-ethoxy]phenyl]amino]-5-oxo-pentanoic acid
3CHP	;	2.1	;	Crystal structure of leukotriene a4 hydrolase in complex with (3S)-3-amino-4-oxo-4-[(4-phenylmethoxyphenyl)amino]butanoic acid
3CHO	;	1.8	;	Crystal structure of leukotriene a4 hydrolase in complex with 2-amino-N-[4-(phenylmethoxy)phenyl]-acetamide
3CHR	;	2.2	;	Crystal structure of leukotriene A4 hydrolase in complex with 4-amino-N-[4-(phenylmethoxy)phenyl]-butanamide
3CHQ	;	2.09	;	Crystal structure of leukotriene a4 hydrolase in complex with N5-[4-(phenylmethoxy)phenyl]-L-glutamine
1V3T	;	2.3	;	Crystal structure of leukotriene B4 12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase
1V3V	;	2.0	;	Crystal structure of leukotriene B4 12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase complexed with NADP and 15-oxo-PGE2
1V3U	;	2.0	;	Crystal structure of leukotriene B4 12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase in apo form
3F3C	;	2.1	;	Crystal structure of LeuT bound to 4-Fluoro-L-Phenylalanine and sodium
3F4J	;	2.15	;	Crystal structure of LeuT bound to glycine and sodium
7LQJ	;	2.144	;	Crystal structure of LeuT bound to L-Alanine
3F48	;	1.9	;	Crystal structure of LeuT bound to L-alanine and sodium
3F3E	;	1.8	;	Crystal structure of LeuT bound to L-leucine (30 mM) and sodium
3USG	;	2.502	;	Crystal structure of LeuT bound to L-leucine in space group C2 from lipid bicelles
3USI	;	3.106	;	Crystal structure of LeuT bound to L-leucine in space group P2 from lipid bicelles
3USJ	;	3.5	;	Crystal structure of LeuT bound to L-leucine in space group P21 from lipid bicelles
3USK	;	4.5	;	Crystal structure of LeuT bound to L-leucine in space group P21 from lipid bicelles
3F3D	;	2.3	;	Crystal structure of LeuT bound to L-Methionine and sodium
3F4I	;	1.95	;	Crystal Structure of LeuT bound to L-selenomethionine and sodium
3USL	;	2.71	;	Crystal Structure of LeuT bound to L-selenomethionine in space group C2 from lipid bicelles
3USM	;	3.008	;	Crystal Structure of LeuT bound to L-selenomethionine in space group C2 from lipid bicelles (collected at 1.2 A)
3USO	;	4.5	;	Crystal structure of LeuT bound to L-selenomethionine in space group P21212 from lipid bicelles
3F3A	;	2.0	;	Crystal Structure of LeuT bound to L-Tryptophan and Sodium
3USP	;	2.1	;	Crystal structure of LeuT in heptyl-beta-D-Selenoglucoside
7DIX	;	3.49	;	Crystal structure of LeuT in lipidic cubic phase at pH 5
7DII	;	2.403	;	Crystal structure of LeuT in lipidic cubic phase at pH 7
3TT3	;	3.22	;	Crystal Structure of LeuT in the inward-open conformation in complex with Fab
3TT1	;	3.099	;	Crystal Structure of LeuT in the outward-open conformation in complex with Fab
3QS4	;	2.631	;	Crystal structure of LeuT mutant F259V bound to sodium and L-tryptophan
3QS6	;	2.801	;	Crystal structure of LeuT mutant F259V,I359Q bound to sodium and L-tryptophan
3QS5	;	2.6	;	Crystal structure of LeuT mutant I359Q bound to sodium and L-tryptophan
8FT5	;	3.8	;	Crystal structure of LeuT soaked with Crown-5
3GJD	;	2.0	;	Crystal Structure of LeuT with bound OG
4HMK	;	3.0	;	Crystal structure of LeuT-E290S with bound Br
4HOD	;	3.3	;	Crystal structure of LeuT-E290S with bound Cl
4FXZ	;	2.601	;	Crystal structure of LeuT-F253A bound to L-leucine from lipid bicelles
4FY0	;	3.0	;	Crystal structure of LeuT-F253A bound to L-selenomethionine from lipid bicelles
2A65	;	1.65	;	Crystal structure of LEUTAA, a bacterial homolog of Na+/Cl--dependent neurotransmitter transporters
4FFI	;	2.3	;	Crystal Structure of Levan Fructotransferase D54N mutant from Arthrobacter ureafaciens in complex with levanbiose
4FFH	;	2.2	;	Crystal Structure of Levan Fructotransferase D54N mutant from Arthrobacter ureafaciens in complex with sucrose
4FFF	;	2.57	;	Crystal Structure of Levan Fructotransferase from Arthrobacter ureafaciens
4FFG	;	2.3	;	Crystal Structure of Levan Fructotransferase from Arthrobacter ureafaciens in complex with DFA-IV
1PT2	;	2.1	;	Crystal structure of levansucrase (E342A) complexed with sucrose
6PWQ	;	2.6	;	Crystal structure of Levansucrase from Bacillus subtilis mutant S164A at 2.6 A
1W18	;	2.5	;	Crystal Structure of levansucrase from Gluconacetobacter diazotrophicus
1IY8	;	1.6	;	Crystal Structure of Levodione Reductase
4GQ7	;	2.53	;	Crystal structure of Lg-Flo1p
5VO5	;	2.004	;	Crystal structure of Lgd-Shrub complex, single chain fusion
5AZG	;	1.81	;	Crystal structure of LGG-1 complexed with a UNC-51 peptide
5AZF	;	1.6	;	Crystal structure of LGG-1 complexed with a WEEL peptide
5AZH	;	2.3	;	Crystal structure of LGG-2 fused with an EEEWEEL peptide
5Y30	;	1.781	;	Crystal structure of LGI1 LRR domain
3RO3	;	1.1	;	crystal structure of LGN/mInscuteable complex
8ENF	;	3.29	;	Crystal structure of LGR ligand alpha2/beta5 from C. elegans in crystal form 1 (native)
8END	;	3.54	;	Crystal structure of LGR ligand alpha2/beta5 from C. elegans in crystal form 1 (SeMet)
8ENB	;	2.35	;	Crystal structure of LGR ligand alpha2/beta5 from C. elegans in crystal form 2
4QXE	;	2.2	;	Crystal structure of LGR4 fused with hagfish VLR
1NKZ	;	2.0	;	Crystal structure of LH2 B800-850 from Rps. acidophila at 2.0 Angstrom resolution
3SZ5	;	2.8	;	Crystal Structure of LHK-Exo in complex with 5-phosphorylated oligothymidine (dT)4
3SZ4	;	2.59	;	Crystal Structure of LHK-Exo in complex with dAMP
2RGT	;	2.05	;	Crystal Structure of Lhx3 LIM domains 1 and 2 with the binding domain of Isl1
7EV1	;	1.38	;	Crystal structure of LI-Cadherin EC1-2
7CYM	;	2.7	;	Crystal structure of LI-Cadherin EC1-4
3KYK	;	3.2	;	Crystal structure of li33 Igg1 Fab
3KYM	;	2.62	;	Crystal structure of Li33 IgG2 di-Fab
4R78	;	1.45	;	Crystal structure of LicA in complex with AMP
6ST5	;	2.82	;	crystal structure of LicM2
7A4V	;	1.94	;	Crystal structure of lid-truncated ADP-bound BiP in an oligomeric state
7A4U	;	1.77	;	Crystal structure of lid-truncated apo BiP in an oligomeric state
7S4E	;	2.25	;	Crystal Structure of ligand ACBi1 in complex with bromodomain of human Smarca2 and pVHL:ElonginC:ElonginB complex
8QVU	;	2.24	;	Crystal Structure of ligand ACBI3 in complex with KRAS G12D C118S GDP and pVHL:ElonginC:ElonginB complex
4LQ2	;	2.694	;	Crystal structure of ligand binding domain of CysB, a LysR member from Salmonella typhimurium in complex with effector ligand, O-acetylserine
4M4G	;	2.7	;	Crystal structure of ligand binding domain of CysB, a LysR member from Salmonella typhimurium LT2 in complex with effector ligand, N-acetylserine.
4LQ5	;	2.803	;	Crystal structure of ligand binding domain of CysB, a LysR member from Salmonella typhimurium LT2 in complex with effector ligand, O-acetylserine at 2.8A
1UFU	;	3.0	;	Crystal structure of ligand binding domain of immunoglobulin-like transcript 2 (ILT2; LIR-1)
4GWO	;	2.394	;	Crystal structure of ligand binding domain of LysR family member,CysB in complex with sulfate from Salmonella typhimurium LT2
3KL3	;	2.33	;	Crystal structure of Ligand bound XynC
4L13	;	1.66	;	Crystal structure of Ligand Free EGFP-based Calcium Sensor CatchER
2WDP	;	1.95	;	Crystal Structure of Ligand Free Human Caspase-6
4EMU	;	1.9	;	Crystal structure of ligand free human STING
4F5W	;	2.201	;	Crystal structure of ligand free human STING CTD
7NBZ	;	1.35	;	Crystal structure of ligand free open conformation of sulfoquinovosyl binding protein (SQBP) from Agrobacterium tumefaciens
6PVG	;	1.709	;	Crystal structure of ligand free PhqK
6W3R	;	1.38	;	Crystal structure of ligand-binding domain of Campylobacter jejuni chemoreceptor Tlp3 in complex with 3-methylisoleucine
6W3O	;	1.42	;	Crystal structure of ligand-binding domain of Campylobacter jejuni chemoreceptor Tlp3 in complex with 4-methylisoleucine
6W3P	;	1.383	;	Crystal structure of ligand-binding domain of Campylobacter jejuni chemoreceptor Tlp3 in complex with beta-methylnorleucine
6W3Y	;	1.32	;	Crystal structure of ligand-binding domain of Campylobacter jejuni chemoreceptor Tlp3 in complex with L-alanine
6W3S	;	1.4	;	Crystal structure of ligand-binding domain of Campylobacter jejuni chemoreceptor Tlp3 in complex with L-leucine
6W3T	;	2.1	;	Crystal structure of ligand-binding domain of Campylobacter jejuni chemoreceptor Tlp3 in complex with L-norvaline
6W3V	;	1.47	;	Crystal structure of ligand-binding domain of Campylobacter jejuni chemoreceptor Tlp3 in complex with L-phenylalanine
6W3X	;	1.4	;	Crystal structure of ligand-binding domain of Campylobacter jejuni chemoreceptor Tlp3 in complex with L-valine
3D24	;	2.11	;	Crystal structure of ligand-binding domain of estrogen-related receptor alpha (ERRalpha) in complex with the peroxisome proliferators-activated receptor coactivator-1alpha box3 peptide (PGC-1alpha)
6PYI	;	1.95	;	Crystal structure of ligand-binding domain of Pseudomonas fluorescens chemoreceptor CtaA
6PXY	;	2.0	;	Crystal structure of ligand-binding domain of Pseudomonas fluorescens chemoreceptor CtaA in complex with L-alanine
6PY3	;	1.9	;	Crystal structure of ligand-binding domain of Pseudomonas fluorescens chemoreceptor CtaA in complex with L-isoleucine
6PY4	;	2.0	;	Crystal structure of ligand-binding domain of Pseudomonas fluorescens chemoreceptor CtaA in complex with L-leucine
6Q0G	;	2.0	;	Crystal structure of ligand-binding domain of Pseudomonas fluorescens chemoreceptor CtaA in complex with L-proline
6PY5	;	1.9	;	Crystal structure of ligand-binding domain of Pseudomonas fluorescens chemoreceptor CtaA in complex with L-serine
6Q0F	;	2.2	;	Crystal structure of ligand-binding domain of Pseudomonas fluorescens chemoreceptor CtaA in complex with L-valine
1J8E	;	1.85	;	Crystal structure of ligand-binding repeat CR7 from LRP
4CQK	;	1.6	;	Crystal structure of ligand-bound NaD1
5Y41	;	2.05	;	Crystal Structure of LIGAND-BOUND NURR1-LBD
4ZMJ	;	3.31	;	Crystal Structure of Ligand-Free BG505 SOSIP.664 HIV-1 Env Trimer
3NRS	;	1.8	;	Crystal structure of ligand-free bifunctional folylpolyglutamate synthase/dihydrofolate synthase from yersinia pestis c092
7EIP	;	1.88	;	Crystal structure of ligand-free chondroitin ABC lyase I
7QNO	;	2.38	;	Crystal structure of ligand-free Danio rerio HDAC6 CD1 CD2
7COK	;	1.5	;	Crystal structure of ligand-free form of 5-ketofructose reductase of Gluconobacter sp. strain CHM43
5ZNN	;	2.448	;	Crystal structure of ligand-free form of the Vps10 ectodomain of Sortilin
3IT2	;	1.838	;	Crystal structure of ligand-free Francisella tularensis histidine acid phosphatase
3EUE	;	2.3	;	Crystal structure of ligand-free human uridine phosphorylase 1 (hUPP1)
1UFQ	;	2.5	;	Crystal structure of ligand-free human uridine-cytidine kinase 2
6PER	;	2.1	;	Crystal Structure of Ligand-Free iSeroSnFR
5AIQ	;	2.716	;	Crystal structure of ligand-free NadR
6J33	;	1.297	;	Crystal structure of ligand-free of PulA from Klebsiella pneumoniae
6J35	;	1.839	;	Crystal structure of ligand-free of PulA-G680L mutant from Klebsiella pneumoniae
5AJT	;	2.43	;	Crystal structure of ligand-free phosphoribohydrolase lonely guy from Claviceps purpurea
5AJU	;	2.5	;	Crystal structure of ligand-free phosphoribohydroxylase lonely guy from Claviceps purpurea in complex with phosphoribose
7KK7	;	2.8	;	crystal structure of ligand-free PLEKHA7 PH domain
3RDX	;	2.101	;	Crystal structure of ligand-free R7-2 streptavidin
6JCM	;	2.08	;	Crystal structure of ligand-free Rv0187.
7BAJ	;	1.65	;	Crystal structure of ligand-free SARS-CoV-2 main protease
7UXT	;	3.4	;	Crystal structure of ligand-free SeThsA
4XG2	;	2.21	;	Crystal structure of ligand-free Syk
6AJ5	;	3.5	;	Crystal structure of ligand-free type DHODH from Eimeria tenella
6VLB	;	1.85	;	Crystal structure of ligand-free UDP-GlcNAc 2-epimerase from Neisseria meningitidis
5JXA	;	1.6	;	Crystal structure of ligand-free VRC03 antigen-binding fragment.
4ZS8	;	2.6	;	Crystal structure of ligand-free, full length DasR
1HBP	;	1.9	;	CRYSTAL STRUCTURE OF LIGANDED AND UNLIGANDED FORMS OF BOVINE PLASMA RETINOL-BINDING PROTEIN
1HBQ	;	1.7	;	CRYSTAL STRUCTURE OF LIGANDED AND UNLIGANDED FORMS OF BOVINE PLASMA RETINOL-BINDING PROTEIN
7UF7	;	2.0	;	Crystal structure of liganded Hb with the 5-HMF analog, MMA503
7UF6	;	2.0	;	Crystal structure of liganded Hb with the 5-HMF analog, MMA509
3R5I	;	2.2	;	Crystal structure of liganded Hemoglobin complexed with a potent Antisickling agent, INN-312
3IC2	;	2.4	;	Crystal Structure of liganded hemoglobin in complex with a potent antisickling agent, INN-266
3IC0	;	1.8	;	Crystal Structure of liganded hemoglobin in complex with a potent antisickling agent, INN-298
4NQA	;	3.102	;	Crystal structure of liganded hRXR-alpha/hLXR-beta heterodimer on DNA
1TUK	;	1.12	;	Crystal structure of liganded type 2 non specific lipid transfer protein from wheat
7SXE	;	3.0	;	Crystal structure of ligase I with nick duplexes containing cognate G:T
7SX5	;	2.8	;	Crystal structure of ligase I with nick duplexes containing mismatch A:C
4Y9D	;	2.012	;	Crystal structure of LigD in complex with NADH from Sphingobium sp. strain SYK-6
4Y98	;	2.648	;	Crystal structure of LigD-apo form from Sphingobium sp. strain SYK-6
4YAN	;	2.593	;	Crystal structure of LigE in complex with glutathione (GSH) from Sphingobium sp. strain SYK-6
4YAM	;	1.905	;	Crystal structure of LigE-apo form from Sphingobium sp. strain SYK-6
4YAV	;	1.401	;	Crystal structure of LigG in complex with B-glutathionyl-acetoveratrone (GS-AV) from Sphingobium sp. strain SYK-6
4YAP	;	1.111	;	Crystal structure of LigG-apo form from Sphingobium sp. strain SYK-6
4EN0	;	2.59	;	Crystal structure of light
3P7N	;	2.1	;	Crystal structure of light activated transcription factor El222 from Erythrobacter litoralis
4J6G	;	2.4	;	CRYSTAL STRUCTURE OF LIGHT AND DcR3 COMPLEX
4KG8	;	2.25	;	Crystal structure of light mutant
4KGG	;	2.78	;	Crystal structure of light mutant2 and dcr3 complex
8A5R	;	1.85	;	Crystal structure of light-activated DNA-binding protein EL222 from Erythrobacter litoralis crystallized and measured in dark.
8A5S	;	1.85	;	Crystal structure of light-activated DNA-binding protein EL222 from Erythrobacter litoralis crystallized in dark, measured illuminated.
6L1G	;	2.2	;	Crystal structure of light-dependent protochlorophyllide oxidoreductase from Synechocystis sp. PCC 6803
6L1H	;	2.409	;	Crystal structure of light-dependent protochlorophyllide oxidoreductase from Thermosynechococcus elongatus
5C8F	;	2.65	;	Crystal structure of light-exposed full-length Thermus thermophilus CarH bound to cobalamin
4YAI	;	1.6	;	Crystal structure of LigL in complex with NADH and GGE from Sphingobium sp. strain SYK-6
4YAG	;	1.5	;	Crystal structure of LigL in complex with NADH from Sphingobium sp. strain SYK-6
4YAE	;	1.602	;	Crystal structure of LigL-apo form from Sphingobium sp. strain SYK-6
6XM8	;	1.85	;	Crystal structure of lignostilbene bound to Co-LSD4 from Sphingobium sp. strain SYK-6
4YAC	;	1.699	;	Crystal structure of LigO in complex with NADH from Sphingobium sp. strain SYK-6
4YA6	;	1.799	;	Crystal structure of LigO-apo form from Sphingobium sp. strain SYK-6
6P3J	;	2.02	;	Crystal structure of LigU
6P3K	;	1.88	;	Crystal structure of LigU(C100S)
6P3H	;	1.62	;	Crystal structure of LigU(K66M) bound to substrate
5VN5	;	1.9	;	Crystal structure of LigY from Sphingobium sp. strain SYK-6
7KFK	;	2.63	;	Crystal structure of LILRB1 D3D4 domain in complex with Plasmodium RIFIN (PF3D7_1373400) V2 domain
2DYP	;	2.5	;	Crystal Structure of LILRB2(LIR2/ILT4/CD85d) complexed with HLA-G
1H34	;	2.04	;	Crystal structure of lima bean trypsin inhibitor
8JE4	;	2.19	;	Crystal structure of LimF prenyltransferase (H239G/W273T mutant) bound with the thiodiphosphate moiety of farnesyl S-thiolodiphosphate (FSPP)
7VMW	;	1.93	;	Crystal structure of LimF prenyltransferase bound with a peptide substrate and GSPP
7VMY	;	1.77	;	Crystal structure of LimF prenyltransferase bound with GSPP
5K5W	;	2.591	;	Crystal structure of limiting CO2-inducible protein LCIB
5B5X	;	2.511	;	Crystal structure of limiting CO2-inducible protein LCIC
5HVJ	;	2.2	;	Crystal structure of LIMK1 D460N mutant in complex with AMP-PNP
5HVK	;	3.5	;	Crystal structure of LIMK1 mutant D460N in complex with full-length cofilin-1
4Q4F	;	2.8	;	Crystal structure of LIMP-2 (space group C2)
4Q4B	;	2.82	;	Crystal structure of LIMP-2 (space group C2221)
1QTJ	;	3.0	;	CRYSTAL STRUCTURE OF LIMULUS POLYPHEMUS SAP
7N40	;	2.55	;	Crystal structure of LIN9-RbAp48-LIN37, a MuvB subcomplex
5NX4	;	2.38	;	Crystal structure of Linalool/Nerolidol synthase from Streptomyces clavuligerus
5NX5	;	1.82	;	Crystal structure of Linalool/Nerolidol synthase from Streptomyces clavuligerus in complex with 2-fluorogeranyl diphosphate
4FO1	;	2.15	;	Crystal structure of lincosamide antibiotic adenylyltransferase LnuA, apo
4WH5	;	1.82	;	Crystal structure of lincosamide antibiotic adenylyltransferase LnuA, lincomycin-bound
2W9N	;	2.25	;	crystal structure of linear di-ubiquitin
3AXC	;	2.19	;	Crystal structure of linear diubiquitin
4RA6	;	2.503	;	Crystal structure of linker less Pyrococcus furiosus L-asparaginase
5CMR	;	3.792	;	Crystal Structure of Linker-Mediated Zn-bound Human H-Ferritin variant 122H-delta C-star
1IGZ	;	2.9	;	Crystal Structure of Linoleic acid Bound in the Cyclooxygenase Channel of Prostaglandin Endoperoxide H Synthase-1.
3O0D	;	1.7	;	Crystal structure of Lip2 lipase from Yarrowia lipolytica at 1.7 A resolution
4TXP	;	3.01	;	Crystal structure of LIP5 N-terminal domain
4TXQ	;	2.21	;	Crystal structure of LIP5 N-terminal domain complexed with CHMP1B MIM
4TXR	;	1.0	;	Crystal structure of LIP5 N-terminal domain complexed with CHMP1B MIM and CHMP5 MIM
2QUA	;	1.95	;	Crystal structure of LipA from Serratia marcescens
4X6U	;	2.201	;	Crystal Structure of lipase from Geobacillus stearothermophilus T6
6FZA	;	1.75	;	Crystal Structure of lipase from Geobacillus stearothermophilus T6 methanol stable variant A187F
6FZ9	;	1.2463	;	Crystal Structure of lipase from Geobacillus stearothermophilus T6 methanol stable variant A187F/L360F
4X71	;	2.0	;	Crystal Structure of lipase from Geobacillus stearothermophilus T6 methanol stable variant A269T
6S3V	;	2.0	;	Crystal Structure of lipase from Geobacillus stearothermophilus T6 methanol stable variant E251C/G332C
4X7B	;	2.4	;	Crystal Structure of lipase from Geobacillus stearothermophilus T6 methanol stable variant H86Y/A269T
4X85	;	2.192	;	Crystal Structure of lipase from Geobacillus stearothermophilus T6 methanol stable variant H86Y/A269T/R374W
6FZ7	;	1.736	;	Crystal Structure of lipase from Geobacillus stearothermophilus T6 methanol stable variant L184F
6FZ8	;	2.2	;	Crystal Structure of lipase from Geobacillus stearothermophilus T6 methanol stable variant L184F/A187F
6FZ1	;	2.2	;	Crystal Structure of lipase from Geobacillus stearothermophilus T6 methanol stable variant L360F
6S3G	;	1.9	;	Crystal Structure of lipase from Geobacillus stearothermophilus T6 variant A187C/F291C
6S3J	;	1.9	;	Crystal Structure of lipase from Geobacillus stearothermophilus T6 variant E134C/F149C
6FZD	;	1.8	;	Crystal Structure of lipase from Geobacillus stearothermophilus T6 variant L184F/A187F/L360F
6FZC	;	2.7	;	Crystal Structure of lipase from Geobacillus stearothermophilus T6 variant L184F/L360F
3NGM	;	2.8	;	Crystal structure of lipase from Gibberella zeae
6A0W	;	2.0	;	Crystal structure of lipase from Rhizopus microsporus var. chinensis
7WOL	;	2.0	;	Crystal structure of lipase TrLipB from Thermomocrobium roseum
3D3N	;	2.5	;	Crystal structure of lipase/esterase (lp_2923) from Lactobacillus plantarum. Northeast Structural Genomics Consortium target LpR108
1X2G	;	2.4	;	Crystal Structure of Lipate-Protein Ligase A from Escherichia coli
1X2H	;	2.91	;	Crystal Structure of Lipate-Protein Ligase A from Escherichia coli complexed with lipoic acid
1Y6H	;	2.2	;	Crystal structure of LIPDF
5H0Q	;	1.501	;	Crystal structure of lipid binding protein Nakanori at 1.5A
4PX7	;	3.2	;	Crystal structure of lipid phosphatase E. coli PgpB
3W9U	;	2.0	;	Crystal structure of Lipk107
2ZZ8	;	2.01	;	Crystal structure of LipL32, the most abundant surface protein of pathogenic leptospira spp
2A8X	;	2.4	;	Crystal Structure of Lipoamide Dehydrogenase from Mycobacterium tuberculosis
2EQ6	;	1.6	;	Crystal structure of lipoamide dehydrogenase from thermus thermophilus HB8
2EQ9	;	2.09	;	Crystal structure of lipoamide dehydrogenase from thermus thermophilus HB8 with psbdb
2EQ7	;	1.8	;	Crystal structure of lipoamide dehydrogenase from thermus thermophilus HB8 with psbdo
2EQ8	;	1.94	;	Crystal structure of lipoamide dehydrogenase from thermus thermophilus HB8 with psbdp
6JOM	;	2.45	;	Crystal structure of lipoate protein ligase from Mycoplasma hyopneumoniae
2ARU	;	2.5	;	Crystal structure of lipoate-protein ligase A bound with ATP
2ART	;	2.4	;	Crystal structure of lipoate-protein ligase A bound with lipoyl-AMP
2ARS	;	2.04	;	Crystal structure of lipoate-protein ligase A From Thermoplasma acidophilum
3RJT	;	1.5	;	Crystal structure of lipolytic protein G-D-S-L family from Alicyclobacillus acidocaldarius subsp. acidocaldarius DSM 446
5BVC	;	2.0	;	Crystal structure of Lipomyces starkeyi levoglucosan kinase bound to ADP, magnesium and levoglucosan in an alternate orientation.
3CAY	;	1.2	;	Crystal structure of Lipopeptide Detergent (LPD-12)
3CBA	;	1.7	;	Crystal structure of Lipopeptide Detergent (LPD-12) (Hexagonal)
4M4D	;	2.909	;	Crystal structure of lipopolysaccharide binding protein
4QC2	;	2.22	;	Crystal structure of lipopolysaccharide transport protein LptB in complex with ATP and Magnesium ions
4HRV	;	1.89	;	Crystal Structure of Lipoprotein GNA1162 from Neisseria meningitidis
3IR1	;	2.15	;	Crystal Structure of Lipoprotein GNA1946 from Neisseria meningitidis
3AB9	;	1.65	;	Crystal Structure of lipoylated E. coli H-protein (reduced form)
8IW5	;	1.7	;	Crystal structure of liprin-beta H2H3 dimer
2GW5	;	1.8	;	Crystal Structure of LIR-2 (ILT4) at 1.8 : differences from LIR-1 (ILT2) in regions implicated in the binding of the Cytomegalovirus class I MHC homolog UL18
1VDG	;	2.8	;	Crystal structure of LIR1.01, one of the alleles of LIR1
1UGN	;	1.8	;	Crystal structure of LIR1.02, one of the alleles of LIR1
3JUL	;	2.4	;	Crystal structure of Listeria innocua D-Tagatose-6-Phosphate Kinase bound with substrate
6XNV	;	2.4	;	CRYSTAL STRUCTURE OF LISTERIA MONOCYTOGENES CBPB PROTEIN (LMO1009) IN COMPLEX WITH C-DI-AMP
4UQF	;	2.4	;	CRYSTAL STRUCTURE OF LISTERIA MONOCYTOGENES GTP CYCLOHYDROLASE I
4NL2	;	2.6	;	Crystal Structure of Listeria monocytogenes Hfq
4NOY	;	2.795	;	Crystal structure of Listeria monocytogenes Hfq F43W
4NL3	;	3.1	;	Crystal Structure of Listeria monocytogenes Hfq in complex with U6 RNA
5HL3	;	1.4	;	Crystal structure of Listeria monocytogenes InlP
5KS7	;	2.9	;	Crystal structure of Listeria monocytogenes OpuCA CBS domain dimer in complex with cyclic-di-AMP
4QSL	;	3.28	;	Crystal Structure of Listeria Monocytogenes Pyruvate Carboxylase
4CDB	;	2.15	;	Crystal structure of listeriolysin O
1IJ8	;	2.0	;	CRYSTAL STRUCTURE OF LITE AVIDIN-BNI COMPLEX
2CYD	;	2.8	;	Crystal structure of Lithium bound rotor ring of the V-ATPase from Enterococcus hirae
4BG4	;	1.601	;	Crystal structure of Litopenaeus vannamei arginine kinase in a ternary analog complex with arginine, ADP-Mg and NO3
4BHL	;	1.9	;	Crystal structure of Litopenaeus vannamei arginine kinase in binary complex with arginine
5EYW	;	1.7	;	Crystal structure of Litopenaeus vannamei triosephosphate isomerase complexed with 2-Phosphoglycolic acid
5JBW	;	2.05	;	Crystal structure of LiuC
5JBX	;	1.1	;	Crystal structure of LiuC in complex with coenzyme A and malonic acid
7N4P	;	2.097	;	Crystal Structure of Lizard Cadherin-23 EC1-2
7ZUA	;	1.68	;	Crystal Structure of Ljungan virus 4 2A2 protein I222 crystal form
7ZUO	;	2.07	;	Crystal Structure of Ljungan virus 4 2A2 protein, P212121 form
8A2F	;	1.73	;	Crystal Structure of Ljunganvirus 1 2A protein
6F7V	;	3.03	;	Crystal structure of LkcE E64Q mutant in complex with LC-KA05
6F7L	;	2.5	;	Crystal structure of LkcE R326Q mutant in complex with its substrate
2Z20	;	1.95	;	Crystal structure of LL-Diaminopimelate Aminotransferase from Arabidopsis thaliana
2Z1Z	;	2.4	;	Crystal structure of LL-Diaminopimelate Aminotransferase from Arabidopsis thaliana complexed with L-malate ion
3EI6	;	1.9	;	Crystal structure of LL-diaminopimelate aminotransferase from Arabidopsis thaliana complexed with PLP-DAP: an external aldimine mimic
3EI5	;	2.05	;	Crystal structure of LL-diaminopimelate aminotransferase from Arabidopsis thaliana complexed with PLP-Glu: an external aldimine mimic
7R73	;	1.76	;	Crystal structure of llama VHH antibody D7 in complex with HIV-1 gp120 core
7R74	;	2.76	;	Crystal structure of llama VHH antibody in complex with HIV-1 HXBC2 gp120 core
8IL0	;	2.81	;	Crystal structure of LmbT from Streptomyces lincolnensis NRRL ISP-5355
8ILA	;	2.79	;	Crystal structure of LmbT from Streptomyces lincolnensis NRRL ISP-5355 in complex with substrates
4KIA	;	1.75	;	Crystal structure of LmHde, heme-degrading enzyme, from Listeria monocytogenes
2I2C	;	1.85	;	Crystal structure of LmNADK1
2I2D	;	2.22	;	Crystal structure of LmNADK1
2I2F	;	1.9	;	Crystal structure of LmNADK1
2I2A	;	2.1	;	Crystal structure of LmNADK1 from Listeria monocytogenes
2I2B	;	2.1	;	Crystal structure of LmNADK1 from Listeria monocytogenes
2Q5F	;	1.9	;	Crystal structure of LMNADK1 from Listeria monocytogenes
2AML	;	1.5	;	Crystal structure of Lmo0035 protein (46906266) from LISTERIA MONOCYTOGENES 4b F2365 at 1.50 A resolution
4KFZ	;	2.8	;	Crystal structure of LMO2 and anti-LMO2 VH complex
3K2T	;	2.4	;	Crystal structure of Lmo2511 protein from Listeria monocytogenes, northeast structural genomics consortium target LkR84A
5GSD	;	2.3	;	Crystal structure of LMP2 peptide from EBV in complex with HLA-A*11:01
1MV5	;	3.1	;	Crystal structure of LmrA ATP-binding domain
6R1L	;	2.095	;	Crystal structure of LmrR with bound copper phenanthroline
6I8N	;	1.79	;	Crystal structure of LmrR with V15 replaced by unnatural amino acid 4-amino-L-phenylalanine
6SNC	;	3.2	;	crystal structure of LN01 Fab in complex with an HIV-1 gp41 peptide
6SND	;	3.1	;	crystal structure of LN01 Fab in complex with an HIV-1 gp41 peptide
6SNE	;	3.9	;	crystal structure of LN01 Fab in complex with an HIV-1 gp41 peptide
4NNQ	;	2.01	;	Crystal structure of LnmF protein from Streptomyces amphibiosporus
5LY0	;	1.877	;	Crystal structure of LOB domain of Ramosa2 from Wheat
5OOW	;	2.9	;	Crystal structure of lobe II from the nucleotide binding domain of DnaK in complex with AMPPCP
4PT1	;	1.65	;	Crystal structure of Locusta migratoria odorant binding proteins lmigOBP1
6HJ6	;	1.98	;	Crystal structure of Loei River virus GP1 glycoprotein at pH 5.0
6HJC	;	2.51	;	Crystal structure of Loei River virus GP1 glycoprotein at pH 8.0
7W2I	;	1.8	;	Crystal structure of LOG (Rv1205) from Mycobacterium tuberculosis
5ITS	;	2.3	;	Crystal structure of LOG from Corynebacterium glutamicum
5YED	;	1.6	;	Crystal structure of LokiProfilin1
5YEE	;	1.81	;	Crystal structure of LokiProfilin1/Rabbit Actin Complex
3BUU	;	1.2	;	Crystal structure of LolA superfamily protein NE2245 from Nitrosomonas europaea
6ZB6	;	1.9	;	Crystal structure of Lolium rigidum GSTF in complex with S-(p-nitrobenzyl) glutathione
3JPZ	;	1.95	;	Crystal Structure of Lombricine Kinase
3JQ3	;	2.503	;	Crystal Structure of Lombricine Kinase, complexed with substrate ADP
4ZPX	;	2.03	;	Crystal structure of Lon ATPase domain from Thermococcus onnurineus NA1
7CAY	;	2.8	;	Crystal Structure of Lon N-terminal domain protein from Xanthomonas campestris
3LJC	;	2.6	;	Crystal structure of Lon N-terminal domain.
3K1J	;	2.0	;	Crystal structure of Lon protease from Thermococcus onnurineus NA1
8SXP	;	2.9	;	Crystal structure of long neurotoxin from the venom of the king cobra (3FTx-L15) in complex with Fab of broadly neutralizing antibody 95Mat5
3B9N	;	2.7	;	Crystal structure of long-chain alkane monooxygenase (LadA)
1XCR	;	1.7	;	Crystal Structure of Longer Splice Variant of PTD012 from Homo sapiens reveals a novel Zinc-containing fold
3STC	;	1.91	;	Crystal structure of loop 7 truncated mutant of 3-deoxy-D-manno-octulosonate 8-phosphate synthase (KDO8PS) from Neisseria meningitidis
8ED5	;	1.79	;	Crystal structure of loop deletion AioX mutant from Pseudorhizobium sp. str. NT-26
3B9G	;	1.4	;	Crystal structure of loop deletion mutant of Trypanosoma vivax nucleoside hydrolase (3GTvNH) in complex with ImmH
2VG9	;	2.0	;	Crystal structure of Loop Swap mutant of Necallimastix patriciarum Xyn11A
4P0J	;	2.298	;	Crystal Structure of Loop-Swapped Interleukin-36Ra
7VE2	;	3.2	;	Crystal Structure of Lopinavir bound Plasmepsin II (PMII) from Plasmodium falciparum
2Q5K	;	1.95	;	Crystal structure of lopinavir bound to wild type HIV-1 protease
8PEH	;	1.95	;	Crystal structure of Lotus japonicus SYMRK kinase domain D738N
8IYN	;	2.081	;	Crystal structure of LOV1 D33N mutant of phototropin from Klebsormidium nitens
8I11	;	1.855	;	Crystal structure of LOV1 domain of phototropin from Klebsormidium nitens
2Z6C	;	2.1	;	Crystal structure of LOV1 domain of phototropin1 from Arabidopsis thaliana
2Z6D	;	2.0	;	Crystal structure of LOV1 domain of phototropin2 from Arabidopsis thaliana
5DJT	;	1.4	;	Crystal structure of LOV2 (C450A) domain in complex with Zdk2
5DJU	;	2.1	;	Crystal structure of LOV2 (C450A) domain in complex with Zdk3
4EEP	;	1.7	;	Crystal structure of LOV2 domain of Arabidopsis thaliana phototropin 2
4EER	;	1.753	;	Crystal structure of LOV2 domain of Arabidopsis thaliana phototropin 2 C426A mutant
5EFW	;	2.1	;	Crystal structure of LOV2-Zdk1 - the complex of oat LOV2 and the affibody protein Zdark1
4LYM	;	2.1	;	CRYSTAL STRUCTURE OF LOW HUMIDITY TETRAGONAL LYSOZYME AT 2.1-ANGSTROMS RESOLUTION. VARIABILITY IN HYDRATION SHELL AND ITS STRUCTURAL CONSEQUENCES
5Z3M	;	2.6	;	Crystal structure of Low Molecular Weight Phosphotyrosine phosphatase (VcLMWPTP-2) from Vibrio choleraeO395
4Z9B	;	2.41	;	Crystal structure of Low Molecular Weight Protein Tyrosine Phosphatase isoform A complexed with benzylphosphonic acid
4Z9A	;	2.1	;	Crystal structure of Low Molecular Weight Protein Tyrosine Phosphatase isoform A complexed with phenylmethanesulfonic acid
1Y9I	;	1.8	;	Crystal structure of low temperature requirement C protein from Listeria monocytogenes
2ZBO	;	1.6	;	Crystal structure of low-redox-potential cytochrom c6 from brown alga Hizikia fusiformis at 1.6 A resolution
3WLX	;	2.51	;	Crystal structure of low-specificity L-threonine aldolase from Escherichia coli
3RLG	;	1.6	;	Crystal structure of Loxosceles intermedia phospholipase D isoform 1 H12A mutant
5YB2	;	3.8	;	Crystal structure of LP-11/N44
5Y14	;	1.762	;	Crystal structure of LP-40/N44
5YC0	;	2.0	;	Crystal structure of LP-46/N44
6M06	;	2.1	;	Crystal structure of Lp-PLA2 in complex with a novel covalent inhibitor
6M07	;	2.64	;	Crystal structure of Lp-PLA2 in complex with a novel covalent inhibitor
6M08	;	2.19	;	Crystal structure of Lp-PLA2 in complex with a novel covalent inhibitor.
3AAP	;	1.6	;	Crystal Structure of Lp1NTPDase from Legionella pneumophila
3AAR	;	1.65	;	Crystal structure of Lp1NTPDase from Legionella pneumophila in complex with AMPPNP
3AAQ	;	2.0	;	Crystal structure of Lp1NTPDase from Legionella pneumophila in complex with the inhibitor ARL 67156
6LG1	;	3.047	;	Crystal structure of LpCGTa in complex with UDP
6LFN	;	2.395	;	Crystal structure of LpCGTb
1XDI	;	2.81	;	Crystal structure of LpdA (Rv3303c) from Mycobacterium tuberculosis
4GYT	;	2.047	;	Crystal structure of lpg0076 protein from Legionella pneumophila
6L6H	;	2.403	;	Crystal structure of Lpg0189
4R0G	;	2.7	;	Crystal structure of Lpg0393 from Legionella pneumophila
5DIP	;	2.097	;	Crystal structure of lpg0406 in reduced form from Legionella pneumophila
7YJI	;	2.1	;	Crystal structure of Lpg1083 from Legionella pneumophila
5T8C	;	1.481	;	Crystal structure of lpg1496 under 300 MPa
5T8B	;	1.5	;	Crystal structure of lpg1496 under 350 MPa
5XTA	;	2.0	;	Crystal structure of lpg1832, a VirK family protein from Legionella pneumophila
4HFV	;	1.901	;	Crystal structure of lpg1851 protein from Legionella pneumophila (putative T4SS effector)
6K3B	;	1.974	;	Crystal structure of Lpg2147-Lpg2149 complex
8CRI	;	2.1	;	Crystal structure of LplA1 in complex with lipoic acid (Listeria monocytogenes)
8CRJ	;	2.6	;	Crystal structure of LplA1 in complex with lipoyl-AMP (Listeria monocytogenes)
8CRL	;	2.6	;	Crystal structure of LplA1 in complex with the inhibitor C3 (Listeria monocytogenes)
6R48	;	1.87	;	Crystal structure of LPOR (Synechocystis) complexed with NADPH at 1.87A resolution.
6R46	;	2.5	;	Crystal structure of LPOR (Thermosynechococcus elongatus) complexed with NADP+ at 2.5A resolution
4TVV	;	1.4	;	Crystal structure of LppA from Legionella pneumophila
6E5D	;	1.65	;	Crystal structure of LpqN involved in cell envelope biogenesis of Mycobacterium tuberculosis
6E5F	;	1.37	;	Crystal structure of LpqN involved in cell envelope biogenesis of Mycobacterium tuberculosis
6MNA	;	1.75	;	Crystal structure of LpqN involved in cell envelope biogenesis of Mycobacterium tuberculosis
2GRV	;	2.4	;	Crystal Structure of LpqW
7APE	;	1.7	;	Crystal structure of LpqY from Mycobacterium thermoresistible in complex with trehalose
4QA8	;	1.1	;	Crystal structure of LprF from Mycobacterium bovis
3MH8	;	1.995	;	Crystal structure of LprG from Mycobacterium tuberculosis
3MHA	;	1.85	;	Crystal structure of LprG from Mycobacterium tuberculosis bound to PIM
3MH9	;	1.794	;	Crystal structure of LprG mutant V91W from Mycobacterium tuberculosis
4W8I	;	2.85	;	Crystal structure of LpSPL/Lpp2128, Legionella pneumophila sphingosine-1 phosphate lyase
3MY2	;	2.2	;	Crystal structure of LptC
8H1R	;	2.98	;	Crystal structure of LptDE-YifL complex
4UU4	;	2.751	;	Crystal structure of LptH, the LptA homologous periplasmic component of the conserved lipopolysaccharide transport device from Pseudomonas aeruginosa
4J09	;	1.9	;	Crystal Structure of LpxA bound to RJPXD33
2VES	;	1.9	;	Crystal Structure of LpxC from Pseudomonas aeruginosa complexed with the potent BB-78485 inhibitor
6E54	;	1.65	;	Crystal structure of LpxC from Pseudomonas aeruginosa in complex with ligand PT802
5UPG	;	1.7	;	Crystal structure of LpxC from Pseudomonas aeruginosa in complex with PF-5081090
6DUI	;	1.55	;	Crystal structure of LpxC from Pseudomonas aeruginosa in complex with PT801
6CAX	;	1.25	;	Crystal structure of LpxC from Pseudomonas aeruginosa in complex with PT805
6C9C	;	2.0	;	Crystal structure of LpxC from Pseudomonas aeruginosa in complex with racemic ligand PT803
3EH0	;	2.6	;	Crystal Structure of LpxD from Escherichia coli
5B4B	;	1.6	;	Crystal structure of LpxH with lipid X in spacegroup C2
5B4A	;	1.72	;	Crystal structure of LpxH with lipid X in spacegroup P21
5B49	;	1.65	;	Crystal structure of LpxH with manganese from Pseudomonas aeruginosa
4EHX	;	1.9	;	Crystal structure of LpxK from Aquifex aeolicus at 1.9 angstrom resolution
4EHW	;	2.3	;	Crystal structure of LpxK from Aquifex aeolicus at 2.3 angstrom resolution
4EHY	;	2.199	;	Crystal structure of LpxK from Aquifex aeolicus in complex with ADP/Mg2+ at 2.2 angstrom resolution
4ITL	;	2.09	;	Crystal structure of LpxK from Aquifex aeolicus in complex with AMP-PCP at 2.1 angstrom resolution
3I3U	;	2.8	;	Crystal structure of lp_1913 protein from lactobacillus plantarum, northeast structural genomics Consortium target lpr140a
3FLH	;	2.0	;	Crystal structure of lp_1913 protein from Lactobacillus plantarum,Northeast Structural Genomics Consortium Target LpR140B
5I9I	;	2.7	;	Crystal structure of LP_PLA2 in complex with Darapladib
5I8P	;	2.37	;	Crystal structure of LP_PLA2 in complex with novel inhibitor
3AH3	;	2.4	;	Crystal structure of LR5-1, 3-isopropylmalate dehydrogenase created by directed evolution
3TX7	;	2.76	;	Crystal structure of LRH-1/beta-catenin complex
3O53	;	2.0	;	Crystal Structure of LRIM1 leucine-rich repeat domain
3OJA	;	2.7	;	Crystal structure of LRIM1/APL1C complex
8FFE	;	1.72	;	Crystal structure of LRP6 E1E2 domains bound to YW210.09 Fab and engineered XWnt8 peptide
6L6R	;	3.8	;	Crystal structure of LRP6 E1E2-SOST complex
8DVN	;	2.53	;	Crystal structure of LRP6 E3E4 in complex with disulfide constrained peptide E3.10
8DVL	;	2.5	;	Crystal structure of LRP6 E3E4 in complex with disulfide constrained peptide E3.18
8DVM	;	2.0	;	Crystal structure of LRP6 E3E4 in complex with disulfide constrained peptide E3.6
3S8V	;	3.1	;	Crystal structure of LRP6-Dkk1 complex
3S94	;	2.8	;	Crystal structure of LRP6-E1E2
3S8Z	;	2.8	;	Crystal structure of LRP6-E3E4
4A0P	;	1.9	;	Crystal structure of LRP6P3E3P4E4
7V8H	;	2.46	;	Crystal structure of LRR domain from Shigella flexneri IpaH1.4
6DLO	;	2.7	;	Crystal structure of LRRK2 WD40 domain dimer
6DLP	;	4.0	;	Crystal structure of LRRK2 WD40 domain dimer
3ZDG	;	2.48	;	Crystal Structure of Ls-AChBP complexed with carbamoylcholine analogue 3-(dimethylamino)butyl dimethylcarbamate (DMABC)
3ZDH	;	2.195	;	Crystal structure of Ls-AChBP complexed with carbamoylcholine analogue N,N-dimethyl-4-(1-methyl-1H-imidazol-2-yloxy)butan-2-amine
4ALX	;	2.3	;	Crystal Structure of Ls-AChBP complexed with the potent nAChR antagonist DHbE
5ISZ	;	2.06	;	Crystal structure of LS01-TCR/M1-HLA-A*02 complex
5JHD	;	2.46	;	Crystal structure of LS10-TCR/M1-HLA-A*02 complex
3LP9	;	2.2	;	Crystal structure of LS24, A Seed Albumin from Lathyrus sativus
2HKO	;	2.8	;	Crystal structure of LSD1
3ABU	;	3.1	;	Crystal Structure of LSD1 in complex with a 2-PCPA derivative, S1201
7W3L	;	2.51	;	Crystal structure of LSD1 in complex with cis-4-Br-2,5-F2-PCPA (S1024)
7VQS	;	2.94	;	Crystal structure of LSD1 in complex with compound 4
7VQT	;	2.91	;	Crystal structure of LSD1 in complex with compound 5
7VQU	;	2.94	;	Crystal structure of LSD1 in complex with compound S1427
3ABT	;	3.2	;	Crystal Structure of LSD1 in complex with trans-2-pentafluorophenylcyclopropylamine
2XAH	;	3.1	;	Crystal structure of LSD1-CoREST in complex with (+)-trans-2- phenylcyclopropyl-1-amine
2XAJ	;	3.3	;	Crystal structure of LSD1-CoREST in complex with (-)-trans-2- phenylcyclopropyl-1-amine
2Y48	;	3.0	;	Crystal structure of LSD1-CoREST in complex with a N-terminal SNAIL peptide
2XAS	;	3.2	;	Crystal structure of LSD1-CoREST in complex with a tranylcypromine derivative (MC2580, 14e)
2XAQ	;	3.2	;	Crystal structure of LSD1-CoREST in complex with a tranylcypromine derivative (MC2584, 13b)
2XAF	;	3.25	;	Crystal structure of LSD1-CoREST in complex with para-bromo-(+)-cis-2- phenylcyclopropyl-1-amine
2XAG	;	3.1	;	Crystal structure of LSD1-CoREST in complex with para-bromo-(-)-trans- 2-phenylcyclopropyl-1-amine
5H6Q	;	2.53	;	Crystal structure of LSD1-CoREST in complex with peptide 11
5H6R	;	2.6	;	Crystal structure of LSD1-CoREST in complex with peptide 13
5X60	;	2.69	;	Crystal structure of LSD1-CoREST in complex with peptide 9
7CDE	;	2.68	;	Crystal structure of LSD1-CoREST in complex with PRSFLVRKR peptide
7CDD	;	2.76	;	Crystal structure of LSD1-CoREST in complex with PRSFLVRR peptide
7CDF	;	2.68	;	Crystal structure of LSD1-CoREST in complex with PRSFLVRRK peptide
7CDC	;	2.64	;	Crystal structure of LSD1-CoREST in complex with PRSFLVRRP peptide
7CDG	;	2.8	;	Crystal structure of LSD1-CoREST in complex with PRSFLVRRR peptide
8WVB	;	2.5	;	Crystal structure of Lsd18 mutant S195M
8WVF	;	3.757	;	Crystal structure of Lsd18 mutant T189M and S195M
4GU1	;	2.939	;	Crystal structure of LSD2
7XE3	;	2.82	;	Crystal structure of LSD2 in complex with cis-4-Br-2,5-F2-PCPA (S1024)
7XE1	;	2.07	;	Crystal structure of LSD2 in complex with cis-4-Br-PCPA
7XE2	;	2.05	;	Crystal structure of LSD2 in complex with trans-4-Br-PCPA
4GU0	;	3.103	;	Crystal structure of LSD2 with H3
4GUT	;	1.998	;	Crystal structure of LSD2-NPAC
4GUR	;	2.506	;	Crystal structure of LSD2-NPAC with H3 in space group P21
4GUS	;	2.23	;	Crystal structure of LSD2-NPAC with H3 in space group P3221
4HSU	;	1.988	;	Crystal structure of LSD2-NPAC with H3(1-26)in space group P21
4GUU	;	2.302	;	Crystal structure of LSD2-NPAC with tranylcypromine
4M75	;	2.95	;	Crystal structure of Lsm1-7 complex
4N0A	;	3.15	;	Crystal structure of Lsm2-3-Pat1C complex from Saccharomyces cerevisiae
4M7A	;	2.781	;	Crystal structure of Lsm2-8 complex bound to the 3' end sequence of U6 snRNA
4M7D	;	2.595	;	Crystal structure of Lsm2-8 complex bound to the RNA fragment CGUUU
4M77	;	3.111	;	Crystal structure of Lsm2-8 complex, space group I212121
4M78	;	2.794	;	Crystal structure of Lsm2-8 complex, space group P21
3PLT	;	2.9	;	Crystal structure of Lsp1 from Saccharomyces cerevisiae
3T95	;	1.75	;	Crystal structure of LsrB from Yersinia pestis complexed with autoinducer-2
5YA0	;	2.997	;	Crystal structure of LsrK and HPr complex
5YA2	;	2.701	;	Crystal structure of LsrK-HPr complex with ADP
5YA1	;	2.701	;	crystal structure of LsrK-HPr complex with ATP
3NT9	;	1.99	;	CRYSTAL STRUCTURE OF LSSmKate1 red fluorescent proteins with large Stokes shift
3NT3	;	1.5	;	CRYSTAL STRUCTURE OF LSSmKate2 red fluorescent proteins with large Stokes shift
7OIN	;	1.4	;	Crystal structure of LSSmScarlet - a genetically encoded red fluorescent protein with a large Stokes shift
8ARM	;	1.41	;	Crystal structure of LSSmScarlet2
5N3W	;	2.3	;	Crystal structure of LTA4H bound to a selective inhibitor against LTB4 generation
5H9L	;	1.37	;	Crystal Structure of LTBP1 in complex with cleaved Leukotriene C4
5HAE	;	2.002	;	Crystal structure of LTBP1 LTC4 complex collected on an in-house source
5H9N	;	1.28	;	Crystal structure of LTBP1 Y114A mutant in complex with leukotriene C4
6R7D	;	2.35	;	Crystal structure of LTC4S in complex with AZ13690257
8B9V	;	2.16	;	Crystal structure of Lu AF82422 in complex with alpha-synuclein 110-120
7BB9	;	1.97	;	Crystal structure of Lugdulysin E242Q Y315F mutant
7BB8	;	1.506	;	Crystal structure of Lugdulysin, a Staphylococcus lugdunensis M30 zinc metallopeptidase
5K59	;	2.84	;	Crystal structure of LukGH from Staphylococcus aureus in complex with a neutralising antibody
1NQX	;	1.82	;	Crystal Structure of Lumazine Synthase from Aquifex aeolicus in Complex with Inhibitor: 3-(7-hydroxy-8-ribityllumazine-6-yl)propionic acid
1NQW	;	2.2	;	Crystal Structure of Lumazine Synthase from Aquifex aeolicus in Complex with Inhibitor: 5-(6-D-ribitylamino-2,4(1H,3H)pyrimidinedione-5-yl)-1-pentyl-phosphonic acid
1NQV	;	2.05	;	Crystal Structure of Lumazine Synthase from Aquifex aeolicus in Complex with Inhibitor: 5-nitroso-6-ribityl-amino-2,4(1H,3H)pyrimidinedione
1NQU	;	1.75	;	Crystal Structure of Lumazine Synthase from Aquifex aeolicus in Complex with Inhibitor: 6,7-dioxo-5H-8-ribitylaminolumazine
4V7G	;	3.5	;	Crystal Structure of Lumazine Synthase from Bacillus Anthracis
1DI0	;	2.7	;	CRYSTAL STRUCTURE OF LUMAZINE SYNTHASE FROM BRUCELLA ABORTUS
1XN1	;	3.05	;	Crystal Structure Of Lumazine Synthase From Brucella Abortus (Orthorhombic Form At 3.05 Angstroms)
1T13	;	2.9	;	Crystal Structure Of Lumazine Synthase From Brucella Abortus Bound To 5-nitro-6-(D-ribitylamino)-2,4(1H,3H) pyrimidinedione
3MK3	;	3.569	;	Crystal structure of Lumazine synthase from Salmonella typhimurium LT2
4OTY	;	2.354	;	Crystal structure of lumiracoxib bound to the apo-mouse-cyclooxygenase-2
3A3G	;	2.0	;	Crystal structure of LumP complexed with 6,7-dimethyl-8-(1'-D-ribityl) lumazine
3A3B	;	2.0	;	Crystal structure of LumP complexed with flavin mononucleotide
3A35	;	1.421	;	Crystal structure of LumP complexed with riboflavin
3ONE	;	1.35	;	Crystal structure of Lupinus luteus S-adenosyl-L-homocysteine hydrolase in complex with adenine
3OND	;	1.17	;	Crystal structure of Lupinus luteus S-adenosyl-L-homocysteine hydrolase in complex with adenosine
3ONF	;	2.0	;	Crystal structure of Lupinus luteus S-adenosyl-L-homocysteine hydrolase in complex with cordycepin
1OOI	;	2.04	;	Crystal structure of LUSH from Drosophila melanogaster at pH 6.5
1T14	;	1.86	;	Crystal structure of LUSH from Drosophila melanogaster: apo protein
4J2P	;	1.85	;	Crystal structure of LuxF from Photobacterium leiognathi
1JX6	;	1.5	;	CRYSTAL STRUCTURE OF LUXP FROM VIBRIO HARVEYI COMPLEXED WITH AUTOINDUCER-2
4YP9	;	2.7	;	Crystal Structure of LuxP In Complex With a Formose Derived AI-2 Analogue
4YRZ	;	2.571	;	Crystal Structure of LuxP In Complex With L-xylulofuranose-1,2-borate
1IE0	;	1.6	;	CRYSTAL STRUCTURE OF LUXS
4K82	;	1.6	;	Crystal structure of lv-ranaspumin (Lv-RSN-1) from the foam nest of Leptodactylus vastus, monoclinic crystal form
4K83	;	1.75	;	Crystal structure of lv-ranaspumin (Lv-RSN-1) from the foam nest of Leptodactylus vastus, orthorhombic crystal form
4DK7	;	2.45	;	Crystal structure of LXR ligand binding domain in complex with full agonist 1
4DK8	;	2.75	;	Crystal structure of LXR ligand binding domain in complex with partial agonist 5
5AVL	;	2.8	;	Crystal structure of LXRalpha in complex with tert-butyl benzoate analog, compound 32b
5AVI	;	2.7	;	Crystal structure of LXRalpha in complex with tert-butyl benzoate analog, compound 4
5JY3	;	2.4	;	CRYSTAL STRUCTURE OF LXRbeta (NUCLEAR RECEPTOR SUBFAMILY 1, GROUP H, MEMBER 2) COMPLEXED WITH BMS-852927
5XFF	;	2.7	;	Crystal structure of LY2874455 in complex of FGFR4 gatekeeper mutation (V550L)
5XFJ	;	3.25	;	Crystal structure of LY2874455 in complex of FGFR4 gatekeeper mutation (V550M)
2G5X	;	1.7	;	Crystal structure of lychnin a type 1 Ribosome Inactivating Protein (RIP)
4U4U	;	3.0	;	Crystal structure of Lycorine bound to the yeast 80S ribosome
6XWE	;	1.49	;	Crystal structure of LYK3 ectodomain
5A96	;	1.914	;	Crystal structure of Lymantria dispar CPV14 polyhedra
8QPH	;	1.34	;	Crystal structure of Lymantria dispar CPV14 polyhedra 14 crystals
8QQC	;	1.3	;	Crystal structure of Lymantria dispar CPV14 polyhedra single crystal
1G5Z	;	2.51	;	CRYSTAL STRUCTURE OF LYME DISEASE ANTIGEN OUTER SURFACE PROTEIN C (OSPC) FROM BORRELIA BURGDORFERI STRAIN N40
1L8W	;	2.3	;	Crystal Structure of Lyme Disease Variable Surface Antigen VlsE of Borrelia burgdorferi
7DJI	;	2.2	;	Crystal structure of Lymnaea stagnalis Acetylcholine binding protein (AChBP) complexed with Paraherquamide A
2ZJV	;	2.7	;	Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Clothianidin
2ZJU	;	2.58	;	Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Imidacloprid
3WTN	;	2.09	;	Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Desnitro-imidacloprid
3WTL	;	2.3	;	Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Nitromethylene Analogue of Imidacloprid
3WTJ	;	2.24	;	Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Thiacloprid
7PDR	;	2.33	;	Crystal structure of Lymnaea stagnalis Acetylcholine-binding protein (Ls-AChBP) Q55R/M114V double mutant complexed with Dichloromezotiaz
7PDB	;	2.33	;	Crystal structure of Lymnaea stagnalis Acetylcholine-binding protein (Ls-AChBP) Q55R/M114V double mutant complexed with Flupyradifurone
7PE6	;	2.01	;	Crystal structure of Lymnaea stagnalis Acetylcholine-binding protein (Ls-AChBP) Q55R/M114V double mutant complexed with Flupyrimin
7PD6	;	2.0	;	Crystal structure of Lymnaea stagnalis Acetylcholine-binding protein (Ls-AChBP) Q55R/M114V double mutant complexed with Sulfoxaflor
7PE5	;	2.1	;	Crystal structure of Lymnaea stagnalis Acetylcholine-binding protein (Ls-AChBP) Q55R/M114V double mutant complexed with Triflumezopyrim
4ZK1	;	1.75	;	Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein (LsAChBP) in Complex with 3-Pyrrolylmethylene Anabaseine
3WTI	;	2.68	;	Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Clothianidin
3WTO	;	2.25	;	Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Desnitro-imidacloprid
3WTH	;	2.54	;	Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Imidacloprid
3WTM	;	2.48	;	Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Nitromethylene Analogue of Imidacloprid
3WTK	;	2.69	;	Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Thiacloprid
5T2T	;	1.967	;	Crystal structure of Lymphocytic choriomeningitis mammarenavirus endonuclease bound to compound L742001
5LTF	;	2.43	;	Crystal structure of Lymphocytic choriomeningitis mammarenavirus endonuclease complexed with catalytic ions
5LTN	;	1.88	;	Crystal structure of Lymphocytic choriomeningitis mammarenavirus endonuclease complexed with DPBA
5LTS	;	2.51	;	Crystal structure of Lymphocytic choriomeningitis mammarenavirus endonuclease Mutant D118A
5XY1	;	2.7	;	Crystal structure of Lyn kinase domain in complex with N-(1H-indazol-6-yl)-8-(piperidin-4-yloxy)-6-propylquinazolin-2-amine
7BAX	;	2.9	;	Crystal structure of LYS11 ectodomain
2EBE	;	1.8	;	Crystal structure of Lys11 to Met mutant of hypothetical protein from Thermus thermophilus
2HW9	;	1.6	;	Crystal structure of Lys12Cys/Cys117Val mutant of human acidic fibroblast Growth factor at 1.60 angstrom resolution.
2HWA	;	1.65	;	Crystal structure of Lys12Thr/Cys117Val mutant of human acidic fibroblast growth factor at 1.65 angstrom resolution.
2HZ9	;	1.7	;	Crystal structure of Lys12Val/Asn95Val/Cys117Val mutant of human acidic fibroblast growth factor at 1.70 angstrom resolution.
2HWM	;	1.6	;	Crystal structure of Lys12Val/Cys117Val mutant of human acidic fibroblast growth factor at 1.60 angstrom resolution
1Z88	;	2.1	;	Crystal structure of Lys154Arg mutant of mature AphA of S. typhimurium
2AUT	;	2.25	;	Crystal structure of Lys154Asn mutant of mature AphA of S. typhimurium
7D55	;	1.397	;	Crystal structure of lys170 CBD
2DV7	;	2.3	;	Crystal structure of Lys187 to Arg mutant of Diphthine synthase
2DSG	;	2.0	;	Crystal structure of Lys26 to Arg mutant of Diphthine synthase
2DSH	;	2.0	;	Crystal structure of Lys26 to Tyr mutant of Diphthine synthase
6ISU	;	1.866	;	Crystal structure of Lys27-linked di-ubiquitin in complex with its selective interacting protein UCHL3
8TW1	;	1.27	;	Crystal structure of Lys2972, a phage endolysin targeting Streptococcus thermophilus
8E7O	;	1.7	;	CRYSTAL STRUCTURE OF LYS48-LINKED TETRAUBIQUITIN
2Z6R	;	1.5	;	Crystal structure of Lys49 to Arg mutant of Diphthine synthase
1S8G	;	2.3	;	Crystal structure of Lys49-Phospholipase A2 from Agkistrodon contortrix laticinctus, fatty acid bound form
1S8H	;	1.8	;	Crystal structure of Lys49-Phospholipase A2 from Agkistrodon contortrix laticinctus, first fatty acid free form
1S8I	;	1.609	;	Crystal structure of Lys49-Phospholipase A2 from Agkistrodon contortrix laticinctus, second fatty acid free form
2JF5	;	1.95	;	crystal structure of Lys63-linked di-ubiquitin
6AKV	;	2.4	;	Crystal structure of LysB4, the endolysin from Bacillus cereus-targeting bacteriophage B4
5EC5	;	3.1	;	Crystal structure of lysenin pore
3HC7	;	2.0	;	Crystal structure of lysin B from Mycobacteriophage D29
1XRS	;	2.8	;	Crystal structure of Lysine 5,6-Aminomutase in complex with PLP, cobalamin, and 5'-deoxyadenosine
3WWL	;	1.2	;	Crystal structure of lysine biosynthetic amino acid carrier protein LysW from Thermus thermophilus conjugated with alpha-aminoadipate
5GJM	;	2.91	;	Crystal structure of Lysine decarboxylase from Selenomonas ruminantium in C2 space group
5GJN	;	2.0	;	Crystal structure of Lysine decarboxylase from Selenomonas ruminantium in P43212 space group
3D0U	;	2.8	;	Crystal Structure of Lysine Riboswitch Bound to Lysine
6W4K	;	2.93	;	Crystal structure of Lysine Specific Demethylase 1 (LSD1) with CC-90011
7XW8	;	2.28	;	Crystal structure of Lysine Specific Demethylase 1 (LSD1) with TAK-418 distomer, FAD-adduct
7E0G	;	2.25	;	Crystal structure of Lysine Specific Demethylase 1 (LSD1) with TAK-418, FAD-adduct
2Q3K	;	2.0	;	Crystal Structure of Lysine Sulfonamide Inhibitor Reveals the Displacement of the Conserved Flap Water Molecule in HIV-1 Protease
2Z3Y	;	2.25	;	Crystal structure of Lysine-specific demethylase1
2Z5U	;	2.25	;	Crystal structure of Lysine-specific histone demethylase 1
2PLK	;	2.14	;	Crystal structure of lysine/ornithine decarboxylase complexed with cadaverine from Vibrio vulnificus
2PLJ	;	1.7	;	Crystal structure of lysine/ornithine decarboxylase complexed with putrescine from Vibrio vulnificus
5XOY	;	2.39	;	Crystal structure of LysK from Thermus thermophilus in complex with Lysine
5BUM	;	2.5	;	Crystal Structure of LysM domain from Equisetum arvense chitinase A
4PXV	;	1.8	;	Crystal Structure of LysM domain from pteris ryukyuensis chitinase A
5YLG	;	1.48	;	Crystal Structure of LysM domain from pteris ryukyuensis chitinase A
5K2L	;	1.2	;	Crystal structure of LysM domain from Volvox carteri chitinase
2ZYJ	;	1.67	;	Crystal structure of LysN, alpha-aminoadipate aminotransferase (complexed with N-(5'-phosphopyridoxyl)-L-glutamate), from Thermus thermophilus HB27
2Z1Y	;	1.75	;	Crystal structure of LysN, alpha-aminoadipate aminotransferase (complexed with N-(5'-phosphopyridoxyl)-L-leucine), from Thermus thermophilus HB27
2ZP7	;	2.26	;	Crystal structure of LysN, alpha-aminoadipate aminotransferase (Leucine complex), from Thermus thermophilus HB27
2EGY	;	2.67	;	Crystal structure of LysN, alpha-aminoadipate aminotransferase (substrate free form), from Thermus thermophilus HB27
3CBF	;	1.67	;	Crystal structure of LysN, alpha-aminoadipate aminotransferase, from Thermus thermophilus HB27
8ITR	;	2.44	;	Crystal structure of lysophosphatidylcholine in complex with human serum albumin
8ITT	;	3.03	;	Crystal structure of lysophosphatidylcholine in complex with human serum albumin and myristate
6BJE	;	2.7	;	Crystal Structure of Lysophospholipase A2 Conjugated with Phenylmethylsulfonyl Fluoride
7YMQ	;	2.29	;	Crystal structure of lysoplasmalogen specific phopholipase D, F211L mutant
7YMP	;	2.57	;	Crystal structure of lysoplasmalogen specific phospholipase D
4X90	;	1.84	;	Crystal structure of Lysosomal Phospholipase A2
4X94	;	2.7	;	Crystal structure of Lysosomal Phospholipase A2 crystallized in the presence of methyl arachidonyl fluorophosphonate (hexagonal form)
4X93	;	2.6	;	Crystal structure of Lysosomal Phospholipase A2 crystallized in the presence of methyl arachidonyl fluorophosphonate (tetragonal form)
4X91	;	2.3	;	Crystal structure of Lysosomal Phospholipase A2 in complex with Isopropyl dodec-11-enylfluorophosphonate (IDFP)
4X97	;	2.65	;	Crystal structure of Lysosomal Phospholipase A2 in complex with methyl arachidonyl fluorophosphonate (MAFP)
4X92	;	3.0	;	Crystal structure of Lysosomal Phospholipase A2-S165A
5K2K	;	1.65	;	Crystal structure of lysozyme
5K2P	;	1.24	;	Crystal structure of lysozyme
5K2R	;	1.6	;	Crystal structure of lysozyme
7F26	;	1.7	;	Crystal structure of lysozyme
7WBF	;	1.6	;	Crystal structure of lysozyme
8GMV	;	2.2	;	Crystal structure of lysozyme
8GMW	;	1.35	;	Crystal structure of lysozyme
7WBE	;	1.9	;	Crystal structure of lysozyme (multilcrystal diffraction, CrystFEL/MOSFLM)
7WBD	;	1.9	;	Crystal structure of lysozyme (multilcrystal diffraction, CrystFEL/XGANDALF)
8WDI	;	2.2	;	Crystal structure of lysozyme by fixed-target pink-beam serial synchrotron crystallography
6IRJ	;	1.65	;	Crystal structure of lysozyme by fixed-target serial femtosecond crystallography
6LL3	;	1.85	;	Crystal structure of lysozyme by fixed-target serial femtosecond crystallography
7CVJ	;	1.5	;	Crystal structure of lysozyme by fixed-target serial synchrotron crystallography (100 ms)
7CVL	;	1.6	;	Crystal structure of lysozyme by fixed-target serial synchrotron crystallography (500 ms)
8YBH	;	1.55	;	Crystal structure of lysozyme by macromolecular crystallography
8YBG	;	1.55	;	Crystal structure of lysozyme by serial synchrotron crystallography
6K5Q	;	1.177	;	Crystal structure of lysozyme complexed with a bioactive compound from Jatropha gossypiifolia
7BVO	;	1.9	;	Crystal structure of lysozyme delivered in alginate
6IG6	;	1.7	;	Crystal structure of lysozyme delivered in polyacrylamide using x-ray free electron laser
7BVM	;	2.0	;	Crystal structure of lysozyme delivered in wheat starch
3B6L	;	2.3	;	Crystal structure of lysozyme folded in SDS and 2-methyl-2,4-pentanediol
3B72	;	1.5	;	Crystal structure of lysozyme folded in SDS and 2-methyl-2,4-pentanediol
5XUW	;	1.76	;	Crystal structure of lysozyme from Equus asinus
3RNX	;	1.856	;	Crystal Structure of Lysozyme in 30% ethanol
3RW8	;	1.855	;	Crystal structure of lysozyme in 40% ethanol
3T6U	;	2.213	;	Crystal Structure of Lysozyme in 40% sucrose
7OL5	;	0.94	;	Crystal structure of Lysozyme in complex with Hepes
7OL6	;	1.1	;	Crystal structure of Lysozyme in complex with Imidazole
7OL8	;	1.15	;	Crystal structure of Lysozyme in complex with trifluoroethanol: orthorhombic form
7OL7	;	1.15	;	Crystal structure of Lysozyme in complex with trifluoroethanol: tetragonal form
4B1A	;	1.67	;	Crystal structure of lysozyme with Keggin molecule
3KN3	;	2.412	;	Crystal Structure of LysR Substrate Binding Domain (25-263) of Putative Periplasmic Protein from Wolinella succinogenes
5EIO	;	1.8	;	Crystal structure of LysY from Thermus thermophilus complexed with NADP+ and LysW-gamma-aminoadipic semialdehyde
6NRZ	;	2.1	;	Crystal Structure of Lysyl-tRNA Synthetase from Chlamydia trachomatis complexed with L-lysine and Adenosine
6NS0	;	2.2	;	Crystal Structure of Lysyl-tRNA Synthetase from Chlamydia trachomatis complexed with L-lysine and Cladosporin
6O3F	;	2.4	;	Crystal Structure of Lysyl-tRNA Synthetase from Chlamydia trachomatis with complexed with L-lysine and a difluoro cyclohexyl chromone ligand
5ELN	;	1.9	;	Crystal Structure of Lysyl-tRNA Synthetase from Cryptosporidium parvum complexed with L-lysine
6HCW	;	1.46	;	Crystal Structure of Lysyl-tRNA Synthetase from Cryptosporidium parvum complexed with L-lysine and a difluoro cyclohexyl chromone ligand
6BNI	;	1.85	;	Crystal Structure of Lysyl-tRNA Synthetase from Cryptosporidium parvum complexed with L-lysine and Adenosine
5ELO	;	1.9	;	Crystal Structure of Lysyl-tRNA Synthetase from Cryptosporidium parvum complexed with L-lysine and cladosporin
6C86	;	2.15	;	Crystal Structure of Lysyl-tRNA Synthetase from Cryptosporidium parvum complexed with L-Lysylsulfamoyl Adenosine
6AQH	;	2.35	;	Crystal Structure of Lysyl-tRNA Synthetase from Mycobacterium thermoresistibile complexed with L-lysine and Cladosporin
7QH8	;	1.92	;	CRYSTAL STRUCTURE OF LYSYL-TRNA SYNTHETASE FROM Mycobacterium tuberculosis COMPLEXED WITH L-LYSINE
7QHN	;	2.58	;	CRYSTAL STRUCTURE OF LYSYL-TRNA SYNTHETASE FROM Mycobacterium tuberculosis COMPLEXED WITH L-LYSINE and an inhibitor
7QI8	;	2.2	;	CRYSTAL STRUCTURE OF LYSYL-TRNA SYNTHETASE FROM Mycobacterium tuberculosis COMPLEXED WITH L-LYSINE AND INHIBITOR
5VL1	;	2.7	;	Crystal Structure of Lysyl-tRNA Synthetase from Mycobacterium ulcerans complexed with L-lysine
6AQG	;	2.25	;	Crystal Structure of Lysyl-tRNA Synthetase from Mycobacterium ulcerans complexed with L-lysine and Cladosporin
6HCU	;	1.62	;	Crystal Structure of Lysyl-tRNA Synthetase from Plasmodium falciparum bound to a difluoro cyclohexyl chromone ligand
6HCV	;	2.2	;	Crystal Structure of Lysyl-tRNA Synthetase from Plasmodium falciparum complexed with a chromone ligand
6L4Q	;	3.1	;	Crystal Structure of Lysyl-tRNA Synthetase from Plasmodium falciparum complexed with L-lysine and Clado-B
6L3Y	;	3.1	;	Crystal Structure of Lysyl-tRNA Synthetase from Plasmodium falciparum complexed with L-lysine and Clado-C
6M0T	;	2.68	;	Crystal Structure of Lysyl-tRNA Synthetase from Plasmodium falciparum complexed with L-lysine and Cladosporin derivative (CL-2)
6WBD	;	2.05	;	Crystal Structure of Lysyl-tRNA synthetase from Stenotrophomonas maltophilia with bound L-lysine
4EX5	;	2.4	;	Crystal structure of lysyl-tRNA synthetase LysRS from Burkholderia thailandensis bound to lysine
3WWN	;	1.85	;	Crystal structure of LysZ from Thermus thermophilus complex with LysW
3WWM	;	2.8	;	Crystal structure of LysZ from Thermus thermophilus with ADP
3T36	;	2.25	;	Crystal structure of lytic transglycosylase MltE from Eschericha coli
1MFR	;	2.8	;	CRYSTAL STRUCTURE OF M FERRITIN
2PKF	;	1.5	;	Crystal structure of M tuberculosis Adenosine Kinase (apo)
2PKK	;	1.93	;	Crystal structure of M tuberculosis Adenosine Kinase complexed with 2-fluro adenosine
4UBE	;	1.933	;	CRYSTAL STRUCTURE OF M TUBERCULOSIS ADENOSINE KINASE COMPLEXED WITH 2-FLURO ADENOSINE
2PKM	;	1.9	;	Crystal structure of M tuberculosis Adenosine Kinase complexed with adenosine
2PKN	;	1.9	;	Crystal structure of M tuberculosis Adenosine Kinase complexed with AMP-PCP (non-hydrolyzable ATP analog)
1DF0	;	2.6	;	Crystal structure of M-Calpain
5HT9	;	1.869	;	Crystal structure of M-crystallin in the presence of nickel
3TPW	;	1.65	;	CRYSTAL STRUCTURE OF M-PMV DUTPASE - DUPNPP complex revealing distorted ligand geometry (approach intermediate)
3TPS	;	1.85	;	Crystal structure of M-PMV dUTPASE complexed with dUPNPP substrate
3TPN	;	1.65	;	Crystal structure of M-PMV dUTPASE complexed with dUPNPP, substrate
2D4N	;	1.53	;	Crystal Structure of M-PMV dUTPase complexed with dUPNPP, substrate analogue
3TQ5	;	1.4	;	Crystal structure of M-PMV dUTPASE post-inversion product (dUMP) COMPLEX
3TRL	;	1.8	;	Crystal structure of M-PMV dUTPASE post-inversion product (dUMP) complex
3TRN	;	1.83	;	Crystal structure of M-PMV dUTPASE post-inversion product (dUMP) complex
3TS6	;	1.84	;	Crystal structure of M-PMV DUTPASE relaxed end-product (dUMP) complex
3TSL	;	2.2	;	Crystal structure of M-PMV DUTPASE relaxed end-product (dUMP) complex
3TTA	;	2.0	;	Crystal structure of M-PMV DUTPASE relaxed end-product (dUMP) complex
3TPY	;	1.75	;	Crystal structure of M-PMV dUTPase with a mixed population of substrate (dUPNPP) and post-inversion product (dUMP) in the active sites
3TQ3	;	1.85	;	Crystal structure of M-PMV dUTPase with a mixed population of substrate (dUPNPP) and post-inversion product (dUMP) in the active sites
3TQ4	;	1.6	;	Crystal structure of M-PMV dUTPase with a mixed population of substrate (dUPNPP) and post-inversion product (dUMP) in the active sites
1X1R	;	1.3	;	Crystal structure of M-Ras in complex with GDP
1X1S	;	2.2	;	Crystal structure of M-Ras in complex with GppNHp
3KKQ	;	1.2	;	Crystal structure of M-Ras P40D in complex with GDP
3KKP	;	1.35	;	Crystal structure of M-Ras P40D in complex with GppNHp
3KKO	;	1.9	;	Crystal structure of M-Ras P40D/D41E/L51R in complex with GppNHp
3PIR	;	2.75	;	Crystal structure of M-RasD41E in complex with GppNHp (type 1)
3PIT	;	1.55	;	Crystal structure of M-RasD41E in complex with GppNHp (type 2)
5B86	;	3.017	;	Crystal structure of M-Sec
3CFX	;	1.6	;	Crystal structure of M. acetivorans periplasmic binding protein ModA/WtpA with bound tungstate
4XUL	;	2.26	;	Crystal structure of M. chilensis Mg662 protein complexed with GTP
1XHK	;	1.9	;	Crystal structure of M. jannaschii Lon proteolytic domain
3CFZ	;	1.7	;	Crystal structure of M. jannaschii periplasmic binding protein ModA/WtpA with bound tungstate
3A27	;	2.005	;	Crystal structure of M. jannaschii TYW2 in complex with AdoMet
4CDM	;	2.7	;	Crystal structure of M. mazei photolyase soaked with synthetic 8-HDF
4CDN	;	1.9	;	Crystal structure of M. mazei photolyase with its in vivo reconstituted 8-HDF antenna chromophore
4C03	;	1.58	;	Crystal structure of M. musculus protein arginine methyltransferase PRMT6 reduced
4C08	;	1.338	;	Crystal structure of M. musculus protein arginine methyltransferase PRMT6 with CaCl2 at 1.34 Angstroms
4C07	;	1.499	;	Crystal structure of M. musculus protein arginine methyltransferase PRMT6 with CaCl2 at 1.5 Angstroms
4C04	;	1.576	;	Crystal structure of M. musculus protein arginine methyltransferase PRMT6 with inhibitor
4C06	;	1.6	;	Crystal structure of M. musculus protein arginine methyltransferase PRMT6 with MgCl2
4C05	;	2.195	;	Crystal structure of M. musculus protein arginine methyltransferase PRMT6 with SAH
5FQO	;	1.899	;	Crystal structure of M. musculus protein arginine methyltransferase PRMT6 with SAH and magnesium
5FQN	;	1.657	;	Crystal structure of M. musculus protein arginine methyltransferase PRMT6 with SAH at 1.65 Angstroms
7DIE	;	1.9	;	Crystal structure of M. penetrans Ferritin
3WA8	;	2.8	;	Crystal structure of M. ruber CasB
4F4Q	;	2.619	;	Crystal structure of M. smegmatis DprE1 in complex with FAD and covalently bound BTZ043
2A5V	;	2.2	;	Crystal structure of M. tuberculosis beta carbonic anhydrase, Rv3588c, tetrameric form
4C6W	;	1.7	;	Crystal structure of M. tuberculosis C171Q KasA
4C6X	;	1.95	;	Crystal structure of M. tuberculosis C171Q KasA in complex with thiolactomycin (TLM)
4C71	;	1.8	;	Crystal structure of M. tuberculosis C171Q KasA in complex with TLM18
4C6Z	;	1.8	;	Crystal structure of M. tuberculosis C171Q KasA in complex with TLM3
4C70	;	1.75	;	Crystal structure of M. tuberculosis C171Q KasA in complex with TLM4
4C72	;	1.5	;	Crystal structure of M. tuberculosis C171Q KasA in complex with TLM5
4C73	;	1.8	;	Crystal structure of M. tuberculosis C171Q KasA in complex with TLM6
1HX5	;	3.5	;	Crystal structure of M. tuberculosis chaperonin-10
4U0H	;	3.2479	;	Crystal Structure of M. tuberculosis ClpP1P1
4U0G	;	3.1978	;	Crystal Structure of M. tuberculosis ClpP1P2 bound to ADEP and agonist
8AMO	;	1.4	;	Crystal structure of M. tuberculosis CYP143
4NCR	;	1.881	;	Crystal structure of M. tuberculosis DprE1 in complex with PBTZ169
6G83	;	2.4	;	Crystal structure of M. tuberculosis DprE1 in complex with sPBTZ169 (sulfonylPBTZ)
4P8H	;	3.0	;	Crystal structure of M. tuberculosis DprE1 in complex with the nitro-benzothiazole 6a
4P8M	;	2.09	;	Crystal structure of M. tuberculosis DprE1 in complex with the non-covalent inhibitor QN114
4P8N	;	1.79	;	Crystal structure of M. tuberculosis DprE1 in complex with the non-covalent inhibitor QN118
4P8C	;	1.95	;	Crystal structure of M. tuberculosis DprE1 in complex with the non-covalent inhibitor QN127
4P8P	;	2.2	;	Crystal structure of M. tuberculosis DprE1 in complex with the non-covalent inhibitor QN127
4P8T	;	2.55	;	Crystal structure of M. tuberculosis DprE1 in complex with the non-covalent inhibitor QN129
4P8Y	;	2.01	;	Crystal structure of M. tuberculosis DprE1 in complex with the non-covalent inhibitor Ty21c
4P8L	;	2.02	;	Crystal structure of M. tuberculosis DprE1 in complex with the non-covalent inhibitor Ty36c
4P8K	;	2.49	;	Crystal structure of M. tuberculosis DprE1 in complex with the non-covalent inhibitor Ty38c
5DTP	;	1.91	;	Crystal structure of M. tuberculosis EchA6 (apo, trigonal crystal form)
5DTW	;	2.439	;	Crystal structure of M. tuberculosis EchA6 bound to C20-CoA
5DU8	;	2.23	;	Crystal structure of M. tuberculosis EchA6 bound to GSK572A
5DU6	;	2.61	;	Crystal structure of M. tuberculosis EchA6 bound to ligand GSK059A.
5DU4	;	1.702	;	Crystal structure of M. tuberculosis EchA6 bound to ligand GSK366A
5DUF	;	1.5	;	Crystal structure of M. tuberculosis EchA6 bound to ligand GSK729A
5DUC	;	2.704	;	Crystal structure of M. tuberculosis EchA6 bound to ligand GSK951A
6HRD	;	2.11	;	Crystal structure of M. tuberculosis FadB2 (Rv0468)
3E25	;	2.7	;	Crystal structure of M. tuberculosis glucosyl-3-phosphoglycerate synthase
3E26	;	2.5	;	Crystal structure of M. tuberculosis glucosyl-3-phosphoglycerate synthase
6OFC	;	3.14	;	Crystal structure of M. tuberculosis glutamine-dependent NAD+ synthetase complexed with Sulfonamide derivative 1, pyrophosphate, and glutamine
4PFD	;	2.3	;	Crystal structure of M. tuberculosis in complex with a cBT - non-covalent adduct
4PFA	;	2.56	;	Crystal structure of M. tuberculosis in complex with BTO - covalent adduct
6SQ7	;	1.76	;	Crystal structure of M. tuberculosis InhA in complex with NAD+ and 2-(4-chloro-3-nitrobenzoyl)benzoic acid
6SQD	;	1.72	;	Crystal structure of M. tuberculosis InhA in complex with NAD+ and 2-pyrazol-1-ylbenzoic acid
6SQB	;	1.774	;	Crystal structure of M. tuberculosis InhA in complex with NAD+ and 3-(3-chlorophenyl)propanoic acid
6SQ9	;	1.75	;	Crystal structure of M. tuberculosis InhA in complex with NAD+ and 3-hydroxynaphthalene-2-carboxylic acid
6SQ5	;	1.84	;	Crystal structure of M. tuberculosis InhA in complex with NAD+ and 3-[3-(trifluoromethyl)phenyl]prop-2-enoic acid
6SQL	;	2.35	;	Crystal structure of M. tuberculosis InhA in complex with NAD+ and N-(3-(aminomethyl)phenyl)-5-chloro-3-methylbenzo[b]thiophene-2-sulfonamide
5UGS	;	2.8	;	Crystal structure of M. tuberculosis InhA inhibited by PT501
5UGT	;	2.6	;	Crystal structure of M. tuberculosis InhA inhibited by PT504
5UGU	;	1.95	;	Crystal structure of M. tuberculosis InhA inhibited by PT506
5MTQ	;	2.6	;	Crystal structure of M. tuberculosis InhA inhibited by PT511
5MTR	;	2.0	;	Crystal structure of M. tuberculosis InhA inhibited by PT512
5MTP	;	2.0	;	Crystal structure of M. tuberculosis InhA inhibited by PT514
2X22	;	2.1	;	crystal structure of M. tuberculosis InhA inhibited by PT70
2X23	;	1.807	;	crystal structure of M. tuberculosis InhA inhibited by PT70
6YUU	;	2.01	;	Crystal structure of M. tuberculosis InhA inhibited by SKTS1
6Y2J	;	2.886	;	Crystal structure of M. tuberculosis KasA in complex with 4,4,4-trifluoro-N-(isoquinolin-6-yl)butane-1-sulfonamide
6Y2I	;	1.533	;	Crystal structure of M. tuberculosis KasA in complex with N-(1H-indazol-5-yl)butane-1-sulfonamide
4C6U	;	2.4	;	Crystal structure of M. tuberculosis KasA in complex with TLM5
4C6V	;	2.7	;	Crystal structure of M. tuberculosis KasA in complex with TLM5 (Soak for 5 min)
3TUR	;	1.72	;	Crystal Structure of M. tuberculosis LD-transpeptidase type 2 complexed with a peptidoglycan fragment
3U1Q	;	2.4	;	Crystal Structure of M. tuberculosis LD-transpeptidase type 2 with 2-Mercaptoethanol
3U1P	;	2.8	;	Crystal Structure of M. tuberculosis LD-transpeptidase type 2 with Modified Catalytic Cysteine (C354)
3VAE	;	2.8	;	Crystal Structure of M. tuberculosis LD-transpeptidase type 2 with Modified Catalytic Cysteine (C354)
5EXJ	;	1.64	;	Crystal structure of M. tuberculosis lipoyl synthase at 1.64 A resolution
5EXI	;	2.28	;	Crystal structure of M. tuberculosis lipoyl synthase at 2.28 A resolution
5EXK	;	1.86	;	Crystal structure of M. tuberculosis lipoyl synthase with 6-thiooctanoyl peptide intermediate
5HK0	;	2.25	;	Crystal structure of M. tuberculosis MazF-mt3 (Rv1991c) in complex with RNA
5HKC	;	1.68	;	Crystal structure of M. tuberculosis MazF-mt3 T52D-F62D mutant in complex with 8-mer RNA
5HK3	;	1.56	;	Crystal structure of M. tuberculosis MazF-mt3 T52D-F62D mutant in complex with DNA
5ESS	;	2.2	;	Crystal Structure of M. tuberculosis MenD bound to Mg2+ and covalent intermediate I (a ThDP and decarboxylated 2-oxoglutarate adduct)
5ESU	;	2.2	;	Crystal Structure of M. tuberculosis MenD bound to Mg2+ and Covalent Intermediate II (a ThDP + de-carboxylated 2-oxoglutarate + Isochorismate adduct)
5ESD	;	2.25	;	Crystal Structure of M. tuberculosis MenD bound to ThDP and Mn2+
5ESO	;	2.05	;	Crystal Structure of M. tuberculosis MenD with ThDP, Mg2+ and Isochorismate bound
4QJK	;	1.59	;	Crystal structure of M. tuberculosis phosphopantetheinyl transferase PptT
3F61	;	1.8	;	Crystal Structure of M. tuberculosis PknB Leu33Asp/Val222Asp double mutant in complex with ADP
1I80	;	2.0	;	CRYSTAL STRUCTURE OF M. TUBERCULOSIS PNP IN COMPLEX WITH IMINORIBITOL, 9-DEAZAHYPOXANTHINE AND PHOSPHATE ION
3GO7	;	2.5	;	Crystal Structure of M. tuberculosis ribokinase (Rv2436) in complex with ribose
3GO6	;	1.98	;	Crystal Structure of M. tuberculosis ribokinase (Rv2436) in complex with ribose and AMP-PNP
2A87	;	3.0	;	Crystal Structure of M. tuberculosis Thioredoxin reductase
4FX0	;	2.6981	;	Crystal structure of M. tuberculosis transcriptional regulator MosR
4FX4	;	3.1001	;	Crystal structure of M. tuberculosis transcriptional regulator MOSR (Rv1049) in compex with DNA
4LXF	;	2.6	;	Crystal structure of M. tuberculosis TreS
3TWP	;	1.83	;	Crystal structure of M. tuberculosis TrpD in complex with an inhibitor
5K2Y	;	2.41	;	Crystal structure of M. tuberculosis UspC (monoclinic crystal form)
5K2X	;	1.5	;	Crystal structure of M. tuberculosis UspC (tetragonal crystal form)
3CTO	;	2.5	;	Crystal Structure of M. tuberculosis YefM antitoxin
3D55	;	2.13	;	Crystal structure of M. tuberculosis YefM antitoxin
4QJL	;	1.65	;	Crystal structure of M. ulcerans phosphopantetheinyl transferase MuPPT
1G61	;	1.3	;	CRYSTAL STRUCTURE OF M.JANNASCHII EIF6
2YX1	;	2.2	;	Crystal structure of M.jannaschii tRNA m1G37 methyltransferase
8AMP	;	2.0	;	Crystal structure of M.tuberculosis ferredoxin Fdx
7DDV	;	2.2	;	Crystal structure of M.tuberculosis imidazole glycerol phosphate dehydratase in complex with an inhibitor
7DNQ	;	2.28	;	Crystal structure of M.tuberculosis imidazole glycerol phosphate dehydratase in complex with an inhibitor
7FCY	;	1.848	;	Crystal structure of M.tuberculosis imidazole glycerol phosphate dehydratase in complex with an inhibitor
5XKA	;	1.599	;	Crystal structure of M.tuberculosis PknI kinase domain
6JMI	;	2.896	;	Crystal structure of M.tuberculosis Rv0081
6IFG	;	1.9	;	Crystal structure of M1 zinc metallopeptidase E323A mutant bound to Tyr-ser-ala substrate from Deinococcus radiodurans
6IFF	;	1.83	;	Crystal structure of M1 zinc metallopeptidase E323A mutant from Deinococcus radiodurans
6A8Z	;	2.045	;	Crystal structure of M1 zinc metallopeptidase from Deinococcus radiodurans
5HEK	;	3.0	;	crystal structure of M1.HpyAVI
5HFJ	;	3.1	;	crystal structure of M1.HpyAVI-SAM complex
3BL2	;	2.3	;	Crystal Structure of M11, the BCL-2 Homolog of Murine Gamma-herpesvirus 68, Complexed with Mouse Beclin1 (residues 106-124)
2O42	;	2.91	;	Crystal Structure of M11L, Bcl-2 homolog from myxoma virus
5XCN	;	1.69	;	Crystal structure of M120A mutant of O-acetyl-L-serine sulfahydrylase from Haemophilus influenzae
6AIF	;	2.3	;	Crystal structure of M120A mutant of O-acetylserine sulfhydrylase from Haemophilus influenzae in complex with high affinity inhibitory peptide from serine acetyl transferase of Salmonella typhimurium
4MFH	;	1.54	;	Crystal Structure of M121G Azurin
1GS6	;	2.2	;	Crystal structure of M144A mutant of Alcaligenes xylosoxidans Nitrite Reductase
2NYK	;	2.1	;	Crystal structure of m157 from mouse cytomegalovirus
1LWC	;	2.62	;	CRYSTAL STRUCTURE OF M184V MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH NEVIRAPINE
5ZK8	;	3.0	;	Crystal structure of M2 muscarinic acetylcholine receptor bound with NMS
6GG3	;	3.72	;	Crystal structure of M2 PYK in complex with Alanine.
6GG4	;	2.46	;	Crystal structure of M2 PYK in complex with Phenyalanine.
6GG6	;	2.96	;	Crystal structure of M2 PYK in complex with Serine.
6GG5	;	3.2	;	Crystal structure of M2 PYK in complex with Tryptophan.
4S0Z	;	1.45	;	Crystal structure of M26V human DJ-1
4XX7	;	1.77	;	Crystal structure of M2A mutant of human macrophage migration inhibitory factor
8H3C	;	3.43	;	Crystal structure of M2e Influenza peptide in complex with antibody scFv
5J3Z	;	1.8	;	Crystal structure of m2hTDP2-CAT in complex with a small molecule inhibitor
5J42	;	1.7	;	Crystal structure of m2hTDP2-CAT in complex with a small molecule inhibitor
5GIV	;	2.4	;	Crystal structure of M32 carboxypeptidase from Deinococcus radiodurans R1
2ORY	;	2.2	;	Crystal structure of M37 lipase
1LWE	;	2.81	;	CRYSTAL STRUCTURE OF M41L/T215Y MUTANT HIV-1 REVERSE TRANSCRIPTASE (RTMN) IN COMPLEX WITH NEVIRAPINE
2HS2	;	1.22	;	Crystal structure of M46L mutant of HIV-1 protease complexed with TMC114 (darunavir)
7KLC	;	4.3	;	Crystal structure of M4H2K1 Fab bound to HIV-1 BG505 gp120 core and to 17b Fab
4MEZ	;	2.047	;	Crystal structure of M68L/M69T double mutant TEM-1
3V5M	;	1.3	;	Crystal structure of M69V mutant of SHV beta-lactamase
5XCP	;	2.043	;	Crystal structure of M92A mutant of O-acetyl-L-serine sulfhydrylase from Haemophilus influenzae
5XCW	;	1.89	;	Crystal structure of M92A-M120A double mutant of O-acetyl-L-serine sulfhydrylase from Haemophilus influenzae
7C35	;	2.1	;	Crystal structure of M96A mutant of O-acetyl-L-serine sulfhydrylase from Haemophilus influenzae
4A2N	;	3.4	;	Crystal Structure of Ma-ICMT
3SGE	;	1.89	;	Crystal structure of mAb 17.2 in complex with R13 peptide
5OVL	;	2.4	;	crystal structure of MabA bound to NADP+ from M. smegmatis
2NTN	;	2.3	;	Crystal structure of MabA-C60V/G139A/S144L
2DS2	;	1.7	;	Crystal structure of mabinlin II
8CDA	;	2.1	;	Crystal structure of MAB_4123 from Mycobacterium abscessus
7Q3A	;	2.0	;	Crystal structure of MAB_4324 a tandem repeat GNAT from Mycobacterium abscessus
5OVY	;	1.9	;	Crystal structure of MAB_4384 tetR
4DK0	;	3.5	;	Crystal structure of MacA from Actinobacillus actinomycetemcomitans
4DK1	;	3.499	;	Crystal Structure of MacA-MexA chimeric protein, containing the Pseudomonas aeruginosa MexA alpha-hairpin domain.
6VOR	;	1.85	;	Crystal structure of macaque anti-HIV-1 antibody RM20E1
6VSR	;	2.176	;	Crystal structure of macaque anti-HIV-1 antibody RM20F
6VOS	;	2.299	;	Crystal structure of macaque anti-HIV-1 antibody RM20J
5W3V	;	2.243	;	Crystal Structure of macaque APOBEC3H in complex with RNA
2XUO	;	2.8	;	CRYSTAL STRUCTURE OF MACHE-Y337A mutant in complex with soaked TZ2PA6 ANTI inhibitor
2XUF	;	2.55	;	CRYSTAL STRUCTURE OF MACHE-Y337A-TZ2PA6 ANTI COMPLEX (1 MTH)
2XUG	;	2.6	;	Crystal structure of mAChE-Y337A-TZ2PA6 anti complex (1 wk)
2XUH	;	2.65	;	CRYSTAL STRUCTURE OF MACHE-Y337A-TZ2PA6 ANTI COMPLEX (10 MTH)
2XUJ	;	2.65	;	CRYSTAL STRUCTURE OF MACHE-Y337A-TZ2PA6 SYN COMPLEX (1 MTH)
2XUI	;	2.6	;	CRYSTAL STRUCTURE OF MACHE-Y337A-TZ2PA6 SYN COMPLEX (1 WK)
2XUK	;	2.75	;	CRYSTAL STRUCTURE OF MACHE-Y337A-TZ2PA6 SYN COMPLEX (10 MTH)
2WFO	;	1.73	;	Crystal structure of Machupo virus envelope glycoprotein GP1
3GPG	;	1.65	;	Crystal structure of macro domain of Chikungunya virus
3GPO	;	1.9	;	Crystal structure of macro domain of Chikungunya virus in complex with ADP-ribose
3GPQ	;	2.0	;	Crystal structure of macro domain of Chikungunya virus in complex with RNA
3GQE	;	2.3	;	Crystal structure of macro domain of Venezuelan Equine Encephalitis virus
3GQO	;	2.6	;	Crystal structure of macro domain of Venezuelan Equine Encephalitis virus in complex with ADP-ribose
7M4S	;	2.493	;	Crystal structure of macrocyclase AMdnB from Anabaena sp. PCC 7120
5IG8	;	2.278	;	Crystal structure of macrocyclase MdnB from Microcystis aeruginosa MRC
5IG9	;	2.665	;	Crystal structure of macrocyclase MdnC bound with precursor peptide MdnA from Microcystis aeruginosa MRC
4NTP	;	1.987	;	Crystal structure of macrocycles containing A 17-23 (LV(PHI)FAED) and A 30-36 (AII(SAR)L(ORN)V)
5V64	;	2.023	;	Crystal structure of macrocycles containing Abeta 15-21 (QKLV(PHI)FA) and Abeta 30-36 (AII(SAR)L(ORN)V)
5V63	;	2.091	;	Crystal structure of macrocycles containing Abeta 16-22 (KLV(PHI)FAE) and Abeta 30-36 (AII(SAR)L(ORN)V)
5V65	;	2.52	;	Crystal structure of macrocycles containing Abeta 17-23 (LV(PHI)FAED) and Abeta 30-36 (AII(SAR)L(ORN)V)
4NTR	;	1.7	;	Crystal structure of macrocycles containing Abeta 17-23 (LVFFAED) and Abeta 30-36 (AII(SAR)L(ORN)V)
4NW8	;	2.02	;	Crystal structure of macrocycles containing Abeta17-23 (LV(PHI)(MEA)AED) and Abeta30-36 (AIIGL(ORN)V)
4NW9	;	1.66	;	Crystal structure of macrocycles containing Abeta17-23 (LVF(MEA)AED) and Abeta30-36 (AIIGL(ORN)V)
7WMC	;	2.55	;	Crystal structure of macrocyclic peptide 1 bound to human Nicotinamide N-methyltransferase
6SIS	;	3.5	;	Crystal structure of macrocyclic PROTAC 1 in complex with the second bromodomain of human Brd4 and pVHL:ElonginC:ElonginB
8DMT	;	2.28	;	Crystal structure of macrodomain CG2909 from Drosophila melanogaster in complex with ADP-ribose
8DMU	;	2.0	;	Crystal structure of macrodomain CG3568 from Drosophila melanogaster in complex with ADP-ribose
5UXA	;	1.95	;	Crystal structure of macrolide 2'-phosphotransferase MphB from Escherichia coli
5UXD	;	1.7	;	Crystal structure of macrolide 2'-phosphotransferase MphH from Brachybacterium faecium in complex with azithromycin
5UXC	;	1.72	;	Crystal structure of macrolide 2'-phosphotransferase MphH from Brachybacterium faecium in complex with GDP
5UXB	;	2.794	;	Crystal structure of macrolide 2'-phosphotransferase MphH from Brachybacterium faecium, apoenzyme
4M60	;	1.77	;	Crystal structure of macrolide glycosyltransferases OleD
3OP1	;	2.488	;	Crystal Structure of Macrolide-efflux Protein SP_1110 from Streptococcus pneumoniae
8UZ4	;	2.4	;	Crystal Structure of macrophage migration inhibitory factor (MIF) from Trichomonas vaginalis (Apo, P41212 form)
8UR2	;	1.9	;	Crystal Structure of macrophage migration inhibitory factor (MIF) from Trichomonas vaginalis (I41 form)
8UR4	;	2.55	;	Crystal Structure of macrophage migration inhibitory factor (MIF) from Trichomonas vaginalis (I4122 form)
5HVS	;	1.75	;	Crystal Structure of Macrophage Migration Inhibitory Factor (MIF) with a Biaryltriazole Inhibitor (3i-305)
5HVT	;	1.75	;	Crystal Structure of Macrophage Migration Inhibitory Factor (MIF) with a Potent Inhibitor (NVS-2)
3L5U	;	1.9	;	Crystal structure of macrophage migration inhibitory factor (MIF) with benzothiazole inhibitor at 1.90A resolution
3L5V	;	1.7	;	Crystal structure of macrophage migration inhibitory factor (MIF) with glycerol at 1.70A resolution
3JSF	;	1.93	;	Crystal structure of macrophage migration inhibitory factor (mif) with hydroxyquinoline inhibitor 638 at 1.93a resolution
3JSG	;	1.58	;	Crystal structure of macrophage migration inhibitory factor (mif) with hydroxyquinoline inhibitor 707 at 1.58a resolution
3JTU	;	1.86	;	Crystal structure of macrophage migration inhibitory factor (mif) with hydroxyquinoline inhibitor 708 at 1.86a resolution
3L5P	;	1.8	;	Crystal structure of macrophage migration inhibitory factor (MIF) with imidazopyridazinol inhibitor at 1.80A resolution
3L5S	;	1.86	;	Crystal structure of macrophage migration inhibitory factor (MIF) with imidazopyrimidinylphenyl inhibitor at 1.86A resolution
3L5R	;	1.94	;	Crystal structure of macrophage migration inhibitory factor (MIF) with phenylchromenone inhibitor at 1.94A resolution
3L5T	;	1.86	;	Crystal structure of macrophage migration inhibitory factor (MIF) with thiophenepiperazinylquinolinone inhibitor at 1.86A resolution
3DJI	;	1.95	;	Crystal Structure of Macrophage Migration Inhibitory Factor Bound to an Acetaminophen Dimer Derived from NAPQI
5XEJ	;	2.5	;	Crystal Structure of Macrophage Migration Inhibitory Factor bound to MTX
1MFI	;	1.8	;	CRYSTAL STRUCTURE OF MACROPHAGE MIGRATION INHIBITORY FACTOR COMPLEXED WITH (E)-2-FLUORO-P-HYDROXYCINNAMATE
1LJT	;	2.0	;	Crystal Structure of Macrophage Migration Inhibitory Factor complexed with (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole-acetic acid methyl ester (ISO-1)
2WKB	;	1.78	;	Crystal Structure of Macrophage Migration Inhibitory Factor from Plasmodium berghei
2WKF	;	2.05	;	Crystal Structure of Macrophage Migration Inhibitory Factor from Plasmodium falciparum
9B0M	;	1.8	;	Crystal structure of Macrophage migration inhibitory factor from Plasmodium vivax
1UIZ	;	2.5	;	Crystal Structure Of Macrophage Migration Inhibitory Factor From Xenopus Laevis.
2XCZ	;	1.64	;	Crystal Structure of macrophage migration inhibitory factor homologue from Prochlorococcus marinus
4PLU	;	1.63	;	Crystal structure of Macrophage Migration Inhibitory Factor in complex with benzaldehyde
5B4O	;	1.37	;	Crystal structure of Macrophage Migration Inhibitory Factor in complex with BTZO-14
4PKK	;	1.78	;	Crystal structure of Macrophage Migration inhibitory factor in complex with furan-2-ylmethyl)imino methanethiol
4TRF	;	1.63	;	Crystal structure of Macrophage Migration Inhibitory Factor in complex with N-(pyridin-3-ylmethyl)thioformamide
8VJ2	;	1.9	;	Crystal Structure of Macrophage migration inhibitory factor-1 (MIF1) from Onchocerca volvulus
6CUQ	;	2.45	;	Crystal structure of Macrophage migration inhibitory factor-like protein (EhMIF) from Entamoeba histolytica
7D17	;	2.998	;	Crystal structure of Macrostomum lignano glutaminyl cyclase
3DIT	;	3.2	;	Crystal structure of MAD MH2 domain
3GMJ	;	2.8	;	Crystal structure of MAD MH2 domain
1NLW	;	2.0	;	Crystal structure of Mad-Max recognizing DNA
1GO4	;	2.05	;	Crystal structure of Mad1-Mad2 reveals a conserved Mad2 binding motif in Mad1 and Cdc20.
7K75	;	2.5	;	Crystal structure of MAD2-6 IgA Fab in complex with PfCSP N-terminal peptide.
7K76	;	2.14	;	Crystal structure of MAD2-6 IgG Fab in complex with PfCSP N-terminal peptide.
5XPU	;	2.304	;	Crystal structure of MAD2L2/REV7 in complex with a CAMP fragment in a monoclinic crystal
5XPT	;	2.102	;	Crystal structure of MAD2L2/REV7 in complex with a CAMP fragment in a tetragonal crystal
6JQH	;	2.303	;	Crystal structure of MaDA
7E2V	;	2.94	;	Crystal structure of MaDA-3
8C84	;	1.9	;	Crystal structure of MADS-box/MEF2D N-terminal domain complex
2P5X	;	2.0	;	Crystal structure of Maf domain of human N-acetylserotonin O-methyltransferase-like protein
6XI4	;	2.22	;	Crystal structure of Maf domain of human N-acetylserotonin O-methyltransferase-like protein soaked with TFBQ
4OO0	;	2.15	;	Crystal Structure of Maf-like protein BceJ2315_23540 from Burkholderia cenocepacia
2AMH	;	2.0	;	Crystal Structure of Maf-like Protein Tbru21784AAA from T.brucei
3A5T	;	2.8	;	Crystal structure of MafG-DNA complex
6WJH	;	2.19	;	Crystal structure of MAGE-A11 bound to the PCF11 degron
5WY5	;	2.92	;	Crystal structure of MAGEG1 and NSE1 complex
6JJZ	;	1.65	;	Crystal Structure of MAGI2 and Dendrin complex
7YKH	;	2.5	;	Crystal structure of MAGI2 PDZ0-GK domain in complex with phospho-SAPAP1 GBR2 peptide
7YKI	;	2.0	;	Crystal structure of MAGI2 PDZ0-GK domain in complex with phospho-SAPAP1 GBR3 peptide
7YKF	;	2.28	;	Crystal structure of MAGI2 PDZ0-GK/pEphexin4 complex
7YKG	;	2.16	;	Crystal structure of MAGI2 PDZ0-GK/pSGEF complex
6KKG	;	2.15	;	Crystal structure of MAGI2-Dendrin complex
4HG0	;	3.102	;	Crystal Structure of magnesium and cobalt efflux protein CorC, Northeast Structural Genomics Consortium (NESG) Target ER40
4QDK	;	1.7	;	Crystal structure of magnesium protoporphyrin IX methyltransferase (ChlM) from Synechocystis PCC 6803 with bound SAH
4QDJ	;	1.6	;	Crystal structure of magnesium protoporphyrin IX methyltransferase (ChlM) from Synechocystis PCC 6803 with bound SAM
2YVX	;	3.5	;	Crystal structure of magnesium transporter MgtE
4WIB	;	3.2	;	Crystal structure of Magnesium transporter MgtE
2YVY	;	2.3	;	Crystal structure of magnesium transporter MgtE cytosolic domain, Mg2+ bound form
2YVZ	;	3.9	;	Crystal structure of magnesium transporter MgtE cytosolic domain, Mg2+-free form
5BY0	;	1.8	;	Crystal structure of magnesium-bound Duf89 protein Saccharomyces cerevisiae
4HQL	;	2.241	;	Crystal structure of magnesium-loaded Plasmodium vivax TRAP protein
4RAY	;	1.55	;	Crystal structure of Magnetospirillum gryphiswaldense MSR-1 Apo-Fur
4RB1	;	2.75	;	Crystal structure of Magnetospirillum gryphiswaldense MSR-1 Fur-Mn2+-E. coli Fur box
4RB3	;	2.6	;	Crystal structure of Magnetospirillum gryphiswaldense MSR-1 Fur-Mn2+-feoAB1 operator
4RAZ	;	1.9	;	Crystal structure of Magnetospirillum gryphiswaldense MSR-1 holo-Fur
4RB0	;	1.85	;	Crystal structure of Magnetospirillum gryphiswaldense MSR-1 SeMet-Apo-Fur
4RB2	;	2.82	;	Crystal structure of Magnetospirillum gryphiswaldense MSR-1 SeMet-Fur-Mn2+-feoAB1 operator
1HXS	;	2.2	;	CRYSTAL STRUCTURE OF MAHONEY STRAIN OF POLIOVIRUS AT 2.2A RESOLUTION
8FTC	;	2.0	;	Crystal structure of main protease of SARS-CoV-2 complexed with inhibitor
5JGW	;	2.3	;	Crystal structure of maize AKR4C13 in complex with NADP and acetate
5JGY	;	1.45	;	Crystal structure of maize AKR4C13 in P21 space group
5OU5	;	2.2	;	Crystal structure of maize chloroplastic photosynthetic NADP(+)-dependent malic enzyme
3PZH	;	1.919	;	Crystal structure of maize CK2 alpha in complex with emodin at 1.92 A resolution
1OM1	;	1.68	;	Crystal structure of maize CK2 alpha in complex with IQA
3PWD	;	2.2	;	Crystal structure of maize CK2 in complex with NBC (Z1)
4DGM	;	1.65	;	Crystal Structure of maize CK2 in complex with the inhibitor apigenin
4DGN	;	1.75	;	Crystal Structure of maize CK2 in complex with the inhibitor luteolin
6QS5	;	1.961	;	Crystal Structure of maize CK2 in complex with tyrphostin AG99
8CK6	;	1.9	;	Crystal structure of maize CKO/CKX8 in complex with urea-derived inhibitor 2-[(3,5-dichlorophenyl)carbamoylamino]-4-methoxy-benzamide
8CJ9	;	1.93	;	Crystal structure of maize CKO/CKX8 in complex with urea-derived inhibitor 2-[(3,5-dichlorophenyl)carbamoylamino]benzamide
8CKT	;	2.0	;	Crystal structure of maize cytokinin oxidase/dehydrogenase 4 (CKO/CKX4) in complex with inhibitor 2-[(3,5-dichlorophenyl)carbamoylamino]-4-(trifluoromethoxy)benzamide
8CLW	;	1.8	;	Crystal structure of maize cytokinin oxidase/dehydrogenase 4 (CKO/CKX4) in complex with inhibitor 2-[(3,5-dichlorophenyl)carbamoylamino]-4-methoxy-benzamide
8CKQ	;	2.0	;	Crystal structure of maize cytokinin oxidase/dehydrogenase 4 (CKO/CKX4) in complex with inhibitor 2-[(3,5-dichlorophenyl)carbamoylamino]benzamide
8CM2	;	2.05	;	Crystal structure of maize cytokinin oxidase/dehydrogenase 4 (CKO/CKX4) in complex with inhibitor 2-[[3,5-dichloro-2-(2-hydroxyethyl)phenyl]carbamoylamino]-4-(trifluoromethoxy)benzamide
5HHZ	;	2.0	;	Crystal structure of maize cytokinin oxidase/dehydrogenase 4 (ZmCKO4) in complex with 6-(3-methylpyrrol-1-yl)-9H-purine
5HMR	;	2.0	;	Crystal structure of maize cytokinin oxidase/dehydrogenase 4 (ZmCKO4) in complex with phenylurea inhibitor 3FMTDZ
4O95	;	1.75	;	Crystal structure of maize cytokinin oxidase/dehydrogenase 4 (ZmCKO4) in complex with phenylurea inhibitor CPPU
4OAL	;	1.9	;	Crystal structure of maize cytokinin oxidase/dehydrogenase 4 (ZmCKO4) in complex with phenylurea inhibitor CPPU in alternative spacegroup
5HQX	;	2.05	;	Crystal structure of maize cytokinin oxidase/dehydrogenase 4 (ZmCKO4) in complex with phenylurea inhibitor HETDZ
2QKN	;	2.15	;	Crystal structure of Maize cytokinin oxidase/dehydrogenase complexed with phenylurea inhibitor CPPU
5D0N	;	3.2	;	Crystal structure of maize PDRP bound with AMP
5D1F	;	3.4	;	Crystal structure of maize PDRP bound with AMP and Hg2+
7W82	;	3.1	;	Crystal structure of maize RDR2
7EEZ	;	1.902	;	crystal structure of maize SHH2 SAWADEE domain
7EF0	;	1.5	;	Crystal structure of maize SHH2 SAWADEE domain in complex with an H3K9M peptide
7EF2	;	2.0	;	Crystal structure of maize SHH2 SAWADEE domain in complex with an H3K9me3 peptide
7EF1	;	1.9	;	crystal structure of maize SHH2 SAWADEE domain in complex with and H3K9me1 peptide
7EF3	;	2.1	;	crystal structure of maize SHH2 SAWADEE domain in complex with H3K9me2 peptide
5UV4	;	2.3	;	Crystal Structure of Maize SIRK1 (sucrose-induced receptor kinase 1) kinase domain bound to AMP-PNP
7V3K	;	2.49	;	crystal structure of MAJ1
3EBK	;	1.9	;	Crystal structure of major allergens, Bla g 4 from cockroaches
3EBW	;	2.8	;	Crystal structure of major allergens, Per a 4 from cockroaches
6FXO	;	2.5	;	Crystal structure of Major Bifunctional Autolysin
4A84	;	1.5	;	Crystal Structure of Major Birch Pollen Allergen Bet v 1 a F30V mutant in complex with deoxycholate.
4A80	;	1.96	;	Crystal Structure of Major Birch Pollen Allergen Bet v 1 a in complex with 8-Anilinonaphthalene-1-sulfonate (ANS)
4A83	;	1.54	;	Crystal Structure of Major Birch Pollen Allergen Bet v 1 a in complex with deoxycholate.
4A8G	;	2.1	;	Crystal Structure of Major Birch Pollen Allergen Bet v 1 a in complex with dimethylbenzylammonium propane sulfonate
4A85	;	1.4	;	Crystal Structure of Major Birch Pollen Allergen Bet v 1 a in complex with kinetin.
4A87	;	1.24	;	Crystal Structure of Major Birch Pollen Allergen Bet v 1 a in complex with naringenin.
4A81	;	2.05	;	Crystal Structure of Major Birch Pollen Allergen Bet v 1 a in ternary complex with 8-Anilinonaphthalene-1-sulfonate (ANS) and deoxycholic acid
4A86	;	1.59	;	Crystal Structure of Major Birch Pollen Allergen Bet v 1 a in ternary complex with kinetin and 8-Anilinonaphthalene-1-sulfonate (ANS)
4QIP	;	2.0	;	Crystal Structure of Major Birch Pollen Allergen Bet v 1 isoform a in complex with Sodium Dodecyl Sulfate
4EGT	;	2.0	;	Crystal structure of major capsid protein P domain from rabbit hemorrhagic disease virus
4EJR	;	2.0	;	Crystal structure of major capsid protein S domain from rabbit hemorrhagic disease virus
5HLJ	;	2.406	;	Crystal Structure of Major Envelope Protein VP24 from White Spot Syndrome Virus
3SMH	;	2.433	;	Crystal structure of major peanut allergen Ara h 1
4S3L	;	2.8	;	Crystal Structure of major pilin protein PitB from type II pilus of Streptococcus pneumoniae
2Y92	;	3.01	;	Crystal structure of MAL adaptor protein
6UCT	;	3.47	;	Crystal structure of Mal de Rio Cuarto virus P9-1 viroplasm protein (C-arm deletion mutant)
3TPM	;	2.1	;	Crystal structure of MAL RPEL domain in complex with importin-alpha
5WGY	;	2.0	;	Crystal Structure of MalA' C112S/C128S, malbrancheamide B complex
5WGV	;	2.3	;	Crystal Structure of MalA' C112S/C128S, premalbrancheamide complex
5WGU	;	2.052	;	Crystal Structure of MalA' E494D, premalbrancheamide complex
5WGX	;	1.973	;	Crystal Structure of MalA' H253A, malbrancheamide B complex
5WGT	;	2.093	;	Crystal Structure of MalA' H253A, premalbrancheamide complex
5WGS	;	2.34	;	Crystal Structure of MalA' H253F, premalbrancheamide complex
3FS3	;	2.3	;	Crystal structure of malaria parasite Nucleosome Assembly Protein (NAP)
6E64	;	3.15	;	Crystal structure of malaria transmission-blocking antibody 85RF45.1
6E65	;	1.5	;	Crystal structure of malaria transmission-blocking antibody TB31F
6E62	;	2.7	;	Crystal structure of malaria transmission-blocking antigen Pfs48/45 6C in complex with antibody 85RF45.1
6E63	;	2.6	;	Crystal structure of malaria transmission-blocking antigen Pfs48/45 6C in complex with antibody TB31F
7UNB	;	2.18	;	Crystal structure of malaria transmission-blocking antigen Pfs48/45-6C variant in complex with human antibodies RUPA-117 and RUPA-47
7UXL	;	2.86	;	Crystal structure of malaria transmission-blocking antigen Pfs48/45-6C variant in complex with human antibodies RUPA-44 and RUPA-29
3D5T	;	2.51	;	Crystal structure of malate dehydrogenase from Burkholderia pseudomallei
6ITK	;	2.0	;	Crystal structure of malate dehydrogenase from Corynebacterium glutamicum ATCC 13032 in complex with NAD and malate
3I0P	;	2.6	;	Crystal structure of malate dehydrogenase from Entamoeba histolytica
7Q3X	;	1.95	;	Crystal structure of Malate dehydrogenase from Haloarcula marismortui with Potassium and Chloride ions
6PBL	;	1.85	;	Crystal structure of Malate dehydrogenase from Legionella pneumophila Philadelphia 1
6ITL	;	1.97	;	Crystal structure of malate dehydrogenase from Mannheimia succiniciproducens in complex with NAD
6IHD	;	2.3	;	Crystal structure of Malate dehydrogenase from Metallosphaera sedula
6IHE	;	1.9	;	Crystal structure of Malate dehydrogenase from Metallosphaera sedula
6UM4	;	2.05	;	Crystal structure of malate dehydrogenase from Naegleria fowleri ATCC 30863
5NFR	;	2.4	;	Crystal structure of malate dehydrogenase from Plasmodium falciparum (PfMDH)
6R8G	;	2.0	;	Crystal structure of malate dehydrogenase from Plasmodium Falciparum in complex with 4-(3,4-difluorophenyl)thiazol-2-amine
6Y91	;	2.5	;	Crystal structure of malate dehydrogenase from Plasmodium Falciparum in complex with NADH
3FI9	;	1.9	;	Crystal structure of malate dehydrogenase from Porphyromonas gingivalis
1IZ9	;	2.0	;	Crystal Structure of Malate Dehydrogenase from Thermus thermophilus HB8
7NRZ	;	2.6	;	Crystal structure of malate dehydrogenase from Trypanosoma cruzi
5OAS	;	1.62	;	Crystal structure of malate synthase G from Pseudomonas aeruginosa in apo form.
1LAX	;	1.85	;	CRYSTAL STRUCTURE OF MALE31, A DEFECTIVE FOLDING MUTANT OF MALTOSE-BINDING PROTEIN
3HL0	;	1.6	;	Crystal structure of Maleylacetate reductase from Agrobacterium tumefaciens
3W5S	;	1.49	;	Crystal Structure of Maleylacetate Reductase from Rhizobium sp. strain MTP-10005
4IGJ	;	1.48	;	Crystal structure of Maleylacetoacetate isomerase from Anaeromyxobacter dehalogenans 2CP-1, target EFI-507175
4KAE	;	1.5	;	Crystal structure of Maleylacetoacetate isomerase from Anaeromyxobacter dehalogenans 2CP-1, TARGET EFI-507175, with bound dicarboxyethyl glutathione and citrate in the active site
4KDY	;	1.5	;	Crystal structure of maleylacetoacetate isomerase from Anaeromyxobacter dehalogenans 2CP-1, Target EFI-507175, with bound GSH in the active site
4PX1	;	1.85	;	CRYSTAL STRUCTURE OF Maleylacetoacetate isomerase from Methylobacteriu extorquens AM1 WITH BOUND MALONATE (TARGET EFI-507068)
4PXO	;	1.8	;	Crystal structure of Maleylacetoacetate isomerase from Methylobacteriu extorquens AM1 WITH BOUND MALONATE AND GSH (TARGET EFI-507068)
6JVW	;	2.25	;	Crystal structure of maleylpyruvate hydrolase from Sphingobium sp. SYK-6 in complex with manganese (II) ion and pyruvate
6JVV	;	1.51	;	Crystal structure of maleylpyruvate hydrolase from Sphingobium.sp SYK-6
6JWK	;	1.86	;	Crystal structure of maleylpyruvate isomerase from Pseudomonas aeruginosa PAO1
1LLQ	;	2.3	;	Crystal Structure of Malic Enzyme from Ascaris suum Complexed with Nicotinamide Adenine Dinucleotide
1WW8	;	2.5	;	Crystal Structure of malic enzyme from Pyrococcus horikoshii Ot3
3R90	;	1.7	;	Crystal structure of Malignant T cell-amplified sequence 1 protein
6XQW	;	2.991	;	Crystal Structure of MaliM03 Fab in complex with Pfmsp1-19
5K87	;	1.219	;	crystal structure of malonate bound to methylaconitate isomerase PrpF from Shewanella oneidensis
3DG9	;	1.5	;	Crystal Structure of Malonate Decarboxylase from Bordatella bronchiseptica
3E4P	;	2.3	;	Crystal structure of malonate occupied DctB
4PVP	;	1.85	;	Crystal structure of malonate-bound human L-asparaginase protein
3G87	;	2.3	;	Crystal structure of malonyl CoA-acyl carrier protein transacylase from Burkholderia pseudomallei using dried seaweed as nucleant or protease
3PTW	;	2.1	;	CRYSTAL STRUCTURE OF malonyl CoA-acyl carrier protein transacylase from Clostridium perfringens Atcc 13124
2CUY	;	2.1	;	Crystal structure of malonyl CoA-acyl carrier protein transacylase from Thermus thermophilus HB8
2X2B	;	2.69	;	Crystal structure of malonyl-ACP (acyl carrier protein) from Bacillus subtilis
4KS9	;	2.3	;	Crystal Structure of Malonyl-CoA decarboxylase (Rmet_2797) from Cupriavidus metallidurans, Northeast Structural Genomics Consortium Target CrR76
4KSF	;	3.1	;	Crystal Structure of Malonyl-CoA decarboxylase from Agrobacterium vitis, Northeast Structural Genomics Consortium Target RiR35
4KSA	;	2.7	;	Crystal Structure of Malonyl-CoA decarboxylase from Rhodopseudomonas palustris, Northeast Structural Genomics Consortium Target RpR127
3R97	;	2.3	;	Crystal structure of malonyl-CoA:acyl carrier protein transacylase (FabD), Xoo0880, from Xanthomonas oryzae pv. oryzae KACC10331
2H1Y	;	2.5	;	Crystal structure of malonyl-CoA:Acyl carrier protein transacylase (MCAT) from Helicobacter pylori
5BN7	;	3.7	;	Crystal structure of maltodextrin glucosidase from E.coli at 3.7 A resolution
4AEE	;	2.28	;	CRYSTAL STRUCTURE OF MALTOGENIC AMYLASE FROM S.MARINUS
1WPC	;	1.9	;	Crystal structure of maltohexaose-producing amylase complexed with pseudo-maltononaose
1WP6	;	2.1	;	Crystal structure of maltohexaose-producing amylase from alkalophilic Bacillus sp.707.
2D3N	;	1.9	;	Crystal structure of maltohexaose-producing amylase from Bacillus sp.707 complexed with maltohexaose
2D3L	;	2.3	;	Crystal structure of maltohexaose-producing amylase from Bacillus sp.707 complexed with maltopentaose.
1IV8	;	1.9	;	Crystal Structure of Maltooligosyl trehalose synthase
5BK2	;	2.6	;	Crystal structure of maltose binding protein in complex with a peristeric synthetic antibody
5BJZ	;	1.95	;	Crystal structure of maltose binding protein in complex with an allosteric synthetic antibody
5BK1	;	2.15	;	Crystal structure of maltose binding protein in complex with an endosteric synthetic antibody
3PGF	;	2.1	;	Crystal structure of maltose bound MBP with a conformationally specific synthetic antigen binder (sAB)
3IGJ	;	2.6	;	Crystal Structure of Maltose O-acetyltransferase Complexed with Acetyl Coenzyme A from Bacillus anthracis
3HJJ	;	2.153	;	Crystal Structure of Maltose O-acetyltransferase from Bacillus anthracis
6AG8	;	1.34	;	Crystal structure of Maltose O-acetyltransferase from E. coli
2IC7	;	1.78	;	Crystal Structure of Maltose Transacetylase from Geobacillus kaustophilus
2P2O	;	1.74	;	Crystal structure of maltose transacetylase from Geobacillus kaustophilus P2(1) crystal form
3HPI	;	2.0	;	Crystal structure of maltose-binding protein mutant with bound sucrose
4ZWB	;	2.4	;	Crystal structure of maltose-bound human GLUT3 in the outward-occluded conformation at 2.4 angstrom
4ZWC	;	2.6	;	Crystal structure of maltose-bound human GLUT3 in the outward-open conformation at 2.6 angstrom
1FQD	;	2.3	;	CRYSTAL STRUCTURE OF MALTOTETRAITOL BOUND TO CLOSED-FORM MALTODEXTRIN BINDING PROTEIN
6J34	;	1.498	;	Crystal Structure of maltotriose-complex of PulA from Klebsiella pneumoniae
6J4H	;	1.641	;	Crystal Structure of maltotriose-complex of PulA-G680L mutant from Klebsiella pneumoniae
1FQC	;	2.3	;	CRYSTAL STRUCTURE OF MALTOTRIOTOL BOUND TO CLOSED-FORM MALTODEXTRIN BINDING PROTEIN
6YSB	;	1.2	;	Crystal structure of Malus domestica Double Bond Reductase (MdDBR) apo form
6YTZ	;	1.4	;	Crystal structure of Malus domestica Double Bond Reductase (MdDBR) in complex with NADPH
6YUX	;	1.36	;	Crystal structure of Malus domestica Double Bond Reductase (MdDBR) ternary complex
3VTY	;	2.0	;	Crystal structure of MamA
3VTX	;	1.75	;	Crystal structure of MamA protein
8DA0	;	2.2	;	Crystal structure of Mamba alpha-neurotoxin in complex with Centi-3FTX-D09 antibody
4ORC	;	2.7	;	Crystal structure of mammalian calcineurin
3RTX	;	2.81	;	Crystal structure of mammalian capping enzyme (Mce1) and Pol II CTD complex
2O48	;	2.59	;	Crystal structure of Mammalian Dimeric Dihydrodiol Dehydrogenase
2O4U	;	2.0	;	Crystal structure of Mammalian Dimeric Dihydrodiol Dehydrogenase
3OHS	;	1.9	;	Crystal Structure of Mammalian Dimeric Dihydrodiol Dehydrogenase in complex with Dihydroxyacetone
2VZ8	;	3.219	;	Crystal Structure of Mammalian Fatty Acid Synthase
2VZ9	;	3.3	;	Crystal Structure of Mammalian Fatty Acid Synthase in complex with NADP
2WCU	;	1.9	;	Crystal structure of mammalian FucU
1WLE	;	1.65	;	Crystal Structure of mammalian mitochondrial seryl-tRNA synthetase complexed with seryl-adenylate
4Q8S	;	2.09	;	Crystal structure of mammalian Peptidoglycan recognition protein PGRP-S with paranitrophenyl palmitate and N-acetyl glucosamine at 2.09 A resolution
4U8H	;	2.798	;	Crystal Structure of Mammalian Period-Cryptochrome Complex
1F5A	;	2.5	;	CRYSTAL STRUCTURE OF MAMMALIAN POLY(A) POLYMERASE
1Q79	;	2.15	;	CRYSTAL STRUCTURE OF MAMMALIAN POLY(A) POLYMERASE
6EKJ	;	1.6	;	Crystal structure of mammalian Rev7 in complex with human Chromosome alignment-maintaining phosphoprotein 1
6EKL	;	1.6	;	Crystal structure of mammalian Rev7 in complex with human Chromosome alignment-maintaining phosphoprotein 1
6EKM	;	2.76	;	Crystal structure of mammalian Rev7 in complex with human Rev3 second binding site
5O8K	;	1.8	;	Crystal structure of mammalian Rev7 in complex with Rev3 1875-1895
6TYL	;	3.3	;	Crystal structure of mammalian Ric-8A:Galpha(i):nanobody complex
8J72	;	3.16	;	Crystal structure of mammalian Trim71 in complex with lncRNA Trincr1
5HM9	;	2.6	;	Crystal structure of MamO protease domain from Magnetospirillum magneticum (apo form)
5HMA	;	2.299	;	Crystal structure of MamO protease domain from Magnetospirillum magneticum (Ni bound form)
4JJ0	;	1.8	;	Crystal structure of MamP
4JJ3	;	2.8	;	Crystal structure of MamP soaked with iron(II)
4H83	;	2.094	;	Crystal structure of Mandelate racemase/muconate lactonizing enzyme (EFI target:502127)
3T8Q	;	2.0	;	Crystal structure of mandelate racemase/muconate lactonizing enzyme family protein from Hoeflea phototrophica
3MSY	;	2.5	;	Crystal Structure of Mandelate racemase/muconate lactonizing enzyme from a Marine actinobacterium
3NO1	;	2.16	;	Crystal Structure of Mandelate racemase/muconate lactonizing enzyme from a Marine actinobacterium in complex with magnesium
2GDQ	;	1.8	;	Crystal structure of mandelate racemase/muconate lactonizing enzyme from Bacillus subtilis at 1.8 A resolution
2GGE	;	1.89	;	Crystal Structure of Mandelate Racemase/Muconate Lactonizing Enzyme from Bacillus Subtilis complexed with MG++ at 1.8 A
3DDM	;	2.6	;	CRYSTAL STRUCTURE OF MANDELATE RACEMASE/MUCONATE LACTONIZING ENZYME FROM Bordetella bronchiseptica RB50
4J3Z	;	2.5	;	Crystal structure of mandelate racemase/muconate lactonizing enzyme from Jannaschia sp. CCS1
2OG9	;	1.9	;	Crystal Structure of mandelate racemase/muconate lactonizing enzyme from Polaromonas sp. JS666
2RDX	;	2.0	;	Crystal structure of mandelate racemase/muconate lactonizing enzyme from Roseovarius nubinhibens ISM
3RCY	;	1.994	;	CRYSTAL STRUCTURE OF Mandelate racemase/muconate lactonizing enzyme-like protein from Roseovarius sp. TM1035
2QQ6	;	2.9	;	Crystal structure of mandelate racemase/muconate lactonizing enzyme-like protein from Rubrobacter xylanophilus DSM 9941
2QDE	;	1.93	;	Crystal structure of mandelate racemase/muconate lactonizing family protein from Azoarcus sp. EbN1
3N6J	;	2.4	;	Crystal structure of Mandelate racemase/muconate lactonizing protein from Actinobacillus succinogenes 130Z
3N6H	;	2.3	;	Crystal structure of Mandelate racemase/muconate lactonizing protein from Actinobacillus succinogenes 130Z complexed with magnesium/sulfate
3N4F	;	1.88	;	CRYSTAL STRUCTURE OF Mandelate racemase/muconate lactonizing protein from Geobacillus sp. Y412MC10
3OPS	;	2.2	;	Crystal structure of mandelate racemase/muconate lactonizing protein FROM GEOBACILLUS SP. Y412MC10 complexed with magnesium/tartrate
3IK4	;	2.1	;	CRYSTAL STRUCTURE OF mandelate racemase/muconate lactonizing protein from Herpetosiphon aurantiacus
3N4E	;	2.4	;	CRYSTAL STRUCTURE OF mandelate racemase/muconate lactonizing protein from Paracoccus denitrificans Pd1222
4DWD	;	1.5	;	Crystal structure of mandelate racemase/muconate lactonizing protein from Paracoccus denitrificans PD1222 complexed with magnesium
5AJA	;	2.649	;	Crystal structure of mandrill SAMHD1 (amino acid residues 1-114) bound to Vpx isolated from mandrill and human DCAF1 (amino acid residues 1058-1396)
3HHS	;	1.97	;	Crystal Structure of Manduca sexta prophenoloxidase
6CJ7	;	1.6	;	Crystal structure of Manduca sexta Serine protease inhibitor (Serpin)-12
8FFD	;	2.2	;	Crystal structure of manganeese bound Dps protein (PA0962) from Pseudomonas aeruginosa (cubic form)
4NNO	;	1.174	;	Crystal Structure of Manganese ABC transporter substrate-binding protein MntC from Staphylococcus Aureus bound to a Zinc ion
3PDR	;	1.853	;	Crystal structure of manganese bound M-box RNA
1JKU	;	1.84	;	Crystal Structure of Manganese Catalase from Lactobacillus plantarum
1JKV	;	1.39	;	Crystal Structure of Manganese Catalase from Lactobacillus plantarum complexed with azide
4BM1	;	1.098	;	CRYSTAL STRUCTURE OF MANGANESE PEROXIDASE 4 FROM PLEUROTUS OSTREATUS - CRYSTAL FORM I
4BM2	;	1.391	;	CRYSTAL STRUCTURE OF MANGANESE PEROXIDASE 4 FROM PLEUROTUS OSTREATUS - CRYSTAL FORM II
4BM3	;	1.65	;	CRYSTAL STRUCTURE OF MANGANESE PEROXIDASE 4 FROM PLEUROTUS OSTREATUS - CRYSTAL FORM III
4BM4	;	2.3	;	CRYSTAL STRUCTURE OF MANGANESE PEROXIDASE 4 FROM PLEUROTUS OSTREATUS - CRYSTAL FORM IV
1PM2	;	1.8	;	CRYSTAL STRUCTURE OF MANGANESE SUBSTITUTED R2-D84E (D84E MUTANT OF THE R2 SUBUNIT OF E. COLI RIBONUCLEOTIDE REDUCTASE)
4C7U	;	1.951	;	Crystal structure of manganese superoxide dismutase from Arabidopsis thaliana
1Y67	;	1.853	;	Crystal Structure of Manganese Superoxide Dismutase from Deinococcus radiodurans
6BEJ	;	1.894	;	Crystal structure of manganese superoxide dismutase from Xanthomonas citri
1JR9	;	2.8	;	Crystal Structure of manganese superoxide dismutases from Bacillus halodenitrificans
2CWL	;	1.65	;	Crystal structure of manganese-free form of pseudocatalase from Thermus thermophilus HB8
8IUV	;	1.75	;	Crystal structure of Manganese-free N(omega)-hydroxy-L-arginine hydrolase with oxidized Cys86
8IUS	;	2.14	;	Crystal structure of Manganese-free N(omega)-hydroxy-L-arginine hydrolase with reduced Cys86
4HQN	;	2.196	;	Crystal structure of manganese-loaded Plasmodium vivax TRAP protein
3D2O	;	2.04	;	Crystal Structure of Manganese-metallated GTP Cyclohydrolase Type IB
8IUU	;	1.26	;	Crystal structure of Manganese-rebound N(omega)-hydroxy-L-arginine hydrolase with oxidized Cys86
1EF2	;	2.5	;	CRYSTAL STRUCTURE OF MANGANESE-SUBSTITUTED KLEBSIELLA AEROGENES UREASE
7YRO	;	2.42	;	Crystal structure of mango fucosyltransferase 13
1J9Y	;	1.85	;	Crystal structure of mannanase 26A from Pseudomonas cellulosa
1SI0	;	1.35	;	Crystal Structure of Mannheimia haemolytica Ferric iron-Binding Protein A in a closed conformation
1SI1	;	1.45	;	Crystal Structure of Mannheimia haemolytica Ferric iron-Binding Protein A in an open conformation
7KRG	;	2.03797	;	Crystal Structure of Mannitol Dehydrogenase (ChMDH) from Cladosporium herbarum in complex with NADP+ and Na
1LJ8	;	1.7	;	Crystal structure of mannitol dehydrogenase in complex with NAD
3BRJ	;	2.75	;	Crystal structure of mannitol operon repressor (MtlR) from Vibrio parahaemolyticus RIMD 2210633
4PFT	;	1.747	;	Crystal structure of mannobiose bound oligopeptide ABC transporter, periplasmic oligopeptide-binding protein (TM1223) from THERMOTOGA MARITIMA at 1.75 A resolution
4PFU	;	2.049	;	Crystal structure of mannobiose bound oligopeptide ABC transporter, periplasmic oligopeptide-binding protein (TM1226) from THERMOTOGA MARITIMA at 2.05 A resolution
4PFY	;	1.5	;	Crystal structure of mannohexaose bound oligopeptide ABC transporter, periplasmic oligopeptide-binding protein (TM1223) from THERMOTOGA MARITIMA at 1.5 A resolution
4PFW	;	2.198	;	Crystal structure of mannohexaose bound oligopeptide ABC transporter, periplasmic oligopeptide-binding protein (TM1226) from THERMOTOGA MARITIMA at 2.2 A resolution
3VCN	;	1.45	;	Crystal structure of mannonate dehydratase (target EFI-502209) from Caulobacter crescentus CB15
4GME	;	2.0	;	Crystal structure of mannonate dehydratase (target EFI-502209) from caulobacter crescentus cb15 complexed with magnesium and d-mannonate
4EAC	;	2.3	;	Crystal structure of mannonate dehydratase from Escherichia coli strain K12
4FI4	;	2.0	;	Crystal structure of mannonate dehydratase PRK15072 (TARGET EFI-502214) from Caulobacter sp. K31
2WFP	;	1.67	;	Crystal structure of mannose 6-phosphate isomerase (apo form) from Salmonella typhimurium
3H1M	;	2.5	;	Crystal structure of mannose 6-phosphate isomerase (holo; zinc bound)
3H1W	;	1.94	;	Crystal structure of mannose 6-phosphate isomerase bound with zinc and yttrium
3H1Y	;	2.04	;	Crystal structure of mannose 6-phosphate isomerase from Salmonella typhimurium bound to substrate (f6p)and metal atom (zn)
2CU2	;	2.2	;	Crystal structure of mannose-1-phosphate geranyltransferase from Thermus thermophilus HB8
2QH5	;	2.3	;	Crystal structure of mannose-6-phosphate isomerase from Helicobacter pylori
7S5F	;	1.72	;	Crystal structure of mannose-6-phosphate reductase from celery (Apium graveolens) leaves with NADP+ and mannonic acid bound
2ZOS	;	1.7	;	Crystal structure of mannosyl-3-phosphoglycerate phosphatase from Pyrococcus horikoshii
2ZU7	;	2.5	;	Crystal structure of mannosyl-3-phosphoglycerate synthase from Pyrococcus horikoshii
2ZU8	;	2.4	;	Crystal structure of mannosyl-3-phosphoglycerate synthase from Pyrococcus horikoshii
2ZU9	;	2.0	;	Crystal structure of mannosyl-3-phosphoglycerate synthase from Pyrococcus horikoshii
3KIA	;	2.8	;	Crystal structure of mannosyl-3-phosphoglycerate synthase from Rubrobacter xylanophilus
3LFH	;	1.805	;	Crystal structure of manxA from Thermoanaerobacter tengcongensis
3LFJ	;	1.556	;	Crystal structure of manxB from Thermoanaerobacter tengcongensis
1S3E	;	1.6	;	Crystal structure of MAOB in complex with 6-hydroxy-N-propargyl-1(R)-aminoindan
1S3B	;	1.65	;	Crystal structure of MAOB in complex with N-methyl-N-propargyl-1(R)-aminoindan
1S2Q	;	2.07	;	Crystal structure of MAOB in complex with N-propargyl-1(R)-aminoindan (Rasagiline)
1S2Y	;	2.12	;	Crystal structure of MAOB in complex with N-propargyl-1(S)-aminoindan
3KH8	;	2.0	;	Crystal structure of MaoC-like dehydratase from Phytophthora Capsici
3GCG	;	2.3	;	crystal structure of MAP and CDC42 complex
3N9X	;	2.05	;	Crystal structure of Map Kinase from plasmodium berghei, PB000659.00.0
7BE4	;	2.1	;	Crystal structure of MAP kinase p38 alpha in complex with inhibitor SR159
7BE5	;	1.80005	;	Crystal structure of MAP kinase p38 alpha in complex with inhibitor SR276
1LEZ	;	2.3	;	CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS ACTIVATOR MKK3B
1LEW	;	2.3	;	CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS NUCLEAR SUBSTRATE MEF2A
8PM3	;	2.0	;	Crystal structure of MAP2K6 with a covalent compound GCL94
8P7J	;	2.4	;	Crystal structure of MAP2K6 with a covalent compound GCL96
7CBX	;	2.061	;	Crystal structure of MAP2K7 complexed with a covalent inhibitor 12
5JGF	;	1.83	;	Crystal structure of mApe1
3OZ6	;	2.37	;	Crystal structure of MapK from Cryptosporidium Parvum, cgd2_1960
4QNY	;	2.257	;	Crystal structure of MapK from Leishmania donovani, LDBPK_331470
4YNO	;	1.7	;	Crystal structure of MAPK13 at INACTIVE FORM
5EKN	;	2.594	;	Crystal structure of MAPK13 complex with inhibitor
5EKO	;	2.0	;	Crystal structure of MAPK13 complex with inhibitor
4B99	;	2.8	;	Crystal Structure of MAPK7 (ERK5) with inhibitor
3M2W	;	2.41	;	Crystal structure of MAPKAK kinase 2 (MK2) complexed with a spiroazetidine-tetracyclic ATP site inhibitor
3KGA	;	2.55	;	Crystal structure of MAPKAP kinase 2 (MK2) complexed with a potent 3-aminopyrazole ATP site inhibitor
3M42	;	2.68	;	Crystal structure of MAPKAP kinase 2 (MK2) complexed with a tetracyclic ATP site inhibitor
3WI6	;	2.99	;	Crystal structure of MAPKAP Kinase-2 (MK2) in complex with non-selective inhibitor
1KWP	;	2.8	;	Crystal Structure of MAPKAP2
6T8X	;	2.81	;	Crystal structure of MAPKAPK2 (MK2) complexed with PF-3644022 and 5-(4-bromophenyl)-N-[4-(1-piperazinyl)phenyl]-N-(2-pyridinylmethyl)-2-furancarboxamide
5UQY	;	3.6	;	Crystal structure of Marburg virus GP in complex with the human survivor antibody MR78
5F5M	;	2.902	;	Crystal structure of Marburg virus nucleoprotein core domain
5F5O	;	2.2	;	Crystal structure of Marburg virus nucleoprotein core domain bound to VP35 regulation peptide
4OR8	;	2.654	;	Crystal structure of Marburg virus VP24
4GH9	;	1.65	;	Crystal structure of Marburg virus VP35 RNA binding domain
4GHA	;	2.5	;	Crystal structure of Marburg virus VP35 RNA binding domain bound to 12-bp dsRNA
5B0V	;	2.81	;	Crystal Structure of Marburg virus VP40 Dimer
5YPT	;	2.394	;	Crystal structure of Marchantia paleacea chalone synthase like 1 (CHSL1)
2P0U	;	1.9	;	crystal structure of Marchantia polymorpha stilbenecarboxylate synthase 2 (STCS2)
1IWQ	;	2.0	;	Crystal Structure of MARCKS calmodulin binding domain peptide complexed with Ca2+/Calmodulin
5YAD	;	1.76	;	Crystal structure of Marf1 Lotus domain from Mus musculus
5YAA	;	1.75	;	Crystal structure of Marf1 NYN domain from Mus musculus
6J4C	;	1.58	;	Crystal structure of MarH, an epimerase for biosynthesis of Maremycins in Streptomyces, under 10 mM ZnSO4
6J4B	;	1.58	;	Crystal structure of MarH, an epimerase for biosynthesis of Maremycins in Streptomyces, under 400 mM Zinc acetate
6J4D	;	1.4	;	Crystal structure of MarH, an epimerase for biosynthesis of Maremycins in Streptomyces, under pH 4.7, without Zn
6PI1	;	1.7	;	Crystal structure of Marinobacter subterrani acetylpolyamine amidohydrolase (msAPAH) complexed with 4-(dimethylamino)-N-[7-hydroxyamino)-7-oxoheptyl]benzamide
6PHR	;	1.65	;	Crystal structure of Marinobacter subterrani acetylpolyamine amidohydrolase (msAPAH) complexed with 5-[(3-aminopropyl)amino]pentane-1-thiol
6PHT	;	1.8	;	Crystal structure of Marinobacter subterrani acetylpolyamine amidohydrolase (msAPAH) complexed with 5-[(3-aminopropyl)amino]pentylboronic acid
6PIC	;	2.031	;	Crystal structure of Marinobacter subterrani acetylpolyamine amidohydrolase (msAPAH) complexed with 6-amino-N-hydroxyhexanamide
6PIA	;	1.75	;	Crystal structure of Marinobacter subterrani acetylpolyamine amidohydrolase (msAPAH) complexed with 6-[(3-aminopropyl)amino]-N-hydroxyhexanamide
6PHZ	;	2.0	;	Crystal structure of Marinobacter subterrani acetylpolyamine amidohydrolase (msAPAH) complexed with 7-[(3-aminopropyl)amino]-1,1,1-trifluoroheptan-2-one
6PID	;	1.546	;	Crystal structure of Marinobacter subterrani acetylpolyamine amidohydrolase (msAPAH) complexed with 8-amino-N-hydroxyoctanamide
6PI8	;	1.635	;	Crystal structure of Marinobacter subterrani acetylpolyamine amidohydrolase (msAPAH) complexed with acetate
3BPV	;	1.4	;	Crystal Structure of MarR
3BPX	;	1.95	;	Crystal Structure of MarR
3BJ6	;	2.01	;	Crystal structure of MarR family transcription regulator SP03579
3BOQ	;	2.39	;	Crystal structure of MarR family transcriptional regulator from Silicibacter pomeroyi
3U2R	;	2.2	;	Crystal structure of MarR transcription factor from Planctomyces limnophilus
3NRV	;	2.001	;	Crystal structure of MarR/EmrR family transcriptional regulator from Acinetobacter sp. ADP1
7EI4	;	1.66	;	Crystal structure of MasL in complex with a novel covalent inhibitor, collimonin C
7EI3	;	1.78	;	Crystal structure of MasL, a thiolase from Massilia sp. YMA4
3POF	;	1.501	;	Crystal structure of MASP-1 CUB2 domain bound to Ca2+
3POJ	;	1.451	;	Crystal structure of MASP-1 CUB2 domain bound to Ethylamine
3POI	;	1.701	;	Crystal structure of MASP-1 CUB2 domain bound to Methylamine
3POB	;	1.801	;	Crystal structure of MASP-1 CUB2 domain in complex with the collagen-like domain of MBL
4G3A	;	1.994	;	Crystal Structure of MAST/Orbit N-terminal domain
5XP0	;	2.0	;	Crystal structure of master biofilm regulator CsgD regulatory domain
6FWB	;	1.79	;	Crystal structure of Mat2A at 1.79 Angstron resolution
7BHW	;	1.15	;	Crystal structure of MAT2a bound to allosteric inhibitor (compound 29)
7BHX	;	1.08	;	Crystal structure of MAT2a bound to allosteric inhibitor (compound 31)
7BHV	;	1.16	;	Crystal structure of MAT2a bound to allosteric inhibitor and in vivo tool compound 28
5UGH	;	2.062	;	Crystal structure of Mat2a bound to the allosteric inhibitor PF-02929366
7BHU	;	1.15	;	Crystal structure of MAT2a with elaborated fragment 26 bound in the allosteric site
7BHS	;	1.05	;	Crystal structure of MAT2a with quinazoline fragment 2 bound in the allosteric site
7BHT	;	1.052	;	Crystal structure of MAT2a with quinazolinone fragment 5 bound in the allosteric site
7BHR	;	1.08	;	Crystal structure of MAT2a with triazinone fragment 1 bound in the allosteric site
3VVP	;	2.91	;	Crystal structure of MATE in complex with Br-NRF
3VVS	;	2.6	;	Crystal structure of MATE in complex with MaD3S
3VVR	;	3.0	;	Crystal structure of MATE in complex with MaD5
3WBN	;	2.45	;	Crystal structure of MATE in complex with MaL6
3VVO	;	2.504	;	Crystal structure of MATE in the bent conformation
3VVN	;	2.398	;	Crystal structure of MATE in the straight conformation
3W4T	;	2.096	;	Crystal structure of MATE P26A mutant
4IXP	;	2.749	;	Crystal structure of Maternal Embryonic Leucine Zipper Kinase (MELK)
6GVX	;	2.24	;	Crystal structure of Maternal Embryonic Leucine Zipper Kinase (MELK) in complex with dorsomorphin (Compound C)
3VEB	;	2.8	;	Crystal Structure of Matp-matS
3VEA	;	2.55	;	Crystal Structure of matP-matS23mer
4JYT	;	2.0	;	Crystal Structure of Matriptase in complex with Inhibitor
4JZ1	;	1.9	;	Crystal Structure of Matriptase in complex with Inhibitor
4O97	;	2.2	;	Crystal structure of matriptase in complex with inhibitor
4O9V	;	1.9	;	Crystal structure of matriptase in complex with inhibitor
4R0I	;	1.9	;	CRYSTAL STRUCTURE of MATRIPTASE in COMPLEX WITH INHIBITOR
4JZI	;	2.0	;	Crystal Structure of Matriptase in complex with Inhibitor"".
4ISN	;	2.45	;	Crystal Structure of Matriptase in complex with its inhibitor HAI-1
4ISO	;	2.01	;	Crystal Structure of Matriptase in complex with its inhibitor HAI-1
2GV6	;	2.1	;	Crystal Structure of Matriptase with Inhibitor CJ-730
6N4T	;	1.945	;	Crystal structure of Matriptase1 in complex with a peptidomimetic benzothiazole
2Z16	;	2.02	;	Crystal structure of Matrix protein 1 from influenza A virus A/crow/Kyoto/T1/2004(H5N1)
5M1M	;	1.5	;	Crystal structure of matrix protein 1 from Influenza C virus (strain C/Ann Arbor/1/1950)
3TCQ	;	1.6	;	Crystal Structure of matrix protein VP40 from Ebola virus Sudan
2AS8	;	1.95	;	Crystal structure of mature and fully active Der p 1 allergen
3IV2	;	2.2	;	Crystal structure of mature apo-Cathepsin L C25A mutant
3K24	;	2.5	;	Crystal structure of mature apo-Cathepsin L C25A mutant in complex with Gln-Leu-Ala peptide
5N71	;	1.88	;	CRYSTAL STRUCTURE OF MATURE CATHEPSIN D FROM THE TICK IXODES RICINUS (IRCD1)
5N7Q	;	1.45	;	CRYSTAL STRUCTURE OF MATURE CATHEPSIN D FROM THE TICK IXODES RICINUS (IRCD1) IN COMPLEX WITH THE INHIBITOR PEPSTATIN A
5N70	;	1.81	;	CRYSTAL STRUCTURE OF MATURE CATHEPSIN D FROM THE TICK IXODES RICINUS (IRCD1) IN COMPLEX WITH THE N-TERMINAL OCTAPEPTIDE OF THE PROPEPTID
3DOR	;	2.2	;	Crystal Structure of mature CPAF
2Z2X	;	1.7	;	Crystal structure of mature form of Tk-subtilisin
4MTH	;	1.47	;	Crystal structure of mature human RegIIIalpha
3TM2	;	2.0	;	Crystal structure of mature ThnT with a covalently bound product mimic
3TM1	;	1.8	;	Crystal structure of mature ThnT, a pantetheine hydrolase
6TH5	;	1.99	;	Crystal structure of mature wildtype primitive Phytochelatin synthase from Nostoc spec. - Alr0975
1QYF	;	1.5	;	Crystal structure of matured green fluorescent protein R96A variant
6UMS	;	2.344	;	Crystal structure of MavC in complex with its substrate mimic in C222(1) space group
6UMP	;	2.8	;	Crystal structure of MavC in complex with substrate mimic in P65 space group
6P5B	;	2.099	;	Crystal Structure of MavC in Complex with Ub-UbE2N
6KFP	;	2.92	;	Crystal structure of MavC ternary complex
6KL4	;	2.85	;	Crystal structure of MavC-UBE2N-Ub
6KG6	;	2.39	;	Crystal structure of MavC/UBE2N-Ub complex
1WS7	;	1.9	;	Crystal Structure of Mavicyanin from Cucurbita pepo medullosa (Zucchini)
1WS8	;	1.6	;	Crystal Structure of Mavicyanin from Cucurbita pepo medullosa (Zucchini)
6G45	;	2.5	;	Crystal structure of mavirus major capsid protein
6G44	;	1.5	;	Crystal structure of mavirus major capsid protein lacking the C-terminal domain
6G42	;	2.7	;	Crystal structure of mavirus penton protein
3U5V	;	1.7	;	Crystal structure of Max-E47
7D2Q	;	1.99	;	Crystal structure of MazE-MazF (Form-I) from Deinococcus radiodurans
7D2P	;	2.07	;	Crystal structure of MazE-MazF (Form-II) from Deinococcus radiodurans
7D2N	;	1.6	;	Crystal structure of MazE-MazF (Form-III) from Deinococcus radiodurans
1UB4	;	1.7	;	crystal structure of MazEF complex
7D28	;	1.5	;	Crystal structure of MazF (Form-I) from Deinococcus radiodurans
7D2M	;	1.79	;	Crystal structure of MazF (Form-II) from Deinococcus radiodurans
7DHP	;	1.3	;	Crystal structure of MazF from Deinococcus radiodurans
1VMG	;	1.46	;	Crystal structure of MazG nucleotide pyrophosphohydrolase (13816655) from Sulfolobus solfataricus at 1.46 A resolution
2YXH	;	2.0	;	Crystal structure of mazG-related protein from Thermotoga maritima
5E95	;	1.402	;	Crystal Structure of Mb(NS1)/H-Ras Complex
6CNP	;	2.1	;	Crystal structure of MBD2 complex with methylated CpG island
7MWK	;	2.453	;	Crystal structure of MBD2 with DNA
7MWM	;	1.601	;	Crystal structure of MBD2 with DNA
7RAY	;	1.78	;	Crystal structure of MBD2 with DNA
4DK9	;	2.76	;	Crystal Structure of MBD4 Catalytic Domain Bound to Abasic DNA
4UDS	;	1.76	;	Crystal structure of MbdR regulator from Azoarcus sp. CIB
3POD	;	1.497	;	Crystal structure of MBL collagen-like peptide
3PON	;	1.5	;	Crystal structure of MBL collagen-like peptide
3D2N	;	2.7	;	Crystal structure of MBNL1 tandem zinc finger 1 and 2 domain
3D2Q	;	1.5	;	Crystal structure of MBNL1 tandem zinc finger 3 and 4 domain
3D2S	;	1.7	;	Crystal structure of MBNL1 tandem zinc finger 3 and 4 domain in complex with CGCUGU RNA
5W0Z	;	3.61	;	Crystal structure of MBP fused activation-induced cytidine deaminase (AID)
5W0R	;	2.4	;	Crystal structure of MBP fused activation-induced cytidine deaminase (AID) in complex with cacodylic acid
5W1C	;	3.18	;	Crystal structure of MBP fused activation-induced cytidine deaminase (AID) in complex with cytidine
5W0U	;	2.9	;	Crystal structure of MBP fused activation-induced cytidine deaminase (AID) in complex with dCMP
8IIY	;	2.15	;	Crystal structure of MBP fused GAS41 YEATS domain in complex with H3K14ac peptide
8IIZ	;	2.1	;	Crystal structure of MBP fused GAS41 YEATS domain in complex with H3K27ac peptide
4KEG	;	2.5	;	Crystal Structure of MBP Fused Human SPLUNC1
6M4V	;	2.92	;	Crystal structure of MBP fused split FKBP in complex with rapamycin
6M4W	;	3.11	;	Crystal structure of MBP fused split FKBP-FRB T2098L mutant in complex with rapamycin
7VN2	;	2.42	;	Crystal structure of MBP-fused BIL1/BZR1 (21-90) in complex with double-stranded DNA contaning ATCACGTGAT
7VN3	;	1.94	;	Crystal structure of MBP-fused BIL1/BZR1 (21-90) in complex with double-stranded DNA contaning CACACGTGTG
7VN6	;	2.79	;	Crystal structure of MBP-fused BIL1/BZR1 (21-90) in complex with double-stranded DNA contaning CGCACGTGCG
7VN7	;	2.11	;	Crystal structure of MBP-fused BIL1/BZR1 (21-90) in complex with double-stranded DNA contaning GACACGTGTC
7VN8	;	2.04	;	Crystal structure of MBP-fused BIL1/BZR1 (21-90) in complex with double-stranded DNA contaning GTCACGTGAC
7VN4	;	2.1	;	Crystal structure of MBP-fused BIL1/BZR1 (21-90) in complex with double-stranded DNA contaning TCCACGTGGA
7VN5	;	1.95	;	Crystal structure of MBP-fused BIL1/BZR1 (21-90) in complex with double-stranded DNA contaning TTCACGTGAA
5ZD4	;	2.17	;	Crystal structure of MBP-fused BIL1/BZR1 in complex with double-stranded DNA
6X91	;	3.51	;	Crystal structure of MBP-fused human APOBEC1
4EGC	;	1.994	;	Crystal Structure of MBP-fused Human Six1 Bound to Human Eya2 Eya Domain
7WR3	;	1.87	;	Crystal structure of MBP-fused OspC3 in complex with calmodulin
5AZA	;	2.08	;	Crystal structure of MBP-sAglB fusion protein with a 20-residue spacer in the connector helix
6KEA	;	2.35	;	crystal structure of MBP-tagged REV7-IpaB complex
5AZ8	;	1.7	;	Crystal structure of MBP-Tom20 fusion protein tethered with ALDH presequence via a disulfide bond
5AZ6	;	2.56	;	Crystal structure of MBP-Tom20 fusion protein with a 2-residue spacer in the connector helix
5AZ7	;	1.96	;	Crystal structure of MBP-Tom20 fusion protein with a 4-residue spacer in the connector helix
6XDS	;	1.466	;	Crystal structure of MBP-TREM2 Ig domain fusion with fragment, 2-((4-bromophenyl)amino)ethan-1-ol
6K7D	;	2.0	;	Crystal structure of MBPapo-Tim21 fusion protein with a 16-residue helical linker
6K7E	;	1.534	;	Crystal structure of MBPapo-Tim21 fusion protein with a 17-residue helical linker
6K7F	;	1.8	;	Crystal structure of MBPholo-Tim21 fusion protein with a 17-residue helical linker
5WVN	;	2.8	;	Crystal structure of MBS-BaeS fusion protein
4C5I	;	2.586	;	Crystal structure of MBTD1 YY1 complex
3LOG	;	1.73	;	Crystal structure of MbtI from Mycobacterium tuberculosis
2BBR	;	1.2	;	Crystal Structure of MC159 Reveals Molecular Mechanism of DISC Assembly and vFLIP Inhibition
2BBZ	;	3.8	;	Crystal Structure of MC159 Reveals Molecular Mechanism of DISC Assembly and vFLIP Inhibition
4OQW	;	2.21	;	Crystal structure of mCardinal far-red fluorescent protein
2QC3	;	2.3	;	Crystal structure of MCAT from Mycobacterium tuberculosis
3IM9	;	1.46	;	Crystal structure of MCAT from Staphylococcus aureus
3IM8	;	2.1	;	Crystal structure of MCAT from Streptococcus pneumoniae
5FCD	;	2.1	;	Crystal structure of MccD protein
4H1H	;	2.46	;	Crystal structure of MccF homolog from Listeria monocytogenes EGD-e
5FD8	;	2.05	;	Crystal Structure of MccF-like Protein (BA_5613) in complex with ASA (alanyl sulfamoyl adenylates)
5USD	;	2.095	;	Crystal structure of MccF-like protein (BA_5613) in the complex with aspartyl sulfamoyl adenylate
4E94	;	1.651	;	Crystal structure of MccF-like protein from Streptococcus pneumoniae
4EYS	;	1.58	;	Crystal structure of MccF-like protein from Streptococcus pneumoniae in complex with AMP
4E5S	;	1.952	;	Crystal structure of MccFlike protein (BA_5613) from Bacillus anthracis str. Ames
6MJ4	;	2.0	;	Crystal structure of MCD1D/INKTCR TERNARY COMPLEX bound to glycolipid (XXW)
7AI3	;	2.9	;	Crystal structure of MCE domain of Mce4A from Mycobacterium tuberculosis H37Rv
3A4U	;	1.84	;	Crystal structure of MCFD2 in complex with carbohydrate recognition domain of ERGIC-53
6RIX	;	1.655	;	Crystal structure of MchDnaB-1 intein
6RIY	;	1.63	;	Crystal structure of MchDnaB-1 intein (N145AA)
2H5Q	;	1.36	;	Crystal structure of mCherry
5FHV	;	1.55	;	Crystal structure of mCherry after reaction with 2-mercaptoethanol
5C3F	;	1.43	;	Crystal structure of Mcl-1 bound to BID-MM
6VBX	;	1.95	;	Crystal structure of Mcl-1 in complex with 138E12 peptide, Lys-covalent antagonist
5VKC	;	2.31	;	Crystal structure of MCL-1 in complex with a BIM competitive inhibitor
6B4L	;	2.25	;	Crystal structure of MCL-1 in complex with a BIM competitive inhibitor
6B4U	;	1.95	;	Crystal structure of MCL-1 in complex with a BIM competitive inhibitor
6ZIE	;	2.3	;	Crystal structure of MCL-1 in complex with a neutralizing Alphabody CMPX-383B
3D7V	;	2.03	;	Crystal structure of Mcl-1 in complex with an Mcl-1 selective BH3 ligand
3WIY	;	2.15	;	Crystal structure of Mcl-1 in complex with compound 10
3WIX	;	1.9	;	Crystal structure of Mcl-1 in complex with compound 4
6P3P	;	1.61	;	Crystal structure of Mcl-1 in complex with compound 65
7XGE	;	2.38	;	Crystal structure of MCL-1 in complex with computationally designed inhibitor protein
3PK1	;	2.486	;	Crystal structure of Mcl-1 in complex with the BaxBH3 domain
5KU9	;	2.2	;	Crystal structure of MCL1 with compound 1
6OQN	;	1.7	;	Crystal structure of Mcl1 with inhibitor 7
6OQD	;	1.48	;	Crystal structure of Mcl1 with inhibitor 8
6OQC	;	1.8	;	Crystal structure of Mcl1 with inhibitor 9
5JSB	;	2.74	;	Crystal structure of Mcl1-inhibitor complex
6TTD	;	1.801	;	Crystal structure of McoA multicopper oxidase 2F4 variant from the hyperthermophile Aquifex aeolicus
6SYY	;	1.794	;	Crystal structure of McoA multicopper oxidase from the hyperthermophile Aquifex aeolicus
3V34	;	2.003	;	Crystal structure of MCPIP1 conserved domain with magnesium ion in the catalytic center
3V33	;	2.005	;	Crystal structure of MCPIP1 conserved domain with zinc-finger motif
3V32	;	2.0	;	Crystal structure of MCPIP1 N-terminal conserved domain
3C8C	;	1.5	;	Crystal structure of Mcp_N and cache domains of methyl-accepting chemotaxis protein from Vibrio cholerae
5GRR	;	1.45	;	Crystal structure of MCR-1
5YLC	;	1.5	;	Crystal Structure of MCR-1 Catalytic Domain
7YJP	;	1.88	;	Crystal structure of MCR-1 treated by AuCl
5GOV	;	2.33	;	Crystal Structure of MCR-1, a phosphoethanolamine transferase, extracellular domain
6LI4	;	1.78	;	Crystal structure of MCR-1-S
7WAA	;	1.58	;	Crystal structure of MCR-1-S treated by AgNO3
6LI6	;	1.68	;	Crystal structure of MCR-1-S treated by Au(PEt3)Cl
7YJQ	;	1.6	;	Crystal structure of MCR-1-S treated by auranofin
7YJT	;	2.1	;	Crystal structure of MCR-1-S treated by aurothioglucose
7YJR	;	2.3	;	Crystal structure of MCR-1-S treated by sodium aurothiomalate
7YJS	;	2.5	;	Crystal structure of MCR-1-S treated by sodium aurothiosulfate
1VR4	;	2.09	;	Crystal Structure of MCSG TArget APC22750 from Bacillus cereus
1XPJ	;	2.3	;	Crystal Structure of MCSG Target APC26283 from Vibrio cholerae
1Y2I	;	2.3	;	Crystal Structure of MCSG Target APC27401 from Shigella flexneri
1XA0	;	2.8	;	Crystal Structure of MCSG Target APC35536 from Bacillus stearothermophilus
3UN0	;	2.3	;	Crystal Structure of MDC1 FHA Domain
3UOT	;	1.8	;	Crystal Structure of MDC1 FHA Domain in Complex with a Phosphorylated Peptide from the MDC1 N-terminus
2ETX	;	1.33	;	Crystal Structure of MDC1 Tandem BRCT Domains
1Z2C	;	3.0	;	Crystal structure of mDIA1 GBD-FH3 in complex with RhoC-GMPPNP
3EG5	;	2.7	;	Crystal structure of MDIA1-TSH GBD-FH3 in complex with CDC42-GMPPNP
5UWP	;	2.054	;	Crystal Structure of mDia2 NES Peptide in complex with CRM1-Ran-RanBP1
6X2Y	;	2.304	;	Crystal Structure of mDia2NES peptide bound to CRM1(E571K)
5CH8	;	1.62	;	Crystal structure of MDLA N225Q mutant form Penicillium cyclopium
5GYD	;	3.106	;	Crystal Structure of Mdm12
5VKZ	;	4.1	;	Crystal structure of Mdm12 and combinatorial reconstitution of Mdm12/Mmm1 ERMES complexes for structural studies
5GYK	;	3.596	;	Crystal Structure of Mdm12-deletion mutant
5YK7	;	3.799	;	Crystal Structure of Mdm12-Mmm1 complex
4ERE	;	1.8	;	crystal structure of MDM2 (17-111) in complex with compound 23
4ERF	;	2.0	;	crystal structure of MDM2 (17-111) in complex with compound 29 (AM-8553)
6H22	;	2.006	;	Crystal structure of Mdm2 bound to a stapled peptide
6I3S	;	1.77	;	Crystal structure of MDM2 in complex with compound 13.
3JZK	;	2.1	;	crystal structure of MDM2 with chromenotriazolopyrimidine 1
4YTV	;	1.45	;	Crystal structure of Mdm35
4RXZ	;	1.55	;	Crystal Structure of MDMX phosporylated Tyr99 in complex with a 12-mer peptide
7X11	;	2.07	;	Crystal structure of ME1 in complex with NADPH
7X12	;	2.07	;	Crystal structure of ME1 in complex with NADPH
3EVF	;	1.45	;	Crystal structure of Me7-GpppA complex of yellow fever virus methyltransferase and S-adenosyl-L-homocysteine
2OXT	;	2.9	;	Crystal structure of Meaban virus nucleoside-2'-O-methyltransferase
8HGN	;	1.95	;	Crystal structure of MeaC (Mesaconyl-CoA hydratase)
5E4V	;	2.71	;	Crystal structure of measles N0-P complex
7SKS	;	2.541	;	Crystal structure of measles virus matrix protein
5BSE	;	1.7	;	Crystal structure of Medicago truncatula (delta)1-Pyrroline-5-Carboxylate Reductase (MtP5CR)
5BSH	;	2.1	;	Crystal structure of Medicago truncatula (delta)1-Pyrroline-5-Carboxylate Reductase (MtP5CR) in complex with L-Proline
5BSF	;	1.85	;	Crystal structure of Medicago truncatula (delta)1-Pyrroline-5-Carboxylate Reductase (MtP5CR) in complex with NAD+
5BSG	;	1.95	;	Crystal structure of Medicago truncatula (delta)1-Pyrroline-5-Carboxylate Reductase (MtP5CR) in complex with NADP+
6NIB	;	1.2	;	Crystal Structure of Medicago truncatula Agmatine Iminohydrolase (Deiminase)
6NIC	;	2.2	;	Crystal Structure of Medicago truncatula Agmatine Iminohydrolase (Deiminase) in Complex with 6-aminohexanamide
6CZL	;	2.92	;	Crystal structure of Medicago truncatula ATP-phosphoribosyltransferase in relaxed form
6CZM	;	2.88	;	Crystal structure of Medicago truncatula ATP-phosphoribosyltransferase in tense form
4R1U	;	2.18	;	Crystal structure of Medicago truncatula cinnamoyl-CoA reductase
8BJ4	;	1.45	;	Crystal structure of Medicago truncatula histidinol-phosphate aminotransferase (HISN6) in apo form
8BJ3	;	1.61	;	Crystal structure of Medicago truncatula histidinol-phosphate aminotransferase (HISN6) in complex with histidinol-phosphate
8BJ2	;	1.4	;	Crystal structure of Medicago truncatula histidinol-phosphate aminotransferase (HISN6) in the closed state
8BJ1	;	1.57	;	Crystal structure of Medicago truncatula histidinol-phosphate aminotransferase (HISN6) in the open state
5EQ7	;	1.19	;	Crystal structure of Medicago truncatula Histidinol-Phosphate Phosphatase (MtHPP) in complex with free phosphate
5EQ8	;	1.3	;	Crystal structure of Medicago truncatula Histidinol-Phosphate Phosphatase (MtHPP) in complex with L-histidinol
5EQ9	;	1.36	;	Crystal structure of Medicago truncatula Histidinol-Phosphate Phosphatase (MtHPP) in complex with L-histidinol phosphate and Mg2+
5EQA	;	1.32	;	Crystal structure of Medicago truncatula Histidinol-Phosphate Phosphatase (MtHPP) with intermolecular cross-link between Lys158 and Cys245
5VLB	;	2.25	;	Crystal Structure of Medicago truncatula L-Histidinol Dehydrogenase in Complex with Imidazole
5VLD	;	2.59	;	Crystal Structure of Medicago truncatula L-Histidinol Dehydrogenase in Complex with L-Histidine and NAD+
5VLC	;	1.97	;	Crystal Structure of Medicago truncatula L-Histidinol Dehydrogenase in Complex with L-Histidinol
5H8K	;	2.39	;	Crystal structure of Medicago truncatula N-carbamoylputrescine amidohydrolase (MtCPA) C158S mutant
5H8L	;	2.29	;	Crystal structure of Medicago truncatula N-carbamoylputrescine amidohydrolase (MtCPA) C158S mutant in complex with putrescine
5H8J	;	2.19	;	Crystal structure of Medicago truncatula N-carbamoylputrescine amidohydrolase (MtCPA) in complex with cadaverine
5H8I	;	1.97	;	Crystal structure of Medicago truncatula N-carbamoylputrescine amidohydrolase (MtCPA) in complex with N-(dihydroxymethyl)putrescine
7QB6	;	2.52	;	Crystal Structure of Medicago truncatula Nodulin 13 (MtN13) in complex with 3-carboxybenzophenone
4JHH	;	2.2	;	Crystal Structure of Medicago truncatula Nodulin 13 (MtN13) in complex with kinetin
4JHI	;	2.6	;	Crystal Structure of Medicago truncatula Nodulin 13 (MtN13) in complex with N6-benzyladenine
4GY9	;	2.04	;	Crystal Structure of Medicago truncatula Nodulin 13 (MtN13) in complex with N6-isopentenyladenine (2iP)
4JHG	;	1.85	;	Crystal Structure of Medicago truncatula Nodulin 13 (MtN13) in complex with trans-zeatin
6VCW	;	1.4	;	Crystal structure of Medicago truncatula S-adenosylmethionine Synthase 3A (MtMAT3A)
6CCZ	;	2.14	;	Crystal structure of Medicago truncatula serine hydroxymethyltransferase 3 (MtSHMT3) soaked with selenourea
6CD1	;	1.91	;	Crystal structure of Medicago truncatula serine hydroxymethyltransferase 3 (MtSHMT3), complexes with reaction intermediates
6CD0	;	1.74	;	Crystal structure of Medicago truncatula serine hydroxymethyltransferase 3 (MtSHMT3), PLP-internal aldimine and apo form
6BQ2	;	1.68	;	Crystal structure of Medicago truncatula Thermospermine Synthase (MtTSPS)
6BQ5	;	1.8	;	Crystal structure of Medicago truncatula Thermospermine Synthase (MtTSPS) in complex with 5'-methylthioadenosine
6BQ3	;	1.91	;	Crystal structure of Medicago truncatula Thermospermine Synthase (MtTSPS) in complex with 5'-S-(3-aminopropyl)-5'-thioadenosine
6BQ4	;	1.89	;	Crystal structure of Medicago truncatula Thermospermine Synthase (MtTSPS) in complex with adenosine
6BQ7	;	1.95	;	Crystal structure of Medicago truncatula Thermospermine Synthase (MtTSPS) in complex with spermidine
6BQ6	;	1.65	;	Crystal structure of Medicago truncatula Thermospermine Synthase (MtTSPS) in complex with thermospermine
2ACV	;	2.0	;	Crystal Structure of Medicago truncatula UGT71G1
2ACW	;	2.6	;	Crystal Structure of Medicago truncatula UGT71G1 complexed with UDP-glucose
2PQ6	;	2.1	;	Crystal structure of Medicago truncatula UGT85H2- Insights into the structural basis of a multifunctional (Iso) flavonoid glycosyltransferase
8BBU	;	1.1	;	Crystal structure of medical leech destabilase (high salt)
8BBW	;	1.4	;	Crystal structure of medical leech destabilase (low salt)
1UKW	;	2.4	;	Crystal structure of medium-chain acyl-CoA dehydrogenase from Thermus thermophilus HB8
1EGW	;	1.5	;	CRYSTAL STRUCTURE OF MEF2A CORE BOUND TO DNA
7X1N	;	3.315	;	Crystal structure of MEF2D-MRE complex
6XVI	;	2.596	;	Crystal structure of Megabody Mb-Nb207-c7HopQ_A12
6XV8	;	3.15	;	Crystal structure of Megabody Mb-Nb207-c7HopQ_G10
6XUX	;	1.90001	;	Crystal structure of Megabody Mb-Nb207-cYgjK_NO
4Z1Z	;	3.2	;	Crystal Structure of Meganuclease I-SmaMI Bound to Uncleaveable DNA with a TTCT Central Four
4Z20	;	3.2	;	Crystal Structure of Meganuclease I-SmaMI Bound to Uncleaveable DNA with a TTGT Central Four
4TQG	;	2.2	;	Crystal structure of Megavirus UDP-GlcNAc 4,6-dehydratase, 5-epimerase Mg534
8HGW	;	2.80001	;	Crystal structure of MehpH in complex with MBP
7EIO	;	1.895	;	Crystal Structure of Mei2 RRM3
7EIU	;	2.349	;	Crystal structure of Mei2 RRM3 in complex with 8mer meiRNA
7DUS	;	2.5	;	Crystal structure of Mei2-RRM3 domain in S.pombe
7F2X	;	2.007	;	Crystal structure of MEK1 C121S mutant
3ZM4	;	2.37	;	Crystal structure of MEK1 in complex with fragment 1
3ZLX	;	2.2	;	Crystal structure of MEK1 in complex with fragment 18
3ZLW	;	2.12	;	Crystal structure of MEK1 in complex with fragment 3
3ZLS	;	2.5	;	Crystal structure of MEK1 in complex with fragment 6
3ZLY	;	2.11	;	Crystal structure of MEK1 in complex with fragment 8
4LMN	;	2.8	;	Crystal Structure of MEK1 kinase bound to GDC0973
6X2S	;	2.496	;	Crystal Structure of Mek1(NQ)NES peptide bound to CRM
6X2X	;	2.458	;	Crystal Structure of Mek1NES peptide bound to CRM1(E571K)
1TVB	;	1.8	;	Crystal structure of Melanoma Antigen gp100(209-217) Bound to Human Class I MHC HLA-A2
3W6Q	;	2.052	;	Crystal structure of melB apo-protyrosinase from Asperugillus oryzae
3W6W	;	1.394	;	Crystal structure of melB holo-protyrosinase from Asperugillus oryzae
5M5A	;	1.9	;	Crystal structure of MELK in complex with an inhibitor
5MAF	;	2.8	;	Crystal structure of MELK in complex with an inhibitor
5MAG	;	2.35	;	Crystal structure of MELK in complex with an inhibitor
5MAH	;	2.0	;	Crystal structure of MELK in complex with an inhibitor
5MAI	;	2.15	;	Crystal structure of MELK in complex with an inhibitor
6E0S	;	1.78	;	Crystal structure of MEM-A1, a subclass B3 metallo-beta-lactamase isolated from a soil metagenome library
4HC5	;	1.45	;	Crystal structure of member of Glyoxalase/bleomycin resistance protein/dioxygenase superfamily from Sphaerobacter thermophilus DSM 20745
5F2T	;	2.06	;	Crystal structure of membrane associated PatA from Mycobacterium smegmatis in complex with palmitate - C 2 space group
5F31	;	2.43	;	Crystal structure of membrane associated PatA from Mycobacterium smegmatis in complex with palmitate - P 42 21 2 space group
5F2Z	;	2.9	;	Crystal structure of membrane associated PatA from Mycobacterium smegmatis in complex with palmitate - P21 space group
5F34	;	3.281	;	Crystal structure of membrane associated PatA from Mycobacterium smegmatis in complex with S-hexadecyl Coenzyme A - P21 space group
2PNW	;	1.9	;	Crystal structure of membrane-bound lytic murein transglycosylase from Agrobacterium tumefaciens
3NPS	;	1.5	;	Crystal structure of membrane-type serine protease 1 (MT-SP1) in complex with the Fab Inhibitor S4
3BCZ	;	2.1	;	Crystal structure of Memo
3BD0	;	3.01	;	Crystal structure of Memo, form II
3P4S	;	3.1	;	Crystal structure of Menaquinol:fumarate oxidoreductase in complex with a 3-nitropropionate adduct
3P4P	;	2.8	;	Crystal structure of Menaquinol:fumarate oxidoreductase in complex with fumarate
3P4R	;	3.05	;	Crystal structure of Menaquinol:fumarate oxidoreductase in complex with glutarate
3P4Q	;	3.35	;	Crystal structure of Menaquinol:oxidoreductase in complex with oxaloacetate
3HWW	;	1.95	;	Crystal structure of menaquinone synthesis protein MenD from E. coli in complex with oxoglutarate
3HWX	;	2.6	;	Crystal structure of menaquinone synthesis protein MenD from E. coli in complex with ThDP
3GSE	;	2.28	;	Crystal structure of menaquinone-specific isochorismate synthase from Yersinia pestis CO92
1RJM	;	2.15	;	Crystal Structure of MenB (Rv0548c) from Mycobacterium tuberculosis
4QIJ	;	2.2	;	Crystal structure of MenB from Mycobacteria tuberculosis in complex with 1-HNA-CoA
2PGE	;	1.6	;	Crystal structure of MenC from Desulfotalea psychrophila LSv54
3FLM	;	2.7	;	Crystal structure of menD from E.coli
6YDR	;	1.34	;	Crystal structure of Mengla Virus VP30 C-terminal domain
8IG0	;	2.6	;	Crystal structure of menin in complex with DS-1594b
3RE2	;	1.95	;	Crystal structure of menin reveals the binding site for Mixed Lineage Leukemia (MLL) protein
5DTL	;	2.7	;	Crystal structure of mEos2-A69T fluorescent protein
3P8U	;	2.25	;	Crystal structure of mEosFP in its green state
4LQE	;	2.1	;	Crystal Structure of MepB
4L9N	;	1.6	;	Crystal structure of MepR A103V mutant from multidrug resistant S. aureus clinical isolate
4L9T	;	1.794	;	Crystal structure of MepR F27L mutant from multidrug resistant S. aureus clinical isolate
4XRF	;	2.16	;	Crystal structure of MepR like protein complexed with pseudoligands
4LD5	;	2.4	;	Crystal structure of MepR Q18P mutant from multidrug resistant S. aureus clinical isolate
3ECO	;	2.4	;	Crystal structure of MepR, a transcription regulator of the Staphylococcus aureus multidrug efflux pump MepA
3FN8	;	1.88	;	Crystal Structure of MerB complexed with mercury
3F2G	;	1.781	;	Crystal structure of MerB mutant C160S, the Organomercurial Lyase involved in a bacterial mercury resistance system
3F0O	;	1.76	;	Crystal structure of MerB, the Organomercurial Lyase involved in a bacterial mercury resistance system
1FMJ	;	2.0	;	CRYSTAL STRUCTURE OF MERCURY DERIVATIVE OF RETINOL DEHYDRATASE IN A COMPLEX WITH RETINOL AND PAP
5YDC	;	1.91	;	Crystal structure of mercury soaked C-terminal domain of Rv1828 from Mycobacterium tuberculosis
1FE4	;	1.75	;	CRYSTAL STRUCTURE OF MERCURY-HAH1
6ZLZ	;	3.52	;	Crystal Structure of Merkel Cell Polyomavirus Virus-like Particle
3WA0	;	2.31	;	Crystal structure of merlin complexed with DCAF1/VprBP
1ISN	;	2.9	;	Crystal structure of merlin FERM domain
4ZRI	;	2.7	;	Crystal structure of Merlin-FERM and Lats2
8E6B	;	1.55	;	Crystal structure of MERS 3CL protease in complex with a dimethyl sulfinyl benzene inhibitor
8E6C	;	2.7	;	Crystal structure of MERS 3CL protease in complex with a m-fluorophenyl dimethyl sulfane inhibitor
8E6D	;	2.7	;	Crystal structure of MERS 3CL protease in complex with a p-fluorophenyl dimethyl sulfane inhibitor
8E6E	;	1.5	;	Crystal structure of MERS 3CL protease in complex with a phenyl sulfane inhibitor
5C3N	;	3.0	;	Crystal structure of MERS coronavirus main protease in spacegroup C2221
4R3D	;	2.818	;	Crystal structure of MERS Coronavirus papain like protease
8IG6	;	2.07	;	Crystal structure of MERS main protease in complex with GC376
7XRY	;	1.99	;	Crystal structure of MERS main protease in complex with inhibitor YH-53
7WQJ	;	2.75	;	Crystal structure of MERS main protease in complex with PF07304814
7VTC	;	2.53866	;	Crystal structure of MERS main protease in complex with PF07321332
8HUT	;	1.98	;	Crystal structure of MERS main protease in complex with S217622
7DR9	;	2.77587	;	Crystal structure of MERS-CoV 3CL protease (C148A) in spacegroup P212121
7DRA	;	2.7841	;	Crystal structure of MERS-CoV 3CL protease (C148A) in spacegroup P212121,pH 9.0
7DR8	;	2.33815	;	Crystal structure of MERS-CoV 3CL protease in spacegroup P212121
7ENE	;	2.98	;	Crystal structure of MERS-CoV 3CLpro in complex with the non-covalent inhibitor WU-04
4L72	;	3.005	;	Crystal structure of MERS-CoV complexed with human DPP4
5ZU9	;	1.499	;	Crystal structure of MERS-CoV macro domain in complex with ADP
5DUS	;	1.432	;	Crystal structure of MERS-CoV macro domain in complex with ADP-ribose
5ZU7	;	1.705	;	Crystal structure of MERS-CoV macro domain in complex with AMP
5ZUA	;	2.471	;	Crystal structure of MERS-CoV macro domain in complex with ATP
5ZUB	;	1.677	;	Crystal structure of MERS-CoV macro domain in complex with NAD
8R5J	;	1.898	;	Crystal structure of MERS-CoV main protease
6KL6	;	2.77	;	Crystal structure of MERS-CoV N-NTD complexed with 5-Benzyloxygramine
6LNN	;	2.634	;	Crystal structure of MERS-CoV N-NTD complexed with ligand P4-1
7DYD	;	2.39	;	Crystal structure of MERS-CoV N-NTD complexed with ligand P4-2
6LZ6	;	2.646	;	Crystal structure of MERS-CoV N-NTD complexed with ligand P4-3
6LZ8	;	2.59	;	Crystal structure of MERS-CoV N-NTD complexed with ligand P4-4
6PXG	;	2.1	;	Crystal Structure of MERS-CoV neutralizing antibody G2 Fab
5VZR	;	1.57	;	Crystal Structure of MERS-CoV neutralizing antibody G4 Fab
5YN5	;	1.96	;	Crystal structure of MERS-CoV nsp10/nsp16 complex
5YN6	;	1.947	;	Crystal structure of MERS-CoV nsp10/nsp16 complex bound to SAM
5YNF	;	1.791	;	Crystal structure of MERS-CoV nsp16/nsp10 complex bound to m7GpppA
5YNJ	;	2.043	;	Crystal structure of MERS-CoV nsp16/nsp10 complex bound to m7GpppG
5YN8	;	1.97	;	Crystal structure of MERS-CoV nsp16/nsp10 complex bound to SAH
5YNO	;	1.96	;	Crystal structure of MERS-CoV nsp16/nsp10 complex bound to SAH and m7GpppA
5YNQ	;	1.958	;	Crystal structure of MERS-CoV nsp16/nsp10 complex bound to SAH and m7GpppG
5YNM	;	1.68	;	Crystal structure of MERS-CoV nsp16/nsp10 complex bound to SAM and m7GpppA
5YNI	;	2.07	;	Crystal structure of MERS-CoV nsp16/nsp10 complex bound to SAM and m7GpppG
5YNB	;	1.98	;	Crystal structure of MERS-CoV nsp16/nsp10 complex bound to Sinefungin
5YNP	;	2.27	;	Crystal structure of MERS-CoV nsp16/nsp10 complex bound to sinefungin and m7GpppA
5YNN	;	1.86	;	Crystal structure of MERS-CoV nsp16/nsp10complex bound to sinefungin and m7GpppG
5W8T	;	2.758	;	Crystal structure of MERS-CoV papain-like protease in complex with the C-terminal domain of human ISG15
5W8U	;	2.411	;	Crystal structure of MERS-CoV papain-like protease in complex with the C-terminal domain of human ISG15
5VYH	;	2.0	;	Crystal Structure of MERS-CoV S1 N-terminal Domain
6PXH	;	2.3	;	Crystal Structure of MERS-CoV S1-NTD bound with G2 Fab
8DGX	;	2.89	;	Crystal structure of MERS-CoV spike stem helix peptide in complex with Fab of broadly neutralizing antibody CC68.109 isolated from a vaccinated COVID-19 convalescent
8DGV	;	2.3	;	Crystal structure of MERS-CoV spike stem helix peptide in complex with Fab of broadly neutralizing antibody CC99.103 isolated from a vaccinated COVID-19 convalescent
7AAZ	;	1.855	;	Crystal structure of MerTK in complex with a type 1.5 aminopyridine inhibitor
7AB1	;	1.93	;	Crystal structure of MerTK kinase domain in complex with Gilteritinib
7AAX	;	1.762	;	Crystal structure of MerTK kinase domain in complex with LDC1267
7AAY	;	1.87	;	Crystal structure of MerTK kinase domain in complex with Merestinib
7AB2	;	1.78	;	Crystal structure of MerTK kinase domain in complex with UNC2025
7XHY	;	2.16	;	Crystal structure of MerTK Kinase domain with BMS794833
1S7C	;	2.04	;	Crystal structure of MES buffer bound form of glyceraldehyde 3-phosphate dehydrogenase from Escherichia coli
6YVG	;	2.2	;	Crystal structure of MesI (Lpg2505) from Legionella pneumophila
3WGY	;	2.0	;	Crystal structure of meso-dapdh Q154L/T173I/R199M/P248S/H249N/N276S mutant with 4-methyl-2-oxovalerate of from Clostridium tetani E88
3WGZ	;	2.25	;	Crystal structure of meso-dapdh Q154L/T173I/R199M/P248S/H249N/N276S mutant with D-leucine of from Clostridium tetani E88
3WGQ	;	2.0	;	Crystal structure of meso-dapdh Q154L/T173I/R199M/P248S/H249N/N276S mutant with DAP of from Clostridium tetani E88
5X7M	;	2.4	;	Crystal structure of meso-diaminopimelate decarboxylase (DAPDC) from Corynebacterium glutamicum
5X7N	;	1.72	;	Crystal structure of meso-diaminopimelate decarboxylase (DAPDC) from Corynebacterium glutamicum
8HP0	;	2.47	;	Crystal structure of meso-diaminopimelate dehydrogenase from Prevotella timonensis
8HP3	;	3.07	;	Crystal structure of meso-diaminopimelate dehydrogenase from Prevotella timonensis
3WBF	;	2.12	;	Crystal Structure of meso-diaminopimelate dehydrogenase from Symbiobacterium thermophilum co-crystallized with NADP+ and DAP
1JN2	;	1.9	;	Crystal Structure of meso-tetrasulphonatophenyl porphyrin complexed with Concanavalin A
1RIR	;	2.9	;	Crystal structure of meso-tetrasulphonatophenylporphyrin in complex with Peanut lectin.
1KOK	;	1.7	;	Crystal Structure of Mesopone Cytochrome c Peroxidase (MpCcP)
1S73	;	1.53	;	Crystal Structure of Mesopone Cytochrome c Peroxidase (R-isomer) [MpCcP-R]
2Z7B	;	1.9	;	Crystal Structure of Mesorhizobium loti 3-hydroxy-2-methylpyridine-4,5-dicarboxylate decarboxylase
4NV7	;	2.02	;	Crystal Structure of Mesorhizobium Loti Arylamine N-acetyltransferase 1 In Complex With CoA
4NV8	;	1.84	;	Crystal Structure of Mesorhizobium Loti Arylamine N-acetyltransferase F42W Mutant
7U8C	;	1.74	;	Crystal structure of Mesothelin C-terminal peptide-MORAb 15B6 FAB complex
7U9J	;	2.09	;	Crystal structure of Mesothelin-207 fragment
6HAR	;	1.497	;	Crystal structure of Mesotrypsin in complex with APPI-M17C/I18F/F34C
1GY2	;	1.82	;	Crystal structure of Met148Leu rusticyanin
1ZDS	;	1.55	;	Crystal Structure of Met150Gly AfNiR with Acetamide Bound
1ZDQ	;	1.8	;	Crystal Structure of Met150Gly AfNiR with Methylsulfanyl Methane Bound
1J5O	;	3.5	;	CRYSTAL STRUCTURE OF MET184ILE MUTANT OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH DOUBLE STRANDED DNA TEMPLATE-PRIMER
4XMZ	;	2.15	;	Crystal Structure of Met260Ala mutant of E. coli Aminopeptidase N in complex with 2,4-diaminobutyric acid
4XMX	;	2.3	;	Crystal Structure of Met260Ala mutant of E. coli Aminopeptidase N in complex with Bestatin
4XMT	;	2.0	;	Crystal Structure of Met260Ala mutant of E. coli Aminopeptidase N in complex with L-2,3-Diaminopropionic acid
4XMU	;	2.91	;	Crystal Structure of Met260Ala mutant of E. coli Aminopeptidase N in complex with L-Alanine
4XMV	;	2.92	;	Crystal Structure of Met260Ala mutant of E. coli Aminopeptidase N in complex with L-Arginine
4XMW	;	2.2	;	Crystal Structure of Met260Ala mutant of E. coli Aminopeptidase N in complex with L-aspartic acid
4XN1	;	2.2	;	Crystal Structure of Met260Ala mutant of E. coli Aminopeptidase N in complex with L-Glutamate
4XN2	;	2.11	;	Crystal Structure of Met260Ala mutant of E. coli Aminopeptidase N in complex with L-Leucine
4XN4	;	1.99	;	Crystal Structure of Met260Ala mutant of E. coli Aminopeptidase N in complex with L-Methionine
4XN5	;	2.66	;	Crystal Structure of Met260Ala mutant of E. coli Aminopeptidase N in complex with L-Phenylalanine
6MN0	;	2.4	;	Crystal structure of meta-AAC0038, an environmental aminoglycoside resistance enzyme, H168A mutant in complex with acetyl-CoA
6MMZ	;	3.3	;	Crystal structure of meta-AAC0038, an environmental aminoglycoside resistance enzyme, H29A mutant apoenzyme
6MN1	;	2.25	;	Crystal structure of meta-AAC0038, an environmental aminoglycoside resistance enzyme, mutant H168A in abortive complex with gentamicin-CoA
6MN2	;	2.744	;	Crystal structure of meta-AAC0038, an environmental aminoglycoside resistance enzyme, mutant H168A in abortive complex with sisomicin-CoA
7KES	;	2.36	;	Crystal structure of meta-AAC0038, an environmental aminoglycoside resistance enzyme, mutant H168A in complex with apramycin and CoA
3SM9	;	2.26	;	Crystal Structure of Metabotropic glutamate receptor 3 precursor in presence of LY341495 antagonist
1ISS	;	3.3	;	Crystal Structure of Metabotropic Glutamate Receptor Subtype 1 Complexed with an antagonist
1EWK	;	2.2	;	CRYSTAL STRUCTURE OF METABOTROPIC GLUTAMATE RECEPTOR SUBTYPE 1 COMPLEXED WITH GLUTAMATE
1ISR	;	4.0	;	Crystal Structure of Metabotropic Glutamate Receptor Subtype 1 Complexed with Glutamate and Gadolinium Ion
1EWT	;	3.7	;	CRYSTAL STRUCTURE OF METABOTROPIC GLUTAMATE RECEPTOR SUBTYPE 1 LIGAND FREE FORM I
1EWV	;	4.0	;	CRYSTAL STRUCTURE OF METABOTROPIC GLUTAMATE RECEPTOR SUBTYPE 1 LIGAND FREE FORM II
6W8R	;	2.801	;	Crystal structure of metacaspase 4 C139A from Arabidopsis
6W8S	;	3.484	;	Crystal structure of metacaspase 4 from Arabidopsis
6W8T	;	3.2	;	Crystal structure of metacaspase 4 from Arabidopsis (microcrystals treated with calcium)
7QP1	;	3.0	;	Crystal structure of metacaspase from candida glabrata with calcium
7QP0	;	1.6	;	Crystal structure of metacaspase from candida glabrata with magnesium
3WX5	;	1.85	;	Crystal structure of metagenome-derived glycoside hydrolase family 12 endoglucanase
3X17	;	2.15	;	Crystal structure of metagenome-derived glycoside hydrolase family 9 endoglucanase
8EO7	;	2.15	;	Crystal structure of metagenomic beta-lactamase LRA-5 Y69Q/V166E mutant at 2.15 Angstrom resolution
8EO6	;	2.35	;	Crystal structure of metagenomic class A beta-lactamase precursor LRA-5 in complex with ceftazidime at 2.35 Angstrom resolution
2GUB	;	1.8	;	Crystal Structure of Metal Free D-Xylose Isomerase.
7WGU	;	1.85	;	Crystal structure of metal-binding protein EfeO from Escherichia coli
1TXL	;	1.7	;	Crystal structure of metal-binding protein yodA from E. coli, Pfam DUF149
7CJO	;	1.4	;	Crystal structure of metal-bound state of glucose isomerase
4NRN	;	1.802	;	Crystal structure of metal-bound toxin from Helicobacter pylori
7F6P	;	2.15	;	Crystal structure of metal-citrate-binding mutant (D28A) protein (MctA) of ABC transporter endogenously bound to citrate
7F6R	;	2.09	;	Crystal structure of metal-citrate-binding mutant (S164A) protein (MctA) of ABC transporter in apo state
7F6N	;	2.3	;	Crystal structure of metal-citrate-binding mutant (S26A) protein (MctA) of ABC transporter endogenously bound to Mg2+-citrate complex
7F6O	;	2.5	;	Crystal structure of metal-citrate-binding mutant (S26A) protein (MctA) of ABC transporter endogenously bound to Mn2+-citrate complex
7F6Q	;	1.63	;	Crystal structure of metal-citrate-binding mutant (S79A) protein (MctA) of ABC transporter in apo state
7F6S	;	1.8	;	Crystal structure of metal-citrate-binding mutant (T199A) protein (MctA) of ABC transporter in apo state
7F6U	;	1.75	;	Crystal structure of metal-citrate-binding mutant (Y221A) protein (MctA) of ABC transporter in apo state
7F6T	;	1.9	;	Crystal structure of metal-citrate-binding mutant (Y221F) protein (MctA) of ABC transporter in apo state
7F6K	;	2.1	;	Crystal structure of metal-citrate-binding protein (MctA) of ABC transporter endogenously bound to citrate
7F6E	;	1.77	;	Crystal structure of metal-citrate-binding protein (MctA) of ABC transporter endogenously bound to Mg2+-citrate complex (Form I)
7F6F	;	2.1	;	Crystal structure of metal-citrate-binding protein (MctA) of ABC transporter endogenously bound to Mg2+-citrate complex (Form II)
8Q59	;	2.0	;	Crystal structure of metal-dependent class II sulfofructose phosphate aldolase from Yersinia aldovae in complex with sulfofructose phosphate (YaSqiA-Zn-SFP)
8Q5A	;	2.8	;	Crystal structure of metal-dependent class II sulfofructosephosphate aldolase from Hafnia paralvei HpSqiA-Zn in complex with dihydroxyacetone phosphate (DHAP)
8Q58	;	1.7	;	Crystal structure of metal-dependent classII sulfofructosephosphate aldolase (SFPA) from Hafnia paralvei HpSqiA-Zn
8HMO	;	2.53	;	Crystal Structure of metal-dependent hydrolase complexed with manganese from Bacillus smithii
1J6P	;	1.9	;	Crystal structure of Metal-dependent hydrolase of cytosinedemaniase/chlorohydrolase family (TM0936) from Thermotoga maritima at 1.9 A resolution
1XM5	;	2.7	;	Crystal structure of metal-dependent hydrolase ybeY from E. coli, Pfam UPF0054
3BDF	;	1.4	;	Crystal structure of metal-free E. coli alkaline phosphatase (T155V)
3TF3	;	1.64	;	Crystal structure of metal-free Human Arginase I
1HZT	;	1.45	;	CRYSTAL STRUCTURE OF METAL-FREE ISOPENTENYL DIPHOSPHATE:DIMETHYLALLYL DIPHOSPHATE ISOMERASE
6PPX	;	1.85	;	Crystal structure of metal-free NeuB, an N-acetylneuraminate synthase from Neisseria meningitidis in complex with malate
7CJP	;	1.5	;	Crystal structure of metal-free state of glucose isomerase
6V72	;	1.5	;	Crystal Structure of Metallo Beta Lactamase from Erythrobacter litoralis
6V73	;	2.4	;	Crystal Structure of Metallo Beta Lactamase from Erythrobacter litoralis with beta mercaptoethanol in the active site
6V54	;	1.45	;	Crystal Structure of Metallo Beta Lactamase from Hirschia baltica
6V5M	;	1.5	;	Crystal Structure of Metallo Beta Lactamase from Hirschia baltica in Complex with Succinate
6V61	;	1.58	;	Crystal Structure of Metallo Beta Lactamase from Hirschia baltica in the Complex with the Inhibitor Captopril
6V70	;	1.95	;	Crystal Structure of Metallo Beta Lactamase from Hirschia baltica with Cadmium in the Active Site
6V71	;	1.4	;	Crystal Structure of Metallo Beta Lactamase from Hirschia baltica with Nitrate in the Active Site
3LY0	;	1.399	;	Crystal structure of metallo peptidase from Rhodobacter sphaeroides liganded with phosphinate mimic of dipeptide L-Ala-D-Ala
2ZO4	;	2.1	;	Crystal structure of metallo-beta-lactamase family protein TTHA1429 from Thermus thermophilus HB8
3X30	;	1.921	;	Crystal structure of metallo-beta-lactamase from Thermotoga maritima
3X2X	;	3.42	;	Crystal structure of metallo-beta-lactamase H48A from Thermotoga maritima
3X2Y	;	2.67	;	Crystal structure of metallo-beta-lactamase H8A from Thermotoga maritima
7XHW	;	1.94	;	Crystal structure of metallo-beta-lactamase IMP-1
5HH4	;	2.0	;	Crystal structure of metallo-beta-lactamase IMP-1 in complex with a phosphonate-based inhibitor
7DTM	;	2.0	;	Crystal structure of metallo-beta-lactamase IMP-1 in complex with citrate.
7DTN	;	1.85	;	Crystal structure of metallo-beta-lactamase IMP-1 mutant (D120E) in complex with citrate.
1WUO	;	2.01	;	Crystal structure of metallo-beta-lactamase IMP-1 mutant (D81A)
1WUP	;	3.0	;	Crystal structure of metallo-beta-lactamase IMP-1 mutant (D81E)
5B3R	;	2.0	;	Crystal structure of metallo-beta-lactamase IMP-18 from Pseudomonas aeruginosa
6L3S	;	1.7	;	Crystal structure of metallo-beta-lactamase IMP-27 from Morganella morganii
7XHX	;	1.7	;	Crystal structure of metallo-beta-lactamase IMP-6
7WZU	;	1.954	;	Crystal structure of metallo-beta-lactamase IMP-6.
3X2Z	;	2.33	;	Crystal structure of metallo-beta-lactamase in complex with nickel from Thermotoga maritima
3L6N	;	1.65	;	Crystal structure of metallo-beta-lactamase IND-7
7FCT	;	1.8	;	Crystal structure of metallo-beta-lactamase MBLBt2
3VPE	;	1.6	;	Crystal Structure of Metallo-beta-Lactamase SMB-1
5AXR	;	2.1	;	Crystal Structure of Metallo-beta-Lactamase SMB-1 Bound to 2-mercaptoethanesulfonate
5B15	;	1.39	;	Crystal Structure of Metallo-beta-Lactamase SMB-1 Bound to Hydrolyzed Doripenem
5B1U	;	1.57	;	Crystal Structure of Metallo-beta-Lactamase SMB-1 Bound to Hydrolyzed Imipenem
5AXO	;	1.39	;	Crystal Structure of Metallo-beta-Lactamase SMB-1 Bound to Hydrolyzed Meropenem
5AYA	;	2.02	;	Crystal Structure of Metallo-beta-Lactamase SMB-1 Bound to L-captopril
5NDB	;	2.38	;	Crystal structure of metallo-beta-lactamase SPM-1 complexed with cyclobutanone inhibitor
5NDE	;	1.7	;	Crystal structure of metallo-beta-lactamase SPM-1 in space group P4222
5LS3	;	1.754	;	Crystal structure of metallo-beta-lactamase SPM-1 with Y58C mutation
8U00	;	1.85	;	Crystal structure of metallo-beta-lactamase superfamily protein from Caulobacter vibrioides
5N5H	;	1.3	;	Crystal structure of metallo-beta-lactamase VIM-1 in complex with ML302F inhibitor
6JV4	;	1.7	;	Crystal structure of metallo-beta-lactamase VMB-1
3VQZ	;	2.2	;	Crystal structure of metallo-beta-lactamase, SMB-1, in a complex with mercaptoacetic acid
8Y0S	;	2.75	;	Crystal structure of metallo-beta-lactamse, IMP-1, complexed with a quinolinone-based inhibitor
6JKA	;	2.006	;	Crystal structure of metallo-beta-lactamse, IMP-1, in complex with a thiazole-bearing inhibitor
6JKB	;	2.444	;	Crystal structure of metallo-beta-lactamse, NDM-1, in complex with hydrolyzed ampicillin
4B6Z	;	1.9	;	Crystal structure of metallo-carboxypeptidase from Burkholderia cenocepacia
4L24	;	2.7	;	Crystal structure of metallo-DNA duplex containing consecutive T-Hg(II)-T base pairs
5IX7	;	1.398	;	Crystal structure of metallo-DNA nanowire with infinite one-dimensional silver array
7Y7O	;	1.9	;	Crystal structure of metallo-endoribonuclease YbeY from Staphylococcus aureus
4RZY	;	1.949	;	Crystal structure of metallopeptidase-like dimethylsulphoniopropionate (DMSP) lyase RlDddP in complex with MES
4RZZ	;	2.1	;	Crystal structure of metallopeptidase-like dimethylsulphoniopropionate (DMSP) lyase RlDddP in complex with phosphate
4S01	;	2.1	;	Crystal structure of metallopeptidase-like dimethylsulphoniopropionate (DMSP) lyase RlDddP mutant D377N in complex with acrylate
4S00	;	2.099	;	Crystal structure of metallopeptidase-like dimethylsulphoniopropionate (DMSP) lyase RlDddP mutant Y366A in complex with acrylate
3RQZ	;	1.95	;	Crystal structure of metallophosphoesterase from Sphaerobacter thermophilus
2IF6	;	1.8	;	Crystal structure of metalloprotein yiiX from Escherichia coli O157:H7, DUF1105
4ON1	;	2.13	;	Crystal Structure of metalloproteinase-II from Bacteroides fragilis
4IR0	;	1.6	;	Crystal Structure of Metallothiol Transferase FosB 2 from Bacillus anthracis str. Ames
4JD1	;	1.7	;	Crystal Structure of Metallothiol Transferase FosB 2 from Bacillus anthracis str. Ames
5F6Q	;	1.52	;	Crystal Structure of Metallothiol Transferase from Bacillus anthracis str. Ames
6AUF	;	2.603	;	Crystal structure of Metalo beta Lactamases MIM-1 from Novosphingobium pentaromativorans
1R5G	;	2.0	;	Crystal Structure of MetAP2 complexed with A311263
1R5H	;	2.4	;	Crystal Structure of MetAP2 complexed with A320282
1R58	;	1.9	;	Crystal Structure of MetAP2 complexed with A357300
7K4M	;	2.5	;	Crystal structure of MetAP2 Modified Hemoglobin S
4HJW	;	2.6	;	Crystal structure of Metarhizium anisopliae IDCase in apo form
3PXO	;	3.0	;	Crystal structure of Metarhodopsin II
3PQR	;	2.85	;	Crystal structure of Metarhodopsin II in complex with a C-terminal peptide derived from the Galpha subunit of transducin
3CGA	;	2.03	;	Crystal structure of metastasis-associated protein S100A4 in the active, calcium-bound form
5X5H	;	1.51	;	Crystal structure of metB from Corynebacterium glutamicum
3L8A	;	1.539	;	Crystal structure of MetC from Streptococcus mutans
3L7R	;	2.397	;	crystal structure of MetE from streptococcus mutans
8SP2	;	2.2	;	Crystal structure of metformin hydrolase (MfmAB) from Pseudomonas mendocina sp. MET-2 apo form
8SNK	;	1.85	;	Crystal structure of metformin hydrolase (MfmAB) from Pseudomonas mendocina sp. MET-2 mutant (MfmA/D188N)
8SNF	;	2.3	;	Crystal structure of metformin hydrolase (MfmAB) from Pseudomonas mendocina sp. MET-2 with Ni2+2 bound
1KUU	;	2.2	;	CRYSTAL STRUCTURE OF METHANOBACTERIUM THERMOAUTOTROPHICUM CONSERVED PROTEIN MTH1020 REVEALS AN NTN-HYDROLASE FOLD
1M8K	;	3.0	;	Crystal Structure Of Methanobacterium Thermoautotrophicum Nicotinamide Mononucleotide Adenylyltransferase Mutant H19A complexed with NAD
1M8F	;	2.4	;	Crystal Structure Of Methanobacterium Thermoautotrophicum Nicotinamide Mononucleotide Adenylyltransferase Mutant R11A complexed with NAD
1M8G	;	2.0	;	Crystal Structure Of Methanobacterium Thermoautotrophicum Nicotinamide Mononucleotide Adenylyltransferase Mutant R11K complexed with NAD
1M8J	;	2.4	;	Crystal Structure Of Methanobacterium Thermoautotrophicum Nicotinamide Mononucleotide Adenylyltransferase Mutant R136A complexed with NAD
1EJ2	;	1.9	;	Crystal structure of methanobacterium thermoautotrophicum nicotinamide mononucleotide adenylyltransferase with bound NAD+
4YP5	;	2.21	;	Crystal structure of Methanobacterium thermoautotrophicum NMNAT in complex with NADP
4YP6	;	1.9	;	Crystal structure of Methanobacterium thermoautotrophicum NMNAT in complex with NADP
4YP7	;	2.3	;	Crystal structure of Methanobacterium thermoautotrophicum NMNAT in complex with NADP
1ZPS	;	1.7	;	Crystal structure of Methanobacterium thermoautotrophicum phosphoribosyl-AMP cyclohydrolase HisI
6Q2E	;	1.768	;	Crystal structure of Methanobrevibacter smithii Dph2 bound to 5'-methylthioadenosine
6Q2D	;	3.45	;	Crystal structure of Methanobrevibacter smithii Dph2 in complex with Methanobrevibacter smithii elongation factor 2
3FHF	;	1.995	;	Crystal structure of Methanocaldococcus jannaschii 8-oxoguanine DNA glycosylase (MjOgg)
3KNT	;	2.7	;	Crystal structure of Methanocaldococcus jannaschii 8-oxoguanine glycosylase/lyase in complex with 15mer DNA containing 8-oxoguanine
4QHG	;	2.2	;	Crystal structure of Methanocaldococcus jannaschii dimeric selecase
5DNI	;	2.3	;	Crystal structure of Methanocaldococcus jannaschii Fumarate hydratase beta subunit
4QHF	;	2.1	;	Crystal structure of Methanocaldococcus jannaschii monomeric selecase
2C49	;	1.92	;	Crystal Structure of Methanocaldococcus jannaschii Nucleoside Kinase - An Archaeal Member of the Ribokinase Family
2C4E	;	1.7	;	Crystal Structure of Methanocaldococcus jannaschii Nucleoside Kinase - An Archaeal Member of the Ribokinase Family
2YX5	;	2.3	;	Crystal Structure of Methanocaldococcus jannaschii PurS, One of the Subunits of Formylglycinamide Ribonucleotide Amidotransferase in the Purine Biosynthetic Pathway
4QHJ	;	1.75	;	Crystal structure of Methanocaldococcus jannaschii selecase mutant I100F+H107F
4QHI	;	2.3	;	Crystal structure of Methanocaldococcus jannaschii selecase mutant R36W
4QHH	;	3.0	;	Crystal structure of Methanocaldococcus jannaschii tetrameric selecase
3AY0	;	3.05	;	Crystal structure of Methanocaldococcus jannaschii Trm5 in complex with adenosine
7XKY	;	2.46	;	Crystal structure of Methanocaldococcus jannaschii two-subunit Fumarate hydratase apo-protein complex
4NES	;	1.42	;	Crystal structure of Methanocaldococcus jannaschii UDP-GlcNAc 2-epimerase in complex with UDP-GlcNAc and UDP
2DU7	;	3.6	;	Crystal structure of Methanococcus jannacshii O-phosphoseryl-tRNA synthetase
1QWG	;	1.6	;	Crystal structure of Methanococcus jannaschii phosphosulfolactate synthase
2EB0	;	2.2	;	Crystal structure of Methanococcus jannaschii putative family II inorganic pyrophosphatase
3VBA	;	2.0	;	Crystal structure of methanogen 3-isopropylmalate isomerase small subunit
5H02	;	1.776	;	Crystal structure of Methanohalophilus portucalensis glycine sarcosine N-methyltransferase tetramutant (H21G, E23T, E24N, L28S)
2D0V	;	2.49	;	Crystal structure of methanol dehydrogenase from Hyphomicrobium denitrificans
2AD6	;	1.5	;	crystal structure of methanol dehydrogenase from M. W3A1 (form C)
2AD8	;	1.6	;	crystal structure of methanol dehydrogenase from M. W3A1 (form C) in the presence of ethanol
2AD7	;	1.5	;	crystal structure of methanol dehydrogenase from M. W3A1 (form C) in the presence of methanol
5XM3	;	1.701	;	Crystal Structure of Methanol dehydrogenase from Methylophaga aminisulfidivorans
1LRW	;	2.5	;	Crystal structure of methanol dehydrogenase from P. denitrificans
2I2X	;	2.5	;	Crystal structure of methanol:cobalamin methyltransferase complex MtaBC from Methanosarcina barkeri
7U0R	;	1.8	;	Crystal structure of Methanomethylophilus alvus PylRS(N166A/V168A) complexed with meta-trifluoromethyl-2-benzylmalonate and AMP-PNP
6U45	;	2.35	;	Crystal structure of Methanoperedens nitroreducens elongation factor 2 bound to GMPPCP and magnesium
6U44	;	2.1	;	Crystal structure of Methanoperedens nitroreducens elongation factor 2 H595N bound to GMPPCP and magnesium (monoclinic crystal form)
6U43	;	1.4	;	Crystal structure of Methanoperedens nitroreducens elongation factor 2 H595N bound to GMPPCP and magnesium (triclinic crystal form)
5CAX	;	2.451	;	CRYSTAL STRUCTURE OF METHANOSARCINA ACETIVORANS METHANOREDOXIN
2CIM	;	2.51	;	Crystal structure of Methanosarcina barkeri seryl-tRNA synthetase
2CJ9	;	2.3	;	Crystal structure of Methanosarcina barkeri seryl-tRNA synthetase complexed with an analog of seryladenylate
2CJA	;	2.2	;	Crystal structure of Methanosarcina barkeri seryl-tRNA synthetase complexed with ATP
2CJB	;	2.7	;	Crystal structure of Methanosarcina barkeri seryl-tRNA synthetase complexed with serine
6AAQ	;	1.551	;	Crystal structure of Methanosarcina mazei PylRS(Y306A/Y384F) complexed with BCNLys
6AAC	;	1.479	;	Crystal structure of Methanosarcina mazei PylRS(Y306A/Y384F) complexed with mAzZLys
6AAN	;	1.51	;	Crystal structure of Methanosarcina mazei PylRS(Y306A/Y384F) complexed with mEtZLys
6AAD	;	1.444	;	Crystal structure of Methanosarcina mazei PylRS(Y306A/Y384F) complexed with mTmdZLys
6AB1	;	1.381	;	Crystal structure of Methanosarcina mazei PylRS(Y306A/Y384F) complexed with oAzZLys
6ABL	;	1.47	;	Crystal structure of Methanosarcina mazei PylRS(Y306A/Y384F) complexed with oBrZLys
6AB2	;	1.4	;	Crystal structure of Methanosarcina mazei PylRS(Y306A/Y384F) complexed with oClZLys
6AB0	;	1.441	;	Crystal structure of Methanosarcina mazei PylRS(Y306A/Y384F) complexed with pAmPyLys
6AAZ	;	1.842	;	Crystal structure of Methanosarcina mazei PylRS(Y306A/Y384F) complexed with pNO2ZLys
6ABM	;	1.368	;	Crystal structure of Methanosarcina mazei PylRS(Y306A/Y384F) complexed with pTmdZLys
6AAO	;	1.403	;	Crystal structure of Methanosarcina mazei PylRS(Y306A/Y384F) complexed with TCO*Lys
6ABK	;	1.58	;	Crystal structure of Methanosarcina mazei PylRS(Y306A/Y384F) complexed with TeocLys
6AAP	;	1.5	;	Crystal structure of Methanosarcina mazei PylRS(Y306A/Y384F) complexed with ZaeSeCys
6AB8	;	1.753	;	Crystal structure of Methanosarcina mazei PylRS(Y306A/Y384F) complexed with ZLys
2QBU	;	2.1	;	Crystal structure of Methanothermobacter thermautotrophicus CbiL
3SSJ	;	1.4	;	Crystal structure of Methanothermobacter thermautotrophicus orotidine 5'-monophosphate decarboxylase complexed with 5-fluoro-6-amino-UMP
3THQ	;	1.5	;	Crystal structure of Methanothermobacter thermautotrophicus orotidine 5'-monophosphate decarboxylase complexed with 6-amino-UMP
3SEC	;	1.7	;	Crystal structure of Methanothermobacter thermautotrophicus orotidine 5'-monophosphate decarboxylase complexed with pyrazofurin monophosphate
3SW6	;	1.5	;	Crystal structure of Methanothermobacter thermautotrophicus orotidine 5'-monophosphate decarboxylase covalently modified by 5-fluoro-6-azido-UMP
3SGU	;	1.7	;	Crystal structure of Methanothermobacter thermautotrophicus orotidine 5'-monophosphate decarboxylase covalently modified by 5-fluoro-6-iodo-UMP
1SBQ	;	2.2	;	Crystal Structure of methenyltetrahydrofolate synthetase from Mycoplasma pneumoniae at 2.2 resolution
4FIO	;	1.37	;	Crystal Structure of Methenyltetrahydromethanopterin Cyclohydrolase from Methanobrevibacter ruminantium
6S81	;	1.784	;	Crystal structure of methionine adenosyltransferase from Pyrococcus furiosus
6S83	;	2.336	;	Crystal structure of methionine adenosyltransferase from Pyrococcus furiosus in complex with AMPPCP, SAM, and PCP
2EVO	;	1.7	;	crystal structure of methionine amino peptidase in complex with N-cyclopentyl-N-(thiazol-2-yl)oxalamide
1O0X	;	1.9	;	Crystal structure of Methionine aminopeptidase (TM1478) from Thermotoga maritima at 1.90 A resolution
3S6B	;	1.95	;	Crystal structure of methionine aminopeptidase 1b from Plasmodium Falciparum, PF10_0150
6LVH	;	3.2	;	Crystal structure of methionine aminopeptidase from Pyrococcus furiosus
6M00	;	3.2	;	crystal structure of Methionine aminopeptidase from Pyrococcus furiosus
3MR1	;	2.0	;	Crystal structure of methionine aminopeptidase from Rickettsia prowazekii
3MX6	;	1.7	;	Crystal structure of methionine aminopeptidase from Rickettsia prowazekii bound to methionine
2EVM	;	1.7	;	crystal structure of methionine aminopeptidase in complex with 5-(2,5-dichlorophenyl)furan-2-carboxylic acid
6S0C	;	1.46	;	Crystal structure of methionine gamma-lyase from Citrobacter freundii modified by dimethylthiosulfinate
5K30	;	1.59	;	Crystal structure of methionine gamma-lyase from Citrobacter freundii modified by S-Ethyl-L-cysteine sulfoxide
5E4Z	;	2.27	;	Crystal structure of methionine gamma-lyase from Citrobacter freundii with C115A substitution
5D5S	;	1.7	;	Crystal structure of methionine gamma-lyase from Citrobacter freundii, S339A mutant
5DX5	;	2.37	;	Crystal structure of methionine gamma-lyase from Clostridium sporogenes
6LXU	;	1.19	;	Crystal structure of methionine gamma-lyase from Fusobacterium nucleatum
7BQW	;	2.5	;	Crystal structure of Methionine gamma-lyase from Fusobacterium nucleatum
3DHW	;	3.7	;	Crystal structure of methionine importer MetNI
4LWJ	;	1.8	;	Crystal structure of methionine sulfoxide reductase U16C from clostridium oremlandii
4LWL	;	1.6	;	Crystal structure of methionine sulfoxide reductase U16C/E55A from clostridium oremlandii
4LWM	;	1.804	;	Crystal structure of methionine sulfoxide reductase U16C/E55D from clostridium oremlandii with methionie sulfoxide
4LWK	;	1.8	;	Crystal structure of methionine sulfoxide reductase U16S from clostridium oremlandii
3CEZ	;	2.1	;	Crystal structure of methionine-R-sulfoxide reductase from Burkholderia pseudomallei
7ULZ	;	2.8	;	Crystal Structure of Methionine-tRNA ligase / Methionyl-tRNA synthetase (MetRS) from Pseudomonas aeruginosa PAO1
2D54	;	2.0	;	Crystal Structure of Methionyl tRNA Synthetase Y225A Mutant from Thermus Thermophilus
1WOY	;	2.0	;	Crystal structure of methionyl tRNA synthetase Y225F mutant from Thermus thermophilus
5UAI	;	2.75	;	Crystal structure of Methionyl-tRNA formyltransferase from Pseudomonas aeruginosa
3R8X	;	2.256	;	Crystal Structure of Methionyl-tRNA Formyltransferase from Yersinia pestis complexed with L-methionine
5URB	;	1.9	;	Crystal Structure of Methionyl-tRNA synthetase (MetRS) from Acinetobacter baumannii with bound L-Methionine
4DLP	;	2.65	;	Crystal structure of methionyl-tRNA synthetase MetRS from Brucella melitensis bound to selenomethionine
4PY2	;	2.15	;	Crystal structure of methionyl-tRNA synthetase MetRS from Brucella melitensis in complex with inhibitor 1-{3-[(3,5-DICHLOROBENZYL)AMINO]PROPYL}-3-THIOPHEN-3-YLUREA
5K0S	;	2.45	;	Crystal structure of methionyl-tRNA synthetase MetRS from Brucella melitensis in complex with inhibitor Chem 1312
5K0T	;	2.6	;	Crystal structure of methionyl-tRNA synthetase MetRS from Brucella melitensis in complex with inhibitor Chem 1415
3AD4	;	2.2	;	Crystal Structure of Methoxy Benzofuran Derivative bound to the Kinase domain of human LCK, (auto-phosphorylated on TYR394)
4IQF	;	2.378	;	Crystal Structure of Methyionyl-tRNA Formyltransferase from Bacillus anthracis
3VXX	;	2.204	;	Crystal structure of methyl CpG binding domain of MBD4 in complex with the 5mCG/5mCG sequence
3VYB	;	2.4	;	Crystal structure of methyl CpG binding domain of MBD4 in complex with the 5mCG/hmCG sequence
3VXV	;	2.0	;	Crystal structure of methyl CpG Binding Domain of MBD4 in complex with the 5mCG/TG sequence
6MRO	;	1.6	;	Crystal structure of methyl transferase from Methanosarcina acetivorans at 1.6 Angstroms resolution, Northeast Structural Genomics Consortium (NESG) Target MvR53.
3MGG	;	1.86	;	Crystal Structure of Methyl Transferase from Methanosarcina mazei
2QHK	;	1.91	;	Crystal structure of methyl-accepting chemotaxis protein from Vibrio parahaemolyticus RIMD 2210633
2PVZ	;	1.97	;	Crystal structure of methylaconitate isomerase PrpF from Shewanella oneidensis
6IE2	;	2.8	;	Crystal structure of methyladenine demethylase
6IE3	;	1.97	;	Crystal structure of methyladenine demethylase
6KR7	;	4.0	;	Crystal structure of methylated human leucyl-tRNA synthetase, Leu-AMS-bound form
6JDR	;	2.5	;	Crystal structure of methylated PRRSV nsp10 (helicase)
1Z1Y	;	2.0	;	Crystal structure of Methylated Pvs25, an ookinete protein from Plasmodium vivax
3HHL	;	2.65	;	Crystal structure of methylated RPA0582 protein
4ZYG	;	2.8	;	Crystal structure of methylated Sulfolobus solfataricus O6-methylguanine methyltransferase
3HWK	;	2.3	;	Crystal structure of methylcitrate synthase from Mycobacterium tuberculosis
7WMW	;	2.053	;	Crystal structure of methylenetetrahydrofolate reductase MSMEG_6649 from Mycobacterium smegmatis
7WMX	;	2.264	;	Crystal structure of methylenetetrahydrofolate reductase MSMEG_6649 from Mycobacterium smegmatis with 5,10-methylenetetrahydrofolate
7WMY	;	2.266	;	Crystal structure of methylenetetrahydrofolate reductase MSMEG_6649 from Mycobacterium smegmatis with 5-methyltetrahydrofolate
7WMZ	;	1.916	;	Crystal structure of methylenetetrahydrofolate reductase MSMEG_6649 from Mycobacterium smegmatis with NADH
1Z69	;	2.61	;	Crystal structure of methylenetetrahydromethanopterin reductase (Mer) in complex with coenzyme F420
1VMD	;	2.06	;	Crystal structure of Methylglyoxal synthase (TM1185) from Thermotoga maritima at 2.06 A resolution
8U2V	;	2.5	;	Crystal Structure of methylglyoxal synthase from Borrelia burgdorferi
6PHE	;	2.1	;	Crystal structure of Methylglyoxal synthase from Elizabethkingia anophelis NUHP1
1WO8	;	1.7	;	Crystal structure of methylglyoxal synthase from Thermus thermophilus HB8
3G7K	;	2.7	;	Crystal Structure of Methylitaconate-delta-isomerase
1T90	;	2.5	;	Crystal structure of methylmalonate semialdehyde dehydrogenase from Bacillus subtilis
4ZZ7	;	2.9	;	Crystal structure of methylmalonate-semialdehyde dehydrogenase (DddC) from Oceanimonas doudoroffii
2WWW	;	2.64	;	Crystal Structure of Methylmalonic Acidemia Type A Protein
1EF8	;	1.85	;	CRYSTAL STRUCTURE OF METHYLMALONYL COA DECARBOXYLASE
6BU2	;	1.997	;	Crystal structure of methylmalonyl-CoA epimerase from Mycobacterium tuberculosis
4ROS	;	1.95	;	Crystal structure of Methylobacterium extorquens malate dehydrogenase complexed with oxaloacetate and adenosine-5-diphosphoribose
3T7V	;	1.5	;	Crystal structure of methylornithine synthase (PylB)
3CHX	;	3.9	;	Crystal structure of Methylosinus trichosporium OB3b particulate methane monooxygenase (pMMO)
6VK6	;	1.52	;	Crystal Structure of Methylosinus trichosporium OB3b Soluble Methane Monooxygenase Hydroxylase
6VK4	;	2.35	;	Crystal Structure of Methylosinus trichosporium OB3b Soluble Methane Monooxygenase Hydroxylase and Regulatory Component Complex
6VK5	;	1.86	;	Crystal Structure of Methylosinus trichosporium OB3b Soluble Methane Monooxygenase Hydroxylase and Regulatory Component Complex
6VK8	;	2.03	;	Crystal Structure of Methylosinus trichosporium OB3b Soluble Methane Monooxygenase Hydroxylase and Regulatory Component Complex with small organic carboxylate at active center
4GLJ	;	1.9	;	Crystal structure of methylthioadenosine phosphorylase in complex with rhodamine B
4GLF	;	1.98	;	Crystal structure of methylthioadenosine phosphorylase sourced from an antarctic soil metagenomic library
6E1J	;	2.096	;	Crystal Structure of Methylthioalkylmalate Synthase (BjuMAM1.1) from Brassica juncea
3VSE	;	2.099	;	Crystal structure of methyltransferase
4Z2Y	;	3.4	;	Crystal structure of methyltransferase CalO6
6IWT	;	2.53	;	Crystal structure of methyltransferase COMT-S in P. praeruptorum
3BO5	;	1.59	;	Crystal structure of methyltransferase domain of human Histone-lysine N-methyltransferase SETMAR
3RAY	;	1.73	;	Crystal structure of Methyltransferase domain of human PR domain-containing protein 11
3DB5	;	2.15	;	Crystal structure of methyltransferase domain of human PR domain-containing protein 4
4IJD	;	2.15	;	Crystal structure of methyltransferase domain of human PR domain-containing protein 9
4FMW	;	2.0	;	Crystal structure of methyltransferase domain of human RNA (guanine-9-) methyltransferase domain containing protein 2
4FMU	;	2.1	;	Crystal structure of Methyltransferase domain of human SET domain-containing protein 2 Compound: Pr-SNF
2PY6	;	2.15	;	Crystal structure of Methyltransferase FkbM (YP_546752.1) from Methylobacillus flagellatus KT at 2.20 A resolution
3L8D	;	1.7	;	Crystal structure of methyltransferase from Bacillus Thuringiensis
3EVZ	;	2.2	;	Crystal structure of Methyltransferase from Pyrococcus furiosus
2NQ5	;	1.9	;	Crystal structure of methyltransferase from Streptococcus mutans
4KIG	;	2.4	;	Crystal structure of methyltransferase from Streptomyces hygroscopicus complexed with 4-hydroxyphenylpyruvic acid
4KIF	;	2.5	;	Crystal structure of methyltransferase from Streptomyces hygroscopicus complexed with phenylpyruvic acid
4KIB	;	2.0	;	Crystal structure of methyltransferase from Streptomyces hygroscopicus complexed with S-adenosyl-L-homocysteine and methylphenylpyruvic acid
4KIC	;	2.43	;	Crystal structure of methyltransferase from Streptomyces hygroscopicus complexed with S-adenosyl-L-methionine and phenylpyruvic acid
3DOU	;	1.45	;	Crystal structure of methyltransferase involved in cell division from thermoplasma volcanicum gss1
1G60	;	1.74	;	Crystal Structure of Methyltransferase MboIIa (Moraxella bovis)
7DLZ	;	3.002	;	Crystal Structure of Methyltransferase Ribozyme
4DCM	;	2.297	;	Crystal Structure of methyltransferase RlmG modifying G1835 of 23S rRNA in Escherichia coli
5GM1	;	2.501	;	Crystal structure of methyltransferase TleD complexed with SAH
5GM2	;	2.8	;	Crystal structure of methyltransferase TleD complexed with SAH and teleocidin A1
2CX8	;	2.53	;	Crystal structure of methyltransferase with ligand(SAH)
2CWP	;	2.1	;	Crystal structure of MetRS related protein from Pyrococcus horikoshii
7YF4	;	2.75	;	Crystal structure of METTL9 in complex with SLC39A5 mutant peptide and SAH
7Y9C	;	2.1	;	Crystal structure of METTL9 in complex with SLC39A5 peptide and SAH
7YF3	;	3.434	;	Crystal structure of METTL9 in complex with unmethylated S100A9 peptide and SAH
7YF2	;	1.691	;	Crystal structure of METTL9 in complex with unmethylated SLC39A5 peptide and SAH
8GZF	;	2.5	;	Crystal Structure of METTL9-SAH
7T71	;	2.19	;	Crystal Structure of Mevalonate 3,5-Bisphosphate Decarboxylase from Picrophilus Torridus
2HK2	;	2.3	;	Crystal structure of mevalonate diphosphate decarboxylase from Staphylococcus aureus (monoclinic form)
2HK3	;	2.3	;	Crystal structure of mevalonate diphosphate decarboxylase from Staphylococcus aureus (orthorhombic form)
1VIS	;	2.69	;	Crystal structure of mevalonate kinase
2X7I	;	2.2	;	Crystal structure of mevalonate kinase from methicillin-resistant Staphylococcus aureus MRSA252
4RKP	;	2.1	;	Crystal Structure of Mevalonate-3-Kinase from Thermoplasma acidophilum (apo form)
4RKZ	;	2.3	;	Crystal Structure of Mevalonate-3-Kinase from Thermoplasma acidophilum (Mevalonate 3-Phosphate/ADP Bound)
4RKS	;	2.0	;	Crystal Structure of Mevalonate-3-Kinase from Thermoplasma acidophilum (Mevalonate Bound)
6EXZ	;	1.3	;	Crystal structure of Mex67 C-term
1OF5	;	2.8	;	Crystal structure of Mex67-Mtr2
3MEX	;	2.1	;	Crystal structure of MexR in oxidized state
2WUI	;	2.9	;	Crystal Structure of MexZ, a key repressor responsible for antibiotic resistance in Pseudomonas aeruginosa.
4NU3	;	1.399	;	Crystal structure of mFfIBP, a capping head region swapped mutant of ice-binding protein
7UX8	;	1.4	;	Crystal structure of MfnG, an L- and D-tyrosine O-methyltransferase from the marformycin biosynthesis pathway of Streptomyces drozdowiczii, with SAH and L-Tyrosine bound at 1.4 A resolution (P212121 - form II)
7UX7	;	1.14	;	Crystal structure of MfnG, an L- and D-tyrosine O-methyltransferase from the marformycin biosynthesis pathway of Streptomyces drozdowiczii, with SAH bound at 1.2 A resolution (P212121 - form II)
7UX6	;	1.35	;	Crystal structure of MfnG, an L- and D-tyrosine O-methyltransferase from the marformycin biosynthesis pathway of Streptomyces drozdowiczii, with SAH bound at 1.35 A resolution (P212121 - form I)
2FKA	;	2.0	;	Crystal structure of Mg(2+) and BeF(3)(-)-bound CheY in complex with CheZ(200-214) solved from a F432 crystal grown in CAPS (pH 10.5)
3H1E	;	2.4	;	Crystal structure of Mg(2+) and BeH(3)(-)-bound CheY of Helicobacter pylori
1J34	;	1.55	;	Crystal Structure of Mg(II)-and Ca(II)-bound Gla Domain of Factor IX Complexed with Binding Protein
1RC5	;	2.3	;	CRYSTAL STRUCTURE OF MG(II)-COMPLEX OF RNASE III ENDONUCLEASE DOMAIN FROM AQUIFEX AEOLICUS AT 2.30 ANGSTROM RESOLUTION
7BGP	;	1.68	;	Crystal structure of MG-132 covalently bound to the main protease (3CLpro/Mpro) of SARS-CoV-2 in absence of DTT.
7NF5	;	1.94	;	Crystal structure of MG-132 covalently bound to the main protease (3CLpro/Mpro) of SARS-CoV-2 in spacegroup C2.
7NG6	;	1.87	;	Crystal structure of MG-132 covalently bound to the main protease (3CLpro/Mpro) of SARS-CoV-2 in spacegroup P1 in absence of DTT.
7NG3	;	1.8	;	Crystal structure of MG-132 covalently bound to the main protease (3CLpro/Mpro) of SARS-CoV-2 in spacegroup P1.
7BE7	;	1.68	;	Crystal structure of MG-132 covalently bound to the main protease (3CLpro/Mpro) of SARS-CoV-2.
1M74	;	3.0	;	Crystal structure of Mg-ADP-bound SecA from Bacillus subtilis
3GWI	;	1.6	;	Crystal Structure of Mg-ATPase Nucleotide binding domain
7EYX	;	1.82	;	Crystal structure of Mg-free KRAS-G12D bound to GDP
6MBQ	;	1.35	;	Crystal structure of Mg-free wild-type KRAS (2-166) bound to GMPPNP in the state 1 conformation
1L5Y	;	2.1	;	CRYSTAL STRUCTURE OF MG2+ / BEF3-BOUND RECEIVER DOMAIN OF SINORHIZOBIUM MELILOTI DCTD
2FMH	;	2.001	;	Crystal structure of Mg2+ and BeF3- bound CheY in complex with CheZ 200-214 solved from a F432 crystal grown in Tris (pH 8.4)
2FMK	;	1.999	;	Crystal structure of Mg2+ and BeF3- bound CheY in complex with CheZ 200-214 solved from a P2(1)2(1)2 crystal grown in MES (pH 6.0)
2FLW	;	2.0	;	Crystal structure of Mg2+ and BeF3- ound CheY in complex with CheZ 200-214 solved from a F432 crystal grown in Hepes (pH 7.5)
4QHE	;	1.4	;	Crystal structure of Mg2+ bound human APE1
4YEH	;	2.45	;	Crystal structure of Mg2+ ion containing hemopexin fold from Kabuli chana (chickpea white) at 2.45A resolution reveals a structural basis of metal ion transport
2AFI	;	3.1	;	Crystal Structure of MgADP bound Av2-Av1 Complex
8V9Q	;	2.29	;	Crystal structure of mGalNAc-T1 in complex with the mucin glycopeptide Muc5AC-13, Mn2+, and UDP.
4WZB	;	2.3	;	Crystal Structure of MgAMPPCP-bound Av2-Av1 complex
8CE3	;	1.89	;	Crystal structure of MGAT5 (alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase V) luminal domain with a Lys329-Ile345 loop truncation, in complex with 3D fragment 2548
6YJS	;	1.6	;	Crystal structure of MGAT5 (alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase V) luminal domain with a Lys329-Ile345 loop truncation, in complex with biantennary pentasaccharide M592
6YJT	;	1.7	;	Crystal structure of MGAT5 (alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase V) luminal domain with a Lys329-Ile345 loop truncation, in complex with UDP
6YJU	;	1.96	;	Crystal structure of MGAT5 (alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase V) luminal domain with a Lys329-Ile345 loop truncation, in complex with UDP and biantennary pentasaccharide M592
4PUR	;	2.95	;	Crystal structure of MglA from Francisella tularensis
5JX2	;	2.0504	;	Crystal structure of MglB-2 (Tp0684) from Treponema pallidum
7CT3	;	1.85	;	Crystal Structure of MglC from Myxococcus xanthus
7CY1	;	2.19	;	Crystal Structure of MglC from Myxococcus xanthus
3AGE	;	2.6	;	Crystal structure of Mglu in its L-glutamate binding form in the presence of 4.3M NaCl
3AGD	;	2.2	;	Crystal structure of Mglu in its native form in the presence of 4.3M NaCl
7EPE	;	2.5	;	Crystal structure of mGlu2 bound to NAM563
7EPF	;	2.7	;	Crystal structure of mGlu2 bound to NAM597
6FFH	;	2.65	;	Crystal Structure of mGluR5 in complex with Fenobam at 2.65 A
6FFI	;	2.2	;	Crystal Structure of mGluR5 in complex with MMPEP at 2.2 A
3LX5	;	1.9	;	Crystal structure of mGMPPNP-bound NFeoB from S. thermophilus
2BV6	;	2.8	;	Crystal structure of MgrA, a global regulator and major virulence determinant in Staphylococcus aureus
2YVQ	;	1.98	;	Crystal structure of MGS domain of carbamoyl-phosphate synthetase from homo sapiens
4Q3K	;	1.57	;	Crystal structure of MGS-M1, an alpha/beta hydrolase enzyme from a Medee basin deep-sea metagenome library
4Q3L	;	3.01	;	Crystal structure of MGS-M2, an alpha/beta hydrolase enzyme from a Medee basin deep-sea metagenome library
4Q3M	;	2.552	;	Crystal structure of MGS-M4, an aldo-keto reductase enzyme from a Medee basin deep-sea metagenome library
4Q3N	;	1.97	;	Crystal structure of MGS-M5, a lactate dehydrogenase enzyme from a Medee basin deep-sea metagenome library
5JD6	;	2.463	;	Crystal structure of MGS-MChE2, an alpha/beta hydrolase enzyme from the metagenome of sediments from the lagoon of Mar Chica, Morocco
5JD5	;	1.95	;	Crystal structure of MGS-MilE3, an alpha/beta hydrolase enzyme from the metagenome of pyrene-phenanthrene enrichment culture with sediment sample of Milazzo Harbor, Italy
4Q3O	;	1.74	;	Crystal structure of MGS-MT1, an alpha/beta hydrolase enzyme from a Lake Matapan deep-sea metagenome library
1F3B	;	2.0	;	CRYSTAL STRUCTURE OF MGSTA1-1 IN COMPLEX WITH GLUTATHIONE CONJUGATE OF BENZO[A]PYRENE EPOXIDE
1F3A	;	1.9	;	CRYSTAL STRUCTURE OF MGSTA1-1 IN COMPLEX WITH GSH
1ML6	;	1.9	;	Crystal Structure of mGSTA2-2 in Complex with the Glutathione Conjugate of Benzo[a]pyrene-7(R),8(S)-Diol-9(S),10(R)-Epoxide
1B48	;	2.6	;	CRYSTAL STRUCTURE OF MGSTA4-4 IN COMPLEX WITH GSH CONJUGATE OF 4-HYDROXYNONENAL IN ONE SUBUNIT AND GSH IN THE OTHER: EVIDENCE OF SIGNALING ACROSS DIMER INTERFACE IN MGSTA4-4
5HWA	;	1.35	;	Crystal Structure of MH-K1 chitosanase in substrate-bound form
1G7Q	;	1.6	;	CRYSTAL STRUCTURE OF MHC CLASS I H-2KB HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND MUC1 VNTR PEPTIDE SAPDTRPA
1G7P	;	1.5	;	CRYSTAL STRUCTURE OF MHC CLASS I H-2KB HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND YEAST ALPHA-GLUCOSIDASE
3MRK	;	1.4	;	Crystal Structure of MHC class I HLA-A2 molecule complexed with AFP137 nonapeptide
3MRE	;	1.1	;	Crystal Structure of MHC class I HLA-A2 molecule complexed with EBV bmlf1-280-288 nonapeptide
3MRF	;	2.3	;	Crystal Structure of MHC class I HLA-A2 molecule complexed with EBV bmlf1-280-288 nonapeptide T4P variant
3MRB	;	1.4	;	Crystal Structure of MHC class I HLA-A2 molecule complexed with HCMV pp65-495-503 nonapeptide A7H variant
3MR9	;	1.93	;	Crystal Structure of MHC class I HLA-A2 molecule complexed with HCMV pp65-495-503 nonapeptide M5A variant
3MRC	;	1.8	;	Crystal Structure of MHC class I HLA-A2 molecule complexed with HCMV pp65-495-503 nonapeptide V6C variant
3MRD	;	1.7	;	Crystal Structure of MHC class I HLA-A2 molecule complexed with HCMV pp65-495-503 nonapeptide V6G variant
3MRG	;	1.3	;	Crystal Structure of MHC class I HLA-A2 molecule complexed with HCV NS3-1073-1081 nonapeptide
3MRL	;	2.41	;	Crystal Structure of MHC class I HLA-A2 molecule complexed with HCV NS3-1073-1081 nonapeptide C6V variant
3MRI	;	2.1	;	Crystal Structure of MHC class I HLA-A2 molecule complexed with HCV NS3-1073-1081 nonapeptide G4M-V5W variant
3MRH	;	2.4	;	Crystal Structure of MHC class I HLA-A2 molecule complexed with HCV NS3-1073-1081 nonapeptide N3S variant
3MRJ	;	1.87	;	Crystal Structure of MHC class I HLA-A2 molecule complexed with HCV NS3-1073-1081 nonapeptide V5M variant
3MRM	;	1.9	;	Crystal Structure of MHC class I HLA-A2 molecule complexed with HCV NS3-1406-1415 decapeptide
3MRN	;	2.3	;	Crystal Structure of MHC class I HLA-A2 molecule complexed with HCV NS4b-1807-1816 decapeptide
3MRR	;	1.6	;	Crystal Structure of MHC class I HLA-A2 molecule complexed with Human Prostaglandin Transporter decapeptide
3MRO	;	2.35	;	Crystal Structure of MHC class I HLA-A2 molecule complexed with Melan-A MART1 decapeptide variant
3MRP	;	2.1	;	Crystal Structure of MHC class I HLA-A2 molecule complexed with Melan-A MART1 decapeptide variant
3MRQ	;	2.2	;	Crystal Structure of MHC class I HLA-A2 molecule complexed with Melan-A MART1 decapeptide variant
2X4T	;	2.3	;	Crystal structure of MHC CLass I HLA-A2.1 bound to a Peiodate- cleavable peptide
2X4S	;	2.55	;	Crystal structure of MHC CLass I HLA-A2.1 bound to a peptide representing the epitope of the H5N1 (Avian Flu) Nucleoprotein
2X4P	;	2.3	;	Crystal structure of MHC CLass I HLA-A2.1 bound to a photocleavable peptide
2X4Q	;	1.9	;	Crystal structure of MHC CLass I HLA-A2.1 bound to a photocleavable peptide
2X70	;	2.0	;	Crystal structure of MHC CLass I HLA-A2.1 bound to a photocleavable peptide
2X4R	;	2.3	;	Crystal structure of MHC CLass I HLA-A2.1 bound to Cytomegalovirus (CMV) pp65 epitope
2X4O	;	2.3	;	Crystal structure of MHC CLass I HLA-A2.1 bound to HIV-1 envelope peptide env120-128
2X4U	;	2.1	;	Crystal structure of MHC CLass I HLA-A2.1 bound to HIV-1 Peptide RT468-476
2X4N	;	2.34	;	Crystal structure of MHC CLass I HLA-A2.1 bound to residual fragments of a photocleavable peptide that is cleaved upon UV-light treatment
1ICF	;	2.0	;	CRYSTAL STRUCTURE OF MHC CLASS II ASSOCIATED P41 II FRAGMENT IN COMPLEX WITH CATHEPSIN L
5TRZ	;	2.247	;	Crystal structure of MHC-I H2-KD complexed with peptides of Mycobacterial tuberculosis (YQSGLSIVM)
5TS1	;	2.3	;	Crystal structure of MHC-I H2-KD complexed with peptides of Mycobacterial tuberculosis (YYQSGLSIV)
6BMH	;	2.298	;	Crystal structure of MHC-I like protein
6BMK	;	2.43	;	Crystal structure of MHC-I like protein
6A97	;	2.148	;	Crystal structure of MHC-like MILL2
6JTU	;	2.1	;	Crystal structure of MHETase from Ideonella sakaiensis
4DRA	;	2.414	;	Crystal structure of MHF complex
4H2N	;	2.302	;	Crystal structure of MHPCO, Y270F mutant
6YU4	;	2.26	;	Crystal structure of MhsT in complex with L-4F-phenylalanine
6YU2	;	3.1	;	Crystal structure of MhsT in complex with L-isoleucine
6YU6	;	2.35	;	Crystal structure of MhsT in complex with L-leucine
6YU3	;	2.25	;	Crystal structure of MhsT in complex with L-phenylalanine
6YU7	;	2.3	;	Crystal structure of MhsT in complex with L-tyrosine
6YU5	;	2.6	;	Crystal structure of MhsT in complex with L-valine
6PLE	;	2.5	;	Crystal structure of MhuD R26S mutant in complex with biliverdin
6DS7	;	1.9	;	Crystal structure of MhuD R26S mutant with two hemes bound per active site
6DS8	;	2.4	;	Crystal structure of MhuD R26S mutant with two Manganese protoporphyrin IX bound per active site
4Z5V	;	3.049	;	Crystal Structure of MHV ns2 PDE Domain
1WDF	;	2.5	;	crystal structure of MHV spike protein fusion core
1WDG	;	2.06	;	crystal structure of MHV spike protein fusion core
4BLG	;	2.2	;	Crystal structure of MHV-68 Latency-associated nuclear antigen (LANA) C-terminal DNA binding domain
6ZTK	;	1.55	;	Crystal structure of Mialostatin, a gut cystatin from the hard tick Ixodes ricinus
5UAO	;	1.88	;	Crystal structure of MibH, a lathipeptide tryptophan 5-halogenase
3OMZ	;	3.04	;	Crystal structure of MICA-specific human gamma delta T cell receptor
7VA8	;	2.85003	;	Crystal structure of MiCGT
7VAA	;	3.10003	;	Crystal structure of MiCGT(W93V/V124F/ F191A/R282H) in complex with UDPs
2D20	;	1.85	;	Crystal structure of michaelis complex of catalytic-site mutant xylanase from Streptomyces olivaceoviridis E-86
2D32	;	2.4	;	Crystal Structure of Michaelis Complex of gamma-Glutamylcysteine Synthetase
5GQE	;	2.5	;	Crystal structure of michaelis complex of xylanase mutant (T82A, N127S, and E128H) from Streptomyces olivaceoviridis E-86
1K9O	;	2.3	;	CRYSTAL STRUCTURE OF MICHAELIS SERPIN-TRYPSIN COMPLEX
4RPG	;	2.4001	;	Crystal structure of Micobacterium tuberculosis UDP-Galactopyranose mutase in complex with substrate UDP-Galp
4RPH	;	2.6	;	Crystal structure of Micobacterium tuberculosis UDP-Galactopyranose mutase in complex with substrate UDP-Galp (reduced)
4RPK	;	2.55	;	Crystal structure of Micobacterium tuberculosis UDP-Galactopyranose mutase in complex with tetrafluorinated substrate analog UDP-F4-Galf
4RPL	;	2.2499	;	Crystal structure of Micobacterium tuberculosis UDP-Galactopyranose mutase in complex with tetrafluorinated substrate analog UDP-F4-Galp
4RPJ	;	2.5	;	Crystal structure of Micobacterium tuberculosis UDP-Galactopyranose mutase in complex with UDP
3R95	;	1.6	;	Crystal structure of Microcin C7 self immunity acetyltransferase MccE in complex with Acetyl-CoA
3R96	;	1.3	;	Crystal structure of Microcin C7 self immunity acetyltransferase MccE in complex with Acetyl-CoA and AMP
3R9E	;	1.25	;	Crystal structure of Microcin C7 self immunity acetyltransferase MccE in complex with coenzyme A and aspartyl sulfamoyl adenosine (DSA)
3R9F	;	1.2	;	Crystal structure of Microcin C7 self immunity acetyltransferase MccE in complex with Coenzyme A and Glutamyl sulfamoyl adenosine (ESA)
3R9G	;	1.35	;	Crystal structure of Microcin C7 self immunity acetyltransferase MccE in complex with Coenzyme A and processed Microcin C7 antibiotic
5K99	;	1.5	;	Crystal structure of microcin immunity protein MccF from Bacillus anthracis in complex with McC
3GJZ	;	2.1	;	Crystal structure of microcin immunity protein MccF from Bacillus anthracis str. Ames
7YLQ	;	2.68	;	Crystal structure of Microcystinase C from Sphingomonas sp. ACM-3962 at 2.6 A resolution
5WXX	;	2.35	;	Crystal structure of Microcystis aeruginosa PCC 7806 aspartate racemase in complex with citrate
5WXZ	;	2.8	;	Crystal structure of Microcystis aeruginosa PCC 7806 aspartate racemase in complex with D-aspartate
5XNK	;	3.4	;	Crystal structure of Microcystis aeruginosa PCC 7806 aspartate racemase in complex with DL-methyl-aspartate
5WXY	;	2.63	;	Crystal structure of Microcystis aeruginosa PCC 7806 aspartate racemase in complex with L-aspartate
5XNI	;	3.22	;	Crystal structure of Microcystis aeruginosa PCC 7806 aspartate/glutamate racemase in complex with D-glutamate
5XNJ	;	2.82	;	Crystal structure of Microcystis aeruginosa PCC 7806 aspartate/glutamate racemase in complex with L-glutamate
1WY9	;	2.1	;	Crystal structure of microglia-specific protein, Iba1
1L4D	;	2.3	;	CRYSTAL STRUCTURE OF MICROPLASMINOGEN-STREPTOKINASE ALPHA DOMAIN COMPLEX
5ES1	;	2.8	;	CRYSTAL STRUCTURE OF MICROTUBULE AFFINITY-REGULATING KINASE 4 CATALYTIC DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
3CO1	;	1.4	;	Crystal structure of microtubule binding domain of human EB3
3LUC	;	1.691	;	Crystal structure of MID domain from hAGO2
3LUK	;	1.7	;	Crystal structure of MID domain from hAGO2
3LUD	;	2.095	;	Crystal structure of MID domain from hAGO2 in complex with AMP
3QX9	;	2.0	;	Crystal structure of MID domain from hAGO2 in complex with ATP
3LUG	;	1.849	;	Crystal structure of MID domain from hAGO2 in complex with CMP
3LUH	;	1.999	;	Crystal structure of MID domain from hAGO2 in complex with GMP
3QX8	;	2.3	;	Crystal structure of MID domain from hAGO2 in complex with m7GpppG
3LUJ	;	1.796	;	Crystal structure of MID domain from hAGO2 in complex with UMP
4ZVC	;	1.5	;	Crystal structure of MID domain of the E. coli DosC - form I
4ZVD	;	1.9	;	Crystal structure of MID domain of the E. coli DosC - form II
4XXD	;	2.41	;	Crystal Structure of mid-region amyloid beta capture by solanezumab
4U1F	;	2.2	;	Crystal structure of middle domain of eukaryotic translation initiation factor eIF3b
6L1E	;	2.0939	;	Crystal structure of middle domain of hSSRP1
5UMS	;	1.569	;	Crystal structure of middle double PH domain of human FACT complex subunit SSRP1
8E7T	;	2.5	;	Crystal structure of Middle East respiratory syndrome coronavirus (MERS-CoV) 3CL protease inactive mutant C148A
5WWP	;	3.0	;	Crystal structure of Middle East respiratory syndrome coronavirus helicase (MERS-CoV nsp13)
4NJL	;	2.3	;	Crystal structure of middle east respiratory syndrome coronavirus S2 protein fusion core
6C6Y	;	3.32	;	Crystal structure of Middle-East Respiratory Syndrome (MERS) coronavirus neutralizing antibody JC57-14 isolated from a vaccinated rhesus macaque in complex with MERS Receptor Binding Domain
6C6X	;	1.99	;	Crystal structure of Middle-East Respiratory Syndrome (MERS) coronavirus neutralizing antibody JC57-14 isolated from a vaccinated rhesus macaque.
2OOH	;	1.85	;	Crystal Structure of MIF bound to a Novel Inhibitor, OXIM-11
7E4A	;	1.475	;	Crystal structure of MIF bound to compound 13
7E4B	;	1.772	;	Crystal structure of MIF bound to compound 5
7E49	;	1.574	;	Crystal structure of MIF bound to compound10
7E4C	;	1.644	;	Crystal structure of MIF bound to compound11
4EVG	;	1.7	;	Crystal Structure of MIF L46A mutant
4EUI	;	1.7	;	Crystal Structure of MIF L46F mutant
4ETG	;	1.61	;	Crystal Structure of MIF L46G mutant
7X15	;	2.852	;	Crystal structure of MIGA2 LD targeting domain
1W94	;	2.0	;	Crystal Structure of Mil (Mth680), an archaeal Imp4-like protein
4JEM	;	1.553	;	Crystal structure of MilB complexed with cytidine 5'-monophosphate
4OHB	;	2.4	;	Crystal structure of MilB E103A in complex with 5-hydroxymethylcytidine 5'-monophosphate (hmCMP) from Streptomyces rimofaciens
4OHR	;	1.8	;	Crystal structure of MilB from Streptomyces rimofaciens
4H0H	;	2.0	;	Crystal structure of mimicry-recognizing 2D10 scFv with peptide
4H0G	;	2.3	;	Crystal structure of mimicry-recognizing native 2D10 scFv
6LYE	;	3.1	;	Crystal Structure of mimivirus UNG Y322F in complex with UGI
6LYD	;	2.598	;	Crystal Structure of mimivirus UNG Y322L in complex with UGI
5X55	;	2.302	;	Crystal structure of mimivirus uracil-DNA glycosylase
8HB5	;	2.6	;	Crystal structure of Mincle in complex with HD-275
5MN9	;	2.05	;	Crystal structure of MINDY-1 tMIU in complex with K48-diUb
6TUV	;	2.16	;	Crystal structure of Mindy1 in complex with Lys48 linked di-ubiquitin
6TXB	;	2.18	;	Crystal structure of Mindy1 mutant (P138A) in complex with Lys48 linked di-ubiquitin
6Z90	;	3.59	;	Crystal structure of MINDY1 mutant-P138A
6YJG	;	3.28	;	Crystal structure of MINDY1 mutant-Y114F
6Y6R	;	3.32	;	Crystal structure of MINDY1 T335D mutant
6Z7V	;	2.65	;	Crystal structure of Mindy2 (C266A) in complex with Lys48 linked di-ubiquitin (K48-Ub2)
7NPI	;	2.81	;	Crystal structure of Mindy2 (C266A) in complex with Lys48-linked penta-ubiquitin (K48-Ub5)
3FNV	;	2.1	;	Crystal Structure of Miner1: The Redox-active 2Fe-2S Protein Causative in Wolfram Syndrome 2
6L88	;	3.0	;	Crystal structure of mineralocorticoid receptor ligand binding domain in complex with esaxerenone
1OX3	;	2.0	;	crystal structure of mini-fibritin
1TGR	;	1.42	;	Crystal Structure of mini-IGF-1(2)
4OUN	;	1.8	;	Crystal Structure of Mini-ribonuclease 3 from Bacillus subtilis
6MII	;	3.15	;	Crystal structure of minichromosome maintenance protein MCM/DNA complex
1Q81	;	2.95	;	Crystal Structure of minihelix with 3' puromycin bound to A-site of the 50S ribosomal subunit.
3JS2	;	2.2	;	Crystal structure of minimal kinase domain of fibroblast growth factor receptor 1 in complex with 5-(2-thienyl)nicotinic acid
6GPU	;	1.17	;	Crystal structure of miniSOG at 1.17A resolution
8Q5F	;	2.0	;	Crystal structure of miniSOG protein from Arabidopsis thaliana with covalent FMN
3WSW	;	2.3	;	Crystal structure of minor L-lactate dehydrogenase from Enterococcus mundtii in the ligands-bound form
3WSV	;	2.38	;	Crystal structure of minor L-lactate dehydrogenase from Enterococcus mundtii in the ligands-unbound form
5YPZ	;	3.521	;	Crystal structure of minor pilin CofB from CFA/III complexed with N-terminal peptide fragment of CofJ
7W63	;	2.32	;	Crystal structure of minor pilin TcpB from Vibrio cholerae
7W64	;	2.3	;	Crystal structure of minor pilin TcpB from Vibrio cholerae complexed with N-terminal peptide fragment of TcpF
7W65	;	4.05	;	Crystal structure of minor pilin TcpB from Vibrio cholerae complexed with secreted protein TcpF
6UTU	;	2.85	;	Crystal structure of minor pseudopilin ternary complex of XcpVWX from the Type 2 secretion system of Pseudomonas aeruginosa in the P3 space group
3IIR	;	2.9	;	Crystal Structure of Miraculin like protein from seeds of Murraya koenigii
5CFF	;	2.5	;	Crystal structure of Miranda/Staufen dsRBD5 complex
7C3K	;	2.6	;	Crystal Structure of mIRGB10
5HJ0	;	2.64	;	Crystal Structure of Mis18 'Yippee-like' Domain
5J6P	;	2.6	;	Crystal Structure of Mis18(17-118) from Schizosaccharomyces pombe
7SFZ	;	3.002	;	Crystal structure of Mis18a-yippee domain
6J62	;	2.486	;	Crystal structure of mISG15/NS1B complex
2R9K	;	2.7	;	Crystal Structure of Misteltoe Lectin I in Complex with Phloretamide
6ELY	;	2.84	;	Crystal Structure of Mistletoe Lectin I (ML-I) from Viscum album in Complex with 4-N-Furfurylcytosine at 2.84 A Resolution
5VPK	;	2.0	;	CRYSTAL STRUCTURE OF MITE ALLERGEN DER F 1
6OVQ	;	1.8	;	Crystal structure of mithramycin 3-side chain keto-reductase MtmW
6OW0	;	2.67	;	Crystal structure of mithramycin 3-side chain keto-reductase MtmW in complex with NAD+ and PEG
6OVX	;	2.1	;	Crystal structure of mithramycin 3-side chain keto-reductase MtmW in complex with NAD+, P422 form
5JW2	;	3.1	;	Crystal structure of mithramycin analogue MTM SA-Phe in complex with a 10-mer DNA AGGGATCCCT
5JW0	;	2.4	;	Crystal structure of mithramycin analogue MTM SA-Phe in complex with a 10-mer DNA AGGGTACCCT
5JVW	;	2.0	;	Crystal structure of mithramycin analogue MTM SA-Trp in complex with a 10-mer DNA AGAGGCCTCT.
4MUM	;	1.271	;	Crystal structure of mitochondrial 5'(3')-deoxy ribonucleotidase alternative spliced variant
5YAT	;	1.745	;	Crystal structure of mitochondrial alcohol dehydrogenase isozyme III from Komagataella phaffii GS115
6IIH	;	1.958	;	crystal structure of mitochondrial calcium uptake 2(MICU2)
8GQZ	;	1.42	;	Crystal structure of mitochondrial citrate synthase (Cit1) from Saccharomyces cerevisiae
1R4W	;	2.5	;	Crystal structure of Mitochondrial class kappa glutathione transferase
1NTM	;	2.4	;	Crystal Structure of Mitochondrial Cytochrome bc1 Complex at 2.4 Angstrom
1NTZ	;	2.6	;	Crystal Structure of Mitochondrial Cytochrome bc1 Complex Bound with Ubiquinone
1NU1	;	3.2	;	Crystal Structure of Mitochondrial Cytochrome bc1 Complexed with 2-nonyl-4-hydroxyquinoline N-oxide (NQNO)
1NTK	;	2.6	;	Crystal Structure of Mitochondrial Cytochrome bc1 in Complex with Antimycin A1
1D2E	;	1.94	;	CRYSTAL STRUCTURE OF MITOCHONDRIAL EF-TU IN COMPLEX WITH GDP
6MSO	;	2.053	;	Crystal structure of mitochondrial fumarate hydratase from Leishmania major in a complex with inhibitor thiomalate
3KC2	;	1.55	;	Crystal structure of mitochondrial HAD-like phosphatase from Saccharomyces cerevisiae
4IVG	;	1.749	;	Crystal structure of mitochondrial Hsp90 (TRAP1) NTD-Middle domain dimer with AMPPNP
4IPE	;	2.289	;	Crystal structure of mitochondrial Hsp90 (TRAP1) with AMPPNP
5TVU	;	3.5	;	Crystal structure of mitochondrial Hsp90 (TRAP1) with ATP in absence of Mg
5TVX	;	2.2	;	Crystal structure of mitochondrial Hsp90 (TRAP1) with ATP in absence of Mg, fully hydrolyzed
5TVW	;	2.5	;	Crystal structure of mitochondrial Hsp90 (TRAP1) with ATP in absence of Mg, hemi-hydrolyzed
4QQF	;	2.672	;	Crystal structure of mitochondrial import inner membrane translocase subunit TIM50
4FAI	;	1.65	;	Crystal structure of mitochondrial isoform of glutaminyl cyclase from Drosophila melanogaster
7R4M	;	2.29	;	Crystal structure of mitochondrial NAD kinase
4WZ7	;	3.6	;	Crystal structure of mitochondrial NADH:ubiquinone oxidoreductase from Yarrowia lipolytica.
1ZP0	;	3.5	;	Crystal Structure of Mitochondrial Respiratory Complex II bound with 3-nitropropionate and 2-thenoyltrifluoroacetone
1ZOY	;	2.4	;	Crystal Structure of Mitochondrial Respiratory Complex II from porcine heart at 2.4 Angstroms
4YSZ	;	3.3	;	Crystal structure of Mitochondrial rhodoquinol-fumarate reductase from Ascaris suum with 2-iodo-N-[3-(1-methylethoxy)phenyl]benzamide
4YT0	;	3.66	;	Crystal structure of Mitochondrial rhodoquinol-fumarate reductase from Ascaris suum with 2-methyl-N-[3-(1-methylethoxy)phenyl]benzamide.
4YTM	;	3.4	;	Crystal structure of Mitochondrial rhodoquinol-fumarate reductase from Ascaris suum with N-biphenyl-3-yl-2-(trifluoromethyl)benzamide
4YSY	;	3.1	;	Crystal structure of Mitochondrial rhodoquinol-fumarate reductase from Ascaris suum with N-[(2,4-dichlorophenyl)methyl]-2-(trifluoromethyl)benzamide
4YTN	;	3.0	;	Crystal structure of Mitochondrial rhodoquinol-fumarate reductase from Ascaris suum with N-[3-(pentafluorophenoxy)phenyl]-2-(trifluoromethyl)benzamide
5C2T	;	2.75	;	Crystal structure of Mitochondrial rhodoquinol-fumarate reductase from Ascaris suum with rhodoquinone-2
4YSX	;	2.25	;	Crystal structure of Mitochondrial rhodoquinol-fumarate reductase from Ascaris suum with the specific inhibitor NN23
5C3J	;	2.8	;	Crystal structure of Mitochondrial rhodoquinol-fumarate reductase from Ascaris suum with Ubiquinone-1
6CQO	;	2.8	;	Crystal Structure of mitochondrial single-stranded DNA binding proteins from S. cerevisiae (SeMet Labeled), Rim1 (Form2)
6CQK	;	2.8	;	Crystal Structure of mitochondrial single-stranded DNA binding proteins from S. cerevisiae, Rim1 (Form1)
6CQM	;	3.0	;	Crystal Structure of mitochondrial single-stranded DNA binding proteins from S. cerevisiae, Rim1 (Form2)
2OE0	;	2.0	;	Crystal Structure of Mitochondrial Thioredoxin 3 from Saccharomyces cerevisiae
2OE3	;	1.8	;	Crystal Structure of Mitochondrial Thioredoxin 3 from Saccharomyces cerevisiae (oxidized form)
2OE1	;	2.1	;	Crystal Structure of Mitochondrial Thioredoxin 3 from Saccharomyces cerevisiae (reduced form)
7W5C	;	2.201	;	Crystal structure of Mitogen Activated Protein Kinase 4 (MPK4) from Arabidopsis thaliana
4S31	;	1.45	;	Crystal structure of mitogen-activated protein kinase 1 wtERK2 at 1.45A
4KIP	;	2.27	;	Crystal structure of mitogen-activated protein kinase 14 (P38-H5) complex with 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL)-1,3-THIAZOLE-5-CARBOXAMIDE
4KIN	;	1.97	;	Crystal structure of mitogen-activated protein kinase 14 (P38-H5) complex with 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
4KIQ	;	2.5	;	Crystal structure of mitogen-activated protein kinase 14 (P38-H5) complex with ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL)CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
2IRM	;	3.0	;	Crystal structure of mitogen-activated protein kinase kinase kinase 7 interacting protein 1 from Anopheles gambiae
5Z33	;	1.99	;	Crystal structure of Mitogen-activated Protein Kinase Mps1 in Magnaporthe oryzae
2A4W	;	1.5	;	Crystal Structure Of Mitomycin C-Binding Protein Complexed with Copper(II)-Bleomycin A2
2A4X	;	1.4	;	Crystal Structure Of Mitomycin C-Binding Protein Complexed with Metal-Free Bleomycin A2
2QD0	;	1.81	;	Crystal structure of mitoNEET
3REE	;	1.76	;	Crystal structure of mitoNEET
4AEZ	;	2.3	;	Crystal Structure of Mitotic Checkpoint Complex
5XG5	;	1.54	;	Crystal structure of Mitsuba-1 with bound NAcGal
7EHG	;	1.95	;	Crystal Structure of MiXBM
3DTC	;	2.6	;	Crystal structure of mixed-lineage kinase MLK1 complexed with compound 16
7T58	;	2.05333	;	Crystal structure of Miz1 BTB domain
6WRN	;	1.6	;	Crystal structure of Mj 3-nitro-tyrosine tRNA synthetase (5B) C70A variant bound to 3-nitro-tyrosine
6WRT	;	1.55	;	Crystal structure of Mj 3-nitro-tyrosine tRNA synthetase (5B) C70A/S158C variant bound to 3-nitro-tyrosine
6WRQ	;	1.85	;	Crystal structure of Mj 3-nitro-tyrosine tRNA synthetase (5B) S158C variant bound to 3-nitro-tyrosine
1DK4	;	2.6	;	CRYSTAL STRUCTURE OF MJ0109 GENE PRODUCT INOSITOL MONOPHOSPHATASE
1G0H	;	2.3	;	CRYSTAL STRUCTURE OF MJ0109 GENE PRODUCT INOSITOL MONOPHOSPHATASE-FRUCTOSE 1,6 BISPHOSPHATASE
1G0I	;	2.4	;	CRYSTAL STRUCTURE OF MJ0109 GENE PRODUCT INOSITOL MONOPHOSPHATASE-FRUCTOSE 1,6 BISPHOSPHATASE
2PA6	;	1.85	;	Crystal structure of MJ0232 from Methanococcus jannaschii
1HYG	;	2.8	;	Crystal structure of MJ0490 gene product, the family of lactate/malate dehydrogenase
2Z61	;	2.2	;	Crystal structure of MJ0684 from Methanococcus jannaschii reveals its similarity in the active site to kynurenine aminotransferases
1F3O	;	2.7	;	Crystal structure of MJ0796 ATP-binding cassette
3EYQ	;	2.4	;	Crystal structure of MJ5 Fab, a germline antibody variant of anti-human cytomegalovirus antibody 8f9
2P5D	;	1.7	;	Crystal structure of MJECL36 from Methanocaldococcus jannaschii DSM 2661
8OG0	;	1.712	;	Crystal structure of MJF14-6-4-2 Fab fragment in complex with epitope peptide
5JMV	;	3.38647	;	Crystal structure of mjKae1-pfuPcc1 complex
4TUI	;	3.59	;	Crystal structure of MjMre11-DNA1 complex
4TUG	;	3.55	;	Crystal structure of MjMre11-DNA2 complex
4ZN1	;	2.8	;	Crystal Structure of MjSpt4:Spt5 complex conformation A
4ZN3	;	2.3	;	Crystal Structure of MjSpt4:Spt5 complex conformation B
3T0R	;	2.49	;	Crystal Structure of MjTX-I, a myotoxic Lys49-phospholipase A2 from Bothrops moojeni
3SVU	;	2.695	;	Crystal structure of mKate mutant S143C
3SVO	;	1.984	;	Crystal structure of mKate mutant S158A/S143C at pH 10.0
3SVS	;	1.74	;	Crystal structure of mkate mutant S158A/S143C at pH 4.0
3SVR	;	1.907	;	Crystal structure of mkate mutant S158A/S143C at pH 7.5
3SVN	;	1.899	;	Crystal structure of mKate S158A mutant at pH 7.5
8OMG	;	1.82	;	Crystal structure of mKHK (apo)
8OMD	;	2.0	;	Crystal structure of mKHK in complex with compound-4
6YG3	;	2.05	;	Crystal structure of MKK7 (MAP2K7) covalently bound with CPT1-70-1
6YG7	;	2.2	;	Crystal structure of MKK7 (MAP2K7) covalently bound with type-II inhibitor SB1-G-23
6YG6	;	2.15	;	Crystal structure of MKK7 (MAP2K7) covalently bound with type-II inhibitor TL10-105
6YG1	;	2.22	;	Crystal structure of MKK7 (MAP2K7) in an active state, allosterically triggered by the N-terminal helix
6YG5	;	2.4	;	Crystal structure of MKK7 (MAP2K7) in complex with ASC69
6YG2	;	2.0	;	Crystal structure of MKK7 (MAP2K7) in complex with ibrutnib, with covalent and allosteric binding modes
6YG4	;	2.3	;	Crystal structure of MKK7 (MAP2K7) in complex with K00007
6YZ4	;	1.7	;	Crystal structure of MKK7 (MAP2K7) with ibrutinib bound at allosteric site
6YFZ	;	1.9	;	Crystal structure of MKK7 (MAP2K7), apo form
3LJ8	;	2.7	;	Crystal Structure of MKP-4
2CKD	;	2.8	;	Crystal structure of ML2640 from Mycobacterium leprae
2UYO	;	1.7	;	Crystal structure of ML2640c from Mycobacterium leprae in an hexagonal crystal form
2UYQ	;	1.8	;	Crystal structure of ML2640c from Mycobacterium leprae in complex with S-adenosylmethionine
7VR6	;	2.5	;	Crystal structure of MlaC from Escherichia coli in quasi-open state
1U3Z	;	1.9	;	Crystal structure of MLAC mutant of dimerisation domain of NF-kB p50 transcription factor
1U42	;	2.699	;	Crystal structure of MLAM mutant of dimerisation domain of NF-kB p50 transcription factor
1U3J	;	1.901	;	Crystal structure of MLAV mutant of dimerisation domain of NF-kB p50 transcription factor
1Z6R	;	2.7	;	Crystal structure of Mlc from Escherichia coli
3BP8	;	2.85	;	Crystal structure of Mlc/EIIB complex
1M45	;	1.65	;	CRYSTAL STRUCTURE OF MLC1P BOUND TO IQ2 OF MYO2P, A CLASS V MYOSIN
1M46	;	2.103	;	CRYSTAL STRUCTURE OF MLC1P BOUND TO IQ4 OF MYO2P, A CLASS V MYOSIN
8JDC	;	1.696	;	Crystal structure of mLDHD in apo form
8JDZ	;	1.56	;	Crystal structure of mLDHD in complex with 2-keto-3-methylvaleric acid
8JDT	;	1.55	;	Crystal structure of mLDHD in complex with 2-ketobutanoic acid
8JDV	;	1.96	;	Crystal structure of mLDHD in complex with 2-ketohexanoic acid
8JDY	;	1.59	;	Crystal structure of mLDHD in complex with 2-ketoisocaproic acid
8JDX	;	1.79	;	Crystal structure of mLDHD in complex with 2-ketoisovaleric acid
8JDU	;	1.67	;	Crystal structure of mLDHD in complex with 2-ketovaleric acid
8JDE	;	1.729	;	Crystal structure of mLDHD in complex with D-lactate
8JDS	;	1.636	;	Crystal structure of mLDHD in complex with Pyruvate
1F9C	;	2.5	;	CRYSTAL STRUCTURE OF MLE D178N VARIANT
5ZTM	;	2.899	;	Crystal structure of MLE dsRBDs in complex with roX2 (R2H1)
4NUH	;	1.34	;	Crystal structure of mLeIBP, a capping head region swapped mutant of ice-binding protein
6ZZ1	;	1.64	;	Crystal structure of MLKL executioner domain in complex with a covalent inhibitor
4NW3	;	2.82	;	Crystal structure of MLL CXXC domain in complex with a CpG DNA
3LQI	;	1.92	;	Crystal structure of MLL1 PHD3-Bromo complexed with H3(1-9)K4me2 peptide
3LQJ	;	1.9	;	Crystal structure of MLL1 PHD3-Bromo complexed with H3(1-9)K4me3 peptide
3LQH	;	1.72	;	Crystal structure of MLL1 PHD3-Bromo in the free form
3RD6	;	2.8	;	Crystal structure of Mll3558 protein from Rhizobium loti. Northeast Structural Genomics Consortium target id MlR403
3PKN	;	1.8	;	Crystal structure of MLLE domain of poly(A) binding protein in complex with PAM2 motif of La-related protein 4 (LARP4)
6T1M	;	1.85	;	Crystal structure of MLLT1 (ENL) YEATS domain in complexed with benzimidazole-amide derivative 4
6T1N	;	1.95	;	Crystal structure of MLLT1 (ENL) YEATS domain in complexed with benzimidazole-amide derivative 5
6T1O	;	1.9	;	Crystal structure of MLLT1 (ENL) YEATS domain in complexed with benzimidazole-amide derivative 6
6HT0	;	1.8	;	Crystal structure of MLLT1 (ENL) YEATS domain in complexed with compound 94
6T1I	;	1.8	;	Crystal structure of MLLT1 (ENL) YEATS domain in complexed with piperazine-urea derivative 1
6T1J	;	1.97	;	Crystal structure of MLLT1 (ENL) YEATS domain in complexed with piperazine-urea derivative 2
6T1L	;	2.0	;	Crystal structure of MLLT1 (ENL) YEATS domain in complexed with piperazine-urea derivative 3
6HT1	;	2.1	;	Crystal structure of MLLT1 (ENL) YEATS domain in complexed with SGC-iMLLT (compound 92)
7B10	;	1.92	;	Crystal structure of MLLT1 YEATS domain T1 mutant in complex with benzimidazole-amide based compound 1
7B0T	;	2.05	;	Crystal structure of MLLT1 YEATS domain T3 mutant in complex with benzimidazole-amide based compound 1
2GAE	;	2.5	;	Crystal structure of MltA from E. coli
2AE0	;	2.0	;	Crystal structure of MltA from Escherichia coli reveals a unique lytic transglycosylase fold
2G6G	;	2.2	;	Crystal structure of MltA from Neisseria gonorrhoeae
2G5D	;	1.95	;	Crystal structure of MltA from Neisseria gonorrhoeae Monoclinic form
4CHX	;	2.45	;	Crystal structure of MltC in complex with disaccharide pentapeptide DHl89
4CFP	;	2.15	;	Crystal structure of MltC in complex with tetrasaccharide at 2.15 A resolution
4P0G	;	1.65	;	Crystal structure of MltF from Pseudomonas aeruginosa complexed with bulgecin and muropeptide
4OWD	;	2.21	;	Crystal structure of MltF from Pseudomonas aeruginosa complexed with cysteine
4OZ9	;	2.24	;	Crystal structure of MltF from Pseudomonas aeruginosa complexed with isoleucine
4OYV	;	2.31	;	Crystal structure of MltF from Pseudomonas aeruginosa complexed with leucine
4OXV	;	2.2	;	Crystal structure of MltF from Pseudomonas aeruginosa complexed with valine
5AA4	;	2.4	;	Crystal structure of MltF from Pseudomonas aeruginosa in complex with cell-wall tetrapeptide
5AA1	;	2.89	;	Crystal structure of MltF from Pseudomonas aeruginosa in complex with NAG-anhNAM-pentapeptide
5AA2	;	2.8	;	Crystal structure of MltF from Pseudomonas aeruginosa in complex with NAM-pentapeptide.
5AA3	;	3.2	;	Crystal structure of MltF from Pseudomonas aeruginosa in the presence of tetrasaccharide and tetrapeptide
3SC0	;	1.95	;	Crystal Structure of MMACHC (1-238), a human B12 processing enzyme, complexed with MethylCobalamin
5LNX	;	2.6	;	Crystal structure of MmgC, an acyl-CoA dehydrogenase from bacillus subtilis.
5DNP	;	2.3	;	Crystal structure of Mmi1 YTH domain
5DNO	;	1.8	;	Crystal structure of Mmi1 YTH domain complex with RNA
7WW3	;	1.9	;	Crystal structure of MmIMP1-KH34 tandem domain
7VKL	;	1.95	;	Crystal structure of MmIMP3-KH12 in complex with zipcode RNA
7VSJ	;	2.38	;	Crystal structure of MmIMP3-RRM12 in complex with 9-mer RNA
5YK6	;	2.8	;	Crystal Structure of Mmm1
3S7Y	;	4.3077	;	Crystal structure of mmNAGS in Space Group P3121 at 4.3 A resolution
3LJX	;	2.3	;	Crystal Structure of MmoQ Response regulator (fragment 20-298) from Methylococcus capsulatus str. Bath, Northeast Structural Genomics Consortium Target McR175G
3P3Q	;	2.4	;	Crystal Structure of MmoQ Response regulator from Methylococcus capsulatus str. Bath at the resolution 2.4A, Northeast Structural Genomics Consortium Target McR175M
4AUO	;	3.0	;	Crystal structure of MMP-1(E200A) in complex with a triple-helical collagen peptide
1UTZ	;	2.5	;	Crystal Structure of MMP-12 complexed to (2R)-3-({[4-[(pyridin-4-yl)phenyl]-thien-2-yl}carboxamido)(phenyl)propanoic acid
1ROS	;	2.0	;	Crystal structure of MMP-12 complexed to 2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl-4-(4-ethoxy[1,1-biphenyl]-4-yl)-4-oxobutanoic acid
1UTT	;	2.2	;	Crystal Structure of MMP-12 complexed to 2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl-4-(4-ethoxy[1,1-biphenyl]-4-yl)-4-oxobutanoic acid
3ELM	;	1.9	;	Crystal Structure of MMP-13 Complexed with Inhibitor 24f
3KRY	;	1.9	;	Crystal structure of MMP-13 in complex with SC-78080
3AYU	;	2.0	;	Crystal structure of MMP-2 active site mutant in complex with APP-drived decapeptide inhibitor
1JH1	;	2.7	;	Crystal Structure of MMP-8 complexed with a 6H-1,3,4-thiadiazine derived inhibitor
6EOX	;	1.3	;	Crystal structure of MMP12 in complex with carboxylic inhibitor LP165.
6ENM	;	1.59	;	Crystal structure of MMP12 in complex with hydroxamate inhibitor LP168.
6ELA	;	1.485	;	Crystal structure of MMP12 in complex with inhibitor BE4.
6EKN	;	1.2	;	Crystal structure of MMP12 in complex with inhibitor BE7.
5L79	;	2.07	;	Crystal structure of MMP12 in complex with RXP470.1 conjugated with fluorophore Cy5,5 in space group P21212.
5L7F	;	1.8	;	Crystal structure of MMP12 mutant K421A in complex with RXP470.1 conjugated with fluorophore Cy5,5 in space group P21.
1D8M	;	2.44	;	CRYSTAL STRUCTURE OF MMP3 COMPLEXED WITH A HETEROCYCLE-BASED INHIBITOR
1D7X	;	2.0	;	CRYSTAL STRUCTURE OF MMP3 COMPLEXED WITH A MODIFIED PROLINE SCAFFOLD BASED INHIBITOR.
1D8F	;	2.4	;	CRYSTAL STRUCTURE OF MMP3 COMPLEXED WITH A PIPERAZINE BASED INHIBITOR.
1D5J	;	2.6	;	CRYSTAL STRUCTURE OF MMP3 COMPLEXED WITH A THIAZEPINE BASED INHIBITOR.
1BZS	;	1.7	;	CRYSTAL STRUCTURE OF MMP8 COMPLEXED WITH HMR2909
1JJ9	;	2.0	;	Crystal Structure of MMP8-Barbiturate Complex Reveals Mechanism for Collagen Substrate Recognition
6ESM	;	1.104	;	Crystal structure of MMP9 in complex with inhibitor BE4.
6N40	;	3.307	;	Crystal structure of MmpL3 from Mycobacterium smegmatis
6TBL	;	2.65	;	Crystal structure of MMS19(CTD)-CIAO1-CIAO2B CIA targeting complex
6TC0	;	3.6	;	Crystal structure of MMS19-CIAO1-CIAO2B CIA targeting complex
1J74	;	1.9	;	Crystal Structure of Mms2
3HTK	;	2.31	;	Crystal structure of Mms21 and Smc5 complex
3FD2	;	2.69	;	Crystal structure of mMsoI/DNA complex with calcium
7VVV	;	2.45	;	Crystal structure of MmtN
3FK9	;	2.5	;	Crystal structure of mMutator MutT protein from Bacillus halodurans
2V8T	;	0.98	;	Crystal structure of Mn catalase from Thermus Thermophilus complexed with chloride
2R34	;	2.25	;	Crystal structure of MN human arg-insulin
5TIR	;	1.62	;	Crystal Structure of Mn Superoxide Dismutase mutant M27V from Trichoderma reesei
8FJ8	;	2.17	;	Crystal structure of Mn(2+),Ca(2+)-S100B
1QB4	;	2.6	;	CRYSTAL STRUCTURE OF MN(2+)-BOUND PHOSPHOENOLPYRUVATE CARBOXYLASE
4XJK	;	1.76	;	Crystal structure of Mn(II) Ca(II) Na(I) bound calprotectin
1XNZ	;	1.52	;	Crystal Structure of Mn(II) form of E. coli. Methionine Aminopeptidase in complex with 5-(2-chlorophenyl)furan-2-carboxylic acid
1JFZ	;	2.1	;	Crystal Structure of MN(II)-Complex of RNAse III Endonuclease Domain from Aquifex Aeolicus at 2.10 Angstrom Resolution
4CMQ	;	3.09	;	Crystal structure of Mn-bound S.pyogenes Cas9
4H9D	;	2.599	;	Crystal Structure of Mn-dependent Gme HNH nicking endonuclease from Geobacter metallireducens GS-15, Northeast Structural Genomics Consortium (NESG) Target GmR87
5H7F	;	1.601	;	Crystal Structure of Mn-derivative drCPDase
5ZIS	;	3.1	;	Crystal structure of Mn-ProtoporphyrinIX-reconstituted P450BM3
5ZLH	;	3.4	;	Crystal structure of Mn-ProtoporphyrinIX-reconstituted P450BM3
4GGF	;	1.6	;	Crystal structure of Mn2+ bound calprotectin
2HXG	;	2.8	;	Crystal Structure of Mn2+ bound ECAI
4QH9	;	2.175	;	Crystal structure of Mn2+ bound human APE1
4GWC	;	1.9	;	Crystal Structure of Mn2+2,Zn2+-Human Arginase I
4Z3B	;	1.42	;	Crystal structure of MnCO/apo-R52CFr
5WPZ	;	2.0	;	Crystal structure of MNDA PYD with MBP tag
2HW6	;	2.5	;	Crystal structure of Mnk1 catalytic domain
6CJ5	;	2.8	;	Crystal Structure of Mnk2-D228G in Complex With Inhibitor
6CJE	;	3.36	;	Crystal Structure of Mnk2-D228G in complex with Inhibitor
6CJW	;	3.38	;	Crystal Structure of Mnk2-D228G in Complex With Inhibitor
6CJY	;	3.05	;	Crystal Structure of Mnk2-D228G in complex with Inhibitor
6CK6	;	3.32	;	Crystal Structure of Mnk2-D228G in complex with Inhibitor
2HW7	;	2.71	;	Crystal Structure of Mnk2-D228G in complex with Staurosporine
1XMO	;	3.25	;	Crystal Structure of mnm5U34t6A37-tRNALysUUU Complexed with AAG-mRNA in the Decoding Center
3PS9	;	2.54	;	Crystal structure of MnmC from E. coli
3VYW	;	2.49	;	Crystal structure of MNMC2 from Aquifex Aeolicus
3GEI	;	3.4	;	Crystal structure of MnmE from Chlorobium tepidum in complex with GCP
3GEE	;	2.95	;	Crystal structure of MnmE from Chlorobium tepidum in complex with GDP and FOLINIC ACID
3GEH	;	3.2	;	Crystal structure of MnmE from Nostoc in complex with GDP, FOLINIC ACID and ZN
8H0S	;	2.9	;	Crystal structure of MnmM from B. subtilis complexed with Gln-TTG anti-codon stem loop and SAM (2.90 A)
8H0T	;	1.17	;	Crystal structure of MnmM from B. subtilis complexed with SAH (1.17 A)
8H26	;	1.5	;	Crystal structure of MnmM from S. aureus complexed with SAH (1.50 A)
8H27	;	2.04	;	Crystal structure of MnmM from S. aureus complexed with SAM (2.04 A)
8H1B	;	1.55	;	Crystal structure of MnmM from S. aureus complexed with SAM and tRNA anti-codon stem loop (ASL) (1.55 A)
8H1A	;	1.44	;	Crystal structure of MnmM from S. aureus in apo state (1.44 A)
1NXD	;	1.9	;	Crystal structure of MnMn Concanavalin A
4IRM	;	3.5	;	Crystal structure of mntc r116a mutant exhibits flexibility in the c-terminal domain
1UPL	;	2.6	;	Crystal structure of MO25 alpha
1UPK	;	1.85	;	Crystal structure of MO25 in complex with a C-terminal peptide of STRAD
2IHO	;	2.41	;	Crystal structure of MOA, a lectin from the mushroom Marasmius oreades in complex with the trisaccharide Gal(1,3)Gal(1,4)GlcNAc
1R2K	;	2.1	;	Crystal structure of MoaB from Escherichia coli
1MKZ	;	1.6	;	Crystal structure of MoaB protein at 1.6 A resolution.
1V8C	;	1.6	;	Crystal Structure of MoaD related protein from Thermus thermophilus HB8
8HLG	;	2.0	;	Crystal structure of MoaE
5B5W	;	2.957	;	Crystal structure of MOB1-LATS1 NTR domain complex
5C8O	;	2.09	;	Crystal structure of MoCVNH3 variant (Mo0v)
5C8P	;	2.2	;	Crystal structure of MoCVNH3 variant (Mo0v) in complex with (N-GlcNAc)3
5C8Q	;	1.9	;	Crystal structure of MoCVNH3 variant (Mo0v) in complex with (N-GlcNAc)4
1WOD	;	1.75	;	CRYSTAL STRUCTURE OF MODA, A MOLYBDATE PROTEIN, COMPLEXED WITH TUNGSTATE
1AMF	;	1.75	;	CRYSTAL STRUCTURE OF MODA, A MOLYBDATE TRANSPORT PROTEIN, COMPLEXED WITH MOLYBDATE
8DFI	;	1.9	;	Crystal structure of moderately neutralizing / interfering human monoclonal antibody 42C11 Fab in complex with MSP1-19
5BRO	;	2.4	;	Crystal structure of modified HexB (modB)
1TVH	;	1.802	;	Crystal structure of Modified Melanoma Antigen gp100(209-T2M) Bound to Human Class I MHC HLA-A2
3SZR	;	3.5	;	Crystal structure of modified nucleotide-free human MxA
2ZR8	;	2.2	;	Crystal Structure of Modified Serine Racemase complexed with Serine
2ZPU	;	1.7	;	Crystal Structure of Modified Serine Racemase from S.pombe.
2X0K	;	1.95	;	Crystal structure of modular FAD synthetase from Corynebacterium ammoniagenes
7S6B	;	2.35	;	Crystal structure of modular polyketide synthase apo-Lsd14 from the Lasalocid biosynthesis pathway, trapped in the transacylation step
2AMJ	;	1.8	;	Crystal Structure of Modulator of Drug Activity B from Escherichia coli O157:H7
2B3D	;	2.1	;	Crystal structure of Modulator of Drug activity B in complex with flavin adenine dinucleotide
3VK5	;	1.39	;	Crystal structure of MoeO5 in complex with its product FPG
3VKA	;	1.57	;	Crystal structure of MoeO5 soaked for 3 hours in FsPP
3VKD	;	1.66	;	Crystal structure of MoeO5 soaked with 3-phosphoglycerate
3VKB	;	1.8	;	Crystal structure of MoeO5 soaked with FsPP overnight
3VKC	;	1.66	;	Crystal structure of MoeO5 soaked with pyrophosphate
4RTF	;	2.77	;	Crystal structure of molecular chaperone DnaK from Mycobacterium tuberculosis H37Rv
4WGX	;	2.29	;	Crystal Structure of Molinate Hydrolase
4RXL	;	1.52	;	Crystal structure of Molybdenum ABC transporter solute binding protein Vc_A0726 from Vibrio Cholerae, Target EFI-510913, in complex with tungstate
2PBQ	;	1.7	;	Crystal structure of molybdenum cofactor biosynthesis (aq_061) From aquifex aeolicus VF5
3MCI	;	1.7	;	Crystal structure of molybdenum cofactor biosynthesis (AQ_061) from aquifex aeolicus VF5
2QQ1	;	1.9	;	Crystal Structure Of Molybdenum Cofactor Biosynthesis (aq_061) Other Form From Aquifex Aeolicus Vf5
3MCJ	;	1.9	;	Crystal structure of molybdenum cofactor biosynthesis (AQ_061) other form from aquifex aeolicus VF5
1Y5E	;	1.9	;	Crystal structure of Molybdenum cofactor biosynthesis protein B
2F7W	;	1.9	;	Crystal structure of Molybdenum cofactor biosynthesis protein Mog from Shewanella oneidensis
2F7Y	;	2.3	;	Crystal structure of Molybdenum cofactor biosynthesis protein Mog from Shewanella oneidensis
3K6A	;	1.89	;	Crystal structure of molybdenum cofactor biosynthesis protein mog from shewanella oneidensis
4XCW	;	1.8	;	Crystal structure of molybdenum cofactor biosynthesis protein MogA from Helicobacter pylori str. J99
3OI9	;	1.95	;	Crystal structure of molybdenum cofactor synthesis domain from Mycobacterium avium
1FC5	;	2.2	;	CRYSTAL STRUCTURE OF MOLYBDOPTERIN BIOSYNTHESIS MOEA PROTEIN
1WU2	;	2.3	;	Crystal Structure of molybdopterin biosynthesis moeA protein from Pyrococcus horikoshii OT3
3PZY	;	1.8	;	Crystal structure of Molybdopterin biosynthesis mog protein from Mycobacterium paratuberculosis
2OMD	;	2.0	;	Crystal structure of molybdopterin converting factor subunit 2 (aq_2181) from aquifex aeolicus VF5
2F1R	;	2.1	;	Crystal Structure of molybdopterin-guanine biosynthesis protein B (mobB)
3NGW	;	2.31	;	Crystal Structure of Molybdopterin-guanine dinucleotide biosynthesis protein A from Archaeoglobus fulgidus, Northeast Structural Genomics Consortium Target GR189
4P6W	;	1.951	;	Crystal Structure of mometasone furoate-bound glucocorticoid receptor ligand binding domain
6KM8	;	3.099	;	Crystal Structure of Momordica charantia 7S globulin
1MOM	;	2.16	;	CRYSTAL STRUCTURE OF MOMORDIN, A TYPE I RIBOSOME INACTIVATING PROTEIN FROM THE SEEDS OF MOMORDICA CHARANTIA
8T3P	;	1.9	;	Crystal structure of MonC1 (a flavin-dependent monooxygenase)
4YU4	;	2.8	;	Crystal structure of Mongoose (Helogale parvula) hemoglobin at pH 7.0
5XVQ	;	2.29	;	Crystal structure of monkey Nicotinamide N-methyltransferase (NNMT) bound with end product, 1-methyl Nicotinamide (MNA)
8S9H	;	2.437	;	Crystal structure of monkey TLR7 ectodomain with compound 14
8TTZ	;	3.14	;	Crystal structure of monkey TLR7 ectodomain with compound 20
8TTY	;	2.101	;	Crystal structure of monkey TLR7 ectodomain with compound 5
6IF5	;	2.0	;	Crystal structure of monkey TLR7 in complex with 2',3'-cGMP (Guanosine 2',3'-cyclic phosphate)
5ZSN	;	2.4	;	Crystal structure of monkey TLR7 in complex with AAUUAA
5ZSH	;	2.6	;	Crystal structure of monkey TLR7 in complex with CL075
5ZSI	;	2.7	;	Crystal structure of monkey TLR7 in complex with CL097
5ZSG	;	2.3	;	Crystal structure of monkey TLR7 in complex with gardiquimod
5ZSM	;	2.5	;	Crystal structure of monkey TLR7 in complex with GGUCCC
5ZSL	;	2.3	;	Crystal structure of monkey TLR7 in complex with GGUUGG
5ZSJ	;	2.4	;	Crystal structure of monkey TLR7 in complex with GS9620
5GMF	;	2.5	;	Crystal structure of monkey TLR7 in complex with guanosine and polyU
5ZSB	;	2.7	;	Crystal structure of monkey TLR7 in complex with IMDQ and AAUUAA
5ZSC	;	2.2	;	Crystal structure of monkey TLR7 in complex with IMDQ and CCUUCC
5ZSE	;	2.201	;	Crystal structure of monkey TLR7 in complex with IMDQ and GGUCCC
5ZSD	;	2.603	;	Crystal structure of monkey TLR7 in complex with IMDQ and GGUUGG
5ZSA	;	2.5	;	Crystal structure of monkey TLR7 in complex with IMDQ and UUUUUU
5ZSF	;	2.1	;	Crystal structure of monkey TLR7 in complex with imiquimod
5GMG	;	2.6	;	Crystal structure of monkey TLR7 in complex with loxoribine and polyU
5GMH	;	2.2	;	Crystal structure of monkey TLR7 in complex with R848
8CEV	;	2.14	;	Crystal structure of monkeypox virus methyltransferase VP39 in complex with inhibitor TO1119
8CEQ	;	2.5	;	Crystal structure of monkeypox virus methyltransferase VP39 in complex with inhibitor TO427
8CER	;	2.6	;	Crystal structure of monkeypox virus methyltransferase VP39 in complex with inhibitor TO494
8CES	;	2.5	;	Crystal structure of monkeypox virus methyltransferase VP39 in complex with inhibitor TO500
8CET	;	2.5	;	Crystal structure of monkeypox virus methyltransferase VP39 in complex with inhibitor TO507
8B07	;	2.05	;	Crystal structure of monkeypox virus methyltransferase VP39 in complex with sinefungin
8P44	;	1.93	;	Crystal structure of monkeypox virus poxin in complex with the STING agonist MD1202D
8ORV	;	1.65	;	Crystal structure of monkeypox virus poxin in complex with the STING agonist MD1203
5XK2	;	1.695	;	Crystal structure of mono- and diacylglycerol lipase from Aspergillus oryzae
3UUE	;	1.45	;	Crystal structure of mono- and diacylglycerol lipase from Malassezia globosa
3UUF	;	2.6	;	Crystal structure of mono- and diacylglycerol lipase from Malassezia globosa
7AE9	;	2.9	;	Crystal structure of mono-AMPylated HEPN(R46E) toxin in complex with MNT antitoxin
4O23	;	2.09	;	Crystal structure of mono-zinc form of succinyl diaminopimelate desuccinylase from Neisseria meningitidis MC58
3ISZ	;	2.0	;	Crystal structure of mono-zinc form of succinyl-diaminopimelate desuccinylase from Haemophilus influenzae
3VGW	;	1.6	;	Crystal structure of monoAc-biotin-avidin complex
7E0N	;	1.85	;	Crystal structure of Monoacylglycerol Lipase chimera
3RM3	;	1.2	;	Crystal structure of monoacylglycerol lipase from Bacillus sp. H257
3RLI	;	1.854	;	Crystal structure of monoacylglycerol lipase from Bacillus sp. H257 in complex with PMSF
5XKS	;	2.189	;	Crystal structure of monoacylglycerol lipase from thermophilic Geobacillus sp. 12AMOR
8HGV	;	2.30006	;	Crystal structure of monoalkyl phthalate hydrolase MehpH
7P4H	;	2.1	;	Crystal Structure of Monoamine Oxidase B in complex with inhibitor (+)-2
7P4F	;	2.3	;	Crystal Structure of Monoamine Oxidase B in complex with inhibitor 1
3T04	;	2.1	;	Crystal structure of monobody 7c12/abl1 sh2 domain complex
5DC4	;	1.48	;	CRYSTAL STRUCTURE OF MONOBODY AS25/ABL1 SH2 DOMAIN COMPLEX, CRYSTAL A
5DC9	;	1.56	;	CRYSTAL STRUCTURE OF MONOBODY AS25/ABL1 SH2 DOMAIN COMPLEX, CRYSTAL B
4JEG	;	2.3	;	Crystal Structure of Monobody CS1/SHP2 C-SH2 Domain Complex
5DC0	;	2.23	;	CRYSTAL STRUCTURE OF MONOBODY GG3/ABL1 SH2 DOMAIN COMPLEX
3K2M	;	1.75	;	Crystal Structure of Monobody HA4/Abl1 SH2 Domain Complex
5ECJ	;	3.05	;	Crystal structure of monobody Mb(S4) bound to Prdm14 in complex with Mtgr1
7TVJ	;	2.39	;	Crystal Structure of Monobody Mb(SHP2PTP_13)/SHP2 PTP Domain Complex
2OBG	;	2.35	;	Crystal Structure of Monobody MBP-74/Maltose Binding Protein Fusion Complex
4JE4	;	2.31	;	Crystal Structure of Monobody NSa1/SHP2 N-SH2 Domain Complex
3UYO	;	1.83	;	Crystal structure of monobody SH13/ABL1 SH2 domain complex
3CSG	;	1.798	;	Crystal Structure of Monobody YS1(MBP-74)/Maltose Binding Protein Fusion Complex
3CSB	;	1.999	;	Crystal Structure of Monobody YSX1/Maltose Binding Protein Fusion Complex
6RP5	;	1.49	;	Crystal structure of monocarboxylated hemoglobin from the sub-Antarctic fish Eleginops maclovinus
1JAZ	;	2.27	;	Crystal Structure of Monoclinic Form of D90E Mutant of Escherichia coli Asparaginase II
2P7L	;	2.2	;	Crystal structure of monoclinic form of genomically encoded fosfomycin resistance protein, FosX, from Listeria monocytogenes at pH 5.75
2P7M	;	1.85	;	Crystal structure of monoclinic form of genomically encoded fosfomycin resistance protein, FosX, from Listeria monocytogenes at pH 6.5
2AVW	;	2.0	;	Crystal structure of monoclinic form of streptococcus Mac-1
1JJ3	;	1.9	;	CRYSTAL STRUCTURE OF MONOCLINIC LYSOZYME GROWN AT PH 4.6
1LJ3	;	2.0	;	CRYSTAL STRUCTURE OF MONOCLINIC LYSOZYME GROWN AT PH 4.6
1LJ4	;	1.95	;	CRYSTAL STRUCTURE OF MONOCLINIC LYSOZYME GROWN AT PH 4.6
1LJI	;	2.0	;	CRYSTAL STRUCTURE OF MONOCLINIC LYSOZYME GROWN IN PRESENCE 10% SORBITOL
1LJE	;	2.0	;	CRYSTAL STRUCTURE OF MONOCLINIC LYSOZYME GROWN IN PRESENCE OF 10% SUCROSE
1LJF	;	1.8	;	CRYSTAL STRUCTURE OF MONOCLINIC LYSOZYME GROWN IN PRESENCE OF 10% SUCROSE
1LJJ	;	2.0	;	CRYSTAL STRUCTURE OF MONOCLINIC LYSOZYME GROWN IN PRESENCE OF 10% TREHALOSE
1LJK	;	2.1	;	CRYSTAL STRUCTURE OF MONOCLINIC LYSOZYME GROWN IN PRESENCE OF 15% TREHALOSE
1LJG	;	1.9	;	CRYSTAL STRUCTURE OF MONOCLINIC LYSOZYME GROWN IN PRESENCE OF 5% GLYCEROL
1LJH	;	1.8	;	CRYSTAL STRUCTURE OF MONOCLINIC LYSOZYME GROWN IN PRESENCE OF 5% GLYCEROL
6P6U	;	2.42	;	Crystal Structure of Monoclinic Rabbit Muscle Lactate Dehydrogenase with Four Tetramers as the Asymmetric Unit
2ADG	;	2.5	;	Crystal structure of monoclonal anti-CD4 antibody Q425
2ADI	;	2.8	;	Crystal structure of monoclonal anti-CD4 antibody Q425 in complex with Barium
2ADJ	;	2.9	;	Crystal structure of monoclonal anti-CD4 antibody Q425 in complex with Calcium
4YNY	;	1.584	;	Crystal structure of monoclonal anti-human podoplanin antibody NZ-1
4YO0	;	1.56	;	Crystal structure of monoclonal anti-human podoplanin antibody NZ-1 with bound PA peptide
1NC4	;	2.25	;	Crystal Structure of Monoclonal Antibody 2D12.5 Fab Complexed with Gd-DOTA
1NC2	;	2.1	;	Crystal Structure of Monoclonal Antibody 2D12.5 Fab Complexed with Y-DOTA
3VFG	;	1.65	;	Crystal structure of monoclonal antibody 3F8 Fab fragment that binds to GD2 ganglioside
4TRP	;	1.25	;	Crystal structure of monoclonal antibody against neuroblastoma associated antigen.
4TUJ	;	1.89	;	Crystal structure of monoclonal antibody against neuroblastoma associated antigen.
4TUK	;	1.6	;	Crystal structure of monoclonal antibody against neuroblastoma associated antigen.
4TUL	;	1.4	;	Crystal structure of monoclonal antibody against neuroblastoma associated antigen.
4TUO	;	1.55	;	Crystal structure of monoclonal antibody against neuroblastoma associated antigen.
8HN6	;	2.07	;	Crystal structure of monoclonal antibody complexed with SARS-CoV-2 RBD
8HN7	;	3.0	;	Crystal structure of monoclonal antibody complexed with SARS-CoV-2 RBD
3L1O	;	2.0	;	Crystal structure of monoclonal antibody MN423 Fab fragment with free combining site, crystallized in the presence of zinc
5JRP	;	2.0	;	crystal structure of monoclonal antibody MR78 Fab
3C5S	;	2.0	;	Crystal Structure of monoclonal Fab F22-4 specific for Shigella flexneri 2a O-Ag
3V95	;	2.7	;	Crystal structure of monoclonal human anti-rhesus D Fc and IgG1 t125(yb2/0) in the presence of EDTA
3V8C	;	2.77	;	Crystal structure of monoclonal human anti-rhesus D Fc IgG1 t125(yb2/0) double mutant (H310 and H435 in K)
3V7M	;	2.02	;	Crystal structure of monoclonal human anti-Rhesus D Fc IgG1 T125(YB2/0) in the presence of Zn2+
7TQA	;	2.328	;	Crystal Structure of monoclonal S9.6 Fab
7TQB	;	3.1	;	Crystal structure of monoclonal S9.6 Fab bound to DNA-RNA hybrid
3OL0	;	1.483	;	Crystal structure of Monofoil-4P homo-trimer: de novo designed monomer trefoil-fold sub-domain which forms homo-trimer assembly
4KE7	;	1.699	;	Crystal structure of Monoglyceride lipase from Bacillus sp. H257 in complex with an 1-myristoyl glycerol analogue
4KE9	;	2.2	;	Crystal structure of Monoglyceride lipase from Bacillus sp. H257 in complex with an 1-stearyol glycerol analogue
4KE8	;	1.85	;	Crystal structure of Monoglyceride lipase from Bacillus sp. H257 in complex with monopalmitoyl glycerol analogue
5DG4	;	1.5	;	Crystal structure of monomer human cellular retinol binding protein II-Y60L
4ZGU	;	1.49	;	Crystal structure of monomer Y60W hCRBPII
4I20	;	3.34	;	Crystal structure of monomeric (V948R) primary oncogenic mutant L858R EGFR kinase domain
3EL2	;	2.5	;	Crystal Structure of Monomeric Actin Bound to Ca-ATP
3EKS	;	1.8	;	Crystal Structure of Monomeric Actin bound to Cytochalasin D
3EKU	;	2.5	;	Crystal Structure of Monomeric Actin bound to Cytochalasin D
2HF4	;	1.8	;	Crystal structure of Monomeric Actin in its ATP-bound state
2HF3	;	1.8	;	Crystal structure of monomeric Actin in the ADP bound state
1NWK	;	1.85	;	CRYSTAL STRUCTURE OF MONOMERIC ACTIN IN THE ATP STATE
4IJG	;	1.701	;	Crystal structure of monomeric bacteriophytochrome
4ZRR	;	1.5	;	Crystal Structure of Monomeric Bacteriophytochrome mutant D207L Y263F at 1.5 A resolution Using a home source.
4Z1W	;	1.3	;	CRYSTAL STRUCTURE OF MONOMERIC BACTERIOPHYTOCHROME mutant D207L Y263F From Synchrotron
5B6Q	;	1.78	;	Crystal structure of monomeric cytochrome c5 from Shewanella violacea
6I7J	;	2.65	;	Crystal structure of monomeric FICD mutant L258D
6I7L	;	2.32	;	Crystal structure of monomeric FICD mutant L258D complexed with MgAMP-PNP
6I7K	;	2.54	;	Crystal structure of monomeric FICD mutant L258D complexed with MgATP
3KZI	;	3.6	;	Crystal Structure of Monomeric Form of Cyanobacterial Photosystem II
3W9P	;	2.1	;	Crystal structure of monomeric FraC (second crystal form)
3WLD	;	2.7	;	Crystal structure of monomeric GCaMP6m
3L01	;	2.6	;	Crystal structure of monomeric glycogen synthase from Pyrococcus abyssi
6AO9	;	1.13	;	Crystal structure of monomeric guanylyl cyclase domain of RhoGC fusion protein from the aquatic fungus Blastocladiella emersonii
3M7M	;	2.9	;	Crystal structure of monomeric hsp33
5KVI	;	1.995	;	Crystal structure of monomeric human apoptosis-inducing factor with E413A/R422A/R430A mutations
1LDS	;	1.8	;	Crystal Structure of monomeric human beta-2-microglobulin
3GAX	;	1.7	;	Crystal structure of monomeric human cystatin C stabilized against aggregation
6VFQ	;	2.3	;	Crystal structure of monomeric human protocadherin 10 EC1-EC4
7UGS	;	1.63	;	Crystal structure of monomeric hyperfolder YFP (K206V mutant)
3MBC	;	1.9	;	Crystal structure of monomeric isocitrate dehydrogenase from Corynebacterium glutamicum in complex with NADP
3O80	;	2.18	;	Crystal structure of monomeric KlHxk1 in crystal form IX (open state)
3O6W	;	1.48	;	Crystal structure of monomeric KlHxk1 in crystal form VIII (open state)
3O8M	;	1.42	;	Crystal structure of monomeric KlHxk1 in crystal form XI with glucose bound (closed state)
2ZMW	;	2.0	;	Crystal Structure of Monomeric Kusabira-Orange (MKO), Orange-Emitting GFP-like Protein, at pH 6.0
3MGF	;	1.8	;	Crystal Structure of Monomeric Kusabira-Orange (MKO), Orange-Emitting GFP-like Protein, at pH 7.5
2ZMU	;	1.65	;	Crystal Structure of Monomeric Kusabira-Orange (MKO), Orange-Emitting GFP-like Protein, at pH 9.1
4LP2	;	2.3	;	Crystal structure of monomeric ligand binding domain of S. typhimurium CysB, a LysR transcriptional regulator at 2.2A
3SQF	;	1.6324	;	Crystal structure of monomeric M-PMV retroviral protease
2XIT	;	1.8	;	Crystal structure of monomeric MipZ
5W0T	;	2.63	;	Crystal structure of monomeric Msp1 from S. cerevisiae
3W8S	;	2.07	;	Crystal structure of monomeric Na-GST-3, a glutathione s-transferase from the major human hookworm parasite Necator americanus
5VIV	;	1.33	;	Crystal structure of monomeric near-infrared fluorescent protein miRFP670
5VIK	;	1.35	;	Crystal structure of monomeric near-infrared fluorescent protein miRFP703
5VIQ	;	1.34	;	Crystal structure of monomeric near-infrared fluorescent protein miRFP709
3WCK	;	2.3	;	Crystal structure of monomeric photosensitizing fluorescent protein, Supernova
3U8A	;	1.783	;	Crystal structure of monomeric reversibly photoswitchable red fluorescent protein rsTagRFP in the OFF state
3U8C	;	2.188	;	Crystal structure of monomeric reversibly photoswitchable red fluorescent protein rsTagRFP in the ON state
1ZOV	;	1.86	;	Crystal Structure of Monomeric Sarcosine Oxidase from Bacillus sp. NS-129
4LON	;	2.2	;	Crystal structure of monomeric sulphate free form of ligand binding domain of CysB,an LTTR from Salmonella typhimurium LT2
4LPT	;	2.544	;	Crystal structure of monomeric TENCON variant P54CR4-31
2F0A	;	1.8	;	Crystal Structure of Monomeric Uncomplexed form of Xenopus dishevelled PDZ domain
4E82	;	1.7	;	Crystal structure of monomeric variant of human alpha-defensin 5, HD5 (Glu21EMe mutant)
6N29	;	2.5	;	Crystal structure of monomeric von Willebrand Factor D`D3 assembly
4AZW	;	2.47	;	Crystal structure of monomeric WbdD.
4M9O	;	2.14	;	Crystal Structure of monomeric zebrafish beta-2-microglobulin
3BS2	;	1.15	;	Crystal Structure of Monomine
3BU1	;	1.4	;	Crystal structure of monomine-histamine complex
2I7G	;	1.73	;	Crystal Structure of Monooxygenase from Agrobacterium tumefaciens
7BIP	;	1.6	;	Crystal structure of monooxygenase RslO1 from Streptomyces bottropensis
7BIO	;	1.795	;	Crystal structure of monooxygenase RslO4 from Streptomyces bottropensis
6SGN	;	2.501	;	Crystal structure of monooxygenase RutA complexed with 2,4-dimethoxypyrimidine.
6SGM	;	2.0	;	Crystal structure of monooxygenase RutA complexed with 4-Thiouracil.
6TEF	;	1.8	;	Crystal structure of monooxygenase RutA complexed with dioxygen under 0.5 MPa / 5 bars of oxygen pressure.
6SGG	;	1.8	;	Crystal structure of monooxygenase RutA complexed with dioxygen under 1.5 MPa / 15 bars of oxygen pressure.
6TEG	;	1.8	;	Crystal structure of monooxygenase RutA complexed with uracil and dioxygen under 1.5 MPa / 15 bars of oxygen pressure.
6SGL	;	2.01	;	Crystal structure of monooxygenase RutA complexed with Uracil under atmospheric pressure.
6TEE	;	2.2	;	Crystal structure of monooxygenase RutA under anaerobic conditions.
7EPW	;	2.23	;	Crystal structure of monooxygenase Tet(X4) with tigecycline
6V6Q	;	2.46	;	Crystal Structure of Monophosphorylated FGF Receptor 2 isoform IIIb with PTR657
8G19	;	1.77	;	Crystal structure of monoreactive 4C05 human Fab
6BFG	;	2.2	;	Crystal structure of monotopic membrane protein (S)-mandelate dehydrogenase
7BBD	;	2.2	;	Crystal structure of monoubiquitinated TRIM21 RING (Ub-RING) In complex with ubiquitin charged Ube2N (Ube2N~Ub) and Ube2V2
3VHI	;	1.76	;	Crystal structure of monoZ-biotin-avidin complex
7WWW	;	1.88	;	Crystal Structure of Moonlighting GAPDH protein of Lactobacillus gasseri
2V9V	;	1.1	;	Crystal Structure of Moorella thermoacetica SelB(377-511)
5D70	;	2.06	;	Crystal structure of MOR03929, a neutralizing anti-human GM-CSF antibody Fab fragment in complex with human GM-CSF
5D72	;	2.6	;	Crystal structure of MOR04252, a neutralizing anti-human GM-CSF antibody Fab fragment in complex with human GM-CSF
5D71	;	2.25	;	Crystal structure of MOR04302, a neutralizing anti-human GM-CSF antibody Fab fragment in complex with human GM-CSF
5D7S	;	1.88	;	Crystal structure of MOR04357, a neutralizing anti-human GM-CSF antibody Fab fragment
5C7X	;	2.95	;	Crystal structure of MOR04357, a neutralizing anti-human GM-CSF antibody Fab fragment in complex with human GM-CSF
2H5O	;	1.08	;	Crystal structure of mOrange
7FCM	;	2.22	;	Crystal structure of Moraxella catarrhalis enoyl-ACP-reductase (FabI) in complex with NAD and Triclosan
7F44	;	2.12	;	Crystal structure of Moraxella catarrhalis enoyl-ACP-reductase (FabI) in complex with the cofactor NAD
6O5W	;	1.412	;	Crystal structure of MORC3 CW domain fused with viral influenza A NS1 peptide
6JLE	;	1.55	;	Crystal structure of MORN4/Myo3a complex
8D50	;	4.32	;	Crystal Structure of Mosaic HIV-1 Envelope (MosM3.1) in Complex with antibodies PGT124 and 35O22 at 4.3 Angstrom
8D4R	;	3.81	;	Crystal Structure of Mosaic HIV-1 Envelope (MosM3.2) in Complex with antibodies PGT124 and 35O22 at 3.8 Angstrom
4FD4	;	1.95	;	Crystal structure of mosquito arylalkylamine N-Acetyltransferase like 5b
5YAG	;	1.95	;	Crystal structure of mosquito arylalkylamine N-Acetyltransferase like 5b/spermine N-Acetyltransferase
7E4V	;	1.37	;	Crystal structure of mosquito Staufen dsRNA binding domain 4
4BHK	;	2.32	;	Crystal Structure of Moss Leafy bound to DNA
5ZG9	;	2.04	;	Crystal structure of MoSub1-ssDNA complex in phosphate buffer
4ZYP	;	5.5	;	Crystal Structure of Motavizumab and Quaternary-Specific RSV-Neutralizing Human Antibody AM14 in Complex with Prefusion RSV F Glycoprotein
3IXT	;	2.75	;	Crystal Structure of Motavizumab Fab Bound to Peptide Epitope
3OQ0	;	2.7	;	Crystal Structure of motif N of Saccharomyces cerevisiae Dbf4
3OQ4	;	2.4	;	Crystal Structure of motif N of Saccharomyces cerevisiae Dbf4
6W1W	;	2.58	;	Crystal Structure of Motility Associated Killing Factor B from Vibrio cholerae
6W08	;	1.75	;	Crystal Structure of Motility Associated Killing Factor E from Vibrio cholerae
2ZF8	;	2.85	;	Crystal structure of MotY
3V9L	;	1.502	;	Crystal structure of mouse 1-pyrroline-5-carboxylate dehydrogenase complexed with NAD+
3V9J	;	1.299	;	Crystal structure of mouse 1-pyrroline-5-carboxylate dehydrogenase complexed with sulfate ion
3V9K	;	1.501	;	Crystal structure of mouse 1-pyrroline-5-carboxylate dehydrogenase complexed with the product glutamate
7EXE	;	2.75	;	Crystal structure of mouse 14-3-3zeta in complex with doubly phosphorylated ADAM22 peptide
2ZB3	;	2.0	;	Crystal structure of mouse 15-ketoprostaglandin delta-13-reductase in complex with NADPH
2P5N	;	1.8	;	Crystal structure of mouse 17-alpha hydroxysteroid dehydrogenase in complex with coenzyme NADPH
5HCU	;	2.4151	;	Crystal structure of mouse acetylchoinesterase inhibited by DFP
5DTI	;	2.003	;	Crystal structure of mouse acetylcholinesterase
2HA0	;	2.2	;	Crystal structure of mouse acetylcholinesterase complexed with 4-ketoamyltrimethylammonium
2HA3	;	2.25	;	Crystal structure of mouse acetylcholinesterase complexed with choline
2H9Y	;	2.4	;	Crystal structure of mouse acetylcholinesterase complexed with m-(N,N,N-trimethylammonio)trifluoroacetophenone
2HA2	;	2.05	;	Crystal structure of mouse acetylcholinesterase complexed with succinylcholine
5FKJ	;	3.133	;	Crystal structure of mouse acetylcholinesterase in complex with C-547, an alkyl ammonium derivative of 6-methyl uracil
3ZLU	;	2.6	;	Crystal structure of mouse acetylcholinesterase in complex with cyclosarin
2WU3	;	2.7	;	CRYSTAL STRUCTURE OF MOUSE ACETYLCHOLINESTERASE IN COMPLEX WITH FENAMIPHOS AND HI-6
2WU4	;	2.4	;	CRYSTAL STRUCTURE OF MOUSE ACETYLCHOLINESTERASE IN COMPLEX WITH FENAMIPHOS AND ORTHO-7
3ZLV	;	2.5	;	Crystal structure of mouse acetylcholinesterase in complex with tabun and HI-6
1J06	;	2.35	;	Crystal structure of mouse acetylcholinesterase in the apo form
2JGM	;	2.9	;	Crystal structure of mouse acetylcholinesterase inhibited by aged diisopropyl fluorophosphate (DFP)
2JGK	;	2.9	;	Crystal structure of mouse acetylcholinesterase inhibited by aged fenamiphos
2JGJ	;	2.5	;	Crystal structure of mouse acetylcholinesterase inhibited by aged methamidophos
2JGL	;	2.6	;	Crystal structure of mouse acetylcholinesterase inhibited by aged VX and sarin
2JGI	;	2.9	;	Crystal structure of mouse acetylcholinesterase inhibited by non-aged diisopropyl fluorophosphate (DFP)
2JGF	;	2.5	;	Crystal structure of mouse acetylcholinesterase inhibited by non-aged fenamiphos
2JGE	;	2.6	;	Crystal structure of mouse acetylcholinesterase inhibited by non-aged methamidophos
6VFY	;	2.6	;	Crystal structure of mouse acyl-CoA thioesterase 7 with CoA
7NZ7	;	2.96	;	Crystal structure of mouse ADAT2/ADAT3 tRNA deamination complex 1
7NZ8	;	2.12	;	Crystal structure of mouse ADAT2/ADAT3 tRNA deamination complex 2
7NZ9	;	1.99	;	Crystal structure of mouse ADAT2/ADAT3 tRNA deamination complex V128L mutant
2QTY	;	1.8	;	Crystal Structure of mouse ADP-ribosylhydrolase 3 (mARH3)
6VLG	;	2.5	;	Crystal structure of mouse alpha 1,6-fucosyltransferase, FUT8 bound to GDP
6VLF	;	1.8	;	Crystal structure of mouse alpha 1,6-fucosyltransferase, FUT8 in its Apo-form
1ON6	;	2.3	;	Crystal structure of mouse alpha-1,4-N-acetylhexosaminotransferase (EXTL2) in complex with UDPGlcNAc
1OMX	;	2.4	;	Crystal structure of mouse alpha-1,4-N-acetylhexosaminyltransferase (EXTL2)
1OMZ	;	2.1	;	crystal structure of mouse alpha-1,4-N-acetylhexosaminyltransferase (EXTL2) in complex with UDPGalNAc
1ON8	;	2.7	;	Crystal structure of mouse alpha-1,4-N-acetylhexosaminyltransferase (EXTL2) with UDP and GlcUAb(1-3)Galb(1-O)-naphthalenelmethanol an acceptor substrate analog
3W67	;	2.61	;	Crystal structure of mouse alpha-tocopherol transfer protein in complex with alpha-tocopherol and phosphatidylinositol-(3,4)-bisphosphate
3W68	;	2.05	;	Crystal structure of mouse alpha-tocopherol transfer protein in complex with alpha-tocopherol and phosphatidylinositol-(4,5)-bisphosphate
2CVP	;	1.8	;	Crystal structure of mouse AMF
2CXR	;	1.7	;	Crystal structure of mouse AMF / 6PG complex
2CXP	;	1.7	;	Crystal structure of mouse AMF / A5P complex
2CXO	;	1.8	;	Crystal structure of mouse AMF / E4P complex
2CXS	;	1.5	;	Crystal structure of mouse AMF / F6P complex
2CXT	;	1.5	;	Crystal structure of mouse AMF / F6P complex
2CXU	;	1.65	;	Crystal structure of mouse AMF / M6P complex
2CXN	;	1.4	;	Crystal structure of mouse AMF / phosphate complex
2CXQ	;	1.5	;	Crystal structure of mouse AMF / S6P complex
2WXX	;	2.95	;	Crystal structure of mouse angiotensinogen in the oxidised form
2WY0	;	2.38	;	Crystal structure of mouse angiotensinogen in the oxidised form with space group P6122
2WXY	;	2.1	;	Crystal structure of mouse angiotensinogen in the reduced form
7KKZ	;	1.5	;	Crystal structure of mouse anti-HIV potent neutralizing antibody M4H2K1
8E0P	;	2.33	;	Crystal structure of mouse APCDD1 in fusion with engineered MBP
8E0W	;	2.15	;	Crystal structure of mouse APCDD1 in P1 space group
8E0R	;	1.95	;	Crystal structure of mouse APCDD1 in P21 space group
2DG2	;	2.45	;	Crystal Structure of Mouse Apolipoprotein A-I Binding Protein
2O8N	;	2.0	;	Crystal Structure of Mouse Apolipoprotein A-I Binding Protein
3RNO	;	2.5	;	Crystal Structure of Mouse Apolipoprotein A-I Binding Protein in Complex with NADP.
3ROZ	;	2.8	;	Crystal Structure of Mouse Apolipoprotein A-I Binding Protein in Complex with Nicotinamide
3ROX	;	2.4	;	Crystal Structure of Mouse Apolipoprotein A-I Binding Protein in Complex with Theophylline
3ROE	;	2.11	;	Crystal Structure of Mouse Apolipoprotein A-I Binding Protein in Complex with Thymidine
3ROG	;	2.05	;	Crystal Structure of Mouse Apolipoprotein A-I Binding Protein in Complex with Thymidine 3'-monophosphate
3RO7	;	2.5	;	Crystal Structure of Mouse Apolipoprotein A-I Binding Protein in Complex with Thymine.
2XKL	;	2.5	;	Crystal Structure of Mouse Apolipoprotein M
1O3Y	;	1.5	;	Crystal structure of mouse ARF1 (delta17-Q71L), GTP form
3D15	;	2.3	;	Crystal structure of mouse Aurora A (Asn186->Gly, Lys240->Arg, Met302->Leu) in complex with 1-(3-chloro-phenyl)-3-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)- ethyl]-thiazol-2-yl}-urea [SNS-314]
3D2I	;	2.9	;	Crystal structure of mouse Aurora A (Asn186->Gly, Lys240->Arg, Met302->Leu) in complex with 1-{5-[2-(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-ylamino)-ethyl]-thiazol-2-yl}-3-(3-trifluoromethyl-phenyl)-urea
3D14	;	1.9	;	Crystal structure of mouse Aurora A (Asn186->Gly, Lys240->Arg, Met302->Leu) in complex with 1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)-ethyl]- thiazol-2-yl}-3-(3-trifluoromethyl-phenyl)-urea
3D2K	;	2.5	;	Crystal structure of mouse Aurora A (Asn186->Gly, Lys240->Arg, Met302->Leu) in complex with [7-(2-{2-[3-(3-chloro-phenyl)-ureido]-thiazol-5-yl}-ethylamino)-pyrazolo[4,3-d]pyrimidin-1-yl]-acetic acid
3NKM	;	2.002	;	Crystal structure of mouse autotaxin
3NKN	;	1.8	;	Crystal structure of mouse autotaxin in complex with 14:0-LPA
3NKO	;	1.75	;	Crystal structure of mouse autotaxin in complex with 16:0-LPA
3NKP	;	1.751	;	Crystal structure of mouse autotaxin in complex with 18:1-LPA
3NKQ	;	1.7	;	Crystal structure of mouse autotaxin in complex with 18:3-LPA
3NKR	;	1.704	;	Crystal structure of mouse autotaxin in complex with 22:6-LPA
5HRT	;	1.997	;	Crystal structure of mouse autotaxin in complex with a DNA aptamer
6Y5M	;	2.011	;	Crystal structure of mouse Autotaxin in complex with compound 1a
6VIL	;	3.301	;	Crystal structure of mouse BAHCC1 BAH domain in complex with H3K27me3
6MCY	;	1.748	;	Crystal structure of mouse Bak
5KTG	;	2.802	;	Crystal structure of mouse Bak BH3-in-groove homodimer (GFP)
5W62	;	2.196	;	Crystal structure of mouse BAX monomer
1PQ0	;	2.2	;	Crystal structure of mouse Bcl-xl
3IHC	;	1.85	;	Crystal structure of mouse Bcl-xl (wt) at pH 5.0
3IIH	;	2.75	;	Crystal structure of mouse Bcl-xl (wt) at pH 6.0
3IIG	;	2.3	;	Crystal structure of mouse Bcl-xl mutant (F105A) at pH 5.0
3IHE	;	3.0	;	Crystal structure of mouse Bcl-xl mutant (F105A) at pH 6.0
3IHF	;	2.28	;	Crystal structure of mouse Bcl-xl mutant (R139A) at pH 5.0
3ILB	;	2.38	;	Crystal structure of mouse Bcl-xl mutant (R139A) at pH 6.0
3IHD	;	1.88	;	Crystal structure of mouse Bcl-xl mutant (Y101A) at pH 5.0
3ILC	;	1.64	;	Crystal structure of mouse Bcl-xl mutant (Y101A) at pH 6.0
3NI0	;	1.601	;	Crystal Structure of Mouse BST-2/Tetherin Ectodomain
6MNY	;	2.8	;	Crystal structure of mouse BTK kinase domain in complex with compound 9a
4D7Y	;	1.44	;	Crystal structure of mouse C1QL1 globular domain
2A4C	;	2.9	;	Crystal structure of mouse cadherin-11 EC1
2A4E	;	3.2	;	Crystal structure of mouse cadherin-11 EC1-2
2WBX	;	1.5	;	Crystal structure of mouse cadherin-23 EC1
2WCP	;	1.98	;	CRYSTAL STRUCTURE OF MOUSE CADHERIN-23 EC1-2
2WHV	;	2.36	;	CRYSTAL STRUCTURE OF MOUSE CADHERIN-23 EC1-2 (ALL CATION BINDING SITES OCCUPIED BY CALCIUM)
4APX	;	1.65	;	CRYSTAL STRUCTURE OF MOUSE CADHERIN-23 EC1-2 AND PROTOCADHERIN-15 EC1- 2 FORM I
4AQ8	;	2.63	;	CRYSTAL STRUCTURE OF MOUSE CADHERIN-23 EC1-2 AND PROTOCADHERIN-15 EC1- 2 FORM II
4AXW	;	2.23	;	CRYSTAL STRUCTURE OF MOUSE CADHERIN-23 EC1-2 AND PROTOCADHERIN-15 EC1- 2, FORM I 2.2A.
4XXW	;	2.261	;	Crystal structure of mouse Cadherin-23 EC1-2 and Protocadherin-15 EC1-2 splice variant
5VH2	;	2.84	;	Crystal Structure of Mouse Cadherin-23 EC12-13 with Engineered Mutation S1339D
7U71	;	1.975	;	Crystal Structure of Mouse Cadherin-23 EC13-15
7SKH	;	2.265	;	Crystal Structure of Mouse Cadherin-23 EC16-17
5WJM	;	2.9	;	Crystal Structure of Mouse Cadherin-23 EC17-18
7T80	;	2.301	;	Crystal Structure of Mouse Cadherin-23 EC18-19
5ULU	;	2.85	;	Crystal Structure of Mouse Cadherin-23 EC19-21 (S2087P) with non-syndromic deafness (DFNB12) associated mutation D2148N
5I8D	;	2.69	;	Crystal Structure of Mouse Cadherin-23 EC19-21 S2064P
5UN2	;	2.96	;	Crystal Structure of Mouse Cadherin-23 EC19-21 with non-syndromic deafness (DFNB12) associated mutation R2029W
5TFK	;	2.8	;	Crystal Structure of Mouse Cadherin-23 EC19-21 WT
5UZ8	;	1.85	;	Crystal Structure of Mouse Cadherin-23 EC22-24
5VT8	;	2.92	;	Crystal Structure of Mouse Cadherin-23 EC24-25
7SUU	;	2.248	;	Crystal Structure of Mouse Cadherin-23 EC25-26
5TFL	;	3.56	;	Crystal Structure of Mouse Cadherin-23 EC7+8
7T3S	;	2.966	;	Crystal Structure of Mouse Cadherin-23 EC8-9
7UQU	;	1.976	;	Crystal Structure of Mouse Cadherin-23 EC9
2A62	;	4.5	;	Crystal structure of mouse cadherin-8 EC1-3
4ORB	;	3.108	;	Crystal structure of mouse calcineurin
5IS7	;	2.29	;	Crystal structure of mouse CARM1 in complex with decarboxylated SAH
7QRD	;	2.0	;	Crystal structure of mouse CARM1 in complex with histone H3_10-25
7OKP	;	2.2	;	Crystal structure of mouse CARM1 in complex with histone H3_13-22 K18 acetylated
7OS4	;	2.54	;	Crystal structure of mouse CARM1 in complex with histone H3_13-31 K18
7QPH	;	1.9	;	Crystal structure of mouse CARM1 in complex with histone H3_22-31 K27 acetylated
5TBH	;	2.341	;	Crystal structure of mouse CARM1 in complex with inhibitor LH1236
5LV2	;	2.29	;	Crystal structure of mouse CARM1 in complex with inhibitor LH1246
5TBI	;	2.294	;	Crystal structure of mouse CARM1 in complex with inhibitor LH1427
5TBJ	;	2.32	;	Crystal structure of mouse CARM1 in complex with inhibitor LH1452
5IS8	;	2.709	;	Crystal structure of mouse CARM1 in complex with inhibitor SA0271
5IS9	;	2.4	;	Crystal structure of mouse CARM1 in complex with inhibitor SA0375
5ISA	;	2.4	;	Crystal structure of mouse CARM1 in complex with inhibitor SA0401
5ISB	;	2.0	;	Crystal structure of mouse CARM1 in complex with inhibitor SA0435
5ISC	;	2.6	;	Crystal structure of mouse CARM1 in complex with inhibitor SA0491
5ISD	;	2.601	;	Crystal structure of mouse CARM1 in complex with inhibitor SA0592
5ISE	;	2.1	;	Crystal structure of mouse CARM1 in complex with inhibitor SA0649
5NTC	;	2.25	;	Crystal structure of mouse CARM1 in complex with inhibitor SA0678
5ISF	;	2.22	;	Crystal structure of mouse CARM1 in complex with inhibitor SA0705
5ISG	;	2.418	;	Crystal structure of mouse CARM1 in complex with inhibitor SA0707
5ISH	;	2.152	;	Crystal structure of mouse CARM1 in complex with inhibitor SA0765
5ISI	;	2.74	;	Crystal structure of mouse CARM1 in complex with inhibitor SA0920 (5'-amino-5'-deoxyadenosine)
5K8W	;	2.1	;	Crystal structure of mouse CARM1 in complex with inhibitor U2
5K8X	;	1.991	;	Crystal structure of mouse CARM1 in complex with inhibitor U3
5LV3	;	1.8	;	Crystal structure of mouse CARM1 in complex with ligand LH1561Br
5LGP	;	2.04	;	Crystal structure of mouse CARM1 in complex with ligand P1C3s
5LGR	;	2.0	;	Crystal structure of mouse CARM1 in complex with ligand P1C3u
5LGQ	;	2.11	;	Crystal structure of mouse CARM1 in complex with ligand P2C3s
5LGS	;	2.1	;	Crystal structure of mouse CARM1 in complex with ligand P2C3u
5LKJ	;	2.595	;	Crystal structure of mouse CARM1 in complex with ligand SA684
5IH3	;	1.77	;	Crystal structure of mouse CARM1 in complex with SAH at 1.8 Angstroms resolution
5IS6	;	2.007	;	Crystal structure of mouse CARM1 in complex with Sinefungin at 2.0 Angstroms resolution
4K17	;	2.895	;	Crystal Structure of mouse CARMIL residues 1-668
1XL7	;	2.0	;	Crystal Structure of Mouse Carnitine Octanoyltransferase
1XL8	;	2.2	;	Crystal structure of mouse carnitine octanoyltransferase in complex with octanoylcarnitine
2ZOF	;	2.3	;	Crystal structure of mouse carnosinase CN2 complexed with MN and bestatin
2ZOG	;	1.7	;	Crystal structure of mouse carnosinase CN2 complexed with ZN and bestatin
4EV8	;	1.9	;	Crystal structure of mouse catenin beta-59 in 2.4M urea.
4EV9	;	2.1	;	Crystal Structure of Mouse Catenin beta-59 in 4.0M urea
4EVA	;	2.003	;	Crystal Structure of Mouse Catenin beta-59 in 5.6M urea
4EVP	;	2.255	;	Crystal Structure of Mouse Catenin beta-59 in 7.2M urea
4EVT	;	2.339	;	Crystal Structure of Mouse Catenin beta-59 in 8.3M urea
5T6U	;	2.9	;	Crystal structure of mouse cathepsin K at 2.9 Angstroms resolution.
5Y3B	;	3.0	;	Crystal structure of mouse Ccd1 DIX domain
6RHV	;	2.29	;	Crystal structure of mouse CD11b I-domain (CD11b-I) in complex with Staphylococcus aureus octameric bi-component leukocidin LukGH (LukH K319A mutant)
1ZHN	;	2.8	;	Crystal Structure of mouse CD1d bound to the self ligand phosphatidylcholine
3AU1	;	2.5	;	Crystal structure of mouse CD1d in complex with ganglioside GD3
5EFI	;	1.8	;	Crystal structure of mouse CD1d in complex with the p99p lipopeptide
3HE7	;	2.8	;	Crystal structure of mouse CD1d-alpha-galactosylceramide with mouse Valpha14-Vbeta7 NKT TCR
3HE6	;	2.9	;	Crystal structure of mouse CD1d-alpha-galactosylceramide with mouse Valpha14-Vbeta8.2 NKT TCR
3QI9	;	2.3	;	Crystal structure of mouse CD1d-alpha-phosphotidylinositol with mouse Valpha14-Vbeta6 2A3-D NKT TCR
5FFL	;	1.602	;	Crystal structure of mouse CD300lf at 1.6 Angstroms resolution.
3R08	;	4.1	;	Crystal structure of mouse cd3epsilon in complex with antibody 2C11 Fab
5B1R	;	1.2	;	Crystal structure of mouse CD72a CTLD
4KBR	;	2.547	;	Crystal structure of mouse Ceramide-1-phosphate transfer protein (apo-form)
8AXC	;	2.12	;	Crystal structure of mouse Ces2c
5N6I	;	3.6	;	Crystal structure of mouse cGAS in complex with 39 bp DNA
6R6T	;	2.535	;	Crystal structure of mouse cis-aconitate decarboxylase
4P79	;	2.4	;	Crystal structure of mouse claudin-15
3X29	;	3.7	;	CRYSTAL STRUCTURE of MOUSE CLAUDIN-19 IN COMPLEX with C-TERMINAL FRAGMENT OF CLOSTRIDIUM PERFRINGENS ENTEROTOXIN
6AKE	;	3.6	;	Crystal structure of mouse claudin-3 in complex with C-terminal fragment of Clostridium perfringens enterotoxin
6AKF	;	3.9	;	Crystal structure of mouse claudin-3 P134A mutant in complex with C-terminal fragment of Clostridium perfringens enterotoxin
6AKG	;	4.3	;	Crystal structure of mouse claudin-3 P134G mutant in complex with C-terminal fragment of Clostridium perfringens enterotoxin
7QZS	;	1.8	;	Crystal structure of mouse CNPase catalytic domain, G324D mutant
7QZK	;	1.66	;	Crystal structure of mouse CNPase catalytic domain, V318I mutant
5E7L	;	2.002	;	Crystal structure of mouse CNTN2 FN1-FN3 domains
5E4Q	;	2.822	;	Crystal structure of mouse CNTN3 FN1-FN3 domains
5I99	;	2.4	;	Crystal structure of mouse CNTN3 Ig5-Fn2 domains
5E4S	;	2.5	;	Crystal structure of mouse CNTN4 FN1-FN3 domains
5E4I	;	2.6	;	Crystal structure of mouse CNTN5 Ig1-Ig4 domains
5E55	;	2.702	;	Crystal structure of mouse CNTN6 FN1-FN3 domains
4P58	;	2.06	;	Crystal structure of mouse comt bound to an inhibitor
7OL2	;	3.89	;	Crystal structure of mouse contactin 1 immunoglobulin domains
8A0Y	;	3.5	;	Crystal structure of mouse contactin 2 immunoglobulin domains
3R4D	;	3.1	;	Crystal structure of mouse coronavirus receptor-binding domain complexed with its murine receptor
6UIO	;	1.83	;	Crystal structure of mouse CRES (Cystatin-Related Epididymal Spermatogenic)
5UQC	;	1.78	;	Crystal structure of mouse CRMP2
7DLI	;	2.2	;	Crystal structure of mouse CRY1 in complex with KL001 compound
7D0M	;	1.95	;	Crystal structure of mouse CRY1 with bound cryoprotectant
7D0N	;	2.8	;	Crystal structure of mouse CRY2 apo form
7V8Y	;	1.9	;	Crystal structure of mouse CRY2 in complex with SHP1703 compound
7V8Z	;	1.95	;	Crystal structure of mouse CRY2 in complex with SHP656 compound
4K0R	;	2.65	;	Crystal structure of mouse Cryptochrome 1
6KX4	;	2.0	;	Crystal structure of mouse Cryptochrome 1 apo form
6LUE	;	2.1	;	Crystal structure of mouse Cryptochrome 1 in complex with compound KL201
7D19	;	2.35	;	Crystal structure of mouse Cryptochrome 1 in complex with compound TH129
7D1C	;	1.91	;	Crystal structure of mouse Cryptochrome 1 in complex with compound TH303
6KX5	;	2.0	;	Crystal structure of mouse Cryptochrome 1 in complex with KL044 compound
6KX6	;	2.0	;	Crystal structure of mouse Cryptochrome 1 in complex with KL101 compound
6KX7	;	2.1	;	Crystal structure of mouse Cryptochrome 1 in complex with TH301 compound
7WVA	;	2.05	;	Crystal structure of mouse Cryptochrome 1 in complex with TH401 compound
6KX8	;	2.25	;	Crystal structure of mouse Cryptochrome 2 in complex with TH301 compound
4CT0	;	2.45	;	Crystal Structure of Mouse Cryptochrome1 in Complex with Period2
6ZEK	;	2.1	;	Crystal structure of mouse CSAD
7A0A	;	2.8	;	Crystal structure of mouse CSAD in apo form
5E56	;	1.504	;	Crystal structure of mouse CTLA-4
5E5M	;	2.182	;	Crystal structure of mouse CTLA-4 in complex with nanobody
5E03	;	1.685	;	Crystal structure of mouse CTLA-4 nanobody
1ZAB	;	2.36	;	Crystal Structure of Mouse Cytidine Deaminase Complexed with 3-Deazauridine
2FR6	;	2.07	;	Crystal Structure of Mouse Cytidine Deaminase Complexed with Cytidine
2FR5	;	1.48	;	Crystal Structure of Mouse Cytidine Deaminase Complexed with Tetrahydrouridine
5YZH	;	1.994	;	Crystal Structure of Mouse Cytosolic Isocitrate Dehydrogenase
5YZI	;	2.519	;	Crystal Structure of Mouse Cytosolic Isocitrate Dehydrogenase complexed with Cadmium
2ZVQ	;	1.3	;	Crystal structure of mouse cytosolic sulfotransferase mSULT1D1 complex with PAP and alpha-naphthol
2ZVP	;	1.3	;	Crystal structure of mouse cytosolic sulfotransferase mSULT1D1 complex with PAP and p-nitrophenol
2ZYW	;	1.8	;	crystal structure of mouse cytosolic sulfotransferase mSULT1D1 complex with PAP and p-nitrophenol, obtained by two-step soaking method
2ZYT	;	1.55	;	Crystal structure of mouse cytosolic sulfotransferase mSULT1D1 complex with PAPS
2ZYU	;	1.8	;	Crystal structure of mouse cytosolic sulfotransferase mSULT1D1 complex with PAPS and p-nitrophenyl sulfate
2ZYV	;	1.81	;	Crystal structure of mouse cytosolic sulfotransferase mSULT1D1 complex with PAPS/PAP and p-nitrophenol
7EOV	;	2.6	;	Crystal structure of mouse cytosolic sulfotransferase mSULT2A8 in complex with PAP and cholic acid
7V1O	;	2.4	;	Crystal structure of mouse cytosolic sulfotransferase mSULT3A1
6KZR	;	2.304	;	Crystal structure of mouse DCAR2 CRD domain
6LKR	;	1.84	;	Crystal structure of mouse DCAR2 CRD domain complex
6LFJ	;	1.84	;	Crystal structure of mouse DCAR2 CRD domain complex with IPM2
3AV4	;	2.75	;	Crystal structure of mouse DNA methyltransferase 1
5WY1	;	3.27	;	Crystal structure of mouse DNA methyltransferase 1 (T1505A mutant)
3AV5	;	3.25	;	Crystal structure of mouse DNA methyltransferase 1 with AdoHcy
3AV6	;	3.09	;	Crystal structure of mouse DNA methyltransferase 1 with AdoMet
6W8V	;	3.12	;	Crystal structure of mouse DNMT1 in complex with ACG DNA
6W8W	;	3.0	;	Crystal structure of mouse DNMT1 in complex with CCG DNA
3PT6	;	3.0	;	Crystal structure of mouse DNMT1(650-1602) in complex with DNA
3PT9	;	2.5	;	Crystal structure of mouse DNMT1(731-1602) in the free state
5ULI	;	2.1	;	Crystal Structure of mouse DXO in complex with (3'-NADP)+ and calcium ion
6WUF	;	1.6	;	Crystal structure of mouse DXO in complex with 3'-FADP
6WRE	;	2.0	;	Crystal structure of mouse DXO in complex with 5'-OH RNA substrate mimic and calcium ion
6WUK	;	1.599	;	Crystal structure of mouse DXO in complex with CoA
4J7N	;	1.5	;	Crystal structure of mouse DXO in complex with M7GPPPG cap
4J7L	;	1.8	;	Crystal structure of mouse DXO in complex with PRODUCT RNA AND two MAGNESIUM ions
4J7M	;	1.7	;	Crystal structure of mouse DXO in complex with substrate mimic RNA and calcium ion
3Q2V	;	3.4	;	Crystal structure of mouse E-cadherin ectodomain
3JTG	;	2.2	;	Crystal structure of mouse Elf3 C-terminal DNA-binding domain in complex with type II TGF-beta receptor promoter DNA
3W0F	;	2.0	;	Crystal structure of mouse Endonuclease VIII-LIKE 3 (mNEIL3)
4GTW	;	2.7	;	Crystal structure of mouse Enpp1 in complex with AMP
4GTZ	;	3.191	;	Crystal structure of mouse Enpp1 in complex with CMP
4GTY	;	3.19	;	Crystal structure of mouse Enpp1 in complex with GMP
4GTX	;	3.201	;	Crystal structure of mouse Enpp1 in complex with TMP
5DMQ	;	4.0	;	Crystal structure of mouse eRF1 in complex with Reverse Transcriptase (RT) of Moloney Murine Leukemia Virus
7CQZ	;	2.3497	;	crystal structure of mouse FAM46C (TENT5C)
6HPV	;	2.3	;	Crystal structure of mouse fetuin-B
1QQJ	;	1.55	;	CRYSTAL STRUCTURE OF MOUSE FUMARYLACETOACETATE HYDROLASE REFINED AT 1.55 ANGSTROM RESOLUTION
6ENZ	;	3.0	;	Crystal structure of mouse GADL1
4LBQ	;	2.4	;	Crystal structure of mouse galectin-1
8ILU	;	1.8	;	Crystal structure of mouse Galectin-3 in complex with small molecule inhibitor
8IU1	;	1.97	;	Crystal structure of mouse Galectin-3 in complex with small molecule inhibitor
2D6K	;	2.5	;	Crystal structure of mouse galectin-9 N-terminal CRD (crystal form 1)
2D6L	;	2.5	;	Crystal structure of mouse galectin-9 N-terminal CRD (crystal form 2)
2D6M	;	1.6	;	Crystal structure of mouse galectin-9 N-terminal CRD in complex with lactose
2D6N	;	2.0	;	Crystal structure of mouse galectin-9 N-terminal CRD in complex with N-acetyllactosamine
2D6O	;	1.78	;	Crystal structure of mouse galectin-9 N-terminal CRD in complex with N-acetyllactosamine dimer
2D6P	;	2.7	;	Crystal structure of mouse galectin-9 N-terminal CRD in complex with T-antigen
6IKO	;	3.756	;	Crystal structure of mouse GAS7cb
2Q8O	;	1.75	;	crystal structure of mouse GITR ligand dimer
2QDN	;	2.09	;	Crystal Structure of mouse GITRL
3B9I	;	2.49	;	Crystal Structure of mouse GITRL at 2.5 A.
4JKT	;	2.77	;	Crystal structure of mouse Glutaminase C, BPTES-bound form
3SS5	;	2.8	;	Crystal structure of mouse Glutaminase C, L-glutamate-bound form
3SS3	;	2.42	;	Crystal structure of mouse Glutaminase C, ligand-free form
3SS4	;	2.85	;	Crystal structure of mouse Glutaminase C, phosphate-bound form
2DC5	;	1.6	;	Crystal structure of mouse glutathione S-transferase, mu7 (GSTM7) at 1.6 A resolution
1R8Y	;	3.0	;	Crystal Structure of Mouse Glycine N-Methyltransferase (Monoclinic Form)
1R8X	;	2.95	;	Crystal Structure of Mouse Glycine N-Methyltransferase (Tetragonal Form)
6L0U	;	1.95	;	Crystal structure of mouse glyoxalase I complexed with a small molecule inhibitor
4X2A	;	2.0	;	Crystal structure of mouse glyoxalase I complexed with baicalein
4KYK	;	2.0	;	Crystal structure of mouse glyoxalase I complexed with indomethacin
4OPN	;	2.1	;	Crystal structure of mouse glyoxalase I complexed with mAH
2ZA0	;	1.7	;	Crystal structure of mouse glyoxalase I complexed with methyl-gerfelin
4KYH	;	2.5	;	Crystal structure of mouse glyoxalase I complexed with zopolrestat
4PV5	;	2.3	;	Crystal structure of mouse glyoxalase I in complexed with 18-beta-glycyrrhetinic acid
2AGC	;	2.5	;	Crystal Structure of mouse GM2- activator Protein
1LVG	;	2.1	;	Crystal structure of mouse guanylate kinase in complex with GMP and ADP
3ECB	;	1.698	;	Crystal structure of mouse H-2Dd in complex with peptide P18-I10 derived from human immunodeficiency virus envelope glycoprotein 120
1K8I	;	3.1	;	CRYSTAL STRUCTURE OF MOUSE H2-DM
5JIF	;	2.0	;	Crystal structure of mouse hepatitis virus strain DVIM Hemagglutinin-Esterase
4C7L	;	2.1	;	Crystal structure of Mouse Hepatitis virus strain S Hemagglutinin- esterase
4C7W	;	2.5	;	Crystal structure of Mouse Hepatitis virus strain S Hemagglutinin- esterase in complex with 4-O-acetylated sialic acid
6M3H	;	1.71	;	Crystal structure of mouse HPF1
5VAA	;	1.55	;	Crystal structure of mouse IgG2a Fc T370K mutant
6KRU	;	2.3	;	Crystal structure of mouse IgG2b Fc
6KRV	;	3.3	;	Crystal structure of mouse IgG2b Fc complexed with B domain of Protein A
8FUC	;	2.1	;	Crystal structure of mouse Importin alpha in complex with Hendra virus matrix protein minor site NLS2
8FUA	;	1.9	;	Crystal structure of mouse Importin alpha in complex with Hendra virus matrix protein NLS1
5WUN	;	2.2	;	Crystal structure of mouse importin-alpha1 bound to non-phosphorylated NLS of EBNA1
5WUM	;	2.0	;	Crystal structure of mouse importin-alpha1 bound to S385-phosphorylated NLS of EBNA1
5X8N	;	2.15	;	Crystal structure of mouse importin-alpha1 bound to the nuclear localization signal of Epstein-Barr virus EBNA-LP protein
7E0E	;	2.102	;	Crystal structure of mouse interferon alpha2 at 2.1 angstrom resolution
4EXN	;	2.7	;	Crystal structure of mouse Interleukin-34
2R3Z	;	2.5	;	Crystal structure of mouse IP-10
5TLA	;	3.244	;	Crystal structure of mouse ISG15
5H3F	;	3.29	;	Crystal structure of mouse isocitrate dehydrogenases 2 complexed with isocitrate
5H3E	;	2.21	;	Crystal structure of mouse isocitrate dehydrogenases 2 K256Q mutant complexed with isocitrate
4QSZ	;	2.86	;	Crystal structure of mouse JMJd7 fused with maltose-binding protein
5JYJ	;	2.3	;	Crystal structure of mouse JUNO
6TLH	;	1.8	;	Crystal structure of mouse KANK3 ankyrin repeats
4TN7	;	2.2	;	Crystal structure of mouse KDM2A-H3K36ME-NO complex
5FJY	;	4.0	;	Crystal structure of mouse kinesin light chain 2 (residues 161-480)
3E2Y	;	2.26	;	Crystal structure of mouse kynurenine aminotransferase III in complex with glutamine
3E2Z	;	2.81	;	Crystal structure of mouse kynurenine aminotransferase III in complex with kynurenine
3E2F	;	2.59	;	Crystal structure of mouse kynurenine aminotransferase III, PLP-bound form
1WNH	;	1.83	;	Crystal structure of mouse Latexin (tissue carboxypeptidase inhibitor)
8HPW	;	2.39	;	Crystal structure of mouse LGI1 LRR domain in space group P21
5JNU	;	2.535	;	Crystal structure of mouse Low-Molecular Weight Protein Tyrosine Phosphatase type A (LMPTP-A) complexed with phosphate
8VZ9	;	3.4	;	Crystal structure of mouse MAIT M2A TCR-MR1-5-OP-RU complex
8VZ8	;	3.45	;	Crystal structure of mouse MAIT M2B TCR-MR1-5-OP-RU complex
1I05	;	2.0	;	CRYSTAL STRUCTURE OF MOUSE MAJOR URINARY PROTEIN (MUP-I) COMPLEXED WITH HYDROXY-METHYL-HEPTANONE
1I06	;	1.9	;	CRYSTAL STRUCTURE OF MOUSE MAJOR URINARY PROTEIN (MUP-I) COMPLEXED WITH SEC-BUTYL-THIAZOLINE
1I04	;	2.0	;	CRYSTAL STRUCTURE OF MOUSE MAJOR URINARY PROTEIN-I FROM MOUSE LIVER
3M7O	;	1.65	;	Crystal structure of mouse MD-1 in complex with phosphatidylcholine
3C6L	;	3.4	;	Crystal structure of mouse MHC class II I-Ab/3K peptide complexed with mouse TCR 2W20
3C5Z	;	2.55	;	Crystal structure of mouse MHC class II I-Ab/3K peptide complexed with mouse TCR B3K506
3C60	;	3.05	;	Crystal structure of mouse MHC class II I-Ab/3K peptide complexed with mouse TCR YAe62
3PDB	;	2.4	;	Crystal structure of mouse mitochondrial aspartate aminotransferase in complex with oxaloacetic acid
3PD6	;	2.4	;	Crystal structure of mouse mitochondrial aspartate aminotransferase, a newly identified kynurenine aminotransferase-IV
3HLM	;	2.5	;	Crystal Structure of Mouse Mitochondrial Aspartate Aminotransferase/Kynurenine Aminotransferase IV
3DGZ	;	2.25	;	Crystal Structure of Mouse Mitochondrial Thioredoxin Reductase, C-terminal 3-residue truncation
5IX1	;	2.6	;	Crystal structure of mouse Morc3 ATPase-CW cassette in complex with AMPPNP and H3K4me3 peptide
5IX2	;	2.9	;	Crystal structure of mouse Morc3 ATPase-CW cassette in complex with AMPPNP and unmodified H3 peptide
7YDT	;	2.055	;	Crystal structure of mouse MPND
5MZG	;	1.85	;	Crystal structure of mouse MTH1 in complex with TH588
6EHH	;	2.4	;	Crystal structure of mouse MTH1 mutant L116M with inhibitor TH588
5MZE	;	2.1	;	Crystal structure of mouse MTH1 with 8-oxo-dGTP
7EF8	;	2.45	;	Crystal structure of mouse MUTYH in complex with DNA containing AP site analogue:8-oxoG (Form I)
7EF9	;	1.97	;	Crystal structure of mouse MUTYH in complex with DNA containing AP site analogue:8-oxoG (Form II)
6JO7	;	2.4	;	Crystal structure of mouse MXRA8
3BXD	;	2.0	;	Crystal structure of Mouse Myo-inositol oxygenase (re-refined)
2HUO	;	2.0	;	Crystal structure of mouse myo-inositol oxygenase in complex with substrate
4ZLK	;	2.502	;	Crystal structure of mouse myosin-5a in complex with calcium-bound calmodulin
4NUM	;	3.3	;	Crystal structure of mouse N-cadherin EC1-2 A78SI92M
4NUQ	;	2.116	;	Crystal structure of mouse N-cadherin EC1-2 W2F
4NUP	;	2.7	;	Crystal structure of mouse N-cadherin EC1-2 with AA insertion between residues 2 and 3
3Q2W	;	3.2	;	Crystal structure of mouse N-cadherin ectodomain
1DXQ	;	2.8	;	CRYSTAL STRUCTURE OF MOUSE NAD[P]H-QUINONE OXIDOREDUCTASE
4FMK	;	2.56	;	Crystal structure of mouse nectin-2 extracellular fragment D1-D2
4FN0	;	3.35	;	Crystal structure of mouse nectin-2 extracellular fragment D1-D2, 2nd crystal form
5ZO1	;	2.201	;	Crystal structure of mouse nectin-like molecule 4 (mNecl-4) full ectodomain (Ig1-Ig3), 2.2A
5ZO2	;	3.29	;	Crystal structure of mouse nectin-like molecule 4 (mNecl-4) full ectodomain in complex with mouse nectin-like molecule 1 (mNecl-1) Ig1 domain, 3.3A
3JSV	;	2.7	;	Crystal structure of mouse NEMO CoZi in complex with Lys63-linked di-ubiquitin
4OFD	;	3.94	;	Crystal Structure of mouse Neph1 D1-D2
8SNP	;	3.4	;	Crystal structure of mouse Netrin-1 in complex with samarium ions
7OK5	;	2.97	;	Crystal structure of mouse neurofascin 155 immunoglobulin domains
7CEE	;	2.763	;	Crystal structure of mouse neuroligin-3
1JJO	;	3.06	;	Crystal Structure of Mouse Neuroserpin (Cleaved form)
5XVK	;	1.88	;	Crystal structure of mouse Nicotinamide N-methyltransferase (NNMT) bound with end product, 1-methyl Nicotinamide (MNA)
2H3B	;	1.95	;	Crystal Structure of Mouse Nicotinamide Phosphoribosyltransferase/Visfatin/Pre-B Cell Colony Enhancing Factor 1
2H3D	;	2.1	;	Crystal Structure of Mouse Nicotinamide Phosphoribosyltransferase/Visfatin/Pre-B Cell Colony Enhancing Factor in Complex with Nicotinamide Mononuleotide
2W1V	;	1.49	;	Crystal structure of mouse nitrilase-2 at 1.4A resolution
4NQQ	;	3.2	;	Crystal structure of mouse P-cadherin extracellular domains EC1-EC2
3LLL	;	3.3	;	Crystal structure of mouse pacsin2 F-BAR domain
3M3W	;	2.6	;	Crystal structure of mouse PACSIN3 BAR domain mutant
3D45	;	3.0	;	Crystal structure of mouse PARN in complex with m7GpppG
6C10	;	1.399	;	Crystal structure of mouse PCDH15 EC11-EL
5DXW	;	1.441	;	Crystal structure of mouse PD-L1 nanobody
6LOS	;	2.476	;	Crystal structure of mouse PEDF in complex with heterotrimeric collagen model peptide.
2I74	;	1.75	;	Crystal structure of mouse Peptide N-Glycanase C-terminal domain in complex with mannopentaose
3QD2	;	2.81	;	Crystal structure of mouse PERK kinase domain
4O3F	;	2.106	;	Crystal Structure of mouse PGK1 3PG and terazosin(TZN) ternary complex
1U0E	;	1.6	;	Crystal structure of mouse phosphoglucose isomerase
1U0G	;	1.7	;	Crystal structure of mouse phosphoglucose isomerase in complex with erythrose 4-phosphate
1U0F	;	1.6	;	Crystal structure of mouse phosphoglucose isomerase in complex with glucose 6-phosphate
5L71	;	1.8	;	Crystal structure of mouse phospholipid hydroperoxide glutathione peroxidase 4 (GPx4)
7JFM	;	2.23	;	Crystal structure of mouse phosphorylated IRF-3 bound to CBP
5AE8	;	2.42	;	Crystal structure of mouse PI3 kinase delta in complex with GSK2269557
5AE9	;	2.44	;	Crystal structure of mouse PI3 kinase delta in complex with GSK2292767
1KCM	;	2.0	;	Crystal Structure of Mouse PITP Alpha Void of Bound Phospholipid at 2.0 Angstroms Resolution
8V05	;	2.08	;	Crystal structure of mouse PLD3
8V07	;	1.99	;	Crystal structure of mouse PLD3 co-crystallized with 5'Pi-ssDNA for 30 days
8V06	;	2.73	;	Crystal structure of mouse PLD3 co-crystallized with 5'Pi-ssDNA for 9 days
3IG3	;	1.99	;	Crystal structure of mouse Plexin A3 intracellular domain
8BB7	;	2.95	;	Crystal structure of Mouse Plexin-B1 (20-535) in complex with VHH15
8BF4	;	2.15	;	Crystal structure of Mouse Plexin-B1 (20-535) in complex with VHH15 and VHH14
5X3S	;	2.899	;	Crystal structure of mouse Plk1-PBD in complex with phosphopeptide from HEF1 (799-809)
4FC2	;	1.91	;	Crystal structure of mouse poly(ADP-ribose) glycohydrolase (PARG) catalytic domain
4NA5	;	2.0	;	Crystal structure of mouse poly(ADP-ribose) glycohydrolase (PARG) catalytic domain mutant E748N
4N9Y	;	2.3	;	Crystal structure of mouse poly(ADP-ribose) glycohydrolase (PARG) catalytic domain mutant E748Q
4NA6	;	2.48	;	Crystal structure of mouse poly(ADP-ribose) glycohydrolase (PARG) catalytic domain mutant E749N
4N9Z	;	1.9	;	Crystal structure of mouse poly(ADP-ribose) glycohydrolase (PARG) catalytic domain mutant E749Q
4NA4	;	2.5	;	Crystal structure of mouse poly(ADP-ribose) glycohydrolase (PARG) catalytic domain with ADP-HPD
4NA0	;	2.4	;	Crystal structure of mouse poly(ADP-ribose) glycohydrolase (PARG) catalytic domain with ADPRibose
6EF4	;	3.4	;	Crystal structure of mouse PP2A Aalpha P179R mutant
4MA8	;	2.2	;	Crystal structure of mouse prion protein complexed with Chlorpromazine
4MA7	;	1.97	;	Crystal structure of mouse prion protein complexed with Promazine
7NUD	;	1.65	;	Crystal structure of mouse PRMT6 in complex with inhibitor EML734
7NUE	;	2.0	;	Crystal structure of mouse PRMT6 in complex with inhibitor EML736
7P2R	;	2.3	;	Crystal structure of mouse PRMT6 in complex with inhibitor EML980
5LV4	;	1.66	;	Crystal structure of mouse PRMT6 in complex with inhibitor LH1236
5LV5	;	1.802	;	Crystal structure of mouse PRMT6 in complex with inhibitor LH1458
6SQ3	;	2.15	;	Crystal structure of mouse PRMT6 in complex with inhibitor U1
6SQ4	;	1.7	;	Crystal structure of mouse PRMT6 in complex with inhibitor U2
6SQI	;	1.6	;	Crystal structure of mouse PRMT6 with C-terminal TEV cleavage site
6SQK	;	1.4	;	Crystal structure of mouse PRMT6 with modified H7-4 peptide
6SQH	;	2.39	;	Crystal structure of mouse PRMT6 with partial C-terminal TEV cleavage site
5MKT	;	3.2	;	Crystal structure of mouse prorenin
4C4A	;	1.7	;	Crystal structure of mouse protein arginine methyltransferase 7 in complex with SAH
6OGN	;	2.4	;	Crystal structure of mouse protein arginine methyltransferase 7 in complex with SGC8158 chemical probe
6N22	;	2.4	;	Crystal structure of mouse Protocadherin-15 EC1-2 BAP
5W1D	;	3.35	;	Crystal Structure of Mouse Protocadherin-15 EC4-7
6BXU	;	3.79	;	Crystal Structure of Mouse Protocadherin-15 EC5-7 I582T
6BWN	;	2.94	;	Crystal Structure of Mouse Protocadherin-15 EC6-7
5TPK	;	2.0	;	Crystal Structure of Mouse Protocadherin-15 EC7-8 V875A
5KJ4	;	3.35	;	Crystal Structure of Mouse Protocadherin-15 EC9-10
6EET	;	3.23	;	Crystal structure of mouse Protocadherin-15 EC9-MAD12
5CYX	;	2.1	;	Crystal Structure of Mouse Protocadherin-24 EC1-3
3SR9	;	2.4	;	Crystal structure of mouse PTPsigma
2HCM	;	2.0	;	Crystal structure of mouse putative dual specificity phosphatase complexed with zinc tungstate, New York Structural Genomics Consortium
6YJZ	;	2.45	;	Crystal structure of mouse pyridoxal kinase in apo form
6YK0	;	2.9	;	Crystal structure of mouse pyridoxal kinase in complex with ATP-gamma-S
6YK1	;	2.4	;	Crystal structure of mouse pyridoxal kinase in complex with ATP-gamma-S and artesunate
2IEY	;	3.18	;	Crystal Structure of mouse Rab27b bound to GDP in hexagonal space group
2IEZ	;	2.8	;	Crystal Structure of mouse Rab27b bound to GDP in monoclinic space group
2IF0	;	2.8	;	Crystal Structure of mouse Rab27b bound to GDP in monoclinic space group
6VIJ	;	1.95	;	Crystal structure of mouse RABL3 in complex with GDP
6VII	;	2.0	;	Crystal structure of mouse RABL3 in complex with GTPgammaS
3ME4	;	2.01	;	Crystal structure of mouse RANK
4GIQ	;	2.7	;	Crystal Structure of mouse RANK bound to RANKL
4E4D	;	2.7	;	Crystal structure of mouse RANKL-OPG complex
3ME2	;	2.8	;	Crystal structure of mouse RANKL-RANK complex
6NXF	;	2.791	;	Crystal structure of mouse REC114 PH domain in complex with ANKRD31 C terminus
5UXF	;	1.501	;	Crystal Structure of mouse RECON (AKR1C13) in complex with Cyclic di-AMP
3TVD	;	2.989	;	Crystal Structure of Mouse RhoA-GTP complex
1W68	;	2.2	;	Crystal Structure of Mouse Ribonucleotide Reductase Subunit R2 under Oxidizing Conditions. A Fully Occupied Dinuclear Iron Cluster.
1W69	;	2.2	;	Crystal Structure of Mouse Ribonucleotide Reductase Subunit R2 under Reducing Conditions. A Fully Occupied Dinuclear Iron Cluster and Bound Acetate.
3T6Q	;	1.9	;	Crystal structure of mouse RP105/MD-1 complex
4KEI	;	2.406	;	Crystal structure of mouse Ryanodine Receptor 2 (1-217) disease mutant P164S
4KEJ	;	2.553	;	Crystal structure of mouse Ryanodine Receptor 2 (1-217) disease mutant R169Q
4KEK	;	2.146	;	Crystal structure of mouse Ryanodine Receptor 2 (1-217) disease mutant R176Q
4ETV	;	1.65	;	Crystal structure of mouse ryanodine receptor 2 (2699-2904)
3IM5	;	2.55	;	Crystal structure of mouse Ryanodine Receptor 2 (residues 1-217)
3IM6	;	1.7	;	Crystal structure of mouse Ryanodine Receptor 2 mutant V186M
3IM7	;	2.21	;	Crystal structure of mouse Ryanodine Receptor 2 N-terminal domain (1-217) disease mutant A77V
5C33	;	1.21	;	Crystal Structure of Mouse Ryanodine Receptor 2 SPRY1 Domain
6J6L	;	1.452	;	Crystal structure of mouse Ryanodine Receptor 2 SPRY1 Domain (650-844) disease mutant I784F
4P9I	;	1.3401	;	Crystal Structure of mouse Ryanodine Receptor 2 SPRY2 Domain (1080-1253)
4P9L	;	1.4361	;	Crystal Structure of mouse Ryanodine Receptor 2 SPRY2 Domain (1080-1253) disease mutant A1107M
5VSN	;	1.439	;	Crystal structure of mouse ryanodine receptor 2 SPRY2 domain (1080-1253) disease mutant P1124L
4L4H	;	2.0	;	Crystal structure of mouse Ryanodine Receptor isoform 2 (RyR2) 1-547
4L4I	;	2.15	;	Crystal structure of mouse Ryanodine Receptor isoform 2 (RyR2) 1-547 disease mutant R420Q
5AXC	;	1.55	;	Crystal structure of mouse SAHH complexed with 3'-keto aristeromycin
5AXA	;	1.55	;	Crystal structure of mouse SAHH complexed with adenosine
5AXB	;	1.65	;	Crystal structure of mouse SAHH complexed with noraristeromycin
5AXD	;	1.6	;	Crystal structure of mouse SAHH complexed with ribavirin
6F2O	;	3.0	;	Crystal structure of mouse SALM5 adhesion protein extracellular LRR-Ig domain fragment
4A90	;	1.9	;	Crystal structure of mouse SAP18 residues 1-143
4A6Q	;	1.5	;	Crystal structure of mouse SAP18 residues 6-143
6WF2	;	3.51	;	Crystal structure of mouse SCD1 with a diiron center
5B26	;	2.6	;	Crystal structure of mouse SEL1L
3BC8	;	1.65	;	Crystal structure of mouse selenocysteine synthase
3BCA	;	2.25	;	Crystal structure of mouse selenocysteine synthase, sodium iodide soak
3BCB	;	1.85	;	Crystal structure of mouse selenocysteine synthase, sodium phosphate soak
4Q5G	;	2.057	;	Crystal Structure of mouse Serum Amyloid A3
6PY0	;	2.204	;	Crystal Structure of mouse Serum Amyloid A3 (SAA3) bound with Retinol
6PXZ	;	1.7	;	Crystal Structure of mouse Serum Amyloid A3 (SAA3) in the trimeric form
2ZAO	;	3.2	;	Crystal structure of mouse SKD1/VPS4B ADP-form
2ZAM	;	3.5	;	Crystal structure of mouse SKD1/VPS4B apo-form
2ZAN	;	3.0	;	Crystal structure of mouse SKD1/VPS4B ATP-form
7DG5	;	2.0	;	Crystal structure of mouse Smc1-Smc3 hinge domain containing a D574Y mutation
6N64	;	3.3	;	Crystal structure of mouse SMCHD1 hinge domain
8HQL	;	2.4	;	Crystal structure of mouse SNX25 PX domain
7WF8	;	1.35	;	Crystal structure of mouse SNX25 RGS domain in space group P212121
7WF9	;	2.55	;	Crystal structure of mouse SNX25 RGS domain in space group P41212
4YF2	;	2.15	;	Crystal structure of mouse sperm C-type lysozyme-like protein 1
6XNN	;	2.49	;	Crystal Structure of Mouse STING CTD complex with SR-717.
2IKQ	;	2.609	;	Crystal structure of mouse Sts-1 PGM domain in complex with phosphate
2ZPT	;	1.15	;	Crystal structure of mouse sulfotransferase SULT1D1 complex with PAP
5X2B	;	2.08	;	Crystal structure of mouse sulfotransferase SULT7A1 complexed with PAP
4ZG0	;	2.006	;	Crystal structure of Mouse Syndesmos protein
3K6F	;	1.813	;	Crystal structure of mouse T-cadherin EC1
3K5R	;	2.0	;	Crystal Structure of mouse T-cadherin EC1 EC2
5EKZ	;	2.0	;	Crystal structure of mouse Taco1
5HKP	;	2.2	;	Crystal structure of mouse Tankyrase/human TRF1 complex
4JL9	;	3.0999	;	Crystal structure of mouse TBK1 bound to BX795
4JLC	;	3.0	;	Crystal structure of mouse TBK1 bound to SU6668
1U3H	;	2.42	;	Crystal structure of mouse TCR 172.10 complexed with MHC class II I-Au molecule at 2.4 A
3D2W	;	1.65	;	Crystal structure of mouse TDP-43 RRM2 domain in complex with DNA
2AIU	;	1.6	;	Crystal Structure of Mouse Testicular Cytochrome C at 1.6 Angstrom
1KEY	;	2.65	;	Crystal Structure of Mouse Testis/Brain RNA-binding Protein (TB-RBP)
7BPS	;	2.35	;	Crystal structure of mouse TEX101
5A65	;	1.98	;	Crystal structure of mouse thiamine triphosphatase in complex with thiamine diphosphate, orthophosphate and magnesium ions.
5A64	;	2.1	;	Crystal structure of mouse thiamine triphosphatase in complex with thiamine triphosphate.
1ZDL	;	3.0	;	Crystal Structure of Mouse Thioredoxin Reductase Type 2
1ZKQ	;	2.6	;	Crystal structure of mouse thioredoxin reductase type 2
3IHI	;	1.94	;	Crystal structure of mouse thymidylate synthase
4EIN	;	1.75	;	Crystal structure of mouse thymidylate synthase in binary complex with a substrate analogue and strong inhibitor, N(4)-hydroxy-2'-deoxycytidine-5'-monophosphate
4E5O	;	1.7	;	Crystal structure of mouse thymidylate synthase in complex with dUMP
4EB4	;	1.74	;	Crystal structure of mouse thymidylate synthase in ternary complex with dUMP and Tomudex
4EZ8	;	1.17	;	Crystal structure of mouse thymidylate sythase in ternary complex with N(4)-hydroxy-2'-deoxycytidine-5'-monophosphate and the cofactor product, dihydrofolate
6L9U	;	2.601	;	Crystal structure of mouse TIFA
6L9V	;	3.05	;	Crystal structure of mouse TIFA (T9D/C36S mutant)
6L9W	;	2.9	;	Crystal structure of mouse TIFA (T9E/C36S mutant)
8WWY	;	1.79	;	Crystal structure of mouse TIFA/TIFAB heterodimer
3DJN	;	2.2	;	Crystal structure of mouse TIS21
3CIG	;	2.66	;	Crystal structure of mouse TLR3 ectodomain
2Z64	;	2.84	;	Crystal structure of mouse TLR4 and mouse MD-2 complex
7MLM	;	2.104	;	Crystal structure of mouse TLR4/MD-2 in complex with sulfatides
3VQ1	;	2.7	;	Crystal structure of mouse TLR4/MD-2/lipid IVa complex
3VQ2	;	2.48	;	Crystal structure of mouse TLR4/MD-2/LPS complex
3WPF	;	1.959	;	Crystal structure of mouse TLR9 (unliganded form)
3WPG	;	2.246	;	Crystal structure of mouse TLR9 in complex with inhibitory DNA4084 (form 1)
3WPH	;	2.327	;	Crystal structure of mouse TLR9 in complex with inhibitory DNA4084 (form 2)
3WPI	;	2.246	;	Crystal structure of mouse TLR9 in complex with inhibitory DNA_super
5ZLN	;	2.3	;	Crystal structure of mouse TLR9 in complex with two DNAs (CpG DNA and TCGCCA DNA)
5W0X	;	2.717	;	Crystal structure of mouse TOR signaling pathway regulator-like (TIPRL) delta 94-103
8SLR	;	2.4	;	Crystal Structure of mouse TRAIL
2CWN	;	2.1	;	Crystal structure of mouse transaldolase
2E1D	;	2.0	;	Crystal structure of mouse transaldolase
2QPF	;	2.05	;	Crystal Structure of Mouse Transthyretin
1U9K	;	1.76	;	Crystal Structure of Mouse Triggering Receptor Expressed on Myeloid Cells 1 (TREM-1) at 1.76
3RG5	;	2.0	;	Crystal Structure of Mouse tRNA(Sec)
5ELH	;	1.8	;	Crystal structure of mouse Unkempt zinc fingers 1-3 (ZnF1-3), bound to RNA
5ELK	;	2.3	;	Crystal structure of mouse Unkempt zinc fingers 4-6 (ZnF4-6), bound to RNA
6Q2P	;	1.452	;	Crystal structure of mouse viperin bound to cytidine triphosphate and S-adenosylhomocysteine
6Q2Q	;	1.892	;	Crystal structure of mouse viperin bound to uridine triphosphate and S-adenosylhomocysteine
2R51	;	2.1	;	Crystal Structure of mouse Vps26B
3LH8	;	2.6	;	Crystal structure of mouse VPS26B in spacegroup P41 21 2
3LH9	;	2.4	;	Crystal structure of mouse VPS26B(L197S/R199E) in spacegroup P41 21 2
3LHA	;	2.8	;	Crystal structure of mouse VPS26B(R240S/G241A/E242S) in spacegroup P41 21 2
1Z2X	;	2.22	;	Crystal structure of mouse Vps29
1Z2W	;	2.0	;	Crystal structure of mouse Vps29 complexed with Mn2+
3PSN	;	2.4	;	Crystal structure of mouse VPS29 complexed with Mn2+
3PSO	;	3.2	;	Crystal structure of mouse VPS29 complexed with Zn2+
2QYW	;	2.0	;	Crystal structure of mouse vti1b Habc domain
6VIK	;	1.7	;	Crystal structure of mouse xm RABL3 in complex with GTPgammsS
4WM0	;	2.37	;	Crystal structure of mouse Xyloside xylosyltransferase 1 complexed with acceptor ligand
4WLM	;	3.0	;	Crystal structure of mouse Xyloside xylosyltransferase 1 complexed with manganese
4WLZ	;	3.03	;	Crystal structure of mouse Xyloside xylosyltransferase 1 complexed with manganese and UDP
4WMB	;	2.05	;	crystal structure of mouse Xyloside xylosyltransferase 1 complexed with manganese, acceptor ligand and UDP
4WMI	;	1.87	;	Crystal structure of mouse Xyloside xylosyltransferase 1 complexed with manganese, product ligand and UDP (Product complex I)
4WMK	;	2.08	;	Crystal structure of mouse Xyloside xylosyltransferase 1 complexed with manganese, product ligand and UDP (Product complex II)
4WN2	;	1.95	;	Crystal structure of mouse Xyloside xylosyltransferase 1 complexed with manganese, product ligand and UDP (Product complex III)
4WMA	;	1.62	;	Crystal structure of mouse Xyloside xylosyltransferase 1 complexed with manganese,acceptor ligand and UDP-Glucose
4WNH	;	1.95	;	Crystal structure of mouse Xyloside xylosyltransferase 1 complexed with manganese,acceptor ligand and UDP-Xylose
4WLG	;	3.0	;	crystal structure of mouse Xyloside xylosyltransferase 1, apo form
5ZYB	;	2.13	;	Crystal structure of MOX-1 complexed with a boronic acid transition state inhibitor S02030
2XKK	;	3.25	;	CRYSTAL STRUCTURE OF MOXIFLOXACIN, DNA, and A. BAUMANNII TOPO IV (PARE-PARC FUSION TRUNCATE)
4HKE	;	1.87	;	Crystal Structure of MoxT of Bacillus anthracis
3V43	;	1.47	;	Crystal structure of MOZ
4LJN	;	3.0	;	Crystal Structure of MOZ double PHD finger
5B76	;	1.653	;	Crystal structure of MOZ double PHD finger domain in complex with histone H3 crotonylation at K14
4LK9	;	1.6	;	Crystal Structure of MOZ double PHD finger histone H3 tail complex
4LLB	;	2.5	;	Crystal Structure of MOZ double PHD finger histone H3K14ac complex
4LKA	;	1.61	;	Crystal Structure of MOZ double PHD finger histone H3K9ac complex
5B75	;	1.704	;	Crystal structure of MOZ double PHD finger in complex with histone H3 butyrylation at K14
5B78	;	1.4	;	Crystal structure of MOZ double PHD finger mutant-S210D/N235R in complex with histone H3 crotonylation at K14
3L1N	;	1.3	;	Crystal structure of Mp1p ligand binding domain 2 complexd with palmitic acid
3SYV	;	3.1	;	Crystal structure of mPACSIN 3 F-BAR domain mutant
5BQG	;	1.436	;	Crystal Structure of mPGES-1 Bound to an Inhibitor
6VL4	;	1.4	;	Crystal Structure of mPGES-1 bound to DG-031
5T36	;	1.4	;	Crystal structure of mPGES-1 bound to inhibitor
5T37	;	1.761	;	crystal structure of mPGES-1 bound to inhibitor
5TL9	;	1.2	;	crystal structure of mPGES-1 bound to inhibitor
4WAB	;	2.704	;	Crystal structure of mPGES1 solved by native-SAD phasing
7W1A	;	2.17	;	Crystal Structure of MPH-E in complex with GMP and Azithromycin
7W15	;	1.77	;	Crystal Structure of MPH-E in complex with GTP and Erythromycin
4O2Z	;	2.71	;	Crystal Structure of MPK3 from Leishmania donovani, LdBPK_100540 in the presence of NVP-BBT594
4E0Q	;	2.5	;	Crystal structure of MPN domain from COP9 signalosome
2I15	;	2.4	;	Crystal structure of MPN423 from Mycoplasma pneumoniae
3U7E	;	1.7	;	Crystal structure of mPNKP catalytic fragment (D170A)
3U7G	;	2.1	;	Crystal structure of mPNKP catalytic fragment (D170A) bound to single-stranded DNA (TCCTAp)
3U7F	;	1.8	;	Crystal structure of mPNKP catalytic fragment (D170A) bound to single-stranded DNA (TCCTCp)
3U7H	;	2.0	;	Crystal structure of mPNKP catalytic fragment (D170A) bound to single-stranded DNA (TCCTTp)
6B9T	;	2.35	;	Crystal structure of MPnS with substrate 2-hydroxyethylphosphonate (2-HEP) and Fe(II) bound
5V50	;	2.43	;	Crystal Structure of MpPR-1i
5V51	;	2.92	;	Crystal Structure of MpPR-1i Soaked with Selenourea for 10 min
7LTN	;	1.79	;	Crystal structure of Mpro in complex with inhibitor CDD-1713
7JP0	;	1.65	;	Crystal structure of Mpro with inhibitor r1
8GZ4	;	1.802	;	Crystal structure of MPXV phosphatase
5HAB	;	2.3	;	Crystal structure of mpy-RNase J (mutant H84A), an archaeal RNase J from Methanolobus psychrophilus R15, complex with RNA
5WS2	;	2.398	;	Crystal structure of mpy-RNase J (mutant S247A), an archaeal RNase J from Methanolobus psychrophilus R15, complex with RNA
6LLB	;	2.6	;	Crystal structure of mpy-RNase J (mutant S247A), an archaeal RNase J from Methanolobus psychrophilus R15, in complex with 6 nt RNA
5HAA	;	2.904	;	Crystal structure of mpy-RNase J, an archaeal RNase J from Methanolobus psychrophilus R15
6O9A	;	2.326	;	Crystal structure of MqnA complexed with 3-hydroxybenzoic acid
3A3U	;	1.65	;	Crystal structure of MqnD (TTHA1568), a menaquinone biosynthetic enzyme from Thermus thermophilus HB8
2CZL	;	1.55	;	Crystal structure of MqnD (TTHA1568), a menaquinone biosynthetic enzyme from Thermus thermophilus HB8 (Cys11 modified with beta-mercaptoethanol)
6OZ6	;	3.7	;	Crystal structure of MraY bound to 3'-hydroxymureidomycin A
8CXR	;	3.65	;	Crystal structure of MraY bound to a sphaerimicin analogue
6OYZ	;	3.62	;	Crystal structure of MraY bound to capuramycin
6OYH	;	2.95	;	Crystal structure of MraY bound to carbacaprazamycin
5CKR	;	2.95	;	Crystal Structure of MraY in complex with Muraymycin D2
3THN	;	2.811	;	Crystal structure of Mre11 core with manganese
2Q8U	;	2.2	;	CRYSTAL STRUCTURE OF MRE11 FROM THERMOTOGA MARITIMA MSB8 (TM1635) AT 2.20 A RESOLUTION
3AUZ	;	3.206	;	Crystal structure of Mre11 with manganese
1S8E	;	2.3	;	Crystal structure of Mre11-3
3AV0	;	3.1	;	Crystal structure of Mre11-Rad50 bound to ATP S
3THO	;	2.6081	;	Crystal structure of Mre11:Rad50 in its ATP/ADP bound state
7BVY	;	2.5	;	Crystal structure of MreB 5 of Spiroplasma citri bound to AMPPNP
7ZPT	;	1.8	;	Crystal structure of MreB from Geobacillus stearothermophilus ATCC7953
8AAM	;	2.29	;	Crystal structure of MreB from Geobacillus stearothermophilus ATCC7953
7ZPU	;	1.96	;	Crystal structure of MreB from Geobacillus stearothermophilus ATCC7953 in complex with ATP
8AZG	;	2.29	;	Crystal structure of MreB from Geobacillus stearothermophilus ATCC7953 in complex with ATP
8AB4	;	2.22	;	Crystal structure of MreB from Geobacillus stearothermophilus ATCC7953 in complex with GTP
7BVZ	;	2.3	;	Crystal structure of MreB5 of Spiroplasma citri bound to ADP
6ZM0	;	1.471	;	Crystal structure of MreC from Pseudomonas aeruginosa
6WBH	;	2.455	;	Crystal structure of mRECK(CC4) in fusion with engineered MBP at medium resolution
2F5J	;	2.2	;	Crystal structure of MRG domain from human MRG15
6AGO	;	3.103	;	Crystal structure of MRG15-ASH1L Histone methyltransferase complex
6OKO	;	2.1	;	Crystal structure of mRIPK3 complexed with N-(3-fluoro-4-{1H-pyrrolo[2,3-b]pyridin-4-yloxy}phenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide
8JED	;	2.16	;	Crystal structure of mRNA cap (guanine-N7) methyltransferase E12 subunit from monkeypox virus and discovery of its inhibitors
3EPP	;	2.41	;	Crystal structure of mRNA cap guanine-N7 methyltransferase (RNMT) in complex with sinefungin
5E8J	;	2.35	;	Crystal structure of mRNA cap guanine-N7 methyltransferase in complex with RAM
3BGV	;	2.3	;	Crystal structure of mRNA cap guanine-N7 methyltransferase in complex with SAH
5E9W	;	2.283	;	Crystal structure of mRNA cap guanine-N7 methyltransferase obtained by limited proteolysis
1VLR	;	1.83	;	Crystal structure of mRNA decapping enzyme (DcpS) from Mus musculus at 1.83 A resolution
5H87	;	2.24	;	Crystal structure of mRojoA mutant - P63H - W143S
5H89	;	1.76	;	Crystal structure of mRojoA mutant - T16V - P63Y - W143G - L163V
5H88	;	2.06	;	Crystal structure of mRojoA mutant - T16V -P63F - W143A - L163V
4NWB	;	1.8	;	Crystal structure of Mrt4
2DUK	;	2.62	;	Crystal structure of MS0616
2DTC	;	1.7	;	Crystal structure of MS0666
2YY0	;	2.4	;	Crystal Structure of MS0802, c-Myc-1 binding protein domain from Homo sapiens
2YVR	;	1.8	;	Crystal structure of MS1043
1BMS	;	2.7	;	CRYSTAL STRUCTURE OF MS2 CAPSIDS WITH MUTATIONS IN THE SUBUNIT FG LOOP
1MST	;	2.6	;	CRYSTAL STRUCTURE OF MS2 CAPSIDS WITH MUTATIONS IN THE SUBUNIT FG LOOP
1MSC	;	2.0	;	CRYSTAL STRUCTURE OF MS2 COAT PROTEIN DIMER
6L77	;	1.9	;	Crystal structure of MS5 from Brassica napus
4JKZ	;	1.8	;	Crystal structure of ms6564 from mycobacterium smegmatis
4JL3	;	2.5	;	Crystal structure of ms6564-dna complex
5B6O	;	2.202	;	Crystal structure of MS8104
3B5Z	;	4.2	;	Crystal Structure of MsbA from Salmonella typhimurium with ADP Vanadate
3B5Y	;	4.5	;	Crystal Structure of MsbA from Salmonella typhimurium with AMPPNP
3B60	;	3.7	;	Crystal Structure of MsbA from Salmonella typhimurium with AMPPNP, higher resolution form
3B5X	;	5.5	;	Crystal Structure of MsbA from Vibrio cholerae
5EHX	;	2.1	;	Crystal structure of MSF-aged Torpedo californica Acetylcholinesterase
5EI5	;	2.1	;	Crystal structure of MSF-aged Torpedo californica Acetylcholinesterase in complex with alkylene-linked bis-tacrine dimer (7 carbon linker)
4EWL	;	1.85	;	Crystal Structure of MshB with glycerol and Acetate bound in the active site
4WAN	;	1.8	;	Crystal structure of Msl5 protein in complex with RNA at 1.8 A
4F3F	;	2.65	;	Crystal Structure of Msln7-64 MORAb-009 FAB complex
6OWN	;	1.95	;	Crystal structure of Msm DnaB1 intein splicing domain bound with zinc
4ZRC	;	2.7	;	Crystal structure of MSM-13, a putative T1-like thiolase from Mycobacterium smegmatis
5BYV	;	2.162	;	Crystal structure of MSM-13, a putative T1-like thiolase from Mycobacterium smegmatis
5XKP	;	3.0	;	Crystal structure of Msmeg3575 in complex with 5-azacytosine
5XKQ	;	2.7	;	Crystal structure of Msmeg3575 in complex with ammeline
5XKR	;	1.38	;	Crystal structure of Msmeg3575 in complex with benzoguanamine
5E7P	;	2.507	;	Crystal Structure of MSMEG_0858 (Uniprot A0QQS4), a AAA ATPase.
6HB0	;	1.9	;	Crystal structure of MSMEG_1712 from Mycobacterium smegmatis
6HBM	;	2.76	;	Crystal structure of MSMEG_1712 from Mycobacterium smegmatis in complex with alpha-L-arabinofuranose
6HYH	;	2.5	;	Crystal structure of MSMEG_1712 from Mycobacterium smegmatis in complex with Beta-D-Fucofuranose
6HBD	;	2.44	;	Crystal structure of MSMEG_1712 from Mycobacterium smegmatis in complex with Beta-D-Galactofuranose
5E0N	;	2.061	;	Crystal Structure of MSMEG_3139, a monofunctional enoyl CoA isomerase from M.smegmatis
7WA9	;	1.9	;	Crystal structure of MSMEG_5634 from Mycobacterium smegmatis
3AJA	;	2.9	;	Crystal Structure of MSMEG_6394
5T2V	;	1.9	;	Crystal structure of MSMEG_6753 a putative betaketoacyl-ACP reductase
6YEV	;	2.94	;	Crystal structure of MsrA C206 and Trx C35S complex from Escherichia coli
7OT4	;	2.19	;	Crystal structure of MsrA variant C198C206 from Escherichia coli, oxidized
3E0O	;	2.6	;	Crystal structure of MsrB
1HXR	;	1.65	;	CRYSTAL STRUCTURE OF MSS4 AT 1.65 ANGSTROMS
3COM	;	2.2	;	Crystal structure of Mst1 kinase
5DH3	;	2.468	;	Crystal structure of MST2 in complex with XMU-MP-1
8A66	;	1.901	;	Crystal structure of MST2 in complex with XMU-MP-1
4U8Z	;	1.63	;	Crystal structure of MST3 with a pyrrolopyrimidine inhibitor (PF-06447475)
4W8D	;	1.77	;	Crystal structure of MST3 with a pyrrolopyrimidine inhibitor (PF-06454589).
4O27	;	3.185	;	Crystal structure of MST3-MO25 complex with WIF motif
4GEH	;	1.95	;	Crystal structure of MST4 dimerization domain complex with PDCD10
4FZA	;	3.15	;	Crystal structure of MST4-MO25 complex
4FZF	;	3.64	;	Crystal structure of MST4-MO25 complex with DKI
4FZD	;	3.25	;	Crystal structure of MST4-MO25 complex with WSF motif
4LOJ	;	1.77	;	Crystal structure of mSting in complex with c[G(2',5')pA(3',5')p]
4LOK	;	2.07	;	Crystal structure of mSting in complex with c[G(3',5')pA(3',5')p]
4LOL	;	2.43	;	Crystal structure of mSting in complex with DMXAA
2H5R	;	1.6	;	Crystal structure of mStrawberry at pH 10.5
2H5P	;	1.21	;	Crystal structure of mStrawberry at pH 9.5
5TFV	;	2.54	;	Crystal Structure of MT-I isolated from Bothrops asper venom.
3NCL	;	1.19	;	Crystal Structure of MT-SP1 bound to Benzamidine Phosphonate Inhibitor
3P8G	;	1.2	;	Crystal Structure of MT-SP1 in complex with benzamidine
3BN9	;	2.173	;	Crystal Structure of MT-SP1 in complex with Fab Inhibitor E2
3P8F	;	2.0	;	Crystal Structure of MT-SP1 in complex with SFTI-1
1Z5O	;	2.0	;	Crystal structure of MTA/AdoHcy nucleosidase Asp197Asn mutant complexed with 5'-methylthioadenosine
1Y6R	;	2.2	;	Crystal structure of MTA/AdoHcy nucleosidase complexed with MT-ImmA.
1Z5N	;	2.1	;	Crystal structure of MTA/AdoHcy nucleosidase Glu12Gln mutant complexed with 5-methylthioribose and adenine
1Z5P	;	2.0	;	Crystal structure of MTA/AdoHcy nucleosidase with a ligand-free purine binding site
7F4R	;	1.83	;	Crystal structure of MTA1
7F4L	;	2.72	;	Crystal structure of MTA1-p1-p2 complex
7F4O	;	3.1	;	Crystal structure of MTA1-p2 complex
1R8D	;	2.7	;	Crystal Structure of MtaN Bound to DNA
1JBG	;	2.75	;	Crystal Structure of MtaN, the Bacillus subtilis Multidrug Transporter Activator, N-terminus
6OZ8	;	2.7	;	Crystal structure of Mtb aspartate decarboxylase in active form
6P1Y	;	2.33	;	Crystal structure of Mtb aspartate decarboxylase mutant M117I
6P02	;	2.25	;	Crystal structure of Mtb aspartate decarboxylase, 6-Chlorine pyrazinoic acid complex
6OYY	;	2.7	;	Crystal structure of Mtb aspartate decarboxylase, pyrazinoic acid complex
4JR4	;	2.498	;	Crystal structure of Mtb DsbA (Oxidized)
4IR7	;	2.8	;	Crystal Structure of Mtb FadD10 in Complex with Dodecanoyl-AMP
4WOU	;	2.122	;	Crystal Structure of Mtb PEPCK in complex with GDP and metals
4WL8	;	1.61	;	Crystal Structure of Mtb PEPCK in complex with non-hydrolyzable analog of GTP
4WPT	;	1.6	;	Crystal Structure of Mtb PEPCK in complex with PEP
7M7V	;	2.29	;	Crystal Structure of Mtb Pks13 Thioesterase domain in complex with Compound 6
5V3X	;	1.936	;	Crystal Structure of Mtb Pks13 Thioesterase domain in complex with inhibitor TAM1
5V3Y	;	1.98	;	Crystal Structure of Mtb Pks13 Thioesterase domain in complex with inhibitor TAM16
5V42	;	1.987	;	Crystal Structure of Mtb Pks13 Thioesterase domain in complex with inhibitor TAM3
5V41	;	2.051	;	Crystal Structure of Mtb Pks13 Thioesterase domain in complex with inhibitor TAM5
5V40	;	1.991	;	Crystal Structure of Mtb Pks13 Thioesterase domain in complex with inhibitor TAM6
7VJT	;	1.94	;	Crystal Structure of Mtb Pks13-TE in complex with inhibitor coumestan derivative 8
6TYE	;	3.79	;	Crystal structure of MTB sigma L transcription initiation complex with 5 nt long RNA primer
6TYF	;	3.8	;	Crystal structure of MTB sigma L transcription initiation complex with 6 nt long RNA primer
6TYG	;	3.5	;	Crystal structure of MTB sigma L transcription initiation complex with 9 nt long RNA primer
4FOG	;	2.4	;	Crystal Structure of Mtb ThyA in Complex with 5-Fluoro-dUMP and 5-methyltetrahydrofolic acid
4FOX	;	2.3	;	Crystal Structure of Mtb ThyA in complex with dUMP and Raltitrexed
5CCA	;	3.2	;	Crystal structure of Mtb toxin
4I14	;	3.0	;	Crystal Structure of Mtb-ribA2 (Rv1415)
4PCQ	;	2.95	;	Crystal Structure of MtbAldR (Rv2779c)
3I54	;	2.2	;	Crystal structure of MtbCRP in complex with cAMP
3I59	;	2.29	;	Crystal structure of MtbCRP in complex with N6-cAMP
7OZM	;	2.15	;	Crystal Structure of mtbMGL K74A (Closed Cap Conformation)
7P0Y	;	2.25	;	Crystal Structure of mtbMGL K74A (Substrate Analog Complex)
1A1X	;	2.0	;	CRYSTAL STRUCTURE OF MTCP-1 INVOLVED IN T CELL MALIGNANCIES
7XPU	;	2.2	;	crystal structure of MtdL-S228A-His soaked GDP-Fucp and Mn
6SBA	;	1.3	;	Crystal Structure of mTEAD with a VGL4 Tertiary Structure Mimetic
5EXH	;	1.3	;	Crystal structure of mTET3-CXXC domain in complex with 5-carboxylcytosine DNA at 1.3 Angstroms resolution.
7VT8	;	2.99	;	Crystal structure of MtGlu5 from Meiothermus taiwanensis WR-220
6AA3	;	2.001	;	Crystal structure of MTH1 in apo form (cocktail No. 1)
6IMZ	;	2.1	;	Crystal structure of MTH1 in complex with 18-Crown-6
6AA5	;	1.901	;	Crystal structure of MTH1 in complex with 3-isomangostin
6AA4	;	1.9	;	Crystal structure of MTH1 in complex with alpha-mangostin (cocktail No. 9)
7N03	;	1.13	;	Crystal structure of MTH1 in complex with compound 31
7N13	;	1.59	;	Crystal structure of MTH1 in complex with compound 32
7BGM	;	1.6	;	Crystal structure of MtHISN2, a bifunctional enzyme from the histidine biosynthetic pathway
7BGN	;	2.7	;	Crystal structure of MtHISN2-AMP complex, a bifunctional enzyme from the histidine biosynthetic pathway
1LNQ	;	3.3	;	CRYSTAL STRUCTURE OF MTHK AT 3.3 A
4RO0	;	3.18	;	Crystal structure of MthK gating ring in a ligand-free form
4HYO	;	1.65	;	Crystal Structure of MthK Pore
2FY8	;	2.79	;	Crystal structure of MthK rck domain in its ligand-free gating-ring form
2WBM	;	1.75	;	Crystal structure of mthSBDS, the homologue of the Shwachman-Bodian- Diamond syndrome protein in the euriarchaeon Methanothermobacter thermautotrophicus
2R47	;	1.88	;	Crystal structure of MTH_862 protein of unknown function from Methanothermobacter thermautotrophicus
4R1E	;	1.98	;	Crystal Structure of MTIP from Plasmodium falciparum in complex with a peptide-fragment chimera
4MZL	;	2.01	;	Crystal Structure of MTIP from Plasmodium falciparum in complex with HBS myoA, a hydrogen bond surrogate myoA helix mimetic
4MZJ	;	1.474	;	Crystal Structure of MTIP from Plasmodium falciparum in complex with pGly[801,805], a stapled myoA tail peptide
4MZK	;	1.82	;	Crystal Structure of MTIP from Plasmodium falciparum in complex with pGly[807,811], a stapled myoA tail peptide
5JXR	;	2.404	;	Crystal structure of MtISWI
5JXT	;	3.009	;	Crystal structure of MtISWI bound with histone H4 tail
5JNM	;	1.701	;	Crystal structure of MtlD from Staphylococcus aureus at 1.7-Angstrom resolution
4RV9	;	2.2	;	Crystal structure of MtmC in complex with SAH
4RVH	;	2.4	;	Crystal structure of MtmC in complex with SAH and TDP-4-keto-D-olivose
4RVD	;	2.2	;	Crystal structure of MtmC in complex with SAM
4RVG	;	2.3	;	Crystal structure of MtmC in complex with SAM and TDP
4RVF	;	2.7	;	Crystal structure of MtmC in complex with TDP
1ZVR	;	1.98	;	Crystal Structure of MTMR2 in complex with phosphatidylinositol 3,5-bisphosphate
1ZSQ	;	1.82	;	Crystal Structure of MTMR2 in complex with phosphatidylinositol 3-phosphate
4Y7I	;	2.802	;	Crystal Structure of MTMR8
3FPF	;	1.66	;	Crystal Structure of MtNAS in complex with MTA and tNA
3FPE	;	1.7	;	Crystal Structure of MtNAS in complex with thermonicotianamine
2FEA	;	2.0	;	Crystal structure of MtnX phosphatase from Bacillus Subtilis at 2.00 A resolution
6GDJ	;	1.5	;	Crystal structure of Mto2 twin-cysteine dimerisation domain
3JBZ	;	28.0	;	Crystal structure of mTOR docked into EM map of dimeric ATM kinase
5WBU	;	3.42	;	Crystal structure of mTOR(deltaN)-mLST8-PRAS40(alpha-helix & beta-strand) complex
5WBY	;	3.1	;	Crystal structure of mTOR(deltaN)-mLST8-PRAS40(beta-strand) complex
5A2V	;	1.82	;	Crystal structure of mtPAP in Apo form
5A2W	;	2.5	;	Crystal structure of mtPAP in complex with ATPgammaS
5A2X	;	3.1	;	Crystal structure of mtPAP in complex with CTP
5A2Z	;	2.45	;	Crystal structure of mtPAP in complex with GTP
5A2Y	;	2.75	;	Crystal structure of mtPAP in complex with UTP
5A30	;	2.75	;	Crystal structure of mtPAP N472D mutant in complex with ATPgammaS
6YFV	;	2.75	;	Crystal structure of Mtr4-Red1 minimal complex from Chaetomium thermophilum
6QYC	;	2.29	;	Crystal structure of MtrC from Shewanella baltica OS185
2OA8	;	2.1	;	Crystal Structure of mTREX1 with ssDNA
8HCE	;	1.501	;	Crystal structure of mTREX1-CMP complex
8HCG	;	1.799	;	Crystal structure of mTREX1-dAMP complex
8HCD	;	2.0	;	Crystal structure of mTREX1-DNA product complex (dNMP)
8HCC	;	2.0	;	Crystal structure of mTREX1-RNA product complex (AMP)
8HCF	;	1.6	;	Crystal structure of mTREX1-UMP complex
8HCH	;	2.0	;	Crystal structure of mTREX1-Uridine complex
5HZR	;	2.33	;	Crystal structure of MtSnf2
1EAX	;	1.3	;	Crystal structure of MTSP1 (matriptase)
2IMZ	;	1.7	;	Crystal structure of Mtu recA intein splicing domain
2IN0	;	1.6	;	crystal structure of Mtu recA intein splicing domain
2IN8	;	1.7	;	crystal structure of Mtu recA intein, splicing domain
2IN9	;	1.8	;	crystal structure of Mtu recA intein, splicing domain
3IFJ	;	1.9	;	Crystal structure of Mtu recA intein, splicing domain
3IGD	;	2.4	;	Crystal structure of Mtu recA intein, splicing domain
4K06	;	2.08	;	Crystal structure of MTX-II from Bothrops brazili venom complexed with polyethylene glycol
3GUR	;	2.5	;	Crystal Structure of mu class glutathione S-transferase (GSTM2-2) in complex with glutathione and 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX)
4MT5	;	2.6	;	Crystal structure of Mub-RV
6IN8	;	2.2	;	Crystal structure of MucB
6IN9	;	1.801	;	Crystal structure of MucB in complex with MucA(peri)
8K2Y	;	2.7	;	Crystal structure of MucD
4WLQ	;	2.85	;	Crystal structure of mUCH37-hRPN13 CTD complex
4WLR	;	1.997	;	Crystal Structure of mUCH37-hRPN13 CTD-hUb complex
3I6T	;	1.9	;	Crystal structure of muconate cycloisomerase from Jannaschia sp.
3CT2	;	1.8	;	Crystal structure of muconate cycloisomerase from Pseudomonas fluorescens
2ZAD	;	1.6	;	Crystal Structure of Muconate Cycloisomerase from Thermotoga maritima MSB8
3I4K	;	2.2	;	Crystal structure of Muconate lactonizing enzyme from Corynebacterium glutamicum
3FCP	;	1.8	;	Crystal structure of Muconate lactonizing enzyme from Klebsiella pneumoniae
3DG3	;	1.6	;	Crystal structure of muconate lactonizing enzyme from Mucobacterium Smegmatis
3DG6	;	1.6	;	Crystal structure of muconate lactonizing enzyme from Mucobacterium Smegmatis complexed with muconolactone
3DG7	;	2.0	;	Crystal structure of muconate lactonizing enzyme from Mucobacterium Smegmatis complexed with muconolactone
3DGB	;	1.7	;	Crystal structure of muconate lactonizing enzyme from Pseudomonas Fluorescens complexed with muconolactone
3FJ4	;	1.8	;	Crystal structure of muconate lactonizing enzyme from Pseudomonas Fluorescens complexed with muconolactone
3I6E	;	1.7	;	CRYSTAL STRUCTURE OF MUCONATE LACTONIZING ENZYME FROM Ruegeria pomeroyi.
1MLI	;	3.3	;	CRYSTAL STRUCTURE OF MUCONOLACTONE ISOMERASE AT 3.3 ANGSTROMS RESOLUTION
5EM0	;	1.1	;	Crystal structure of mugwort allergen Art v 4
3EUK	;	4.0	;	Crystal structure of MukE-MukF(residues 292-443)-MukB(head domain)-ATPgammaS complex, asymmetric dimer
3EUJ	;	3.1	;	Crystal structure of MukE-MukF(residues 292-443)-MukB(head domain)-ATPgammaS complex, symmetric dimer
1T98	;	2.9	;	Crystal Structure of MukF(1-287)
6XIZ	;	1.8	;	Crystal structure of multi-copper oxidase from Pediococcus acidilactici
6XJ0	;	2.34	;	Crystal structure of multi-copper oxidase from Pediococcus pentosaceus
6VOX	;	3.8	;	Crystal structure of multi-copper oxidase from Pseudomonas Parafulva
6VOW	;	1.92	;	Crystal structure of multi-copper oxidase from Pseudomonas Thermotolerans
5UAN	;	3.508	;	Crystal structure of multi-domain RAR-beta-RXR-alpha heterodimer on DNA
5T2E	;	1.5	;	Crystal Structure of multi-drug resistant HIV-1 protease PR-S17
6O54	;	1.21	;	Crystal Structure of multi-drug resistant HIV-1 protease PR-S17 (D25N)
5T2Z	;	1.5	;	Crystal Structure of Multi-drug Resistant HIV-1 Protease PR-S17 in Complex with Darunavir
6O57	;	1.71	;	Crystal Structure of multi-drug resistant HIV-1 protease PR-S17 with a substrate analog p2-NC in P41
6O5A	;	1.67	;	Crystal Structure of multi-drug resistant HIV-1 protease PR-S17 with a substrate analog p2-NC in P61
6O5X	;	1.7	;	Crystal Structure of multi-drug resistant HIV-1 protease PR-S17 with substrate analog CA-p2
7FHX	;	2.63	;	Crystal structure of Multi-functional Polysaccharide lyase Smlt1473 (WT) from Stenotrophomonas maltophilia (strain K279a) in apo form at pH 5.0
7FHV	;	2.28	;	Crystal structure of Multi-functional Polysaccharide lyase Smlt1473 (WT) from Stenotrophomonas maltophilia (strain K279a) in apo form at pH 6.5
7FHY	;	2.2	;	Crystal structure of Multi-functional Polysaccharide lyase Smlt1473 (WT) from Stenotrophomonas maltophilia (strain K279a) in apo form at pH 7.0
7FHZ	;	2.5	;	Crystal structure of Multi-functional Polysaccharide lyase Smlt1473 (WT) from Stenotrophomonas maltophilia (strain K279a) in apo form at pH 9.0
7FI0	;	2.31	;	Crystal structure of Multi-functional Polysaccharide lyase Smlt1473 (WT) from Stenotrophomonas maltophilia (strain K279a) in ManA bound form at pH-5.0
7FI1	;	2.43	;	Crystal structure of Multi-functional Polysaccharide lyase Smlt1473 (WT) from Stenotrophomonas maltophilia (strain K279a) in ManA bound form at pH-7.0
7FHW	;	2.061	;	Crystal structure of Multi-functional Polysaccharide lyase Smlt1473 from Stenotrophomonas maltophilia (strain K279a) in apo form at pH 5.5
7FHU	;	2.43	;	Crystal structure of Multi-functional Polysaccharide lyase Smlt1473 from Stenotrophomonas maltophilia (strain K279a) in apo form at pH 8.5
7FI2	;	2.6	;	Crystal structure of Multi-functional Polysaccharide lyase Smlt1473-H168A from Stenotrophomonas maltophilia (strain K279a) at pH-5.0
3GDC	;	1.8	;	Crystal structure of multicopper oxidase
5YS1	;	1.49	;	Crystal structure of Multicopper Oxidase CueO G304K mutant
5YS5	;	2.2	;	Crystal structure of Multicopper Oxidase CueO G304K mutant with seven copper ions
7WW4	;	2.23006	;	Crystal structure of multidomain beta-1,3(4)-glucanase
3EZU	;	1.95	;	Crystal structure of multidomain protein of unknown function with GGDEF-domain (NP_951600.1) from GEOBACTER SULFURREDUCENS at 1.95 A resolution
5K9O	;	3.387	;	Crystal structure of multidonor HV1-18+HD3-9 class broadly neutralizing Influenza A antibody 31.b.09 in complex with Hemagglutinin H1 A/California/04/2009
5K9Q	;	2.503	;	Crystal structure of multidonor HV1-18-class broadly neutralizing Influenza A antibody 16.a.26 in complex with A/Hong Kong/1-4-MA21-1/1968 (H3N2) Hemagglutinin
5KAN	;	2.785	;	Crystal structure of multidonor HV1-18-class broadly neutralizing Influenza A antibody 16.g.07 in complex with A/Hong Kong/1-4-MA21-1/1968 (H3N2) Hemagglutinin
5K9K	;	2.97	;	Crystal structure of multidonor HV6-1-class broadly neutralizing Influenza A antibody 56.a.09 in complex with Hemagglutinin Hong Kong 1968.
5K9J	;	1.904	;	Crystal structure of multidonor HV6-1-class broadly neutralizing Influenza A antibody 56.a.09 isolated following H5 immunization.
3HTJ	;	2.7	;	Crystal structure of multidrug binding protein EbrR complexed with ethidium
3HTA	;	2.3	;	Crystal structure of multidrug binding protein EbrR complexed with imidazole
3HTI	;	2.5	;	Crystal structure of multidrug binding protein EbrR complexed with malachite green
3HTH	;	2.7	;	Crystal structure of multidrug binding protein EbrR complexed with proflavin
2HQ5	;	2.8	;	Crystal structure of multidrug binding protein QacR from Staphylococcus aureus cocrystallized with compound DB359
2DTZ	;	2.8	;	Crystal Structure of multidrug binding protein QacR from Staphylococcus aureus cocrystallized with compound DB75
3F8F	;	2.2	;	Crystal structure of multidrug binding transcriptional regulator LmrR complexed with Daunomycin
3F8C	;	2.2	;	Crystal structure of multidrug binding transcriptional regulator LmrR complexed with Hoechst 33342
7CZ9	;	1.85	;	Crystal structure of multidrug efflux transporter OqxB from Klebsiella pneumoniae
4ZZD	;	2.351	;	CRYSTAL STRUCTURE OF MULTIDRUG RESISTANCE REGULATOR LMRR BOUND TO RIBOFLAVIN
4YHQ	;	1.3	;	Crystal structure of multidrug resistant clinical isolate PR20 with GRL-5010A
3UF3	;	1.63	;	Crystal Structure of Multidrug Resistant HIV-1 Protease Clinical isolate PR20
4J5J	;	1.8	;	Crystal Structure of Multidrug Resistant HIV-1 Protease Clinical Isolate PR20 in Complex with Amprenavir
3UCB	;	1.38	;	Crystal Structure of Multidrug Resistant HIV-1 Protease Clinical Isolate PR20 in Complex with Darunavir
3UHL	;	2.2	;	Crystal Structure of Multidrug Resistant HIV-1 Protease Clinical Isolate PR20 in Complex with p2-NC substrate analog
3UFN	;	1.45	;	Crystal Structure of Multidrug Resistant HIV-1 Protease Clinical Isolate PR20 in Complex with Saquinavir
4YE3	;	1.35	;	Crystal Structure of Multidrug Resistant HIV-1 Protease Clinical Isolate PR20 with Inhibitor GRL-4410A
4J55	;	1.31	;	Crystal Structure of Multidrug Resistant HIV-1 Protease Clinical isolate PR20 with the potent antiviral inhibitor GRL-02031
4J54	;	1.55	;	Crystal Structure of Multidrug Resistant HIV-1 Protease Clinical isolate PR20 with the potent antiviral inhibitor GRL-0519A
4Z4X	;	1.75	;	Crystal Structure of Multidrug Resistant HIV-1 Protease Clinical Isolate PR20D25N with Open Flap
4Z50	;	1.45	;	Crystal Structure of Multidrug Resistant HIV-1 Protease Clinical Isolate PR20D25N with Tucked Flap
4EYR	;	1.8	;	Crystal structure of multidrug-resistant clinical isolate 769 HIV-1 protease in complex with ritonavir
4RVJ	;	1.6	;	Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with amprenavir
4NJT	;	1.95	;	Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with darunavir
4NJS	;	1.8	;	Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with non-peptidic inhibitor, GRL008
4RVI	;	1.99	;	Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with non-peptidic inhibitor, GRL0519
4RVX	;	1.955	;	Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with non-peptidic inhibitor, GRL079
4NJV	;	1.8	;	Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with ritonavir
4NJU	;	1.8	;	Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with tipranavir
2EX0	;	1.65	;	Crystal structure of multifunctional sialyltransferase from Pasteurella Multocida
2ILV	;	2.27	;	crystal structure of multifunctional sialyltransferase from Pasteurella multocida with CMP and alpha-lactose bound
2IHK	;	1.9	;	crystal structure of multifunctional sialyltransferase from pasteurella multocida with CMP-3F(equatorial)-Neu5Ac bound
2IHZ	;	2.0	;	Crystal structure of multifunctional sialyltransferase from pasteurella multocida with CMP-3F-Neu5Ac and alpha-lactose bound
2IHJ	;	2.0	;	crystal structure of multifunctional sialyltransferase from pasteurella multocida with CMP-3F-Neu5Ac bound
1WVL	;	2.6	;	Crystal Structure of Multimeric DNA-binding Protein Sac7d-GCN4 with DNA decamer
2QWW	;	2.07	;	Crystal structure of multiple antibiotic-resistance repressor (MarR) (YP_013417.1) from Listeria monocytogenes 4b F2365 at 2.07 A resolution
1WST	;	1.95	;	Crystal structure of multiple substrate aminotransferase (MsAT) from Thermococcus profundus
2D62	;	2.1	;	Crystal structure of multiple sugar binding transport ATP-binding protein
5B2C	;	2.238	;	Crystal structure of Mumps virus hemagglutinin-neuraminidase
5B2D	;	2.177	;	Crystal structure of Mumps virus hemagglutinin-neuraminidase bound to 3-sialyllactose
6JJN	;	2.5	;	Crystal structure of Mumps virus hemagglutinin-neuraminidase bound to sialyl lewisX
6JJM	;	2.049	;	Crystal structure of Mumps virus hemagglutinin-neuraminidase bound to the oligosaccharide portion of the GM2 ganglioside
4Y21	;	2.9	;	Crystal Structure of Munc13-1 MUN domain
5UF7	;	2.896	;	CRYSTAL STRUCTURE OF MUNC13-1 MUN DOMAIN
6A30	;	2.793	;	Crystal Structure of Munc13-1 MUN Domain and Synaptobrevin-2 Juxtamembrane Linker Region
4JEH	;	2.5	;	Crystal Structure of Munc18a and Syntaxin1 lacking N-peptide complex
4JEU	;	3.2	;	Crystal Structure of Munc18a and Syntaxin1 with native N-terminus complex
1SBW	;	1.8	;	CRYSTAL STRUCTURE OF MUNG BEAN INHIBITOR LYSINE ACTIVE FRAGMENT COMPLEX WITH BOVINE BETA-TRYPSIN AT 1.8A RESOLUTION
1D02	;	1.7	;	CRYSTAL STRUCTURE OF MUNI RESTRICTION ENDONUCLEASE IN COMPLEX WITH COGNATE DNA
4XH7	;	1.65	;	Crystal structure of MUPP1 PDZ4
5DTH	;	1.95	;	Crystal structure of MUPP1 PDZ8 domain from rattus norvegicus
6FXD	;	1.45	;	Crystal structure of MupZ from Pseudomonas fluorescens
6Q03	;	1.7	;	Crystal structure of MurA from Clostridium difficile in the presence of UDP-N-acetyl-alpha-D-muramic acid with modified Cys116 (S-[(1S)-1-carboxy-1-(phosphonooxy)ethyl]-L-cysteine)
6Q0Y	;	1.7	;	Crystal structure of MurA from Clostridium difficile, mutant C116S, in the presence of Uridine-Diphosphate-N-Acetylglucosamine
6Q0A	;	1.65	;	Crystal structure of MurA from Clostridium difficile, mutation C116D, n the presence of UDP-N-acetylmuramic acid
6Q11	;	1.8	;	Crystal structure of MurA from Clostridium difficile, mutation C116S, in the presence of URIDINE-DIPHOSPHATE-2(N-ACETYLGLUCOSAMINYL) BUTYRIC ACID
6ET6	;	1.2	;	Crystal structure of muramidase from Acinetobacter baumannii AB 5075UW prophage
6UUK	;	2.348	;	Crystal structure of muramoyltetrapeptide carboxypeptidase from Oxalobacter formigenes
5A5E	;	1.84	;	CRYSTAL STRUCTURE OF MURD LIGASE FROM ESCHERICHIA COLI
5A5F	;	1.9	;	CRYSTAL STRUCTURE OF MURD LIGASE FROM ESCHERICHIA COLI IN COMPLEX WITH UMA AND ADP
4BUC	;	2.17	;	CRYSTAL STRUCTURE OF MURD LIGASE FROM THERMOTOGA MARITIMA IN APO FORM
2WJP	;	1.6	;	CRYSTAL STRUCTURE OF MURD LIGASE IN COMPLEX WITH D-GLU CONTAINING RHODANINE INHIBITOR
2JFF	;	1.89	;	Crystal structure of MurD ligase in complex with D-Glu containing sulfonamide inhibitor
2UUO	;	2.5	;	Crystal structure of MurD ligase in complex with D-Glu containing sulfonamide inhibitor
2UUP	;	1.88	;	Crystal structure of MurD ligase in complex with D-Glu containing sulfonamide inhibitor
2VTD	;	1.94	;	Crystal structure of MurD ligase in complex with D-Glu containing sulfonamide inhibitor
2VTE	;	2.2	;	Crystal structure of MurD ligase in complex with D-Glu containing sulfonamide inhibitor
2JFH	;	1.97	;	Crystal structure of MurD ligase in complex with L-Glu containing sulfonamide inhibitor
2JFG	;	1.52	;	Crystal structure of MurD ligase in complex with UMA and ADP
7B53	;	1.75	;	Crystal structure of MurE from E.coli
7B6J	;	2.09	;	Crystal structure of MurE from E.coli in complex with minifrag succinimide
7B6M	;	1.67	;	Crystal structure of MurE from E.coli in complex with Z1198948504
7B60	;	1.91	;	Crystal structure of MurE from E.coli in complex with Z1269139261
7B6I	;	2.069	;	Crystal structure of MurE from E.coli in complex with Z1373445602
7B6G	;	1.937	;	Crystal structure of MurE from E.coli in complex with Z1675346324
7B9E	;	2.12	;	Crystal structure of MurE from E.coli in complex with Z275151340
7B6L	;	2.08	;	Crystal structure of MurE from E.coli in complex with Z57299368
7B61	;	1.65	;	Crystal structure of MurE from E.coli in complex with Z57299526
7B68	;	1.89	;	Crystal structure of MurE from E.coli in complex with Z57299526
7B6Q	;	1.82	;	Crystal structure of MurE from E.coli in complex with Z57299526
7B6K	;	1.838	;	Crystal structure of MurE from E.coli in complex with Z57715447
7B9W	;	1.82	;	Crystal structure of MurE from E.coli in complex with Z757284380
7B6N	;	1.79	;	Crystal structure of MurE from E.coli in complex with Z757284952
4BUB	;	2.9	;	CRYSTAL STRUCTURE OF MURE LIGASE FROM THERMOTOGA MARITIMA IN COMPLEX WITH ADP
5HXD	;	2.6	;	Crystal structure of murein-tripeptide amidase MpaA from Escherichia coli O157
3ZL8	;	1.65	;	CRYSTAL STRUCTURE OF MURF LIGASE FROM THERMOTOGA MARITIMA IN COMPLEX WITH ADP
3ZM5	;	2.94	;	CRYSTAL STRUCTURE OF MURF LIGASE IN COMPLEX WITH CYANOTHIOPHENE INHIBITOR
3ZM6	;	1.84	;	CRYSTAL STRUCTURE OF MURF LIGASE IN COMPLEX WITH CYANOTHIOPHENE INHIBITOR
1NLM	;	2.5	;	CRYSTAL STRUCTURE OF MURG:GLCNAC COMPLEX
5QIJ	;	2.65	;	CRYSTAL STRUCTURE OF MURINE 11B- HYDROXYSTEROIDDEHYDROGENASE COMPLEXED WITH 2-(3-(1-(4- CHLOROPHENYL)CYCLOPROPYL)-[1,2,4]TRIAZOLO[4,3-A]PYRIDIN-8- YL)PROPAN-2-OL
5PGZ	;	2.9	;	CRYSTAL STRUCTURE OF MURINE 11BETA- HYDROXYSTEROIDDEHYDROGENASE COMPLEXED WITH 2-[(5R,7S)-6-HYDROXY-2-PHENYLADAMANTAN-2-YL]-1-(3-HYDROXYAZETIDIN-1-YL)ETHAN-1-ONE (BMS-816336)
4X8J	;	2.35	;	Crystal Structure of murine 12F4 Fab monoclonal antibody against ADAMTS5
4Q6I	;	3.65	;	Crystal structure of murine 2D5 Fab, a potent anti-CD4 HIV-1-neutralizing antibody in complex with CD4
5WI8	;	2.95	;	Crystal structure of murine 4-1BB from HEK293T cells in P21 space group
5WJF	;	2.6	;	Crystal structure of murine 4-1BB from HEK293T cells in P21212 space group
6MKB	;	2.5	;	Crystal structure of murine 4-1BB ligand
5WIW	;	2.3	;	Crystal structure of murine 4-1BB N128A mutant from HEK293T cells in P43 space group
6MKZ	;	2.65	;	Crystal structure of murine 4-1BB/4-1BBL complex
4X80	;	2.6	;	Crystal Structure of murine 7B4 Fab monoclonal antibody against ADAMTS5
1GUK	;	2.9	;	CRYSTAL STRUCTURE OF MURINE ALPHA-CLASS GSTA4-4
3NH4	;	2.0	;	Crystal structure of murine aminoacylase 3
3NFZ	;	2.147	;	Crystal structure of murine aminoacylase 3 in complex with N-acetyl-L-tyrosine
3NH8	;	2.802	;	Crystal structure of murine aminoacylase 3 in complex with N-acetyl-S-1,2-dichlorovinyl-L-cysteine
3ZBV	;	1.64	;	Crystal Structure of murine Angiogenin-2
3ZBW	;	1.801	;	Crystal Structure of murine Angiogenin-3
1U5X	;	1.8	;	Crystal structure of murine APRIL at pH 5.0
1U5Y	;	2.3	;	Crystal structure of murine APRIL, pH 8.0
1FZQ	;	1.7	;	CRYSTAL STRUCTURE OF MURINE ARL3-GDP
8A1I	;	2.69	;	Crystal structure of murine Armc8 isoform beta
5LIA	;	1.92	;	Crystal structure of murine autotaxin in complex with a small molecule inhibitor
4I0K	;	2.97	;	Crystal structure of murine B7-H3 extracellular domain
2H3P	;	2.2	;	Crystal structure of murine carnitine acetyltransferase in complex with carnitine and acetyl-CoA
2H3U	;	1.9	;	Crystal structure of murine carnitine acetyltransferase in complex with carnitine and CoA
6NS7	;	2.4	;	Crystal structure of murine caspase-11
6C74	;	1.358	;	Crystal Structure of Murine CD300lf in complex with phosphocholine
1L6Z	;	3.32	;	CRYSTAL STRUCTURE OF MURINE CEACAM1A[1,4]: A CORONAVIRUS RECEPTOR AND CELL ADHESION MOLECULE IN THE CEA FAMILY
5VST	;	3.1	;	Crystal structure of murine CEACAM1b
4TZU	;	2.0	;	Crystal Structure of Murine Cereblon in Complex with Pomalidomide
4TZC	;	1.88	;	Crystal Structure of Murine Cereblon in Complex with Thalidomide
4BX3	;	2.193	;	Crystal Structure of murine Chronophin (Pyridoxal Phosphate Phosphatase)
5AES	;	2.751	;	Crystal Structure of murine Chronophin (Pyridoxal Phosphate Phosphatase) in Complex with a PNP-derived Inhibitor
4BX2	;	2.193	;	Crystal Structure of murine Chronophin (Pyridoxal Phosphate Phosphatase) in complex with Beryllium trifluoride
5X17	;	2.0	;	Crystal structure of murine CK1d in complex with ADP
1FFP	;	2.6	;	CRYSTAL STRUCTURE OF MURINE CLASS I H-2DB COMPLEXED WITH PEPTIDE GP33 (C9M/K1S)
1FFN	;	2.7	;	CRYSTAL STRUCTURE OF MURINE CLASS I H-2DB COMPLEXED WITH PEPTIDE GP33(C9M)
1FFO	;	2.65	;	CRYSTAL STRUCTURE OF MURINE CLASS I H-2DB COMPLEXED WITH SYNTHETIC PEPTIDE GP33 (C9M/K1A)
1BZ9	;	2.8	;	CRYSTAL STRUCTURE OF MURINE CLASS I MHC H2-DB COMPLEXED WITH A SYNTHETIC PEPTIDE P1027
1MUJ	;	2.15	;	Crystal structure of murine class II MHC I-Ab in complex with a human CLIP peptide
2AQ5	;	1.75	;	Crystal Structure of Murine Coronin-1
2B4E	;	2.3	;	Crystal Structure of Murine Coronin-1: monoclinic form
4M10	;	2.01	;	Crystal Structure of Murine Cyclooxygenase-2 Complex with Isoxicam
4M11	;	2.45	;	Crystal Structure of Murine Cyclooxygenase-2 Complex with Meloxicam
4RUT	;	2.16	;	crystal structure of murine cyclooxygenase-2 with 13-methyl-arachidonic Acid
2RMC	;	1.64	;	Crystal structure of murine cyclophilin C complexed with immunosuppressive drug cyclosporin A
6V3R	;	2.66	;	Crystal structure of murine cycloxygenase in complex with a harmaline analog, 4,9-dihydro-3H-pyrido[3,4-b]indole
6O16	;	2.875	;	Crystal structure of murine DHX37 in complex with RNA
1F5Q	;	2.5	;	CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
7E57	;	3.302	;	Crystal structure of murine GITR-GITRL complex
6N9N	;	3.3	;	Crystal structure of murine GSDMD
4RS0	;	2.807	;	Crystal Structure of Murine H90W Cyclooxygenase-2 Complexed with S-ibuprofen
5O9K	;	4.014	;	Crystal structure of Murine Histmaine-Releasing Factor (HRF/TCTP)
3KHO	;	3.11	;	Crystal structure of murine Ig-beta (CD79b) homodimer
3KHQ	;	1.7	;	Crystal structure of murine Ig-beta (CD79b) in the monomeric form
1QW4	;	2.4	;	Crystal Structure of Murine Inducible Nitric Oxide Synthase Oxygenase Domain in complex with N-omega-propyl-L-arginine.
3B5K	;	2.5	;	Crystal structure of murine interleukin-5
4PL3	;	2.9	;	Crystal structure of murine IRE1 in complex with MKC9989 inhibitor
4PL4	;	3.0	;	Crystal structure of murine IRE1 in complex with OICR464 inhibitor
4PL5	;	3.4	;	Crystal structure of murine IRE1 in complex with OICR573 inhibitor
5CHF	;	2.3	;	Crystal structure of murine ISG15 in space group P21212
5CGJ	;	3.36	;	Crystal structure of murine Keap1 in complex with RA839, a non-covalent small-molecule binder to Keap1 and selective activator of Nrf2 signalling.
1LDP	;	3.1	;	CRYSTAL STRUCTURE OF MURINE MHC CLASS I H-2LD WITH A MIXTURE OF BOUND PEPTIDES
5T7G	;	1.961	;	Crystal Structure of Murine MHC-I H-2Dd in complex with Murine Beta2-Microglobulin and a Variant of Peptide (PT9) of HIV gp120 MN Isolate (IGPGRAFYT)
5KD7	;	2.35	;	Crystal Structure of Murine MHC-I H-2Dd in complex with Murine Beta2-Microglobulin and a Variant of Peptide (PV9) of HIV gp120 MN Isolate (IGPGRAFYV)
5KD4	;	3.05	;	Crystal Structure of Murine MHC-I H-2Dd in complex with Murine Beta2-Microglobulin and a Variant of Peptide (PVI10) of HIV gp120 MN Isolate (IGPGRAFYVI)
6NK3	;	2.2	;	Crystal structure of murine Mxra8 ectodomain
7VMT	;	1.95001	;	Crystal structure of murine N-acetylglucosaminyl transferase IVa (GnT-IVa) lectin domain in unliganded form
5LAE	;	1.85	;	Crystal structure of murine N1-acetylpolyamine oxidase
5LGB	;	1.8	;	Crystal structure of murine N1-acetylpolyamine oxidase in complex with MDL72527
5LFO	;	1.66	;	Crystal structure of murine N1-acetylpolyamine oxidase in complex with N1-acetylspermine
3G8K	;	2.0	;	Crystal structure of murine natural killer cell receptor, Ly49L4
3G8L	;	2.5	;	Crystal structure of murine natural killer cell receptor, Ly49L4
1Q1F	;	1.5	;	Crystal structure of murine neuroglobin
5EOH	;	1.9	;	Crystal structure of murine neuroglobin at 270 MPa pressure
5EQM	;	2.05	;	Crystal structure of murine neuroglobin at 310 MPa pressure
5EET	;	2.0	;	Crystal structure of murine neuroglobin at ambient pressure
6I40	;	1.9	;	Crystal structure of murine neuroglobin bound to CO at 15K under illumination using optical fiber
6I3T	;	2.0	;	Crystal structure of murine neuroglobin bound to CO at 40 K.
4O1T	;	1.6	;	Crystal structure of murine neuroglobin mutant F106W
5F0B	;	2.146	;	Crystal structure of murine neuroglobin mutant F106W at 280 MPa pressure
5F2A	;	2.1	;	Crystal structure of murine neuroglobin mutant F106W at 310 MPa pressure
5EYS	;	1.75	;	Crystal structure of murine neuroglobin mutant F106W at ambient pressure
4MU5	;	1.8	;	Crystal structure of murine neuroglobin mutant M144W
5EV5	;	2.0	;	Crystal structure of murine neuroglobin mutant V101F at 150 MPa pressure
5EYJ	;	2.4	;	Crystal structure of murine neuroglobin mutant V101F at 240 MPa pressure
5EU2	;	2.0	;	Crystal structure of murine neuroglobin mutant V101F at ambient pressure
4NZI	;	2.1	;	Crystal structure of murine neuroglobin mutant V140W
5O18	;	1.86	;	Crystal structure of murine neuroglobin mutant V140W
5O1K	;	2.05	;	Crystal structure of murine neuroglobin mutant V140W under 20 bar xenon pressure
5O27	;	2.31	;	Crystal structure of murine neuroglobin mutant V140W under 30 bar xenon pressure
5O17	;	1.8	;	Crystal structure of murine neuroglobin under 100 bar krypton
6EYE	;	1.7	;	Crystal structure of murine neuroglobin under 150 bar krypton
5NVI	;	1.6	;	Crystal structure of murine neuroglobin under 50 bar argon pressure
5NW6	;	1.7	;	Crystal structure of murine neuroglobin under 50 bar krypton pressure
3GKT	;	1.86	;	Crystal structure of murine neuroglobin under Kr pressure
4G3F	;	1.642	;	Crystal structure of murine NF-kappaB inducing kinase (NIK) bound to a 2-(aminothiazoly)phenol (cmp2)
4G3E	;	2.5	;	Crystal structure of murine NF-kappaB inducing kinase (NIK) bound to a 6-alkynylindoline (cmp1)
5T8Q	;	2.63	;	Crystal structure of murine NF-kappaB inducing kinase (NIK) bound to aryl pyrrole fragment 17
5T8P	;	2.32	;	Crystal structure of murine NF-kappaB inducing kinase (NIK) bound to benzoxepin compound 2
5T8O	;	2.41	;	Crystal structure of murine NF-kappaB inducing kinase (NIK) bound to Imidazobenzoxepin Compound 3
6MYN	;	2.744	;	Crystal structure of murine NF-kappaB inducing kinase (NIK) bound to inhibitor R7
6G4Y	;	2.65	;	Crystal structure of murine NF-kappaB inducing kinase (NIK) in complex with compound 1a
6G4Z	;	2.84	;	Crystal structure of murine NF-kappaB inducing kinase (NIK) in complex with compound 2f
4G3G	;	2.5	;	Crystal structure of murine NF-kappaB inducing kinase (NIK) V408L bound to a 2-(aminothiazolyl)phenol (cmp3)
3GK9	;	1.8	;	Crystal structure of murine Ngb under Xe pressure
1JFM	;	2.85	;	CRYSTAL STRUCTURE OF MURINE NK CELL LIGAND RAE-1 BETA
4PP8	;	1.95	;	Crystal structure of murine NK cell ligand RAE-1 beta in complex with NKG2D
2GVL	;	2.1	;	Crystal Structure of Murine NMPRTase
6XW5	;	1.72	;	Crystal structure of murine norovirus P domain in complex with Nanobody NB-5820
6XW7	;	2.15	;	Crystal structure of murine norovirus P domain in complex with Nanobody NB-5829 and glycochenodeoxycholate (GCDCA)
6XW6	;	1.96	;	Crystal structure of murine norovirus P domain in complex with Nanobody NB-5853
6XW4	;	2.19	;	Crystal structure of murine norovirus P domain in complex with Nanobody NB-5867
3LQ6	;	2.0	;	Crystal Structure of Murine Norovirus Protruding (P) Domain
3SFG	;	2.209	;	crystal structure of murine norovirus RNA dependent RNA polymerase in complex with 2thiouridine(2TU)
3SFU	;	2.501	;	crystal structure of murine norovirus RNA dependent RNA polymerase in complex with ribavirin
3UPF	;	2.6	;	Crystal structure of murine norovirus RNA-dependent RNA polymerase bound to NF023
1F35	;	2.3	;	CRYSTAL STRUCTURE OF MURINE OLFACTORY MARKER PROTEIN
1JOB	;	2.4	;	Crystal Structure of Murine Olfactory Marker Protein in Spacegroup P3121
1JOD	;	3.2	;	Crystal Structure of Murine Olfactory Marker Protein in Spacegroup P43212
2HEY	;	2.0	;	Crystal structure of murine OX40L bound to human OX40
5M02	;	1.75	;	Crystal structure of murine P14 TCR / H-2Db with PF, modified gp33 peptide from LCMV
5M00	;	1.95	;	Crystal structure of murine P14 TCR complex with H-2Db and Y4A, modified gp33 peptide from LCMV
5M01	;	1.95	;	Crystal structure of murine P14 TCR/ H-2Db complex with PA, modified gp33 peptide from LCMV
6SB1	;	2.05	;	Crystal structure of murine perforin-2 P2 domain crystal form 1
6SB4	;	3.17	;	Crystal structure of murine perforin-2 P2 domain crystal form 2
8F69	;	2.2	;	Crystal structure of murine PolG2 dimer bound to DNA
8F6B	;	2.75	;	Crystal structure of murine PolG2 hexamer bound to DNA
5CPU	;	1.64	;	Crystal structure of murine polyomavirus PTA strain VP1
5CPX	;	1.87	;	Crystal structure of murine polyomavirus PTA strain VP1 in complex with the DSLNT glycan
5CPY	;	1.93	;	Crystal structure of murine polyomavirus PTA strain VP1 in complex with the GD1a glycan
5CPW	;	1.75	;	Crystal structure of murine polyomavirus PTA strain VP1 in complex with the GT1a glycan
5CQ0	;	1.9	;	Crystal structure of murine polyomavirus RA strain VP1 in complex with the GD1a glycan
5CPZ	;	1.71	;	Crystal structure of murine polyomavirus RA strain VP1 in complex with the GT1a glycan
5WNL	;	2.5	;	Crystal structure of murine receptor-interacting protein 4 (Ripk4) D143N bound to staurosporine
5WNK	;	3.11	;	Crystal structure of murine receptor-interacting protein 4 (Ripk4) D143N bound to TG100-115
5WNM	;	2.6	;	Crystal structure of murine receptor-interacting protein 4 (Ripk4) D143N bound to tozasertib (VX-680)
5WNI	;	2.65	;	Crystal structure of murine receptor-interacting protein kinase 4 (Ripk4) D143N in complex with ATP
5WNJ	;	2.55	;	Crystal structure of murine receptor-interacting protein kinase 4 (Ripk4) D143N in complex with lestaurtinib
2VXU	;	2.36	;	Crystal structure of murine reference antibody 125-2H Fab fragment
6ZFE	;	2.35	;	Crystal structure of murine S100A9 mutant C80A bound to calcium and zinc
3S26	;	1.8	;	Crystal Structure of Murine Siderocalin (Lipocalin 2, 24p3)
3U9P	;	2.8	;	Crystal Structure of Murine Siderocalin in Complex with an Fab Fragment
1EK2	;	3.0	;	CRYSTAL STRUCTURE OF MURINE SOLUBLE EPOXIDE HYDROLASE COMPLEXED WITH CDU INHIBITOR
1EK1	;	3.1	;	CRYSTAL STRUCTURE OF MURINE SOLUBLE EPOXIDE HYDROLASE COMPLEXED WITH CIU INHIBITOR
1CR6	;	2.8	;	CRYSTAL STRUCTURE OF MURINE SOLUBLE EPOXIDE HYDROLASE COMPLEXED WITH CPU INHIBITOR
1CQZ	;	2.8	;	CRYSTAL STRUCTURE OF MURINE SOLUBLE EPOXIDE HYDROLASE.
5DBX	;	2.5	;	Crystal structure of murine SPAK(T243D) in complex with AMPPNP
1JNP	;	2.5	;	Crystal Structure of Murine Tcl1 at 2.5 Resolution
1KEJ	;	3.0	;	Crystal Structure of Murine Terminal Deoxynucleotidyl Transferase complexed with ddATP
4GC5	;	1.801	;	Crystal structure of murine TFB1M
4GC9	;	2.103	;	Crystal structure of murine TFB1M in complex with SAM
2PUX	;	2.0	;	Crystal structure of murine thrombin in complex with the extracellular fragment of murine PAR3
2PV9	;	3.5	;	Crystal structure of murine thrombin in complex with the extracellular fragment of murine PAR4
3HK3	;	1.94	;	Crystal structure of murine thrombin mutant W215A/E217A (one molecule in the asymmetric unit)
3HK6	;	3.2	;	Crystal structure of murine thrombin mutant W215A/E217A (two molecules in the asymmetric unit)
3HKI	;	2.2	;	Crystal structure of murine thrombin mutant W215A/E217A in complex with the extracellular fragment of human PAR1
5JXD	;	2.029	;	Crystal structure of murine Tnfaip8 C165S mutant
7WAG	;	2.55	;	Crystal structure of MurJ squeezed form
4M0D	;	2.577	;	Crystal structure of MurQ from H.influenzae in apo form
4LZJ	;	2.405	;	Crystal Structure of MurQ from H.influenzae with bound inhibitor
3ZC9	;	2.24	;	Crystal Structure of Murraya koenigii Miraculin-Like Protein at 2.2 A resolution at pH 4.6
3ZC8	;	2.24	;	Crystal Structure of Murraya koenigii Miraculin-Like Protein at 2.2 A resolution at pH 7.0
6OZQ	;	2.153	;	Crystal structure of Mus musculus (Mm) Endonuclease V (K155M) in complex with a 23mer RNA oligo containing an inosine after a 100 min soak in 10 mM Mn2+ and K+
6OZK	;	2.104	;	Crystal structure of Mus musculus (Mm) Endonuclease V in complex with a 23mer RNA oligo containing an inosine after 68h soak in Ca2+
6OZM	;	2.15	;	Crystal structure of Mus musculus (Mm) Endonuclease V in complex with a 23mer RNA oligo containing an inosine after a 10 min soak in 10 mM Mn2+
6OZR	;	2.15	;	Crystal structure of Mus musculus (Mm) Endonuclease V in complex with a 23mer RNA oligo containing an inosine after a 15 min soak in 10 mM Mg2+
6OZN	;	1.9	;	Crystal structure of Mus musculus (Mm) Endonuclease V in complex with a 23mer RNA oligo containing an inosine after a 15 min soak in 10 mM Mn2+
6OZP	;	1.96	;	Crystal structure of Mus musculus (Mm) Endonuclease V in complex with a 23mer RNA oligo containing an inosine after a 180 min soak in 10 mM Mn2+
6OZL	;	2.1	;	Crystal structure of Mus musculus (Mm) Endonuclease V in complex with a 23mer RNA oligo containing an inosine after a 2 min soak in Mn2+
6OZO	;	2.235	;	Crystal structure of Mus musculus (Mm) Endonuclease V in complex with a 23mer RNA oligo containing an inosine after a 30 min soak in 10 mM Mn2+
6OZS	;	2.41	;	Crystal structure of Mus musculus (Mm) Endonuclease V in complex with a 23mer RNA oligo containing an inosine after a 90 min soak in 10 mM Mg2+
6OZJ	;	2.247	;	Crystal structure of Mus musculus (Mm) Endonuclease V in complex with a 23mer RNA oligo containing an inosine in the absence of divalent cation
4E3X	;	1.24	;	Crystal Structure of Mus musculus 1-pyrroline-5-carboxylate dehydrogenase cryoprotected in proline
2WLS	;	2.6	;	Crystal structure of Mus musculus Acetylcholinesterase in complex with AMTS13
2GYU	;	2.2	;	Crystal structure of Mus musculus Acetylcholinesterase in complex with HI-6
2GYW	;	2.4	;	Crystal Structure of Mus musculus Acetylcholinesterase in Complex with Obidoxime
2GYV	;	2.5	;	Crystal structure of Mus musculus Acetylcholinesterase in complex with Ortho-7
3GB5	;	2.0	;	Crystal structure of Mus musculus iodotyrosine deiodinase (IYD) bound to FMN
3GH8	;	2.61	;	Crystal structure of Mus musculus iodotyrosine deiodinase (IYD) bound to FMN and di-iodotyrosine (DIT)
3GFD	;	2.45	;	Crystal structure of Mus musculus iodotyrosine deiodinase (IYD) bound to FMN and mono-iodotyrosine (MIT)
3TO0	;	2.655	;	Crystal structure of Mus musculus iodotyrosine deiodinase (IYD) C217A, C239A bound to FMN
3TNZ	;	2.25	;	Crystal structure of Mus musculus iodotyrosine deiodinase (IYD) C217A, C239A bound to FMN and mono-iodotyrosine (MIT)
7BR9	;	3.3	;	Crystal structure of mus musculus IRG1
8BVA	;	2.19	;	Crystal Structure of Mus musculus Protein Arginine Methyltransferase 2 in complex with RSF1_114-126
8C1J	;	2.0	;	Crystal Structure of Mus musculus Protein Arginine Methyltransferase 2 in complex with RSF1_18-30
5FWA	;	1.8	;	Crystal Structure of Mus musculus Protein Arginine Methyltransferase 2 with CP1
5FWD	;	2.0	;	Crystal Structure of Mus musculus Protein Arginine Methyltransferase 2 with CP2
5JMQ	;	1.795	;	Crystal Structure of Mus musculus Protein Arginine Methyltransferase 2 with CP3
5FUL	;	1.89	;	Crystal Structure of Mus musculus Protein Arginine Methyltransferase 2 with SAH
5K8V	;	2.25	;	Crystal Structure of Mus musculus Protein Arginine Methyltransferase 4 (CARM1 130-487) with CP1
6MBX	;	2.4	;	CRYSTAL STRUCTURE OF MUSKMELON ALLERGEN CUC M 2
4XY5	;	1.8	;	Crystal Structure of mutant (Asp52Ala) Hypothetical Thioesterase Protein SP_1851 from Streptococcus pneumoniae TIGR4
3TX4	;	2.32	;	Crystal Structure of Mutant (C354A) M. tuberculosis LD-transpeptidase type 2
4GVI	;	1.55	;	Crystal structure of mutant (D248N) Salmonella typhimurium family 3 glycoside hydrolase (NagZ) in complex with GlcNAc-1,6-anhMurNAc
4ZO6	;	2.0	;	Crystal Structure of mutant (D270A) beta-glucosidase from Listeria innocua in complex with cellobiose
4ZO7	;	2.0	;	Crystal structure of mutant (D270A) beta-glucosidase from Listeria innocua in complex with gentiobiose
4ZO9	;	1.99	;	Crystal Structure of mutant (D270A) beta-glucosidase from Listeria innocua in complex with laminaribiose
4ZO8	;	2.0	;	Crystal Structure of mutant (D270A) beta-glucosidase from Listeria innocua in complex with sophorose
4ZOC	;	1.79	;	Crystal Structure of mutant (D270A) beta-glucosidase from Listeria innocua in complex with sophorotriose
5XXN	;	2.05	;	Crystal Structure of mutant (D286N) beta-glucosidase from Bacteroides thetaiotaomicron in complex with sophorose
5XXO	;	2.02	;	Crystal structure of mutant (D286N) GH3 beta-glucosidase from Bacteroides thetaiotaomicron in complex with sophorotriose
4GYJ	;	1.65	;	Crystal structure of mutant (D318N) bacillus subtilis family 3 glycoside hydrolase (nagz) in complex with glcnac-murnac (space group P1)
4GYK	;	1.8	;	Crystal structure of mutant (D318N) bacillus subtilis family 3 glycoside hydrolase (nagz) in complex with glcnac-murnac (space group P1211)
1MZZ	;	2.0	;	Crystal Structure of Mutant (M182T)of Nitrite Reductase
4XY6	;	2.0	;	Crystal Structure of mutant (Thr68Ala) Hypothetical Thioesterase Protein SP_1851 from Streptococcus pneumoniae TIGR4
5UQU	;	1.7	;	Crystal structure of mutant 2-methylcitrate synthase (mcsAG352A) from Aspergillus fumigatus
6BOM	;	2.05	;	Crystal structure of mutant 2-methylcitrate synthase mcsAG306A from Aspergillus fumigatus.
6BOL	;	2.2	;	Crystal structure of mutant 2-methylcitrate synthase mcsAG419A from Aspergillus fumigatus.
3DK3	;	2.02	;	Crystal structure of mutant ABL kinase domain in complex with small molecule fragment
3DK6	;	2.02	;	Crystal structure of mutant ABL kinase domain in complex with small molecule fragment
3DK7	;	2.01	;	Crystal structure of mutant ABL kinase domain in complex with small molecule fragment
5OAN	;	2.6	;	Crystal structure of mutant AChBP in complex with glycine (T53F, Q74R, Y110A, I135S, G162E, S206CCP_KGTG)
5OAD	;	2.1	;	Crystal structure of mutant AChBP in complex with HEPES (T53F, Q74R, Y110A, I135S, G162E)
5OAL	;	3.2	;	Crystal structure of mutant AChBP in complex with strychnine (T53F, Q74R, Y110A, I135S, G162E)
5OA0	;	2.6	;	Crystal structure of mutant AChBP in complex with strychnine (T53F, Q74R, Y110A, I135S, W164F)
5OAJ	;	2.47	;	Crystal structure of mutant AChBP in complex with tropisetron (T53F, Q74R, Y110A, I135S, G162E)
7YXR	;	2.5	;	Crystal structure of mutant AncGR2-LBD (Y545A) bound to dexamethasone and SHP coregulator fragment
8FH1	;	1.69	;	Crystal structure of mutant Androgen Receptor ligand binding domain F877L/T878A with DHT
8FH0	;	1.59	;	Crystal structure of mutant Androgen Receptor ligand binding domain H875Y/F877L/T878A with DHT
8FH2	;	1.59	;	Crystal structure of mutant Androgen Receptor ligand binding domain L702H/H875Y with DHT
8FGZ	;	1.61	;	Crystal structure of mutant Androgen Receptor ligand binding domain L702H/H875Y/F877L with DHT
8FGY	;	2.2	;	Crystal structure of mutant Androgen Receptor ligand binding domain L702H/H875Y/F877L/T878A with DHT
7ZTV	;	1.94	;	Crystal structure of mutant AR-LBD (F755L) bound to dihydrotestosterone
7ZTX	;	1.89	;	Crystal structure of mutant AR-LBD (F755V) bound to dihydrotestosterone
7ZU2	;	1.74	;	Crystal structure of mutant AR-LBD (Q799E) bound to dihydrotestosterone
7ZU1	;	1.68	;	Crystal structure of mutant AR-LBD (V758A) bound to dihydrotestosterone
7ZTZ	;	1.4	;	Crystal structure of mutant AR-LBD (Y764C) bound to dihydrotestosterone
6NL6	;	1.4	;	Crystal structure of mutant B1 immunoglobulin-binding domain of Streptococcal Protein G (T16F, T18A, V21E, T25L, K28Y, V29I, K31R, Q32H, Y33L, N35K, D36H, N37Q)
6DUC	;	1.791	;	Crystal structure of mutant beta-K167T tryptophan synthase in complex with inhibitor N-(4'-trifluoromethoxybenzenesulfonyl)-2-amino-1-ethylphosphate (F9F) at the alpha-site, cesium ion at the metal coordination site, and 2-aminophenol quinonoid (1D0) at the beta-site
3T9M	;	2.03	;	Crystal structure of Mutant C221D of Carbapenemase CphA from Aeromonas Hydrophila
5ZLA	;	1.7	;	Crystal structure of mutant C387A of DFA-IIIase from Arthrobacter chlorophenolicus A6 in complex with DFA-III
4M05	;	2.28	;	Crystal Structure of Mutant Chlorite Dismutase from Candidatus Nitrospira defluvii R173E
4M07	;	2.5	;	Crystal Structure of Mutant Chlorite Dismutase from Candidatus Nitrospira defluvii W145F
4M06	;	2.6	;	Crystal Structure of Mutant Chlorite Dismutase from Candidatus Nitrospira defluvii W145F in Complex with Cyanide
4M08	;	2.799	;	Crystal Structure of Mutant Chlorite Dismutase from Candidatus Nitrospira defluvii W145V
4M09	;	2.45	;	Crystal Structure of Mutant Chlorite Dismutase from Candidatus Nitrospira defluvii W146Y R173Q
5W2D	;	2.7	;	Crystal structure of mutant CJ YCEI protein (CJ-G34C) for nanotechnology applications
5W2R	;	2.9	;	Crystal structure of mutant CJ YCEI protein (CJ-G34C) with 5-mercapto-2-nitrobenzoic acid guest structure
5W2K	;	2.78	;	Crystal structure of mutant CJ YCEI protein (CJ-G34C) with hydroxymercuribenzoic acid guest structure
5W2V	;	2.9	;	Crystal structure of mutant CJ YCEI protein (CJ-G34C) with selenocysteine guest structure
5W37	;	2.52	;	Crystal structure of mutant CJ YCEI protein (CJ-N182C) for nanotechnology applications
5W3A	;	2.76	;	Crystal structure of mutant CJ YCEI protein (CJ-N182C) with 5-mercapto-2-nitrobenzoic acid guest structure
5W3B	;	2.7	;	Crystal structure of mutant CJ YCEI protein (CJ-N182C) with mercuribenzoic acid guest structure
5W39	;	2.48	;	Crystal structure of mutant CJ YCEI protein (CJ-N182C) with monobromobimane guest structure
5W3C	;	2.87	;	Crystal structure of mutant CJ YCEI protein (CJ-N182C) with selenocysteine guest structure
5W2X	;	2.73	;	Crystal structure of mutant CJ YCEI protein (CJ-N48C) for nanotechnology applications
5W2Z	;	2.8	;	Crystal structure of mutant CJ YCEI protein (CJ-N48C) with 5-mercapto-2-nitrobenzoic acid guest structure
5W31	;	2.56	;	Crystal structure of mutant CJ YCEI protein (CJ-N48C) with mercuribenzoic acid guest structure
5W30	;	2.75	;	Crystal structure of mutant CJ YCEI protein (CJ-N48C) with monobromobimane guest structure
5W32	;	2.6	;	Crystal structure of mutant CJ YCEI protein (CJ-N48C) with selenocysteine guest structure
3GJP	;	2.0	;	Crystal structure of mutant coiled coil GCN4 leucine zipper
3BT8	;	2.7	;	Crystal Structure of Mutant Cyclophilin (R147A) from Leishmania donovani
6JHH	;	2.025	;	Crystal structure of mutant D350A of Pullulanase from Paenibacillus barengoltzii complexed with maltotriose
6JHI	;	2.319	;	Crystal structure of mutant D470A of Pullulanase from Paenibacillus barengoltzii complexed with maltotetraose
3LY8	;	1.9	;	Crystal structure of mutant D471E of the periplasmic domain of CadC
3LY9	;	2.2	;	Crystal structure of mutant D471N of the periplasmic domain of CadC
1GS8	;	1.9	;	Crystal structure of mutant D92N Alcaligenes xylosoxidans Nitrite Reductase
3PWT	;	1.9	;	Crystal structure of mutant E.coli topoisomerase IA
2V8D	;	2.3	;	Crystal structure of mutant E159A of beta-alanine synthase from Saccharomyces kluyveri
2V8H	;	2.0	;	Crystal structure of mutant E159A of beta-alanine synthase from Saccharomyces kluyveri in complex with its substrate N-carbamyl-beta- alanine
1F8U	;	2.9	;	CRYSTAL STRUCTURE OF MUTANT E202Q OF HUMAN ACETYLCHOLINESTERASE COMPLEXED WITH GREEN MAMBA VENOM PEPTIDE FASCICULIN-II
7VT4	;	1.93	;	Crystal structure of mutant E393Q of MtGlu5
1W00	;	2.2	;	Crystal structure of mutant enzyme D103L of Ketosteroid Isomerase from Pseudomonas putida biotype B
1W02	;	2.3	;	Crystal structure of mutant enzyme Y16F/D103L of ketosteroid isomerase from Pseudomonas putida biotype B
1DMQ	;	2.15	;	CRYSTAL STRUCTURE OF MUTANT ENZYME Y32F OF KETOSTEROID ISOMERASE FROM PSEUDOMONAS PUTIDA BIOTYPE B
1VZZ	;	2.3	;	CRYSTAL STRUCTURE OF MUTANT ENZYME Y32F/D103L OF KETOSTEROID ISOMERASE FROM PSEUDOMONAS PUTIDA BIOTYPE B
1DMN	;	2.05	;	CRYSTAL STRUCTURE OF MUTANT ENZYME Y32F/Y57F OF KETOSTEROID ISOMERASE FROM PSEUDOMONAS PUTIDA BIOTYPE B
1W01	;	2.2	;	Crystal structure of mutant enzyme Y57F/D103L of ketosteroid isomerase from Pseudomonas putida biotype B
7WNV	;	2.3	;	Crystal structure of mutant estrogen receptor alpha Y537S in complex with CO9
8T3I	;	1.57	;	Crystal structure of mutant exfoliative toxin C (ExhC) from Mammaliicoccus sciuri
4FS0	;	3.25	;	Crystal structure of mutant F136D of mouse nectin-2 extracellular fragment D1-D2
1X91	;	1.5	;	Crystal structure of mutant form A of a pectin methylesterase inhibitor from Arabidopsis
1X90	;	2.68	;	Crystal structure of mutant form B of a pectin methylesterase inhibitor from Arabidopsis
4HQ0	;	3.0	;	Crystal Structure of mutant form of Caspase-7
4HQR	;	3.0	;	Crystal Structure of mutant form of Caspase-7
8HWO	;	1.96	;	Crystal Structure of mutant GDSL Esterase of Photobacterium sp. J15
8HWP	;	1.73	;	Crystal Structure of Mutant GDSL Esterase of Photobacterium sp. J15 S12A in Complex with Butyrate
4ACS	;	2.1	;	Crystal structure of mutant GST A2-2 with enhanced catalytic efficiency with azathioprine
8GUN	;	2.30001	;	Crystal structure of mutant H528A of EsaD from Staphylococcus aureus
3QKZ	;	1.87	;	Crystal structure of mutant His269Arg AKR1B14
6C57	;	3.5	;	Crystal structure of mutant human geranylgeranyl pyrophosphate synthase (Y246D) in complex with bisphosphonate inhibitor FV0109
6C56	;	2.8	;	Crystal structure of mutant human geranylgeranyl pyrophosphate synthase (Y246D) in its Apo form
1GDW	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT LEFT-HANDED HELICAL POSITIONS
1GDX	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT LEFT-HANDED HELICAL POSITIONS
1GE0	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT LEFT-HANDED HELICAL POSITIONS
1GE1	;	1.7	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT LEFT-HANDED HELICAL POSITIONS
1GE2	;	2.0	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT LEFT-HANDED HELICAL POSITIONS
1GE3	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT LEFT-HANDED HELICAL POSITIONS
1GE4	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT LEFT-HANDED HELICAL POSITIONS
1GAY	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT THE SURFACE POSITIONS
1GAZ	;	1.8	;	Crystal Structure of Mutant Human Lysozyme Substituted at the Surface Positions
1GB0	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT THE SURFACE POSITIONS
1GB2	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT THE SURFACE POSITIONS
1GB3	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT THE SURFACE POSITIONS
1GB5	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT THE SURFACE POSITIONS
1GB6	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT THE SURFACE POSITIONS
1GB7	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT THE SURFACE POSITIONS
1GB8	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT THE SURFACE POSITIONS
1GB9	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT THE SURFACE POSITIONS
1GBO	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT THE SURFACE POSITIONS
1GBW	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT THE SURFACE POSITIONS
1GBX	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT THE SURFACE POSITIONS
1GBY	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT THE SURFACE POSITIONS
1GBZ	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT THE SURFACE POSITIONS
1GF8	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT THE SURFACE POSITIONS
1GF9	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT THE SURFACE POSITIONS
1GFA	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT THE SURFACE POSITIONS
1GFE	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT THE SURFACE POSITIONS
1GFG	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT THE SURFACE POSITIONS
1GFH	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT THE SURFACE POSITIONS
1GFJ	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT THE SURFACE POSITIONS
1GFK	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT THE SURFACE POSITIONS
1GFR	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT THE SURFACE POSITIONS
1GFT	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT THE SURFACE POSITIONS
1GFU	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT THE SURFACE POSITIONS
1GFV	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT THE SURFACE POSITIONS
1INU	;	1.8	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME SUBSTITUTED AT THE SURFACE POSITIONS
1C7P	;	2.4	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME WITH FOUR EXTRA RESIDUES (EAEA) AT THE N-TERMINAL
1IOC	;	2.4	;	CRYSTAL STRUCTURE OF MUTANT HUMAN LYSOZYME, EAEA-I56T
5UD8	;	1.8	;	Crystal Structure of Mutant Ig-like Domain
1ZU3	;	1.33	;	Crystal Structure Of Mutant K8A Of Scorpion alpha-Like Neurotoxin Bmk M1 From Buthus Martensii Karsch
1ZVG	;	1.2	;	Crystal Structure Of Mutant K8DP9S Of Scorpion alpha-Like Neurotoxin Bmk M1 From Buthus Martensii Karsch
1ZUT	;	1.7	;	Crystal Structure Of Mutant K8DP9SR58K Of Scorpion alpha-Like Neurotoxin Bmk M1 From Buthus Martensii Karsch
1ZYW	;	1.3	;	Crystal Structure Of Mutant K8DP9SR58KP60G Of Scorpion alpha-Like Neurotoxin Bmk M1 From Buthus Martensii Karsch
1ZYV	;	1.5	;	Crystal Structure Of Mutant K8DP9SR58KV59G Of Scorpion alpha-Like Neurotoxin Bmk M1 From Buthus Martensii Karsch
1ZVE	;	1.7	;	Crystal Structure Of Mutant K8G Of Scorpion alpha-Like Neurotoxin Bmk M1 From Buthus Martensii Karsch
7R6A	;	1.89	;	Crystal structure of mutant L124D/R125A/C273S of L-Asparaginase I from Yersinia pestis
1T7A	;	1.5	;	Crystal structure of mutant Lys8Asp of scorpion alpha-like neurotoxin BmK M1 from Buthus martensii Karsch
1T7B	;	1.85	;	Crystal structure of mutant Lys8Gln of scorpion alpha-like neurotoxin BmK M1 from Buthus martensii Karsch
1QZ3	;	2.3	;	CRYSTAL STRUCTURE OF MUTANT M211S/R215L OF CARBOXYLESTERASE EST2 COMPLEXED WITH HEXADECANESULFONATE
5O4I	;	1.8	;	Crystal Structure of mutant M54L/M64L/M96L of Two-Domain Laccase from Streptomyces griseoflavus dialyzed against solution containing 0.25 mM copper sulfate
5O4Q	;	1.9	;	Crystal Structure of mutant M54L/M64L/M96L of Two-Domain Laccase from Streptomyces griseoflavus with 0.25 mM copper sulfate on growth medium
5O3K	;	2.1	;	Crystal Structure of mutant M54L/M64L/M96L of Two-Domain Laccase from Streptomyces griseoflavus with 1 mM copper sulfate on growth medium
1J72	;	2.5	;	Crystal Structure of Mutant Macrophage Capping Protein (Cap G) with Actin-severing Activity in the Ca2+-Free Form
3VOD	;	2.6	;	Crystal Structure of mutant MarR C80S from E.coli
5H3R	;	2.67	;	Crystal Structure of mutant MarR C80S from E.coli complexed with operator DNA
4H1Q	;	1.59	;	Crystal structure of mutant MMP-9 catalytic domain in complex with a twin inhibitor.
4H82	;	1.9	;	Crystal structure of mutant MMP-9 catalytic domain in complex with a twin inhibitor.
5F78	;	1.8518	;	Crystal structure of Mutant N87T of adenosine/Methylthioadenosine phosphorylase from Schistosoma mansoni in APO form
5F7J	;	1.66	;	Crystal structure of Mutant N87T of adenosine/Methylthioadenosine phosphorylase from Schistosoma mansoni in complex with Adenine
2NOO	;	1.65	;	Crystal Structure of Mutant NikA
3WJD	;	1.1	;	Crystal structure of mutant nitrobindin F44W/M75L/H76L/Q96C/M148L/H158L (NB5) from Arabidopsis thaliana
4YMY	;	1.0	;	Crystal structure of mutant nitrobindin M75A/H76L/Q96C/M148L/H158A (NB11) from Arabidopsis thaliana
3WJB	;	2.2	;	Crystal structure of mutant nitrobindin M75L/H76L/Q96C/M148L/H158L (NB4) from Arabidopsis thaliana
3WJC	;	2.0	;	Crystal structure of mutant nitrobindin M75L/H76L/Q96C/M148L/H158L covalently linked with [Rh(Cp-Mal)(COD)] (NB4-Rh) from Arabidopsis thaliana
3WJG	;	1.1	;	Crystal structure of mutant nitrobindin M75L/H76L/Q96C/M148W/H158L (NB10) from Arabidopsis thaliana
3WJF	;	2.2	;	Crystal structure of mutant nitrobindin M75L/H76L/Q96C/V128W/M148L/H158L (NB9) from Arabidopsis thaliana
3WJE	;	1.7	;	Crystal structure of mutant nitrobindin M75W/H76L/Q96C/M148L/H158L (NB6) from Arabidopsis thaliana
4YBV	;	2.0	;	Crystal Structure of mutant of (Q32A) thioesterase enzyme SAV0944 from Staphylococcus aureus subsp. aureus Mu50
7CQB	;	1.86	;	Crystal structure of mutant of a Petase mutant
3PII	;	2.9	;	Crystal structure of Mutant of ht- Alcohol Dehydrogenase with substrate analogue butyramide
4H0E	;	1.973	;	Crystal Structure of mutant ORR3 in complex with NTD of AraR
8B8Z	;	2.22	;	Crystal structure of mutant PPARG (C313A) and NCOR2 with an inverse agonist (compound 7e)
8B91	;	2.23	;	Crystal structure of mutant PPARG (C313A) and NCOR2 with an inverse agonist (compound SI-1)
8AG0	;	2.7	;	Crystal structure of mutant PRELID3a-TRIAP1 complex - R53E
1T7E	;	1.4	;	Crystal structure of mutant Pro9Ser of scorpion alpha-like neurotoxin BmK M1 from Buthus martensii Karsch
5F7O	;	1.8148	;	Crystal structure of Mutant Q289L of adenosine/Methylthioadenosine phosphorylase from Schistosoma mansoni in complex with Adenine
5F7X	;	1.77	;	Crystal structure of Mutant Q289L of adenosine/Methylthioadenosine phosphorylase from Schistosoma mansoni in complex with Tubercidin
1I5O	;	2.8	;	CRYSTAL STRUCTURE OF MUTANT R105A OF E. COLI ASPARTATE TRANSCARBAMOYLASE
2V8V	;	2.9	;	Crystal structure of mutant R322A of beta-alanine synthase from Saccharomyces kluyveri
7R69	;	1.8	;	Crystal structure of mutant R43D/C273S of L-Asparaginase I from Yersinia pestis
7R6B	;	2.03	;	Crystal structure of mutant R43D/L124D/R125A/C273S of L-Asparaginase I from Yersinia pestis
4X44	;	2.0535	;	Crystal Structure of Mutant R89Q of human Adenine phosphoribosyltransferase
4HLS	;	1.45	;	Crystal structure of mutant rabbit PRP 121-230 (S170N)
4HMR	;	1.6	;	Crystal structure of mutant rabbit PRP 121-230 (S170N/S174N)
4HMM	;	1.5	;	Crystal structure of mutant rabbit PRP 121-230 (S174N)
1Z3M	;	2.0	;	Crystal structure of mutant Ribonuclease S (F8Nva)
4QGB	;	2.6	;	Crystal structure of mutant ribosomal protein G219V TthL1
4QG3	;	2.0	;	Crystal structure of mutant ribosomal protein G219V TthL1 in complex with 80nt 23S RNA from Thermus thermophilus
4LQ4	;	1.75	;	crystal structure of mutant ribosomal protein L1 from Methanococcus jannaschii with deletion of 8 residues from C-terminus
4QVI	;	1.9	;	Crystal structure of mutant ribosomal protein M218L TthL1 in complex with 80nt 23S RNA from Thermus thermophilus
3UMY	;	1.9	;	Crystal structure of mutant ribosomal protein T217A TthL1 in complex with 80nt 23S RNA from Thermus thermophilus
3U56	;	2.1	;	Crystal structure of mutant ribosomal protein T217V TthL1 in complex with 80nt 23S RNA from Thermus thermophilus
5NPM	;	2.7	;	CRYSTAL STRUCTURE OF MUTANT RIBOSOMAL PROTEIN TTHL1 LACKING 8 N-TERMINAL RESIDUES IN COMPLEX WITH 80NT 23S RNA FROM THERMUS THERMOPHILUS
6WUI	;	1.9	;	Crystal Structure of mutant S. pombe Rai1 (E150S/E199Q/E239Q) in complex with 3'-FADP
5F77	;	2.02	;	Crystal structure of Mutant S12T of adenosine/Methylthioadenosine phosphorylase from Schistosoma mansoni in complex with Adenine
5F76	;	1.95	;	Crystal structure of Mutant S12T of Adenosine/Methylthioadenosine Phosphorylase from Schistosoma mansoni in complex with Methylthioadenosine
5F73	;	2.06	;	Crystal structure of Mutant S12T of Adenosine/Methylthioadenosine Phosphorylase in APO form
1RM5	;	2.1	;	Crystal structure of mutant S188A of photosynthetic glyceraldehyde-3-phosphate dehydrogenase A4 isoform, complexed with NADP
3QT8	;	2.1	;	Crystal structure of mutant S192A Staphylococcus epidermidis mevalonate diphosphate decarboxylase complexed with inhibitor 6-FMVAPP
2HA5	;	2.15	;	Crystal structure of mutant S203A of acetylcholinesterase complexed with acetylthiocholine
2HA4	;	2.56	;	Crystal structure of mutant S203A of mouse acetylcholinesterase complexed with acetylcholine
2HA7	;	2.66	;	Crystal structure of mutant S203A of mouse acetylcholinesterase complexed with butyrylthiocholine
2HA6	;	2.25	;	Crystal structure of mutant S203A of mouse acetylcholinesterase complexed with succinylcholine
4F1P	;	2.3	;	Crystal Structure of mutant S554D for ArfGAP and ANK repeat domain of ACAP1
6B3K	;	2.09	;	Crystal structure of mutant Spinach RNA aptamer in complex with Fab BL3-6
1I2C	;	1.6	;	CRYSTAL STRUCTURE OF MUTANT T145A SQD1 PROTEIN COMPLEX WITH NAD AND UDP-GLUCOSE
1I2B	;	1.75	;	CRYSTAL STRUCTURE OF MUTANT T145A SQD1 PROTEIN COMPLEX WITH NAD AND UDP-SULFOQUINOVOSE/UDP-GLUCOSE
1RM3	;	2.2	;	Crystal structure of mutant T33A of photosynthetic glyceraldehyde-3-phosphate dehydrogenase A4 isoform, complexed with NADP
4QDA	;	2.299	;	Crystal structure of mutant Thioesterase PA1618 (E64A) from Pseudomonas aeruginosa
4QDB	;	2.023	;	Crystal structure of mutant Thioesterase PA1618 (Q49A) from Pseudomonas aeruginosa
7EDC	;	1.946	;	Crystal structure of mutant tRNA [Gm18] methyltransferase TrmH (E107G) in complex with S-adenosyl-L-methionine from Escherichia coli
1WCX	;	2.0	;	Crystal Structure of Mutant Uroporphyrinogen III Synthase from an Extremely Thermophilic Bacterium Thermus thermophilus HB8 (L75M/I193M/L248M, SeMet derivative, Form-1 crystal)
7DP5	;	1.6	;	Crystal structure of mutant V45A Brugia malayi thymidylate synthase complexed with 2'-deoxyuridine monophosphate and methotrexate
7DP6	;	1.85	;	Crystal structure of mutant V45T Brugia malayi thymidylate synthase complexed with 2'-deoxyuridine monophosphate
6T8F	;	2.0	;	Crystal structure of mutant xylose isomerase (V270A/A273G) from Piromyces E2 grown in yeast, in complex with xylose
3NBB	;	2.05	;	Crystal structure of mutant Y305F expressed in E. coli in the copper amine oxidase from hansenula polymorpha
5IKE	;	2.09	;	Crystal structure of mutant-D97N of peptidyl-tRNA hydrolase from Vibrio cholerae
5EKT	;	1.63	;	Crystal structure of mutant-K146A of peptidyl-tRNA hydrolase from Vibrio cholerae at 1.63A resolution.
1UWI	;	2.55	;	CRYSTAL STRUCTURE OF MUTATED BETA-GLYCOSIDASE FROM SULFOLOBUS SOLFATARICUS, WORKING AT MODERATE TEMPERATURE
5GTX	;	2.28	;	Crystal structure of mutated buckwheat glutaredoxin
4FRV	;	1.1	;	Crystal structure of mutated cyclophilin B that causes hyperelastosis cutis in the American Quarter Horse
2EB2	;	2.5	;	Crystal structure of mutated EGFR kinase domain (G719S)
2EB3	;	2.84	;	Crystal structure of mutated EGFR kinase domain (L858R) in complex with AMPPNP
2QZP	;	2.7	;	Crystal structure of mutation of an acylptide hydrolase/esterase from Aeropyrum pernix K1
3HHJ	;	2.1	;	Crystal structure of mutator mutT from Bartonella henselae
2AOR	;	2.0	;	Crystal structure of MutH-hemimethylated DNA complex
2AOQ	;	2.2	;	Crystal structure of MutH-unmethylated DNA complex
2EX1	;	2.0	;	Crystal structure of mutifunctional sialyltransferase from Pasteurella multocida with CMP bound
3RBN	;	2.16	;	Crystal structure of MutL protein homolog 1 isoform 1 [Homo sapiens]
1EE8	;	1.9	;	CRYSTAL STRUCTURE OF MUTM (FPG) PROTEIN FROM THERMUS THERMOPHILUS HB8
6TC6	;	2.9	;	Crystal structure of MutM from Neisseria meningitidis
6TC9	;	2.175	;	Crystal structure of MutM from Neisseria meningitidis
4DYW	;	2.5	;	Crystal structure of MutT NUDIX hydrolase from Burkholderia pseudomallei
3GRN	;	1.7	;	CRYSTAL STRUCTURE OF MUTT PROTEIN FROM Methanosarcina mazei Go1
3A6T	;	1.96	;	Crystal structure of MutT-8-OXO-DGMP complex
7X9O	;	1.58	;	Crystal structure of MutT-8-oxo-dGMP complex with Mg2+ ions: Reaction using Mg2+
3A6U	;	2.56	;	Crystal structure of MutT-8-OXO-dGMP-MN(II) complex
7WW5	;	1.57	;	Crystal structure of MutT-8-oxo-dGTP complex
7X9N	;	1.7	;	Crystal structure of MutT-8-oxo-dGTP complex with three Mg2+ ions: Reaction using Mg2+
7WW7	;	1.67	;	Crystal structure of MutT-8-oxo-dGTP complex: Reaction for 1 hr in 5 mM Mn2+
7WW9	;	1.8	;	Crystal structure of MutT-8-oxo-dGTP complex: Reaction for 1.5 hr in 20 mM Mn2+
7X9I	;	1.9	;	Crystal structure of MutT-8-oxo-dGTP complex: Reaction for 12 hr using 5 mM Mn2+
7X9K	;	1.81	;	Crystal structure of MutT-8-oxo-dGTP complex: Reaction for 2 hr using 10 mM Mn2+
7WWA	;	1.9	;	Crystal structure of MutT-8-oxo-dGTP complex: Reaction for 2.5 hr in 20 mM Mn2+
7WW6	;	1.36	;	Crystal structure of MutT-8-oxo-dGTP complex: Reaction for 20 min in 5 mM Mn2+
7X9J	;	1.98	;	Crystal structure of MutT-8-oxo-dGTP complex: Reaction for 24 hr using 5 mM Mn2+
7X9L	;	1.82	;	Crystal structure of MutT-8-oxo-dGTP complex: Reaction for 4 hr using 10 mM Mn2+
7WW8	;	1.64	;	Crystal structure of MutT-8-oxo-dGTP complex: Reaction for 5 hr in 5 mM Mn2+
7X9H	;	1.69	;	Crystal structure of MutT-8-oxo-dGTP complex: Reaction for 9 hr using 5 mM Mn2+
3DUP	;	1.8	;	Crystal structure of mutt/nudix family hydrolase from rhodospirillum rubrum atcc 11170
2FML	;	2.26	;	Crystal structure of MutT/nudix family protein from Enterococcus faecalis
2PQV	;	1.63	;	Crystal structure of MutT/nudix family protein from Streptococcus pneumoniae
1DL3	;	2.7	;	CRYSTAL STRUCTURE OF MUTUALLY GENERATED MONOMERS OF DIMERIC PHOSPHORIBOSYLANTRANILATE ISOMERASE FROM THERMOTOGA MARITIMA
4YOQ	;	2.21	;	Crystal Structure of MutY bound to its anti-substrate
4YPH	;	2.32	;	Crystal Structure of MutY bound to its anti-substrate with the disulfide cross-linker reduced
3G0Q	;	2.2	;	Crystal Structure of MutY bound to its inhibitor DNA
8ISC	;	2.27	;	Crystal structure of MV in complex with LLP
8IVP	;	1.93	;	Crystal structure of MV in complex with LLP and FRU from Mycobacterium vanbaalenii
6K11	;	1.936	;	Crystal structure of MvcA from Legionella pneumophila
6JKY	;	2.454	;	Crystal structure of MvcA-UBE2N-Ub complex from Legionella pneumophila
6B8A	;	2.65	;	Crystal structure of MvfR ligand binding domain in complex with M64
4XU5	;	2.1	;	Crystal structure of MvINS bound to a bromine-derived 14C Diacylglycerol (DAG) at 2.1A resolution
1ZHS	;	1.8	;	Crystal structure of MVL bound to Man3GlcNAc2
6CIT	;	2.027	;	Crystal Structure of MVM NS2 NES Peptide in complex with CRM1-Ran-RanBP1
3A42	;	2.6	;	Crystal structure of MvNei1
3A46	;	2.2	;	Crystal structure of MvNei1/THF complex
3A45	;	2.3	;	Crystal structure of MvNei1_2
5SV6	;	1.92	;	Crystal structure of MxaJ from Methlophaga aminisulfidivorans MPT
3PIN	;	2.7	;	Crystal structure of Mxr1 from Saccharomyces cerevisiae in complex with Trx2
3PIL	;	2.04	;	Crystal structure of Mxr1 from Saccharomyces cerevisiae in reduced form
3PIM	;	1.9	;	Crystal structure of Mxr1 from Saccharomyces cerevisiae in unusual oxidized form
6ZVA	;	2.68	;	Crystal structure of My5
1NKP	;	1.8	;	Crystal structure of Myc-Max recognizing DNA
4RQW	;	2.2	;	Crystal structure of Myc3 N-terminal JAZ-binding domain [44-238] from Arabidopsis
4YWC	;	2.4	;	Crystal structure of Myc3(5-242) fragment in complex with Jaz9(218-239) peptide
4YZ6	;	1.95	;	Crystal Structure of Myc3[44-238] from Arabidopsis in complex with Jaz1 peptide [200-221]
6E29	;	1.818	;	Crystal structure of Myceliophteria_thermophila Cps50 (Swd1) beta-propeller domain
5LOI	;	3.153	;	Crystal structure of Myceliophthora thermophila Rad26 (residues 373-841)
5FOI	;	2.21	;	Crystal structure of mycinamicin VIII C21 methyl hydroxylase MycCI from Micromonospora griseorubida bound to mycinamicin VIII
5F2N	;	1.9	;	Crystal structure of mycobacterial fatty acid O-methyltransferase in complex with SAH and 3-hydroxy-decanoate.
5F2K	;	1.6	;	Crystal structure of mycobacterial fatty acid O-methyltransferase in complex with SAH and octanoate
5F2O	;	1.85	;	Crystal structure of mycobacterial fatty acid O-methyltransferase Q154A mutant in complex with SAH and 3-hydroxy-decanoate.
4N8N	;	1.874	;	Crystal structure of Mycobacterial FtsX extracellular domain
4N8O	;	2.3	;	Crystal structure of Mycobacterial FtsX extracellular domain, bromide derivative
7BDW	;	2.55	;	Crystal structure of mycobacterial PptAb in complex with ACP and compound 8918
2FHG	;	3.23	;	Crystal Structure of Mycobacterial Tuberculosis Proteasome
4J2N	;	2.348	;	Crystal Structure of mycobacteriophage Pukovnik Xis
7YWM	;	1.624	;	Crystal structure of Mycobacterium abcessus Phosphopantetheine adenylyltransferase in complex with ATP
5UWV	;	2.98	;	Crystal structure of Mycobacterium abscessus L,D-transpeptidase 2
7YY0	;	1.745	;	Crystal structure of Mycobacterium abscessus Phosphopantetheine adenylyltransferase in complex with 4'-phosphopantetheine
7YXZ	;	1.779	;	Crystal structure of Mycobacterium abscessus Phosphopantetheine adenylyltransferase in complex with Coenzyme A
7YY2	;	1.598	;	Crystal structure of Mycobacterium abscessus Phosphopantetheine adenylyltransferase in complex with Compound 20
7YY6	;	1.506	;	Crystal structure of Mycobacterium abscessus Phosphopantetheine adenylyltransferase in complex with Fragment 10
7YY7	;	1.538	;	Crystal structure of Mycobacterium abscessus Phosphopantetheine adenylyltransferase in complex with Fragment 11
7YY8	;	1.516	;	Crystal structure of Mycobacterium abscessus Phosphopantetheine adenylyltransferase in complex with Fragment 12
7YY9	;	1.485	;	Crystal structure of Mycobacterium abscessus Phosphopantetheine adenylyltransferase in complex with Fragment 13
7YYA	;	1.807	;	Crystal structure of Mycobacterium abscessus Phosphopantetheine adenylyltransferase in complex with Fragment 14
7YYB	;	1.751	;	Crystal structure of Mycobacterium abscessus Phosphopantetheine adenylyltransferase in complex with Fragment 15
7YYC	;	1.499	;	Crystal structure of Mycobacterium abscessus Phosphopantetheine adenylyltransferase in complex with Fragment 16
7YY3	;	1.535	;	Crystal structure of Mycobacterium abscessus Phosphopantetheine adenylyltransferase in complex with Fragment 7
7YY4	;	1.671	;	Crystal structure of Mycobacterium abscessus Phosphopantetheine adenylyltransferase in complex with Fragment 8
7YY5	;	1.499	;	Crystal structure of Mycobacterium abscessus Phosphopantetheine adenylyltransferase in complex with Fragment 9
5IS2	;	1.881	;	Crystal structure of Mycobacterium avium SerB2 at pH 6.6
5JLP	;	2.495	;	Crystal structure of Mycobacterium avium SerB2 in complex with serine at ACT domain
5JMA	;	2.03	;	Crystal structure of Mycobacterium avium SerB2 in complex with serine at catalytic (PSP) domain
5JJB	;	2.305	;	Crystal structure of Mycobacterium avium SerB2 mutant D343G
5IT4	;	2.102	;	Crystal structure of Mycobacterium avium SerB2 mutant D343N
5IT0	;	1.968	;	Crystal structure of Mycobacterium avium SerB2 mutant D343N/D347N
5T41	;	3.149	;	Crystal structure of Mycobacterium avium SerB2 mutant S275A/R279A at pH 6.6 with ethylene glycol bound at ACT- I domain
5JLR	;	2.261	;	Crystal structure of Mycobacterium avium SerB2 with serine present at slightly different position near ACT domain
7P8G	;	2.13	;	Crystal structure of Mycobacterium hassiacum glucosyl-3-phosphoglycerate synthase at pH 5.5 - apo form
7PD5	;	1.95	;	Crystal structure of Mycobacterium hassiacum glucosyl-3-phosphoglycerate synthase at pH 5.5 in complex with 4-aminobenzoic acid
7PDO	;	1.97	;	Crystal structure of Mycobacterium hassiacum glucosyl-3-phosphoglycerate synthase at pH 5.5 in complex with UDP
7PE4	;	2.05	;	Crystal structure of Mycobacterium hassiacum glucosyl-3-phosphoglycerate synthase at pH 5.5 in complex with UDP-glucose
7P5L	;	1.22	;	Crystal structure of Mycobacterium hassiacum glucosyl-3-phosphoglycerate synthase at pH 7.1 - apo form
7PHO	;	1.27	;	Crystal structure of Mycobacterium hassiacum glucosyl-3-phosphoglycerate synthase at pH 7.1 in complex with 4-hydroxybenzaldehyde
7QCP	;	1.11	;	Crystal structure of Mycobacterium hassiacum glucosyl-3-phosphoglycerate synthase at pH 7.2 - apo form
7QI9	;	1.23	;	Crystal structure of Mycobacterium hassiacum glucosyl-3-phosphoglycerate synthase at pH 7.2 in complex with UDP
7PVL	;	1.43	;	Crystal structure of Mycobacterium hassiacum glucosyl-3-phosphoglycerate synthase at pH 8.5 - apo form
7QIB	;	1.6	;	Crystal structure of Mycobacterium hassiacum glucosyl-3-phosphoglycerate synthase at pH 8.5 in complex with UDP
7QOQ	;	1.93	;	Crystal structure of Mycobacterium hassiacum glucosyl-3-phosphoglycerate synthase at pH 8.5 in complex with UMP and Magnesium
3WY7	;	2.3	;	Crystal structure of Mycobacterium smegmatis 7-Keto-8-aminopelargonic acid (KAPA) synthase BioF
2XT6	;	2.74	;	Crystal structure of Mycobacterium smegmatis alpha-ketoglutarate decarboxylase homodimer (orthorhombic form)
5E57	;	1.98	;	Crystal structure of Mycobacterium smegmatis AmtR
5XS9	;	1.9	;	Crystal structure of Mycobacterium smegmatis BioQ
3JZ6	;	1.9	;	Crystal structure of Mycobacterium smegmatis Branched Chain Aminotransferase in complex with pyridoxal-5'-phosphate at 1.9 angstrom.
6TH2	;	1.844	;	Crystal structure of Mycobacterium smegmatis CoaB in complex with CTP
6THC	;	2.033	;	Crystal structure of Mycobacterium smegmatis CoaB in complex with CTP and (4-hydroxyphenyl)(2,3,4-trihydroxyphenyl)methanone
6TGV	;	2.5	;	Crystal structure of Mycobacterium smegmatis CoaBC in complex with CTP and FMN
3R9B	;	1.89	;	Crystal structure of Mycobacterium smegmatis CYP164A2 in ligand free state
3R9C	;	2.14	;	Crystal structure of Mycobacterium smegmatis CYP164A2 with Econazole bound
4QB9	;	3.293	;	Crystal structure of Mycobacterium smegmatis Eis in complex with paromomycin
7N3V	;	1.83	;	Crystal structure of Mycobacterium smegmatis LmcA
7SHW	;	1.79	;	Crystal structure of Mycobacterium smegmatis LmcA with xenon
2X1M	;	2.8	;	Crystal structure of Mycobacterium smegmatis methionyl-tRNA synthetase in complex with methionine
2X1L	;	2.3	;	Crystal structure of Mycobacterium smegmatis methionyl-tRNA synthetase in complex with methionine and adenosine
6AC8	;	2.75	;	Crystal structure of Mycobacterium smegmatis Mfd at 2.75 A resolution
6ACX	;	3.5	;	Crystal structure of Mycobacterium smegmatis Mfd in complex with ADP + Pi at 3.5 A resolution.
8HFM	;	2.41	;	Crystal Structure of Mycobacterium smegmatis MshC
8HFN	;	1.98	;	Crystal Structure of Mycobacterium smegmatis MshC in Complex with Compound 7b
8HFO	;	2.77	;	Crystal Structure of Mycobacterium smegmatis MshC in Complex with Compound 7d
5GG5	;	1.64	;	Crystal structure of Mycobacterium smegmatis MutT1
5GGB	;	1.1	;	Crystal structure of Mycobacterium smegmatis MutT1 in complex with 8-oxo-dGDP
6M72	;	1.6	;	Crystal structure of Mycobacterium smegmatis MutT1 in complex with 8-oxo-dGDP
5GG6	;	1.75	;	Crystal structure of Mycobacterium smegmatis MutT1 in complex with 8-oxo-dGTP
6M6Y	;	1.5	;	Crystal structure of Mycobacterium smegmatis MutT1 in complex with 8-oxo-dGTP
5GG7	;	1.7	;	Crystal structure of Mycobacterium smegmatis MutT1 in complex with 8-oxo-dGTP, 8-oxo-dGMP and pyrophosphate (I)
5GG8	;	1.85	;	Crystal structure of Mycobacterium smegmatis MutT1 in complex with 8-oxo-dGTP, 8-oxo-dGMP and pyrophosphate (II)
5GGA	;	1.75	;	Crystal structure of Mycobacterium smegmatis MutT1 in complex with 8-oxo-GDP, 8-oxo-GMP and pyrophosphate
5GG9	;	1.6	;	Crystal structure of Mycobacterium smegmatis MutT1 in complex with 8-oxo-GTP, 8-oxo-GMP and pyrophosphate
5XD1	;	1.6	;	Crystal structure of Mycobacterium smegmatis MutT1 in complex with Ap5A, ATP and magnesium
5XD2	;	1.75	;	Crystal structure of Mycobacterium smegmatis MutT1 in complex with Ap5A, ATP and manganese
5XD3	;	1.78	;	Crystal structure of Mycobacterium smegmatis MutT1 in complex with ATP (I)
5XD4	;	1.47	;	Crystal structure of Mycobacterium smegmatis MutT1 in complex with ATP (II)
5XD5	;	1.75	;	Crystal structure of Mycobacterium smegmatis MutT1 in complex with ATP, magnesium fluoride and phosphate
6M69	;	1.5	;	Crystal structure of Mycobacterium smegmatis MutT1 in complex with GMPPCP (GDP)
6M65	;	1.44	;	Crystal structure of Mycobacterium smegmatis MutT1 in complex with GMPPNP (GDP)
5GGC	;	1.85	;	Crystal structure of Mycobacterium smegmatis MutT1 in complex with phosphate and magnesium ions (excess magnesium, I)
5GGD	;	1.7	;	Crystal structure of Mycobacterium smegmatis MutT1 in complex with phosphate and magnesium ions (excess magnesium, II)
8CCI	;	1.56	;	Crystal structure of Mycobacterium smegmatis thioredoxin reductase
8CCM	;	1.73	;	Crystal structure of Mycobacterium smegmatis thioredoxin reductase in complex with Compound 2-06
8CCL	;	1.85	;	Crystal structure of Mycobacterium smegmatis thioredoxin reductase in complex with fragment F2X-Entry A09
8CCK	;	1.63	;	Crystal structure of Mycobacterium smegmatis thioredoxin reductase in complex with fragment F2X-Entry H07
8CCJ	;	1.8	;	Crystal structure of Mycobacterium smegmatis thioredoxin reductase in complex with NADPH
6PCM	;	3.107	;	Crystal Structure of Mycobacterium smegmatis Topoisomerase I with ssDNA bound to both N- and C-terminal domains
8G6P	;	1.45	;	Crystal structure of Mycobacterium thermoresistibile MurE in complex with ADP and 2,6-Diaminopimelic acid
3LV2	;	2.18	;	Crystal structure of Mycobacterium tuberculosis 7,8-diaminopelargonic acid synthase in complex with substrate analog sinefungin
7RYT	;	2.67	;	Crystal structure of Mycobacterium tuberculosis acetylated Homoserine transacetylase with Coenzyme A
2CDN	;	1.9	;	Crystal structure of Mycobacterium tuberculosis adenylate kinase complexed with two molecules of ADP and Mg
3B4W	;	1.8	;	Crystal structure of Mycobacterium tuberculosis aldehyde dehydrogenase complexed with NAD+
1GU9	;	1.9	;	Crystal Structure of Mycobacterium tuberculosis Alkylperoxidase AhpD
1ME5	;	2.4	;	Crystal Structure of Mycobacterium Tuberculosis Alkylperoxidase AhpD H132Q Mutant
1LW1	;	2.3	;	Crystal Structure Of Mycobacterium Tuberculosis Alkylperoxidase Ahpd H137F mutant
3HUG	;	2.35	;	Crystal structure of Mycobacterium tuberculosis anti-sigma factor RslA in complex with -35 promoter binding domain of sigL
7NLF	;	2.08	;	Crystal structure of Mycobacterium tuberculosis ArgB in apo form.
7NLU	;	2.235	;	Crystal structure of Mycobacterium tuberculosis ArgB in complex with 1-(1H-indol-3-yl)ethan-1-one
7NM0	;	2.281	;	Crystal structure of Mycobacterium tuberculosis ArgB in complex with 1-(2,6-dihydroxyphenyl)ethan-1-one.
7NN8	;	2.267	;	Crystal structure of Mycobacterium tuberculosis ArgB in complex with 1H-indole-3-carbonitrile.
7NNB	;	2.186	;	Crystal structure of Mycobacterium tuberculosis ArgB in complex with 2,8-bis(trifluoromethyl)quinolin-4-ol.
7NLW	;	2.32	;	Crystal structure of Mycobacterium tuberculosis ArgB in complex with 2-(5-methoxy-1H-indol-3-yl)acetonitrile
7NLQ	;	2.497	;	Crystal structure of Mycobacterium tuberculosis ArgB in complex with 2-(isoxazol-5-yl)phenol
7NLY	;	2.246	;	Crystal structure of Mycobacterium tuberculosis ArgB in complex with 2-Chlorobenzimidazole.
7NLR	;	2.254	;	Crystal structure of Mycobacterium tuberculosis ArgB in complex with 2-phenyl-1H-imidazole
7NLT	;	2.225	;	Crystal structure of Mycobacterium tuberculosis ArgB in complex with 4-(4-methylpiperazin-1-yl)benzoic acid
7NLZ	;	2.163	;	Crystal structure of Mycobacterium tuberculosis ArgB in complex with 5-Methoxy-6-(trifluoromethyl)indole.
7NLX	;	2.234	;	Crystal structure of Mycobacterium tuberculosis ArgB in complex with 7-(trifluoromethyl)quinolin-4-ol.
7NN7	;	2.172	;	Crystal structure of Mycobacterium tuberculosis ArgB in complex with dimethyl 5-hydroxyisophthalate.
7NLO	;	1.82	;	Crystal structure of Mycobacterium tuberculosis ArgB in complex with L-arginine
7NLP	;	2.213	;	Crystal structure of Mycobacterium tuberculosis ArgB in complex with L-canavanine
7NLS	;	2.648	;	Crystal structure of Mycobacterium tuberculosis ArgB in complex with methyl 4-hydroxy-3-iodobenzoate
7NLN	;	1.92	;	Crystal structure of Mycobacterium tuberculosis ArgB in complex with N-acetyl-glutamate
7NNI	;	1.544	;	Crystal structure of Mycobacterium tuberculosis ArgC apoenzyme
7NPH	;	2.57	;	Crystal structure of Mycobacterium tuberculosis ArgC in complex with 5-methoxy-1,3-benzoxazole-2-carboxylic acid
7NPJ	;	2.81	;	Crystal structure of Mycobacterium tuberculosis ArgC in complex with 6-phenoxy-3-pyridinamine
7NNQ	;	1.73	;	Crystal structure of Mycobacterium tuberculosis ArgC in complex with nicotinamide adenine dinucleotide phosphate (NADP+)
7NOT	;	2.54	;	Crystal structure of Mycobacterium tuberculosis ArgC in complex with nicotinamide adenine dinucleotide phosphate (NADP+) and 5-Methoxy-3-indoleacetic acid
7NNR	;	1.7	;	Crystal structure of Mycobacterium tuberculosis ArgC in complex with xanthene-9-carboxylic acid
7NN1	;	1.54	;	Crystal structure of Mycobacterium tuberculosis ArgD with prosthetic group pyridoxal 5'-phosphate
7NN4	;	1.47	;	Crystal structure of Mycobacterium tuberculosis ArgD with prosthetic group pyridoxal 5'-phosphate and 3-hydroxy-2-naphthoic acid.
7NNC	;	1.7	;	Crystal structure of Mycobacterium tuberculosis ArgD with prosthetic group pyridoxal-5'-phosphate and 6-Methoxyquinoline-3-carboxylic acid
7NNF	;	1.52	;	Crystal structure of Mycobacterium tuberculosis ArgF in apo form.
7NOU	;	1.98	;	Crystal structure of Mycobacterium tuberculosis ArgF in complex with (3,5-dichlorophenyl)boronic acid.
7NOV	;	1.9	;	Crystal structure of Mycobacterium tuberculosis ArgF in complex with (4-methyl-3-nitrophenyl)boronic acid.
7NP0	;	1.76	;	Crystal structure of Mycobacterium tuberculosis ArgF in complex with (4-nitrophenyl)boronic acid.
7NOR	;	1.59	;	Crystal structure of Mycobacterium tuberculosis ArgF in complex with 2-fluoro-4-hydroxybenzonitrile.
7NOS	;	1.77	;	Crystal structure of Mycobacterium tuberculosis ArgF in complex with 4-bromo-6-(trifluoromethyl)-1H-benzo[d]imidazole.
7NNZ	;	1.68	;	Crystal structure of Mycobacterium tuberculosis ArgF in complex with 5-methyl-4-phenylthiazol-2-amine.
7NNV	;	1.67	;	Crystal structure of Mycobacterium tuberculosis ArgF in complex with carbamoyl phosphate.
7NNW	;	1.78	;	Crystal structure of Mycobacterium tuberculosis ArgF in complex with methyl 4-hydroxy-3-iodobenzoate.
7NNY	;	1.57	;	Crystal structure of Mycobacterium tuberculosis ArgF in complex with naphthalen-1-ol.
5IET	;	2.88	;	Crystal Structure of Mycobacterium Tuberculosis ATP-independent Proteasome activator
5IEU	;	2.8	;	Crystal Structure of Mycobacterium Tuberculosis ATP-independent Proteasome Activator Tetramer
3QD8	;	3.0	;	Crystal structure of Mycobacterium tuberculosis BfrB
6GE8	;	1.869	;	Crystal structure of Mycobacterium tuberculosis BioA
2WGF	;	2.15	;	Crystal structure of Mycobacterium tuberculosis C171Q KasA variant
2WGG	;	2.0	;	Crystal Structure of Mycobacterium tuberculosis C171Q KasA variant with bound TLM
4ILU	;	2.3	;	Crystal structure of Mycobacterium tuberculosis CarD
4MFR	;	2.5	;	Crystal structure of Mycobacterium tuberculosis CarD
1SJ2	;	2.41	;	Crystal structure of Mycobacterium tuberculosis catalase-peroxidase
5W5A	;	1.85	;	Crystal structure of Mycobacterium tuberculosis CRP-FNR family transcription factor Cmr (Rv1675c)
5W5B	;	1.8	;	Crystal structure of Mycobacterium tuberculosis CRP-FNR family transcription factor Cmr (Rv1675c), truncated construct
6UPI	;	1.808	;	Crystal structure of Mycobacterium tuberculosis CYP121 bound with a hydroxylated intermediate of cYF-4-OMe
4G2G	;	2.25	;	Crystal structure of Mycobacterium tuberculosis CYP121 in complex with 4,4'-(1H-1,2,3-triazole-1,5-diyl)diphenol
4KTL	;	1.95	;	Crystal structure of Mycobacterium tuberculosis CYP121 in complex with 4,4'-(3-((4-hydroxyphenyl)amino)-1H-pyrazole-4,5-diyl)diphenol
4KTF	;	1.35	;	Crystal structure of Mycobacterium tuberculosis CYP121 in complex with 4,4'-(3-amino-1H-pyrazole-4,5-diyl)diphenol
4G1X	;	1.3	;	Crystal structure of Mycobacterium tuberculosis CYP121 in complex with 4-(1H-1,2,4-triazol-1-yl)quinolin-6-amine
4KTJ	;	1.35	;	Crystal structure of Mycobacterium tuberculosis CYP121 in complex with 4-(3-amino-1H-pyrazol-4-yl)phenol
4KTK	;	1.4	;	Crystal structure of Mycobacterium tuberculosis CYP121 in complex with 4-(3-amino-4-(4-hydroxyphenyl)-1H-pyrazol-5-yl)benzene-1,3-diol
6UPG	;	1.393	;	Crystal structure of Mycobacterium tuberculosis CYP121 in complex with cYF-4-OMe
5EDT	;	2.45	;	Crystal structure of Mycobacterium tuberculosis CYP121 in complex with LIG9
5LI7	;	1.58	;	Crystal structure of Mycobacterium tuberculosis CYP126A1 in complex with 1-(3-(1H-imidazol-1-yl)propyl)-3-((3s,5s,7s)-adamantan-1-yl)urea
5LIE	;	1.799	;	Crystal structure of Mycobacterium tuberculosis CYP126A1 in complex with imidazole
5LI8	;	1.83	;	Crystal structure of Mycobacterium tuberculosis CYP126A1 in complex with ketoconazole
5LI6	;	1.95	;	Crystal structure of Mycobacterium tuberculosis CYP126A1 in complex with N-isopropyl-N-((3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl)methyl)-2-(4-nitrophenyl)acetamide
2XKR	;	1.601	;	Crystal Structure of Mycobacterium tuberculosis CYP142: A novel cholesterol oxidase
3DWI	;	2.81	;	Crystal structure of Mycobacterium tuberculosis CysM, the cysteine synthase B
3DWM	;	2.69	;	Crystal structure of Mycobacterium tuberculosis CysO, an antigen
6GEO	;	1.5	;	Crystal structure of Mycobacterium tuberculosis cytochrome P450 CYP121A1 in complex with Triazole Pyrazole inhibitor 10j
6GEQ	;	1.6	;	Crystal structure of Mycobacterium tuberculosis cytochrome P450 CYP121A1 in complex with Triazole Pyrazole inhibitor 14a
3IW1	;	2.0	;	Crystal structure of Mycobacterium tuberculosis cytochrome P450 CYP125 in complex with androstenedione
3IW2	;	2.19	;	Crystal structure of Mycobacterium tuberculosis cytochrome P450 CYP125 in complex with econazole
3IW0	;	1.7	;	Crystal structure of Mycobacterium tuberculosis cytochrome P450 CYP125, C2221 crystal form
3IVY	;	1.352	;	Crystal structure of Mycobacterium tuberculosis cytochrome P450 CYP125, p212121 crystal form
4PPR	;	2.0	;	Crystal structure of Mycobacterium tuberculosis D,D-peptidase Rv3330 in complex with meropenem
4ONC	;	1.83	;	Crystal Structure of Mycobacterium Tuberculosis Decaprenyl Diphosphate Synthase in Complex with BPH-640
3FMF	;	2.05	;	Crystal structure of Mycobacterium tuberculosis dethiobiotin synthetase complexed with 7,8 diaminopelargonic acid carbamate
3FMI	;	2.18	;	Crystal structure of Mycobacterium tuberculosis dethiobiotin synthetase complexed with 7-Keto 8-aminopelargonic acid
3FPA	;	2.3	;	Crystal structure of Mycobacterium tuberculosis dethiobiotin synthetase complexed with dethiobiotin and phosphate
6NKA	;	2.23	;	Crystal structure of Mycobacterium tuberculosis dethiobiotin synthetase in complex with 2'-deoxycytidine
6NN0	;	2.343	;	Crystal structure of Mycobacterium tuberculosis dethiobiotin synthetase in complex with 2'-deoxycytidine and fragment degradation product B9D
6NL5	;	2.314	;	Crystal structure of Mycobacterium tuberculosis dethiobiotin synthetase in complex with 2'-deoxycytidine triphosphate
6CZD	;	2.4	;	Crystal structure of Mycobacterium tuberculosis dethiobiotin synthetase in complex with adenosine diphosphate
6CVV	;	2.41	;	Crystal structure of Mycobacterium tuberculosis dethiobiotin synthetase in complex with adenosine triphosphate (ATP) - promiscuous binding mode with disordered nucleoside
6NMZ	;	2.4	;	Crystal structure of Mycobacterium tuberculosis dethiobiotin synthetase in complex with an intentionally produced fragment degradation product B9D
6CVU	;	2.426	;	Crystal structure of Mycobacterium tuberculosis dethiobiotin synthetase in complex with cytidine
6CVF	;	2.3	;	Crystal structure of Mycobacterium tuberculosis dethiobiotin synthetase in complex with cytidine diphosphate
6CVE	;	2.2	;	Crystal structure of Mycobacterium tuberculosis dethiobiotin Synthetase in complex with cytidine triphosphate and 7,8-diaminopelargonic acid
6E06	;	2.5	;	Crystal structure of Mycobacterium tuberculosis dethiobiotin synthetase in complex with cytidine triphosphate solved by precipitant-ligand exchange (crystals grown in citrate precipitant)
6E05	;	2.5	;	Crystal structure of Mycobacterium tuberculosis dethiobiotin synthetase in complex with cytidine triphosphate solved by precipitant-ligand exchange (crystals grown in sulfate precipitant)
6NWG	;	1.939	;	Crystal structure of Mycobacterium tuberculosis dethiobiotin synthetase in complex with fragment analogue 3a
6NNZ	;	2.3	;	Crystal structure of Mycobacterium tuberculosis dethiobiotin synthetase in complex with fragment analogue 4
6NU6	;	2.437	;	Crystal structure of Mycobacterium tuberculosis dethiobiotin synthetase in complex with fragment analogue 5
6NVC	;	2.25	;	Crystal structure of Mycobacterium tuberculosis dethiobiotin synthetase in complex with fragment analogue 6
6NVE	;	2.0	;	Crystal structure of Mycobacterium tuberculosis dethiobiotin synthetase in complex with fragment analogue 7
6NVF	;	1.989	;	Crystal structure of Mycobacterium tuberculosis dethiobiotin synthetase in complex with fragment analogue 8
6NLZ	;	1.9	;	Crystal structure of Mycobacterium tuberculosis dethiobiotin synthetase in complex with fragment degradation product B9D
6NL4	;	1.991	;	Crystal structure of Mycobacterium tuberculosis dethiobiotin synthetase in complex with gemcitabine
6NWN	;	2.005	;	Crystal structure of Mycobacterium tuberculosis dethiobiotin synthetase in complex with glutamic acid linked compound 10
6CZE	;	2.3	;	Crystal structure of Mycobacterium tuberculosis dethiobiotin synthetase in complex with inosine triphosphate (ITP) - promiscuous binding mode with disordered nucleoside
6CZC	;	2.3	;	Crystal structure of Mycobacterium tuberculosis dethiobiotin synthetase in complex with thymidine triphosphate (TTP) - promiscuous binding mode with disordered nucleoside
6NVD	;	2.44	;	Crystal structure of Mycobacterium tuberculosis dethiobiotin synthetase in complex with triazole linked compound 9
6CZB	;	2.4	;	Crystal structure of Mycobacterium tuberculosis dethiobiotin synthetase in complex with uridine triphosphate (UTP) - promiscuous binding mode with disordered nucleoside
1YL5	;	2.3	;	Crystal structure of Mycobacterium tuberculosis dihydrodipicolinate reductase (RV2773C) (crystal form A)
1YL6	;	2.9	;	crystal structure of Mycobacterium tuberculosis dihydrodipicolinate reductase (Rv2773c) (crystal form B)
5UJF	;	2.3	;	Crystal Structure of Mycobacterium tuberculosis Dihydrofolate Reductase Bound p218 Inhibitor
5U26	;	1.85	;	Crystal Structure of Mycobacterium tuberculosis Dihydrofolate Reductase Bound to NADP and p218 Inhibitor
5U27	;	2.05	;	Crystal Structure of Mycobacterium tuberculosis Dihydrofolate Reductase Bound to NADP and p65 Inhibitor
5EDD	;	1.97	;	Crystal structure of Mycobacterium tuberculosis dUTPase R140K, H145W mutant
3I93	;	1.8	;	Crystal structure of Mycobacterium tuberculosis dUTPase STOP138T mutant
4A03	;	1.65	;	Crystal Structure of Mycobacterium tuberculosis DXR in complex with the antibiotic FR900098 and cofactor NADPH
4JD6	;	3.5	;	Crystal structure of Mycobacterium tuberculosis Eis in complex with coenzyme A and tobramycin
7CDW	;	3.0	;	Crystal Structure of Mycobacterium Tuberculosis Elongation Factor G1
4U0J	;	1.62	;	Crystal structure of Mycobacterium tuberculosis enoyl reductase (INHA) complexed with 1-CYCLOHEXYL-5-OXO-N-PHENYLPYRROLIDINE-3-CARBOXAMIDE, refined with new ligand restraints
4TZK	;	1.62	;	Crystal structure of Mycobacterium tuberculosis enoyl reductase (INHA) complexed WITH 1-CYCLOHEXYL-N-(3,5-DICHLOROPHENYL)-5-OXOPYRROLIDINE-3-CARBOXAMIDE
4TRJ	;	1.73	;	Crystal structure of Mycobacterium tuberculosis enoyl reductase (INHA) complexed with N-(3-bromophenyl)-1-cyclohexyl-5-oxopyrrolidine-3-carboxamide, refined with new ligand restraints
4TZT	;	1.86	;	CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS ENOYL REDUCTASE (INHA) COMPLEXED WITH N-(3-CHLORO-2-METHYLPHENYL)-1-CYCLOHEXYL- 5-OXOPYRROLIDINE-3-CARBOXAMIDE
2B37	;	2.6	;	Crystal structure of Mycobacterium tuberculosis enoyl reductase (InhA) inhibited by 5-octyl-2-phenoxyphenol
2B36	;	2.8	;	Crystal structure of Mycobacterium tuberculosis enoyl reductase (InhA) inhibited by 5-pentyl-2-phenoxyphenol
2B35	;	2.3	;	Crystal structure of Mycobacterium tuberculosis enoyl reductase (InhA) inhibited by triclosan
4U0K	;	1.9	;	Crystal structure of Mycobacterium tuberculosis enoyl reductase complexed with N-(5-chloro-2-methylphenyl)-1-cyclohexyl-5-oxopyrrolidine-3-carboxamide
2ZJF	;	2.4	;	Crystal structure of Mycobacterium tuberculosis epoxide hydrolase B complexed with an inhibitor
3QYX	;	3.75	;	Crystal structure of Mycobacterium tuberculosis EspR in complex with a small DNA fragment
4NDW	;	3.3	;	Crystal STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS ESX-1 SECRETED PROTEIN REGULATOR (EspR)
5XE7	;	2.162	;	Crystal structure of Mycobacterium tuberculosis extracytoplasmic function sigma factor SigJ
4B3H	;	2.3	;	Crystal structure of Mycobacterium tuberculosis fatty acid beta- oxidation complex
4B3I	;	2.63	;	Crystal structure of Mycobacterium tuberculosis fatty acid beta- oxidation complex with CoenzymeA bound at the hydratase active sites
4B3J	;	2.5	;	Crystal structure of Mycobacterium tuberculosis fatty acid beta- oxidation complex with CoenzymeA bound at the hydratase and thiolase active sites
2AF6	;	2.01	;	Crystal structure of Mycobacterium tuberculosis Flavin dependent thymidylate synthase (Mtb ThyX) in the presence of co-factor FAD and substrate analog 5-Bromo-2'-Deoxyuridine-5'-Monophosphate (BrdUMP)
4APA	;	2.04	;	Crystal structure of Mycobacterium tuberculosis fumarase (Rv1098c) S318A in apo form
4APB	;	1.94	;	Crystal structure of Mycobacterium tuberculosis fumarase (Rv1098c) S318C in complex with fumarate
2WHI	;	2.2	;	Crystal structure of Mycobacterium Tuberculosis Glutamine Synthetase in complex with a purine analogue inhibitor and L-methionine-S- sulfoximine phosphate.
2WGS	;	2.55	;	Crystal structure of Mycobacterium Tuberculosis Glutamine Synthetase in complex with a purine analogue inhibitor.
2BVC	;	2.1	;	Crystal structure of Mycobacterium tuberculosis glutamine synthetase in complex with a transition state mimic
4ACF	;	2.0	;	CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS GLUTAMINE SYNTHETASE IN COMPLEX WITH IMIDAZOPYRIDINE INHIBITOR ((4-(6-BROMO-3-(BUTYLAMINO)IMIDAZO(1,2-A)PYRIDIN-2-YL)PHENOXY) ACETIC ACID) AND L-METHIONINE-S-SULFOXIMINE PHOSPHATE.
3ZXR	;	2.15	;	Crystal structure of Mycobacterium Tuberculosis Glutamine Synthetase in complex with tri-substituted imidazole inhibitor (3-(2-tert-butyl- 5-(pyridin-4-yl)-1H-imidazol-4-yl)quinoline) and L-methionine-S- sulfoximine phosphate.
3ZXV	;	2.26	;	Crystal structure of Mycobacterium Tuberculosis Glutamine Synthetase in complex with tri-substituted imidazole inhibitor (4-(2-tert-butyl- 4-(6-methoxynaphthalen-2-yl)-1H-imidazol-5-yl)pyridin-2-amine) and L- methionine-S-sulfoximine phosphate
3M6C	;	2.2	;	Crystal structure of Mycobacterium tuberculosis GroEL1 apical domain
1ZNY	;	2.3	;	Crystal Structure Of Mycobacterium tuberculosis Guanylate Kinase In Complex With GDP
1ZNX	;	2.35	;	Crystal Structure Of Mycobacterium tuberculosis Guanylate Kinase In Complex With GMP
5HKF	;	2.25	;	Crystal structure of Mycobacterium tuberculosis H37Rv orotate phosphoribosyltransferase in complex with 5-phospho-alpha-D-ribosyl 1-diphosphate (PRPP)
5HKI	;	2.4	;	Crystal structure of Mycobacterium tuberculosis H37Rv orotate phosphoribosyltransferase in complex with Fe(III) dicitrate
5HKL	;	1.899	;	Crystal structure of Mycobacterium tuberculosis H37Rv orotate phosphoribosyltransferase in complex with inorganic phosphate
7NAA	;	2.75	;	Crystal structure of Mycobacterium tuberculosis H37Rv PknF kinase domain
5XDS	;	1.75	;	Crystal structure of Mycobacterium tuberculosis HisB bound with an inhibitor
5ZQN	;	1.8	;	Crystal structure of Mycobacterium tuberculosis HisB in complex with a ligand
4LOM	;	2.1	;	Crystal Structure of Mycobacterium tuberculosis HisB in complex with its substrate
8F2L	;	2.89	;	Crystal structure of Mycobacterium tuberculosis Homoserine transacetylase in complex with L-Homoserine
6IEO	;	1.83	;	Crystal structure of Mycobacterium tuberculosis HtrA1 (Rv1223) in regulated conformation
5KNY	;	2.91	;	Crystal structure of Mycobacterium tuberculosis hypoxanthine guanine phosphoribosyltransferase in complex with (3-((3R,4R)-3-(Guanin-9-yl)-4-((S)-2-hydroxy-2-phosphonoethoxy)pyrrolidin-1-yl)-3-oxopropyl)phosphonic acid
5KNQ	;	2.553	;	Crystal structure of Mycobacterium tuberculosis hypoxanthine guanine phosphoribosyltransferase in complex with [3S,4R]-(4-(Guanin-9-yl)pyrrolidin-3-yl)oxymethanephosphonic acid and pyrophosphate
5KNP	;	2.45	;	Crystal structure of Mycobacterium tuberculosis hypoxanthine guanine phosphoribosyltransferase in complex with [3S,4R]-(4-(Hypoxanthin-9-yl)pyrrolidin-3-yl)-oxymethanephosphonic acid
6EE1	;	2.36	;	Crystal structure of Mycobacterium tuberculosis ICL2 in complex with acetyl-CoA
6EDZ	;	2.67	;	Crystal structure of Mycobacterium tuberculosis ICL2 in complex with acetyl-CoA, form I
6EDW	;	1.8	;	Crystal structure of Mycobacterium tuberculosis ICL2 in the apo form
4LPF	;	2.3	;	Crystal structure of Mycobacterium tuberculosis imidazole glycerol phosphate dehydratase in complex with an inhibitor
3T40	;	1.752	;	Crystal Structure of Mycobacterium tuberculosis Indole Glycerol Phosphate Synthase (IGPS) complex with N-2-Carboxyphenyl Glycine (CPG)
3T78	;	1.6	;	Crystal Structure of Mycobacterium tuberculosis Indole Glycerol Phosphate Synthase (IGPS) in Complex with 5-Fluoroanthranilate
3T44	;	1.6	;	Crystal structure of Mycobacterium tuberculosis Indole Glycerol Phosphate Synthase (IGPS) in complex with indole glycerol phosphate (IGP) amd anthranilate
3T55	;	2.06	;	Crystal structure of Mycobacterium tuberculosis Indole Glycerol Phosphate Synthase (IGPS) in complex with Phenoxymethyl Benzoic Acid (PMBA)
4OIM	;	1.848	;	Crystal structure of Mycobacterium tuberculosis InhA in complex with inhibitor PT119 in 2.4 M acetate
4OHU	;	1.598	;	Crystal structure of Mycobacterium tuberculosis InhA in complex with inhibitor PT92
6CON	;	2.1	;	Crystal structure of Mycobacterium tuberculosis IpdAB
5W2O	;	1.8	;	Crystal structure of Mycobacterium tuberculosis KasA
5W2P	;	2.0	;	Crystal structure of Mycobacterium tuberculosis KasA in complex with 6U5
5W2Q	;	1.8	;	Crystal structure of Mycobacterium tuberculosis KasA in complex with 6U5
6P9L	;	2.305	;	Crystal structure of Mycobacterium tuberculosis KasA in complex with JFX
5W2S	;	2.399	;	Crystal Structure of Mycobacterium Tuberculosis KasA in complex with KMG
6P9K	;	1.703	;	Crystal structure of Mycobacterium tuberculosis KasA in complex with O6G
6P9M	;	2.256	;	Crystal structure of Mycobacterium tuberculosis KasA in complex with O6J
4YPO	;	1.001	;	Crystal structure of Mycobacterium tuberculosis ketol-acid reductoisomerase in complex with Mg2+
5CXI	;	2.0	;	Crystal structure of Mycobacterium tuberculosis KstR in complex with 3-oxo-23,24-bisnorchol-4-en-22-oyl-CoA (4-BNC-CoA)
5CW8	;	2.6	;	Crystal structure of Mycobacterium tuberculosis KstR in complex with 3-oxo-4-cholesten-26-oyl-CoA
5CXG	;	2.1001	;	Crystal structure of Mycobacterium tuberculosis KstR in complex with PEG
5E5L	;	1.89	;	Crystal structure of Mycobacterium tuberculosis L,D-transpeptidase 1 at 1.89 Angstrom
5E51	;	2.25	;	Crystal structure of Mycobacterium tuberculosis L,D-transpeptidase 1 with Faropenem adduct
5DZJ	;	2.095	;	Crystal structure of Mycobacterium tuberculosis L,D-transpeptidase 2 with carbapenem drug T206 in conformation A
5DZP	;	2.19	;	Crystal structure of Mycobacterium tuberculosis L,D-transpeptidase 2 with carbapenem drug T206 in conformation B
5E1G	;	1.852	;	Crystal structure of Mycobacterium tuberculosis L,D-transpeptidase 2 with carbapenem drug T208
5E1I	;	2.003	;	Crystal structure of Mycobacterium tuberculosis L,D-transpeptidase 2 with carbapenem drug T210
5K69	;	2.001	;	Crystal structure of Mycobacterium tuberculosis L,D-transpeptidase 2 with carbapenem drug T224
5DVP	;	2.18	;	Crystal structure of Mycobacterium tuberculosis L,D-transpeptidase 2 with Doripenem adduct
3VYO	;	1.8	;	Crystal structure of Mycobacterium tuberculosis L,D-transpeptidase LdtMt2 N140 truncation mutant (resideus 140-408)
3VYN	;	2.5	;	Crystal structure of Mycobacterium tuberculosis L,D-transpeptidase LdtMt2 N55 truncation mutant (resideus 55-408)
3VYP	;	1.4	;	Crystal structure of Mycobacterium tuberculosis L,D-transpeptidase LdtMt2-N140 adduct with meropenem
3HPX	;	2.03	;	Crystal structure of Mycobacterium tuberculosis LeuA active site domain 1-425 (truncation mutant delta:426-644)
3HPZ	;	2.2	;	Crystal structure of Mycobacterium tuberculosis LeuA complexed with bromopyruvate
3HQ1	;	1.7	;	Crystal structure of Mycobacterium tuberculosis LeuA complexed with citrate and Mn2+
3HPS	;	1.8	;	Crystal structure of Mycobacterium tuberculosis LeuA complexed with ketoisocaproate (KIC)
2QZ8	;	2.16	;	Crystal structure of Mycobacterium tuberculosis Leucine response regulatory protein (LrpA)
2BYO	;	2.15	;	Crystal structure of Mycobacterium tuberculosis lipoprotein LppX (Rv2945c)
1U2P	;	1.9	;	Crystal structure of Mycobacterium tuberculosis Low Molecular Protein Tyrosine Phosphatase (MPtpA) at 1.9A resolution
1U2Q	;	2.5	;	Crystal structure of Mycobacterium tuberculosis Low Molecular Weight Protein Tyrosine Phosphatase (MPtpA) at 2.5A resolution with glycerol in the active site
4ZJM	;	2.851	;	Crystal Structure of Mycobacterium tuberculosis LpqH (Rv3763)
8JA9	;	2.1	;	Crystal structure of Mycobacterium tuberculosis LpqY in complex with trehalose analogue YB-03
8JAA	;	1.7	;	Crystal structure of Mycobacterium tuberculosis LpqY in complex with trehalose analogue YB-04
8JAB	;	1.7	;	Crystal structure of Mycobacterium tuberculosis LpqY in complex with trehalose analogue YB-06
8JAC	;	2.1	;	Crystal structure of Mycobacterium tuberculosis LpqY in complex with trehalose analogue YB-16
8JAD	;	2.3	;	Crystal structure of Mycobacterium tuberculosis LpqY in complex with trehalose analogue YB-17
8JA8	;	1.6	;	Crystal structure of Mycobacterium tuberculosis LpqY with trehalose bound in a closed liganded form
4ZRA	;	1.83	;	CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS LPRG BINDING TO TRIACYLGLYCERIDE
5H8M	;	2.7	;	Crystal structure of Mycobacterium tuberculosis malate synthase C619A, G459A mutant in complex with product malate
5H8P	;	2.105	;	Crystal structure of Mycobacterium tuberculosis malate synthase in apo form
5C9W	;	2.0928	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with (Z)-N-(2-bromophenyl)-2-(hydroxyimino)acetamide
5CC5	;	2.14	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 1H-indole-3-carboxylic acid
5CC6	;	2.1	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 1H-indole-5-carboxylic acid
5CC7	;	2.12	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 1H-indole-6-carboxylic acid
5C7V	;	2.504	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 1H-pyrrole-2-carboxylic acid
5C9X	;	2.1	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 2,4-dichloro-5-fluorobenzoic acid
6DL9	;	1.8	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 2,6-Cl-phenyldiketoacid
6DKO	;	1.556	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 2,6-F-phenyldiketoacid
5C9U	;	1.95	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 2-(2-(2,4-dichlorophenyl)hydrazinyl)-2-oxoacetic acid
5CEW	;	2.03	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 2-(pyridin-4-yl)thiazolidine-4-carboxylic acid
3S9I	;	1.9	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 2-4-dioxo-4-phenylbutanoic acid inhibitor
6BU1	;	1.584	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 2-Br-3-OH-phenyldiketoacid
6C6O	;	2.3	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 2-Br-4-OH-phenyldiketoacid
6C2X	;	2.6	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 2-Br-6-Me-phenyldiketoacid
5E9X	;	1.943	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 2-chloro-6H-thieno[2,3-b]pyrrole-5-carboxylic acid
6BA7	;	2.496	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 2-Cl-4-OH-phenyldiketoacid
6DNP	;	1.711	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 2-F-3-Methyl-6-F-phenyldiketoacid
6C8P	;	1.635	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 2-F-phenyldiketoacid
5CAK	;	1.99	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 2-hydroxy-3-(1H-indol-3-yl)propanoic acid
5DRC	;	2.18	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 2-hydroxy-4-(1H-indol-3-yl)-4-oxobut-2-enoic acid
5DRI	;	2.8	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 2-hydroxy-4-(1H-indol-5-yl)-4-oxobut-2-enoic acid inhibitor
5ECV	;	2.085	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 2-hydroxy-4-(4-methyl-1H-indol-5-yl)-4-oxobut-2-enoic acid
6AXB	;	1.8	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 2-naphthyldiketoacid
6DLJ	;	2.604	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 2-Nitro-phenyldiketoacid
5T8G	;	2.04	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 2-oxo-4-((thiophene-2-carbonyl)oxy)butanoic acid
5C9R	;	2.0	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 3-((4-chlorophenyl)thio)propanoic acid
5CJN	;	2.19	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 3-(3-oxo-3,4-dihydroquinoxalin-2-yl)acrylate
5CCZ	;	2.136	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 3-(4-fluorophenyl)-4-methyl-1H-pyrazol-5-amine
5CBJ	;	1.957	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 3-(phenylthio)acrylic acid
6APZ	;	2.254	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 3-hydroxy-phenyldiketoacid
6AS6	;	1.4	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 3-Prop-6-Me-phenyldiketoacid
3S9Z	;	1.793	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 4-(2-bromophenyl)-2,4-dioxobutanoic acid inhibitor
3SB0	;	2.199	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 4-(2-chloro-6-fluoro-3-methylphenyl)-2,4-dioxobutanoic acid inhibitor
3SAD	;	1.82	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 4-(2-mehtylphenyl)-2,4-dioxobutanoic acid inhibitor
3SAZ	;	2.04	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 4-(3-bromophenyl)-2,4-dioxobutanoic acid inhibitor
6ASU	;	2.316	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 4-methyl-phenyldiketoacid
5CJM	;	2.13	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 4H-thieno[3,2-b]pyrrole-5-carboxylic acid
5CBB	;	2.012	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 5-(3H-indol-3-ylidene)-2,5-dihydro-1H-pyrazole-3-carboxylate
5DX7	;	2.1	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 5-(5-chlorothiophen-2-yl)isoxazole-3-carboxylic acid
5CBI	;	1.988	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 5-chloro-2-hydroxybenzonitrile
5CC3	;	2.204	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 6-bromo-1H-indole-2-carboxylic acid
5CAH	;	2.303	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 6H-thieno[2,3-b]pyrrole-5-carboxylic acid
6AU9	;	2.1	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with dioxine-phenyldiketoacid
6C7B	;	2.133	;	Crystal structure of Mycobacterium tuberculosis malate synthase in complex with Methoxynaphthyldiketoacid
4O7O	;	2.4006	;	Crystal structure of Mycobacterium tuberculosis maltose kinase MaK
4O7P	;	2.9	;	Crystal structure of Mycobacterium tuberculosis maltose kinase MaK complexed with maltose
5HSM	;	1.9	;	CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS MARR FAMILY PROTEIN RV2887
5HSO	;	2.5	;	Crystal structure of MYCOBACTERIUM TUBERCULOSIS MARR FAMILY PROTEIN Rv2887 complex with DNA
5X7Z	;	2.2	;	CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS MARR FAMILY PROTEIN RV2887 COMPLEX WITH P-AMINOSALICYLIC ACID
5X80	;	2.4	;	CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS MARR FAMILY PROTEIN RV2887 COMPLEX WITH SALICYLIC ACID
1Q51	;	2.3	;	Crystal Structure of Mycobacterium tuberculosis MenB in Complex with Acetoacetyl-Coenzyme A, a Key Enzyme in Vitamin K2 Biosynthesis
3T8A	;	2.245	;	Crystal structure of Mycobacterium tuberculosis MenB in complex with substrate analogue, OSB-NCoA
3T8B	;	1.649	;	Crystal structure of Mycobacterium tuberculosis MenB with altered hexameric assembly
1Q52	;	1.8	;	Crystal Structure of Mycobacterium tuberculosis MenB, a Key Enzyme in Vitamin K2 Biosynthesis
8XHR	;	2.1	;	Crystal structure of Mycobacterium tuberculosis MenT3 bound with CTP
5XET	;	2.38	;	Crystal structure of Mycobacterium tuberculosis methionyl-tRNA synthetase bound by methionyl-adenylate (Met-AMP)
6ACA	;	3.6	;	Crystal structure of Mycobacterium tuberculosis Mfd at 3.6 A resolution
8F5V	;	1.45	;	Crystal structure of Mycobacterium tuberculosis Mycothiol S-transferase enzyme in complex with mycothiol and Zn2+
1U0R	;	2.8	;	Crystal structure of Mycobacterium tuberculosis NAD kinase
1U0T	;	2.3	;	Crystal structure of Mycobacterium tuberculosis NAD kinase
1Y3I	;	2.6	;	Crystal Structure of Mycobacterium tuberculosis NAD kinase-NAD complex
1K0R	;	1.7	;	Crystal Structure of Mycobacterium tuberculosis NusA
4BHB	;	1.8	;	Crystal structure of Mycobacterium tuberculosis O6-METHYLGUANINE METHYLTRANSFERASE
4WX9	;	3.0	;	Crystal structure of Mycobacterium tuberculosis OGT in complex with DNA
4WXD	;	2.3	;	Crystal structure of Mycobacterium tuberculosis OGT-R37K
4WXC	;	2.6	;	Crystal structure of Mycobacterium tuberculosis OGT-Y139F
8J5U	;	1.98	;	Crystal structure of Mycobacterium tuberculosis OppA complexed with an endogenous oligopeptide
4BFY	;	2.3	;	Crystal structure of Mycobacterium tuberculosis PanK in complex with a biaryl inhibitory compound (2a) and phosphate
4BFZ	;	2.1	;	Crystal structure of Mycobacterium tuberculosis PanK in complex with a biaryl inhibitory compound (2b) and phosphate
4BFS	;	2.9	;	Crystal structure of Mycobacterium tuberculosis PanK in complex with a triazole inhibitory compound (1a)
4BFT	;	2.29	;	Crystal structure of Mycobacterium tuberculosis PanK in complex with a triazole inhibitory compound (1b) and phosphate
4BFU	;	2.28	;	Crystal structure of Mycobacterium tuberculosis PanK in complex with a triazole inhibitory compound (1c) and phosphate
4BFV	;	2.29	;	Crystal structure of Mycobacterium tuberculosis PanK in complex with a triazole inhibitory compound (1d) and phosphate
4BFW	;	2.27	;	Crystal structure of Mycobacterium tuberculosis PanK in complex with a triazole inhibitory compound (1e) and phosphate
4BFX	;	2.7	;	Crystal structure of Mycobacterium tuberculosis PanK in complex with a triazole inhibitory compound (1f) and phosphate
3COV	;	1.5	;	Crystal Structure of Mycobacterium Tuberculosis Pantothenate Synthetase at 1.5 Ang resolution- apo form
3IMC	;	1.6	;	Crystal Structure of Mycobacterium Tuberculosis Pantothenate Synthetase at 1.6 Ang resolution in complex with fragment compound 5-methoxyindole, sulfate and glycerol
3LE8	;	1.7	;	Crystal Structure of Mycobacterium Tuberculosis Pantothenate Synthetase at 1.70 Angstrom resolution in complex with 2-(2-((benzofuran-2-carboxamido)methyl)-5-methoxy-1H-indol-1-yl)acetic acid
3IOD	;	1.75	;	Crystal Structure of Mycobacterium Tuberculosis Pantothenate Synthetase at 1.75 Ang resolution in complex with 5'-deoxy-5'-((3-nitrobenzyl)disulfanyl)-adenosine
3IMG	;	1.8	;	Crystal Structure of Mycobacterium Tuberculosis Pantothenate Synthetase at 1.8 Ang resolution in a ternary complex with fragment compounds 5-methoxyindole and 1-benzofuran-2-carboxylic acid
3COW	;	1.8	;	Crystal Structure of Mycobacterium Tuberculosis Pantothenate Synthetase at 1.8 Ang resolution- in complex with sulphonamide inhibitor 2
3IOB	;	1.8	;	Crystal Structure of Mycobacterium Tuberculosis Pantothenate Synthetase at 1.80 Ang resolution in complex with 5'-deoxy-5'-thioadenosine
3IOE	;	1.95	;	Crystal Structure of Mycobacterium Tuberculosis Pantothenate Synthetase at 1.95 Ang resolution in complex with 5'-deoxy-5'-((R)-3,4-dihydroxybutylthio)-adenosine
3COZ	;	2.0	;	Crystal Structure of Mycobacterium Tuberculosis Pantothenate Synthetase at 2.0 Ang resolution- in complex with sulphonamide inhibitor 4
3COY	;	2.03	;	Crystal Structure of Mycobacterium Tuberculosis Pantothenate Synthetase at 2.05 Ang resolution- in complex with sulphonamide inhibitor 3
3IME	;	2.39	;	Crystal Structure of Mycobacterium Tuberculosis Pantothenate Synthetase at 2.40 Ang resolution in complex with fragment compound 1-Benzofuran-2-carboxylic acid
3IOC	;	2.5	;	Crystal Structure of Mycobacterium Tuberculosis Pantothenate Synthetase at 2.50 Ang resolution in complex with 5'-deoxy-5'-(benzyldisulfanyl)-adenosine
4G5Y	;	1.8	;	Crystal Structure of Mycobacterium tuberculosis Pantothenate synthetase in a ternary complex with ATP and N,N-DIMETHYLTHIOPHENE-3-SULFONAMIDE
4EF6	;	1.94	;	Crystal Structure of Mycobacterium tuberculosis Pantothenate synthetase in complex with fragment 1
3E3U	;	1.56	;	Crystal structure of Mycobacterium tuberculosis peptide deformylase in complex with inhibitor
7DAW	;	2.83	;	Crystal structure of Mycobacterium tuberculosis phenylalanyl-tRNA synthetase
7DB7	;	2.71	;	Crystal structure of Mycobacterium tuberculosis phenylalanyl-tRNA synthetase in complex with compound GDI05-001
7DB8	;	2.3	;	Crystal structure of Mycobacterium tuberculosis phenylalanyl-tRNA synthetase in complex with compound PF-3845
6H53	;	2.9	;	Crystal structure of Mycobacterium tuberculosis phosphatidylinositol phosphate synthase (PgsA1) in apo form
6H5A	;	1.88	;	Crystal structure of Mycobacterium tuberculosis phosphatidylinositol phosphate synthase (PgsA1) in complex with manganese and citrate
6H59	;	1.8	;	Crystal structure of Mycobacterium tuberculosis phosphatidylinositol phosphate synthase (PgsA1) with CDP-DAG bound
2Y88	;	1.33	;	CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS PHOSPHORIBOSYL ISOMERASE (VARIANT D11N) WITH BOUND PRFAR
2Y89	;	2.5	;	CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS PHOSPHORIBOSYL ISOMERASE A (VARIANT D11N)
3ZS4	;	1.9	;	CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS PHOSPHORIBOSYL ISOMERASE WITH BOUND PRFAR
2Y85	;	2.4	;	CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS PHOSPHORIBOSYL ISOMERASE WITH BOUND RCDRP
5M06	;	2.0	;	Crystal structure of Mycobacterium tuberculosis PknI kinase domain
5M07	;	2.5	;	Crystal structure of Mycobacterium tuberculosis PknI kinase domain, C20A mutant
5M08	;	3.03	;	Crystal structure of Mycobacterium tuberculosis PknI kinase domain, C20A_R136A double mutant
5M09	;	2.98	;	Crystal structure of Mycobacterium tuberculosis PknI kinase domain, C20A_R136N double mutant
4JAR	;	1.98	;	Crystal structure of mycobacterium tuberculosis pks11 in complex with polyketide intermediates and evidence that it synthesize ALKYLPYRONES
4JAO	;	2.05	;	Crystal Structure of Mycobacterium tuberculosis PKS11 Reveals Intermediates in the Synthesis of Methyl-branched Alkylpyrones
4JAP	;	1.833	;	Crystal Structure of Mycobacterium tuberculosis PKS11 Reveals Intermediates in the Synthesis of Methyl-branched Alkylpyrones
4JAQ	;	1.73	;	Crystal Structure of Mycobacterium tuberculosis PKS11 Reveals Intermediates in the Synthesis of Methyl-branched Alkylpyrones
4JAT	;	2.42	;	Crystal Structure of Mycobacterium tuberculosis PKS11 Reveals Intermediates in the Synthesis of Methyl-branched Alkylpyrones
4JD3	;	2.25	;	Crystal Structure of Mycobacterium tuberculosis PKS11 Reveals Intermediates in the Synthesis of Methyl-branched Alkylpyrones
1N3I	;	1.9	;	Crystal Structure of Mycobacterium tuberculosis PNP with transition state analog DADMe-ImmH
3MI0	;	2.2	;	Crystal Structure of Mycobacterium Tuberculosis Proteasome at 2.2 A
2FHH	;	2.99	;	Crystal Structure of Mycobacterium Tuberculosis Proteasome in complex with a peptidyl boronate inhibitor MLN-273
3KRD	;	2.5	;	Crystal Structure of Mycobacterium Tuberculosis Proteasome in complex with Fellutamide B
5THO	;	3.002	;	Crystal Structure of Mycobacterium Tuberculosis Proteasome in complex with N,C-capped Dipeptide Inhibitor PKS2205
6OCW	;	2.6	;	Crystal Structure of Mycobacterium tuberculosis Proteasome in Complex with Phenylimidazole-based Inhibitor A85
6OCZ	;	2.65	;	Crystal Structure of Mycobacterium tuberculosis Proteasome in Complex with Phenylimidazole-based Inhibitor A86
6ODE	;	2.9	;	Crystal Structure of Mycobacterium tuberculosis Proteasome in Complex with Phenylimidazole-based Inhibitor B6
3H6I	;	2.43	;	Crystal Structure of Mycobacterium Tuberculosis Proteasome Modified by inhibitor GL1
3H6F	;	2.51	;	Crystal Structure of Mycobacterium Tuberculosis Proteasome Modified by inhibitor HT1171
3HFA	;	2.504	;	Crystal Structure of Mycobacterium Tuberculosis Proteasome open-gate mutant
3HF9	;	2.878	;	Crystal Structure of Mycobacterium Tuberculosis Proteasome open-gate mutant modified by inhibitor GL1
3MFE	;	2.6	;	Crystal Structure of Mycobacterium Tuberculosis Proteasome open-gate mutant with H0 movement
3MKA	;	2.51	;	Crystal Structure of Mycobacterium Tuberculosis Proteasome with propetide and an T1A mutation at beta-subunit
5UN0	;	3.0	;	Crystal Structure of Mycobacterium Tuberculosis Proteasome-assembly chaperone homologue Rv2125
1YWF	;	1.71	;	Crystal Structure of Mycobacterium Tuberculosis Protein Tyrosine Phosphatase PtpB
2OZ5	;	2.0	;	Crystal structure of Mycobacterium tuberculosis protein tyrosine phosphatase PtpB in complex with the specific inhibitor OMTS
4A1O	;	2.48	;	Crystal structure of Mycobacterium tuberculosis PurH complexed with AICAR and a novel nucleotide CFAIR, at 2.48 A resolution.
3ZZM	;	2.2	;	Crystal structure of Mycobacterium tuberculosis PurH with a novel bound nucleotide CFAIR, at 2.2 A resolution.
8IBP	;	1.45	;	Crystal structure of Mycobacterium tuberculosis R21K ClpC1 N-terminal domain in complex with Lassomycin
3OEI	;	2.145	;	Crystal structure of Mycobacterium tuberculosis RelJK (Rv3357-Rv3358-RelBE3)
4CGE	;	2.756	;	Crystal structure of Mycobacterium tuberculosis Resuscitation promoting factor E
2VVO	;	1.85	;	Crystal structure of Mycobacterium tuberculosis ribose-5-phosphate isomerase B in complex with alpha d-allose 6-phosphate
2VVP	;	1.65	;	Crystal structure of Mycobacterium tuberculosis ribose-5-phosphate isomerase B in complex with its substrates ribose 5-phosphate and ribulose 5-phosphate
2VVQ	;	2.0	;	Crystal structure of Mycobacterium tuberculosis ribose-5-phosphate isomerase B in complex with the inhibitor 5-deoxy-5-phospho-D- ribonate
3B4T	;	2.1	;	Crystal structure of Mycobacterium tuberculosis RNase PH, the Mycobacterium tuberculosis Structural Genomics Consortium target Rv1340
5D18	;	2.04	;	Crystal structure of Mycobacterium tuberculosis Rv0302, form I
5D19	;	2.655	;	Crystal structure of Mycobacterium tuberculosis Rv0302, form II
2WAW	;	1.6	;	crystal structure of Mycobacterium tuberculosis rv0371c homolog from mycobacterium sp. strain JC1
2WE7	;	2.9	;	Crystal structure of Mycobacterium tuberculosis Rv0376c homologue from Mycobacterium smegmatis
2WE8	;	2.3	;	Crystal structure of Mycobacterium tuberculosis Rv0376c homologue from Mycobacterium smegmatis
5D1R	;	2.0	;	Crystal structure of Mycobacterium tuberculosis Rv1816 transcriptional regulator.
5D1W	;	3.59	;	Crystal structure of Mycobacterium tuberculosis Rv3249c transcriptional regulator.
3CAI	;	1.8	;	Crystal structure of Mycobacterium tuberculosis Rv3778c protein
2ZJ0	;	2.42	;	Crystal structure of Mycobacterium tuberculosis S-Adenosyl-L-homocysteine hydrolase in ternary complex with NAD and 2-fluoroadenosine
2ZJ1	;	2.01	;	Crystal structure of Mycobacterium tuberculosis S-adenosyl-L-homocysteine hydrolase in ternary complex with NAD and 3'-keto-aristeromycin
2ZIZ	;	2.2	;	Crystal structure of Mycobacterium tuberculosis S-adenosyl-L-homocysteine hydrolase in ternary complex with NAD and 3-deazaadenosine
3CE6	;	1.6	;	Crystal structure of Mycobacterium tuberculosis S-adenosyl-L-homocysteine hydrolase in ternary complex with NAD and adenosine
4P4G	;	1.7	;	Crystal Structure of Mycobacterium tuberculosis Shikimate Dehydrogenase
4P4L	;	2.009	;	Crystal Structure of Mycobacterium tuberculosis Shikimate Dehydrogenase
4P4N	;	1.95	;	Crystal Structure of Mycobacterium tuberculosis Shikimate Dehydrogenase
2G1J	;	2.0	;	Crystal structure of Mycobacterium tuberculosis Shikimate Kinase at 2.0 angstrom resolution
4BQS	;	2.15	;	Crystal structure of Mycobacterium tuberculosis shikimate kinase in complex with ADP and a shikimic acid derivative.
1U8A	;	2.15	;	Crystal Structure of Mycobacterium Tuberculosis Shikimate Kinase in Complex with Shikimate and ADP at 2.15 Angstrom Resolution
1ZYU	;	2.9	;	Crystal structure of Mycobacterium tuberculosis shikimate kinase in complex with shikimate and amppcp at 2.85 angstrom resolution
2G1K	;	1.75	;	Crystal structure of Mycobacterium tuberculosis shikimate kinase in complex with shikimate at 1.75 angstrom resolution
5Z9Y	;	1.48	;	Crystal structure of Mycobacterium tuberculosis thiazole synthase (ThiG) complexed with DXP
4FQS	;	1.8	;	Crystal Structure of Mycobacterium tuberculosis ThyA in complex with UMP and Pemetrexed
1MRS	;	2.0	;	CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS THYMIDYLATE KINASE COMPLEXED WITH 5-CH2OH DEOXYURIDINE MONOPHOSPHATE
1W2H	;	2.0	;	Crystal Structure Of Mycobacterium Tuberculosis Thymidylate Kinase Complexed With Azidothymidine Monophosphate (AZT-MP) (2.0 A Resolution)
1MRN	;	2.45	;	CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS THYMIDYLATE KINASE COMPLEXED WITH BISUBSTRATE INHIBITOR (TP5A)
1W2G	;	2.1	;	Crystal Structure Of Mycobacterium Tuberculosis Thymidylate Kinase Complexed With Deoxythymidine (dT) (2.1 A Resolution)
1N5J	;	1.85	;	CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS THYMIDYLATE KINASE COMPLEXED WITH THYMIDINE DIPHOSPHATE (TDP) AND THYMIDINE TRIPHOSPHATE (TTP) AT PH 5.4 (1.85 A RESOLUTION)
1G3U	;	1.95	;	CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS THYMIDYLATE KINASE COMPLEXED WITH THYMIDINE MONOPHOSPHATE (TMP)
1GSI	;	1.6	;	CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS THYMIDYLATE KINASE COMPLEXED WITH THYMIDINE MONOPHOSPHATE (TMP)
1GTV	;	1.55	;	CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS THYMIDYLATE KINASE COMPLEXED WITH THYMIDINE-5'-DIPHOSPHATE (TDP)
1N5K	;	2.1	;	CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS THYMIDYLATE KINASE CRYSTALLIZED IN SODIUM MALONATE (RESOLUTION 2.1 A)
1N5L	;	2.3	;	CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS THYMIDYLATE KINASE CRYSTALLIZED IN SODIUM MALONATE, AFTER CATALYSIS IN THE CRYSTAL (2.3 A RESOLUTION)
3GWC	;	1.9	;	Crystal structure of Mycobacterium tuberculosis thymidylate synthase X bound to FdUMP and FAD
3HZG	;	2.45	;	Crystal structure of mycobacterium tuberculosis thymidylate synthase X bound with FAD
5D5H	;	2.52	;	Crystal structure of Mycobacterium tuberculosis Topoisomerase I
5UJ1	;	2.153	;	Crystal structure of Mycobacterium tuberculosis Topoisomerase I at 2.15A resolution limit
6CQ2	;	3.004	;	Crystal structure of Mycobacterium tuberculosis Topoisomerase I in complex with oligonucleotide MTS2-12 and Magnesium
5UHA	;	3.906	;	Crystal structure of Mycobacterium tuberculosis transcription initiation complex
5UH9	;	4.402	;	Crystal structure of Mycobacterium tuberculosis transcription initiation complex containing 2nt RNA
5UH6	;	3.837	;	Crystal structure of Mycobacterium tuberculosis transcription initiation complex containing 2ntRNA in complex with Rifampin
5UH5	;	3.746	;	Crystal structure of Mycobacterium tuberculosis transcription initiation complex containing 3 nt of RNA
5UHC	;	3.796	;	Crystal structure of Mycobacterium tuberculosis transcription initiation complex containing 3nt RNA in complex with Rifampin
5UH8	;	4.176	;	Crystal structure of Mycobacterium tuberculosis transcription initiation complex containing 4nt RNA
5UHD	;	4.01	;	Crystal structure of Mycobacterium tuberculosis transcription initiation complex containing 4nt RNA in complex with Rifampin
5UHE	;	4.039	;	Crystal structure of Mycobacterium tuberculosis transcription initiation complex in complex with D-AAP1
5UHG	;	3.971	;	Crystal structure of Mycobacterium tuberculosis transcription initiation complex in complex with D-AAP1 and Rifampin
5UHF	;	4.345	;	Crystal structure of Mycobacterium tuberculosis transcription initiation complex in complex with D-IX336
5UHB	;	4.29	;	Crystal structure of Mycobacterium tuberculosis transcription initiation complex in complex with Rifampin
6DVE	;	3.812	;	Crystal structure of Mycobacterium tuberculosis transcription initiation complex(ECF selenomethionine-labelled sigma factor L) with 6 nt spacer
6DV9	;	3.8	;	Crystal structure of Mycobacterium tuberculosis transcription initiation complex(ECF sigma factor L) containing 5nt RNA with 4nt spacer
6DVB	;	3.8	;	Crystal structure of Mycobacterium tuberculosis transcription initiation complex(ECF sigma factor L) containing 5nt RNA with 5nt spacer
6DVC	;	3.3	;	Crystal structure of Mycobacterium tuberculosis transcription initiation complex(ECF sigma factor L) containing 5nt RNA with 6nt spacer
6DVD	;	3.899	;	Crystal structure of Mycobacterium tuberculosis transcription initiation complex(ECF sigma factor L) with 6 nt spacer and bromine labelled in position ""-11
3RIM	;	2.49	;	Crystal structure of mycobacterium tuberculosis Transketolase (Rv1449c)
2GKM	;	1.731	;	Crystal structure of Mycobacterium tuberculosis trHbN TyrB10Phe mutant
2GLN	;	1.98	;	Crystal structure of Mycobacterium tuberculosis trHbN, GlnE11Ala mutant
2GKN	;	2.1	;	Crystal structure of Mycobacterium tuberculosis trHbN, GlnE11Val mutant
2GL3	;	1.92	;	Crystal structure of Mycobacterium tuberculosis trHbN, TyrB10Phe GlnE11Val mutant
2QRW	;	1.93	;	Crystal structure of Mycobacterium tuberculosis trHbO WG8F mutant
7EL8	;	2.1	;	Crystal structure of Mycobacterium tuberculosis tryptophanyl-tRNA synthetase
7ENS	;	2.2	;	Crystal structure of Mycobacterium tuberculosis tryptophanyl-tRNA synthetase complexed with Indolmycin and ATP
7ELT	;	1.9	;	Crystal structure of Mycobacterium tuberculosis tryptophanyl-tRNA synthetase complexed with Trp-AMP
7EV3	;	2.7	;	Crystal structure of Mycobacterium tuberculosis tryptophanyl-tRNA synthetase complexed with Y-10 and ATP
7EV2	;	2.1	;	Crystal structure of Mycobacterium tuberculosis tryptophanyl-tRNA synthetase complexed with Y-11 and ATP
7ENT	;	2.4	;	Crystal structure of Mycobacterium tuberculosis tryptophanyl-tRNA synthetase complexed with Y-13 and ATP
4CIY	;	2.1	;	Crystal structure of Mycobacterium tuberculosis type 2 dehydroquinase in complex with (1R,4R,5R)-1,4,5-trihydroxy-3-((1R)-1-hydroxy-2- phenyl)ethylcyclohex-2-en-1-carboxylic acid
4CIW	;	2.2	;	Crystal structure of Mycobacterium tuberculosis type 2 dehydroquinase in complex with (1R,4R,5R)-1,4,5-trihydroxy-3-(2-hydroxy)ethylcyclohex-2-ene-1-carboxylic acid
4CIV	;	2.9	;	Crystal structure of Mycobacterium tuberculosis type 2 dehydroquinase in complex with (1R,4R,5R)-1,4,5-trihydroxy-3-hydroxymethylcyclohex-2-ene-1-carboxylic acid
4CIX	;	2.9	;	Crystal structure of Mycobacterium tuberculosis type 2 dehydroquinase in complex with(1R,4R,5R)-1,4,5-trihydroxy-3-((1S)-1-hydroxy-2-phenyl) ethylcyclohex-2-en-1-carboxylic acid
4V0S	;	1.55	;	Crystal structure of Mycobacterium tuberculosis Type II Dehydroquinase D88N mutant inhibited by a 3-dehydroquinic acid derivative
4MFI	;	1.5	;	Crystal structure of Mycobacterium tuberculosis UgpB
2WAM	;	2.6	;	Crystal structure of Mycobacterium tuberculosis unknown function protein Rv2714
8I67	;	1.72	;	Crystal structure of Mycobacterium tuberculosis Uracil-DNA glycosylase in complex with 2,4-Thiazolidinedione, Form I
4WS8	;	1.4	;	Crystal structure of Mycobacterium tuberculosis uracil-DNA glycosylase in complex with 2-thiouracil, Form V
4WS6	;	1.1	;	Crystal structure of Mycobacterium tuberculosis uracil-DNA glycosylase in complex with 5-aminouracil, Form I
4WS7	;	1.88	;	Crystal structure of Mycobacterium tuberculosis uracil-DNA glycosylase in complex with 5-chlorouracil, Form II
8I69	;	2.0	;	Crystal structure of Mycobacterium tuberculosis Uracil-DNA glycosylase in complex with 5-Fluoroorotic acid and Citric acid, Form I
4WS0	;	1.974	;	Crystal structure of Mycobacterium tuberculosis uracil-DNA glycosylase in complex with 5-fluorouracil (A), Form II
4WRZ	;	1.193	;	Crystal structure of Mycobacterium tuberculosis uracil-DNA glycosylase in complex with 5-fluorouracil (AB), Form I
4WS1	;	1.4	;	Crystal structure of Mycobacterium tuberculosis uracil-DNA glycosylase in complex with 5-fluorouracil (AB), Form II
4WRY	;	1.43	;	Crystal structure of Mycobacterium tuberculosis uracil-DNA glycosylase in complex with 5-fluorouracil(B), Form I
8I6B	;	1.6	;	Crystal structure of Mycobacterium tuberculosis Uracil-DNA glycosylase in complex with 5-Hydroxy-2,4(1H,3H)-pyrimidinedione, Form I
8I6D	;	2.4	;	Crystal structure of Mycobacterium tuberculosis Uracil-DNA glycosylase in complex with 5-Hydroxy-2,4(1H,3H)-pyrimidinedione, Form VI
4WS4	;	1.18	;	Crystal structure of Mycobacterium tuberculosis uracil-DNA glycosylase in complex with 5-nitrouracil, Form I
4WS5	;	1.4	;	Crystal structure of Mycobacterium tuberculosis uracil-DNA glycosylase in complex with 5-nitrouracil, Form III
4WS2	;	1.13	;	Crystal structure of Mycobacterium tuberculosis uracil-DNA glycosylase in complex with 6-aminouracil, Form I
4WS3	;	1.4	;	Crystal structure of Mycobacterium tuberculosis uracil-DNA glycosylase in complex with 6-aminouracil, Form IV
8I6C	;	2.28	;	Crystal structure of Mycobacterium tuberculosis Uracil-DNA glycosylase in complex with 6-Formyl-uracil, Form III
8I61	;	1.24	;	Crystal structure of Mycobacterium tuberculosis Uracil-DNA glycosylase in complex with Barbituric acid and Citric acid, Form I
8I62	;	1.26	;	Crystal structure of Mycobacterium tuberculosis Uracil-DNA glycosylase in complex with Barbituric acid, Form I
8I64	;	2.26	;	Crystal structure of Mycobacterium tuberculosis Uracil-DNA glycosylase in complex with Barbituric acid, Form II
8I63	;	1.95	;	Crystal structure of Mycobacterium tuberculosis Uracil-DNA glycosylase in complex with Barbituric acid, Form III
8I66	;	2.6	;	Crystal structure of Mycobacterium tuberculosis Uracil-DNA glycosylase in complex with isoorotic acid (2,4-Dihydroxypyrimidine-5-carboxylic Acid) and citric acid, Form I
8I65	;	1.72	;	Crystal structure of Mycobacterium tuberculosis Uracil-DNA glycosylase in complex with isoorotic acid (2,4-Dihydroxypyrimidine-5-carboxylic Acid), Form I
8I6A	;	2.0	;	Crystal structure of Mycobacterium tuberculosis Uracil-DNA glycosylase in complex with Orotic acid, Form III
4WPL	;	1.15	;	Crystal structure of Mycobacterium tuberculosis uracil-DNA glycosylase in complex with uracil, Form I
4WRU	;	1.24	;	Crystal structure of Mycobacterium tuberculosis uracil-DNA glycosylase in complex with uracil, Form II
4WRV	;	1.44	;	Crystal structure of Mycobacterium tuberculosis uracil-DNA glycosylase in complex with uracil, Form III
8I68	;	1.88	;	Crystal structure of Mycobacterium tuberculosis Uracil-DNA glycosylase in complex with Uric acid, Form III
4WPK	;	0.98	;	Crystal structure of Mycobacterium tuberculosis uracil-DNA glycosylase, Form I
4WRW	;	1.9	;	Crystal structure of Mycobacterium tuberculosis uracil-DNA glycosylase, Form IV
4WRX	;	1.4	;	Crystal structure of Mycobacterium tuberculosis uracil-DNA glycosylase, Form V
6A7V	;	1.67	;	Crystal structure of Mycobacterium tuberculosis VapBC11 toxin-antitoxin complex
5WZ4	;	1.775	;	Crystal structure of Mycobacterium tuberculosis VapC20 (Rv2549c), Sarcin-Ricin loop cleaving toxin
5WZF	;	1.75	;	Crystal structure of Mycobacterium tuberculosis VapC20 (Rv2549c), Sarcin-Ricin loop cleaving toxin
5H8U	;	2.85	;	Crystal structure of mycobacterium tuberculosis wild-type malate synthase in complex with product malate
3ZUK	;	2.6	;	CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS ZINC METALLOPROTEASE ZMP1 IN COMPLEX WITH INHIBITOR
6BWH	;	2.18	;	Crystal structure of Mycoibacterium tuberculosis Rv2983 in complex with PEP
1KPG	;	2.0	;	Crystal Structure of mycolic acid cyclopropane synthase CmaA1 complexed with SAH and CTAB
1KPH	;	2.0	;	Crystal Structure of mycolic acid cyclopropane synthase CmaA1 complexed with SAH and DDDMAB
1KP9	;	2.21	;	Crystal structure of mycolic acid cyclopropane synthase CmaA1, apo-form
1KPI	;	2.65	;	Crystal Structure of mycolic acid cyclopropane synthase CmaA2 complexed with SAH and DDDMAB
1L1E	;	2.0	;	Crystal Structure of Mycolic Acid Cyclopropane Synthase PcaA Complexed with S-adenosyl-L-homocysteine
6AJF	;	2.698	;	Crystal structure of mycolic acid transporter MmpL3 from Mycobacterium smegmatis
6AJH	;	2.818	;	Crystal structure of mycolic acid transporter MmpL3 from Mycobacterium smegmatis complexed with AU1235
6AJJ	;	2.794	;	Crystal structure of mycolic acid transporter MmpL3 from Mycobacterium smegmatis complexed with ICA38
7C2M	;	3.1	;	Crystal structure of mycolic acid transporter MmpL3 from Mycobacterium smegmatis complexed with NITD-349
6AJI	;	2.9	;	Crystal structure of mycolic acid transporter MmpL3 from Mycobacterium smegmatis complexed with Rimonabant
7C2N	;	2.82	;	Crystal structure of mycolic acid transporter MmpL3 from Mycobacterium smegmatis complexed with SPIRO
6AJG	;	2.604	;	Crystal structure of mycolic acid transporter MmpL3 from Mycobacterium smegmatis complexed with SQ109
6Q5T	;	2.54	;	Crystal structure of Mycolicibacterium hassiacum glucosylglycerate hydrolase (MhGgH) - apo form
5OHZ	;	2.036	;	Crystal structure of Mycolicibacterium hassiacum glucosylglycerate hydrolase (MhGgH) - SeMet derivative
5OIW	;	1.71	;	Crystal structure of Mycolicibacterium hassiacum glucosylglycerate hydrolase (MhGgH) D182A variant in complex with glucosylglycerate
5ONZ	;	1.93	;	Crystal structure of Mycolicibacterium hassiacum glucosylglycerate hydrolase (MhGgH) D182A variant in complex with glucosylglycolate
5OJ4	;	1.79	;	Crystal structure of Mycolicibacterium hassiacum glucosylglycerate hydrolase (MhGgH) D182A variant in complex with mannosylglycerate
5OI1	;	1.75	;	Crystal structure of Mycolicibacterium hassiacum glucosylglycerate hydrolase (MhGgH) D182A variant in complex with serine and glycerol
5OIV	;	1.783	;	Crystal structure of Mycolicibacterium hassiacum glucosylglycerate hydrolase (MhGgH) D43A variant in complex with serine and glycerol
5OJU	;	2.17	;	Crystal structure of Mycolicibacterium hassiacum glucosylglycerate hydrolase (MhGgH) E419A variant in complex with glucosylglycerate
5OO2	;	2.06	;	Crystal structure of Mycolicibacterium hassiacum glucosylglycerate hydrolase (MhGgH) E419A variant in complex with glucosylglycolate
5OJV	;	2.062	;	Crystal structure of Mycolicibacterium hassiacum glucosylglycerate hydrolase (MhGgH) E419A variant in complex with mannosylglycerate
5OIE	;	2.071	;	Crystal structure of Mycolicibacterium hassiacum glucosylglycerate hydrolase (MhGgH) E419A variant in complex with serine and glycerol
5OHC	;	2.0	;	Crystal structure of Mycolicibacterium hassiacum glucosylglycerate hydrolase (MhGgH) in complex with glycerol
5OI0	;	1.68	;	Crystal structure of Mycolicibacterium hassiacum glucosylglycerate hydrolase (MhGgH) in complex with serine and glycerol
5ONT	;	2.05	;	Crystal structure of Mycolicibacterium hassiacum glucosylglycerate hydrolase(MhGgH) E419A variant in complex with glucosylglycerol
3KPH	;	2.8	;	Crystal structure of Mycoplasma arthritidis-derived mitogen
6J36	;	2.301	;	crystal structure of Mycoplasma hyopneumoniae Enolase
3ZIU	;	2.07	;	Crystal structure of Mycoplasma mobile Leucyl-tRNA Synthetase with Leu-AMS in the active site
7E2Q	;	1.8	;	Crystal structure of Mycoplasma pneumoniae Enolase
8QCK	;	4.7	;	Crystal structure of mycothiol disulfide reductase Mtr from Mycobacterium smegmatis
8QCJ	;	2.9	;	Crystal structure of mycothiol disulfide reductase Mtr from Rhodococcus erythropolis
4KB5	;	2.15	;	Crystal structure of MycP1 from Mycobacterium smegmatis
4J94	;	1.857	;	Crystal structure of MycP1 from the ESX-1 type VII secretion system
4KPG	;	2.148	;	Crystal structure of MycP1 from the ESX-1 type VII secretion system
4M1Z	;	2.25	;	Crystal structure of MycP1 with the N-terminal propeptide removed
6IGO	;	2.746	;	Crystal structure of myelin protein zero-like protein 1 (MPZL1)
5H5P	;	2.461	;	Crystal structure of Myelin-gene Regulatory Factor DNA binding domain
3F9P	;	2.93	;	Crystal structure of myeloperoxidase from human leukocytes
6WYD	;	2.55	;	CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) COMPLEX WITH Compound-12 (AKA; 7-benzyl-1H-[1,2,3]triazolo[4,5-b]pyrid
7LAG	;	2.85	;	CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) COMPLEX WITH Compound-14 AKA 7-({1-[(3-phenoxyphenyl)methyl]-1H-pyrazol-4-yl}methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine
7LAL	;	2.75	;	CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) COMPLEX WITH COMPOUND-18 AKA 7-(3-(2,3-DIHYDRO-1H-INDEN-1-YLAMINO)-1-PHENYLPROPYL)-1H-[1,2,3]TRIAZOLO[4,5-B]PYRIDIN-5-AMINE
5QJ3	;	2.76	;	CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) COMPLEX WITH COMPOUND-24 AKA 7-({4-CHLORO-3'-FLUORO-[1,1'- BIPHENYL]-3-YL}METHOXY)-3H-[1,2,3]TRIAZOLO[4,5-B]PYRIDIN- 5-AMINE
6WXZ	;	2.226	;	CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) COMPLEX WITH Compound-29 A.K.A 7-(1,2-DIPHENYLETHYL)-1H-[1,2,3]TRIAZOLO[4,5-B]PYRIDIN-5-AMINE
7LAN	;	2.28	;	CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) COMPLEX WITH COMPOUND-30 AKA 7-[(3~{S},4~{R},6~{R})-4-benzyl-2-oxa-7,13,14-triazatetracyclo[14.3.1.1^{3,6}.1^{11,14}]docosa-1(19),11(21),12,16(20),17-pentaen-10-yl]-3~{H}-triazolo[4,5-b]pyridin-5-amine
6WY5	;	2.898	;	CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) COMPLEX WITH Compound-37 A.K.A 7-(1-phenyl-3-(((1S,3S)-3-phenyl-2,3-dihydro-1H-inden-1-yl)amino)propyl)-1H-[1,2,3]triazolo[4,5-b]pyridin-5-amine
7LAE	;	2.97	;	CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) COMPLEX WITH Compound-4
6WY0	;	2.799	;	CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) COMPLEX WITH Compound-40 A.K.A 7-[(1R)-1-phenyl-3-{[(1r,4r)-4-phenylcyclohexyl]amino}propyl]-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine
6WY7	;	2.089	;	CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) COMPLEX WITH Compound-41 A.K.A 7-[1-phenyl-3-({4-phenylbicyclo[2.2.2]octan-1-yl}amino)propyl]-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine
5WDJ	;	2.4	;	CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) COMPLEX WITH COMPOUND-6 AKA 7-(BENZYLOXY)-1H-[1,2, 3]TRIAZOLO[4,5-D]PYRIMIDIN-5-AMINE
5QJ2	;	2.82	;	CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) OMPLEX WITH COMPOUND-20 AKA 7-((3-(1-METHYL-1H-PYRAZOL-3- YL)BENZYL)OXY)- 1H-[1,2,3]TRIAZOLO[4,5-B]PYRIDIN-5-AMINE
1RM0	;	2.05	;	Crystal Structure of Myo-Inositol 1-Phosphate Synthase From Saccharomyces cerevisiae In Complex With NAD+ and 2-deoxy-D-glucitol 6-(E)-vinylhomophosphonate
3CEA	;	2.4	;	Crystal structure of myo-inositol 2-dehydrogenase (NP_786804.1) from Lactobacillus plantarum at 2.40 A resolution
3NT2	;	2.3003	;	Crystal structure of myo-inositol dehydrogenase from Bacillus subtilis with bound cofactor
3NT5	;	2.9006	;	Crystal structure of myo-inositol dehydrogenase from Bacillus subtilis with bound cofactor and product inosose
3NT4	;	2.5001	;	Crystal structure of myo-inositol dehydrogenase from Bacillus subtilis with bound cofactor NADH and inositol
4MJL	;	1.6	;	Crystal Structure of myo-inositol dehydrogenase from Lactobacillus casei in complex with NAD and D-chiro-inositol
4MIY	;	1.42	;	Crystal Structure of myo-inositol dehydrogenase from Lactobacillus casei in complex with NAD and myo-inositol
4MIO	;	1.5	;	Crystal Structure of myo-inositol dehydrogenase from Lactobacillus casei in complex with NAD(H) and myo-inositol
4MIN	;	1.6	;	Crystal Structure of myo-inositol dehydrogenase from Lactobacillus casei with bound cofactor NAD
2PCR	;	2.6	;	Crystal structure of Myo-inositol-1(or 4)-monophosphatase (aq_1983) from Aquifex Aeolicus VF5
5ET1	;	1.65	;	Crystal structure of Myo3b-ARB1 in complex with Espin1-AR
5ET0	;	2.3	;	Crystal structure of Myo3b-ARB2 in complex with Espin1-AR
4LX1	;	1.87	;	Crystal structure of Myo5a globular tail domain
4LX2	;	1.5	;	Crystal structure of Myo5a globular tail domain in complex with melanophilin GTBD
4LX0	;	2.19	;	Crystal structure of Myo5b globular tail domain in complex with active Rab11a
4LWZ	;	2.55	;	Crystal structure of Myo5b globular tail domain in complex with inactive Rab11a
5WST	;	2.1	;	Crystal structure of Myo7a SAH
5XBF	;	1.802	;	Crystal Structure of Myo7b C-terminal MyTH4-FERM in complex with USH1C PDZ3
5F3Y	;	3.409	;	Crystal Structure of Myo7b N-MyTH4-FERM-SH3 in complex with Anks4b CEN
1MDY	;	2.8	;	CRYSTAL STRUCTURE OF MYOD BHLH DOMAIN BOUND TO DNA: PERSPECTIVES ON DNA RECOGNITION AND IMPLICATIONS FOR TRANSCRIPTIONAL ACTIVATION
7WZ6	;	2.05	;	Crystal structure of MyoD-E47
6EEL	;	1.93	;	Crystal Structure of Myoferlin C2A with divalent cation
2VLY	;	1.6	;	Crystal structure of myoglobin compound III (radiation-induced)
4DC7	;	1.5	;	Crystal Structure of Myoglobin Exposed to Excessive SONICC Imaging Laser Dose.
2EKT	;	1.1	;	Crystal structure of myoglobin reconstituted with 6-methyl-6-depropionatehemin
2EKU	;	1.4	;	Crystal structure of myoglobin reconstituted with 7-methyl-7-depropionatehemin
2D6C	;	2.26	;	Crystal structure of myoglobin reconstituted with iron porphycene
4DC8	;	1.5	;	Crystal Structure of Myoglobin Unexposed to Excessive SONICC Imaging Laser Dose.
2IN4	;	2.15	;	Crystal Structure of Myoglobin with Charge Neutralized Heme, ZnDMb-dme
7QQH	;	2.25	;	Crystal structure of MYORG (D520N) in complex with Gal-a1,4-Glc
7QQG	;	2.43	;	Crystal structure of MYORG bound to 1-deoxygalactonojirimycin
5V7X	;	3.141	;	Crystal Structure of Myosin 1b residues 1-728 with bound sulfate and Calmodulin
1W8J	;	2.7	;	Crystal Structure Of Myosin V Motor Domain - Nucleotide-Free
1W7J	;	2.0	;	Crystal Structure Of Myosin V Motor With Essential Light Chain + ADP-BeFx - Near Rigor
1OE9	;	2.05	;	Crystal structure of Myosin V motor with essential light chain-nucleotide-free
1W7I	;	3.0	;	Crystal Structure Of Myosin V Motor Without nucleotide soaked in 10 mM MgADP
6J56	;	1.798	;	Crystal structure of Myosin VI CBD in complex with Tom1 MBM
3H8D	;	2.2	;	Crystal structure of Myosin VI in complex with Dab2 peptide
5V6E	;	3.506	;	Crystal structure of Myosin VI in complex with GH2 domain of GIPC1
5V6H	;	3.601	;	Crystal structure of Myosin VI in complex with GH2 domain of GIPC2
5WSV	;	2.33	;	Crystal structure of Myosin VIIa IQ5 in complex with Ca2+-CaM
5WSU	;	3.0	;	Crystal structure of Myosin VIIa IQ5-SAH in complex with apo-CaM
5I0H	;	1.8	;	Crystal structure of myosin X motor domain in pre-powerstroke state
5I0I	;	3.15	;	Crystal structure of myosin X motor domain with 2IQ motifs in pre-powerstroke state
4R8G	;	3.503	;	Crystal Structure of Myosin-1c tail in complex with Calmodulin
3MKD	;	2.4	;	Crystal structure of myosin-2 dictyostelium discoideum motor domain S456Y mutant in complex with adp-orthovanadate
2JJ9	;	2.3	;	Crystal structure of myosin-2 in complex with ADP-metavanadate
2XO8	;	2.4	;	Crystal Structure of Myosin-2 in Complex with Tribromodichloropseudilin
2JHR	;	2.8	;	Crystal structure of myosin-2 motor domain in complex with ADP- metavanadate and pentabromopseudilin
2X9H	;	2.7	;	CRYSTAL STRUCTURE OF MYOSIN-2 MOTOR DOMAIN IN COMPLEX WITH ADP- METAVANADATE AND PENTACHLOROCARBAZOLE
3MJX	;	2.2	;	Crystal structure of myosin-2 motor domain in complex with ADP-Metavanadate and blebbistatin
3MNQ	;	2.2	;	Crystal structure of myosin-2 motor domain in complex with ADP-metavanadate and resveratrol
7DHW	;	2.84	;	Crystal structure of myosin-XI motor domain in complex with ADP-ALF4
6DKU	;	2.6	;	Crystal structure of Myotis VP35 mutant of interferon inhibitory domain
6CE2	;	2.15	;	Crystal structure of Myotoxin I (MjTX-I) from Bothrops moojeni complexed to inhibitor suramin
4KF3	;	1.92	;	Crystal Structure of Myotoxin II (MjTX-II), a myotoxic Lys49-phospholipase A2 from Bothrops moojeni.
6B84	;	1.997	;	Crystal structure of Myotoxin II from Bothrops moojeni
6B83	;	1.7	;	Crystal structure of Myotoxin II from Bothrops moojeni complexed to Caproic acid
6B81	;	1.76	;	Crystal structure of Myotoxin II from Bothrops moojeni complexed to Caprylic acid
6B80	;	1.949	;	Crystal structure of myotoxin II from Bothrops moojeni complexed to myristic acid
4YV5	;	1.9	;	Crystal Structure of Myotoxin II from Bothrops moojeni complexed to Suramin
1LW3	;	2.3	;	Crystal Structure of Myotubularin-related protein 2 complexed with phosphate
1M7R	;	2.6	;	Crystal Structure of Myotubularin-related Protein-2 (MTMR2) Complexed with Phosphate
3WB8	;	2.499	;	Crystal Structure of MyoVa-GTD
6KU0	;	1.6	;	Crystal structure of MyoVa-GTD in complex with MICAL1-GTBM
4KP3	;	2.405	;	Crystal Structure of MyoVa-GTD in Complex with Two Cargos
7B3E	;	1.77	;	Crystal structure of myricetin covalently bound to the main protease (3CLpro/Mpro) of SARS-CoV-2
4DFZ	;	2.0	;	Crystal structure of myristoylated K7C catalytic subunit of cAMP-dependent protein kinase in complex with SP20
4DFX	;	1.35	;	Crystal structure of myristoylated K7C catalytic subunit of cAMP-dependent protein kinase in complex with SP20 and AMP-PNP
4DG2	;	2.0	;	Crystal structure of myristoylated WT catalytic subunit of cAMP-dependent protein kinase in complex with SP20
4DG0	;	2.0	;	Crystal structure of myristoylated WT catalytic subunit of cAMP-dependent protein kinase in complex with SP20 and AMP-PNP
5HYB	;	1.94	;	Crystal structure of myristoylated Y81A mutant MMTV matrix protein
5CZW	;	1.6	;	Crystal structure of myroilysin
6BA4	;	1.949	;	Crystal structure of MYST acetyltransferase domain in complex with Acetyl-CoA cofactor
6BA2	;	1.85004	;	Crystal structure of MYST acetyltransferase domain in complex with inhibitor
6OIP	;	1.8	;	Crystal structure of MYST acetyltransferase domain in complex with inhibitor 34
6PD8	;	2.738	;	Crystal structure of MYST acetyltransferase domain in complex with inhibitor 39
6PDE	;	2.22	;	Crystal structure of MYST acetyltransferase domain in complex with inhibitor 40
6PDD	;	2.15	;	Crystal structure of MYST acetyltransferase domain in complex with inhibitor 41
6PDC	;	1.96	;	Crystal structure of MYST acetyltransferase domain in complex with inhibitor 42
6PDF	;	2.22	;	Crystal structure of MYST acetyltransferase domain in complex with inhibitor 55
6OIO	;	1.7	;	Crystal structure of MYST acetyltransferase domain in complex with inhibitor 60
6PD9	;	2.8	;	Crystal structure of MYST acetyltransferase domain in complex with inhibitor 60
6OIR	;	2.03	;	Crystal structure of MYST acetyltransferase domain in complex with inhibitor 62
6OIQ	;	1.75	;	Crystal structure of MYST acetyltransferase domain in complex with inhibitor 63
6PDA	;	2.448	;	Crystal structure of MYST acetyltransferase domain in complex with inhibitor 74
6PDB	;	2.42	;	Crystal structure of MYST acetyltransferase domain in complex with inhibitor 80
6PDG	;	1.919	;	Crystal structure of MYST acetyltransferase domain in complex with inhibitor 83
6OWI	;	1.75	;	Crystal structure of MYST acetyltransferase domain in complex with inhibitor 85
6OWH	;	2.0	;	Crystal structure of MYST acetyltransferase domain in complex with inhibitor 92
6OIN	;	1.7	;	Crystal structure of MYST acetyltransferase domain in complex with inhibitor CTX-124143
5LIV	;	2.67	;	Crystal structure of myxobacterial CYP260A1
6GK6	;	1.6	;	Crystal structure of myxobacterial cytochrome P450 CYP267B1 in complex with myristic acid
3NOK	;	1.65	;	Crystal structure of Myxococcus xanthus Glutaminyl Cyclase
1NHK	;	1.9	;	CRYSTAL STRUCTURE OF MYXOCOCCUS XANTHUS NUCLEOSIDE DIPHOSPHATE KINASE AND ITS INTERACTION WITH A NUCLEOTIDE SUBSTRATE AT 2.0 ANGSTROMS RESOLUTION
1NLK	;	2.0	;	CRYSTAL STRUCTURE OF MYXOCOCCUS XANTHUS NUCLEOSIDE DIPHOSPHATE KINASE AND ITS INTERACTION WITH A NUCLEOTIDE SUBSTRATE AT 2.0 ANGSTROMS RESOLUTION
2NCK	;	2.0	;	CRYSTAL STRUCTURE OF MYXOCOCCUS XANTHUS NUCLEOSIDE DIPHOSPHATE KINASE AND ITS INTERACTION WITH A NUCLEOTIDE SUBSTRATE AT 2.0 ANGSTROMS RESOLUTION
5CZ3	;	2.5	;	Crystal Structure of Myxoma Virus M64
3H4L	;	2.5	;	Crystal Structure of N terminal domain of a DNA repair protein
1Q1C	;	1.9	;	Crystal structure of N(1-260) of human FKBP52
6LUG	;	1.9	;	Crystal structure of N(omega)-hydroxy-L-arginine hydrolase
7EUN	;	1.28	;	Crystal structure of N(omega)-hydroxy-L-arginine hydrolase in complex with ABH
7EUK	;	1.4	;	Crystal structure of N(omega)-hydroxy-L-arginine hydrolase in complex with L-Orn
4D7K	;	2.22	;	Crystal structure of N,N-8-amino-8-demethyl-D-riboflavin dimethyltransferase (RosA) from Streptomyces davawensis
2XX8	;	1.55	;	Crystal structure of N,N-dimethyl-4-(3-(trifluoromethyl)-4,5,6,7- tetrahydro-1H-indazol-1-yl)benzamide in complex with the ligand binding domain of the Rat GluA2 receptor and glutamate at 2.2A resolution.
7NG0	;	2.95	;	Crystal structure of N- and C-terminally truncated Geobacillus thermoleovorans nucleoid occlusion protein Noc
2XHD	;	1.8	;	Crystal structure of N-((2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H- inden-2-yl)-2-propanesulfonamide in complex with the ligand binding domain of the human GluA2 receptor
2CFF	;	2.5	;	Crystal Structure Of N-((5'-Phosphoribosyl)-Formimino)-5- Aminoimidazol-4-Carboxamid Ribonucleotid Isomerase mutant D127V (Ec 3. 1.3.15, Hisa)
1QO2	;	1.85	;	Crystal structure of N-((5'-phosphoribosyl)-formimino)-5-aminoimidazol-4-carboxamid ribonucleotid isomerase (EC 3.1.3.15, HisA)
4KKY	;	2.0	;	Crystal structure of N-(1-Pyrene)acetamide labeled P450cam in substrate bound form.
7L5F	;	1.51	;	Crystal Structure of N-(2-oxocyclobutyl) decanamide Bound AiiA-Co
6UF0	;	1.96	;	Crystal structure of N-(4-((4-methoxy-N-(2,2,2-trifluoroethyl)phenyl)sulfonamido)isoquinolin-1-yl)-N-((4-methoxyphenyl)sulfonyl)glycine bound to human Keap1 Kelch domain
6JDH	;	1.9	;	Crystal structure of N-acetyl mannosmaine kinase from Pasteurella multocida
6JDC	;	2.271	;	Crystal structure of N-acetyl mannosmaine kinase in complex with ManNAc from Haemophilus influenzae
6JDB	;	2.65	;	Crystal structure of N-acetyl mannosmaine kinase in complex with ManNAc-6P and ADP from Haemophilus influenzae
6JDA	;	2.9	;	Crystal structure of N-acetyl mannosmaine kinase in complex with N-acetylmannosamine in Pasteurella multocida
6JDO	;	2.002	;	Crystal structure of N-acetyl mannosmaine kinase with AMP-PNP from Pasteurella multocida
2P53	;	2.1	;	Crystal structure of N-acetyl-D-glucosamine-6-phosphate deacetylase D273N mutant complexed with N-acetyl phosphonamidate-d-glucosamine-6-phosphate
6FV3	;	2.58	;	Crystal structure of N-acetyl-D-glucosamine-6-phosphate deacetylase from Mycobacterium smegmatis.
2P50	;	2.2	;	Crystal structure of N-acetyl-D-Glucosamine-6-Phosphate deacetylase liganded with Zn
2I3A	;	2.15	;	Crystal structure of N-Acetyl-gamma-Glutamyl-Phosphate Reductase (Rv1652) from Mycobacterium tuberculosis
2NQT	;	1.58	;	Crystal structure of N-Acetyl-gamma-Glutamyl-Phosphate Reductase (Rv1652) from Mycobacterium tuberculosis at 1.58 A resolution
2I3G	;	1.85	;	Crystal structure of N-Acetyl-gamma-Glutamyl-Phosphate Reductase (Rv1652) from Mycobacterium tuberculosis in complex with NADP+.
1VKN	;	1.8	;	Crystal structure of N-acetyl-gamma-glutamyl-phosphate reductase (TM1782) from Thermotoga maritima at 1.80 A resolution
2OZP	;	2.01	;	Crystal structure of N-acetyl-gamma-glutamyl-phosphate reductase (TTHA1904) from Thermus thermophilus
3T7B	;	2.5	;	Crystal Structure of N-acetyl-L-glutamate kinase from Yersinia pestis
3KZC	;	2.2	;	Crystal structure of N-acetyl-L-ornithine transcarbamylase
3KZM	;	1.95	;	Crystal structure of N-acetyl-L-ornithine transcarbamylase complexed with carbamyl phosphate
3KZO	;	1.9	;	Crystal structure of N-acetyl-L-ornithine transcarbamylase complexed with carbamyl phosphate and N-acetyl-L-norvaline
3KZN	;	1.8	;	Crystal structure of N-acetyl-L-ornithine transcarbamylase complexed with N-acetyl-L-ornirthine
3M4J	;	2.2	;	Crystal structure of N-acetyl-L-ornithine transcarbamylase complexed with PALAO
3L02	;	2.3	;	Crystal structure of N-acetyl-L-ornithine transcarbamylase E92A mutant complexed with carbamyl phosphate and N-succinyl-L-norvaline
3L04	;	2.5	;	Crystal structure of N-acetyl-L-ornithine transcarbamylase E92P mutant complexed with carbamyl phosphate and N-succinyl-L-norvaline
3L05	;	2.8	;	Crystal structure of N-acetyl-L-ornithine transcarbamylase E92S mutant complexed with carbamyl phosphate and N-succinyl-L-norvaline
3L06	;	2.81	;	Crystal structure of N-acetyl-L-ornithine transcarbamylase E92V mutant complexed with carbamyl phosphate and N-succinyl-L-norvaline
3M4N	;	1.9	;	Crystal structure of N-acetyl-L-ornithine transcarbamylase K302A mutant complexed with PALAO
3M5C	;	1.85	;	Crystal structure of N-acetyl-L-ornithine transcarbamylase K302E mutant complexed with PALAO
3M5D	;	2.2	;	Crystal structure of N-acetyl-L-ornithine transcarbamylase K302R mutant complexed with PALAO
4Q7A	;	2.048	;	Crystal Structure of N-acetyl-ornithine/N-acetyl-lysine Deacetylase from Sphaerobacter thermophilus
6P0Z	;	1.011	;	Crystal structure of N-acetylated KRAS (2-169) bound to GDP and Mg
2IXB	;	2.4	;	Crystal structure of N-ACETYLGALACTOSAMINIDASE in complex with GalNAC
1FXJ	;	2.25	;	CRYSTAL STRUCTURE OF N-ACETYLGLUCOSAMINE 1-PHOSPHATE URIDYLTRANSFERASE
1FWY	;	2.3	;	CRYSTAL STRUCTURE OF N-ACETYLGLUCOSAMINE 1-PHOSPHATE URIDYLTRANSFERASE BOUND TO UDP-GLCNAC
2DWH	;	2.8	;	Crystal structure of N-acetylglucosamine complex of bovine lactoferrin C-lobe at 2.8 A resolution
2HOE	;	2.46	;	Crystal structure of N-acetylglucosamine kinase (TM1224) from Thermotoga maritima at 2.46 A resolution
3FOQ	;	3.41	;	Crystal structure of N-acetylglucosamine-1-phosphate uridyltransferase (GlmU) from Mycobacterium tuberculosis in a cubic space group.
1O12	;	2.5	;	Crystal structure of N-acetylglucosamine-6-phosphate deacetylase (TM0814) from Thermotoga maritima at 2.5 A resolution
6JKU	;	1.95	;	Crystal structure of N-acetylglucosamine-6-phosphate deacetylase from Pasteurella Multocida
2DKA	;	1.93	;	Crystal structure of N-acetylglucosamine-phosphate mutase, a member of the alpha-D-phosphohexomutase superfamily, in the apo-form
2DKD	;	2.1	;	Crystal structure of N-acetylglucosamine-phosphate mutase, a member of the alpha-D-phosphohexomutase superfamily, in the product complex
2DKC	;	2.2	;	Crystal structure of N-acetylglucosamine-phosphate mutase, a member of the alpha-D-phosphohexomutase superfamily, in the substrate complex
1FO8	;	1.4	;	CRYSTAL STRUCTURE OF N-ACETYLGLUCOSAMINYLTRANSFERASE I
1FO9	;	1.5	;	CRYSTAL STRUCTURE OF N-ACETYLGLUCOSAMINYLTRANSFERASE I
1FOA	;	1.8	;	CRYSTAL STRUCTURE OF N-ACETYLGLUCOSAMINYLTRANSFERASE I
2AM5	;	1.6	;	Crystal Structure of N-Acetylglucosaminyltransferase I in Complex with UDP
2AM4	;	1.7	;	Crystal Structure of N-Acetylglucosaminyltransferase I in Complex with UDP-2-deoxy-2-fluoro-glucose
2APC	;	1.5	;	Crystal Structure of N-Acetylglucosaminyltransferase I in Complex with UDP-GlcNAc phosphonate
2AM3	;	1.8	;	Crystal Structure of N-Acetylglucosaminyltransferase I in Complex with UDP-Glucose
2R98	;	2.4	;	Crystal Structure of N-acetylglutamate synthase (selenoMet substituted) from Neisseria gonorrhoeae
3D2P	;	2.56	;	Crystal structure of N-acetylglutamate synthase from Neisseria gonorrhoeae complexed with coenzyme A and L-arginine
3D2M	;	2.21	;	Crystal structure of N-acetylglutamate synthase from Neisseria gonorrhoeae complexed with coenzyme A and L-glutamate
2YI1	;	2.15	;	Crystal structure of N-Acetylmannosamine kinase in complex with N- acetyl mannosamine 6-phosphate and ADP.
8U90	;	1.85	;	Crystal structure of N-acetylneuraminate lyase (NanA) from Klebsiella aerogenes (Apo, hexagonal form)
8U91	;	2.65	;	Crystal structure of N-acetylneuraminate lyase (NanA) from Klebsiella aerogenes (Apo, Orthorhombic P form)
8U93	;	1.9	;	Crystal structure of N-acetylneuraminate lyase (NanA) from Klebsiella aerogenes (PEG bound)
8U8W	;	1.8	;	Crystal structure of N-acetylneuraminate lyase (NanA) from Klebsiella aerogenes (pyruvate and halides bound)
8U92	;	2.1	;	Crystal structure of N-acetylneuraminate lyase (NanA) from Klebsiella aerogenes (pyruvate bound, Orthorhombic P form)
1HL2	;	1.8	;	Crystal structure of N-acetylneuraminate lyase from E. coli mutant L142R in complex with b-hydroxypyruvate
5ZJM	;	2.323	;	Crystal structure of N-acetylneuraminate lyase from Fusobacterium nucleatum
5ZKA	;	1.76	;	Crystal structure of N-acetylneuraminate lyase from Fusobacterium nucleatum complexed with Pyruvate
4N4P	;	1.8	;	Crystal Structure of N-acetylneuraminate lyase from Mycoplasma synoviae, crystal form I
4N4Q	;	2.0	;	Crystal Structure of N-acetylneuraminate lyase from Mycoplasma synoviae, crystal form II
6NCS	;	1.8	;	Crystal structure of N-acetylneuraminic acid (Sialic acid) synthetase from Leptospira borgpetersenii serovar Hardjo-bovis in complex with citrate
4AHO	;	2.0	;	Crystal Structure of N-acetylneuraminic acid lyase from Staphylococcus aureus with the chemical modification thia-lysine at position 165
4AMA	;	2.35	;	Crystal Structure of N-acetylneuraminic acid lyase from Staphylococcus aureus with the chemical modification thia-lysine at position 165 in complex with pyruvate
4AHQ	;	1.95	;	Crystal Structure of N-acetylneuraminic acid lyase mutant K165C from Staphylococcus aureus
6W7X	;	1.9	;	Crystal structure of N-acetylornithine aminotransferase from Stenotrophomonas maltophilia K279a
7XRJ	;	2.2	;	crystal structure of N-acetyltransferase DgcN-25328
4LUA	;	1.6001	;	Crystal structure of N-acetyltransferase from Staphylococcus aureus Mu50
4M85	;	2.0	;	Crystal structure of N-acetyltransferase from Staphylococcus aureus Mu50
4MBU	;	2.15	;	Crystal structure of N-acetyltransferase from Staphylococcus aureus Mu50
5IX3	;	1.81	;	Crystal structure of N-acetyltransferase from Staphylococcus aureus.
1FP3	;	2.0	;	CRYSTAL STRUCTURE OF N-ACYL-D-GLUCOSAMINE 2-EPIMERASE FROM PORCINE KIDNEY
3GIQ	;	1.8	;	Crystal structure of N-acyl-D-Glutamate Deacylase from Bordetella Bronchiseptica complexed with zinc and phosphonate inhibitor, a mimic of the reaction tetrahedral intermediate.
3GIP	;	1.5	;	Crystal structure of N-acyl-D-Glutamate Deacylase from Bordetella Bronchiseptica complexed with zinc, acetate and formate ions.
2ZC8	;	1.95	;	Crystal structure of N-Acylamino Acid Racemase from Thermus thermophilus HB8
3G2N	;	2.1	;	Crystal structure of N-acylglucosylamine with glycogen phosphorylase
5L10	;	2.75	;	Crystal Structure of N-Acylhomoserine Lactone Dependent LuxR Family Transcriptionl Factor CepR2 from Burkholderia cenocepacia
1UHK	;	1.6	;	Crystal structure of n-aequorin
2QVI	;	3.012	;	Crystal structure of N-cadherin domains EC12
3EEF	;	2.35	;	Crystal structure of N-carbamoylsarcosine amidase from thermoplasma acidophilum
1ERZ	;	1.7	;	CRYSTAL STRUCTURE OF N-CARBAMYL-D-AMINO ACID AMIDOHYDROLASE WITH A NOVEL CATALYTIC FRAMEWORK COMMON TO AMIDOHYDROLASES
1ZNS	;	2.5	;	Crystal structure of N-ColE7/12-bp DNA/Zn complex
6K8V	;	2.2	;	Crystal structure of N-domain of baterial malonyl-CoA reductase
6K8W	;	3.17	;	Crystal structure of N-domain with NADP of baterial malonyl-CoA reductase
8BPP	;	3.1	;	crystal structure of N-ethylmaleimide reductase (nemA) from Escherichia coli
7TMB	;	2.1	;	Crystal Structure of N-ethylmaleimide reductase from Klebsiella pneumoniae
3GKA	;	2.3	;	Crystal structure of N-ethylmaleimidine reductase from Burkholderia pseudomallei
2Q7S	;	2.0	;	Crystal structure of N-formylglutamate amidohydrolase (YP_297560.1) from Ralstonia eutropha JMP134 at 2.00 A resolution
5SUO	;	2.1	;	Crystal structure of N-glycan transport solute binding protein (NgtS) from Streptococcus pneumoniae
5SWA	;	3.0	;	Crystal structure of N-glycan transport solute binding protein (NgtS) from Streptococcus pneumoniae in complex with Man1GlcNAc
5SWB	;	1.73	;	Crystal structure of N-glycan transport solute binding protein (NgtS) from Streptococcus pneumoniae in complex with Man5GlcNAc
6PFO	;	1.78	;	Crystal structure of N-glycosylated human calcitonin receptor extracellular domain in complex with salmon calcitonin (16-32)
6PGQ	;	2.85	;	Crystal structure of N-glycosylated human calcitonin receptor extracellular domain in complex with salmon calcitonin (22-32)
4ACR	;	2.55	;	Crystal structure of N-glycosylated, C-terminally truncated human glypican-1
2QT3	;	2.24	;	Crystal structure of N-Isopropylammelide isopropylaminohydrolase AtzC from Pseudomonas sp. strain ADP complexed with Zn
6NBO	;	1.95	;	Crystal structure of N-isopropylammelide isopropylaminohydrolase from Burkholderia multivorans ATCC 17616
4R7V	;	1.73	;	Crystal structure of N-lobe of human ARRDC3(1-165)
4R7X	;	2.61	;	Crystal structure of N-lobe of human ARRDC3(1-180)
7JX4	;	0.95	;	Crystal Structure of N-Lysine Peptoid-modified Collagen Triple Helix
4INE	;	1.45	;	Crystal structure of N-methyl transferase (PMT-2) from Caenorhabditis elegant complexed with S-adenosyl homocysteine and phosphoethanolamine
4IV8	;	1.9	;	Crystal structure of N-methyl transferase from Plasmodium knowlesi complexed with S-adenosyl methionine
4IV0	;	1.4	;	Crystal structure of N-methyl transferase from Plasmodium vivax complexed with S-adenosyl methionine and phosphate
4MWZ	;	1.5	;	Crystal structure of N-methyl transferase from Plasmodium vivax complexed with S-adenosyl methionine, phosphate and amodiaquine
8IOF	;	2.33	;	Crystal structure of N-methyl-Cis-4-hydroxy-D-proline dehydratase in Clostridium sp. FS41
8ID1	;	3.115	;	Crystal structure of N-Methyl-cis-4-hydroxy-L-proline dehydratase in Intestinibacter bartlettii
3OFJ	;	2.43	;	Crystal structure of N-methyltransferase NodS from Bradyrhizobium japonicum WM9
3OFK	;	1.85	;	Crystal structure of N-methyltransferase NodS from Bradyrhizobium japonicum WM9 in complex with S-adenosyl-l-homocysteine (SAH)
6MB1	;	1.5	;	Crystal structure of N-myristoyl transferase (NMT) from Plasmodium vivax in complex with inhibitor IMP-1002
6MAY	;	2.05	;	Crystal structure of N-myristoyl transferase (NMT) G386E mutant from Plasmodium vivax
6MAZ	;	1.55	;	Crystal structure of N-myristoyl transferase (NMT) G386E mutant from Plasmodium vivax in complex with inhibitor IMP-0366
6MB0	;	1.55	;	Crystal structure of N-myristoyl transferase (NMT) G386E mutant from Plasmodium vivax in complex with inhibitor IMP-1002
4QBJ	;	2.1	;	Crystal structure of N-myristoyl transferase from Aspergillus fumigatus complexed with a synthetic inhibitor
4ZV5	;	1.57	;	Crystal structure of N-myristoylated mouse mammary tumor virus matrix protein
7JX5	;	1.1	;	Crystal Structure of N-Phenylalanine Peptoid-modified Collagen Triple Helix
2IUR	;	1.3	;	CRYSTAL STRUCTURE OF N-QUINOL FORM OF AROMATIC AMINE DEHYDROGENASE (AADH) FROM ALCALIGENES FAECALIS, FORM A COCRYSTAL
2IUV	;	1.55	;	CRYSTAL STRUCTURE OF N-QUINOL FORM OF AROMATIC AMINE DEHYDROGENASE (AADH) FROM ALCALIGENES FAECALIS, FORM B
7F68	;	1.24	;	Crystal structure of N-ras S89D
2P88	;	2.4	;	Crystal structure of N-succinyl Arg/Lys racemase from Bacillus cereus ATCC 14579
2P8C	;	2.0	;	Crystal structure of N-succinyl Arg/Lys racemase from Bacillus cereus ATCC 14579 complexed with N-succinyl Arg.
2P8B	;	1.7	;	Crystal structure of N-succinyl Arg/Lys racemase from Bacillus cereus ATCC 14579 complexed with N-succinyl Lys.
1YNF	;	1.9	;	Crystal Structure of N-Succinylarginine Dihydrolase, AstB, bound to Substrate and Product, an Enzyme from the Arginine Catabolic Pathway of Escherichia coli
1YNH	;	1.95	;	Crystal Structure of N-Succinylarginine Dihydrolase, AstB, bound to Substrate and Product, an Enzyme from the Arginine Catabolic Pathway of Escherichia coli
1YNI	;	2.2	;	Crystal Structure of N-Succinylarginine Dihydrolase, AstB, bound to Substrate and Product, an Enzyme from the Arginine Catabolic Pathway of Escherichia coli
1Q25	;	1.8	;	Crystal structure of N-terminal 3 domains of CI-MPR
1NHI	;	2.0	;	Crystal structure of N-terminal 40KD MutL (LN40) complex with ADPnP and one potassium
1NHH	;	2.4	;	Crystal structure of N-terminal 40KD MutL protein (LN40) complex with ADPnP and one Rubidium
1NHJ	;	2.3	;	Crystal structure of N-terminal 40KD MutL/A100P mutant protein complex with ADPnP and one sodium
3M6K	;	2.6	;	Crystal Structure of N-terminal 44 kDa fragment of topoisomerase V in the presence of guanidium hydrochloride
2B1L	;	1.9	;	Crystal structure of N-terminal 57 residue deletion mutant of E. coli CcmG protein(residues 58-185)
4JW1	;	3.16	;	Crystal structure of N-terminal 618-residue fragment of LepB from Legionella pneumophila
4KUD	;	3.203	;	Crystal structure of N-terminal acetylated Sir3 BAH domain D205N mutant in complex with yeast nucleosome core particle
4KUI	;	1.85	;	Crystal structure of N-terminal acetylated yeast Sir3 BAH domain
4KUL	;	2.62	;	Crystal structure of N-terminal acetylated yeast Sir3 BAH domain V83P mutant
3FER	;	2.4	;	Crystal structure of n-terminal actin-binding domain from human filamin b (tandem ch-domains). northeast structural genomics consortium target hr5571a.
5HYY	;	2.323	;	Crystal structure of N-terminal amidase
5K5U	;	2.7	;	Crystal structure of N-terminal amidase
5K5V	;	1.947	;	Crystal structure of N-terminal amidase C187S
5K62	;	1.899	;	Crystal structure of N-terminal amidase C187S
5K63	;	2.5	;	Crystal structure of N-terminal amidase C187S
5K66	;	2.002	;	Crystal structure of N-terminal amidase with Asn-Glu peptide
5B62	;	3.042	;	Crystal structure of N-terminal amidase with Asn-Glu-Ala peptide
5K61	;	2.001	;	Crystal structure of N-terminal amidase with Gln-Gly peptide
5K60	;	1.9	;	Crystal structure of N-terminal amidase with Gln-Val peptide
4TL7	;	1.936	;	Crystal structure of N-terminal C1 domain of KaiC
4TL8	;	1.859	;	Crystal structure of N-terminal C1 domain of KaiC
4TL9	;	1.822	;	Crystal structure of N-terminal C1 domain of KaiC
4TLA	;	1.8	;	Crystal structure of N-terminal C1 domain of KaiC
4TLB	;	1.983	;	Crystal structure of N-terminal C1 domain of KaiC
4TLC	;	2.09	;	Crystal structure of N-terminal C1 domain of KaiC
4TLD	;	1.949	;	Crystal structure of N-terminal C1 domain of KaiC
4TLE	;	1.936	;	Crystal structure of N-terminal C1 domain of KaiC
5YZ8	;	2.81	;	Crystal Structure of N-terminal C1 domain of KaiC
4N5X	;	2.1	;	Crystal structure of N-terminal calmodulin-like Calcium sensor of human mitochondrial ATP-Mg/Pi carrier SCaMC1
7ZOM	;	1.601	;	Crystal structure of N-terminal catalytic domain of human PLAAT3
3G05	;	3.49	;	Crystal structure of N-terminal domain (2-550) of E.coli MnmG
3QOC	;	2.15	;	Crystal structure of N-terminal domain (Creatinase/Prolidase like domain) of putative metallopeptidase from Corynebacterium diphtheriae
4LGO	;	1.7	;	Crystal Structure of N-terminal domain 1 of VompD from Bartonella quintana
5XOP	;	1.9	;	Crystal Structure of N-terminal domain EhCaBP1 EF-2 mutant
3E53	;	2.35	;	Crystal structure of N-terminal domain of a Fatty Acyl AMP Ligase FAAL28 from Mycobacterium tuberculosis
2V1O	;	1.78	;	Crystal structure of N-terminal domain of acyl-CoA thioesterase 7
6JUZ	;	1.21	;	Crystal Structure of N-terminal domain of ArgZ(N71S) covalently bond to a reaction intermediate
6JV0	;	1.14	;	Crystal Structure of N-terminal domain of ArgZ, bound to Product, an arginine dihydrolase from the Ornithine-Ammonia Cycle in Cyanobacteria
6JV1	;	1.2	;	Crystal Structure of N-terminal domain of ArgZ, C264S mutant, bound to Substrate, an arginine dihydrolase from the Ornithine-Ammonia Cycle in Cyanobacteria
5OFJ	;	1.34	;	Crystal structure of N-terminal domain of bifunctional CbXyn10C
5E2C	;	1.7	;	Crystal structure of N-terminal domain of cytoplasmic peptidase PepQ from Mycobacterium tuberculosis H37Rv
3TUO	;	1.697	;	Crystal structure of N-terminal domain of DNA-binding protein satb1
1HX8	;	2.2	;	CRYSTAL STRUCTURE OF N-TERMINAL DOMAIN OF DROSOPHILA AP180
3EOD	;	1.75	;	Crystal structure of N-terminal domain of E. coli RssB
2ANE	;	2.03	;	Crystal structure of N-terminal domain of E.Coli Lon Protease
4F3V	;	2.0	;	Crystal structure of N-terminal domain of EccA1 ATPase from ESX-1 secretion system of Mycobacterium tuberculosis
3T5A	;	2.05	;	Crystal structure of N-terminal domain of FAAL28 G330W mutant from Mycobacterium tuberculosis
3T5B	;	2.35	;	Crystal structure of N-terminal domain of FACL13 from Mycobacterium tuberculosis
3T5C	;	2.09	;	Crystal structure of N-terminal domain of FACL13 from Mycobacterium tuberculosis in different space group C2
2Y3P	;	2.62	;	Crystal structure of N-terminal domain of GyrA with the antibiotic simocyclinone D8
4XKK	;	2.7	;	Crystal structure of N-terminal domain of Hsp90 from Dictyostelium discoideum
5UMT	;	2.092	;	Crystal structure of N-terminal domain of human FACT complex subunit SPT16
5UMR	;	1.501	;	Crystal structure of N-terminal domain of human FACT complex subunit SSRP1
2YV8	;	1.92	;	Crystal structure of N-terminal domain of human galectin-8
2YXS	;	2.13	;	Crystal Structure of N-terminal domain of human galectin-8 with D-lactose
2YY1	;	2.17	;	Crystal structure of N-terminal domain of human galectin-9 containing L-acetyllactosamine
1P9A	;	1.7	;	Crystal Structure of N-Terminal Domain of Human Platelet Receptor Glycoprotein Ib-alpha at 1.7 Angstrom Resolution
1QYY	;	2.8	;	Crystal Structure of N-Terminal Domain of Human Platelet Receptor Glycoprotein Ib-alpha at 2.8 Angstrom Resolution
5GGO	;	1.502	;	Crystal structure of N-terminal domain of human protein O-mannose beta-1,2-N-acetylglucosaminyltransferase in complex with GalNac-beta1,3-GlcNAc-beta-pNP
5GGL	;	1.27	;	Crystal structure of N-terminal domain of human protein O-mannose beta-1,2-N-acetylglucosaminyltransferase in complex with GlcNAc-alpha-pNP
5GGN	;	1.211	;	Crystal structure of N-terminal domain of human protein O-mannose beta-1,2-N-acetylglucosaminyltransferase in complex with GlcNAc-beta-pNP
5GGP	;	1.599	;	Crystal structure of N-terminal domain of human protein O-mannose beta-1,2-N-acetylglucosaminyltransferase in complex with GlcNAc-beta1,2-Man-peptide
5GGJ	;	1.424	;	Crystal structure of N-terminal domain of human protein O-mannose beta-1,2-N-acetylglucosaminyltransferase in complex with Man-alpha-pNP
5GGK	;	1.3	;	Crystal structure of N-terminal domain of human protein O-mannose beta-1,2-N-acetylglucosaminyltransferase in complex with Man-beta-pNP
5IQZ	;	2.334	;	Crystal structure of N-terminal domain of Human SIRT7
6L1R	;	1.79844	;	Crystal structure of N-terminal domain of human SSRP1
1WV3	;	1.75	;	Crystal structure of N-terminal domain of hypothetical protein SAV0287 from Staphylococcus aureus
4TL6	;	1.763	;	Crystal structure of N-terminal domain of KaiC
5I5N	;	1.418	;	Crystal Structure of N-terminal Domain of Matrix Protein of Thogoto Virus at Acidic pH.
5I5O	;	2.682	;	Crystal Structure of N-terminal Domain of Matrix Protein of Thogoto Virus at Neutral pH.
6VBK	;	2.0	;	Crystal structure of N-terminal domain of Mycobacterium tuberculosis complex Lon protease
8X1H	;	2.0	;	Crystal structure of N-terminal domain of Nucleocapsid protein of SARS-CoV-2
3K60	;	2.3	;	Crystal structure of N-terminal domain of Plasmodium falciparum Hsp90 (PF07_0029) bound to ADP
3IED	;	2.01	;	Crystal structure of N-terminal domain of Plasmodium falciparum Hsp90 (PF14_0417) in complex with AMPPN
5ZKH	;	2.991	;	Crystal Structure of N-terminal Domain of Plasmodium falciparum p43
5ZKF	;	2.75	;	Crystal Structure of N-terminal Domain of Plasmodium vivax p43 in space group P21
5ZKE	;	1.492	;	Crystal Structure of N-terminal Domain of Plasmodium vivax p43 in space group P212121
3F6C	;	1.45	;	CRYSTAL STRUCTURE OF N-TERMINAL DOMAIN OF POSITIVE TRANSCRIPTION REGULATOR evgA FROM ESCHERICHIA COLI
2D7E	;	2.5	;	Crystal structure of N-terminal domain of PriA from E.coli
1NPS	;	1.8	;	CRYSTAL STRUCTURE OF N-TERMINAL DOMAIN OF PROTEIN S
3EWB	;	2.1	;	Crystal structure of N-terminal domain of putative 2-isopropylmalate synthase from Listeria monocytogenes
3G5J	;	1.76	;	Crystal structure of N-terminal domain of putative ATP/GTP binding protein from Clostridium difficile 630
2HBA	;	1.25	;	Crystal Structure of N-terminal Domain of Ribosomal Protein L9 (NTL9) K12M
2HVF	;	1.57	;	Crystal Structure of N-terminal Domain of Ribosomal Protein L9 (NTL9), G34dA
7XQC	;	2.8	;	Crystal structure of N-terminal domain of Rv2908c fused with Maltose Binding Protein (MBP)
5FIE	;	2.0	;	Crystal structure of N-terminal domain of shaft pilin spaA from Lactobacillus rhamnosus GG
8CBA	;	1.25	;	Crystal structure of N-terminal domain of TraF, protein of a type IV secretion system from E.faecalis (pIP501)
6JQY	;	1.643	;	Crystal structure of N-terminal domain of VapB46 antitoxin from Mycobacterium tuberculosis
1TBU	;	2.2	;	Crystal structure of N-terminal domain of yeast peroxisomal thioesterase-1
2R2A	;	1.82	;	Crystal structure of N-terminal domain of zonular occludens toxin from Neisseria meningitidis
5CUX	;	2.8	;	Crystal structure of N-terminal domain truncated Trypanosoma cruzi Vacuolar Soluble Pyrophosphatases in complex with PPi
2VON	;	2.1	;	Crystal structure of N-terminal domains of Human La protein complexed with RNA oligomer AUAAUUU
2VOD	;	2.1	;	Crystal structure of N-terminal domains of Human La protein complexed with RNA oligomer AUAUUUU
2VOP	;	2.8	;	Crystal structure of N-terminal domains of Human La protein complexed with RNA oligomer AUUUU
2VOO	;	1.8	;	Crystal structure of N-terminal domains of Human La protein complexed with RNA oligomer UUUUUUUU
3UUN	;	2.3	;	Crystal Structure of N-terminal first spectrin repeat of dystrophin
3UUM	;	2.0	;	Crystal Structure of N-terminal first spectrin repeat of utrophin
8HN0	;	2.2	;	Crystal structure of N-terminal fragment (20-132aa) of human SCARF1
8HNA	;	2.6	;	Crystal structure of N-terminal fragment (20-221aa) of human SCARF1
6BXA	;	2.298	;	Crystal structure of N-terminal fragment of Zebrafish Toll-Like Receptor 5 (TLR5) with Lamprey Variable Lymphocyte Receptor 2 (VLR2) bound
6BXC	;	2.5	;	Crystal structure of N-terminal fragment of Zebrafish Toll-Like Receptor 5 (TLR5) with Lamprey Variable Lymphocyte Receptor 9 (VLR9) bound
4P22	;	2.75	;	Crystal Structure of N-terminal Fragments of E1
5X4B	;	1.5	;	Crystal Structure of N-terminal G-domain of EngA from Bacillus subtilis
2DYK	;	1.96	;	Crystal structure of N-terminal GTP-binding domain of EngA from Thermus thermophilus HB8
5VYL	;	3.51	;	Crystal Structure of N-terminal half of Herpes Simplex virus Type 1 UL37 protein
4K70	;	2.0	;	Crystal Structure of N-terminal half of Pseudorabiesvirus UL37 protein
7CJ8	;	2.05	;	Crystal structure of N-terminal His-tagged D-allulose 3-epimerase from Methylomonas sp. in complex with D-allulose
7CJ9	;	1.58	;	Crystal structure of N-terminal His-tagged D-allulose 3-epimerase from Methylomonas sp. with additional C-terminal residues
4HOU	;	1.95	;	Crystal Structure of N-terminal Human IFIT1
4QCF	;	2.26	;	Crystal structure of N-terminal mutant (V1A) of an alkali thermostable GH10 xylanase from Bacillus sp. NG-27
4QDM	;	1.964	;	Crystal structure of N-terminal mutant (V1L) of an alkali thermostable GH10 xylanase from Bacillus sp. NG-27
3SLR	;	1.712	;	Crystal structure of N-terminal part of the protein BF1531 from Bacteroides fragilis containing phosphatase domain complexed with Mg.
4YDP	;	1.4	;	Crystal structure of N-terminal PDZ domain of ZASP in complex with myotilin C-terminal peptide.
7YIR	;	2.099	;	Crystal structure of N-terminal PH domain of ARAP3 protein from human
7YIS	;	3.3	;	Crystal structure of N-terminal PH domain of ARAP3 protein in complex with inositol 1,3,4,5-tetrakisphosphate
4H9J	;	1.6	;	Crystal structure of N-terminal protease (Npro) of classical swine fever virus.
3U0C	;	2.05	;	Crystal structure of N-terminal region of Type III Secretion First Translocator IpaB (residues 74-224)
3TUL	;	2.793	;	Crystal structure of N-terminal region of Type III Secretion Major Translocator SipB (residues 82-226)
3RUJ	;	2.1	;	Crystal Structure of N-terminal region of yeast Atg7
5XOR	;	2.699	;	Crystal structure of N-terminal replicase protein of porcine circovirus type 2
8CRM	;	1.42	;	Crystal structure of N-terminal SARS-CoV-2 nsp1 in complex with fragment hit 11C6 refined against anomalous diffraction data
8CRF	;	1.15	;	Crystal structure of N-terminal SARS-CoV-2 nsp1 in complex with fragment hit 5E11 refined against anomalous diffraction data
8CRK	;	1.1	;	Crystal structure of N-terminal SARS-CoV-2 nsp1 in complex with fragment hit 7H2 refined against anomalous diffraction data
3U2P	;	2.57	;	Crystal structure of N-terminal three extracellular domains of ErbB4/Her4
2IKS	;	1.85	;	Crystal structure of N-terminal truncated DNA-binding transcriptional dual regulator from Escherichia coli K12
5CV0	;	1.9	;	Crystal structure of N-terminal truncated human B12-chaperone CblD (108-296)
1T92	;	1.6	;	Crystal structure of N-terminal truncated pseudopilin PulG
3CR7	;	2.5	;	Crystal structure of N-terminal truncation of APS Kinase from Penicillium chrysogenum: Ternary structure with ADP and PAPS
5M1C	;	2.75	;	Crystal structure of N-terminally tagged apo-UbiD from E. coli
5M1D	;	2.7	;	Crystal structure of N-terminally tagged UbiD from E. coli reconstituted with prFMN cofactor
5M1E	;	2.62	;	Crystal structure of N-terminally tagged UbiD from E. coli reconstituted with prFMN cofactor
4CII	;	2.15	;	Crystal structure of N-terminally truncated Helicobacter pylori T4SS Protein CagL as domain swapped dimer
6TWT	;	0.95	;	Crystal structure of N-terminally truncated NDM-1 metallo-beta-lactamase
8AID	;	1.52	;	Crystal structure of N-terminally truncated PA4183 from P. aeruginosa PAO1
3VWV	;	1.8	;	crystal structure of N-terminally truncated peroxiredoxin 4 from M. musculus
6AF2	;	3.001	;	Crystal structure of N-terminus deletion mutant of Mycobacterium avium diadenosine 5',5'''-P1,P4-tetraphosphate phosphorylase
4TXA	;	2.75	;	Crystal structure of N-terminus of Roquin
7FA1	;	1.6	;	Crystal Structure of N-terminus of the non-structural protein 2 from SARS coronavirus
5L16	;	1.882	;	Crystal Structure of N-terminus truncated selenophosphate synthetase from Leishmania major
6X8Z	;	2.5	;	Crystal structure of N-truncated human B12 chaperone CblD(C262S)-thiolato-cob(III)alamin complex (108-296)
2VCP	;	3.2	;	Crystal structure of N-Wasp VC domain in complex with skeletal actin
6V6Z	;	1.6	;	Crystal structure of N-[(4-methoxyphenyl)sulfonyl]-N-(4-{[(4-methoxyphenyl)sulfonyl]amino}naphthalen-1-yl)glycine bound to human Keap1 Kelch domain
5DKP	;	2.381	;	Crystal Structure of N. meningitidis ClpP in complex with agonist ADEP A54556.
5IG4	;	2.35	;	Crystal structure of N. vectensis CaMKII-A hub
5IG5	;	3.0	;	Crystal structure of N. vectensis CaMKII-B hub at pH 4.2
7S0I	;	2.892	;	CRYSTAL STRUCTURE OF N1 NEURAMINIDASE FROM A/Michigan/45/2015(H1N1)
7M58	;	2.45	;	Crystal structure of N1, a member of cis-3-chloroacrylic acid dehalogenase (cis-CaaD) family
1Z5M	;	2.17	;	Crystal Structure Of N1-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2,2-dimethylpropanediamide Complexed with Human PDK1
4JJZ	;	2.5	;	Crystal Structure of N10-Formyltetrahydrofolate Synthetase with ADP and Formylphosphate
3QUS	;	2.84	;	Crystal Structure of N10-Formyltetrahydrofolate Synthetase with ATPgS
4JJK	;	3.0	;	Crystal Structure of N10-Formyltetrahydrofolate Synthetase with Folate
4JKI	;	2.6	;	Crystal Structure of N10-Formyltetrahydrofolate Synthetase with ZD9331, Formylphosphate, and ADP
5V70	;	1.94	;	Crystal structure of N102A mutant of human macrophage migration inhibitory factor
7DW7	;	1.8	;	Crystal Structure of N1051A mutant of Formylglycinamidine Synthetase
5BS9	;	1.98	;	Crystal structure of N109A mutant of human macrophage migration inhibitory factor
7D97	;	1.89	;	Crystal structure of N109P mutant of GATase subunit of Methanocaldococcus jannaschii GMP synthetase
5V73	;	1.68	;	Crystal structure of N110A mutant of human macrophage migration inhibitory factor
1XGK	;	1.4	;	CRYSTAL STRUCTURE OF N12G AND A18G MUTANT NMRA
1JVJ	;	1.73	;	CRYSTAL STRUCTURE OF N132A MUTANT OF TEM-1 BETA-LACTAMASE IN COMPLEX WITH A N-FORMIMIDOYL-THIENAMYCINE
7CIY	;	1.47	;	Crystal structure of N191G-mutated tyrosinase from Streptomyces castaneoglobisporus in complex with the caddie protein obtained by soaking in the solution containing Cu(II) and hydroxylamine for 24 h
5FZY	;	2.47	;	CRYSTAL STRUCTURE OF N19D POTATO STI-KUNITZ BI-FUNCTIONAL INHIBITOR OF SERINE AND ASPARTIC PROTEASES IN SPACE GROUP C2221 AND PH 3.5
5FZU	;	2.43	;	CRYSTAL STRUCTURE OF N19D POTATO STI-KUNITZ BI-FUNCTIONAL INHIBITOR OF SERINE AND ASPARTIC PROTEASES IN SPACE GROUP P4322 AND PH 7.2
2CHM	;	1.6	;	Crystal structure of N2 substituted pyrazolo pyrimidinones - a flipped binding mode in PDE5
7M59	;	1.65	;	Crystal structure of N2, a member of 4-oxalocrotonate tautomerase (4-OT) family
3H2I	;	2.1	;	Crystal structure of N228W mutant of the rice cell wall degrading esterase LipA from Xanthomonas oryzae
3QL0	;	1.6	;	Crystal structure of N23PP/S148A mutant of E. coli dihydrofolate reductase
6EIG	;	2.7	;	Crystal structure of N24Q/C128T mutant of Channelrhodopsin 2
4FZE	;	1.999	;	Crystal structure of N26_i1 Fab, an ADCC mediating anti-HIV-1 antibody.
5IMP	;	2.038	;	Crystal structure of N299A Aspergillus terreus aristolochene synthase complexed with (1S,8S,9aR)-1,9a-dimethyl-8-(prop-1-en-2-yl)decahydroquinolizin-5-ium
5IMN	;	2.527	;	Crystal structure of N299A/S303A Aspergillus terreus aristolochene synthase complexed with (1S,8S,9aR)-1,9a-dimethyl-8-(prop-1-en-2-yl)decahydroquinolizin-5-ium
6FK6	;	2.36	;	Crystal structure of N2C/D282C stabilized opsin bound to RS01
6FK7	;	2.62	;	Crystal structure of N2C/D282C stabilized opsin bound to RS06
6FK8	;	2.87	;	Crystal structure of N2C/D282C stabilized opsin bound to RS08
6FK9	;	2.63	;	Crystal structure of N2C/D282C stabilized opsin bound to RS09
6FKA	;	2.7	;	Crystal structure of N2C/D282C stabilized opsin bound to RS11
6FKB	;	3.03	;	Crystal structure of N2C/D282C stabilized opsin bound to RS13
6FKC	;	2.46	;	Crystal structure of N2C/D282C stabilized opsin bound to RS15
6FKD	;	2.49	;	Crystal structure of N2C/D282C stabilized opsin bound to RS16
2VMO	;	1.74	;	Crystal structure of N341AbsSHMT Gly external aldimine
2VMN	;	1.74	;	Crystal structure of N341AbsSHMT internal aldimine
2VMP	;	1.74	;	Crystal structure of N341AbsSHMT L-Ser external aldimine
3KE0	;	2.7	;	Crystal structure of N370S Glucocerebrosidase at acidic pH.
3KEH	;	2.8	;	Crystal Structure of N370S Glucocerebrosidase mutant at pH 7.4
2DZY	;	2.57	;	Crystal structure of N392A mutant of yeast bleomycin hydrolase
2E00	;	2.0	;	Crystal structure of N392L mutant of yeast bleomycin hydrolase
2DZZ	;	2.15	;	Crystal structure of N392V mutant of yeast bleomycin hydrolase
6O55	;	1.7	;	Crystal Structure of N5-carboxyaminoimidazole ribonucleotide mutase (PurE) from Legionella pneumophila
3ORS	;	1.45	;	Crystal Structure of N5-Carboxyaminoimidazole Ribonucleotide Mutase from Staphylococcus aureus
3AX6	;	2.2	;	Crystal structure of N5-carboxyaminoimidazole ribonucleotide synthetase from Thermotoga maritima
3AW8	;	2.6	;	Crystal structure of N5-carboxyaminoimidazole ribonucleotide synthetase from Thermus thermophilus HB8
3K5I	;	2.0	;	Crystal structure of N5-carboxyaminoimidazole synthase from aspergillus clavatus in complex with ADP and 5-aminoimadazole ribonucleotide
3ORR	;	2.23	;	Crystal Structure of N5-Carboxyaminoimidazole synthetase from Staphylococcus aureus
3ORQ	;	2.23	;	Crystal Structure of N5-Carboxyaminoimidazole synthetase from Staphylococcus aureus complexed with ADP
1VQ1	;	2.8	;	Crystal structure of N5-glutamine methyltransferase, HemK(EC 2.1.1.-) (TM0488) from Thermotoga maritima at 2.80 A resolution
3TNN	;	1.95	;	Crystal structure of N5-i5 Fab, an ADCC mediating and non-neutralizing CD4i anti-HIV- 1 antibody.
4WQN	;	2.121	;	Crystal structure of N6-methyladenosine RNA reader YTHDF2
7MRI	;	2.46	;	Crystal structure of N63T yeast iso-1-cytochrome c
3ZOY	;	2.3	;	Crystal Structure of N64Del Mutant of Nitrosomonas europaea Cytochrome c552 (hexagonal space group)
3ZOX	;	2.1	;	Crystal Structure of N64Del Mutant of Nitrosomonas europaea Cytochrome c552 (monoclinic space group)
2PXS	;	2.2	;	Crystal Structure of N66D Mutant of Green Fluorescent Protein from Zoanthus sp. at 2.2 A Resolution (Mature State)
2PXW	;	2.4	;	Crystal Structure of N66D Mutant of Green Fluorescent Protein from Zoanthus sp. at 2.4 A Resolution (Transition State)
3KT2	;	1.651	;	Crystal Structure of N88D mutant HIV-1 Protease
3KT5	;	1.801	;	Crystal Structure of N88S mutant HIV-1 Protease
6XO1	;	1.758	;	Crystal structure of N97A mutant of human CEACAM1
5UZY	;	1.71	;	Crystal structure of N97A mutant of human macrophage migration inhibitory factor
3LWX	;	1.1	;	Crystal structure of Na(+)-translocating NADH-quinone reductase subunit C (YP_001302508.1) from Parabacteroides distasonis ATCC 8503 at 1.10 A resolution
6A31	;	2.19	;	Crystal structure of Na+ bound Peptidyl-tRNA Hydrolase from Acinetobacter baumannii at 2.19 A resolution
8JBK	;	2.8	;	Crystal structure of Na+,K+-ATPase in the E1.3Na+ state
8JBL	;	3.0	;	Crystal structure of Na+,K+-ATPase in the E1.Mg2+ state
8JBM	;	2.9	;	Crystal structure of Na+,K+-ATPase in the E1.Mn2+ state
4HQJ	;	4.3	;	Crystal structure of Na+,K+-ATPase in the Na+-bound state
1Q3I	;	2.6	;	Crystal Structure of Na,K-ATPase N-domain
3NT8	;	2.2	;	Crystal Structure of Na-ASP-1
6L9S	;	2.0	;	Crystal structure of Na-dithionite reduced auracyanin from photosynthetic bacterium Roseiflexus castenholzii
3GIS	;	2.4	;	Crystal Structure of Na-free Thrombin in Complex with Thrombomodulin
4KVX	;	2.0	;	Crystal structure of Naa10 (Ard1) bound to AcCoA
5WJE	;	1.765	;	Crystal structure of Naa80 bound to a bisubstrate analogue
5WJD	;	2.001	;	Crystal structure of Naa80 bound to acetyl-CoA
4LY5	;	1.664	;	Crystal structure of NaASP2 with Zn2+
3MCB	;	1.9	;	Crystal structure of NAC domains of human nascent polypeptide-associated complex (NAC)
4GQA	;	2.42	;	Crystal structure of NAD binding oxidoreductase from Klebsiella pneumoniae
8DU1	;	1.85	;	Crystal Structure of NAD bound dTDP-glucose 4,6-dehydratase from Elizabethkingia anophelis
4WLV	;	2.4	;	Crystal structure of NAD bound MDH2
1WMB	;	2.0	;	Crystal structure of NAD dependent D-3-hydroxybutylate dehydrogenase
2D4V	;	1.9	;	Crystal structure of NAD dependent isocitrate dehydrogenase from Acidithiobacillus thiooxidans
2I1W	;	2.34	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes
2I29	;	2.1	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes
4DY6	;	2.2	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with 2'-phosphate bis(adenosine)-5'-diphosphate
3V7W	;	2.0102	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with 5'-azido-5'-deoxyadenosine
3V7Y	;	1.97	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with 5'-N-Propargylamino-5'-deoxyadenosine
3V80	;	2.0301	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with 5'-O-Propargylamino-5'-deoxyadenosine
3V8N	;	2.3801	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with 8-bromo-5'-amino-5'-deoxyadenosine, reacted with a citrate molecule in N site
8B47	;	2.53	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with a cyclic di-adenosine derivative
6Z61	;	2.47	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with a di-adenosine derivative
6Z64	;	1.89	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with a di-adenosine derivative
6Z65	;	1.97	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with a di-adenosine derivative
7ZZ7	;	2.0	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with a linear di-adenosine derivative
7ZZ9	;	1.89	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with a linear di-adenosine derivative
7ZZA	;	2.05	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with a linear di-adenosine derivative
7ZZB	;	1.56	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with a linear di-adenosine derivative
7ZZC	;	2.1	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with a linear di-adenosine derivative
7ZZD	;	1.79	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with a linear di-adenosine derivative
7ZZE	;	1.78	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with a linear di-adenosine derivative
7ZZF	;	2.41	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with a linear di-adenosine derivative
7ZZG	;	2.3	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with a linear di-adenosine derivative
7ZZH	;	2.0	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with a linear di-adenosine derivative
7ZZJ	;	1.99	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with a linear di-adenosine derivative
8A9V	;	1.984	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with a linear di-adenosine derivative
3V8P	;	2.2901	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with a new di-adenosine inhibitor formed in situ
5DHP	;	2.27	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with a novel inhibitor
5DHQ	;	2.29	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with a novel inhibitor
5DHR	;	2.31	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with a novel inhibitor
5DHS	;	2.62	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with a novel inhibitor
5DHT	;	2.59	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with a novel inhibitor
5DHU	;	2.33	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with a novel inhibitor
6RGE	;	1.801	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with an inhibitor
6RGF	;	2.3	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with an inhibitor
3V7U	;	1.97	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complex with MTA
3V8M	;	2.48	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with 5'-azido-8-bromo-5'-deoxyadenosine
6RBO	;	1.941	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with an adenine derivative
6RBP	;	2.473	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with an adenine derivative
6RBQ	;	2.236	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with an adenine derivative
6RBR	;	2.06	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with an adenine derivative
6RBS	;	2.324	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with an adenine derivative
6RBT	;	2.55	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with an adenine derivative
6RBU	;	1.97	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with an adenine derivative
6RBV	;	2.29	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with an adenine derivative
6RBW	;	2.5	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with an adenine derivative
6RBX	;	2.47	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with an adenine derivative
6RBY	;	2.312	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with an adenine derivative
6RBZ	;	2.318	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with an adenine derivative
6RC0	;	2.75	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with an adenine derivative
6RC1	;	2.54	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with an adenine derivative
6RC2	;	2.048	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with an adenine derivative
6RC3	;	2.315	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with an adenine derivative
6RC4	;	2.278	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with an adenine derivative
6RC5	;	2.038	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with an adenine derivative
6RC6	;	2.29	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with an adenine derivative
6RR2	;	1.991	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with an adenine derivative
6RG6	;	2.52	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with an inhibitor
6RG7	;	2.08	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with an inhibitor
6RG8	;	2.47	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with an inhibitor
6RG9	;	2.08	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with an inhibitor
6RGA	;	2.18	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with an inhibitor
6RGB	;	2.25	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with an inhibitor
6RGC	;	2.19	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with an inhibitor
6RGD	;	2.3	;	Crystal structure of NAD kinase 1 from Listeria monocytogenes in complexe with an inhibitor
3V8Q	;	2.37	;	Crystal structure of NAD kinase 1 H223E mutant from Listeria monocytogenes in complex with 5'-amino-5'-deoxyadenosine
3V8R	;	2.39	;	Crystal structure of NAD kinase 1 H223E mutant from Listeria monocytogenes in complex with 5'-amino-8-bromo-5'-deoxyadenosine
7MH7	;	2.61	;	crystal structure of NAD kinase from Pseudomonas aeruginosa PAO1
1YT5	;	2.3	;	Crystal structure of NAD kinase from Thermotoga maritima
5EJF	;	2.12	;	Crystal structure of NAD kinase P101A mutant from Listeria monocytogenes
5EJG	;	2.877	;	Crystal structure of NAD kinase P252D mutant from Listeria monocytogenes
5EJH	;	2.0	;	Crystal structure of NAD kinase V98S mutant from Listeria monocytogenes
5EJI	;	2.292	;	Crystal structure of NAD kinase W78F mutant from Listeria monocytogenes in complex with NADP/Mn++/PPi
6C8Q	;	2.583	;	Crystal structure of NAD synthetase (NadE) from Enterococcus faecalis in complex with NAD+
5WP0	;	2.6	;	Crystal structure of NAD synthetase NadE from Vibrio fischeri
1RJW	;	2.35	;	CRYSTAL STRUCTURE OF NAD(+)-DEPENDENT ALCOHOL DEHYDROGENASE FROM BACILLUS STEAROTHERMOPHILUS STRAIN LLD-R
2CVQ	;	2.08	;	Crystal structure of NAD(H)-dependent malate dehydrogenase complexed with NADPH
1Y7T	;	1.65	;	Crystal structure of NAD(H)-depenent malate dehydrogenase complexed with NADPH
5EAI	;	2.9	;	Crystal Structure of NAD(P)H dehydrogenase, quinone 1 complexed with a chemotherapeutic naphthoquinone E6a
7TMG	;	1.9	;	Crystal Structure of NAD(P)H nitroreductase from Klebsiella pneumoniae (long b-axis)
7TMF	;	1.97	;	Crystal Structure of NAD(P)H nitroreductase from Klebsiella pneumoniae (short b-axis)
7JH4	;	2.0	;	Crystal structure of NAD(P)H-flavin oxidoreductase (NfoR) from S. aureus complexed with reduced FMN and NAD+
2H0U	;	1.9	;	Crystal structure of NAD(P)H-flavin oxidoreductase from Helicobacter pylori
1QFJ	;	2.2	;	CRYSTAL STRUCTURE OF NAD(P)H:FLAVIN OXIDOREDUCTASE FROM ESCHERICHIA COLI
8GXB	;	2.15	;	Crystal structure of NAD+ -II riboswitch in complex with NAD+
8GXC	;	2.5	;	Crystal structure of NAD+ -II riboswitch in complex with NMN
3DPI	;	2.2	;	Crystal Structure of NAD+ synthetase from Burkholderia Pseudomallei
6KV3	;	2.3	;	Crystal Structure of NAD+ Synthetase from Staphylococcus aureus
1ZEM	;	1.9	;	Crystal Structure of NAD+-Bound Xylitol Dehydrogenase
1V9P	;	2.9	;	Crystal Structure Of Nad+-Dependent DNA Ligase
1DGS	;	2.9	;	CRYSTAL STRUCTURE OF NAD+-DEPENDENT DNA LIGASE FROM T. FILIFORMIS
4H0V	;	2.03	;	Crystal structure of NAD+-Ia(E378S)-actin complex
4H0X	;	2.33	;	Crystal structure of NAD+-Ia(E380A)-actin complex
4H0Y	;	1.94	;	Crystal structure of NAD+-Ia(E380S)-actin complex
4H03	;	1.75	;	Crystal structure of NAD+-Ia-actin complex
5XF9	;	2.58	;	Crystal structure of NAD+-reducing [NiFe]-hydrogenase in the air-oxidized state
5XFA	;	2.7	;	Crystal structure of NAD+-reducing [NiFe]-hydrogenase in the H2-reduced state
4GBJ	;	2.05	;	Crystal structure of NAD-binding 6-phosphogluconate dehydrogenase from Dyadobacter fermentans
3QSG	;	1.9	;	Crystal structure of NAD-binding phosphogluconate dehydrogenase-like protein from Alicyclobacillus acidocaldarius
3E18	;	1.95	;	CRYSTAL STRUCTURE OF NAD-BINDING PROTEIN FROM Listeria innocua
7QOZ	;	1.85	;	Crystal structure of NAD-bound glycosomal malate dehydrogenase from Trypanosoma cruzi
2VUT	;	2.3	;	Crystal structure of NAD-bound NmrA-AreA zinc finger complex
2EIH	;	2.3	;	Crystal Structure of NAD-dependent alcohol dehydrogenase
5UJU	;	2.05	;	Crystal structure of NAD-dependent aldehyde dehydrogenase from Burkholderia multivorans
3ROS	;	1.88	;	Crystal structure of NAD-dependent aldehyde dehydrogenase from Lactobacillus acidophilus
3U4J	;	2.0	;	Crystal structure of NAD-dependent aldehyde dehydrogenase from Sinorhizobium meliloti
3R6D	;	1.25	;	Crystal structure of NAD-dependent epimerase/dehydratase from Veillonella parvula DSM 2008 with Cz-methylated lysine
6TTB	;	2.7	;	Crystal structure of NAD-dependent formate dehydrogenase from Staphylococcus aureus in complex with NAD
8QC6	;	2.4	;	Crystal Structure of NAD-dependent glycoside hydrolase from Arthrobacter sp. U41 in complex with NAD+ and sulfoquinovose (SQ)
8QC5	;	1.95	;	crystal structure of NAD-dependent glycoside hydrolase from Arthrobacter sp. U41 in complex with NAD+ cofactor and citrate
8QC8	;	2.35	;	Crystal structure of NAD-dependent glycoside hydrolase from Flavobacterium sp. (strain K172) in complex with co-factor NAD+
8QC2	;	2.3	;	Crystal structure of NAD-dependent glycoside hydrolase from Flavobacterium sp. (strain K172) in complex with co-factor NAD+ and sulfoquinovose (SQ)
1VL6	;	2.61	;	Crystal structure of NAD-dependent malic enzyme (TM0542) from Thermotoga maritima at 2.61 A resolution
8HBA	;	2.64	;	Crystal structure of NAD-II riboswitch (single strand) with NAD
8HB8	;	2.3	;	Crystal structure of NAD-II riboswitch (single strand) with NMN
8HB1	;	2.23	;	Crystal structure of NAD-II riboswitch (two strands) with NMN
8I3Z	;	1.67	;	Crystal structure of NAD-II riboswitch (two strands) with NMN at 1.67 angstrom
8HB3	;	2.87	;	Crystal structure of NAD-II riboswitch (two strands) with NR
5HUO	;	2.8	;	Crystal Structure of NadC Deletion Mutant in C2221 Space Group
5HUL	;	2.855	;	Crystal Structure of NadC Deletion Mutant in Cubic Space Group
5HUP	;	3.42	;	Crystal Structure of NadC from Streptococcus pyogenes
5HUH	;	2.5	;	Crystal Structure of NadE from Streptococcus pyogenes
5HUJ	;	2.1	;	Crystal Structure of NadE from Streptococcus pyogenes
5H5X	;	2.3	;	Crystal structure of NADH bound carbonyl reductase from Streptomyces coelicolor
7CTL	;	1.97	;	Crystal structure of NADH bound holo form of alpha-glucuronidase (TM0752) from Thermotoga maritima at 1.97 Angstrom resolution
3MCR	;	2.65	;	Crystal structure of NADH dehydrogenase subunit C (Tfu_2693) from THERMOBIFIDA FUSCA YX-ER1 at 2.65 A resolution
1F8W	;	2.45	;	CRYSTAL STRUCTURE OF NADH PEROXIDASE MUTANT: R303M
1VK6	;	2.2	;	Crystal structure of NADH pyrophosphatase (1790429) from Escherichia coli k12 at 2.20 A resolution
2GB5	;	2.3	;	Crystal structure of NADH pyrophosphatase (EC 3.6.1.22) (1790429) from Escherichia coli K12 at 2.30 A resolution
1NDH	;	2.1	;	CRYSTAL STRUCTURE OF NADH-CYTOCHROME B5 REDUCTASE FROM PIG LIVER AT 2.4 ANGSTROMS RESOLUTION
1VLJ	;	1.78	;	Crystal structure of NADH-dependent butanol dehydrogenase A (TM0820) from Thermotoga maritima at 1.78 A resolution
6L1K	;	1.97	;	Crystal structure of NADH-dependent butanol dehydrogenase A from Fusobacterium nucleatum
1D7Y	;	2.1	;	CRYSTAL STRUCTURE OF NADH-DEPENDENT FERREDOXIN REDUCTASE, BPHA4
3AK4	;	2.0	;	Crystal structure of NADH-dependent quinuclidinone reductase from agrobacterium tumefaciens
4TKM	;	2.67	;	Crystal structure of NADH-dependent reductase A1-R' complexed with NAD
4TKL	;	1.8	;	Crystal structure of NADH-dependent reductase A1-R' responsible for alginate metabolism
4YWN	;	1.8	;	Crystal structure of NADH-FMN oxidoreductase from Mycobacterium avium
3K86	;	2.0	;	Crystal structure of NADH:FAD oxidoreductase (TftC) - apo form
3K87	;	2.0	;	Crystal structure of NADH:FAD oxidoreductase (TftC) - FAD complex
3K88	;	2.0	;	Crystal structure of NADH:FAD oxidoreductase (TftC) - FAD, NADH complex
3E4V	;	1.4	;	Crystal structure of NADH:FMN oxidoreductase like protein in complex with FMN (YP_544701.1) from METHYLOBACILLUS FLAGELLATUS KT at 1.40 A resolution
6E2A	;	2.2	;	Crystal structure of NADH:quinone reductase PA1024 from Pseudomonas aeruginosa PAO1 in complex with NAD+
3KLJ	;	2.1	;	Crystal structure of NADH:rubredoxin oxidoreductase from Clostridium acetobutylicum
8DU0	;	2.1	;	Crystal Structure of NADP bound GDP-L-fucose synthase from Brucella ovis
3W6Z	;	1.44	;	Crystal structure of NADP bound L-serine 3-dehydrogenase (K170M) from Hyperthermophilic Archaeon Pyrobaculum calidifontis
3W6U	;	2.0	;	Crystal structure of NADP bound L-serine 3-dehydrogenase from Hyperthermophilic Archaeon Pyrobaculum calidifontis
2ZZC	;	2.6	;	Crystal structure of NADP(H):human thioredoxin reductase I
4RF2	;	2.089	;	Crystal structure of NADP+ bound ketoreductase from Lactobacillus kefir
8I70	;	1.9	;	Crystal structure of NADP-binding form of malonyl-CoA reductase C-domain from Chloroflexus aurantiacus
2VUU	;	2.8	;	Crystal structure of NADP-bound NmrA-AreA zinc finger complex
4J2O	;	2.653	;	Crystal structure of NADP-bound WbjB from A. baumannii community strain D1279779
5TQV	;	1.65	;	Crystal structure of NADP-dependent carbonyl reductase from Burkholderia multivorans
5U1P	;	1.9	;	Crystal structure of NADP-dependent carbonyl reductase from Burkholderia multivorans in complex with NADP
5C5I	;	2.2	;	Crystal structure of NADP-dependent dehydrogenase from Rhodobacter sphaeroides
4ZQB	;	1.85	;	Crystal structure of NADP-dependent dehydrogenase from Rhodobactersphaeroides in complex with NADP and sulfate
3PRL	;	2.0	;	Crystal structure of NADP-dependent glyceraldehyde-3-phosphate dehydrogenase from Bacillus halodurans C-125
3RHH	;	2.3	;	Crystal structure of NADP-dependent glyceraldehyde-3-phosphate dehydrogenase from Bacillus halodurans C-125 complexed with NADP
2D2I	;	2.5	;	Crystal Structure of NADP-Dependent Glyceraldehyde-3-Phosphate Dehydrogenase from Synechococcus Sp. complexed with Nadp+
1LWD	;	1.85	;	CRYSTAL STRUCTURE OF NADP-DEPENDENT ISOCITRATE DEHYDROGENASE FROM PORCINE HEART MITOCHONDRIA
7TWZ	;	2.1	;	Crystal Structure of NADP-linked putative oxidoreductase from Klebsiella pneumoniae
6JHB	;	2.27	;	Crystal structure of NADPH and 4-hydroxyphenylpyruvic acid bound AerF from Microcystis aeruginosa
6JHA	;	1.78	;	Crystal structure of NADPH bound AerF from Microcystis aeruginosa
5B1Y	;	2.09	;	Crystal structure of NADPH bound carbonyl reductase from Aeropyrum pernix
3WXB	;	1.98	;	Crystal structure of NADPH bound carbonyl reductase from chicken fatty liver
1TH3	;	2.8	;	Crystal structure of NADPH depleted bovine live catalase complexed with cyanide
1TH4	;	2.98	;	crystal structure of NADPH depleted bovine liver catalase complexed with 3-amino-1,2,4-triazole
1TH2	;	2.8	;	crystal structure of NADPH depleted bovine liver catalase complexed with azide
3QFT	;	1.4	;	Crystal Structure of NADPH-Cytochrome P450 Reductase (FAD/NADPH domain and R457H Mutant)
3QFS	;	1.4	;	Crystal Structure of NADPH-Cytochrome P450 Reductase (FAD/NADPH domain)
5TSD	;	1.9	;	Crystal structure of NADPH-dependent 2-hydroxyacid dehydrogenase from Rhizobium etli CFN 42 in complex with NADPH and oxalate
4O0L	;	2.2	;	Crystal structure of NADPH-Dependent 3-Quinuclidinone Reductase from Rhodotorula Rubra
5UNN	;	2.0	;	Crystal structure of NADPH-dependent glyoxylate/hydroxypyruvate reductase SMc02828 (SmGhrA) from Sinorhizobium meliloti in apo form
4WEQ	;	2.0	;	Crystal structure of NADPH-dependent glyoxylate/hydroxypyruvate reductase SMc02828 (SmGhrA) from Sinorhizobium meliloti in complex with NADP and sulfate
4Z0P	;	1.7	;	Crystal structure of NADPH-dependent glyoxylate/hydroxypyruvate reductase SMc02828 (SmGhrA) from Sinorhizobium meliloti in complex with NADPH and oxalate
5UOG	;	2.4	;	Crystal structure of NADPH-dependent glyoxylate/hydroxypyruvate reductase SMc04462 (SmGhrB) from Sinorhizobium meliloti in apo form
5J23	;	2.3	;	Crystal structure of NADPH-dependent glyoxylate/hydroxypyruvate reductase SMc04462 (SmGhrB) from Sinorhizobium meliloti in complex with 2'-phospho-ADP-ribose
5V72	;	2.1	;	Crystal structure of NADPH-dependent glyoxylate/hydroxypyruvate reductase SMc04462 (SmGhrB) from Sinorhizobium meliloti in complex with citrate
5V7N	;	1.75	;	Crystal structure of NADPH-dependent glyoxylate/hydroxypyruvate reductase SMc04462 (SmGhrB) from Sinorhizobium meliloti in complex with NADP and 2-Keto-D-gluconic acid
5V6Q	;	1.95	;	Crystal structure of NADPH-dependent glyoxylate/hydroxypyruvate reductase SMc04462 (SmGhrB) from Sinorhizobium meliloti in complex with NADP and malonate
5V7G	;	1.75	;	Crystal structure of NADPH-dependent glyoxylate/hydroxypyruvate reductase SMc04462 (SmGhrB) from Sinorhizobium meliloti in complex with NADPH and oxalate
2ZCV	;	2.3	;	Crystal structure of NADPH-dependent quinone oxidoreductase QOR2 complexed with NADPH from escherichia coli
4GDE	;	2.2	;	Crystal structure of NADPH-reduced Aspergillus fumigatus UDP-galactopyranose
5AIP	;	2.3	;	Crystal structure of NadR in complex with 4-hydroxyphenylacetate
6GZO	;	3.0	;	Crystal structure of NadR protein in complex with NAD and AMP-PNP
6GYE	;	2.3	;	Crystal structure of NadR protein in complex with NR
6GYF	;	2.7	;	Crystal structure of NadR protein in complex with NR
1IAW	;	2.4	;	CRYSTAL STRUCTURE OF NAEI COMPLEXED WITH 17MER DNA
4OOA	;	1.58	;	CRYSTAL STRUCTURE of NAF1 (MINER1): H114C THE REDOX-ACTIVE 2FE-2S PROTEIN
3AB6	;	1.78	;	Crystal structure of NAG3 bound lysozyme from Meretrix lusoria
8EOL	;	2.17	;	CRYSTAL STRUCTURE OF NAGB-II PHOSPHOSUGAR ISOMERASE FROM SHEWANELLA DENITRIFICANS OS217 AT 2.17 A RESOLUTION
8EYM	;	2.311	;	CRYSTAL STRUCTURE OF NAGB-II PHOSPHOSUGAR ISOMERASE FROM SHEWANELLA DENITRIFICANS OS217 IN COMPLEX WITH GLUCITOLAMINE-6-PHOSPHATE AND N-ACETYLGLUCOSAMINE-6-PHOSPHATE AT 2.31 A RESOLUTION
8FDB	;	3.06	;	CRYSTAL STRUCTURE OF NAGB-II PHOSPHOSUGAR ISOMERASE FROM Shewanella denitrificans OS217 IN COMPLEX WITH GLUCITOLAMINE-6-PHOSPHATE AT 3.06 A RESOLUTION.
4U52	;	3.0	;	Crystal structure of Nagilactone C bound to the yeast 80S ribosome
6JTJ	;	2.18	;	Crystal structure of NagZ from Neisseria gonorrhoeae in complex with N-acetylglucosamine
6JTK	;	2.2	;	Crystal structure of NagZ from Neisseria gonorrhoeae in complex with N-trifluoroacetyl-D-glucosamine
6JTL	;	2.4	;	Crystal structure of NagZ from Neisseria gonorrhoeae in complex with zinc ion
5G1M	;	1.8	;	Crystal structure of NagZ from Pseudomonas aeruginosa
5G2M	;	3.0	;	Crystal structure of NagZ from Pseudomonas aeruginosa in complex with N-acetylglucosamine
5G3R	;	2.18	;	Crystal structure of NagZ from Pseudomonas aeruginosa in complex with N-acetylglucosamine and L-Ala-1,6-anhydroMurNAc
5G5K	;	3.1	;	Crystal structure of NagZ from Pseudomonas aeruginosa in complex with the inhibitor 2-acetamido-1,2-dideoxynojirimycin
5G5U	;	2.25	;	Crystal structure of NagZ H174A mutant from Pseudomonas aeruginosa
5LY7	;	3.1	;	Crystal structure of NagZ H174A mutant from Pseudomonas aeruginosa in complex with the inhibitor 2-acetamido-1,2-dideoxynojirimycin
8DO5	;	2.1	;	Crystal structure of NahE in complex with intermediate (R)-4-hydroxy-4-(2-hydroxyphenyl)-2-iminobutanoate
2Q67	;	2.3	;	Crystal Structure of Nak channel D66A mutant
2Q68	;	2.5	;	Crystal Structure of Nak channel D66A, S70E double mutants
2Q6A	;	2.6	;	Crystal Structure of Nak channel D66E mutant
2Q69	;	2.4	;	Crystal Structure of Nak channel D66N mutant
3T1C	;	1.802	;	Crystal Structure of NaK Channel D66Y Mutant
3T2M	;	1.953	;	Crystal Structure of NaK Channel N68D Mutant
3TCU	;	1.75	;	Crystal Structure of NaK2K Channel D68E Mutant
3T4D	;	1.7	;	Crystal Structure of NaK2K Channel Y55F Mutant
3T4Z	;	1.901	;	Crystal Structure of NaK2K Channel Y55W Mutant
3TET	;	1.9	;	Crystal Structure of NaK2K Channel Y66F Mutant
5DAJ	;	2.65	;	Crystal structure of NalD, the secondary repressor of MexAB-OprM multidrug efflux pump in Pseudomonas aeruginosa
8ABT	;	1.39	;	Crystal structure of NaLdpA in complex with the product analog Resveratrol
8ABU	;	1.661	;	Crystal structure of NaLdpA mutant H97Q in complex with erythro-DGPD
3QF2	;	1.7	;	Crystal structure of NALP3 PYD
7Q8T	;	2.15	;	Crystal structure of NAMPT bound to ligand TSY535(compound 9a)
7PPE	;	1.86	;	CRYSTAL STRUCTURE OF NAMPT IN COMPLEX WITH COMPOUND 1
7PPH	;	1.74	;	CRYSTAL STRUCTURE OF NAMPT IN COMPLEX WITH Compound 10
7PPI	;	2.33	;	Crystal STRUCTURE OF NAMPT IN COMPLEX WITH Compound 11
7PPF	;	2.36	;	CRYSTAL STRUCTURE OF NAMPT IN COMPLEX WITH COMPOUND 8
7PPG	;	2.13	;	CRYSTAL STRUCTURE OF NAMPT IN COMPLEX WITH COMPOUND 9
4XIK	;	1.91	;	Crystal structure of NanB sialidase from streptococcus pneumoniae in complex with DMSO
6JRI	;	3.101	;	Crystal structure of Nanobody
7X2M	;	1.8	;	Crystal structure of nanobody 1-2C7 with SARS-CoV-2 RBD
7X2L	;	2.4	;	Crystal structure of nanobody 3-2A2-4 with SARS-CoV-2 RBD
7X4I	;	3.38	;	Crystal structure of nanobody aSA3 in complex with dimer SARS-CoV-1 RBD
6JB9	;	1.15	;	Crystal structure of nanobody D3-L11 (unbound form)
6JB8	;	1.65	;	Crystal structure of nanobody D3-L11 in complex with hen egg-white lysozyme
6JB2	;	1.5	;	Crystal structure of nanobody D3-L11 mutant Y102A in complex with hen egg-white lysozyme
6JB5	;	1.55	;	Crystal structure of nanobody D3-L11 mutant Y102A in complex with hen egg-white lysozyme (form II)
7RBY	;	2.82	;	Crystal structure of Nanobody nb112 and SARS-CoV-2 RBD
7X2K	;	2.4	;	Crystal structure of nanobody Nb70 with antibody 1F11 fab and SARS-CoV-2 RBD
7X2J	;	2.4	;	Crystal structure of nanobody Nb70 with SARS-CoV RBD
7NDF	;	2.1	;	Crystal structure of nanobody Nb_MsbA#1 in complex with the nucleotide binding domain of MsbA
8IDM	;	3.59	;	Crystal structure of nanobody VHH-227 with nanobody VHH-T71 and MERS-CoV RBD
8IEE	;	3.21	;	Crystal structure of nanobody VHH-31 with MERS-CoV RBD
8IDO	;	2.5	;	Crystal structure of nanobody VHH-T148 with MERS-CoV RBD
8IDI	;	1.901	;	Crystal structure of nanobody VHH-T71 with MERS-CoV RBD
8EVD	;	2.0	;	Crystal Structure of Nanobody VHH101 Bound to Its Antigen PA14 Cif
8F6V	;	2.3	;	Crystal Structure of Nanobody VHH108 Bound to Its Antigen PA14 Cif
8E1B	;	1.65	;	Crystal Structure of Nanobody VHH108 Specific for PA14 Cif
8F6U	;	1.7	;	Crystal Structure of Nanobody VHH113 Bound to Its Antigen PA14 Cif
8E2N	;	1.1	;	Crystal Structure of Nanobody VHH113 Specific for PA14 Cif
8EE2	;	2.4	;	Crystal Structure of Nanobody VHH219 Bound to Its Antigen PA14 Cif
8ELN	;	2.4	;	Crystal Structure of Nanobody VHH222 Bound to Its Antigen PA14 Cif
8E1C	;	1.9	;	Crystal Structure of Nanobody VHH222 Specific for PA14 Cif
7RGA	;	2.9	;	Crystal structure of nanoCLAMP3:VHH in complex with MTX
7RG7	;	1.83	;	Crystal structure of nanoclamp8:VHH in complex with MTX
7MJB	;	1.7	;	Crystal Structure of Nanoluc Luciferase Mutant R164Q
3ALR	;	2.1	;	Crystal structure of Nanos
3PT5	;	1.6	;	Crystal structure of NanS
7EA2	;	2.14	;	crystal structure of NAP1 FIR in complex with RB1CC1 Claw domain
7EA7	;	2.69	;	crystal structure of NAP1 LIR in complex with GABARAP
2HMO	;	1.6	;	Crystal Structure of Naphthalene 1,2-Dioxygenase Bound to 3-Nitrotoluene.
2HMM	;	1.6	;	Crystal Structure of Naphthalene 1,2-Dioxygenase Bound to Anthracene
2HMK	;	1.65	;	Crystal Structure of Naphthalene 1,2-Dioxygenase Bound to Phenanthrene
2B1X	;	2.0	;	Crystal structure of naphthalene 1,2-dioxygenase from Rhodococcus sp.
2B24	;	3.0	;	Crystal structure of naphthalene 1,2-dioxygenase from Rhodococcus sp. bound to indole
4CCW	;	1.75	;	Crystal structure of naproxen esterase (carboxylesterase NP) from Bacillus subtilis
2C7X	;	1.75	;	Crystal structure of narbomycin-bound cytochrome P450 PikC (CYP107L1)
8GUE	;	1.9	;	Crystal Structure of narbomycin-bound cytochrome P450 PikC with the unnatural amino acid p-Acetyl-L-Phenylalanine incorporated at position 238
1NAR	;	1.8	;	CRYSTAL STRUCTURE OF NARBONIN REFINED AT 1.8 ANGSTROMS RESOLUTION
4U51	;	3.2	;	Crystal structure of Narciclasine bound to the yeast 80S ribosome
1R27	;	2.0	;	Crystal Structure of NarGH complex
3IR5	;	2.3	;	Crystal structure of NarGHI mutant NarG-H49C
3IR6	;	2.8	;	Crystal structure of NarGHI mutant NarG-H49S
3IR7	;	2.5	;	Crystal structure of NarGHI mutant NarG-R94S
3WHJ	;	1.65	;	Crystal structure of Nas2 N-terminal domain
3WHL	;	4.0	;	Crystal structure of Nas2 N-terminal domain complexed with PAN-Rpt5C chimera
2UWC	;	2.3	;	Crystal structure of Nasturtium xyloglucan hydrolase isoform NXG2
4U9V	;	1.78	;	Crystal structure of NatD (Naa40p) bound to acetyl CoA
4U9W	;	2.49	;	Crystal Structure of NatD bound to H4/H2A peptide and CoA
5C1J	;	1.7	;	Crystal Structure of native (reduced) CorB
3VSI	;	2.5	;	Crystal structure of native 1,6-APD (2-Animophenol-1,6-dioxygenase) complex with 4-Nitrocatechol
3VSH	;	2.7	;	Crystal structure of native 1,6-APD (with Iron), 2-Animophenol-1,6-Dioxygenase
4X19	;	1.944	;	Crystal structure of native 4-OT from Pseudomonas putida mt-2 at 1.94 Angstrom
5NAQ	;	2.48	;	Crystal structure of native 6-phospho-glucosidase LpBgl from Lactobacillus plantarum
3KLX	;	2.5	;	Crystal structure of native abscisic acid receptor PYL3
4JDL	;	2.65	;	Crystal structure of native abscisic acid receptor PYL5 at 2.65 Angstrom
3OQU	;	2.68	;	Crystal structure of native abscisic acid receptor PYL9 with ABA
6GSZ	;	1.38	;	Crystal structure of native alfa-L-rhamnosidase from Aspergillus terreus
5NBU	;	1.67	;	Crystal structure of native alpha-1-antitrypsin with seven stabilising mutations
5NBV	;	1.73	;	Crystal structure of native alpha-1-antitrypsin with seven stabilising mutations
4ZJG	;	2.3	;	Crystal structure of native alpha-2-macroglobulin from Escherichia coli spanning domains MG0-NIE-MG1.
4ZJH	;	1.6	;	Crystal structure of native alpha-2-macroglobulin from Escherichia coli spanning domains NIE-MG1.
4ZIU	;	2.7	;	Crystal structure of native alpha-2-macroglobulin from Escherichia coli spanning the residues from domain MG7 to the C-terminus.
3DC0	;	2.78	;	Crystal structure of native alpha-amylase from Bacillus sp. KR-8104
4GZB	;	1.79	;	Crystal structure of native AmpC beta-lactamase from Pseudomonas aeruginosa PAO1
1T1F	;	2.75	;	Crystal Structure of Native Antithrombin in its Monomeric Form
6IXG	;	3.801	;	Crystal structure of native apo SH3BP5 (P41)
4LTT	;	1.28	;	Crystal structure of native apo toxin from Helicobacter pylori
4QJY	;	2.294	;	Crystal structure of native Ara127N, a GH127 beta-L-arabinofuranosidase from Geobacillus Stearothermophilus T6
4FD6	;	1.8	;	Crystal structure of native arylalkylamine N-Acetyltransferase 2 from the yellow fever mosquito, Aedes aegypti
5F9M	;	2.402	;	Crystal structure of native B3275, member of MccF family of enzymes
5OAR	;	2.3	;	Crystal structure of native beta-N-acetylhexosaminidase isolated from Aspergillus oryzae
4A8U	;	1.16	;	Crystal Structure of native Birch Pollen Allergen Bet v 1 isoform j
7JSM	;	2.5	;	CRYSTAL STRUCTURE OF NATIVE BOVINE ARRESTIN 1
7MP1	;	2.66	;	CRYSTAL STRUCTURE OF NATIVE BOVINE ARRESTIN 1 IN COMPLEX WITH 1,5-DI-METHYLENEBISPHOSPHONATE INOSITOL TETRAKISPHOSPHATE (1,5-PCP-IP4)
7MP2	;	3.0	;	CRYSTAL STRUCTURE OF NATIVE BOVINE ARRESTIN 1 IN COMPLEX WITH 1D-MYO-INOSITOL 1,5-BISDIPHOSPHATE TETRAKISPHOSPHATE (1,5-PP IP4)
7MP0	;	2.6	;	CRYSTAL STRUCTURE OF NATIVE BOVINE ARRESTIN 1 IN COMPLEX WITH 1D-MYO-INOSITOL 5-DIPHOSPHATE PENTAKISPHOSPHATE (5-PP IP5)
7MOR	;	2.8	;	CRYSTAL STRUCTURE OF NATIVE BOVINE ARRESTIN 1 IN COMPLEX WITH 5-METHYLENEBIPHOSPHONATE INOSITOL PENTAKISPHAOPHATE (5-PCP IP5)
7JXA	;	2.4	;	CRYSTAL STRUCTURE OF NATIVE BOVINE ARRESTIN 1 IN COMPLEX WITH INOSITOL 1,4,5-TRIPHOSPHATE
7JTB	;	2.6	;	CRYSTAL STRUCTURE OF NATIVE BOVINE ARRESTIN 1 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
3MQ3	;	2.8	;	Crystal structure of native bovine PDP1c
1XVT	;	2.3	;	Crystal Structure of Native CaiB in complex with coenzyme A
1WUV	;	2.3	;	Crystal structure of native Canavalia gladiata lectin (CGL): a tetrameric ConA-like lectin
5SW5	;	2.05	;	Crystal structure of native catalase-peroxidase KatG at pH7.5
5SW4	;	1.9	;	Crystal structure of native catalase-peroxidase KatG at pH8.0
3N4G	;	2.44	;	Crystal structure of native Cg10062
7MS0	;	1.37	;	Crystal structure of native Cg10062
1EI3	;	5.5	;	CRYSTAL STRUCTURE OF NATIVE CHICKEN FIBRINOGEN
1M1J	;	2.7	;	Crystal structure of native chicken fibrinogen with two different bound ligands
7C6C	;	1.258	;	Crystal structure of native chitosanase from Bacillus subtilis MY002
3MF8	;	2.01	;	Crystal Structure of Native cis-CaaD
1FBB	;	3.2	;	CRYSTAL STRUCTURE OF NATIVE CONFORMATION OF BACTERIORHODOPSIN
4HBT	;	1.1	;	Crystal structure of native CTX-M-15 extended-spectrum beta-lactamase
6OS3	;	1.7	;	Crystal structure of native CymD prenyltransferase
6PNU	;	2.0	;	Crystal structure of native DauA
8DB1	;	2.72	;	Crystal structure of native DMATS1 prenyltransferase
5Y26	;	2.003	;	Crystal structure of native Dpb4-Dpb3
5H7E	;	1.6	;	Crystal Structure of native drCPDase
7DKR	;	2.378	;	Crystal structure of native E. coli Grx2 at 2.38 A
6G3D	;	2.221	;	Crystal structure of Native EDDS lyase
8T3J	;	2.705	;	Crystal structure of native exfoliative toxin C (ExhC) from Mammaliicoccus sciuri
6GGU	;	2.6	;	Crystal structure of native FE-hydrogenase from Methanothermobacter marburgensis
4LHP	;	2.02	;	Crystal Structure of Native FG41Malonate Semialdehyde Decarboxylase
6BLM	;	1.488	;	Crystal Structure of Native Fused 4-OT
4Y2F	;	1.396	;	CRYSTAL STRUCTURE OF NATIVE GAF DOMAIN of POTASSIUM SENSOR HISTIDINE KINASE KDPD FROM ESCHERICHIA COLI
6PHI	;	1.1	;	Crystal structure of native glucagon in space group I41 at 1.1 A resolution
6PHJ	;	1.99	;	Crystal structure of native glucagon in space group P213 at 1.99 A resolution
1JMJ	;	2.35	;	Crystal Structure of Native Heparin Cofactor II
3FLP	;	2.3	;	Crystal structure of native heptameric SAP-like pentraxin from Limulus polyphemus
5C21	;	2.5	;	Crystal structure of native HlyD from E. coli
1E51	;	2.83	;	Crystal structure of native human erythrocyte 5-aminolaevulinic acid dehydratase
4HD9	;	1.7	;	Crystal structure of native human MAdCAM-1 D1D2 domain
7NI3	;	2.1	;	CRYSTAL STRUCTURE OF NATIVE HUMAN MYELOPEROXIDASE IN COMPLEX WITH CPD 3
7NI1	;	2.11	;	CRYSTAL STRUCTURE OF NATIVE HUMAN MYELOPEROXIDASE IN COMPLEX WITH CPD 9
3FGQ	;	2.09	;	Crystal structure of native human neuroserpin
6MP5	;	2.99	;	Crystal structure of native human sulfide:quinone oxidoreductase
4UP1	;	2.991	;	Crystal structure of native human Thymidylate synthase in active form
7ZBF	;	2.3	;	Crystal structure of native Iripin-4 serpin from tick Ixodes ricinus
7PMU	;	1.89	;	Crystal structure of native Iripin-8
5JRR	;	1.9	;	Crystal structure of native laccase from Thermus thermophilus HB27
5U3E	;	2.3	;	Crystal Structure of Native Lectin from Canavalia bonariensis Seeds (CaBo) complexed with alpha-methyl-D-mannoside
5U38	;	1.6	;	Crystal structure of native lectin from Platypodium elegans seeds (PELa) complexed with Man1-3Man-OMe.
4A88	;	1.51	;	Crystal Structure of native Major Birch Pollen Allergen Bet v 1 isoform a
1SD6	;	2.65	;	Crystal Structure of Native MecI at 2.65 A
1JC5	;	2.2	;	Crystal Structure of Native Methylmalonyl-CoA Epimerase
3S6H	;	3.102	;	Crystal structure of native mmNAGS/k
5XKO	;	1.89	;	Crystal structure of native Msmeg3575 deaminase from Mycobacterium smegmatis
6JTI	;	2.2	;	Crystal structure of native NagZ from Neisseria gonorrhoeae
5H9T	;	2.89	;	Crystal structure of native NalD at resolution of 2.9, the secondary repressor of MexAB-OprM multidrug efflux pump in Pseudomonas aeruginosa
2HI2	;	2.3	;	Crystal structure of native Neisseria gonorrhoeae Type IV pilin at 2.3 Angstroms Resolution
3FLR	;	3.0	;	Crystal structure of native octameric SAP-like pentraxin from Limulus polyphemus
3CAP	;	2.9	;	Crystal Structure of Native Opsin: the G Protein-Coupled Receptor Rhodopsin in its Ligand-free State
1XQO	;	1.03	;	Crystal structure of native Pa-AGOG, 8-oxoguanine DNA glycosylase from Pyrobaculum aerophilum
2A1S	;	2.6	;	Crystal structure of native PARN nuclease domain
4LWQ	;	1.38	;	Crystal structure of native peptidyl t-RNA hydrolase from Acinetobacter baumannii at 1.38A resolution
3KJZ	;	2.4	;	Crystal structure of native peptidyl-tRNA hydrolase from Mycobacterium smegmatis
1QXJ	;	1.8	;	Crystal structure of native phosphoglucose isomerase from Pyrococcus furiosus
1TZB	;	1.16	;	Crystal structure of native phosphoglucose/phosphomannose isomerase from Pyrobaculum aerophilum
6YYJ	;	2.16	;	Crystal structure of native Phycocyanin from T. elongatus in spacegroup P21212 at 2.1 Angstroms
6YQ8	;	1.82	;	Crystal structure of native Phycocyanin from T. elongatus in spacegroup P63 at 1.8 Angstroms
6YPQ	;	1.29	;	Crystal structure of native Phycocyanin from T. elongatus in spacegroup R32 at 1.29 Angstroms
6YQG	;	1.45	;	Crystal structure of native Phycocyanin in spacegroup P63 at 1.45 Angstroms.
1DB2	;	2.7	;	CRYSTAL STRUCTURE OF NATIVE PLASMINOGEN ACTIVATOR INHIBITOR-1
5C9L	;	1.65	;	Crystal structure of native PLL lectin from Photorhabdus luminescens at 1.65 A resolution
4LA4	;	2.07	;	Crystal structure of native PnpB
4DY0	;	2.35	;	Crystal structure of native protease nexin-1 with heparin
2AIP	;	1.65	;	Crystal structure of native protein C activator from the venom of copperhead snake Agkistrodon contortrix contortrix
5UIF	;	2.57	;	Crystal Structure of Native Ps01740
3EF4	;	1.18	;	Crystal structure of native pseudoazurin from Hyphomicrobium denitrificans
1Z27	;	2.08	;	Crystal structure of Native Pvs25, an ookinete protein from Plasmodium vivax.
3TRQ	;	1.76	;	Crystal structure of native rabbit skeletal calsequestrin
4ATD	;	2.1	;	Crystal structure of native Raucaffricine glucosidase
6H0T	;	1.9	;	Crystal structure of native recombinant human bile salt activated lipase
4U5P	;	1.782	;	Crystal structure of native RhCC (YP_702633.1) from Rhodococcus jostii RHA1 at 1.78 Angstrom
5XXS	;	2.09	;	Crystal structure of native ribT from Bacillus subtilis
6BWG	;	1.99	;	Crystal structure of native Rv2983 from Mycobacterium tuberculosis
1JOU	;	1.8	;	Crystal Structure of Native S195A Thrombin with an Unoccupied Active Site
1Z1I	;	2.8	;	Crystal structure of native SARS CLpro
1U7S	;	1.4	;	Crystal structure of Native Sperm Whale myoglobin from low ionic strength enviroment (Form 1)
1U7R	;	1.15	;	Crystal structure of Native Sperm Whale myoglobin from low ionic strength enviroment (Form2 )
2FP9	;	2.96	;	Crystal structure of Native Strictosidine Synthase
5T1X	;	1.7	;	Crystal Structure of Native Tarin Lectin
1C3Q	;	2.0	;	CRYSTAL STRUCTURE OF NATIVE THIAZOLE KINASE IN THE MONOCLINIC FORM
4XHI	;	2.15	;	Crystal structure of native Thosea asigna virus RNA-dependent RNA polymerase (RdRP) at 2.15 Angstrom resolution
2BF2	;	2.1	;	Crystal structure of native toluene-4-monooxygenase catalytic effector protein, T4moD
5DUO	;	2.4	;	Crystal structure of native translocator protein 18kDa (TSPO) from Rhodobacter sphaeroides (A139T Mutant) in C2 space group
2DJX	;	1.58	;	Crystal structure of native Trypanosoma cruzi dihydroorotate dehydrogenase
1EWX	;	1.7	;	Crystal structure of native tryparedoxin I from Crithidia fasciculata
3IEK	;	2.05	;	Crystal Structure of native TTHA0252 from Thermus thermophilus HB8
3S9Q	;	1.67	;	Crystal structure of native type 1 ribosome inactivating protein from Momordica balsamina at 1.67 A resolution
5Y98	;	1.36	;	Crystal structure of native unbound peptidyl tRNA hydrolase from Acinetobacter baumannii at 1.36 A resolution
1IDQ	;	2.03	;	CRYSTAL STRUCTURE OF NATIVE VANADIUM-CONTAINING CHLOROPEROXIDASE FROM CURVULARIA INAEQUALIS
1VBU	;	1.8	;	Crystal structure of native xylanase 10B from Thermotoga maritima
3NIY	;	1.58	;	Crystal structure of native xylanase 10B from Thermotoga petrophila RKU-1
5NH5	;	1.8	;	Crystal structure of native xylose isomerase from Piromyces E2
6T8E	;	1.86	;	Crystal structure of native xylose isomerase from Piromyces E2 grown in yeast, in complex with xylose
7DAO	;	2.28	;	Crystal structure of native yak lactoperoxidase at 2.28 A resolution
5OK4	;	1.29	;	Crystal structure of native [Fe]-hydrogenase Hmd from Methanothermobacter marburgensis inactivated by O2.
2PHA	;	1.9	;	Crystal structure of native, unliganded human arginase at 1.90 resolution
2Z46	;	2.97	;	Crystal Structure of Native-ORF134
2OSH	;	2.2	;	crystal structure of Natratoxin, a snake sPLA2 that blocks A-type K+ channel
1XX5	;	2.4	;	Crystal Structure of Natrin from Naja atra snake venom
1XTA	;	1.58	;	Crystal Structure of Natrin, a snake venom CRISP from Taiwan cobra (Naja atra)
3QDC	;	2.5	;	Crystal structure of Natronomonas pharaonis sensory rhodopsin II in the active state
3QAP	;	1.9	;	Crystal structure of Natronomonas pharaonis sensory rhodopsin II in the ground state
7VYU	;	1.8	;	Crystal structure of NatS
4DWW	;	1.74	;	Crystal Structure of Nattokinase from Bacillus subtilis natto
2VLC	;	2.95	;	Crystal structure of Natural Cinnamomin (Isoform III)
3NOI	;	1.842	;	Crystal Structure of Natural Killer Cell Cytotoxicity Receptor NKp30 (NCR3)
3CAD	;	2.6	;	Crystal structure of Natural Killer Cell Receptor, Ly49G
4QFQ	;	2.035	;	Crystal structure of natvie Npu DnaE split intein
3WFN	;	1.95	;	Crystal Structure of Nav1.6 IQ motif in complex with apo-CaM
8DIW	;	3.11	;	Crystal structure of NavAb E96P as a basis for the human Nav1.7 Inherited Erythromelalgia S211P mutation
8DIZ	;	2.75	;	Crystal structure of NavAb I119T as a basis for the human Nav1.7 Inherited Erythromelalgia I234T mutation
8DIV	;	2.54	;	Crystal structure of NavAb I22V as a basis for the human Nav1.7 Inherited Erythromelalgia I136V mutation
8DIY	;	2.85	;	Crystal structure of NavAb L101S as a basis for the human Nav1.7 Inherited Erythromelalgia F216S mutation
8DJ0	;	2.7	;	Crystal structure of NavAb L123T as a basis for the human Nav1.7 Inherited Erythromelalgia I848T mutation
8DJ1	;	3.1	;	Crystal structure of NavAb V126T as a basis for the human Nav1.7 Inherited Erythromelalgia S241T mutation
4DXW	;	3.052	;	Crystal structure of NavRh, a voltage-gated sodium channel
5VNV	;	1.4	;	Crystal structure of Nb.b201
5VNW	;	2.6	;	Crystal structure of Nb.b201 bound to human serum albumin
8F8V	;	1.81	;	Crystal structure of Nb.X0
8F8W	;	2.71	;	Crystal structure of Nb.X0 bound to the afucosylated human IgG1 fragment crystal form I
8F8X	;	2.6	;	Crystal structure of Nb.X0 bound to the afucosylated human IgG1 fragment crystal form II
6XXP	;	1.5	;	Crystal structure of NB37, a nanobody targeting prostate specific membrane antigen
6XXN	;	2.65	;	Crystal structure of NB7, a nanobody targeting prostate specific membrane antigen
6XXO	;	1.5	;	Crystal structure of NB8, a nanobody targeting prostate specific membrane antigen
1OJH	;	1.8	;	Crystal structure of NblA from PCC 7120
7R9D	;	1.83	;	Crystal structure of Nb_0 in complex with Fab_8D3
2VAJ	;	2.701	;	Crystal structure of NCAM2 Ig1 (I4122 cell unit)
2XY2	;	1.82	;	CRYSTAL STRUCTURE OF NCAM2 IG1-2
2WIM	;	3.0	;	Crystal structure of NCAM2 IG1-3
2V5T	;	2.0	;	Crystal structure of NCAM2 Ig2-3
2XY1	;	1.979	;	CRYSTAL STRUCTURE OF NCAM2 IG3-4
2XYC	;	2.51	;	CRYSTAL STRUCTURE OF NCAM2 IGIV-FN3I
2JLL	;	2.3	;	Crystal structure of NCAM2 IgIV-FN3II
4G6H	;	2.262	;	Crystal structure of NDH with NADH
4G73	;	2.522	;	Crystal structure of NDH with NADH and Quinone
4G74	;	2.48	;	Crystal structure of NDH with Quinone
4G6G	;	2.39	;	Crystal structure of NDH with TRT
5ZGE	;	1.0	;	Crystal structure of NDM-1 at pH5.5 (Bis-Tris) in complex with hydrolyzed ampicillin
8GPC	;	1.4	;	Crystal structure of NDM-1 at pH5.5 (Succinate) in complex with hydrolyzed ampicillin
8I8F	;	1.89	;	Crystal structure of NDM-1 at pH5.5 (Succinate) in complex with hydrolyzed compound 1
8GPE	;	1.4	;	Crystal structure of NDM-1 at pH5.5 (Succinate) in complex with hydrolyzed penicillin G
8GPD	;	1.4	;	Crystal structure of NDM-1 at pH5.5 (Succinate) in complex with hydrolyzed penicillin V
5ZGP	;	1.15	;	Crystal structure of NDM-1 at pH6.2 (Bis-Tris) in complex with hydrolyzed ampicillin
5ZGI	;	0.98	;	Crystal structure of NDM-1 at pH6.5 (Succinate) with 1 molecule per asymmetric unit
5ZGU	;	1.55	;	Crystal structure of NDM-1 at pH7.0 (HEPES) with 2 molecules per asymmetric unit
5ZGR	;	1.15	;	Crystal structure of NDM-1 at pH7.3 (HEPES) in complex with hydrolyzed ampicillin
5ZGY	;	0.95	;	Crystal structure of NDM-1 at pH7.5 (Bis-Tris) with 1 molecule per asymmetric unit
5ZGT	;	1.2	;	Crystal structure of NDM-1 at pH7.5 (HEPES) with 2 molecules per asymmetric unit
5ZGZ	;	0.95	;	Crystal structure of NDM-1 at pH7.5 (Imidazole) with 1 molecule per asymmetric unit
5ZH1	;	1.05	;	Crystal structure of NDM-1 at pH7.5 (Imidazole) with 2 molecules per asymmetric unit
5ZGX	;	0.95	;	Crystal structure of NDM-1 at pH7.5 (Succinate) with 1 molecule per asymmetric unit
5ZGQ	;	1.5	;	Crystal structure of NDM-1 at pH7.5 (Tris-HCl, (NH4)2SO4) in complex with hydrolyzed ampicillin
5ZGW	;	0.95	;	Crystal structure of NDM-1 at pH7.5 with 1 molecule per asymmetric unit (crystallized at succinate pH5.5 and soaked at succinate pH7.5)
5ZGV	;	1.15	;	Crystal structure of NDM-1 at pH8.0 (Tris) with 2 molecules per asymmetric unit
6Q30	;	1.5	;	Crystal structure of NDM-1 beta-lactamase in complex with boronic inhibitor cpd 5
6IBS	;	1.37	;	Crystal structure of NDM-1 beta-lactamase in complex with boronic inhibitor cpd 6
6IBV	;	1.4	;	Crystal structure of NDM-1 beta-lactamase in complex with broad spectrum boronic inhibitor cpd 1
6Q2Y	;	1.0	;	Crystal structure of NDM-1 beta-lactamase in complex with broad spectrum boronic inhibitor cpd3
4EXY	;	1.47	;	Crystal structure of NDM-1 bound to ethylene glycol
4EYF	;	1.8	;	Crystal structure of NDM-1 bound to hydrolyzed benzylpenicillin
5YPI	;	2.3	;	Crystal structure of NDM-1 bound to hydrolyzed imipenem representing an EI1 complex
5YPK	;	2.0	;	Crystal structure of NDM-1 bound to hydrolyzed imipenem representing an EI2 complex
5YPL	;	1.8	;	Crystal structure of NDM-1 bound to hydrolyzed imipenem representing an EP complex
4EYL	;	1.9	;	Crystal structure of NDM-1 bound to hydrolyzed meropenem
5YPM	;	2.15	;	Crystal structure of NDM-1 bound to hydrolyzed meropenem representing an EI1 complex
5YPN	;	2.12	;	Crystal structure of NDM-1 bound to hydrolyzed meropenem representing an EI2 complex
4EY2	;	1.17	;	Crystal structure of NDM-1 bound to hydrolyzed methicillin
4EYB	;	1.16	;	Crystal structure of NDM-1 bound to hydrolyzed oxacillin
4EXS	;	2.4	;	Crystal structure of NDM-1 bound to L-captopril
6D1A	;	1.25	;	Crystal structure of NDM-1 complexed with compound 1
6D1H	;	1.25	;	Crystal structure of NDM-1 complexed with compound 11
6D1I	;	1.1	;	Crystal structure of NDM-1 complexed with compound 12
6D1J	;	1.15	;	Crystal structure of NDM-1 complexed with compound 13
6D1K	;	1.2	;	Crystal structure of NDM-1 complexed with compound 14
6D1B	;	1.25	;	Crystal structure of NDM-1 complexed with compound 2
6D1C	;	1.25	;	Crystal structure of NDM-1 complexed with compound 3
6D1D	;	1.4	;	Crystal structure of NDM-1 complexed with compound 6
6D1E	;	1.15	;	Crystal structure of NDM-1 complexed with compound 7
6D1F	;	1.15	;	Crystal structure of NDM-1 complexed with compound 8
6D1G	;	1.15	;	Crystal structure of NDM-1 complexed with compound 9
6NY7	;	1.4	;	Crystal Structure of NDM-1 D199N with Compound 16
6O3R	;	1.3	;	Crystal Structure of NDM-1 D199N with Compound 7
8R5T	;	1.58	;	Crystal structure of NDM-1 in complex with benzobisheterocycle compound 14.
5N0I	;	1.47	;	Crystal structure of NDM-1 in complex with beta-mercaptoethanol - new refinement
5ZJ2	;	1.1	;	Crystal structure of NDM-1 in complex with D-captopril
5ZJ7	;	0.96	;	Crystal structure of NDM-1 in complex with D-captopril derivative CY22
5ZJ8	;	0.96	;	Crystal structure of NDM-1 in complex with D-captopril derivative CY32
5ZJC	;	0.96	;	Crystal structure of NDM-1 in complex with D-captopril derivative CY41
5ZJ1	;	0.96	;	Crystal structure of NDM-1 in complex with D-captopril derivative CYT-14
6LIZ	;	1.05	;	Crystal structure of NDM-1 in complex with D-captopril derivative wss02120
6LJ0	;	1.2	;	Crystal structure of NDM-1 in complex with D-captopril derivative wss02122
6LJ1	;	1.151	;	Crystal structure of NDM-1 in complex with D-captopril derivative wss02127 monomer
6LIP	;	0.98	;	Crystal structure of NDM-1 in complex with D-captopril derivative wss0218
6LJ8	;	1.4	;	Crystal structure of NDM-1 in complex with D-captopril derivative wss04134
6LJ5	;	1.26	;	Crystal structure of NDM-1 in complex with D-captopril derivative wss04145
6LJ4	;	1.15	;	Crystal structure of NDM-1 in complex with D-captopril derivative wss04146
6LJ6	;	1.27	;	Crystal structure of NDM-1 in complex with D-captopril derivative wss05008
6LJ7	;	1.16	;	Crystal structure of NDM-1 in complex with D-captopril derivative wss05010
6LJ2	;	1.35	;	Crystal structure of NDM-1 in complex with heterodimer of D-captopril derivative wss02127 stereoisomer
7VQJ	;	2.45	;	Crystal structure of NDM-1 in complex with hydrolyzed 1u.
5O2F	;	2.01	;	Crystal structure of NDM-1 in complex with hydrolyzed ampicillin - new refinement
5O2E	;	1.3	;	Crystal structure of NDM-1 in complex with hydrolyzed cefuroxime - new refinement
5N0H	;	1.9	;	Crystal structure of NDM-1 in complex with hydrolyzed meropenem - new refinement
5ZIO	;	0.98	;	Crystal structure of NDM-1 in complex with L-captopril
6TGD	;	1.33	;	Crystal structure of NDM-1 in complex with triazole-based inhibitor OP31
5ZR8	;	1.5	;	Crystal Structure Of NDM-1 Metallo-beta-lactamase
6CAC	;	1.79	;	Crystal structure of NDM-1 metallo-beta-lactamase harboring an insertion of a Pro residue in L3 loop
6EX7	;	1.95	;	Crystal structure of NDM-1 metallo-beta-lactamase in complex with Cd ions and a hydrolyzed beta-lactam ligand - new refinement
6KXI	;	1.38	;	Crystal Structure Of NDM-1 Metallo-beta-lactamase In Complex With Inhibitor NO9
6KZL	;	1.763	;	Crystal Structure Of NDM-1 Metallo-beta-lactamase In Complex With Inhibitor X2
5ZGF	;	1.2	;	Crystal structure of NDM-1 Q123G mutant
6MDU	;	1.15	;	Crystal structure of NDM-1 with compound 7
6EFJ	;	1.65	;	Crystal structure of NDM-1 with compound 9
6RMF	;	1.51	;	Crystal structure of NDM-1 with VNRX-5133
6OL8	;	2.1	;	Crystal structure of NDM-12 metallo-beta-lactamase in complex with hydrolyzed ampicillin
6OGO	;	1.43	;	Crystal structure of NDM-9 metallo-beta-lactamase
4H2D	;	1.8	;	Crystal structure of NDOR1
2BEF	;	2.3	;	CRYSTAL STRUCTURE OF NDP KINASE COMPLEXED WITH MG, ADP, AND BEF3
3G79	;	2.4	;	Crystal structure of NDP-N-acetyl-D-galactosaminuronic acid dehydrogenase from Methanosarcina mazei Go1
7EAA	;	2.6	;	crystal structure of NDP52 SKICH domain in complex with RB1CC1 coiled-coil domain
5Z7A	;	2.38	;	Crystal structure of NDP52 SKICH region
5Z7L	;	2.02	;	Crystal structure of NDP52 SKICH region in complex with NAP1
4XKL	;	2.1	;	Crystal structure of NDP52 ZF2 in complex with mono-ubiquitin
2YVN	;	1.84	;	Crystal structure of NDX2 from thermus thermophilus HB8
2YVO	;	1.67	;	Crystal structure of NDX2 in complex with MG2+ and AMP from thermus thermophilus HB8
2YVP	;	1.66	;	Crystal structure of NDX2 in complex with MG2+ and ampcpr from thermus thermophilus HB8
2YVM	;	1.7	;	Crystal structure of NDX2 in complex with MG2+ from thermus thermophilus HB8
7C3S	;	1.66	;	Crystal structure of NE0047 (E143D) mutant in complex with 8-azaguanine
7C3U	;	1.86	;	Crystal structure of NE0047 (N66A) mutant in complex with 8-azaguanine
7C3T	;	2.07	;	Crystal structure of NE0047 (N66Q) mutant in complex with 8-azaguanine
4LD2	;	1.55	;	Crystal structure of NE0047 in complex with cytidine
4LD4	;	3.0	;	Crystal structure of NE0047 in complex with cytosine
4LCO	;	2.7	;	Crystal structure of NE0047 with complex with substrate ammeline
2PD1	;	1.86	;	Crystal structure of NE2512 protein of unknown function from Nitrosomonas europaea
5NX8	;	1.7	;	Crystal structure of Neanderthal Adenylosuccinate Lyase (ADSL)
5NX9	;	2.3	;	Crystal structure of Neanderthal Adenylosuccinate Lyase (ADSL) in complex with its products AMP and fumarate
5NXA	;	2.4	;	Crystal structure of Neanderthal Adenylosuccinate Lyase (ADSL)in complex with its products AICAR and fumarate
6I34	;	2.1	;	Crystal structure of Neanderthal glycine decarboxylase (P-protein)
5KZF	;	3.49	;	Crystal structure of near full-length hexameric Mycobacterium tuberculosis proteasomal ATPase Mpa in apo form
7LSC	;	1.8	;	Crystal structure of near-infrared fluorescent protein miRFP670nano3
7LSD	;	1.7	;	Crystal structure of near-infrared fluorescent protein miRFP718nano
4KGE	;	2.3	;	Crystal structure of near-infrared fluorescent protein with an extended stokes shift, pH 4.5
4KGF	;	2.3	;	Crystal structure of near-infrared fluorescent protein with an extended stokes shift, ph 8.0
2Z6F	;	1.9	;	Crystal structure of NEAT domain from Staphylococcus aureus in complex with heme
5JRE	;	2.1	;	Crystal structure of NeC3PO in complex with ssDNA.
5JRC	;	1.9	;	Crystal structure of NeC3PO in complex with ssRNA.
3ST1	;	1.8	;	Crystal structure of Necrosis and Ethylene inducing Protein 2 from the causal agent of cocoa's Witches Broom disease
3U83	;	2.499	;	Crystal structure of nectin-1
1Z9M	;	2.4	;	Crystal Structure of Nectin-like molecule-1 protein Domain 1
5V4K	;	2.099	;	Crystal structure of NEDD4 LIR-fused human LC3B_2-119
5C7J	;	3.0	;	CRYSTAL STRUCTURE OF NEDD4 WITH A UB VARIANT
5L3X	;	2.75	;	Crystal structure of negative elongation factor subcomplex NELF-AC
8B9N	;	2.0	;	Crystal structure of NEI domain of mouse NEIL3 trapped in covalent complex with ssDNA with abasic site
8DR2	;	2.81	;	Crystal structure of Neisseria gonorrhoeae carbonic anhydrase with 2-cyclohexyl-N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide
8DRB	;	2.59	;	Crystal structure of Neisseria gonorrhoeae carbonic anhydrase with 3-phenyl-N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)propanamide
8DPO	;	2.6	;	Crystal structure of Neisseria gonorrhoeae carbonic anhydrase with Acetazolamide
8DYQ	;	2.15	;	Crystal structure of Neisseria gonorrhoeae carbonic anhydrase with Acetazolamide
8DQF	;	2.8	;	Crystal structure of Neisseria gonorrhoeae carbonic anhydrase with N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)cyclohexanecarboxamide
7NU4	;	2.18	;	Crystal Structure of Neisseria gonorrhoeae LeuRS
7NU1	;	2.51	;	Crystal Structure of Neisseria gonorrhoeae LeuRS E169G mutant
7NU3	;	2.27	;	Crystal Structure of Neisseria gonorrhoeae LeuRS E169G mutant in Complex with ATP and L-leucinol
7NU2	;	2.1	;	Crystal Structure of Neisseria gonorrhoeae LeuRS E169G mutant in Complex with the Reaction Intermediate Leu-AMP
7NU9	;	2.17	;	Crystal Structure of Neisseria gonorrhoeae LeuRS in Complex with ATP and L-leucinol
7NU6	;	2.2	;	Crystal Structure of Neisseria gonorrhoeae LeuRS in Complex with ATP in Conformation 1
7NU7	;	2.31	;	Crystal Structure of Neisseria gonorrhoeae LeuRS in Complex with ATP in Conformation 2
7NU5	;	2.58	;	Crystal Structure of Neisseria gonorrhoeae LeuRS in Complex with L-leucine
7NU8	;	2.11	;	Crystal Structure of Neisseria gonorrhoeae LeuRS in Complex with the Reaction Intermediate Leu-AMP
7NTY	;	2.39	;	Crystal Structure of Neisseria gonorrhoeae LeuRS L550A mutant
7NU0	;	1.89	;	Crystal Structure of Neisseria gonorrhoeae LeuRS L550A mutant in Complex with ATP and L-leucinol
7NTZ	;	2.1	;	Crystal Structure of Neisseria gonorrhoeae LeuRS L550A mutant in Complex with the Reaction Intermediate Leu-AMP
7NUA	;	3.09	;	Crystal Structure of Neisseria gonorrhoeae LeuRS L550G mutant
7NUC	;	2.77	;	Crystal Structure of Neisseria gonorrhoeae LeuRS L550G mutant in Complex with ATP and L-leucinol
7NUB	;	3.02	;	Crystal Structure of Neisseria gonorrhoeae LeuRS L550G mutant in Complex with the Reaction Intermediate Leu-AMP
6WYE	;	2.01	;	Crystal structure of Neisseria gonorrhoeae serine acetyltransferase (CysE)
7RA4	;	2.8	;	Crystal structure of Neisseria gonorrhoeae serine acetyltransferase (CysE) in complex with serine
6NAW	;	2.399	;	Crystal structure of Neisseria meningitidis ClpP E58A activated mutant
6W9T	;	1.64	;	Crystal structure of Neisseria meningitidis ClpP protease complex with small molecule activator ACP1-06
6NAY	;	2.199	;	Crystal structure of Neisseria meningitidis ClpP protease E31A+E58A activated double mutant
6NAQ	;	2.022	;	Crystal structure of Neisseria meningitidis ClpP protease in Apo form
6NAH	;	2.7	;	Crystal structure of Neisseria meningitidis ClpP protease in complex with Acyldepsipeptide-14 (ADEP-14)
6DNU	;	2.283	;	Crystal Structure of Neisseria meningitidis DsbD c-terminal domain in the oxidised form
6DNL	;	1.7	;	Crystal Structure of Neisseria meningitidis DsbD c-terminal domain in the reduced form
6DPS	;	2.556	;	Crystal Structure of Neisseria meningitidis DsbD n-terminal domain in the oxidised form
6DNV	;	1.603	;	Crystal Structure of Neisseria meningitidis DsbD n-terminal domain in the reduced form
7F2A	;	2.58	;	Crystal structure of Neisseria meningitidis EarP bound TDP
7VCH	;	2.85	;	Crystal structure of Neisseria meningitidis EarP bound TDP-L-Rhamnose
7COX	;	3.0	;	Crystal structure of Neisseria meningitidis EarP R268A mutant
6EUP	;	2.65	;	Crystal structure of Neisseria meningitidis NadA variant 3 double mutant A33I-I38L
1RV9	;	1.53	;	Crystal Structure of Neisseria meningitidis protein NMB0706, Pfam DUF152
4CJD	;	2.056	;	Crystal structure of Neisseria meningitidis trimeric autotransporter and vaccine antigen NadA
6EUN	;	2.45	;	Crystal structure of Neisseria meningitidis vaccine antigen NadA variant 3
5N6V	;	1.6	;	Crystal structure of Neisseria polysaccharea amylosucrase mutant derived from Neutral genetic Drift-based engineering
5N7J	;	2.001	;	Crystal structure of Neisseria polysaccharea amylosucrase mutant efficient for the synthesis of controlled size maltooligosaccharides
3AY2	;	1.9	;	Crystal structure of Neisserial azurin
1P4T	;	2.55	;	Crystal structure of Neisserial surface protein A (NspA)
6S75	;	3.3	;	Crystal structure of Nek7 bound to compound 51
6S73	;	3.5	;	Crystal structure of Nek7 SRS mutant bound to compound 51
3EL5	;	1.6	;	Crystal structure of nelfinavir (NFV) complexed with a multidrug variant (ACT) (V82T/I84V) of HIV-1 protease
4OBD	;	1.9	;	Crystal Structure of Nelfinavir-Resistant, Inactive HIV-1 Protease (D30N/N88D) in Complex with the p1-p6 substrate variant (L449F/S451N)
4OBG	;	1.78	;	Crystal Structure of Nelfinavir-Resistant, Inactive HIV-1 Protease (D30N/N88D) in Complex with the p1-p6 substrate.
4OBF	;	1.68	;	Crystal Structure of Nelfinavir-Resistant, Inactive HIV-1 Protease Variant (D30N/N88D) in Complex with the p1-p6 substrate variant (S451N)
7BII	;	3.037	;	Crystal structure of Nematocida HUWE1
6LE8	;	1.39909	;	Crystal structure of nematode family I chitinase,CeCht1, in complex with dihydropyrrolopyrazol-6-one derivate 1
6LE7	;	1.85753	;	Crystal structure of nematode family I chitinase,CeCht1, in complex with dihydropyrrolopyrazol-6-one derivate 2
7TV4	;	4.2	;	Crystal structure of NEMO CoZi in complex with HOIP NZF1 and linear diubiquitin
6XX0	;	2.6	;	Crystal structure of NEMO in complex with Ubv-LIN
6XDH	;	2.35	;	Crystal Structure of NendoU (Uridylate-specific endoribonuclease, nsp15) from Betacoronavirus SARS-CoV-2
8U2X	;	2.25	;	Crystal Structure of NendoU (Uridylate-specific endoribonuclease, nsp15) from Betacoronavirus SARS-CoV-2 (H235A mutant)
2D04	;	2.76	;	Crystal structure of neoculin, a sweet protein with taste-modifying activity.
1J0I	;	2.4	;	Crystal structure of neopullulanase complex with panose
1J0K	;	3.2	;	Crystal structure of neopullulanase E357Q complex with isopanose
1J0J	;	2.8	;	Crystal structure of neopullulanase E357Q complex with maltotetraose
6SUK	;	1.75	;	Crystal structure of Neprilysin in complex with Omapatrilat.
6SVY	;	2.6	;	Crystal structure of Neprilysin in complex with Sampatrilat-ASP.
6XVP	;	2.65	;	Crystal structure of Neprilysin in complex with Sampatrilat.
5OXZ	;	1.2	;	Crystal Structure of NeqN/NeqC complex from Nanoarcheaum equitans at 1.2A
5OXX	;	1.74	;	Crystal structure of NeqN/NeqC complex from Nanoarcheaum equitans at 1.7A
4XPJ	;	2.605	;	Crystal structure of Nerve growth factor in complex with lysophosphatidylinositol
7EE4	;	1.4	;	Crystal structure of Neu5Ac bound PltC
7EE5	;	1.24	;	Crystal structure of Neu5Gc bound PltC
6PPW	;	1.85	;	Crystal structure of NeuB, an N-acetylneuraminate synthase from Neisseria meningitidis, in complex with magnesium and malate
6PPZ	;	2.4	;	Crystal structure of NeuB, an N-acetylneuraminate synthase from Neisseria meningitidis, in complex with manganese, inorganic phosphate, and N-acetylmannosamine (NeuB.Mn2+.Pi.ManNAc)
6PPY	;	2.0	;	Crystal structure of NeuNAc oxime complexed with NeuB, an N-acetylneuraminate synthase from Neisseria meningitidis
4CBP	;	1.6	;	Crystal structure of neural ectodermal development factor IMP-L2.
4QN4	;	1.8	;	Crystal structure of Neuraminidase N6
4QN6	;	1.945	;	Crystal structure of Neuraminidase N6 complexed with Laninamivir
4QN3	;	2.092	;	Crystal structure of Neuraminidase N7
4QN7	;	2.302	;	Crystal structure of neuramnidase N7 complexed with Oseltamivir
3VKF	;	3.3	;	Crystal Structure of Neurexin 1beta/Neuroligin 1 complex
6CW1	;	2.84	;	Crystal structure of Neurexin-1 alpha ectodomain fragment, L2-L3
4YU8	;	1.8	;	Crystal structure of Neuroblastoma suppressor of tumorigenicity 1
3P40	;	3.2	;	Crystal structure of neurofascin adhesion complex in space group p3221
3P3Y	;	2.6	;	Crystal structure of neurofascin homophilic adhesion complex in space group p6522
3PEG	;	2.524	;	Crystal structure of Neurofibromins Sec14-PH module containing a patient derived duplication (TD)
8UFN	;	2.73	;	Crystal Structure of neuronal HAstV VA1 capsid spike domain at 2.73 A resolution
2XOT	;	2.0	;	Crystal structure of neuronal leucine rich repeat protein AMIGO-1
1URQ	;	2.0	;	Crystal structure of neuronal Q-SNAREs in complex with R-SNARE motif of Tomosyn
7JJC	;	2.36	;	Crystal structure of neuropilin-1 b1 domain in complex with SARS-CoV-2 S1 C-end rule (CendR) peptide
1XTG	;	2.1	;	Crystal structure of NEUROTOXIN BONT/A complexed with Synaptosomal-associated protein 25
6U7N	;	3.321	;	Crystal structure of neurotrimin (NTM)
7SI2	;	3.2	;	Crystal structure of neutralizing antibody 10-28 in complex with SARS-CoV-2 spike receptor binding domain (RBD)
8DNN	;	3.12	;	Crystal structure of neutralizing antibody 80 in complex with SARS-CoV-2 receptor binding domain
8DW9	;	4.0	;	Crystal structure of neutralizing antibody D29 Fab in complex with SARS-CoV-2 spike receptor binding domain (RBD)
4YE4	;	2.72	;	Crystal Structure of Neutralizing Antibody HJ16 in Complex with HIV-1 gp120
8DWA	;	3.2	;	Crystal structure of neutralizing antibody P1D9 Fab in complex with SARS-CoV-2 spike receptor binding domain (RBD)
8GZ5	;	1.7	;	Crystal structure of neutralizing VHH P17 in complex with SARS-CoV-2 Alpha variant spike receptor-binding domain
8GZ6	;	1.35	;	Crystal structure of neutralizing VHH P17 in complex with SARS-CoV-2 Alpha variant spike receptor-binding domain
8D4Q	;	2.2	;	Crystal Structure of Neutrophil Elastase Inhibited by Eap1 from S. aureus
8D4U	;	1.9	;	Crystal Structure of Neutrophil Elastase Inhibited by Eap2 from S. aureus
3TF6	;	2.35	;	Crystal structure of Neutrophil gelatinase-associated lipocalin (C87S mutant) in complex with Europium and the siderophore analog tren(cam)(1,2-hopo)2
3TZS	;	2.45	;	Crystal structure of Neutrophil gelatinase-associated lipocalin NGAL (C87S mutant) in complex with fragment 1026, phenylurea
3SBL	;	2.31	;	Crystal Structure of New Delhi Metal-beta-lactamase-1 from Klebsiella pneumoniae
3S0Z	;	2.5	;	Crystal structure of New Delhi Metallo-beta-lactamase (NDM-1)
4GYU	;	1.803	;	Crystal Structure of New Delhi Metallo-beta-Lactamase-1 A121F mutant from Klebsiella pneumoniae
4GYQ	;	1.351	;	Crystal Structure of New Delhi Metallo-beta-Lactamase-1 D223A mutant from Klebsiella pneumoniae
3RKK	;	2.35	;	Crystal Structure of New Delhi Metallo-Beta-Lactamase-1 from Klebsiella pneumoniae
3RKJ	;	2.0	;	Crystal Structure of New Delhi Metallo-Beta-Lactamase-1 from Klebsiella pnueumoniae
4RBS	;	2.405	;	Crystal Structure of New Delhi Metallo-beta-Lactamase-1 in the Complex with Hydrolyzed Meropenem
4RAW	;	1.302	;	Crystal Structure of New Delhi Metallo-beta-Lactamase-1 Mutant M67V Complexed with Hydrolyzed Ampicillin
4RAM	;	1.495	;	Crystal Structure of New Delhi Metallo-beta-Lactamase-1 Mutant M67V Complexed with Hydrolyzed Penicillin G
4HL1	;	1.5	;	Crystal Structure of New Delhi Metallo-beta-Lactamase-1, Complexed with Cd and Ampicillin
3D38	;	3.21	;	Crystal structure of new trigonal form of photosynthetic reaction center from Blastochloris viridis. Crystals grown in microfluidics by detergent capture.
4G1G	;	2.2	;	Crystal structure of Newcastle disease virus matrix protein
4G1L	;	2.207	;	Crystal structure of Newcastle disease virus matrix protein
4G1O	;	2.2	;	Crystal structure of Newcastle disease virus matrix protein
1OOA	;	2.45	;	CRYSTAL STRUCTURE OF NF-kB(p50)2 COMPLEXED TO A HIGH-AFFINITY RNA APTAMER
4DN5	;	2.5	;	Crystal Structure of NF-kB-inducing Kinase (NIK)
5DV7	;	3.5	;	Crystal Structure of NF90 tandem dsRBDs with dsRNA
2O93	;	3.05	;	Crystal structure of NFAT bound to the HIV-1 LTR tandem kappaB enhancer element
5FH9	;	3.159	;	Crystal structure of NFeoB from Escherichia coli BL21 in the apo state.
3W5I	;	2.15	;	Crystal structure of NfeoB from Gallionella capsiferriformans
3K53	;	2.7	;	Crystal Structure of NFeoB from P. furiosus
3SS8	;	2.51	;	Crystal structure of NFeoB from S. thermophilus bound to GDP.AlF4- and K+
8K89	;	2.1	;	Crystal structure of NFIL3
8K8A	;	2.07	;	Crystal structure of NFIL3 in complex with TTACGTAA DNA
8K86	;	2.06	;	Crystal structure of NFIL3 in complex with TTATGTAA DNA
2O61	;	2.8	;	Crystal Structure of NFkB, IRF7, IRF3 bound to the interferon-b enhancer
4Q3J	;	1.862	;	Crystal structure of NFkB-p65-degrading zinc protease family protein
4Q76	;	1.9	;	Crystal structure of Nfs2 C384S mutant, the plastidial cysteine desulfurase from Arabidopsis thaliana
4Q75	;	1.709	;	Crystal structure of Nfs2, the plastidial cysteine desulfurase from Arabidopsis thaliana
3KXA	;	2.8	;	Crystal Structure of NGO0477 from Neisseria gonorrhoeae
2QHB	;	2.4	;	Crystal structure of NgTRF complexed with telomeric DNA
2CKX	;	1.9	;	Crystal structure of NgTRF1, double-stranded telomeric repeat binding factor from Nicotiana tabacum.
5F23	;	1.5	;	Crystal structure of NH(3)-dependent NAD(+) synthetase Pseudomonas aeruginosa in complex with NAD
1NSY	;	2.0	;	CRYSTAL STRUCTURE OF NH3-DEPENDENT NAD+ SYNTHETASE FROM BACILLUS SUBTILIS
1FYD	;	2.25	;	CRYSTAL STRUCTURE OF NH3-DEPENDENT NAD+ SYNTHETASE FROM BACILLUS SUBTILIS COMPLEXED WITH ONE MOLECULE AMP, ONE PYROPHOSPHATE ION AND ONE MG2+ ION
1EE1	;	2.06	;	CRYSTAL STRUCTURE OF NH3-DEPENDENT NAD+ SYNTHETASE FROM BACILLUS SUBTILIS COMPLEXED WITH ONE MOLECULE ATP, TWO MOLECULES DEAMIDO-NAD+ AND ONE MG2+ ION
1IFX	;	2.25	;	CRYSTAL STRUCTURE OF NH3-DEPENDENT NAD+ SYNTHETASE FROM BACILLUS SUBTILIS COMPLEXED WITH TWO MOLECULES DEAMIDO-NAD
2NSY	;	2.0	;	CRYSTAL STRUCTURE OF NH3-DEPENDENT NAD+ SYNTHETASE FROM BACILLUS SUBTILIS IN COMPLEX WITH NAD-ADENYLATE
1XNG	;	1.7	;	Crystal Structure of NH3-dependent NAD+ synthetase from Helicobacter pylori
1XNH	;	2.3	;	Crystal Structure of NH3-dependent NAD+ synthetase from Helicobacter pylori
3N05	;	2.35	;	CRYSTAL STRUCTURE OF NH3-DEPENDENT NAD+ SYNTHETASE FROM STREPTOMYCES AVERMITILIS
4LMM	;	1.1	;	Crystal structure of NHERF1 PDZ1 domain complexed with the CXCR2 C-terminal tail in P21 space group
4MPA	;	1.097	;	Crystal structure of NHERF1-CXCR2 signaling complex in P21 space group
4P0C	;	1.339	;	Crystal Structure of NHERF2 PDZ1 Domain in Complex with LPA2
7B2R	;	1.6	;	Crystal structure of NHL domain of TRIM2
7QRV	;	1.45	;	Crystal structure of NHL domain of TRIM2 (full C-terminal)
7QRW	;	1.7	;	Crystal structure of NHL domain of TRIM3
7QRX	;	2.2	;	Crystal structure of NHL domain of TRIM71
6G7W	;	1.746	;	Crystal structure of NHL repeat containing domain of human NHLRC2
6WIT	;	2.79	;	Crystal structure of NHP D15.SD7 Fab in complex with 16055 V1V2 1FD6 scaffold
6XSN	;	2.87	;	Crystal structure of NHP VD20.5A4 Fab in complex with 16055 V1V2 1FD6 scaffold
2R36	;	2.0	;	Crystal structure of ni human ARG-insulin
5W1F	;	2.6	;	Crystal structure of Ni(II)- and Ca(II)-bound human calprotectin
6DS2	;	2.1	;	Crystal structure of Ni(II)-bound human calprotectin
7RWU	;	1.8	;	Crystal structure of Ni-bound RIDC1 variant in the presence of reductant
1Q0D	;	2.2	;	Crystal structure of Ni-containing superoxide dismutase with Ni-ligation corresponding to the oxidized state
1Q0G	;	1.6	;	Crystal structure of Ni-containing superoxide dismutase with Ni-ligation corresponding to the state after full x-ray-induced reduction
1Q0M	;	1.68	;	Crystal structure of Ni-containing superoxide dismutase with Ni-ligation corresponding to the state after full x-ray-induced reduction
1Q0F	;	2.2	;	Crystal structure of Ni-containing superoxide dismutase with Ni-ligation corresponding to the state after partial x-ray-induced reduction
1Q0K	;	2.1	;	Crystal structure of Ni-containing superoxide dismutase with Ni-ligation corresponding to the thiosulfate-reduced state
4GSM	;	1.7	;	Crystal Structure of Ni2+2-Human Arginase I
6P2L	;	1.08	;	Crystal structure of Niastella koreensis GH74 (NkGH74) enzyme
3T66	;	2.8	;	Crystal structure of Nickel ABC transporter from Bacillus halodurans
1FN3	;	2.48	;	CRYSTAL STRUCTURE OF NICKEL RECONSTITUTED HEMOGLOBIN-A CASE FOR PERMANENT, T-STATE HEMOGLOBIN
1P25	;	2.9	;	Crystal structure of nickel(II)-d(GGCGCC)2
1ZIU	;	2.0	;	Crystal Structure of nickel-bound engineered Maltose Binding Protein
4NUK	;	2.4	;	Crystal structure of nickel-bound Na-ASP-2
1G3V	;	3.1	;	CRYSTAL STRUCTURE OF NICKEL-D[CGTGTACACG]2
1IQY	;	1.8	;	CRYSTAL STRUCTURE OF NICKEL-SUBSTITUTED AMINE OXIDASE FROM ARTHROBACTER GLOBIFORMIS
1IOO	;	1.55	;	CRYSTAL STRUCTURE OF NICOTIANA ALATA GEMETOPHYTIC SELF-INCOMPATIBILITY ASSOCIATED SF11-RNASE
2XR7	;	3.1	;	Crystal Structure of Nicotiana tabacum malonyltransferase (NtMat1) complexed with malonyl-coa
5ZN8	;	2.0	;	Crystal structure of nicotinamidase PncA from Bacillus subtilis
6A8L	;	2.0	;	Crystal structure of nicotinamidase/ pyrazinamidase PncA from Bacillus subtilis
5KIT	;	1.6	;	Crystal Structure of Nicotinamide Phosphoribosyltransferase (Nampt) in Complex with Inhibitors 37
3HRD	;	2.2	;	Crystal structure of nicotinate dehydrogenase
1D0S	;	1.9	;	CRYSTAL STRUCTURE OF NICOTINATE MONONUCLEOTIDE : 5,6-DIMETHYLBENZIMIDAZOLE PHOSPHORIBOSYLTRANSFERASE (COBT) FROM SALMONELLA TYPHIMURIUM COMPLEXED WITH 5, 6-DIMETHYLBENZIMIDAZOLE
2QTM	;	2.4	;	Crystal Structure of Nicotinate Mononucleotide Adenylyltransferase
2QTN	;	2.4	;	Crystal Structure of Nicotinate Mononucleotide Adenylyltransferase
2QTR	;	1.7	;	Crystal Structure of Nicotinate Mononucleotide Adenylyltransferase
4RPI	;	2.417	;	Crystal Structure of Nicotinate Mononucleotide Adenylyltransferase from Mycobacterium tuberculosis
6B5F	;	1.95	;	Crystal structure of nicotinate mononucleotide-5,6-dimethylbenzimidazole phosphoribosyltransferase CobT from Yersinia enterocolitica
1D0V	;	1.9	;	CRYSTAL STRUCTURE OF NICOTINATE MONONUCLEOTIDE:5,6-DIMETHYLBENZIMIDAZOLE PHOSPHORIBOSYLTRANSFERASE (COBT) FROM SALMONELLA TYPHIMURIUM COMPLEXED WITH ITS REACTION PRODUCTS DETERMINED TO 1.9 A RESOLUTION
4HL7	;	1.8	;	Crystal structure of nicotinate phosphoribosyltransferase (target NYSGR-026035) from Vibrio cholerae
2IM5	;	2.2	;	Crystal structure of Nicotinate phosphoribosyltransferase from Porphyromonas Gingivalis
3GNN	;	2.25	;	Crystal structure of nicotinate-nucleotide pyrophosphorylase from Burkholderi pseudomallei
3L0G	;	2.05	;	Crystal structure of Nicotinate-nucleotide pyrophosphorylase from Ehrlichia chaffeensis at 2.05A resolution
2I14	;	2.9	;	Crystal structure of nicotinate-nucleotide pyrophosphorylase from Pyrococcus furiosus
5TTJ	;	2.2	;	Crystal Structure of Nicotine Oxidoreductase from Pseudomonas putida
3DV2	;	2.3	;	Crystal Structure of nicotinic acid mononucleotide adenylyltransferase from Bacillus anthracis
1YUL	;	2.0	;	Crystal Structure of Nicotinic Acid Mononucleotide Adenylyltransferase from Pseudomonas aeruginosa
1YUM	;	1.7	;	Crystal Structure of Nicotinic Acid Mononucleotide Adenylyltransferase from Pseudomonas aeruginosa
1YUN	;	2.0	;	Crystal Structure of Nicotinic Acid Mononucleotide Adenylyltransferase from Pseudomonas aeruginosa
2H29	;	2.0	;	Crystal structure of Nicotinic acid mononucleotide Adenylyltransferase from Staphylococcus aureus: product bound form 1
2H2A	;	2.1	;	Crystal structure of Nicotinic acid mononucleotide adenylyltransferase from Staphylococcus aureus: product bound form 2
6KH2	;	3.04	;	Crystal structure of Nicotinic acid mononucleotide adenylyltransferase mutant P22K/Y84V/Y118D/C132L/W176Y from Escherichia coli
6KG3	;	3.08	;	Crystal structure of Nicotinic acid mononucleotide adenylyltransferase mutant P22K/Y84V/Y118D/C132Q/W176F from Escherichia coli
1WX1	;	1.97	;	Crystal structure of nictinate-nucleotide-dimethylbenzimidazole phosphoribosyltransferase from Thermus thermophilus HB8
1NPE	;	2.3	;	Crystal structure of Nidogen/Laminin Complex
3RXY	;	2.0	;	Crystal structure of NIF3 superfamily protein from Sphaerobacter thermophilus
5M41	;	2.1	;	Crystal structure of nigritoxine
3U7W	;	2.6	;	Crystal structure of NIH45-46 Fab
5IGX	;	3.39	;	Crystal structure of NIH45-46 Fab germline precursor in complex with 426c.TM1deltaV1-3 gp120
4IDT	;	2.4	;	Crystal Structure of NIK with 11-bromo-5,6,7,8-tetrahydropyrimido[4',5':3,4]cyclohepta[1,2-b]indol-2-amine (T28)
4IDV	;	2.9	;	Crystal Structure of NIK with compound 4-{3-[2-amino-5-(2-methoxyethoxy)pyrimidin-4-yl]-1H-indol-5-yl}-2-methylbut-3-yn-2-ol (13V)
4OES	;	1.951	;	Crystal structure of NikA from Brucella suis in complex with Fe(III)-EDTA
4OER	;	1.85	;	Crystal structure of NikA from Brucella suis, unliganded form
4OFJ	;	1.7	;	Crystal structure of NikA from Staphylococcus aureus in complex with Ni(L-His)2
4XKP	;	1.9	;	Crystal structure of NikA from Staphylococcus aureus in complex with Ni(L-His)2 (co-crystallization with Ni(II) and BHI medium supernatant)
4XKQ	;	1.9	;	Crystal structure of NikA from Staphylococcus aureus in complex with Ni(L-His)2 (co-crystallization with Ni(II) and CD medium supernatant)
4XKN	;	1.85	;	Crystal structure of NikA from Staphylococcus aureus in complex with Ni(L-His)2 (co-crystallization with Ni(II) and L-Histidine)
4XKR	;	1.75	;	Crystal structure of NikA from Staphylococcus aureus in complex with Ni-(L-His)(2-methyl-thiazolidine dicarboxylate) (co-crystallization with Ni(II) and CDdeltaHis medium supernatant)
8SPM	;	2.15	;	Crystal structure of NikA in complex Ni-AMA
5ON4	;	2.3	;	Crystal structure of NikA in complex with Fe-L1 (N-(2-hydroxybenzyl)-N'-(2-thiomethylbenzyl)-N,N'-ethylenediamine diacetic acid)
5ON5	;	1.7	;	Crystal structure of NikA in complex with Fe-L2 (Fe-L2 (N-(2-hydroxy-3-methoxybenzyl)-N'-(2-thiomethylbenzyl)- N,N'-ethylenediamine diacetic acid) after dioxygen oxidation
5ON0	;	1.9	;	Crystal structure of NikA in complex with Fe-L2 (N-(2-hydroxy-3methoxybenzyl)-N-N'-ethylenediaminediacetic acid)
5ON1	;	1.7	;	Crystal structure of NikA in complex with hydroxylated Fe-L1 (N-(2-hydroxybenzyl)-N'-(2-thiomethylbenzyl)-N,N'-ethylenediamine diacetic acid)
5ON9	;	1.7	;	Crystal structure of NikA in complex with reduced Fe-L1 (N-(2-hydroxybenzyl)-N'-(2-thiomethylbenzyl)-N,N'-ethylenediamine diacetic acid)
5ON8	;	1.6	;	Crystal structure of NikA in complex with reduced Fe-L2 (N-(2-hydroxy-3-methoxybenzyl)-N'-(2-thiomethylbenzyl)- N,N'-ethylenediamine diacetic acid)
3LGH	;	2.37	;	Crystal structure of NikR from Helicobacter pylori with variable Ni site coordination
4OEV	;	1.9	;	Crystal structure of NikZ from Campylobacter jejuni in complex with Ni(II) ion
4OEU	;	2.2	;	Crystal structure of NikZ from Campylobacter jejuni in complex with Ni(L-His)
4OET	;	2.4	;	Crystal structure of NikZ from Campylobacter jejuni, unliganded form
1W3O	;	1.6	;	Crystal structure of NimA from D. radiodurans
6VY5	;	3.4	;	Crystal structure of Nipah receptor binding protein head domain in complex with human neutralizing antibody HENV-26
1WP7	;	2.2	;	crystal structure of Nipah Virus fusion core
5EVM	;	3.367	;	Crystal Structure of Nipah Virus Fusion Glycoprotein in the Prefusion State
7SKT	;	2.048	;	Crystal structure of Nipah virus matrix protein
3G50	;	1.9	;	Crystal Structure of NiSOD D3A mutant at 1.9 A
4NCQ	;	2.08	;	Crystal structure of NiSOD H1A mutant
3G4X	;	2.01	;	Crystal Structure of NiSOD Y9F mutant
3G4Z	;	1.87	;	Crystal Structure of NiSOD Y9F mutant at 1.9 A
3WUY	;	3.1	;	Crystal structure of Nit6803
1Q16	;	1.9	;	Crystal structure of Nitrate Reductase A, NarGHI, from Escherichia coli
2BII	;	1.7	;	crystal structure of nitrate-reducing fragment of assimilatory nitrate reductase from Pichia angusta
4JR9	;	2.6	;	Crystal structure of nitrate/nitrite exchanger NarK
4JRE	;	2.8	;	Crystal structure of nitrate/nitrite exchanger NarK with nitrite bound
5OCB	;	1.78	;	Crystal structure of nitric oxide bound D97N mutant of three-domain heme-Cu nitrite reductase from Ralstonia pickettii
5OCF	;	1.8	;	Crystal structure of nitric oxide bound to three-domain heme-Cu nitrite reductase from Ralstonia pickettii
3AYF	;	2.5	;	Crystal structure of nitric oxide reductase
3AYG	;	2.7	;	Crystal structure of nitric oxide reductase complex with HQNO
3O0R	;	2.7	;	Crystal structure of nitric oxide reductase from Pseudomonas aeruginosa in complex with antibody fragment
2FLQ	;	3.2	;	Crystal Structure of Nitric Oxide Synthase from Geobacillus Stearothermophilus (ATCC 12980) complexed with L-arginine
1ROM	;	2.0	;	CRYSTAL STRUCTURE OF NITRIC REDUCTASE FROM DENITRIFYING FUNGUS FUSARIUM OXYSPORUM
2ROM	;	2.0	;	CRYSTAL STRUCTURE OF NITRIC REDUCTASE FROM DENITRIFYING FUNGUS FUSARIUM OXYSPORUM COMPLEX WITH CARBON MONOXIDE
3A8O	;	1.47	;	Crystal structure of Nitrile Hydratase complexed with Trimethylacetamide
1V29	;	2.6	;	Crystal structure of Nitrile hydratase from a thermophile Bacillus smithii
4OB3	;	1.92	;	Crystal Structure of Nitrile Hydratase from Pseudonocardia thermophila : A Reference Structure to Boronic Acid Inhibition of Nitrile Hydratase
4OB1	;	1.631	;	Crystal Structure of Nitrile Hydratase from Pseudonocardia thermophila bound to Butaneboronic Acid via Co-crystallization
4OB2	;	1.52	;	Crystal Structure of Nitrile Hydratase from Pseudonocardia thermophila bound to Butaneboronic Acid via Crystal Soaking
4OB0	;	1.2	;	Crystal Structure of Nitrile Hydratase from Pseudonocardia thermophila bound to Phenyl Boronic Acid
3X28	;	1.65	;	Crystal structure of Nitrile Hydratase mutant bR56K
3WVE	;	1.57	;	Crystal structure of Nitrile Hydratase mutant bR56K complexed with Trimethylacetonitrile, before photo-activation
3X24	;	1.24	;	Crystal structure of Nitrile Hydratase mutant bR56K complexed with Trimethylacetonitrile, photo-activated for 120 min
3X20	;	1.18	;	Crystal structure of Nitrile Hydratase mutant bR56K complexed with Trimethylacetonitrile, photo-activated for 25 min
3X26	;	1.34	;	Crystal structure of Nitrile Hydratase mutant bR56K complexed with Trimethylacetonitrile, photo-activated for 5 min
3WVD	;	1.18	;	Crystal structure of Nitrile Hydratase mutant bR56K complexed with Trimethylacetonitrile, photo-activated for 50 min
3X25	;	1.2	;	Crystal structure of Nitrile Hydratase mutant bR56K complexed with Trimethylacetonitrile, photo-activated for 700 min
3A8H	;	1.66	;	Crystal structure of Nitrile Hydratase mutant S113A complexed with Trimethylacetamide
3A8G	;	1.11	;	Crystal structure of Nitrile Hydratase mutant S113A complexed with Trimethylacetonitrile
3A8M	;	1.32	;	Crystal structure of Nitrile Hydratase mutant Y72F complexed with Trimethylacetonitrile
3NFW	;	1.6	;	Crystal structure of nitrilotriacetate monooxygenase component B (A0R521 homolog) from Mycobacterium thermoresistibile
3BPK	;	1.56	;	Crystal structure of nitrilotriacetate monooxygenase component B from Bacillus cereus
6TFD	;	2.25	;	Crystal structure of nitrite and NO bound three-domain copper-containing nitrite reductase from Hyphomicrobium denitrificans strain 1NES1
5OBO	;	1.89	;	Crystal structure of nitrite bound D97N mutant of three-domain heme-Cu nitrite reductase from Ralstonia pickettii
6QPT	;	1.9	;	Crystal structure of nitrite bound synthetic core domain of nitrite reductase from Ralstonia pickettii (residues 1-331)
6QPX	;	1.7	;	Crystal structure of nitrite bound Y323A mutant of haem-Cu containing nitrite reductase from Ralstonia pickettii
6QQ0	;	1.4	;	Crystal structure of nitrite bound Y323E mutant of haem-Cu containing nitrite reductase from Ralstonia pickettii
6QQ2	;	2.6	;	Crystal structure of nitrite bound Y323F mutant of haem-Cu containing nitrite reductase from Ralstonia pickettii
1MZY	;	1.46	;	Crystal Structure of Nitrite Reductase
1ET5	;	1.9	;	CRYSTAL STRUCTURE OF NITRITE REDUCTASE ASP98ASN MUTANT FROM ALCALIGENES FAECALIS S-6
2DV6	;	2.2	;	Crystal structure of nitrite reductase from Hyphomicrobium denitrificans
2ZOO	;	1.95	;	Crystal structure of nitrite reductase from Pseudoalteromonas haloplanktis TAC125
1ET8	;	1.8	;	CRYSTAL STRUCTURE OF NITRITE REDUCTASE HIS255ASN MUTANT FROM ALCALIGENES FAECALIS
1ET7	;	1.7	;	CRYSTAL STRUCTURE OF NITRITE REDUCTASE HIS255ASP MUTANT FROM ALCALIGENES FAECALIS S-6
1L9O	;	1.7	;	CRYSTAL STRUCTURE OF NITRITE SOAKED I257A VARIANT OF THE COPPER-CONTAINING NITRITE REDUCTASE FROM ALCALIGENES FAECALIS
1L9P	;	1.75	;	CRYSTAL STRUCTURE OF NITRITE SOAKED I257G VARIANT OF THE COPPER-CONTAINING NITRITE REDUCTASE FROM ALCALIGENES FAECALIES S-6
1J9Q	;	1.65	;	Crystal structure of nitrite soaked oxidized D98N AFNIR
1J9S	;	1.9	;	Crystal structure of nitrite soaked oxidized H255N AFNIR
1J9R	;	2.0	;	Crystal structure of nitrite soaked reduced D98N AFNIR
1J9T	;	1.95	;	Crystal structure of nitrite soaked reduced H255N AFNIR
4QIS	;	1.906	;	Crystal structure of Nitroalkane Oxidase from Pseudomonas aeruginosa
4QIT	;	1.4	;	Crystal structure of Nitroalkane Oxidase from Pseudomonas aeruginosa in mutant complex form
4QIU	;	1.401	;	Crystal structure of Nitroalkane Oxidase from Pseudomonas aeruginosa in Mutant complex form
2C12	;	2.07	;	Crystal Structure of Nitroalkane Oxidase in Complex with Spermine, a Competitive Inhibitor
2A0J	;	2.5	;	Crystal Structure of Nitrogen Regulatory Protein IIA-Ntr from Neisseria meningitidis
7JMB	;	3.0	;	Crystal structure of Nitrogenase iron-molybdenum cofactor biosynthesis enzyme NifB from Methanothermobacter thermautotrophicus with three Fe4S4 clusters
3ENU	;	1.86	;	Crystal structure of Nitrollin, a betagamma-crystallin from Nitrosospira multiformis
3ENT	;	2.14	;	Crystal structure of Nitrollin, a betagamma-crystallin from Nitrosospira multiformis-in alternate space group (P65)
5LSM	;	2.5	;	Crystal structure of nitronate monooxygenase (SO_0471) from Shewanella oneidensis MR-1
6BKA	;	1.65	;	Crystal Structure of Nitronate Monooxygenase from Cyberlindnera saturnus
4Q4K	;	1.44	;	Crystal structure of nitronate monooxygenase from Pseudomonas aeruginosa PAO1
2NP1	;	2.0	;	CRYSTAL STRUCTURE OF NITROPHORIN 1 FROM RHODNIUS PROLIXUS
1EUO	;	2.0	;	Crystal structure of nitrophorin 2 (prolixin-S)
2A3F	;	1.4	;	Crystal structure of nitrophorin 2 aqua complex
2ACP	;	1.4	;	Crystal structure of nitrophorin 2 aqua complex
2AH7	;	1.7	;	Crystal structure of nitrophorin 2 aqua complex
1PEE	;	1.5	;	Crystal Structure of Nitrophorin 2 complex with imidazole
1T68	;	1.45	;	Crystal structure of nitrophorin 2 complex with NO
2GTF	;	1.4	;	Crystal structure of nitrophorin 2 complex with pyrimidine
2HYS	;	1.2	;	Crystal structure of nitrophorin 2 complexed with cyanide
2AL0	;	1.6	;	Crystal structure of nitrophorin 2 ferrous aqua complex
1PM1	;	1.1	;	Crystal structure of nitrophorin 2 L122V/L132V mutant complex with imidazole
1ML7	;	1.25	;	Crystal structure of nitrophorin 4 complexed with 4-iodopyrazole
1EQD	;	1.6	;	CRYSTAL STRUCTURE OF NITROPHORIN 4 COMPLEXED WITH CN
1ERX	;	1.4	;	CRYSTAL STRUCTURE OF NITROPHORIN 4 COMPLEXED WITH NO
5HWZ	;	1.45	;	Crystal structure of nitrophorin 4 D30N mutant with nitrite
1NP4	;	1.5	;	CRYSTAL STRUCTURE OF NITROPHORIN 4 FROM RHODNIUS PROLIXUS
4HPB	;	1.6	;	Crystal structure of Nitrophorin 4 from Rhodnius prolixus Complexed with Beta-Mercaptoethanol at pH 7.4
4HPC	;	1.4	;	Crystal structure of Nitrophorin 4 from Rhodnius prolixus Complexed with Cysteine at pH 7.4
1IKE	;	1.5	;	Crystal Structure of Nitrophorin 4 from Rhodnius Prolixus Complexed with Histamine at 1.5 A Resolution
4HPD	;	1.3	;	Crystal structure of Nitrophorin 4 from Rhodnius prolixus Complexed with homocysteine at pH 7.4
1KOI	;	1.08	;	CRYSTAL STRUCTURE OF NITROPHORIN 4 FROM RHODNIUS PROLIXUS COMPLEXED WITH NITRIC OXIDE AT 1.08 A RESOLUTION
3MVF	;	1.4	;	Crystal Structure of Nitrophorin 4 from Rhodnius prolixus Complexed with Nitrite at pH 7.4
4HPA	;	1.5	;	Crystal structure of Nitrophorin 4 from Rhodnius prolixus Complexed with sulfide ion at pH 7.4
4GNW	;	1.15	;	Crystal structure of nitrophorin 4 triple mutant complex with ammonia
4GRJ	;	1.15	;	Crystal structure of nitrophorin 4 triple mutant complex with NO
1U0X	;	1.45	;	Crystal structure of nitrophorin 4 under pressure of xenon (200 psi)
5M6J	;	1.7	;	Crystal structure of nitrophorin 7 E27V mutant from Rhodnius prolixus
5M6K	;	1.6	;	Crystal structure of nitrophorin 7 E27V mutant from Rhodnius prolixus with imidazole
4XMC	;	1.421	;	Crystal structure of nitrophorin 7 from Rhodnius prolixus at pH 5.8
4XMD	;	1.6	;	Crystal structure of nitrophorin 7 from Rhodnius prolixus at pH 7.8
4XMH	;	1.29	;	Crystal structure of nitrophorin 7 from Rhodnius prolixus at pH 7.8 complexed with Gly-Gly-Gly
4XMF	;	1.6	;	Crystal structure of nitrophorin 7 from Rhodnius prolixus at pH 7.8 complexed with histamine
4XMG	;	1.8	;	Crystal structure of nitrophorin 7 from Rhodnius prolixus at pH 7.8 complexed with imidazole
4XME	;	1.29	;	Crystal structure of nitrophorin 7 from Rhodnius prolixus at pH 7.8 complexed with NO
3G14	;	1.75	;	Crystal structure of nitroreductase family protein (YP_877874.1) from Clostridium novyi NT at 1.75 A resolution
8Q5G	;	2.0	;	Crystal structure of nitroreductase from Bacillus tequilensis with covalent FMN
3EK3	;	1.7	;	Crystal structure of Nitroreductase with Bound FMN (YP_211706.1) from Bacteroides fragilis NCTC 9343 at 1.70 A resolution
7AAS	;	1.8	;	Crystal structure of nitrosoglutathione reductase (GSNOR) from Chlamydomonas reinhardtii
7AAU	;	2.301	;	Crystal structure of nitrosoglutathione reductase from Chlamydomonas reinhardtii in complex with NAD+
3MXL	;	3.15	;	Crystal structure of nitrososynthase from Micromonospora carbonacea var. africana
6VCH	;	2.35	;	Crystal structure of Nitrosotalea devanaterra carotenoid cleavage dioxygenase in complex with 3-hydroxy-beta-apo-14'-carotenal
6VCG	;	2.3	;	Crystal structure of Nitrosotalea devanaterra carotenoid cleavage dioxygenase, cobalt form
6VCF	;	2.687	;	Crystal structure of Nitrosotalea devanaterra carotenoid cleavage dioxygenase, iron form
4G3R	;	2.2	;	Crystal Structure of Nitrosyl Cytochrome P450cam
4FYZ	;	2.32	;	Crystal Structure of Nitrosyl Cytochrome P450cin
1FWX	;	1.6	;	CRYSTAL STRUCTURE OF NITROUS OXIDE REDUCTASE FROM P. DENITRIFICANS
1QNI	;	2.4	;	Crystal Structure of Nitrous Oxide Reductase from Pseudomonas nautica, at 2.4A Resolution
5GGQ	;	1.9	;	Crystal structure of Nivolumab Fab fragment
4WAA	;	2.35	;	Crystal structure of Nix LIR-fused human LC3B_2-119
1P4L	;	2.9	;	Crystal structure of NK receptor Ly49C mutant with its MHC class I ligand H-2Kb
3SP8	;	1.86	;	Crystal structure of NK2 in complex with fractionated Heparin DP10
4S0U	;	2.35	;	Crystal structure of NKG2D in complex with ULBP6
3PV6	;	2.3	;	Crystal structure of NKp30 bound to its ligand B7-H6
3PV7	;	2.0	;	Crystal structure of NKp30 ligand B7-H6
4IOP	;	3.2	;	Crystal structure of NKp65 bound to its ligand KACL
5FLV	;	3.005	;	Crystal structure of NKX2-5 and TBX5 bound to the Nppa promoter region
3KBH	;	3.31	;	Crystal structure of NL63 respiratory coronavirus receptor-binding domain complexed with its human receptor
8ER5	;	1.92	;	Crystal Structure of NlpC/P60 domain from Clostridium innocuum NlpC/P60 domain-containing protein CI_01448.
6B8C	;	2.403	;	Crystal structure of NlpC/p60 domain of peptidoglycan hydrolase SagA
6QBD	;	1.95	;	Crystal structure of NLPPya P41A, D44N, N48E mutant
4KXF	;	3.2	;	Crystal structure of NLRC4 reveals its autoinhibition mechanism
8RI2	;	2.8	;	Crystal structure of NLRP3 in complex with inhibitor NP3-562
7ALV	;	2.835	;	Crystal Structure of NLRP3 NACHT domain in complex with a potent inhibitor
3SLU	;	2.41	;	Crystal structure of NMB0315
3KJJ	;	1.9	;	Crystal structure of NMB1025, a member of YjgF protein family, from Neisseria meningitidis (hexagonal crystal form)
3KJK	;	2.29	;	Crystal structure of NMB1025, a member of YjgF protein family, from Neisseria meningitidis (monoclinic crystal form)
3MW6	;	2.209	;	Crystal structure of NMB1681 from Neisseria meningitidis MC58, a FinO-like RNA chaperone
6JDQ	;	2.95	;	Crystal structure of Nme1Cas9 in complex with sgRNA
6JDV	;	3.1	;	Crystal structure of Nme1Cas9 in complex with sgRNA and target DNA (ATATGATT PAM) in catalytic state
6KC7	;	3.3	;	Crystal structure of Nme1Cas9 in complex with sgRNA and target DNA (ATATGATT PAM) in seed-base paring state
6JE9	;	3.46	;	Crystal structure of Nme1Cas9-sgRNA dimer mediated by double protein inhibitor AcrIIC3 monomers
6JE4	;	3.069	;	Crystal structure of Nme1Cas9-sgRNA-dsDNA dimer mediated by double protein inhibitor AcrIIC3 monomers
6JFU	;	3.2	;	Crystal structure of Nme2Cas9 in complex with sgRNA and target DNA (AGGCCC PAM)
6JE3	;	2.931	;	Crystal structure of Nme2Cas9 in complex with sgRNA and target DNA (AGGCCC PAM) with 5 nt overhang
5VGB	;	1.497	;	Crystal structure of NmeCas9 HNH domain bound to anti-CRISPR AcrIIC1
1KQO	;	2.5	;	Crystal structure of NMN/NaMN adenylyltransferase complexed with deamido-NAD
1KQN	;	2.2	;	Crystal structure of NMN/NaMN adenylyltransferase complexed with NAD
1K6J	;	1.8	;	Crystal structure of Nmra, a negative transcriptional regulator (Monoclinic form)
1K6I	;	1.8	;	Crystal structure of Nmra, a negative transcriptional regulator (Trigonal form)
1K6X	;	1.5	;	Crystal structure of Nmra, a negative transcriptional regulator in complex with NAD at 1.5 A resolution (Trigonal form)
1TI7	;	1.7	;	CRYSTAL STRUCTURE OF NMRA, A NEGATIVE TRANSCRIPTIONAL REGULATOR, IN COMPLEX WITH NADP AT 1.7A RESOLUTION
2WMD	;	2.0	;	Crystal structure of NmrA-like family domain containing protein 1 in complex with NADP and 2-(4-chloro-phenylamino)-nicotinic acid
2WM3	;	1.85	;	Crystal structure of NmrA-like family domain containing protein 1 in complex with niflumic acid
3LMF	;	2.3	;	Crystal Structure of Nmul_A1745 protein from Nitrosospira multiformis, Northeast Structural Genomics Consortium Target NmR72
3WRV	;	2.75	;	Crystal structure of NN domain of resistance protein
1FKO	;	2.9	;	CRYSTAL STRUCTURE OF NNRTI RESISTANT K103N MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH DMP-266(EFAVIRENZ)
1FKP	;	2.9	;	CRYSTAL STRUCTURE OF NNRTI RESISTANT K103N MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH NEVIRAPINE
1F24	;	1.4	;	CRYSTAL STRUCTURE OF NO COMPLEX OF THR243ALA MUTANTS OF CYTOCHROME P450NOR
1F25	;	1.4	;	CRYSTAL STRUCTURE OF NO COMPLEX OF THR243ASN MUTANTS OF CYTOCHROME P450NOR
1F26	;	1.4	;	CRYSTAL STRUCTURE OF NO COMPLEX OF THR243VAL MUTANTS OF CYTOCHROME P450NOR
2OUA	;	1.85	;	Crystal Structure of Nocardiopsis Protease (NAPase)
7AU7	;	2.547	;	Crystal structure of Nod Factor Perception ectodomain
3SIW	;	1.98	;	Crystal structure of NodZ alpha-1,6-fucosyltransferase co-crystallized with GDP
3SIX	;	2.35	;	Crystal structure of NodZ alpha-1,6-fucosyltransferase soaked with GDP-fucose
1P8T	;	3.2	;	Crystal structure of Nogo-66 Receptor
4P8S	;	1.8	;	Crystal structure of Nogo-receptor-2
4OMZ	;	2.64	;	Crystal Structure of NolR from Sinorhizobium fredii
4ON0	;	3.0	;	Crystal Structure of NolR from Sinorhizobium fredii in complex with oligo AA DNA
7X20	;	3.3	;	Crystal structure of non gastric H,K-ATPase alpha2 in (K+)E2-AlF state
7JUL	;	2.53	;	Crystal structure of non phosphorylated PTEN (n-crPTEN-13sp-T1, SDTTDSDPENEG)
4C0N	;	1.77	;	Crystal structure of non symbiotic plant hemoglobin AHb3 (GLB3) from Arabidopsis thaliana
1EZ4	;	2.3	;	CRYSTAL STRUCTURE OF NON-ALLOSTERIC L-LACTATE DEHYDROGENASE FROM LACTOBACILLUS PENTOSUS AT 2.3 ANGSTROM RESOLUTION
5MVG	;	2.2	;	Crystal structure of non-amyloidogenic light chain dimer M7
6AOB	;	1.7	;	Crystal structure of non-canonical dimeric guanylyl cyclase domain of RhoGC fusion protein from the aquatic fungus Blastocladiella emersonii
5M6I	;	2.2	;	Crystal structure of non-cardiotoxic Bence-Jones light chain dimer M8
4I6X	;	1.5	;	Crystal Structure of Non-catalyic Domain of Protein Disulfide Isomerase-related (PDIr) Protein
4KY4	;	2.79	;	Crystal structure of non-classical TS inhibitor 2 in complex with Toxoplasma gondii TS-DHFR
4KYA	;	3.263	;	Crystal structure of non-classical TS inhibitor 3 in complex with Toxoplasma gondii TS-DHFR
4WJ4	;	3.294	;	Crystal structure of non-discriminating aspartyl-tRNA synthetase from Pseudomonas aeruginosa complexed with tRNA(Asn) and aspartic acid
4NRV	;	2.601	;	Crystal Structure of non-edited human NEIL1
5EPA	;	2.24	;	Crystal structure of non-heme alpha ketoglutarate dependent carbocyclase SnoK from nogalamycin biosynthesis
4DGQ	;	1.85	;	Crystal structure of Non-heme chloroperoxidase from Burkholderia cenocepacia
4M23	;	1.76	;	Crystal structure of non-heme iron oxygenase OrfP
4NE0	;	2.17	;	Crystal structure of non-heme iron oxygenase OrfP D157A mutant in complex with (3S)-hydroxy-L-Arg
4M2I	;	2.53	;	Crystal structure of non-heme iron oxygenase OrfP in complex with Fe
4M25	;	1.84	;	Crystal structure of non-heme iron oxygenase OrfP in complex with Fe and alpha-ketoglutaric acid
4M2C	;	2.35	;	Crystal structure of non-heme iron oxygenase OrfP in complex with Fe and D-Arg
4M27	;	2.35	;	Crystal structure of non-heme iron oxygenase OrfP in complex with Fe and L-Arg
4M2F	;	1.92	;	Crystal structure of non-heme iron oxygenase OrfP in complex with Fe and L-canavanine
4M2E	;	2.06	;	Crystal structure of non-heme iron oxygenase OrfP in complex with Fe and L-homoarginine
4M2G	;	2.39	;	Crystal structure of non-heme iron oxygenase OrfP in complex with Fe, succinate, and (3R,4R)-dihydroxy-L-Arg
4M26	;	2.02	;	Crystal structure of non-heme iron oxygenase OrfP in complex with Fe, succinate, and (3S)-hydroxy-L-Arg
4YI8	;	1.2	;	Crystal structure of non-myristoylated E153A recoverin at 1.2 A resolution with calcium ions bound to EF-hands 2 and 3
4YI9	;	1.35	;	Crystal structure of non-myristoylated E153A recoverin at 1.35 A resolution with a sodium ion bound to EF-hand 2 and calcium ion bound to EF-hand 3
5I27	;	2.05	;	Crystal structure of non-myristoylated MMTV matrix protein
4MLW	;	1.45	;	Crystal structure of non-myristoylated recoverin at 1.45 A resolution with calcium bound to EF-hand 3
4M2Q	;	1.9	;	Crystal structure of non-myristoylated recoverin with Cysteine-39 oxidized to sulfenic acid
8DFH	;	2.3	;	Crystal structure of non-neutralizing / interfering human monoclonal antibody 42C3 Fab in complex with MSP1-19
4H8W	;	1.85	;	Crystal structure of non-neutralizing and ADCC-potent antibody N5-i5 in complex with HIV-1 clade A/E gp120 and sCD4.
4Q0X	;	2.9	;	Crystal structure of non-neutralizing antibody in complex with Epitope II of HCV E2
6APB	;	3.0	;	Crystal Structure of Non-Neutralizing Infant Antibody ADI-14359 in Complex with Postfusion RSV F Glycoprotein
5CIN	;	1.7	;	Crystal Structure of non-neutralizing version of 4E10 (DeltaLoop) with epitope bound
5CIL	;	1.81	;	Crystal Structure of non-neutralizing version of 4E10 (WDWD) with epitope bound
4R4H	;	4.28	;	Crystal structure of non-neutralizing, A32-like antibody 2.2c in complex with HIV-1 Env gp120
4R4F	;	3.514	;	Crystal structure of non-neutralizing, A32-like antibody 2.2c in complex with HIV-1 YU2 gp120
4NO5	;	2.101	;	Crystal structure of non-phosphorylated form of AMPD2 phosphopeptide bound to HLA-A2
4NNY	;	1.9	;	Crystal structure of non-phosphorylated form of PKD2 phosphopeptide bound to HLA-A2
6EWC	;	3.2	;	Crystal structure of non-phosphorylated form of RLS PHOSPHOPEPTIDE BOUND TO HLA-A2 in complex with LILRB1
4NO0	;	2.7	;	Crystal structure of non-phosphorylated form of RQA_V phosphopeptide bound to HLA-A2 in complex with LILRB1
6EWO	;	2.3	;	Crystal structure of non-phosphorylated form of RTF PHOSPHOPEPTIDE BOUND TO HLA-A2 in complex with LILRB1
2B9F	;	1.8	;	Crystal structure of non-phosphorylated Fus3
5I4C	;	2.0	;	Crystal structure of non-phosphorylated receiver domain of the stress response regulator RcsB from Escherichia coli
2IVS	;	2.0	;	Crystal structure of non-phosphorylated RET tyrosine kinase domain
8U7X	;	2.06	;	Crystal structure of non-receptor protein tyrosine phosphatase SHP2 in complex with inhibitor compound 24
8U7W	;	2.05	;	Crystal structure of non-receptor protein tyrosine phosphatase SHP2 in complex with inhibitor compound 7
7F7A	;	2.7	;	Crystal structure of Non-specific class-C acid phosphatase from Sphingobium sp. RSMS bound to Adenine at pH 9
7F7C	;	2.2	;	Crystal structure of Non-specific class-C acid phosphatase from Sphingobium sp. RSMS bound to Adenosine at pH 5.5
7F7D	;	2.2	;	Crystal structure of Non-specific class-C acid phosphatase from Sphingobium sp. RSMS bound to Adenosine at pH 5.5
7F7B	;	2.34	;	Crystal structure of Non-specific class-C acid phosphatase from Sphingobium sp. RSMS bound to BIS-TRIS at pH 5.5
5TVI	;	1.87	;	Crystal structure of non-specific lipid transfer protein reveals non-canonical lipid binding: possible relevance in modulating allergenicity
1D8U	;	2.35	;	CRYSTAL STRUCTURE OF NON-SYMBIOTIC PLANT HEMOGLOBIN FROM RICE
2GNV	;	2.3	;	Crystal structure of non-symbiotic plant hemoglobin from rice, B10 mutant F40L
2GNW	;	2.4	;	Crystal structure of non-symbiotic plant hemoglobin from rice, B10 mutant F40W
3QQQ	;	1.84	;	Crystal structure of non-symbiotic plant hemoglobin from Trema tomentosa
6QBE	;	2.0	;	Crystal structure of non-toxic HaNLP3 protein
6GUT	;	1.63	;	CRYSTAL STRUCTURE OF NON-TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN E AND PILA EXPRESSED AS A SINGLE-CHAIN CHIMERIC PROTEIN
3AY4	;	2.2	;	Crystal structure of nonfucosylated Fc complexed with bis-glycosylated soluble form of Fc gamma receptor IIIa
5BW7	;	3.0	;	Crystal structure of nonfucosylated Fc Y296W mutant complexed with bis-glycosylated soluble form of Fc gamma receptor IIIa
7Z1G	;	2.85	;	Crystal structure of nonphosphorylated (Tyr216) GSK3b in complex with CX-4945
6NFY	;	2.17	;	Crystal structure of nonphosphorylated, HPK1 kinase domain in complex with sunitinib in the inactive state.
6LTA	;	2.45	;	Crystal Structure of Nonribosomal peptide synthetases (NRPS), FmoA3 (S1046A)
6LTC	;	3.3	;	Crystal Structure of Nonribosomal peptide synthetases (NRPS), FmoA3 (S1046A)-alpha-methyl-L-serine-AMP bound form
6LTD	;	4.1	;	Crystal Structure of Nonribosomal peptide synthetases (NRPS), FmoA3 (S1046A)-alpha-methyl-L-serine-AMP bound form
6LTB	;	3.1	;	Crystal Structure of Nonribosomal peptide synthetases (NRPS), FmoA3 (S1046A)-AMPPNP bound form
2WD0	;	2.74	;	CRYSTAL STRUCTURE OF NONSYNDROMIC DEAFNESS (DFNB12) ASSOCIATED MUTANT D124G OF MOUSE CADHERIN-23 EC1-2
3VUO	;	3.9	;	Crystal structure of nontoxic nonhemagglutinin subcomponent (NTNHA) from clostridium botulinum serotype D strain 4947
8TV8	;	2.25	;	Crystal structure of nontypeable Haemophilus influenzae SapA
6WPI	;	3.02	;	Crystal structure of Nop9 in complex with ITS1 RNA
8UKE	;	2.4	;	Crystal Structure of Norbelladine O-methyltransferase variant in complex with SAH
8HO2	;	1.711	;	crystal structure of Norcoclaurine synthase from Chinese lotus (Nelumbo nucicera)
3DDC	;	1.8	;	Crystal Structure of NORE1A in Complex with RAS
1WQS	;	2.8	;	Crystal structure of Norovirus 3C-like protease
4RDJ	;	1.5	;	Crystal structure of Norovirus Boxer P domain
4RDK	;	1.629	;	Crystal structure of Norovirus Boxer P domain in complex with Lewis b tetrasaccharide
4RDL	;	1.449	;	Crystal structure of Norovirus Boxer P domain in complex with Lewis y tetrasaccharide
4X7F	;	1.7	;	Crystal structure of norovirus GII.10 P domain in complex with Nano-25
4X7E	;	2.11	;	Crystal structure of norovirus GII.10 P domain in complex with Nano-85
4RLZ	;	1.19	;	Crystal structure of Norovirus OIF P domain
4RM0	;	1.999	;	Crystal structure of Norovirus OIF P domain in complex with Lewis a trisaccharide
5BQE	;	2.3	;	Crystal structure of Norrin in complex with the cysteine-rich domain of Frizzled 4 -Methylated form
5BQC	;	3.0	;	Crystal structure of Norrin in complex with the cysteine-rich domain of Frizzled 4 and sucrose octasulfate
4MY2	;	2.4	;	Crystal Structure of Norrin in fusion with Maltose Binding Protein
5BPU	;	2.4	;	Crystal structure of Norrin, a Wnt signalling activator, Crystal Form I
5BQ8	;	2.0	;	Crystal structure of Norrin, a Wnt signalling activator, Crystal Form II
5BQB	;	2.3	;	Crystal structure of Norrin, a Wnt signalling activator, Crystal Form III
1T5Y	;	2.5	;	Crystal Structure of Northeast Structural Genomics Consortium Target HR2118: A Human Homolog of Saccharomyces cerevisiae Nip7p
1XM3	;	1.8	;	Crystal structure of Northeast Structural Genomics Target SR156
1SH2	;	2.3	;	Crystal Structure of Norwalk Virus Polymerase (Metal-free, Centered Orthorhombic)
1SH3	;	2.95	;	Crystal Structure of Norwalk Virus Polymerase (MgSO4 crystal form)
1SH0	;	2.17	;	Crystal Structure of Norwalk Virus Polymerase (Triclinic)
2FYR	;	2.2	;	Crystal Structure of Norwalk Virus Protease grown in the presence of AEBSF
4ZA1	;	2.5	;	Crystal Structure of NosA Involved in Nosiheptide Biosynthesis
5V7O	;	2.3	;	Crystal Structure of NosK from Streptomyces actuosus
2WC7	;	2.37	;	Crystal structure of Nostoc Punctiforme Debranching Enzyme(NPDE)(Acarbose soaked)
2G18	;	2.5	;	Crystal Structure of Nostoc sp. 7120 phycocyanobilin:ferredoxin oxidoreductase (PcyA) Apoprotein
4ZLP	;	2.479	;	Crystal Structure of Notch3 Negative Regulatory Region
5CZV	;	3.19	;	Crystal structure of Notch3 NRR in complex with 20350 Fab
5CZX	;	2.1	;	Crystal structure of Notch3 NRR in complex with 20358 Fab
5XQN	;	1.19	;	Crystal structure of Notched-fin eelpout type III antifreeze protein (NFE6, AFP), C2221 form.
5XQP	;	1.0	;	Crystal structure of Notched-fin eelpout type III antifreeze protein (NFE6, AFP), P212121 form
5XQU	;	1.0	;	Crystal structure of Notched-fin eelpout type III antifreeze protein A20I mutant (NFE6, AFP), P212121 form
5XQV	;	0.97	;	Crystal structure of Notched-fin eelpout type III antifreeze protein A20L mutant (NFE6, AFP), P21 form
5XR0	;	0.98	;	Crystal structure of Notched-fin eelpout type III antifreeze protein A20T mutant (NFE6, AFP), P21 form
5XQR	;	1.3	;	Crystal structure of Notched-fin eelpout type III antifreeze protein A20V mutant (NFE6, AFP), C2221 form
4E4C	;	1.8	;	Crystal structure of Notexin at 1.8 A resolution
6VYA	;	3.0	;	Crystal structure of NotF in complex with brevianamide F and DMSPP
6VY9	;	3.19	;	Crystal structure of NotF prenyltransferase
3C25	;	2.5	;	Crystal Structure of NotI Restriction Endonuclease Bound to Cognate DNA
5X6L	;	1.862	;	Crystal structure of Notothenia coriiceps adenylate kinase variant
5XRU	;	1.9	;	Crystal structure of Notothenia coriiceps adenylate kinase variant
5YCB	;	2.272	;	Crystal structure of notothenia coriiceps adenylate kinase variant
5YCC	;	2.7	;	Crystal structure of Notothenia coriiceps adenylate kinase variant
7QRR	;	1.9	;	Crystal structure of Noumeavirus NMV_189 protein
5C82	;	2.2	;	Crystal structure of Nourseothricin acetyltransferase
1DT4	;	2.6	;	CRYSTAL STRUCTURE OF NOVA-1 KH3 K-HOMOLOGY RNA-BINDING DOMAIN
1DTJ	;	2.0	;	CRYSTAL STRUCTURE OF NOVA-2 KH3 K-HOMOLOGY RNA-BINDING DOMAIN
1EC6	;	2.4	;	CRYSTAL STRUCTURE OF NOVA-2 KH3 K-HOMOLOGY RNA-BINDING DOMAIN BOUND TO 20-MER RNA HAIRPIN
2IA4	;	1.5	;	Crystal structure of Novel amino acid binding protein from Shigella flexneri
3GUQ	;	2.47	;	Crystal structure of novel carcinogenic factor of H. pylori
5IR2	;	2.079	;	Crystal structure of novel cellulases from microbes associated with the gut ecosystem
4HPP	;	2.5	;	Crystal structure of novel glutamine synthase homolog
2QHL	;	1.56	;	Crystal Structure of Novel Immune-Type Receptor 10 Extracellular Fragment from Ictalurus punctatus
2QJD	;	2.44	;	Crystal Structure of Novel Immune-Type Receptor 10 Extracellular Fragment Mutant N30D
3B5T	;	1.75	;	Crystal Structure of Novel Immune-Type Receptor 10 Se-Met Extracellular Fragment Mutant N30D
2QQQ	;	1.98	;	Crystal Structure of Novel Immune-Type Receptor 11 Extracellular Fragment from Ictalurus punctatus
3BDB	;	2.8	;	Crystal Structure of Novel Immune-Type Receptor 11 Extracellular Fragment from Ictalurus punctatus including Stalk Region
2QTE	;	1.9	;	Crystal Structure of Novel Immune-Type Receptor 11 Extracellular Fragment Mutant N30D
5GGZ	;	2.015	;	Crystal structure of novel inhibitor bound with Hsp90
1UZ3	;	1.1	;	Crystal structure of novel protein EMSY
1UTU	;	2.0	;	Crystal structure of novel protein EMSY truncate
3FJV	;	1.9	;	Crystal structure of novel protein of unknown function (YP_111841.1) from BURKHOLDERIA PSEUDOMALLEI K96243 at 1.90 A resolution
6FF6	;	2.5	;	Crystal structure of novel repeat protein BRIC1
6FES	;	3.0	;	Crystal structure of novel repeat protein BRIC2 fused to DARPin D12
3MEW	;	1.92	;	Crystal structure of Novel Tudor domain-containing protein SGF29
7V3C	;	1.9	;	Crystal structure of NP exonuclease C409A-PCMB complex
7V3B	;	1.8	;	Crystal structure of NP exonuclease C409A-PCMPS complex
7V39	;	2.2	;	Crystal structure of NP exonuclease-PCMB complex
7V38	;	2.403	;	Crystal structure of NP exonuclease-PCMPS complex
5SWZ	;	2.65	;	Crystal Structure of NP1-B17 TCR-H2Db-NP complex
5SWS	;	2.86	;	Crystal Structure of NP2-B17 TCR-H2Db-NP complex
3VHM	;	2.0	;	Crystal structure of NPC-biotin-avidin complex
8EUS	;	2.3	;	Crystal structure of NPC1 luminal domain C
7MK3	;	3.06	;	Crystal structure of NPR1
4GPK	;	3.2	;	Crystal structure of NprR in complex with its cognate peptide NprX
4O1R	;	1.4	;	Crystal structure of NpuDnaB intein
4KL5	;	1.72	;	Crystal structure of NpuDnaE intein
2E03	;	2.13	;	Crystal structure of NQ67E mutant of yeast bleomycin hydrolase
2F1O	;	2.75	;	Crystal Structure of NQO1 with Dicoumarol
4U9O	;	1.6	;	Crystal structure of NqrA from Vibrio cholerae
4U9Q	;	2.1	;	Crystal structure of NqrA in spacegroup P21
4U9S	;	1.7	;	Crystal structure of NqrC from Vibrio cholerae
4U9U	;	1.55	;	Crystal structure of NqrF FAD-binding domain from Vibrio cholerae
4UAJ	;	2.7019	;	Crystal structure of NqrF in hexagonal space group
6ZIO	;	1.55	;	CRYSTAL STRUCTURE OF NRAS (C118S) IN COMPLEX WITH GDP
6ZIR	;	1.9	;	CRYSTAL STRUCTURE OF NRAS (C118S) IN COMPLEX WITH GDP AND COMPOUND 18
6ZIZ	;	1.785	;	CRYSTAL STRUCTURE OF NRAS Q61R IN COMPLEX WITH GTP AND COMPOUND 18
4IUH	;	2.1971	;	Crystal structure of NreA of Staphylococcus carnosus with bound iodide
4IUK	;	2.35	;	Crystal structure of NreA of Staphylococcus carnosus with bound nitrate
8K3D	;	2.3	;	Crystal structure of NRF1 DBD bound to DNA
8K4L	;	2.1	;	Crystal structure of NRF1 homodimer in complex with DNA
8BCX	;	1.941	;	Crystal structure of NrfA-1 from Geobacter metallireducens
5E1B	;	1.65	;	Crystal structure of NRMT1 in complex with SPKRIA peptide
8IVW	;	3.205	;	Crystal structure of NRP2 in complex with aNRP2-10 Fab fragment
8IVX	;	1.9	;	Crystal structure of NRP2 in complex with aNRP2-14 Fab fragment
1SP4	;	2.2	;	Crystal structure of NS-134 in complex with bovine cathepsin B: a two headed epoxysuccinyl inhibitor extends along the whole active site cleft
7Y57	;	2.183	;	Crystal structure of NS1 nuclease domain in P21 space group
7Y56	;	1.752	;	Crystal structure of NS1 nuclease domain in P41212 space group
7RCH	;	3.1	;	Crystal structure of NS1-ED of Vietnam influenza A virus in complex with the p85-beta-iSH2 domain of human PI3K
4WF8	;	1.7	;	Crystal structure of NS3/4A protease in complex with Asunaprevir
3SUD	;	1.96	;	Crystal structure of NS3/4A protease in complex with MK-5172
3SV6	;	1.4	;	Crystal structure of NS3/4A protease in complex with Telaprevir
3SU3	;	1.3	;	Crystal structure of NS3/4A protease in complex with vaniprevir
3SU2	;	1.496	;	Crystal structure of NS3/4A protease variant A156T in complex with danoprevir
3SUG	;	1.8	;	Crystal structure of NS3/4A protease variant A156T in complex with MK-5172
3SV9	;	1.6	;	Crystal structure of NS3/4A protease variant A156T in complex with Telaprevir
3SU6	;	1.1	;	Crystal structure of NS3/4A protease variant A156T in complex with vaniprevir
3SU1	;	1.399	;	Crystal structure of NS3/4A protease variant D168A in complex with danoprevir
3SUF	;	2.19	;	Crystal structure of NS3/4A protease variant D168A in complex with MK-5172
3SV8	;	2.5	;	Crystal structure of NS3/4A protease variant D168A in complex with Telaprevir
3SU5	;	1.55	;	Crystal structure of NS3/4A protease variant D168A in complex with vaniprevir
3SU0	;	1.159	;	Crystal structure of NS3/4A protease variant R155K in complex with danoprevir
3SUE	;	2.2	;	Crystal structure of NS3/4A protease variant R155K in complex with MK-5172
3SV7	;	1.55	;	Crystal structure of NS3/4A protease variant R155K in complex with Telaprevir
3SU4	;	2.255	;	Crystal structure of NS3/4A protease variant R155K in complex with vaniprevir
7ENV	;	2.45	;	crystal structure of NS5 in complex with the N-terminal bromodomain of BRD2 (BRD2-BD1).
2FVC	;	2.0	;	Crystal structure of NS5B BK strain (delta 24) in complex with a 3-(1,1-Dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinone
8FBH	;	2.32	;	Crystal structure of NSD1 Mutant-T1927A
8FBG	;	2.29	;	Crystal structure of NSD1 Mutant-Y1869C
4GND	;	2.27	;	Crystal Structure of NSD3 tandem PHD5-C5HCH domains
4GNF	;	1.55	;	Crystal Structure of NSD3 tandem PHD5-C5HCH domains complexed with H3 peptide 1-15
4GNE	;	1.47	;	Crystal Structure of NSD3 tandem PHD5-C5HCH domains complexed with H3 peptide 1-7
4GNG	;	1.73	;	Crystal Structure of NSD3 tandem PHD5-C5HCH domains complexed with H3K9me3 peptide
2H85	;	2.6	;	Crystal Structure of Nsp 15 from SARS
7K3N	;	1.65	;	Crystal Structure of NSP1 from SARS-CoV-2
2FYG	;	1.8	;	Crystal structure of NSP10 from Sars coronavirus
3R24	;	2.0	;	Crystal structure of nsp10/nsp16 complex of SARS coronavirus
6X4I	;	1.85	;	Crystal Structure of NSP15 Endoribonuclease from SARS CoV-2 in the Complex with 3'-uridinemonophosphate
6WXC	;	1.85	;	Crystal Structure of NSP15 Endoribonuclease from SARS CoV-2 in the Complex with potential repurposing drug Tipiracil
6X1B	;	1.97	;	Crystal Structure of NSP15 Endoribonuclease from SARS CoV-2 in the Complex with the Product Nucleotide GpU.
7K1L	;	2.25	;	Crystal Structure of NSP15 Endoribonuclease from SARS CoV-2 in the Complex with Uridine-2',3'-Vanadate
7K1O	;	2.4	;	Crystal Structure of NSP15 Endoribonuclease from SARS CoV-2 in the Complex with Uridine-3',5'-Diphosphate
6WLC	;	1.82	;	Crystal Structure of NSP15 Endoribonuclease from SARS CoV-2 in the Complex with Uridine-5'-Monophosphate
6VWW	;	2.2	;	Crystal Structure of NSP15 Endoribonuclease from SARS CoV-2.
2RHB	;	2.8	;	Crystal structure of Nsp15-H234A mutant- Hexamer in asymmetric unit
6WVN	;	2.0	;	Crystal Structure of Nsp16-Nsp10 from SARS-CoV-2 in Complex with 7-methyl-GpppA and S-Adenosylmethionine.
6WQ3	;	2.1	;	Crystal Structure of Nsp16-Nsp10 Heterodimer from SARS-CoV-2 in Complex with 7-methyl-GpppA and S-adenosyl-L-homocysteine.
7C2I	;	2.5	;	Crystal structure of nsp16-nsp10 heterodimer from SARS-CoV-2 in complex with SAM (with additional SAM during crystallization)
7C2J	;	2.799	;	Crystal structure of nsp16-nsp10 heterodimer from SARS-CoV-2 in complex with SAM (without additional SAM during crystallization)
6WRZ	;	2.25	;	Crystal Structure of Nsp16-Nsp10 Heterodimer from SARS-CoV-2 with 7-methyl-GpppA and S-adenosyl-L-homocysteine in the Active Site and Sulfates in the mRNA Binding Groove.
4ZTB	;	2.59	;	Crystal structure of nsP2 protease from Chikungunya virus in P212121 space group at 2.59 A (4molecules/ASU).
7F10	;	1.65	;	Crystal structure of NsrQ M128I in complex with substrate analogue 3
7F11	;	1.6	;	Crystal structure of NsrQ M128I in complex with substrate analogue 7
7F0Z	;	2.0	;	Crystal structure of NsrQ W31A
7YTA	;	2.31	;	crystal structure of NtAGDP3 AGD1-2 in complex with an H3K9me2 peptide
7ZIU	;	2.8	;	Crystal structure of Ntaya virus NS5 polymerase domain
2IF7	;	3.0	;	Crystal Structure of NTB-A
3LA7	;	1.9	;	Crystal structure of NtcA in apo-form
3LA3	;	2.4	;	Crystal structure of NtcA in complex with 2,2-difluoropentanedioic acid
3LA2	;	2.6	;	Crystal structure of NtcA in complex with 2-oxoglutarate
4K2B	;	2.31	;	Crystal structure of ntda from bacillus subtilis in complex with the internal aldimine
4K2M	;	1.71	;	Crystal structure of ntda from bacillus subtilis in complex with the plp external aldimine adduct with kanosamine-6-phosphate
4K2I	;	2.225	;	Crystal structure of ntda from bacillus subtilis with bound cofactor pmp
4ONQ	;	2.502	;	Crystal structure of ntDRM E283S/R309S/F310S/Y590S/D591S mutant
3EN8	;	1.85	;	Crystal structure of NTF-2 like protein of unknown function (YP_553245.1) from BURKHOLDERIA XENOVORANS LB400 at 1.85 A resolution
1JB4	;	2.23	;	CRYSTAL STRUCTURE OF NTF2 M102E MUTANT
1JB5	;	2.3	;	CRYSTAL STRUCTURE OF NTF2 M118E MUTANT
1JB2	;	2.0	;	CRYSTAL STRUCTURE OF NTF2 M84E MUTANT
3ER7	;	1.5	;	Crystal structure of NTF2-like protein of unknown function (YP_001812677.1) from EXIGUOBACTERIUM SP. 255-15 at 1.50 A resolution
3LYG	;	1.61	;	Crystal structure of NTF2-like protein of unknown function (YP_270605.1) from Colwellia psychrerythraea 34H at 1.61 A resolution
3F40	;	1.27	;	Crystal structure of NTF2-like protein of unknown function (YP_677363.1) from CYTOPHAGA HUTCHINSONII ATCC 33406 at 1.27 A resolution
3F14	;	1.45	;	Crystal structure of NTF2-like protein of unknown function (YP_680363.1) from CYTOPHAGA HUTCHINSONII ATCC 33406 at 1.45 A resolution
3FSD	;	1.7	;	Crystal structure of NTF2-like protein of unknown function in nutrient uptake (YP_427473.1) from RHODOSPIRILLUM RUBRUM ATCC 11170 at 1.70 A resolution
3HZP	;	1.4	;	Crystal structure of NTF2-like protein of unknown function MN2A_0505 from Prochlorococcus marinus (YP_291699.1) from Prochlorococcus sp. NATL2A at 1.40 A resolution
3GRD	;	1.25	;	Crystal structure of NTF2-superfamily protein with unknown function (NP_977240.1) from BACILLUS CEREUS ATCC 10987 at 1.25 A resolution
7U1M	;	3.17	;	Crystal structure of NTMT1 in complex with compound YD206
5E2B	;	1.95	;	Crystal structure of NTMT1 in complex with N-terminally methylated PPKRIA peptide
5E2A	;	1.75	;	Crystal structure of NTMT1 in complex with N-terminally methylated SPKRIA peptide
5E1M	;	1.75	;	Crystal structure of NTMT1 in complex with PPKRIA peptide
5E1O	;	2.0	;	Crystal structure of NTMT1 in complex with RPKRIA peptide
7XWW	;	2.8	;	Crystal structure of NTR in complex with BN-XB
2Q5C	;	1.49	;	Crystal structure of NtrC family transcriptional regulator from Clostridium acetobutylicum
3FKQ	;	2.1	;	Crystal structure of NtrC-like two-domain protein (RER070207001320) from Eubacterium rectale at 2.10 A resolution
4FTH	;	3.004	;	Crystal Structure of NtrC4 DNA-binding domain bound to double-stranded DNA
6DLF	;	3.446	;	Crystal structure of NTRI homodimer
5M7P	;	2.36	;	Crystal structure of NtrX from Brucella abortus in complex with ADP processed with the CrystalDirect automated mounting and cryo-cooling technology
5M7N	;	2.9	;	Crystal structure of NtrX from Brucella abortus in complex with ATP processed with the CrystalDirect automated mounting and cryo-cooling technology
5M7O	;	2.2	;	Crystal structure of NtrX from Brucella abortus processed with the CrystalDirect automated mounting and cryo-cooling technology
4MZW	;	1.95	;	CRYSTAL STRUCTURE OF NU-CLASS GLUTATHIONE TRANSFERASE YGHU FROM Streptococcus sanguinis SK36, COMPLEX WITH GLUTATHIONE DISULFIDE, TARGET EFI-507286
1BYS	;	2.0	;	CRYSTAL STRUCTURE OF NUC COMPLEXED WITH TUNGSTATE
4QH0	;	2.0	;	Crystal structure of NucA from Streptococcus agalactiae with magnesium ion bound
4QGO	;	1.5	;	Crystal structure of NucA from Streptococcus agalactiae with no metal bound
6AMX	;	2.05	;	Crystal Structure of Nucelotide Binding Domain of O-antigen polysaccharide ABC-transporter
1KKU	;	2.5	;	Crystal structure of nuclear human nicotinamide mononucleotide adenylyltransferase
5DIZ	;	3.2	;	Crystal Structure of nuclear proteinaceous RNase P 2 (PRORP2) from A. thaliana
4RAK	;	2.04	;	Crystal structure of nuclear receptor subfamily 1, group h, member 2 (lxrb) complexed with partial agonist
1OUN	;	2.3	;	CRYSTAL STRUCTURE OF NUCLEAR TRANSPORT FACTOR 2 (NTF2)
2A11	;	2.1	;	Crystal Structure of Nuclease Domain of Ribonuclase III from Mycobacterium Tuberculosis
4IJS	;	3.2	;	Crystal structure of nucleocapsid protein encoded by the prototypic member of orthobunyavirus
7MO0	;	2.45	;	Crystal Structure of Nucleoporin NUP50 Ran-Binding Domain in Complex with Ran-GPPNHP
7NQA	;	2.2	;	Crystal structure of Nucleoporin-98 nanobody MS98-6 complex solved at 2.2A resolution
5B7B	;	3.0	;	Crystal structure of Nucleoprotein-nucleozin complex
1F8X	;	2.5	;	CRYSTAL STRUCTURE OF NUCLEOSIDE 2-DEOXYRIBOSYLTRANSFERASE
2F62	;	1.5	;	Crystal structure of Nucleoside 2-deoxyribosyltransferase from Trypanosoma brucei at 1.5 A resolution with (2-ETHYLPHENYL)METHANOL bound
2F64	;	1.6	;	Crystal structure of Nucleoside 2-deoxyribosyltransferase from Trypanosoma brucei at 1.6 A resolution with 1-METHYLQUINOLIN-2(1H)-ONE bound
2F67	;	1.6	;	Crystal structure of Nucleoside 2-deoxyribosyltransferase from Trypanosoma brucei at 1.6 A resolution with BENZO[CD]INDOL-2(1H)-ONE bound
2F2T	;	1.7	;	Crystal structure of Nucleoside 2-deoxyribosyltransferase from Trypanosoma brucei at 1.7 A resolution with 5-Aminoisoquinoline bound
2A0K	;	1.8	;	Crystal structure of Nucleoside 2-deoxyribosyltransferase from Trypanosoma brucei at 1.8 A resolution
1S57	;	1.8	;	crystal structure of nucleoside diphosphate kinase 2 from Arabidopsis
4S0M	;	1.922	;	Crystal Structure of nucleoside diphosphate kinase at 1.92 A resolution from acinetobacter baumannii
4FKX	;	1.7	;	Crystal structure of nucleoside diphosphate kinase B from Trypanosoma brucei bound to CDP
4FKY	;	1.95	;	Crystal structure of nucleoside diphosphate kinase B from Trypanosoma brucei bound to GTP
4F36	;	2.3	;	Crystal structure of Nucleoside diphosphate kinase B from Trypanosoma brucei, apo form
4F4A	;	2.1	;	Crystal structure of Nucleoside diphosphate kinase B from Trypanosoma brucei, UDP-bound form
3JS9	;	2.5	;	Crystal structure of nucleoside diphosphate kinase family protein from Babesia bovis
1NB2	;	2.2	;	Crystal Structure of Nucleoside Diphosphate Kinase from Bacillus Halodenitrificans
3MPD	;	2.08	;	Crystal structure of nucleoside diphosphate kinase from encephalitozoon cuniculi, cubic form, apo
3R9L	;	2.65	;	Crystal structure of nucleoside diphosphate kinase from Giardia lamblia featuring a disordered dinucleotide binding site
2ZUA	;	2.59	;	Crystal structure of nucleoside diphosphate kinase from Haloarcula quadrata
5V6D	;	1.85	;	Crystal structure of nucleoside diphosphate kinase from Neisseria gonorrhoeae in complex with citrate
6AES	;	3.55	;	Crystal structure of Nucleoside diphosphate kinase from Pseudomonas aeruginosa at 3.55 A resolution.
1PKU	;	2.5	;	Crystal Structure of Nucleoside Diphosphate Kinase from Rice
5IOL	;	1.741	;	Crystal structure of Nucleoside Diphosphate Kinase from Schistosoma mansoni
5KK8	;	2.11	;	Crystal structure of Nucleoside Diphosphate Kinase from Schistosoma mansoni in complex with ADP
5IOM	;	1.9	;	Crystal Structure of Nucleoside Diphosphate Kinase from Schistosoma mansoni is space group P6322
1WKJ	;	2.0	;	Crystal Structure of Nucleoside Diphosphate Kinase from Thermus thermophilus HB8
1WKL	;	2.2	;	Crystal Structure of Nucleoside Diphosphate Kinase from Thermus thermophilus HB8 in Complex with ATP and ADP
1WKK	;	2.7	;	Crystal Structure of Nucleoside Diphosphate Kinase from Thermus thermophilus HB8 in Complex with GDP
2DY9	;	2.01	;	Crystal structure of nucleoside diphosphate kinase in complex with ADP
2DXD	;	1.77	;	Crystal structure of nucleoside diphosphate kinase in complex with ATP analog
2DXE	;	1.7	;	Crystal structure of nucleoside diphosphate kinase in complex with GDP
2DXF	;	1.7	;	Crystal structure of nucleoside diphosphate kinase in complex with GTP analog
1EZR	;	2.5	;	CRYSTAL STRUCTURE OF NUCLEOSIDE HYDROLASE FROM LEISHMANIA MAJOR
3KD6	;	1.88	;	Crystal Structure of Nucleoside Kinase from Chlorobium tepidum in Complex with AMP
7D8I	;	1.62	;	Crystal structure of nucleoside phosphatase Sa1684 complex with ATP analogue from staphylococus aureus
7DL9	;	3.0	;	Crystal structure of nucleoside transporter NupG
7DLA	;	3.0	;	Crystal structure of nucleoside transporter NupG (D323A mutant)
3AGR	;	2.8	;	Crystal structure of nucleoside triphosphate hydrolases from Neospora caninum
7SYC	;	2.0	;	Crystal Structure of Nucleoside triphosphate pyrophosphohydrolase from Klebsiella pneumoniae subsp. pneumoniae
4DI6	;	2.4	;	crystal structure of nucleoside-diphosphate kinase from Borrelia burgdorferi
6WWD	;	2.1	;	Crystal structure of Nucleoside-triphosphatase / dITP/XTP pyrophosphatase from Mycobacterium abscessus ATCC 19977 / DSM 44196
3GYV	;	3.0	;	Crystal structure of nucleosome assembly protein from Plasmodium falciparum
3GYW	;	2.4	;	Crystal structure of nucleosome assembly protein from Plasmodium falciparum at 2.4 A resolution
5X7V	;	2.802	;	Crystal structure of Nucleosome assembly protein S (PfNapS) from Plasmodium falciparum
5GT0	;	2.82	;	Crystal structure of nucleosome complex with human testis-specific histone variants, Th2a
3UT9	;	2.2	;	Crystal Structure of Nucleosome Core Particle Assembled with a Palindromic Widom '601' Derivative (NCP-601L)
3UTA	;	2.07	;	Crystal Structure of Nucleosome Core Particle Assembled with an Alpha-Satellite Sequence Containing Two TTAAA elements (NCP-TA2)
3UTB	;	2.2	;	Crystal Structure of Nucleosome Core Particle Assembled with the 146b Alpha-Satellite Sequence (NCP146b)
3LZ0	;	2.5	;	Crystal Structure of Nucleosome Core Particle Composed of the Widom 601 DNA Sequence (orientation 1)
3LZ1	;	2.5	;	Crystal Structure of Nucleosome Core Particle Composed of the Widom 601 DNA Sequence (orientation 2)
5GSU	;	3.1	;	Crystal structure of nucleosome core particle consisting of human testis-specific histone variants, Th2A and Th2B
3X1T	;	2.808	;	Crystal structure of nucleosome core particle consisting of mouse testis specific histone variants H2aa and H2ba
2FJ7	;	3.2	;	Crystal structure of Nucleosome Core Particle Containing a Poly (dA.dT) Sequence Element
3X1V	;	2.921	;	Crystal structure of nucleosome core particle in the presence of histone variant involved in reprogramming
3X1U	;	3.25	;	Crystal structure of nucleosome core particle in the presence of histone variants involved in reprogramming
5GT3	;	2.91	;	Crystal structure of nucleosome particle in the presence of human testis-specific histone variant, hTh2b
7XX6	;	3.39	;	Crystal Structure of Nucleosome-H1.0 Linker Histone Assembly (sticky-169a DNA fragment)
7XVL	;	3.506	;	Crystal Structure of Nucleosome-H1.0 Linker Histone Assembly (sticky-169an DNA fragment)
7XX5	;	3.19	;	Crystal Structure of Nucleosome-H1.3 Linker Histone Assembly (sticky-169a DNA fragment)
8YTI	;	2.7	;	Crystal Structure of Nucleosome-H1x Linker Histone Assembly (sticky-169a DNA fragment)
7XVM	;	2.84	;	Crystal Structure of Nucleosome-H5 Linker Histone Assembly (sticky-169a DNA fragment)
2CWK	;	1.75	;	Crystal structure of nucleotide diphosphate kinase from Pyrococcus horikoshii
6UK1	;	2.693	;	Crystal structure of nucleotide-binding domain 2 (NBD2) of the human Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
2PH1	;	2.7	;	Crystal structure of nucleotide-binding protein AF2382 from Archaeoglobus fulgidus, Northeast Structural Genomics Target GR165
3HWS	;	3.25	;	Crystal structure of nucleotide-bound hexameric ClpX
4I4L	;	3.6981	;	Crystal Structure of Nucleotide-Bound W-W-W ClpX Hexamer
3VR2	;	2.8	;	Crystal structure of nucleotide-free A3B3 complex from Enterococcus hirae V-ATPase [eA3B3]
2AFH	;	2.1	;	Crystal Structure of Nucleotide-Free Av2-Av1 Complex
3VR5	;	3.9	;	Crystal structure of nucleotide-free Enterococcus hirae V1-ATPase [eV1(L)]
3HTE	;	4.026	;	Crystal structure of nucleotide-free hexameric ClpX
3SNH	;	3.7	;	Crystal structure of nucleotide-free human dynamin1
2XTP	;	1.5	;	Crystal structure of nucleotide-free human GIMAP2, amino acid residues 1-260
5BPN	;	2.1	;	Crystal structure of nucleotide-free human Hsp70 NBD double mutant E268Q+R272K.
5BN8	;	1.34	;	Crystal structure of nucleotide-free human Hsp70 NBD.
7VES	;	2.0	;	Crystal Structure of nucleotide-free Irgb6
8H4O	;	2.05	;	Crystal Structure of nucleotide-free Irgb6_T95D mutant
6QL4	;	3.6	;	Crystal structure of nucleotide-free Mgm1
7DQC	;	2.706	;	Crystal structure of nucleotide-free mutant A(S23C)3B(N64C)3 complex from Enterococcus hirae V-ATPase
4L79	;	2.3	;	Crystal Structure of nucleotide-free Myosin 1b residues 1-728 with bound Calmodulin
4LHX	;	3.05	;	Crystal structure of nucleotide-free Rab8:Rabin8
3C18	;	1.9	;	Crystal structure of nucleotidyltransferase-like protein (ZP_00538802.1) from Exiguobacterium sibiricum 255-15 at 1.90 A resolution
7E44	;	2.0	;	Crystal structure of NudC complexed with dpCoA
2RH0	;	1.95	;	Crystal structure of NudC domain-containing protein 2 (13542905) from Mus musculus at 1.95 A resolution
6DBY	;	2.0	;	Crystal structure of Nudix 1 from Arabidopsis thaliana
6DBZ	;	1.9	;	Crystal structure of Nudix 1 from Arabidopsis thaliana complexed with isopentenyl diphosphate
2YYH	;	1.8	;	Crystal structure of Nudix family protein from Aquifex aeolicus
5ISY	;	2.354	;	Crystal structure of Nudix family protein with NAD
1SJY	;	1.39	;	Crystal Structure of NUDIX HYDROLASE DR1025 FROM DEINOCOCCUS RADIODURANS
1SOI	;	1.8	;	CRYSTAL STRUCTURE OF NUDIX HYDROLASE DR1025 IN COMPLEX WITH SM+3
1SZ3	;	1.6	;	CRYSTAL STRUCTURE OF NUDIX HYDROLASE DR1025 IN COMPLEXED WITH GNP AND MG+2
3QSJ	;	1.7	;	Crystal structure of NUDIX hydrolase from Alicyclobacillus acidocaldarius
3CNG	;	2.0	;	Crystal structure of NUDIX hydrolase from Nitrosomonas europaea
3DKU	;	2.69	;	Crystal structure of Nudix hydrolase Orf153, ymfB, from Escherichia coli K-1
3SHD	;	2.5	;	Crystal structure of Nudix hydrolase Orf153, ymfB, from Escherichia coli K-1
4C9W	;	1.65	;	Crystal structure of NUDT1 (MTH1) with R-crizotinib
4C9X	;	1.2	;	Crystal structure of NUDT1 (MTH1) with S-crizotinib
7NNJ	;	1.755	;	Crystal Structure of NUDT4 (Diphosphoinositol polyphosphate phosphohydrolase 2) in complex with 4-O-Bn-1-PCP-InsP4 (AMR2105)
5LTU	;	2.23	;	Crystal Structure of NUDT4A- Diphosphoinositol polyphosphate phosphohydrolase 2
6HC2	;	4.31	;	Crystal structure of NuMA/LGN hetero-hexamers
8OZB	;	2.09	;	Crystal structure of Nup35-Nb complex
7MNW	;	2.4	;	Crystal Structure of Nup358/RanBP2 Ran-binding domain 1 in complex with Ran-GPPNHP
7MNX	;	2.4	;	Crystal Structure of Nup358/RanBP2 Ran-binding domain 2 in complex with Ran-GPPNHP
7MNY	;	2.7	;	Crystal Structure of Nup358/RanBP2 Ran-binding domain 3 in complex with Ran-GPPNHP
7MNZ	;	2.35	;	Crystal Structure of Nup358/RanBP2 Ran-binding domain 4 in complex with Ran-GPPNHP
3TAI	;	2.82	;	Crystal structure of NurA
3TAZ	;	3.2	;	Crystal structure of NurA bound to dAMP and manganese
3TAL	;	3.15	;	Crystal structure of NurA with manganese
2XYI	;	1.75	;	Crystal Structure of Nurf55 in complex with a H4 peptide
2YBA	;	2.55	;	Crystal structure of Nurf55 in complex with histone H3
2YB8	;	2.3	;	Crystal structure of Nurf55 in complex with Su(z)12
7WNH	;	3.1	;	Crystal structure of Nurr1 binding to NBRE
1OVL	;	2.2	;	Crystal Structure of Nurr1 LBD
1HH2	;	2.1	;	Crystal structure of NusA from Thermotoga maritima
1L2F	;	2.5	;	Crystal structure of NusA from Thermotoga maritima: a structure-based role of the N-terminal domain
6I37	;	1.54	;	Crystal structure of nv1Pizza6-AYW, a circularly permuted designer protein
6I38	;	1.58	;	Crystal structure of nv2Pizza6-AYW, a circularly permuted designer protein
5CHB	;	1.55	;	Crystal structure of nvPizza2-S16H58 coordinating a CdCl2 nanocrystal
4ZCN	;	1.3	;	Crystal structure of nvPizza2-S16S58
7BIE	;	1.8	;	Crystal structure of nvWrap-T, a 7-bladed symmetric propeller
2VH9	;	2.1	;	CRYSTAL STRUCTURE OF NXG1-DELTAYNIIG IN COMPLEX WITH XLLG, A XYLOGLUCAN DERIVED OLIGOSACCHARIDE
3R1Z	;	1.9	;	Crystal structure of NYSGRC enolase target 200555, a putative dipeptide epimerase from Francisella philomiragia : Complex with L-Ala-L-Glu and L-Ala-D-Glu
3R11	;	2.0	;	Crystal structure of NYSGRC enolase target 200555, a putative dipeptide epimerase from Francisella philomiragia : Mg and Fumarate complex
3R10	;	2.0	;	Crystal structure of NYSGRC enolase target 200555, a putative dipeptide epimerase from Francisella philomiragia : Mg complex
3R0U	;	1.9	;	Crystal structure of NYSGRC enolase target 200555, a putative dipeptide epimerase from Francisella philomiragia : Tartrate and Mg complex
3R0K	;	2.0	;	Crystal structure of NYSGRC enolase target 200555, a putative dipeptide epimerase from Francisella philomiragia : Tartrate bound, no Mg
5XCV	;	2.143	;	Crystal structure of NZ-1 Fv-clasp fragment with its antigen peptide
6XAJ	;	1.498	;	Crystal structure of NzeB
6XAM	;	1.481	;	Crystal structure of NzeB in complex with cyclo-(L-Trp-L-homoalanine)
6XAI	;	1.489	;	Crystal structure of NzeB in complex with cyclo-(L-Trp-L-Pro)
6XAK	;	1.479	;	Crystal structure of NzeB in complex with cyclo-(L-Trp-L-Pro) and cyclo-(L-Trp-L-Trp)
6XAL	;	1.349	;	Crystal structure of NzeB in complex with cyclo-(L-Trp-L-Val)
8P61	;	1.9	;	Crystal structure of O'nyong'nyong virus capsid protease (106-256)
7YNW	;	2.79	;	Crystal structure of O-(2-nitrobenzyl)-L-tyrosine-tRNA sythetase in complex with O-(2-nitrobenzyl)-L-tyrosine
2CTZ	;	2.6	;	Crystal structure of o-acetyl homoserine sulfhydrylase from Thermus thermophilus HB8
7DJQ	;	2.3	;	Crystal Structure of O-acetyl L-serine sulfhydrylase from Haemophilus influenzae in complex with C-Terminal peptide of ribosomal S4 Domain protein from Lactobacillus salivarius.
4IL5	;	2.03	;	Crystal structure of O-Acetyl Serine Sulfhydrylase from Entamoeba histolytica in complex with isoleucine
4JBL	;	2.0	;	Crystal structure of O-Acetyl Serine Sulfhydrylase from Entamoeba histolytica in complex with Methionine
4JBN	;	1.87	;	Crystal structure of O-Acetyl Serine Sulfhydrylase from Entamoeba histolytica in complex with Serine acetyl transferase derived tetrapeptide, SPSI
3SPX	;	1.79	;	Crystal structure of O-Acetyl Serine Sulfhydrylase from Leishmania donovani
3T4P	;	1.77	;	Crystal structure of O-Acetyl Serine Sulfhydrylase from Leishmania donovani in complex with designed tetrapeptide
3TBH	;	1.68	;	Crystal structure of O-Acetyl Serine Sulfhydrylase in complex with octapeptide derived from Serine Acetyl Transferase of Leishmania donovani
6KR5	;	1.544	;	Crystal structure of O-Acetyl Serine Sulfhydrylase isoform 3 from Entamoeba histolytica
8OVH	;	2.171	;	Crystal structure of O-acetyl-L-homoserine sulfhydrolase from Saccharomyces cerevisiae in complex with Pyridoxal-5'-phosphate
3BM5	;	2.4	;	Crystal structure of O-acetyl-serine sulfhydrylase from Entamoeba histolytica in complex with cysteine
5IJG	;	2.0	;	Crystal structure of O-acetylhomoserine sulfhydrolase from Brucella melitensis at 2.0 A resolution
8WKO	;	2.91	;	Crystal structure of O-acetylhomoserine sulfhydrylase from Lactobacillus plantarum in the closed form
8WKR	;	2.05	;	Crystal structure of O-acetylhomoserine sulfhydrylase from Lactobacillus plantarum in the open form
6AHI	;	1.9	;	Crystal structure of O-acetylserine dependent cystathionine beta-synthase from Helicobacter pylori.
2EGU	;	1.9	;	Crystal structure of O-acetylserine sulfhydrase from Geobacillus kaustophilus HTA426
1O58	;	1.8	;	Crystal structure of O-acetylserine sulfhydrylase (TM0665) from Thermotoga maritima at 1.80 A resolution
2BHT	;	2.1	;	Crystal structure of O-acetylserine sulfhydrylase B
1Z7W	;	2.2	;	Crystal Structure of O-Acetylserine Sulfhydrylase from Arabidopsis thaliana
2ISQ	;	2.8	;	Crystal Structure of O-Acetylserine Sulfhydrylase from Arabidopsis Thaliana in Complex with C-Terminal Peptide from Arabidopsis Serine Acetyltransferase
4LI3	;	2.592	;	Crystal Structure of O-Acetylserine Sulfhydrylase from Haemophilus influenzae in complex with high affinity inhibitory peptide from Serine acetyl transferase of Salmonella typhimurium
4NU8	;	2.07	;	Crystal structure of O-acetylserine sulfhydrylase from Haemophilus influenzae in complex with high affinity inhibitory peptide from serine acetyl transferase of Salmonella typhimurium at 2.0 A
4ZU1	;	2.202	;	Crystal Structure of O-Acetylserine Sulfhydrylase from Haemophilus influenzae in complex with O-acetyl serine and peptide inhibitor
4ZU6	;	2.03	;	Crystal Structure of O-Acetylserine Sulfhydrylase from Haemophilus influenzae in complex with pre-reactive o-acetyl serine, alpha-aminoacrylate reaction intermediate and Peptide inhibitor at the resolution of 2.25A
5DBE	;	2.25	;	Crystal structure of O-acetylserine sulfhydrylase from Haemophilus influenzae in complex with pre-reactive O-acetyl serine, alpha-aminoacrylate reaction intermediate and peptide inhibitor at the resolution of 2.25A
5DBH	;	1.98	;	Crystal structure of O-acetylserine sulfhydrylase from haemophilus influenzae in complex with reaction intermediate alpha-aminoacrylate
5XA2	;	2.034	;	Crystal Structure of O-acetylserine sulfhydrylase from Planctomyces Limnophila
5XOQ	;	1.87	;	Crystal structure of O-Acetylserine Sulfhydrylase with bound Transcription Factor peptide inhibitor from Planctomyces limnophilus
2CB1	;	2.0	;	Crystal Structure of O-actetyl Homoserine Sulfhydrylase From Thermus Thermophilus HB8,OAH2.
6OIH	;	3.85	;	Crystal structure of O-antigen polysaccharide ABC-transporter
8HIU	;	2.99	;	Crystal structure of O-carbamoyltransferase VtdB and the compound VtdB with carbamoyladenylate from Streptomyces sp. NO1W98
6ELC	;	1.41	;	Crystal Structure of O-linked Glycosylated VSG3
5I2H	;	1.551	;	Crystal structure of O-methyltransferase family 2 protein Plim_1147 from Planctomyces limnophilus DSM 3776 complex with Apigenin
3R3H	;	2.65	;	Crystal structure of O-methyltransferase from Legionella pneumophila
5B3A	;	2.14	;	Crystal Structure of O-Phoshoserine Sulfhydrylase from Aeropyrum pernix in Complexed with the alpha-Aminoacrylate Intermediate
1WKV	;	2.0	;	Crystal structure of O-phosphoserine sulfhydrylase
3VSA	;	2.07	;	Crystal Structure of O-phosphoserine sulfhydrylase without acetate
3AM1	;	2.4	;	Crystal structure of O-Phosphoseryl-tRNA kinase complexed with anticodon-stem/loop truncated tRNA(Sec)
3ADB	;	2.8	;	Crystal structure of O-phosphoseryl-tRNA kinase complexed with selenocysteine tRNA and AMPPNP (crystal type 1)
3ADC	;	2.9	;	Crystal structure of O-phosphoseryl-tRNA kinase complexed with selenocysteine tRNA and AMPPNP (crystal type 2)
3ADD	;	2.4	;	Crystal structure of O-phosphoseryl-tRNA kinase complexed with selenocysteine tRNA and AMPPNP (crystal type 3)
2OPJ	;	1.6	;	Crystal structure of O-succinylbenzoate synthase
2QVH	;	1.76	;	Crystal structure of O-succinylbenzoate synthase complexed with O-succinyl benzoate (OSB)
3CAW	;	1.87	;	Crystal structure of o-succinylbenzoate synthase from Bdellovibrio bacteriovorus liganded with Mg
2OZT	;	1.42	;	Crystal structure of O-succinylbenzoate synthase from Thermosynechococcus elongatus BP-1
3H7V	;	1.7	;	CRYSTAL STRUCTURE OF O-SUCCINYLBENZOATE SYNTHASE FROM THERMOSYNECHOCOCCUS ELONGATUS BP-1 complexed with MG in the active site
3H70	;	1.6	;	Crystal structure of o-succinylbenzoic acid synthetase from staphylococcus aureus Complexed with mg in the active site
2OLA	;	2.45	;	Crystal structure of O-succinylbenzoic acid synthetase from Staphylococcus aureus, cubic crystal form
2OKT	;	1.3	;	Crystal structure of O-succinylbenzoic acid synthetase from Staphylococcus aureus, ligand-free form
3IPL	;	2.3	;	CRYSTAL STRUCTURE OF o-succinylbenzoic acid-CoA ligase FROM Staphylococcus aureus subsp. aureus Mu50
3NDN	;	1.85	;	Crystal structure of O-succinylhomoserine sulfhydrylase from Mycobacterium tuberculosis covalently bound to pyridoxal-5-phosphate
3X43	;	2.25	;	Crystal structure of O-ureido-L-serine synthase
3X44	;	1.9	;	Crystal structure of O-ureido-L-serine-bound K43A mutant of O-ureido-L-serine synthase
7VDY	;	2.12	;	Crystal structure of O-ureidoserine racemase
1WRJ	;	2.0	;	Crystal structure of O6-methylguanine methyltransferase from Sulfolobus tokodaii
7DQT	;	1.13	;	Crystal structure of O6-methylguanine methyltransferase Y91F variant
1MGT	;	1.8	;	CRYSTAL STRUCTURE OF O6-METHYLGUANINE-DNA METHYLTRANSFERASE FROM HYPERTHERMOPHILIC ARCHAEON PYROCOCCUS KODAKARAENSIS STRAIN KOD1
2HEK	;	1.997	;	Crystal structure of O67745, a hypothetical protein from Aquifex aeolicus at 2.0 A resolution.
1FCJ	;	2.0	;	CRYSTAL STRUCTURE OF OASS COMPLEXED WITH CHLORIDE AND SULFATE
6Z4N	;	1.2	;	CRYSTAL STRUCTURE OF OASS COMPLEXED WITH UPAR INHIBITOR
2F8P	;	1.93	;	Crystal structure of obelin following Ca2+ triggered bioluminescence suggests neutral coelenteramide as the primary excited state
4FOZ	;	2.4	;	Crystal Structure of OccD1 (OprD) Y282R/D307H
2PVQ	;	1.803	;	Crystal structure of Ochrobactrum anthropi glutathione transferase Cys10Ala mutant with glutathione bound at the H-site
8JEP	;	1.7	;	Crystal structure of Ociperlimab
4CMN	;	3.13	;	Crystal structure of OCRL in complex with a phosphate ion
3QBT	;	2.0	;	Crystal structure of OCRL1 540-678 in complex with Rab8a:GppNHp
1E3O	;	1.9	;	Crystal structure of Oct-1 POU dimer bound to MORE
1SP3	;	2.2	;	Crystal structure of octaheme cytochrome c from Shewanella oneidensis
8RV0	;	1.55	;	Crystal structure of octaheme nitrite reductase from Trichlorobacter ammonificans in complex with nitrite
8RXU	;	1.737	;	Crystal structure of octaheme nitrite reductase from Trichlorobacter ammonificans in space group P21
8RVM	;	1.6	;	Crystal structure of octaheme nitrite reductase from Trichlorobacter ammonificans in space group P63
1W6T	;	2.1	;	Crystal Structure Of Octameric Enolase From Streptococcus pneumoniae
5YOL	;	2.2	;	Crystal structure of octameric form of Nucleoside diphosphate kinase from Acinetobacter baumannii at 2.2 A resolution
3B07	;	2.495	;	Crystal structure of octameric pore form of gamma-hemolysin from Staphylococcus aureus
2CWX	;	2.0	;	Crystal structure of octameric ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco) from Pyrococcus horikoshii OT3 (form-1 crystal)
2CXE	;	3.0	;	Crystal structure of octameric ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco) from Pyrococcus horikoshii OT3 (form-2 crystal)
7EFV	;	2.77	;	Crystal structure of octameric state of C-phycocyanin from Thermoleptolyngbya sp. O-77
7LBJ	;	1.85	;	Crystal structure of octaprenyl diphosphate synthase from Stenotrophomonas maltophilia
3WJK	;	2.2	;	Crystal structure of Octaprenyl Pyrophosphate synthase from Escherichia coli
5ZE6	;	2.5	;	CRYSTAL STRUCTURE OF OCTAPRENYL PYROPHOSPHATE SYNTHASE FROM ESCHERICHIA COLI WITH BPH-981
3WJN	;	2.6	;	Crystal structure of Octaprenyl Pyrophosphate synthase from Escherichia coli with farnesyl S-thiol-pyrophosphate (FSPP)
3WJO	;	2.45	;	Crystal structure of Octaprenyl Pyrophosphate synthase from Escherichia coli with isopentenyl pyrophosphate (IPP)
5ZLF	;	2.845	;	CRYSTAL STRUCTURE OF OCTAPRENYL PYROPHOSPHATE SYNTHASE FROM ESCHERICHIA COLI WITH ligand BPH-629
3TC1	;	2.0	;	Crystal Structure of Octaprenyl Pyrophosphate Synthase from Helicobacter pylori
1V4E	;	2.28	;	Crystal Structure of Octaprenyl Pyrophosphate Synthase from Hyperthermophilic Thermotoga maritima
1VG2	;	3.1	;	Crystal Structure Of Octaprenyl Pyrophosphate Synthase From Hyperthermophilic Thermotoga Maritima A76Y mutant
1VG3	;	2.7	;	Crystal Structure Of Octaprenyl Pyrophosphate Synthase From Hyperthermophilic Thermotoga Maritima A76Y/S77F mutant
1V4I	;	2.4	;	Crystal Structure of Octaprenyl Pyrophosphate Synthase from Hyperthermophilic Thermotoga maritima F132A mutant
1VG4	;	3.3	;	Crystal Structure Of Octaprenyl Pyrophosphate Synthase From Hyperthermophilic Thermotoga Maritima F132A/L128A mutant
1VG6	;	3.35	;	Crystal Structure Of Octaprenyl Pyrophosphate Synthase From Hyperthermophilic Thermotoga Maritima F132A/L128A/I123A mutant
1VG7	;	3.4	;	Crystal Structure Of Octaprenyl Pyrophosphate Synthase From Hyperthermophilic Thermotoga Maritima F132A/L128A/I123A/D62A mutant
1V4H	;	2.8	;	Crystal Structure of Octaprenyl Pyrophosphate Synthase from Hyperthermophilic Thermotoga maritima F52A mutant
1WL1	;	3.45	;	Crystal Structure Of Octaprenyl Pyrophosphate Synthase From Hyperthermophilic Thermotoga Maritima H74A mutant
1WKZ	;	3.4	;	Crystal Structure Of Octaprenyl Pyrophosphate Synthase From Hyperthermophilic Thermotoga Maritima K41A mutant
1WL0	;	3.2	;	Crystal Structure Of Octaprenyl Pyrophosphate Synthase From Hyperthermophilic Thermotoga Maritima R44A mutant
1WL2	;	2.8	;	Crystal Structure Of Octaprenyl Pyrophosphate Synthase From Hyperthermophilic Thermotoga Maritima R90A mutant
1WL3	;	3.5	;	Crystal Structure Of Octaprenyl Pyrophosphate Synthase From Hyperthermophilic Thermotoga Maritima R91A mutant
1V4K	;	2.45	;	Crystal Structure of Octaprenyl Pyrophosphate Synthase from Hyperthermophilic Thermotoga maritima S77F mutant
1V4J	;	2.85	;	Crystal Structure of Octaprenyl Pyrophosphate Synthase from Hyperthermophilic Thermotoga maritima V73Y mutant
5B7C	;	2.35	;	Crystal structure of octopus S-crystallin Q108F mutant in complex with glutathione
5MZH	;	2.398	;	Crystal structure of ODA16 from Chlamydomonas reinhardtii
5BWA	;	3.2	;	Crystal structure of ODC-PLP-AZ1 ternary complex
1KM6	;	1.5	;	Crystal structure of ODCase mutant D70AK72A complexed with OMP
1KM5	;	1.5	;	Crystal structure of ODCase mutant D75N complexed with 6-azaUMP
1KM3	;	1.5	;	crystal structure of ODCase mutant K42A complexed with 6-azaUMP
1KM4	;	1.5	;	crystal structure of ODCase mutant K72A complexed with UMP
4QCJ	;	2.0	;	Crystal Structure of OdhI from Corynebacterium glutamicum
3K1E	;	1.85	;	Crystal structure of odorant binding protein 1 (AaegOBP1) from Aedes aegypti
8BY4	;	2.0	;	Crystal structure of Odorant Binding Protein 1 from Aedes albopictus (Asian tiger mosquito)
3N7H	;	1.6	;	Crystal structure of Odorant Binding Protein 1 from Anopheles gambiae (AgamOBP1) with DEET (N,N-Diethyl-meta-toluamide) and PEG
5EL2	;	1.75	;	Crystal structure of Odorant Binding Protein 1 from Anopheles gambiae (AgamOBP1) with Icaridin (butan-2-yl 2-(2-hydroxyethyl)piperidine-1-carboxylate)
8C68	;	2.05	;	CRYSTAL STRUCTURE OF ODORANT BINDING PROTEIN 4 FROM ANOPHELES GAMBIAE (AGAMOBP4) AT PH 4.6
8C6G	;	2.05	;	CRYSTAL STRUCTURE OF ODORANT BINDING PROTEIN 4 FROM ANOPHELES GAMBIAE (AGAMOBP4) AT PH 6.5
8C6E	;	2.05	;	CRYSTAL STRUCTURE OF ODORANT BINDING PROTEIN 4 FROM ANOPHELES GAMBIAE (AGAMOBP4) AT PH 8.5
6JPM	;	2.098	;	Crystal Structure of Odorant Binding Protein 4 in the Natural Predator Chrysopa pallens
4IJ7	;	2.25	;	Crystal structure of Odorant Binding Protein 48 from Anopheles gambiae (AgamOBP48) with PEG
4KYN	;	3.3	;	Crystal structure of odorant binding protein 48 from Anopheles gambiae at 3.3 Angstrom resolution
8BXW	;	1.3	;	Crystal structure of Odorant Binding Protein 5 from Anopheles gambiae (AgamOBP5) with Carvacrol
8BXU	;	1.35	;	Crystal structure of Odorant Binding Protein 5 from Anopheles gambiae (AgamOBP5) with MPD (2-Methyl-2,4-pentanediol)
8BXV	;	1.3	;	Crystal structure of Odorant Binding Protein 5 from Anopheles gambiae (AgamOBP5) with Thymol
6Q7O	;	2.0	;	Crystal structure of OE1
6Q7P	;	1.96	;	Crystal structure of OE1.2
6Q7Q	;	1.9	;	Crystal structure of OE1.3
6Q7R	;	1.5	;	Crystal structure of OE1.3 alkylated with the mechanistic inhibitor 2-bromoacetophenone
4JHL	;	1.7	;	Crystal Structure of of Axe2, an Acetylxylan Esterase from Geobacillus stearothermophilus
4BQ1	;	1.5	;	Crystal structure of of LamAcat from Zobellia galactanivorans
2ONG	;	2.7	;	Crystal Structure of of limonene synthase with 2-fluorogeranyl diphosphate (FGPP).
2ONH	;	2.7	;	Crystal Structure of of limonene synthase with 2-fluorolinalyl diphosphate(FLPP)
4JIB	;	1.72	;	Crystal structure of of PDE2-inhibitor complex
6L1C	;	1.58	;	Crystal Structure Of of PHF20L1 Tudor1 Y24L mutant
6L1I	;	1.849	;	Crystal Structure Of of PHF20L1 Tudor1 Y24W/Y29W mutant
3E7P	;	1.9	;	CRYSTAL STRUCTURE OF of putative methyltransferase from Bacteroides vulgatus ATCC 8482
1Y0M	;	1.2	;	Crystal structure of of the SH3 domain of phospholipase C Gamma-1
5YLB	;	1.79	;	Crystal structure of Ofd2 from Schizosaccharomyces pombe at 1.80 A
5YL6	;	2.0	;	Crystal structure of Ofd2 in complex with 2OG from Schizosaccharomyces pombe
2Q37	;	2.5	;	Crystal structure of OHCU decarboxylase in the presence of (S)-allantoin
1Z9C	;	2.64	;	Crystal structure of OhrR bound to the ohrA promoter: Structure of MarR family protein with operator DNA
7KAX	;	3.514	;	Crystal structure of OhyA(E82A) from Staphylococcus aureus
7KAY	;	1.95	;	Crystal structure of OhyA(E82A)-18:1 complex from Staphylococcus aureus
7KAZ	;	1.854	;	Crystal structure of OhyA(E82A)-18:1/h18:0-FAD complex from Staphylococcus aureus
7KAV	;	1.843	;	Crystal structure of OhyA-PEG400 complex from Staphylococcus aureus
7KAW	;	2.105	;	Crystal structure of OhyA-PEG400-FAD complex from Staphylococcus aureus
4EFV	;	2.32	;	Crystal structure of OIF from Llama seminal plasma
4WRI	;	1.4	;	Crystal structure of okadaic acid binding protein 2.1
7QFX	;	2.8	;	Crystal structure of Old Yellow Enzyme AnOYE8 from Aspergillus niger
4TMB	;	1.8	;	CRYSTAL STRUCTURE of OLD YELLOW ENZYME from CANDIDA MACEDONIENSIS AKU4588
4TMC	;	1.8	;	CRYSTAL STRUCTURE of OLD YELLOW ENZYME from CANDIDA MACEDONIENSIS AKU4588 COMPLEXED with P-HYDROXYBENZALDEHYDE
6AGZ	;	2.0	;	Crystal structure of Old Yellow Enzyme from Pichia sp. AKU4542
1K02	;	2.7	;	Crystal Structure of Old Yellow Enzyme Mutant Gln114Asn
1K03	;	2.7	;	Crystal Structure of Old Yellow Enzyme Mutant Gln114Asn Complexed with Para-hydroxy Benzaldehyde
7FEV	;	1.594	;	Crystal structure of Old Yellow Enzyme6 (OYE6)
5Z70	;	2.91	;	Crystal structure of oleate hydratase from Stenotrophomonas sp. KCTC 12332
2OWN	;	2.0	;	Crystal structure of oleoyl thioesterase (putative) (NP_784467.1) from Lactobacillus plantarum at 2.00 A resolution
6ZI3	;	2.08	;	Crystal structure of OleP-6DEB bound to L-rhamnose
6ZI7	;	2.28	;	Crystal structure of OleP-oleandolide(DEO) bound to L-rhamnose
4XAV	;	2.052	;	Crystal structure of olfactomedin domain from gliomedin
2QR4	;	2.5	;	Crystal structure of oligoendopeptidase-F from Enterococcus faecium
3C5M	;	2.6	;	Crystal structure of oligogalacturonate lyase (VPA0088) from Vibrio parahaemolyticus. Northeast Structural Genomics Consortium Target VpR199
4W8W	;	2.803	;	Crystal structure of oligomeric Cmr4 from Pyrococcus furiosus
2AN9	;	2.35	;	Crystal Structure Of Oligomeric E.coli Guanylate Kinase In Complex With GDP
2ANB	;	2.9	;	Crystal Structure Of Oligomeric E.coli Guanylate Kinase In Complex With GMP
2CJR	;	2.5	;	Crystal structure of oligomerization domain of SARS coronavirus nucleocapsid protein.
6NPO	;	2.4	;	Crystal structure of oligopeptide ABC transporter from Bacillus anthracis str. Ames (substrate-binding domain)
1VR5	;	1.73	;	Crystal structure of Oligopeptide ABC transporter, periplasmic oligopeptide-binding (TM1223) from THERMOTOGA MARITIMA at 1.73 A resolution
5HM4	;	2.0	;	Crystal structure of oligopeptide ABC transporter, periplasmic oligopeptide-binding protein (TM1226) from THERMOTOGA MARITIMA at 2.0 A resolution
7VH4	;	2.3	;	Crystal structure of oligoribonuclease of Escherichia coli
7WIK	;	1.87	;	Crystal structure of oligoribonuclease of Mycobacterium smegmatis mc2 155
1YTA	;	2.2	;	Crystal Structure of Oligoribonuclease, the lone essential exoribonuclease in Escherichia coli
6F1E	;	2.296	;	Crystal structure of olive flounder [Paralichthys olivaceus] interferon gamma at 2.3 Angstrom resolution
7SFN	;	2.1	;	Crystal structure of OlmO, a spirocyclase involved in the biosynthesis of oligomycin
1IRQ	;	1.5	;	Crystal structure of omega transcriptional repressor at 1.5A resolution
3A8U	;	1.4	;	Crystal Structure of omega-Amino Acid:Pyruvate Aminotransferase
4BA5	;	1.76	;	Crystal structure of omega-transaminase from Chromobacterium violaceum
3NUI	;	2.0	;	Crystal structure of omega-transferase from Vibrio Fluvialis JS17
7XAZ	;	3.0	;	Crystal structure of Omicron BA.1.1 RBD complexed with hACE2
7XB0	;	2.9	;	Crystal structure of Omicron BA.2 RBD complexed with hACE2
7XB1	;	2.7	;	Crystal structure of Omicron BA.3 RBD complexed with hACE2
8GPY	;	2.51	;	Crystal structure of Omicron BA.4/5 RBD in complex with a neutralizing antibody scFv
7AM8	;	2.04	;	Crystal structure of Omniligase mutant W189F
5O78	;	2.85	;	Crystal structure of Omp35 from Enterobacter aerogenes
5O9C	;	2.469	;	Crystal structure of Omp36 from Enterobacter aerogenes
4G4Y	;	1.7	;	Crystal structure of OmpA peptidoglycan-binding domain from Acinetobacter baumannii
4G4Z	;	1.8	;	Crystal structure of OmpA peptidoglycan-binding domain from Acinetobacter baumannii
4G88	;	1.7	;	Crystal structure of OmpA peptidoglycan-binding domain from Acinetobacter baumannii
3TD4	;	1.79	;	Crystal structure of OmpA-like domain from Acinetobacter baumannii in complex with diaminopimelate
3TD3	;	1.59	;	Crystal structure of OmpA-like domain from Acinetobacter baumannii in complex with glycine
3TD5	;	2.0	;	Crystal structure of OmpA-like domain from Acinetobacter baumannii in complex with L-Ala-gamma-D-Glu-m-DAP-D-Ala-D-Ala
4JFB	;	3.801	;	Crystal structure of OmpF in C2 with tNCS
3O0E	;	3.01	;	Crystal structure of OmpF in complex with colicin peptide OBS1
6ZHP	;	2.053	;	Crystal structure of OmpF porin soaked in ciprofloxacin metaloantibiotic
6ZHV	;	1.945	;	Crystal structure of OmpF porin soaked in ciprofloxacin metaloantibiotic
3NSG	;	2.79	;	Crystal Structure of OmpF, an Outer Membrane Protein from Salmonella typhi
7Q5C	;	2.717	;	Crystal structure of OmpG in space group 96
7V1D	;	1.87	;	Crystal structure of Omsk hemorrhagic fever virus NS5 MTase (in complex with SAH and GpppA)
7V1J	;	1.98	;	Crystal structure of Omsk hemorrhagic fever virus NS5 MTase (in complex with SAH and m7GpppA)
7V1E	;	1.59	;	Crystal structure of Omsk hemorrhagic fever virus NS5 MTase (in complex with SAH and m7GpppAmG)
7V1B	;	1.45	;	Crystal structure of Omsk hemorrhagic fever virus NS5 MTase (in complex with SAH)
7V1F	;	2.0	;	Crystal structure of Omsk hemorrhagic fever virus NS5 MTase (in complex with SAM and GTP)
7V1H	;	2.0	;	Crystal structure of Omsk hemorrhagic fever virus NS5 MTase (in complex with SAM and m7GTP)
7FJT	;	1.4	;	Crystal structure of Omsk hemorrhagic fever virus NS5 MTase (in complex with SAM)
7V1C	;	1.95	;	Crystal structure of Omsk hemorrhagic fever virus NS5 MTase (in complex with SIN)
7V1G	;	1.38	;	Crystal structure of Omsk hemorrhagic fever virus NS5 MTase (with a GMP-Arg28 adduct and in complex with SAM)
7V1I	;	2.06	;	Crystal structure of Omsk hemorrhagic fever virus NS5 MTase (with an m7GMP-Arg28 adduct and in complex with SAH)
1DS3	;	1.65	;	CRYSTAL STRUCTURE OF OMTKY3-CH2-ASP19I
4K3J	;	2.8	;	Crystal structure of Onartuzumab Fab in complex with MET and HGF-beta
7LZ5	;	1.5	;	Crystal structure of oncogenic KRAS Q61E GMPPCP-bound
4CKI	;	2.116	;	Crystal Structure of oncogenic RET tyrosine kinase M918T bound to adenosine
6V6V	;	1.4	;	Crystal structure of oncogenic RhoA mutant G14V complexed with GDP
4O7K	;	1.748	;	Crystal structure of Oncogenic Suppression Activity Protein - A Plasmid Fertility Inhibition Factor
4OVB	;	2.034	;	Crystal structure of Oncogenic Suppression Activity Protein - A Plasmid Fertility Inhibition Factor, Gold (I) Cyanide derivative
3FD7	;	1.531	;	Crystal structure of Onconase C87A/C104A-ONC
3U01	;	1.12	;	Crystal structure of onconase double mutant C30A/C75A at 1.12 A resolution
2GMK	;	1.65	;	Crystal structure of onconase double mutant with spontaneously-assembled (AMP) 4 stack
2I5S	;	1.9	;	Crystal structure of onconase with bound nucleic acid
3U89	;	0.96	;	Crystal structure of one turn of g/c rich b-dna revisited
5GTG	;	1.7	;	Crystal structure of onion lachrymatory factor synthase (LFS) containing 1,2-propanediol
5GTF	;	1.8	;	Crystal structure of onion lachrymatory factor synthase (LFS) containing glycerol
5GTE	;	2.0	;	Crystal structure of onion lachrymatory factor synthase (LFS), solute-free form
4X68	;	1.68	;	Crystal Structure of OP0595 complexed with AmpC
4X69	;	1.42	;	Crystal structure of OP0595 complexed with CTX-M-44
4YFU	;	1.5	;	Crystal structure of open Bacillus fragment DNA polymerase bound to DNA and dTTP
3BZM	;	1.95	;	Crystal Structure of Open form of Menaquinone-Specific Isochorismate Synthase, MenF
3BZN	;	2.0	;	Crystal Structure of Open form of Menaquinone-Specific Isochorismate Synthase, MenF
4DK2	;	1.47	;	Crystal Structure of Open Trypanosoma brucei dUTPase
3S4U	;	3.3	;	Crystal structure of open, unliganded E. coli PhnD H157A
5A9P	;	1.476	;	Crystal structure of Operophtera brumata CPV18 polyhedra
5A99	;	1.511	;	Crystal structure of Operophtera brumata CPV19 polyhedra
5N0P	;	2.16	;	Crystal structure of OphA-DeltaC18 in complex with SAH
5N0Q	;	2.402	;	Crystal structure of OphA-DeltaC6 in complex with SAH
5N0X	;	1.67	;	Crystal structure of OphA-DeltaC6 in complex with SAM
5N0U	;	1.68	;	Crystal structure of OphA-DeltaC6 mutant R72A in complex with SAH
5N0W	;	1.93	;	Crystal structure of OphA-DeltaC6 mutant R72A in complex with SAM
5N4I	;	1.59	;	Crystal structure of OphA-DeltaC6 mutant W400A in complex with SAM
5OUF	;	1.7	;	Crystal structure of OphA-DeltaC6 mutant W400A in complex with Sinefungin
5N0N	;	1.76	;	Crystal structure of OphA-DeltaC6 mutant Y63F in complex with SAM
5N0R	;	1.61	;	Crystal structure of OphA-DeltaC6 mutant Y66F in complex with SAM
5N0V	;	1.91	;	Crystal structure of OphA-DeltaC6 mutant Y76F in complex with SAH
5N0T	;	1.78	;	Crystal structure of OphA-DeltaC6 mutant Y76F in complex with SAM
5N0S	;	1.95	;	Crystal structure of OphA-DeltaC6 mutant Y98A in complex with SAM
3FTO	;	2.38	;	Crystal structure of OppA in a open conformation
3VTV	;	1.7	;	Crystal structure of Optineurin LIR-fused human LC3B_2-119
5B83	;	2.694	;	Crystal structure of Optineurin UBAN in complex with linear ubiquitin
5WQ4	;	3.0	;	Crystal structure of OPTN and linear diubiquitin complex
5EOA	;	2.503	;	Crystal structure of OPTN E50K mutant and TBK1 complex
5EOF	;	2.05	;	Crystal structure of OPTN NTD and TBK1 CTD complex
5NXX	;	2.2	;	Crystal structure of OpuAC from B. subtilis in complex with Arsenobetaine
5NXY	;	1.9	;	Crystal structure of OpuAC from B. subtilis in complex with Arsenobetaine
6EYL	;	1.5	;	Crystal structure of OpuBC in complex with carnitine
5UI2	;	2.1	;	CRYSTAL STRUCTURE OF ORANGE CAROTENOID PROTEIN
5TUW	;	2.302	;	Crystal structure of Orange Carotenoid Protein with partial loss of 3'OH Echinenone chromophore
5C8H	;	2.01	;	Crystal structure of ORC2 C-terminal domain
6JQT	;	1.8	;	Crystal structure of ordered Asn70 and Asn116 in native peptidyl t-RNA hydrolase from Acinetobacter baumannii at 1.80 Angstrom resolution.
7YPV	;	2.415	;	Crystal structure of OrE-ST-F
2HQ1	;	1.9	;	Crystal Structure of ORF 1438 a putative Glucose/ribitol dehydrogenase from Clostridium thermocellum
2HQ4	;	1.99	;	Crystal Structure of ORF 1580 a hypothetical protein from Pyrococcus horikoshii
2P84	;	1.8	;	Crystal structure of ORF041 from Bacteriophage 37
3D8L	;	2.9	;	Crystal structure of ORF12 from the lactococcus lactis bacteriophage p2
2X5T	;	2.2	;	Crystal structure of ORF131 from Sulfolobus islandicus rudivirus 1
3FBL	;	1.95	;	Crystal structure of ORF132 of the archaeal virus Acidianus Filamentous Virus 1 (AFV1)
2X4J	;	1.62	;	Crystal structure of ORF137 from Pyrobaculum spherical virus
3FBZ	;	2.3	;	Crystal structure of ORF140 of the archaeal virus Acidianus Filamentous Virus 1 (AFV1)
3ILE	;	3.3	;	Crystal structure of ORF157-E86A of Acidianus filamentous virus 1
2OA5	;	2.1	;	Crystal structure of ORF52 from Murid herpesvirus (MUHV-4) (Murine gammaherpesvirus 68) at 2.1 A resolution. Northeast Structural Genomics Consortium target MHR28B.
2H3R	;	2.7	;	Crystal structure of ORF52 from Murid herpesvirus 4 (MuHV-4) (Murine gammaherpesvirus 68). Northeast Structural Genomics Consortium target MhR28B.
3R87	;	1.05	;	Crystal Structure of Orf6 protein from Photobacterium profundum
4I45	;	1.4	;	Crystal Structure of Orf6 protein from Photobacterium profundum, Mg2+-bound form
4FAK	;	1.7	;	Crystal Structure of OrfX in Complex with S-Adenosylmethionine
8FBE	;	1.73	;	Crystal structure of OrfX1 from Clostridium botulinum E1
8FBD	;	2.05	;	Crystal structure of OrfX1-OrfX3 complex from Clostridium botulinum E1
8FBF	;	1.85	;	Crystal structure of OrfX2 from Clostridium botulinum E1
3L7G	;	2.7	;	Crystal structure of organophosphate anhydrolase/prolidase
4ZWO	;	2.141	;	Crystal structure of organophosphate anhydrolase/prolidase mutant Y212F
4ZWP	;	2.397	;	Crystal structure of organophosphate anhydrolase/prolidase mutant Y212F
4ZWU	;	2.2	;	Crystal structure of organophosphate anhydrolase/prolidase mutant Y212F, V342L, I215Y
3RVA	;	1.8	;	Crystal structure of organophosphorus acid anhydrolase from Alteromonas macleodii
3F4D	;	2.36	;	Crystal structure of organophosphorus hydrolase from Geobacillus stearothermophilus strain 10
3F4C	;	2.07	;	Crystal structure of organophosphorus hydrolase from Geobacillus stearothermophilus strain 10, with glycerol bound
5A8U	;	1.609	;	Crystal structure of Orgyia pseudotsugata CPV5 polyhedra
5A8V	;	2.074	;	Crystal structure of Orgyia pseudotsugata CPV5 polyhedra with SeMet substitution
3KP1	;	2.01	;	Crystal structure of ornithine 4,5 aminomutase (Resting State)
3KOW	;	2.9	;	Crystal Structure of ornithine 4,5 aminomutase backsoaked complex
3KOX	;	2.4	;	Crystal Structure of ornithine 4,5 aminomutase in complex with 2,4-diaminobutyrate (Anaerobic)
3KP0	;	2.8	;	Crystal Structure of ORNITHINE 4,5 AMINOMUTASE in complex with 2,4-diaminobutyrate (DAB) (Aerobic)
3KOY	;	2.8	;	Crystal Structure of ornithine 4,5 aminomutase in complex with ornithine (Aerobic)
3KOZ	;	2.8	;	Crystal Structure of ornithine 4,5 aminomutase in complex with ornithine (Anaerobic)
1VLV	;	2.25	;	Crystal structure of Ornithine carbamoyltransferase (TM1097) from Thermotoga maritima at 2.25 A resolution
2I6U	;	2.2	;	Crystal Structure of Ornithine Carbamoyltransferase complexed with Carbamoyl Phosphate and L-Norvaline from Mycobacterium tuberculosis (Rv1656) at 2.2 A
4OH7	;	1.5	;	Crystal structure of Ornithine carbamoyltransferase from Brucella melitensis
3GD5	;	2.1	;	Crystal structure of ornithine carbamoyltransferase from Gloeobacter violaceus
7TMD	;	2.35	;	Crystal structure of Ornithine carbamoyltransferase from Klebsiella pneumoniae
2P2G	;	2.7	;	Crystal Structure of Ornithine Carbamoyltransferase from Mycobacterium Tuberculosis (Rv1656): Orthorhombic Form
6OVW	;	1.903	;	Crystal structure of ornithine carbamoyltransferase from Salmonella enterica
2EF0	;	2.0	;	Crystal structure of ornithine carbamoyltransferase from thermus thermophilus
4AIB	;	2.87	;	Crystal Structure of Ornithine Decarboxylase from Entamoeba histolytica.
8QEV	;	1.55	;	Crystal structure of ornithine transcarbamylase from Arabidopsis thaliana (AtOTC) in complex with carbamoyl phosphate
8QEU	;	1.5	;	Crystal structure of ornithine transcarbamylase from Arabidopsis thaliana (AtOTC) in complex with ornithine
7UOC	;	2.3	;	Crystal structure of Orobanche minor KAI2d4
1STO	;	2.6	;	CRYSTAL STRUCTURE OF OROTATE PHOSPHORIBOSYLTRANSFERASE
4OHC	;	1.85	;	Crystal structure of orotate phosphoribosyltransferase (OPRTase) from Burkholderia cenocepacia
2YZK	;	1.8	;	Crystal structure of orotate phosphoribosyltransferase from Aeropyrum pernix
3DEZ	;	2.4	;	Crystal structure of Orotate phosphoribosyltransferase from Streptococcus mutans
2AEE	;	1.95	;	Crystal structure of Orotate phosphoribosyltransferase from Streptococcus pyogenes
1LOR	;	1.6	;	crystal structure of orotidine 5'-monophosphate complexed with BMP
2ZA1	;	2.65	;	Crystal Structure of orotidine 5'-monophosphate decarboxylase complexed with orotidine 5'-monophosphate from P.falciparum
2ZA3	;	2.65	;	Crystal Structure of orotidine 5'-monophosphate decarboxylase complexed with uridine 5'-monophosphate from P.falciparum
4N2Y	;	1.549	;	Crystal structure of orotidine 5'-monophosphate decarboxylase from Archaeoglobus fulgidus
4MUZ	;	1.39	;	Crystal structure of orotidine 5'-monophosphate decarboxylase from Archaeoglobus fulgidus complexed with inhibitor BMP
1DBT	;	2.4	;	CRYSTAL STRUCTURE OF OROTIDINE 5'-MONOPHOSPHATE DECARBOXYLASE FROM BACILLUS SUBTILIS COMPLEXED WITH UMP
3VE9	;	1.45	;	Crystal structure of orotidine 5'-monophosphate decarboxylase from Metallosphaera sedula
3VE7	;	1.539	;	Crystal structure of orotidine 5'-monophosphate decarboxylase from Metallosphaera sedula complexed with inhibitor BMP
3G18	;	1.6	;	Crystal structure of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum
4NT0	;	1.769	;	Crystal structure of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with 3-deazauridine 5'-monophosphate
3G1F	;	2.5	;	Crystal structure of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with 5,6-dihydroorotidine 5'-monophosphate
3G1H	;	2.3	;	Crystal structure of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with 5,6-dihydrouridine 5'-monophosphate
4O8R	;	2.293	;	Crystal structure of orotidine 5'-monophosphate decarboxylase from methanobacterium thermoautotrophicum complexed with 5,6-dihydrouridine 5'-monophosphate
3G1A	;	1.5	;	Crystal structure of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with 6-azauridine 5'-monophosphate
4NX5	;	1.591	;	Crystal structure of orotidine 5'-monophosphate decarboxylase from methanobacterium thermoautotrophicum complexed with 6-azauridine 5'-monophosphate
4O11	;	1.59	;	Crystal structure of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with 6-hydroxyuridine 5'-monophosphate
3LTP	;	1.4	;	Crystal structure of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
3G1D	;	1.5	;	Crystal structure of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with uridine 5'-monophosphate
4NUW	;	1.591	;	Crystal structure of orotidine 5'-monophosphate decarboxylase from methanobacterium thermoautotrophicum complexed with uridine 5'-monophosphate
4LUI	;	1.6	;	Crystal structure of Orotidine 5'-monophosphate decarboxylase from methanocaldococcus jannaschii
4LUJ	;	1.6	;	Crystal structure of Orotidine 5'-monophosphate decarboxylase from methanocaldococcus jannaschii complexed with inhibitor BMP
4DBD	;	1.699	;	Crystal structure of orotidine 5'-monophosphate decarboxylase from Sulfolobus solfataricus
4DBE	;	1.789	;	Crystal structure of orotidine 5'-monophosphate decarboxylase from Sulfolobus solfataricus complexed with inhibitor BMP
4DF0	;	1.5	;	Crystal structure of orotidine 5'-monophosphate decarboxylase from Thermoproteus neutrophilus
4DF1	;	1.899	;	Crystal structure of orotidine 5'-monophosphate decarboxylase from Thermoproteus neutrophilus complexed with inhibitor BMP
1DQW	;	2.1	;	CRYSTAL STRUCTURE OF OROTIDINE 5'-PHOSPHATE DECARBOXYLASE
1VQT	;	2.0	;	Crystal structure of Orotidine 5'-phosphate decarboxylase (TM0332) from Thermotoga maritima at 2.00 A resolution
1DQX	;	2.4	;	CRYSTAL STRUCTURE OF OROTIDINE 5'-PHOSPHATE DECARBOXYLASE COMPLEXED TO 6-HYDROXYURIDINE 5'-PHOSPHATE (BMP)
8CSO	;	2.6	;	Crystal Structure of Orotidine 5'-phosphate decarboxylase from Klebsiella pneumoniae in complex with Uridine-5'-monophosphate
3TFX	;	2.19	;	Crystal structure of Orotidine 5'-phosphate decarboxylase from Lactobacillus acidophilus
2Q8L	;	2.1	;	Crystal structure of orotidine 5'-phosphate decarboxylase from Plasmodium falciparum
2CZ5	;	1.85	;	Crystal structure of orotidine 5'-phosphate decarboxylase from Pyrococcus horikoshii OT3
2CZD	;	1.6	;	Crystal structure of orotidine 5'-phosphate decarboxylase from Pyrococcus horikoshii OT3 at 1.6 A resolution
2CZE	;	1.85	;	Crystal structure of orotidine 5'-phosphate decarboxylase from Pyrococcus horikoshii OT3 complexed with UMP
2CZF	;	1.85	;	Crystal structure of orotidine 5'-phosphate decarboxylase from Pyrococcus horikoshii OT3 complexed with XMP
3R89	;	1.844	;	Crystal structure of orotidine 5-phosphate decarboxylase from Anaerococcus prevotii DSM 20548
1DV7	;	1.8	;	CRYSTAL STRUCTURE OF OROTIDINE MONOPHOSPHATE DECARBOXYLASE
1LOL	;	1.9	;	Crystal structure of orotidine monophosphate decarboxylase complex with XMP
1DVJ	;	1.5	;	CRYSTAL STRUCTURE OF OROTIDINE MONOPHOSPHATE DECARBOXYLASE COMPLEXED WITH 6-AZAUMP
1LP6	;	1.9	;	Crystal structure of orotidine monophosphate decarboxylase complexed with CMP
1LOQ	;	1.5	;	Crystal structure of orotidine monophosphate decarboxylase complexed with product UMP
1KLZ	;	1.5	;	Crystal structure of orotidine monophosphate decarboxylase mutant D70A complexed with UMP
1KM0	;	1.7	;	Crystal structure of orotidine monophosphate decarboxylase mutant D70N complexed with 6-azaUMP
1LOS	;	1.9	;	crystal structure of orotidine monophosphate decarboxylase mutant deltaR203A complexed with 6-azaUMP
1KM2	;	1.5	;	crystal structure of orotidine monophosphate mutant Q185A with 6-azaUMP
5ZM7	;	3.401	;	Crystal structure of ORP1-ORD in complex with cholesterol at 3.4 A resolution
5ZM6	;	2.7	;	Crystal structure of ORP1-ORD in complex with PI(4,5)P2
5ZM8	;	2.7	;	Crystal structure of ORP2-ORD in complex with PI(4,5)P2
5U77	;	2.157	;	Crystal structure of ORP8 PH domain
5U78	;	1.978	;	Crystal structure of ORP8 PH domain in P1211 space group
3KYT	;	2.35	;	Crystal structure of orphan nuclear receptor RORgamma in complex with natural ligand
3L0J	;	2.4	;	Crystal structure of orphan nuclear receptor RORgamma in complex with natural ligand
3L0L	;	1.74	;	Crystal structure of orphan nuclear receptor RORgamma in complex with natural ligand
5W82	;	1.8	;	Crystal structure of Orsay virus delta protein N-terminal fragment (aa 1-101)
4NWV	;	3.25	;	Crystal structure of Orsay virus-like particle
1JJA	;	2.3	;	CRYSTAL STRUCTURE OF ORTHORHOMBIC FORM OF D90E MUTANT OF ESCHERICHIA COLI L-ASPARAGINASE II
1JJ1	;	1.9	;	CRYSTAL STRUCTURE OF ORTHORHOMBIC LYSOZYME GROWN AT PH 4.6 IN PRESENCE OF 5% SORBITOL
6S7N	;	1.2	;	Crystal structure of orthorhombic lysozyme grown at pH 5.5 with a 26% of solvent content
1F0W	;	1.9	;	CRYSTAL STRUCTURE OF ORTHORHOMBIC LYSOZYME GROWN AT PH 6.5
1F10	;	1.7	;	CRYSTAL STRUCTURE OF ORTHORHOMBIC LYSOZYME GROWN AT PH 6.5 AT 88% RELATIVE HUMIDITY
6SYE	;	0.97	;	Crystal structure of orthorhombic lysozyme in presence of the dye bromophenol blue at pH 7.0
5XFH	;	1.903	;	Crystal structure of Orysata lectin in complex with biantennary N-glycan
5H3G	;	1.6	;	Crystal Structure of Oryza sativa Acyl-CoA-Binding Protein 1
5H3I	;	2.302	;	Crystal Structure of Oryza sativa Acyl-CoA-Binding Protein 2
3W04	;	1.45	;	Crystal structure of Oryza sativa DWARF14 (D14)
3W05	;	1.58	;	Crystal structure of Oryza sativa DWARF14 (D14) in complex with PMSF
4KVK	;	1.98	;	Crystal structure of Oryza sativa fatty acid alpha-dioxygenase
4KVJ	;	2.12	;	Crystal structure of Oryza sativa fatty acid alpha-dioxygenase with hydrogen peroxide
4KVL	;	1.96	;	Crystal structure of Oryza sativa fatty acid alpha-dioxygenase Y379F with palmitic acid
5ZQT	;	2.84	;	Crystal structure of Oryza sativa hexokinase 6
7D6A	;	1.7	;	Crystal structure of Oryza sativa Os4BGlu18 monolignol beta-glucosidase
7D6B	;	2.1	;	Crystal structure of Oryza sativa Os4BGlu18 monolignol beta-glucosidase with delta-gluconolactone
7XOF	;	2.56	;	Crystal structure of Oryza sativa plastid glycyl-tRNA synthetase
6KHO	;	1.972	;	Crystal structure of Oryza sativa TDC with PLP
6KHN	;	2.293	;	Crystal structure of Oryza sativa TDC with PLP and SEROTONIN
6KHP	;	2.299	;	Crystal structure of Oryza sativa TDC with PLP and tryptamine
8CID	;	3.6	;	Crystal structure of Oryza sativa UAM 2
6LK7	;	1.903	;	crystal structure of Os1348 from Pseudomonas sp. Os17
5TMD	;	2.19	;	Crystal structure of Os79 from O. sativa in complex with U2F and trichothecene.
6BK3	;	2.17	;	Crystal structure of Os79 from O. sativa in complex with UDP and deoxynivalenol-3-glucoside (glucose moitey not resolved)
5TMB	;	2.34	;	Crystal structure of Os79 from O. sativa in complex with UDP.
5TME	;	1.78	;	Crystal structure of Os79 from O. sativa in complex with UDP.
6BK2	;	1.68	;	Crystal structure of Os79 H122A/L123A from O. sativa in complex with UDP.
6BK0	;	1.47	;	Crystal structure of Os79 Q202A from O. sativa in complex with UDP.
6BK1	;	1.58	;	Crystal structure of Os79 T291V from O. sativa in complex with UDP.
5JCD	;	2.4	;	Crystal structure of OsCEBiP
5JCE	;	2.51	;	Crystal structure of OsCEBiP complex
7XED	;	2.5	;	Crystal Structure of OsCIE1-Ubox and OsUBC8 complex
3VXK	;	1.75	;	Crystal structure of OsD14
5ZHS	;	1.49	;	Crystal structure of OsD14 in complex with covalently bound KK052
5ZHT	;	1.532	;	Crystal structure of OsD14 in complex with covalently bound KK073
5ZHR	;	1.45	;	Crystal structure of OsD14 in complex with covalently bound KK094
5YZ7	;	1.898	;	Crystal structure of OsD14 in complex with D-ring-opened 7'-carba-4BD
3WIO	;	2.1	;	Crystal structure of OSD14 in complex with hydroxy D-ring
7DK8	;	1.99	;	Crystal structure of OsGH3-8 with AMP
5H2A	;	1.9	;	Crystal structure of Osh1 ANK domain from Kluyveromyces lactis
5H28	;	1.5	;	Crystal structure of Osh1 ANK domain from Saccharomyces cerevisia
5WVR	;	2.2	;	Crystal structure of Osh1 ORD domain in complex with cholesterol
5H2D	;	1.6	;	Crystal structure of Osh1 ORD domain in complex with ergosterol
4IC4	;	1.5	;	Crystal structure of Osh3 ORD from Saccharomyces cerevisiae
4INQ	;	2.2	;	Crystal structure of Osh3 ORD in complex with PI(4)P from Saccharomyces cerevisiae
6JJ4	;	2.6	;	Crystal structure of OsHXK6-apo form
6JJ8	;	2.8	;	Crystal structure of OsHXK6-ATP-Mg2+ complex
6JJ7	;	2.9	;	Crystal structure of OsHXK6-Glc complex
6JJ9	;	3.0	;	Crystal structure of OsHXK6-Glc-ATP-Mg2+ complex
1NYE	;	2.4	;	Crystal structure of OsmC from E. coli
1LQL	;	2.85	;	Crystal structure of OsmC like protein from Mycoplasma pneumoniae
4MH4	;	1.9	;	Crystal Structure of OsmC-like protein from Burkholderia cenocepacia J2315
1PCV	;	2.3	;	Crystal structure of osmotin, a plant antifungal protein
4L2J	;	1.61	;	Crystal Structure of Osmotin, an antifungal laticifer protein
2I5V	;	1.1	;	Crystal structure of OspA mutant
3AUM	;	1.6	;	Crystal structure of OspA mutant
7WR4	;	2.75	;	Crystal structure of OspC3-calmodulin-caspase-4 complex
7WR5	;	3.1	;	Crystal structure of OspC3-calmodulin-caspase-4 complex binding with 2'-aF-NAD+
7D3T	;	2.7	;	Crystal structure of OSPHR2 in complex with DNA
3B21	;	2.01	;	Crystal structure of OspI from Shigella flexineri
5ZCL	;	2.661	;	Crystal structure of OsPP2C50 I267L:OsPYL/RCAR3 with (+)-ABA
5ZCH	;	2.474	;	Crystal structure of OsPP2C50 I267W:OsPYL/RCAR3 with (+)-ABA
5ZCG	;	2.1	;	Crystal structure of OsPP2C50 S265L/I267V:OsPYL/RCAR3 with (+)-ABA
7SFP	;	2.2	;	Crystal structure of OssO, a spirocyclase involved in the biosynthesis of ossamycin
6J0D	;	1.9	;	Crystal structure of OsSUF4
3GA4	;	1.3	;	Crystal structure of Ost6L (photoreduced form)
6JMN	;	2.5	;	Crystal structure of Ostrinia furnacalis Chitinase h complexed with compound 2-8-s2
3WL0	;	2.204	;	Crystal structure of Ostrinia furnacalis Group I chitinase catalytic domain E148A mutant in complex with a(GlcNAc)2
3WQV	;	2.043	;	Crystal structure of Ostrinia furnacalis Group I chitinase catalytic domain in complex with a(GlcN)5
3WQW	;	2.0	;	Crystal structure of Ostrinia furnacalis Group I chitinase catalytic domain in complex with a(GlcN)6
3WL1	;	1.772	;	Crystal structure of Ostrinia furnacalis Group I chitinase catalytic domain in complex with reaction products (GlcNAc)2,3
5Y29	;	1.8	;	Crystal structure of Ostrinia furnacalis Group II chitinase catalytic domain 1
6JAY	;	1.498	;	Crystal structure of Ostrinia furnacalis Group II chitinase catalytic domain 1 in complex with a dipyrido-pyrimidine derivative
6JAW	;	1.981	;	Crystal structure of Ostrinia furnacalis Group II chitinase catalytic domain 1 in complex with a napthalimide derivative
6JAV	;	1.437	;	Crystal structure of Ostrinia furnacalis Group II chitinase catalytic domain 1 in complex with a piperidine-thienopyridine derivative
6JAX	;	1.7	;	Crystal structure of Ostrinia furnacalis Group II chitinase catalytic domain 1 in complex with chitooctaose [(GlcN)8]
5Y2B	;	2.2	;	Crystal structure of Ostrinia furnacalis Group II chitinase catalytic domain 1 in complex with HEPTA-N-ACETYLCHITOOCTAOSE (NAG)7
5Y2A	;	1.9	;	Crystal structure of Ostrinia furnacalis Group II chitinase catalytic domain 2
5Y2C	;	2.45	;	Crystal structure of Ostrinia furnacalis Group II chitinase catalytic domain 2 E2180L mutant in complex with PENTA-N-ACETYLCHITOOCTAOSE (NAG)5
6JM7	;	1.572	;	Crystal structure of Ostrinia furnacalis Group IV chitinase
6JM8	;	1.911	;	Crystal structure of Ostrinia furnacalis Group IV chitinase
6JMB	;	1.389	;	Crystal structure of Ostrinia furnacalis Group IV chitinase in complex with allosamidin
5EE0	;	2.2	;	Crystal structure of OsYchF1 at pH 6.5
5EE1	;	2.55	;	Crystal structure of OsYchF1 at pH 7.85
3UOV	;	2.045	;	Crystal Structure of OTEMO (FAD bound form 1)
3UOX	;	1.956	;	Crystal Structure of OTEMO (FAD bound form 2)
3UOY	;	2.0	;	Crystal Structure of OTEMO complex with FAD and NADP (form 1)
3UOZ	;	2.407	;	Crystal Structure of OTEMO complex with FAD and NADP (form 2)
3UP4	;	2.804	;	Crystal Structure of OTEMO complex with FAD and NADP (form 3)
3UP5	;	2.453	;	Crystal Structure of OTEMO complex with FAD and NADP (form 4)
4I6L	;	2.488	;	Crystal structure of OTUB1 in complex with ubiquitin variant
3ZNZ	;	1.9	;	Crystal structure of OTULIN OTU domain (C129A) in complex with Met1- di ubiquitin
6I5B	;	2.2	;	Crystal Structure of Outer Cell Wall Cytochrome OcwA
8BZ2	;	1.7	;	Crystal structure of outer membrane attachment porin OmpM1 SLH domain
1THQ	;	1.9	;	Crystal Structure of Outer Membrane Enzyme PagP
5MDQ	;	2.5	;	Crystal structure of outer membrane expressed Chitoporin VhChip from Vibrio harveyi
5MDS	;	2.6	;	Crystal structure of outer membrane expressed Chitoporin VhChip from Vibrio harveyi in complex with chitotetraose
8T5T	;	1.8	;	Crystal structure of outer membrane lipoprotein carrier protein (LolA) from Borrelia burgdorferi (steric acid bound)
9AZZ	;	2.0	;	Crystal structure of outer membrane lipoprotein carrier protein (LolA) from Ehrlichia ruminantium
8T5J	;	1.55	;	Crystal structure of outer membrane lipoprotein carrier protein (LolA) from Francisella philomiragia
8V1K	;	1.8	;	Crystal structure of outer membrane lipoprotein carrier protein (LolA) from Francisella tularensis
8VEH	;	2.6	;	Crystal structure of outer membrane lipoprotein carrier protein (LolA) from Rickettsia bellii
1I78	;	2.6	;	CRYSTAL STRUCTURE OF OUTER MEMBRANE PROTEASE OMPT FROM ESCHERICHIA COLI
3VZT	;	2.3	;	Crystal Structure of outer membrane protein PorB from Neisseria meningitidis
3VZU	;	2.9	;	Crystal Structure of outer membrane protein PorB from Neisseria meningitidis in complex with AMP-PNP
3VZW	;	3.2	;	Crystal Structure of outer membrane protein PorB from Neisseria meningitidis in complex with galactose
3A2S	;	2.2	;	Crystal Structure of outer membrane protein PorB from Neisseria meningitidis in complex with sucrose
7DE8	;	2.76	;	Crystal Structure of outer membrane protein PorB with G103K mutations from Neisseria meningitidis W135
4N74	;	2.9	;	Crystal Structure of Outer Membrane Protein TamA beta-barrel Domain in E.coli
1OSP	;	1.95	;	CRYSTAL STRUCTURE OF OUTER SURFACE PROTEIN A OF BORRELIA BURGDORFERI COMPLEXED WITH A MURINE MONOCLONAL ANTIBODY FAB
7QDV	;	1.9	;	Crystal structure of outer surface protein BBA14 (OrfD) from Borrelia burgdorferi
1F1M	;	1.8	;	CRYSTAL STRUCTURE OF OUTER SURFACE PROTEIN C (OSPC)
7BML	;	1.85	;	Crystal structure of outer surface protein C (OspC) from Borrelia burgdorferi
7NEN	;	1.98	;	Crystal structure of outer surface protein C (OspC) from Borrelia garinii
7QRN	;	1.83	;	Crystal structure of Ovalbumin-related protein X (OVAX) complexed with fondaparinux
4O1Z	;	2.4	;	Crystal Structure of Ovine Cyclooxygenase-1 Complex with Meloxicam
4LUF	;	2.3	;	Crystal Structure of Ovine Serum Albumin
5Z0Q	;	2.77	;	Crystal Structure of OvoB
3LCE	;	2.0	;	Crystal Structure of Oxa-10 Beta-Lactamase Covalently Bound to Cyclobutanone Beta-Lactam Mimic
6RTN	;	2.17	;	Crystal structure of OXA-10 with VNRX-5133
6ZRH	;	1.88	;	Crystal structure of OXA-10loop24 in complex with ertapenem
6ZRI	;	1.6	;	Crystal structure of OXA-10loop24 in complex with meropenem
6ZRG	;	1.74	;	Crystal structure of OXA-10loop48 in complex with hydrolyzed doripenem
6ZW2	;	1.75	;	Crystal structure of OXA-10loop48 in complex with hydrolyzed meropenem
4S2L	;	1.72	;	Crystal Structure of OXA-163 beta-lactamase
4S2M	;	2.87	;	Crystal Structure of OXA-163 complexed with iodide in the active site
7KHZ	;	2.04	;	Crystal structure of OXA-163 K73A in complex with imipenem
7KHY	;	1.84	;	Crystal structure of OXA-163 K73A in complex with meropenem
5HFO	;	2.21	;	CRYSTAL STRUCTURE OF OXA-232 BETA-LACTAMASE
3ZNT	;	1.95	;	Crystal structure of OXA-24 class D beta-lactamase with tazobactam
5FDH	;	2.26	;	CRYSTAL STRUCTURE OF OXA-405 BETA-LACTAMASE
6HUH	;	2.78	;	CRYSTAL STRUCTURE OF OXA-427 class D BETA-LACTAMASE
4GN2	;	2.01	;	Crystal Structure of OXA-45, a Class D beta-lactamase with extended spectrum activity
3IF6	;	2.4	;	Crystal structure of OXA-46 beta-lactamase from P. aeruginosa
3HBR	;	1.9	;	Crystal structure of OXA-48 beta-lactamase
7AUX	;	2.05	;	Crystal structure of OXA-48 beta-lactamase in the complex with the inhbitor ID2
7AW5	;	1.65	;	Crystal structure of OXA-48 beta-lactamase in the complex with the inhibitor ID3
7KH9	;	2.29	;	Crystal structure of OXA-48 K73A in complex with imipenem
7KHQ	;	2.0	;	Crystal structure of OXA-48 K73A in complex with meropenem
6PK0	;	1.75	;	Crystal Structure of OXA-48 with Hydrolyzed Imipenem
6HB8	;	1.86	;	Crystal structure of OXA-517 beta-lactamase
4OH0	;	1.3	;	Crystal structure of OXA-58 carbapenemase
4Z9Q	;	2.23	;	Crystal structure of OXA-58 with disordered active site
5BOH	;	1.8	;	Crystal Structure of OXA-58 with the Substrate-Binding Cleft in a Closed State
4Y0O	;	2.37	;	Crystal structure of OXA-58, a carbapenem hydrolyzing Class D beta-lactamase from Acinetobacter baumanii.
5MMY	;	1.88	;	Crystal structure of OXA10 with HEPES
5W7P	;	2.4	;	Crystal structure of OxaC
5W7R	;	2.497	;	Crystal structure of OxaC in complex with SAH and oxaline
5W7S	;	2.948	;	Crystal structure of OxaC in complex with sinefungin and meleagrin
5W7K	;	1.994	;	Crystal structure of OxaG
1J58	;	1.75	;	Crystal Structure of Oxalate Decarboxylase
1UW8	;	2.0	;	CRYSTAL STRUCTURE OF OXALATE DECARBOXYLASE
1L3J	;	1.9	;	Crystal Structure of Oxalate Decarboxylase Formate Complex
5EXD	;	2.5	;	Crystal structure of oxalate oxidoreductase from Moorella thermoacetica bound with carboxy-di-oxido-methyl-TPP (COOM-TPP) intermediate
5EXE	;	1.88	;	Crystal structure of oxalate oxidoreductase from Moorella thermoacetica bound with carboxy-TPP adduct
3LYE	;	1.3	;	Crystal structure of oxaloacetate acetylhydrolase
4WLO	;	2.5	;	Crystal structure of oxaloacetate and NADH bound MDH2
3B8I	;	1.9	;	Crystal Structure of Oxaloacetate Decarboxylase from Pseudomonas Aeruginosa (PA4872) in complex with oxalate and Mg2+.
2Q27	;	2.12	;	Crystal structure of oxalyl-coA decarboxylase from Escherichia coli
2Q29	;	1.82	;	Crystal structure of oxalyl-coA decarboxylase from Escherichia coli in complex with acetyl coenzyme A
2Q28	;	1.74	;	Crystal structure of oxalyl-coA decarboxylase from Escherichia coli in complex with adenosine-5`-diphosphate
2C31	;	1.73	;	CRYSTAL STRUCTURE OF OXALYL-COA DECARBOXYLASE IN COMPLEX WITH THE COFACTOR DERIVATIVE THIAMIN-2-THIAZOLONE DIPHOSPHATE AND ADENOSINE DIPHOSPHATE
2QRL	;	1.6	;	Crystal Structure of Oxalylglycine-bound Saccharopine Dehydrogenase (L-Lys Forming) from Saccharomyces cerevisiae
7F30	;	2.0	;	Crystal structure of OxdB E85A in complex with Z-2- (3-bromophenyl) propanal oxime
7F2Y	;	1.55	;	Crystal structure of OxdB E85A mutant (form I)
7F2Z	;	2.3	;	Crystal structure of OxdB E85A mutant (form II)
8I1M	;	1.699	;	Crystal structure of oxidated APSK1 domain from human PAPSS1 in complex with APS and ADP
3W2F	;	1.76	;	Crystal structure of oxidation intermediate (10 min) of NADH-cytochrome b5 reductase from pig liver
3W2H	;	1.752	;	Crystal structure of oxidation intermediate (1min) of NADH-cytochrome b5 reductase from pig liver
3W2E	;	2.1	;	Crystal structure of oxidation intermediate (20 min) of NADH-cytochrome b5 reductase from pig liver
6GAR	;	2.4	;	Crystal structure of oxidised ferredoxin/flavodoxin NADP+ oxidoreductase 1 (FNR1) from Bacillus cereus
6GAS	;	2.4	;	Crystal structure of oxidised ferredoxin/flavodoxin NADP+ oxidoreductase 2 (FNR2) from Bacillus cereus
6FSG	;	1.27	;	Crystal structure of oxidised Flavodoxin 1 from Bacillus cereus (1.27 A resolution)
6FT1	;	1.4	;	Crystal structure of oxidised Flavodoxin 1 from Bacillus cereus (1.4 A resolution)
6GAQ	;	2.5	;	Crystal structure of oxidised Flavodoxin 2 from Bacillus cereus
4YF6	;	3.002	;	Crystal structure of oxidised Rv1284
3HOM	;	2.3	;	Crystal structure of oxidized A66C mutant of Human acidic fibroblast growth factor
6LYX	;	1.696	;	Crystal structure of oxidized ACHT1
1Z8U	;	2.4	;	Crystal structure of oxidized alpha hemoglobin bound to AHSP
6R7P	;	3.22	;	Crystal structure of oxidized Aquifex aeolicus NADH-quinone oxidoreductase subunits NuoE and NuoF S96M
5VWU	;	2.75	;	Crystal structure of oxidized Aspergillus fumigatus UDP-galactopyranose mutase complexed with NADH
5VWT	;	2.75	;	Crystal structure of oxidized Aspergillus fumigatus UDP-galactopyranose mutase complexed with NADPH
3ICR	;	2.1	;	Crystal structure of oxidized Bacillus anthracis CoADR-RHD
1XLN	;	2.03	;	Crystal structure of oxidized C73S/C85S putidaredoxin, a [2Fe-2S] ferredoxin from Pseudomonas putida
5B8A	;	2.7	;	Crystal structure of oxidized chimeric EcAhpC1-186-YFSKHN
2H6B	;	2.2	;	Crystal structure of oxidized CprK in complex with o-chlorophenolacetic acid
5YRC	;	1.67	;	Crystal Structure of Oxidized Cypovirus Polyhedra R13A/E73C/Y83C Mutant
5YRB	;	1.65	;	Crystal Structure of Oxidized Cypovirus Polyhedra R13A/E73C/Y83C/S193C/A194C Mutant
5YRD	;	1.85	;	Crystal Structure of Oxidized Cypovirus Polyhedra R13A/S193C/A194C Mutant
1GU2	;	1.19	;	Crystal structure of oxidized cytochrome c'' from Methylophilus methylotrophus
1C6O	;	2.0	;	CRYSTAL STRUCTURE OF OXIDIZED CYTOCHROME C6 FROM THE GREEN ALGAE SCENEDESMUS OBLIQUUS
2DGE	;	1.5	;	Crystal structure of oxidized cytochrome C6A from Arabidopsis thaliana
3F0L	;	1.3	;	Crystal structure of oxidized D105N Synechocystis sp. PcyA
5H2G	;	2.0	;	Crystal structure of oxidized DapF from Corynebacterium glutamicum
5D9V	;	1.69	;	Crystal structure of oxidized dehydroascorbate reductase (OsDHAR) from Oryza sativa L. japonica
2FCR	;	1.8	;	CRYSTAL STRUCTURE OF OXIDIZED FLAVODOXIN FROM A RED ALGA CHONDRUS CRISPUS REFINED AT 1.8 ANGSTROMS RESOLUTION: DESCRIPTION OF THE FLAVIN MONONUCLEOTIDE BINDING SITE
2FA4	;	2.38	;	Crystal Structure of Oxidized Form from Saccharomyces cerevisiae
4N44	;	1.77	;	Crystal structure of oxidized form of thiolase from Clostridium acetobutylicum
4XL2	;	1.77	;	Crystal structure of oxidized form of thiolase from Clostridium acetobutylicum
7NCW	;	2.4	;	Crystal structure of oxidized glutaredoxin 2 from Chlamydomonas reinhardtii
3C1R	;	2.0	;	Crystal structure of oxidized GRX1
3CTF	;	2.1	;	Crystal structure of oxidized GRX2
3NB8	;	1.3	;	Crystal structure of oxidized H88Q Synechocystis sp. PCYA
4M90	;	1.6	;	crystal structure of oxidized hN33/Tusc3
4YDR	;	1.6	;	Crystal structure of oxidized homoserine dehydrogenase of Sulfolobus tokodaii
4EL1	;	2.883	;	Crystal structure of oxidized hPDI (abb'xa')
2COG	;	2.1	;	Crystal structure of oxidized human cytosolic branched-chain aminotransferase complexed with 4-methylvalerate
2COI	;	1.9	;	Crystal structure of oxidized human cytosolic branched-chain aminotransferase complexed with gabapentin
3U9J	;	1.603	;	Crystal structure of oxidized human FBXL5 hemerythrin like domain
4ENO	;	2.8	;	Crystal structure of oxidized human nm23-H1
6Q1B	;	1.596	;	Crystal structure of oxidized iodotyrosine deiodinase (IYD) bound to FMN and 3-fluoro-L-tyrosine
6Q1L	;	1.6	;	Crystal structure of oxidized iodotyrosine deiodinase (IYD) bound to FMN and 3-iodo-L-tyrosine
6PZ0	;	1.8	;	Crystal structure of oxidized iodotyrosine deiodinase (IYD) bound to FMN and L-Tyrosine
4N6N	;	1.87	;	Crystal structure of oxidized legumain in complex with cystatin E/M
1OSD	;	2.0	;	crystal structure of Oxidized MerP from Ralstonia metallidurans CH34
3G7Y	;	2.215	;	Crystal structure of oxidized Ost6L
6KEW	;	2.29	;	Crystal structure of oxidized phosphoribulokinase from Arabidopsis thaliana
4NMC	;	1.901	;	Crystal structure of oxidized proline utilization A (PutA) from Geobacter sulfurreducens PCA complexed with Zwittergent 3-12
5K2I	;	1.481	;	Crystal structure of Oxidized Prx3 from Vibrio vulnificus
1M70	;	1.25	;	Crystal structure of oxidized recombinant cytochrome c4 from Pseudomonas stutzeri
8QG1	;	2.0	;	Crystal structure of oxidized respiratory Complex I subunits NuoEF from Aquifex aeolicus bound to ADP-ribose
8QGW	;	1.6	;	Crystal structure of oxidized respiratory Complex I subunits NuoEF from Aquifex aeolicus bound to oxidized 3-acetylpyridine adenine dinucleotide
4GL4	;	1.8	;	Crystal structure of oxidized S-nitrosoglutathione reductase from Arabidopsis thalina, complex with NADH
2XC2	;	1.56	;	Crystal structure of oxidized Schistosoma mansoni Thioredoxin pre- protein at 1.6 Angstrom
4B5N	;	1.1	;	Crystal structure of oxidized Shewanella Yellow Enzyme 4 (SYE4)
5K1K	;	1.301	;	Crystal structure of oxidized Shewanella Yellow Enzyme 4 (SYE4) in complex with p-hydroxybenzaldehyde
5K1M	;	1.5	;	Crystal structure of oxidized Shewanella Yellow Enzyme 4 (SYE4) in complex with p-methoxyphenol
5K1Q	;	1.55	;	Crystal structure of oxidized Shewanella Yellow Enzyme 4 (SYE4) in complex with p-methylphenol
5K1W	;	1.6	;	Crystal structure of oxidized Shewanella Yellow Enzyme 4 (SYE4) in complex with trinitrophenol
3QHB	;	1.2	;	Crystal structure of oxidized Symerythrin from Cyanophora paradoxa
3SID	;	1.4	;	Crystal structure of oxidized Symerythrin from Cyanophora paradoxa, azide adduct at 50% occupancy
1XR2	;	2.35	;	Crystal Structure of oxidized T. maritima Cobalamin-Independent Methionine Synthase complexed with Methyltetrahydrofolate
2YZU	;	1.9	;	Crystal structure of oxidized thioredoxin from Thermus thermophilus HB8
4DSG	;	2.249	;	Crystal Structure of oxidized UDP-Galactopyranose mutase
5EQF	;	2.145	;	Crystal structure of oxidized UDP-galactopyranose mutase from Corynebacterium diphtheriae with UDP bound in closed form
7KM4	;	2.65	;	Crystal Structure of Oxidized Version of Redox-Sensitive Superfolder Green Fluorescent Protein
1Z41	;	1.3	;	Crystal structure of oxidized YqjM from Bacillus subtilis
1Z42	;	1.85	;	Crystal structure of oxidized YqjM from Bacillus subtilis complexed with p-hydroxybenzaldehyde
1Z44	;	1.4	;	Crystal structure of oxidized YqjM from Bacillus subtilis complexed with p-nitrophenol
3BIO	;	1.8	;	Crystal structure of oxidoreductase (Gfo/Idh/MocA family member) from Porphyromonas gingivalis W83
5WJS	;	2.15	;	Crystal structure of oxidoreductase (short chain dehydrogenase/reductase family) from Burkholderia thailandensis complexed with NADH
1ZH8	;	2.5	;	Crystal structure of Oxidoreductase (TM0312) from Thermotoga maritima at 2.50 A resolution
4H3V	;	1.68	;	Crystal structure of oxidoreductase domain protein from Kribbella flavida
2REM	;	1.9	;	Crystal Structure of oxidoreductase DsbA from Xylella fastidiosa
4JXK	;	2.0	;	Crystal Structure of Oxidoreductase ROP_24000 (Target EFI-506400) from Rhodococcus opacus B4
6N1F	;	2.05	;	Crystal structure of Oxidoreductase, 2OG-Fe(II) oxygenase family, from Burkholderia pseudomallei
2HO5	;	2.56	;	Crystal structure of Oxidoreductase, Gfo/Idh/MocA family from Streptococcus pneumoniae
4IQ0	;	2.0	;	Crystal structure of oxidoreductase, Gfo/Idh/MocA family from Streptococcus pneumoniae with reductive methylated Lysine
8QC3	;	2.65	;	Crystal structure of oxidoreductive sulfoquinovosidase from Arthrobacter sp. U41 (ArSqgA)in complex with co-factor NAD+
5KHY	;	3.501	;	Crystal structure of oxime-linked K6 diubiquitin
3TYH	;	2.1	;	Crystal structure of oxo-cupper clusters binding to ferric binding protein from Neisseria gonorrhoeae
7VRF	;	1.7	;	Crystal structure of Oxpecker chromodomain in complex with H3K9me3
1F65	;	1.7	;	CRYSTAL STRUCTURE OF OXY SPERM WHALE MYOGLOBIN MUTANT Y(B10)Q(E7)R(E10)
3BCQ	;	2.4	;	Crystal structure of oxy-hemoglobin from Brycon cephalus
1R1X	;	2.15	;	Crystal structure of oxy-human hemoglobin Bassett at 2.15 angstrom
7L3Y	;	1.18	;	Crystal structure of oxy-I107E CuB myoglobin (I107E L29H F43H sperm whale myoglobin; partial occupancy)
1LFK	;	1.7	;	Crystal structure of OxyB, a Cytochrome P450 Implicated in an Oxidative Phenol Coupling Reaction During Vancomycin Biosynthesis
1LG9	;	2.0	;	Crystal structure of OxyB, a Cytochrome P450 Implicated in an Oxidative Phenol Coupling Reaction During Vancomycin Biosynthesis
1LGF	;	2.2	;	Crystal structure of OxyB, a Cytochrome P450 Implicated in an Oxidative Phenol Coupling Reaction During Vancomycin Biosynthesis
1UED	;	1.9	;	Crystal Structure of OxyC a Cytochrome P450 Implicated in an Oxidative C-C Coupling Reaction During Vancomycin Biosynthesis.
3S1I	;	1.77	;	Crystal structure of oxygen-bound hell's gate globin I
8T7W	;	1.55	;	Crystal structure of Oxygen-dependent coproporphyrinogen-III oxidase (hemF) from Klebsiella aerogenes
4YUU	;	2.77	;	Crystal structure of oxygen-evolving photosystem II from a red alga
1HBI	;	1.7	;	CRYSTAL STRUCTURE OF OXYGENATED SCAPHARCA DIMERIC HEMOGLOBIN AT 1.7 ANGSTROMS RESOLUTION
3HO7	;	1.58	;	Crystal structure of OxyR from Porphyromonas gingivalis
3T22	;	2.2	;	Crystal structure of OxyR mutant from Porphyromonas gingivalis
8J48	;	1.94	;	Crystal structure of OY phytoplasma SAP05 in complex with AtGATA18
8J4A	;	1.97	;	Crystal structure of OY phytoplasma SAP05 in complex with AtRPN10
8J4B	;	2.0	;	Crystal structure of OY phytoplasma SAP05 in complex with AtSPL13
8J49	;	1.66	;	Crystal structure of OY phytoplasma SAP05 in complex with AtSPL5
3PUM	;	2.252	;	Crystal structure of P domain dimer of Norovirus VA207
3PVD	;	1.9	;	Crystal structure of P domain dimer of Norovirus VA207 complexed with 3'-sialyl-Lewis x tetrasaccharide
3PUN	;	2.05	;	Crystal structure of P domain dimer of Norovirus VA207 with Lewis y tetrasaccharide
6J0Q	;	2.0	;	Crystal structure of P domain from GII.11 swine norovirus
3ASP	;	1.6	;	Crystal structure of P domain from Norovirus Funabashi258 stain in the complex with A-antigen
3ASQ	;	1.6	;	Crystal structure of P domain from Norovirus Funabashi258 stain in the complex with H-antigen
3ASR	;	1.6	;	Crystal structure of P domain from Norovirus Funabashi258 stain in the complex with Lewis-a
3ASS	;	1.6	;	Crystal structure of P domain from Norovirus Funabashi258 stain in the complex with Lewis-b
8I5L	;	2.7	;	Crystal structure of P domain from norovirus GI.4 capsid protein in complex with broad specificity antibody single-chain Fv fragment CV-2F5.
7VS8	;	2.4	;	Crystal structure of P domain from norovirus GI.9 capsid protein in complex with Lewis b antigen.
7VS9	;	2.26	;	Crystal structure of P domain from norovirus GI.9 capsid protein in complex with Lewis x antigen.
7VP0	;	2.1	;	Crystal structure of P domain from norovirus GI.9 capsid protein.
4OOV	;	1.53	;	Crystal structure of P domain from norovirus strain Farmington Hills 2004
4X05	;	1.98	;	Crystal structure of P domain from norovirus strain Farmington Hills 2004 in complex with HBGA type B (triglycan)
4OPS	;	1.76	;	Crystal structure of P domain from norovirus strain Farmington Hills 2004 in complex with HBGA type Leb (tetraglycan)
4OOS	;	1.64	;	Crystal structure of P domain from norovirus strain NSW0514
4WZT	;	1.91	;	Crystal structure of P domain from norovirus strain NSW0514 in complex with HBGA type A (triglycan)
4OP7	;	1.92	;	Crystal structure of P domain from norovirus strain NSW0514 in complex with HBGA type B (triglycan)
4X0C	;	1.72	;	Crystal structure of P domain from norovirus strain NSW0514 in complex with HBGA type Lex (triglycan)
4OOX	;	1.2	;	Crystal structure of P domain from norovirus strain Saga4
4X07	;	1.46	;	Crystal structure of P domain from norovirus strain Saga4 in complex with HBGA type A (triglycan)
4X06	;	1.218	;	Crystal structure of P domain from norovirus strain Saga4 in complex with HBGA type B (triglycan)
4WZK	;	1.49	;	Crystal structure of P domain from norovirus strain Saga4 in complex with HBGA type H2 (triglycan)
4WZL	;	1.7	;	Crystal structure of P domain from norovirus strain Saga4 in complex with HBGA type Lea (triglycan)
4OPO	;	1.4	;	Crystal structure of P domain from norovirus strain Saga4 in complex with HBGA type Leb (tetraglycan)
4WZE	;	1.46	;	Crystal structure of P domain from norovirus strain Saga4 in complex with HBGA type Ley (tetraglycan)
3ONU	;	1.395	;	Crystal Structure of P Domain from Norwalk Virus Strain Vietnam 026
3Q6Q	;	1.43	;	Crystal Structure of P Domain from Norwalk Virus Strain Vietnam 026 in complex with disordered HBGA type Lea
3Q6R	;	1.4	;	Crystal Structure of P Domain from Norwalk Virus Strain Vietnam 026 in complex with disordered HBGA type Lex
3ONY	;	1.85	;	Crystal Structure of P Domain from Norwalk Virus Strain Vietnam 026 in complex with Fucose
3PA1	;	1.48	;	Crystal Structure of P Domain from Norwalk Virus Strain Vietnam 026 in complex with HBGA type A
3Q38	;	1.28	;	Crystal structure of P domain from norwalk virus strain vietnam 026 in complex with HBGA type B (triglycan)
3Q39	;	1.25	;	Crystal Structure of P Domain from Norwalk Virus Strain Vietnam 026 in complex with HBGA type H2 (diglycan)
3Q3A	;	1.4	;	Crystal Structure of P Domain from Norwalk Virus Strain Vietnam 026 in complex with HBGA type H2 (triglycan)
3PA2	;	1.48	;	Crystal Structure of P Domain from Norwalk Virus Strain Vietnam 026 in complex with HBGA type Ley
4RPD	;	1.51	;	Crystal Structure of P Domain of 485 Norovirus
4ROX	;	1.89	;	Crystal Structure of P Domain of Hawaii Norovirus (GII.1)
4RPB	;	1.61	;	Crystal Structure of P Domain of Snow Mountain Norovirus
3AST	;	1.4	;	Crystal structure of P domain Q389N mutant from Norovirus Funabashi258 stain in the complex with Lewis-b
1ZH6	;	2.5	;	Crystal Structure of p-acetylphenylalanine-tRNA synthetase in complex with p-acetylphenylalanine
4ZJ1	;	1.54	;	Crystal Structure of p-acrylamido-phenylalanine modified TEM1 beta-lactamase from Escherichia coli : V216AcrF mutant
4ZJ2	;	1.8	;	Crystal Structure of p-acrylamido-phenylalanine modified TEM1 beta-lactamase from Escherichia coli :E166N mutant
2AG6	;	1.9	;	Crystal structure of p-bromo-l-phenylalanine-tRNA sythetase in complex with p-bromo-l-phenylalanine
2GC9	;	1.7	;	Crystal structure of p-coumaric acid decarboxylase (NP_786857.1) from Lactobacillus plantarum at 1.70 A resolution
2W2A	;	1.38	;	Crystal Structure of p-coumaric Acid Decarboxylase from Lactobacillus plantarum: structural insights into the active site and decarboxylation catalytic mechanism
1DII	;	2.5	;	CRYSTAL STRUCTURE OF P-CRESOL METHYLHYDROXYLASE AT 2.5 A RESOLUTION
1DIQ	;	2.75	;	CRYSTAL STRUCTURE OF P-CRESOL METHYLHYDROXYLASE WITH SUBSTRATE BOUND
5X3O	;	2.194	;	Crystal structure of p-DiUb-S65-COOH
1PHH	;	2.3	;	CRYSTAL STRUCTURE OF P-HYDROXYBENZOATE HYDROXYLASE COMPLEXED WITH ITS REACTION PRODUCT 3,4-DIHYDROXYBENZOATE
1PDH	;	2.1	;	CRYSTAL STRUCTURE OF P-HYDROXYBENZOATE HYDROXYLASE RECONSTITUTED WITH THE MODIFIED FAD PRESENT IN ALCOHOL OXIDASE FROM METHYLOTROPHIC YEASTS: EVIDENCE FOR AN ARABINOFLAVIN
5DAM	;	1.95	;	Crystal Structure of p-iodoHoechst bound to d(CGCAAATTTGCG)
3QJY	;	2.35	;	Crystal structure of P-loop G234A mutant of subunit A of the A1AO ATP synthase
3QIA	;	2.6	;	Crystal structure of P-loop G237A mutant of subunit A of the A1AO ATP synthase
3QG1	;	2.95	;	Crystal structure of P-loop G239A mutant of subunit A of the A1AO ATP synthase
6AIN	;	2.48	;	Crystal structure of p-nitrophenol 4-monooxygenase PnpA from Pseudomonas putida DLL-E4
6AIO	;	2.04	;	Crystal structure of p-nitrophenol 4-monooxygenase PnpA from Pseudomonas putida DLL-E4
1G1Q	;	2.4	;	Crystal structure of P-selectin lectin/EGF domains
1G1R	;	3.4	;	Crystal structure of P-selectin lectin/EGF domains complexed with SLeX
4OGR	;	3.0	;	crystal structure of P-TEFb complex with AFF4 and Tat
5X3M	;	1.818	;	crystal structure of p-Ub-S65-NH2
2V94	;	1.9	;	Crystal structure of P. abyssi RPS24
6F8Y	;	2.86	;	Crystal structure of P. abyssi Sua5 complexed with L-threonine
6F87	;	2.62	;	Crystal structure of P. abyssi Sua5 complexed with L-threonine and PPi
3LGA	;	2.05	;	Crystal structure of P. abyssi tRNA m1A58 methyltransferase in complex with S-adenosyl-L-homocysteine
3LHD	;	2.59	;	Crystal structure of P. abyssi tRNA m1A58 methyltransferase in complex with S-adenosyl-L-homocysteine
3MB5	;	1.6	;	Crystal structure of P. abyssi tRNA m1A58 methyltransferase in complex with S-adenosyl-L-methionine
3U25	;	1.18	;	Crystal structure of P. aeruginoas azurin containing a Tyr-His hydrogen bonded pair
3U9S	;	3.5	;	Crystal structure of P. aeruginosa 3-methylcrotonyl-CoA carboxylase (MCC) 750 kD holoenzyme, CoA complex
3U9T	;	2.9	;	Crystal structure of P. aeruginosa 3-methylcrotonyl-CoA carboxylase (MCC) 750 kD holoenzyme, free enzyme
3U9R	;	1.5	;	Crystal structure of P. aeruginosa 3-methylcrotonyl-CoA carboxylase (MCC), beta subunit
4WYY	;	1.28	;	Crystal Structure of P. aeruginosa AmpC
4WZ4	;	1.05	;	Crystal structure of P. aeruginosa AmpC
3G6O	;	2.85	;	Crystal structure of P. aeruginosa bacteriophytochrome PaBphP photosensory core domain mutant Q188L
3IBR	;	2.97	;	Crystal Structure of P. aeruginosa Bacteriophytochrome Photosensory Core Module Mutant Q188L in the Mixed Pr/Pfr State
4E37	;	2.53	;	Crystal Structure of P. aeruginosa catalase, KatA tetramer
5IKL	;	2.4	;	Crystal structure of P. aeruginosa geranyl-CoA carboxylase (GCC), beta subunit
7K9A	;	2.0	;	Crystal Structure of P. aeruginosa LpxC with N-Hydroxyformamide inhibitor
7K99	;	1.9	;	Crystal Structure of P. aeruginosa LpxC with N-Hydroxyformamide inhibitor 19
4JAY	;	2.23	;	Crystal structure of P. aeruginosa MurB in complex with NADP+
4JB1	;	2.1	;	Crystal structure of P. aeruginosa MurB in complex with NADP+
1N2F	;	2.01	;	CRYSTAL STRUCTURE OF P. AERUGINOSA OHR
4WZ5	;	1.6	;	Crystal structure of P. aeruginosa OXA10
1LRY	;	2.6	;	Crystal Structure of P. aeruginosa Peptide Deformylase Complexed with Antibiotic Actinonin
4FYJ	;	1.77	;	Crystal Structure of P. aeruginosa peptidyl-tRNA hydrolase
3JVV	;	2.6	;	Crystal Structure of P. aeruginosa PilT with bound AMP-PCP
6SW2	;	1.7	;	Crystal Structure of P. aeruginosa PqsL in complex with 2-aminobenzoylacetate
6SW1	;	1.8	;	Crystal Structure of P. aeruginosa PqsL: R41Y, I43R, G45R, C105G mutant
4R0S	;	2.03	;	Crystal structure of P. aeruginosa TpbA
4R0T	;	2.603	;	Crystal structure of P. aeruginosa TpbA (C132S) in complex with pTyr
8B62	;	2.02	;	Crystal Structure of P. aeruginosa WaaG in complex with UDP-galactose
8B63	;	2.2	;	Crystal Structure of P. aeruginosa WaaG in complex with UDP-GalNAc
8B5S	;	1.95	;	Crystal Structure of P. aeruginosa WaaG in complex with UDP-glucose
8B5Q	;	2.0	;	Crystal Structure of P. aeruginosa WaaG in complex with UMP
1M8P	;	2.6	;	Crystal Structure of P. chrysogenum ATP Sulfurylase in the T-state
3SL0	;	1.997	;	Crystal Structure of P. falciparum arginase complexed with 2-amino-6-borono-2-(difluoromethyl)hexanoic acid
3SL1	;	1.902	;	Crystal Structure of P. falciparum arginase complexed with 2-amino-6-borono-2-methylhexanoic acid
5T8U	;	2.324	;	Crystal structure of P. falciparum LipL1 in complex lipoate
4H02	;	2.905	;	Crystal structure of P. falciparum Lysyl-tRNA synthetase
3S9Y	;	1.7	;	Crystal Structure of P. falciparum orotidine 5'-monophosphate decarboxylase complexed with 5-fluoro-6-amino-UMP in space group P21, produced from 5-fluoro-6-azido-UMP
3BPW	;	1.7	;	Crystal Structure of P. falciparum Orotidine 5'-monophosphate Decarboxylase Complexed with XMP
3DSC	;	2.7	;	Crystal structure of P. furiosus Mre11 DNA synaptic complex
1II7	;	2.2	;	Crystal structure of P. furiosus Mre11 with manganese and dAMP
3DSD	;	2.2	;	Crystal structure of P. furiosus Mre11-H85S bound to a branched DNA and manganese
3CG1	;	1.6	;	Crystal structure of P. furiosus periplasmic binding protein ModA/WtpA with bound tungstate
3CG3	;	1.8	;	Crystal structure of P. horikoshii periplasmic binding protein ModA/WtpA with bound tungstate
2YX0	;	2.21	;	Crystal structure of P. horikoshii TYW1
3A25	;	2.3	;	Crystal structure of P. horikoshii TYW2 in complex with AdoMet
3A26	;	2.5	;	Crystal structure of P. horikoshii TYW2 in complex with MeSAdo
3RYW	;	2.9	;	Crystal structure of P. vivax geranylgeranyl diphosphate synthase complexed with BPH-811
7CI4	;	2.0	;	Crystal structure of P.aeruginosa LpxC in complex with inhibitor
7CI5	;	2.5	;	Crystal structure of P.aeruginosa LpxC in complex with inhibitor
7CI6	;	2.7	;	Crystal structure of P.aeruginosa LpxC in complex with inhibitor
7CI7	;	2.1	;	Crystal structure of P.aeruginosa LpxC in complex with inhibitor
7CI8	;	3.0	;	Crystal structure of P.aeruginosa LpxC in complex with inhibitor
7CI9	;	1.9	;	Crystal structure of P.aeruginosa LpxC in complex with inhibitor
7CIA	;	1.92	;	Crystal structure of P.aeruginosa LpxC in complex with inhibitor
7CIB	;	1.61	;	Crystal structure of P.aeruginosa LpxC in complex with inhibitor
7CIC	;	1.78	;	Crystal structure of P.aeruginosa LpxC in complex with inhibitor
7CID	;	2.49	;	Crystal structure of P.aeruginosa LpxC in complex with inhibitor
7CIE	;	2.15	;	Crystal structure of P.aeruginosa LpxC in complex with inhibitor
7DEL	;	2.15	;	Crystal structure of P.aeruginosa LpxC in complex with inhibitor
7DEM	;	1.9	;	Crystal structure of P.aeruginosa LpxC in complex with inhibitor
7DEN	;	2.07	;	Crystal structure of P.aeruginosa LpxC in complex with inhibitor
3BRE	;	2.4	;	Crystal Structure of P.aeruginosa PA3702
4L0L	;	2.1	;	Crystal structure of P.aeruginosa PBP3 in complex with compound 4
1IX1	;	1.85	;	Crystal Structure of P.aeruginosa Peptide deformylase Complexed with Antibiotic Actinonin
7TCL	;	1.97	;	Crystal structure of P.IsnB complexed with tyrosine isonitrile
1XTL	;	2.0	;	Crystal structure of P104H mutant of SOD-like protein from Bacillus subtilis.
4HRG	;	2.0001	;	Crystal Structure of p11-Annexin A2(N-terminal) Fusion Protein in Complex with AHNAK1 Peptide
4HRH	;	3.001	;	Crystal Structure of p11-Annexin A2(N-terminal) Fusion Protein in Complex with SMARCA3 Peptide
4HRE	;	2.7852	;	Crystal Structure of p11/Annexin A2 Heterotetramer in Complex with SMARCA3 Peptide
4L1B	;	2.586	;	Crystal Structure of p110alpha complexed with niSH2 of p85alpha
4L2Y	;	2.8	;	Crystal Structure of p110alpha complexed with niSH2 of p85alpha and compound 9d
4L23	;	2.501	;	Crystal Structure of p110alpha complexed with niSH2 of p85alpha and PI-103
3HIZ	;	3.3	;	Crystal structure of p110alpha H1047R mutant in complex with niSH2 of p85alpha
3HHM	;	2.8	;	Crystal structure of p110alpha H1047R mutant in complex with niSH2 of p85alpha and the drug wortmannin
4A55	;	3.5	;	Crystal structure of p110alpha in complex with iSH2 of p85alpha and the inhibitor PIK-108
4OVU	;	2.96	;	Crystal Structure of p110alpha in complex with niSH2 of p85alpha
2Y3A	;	3.3	;	Crystal structure of p110beta in complex with icSH2 of p85beta and the drug GDC-0941
5H0Z	;	1.735	;	Crystal structure of P113A mutated human transthyretin
1IAP	;	1.9	;	CRYSTAL STRUCTURE OF P115RHOGEF RGRGS DOMAIN
3AB3	;	2.4	;	Crystal structure of p115RhoGEF RGS domain in complex with G alpha 13
3L6X	;	2.4	;	Crystal structure of p120 catenin in complex with E-cadherin
3L6Y	;	3.0	;	Crystal structure of p120 catenin in complex with E-cadherin
8DGQ	;	1.95	;	Crystal structure of p120RasGAP SH2-SH3-SH2 in complex with p190RhoGAP doubly phosphorylated peptide
1OYH	;	2.62	;	Crystal Structure of P13 Alanine Variant of Antithrombin
2HIJ	;	2.9	;	Crystal Structure of P14 Alanine Variant of Antithrombin
1VET	;	1.9	;	Crystal Structure of p14/MP1 at 1.9 A resolution
2G0F	;	2.2	;	Crystal Structure of P144A mutant of E.coli CcmG protein
1JSG	;	2.5	;	CRYSTAL STRUCTURE OF P14TCL1, AN ONCOGENE PRODUCT INVOLVED IN T-CELL PROLYMPHOCYTIC LEUKEMIA, REVEALS A NOVEL B-BARREL TOPOLOGY
2HQH	;	1.8	;	Crystal structure of p150Glued and CLIP-170
1IHB	;	1.95	;	CRYSTAL STRUCTURE OF P18-INK4C(INK6)
1R9F	;	1.85	;	Crystal structure of p19 complexed with 19-bp small interfering RNA
4J39	;	1.7	;	Crystal structure of p19 in complex with double-helical 19mer RNA p(CAG)3C(CUG)3
4J5V	;	2.15	;	Crystal structure of p19 in complex with double-helical RNA 19mer p(CAG)3C(CCG)3
7MW7	;	1.1	;	Crystal structure of P1G mutant of D-dopachrome tautomerase
4PKZ	;	1.9	;	Crystal structure of P1M mutant of Macrophage Migration Inhibitory Factor
2XCJ	;	1.8	;	Crystal structure of P2 C, the immunity repressor of temperate E. coli phage P2
2ZPK	;	1.8	;	Crystal structure of P20.1 Fab fragment in complex with its antigen peptide
5XCQ	;	1.313	;	Crystal structure of P20.1 Fv-clasp fragment with its antigen peptide
5XCR	;	1.75	;	Crystal structure of P20.1 Fv-clasp fragment with its antigen peptide
5XCT	;	1.17	;	Crystal structure of P20.1 Fv-clasp fragment with its antigen peptide
4L5Q	;	2.23	;	Crystal structure of p202 HIN1
4L5R	;	1.873	;	Crystal structure of p202 HIN1 in complex with 20-mer dsDNA
6OE9	;	1.94	;	Crystal structure of p204 HIN1 domain
5YZP	;	1.581	;	Crystal structure of p204 HINa domain
5YZW	;	2.001	;	Crystal structure of p204 HINb domain
4ZY4	;	2.6	;	Crystal structure of P21 activated kinase 1 in complex with an inhibitor compound 4
5IME	;	2.217	;	Crystal structure of P21-activated kinase 1 (PAK1) in complex with compound 9
4ZY5	;	2.35	;	Crystal Structure of p21-activated kinase 1 in complex with an inhibitor compound 17
4ZY6	;	2.15	;	Crystal structure of P21-activated kinase 1 in complex with an inhibitor compound 29
5BMS	;	2.903	;	Crystal structure of P21-activated kinase 4 in complex with an inhibitor compound 29
6SXN	;	2.66	;	Crystal structure of P212121 apo form of CrtE
2ANV	;	1.04	;	crystal structure of P22 lysozyme mutant L86M
1TSP	;	2.0	;	CRYSTAL STRUCTURE OF P22 TAILSPIKE PROTEIN: INTERDIGITATED SUBUNITS IN A THERMOSTABLE TRIMER
3WOE	;	2.351	;	Crystal structure of P23-45 gp39 (6-109) bound to Thermus thermophilus RNA polymerase beta-flap domain
3WOF	;	3.298	;	Crystal structure of P23-45 gp39 (6-132) bound to Thermus thermophilus RNA polymerase beta-flap domain
5AZW	;	1.5	;	Crystal structure of p24beta1 GOLD domain
5AZX	;	1.58	;	Crystal structure of p24delta1 GOLD domain (native 1)
5AZY	;	1.8	;	Crystal structure of p24delta1 GOLD domain (Native 2)
5GU5	;	2.8	;	Crystal structure of p24gamma2 GOLD domain determined by sulfur-SAD
1XCF	;	1.8	;	Crystal structure of P28L/Y173F tryptophan synthase alpha-subunits from Escherichia coli
4PXZ	;	2.5	;	Crystal structure of P2Y12 receptor in complex with 2MeSADP
4PY0	;	3.1	;	Crystal structure of P2Y12 receptor in complex with 2MeSATP
7QGS	;	2.0	;	Crystal structure of p300 CH1 domain in complex with CITIF (a CITED2-HIF-1alpha hybrid)
3BIY	;	1.7	;	Crystal structure of p300 histone acetyltransferase domain in complex with a bisubstrate inhibitor, Lys-CoA
4PZS	;	1.94	;	Crystal structure of p300 histone acetyltransferase domain in complex with Acetyl-Coenzyme A
4PZT	;	2.8	;	Crystal structure of p300 histone acetyltransferase domain in complex with an inhibitor, Acetonyl-Coenzyme A
4PZR	;	2.099	;	Crystal structure of p300 histone acetyltransferase domain in complex with Coenzyme A
6DS6	;	1.95	;	Crystal structure of p300 ZZ domain in complex with histone H3 peptide
1YQJ	;	2.0	;	Crystal Structure of p38 Alpha in Complex with a Selective Pyridazine Inhibitor
6SFI	;	1.6	;	Crystal structure of p38 alpha in complex with compound 75 (MCP33)
6SFJ	;	1.95	;	Crystal structure of p38 alpha in complex with compound 77 (MCP41)
6SFK	;	1.8	;	Crystal structure of p38 alpha in complex with compound 81 (MCP42)
3NNU	;	2.4	;	Crystal structure of P38 alpha in complex with DP1376
3NNV	;	2.1	;	Crystal structure of P38 alpha in complex with DP437
3NNW	;	1.89	;	Crystal structure of P38 alpha in complex with DP802
4R3C	;	2.06	;	Crystal structure of p38 alpha MAP kinase in complex with a novel isoform selective drug candidate
5LAR	;	1.5	;	Crystal structure of p38 alpha MAPK14 in complex with VPC00628
2PUU	;	2.5	;	Crystal structure of p38 complex with 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)naphthalen-1-yl]urea
2ZAZ	;	1.8	;	Crystal structure of P38 in complex with 4-anilino quinoline inhibitor
3IPH	;	2.1	;	Crystal structure of p38 in complex with a biphenylamide inhibitor
2ZB0	;	2.1	;	Crystal structure of P38 in complex with biphenyl amide inhibitor
2ZB1	;	2.5	;	Crystal structure of P38 in complex with biphenyl amide inhibitor
6YK7	;	1.9	;	Crystal structure of p38 in complex with SR43
6Y4T	;	1.98	;	Crystal structure of p38 in complex with SR63.
6Y4U	;	1.86	;	Crystal structure of p38 in complex with SR65
6Y4V	;	1.75	;	Crystal structure of p38 in complex with SR68
6Y4W	;	1.86	;	Crystal structure of p38 in complex with SR69
6Y4X	;	1.6	;	Crystal structure of p38 in complex with SR72
3FC1	;	2.4	;	Crystal structure of p38 kinase bound to pyrimido-pyridazinone inhibitor
3E92	;	2.0	;	Crystal Structure of P38 Kinase in Complex with A Biaryl Amide Inhibitor
3E93	;	2.0	;	Crystal Structure of P38 Kinase in Complex with A Biaryl Amide Inhibitor
3D7Z	;	2.1	;	Crystal Structure of P38 Kinase in Complex with a biphenyl amide inhibitor
3D83	;	1.9	;	Crystal structure of P38 kinase in complex with a biphenyl amide inhibitor
3MPT	;	1.89	;	Crystal structure of P38 kinase in complex with a pyrrole-2-carboxamide inhibitor
1M7Q	;	2.4	;	Crystal structure of p38 MAP kinase in complex with a dihydroquinazolinone inhibitor
1ZZL	;	2.0	;	Crystal structure of P38 with triazolopyridine
3ITZ	;	2.25	;	Crystal Structure of p38a Mitogen-Activated Protein Kinase in Complex with a Pyrazolopyridazine Inhibitor
3GFE	;	2.1	;	Crystal Structure of p38a Mitogen-Activated Protein Kinase in Complex with a Pyrazolopyridinone Inhibitor
3LHJ	;	3.31	;	Crystal Structure of p38a Mitogen-Activated Protein Kinase in Complex with a Pyrazolopyridinone Inhibitor.
3U8W	;	2.15	;	Crystal Structure of p38a Mitogen-Activated Protein Kinase in Complex with a Triazolopyridazinone inhibitor
7Z9T	;	2.6	;	Crystal structure of p38alpha C162S in complex with ATPgS and CAS 2094667-81-7 (in catalytic site, Y35 out), P 1 21 1
7PVU	;	2.154	;	Crystal structure of p38alpha C162S in complex with CAS2094511-69-8, P 1 21 1
7Z6I	;	2.25	;	Crystal structure of p38alpha C162S in complex with SB20358 and CAS 2094667-81-7 (behind catalytic site; Y35 in), P 21 21 21
3TG1	;	2.71	;	Crystal structure of p38alpha in complex with a MAPK docking partner
6HWV	;	1.7	;	Crystal structure of p38alpha in complex with a photoswitchable 2-Azoimidazol-based Inhibitor (compound 3)
6HWU	;	2.3	;	Crystal structure of p38alpha in complex with a photoswitchable 2-Azothiazol-based Inhibitor (compound 2)
6HWT	;	1.7	;	Crystal structure of p38alpha in complex with a reduced photoswitchable 2-Azothiazol-based Inhibitor (compound 31)
5N63	;	2.4	;	Crystal Structure of p38alpha in Complex with Lipid Pocket Ligand 9c
5N64	;	2.4	;	Crystal Structure of p38alpha in Complex with Lipid Pocket Ligand 9g
5N65	;	2.0	;	Crystal Structure of p38alpha in Complex with Lipid Pocket Ligand 9h
5N66	;	2.4	;	Crystal Structure of p38alpha in Complex with Lipid Pocket Ligand 9j
5N67	;	1.9	;	Crystal Structure of p38alpha in Complex with Lipid Pocket Ligand 9l
5N68	;	1.85	;	Crystal Structure of p38alpha in Complex with Lipid Pocket Ligand 9m
6YJC	;	1.74101	;	Crystal structure of p38alpha in complex with SR154
3ODY	;	2.2	;	Crystal structure of p38alpha Y323Q active mutant
3ODZ	;	2.3	;	Crystal structure of P38alpha Y323R active mutant
3OD6	;	2.682	;	Crystal structure of p38alpha Y323T active mutant
3COI	;	2.09	;	Crystal structure of p38delta kinase
2XSO	;	2.2	;	CRYSTAL STRUCTURE OF P4 VARIANT OF BIPHENYL DIOXYGENASE FROM BURKHOLDERIA XENOVORANS LB400
2XSH	;	2.29	;	CRYSTAL STRUCTURE OF P4 VARIANT OF BIPHENYL DIOXYGENASE FROM BURKHOLDERIA XENOVORANS LB400 IN COMPLEX WITH 2,6 DI CHLOROBIPHENYL
1M59	;	1.9	;	Crystal Structure of P40V Mutant of Trypsin-solubilized Fragment of Cytochrome b5
3KYF	;	2.1	;	Crystal structure of P4397 complexed with c-di-GMP
3UGU	;	1.85	;	Crystal Structure of p44 (Splice Variant of Visual Arrestin)
4H1N	;	2.99	;	Crystal Structure of P450 2B4 F297A Mutant in Complex with Anti-platelet Drug Clopidogrel
3TMZ	;	2.248	;	Crystal Structure of P450 2B4(H226Y) in complex with Amlodipine
4JLT	;	2.14	;	Crystal structure of P450 2B4(H226Y) in complex with paroxetine
3UA5	;	2.8	;	Crystal Structure of P450 2B6 (Y226H/K262R) in complex with two molecules of Amlodipine
4HGJ	;	1.9	;	Crystal structure of P450 BM3 5F5 heme domain variant
4HGH	;	1.4	;	Crystal structure of P450 BM3 5F5 heme domain variant complexed with styrene (dataset I)
4HGI	;	1.5	;	Crystal structure of P450 BM3 5F5 heme domain variant complexed with styrene (dataset II)
4HGF	;	1.7	;	Crystal structure of P450 BM3 5F5K heme domain variant complexed with styrene
4HGG	;	1.7	;	Crystal structure of P450 BM3 5F5R heme domain variant complexed with styrene
5E7Y	;	2.0	;	Crystal structure of P450 BM3 heme domain M7 variant
5E78	;	2.0	;	Crystal structure of P450 BM3 heme domain variant complexed with Co(III)Sep
7Y9M	;	2.16	;	Crystal structure of P450 BM3-2F from Bacillus megaterium
7Y9L	;	1.76	;	Crystal structure of P450 BM3-2F from Bacillus megaterium in complex with 2-Hydroxy-5-Nitrobenzonitrile
7Y9K	;	2.23	;	Crystal structure of P450 BM3-TMK from Bacillus megaterium
7Y9J	;	1.83	;	Crystal structure of P450 BM3-TMK from Bacillus megaterium in complex with 5-nitro-1,2-benzisoxazole
5O4L	;	1.64	;	Crystal structure of P450 CYP121 in complex with compound 6a.
5O4K	;	1.5	;	Crystal structure of P450 CYP121 in complex with compound 6b.
3MGX	;	2.1	;	Crystal Structure of P450 OxyD that is involved in the Biosynthesis of Vancomycin-type Antibiotics
1R9O	;	2.0	;	Crystal Structure of P4502C9 with Flurbiprofen bound
3EJD	;	2.1	;	Crystal Structure of P450BioI in complex with hexadec-9Z-enoic acid ligated Acyl Carrier Protein
3EJE	;	2.1	;	Crystal Structure of P450BioI in complex with octadec-9Z-enoic acid ligated Acyl Carrier Protein
3EJB	;	2.0	;	Crystal Structure of P450BioI in complex with tetradecanoic acid ligated Acyl Carrier Protein
5B2X	;	1.9	;	Crystal Structure of P450BM3 mutant with N-perfluoroheptanoyl-L-tryptophan
5XHJ	;	2.0	;	Crystal Structure of P450BM3 with 5-Cyclohexylvaleroyl-L-Tryptophan
5XA3	;	2.2	;	Crystal Structure of P450BM3 with Benzyloxycarbonyl-L-prolyl-L-phenylalanine
7XZK	;	1.54	;	Crystal Structure of P450BM3 with N-(3-cyclohexylpropanoyl)-L-pipecolyl-L-phenylalanine
6K3Q	;	2.06	;	Crystal Structure of P450BM3 with N-(3-cyclohexylpropanoyl)-L-prolyl-L-phenylalanine
6L1B	;	1.74	;	Crystal Structure of P450BM3 with N-(3-cyclopentylpropanoyl)-L-pipecolyl-L-phenylalanine
6L1A	;	1.84	;	Crystal Structure of P450BM3 with N-enanthoyl-L-prolyl-L-phenylalanine
5B2Y	;	2.01	;	Crystal Structure of P450BM3 with N-perfluorodecanoyl-L-tryptophan
5B2W	;	1.65	;	Crystal Structure of P450BM3 with N-perfluorododecanoyl-L-tryptophan
5B2U	;	1.9	;	Crystal Structure of P450BM3 with N-perfluorohexanoyl -L-tryptophan
5B2V	;	2.3	;	Crystal Structure of P450BM3 with N-perfluorohexanoyl-L-tryptophan
3WSP	;	1.8	;	Crystal Structure of P450BM3 with N-perfluorononanoyl-L-tryptophan
8HKD	;	2.35	;	Crystal structure of P450BSbeta-L78G/Q85F/F173S/G290I variant in complex with palmitoleic acid
7WYG	;	2.0	;	Crystal structure of P450BSbeta-L78I/Q85H/G290I variant in complex with palmitic acid.
3WRH	;	1.62	;	Crystal structure of P450cam
3WRI	;	2.9	;	Crystal structure of P450cam
3WRJ	;	1.85	;	Crystal structure of P450cam
3WRK	;	2.609	;	Crystal structure of P450cam
3WRL	;	1.65	;	Crystal structure of P450cam
3WRM	;	1.95	;	Crystal structure of P450cam
4LHT	;	2.137	;	Crystal Structure of P450cin Y81F mutant, crystallized in 3 mM 1,8-cineole
4L6G	;	1.371	;	Crystal Structure of P450cin Y81F mutant, crystallized in 7 mM 1,8-cineole
1XQD	;	1.8	;	Crystal structure of P450NOR complexed with 3-pyridinealdehyde adenine dinucleotide
1ULW	;	2.0	;	Crystal structure of P450nor Ser73Gly/Ser75Gly mutant
8FBC	;	1.53	;	Crystal structure of P450T2
5WIX	;	2.8	;	Crystal structure of P47 of Clostridium botulinum E1
1G6B	;	1.9	;	CRYSTAL STRUCTURE OF P47S MUTANT OF FERREDOXIN I
3W8J	;	2.1	;	Crystal structure of P5 a0 in a complex with Prx4 c-term
4HJE	;	1.907	;	Crystal structure of p53 core domain in complex with DNA
7YGI	;	2.1	;	Crystal structure of p53 DBD domain in complex with azurin
5SWK	;	1.923	;	Crystal structure of p53 epitope-scaffold based on a inhibitor of cysteine proteases in complex with human MDM2
1C26	;	1.7	;	CRYSTAL STRUCTURE OF P53 TETRAMERIZATION DOMAIN
8DC8	;	1.7201	;	Crystal structure of p53 Y220C covalently bound to azaindole KG13
8DC4	;	2.4	;	Crystal structure of p53 Y220C covalently bound to carbazole KG3
8DC7	;	1.98701	;	Crystal structure of p53 Y220C covalently bound to indole KG10
8DC6	;	1.60001	;	Crystal structure of p53 Y220C covalently bound to indole KG6
6LHD	;	2.499	;	Crystal structure of p53/BCL-xL fusion complex
8HLL	;	2.62	;	Crystal structure of p53/BCL2 fusion complex (complex 1)
8HLM	;	2.522	;	Crystal structure of p53/BCL2 fusion complex (complex 2)
8HLN	;	2.354	;	Crystal structure of p53/BCL2 fusion complex(complex3)
2PCX	;	1.54	;	Crystal structure of p53DBD(R282Q) at 1.54-angstrom Resolution
3IEG	;	2.51	;	Crystal Structure of P58(IPK) TPR Domain at 2.5 A
2GR9	;	3.1	;	Crystal structure of P5CR complexed with NADH
6MIU	;	1.9	;	Crystal structure of p62 ZZ domain in complex with Arg-Glu peptide
6MJ7	;	1.412	;	Crystal structure of p62 ZZ domain in complex with free arginine
7Z71	;	1.85	;	Crystal structure of p63 DBD in complex with darpin C14
7Z7E	;	1.8	;	Crystal structure of p63 DNA binding domain in complex with inhibitory DARPin G4
7Z72	;	1.8	;	Crystal structure of p63 SAM in complex with darpin A5
7Z73	;	2.27	;	Crystal structure of p63 tetramerization domain in complex with darpin 8F1
8P9D	;	2.7	;	Crystal structure of p63-p73 heterotetramer (tetramerisation domain) in complex with darpin 1810 A2
8P9C	;	1.76	;	Crystal structure of p63-p73 heterotetramer (tetramerisation domain) in complex with darpin 1810 F11
2RGN	;	3.5	;	Crystal Structure of p63RhoGEF complex with Galpha-q and RhoA
1FYX	;	2.8	;	CRYSTAL STRUCTURE OF P681H MUTANT OF TIR DOMAIN OF HUMAN TLR2
7EZJ	;	2.9	;	Crystal structure of p73 DNA binding domain complex bound with 1 bp and 2 bp spacer DNA response elements.
4G82	;	3.1	;	Crystal Structure of p73 DNA-Binding Domain Tetramer bound to a Full Response-Element
4G83	;	4.0	;	Crystal Structure of p73 DNA-Binding Domain Tetramer bound to a Full Response-Element
8F5M	;	2.4	;	Crystal structure of P74 gp62
7QUX	;	1.48	;	Crystal structure of P7C8 bound to CK2alpha
6J98	;	1.56	;	Crystal structure of P8 from Lactobacillus rhamnosus
6YZH	;	1.19	;	Crystal structure of P8C9 bound to CK2alpha
6Z19	;	1.47	;	Crystal structure of P8C9 bound to CK2alpha
5D1D	;	2.011	;	Crystal structure of P91L-Y306F HDAC8 in complex with a tetrapeptide substrate
8HL7	;	2.8	;	Crystal structure of p97 N/D1 in complex with a valosin-containing protein methyltransferase
3QQ8	;	2.0	;	Crystal structure of p97-N in complex with FAF1-UBX
4KDI	;	1.86	;	Crystal structure of p97/VCP N in complex with OTU1 UBXL
4KDL	;	1.81	;	Crystal structure of p97/VCP N in complex with OTU1 UBXL
3TIW	;	1.802	;	Crystal structure of p97N in complex with the C-terminus of gp78
5XHR	;	1.8	;	Crystal structure of P99 beta-lactamase in complex with a penicillin derivative MPC-1
2WYF	;	2.4	;	Crystal structure of PA-IL lectin complexed with aGal12bGal-O-Met at 2.4 A resolution
2VXJ	;	1.9	;	CRYSTAL STRUCTURE OF PA-IL LECTIN COMPLEXED WITH AGAL13BGAL14GLC AT 1.9 A RESOLUTION
3ZYB	;	2.29	;	CRYSTAL STRUCTURE OF PA-IL LECTIN COMPLEXED WITH GALAG0 AT 2.3 A RESOLUTION
3ZYH	;	1.501	;	CRYSTAL STRUCTURE OF PA-IL LECTIN COMPLEXED WITH GALBG0 AT 1.5 A RESOLUTION
3ZYF	;	1.944	;	CRYSTAL STRUCTURE OF PA-IL LECTIN COMPLEXED WITH NPG AT 1.9 A RESOLUTION
2ZNL	;	2.3	;	Crystal structure of PA-PB1 complex form influenza virus RNA polymerase
5ZBU	;	3.2	;	Crystal Structure of PA-TM-RING E3 ligase RNF13 RING domain in complex with E2~Ub
2QNU	;	2.05	;	Crystal structure of PA0076 from Pseudomonas aeruginosa PAO1 at 2.05 A resolution
4MTK	;	3.322	;	Crystal structure of PA0091 VgrG1, the central spike of the Type VI Secretion System
3FZV	;	2.71	;	Crystal structure of PA01 protein, putative LysR family transcriptional regulator from Pseudomonas aeruginosa
6JFW	;	2.002	;	Crystal structure of PA0833 periplasmic domain from Pseudomonas aeruginosa reveals an unexpected enlarged peptidoglycan binding pocket
2AZP	;	2.13	;	Crystal Structure of PA1268 Solved by Sulfur SAD
5J6Y	;	1.03	;	Crystal structure of PA14 domain of MpAFP Antifreeze protein
2F2E	;	1.85	;	Crystal Structure of PA1607, a Putative Transcription Factor
4EQ8	;	1.392	;	Crystal structure of PA1844 from Pseudomonas aeruginosa PAO1
4EQA	;	1.6	;	Crystal structure of PA1844 in complex with PA1845 from Pseudomonas aeruginosa PAO1
3KAW	;	2.4	;	Crystal Structure of PA2107 PROTEIN from Pseudomonas aeruginosa, Northeast Structural Genomics Consortium Target PaR198
1U69	;	1.6	;	Crystal Structure of PA2721 Protein of Unknown Function from Pseudomonas aeruginosa PAO1
8AJQ	;	1.25	;	Crystal structure of PA2722 from Pseudomonas aeruginosa PAO1
5XMG	;	2.8	;	Crystal structure of PA3488 from Pseudomonas aeruginosa
1X7V	;	1.78	;	Crystal structure of PA3566 from Pseudomonas aeruginosa
2X4G	;	2.65	;	Crystal structure of PA4631, a nucleoside-diphosphate-sugar epimerase from Pseudomonas aeruginosa
6LB3	;	2.497	;	Crystal structure of PA4674 in complex with its operator DNA (18bp) from Pseudomonas aeruginosa
6JPI	;	3.143	;	Crystal structure of PA4674 in complex with its operator DNA (28bp) from Pseudomonas aeruginosa
4R8Z	;	2.2	;	Crystal Structure of PA4781 HD-GYP domain from Pseudomonas aeruginosa at 2.2A resolution showing a bi-metallic Ni ion center
3PGP	;	1.42	;	Crystal structure of PA4794 - GNAT superfamily protein in complex with AcCoA
6M10	;	2.985	;	Crystal structure of PA4853 (Fis) from Pseudomonas aeruginosa
1J1Y	;	1.7	;	Crystal Structure of PaaI from Thermus thermophilus HB8
2Y27	;	1.6	;	crystal structure of PaaK1 in complex with ATP from Burkholderia cenocepacia
2Y4O	;	1.9	;	Crystal Structure of PaaK2 in complex with phenylacetyl adenylate
4GRN	;	1.25	;	crystal structure of PAAM mutant of human MIF
8A39	;	2.3	;	Crystal Structure of PaaX from Escherichia coli W
4N65	;	1.816	;	Crystal structure of paAzoR1 bound to anthraquinone-2-sulphonate
4N9Q	;	2.0	;	Crystal structure of paAzoR1 bound to ubiquinone-1
7OLI	;	1.65	;	Crystal structure of Pab-AGOG in complex with 8-oxoguanosine
7OLB	;	1.1	;	Crystal structure of Pab-AGOG, an 8-oxoguanine DNA glycosylase from Pyrococcus abyssi
4GRH	;	2.25	;	Crystal structure of pabB of Stenotrophomonas maltophilia
6RPP	;	1.6	;	Crystal structure of PabCDC21-1 intein
7JQD	;	2.7	;	Crystal Structure of PAC1r in complex with peptide antagonist
3MNF	;	2.97	;	Crystal structure of PAC2 family protein from Streptomyces avermitilis MA
3M7K	;	1.92	;	Crystal structure of PacI-DNA Enzyme product complex
7VS4	;	2.55	;	Crystal structure of PacII_M1M2S-DNA(m6A)-SAH complex
7VRU	;	2.4	;	Crystal structure of PacII_M1M2S-DNA-SAH complex
4U4Y	;	3.2	;	Crystal structure of Pactamycin bound to the yeast 80S ribosome
5Z4Z	;	2.053	;	Crystal structure of PaCysB NTD domain with space group C2
5Z4Y	;	2.401	;	Crystal structure of PaCysB NTD domain with space group P4
5Z50	;	2.206	;	Crystal structure of PaCysB regulatory domain
6P90	;	1.9	;	Crystal structure of PaDHDPS2-H56Q mutant
4EJO	;	2.1	;	Crystal structure of padr family transcriptional regulator from Eggerthella lenta DSM 2243
8IOI	;	2.94	;	Crystal Structure of PadR- family transcriptional regulator Rv1176c from Mycobacterium tuberculosis H37Rv.
4ESB	;	2.5	;	Crystal structure of PadR-like transcriptional regulator (BC4206) from Bacillus cereus strain ATCC 14579
4ESF	;	2.2	;	Crystal structure of PadR-like transcriptional regulator (BCE3449) from Bacillus cereus strain ATCC 10987
2FE1	;	2.2	;	Crystal Structure of PAE0151 from Pyrobaculum aerophilum
1V8O	;	2.8	;	Crystal Structure of PAE2754 from Pyrobaculum aerophilum
1V8P	;	2.52	;	Crystal structure of PAE2754 from Pyrobaculum aerophilum
6P2N	;	1.35	;	Crystal structure of Paenibacillus graminis GH74 (PgGH74)
5X7O	;	2.0	;	Crystal structure of Paenibacillus sp. 598K alpha-1,6-glucosyltransferase
5X7P	;	2.4	;	Crystal structure of Paenibacillus sp. 598K alpha-1,6-glucosyltransferase complexed with acarbose
5X7R	;	1.95	;	Crystal structure of Paenibacillus sp. 598K alpha-1,6-glucosyltransferase complexed with isomaltohexaose
5X7Q	;	1.95	;	Crystal structure of Paenibacillus sp. 598K alpha-1,6-glucosyltransferase complexed with maltohexaose
5X7S	;	2.4	;	Crystal structure of Paenibacillus sp. 598K alpha-1,6-glucosyltransferase, terbium derivative
5X7G	;	2.2	;	Crystal Structure of Paenibacillus sp. 598K cycloisomaltooligosaccharide glucanotransferase
5X7H	;	2.6	;	Crystal Structure of Paenibacillus sp. 598K cycloisomaltooligosaccharide glucanotransferase complexed with cycloisomaltoheptaose
6HA4	;	1.33	;	Crystal structure of PAF - p-sulfonatocalix[4]arene complex
6HAH	;	1.45	;	Crystal structure of PAF - p-sulfonatocalix[6]arene complex
6HAJ	;	1.5	;	Crystal structure of PAF - p-sulfonatocalix[8]arene complex
4R8A	;	3.2	;	Crystal structure of paFAN1 - 5' flap DNA complex
4R89	;	4.002	;	Crystal structure of paFAN1 - 5' flap DNA complex with Manganase
5Y7G	;	3.4	;	Crystal structure of paFAN1 bound to 1nt 5'flap DNA with gap
5Y7Q	;	2.7	;	Crystal structure of paFAN1 bound to 2nt 5'flap DNA with gap
5Z6W	;	3.2	;	Crystal structure of paFAN1 bound to 2nt 5'flap DNA with gap with Manganese
7BAE	;	1.2	;	Crystal structure of PAFB
7BAD	;	1.69	;	Crystal structure of PAFB in complex with p-sulfonato-calix[8]arene and zinc
7BAF	;	1.123	;	Crystal structure of PAFB in complex with zinc
4LE4	;	1.8	;	Crystal structure of PaGluc131A with cellotriose
3GP6	;	1.4	;	Crystal structure of PagP in SDS/MPD
4IC0	;	2.32	;	Crystal Structure of PAI-1 in Complex with Gallate
3K9U	;	2.3	;	Crystal structure of paia acetyltransferase (ta0374) from thermoplasma acidophilum
3NE7	;	2.3	;	Crystal structure of paia n-acetyltransferase from thermoplasma acidophilum in complex with coenzyme a
8HUC	;	1.984	;	Crystal structure of PaIch (Pec1)
5DEW	;	1.9	;	Crystal structure of PAK1 in complex with an inhibitor compound 5
5DFP	;	2.2	;	Crystal structure of PAK1 in complex with an inhibitor compound FRAX1036
5DEY	;	2.1	;	Crystal structure of PAK1 in complex with an inhibitor compound G-5555
4EQC	;	2.01	;	Crystal structure of PAK1 kinase domain in complex with FRAX597 inhibitor
1YHW	;	1.8	;	Crystal Structure of PAK1 kinase domain with one point mutations (K299R)
3FY0	;	2.35	;	Crystal structure of PAK1 kinase domain with ruthenium complex DW1
3FXZ	;	1.64	;	Crystal structure of PAK1 kinase domain with ruthenium complex lambda-FL172
4DAW	;	2.0	;	Crystal structure of PAK1 kinase domain with the ruthenium phthalimide complex
1YHV	;	1.8	;	Crystal Structure of PAK1 kinase domain with two point mutations (K299R, T423E)
7CMB	;	2.592	;	Crystal Structure of PAK4 in complex with inhibitor 41
7CP3	;	2.9	;	Crystal Structure of PAK4 in complex with inhibitor 47
7CP4	;	2.5	;	Crystal Structure of PAK4 in complex with inhibitor 55
5ZJW	;	1.798	;	Crystal Structure of PAK4 in complex with inhibitor CZg353
5XVF	;	2.655	;	Crystal Structure of PAK4 in complex with inhibitor CZH062
5XVA	;	1.847	;	Crystal Structure of PAK4 in complex with inhibitor CZH216
5XVG	;	2.1	;	Crystal Structure of PAK4 in complex with inhibitor CZH226
3R7L	;	2.585	;	Crystal Structure of PALA-bound Aspartate Transcarbamoylase from Bacillus subtilis
6QE2	;	1.7461	;	Crystal structure of Paleococcus ferrophilus monoacylglycerol lipase.
1EI9	;	2.25	;	CRYSTAL STRUCTURE OF PALMITOYL PROTEIN THIOESTERASE 1
1EXW	;	2.4	;	CRYSTAL STRUCTURE OF PALMITOYL PROTEIN THIOESTERASE 1 COMPLEXED WITH HEXADECYLSULFONYL FLUORIDE
1EH5	;	2.5	;	CRYSTAL STRUCTURE OF PALMITOYL PROTEIN THIOESTERASE 1 COMPLEXED WITH PALMITATE
4WSI	;	2.95	;	Crystal Structure of PALS1/Crb complex
5AC3	;	1.8	;	Crystal structure of PAM12A
3KCS	;	1.5	;	Crystal structure of PAmCherry1 in the dark state
3KCT	;	1.65	;	CRYSTAL STRUCTURE OF PAmCherry1 in the photoactivated state
8HHD	;	2.27	;	Crystal structure of PaMurU
7B3A	;	1.34	;	Crystal structure of PamZ
6BTJ	;	1.999	;	Crystal structure of pan-H7, anti-hemagglutinin monoclonal antibody H7.5 (Fab fragment)
3WHK	;	2.6	;	Crystal structure of PAN-Rpt5C chimera
3HWR	;	2.15	;	Crystal structure of PanE/ApbA family ketopantoate reductase (YP_299159.1) from Ralstonia eutropha JMP134 at 2.15 A resolution
5SX5	;	2.5	;	Crystal Structure of panitumumab in complex with epidermal growth factor receptor domain 3 mutant S468R.
5SX4	;	2.8	;	Crystal Structure of panitumumab in complex with epidermal growth factor receptor domain 3.
2EJC	;	2.4	;	Crystal Structure Of Pantoate--Beta-Alanine Ligase (panC) From Thermotoga maritima
3UY4	;	1.851	;	Crystal Structure of Pantoate--Beta-Alanine Ligase from Campylobacter jejuni complexed with AMP and vitamin B5
1V8F	;	1.9	;	Crystal Structure of Pantoate-beta-Alanine (Pantothenate Synthetase) from Thermus Thermophilus HB8
3MXT	;	1.85	;	Crystal Structure of Pantoate-Beta-alanine Ligase from Campylobacter jejuni
3N8H	;	2.001	;	Crystal Structure of Pantoate-beta-alanine Ligase from Francisella tularensis
5HG0	;	2.4	;	Crystal Structure of Pantoate-beta-alanine Ligase from Francisella tularensis complex with SAM
3QTT	;	2.599	;	Crystal Structure of Pantoate-beta-alanine Ligase from Francisella tularensis Complexed with Beta-gamma ATP and Beta-alanine
3MUE	;	2.701	;	Crystal Structure of Pantoate-beta-Alanine Ligase from Salmonella typhimurium
3INN	;	2.1	;	Crystal structure of pantoate-beta-alanine-ligase in complex with ATP at low occupancy at 2.1 A resolution
3DJC	;	2.4	;	CRYSTAL STRUCTURE OF PANTOTHENATE KINASE FROM LEGIONELLA PNEUMOPHILA
7TOT	;	1.8	;	Crystal Structure of pantothenate synthetase from Bartonella henselae
1N2I	;	1.7	;	Crystal Structure of Pantothenate Synthetase from M. tuberculosis in complex with a reaction intermediate, pantoyl adenylate, different occupancies of pantoyl adenylate
1N2O	;	2.1	;	Crystal Structure of Pantothenate Synthetase from M. tuberculosis, low occupancy of beta-alanine at the pantoate binding sites
3IUB	;	1.5	;	Crystal structure of pantothenate synthetase from Mycobacterium tuberculosis in complex with 5-Methoxy-N-(5-methylpyridin-2-ylsulfonyl)-1H-indole-2-carboxamide
3ISJ	;	2.2	;	Crystal structure of pantothenate synthetase from Mycobacterium tuberculosis in complex with 5-methoxy-N-(methylsulfonyl)-1H-indole-2-carboxamide
3AG5	;	2.5	;	Crystal Structure of Pantothenate Synthetase from Staphylococcus aureus
3AG6	;	1.85	;	Crystal Structure of Pantothenate Synthetase from Staphylococcus aureus in complex with pantoyl adenylate
1UFV	;	2.05	;	Crystal Structure Of Pantothenate Synthetase From Thermus Thermophilus HB8
3IVG	;	1.95	;	Crystal structure of pantothenate synthetase in complex with 2-(2-((benzofuran-2-sulfonamido)methyl)-5-methoxy-1H-indol-1-yl)acetic acid
3IVC	;	2.13	;	Crystal structure of pantothenate synthetase in complex with 2-(2-((benzofuran-2-ylmethoxy)carbonyl)-5-methoxy-1H-indol-1-yl)acetic acid
4MUF	;	2.5	;	Crystal structure of pantothenate synthetase in complex with 2-(2-(4-tert-butylphenylsulfonylcarbamoyl)-5-methoxy-1H-indol-1-yl)acetic acid
4MUH	;	1.72	;	Crystal structure of pantothenate synthetase in complex with 2-(2-(5-acetamido-1,3,4-thiadiazol-2-ylsulfonylcarbamoyl)-5-methoxy-1H-indol-1-yl)acetic acid
3IVX	;	1.73	;	Crystal structure of pantothenate synthetase in complex with 2-(2-(benzofuran-2-ylsulfonylcarbamoyl)-5-methoxy-1H-indol-1-yl)acetic acid
4MUJ	;	1.92	;	Crystal structure of pantothenate synthetase in complex with 2-(2-(benzylsulfonylcarbamoyl)-5-methoxy-1H-indol-1-yl)acetic acid
4MUN	;	1.57	;	Crystal structure of pantothenate synthetase in complex with 2-(5-methoxy-2-(2-nitro-4-(trifluoromethyl)phenylsulfonylcarbamoyl)-1H-indol-1-yl)acetic acid
4MUK	;	1.9	;	Crystal structure of pantothenate synthetase in complex with 2-(5-methoxy-2-(4-(trifluoromethyl)benzylsulfonylcarbamoyl)-1H-indol-1-yl)acetic acid
4MUI	;	2.1	;	Crystal structure of pantothenate synthetase in complex with 2-(5-methoxy-2-(4-methoxyphenylsulfonylcarbamoyl)-1H-indol-1-yl)acetic acid
3IUE	;	1.73	;	Crystal structure of pantothenate synthetase in complex with 2-(5-methoxy-2-(5-Methylpyridin-2-ylsulfonylcarbamoyl)-1H-indol-1-yl) acetic acid
4MUG	;	1.54	;	Crystal structure of pantothenate synthetase in complex with 2-(5-methoxy-2-(morpholinosulfonylcarbamoyl)-1H-indol-1-yl)acetic acid
4MUL	;	1.75	;	Crystal structure of pantothenate synthetase in complex with 2-(5-methoxy-2-(naphthalen-2-ylsulfonylcarbamoyl)-1H-indol-1-yl)acetic acid
2Q8W	;	1.7	;	Crystal structure of PAP-S1aci, a pokeweed antiviral protein from seeds of Phytolacca acinosa
6H8T	;	2.1	;	Crystal structure of Papain modify by achiral Ru(II)complex
1PPP	;	1.9	;	CRYSTAL STRUCTURE OF PAPAIN-E64-C COMPLEX. BINDING DIVERSITY OF E64-C TO PAPAIN S2 AND S3 SUBSITES
1PIP	;	1.7	;	CRYSTAL STRUCTURE OF PAPAIN-SUCCINYL-GLN-VAL-VAL-ALA-ALA-P-NITROANILIDE COMPLEX AT 1.7 ANGSTROMS RESOLUTION: NONCOVALENT BINDING MODE OF A COMMON SEQUENCE OF ENDOGENOUS THIOL PROTEASE INHIBITORS
6EEM	;	2.61001	;	Crystal structure of Papaver somniferum tyrosine decarboxylase in complex with L-tyrosine
2FAW	;	1.7	;	crystal structure of papaya glutaminyl cyclase
4DOX	;	2.7	;	Crystal Structure of Papaya mosaic virus capsid protein
2V9P	;	3.0	;	Crystal structure of papillomavirus E1 hexameric helicase DNA-free form
2GXA	;	3.15	;	Crystal structure of papillomavirus E1 hexameric helicase with ssDNA and MgADP
4I6P	;	2.9	;	Crystal structure of Par3-NTD domain
3EA0	;	2.2	;	Crystal Structure of ParA Family ATPase from Chlorobium tepidum TLS
3H9M	;	1.57	;	Crystal structure of para-aminobenzoate synthetase, component I from Cytophaga hutchinsonii
5F2F	;	1.665	;	Crystal structure of para-biphenyl-2-methyl-3', 5' di-methyl amide mannoside bound to FimH lectin domain
5F3F	;	1.76	;	Crystal structure of para-biphenyl-2-methyl-3'-methyl amide mannoside bound to FimH lectin domain
7ON9	;	1.63	;	Crystal structure of para-hydroxybenzoate-3-hydroxylase PraI
7QEF	;	2.41	;	Crystal structure of para-nitrophenyl-Beta-D-glucuronide bound to a mutant of SN243 (D415A)
6DXU	;	1.9	;	Crystal Structure of Parabacteroides merdae Beta-Glucuronidase (GUS)
6CK1	;	2.15	;	Crystal structure of Paracoccus denitrificans AztD
6YWF	;	1.9	;	Crystal structure of Paradendryphiella salina PL7A alginate lyase
7PBF	;	1.54	;	Crystal structure of Paradendryphiella salina PL7A alginate lyase in complex with di-mannuronic acid
7P25	;	1.47	;	Crystal structure of Paradendryphiella salina PL7A alginate lyase in complex with hexa-mannuronic acid products
7ORY	;	1.46	;	Crystal structure of Paradendryphiella salina PL7A alginate lyase in complex with penta-mannuronic acid products
7P90	;	1.87	;	Crystal structure of Paradendryphiella salina PL7A alginate lyase in complex with tetra-mannuronic acid products
7OOF	;	1.3	;	Crystal structure of Paradendryphiella salina PL7A alginate lyase in complex with tri-mannuronic acid
7NL3	;	1.7	;	Crystal structure of Paradendryphiella salina PL7A alginate lyase mutant Y223F
7NM6	;	1.78	;	Crystal structure of Paradendryphiella salina PL7A alginate lyase mutant Y223F in complex with di-mannuronic acid
7NCZ	;	1.64	;	Crystal structure of Paradendryphiella salina PL7A alginate lyase mutant Y223F in complex with hexa-mannuronic acid
7NPP	;	1.45	;	Crystal structure of Paradendryphiella salina PL7A alginate lyase mutant Y223F in complex with penta-mannuronic acid
7NY3	;	1.82	;	Crystal structure of Paradendryphiella salina PL7A alginate lyase mutant Y223F in complex with tetra-mannuronic acid
7O6H	;	1.66	;	Crystal structure of Paradendryphiella salina PL7A alginate lyase mutant Y223F in complex with tri-mannuronic acid
8BJR	;	1.1	;	Crystal structure of Paradendryphiella salina PL7C alginate lyase
8C3X	;	0.82	;	Crystal structure of Paradendryphiella salina PL7C alginate lyase
8PC3	;	1.1	;	Crystal structure of Paradendryphiella salina PL7C alginate lyase in complex with pentamannuronic acid
8R43	;	0.87	;	Crystal structure of Paradendryphiella salina PL7C alginate lyase mutant H110N in complex with tri-mannuronic acid
8RBI	;	0.98	;	Crystal structure of Paradendryphiella salina PL7C alginate lyase mutant H124
8C0M	;	1.2	;	Crystal structure of Paradendryphiella salina PL7C alginate lyase mutant Y220F
8P6O	;	1.05	;	Crystal structure of Paradendryphiella salina PL7C alginate lyase mutant Y220F in complex with di-mannuronic acid
8BJO	;	1.51	;	Crystal structure of Paradendryphiella salina PL7C alginate lyase mutant Y220F in complex with hexa-mannuronic acid
8BXZ	;	1.2	;	Crystal structure of Paradendryphiella salina PL7C alginate lyase mutant Y220F in complex with penta-mannuronic acid
8PDT	;	1.09	;	Crystal structure of Paradendryphiella salina PL7C alginate lyase soaked with dimannuronic acid
8PC8	;	1.24	;	Crystal structure of Paradendryphiella salina PL7C alginate lyase soaked with hexamannuronic acid
8PCX	;	1.14	;	Crystal structure of Paradendryphiella salina PL7C alginate lyase soaked with tetramannuronic acid
8PED	;	1.1	;	Crystal structure of Paradendryphiella salina PL7C alginate lyase soaked with trimannuronic acid
8BZK	;	1.45	;	Crystal structure of Paradendryphiella salina PL7C alginate lyase with sulphate bound in the active site
2YIL	;	1.95	;	Crystal Structure of Parasite Sarcocystis muris Lectin SML-2
2YIO	;	2.43	;	Crystal Structure of Parasite Sarcocystis muris Microneme Protein SML- 2 in complex with 1-Thio-beta-D-Galactose (SPACEGROUP C2221)
2YIP	;	2.14	;	Crystal Structure of Parasite Sarcocystis muris Microneme Protein SML- 2 in complex with 1-Thio-beta-D-Galactose (SPACEGROUP P212121)
3QQR	;	2.16	;	Crystal structure of Parasponia hemoglobin; Differential Heme Coordination is Linked to Quaternary Structure
6CKA	;	1.559	;	Crystal Structure of Paratox
7BNK	;	1.9	;	Crystal structure of ParB from Myxococcus xanthus bound to CDP and Monothiophosphate
3LPS	;	2.29	;	Crystal structure of parE
3LNU	;	2.2	;	Crystal structure of ParE subunit
4Z92	;	3.1	;	crystal structure of parechovirus-1 virion
7PDX	;	2.27	;	Crystal structure of parent MAGE-A10 TCR (728)
7PDW	;	1.82	;	Crystal structure of parent TCR (728) complexed to HLA-A*02:01 presenting MAGE-A10 9-mer peptide
4MQ0	;	2.12	;	Crystal structure of Parkia biglobosa seed lectin (PBL) in complex with methyl alpha D-mannopyranoside
4K95	;	6.499	;	Crystal Structure of Parkin
4K7D	;	2.8	;	Crystal Structure of Parkin C-terminal RING domains
4ZYN	;	2.54	;	Crystal Structure of Parkin E3 ubiquitin ligase (linker deletion; delta 86-130)
3B1L	;	1.85	;	Crystal Structure of parkin ubiquitin-like domain R33Q mutant
2A1R	;	2.6	;	Crystal structure of PARN nuclease domain
5NDV	;	3.3	;	Crystal structure of Paromomycin bound to the yeast 80S ribosome
4HHY	;	2.3637	;	Crystal structure of PARP catalytic domain in complex with novel inhibitors
4HHZ	;	2.7199	;	Crystal structure of PARP catalytic domain in complex with novel inhibitors
5V7T	;	2.3	;	crystal structure of PARP14 bound to N-{4-[4-(diphenylmethoxy)piperidin-1-yl]butyl}[1,2,4]triazolo[4,3-b]pyridazin-6-amine inhibitor
2ZFB	;	3.0	;	Crystal structure of parrot hemoglobin (Psittacula krameri) at pH 7.5
3OGJ	;	2.751	;	Crystal structure of partial apo (92-227) of cGMP-dependent protein kinase
2F61	;	2.5	;	Crystal structure of partially deglycosylated acid beta-glucosidase
3KK0	;	2.65	;	Crystal structure of partially folded intermediate state of peptidyl-tRNA hydrolase from Mycobacterium smegmatis
1J7Y	;	1.7	;	Crystal structure of partially ligated mutant of HbA
6Q47	;	1.57	;	Crystal structure of partially oxidized thioredoxin h1 from Chlamydomonas reinhardtii
6I82	;	2.05	;	Crystal structure of partially phosphorylated RET V804M tyrosine kinase domain complexed with PDD00018412
3ICS	;	1.94	;	Crystal structure of partially reduced Bacillus anthracis CoADR-RHD
3O5A	;	1.72	;	Crystal Structure of partially reduced Periplasmic Nitrate Reductase from Cupriavidus necator using Ionic Liquids
3NQU	;	2.5	;	Crystal structure of partially trypsinized (CENP-A/H4)2 heterotetramer
4PVR	;	1.75	;	Crystal structure of partially-cleaved human l-asparaginase protein in complex with l-aspartate
1YEW	;	2.801	;	Crystal structure of particulate methane monooxygenase
3RFR	;	2.68	;	Crystal Structure of particulate methane monooxygenase (pMMO) from Methylocystis sp. strain M
3RGB	;	2.8	;	Crystal structure of particulate methane monooxygenase from Methylococcus capsulatus (Bath)
4PHZ	;	2.59	;	Crystal structure of particulate methane monooxygenase from Methylocystis sp. ATCC 49242 (Rockwell)
4PI0	;	3.15	;	Crystal structure of particulate methane monooxygenase from Methylocystis sp. ATCC 49242 (Rockwell) soaked in copper
4PI2	;	3.33	;	Crystal structure of particulate methane monooxygenase from Methylocystis sp. ATCC 49242 (Rockwell) soaked in zinc
6CXH	;	2.704	;	Crystal structure of particulate methane monooxygenase from Methylomicrobium alcaliphilum 20Z
3ES5	;	3.3	;	Crystal Structure of Partitivirus (PsV-F)
5ZH6	;	1.54	;	Crystal structure of Parvalbumin SPV-II of Mustelus griseus
5ZGM	;	1.399	;	Crystal Structure of Parvalbumin SPVI, the Major Allergens in Mustelus griseus
4HP4	;	2.0	;	Crystal structure of PAS domain from the fruit-fly ELK potassium channel
4HQA	;	1.96	;	Crystal structure of PAS domain from the human ERG (hERG) potassium channel
4HOI	;	1.85	;	Crystal structure of PAS domain from the mouse EAG1 potassium channel
3BWL	;	1.73	;	Crystal structure of PAS domain of HTR-like protein from Haloarcula marismortui
3FG8	;	1.8	;	Crystal structure of PAS domain of RHA05790
4MN5	;	2.0	;	Crystal structure of PAS domain of S. aureus YycG
3CWF	;	2.2	;	Crystal structure of PAS domain of two-component sensor histidine kinase
7YRT	;	2.27	;	Crystal structure of PAS like domain of FlrB, the histidine kinase involved in flagellar synthesis of Vibrio cholerae
5HWW	;	2.0	;	Crystal structure of PAS1 complexed with 1,2,4-TMB
5HWV	;	1.65	;	Crystal structure of PAS1 complexed with toluene
5E0Y	;	2.001	;	Crystal Structure of PASTA Domain 4 of Mycobacterium tuberculosis Protein Kinase B
5E10	;	1.801	;	Crystal Structure of PASTA Domains 1 and 2 of Mycobacterium tuberculosis Protein Kinase B
5E12	;	2.208	;	Crystal Structure of PASTA Domains 2, 3 and 4 of Mycobacterium tuberculosis Protein Kinase B
5E0Z	;	2.0	;	Crystal Structure of PASTA Domains 3 and 4 of Mycobacterium tuberculosis Protein Kinase B
7O4C	;	1.51	;	Crystal structure of PASTA domains of the Penicillin-Binding Protein 1 (PBP1) from Staphylococcus aureus
1Q35	;	1.2	;	Crystal Structure of Pasteurella haemolytica Apo Ferric ion-Binding Protein A
4IMC	;	1.85	;	Crystal Structure of Pasteurella multocida N-Acetyl-D-Neuraminic acid lyase
4IMF	;	1.9	;	Crystal Structure of Pasteurella multocida N-Acetyl-D-Neuraminic acid lyase K164 mutant complexed with N-Acetylneuraminic acid
4IMG	;	1.85	;	Crystal Structure of Pasteurella multocida N-Acetyl-D-Neuraminic acid lyase K164 mutant complexed with N-Glycolylneuraminic acid
4IME	;	1.75	;	Crystal Structure of Pasteurella multocida N-Acetyl-D-Neuraminic acid lyase K164A Mutant
4IMD	;	2.1	;	Crystal Structure of Pasteurella multocida N-Acetyl-D-Neuraminic acid lyase trapped with pyruvate covalently bound through a Schiff base to Lys164
2II6	;	1.75	;	Crystal structure of Pasteurella multocida sialyltransferase D141N mutant in open conformation with CMP bound
2IIB	;	2.2	;	Crystal structure of Pasteurella multocida sialyltransferase D141N mutant with CMP bound
2IIQ	;	2.3	;	Crystal structure of Pasteurella multocida sialyltransferase in an open conformation with CMP bound
3S44	;	1.45	;	Crystal Structure of Pasteurella multocida sialyltransferase M144D mutant with CMP bound
4PKA	;	2.6	;	Crystal structure of patatin aged with diisopropylphosphorofluoridate
4PKB	;	2.09	;	CRYSTAL STRUCTURE OF PATATIN-17 COMPLEXED WITH METHYL ARACHIDONYL FLUOROPHOSPHONATE (MAFP)
6RVC	;	2.2	;	Crystal structure of Patched-1 ectodomain 2 (PTCH1-ECD2) in complex with nanobody 75
6CTH	;	1.7	;	Crystal Structure of Pathogenesis-related Protein 1G (PR-1G) Kinase Domain from Cacao
8H3J	;	1.75	;	Crystal Structure of Pathogenesis-related Protein HcPR10 from Halostachys caspica in complex with trans-Zeatin-riboside
1XDF	;	1.9	;	Crystal structure of pathogenesis-related protein LlPR-10.2A from yellow lupine
2QIM	;	1.35	;	Crystal Structure of Pathogenesis-related Protein LlPR-10.2B from yellow lupine in complex with Cytokinin
3E85	;	1.95	;	Crystal Structure of Pathogenesis-related Protein LlPR-10.2B from yellow lupine in complex with Diphenylurea
1ICX	;	1.95	;	CRYSTAL STRUCTURE OF PATHOGENESIS-RELATED PROTEIN LLPR10.1A FROM YELLOW LUPINE
1IFV	;	2.25	;	CRYSTAL STRUCTURE OF PATHOGENESIS-RELATED PROTEIN LLPR10.1B FROM YELLOW LUPINE
5MGH	;	1.87	;	Crystal structure of pathogenic mutants of human mitochodnrial PheRS
6HV6	;	2.001	;	Crystal structure of PatoxP, a cysteine protease-like domain of Photorhabdus asymbiotica toxin PaTox
5UWH	;	2.26	;	Crystal Structure of Paxillin NES Peptide in complex with CRM1-Ran-RanBP1
4WJA	;	2.6	;	Crystal Structure of PAXX
1N0Y	;	1.75	;	Crystal Structure of Pb-bound Calmodulin
5NGJ	;	2.2	;	Crystal structure of pb6, major tail tube protein of bacteriophage T5
4JMQ	;	1.895	;	Crystal structure of pb9: The Dit of bacteriophage T5.
3Q5I	;	2.1	;	Crystal Structure of PBANKA_031420
3KK5	;	10.6	;	Crystal structure of PBCV-1 VP54 fitted into a cryo-EM reconstruction of the virophage Sputnik
3VDH	;	1.62	;	Crystal structure of PbGH5A, a glycoside hydrolase family 5 enzyme from Prevotella bryantii B14
5D9O	;	1.55	;	Crystal structure of PbGH5A, a glycoside hydrolase family 5 enzyme from Prevotella bryantii B14, E280A mutant in complex with cellotetraose
5D9M	;	1.9	;	Crystal structure of PbGH5A, a glycoside hydrolase family 5 enzyme from Prevotella bryantii B14, E280A mutant in complex with the xyloglucan tetradecasaccharide XXXGXXXG
5D9P	;	1.8	;	Crystal structure of PbGH5A, a glycoside hydrolase family 5 enzyme from Prevotella bryantii B14, in complex with an inhibitory N-bromoacetylglycosylamine derivative of XXXG
5D9N	;	1.86	;	Crystal structure of PbGH5A, a glycoside hydrolase family 5 member from Prevotella bryantii B14, in complex with the xyloglucan heptasaccharide XXXG
3SLG	;	2.1	;	Crystal structure of PbgP3 protein from Burkholderia pseudomallei
8FEK	;	2.058	;	Crystal structure of PBP cyclase Ulm16
7EJG	;	1.68	;	Crystal structure of PBP domain of RMCA
2V2F	;	1.9	;	Crystal structure of PBP1a from drug-resistant strain 5204 from Streptococcus pneumoniae
4OON	;	3.2	;	Crystal structure of PBP1a in complex with compound 17 ((4Z,8S,11E,14S)-5-(2-amino-1,3-thiazol-4-yl)-14-(5,6-dihydroxy-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-8-formyl-2-methyl-6-oxo-3,10-dioxa-4,7,11-triazatetradeca-4,11-diene-2,12,14-tricarboxylic acid)
4BL2	;	2.72	;	Crystal structure of PBP2a clinical mutant E150K from MRSA
4BL3	;	3.0	;	Crystal structure of PBP2a clinical mutant N146K from MRSA
4CPK	;	2.35	;	Crystal structure of PBP2a double clinical mutant N146K-E150K from MRSA
3ZG5	;	2.55	;	Crystal structure of PBP2a from MRSA in complex with peptidoglycan analogue at allosteric
6Q9N	;	2.5	;	Crystal structure of PBP2a from MRSA in complex with piperacillin and quinazolinone
6H5O	;	2.82	;	Crystal structure of PBP2a from MRSA in complex with piperacillin at active site.
4CJN	;	1.947	;	Crystal structure of PBP2a from MRSA in complex with quinazolinone ligand
5M18	;	1.98	;	Crystal structure of PBP2a from MRSA in the presence of Cefepime ligand
5M1A	;	2.0	;	Crystal structure of PBP2a from MRSA in the presence of Ceftazidime ligand
5M19	;	2.0	;	Crystal structure of PBP2a from MRSA in the presence of Oxacillin ligand
3PBS	;	2.0	;	Crystal structure of PBP3 complexed with aztreonam
3PBO	;	1.74	;	Crystal structure of PBP3 complexed with ceftazidime
3PBQ	;	1.7	;	Crystal structure of PBP3 complexed with imipenem
3PBT	;	1.641	;	Crystal structure of PBP3 complexed with MC-1
3PBR	;	1.95	;	Crystal structure of PBP3 complexed with meropenem
7ONW	;	2.7	;	Crystal structure of PBP3 from E. coli in complex with AIC499
7ONX	;	2.16	;	Crystal structure of PBP3 from P. aeruginosa
7ONY	;	1.77	;	Crystal structure of PBP3 from P. aeruginosa
7ONZ	;	1.86	;	Crystal structure of PBP3 from P. aeruginosa
7ONK	;	1.73	;	Crystal structure of PBP3 from P. aeruginosa in complex with AIC499
4OOM	;	2.0	;	Crystal structure of PBP3 in complex with BAL30072 ((2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(1,5-dihydroxy-4-oxo-1,4-dihydropyridin-2-yl)methoxy]imino}-N-{(2S)-1-hydroxy-3-methyl-3-[(sulfooxy)amino]butan-2-yl}ethanamide)
4OOL	;	2.3	;	Crystal structure of PBP3 in complex with compound 14 ((2E)-2-({[(2S)-2-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(1,5-dihydroxy-4-oxo-1,4-dihydropyridin-2-yl)methoxy]imino}acetyl]amino}-3-oxopropyl]oxy}imino)pentanedioic acid)
7ONO	;	2.3	;	Crystal structure of PBP3 transpeptidase domain from E. coli
7ONN	;	1.92	;	Crystal structure of PBP3 transpeptidase domain from E. coli in complex with AIC499
1W5D	;	2.1	;	Crystal structure of PBP4a from Bacillus subtilis
6C84	;	2.511	;	Crystal structure of PBP5 from Enterococcus faecium
3LO7	;	2.05	;	Crystal structure of PBPA from Mycobacterium tuberculosis
3UN7	;	2.0	;	Crystal structure of PBPA from MYCOBACTERIUM TUBERCULOSIS
6I56	;	2.12	;	Crystal structure of PBSX exported protein XepA
8GBV	;	2.08	;	Crystal structure of PC39-17A, an anti-HIV broadly neutralizing antibody
8GBW	;	1.5	;	Crystal structure of PC39-23D, an anti-HIV broadly neutralizing antibody
8GBY	;	2.35	;	Crystal structure of PC39-50E, an anti-HIV broadly neutralizing antibody
8GBX	;	2.7	;	Crystal structure of PC39-50I, an anti-HIV broadly neutralizing antibody
8GC0	;	2.43	;	Crystal structure of PC39-50L, an anti-HIV broadly neutralizing antibody
8GBZ	;	1.97	;	Crystal structure of PC39-55C, an anti-HIV broadly neutralizing antibody
4USG	;	1.973	;	Crystal structure of PC4 W89Y mutant complex with DNA
4NSQ	;	2.3108	;	Crystal structure of PCAF
6LFV	;	1.9	;	Crystal structure of PCB4scFv(hN56D)
6LFW	;	1.41	;	Crystal structure of PCB4scFv(hN56D) in complex with PCB#126
6LFX	;	1.43	;	Crystal structure of PCB4scFv(hN56D) in complex with PCB#77
7RDK	;	2.46	;	Crystal structure of PCDN-16B, an anti-HIV antibody from the PCDN bnAb lineage (cysteinylated state)
7RDJ	;	1.93	;	Crystal structure of PCDN-16B, an anti-HIV antibody from the PCDN bnAb lineage (non-cysteinylated state)
7RDL	;	2.71	;	Crystal structure of PCDN-22A, an anti-HIV antibody from the PCDN bnAb lineage
5BZD	;	2.7	;	Crystal Structure of PCDN-27A, an antibody from the PCDN family of HIV-1 antibodies
5BZW	;	2.9	;	Crystal Structure of PCDN-27B, an antibody from the PCDN family of HIV-1 antibodies
7RDM	;	2.08	;	Crystal structure of PCDN-38B, a broadly neutralizing anti-HIV antibody
3CHM	;	1.5	;	Crystal structure of PCI domain from A. thaliana COP9 signalosome subunit 7 (CSN7)
5MOM	;	2.27	;	Crystal Structure of PCNA encoding the hypomorphic mutation S228I
7O1E	;	2.34	;	Crystal structure of PCNA from Chaetomium thermophilum
4HK1	;	2.001	;	Crystal Structure of PCNA from Drosophila melanogaster
4CS5	;	3.0	;	Crystal Structure of PCNA from Litopenaeus vannamei
7EP8	;	1.95	;	Crystal structure of PCNA from Neurospora crassa
6T7X	;	2.3	;	Crystal structure of PCNA from P. abyssi
7BUP	;	2.7	;	Crystal structure of PCNA from pathogenic yeast Candida albicans
2ZVK	;	2.7	;	Crystal structure of PCNA in complex with DNA polymerase eta fragment
2ZVM	;	2.3	;	Crystal structure of PCNA in complex with DNA polymerase iota fragment
2ZVL	;	2.5	;	Crystal structure of PCNA in complex with DNA polymerase kappa fragment
6AIG	;	2.0	;	Crystal structure of PCNA1 from Aeropyrum pernix
2IO4	;	2.6	;	Crystal structure of PCNA12 dimer from Sulfolobus solfataricus.
2NTI	;	2.5	;	Crystal structure of PCNA123 heterotrimer.
3AIX	;	2.9	;	Crystal structure of PCNA2-PCNA3 complex from Sulfolobus tokodaii (I222)
3AIZ	;	2.8	;	Crystal structure of PCNA2-PCNA3 complex from Sulfolobus tokodaii (P21212)
2IJX	;	1.9	;	Crystal structure of PCNA3 monomer from Sulfolobus solfataricus.
7CXZ	;	1.561	;	crystal structure of pco2
7CHJ	;	2.44	;	crystal structure of pco4
7CHI	;	2.502	;	crystal structure of pco5
1LYQ	;	1.5	;	Crystal Structure of PcoC, a Methionine Rich Copper Resistance Protein from Escherichia coli
3VZZ	;	2.04	;	Crystal structure of PcrB complexed with FsPP from bacillus subtilis subap. subtilis str. 168
3W00	;	2.5	;	Crystal structure of PcrB complexed with G1P and FsPP from bacillus subtilis subap. subtilis str. 168
3VZY	;	1.63	;	Crystal structure of PcrB complexed with G1P from bacillus subtilis subap. subtilis str. 168
3W01	;	1.54	;	Crystal structure of PcrB complexed with PEG from Staphylococcus aureus subsp. aureus Mu3
3W02	;	2.98	;	Crystal structure of PcrB complexed with SO4 from Staphylococcus aureus subsp. aureus Mu3
3VZX	;	1.54	;	Crystal structure of PcrB from bacillus subtilis subap. subtilis str. 168
2XCC	;	2.13	;	Crystal structure of PcrH from Pseudomonas aeruginosa
4JL0	;	2.22	;	Crystal structure of PcrH in complex with the chaperone binding region of PopB
2XCB	;	1.85	;	Crystal structure of PcrH in complex with the chaperone binding region of PopD
8E75	;	1.25	;	Crystal structure of Pcryo_0616, the aminotransferase required to synthesize UDP-N-acetyl-3-amino-D-glucosaminuronic acid (UDP-GlcNAc3NA)
2P4E	;	1.98	;	Crystal Structure of PCSK9
3H42	;	2.3	;	Crystal structure of PCSK9 in complex with Fab from LDLR competitive antibody
4OV6	;	2.69	;	Crystal structure of PCSK9(53-451) with Adnectin
6CA7	;	1.643	;	Crystal structure of PCT64_13C, a strain specific anti-HIV antibody
5FEH	;	3.1	;	Crystal structure of PCT64_35B, a broadly neutralizing anti-HIV antibody
6CA6	;	2.43	;	Crystal structure of PCT64_35S, a broadly neutralizing anti-HIV antibody.
3AJG	;	1.9	;	Crystal structure of PcyA V225D-biliverdin IX alpha complex
3AJH	;	2.25	;	Crystal structure of PcyA V225D-biliverdin XIII alpha complex
3I8U	;	1.48	;	Crystal structure of PcyA-181,182-dihydrobiliverdin complex
2D1E	;	1.51	;	Crystal structure of PcyA-biliverdin complex
3I94	;	1.04	;	Crystal structure of PcyA-biliverdin XIII alpha complex
3AF8	;	1.66	;	Crystal Structure of Pd(ally)/apo-C126AFr
3AF9	;	1.85	;	Crystal Structure of Pd(allyl)/apo-C48AFr
3NP2	;	1.86	;	Crystal Structure of Pd(allyl)/apo-E45C/C48A-rHLFr
3NP0	;	1.48	;	Crystal Structure of Pd(allyl)/apo-E45C/H49A/R52H-rHLFr
3NOZ	;	1.52	;	Crystal Structure of Pd(allyl)/apo-E45C/R52H-rHLFr
2ZG7	;	1.7	;	Crystal Structure of Pd(allyl)/apo-Fr
2ZG9	;	1.75	;	Crystal Structure of Pd(allyl)/apo-H114AFr
2ZG8	;	1.6	;	Crystal Structure of Pd(allyl)/apo-H49AFr
5YHB	;	2.08	;	Crystal structure of Pd(allyl)/polyhedra mutant with deletion of Gly192-Ala194
5YHA	;	1.58	;	Crystal structure of Pd(allyl)/Wild Type Polyhedra
7BXA	;	3.32	;	Crystal structure of PD-1 in complex with tislelizumab Fab
5JDS	;	1.7	;	Crystal structure of PD-L1 complexed with a nanobody at 1.7 Angstron resolution
5XXY	;	2.9	;	Crystal structure of PD-L1 complexed with atezolizumab fab at 2.9A
3LE7	;	1.65	;	Crystal structure of PD-L1 from P. dioica in complex with adenine
7CZD	;	1.64	;	Crystal structure of PD-L1 in complex with a VHH
8SDL	;	1.75	;	Crystal structure of PDC-3 beta-lactamase
8SDR	;	1.35	;	Crystal structure of PDC-3 beta-lactamase in complex with the boronic acid inhibitor LP-06
8SDT	;	1.38	;	Crystal structure of PDC-3 beta-lactamase in complex with the boronic acid inhibitor S02030
8SDN	;	2.1	;	Crystal structure of PDC-3 Y221H beta-lactamase
8SDS	;	1.63	;	Crystal structure of PDC-3 Y221H beta-lactamase in complex with the boronic acid inhibitor LP-06
8SDV	;	1.42	;	Crystal structure of PDC-3 Y221H beta-lactamase in complex with the boronic acid inhibitor S02030
3EIJ	;	2.8	;	Crystal structure of Pdcd4
3EIQ	;	3.5	;	Crystal structure of Pdcd4-eIF4A
6IJI	;	2.7	;	Crystal structure of PDE10 in complex with inhibitor 2b
6IJH	;	2.6	;	Crystal structure of PDE10 in complex with inhibitor AF-399/14387019
2OUP	;	1.56	;	crystal structure of PDE10A
5ZNL	;	2.8	;	Crystal structure of PDE10A catalytic domain complexed with LHB-6
4WN1	;	3.13	;	Crystal structure of PDE10A in complex with 1-methyl-5-(1-methyl-3-{[4-(quinolin-2-yl)phenoxy]methyl}-1H-pyrazol-4-yl)pyridin-2(1H)-one
5XUI	;	2.77	;	Crystal structure of PDE10A in complex with 2-methyl-5-[2-([1,2,4]triazolo[1,5-a]pyrimidin-2-yl)et hyl]pyrazolo[1,5-a]pyrimidin-7-ol
5XUJ	;	2.44	;	Crystal structure of PDE10A in complex with 7-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]pyrimidine
3WS9	;	2.99	;	Crystal structure of PDE10A in complex with a benzimdazole inhibitor
3WS8	;	2.6	;	Crystal structure of PDE10A in complex with a benzimidazole inhibitor
6KDX	;	2.44	;	Crystal structure of PDE10A in complex with a triazolopyrimidine inhibitor
6KDZ	;	3.1	;	Crystal structure of PDE10A in complex with a triazolopyrimidine inhibitor
6KE0	;	2.95	;	Crystal structure of PDE10A in complex with a triazolopyrimidine inhibitor
4XY2	;	2.03	;	Crystal structure of PDE10A in complex with ASP9436
3WI2	;	2.26	;	Crystal structure of PDE10A in complex with inhibitor
4PHW	;	2.5	;	Crystal Structure of PDE10A with 1H-benzimidazol-2-yl(4-((3-(tetrahydro-2H-pyran-4-yl)-2-pyridinyl)oxy)phenyl)methanone
4HEU	;	2.0	;	Crystal Structure of PDE10A with a biaryl ether inhibitor ((1-(3-(4-((1H-benzo[d]imidazol-2-yl)amino)phenoxy)pyridin-2-yl)piperidin-4-yl)methanol)
4HF4	;	2.0	;	Crystal Structure of PDE10A with a biaryl ether inhibitor (1-(1-(3-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyrazin-2-yl)piperidin-4-yl)ethanol)
4P0N	;	2.08	;	Crystal structure of PDE10a with a novel Imidazo[4,5-b]pyridine inhibitor
4P1R	;	2.243	;	Crystal Structure of PDE10A with Imidazo[4,5-b]pyridines as Potent and Selective Inhibitors
4MUW	;	2.639	;	Crystal Structure of PDE10A with Novel Keto-Benzimidazole Inhibitor
4MVH	;	2.496	;	Crystal Structure of PDE10A with Novel Keto-Benzimidazole Inhibitor
2OUN	;	1.56	;	crystal structure of PDE10A2 in complex with AMP
2OUQ	;	1.9	;	crystal structure of PDE10A2 in complex with GMP
2OUY	;	1.9	;	crystal structure of pde10a2 mutant D564A in complex with cAMP.
2OUS	;	1.45	;	crystal structure of PDE10A2 mutant D674A
2OUR	;	1.45	;	crystal structure of PDE10A2 mutant D674A in complex with cAMP
2OUU	;	1.52	;	crystal structure of PDE10A2 mutant D674A in complex with cGMP
2OUV	;	1.56	;	crystal structure of pde10a2 mutant of D564N
4MRW	;	1.96	;	Crystal structure of PDE10A2 with fragment ZT0120 (7-chloroquinolin-4-ol)
4MSH	;	2.3	;	Crystal Structure of PDE10A2 with fragment ZT0143 ((2S)-4-chloro-2,3-dihydro-1,3-benzothiazol-2-amine)
4LKQ	;	1.62	;	Crystal structure of PDE10A2 with fragment ZT017
4MRZ	;	1.58	;	Crystal structure of PDE10A2 with fragment ZT0429 (4-methyl-3-nitropyridin-2-amine)
4MS0	;	1.79	;	Crystal structure of PDE10A2 with fragment ZT0443 (6-chloropyrimidine-2,4-diamine)
4MSA	;	1.62	;	Crystal structure of PDE10A2 with fragment ZT0449 (5-nitro-1H-benzimidazole)
4MSN	;	2.3	;	Crystal structure of PDE10A2 with fragment ZT0451 (8-nitroquinoline)
4MSC	;	2.47	;	Crystal structure of PDE10A2 with fragment ZT1595 (2-[(quinolin-7-yloxy)methyl]quinoline)
4MSE	;	2.81	;	Crystal structure of PDE10A2 with fragment ZT1597 (2-({[(2S)-2-methyl-2,3-dihydro-1,3-benzothiazol-5-yl]oxy}methyl)quinoline)
4LLJ	;	1.56	;	Crystal structure of PDE10A2 with fragment ZT214
4LLK	;	1.55	;	Crystal structure of PDE10A2 with fragment ZT217
4LLP	;	1.75	;	Crystal structure of PDE10A2 with fragment ZT401
4LLX	;	1.75	;	Crystal structure of PDE10A2 with fragment ZT434
4LM0	;	1.66	;	Crystal structure of PDE10A2 with fragment ZT448
4LM1	;	1.6	;	Crystal structure of PDE10A2 with fragment ZT450
4LM2	;	1.55	;	Crystal structure of PDE10A2 with fragment ZT462
4LM3	;	1.49	;	Crystal structure of PDE10A2 with fragment ZT464
4LM4	;	1.48	;	Crystal structure of PDE10A2 with fragment ZT902
4HTX	;	1.9	;	Crystal structure of PDE2 catalytic domain in complex with BAY60-7550
4HTZ	;	2.0	;	Crystal structure of PDE2 catalytic domain in space group P1
6B97	;	1.76	;	Crystal structure of PDE2 in complex with complex 9
6B96	;	1.88	;	Crystal Structure of PDE2 in complex with compound 16
8SYC	;	2.7	;	Crystal structure of PDE3B in complex with GSK4394835A
2QYK	;	2.1	;	Crystal structure of PDE4A10 in complex with inhibitor NPV
3D3P	;	1.75	;	Crystal structure of PDE4B catalytic domain in complex with a pyrazolopyridine inhibitor
1RO6	;	2.0	;	Crystal structure of PDE4B2B complexed with Rolipram (R & S)
2QYL	;	1.95	;	Crystal structure of PDE4B2B in complex with inhibitor NPV
1MKD	;	2.9	;	crystal structure of PDE4D catalytic domain and zardaverine complex
7W4X	;	2.20007	;	Crystal structure of PDE4D catalytic domain complexed with 17
7W4Y	;	2.10003	;	Crystal structure of PDE4D catalytic domain complexed with 33a
6KJZ	;	2.2	;	Crystal structure of PDE4D catalytic domain complexed with compound 1
7F2K	;	2.10002	;	Crystal structure of PDE4D catalytic domain complexed with compound 17a
7F2L	;	2.10111	;	Crystal structure of PDE4D catalytic domain complexed with compound 18a
7F2M	;	2.20004	;	Crystal structure of PDE4D catalytic domain complexed with compound 18d
7XAA	;	2.10041	;	Crystal structure of PDE4D catalytic domain complexed with compound 21d
7XAB	;	2.00067	;	Crystal structure of PDE4D catalytic domain complexed with compound 22d
7XBB	;	2.10001	;	Crystal structure of PDE4D catalytic domain complexed with compound 23a
6KK0	;	2.20009	;	Crystal structure of PDE4D catalytic domain complexed with compound 4e
5WQA	;	2.3	;	Crystal structure of PDE4D catalytic domain complexed with Selaginpulvilins K
7CBQ	;	1.59	;	Crystal structure of PDE4D catalytic domain in complex with Apremilast
6LRM	;	1.45	;	Crystal structure of PDE4D catalytic domain in complex with arctigenin
7CBJ	;	1.5	;	Crystal structure of PDE4D catalytic domain in complex with compound 36
6IM6	;	1.702	;	Crystal structure of PDE4D complexed with a novel inhibitor
6IMB	;	1.549	;	Crystal structure of PDE4D complexed with a novel inhibitor
6IMD	;	1.499	;	Crystal structure of PDE4D complexed with a novel inhibitor
6IMI	;	1.46	;	Crystal structure of PDE4D complexed with a novel inhibitor
6IMO	;	1.55	;	Crystal structure of PDE4D complexed with a novel inhibitor
6IMR	;	1.503	;	Crystal structure of PDE4D complexed with a novel inhibitor
6IMT	;	1.483	;	Crystal structure of PDE4D complexed with a novel inhibitor
6IND	;	1.872	;	Crystal structure of PDE4D complexed with a novel inhibitor
6INK	;	1.7	;	Crystal structure of PDE4D complexed with a novel inhibitor
6INM	;	1.999	;	Crystal structure of PDE4D complexed with a novel inhibitor
8K4H	;	1.95	;	Crystal structure of PDE4D complexed with benzbromarone
8W4R	;	1.37	;	Crystal structure of PDE4D complexed with CVT-313
8W4Q	;	1.55	;	Crystal structure of PDE4D complexed with CX-4945
8K4C	;	2.1	;	Crystal structure of PDE4D complexed with ethaverine hydrochloride
7YQF	;	1.54	;	Crystal structure of PDE4D complexed with glycyrrhisoflavone
7YSX	;	1.65	;	Crystal structure of PDE4D complexed with licoisoflavone A
2FM0	;	2.0	;	Crystal structure of PDE4D in complex with L-869298
1OYN	;	2.0	;	Crystal structure of PDE4D2 in complex with (R,S)-rolipram
5WH6	;	1.6	;	Crystal structure of PDE4D2 in complex with inhibitor (S_Zl-n-91)
2FM5	;	2.03	;	Crystal structure of PDE4D2 in complex with inhibitor L-869299
6ZBA	;	1.6	;	Crystal structure of PDE4D2 in complex with inhibitor LEO39652
2QYN	;	1.57	;	Crystal structure of PDE4D2 in complex with inhibitor NPV
6VBI	;	2.30001	;	crystal structure of PDE5 in complex with a non-competitive inhibitor
4MD6	;	2.0	;	Crystal structure of PDE5 in complex with inhibitor 5R
5ZZ2	;	2.6	;	Crystal structure of PDE5 in complex with inhibitor LW1634
6ACB	;	2.8	;	Crystal structure of PDE5 in complex with inhibitor LW1805
2H42	;	2.3	;	Crystal structure of PDE5 in complex with sildenafil
4G2Y	;	2.4	;	Crystal structure of PDE5A complexed with its inhibitor
3MF0	;	3.1	;	Crystal structure of PDE5A GAF domain (89-518)
6IWI	;	2.155	;	Crystal structure of PDE5A in complex with a novel inhibitor
8W4T	;	2.199	;	Crystal structure of PDE5A in complex with a novel inhibitor
8W4S	;	1.848	;	Crystal structure of PDE5A in complex with CVT-313
7FAQ	;	2.20014	;	Crystal structure of PDE5A in complex with inhibitor L1
7FAR	;	2.40006	;	Crystal structure of PDE5A in complex with inhibitor L12
4G2W	;	2.28	;	Crystal structure of PDE5A in complex with its inhibitor
3B2R	;	2.07	;	Crystal Structure of PDE5A1 catalytic domain in complex with Vardenafil
2H44	;	1.8	;	Crystal structure of PDE5A1 in complex with icarisid II
1RKP	;	2.05	;	Crystal structure of PDE5A1-IBMX
7QF9	;	1.95	;	Crystal structure of PDE6D bound to HRas peptide
7Q9Q	;	1.45	;	Crystal structure of PDE6D Geranylgeranylated cystein complex
5T4X	;	1.81	;	CRYSTAL STRUCTURE OF PDE6D IN APO-STATE
7QJK	;	3.1	;	Crystal structure of PDE6D in complex with Compound-2
4JVB	;	1.75	;	Crystal structure of PDE6D in complex with the inhibitor rac-2
7Q9S	;	1.85	;	Crystal structure of PDE6D KRas peptide complex with Compound-1
7VSL	;	2.50007	;	Crystal structure of PDE8A catalytic domain in complex with 10
7VTV	;	2.8	;	Crystal structure of PDE8A catalytic domain in complex with 15
7VTW	;	2.79971	;	Crystal structure of PDE8A catalytic domain in complex with 17
7VTX	;	2.50011	;	Crystal structure of PDE8A catalytic domain in complex with 22
7CWF	;	2.8	;	Crystal structure of PDE8A catalytic domain in complex with 2c
7CWG	;	2.8	;	Crystal structure of PDE8A catalytic domain in complex with 3a
7CWA	;	2.8	;	Crystal structure of PDE8A catalytic domain in complex with clofarabine
3ECN	;	2.1	;	Crystal structure of PDE8A catalytic domain in complex with IBMX
2HD1	;	2.23	;	Crystal structure of PDE9 in complex with IBMX
4Y86	;	2.01	;	Crystal structure of PDE9 in complex with racemic inhibitor C33
3N3Z	;	2.75	;	Crystal structure of PDE9A (E406A) mutant in complex with IBMX
3QI4	;	2.5	;	Crystal structure of PDE9A(Q453E) in complex with IBMX
3QI3	;	2.3	;	Crystal structure of PDE9A(Q453E) in complex with inhibitor BAY73-6691
5MTC	;	1.7	;	Crystal structure of PDF from the Vibrio parahaemolyticus bacteriophage VP16T - crystal form I
5MTD	;	1.5	;	Crystal structure of PDF from the Vibrio parahaemolyticus bacteriophage VP16T - crystal form II
5MTE	;	1.4	;	Crystal structure of PDF from the Vibrio parahaemolyticus bacteriophage VP16T in complex with actinonin - crystal form II
6JOL	;	1.9	;	Crystal structure of PDGFRA in complex with imatinib by co-crystallization
6JOK	;	3.8	;	Crystal structure of PDGFRA in complex with sunitinib by soaking
5GRN	;	1.77	;	Crystal structure of PDGFRA in Complex with WQ-C-159
6A32	;	1.87	;	Crystal structure of PDGFRA kinase domain mutant T674I
6JOI	;	3.1	;	Crystal structure of PDGFRA T674I in complex with crenolanib by co-crystallization
6JOJ	;	2.6	;	Crystal structure of PDGFRA T674I in complex with crenolanib by soaking
7JWF	;	2.187	;	Crystal structure of PdGH110B D344N in complex with alpha-(1,3)-galactobiose
7JW4	;	2.342	;	Crystal structure of PdGH110B in complex with D-galactose
2XCH	;	2.0	;	Crystal structure of PDK1 in complex with a pyrazoloquinazoline inhibitor
2XCK	;	2.3	;	Crystal structure of PDK1 in complex with a pyrazoloquinazoline inhibitor
4RRV	;	1.412	;	Crystal structure of PDK1 in complex with ATP and PIFtide
4XX9	;	1.4	;	Crystal structure of PDK1 in complex with ATP and the PIF-pocket ligand RF4
4RQK	;	1.55	;	Crystal structure of PDK1 in complex with ATP and the PIF-pocket ligand RS1
4RQV	;	1.502	;	Crystal structure of PDK1 in complex with ATP and the PIF-pocket ligand RS2
4OZD	;	2.95	;	Crystal structure of PdSP15a
4QIG	;	3.297	;	Crystal Structure of PduA with edge mutation K26A and pore mutation S40C
4QIF	;	1.9951	;	Crystal Structure of PduA with edge mutation K26A and pore mutation S40H
4QIE	;	2.3501	;	Crystal Structure of PduA with edge mutation K26D
5CX7	;	1.97	;	Crystal Structure of PduOC:Heme Complex
3PAC	;	1.86	;	Crystal structure of PduT a trimeric bacterial microcompartment protein with 4Fe-4S cluster binding site
2Z17	;	2.7	;	Crystal structure of PDZ domain from human Pleckstrin homology, Sec7
2EAQ	;	1.46	;	Crystal structure of PDZ domain of KIAA0858 (LIM), MS0793 from Homo sapiens
5HJ1	;	1.5	;	Crystal structure of PDZ domain of pullulanase C protein of type II secretion system from Klebsiella pneumoniae in complex with fatty acid
3QE1	;	1.68	;	Crystal Structure of PDZ domain of sorting nexin 27 (SNX27) fused to the C-terminal residues (ESESKV) of GIRK3
3QDO	;	1.88	;	Crystal Structure of PDZ domain of sorting nexin 27 (SNX27) fused to the Gly-Gly linker followed by C-terminal (ESESKV) of GIRK3
3QGL	;	3.31	;	Crystal Structure of PDZ domain of sorting nexin 27 (SNX27) in complex with the ESESKV peptide corresponding to the C-terminal tail of GIRK3
2JIK	;	1.35	;	Crystal structure of PDZ domain of Synaptojanin-2 binding protein
2JIN	;	1.5	;	Crystal structure of PDZ domain of Synaptojanin-2 binding protein
5J0A	;	2.74	;	Crystal structure of PDZ-binding kinase
5GLJ	;	1.6	;	Crystal Structure of PDZ1 Domain of Human Protein Tyrosine Phosphatase PTP-Bas
6SPV	;	2.04	;	Crystal structure of PDZ1-2 from PSD-95
6SPZ	;	2.08	;	Crystal structure of PDZ1-2 from PSD-95 with peptide ligand sequence RRESEI bound to both domains
1TP5	;	1.54	;	Crystal structure of PDZ3 domain of PSD-95 protein complexed with a peptide ligand KKETWV
3TSZ	;	2.502	;	crystal structure of PDZ3-SH3-GUK core module from human ZO-1 in complex with 12mer peptide from human JAM-A cytoplasmic tail
7DE7	;	1.49	;	Crystal structure of PDZD7 HHD domain
3CX6	;	2.5	;	Crystal Structure of PDZRhoGEF rgRGS Domain in a Complex with Galpha-13 Bound to GDP
3CX7	;	2.25	;	Crystal Structure of PDZRhoGEF rgRGS Domain in a Complex with Galpha-13 Bound to GDP-AlF4
3CX8	;	2.0	;	Crystal Structure of PDZRhoGEF rgRGS Domain in a Complex with Galpha-13 Bound to GTP-gamma-S
3FLT	;	2.7	;	Crystal structure of PE-bound octameric SAP-like pentraxin from Limulus polyphemus
8ITE	;	2.1	;	Crystal structure of pE301R from African swine fever virus
5XFS	;	2.9	;	Crystal structure of PE8-PPE15 in complex with EspG5 from M. tuberculosis
3KSC	;	2.606	;	Crystal structure of pea prolegumin, an 11S seed globulin from Pisum sativum L.
1H65	;	2.0	;	Crystal structure of pea Toc34 - a novel GTPase of the chloroplast protein translocon
2ALG	;	2.3	;	Crystal structure of peach Pru p3, the prototypic member of the family of plant non-specific lipid transfer protein pan-allergens
2B5S	;	2.35	;	Crystal structure of peach Pru p3, the prototypic member of the family of plant non-specific lipid transfer protein pan-allergens
4ESP	;	1.1	;	Crystal Structure of Peanut Allergen Ara h 5
2DVD	;	2.25	;	Crystal structure of peanut lectin GAL-ALPHA-1,3-GAL complex
2DVG	;	2.78	;	Crystal structure of peanut lectin GAL-ALPHA-1,6-GLC complex
2DV9	;	2.48	;	Crystal structure of peanut lectin GAL-BETA-1,3-GAL complex
2DVA	;	2.2	;	Crystal structure of peanut lectin GAL-BETA-1,3-GALNAC-ALPHA-O-ME (Methyl-T-antigen) complex
2DVB	;	2.25	;	Crystal structure of peanut lectin GAl-beta-1,6-GalNAc complex
1RIT	;	2.85	;	Crystal structure of Peanut lectin in complex with meso-tetrasulphonatophenylporphyrin and lactose
2DH1	;	7.65	;	Crystal structure of peanut lectin lactose-azobenzene-4,4'-dicarboxylic acid-lactose complex
3C3V	;	1.73	;	Crystal structure of peanut major allergen ara h 3
2HXW	;	1.6	;	Crystal Structure of Peb3 from Campylobacter jejuni
5C14	;	2.8	;	Crystal structure of PECAM-1 D1D2 domain
5E1R	;	2.651	;	Crystal structure of pecan (carya illinoinensis) vicilin, a new food allergen
1JTA	;	1.8	;	Crystal Structure of Pectate Lyase A (C2 form)
3VMV	;	1.54	;	Crystal structure of pectate lyase Bsp165PelA from Bacillus sp. N165
3VMW	;	1.9	;	Crystal structure of pectate lyase Bsp165PelA from Bacillus sp. N165 in complex with trigalacturonate
2EWE	;	2.2	;	Crystal structure of Pectate Lyase C R218K mutant in complex with pentagalacturonic acid
1EE6	;	2.3	;	CRYSTAL STRUCTURE OF PECTATE LYASE FROM BACILLUS SP. STRAIN KSM-P15.
4U4B	;	2.1	;	Crystal Structure of Pectate Lyase Pel3 from Pectobacterium carotovorum with one monomer in the A.U.
4U49	;	1.8	;	Crystal structure of Pectate Lyase Pel3 from Pectobacterium carotovorum with two monomers in the A.U
1RU4	;	1.6	;	Crystal structure of pectate lyase Pel9A
3B8Y	;	2.3	;	Crystal Structure of Pectate Lyase PelI from Erwinia chrysanthemi in complex with tetragalacturonic acid
2NSP	;	1.7	;	Crystal structure of pectin methylesterase D178A mutant in complex with hexasaccharide I
2NST	;	1.7	;	Crystal structure of pectin methylesterase D178A mutant in complex with hexasaccharide II
2NT6	;	1.7	;	Crystal structure of pectin methylesterase D178A mutant in complex with hexasaccharide III
2NT9	;	1.9	;	Crystal structure of pectin methylesterase D178A mutant in complex with hexasaccharide IV
2NTB	;	1.8	;	Crystal structure of pectin methylesterase in complex with hexasaccharide V
2NTP	;	1.7	;	Crystal structure of pectin methylesterase in complex with hexasaccharide VI
2NTQ	;	1.8	;	Crystal structure of pectin methylesterase in complex with hexasaccharide VII
4ZA2	;	1.55	;	Crystal structure of Pectobacterium carotovorum 2-keto-3-deoxy-D-gluconate dehydrogenase complexed with NAD+
4N58	;	1.86	;	Crystal Structure of Pectocin M2 at 1.86 Angstroms
2IP6	;	1.35	;	Crystal structure of PedB
6RHS	;	2.6	;	Crystal structure of Pediococcus acidilactici (Putative)lactate oxidase Refolded WT protein
6R9V	;	2.0	;	Crystal structure of Pediococcus acidilactici lactate oxidase A94G mutant
4XPP	;	2.3	;	Crystal structure of Pedobacter saltans GH31 alpha-galactosidase complexed with D-galactose
4XPQ	;	1.85	;	Crystal structure of Pedobacter saltans GH31 alpha-galactosidase complexed with L-fucose
5HIY	;	3.0	;	Crystal structure of PEDV NSP9 Mutant-C59A
5ZZV	;	1.57	;	Crystal structure of PEG-1500 crystallized Peptidyl-tRNA Hydrolase from Acinetobacter baumannii at 1.5 A resolution
5XG9	;	1.78	;	Crystal Structure of PEG-bound SH3 domain of Myosin IB from Entamoeba histolytica
4R0O	;	4.2	;	Crystal structure of PEGylated plastocyanin at 4.2 A resolution
4ETX	;	2.0	;	Crystal Structure of PelD 158-CT from Pseudomonas aeruginosa PAO1
4ETZ	;	2.05	;	Crystal Structure of PelD 158-CT from Pseudomonas aeruginosa PAO1
4EU0	;	1.7	;	Crystal Structure of PelD 158-CT from Pseudomonas aeruginosa PAO1
4EUV	;	2.0	;	Crystal Structure of PelD 158-CT from Pseudomonas aeruginosa PAO1, in complex with c-di-GMP, form 1
3EGA	;	1.8	;	Crystal structure of Pellino2 FHA Domain at 1.8 Angstroms resolution
5EO3	;	2.6	;	Crystal Structure of Pelota C terminal domain from human
5DK3	;	2.28	;	Crystal Structure of Pembrolizumab, a full length IgG4 antibody
3W4Q	;	1.2	;	Crystal structure of PenA beta-lactamase from Burkholderia multivorans at pH4.2
7DOO	;	1.6	;	Crystal Structure of PenA beta-Lactamase-Avibactam Complex
7DDM	;	1.2	;	Crystal Structure of PenA39 beta-Lactamase
3N7X	;	2.5	;	Crystal structure of Penaeus stylirostris densovirus capsid
4MBF	;	1.54	;	Crystal structure of Penam sulfone PSR-4-157 bound to SHV-1 beta-lactamase
6MKH	;	2.62	;	Crystal structure of pencillin binding protein 4 (PBP4) from Enterococcus faecalis in the imipenem-bound form
3W4P	;	1.05	;	Crystal structure of PenI beta-lactamase from Burkholderia pseudomallei at pH7.5
3W4O	;	1.18	;	Crystal structure of PenI beta-lactamase from Burkholderia pseudomallei at pH9.5
6KGH	;	2.108	;	Crystal structure of Penicillin binding protein 3 (PBP3) from Mycobacterium tuerculosis (apo-form)
6KGV	;	2.301	;	Crystal structure of Penicillin binding protein 3 (PBP3) from Mycobacterium tuerculosis, complexed with amoxicillin
6KGW	;	2.407	;	Crystal structure of Penicillin binding protein 3 (PBP3) from Mycobacterium tuerculosis, complexed with ampicillin
6KGU	;	2.106	;	Crystal structure of Penicillin binding protein 3 (PBP3) from Mycobacterium tuerculosis, complexed with aztreonam
6KGT	;	2.308	;	Crystal structure of Penicillin binding protein 3 (PBP3) from Mycobacterium tuerculosis, complexed with faropenem
6KGS	;	2.309	;	Crystal structure of Penicillin binding protein 3 (PBP3) from Mycobacterium tuerculosis, complexed with meropenem
2EX2	;	1.55	;	Crystal structure of penicillin binding protein 4 (dacB) from Escherichia coli
2EX6	;	1.6	;	Crystal structure of penicillin binding protein 4 (dacB) from Escherichia coli, complexed with ampicillin
2EXA	;	1.7	;	Crystal structure of penicillin binding protein 4 (dacB) from Escherichia coli, complexed with FAROM
2EXB	;	1.75	;	Crystal structure of penicillin binding protein 4 (dacB) from Escherichia coli, complexed with FLOMOX
2EX8	;	1.6	;	Crystal structure of penicillin binding protein 4 (dacB) from Escherichia coli, complexed with penicillin-G
2EX9	;	1.65	;	Crystal structure of penicillin binding protein 4 (dacB) from Escherichia coli, complexed with penicillin-V
3A3D	;	1.6	;	Crystal structure of penicillin binding protein 4 (dacB) from Haemophilus influenzae
3A3I	;	2.0	;	Crystal structure of penicillin binding protein 4 (dacB) from Haemophilus influenzae, complexed with ampicillin (AIX)
3A3E	;	2.4	;	Crystal structure of penicillin binding protein 4 (dacB) from Haemophilus influenzae, complexed with novel beta-lactam (CMV)
3A3F	;	2.1	;	Crystal structure of penicillin binding protein 4 (dacB) from Haemophilus influenzae,complexed with novel beta-lactam (FMZ)
3ZG8	;	2.094	;	Crystal Structure of Penicillin Binding Protein 4 from Listeria monocytogenes in the Ampicillin bound form
3HUN	;	2.0	;	Crystal structure of Penicillin binding protein 4 from Staphylococcus aureus COL in complex with Ampicillin
3HUM	;	2.3	;	Crystal structure of Penicillin binding protein 4 from Staphylococcus aureus COL in complex with Cefotaxime
6MKG	;	2.94	;	Crystal structure of penicillin binding protein 5 (PBP5) from Enterococcus faecium in the benzylpenicilin-bound form
6MKJ	;	2.864	;	Crystal structure of penicillin binding protein 5 (PBP5) from Enterococcus faecium in the closed conformation
6MKF	;	2.8	;	Crystal structure of penicillin binding protein 5 (PBP5) from Enterococcus faecium in the imipenem-bound form
6MKA	;	2.698	;	Crystal structure of penicillin binding protein 5 (PBP5) from Enterococcus faecium in the open conformation
8F3V	;	3.1	;	Crystal structure of Penicillin Binding Protein 5 (PBP5) PAPAPAP variant apo form from Enterococcus faecium
8F3W	;	3.0	;	Crystal structure of Penicillin Binding Protein 5 (PBP5) PAPAPAP variant penicillin bound form from Enterococcus faecium
8F3X	;	3.4	;	Crystal structure of Penicillin Binding Protein 5 (PBP5) Poly-Gly variant apo form from Enterococcus faecium
8F3Y	;	2.99	;	Crystal structure of Penicillin Binding Protein 5 (PBP5) Poly-Gly variant penicillin bound form from Enterococcus faecium
8F3O	;	3.0	;	Crystal structure of Penicillin Binding Protein 5 (PBP5) R464A variant apo form from Enterococcus faecium
8F3P	;	3.09	;	Crystal structure of Penicillin Binding Protein 5 (PBP5) R464A variant penicillin bound form from Enterococcus faecium
8F3Z	;	2.8	;	Crystal structure of Penicillin Binding Protein 5 (PBP5) S422A variant apo form from Enterococcus faecium
8F3H	;	2.6	;	Crystal structure of Penicillin Binding Protein 5 (PBP5) S466 insertion variant apo form from Enterococcus faecium
8F3I	;	2.8	;	Crystal structure of Penicillin Binding Protein 5 (PBP5) S466 insertion variant penicillin bound form from Enterococcus faecium
8F3J	;	2.59	;	Crystal structure of Penicillin Binding Protein 5 (PBP5) T485A variant apo form from Enterococcus faecium
8F3L	;	3.4	;	Crystal structure of Penicillin Binding Protein 5 (PBP5) T485A variant penicillin bound form from Enterococcus faecium
8F3M	;	2.81	;	Crystal structure of Penicillin Binding Protein 5 (PBP5) T485A variant with S466 insertion apo form from Enterococcus faecium
8F3N	;	2.99	;	Crystal structure of Penicillin Binding Protein 5 (PBP5) T485A variant with S466 insertion penicillin bound form from Enterococcus faecium
8F3T	;	2.56	;	Crystal structure of Penicillin Binding Protein 5 (PBP5) T485M T499I V629E variant apo form from Enterococcus faecium
8F3U	;	2.6	;	Crystal structure of Penicillin Binding Protein 5 (PBP5) T485M T499I V629E variant penicillin bound form from Enterococcus faecium
8F3R	;	3.3	;	Crystal structure of Penicillin Binding Protein 5 (PBP5) T485M T499I variant apo form from Enterococcus faecium
8F3S	;	3.5	;	Crystal structure of Penicillin Binding Protein 5 (PBP5) T485M T499I variant penicillin bound form from Enterococcus faecium
8F3F	;	2.84	;	Crystal structure of Penicillin Binding Protein 5 (PBP5) T485M variant apo form from Enterococcus faecium
8F3G	;	3.59	;	Crystal structure of Penicillin Binding Protein 5 (PBP5) T485M variant in the penicillin bound form from Enterococcus faecium
8F3Q	;	2.9	;	Crystal structure of Penicillin Binding Protein 5 (PBP5) Y460A variant apo form from Enterococcus faecium
5FSR	;	2.4	;	Crystal structure of penicillin binding protein 6B from Escherichia coli
6NVW	;	2.203	;	Crystal structure of penicillin G acylase from Bacillus megaterium
6NVX	;	1.36	;	Crystal structure of penicillin G acylase from Bacillus sp. FJAT-27231
6NVY	;	2.27	;	Crystal structure of penicillin G acylase from Bacillus thermotolerans
1CP9	;	2.5	;	CRYSTAL STRUCTURE OF PENICILLIN G ACYLASE FROM THE BRO1 MUTANT STRAIN OF PROVIDENCIA RETTGERI
2OQC	;	2.5	;	Crystal Structure of Penicillin V acylase from Bacillus subtilis
7O49	;	3.03	;	Crystal structure of Penicillin-Binding Protein 1 (PBP1) from Staphylococcus aureus
7O4B	;	2.593	;	Crystal structure of Penicillin-Binding Protein 1 (PBP1) from Staphylococcus aureus in complex with penicillin G
7OK9	;	3.36	;	Crystal structure of Penicillin-Binding Protein 1 (PBP1) from Staphylococcus aureus in complex with pentaglycine
7O4A	;	3.028	;	Crystal structure of Penicillin-Binding Protein 1 (PBP1) from Staphylococcus aureus in complex with piperacillin
7U4H	;	3.1	;	Crystal Structure of Penicillin-binding protein 1A (Pbp1a) from Chlamydia trachomatis
3EQU	;	2.4	;	Crystal structure of penicillin-binding protein 2 from Neisseria gonorrhoeae
5KSH	;	2.4	;	Crystal structure of penicillin-binding protein 2 from Neisseria gonorrhoeae containing an A501T mutation associated with cephalosporin resistance
3EQV	;	2.4	;	Crystal structure of penicillin-binding protein 2 from Neisseria gonorrhoeae containing four mutations associated with penicillin resistance
6TII	;	2.26	;	Crystal structure of penicillin-binding protein 2 from Yersinia pestis
6XV5	;	2.673	;	Crystal structure of penicillin-binding protein 2 from Yersinia pestis in complex with ertapenem
6TIX	;	2.8	;	Crystal structure of penicillin-binding protein 2 from Yersinia pestis in complex with mecillinam
3VSK	;	2.301	;	Crystal structure of penicillin-binding protein 3 (PBP3) from methicilin-resistant Staphylococcus aureus in the apo form.
3VSL	;	2.4	;	Crystal structure of penicillin-binding protein 3 (PBP3) from methicilin-resistant Staphylococcus aureus in the cefotaxime bound form.
8C5B	;	2.5	;	Crystal Structure of Penicillin-binding Protein 3 (PBP3) from Staphylococcus Epidermidis
8C5W	;	2.51	;	Crystal Structure of Penicillin-binding Protein 3 (PBP3) from Staphylococcus Epidermidis in complex with Cefotaxime
8C5O	;	2.3	;	Crystal Structure of Penicillin-binding Protein 3 (PBP3) from Staphylococcus Epidermidis in complex with Vaborbactam
3OC2	;	1.968	;	Crystal structure of penicillin-binding protein 3 from Pseudomonas aeruginosa
4KQQ	;	2.1	;	CRYSTAL STRUCTURE OF PENICILLIN-BINDING PROTEIN 3 FROM PSEUDOMONAS AERUGINOSA IN COMPLEX WITH (5S)-Penicilloic Acid
4KQR	;	2.01	;	CRYSTAL STRUCTURE OF PENICILLIN-BINDING PROTEIN 3 FROM PSEUDOMONAS AERUGINOSA IN COMPLEX WITH (5S)-Penicilloic Acid
5DF7	;	2.0	;	CRYSTAL STRUCTURE OF PENICILLIN-BINDING PROTEIN 3 FROM PSEUDOMONAS AERUGINOSA IN COMPLEX WITH AZLOCILLIN
3OCL	;	2.3	;	Crystal structure of penicillin-binding protein 3 from Pseudomonas aeruginosa in complex with carbenicillin
5DF8	;	2.0	;	CRYSTAL STRUCTURE OF PENICILLIN-BINDING PROTEIN 3 FROM PSEUDOMONAS AERUGINOSA IN COMPLEX WITH CEFOPERAZONE
3OCN	;	2.61	;	Crystal structure of penicillin-binding protein 3 from Pseudomonas aeruginosa in complex with ceftazidime
4KQO	;	2.31	;	Crystal structure of penicillin-binding protein 3 from pseudomonas aeruginosa in complex with piperacillin
5DF9	;	2.7	;	CRYSTAL STRUCTURE OF PENICILLIN-BINDING PROTEIN 3 IN COMPLEX WITH DEACYLATED PRODUCT OF CEFOPERAZONE
6BSR	;	2.34	;	Crystal structure of penicillin-binding protein 4 (PBP4) from Enterococcus faecalis in the benzylpenicillin bound form.
6MKI	;	2.984	;	Crystal structure of penicillin-binding protein 4 (PBP4) from Enterococcus faecalis in the ceftaroline-bound form
1TVF	;	2.0	;	Crystal Structure of penicillin-binding protein 4 (PBP4) from Staphylococcus aureus
3ZG7	;	1.991	;	Crystal Structure of Penicillin-Binding Protein 4 from Listeria monocytogenes in the apo form
3ZGA	;	2.005	;	Crystal Structure of Penicillin-Binding Protein 4 from Listeria monocytogenes in the Carbenicillin bound form
3ZG9	;	1.804	;	Crystal Structure of Penicillin-Binding Protein 4 from Listeria monocytogenes in the Cefuroxime bound form
4K91	;	2.05	;	Crystal structure of Penicillin-Binding Protein 5 (PBP5) from Pseudomonas aeruginosa in apo state
1Z6F	;	1.6	;	Crystal structure of penicillin-binding protein 5 from E. coli in complex with a boronic acid inhibitor
3ITA	;	1.8	;	Crystal structure of Penicillin-Binding Protein 6 (PBP6) from E. coli in acyl-enzyme complex with ampicillin
3IT9	;	2.1	;	Crystal structure of Penicillin-Binding Protein 6 (PBP6) from E. coli in apo state
3ITB	;	1.8	;	Crystal structure of Penicillin-Binding Protein 6 (PBP6) from E. coli in complex with a substrate fragment
5ZQC	;	1.702	;	Crystal Structure of Penicillin-Binding Protein D2 from Listeria monocytogenes in the Ampicillin bound form
5ZQA	;	1.55	;	Crystal Structure of Penicillin-Binding Protein D2 from Listeria monocytogenes in the apo form
5ZQD	;	1.888	;	Crystal Structure of Penicillin-Binding Protein D2 from Listeria monocytogenes in the Cefotaxime bound form
5ZQE	;	1.996	;	Crystal Structure of Penicillin-Binding Protein D2 from Listeria monocytogenes in the Cefuroxime bound form
5ZQB	;	1.896	;	Crystal Structure of Penicillin-Binding Protein D2 from Listeria monocytogenes in the Penicillin G bound form
1RZN	;	2.302	;	Crystal Structure of Penicillin-binding protein-related factor A from Bacillus Subtilis.
5Z6O	;	1.7	;	Crystal structure of Penicillium cyclopium protease
6FHV	;	2.0	;	Crystal structure of Penicillium oxalicum Glucoamylase
6V0K	;	2.41	;	Crystal structure of Penicillium verruculosum copalyl diphosphate synthase (PvCPS) alpha prenyltransferase domain
7S09	;	3.1	;	Crystal structure of Penicillium verruculosum copalyl diphosphate synthase (PvCPS) alpha prenyltransferase domain variant, F760A
7S0A	;	2.8	;	Crystal structure of Penicillium verruculosum copalyl diphosphate synthase (PvCPS) alpha prenyltransferase domain variant, H786A
7S0L	;	2.65	;	Crystal structure of Penicillium verruculosum copalyl diphosphate synthase (PvCPS) alpha prenyltransferase domain variant, S723F
7S0M	;	2.0	;	Crystal structure of Penicillium verruculosum copalyl diphosphate synthase (PvCPS) alpha prenyltransferase domain variant, S723T, bound with non-productive isopentenyl diphosphate
7S0H	;	3.15	;	Crystal structure of Penicillium verruculosum copalyl diphosphate synthase (PvCPS) alpha prenyltransferase domain variant, S723Y
7BQ6	;	1.89	;	Crystal structure of Pennisetum glaucum monodehydroascorbate reductase
7BUZ	;	2.288	;	Crystal structure of Pennisetum glaucum monodehydroascorbate reductase
7BVI	;	2.391	;	Crystal structure of Pennisetum glaucum monodehydroascorbate reductase
7BTJ	;	2.373	;	Crystal structure of Pennisetum glaucum monodehydroascorbate reductase in complex with FADH2
8R3D	;	1.71	;	Crystal structure of Pent only at pH 8.8
5VHG	;	1.27	;	Crystal structure of pentad mutant GAPR-1
6GIA	;	1.7	;	Crystal structure of pentaerythritol tetranitrate reductase (PETNR) mutant I107A
6GI9	;	1.45	;	Crystal structure of pentaerythritol tetranitrate reductase (PETNR) mutant I107L
6GI8	;	1.42	;	Crystal structure of pentaerythritol tetranitrate reductase (PETNR) mutant L25A
6GI7	;	1.3	;	Crystal structure of pentaerythritol tetranitrate reductase (PETNR) mutant L25I
3KFT	;	2.1	;	Crystal structure of Pentaerythritol Tetranitrate Reductase complex with 1,4,5,6-tetrahydro NADH
3F03	;	1.34	;	Crystal structure of Pentaerythritol Tetranitrate Reductase complex with 1-nitrocyclohexene
6WKD	;	2.2	;	Crystal structure of pentalenene synthase complexed with 12,13-difluorofarnesyl diphosphate
6WKC	;	1.65	;	Crystal structure of pentalenene synthase complexed with Mg2+ ions
6WKI	;	2.35	;	Crystal structure of pentalenene synthase mutant F76H
6WKJ	;	2.3	;	Crystal structure of pentalenene synthase mutant F76H complexed with 12,13-difluorofarnesyl diphosphate
6WKG	;	2.3	;	Crystal structure of pentalenene synthase mutant F76W
6WKH	;	2.55	;	Crystal structure of pentalenene synthase mutant F76W complexed with 12,13-difluorofarnesyl diphosphate
6WKE	;	2.4	;	Crystal structure of pentalenene synthase mutant F76Y
6WKF	;	2.5	;	Crystal structure of pentalenene synthase mutant F76Y complexed with 12,13-difluorofarnesyl diphosphate
5BXB	;	2.171	;	Crystal structure of pentameric KCTD1 BTB domain form 1
5BXD	;	1.796	;	Crystal structure of pentameric KCTD1 BTB domain form 2
5BXH	;	2.76	;	Crystal structure of pentameric KCTD9 BTB domain
3KL9	;	2.7	;	Crystal structure of PepA from Streptococcus pneumoniae
4WIU	;	2.02	;	Crystal Structure of PEPCK (Rv0211) from Mycobacterium tuberculosis in complex with oxalate and Mn2+
4IUW	;	1.85	;	Crystal structure of PEPO from Lactobacillus rhamnosis HN001 (DR20)
7SZU	;	2.24	;	Crystal structure of Pepper RNA aptamer in complex with HBC ligand and Fab BL3-6
7U0Y	;	2.66	;	Crystal structure of Pepper RNA aptamer in complex with HBC599 ligand and Fab BL3-6
5GR8	;	2.587	;	Crystal structure of PEPR1-AtPEP1
4ICS	;	1.97	;	Crystal structure of PepS from Streptococcus pneumoniae in complex with a substrate
7EV0	;	2.7	;	Crystal structure of pepsin cleaved C-terminal half of lactoferrin at 2.7A resolution
7FDW	;	2.277	;	Crystal structure of pepsin cleaved lactoferrin C-lobe at 2.28 A resolution
3FNT	;	3.3	;	Crystal structure of pepstatin A bound histo-aspartic protease (HAP) from Plasmodium falciparum
6CXD	;	2.75	;	Crystal structure of peptidase B from Yersinia pestis CO92 at 2.75 A resolution
6IRU	;	2.7	;	Crystal structure of Peptidase E from Deinococcus radiodurans in P6422 space group
6A4T	;	2.0	;	Crystal structure of Peptidase E from Deinococcus radiodurans R1
6A4S	;	1.9	;	Crystal structure of peptidase E with ordered active site loop from Salmonella enterica
3GWB	;	1.9	;	Crystal structure of peptidase M16 inactive domain from Pseudomonas fluorescens. Northeast Structural Genomics target PlR293L
3IIB	;	1.7	;	Crystal structure of Peptidase M28 precursor (YP_926796.1) from SHEWANELLA AMAZONENSIS SB2B at 1.70 A resolution
3O6P	;	1.65	;	Crystal structure of peptide ABC transporter, peptide-binding protein
1ZBT	;	2.34	;	Crystal structure of Peptide chain release factor 1 (RF-1) (SMU.1085) from Streptococcus mutans at 2.34 A resolution
2OKL	;	1.7	;	Crystal structure of Peptide Deformylase 2 with actinonin from Bacillus cereus
3OCA	;	2.4	;	Crystal structure of peptide deformylase from Ehrlichia chaffeensis
3U04	;	1.7	;	Crystal structure of peptide deformylase from ehrlichia chaffeensis in complex with actinonin
1VEV	;	2.51	;	Crystal structure of peptide deformylase from Leptospira Interrogans (LiPDF) at pH6.5
1VEY	;	3.3	;	Crystal Structure of Peptide Deformylase from Leptospira Interrogans (LiPDF) at pH7.0
1SV2	;	3.0	;	Crystal Structure of Peptide Deformylase from Leptospira Interrogans (LiPDF) at pH7.5
1SZZ	;	3.3	;	Crystal structure of peptide deformylase from Leptospira Interrogans complexed with inhibitor actinonin
1VEZ	;	2.3	;	Crystal Structure of Peptide Deformylase from Leptospira Interrogans(LiPDF) at pH8.0
1N5N	;	1.8	;	Crystal Structure of Peptide Deformylase from Pseudomonas aeruginosa
1LM6	;	1.75	;	Crystal Structure of Peptide Deformylase from Streptococcus pneumoniae
1LME	;	2.2	;	Crystal Structure of Peptide Deformylase from Thermotoga maritima
3CMD	;	2.7	;	Crystal structure of peptide deformylase from VRE-E.faecium
6JP3	;	1.66	;	Crystal structure of peptide in complex with HLA-A1101.
4NM0	;	2.5	;	Crystal structure of peptide inhibitor-free GSK-3/Axin complex
7X1B	;	1.399	;	Crystal structure of peptide KAGQVVTI in complex with HLA-B5801
7WZZ	;	1.305	;	Crystal structure of peptide KAGQVVTIW in complex with HLA-B5801
1RQ0	;	2.65	;	Crystal structure of peptide releasing factor 1
6GS4	;	2.645	;	Crystal structure of peptide transporter DtpA-nanobody in complex with valganciclovir
6GS7	;	3.3	;	Crystal structure of peptide transporter DtpA-nanobody in glycine buffer
6GS1	;	3.29	;	Crystal structure of peptide transporter DtpA-nanobody in MES buffer
4IKV	;	1.9	;	Crystal structure of peptide transporter POT
4IKX	;	2.3	;	Crystal structure of peptide transporter POT (E310Q mutant)
4IKZ	;	2.4	;	Crystal structure of peptide transporter POT (E310Q mutant) in complex with alafosfalin
4IKY	;	2.1	;	Crystal structure of peptide transporter POT (E310Q mutant) in complex with sulfate
4IKW	;	2.004	;	Crystal structure of peptide transporter POT in complex with sulfate
7X00	;	1.45	;	Crystal structure of peptide VSFIEFVGW in complex with HLA-B5801
7X1C	;	1.409	;	Crystal structure of peptide VSFIEFVI in complex with HLA-B5801
3H0X	;	1.92	;	Crystal structure of peptide-binding domain of Kar2 protein from Saccharomyces cerevisiae
6JZD	;	2.479	;	Crystal structure of peptide-bound VASH2-SVBP complex
5XOV	;	2.684	;	Crystal structure of peptide-HLA-A24 bound to S19-2 V-delta/V-beta TCR
1PNG	;	2.2	;	CRYSTAL STRUCTURE OF PEPTIDE-N(4)-(N-ACETYL-BETA-D-GLUCOSAMINYL) ASPARAGINE AMIDASE AT 2.2 ANGSTROMS RESOLUTION
1TJC	;	2.3	;	Crystal structure of peptide-substrate-binding domain of human type I collagen prolyl 4-hydroxylase
6EVN	;	1.48	;	Crystal structure of peptide-substrate-binding domain of human type II collagen prolyl 4-hydroxylase complex with Pro-Pro-Gly-Pro-Ala-Gly-Pro-Pro-Gly.
4LY4	;	2.199	;	Crystal structure of peptidoglycan deacetylase (HP0310) with Zinc from Helicobacter pylori
4JBF	;	1.92	;	Crystal structure of peptidoglycan glycosyltransferase from Atopobium parvulum DSM 20469.
2ZYC	;	1.74	;	Crystal structure of peptidoglycan hydrolase from Sphingomonas sp. A1
3VWO	;	1.802	;	Crystal structure of peptidoglycan hydrolase mutant from Sphingomonas sp. A1
5XGY	;	2.45	;	Crystal structure of peptidoglycan recognition protein (PGRP-S) at 2.45 A resolution
6IDM	;	3.2	;	Crystal structure of Peptidoglycan recognition protein (PGRP-S) with Tartaric acid at 3.20 A resolution
3C2X	;	1.83	;	Crystal structure of peptidoglycan recognition protein at 1.8A resolution
2CB3	;	2.4	;	Crystal structure of peptidoglycan recognition protein-LE in complex with tracheal cytotoxin (monomeric diaminopimelic acid-type peptidoglycan)
3UMQ	;	2.2	;	Crystal structure of peptidoglycan recognition protein-S complexed with butyric acid at 2.2 A resolution
4G4V	;	1.9	;	Crystal structure of peptidoglycan-associated lipoprotein from Acinetobacter baumannii
4G4W	;	1.9	;	Crystal structure of peptidoglycan-associated lipoprotein from Acinetobacter baumannii
4G4X	;	1.5	;	Crystal structure of peptidoglycan-associated lipoprotein from Acinetobacter baumannii
4PWT	;	1.752	;	Crystal structure of peptidoglycan-associated outer membrane lipoprotein from Yersinia pestis CO92
6CE1	;	2.8	;	Crystal structure of Peptidyl Arginine Deiminase Type III (PADI3)
4FNO	;	2.25	;	Crystal structure of peptidyl t-RNA hydrolase from Pseudomonas aeruginosa at 2.2 Angstrom resolution
4HOY	;	1.78	;	Crystal structure of Peptidyl- tRNA Hydrolase from Acinetobacter baumannii at 1.78 A resolution
4FOT	;	2.2	;	Crystal structure of Peptidyl- tRNA Hydrolase from Acinetobacter baumannii at 2.20 A resolution
4ZXP	;	1.63	;	Crystal structure of Peptidyl- tRNA Hydrolase from Vibrio cholerae
4G2P	;	1.82	;	Crystal structure of peptidyl-prolyl cis-trans isomerase domain II of molecular chaperone SurA from Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S
3K2C	;	1.95	;	Crystal structure of peptidyl-prolyl cis-trans isomerase from Encephalitozoon cuniculi at 1.9 A resolution
7L6Z	;	1.88	;	Crystal Structure of Peptidyl-Prolyl Cis-Trans Isomerasefrom (PpiB) Streptococcus pneumoniae R6
4YLY	;	2.25	;	Crystal structure of peptidyl-tRNA hydrolase from a Gram-positive bacterium, staphylococcus aureus at 2.25 angstrom resolution
4QT4	;	2.19	;	Crystal structure of Peptidyl-tRNA hydrolase from a Gram-positive bacterium, Streptococcus pyogenes at 2.19 Angstrom resolution shows the Closed Structure of the Substrate Binding Cleft
6J93	;	0.95	;	Crystal structure of Peptidyl-tRNA hydrolase from Acinetobacter baumannii at 0.95 A resolution
6JJ1	;	0.97	;	Crystal structure of peptidyl-tRNA hydrolase from Acinetobacter baumannii at 0.97 A resolution with disordered five N-terminal residues
6JJQ	;	0.99	;	Crystal structure of peptidyl-tRNA hydrolase from Acinetobacter baumannii at 0.99 A resolution.
7CSN	;	1.0	;	Crystal structure of peptidyl-tRNA hydrolase from Acinetobacter baumannii at 1.00 A resolution
4FOP	;	1.86	;	Crystal Structure of Peptidyl-tRNA hydrolase from Acinetobacter baumannii at 1.86 A resolution
6IYE	;	1.55	;	Crystal structure of peptidyl-tRNA hydrolase from Acinetobacter baumannii with 12% PEG 1500 at 1.55 A resolution.
7Y52	;	1.92	;	Crystal structure of peptidyl-tRNA hydrolase from Enterococcus faecium
3VJR	;	2.4	;	Crystal structure of Peptidyl-tRNA hydrolase from Escherichia coli in complex with the CCA-acceptor-T[PSI]C domain of tRNA
3OFV	;	3.2	;	Crystal structure of peptidyl-tRNA hydrolase from Escherichia Coli, I222 crystal form
3NEA	;	2.25	;	Crystal Structure of Peptidyl-tRNA hydrolase from Francisella tularensis
7BRD	;	1.892	;	Crystal structure of Peptidyl-tRNA hydrolase from Klebsiella pneumoniae
3P2J	;	2.22	;	Crystal structure of peptidyl-tRNA hydrolase from Mycobacterium smegmatis at 2.2 A resolution
2Z2I	;	1.98	;	Crystal structure of Peptidyl-tRNA hydrolase from Mycobacterium tuberculosis
2Z2J	;	2.35	;	Crystal structure of Peptidyl-tRNA hydrolase from Mycobacterium tuberculosis
2Z2K	;	2.5	;	Crystal structure of Peptidyl-tRNA hydrolase from Mycobacterium tuberculosis
3TCK	;	2.3	;	Crystal structure of Peptidyl-tRNA hydrolase from Mycobacterium tuberculosis - Form 4
4QAJ	;	1.5	;	Crystal structure of Peptidyl-tRNA hydrolase from Pseudomonas aeruginosa at 1.5 Angstrom resolution
4JC4	;	2.25	;	Crystal structure of Peptidyl-tRNA hydrolase from Pseudomonas aeruginosa at 2.25 angstrom resolution
4QD3	;	1.89	;	Crystal structure of Peptidyl-tRNA hydrolase from Pseudomonas aeruginosa with 5-azacytidine at 1.89 Angstrom resolution
4DHW	;	2.43	;	Crystal structure of Peptidyl-tRNA hydrolase from Pseudomonas aeruginosa with Adipic acid at 2.4 Angstrom resolution
5ZX8	;	1.0	;	Crystal structure of peptidyl-tRNA hydrolase from Thermus thermophilus
5GVZ	;	1.75	;	Crystal structure of Peptidyl-tRNA hydrolase from Vibrio cholerae in space group C2221 at resolution 1.75A.
5B6J	;	2.43	;	Crystal structure of Peptidyl-tRNA hydrolase mutant -H24N from Vibrio cholerae
5ZK0	;	2.55	;	Crystal structure of Peptidyl-tRNA hydrolase mutant -M71A from Vibrio cholerae
4Z86	;	1.63	;	Crystal structure of Peptidyl-tRNA hydrolase mutant -N118D from Vibrio cholerae at 1.63A resolution.
8IU6	;	2.9	;	Crystal structure of peptidyl-tRNA hydrolase mutant from Enterococcus faecium
5IMB	;	2.4	;	Crystal structure of peptidyl-tRNA hydrolase mutant-N14D from Vibrio cholerae
6JKX	;	1.08	;	Crystal structure of peptidyl-tRNA hydrolase with multiple sodium and chloride ions at 1.08 A resolution.
6XD8	;	1.52	;	Crystal Structure of Peptidylprolyl Isomerase (PrsA) Fragment from Bacillus anthracis
6B4P	;	1.55	;	Crystal Structure of Peptidylprolyl Isomerase from Naegleria fowleri
6MKE	;	2.05	;	Crystal Structure of Peptidylprolyl Isomerase from Naegleria fowleri with bound FK506
7L75	;	3.15	;	Crystal Structure of Peptidylprolyl Isomerase PrsA from Streptococcus mutans.
7AM4	;	1.81	;	Crystal structure of Peptiligase mutant - L217H/M222P
7AM5	;	2.3	;	Crystal structure of Peptiligase mutant - L217H/M222P/A225N
7AM6	;	2.7	;	Crystal structure of Peptiligase mutant - L217H/M222P/A225N/F189W
7AM3	;	1.61	;	Crystal structure of Peptiligase mutant - M222P
7AM7	;	2.61	;	Crystal structure of Peptiligase mutant - M222P/L217H/A225N/F189W/N218D
7RB4	;	2.19	;	Crystal structure of Peptono Toxin, a diphtheria toxin homolog, from Seinonella peptonophila
1LFW	;	1.8	;	Crystal structure of pepV
4K7C	;	1.66	;	Crystal structure of pepw from lactobacillus rhamnosis hn001 (dr20) determined as the selenomet derivative
3UYI	;	2.313	;	Crystal Structure of Perakine Reductase, Founder Member of a Novel AKR Subfamily with Unique Conformational Changes during NADPH Binding
3V0S	;	1.773	;	Crystal Structure of Perakine Reductase, Founder Member of a Novel AKR Subfamily with Unique Conformational Changes during NADPH Binding
3V0T	;	2.333	;	Crystal Structure of Perakine Reductase, Founder Member of a Novel AKR Subfamily with Unique Conformational Changes during NADPH Binding
3V0U	;	2.203	;	Crystal Structure of Perakine Reductase, Founder Member of a Novel AKR Subfamily with Unique Conformational Changes during NADPH Binding
1QAH	;	1.8	;	CRYSTAL STRUCTURE OF PERCHLORIC ACID SOLUBLE PROTEIN-A TRANSLATIONAL INHIBITOR
2PLL	;	1.9	;	Crystal structure of perdeuterated human arginase I
7BB4	;	1.7	;	Crystal structure of perdeuterated PLL lectin in complex with L-fucose
3P9C	;	1.8	;	Crystal structure of perennial ryegrass LpOMT1 bound to SAH
3P9K	;	2.25	;	Crystal structure of perennial ryegrass LpOMT1 complexed with S-adenosyl-L-homocysteine and coniferaldehyde
3P9I	;	1.85	;	Crystal structure of perennial ryegrass LpOMT1 complexed with S-adenosyl-L-homocysteine and sinapaldehyde
5B7N	;	1.399	;	Crystal structure of periplasmic 5-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Aeromonas hydrophila
4RXM	;	1.75	;	Crystal structure of periplasmic ABC transporter solute binding protein A7JW62 from Mannheimia haemolytica PHL213, Target EFI-511105, in complex with Myo-inositol
8IM8	;	2.7	;	Crystal structure of Periplasmic alpha-amylase (MalS) from E.coli
4MLZ	;	1.72	;	Crystal structure of periplasmic binding protein from Jonesia denitrificans
4MPT	;	1.75	;	Crystal Structure of Periplasmic binding Protein Type 1 from Bordetella pertussis Tohama I
4Q6W	;	1.84	;	Crystal Structure of Periplasmic Binding Protein type 1 from Bordetella pertussis Tohama I complexed with 3-Hydroxy Benzoic Acid
6ONP	;	2.27	;	Crystal structure of periplasmic binding protein XoxJ from Methylobacterium extorquens AM1
3CTP	;	1.41	;	Crystal structure of periplasmic binding protein/LacI transcriptional regulator from Alkaliphilus metalliredigens QYMF complexed with D-xylulofuranose
3HS3	;	1.6	;	Crystal structure of periplasmic binding ribose operon repressor protein from Lactobacillus acidophilus
4F3S	;	2.14	;	Crystal structure of periplasmic D-alanine ABC transporter from Salmonella enterica
5F1Q	;	1.956	;	Crystal Structure of Periplasmic Dipeptide Transport Protein from Yersinia pestis
1VHF	;	1.54	;	Crystal structure of periplasmic divalent cation tolerance protein
1O5J	;	1.95	;	Crystal structure of Periplasmic divalent cation tolerance protein (TM1056) from Thermotoga maritima at 1.95 A resolution
6PSH	;	2.21	;	Crystal structure of periplasmic domain of antiholin RI from T4 phage
7SGN	;	2.8	;	Crystal structure of periplasmic domain of Helicobacter pylori FliL (residues 81 to 183) (crystal form A)
7SGO	;	2.695	;	Crystal structure of periplasmic domain of Helicobacter pylori FliL (residues 81 to 183) (crystal form B)
7SGP	;	2.1	;	Crystal structure of periplasmic domain of Helicobacter pylori FliL (residues 81 to 183) (crystal form C)
5XPJ	;	2.5	;	Crystal Structure of Periplasmic glucose binding protein ppGBP deletion mutant- Del-ppGBP
1YDY	;	1.7	;	Crystal structure of periplasmic glycerophosphodiester phosphodiesterase from Escherichia coli
5KHL	;	2.397	;	Crystal Structure of periplasmic Heme binding protein HutB of Vibrio cholerae
4KQ9	;	1.9	;	Crystal structure of periplasmic ribose ABC transporter from Conexibacter woesei DSM 14684
4RY1	;	1.4	;	Crystal structure of periplasmic solute binding protein ECA2210 from Pectobacterium atrosepticum SCRI1043, Target EFI-510858
4MDY	;	1.78	;	Crystal structure of periplasmic solute binding protein from Mycobacterium smegmatis str. MC2 155
4OVK	;	1.71	;	Crystal structure of periplasmic solute binding protein from Veillonella parvula DSM 2008
3D02	;	1.3	;	Crystal structure of periplasmic sugar-binding protein (YP_001338366.1) from Klebsiella pneumoniae subsp. pneumoniae MGH 78578 at 1.30 A resolution
5YSC	;	1.673	;	Crystal Structure of periplasmic Vitamin B12 binding protein BtuF of Vibrio cholerae
3MGL	;	2.25	;	Crystal structure of permease family protein from Vibrio cholerae
4USC	;	2.6	;	Crystal structure of peroxidase from palm tree Chamaerops excelsa
5EPF	;	1.35	;	Crystal structure of Peroxidoxin BcpB from Mycobacterium tuberculosis
4BTZ	;	1.47	;	Crystal Structure of peroxinitrite treated Major Birch Pollen Allergen Bet v 1.0101 (isoform a)
1WE0	;	2.9	;	Crystal structure of peroxiredoxin (AhpC) from Amphibacillus xylanus
3VWU	;	3.3	;	Crystal structure of peroxiredoxin 4 from M. musculus
2XHF	;	1.3	;	Crystal structure of peroxiredoxin 5 from Alvinella pompejana
2WFC	;	1.75	;	Crystal structure of peroxiredoxin 5 from Arenicola Marina
4DSS	;	2.1	;	Crystal structure of peroxiredoxin Ahp1 from Saccharomyces cerevisiae in complex with thioredoxin Trx2
4DSQ	;	2.4	;	Crystal structure of peroxiredoxin Ahp1 from Saccharomyces cerevisiae in oxidized form
4DSR	;	2.91	;	Crystal structure of peroxiredoxin Ahp1 from Saccharomyces cerevisiae in reduced form
5J9B	;	2.1	;	Crystal structure of peroxiredoxin Asp f3
5J9C	;	1.956	;	Crystal structure of peroxiredoxin Asp f3 C31S/C61S variant
7WEU	;	1.81	;	Crystal structure of Peroxiredoxin I in complex with compound 19-048
7WET	;	1.76	;	Crystal structure of Peroxiredoxin I in complex with the inhibitor Cela
3QPM	;	1.9	;	Crystal structure of peroxiredoxin Prx4 from Pseudosciaena crocea
7E4U	;	2.6	;	Crystal structure of Peroxiredoxin-1
4KW6	;	3.0	;	Crystal structure of Peroxiredoxin-1 (C-terminal truncation mutant) from the human hookworm Ancylostoma ceylanicum bound to conoidin A
4FH8	;	2.11	;	Crystal Structure of Peroxiredoxin-1 from the human hookworm Ancylostoma ceylanicum
2YZH	;	1.85	;	Crystal structure of peroxiredoxin-like protein from Aquifex aeolicus
2YWN	;	1.6	;	Crystal structure of peroxiredoxin-like protein from Sulfolobus tokodaii
1IS2	;	2.2	;	Crystal Structure of Peroxisomal Acyl-CoA Oxidase-II from Rat Liver
2XQ1	;	2.9	;	Crystal structure of peroxisomal catalase from the yeast Hansenula polymorpha
8GR9	;	1.48	;	Crystal structure of peroxisomal citrate synthase (Cit2) from Saccharomyces cerevisiae in complex with oxaloacetate and coenzyme-A
8GR8	;	2.39	;	Crystal structure of peroxisomal citrate synthase (Cit2) from Saccharomycescerevisiae
1HNO	;	2.5	;	CRYSTAL STRUCTURE OF PEROXISOMAL DELTA3-DELTA2-ENOYL-COA ISOMERASE FROM SACCHAROMYCES CEREVISIAE
1HNU	;	2.15	;	CRYSTAL STRUCTURE OF PEROXISOMAL DELTA3-DELTA2-ENOYL-COA ISOMERASE FROM SACCHAROMYCES CEREVISIAE
2WU9	;	1.5	;	Crystal structure of peroxisomal KAT2 from Arabidopsis thaliana
1YXM	;	1.9	;	Crystal structure of peroxisomal trans 2-enoyl CoA reductase
3GZ9	;	2.0	;	Crystal Structure of Peroxisome Proliferator-Activated Receptor Delta (PPARd) in Complex with a Full Agonist
6A6P	;	2.1	;	Crystal Structure of Peroxisome Proliferator-Activated Receptor Delta (PPARd)LBD in Complex with DN003316
3H0A	;	2.1	;	Crystal Structure of Peroxisome Proliferator-Activated Receptor Gamma (PPARg) and Retinoic Acid Receptor Alpha (RXRa) in Complex with 9-cis Retinoic Acid, Co-activator Peptide, and a Partial Agonist
6TSG	;	2.98	;	Crystal structure of Peroxisome proliferator-activated receptor gamma (PPARG) in complex with TETRAC
7AWD	;	1.93	;	Crystal structure of Peroxisome proliferator-activated receptor gamma (PPARG)in complex with garcinoic acid
7AWC	;	1.74	;	Crystal structure of Peroxisome proliferator-activated receptor gamma (PPARG)in complex with rosiglitazone
3KDU	;	2.07	;	Crystal structure of peroxisome proliferator-activatedeceptor alpha (PPARalpha) complex with N-3-((2-(4-Chlorophenyl)-5-methyl-1,3-oxazol-4-yl)methoxy)benzyl)-N-((4-methylphenoxy)carbonyl)glycine
3KDT	;	2.7	;	Crystal structure of peroxisome proliferator-activatedeceptor alpha (PPARalpha) complex with N-3-((2-(4-Chlorophenyl)-5-methyl-1,3-oxazol-4-yl)methoxy)benzyl)-N-(methoxycarbonyl)glycine
2VLX	;	1.3	;	Crystal structure of peroxymyoglobin generated by cryoradiolytic reduction of myoglobin compound III
2VLZ	;	1.5	;	Crystal structure of peroxymyoglobin generated by cryoradiolytic reduction of myoglobin compound III
1SDA	;	2.5	;	CRYSTAL STRUCTURE OF PEROXYNITRITE-MODIFIED BOVINE CU,ZN SUPEROXIDE DISMUTASE
3F8N	;	3.15	;	Crystal structure of PerR-Zn-Mn
5VE5	;	2.35	;	Crystal structure of persulfide dioxygenase rhodanese fusion protein with rhodanese domain inactivating mutation (C314S) from Burkholderia phytofirmans in complex with glutathione
5VE4	;	2.65	;	Crystal structure of persulfide dioxygenase-rhodanese fusion protein with rhodanese domain inactivating mutation (C314S) from Burkholderia phytofirmans
4LLY	;	1.6	;	Crystal structure of Pertuzumab Clambda Fab with variable and constant domain redesigns (VRD2 and CRD2) at 1.6A
4LLW	;	1.95	;	Crystal structure of Pertuzumab Clambda Fab with variable domain redesign (VRD2) at 1.95A
6ORM	;	2.15	;	Crystal Structure of Peruvianin-I (Cysteine peptidase from Thevetia peruviana latex)
6EXX	;	1.1	;	Crystal Structure of Pes4 RRM4
4AQN	;	1.98	;	Crystal structure of pesticin from Y. pestis
7CEF	;	1.6	;	Crystal structure of PET-degrading cutinase Cut190 /S226P/R228S/ mutant with the C-terminal three residues deletion
5ZRS	;	1.4	;	Crystal structure of PET-degrading cutinase Cut190 S176A/S226P/R228S mutant in monoethyl adipate bound state
5ZRR	;	1.34	;	Crystal structure of PET-degrading cutinase Cut190 S176A/S226P/R228S mutant in monoethyl succinate bound state
5ZRQ	;	1.12	;	Crystal structure of PET-degrading cutinase Cut190 S176A/S226P/R228S mutant in Zn(2+)-bound state
5ZNO	;	1.60264	;	Crystal structure of PET-degrading cutinase Cut190 S176A/S226P/R228S/ mutant in Ca(2+)-bound state
7CEH	;	1.09	;	Crystal structure of PET-degrading cutinase Cut190 S176A/S226P/R228S/ mutant with the C-terminal three residues deletion in ligand ejecting form
4WFJ	;	1.75	;	Crystal structure of PET-degrading cutinase Cut190 S226P mutant in Ca(2+)-bound state at 1.75 angstrom resolution
4WFK	;	2.35	;	Crystal structure of PET-degrading cutinase Cut190 S226P mutant in Ca(2+)-bound state at 2.35 angstrom resolution
4WFI	;	1.446	;	Crystal structure of PET-degrading cutinase Cut190 S226P mutant in Ca(2+)-free state
5XJH	;	1.54	;	Crystal structure of PETase from Ideonella sakaiensis
6ILW	;	1.575	;	Crystal structure of PETase from Ideonella sakaiensis
8H5L	;	1.7	;	Crystal structure of PETase N37D/S121E/R132E/A171C/A180V/P181V/D186H/S193C/A202C/V211C/S214Y/R224E/N233C/S242T/N246D/N275C/S282C/F284C mutant from Ideonella sakaiensis
8H5K	;	1.2	;	Crystal structure of PETase N37D/S121E/R132E/A171C/A180V/P181V/D186H/S193C/R224E/N233C/S242T/N246D/S282C mutant from Ideonella sakaiensis
6IJ5	;	1.72	;	Crystal structure of PETase P181A mutant from Ideonella sakaiensis
5YNS	;	1.36	;	Crystal structure of PETase R280A mutant from Ideonella sakaiensis
6IJ3	;	1.4	;	Crystal structure of PETase S121D, D186H mutant from Ideonella sakaiensis
6IJ4	;	1.86	;	Crystal structure of PETase S121E, D186H mutant from Ideonella sakaiensis
6IJ6	;	1.95	;	Crystal structure of PETase S121E, D186H, R280A mutant from Ideonella sakaiensis
8H5J	;	1.4	;	Crystal structure of PETase S121E/A180V/P181V/D186H/N233C/S242T/N246D/S282C mutant from Ideonella sakaiensis
8H5M	;	1.89	;	Crystal structure of PETase S121E/D186H/N233C/S242T/N246D/S282C mutant from Ideonella sakaiensis
8H5O	;	2.1	;	Crystal structure of PETase S121E/P181V/D186H/N233C/S242T/N246D/S282C mutant from Ideonella sakaiensis
6ILX	;	1.45	;	Crystal structure of PETase W159F mutant from Ideonella sakaiensis
3TO3	;	2.382	;	Crystal Structure of Petrobactin Biosynthesis Protein AsbB from Bacillus anthracis str. Sterne
3GFV	;	1.75	;	Crystal Structure of Petrobactin-binding Protein YclQ from Bacillu subtilis
4R1S	;	1.6	;	Crystal structure of Petunia hydrida cinnamoyl-CoA reductase
4R1T	;	1.7	;	Crystal structure of Petunia hydrida cinnamoyl-CoA reductase
2ZFW	;	2.9	;	Crystal structure of Pex from Synechococcus sp. (strain PCC 7942) (Anacystis nidulans R2)
7Z35	;	2.3	;	Crystal structure of PEX13 SH3 domain of Trypanosoma cruzi
1JQQ	;	2.65	;	Crystal structure of Pex13p(301-386) SH3 domain
1Q4J	;	2.2	;	Crystal Structure of Pf-GST1 with its inhibitor s-hexyl-GSH
2DFI	;	2.1	;	Crystal structure of Pf-MAP(1-292)-C
2DF5	;	2.3	;	Crystal Structure of Pf-PCP(1-204)-C
3NRN	;	2.1	;	Crystal Structure of PF1083 protein from Pyrococcus furiosus, Northeast Structural Genomics Consortium Target PfR223
3TLX	;	2.75	;	Crystal Structure of PF10_0086, adenylate kinase from plasmodium falciparum
3UOW	;	2.72	;	Crystal Structure of PF10_0123, a GMP Synthetase from Plasmodium Falciparum
3NIE	;	2.3	;	Crystal Structure of PF11_0147
2YMO	;	1.9	;	Crystal structure of Pf12 tandem 6-cys domains from Plasmodium falciparum
3LLT	;	2.5	;	Crystal structure of PF14_0431, kinase domain.
5CHI	;	2.472	;	Crystal structure of PF2046 in complex with ssDNA
4NXJ	;	2.18	;	Crystal Structure of PF3D7_1475600, a bromodomain from Plasmodium Falciparum
4YS4	;	2.45	;	Crystal structure of Pf41 tandem 6-cys domains from Plasmodium falciparum
4ZQT	;	1.981	;	Crystal structure of PfA-M1 with virtual ligand inhibitor
5CBM	;	2.3	;	Crystal structure of PfA-M17 with virtual ligand inhibitor
4Z9R	;	2.8	;	Crystal structure of PfaD from Shewanella oneidensis in complex with NAD+ determined by in-situ diffraction.
6LKC	;	1.998	;	Crystal structure of PfaD from Shewanella piezotolerans in complex with FMN
1TQX	;	2.0	;	Crystal Structure of Pfal009167 A Putative D-Ribulose 5-Phosphate 3-Epimerase from P.falciparum
8G6B	;	1.55	;	Crystal structure of PfAMA1-RON2L chimera
4MR0	;	1.95	;	Crystal structure of PfbA, a surface adhesin of Streptococcus pneumoniae
3NI8	;	2.5	;	Crystal Structure of PFC0360w, an HSP90 activator from plasmodium falciparum
7RD3	;	1.81	;	Crystal structure of PfCSP peptide 21 with vaccine-elicited human anti-malaria antibody m42.126
7LKB	;	1.8	;	Crystal structure of PfCSP peptide 21 with vaccine-elicited human anti-malaria antibody m42.127
7RDA	;	1.92	;	Crystal structure of PfCSP peptide 21 with vaccine-elicited human anti-malaria antibody m43.138
7RD4	;	1.75	;	Crystal structure of PfCSP peptide 21 with vaccine-elicited human anti-malaria antibody m43.149
7LKG	;	2.02	;	Crystal structure of PfCSP peptide 21 with vaccine-elicited human anti-malaria antibody m43.151
7RD9	;	1.91	;	Crystal structure of PfCSP peptide 21 with vaccine-elicited human anti-malaria antibody m43.159
7RCS	;	2.4	;	Crystal structure of PfCSP peptide 21 with vaccine-elicited human anti-malaria antibody m43.160
5EZN	;	2.51	;	Crystal Structure of PfCyRPA
5EZO	;	3.63	;	Crystal Structure of PfCyRPA in complex with an invasion-inhibitory antibody Fab.
3WQR	;	1.97	;	Crystal structure of pfdxr complexed with inhibitor-12
3WQS	;	2.35	;	Crystal structure of pfdxr complexed with inhibitor-126
3WQQ	;	2.25	;	Crystal structure of PfDXR complexed with inhibitor-3
4K2U	;	2.45	;	Crystal structure of PfEBA-175 F1 in complex with R218 antibody Fab fragment
4QEX	;	4.5	;	Crystal structure of PfEBA-175 RII in complex with a Fab fragment from inhibitory antibody R217
3KHD	;	2.7	;	Crystal Structure of PFF1300w.
1N81	;	2.1	;	Crystal structure of Pfg27 from Plasmodium falciparum
4ZEW	;	1.9	;	Crystal structure of PfHAD1 in complex with glucose-6-phosphate
4ZEX	;	2.0	;	Crystal structure of PfHAD1 in complex with glyceraldehyde-3-phosphate
4ZEV	;	1.8	;	Crystal structure of PfHAD1 in complex with mannose-6-phosphate
7XNT	;	1.822	;	Crystal structure of PfHPPD-Y13161 complex
7X8E	;	2.749	;	Crystal structure of PfHPPD-Y13287 complex
4A3S	;	2.3	;	Crystal structure of PFK from Bacillus subtilis
1VK4	;	1.91	;	Crystal structure of PfkB Carbohydrate kinase (TM0415) from Thermotoga maritima at 1.91 A resolution
4GM6	;	2.0	;	Crystal structure of PfkB family carbohydrate kinase(TARGET EFI-502146 FROM Listeria grayi DSM 20601
4DU5	;	2.7	;	Crystal structure of PfkB protein from Polaromonas sp. JS666
2I1V	;	2.5	;	Crystal structure of PFKFB3 in complex with ADP and Fructose-2,6-bisphosphate
6AGT	;	1.953	;	Crystal structure of PfKRS complexed with chromone inhibitor
5ZH5	;	3.08	;	CRYSTAL STRUCTURE OF PfKRS WITH INHIBITOR CLADO-2
5ZH2	;	2.66	;	CRYSTAL STRUCTURE OF PfKRS WITH INHIBITOR CLADO-5
5ZH3	;	2.86	;	CRYSTAL STRUCTURE OF PfKRS WITH INHIBITOR CLADO-6
5ZH4	;	2.6	;	CRYSTAL STRUCTURE OF PfKRS WITH INHIBITOR CLADO-7
2PFL	;	2.9	;	CRYSTAL STRUCTURE OF PFL FROM E.COLI
3PFL	;	2.6	;	CRYSTAL STRUCTURE OF PFL FROM E.COLI IN COMPLEX WITH SUBSTRATE ANALOGUE OXAMATE
4P7S	;	2.87	;	Crystal structure of PfMIF in complex with 4-(3-methoxy-5-methylphenoxy)-2-(4-methoxyphenyl)-6-methylpyridine
3C3Y	;	1.371	;	Crystal Structure of PFOMT, Phenylpropanoid and Flavonoid O-methyltransferase from M. crystallinum
2PML	;	2.6	;	Crystal structure of PfPK7 in complex with an ATP analogue
2PMN	;	2.8	;	Crystal structure of PfPK7 in complex with an ATP-site inhibitor
2PMO	;	2.9	;	Crystal structure of PfPK7 in complex with hymenialdisine
4WAT	;	2.18	;	Crystal structure of PfRh5, an essential P. falciparum ligand for invasion of human erythrocytes
6AZZ	;	2.4	;	Crystal structure of Pfs25 in complex with the transmission blocking antibody 1190
6B0G	;	1.9	;	Crystal structure of Pfs25 in complex with the transmission blocking antibody 1245
6B0E	;	3.3	;	Crystal structure of Pfs25 in complex with the transmission blocking antibody 1260
6B0H	;	2.7	;	Crystal structure of Pfs25 in complex with the transmission blocking antibody 1262
6B0A	;	2.5	;	Crystal structure of Pfs25 in complex with the transmission blocking antibody 1269
6B08	;	2.2	;	Crystal structure of Pfs25 in complex with the transmission blocking antibody 1276
4LVN	;	2.25	;	Crystal structure of PfSUB1-prodomain-NIMP.M7 Fab complex
4LVO	;	2.26	;	Crystal structure of PfSUB1-prodomain-NIMP.M7 Fab complex with added CaCl2
1ZD0	;	1.7	;	Crystal structure of Pfu-542154 conserved hypothetical protein
4PSL	;	3.5	;	Crystal structure of pfuThermo-DBP-RP1 (crystal form I)
4PSM	;	2.43	;	Crystal structure of pfuThermo-DBP-RP1 (crystal form II)
5YD6	;	2.34	;	Crystal structure of PG-bound Nurr1-LBD
4DQO	;	2.438	;	Crystal Structure of PG16 Fab in Complex with V1V2 Region from HIV-1 strain ZM109
3U36	;	3.281	;	Crystal Structure of PG9 Fab
3U4E	;	2.185	;	Crystal Structure of PG9 Fab in Complex with V1V2 Region from HIV-1 strain CAP45
3U2S	;	1.797	;	Crystal Structure of PG9 Fab in Complex with V1V2 Region from HIV-1 strain ZM109
3MUH	;	3.0	;	Crystal structure of PG9 light chain
5WKI	;	2.75	;	Crystal structure of PG90 TCR-CD1b-PG complex
2QA1	;	1.8	;	Crystal structure of PgaE, an aromatic hydroxylase involved in angucycline biosynthesis
3NBU	;	2.05	;	Crystal structure of pGI glucosephosphate isomerase
4ZXM	;	2.8	;	Crystal structure of PGRP domain from Branchiostoma belcheri tsingtauense peptidoglycan recognition protein 3
3USX	;	2.28	;	Crystal structure of PGRP-S complexed with Myristic Acid at 2.28 A resolution
4JM4	;	1.751	;	Crystal Structure of PGT 135 Fab
4JM2	;	3.1	;	Crystal Structure of PGT 135 Fab in Complex with gp120 Core Protein from HIV-1 Strain JR-FL Bound to CD4 and 17b Fab
4FQ1	;	3.0	;	Crystal Structure of PGT121 Fab
4FQC	;	2.4	;	Crystal Structure of PGT121 Fab Bound to a complex-type sialylated N-glycan
4R2G	;	3.283	;	Crystal Structure of PGT124 Fab bound to HIV-1 JRCSF gp120 core and to CD4
5C6R	;	1.8	;	Crystal structure of PH domain of ASAP1
2Z0P	;	2.58	;	Crystal structure of PH domain of Bruton's tyrosine kinase
4IAP	;	2.3	;	Crystal structure of PH domain of Osh3 from Saccharomyces cerevisiae
2DBB	;	2.0	;	Crystal structure of PH0061
1WNF	;	2.5	;	Crystal Structure of PH0066 from Pyrococcus horikoshii
7FBY	;	2.001	;	Crystal Structure of PH0140 from Pyrococcus horikosii OT3
1VE3	;	2.1	;	Crystal structure of PH0226 protein from Pyrococcus horikoshii OT3
3VRH	;	2.1	;	Crystal structure of ph0300
2CQZ	;	2.6	;	Crystal Structure of PH0347 protein from Pyrococcus horikoshii OT3
2DB0	;	2.2	;	Crystal structure of PH0542
2D8A	;	2.05	;	Crystal Structure of PH0655 from Pyrococcus horikoshii OT3
2E8H	;	2.1	;	Crystal structure of PH0725 from Pyrococcus horikoshii OT3
2HR8	;	2.8	;	Crystal structure of PH0725 from Pyrococcus horikoshii OT3
2HUQ	;	2.2	;	Crystal structure of PH0725 from Pyrococcus horikoshii OT3
2HUT	;	2.4	;	Crystal structure of PH0725 from Pyrococcus horikoshii OT3
2HUV	;	2.1	;	Crystal structure of PH0725 from Pyrococcus horikoshii OT3
2HUX	;	2.4	;	Crystal structure of PH0725 from Pyrococcus horikoshii OT3
2OWF	;	2.2	;	Crystal structure of PH0725 from Pyrococcus horikoshii OT3
2OWG	;	2.1	;	Crystal structure of PH0725 from Pyrococcus horikoshii OT3
2OWK	;	2.0	;	Crystal structure of PH0725 from Pyrococcus horikoshii OT3
2OWU	;	2.2	;	Crystal structure of PH0725 from Pyrococcus horikoshii OT3
2OWV	;	2.8	;	Crystal structure of PH0725 from Pyrococcus horikoshii OT3
2P2X	;	2.9	;	Crystal structure of PH0725 from Pyrococcus horikoshii OT3
2P5C	;	2.4	;	Crystal structure of PH0725 from Pyrococcus horikoshii OT3
2P5F	;	2.5	;	Crystal structure of PH0725 from Pyrococcus horikoshii OT3
2P6D	;	2.4	;	Crystal structure of PH0725 from Pyrococcus horikoshii OT3
2P6I	;	2.2	;	Crystal structure of PH0725 from Pyrococcus horikoshii OT3
2P6K	;	2.1	;	Crystal structure of PH0725 from Pyrococcus horikoshii OT3
2P6L	;	2.0	;	Crystal structure of PH0725 from Pyrococcus horikoshii OT3
2P9D	;	2.1	;	Crystal structure of PH0725 from Pyrococcus horikoshii OT3
2PB4	;	2.1	;	Crystal structure of PH0725 from Pyrococcus horikoshii OT3
2PB5	;	2.1	;	Crystal structure of PH0725 from Pyrococcus horikoshii OT3
2PB6	;	2.2	;	Crystal structure of PH0725 from Pyrococcus horikoshii OT3
2PCA	;	2.0	;	Crystal structure of PH0725 from Pyrococcus horikoshii OT3
2PCG	;	2.2	;	Crystal structure of PH0725 from Pyrococcus horikoshii OT3
2PCH	;	2.0	;	Crystal structure of PH0725 from Pyrococcus horikoshii OT3
2PCI	;	2.0	;	Crystal structure of PH0725 from Pyrococcus horikoshii OT3
2PCK	;	2.6	;	Crystal structure of PH0725 from Pyrococcus horikoshii OT3
2PCM	;	2.4	;	Crystal structure of PH0725 from Pyrococcus horikoshii OT3
2CSU	;	2.2	;	Crystal structure of PH0766 from Pyrococcus horikoshii OT3
2YX6	;	2.0	;	Crystal structure of PH0822
2P9X	;	1.65	;	Crystal structure of PH0832 from Pyrococcus horikoshii OT3
2YXL	;	2.55	;	Crystal Structure of PH0851
1WMM	;	2.2	;	Crystal structure of PH1033 from Pyrococcus horikoshii Ot3
2HD9	;	1.35	;	Crystal structure of PH1033 from Pyrococcus horikoshii OT3
2ZBN	;	2.0	;	Crystal structure of PH1033 from Pyrococcus horikoshii OT3
2D13	;	2.4	;	Crystal Structure of PH1257 from Pyrococcus horikoshii OT3
1VBK	;	1.9	;	Crystal structure of PH1313 from Pyrococcus horikoshii Ot3
1WL8	;	1.45	;	Crystal structure of PH1346 protein from Pyrococcus horikoshii
2CYY	;	1.8	;	Crystal structure of PH1519 from Pyrococcus horikosii OT3
2ZSK	;	2.55	;	Crystal structure of PH1733, an aspartate racemase homologue, from Pyrococcus horikoshii OT3
1WR2	;	2.0	;	Crystal structure of PH1788 from Pyrococcus horikoshii Ot3
2AS0	;	1.8	;	Crystal Structure of PH1915 (APC 5817): A Hypothetical RNA Methyltransferase
2D16	;	1.65	;	Crystal Structure of PH1918 protein from Pyrococcus horikoshii OT3
1WWZ	;	1.75	;	Crystal structure of PH1933 from Pyrococcus horikoshii OT3
2DM9	;	1.85	;	Crystal Structure of PH1978 from Pyrococcus horikoshii OT3
2DMA	;	2.05	;	Crystal Structure of PH1978 from Pyrococcus horikoshii OT3 (form II)
5AVA	;	3.0	;	Crystal structure of PHA-E lectin in complex with bisected glycan
3VZP	;	1.792	;	Crystal structure of PhaB from Ralstonia eutropha
3VZS	;	2.14	;	Crystal structure of PhaB from Ralstonia eutropha in complex with Acetoacetyl-CoA and NADP
4RZI	;	2.891	;	Crystal structure of PhaB from Synechocystis sp. PCC 6803
5HZ2	;	1.8	;	Crystal structure of PhaC1 from Ralstonia eutropha
5T1E	;	1.83	;	Crystal structure of Phaeospaeria nodrum fructosyl peptide oxidase
5T1F	;	1.98	;	Crystal structure of Phaeospaeria nodrum fructosyl peptide oxidase mutant Asn56Ala
5XAO	;	1.8	;	Crystal structure of Phaeospaeria nodrum fructosyl peptide oxidase mutant Asn56Ala in complexes with sodium and chloride ions
3TXQ	;	2.8	;	Crystal Structure of phage 44RR small terminase gp16
3TXS	;	1.81	;	Crystal Structure of phage 44RR small terminase gp16
2H9G	;	2.32	;	Crystal structure of phage derived Fab BdF1 with human Death Receptor 5 (DR5)
1DZB	;	2.0	;	Crystal structure of phage library-derived single-chain Fv fragment 1F9 in complex with turkey egg-white lysozyme
3K93	;	2.15	;	Crystal structure of phage related exonuclease (YP_719632.1) from HAEMOPHILUS SOMNUS 129PT at 2.15 A resolution
1SSY	;	2.4	;	Crystal structure of phage T4 lysozyme mutant G28A/I29A/G30A/C54T/C97A
1T8G	;	1.8	;	Crystal structure of phage T4 lysozyme mutant L32A/L33A/T34A/C54T/C97A/E108V
1T8F	;	2.15	;	Crystal structure of phage T4 lysozyme mutant R14A/K16A/I17A/K19A/T21A/E22A/C54T/C97A
1SSW	;	2.13	;	Crystal structure of phage T4 lysozyme mutant Y24A/Y25A/T26A/I27A/C54T/C97A
4PPJ	;	2.3	;	Crystal structure of Phanta, a weakly fluorescent photochromic GFP-like protein. ON state
3ABW	;	1.9	;	Crystal structure of pharaonis halorhodopsin in complex with azide ion
5JO1	;	2.3	;	Crystal structure of phaseic acid-bound abscisic acid receptor PYL3 in complex with type 2C protein phosphatase HAB1
2D80	;	1.7	;	Crystal structure of PHB depolymerase from Penicillium funiculosum
4PZO	;	2.25	;	Crystal structure of PHC3 SAM L967R
4PZN	;	2.3	;	Crystal structure of PHC3 SAM L971E
3SHB	;	1.8	;	Crystal Structure of PHD Domain of UHRF1
2F6N	;	2.0	;	Crystal structure of PHD finger-linker-bromodomain fragment of human BPTF in the free form
2FSA	;	1.9	;	Crystal structure of PHD finger-linker-bromodomain fragment of human BPTF in the H3(1-15)K4ME2 bound state
2F6J	;	2.0	;	Crystal structure of PHD finger-linker-bromodomain fragment of human BPTF in the H3(1-15)K4me3 bound state
2RI7	;	1.45	;	Crystal structure of PHD finger-linker-bromodomain Y17E mutant from human BPTF in the H3(1-9)K4ME2 bound state
3HRY	;	2.25	;	Crystal structure of PHD in a trigonal space group and partially disordered
3HS2	;	2.2	;	Crystal structure of PHD truncated to residue 57 in an orthorhombic space group
7UMP	;	1.8	;	CRYSTAL STRUCTURE OF PHD2 CATALYTIC DOMAIN (CID 7465) IN COMPLEX WITH AKB-6548 AT 1.8 A RESOLUTION
1JME	;	2.0	;	Crystal Structure of Phe393His Cytochrome P450 BM3
7Z3S	;	1.99	;	CRYSTAL STRUCTURE of PheF from Geobacillus stearothermophilus
6UI4	;	2.65	;	Crystal structure of phenamacril-bound F. graminearum myosin I
7ENZ	;	1.7	;	Crystal structure of Phenanthredinone moiety in complex with the second bromodomain of BRD2 (BRD2-BD2).
7PDA	;	2.65	;	Crystal structure of Phenazine 1-carboxylic acid decarboxylase from Mycobacterium fortuitum
3B4O	;	1.9	;	Crystal structure of phenazine biosynthesis protein PhzA/B from Burkholderia cepacia R18194, apo form
3B4P	;	1.7	;	Crystal structure of phenazine biosynthesis protein PhzA/B from Burkholderia cepacia R18194, complex with 2-(cyclohexylamino)benzoic acid
3CNM	;	1.65	;	Crystal Structure of Phenazine Biosynthesis Protein PhzA/B from Burkholderia cepacia R18194, DHHA complex
1S7J	;	2.3	;	Crystal structure of phenazine biosynthesis protein PhzF family (Enterococcus faecalis)
3SK2	;	1.01	;	Crystal structure of phenazine resistance protein EhpR from Enterobacter agglomerans (Erwinia herbicola, Pantoea agglomerans) Eh1087 in complex with griseoluteic acid
3SK1	;	2.15	;	Crystal structure of phenazine resistance protein EhpR from Enterobacter agglomerans (Erwinia herbicola, Pantoea agglomerans) Eh1087, apo form
2P8G	;	1.36	;	Crystal structure of phenolic acid decarboxylase (2635953) from Bacillus subtilis at 1.36 A resolution
3NAD	;	1.69	;	Crystal Structure of Phenolic Acid Decarboxylase from Bacillus pumilus UI-670
2I0T	;	1.35	;	Crystal structure of phenylacetaldehyde derived R-carbinolamine adduct of aromatic amine dehydrogenase
3HRX	;	1.85	;	Crystal structure of phenylacetic acid degradation protein PaaG
2EJB	;	2.15	;	Crystal Structure Of Phenylacrylic Acid Decarboxylase from Aquifex aeolicus
6RGS	;	2.42001	;	Crystal Structure of Phenylalanine Ammonia Lyase (PAL) from Petroselinum crispum bound to cinnamate
1T6J	;	2.1	;	Crystal Structure of Phenylalanine Ammonia Lyase from Rhodosporidium toruloides
1T6P	;	2.7	;	Crystal Structure of Phenylalanine Ammonia Lyase from Rhodosporidium toruloides
2NYN	;	1.9	;	Crystal structure of phenylalanine ammonia-lyase from Anabaena variabilis
5LTM	;	2.413	;	Crystal structure of phenylalanine ammonia-lyase from Anabaena variabilis (Y78F-C503S-C565S) bound to cinnamate
2NYF	;	2.5	;	Crystal structure of phenylalanine ammonia-lyase from Nostoc punctiforme
1Y2M	;	1.6	;	Crystal structure of phenylalanine ammonia-lyase from yeast Rhododporidium toruloides
1TG2	;	2.2	;	Crystal structure of phenylalanine hydroxylase A313T mutant with 7,8-dihydrobiopterin bound
7VGM	;	2.27	;	Crystal structure of Phenylalanine hydroxylase from Bacillus cereus ATCC 14579
3TK4	;	1.5	;	Crystal structure of phenylalanine hydroxylase from Chromobacterium violaceum bound to cobalt
4JPX	;	1.55	;	Crystal structure of phenylalanine hydroxylase S203P mutant from Chromobacterium violaceum
6Y3G	;	3.1	;	Crystal structure of phenylalanine tRNA from Escherichia coli
1KFL	;	2.8	;	Crystal structure of phenylalanine-regulated 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase (DAHP synthase) from E.coli complexed with Mn2+, PEP, and Phe
1QR7	;	2.6	;	CRYSTAL STRUCTURE OF PHENYLALANINE-REGULATED 3-DEOXY-D-ARABINO-HEPTULOSONATE-7-PHOSPHATE SYNTHASE FROM ESCHERICHIA COLI COMPLEXED WITH PB2+ AND PEP
2AMC	;	2.7	;	Crystal structure of Phenylalanyl-tRNA synthetase complexed with L-tyrosine
2ZYB	;	2.55	;	Crystal structure of phenylimidazo pyrazin 2 bound to the kinase domain of human LCK, (auto-phosphorylated on TYR394)
2NXW	;	1.5	;	Crystal structure of phenylpyruvate decarboxylase of Azospirillum brasilense
8HPG	;	3.895	;	Crystal structure of phenylpyruvate reductase from Lactobacillus sp. CGMCC 9967
1V72	;	2.05	;	Crystal Structure of Phenylserine Aldolase from Pseudomonas Putida
4WHB	;	2.958	;	Crystal structure of phenylurea hydrolase B
6WAV	;	1.7	;	Crystal structure of PHF1 in complex with H3K36me3 substitution
7LKY	;	1.85	;	Crystal Structure of PHF1 Tudor domain in complex with a peptidomimetic ligand UNC6641
8H43	;	2.3	;	Crystal structure of PHF1 Tudor domain in complex with hit 1
3O7A	;	1.67	;	Crystal structure of PHF13 in complex with H3K4me3
3KQI	;	1.78	;	crystal structure of PHF2 PHD domain complexed with H3K4Me3 peptide
6L1P	;	1.231	;	Crystal structure of PHF20L1 in complex with Hit 1
6L1F	;	1.9	;	Crystal structure of PHF20L1 Tudor1 in complex with K142me1 DNMT1
6RJ6	;	1.984	;	Crystal structure of PHGDH in complex with BI-4924
6RJ3	;	1.42	;	Crystal structure of PHGDH in complex with compound 15
6RJ5	;	1.89	;	Crystal structure of PHGDH in complex with compound 39
6RJ2	;	2.0	;	Crystal structure of PHGDH in complex with compound 40
6RIH	;	2.15	;	Crystal structure of PHGDH in complex with compound 9
4KZ2	;	3.05	;	Crystal Structure of phi29 pRNA 3WJ Core
6JXM	;	3.32	;	Crystal Structure of phi29 pRNA domain II
8ANV	;	2.2	;	Crystal structure of phi3T_93 and phi3T AimX complex
8C8E	;	2.2	;	Crystal structure of phi3T_93 L23D mutant
5JS4	;	1.48	;	Crystal structure of phiAB6 tailspike
5JSD	;	1.48	;	Crystal structure of phiAB6 tailspike in complex with five-repeated oligosaccharides of Acinetobacter baumannii surface polysaccharide
5JSE	;	1.89	;	Crystal structure of phiAB6 tailspike in complex with three-repeated oligosaccharides of Acinetobacter baumannii surface polysaccharide
4EEU	;	1.4068	;	Crystal structure of phiLOV2.1
7D2W	;	1.97	;	Crystal structure of PHIT/PHISTa-like subfamily PF3D7_1372300 protein from plasmodium falciparum
1N10	;	2.9	;	Crystal Structure of Phl p 1, a Major Timothy Grass Pollen Allergen
3TSH	;	1.9	;	Crystal structure of Phl p 4, a grass pollen allergen with glucose dehydrogenase activity
3TSJ	;	2.0	;	Crystal structure of Phl p 4, a grass pollen allergen with glucose dehydrogenase activity
1NLX	;	2.8	;	Crystal Structure of PHL P 6, A Major Timothy Grass Pollen Allergen Co-Crystallized with Zinc
5XOT	;	2.787	;	Crystal structure of pHLA-B35 in complex with TU55 T cell receptor
7E1N	;	2.1	;	Crystal structure of PhlH in complex with 2,4-diacetylphloroglucinol
7E5U	;	1.62	;	Crystal structure of Phm7
7E5V	;	1.61	;	Crystal structure of Phm7 in complex with inhibitor
7S6G	;	2.02	;	Crystal structure of PhnD from Synechococcus MITS9220 in complex with phosphate
2FA1	;	1.7	;	Crystal structure of PhnF C-terminal domain
3F8M	;	1.8	;	Crystal Structure of PhnF from Mycobacterium smegmatis
3P2U	;	1.48	;	Crystal structure of PhnP in complex with orthovanadate
4MLM	;	1.7	;	Crystal Structure of PhnZ from uncultured bacterium HF130_AEPn_1
6O19	;	1.596	;	Crystal Structure of Pho7 complex with pho1 promoter site 2
6E33	;	1.705	;	Crystal Structure of Pho7-DNA complex
4KRD	;	1.952	;	Crystal Structure of Pho85-Pcl10 Complex
4KRC	;	2.597	;	Crystal Structure of Pho85-Pcl10-ATP-gamma-S Complex
6RPQ	;	2.654	;	Crystal structure of PhoCDC21-1 intein
7DNB	;	2.81	;	Crystal structure of PhoCl barrel
6FX2	;	1.7	;	crystal structure of Pholiota squarrosa lectin in complex with a decasaccharide
6FX3	;	1.7	;	crystal structure of Pholiota squarrosa lectin in complex with a dodecasaccharide
6FX1	;	2.1	;	Crystal structure of Pholiota squarrosa lectin in complex with an octasaccharide
5FVB	;	1.93	;	CRYSTAL STRUCTURE OF PHORMIDIUM C-PHYCOERYTHRIN AT PH 5.0
5AQD	;	2.121	;	Crystal structure of Phormidium Phycoerythrin at pH 8.5
6XWK	;	1.17	;	Crystal structure of Phormidium rubidum phycocyanin
5Y7M	;	3.1	;	Crystal structure of PhoRpp38 bound to a K-turn in P12.1 helix
5XTM	;	2.1	;	Crystal structure of PhoRpp38 bound to a K-turn in P12.2 helix
5DCV	;	3.401	;	Crystal structure of PhoRpp38-SL12M complex
3IRU	;	2.3	;	Crystal structure of phoshonoacetaldehyde hydrolase like protein from Oleispira antarctica
1YS9	;	2.56	;	Crystal structure of phosphatase SPy1043 from Streptococcus pyogenes
4EXL	;	1.7	;	Crystal structure of phosphate ABC transporter, periplasmic phosphate-binding protein PstS 1 (PBP1) from Streptococcus pneumoniae Canada MDR_19A
4LAT	;	1.88	;	Crystal structure of phosphate ABC transporter, periplasmic phosphate-binding protein PstS 1 (PBP1) from Streptococcus pneumoniae Canada MDR_19A in complex with phosphate
3L6O	;	2.2	;	Crystal Structure of Phosphate bound apo Glyceraldehyde-3-phosphate dehydrogenase 1 from MRSA252 at 2.2 Angstrom resolution
3K73	;	2.5	;	Crystal Structure of Phosphate bound Holo Glyceraldehyde-3-phosphate dehydrogenase 1 from MRSA252 at 2.5 Angstrom resolution
3FJM	;	1.6	;	crystal structure of phosphate bound PEB3
2Z22	;	2.0	;	Crystal structure of phosphate preplasmic binding protein psts from yersinia pestis
2A96	;	2.5	;	Crystal structure of phosphate tethered PhoN of S. typhimurium
1T72	;	2.9	;	Crystal structure of phosphate transport system protein phoU from Aquifex aeolicus
5WNN	;	1.85	;	Crystal structure of Phosphate-binding protein PstS protein from Burkholderia pseudomallei
3GZH	;	1.9	;	Crystal structure of phosphate-bound adenylosuccinate lyase from E. coli
4NK1	;	2.21	;	Crystal structure of phosphate-bound Hell's gate globin IV
6KYL	;	3.55	;	Crystal Structure of Phosphatidic acid Transporter Ups1/Mdm35 in Complex with (2R)-3-(phosphonooxy)propane-1,2-diyl dihexanoate
5JQM	;	1.5	;	Crystal Structure of Phosphatidic acid Transporter Ups1/Mdm35 Void of Bound Phospholipid from Saccharomyces Cerevisiae at 1.5 Angstroms Resolution
5JQL	;	2.9	;	Crystal Structure of Phosphatidic acid Transporter Ups1/Mdm35 Void of Bound Phospholipid from Saccharomyces Cerevisiae at 2.9 Angstroms Resolution
4PLA	;	2.771	;	Crystal structure of phosphatidyl inositol 4-kinase II alpha in complex with ATP
4YC4	;	2.58	;	Crystal structure of phosphatidyl inositol 4-kinase II alpha in complex with nucleotide analog
5EUT	;	2.802	;	Crystal structure of phosphatidyl inositol 4-kinase II alpha in the apo state
8A5X	;	2.4	;	Crystal structure of phosphatidyl inositol 4-kinase II beta in complex with MM1373
4N9W	;	1.94	;	Crystal structure of phosphatidyl mannosyltransferase PimA
4NC9	;	3.192	;	Crystal structure of phosphatidyl mannosyltransferase PimA
7B1K	;	2.2	;	Crystal structure of phosphatidyl serine synthase (PSS) in the closed conformation with bound citrate.
7B1L	;	1.85	;	Crystal structure of phosphatidyl serine synthase (PSS) in the closed conformation with bound citrate.
7B1N	;	2.8	;	Crystal structure of phosphatidyl serine synthase (PSS) in the closed conformation with bound citrate.
7POW	;	2.51	;	Crystal structure of phosphatidyl serine synthase (PSS) in transition state.
2R77	;	1.65	;	Crystal structure of phosphatidylethanolamine-binding protein, pfl0955c, from Plasmodium falciparum
7DRK	;	3.0	;	Crystal structure of phosphatidylglycerol phosphate synthase in complex with cytidine diphosphate-diacylglycerol
7DRJ	;	2.5	;	Crystal structure of phosphatidylglycerol phosphate synthase in complex with phosphatidylglycerol phosphate
7QIE	;	2.39	;	Crystal Structure of Phosphatidylinositol 5-Phosphate 4-Kinase (PI5P4K2C) bound to an allosteric inhibitor
7QPN	;	1.95	;	Crystal Structure of Phosphatidylinositol 5-Phosphate 4-Kinase (PI5P4K2C) bound to an allosteric inhibitor and AMP-PNP
8BQ4	;	2.42	;	Crystal Structure of Phosphatidylinositol 5-Phosphate 4-Kinase (PI5P4K2C) bound to an inhibitor
8C8C	;	2.096	;	Crystal Structure of Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha (PI5P4Ka) bound to an inhibitor
2GEK	;	2.4	;	Crystal Structure of phosphatidylinositol mannosyltransferase (PimA) from Mycobacterium smegmatis in complex with GDP
2GEJ	;	2.6	;	Crystal Structure of phosphatidylinositol mannosyltransferase (PimA) from Mycobacterium smegmatis in complex with GDP-Man
5E3S	;	3.1	;	Crystal structure of Phosphatidylinositol-4-phosphate 5-kinase
5E3T	;	3.3	;	Crystal structure of phosphatidylinositol-4-phosphate 5-kinase
5E3U	;	3.6	;	Crystal structure of phosphatidylinositol-4-phosphate 5-kinase
3HSI	;	2.2	;	Crystal structure of phosphatidylserine synthase Haemophilus influenzae Rd KW20
1YR0	;	2.0	;	Crystal structure of phosphinothricin acetyltransferase from agrobacterium tumefaciens
8I83	;	2.62	;	Crystal Structure of phosphinothricin dehydrogenase
5DWM	;	1.45	;	Crystal structure of Phosphinothricin N-acetyltransferase from Brucella ovis
5DWN	;	1.95	;	Crystal structure of Phosphinothricin N-acetyltransferase from Brucella ovis in complex with AcetylCoA <structure_details =
6IH2	;	2.048	;	Crystal structure of Phosphite Dehydrogenase from Ralstonia sp. 4506
6IH3	;	1.942	;	Crystal structure of Phosphite Dehydrogenase from Ralstonia sp. 4506 in complex with non-natural cofactor Nicotinamide Cytosine Dinucleotide
6IH4	;	2.6	;	Crystal structure of Phosphite Dehydrogenase mutant I151R/P176E from Ralstonia sp. 4506
6IH5	;	2.468	;	Crystal structure of Phosphite Dehydrogenase mutant I151R/P176E from Ralstonia sp. 4506 in complex with non-natural cofactor Nicotinamide Cytosine dinucleotide
6IH8	;	2.25	;	Crystal structure of Phosphite Dehydrogenase mutant I151R/P176R/M207A from Ralstonia sp. 4506
1VR6	;	1.92	;	Crystal structure of Phospho-2-dehydro-3-deoxyheptonate aldolase (DAHP synthase) (TM0343) from Thermotoga Maritima at 1.92 A resolution
2CCI	;	2.7	;	Crystal structure of phospho-CDK2 Cyclin A in complex with a peptide containing both the substrate and recruitment sites of CDC6
2JGZ	;	2.9	;	Crystal structure of phospho-CDK2 in complex with Cyclin B
7X14	;	1.675	;	Crystal structure of phospho-FFAT motif of MIGA2 bound to VAPB
7LWB	;	1.9	;	Crystal Structure of phospho-Rab8a with the RH2 domain (117-165) of RILPL2
7RGE	;	2.38	;	Crystal structure of phosphoadenylyl-sulfate (PAPS) reductase from Candida auris, phosphate complex
3X1K	;	2.547	;	crystal structure of Phosphoapantetheine adenylyltransferase PPAT/CoaD with AMP-PNP from Pseudomonas aerugonosa
4RUK	;	2.2	;	crystal structure of Phosphoapantetheine adenylyltransferase PPAT/CoaD with CoA and pyrophosphate from Pseudomonas aeruginosa
3WD9	;	2.5	;	Crystal structure of phosphodiesterase 4B in complex with compound 10f
3W5E	;	2.3	;	Crystal structure of phosphodiesterase 4B in complex with compound 31e
4Y87	;	3.1	;	Crystal structure of phosphodiesterase 9 in complex with (R)-C33 (6-{[(1R)-1-(4-chlorophenyl)ethyl]amino}-1-cyclopentyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one)
4Y8C	;	2.7	;	Crystal structure of phosphodiesterase 9 in complex with (S)-C33
5VYD	;	2.3	;	Crystal structure of phosphodiesterase domain of RhoPDE fusion protein from the Choanoflagellate Salpingoeca rosetta
7DCK	;	2.34	;	Crystal structure of phosphodiesterase tw9814
1II2	;	2.0	;	Crystal Structure of Phosphoenolpyruvate Carboxykinase (PEPCK) from Trypanosoma cruzi
1YLH	;	1.7	;	Crystal Structure of Phosphoenolpyruvate Carboxykinase from Actinobaccilus succinogenes in Complex with Manganese and Pyruvate
1YGG	;	1.85	;	Crystal structure of phosphoenolpyruvate carboxykinase from Actinobacillus succinogenes
1YTM	;	2.2	;	Crystal structure of phosphoenolpyruvate carboxykinase of Anaerobiospirillum succiniciproducens complexed with ATP, oxalate, magnesium and manganese ions
5FDN	;	2.2	;	Crystal structure of phosphoenolpyruvate carboxylase from Arabidopsis thaliana in complex with aspartate and citrate
1S2V	;	2.1	;	Crystal structure of phosphoenolpyruvate mutase complexed with Mg(II)
1M1B	;	2.25	;	Crystal Structure of Phosphoenolpyruvate Mutase Complexed with Sulfopyruvate
1S2W	;	1.69	;	Crystal structure of phosphoenolpyruvate mutase in high ionic strength
4QAK	;	2.025	;	Crystal structure of phosphoesterase
4FGZ	;	1.994	;	Crystal Structure of Phosphoethanolamine Methyltransferase from Plasmodium falciparum in Complex with Amodiaquine
2HIG	;	2.4	;	Crystal Structure of Phosphofructokinase apoenzyme from Trypanosoma brucei.
5XZ8	;	1.95	;	Crystal Structure of Phosphofructokinase from Staphylococcus aureus in complex with adenylylimidodiphosphate (the ATP analog) and fructose-6-phosphate
5XZ6	;	2.7	;	Crystal Structure of Phosphofructokinase from Staphylococcus aureus in complex with adenylylimidodiphosphate, the ATP analogue
5XZ7	;	1.6	;	Crystal Structure of Phosphofructokinase from Staphylococcus aureus in complex with adenylylimidodiphosphate, the ATP analogue
5XZ9	;	2.0	;	Crystal Structure of Phosphofructokinase from Staphylococcus aureus in complex with adenylylimidodiphosphate, the ATP analogue
5XZA	;	1.9	;	Crystal Structure of Phosphofructokinase from Staphylococcus aureus in complex with ADP
6QU5	;	3.4	;	Crystal Structure of Phosphofructokinase from Trypanosoma brucei in complex with an allosteric inhibitor ctcb12
6QU3	;	2.35	;	Crystal Structure of Phosphofructokinase from Trypanosoma brucei in complex with an allosteric inhibitor ctcb360
6QU4	;	2.75	;	Crystal Structure of Phosphofructokinase from Trypanosoma brucei in complex with an allosteric inhibitor ctcb405
4QG5	;	3.5	;	Crystal structure of phosphoglucomutase from Leishmania major at 3.5 angstrom resolution
5KL0	;	1.853	;	Crystal Structure of Phosphoglucomutase from Xanthomonas citri citri complexed with Glucose-1,6-biphosphate
5BMP	;	1.85	;	Crystal Structure of Phosphoglucomutase from Xanthomonas citri complexed with glucose-1-phosphate
3PDK	;	2.7	;	crystal structure of phosphoglucosamine mutase from B. anthracis
1QXR	;	1.7	;	Crystal structure of phosphoglucose isomerase from Pyrococcus furiosus in complex with 5-phosphoarabinonate
1QY4	;	1.8	;	Crystal structure of phosphoglucose isomerase from Pyrococcus furiosus in complex with gluconate 6-phosphate
1X82	;	1.5	;	CRYSTAL STRUCTURE OF PHOSPHOGLUCOSE ISOMERASE FROM PYROCOCCUS FURIOSUS WITH BOUND 5-phospho-D-arabinonate
2O2C	;	1.58	;	Crystal structure of phosphoglucose isomerase from T. brucei containing glucose-6-phosphate in the active site
2O2D	;	1.9	;	Crystal structure of phosphoglucose isomerase from Trypanosoma brucei complexed with citrate
1TZC	;	1.45	;	Crystal structure of phosphoglucose/phosphomannose isomerase from Pyrobaculum aerophilum in complex with 5-phosphoarabinonate
1X9H	;	1.5	;	Crystal structure of phosphoglucose/phosphomannose isomerase from Pyrobaculum aerophilum in complex with fructose 6-phosphate
4NJM	;	1.79	;	Crystal Structure of phosphoglycerate bound 3-phosphoglycerate dehydrogenase in Entamoeba histolytica
3EVT	;	2.2	;	Crystal structure of phosphoglycerate dehydrogenase from Lactobacillus plantarum
1WWK	;	1.9	;	Crystal structure of phosphoglycerate dehydrogenase from Pyrococcus horikoshii OT3
3UWD	;	1.68	;	Crystal Structure of Phosphoglycerate Kinase from Bacillus Anthracis
3Q3V	;	2.145	;	Crystal structure of Phosphoglycerate Kinase from Campylobacter jejuni.
7LA1	;	1.6	;	Crystal structure of phosphoglycerate kinase from Mycobacterium avium
1LTK	;	3.0	;	CRYSTAL STRUCTURE OF PHOSPHOGLYCERATE KINASE FROM PLASMODIUM FALCIPARUM, IN THE OPEN CONFORMATION
2CUN	;	2.1	;	Crystal structure of Phosphoglycerate Kinase from Pyrococcus horikoshii OT3
3ZLB	;	1.78	;	Crystal structure of phosphoglycerate kinase from Streptococcus pneumoniae
1V6S	;	1.5	;	Crystal Structure of Phosphoglycerate Kinase from Thermus thermophilus HB8
2P9Q	;	2.7	;	Crystal Structure of Phosphoglycerate Kinase-2
2P9T	;	2.0	;	Crystal Structure of Phosphoglycerate Kinase-2 bound to 3-phosphoglycerate
2PAA	;	2.7	;	Crystal structure of phosphoglycerate kinase-2 bound to atp and 3pg
3R7A	;	1.845	;	Crystal structure of phosphoglycerate mutase from Bacillus anthracis str. Sterne
1EQJ	;	1.7	;	CRYSTAL STRUCTURE OF PHOSPHOGLYCERATE MUTASE FROM BACILLUS STEAROTHERMOPHILUS COMPLEXED WITH 2-PHOSPHOGLYCERATE
3D8H	;	2.01	;	Crystal structure of phosphoglycerate mutase from Cryptosporidium parvum, cgd7_4270
1RII	;	1.7	;	Crystal structure of phosphoglycerate mutase from M. Tuberculosis
5VVE	;	1.7	;	Crystal structure of phosphoglycerate mutase from Naegleria fowleri
3EOZ	;	2.4	;	Crystal Structure of Phosphoglycerate Mutase from Plasmodium Falciparum, PFD0660w
4NWX	;	2.01	;	Crystal structure of phosphoglycerate mutase from Staphylococcus aureus in 2-phosphoglyceric acid bound form
4MY4	;	2.0	;	Crystal structure of phosphoglycerate mutase from Staphylococcus aureus.
1V37	;	1.4	;	Crystal structure of phosphoglycerate mutase from Thermus thermophilus HB8
1V7Q	;	1.59	;	Crystal structure of phosphoglycerate mutase from Thermus thermophilus HB8
3NVL	;	2.3	;	Crystal Structure of Phosphoglycerate Mutase from Trypanosoma brucei
4S1V	;	2.1	;	Crystal structure of phosphoglycerate oxidoreductase from Vibrio Cholerae o395
3EZN	;	2.1	;	Crystal structure of phosphoglyceromutase from burkholderia pseudomallei 1710b
3FDZ	;	2.25	;	Crystal structure of phosphoglyceromutase from burkholderia pseudomallei 1710b with bound 2,3-diphosphoglyceric acid and 3-phosphoglyceric acid
3LNT	;	2.1	;	Crystal structure of phosphoglyceromutase from Burkholderia Pseudomallei 1710B with bound malonic acid
3GP3	;	1.5	;	Crystal structure of phosphoglyceromutase from Burkholderia pseudomallei with 2-phosphoserine
3GP5	;	2.25	;	Crystal structure of phosphoglyceromutase from Burkholderia pseudomallei with 3-phosphoglyceric acid and vanadate
3GW8	;	1.93	;	Crystal structure of phosphoglyceromutase from Burkholderia pseudomallei with vanadate and glycerol
1TK9	;	2.1	;	Crystal Structure of Phosphoheptose isomerase 1
2Q14	;	2.2	;	Crystal structure of Phosphohydrolase (BT4208) from Bacteroides thetaiotaomicron VPI-5482 at 2.20 A resolution
3O7L	;	2.8	;	Crystal Structure of phospholamban (1-19):PKA C-subunit:AMP-PNP:Mg2+ complex
4QNN	;	2.5	;	Crystal Structure of phospholipase A 1 from hornet(Vespa basalis) venom
2YIJ	;	2.0	;	Crystal Structure of phospholipase A1
4HYQ	;	1.75	;	Crystal structure of phospholipase A1 from Streptomyces albidoflavus NA297
7X0C	;	1.7991	;	Crystal structure of phospholipase A1, AtDSEL
7X0D	;	2.39725	;	Crystal structure of phospholipase A1, CaPLA1
6KQU	;	2.0	;	Crystal structure of phospholipase A2
1PWO	;	2.6	;	Crystal Structure of Phospholipase A2 (MIPLA2) from Micropechis Ikaheka
1OZY	;	2.7	;	Crystal Structure of Phospholipase A2 (MIPLA3) From Micropechis Ikaheka
1P7O	;	2.3	;	Crystal structure of phospholipase A2 (MIPLA4) from Micropechis ikaheka
3FVJ	;	2.3	;	Crystal structure of phospholipase A2 1B crystallized in the presence of octyl sulfate
3G8G	;	1.7	;	Crystal structure of phospholipase A2 ammodytoxin A from vipera ammodytes ammodytes
3G8H	;	1.35	;	Crystal structure of phospholipase A2 ammodytoxin C from vipera ammodytes ammodytes
2Q1P	;	1.5	;	Crystal Structure of Phospholipase A2 complex with propanol at 1.5 A resolution
1CL5	;	2.45	;	CRYSTAL STRUCTURE OF PHOSPHOLIPASE A2 FROM DABOIA RUSSELLI PULCHELLA
1PSH	;	2.3	;	CRYSTAL STRUCTURE OF PHOSPHOLIPASE A2 FROM INDIAN COBRA REVEALS A TRIMERIC ASSOCIATION
1TH6	;	1.23	;	Crystal structure of phospholipase A2 in complex with atropine at 1.23A resolution
5Y5E	;	1.8	;	Crystal structure of phospholipase A2 with inhibitor
2ZKM	;	1.62	;	Crystal Structure of Phospholipase C Beta 2
4PQW	;	1.47	;	Crystal Structure of Phospholipase C beta 3 in Complex with PDZ1 of NHERF1
7E0M	;	1.79	;	Crystal structure of phospholipase D
7WU1	;	2.3	;	Crystal structure of phospholipase D from Moritella sp. JT01
7V55	;	3.0	;	Crystal structure of phospholipase D from Pseudomonas aeruginosa PAO1 using in situ proteolysis
2ZE4	;	2.5	;	Crystal structure of phospholipase D from streptomyces antibioticus
4H0C	;	1.62	;	Crystal structure of phospholipase/Carboxylesterase from Dyadobacter fermentans DSM 18053
4Q82	;	1.848	;	Crystal Structure of Phospholipase/Carboxylesterase from Haliangium ochraceum
1K35	;	2.2	;	Crystal Structure of Phosphomannomutase/Phosphoglucomutase from P.aeruginosa
1K2Y	;	1.75	;	Crystal Structure of Phosphomannomutase/Phosphoglucomutase S108A mutant from P. aeruginosa
7XND	;	1.6	;	Crystal structure of Phosphomevalonate kinase from Silkworm
4UPH	;	2.5	;	Crystal Structure of Phosphonate Monoester Hydrolase of Agrobacterium radiobacter
1MPL	;	1.12	;	CRYSTAL STRUCTURE OF PHOSPHONATE-INHIBITED D-ALA-D-ALA PEPTIDASE REVEALS AN ANALOG OF A TETRAHEDRAL TRANSITION STATE
2XZC	;	1.36	;	Crystal Structure of phosphonate-modified recombinant A.17 antibody FAB fragment
2IOH	;	2.9	;	Crystal structure of phosphonoacetaldehyde hydrolase with a K53R mutation
2IOF	;	2.5	;	Crystal structure of phosphonoacetaldehyde hydrolase with sodium borohydride-reduced substrate intermediate
1EI6	;	2.1	;	CRYSTAL STRUCTURE OF PHOSPHONOACETATE HYDROLASE COMPLEXED WITH PHOSPHONOFORMATE
3SZY	;	1.35	;	Crystal Structure of Phosphonoacetate hydrolase from Sinorhizobium meliloti 1021 in APO form
3SZZ	;	2.0	;	Crystal Structure of Phosphonoacetate hydrolase from Sinorhizobium meliloti 1021 in complex with Acetate
3T02	;	2.0	;	Crystal Structure of Phosphonoacetate hydrolase from Sinorhizobium meliloti 1021 in complex with Phosphonoacetate
3T01	;	1.6	;	Crystal Structure of Phosphonoacetate hydrolase from Sinorhizobium meliloti 1021 in complex with Phosphonoformate
3T00	;	1.8	;	Crystal Structure of Phosphonoacetate hydrolase from Sinorhizobium meliloti 1021 in complex with vanadate
2HRW	;	2.2	;	Crystal Structure of Phosphonopyruvate Hydrolase
2DUA	;	2.0	;	Crystal Structure of Phosphonopyruvate Hydrolase Complex with Oxalate and Mg++
2HJP	;	1.9	;	Crystal Structure of Phosphonopyruvate Hydrolase Complex with Phosphonopyruvate and Mg++
3ND5	;	2.3	;	Crystal structure of phosphopantetheine adenylyltransferase (PPAT) from Enterococcus faecalis
3ND6	;	2.3	;	Crystal structure of phosphopantetheine adenylyltransferase (PPAT) in complex with ATP from Enterococcus faecalis
3X1J	;	2.334	;	Crystal Structure of Phosphopantetheine adenylyltransferase (PPAT/CoaD) with AcCoA from Pseudomonas aeruginosa
1VLH	;	2.2	;	Crystal structure of Phosphopantetheine adenylyltransferase (TM0741) from Thermotoga maritima at 2.20 A resolution
3PXU	;	2.1	;	Crystal structure of phosphopantetheine adenylyltransferase from Burkholderia pseudomallei bound to dephospho-coenzyme A
3K9W	;	1.6	;	Crystal structure of phosphopantetheine adenylyltransferase from Burkholderia pseudomallei with hydrolyzed 3'-dephospho Coenzyme A
3ND7	;	2.4	;	Crystal structure of phosphopantetheine adenylyltransferase from Enterococcus faecalis in the ligand-unbound state and in complex with ATP and pantetheine
8I8I	;	2.59	;	Crystal structure of Phosphopantetheine adenylyltransferase from Klebsiella pneumoniae at 2.59 A resolution
5O0H	;	1.599	;	Crystal structure of Phosphopantetheine adenylyltransferase from Mycobacterium abcessus in complex with 2-(4-Chloro-3-nitrobenzoyl)benzoic acid (Fragment 6)
5O0C	;	1.642	;	Crystal structure of Phosphopantetheine adenylyltransferase from Mycobacterium abcessus in complex with 3-(3-methyl-1H-indol-1-yl)propanoic acid (Fragment 3)
5O0F	;	1.704	;	Crystal structure of Phosphopantetheine adenylyltransferase from Mycobacterium abcessus in complex with 3-(indol-3-yl)propanoic acid (Fragment 5)
5O0B	;	1.735	;	Crystal structure of Phosphopantetheine adenylyltransferase from Mycobacterium abcessus in complex with 3-Bromo-1H-indazole-5-carboxylic acid (Fragment 2)
5O0D	;	1.539	;	Crystal structure of Phosphopantetheine adenylyltransferase from Mycobacterium abcessus in complex with 3-Phenoxymandelic acid (Fragment 4)
5O0A	;	1.805	;	Crystal structure of Phosphopantetheine adenylyltransferase from Mycobacterium abcessus in complex with 5-methyl-1-phenyl-pyrazole-4-carboxylic acid (Fragment 1)
5O08	;	1.552	;	Crystal structure of Phosphopantetheine adenylyltransferase from Mycobacterium abcessus in complex with Dephospho-coenzyme A
5X6F	;	2.593	;	Crystal structure of Phosphopantetheine adenylyltransferase from Pseudomonas aeruginosa
1O6B	;	2.2	;	Crystal structure of phosphopantetheine adenylyltransferase with ADP
3X1M	;	2.5	;	Crystal structure of Phosphopantetheine adenylyltransferase/PPAT from Pseudomonas aeruginosa with CoA
1P9O	;	2.3	;	Crystal Structure of Phosphopantothenoylcysteine Synthetase
3M7V	;	2.0	;	Crystal structure of phosphopentomutase from streptococcus mutans
4NWJ	;	2.01	;	Crystal structure of phosphopglycerate mutase from Staphylococcus aureus in 3-phosphoglyceric acid bound form.
3OA1	;	2.2	;	Crystal structure of phosphoprotein/Protein P/Protein M1 residues 69-297 from Rabies virus reveals degradation to C-terminal domain only
1LBM	;	2.8	;	CRYSTAL STRUCTURE OF PHOSPHORIBOSYL ANTHRANILATE ISOMERASE (PRAI) IN COMPLEX WITH REDUCED 1-(O-CARBOXYPHENYLAMINO)-1-DEOXYRIBULOSE 5-PHOSPHATE (RCDRP)
1NSJ	;	2.0	;	CRYSTAL STRUCTURE OF PHOSPHORIBOSYL ANTHRANILATE ISOMERASE FROM THERMOTOGA MARITIMA
1V5X	;	2.0	;	Crystal structure of Phosphoribosyl anthranilate isomerase from Thermus Thermophilus
1U9Z	;	2.8	;	Crystal Structure of Phosphoribosyl Diphosphate Synthase Complexed with AMP and Ribose 5-Phosphate
1U9Y	;	2.65	;	Crystal Structure of Phosphoribosyl Diphosphate Synthase from Methanocaldococcus jannaschii
5DN1	;	1.953	;	Crystal structure of Phosphoribosyl isomerase A from Streptomyces coelicolor
2A7W	;	2.8	;	Crystal Structure of Phosphoribosyl-ATP Pyrophosphatase from Chromobacterium violaceum (ATCC 12472). NESG TARGET CVR7
1YXB	;	2.6	;	Crystal structure of Phosphoribosyl-ATP pyrophosphatase from Streptomyces coelicolor. NESG target RR8.
1YVW	;	2.6	;	Crystal structure of Phosphoribosyl-ATP pyrophosphohydrolase from Bacillus cereus. NESGC target BcR13.
1VKZ	;	2.3	;	Crystal structure of Phosphoribosylamine--glycine ligase (TM1250) from Thermotoga maritima at 2.30 A resolution
3LP8	;	2.15	;	Crystal structure of phosphoribosylamine-glycine ligase from Ehrlichia chaffeensis
5VEV	;	1.9	;	Crystal Structure of Phosphoribosylamine-glycine Ligase from Neisseria gonorrhoeae
2Z04	;	2.35	;	Crystal structure of phosphoribosylaminoimidazole carboxylase ATPase subunit from Aquifex aeolicus
4GRD	;	1.85	;	Crystal structure of Phosphoribosylaminoimidazole carboxylase catalytic subunit from Burkholderia cenocepacia J2315
2YWX	;	2.31	;	Crystal structure of phosphoribosylaminoimidazole carboxylase catalytic subunit from Methanocaldococcus jannaschii
4E4T	;	1.55	;	Crystal structure of Phosphoribosylaminoimidazole carboxylase, ATPase subunit from Burkholderia ambifaria
3M84	;	1.699	;	Crystal Structure of Phosphoribosylaminoimidazole Synthetase from Francisella tularensis
3QTY	;	1.8	;	Crystal structure of Phosphoribosylaminoimidazole Synthetase from Francisella tularensis complexed with pyrophosphate
2Z01	;	2.2	;	Crystal structure of phosphoribosylaminoimidazole synthetase from Geobacillus kaustophilus
3NUA	;	1.4	;	Crystal Structure of Phosphoribosylaminoimidazole-Succinocarboxamide Synthase from Clostridium perfringens
3KRE	;	1.8	;	Crystal structure of phosphoribosylaminoimidazole-succinocarboxamide synthase from Ehrlichia chaffeensis at 1.8A resolution
2YZL	;	2.2	;	Crystal structure of phosphoribosylaminoimidazole-succinocarboxamide synthase with ADP from Methanocaldococcus jannaschii
1ZCZ	;	1.88	;	Crystal structure of Phosphoribosylaminoimidazolecarboxamide formyltransferase / IMP cyclohydrolase (TM1249) from THERMOTOGA MARITIMA at 1.88 A resolution
2Z02	;	2.03	;	Crystal structure of phosphoribosylaminoimidazolesuccinocarboxamide synthase wit ATP from Methanocaldococcus jannaschii
2BTU	;	2.31	;	Crystal structure of Phosphoribosylformylglycinamidine cyclo-ligase from Bacillus Anthracis at 2.3A resolution.
1VK3	;	2.15	;	Crystal structure of Phosphoribosylformylglycinamidine synthase II (TM1246) from Thermotoga maritima at 2.15 A resolution
1VQ3	;	1.9	;	Crystal structure of Phosphoribosylformylglycinamidine synthase, purS subunit (EC 6.3.5.3) (TM1244) from Thermotoga maritima at 1.90 A resolution
3KCQ	;	2.2	;	Crystal structure of phosphoribosylglycinamide formyltransferase from anaplasma phagocytophilum
3P9X	;	1.9	;	Crystal structure of phosphoribosylglycinamide formyltransferase from Bacillus Halodurans
4DS3	;	1.85	;	Crystal Structure of Phosphoribosylglycinamide formyltransferase from Brucella melitensis
4DIM	;	2.61	;	Crystal structure of phosphoribosylglycinamide synthetase from Anaerococcus prevotii
5MP7	;	2.4	;	Crystal structure of phosphoribosylpyrophosphate synthetase from Mycobacterium smegmatis
2P1Z	;	2.44	;	Crystal structure of phosphoribosyltransferase from Corynebacterium diphtheriae
5B3F	;	2.5	;	Crystal structure of phosphoribulokinase from Methanospirillum hungatei
8SLZ	;	2.3	;	Crystal structure of phosphorylated (T357/S358) human MLKL pseudokinase domain
5TRC	;	2.9	;	Crystal structure of phosphorylated AC3-AC5 domains of yeast acetyl-CoA carboxylase
7XBR	;	3.2	;	Crystal structure of phosphorylated AtMKK5
4ISW	;	3.14	;	Crystal Structure of Phosphorylated C.elegans Thymidylate Synthase in Complex with dUMP
5IUM	;	3.162	;	Crystal structure of phosphorylated DesKC
3GIG	;	3.502	;	Crystal structure of phosphorylated DesKC in complex with AMP-PCP
3OLL	;	1.5	;	Crystal structure of phosphorylated estrogen receptor beta ligand binding domain
3WU0	;	2.6	;	Crystal structure of phosphorylated ETS-1 DNA binding and autoinhibitory domains (276-441)
3CD3	;	1.98	;	Crystal structure of phosphorylated human feline sarcoma viral oncogene homologue (v-FES) in complex with staurosporine and a consensus peptide
3DKL	;	1.89	;	Crystal structure of phosphorylated mimic form of human NAMPT complexed with benzamide and phosphoribosyl pyrophosphate
3DHF	;	1.8	;	Crystal structure of phosphorylated mimic form of human NAMPT complexed with nicotinamide mononucleotide and pyrophosphate
6ADE	;	3.15	;	Crystal structure of phosphorylated mutant of glyceraldehyde 3-phosphate dehydrogenase from human placenta at 3.15A resolution
3NNX	;	2.28	;	Crystal structure of phosphorylated P38 alpha in complex with DP802
3PY3	;	2.1	;	Crystal structure of phosphorylated p38alpha MAP kinase
5NZZ	;	2.6	;	Crystal structure of phosphorylated p38aMAPK in complex with TAB1
3A62	;	2.35	;	Crystal structure of phosphorylated p70S6K1
4N7T	;	1.996	;	Crystal structure of phosphorylated phosphopentomutase from streptococcus mutans
1EUD	;	2.1	;	CRYSTAL STRUCTURE OF PHOSPHORYLATED PIG HEART, GTP-SPECIFIC SUCCINYL-COA SYNTHETASE
7P7F	;	1.96	;	Crystal structure of phosphorylated pT220 Casein Kinase I delta (CK1d), conformation 1
7P7G	;	1.7	;	Crystal structure of phosphorylated pT220 Casein Kinase I delta (CK1d), conformation 2 and 3
6RIR	;	1.767	;	Crystal structure of phosphorylated Rab8a in complex with the Rab-binding domain of RILPL2
7M4O	;	2.21	;	Crystal structure of phosphorylated RBR E3 ligase RNF216 in complex with K63-linked di-ubiquitin
2IVT	;	2.6	;	Crystal structure of phosphorylated RET tyrosine kinase domain
6VHG	;	2.303	;	Crystal structure of phosphorylated RET tyrosine kinase domain complexed with a pyrazolo[1,5-a]pyrimidine inhibitor
7RUN	;	3.51	;	Crystal structure of phosphorylated RET tyrosine kinase domain complexed with a pyrrolo[2,3-d]pyrimidine inhibitor.
2IVV	;	2.25	;	Crystal structure of phosphorylated RET tyrosine kinase domain complexed with the inhibitor PP1
2IVU	;	2.5	;	Crystal structure of phosphorylated RET tyrosine kinase domain complexed with the inhibitor ZD6474
2X2K	;	2.6	;	Crystal Structure of phosphorylated RET tyrosine kinase domain with inhibitor
2X2L	;	2.0	;	Crystal Structure of phosphorylated RET tyrosine kinase domain with inhibitor
2X2M	;	2.5	;	Crystal Structure of phosphorylated RET tyrosine kinase domain with inhibitor
6I83	;	1.88	;	Crystal structure of phosphorylated RET V804M tyrosine kinase domain complexed with PDD00018366
7C48	;	1.6	;	Crystal structure of phosphorylated Ser78 form of Rv1045 toxin
3DAE	;	2.899	;	Crystal structure of phosphorylated SNF1 kinase domain
1M9I	;	2.65	;	Crystal Structure Of Phosphorylation-Mimicking Mutant T356D Of Annexin VI
1I4A	;	2.0	;	CRYSTAL STRUCTURE OF PHOSPHORYLATION-MIMICKING MUTANT T6D OF ANNEXIN IV
1WRA	;	2.0	;	Crystal Structure of Phosphorylcholine Esterase Domain of the Virulence Factor Choline Binding Protein E from Streptococcus Pneumoniae
6XDK	;	1.6	;	Crystal structure of Phosphoserine aminotransferase (SerC) from Stenotrophomonas maltophilia K279a
1W23	;	1.08	;	Crystal structure of phosphoserine aminotransferase from Bacillus alcalophilus
1W3U	;	1.5	;	Crystal structure of phosphoserine aminotransferase from Bacillus circulans var. alkalophilus
2C0R	;	1.2	;	CRYSTAL STRUCTURE OF PHOSPHOSERINE AMINOTRANSFERASE FROM BACILLUS CIRCULANS VAR. ALKALOPHILUS AT pH 8.5
3M5U	;	2.152	;	Crystal Structure of Phosphoserine Aminotransferase from Campylobacter jejuni
7T7J	;	1.5	;	Crystal Structure of Phosphoserine aminotransferase from Klebsiella pneumoniae subsp. pneumoniae in complex with Pyridoxal phosphate
3QBO	;	2.36	;	Crystal structure of phosphoserine aminotransferase from Yersinia pestis CO92
7QPL	;	1.77	;	Crystal structure of phosphoserine phosphatase (SerB) from Brucella melitensis in complex with phosphate and magnesium
5ZKK	;	2.0	;	Crystal structure of Phosphoserine phosphatase from Entamoeba histolytica
1F5S	;	1.8	;	CRYSTAL STRUCTURE OF PHOSPHOSERINE PHOSPHATASE FROM METHANOCOCCUS JANNASCHII
4B6J	;	3.34	;	Crystal structure of phosphoserine phosphatase from T. onnurineus
4AP9	;	1.783	;	Crystal structure of phosphoserine phosphatase from T. onnurineus in complex with NDSB-201
1L7O	;	2.2	;	CRYSTAL STRUCTURE OF PHOSPHOSERINE PHOSPHATASE IN APO FORM
6M1X	;	2.48	;	Crystal structure of Phosphoserine Phosphatase in complex with 3-Phosphoglyceric Acid from Entamoeba histolytica
5ZR2	;	2.95	;	Crystal Structure of Phosphoserine Phosphatase Mutant (H9A) from Entamoeba histolytica in complex with Phosphoserine
8A1Z	;	2.28	;	Crystal structure of Phosphoserine phosphatase SerB from Mycobacterium avium in complex with 1-(2,4-dichlorophenyl)-3-hydroxyurea
8A21	;	2.18	;	Crystal structure of Phosphoserine phosphatase SerB from Mycobacterium avium in complex with phenylimidazole
3P96	;	2.05	;	Crystal structure of Phosphoserine phosphatase SerB from Mycobacterium avium, native form
6SUT	;	1.2	;	Crystal structure of phosphothreonine MCR-2
7VG9	;	2.91	;	Crystal structure of phosphotransbutyrylase from Clostridium acetobutylicum
4TKZ	;	1.8	;	Crystal structure of phosphotransferase system component EIIA from Streptococcus agalactiae
5HRM	;	2.051	;	Crystal structure of phosphotriesterase from Sphingobium sp. TCM1
4LEF	;	1.842	;	Crystal structure of PHOSPHOTRIESTERASE HOMOLOGY PROTEIN FROM ESCHERICHIA COLI complexed with phosphate in active site
1P6C	;	2.0	;	crystal structure of phosphotriesterase triple mutant H254G/H257W/L303T complexed with diisopropylmethylphosphonate
4PCP	;	1.63	;	Crystal structure of Phosphotriesterase variant R0
2CY4	;	1.94	;	Crystal structure of phosphotyrosine binding (PTB) domain of epidermal growth factor receptor pathway substrate-8 (EPS8) related protein 1 from Mus musculus (form-1 crystal)
2CY5	;	1.9	;	Crystal structure of phosphotyrosine binding (PTB) domain of epidermal growth factor receptor pathway substrate-8 (EPS8) related protein 1 from Mus musculus (form-2 crystal)
3HQC	;	1.8	;	Crystal structure of Phosphotyrosine-binding domain from the Human Tensin-like C1 domain-containing phosphatase (TENC1)
2HV7	;	2.5	;	Crystal structure of phosphotyrosyl phosphatase activator bound to ATPgammaS
1RQL	;	2.4	;	Crystal Structure of Phosponoacetaldehyde Hydrolase Complexed with Magnesium and the Inhibitor Vinyl Sulfonate
6Q2M	;	2.75	;	Crystal structure of Photinus pyralis Luciferase Pps6 mutant in complex with DLSA
3A8L	;	1.63	;	Crystal structure of photo-activation state of Nitrile Hydratase mutant S113A
4YUS	;	1.8	;	Crystal structure of photoactivated adenylyl cyclase of a cyanobacteriaOscillatoria acuminata in hexagonal form
4YUT	;	2.9	;	Crystal structure of photoactivated adenylyl cyclase of a cyanobacteriaOscillatoria acuminata in orthorhombic form
8FD1	;	4.25	;	Crystal structure of photoactivated rhodopsin in complex with a nanobody
6UMZ	;	0.9	;	Crystal structure of photoactive yellow protein (PYP); 3-Br-p-coumaric acid chromophore
6UN2	;	0.97	;	Crystal structure of photoactive yellow protein (PYP); C69U construct (selenocysteine incorporation)
7SPX	;	0.97	;	Crystal structure of photoactive yellow protein (PYP); F28oCNF construct
7SPW	;	1.05	;	Crystal structure of photoactive yellow protein (PYP); F62oCNF construct
7SPV	;	1.18	;	Crystal structure of photoactive yellow protein (PYP); F92oCNF construct
6UMY	;	0.923	;	Crystal structure of photoactive yellow protein (PYP); F96(4-IF) construct
6UN0	;	0.85	;	Crystal structure of photoactive yellow protein (PYP); F96(4-IF) construct with 3-Br-p-coumaric acid chromophore
7SJJ	;	0.95	;	Crystal structure of photoactive yellow protein (PYP); F96oCNF construct
8DZY	;	1.01	;	Crystal structure of photoactive yellow protein (PYP); F96oCNF I49T construct
8E03	;	1.24	;	Crystal structure of photoactive yellow protein (PYP); F96oCNF M100D construct
8E09	;	1.01	;	Crystal structure of photoactive yellow protein (PYP); F96oCNF M100E construct
8DZU	;	1.04	;	Crystal structure of photoactive yellow protein (PYP); F96oCNF M100H construct
8DZX	;	1.14	;	Crystal structure of photoactive yellow protein (PYP); F96oCNF M100K construct
8E1L	;	1.2	;	Crystal structure of photoactive yellow protein (PYP); F96oCNF M100N construct
8E1K	;	1.02	;	Crystal structure of photoactive yellow protein (PYP); F96oCNF M100Q construct
8E02	;	1.09	;	Crystal structure of photoactive yellow protein (PYP); F96oCNF T103V construct
5HZI	;	2.6	;	Crystal structure of photoinhibitable Intersectin1 containing C450M mutant LOV2 domain
5HZJ	;	2.6	;	Crystal structure of photoinhibitable Intersectin1 containing wildtype LOV2 domain
5HZK	;	3.3	;	Crystal structure of photoinhibitable Intersectin1 containing wildtype LOV2 domain in complex with Cdc42
5HZH	;	2.6	;	Crystal structure of photoinhibitable Rac1 containing C450A mutant LOV2 domain
1IQU	;	2.2	;	Crystal structure of photolyase-thymine complex
7YNV	;	1.39	;	Crystal structure of photolysed Hen Egg white LYSOZYME introduced with O-(2-nitrobenzyl)-L-tyrosine
4NC4	;	1.75	;	Crystal structure of photoreceptor AtUVR8 mutant W285F and light-induced structural changes at 120K
5ILG	;	2.4	;	Crystal structure of photoreceptor dehydrogenase from Drosophila melanogaster
5ILO	;	2.71	;	Crystal structure of photoreceptor dehydrogenase from Drosophila melanogaster
4Q7T	;	1.94	;	Crystal structure of photoswitchable fluorescent protein PSmOrange
4Q7U	;	1.3	;	Crystal structure of photoswitchable fluorescent protein PSmOrange2
3K2B	;	2.6	;	Crystal structure of photosynthetic A4 isoform glyceraldehyde-3-phosphate dehydrogenase complexed with NAD, from Arabidopsis thaliana
2HKI	;	3.0	;	Crystal structure of photosynthetic glyceraldehyde-3-phosphate dehydrogenase A4 isoform
7ZQK	;	2.2	;	Crystal structure of photosynthetic glyceraldehyde-3-phosphate dehydrogenase from Chlamydomonas reinhardtii (CrGAPA) complexed with NAD+
7ZQ3	;	1.5	;	Crystal structure of photosynthetic glyceraldehyde-3-phosphate dehydrogenase from Chlamydomonas reinhardtii (CrGAPA) complexed with NADP+
7ZQ4	;	1.7	;	Crystal structure of photosynthetic glyceraldehyde-3-phosphate dehydrogenase from Chlamydomonas reinhardtii (CrGAPA) complexed with NADP+ and the oxidated catalytic cysteine
1EYS	;	2.2	;	CRYSTAL STRUCTURE OF PHOTOSYNTHETIC REACTION CENTER FROM A THERMOPHILIC BACTERIUM, THERMOCHROMATIUM TEPIDUM
1JB0	;	2.5	;	Crystal Structure of Photosystem I: a Photosynthetic Reaction Center and Core Antenna System from Cyanobacteria
1IZL	;	3.7	;	Crystal Structure of Photosystem II
7YQ2	;	1.9	;	Crystal structure of photosystem II expressing psbA2 gene only
7YQ7	;	1.9	;	Crystal structure of photosystem II expressing psbA3 gene only
5ZZN	;	2.1	;	Crystal structure of photosystem II from an SQDG-deficient mutant of Thermosynechococcus elongatus
2AXT	;	3.0	;	Crystal Structure of Photosystem II from Thermosynechococcus elongatus
4Q25	;	2.28	;	Crystal structure of PhoU from Pseudomonas aeruginosa
4AZ9	;	1.75	;	Crystal structure of phox homology domain of human sorting nexin 24
6PVF	;	1.69	;	Crystal structure of PhqK in complex with malbrancheamide B
6PVJ	;	1.25	;	Crystal structure of PhqK in complex with malbrancheamide C
6PVH	;	1.89	;	Crystal structure of PhqK in complex with paraherquamide K
6PVI	;	2.093	;	Crystal structure of PhqK in complex with paraherquamide L
7FJL	;	2.11	;	Crystal Structure of phthalate dioxygenase from Comamonas testosteroni KF1
7V25	;	2.74	;	Crystal Structure of phthalate dioxygenase in complex with phthalate
7V28	;	3.07	;	Crystal Structure of phthalate dioxygenase in complex with terephthalate
4O4O	;	1.95	;	Crystal structure of phycobiliprotein lyase CpcT
4O4S	;	2.5	;	Crystal structure of phycobiliprotein lyase CpcT complexed with phycocyanobilin (PCB)
3PRU	;	2.677	;	Crystal Structure of Phycobilisome 32.1 kDa linker polypeptide, phycocyanin-associated, rod 1 (fragment 14-158) from Synechocystis sp. PCC 6803, Northeast Structural Genomics Consortium Target SgR182A
4YJJ	;	2.7	;	Crystal structure of Phycocyanin from marine cyanobacterium Phormidium rubidum sp. A09DM
6JPR	;	2.35	;	Crystal structure of Phycocyanin from Nostoc sp. R76DM
7D6W	;	2.15	;	Crystal structure of Phycocyanin from Synechococcus sp. R42DM
5B13	;	2.094	;	Crystal structure of phycoerythrin
1QGW	;	1.63	;	CRYSTAL STRUCTURE OF PHYCOERYTHRIN 545 FROM THE MARINE CRYPTOPHYTE RHODOMONAS CS24
7AP5	;	2.131	;	Crystal structure of phycoerythrin from cyanobacterium Nostoc sp. WR13 contains multiple stacks of hexameric assemblies which resemble the rods of phycobilisome.
7F86	;	2.21	;	Crystal structure of Phycoerythrin from Halomicronema Sp. R31DM
4U4Z	;	3.1	;	Crystal structure of Phyllanthoside bound to the yeast 80S ribosome
6JQA	;	2.402	;	Crystal structure of phyllogen, a phyllody inducing effector protein of phytoplasma.
2XPJ	;	3.4	;	Crystal structure of Physalis Mottle Virus with intact ordered RNA
6ATX	;	2.74034	;	Crystal structure of Physcomitrella patens KAI2-like C
6AZB	;	2.00004	;	Crystal structure of Physcomitrella patens KAI2-like E
6AZC	;	2.00001	;	Crystal structure of Physcomitrella patens KAI2-like E S166A
6AZD	;	1.97011	;	Crystal structure of Physcomitrella patens KAI2-like H
1QLG	;	2.2	;	Crystal structure of phytase with magnesium from Bacillus amyloliquefaciens
1DKQ	;	2.05	;	CRYSTAL STRUCTURE OF PHYTATE COMPLEX ESCHERICHIA COLI PHYTASE AT PH 5.0. PHYTATE IS BOUND WITH ITS 3-PHOSPHATE IN THE ACTIVE SITE. HG2+ CATION ACTS AS AN INTERMOLECULAR BRIDGE
1DKP	;	2.28	;	CRYSTAL STRUCTURE OF PHYTATE COMPLEX OF ESCHERICHIA COLI PHYTASE AT PH 6.6. PHYTATE IS BOUND WITH ITS 3-PHOSPHATE IN THE ACTIVE SITE. HG2+ CATION ACTS AS AN INTERMOLECULAR BRIDGE
6KME	;	1.95	;	Crystal structure of phytochromobilin synthase from tomato in complex with biliverdin
4DGK	;	2.35	;	Crystal structure of Phytoene desaturase CRTI from Pantoea ananatis
4Q0K	;	1.34	;	Crystal Structure of Phytohormone Binding Protein from Medicago truncatula in complex with gibberellic acid (GA3)
4PSB	;	1.42	;	Crystal Structure of Phytohormone Binding Protein from Vigna radiata in complex with gibberellic acid (GA3)
7VEK	;	2.6	;	Crystal structure of Phytolacca americana UGT3 with capsaicin and UDP-2fluoroglucose
7VEJ	;	1.85	;	Crystal structure of Phytolacca americana UGT3 with kaempferol and UDP-2fluoroglucose
7VEL	;	2.15	;	Crystal structure of Phytolacca americana UGT3 with UDP-2fluoroglucose
5GNC	;	2.8	;	Crystal structure of Phytophthora. sojae PSR2
3JUQ	;	1.75	;	Crystal Structure of PhzA/B from Burkholderia cepacia R18194 cocrystallized with 2 mM racemic 5-bromo-2-(piperidin-3-ylamino)benzoic acid
3EX9	;	2.2	;	Crystal structure of PhzA/B from Burkholderia cepacia R18194 crystallized in C2221
3DZL	;	1.75	;	Crystal structure of PhzA/B from Burkholderia cepacia R18194 in complex with (R)-3-oxocyclohexanecarboxylic acid
3JUO	;	2.2	;	Crystal Structure of PhzA/B from Burkholderia cepacia R18194 in complex with (R)-5-bromo-2-(piperidin-3-ylamino)benzoic acid
3JUP	;	1.9	;	Crystal Structure of PhzA/B from Burkholderia cepacia R18194 in complex with (S)-5-bromo-2-(piperidin-3-ylamino)benzoic acid
3JUM	;	1.45	;	Crystal Structure of PhzA/B from Burkholderia cepacia R18194 in complex with 5-bromo-2-((1S,3R)-3-carboxycyclohexylamino)benzoic acid
3JUN	;	1.8	;	Crystal Structure of PhzA/B from Burkholderia cepacia R18194 in simultaneous complex with racemic 5-bromo-2-(piperidin-3-ylamino)benzoic acid
1NF8	;	1.6	;	Crystal structure of PhzD protein active site mutant with substrate
1NF9	;	1.5	;	Crystal Structure of PhzD protein from Pseudomonas aeruginosa
1T6K	;	1.8	;	Crystal structure of phzF from Pseudomonas fluorescens 2-79
4HMW	;	1.53	;	Crystal structure of PhzG from Burkholderia lata 383
4HMX	;	1.59	;	Crystal structure of PhzG from Burkholderia lata 383 in complex with tetrahydrophenazine-1-carboxylic acid
4HMS	;	1.33	;	Crystal structure of PhzG from Pseudomonas fluorescens 2-79 in complex with a second FMN in the substrate binding site
4HMT	;	1.42	;	Crystal structure of PhzG from Pseudomonas fluorescens 2-79 in complex with hexahydrophenazine-1,6-dicarboxylic acid
4HMU	;	1.56	;	Crystal structure of PhzG from Pseudomonas fluorescens 2-79 in complex with tetrahydrophenazine-1-carboxylic acid after 1 day of soaking
4HMV	;	1.45	;	Crystal structure of PhzG from Pseudomonas fluorescens 2-79 in complex with tetrahydrophenazine-1-carboxylic acid after 5 days of soaking
1EOG	;	2.1	;	CRYSTAL STRUCTURE OF PI CLASS GLUTATHIONE TRANSFERASE
2NRA	;	3.1	;	Crystal structure of Pi initiator protein in complex with iteron DNA
1DFA	;	2.0	;	CRYSTAL STRUCTURE OF PI-SCEI IN C2 SPACE GROUP
1EF0	;	2.1	;	CRYSTAL STRUCTURE OF PI-SCEI MINIPRECURSOR
6WRP	;	2.08	;	Crystal Structure of PI3-E12 Fab, An Antibody Against Human Parainfluenza Virus Type III
6GVF	;	2.5	;	Crystal structure of PI3K alpha in complex with 3-(2-Amino-benzooxazol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine
6GVI	;	2.9	;	Crystal structure of PI3K alpha in complex with 3-(2-Amino-benzooxazol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine
6GVG	;	3.0	;	Crystal structure of PI3K alpha in complex with 3-(2-Amino-benzooxazol-5-yl)-1-isopropyl-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine
6GVH	;	2.74	;	Crystal structure of PI3K alpha in complex with 3-(2-Amino-benzooxazol-5-yl)-4-chloro-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine
5UBR	;	2.4	;	CRYSTAL STRUCTURE OF PI3K ALPHA IN COMPLEX WITH A 7-(3-(PIPERAZIN-1-YL)PHENYL)PYRROLO[2,1-F][1,2,4] TRIAZIN-4-AMINE DERIVIATINE
5ITD	;	3.02	;	Crystal structure of PI3K alpha with PI3K delta inhibitor
5XGH	;	2.97	;	Crystal structure of PI3K complex with an inhibitor
5XGI	;	2.56	;	Crystal structure of PI3K complex with an inhibitor
5XGJ	;	2.97	;	Crystal structure of PI3K complex with an inhibitor
5UBT	;	2.83	;	CRYSTAL STRUCTURE OF PI3K DELTA IN COMPLEX WITH A 7-(3-(PIPERAZIN-1-YL)PHENYL)PYRROLO[2,1-F][1,2,4] TRIAZIN-4-AMINE DERIVIATINE
5VLR	;	2.8	;	CRYSTAL STRUCTURE OF PI3K DELTA IN COMPLEX WITH A TRIFLUORO-ETHYL-PYRAZOL-PYROLOTRIAZINE INHIBITOR
3P2B	;	3.2	;	Crystal Structure of PI3K gamma with 3-(2-morpholino-6-(pyridin-3-ylamino)pyrimidin-4-yl)phenol
3SD5	;	3.2	;	Crystal Structure of PI3K gamma with 5-(2,4-dimorpholinopyrimidin-6-yl)-4-(trifluoromethyl)pyridin-2-amine
3TJP	;	2.7	;	Crystal Structure of PI3K gamma with N6-(3,4-dimethoxyphenyl)-2-morpholino-[4,5'-bipyrimidine]-2',6-diamine
3CSF	;	2.8	;	Crystal structure of PI3K p110gamma catalytical domain in complex with organoruthenium inhibitor DW2
3CST	;	3.2	;	Crystal structure of PI3K p110gamma catalytical domain in complex with organoruthenium inhibitor E5E2
3I5S	;	3.0	;	Crystal structure of PI3K SH3
8EXO	;	2.46	;	Crystal structure of PI3K-alpha in complex with compound 19
8EXU	;	2.68	;	Crystal structure of PI3K-alpha in complex with compound 30
8EXV	;	2.48	;	Crystal structure of PI3K-alpha in complex with compound 32
8EXL	;	1.989	;	Crystal structure of PI3K-alpha in complex with taselisib
6VO7	;	2.31	;	Crystal structure of PI3K-alpha Ras Binding Domain (RBD)
3S2A	;	2.55	;	Crystal structure of PI3K-gamma in complex with a quinoline inhibitor
3QJZ	;	2.9	;	Crystal structure of PI3K-gamma in complex with benzothiazole 1
3QK0	;	2.85	;	Crystal structure of PI3K-gamma in complex with benzothiazole 82
4FHK	;	3.0	;	Crystal Structure of PI3K-gamma in Complex with Imidazopyridazine 19e
4FHJ	;	2.6	;	Crystal Structure of PI3K-gamma in Complex with Imidazopyridine 2
4FJZ	;	3.0	;	Crystal structure of PI3K-gamma in complex with pyrrolo-pyridine inhibitor 63
4FJY	;	2.9	;	Crystal structure of PI3K-gamma in complex with quinoline-indoline inhibitor 24f
3QAQ	;	2.9	;	Crystal structure of PI3K-gamma in complex with triazine-benzimidazole 1
3QAR	;	2.65	;	Crystal structure of PI3K-gamma in complex with triazine-benzimidazole 32
7PG5	;	2.20029	;	Crystal Structure of PI3Kalpha
4OVV	;	3.5	;	Crystal Structure of PI3Kalpha in complex with diC4-PIP2
5SXA	;	3.35	;	Crystal Structure of PI3Kalpha in complex with fragment 10
5SXI	;	3.4	;	Crystal Structure of PI3Kalpha in complex with fragment 13
5SX9	;	3.52	;	Crystal Structure of PI3Kalpha in complex with fragment 14
5SXK	;	3.55	;	Crystal Structure of PI3Kalpha in complex with fragment 18
5SXD	;	3.5	;	Crystal Structure of PI3Kalpha in complex with fragment 22
5SXB	;	3.3	;	Crystal Structure of PI3Kalpha in complex with fragment 23
5SXJ	;	3.42	;	Crystal Structure of PI3Kalpha in complex with fragment 29
5SXC	;	3.55	;	Crystal Structure of PI3Kalpha in complex with fragment 8
5SXF	;	3.46	;	Crystal Structure of PI3Kalpha in complex with fragment 9
5SX8	;	3.47	;	Crystal Structure of PI3Kalpha in complex with fragments 12 and 15
5SWT	;	3.49	;	Crystal Structure of PI3Kalpha in complex with fragments 17 and 27
5SXE	;	3.51	;	Crystal Structure of PI3Kalpha in complex with fragments 19 and 28
5SWR	;	3.31	;	Crystal Structure of PI3Kalpha in complex with fragments 20 and 26
5SWO	;	3.5	;	Crystal Structure of PI3Kalpha in complex with fragments 4 and 19
5SWG	;	3.11	;	Crystal Structure of PI3Kalpha in complex with fragments 5 and 21
5SWP	;	3.41	;	Crystal Structure of PI3Kalpha in complex with fragments 6 and 24
5SW8	;	3.3	;	Crystal structure of PI3Kalpha in complex with fragments 7 and 11
7PG6	;	2.49944	;	Crystal Structure of PI3Kalpha in complex with the inhibitor NVP-BYL719
7K6O	;	2.738	;	Crystal structure of PI3Kalpha inhibitor 10-5429
7K71	;	2.9	;	Crystal structure of PI3Kalpha inhibitor 4-0686
7K6N	;	2.77	;	Crystal structure of PI3Kalpha selective Inhibitor 11-1575
7K6M	;	2.413	;	Crystal structure of PI3Kalpha selective Inhibitor PF-06843195
6T3C	;	2.62	;	Crystal structure of PI3Kgamma in complex with DNA-PK inhibitor AZD7648
7Z61	;	2.738	;	Crystal structure of PI3Kgamma with a dihydropurinone inhibitor (compound 18)
6T3B	;	3.01	;	Crystal structure of PI3Kgamma with a dihydropurinone inhibitor (compound 4)
7N6Z	;	2.2	;	Crystal Structure of PI5P4KIIAlpha
7N71	;	2.5	;	Crystal Structure of PI5P4KIIAlpha
7N7J	;	2.1	;	Crystal Structure of PI5P4KIIAlpha complex with AMPPNP
7N7K	;	2.0	;	Crystal Structure of PI5P4KIIAlpha complex with AMPPNP
7N7M	;	2.6	;	Crystal Structure of PI5P4KIIAlpha complex with BI-2536
7N7L	;	2.7	;	Crystal Structure of PI5P4KIIAlpha complex with BI-D1870
7N7O	;	2.7	;	Crystal Structure of PI5P4KIIAlpha complex with Palbociclib
7N7N	;	2.3	;	Crystal Structure of PI5P4KIIAlpha complex with Volasertib
7N80	;	2.5	;	Crystal Structure of PI5P4KIIBeta
7N81	;	2.7	;	Crystal Structure of PI5P4KIIBeta complex with CC260
1N9E	;	1.65	;	Crystal structure of Pichia pastoris Lysyl Oxidase PPLO
3OPY	;	3.05	;	Crystal structure of Pichia pastoris phosphofructokinase in the T-state
6AR4	;	1.69	;	Crystal structure of PICK1 in complex with the small molecule inhibitor 1o
6U0P	;	2.02	;	Crystal structure of PieE, the flavin-dependent monooxygenase involved in the biosynthesis of piericidin A1
8BNV	;	2.86	;	Crystal structure of Pif1 from Deferribacter desulfuricans in apo from
8BNX	;	3.12	;	Crystal structure of Pif1 from Deferribacter desulfuricans in complex with AMPPNP
8BNS	;	3.24	;	Crystal structure of Pif1 from Sulfurihydrogenibium sp in complex with ADP
5FTD	;	1.695	;	Crystal structure of Pif1 helicase from Bacteroides apo form
5FTF	;	2.412	;	Crystal structure of Pif1 helicase from Bacteroides double mutant L95C-I339C
5FTC	;	2.269	;	Crystal structure of Pif1 helicase from Bacteroides in complex with ADP
5FTE	;	3.19	;	Crystal structure of Pif1 helicase from Bacteroides in complex with ADP-AlF3 and ssDNA
5FTB	;	1.38	;	Crystal structure of Pif1 helicase from Bacteroides in complex with AMPPNP
7OTJ	;	2.58	;	Crystal structure of Pif1 helicase from Candida albicans
1IVI	;	8.0	;	Crystal Structure of pig dihydrolipoamide dehydrogenase
2FPI	;	2.7	;	Crystal structure of pig GTP-specific succinyl-CoA synthetase from polyethylene glycol
2FPP	;	2.35	;	Crystal structure of pig GTP-specific succinyl-CoA synthetase from polyethylene glycol with chloride ions
2FPG	;	2.96	;	Crystal structure of pig GTP-specific succinyl-CoA synthetase in complex with GDP
2FP4	;	2.08	;	Crystal structure of pig GTP-specific succinyl-CoA synthetase in complex with GTP
1KF0	;	2.5	;	Crystal Structure of Pig Muscle Phosphoglycerate Kinase Ternary Complex with AMP-PCP and 3PG
1GZD	;	2.5	;	Crystal structure of pig phosphoglucose isomerase
6BXZ	;	2.09	;	Crystal Structure of Pig Protocadherin-15 EC10-MAD12
7OV8	;	2.3	;	Crystal structure of pig purple acid phosphatase in complex with 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and glycerol
7OV2	;	2.1	;	Crystal structure of pig purple acid phosphatase in complex with L-glutamine, (poly)ethylene glycol fragments and glycerol
7OV3	;	2.0	;	Crystal structure of pig purple acid phosphatase in complex with Maybridge fragment CC063346, dimethyl sulfoxide and citrate
5YHW	;	2.7	;	Crystal structure of Pig SAMHD1
4PPM	;	2.3	;	Crystal structure of PigE: a transaminase involved in the biosynthesis of 2-methyl-3-n-amyl-pyrrole (MAP) from Serratia sp. FS14
6PTZ	;	1.793	;	Crystal structure of pigeon Cryptochrome 4 mutant Y319D in complex with flavin adenine dinucleotide
4G7E	;	2.2	;	Crystal structure of pigeon pea urease
5GXT	;	2.245	;	Crystal structure of PigG
5GXV	;	2.1	;	Crystal structure of PigG
7THN	;	1.6	;	Crystal structure of PigI trapped with PigG using a proline adenosine vinylsulfonamide inhibitor
1UL3	;	2.0	;	Crystal Structure of PII from Synechocystis sp. PCC 6803
4E4S	;	1.95	;	Crystal structure of Pika GITRL
5ZFR	;	3.1	;	Crystal structure of PilB, an extension ATPase motor of Type IV pilus, from Geobacter sulfurreducens
2FI7	;	2.2	;	Crystal Structure of PilF : Functional implication in the type 4 pilus biogenesis in Pseudomonas aeruginosa
5OIU	;	2.44	;	Crystal structure of PilF type IV pilus assembly ATPase from Thermus thermophilus
7CG9	;	2.05	;	Crystal structure of pilin-specific sortase SrtC1 from Lactobacillus rhamnosus GG
8GMX	;	2.61	;	Crystal structure of pilin-specific sortase SrtC2 from Lactobacillus rhamnosus GG
5ZFQ	;	2.6	;	Crystal structure of PilT-4, a retraction ATPase motor of Type IV pilus , from Geobacter sulfurreducens
6M3Y	;	1.93	;	Crystal structure of pilus adhesin, SpaC from Lactobacillus rhamnosus GG - open conformation
6M48	;	2.5	;	Crystal structure of pilus adhesin, SpaC from Lactobacillus rhamnosus GG - P21212 form
8GR6	;	2.06	;	Crystal Structure of pilus-specific Sortase C from Streptococcus sanguinis
8GUU	;	2.008	;	Crystal structure of pilus-specific sortase C mutant from Streptococcus sanguinis
2VQ2	;	1.54	;	Crystal structure of PilW, widely conserved type IV pilus biogenesis factor
3CNR	;	1.9	;	Crystal Structure of PilZ (XAC1133) from Xanthomonas axonopodis pv citri
4I86	;	2.098	;	Crystal structure of PilZ domain of CeSA from cellulose synthesizing bacterium
1YI3	;	2.5	;	Crystal Structure of Pim-1 bound to LY294002
1YHS	;	2.15	;	Crystal structure of Pim-1 bound to staurosporine
4LL5	;	2.0	;	Crystal Structure of Pim-1 in complex with the fluorescent compound SKF86002
4MTA	;	2.2	;	Crystal structure of Pim-1 kinase domain in complex with 2-methyl-5-phenylfuran-3-carboxylic acid
4ENY	;	2.801	;	Crystal Structure of Pim-1 kinase in complex with (2E,5Z)-2-(2-chlorophenylimino)-5-(4-hydroxy-3-methoxybenzylidene)thiazolidin-4-one
4ENX	;	2.8	;	Crystal Structure of Pim-1 Kinase in complex with inhibitor (2E,5Z)-2-(2-chlorophenylimino)-5-(4-hydroxy-3-nitrobenzylidene)thiazolidin-4-one
4LM5	;	2.25	;	Crystal structure of Pim1 in complex with 2-{4-[(3-aminopropyl)amino]quinazolin-2-yl}phenol (resulting from displacement of SKF86002)
4BZN	;	1.9	;	Crystal structure of PIM1 in complex with a Pyrrolo(1,2-a)Pyrazinone inhibitor
7ZUN	;	2.5	;	Crystal structure of PIM1 in complex with a Pyrrolo-Pyrazinone compound
4BZO	;	2.1	;	Crystal structure of PIM1 in complex with a Pyrrolo-Pyrazinone inhibitor
7OOV	;	1.96	;	Crystal structure of PIM1 in complex with ARC-1411
7OOW	;	1.95	;	Crystal structure of PIM1 in complex with ARC-1415
7OOX	;	1.97	;	Crystal structure of PIM1 in complex with ARC-3126
4LMU	;	2.38	;	Crystal structure of Pim1 in complex with the inhibitor Quercetin (resulting from displacement of SKF86002)
4JX3	;	2.5	;	Crystal structure of Pim1 kinase
3UMW	;	2.08	;	Crystal structure of Pim1 kinase in complex with inhibitor (Z)-2-[(1H-indazol-3-yl)methylene]-6-methoxy-7-(piperazin-1-ylmethyl)benzofuran-3(2H)-one
3UMX	;	2.55	;	Crystal structure of Pim1 kinase in complex with inhibitor (Z)-2-[(1H-indol-3-yl)methylene]-7-(azepan-1-ylmethyl)-6-hydroxybenzofuran-3(2H)-one
4JX7	;	2.4	;	Crystal structure of Pim1 kinase in complex with inhibitor 2-[(trans-4-aminocyclohexyl)amino]-4-{[3-(trifluoromethyl)phenyl]amino}pyrido[4,3-d]pyrimidin-5(6H)-one
3UIX	;	2.2	;	Crystal structure of Pim1 kinase in complex with small molecule inhibitor
5O11	;	2.4	;	Crystal structure of PIM1 kinase in complex with small-molecule inhibitor
5O12	;	2.4	;	Crystal structure of PIM1 kinase in complex with small-molecule inhibitor
5O13	;	2.44	;	Crystal structure of PIM1 kinase in complex with small-molecule inhibitor
4A7C	;	2.3	;	Crystal structure of PIM1 kinase with ETP46546
5KGI	;	2.13	;	Crystal structure of PIM1 with inhibitor 2-[3,4-bis(chloranyl)phenoxy]ethanamine
5KGG	;	1.95	;	Crystal structure of PIM1 with inhibitor: 2-(5-chloranyl-1~{H}-indol-3-yl)ethanamine
5KGD	;	1.98	;	Crystal structure of PIM1 with inhibitor: 2-pyridin-3-yl-1~{H}-benzimidazole
5KGK	;	2.66	;	Crystal structure of PIM1 with inhibitor: 3-(4-methoxyphenyl)-1~{H}-pyrazol-5-amine
5KGE	;	2.23	;	Crystal structure of PIM1 with inhibitor: 5-(3,4-dichlorophenyl)-1~{H}-pyrazol-3-amine
2O63	;	2.0	;	Crystal structure of Pim1 with Myricetin
2O65	;	2.85	;	Crystal structure of Pim1 with Pentahydroxyflavone
2O64	;	2.44	;	Crystal structure of Pim1 with Quercetagetin
2O3P	;	2.24	;	Crystal structure of Pim1 with Quercetin
4RWV	;	1.859	;	Crystal structure of PIP3 bound human nuclear receptor LRH-1 (Liver Receptor Homolog 1, NR5A2) in complex with a co-regulator DAX-1 (NR0B1) peptide at 1.86 A resolution
3WZZ	;	2.6	;	Crystal structure of PIP4KIIBETA
3X01	;	2.15	;	Crystal structure of PIP4KIIBETA complex with AMP
3X03	;	2.7	;	Crystal structure of PIP4KIIBETA complex with AMPPNP
3X02	;	2.45	;	Crystal structure of PIP4KIIBETA complex with GMP
3X04	;	2.6	;	Crystal structure of PIP4KIIBETA complex with GMPPNP
3X09	;	2.7	;	Crystal structure of PIP4KIIBETA F205L complex with AMP
3X0A	;	2.6	;	Crystal structure of PIP4KIIBETA F205L complex with GMP
3X0B	;	2.6	;	Crystal structure of PIP4KIIBETA I368A complex with AMP
3X0C	;	2.55	;	Crystal structure of PIP4KIIBETA I368A complex with GMP
3X07	;	2.6	;	Crystal structure of PIP4KIIBETA N203A complex with AMP
3X08	;	2.75	;	Crystal structure of PIP4KIIBETA N203A complex with GMP
3X05	;	2.5	;	Crystal structure of PIP4KIIBETA T201M complex with AMP
3X06	;	2.65	;	Crystal structure of PIP4KIIBETA T201M complex with GMP
6CQB	;	2.91	;	Crystal Structure of Piper methysticum Chalcone Synthase
6NBR	;	2.8	;	Crystal Structure of Piper methysticum Kavalactone Reductase 1 in complex with NADP
6OP5	;	2.7	;	Crystal Structure of Piper methysticum Styrylpyrone Synthase 1 in complex with p-coumaroyl-CoA
6KL8	;	1.94	;	Crystal structure of Piptidyl t-RNA hydrolase from Acinetobacter baumannii with bound NaCl at the substrate binding site
3X0T	;	1.17	;	Crystal structure of PirA
3CYL	;	1.87	;	Crystal structure of Piratoxin I (a myotoxic Lys49-PLA2) complexed with alpha-tocopherol
4YZ7	;	1.9589	;	Crystal structure of Piratoxin I (PrTX-I) complexed to aristolochic acid
4YU7	;	1.647	;	Crystal structure of Piratoxin I (PrTX-I) complexed to caffeic acid
3X0U	;	1.7	;	Crystal structure of PirB
7FDP	;	2.1	;	Crystal structure of PirB insecticidal protein from Photorhabdus akhurstii
4YZC	;	2.494	;	Crystal structure of pIRE1alpha in complex with staurosporine
7YNX	;	2.3	;	Crystal structure of Pirh2 bound to poly-Ala peptide
5KTJ	;	2.97	;	Crystal structure of Pistol, a class of self-cleaving ribozyme
5T7P	;	2.16	;	Crystal structure of Pisum arvense lectin (PAL) complexed with X-Man
7U1J	;	2.701	;	Crystal structure of Pisum sativum convicilin
7K2Z	;	1.61	;	Crystal structure of Pisum sativum KAI2 Apo form
7K38	;	2.0	;	Crystal structure of Pisum sativum KAI2 in complex with GR24-ent5DS product
7U1I	;	3.1	;	Crystal structure of Pisum sativum vicilin
7VCR	;	2.0	;	Crystal Structure of PitA fragment from pilus islet-2 of Streptococcus oralis
7VCN	;	2.343	;	Crystal Structure of PitA fragment from pilus islet-2 of Streptococcus oralis with Tb-Xo4
7W6B	;	2.984	;	Crystal Structure of PitA from pilus islet-2 of Streptococcus oralis
1Q2L	;	2.2	;	Crystal Structure of pitrilysin
3DA5	;	1.94	;	Crystal Structure of Piwi/Argonaute/Zwille(PAZ) domain from Thermococcus thioreducens
3QIR	;	2.45	;	Crystal structure of PIWIL2 PAZ domain
6F0Q	;	1.3	;	Crystal structure of Pizza6-AYW
7ZQG	;	1.8	;	Crystal structure of Pizza6-KSH-TSH with Silicotungstic Acid (STA) polyoxometalate
7ZQ2	;	1.6	;	Crystal structure of Pizza6-RSH-TSH with Silicotungstic Acid (STA) polyoxometalate
6REI	;	1.5	;	Crystal structure of Pizza6-S with Cd2+
6REH	;	1.73	;	Crystal structure of Pizza6-S with Cu2+
6REG	;	1.3	;	Crystal structure of Pizza6-S with Zn2+
6F0T	;	1.74	;	Crystal structure of Pizza6-SFW
6REL	;	1.08	;	Crystal structure of Pizza6-SH with CdCl2 nanocrystal
6REK	;	1.1	;	Crystal structure of Pizza6-SH with Cu2+
6REM	;	1.6	;	Crystal structure of Pizza6-SH with Sulphate ion
6REJ	;	1.65	;	Crystal structure of Pizza6-SH with Zn2+
6F0S	;	1.5	;	Crystal structure of Pizza6-SYW
7ZCJ	;	1.56	;	Crystal structure of Pizza6-TNH-TSH with Silicotungstic Acid (STA) polyoxometalate
7ZPH	;	1.66	;	Crystal structure of Pizza6-TNK-RSH with Silicotungstic Acid (STA) polyoxometalate
7ZPW	;	1.8	;	Crystal structure of Pizza6-TSK-TSH with Silicotungstic Acid (STA) polyoxometalate
7ZPZ	;	1.57	;	Crystal structure of Pizza6-TSR-TSH with Silicotungstic Acid (STA) polyoxometalate
6QSD	;	1.45	;	Crystal structure of Pizza6S
6QSE	;	1.9	;	Crystal structure of Pizza6S in the presence of Anderson-Evans (TEW)
6QSF	;	1.5	;	Crystal structure of Pizza6S in the presence of Keggin (STA)
5UZK	;	2.3	;	Crystal Structure of PKA bound to an pyrrolo pyridine inhibitor
4YXR	;	2.0	;	CRYSTAL STRUCTURE OF PKA IN COMPLEX WITH inhibitor.
3IM3	;	2.0	;	Crystal structure of PKA RI alpha dimerization/docking domain
4MX3	;	3.88	;	Crystal Structure of PKA RIalpha Homodimer
3PLQ	;	2.3	;	Crystal structure of PKA type I regulatory subunit bound with Rp-8-Br-cAMPS
3L9L	;	2.0	;	Crystal structure of pka with compound 36
3L9M	;	1.9	;	Crystal structure of PKAB3 (pka triple mutant V123A, L173M, Q181K) with compound 18
3L9N	;	2.0	;	crystal structure of PKAB3 (pka triple mutant V123A, L173M, Q181K) with compound 27
7E12	;	2.796	;	Crystal structure of PKAc-A11E complex
7E0Z	;	2.162	;	Crystal structure of PKAc-PLN complex
7E11	;	3.43	;	Crystal structure of PKAc-PLN R9C complex
3IW4	;	2.8	;	Crystal structure of PKC alpha in complex with NVP-AEB071
5LPX	;	1.9	;	Crystal structure of PKC phosphorylation-mimicking mutant (S26E) Annexin A2
1XJD	;	2.0	;	Crystal Structure of PKC-theta complexed with Staurosporine at 2A resolution
6ILZ	;	3.261	;	Crystal structure of PKCiota in complex with inhibitor
3A8W	;	2.1	;	Crystal Structure of PKCiota kinase domain
3A8X	;	2.0	;	Crystal Structure of PKCiota kinase domain
4NNX	;	2.104	;	Crystal structure of PKD2 phosphopeptide bound to HLA-A2
3BGM	;	1.6	;	Crystal Structure of PKD2 Phosphopeptide Bound to Human Class I MHC HLA-A2
5DH9	;	2.55	;	Crystal Structure of PKI NES Flip Mutant Peptide in complex with CRM1-Ran-RanBP1
6X2V	;	2.822	;	Crystal Structure of PKI(DE)NES peptide bound to CRM1
6X2U	;	2.2	;	Crystal Structure of PKINES peptide bound to CRM1
6X2W	;	3.001	;	Crystal Structure of PKINES peptide bound to CRM1(E571K)
4YJ5	;	2.41	;	Crystal structure of PKM2 mutant
8HMS	;	2.1	;	Crystal Structure of PKM2 mutant C474S
8HMR	;	2.6	;	Crystal Structure of PKM2 mutant L144P
8HMQ	;	2.5	;	Crystal Structure of PKM2 mutant P403A
8HMU	;	2.5	;	Crystal Structure of PKM2 mutant R516C
5X0I	;	2.64	;	Crystal structure of PKM2 R399E mutant complexed with FBP and serine
4QG8	;	2.3	;	crystal structure of PKM2-K305Q mutant
4QGC	;	2.296	;	crystal structure of PKM2-K422R mutant
4RPP	;	2.585	;	crystal structure of PKM2-K422R mutant bound with FBP
4QG9	;	2.381	;	crystal structure of PKM2-R399E mutant
4QG6	;	3.207	;	crystal structure of PKM2-Y105E mutant
4B0N	;	2.85	;	Crystal structure of PKS-I from the brown algae Ectocarpus siliculosus
7WRP	;	1.794	;	Crystal Structure of pks13-ACP domain from Corynebacterium diphtheriae
8AW0	;	2.2	;	Crystal structure of PksD, the trans-acting acyl hydrolase domain from the bacillaene trans-AT PKS (native)
8AVZ	;	1.96	;	Crystal structure of PksD, the trans-acting acyl hydrolase domain from the bacillaene trans-AT PKS (SeMet derivative)
4LB5	;	2.0	;	Crystal structure of PKZ Zalpha in complex with ds(CG)6 (hexagonal form)
4LB6	;	1.8	;	Crystal structure of PKZ Zalpha in complex with ds(CG)6 (tetragonal form)
7WXJ	;	2.1	;	Crystal Structure of PL-5 family polysaccharide lyase PanPL from Pandoraea apista at pH3.5 in apo form
7WXK	;	1.68	;	Crystal Structure of PL-5 family polysaccharide lyase PanPL from Pandoraea apista at pH4.5 in apo form
7WXL	;	1.45	;	Crystal Structure of PL-5 family polysaccharide lyase PanPL from Pandoraea apista at pH5.5 in apo form
7WXM	;	1.23	;	Crystal Structure of PL-5 family polysaccharide lyase PanPL from Pandoraea apista at pH6.5 in apo form
7WXN	;	2.4	;	Crystal Structure of PL-5 family polysaccharide lyase PanPL from Pandoraea apista at pH7.5 in apo form
7WXO	;	1.96	;	Crystal Structure of PL-5 family polysaccharide lyase PanPL from Pandoraea apista at pH8.5 in apo form
7WXQ	;	2.03	;	Crystal Structure of PL-5 family polysaccharide lyase PanPL-H172A mutant from Pandoraea apista in apo form
7WXP	;	2.2	;	Crystal Structure of PL-5 family polysaccharide lyase PanPL-H172A mutant from Pandoraea apista in ManA bound form
7WXR	;	1.88	;	Crystal Structure of PL-5 family polysaccharide lyase PanPL-N171L mutant from Pandoraea apista in apo form
7XTE	;	2.3	;	Crystal Structure of PL-5 family polysaccharide lyase PanPL-N171L mutant from Pandoraea apista in apo form at pH3.5
7XTF	;	1.73	;	Crystal Structure of PL-5 family polysaccharide lyase PanPL-Y226F mutant from Pandoraea apista in apo form at pH5.5
7M6C	;	1.95	;	Crystal structure of PLA2 from snake venom of peruvian Bothrops atrox
7ZOT	;	1.735	;	crystal structure of PLAAT4 N-terminal domain
2BEX	;	1.99	;	Crystal structure of Placental Ribonuclease Inhibitor in complex with Human Eosinophil Derived Neurotoxin at 2A resolution
7EU4	;	3.2	;	Crystal structure of plant ATG12 complexed with the AIM12 of ATG3
2XQR	;	2.58	;	Crystal structure of plant cell wall invertase in complex with a specific protein inhibitor
2PRE	;	2.7	;	Crystal structure of plant cysteine protease Ervatamin-C complexed with irreversible inhibitor E-64 at 2.7 A resolution
3A68	;	1.8	;	Crystal structure of plant ferritin reveals a novel metal binding site that functions as a transit site for metal transfer in ferritin
2GWC	;	2.18	;	Crystal structure of plant glutamate cysteine ligase in complex with a transition state analogue
2GWD	;	2.09	;	Crystal structure of plant glutamate cysteine ligase in complex with Mg2+ and L-glutamate
6A5D	;	1.401	;	Crystal structure of plant Glycosylphosphatidylinositol-anchored Protein LLG1
3WCS	;	1.75	;	Crystal structure of plant lectin (ligand-bound form)
3WCR	;	2.45	;	Crystal structure of plant lectin (ligand-free form)
4OEI	;	2.6	;	Crystal structure of plant lectin from Cicer arietinum at 2.6 angstrom resolution
4LL2	;	2.6	;	Crystal structure of plant lectin with two metal binding sites from cicer arietinum at 2.6 angstrom resolution
6A5E	;	2.766	;	Crystal structure of plant peptide RALF23 in complex with FER and LLG2
6KZ9	;	1.801	;	Crystal structure of plant Phospholipase D alpha
6KZ8	;	2.291	;	Crystal structure of plant Phospholipase D alpha complex with phosphatidic acid
1QZV	;	4.44	;	Crystal structure of plant photosystem I
4RKU	;	3.0	;	Crystal structure of plant Photosystem I at 3 Angstrom resolution
4XK8	;	2.8	;	Crystal structure of plant photosystem I-LHCI super-complex at 2.8 angstrom resolution
4FLN	;	2.8	;	Crystal structure of plant protease Deg2
5XKJ	;	3.475	;	Crystal structure of plant receptor ERL1-TMM in complexe with EPF2
5XKN	;	3.651	;	Crystal structure of plant receptor ERL2 in complexe with EPFL4
7DRB	;	3.3	;	Crystal structure of plant receptor like protein RXEG1 with xyloglucanase XEG1
6A5A	;	2.942	;	Crystal structure of plant Receptor-like Kinase ANX1
6A5C	;	1.68	;	Crystal structure of plant Receptor-like Kinase ANX2
6A5B	;	2.205	;	Crystal structure of plant Receptor-like Kinase FER
7BZB	;	2.148	;	Crystal structure of plant sesterterpene synthase AtTPS18
7BZC	;	2.303	;	Crystal structure of plant sesterterpene synthase AtTPS18 complexed with farnesyl thiolodiphosphate (FSPP)
3M71	;	1.2	;	Crystal Structure of Plant SLAC1 homolog TehA
3M72	;	1.7	;	Crystal Structure of Plant SLAC1 homolog TehA
3M73	;	1.15	;	Crystal Structure of Plant SLAC1 homolog TehA
3M74	;	1.65	;	Crystal Structure of Plant SLAC1 homolog TehA
3M75	;	1.6	;	Crystal Structure of Plant SLAC1 homolog TehA
3M76	;	1.5	;	Crystal Structure of Plant SLAC1 homolog TehA
3M77	;	1.5	;	Crystal Structure of Plant SLAC1 homolog TehA
3M78	;	2.6	;	Crystal Structure of Plant SLAC1 homolog TehA
3M7B	;	1.5	;	Crystal Structure of Plant SLAC1 homolog TehA
3M7C	;	1.7	;	Crystal Structure of Plant SLAC1 homolog TehA
3M7E	;	1.8	;	Crystal Structure of Plant SLAC1 homolog TehA
3M7L	;	1.5	;	Crystal Structure of Plant SLAC1 homolog TehA
6DD7	;	2.0	;	Crystal structure of plant UVB photoreceptor UVR8 from in situ serial Laue diffraction
4FYP	;	1.8	;	Crystal Structure of Plant Vegetative Storage Protein
6WI6	;	1.8	;	Crystal structure of plantacyclin B21AG
5Z0B	;	2.17	;	Crystal structure of plasma-derived human serum albumin
1LEE	;	1.9	;	CRYSTAL STRUCTURE OF PLASMEPSIN FROM P. FALCIPARUM IN COMPLEX WITH INHIBITOR RS367
3QRV	;	2.4	;	Crystal structure of plasmepsin I (PMI) from Plasmodium falciparum
1LF3	;	2.7	;	CRYSTAL STRUCTURE OF PLASMEPSIN II FROM P FALCIPARUM IN COMPLEX WITH INHIBITOR EH58
1LF2	;	1.8	;	CRYSTAL STRUCTURE OF PLASMEPSIN II FROM P FALCIPARUM IN COMPLEX WITH INHIBITOR RS370
1ME6	;	2.7	;	CRYSTAL STRUCTURE OF PLASMEPSIN II, AN ASPARTYL PROTEASE FROM PLASMODIUM FALCIPARUM, IN COMPLEX WITH A STATINE-BASED INHIBITOR
5I70	;	3.0	;	Crystal Structure of plasmepsin IV
1LS5	;	2.8	;	Crystal structure of plasmepsin IV from P. falciparum in complex with pepstatin A
7TBB	;	1.85	;	Crystal structure of Plasmepsin X from Plasmodium falciparum
7TBC	;	2.76	;	Crystal structure of Plasmepsin X from Plasmodium falciparum in complex with WM382
7TBD	;	2.22	;	Crystal structure of Plasmepsin X from Plasmodium vivax in complex with WM382
7TBE	;	3.35	;	Crystal structure of Plasmepsin X from Plasmodium vivax in complex with WM4
2RH3	;	1.7	;	Crystal structure of plasmid pTiC58 VirC2
1ZC2	;	2.09	;	Crystal Structure of plasmid-encoded class C beta-lactamase CMY-2 complexed with citrate molecule
3Q02	;	2.3	;	Crystal structure of plasminogen activator inhibitor-1 in a metastable active conformation.
3Q03	;	2.6401	;	Crystal structure of plasminogen activator inhibitor-1 in a metastable active conformation.
4ADT	;	2.42	;	Crystal structure of plasmodial PLP synthase
4ADS	;	3.61	;	Crystal structure of plasmodial PLP synthase complex
4ADU	;	2.44	;	Crystal structure of plasmodial PLP synthase with bound R5P intermediate
2XFA	;	2.1	;	Crystal structure of Plasmodium berghei actin depolymerization factor 2
4CBW	;	2.501	;	Crystal structure of Plasmodium berghei actin I with D-loop from muscle actin
4CBX	;	2.2	;	Crystal structure of Plasmodium berghei actin II
6I4M	;	1.873	;	Crystal Structure of Plasmodium berghei actin II in the Mg-ADP state
3F4B	;	2.49	;	Crystal structure of Plasmodium berghei Enoyl-acyl-carrier-protein reductase with TRICLOSAN
2FDS	;	1.72	;	Crystal Structure of Plasmodium Berghei Orotidine 5'-monophosphate Decarboxylase (ortholog of Plasmodium falciparum PF10_0225)
4GAE	;	2.3	;	Crystal structure of plasmodium dxr in complex with a pyridine-containing inhibitor
3OZA	;	3.0	;	Crystal Structure of Plasmodium falciparum 3-Phosphoglycerate Kinase
2XF1	;	1.96	;	Crystal structure of Plasmodium falciparum actin depolymerization factor 1
4CBU	;	1.3	;	Crystal structure of Plasmodium falciparum actin I
6I4F	;	1.5	;	Crystal Structure of Plasmodium falciparum actin I (A272W mutant) in the Mg-K-ATP/ADP state
6I4H	;	1.4	;	Crystal Structure of Plasmodium falciparum actin I (F54Y mutant) in the Ca-ATP state
6I4J	;	1.5	;	Crystal Structure of Plasmodium falciparum actin I (F54Y mutant) in the Mg-ADP state
6I4I	;	1.9	;	Crystal Structure of Plasmodium falciparum actin I (F54Y mutant) in the Mg-K-ADP-AlFn state
6I4K	;	1.83	;	Crystal Structure of Plasmodium falciparum actin I (G115A mutant) in the Ca-ATP state
6I4L	;	1.83	;	Crystal Structure of Plasmodium falciparum actin I (G115A mutant) in the Mg-K-ATP/ADP state
6I4G	;	2.0	;	Crystal Structure of Plasmodium falciparum actin I (H74Q) in the Mg-K-ATP state
6I4E	;	1.22	;	Crystal Structure of Plasmodium falciparum actin I in the Mg-ADP state
6I4D	;	1.24	;	Crystal Structure of Plasmodium falciparum actin I in the Mg-K-ATP/ADP state
5MVV	;	1.4	;	Crystal structure of Plasmodium falciparum actin I- gelsolin segment 1 -CdATP complex
6II7	;	2.48	;	Crystal structure of Plasmodium falciparum adenosine deaminase C27Q+L227I mutant co-complexed with Zn ion, hypoxanthine and inosine
3LRP	;	2.5	;	Crystal Structure of Plasmodium falciparum ADP-Ribosylation Factor 1
3SRI	;	1.6	;	Crystal structure of Plasmodium falciparum AMA1 in complex with a 29aa PfRON2 peptide
5NQF	;	1.9	;	Crystal structure of Plasmodium falciparum AMA1 in complex with a 39 aa PvRON2 peptide
3ZWZ	;	2.1	;	Crystal structure of Plasmodium falciparum AMA1 in complex with a 39aa PfRON2 peptide
5Y19	;	1.83	;	Crystal structure of Plasmodium falciparum aminopeptidase N in complex with (S)-2-((2S,3R)-3-amino-2-hydroxy-4-phenylbutanamido)- N-hydroxy-4-methylpentanamide.
5XM7	;	1.96	;	Crystal structure of Plasmodium falciparum aminopeptidase N in complex with (S)-2-((2S,3R)-3-amino-2-hydroxy-4-phenylbutanamido)-N-hydroxy-4-methylpentanamide
5Y1T	;	2.14	;	Crystal structure of Plasmodium falciparum aminopeptidase N in complex with (S)-2-(3-(2,3-dimethylbenzyl)ureido)-N-hydroxy-4-methylpentanamide
5Y1H	;	1.73	;	Crystal structure of Plasmodium falciparum aminopeptidase N in complex with (S)-2-(3-(2,4-difluorobenzyl)ureido)-N-hydroxy-4-methylpentanamide
5Y1V	;	1.62	;	Crystal structure of Plasmodium falciparum aminopeptidase N in complex with (S)-2-(3-(2,6-diethylphenyl)ureido)- N-hydroxy-4-methylpentanamide
5Y1K	;	1.81	;	Crystal structure of Plasmodium falciparum aminopeptidase N in complex with (S)-2-(3-(2-chlorobenzyl)ureido)-N-hydroxy-4-methylpentanamide
5Y1S	;	1.66	;	Crystal structure of Plasmodium falciparum aminopeptidase N in complex with (S)-2-(3-(3,4-dimethylbenzyl)ureido)-N-hydroxy-4-methylpentanamide
5Y1Q	;	2.14	;	Crystal structure of Plasmodium falciparum aminopeptidase N in complex with (S)-2-(3-(3-chlorobenzyl)ureido)-N-hydroxy-4-methylpentanamide
5Y1R	;	1.69	;	Crystal structure of Plasmodium falciparum aminopeptidase N in complex with (S)-N-hydroxy-4-methyl-2-(3-( o-tolyl)ureido)pentanamide
5Y3I	;	1.73	;	Crystal structure of Plasmodium falciparum aminopeptidase N in complex with (S)-N-hydroxy-4-methyl-2-(3-(3-methylbenzyl)ureido)pentanamide
5Y1X	;	1.55	;	Crystal structure of Plasmodium falciparum aminopeptidase N in complex with actinonin
5Y1W	;	1.56	;	Crystal structure of Plasmodium falciparum aminopeptidase N with Magnesium bound to active site Zinc
1XIY	;	1.8	;	Crystal Structure of Plasmodium falciparum antioxidant protein (1-Cys peroxiredoxin)
8AHT	;	2.2	;	Crystal structure of Plasmodium falciparum Ca2+/Calmodulin in complex with melittin
4MVF	;	2.0	;	Crystal Structure of Plasmodium falciparum CDPK2 complexed with inhibitor staurosporine
5CS2	;	1.65	;	Crystal structure of Plasmodium falciparum diadenosine triphosphate hydrolase in complex with Cyclomarin A
4RX0	;	2.25	;	Crystal structure of Plasmodium falciparum dihydroorotate dehydrogenase bound with Inhibitor DSM265
5BOO	;	2.8	;	Crystal structure of Plasmodium falciparum dihydroorotate dehydrogenase bound with Inhibitor DSM265
3SFK	;	2.95	;	Crystal structure of Plasmodium falciparum dihydroorotate dehydrogenase bound with Inhibitor DSM267
4ORM	;	2.07	;	Crystal structure of Plasmodium falciparum dihydroorotate dehydrogenase bound with Inhibitor DSM338 (N-[3,5-difluoro-4-(trifluoromethyl)phenyl]-5-methyl-2-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine)
5TBO	;	2.151	;	Crystal structure of Plasmodium falciparum dihydroorotate dehydrogenase bound with Inhibitor DSM421
6VTY	;	1.78	;	Crystal structure of Plasmodium falciparum dihydroorotate dehydrogenase bound with Inhibitor DSM483
6VTN	;	2.25	;	Crystal structure of Plasmodium falciparum dihydroorotate dehydrogenase bound with Inhibitor DSM557
7KYK	;	2.15	;	Crystal structure of Plasmodium falciparum dihydroorotate dehydrogenase bound with Inhibitor DSM589 (ethyl 3-methyl-4-((4-(trifluoromethyl)benzo[d]oxazol-7-yl)methyl)-1H-pyrrole-2-carboxylate)
5DEL	;	2.2	;	Crystal structure of Plasmodium falciparum dihydroorotate dehydrogenase bound with Inhibitor DSM59
7KYV	;	2.4	;	Crystal structure of Plasmodium falciparum dihydroorotate dehydrogenase bound with Inhibitor DSM634 (3-methyl-N-(1-(5-methylisoxazol-3-yl)ethyl)-4-(4-(trifluoromethyl)benzyl)-1H-pyrrole-2-carboxamide)
7KYY	;	2.0	;	Crystal structure of Plasmodium falciparum dihydroorotate dehydrogenase bound with Inhibitor DSM697 (3-methyl-N-(1-(5-methylisoxazol-3-yl)ethyl)-4-(6-(trifluoromethyl)-1H-indol-3-yl)-1H-pyrrole-2-carboxamide)
7KZ4	;	1.75	;	Crystal structure of Plasmodium falciparum dihydroorotate dehydrogenase bound with Inhibitor DSM705 (N-(1-(1H-1,2,4-triazol-3-yl)ethyl)-3-methyl-4-(1-(6-(trifluoromethyl)pyridin-3-yl)cyclopropyl)-1H-pyrrole-2-carboxamide)
7KZY	;	1.75	;	Crystal structure of Plasmodium falciparum dihydroorotate dehydrogenase bound with Inhibitor DSM778 (3-methyl-N-(1-(5-methyl-1H-pyrazol-3-yl)ethyl)-4-(1-(6-(trifluoromethyl)pyridin-3-yl)cyclopropyl)-1H-pyrrole-2-carboxamide)
7L01	;	1.6	;	Crystal structure of Plasmodium falciparum dihydroorotate dehydrogenase bound with Inhibitor DSM782 (N-(1-(5-cyano-1H-pyrazol-3-yl)ethyl)-3-methyl-4-(1-(6-(trifluoromethyl)pyridin-3-yl)cyclopropyl)-1H-pyrrole-2-carboxamide)
7L0K	;	1.96	;	Crystal structure of Plasmodium falciparum dihydroorotate dehydrogenase bound with Inhibitor DSM784 (3-(1-(3-methyl-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1H-pyrrole-2-carboxamido)ethyl)-1H-pyrazole-5-carboxamide)
3O8A	;	2.3	;	Crystal structure of Plasmodium falciparum dihydroorotate dehydrogenase bound with novel Inhibitor Genz667348
5FI8	;	2.32	;	Crystal structure of plasmodium falciparum dihydroorotate dehydrogenase bounded with DSM422 (Tetrahydro-2-naphthyl and 2-indanyl triazolopyrimidine)
2OL4	;	2.26	;	Crystal structure of plasmodium falciparum enoyl ACP reductase with triclosan reductase
2OOS	;	2.1	;	Crystal structure of plasmodium falciparum enoyl ACP reductase with triclosan reductase
2OP0	;	2.8	;	Crystal structure of plasmodium falciparum enoyl ACP reductase with triclosan reductase
2OP1	;	2.6	;	Crystal structure of plasmodium falciparum enoyl ACP reductase with triclosan reductase
4GF2	;	2.4	;	Crystal structure of Plasmodium falciparum Erythrocyte Binding Antigen 140 (PfEBA-140/BAEBL)
4JNO	;	3.0	;	Crystal structure of Plasmodium falciparum Erythrocyte Binding Antigen 140 (PfEBA-140/BAEBL) Region II in complex with sialyllactose
4IGF	;	2.3	;	Crystal structure of Plasmodium falciparum FabI complexed with NAD and inhibitor 3-(4-Chloro-2-hydroxyphenoxy)-7-hydroxy-2H-chromen-2-one
4IGE	;	2.15	;	Crystal structure of Plasmodium falciparum FabI complexed with NAD and inhibitor 7-(4-Chloro-2-hydroxyphenoxy)-4-methyl-2H-chromen-2-one
1Z6B	;	2.09	;	Crystal structure of Plasmodium falciparum FabZ at 2.1 A
3PR3	;	2.45	;	Crystal structure of Plasmodium falciparum glucose-6-phosphate isomerase (PF14_0341) in complex with fructose-6-phosphate
1ONF	;	2.6	;	Crystal structure of Plasmodium falciparum Glutathione reductase
2W41	;	2.41	;	Crystal structure of Plasmodium falciparum glycerol kinase with ADP
2W40	;	1.49	;	Crystal structure of Plasmodium falciparum glycerol kinase with bound glycerol
8D1W	;	2.1	;	Crystal structure of Plasmodium falciparum GRP78 in complex with (2R,3R,4S,5R)-2-(6-amino-8-((2-chlorobenzyl)amino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
8D20	;	1.95	;	Crystal structure of Plasmodium falciparum GRP78 in complex with 5'-Methylthioadenosine
8D1S	;	2.25	;	Crystal structure of Plasmodium falciparum GRP78 in complex with Toyocamycin
8D1Y	;	1.9	;	Crystal structure of Plasmodium falciparum GRP78 in complex with Trans-Zeatin Riboside
8D1P	;	1.88	;	Crystal structure of Plasmodium falciparum GRP78-NBD in complex with 7-Deaza-2'-C-methyladenosine
8D1Q	;	2.15	;	Crystal structure of Plasmodium falciparum GRP78-NBD in complex with 8-Aminoadenosine
8D22	;	2.0	;	Crystal structure of Plasmodium falciparum GRP78-NBD in complex with Piclidenoson
8D24	;	1.75	;	Crystal structure of Plasmodium falciparum GRP78-NBD in complex with VER155008
6M2L	;	3.7	;	Crystal structure of Plasmodium falciparum hexose transporter PfHT1 bound with C3361
6M20	;	2.6	;	Crystal structure of Plasmodium falciparum hexose transporter PfHT1 bound with glucose
6KUB	;	2.0	;	Crystal structure of Plasmodium falciparum histo-aspartic protease (HAP) zymogen (Form 1)
6KUC	;	2.5	;	Crystal structure of Plasmodium falciparum histo-aspartic protease (HAP) zymogen (Form 2)
6KUD	;	2.9	;	Crystal structure of Plasmodium falciparum histo-aspartic protease (HAP) zymogen (Form 3)
6JWS	;	2.3	;	Crystal structure of Plasmodium falciparum HPPK-DHPS A437G with Pteroate
6JWY	;	2.5	;	Crystal structure of Plasmodium falciparum HPPK-DHPS A437G with SDX-DHP
6JWV	;	2.7	;	Crystal structure of Plasmodium falciparum HPPK-DHPS A437G with STZ-DHP
6KCL	;	2.7	;	Crystal structure of Plasmodium falciparum HPPK-DHPS A437G/K540E with pterin and p-hydroxybenzoate
6JWZ	;	2.95	;	Crystal structure of Plasmodium falciparum HPPK-DHPS S436F/A437G/A613S triple mutant with SDX-DHP
6KCM	;	2.3	;	Crystal structure of Plasmodium falciparum HPPK-DHPS S436F/A437G/A613S with pterin and p-hydrobenzoate
6JWT	;	2.56	;	Crystal structure of Plasmodium falciparum HPPK-DHPS S436F/A437G/A613T triple mutant with Pteroate
6JWW	;	2.75	;	Crystal structure of Plasmodium falciparum HPPK-DHPS S436F/A437G/A613T triple mutant with STZ-DHP
6JWQ	;	2.5	;	Crystal structure of Plasmodium falciparum HPPK-DHPS wild type
6KCK	;	2.5	;	Crystal structure of Plasmodium falciparum HPPK-DHPS wild type with pterin and p-hydroxybenzoate
6JWR	;	2.6	;	Crystal structure of Plasmodium falciparum HPPK-DHPS wild type with Pteroate
6JWX	;	2.5	;	Crystal structure of Plasmodium falciparum HPPK-DHPS wild type with SDX-DHP
6JWU	;	2.65	;	Crystal structure of Plasmodium falciparum HPPK-DHPS wild type with STZ-DHP
3OZF	;	1.944	;	Crystal Structure of Plasmodium falciparum Hypoxanthine-Guanine-Xanthine Phosphoribosyltransferase in complex with hypoxanthine
3OZG	;	1.993	;	Crystal Structure of Plasmodium falciparum Hypoxanthine-Guanine-Xanthine Phosphoribosyltransferase in complex with S-SerMe-ImmH phosphonate
7TUX	;	1.62	;	Crystal Structure of Plasmodium falciparum Hypoxanthine-Guanine-Xanthine Phosphoribosyltransferase in complex with [(3S)-4-Hydroxy-3-[({2-amino-4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl}methyl)amino]butyl]phosphonic acid
4PLZ	;	1.05	;	Crystal structure of Plasmodium falciparum lactate dehydrogenase mutant W107fA.
4P7M	;	3.02	;	Crystal structure of Plasmodium falciparum MIF in complex with 3-[(2-methyl-6-phenylpyridin-4-yl)oxy]phenol
6T4D	;	2.14	;	Crystal structure of Plasmodium falciparum Morn1
8E1Z	;	2.3	;	Crystal structure of Plasmodium falciparum ookinete surface antigen Pfs28
4FYM	;	2.6	;	Crystal structure of Plasmodium falciparum orotate phosphoribosyltransferase
3N2M	;	1.8	;	Crystal structure of Plasmodium falciparum orotidine 5'-monophosphate decarboxylase complexed with 5-fluoro-6-amino-UMP
3N34	;	1.55	;	Crystal structure of Plasmodium falciparum orotidine 5'-monophosphate decarboxylase complexed with 5-fluoro-6-amino-UMP, produced from 5-fluoro-6-azido-UMP
3N3M	;	1.47	;	Crystal structure of Plasmodium falciparum orotidine 5'-monophosphate decarboxylase complexed with 6-amino-UMP
3MWA	;	1.75	;	Crystal structure of Plasmodium falciparum orotidine 5'-monophosphate decarboxylase covalently modified by 2-prime-fluoro-6-iodo-UMP
2Q8Z	;	1.8	;	Crystal structure of Plasmodium falciparum orotidine 5'-phosphate decarboxylase complexed with 6-amino-UMP
3BAR	;	1.9	;	Crystal structure of Plasmodium falciparum orotidine 5'-phosphate decarboxylase covalently modified by 6-azido-UMP
2QAF	;	1.95	;	Crystal structure of Plasmodium falciparum orotidine 5'-phosphate decarboxylase covalently modified by 6-iodo-UMP
4B1B	;	2.9	;	Crystal structure of Plasmodium falciparum oxidised Thioredoxin Reductase at 2.9 angstrom
4N10	;	1.87	;	Crystal structure of plasmodium falciparum oxidized glutaredoxin 1 (PfGrx1) complexed with cisplatin
6SU9	;	2.15	;	Crystal structure of Plasmodium falciparum PdxK with ligands AMP-PNP and PL
5JKQ	;	2.35	;	Crystal structure of Plasmodium falciparum Pf3D7_0606800 (PfVFT1)
1Q1G	;	2.02	;	Crystal structure of Plasmodium falciparum PNP with 5'-methylthio-immucillin-H
6AQS	;	1.57	;	Crystal structure of Plasmodium falciparum purine nucleoside phosphorylase (V181D) mutant complexed with DADMe-ImmG and phosphate
3PHC	;	2.0	;	Crystal Structure of Plasmodium falciparum purine nucleoside phosphorylase in complex with DADMe-ImmG
1NW4	;	2.2	;	Crystal Structure of Plasmodium falciparum Purine Nucleoside Phosphorylase in complex with ImmH and Sulfate
6AQU	;	2.6	;	Crystal Structure of Plasmodium falciparum purine nucleoside phosphorylase: The M183L mutant
4RZ0	;	2.487	;	Crystal Structure of Plasmodium falciparum putative histone methyltransferase PFL0690c
2RCY	;	2.3	;	Crystal structure of Plasmodium falciparum pyrroline carboxylate reductase (MAL13P1.284) with NADP bound
3BFK	;	1.8	;	Crystal structure of Plasmodium falciparum Rab11a in complex with GDP
1D5C	;	2.3	;	CRYSTAL STRUCTURE OF PLASMODIUM FALCIPARUM RAB6 COMPLEXED WITH GDP
4N11	;	1.97	;	Crystal structure of plasmodium falciparum reduced glutaredoxin 1 (PfGrx1) complexed with cisplatin
3JWP	;	2.65	;	Crystal structure of Plasmodium falciparum SIR2A (PF13_0152) in complex with AMP
4UOE	;	2.05	;	Crystal Structure of Plasmodium Falciparum Spermidine Synthase in Complex with 5'-Deoxy-5'-Methylioadenosine and 4-Aminomethylaniline
4BP1	;	2.17	;	Crystal Structure of Plasmodium Falciparum Spermidine Synthase in Complex with 5'-Methylthioadenosine and Putrescine
4BP3	;	1.75	;	Crystal Structure of Plasmodium Falciparum Spermidine Synthase in Complex with DECARBOXYLATED S-ADENOSYLMETHIONINE5' AND 4- METHYLANILINE
4CXM	;	1.75	;	Crystal Structure of Plasmodium Falciparum Spermidine Synthase in Complex with METHYLTHIOADENOSIN AND SPERMIDINE after catalysis in crystal
8POL	;	3.09	;	Crystal structure of Plasmodium falciparum Sub1 protease
3CXG	;	2.0	;	Crystal structure of Plasmodium falciparum thioredoxin, PFI0790w
6CA8	;	2.331	;	Crystal structure of Plasmodium falciparum topoisomerase II DNA-binding, cleavage and re-ligation domain
4HQF	;	2.2	;	Crystal structure of Plasmodium falciparum TRAP, I4 form
4HQK	;	2.249	;	Crystal structure of Plasmodium falciparum TRAP, P4212 form
4JFA	;	2.6	;	Crystal Structure of Plasmodium falciparum Tryptophanyl-tRNA synthetase
2WE6	;	2.42	;	Crystal Structure of Plasmodium falciparum Ubiquitin Carboxyl- terminal Hydrolase 3 (UCHL3)
4JUE	;	1.851	;	Crystal structure of Plasmodium falciparum ubiquitin conjugating enzyme UBC9
4M1N	;	1.5	;	Crystal structure of Plasmodium falciparum ubiquitin conjugating enzyme UBC9
2WDT	;	2.3	;	Crystal structure of Plasmodium falciparum UCHL3 in complex with the suicide inhibitor UbVME
3C5I	;	2.2	;	Crystal structure of Plasmodium knowlesi choline kinase, PKH_134520
2AWP	;	2.0	;	Crystal structure of Plasmodium knowlesi structure of Iron Super-Oxide Dismutase
7BT5	;	2.493	;	Crystal structure of plasmodium LysRS complexing with an antitumor compound
6KA6	;	1.891	;	Crystal structure of plasmodium lysyl-tRNA synthetase in complex with a cladosporin derivative 1
6KAB	;	2.892	;	Crystal structure of plasmodium lysyl-tRNA synthetase in complex with a cladosporin derivative 2
6KBF	;	1.92	;	Crystal structure of plasmodium lysyl-tRNA synthetase in complex with a cladosporin derivative 3
6KCN	;	2.2	;	Crystal structure of plasmodium lysyl-tRNA synthetase in complex with a cladosporin derivative 4
6KCT	;	3.25	;	Crystal structure of plasmodium lysyl-tRNA synthetase in complex with a cladosporin derivative 5
2I81	;	2.45	;	Crystal Structure of Plasmodium vivax 2-Cys Peroxiredoxin, Reduced
5NQG	;	2.15	;	Crystal structure of Plasmodium vivax AMA1 in complex with a 39 aa PvRON2 peptide
5TSZ	;	3.002	;	Crystal structure of Plasmodium vivax CelTOS
3RBM	;	2.61	;	Crystal structure of Plasmodium vivax geranylgeranylpyrophosphate synthase complexed with BPH -703
5HN7	;	2.15	;	Crystal structure of Plasmodium vivax geranylgeranylpyrophosphate synthase complexed with BPH-1158
5HN8	;	2.7	;	Crystal structure of Plasmodium vivax geranylgeranylpyrophosphate synthase complexed with BPH-1182
5HN9	;	2.12	;	Crystal structure of Plasmodium vivax geranylgeranylpyrophosphate synthase complexed with BPH-1186
5HNA	;	2.693	;	Crystal structure of Plasmodium vivax geranylgeranylpyrophosphate synthase complexed with BPH-1251
3EZ3	;	2.304	;	Crystal Structure of Plasmodium vivax geranylgeranylpyrophosphate synthase PVX_092040 with zoledronate and IPP bound
3LDW	;	2.47	;	Crystal Structure of Plasmodium vivax geranylgeranylpyrophosphate synthase PVX_092040 with zoledronate and IPP bound
8FBQ	;	1.65	;	Crystal structure of Plasmodium vivax glycylpeptide N-tetradecanoyltransferase (N-myristoyltransferase, NMT) bound to myristoyl-CoA and inhibitor 12b
2QOR	;	1.8	;	Crystal structure of Plasmodium vivax guanylate kinase
6BO7	;	2.856	;	Crystal structure of Plasmodium vivax hypoxanthine guanine phosphoribosyltransferase in complex with [3R,4R]-4-guanin-9-yl-3-((S)-2-hydroxy-2-phosphonoethyl)oxy-1-N-(phosphonopropionyl)pyrrolidine
2AA3	;	2.05	;	Crystal structure of Plasmodium vivax lactate dehydrogenase complex with APADH
5HRU	;	1.71	;	Crystal structure of Plasmodium vivax LDH in complex with a DNA aptamer called pL1
5HTO	;	1.9	;	Crystal structure of Plasmodium Vivax LDH in complex with a DNA aptamer called pL1 (tetrameric LDH in an asymmetric unit)
2GUU	;	1.86	;	crystal structure of Plasmodium vivax orotidine 5-monophosphate decarboxylase with 6-aza-UMP bound
2FFC	;	1.7	;	Crystal Structure of Plasmodium Vivax Orotidine-Monophosphate-Decarboxyl UMP Bound
3EMV	;	1.85	;	Crystal structure of Plasmodium vivax PNP with sulphate
4L0U	;	2.5	;	Crystal structure of Plasmodium vivax Prx1a
3MAV	;	2.1	;	Crystal structure of Plasmodium vivax putative farnesyl pyrophosphate synthase (Pv092040)
3CC9	;	2.3	;	Crystal structure of Plasmodium vivax putative polyprenyl pyrophosphate synthase in complex with geranylgeranyl diphosphate
3PH7	;	2.5	;	Crystal structure of Plasmodium vivax putative polyprenyl pyrophosphate synthase in complex with geranylgeranyl diphosphate
4PFN	;	2.5	;	Crystal structure of Plasmodium vivax SHMT with L-serine Schiff base
4PFF	;	2.3	;	Crystal structure of Plasmodium vivax SHMT with PLP Schiff base
4HQO	;	2.194	;	Crystal structure of Plasmodium vivax TRAP protein
2AMX	;	2.02	;	Crystal structure of Plasmodium Yoelii Adenosine deaminase (PY02076)
2GHI	;	2.2	;	Crystal Structure of Plasmodium yoelii Multidrug Resistance Protein 2
2AV4	;	1.73	;	Crystal structure of Plasmodium yoelii thioredoxin-like protein 4A (DIM1)
7B1W	;	1.935	;	Crystal structure of plastidial ribulose epimerase RPE1 from the model alga Chlamydomonas reinhardtii
2CJ3	;	1.7	;	CRYSTAL STRUCTURE OF PLASTOCYANIN FROM A CYANOBACTERIUM, ANABAENA VARIABILIS
1F9Q	;	2.0	;	CRYSTAL STRUCTURE OF PLATELET FACTOR 4
4R9W	;	2.5	;	Crystal structure of platelet factor 4 complexed with fondaparinux
1F9R	;	2.0	;	CRYSTAL STRUCTURE OF PLATELET FACTOR 4 MUTANT 1
1F9S	;	2.38	;	CRYSTAL STRUCTURE OF PLATELET FACTOR 4 MUTANT 2
6EU9	;	2.69	;	Crystal structure of Platynereis dumerilii RAR ligand-binding domain in complex with all-trans retinoic acid
2IL9	;	3.1	;	Crystal Structure of Plautia Stali Intestine Virus Intergenic Region Internal Ribosome Entry Site Ribosomal Binding Domain RNA at 3.1 Angstroms
7E4D	;	2.6	;	Crystal structure of PlDBR
7VPA	;	2.35	;	Crystal structure of Ple629 from marine microbial consortium
3HSA	;	1.99	;	Crystal structure of pleckstrin homology domain (YP_926556.1) from SHEWANELLA AMAZONENSIS SB2B at 1.99 A resolution
4Q59	;	2.3	;	Crystal structure of plectin 1a actin-binding domain
7KJZ	;	2.43	;	crystal structure of PLEKHA7 PH domain biding inositol-tetraphosphate
7KJO	;	1.45	;	crystal structure of PLEKHA7 PH domain biding SO4
5DPW	;	2.185	;	Crystal structure of PLEKHM1 LIR in complex with human LC3C_8-125
5DPT	;	2.9	;	Crystal structure of PLEKHM1 LIR-fused human GABARAPL1_2-117
5DPS	;	2.0	;	Crystal structure of PLEKHM1 LIR-fused human GABARAP_2-117
5DPR	;	2.5	;	Crystal structure of PLEKHM1 LIR-fused human LC3A_2-121
3X0W	;	2.71	;	Crystal structure of PLEKHM1 LIR-fused human LC3B_2-119
8JC5	;	2.01	;	Crystal structure of PLEKHM1 RUN domain in complex with GTP-bound Arl8b(Q75L)
3Q3J	;	1.971	;	Crystal structure of plexin A2 RBD in complex with Rnd1
5B4W	;	2.6	;	Crystal structure of Plexin inhibitor complex
4M8N	;	3.294	;	Crystal Structure of PlexinC1/Rap1B Complex
1RV6	;	2.45	;	Crystal Structure of PlGF in Complex with Domain 2 of VEGFR1
3OE3	;	1.51	;	Crystal structure of PliC-St, periplasmic lysozyme inhibitor of C-type lysozyme from Salmonella typhimurium
3OD9	;	1.411	;	Crystal structure of PliI-Ah, periplasmic lysozyme inhibitor of I-type lysozyme from Aeromonas hydrophyla
4H7L	;	2.452	;	Crystal structure of Plim_4148 protein from Planctomyces limnophilus
5TA8	;	2.6	;	Crystal structure of PLK1 in complex with a novel 5,6-dihydroimidazolo[1,5-f]pteridine inhibitor
5TA6	;	2.5	;	Crystal structure of PLK1 in complex with a novel 5,6-dihydroimidazolo[1,5-f]pteridine inhibitor.
4J52	;	2.3	;	Crystal structure of PLK1 in complex with a pyrimidodiazepinone inhibitor
4J53	;	2.5	;	Crystal structure of PLK1 in complex with TAK-960
4RCP	;	1.6	;	Crystal structure of Plk1 Polo-box domain in complex with PL-2
4HY2	;	2.0	;	Crystal structure of Plk1 Polo-box domain in complex with PL-42
4HAB	;	2.65	;	Crystal structure of Plk1 Polo-box domain in complex with PL-49
4LKL	;	1.58	;	Crystal structure of Plk1 Polo-box domain in complex with PL-55
4LKM	;	2.0	;	Crystal structure of Plk1 Polo-box domain in complex with PL-74
3COK	;	2.25	;	Crystal structure of PLK4 kinase
4YUR	;	2.65	;	Crystal Structure of Plk4 Kinase Domain Bound to Centrinone
4JXF	;	2.4	;	Crystal Structure of PLK4 Kinase with an inhibitor: 400631 ((1R,2S)-2-{3-[(E)-2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}ETHENYL]-2H-INDAZOL-6-YL}-5'-METHOXYSPIRO[CYCLOPROPANE-1,3'-INDOL]-2'(1'H)-ONE)
3AQY	;	1.58	;	Crystal structure of Plodia interpunctella beta-GRP/GNBP3 N-terminal domain
3AQZ	;	2.2	;	Crystal structure of Plodia interpunctella beta-GRP/GNBP3 N-terminal domain with laminarihexaoses
3DOD	;	1.9	;	Crystal Structure of PLP Bound 7,8-Diaminopelargonic Acid Synthase in Bacillus subtilis
3BV0	;	2.21	;	Crystal Structure of PLP Bound 7,8-Diaminopelargonic Acid Synthase in Mycobacterium Tuberculosis
5YGR	;	2.5	;	Crystal structure of PLP bound Diaminopropionate ammonia lyase from Salmonella typhimurium
5F8V	;	2.14	;	Crystal structure of PLP bound phosphoserine aminotransferase (PSAT) from Trichomonas vaginalis
5DB5	;	2.75	;	Crystal structure of PLP-bound E. coli SufS (cysteine persulfide intermediate) in space group P21
3ASB	;	2.7	;	Crystal structure of PLP-bound LL-diaminopimelate aminotransferase from Chlamydia trachomatis
4DQ6	;	1.5	;	Crystal structure of PLP-bound putative aminotransferase from Clostridium difficile 630
4DGT	;	1.55	;	Crystal structure of PLP-bound putative aminotransferase from Clostridium difficile 630 crystallized with magnesium formate
4ZM3	;	2.27	;	Crystal structure of PLP-Dependent 3-Aminobenzoate Synthase PctV wild-type
4M2J	;	2.95	;	Crystal structure of PLP-dependent cyclase OrfR in complex with Au
4M2K	;	2.0	;	Crystal structure of PLP-dependent cyclase OrfR in complex with PLP
4M2M	;	1.58	;	Crystal structure of PLP-dependent cyclase OrfR in complex with PLP-L-Arg
8DL5	;	2.1	;	Crystal structure of PLP-dependent Mannich cyclase LolT
4H6D	;	2.9	;	Crystal structure of PLP-soaked HMP synthase Thi5 from S. cerevisiae
4PT5	;	2.59	;	Crystal structure of PLpro from Middle East Respiratory Syndrome (MERS) coronavirus
4RNA	;	1.794	;	Crystal structure of PLpro from Middle East Respiratory Syndrome (MERS) coronavirus
7DH6	;	2.584	;	Crystal structure of PLRG1
5XJ7	;	1.772	;	Crystal structure of PlsY (YgiH), an integral membrane glycerol 3-phosphate acyltransferase - the acyl phosphate form
5XJ6	;	2.37	;	Crystal structure of PlsY (YgiH), an integral membrane glycerol 3-phosphate acyltransferase - the glycerol 3-phosphate form
5XJ8	;	2.41	;	Crystal structure of PlsY (YgiH), an integral membrane glycerol 3-phosphate acyltransferase - the lysphosphatidic acid form
5XJ5	;	1.481	;	Crystal structure of PlsY (YgiH), an integral membrane glycerol 3-phosphate acyltransferase - the monoacylglycerol form
5XJ9	;	1.83	;	Crystal structure of PlsY (YgiH), an integral membrane glycerol 3-phosphate acyltransferase - the orthophosphate form
4RHR	;	2.079	;	Crystal structure of PltB
7EE3	;	1.33	;	Crystal structure of PltC
7EE6	;	2.29	;	Crystal structure of PltC toxin
7THQ	;	2.46	;	Crystal structure of PltF trapped with PigG using a proline adenosine vinylsulfonamide inhibitor
6O6E	;	2.14	;	Crystal structure of PltF trapped with PltL using a proline adenosine vinylsulfonamide inhibitor
4MV2	;	1.349	;	Crystal structure of plu4264 protein from Photorhabdus luminescens
6L6Y	;	3.0	;	Crystal Structure of Pluripotency Reprogramming Factor Sox17 mutant (Sox17EK) HMG Domain bound to DNA
8FBY	;	2.4	;	Crystal structure of PLVAP CC1 determined by sulfur SAD
8FCF	;	1.95	;	Crystal structure of PLVAP CC1 in I212121 space group
8H1I	;	2.1	;	Crystal structure of PlyGRCS, a bacteriophage Endolysin in complex with Cold shock protein C
6LZ4	;	2.49	;	Crystal structure of PMab-1 Fv-clasp fragment with its antigen peptide
1M43	;	2.4	;	Crystal structure of PMII in complex with pepstatin a to 2.4 A
7XP0	;	2.61	;	Crystal structure of PmiR from Pseudomonas aeruginosa
7XP1	;	2.5	;	Crystal structure of PmiR from Pseudomonas aeruginosa
8J2P	;	2.09	;	Crystal structure of PML B-box2
8J25	;	2.6	;	Crystal structure of PML B-box2 mutant
6IMQ	;	2.06	;	Crystal structure of PML B1-box multimers
5YUF	;	1.6	;	Crystal Structure of PML RING tetramer
6CPD	;	1.903	;	Crystal structure of PmoD soluble domain from Methylocystis sp. ATCC 49242 (Rockwell)
7E6B	;	1.84	;	Crystal structure of PMP-bound form of cysteine desulfurase SufS C361A from Bacillus subtilis
7CEO	;	2.43	;	Crystal structure of PMP-bound form of cysteine desulfurase SufS from Bacillus subtilis
7E6E	;	2.28	;	Crystal structure of PMP-bound form of cysteine desulfurase SufS R376A from Bacillus subtilis in D-cycloserine-inhibition
7E6F	;	2.74	;	Crystal structure of PMP-bound form of cysteine desulfurase SufS R376A from Bacillus subtilis in L-cycloserine-inhibition
7RCK	;	2.04	;	Crystal Structure of PMS2 with Substrate
1KLT	;	1.9	;	CRYSTAL STRUCTURE OF PMSF-TREATED HUMAN CHYMASE AT 1.9 ANGSTROMS RESOLUTION
8GV5	;	3.2	;	Crystal structure of PN-SIA28 in complex with influenza hemagglutinin A/swine/Guangdong/104/2013 (H1N1)
8GV6	;	3.4	;	Crystal structure of PN-SIA28 in complex with influenza hemagglutinin H14 (A/long-tailed duck/Wisconsin/10OS3912/2010)
8GV7	;	2.6	;	Crystal structure of PN-SIA28 in complex with influenza hemagglutinin H18 A/flat-faced bat/Peru/033/2010
3R2J	;	2.68	;	Crystal Structure of PnC1 from L. infantum in complex with nicotinate
2VU5	;	2.0	;	Crystal structure of Pndk from Bacillus anthracis
4R7B	;	2.01	;	Crystal structure of pneumococcal LicA in complex with choline
4Q2W	;	1.65	;	Crystal Structure of pneumococcal peptidoglycan hydrolase LytB
4UTO	;	1.55	;	Crystal structure of pneumococcal surface antigen PsaA D280N in the Cd-bound, open state
3ZKA	;	1.55	;	CRYSTAL STRUCTURE OF PNEUMOCOCCAL SURFACE ANTIGEN PSAA D280N IN THE METAL-BOUND, OPEN STATE
3ZK9	;	1.45	;	CRYSTAL STRUCTURE OF PNEUMOCOCCAL SURFACE ANTIGEN PSAA D280N IN THE METAL-FREE, OPEN STATE
3ZK8	;	1.65	;	CRYSTAL STRUCTURE OF PNEUMOCOCCAL SURFACE ANTIGEN PSAA E205Q IN THE METAL-FREE, OPEN STATE
4UTP	;	2.0	;	Crystal structure of pneumococcal surface antigen PsaA in the Cd- bound, closed state
3ZK7	;	1.69	;	CRYSTAL STRUCTURE OF PNEUMOCOCCAL SURFACE ANTIGEN PSAA IN THE METAL-FREE, OPEN STATE
3ZTT	;	2.7	;	Crystal structure of pneumococcal surface antigen PsaA with manganese
1KLK	;	2.3	;	CRYSTAL STRUCTURE OF PNEUMOCYSTIS CARINII DIHYDROFOLATE REDUCTASE TERNARY COMPLEX WITH PT653 AND NADPH
5AOE	;	2.5	;	Crystal structure of pneumolysin D168A mutant.
5AOF	;	2.45	;	Crystal structure of pneumolysin deletion mutant Delta146_147.
4QQA	;	2.802	;	Crystal structure of pneumolysin from Streptococcus pneumoniae
4QQQ	;	2.5	;	Crystal structure of pneumolysin from Streptococcus pneumoniae, in complex with mannose as a component of cell membrane
3OF3	;	1.83	;	Crystal structure of PNP with an inhibitor DADME_immH from Vibrio cholerae
3OCC	;	1.7	;	Crystal structure of PNP with DADMEimmH from Yersinia pseudotuberculosis
5YJJ	;	2.2	;	Crystal structure of PNPase from Staphylococcus epidermidis
4LAF	;	1.761	;	Crystal structure of PnpB complex with FMN
4GO3	;	2.704	;	Crystal structure of PnpE from Pseudomonas sp. WBC-3
4GO4	;	3.099	;	Crystal structure of PnpE in complex with Nicotinamide adenine dinucleotide
6Y9U	;	2.5	;	Crystal structure of PnrA from S. pneumoniae in complex with adenosine
6YA4	;	2.2	;	Crystal structure of PnrA from S. pneumoniae in complex with cytidine
6YA3	;	2.28	;	Crystal structure of PnrA from S. pneumoniae in complex with guanosine
6YAG	;	2.55	;	Crystal structure of PnrA from S. pneumoniae in complex with thymidine
6YAB	;	2.3	;	Crystal structure of PnrA from S. pneumoniae in complex with uridine
6LFQ	;	2.359	;	Crystal structure of Poa1p in apo form
4PQ0	;	1.65	;	Crystal structure of POB3 middle domain at 1.65A
4Y6W	;	1.587	;	Crystal structure of Podosopora anserina putative kinesin light chain nearly identical TPR-like repeats
3ZM8	;	2.85	;	Crystal structure of Podospora anserina GH26-CBM35 beta-(1,4)- mannanase
3ZIZ	;	1.4	;	Crystal structure of Podospora anserina GH5 beta-(1,4)-mannanase
5YCD	;	1.8	;	Crystal structure of Poecilia reticulata adenylate kinase
3ZY4	;	1.74	;	Crystal structure of POFUT1 apo-form (crystal-form-I)
3ZY3	;	1.86	;	Crystal structure of POFUT1 in complex with GDP (crystal-form-III)
3ZY2	;	1.54	;	Crystal structure of POFUT1 in complex with GDP (High resolution dataset)
3ZY5	;	1.96	;	Crystal structure of POFUT1 in complex with GDP-fucose (crystal-form-I)
3ZY6	;	1.91	;	Crystal structure of POFUT1 in complex with GDP-fucose (crystal-form-II)
6DL0	;	1.2	;	Crystal structure of pohlianin C, an orbitide from Jatropha pohliana
4D3P	;	1.27	;	crystal structure of point mutated DUSP19 (C150A)
4D3R	;	1.67	;	Crystal structure of point mutated DUSP19 (I187A)
4D3Q	;	1.64	;	crystal structure of point mutated DUSP19 (R156A)
1ULK	;	1.8	;	Crystal Structure of Pokeweed Lectin-C
1ULN	;	1.65	;	Crystal Structure of Pokeweed Lectin-D1
1UHA	;	1.5	;	Crystal Structure of Pokeweed Lectin-D2
1ULM	;	1.8	;	Crystal Structure of Pokeweed Lectin-D2 complexed with tri-N-acetylchitotriose
3IKL	;	3.1	;	Crystal structure of Pol gB delta-I4.
7ZX1	;	2.829	;	Crystal structure of Pol theta polymerase domain in complex with compound 22
7ZX0	;	2.99	;	Crystal structure of Pol theta polymerase domain in complex with compound 5
7C03	;	2.501	;	Crystal structure of POLArISact(T57S), genetically encoded probe for fluorescent polarization
3RX6	;	2.039	;	Crystal structure of Polarity Suppression protein from Enterobacteria phage P4
8S95	;	3.1	;	Crystal Structure of Poliovirus (type 1 Mahoney) cloverleaf RNA with tRNA scaffold
2ILY	;	2.6	;	Crystal structure of poliovirus polymerase complexed with ATP and Mg2+
2IM0	;	2.25	;	Crystal structure of poliovirus polymerase complexed with CTP and Mg2+
2IM1	;	2.5	;	Crystal structure of poliovirus polymerase complexed with CTP and Mn2+
2ILZ	;	2.5	;	Crystal structure of poliovirus polymerase complexed with GTP and Mn2+
2IM2	;	2.35	;	Crystal structure of poliovirus polymerase complexed with UTP and Mg2+
2IM3	;	2.6	;	Crystal structure of poliovirus polymerase complexed with UTP and Mn2+
3FT1	;	1.79	;	Crystal structure of pollen allergen Phl p 3
7MSO	;	1.85	;	Crystal Structure of Polo Box Domain in Complex with Cyclic Peptide Inhibitor
4J7B	;	2.3	;	Crystal structure of polo-like kinase 1
4A4O	;	2.7	;	CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 2-(2-AMINO- PYRIMIDIN-4-YL)-1,5,6,7-TETRAHYDRO-PYRROLOPYRIDIN-4-ONE INHIBITOR
4A4L	;	2.35	;	CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 5-(2-AMINO- PYRIMIDIN-4-YL)-1H-PYRROLE INHIBITOR
3KB7	;	2.5	;	Crystal structure of Polo-like kinase 1 in complex with a pyrazoloquinazoline inhibitor
2YAC	;	2.2	;	Crystal structure of Polo-like kinase 1 in complex with NMS-P937
4O9W	;	1.694	;	Crystal structure of polo-like kinase(PLK1)PBD in complex with phospho peptide
1Q78	;	2.8	;	Crystal structure of poly(A) polymerase in complex with 3'-dATP and magnesium chloride
5ZDA	;	1.548	;	Crystal structure of poly(ADP-ribose) glycohydrolase (PARG) from Deinococcus radiodurans in apo form
5ZDB	;	1.972	;	Crystal structure of poly(ADP-ribose) glycohydrolase (PARG) from Deinococcus radiodurans in complex with ADP-ribose (P21)
5ZDD	;	2.725	;	Crystal structure of poly(ADP-ribose) glycohydrolase (PARG) from Deinococcus radiodurans in complex with ADP-ribose (P212121)
5ZDC	;	1.979	;	Crystal structure of poly(ADP-ribose) glycohydrolase (PARG) from Deinococcus radiodurans in complex with ADP-ribose (P32)
5ZDE	;	2.8	;	Crystal structure of poly(ADP-ribose) glycohydrolase (PARG) from Deinococcus radiodurans in complex with ADP-ribose (P3221)
5ZDF	;	2.504	;	Crystal structure of poly(ADP-ribose) glycohydrolase (PARG) T267K mutant from Deinococcus radiodurans in complex with ADP-ribose
5ZDG	;	2.594	;	Crystal structure of poly(ADP-ribose) glycohydrolase (PARG) T267R mutant from Deinococcus radiodurans in complex with ADP-ribose
3LNR	;	2.64	;	Crystal structure of poly-HAMP domains from the P. aeruginosa soluble receptor Aer2
1CVX	;	2.27	;	CRYSTAL STRUCTURE OF POLYAMIDE DIMER (IMPYHPPYBETADP)2 BOUND TO B-DNA DECAMER CCAGATCTGG
1CVY	;	2.15	;	CRYSTAL STRUCTURE OF POLYAMIDE DIMER (IMPYPYPYBETADP)2 BOUND TO CCAGATCTGG
1UIR	;	2.0	;	Crystal Structure of Polyamine Aminopropyltransfease from Thermus thermophilus
3BNM	;	2.2	;	Crystal structure of polyamine oxidase FMS1 from Saccharomyces cerevisiae in complex with bis-(3R,3'R)-methylated spermine
3BNU	;	2.2	;	Crystal structure of polyamine oxidase FMS1 from Saccharomyces cerevisiae in complex with bis-(3S,3'S)-methylated spermine
1IB4	;	2.0	;	Crystal Structure of Polygalacturonase from Aspergillus Aculeatus at Ph4.5
3A0E	;	2.0	;	Crystal Structure of Polygonatum cyrtonema lectin (PCL) complexed with dimannoside
3A0D	;	2.2	;	Crystal Structure of Polygonatum cyrtonema lectin (PCL) complexed with monomannoside
7F27	;	1.806	;	Crystal structure of polyketide ketosynthase
5IF5	;	2.25	;	Crystal structure of polymerase acid protein (PA) from Influenza A virus, WILSON-SMITH/1933 (H1N1) bound to EBSI-39 (2,3-dichlorophenyl)methanol
5IFB	;	2.45	;	Crystal structure of polymerase acid protein (PA) from Influenza A virus, WILSON-SMITH/1933 (H1N1) bound to follow on fragment EBSI-4719 5-chloro-2-(1H-imidazol-1-yl)aniline
5IFC	;	2.65	;	Crystal structure of polymerase acid protein (PA) from Influenza A virus, WILSON-SMITH/1933 (H1N1) bound to follow on fragment EBSI-4720 1-(4-bromophenyl)-1H-imidazole
5IFD	;	2.65	;	Crystal structure of polymerase acid protein (PA) from Influenza A virus, WILSON-SMITH/1933 (H1N1) bound to follow on fragment EBSI-4721 1-(4-fluorophenyl)-1H-imidazole
5V0U	;	2.45	;	Crystal structure of polymerase acid protein (PA) from Influenza A virus, WILSON-SMITH/1933 (H1N1) bound to follow on fragment EBSI-4723 4-(5-chlorothiophen-2-yl)-1H-pyrazole
6CFP	;	2.45	;	CRYSTAL STRUCTURE OF POLYMERASE ACID PROTEIN (PA) FROM INFLUENZA A VIRUS, WILSON-SMITH/1933 (H1N1) BOUND TO FRAGMENT HIT BSI-70565 1-{1-[4-FLUOROPHENYL)METHYL]-2-METHYL-1H-IMIDAZOL-4-YL}ETHAN-1-ONE
5IF8	;	2.3	;	Crystal structure of polymerase acid protein (PA) from Influenza A virus, WILSON-SMITH/1933 (H1N1) bound to fragment hit EBSI-2643 5-[(4-chlorophenyl)methyl]-1,3,4-oxadiazol-2-amine
5IF7	;	2.65	;	Crystal structure of polymerase acid protein (PA) from Influenza A virus, WILSON-SMITH/1933 (H1N1) bound to fragment hit EBSI-279 N-[(4-chlorophenyl)methyl]-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
5IF2	;	2.35	;	Crystal structure of polymerase acid protein (PA) from Influenza A virus, WILSON-SMITH/1933 (H1N1) bound to fragment hit EBSI-576 (5,6-dichloro-1H-1,3-benzodiazol-2-yl)methanol
5IEQ	;	2.2	;	Crystal structure of polymerase acid protein (PA) from Influenza A virus, WILSON-SMITH/1933 (H1N1) bound to fragment hit EBSI-747 1-(4-chlorophenyl)-1H-imidazole
3R2V	;	1.3	;	Crystal structure of polymerase basic protein 2 E538-R753 from Influenza A virus A/Yokohama/2017/03 H3N2
7R0K	;	2.972	;	Crystal structure of Polymerase I from phage G20c
4NFZ	;	2.7	;	Crystal structure of polymerase subunit PA N-terminal endonuclease domain from bat-derived influenza virus H17N10
2WFL	;	2.1	;	Crystal structure of polyneuridine aldehyde esterase
3GZJ	;	2.19	;	Crystal Structure of Polyneuridine Aldehyde Esterase Complexed with 16-epi-Vellosimine
2WFM	;	2.2	;	Crystal structure of polyneuridine aldehyde esterase mutant (H244A)
3GLL	;	2.7	;	Crystal structure of Polynucleotide Phosphorylase (PNPase) core
3H1C	;	3.57	;	Crystal structure of Polynucleotide Phosphorylase (PNPase) core bound to RNase E and Tungstate
3GME	;	2.4	;	Crystal Structure of Polynucleotide Phosphorylase in complex with RNase E and manganese
7E6O	;	2.1	;	Crystal structure of polyol dehydrogenase from Paracoccus denitrificans
6DZG	;	1.87	;	Crystal structure of polyphosphate kinase 2 class I (SMc02148) in complex with ADP
3RHF	;	2.45	;	Crystal structure of Polyphosphate Kinase 2 from Arthrobacter aurescens TC1
7BMM	;	2.06	;	Crystal structure of Polyphosphate Kinase 2 from Deinococcus radiodurans in apo form
7NMJ	;	2.08	;	Crystal structure of Polyphosphate Kinase 2 from Deinococcus radiodurans in complex with ADP
5LDB	;	2.3	;	Crystal Structure of Polyphosphate Kinase from Meiothermus ruber bound to ADP
5MAQ	;	2.46	;	Crystal Structure of Polyphosphate Kinase from Meiothermus ruber bound to ADP and PPi
5LD1	;	2.09	;	Crystal Structure of Polyphosphate Kinase from Meiothermus ruber bound to ATP
2O8R	;	2.7	;	Crystal Structure of Polyphosphate Kinase from Porphyromonas Gingivalis
4LOB	;	2.0	;	Crystal structure of polyprenyl diphosphate synthase A1S_2732 (Target EFI-509223) from Acinetobacter baumannii
5E8K	;	3.028	;	Crystal structure of polyprenyl pyrophosphate synthase 2 from Arabidopsis thaliana
3OYR	;	2.0	;	Crystal structure of polyprenyl synthase from Caulobacter crescentus CB15 complexed with calcium and isoprenyl diphosphate
3P8L	;	2.0	;	Crystal structure of polyprenyl synthase from Enterococcus faecalis V583
3P8R	;	2.5	;	CRYSTAL STRUCTURE OF POLYPRENYL SYNTHASE FROM Vibrio cholerae
4JXN	;	2.3	;	CRYSTAL STRUCTURE OF POLYPRENYL SYNTHASE ISP_B (TARGET EFI-509198) FROM Roseobacter denitrificans
4JXY	;	1.9	;	CRYSTAL STRUCTURE OF POLYPRENYL SYNTHASE PATL_3739 (TARGET EFI-509195) FROM Pseudoalteromonas atlantica
4JYX	;	2.3	;	Crystal structure of polyprenyl synthase PATL_3739 (TARGET EFI-509195) FROM PSEUDOALTEROMONAS ATLANTICA, COMPLEX WITH INORGANIC PHOSPHATE AND AN UNKNOWN LIGAND
3P41	;	1.76	;	Crystal structure of polyprenyl synthetase from pseudomonas fluorescens pf-5 complexed with magnesium and isoprenyl pyrophosphate
3NF2	;	2.2	;	Crystal structure of polyprenyl synthetase from Streptomyces coelicolor A3(2)
4J72	;	3.3	;	Crystal Structure of polyprenyl-phosphate N-acetyl hexosamine 1-phosphate transferase
8G1B	;	1.67	;	Crystal structure of polyreactive 2G02 human Fab
8FZO	;	1.83	;	Crystal structure of polyreactive 338E6 mouse Fab
8G1C	;	1.63	;	Crystal structure of polyreactive 3B03 human Fab
8FZP	;	1.63	;	Crystal structure of polyreactive 43G10 mouse Fab
4Q8K	;	1.646	;	Crystal structure of polysaccharide lyase family 18 aly-SJ02 P-CATD
7DRQ	;	1.79	;	Crystal structure of polysaccharide lyase Uly1
7A8V	;	1.94961	;	Crystal structure of Polysaccharide monooxygenase from P.verruculosum
4Q8L	;	2.099	;	Crystal structure of polysacchride lyase family 18 aly-SJ02 r-CATD
5VIX	;	1.55	;	Crystal structure of Polyubiquitin with 3 ub domains, domains 1 and 2, from Naegleria fowleri ATCC 30863
3H4J	;	2.8	;	crystal structure of pombe AMPK KDAID fragment
6L80	;	2.0005	;	Crystal structure of pombe Mod21 N-terminus and Mozart1
7E9J	;	2.4	;	Crystal Structure of POMGNT2 in complex with UDP
7E9K	;	2.05	;	Crystal Structure of POMGNT2 in complex with UDP and mono-mannosyl peptide (379Man long peptide)
7E9L	;	2.1	;	Crystal Structure of POMGNT2 in complex with UDP and mono-mannosyl peptide (379Man short peptide)
7XW0	;	2.95	;	Crystal structure of pOmpT
3WL6	;	1.6	;	Crystal Structure of pOPH Native
3WL8	;	1.6	;	Crystal Structure of pOPH S172A with octanoic acid
3WL5	;	1.6	;	Crystal structure of pOPH S172C
3FZ9	;	1.7	;	Crystal structure of poplar glutaredoxin S12 in complex with glutathione
3FZA	;	1.8	;	Crystal structure of poplar glutaredoxin S12 in complex with glutathione and beta-mercaptoethanol
4RI6	;	1.523	;	Crystal structure of poplar glutathione transferase F1
4RI7	;	1.798	;	Crystal structure of poplar glutathione transferase F1 mutant SER 13 CYS
7ZS3	;	1.603	;	Crystal structure of poplar glutathione transferase U19
7ZVP	;	1.61	;	Crystal structure of poplar glutathione transferase U19 in complex with glutathione
7ZZN	;	2.01	;	Crystal structure of poplar glutathione transferase U20
8A0Q	;	2.048	;	Crystal structure of poplar glutathione transferase U20 in complex with baicalein
8A0O	;	1.837	;	Crystal structure of poplar glutathione transferase U20 in complex with galangin
8A08	;	1.645	;	Crystal structure of poplar glutathione transferase U20 in complex with glutathione
8A0I	;	1.624	;	Crystal structure of poplar glutathione transferase U20 in complex with glutathionylphenylacetophenone
8A0P	;	1.686	;	Crystal structure of poplar glutathione transferase U20 in complex with morin
8A0R	;	1.6	;	Crystal structure of poplar glutathione transferase U20 in complex with pinocembrin
5W3Y	;	2.2	;	Crystal structure of PopP2 C321A in complex with IP6 and AcCoA
5W40	;	2.53	;	Crystal structure of PopP2 F318S in complex with IP6 and AcCoA
5W3T	;	2.15	;	Crystal structure of PopP2 in complex with IP6
5W3X	;	2.0	;	Crystal structure of PopP2 in complex with IP6, AcCoA and the WRKY domain of RRS1-R .
2VQG	;	1.82	;	Crystal structure of PorB from Corynebacterium glutamicum (crystal form I)
2VQH	;	2.89	;	Crystal structure of PorB from Corynebacterium glutamicum (crystal form II)
2VQL	;	3.16	;	Crystal structure of PorB from Corynebacterium glutamicum (crystal form III)
2VQK	;	4.2	;	Crystal structure of PorB from Corynebacterium glutamicum (crystal form IV)
3VY9	;	2.63	;	Crystal structure of PorB from Neisseria meningitidis in complex with cesium ion, space group H32
3VY8	;	2.12	;	Crystal Structure of PorB from Neisseria meningitidis in complex with Cesium ion, space group P63
6Q67	;	2.249	;	Crystal structure of porcine ACBD3 GOLD domain in complex with 3A protein of Aichivirus C
6Q69	;	2.747	;	Crystal structure of porcine ACBD3 GOLD domain in complex with 3A protein of enterovirus-G1
1CWN	;	2.0	;	CRYSTAL STRUCTURE OF PORCINE ALDEHYDE REDUCTASE HOLOENZYME
3CV7	;	2.412	;	Crystal structure of porcine aldehyde reductase ternary complex
1UHB	;	2.15	;	Crystal structure of porcine alpha trypsin bound with auto catalyticaly produced native peptide at 2.15 A resolution
4OU3	;	1.95	;	Crystal structure of porcine aminopeptidase N complexed with CNGRCG tumor-homing peptide
5Z65	;	2.65	;	Crystal structure of porcine aminopeptidase N ectodomain in functional form
4FKE	;	1.85	;	Crystal structure of porcine aminopeptidase-N
4FKH	;	2.05	;	Crystal structure of porcine aminopeptidase-N complexed with alanine
4FKK	;	2.6	;	Crystal structure of porcine aminopeptidase-N complexed with bestatin
4NZ8	;	2.0	;	Crystal structure of porcine aminopeptidase-N complexed with cleaved poly-alanine
4NAQ	;	2.1	;	Crystal structure of porcine aminopeptidase-N complexed with poly-alanine
4HOM	;	1.9	;	Crystal structure of porcine aminopeptidase-N complexed with substance P
6BV0	;	1.86	;	Crystal structure of porcine aminopeptidase-N with Arginine
6BV1	;	2.0	;	Crystal structure of porcine aminopeptidase-N with Aspartic acid
6BUY	;	2.1	;	Crystal structure of porcine aminopeptidase-N with Glycine
6BV2	;	2.14	;	Crystal structure of porcine aminopeptidase-N with Isoleucine
6BV3	;	2.2	;	Crystal structure of porcine aminopeptidase-N with Leucine
6BV4	;	2.02	;	Crystal structure of porcine aminopeptidase-N with Methionine
1FNI	;	1.6	;	CRYSTAL STRUCTURE OF PORCINE BETA TRYPSIN WITH 0.01% POLYDOCANOL
1FMG	;	1.9	;	CRYSTAL STRUCTURE OF PORCINE BETA TRYPSIN WITH 0.04% POLYDOCANOL
1FN6	;	1.8	;	CRYSTAL STRUCTURE OF PORCINE BETA TRYPSIN WITH 0.1% POLYDOCANOL
1QQU	;	1.63	;	CRYSTAL STRUCTURE OF PORCINE BETA TRYPSIN WITH BOUND ACETATE ION
4MO3	;	1.702	;	Crystal Structure of Porcine C2 Domain of Blood Coagulation Factor VIII
8PCH	;	2.1	;	CRYSTAL STRUCTURE OF PORCINE CATHEPSIN H DETERMINED AT 2.1 ANGSTROM RESOLUTION: LOCATION OF THE MINI-CHAIN C-TERMINAL CARBOXYL GROUP DEFINES CATHEPSIN H AMINOPEPTIDASE FUNCTION
3SIT	;	1.8	;	Crystal structure of porcine CRW-8 Rotavirus VP8* in complex with aceramido-GM3
3SIS	;	2.2	;	Crystal structure of Porcine CRW-8 Rotavirus VP8* in complex with aceramido-GM3_Gc
5YM6	;	1.803	;	Crystal Structure of porcine delta coronavirus nsp9
5YM8	;	1.992	;	Crystal Structure of porcine delta coronavirus nsp9-N7
8E7C	;	2.45	;	Crystal Structure of Porcine Deltacoronavirus (HKU-15) Mpro with Pfizer Intravenous Inhibitor PF-00835231
1ORV	;	1.8	;	Crystal Structure of Porcine Dipeptidyl Peptidase IV (CD26)
2BUA	;	2.56	;	Crystal Structure Of Porcine Dipeptidyl Peptidase IV (Cd26) in Complex With a Low Molecular Weight Inhibitor.
1ORW	;	2.84	;	Crystal Structure of Porcine Dipeptidyl Peptidase IV (CD26) in Complex with a Peptidomimetic Inhibitor
2BUC	;	2.5	;	Crystal Structure Of Porcine Dipeptidyl Peptidase IV (CD26) in Complex with a Tetrahydroisoquinoline Inhibitor
7S0P	;	1.3	;	Crystal structure of Porcine Factor VIII C2 Domain Bound to Phosphatidylserine
1KZ8	;	2.0	;	CRYSTAL STRUCTURE OF PORCINE FRUCTOSE-1,6-BISPHOSPHATASE COMPLEXED WITH A NOVEL ALLOSTERIC-SITE INHIBITOR
3AE2	;	3.1	;	Crystal structure of porcine heart mitochondrial complex II bound with 2-Hydroxy-N-phenyl-benzamide
3AEC	;	3.61	;	Crystal structure of porcine heart mitochondrial complex II bound with 2-Iodo-N-(1-methylethyl)-benzamid
3AE7	;	3.62	;	Crystal structure of porcine heart mitochondrial complex II bound with 2-Iodo-N-(3-isopropoxy-phenyl)-benzamide
3AE4	;	2.91	;	Crystal structure of porcine heart mitochondrial complex II bound with 2-Iodo-N-methyl-benzamide
3AED	;	3.52	;	Crystal structure of porcine heart mitochondrial complex II bound with 2-Iodo-N-phenyl-benzamide
3AE5	;	3.41	;	Crystal structure of porcine heart mitochondrial complex II bound with 2-Methyl-N-(3-isopropoxy-phenyl)-benzamide
3AE3	;	3.35	;	Crystal structure of porcine heart mitochondrial complex II bound with 2-Nitro-N-phenyl-benzamide
3AEE	;	3.22	;	Crystal structure of porcine heart mitochondrial complex II bound with Atpenin A5
4YXD	;	3.0	;	CRYSTAL STRUCTURE OF PORCINE HEART MITOCHONDRIAL COMPLEX II BOUND WITH flutolanil
3AEA	;	3.39	;	Crystal structure of porcine heart mitochondrial complex II bound with N-(3-Dimethylaminomethyl-phenyl)-2-trifluoromethyl-benzamide
3AE8	;	3.4	;	Crystal structure of porcine heart mitochondrial complex II bound with N-(3-Isopropoxy-phenyl)-2-trifluoromethylbenzamide
3AE6	;	3.4	;	Crystal structure of porcine heart mitochondrial complex II bound with N-(3-Isopropoxy-phenyl)-phthalamicacid
3AE9	;	3.31	;	Crystal structure of porcine heart mitochondrial complex II bound with N-(3-Pentafluorophenyloxy-phenyl)-2-trifluoromethyl-benzamide
3AEB	;	3.0	;	Crystal structure of porcine heart mitochondrial complex II bound with N-(3-Phenoxy-phenyl)-2-trifluoromethyl-benzamide
3AEG	;	3.27	;	Crystal structure of porcine heart mitochondrial complex II bound with N-Biphenyl-3-yl-2-iodo-benzamide
3ABV	;	3.24	;	Crystal structure of porcine heart mitochondrial complex II bound with N-Biphenyl-3-yl-2-trifluoromethyl-benzamide
3AE1	;	3.139	;	Crystal structure of porcine heart mitochondrial complex II bound with N-Phenyl-2-(trifluoromethyl)-benzamide
4YTP	;	3.1	;	CRYSTAL STRUCTURE OF PORCINE HEART MITOCHONDRIAL COMPLEX II BOUND WITH N-[(4-tert-butylphenyl)methyl]-2-(trifluoromethyl)benzamide
3AEF	;	2.8	;	Crystal structure of porcine heart mitochondrial complex II with an empty quinone-binding pocket
6QFY	;	2.97	;	CRYSTAL STRUCTURE OF PORCINE HEMAGGLUTINATING ENCEPHALOMYELITIS VIRUS SPIKE PROTEIN LECTIN DOMAIN
5WWV	;	3.2	;	Crystal structure of porcine kidney D-amino acid oxidase mutant (I230A/R283G)
5WX2	;	3.0	;	Crystal structure of porcine kidney D-amino acid oxidase mutant (I230A/R283G)
3SFD	;	2.61	;	crystal structure of porcine mitochondrial respiratory complex II bound with oxaloacetate and pentachlorophenol
3SFE	;	2.81	;	crystal structure of porcine mitochondrial respiratory complex II bound with oxaloacetate and thiabendazole
4RWP	;	2.25	;	Crystal structure of porcine OAS1 in complex with dsRNA
1Q8H	;	2.0	;	Crystal structure of porcine osteocalcin
6QBU	;	1.38	;	Crystal structure of Porcine Pancreatic Elastase (PPE) in complex with the 3-Oxo-beta-Sultam inhibitor LMC188
6QEN	;	1.195	;	Crystal structure of Porcine Pancreatic Elastase (PPE) in complex with the 3-Oxo-beta-Sultam inhibitor LMC240
6QEO	;	1.3	;	Crystal structure of Porcine Pancreatic Elastase (PPE) in complex with the 3-Oxo-beta-Sultam inhibitor LMC269
4YM9	;	1.8	;	Crystal structure of Porcine Pancreatic Elastase (PPE) in complex with the novel inhibitor JM102
2CV3	;	1.9	;	Crystal structure of porcine pancreatic elastase complexed with a macroclyclic peptide inhibitor
2DE9	;	1.3	;	Crystal structure of porcine pancreatic elastase complexed with Tris after soaking a tris-free solution
2DE8	;	1.5	;	Crystal structure of porcine pancreatic elastase with a unique conformation induced by Tris
1B0E	;	1.8	;	CRYSTAL STRUCTURE OF PORCINE PANCREATIC ELASTASE WITH MDL 101,146
4DBK	;	2.3	;	Crystal structure of porcine pancreatic phospholipase A2 complexed with berberine
3L30	;	2.4	;	Crystal structure of porcine pancreatic phospholipase A2 complexed with dihydroxyberberine
3O4M	;	2.5	;	Crystal structure of porcine pancreatic phospholipase A2 in complex with 1,2-dihydroxybenzene
4O1Y	;	2.5	;	Crystal structure of Porcine Pancreatic Phospholipase A2 in complex with 1-Naphthaleneacetic acid
3HSW	;	2.5	;	Crystal Structure of Porcine Pancreatic Phospholipase A2 in Complex with 2-methoxycyclohexa-2-5-diene-1,4-dione
2AZY	;	1.9	;	Crystal Structure of Porcine Pancreatic Phospholipase A2 in Complex with Cholate
2B04	;	2.5	;	Crystal Structure of Porcine Pancreatic Phospholipase A2 in Complex with Glycochenodeoxycholate
2B00	;	1.85	;	Crystal Structure of Porcine Pancreatic Phospholipase A2 in Complex with Glycocholate
3QLM	;	2.5	;	Crystal structure of porcine pancreatic phospholipase A2 in complex with n-hexadecanoic acid
2B01	;	2.2	;	Crystal Structure of Porcine Pancreatic Phospholipase A2 in Complex with Taurochenodeoxycholate
2B03	;	2.3	;	Crystal Structure of Porcine Pancreatic Phospholipase A2 in Complex with Taurochenodeoxycholate
2AZZ	;	2.2	;	Crystal Structure of Porcine Pancreatic Phospholipase A2 in Complex with Taurocholate
4G5I	;	2.4	;	Crystal Structure of Porcine pancreatic PlA2 in complex with DBP
5XW8	;	2.002	;	Crystal Structure of Porcine pancreatic trypsin with tripeptide inhibitor, PRN, at pH 7
5XW1	;	1.9	;	Crystal Structure of Porcine pancreatic trypsin with tripeptide inhibitor, PRN, at pH10
5XWA	;	1.9	;	Crystal Structure of Porcine pancreatic trypsin with tripeptide inhibitor, PRY, at pH 10
5XW9	;	2.0	;	Crystal Structure of Porcine pancreatic trypsin with tripeptide inhibitor, PRY, at pH 7
5XWL	;	2.1	;	Crystal Structure of Porcine pancreatic trypsin with tripeptide inhibitor, TRE, at pH 10
5XWJ	;	1.8	;	Crystal Structure of Porcine pancreatic trypsin with tripeptide inhibitor, TRE, at pH 7
5AR6	;	1.25	;	crystal structure of porcine RNase 4
5ARJ	;	2.9	;	crystal structure of porcine RNase 4 D80A mutant
5ARL	;	2.61	;	crystal structure of porcine RNase 4 D80A mutant in complex with dCMP
5ARK	;	2.28	;	crystal structure of porcine RNase 4 in complex with dUMP
3TAY	;	1.85	;	Crystal structure of porcine rotavirus CRW-8 VP8* in complex with N-glycolylneuraminic acid
1N5D	;	2.3	;	CRYSTAL STRUCTURE OF PORCINE TESTICULAR CARBONYL REDUCTASE/ 20BETA-HYDROXYSTEROID DEHYDROGENASE
2AMP	;	2.7	;	Crystal Structure Of Porcine Transmissible Gastroenteritis Virus Mpro in Complex with an Inhibitor N1
1I8J	;	1.9	;	CRYSTAL STRUCTURE OF PORPHOBILINOGEN SYNTHASE COMPLEXED WITH THE INHIBITOR 4,7-DIOXOSEBACIC ACID
1L6S	;	1.7	;	Crystal Structure of Porphobilinogen Synthase Complexed with the Inhibitor 4,7-Dioxosebacic Acid
1L6Y	;	1.9	;	Crystal Structure of Porphobilinogen Synthase Complexed with the Inhibitor 4-Oxosebacic Acid
3ILF	;	1.8	;	Crystal structure of porphyranase A (PorA) in complex with neo-porphyrotetraose
3JUU	;	1.8	;	Crystal structure of porphyranase B (PorB) from Zobellia galactanivorans
5JXK	;	2.85	;	Crystal structure of Porphyromonas endodontalis DPP11
5JXP	;	2.5	;	Crystal structure of Porphyromonas endodontalis DPP11 in alternate conformation
5JWG	;	2.2	;	Crystal structure of Porphyromonas endodontalis DPP11 in complex with dipeptide Arg-Asp
5JWI	;	2.1	;	Crystal structure of Porphyromonas endodontalis DPP11 in complex with dipeptide Arg-Glu
5JY0	;	2.599	;	Crystal structure of Porphyromonas endodontalis DPP11 in complex with substrate
6IOY	;	1.94	;	Crystal structure of Porphyromonas gingivalis acetate kinase
5OLJ	;	2.2	;	Crystal structure of Porphyromonas gingivalis dipeptidyl peptidase 4
5JWF	;	2.4	;	Crystal structure of Porphyromonas gingivalis DPP11
4IQL	;	1.938	;	Crystal Structure of Porphyromonas gingivalis Enoyl-ACP Reductase II (FabK) with cofactors NADPH and FMN
6QQL	;	2.814	;	Crystal structure of Porphyromonas gingivalis glutaminyl cyclase
4YTB	;	1.4	;	Crystal structure of Porphyromonas gingivalis peptidylarginine deiminase (PPAD) in complex with dipeptide Asp-Gln.
4YTG	;	1.8	;	Crystal structure of Porphyromonas gingivalis peptidylarginine deiminase (PPAD) mutant C351A in complex with dipeptide Met-Arg.
4YT9	;	1.5	;	Crystal structure of Porphyromonas gingivalis peptidylarginine deiminase (PPAD) substrate-unbound.
6IOW	;	1.7	;	Crystal structure of Porphyromonas gingivalis phosphotransacetylase
6IOX	;	2.04	;	Crystal structure of Porphyromonas gingivalis phosphotransacetylase in complex with acetyl-CoA
8FEB	;	1.84	;	Crystal Structure of Porphyromonas gingivalis Sialidase (PG_0352)
8T1Z	;	1.93	;	Crystal Structure of Porphyromonas gingivalis Sialidase (PG_0352) Bound to Neu5Ac (NANA)
8T1Y	;	2.14	;	Crystal Structure of Porphyromonas gingivalis Sialidase (PG_0352) Bound to Neu5Ac2en (DANA)
8T26	;	1.42	;	Crystal Structure of Porphyromonas gingivalis Sialidase (PG_0352) D219A mutant bound to 3'-Sialyllactose (only Neu5Ac visible)
8T27	;	1.41	;	Crystal Structure of Porphyromonas gingivalis Sialidase (PG_0352) D219A mutant bound to 6'-Sialyllactose (only Neu5Ac visible)
8T24	;	2.29	;	Crystal Structure of Porphyromonas gingivalis Sialidase (PG_0352)- Fructose bound in CBM
1UER	;	1.6	;	Crystal structure of Porphyromonas gingivalis SOD
1UES	;	1.6	;	Crystal structure of Porphyromonas gingivalis SOD
8P6F	;	2.0	;	Crystal structure of PorX-Fj
2AJR	;	2.46	;	Crystal structure of Possible 1-phosphofructokinase (EC 2.7.1.56) (tm0828) from Thermotoga Maritima at 2.46 A resolution
3FZ5	;	2.4	;	Crystal structure of possible 2-hydroxychromene-2-carboxylate isomerase from Rhodobacter sphaeroides
4E98	;	2.0	;	Crystal structure of possible CutA1 divalent ion tolerance protein from Cryptosporidium parvum Iowa II
2HX1	;	2.1	;	Crystal structure of possible sugar phosphatase, HAD superfamily (ZP_00311070.1) from CYTOPHAGA HUTCHINSONII ATCC 33406 at 2.10 A resolution
3F6V	;	1.48	;	Crystal structure of Possible transcriptional regulator for arsenical resistance
3GW2	;	2.1	;	Crystal structure of possible transcriptional regulatory protein (fragment 1-100) from Mycobacterium bovis. Northeast Structural Genomics Consortium Target MbR242E.
6M1V	;	1.5	;	Crystal structure of post fusion core of 2019-nCoV S2 subunit
4QAX	;	2.0	;	Crystal structure of post-catalytic binary complex of Phosphoglycerate mutase from Staphylococcus aureus
3M6H	;	1.994	;	Crystal Structure of Post-isomerized Ertapenem Covalent Adduct with TB B-lactamase
7R97	;	1.804	;	Crystal structure of postcleavge complex of Escherichia coli RNase III
1QZG	;	1.9	;	Crystal structure of Pot1 (protection of telomere)- ssDNA complex
1QZH	;	2.4	;	Crystal structure of Pot1 (protection of telomere)- ssDNA complex
2NZ0	;	3.2	;	Crystal structure of potassium channel Kv4.3 in complex with its regulatory subunit KChIP1
7DMR	;	2.2	;	Crystal structure of potassium induced heme modification in yak lactoperoxidase at 2.20 A resolution
6L32	;	2.3	;	Crystal structure of potassium induced heme modification in yak lactoperoxidase at 2.30 A resolution
4PV2	;	1.79	;	Crystal structure of potassium-dependent plant-type L-asparaginase from Phaseolus vulgaris in complex with K+ and Na+ cations
4PU6	;	2.3	;	Crystal structure of potassium-dependent plant-type L-asparaginase from Phaseolus vulgaris in complex with K+ cations
4PV3	;	2.09	;	Crystal structure of potassium-dependent plant-type L-asparaginase from Phaseolus vulgaris in complex with Na+ cations
2GEZ	;	2.6	;	Crystal structure of potassium-independent plant asparaginase
7XBQ	;	2.45	;	Crystal structure of potato 14-3-3 protein St14f
1RFJ	;	2.0	;	Crystal Structure of Potato Calmodulin PCM6
7RLM	;	1.8	;	Crystal Structure of Potato Leafroll Virus (PLRV) Coat Protein
2W9P	;	2.7	;	Crystal Structure of Potato Multicystatin
2W9Q	;	2.5	;	Crystal Structure of Potato Multicystatin-P212121
4M70	;	2.103	;	Crystal structure of potato Rx-CC domain in complex with RanGAP2-WPP domain
3TC2	;	1.6	;	Crystal structure of potato serine protease inhibitor.
5FZZ	;	2.55	;	CRYSTAL STRUCTURE OF POTATO STI-KUNITZ BI-FUNCTIONAL INHIBITOR OF SERINE AND ASPARTIC PROTEASES IN SPACE GROUP P22121 AND PH 7.0
1YP2	;	2.11	;	Crystal structure of potato tuber ADP-glucose pyrophosphorylase
1YP4	;	2.3	;	Crystal structure of potato tuber ADP-glucose pyrophosphorylase in complex with ADP-glucose
1YP3	;	2.6	;	Crystal structure of potato tuber ADP-glucose pyrophosphorylase in complex with ATP
5MUT	;	1.75	;	Crystal structure of potent human Dihydroorotate Dehydrogenase inhibitors based on hydroxylated azole scaffolds
5MVC	;	1.85	;	Crystal structure of potent human Dihydroorotate Dehydrogenase inhibitors based on hydroxylated azole scaffolds
5MVD	;	1.95	;	Crystal structure of potent human Dihydroorotate Dehydrogenase inhibitors based on hydroxylated azole scaffolds
7TTY	;	3.11	;	Crystal structure of potent neutralizing antibody 10-40 in complex with bat WIV1 receptor-binding domain
7TTX	;	2.8	;	Crystal structure of potent neutralizing antibody 10-40 in complex with Sarbecovirus bat RaTG13 receptor-binding domain
7TTM	;	2.24	;	Crystal structure of potent neutralizing antibody 10-40 in complex with Sarbecovirus bat SHC014 receptor-binding domain
6C6Z	;	2.1	;	Crystal structure of potent neutralizing antibody CDC2-C2 in complex with MERS-CoV S1 RBD
4XAK	;	2.45	;	Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD
8DFG	;	2.0	;	Crystal structure of potently neutralizing human monoclonal antibody 42D6 Fab in complex with MSP1-19
8OXK	;	1.37	;	crystal structure of powdery mildews Blumeria graminis f. sp. hordei AVRA10
8OXJ	;	1.64	;	crystal structure of powdery mildews Blumeria graminis f. sp. hordei AVRA22
8OXH	;	2.5	;	crystal structure of powdery mildews Blumeria graminis f. sp. hordei AVRA6
8OXL	;	1.56	;	crystal structure of powdery mildews Blumeria graminis f. sp. hordei AVRA7
8PHY	;	1.06	;	crystal structure of powdery mildews Blumeria graminis f. sp. tritici AVRPM2 (2)
8OXI	;	1.51	;	crystal structure of powdery mildews Blumeria graminis f. sp. tritici AVRPM2(1)
5XXE	;	2.5	;	Crystal structure of Poz1 and Tpz1
5XXF	;	3.1	;	Crystal structure of Poz1, Tpz1 and Rap1
2D7R	;	2.8	;	Crystal structure of pp-GalNAc-T10 complexed with GalNAc-Ser on lectin domain
2D7I	;	2.5	;	Crystal structure of pp-GalNAc-T10 with UDP, GalNAc and Mn2+
4RAF	;	2.001	;	Crystal structure of PP2Ca-D38A
2JE0	;	2.4	;	Crystal Structure of pp32
1Y0S	;	2.65	;	Crystal structure of PPAR delta complexed with GW2331
8CPJ	;	2.4	;	Crystal structure of PPAR gamma (PPARG) in an inactive form
8ATY	;	1.9	;	Crystal structure of PPAR gamma (PPARG) in complex with JP85 (compound 1).
8ATZ	;	1.95	;	Crystal structure of PPAR gamma (PPARG) in complex with SA112 (compound 2).
8CPI	;	2.1	;	Crystal structure of PPAR gamma (PPARG) in complex with WY-14643
8CPH	;	2.4	;	Crystal structure of PPAR gamma (PPARG) in complex with WY-14643 (inactive form)
6DCU	;	2.95	;	Crystal structure of PPAR gamma co-crystallized with nTZDpa
2Q6R	;	2.407	;	Crystal structure of PPAR gamma complexed with partial agonist SF147
7RLE	;	2.5	;	Crystal structure of PPAR gamma in complex with CREB-binding protein and agonist GW1929
6D94	;	1.9	;	Crystal structure of PPAR gamma in complex with Mediator of RNA polymerase II transcription subunit 1
6DBH	;	2.597	;	Crystal structure of PPAR gamma in complex with NMP422
3T03	;	2.1	;	Crystal structure of PPAR gamma ligand binding domain in complex with a novel partial agonist GQ-16
2HFP	;	2.0	;	Crystal Structure of PPAR Gamma with N-sulfonyl-2-indole carboxamide ligands
3D5F	;	2.2	;	Crystal Structure of PPAR-delta complex
3CDP	;	2.8	;	Crystal structure of PPAR-gamma LBD complexed with a partial agonist, analogue of clofibric acid
2REW	;	2.35	;	Crystal Structure of PPARalpha ligand binding domain with BMS-631707
8B93	;	2.21	;	Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 15b)
8AQM	;	2.3	;	Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 6a)
8B8W	;	1.86	;	Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 7a)
8B90	;	2.1	;	Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 7d)
8B8Y	;	2.0	;	Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 7e)
8B92	;	1.66	;	Crystal structure of PPARG and NCOR2 with an inverse agonist (compound SI-2)
8AQN	;	1.9	;	Crystal structure of PPARG and NCOR2 with BAY-4931, an inverse agonist (compound 6c)
8B94	;	1.55	;	Crystal structure of PPARG and NCOR2 with BAY-5516, an inverse agonist
8B95	;	1.72	;	Crystal structure of PPARG and NCOR2 with BAY-9683, an inverse agonist
8B8X	;	1.78	;	Crystal structure of PPARG and NCOR2 with SR10221, an inverse agonist
3FUR	;	2.3	;	Crystal Structure of PPARg in complex with INT131
3K8S	;	2.55	;	Crystal Structure of PPARg in complex with T2384
8HHP	;	2.45	;	Crystal structure of PPARg-LBD complexed with three partial agonists, one nTZDpa and two LT175
2Q5P	;	2.3	;	Crystal Structure of PPARgamma bound to partial agonist MRL24
2Q5S	;	2.05	;	Crystal Structure of PPARgamma bound to partial agonist nTZDpa
3VN2	;	2.18	;	Crystal Structure of PPARgamma complexed with Telmisartan
6Y3U	;	2.62	;	Crystal structure of PPARgamma in complex with compound (R)-16
4HEE	;	2.5	;	Crystal structure of PPARgamma in complex with compound 13
6T6B	;	2.8	;	Crystal structure of PPARgamma in complex with compound 16 (MF27)
7P4E	;	2.4	;	Crystal structure of PPARgamma in complex with compound FL217
7A7H	;	2.4	;	Crystal structure of PPARgamma in complex with compound TK90
4R2U	;	2.3	;	Crystal Structure of PPARgamma in complex with SR1664
2Q59	;	2.2	;	Crystal Structure of PPARgamma LBD bound to full agonist MRL20
2Q61	;	2.197	;	Crystal Structure of PPARgamma ligand binding domain bound to partial agonist SR145
6K0T	;	1.84	;	Crystal Structure of PPARgamma Ligand Binding Domain in complex with dibenzooxepine derivative compound-17
6AD9	;	2.2	;	Crystal Structure of PPARgamma Ligand Binding Domain in complex with dibenzooxepine derivative compound-9
3PBA	;	2.3	;	Crystal structure of PPARgamma ligand binding domain in complex with monosulfate tetrabromo-bisphenol A (MonoTBBPA)
6ONI	;	1.8	;	Crystal structure of PPARgamma ligand binding domain in complex with N-CoR peptide and inverse agonist T0070907
6PDZ	;	2.1	;	Crystal structure of PPARgamma ligand binding domain in complex with SMRT peptide and inverse agonist T0070907
3OSW	;	2.55	;	Crystal structure of PPARgamma ligand binding domain in complex with tetrabromo-bisphenol A (TBBPA)
3OSI	;	2.7	;	Crystal structure of PPARgamma ligand binding domain in complex with tetrachloro-bisphenol A (TCBPA)
6ONJ	;	2.3	;	Crystal structure of PPARgamma ligand binding domain in complex with TRAP220 peptide and agonist rosiglitazone
3WJ4	;	1.95	;	Crystal structure of PPARgamma ligand binding domain in complex with tributyltin
3WJ5	;	1.89	;	Crystal structure of PPARgamma ligand binding domain in complex with triphenyltin
3PO9	;	2.35	;	Crystal structure of PPARgamma ligand binding domain in complex with tripropyltin
8FHE	;	1.8	;	Crystal structure of PPARgamma ligand-binding domain in complex with N-CoR peptide and GW9662
8FHG	;	1.8	;	Crystal structure of PPARgamma ligand-binding domain in complex with N-CoR peptide and ZINC5672437
8FHF	;	2.1	;	Crystal structure of PPARgamma ligand-binding domain in complex with ZINC5672437
7AHJ	;	2.1	;	Crystal structure of PPARgamma V290M mutant ligand binding domain in complex with farglitazar
3R8I	;	2.3	;	Crystal Structure of PPARgamma with an achiral ureidofibrate derivative (RT86)
6ILQ	;	2.408	;	Crystal structure of PPARgamma with compound BR101549
6ICJ	;	2.483	;	Crystal structure of PPARgamma with compound BR102375K
4E4Q	;	2.5	;	Crystal structure of PPARgamma with the ligand FS214
4E4K	;	2.5	;	Crystal Structure of PPARgamma with the ligand JO21
3R5N	;	2.0	;	Crystal structure of PPARgammaLBD complexed with the agonist magnolol
4R6S	;	2.301	;	Crystal structure of PPARgammma in complex with SR1663
6DJW	;	3.801	;	Crystal Structure of pParkin (REP and RING2 deleted)-pUb-UbcH7 complex
6DJX	;	4.801	;	Crystal Structure of pParkin-pUb-UbcH7 complex
8GN2	;	1.95	;	Crystal structure of PPBQ-bound photosystem II complex
4RAG	;	1.85	;	CRYSTAL STRUCTURE of PPC2A-D38K
4HDL	;	1.9	;	Crystal structure of PpcA F15L mutant
4HB6	;	1.9	;	Crystal structure of PpcA K22E mutant
4HB8	;	1.9	;	Crystal structure of PpcA K22Q mutant
4HAJ	;	1.9	;	Crystal structure of PpcA K9E mutant
4HBF	;	1.9	;	Crystal structure of PpcA V13A mutant
4HC3	;	1.95	;	Crystal structure of PpcA V13T mutant
6R59	;	1.65	;	Crystal structure of PPEP-1(E143A/Y178F) in complex with substrate peptide Ac-EVAPPVP-NH2
6R4X	;	1.831	;	Crystal structure of PPEP-1(E143A/Y178F) in complex with substrate peptide Ac-EVNPAVP-CONH2
6R58	;	1.9	;	Crystal structure of PPEP-1(E143A/Y178F/E184A) in complex with substrate peptide Ac-EVNAPVP-CONH2
6R57	;	1.899	;	Crystal structure of PPEP-1(E143A/Y178F/E184A) in complex with substrate peptide Ac-EVNPPVP-CONH2
6R54	;	1.417	;	Crystal structure of PPEP-1(E184A)
6R55	;	1.401	;	Crystal structure of PPEP-1(E184K)
6R52	;	2.022	;	Crystal structure of PPEP-1(K101A)
6R56	;	1.77	;	Crystal structure of PPEP-1(K101E/E184K)
6R53	;	1.798	;	Crystal structure of PPEP-1(K101R)
6R5A	;	1.48	;	Crystal structure of PPEP-1(W103F)
6R5C	;	1.881	;	Crystal structure of PPEP-1(W103F/E143A/Y178F) in complex with substrate peptide Ac-EVNPPVP-CONH2
6R5B	;	2.06	;	Crystal structure of PPEP-1(W103H/E143A/Y178F) in complex with substrate peptide Ac-EVNPPVP-CONH2
6G14	;	1.8	;	Crystal structure of ppGpp bound RbgA from S. aureus
8HM4	;	3.79	;	Crystal structure of PPIase
3GPK	;	1.55	;	Crystal Structure of PpiC-type peptidyl-prolyl cis-trans isomerase domain at 1.55A resolution.
6AU0	;	2.1	;	Crystal structure of PPK2 (Class III) in complex with bisphosphonate inhibitor (2-((3,5-dichlorophenyl)amino)ethane-1,1-diyl)diphosphonic acid
6AN9	;	1.891	;	Crystal structure of PPk2 class III in complex with ADP from Cytophaga hutchinsonii ATCC 33406
6ANH	;	2.65	;	Crystal structure of PPK2 class III in complex with Guanosine 5-tetraphosphate
6ANG	;	2.45	;	Crystal structure of PPK2 Class III in the complex with AMP from Cytophaga hutchinsonii ATCC 33406
6AQE	;	1.805	;	Crystal structure of PPK2 in complex with Mg ATP
6AQN	;	2.199	;	Crystal structure of PPK2 in complex with phosphonic acid inhibitor
6B18	;	2.3	;	Crystal structure of PPK3 Class III in complex with inhibitor
5HNV	;	1.41	;	Crystal structure of PpkA
5YRE	;	1.4	;	Crystal structure of PPL3A
5YRH	;	1.2	;	Crystal structure of PPL3B
5YRK	;	1.35	;	Crystal structure of PPL3C
6AK7	;	2.605	;	Crystal structure of PPM1K-N94K
3I6D	;	2.9	;	Crystal structure of PPO from bacillus subtilis with AF
2Y9W	;	2.3	;	Crystal structure of PPO3, a tyrosinase from Agaricus bisporus, in deoxy-form that contains additional unknown lectin-like subunit
2Y9X	;	2.78	;	Crystal structure of PPO3, a tyrosinase from Agaricus bisporus, in deoxy-form that contains additional unknown lectin-like subunit, with inhibitor tropolone
6G15	;	1.65	;	Crystal structure of pppGpp bound RbgA from S. aureus
6A29	;	2.399	;	Crystal structure of PprA A139R mutant
6MC8	;	2.5	;	Crystal structure of PprA dimer from Deinococcus deserti
6O5L	;	3.3	;	Crystal structure of PprA filament from Deinococcus peraridilitoris
6MC6	;	2.747	;	Crystal structure of PprA filament from Deinococcus radiodurans
6NEO	;	5.94	;	Crystal structure of PprA filament from Deinococcus radiodurans
6BDU	;	2.0	;	Crystal structure of PprA from Deinococcus radiodurans
6A27	;	1.353	;	Crystal structure of PprA W183R mutant form 1
6A28	;	2.193	;	Crystal structure of PprA W183R mutant form 2
8Q5E	;	2.4	;	Crystal structure of PpSB1-LOV protein from Pseudomonas putida with covalent FMN
7R4S	;	2.75	;	Crystal structure of PpSB1-LOV-I48T mutant (dark state)
7R56	;	2.85	;	Crystal structure of PpSB1-LOV-I48T mutant (light state)
8A36	;	2.7	;	Crystal structure of PpSB1-LOV-K117E mutant (dark state), monoclinic form
8A37	;	1.91	;	Crystal structure of PpSB1-LOV-K117E mutant (dark state), tetragonal form
8A33	;	2.95	;	Crystal structure of PpSB1-LOV-K117E mutant (light state)
4JBD	;	1.3	;	Crystal structure of Pput_1285, a putative hydroxyproline epimerase from Pseudomonas putida f1 (target EFI-506500), open form, space group I2, bound citrate
4JD7	;	1.5	;	Crystal structure of pput_1285, a putative hydroxyproline epimerase from Pseudomonas putida f1 (target EFI-506500), open form, space group P212121, bound sulfate
4CDO	;	2.5	;	Crystal structure of PQBP1 bound to spliceosomal U5-15kD
6JT5	;	1.5	;	Crystal structure of PQQ doamin of Pyranose Dehydrogenase from Coprinopsis cinerea: apo-from
3A9G	;	2.39	;	Crystal Structure of PQQ-dependent sugar dehydrogenase apo-form
3A9H	;	2.5	;	Crystal Structure of PQQ-dependent sugar dehydrogenase holo-form
3HML	;	2.35	;	Crystal Structure of PqqC Active Site Mutant H154S in Complex with PQQ
3HLX	;	1.3	;	Crystal Structure of PqqC Active Site Mutant Y175F in Complex with PQQ
3HNH	;	1.8	;	Crystal Structure of PqqC Active Site Mutant Y175S,R179S in complex with a reaction intermediate
1OTW	;	2.3	;	Crystal structure of PqqC in complex with PQQ and a putative H2O2
3G2B	;	1.66	;	crystal structure of PqqD from xanthomonas campestris
5CIO	;	2.5	;	Crystal structure of PqqF
5HIQ	;	2.1	;	Crystal Structure of PQS Response Protein PqsE in Complex with 2-(1H-pyrrol-1-yl)benzoic acid
5HIP	;	1.992	;	Crystal Structure of PQS Response Protein PqsE in Complex with 2-(pyridin-3-yl)benzoic acid
5HIO	;	1.9	;	Crystal Structure of PQS Response Protein PqsE in Complex with 2-aminobenzoylacetate
5HIS	;	1.77	;	Crystal Structure of PQS Response Protein PqsE in Complex with 3-methylthiophene-2-carboxylic acid
6ET0	;	1.53	;	Crystal structure of PqsBC (C129A) mutant from Pseudomonas aeruginosa (crystal form 1)
6ET2	;	2.6	;	Crystal structure of PqsBC (C129A) mutant from Pseudomonas aeruginosa (crystal form 3)
6ET3	;	2.25	;	Crystal structure of PqsBC (C129S) mutant from Pseudomonas aeruginosa (crystal form 4)
6ESZ	;	1.84	;	Crystal structure of PqsBC from Pseudomonas aeruginosa (crystal form 1)
6ET1	;	2.65	;	Crystal structure of PqsBC from Pseudomonas aeruginosa (crystal form 2)
3H76	;	1.8	;	Crystal structure of PqsD, a key enzyme in Pseudomonas aeruginosa quinolone signal biosynthesis pathway
2X3N	;	1.75	;	Crystal structure of pqsL, a probable FAD-dependent monooxygenase from Pseudomonas aeruginosa
6FHO	;	1.75	;	Crystal structure of pqsL, a probable FAD-dependent monooxygenase from Pseudomonas aeruginosa - new refinement
7P4U	;	2.74	;	Crystal structure of PqsR (MvfR) ligand-binding domain in complex with 3-PYRIDIN-4-YL-2,4-DIHYDRO-INDENO[1,2-.C.]PYRAZOLE
7NBW	;	2.28	;	Crystal structure of PqsR (MvfR) ligand-binding domain in complex with a pyridin agonist
6Q7V	;	2.56	;	Crystal structure of PqsR (MvfR) ligand-binding domain in complex with compound 11
7QA0	;	2.67	;	Crystal structure of PqsR (MvfR) ligand-binding domain in complex with compound 1456
6Q7W	;	2.82	;	Crystal structure of PqsR (MvfR) ligand-binding domain in complex with compound 20
7QAV	;	2.65	;	Crystal structure of PqsR (MvfR) ligand-binding domain in complex with compound N-((2-(4-cyclopropylphenyl)thiazol-5-yl)methyl)-2-(trifluoromethyl)pyridin-4-amine
7QA3	;	2.67	;	Crystal structure of PqsR (MvfR) ligand-binding domain in complex with compound N-((2-(4-phenoxyphenyl)thiazol-5-yl)methyl)-2-(trifluoromethyl)pyridin-4-amine
6Q7U	;	3.14	;	Crystal structure of PqsR (MvfR) ligand-binding domain in complex with HHQ
6YIZ	;	2.163	;	Crystal structure of PqsR (MvfR) ligand-binding domain in complex with triazolo-pyridine inverse agonist A
4JVC	;	2.5	;	Crystal structure of PqsR co-inducer binding domain
4JVI	;	2.9	;	Crystal structure of PqsR co-inducer binding domain of Pseudomonas aeruginosa with inhibitor 3NH2-7Cl-C9QZN
4JVD	;	2.95	;	Crystal structure of PqsR coinducer binding domain of Pseudomonas aeruginosa with ligand NHQ
7E1I	;	3.301	;	Crystal structure of Pr55Gag-matrix domain in complex with IP6 at ambient temperature in space group P1
7E1J	;	2.72	;	Crystal structure of Pr55Gag-matrix domain in complex with IP6 in space group C121
7E1K	;	2.4	;	Crystal structure of Pr55Gag-matrix domain in complex with IP6 in space group R32
5JH9	;	2.1	;	Crystal structure of prApe1
3QA9	;	1.9	;	Crystal Structure of Prb (PH1109 protein redesigned for binding)
6IQS	;	2.69	;	Crystal structure of Prc with L245A and L340G mutations in complex with NlpI
6IQU	;	2.9	;	Crystal structure of Prc with PDZ domain deletion in complex with NlpI
6IQR	;	3.42	;	Crystal structure of Prc with S452I and L252Y mutations
6IQQ	;	2.8	;	Crystal structure of Prc with S452I and L252Y mutations in complex with NlpI
3HTR	;	2.06	;	Crystal Structure of PRC-barrel Domain Protein from Rhodopseudomonas palustris
3FZY	;	1.95	;	Crystal Structure of Pre-cleavage Form of Cysteine Protease Domain from Vibrio cholerae RtxA Toxin
5DWA	;	1.5	;	Crystal structure of pre-specific restriction endonuclease AgeI-DNA complex
4ZSF	;	1.8	;	Crystal structure of pre-specific restriction endonuclease BsaWI-DNA complex
3NDC	;	2.0	;	Crystal structure of Precorrin-4 C11-methyltransferase from Rhodobacter capsulatus
3NEI	;	2.5	;	Crystal structure of Precorrin-4 C11-methyltransferase from Rhodobacter capsulatus (no SAH bound)
3ND1	;	1.5	;	Crystal structure of Precorrin-6A synthase from Rhodobacter capsulatus
3E05	;	1.8	;	CRYSTAL STRUCTURE OF Precorrin-6y C5,15-methyltransferase FROM Geobacter metallireducens GS-15
3E7D	;	1.8	;	Crystal Structure of Precorrin-8X Methyl Mutase CbiC/CobH from Brucella melitensis
1QXT	;	2.0	;	Crystal structure of precyclized intermediate for the green fluorescent protein R96A variant (A)
1QY3	;	2.0	;	Crystal structure of precyclized intermediate for the green fluorescent protein R96A variant (B)
3B9T	;	1.58	;	Crystal structure of predicted acetamidase/formamidase (YP_546212.1) from Methylobacillus flagellatus KT at 1.58 A resolution
3MGD	;	1.9	;	Crystal Structure of predicted acetyltransferase with acetyl-CoA from Clostridium acetobutylicum at the resolution 1.9A, Northeast Structural Genomics Consortium Target CaR165
5I0C	;	1.92	;	Crystal structure of predicted acyltransferase YjdJ with acyl-CoA N-acyltransferase domain from Escherichia coli str. K-12
2R1F	;	2.21	;	Crystal structure of predicted aminodeoxychorismate lyase from Escherichia coli
3BDI	;	1.45	;	Crystal structure of predicted CIB-like hydrolase (NP_393672.1) from Thermoplasma acidophilum at 1.45 A resolution
3B81	;	2.1	;	Crystal structure of predicted DNA-binding transcriptional regulator of TetR/AcrR family (NP_350189.1) from Clostridium acetobutylicum at 2.10 A resolution
4TN5	;	2.285	;	Crystal Structure of Predicted Fructose Specific IIB from Escherichia Coli
2PQ7	;	1.45	;	Crystal structure of predicted HD superfamily hydrolase (104161995) from uncultured Thermotogales bacterium at 1.45 A resolution
3CCG	;	1.5	;	Crystal structure of predicted HD superfamily hydrolase involved in NAD metabolism (NP_347894.1) from Clostridium acetobutylicum at 1.50 A resolution
3CNH	;	1.66	;	Crystal structure of predicted hydrolase of haloacid dehalogenase-like superfamily (NP_295428.1) from Deinococcus radiodurans at 1.66 A resolution
2HZG	;	2.02	;	Crystal structure of predicted Mandelate racemase from Rhodobacter sphaeroides
2ANU	;	2.4	;	Crystal structure of Predicted metal-dependent phosphoesterase (PHP family) (tm0559) from THERMOTOGA MARITIMA at 2.40 A resolution
3KH1	;	1.37	;	Crystal structure of Predicted metal-dependent phosphohydrolase (ZP_00055740.2) from Magnetospirillum magnetotacticum MS-1 at 1.37 A resolution
4QVT	;	1.948	;	Crystal structure of predicted N-acyltransferase (ypeA) in complex with acetyl-CoA from Escherichia coli
3BQ9	;	1.8	;	Crystal structure of predicted nucleotide-binding protein from Idiomarina baltica OS145
2PMB	;	1.99	;	Crystal structure of predicted nucleotide-binding protein from Vibrio cholerae
3GH1	;	1.9	;	Crystal structure of predicted nucleotide-binding protein from Vibrio cholerae
3B85	;	2.35	;	Crystal structure of predicted phosphate starvation-induced ATPase PhoH2 from Corynebacterium glutamicum
2ZDI	;	3.0	;	Crystal structure of Prefoldin from Pyrococcus horikoshii OT3
5EJB	;	3.2	;	Crystal structure of prefusion Hendra virus F protein
5EA8	;	2.6	;	Crystal Structure of Prefusion RSV F Glycoprotein Fusion Inhibitor Resistance Mutant D489Y
5TDG	;	2.65	;	Crystal structure of prefusion-stabilized bovine RSV F (DS-Cav1 variant: strain ATue51908)
5TDL	;	3.5	;	Crystal structure of prefusion-stabilized bovine RSV fusion glycoprotein (single-chain DS2-v1 variant: strain 391-2 sc9 DS-Cav1 Q98C Q361C)
5K6B	;	2.981	;	Crystal structure of prefusion-stabilized RSV F single-chain 9 DS-Cav1 variant.
5K6H	;	2.648	;	Crystal structure of prefusion-stabilized RSV F single-chain 9-10 DS-Cav1 A149C-Y458C variant.
5K6I	;	2.92	;	Crystal structure of prefusion-stabilized RSV F single-chain 9-10 DS-Cav1 A149C-Y458C, S46G-E92D-S215P-K465Q variant.
5K6C	;	3.576	;	Crystal structure of prefusion-stabilized RSV F single-chain 9-10 DS-Cav1 variant.
5K6F	;	2.59	;	Crystal structure of prefusion-stabilized RSV F single-chain 9-19 DS-Cav1 variant.
5K6G	;	2.9	;	Crystal structure of prefusion-stabilized RSV F single-chain 9-24 DS-Cav1 variant.
4MMS	;	2.397	;	Crystal Structure of Prefusion-stabilized RSV F Variant Cav1 at pH 5.5
4MMR	;	3.1	;	Crystal Structure of Prefusion-stabilized RSV F Variant Cav1 at pH 9.5
4MMQ	;	3.253	;	Crystal Structure of Prefusion-stabilized RSV F Variant DS
4MMU	;	3.0	;	Crystal Structure of Prefusion-stabilized RSV F Variant DS-Cav1 at pH 5.5
4MMT	;	3.05	;	Crystal Structure of Prefusion-stabilized RSV F Variant DS-Cav1 at pH 9.5
8PHI	;	2.289	;	Crystal structure of prefusion-stabilized RSV F Variant DS-Cav1 in complex with Lonafarnib
4MMV	;	2.81	;	Crystal Structure of Prefusion-stabilized RSV F Variant DS-Cav1-TriC at pH 9.5
5C69	;	2.3	;	Crystal Structure of Prefusion-stabilized RSV F variant PR-DM
5C6B	;	2.4	;	Crystal Structure of Prefusion-stabilized RSV F variant SC-TM
8F5Y	;	2.15	;	Crystal structure of pregnane X receptor ligand binding domain complexed with JQ1
8E3N	;	2.25	;	Crystal structure of pregnane X receptor ligand binding domain complexed with rifamycin S
8SZV	;	2.2	;	Crystal structure of pregnane X receptor ligand binding domain complexed with T0901317 analog SJPYT-318
8FPE	;	2.3	;	Crystal structure of pregnane X receptor ligand binding domain complexed with T0901317 analog T0-BP
8EQZ	;	2.37	;	Crystal structure of pregnane X receptor ligand binding domain complexed with T0901317 analog T0-C6
5Z43	;	2.361	;	Crystal structure of prenyltransferase AmbP1 apo structure
5Z44	;	2.458	;	Crystal structure of prenyltransferase AmbP1 complexed with GSPP
5Z45	;	2.601	;	Crystal structure of prenyltransferase AmbP1 pH6.5 complexed with GSPP and cis-indolyl vinyl isonitrile
5Z46	;	1.999	;	Crystal structure of prenyltransferase AmbP1 pH8 complexed with GSPP and cis-indolyl vinyl isonitrile
5JXM	;	1.15	;	Crystal Structure of Prenyltransferase PriB Apo Form
5INJ	;	1.4	;	Crystal Structure of Prenyltransferase PriB Ternary Complex with L-Tryptophan and Dimethylallyl thiolodiphosphate (DMSPP)
6VH5	;	2.4	;	Crystal structure of prephenate dehydratase from brucella melitensis biovar abortus 2308 in complex with phenylalanine
3GGP	;	2.25	;	Crystal structure of prephenate dehydrogenase from A. aeolicus in complex with hydroxyphenyl propionate and NAD+
3GGO	;	2.15	;	Crystal structure of prephenate dehydrogenase from A. aeolicus with HPP and NADH
2G5C	;	1.9	;	Crystal Structure of Prephenate Dehydrogenase from Aquifex aeolicus
3B1F	;	2.1	;	Crystal structure of prephenate dehydrogenase from Streptococcus mutans
3DZB	;	2.46	;	Crystal structure of Prephenate dehydrogenase from Streptococcus thermophilus
5UYY	;	2.6	;	Crystal structure of prephenate dehydrogenase tyrA from Bacillus anthracis in complex with L-tyrosine
6U60	;	2.1	;	Crystal structure of prephenate dehydrogenase tyrA from Bacillus anthracis in complex with NAD and L-tyrosine
2FGE	;	2.1	;	Crystal structure of presequence protease PreP from Arabidopsis thaliana
3K65	;	1.85	;	Crystal Structure of Prethombin-2/Fragment-2 Complex
4H6T	;	2.4	;	Crystal structure of prethrombin-2 mutant E14eA/D14lA/E18A/S195A
3SQE	;	1.9	;	Crystal structure of prethrombin-2 mutant S195A in the alternative form
3SQH	;	2.2	;	Crystal structure of prethrombin-2 mutant S195A in the the open form
6D2W	;	2.1	;	Crystal structure of Prevotella bryantii endo-beta-mannanase/endo-beta-glucanase PbGH26A-GH5A
7R5Y	;	1.97	;	Crystal Structure of Prevotella sp. CAG:617 Multiple Inositol Polyphosphate Phosphatase, complex with myo-inositol hexakissulfate
1OMI	;	2.8	;	Crystal structure of PrfA,the transcriptional regulator in Listeria monocytogenes
5X6D	;	2.94	;	Crystal structure of PrfA-DNA binary complex
5X6E	;	2.99	;	Crystal structure of PrfA-DNA binary complex
4W4M	;	3.2	;	Crystal structure of PrgK 19-92
2AXZ	;	3.0	;	Crystal structure of PrgX/cCF10 complex
2GRM	;	3.0	;	Crystal structure of PrgX/iCF10 complex
4X2R	;	1.05	;	Crystal structure of PriA from Actinomyces urogenitalis
1WOC	;	2.0	;	Crystal structure of PriB
5K9M	;	1.5	;	Crystal Structure of PriB Binary Complex with Product Diphosphate
5WQV	;	1.97	;	Crystal structure of PriB mutant - S55A
1V1Q	;	2.1	;	Crystal structure of PriB- a primosomal DNA replication protein of Escherichia coli
6DHW	;	2.013	;	Crystal structure of primase iron-sulfur domain (266-457)
3H20	;	1.99	;	Crystal structure of primase RepB'
7CUY	;	2.081	;	Crystal structure of Primo-1
3KLW	;	2.0	;	Crystal structure of primosomal replication protein n from Bordetella pertussis. northeast structural genomics consortium target ber132.
4WYH	;	1.95	;	Crystal structure of PriX from the hyperthermophilic archaeon Sulfolobus solfataricus
4OTD	;	2.0	;	Crystal Structure of PRK1 Catalytic Domain
4OTG	;	2.6	;	Crystal Structure of PRK1 Catalytic Domain in Complex with Lestaurtinib
4OTH	;	1.8	;	Crystal Structure of PRK1 Catalytic Domain in Complex with Ro-31-8220
4OTI	;	1.93	;	Crystal Structure of PRK1 Catalytic Domain in Complex with Tofacitinib
5BX1	;	1.9	;	Crystal Structure of PRL-1 complex with compound analogy 3
6WUS	;	2.758	;	Crystal structure of PRL-1 phosphatase C104D mutant in complex with the Bateman domain of CNNM2 magnesium transporter
6WUR	;	2.882	;	Crystal structure of PRL-2 phosphatase C101D mutant in complex with the Bateman domain of CNNM3 magnesium transporter
5TSR	;	3.188	;	Crystal structure of PRL-3 phosphatase in complex with the Bateman domain of CNNM3 magnesium transporter
8G2F	;	2.06	;	Crystal Structure of PRMT3 with Compound II710
8G2G	;	2.02	;	Crystal structure of PRMT3 with compound YD1113
8G2H	;	1.49	;	Crystal Structure of PRMT4 with Compound YD1113
8G2I	;	2.17	;	Crystal Structure of PRMT4 with Compound YD1290
5FA5	;	2.34	;	Crystal Structure of PRMT5:MEP50 in complex with MTA and H4 peptide
5EML	;	2.39	;	Crystal structure of PRMT5:MEP50 with Compound 10 and SAM
5EMM	;	2.37	;	Crystal structure of PRMT5:MEP50 with Compound 15 and sinefungin
5EMJ	;	2.273	;	Crystal structure of PRMT5:MEP50 with Compound 8 and sinefungin
5EMK	;	2.52	;	Crystal structure of PRMT5:MEP50 with Compound 9 and sinefungin
4X63	;	3.05	;	Crystal structure of PRMT5:MEP50 with EPZ015666 and SAH
4X61	;	2.85	;	Crystal structure of PRMT5:MEP50 with EPZ015666 and SAM
4X60	;	2.35	;	Crystal structure of PRMT5:MEP50 with EPZ015666 and sinefungin
5C9Z	;	2.36	;	Crystal structure of PRMT5:MEP50 with EPZ015866 and sinefungin
4LWO	;	2.203	;	Crystal structure of PRMT6
4LWP	;	2.353	;	Crystal structure of PRMT6-SAH
3A56	;	1.728	;	Crystal structure of pro- protein-glutaminase
6MSQ	;	1.28	;	Crystal structure of pRO-2.3
6MSR	;	1.55	;	Crystal structure of pRO-2.5
4JP8	;	2.21	;	Crystal structure of Pro-F17H/S324A
8J6K	;	3.12	;	Crystal structure of pro-interleukin-18 and caspase-4 complex
7ETQ	;	1.04	;	Crystal structure of Pro-Met-Leu-Leu
4QRX	;	3.138	;	Crystal structure of pro-papain mutant at pH 4.0
7ETN	;	0.82	;	Crystal structure of Pro-Phe-Leu-Ile
7ETP	;	1.09488	;	Crystal structure of Pro-Phe-Leu-Phe
7AVM	;	2.8	;	Crystal Structure of Pro-Rhodesain C150A
3WIV	;	1.9	;	Crystal structure of Pro-S324A/D356A
3WIU	;	1.8	;	Crystal structure of Pro-S324A/L349A
3RJR	;	3.05	;	Crystal Structure of pro-TGF beta 1
5VQF	;	2.9	;	Crystal Structure of pro-TGF-beta 1
2E1P	;	2.3	;	Crystal structure of pro-Tk-subtilisin
5HVV	;	1.9	;	Crystal structure of Pro1 deletion and M2A double mutant of Macrophage Migration Inhibitory Factor
4XX8	;	1.77	;	Crystal structure of Pro1 deletion mutant of human macrophage migration inhibitory factor
1IIL	;	2.3	;	CRYSTAL STRUCTURE OF PRO253ARG APERT MUTANT FGF RECEPTOR 2 (FGFR2) IN COMPLEX WITH FGF2
3EGO	;	1.9	;	Crystal structure of Probable 2-dehydropantoate 2-reductase panE from Bacillus Subtilis
4I6K	;	2.276	;	Crystal structure of probable 2-PYRONE-4,6-DICARBOXYLIC ACID HYDROLASE ABAYE1769 (TARGET EFI-505029) from Acinetobacter baumannii with citric acid bound
1NSL	;	2.7	;	Crystal structure of Probable acetyltransferase
2GE3	;	2.25	;	Crystal structure of Probable acetyltransferase from Agrobacterium tumefaciens
3KEW	;	2.0	;	Crystal structure of probable alanyl-trna-synthase from Clostridium perfringens
3K9D	;	2.0	;	CRYSTAL STRUCTURE OF PROBABLE ALDEHYDE DEHYDROGENASE FROM Listeria monocytogenes EGD-e
1V70	;	1.3	;	Crystal Structure of probable antibiotics synthesis protein from Thermus thermophilus HB8
3NXK	;	2.4	;	Crystal Structure of Probable Cytoplasmic L-asparaginase from Campylobacter jejuni
3EZY	;	2.04	;	Crystal structure of probable dehydrogenase TM_0414 from Thermotoga maritima
3MAE	;	2.5	;	CRYSTAL STRUCTURE OF PROBABLE DIHYDROLIPOAMIDE ACETYLTRANSFERASE FROM LISTERIA MONOCYTOGENES 4b F2365
4MK6	;	2.35	;	Crystal Structure of Probable Dihydroxyacetone Kinase Regulator DHSK_reg from Listeria monocytogenes EGD-e
3GL5	;	2.15	;	Crystal structure of probable DsbA oxidoreductase SCO1869 from Streptomyces coelicolor
1WZ8	;	1.8	;	Crystal Structure of Probable Enoyl-CoA Dehydratase from Thermus Thermophilus HB8
4HC8	;	2.51	;	CRYSTAL STRUCTURE OF PROBABLE ENOYL-CoA HYDRATASE ECHA3 (Rv0632c, NYSGRC-019494) from Mycobacterium Tuberculosis H37Rv
3MOY	;	1.5	;	Crystal structure of probable enoyl-CoA hydratase from Mycobacterium smegmatis
3T3W	;	1.8	;	Crystal structure of probable enoyl-COA hydratase from mycobacterium thermoresistibile
3MZN	;	1.85	;	Crystal structure of probable glucarate dehydratase from chromohalobacter salexigens dsm 3043
3NFU	;	1.94	;	Crystal structure of probable glucarate dehydratase from chromohalobacter salexigens dsm 3043 complexed with magnesium
3H1N	;	1.83	;	Crystal structure of probable glutathione S-transferase from Bordetella bronchiseptica RB50
7SZS	;	1.5	;	Crystal Structure of Probable GTP-binding protein EngB bound to GDP from Klebsiella pneumoniae subsp. pneumoniae
3M9L	;	1.6	;	Crystal structure of probable had family hydrolase from pseudomonas fluorescens pf-5
3R09	;	2.2	;	Crystal structure of probable HAD family hydrolase from Pseudomonas fluorescens Pf-5 with bound Mg
2YBD	;	2.001	;	Crystal structure of probable had family hydrolase from pseudomonas fluorescens pf-5 with bound phosphate
4E38	;	1.64	;	Crystal structure of probable keto-hydroxyglutarate-aldolase from Vibrionales bacterium SWAT-3 (Target EFI-502156)
3HCW	;	2.2	;	CRYSTAL STRUCTURE OF PROBABLE maltose operon transcriptional repressor malR FROM STAPHYLOCOCCUS AREUS
4IHC	;	2.0	;	Crystal structure of probable mannonate dehydratase Dd703_0947 (target EFI-502222) from Dickeya dadantii Ech703
3KTY	;	2.302	;	Crystal Structure of Probable Methyltransferase from Bordetella pertussis Tohama I
4YMI	;	1.7	;	Crystal structure of probable nicotinate-nucleotide adenylyltransferase from Mycobacterium abcessus in complex with NADP
5VIR	;	1.7	;	Crystal structure of probable nicotinate-nucleotide adenylyltransferase from Mycobacterium abscessus in complex with NADP and compound FOL0091
3MWC	;	1.8	;	Crystal structure of probable o-succinylbenzoic acid synthetase from kosmotoga olearia
4HAD	;	2.0	;	Crystal structure of probable oxidoreductase protein from Rhizobium etli CFN 42
4JDP	;	1.76	;	Crystal structure of probable p-nitrophenyl phosphatase (pho2) (target EFI-501307) from Archaeoglobus fulgidus DSM 4304 with Magnesium bound
2CZG	;	2.35	;	Crystal structure of Probable phosphoribosylglycinamide formyl transferase (PH0318) from Pyrococcus horikoshii OT3
2DWC	;	1.7	;	Crystal structure of Probable phosphoribosylglycinamide formyl transferase from Pyrococcus horikoshii OT3 complexed with ADP
3N28	;	2.3	;	Crystal structure of probable phosphoserine phosphatase from vibrio cholerae, unliganded form
1Z7A	;	1.71	;	Crystal structure of probable Polysaccharide deacetylase from Pseudomonas aeruginosa PAO1
4Q2H	;	1.8	;	Crystal structure of probable proline racemase from agrobacterium radiobacter K84, TARGET EFI-506561, with bound carbonate
3MGK	;	2.0	;	CRYSTAL STRUCTURE OF PROBABLE PROTEASE/AMIDASE FROM Clostridium acetobutylicum ATCC 824
2CXH	;	1.8	;	Crystal structure of probable ribosomal biogenesis protein from Aeropyrum pernix K1
3KW2	;	2.0	;	Crystal structure of probable rRNA-methyltransferase from Porphyromonas gingivalis
3I3V	;	2.3	;	Crystal Structure of probable secreted solute-binding lipoprotein from Streptomyces coelicolor
3GVC	;	2.45	;	Crystal structure of probable short-chain dehydrogenase-reductase from Mycobacterium tuberculosis
3EFB	;	2.001	;	Crystal Structure of Probable sor Operon Regulator from Shigella flexneri
4E3A	;	1.63	;	CRYSTAL STRUCTURE OF probable sugar kinase protein from Rhizobium etli CFN 42
4K8K	;	1.5	;	Crystal structure of probable sugar kinase protein from Rhizobium etli CFN 42 complexed with 1-(4-methoxyphenyl)-1-cyclopropane and 2-aminoperimidine
4KAN	;	1.51	;	Crystal structure of probable sugar kinase protein from Rhizobium etli CFN 42 complexed with 2-(2,5-dimethyl-1,3-thiazol-4-yl)acetic acid
4K8P	;	1.5	;	Crystal structure of probable sugar kinase protein from Rhizobium etli CFN 42 complexed with 2-ethylbenzyl alcohol
4KAH	;	1.8	;	Crystal structure of probable sugar kinase protein from Rhizobium etli CFN 42 complexed with 4-bromo-1H-pyrazole
4LBG	;	1.5	;	Crystal structure of probable sugar kinase protein from Rhizobium Etli CFN 42 complexed with adenosine
4K8C	;	1.51	;	Crystal structure of probable sugar kinase protein from Rhizobium etli CFN 42 complexed with ADP
4KBE	;	1.8	;	Crystal structure of probable sugar kinase protein from Rhizobium etli CFN 42 complexed with benzoguanamine
4LBX	;	1.7	;	Crystal structure of probable sugar kinase protein from Rhizobium Etli CFN 42 complexed with cytidine
4JKS	;	1.51	;	Crystal structure of probable sugar kinase protein from Rhizobium etli CFN 42 complexed with DMSO, NYSGRC Target 14306
4K8T	;	1.7	;	Crystal structure of probable sugar kinase protein from Rhizobium etli CFN 42 complexed with ethyl 3,4-diaminobenzoate
4LC4	;	1.7	;	Crystal structure of probable sugar kinase protein from Rhizobium Etli CFN 42 complexed with guanosine
4K93	;	1.5	;	CRYSTAL STRUCTURE OF probable sugar kinase protein from Rhizobium etli CFN 42 complexed with N-(HYDROXYMETHYL)BENZAMIDE
4K9C	;	1.5	;	CRYSTAL STRUCTURE OF probable sugar kinase protein from Rhizobium etli CFN 42 complexed with N-(HYDROXYMETHYL)BENZAMIDE and 4-METHYL-3,4-DIHYDRO-2H-1,4-BENZOXAZINE-7-CARBOXYLIC ACID
4KAD	;	1.7	;	Crystal structure of probable sugar kinase protein from Rhizobium etli CFN 42 complexed with N1-(2.3-dihydro-1H-inden-5-yl)acetam
4K9I	;	1.7	;	CRYSTAL STRUCTURE OF probable sugar kinase protein from Rhizobium etli CFN 42 complexed with Norharmane
4JKU	;	1.51	;	Crystal structure of probable sugar kinase protein from Rhizobium etli CFN 42 complexed with quinaldic acid, NYSGRC Target 14306
4KAL	;	1.5	;	Crystal structure of probable sugar kinase protein from Rhizobium etli CFN 42 complexed with quinoline-3-carboxylic acid
4LCA	;	1.5	;	Crystal structure of probable sugar kinase protein from Rhizobium Etli CFN 42 complexed with thymidine
3HM0	;	2.5	;	Crystal Structure of Probable Thioesterase from Bartonella henselae
2EG3	;	1.8	;	Crystal Structure of Probable Thiosulfate Sulfurtransferase
2EG4	;	1.7	;	Crystal Structure of Probable Thiosulfate Sulfurtransferase
3HWI	;	2.29	;	Crystal structure of probable thiosulfate sulfurtransferase Cysa2 (Rhodanese-like protein) from Mycobacterium tuberculosis
3AAX	;	2.5	;	Crystal structure of probable thiosulfate sulfurtransferase cysa3 (RV3117) from Mycobacterium tuberculosis: monoclinic FORM
3AAY	;	1.9	;	Crystal structure of probable thiosulfate sulfurtransferase CYSA3 (RV3117) from Mycobacterium tuberculosis: orthorhombic form
3HZU	;	2.1	;	Crystal structure of probable thiosulfate sulfurtransferase SSEA (rhodanese) from Mycobacterium tuberculosis
2H0A	;	2.8	;	Crystal structure of probable Transcription regulator from Thermus thermophilus
2NNN	;	2.4	;	Crystal structure of probable transcriptional regulator from Pseudomonas aeruginosa
2IBD	;	1.5	;	Crystal structure of Probable transcriptional regulatory protein RHA5900
4WSH	;	1.95	;	Crystal structure of Probable Uroporphyrinogen decarboxylase (UPD) (URO-D) from Pseudomonas aeruginosa
3MN1	;	1.8	;	Crystal structure of probable yrbi family phosphatase from pseudomonas syringae pv.phaseolica 1448a
3NRJ	;	1.9	;	Crystal structure of probable yrbi family phosphatase from pseudomonas syringae pv.phaseolica 1448a complexed with magnesium
1K88	;	2.7	;	Crystal structure of procaspase-7
6PX9	;	2.88	;	Crystal structure of procaspase-8 in complex with covalent small molecule inhibitor 63-R
1CS8	;	1.8	;	CRYSTAL STRUCTURE OF PROCATHEPSIN L
2O6X	;	1.4	;	Crystal Structure of ProCathepsin L1 from Fasciola hepatica
2W8B	;	1.86	;	Crystal structure of processed TolB in complex with Pal
4J5T	;	2.04	;	Crystal structure of Processing alpha-Glucosidase I
4KVS	;	1.67	;	Crystal Structure of Prochlorococcus marinus aldehyde-deformylating oxygenase (mutant A134F)
4KVR	;	1.88	;	Crystal Structure of Prochlorococcus marinus aldehyde-deformylating oxygenase (mutant V41Y)
4KVQ	;	1.842	;	Crystal Structure of Prochlorococcus marinus aldehyde-deformylating oxygenase wild type with palmitic acid bound
3KGL	;	2.981	;	Crystal structure of procruciferin, 11S globulin from Brassica napus
4WCL	;	1.85	;	Crystal Structure of product bound Cell Shape Determinant protein Csd4 from Helicobacter pylori
4GWW	;	3.2	;	Crystal Structure of product complexes of Porcine Liver Fructose-1,6-bisphosphatase with blocked subunit pair rotation
4GWX	;	2.35	;	Crystal Structure of product complexes of Porcine Liver Fructose-1,6-bisphosphatase with restrained subunit pair rotation
6E1X	;	1.35	;	Crystal structure of product-bound complex of spermidine/spermine N-acetyltransferase SpeG
3ZFN	;	1.5	;	Crystal structure of product-like, processed N-terminal protease Npro
3ZFT	;	1.8	;	Crystal structure of product-like, processed N-terminal protease Npro at pH 3
3ZFP	;	1.25	;	Crystal structure of product-like, processed N-terminal protease Npro with internal His-Tag
3ZFR	;	1.8	;	Crystal structure of product-like, processed N-terminal protease Npro with iridium
3ZFQ	;	2.65	;	Crystal structure of product-like, processed N-terminal protease Npro with mercury
4NOK	;	2.5	;	Crystal structure of proenzyme asparaginyl endopeptidase (AEP)/Legumain at pH 7.5
4NOL	;	2.7	;	Crystal structure of proenzyme asparaginyl endopeptidase (AEP)/Legumain mutant D233A at pH 7.5
3D9Y	;	1.65	;	Crystal Structure of Profilin from Schizosaccharomyces pombe
3FT6	;	1.12	;	Crystal Structure of Proflavine in Complex with a DNA hexamer duplex
7PND	;	1.85	;	Crystal structure of profragilysin-3 (proBFT-3) from Bacteroides fragilis at 1.85 A resolution.
7POL	;	1.95	;	Crystal structure of profragilysin-3 (proBFT-3) from Bacteroides fragilis in complex with flumequine
7POO	;	2.7	;	Crystal structure of profragilysin-3 (proBFT-3) from Bacteroides fragilis in complex with foliosidine in P212121.
7POQ	;	1.85	;	Crystal structure of profragilysin-3 (proBFT-3) from Bacteroides fragilis in complex with foliosidine in P41212.
7POU	;	2.03	;	Crystal structure of profragilysin-3 (proBFT-3) from Bacteroides fragilis in complex with hesperetin.
1UCX	;	3.2	;	Crystal structure of proglycinin C12G mutant
1UD1	;	3.1	;	Crystal structure of proglycinin mutant C88S
3AJM	;	2.3	;	Crystal structure of programmed cell death 10 in complex with inositol 1,3,4,5-tetrakisphosphate
2RG8	;	1.8	;	Crystal Structure of Programmed for Cell Death 4 Middle MA3 domain
2E9Y	;	1.8	;	Crystal structure of project APE1968 from Aeropyrum pernix K1
1VCE	;	2.1	;	Crystal structure of project ID PH0725 from Pyrococcus horikoshii OT3
2DEK	;	1.65	;	Crystal structure of project ID PH0725 from Pyrococcus horikoshii OT3 at 1.65 A resolution
1WN2	;	1.2	;	Crystal structure of project ID PH1539 from Pyrococcus horikoshii OT3
2DSJ	;	1.8	;	Crystal structure of project ID TT0128 from Thermus thermophilus HB8
1WS9	;	2.3	;	Crystal structure of project ID TT0172 from Thermus thermophilus HB8
1X1O	;	1.9	;	Crystal structure of project ID TT0268 from Thermus thermophilus HB8
2DY0	;	1.25	;	Crystal structure of project JW0458 from Escherichia coli
2ZV3	;	2.1	;	Crystal structure of project MJ0051 from Methanocaldococcus jannaschii DSM 2661
2E18	;	2.1	;	Crystal structure of project PH0182 from Pyrococcus horikoshii OT3
1WU8	;	2.6	;	Crystal structure of project PH0463 from Pyrococcus horikoshii OT3
2DVL	;	2.5	;	Crystal structure of project TT0160 from Thermus thermophilus HB8
1LWB	;	1.05	;	Crystal structure of prokaryotic phospholipase A2 at atomic resolution
4FGU	;	3.9	;	Crystal structure of prolegumain
3N2C	;	2.81	;	Crystal structure of prolidase eah89906 complexed with n-methylphosphonate-l-proline
1RWZ	;	1.8	;	Crystal Structure of Proliferating Cell Nuclear Antigen (PCNA) from A. fulgidus
3HI8	;	3.202	;	Crystal structure of proliferating cell nuclear antigen (PCNA) from Haloferax volcanii
1UD9	;	1.68	;	Crystal Structure of Proliferating Cell Nuclear Antigen (PCNA) Homolog From Sulfolobus tokodaii
2ZVW	;	2.5	;	Crystal structure of Proliferating cell nuclear antigen 2 and Short peptide from human P21
5H0T	;	2.73	;	Crystal structure of proliferating cell nuclear antigen from Leishmania donovani at 2.73 Angstrom resolution
5HAC	;	2.95	;	Crystal structure of Proliferating Cell Nuclear Antigen from Leishmania donovani at 2.95 A resolution
5CFK	;	3.2	;	Crystal structure of Proliferating Cell Nuclear Antigen from Leishmania donovani at 3.2 A resolution
6J0J	;	3.1	;	Crystal structure of Proliferating Cell Nuclear Antigen from Leishmania donovani with an unexplained density near residues Pro229,Pr0267 and Ala285
2ZVV	;	2.0	;	Crystal structure of Proliferating cellular nuclear antigen 1 and Short peptide from human P21
3P91	;	2.4	;	Crystal structure of Proliferating Cellular Nuclear Antigen from Entamoeba histolytica
3NWO	;	1.9	;	Crystal structure of Proline iminopeptidase Mycobacterium smegmatis
6J7C	;	2.7	;	Crystal structure of proline racemase-like protein from Thermococcus litoralis in complex with proline
5UR2	;	2.23	;	Crystal structure of proline utilization A (PutA) from Bdellovibrio bacteriovorus inactivated by N-propargylglycine
4NMB	;	2.198	;	Crystal structure of proline utilization A (PutA) from Geobacter sulfurreducens PCA in complex with L-lactate
4NMA	;	2.101	;	Crystal structure of proline utilization A (PutA) from Geobacter sulfurreducens PCA in complex with L-tetrahydro-2-furoic acid
4NME	;	2.088	;	Crystal structure of proline utilization A (PutA) from Geobacter sulfurreducens PCA inactivated by N-propargylglycine
4NMF	;	1.95	;	Crystal structure of proline utilization A (PutA) from Geobacter sulfurreducens PCA inactivated by N-propargylglycine and complexed with menadione bisulfite
4NMD	;	1.979	;	Crystal structure of proline utilization A (PutA) from Geobacter sulfurreducens PCA reduced with dithionite
1WM1	;	2.1	;	Crystal Structure of Prolyl Aminopeptidase, Complex with Pro-TBODA
6JYM	;	1.5	;	Crystal structure of Prolyl Endopeptidase from Haliotis discus hannai
6JCI	;	1.493	;	Crystal structure of Prolyl Endopeptidase from Haliotis discus hannai with SUAM-14746
7VGC	;	2.722	;	Crystal structure of prolyl oligopeptidase from Microbulbifer arenaceous complex with a transition state analog inhibitor ZPR
7Y1X	;	1.67	;	Crystal structure of prolyl oligopeptidase from Microbulbifer arenaceous complex with PEG400 and MES
2D5L	;	2.1	;	Crystal Structure of Prolyl Tripeptidyl Aminopeptidase from Porphyromonas gingivalis
4NCX	;	1.85	;	Crystal Structure of Prolyl-tRNA synthetase (ProRS, Proline--tRNA ligase) from Plasmodium falciparum 3D7
5IFU	;	2.45	;	Crystal Structure of Prolyl-tRNA synthetase (ProRS, Proline--tRNA ligase) from Plasmodium falciparum in complex with Glyburide
4Q15	;	2.35	;	Crystal Structure of Prolyl-tRNA synthetase (ProRS, Proline--tRNA ligase) from Plasmodium falciparum in complex with Halofuginone and AMPPNP in space group P212121 at 2.35 A
6T7K	;	1.79	;	Crystal Structure of Prolyl-tRNA synthetase (ProRS, Proline--tRNA ligase) from Plasmodium falciparum in complex with NCP-26 and L-Proline
4WI1	;	1.65	;	Crystal Structure of Prolyl-tRNA synthetase (ProRS, Proline--tRNA ligase) from Plasmodium falciparum in complex with TCMDC-124506
4OLF	;	2.9	;	Crystal Structure of Prolyl-tRNA synthetase (ProRS, Proline--tRNA ligase)from Plasmodium falciparum in complex with Halofuginone and AMPPNP
7QC2	;	2.28	;	Crystal Structure of Prolyl-tRNA synthetase (ProRS, Proline-tRNA ligase) from Plasmodium falciparum in complex with MAT334 and L-Proline
7QB7	;	1.9	;	Crystal Structure of Prolyl-tRNA synthetase (ProRS, Proline-tRNA ligase) from Plasmodium falciparum in complex with MAT345 and L-Proline
7QC1	;	2.51	;	Crystal Structure of Prolyl-tRNA synthetase (ProRS, Proline-tRNA ligase) from Plasmodium falciparum in complex with MAT436
4TWA	;	3.0	;	Crystal Structure of Prolyl-tRNA Synthetase (PRS) from Plasmodium falciparum
4YDQ	;	2.3	;	Crystal Structure of Prolyl-tRNA Synthetase (PRS) from Plasmodium falciparum in complex with Halofuginone and AMPPNP
5XIF	;	2.48	;	Crystal Structure of Prolyl-tRNA Synthetase (PRS) from Toxoplasma gondii
5F9Z	;	2.4	;	Crystal Structure of Prolyl-tRNA Synthetase from Cryptosporidium parvum complexed with Halofuginone and AMPPNP
5F9Y	;	2.8	;	Crystal Structure of Prolyl-tRNA Synthetase from Cryptosporidium parvum complexed with L-Proline and AMP
1NJ8	;	3.2	;	Crystal Structure of Prolyl-tRNA Synthetase from Methanocaldococcus janaschii
1NJ2	;	3.11	;	Crystal structure of Prolyl-tRNA Synthetase from Methanothermobacter thermautotrophicus
1NJ6	;	2.85	;	Crystal structure of Prolyl-tRNA Synthetase from Methanothermobacter thermautotrophicus bound to alanine sulfamoyl adenylate
1NJ1	;	2.55	;	Crystal structure of Prolyl-tRNA Synthetase from Methanothermobacter thermautotrophicus bound to cysteine sulfamoyl adenylate
1NJ5	;	2.8	;	Crystal structure of Prolyl-tRNA Synthetase from Methanothermobacter thermautotrophicus bound to proline sulfamoyl adenylate
6UYH	;	1.75	;	Crystal structure of prolyl-tRNA synthetase from Naegleria fowleri in complex with halofuginone and AMPPNP
6NAB	;	2.0	;	Crystal structure of prolyl-tRNA synthetase from Naegleria fowleri in complex with proline and adenosine monophophsphate (AMP)
6MN8	;	2.35	;	Crystal Structure of Prolyl-tRNA Synthetase from Onchocerca volvulus with bound Halofuginone and nucleotide
5UCM	;	2.6	;	Crystal Structure of Prolyl-tRNA Synthetase from Pseudomonas aeruginosa
7OMT	;	2.0	;	Crystal structure of ProMacrobody 21 with bound maltose
3AFG	;	2.0	;	Crystal structure of ProN-Tk-SP from Thermococcus kodakaraensis
3RD4	;	2.9	;	Crystal structure of PROPEN_03304 from Proteus penneri ATCC 35198 Northeast Structural Genomics Consortium target id PvR55
6S08	;	2.03	;	Crystal Structure of Properdin (TSR domains N1 & 456)
6S0A	;	2.52	;	Crystal Structure of Properdin (TSR domains N12 & 456)
6S0B	;	2.312	;	Crystal Structure of Properdin in complex with the CTC domain of C3/C3b
3CDD	;	2.1	;	Crystal structure of prophage MuSo2, 43 kDa tail protein from Shewanella oneidensis
3GS9	;	1.7	;	Crystal structure of prophage tail protein gp18 (NP_465809.1) from Listeria monocytogenes EGD-e at 1.70 A resolution
2B9L	;	2.0	;	Crystal structure of prophenoloxidase activating factor-II from the beetle Holotrichia diomphalia
8JI8	;	2.65	;	Crystal Structure of Prophenoloxidase PPO6 chimeric mutant (F215EASNRAIVD224 to G215DGPDSVVR223) from Aedes aegypti
8JIB	;	3.15	;	Crystal Structure of Prophenoloxidase PPO6 from Aedes aegypti
1QDM	;	2.3	;	CRYSTAL STRUCTURE OF PROPHYTEPSIN, A ZYMOGEN OF A BARLEY VACUOLAR ASPARTIC PROTEINASE.
2PJU	;	2.1	;	Crystal structure of propionate catabolism operon regulatory protein prpR
2E1Y	;	2.6	;	Crystal structure of propionate kinase (TdcD) from Salmonella typhimurium
1VRG	;	2.3	;	Crystal structure of propionyl-CoA carboxylase, beta subunit (TM0716) from THERMOTOGA MARITIMA at 2.30 A resolution
1MIQ	;	2.5	;	Crystal structure of proplasmepsin from the human malarial pathogen Plasmodium vivax
6ZTC	;	1.84	;	CRYSTAL STRUCTURE OF PROSTAGLANDIN D2 SYNTHASE IN COMPLEX WITH FRAGMENT 1A AT 1.84A RESOLUTION.
2F38	;	2.0	;	Crystal structure of prostaglandin F synathase containing bimatoprost
4FZI	;	2.6	;	Crystal structure of prostaglandin F synthase from Trypanosoma cruzi
4GIE	;	1.25	;	Crystal structure of prostaglandin F synthase from Trypanosoma cruzi bound to NADP
1Z8L	;	3.5	;	Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase
6HAY	;	2.24	;	Crystal structure of PROTAC 1 in complex with the bromodomain of human SMARCA2 and pVHL:ElonginC:ElonginB
6HAX	;	2.35	;	Crystal structure of PROTAC 2 in complex with the bromodomain of human SMARCA2 and pVHL:ElonginC:ElonginB
6HR2	;	1.76	;	Crystal structure of PROTAC 2 in complex with the bromodomain of human SMARCA4 and pVHL:ElonginC:ElonginB
7Z6L	;	2.24	;	Crystal structure of PROTAC 5 in complex with the bromodomain of human SMARCA2 and pVHL:ElonginC:ElonginB
7JTO	;	1.7	;	Crystal structure of Protac MS33 in complex with the WD repeat-containing protein 5 and pVHL:ElonginC:ElonginB
7JTP	;	2.12	;	Crystal structure of Protac MS67 in complex with the WD repeat-containing protein 5 and pVHL:ElonginC:ElonginB
6F2F	;	1.65	;	Crystal structure of Protease 1 from Pyrococcus Horikoshii co-cystallized in presence of 10 mM Tb-Xo4 and ammonium sulfate.
8GPH	;	1.608	;	Crystal structure of protease 3C (C160A mutant) from Seneca Valley Virus
3WY8	;	1.7	;	Crystal Structure of Protease Anisep from Arthrobacter Nicotinovorans
5ILB	;	1.852	;	Crystal structure of protease domain of Deg2 linked with the PDZ domain of Deg9
3GI6	;	1.84	;	Crystal structure of protease inhibitor, AD78 in complex with wild type HIV-1 protease
3GI4	;	1.85	;	Crystal structure of protease inhibitor, KB60 in complex with wild type HIV-1 protease
3GI5	;	1.8	;	Crystal structure of protease inhibitor, KB62 in complex with wild type HIV-1 protease
2QHY	;	1.85	;	Crystal Structure of protease inhibitor, MIT-1-AC86 in complex with wild type HIV-1 protease
2QHZ	;	1.85	;	Crystal structure of protease inhibitor, MIT-1-AC87 in complex with wild type HIV-1 protease
2QI0	;	2.1	;	Crystal structure of protease inhibitor, MIT-1-KK80 in complex with wild type HIV-1 protease
2QI1	;	2.0	;	Crystal structure of protease inhibitor, MIT-1-KK81 in complex with wild type HIV-1 protease
2QI7	;	1.85	;	Crystal structure of protease inhibitor, MIT-2-AD86 in complex with wild type HIV-1 protease
2QI4	;	1.8	;	Crystal structure of protease inhibitor, MIT-2-AD93 in complex with wild type HIV-1 protease
2QI3	;	1.95	;	Crystal structure of protease inhibitor, MIT-2-AD94 in complex with wild type HIV-1 protease
2QI6	;	1.85	;	Crystal structure of protease inhibitor, MIT-2-KB98 in complex with wild type HIV-1 protease
2QI5	;	1.85	;	Crystal structure of protease inhibitor, MIT-2-KC08 in complex with wild type HIV-1 protease
4TJV	;	1.651	;	Crystal structure of protease-associated domain of Arabidopsis vacuolar sorting receptor 1
8HYG	;	1.6	;	Crystal structure of protease-associated domain of Arabidopsis vacuolar sorting receptor 1 at pH 4.6
4TJX	;	1.902	;	Crystal structure of protease-associated domain of Arabidopsis VSR1 in complex with aleurain peptide
2Z5E	;	2.0	;	Crystal Structure of Proteasome Assembling Chaperone 3
3Q8C	;	2.85	;	Crystal structure of Protective Antigen W346F (pH 5.5)
3Q8E	;	2.098	;	Crystal structure of Protective Antigen W346F (pH 8.5)
5FHB	;	1.973	;	Crystal Structure of Protective Ebola Virus Antibody 100
5FHA	;	1.973	;	Crystal Structure of Protective Ebola Virus Antibody 114
5FHC	;	6.704	;	Crystal Structure of Protective Human Antibodies 100 and 114 in Complex with Ebola Virus Fusion Glycoprotein (GP)
7RPT	;	2.5	;	Crystal Structure of Protective Human Antibody 3A6 Fab Against Ebola Virus
7RPU	;	1.27	;	Crystal Structure of Protective Human Antibody 3A6 Fab Against Ebola Virus with GP Stalk/MPER Epitope Peptide
5I20	;	2.4	;	Crystal structure of protein
3HA2	;	1.8	;	Crystal Structure of Protein (NADPH-quinone reductase) from P.pentosaceus, Northeast Structural Genomics Consortium Target PtR24A
3F8K	;	1.84	;	Crystal structure of protein acetyltransferase (PAT) from Sulfolobus solfataricus
2B3M	;	1.85	;	Crystal structure of protein AF1124 from Archaeoglobus fulgidus
3K67	;	1.25	;	Crystal structure of protein af1124 from archaeoglobus fulgidus
2IOJ	;	2.15	;	Crystal structure of protein AF1212 from Archaeoglobus fulgidus, Pfam DRTGG
2NWI	;	2.2	;	Crystal structure of protein AF1396 from Archaeoglobus fulgidus, Pfam DUF98
2OO2	;	1.8	;	Crystal structure of protein AF1782 from Archaeoglobus fulgidus, Pfam DUF357
2OGK	;	3.0	;	Crystal structure of protein AF2318 from Archaeglobus fulgidus, Pfam DUF54
3BUT	;	1.91	;	Crystal structure of protein Af_0446 from Archaeoglobus fulgidus
2NS9	;	1.8	;	Crystal structure of protein APE2225 from Aeropyrum pernix K1, Pfam COXG
4N20	;	1.657	;	Crystal structure of Protein Arginine Deiminase 2 (0 mM Ca2+)
4N28	;	1.879	;	Crystal structure of Protein Arginine Deiminase 2 (1 mM Ca2+)
4N2B	;	1.69	;	Crystal structure of Protein Arginine Deiminase 2 (10 mM Ca2+)
4N24	;	1.968	;	Crystal structure of Protein Arginine Deiminase 2 (100 uM Ca2+)
4N25	;	1.931	;	Crystal structure of Protein Arginine Deiminase 2 (250 uM Ca2+)
4N2A	;	1.7	;	Crystal structure of Protein Arginine Deiminase 2 (5 mM Ca2+)
4N22	;	1.889	;	Crystal structure of Protein Arginine Deiminase 2 (50 uM Ca2+)
4N26	;	1.943	;	Crystal structure of Protein Arginine Deiminase 2 (500 uM Ca2+)
4N2D	;	2.0	;	Crystal structure of Protein Arginine Deiminase 2 (D123N, 0 mM Ca2+)
4N2E	;	1.858	;	Crystal structure of Protein Arginine Deiminase 2 (D123N, 10 mM Ca2+)
4N2F	;	1.8	;	Crystal structure of Protein Arginine Deiminase 2 (D169A, 0 mM Ca2+)
4N2G	;	1.85	;	Crystal structure of Protein Arginine Deiminase 2 (D169A, 10 mM Ca2+)
4N2H	;	1.808	;	Crystal structure of Protein Arginine Deiminase 2 (D177A, 0 mM Ca2+)
4N2I	;	1.9	;	Crystal structure of Protein Arginine Deiminase 2 (D177A, 10 mM Ca2+)
4N2M	;	1.599	;	Crystal structure of Protein Arginine Deiminase 2 (E354A, 0 mM Ca2+)
4N2N	;	1.8	;	Crystal structure of Protein Arginine Deiminase 2 (E354A, 10 mM Ca2+)
4N2C	;	3.022	;	Crystal structure of Protein Arginine Deiminase 2 (F221/222A, 10 mM Ca2+)
4N2K	;	1.57	;	Crystal structure of Protein Arginine Deiminase 2 (Q350A, 0 mM Ca2+)
4N2L	;	2.1	;	Crystal structure of Protein Arginine Deiminase 2 (Q350A, 10 mM Ca2+)
3SMQ	;	2.0	;	Crystal structure of protein arginine methyltransferase 3
3UA4	;	3.005	;	Crystal Structure of Protein Arginine Methyltransferase PRMT5
3UA3	;	3.0	;	Crystal Structure of Protein Arginine Methyltransferase PRMT5 in complex with SAH
4X41	;	3.5	;	Crystal Structure of Protein Arginine Methyltransferase PRMT8
2HWJ	;	2.61	;	Crystal structure of protein Atu1540 from Agrobacterium tumefaciens
2OB5	;	1.6	;	Crystal structure of protein Atu2016, putative sugar binding protein
2O8I	;	2.6	;	Crystal structure of protein Atu2327 from Agrobacterium tumefaciens str. C58
3DO9	;	2.75	;	Crystal structure of protein ba1542 from bacillus anthracis str.ames
3CYM	;	2.1	;	Crystal structure of protein BAD_0989 from Bifidobacterium adolescentis
3NRH	;	1.8	;	Crystal Structure of protein BF1032 from Bacteroides fragilis, Northeast Structural Genomics Consortium Target BfR309
2NLY	;	2.5	;	Crystal structure of protein BH1492 from Bacillus halodurans, Pfam DUF610
2IA1	;	1.59	;	Crystal structure of protein BH3703 from Bacillus halodurans, Pfam DUF600
2P5I	;	2.21	;	Crystal structure of protein BH3822 from Bacillus halodurans, a member of the biotin/lipoate A/B protein ligase family
3C6F	;	2.5	;	Crystal structure of protein Bsu07140 from Bacillus subtilis
2F06	;	2.1	;	Crystal structure of protein BT0572 from Bacteroides thetaiotaomicron
3HNM	;	3.0	;	Crystal Structure of Protein BT_411 (putative chitobiase, fragment 298-461) from Bacteroides thetaiotaomicron, Northeast Structural Genomics Consortium Target BtR319D
1XFJ	;	1.75	;	Crystal structure of protein CC_0490 from Caulobacter crescentus, Pfam DUF152
6CHU	;	1.61	;	CRYSTAL STRUCTURE OF PROTEIN CITE FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MAGNESIUM AND ACETATE
6CJ4	;	1.73	;	CRYSTAL STRUCTURE OF PROTEIN CITE FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MAGNESIUM AND ACETOACETATE
6CJ3	;	1.73	;	CRYSTAL STRUCTURE OF PROTEIN CITE FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MAGNESIUM AND PYRUVATE
6AS5	;	2.035	;	CRYSTAL STRUCTURE OF PROTEIN CitE FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MAGNESIUM, ACETOACETATE AND COENZYME A
6AQ4	;	1.825	;	CRYSTAL STRUCTURE OF PROTEIN CiTE FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MAGNESIUM, PYRUVATE AND CITRAMALYL-COA
6ARB	;	1.717	;	CRYSTAL STRUCTURE OF PROTEIN CitE FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MAGNESIUM, PYRUVATE AND COENZYME A
3PG5	;	3.3	;	Crystal structure of protein DIP2308 from Corynebacterium diphtheriae, Northeast Structural Genomics Consortium Target CdR78
3BH1	;	2.51	;	Crystal structure of protein DIP2346 from Corynebacterium diphtheriae
2I6E	;	2.5	;	Crystal structure of protein DR0370 from Deinococcus radiodurans, Pfam DUF178
1SFN	;	2.46	;	Crystal structure of protein DR1152 from Deinococcus radiodurans R1, Pfam DUF861
2O34	;	1.95	;	Crystal structure of protein DVU1097 from Desulfovibrio vulgaris Hildenborough, Pfam DUF375
6GUS	;	1.92	;	CRYSTAL STRUCTURE OF PROTEIN E FROM NON-TYPEABLE HAEMOPHILUS INFLUENZAE
2GMQ	;	1.76	;	Crystal structure of protein EF0006 from Enterococcus faecalis
2OX7	;	1.777	;	Crystal structure of protein EF1440 from Enterococcus faecalis
1T62	;	3.0	;	Crystal structure of protein EF3133 from Enterococcus faecalis V583, Pfam DUF984
1FT1	;	2.25	;	CRYSTAL STRUCTURE OF PROTEIN FARNESYLTRANSFERASE AT 2.25 ANGSTROMS RESOLUTION
2HO4	;	2.2	;	Crystal Structure of Protein from Mouse Mm.236127
1TSJ	;	2.6	;	Crystal structure of protein from Staphylococcus aureus
3OKZ	;	2.7	;	Crystal Structure of protein gbs0355 from Streptococcus agalactiae, Northeast Structural Genomics Consortium Target SaR127
1WUF	;	2.9	;	Crystal structure of protein GI:16801725, member of Enolase superfamily from Listeria innocua Clip11262
1WUE	;	2.1	;	Crystal structure of protein GI:29375081, unknown member of enolase superfamily from enterococcus faecalis V583
3BIJ	;	2.5	;	Crystal structure of protein GSU0716 from Geobacter sulfurreducens. Northeast Structural Genomics target GsR13
4ES7	;	2.001	;	crystal structure of protein HC from Homo sapiens at 2 angstrom
2ATZ	;	2.0	;	Crystal structure of protein HP0184 from Helicobacter pylori
4U12	;	1.94	;	Crystal structure of protein HP0242 from Helicobacter pylori at 1.94 A resolution: a knotted homodimer
1SVE	;	2.49	;	Crystal Structure of Protein Kinase A in Complex with Azepane Derivative 1
1SVG	;	2.02	;	Crystal Structure of Protein Kinase A in Complex with Azepane Derivative 4
1VEB	;	2.89	;	Crystal Structure of Protein Kinase A in Complex with Azepane Derivative 5
1SVH	;	2.3	;	Crystal Structure of Protein Kinase A in Complex with Azepane Derivative 8
2OH0	;	2.2	;	Crystal structure of Protein Kinase A in complex with Pyridine-Pyrazolopyridine Based Inhibitors
2OJF	;	2.1	;	Crystal structure of Protein Kinase A in complex with Pyridine-Pyrazolopyridine based inhibitors
6E9L	;	2.8	;	Crystal structure of Protein Kinase A in complex with the PKI peptide and a pyridinylbenzamide based inhibitor
5VHB	;	1.61	;	Crystal structure of Protein Kinase A in complex with the PKI peptide and Aminobenzothiazole based inhibitor
5VI9	;	1.95	;	Crystal structure of Protein Kinase A in complex with the PKI peptide and Aminobenzothiazole based inhibitors
5VIB	;	2.37	;	Crystal structure of Protein Kinase A in complex with the PKI peptide and Aminobenzothiazole based inhibitors
6E99	;	1.88	;	Crystal structure of Protein Kinase A in complex with the PKI peptide and an amino-pyridinylbenzamide based inhibitor.
1ZOG	;	2.3	;	Crystal structure of protein kinase CK2 in complex with TBB-derivatives
1ZOE	;	1.77	;	Crystal structure of protein kinase CK2 in complex with TBB-derivatives inhibitors
1ZOH	;	1.81	;	Crystal structure of protein kinase CK2 in complex with TBB-derivatives inhibitors
2PZI	;	2.4	;	Crystal Structure of Protein kinase PknG from Mycobacterium tuberculosis in Complex with Tetrahydrobenzothiophene AX20017
1VBF	;	2.8	;	Crystal structure of protein L-isoaspartate O-methyltransferase homologue from Sulfolobus tokodaii
3LBF	;	1.8	;	Crystal structure of Protein L-isoaspartyl methyltransferase from Escherichia coli
4L7V	;	2.05	;	Crystal structure of Protein L-isoaspartyl-O-methyltransferase of Vibrio cholerae
2IM9	;	1.67	;	Crystal structure of protein LPG0564 from Legionella pneumophila str. Philadelphia 1, Pfam DUF1460
2OO3	;	2.0	;	Crystal structure of protein LPL1258 from Legionella pneumophila str. Philadelphia 1, Pfam DUF519
5OK8	;	1.874	;	Crystal structure of protein Lpp20 (HP1456) from Helicobacter pylori
3K2Y	;	2.4	;	Crystal structure of protein lp_0118 from Lactobacillus plantarum,northeast structural genomics consortium target LpR91B
4AVA	;	1.698	;	Crystal structure of protein lysine acetyltransferase Rv0998 from Mycobacterium tuberculosis
4AVB	;	1.8	;	Crystal structure of protein lysine acetyltransferase Rv0998 in complex with acetyl CoA and cAMP
4AVC	;	2.806	;	Crystal structure of protein lysine acetyltransferase Rv0998 in complex with acetyl CoA and cAMP
4WUY	;	1.63	;	Crystal Structure of Protein Lysine Methyltransferase SMYD2 in complex with LLY-507, a Cell-Active, Potent and Selective Inhibitor
7R22	;	2.73	;	Crystal structure of protein Mab3862 from Mycobacterium abscessus
2OGF	;	1.89	;	Crystal structure of protein MJ0408 from Methanococcus jannaschii, Pfam DUF372
2B0A	;	1.45	;	Crystal structure of protein MJ0783 from Methanococcus jannaschii
6H1W	;	2.394	;	Crystal Structure of protein MJ1004 from Mathanocaldococcus jannaschii
3KH5	;	2.1	;	Crystal Structure of Protein MJ1225 from Methanocaldococcus jannaschii, a putative archaeal homolog of g-AMPK.
3LFZ	;	2.2	;	Crystal Structure of Protein MJ1225 from Methanocaldococcus jannaschii, a putative archaeal homolog of g-AMPK.
2F4N	;	2.5	;	Crystal structure of protein MJ1651 from Methanococcus jannaschii DSM 2661, Pfam DUF62
3C19	;	2.5	;	Crystal structure of protein MK0293 from Methanopyrus kandleri AV19
3UID	;	1.571	;	Crystal Structure of Protein Ms6760 from Mycobacterium smegmatis
2PTF	;	2.35	;	Crystal structure of protein MTH_863 from Methanobacterium thermoautotrophicum bound to FMN
3K6C	;	2.2	;	Crystal structure of protein ne0167 from nitrosomonas europaea
2I45	;	2.5	;	Crystal structure of protein NMB1881 from Neisseria meningitidis
3EO6	;	0.97	;	Crystal structure of protein of unknown function (DUF1255) (AFE_2634) from ACIDITHIOBACILLUS FERROOXIDANS NCIB8455 at 0.97 A resolution
3HQX	;	1.66	;	Crystal structure of protein of unknown function (DUF1255,PF06865) from Acinetobacter sp. ADP1
3ES4	;	1.64	;	Crystal structure of Protein of unknown function (DUF861) with a RmlC-like cupin fold (17741406) from AGROBACTERIUM TUMEFACIENS str. C58 (Dupont) at 1.64 A resolution
3LOT	;	1.89	;	Crystal structure of PROTEIN OF UNKNOWN FUNCTION (NP_070038.1) from ARCHAEOGLOBUS FULGIDUS at 1.89 A resolution
3KZT	;	2.1	;	Crystal structure of Protein of unknown function (NP_812423.1) from BACTEROIDES THETAIOTAOMICRON VPI-5482 at 2.10 A resolution
1YLO	;	2.15	;	Crystal Structure of Protein of Unknown Function (Possible Aminopeptidase) S2589 from Shigella flexneri 2a str. 2457T
3K8R	;	2.75	;	Crystal structure of protein of unknown function (YP_427503.1) from Rhodospirillum rubrum ATCC 11170 at 2.75 A resolution
1Y88	;	1.85	;	Crystal Structure of Protein of Unknown Function AF1548
2I3D	;	1.5	;	Crystal Structure of Protein of Unknown Function ATU1826, a Putative Alpha/Beta Hydrolase from Agrobacterium tumefaciens
2B1Y	;	1.8	;	Crystal Structure of Protein of Unknown Function ATU1913 from Agrobacterium tumefaciens str. C58
3K6O	;	2.0	;	Crystal structure of protein of unknown function DUF1344 (YP_001299214.1) from Bacteroides vulgatus ATCC 8482 at 2.00 A resolution
2P12	;	1.63	;	Crystal structure of protein of unknown function DUF402 from Rhodococcus sp. RHA1
2QNT	;	1.4	;	Crystal structure of protein of unknown function from Agrobacterium tumefaciens str. C58
1T6A	;	2.05	;	Crystal Structure of Protein of Unknown Function from Bacillus stearothermophilus
3NA2	;	2.293	;	Crystal Structure of Protein of Unknown Function from Mine Drainage Metagenome Leptospirillum rubarum
2QSV	;	2.1	;	Crystal structure of protein of unknown function from Porphyromonas gingivalis W83
2ARZ	;	2.0	;	Crystal Structure of Protein of Unknown Function from Pseudomonas aeruginosa
2I1S	;	2.3	;	Crystal Structure of Protein of Unknown Function MM3350 from Methanosarcina mazei Go1
5IR0	;	3.297	;	Crystal structure of protein of unknown function ORF19 from Vibrio cholerae O1 PICI-like element, C57S I109M mutant
1U7I	;	1.4	;	Crystal Structure of Protein of Unknown Function PA1358 from Pseudomonas aeruginosa
1YX1	;	1.8	;	Crystal Structure of Protein of Unknown Function PA2260 from Pseudomonas aeruginosa, Possible Sugar Phosphate Isomerase
1TU1	;	1.95	;	Crystal Structure of Protein of Unknown Function PA94 from Pseudomonas aeruginosa, Putative Regulator
2H5N	;	2.01	;	Crystal Structure of Protein of Unknown Function PG1108 from Porphyromonas gingivalis W83
1XG8	;	2.1	;	Crystal Structure of Protein of Unknown Function SA0789 from Staphylococcus aureus
2NR5	;	1.9	;	Crystal Structure of Protein of Unknown Function SO2669 from Shewanella oneidensis MR-1
2A5Z	;	2.015	;	Crystal Structure of Protein of Unknown Function SO2946 from Shewanella oneidensis MR-1
3G8Z	;	1.9	;	Crystal structure of protein of unknown function with cystatin-like fold (NP_639274.1) from Xanthomonas campestris at 1.90 A resolution
3G16	;	1.45	;	Crystal structure of protein of unknown function with cystatin-like fold (YP_001022489.1) from METHYLOBIUM PETROLEOPHILUM PM1 at 1.45 A resolution
3EZ0	;	2.33	;	Crystal structure of protein of unknown function with ferritin-like fold (YP_832262.1) from Arthrobacter sp. FB24 at 2.33 A resolution
1OQ1	;	1.7	;	Crystal Structure of Protein of Unknown Function with Galectin-like Fold from Bacillus subtilis
1XAF	;	2.01	;	Crystal Structure of Protein of Unknown Function YfiH from Shigella flexneri 2a str. 2457T
1SED	;	2.1	;	Crystal Structure of Protein of Unknown Function YhaL from Bacillus subtilis
5TF3	;	2.001	;	Crystal Structure of Protein of Unknown Function YPO2564 from Yersinia pestis
1U6L	;	2.81	;	Crystal structure of protein PA1353 from Pseudomonas aeruginosa
6TCB	;	1.35	;	Crystal structure of protein PA2723 from Pseudomonas aeruginosa PAO1
2APL	;	2.01	;	Crystal structure of protein PG0816 from Porphyromonas gingivalis
2ZAE	;	2.21	;	Crystal structure of protein Ph1601p in complex with protein Ph1771p of archaeal ribonuclease P from Pyrococcus horikoshii OT3
8ANU	;	2.31015	;	Crystal structure of protein phi3T-93
6DNO	;	1.45	;	Crystal structure of Protein Phosphatase 1 (PP1) bound to the muscle glycogen-targeting subunit (Gm)
6ALZ	;	2.208	;	Crystal structure of Protein Phosphatase 1 bound to the natural inhibitor Tautomycetin
7QFB	;	2.05	;	Crystal structure of Protein Phosphatase 1 in complex with PP1-binding peptide from PTG
4LAC	;	2.82	;	Crystal Structure of Protein Phosphatase 2A (PP2A) and PP2A phosphatase activator (PTPA) complex with ATPgammaS
2NYL	;	3.8	;	Crystal structure of Protein Phosphatase 2A (PP2A) holoenzyme with the catalytic subunit carboxyl terminus truncated
2NYM	;	3.6	;	Crystal Structure of Protein Phosphatase 2A (PP2A) with C-terminus truncated catalytic subunit
5W0W	;	3.8	;	Crystal structure of Protein Phosphatase 2A bound to TIPRL
3UJK	;	1.9	;	Crystal structure of protein phosphatase ABI2
3E7B	;	1.7	;	Crystal Structure of Protein Phosphatase-1 Bound to the natural toxin inhibitor Tautomycin
3E7A	;	1.63	;	Crystal Structure of Protein Phosphatase-1 Bound to the natural toxin Nodularin-R
4XPN	;	2.285	;	Crystal Structure of Protein Phosphate 1 complexed with PP1 binding domain of GADD34
5ZT0	;	3.32043	;	Crystal Structure of Protein Phosphate 1 Complexed with PP1 binding domain of GL
5ZQV	;	2.95	;	Crystal Structure of Protein Phosphate 1 complexed with PP1 binding domain of GM
7F7Y	;	2.13	;	Crystal Structure of protein PitB from pilus islet-2 of Streptococcus pneumoniae
2PAG	;	1.6	;	Crystal structure of protein PSPTO_5518 from Pseudomonas syringae pv. tomato
2I52	;	2.08	;	Crystal structure of protein PTO0218 from Picrophilus torridus, Pfam DUF372
3BDU	;	1.9	;	Crystal structure of protein Q6D8G1 at the resolution 1.9 A. Northeast Structural Genomics Consortium target EwR22A.
4JPH	;	2.25	;	Crystal structure of Protein Related to DAN and Cerberus (PRDC)
2HQ7	;	2.0	;	Crystal structure of Protein related to general stress protein 26(GS26) of B.subtilis (pyridoxinephosphate oxidase family) (NP_350077.1) from CLOSTRIDIUM ACETOBUTYLICUM at 2.00 A resolution
2NS0	;	2.005	;	Crystal structure of protein RHA04536 from Rhodococcus sp
2OV9	;	1.9	;	Crystal structure of protein RHA08564, thioesterase superfamily protein
3FOV	;	1.88	;	Crystal structure of protein RPA0323 of unknown function from Rhodopseudomonas palustris
2IJQ	;	1.88	;	Crystal structure of protein rrnAC1037 from Haloarcula marismortui, Pfam DUF309
3NRL	;	1.9	;	Crystal Structure of protein RUMGNA_01417 from Ruminococcus gnavus, Northeast Structural Genomics Consortium Target UgR76
1TQ8	;	2.4	;	Crystal Structure of protein Rv1636 from Mycobacterium tuberculosis H37Rv
6Y20	;	1.849	;	Crystal structure of Protein Scalloped (222-440) bound to Protein Vestigial (298-337)
8A8Q	;	1.465	;	Crystal structure of Protein Scalloped in complex with YAP peptide
2NXO	;	2.04	;	Crystal structure of protein SCO4506 from Streptomyces coelicolor, Pfam DUF178
3JU2	;	1.8	;	CRYSTAL STRUCTURE OF PROTEIN SMc04130 FROM Sinorhizobium meliloti 1021
2BBE	;	1.97	;	Crystal structure of protein SO0527 from Shewanella oneidensis
2HA9	;	2.7	;	Crystal structure of protein SP0239 from Streptococcus pneumoniae
2IMH	;	1.57	;	Crystal structure of protein SPO2555 from Silicibacter pomeroyi, Pfam DUF1028
2FU2	;	2.15	;	Crystal structure of protein SPy2152 from Streptococcus pyogenes
4G06	;	2.905	;	Crystal structure of protein SP_0782 (7-79) from Streptococcus pneumoniae complexed with ssDNA. Northeast Structural Genomics Consortium (NESG) target SPR104
2NRQ	;	2.6	;	Crystal structure of protein SSO0741 from Sulfolobus solfataricus, Pfam DUF54
2NWU	;	2.4	;	Crystal structure of protein SSO1042 from Sulfolobus solfataricus, Pfam DUF54
5TGN	;	2.001	;	Crystal structure of protein Sthe_2403 from Sphaerobacter thermophilus
2P61	;	2.7	;	Crystal structure of protein TM1646 from Thermotoga maritima, Pfam DUF327
2I76	;	3.0	;	Crystal structure of protein TM1727 from Thermotoga maritima
1C86	;	2.3	;	CRYSTAL STRUCTURE OF PROTEIN TYROSINE PHOSPHATASE 1B (R47V,D48N) COMPLEXED WITH 2-(OXALYL-AMINO-4,7-DIHYDRO-5H-THIENO[2,3-C]PYRAN-3-CARBOXYLIC ACID
1C88	;	1.8	;	CRYSTAL STRUCTURE OF PROTEIN TYROSINE PHOSPHATASE 1B COMPLEXED WITH 2-(OXALYL-AMINO)-4,5,6,7-TETRAHYDRO-THIENO[2,3-C]PYRIDINE-3-CARBOXYLIC ACID
1C85	;	2.72	;	CRYSTAL STRUCTURE OF PROTEIN TYROSINE PHOSPHATASE 1B COMPLEXED WITH 2-(OXALYL-AMINO)-BENZOIC ACID
1C87	;	2.1	;	CRYSTAL STRUCTURE OF PROTEIN TYROSINE PHOSPHATASE 1B COMPLEXED WITH 2-(OXALYL-AMINO-4,7-DIHYDRO-5H-THIENO[2,3-C]PYRAN-3-CARBOXYLIC ACID
1C84	;	2.35	;	CRYSTAL STRUCTURE OF PROTEIN TYROSINE PHOSPHATASE 1B COMPLEXED WITH 3-(OXALYL-AMINO)-NAPHTHALENE-2-CARBOXLIC ACID
1ECV	;	1.95	;	CRYSTAL STRUCTURE OF PROTEIN TYROSINE PHOSPHATASE 1B COMPLEXED WITH 5-IODO-2-(OXALYL-AMINO)-BENZOIC ACID
1C83	;	1.8	;	CRYSTAL STRUCTURE OF PROTEIN TYROSINE PHOSPHATASE 1B COMPLEXED WITH 6-(OXALYL-AMINO)-1H-INDOLE-5-CARBOXYLIC ACID
1G1H	;	2.4	;	CRYSTAL STRUCTURE OF PROTEIN TYROSINE PHOSPHATASE 1B COMPLEXED WITH A BIS-PHOSPHORYLATED PEPTIDE (ETD(PTR)(PTR)RKGGKGLL) FROM THE INSULIN RECEPTOR KINASE
1G1G	;	2.2	;	CRYSTAL STRUCTURE OF PROTEIN TYROSINE PHOSPHATASE 1B COMPLEXED WITH A MONO-PHOSPHORYLATED PEPTIDE (ETDY(PTR)RKGGKGLL) FROM THE INSULIN RECEPTOR KINASE
1G1F	;	2.0	;	CRYSTAL STRUCTURE OF PROTEIN TYROSINE PHOSPHATASE 1B COMPLEXED WITH A TRI-PHOSPHORYLATED PEPTIDE (RDI(PTR)ETD(PTR)(PTR)RK) FROM THE INSULIN RECEPTOR KINASE
1EEN	;	1.9	;	CRYSTAL STRUCTURE OF PROTEIN TYROSINE PHOSPHATASE 1B COMPLEXED WITH ACETYL-D-A-D-BPA-PTYR-L-I-P-Q-Q-G
1EEO	;	1.8	;	CRYSTAL STRUCTURE OF PROTEIN TYROSINE PHOSPHATASE 1B COMPLEXED WITH ACETYL-E-L-E-F-PTYR-M-D-Y-E-NH2
1PTV	;	2.3	;	CRYSTAL STRUCTURE OF PROTEIN TYROSINE PHOSPHATASE 1B COMPLEXED WITH PHOSPHOTYROSINE
1PTU	;	2.6	;	CRYSTAL STRUCTURE OF PROTEIN TYROSINE PHOSPHATASE 1B COMPLEXED WITH PHOSPHOTYROSINE-CONTAINING HEXA-PEPTIDE (DADEPYL-NH2)
1PTT	;	2.9	;	CRYSTAL STRUCTURE OF PROTEIN TYROSINE PHOSPHATASE 1B COMPLEXED WITH PHOSPHOTYROSINE-CONTAINING TETRA-PEPTIDE (AC-DEPYL-NH2)
1AAX	;	1.9	;	CRYSTAL STRUCTURE OF PROTEIN TYROSINE PHOSPHATASE 1B COMPLEXED WITH TWO BIS(PARA-PHOSPHOPHENYL)METHANE (BPPM) MOLECULES
1PTY	;	1.85	;	CRYSTAL STRUCTURE OF PROTEIN TYROSINE PHOSPHATASE 1B COMPLEXED WITH TWO PHOSPHOTYROSINE MOLECULES
4I8N	;	2.5	;	CRYSTAL STRUCTURE of PROTEIN TYROSINE PHOSPHATASE 1B IN COMPLEX WITH AN INHIBITOR [(4-{(2S)-2-(1,3-BENZOXAZOL-2-YL)-2-[(4-FLUOROPHENYL)SULFAMOYL]ETHYL}PHENYL)AMINO](OXO)ACETIC ACID
2VEU	;	2.4	;	Crystal structure of protein tyrosine phosphatase 1B in complex with an isothiazolidinone-containing inhibitor
2VEV	;	1.8	;	CRYSTAL STRUCTURE OF PROTEIN TYROSINE PHOSPHATASE 1B IN COMPLEX WITH AN ISOTHIAZOLIDINONE-CONTAINING INHIBITOR
2VEW	;	2.0	;	CRYSTAL STRUCTURE OF PROTEIN TYROSINE PHOSPHATASE 1B IN COMPLEX WITH AN ISOTHIAZOLIDINONE-CONTAINING INHIBITOR
2VEX	;	2.2	;	CRYSTAL STRUCTURE OF PROTEIN TYROSINE PHOSPHATASE 1B IN COMPLEX WITH AN ISOTHIAZOLIDINONE-CONTAINING INHIBITOR
2VEY	;	2.2	;	CRYSTAL STRUCTURE OF PROTEIN TYROSINE PHOSPHATASE 1B IN COMPLEX WITH AN ISOTHIAZOLIDINONE-CONTAINING INHIBITOR
1PXH	;	2.15	;	Crystal structure of protein tyrosine phosphatase 1B with potent and selective bidentate inhibitor compound 2
3IDO	;	2.2	;	Crystal structure of protein tyrosine phosphatase from Entamoeba histolytica with a phosphotyrosine crude mimic HEPES molecule in the active site
3JS5	;	1.94	;	Crystal structure of protein tyrosine phosphatase from Entamoeba histolytica with Hepes in the active site. High resolution, alternative crystal form with 1 molecule in asymmetric unit
4PVG	;	2.4	;	Crystal structure of protein tyrosine phosphatase Shp2 catalytic domain complex with small molecular compound L88N79
1ZWY	;	1.9	;	Crystal structure of protein VC0702 from Vibrio cholerae
1XMX	;	2.1	;	Crystal structure of protein VC1899 from Vibrio cholerae
1R3D	;	1.9	;	Crystal structure of protein VC1974 from Vibrio cholerae, Pfam abhydrolase
3ES1	;	1.91	;	Crystal structure of protein with a cupin-like fold and unknown function (YP_001165807.1) from NOVOSPHINGOBIUM AROMATICIVORANS DSM 12444 at 1.91 A resolution
3KOP	;	1.9	;	Crystal structure of Protein with a cyclophilin-like fold (YP_831253.1) from Arthrobacter sp. FB24 at 1.90 A resolution
4NPO	;	1.47	;	Crystal structure of protein with unknown function from Deinococcus radiodurans at P61 spacegroup
3IRB	;	1.8	;	Crystal structure of protein with unknown function from DUF35 family (13815350) from SULFOLOBUS SOLFATARICUS at 1.80 A resolution
3L5O	;	2.01	;	Crystal structure of protein with unknown function from DUF364 family (ZP_00559375.1) from Desulfitobacterium hafniense DCB-2 at 2.01 A resolution
3LUU	;	1.93	;	Crystal structure of Protein with unknown function which belongs to Pfam DUF971 family (AFE_2189) from Acidithiobacillus ferrooxidans ATCC 23270 at 1.93 A resolution
2IQI	;	2.7	;	Crystal structure of protein XCC0632 from Xanthomonas campestris, Pfam DUF330
1RW0	;	2.0	;	Crystal structure of protein yfiH from Salmonella enterica serovar Typhi, Pfam DUF152
1U05	;	2.5	;	Crystal structure of protein yfiH from Shigella flexneri, Pfam DUF152
1RC6	;	2.6	;	Crystal structure of protein Ylba from E. coli, Pfam DUF861
2PIH	;	2.1	;	Crystal structure of Protein ymcA from Bacillus subtilis, NorthEast Structural Genomics target SR375
1TLQ	;	2.4	;	Crystal structure of protein ypjQ from Bacillus subtilis, Pfam DUF64
2NX2	;	2.0	;	Crystal structure of protein ypsA from Bacillus subtilis, Pfam DUF1273
3F1S	;	2.3	;	Crystal structure of Protein Z complexed with protein Z-dependent inhibitor
3GMF	;	1.76	;	Crystal structure of protein-disulfide isomerase from Novosphingobium aromaticivorans
2ZK9	;	1.15	;	Crystal Structure of Protein-glutaminase
3WBM	;	2.0	;	Crystal Structure of protein-RNA complex
3A5J	;	1.7	;	Crystal structure of protein-tyrosine phosphatase 1B
3A5K	;	1.85	;	Crystal structure of protein-tyrosine phosphatase 1B
7E8K	;	2.25	;	Crystal structure of Proteinaceous RNase P (PRORP) from Planctomycetes bacterium GWF2_40_8
7E8J	;	2.1	;	Crystal structure of Proteinaceous RNase P (PRORP) from Thermococcus celer
4G26	;	1.75	;	Crystal Structure of proteinaceous RNase P 1 (PRORP1) from A. thaliana with Ca
4G23	;	1.98	;	Crystal Structure of proteinaceous RNase P 1 (PRORP1) from A. thaliana with Mn
4G24	;	1.95	;	Crystal Structure of proteinaceous RNase P 1 (PRORP1) from A. thaliana with Mn
4G25	;	2.0	;	Crystal Structure of proteinaceous RNase P 1 (PRORP1) from A. thaliana, SeMet substituted form with Sr
7E8O	;	2.804	;	Crystal structure of proteinaceous RNase P(PRORP) from Planctomycetes bacterium GWF2_40_8 complexed with Escherichia coli histidine pre-tRNA
2ID8	;	1.27	;	Crystal structure of Proteinase K
2HPZ	;	1.69	;	Crystal structure of proteinase K complex with a synthetic peptide KLKLLVVIRLK at 1.69 A resolution
6KKF	;	1.4	;	Crystal structure of proteinase K complexed with a triglycine
5AVJ	;	1.45	;	Crystal structure of proteinase K from Engyodontium album
5AVK	;	1.45	;	Crystal structure of proteinase K from Engyodontium album
5B1D	;	2.3	;	Crystal structure of proteinase K from Engyodontium album
5B1E	;	2.3	;	Crystal structure of proteinase K from Engyodontium album
5WRC	;	1.5	;	Crystal structure of proteinase K from Engyodontium album
6K2P	;	1.6	;	Crystal structure of proteinase K from Engyodontium album
6K2R	;	1.6	;	Crystal structure of proteinase K from Engyodontium album
6K2S	;	1.6	;	Crystal structure of proteinase K from Engyodontium album
6K2T	;	1.6	;	Crystal structure of proteinase K from Engyodontium album
6K2V	;	1.6	;	Crystal structure of proteinase K from Engyodontium album
6K2W	;	1.7	;	Crystal structure of proteinase K from Engyodontium album
6K2X	;	1.65	;	Crystal structure of proteinase K from Engyodontium album
4ZAR	;	1.15	;	Crystal Structure of Proteinase K from Engyodontium albuminhibited by METHOXYSUCCINYL-ALA-ALA-PRO-PHE-CHLOROMETHYL KETONE at 1.15 A resolution
3PTL	;	1.3	;	Crystal structure of proteinase K inhibited by a lactoferrin nonapeptide, Lys-Gly-Glu-Ala-Asp-Ala-Leu-Ser-Leu-Asp at 1.3 A resolution.
2HD4	;	2.15	;	Crystal structure of proteinase K inhibited by a lactoferrin octapeptide Gly-Asp-Glu-Gln-Gly-Glu-Asn-Lys at 2.15 A resolution
6ZEU	;	2.004	;	Crystal structure of proteinase K lamella by electron diffraction with a 50 micrometre C2 condenser aperture
6ZEV	;	2.4	;	Crystal structure of proteinase K lamellae by electron diffraction with a 20 micrometre C2 condenser aperture
6ZET	;	2.701	;	Crystal structure of proteinase K nanocrystals by electron diffraction with a 20 micrometre C2 condenser aperture
5AMX	;	1.01	;	Crystal Structure of Proteinase K processed with the CrystalDirect automated mounting and cryo-cooling technology
1YE9	;	2.8	;	Crystal structure of proteolytically truncated catalase HPII from E. coli
3ZVQ	;	2.0	;	Crystal Structure of proteolyzed lysozyme
4XVW	;	2.6	;	Crystal structure of Proteus mirabilis ScsC in a compact conformation
5IDR	;	2.562	;	Crystal structure of Proteus Mirabilis ScsC in a transitional conformation
5ID4	;	2.921	;	Crystal structure of Proteus mirabilis ScsC in an extended conformation
4Q11	;	1.95	;	Crystal structure of Proteus mirabilis transcriptional regulator protein Crl at 1.95A resolution
5EDK	;	3.214	;	Crystal structure of prothrombin deletion mutant residues 146-167 ( Form II ).
5EDM	;	2.2	;	Crystal structure of prothrombin deletion mutant residues 154-167 ( Form I )
6BJR	;	6.0	;	Crystal structure of prothrombin mutant S101C/A470C
4XH6	;	2.04	;	Crystal structure of proto-oncogene kinase Pim1 bound to hispidulin
4ZPM	;	2.4	;	Crystal Structure of Protocadherin Alpha C2 EC1-3
4ZPL	;	3.3	;	Crystal Structure of Protocadherin Beta 1 EC1-3
4ZPS	;	2.9	;	Crystal Structure of Protocadherin Gamma A8 EC1-3
4ZPO	;	2.9	;	Crystal Structure of Protocadherin Gamma C5 EC1-3
4ZPP	;	3.002	;	Crystal Structure of Protocadherin Gamma C5 EC1-3
4ZPQ	;	3.099	;	Crystal Structure of Protocadherin Gamma C5 EC1-3
4ZPN	;	3.3	;	Crystal Structure of Protocadherin Gamma C5 EC1-3 with extended N-terminus
2BUX	;	1.8	;	Crystal Structure of Protocatechuate 3,4-Dioxygenase from Acinetobacter Sp. ADP1 Mutant R133H
2BUZ	;	1.8	;	Crystal Structure of Protocatechuate 3,4-Dioxygenase from Acinetobacter Sp. ADP1 Mutant R133H in Complex with 4-Nitrocatechol
2BUY	;	1.8	;	Crystal Structure of Protocatechuate 3,4-Dioxygenase from Acinetobacter Sp. ADP1 Mutant R133H in Complex with Catechol
2BV0	;	1.8	;	Crystal Structure of Protocatechuate 3,4-Dioxygenase from Acinetobacter Sp. ADP1 Mutant R133H in Complex with Protocatechuate.
2BUT	;	1.85	;	Crystal Structure Of Protocatechuate 3,4-Dioxygenase from Acinetobacter Sp. ADP1 Mutant R457S - APO
2BUW	;	1.8	;	Crystal Structure of Protocatechuate 3,4-Dioxygenase from Acinetobacter Sp. ADP1 Mutant R457S in Complex with 4-Hydroxybenzoate
2BUU	;	1.8	;	Crystal Structure Of Protocatechuate 3,4-Dioxygenase from Acinetobacter Sp. ADP1 Mutant R457S in complex with 4-Nitrocatechol
2BUV	;	1.8	;	Crystal Structure Of Protocatechuate 3,4-Dioxygenase from Acinetobacter Sp. ADP1 Mutant R457S in Complex with Protocatechuate
7Q37	;	2.25	;	Crystal structure of proton pump MAR rhodopsin pressurized with krypton
5GPJ	;	3.5	;	Crystal Structure of Proton-Pumping Pyrophosphatase
1SEZ	;	2.9	;	Crystal Structure of Protoporphyrinogen IX Oxidase
7KSF	;	2.9	;	Crystal structure of Prototype Foamy Virus Protease-Reverse Transcriptase (native)
7KSE	;	3.0	;	Crystal structure of Prototype Foamy Virus Protease-Reverse Transcriptase CSH mutant (selenomethionine-labeled)
6LLA	;	1.88	;	Crystal structure of Providencia alcalifaciens 3-dehydroquinate synthase (DHQS) in complex with Mg2+ and NAD
6LK2	;	2.503	;	Crystal structure of Providencia alcalifaciens 3-dehydroquinate synthase (DHQS) in complex with Mg2+, NAD and chlorogenic acid
1SW2	;	2.1	;	Crystal structure of ProX from Archeoglobus fulgidus in complex with glycine betaine
1SW1	;	1.9	;	Crystal structure of ProX from Archeoglobus fulgidus in complex with proline betaine
1SW4	;	1.9	;	Crystal structure of ProX from Archeoglobus fulgidus in complex with trimethyl ammonium
1SW5	;	1.8	;	Crystal structure of ProX from Archeoglobus fulgidus in the ligand free form
2Z0K	;	2.2	;	Crystal structure of ProX-AlaSA complex from T. thermophilus
2Z0X	;	1.64	;	Crystal structure of ProX-CysSA complex from T. thermophilus
4W67	;	1.001	;	Crystal structure of Prp peptide
4W5Y	;	1.122	;	Crystal structure of Prp pepttide
3KX2	;	2.2	;	Crystal structure of Prp43p in complex with ADP
3ENB	;	1.85	;	Crystal Structure of PRP8 core domain IV
4I43	;	2.0	;	Crystal structure of Prp8:Aar2 complex
3ZEF	;	3.1	;	Crystal structure of Prp8:Aar2 complex: second crystal form at 3.1 Angstrom resolution
4LG8	;	1.89	;	Crystal structure of PRPF19 WD40 repeats
6JDU	;	2.81	;	Crystal structure of PRRSV nsp10 (helicase)
4WO7	;	2.63	;	Crystal Structure of PrsA from Bacillus subtilis
5HTF	;	2.1	;	Crystal Structure of PrsA1 from Listeria monocytogenes
3QNL	;	1.77	;	Crystal structure of PrTX-I complexed to Rosmarinic Acid
2Q2J	;	1.65	;	Crystal structure of PrTX-I, a PLA2 homolog from Bothrops pirajai
3EHK	;	3.2	;	Crystal structure of Pru du amandin, an allergenic protein from prunus dulcis
6KHX	;	2.58	;	Crystal structure of Prx from Akkermansia muciniphila
5ZTE	;	2.6	;	Crystal structure of PrxA C119S mutant from Arabidopsis thaliana
6BIA	;	2.8	;	Crystal structure of Ps i-CgsB
6B1V	;	2.84	;	Crystal structure of Ps i-CgsB C78S in complex with i-neocarratetraose
6B0K	;	2.15	;	Crystal structure of Ps i-CgsB C78S in complex with k-carrapentaose
6B0J	;	2.5	;	Crystal structure of Ps i-CgsB in complex with k-i-k-neocarrahexaose
2BWR	;	1.5	;	Crystal Structure of Psathyrella Velutina Lectin at 1.5A Resolution
5X56	;	1.85	;	Crystal structure of PSB27 from Arabidopsis thaliana
1V2B	;	1.6	;	Crystal Structure of PsbP Protein in the Oxygen-Evolving Complex of Photosystem II from Higher Plants
1NZE	;	1.95	;	Crystal structure of PsbQ polypeptide of photosystem II from higher plants
1VYK	;	1.49	;	CRYSTAL STRUCTURE OF PSBQ PROTEIN OF PHOTOSYSTEM II FROM HIGHER PLANTS
5YPO	;	2.29	;	Crystal structure of PSD-95 GK domain in complex with phospho-SAPAP peptide
7CQF	;	1.8	;	Crystal structure of PSD-95 PDZ3 fused with ADAM22 C-terminal peptide
5YPR	;	2.349	;	Crystal Structure of PSD-95 SH3-GK domain in complex with a synthesized inhibitor
3GSL	;	2.05	;	Crystal structure of PSD-95 tandem PDZ domains 1 and 2
6BHC	;	2.3	;	Crystal structure of pseduokinase PEAK1 (Sugen Kinase 269)
3HBM	;	1.8	;	Crystal Structure of PseG from Campylobacter jejuni
7V8X	;	2.34	;	Crystal structure of PsEst3 complexed with Phenylmethylsulfonyl fluoride (PMSF)
7V8V	;	2.4	;	Crystal structure of PsEst3 S128A mutant
7V8W	;	1.8	;	Crystal structure of PsEst3 S128A variant complexed with malonate
7V8U	;	2.25	;	Crystal structure of PsEst3 wild-type
2DDA	;	2.25	;	Crystal structure of pseudechetoxin from Pseudechis australis
2DDB	;	1.9	;	Crystal structure of pseudecin from Pseudechis porphyriacus
3ITN	;	1.63	;	Crystal structure of Pseudo-activated Procaspase-3
7OG2	;	2.8	;	Crystal structure of Pseudoalteromonas luteoviolacea L-amino acid oxidase
7OAL	;	2.17	;	Crystal structure of pseudokinase CASK in complex with compound 25
7OAK	;	2.23	;	Crystal structure of pseudokinase CASK in complex with compound 26
7OAJ	;	1.93	;	Crystal structure of pseudokinase CASK in complex with compound 7
7OAI	;	2.3	;	Crystal structure of pseudokinase CASK in complex with PFE-PKIS12
6WYZ	;	1.7	;	Crystal structure of Pseudomonas 7A Glutaminase-Asparaginase (mutant K173M) in complex with D-Glu at pH 5.5
6WYW	;	2.13	;	Crystal structure of Pseudomonas 7A Glutaminase-Asparaginase in complex with L-Asp at pH 4.5
6WYX	;	1.48	;	Crystal structure of Pseudomonas 7A Glutaminase-Asparaginase in complex with L-Asp at pH 5.0
6WYY	;	1.35	;	Crystal structure of Pseudomonas 7A Glutaminase-Asparaginase in complex with L-Glu at pH 6.5
1DJP	;	1.9	;	CRYSTAL STRUCTURE OF PSEUDOMONAS 7A GLUTAMINASE-ASPARAGINASE WITH THE INHIBITOR DON COVALENTLY BOUND IN THE ACTIVE SITE
1DJO	;	2.0	;	Crystal structure of Pseudomonas 7A Glutaminase-asparaginase with the inhibitor donv covalently bound in the active site
3VI1	;	2.0	;	Crystal structure of Pseudomonas aerginosa alkaline protease complexed with Substance P(1-6)
3JZZ	;	1.597	;	Crystal structure of Pseudomonas aeruginosa (strain: Pa110594) typeIV pilin in space group P212121
3JYZ	;	1.55	;	Crystal structure of Pseudomonas aeruginosa (strain: Pa110594) typeIV pilin in space group P41212
4IPU	;	1.351	;	Crystal structure of Pseudomonas aeruginosa (strain: PAO1) type IV minor pilin FimU in space group P21
4IPV	;	1.4	;	Crystal structure of Pseudomonas aeruginosa (strain: PAO1) type IV minor pilin FimU in space group P65
3QBX	;	2.1	;	Crystal structure of pseudomonas aeruginosa 1,6-anhydro-n-actetylmuramic acid kinase (ANMK) bound to 1,6-anhydro-n-actetylmuramic acid
3QBW	;	2.23	;	Crystal structure of pseudomonas aeruginosa 1,6-anhydro-n-actetylmuramic acid kinase (ANMK) bound to adenosine diphosphate
4HZ1	;	2.2	;	Crystal Structure of Pseudomonas aeruginosa azurin with iron(II) at the copper-binding site.
7M1M	;	2.6	;	Crystal structure of Pseudomonas aeruginosa ClpP1
7M1L	;	2.0	;	Crystal structure of Pseudomonas aeruginosa ClpP2
3Q48	;	2.5	;	Crystal structure of Pseudomonas aeruginosa CupB2 chaperone
3NYC	;	1.06	;	Crystal Structure of Pseudomonas aeruginosa D-Arginine Dehydrogenase
3SM8	;	1.07	;	Crystal Structure of Pseudomonas aeruginosa D-Arginine Dehydrogenase in Complex with an (N5) Flavin Adduct
3NYE	;	1.3	;	Crystal Structure of Pseudomonas aeruginosa D-Arginine Dehydrogenase in Complex with Imino-Arginine
3NYF	;	1.3	;	Crystal Structure of Pseudomonas aeruginosa D-Arginine Dehydrogenase in Complex with Imino-Histidine
7RDF	;	1.29	;	Crystal structure of Pseudomonas aeruginosa D-Arginine Dehydrogenase Y249F co-crystallized in the presence of D-arginine
6PLD	;	1.55	;	Crystal Structure of Pseudomonas aeruginosa D-Arginine Dehydrogenase Y249F variant with 6-OH-FAD - Green fraction
6P9D	;	1.329	;	Crystal Structure of Pseudomonas aeruginosa D-Arginine Dehydrogenase Y249F variant with FAD - Yellow fraction
3H93	;	1.501	;	Crystal Structure of Pseudomonas aeruginosa DsbA
5DCH	;	1.447	;	Crystal structure of Pseudomonas aeruginosa DsbA E82I in complex with MIPS-0000851 (3-[(2-METHYLBENZYL)SULFANYL]-4H-1,2,4-TRIAZOL-4-AMINE)
4ZL7	;	1.922	;	Crystal structure of Pseudomonas aeruginosa DsbA E82I: Crystal I
4ZL8	;	1.395	;	Crystal structure of Pseudomonas aeruginosa DsbA E82I: Crystal II
4ZL9	;	1.7	;	Crystal structure of Pseudomonas aeruginosa DsbA E82I: Crystal III
4N30	;	1.3	;	Crystal structure of Pseudomonas aeruginosa DsbA2
6J7J	;	1.75	;	Crystal structure of Pseudomonas aeruginosa Earp
6J7L	;	1.851	;	Crystal structure of Pseudomonas aeruginosa Earp in complex with TDP
6J7K	;	2.15	;	Crystal structure of Pseudomonas aeruginosa Earp in complex with TDP-Rha
4NX9	;	2.1	;	Crystal structure of Pseudomonas aeruginosa flagellin FliC
7PJI	;	1.65	;	Crystal structure of Pseudomonas aeruginosa guaB (IMP dehydrogenase) bound to ATP and GDP at 1.65A resolution
3NIO	;	2.0	;	Crystal structure of Pseudomonas aeruginosa guanidinobutyrase
3NIQ	;	2.07	;	Crystal structure of Pseudomonas aeruginosa guanidinopropionase
3NIP	;	2.5	;	Crystal structure of Pseudomonas aeruginosa guanidinopropionase complexed with 1,6-diaminohexane
3QUI	;	1.933	;	Crystal structure of Pseudomonas aeruginosa Hfq in complex with ADPNP
5Y6I	;	2.517	;	Crystal structure of Pseudomonas aeruginosa HmgR
3ZFH	;	2.25	;	Crystal structure of Pseudomonas aeruginosa inosine 5'-monophosphate dehydrogenase
4AVF	;	2.23	;	Crystal structure of Pseudomonas aeruginosa inosine 5'-monophosphate dehydrogenase
3HGX	;	2.5	;	Crystal Structure of Pseudomonas aeruginosa Isochorismate-Pyruvate Lyase K42A mutant in complex with salicylate and pyruvate
2BP6	;	1.5	;	crystal Structure of pseudomonas aeruginosa lectin (PA-IIL) complexed with a-L-Galactopyranoside
2BOJ	;	1.8	;	crystal Structure of pseudomonas aeruginosa lectin (PA-IIL) complexed with methyl-B-D-Arabinopyranoside
1OKO	;	1.6	;	Crystal structure of Pseudomonas Aeruginosa Lectin 1 complexed with galactose at 1.6 A resolution
1L7L	;	1.5	;	Crystal structure of Pseudomonas aeruginosa lectin 1 determined by single wavelength anomalous scattering phasing method
1UOJ	;	2.4	;	CRYSTAL STRUCTURE OF PSEUDOMONAS AERUGINOSA LECTIN 1 IN THE CALCIUM-FREE STATE
4LJH	;	1.45	;	Crystal Structure of Pseudomonas aeruginosa Lectin LecA Complexed with 1-Methyl-3-indolyl-b-D-galactopyranoside at 1.45 A Resolution
4LK6	;	2.859	;	Crystal Structure of Pseudomonas aeruginosa Lectin LecA Complexed with Chlorophenol Red-b-D-galactopyranoside at 2.86 A Resolution
4LKD	;	2.307	;	Crystal Structure of Pseudomonas aeruginosa Lectin LecA Complexed with GalA-QRS at 2.31 A Resolution
4LKF	;	1.64	;	Crystal Structure of Pseudomonas aeruginosa Lectin LecA Complexed with GalA-WKY at 1.64 A Resolution
4LKE	;	1.653	;	Crystal Structure of Pseudomonas aeruginosa Lectin LecA Complexed with GalA-WRI at 1.65 A Resolution
4LK7	;	1.758	;	Crystal Structure of Pseudomonas aeruginosa Lectin LecA Complexed with Resorufin-b-D-galactopyranoside at 1.76 A Resolution
2FAO	;	1.5	;	Crystal Structure of Pseudomonas aeruginosa LigD polymerase domain
2FAQ	;	1.9	;	Crystal Structure of Pseudomonas aeruginosa LigD polymerase domain with ATP and Manganese
2FAR	;	1.9	;	Crystal Structure of Pseudomonas aeruginosa LigD polymerase domain with dATP and Manganese
7OJ6	;	1.84	;	Crystal structure of Pseudomonas aeruginosa LpxA in complex with compound 1
7OJP	;	2.84	;	Crystal structure of Pseudomonas aeruginosa LpxA in complex with compound 1
7OKA	;	2.74	;	Crystal structure of Pseudomonas aeruginosa LpxA in complex with compound 14
7OK1	;	1.92	;	Crystal structure of Pseudomonas aeruginosa LpxA in complex with compound 3
7OK2	;	2.89	;	Crystal structure of Pseudomonas aeruginosa LpxA in complex with compound 3
7OKB	;	3.58	;	Crystal structure of Pseudomonas aeruginosa LpxA in complex with compound 45
7OJY	;	2.0	;	Crystal structure of Pseudomonas aeruginosa LpxA in complex with compound 6
7OJQ	;	1.87	;	Crystal structure of Pseudomonas aeruginosa LpxA in complex with compound 7
7OJW	;	1.72	;	Crystal structure of Pseudomonas aeruginosa LpxA in complex with compound 93
5N8C	;	1.9	;	Crystal structure of Pseudomonas aeruginosa LpxC complexed with inhibitor
7SQX	;	3.0	;	Crystal Structure of Pseudomonas aeruginosa lytic polysaccharide monooxygenase CbpD
3F6Z	;	2.5	;	Crystal structure of Pseudomonas aeruginosa MliC in complex with hen egg white lysozyme
4UBR	;	2.21	;	Crystal structure of Pseudomonas aeruginosa N-aetyltransferase PA4534
4A5O	;	2.2	;	Crystal structure of Pseudomonas aeruginosa N5, N10- methylenetetrahydrofolate dehydrogenase-cyclohydrolase (FolD)
3SY9	;	2.8	;	Crystal structure of Pseudomonas aeruginosa OccD2 (OpdC)
3SYB	;	2.7	;	Crystal structure of Pseudomonas aeruginosa OccD3 (OpdP)
4FSO	;	2.75	;	Crystal Structure of Pseudomonas aeruginosa OccK10 (OpdN)
4FSP	;	2.323	;	Crystal Structure of Pseudomonas aeruginosa OccK11 (OpdR)
3SZD	;	2.311	;	Crystal structure of Pseudomonas aeruginosa OccK2 (OpdF)
4FMS	;	2.45	;	Crystal structure of Pseudomonas aeruginosa OccK2 (OpdF) in complex with glucuronate
3SZV	;	1.45	;	Crystal structure of Pseudomonas aeruginosa OccK3 (OpdO)
3T0S	;	2.2	;	Crystal structure of Pseudomonas aeruginosa OccK4 (OpdL)
3T20	;	2.6	;	Crystal structure of Pseudomonas aeruginosa OccK5 (OpdH)
4FRT	;	3.166	;	Crystal Structure of Pseudomonas aeruginosa OccK7 (OpdD)
4FRX	;	1.9	;	Crystal Structure of Pseudomonas aeruginosa OccK8 (OprE)
4FT6	;	2.603	;	Crystal Structure of Pseudomonas aeruginosa OccK9 (OpdG)
2Y2X	;	1.65	;	Crystal Structure of Pseudomonas Aeruginosa OpdK with Vanillate
2Y0H	;	2.2	;	Crystal Structure of Pseudomonas Aeruginosa OpdL
2Y0K	;	2.295	;	Crystal Structure of Pseudomonas Aeruginosa OpdO
2Y0L	;	2.59	;	Crystal Structure of Pseudomonas Aeruginosa OpdO
3T24	;	2.4	;	Crystal structure of Pseudomonas aeruginosa OpdQ
4RJW	;	1.52	;	Crystal structure of Pseudomonas aeruginosa OprO
7KIS	;	2.869	;	Crystal structure of Pseudomonas aeruginosa PBP2 in complex with WCK 5153
4FSF	;	2.2	;	Crystal structure of Pseudomonas aeruginosa PBP3 complexed with compound 14
7KIV	;	2.389	;	Crystal structure of Pseudomonas aeruginosa PBP3 in complex with avibactam
7LC4	;	2.0	;	Crystal structure of Pseudomonas aeruginosa PBP3 in complex with gamma-lactam YU253911
6UN1	;	2.26	;	Crystal structure of Pseudomonas aeruginosa PBP3 in complex with temocillin
6UN3	;	1.9	;	Crystal structure of Pseudomonas aeruginosa PBP3 in complex with ticarcillin
7LY1	;	2.2	;	Crystal structure of Pseudomonas aeruginosa PBP3 in complex with vaborbactam
7KIT	;	2.089	;	Crystal structure of Pseudomonas aeruginosa PBP3 in complex with WCK 4234
7KIW	;	2.49	;	Crystal structure of Pseudomonas aeruginosa PBP3 in complex with zidebactam
4WEJ	;	2.045	;	Crystal structure of Pseudomonas aeruginosa PBP3 with a R4 substituted allyl monocarbam
4WEK	;	1.74	;	Crystal structure of Pseudomonas aeruginosa PBP3 with a R4 substituted vinyl monocarbam
4WEL	;	1.99	;	Crystal structure of Pseudomonas aeruginosa PBP3 with SMC-3176
7JWL	;	2.2	;	Crystal Structure of Pseudomonas aeruginosa Penicillin Binding Protein 3 (PAE-PBP3) bound to ETX0462
6VJE	;	1.76	;	Crystal structure of Pseudomonas aeruginosa penicillin-binding protein 3 (PBP3) complexed with ceftobiprole
6I1E	;	1.64	;	Crystal structure of Pseudomonas aeruginosa Penicillin-Binding Protein 3 in complex with amoxicillin
3BJZ	;	2.4	;	Crystal structure of Pseudomonas aeruginosa phosphoheptose isomerase
1X92	;	2.3	;	CRYSTAL STRUCTURE OF PSEUDOMONAS AERUGINOSA PHOSPHOHEPTOSE ISOMERASE IN COMPLEX WITH REACTION PRODUCT D-GLYCERO-D-MANNOPYRANOSE-7-PHOSPHATE
3HX6	;	2.1	;	Crystal structure of Pseudomonas aeruginosa PilY1 C-terminal domain
7EYP	;	1.5	;	Crystal structure of Pseudomonas aeruginosa ppnP
3H78	;	1.7	;	Crystal structure of Pseudomonas aeruginosa PqsD C112A mutant in complex with anthranilic acid
3H77	;	1.8	;	Crystal structure of Pseudomonas aeruginosa PqsD in a covalent complex with anthranilate
4M1J	;	1.8	;	Crystal structure of Pseudomonas aeruginosa PvdQ in complex with a transition state analogue
7Y0Z	;	2.3	;	Crystal structure of Pseudomonas aeruginosa PvrA
7Y0Y	;	2.09	;	Crystal structure of Pseudomonas aeruginosa PvrA (SeMet)
8HJB	;	2.65	;	Crystal structure of Pseudomonas aeruginosa PvrA with coenzyme A
4K59	;	2.22	;	Crystal Structure of Pseudomonas Aeruginosa RsmF
7ZD0	;	1.87	;	Crystal structure of Pseudomonas aeruginosa S-adenosyl-L-homocysteine hydrolase inhibited by Cd2+ ions
7ZD2	;	2.16	;	Crystal structure of Pseudomonas aeruginosa S-adenosyl-L-homocysteine hydrolase inhibited by Co2+ ions.
7ZD1	;	1.56	;	Crystal structure of Pseudomonas aeruginosa S-adenosyl-L-homocysteine hydrolase inhibited by Hg2+ ions
7ZD3	;	1.9	;	Crystal structure of Pseudomonas aeruginosa S-adenosyl-L-homocysteine hydrolase inhibited by Zn2+ ions
7ZD4	;	2.14	;	Crystal structure of Pseudomonas aeruginosa S-adenosyl-L-homocysteine hydrolase soaked with Cu+ ions
4K89	;	1.39	;	Crystal structure of Pseudomonas aeruginosa strain K solvent tolerant elastase
4L62	;	2.9	;	Crystal Structure of Pseudomonas aeruginosa transcriptional regulator PA2196 bound to its operator DNA
7W2Q	;	1.8	;	Crystal structure of Pseudomonas aeruginosa transcriptional regulator PvrA in the narrow conformation
7W2O	;	3.21	;	Crystal structure of Pseudomonas aeruginosa transcriptional regulator PvrA in the wide conformation
3VPV	;	1.8	;	Crystal Structure of Pseudomonas aeruginosa Tsi2
8F73	;	2.9	;	Crystal structure of Pseudomonas aeruginosa UDP-glucose phosphorylase in complex with UDP-glucose
1SB9	;	2.5	;	Crystal structure of Pseudomonas aeruginosa UDP-N-acetylglucosamine 4-epimerase complexed with UDP-glucose
1SB8	;	2.1	;	Crystal structure of Pseudomonas aeruginosa UDP-N-acetylglucosamine 4-epimerase complexed with UDP-N-acetylgalactosamine
1AZR	;	2.4	;	CRYSTAL STRUCTURE OF PSEUDOMONAS AERUGINOSA ZINC AZURIN MUTANT ASP47ASP AT 2.4 ANGSTROMS RESOLUTION
6VOT	;	2.4	;	Crystal structure of Pseudomonas aerugonisa PBP3 complexed to gamma-lactam YU253434
1UKF	;	1.35	;	Crystal Structure of Pseudomonas Avirulence Protein AvrPphB
5V2D	;	1.9	;	Crystal structure of Pseudomonas brassicacearum lignostilbene dioxygenase
2ODO	;	2.8	;	Crystal structure of Pseudomonas Fluorescens alanine racemase
1CJX	;	2.4	;	CRYSTAL STRUCTURE OF PSEUDOMONAS FLUORESCENS HPPD
5X6P	;	1.78	;	Crystal structure of Pseudomonas fluorescens KMO
5X6Q	;	1.897	;	Crystal structure of Pseudomonas fluorescens KMO in complex with Ro 61-8048
5Y7A	;	1.846	;	Crystal structure of Pseudomonas fluorescens Kynurenine 3-monooxygenase in complex with L-KYN
5Y77	;	1.6	;	Crystal structure of Pseudomonas fluorescens Kynurenine 3-monooxygenase in complex with L-KYN (seMet derivative)
5Y66	;	2.34	;	Crystal structure of Pseudomonas fluorescens Kynurenine 3-monooxygenase in complex with L-KYN and Ro61-8048
5FN0	;	3.19	;	Crystal structure of Pseudomonas fluorescens kynurenine-3- monooxygenase (KMO) in complex with GSK180
5VIP	;	1.857	;	Crystal structure of Pseudomonas malonate decarboxylase MdcD-MdcE hetero-dimer
4O98	;	2.251	;	Crystal structure of Pseudomonas oleovorans PoOPH mutant H250I/I263W
1QS0	;	2.4	;	Crystal Structure of Pseudomonas Putida 2-oxoisovalerate Dehydrogenase (Branched-Chain Alpha-Keto Acid Dehydrogenase, E1B)
4J0Q	;	2.294	;	Crystal structure of Pseudomonas putida elongation factor Tu (EF-Tu)
5X30	;	1.7	;	Crystal structure of Pseudomonas putida methionine gamma-lyase C116H mutant with L-homocysteine intermediates.
5X2Z	;	1.8	;	Crystal structure of Pseudomonas putida methionine gamma-lyase C116H mutant with L-methionine intermediates
5X2Y	;	1.79	;	Crystal structure of Pseudomonas putida methionine gamma-lyase C116H mutant without sulfate ion
7F1P	;	2.4	;	Crystal structure of Pseudomonas putida methionine gamma-lyase Q349S mutant ligand-free form.
7F1V	;	2.25	;	Crystal structure of Pseudomonas putida methionine gamma-lyase Q349S mutant with L-homocysteine intermediates
7F1U	;	2.4	;	Crystal structure of Pseudomonas putida methionine gamma-lyase Q349S mutant with L-methionine intermediates
5X2X	;	2.0	;	Crystal structure of Pseudomonas putida methionine gamma-lyase wild type with L-homocysteine intermediates
5X2W	;	2.7	;	Crystal structure of Pseudomonas putida methionine gamma-lyase wild type with L-methionine intermediates
5X2V	;	2.4	;	Crystal structure of Pseudomonas putida methionine gamma-lyase wild type without sulfate ion
6NVO	;	2.196	;	Crystal structure of Pseudomonas putida nuclease MPE
6NVP	;	2.0	;	Crystal structure of Pseudomonas putida nuclease MPE
3A6Z	;	2.15	;	Crystal structure of Pseudomonas sp. MIS38 lipase (PML) in the open conformation following dialysis against Ca-free buffer
2ZVD	;	2.15	;	Crystal structure of Pseudomonas sp. MIS38 lipase in an open conformation
3A70	;	2.15	;	Crystal structure of Pseudomonas sp. MIS38 lipase in complex with diethyl phosphate
1NU5	;	1.95	;	Crystal structure of Pseudomonas sp. P51 Chloromuconate lactonizing enzyme
7KZ9	;	1.9	;	Crystal structure of Pseudomonas sp. PDC86 substrate-binding protein Aapf in complex with a signaling molecule HEHEAA
6DVS	;	1.821	;	Crystal structure of Pseudomonas stutzeri D-phenylglycine aminotransferase
6R2J	;	1.44	;	Crystal Structure of Pseudomonas stutzeri endoglucanase Cel5A in complex with cellobiose
5MGY	;	2.6	;	Crystal structure of Pseudomonas stutzeri flavinyl transferase ApbE, apo form
3ITO	;	1.9	;	Crystal structure of Pseudomonas stutzeri L-rhamnose isomerase mutant D327N in complex with D-psicose
3ITL	;	1.7	;	Crystal structure of Pseudomonas stutzeri L-rhamnose isomerase mutant D327N in complex with L-rhamnulose
4GJJ	;	2.38	;	Crystal structure of Pseudomonas stutzeri L-rhamnose isomerase mutant H101N in complex with D-allopyranose
4GJI	;	1.7	;	Crystal structure of Pseudomonas stutzeri L-rhamnose isomerase mutant H101N in complex with L-rhamnopyranose
3M0Y	;	1.96	;	Crystal structure of Pseudomonas stutzeri L-rhamnose isomerase mutant S329A in complex with L-rhamnose
3M0M	;	1.45	;	Crystal structure of Pseudomonas stutzeri L-rhamnose isomerase mutant S329F in complex with D-allose
3M0L	;	1.85	;	Crystal structure of Pseudomonas stutzeri L-rhamnose isomerase mutant S329F in complex with D-psicose
3M0H	;	1.58	;	Crystal structure of Pseudomonas stutzeri L-rhamnose isomerase mutant S329F in complex with L-rhamnose
3ITV	;	1.6	;	Crystal structure of Pseudomonas stutzeri L-rhamnose isomerase mutant S329K in complex with D-psicose
3ITT	;	1.96	;	Crystal structure of Pseudomonas stutzeri L-rhamnose isomerase mutant S329K in complex with L-rhamnose
3M0X	;	1.79	;	Crystal structure of Pseudomonas stutzeri L-rhamnose isomerase mutant S329L in complex with D-psicose
3M0V	;	1.79	;	Crystal structure of Pseudomonas stutzeri L-rhamnose isomerase mutant S329L in complex with L-rhamnose
7R8F	;	3.16	;	Crystal structure of Pseudooceanicola lipolyticus Argonaute
7R8K	;	3.28	;	Crystal structure of Pseudooceanicola lipolyticus Argonaute (SeMet labeled protein)
7R8G	;	2.5	;	Crystal structure of Pseudooceanicola lipolyticus Argonaute bound to 5' OH guide DNA
7R8I	;	2.4	;	Crystal structure of Pseudooceanicola lipolyticus Argonaute bound to 5' OH guide DNA in the presence of Mg2+
7R8H	;	2.54	;	Crystal structure of Pseudooceanicola lipolyticus Argonaute bound to 5' p guide DNA
7R8J	;	2.7	;	Crystal structure of Pseudooceanicola lipolyticus Argonaute bound to 5' p guide DNA in the presence of Mg2+
2XQY	;	2.05	;	CRYSTAL STRUCTURE OF PSEUDORABIES CORE FRAGMENT OF GLYCOPROTEIN H IN COMPLEX WITH FAB D6.3
6ESC	;	2.7	;	Crystal structure of Pseudorabies virus glycoprotein B
5X5V	;	1.5	;	Crystal structure of pseudorabies virus glycoprotein D
5X5W	;	2.7	;	Crystal structure of pseudorabies virus glycoprotein D
2NQP	;	3.5	;	Crystal structure of pseudoudirinde synthase TruA in complex with leucyl tRNA
2NR0	;	3.9	;	Crystal structure of pseudoudirinde synthase TruA in complex with leucyl tRNA
2NRE	;	4.0	;	Crystal structure of pseudoudirinde synthase TruA in complex with leucyl tRNA
4GIM	;	1.802	;	Crystal Structure of Pseudouridine Monophosphate Glycosidase Complexed with Pseudouridine 5'-phosphate
4GIJ	;	1.941	;	Crystal Structure of Pseudouridine Monophosphate Glycosidase Complexed with Sulfate
4GIL	;	2.539	;	Crystal Structure of Pseudouridine Monophosphate Glycosidase/Linear Pseudouridine 5'-Phosphate Adduct
4GIK	;	2.187	;	Crystal Structure of Pseudouridine Monophosphate Glycosidase/Linear R5P Adduct
2I82	;	2.05	;	Crystal structure of pseudouridine synthase RluA: indirect sequence readout through protein-induced RNA structure
1PRZ	;	1.8	;	Crystal structure of pseudouridine synthase RluD catalytic module
1VIO	;	1.59	;	Crystal structure of pseudouridylate synthase
7UJ1	;	3.5	;	Crystal structure of PSF-RNA complex
7RTY	;	1.963	;	Crystal Structure of PsfC from Pseudomonas syringae PB-5123
7AJ0	;	2.5	;	Crystal structure of PsFucS1 sulfatase from Pseudoalteromonas sp.
6EBN	;	1.96631	;	Crystal structure of Psilocybe cubensis noncanonical aromatic amino acid decarboxylase
7DTL	;	1.8	;	Crystal structure of PSK, an antimicrobial peptide from Chrysomya megacephala
6LF8	;	2.5	;	Crystal structure of pSLA-1*0401 complex with dodecapeptide RVEDVTNTAEYW
6KWK	;	2.5	;	Crystal structure of pSLA-1*0401 complex with FMDV-derived epitope MTAHITVPY
6KWL	;	1.8	;	Crystal structure of pSLA-1*0401(R156A) complex with FMDV-derived epitope MTAHITVPY
6LF9	;	2.5	;	Crystal structure of pSLA-1*1301 complex with dodecapeptide RVEDVTNTAEYW
6KWO	;	1.803	;	Crystal structure of pSLA-1*1301 complex with mutant epitope ESDTVGWSW
6KWN	;	2.4	;	Crystal structure of pSLA-1*1301(F99Y) complex with S-OIV-derived epitope NSDTVGWSW
4NWS	;	2.7	;	Crystal structure of PSLssmKate, a photoswitchable LSSmKate variant
6KJG	;	1.99	;	Crystal structure of PsoF
6KJI	;	1.99	;	Crystal structure of PsoF with SAH
4QNM	;	1.628	;	CRYSTAL STRUCTURE of PSPF(1-265) E108Q MUTANT
4QOS	;	1.42	;	CRYSTAL STRUCTURE OF PSPF(1-265) E108Q MUTANT bound to ADP
4QNR	;	1.539	;	CRYSTAL STRUCTURE OF PSPF(1-265) E108Q MUTANT bound to ATP
2BJV	;	1.7	;	Crystal Structure of PspF(1-275) R168A mutant
3K0T	;	2.1	;	Crystal structure of PSPTO -PSP protein in complex with D-beta-Glucose from Pseudomonas syringae pv. tomato str. DC3000
2ODA	;	1.9	;	Crystal Structure of PSPTO_2114
6PSO	;	2.0	;	Crystal structure of PsS1_19B C77S in complex with iota-neocarratetraose
6PSM	;	1.95	;	Crystal structure of PsS1_19B C77S in complex with kappa-neocarrabiose
6PT6	;	2.25	;	Crystal structure of PsS1_NC C84S in complex with i-neocarratetraose
6PT9	;	1.66	;	Crystal structure of PsS1_NC C84S in complex with k-neocarrabiose
6R2M	;	1.617	;	Crystal structure of PssZ from Listeria monocytogenes
4N13	;	1.3	;	Crystal Structure of PstS (BB_0215) from Borrelia burgdorferi
7XG8	;	2.25	;	Crystal structure of PstS protein from cyanophage P-SSM2
7XG7	;	1.7	;	Crystal structure of PstS protein from cyanophage Syn19
3VU9	;	1.75	;	Crystal Structure of Psy3-Csm2 complex
3W53	;	2.2	;	Crystal structure of psychrophilic beta-glucosidase BglU from Micrococcus antarcticus
6I06	;	2.0	;	Crystal structure of psychrophilic phosphoglycerate kinase from Pseudomonas TACII18
6HXE	;	2.1	;	Crystal structure of psychrophilic phosphoglycerate kinase from Pseudomonas TACII18 in complex with 3-phosphoglycerate
1V6C	;	1.8	;	Crystal Structure of Psychrophilic Subtilisin-like Protease Apa1 from Antarctic Psychrotroph Pseudoalteromonas sp. AS-11
1WVM	;	1.6	;	Crystal Structure of Psychrophilic Subtilisin-like Serine Protease APA1 from Antarctic Psychrotroph Pseudoaleromonas sp. AS-11, Complexed with Inhibitor Chymostatin
1Y9Z	;	1.4	;	Crystal Structure of Psychrophilic Subtilisin-like Serine Protease from Antarctic Psychrotroph Pseudoalteromonas sp. AS-11 at 0.14 nm resolution
3HP4	;	1.35	;	Crystal structure of psychrotrophic esterase EstA from Pseudoalteromonas sp. 643A inhibited by monoethylphosphonate
3AZ5	;	2.34	;	Crystal structure of Pt/O-HEWL
3AZ7	;	2.1	;	Crystal structure of Pt/T-HEWL
5UNQ	;	1.976	;	Crystal Structure of Pt0534 Inactivated by 2-Oxo-3-pentynoate
6D0B	;	1.6	;	Crystal structure of PT1614 bound to HIF2a-B*:ARNT-B* complex
6X21	;	1.54	;	Crystal structure of PT1673 bound to HIF2a-B*:ARNT-B* complex
6CZW	;	1.6	;	Crystal structure of PT1940 bound to HIF2a-B*:ARNT-B* complex
6X28	;	1.92	;	Crystal structure of PT2243 bound to HIF2a-B*:ARNT-B* complex
5TBM	;	1.85	;	Crystal structure of PT2385 bound to HIF2a-B*:ARNT-B* complex
5UFP	;	1.9	;	Crystal structure of PT2399 bound to HIF2a-B*:ARNT-B* complex
6D09	;	1.85	;	Crystal structure of PT2440 bound to HIF2a-B*:ARNT-B* complex
6X2H	;	2.0	;	Crystal structure of PT2863 bound to HIF2a-B*:ARNT-B* complex
6X37	;	1.94	;	Crystal structure of PT3245 bound to HIF2a-B*:ARNT-B* complex
6X3D	;	2.0	;	Crystal structure of PT3388 bound to HIF2a-B*:ARNT-B* complex
4NU5	;	2.35	;	Crystal Structure of PTDH R301A
4NU6	;	2.65	;	Crystal Structure of PTDH R301K
3CS2	;	1.95	;	Crystal structure of PTE G60A mutant
3UR2	;	2.0	;	Crystal Structure of PTE mutant H254G/H257W/L303T/K185R/I274N/A80V
3URA	;	1.88	;	Crystal Structure of PTE mutant H254G/H257W/L303T/K185R/I274N/A80V/S61T
3URN	;	1.95	;	Crystal Structure of PTE mutant H254G/H257W/L303T/K185R/I274N/A80V/S61T with cyclohexyl methylphosphonate inhibitor
3URB	;	1.77	;	Crystal Structure of PTE mutant H254G/H257W/L303T/M317L/I106C/F132I/L271I/K185R/I274N/A80V/R67H
3URQ	;	2.1	;	Crystal Structure of PTE mutant H254G/H257W/L303T/M317L/I106C/F132I/L271I/K185R/I274N/A80V/R67H with cyclohexyl methylphosphonate inhibitor
3UPM	;	1.95	;	Crystal Structure of PTE mutant H254Q/H257F/K185R/I274N
3UR5	;	1.6	;	Crystal Structure of PTE mutant K185R/I274N
7JVX	;	3.2	;	Crystal structure of PTEN (aa 7-353 followed by spacer TGGGSGGTGGGSGGTGGGCY ligated to peptide pSDpTpTDpSDPENEPFDED)
7JUK	;	3.15	;	Crystal structure of PTEN with a tetra-phosphorylated tail (4p-crPTEN-13sp-T2, SDTTDSDPENEG)
3AWF	;	1.99	;	Crystal structure of Pten-like domain of Ci-VSP (236-576)
3AWE	;	2.77	;	Crystal structure of Pten-like domain of Ci-VSP (248-576)
3AWG	;	2.39	;	Crystal structure of Pten-like domain of Ci-VSP G356A mutant (248-576)
2XOX	;	2.5	;	Crystal structure of pteridine reductase (PTR1) from Leishmania donovani
3JQF	;	1.6	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor (NADP+) and inhibitor 1,3,5-triazine-2,4,6-triamine (AX2)
3JQA	;	1.9	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor (NADP+) and inhibitor 2-amino-1,9-dihydro-6H-purine-6-thione (DX4)
3JQD	;	1.6	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor (NADP+) and inhibitor 2-amino-4-oxo-6-phenyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile (DX7)
3JQB	;	2.4	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor (NADP+) and inhibitor 2-amino-5-(2-phenylethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (DX6)
3JQ9	;	2.3	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor (NADP+) and inhibitor 2-amino-6-(1,3-benzodioxol-5-yl)-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile (AX1)
3JQE	;	2.0	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor (NADP+) and inhibitor 2-amino-6-(4-methoxyphenyl)-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile (DX8)
3JQC	;	1.8	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor (NADP+) and inhibitor 2-amino-6-bromo-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile (JU2)
3JQ8	;	1.95	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor (NADP+) and inhibitor 6,7,7-trimethyl-7,8-dihydropteridine-2,4-diamine (DX3)
3JQ6	;	1.8	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor (NADP+) and inhibitor 6,7-bis(1-methylethyl)pteridine-2,4-diamine (DX1)
3JQ7	;	1.8	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor (NADP+) and inhibitor 6-phenylpteridine-2,4,7-triamine (DX2)
3JQG	;	1.9	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor (NADP+) and inhibitor 6-[(4-methoxybenzyl)sulfanyl]pyrimidine-2,4-diamine (AX6)
4CL8	;	2.2	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor and inhibitor
4CLD	;	1.77	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor and inhibitor
4CLE	;	1.8	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor and inhibitor
4CLH	;	1.85	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor and inhibitor
4CLO	;	1.88	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor and inhibitor
4CLR	;	1.75	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor and inhibitor
4CLX	;	1.85	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor and inhibitor
4CM1	;	1.9	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor and inhibitor
4CM3	;	1.95	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor and inhibitor
4CM4	;	1.81	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor and inhibitor
4CM5	;	1.99	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor and inhibitor
4CM6	;	1.7	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor and inhibitor
4CM7	;	1.9	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor and inhibitor
4CM8	;	1.9	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor and inhibitor
4CM9	;	1.9	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor and inhibitor
4CMA	;	1.85	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor and inhibitor
4CMB	;	1.96	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor and inhibitor
4CMC	;	1.85	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor and inhibitor
4CME	;	1.85	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor and inhibitor
4CMG	;	2.0	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor and inhibitor
4CMI	;	1.9	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor and inhibitor
4CMJ	;	2.2	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor and inhibitor
4CMK	;	2.0	;	Crystal structure of pteridine reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor and inhibitor
2EBB	;	1.6	;	Crystal structure of pterin-4-alpha-carbinolamine dehydratase (pterin carbinolamine dehydratase) from Geobacillus kaustophilus HTA426
3RFQ	;	2.25	;	Crystal structure of Pterin-4-alpha-carbinolamine dehydratase MoaB2 from Mycobacterium marinum
6I8Z	;	1.99	;	Crystal structure of PTK2 in complex with BI-4464.
5D7V	;	2.33	;	Crystal structure of PTK6 kinase domain
5H2U	;	2.24	;	Crystal structure of PTK6 Kinase Domain complexed with Dasatinib
5DA3	;	1.7	;	Crystal structure of PTK6 Kinase domain with inhibitor
5B5Z	;	1.6	;	Crystal structure of PtLCIB4 H88A mutant, a homolog of the limiting CO2-inducible protein LCIB
5B60	;	2.2	;	Crystal structure of PtLCIB4 S47R mutant, a homolog of the limiting CO2-inducible protein LCIB
5B5Y	;	1.75	;	Crystal structure of PtLCIB4, a homolog of the limiting CO2-inducible protein LCIB
2RDN	;	1.35	;	Crystal Structure of PtlH with AKG and ent-1PL bound
2RDQ	;	1.31	;	Crystal Structure of PtlH with Fe/alpha ketoglutarate bound
2RDS	;	1.65	;	Crystal Structure of PtlH with Fe/oxalylglycine and ent-1-deoxypentalenic acid bound
2RDR	;	1.7	;	Crystal Structure of PtlH with Fe/oxalylglycine bound
6OMQ	;	1.86	;	Crystal structure of PtmU3 complexed with PTM substrate
6OMR	;	2.45	;	Crystal structure of PtmU3 complexed with PTN substrate
4YFE	;	1.972	;	Crystal structure of PTP delta Fn1-Fn2
5Y32	;	2.701	;	Crystal structure of PTP delta Ig1-Ig2 in complex with IL1RAPL1
5WY8	;	3.07	;	Crystal structure of PTP delta Ig1-Ig3 in complex with IL1RAPL1 Ig1-Ig3
4YFG	;	3.491	;	Crystal structure of PTP delta meA3/meB minus variant Ig1-Fn1
6D4F	;	1.909	;	Crystal structure of PTP epsilon D2 domain (A455N/V457Y/E597D)
1L8G	;	2.5	;	Crystal structure of PTP1B complexed with 7-(1,1-Dioxo-1H-benzo[d]isothiazol-3-yloxymethyl)-2-(oxalyl-amino)-4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acid
8EXJ	;	2.301	;	Crystal structure of PTP1B D181A/Q262A phosphatase domain in complex with a JAK1 activation loop phosphopeptide
8EXM	;	2.349	;	Crystal structure of PTP1B D181A/Q262A phosphatase domain with a JAK3 activation loop phosphopeptide
8EXK	;	2.096	;	Crystal structure of PTP1B D181A/Q262A phosphatase domain with JAK2 activation loop phosphopeptide
8EXN	;	2.151	;	Crystal structure of PTP1B D181A/Q262A phosphatase domain with TYK2 activation loop phosphopeptide
8EYA	;	2.099	;	Crystal structure of PTP1B D181A/Q262A/C215A phosphatase domain with a JAK2 activation loop phosphopeptide
8EYB	;	2.349	;	Crystal structure of PTP1B D181A/Q262A/C215A phosphatase domain with JAK2 activation loop phosphopeptide
8F88	;	3.1	;	Crystal structure of PTP1B D181A/Q262A/C215A phosphatase domain with monophosphorylated JAK2 activation loop phosphopeptide
8EYC	;	2.99	;	Crystal structure of PTP1B D181A/Q262A/C215A phosphatase domain with TYK2 activation loop phosphopeptide
2H4K	;	2.3	;	Crystal structure of PTP1B with a monocyclic thiophene inhibitor
2AZR	;	2.0	;	Crystal structure of PTP1B with Bicyclic Thiophene inhibitor
2H4G	;	2.5	;	Crystal structure of PTP1B with monocyclic thiophene inhibitor
2HB1	;	2.0	;	Crystal Structure of PTP1B with Monocyclic Thiophene Inhibitor
2B07	;	2.1	;	Crystal structure of PTP1B with Tricyclic Thiophene inhibitor.
2NT7	;	2.1	;	Crystal structure of PTP1B-inhibitor complex
2NTA	;	2.1	;	Crystal Structure of PTP1B-inhibitor Complex
2QBP	;	2.5	;	Crystal structure of ptp1b-inhibitor complex
2QBQ	;	2.1	;	Crystal structure of ptp1b-inhibitor complex
2QBR	;	2.3	;	Crystal structure of ptp1b-inhibitor complex
2QBS	;	2.1	;	Crystal structure of ptp1b-inhibitor complex
2ZMM	;	2.1	;	Crystal structure of PTP1B-inhibitor complex
4YH7	;	4.4	;	Crystal structure of PTPdelta ectodomain in complex with IL1RAPL1
5XWT	;	4.178	;	Crystal structure of PTPdelta Ig1-Fn1 in complex with SALM5 LRR-Ig
5XWU	;	3.162	;	Crystal structure of PTPdelta Ig1-Ig3 in complex with SALM2 LRR-Ig
1WCH	;	1.85	;	Crystal structure of PTPL1 human tyrosine phosphatase mutated in colorectal cancer - evidence for a second phosphotyrosine substrate recognition pocket
3RGO	;	1.928	;	Crystal Structure of PTPMT1
3RGQ	;	2.05	;	Crystal Structure of PTPMT1 in complex with PI(5)P
5DF6	;	1.78	;	Crystal structure of PTPN11 tandem SH2 domains in complex with a TXNIP peptide
5HDE	;	1.62	;	Crystal Structure of PTPN12 Catalytic Domain
7F5O	;	1.7	;	Crystal structure of PTPN2 catalytic domain
3OMH	;	2.9	;	Crystal structure of PTPN22 in complex with SKAP-HOM pTyr75 peptide
4RI5	;	1.26	;	Crystal structure of PTPN3 (PTPH1) D811E mutant in complex with metavanadate
4RHG	;	1.581	;	Crystal structure of PTPN3 (PTPH1) D811E, C842S mutant in complex with Eps15 pTyr849 peptide
4RH9	;	1.598	;	Crystal structure of PTPN3 (PTPH1) H812F, M883G mutant in complex with Eps15 pTyr849 peptide
4QUM	;	2.516	;	Crystal structure of PTPN3 (PTPH1) in complex with a dually phosphorylated MAPK12 peptide
4S0G	;	1.723	;	Crystal structure of PTPN3 (PTPH1) in complex with Eps15 pTyr849 P850V peptide
4RH5	;	1.6	;	Crystal structure of PTPN3 (PTPH1) in complex with Eps15 pTyr849 peptide
4RI4	;	1.596	;	Crystal structure of PTPN3 (PTPH1) Y676I mutant in complex with vanadate
7VZE	;	2.882	;	Crystal structure of PTPN4 PDZ bound to the PBM of HPV16 E6
6KIP	;	1.911	;	Crystal structure of PTPRD phosphatase domain in complex with Liprin-alpha3 tandem SAM domains
3EYE	;	1.45	;	Crystal structure of PTS system N-acetylgalactosamine-specific IIB component 1 from Escherichia coli
5ZNR	;	3.202	;	Crystal structure of PtSHL in complex with an H3K27me3 peptide
5ZNP	;	2.8	;	Crystal structure of PtSHL in complex with an H3K4me3 peptide
2H0E	;	2.2	;	Crystal Structure of PucM in the absence of substrate
2H0J	;	2.9	;	Crystal structure of PucM in the presence of 5,6-diaminouracil
2H0F	;	2.7	;	Crystal Structure of PucM in the presence of 8-azaxanthine
4JDE	;	1.9	;	Crystal structure of PUD-1/PUD-2 heterodimer
3V71	;	2.902	;	Crystal structure of PUF-6 in complex with 5BE13 RNA
7CGF	;	1.7	;	Crystal Structure of PUF-8 in Complex with PBE-RNA
7CGG	;	2.7	;	Crystal Structure of PUF-8 in Complex with PBE-RNA
7CGH	;	2.4	;	Crystal Structure of PUF-8 in Complex with PBE-RNA
7CGI	;	2.796	;	Crystal Structure of PUF-8 in Complex with PBE-RNA
7CGJ	;	2.546	;	Crystal Structure of PUF-8 in Complex with PBE-RNA
7CGK	;	2.4	;	Crystal Structure of PUF-8 in Complex with PBE-RNA
7CGL	;	2.5	;	Crystal Structure of PUF-8 in Complex with PBE-RNA
7CGM	;	2.6	;	Crystal Structure of PUF-8 in Complex with PBE-RNA
6SLO	;	1.94	;	Crystal structure of PUF60 UHM domain in complex with 7,8 dimethoxyperphenazine
3GAE	;	1.6	;	Crystal Structure of PUL
3PSP	;	2.422	;	Crystal structure of PUL and PFU domain
3PST	;	1.999	;	Crystal structure of PUL and PFU(mutate) domain
2YOC	;	2.88	;	Crystal structure of PulA from Klebsiella oxytoca
8A9W	;	1.895	;	Crystal structure of PulL C-ter domain
3WDJ	;	2.22	;	Crystal structure of Pullulanase complexed with maltotetraose from Anoxybacillus sp. LM18-11
3WDI	;	2.2	;	Crystal structure of Pullulanase complexed with maltotriose from Anoxybacillus sp. LM18-11
3WDH	;	1.75	;	Crystal structure of Pullulanase from Anoxybacillus sp. LM18-11
5YN7	;	2.586	;	Crystal structure of Pullulanase from Klebsiella pneumoniae complex at 0.1 mM beta-cyclodextrin
5YNA	;	1.96	;	Crystal structure of Pullulanase from Klebsiella pneumoniae complex at 1 mM alpha-cyclodextrin
5YNC	;	2.32	;	Crystal structure of Pullulanase from Klebsiella pneumoniae complex at 1 mM beta-cyclodextrin
5YND	;	2.227	;	Crystal structure of Pullulanase from Klebsiella pneumoniae complex at 1 mM gamma-cyclodextrin
5YNE	;	2.199	;	Crystal structure of Pullulanase from Klebsiella pneumoniae complex at 10 mM alpha-cyclodextrin
5YNH	;	2.05	;	Crystal structure of Pullulanase from Klebsiella pneumoniae complex at 10 mM gamma-cyclodextrin
6JEQ	;	1.802	;	Crystal structure of Pullulanase from Paenibacillus barengoltzii complex with beta-cyclodextrin
6JFJ	;	1.932	;	Crystal structure of Pullulanase from Paenibacillus barengoltzii complex with maltohexaose and alpha-cyclodextrin
6JFX	;	1.981	;	Crystal structure of Pullulanase from Paenibacillus barengoltzii complex with maltopentaose
2E8Y	;	2.11	;	Crystal structure of pullulanase type I from Bacillus subtilis str. 168
2E8Z	;	2.2	;	Crystal structure of pullulanase type I from Bacillus subtilis str. 168 complexed with alpha-cyclodextrin
2E9B	;	2.3	;	Crystal structure of pullulanase type I from Bacillus subtilis str. 168 complexed with maltose
8A9X	;	1.523	;	Crystal structure of PulM C-ter domain
2EVX	;	2.6	;	Crystal structure of pumpkin seed globulin
7KSC	;	2.4	;	Crystal structure of Pun g 1.0101
1XMP	;	1.8	;	Crystal Structure of PurE (BA0288) from Bacillus anthracis at 1.8 Resolution
5EXZ	;	1.9	;	Crystal structure of purified recombinant CPV1 Polyhedra
1VHJ	;	2.23	;	Crystal structure of purine nucleoside phosphorylase
5ETJ	;	2.3	;	Crystal structure of purine nucleoside phosphorylase (E258D, L261A) mutant from human complexed with DADMe-ImmG and phosphate
1VMK	;	2.01	;	Crystal structure of Purine nucleoside phosphorylase (TM1596) from Thermotoga maritima at 2.01 A resolution
4EAR	;	1.7	;	Crystal structure of purine nucleoside phosphorylase (W16Y, W94Y, W178Y, H257W) mutant from human complexed with DADMe-ImmG and phosphate
4EB8	;	2.3	;	Crystal structure of purine nucleoside phosphorylase (W16Y, W94Y, W178Y, H257W) mutant from human complexed with DADMe-ImmG and phosphate
4ECE	;	2.6	;	Crystal structure of purine nucleoside phosphorylase (W16Y, W94Y, W178Y, H257W) mutant from human complexed with guanine
4GKA	;	2.2	;	Crystal structure of purine nucleoside phosphorylase (W16Y, W94Y, W178Y, H257W) mutant from human complexed with phosphate
1XE3	;	2.24	;	Crystal Structure of purine nucleoside phosphorylase DeoD from Bacillus anthracis
3TL6	;	2.65	;	Crystal structure of purine nucleoside phosphorylase from Entamoeba histolytica
4M7W	;	1.9	;	Crystal structure of purine nucleoside phosphorylase from Leptotrichia buccalis C-1013-b, NYSGRC Target 029767.
4MAR	;	2.16	;	Crystal structure of purine nucleoside phosphorylase from Meiothermus ruber DSM 1279 complexed with sulfate.
4M3N	;	1.6	;	Crystal structure of purine nucleoside phosphorylase from Meiothermus ruber DSM 1279, NYSGRC Target 029804.
3IOM	;	2.14	;	Crystal structure of Purine Nucleoside Phosphorylase from Mycobacterium tuberculosis in complex with 2'-Deoxyguanosine
1G2O	;	1.75	;	CRYSTAL STRUCTURE OF PURINE NUCLEOSIDE PHOSPHORYLASE FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH A TRANSITION-STATE INHIBITOR
3IX2	;	2.1	;	CRYSTAL STRUCTURE OF PURINE NUCLEOSIDE PHOSPHORYLASE FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH ACYCLOVIR
4NSN	;	1.6	;	Crystal structure of purine nucleoside phosphorylase from Porphyromonas gingivalis ATCC 33277, NYSGRC Target 030972, orthorhombic symmetry
4NS1	;	1.64	;	Crystal structure of purine nucleoside phosphorylase from Porphyromonas gingivalis ATCC 33277, NYSGRC Target 30972
3E9Z	;	2.31	;	Crystal structure of purine nucleoside phosphorylase from Schistosoma mansoni in complex with 6-chloroguanine
3E9R	;	1.85	;	Crystal structure of purine nucleoside phosphorylase from Schistosoma mansoni in complex with adenine
4TYM	;	2.399	;	Crystal structure of purine nucleoside phosphorylase from Streptococcus agalactiae 2603V/R, NYSGRC Target 030935
3MB8	;	1.9	;	Crystal structure of purine nucleoside phosphorylase from toxoplasma gondii in complex with immucillin-H
2ISC	;	2.7	;	Crystal structure of Purine Nucleoside Phosphorylase from Trichomonas vaginalis with DADMe-Imm-A
2I4T	;	2.74	;	Crystal structure of Purine Nucleoside Phosphorylase from Trichomonas vaginalis with Imm-A
4M1E	;	1.9	;	Crystal structure of purine nucleoside phosphorylase I from Planctomyces limnophilus DSM 3776, NYSGRC Target 029364.
4LNA	;	2.1	;	CRYSTAL STRUCTURE OF purine nucleoside phosphorylase I from Spirosoma linguale DSM 74, NYSGRC Target 029362
3FB1	;	2.002	;	Crystal Structure of Purine Nucleoside Phosphorylase in Complex with Ribose-1-Phosphate
6BI1	;	1.42	;	Crystal Structure of Purine Nucleoside Phosphorylase Isoform 2 from Schistosoma mansoni in complex with (2R)-2-amino-3-(benzyloxy)propan-1-ol
6B7I	;	1.54	;	Crystal Structure of Purine Nucleoside Phosphorylase Isoform 2 from Schistosoma mansoni in complex with (2S)-2-(3,5-difluorophenyl)-2-hydroxyacetic acid
6AXA	;	1.59	;	Crystal Structure of Purine Nucleoside Phosphorylase Isoform 2 from Schistosoma mansoni in complex with (3S)-5-fluoro-3-hydroxy-1,3-dihydroindol-2-one
6BI9	;	1.59	;	Crystal Structure of Purine Nucleoside Phosphorylase Isoform 2 from Schistosoma mansoni in complex with 1,2,5-trimethyl-1H-pyrrole-3-carboxylic acid
6B37	;	1.5	;	Crystal Structure of Purine Nucleoside Phosphorylase Isoform 2 from Schistosoma mansoni in complex with 1,3-benzothiazol-2-ol
6BIF	;	1.6	;	Crystal Structure of Purine Nucleoside Phosphorylase Isoform 2 from Schistosoma mansoni in complex with 1-(4-amino-2-hydroxyphenyl)ethan-1-one
6B3L	;	1.52	;	Crystal Structure of Purine Nucleoside Phosphorylase Isoform 2 from Schistosoma mansoni in complex with 2,3-dihydro-1H-inden-2-amine
6BHB	;	2.0	;	Crystal Structure of Purine Nucleoside Phosphorylase Isoform 2 from Schistosoma mansoni in complex with 2-aminopyrimidin-5-ol
6AWE	;	1.65	;	Crystal Structure of Purine Nucleoside Phosphorylase Isoform 2 from Schistosoma mansoni in complex with 2-fluoro-6-(2-pyridin-2-ylethylamino)benzonitrile
6BJ6	;	1.73	;	Crystal Structure of Purine Nucleoside Phosphorylase Isoform 2 from Schistosoma mansoni in complex with 2-{[(S)-benzenesulfinyl]methyl}benzoic acid
6BB7	;	1.44	;	Crystal Structure of Purine Nucleoside Phosphorylase Isoform 2 from Schistosoma mansoni in complex with 3-methyl-1,2-dihydropyridin-2-one
6BJ7	;	1.56	;	Crystal Structure of Purine Nucleoside Phosphorylase Isoform 2 from Schistosoma mansoni in complex with 4-chloro-6-methylpyrimidin-2-amine
6B4T	;	1.51	;	Crystal Structure of Purine Nucleoside Phosphorylase Isoform 2 from Schistosoma mansoni in complex with 4-methylpyridin-2-ol
6B56	;	1.42	;	Crystal Structure of Purine Nucleoside Phosphorylase Isoform 2 from Schistosoma mansoni in complex with 5-butylpyridine-2-carboxylic acid
6BFV	;	1.921	;	Crystal Structure of Purine Nucleoside Phosphorylase Isoform 2 from Schistosoma mansoni in complex with 5-fluoro-1,2-dihydropyrimidin-2-one
6B6K	;	1.46	;	Crystal Structure of Purine Nucleoside Phosphorylase Isoform 2 from Schistosoma mansoni in complex with 6-methyl-2,3-dihydropyridazin-3-one
6B2L	;	1.56	;	Crystal Structure of Purine Nucleoside Phosphorylase Isoform 2 from Schistosoma mansoni in complex with piperidin-2-Imine
6B4Q	;	1.6	;	Crystal Structure of Purine Nucleoside Phosphorylase Isoform 2 from Schistosoma mansoni in complex with pyridin-4-ol
6B71	;	1.52	;	Crystal Structure of Purine Nucleoside Phosphorylase Isoform 2 from Schistosoma mansoni in complex with3-(4-chlorophenyl)-5H,6H-imidazo[2,1-b][1,3]thiazole
1VHW	;	1.54	;	Crystal structure of purine nucleoside phosphorylase with adenosine
1VDM	;	2.5	;	Crystal structure of purine phosphoribosyltransferase from Pyrococcus horikoshii Ot3
3Q2O	;	1.96	;	Crystal Structure of purK: N5-carboxyaminoimidazole ribonucleotide synthetase
3VIU	;	2.35	;	Crystal structure of PurL from thermus thermophilus
3DA8	;	1.3	;	Crystal structure of PurN from Mycobacterium tuberculosis
2NTM	;	2.6	;	Crystal structure of PurO from Methanothermobacter thermoautotrophicus
2NTL	;	2.6	;	Crystal structure of PurO/AICAR from Methanothermobacter thermoautotrophicus
2NTK	;	2.03	;	Crystal structure of PurO/IMP from Methanothermobacter thermoautotrophicus
3AZO	;	2.0	;	Crystal structure of puromycin hydrolase
3AZP	;	2.15	;	Crystal structure of puromycin hydrolase S511A mutant
3AZQ	;	2.7	;	Crystal structure of puromycin hydrolase S511A mutant complexed with PGG
2R87	;	2.3	;	Crystal structure of PurP from Pyrococcus furiosus complexed with ADP
2R85	;	1.7	;	Crystal structure of PurP from Pyrococcus furiosus complexed with AMP
2R84	;	1.9	;	Crystal structure of PurP from Pyrococcus furiosus complexed with AMP and AICAR
2R86	;	2.5	;	Crystal structure of PurP from Pyrococcus furiosus complexed with ATP
3CFE	;	2.99	;	Crystal structure of purple-fluorescent antibody EP2-25C10
1KJ9	;	1.6	;	Crystal structure of purt-encoded glycinamide ribonucleotide transformylase complexed with Mg-ATP
1KJ8	;	1.6	;	Crystal Structure of PurT-Encoded Glycinamide Ribonucleotide Transformylase in Complex with Mg-ATP and GAR
1ZME	;	2.5	;	CRYSTAL STRUCTURE OF PUT3/DNA COMPLEX
4JNY	;	1.9	;	Crystal structure of PutA86-630 mutant D370A complexed with L-Tetrahydro-2-furoic acid
4JNZ	;	1.851	;	Crystal structure of PutA86-630 mutant D370N complexed with L-Tetrahydro-2-furoic acid
7TZP	;	2.6	;	Crystal Structure of Putataive Short-Chain Dehydrogenase/Reductase (FabG) from Klebsiella pneumoniae subsp. pneumoniae NTUH-K2044 in Complex with NADH
3F5S	;	1.36	;	CRYSTAL STRUCTURE OF putatitve short chain dehydrogenase from Shigella flexneri 2a str. 301
3GY0	;	1.55	;	Crystal structure of putatitve short chain dehydrogenase FROM SHIGELLA FLEXNERI 2A STR. 301 complexed with NADP
3OS6	;	2.4	;	Crystal structure of putative 2,3-dihydroxybenzoate-specific isochorismate synthase, DhbC from Bacillus anthracis.
4OL9	;	1.85	;	Crystal Structure of putative 2-dehydropantoate 2-reductase PanE from Mycobacterium tuberculosis complexed with NADP and oxamate
1VR0	;	2.49	;	Crystal structure of putative 2-phosphosulfolactate phosphatase (15026306) from Clostridium acetobutylicum at 2.6 A resolution
2FFI	;	2.61	;	Crystal Structure of Putative 2-Pyrone-4,6-Dicarboxylic Acid Hydrolase from Pseudomonas putida, Northeast Structural Genomics Target PpR23.
3UDU	;	1.85	;	Crystal structure of putative 3-isopropylmalate dehydrogenase from Campylobacter jejuni
3OP4	;	1.6	;	Crystal structure of putative 3-ketoacyl-(acyl-carrier-protein) reductase from Vibrio cholerae O1 biovar eltor str. N16961 in complex with NADP+
3BJD	;	1.85	;	Crystal structure of putative 3-oxoacyl-(acyl-carrier-protein) synthase from Pseudomonas aeruginosa
2ZGI	;	1.93	;	Crystal Structure of Putative 4-amino-4-deoxychorismate lyase
3LUL	;	1.78	;	Crystal structure of Putative 4-amino-4-deoxychorismate lyase. (YP_094631.1) from Legionella pneumophila subsp. pneumophila str. Philadelphia 1 at 1.78 A resolution
3RMT	;	2.8	;	Crystal structure of putative 5-enolpyruvoylshikimate-3-phosphate synthase from Bacillus halodurans C-125
3LWD	;	1.75	;	Crystal structure of Putative 6-phosphogluconolactonase (YP_574786.1) from Chromohalobacter salexigens DSM 3043 at 1.88 A resolution
3LHI	;	1.33	;	Crystal structure of Putative 6-phosphogluconolactonase(YP_207848.1) from Neisseria gonorrhoeae FA 1090 at 1.33 A resolution
3BP1	;	1.53	;	Crystal structure of putative 7-cyano-7-deazaguanine reductase QueF from Vibrio cholerae O1 biovar eltor
4DN7	;	1.6	;	CRYSTAL STRUCTURE OF putative ABC transporter, ATP-binding protein from Methanosarcina mazei Go1
2PC6	;	2.5	;	Crystal structure of putative acetolactate synthase- small subunit from Nitrosomonas europaea
2Z0Z	;	2.0	;	Crystal structure of putative acetyltransferase
2Z10	;	1.77	;	Crystal structure of putative acetyltransferase
2Z11	;	2.15	;	Crystal structure of putative acetyltransferase
3H4Q	;	2.5	;	Crystal structure of putative acetyltransferase (NP_371943.1) from STAPHYLOCOCCUS AUREUS MU50 at 2.50 A resolution
3GY9	;	1.52	;	Crystal structure of putative acetyltransferase (YP_001815201.1) from EXIGUOBACTERIUM SP. 255-15 at 1.52 A resolution
3GYA	;	1.62	;	Crystal structure of putative acetyltransferase (YP_001815201.1) from EXIGUOBACTERIUM SP. 255-15 at 1.62 A resolution
3C8V	;	2.28	;	Crystal structure of putative acetyltransferase (YP_390128.1) from Desulfovibrio desulfuricans G20 at 2.28 A resolution
2R1I	;	1.65	;	Crystal structure of putative acetyltransferase (YP_831484.1) from Arthrobacter sp. FB24 at 1.65 A resolution
1ON0	;	2.2	;	Crystal Structure of Putative Acetyltransferase (YycN) from Bacillus subtilis, NORTHEAST STRUCTURAL GENOMICS CONSORTIUM TARGET SR144
2G3A	;	1.9	;	Crystal structure of putative acetyltransferase from Agrobacterium tumefaciens
3SHP	;	2.21	;	Crystal structure of putative acetyltransferase from Sphaerobacter thermophilus DSM 20745
2ZXV	;	2.3	;	Crystal structure of putative acetyltransferase from T. thermophilus HB8
3EC4	;	1.8	;	Crystal structure of Putative Acetyltransferase from the GNAT family (YP_497011.1) from NOVOSPHINGOBIUM AROMATICIVORANS DSM 12444 at 1.80 A resolution
3LJY	;	2.41	;	Crystal structure of putative adhesin (YP_001304413.1) from Parabacteroides distasonis ATCC 8503 at 2.41 A resolution
1VIQ	;	2.4	;	Crystal structure of putative ADP ribose pyrophosphatase
1VIU	;	2.4	;	Crystal structure of putative ADP ribose pyrophosphatase
3JZD	;	2.1	;	Crystal structure of Putative alcohol dehedrogenase (YP_298327.1) from RALSTONIA EUTROPHA JMP134 at 2.10 A resolution
3UOG	;	2.2	;	Crystal structure of putative Alcohol dehydrogenase from Sinorhizobium meliloti 1021
4J6F	;	2.8	;	Crystal structure of putative alcohol dehydrogenase from Sinorhizobium meliloti 1021, NYSGRC-Target 012230
4DNG	;	2.5	;	Crystal structure of putative aldehyde dehydrogenase from Bacillus subtilis subsp. subtilis str. 168
4DAL	;	2.3	;	Crystal structure of Putative aldehyde dehydrogenase from Sinorhizobium meliloti 1021
4F3X	;	2.01	;	Crystal structure of putative aldehyde dehydrogenase from Sinorhizobium meliloti 1021 complexed with NAD
4R9O	;	1.949	;	Crystal Structure of Putative Aldo/Keto Reductase from Salmonella enterica
3M0Z	;	1.2	;	Crystal structure of putative aldolase from Klebsiella pneumoniae.
3GZA	;	1.6	;	Crystal structure of putative alpha-L-fucosidase (NP_812709.1) from BACTEROIDES THETAIOTAOMICRON VPI-5482 at 1.60 A resolution
3EYP	;	1.9	;	Crystal structure of putative alpha-L-fucosidase from Bacteroides thetaiotaomicron
3HJG	;	2.8	;	Crystal structure of putative alpha-ribazole-5'-phosphate phosphatase CobC FROM Vibrio parahaemolyticus
2QEE	;	1.65	;	Crystal structure of putative amidohydrolase BH0493 from Bacillus halodurans C-125
3S4T	;	1.9	;	Crystal structure of putative amidohydrolase-2 (EFI-target 500288)from Polaromonas sp. JS666
6AA1	;	1.86	;	Crystal structure of putative amino acid binding periplasmic ABC transporter protein from Candidatus Liberibacter asiaticus bound with citrate
6AAL	;	2.6	;	Crystal Structure of putative amino acid binding periplasmic ABC transporter protein from Candidatus Liberibacter asiaticus in complex with Arginine
8GTU	;	2.56	;	Crystal Structure of putative amino acid binding periplasmic ABC transporter protein from Candidatus Liberibacter asiaticus in complex with Clidinium
6A80	;	1.56	;	Crystal Structure of putative amino acid binding periplasmic ABC transporter protein from Candidatus Liberibacter asiaticus in complex with cystine
8GU1	;	2.65	;	Crystal Structure of putative amino acid binding periplasmic ABC transporter protein from Candidatus Liberibacter asiaticus in complex with Pimozide
3IF2	;	2.5	;	Crystal structure of Putative amino-acid aminotransferase (YP_265399.1) from Psychrobacter arcticum 273-4 at 2.50 A resolution
3TTG	;	2.0	;	Crystal structure of putative aminomethyltransferase from Leptospirillum rubarum
3KGW	;	1.65	;	Crystal structure of Putative aminotransferase (AAH25799.1) from MUS MUSCULUS at 1.65 A resolution
3KGX	;	1.8	;	Crystal structure of Putative aminotransferase (AAH25799.1) from MUS MUSCULUS at 1.80 A resolution
3EZ1	;	2.6	;	Crystal structure of putative aminotransferase (MocR family) (YP_604413.1) from DEINOCOCCUS GEOTHERMALIS DSM 11300 at 2.60 A resolution
3FCR	;	1.8	;	Crystal structure of putative aminotransferase (YP_614685.1) from SILICIBACTER SP. TM1040 at 1.80 A resolution
6Y9E	;	1.7	;	Crystal structure of putative ancestral haloalkane dehalogenase AncHLD2 (node 2)
6Y9F	;	1.26	;	Crystal structure of putative ancestral haloalkane dehalogenase AncHLD3 (node 3)
6Y9G	;	1.748	;	Crystal structure of putative ancestral haloalkane dehalogenase AncHLD5 (node 5)
3KKF	;	1.3	;	Crystal structure of Putative antibiotic biosynthesis monooxygenase (NP_810307.1) from Bacteriodes thetaiotaomicron VPI-5482 at 1.30 A resolution
3GZ7	;	2.15	;	Crystal structure of Putative antibiotic biosynthesis monooxygenase (NP_888398.1) from BORDETELLA BRONCHISEPTICA at 2.15 A resolution
4DN9	;	2.05	;	CRYSTAL STRUCTURE OF putative Antibiotic biosynthesis monooxygenase from Chloroflexus aurantiacus J-10-fl
1TZ0	;	1.84	;	Crystal Structure of Putative Antibiotic Biosythesis Monooxygenase from Bacillus cereus
3FNR	;	2.2	;	CRYSTAL STRUCTURE OF PUTATIVE ARGINYL T-RNA SYNTHETASE FROM Campylobacter jejuni;
3LWS	;	2.0	;	Crystal structure of Putative aromatic amino acid beta-eliminating lyase/threonine aldolase. (YP_001813866.1) from Exiguobacterium sp. 255-15 at 2.00 A resolution
3GKX	;	2.2	;	Crystal structure of putative ArsC family related protein from Bacteroides fragilis
3ED4	;	1.7	;	Crystal structure of putative arylsulfatase from escherichia coli
1K2X	;	1.65	;	Crystal structure of putative asparaginase encoded by Escherichia coli ybiK gene
1VRB	;	2.6	;	Crystal structure of Putative asparaginyl hydroxylase (2636534) from Bacillus subtilis at 2.60 A resolution
3G0T	;	1.75	;	Crystal structure of putative aspartate aminotransferase (NP_905498.1) from Porphyromonas gingivalis W83 at 1.75 A resolution
3S81	;	1.796	;	Crystal Structure of Putative Aspartate Racemase from Salmonella Typhimurium
3S7Z	;	2.002	;	Crystal Structure of Putative Aspartate Racemase from Salmonella Typhimurium Complexed with Succinate
5EVC	;	1.7	;	Crystal structure of putative aspartate racemase from Salmonella Typhimurium complexed with sulfate and potassium
3IUK	;	1.85	;	Crystal structure of putative bacterial protein of unknown function (DUF885, PF05960.1, ) from Arthrobacter aurescens TC1, reveals fold similar to that of M32 carboxypeptidases
3LUR	;	1.81	;	Crystal structure of Putative bacterial transcription regulation protein (NP_372959.1) from Staphylococcus aureus MU50 at 1.81 A resolution
3KWO	;	1.985	;	Crystal Structure of Putative Bacterioferritin from Campylobacter jejuni
3CMG	;	1.9	;	Crystal structure of putative beta-galactosidase from Bacteroides fragilis
3FN9	;	2.7	;	Crystal structure of putative beta-galactosidase from bacteroides fragilis
5DXD	;	1.7	;	Crystal structure of Putative beta-glucanase (Rv0315 ortholog) from Mycobacterium abscessus
3CJM	;	1.5	;	Crystal structure of putative beta-lactamase (NP_815223.1) from Enterococcus faecalis V583 at 1.50 A resolution
5TGF	;	1.81	;	Crystal structure of putative beta-lactamase from Bacteroides dorei DSM 17855
3D4E	;	1.4	;	Crystal structure of putative beta-lactamase inhibitor protein (NP_721579.1) from STREPTOCOCCUS MUTANS at 1.40 A resolution
3E58	;	1.86	;	Crystal structure of putative beta-phosphoglucomutase from Streptococcus thermophilus
3KBB	;	1.74	;	Crystal structure of putative beta-phosphoglucomutase from Thermotoga maritima
3K4U	;	2.62	;	CRYSTAL STRUCTURE OF putative binding component of ABC transporter from Wolinella succinogenes DSM 1740 complexed with lysine
4R6H	;	1.5	;	Crystal structure of putative binding protein msme from bacillus subtilis subsp. subtilis str. 168, target efi-510764, an open conformation
3H51	;	1.7	;	Crystal structure of Putative calcium/calmodulin dependent protein kinase II association domain (NP_636218.1) from XANTHOMONAS CAMPESTRIS at 1.70 A resolution
3GWR	;	2.01	;	Crystal structure of Putative calcium/calmodulin-dependent protein kinase type II association domain (YP_315894.1) from THIOBACILLUS DENITRIFICANS ATCC 25259 at 2.00 A resolution
2QEU	;	1.65	;	Crystal structure of putative carboxymuconolactone decarboxylase (YP_555818.1) from Burkholderia xenovorans LB400 at 1.65 A resolution
3MT1	;	2.5	;	Crystal structure of putative carboxynorspermidine decarboxylase protein from Sinorhizobium meliloti
3K2K	;	2.49	;	Crystal structure of putative carboxypeptidase (YP_103406.1) from BURKHOLDERIA MALLEI ATCC 23344 at 2.49 A resolution
3L2N	;	2.39	;	Crystal structure of Putative carboxypeptidase A (YP_562911.1) from SHEWANELLA DENITRIFICANS OS-217 at 2.39 A resolution
3LIU	;	2.05	;	Crystal structure of Putative cell adhesion protein (YP_001304840.1) from Parabacteroides distasonis ATCC 8503 at 2.05 A resolution
3KK7	;	2.46	;	Crystal structure of Putative cell invasion protein with MAC/Perforin domain (NP_812351.1) from BACTERIODES THETAIOTAOMICRON VPI-5482 at 2.46 A resolution
3H4Y	;	1.55	;	Crystal structure of putative chemotaxis protein (YP_009526.1) from DESULFOVIBRIO VULGARIS HILDENBOROUGH at 1.55 A resolution
3EBV	;	1.5	;	Crystal structure of putative Chitinase A from Streptomyces coelicolor.
3QOK	;	2.6	;	Crystal structure of putative chitinase II from Klebsiella pneumoniae
3DTZ	;	1.81	;	Crystal structure of Putative Chlorite dismutase TA0507
2RCC	;	1.9	;	Crystal structure of putative class I ribonucleotide reductase (NP_241368.1) from Bacillus halodurans at 1.90 A resolution
3LYH	;	1.6	;	Crystal structure of Putative cobalamin (vitamin B12) biosynthesis CbiX protein (YP_958415.1) from Marinobacter aquaeolei VT8 at 1.60 A resolution
2NPN	;	1.6	;	Crystal structure of putative cobalamin synthesis related protein (CobF) from Corynebacterium diphtheriae
3G13	;	2.0	;	Crystal structure of putative conjugative transposon recombinase from Clostridium difficile
6FAN	;	2.0	;	Crystal structure of putative CooT from Carboxydothermus hydrogenoformans
4R9X	;	1.8515	;	Crystal Structure of Putative Copper Homeostasis Protein CutC from Bacillus anthracis
3LUB	;	2.11	;	Crystal structure of Putative creatinine amidohydrolase (YP_211512.1) from Bacteroides fragilis NCTC 9343 at 2.11 A resolution
3KRT	;	2.19	;	CRYSTAL STRUCTURE OF putative crotonyl CoA reductase from Streptomyces coelicolor A3(2)
2OQK	;	1.8	;	Crystal structure of putative Cryptosporidium parvum translation initiation factor eIF-1A
3GWY	;	2.0	;	Crystal structure of putative CTP pyrophosphohydrolase from Bacteroides fragilis
2ZFH	;	2.05	;	Crystal structure of putative CutA1 from Homo sapiens at 2.05A resolution
8CU5	;	1.85	;	Crystal Structure of Putative Cyclophilin B from Brugia malayi
3HVY	;	2.0	;	Crystal structure of putative cystathionine beta-lyase involved in aluminum resistance (NP_348457.1) from Clostridium acetobutylicum at 2.00 A resolution
3FD0	;	2.12	;	Crystal structure of putative cystathionine beta-lyase involved in aluminum resistance (NP_470671.1) from LISTERIA INNOCUA at 2.12 A resolution
7SWH	;	2.25	;	Crystal Structure of Putative cystathionine gamma-synthase from Burkholderia pseudomallei in Complex with PLP
4ERU	;	2.1	;	Crystal Structure of Putative Cytoplasmic Protein, YciF Bacterial Stress Response Protein from Salmonella enterica
3GG9	;	1.9	;	CRYSTAL STRUCTURE OF putative D-3-phosphoglycerate dehydrogenase oxidoreductase from Ralstonia solanacearum
4G2N	;	1.7	;	Crystal structure of putative D-isomer specific 2-hydroxyacid dehydrogenase, NAD-binding from Polaromonas sp. JS6 66
2GL5	;	1.6	;	Crystal Structure of Putative Dehydratase from Salmonella Thyphimurium
2OX4	;	1.8	;	Crystal structure of putative dehydratase from Zymomonas mobilis ZM4
4E6M	;	1.8	;	Crystal structure of Putative dehydratase protein from Salmonella enterica subsp. enterica serovar Typhimurium (Salmonella typhimurium)
3EC7	;	2.15	;	Crystal Structure of Putative Dehydrogenase from Salmonella typhimurium LT2
3F67	;	1.74	;	Crystal Structure of Putative Dienelactone Hydrolase from Klebsiella pneumoniae subsp. pneumoniae MGH 78578
4FEK	;	2.0	;	Crystal Structure of putative diflavin flavoprotein A 5 (fragment 1-254) from Nostoc sp. PCC 7120, Northeast Structural Genomics Consortium Target NsR435A , Northeast Structural Genomics Consortium (NESG) Target NsR435A
3N3T	;	2.35	;	Crystal structure of putative diguanylate cyclase/phosphodiesterase complex with cyclic di-gmp
3KZP	;	2.0	;	Crystal structure of putative diguanylate cyclase/phosphodiesterase from Listaria monocytigenes
2R6O	;	1.8	;	Crystal structure of putative diguanylate cyclase/phosphodiesterase from Thiobacillus denitrificans
2PCQ	;	2.1	;	Crystal structure of putative dihydrodipicolinate synthase (TTHA0737) from Thermus Thermophilus HB8
3KGY	;	1.5	;	Crystal structure of Putative dihydrofolate reductase (YP_001636057.1) from CHLOROFLEXUS AURANTIACUS J-10-FL at 1.50 A resolution
3JTW	;	1.9	;	Crystal structure of Putative dihydrofolate reductase (YP_805003.1) from PEDIOCOCCUS PENTOSACEUS ATCC 25745 at 1.90 A resolution
3O1K	;	1.95	;	Crystal structure of putative dihydroneopterin aldolase (FolB) from Vibrio cholerae O1 biovar El Tor str. N16961
2RAF	;	1.6	;	Crystal structure of putative dinucleotide-binding oxidoreductase (NP_786167.1) from Lactobacillus plantarum at 1.60 A resolution
2P8I	;	1.4	;	Crystal structure of putative dioxygenase (YP_555069.1) from Burkholderia xenovorans LB400 at 1.40 A resolution
2NYH	;	1.7	;	Crystal structure of putative dioxygenase (YP_555069.1) from Burkholderia Xenovorans LB400 at 1.70 A resolution
3OAJ	;	1.4	;	CRYSTAL STRUCTURE OF putative dioxygenase from Bacillus subtilis subsp. subtilis str. 168
3I4T	;	2.49	;	Crystal structure of putative diphthine synthase from Entamoeba histolytica
3LHK	;	2.2	;	Crystal structure of putative DNA binding protein from Methanocaldococcus jannaschii.
2AUW	;	1.85	;	Crystal Structure of Putative DNA Binding Protein NE0471 from Nitrosomonas europaea ATCC 19718
1S7O	;	2.31	;	Crystal structure of putative DNA binding protein SP_1288 from Streptococcus pygenes
3LX6	;	2.29	;	Crystal structure of putative dna cytosine methylase from shigella flexneri 2a str. 2457T
3ME5	;	1.75	;	Crystal structure of putative dna cytosine methylase from shigella flexneri 2a str. 2457T
3G7U	;	1.75	;	Crystal structure of putative DNA modification methyltransferase encoded within prophage Cp-933R (E.coli)
3MAJ	;	2.05	;	Crystal structure of putative DNA processing protein DprA from Rhodopseudomonas palustris CGA009
3HWU	;	1.3	;	Crystal structure of Putative DNA-binding protein (YP_299413.1) from Ralstonia eutrophA JMP134 at 1.30 A resolution
3FGG	;	2.3	;	Crystal Structure of Putative ECF-type Sigma Factor Negative Effector from Bacillus cereus
3ME8	;	1.5	;	Crystal structure of putative electron transfer protein aq_2194 from Aquifex aeolicus VF5
3ME7	;	1.5	;	Crystal structure of putative electron transport protein aq_2194 from Aquifex aeolicus VF5
3I47	;	1.58	;	CRYSTAL STRUCTURE OF putative enoyl CoA hydratase/isomerase (crotonase) from Legionella pneumophila subsp. pneumophila str. Philadelphia 1
3HIN	;	2.0	;	CRYSTAL STRUCTURE OF putative enoyl-CoA hydratase from Rhodopseudomonas palustris CGA009
3G64	;	2.05	;	Crystal structure of putative enoyl-CoA hydratase from Streptomyces coelicolor A3(2)
3ISA	;	1.76	;	CRYSTAL STRUCTURE OF putative enoyl-CoA hydratase/isomerase FROM Bordetella parapertussis
4MI2	;	2.3	;	Crystal structure of putative Enoyl-CoA hydratase/isomerase from Mycobacterium abscessus
4JYJ	;	2.2	;	Crystal Structure of putative enoyl-CoA hydratase/isomerase from Novosphingobium aromaticivorans DSM 12444
5FLW	;	1.401	;	Crystal structure of putative exo-beta-1,3-galactanase from Bifidobacterium bifidum s17
3L0A	;	2.19	;	Crystal structure of Putative exonuclease (RER070207002219) from Eubacterium rectale at 2.19 A resolution
3HI0	;	2.3	;	Crystal structure of Putative exopolyphosphatase (17739545) from AGROBACTERIUM TUMEFACIENS str. C58 (Dupont) at 2.30 A resolution
2Z0S	;	3.2	;	Crystal structure of putative exosome complex RNA-binding protein
6OZD	;	1.55	;	Crystal structure of Putative exported protein (BPSS2145) from Burkholderia pseudomallei K96243
4JGB	;	2.05	;	Crystal Structure of Putative exported protein from Burkholderia pseudomallei
3M0G	;	1.9	;	CRYSTAL STRUCTURE OF putative farnesyl diphosphate synthase from Rhodobacter capsulatus
3FGE	;	1.74	;	Crystal structure of putative flavin reductase with split barrel domain (YP_750721.1) from SHEWANELLA FRIGIDIMARINA NCIMB 400 at 1.74 A resolution
3KLB	;	1.75	;	Crystal structure of Putative Flavoprotein in Complex with FMN (YP_213683.1) from Bacteroides fragilis NCTC 9343 at 1.75 A resolution
3DO6	;	1.85	;	Crystal structure of Putative Formyltetrahydrofolate Synthetase (TM1766) from THERMOTOGA MARITIMA at 1.85 A resolution
3F7W	;	1.85	;	Crystal structure of putative fructosamine-3-kinase (YP_290396.1) from THERMOBIFIDA FUSCA YX-ER1 at 1.85 A resolution
3JR1	;	2.32	;	Crystal structure of Putative fructosamine-3-kinase (YP_719053.1) from HAEMOPHILUS SOMNUS 129PT at 2.32 A resolution
3C8U	;	1.95	;	Crystal structure of putative fructose transport system kinase (YP_612366.1) from Silicibacter sp. TM1040 at 1.95 A resolution
7RGN	;	2.2	;	Crystal structure of putative fructose-1,6-bisphosphate aldolase from Candida auris
3K1T	;	1.9	;	Crystal structure of Putative gamma-glutamylcysteine synthetase (YP_546622.1) from METHYLOBACILLUS FLAGELLATUS KT at 1.90 A resolution
3LK5	;	1.9	;	Crystal structure of putative Geranylgeranyl pyrophosphate synthase from Corynebacterium glutamicum
3LJI	;	1.39	;	CRYSTAL STRUCTURE OF putative geranyltranstransferase from Pseudomonas fluorescens Pf-5
3LSN	;	1.35	;	Crystal structure of putative geranyltranstransferase from PSEUDOMONAS fluorescens PF-5 complexed with magnesium
3EU8	;	2.12	;	Crystal structure of putative glucoamylase (YP_210071.1) from Bacteroides fragilis NCTC 9343 at 2.12 A resolution
7V0H	;	1.55	;	Crystal Structure of Putative glucose 1-dehydrogenase from Burkholderia cenocepacia in complex with NADP and a potential reaction product
3FEF	;	2.2	;	Crystal structure of putative glucosidase lplD from bacillus subtilis
4DNA	;	2.8	;	CRYSTAL STRUCTURE OF putative glutathione reductase from Sinorhizobium meliloti 1021
3LG6	;	2.2	;	Crystal structure of putative glutathione transferase from Coccidioides immitis
3N5O	;	1.85	;	Crystal structure of putative glutathione transferase from Coccidioides immitis bound to glutathione
3CWC	;	2.23	;	Crystal structure of putative glycerate kinase 2 from Salmonella typhimurium LT2
3KS6	;	1.8	;	Crystal structure of Putative glycerophosphoryl diester phosphodiesterase (17743486) from AGROBACTERIUM TUMEFACIENS str. C58 (Dupont) at 1.80 A resolution
3KS5	;	2.05	;	Crystal structure of Putative glycerophosphoryl diester phosphodiesterase (17743486) from AGROBACTERIUM TUMEFACIENS str. C58 (Dupont) at 2.05 A resolution
3I10	;	1.35	;	Crystal structure of Putative glycerophosphoryl diester phosphodiesterase (NP_812074.1) from BACTEROIDES THETAIOTAOMICRON VPI-5482 at 1.35 A resolution
3L12	;	1.6	;	Crystal structure of Putative glycerophosphoryl diester phosphodiesterase (YP_165505.1) from Silicibacter pomeroyi DSS-3 at 1.60 A resolution
4R7O	;	2.534	;	Crystal Structure of Putative Glycerophosphoryl Diester Phosphodiesterasefrom Bacillus anthraci
1U8S	;	2.45	;	Crystal structure of putative glycine cleavage system transcriptional repressor
4L22	;	2.45	;	Crystal structure of putative glycogen phosphorylase from Streptococcus mutans
3GYC	;	1.85	;	Crystal structure of putative glycoside hydrolase (YP_001304622.1) from Parabacteroides distasonis ATCC 8503 at 1.85 A resolution
3K11	;	1.8	;	Crystal structure of Putative glycosyl hydrolase (NP_813087.1) from BACTEROIDES THETAIOTAOMICRON VPI-5482 at 1.80 A resolution
3IMM	;	2.0	;	Crystal structure of Putative glycosyl hydrolase (YP_001301887.1) from Parabacteroides distasonis ATCC 8503 at 2.00 A resolution
3HBK	;	2.36	;	Crystal structure of putative glycosyl hydrolase, was Domain of Unknown Function (DUF1080) (YP_001302580.1) from Parabacteroides distasonis ATCC 8503 at 2.36 A resolution
2QQZ	;	1.92	;	Crystal structure of putative glyoxalase family protein from Bacillus anthracis
3IUZ	;	1.9	;	Crystal structure of Putative glyoxalase superfamily protein (YP_299723.1) from RALSTONIA EUTROPHA JMP134 at 1.90 A resolution
8EWO	;	2.47	;	Crystal structure of putative glyoxylase II from Pseudomonas aeruginosa
3EET	;	1.969	;	Crystal structure of putative GntR-family transcriptional regulator
2OWA	;	2.0	;	Crystal structure of putative GTPase activating protein for ADP ribosylation factor from Cryptosporidium parvum (cgd5_1040)
3MMZ	;	1.84	;	CRYSTAL STRUCTURE OF putative HAD family hydrolase from Streptomyces avermitilis MA-4680
3EPR	;	1.55	;	Crystal structure of putative HAD superfamily hydrolase from Streptococcus agalactiae.
3FZQ	;	2.1	;	Crystal structure of putative haloacid dehalogenase-like hydrolase (YP_001086940.1) from Clostridium difficile 630 at 2.10 A resolution
3D6J	;	2.0	;	Crystal structure of Putative haloacid dehalogenase-like hydrolase from Bacteroides fragilis
3GET	;	2.01	;	Crystal structure of putative histidinol-phosphate aminotransferase (NP_281508.1) from Campylobacter jejuni at 2.01 A resolution
3LY1	;	1.8	;	Crystal structure of Putative histidinol-phosphate aminotransferase (YP_050345.1) from Erwinia carotovora atroseptica SCRI1043 at 1.80 A resolution
1VHX	;	1.96	;	Crystal structure of Putative Holliday junction resolvase
3DO5	;	2.2	;	Crystal structure of Putative Homoserine Dehydrogenase (NP_069768.1) from ARCHAEOGLOBUS FULGIDUS at 2.20 A resolution
2P2U	;	2.75	;	Crystal structure of putative host-nuclease inhibitor protein Gam from Desulfovibrio vulgaris
2QSI	;	1.8	;	Crystal structure of putative hydrogenase expression/formation protein hupG from Rhodopseudomonas palustris CGA009
2R11	;	1.96	;	Crystal structure of putative hydrolase (2632844) from Bacillus subtilis at 1.96 A resolution
3LLC	;	1.8	;	Crystal structure of Putative hydrolase (YP_002548124.1) from Agrobacterium vitis S4 at 1.80 A resolution
3LHO	;	1.8	;	Crystal structure of putative hydrolase (YP_751971.1) from Shewanella frigidimarina NCIMB 400 at 1.80 A resolution
7TL5	;	2.69	;	Crystal structure of putative hydrolase yjcS from Klebsiella pneumoniae.
6A6F	;	2.1	;	Crystal structure of Putative iron-sulfur cluster assembly scaffold protein for SUF system (FiSufU) from thermophilic Fervidobacterium Islandicum AW-1
3LQY	;	1.75	;	Crystal structure of putative isochorismatase hydrolase from Oleispira antarctica
6OTV	;	2.4	;	Crystal structure of putative isomerase EC2056
1S5A	;	1.7	;	Crystal Structure of Putative Isomerase from Bacillus subtilis
3DM8	;	1.8	;	Crystal Structure of Putative Isomerase from Rhodopseudomonas palustris
2PPG	;	2.49	;	Crystal structure of putative isomerase from Sinorhizobium meliloti
4H1Z	;	2.012	;	Crystal structure of putative isomerase from Sinorhizobium meliloti, open loop conformation (target EFI-502104)
1Z1S	;	1.49	;	Crystal Structure of Putative Isomerase PA3332 from Pseudomonas aeruginosa
3UDO	;	2.3	;	Crystal structure of putative isopropylamlate dehydrogenase from Campylobacter jejuni
3HX8	;	1.45	;	Crystal structure of putative ketosteroid isomerase (NP_103587.1) from Mesorhizobium loti at 1.45 A resolution
3KE7	;	1.45	;	Crystal structure of putative ketosteroid isomerase (YP_001303366.1) from Parabacteroides distasonis ATCC 8503 at 1.45 A resolution
4LMI	;	1.8	;	Crystal structure of putative ketosteroid isomerase from Kribbella flavida DSM 17836
3HDT	;	2.79	;	Crystal structure of putative kinase from Clostridium symbiosum ATCC 14940
3LM2	;	1.7	;	Crystal structure of Putative kinase. (17743352) from AGROBACTERIUM TUMEFACIENS str. C58 (Dupont) at 1.70 A resolution
2OO6	;	1.8	;	Crystal structure of putative L-alanine-DL-glutamate epimerase from Burkholderia xenovorans strain LB400
3GO2	;	1.7	;	Crystal structure of putative L-alanine-DL-glutamate epimerase from Burkholderia xenovorans strain LB400 bound to magnesium
3SN4	;	1.86	;	Crystal structure of putative L-alanine-DL-glutamate epimerase from Burkholderia xenovorans strain LB400 bound to magnesium and alpha-ketoglutarate
3SN0	;	1.8	;	Crystal structure of putative L-alanine-DL-glutamate epimerase from Burkholderia xenovorans strain LB400 bound to magnesium and fumarate
3SN1	;	1.8	;	Crystal structure of putative L-alanine-DL-glutamate epimerase from Burkholderia xenovorans strain LB400 bound to magnesium and tartrate
3JX8	;	2.16	;	Crystal structure of Putative lipid binding protein (YP_001304415.1) from Parabacteroides distasonis ATCC 8503 at 2.16 A resolution
3LHN	;	1.42	;	Crystal structure of putative lipoprotein (NP_718719.1) from Shewanella oneidensis at 1.42 A resolution
4R7R	;	2.449	;	Crystal Structure of Putative Lipoprotein from Clostridium perfringens
4YCS	;	1.98	;	Crystal structure of putative lipoprotein from Peptoclostridium difficile 630 (fragment)
3GE2	;	2.203	;	Crystal structure of putative lipoprotein SP_0198 from Streptococcus pneumoniae
3IVR	;	2.0	;	CRYSTAL STRUCTURE OF PUTATIVE long-chain-fatty-acid CoA ligase FROM Rhodopseudomonas palustris CGA009
4XEA	;	1.95	;	Crystal structure of putative M16-like peptidase from Alicyclobacillus acidocaldarius
3CPX	;	2.39	;	Crystal structure of putative M42 glutamyl aminopeptidase (YP_676701.1) from Cytophaga hutchinsonii ATCC 33406 at 2.39 A resolution
3DFH	;	2.2	;	crystal structure of putative mandelate racemase / muconate lactonizing enzyme from Vibrionales bacterium SWAT-3
3H12	;	1.5	;	Crystal structure of putative mandelate racemase from Bordetella Bronchiseptica RB50
3OP2	;	2.0	;	Crystal structure of putative mandelate racemase from Bordetella bronchiseptica RB50 complexed with 2-oxoglutarate/phosphate
2OZ8	;	2.48	;	Crystal structure of putative mandelate racemase from Mesorhizobium loti
3S5S	;	2.4	;	Crystal structure of putative mandelate racemase/muconate lactonizing enzyme (PSI/COM target 200551) from Sorangium cellulosum
2PS2	;	1.8	;	Crystal structure of putative mandelate racemase/muconate lactonizing enzyme from Aspergillus oryzae
2PCE	;	2.0	;	Crystal structure of putative mandelate racemase/muconate lactonizing enzyme from Roseovarius nubinhibens ISM
3GY1	;	1.6	;	CRYSTAL STRUCTURE OF putative mandelate racemase/muconate lactonizing protein from Clostridium beijerinckii NCIMB 8052
3FV9	;	1.9	;	Crystal structure of putative mandelate racemase/muconatelactonizing enzyme from ROSEOVARIUS NUBINHIBENS ISM complexed with magnesium
1Y0E	;	1.95	;	Crystal structure of putative ManNAc-6-P epimerase from Staphylococcus aureus (strain N315)
4E3E	;	1.9	;	CRYSTAL STRUCTURE OF putative MaoC domain protein dehydratase from Chloroflexus aurantiacus J-10-fl
4FFU	;	1.8	;	CRYSTAL STRUCTURE OF putative MaoC-like (monoamine oxidase-like) protein, similar to NodN from Sinorhizo Bium meliloti 1021
3K0L	;	2.352	;	Crystal Structure of Putative MarR Family Transcriptional Regulator from Acinetobacter sp. ADP
6Q2B	;	2.72	;	Crystal Structure of Putative MarR Family Transcriptional Regulator from Listeria monocytogenes complexed with 26mer DNA
4RGR	;	2.302	;	Crystal Structure of Putative MarR Family Transcriptional Regulator HcaR from Acinetobacter sp. ADP
5BMZ	;	3.001	;	Crystal Structure of Putative MarR Family Transcriptional Regulator HcaR from Acinetobacter sp. ADP complexed with 24mer DNA.
4RGX	;	2.102	;	Crystal Structure of Putative MarR Family Transcriptional Regulator HcaR from Acinetobacter sp. ADP complexed with 3,4-dihydroxy bezoic acid
4RGU	;	1.891	;	Crystal Structure of Putative MarR Family Transcriptional Regulator HcaR from Acinetobacter sp. ADP complexed with ferulic acid
4RGS	;	2.298	;	Crystal Structure of Putative MarR Family Transcriptional Regulator HcaR from Acinetobacter sp. ADP complexed with Vanilin
3BJA	;	2.38	;	Crystal structure of putative MarR-like transcription regulator (NP_978771.1) from Bacillus cereus ATCC 10987 at 2.38 A resolution
2IIZ	;	2.3	;	Crystal structure of putative melanin biosynthesis protein TyrA with bound heme (NP_716371.1) from Shewanella Oneidensis at 2.30 A resolution
3LSO	;	2.75	;	Crystal structure of Putative membrane anchored protein from Corynebacterium diphtheriae
3KMI	;	1.96	;	Crystal structure of putative membrane protein from Clostridium difficile 630
3G3L	;	2.2	;	Crystal structure of putative membrane-associated protein of unknown function (YP_211325.1) from Bacteroides fragilis NCTC 9343 at 2.20 A resolution
3GP4	;	1.85	;	Crystal structure of putative MerR family transcriptional regulator from listeria monocytogenes
3KL7	;	2.3	;	Crystal structure of Putative metal-dependent hydrolase (YP_001302908.1) from Parabacteroides distasonis ATCC 8503 at 2.30 A resolution
2QPX	;	1.4	;	Crystal structure of putative metal-dependent hydrolase (YP_805737.1) from Lactobacillus casei ATCC 334 at 1.40 A resolution
3GOR	;	2.511	;	Crystal structure of putative metal-dependent hydrolase APC36150
3I7A	;	2.06	;	Crystal structure of Putative metal-dependent phosphohydrolase (YP_926882.1) from Shewanella amazonensis SB2B at 2.06 A resolution
3IEH	;	2.45	;	Crystal structure of Putative metallopeptidase (YP_001051774.1) from SHEWANELLA BALTICA OS155 at 2.45 A resolution
3IUU	;	2.13	;	Crystal structure of Putative metallopeptidase (YP_676511.1) from MESORHIZOBIUM SP. BNC1 at 2.13 A resolution
3IC6	;	2.59	;	Crystal structure of putative methylase family protein from Neisseria gonorrhoeae
2FHP	;	1.6	;	Crystal Structure of Putative Methylase from Enterococcus faecalis
2IFT	;	2.3	;	Crystal structure of putative methylase HI0767 from Haemophilus influenzae. NESG target IR102.
4E4G	;	2.9	;	Crystal structure of putative Methylmalonate-semialdehyde dehydrogenase from Sinorhizobium meliloti 1021
4IYM	;	2.2	;	Crystal structure of putative methylmalonate-semialdehyde dehydrogenase from Sinorhizobium meliloti 1021 complexed with NAD, target 011934
3CCF	;	1.9	;	Crystal structure of putative methyltransferase (YP_321342.1) from Anabaena variabilis ATCC 29413 at 1.90 A resolution
2QNE	;	2.3	;	Crystal structure of putative methyltransferase (ZP_00558420.1) from Desulfitobacterium hafniense Y51 at 2.30 A resolution
3EGE	;	2.4	;	Crystal structure of Putative methyltransferase from antibiotic biosynthesis pathway (YP_324569.1) from ANABAENA VARIABILIS ATCC 29413 at 2.40 A resolution
3KWP	;	2.29	;	Crystal structure of putative methyltransferase from Lactobacillus brevis
4P7C	;	1.85	;	Crystal structure of putative methyltransferase from Pseudomonas syringae pv. tomato
3LL7	;	1.8	;	Crystal structure of putative methyltransferase PG_1098 from Porphyromonas gingivalis W83
3LPM	;	2.4	;	Crystal structure of putative methyltransferase small domain protein from Listeria monocytogenes
3DTN	;	2.09	;	Crystal structure of putative Methyltransferase-MM_2633 from Methanosarcina mazei .
2PLI	;	1.7	;	Crystal structure of putative Mg2+ and Co2+ transporter(CorC)associated region from Neisseria meningitidis MC58
3QTD	;	2.7	;	Crystal structure of putative modulator of gyrase (PmbA) from Pseudomonas aeruginosa PAO1
3IMK	;	1.45	;	Crystal structure of Putative molybdenum carrier protein (YP_461806.1) from SYNTROPHUS ACIDITROPHICUS SB at 1.45 A resolution
3MCS	;	2.55	;	Crystal structure of Putative monooxygenase (FN1347) from FUSOBACTERIUM NUCLEATUM SUBSP. NUCLEATUM ATCC 25586 at 2.55 A resolution
3F44	;	1.55	;	Crystal structure of putative monooxygenase (YP_193413.1) from Lactobacillus acidophilus NCFM at 1.55 A resolution
3KHN	;	2.03	;	Crystal structure of putative MotB like protein DVU_2228 from Desulfovibrio vulgaris.
2CVO	;	2.2	;	Crystal structure of putative N-acetyl-gamma-glutamyl-phosphate reductase (AK071544) from rice (Oryza sativa)
1ZC6	;	2.2	;	Crystal Structure of Putative N-acetylglucosamine Kinase from Chromobacterium violaceum. Northeast Structural Genomics Target Cvr23.
1YXY	;	1.6	;	Crystal Structure of putative N-acetylmannosamine-6-P epimerase from Streptococcus pyogenes (APC29713) Structural genomics, MCSG
3EFA	;	2.423	;	Crystal structure of putative N-acetyltransferase from Lactobacillus plantarum
7S14	;	1.65	;	Crystal structure of putative NAD(P)H-flavin oxidoreductase from Haemophilus influenzae 86-028NP
7LDQ	;	1.15	;	Crystal structure of putative NAD(P)H-flavin oxidoreductase from Haemophilus influenzae R2846
7RZL	;	1.45	;	Crystal structure of putative NAD(P)H-flavin oxidoreductase from Haemophilus influenzae R2846 in complex with 4-nitrophenol
7RZP	;	1.95	;	Crystal structure of putative NAD(P)H-flavin oxidoreductase from Haemophilus influenzae R2866
7S1A	;	1.97	;	Crystal structure of putative NAD(P)H-flavin oxidoreductase from Haemophilus influenzae Rd KW20
6WT2	;	1.75	;	Crystal Structure of Putative NAD(P)H-Flavin Oxidoreductase from Neisseria meningitidis
3M5K	;	1.86	;	Crystal structure of Putative NADH dehydrogenase/NAD(P)H nitroreductase (BDI_1728) from Parabacteroides distasonis ATCC 8503 at 1.86 A resolution
3KWK	;	1.54	;	Crystal structure of Putative NADH dehydrogenase/NAD(P)H nitroreductase (NP_809094.1) from BACTEROIDES THETAIOTAOMICRON VPI-5482 at 1.54 A resolution
3E10	;	1.4	;	Crystal structure of Putative NADH Oxidase (NP_348178.1) from CLOSTRIDIUM ACETOBUTYLICUM at 1.40 A resolution
4AIV	;	2.0	;	Crystal Structure of putative NADH-dependent nitrite reductase small subunit from Mycobacterium tuberculosis
3D1L	;	2.19	;	Crystal structure of putative NADP oxidoreductase BF3122 from Bacteroides fragilis
1VJ1	;	2.1	;	Crystal structure of putative NADPH-dependent oxidoreductase from Mus musculus at 2.10 A resolution
3IUP	;	1.7	;	Crystal structure of Putative NADPH:quinone oxidoreductase (YP_296108.1) from RALSTONIA EUTROPHA JMP134 at 1.70 A resolution
3GMS	;	1.76	;	Crystal structure of putative NADPH:quinone reductase from bacillus thuringiensis
2AFA	;	2.15	;	Crystal Structure of putative NAG isomerase from Salmonella typhimurium
3BGH	;	2.45	;	Crystal structure of putative neuraminyllactose-binding hemagglutinin homolog from Helicobacter pylori
3BO9	;	2.71	;	Crystal structure of putative nitroalkan dioxygenase (TM0800) from Thermotoga maritima at 2.71 A resolution
4DN2	;	1.5	;	CRYSTAL STRUCTURE OF putative Nitroreductase from Geobacter metallireducens GS-15
8DIL	;	1.8	;	Crystal structure of putative nitroreductase from Salmonella enterica
3BEM	;	1.65	;	Crystal structure of putative nitroreductase ydfN (2632848) from Bacillus subtilis at 1.65 A resolution
7LD8	;	1.5	;	Crystal Structure of Putative non-heme bromoperoxidase BpoC from Mycobacterium tuberculosis H37Rv
3K7C	;	2.0	;	Crystal structure of Putative NTF2-like transpeptidase (NP_281412.1) from CAMPYLOBACTER JEJUNI at 2.00 A resolution
3F1Z	;	2.46	;	Crystal structure of putative nucleic acid-binding lipoprotein (YP_001337197.1) from Klebsiella pneumoniae subsp. pneumoniae MGH 78578 at 2.46 A resolution
2QU8	;	2.01	;	Crystal structure of putative nucleolar GTP-binding protein 1 PFF0625w from Plasmodium falciparum
3CGX	;	1.9	;	Crystal structure of putative nucleotide-diphospho-sugar transferase (YP_389115.1) from Desulfovibrio desulfuricans G20 at 1.90 A resolution
1YLQ	;	2.016	;	Crystal structure of putative nucleotidyltransferase
4OK0	;	2.17	;	Crystal structure of putative nucleotidyltransferase from H. pylori
3F13	;	1.7	;	Crystal structure of putative nudix hydrolase family member from Chromobacterium violaceum
2GPY	;	1.9	;	Crystal structure of putative O-methyltransferase from Bacillus halodurans
3V75	;	1.4	;	Crystal structure of putative orotidine 5'-phosphate decarboxylase from Streptomyces avermitilis ma-4680
3BK5	;	2.0	;	Crystal structure of putative outer membrane lipoprotein-sorting protein domain from Vibrio parahaemolyticus
2P2S	;	1.25	;	Crystal structure of putative oxidoreductase (YP_050235.1) from Erwinia carotovora atroseptica SCRI1043 at 1.25 A resolution
3EOF	;	1.99	;	Crystal structure of putative oxidoreductase (YP_213212.1) from Bacteroides fragilis NCTC 9343 at 1.99 A resolution
3OQB	;	2.6	;	CRYSTAL STRUCTURE OF putative oxidoreductase from Bradyrhizobium japonicum USDA 110
3L6D	;	1.9	;	Crystal structure of putative oxidoreductase from Pseudomonas putida KT2440
3EVN	;	2.0	;	CRYSTAL STRUCTURE OF putative oxidoreductase from Streptococcus agalactiae 2603V/r
3GDO	;	2.03	;	Crystal structure of putative oxidoreductase yvaA from Bacillus subtilis
3DKQ	;	2.26	;	Crystal structure of Putative Oxygenase (YP_001051978.1) from SHEWANELLA BALTICA OS155 at 2.26 A resolution
3PDW	;	1.596	;	Crystal structure of putative p-nitrophenyl phosphatase from Bacillus subtilis
3LYC	;	2.3	;	Crystal structure of Putative pectinase (YP_001304412.1) from Parabacteroides distasonis ATCC 8503 at 2.30 A resolution
3K9T	;	2.37	;	Crystal structure of putative peptidase (NP_348812.1) from CLOSTRIDIUM ACETOBUTYLICUM at 2.37 A resolution
3CE2	;	2.6	;	Crystal structure of putative peptidase from Chlamydophila abortus
2HSI	;	1.9	;	Crystal structure of putative peptidase M23 from pseudomonas aeruginosa, New York Structural Genomics Consortium
3TV9	;	2.497	;	Crystal Structure of Putative Peptide Maturation Protein from Shigella flexneri
4GWB	;	1.2	;	Crystal structure of putative Peptide methionine sulfoxide reductase from Sinorhizobium meliloti 1021
3KS7	;	2.3	;	Crystal structure of Putative Peptide:N-glycosidase F (PNGase F) (YP_210507.1) from Bacteroides fragilis NCTC 9343 at 2.30 A resolution
3QBU	;	2.5701	;	Crystal structure of putative peptidoglycan deactelyase (HP0310) from Helicobacter pylori
5JG7	;	1.7	;	Crystal structure of putative periplasmic binding protein from Salmonella typhimurium LT2
2R9I	;	2.6	;	Crystal structure of putative phage capsid protein domain from Corynebacterium diphtheriae
4EVX	;	1.7	;	Crystal structure of putative phage endolysin from S. enterica
3GXH	;	1.4	;	Crystal structure of Putative phosphatase (DUF442) (YP_001181608.1) from SHEWANELLA PUTREFACIENS CN-32 at 1.40 A resolution
3GXG	;	1.6	;	Crystal structure of Putative phosphatase (DUF442) (YP_001181608.1) from SHEWANELLA PUTREFACIENS CN-32 at 1.60 A resolution
3KYA	;	1.77	;	Crystal structure of Putative phosphatase (NP_812416.1) from BACTEROIDES THETAIOTAOMICRON VPI-5482 at 1.77 A resolution
1WVI	;	2.3	;	Crystal structure of putative phosphatase from Streptococcus mutans UA159
1VMI	;	2.32	;	Crystal structure of Putative phosphate acetyltransferase (np_416953.1) from Escherichia coli k12 at 2.32 A resolution
2Z0F	;	2.52	;	Crystal structure of putative phosphoglucomutase from Thermus thermophilus HB8
2HDO	;	1.5	;	Crystal structure of putative phosphoglycolate phosphatase (np_784602.1) from Lactobacillus plantarum at 1.50 A resolution
2HI0	;	1.51	;	Crystal structure of putative phosphoglycolate phosphatase (YP_619066.1) from Lactobacillus delbrueckii subsp. bulgaricus ATCC BAA-365 at 1.51 A resolution
3JX9	;	1.95	;	Crystal structure of Putative phosphoheptose isomerase (YP_001815198.1) from Exiguobacterium sp. 255-15 at 1.95 A resolution
3M1T	;	1.62	;	Crystal structure of Putative phosphohydrolase (YP_929327.1) from Shewanella amazonensis SB2B at 1.62 A resolution
1TUO	;	1.7	;	Crystal structure of putative phosphomannomutase from Thermus Thermophilus HB8
3KIZ	;	1.5	;	Crystal structure of Putative phosphoribosylformylglycinamidine cyclo-ligase (YP_676759.1) from CYTOPHAGA HUTCHINSONII ATCC 33406 at 1.50 A resolution
3FJ1	;	1.75	;	Crystal structure of putative phosphosugar isomerase (YP_167080.1) from SILICIBACTER POMEROYI DSS-3 at 1.75 A resolution
1NRI	;	1.9	;	Crystal Structure of Putative Phosphosugar Isomerase HI0754 from Haemophilus influenzae
3ETN	;	1.7	;	Crystal structure of putative phosphosugar isomerase involved in capsule formation (YP_209877.1) from Bacteroides fragilis NCTC 9343 at 1.70 A resolution
3L39	;	1.93	;	Crystal structure of Putative PhoU-like phosphate regulatory protein (BT4638) from BACTEROIDES THETAIOTAOMICRON VPI-5482 at 1.93 A resolution
4RGK	;	2.15	;	Crystal Structure of Putative Phytanoyl-CoA Dioxygenase Family Protein YbiU from Yersinia pestis
3HG9	;	2.4	;	CRYSTAL STRUCTURE OF putative pilM protein from Pseudomonas aeruginosa 2192
5TVK	;	2.4	;	Crystal Structure of putative plasmid partition protein (BB_S35) from Borrelia burgdorferi B31 bound to AMPPNP
3JU7	;	2.19	;	Crystal structure of Putative PLP-dependent aminotransferase (NP_978343.1) from Bacillus cereus ATCC 10987 at 2.19 A resolution
3K0Z	;	1.91	;	Crystal structure of Putative polyketide cyclase (NP_977253.1) from BACILLUS CEREUS ATCC 10987 at 1.91 A resolution
4U13	;	2.3	;	Crystal structure of putative polyketide cyclase (protein SMa1630) from Sinorhizobium meliloti at 2.3 A resolution
3CZP	;	2.0	;	Crystal structure of putative polyphosphate kinase 2 from Pseudomonas aeruginosa PA01
3CZQ	;	2.23	;	Crystal structure of putative polyphosphate kinase 2 from Sinorhizobium meliloti
3GF8	;	2.2	;	Crystal structure of putative polysaccharide binding proteins (DUF1812) (NP_809975.1) from BACTEROIDES THETAIOTAOMICRON VPI-5482 at 2.20 A resolution
3RXZ	;	2.01	;	Crystal structure of putative polysaccharide deacetylase from Mycobacterium smegmatis
3KOG	;	1.85	;	Crystal structure of Putative pore-forming toxin (YP_001301288.1) from Bacteroides vulgatus ATCC 8482 at 1.85 A resolution
1VCT	;	1.85	;	Crystal structure of putative potassium channel related protein from Pyrococcus horikoshii
3HM2	;	2.205	;	Crystal Structure of Putative Precorrin-6Y C5,15-Methyltransferase Targeted Domain from Corynebacterium diphtheriae
2P9B	;	1.7	;	Crystal structure of putative prolidase from Bifidobacterium longum
3K9I	;	2.71	;	Crystal structure of Putative protein binding protein (NP_241345.1) from Bacillus halodurans at 2.71 A resolution
3EOI	;	1.52	;	CRYSTAL STRUCTURE OF putative PROTEIN PilM from Escherichia coli B7A
3LOV	;	2.06	;	Crystal structure of Putative protoporphyrinogen oxidase (YP_001813199.1) from Exiguobacterium sp. 255-15 at 2.06 A resolution
7RKB	;	2.5	;	Crystal Structure of Putative Pterin Binding Protein (PruR) from Klebsiella pneumoniae in Complex with Neopterin
5UNB	;	1.75	;	Crystal structure of putative Putative deoxyribonuclease-2 from Burkholderia thailandensis in complex with copper
5I3E	;	1.65	;	Crystal structure of putative Putative deoxyribonuclease-2 from Burkholderia thailandensis, E264
3I0Z	;	1.7	;	Crystal structure of putative putative tagatose-6-phosphate ketose/aldose isomerase (NP_344614.1) from STREPTOCOCCUS PNEUMONIAE TIGR4 at 1.70 A resolution
3DB0	;	2.0	;	Crystal structure of Putative Pyridoxamine 5'-phosphate oxidase (NP_472219.1) from LISTERIA INNOCUA at 2.00 A resolution
3FKH	;	2.51	;	Crystal structure of Putative pyridoxamine 5'-phosphate oxidase (NP_601736.1) from CORYNEBACTERIUM GLUTAMICUM ATCC 13032 KITASATO at 2.51 A resolution
3LN3	;	1.18	;	Crystal structure of Putative reductase (NP_038806.2) from MUS MUSCULUS at 1.18 A resolution
2OI8	;	2.5	;	Crystal structure of putative regulatory protein SCO4313
3KY8	;	2.12	;	Crystal structure of Putative riboflavin biosynthesis protein (YP_001092907.1) from SHEWANELLA SP. PV-4 at 2.12 A resolution
3BF5	;	1.91	;	Crystal structure of putative ribokinase (10640157) from Thermoplasma acidophilum at 1.91 A resolution
1U61	;	2.15	;	Crystal Structure of Putative Ribonuclease III from Bacillus cereus
3KWR	;	1.45	;	Crystal structure of Putative RNA-binding protein (NP_785364.1) from LACTOBACILLUS PLANTARUM at 1.45 A resolution
3EEY	;	2.2	;	CRYSTAL STRUCTURE OF PUTATIVE RRNA-METHYLASE FROM Clostridium thermocellum
3G5L	;	2.35	;	Crystal structure of putative S-adenosylmethionine dependent methyltransferase from Listeria monocytogenes
3K50	;	2.0	;	Crystal structure of Putative S41 protease (YP_211611.1) from Bacteroides fragilis NCTC 9343 at 2.00 A resolution
3E8S	;	2.1	;	Crystal structure of Putative SAM Dependent Methyltransferase in Complex with SAH (NP_744700.1) from PSEUDOMONAS PUTIDA KT2440 at 2.10 A resolution
3EF8	;	1.5	;	Crystal structure of Putative Scytalone Dehydratase (YP_496742.1) from NOVOSPHINGOBIUM AROMATICIVORANS DSM 12444 at 1.50 A resolution
2QF9	;	1.69	;	Crystal structure of putative secreted protein DUF305 from Streptomyces coelicolor
7UXG	;	2.24	;	Crystal structure of putative serine protease YdgD from Escherichia coli
3KE3	;	2.2	;	Crystal structure of Putative serine-pyruvate aminotransferase (YP_263484.1) from PSYCHROBACTER ARCTICUM 273-4 at 2.20 A resolution
3F5Q	;	1.76	;	CRYSTAL STRUCTURE OF putative short chain dehydrogenase from Escherichia coli CFT073
3GZ4	;	2.1	;	Crystal structure of putative short chain dehydrogenase FROM ESCHERICHIA COLI CFT073 complexed with NADPH
3L6E	;	2.3	;	Crystal structure of putative short chain dehydrogenase/reductase family oxidoreductase from Aeromonas hydrophila subsp. hydrophila ATCC 7966
4JWV	;	2.1	;	Crystal Structure of putative short chain enoyl-CoA hydratase from Novosphingobium aromaticivorans DSM 12444
5UZX	;	1.5	;	Crystal Structure of Putative short-chain dehydrogenase/reductase from Burkholderia multivorans with bound NADP
5K9Z	;	2.0	;	Crystal Structure of putative short-chain dehydrogenase/reductase from Burkholderia xenovorans LB400
5JY1	;	1.65	;	Crystal Structure of putative short-chain dehydrogenase/reductase from Burkholderia xenovorans LB400 bound to NAD
4DA9	;	2.5	;	Crystal structure of putative Short-chain dehydrogenase/reductase from Sinorhizobium meliloti 1021
2YUT	;	2.2	;	Crystal Structure of Putative Short-Chain Oxidoreductase TTHB094 from Thermus thermophilus HB8
3GZB	;	1.44	;	Crystal structure of putative SnoaL-like polyketide cyclase (YP_001182657.1) from Shewanella putrefaciens CN-32 at 1.44 A resolution
3KKG	;	1.4	;	Crystal structure of Putative SnoaL-like polyketide cyclase (YP_509242.1) from Jannaschia Sp. CCS1 at 1.40 A resolution
3LZA	;	1.7	;	Crystal structure of Putative SnoaL-like polyketide cyclase (YP_563807.1) from SHEWANELLA DENITRIFICANS OS-217 at 1.70 A resolution
3G8R	;	2.49	;	Crystal structure of putative spore coat polysaccharide biosynthesis protein E from Chromobacterium violaceum ATCC 12472
3CZ8	;	2.2	;	Crystal structure of putative sporulation-specific glycosylase ydhD from Bacillus subtilis
4QQ7	;	2.2	;	Crystal Structure of Putative stringent starvation protein A from Burkholderia cenocepacia with bound glutathione
3LWU	;	2.1	;	Crystal structure of Putative succinylglutamate desuccinylase/aspartoacylase (YP_749235.1) from Shewanella frigidimarinA NCIMB 400 at 2.10 A resolution
3K5J	;	1.4	;	Crystal structure of Putative SUFU (suppressor of fused protein) homolog (YP_208451.1) from Neisseria gonorrhoeae FA 1090 at 1.40 A resolution
3KNZ	;	2.5	;	Crystal structure of Putative sugar binding protein (NP_459565.1) from Salmonella typhimurium LT2 at 2.50 A resolution
3KEZ	;	1.9	;	Crystal structure of Putative sugar binding protein (YP_001299726.1) from Bacteroides vulgatus ATCC 8482 at 1.90 A resolution
3KDW	;	1.7	;	Crystal structure of Putative sugar binding protein (YP_001300177.1) from Bacteroides vulgatus ATCC 8482 at 1.70 A resolution
3H3L	;	1.59	;	Crystal structure of PUTATIVE SUGAR HYDROLASE (YP_001304206.1) from Parabacteroides distasonis ATCC 8503 at 1.59 A resolution
3KWS	;	1.68	;	Crystal structure of Putative sugar isomerase (YP_001305149.1) from Parabacteroides distasonis ATCC 8503 at 1.68 A resolution
3KTC	;	1.54	;	Crystal structure of Putative sugar isomerase (YP_050048.1) from ERWINIA CAROTOVORA ATROSEPTICA SCRI1043 at 1.54 A resolution
3LMZ	;	1.44	;	Crystal structure of Putative sugar isomerase. (YP_001305105.1) from Parabacteroides distasonis ATCC 8503 at 1.44 A resolution
3L2H	;	1.85	;	Crystal structure of Putative sugar phosphate isomerase (AFE_0303) from Acidithiobacillus ferrooxidans ATCC 23270 at 1.85 A resolution
3KV1	;	1.7	;	Crystal Structure of Putative Sugar-Binding Domain of Transcriptional Repressor from Vibrio fischeri
3UIF	;	2.6	;	CRYSTAL STRUCTURE OF putative sulfonate ABC transporter, periplasmic sulfonate-binding protein SsuA from Methylobacillus flagellatus KT
2FIQ	;	2.25	;	Crystal structure of putative tagatose 6-phosphate kinase
2IA7	;	1.44	;	Crystal structure of putative tail lysozyme (NP_952040.1) from GEOBACTER SULFURREDUCENS at 1.44 A resolution
4OJL	;	2.0	;	Crystal Structure of Putative Tailspike Protein (TSP1, orf210) from Escherichia coli O157:H7 Bacteriohage CBA120 in Complex with Glucose
4OJO	;	2.0	;	Crystal Structure of Putative Tailspike Protein (TSP1, orf210) from Escherichia coli O157:H7 Bacteriohage CBA120 in Complex with Lactose
4OJP	;	1.948	;	Crystal Structure of Putative Tailspike Protein (TSP1, orf210) from Escherichia coli O157:H7 Bacteriohage CBA120 in Complex with Maltose
3IBZ	;	1.78	;	Crystal structure of putative tellurium resistant like protein (TerD) from Streptomyces coelicolor A3(2)
5C4Y	;	1.77	;	Crystal structure of putative TetR family transcription factor from Listeria monocytogenes
4G12	;	3.44	;	Crystal structure of putative TetR family transcriptional regulator, Fad35R, from Mycobacterium tuberculosis
3CJD	;	1.79	;	Crystal structure of putative TetR transcriptional regulator (YP_510936.1) from Jannaschia sp. CCS1 at 1.79 A resolution
3LWJ	;	2.07	;	Crystal structure of Putative TetR-family transcriptional regulator (YP_752756.1) from Syntrophomonas wolfei str. Goettingen at 2.07 A resolution
2G3B	;	2.0	;	Crystal structure of putative TetR-family transcriptional regulator from Rhodococcus sp.
3CJY	;	1.7	;	Crystal structure of putative thioesterase (YP_496845.1) from Novosphingobium aromaticivorans DSM 12444 at 1.70 A resolution
3GEK	;	2.24	;	Crystal structure of putative thioesterase yhdA from Lactococcus lactis. Northeast Structural Genomics Consortium Target KR113
4U4E	;	2.2	;	Crystal structure of putative thiolase from Sphaerobacter thermophilus DSM 20745
5U63	;	1.99	;	Crystal structure of putative thioredoxin reductase from Haemophilus influenzae
4FK1	;	2.404	;	Crystal Structure of Putative Thioredoxin Reductase TrxB from Bacillus anthracis
3A32	;	2.3	;	Crystal structure of putative threonyl-tRNA synthetase ThrRS-1 from Aeropyrum pernix
3A31	;	2.5	;	Crystal structure of putative threonyl-tRNA synthetase ThrRS-1 from Aeropyrum pernix (selenomethionine derivative)
3K0Y	;	2.16	;	Crystal structure of Putative TOXIN related protein (YP_001303978.1) from Parabacteroides distasonis ATCC 8503 at 2.16 A resolution
3JVD	;	2.3	;	Crystal structure of putative transcription regulation repressor (LACI family) FROM Corynebacterium glutamicum
3COL	;	2.1	;	Crystal structure of putative transcription regulator from Lactobacillus plantarum
2G7L	;	2.1	;	Crystal structure of putative transcription regulator SCO7704 from Streptomyces coelicor
3NRO	;	2.9	;	Crystal Structure of putative transcriptional factor Lmo1026 from Listeria monocytogenes (FRAGMENT 52-321), Northeast Structural Genomics Consortium Target LmR194
3L09	;	2.81	;	Crystal structure of Putative transcriptional regulator (JANN_22DEC04_CONTIG27_REVISED_GENE3569) from Jannaschia sp. CCS1 at 2.81 A resolution
3LWF	;	2.06	;	Crystal structure of Putative transcriptional regulator (NP_470886.1) from LISTERIA INNOCUA at 2.06 A resolution
3CLO	;	2.04	;	Crystal structure of putative transcriptional regulator containing a LuxR DNA binding domain (NP_811094.1) from Bacteroides thetaiotaomicron VPI-5482 at 2.04 A resolution
3QK7	;	2.7	;	Crystal structure of putative Transcriptional regulator from Yersinia pestis biovar Microtus str. 91001
3K4H	;	2.8	;	CRYSTAL STRUCTURE OF putative transcriptional regulator LacI from Bacillus cereus subsp. cytotoxis NVH 391-98
2QSX	;	1.64	;	Crystal structure of putative transcriptional regulator LysR From Vibrio parahaemolyticus
3IC7	;	2.819	;	Crystal Structure of Putative Transcriptional Regulator of GntR Family from Bacteroides thetaiotaomicron
2HR3	;	2.4	;	Crystal structure of putative transcriptional regulator protein from Pseudomonas aeruginosa PA01 at 2.4 A resolution
2O0Y	;	2.0	;	Crystal structure of putative transcriptional regulator RHA1_ro06953 (IclR-family) from Rhodococcus sp.
2PZ9	;	2.8	;	Crystal structure of putative transcriptional regulator SCO4942 from Streptomyces coelicolor
3ELK	;	1.7	;	Crystal structure of putative transcriptional regulator TA0346 from Thermoplasma acidophilum
3LOC	;	2.5	;	Crystal structure of putative transcriptional regulator ycdc
3MEJ	;	2.491	;	Crystal structure of putative transcriptional regulator ywtF from Bacillus subtilis, Northeast Structural Genomics Consortium Target SR736
3OBF	;	2.16	;	Crystal structure of putative transcriptional regulator, IclR family; targeted domain 129...302
2NPO	;	2.2	;	Crystal structure of putative transferase from Campylobacter jejuni subsp. jejuni NCTC 11168
3K6R	;	2.1	;	CRYSTAL STRUCTURE OF putative transferase PH0793 FROM PYROCOCCUS HORIKOSHII
3CZB	;	2.5	;	Crystal structure of putative transglycosylase from Caulobacter crescentus
2DYY	;	2.6	;	Crystal structure of putative translation initiation inhibitor PH0854 from Pyrococcus horikoshii
3H9P	;	2.3	;	Crystal structure of putative triphosphoribosyl-dephospho-coA synthase from Archaeoglobus fulgidus
1XHL	;	2.4	;	Crystal Structure of putative Tropinone Reductase-II from Caenorhabditis Elegans with Cofactor and Substrate
3FRW	;	2.05	;	Crystal structure of putative TrpR protein from Ruminococcus obeum
3I45	;	1.36	;	CRYSTAL STRUCTURE OF putative twin-arginine translocation pathway signal protein from Rhodospirillum rubrum Atcc 11170
3MF4	;	1.8	;	Crystal structure of putative two-component system response regulator/ggdef domain protein
3OC9	;	1.8	;	Crystal structure of putative UDP-N-acetylglucosamine pyrophosphorylase from Entamoeba histolytica
3LYD	;	1.45	;	Crystal structure of Putative uncharacterized protein from Jonesia denitrificans
7MQ5	;	1.25	;	Crystal Structure of Putative Universal Stress Protein from Pseudomonas aeruginosa UCBPP-PA14
3FH0	;	2.15	;	Crystal structure of putative universal stress protein KPN_01444 - ATPase
2QYV	;	2.11	;	Crystal structure of putative Xaa-His dipeptidase (YP_718209.1) from Haemophilus somnus 129PT at 2.11 A resolution
2OFY	;	1.7	;	Crystal structure of putative XRE-family transcriptional regulator from Rhodococcus sp.
3BEE	;	2.15	;	Crystal structure of putative YfrE protein from Vibrio parahaemolyticus
3IH6	;	2.15	;	Crystal structure of putative zinc protease from Bordetella pertussis Tohama I
3IV6	;	2.7	;	Crystal Structure of Putative Zn-dependent Alcohol Dehydrogenases from Rhodobacter sphaeroides.
1Q1R	;	1.91	;	Crystal Structure of Putidaredoxin Reductase from Pseudomonas putida
1Q1W	;	2.6	;	Crystal Structure of Putidaredoxin Reductase from Pseudomonas putida
3TXX	;	3.2	;	Crystal structure of putrescine transcarbamylase from Enterococcus faecalis
4A8T	;	1.59	;	Crystal structure of putrescine transcarbamylase from Enterococcus faecalis lacking its C-terminal Helix, with bound N5-(phosphonoacetyl) -L-ornithine
4A8H	;	2.5	;	Crystal structure of putrescine transcarbamylase from Enterococcus faecalis with N-(phosphonoacetyl)-putrescine
4A8P	;	2.0	;	Crystal structure of putrescine transcarbamylase from Enterococcus faecalis with N5-(phosphonoacetyl)-L-ornithine
6VTV	;	2.06	;	Crystal structure of PuuD gamma-glutamyl-gamma-aminobutyrate hydrolase from E. coli
3CL6	;	1.58	;	Crystal structure of Puue Allantoinase
3CL8	;	2.25	;	Crystal structure of Puue Allantoinase complexed with ACA
3CL7	;	1.8	;	Crystal structure of Puue Allantoinase in complex with Hydantoin
6Z06	;	3.5	;	Crystal structure of Puumala virus Gc in complex with Fab 4G2
5FXU	;	2.28	;	Crystal Structure of Puumala virus Gn glycoprotein ectodomain
5I90	;	1.219	;	Crystal Structure of PvdN from Pseudomonas Aeruginosa
5FAL	;	1.861	;	Crystal structure of PvHCT in complex with CoA and p-coumaroyl-shikimate
5FAN	;	1.901	;	Crystal structure of PvHCT in complex with p-coumaroyl-CoA and protocatechuate
8C13	;	2.3	;	Crystal structure of pVHL:ElonginC:ElonginB complex bound to PROTAC JW48
4TR2	;	2.7	;	Crystal structure of PvSUB1
4OKY	;	2.9	;	Crystal structure of PvuRts1I, a 5-hydroxymethylcytosine DNA restriction endonuclease
5EZR	;	2.5	;	Crystal Structure of PVX_084705 bound to compound
5FET	;	3.07	;	Crystal Structure of PVX_084705 in presence of Compound 2
5F0A	;	2.6	;	CRYSTAL STRUCTURE OF PVX_084705 WITH BOUND 1-tert-butyl-3-(3-chlorophenoxy)-1H-pyrazolo[3,4-d]pyrimidin-4-amine INHIBITOR
4RZ7	;	2.351	;	Crystal Structure of PVX_084705 with bound PCI32765
5XSK	;	2.84	;	Crystal structure of PWWP-DNA complex for human hepatoma-derived growth factor
5ZN9	;	1.776	;	Crystal structure of PX domain
4HAS	;	1.74	;	Crystal structure of PX domain of human sorting nexin SNX27
6DUP	;	2.3	;	CRYSTAL STRUCTURE OF PXR IN COMPLEX WITH COMPOUND 7
6S41	;	2.7	;	CRYSTAL STRUCTURE OF PXR IN COMPLEX WITH XPC-7455
5X0R	;	2.665	;	Crystal Structure of PXR LBD Complexed with SJB7
5GQR	;	3.5	;	Crystal structure of PXY-CLE41-SERK2
5GR9	;	2.767	;	Crystal structure of PXY-TDIF/CLE41
3FZP	;	2.1	;	Crystal structure of PYK2 complexed with ATPgS
3FZS	;	1.75	;	Crystal Structure of PYK2 complexed with BIRB796
3ET7	;	2.7	;	Crystal structure of PYK2 complexed with PF-2318841
3FZR	;	2.7	;	Crystal structure of PYK2 complexed with PF-431396
3FZT	;	1.95	;	Crystal structure of PYK2 complexed with PF-4618433
3H3C	;	2.0	;	Crystal structure of PYK2 in complex with Sulfoximine-substituted trifluoromethylpyrimidine analog
4H1M	;	1.99	;	Crystal structure of PYK2 with the indole 10c
4H1J	;	2.0	;	Crystal structure of PYK2 with the pyrazole 13a
3FZO	;	2.2	;	Crystal Structure of PYK2-Apo, Proline-rich Tyrosine Kinase
3RT0	;	2.113	;	Crystal structure of PYL10-HAB1 complex in the absence of abscisic acid (ABA)
4N0G	;	2.382	;	Crystal Structure of PYL13-PP2CA complex
1UGU	;	1.2	;	Crystal structure of PYP E46Q mutant
3NMT	;	2.56	;	Crystal structure of pyrabactin bound abscisic acid receptor PYL2 mutant A93F in complex with type 2C protein phosphatase HAB1
3NMN	;	2.15	;	Crystal structure of pyrabactin-bound abscisic acid receptor PYL1 in complex with type 2C protein phosphatase ABI1
3NMV	;	2.1	;	Crystal structure of pyrabactin-bound abscisic acid receptor PYL2 mutant A93F in complex with type 2C protein phosphatase ABI2
7EO5	;	2.0	;	Crystal structure of pyrano 1,3, oxazine derivative in complex with the second bromodomain of BRD2
1TT0	;	1.8	;	Crystal Structure of Pyranose 2-Oxidase
1TZL	;	2.35	;	Crystal Structure of Pyranose 2-Oxidase from the White-Rot Fungus Peniophora sp.
2IGO	;	1.95	;	Crystal structure of pyranose 2-oxidase H167A mutant with 2-fluoro-2-deoxy-D-glucose
4H7U	;	1.6	;	Crystal structure of pyranose dehydrogenase from Agaricus meleagris, wildtype
3AC1	;	1.99	;	Crystal structure of pyrazin derivative bound to the kinase domain of Human LCK, (Auto-phosphorylated on TYR394)
1IM5	;	1.65	;	Crystal Structure of Pyrazinamidase of Pyrococcus horikoshii in Complex with Zinc
1ILW	;	2.05	;	Crystal Structure of Pyrazinamidase/Nicotinamidase of Pyrococcus horikoshii
3AC2	;	2.1	;	Crystal structure of pyrazolo pyrimidine derivative bound to the kinase domain of human LCK, (auto-phosphorylated on TYR394)
3AC3	;	2.55	;	Crystal structure of pyrazolo pyrimidine derivative bound to the kinase domain of human LCK, (auto-phosphorylated on TYR394)
3AC8	;	2.3	;	Crystal structure of pyrazolo pyrimidine derivative bound to the kinase domain of human LCK, (auto-phosphorylated on TYR394)
3AD6	;	2.15	;	Crystal structure of Pyrazolo pyrimidine derivative bound to the kinase domain of human LCK, (auto-phosphorylated on TYR394)
5HLT	;	2.672	;	Crystal structure of pyrene- and phenanthrene-modified DNA in complex with the BpuJ1 endonuclease binding domain
5HNF	;	1.546	;	Crystal structure of pyrene- and phenanthrene-modified DNA in complex with the BpuJ1 endonuclease binding domain
5HNH	;	1.876	;	Crystal structure of pyrene- and phenanthrene-modified DNA in complex with the BpuJ1 endonuclease binding domain
3X2S	;	2.8	;	Crystal structure of pyrene-conjugated adenylate kinase
3KD9	;	2.75	;	Crystal structure of pyridine nucleotide disulfide oxidoreductase from Pyrococcus horikoshii
5YBW	;	1.9	;	Crystal structure of pyridoxal 5'-phosphate-dependent aspartate racemase
4FIR	;	3.1	;	Crystal structure of pyridoxal biosynthesis lyase PdxS from Pyrococcus
4FIQ	;	2.7	;	Crystal structure of pyridoxal biosynthesis lyase PdxS from Pyrococcus horikoshii
5ZW9	;	2.6	;	Crystal structure of Pyridoxal kinase (PdxK) from Salmonella typhimurium
5ZWB	;	2.2	;	Crystal structure of Pyridoxal kinase (PdxK) from Salmonella typhimurium in complex with ADP, PL-linked to Lys233 via a Schiff base
5ZWA	;	2.45	;	Crystal structure of Pyridoxal kinase (PdxK) from Salmonella typhimurium in complex with ADP, PL-linked to Lys233 via Schiff base in protomer A and the product (PLP) in protomer B
1RFV	;	2.8	;	Crystal structure of pyridoxal kinase complexed with ADP
1RFU	;	2.8	;	Crystal structure of pyridoxal kinase complexed with ADP and PLP
1RFT	;	2.8	;	Crystal structure of pyridoxal kinase complexed with AMP-PCP and pyridoxamine
1LHR	;	2.6	;	Crystal Structure of Pyridoxal Kinase complexed with ATP
4S1M	;	1.64	;	Crystal Structure of Pyridoxal Kinase from Entamoeba histolytica
3H74	;	1.3	;	Crystal structure of pyridoxal kinase from Lactobacillus plantarum
3HYO	;	1.85	;	Crystal structure of pyridoxal kinase from Lactobacillus plantarum in complex with ADP
3IBQ	;	2.0	;	Crystal structure of pyridoxal kinase from Lactobacillus plantarum in complex with ATP
1LHP	;	2.1	;	Crystal Structure of Pyridoxal Kinase from Sheep Brain
2DDM	;	2.1	;	Crystal Structure of Pyridoxal Kinase from the Escherichia coli PdxK gene at 2.1 A resolution
2DDO	;	2.6	;	Crystal Structure of Pyridoxal Kinase from the Escherichia coli pdxK gene at 2.6 A resolution
2DDW	;	3.2	;	Crystal Structure of Pyridoxal Kinase from the Escherichia coli PdxK gene complexed with pyridoxal at 3.2 A resolution
3ZS7	;	2.0	;	Crystal structure of pyridoxal kinase from Trypanosoma brucei
1YGJ	;	2.7	;	Crystal Structure of Pyridoxal Kinase in Complex with Roscovitine and Derivatives
1YGK	;	2.6	;	Crystal Structure of Pyridoxal Kinase in Complex with Roscovitine and Derivatives
1YHJ	;	2.8	;	Crystal Structure of Pyridoxal Kinase in Complex with Roscovitine and Derivatives
3GK0	;	2.28	;	Crystal structure of pyridoxal phosphate biosynthetic protein from Burkholderia pseudomallei
1YXO	;	2.01	;	Crystal Structure of pyridoxal phosphate biosynthetic protein PdxA PA0593
3F4N	;	2.402	;	Crystal Structure of Pyridoxal Phosphate Biosynthetic Protein PdxJ from Yersinia pestis
3BA3	;	1.55	;	Crystal structure of Pyridoxamine 5'-phosphate oxidase-like protein (NP_783940.1) from Lactobacillus plantarum at 1.55 A resolution
1VI9	;	1.96	;	Crystal structure of pyridoxamine kinase
5TRW	;	1.6	;	Crystal structure of Pyridoxamine kinase PDXY from Burkholderia xenovorans
2Z9W	;	1.7	;	Crystal structure of pyridoxamine-pyruvate aminotransferase complexed with pyridoxal
2Z9V	;	1.7	;	Crystal structure of pyridoxamine-pyruvate aminotransferase complexed with pyridoxamine
2Z9X	;	1.94	;	Crystal structure of pyridoxamine-pyruvate aminotransferase complexed with pyridoxyl-L-alanine
2Z9U	;	2.0	;	Crystal structure of pyridoxamine-pyruvate aminotransferase from Mesorhizobium loti at 2.0 A resolution
4HA6	;	2.095	;	Crystal structure of pyridoxine 4-oxidase - pyridoxamine complex
3T37	;	2.193	;	Crystal structure of pyridoxine 4-oxidase from Mesorbium loti
1HO1	;	2.0	;	CRYSTAL STRUCTURE OF PYRIDOXINE 5'-PHOSPHATE SYNTHASE
1HO4	;	2.3	;	CRYSTAL STRUCTURE OF PYRIDOXINE 5'-PHOSPHATE SYNTHASE IN COMPLEX WITH PYRIDOXINE 5'-PHOSPHATE AND INORGANIC PHOSPHATE
2YZR	;	2.3	;	Crystal structure of pyridoxine biosynthesis protein from Methanocaldococcus jannaschii
2ZBT	;	1.65	;	Crystal structure of pyridoxine biosynthesis protein from Thermus thermophilus HB8
3OPX	;	1.7	;	Crystal structure of pyrimidine 5 -nucleotidase SDT1 from Saccharomyces cerevisiae complexed with uridine 5'-monophosphate
3B2W	;	2.3	;	Crystal structure of pyrimidine amide 11 bound to Lck
8B37	;	3.84	;	Crystal structure of Pyrobaculum aerophilum potassium-independent proton pumping membrane integral pyrophosphatase in complex with imidodiphosphate and magnesium, and with bound sulphate
7P8L	;	1.25	;	Crystal structure of Pyrococcus abyssi 8-oxoguanine DNA glycosylase (PabAGOG) in complex with dsDNA containing cytosine opposite to 8-oxoG
3FRO	;	2.5	;	Crystal structure of Pyrococcus abyssi glycogen synthase with open and closed conformations
7ANU	;	1.64	;	Crystal structure of Pyrococcus abyssi Pbp11
2P38	;	1.8	;	Crystal Structure of Pyrococcus Abyssi Protein Homologue of Saccharomyces Cerevisiae NIP7P
5HJJ	;	2.0	;	Crystal Structure of Pyrococcus abyssi Trm5a
5HJI	;	2.2	;	Crystal Structure of Pyrococcus abyssi Trm5a complexed with adenosine
5HJM	;	1.762	;	Crystal Structure of Pyrococcus abyssi Trm5a complexed with MTA
5HJK	;	2.0	;	Crystal Structure of Pyrococcus abyssi Trm5a complexed with SAH
4NCH	;	2.3	;	Crystal Structure of Pyrococcus furiosis Rad50 L802W mutation
4NCK	;	1.99	;	Crystal Structure of Pyrococcus furiosis Rad50 R797G mutation
4NCI	;	2.3	;	Crystal Structure of Pyrococcus furiosis Rad50 R805E mutation
4NCJ	;	2.0	;	Crystal Structure of Pyrococcus furiosis Rad50 R805E mutation with ADP Beryllium Flouride
4C1K	;	2.15	;	Crystal structure of pyrococcus furiosus 3-deoxy-D-arabino- heptulosonate 7-phosphate synthase
4C1L	;	1.8	;	Crystal structure of pyrococcus furiosus 3-deoxy-D-arabino- heptulosonate 7-phosphate synthase I181D interface mutant
1ZCO	;	2.25	;	Crystal structure of pyrococcus furiosus 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase
4DOZ	;	3.1	;	Crystal structure of Pyrococcus furiosus Cmr2 (Cas10)
4WNZ	;	2.8	;	Crystal structure of Pyrococcus furiosus Cmr4 (Cas7)
3A2F	;	2.67	;	Crystal Structure of Pyrococcus furiosus DNA polymerase/PCNA monomer mutant complex
1G71	;	2.3	;	CRYSTAL STRUCTURE OF PYROCOCCUS FURIOSUS DNA PRIMASE
1WP9	;	2.9	;	Crystal structure of Pyrococcus furiosus Hef helicase domain
4Q0M	;	2.226	;	Crystal structure of Pyrococcus furiosus L-asparaginase
4NJE	;	2.5	;	Crystal structure of Pyrococcus furiosus L-asparaginase with ligand
5Y9N	;	2.55	;	Crystal structure of Pyrococcus furiosus PbaA (monoclinic form), an archaeal homolog of proteasome-assembly chaperone
3WZ2	;	2.25	;	Crystal structure of Pyrococcus furiosus PbaA, an archaeal homolog of proteasome-assembly chaperone
3VR0	;	2.2	;	Crystal structure of Pyrococcus furiosus PbaB, an archaeal proteasome activator
3ENC	;	2.6304	;	Crystal structure of Pyrococcus furiosus PCC1 dimer
3ENO	;	3.0201	;	Crystal structure of Pyrococcus furiosus Pcc1 in complex with Thermoplasma acidophilum Kae1
3V68	;	1.56	;	Crystal structure of Pyrococcus furiosus PF2050, a member of DUF2666 family protein
1X8E	;	2.8	;	Crystal structure of Pyrococcus furiosus phosphoglucose isomerase free enzyme
2AV5	;	3.15	;	Crystal structure of Pyrococcus furiosus Pop5, an archaeal Ribonuclease P protein
2DT4	;	1.6	;	Crystal structure of Pyrococcus horikoshii a plant- and prokaryote-conserved (PPC) protein at 1.60 resolution
2ZUF	;	2.3	;	Crystal structure of Pyrococcus horikoshii arginyl-tRNA synthetase complexed with tRNA(Arg)
2ZUE	;	2.0	;	Crystal structure of Pyrococcus horikoshii arginyl-tRNA synthetase complexed with tRNA(Arg) and an ATP analog (ANP)
1UMJ	;	1.6	;	Crystal structure of Pyrococcus horikoshii CutA in the presence of 3M guanidine hydrochloride
1UKU	;	1.45	;	Crystal Structure of Pyrococcus horikoshii CutA1 Complexed with Cu2+
1V34	;	2.7	;	Crystal structure of Pyrococcus horikoshii DNA primase-UTP complex
6BXK	;	2.347	;	Crystal structure of Pyrococcus horikoshii Dph2 with 4Fe-4S cluster and MTA
6BXL	;	2.301	;	Crystal structure of Pyrococcus horikoshii Dph2 with 4Fe-4S cluster and SAM
3AOW	;	1.56	;	Crystal structure of Pyrococcus horikoshii kynurenine aminotransferase in complex with AKG
3ATH	;	1.69	;	Crystal structure of Pyrococcus horikoshii kynurenine aminotransferase in complex with four AKGs as substrates and allosteric effectors
3AOV	;	1.72	;	Crystal structure of Pyrococcus horikoshii kynurenine aminotransferase in complex with PLP
3WX9	;	1.58	;	Crystal structure of Pyrococcus horikoshii kynurenine aminotransferase in complex with PMP, GLA, 4AD, 2OG, GLU and KYA
3AV7	;	1.84	;	Crystal structure of Pyrococcus horikoshii kynurenine aminotransferase in complex with PMP, KYN as substrates and KYA as products
1WZC	;	1.9	;	Crystal structure of Pyrococcus horikoshii mannosyl-3-phosphoglycerate phosphatase complexed with MG2+ and phosphate
2DX7	;	2.0	;	Crystal structure of Pyrococcus horikoshii OT3 aspartate racemase complex with citric acid
4UZR	;	2.652	;	Crystal Structure of Pyrococcus horikoshii Ph1500
1WQA	;	2.0	;	Crystal Structure of Pyrococcus horikoshii phosphomannomutase/phosphoglucomutase complexed with Mg2+
5KTM	;	1.44	;	Crystal structure of Pyrococcus horikoshii quinolinate synthase (NadA) with a bound Fe4S4 cluster
5KTS	;	1.34	;	Crystal structure of Pyrococcus horikoshii quinolinate synthase (NadA) with bound citraconate and Fe4S4 cluster
5KTN	;	1.34	;	Crystal structure of Pyrococcus horikoshii quinolinate synthase (NadA) with bound dihydroxyacetone phosphate (DHAP) and Fe4S4 cluster
5KTP	;	1.542	;	Crystal structure of Pyrococcus horikoshii quinolinate synthase (NadA) with bound itaconate and Fe4S4 cluster
5KTT	;	1.5	;	Crystal structure of Pyrococcus horikoshii quinolinate synthase (NadA) with bound L-malate and Fe4S4 cluster
5KTR	;	1.34	;	Crystal structure of Pyrococcus horikoshii quinolinate synthase (NadA) with bound maleate and Fe4S4 cluster
5KTO	;	1.442	;	Crystal structure of Pyrococcus horikoshii quinolinate synthase (NadA) with bound quinolinate and Fe4S4 cluster
3JXE	;	3.0	;	Crystal structure of Pyrococcus horikoshii tryptophanyl-tRNA synthetase in complex with TrpAMP
1GDE	;	1.8	;	CRYSTAL STRUCTURE OF PYROCOCCUS PROTEIN A-1 E-FORM
6BII	;	2.0	;	Crystal Structure of Pyrococcus yayanosii Glyoxylate Hydroxypyruvate Reductase in complex with NADP and malonate (re-refinement of 5AOW)
4V4C	;	2.35	;	Crystal Structure of Pyrogallol-Phloroglucinol Transhydroxylase from Pelobacter acidigallici
4V4E	;	2.0	;	Crystal Structure of Pyrogallol-Phloroglucinol Transhydroxylase from Pelobacter acidigallici complexed with inhibitor 1,2,4,5-tetrahydroxy-benzene
4V4D	;	2.2	;	Crystal Structure of Pyrogallol-Phloroglucinol Transhydroxylase from Pelobacter acidigallici complexed with pyrogallol
3QXG	;	1.24	;	Crystal structure of pyrophosphatase from bacteroides thetaiotaomicron complexed with calcium, a closed cap conformation
3QX7	;	2.0	;	Crystal structure of pyrophosphatase from bacteroides thetaiotaomicron complexed with phosphate, a closed cap conformation
3QU2	;	1.95	;	Crystal structure of pyrophosphatase from bacteroides thetaiotaomicron, a closed cap conformation
3QUQ	;	1.65	;	Crystal structure of pyrophosphatase from bacteroides thetaiotaomicron, an open cap conformation
3QU5	;	1.24	;	Crystal structure of pyrophosphatase from bacteroides thetaiotaomicron, asp11asn mutant
3QU4	;	2.1	;	Crystal structure of pyrophosphatase from bacteroides thetaiotaomicron, asp13ala mutant
3QU7	;	1.9	;	Crystal structure of pyrophosphatase from bacteroides thetaiotaomicron, asp13asn mutant complexed with calcium and phosphate
3QU9	;	1.9	;	Crystal structure of pyrophosphatase from bacteroides thetaiotaomicron, asp13asn mutant complexed with magnesium and tartrate
3QUT	;	1.5	;	Crystal structure of pyrophosphatase from bacteroides thetaiotaomicron, asp13asn mutant, an open cap conformation
3QUB	;	1.9	;	Crystal structure of pyrophosphatase from bacteroides thetaiotaomicron, glu47ala mutant complexed with sulfate
3QYP	;	1.6	;	Crystal structure of pyrophosphatase from bacteroides thetaiotaomicron, glu47asn mutant complexed with calcium and phosphate
3QUC	;	2.0	;	Crystal structure of pyrophosphatase from bacteroides thetaiotaomicron, glu47asn mutant complexed with sulfate
3R9K	;	1.8	;	Crystal structure of pyrophosphatase from bacteroides thetaiotaomicron, glu47asp mutant complexed with sulfate, a closed cap conformation
6K31	;	2.6	;	Crystal structure of pyrophosphate-dependent phosphoenolpyruvate carboxykinase (PPi-PEPCK)
3K2Q	;	2.5	;	Crystal structure of Pyrophosphate-dependent phosphofructokinase from Marinobacter aquaeolei, NORTHEAST STRUCTURAL GENOMICS CONSORTIUM TARGET MqR88
3HNO	;	2.0	;	Crystal Structure of Pyrophosphate-dependent phosphofructokinase from Nitrosospira multiformis. Northeast Structural Genomics Consortium target id NmR42
2IGB	;	1.68	;	Crystal Structure of PyrR, The Regulator Of The Pyrimidine Biosynthetic Operon In Bacillus caldolyticus, UMP-bound form
5V9P	;	3.0	;	Crystal structure of pyrrolidine amide inhibitor [(3S)-3-(4-bromo-1H-pyrazol-1-yl)pyrrolidin-1-yl][3-(propan-2-yl)-1H-pyrazol-5-yl]methanone (compound 35) in complex with KDM5A
6LTQ	;	1.85	;	Crystal structure of pyrrolidone carboxyl peptidase from thermophilic keratin degrading bacterium Fervidobacterium islandicum AW-1 (FiPcp)
2EBJ	;	1.9	;	Crystal structure of pyrrolidone carboxyl peptidase from Thermus thermophilus
5Z48	;	1.551	;	Crystal structure of pyrrolidone carboxylate peptidase I from Deinococcus radiodurans R1 bound to pyroglutamate
5Z40	;	1.837	;	Crystal structure of pyrrolidone carboxylate peptidase I from Deionococcus radiodurans R1
5Z47	;	1.7	;	Crystal structure of pyrrolidone carboxylate peptidase I with disordered loop A from Deinococcus radiodurans R1
3GT0	;	2.0	;	Crystal structure of pyrroline 5-carboxylate reductase from Bacillus cereus. Northeast Structural Genomics Consortium Target BcR38B
3ACK	;	2.6	;	Crystal structure of Pyrrolo pyrazine derivative bound to the kinase domain of human LCK, (auto-phosphorylated on TYR394)
3HXJ	;	2.0	;	Crystal Structure of Pyrrolo-quinoline quinone (PQQ_DH) from Methanococcus maripaludis, Northeast Structural Genomics Consortium Target MrR86
7RSM	;	2.15	;	Crystal structure of pyrrolysyl-tRNA synthetase (N346D/C348S/Y384F) in complex with o-Chlorophenylalanine and AMP-PNP
2ZNJ	;	2.5	;	Crystal structure of Pyrrolysyl-tRNA synthetase from Desulfitobacterium hafniense
8IFJ	;	2.78	;	Crystal structure of pyrrolysyl-tRNA synthetase from methanogenic archaeon ISO4-G1
6JP2	;	2.272	;	Crystal structure of pyrrolysyl-tRNA synthetase from Methanomethylophilus alvus
8C49	;	1.82	;	Crystal structure of pyrrolysyl-tRNA synthetase from Methanomethylophilus alvus engineered for 3-Methyl-L-histidine, bound to AMPPNP
8DQJ	;	1.54	;	Crystal structure of pyrrolysyl-tRNA synthetase from Methanomethylophilus alvus engineered for acridone amino acid (AST) bound to ATP and acridone
8DQG	;	1.49	;	Crystal structure of pyrrolysyl-tRNA synthetase from Methanomethylophilus alvus engineered for acridone amino acid (RS1) bound to AMPPNP and acridone
8DQI	;	1.54	;	Crystal structure of pyrrolysyl-tRNA synthetase from Methanomethylophilus alvus engineered for acridone amino acid (RS1) bound to ATP and acridone after 2- weeks of crystal growth
8DQH	;	1.52	;	Crystal structure of pyrrolysyl-tRNA synthetase from Methanomethylophilus alvus engineered for acridone amino acid (RS1) bound to ATP and acridone after 24 hours of crystal growth
2ZNI	;	3.1	;	Crystal structure of Pyrrolysyl-tRNA synthetase-tRNA(Pyl) complex from Desulfitobacterium hafniense
1O5Q	;	2.3	;	Crystal Structure of Pyruvate and Mg2+ bound 2-methylisocitrate lyase (PrpB) from Salmonella typhimurium
3A4V	;	1.78	;	Crystal structure of pyruvate bound L-Threonine dehydrogenase from Hyperthermophilic Archaeon Thermoplasma volcanium
2VK4	;	1.95	;	Crystal structure of pyruvate decarboxylase from Kluyveromyces lactis
4MP2	;	1.751	;	Crystal structure of pyruvate dehydrogenase kinase isoform 2 in complex with inhibitor PA1
4MP7	;	1.8	;	Crystal structure of pyruvate dehydrogenase kinase isoform 2 in complex with inhibitor PA7
4MPN	;	1.752	;	Crystal structure of pyruvate dehydrogenase kinase isoform 2 in complex with inhibitor PS10
4MPC	;	1.699	;	Crystal structure of pyruvate dehydrogenase kinase isoform 2 in complex with inhibitor PS2
5J71	;	1.65	;	Crystal structure of pyruvate dehydrogenase kinase isoform 2 in complex with inhibitor PS35
5J6A	;	2.045	;	Crystal structure of pyruvate dehydrogenase kinase isoform 2 in complex with inhibitor PS46
4MPE	;	1.953	;	Crystal structure of pyruvate dehydrogenase kinase isoform 2 in complex with inhibitor PS8
3D2R	;	2.03	;	Crystal structure of pyruvate dehydrogenase kinase isoform 4 in complex with ADP
2PNQ	;	1.81	;	Crystal structure of pyruvate dehydrogenase phosphatase 1 (PDP1)
1MZO	;	2.7	;	Crystal structure of pyruvate formate-lyase with pyruvate
6ITO	;	2.55	;	Crystal structure of pyruvate kinase (PYK) from Mycobacterium tuberculosis in complex with Oxalate, AMP and inhibitor Ribose 5-Phosphate
6KSH	;	2.6	;	Crystal structure of pyruvate kinase (PYK) from Plasmodium falciparum in complex with oxalate and ATP
3E0W	;	3.1	;	Crystal structure of pyruvate kinase from Leishmania mexicana
3E0V	;	3.3	;	Crystal structure of pyruvate kinase from Leishmania mexicana in complex with sulphate ions
3QTG	;	2.2	;	Crystal structure of pyruvate kinase from Pyrobaculum aerophilum
3EOE	;	2.31	;	Crystal Structure of Pyruvate Kinase from toxoplasma gondii, 55.m00007
6QXL	;	2.43	;	Crystal Structure of Pyruvate Kinase II (PykA) from Pseudomonas aeruginosa in complex with sodium malonate, magnesium and glucose-6-phosphate
1V5F	;	1.8	;	Crystal Structure of Pyruvate oxidase complexed with FAD and TPP, from Aerococcus viridans
1V5E	;	1.6	;	Crystal Structure of Pyruvate oxidase containing FAD, from Aerococcus viridans
2DJI	;	1.6	;	Crystal Structure of Pyruvate Oxidase from Aerococcus viridans containing FAD
2RAA	;	2.12	;	Crystal structure of pyruvate oxidoreductase subunit PORC (EC 1.2.7.1) (TM0015) from Thermotoga maritima at 2.12 A resolution
1B0P	;	2.31	;	CRYSTAL STRUCTURE OF PYRUVATE-FERREDOXIN OXIDOREDUCTASE FROM DESULFOVIBRIO AFRICANUS
2C3M	;	1.84	;	Crystal Structure Of Pyruvate-Ferredoxin Oxidoreductase From Desulfovibrio africanus
2C42	;	1.78	;	Crystal Structure Of Pyruvate-Ferredoxin Oxidoreductase From Desulfovibrio africanus
2C3U	;	2.32	;	Crystal Structure Of Pyruvate-Ferredoxin Oxidoreductase From Desulfovibrio africanus, Oxygen inhibited form
6CIN	;	2.6	;	Crystal structure of pyruvate:ferredoxin oxidoreductase from Moorella thermoacetica
8IL8	;	1.769	;	Crystal structure of Pyruvic Oxime Dioxygenase (POD) from Alcaligenes faecalis
8IQA	;	1.551	;	Crystal structure of Pyruvic Oxime Dioxygenase (POD) from Alcaligenes faecalis deleted N-terminal 18 residues
8IX6	;	2.47	;	Crystal structure of Pyruvic Oxime Dioxygenase (POD) from Bradyrhizobium sp. WSM3983
1MKP	;	2.35	;	CRYSTAL STRUCTURE OF PYST1 (MKP3)
5Y51	;	2.3	;	Crystal structure of PytH_H230A
5DAG	;	1.6	;	Crystal structure of PZP domain of human AF10 protein
5DAH	;	2.611	;	Crystal structure of PZP domain of human AF10 protein fused with Histone H3 peptide
5VKS	;	1.94	;	Crystal structure of P[19] rotavirus VP8* complexed with LNFPI
5VKI	;	1.9	;	Crystal structure of P[19] rotavirus VP8* complexed with mucin core 2
6NIW	;	1.55	;	Crystal structure of P[6] rotavirus
6OAI	;	1.9	;	Crystal structure of P[6] rotavirus vp8* complexed with LNFPI
7KI5	;	1.52	;	Crystal structure of P[6] rotavirus vp8* in complex with LNT
7LHJ	;	1.26	;	Crystal structure of Q108K:K40L:T51V:T53C:R58W:T29L:Y19W:Q4A mutant of cellular retinol binding protein II complex with 15-cis-retinal
7LHN	;	2.11	;	Crystal structure of Q108K:K40L:T51V:T53C:R58W:T29L:Y19W:Q4A mutant of cellular retinol binding protein II complex with all-trans-retinal after exposure to visible light
4GKC	;	1.3	;	Crystal structure of Q108K:K40L:T51V:T53C:R58W:T29L:Y19W:Q4A mutant of cellular retinol binding protein II complex with all-trans-retinal at 1.33
7LHO	;	1.4	;	Crystal structure of Q108K:K40L:T51V:T53C:R58W:T29L:Y19W:Q4A mutant of cellular retinol binding protein II complex with all-trans-retinal in the dark
7LHM	;	1.5	;	Crystal structure of Q108K:K40L:T51V:T53C:R58W:T29L:Y19W:Q4A:Q38L mutant of cellular retinol binding protein II complex with all-trans-retinal
5IN8	;	2.35	;	Crystal structure of Q151H Aspergillus terreus aristolochene synthase
3WGO	;	2.05	;	Crystal structure of Q154L/T173I/R199M/P248S/H249/N276S mutant of meso-dapdh from Clostridium tetani E88
2R9H	;	3.1	;	Crystal Structure of Q207C Mutant of CLC-ec1 in complex with Fab
4TRU	;	1.81	;	Crystal structure of Q24A Q25A mutant of human macrophage migration inhibitory factor
1M64	;	1.8	;	Crystal structure of Q363F mutant flavocytochrome c3
1LJ1	;	2.0	;	Crystal structure of Q363F/R402A mutant flavocytochrome c3
6UQI	;	2.5	;	Crystal structure of Q38A human DNA polymerase eta bound with 8-oxoadenine (oxoA) and non-hydrolyzable dGTP analog (dGTP*)
3VZQ	;	2.0	;	Crystal structure of Q47L mutant of PhaB from Ralstonia eutropha
6XYB	;	1.47	;	Crystal structure of Q4D6Q6, a conserved kinetoplastid-specific protein from Trypanosoma cruzi
6XYD	;	1.81	;	Crystal structure of Q4D6Q6, a conserved kinetoplastid-specific protein from Trypanosoma cruzi
3ASM	;	2.603	;	Crystal structure of Q54A mutant protein of Bst-RNase HIII
4G3X	;	3.25	;	Crystal Structure of Q61L H-Ras-GppNHp bound to the RBD of Raf Kinase
6V6F	;	2.542	;	Crystal structure of Q61L KRAS(GMPPNP)-NF1(GRD)-SPRED1(EVH1) complex
5BRB	;	2.53	;	Crystal structure of Q64E mutant of Triosephosphate isomerase from Plasmodium falciparum
3RRX	;	1.9	;	Crystal Structure of Q683A mutant of Exo-1,3/1,4-beta-glucanase (ExoP) from Pseudoalteromonas sp. BB1
2OJL	;	2.1	;	Crystal structure of Q7WAF1_BORPA from Bordetella parapertussis. Northeast Structural Genomics target BpR68.
2INW	;	1.5	;	Crystal structure of Q83JN9 from Shigella flexneri at high resolution. Northeast Structural Genomics Consortium target SfR137.
2PJQ	;	2.8	;	Crystal structure of Q88U62_LACPL from Lactobacillus plantarum. Northeast Structural Genomics target LpR71
2P0Y	;	3.0	;	Crystal structure of Q88YI3_LACPL from Lactobacillus plantarum. Northeast Structural Genomics Consortium target LpR6
2ES7	;	2.8	;	Crystal structure of Q8ZP25 from Salmonella typhimurium LT2. NESG TARGET STR70
2ES9	;	2.0	;	Crystal structure of Q8ZRJ2 from salmonella typhimurium. NESG TARGET STR65
2OKA	;	2.5	;	Crystal structure of Q9HYQ7_PSEAE from Pseudomonas aeruginosa. Northeast Structural Genomics Consortium target PaR82
2O5A	;	2.7	;	Crystal structure of Q9KD89 from Bacillus halodurans. Northeast Structural Genomics target BhR21
2Q0Z	;	2.0	;	Crystal structure of Q9P172/Sec63 from Homo sapiens. Northeast Structural Genomics Target HR1979.
8IWC	;	2.43	;	Crystal structure of Q9PR55 at pH 6.0
8W68	;	2.3	;	Crystal structure of Q9PR55 at pH 6.0 (use NMR model)
8IWA	;	2.51	;	Crystal structure of Q9PR55 at pH 6.5
8IWB	;	2.42	;	Crystal structure of Q9PR55 at pH 7.5
3BT9	;	2.75	;	crystal structure of QacR(E57Q) bound to Dequalinium
3BTC	;	2.9	;	crystal structure of QacR(E57Q) bound to malachite green
3BTI	;	2.85	;	crystal structure of QacR(E58Q) bound to berberine
3BTJ	;	2.98	;	crystal structure of QacR(E58Q) bound to dequalinium
3BTL	;	2.9	;	crystal structure of QacR(E58Q) bound to malachite green
4O9E	;	2.0	;	Crystal structure of QdtA, a sugar 3,4-ketoisemerase from Thermoanaerobacterium thermosaccharolyticum in complex with TDP
3FS8	;	1.7	;	Crystal structure of QdtC, the dTDP-3-amino-3,6-dideoxy-D-glucose N-acetyl transferase from Thermoanaerobacterium thermosaccharolyticum in complex with Acetyl-CoA
3FSC	;	1.8	;	Crystal structure of QdtC, the dTDP-3-amino-3,6-dideoxy-D-glucose N-acetyl transferase from Thermoanaerobacterium thermosaccharolyticum in complex with CoA and dTDP-3-amino-fucose
3FSB	;	1.95	;	Crystal structure of QdtC, the dTDP-3-amino-3,6-dideoxy-D-glucose N-acetyl transferase from Thermoanaerobacterium thermosaccharolyticum in complex with CoA and dTDP-3-amino-quinovose
4IVH	;	1.77	;	Crystal structure of QKLVFFAED nonapeptide segment from amyloid beta incorporated into a macrocyclic beta-sheet template
7VSX	;	1.698	;	Crystal structure of QL-nanoKAZ (Reverse mutant of nanoKAZ with L18Q and V27L)
6CBQ	;	2.8	;	Crystal structure of QscR bound to agonist S3
6CC0	;	2.5	;	Crystal structure of QscR bound to C12-homoserine lactone
6A2L	;	2.38	;	Crystal structure of quadruple mutant (N51I+C59R+S108N+I164L) Plasmodium falciparum DHFR-TS complexed with BT1, NADPH, and dUMP
6A2N	;	2.45	;	Crystal structure of quadruple mutant (N51I+C59R+S108N+I164L) Plasmodium falciparum DHFR-TS complexed with BT2, NADPH, and dUMP
6A2P	;	2.6	;	Crystal structure of quadruple mutant (N51I+C59R+S108N+I164L) Plasmodium falciparum DHFR-TS complexed with BT3, NADPH, and dUMP
3TJW	;	1.46	;	Crystal Structure of Quasiracemic Villin Headpiece Subdomain Containing (F5Phe10) Substitution
3TRV	;	1.0	;	Crystal structure of quasiracemic villin headpiece subdomain containing (F5Phe17) substitution
4ZYK	;	2.0	;	Crystal Structure of Quaternary-Specific RSV-Neutralizing Human Antibody AM14
3BL5	;	2.95	;	Crystal structure of QueC from Bacillus subtilis: an enzyme involved in preQ1 biosynthesis
5TH5	;	2.407	;	Crystal Structure of QueE from Bacillus subtilis with 6-carboxypterin-5'-deoxyadenosyl ester bound
5TGS	;	2.548	;	Crystal Structure of QueE from Bacillus subtilis with methionine bound
4NJH	;	1.898	;	Crystal Structure of QueE from Burkholderia multivorans in complex with AdoMet and 6-carboxy-5,6,7,8-tetrahydropterin
4NJG	;	2.598	;	Crystal Structure of QueE from Burkholderia multivorans in complex with AdoMet and 6-carboxypterin
4NJJ	;	2.7	;	Crystal Structure of QueE from Burkholderia multivorans in complex with AdoMet, 6-carboxy-5,6,7,8-tetrahydropterin, and Manganese(II)
4NJI	;	2.197	;	Crystal Structure of QueE from Burkholderia multivorans in complex with AdoMet, 6-carboxy-5,6,7,8-tetrahydropterin, and Mg2+
4NJK	;	1.911	;	Crystal Structure of QueE from Burkholderia multivorans in complex with AdoMet, 7-carboxy-7-deazaguanine, and Mg2+
6NHL	;	2.101	;	Crystal structure of QueE from Escherichia coli
1JUH	;	1.6	;	Crystal Structure of Quercetin 2,3-dioxygenase
1H1M	;	1.9	;	CRYSTAL STRUCTURE OF QUERCETIN 2,3-DIOXYGENASE ANAEROBICALLY COMPLEXED WITH THE SUBSTRATE KAEMPFEROL
1H1I	;	1.75	;	CRYSTAL STRUCTURE OF QUERCETIN 2,3-DIOXYGENASE ANAEROBICALLY COMPLEXED WITH THE SUBSTRATE QUERCETN
7U1O	;	2.35	;	Crystal structure of queuine salvage enzyme DUF2419 complexed with queuosine
7ULC	;	1.99	;	Crystal structure of queuine salvage enzyme DUF2419 mutant D231N, in complex with queuosine-5'-monophosphate
7U5A	;	2.5	;	Crystal structure of queuine salvage enzyme DUF2419 mutant K199C, complexed with queuosine
7U07	;	2.1	;	Crystal structure of queuine salvage enzyme DUF2419, apo form
7U91	;	2.4	;	Crystal structure of queuine salvage enzyme DUF2419, in complex with queuosine-5'-monophosphate
7UK3	;	2.31	;	Crystal structure of queuine salvage enzyme DUF2419, wild-type (non-His6x tagged)
2ASH	;	1.9	;	Crystal structure of Queuine tRNA-ribosyltransferase (EC 2.4.2.29) (tRNA-guanine (tm1561) from THERMOTOGA MARITIMA at 1.90 A resolution
4UIK	;	2.0	;	crystal structure of quinine-dependent Fab 314.1
4UIL	;	2.853	;	crystal structure of quinine-dependent Fab 314.1 with quinine
4UIM	;	2.7	;	crystal structure of quinine-dependent Fab 314.3
4UIN	;	2.5	;	crystal structure of quinine-dependent Fab 314.3 with quinine
1KB0	;	1.44	;	Crystal Structure of Quinohemoprotein Alcohol Dehydrogenase from Comamonas testosteroni
5XMJ	;	3.6	;	Crystal structure of quinol:fumarate reductase from Desulfovibrio gigas
1WZU	;	2.0	;	Crystal structure of quinolinate synthase (nadA)
1T3Q	;	1.8	;	Crystal structure of quinoline 2-Oxidoreductase from Pseudomonas Putida 86
2B7N	;	2.3	;	Crystal structure of quinolinic acid phosphoribosyltransferase from Helicobacter pylori
2B7Q	;	3.31	;	Crystal structure of quinolinic acid phosphoribosyltransferase from Helicobacter pylori with nicotinate mononucleotide
2B7P	;	2.51	;	Crystal structure of quinolinic acid phosphoribosyltransferase from Helicobacter pylori with phthalic acid
2VW8	;	1.45	;	Crystal Structure of Quinolone signal response protein pqsE from Pseudomonas aeruginosa
3O73	;	2.0	;	Crystal structure of quinone reductase 2 in complex with the indolequinone MAC627
2QWX	;	1.5	;	Crystal Structure of Quinone Reductase II
2QX4	;	1.65	;	Crystal Structure of Quinone Reductase II
2QX6	;	1.75	;	Crystal Structure of Quinone Reductase II
2QX8	;	1.6	;	Crystal Structure of Quinone Reductase II
2QX9	;	2.31	;	Crystal Structure of Quinone Reductase II
4XDG	;	1.5	;	Crystal Structure of Quinone Reductase II in complex with 2-(4-aminophenyl)-5-methoxy-1-oxy-indol-3-one molecule
4XDH	;	1.9	;	Crystal Structure of Quinone Reductase II in complex with a 2-(4-methoxy-phenyl)-5-methoxy-indol-3-one molecule
4CVB	;	1.72	;	Crystal structure of quinone-dependent alcohol dehydrogenase from Pseudogluconobacter saccharoketogenenes
4CVC	;	1.83	;	Crystal structure of quinone-dependent alcohol dehydrogenase from Pseudogluconobacter saccharoketogenenes with zinc in the active site
8B5U	;	1.8	;	Crystal structure of Quinonoid dihydropteridine reductase from Leishmania donovani
8B5T	;	2.1	;	Crystal structure of Quinonoid dihydropteridine reductase from Leishmania major
3N4Z	;	2.3973	;	Crystal structure of quintuple Arg-to-Lys variant of T. celer L30e
1YJW	;	2.9	;	Crystal Structure Of Quinupristin Bound To The G2099A Mutant 50S Ribosomal Subunit Of Haloarcula Marismortui
2OP4	;	2.85	;	Crystal Structure of Quorum-Quenching Antibody 1G9
2BR6	;	1.7	;	Crystal Structure of Quorum-Quenching N-Acyl Homoserine Lactone Lactonase
1RFY	;	1.6	;	Crystal Structure of Quorum-Sensing Antiactivator TraM
5L07	;	2.2	;	Crystal Structure of Quorum-Sensing Transcriptional Activator from Yersinia enterocolitica
5L09	;	2.0	;	Crystal Structure of Quorum-Sensing Transcriptional Activator from Yersinia enterocolitica in complex with 3-oxo-N-[(3S)-2-oxotetrahydrofuran-3-yl]hexanamide
7R7Z	;	2.286	;	Crystal structure of QW9-HLA-B*5301 specific T Cell Receptor, C3
1RXA	;	2.9	;	CRYSTAL STRUCTURE OF R(CCCCGGGG) IN TWO DISTINCT LATTICES
1RXB	;	1.8	;	CRYSTAL STRUCTURE OF R(CCCCGGGG) IN TWO DISTINCT LATTICES
7MKT	;	1.97	;	Crystal structure of r(GU)11G-NMM complex
332D	;	1.58	;	CRYSTAL STRUCTURE OF R(GUGUGUA)D(C) WITH TANDEM G-U/U-G WOBBLE PAIRS WITH STRAND SLIPPAGE
3V07	;	1.24	;	Crystal structure of R-6'-Me-3'-fluoro hexitol nucleic acid
1NXQ	;	1.79	;	Crystal Structure of R-alcohol dehydrogenase (RADH) (apoenyzme) from Lactobacillus brevis
1F99	;	2.4	;	CRYSTAL STRUCTURE OF R-PHYCOCYANIN FROM POLYSIPHONIA AT 2.4 A RESOLUTION
1EYX	;	2.25	;	CRYSTAL STRUCTURE OF R-PHYCOERYTHRIN AT 2.2 ANGSTROMS
1LIA	;	2.8	;	CRYSTAL STRUCTURE OF R-PHYCOERYTHRIN FROM POLYSIPHONIA AT 2.8 A RESOLUTION
4RCT	;	2.25	;	Crystal structure of R-protein of NgoAVII restriction endonuclease
4BSP	;	2.0	;	Crystal structure of R-spondin 1 (Fu1Fu2) - Holmium soak
4BSO	;	2.2	;	Crystal structure of R-spondin 1 (Fu1Fu2) - Native
6FFX	;	2.5	;	Crystal structure of R. ruber ADH-A, mutant F43H
6FFZ	;	1.71	;	Crystal structure of R. ruber ADH-A, mutant F43H, Y54L
5O8Q	;	2.22	;	Crystal structure of R. ruber ADH-A, mutant Y294F, W295A
5O8H	;	1.96	;	Crystal structure of R. ruber ADH-A, mutant Y294F, W295A, F43H, H39Y
5O9D	;	1.79	;	Crystal structure of R. ruber ADH-A, mutant Y294F, W295A, Y54F, F43H, H39Y
5O9F	;	1.64	;	Crystal structure of R. ruber ADH-A, mutant Y294F, W295A, Y54F, F43S, H39Y
6FG0	;	1.74	;	Crystal structure of R. ruber ADH-A, mutant Y54G, F43T, L119Y, F282W
5OD3	;	1.83	;	Crystal structure of R. ruber ADH-A, mutant Y54G, L119Y
1L7E	;	1.9	;	Crystal Structure of R. rubrum Transhydrogenase Domain I with Bound NADH
1L7D	;	1.81	;	Crystal Structure of R. rubrum Transhydrogenase Domain I without Bound NAD(H)
1PNO	;	2.1	;	Crystal structure of R. rubrum transhydrogenase domain III bound to NADP
1PNQ	;	2.4	;	Crystal structure of R. rubrum transhydrogenase domain III bound to NADPH
8VTM	;	3.51	;	Crystal structure of R. sphaeroides Photosynthetic Reaction Center variant Y(M210)2-bromophenylalanine
8VTJ	;	2.81	;	Crystal structure of R. sphaeroides Photosynthetic Reaction Center variant Y(M210)2-cyanophenylalanine
8VTL	;	3.05	;	Crystal structure of R. sphaeroides Photosynthetic Reaction Center variant Y(M210)2-methoxyphenylalanine
8VTO	;	3.09	;	Crystal structure of R. sphaeroides Photosynthetic Reaction Center variant Y(M210)2-methylphenylalanine
8VTN	;	3.57	;	Crystal structure of R. sphaeroides Photosynthetic Reaction Center variant Y(M210)2-nitrophenylalanine
7MHA	;	2.79	;	Crystal structure of R. sphaeroides Photosynthetic Reaction Center variant; W252V mutant
7MH4	;	2.48	;	Crystal structure of R. sphaeroides Photosynthetic Reaction Center variant; Y(M210)3-bromotyrosine
7MH3	;	2.3	;	Crystal structure of R. sphaeroides Photosynthetic Reaction Center variant; Y(M210)3-chlorotyrosine
7MH5	;	2.85	;	Crystal structure of R. sphaeroides Photosynthetic Reaction Center variant; Y(M210)3-iodotyrosine
7MH8	;	2.75	;	Crystal structure of R. sphaeroides Photosynthetic Reaction Center variant; Y(M210)3-methyltyrosine
7MH9	;	3.1	;	Crystal structure of R. sphaeroides Photosynthetic Reaction Center variant; Y(M210)3-nitrotyrosine
3O3P	;	2.529	;	Crystal structure of R. xylanophilus MpgS in complex with GDP-Mannose
4RD5	;	2.7	;	Crystal structure of R.NgoAVII restriction endonuclease B3 domain with cognate DNA
4RDM	;	2.7	;	Crystal structure of R.NgoAVII restriction endonuclease B3 domain with cognate DNA
5IFF	;	1.9	;	Crystal structure of R.PabI-nonspecific DNA complex
8VTK	;	3.07	;	Crystal structure of R.sphaeroides Photosynthetic Reaction Center variant Y(M210)2-chlorophenylalanine
4YDA	;	1.951	;	Crystal structure of R111K:Y134F:T54V:R132Q:P39Q:R59Y mutant of human cellular retinoic acid binding proteinii with retinal at 1.95 angstrom - after 1hour visible light irradiation - 3rd cycle
4YCH	;	1.96	;	Crystal Structure of R111K:Y134F:T54V:R132Q:P39Q:R59Y mutant of human Cellular Retinoic Acid Binding ProteinII with Retinal at 1.96 Angstrom - UV irradiated Crystal for 1 hour - 2nd cycle
4YGG	;	1.9	;	CRYSTAL STRUCTURE OF R111K:Y134F:T54V:R132Q:P39Y:R59Y MUTANT OF HUMAN CELLULAR RETINOIC ACID BINDING PROTEIN II WITH RETINAL AT 1.9 ANGSTROM RESOLUTION - VISIBLE LIGHT IRRADIATED CRYSTAL - 2ND CYCLE
4YGH	;	2.1	;	Crystal Structure of R111K:Y134F:T54V:R132Q:P39Y:R59Y mutant of human Cellular Retinoic Acid Binding Protein II with Retinal at 2.1 Angstrom resolution - UV irradiated crystal - 2nd cycle
4JTJ	;	1.75	;	Crystal structure of R117K mutant of 3-deoxy-D-manno-octulosonate 8-phosphate synthase (KDO8PS) from Neisseria meningitidis
4JTK	;	1.86	;	Crystal structure of R117Q mutant of 3-deoxy-D-manno-octulosonate 8-phosphate synthase (KDO8PS) from Neisseria meningitidis
7B2G	;	3.0	;	Crystal structure of R120Q GDAP1 mutant
3N8W	;	2.75	;	Crystal Structure of R120Q/Native Cyclooxygenase-1 Heterodimer mutant in complex with Flurbiprofen
6LYK	;	1.7	;	Crystal Structure of R1263A mutant of Formylglycinamidine Synthetase
4R2M	;	2.2	;	Crystal Structure of R134D mutant of YnaF (Universal Stress Protein F) from Salmonella typhimurium
2A9C	;	2.505	;	Crystal structure of R138Q mutant of recombinant chicken sulfite oxidase with the bound product, sulfate, at the active site
2A9B	;	2.503	;	Crystal structure of R138Q mutant of recombinant sulfite oxidase at resting state
7WD1	;	2.5	;	Crystal structure of R14 bound to SARS-CoV-2 RBD
5XBH	;	2.23	;	Crystal structure of R145E mutant of thymidylate kinase (aq_969) from Aquifex Aeolicus VF5
7TKW	;	1.85	;	Crystal structure of R14A human Galectin-7 mutant
7TKX	;	1.83	;	Crystal structure of R14A human Galectin-7 mutant in presence of 4-O-beta-D-Galactopyranosyl-D-glucose
7TRN	;	1.95	;	Crystal structure of R14A-R20A human Galectin-7 mutant
7TRO	;	1.8	;	Crystal structure of R14A-R20A human Galectin-7 mutant in presence of lactose
4JLP	;	1.433	;	Crystal structure of R150K aquifex adenylate kinase mutant
1IB6	;	2.1	;	CRYSTAL STRUCTURE OF R153C E. COLI MALATE DEHYDROGENASE
1IE3	;	2.5	;	CRYSTAL STRUCTURE OF R153C E. COLI MALATE DEHYDROGENASE
6UQN	;	3.298	;	Crystal structure of R173A variant of cytosolic fumarate hydratase from Leishmania major in a complex with fumarate and S-malate
6UQM	;	2.004	;	Crystal structure of R173A variant of cytosolic fumarate hydratase from Leishmania major in a complex with S-malate
1D2H	;	3.0	;	CRYSTAL STRUCTURE OF R175K MUTANT GLYCINE N-METHYLTRANSFERASE COMPLEXED WITH S-ADENOSYLHOMOCYSTEINE
1D2G	;	2.5	;	CRYSTAL STRUCTURE OF R175K MUTANT GLYCINE N-METHYLTRANSFERASE FROM RAT LIVER
3UKK	;	2.75	;	Crystal structure of R182K-UDP-galactopuranose mutase from Aspergillus fumigatus in complex with UDPgalp
5ZOG	;	2.299	;	Crystal Structure of R192F hFen1 in complex with DNA
4DFY	;	2.997	;	Crystal structure of R194A mutant of cAMP-dependent protein kinase with unphosphorylated activation loop
2EI9	;	2.0	;	Crystal structure of R1Bm endonuclease domain
4S37	;	2.2	;	Crystal structure of R2 pyocin membrane-piercing spike
7QBP	;	1.38	;	Crystal structure of R2-like ligand-binding oxidase from Saccharopolyspora Erythraea
6QRZ	;	3.0	;	Crystal structure of R2-like ligand-binding oxidase from Sulfolobus acidocaldarius solved by 3D micro-crystal electron diffraction
7N4O	;	2.05	;	Crystal structure of R20A human Galectin-7 mutant
7N57	;	1.83	;	Crystal structure of R20A human Galectin-7 mutant in presence of lactose
7N8G	;	1.95	;	Crystal structure of R20A-R22A human Galectin-7 mutant
7D5J	;	1.51	;	CRYSTAL STRUCTURE OF R220A VARIANT PENA BETA-LACTAMASE FROM BURKHOLDERIA MULTIVORANS
7N6C	;	2.1	;	Crystal structure of R22A human Galectin-7 mutant
7N8D	;	2.49	;	Crystal structure of R22A human Galectin-7 mutant in presence of Lactose
5OPO	;	2.0	;	Crystal structure of R238G cN-II mutant
2PG8	;	3.0	;	Crystal structure of R254K mutanat of DpgC with bound substrate analog
5ZVR	;	1.93	;	Crystal structure of R274A mutant of phosphomannose isomerase from Salmonella typhimurium
3D6Y	;	2.7	;	Crystal structure of R275E mutant of BMRR bound to DNA and berberine
3D6Z	;	2.6	;	Crystal structure of R275E mutant of BMRR bound to DNA and rhodamine
1L7H	;	1.85	;	Crystal structure of R292K mutant influenza virus neuraminidase in complex with BCX-1812
4IPI	;	1.75	;	Crystal Structure of R314A N-acetyl Neuraminic Acid Synthase from Neiserria meningitidis with Malate bound
4IPJ	;	2.15	;	Crystal Structure of R314K N-acetyl Neuraminic Acid Synthase from Neiserria meningitidis with Malate bound
3UKP	;	3.1	;	Crystal structure of R327A UDP-galactopyranose mutase from Aspergillus fumigatus in complex with UDPgalp
3UKQ	;	3.15	;	Crystal structure of R327K UDP-galactopyranose mutase from Aspergillus fumigatus in complex with UDPgalp
4DG3	;	1.8	;	Crystal structure of R336A mutant of cAMP-dependent protein kinase with unphosphorylated turn motif.
4HIU	;	3.3	;	Crystal structure of R34/53A mutant of borna disease virus matrix protein
4HIY	;	3.31	;	crystal structure of R34/53A, D95N, H112W mutant of borna disease virus matrix protein
4HIW	;	2.9	;	Crystal structure of R34/53A, H112W mutant of borna disease virus matrix protein
3KHZ	;	2.5	;	Crystal Structure of R350A mutant of Staphylococcus aureus metallopeptidase (Sapep/DapE) in the apo-form
5OPN	;	1.77	;	Crystal structure of R39Q cN-II mutant
3RE5	;	1.949	;	Crystal structure of R4-6 streptavidin
3RE6	;	1.823	;	Crystal structure of R4-6 streptavidin
6UQ9	;	2.304	;	Crystal structure of R421A variant of cytosolic fumarate hydratase from Leishmania major in a complex with S-malate
6UQ8	;	1.339	;	Crystal structure of R421A variant of cytosolic fumarate hydratase from Leishmania major in a complex with S-malate and malonate
6UQL	;	2.1	;	Crystal structure of R471A variant of cytosolic fumarate hydratase from Leishmania major in a complex with S-malate
6UQB	;	1.951	;	Crystal structure of R471A variant of cytosolic fumarate hydratase from Leishmania major in a complex with S-malate and malonate
1DJ1	;	1.93	;	CRYSTAL STRUCTURE OF R48A MUTANT OF CYTOCHROME C PEROXIDASE
1DJ5	;	1.93	;	CRYSTAL STRUCTURE OF R48A MUTANT OF CYTOCHROME C PEROXIDASE WITH N-HYDROXYGUANIDINE BOUND
3BHF	;	2.1	;	Crystal structure of R49K mutant of Monomeric Sarcosine Oxidase crystallized in PEG as precipitant
3BHK	;	1.71	;	Crystal structure of R49K mutant of monomeric sarcosine oxidase crystallized in phosphate as precipitant
4HNV	;	2.8	;	Crystal structure of R54E mutant of S. aureus Pyruvate carboxylase
5O7Z	;	2.64	;	Crystal Structure of R67A Mutant of alpha-L-arabinofuranosidase Ara51 from Clostridium thermocellum
5O80	;	2.915	;	Crystal Structure of R67A Mutant of alpha-L-arabinofuranosidase Ara51 from Clostridium thermocellum in complex with L-Arabinofuranose
5O81	;	2.5	;	Crystal Structure of R67A/E173A Mutant of alpha-L-arabinofuranosidase Ara51 from Clostridium thermocellum
5O82	;	2.393	;	Crystal Structure of R67A/E173A Mutant of alpha-L-arabinofuranosidase Ara51 from Clostridium thermocellum in complex with arabinofuranose
3RDO	;	1.404	;	Crystal structure of R7-2 streptavidin complexed with biotin
3RDM	;	1.6	;	Crystal structure of R7-2 streptavidin complexed with biotin/PEG
3RDQ	;	1.6	;	Crystal structure of R7-2 streptavidin complexed with desthiobiotin
3RDU	;	1.5	;	Crystal structure of R7-2 streptavidin complexed with PEG
7MS3	;	3.0	;	Crystal structure of R73A mutant of Cg10062 with a covalent intermediate of the hydration of acetylenecarboxylic acid
5WW9	;	2.0	;	Crystal structure of R73E mutant of the second DNA-Binding protein under starvation from Mycobacterium smegmatis
3BBC	;	1.7	;	Crystal structure of R88A mutant of the NM23-H2 transcription factor
5XB5	;	2.23	;	Crystal structure of R90A mutant of thymidylate kinase (aq_969) from Aquifex Aeolicus VF5
7C3E	;	2.183	;	Crystal structure of R97A/R150A/R203A mutant of AofleA from Arthrobotrys oligospora
8EDJ	;	1.83	;	Crystal structure of rA3G-ssRNA-GA
3P1W	;	1.85	;	Crystal Structure of RAB GDI from Plasmodium Falciparum, PFL2060c
6C87	;	2.6	;	Crystal structure of rab gdp dissociation inhibitor alpha from Naegleria fowleri
1DCE	;	2.0	;	CRYSTAL STRUCTURE OF RAB GERANYLGERANYLTRANSFERASE FROM RAT BRAIN
4Z8Y	;	1.9	;	Crystal structure of Rab GTPase Sec4p mutant - S29V
3L0M	;	3.45	;	Crystal structure of Rab1-activation domain and P4M domain of SidM/DrrA from legionella
2GZH	;	2.47	;	Crystal Structure of Rab11 in Complex with Rab11-Family Interacting Protein 2
2GZD	;	2.44	;	Crystal Structure of Rab11 in Complex with Rab11-FIP2
3NKV	;	1.7	;	Crystal structure of Rab1b covalently modified with AMP at Y77
3E5H	;	1.499	;	Crystal Structure of Rab28 GTPase in the Active (GppNHp-bound) Form
2HXS	;	1.1	;	Crystal Structure of Rab28A GTPase in the Inactive (GDP-3'P-Bound) Form
2EW1	;	2.0	;	Crystal Structure of Rab30 in complex with a GTP analogue
1TU3	;	2.31	;	Crystal Structure of Rab5 complex with Rabaptin5 C-terminal Domain
1TU4	;	2.2	;	Crystal Structure of Rab5-GDP Complex
3CLV	;	1.89	;	Crystal Structure of Rab5a from plasmodium falciparum, PFB0500c
4LHW	;	1.55	;	Crystal structure of Rab8 in its active GppNHp-bound form
4LHV	;	1.95	;	Crystal structure of Rab8 in its inactive GDP-bound form
1S8F	;	1.77	;	Crystal structure of Rab9 complexed to GDP reveals a dimer with an active conformation of switch II
7E1T	;	2.45	;	Crystal structure of Rab9A-GTP-Nde1
5XR7	;	2.6	;	Crystal structure of RabA1a (Q72K) in complex with GTP
5XR4	;	2.8	;	Crystal structure of RabA1a in complex with GDP
5XR6	;	2.6	;	Crystal structure of RabA1a in complex with GppNHp
1Q13	;	2.08	;	Crystal structure of rabbit 20alpha hyroxysteroid dehydrogenase in ternary complex with NADP and testosterone
3HAL	;	1.8	;	Crystal structure of Rabbit acidic fibroblast growth factor
7RA7	;	2.2	;	Crystal structure of rabbit anti-HIV Fab 11A
6CEZ	;	2.399	;	Crystal Structure of Rabbit Anti-HIV-1 gp120 V2 Fab 16C2 in complex with V2 peptide ConB
5V6M	;	1.9	;	Crystal Structure of Rabbit Anti-HIV-1 gp120 V3 Fab 10A3 in complex with V3 peptide ConB
5V6L	;	2.549	;	Crystal Structure of Rabbit Anti-HIV-1 gp120 V3 Fab 10A37 in complex with V3 peptide JR-FL
1CJ0	;	2.8	;	CRYSTAL STRUCTURE OF RABBIT CYTOSOLIC SERINE HYDROXYMETHYLTRANSFERASE AT 2.8 ANGSTROM RESOLUTION
4DB5	;	1.522	;	Crystal structure of Rabbit GITRL
1KHV	;	2.5	;	Crystal Structure of Rabbit Hemorrhagic Disease Virus RNA-dependent RNA polymerase complexed with Lu3+
1KHW	;	2.7	;	Crystal Structure of Rabbit Hemorrhagic Disease Virus RNA-dependent RNA polymerase complexed with Mn2+
1RZY	;	1.8	;	Crystal structure of rabbit Hint complexed with N-ethylsulfamoyladenosine
4I9U	;	2.5	;	Crystal structure of rabbit LDHA in complex with a fragment inhibitor AP26256
4I8X	;	2.23	;	Crystal structure of rabbit LDHA in complex with AP27460
4I9N	;	2.35	;	Crystal structure of rabbit LDHA in complex with AP28161 and AP28122
4I9H	;	2.17	;	Crystal structure of rabbit LDHA in complex with AP28669
1K4Y	;	2.5	;	Crystal Structure of Rabbit Liver Carboxylesterase in Complex with 4-piperidino-piperidine
1BK4	;	2.3	;	CRYSTAL STRUCTURE OF RABBIT LIVER FRUCTOSE-1,6-BISPHOSPHATASE AT 2.3 ANGSTROM RESOLUTION
4JO4	;	2.27	;	Crystal structure of rabbit mAb R20 Fab
4JO3	;	2.6	;	Crystal structure of rabbit mAb R20 Fab in complex with V3 C-terminus of HIV-1 Consensus B gp120
4JO2	;	2.5	;	Crystal structure of rabbit mAb R56 Fab in complex with V3 crown of HIV-1 Consensus A gp120
4JO1	;	2.033	;	Crystal structure of rabbit mAb R56 Fab in complex with V3 crown of HIV-1 JR-FL gp120
6PEH	;	2.296	;	Crystal structure of rabbit monoclonal anti-HIV antibody 1C2
3TU9	;	2.09	;	Crystal structure of rabbit muscle aldolase bound with 5-O-methyl mannitol 1,6-phosphate
3LGE	;	2.2	;	Crystal structure of rabbit muscle aldolase-SNX9 LC4 complex
1LWN	;	2.0	;	Crystal structure of rabbit muscle glycogen phosphorylase a in complex with a potential hypoglycaemic drug at 2.0 A resolution
1LWO	;	2.0	;	Crystal structure of rabbit muscle glycogen phosphorylase a in complex with a potential hypoglycaemic drug at 2.0 A resolution
2IEG	;	1.9	;	Crystal structure of rabbit muscle glycogen phosphorylase in complex with 3,4-dihydro-2-quinolone
2IEI	;	1.91	;	Crystal structure of rabbit muscle glycogen phosphorylase in complex with 3,4-dihydro-2-quinolone
1LL0	;	3.43	;	Crystal Structure of Rabbit Muscle Glycogenin
1LL3	;	1.9	;	Crystal Structure of Rabbit Muscle Glycogenin
1LL2	;	1.9	;	Crystal Structure of Rabbit Muscle Glycogenin Complexed with UDP-glucose and Manganese
1R2R	;	1.5	;	CRYSTAL STRUCTURE OF RABBIT MUSCLE TRIOSEPHOSPHATE ISOMERASE
1R2S	;	2.85	;	CRYSTAL STRUCTURE OF RABBIT MUSCLE TRIOSEPHOSPHATE ISOMERASE
1R2T	;	2.25	;	CRYSTAL STRUCTURE OF RABBIT MUSCLE TRIOSEPHOSPHATE ISOMERASE
4OWG	;	1.55	;	Crystal structure of rabbit muscle triosephosphate isomerase-PEP complex
5IRN	;	2.34	;	Crystal structure of rabbit NOD2 in an ADP-bound state (Crystal form1)
5IRM	;	3.31	;	Crystal structure of rabbit NOD2 in an ADP-bound state (Crystal form2)
5IRL	;	3.09	;	Crystal structure of rabbit NOD2 SER mutant in an ADP-bound state
1KOJ	;	1.9	;	Crystal structure of rabbit phosphoglucose isomerase complexed with 5-phospho-D-arabinonohydroxamic acid
1HOX	;	2.1	;	CRYSTAL STRUCTURE OF RABBIT PHOSPHOGLUCOSE ISOMERASE COMPLEXED WITH FRUCTOSE-6-PHOSPHATE
1XTB	;	2.0	;	Crystal Structure of Rabbit Phosphoglucose Isomerase Complexed with Sorbitol-6-Phosphate
1DQR	;	2.5	;	CRYSTAL STRUCTURE OF RABBIT PHOSPHOGLUCOSE ISOMERASE, A GLYCOLYTIC ENZYME THAT MOONLIGHTS AS NEUROLEUKIN, AUTOCRINE MOTILITY FACTOR, AND DIFFERENTIATION MEDIATOR
4ERT	;	1.95	;	Crystal structure of rabbit ryanodine receptor 1 (2734-2940)
4I0Y	;	2.8	;	CRYSTAL STRUCTURE OF RABBIT RYANODINE RECEPTOR 1 (RESIDUES 1-536) DISEASE MUTANT C36R
4I3N	;	2.95	;	Crystal structure of rabbit ryanodine receptor 1 (residues 1-536) disease mutant D61N
4I1E	;	2.4	;	Crystal structure of Rabbit Ryanodine Receptor 1 (residues 1-536) disease mutant G249R
4I2S	;	2.5	;	Crystal structure of rabbit ryanodine receptor 1 (residues 1-536) disease mutant I404M
4I7I	;	2.9	;	Crystal structure of rabbit ryanodine receptor 1 (residues 1-536) disease mutant L14R
4I37	;	2.95	;	Crystal structure of rabbit ryanodine receptor 1 (residues 1-536) disease mutant R402G
4I8M	;	2.8	;	Crystal structure of rabbit Ryanodine receptor 1 (residues 1-536) disease mutant V219I
4I6I	;	2.5	;	Crystal structure of rabbit ryanodine receptor 1 (residues 1-559) disease mutant R45C
4ETT	;	2.195	;	Crystal structure of rabbit ryanodine receptor 1 mutant E2764K
4ETU	;	2.19	;	Crystal structure of rabbit ryanodine receptor 1 mutant R2939S
4ESU	;	1.59	;	Crystal structure of rabbit ryanodine receptor 1 mutant S2776M
3ILA	;	2.9	;	Crystal structure of rabbit ryanodine receptor 1 N-terminal domain (9-205)
5C30	;	1.55	;	Crystal Structure of Rabbit Ryanodine Receptor 1 Repeat12 Domain
4P9J	;	1.84	;	Crystal Structure of rabbit Ryanodine Receptor 1 SPRY2 Domain (1070-1246)
3V09	;	2.27	;	Crystal structure of Rabbit Serum Albumin
4N3X	;	2.0	;	Crystal structure of Rabex-5 CC domain
2OT3	;	2.1	;	Crystal structure of rabex-5 VPS9 domain in complex with nucleotide free RAB21
4N3Y	;	2.2	;	Crystal structure of Rabex-5CC and Rabaptin-5C21 complex
4N3Z	;	3.1	;	Crystal structure of Rabex-5delta and Rabaptin-5C21 complex
3DSS	;	1.8	;	Crystal structure of RabGGTase(DELTA LRR; DELTA IG)
3PZ3	;	2.0	;	Crystal structure of RabGGTase(DELTA LRR; DELTA IG) in Complex with BMS-analogue 14
3PZ1	;	1.95	;	Crystal structure of RabGGTase(DELTA LRR; DELTA IG) in Complex with BMS3
3PZ2	;	2.35	;	Crystal structure of RabGGTase(DELTA LRR; DELTA IG) in Complex with BMS3 and lipid substrate GGPP
3DSX	;	2.1	;	Crystal structure of RabGGTase(DELTA LRR; DELTA IG)in complex with di-prenylated peptide Ser-Cys(GG)-Ser-Cys(GG) derivated from Rab7
3DSU	;	1.9	;	Crystal structure of RabGGTase(DELTA LRR; DELTA IG)in complex with farnesyl pyrophosphate
3DST	;	1.9	;	Crystal structure of RabGGTase(DELTA LRR; DELTA IG)in complex with geranylgeranyl pyrophosphate
3DSW	;	2.15	;	Crystal structure of RabGGTase(DELTA LRR; DELTA IG)in complex with mono-prenylated peptide Ser-Cys(GG)-Ser-Cys derivated from Rab7
3DSV	;	2.1	;	Crystal structure of RabGGTase(DELTA LRR; DELTA IG)in complex with mono-prenylated peptide Ser-Cys-Ser-Cys(GG) derivated from Rab7
7C20	;	3.0	;	Crystal structure of Rabies virus (Nishigahara strain) phosphoprotein C-terminal domain (K214A)
8FUQ	;	1.8	;	Crystal structure of rabies virus (strain CVS-11) P3 dimerization domain
4GZM	;	2.8	;	Crystal structure of RAC1 F28L mutant
1FOE	;	2.8	;	CRYSTAL STRUCTURE OF RAC1 IN COMPLEX WITH THE GUANINE NUCLEOTIDE EXCHANGE REGION OF TIAM1
3SBD	;	2.1	;	Crystal structure of RAC1 P29S mutant
3SBE	;	2.6	;	Crystal structure of RAC1 P29S mutant
4GZL	;	2.0	;	Crystal structure of RAC1 Q61L mutant
1KRL	;	1.9	;	Crystal Structure of Racemic DL-monellin in P-1
3TRW	;	2.1	;	Crystal structure of racemic villin headpiece subdomain crystallized in space group P-1
3TRY	;	2.3	;	Crystal structure of racemic villin headpiece subdomain in space group I-4c2
3Q7Q	;	2.3	;	Crystal Structure of Rad G-domain Q148A-GTP Analog Complex
3Q72	;	1.655	;	Crystal Structure of Rad G-domain-GTP Analog Complex
3Q7P	;	2.5	;	Crystal Structure of Rad G-domain-GTP Analog Complex
4BU0	;	1.5	;	Crystal structure of Rad4 BRCT1,2 in complex with a Crb2 phosphopeptide
4BU1	;	2.1	;	Crystal structure of Rad4 BRCT1,2 in complex with a Crb2 phosphopeptide
6HM4	;	1.77019	;	Crystal structure of Rad4 BRCT1,2 in complex with a Mdb1 phosphopeptide
6HM3	;	1.77264	;	Crystal structure of Rad4 BRCT1,2 in complex with a Sld3 phosphopeptide
6CFI	;	3.36242	;	Crystal structure of Rad4-Rad23 bound to a 6-4 photoproduct UV lesion
2QSH	;	2.805	;	Crystal structure of Rad4-Rad23 bound to a mismatch DNA
2QSG	;	3.1	;	Crystal structure of Rad4-Rad23 bound to a UV-damaged DNA
4YIR	;	3.0501	;	Crystal structure of Rad4-Rad23 crosslinked to an undamaged DNA
5YRQ	;	1.999	;	Crystal structure of Rad5 and Rev1
1F2U	;	1.6	;	Crystal Structure of RAD50 ABC-ATPase
3AUX	;	2.8	;	Crystal structure of Rad50 bound to ADP
3AUY	;	2.7	;	Crystal structure of Rad50 bound to ADP
5XZW	;	2.8	;	Crystal structure of Rad53 1-466
5XZV	;	3.1	;	Crystal structure of Rad53 1-466 in complex with AMP-PNP
4PDP	;	2.591	;	Crystal structure of Rad53 kinase domain and SCD2
4PDS	;	2.9	;	Crystal structure of Rad53 kinase domain and SCD2 in complex with AMPPNP
5ZB2	;	2.30001	;	Crystal structure of Rad7 and Elc1 complex in yeast
7R7J	;	2.03	;	Crystal structure of RadD with ADP
8H5Y	;	2.7001	;	Crystal structure of RadD- ADP complex
8H5Z	;	3.00003	;	Crystal structure of RadD/ATP analogue complex
2V1H	;	1.3	;	Crystal structure of radiation-induced metmyoglobin - aqua ferrous myoglobin at pH 5.2
2V1I	;	1.2	;	Crystal structure of radiation-induced metmyoglobin - aqua ferrous myoglobin at pH 6.8
2V1J	;	1.4	;	Crystal structure of radiation-induced metmyoglobin - aqua ferrous myoglobin at pH 8.7
2V1G	;	1.35	;	Crystal structure of radiation-induced myoglobin compound II - intermediate H at pH 5.2
2V1E	;	1.3	;	Crystal structure of radiation-induced myoglobin compound II - intermediate H at pH 6.8
2V1F	;	1.2	;	Crystal structure of radiation-induced myoglobin compound II - intermediate H at pH 8.7
2VM0	;	1.6	;	Crystal structure of radiation-induced myoglobin compound II generated after annealing of peroxymyoglobin
3F0M	;	1.5	;	Crystal structure of radical D105N Synechocystis sp. PcyA
3NB9	;	1.5	;	Crystal structure of radical H88Q Synechocystis sp. PCYA
8AI3	;	2.1	;	Crystal structure of radical SAM epimerase EpeE C223A mutant from Bacillus subtilis with [4Fe-4S] clusters and S-adenosyl-L-methionine bound
8AI4	;	1.75	;	Crystal structure of radical SAM epimerase EpeE C223A mutant from Bacillus subtilis with [4Fe-4S] clusters, S-adenosyl-L-homocysteine and RiPP peptide 5 bound
8AI5	;	2.15	;	Crystal structure of radical SAM epimerase EpeE C223A mutant from Bacillus subtilis with [4Fe-4S] clusters, S-adenosyl-L-homocysteine and RiPP peptide 6 bound
8AI6	;	1.95	;	Crystal structure of radical SAM epimerase EpeE D210A mutant from Bacillus subtilis with [4Fe-4S] clusters, S-adenosyl-L-homocysteine and persulfurated cysteine bound
8AI1	;	2.4	;	Crystal structure of radical SAM epimerase EpeE from Bacillus subtilis with [4Fe-4S] clusters and S-adenosyl-L-homocysteine bound.
8AI2	;	2.393	;	Crystal structure of radical SAM epimerase EpeE from Bacillus subtilis with [4Fe-4S] clusters, S-adenosyl-L-homocysteine and RiPP peptide 5 bound
5MQ8	;	2.25	;	Crystal structure of Rae1 (YacP) from Bacillus subtilis
5MQ9	;	3.174	;	Crystal structure of Rae1 (YacP) from Bacillus subtilis (W164L mutant)
6CAD	;	2.55	;	Crystal structure of RAF kinase domain bound to the inhibitor 2a
2I58	;	2.8	;	Crystal Structure of RafE from Streptococcus pneumoniae complexed with raffinose
2V83	;	2.4	;	Crystal structure of RAG2-PHD finger in complex with H3K4me3 peptide
2V89	;	1.1	;	Crystal structure of RAG2-PHD finger in complex with H3K4me3 peptide at 1.1A resolution
2V85	;	2.0	;	Crystal structure of RAG2-PHD finger in complex with H3R2me1K4me3 peptide
2V86	;	2.05	;	Crystal structure of RAG2-PHD finger in complex with H3R2me2aK4me3 peptide
2V88	;	2.0	;	Crystal structure of RAG2-PHD finger in complex with H3R2me2sK4me2 peptide
2V87	;	1.8	;	Crystal structure of RAG2-PHD finger in complex with H3R2me2sK4me3 peptide
6S6D	;	2.5	;	Crystal structure of RagA-Q66L-GTP/RagC-S75N-GDP GTPase heterodimer complex
6S6A	;	2.63	;	Crystal structure of RagA-Q66L/RagC-T90N GTPase heterodimer complex
6B9X	;	1.42	;	Crystal structure of Ragulator
5Y3A	;	2.9	;	Crystal structure of Ragulator complex (p18 49-161)
5Y39	;	2.65	;	Crystal structure of Ragulator complex (p18 76-145)
5EM1	;	1.45	;	Crystal structure of ragweed allergen Amb a 8
5EV0	;	2.1	;	Crystal structure of ragweed profilin Amb a 8 in complex with poly-Pro14
6ZC1	;	1.27	;	Crystal structure of RahU protein from Pseudomonas aeruginosa
6ZC2	;	1.13	;	Crystal structure of RahU protein in complex with TRIS molecule
2O71	;	2.0	;	Crystal structure of RAIDD DD
8FJI	;	1.48	;	Crystal structure of RalA in a covalent complex with SOF-367
8FJH	;	1.54	;	Crystal structure of RalA in a covalent complex with SOF-531
4I5E	;	2.8	;	Crystal structure of Ralstonia sp. alcohol dehydrogenase in complex with NADP+
4I5D	;	2.4	;	Crystal structure of Ralstonia sp. alcohol dehydrogenase in its apo form
4I5F	;	2.1	;	Crystal structure of Ralstonia sp. alcohol dehydrogenase mutant N15G, G37D, R38V, R39S
4I5G	;	2.3	;	Crystal structure of Ralstonia sp. alcohol dehydrogenase mutant N15G, G37D, R38V, R39S, A86N, S88A
1K5G	;	3.1	;	Crystal structure of Ran-GDP-AlFx-RanBP1-RanGAP complex
1K5D	;	2.7	;	Crystal structure of Ran-GPPNHP-RanBP1-RanGAP complex
5DLQ	;	3.2	;	Crystal structure of RanGTP-Exportin 4-eIF5A complex
6Q84	;	3.7	;	Crystal structure of RanGTP-Pdr6-eIF5A export complex
4GYO	;	2.16	;	Crystal Structure of Rap Protein Complexed with Competence and Sporulation Factor
1C1Y	;	1.9	;	CRYSTAL STRUCTURE OF RAP.GMPPNP IN COMPLEX WITH THE RAS-BINDING-DOMAIN OF C-RAF1 KINASE (RAFRBD).
3K6G	;	1.95	;	Crystal structure of Rap1 and TRF2 complex
3UKG	;	2.95	;	Crystal structure of Rap1/DNA complex
1J2X	;	2.0	;	Crystal structure of RAP74 C-terminal domain complexed with FCP1 C-terminal peptide
6BOG	;	3.205	;	Crystal structure of RapA, a Swi2/Snf2 protein that recycles RNA polymerase during transcription
3Q15	;	2.192	;	Crystal Structure of RapH complexed with Spo0F
5ZWX	;	1.9	;	Crystal structure of Raphanus sativus AGDP1 AGD12 in complex with an H3K9me2 peptide
5FLD	;	1.7	;	Crystal structure of raptor adenovirus 1 fibre head, beta-hairpin deleted form
5FJL	;	1.47	;	Crystal structure of raptor adenovirus 1 fibre head, wild-type form
6U25	;	2.61	;	CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS- RORGT(244-487)-L6-SRC1(678-692)) IN COMPLEX WITH A TRICYCLIC INVERSE AGONIST
6VQF	;	2.0	;	CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244- 487)-L6-SRC1(678-692)) IN COMPLEX WITH AN INVERSE AGONIST
7KQJ	;	2.645	;	CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692) IN COMPLEX WITH A NOVEL TRICYCLIC-CARBOCYLIC RORGT INVERSE AGONIST
7LUK	;	2.087	;	CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692) IN COMPLEX WITH AN AZATRICYCLIC RORGT INVERSE AGONIST
6P9F	;	2.8	;	Crystal structure of RAR-related orphan receptor C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) in complex with a phenyl (3-phenylpyrrolidin-3-yl)sulfone inhibitor
7JYM	;	3.051	;	CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) IN COMPLEX WITH A TRICYCLIC SULFONE INVERSE AGONIST
7KXD	;	1.624	;	CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) IN COMPLEX WITH {3,5-DICHLORO-4-[4-METHOXY-3-(PROPAN-2-YL)PHENOXY]PHENYL}METHANOL
7KXE	;	2.42	;	CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) IN COMPLEX WITH {3,5-DICHLORO-4-[4-METHOXY-3-(PROPAN-2-YL)PHENOXY]PHENYL}METHANOL
7KXF	;	2.141	;	CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) IN COMPLEX WITH {3,5-DICHLORO-4-[4-METHOXY-3-(PROPAN-2-YL)PHENOXY]PHENYL}METHANOL
7JTM	;	2.43	;	CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(6T78-692) IN COMPLEX WITH A TRICYCLIC SULFONE RORGT INVERSE AGONIST
6XFV	;	2.15	;	CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C IN COMPLEX WITH A NOVEL INVERSE AGONIST
6O98	;	2.29	;	Crystal structure of RAR-related orphan receptor C in complex with a phenyl (3-phenylpyrrolidin-3-yl)sulfone inhibitor
7JH2	;	2.367	;	CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C IN COMPLEX WITH A POTENT, SELECTIVE AND ORALLY BIOAVAILABLE ROR-GAMMA-T INVERSE AGONIST
7APO	;	2.4	;	Crystal structure of RARalpha ligand binding domain in complex with a fragment of the TIF2 coactivator
3KMR	;	1.8	;	Crystal structure of RARalpha ligand binding domain in complex with an agonist ligand (Am580) and a coactivator fragment
3KMZ	;	2.1	;	Crystal structure of RARalpha ligand binding domain in complex with the inverse agonist BMS493 and a corepressor fragment
7QAA	;	2.76	;	Crystal structure of RARalpha/RXRalpha ligand binding domain heterodimer in complex with BMS614 and oleic acid
4DM6	;	1.9	;	Crystal structure of RARb LBD homodimer in complex with TTNPB
4DM8	;	2.3	;	Crystal structure of RARb LBD in complex with 9cis retinoic acid
4JYG	;	2.35	;	Crystal structure of RARbeta LBD in complex with agonist BMS411 [4-{[(5,5-dimethyl-8-phenyl-5,6-dihydronaphthalen-2-yl)carbonyl]amino}benzoic acid]
6SSQ	;	2.3	;	Crystal structure of RARbeta LBD in complex with LG 100754
4JYH	;	2.6	;	Crystal structure of RARbeta LBD in complex with selective agonist BMS948 [4-{[(8-phenylnaphthalen-2-yl)carbonyl]amino}benzoic acid]
4JYI	;	1.9	;	Crystal structure of RARbeta LBD in complex with selective partial agonist BMS641 [3-chloro-4-[(E)-2-(5,5-dimethyl-8-phenyl-5,6-dihydronaphthalen-2-yl)ethenyl]benzoic acid]
3A9Z	;	1.55	;	Crystal structure of ras selenocysteine lyase in complex with selenopropionate
7LT8	;	1.76	;	Crystal structure of Ras suppressor-1
7LT9	;	3.05011	;	Crystal structure of Ras suppressor-1 in complex with PINCH-1 LIM4-5 domains
1K8R	;	3.0	;	Crystal structure of Ras-Bry2RBD complex
5VCU	;	1.85	;	Crystal structure of ras-related c3 botulinum toxin substrate 1 isoform x2 from Naegleria fowleri in complex with GDP
1LF5	;	1.7	;	Crystal Structure of RasA59G in the GDP-bound Form
1LF0	;	1.7	;	Crystal Structure of RasA59G in the GTP-bound form
6IHI	;	1.78	;	Crystal structure of RasADH 3B3/I91V from Ralstonia.sp in complex with NADPH and A6O
6IHH	;	1.8	;	Crystal structure of RasADH F12 from Ralstonia.sp in complex with NADPH and A6O
1CK4	;	2.2	;	CRYSTAL STRUCTURE OF RAT A1B1 INTEGRIN I-DOMAIN.
1EDY	;	2.3	;	CRYSTAL STRUCTURE OF RAT ALPHA 1-MACROGLOBULIN RECEPTOR BINDING DOMAIN
1RWY	;	1.05	;	CRYSTAL STRUCTURE OF RAT ALPHA-PARVALBUMIN AT 1.05 RESOLUTION
1XVJ	;	1.8	;	Crystal Structure Of Rat alpha-Parvalbumin D94S/G98E Mutant
1S3P	;	2.0	;	Crystal structure of rat alpha-parvalbumin S55D/E59D mutant
2WXZ	;	2.8	;	Crystal structure of rat angiotensinogen in C2 space group
2WY1	;	3.15	;	Crystal structure of rat angiotensinogen in P321 space group
6TU2	;	2.3	;	Crystal structure of rat annexin A11
7R24	;	2.7	;	Crystal structure of rat Arc CTD in complex with two anti-Arc nanobodies
8C4W	;	1.95	;	Crystal structure of rat autotaxin and compound MEY-002
8C7R	;	2.53	;	Crystal structure of rat autotaxin and compound MEY-003
1I7P	;	2.0	;	CRYSTAL STRUCTURE OF RAT B5R IN COMPLEX WITH FAD
1IB0	;	2.3	;	CRYSTAL STRUCTURE OF RAT B5R IN COMPLEX WITH FAD AND NAD
4MPS	;	2.4	;	Crystal structure of rat Beta-galactoside alpha-2,6-sialyltransferase 1 (ST6GAL1), Northeast Structural Genomics Consortium Target RnR367A
1GCU	;	1.4	;	CRYSTAL STRUCTURE OF RAT BILIVERDIN REDUCTASE AT 1.4 A
1L0B	;	2.3	;	Crystal Structure of rat Brca1 tandem-BRCT region
6JV8	;	1.582	;	Crystal structure of Rat C5a
4EYW	;	1.885	;	Crystal structure of rat carnitine palmitoyltransferase 2 in complex with 1-[(R)-2-(3,4-Dihydro-1H-isoquinoline-2-carbonyl)-piperidin-1-yl]-2-phenoxy-ethanone
2FW3	;	2.5	;	Crystal structure of rat carnitine palmitoyltransferase 2 in complex with antidiabetic drug ST1326
4EP9	;	2.03	;	CRYSTAL STRUCTURE OF RAT CARNITINE PALMITOYLTRANSFERASE 2 IN COMPLEX WITH CoA-site inhibitor
4EPH	;	2.3	;	CRYSTAL STRUCTURE OF RAT CARNITINE PALMITOYLTRANSFERASE 2 IN COMPLEX with CoA-site inhibitor
2RCU	;	1.78	;	Crystal structure of rat carnitine palmitoyltransferase 2 in complex with r-3-(hexadecanoylamino)-4-(trimethylazaniumyl)butanoate
2DEB	;	1.6	;	Crystal structure of rat carnitine palmitoyltransferase 2 in space group C2221
2FYO	;	2.0	;	Crystal structure of rat carnitine palmitoyltransferase 2 in space group P43212
2H4T	;	1.9	;	Crystal structure of rat carnitine palmitoyltransferase II
5UX4	;	2.805	;	Crystal Structure of Rat Cathepsin D with (5S)-3-(5,6-dihydro-2H-pyran-3-yl)-1-fluoro- 7-(2-fluoropyridin-3-yl)spiro[chromeno[2,3- c]pyridine-5,4'-[1,3]oxazol]-2'-amine
5FN8	;	2.45	;	Crystal structure of rat CD45 extracellular region, domains d3-d4
5KWR	;	1.795	;	Crystal structure of rat Cerebellin-1
1Q6X	;	2.5	;	Crystal structure of rat choline acetyltransferase
2R6M	;	3.1	;	Crystal structure of rat CK2-beta subunit
4ZXN	;	2.2	;	Crystal structure of rat coronavirus strain New-Jersey Hemagglutinin-Esterase
5JIL	;	1.85	;	Crystal structure of rat coronavirus strain New-Jersey Hemagglutinin-Esterase in complex with 4N-acetyl sialic acid
1OSC	;	2.15	;	Crystal structure of rat CUTA1 at 2.15 A resolution
4TOT	;	2.39	;	Crystal structure of rat cyclophilin D in complex with a potent nonimmunosuppressive inhibitor
3AN1	;	1.73	;	Crystal structure of rat D428A mutant, urate bound form
2OAE	;	3.0	;	Crystal structure of rat dipeptidyl peptidase (DPPIV) with thiazole-based peptide mimetic #31
3V72	;	2.49	;	Crystal Structure of Rat DNA polymerase beta Mutator E295K: Enzyme-dsDNA
3UXO	;	2.1	;	Crystal Structure of Rat DNA Polymerase Beta Mutator I260Q Apoenzyme
3UXN	;	2.5	;	Crystal Structure of Rat DNA Polymerase Beta, Wild Type Apoenzyme
1BPB	;	2.3	;	CRYSTAL STRUCTURE OF RAT DNA POLYMERASE BETA: EVIDENCE FOR A COMMON POLYMERASE MECHANISM
1BPD	;	3.6	;	CRYSTAL STRUCTURE OF RAT DNA POLYMERASE BETA: EVIDENCE FOR A COMMON POLYMERASE MECHANISM
2BPC	;	2.8	;	CRYSTAL STRUCTURE OF RAT DNA POLYMERASE BETA: EVIDENCE FOR A COMMON POLYMERASE MECHANISM
1BPE	;	2.9	;	CRYSTAL STRUCTURE OF RAT DNA POLYMERASE BETA; EVIDENCE FOR A COMMON POLYMERASE MECHANISM
4P5D	;	2.11	;	CRYSTAL STRUCTURE OF RAT DNPH1 (RCL) WITH 6-NAPHTHYL-PURINE-RIBOSIDE-MONOPHOSPHATE
7UGB	;	1.9	;	Crystal structure of rat ERK2 complexed with docking peptide from ISG20
1NL4	;	2.7	;	Crystal Structure of Rat Farnesyl Transferase in Complex With A Potent Biphenyl Inhibitor
2J3P	;	1.4	;	crystal structure of rat FGF1 at 1.4 A
5JP5	;	1.7	;	Crystal structure of rat Galectin 5
4GA9	;	1.88	;	Crystal Structure of Rat Galectin-1 in Complex with Lactose
5L2E	;	4.152	;	Crystal structure of rat Glutamate receptor delta-2 extracellular domain
2IDJ	;	2.35	;	Crystal Structure of Rat Glycine N-Methyltransferase Apoprotein, Monoclinic Form
2IDK	;	2.55	;	Crystal Structure of Rat Glycine N-Methyltransferase Complexed With Folate
1JG5	;	2.6	;	CRYSTAL STRUCTURE OF RAT GTP CYCLOHYDROLASE I FEEDBACK REGULATORY PROTEIN, GFRP
1IS7	;	2.8	;	Crystal structure of rat GTPCHI/GFRP stimulatory complex
1IS8	;	2.7	;	Crystal structure of rat GTPCHI/GFRP stimulatory complex plus Zn
5Y9Z	;	1.09	;	Crystal structure of rat hematopoietic prostaglandin D synthase
1J2C	;	2.4	;	Crystal structure of rat heme oxygenase-1 in complex with biliverdin IXalpha-iron cluster
2ZVU	;	2.2	;	Crystal structure of rat heme oxygenase-1 in complex with ferrous verdoheme
1DVE	;	2.4	;	CRYSTAL STRUCTURE OF RAT HEME OXYGENASE-1 IN COMPLEX WITH HEME
2DY5	;	2.7	;	Crystal structure of rat heme oxygenase-1 in complex with heme and 2-[2-(4-chlorophenyl)ethyl]-2-[(1H-imidazol-1-yl)methyl]-1,3-dioxolane
4G7L	;	1.8	;	Crystal Structure of rat Heme oxygenase-1 in complex with Heme and O2
1IX4	;	1.8	;	Crystal Structure of Rat Heme Oxygenase-1 in complex with Heme bound to Carbon Monoxide
1IX3	;	2.0	;	Crystal Structure of Rat Heme Oxygenase-1 in complex with Heme bound to Cyanide
1DVG	;	2.2	;	CRYSTAL STRUCTURE OF RAT HEME OXYGENASE-1 IN COMPLEX WITH HEME; SELELENO-METHIONINE DERIVATIVE, MUTATED AT M51T,M93L,M155L,M191L.
4MEC	;	3.2	;	Crystal structure of RAT Heme oxygenase-1 in complex with ZN(II)-Protoporphyrin IX
1J02	;	1.7	;	Crystal Structure of Rat Heme Oxygenase-1-Heme Bound to NO
1IVJ	;	1.9	;	Crystal Structure of Rat Hemeoxygenase-1 in Complex with Heme and Azide.
1UBB	;	2.3	;	Crystal structure of rat HO-1 in complex with ferrous heme
2IFB	;	2.0	;	CRYSTAL STRUCTURE OF RAT INTESTINAL FATTY-ACID-BINDING PROTEIN. REFINEMENT AND ANALYSIS OF THE ESCHERICHIA COLI-DRIVED PROTEIN WITH BOUND PALMITATE
1DHR	;	2.3	;	CRYSTAL STRUCTURE OF RAT LIVER DIHYDROPTERIDINE REDUCTASE
3HF4	;	2.7	;	Crystal structure of rat methemoglobin in R2 state
1ED3	;	2.55	;	CRYSTAL STRUCTURE OF RAT MINOR HISTOCOMPATIBILITY ANTIGEN COMPLEX RT1-AA/MTF-E.
3SUZ	;	2.7	;	Crystal structure of Rat Mint2 PPC
1XX4	;	2.2	;	Crystal Structure of Rat Mitochondrial 3,2-Enoyl-CoA
3K9V	;	2.5	;	Crystal structure of rat mitochondrial P450 24A1 S57D in complex with CHAPS
3K9Y	;	2.8	;	Crystal structure of rat mitochondrial P450 24A1 S57D in complex with CYMAL-5
6LPC	;	3.402	;	Crystal Structure of rat Munc18-1 with K332E/K333E mutation
3THR	;	2.0	;	Crystal structure of rat native liver Glycine N-methyltransferase complexed with 5-methyltetrahydrofolate monoglutamate
3THS	;	2.5	;	Crystal structure of rat native liver Glycine N-methyltransferase complexed with 5-methyltetrahydrofolate pentaglutamate
2R1D	;	2.6	;	Crystal structure of rat neurexin 1beta in the Ca2+ containing form
2R1B	;	1.72	;	Crystal Structure of rat neurexin 1beta with a splice insert at SS#4
4FXY	;	2.8	;	Crystal structure of rat neurolysin with bound pyrazolidin inhibitor
1F20	;	1.9	;	CRYSTAL STRUCTURE OF RAT NEURONAL NITRIC-OXIDE SYNTHASE FAD/NADP+ DOMAIN AT 1.9A RESOLUTION.
1TLL	;	2.3	;	CRYSTAL STRUCTURE OF RAT NEURONAL NITRIC-OXIDE SYNTHASE REDUCTASE MODULE AT 2.3 A RESOLUTION.
5H1X	;	2.41	;	Crystal Structure of rat Nup62 Coiled-coil motif
3ZQ3	;	2.8	;	Crystal Structure of Rat Odorant Binding Protein 3 (OBP3)
3L9B	;	1.95	;	Crystal Structure of Rat Otoferlin C2A
1G33	;	1.44	;	CRYSTAL STRUCTURE OF RAT PARVALBUMIN WITHOUT THE N-TERMINAL DOMAIN
3ZW9	;	2.9	;	CRYSTAL STRUCTURE OF RAT PEROXISOMAL MULTIFUNCTIONAL ENZYME TYPE 1 (RPMFE1) COMPLEXED WITH (2S,3S)-3-HYDROXY-2-METHYLBUTANOYL-COA
3ZWB	;	3.1	;	CRYSTAL STRUCTURE OF RAT PEROXISOMAL MULTIFUNCTIONAL ENZYME TYPE 1 (RPMFE1) COMPLEXED WITH 2TRANS-HEXENOYL-COA
3ZWC	;	2.3	;	CRYSTAL STRUCTURE OF RAT PEROXISOMAL MULTIFUNCTIONAL ENZYME TYPE 1 (RPMFE1) COMPLEXED WITH 3S-HYDROXY-DECANOYL-COA
3ZWA	;	2.47	;	CRYSTAL STRUCTURE OF RAT PEROXISOMAL MULTIFUNCTIONAL ENZYME TYPE 1 (RPMFE1) COMPLEXED WITH 3S-HYDROXY-HEXANOYL-COA
3ZW8	;	2.5	;	Crystal Structure Of Rat Peroxisomal Multifunctional Enzyme Type 1 (rpMFE1) In Apo Form
6Z5F	;	2.25	;	CRYSTAL STRUCTURE OF RAT PEROXISOMAL MULTIFUNCTIONAL ENZYME TYPE-1 (RPMFE1) COMPLEXED WITH 3-KETODECANOYL-COA AND OXIDISED NICOTINAMIDE ADENINE DINUCLEOTIDE
6Z5V	;	2.33	;	CRYSTAL STRUCTURE OF RAT PEROXISOMAL MULTIFUNCTIONAL ENZYME TYPE-1 (RPMFE1) COMPLEXED WITH 3-KETODECANOYL-COA IN CROTONASE FOLD AND OXIDISED NICOTINAMIDE ADENINE DINUCLEOTIDE IN HAD FOLD
6ZIC	;	2.2	;	CRYSTAL STRUCTURE OF RAT PEROXISOMAL MULTIFUNCTIONAL ENZYME TYPE-1 (RPMFE1) COMPLEXED WITH 3S-HYDROXYBUTANOYL-COA AND NADH
5MGB	;	2.8	;	Crystal Structure of Rat Peroxisomal Multifunctional enzyme Type-1 (RPMFE1) Complexed with Acetoacetyl-CoA and NAD
6ZIB	;	2.7	;	CRYSTAL STRUCTURE OF RAT PEROXISOMAL MULTIFUNCTIONAL ENZYME TYPE-1 (RPMFE1) COMPLEXED WITH ACETOACETYL-COA AND NADH
6Z5O	;	1.7	;	CRYSTAL STRUCTURE OF RAT PEROXISOMAL MULTIFUNCTIONAL ENZYME TYPE-1 (RPMFE1) COMPLEXED WITH COENZYME-A AND OXIDISED NICOTINAMIDE ADENINE DINUCLEOTIDE
5OMO	;	2.49	;	CRYSTAL STRUCTURE OF RAT PEROXISOMAL MULTIFUNCTIONAL ENZYME TYPE-1 (RPMFE1) COMPLEXED WITH WITH 3S-HYDROXY-DECANOYL-COA AND 3-KETO-DECANOYL-COA
3LXG	;	2.3	;	Crystal structure of rat phosphodiesterase 10A in complex with ligand WEB-3
2VK3	;	1.7	;	Crystal structure of rat profilin 2a
5MLG	;	2.6	;	Crystal structure of rat prorenin
3Q7E	;	2.2	;	Crystal Structure of rat Protein Arginine Methyltransferase 1 (PRMT1)M48L mutant
2ZIR	;	2.4	;	Crystal Structure of rat protein farnesyltransferase complexed with a benzofuran inhibitor and FPP
2ZIS	;	2.6	;	Crystal Structure of rat protein farnesyltransferase complexed with a bezoruran inhibitor and FPP
1JCR	;	2.0	;	CRYSTAL STRUCTURE OF RAT PROTEIN FARNESYLTRANSFERASE COMPLEXED WITH THE NON-SUBSTRATE TETRAPEPTIDE INHIBITOR CVFM AND FARNESYL DIPHOSPHATE SUBSTRATE
1JCS	;	2.2	;	CRYSTAL STRUCTURE OF RAT PROTEIN FARNESYLTRANSFERASE COMPLEXED WITH THE PEPTIDE SUBSTRATE TKCVFM AND AN ANALOG OF FARNESYL DIPHOSPHATE
3I36	;	1.841	;	Crystal Structure of Rat Protein Tyrosine Phosphatase eta Catalytic Domain
6NMG	;	2.2	;	Crystal Structure of Rat Ric-8A G alpha binding domain
6NMJ	;	2.3	;	Crystal Structure of Rat Ric-8A G alpha binding domain, ""Paratone-N Immersed""
3A9X	;	2.0	;	Crystal structure of rat selenocysteine lyase
3A9Y	;	1.85	;	Crystal structure of rat selenocysteine lyase in complex with L-cysteine
1JQI	;	2.25	;	Crystal Structure of Rat Short Chain Acyl-CoA Dehydrogenase Complexed With Acetoacetyl-CoA
5GRM	;	1.55	;	Crystal structure of rat STING in complex with cyclic GMP-AMP with 2'5'and 3'5'phosphodiester linkage(2'3'-cGAMP)
3PAK	;	1.9	;	Crystal Structure of Rat Surfactant Protein A neck and carbohydrate recognition domain (NCRD) complexed with Mannose
1PK8	;	2.1	;	Crystal Structure of Rat Synapsin I C Domain Complexed to Ca.ATP
1PX2	;	2.23	;	Crystal Structure of Rat Synapsin I C Domain Complexed to Ca.ATP (Form 1)
2V1S	;	2.05	;	CRYSTAL STRUCTURE OF RAT TOM20-ALDH PRESEQUENCE COMPLEX
2V1T	;	1.92	;	CRYSTAL STRUCTURE OF RAT TOM20-ALDH PRESEQUENCE COMPLEX
3AX5	;	2.2	;	Crystal structure of rat TOM20-ALDH presequence complex: A complex (form1) between Tom20 and a disulfide-bridged presequence peptide containing D-Cys and L-Cys at the i and i+3 positions.
3AX3	;	2.1	;	Crystal structure of rat TOM20-ALDH presequence complex: a complex (form2) between Tom20 and a disulfide-bridged presequence peptide containing D-Cys and L-Cys at the i and i+3 positions.
3AX2	;	1.9	;	Crystal structure of rat TOM20-ALDH presequence complex: a disulfide-tethered complex with a non-optimized, long linker
3AWR	;	2.0	;	Crystal structure of Rat TOM20-ALDH presequence complex: The intermolecular disulfide bond was cleaved in the crystal of a disulfide-tethered complex.
7D2K	;	3.698	;	Crystal structure of rat TRPV6 in complex with (4- phenylcyclohexyl)piperazine inhibitor Br-cis-22a
6D7O	;	3.45	;	Crystal Structure of Rat TRPV6* in complex with 2-Aminoethoxydiphenyl borate (2-APB)
6D7V	;	4.3	;	Crystal Structure of Rat TRPV6*- in complex with brominated 2-Aminoethoxydiphenyl borate (2-APB-Br)
6D7P	;	3.37	;	Crystal Structure of Rat TRPV6*-Y466A
6D7Q	;	3.497	;	Crystal Structure of Rat TRPV6*-Y466A in complex with 2-Aminoethoxydiphenyl borate (2-APB)
6D7X	;	3.6	;	Crystal Structure of Rat TRPV6*-Y466A- in complex with brominated 2-Aminoethoxydiphenyl borate (2-APB-Br)
3W0G	;	1.94	;	Crystal Structure of Rat VDR Ligand Binding Domain in Complex with Novel Nonsecosteroidal Ligands
3W0H	;	1.8	;	Crystal Structure of Rat VDR Ligand Binding Domain in Complex with Novel Nonsecosteroidal Ligands
3W0I	;	1.9	;	Crystal Structure of Rat VDR Ligand Binding Domain in Complex with Novel Nonsecosteroidal Ligands
3W0J	;	1.84	;	Crystal Structure of Rat VDR Ligand Binding Domain in Complex with Novel Nonsecosteroidal Ligands
3VT6	;	2.3	;	Crystal structure of rat VDR-LBD with 2-Substituted-16-ene-22-thia-1alpha,25-dihydroxy-26,27-dimethyl-19-norvitamin D3
3VTB	;	2.0	;	Crystal structure of rat vitamin D receptor bound to a partial agonist 25-adamantyl-23-yne-19-norvitammin D ADTK1
3VTC	;	1.5	;	Crystal structure of rat vitamin D receptor bound to a partial agonist 26-adamantyl-23-yne-19-norvitammin D ADTK3
3VTD	;	2.7	;	Crystal structure of rat vitamin D receptor bound to a partial agonist 26-adamantyl-23-yne-19-norvitammin D ADTK4
2ZMH	;	2.1	;	Crystal Structure of Rat Vitamin D Receptor Bound to Adamantyl Vitamin D Analogs: Structural Basis for Vitamin D Receptor Antagonism and/or Partial Agonism
2ZMI	;	1.7	;	Crystal Structure of Rat Vitamin D Receptor Bound to Adamantyl Vitamin D Analogs: Structural Basis for Vitamin D Receptor Antagonism and/or Partial Agonism
2ZMJ	;	2.35	;	Crystal Structure of Rat Vitamin D Receptor Bound to Adamantyl Vitamin D Analogs: Structural Basis for Vitamin D Receptor Antagonism and/or Partial Agonism
2O4R	;	1.98	;	Crystal Structure of Rat Vitamin D Receptor Ligand Binding Domain Complexed with VitIII 17-20E and the NR2 Box of DRIP 205
2O4J	;	1.74	;	Crystal Structure of Rat Vitamin D Receptor Ligand Binding Domain Complexed with VitIII 17-20Z and the NR2 Box of DRIP 205
2E3T	;	2.28	;	Crystal structure of rat xanthine oxidoreductase mutant (W335A and F336L)
6HOO	;	2.38	;	Crystal Structure of Rationally Designed OXA-48loop18 beta-lactamase
5ZKB	;	2.95	;	Crystal structure of rationally thermostabilized M2 muscarinic acetylcholine receptor bound with AF-DX 384
5ZKC	;	2.3	;	Crystal structure of rationally thermostabilized M2 muscarinic acetylcholine receptor bound with NMS
5YC8	;	2.5	;	Crystal structure of rationally thermostabilized M2 muscarinic acetylcholine receptor bound with NMS (Hg-derivative)
5ZK3	;	2.6	;	Crystal structure of rationally thermostabilized M2 muscarinic acetylcholine receptor bound with QNB
3G8E	;	3.0	;	Crystal Structure of Rattus norvegicus Visfatin/PBEF/Nampt in Complex with an FK866-based inhibitor
4A3Y	;	2.15	;	Crystal structure of Raucaffricine glucosidase from ajmaline biosynthesis pathway
4ATL	;	2.52	;	Crystal structure of Raucaffricine glucosidase in complex with Glucose
6NII	;	2.15	;	Crystal structure of RavD (residues 1-200) from Legionella pneumophila (strain Corby)
6NJD	;	2.05	;	Crystal structure of RavD (residues 1-200) from Legionella pneumophila (strain Corby) complexed with Met-1 linked di-ubiquitin
2R35	;	2.08	;	Crystal structure of RB human arg-insulin
2P5O	;	2.8	;	Crystal structure of RB69 GP43 in complex with DNA containing an abasic site analog
2DY4	;	2.65	;	Crystal structure of RB69 GP43 in complex with DNA containing Thymine Glycol
2OYQ	;	2.86	;	Crystal structure of RB69 gp43 in complex with DNA with 5-NIMP opposite an abasic site analog
2OZM	;	2.86	;	Crystal structure of RB69 gp43 in complex with DNA with 5-NITP opposite an abasic site analog
2P5G	;	2.8	;	Crystal structure of RB69 gp43 in complex with DNA with dAMP opposite an abasic site analog in a 21mer template
2OZS	;	2.75	;	Crystal structure of RB69 gp43 in complex with DNA with dATP opposite dTMP
3LDS	;	3.0	;	Crystal structure of RB69 gp43 with DNA and dATP opposite 8-oxoG
5Y1U	;	2.141	;	Crystal structure of RBBP4 bound to AEBP2 RRK motif
5VTB	;	2.4	;	Crystal structure of RBBP4 bound to BCL11a peptide
4R7A	;	1.85	;	Crystal Structure of RBBP4 bound to PHF6 peptide
6BW4	;	2.0	;	Crystal structure of RBBP4 in complex with PRDM16 N-terminal peptide
6BW3	;	2.2	;	Crystal structure of RBBP4 in complex with PRDM3 N-terminal peptide
5XWR	;	2.69	;	Crystal Structure of RBBP4-peptide complex
5XXQ	;	1.9	;	Crystal structure of RBBP4: ZNF827 and its function in telomere
6VHF	;	2.311	;	Crystal structure of RbBP5 interacting domain of Cfp1
7OEX	;	1.51	;	Crystal structure of RBBP9 in complex with phenylalanine
6KKM	;	3.0	;	Crystal structure of RbcL-Raf1 complex from Anabaena sp. PCC 7120
3Q20	;	1.71	;	Crystal structure of RbcX C103A mutant from Thermosynechococcus elongatus
2PEO	;	2.5	;	Crystal structure of RbcX from Anabaena CA
3HYB	;	2.3	;	Crystal structure of RbcX from Anabaena, crystal form II
2PEM	;	2.95	;	Crystal structure of RbcX in complex with substrate
2PEK	;	3.1	;	Crystal structure of RbcX point mutant Q29A
2PEJ	;	3.4	;	Crystal structure of RbcX point mutant Y17A/Y20L
2PEN	;	2.8	;	Crystal structure of RbcX, crystal form I
2PEQ	;	1.9	;	Crystal structure of RbcX, crystal form II
5BS1	;	1.6	;	Crystal structure of RbcX-IIa from Chlamydomonas reinhardtii
5BS2	;	1.97	;	Crystal structure of RbcX-IIa from Chlamydomonas reinhardtii in complex with RbcL C-terminal tail
6JVX	;	2.301	;	Crystal structure of RBM38 in complex with RNA
6JVY	;	2.003	;	Crystal structure of RBM38 in complex with single-stranded DNA
7PCV	;	2.42	;	Crystal structure of RBM5 RRM1-zinc finger
7PDV	;	3.49	;	Crystal structure of RBM5 RRM1-zinc finger in complex with RNA
2WQ9	;	1.65	;	Crystal Structure of RBP4 bound to Oleic Acid
7M4N	;	2.52	;	Crystal structure of RBR E3 ligase RNF216 in complex with K63-linked di-ubiquitin
7M4M	;	2.39	;	Crystal structure of RBR E3 ligase RNF216 with ubiquitin
7OD1	;	2.45	;	Crystal structure of RBR ubiquitin ligase ARIH2
3RDZ	;	2.262	;	Crystal Structure of rBTI-trypsin complex at 2.26 angstrom resolution
1PYH	;	4.8	;	Crystal structure of RC-LH1 core complex from Rhodopseudomonas palustris
5GWO	;	2.816	;	Crystal structure of RCAR3:PP2C S265F/I267M with (+)-ABA
5GWP	;	2.577	;	Crystal structure of RCAR3:PP2C wild-type with (+)-ABA
5ZCU	;	2.413	;	Crystal structure of RCAR3:PP2C wild-type with pyrabactin
1WDZ	;	2.63	;	Crystal structure of RCB domain of IRSp53
3AGA	;	2.6	;	Crystal structure of RCC-bound red chlorophyll catabolite reductase from Arabidopsis thaliana
7Q40	;	2.35002	;	Crystal structure of RCC1-Like domain 2 of ubiquitin ligase HERC2
7Q42	;	1.95002	;	Crystal structure of RCC1-Like domain 2 of ubiquitin ligase HERC2 in complex with DXDKDED motif of chromatin reader BAZ2B
7Q43	;	2.40002	;	Crystal structure of RCC1-Like domain 2 of ubiquitin ligase HERC2 in complex with DXDKDED motif of dedicator of cytokinesis protein 10
7Q44	;	2.20008	;	Crystal structure of RCC1-Like domain 2 of ubiquitin ligase HERC2 in complex with DXDKDED motif of deubiquitinase USP35
7Q45	;	2.1	;	Crystal structure of RCC1-Like domain 2 of ubiquitin ligase HERC2 in complex with DXDKDED motif of Myelin transcription factor 1
7Q46	;	2.46003	;	Crystal structure of RCC1-Like domain 2 of ubiquitin ligase HERC2 in complex with DXDKDED motif of pericentriolar material 1 protein
7Q41	;	3.01478	;	Crystal structure of RCC1-Like domain 2 of ubiquitin ligase HERC2 in complex with DXDKDED motif of ubiquitin-protein ligase E3A (E6AP)
3CTW	;	2.9	;	Crystal Structure of RcdA from Caulobacter crescentus CB15
4FYK	;	1.79	;	Crystal structure of rcl with 5'-phiosphorothioate-adenosine
4FYI	;	1.96	;	Crystal structure of rcl with 6-cyclopentyl-AMP
4FYH	;	2.44	;	Crystal structure of rcl with phospho-triciribine
8I3F	;	1.62	;	Crystal structure of Rco1-Eaf3 with peptide of histone H3 N-terminal
7E1H	;	2.805	;	crystal structure of RD-BEF
8IAG	;	1.5	;	Crystal structure of rDcaUPO A161C mutant from Daldinia caldariorum
1K7K	;	1.5	;	crystal structure of RdgB- inosine triphosphate pyrophosphatase from E. coli
3QDL	;	2.0	;	Crystal structure of RdxA from Helicobacter pyroli
2I7S	;	1.35	;	Crystal structure of Re(phen)(CO)3 (Thr124His)(His83Gln) Azurin Cu(II) from Pseudomonas aeruginosa
3W2I	;	1.81	;	Crystal structure of re-oxidized form (60 min) of NADH-cytochrome b5 reductase from pig liver
6QT8	;	2.33	;	Crystal structure of Rea1-MIDAS domain from Chaetomium thermophilum
6QTA	;	1.89	;	Crystal structure of Rea1-MIDAS/Rsa4-UBL complex from Chaetomium thermophilum
6QTB	;	1.89	;	Crystal structure of Rea1-MIDAS/Ytm1-UBL complex from Chaetomium thermophilum
6I3I	;	2.97	;	Crystal structure of reactive center loop (RCL) cleaved angiotensinogen
6F4U	;	1.9	;	Crystal structure of reactive loop cleaved kallistatin at 1.9 angstrom resolution
2O9Z	;	2.494	;	Crystal Structure of RebH, a FAD-dependent halogenase from Lechevalieria aerocolonigenes, the Apo form
2OA1	;	2.15	;	Crystal Structure of RebH, a FAD-dependent halogenase from Lechevalieria aerocolonigenes, the L-Tryptophan with FAD complex
3BUS	;	2.65	;	Crystal Structure of RebM
2DR3	;	2.0	;	Crystal Structure of RecA superfamily ATPase PH0284 from Pyrococcus horikoshii OT3
6TNE	;	1.25	;	Crystal structure of receiver domain from Hybrid Histidine Kinase CckA
4L85	;	2.202	;	Crystal structure of receiver domain of KdpE D52A mutant from E. coli
4E7O	;	2.198	;	Crystal structure of receiver domain of putative NarL family response regulator spr1814 from Streptococcus pneumoniae
4E7P	;	1.892	;	Crystal structure of receiver domain of putative NarL family response regulator spr1814 from Streptococcus pneumoniae in the presence of the phosphoryl analog beryllofluoride
6UWO	;	2.3	;	Crystal structure of receptor binding domain 2 from Clostridium difficile translocase CDTb
7COE	;	2.05	;	Crystal structure of Receptor binding domain of MERS-CoV and KNIH90-F1 Fab complex
6ZER	;	3.8	;	Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with EY6A Fab
6ZCZ	;	2.65	;	Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in ternary complex with EY6A Fab and a nanobody.
4RS1	;	2.68	;	Crystal structure of receptor-cytokine complex
4JZJ	;	2.801	;	Crystal Structure of Receptor-Fab Complex
2ZXO	;	2.5	;	Crystal structure of RecJ from Thermus thermophilus HB8
2ZXR	;	2.15	;	Crystal structure of RecJ in complex with Mg2+ from Thermus thermophilus HB8
2ZXP	;	2.3	;	Crystal structure of RecJ in complex with Mn2+ from Thermus thermophilus HB8
7BHI	;	2.7	;	Crystal structure of RecJ-Cdc45 from Methanothermobacter Thermoautotrophicus
7BIH	;	3.0	;	Crystal structure of RecJ-Cdc45 from Methanothermobacter Thermoautotrophicus in the closed state.
7BMF	;	2.2	;	Crystal structure of RecJCdc45 from Methanothermobacter thermoautotroficus in complex with dCTP
7BJQ	;	2.7	;	Crystal structure of RecJCdc45 from Methanothermobacter thermoautotroficus in complex with ssDNA
4WY7	;	2.1	;	Crystal structure of recombinant 4E10 expressed in Escherichia coli with epitope bound
2XZA	;	1.5	;	Crystal Structure of recombinant A.17 antibody FAB fragment
2ZGL	;	1.9	;	Crystal structure of recombinant Agrocybe aegerita (rAAL)
2ZGN	;	2.5	;	crystal structure of recombinant Agrocybe aegerita lectin, rAAL, complex with galactose
2ZGM	;	1.9	;	Crystal structure of recombinant Agrocybe aegerita lectin,rAAL, complex with lactose
4QCE	;	2.32	;	Crystal structure of recombinant alkali thermostable GH10 xylanase from Bacillus sp. NG-27
1APX	;	2.2	;	CRYSTAL STRUCTURE OF RECOMBINANT ASCORBATE PEROXIDASE
2FO5	;	2.2	;	Crystal structure of recombinant barley cysteine endoprotease B isoform 2 (EP-B2) in complex with leupeptin
1E1H	;	1.8	;	Crystal Structure of recombinant Botulinum Neurotoxin Type A Light Chain, self-inhibiting Zn endopeptidase.
1RFB	;	3.0	;	CRYSTAL STRUCTURE OF RECOMBINANT BOVINE INTERFERON-GAMMA AT 3.0 ANGSTROMS RESOLUTION
1BJF	;	2.4	;	CRYSTAL STRUCTURE OF RECOMBINANT BOVINE NEUROCALCIN DELTA AT 2.4 ANGSTROMS
7O0K	;	1.83	;	Crystal structure of recombinant chichen liver Bile Acid Binding Protein (cL-BABP) in complex with cholic acid
2A99	;	2.202	;	Crystal structure of recombinant chicken sulfite oxidase at resting state
2A9D	;	1.701	;	Crystal structure of recombinant chicken sulfite oxidase with Arg at residue 161
2A9A	;	2.003	;	Crystal structure of recombinant chicken sulfite oxidase with the bound product, sulfate, at the active site
6U4O	;	1.85	;	Crystal structure of recombinant class II fumarase from Schistosoma mansoni
6GT6	;	2.54	;	Crystal structure of recombinant coagulation factor beta-XIIa
5C8C	;	2.5	;	Crystal structure of recombinant coxsackievirus A16 capsid
5EXG	;	1.7	;	Crystal structure of recombinant dimeric Banana lectin
2JE9	;	2.1	;	CRYSTAL STRUCTURE OF RECOMBINANT DIOCLEA GRANDIFLORA LECTIN COMPLEXED WITH 5-BROMO-4-CHLORO-3-INDOLYL-A-D-MANNOSE
2JEC	;	2.0	;	crystal structure of recombinant DiocleA grandiflora lectin mutant E123A-H131N-K132Q complexed witH 5-bromo-4-chloro-3-indolyl-a-D- mannose
2JDZ	;	2.1	;	Crystal structure of recombinant Dioclea guianensis lectin complexed with 5-bromo-4-chloro-3-indolyl-a-D-mannose
2JE7	;	1.65	;	Crystal structure of recombinant Dioclea guianensis lectin S131H complexed with 5-bromo-4-chloro-3-indolyl-a-D-mannose
1SFY	;	2.55	;	Crystal structure of recombinant Erythrina corallodandron Lectin
1FPS	;	2.6	;	CRYSTAL STRUCTURE OF RECOMBINANT FARNESYL DIPHOSPHATE SYNTHASE AT 2.6 ANGSTROMS RESOLUTION
4IV1	;	2.1	;	Crystal structure of recombinant foot-and-mouth-disease virus A22 empty capsid
4IV3	;	2.9	;	Crystal structure of recombinant foot-and-mouth-disease virus A22-H2093C empty capsid
5D8A	;	2.4	;	Crystal structure of recombinant foot-and-mouth-disease virus A22-H2093F empty capsid
5DDJ	;	3.5	;	Crystal structure of recombinant foot-and-mouth-disease virus O1M-S2093Y empty capsid
2PM8	;	2.8	;	Crystal structure of recombinant full length human butyrylcholinesterase
3HUS	;	3.04	;	Crystal structure of recombinant gamma N308K fibrinogen fragment D with the peptide ligand Gly-Pro-Arg-Pro-amide
3BVH	;	2.6	;	Crystal Structure of Recombinant gammaD364A Fibrinogen Fragment D with the Peptide Ligand Gly-Pro-Arg-Pro-Amide
6TJQ	;	1.41	;	Crystal Structure of Recombinant GBA in Complex with 2-Deoxy-2-fluoro-beta-D-glucopyranoside
6TJK	;	1.56	;	Crystal Structure of Recombinant GBA in Complex with Bis-Tris Propane.
4G4G	;	1.55	;	Crystal structure of recombinant glucuronoyl esterase from Sporotrichum thermophile determined at 1.55 A resolution
1KU5	;	2.3	;	Crystal Structure of recombinant histone HPhA from hyperthermophilic archaeon Pyrococcus horikoshii OT3
7VIO	;	1.5	;	Crystal structure of recombinant horse spleen apo-R168H/L169C-Fr
7BON	;	1.48	;	Crystal structure of recombinant horse spleen apo-R52C/E56C/R59C/E63C-Fr
7BOM	;	1.93	;	Crystal structure of recombinant horse spleen apo-R52C/E56C/R59C/E63C-Fr immobilized with gold ions.
4EY6	;	2.3983	;	Crystal Structure of Recombinant Human Acetylcholinesterase in Complex with (-)-galantamine
4EY5	;	2.3012	;	Crystal Structure of Recombinant Human Acetylcholinesterase in Complex with (-)-huperzine A
7D9P	;	2.85	;	Crystal Structure of Recombinant Human Acetylcholinesterase in Complex with Compound 12
7D9O	;	2.45	;	Crystal Structure of Recombinant Human Acetylcholinesterase in Complex with Compound 2
7D9Q	;	2.66	;	Crystal Structure of Recombinant Human Acetylcholinesterase in Complex with Compound 7
4EY7	;	2.3509	;	Crystal Structure of Recombinant Human Acetylcholinesterase in Complex with Donepezil
6CQY	;	2.449	;	Crystal Structure of Recombinant Human Acetylcholinesterase in Complex with EMPA and HI-6
4EY8	;	2.5958	;	Crystal structure of recombinant human acetylcholinesterase in complex with fasciculin-2
6WUY	;	2.46	;	Crystal Structure of Recombinant Human Acetylcholinesterase In Complex with GA and HI-6
6WV1	;	2.372	;	Crystal Structure of Recombinant Human Acetylcholinesterase In Complex with GB and HI-6
6WVO	;	2.19	;	Crystal Structure of Recombinant Human Acetylcholinesterase In Complex with GD and HI-6
6CQV	;	2.601	;	Crystal Structure of Recombinant Human Acetylcholinesterase in Complex with VX(+) and HI-6
6CQW	;	2.278	;	Crystal Structure of Recombinant Human Acetylcholinesterase in Complex with VX(-) and HI-6
4EY4	;	2.156	;	Crystal Structure of Recombinant Human Acetylcholinesterase in the Apo state
6CQT	;	2.273	;	Crystal Structure of Recombinant Human Acetylcholinesterase Inhibited by (-) Stereoisomer of VX
6NTH	;	2.421	;	Crystal Structure of Recombinant Human Acetylcholinesterase Inhibited by (S) Stereoisomer of A-232
6NTO	;	2.052	;	Crystal Structure of Recombinant Human Acetylcholinesterase Inhibited by A-230
6NTN	;	2.697	;	Crystal Structure of Recombinant Human Acetylcholinesterase Inhibited by A-230 in Complex with the Reactivator, HI-6
6NTK	;	2.406	;	Crystal Structure of Recombinant Human Acetylcholinesterase Inhibited by A-232
6NTM	;	2.552	;	Crystal Structure of Recombinant Human Acetylcholinesterase Inhibited by A-232 in Complex with the Reactivator, HI-6
6NTL	;	2.25	;	Crystal Structure of Recombinant Human Acetylcholinesterase Inhibited by A-234
6NTG	;	2.652	;	Crystal Structure of Recombinant Human Acetylcholinesterase Inhibited by A-234 in Complex with Reactivator, HI-6
6WUV	;	2.63	;	Crystal Structure of Recombinant Human Acetylcholinesterase Inhibited by GA
6WUZ	;	2.253	;	Crystal Structure of Recombinant Human Acetylcholinesterase Inhibited by GB
6WVC	;	2.599	;	Crystal Structure of Recombinant Human Acetylcholinesterase Inhibited by GD
6WVP	;	2.308	;	Crystal Structure of Recombinant Human Acetylcholinesterase Inhibited by GF
6WVQ	;	2.289	;	Crystal Structure of Recombinant Human Acetylcholinesterase Inhibited by GP
6CQZ	;	2.216	;	Crystal Structure of Recombinant Human Acetylcholinesterase Inhibited by VX
6CQX	;	2.4	;	Crystal Structure of Recombinant Human Acetylcholinesterase Inhibited by VX(+)
6CQU	;	2.308	;	Crystal Structure of Recombinant Human Acetylcholinesterase with Reactivator HI-6
3B0I	;	1.8	;	Crystal structure of recombinant human alpha lactalbumin
2ZOC	;	2.0	;	Crystal structure of recombinant human annexin IV
6Q6L	;	1.81	;	Crystal structure of recombinant human beta-glucocerebrosidase in complex with adamantyl-cyclophellitol inhibitor (ME656)
6Q6N	;	1.63	;	Crystal structure of recombinant human beta-glucocerebrosidase in complex with biphenyl-cyclophellitol inhibitor (ME655)
6Q6K	;	1.92	;	Crystal structure of recombinant human beta-glucocerebrosidase in complex with cyclophellitol activity based probe with Cy5 tag (ME569)
1HKB	;	2.8	;	CRYSTAL STRUCTURE OF RECOMBINANT HUMAN BRAIN HEXOKINASE TYPE I COMPLEXED WITH GLUCOSE AND GLUCOSE-6-PHOSPHATE
2OVE	;	2.0	;	Crystal Structure of Recombinant Human Complement Protein C8gamma
1XYH	;	2.6	;	Crystal Structure of Recombinant Human Cyclophilin J
1LT9	;	2.8	;	Crystal Structure of Recombinant Human Fibrinogen Fragment D
1LTJ	;	2.8	;	Crystal Structure of Recombinant Human Fibrinogen Fragment D with the Peptide Ligands Gly-Pro-Arg-Pro-Amide and Gly-His-Arg-Pro-Amide
7LUB	;	2.15	;	Crystal structure of recombinant human fumarase in complex with D-2-amino-3-phosphono-propionic acid
4FPA	;	2.48	;	Crystal Structure of recombinant human Hexokinase type I mutant D413N Glucose 6-Phosphate
4FOI	;	2.4	;	Crystal Structure of recombinant human Hexokinase type I mutant D413N with Glucose 1,6-bisphosphate
4FPB	;	3.0	;	Crystal Structure of Recombinant Human Hexokinase Type I with 1,5-Anhydroglucitol 6-Phosphate
4F9O	;	2.65	;	Crystal Structure of recombinant human Hexokinase type I with 2-deoxy-Glucose 6-Phosphate
4FOE	;	2.7	;	Crystal Structure of recombinant human Hexokinase type I with Mannose 6-Phosphate
4C54	;	1.9	;	Crystal structure of recombinant human IgG4 Fc
1I1B	;	2.0	;	CRYSTAL STRUCTURE OF RECOMBINANT HUMAN INTERLEUKIN-1BETA AT 2.0 ANGSTROMS RESOLUTION
1M4R	;	2.0	;	CRYSTAL STRUCTURE OF RECOMBINANT HUMAN INTERLEUKIN-22
2INT	;	2.35	;	CRYSTAL STRUCTURE OF RECOMBINANT HUMAN INTERLEUKIN-4
1HAK	;	3.0	;	CRYSTAL STRUCTURE OF RECOMBINANT HUMAN PLACENTAL ANNEXIN V COMPLEXED WITH K-201 AS A CALCIUM CHANNEL ACTIVITY INHIBITOR
1RHP	;	2.4	;	CRYSTAL STRUCTURE OF RECOMBINANT HUMAN PLATELET FACTOR 4
1NM9	;	2.1	;	Crystal structure of recombinant human salivary amylase mutant W58A
1JYD	;	1.7	;	Crystal Structure of Recombinant Human Serum Retinol-Binding Protein at 1.7 A Resolution
2J7Z	;	1.95	;	Crystal Structure of recombinant Human Stromal Cell-Derived Factor- 1alpha
1HTI	;	2.8	;	CRYSTAL STRUCTURE OF RECOMBINANT HUMAN TRIOSEPHOSPHATE ISOMERASE AT 2.8 ANGSTROMS RESOLUTION. TRIOSEPHOSPHATE ISOMERASE RELATED HUMAN GENETIC DISORDERS AND COMPARISON WITH THE TRYPANOSOMAL ENZYME
5IO1	;	3.34	;	CRYSTAL STRUCTURE OF RECOMBINANT HUMAN Z ALPHA-1-ANTITRYPSIN
4IHR	;	1.6	;	Crystal structure of recombinant kirola (Act d 11)
3T62	;	2.0	;	Crystal structure of recombinant Kunitz Type serine protease Inhibitor-1 from the Caribbean Sea anemone Stichodactyla helianthus in complex with bovine chymotrypsin
3M7Q	;	1.7	;	Crystal structure of recombinant Kunitz Type serine protease Inhibitor-1 from the Caribbean sea anemone stichodactyla helianthus in complex with bovine pancreatic trypsin
3OFW	;	2.5	;	Crystal structure of recombinant Kunitz Type serine protease Inhibitor-1 from the Carribean sea anemone stichodactyla helianthus
8CR7	;	1.5	;	Crystal structure of recombinant LasB from Pseudomonas aeruginosa PA7
8CR3	;	1.12	;	Crystal structure of recombinant LasB from Pseudomonas aeruginosa PAO1
8CR4	;	0.91	;	Crystal structure of recombinant LasBArtif from Pseudomonas aeruginosa AZPAE14816
1JV4	;	1.75	;	Crystal structure of recombinant major mouse urinary protein (rmup) at 1.75 A resolution
5EHA	;	1.35	;	Crystal structure of recombinant MtaL at 1.35 Angstrom resolution
1ALB	;	2.5	;	CRYSTAL STRUCTURE OF RECOMBINANT MURINE ADIPOCYTE LIPID-BINDING PROTEIN
1WU3	;	2.15	;	Crystal structure of recombinant murine interferon beta
6VBE	;	1.899	;	Crystal structure of recombinant mutant H180R of human fumarase
6EBT	;	2.3	;	Crystal structure of recombinant mutant N107T of human fumarase
1OSA	;	1.68	;	CRYSTAL STRUCTURE OF RECOMBINANT PARAMECIUM TETRAURELIA CALMODULIN AT 1.68 ANGSTROMS RESOLUTION
1RM4	;	2.0	;	Crystal structure of recombinant photosynthetic glyceraldehyde-3-phosphate dehydrogenase A4 isoform, complexed with NADP
5C9P	;	1.75	;	Crystal structure of recombinant PLL lectin complexed with L-fucose from Photorhabdus luminescens at 1.75 A resolution
5C9O	;	1.5	;	Crystal structure of recombinant PLL lectin from Photorhabdus luminescens at 1.5 A resolution
4RGZ	;	2.6	;	Crystal structure of recombinant prolidase from Thermococcus sibiricus at P21221 spacegroup
2IGK	;	1.8	;	Crystal structure of recombinant pyranose 2-oxidase
2IGN	;	1.65	;	Crystal structure of recombinant pyranose 2-oxidase H167A mutant
2IGM	;	1.9	;	Crystal structure of recombinant pyranose 2-oxidase H548N mutant
2RIG	;	2.3	;	CRYSTAL STRUCTURE OF RECOMBINANT RABBIT INTERFERON-GAMMA AT 2.7-ANGSTROMS RESOLUTION
3TRP	;	1.8817	;	Crystal structure of recombinant rabbit skeletal calsequestrin
3EAO	;	3.1	;	Crystal structure of recombinant rat selenoprotein thioredoxin reductase 1 with oxidized C-terminal tail
3EAN	;	2.75	;	Crystal structure of recombinant rat selenoprotein thioredoxin reductase 1 with reduced C-terminal tail
1D4F	;	2.8	;	CRYSTAL STRUCTURE OF RECOMBINANT RAT-LIVER D244E MUTANT S-ADENOSYLHOMOCYSTEINE HYDROLASE
7UMJ	;	1.88	;	Crystal structure of recombinant Solieria filiformis lectin (rSfL)
2D5F	;	1.9	;	Crystal Structure of Recombinant Soybean Proglycinin A3B4 subunit, its Comparison with Mature Glycinin A3B4 subunit, Responsible for Hexamer Assembly
2D5H	;	2.8	;	Crystal Structure of Recombinant Soybean Proglycinin A3B4 subunit, its Comparison with Mature Glycinin A3B4 subunit, Responsible for Hexamer Assembly
2W6W	;	1.99	;	Crystal structure of recombinant Sperm Whale Myoglobin under 1atm of Xenon
6UWE	;	1.6	;	Crystal structure of recombinant thiocyanate dehydrogenase from Thioalkalivibrio paradoxus saturated with copper
4U3Q	;	2.4	;	Crystal Structure of Recombinant TP0435 from Treponema pallidum
1EZK	;	1.9	;	Crystal structure of recombinant tryparedoxin I
1EHB	;	1.9	;	CRYSTAL STRUCTURE OF RECOMBINANT TRYPSIN-SOLUBILIZED FRAGMENT OF CYTOCHROME B5
4CQI	;	1.9	;	Crystal structure of recombinant tubulin-binding cofactor A (TBCA) from Leishmania major
2GQ1	;	1.45	;	Crystal Structure of Recombinant Type I Fructose-1,6-bisphosphatase from Escherichia coli Complexed with Sulfate Ions
3FH4	;	1.95	;	Crystal Structure of Recombinant Vibrio proteolyticus aminopeptidase
4D5E	;	1.43	;	Crystal Structure of recombinant wildtype CDH
4PIF	;	1.7	;	Crystal Structure of recombinant WT Banana Lectin
6V8F	;	2.3	;	Crystal structure of recombinat mutant Q185R of human fumarase
5ZWU	;	1.58	;	Crystal structure of recombination mediator protein RecF
5ZVQ	;	2.5	;	Crystal structure of recombination mediator protein RecR
1VDD	;	2.5	;	Crystal structure of recombinational repair protein RecR
3VVT	;	2.4	;	Crystal structure of reconstructed archaeal ancestral NDK, Arc1
3VVU	;	2.4	;	Crystal structure of reconstructed bacterial ancestral NDK, Bac1
5W75	;	2.298	;	Crystal Structure of Reconstructed Bacterial Elongation Factor Node 168
5W76	;	2.152	;	Crystal Structure of Reconstructed Bacterial Elongation Factor Node 168
5W7Q	;	2.5	;	Crystal Structure of Reconstructed Bacterial Elongation Factor Node 168
6CRM	;	2.19286	;	Crystal Structure of RecQ catalytic core from C. sakazakii bound to an unfolded G-quadruplex
4TMU	;	2.4	;	Crystal structure of RecQ catalytic core from C. sakazakii bound to DNA
5Z2V	;	2.2	;	Crystal structure of RecR from Pseudomonas aeruginosa PAO1
5FDK	;	3.208	;	Crystal structure of RecU(D88N) in complex with palindromic DNA duplex
3E3V	;	2.04	;	Crystal structure of RecX from Lactobacillus salivarius
3DFG	;	1.5	;	Crystal Structure of RecX: A Potent Inhibitor Protein of RecA from Xanthomonas campestris
5MR3	;	1.8	;	Crystal structure of red abalone egg VERL repeat 2 with linker in complex with sperm lysin at 1.8 A resolution
5IIB	;	1.64	;	Crystal structure of red abalone egg VERL repeat 3 in complex with sperm lysin at 1.64 A resolution (crystal form II)
5IIA	;	1.7	;	Crystal structure of red abalone egg VERL repeat 3 in complex with sperm lysin at 1.7 A resolution (crystal form I)
5II5	;	1.8	;	Crystal structure of red abalone VERL repeat 1 at 1.8 A resolution
5II4	;	2.0	;	Crystal structure of red abalone VERL repeat 1 with linker at 2.0 A resolution
5MR2	;	2.5	;	Crystal structure of red abalone VERL repeat 2 with linker at 2.5 A resolution
5IIC	;	2.9	;	Crystal structure of red abalone VERL repeat 3 at 2.9 A resolution
2ZXL	;	2.4	;	Crystal structure of red chlorophyll catabolite reductase from Arabidopsis thaliana
7CAO	;	2.05	;	Crystal structure of red chromoprotein from Olindias formosa
4XAI	;	2.6	;	Crystal Structure of red flour beetle NR2E1/TLX
4JGE	;	1.94	;	Crystal structure of red fluorescent gene-engineered variant with improved folding - lanRFP_delS83 (Branchiostoma lanceolatum)
3PJB	;	1.75	;	Crystal structure of red fluorescent protein eqFP578 crystallized at pH 4.0
3PIB	;	1.154	;	Crystal structure of red fluorescent protein eqFP578 crystallized at pH 5.5
2FL1	;	2.4	;	Crystal structure of red fluorescent protein from Zoanthus, zRFP574, at 2.4A resolution
4JEO	;	2.35	;	Crystal structure of red fluorescent protein lanRFPdam exposed to prolonged X-ray irradiation
6IR2	;	1.393	;	Crystal structure of red fluorescent protein mCherry complexed with the nanobody LaM2 at 1.4 Angstron resolution
6IR1	;	1.919	;	Crystal structure of red fluorescent protein mCherry complexed with the nanobody LaM4 at 1.9 Angstron resolution
3IP2	;	1.6	;	Crystal structure of red fluorescent protein Neptune at pH 7.0
6VJ7	;	2.6	;	Crystal structure of red kidney bean purple acid phosphatase in complex with adenosine 5'-(beta,gamma imido)triphosphate
6PY9	;	2.2	;	Crystal structure of red kidney bean purple acid phosphatase in complex with adenosine diphosphate metavanadate
8BRN	;	2.0	;	Crystal structure of red kidney bean purple acid phosphatase in complex with an alpha-aminonaphthylmethylphosphonic acid inhibitor
2QFP	;	2.2	;	Crystal structure of red kidney bean purple acid phosphatase in complex with fluoride
4DSY	;	2.3	;	Crystal structure of red kidney bean purple acid phosphatase in complex with Maybridge fragment CC24201
4DT2	;	2.7	;	Crystal structure of red kidney bean purple acid phosphatase in complex with Maybridge fragment CC27209
4DHL	;	2.3	;	Crystal structure of red kidney bean purple acid phosphatase in complex with Maybridge fragment MO07123
2QFR	;	2.4	;	Crystal structure of red kidney bean purple acid phosphatase with bound sulfate
1G0D	;	2.5	;	CRYSTAL STRUCTURE OF RED SEA BREAM TRANSGLUTAMINASE
6HZK	;	2.4	;	Crystal structure of redox-inhibited phosphoribulokinase from Synechococcus sp. (strain PCC 6301)
6HZL	;	2.77	;	Crystal structure of redox-inhibited phosphoribulokinase from Synechococcus sp. (strain PCC 6301), osmate derivative
5WJ4	;	1.631	;	Crystal structure of redox-sensitive green fluorescent protein Clover mutant roClover1
6H7H	;	2.471	;	Crystal structure of redox-sensitive phosphoribulokinase (PRK) from Arabidopsis thaliana
6H7G	;	2.6	;	Crystal structure of redox-sensitive phosphoribulokinase (PRK) from the green algae Chlamydomonas reinhardtii
6Q9K	;	1.99	;	Crystal structure of reduced Aquifex aeolicus NADH-quinone oxidoreductase subunits NuoE and NuoF S96M bound to NADH
6Q9G	;	2.1	;	Crystal structure of reduced Aquifex aeolicus NADH-quinone oxidoreductase subunits NuoE G129D and NuoF bound to NADH
6Q9J	;	1.83	;	Crystal structure of reduced Aquifex aeolicus NADH-quinone oxidoreductase subunits NuoE G129S and NuoF bound to NADH
1Y0O	;	1.89	;	crystal structure of reduced AtFKBP13
3ICT	;	2.1	;	Crystal structure of reduced Bacillus anthracis CoADR-RHD
1SXA	;	1.9	;	CRYSTAL STRUCTURE OF REDUCED BOVINE ERYTHROCYTE SUPEROXIDE DISMUTASE AT 1.9 ANGSTROMS RESOLUTION
1SXB	;	2.0	;	CRYSTAL STRUCTURE OF REDUCED BOVINE ERYTHROCYTE SUPEROXIDE DISMUTASE AT 1.9 ANGSTROMS RESOLUTION
1SXC	;	1.9	;	CRYSTAL STRUCTURE OF REDUCED BOVINE ERYTHROCYTE SUPEROXIDE DISMUTASE AT 1.9 ANGSTROMS RESOLUTION
3SR6	;	2.1	;	Crystal Structure of Reduced Bovine Xanthine Oxidase in Complex with Arsenite
3IHQ	;	1.9	;	Crystal Structure of Reduced C10S Spx in Complex with the Alpha C-terminal Domain of RNA Polymeras
1XLQ	;	1.45	;	Crystal structure of reduced C73S putidaredoxin from Pseudomonas putida
5B8B	;	3.1	;	Crystal structure of reduced chimeric E.coli AhpC1-186-YFSKHN
2H6C	;	2.9	;	Crystal structure of reduced CprK in absence of any ligand
4EIC	;	0.84	;	Crystal structure of reduced cytochrome c6 from Synechococcus sp. PCC 7002 at ultra-high resolution
1C6R	;	1.9	;	CRYSTAL STRUCTURE OF REDUCED CYTOCHROME C6 FROM THE GREEN ALGAE SCENEDESMUS OBLIQUUS
4JX1	;	2.087	;	Crystal structure of reduced Cytochrome P450cam-putidaredoxin complex bound to camphor and 5-exo-hydroxycamphor
5H2Y	;	2.0	;	Crystal structure of reduced DapF from Corynebacterium glutamicum
3DVW	;	1.5	;	Crystal structure of reduced DsbA1 from Neisseria meningitidis
3DVX	;	2.8	;	Crystal structure of reduced DsbA3 from Neisseria meningitidis
3C7M	;	1.55	;	Crystal structure of reduced DsbL
4N45	;	1.6	;	Crystal structure of reduced form of thiolase from Clostridium acetobutylicum
4XL3	;	1.7	;	Crystal structure of reduced form of thiolase from Clostridium acetobutylicum
3CTG	;	1.5	;	Crystal structure of reduced glutaredoxin 2
7NCV	;	1.5	;	Crystal structure of reduced glutaredoxin 2 from Chlamydomonas reinhardtii
3KJY	;	1.95	;	Crystal structure of reduced HOMO SAPIENS CLIC3
4EKZ	;	2.51	;	Crystal structure of reduced hPDI (abb'xa')
2COJ	;	2.4	;	Crystal structure of reduced human cytosolic branched-chain aminotransferase complexed with gabapentin
3LGM	;	1.88	;	Crystal structure of reduced IsdI in complex with heme
4N6O	;	1.8	;	Crystal structure of reduced legumain in complex with cystatin E/M
1SBM	;	1.69	;	Crystal Structure of Reduced Mesopone cytochrome c peroxidase (R-isomer)
6VK7	;	2.12	;	Crystal Structure of reduced Methylosinus trichosporium OB3b Soluble Methane Monooxygenase Hydroxylase
5MBX	;	1.4	;	Crystal structure of reduced murine N1-acetylpolyamine oxidase in complex with N1-acetylspermine
3G9B	;	1.96	;	Crystal structure of reduced Ost6L
3UKI	;	4.15	;	Crystal structure of reduced OxyR from Porphyromonas gingivalis
6KEX	;	2.5	;	Crystal structure of reduced phosphoribulokinase from Arabidopsis thaliana
5K1G	;	1.899	;	Crystal structure of reduced Prx3 from Vibrio vulnificus
5K2J	;	1.908	;	Crystal structure of reduced Prx3 in complex with h2o2 from Vibrio vulnificus
1M6Z	;	1.35	;	Crystal structure of reduced recombinant cytochrome c4 from Pseudomonas stutzeri
8QH4	;	1.96	;	Crystal structure of reduced respiratory Complex I subunits NuoEF from Aquifex aeolicus bound to oxidized 3-acetylpyridine adenine dinucleotide
8QHK	;	1.95	;	Crystal structure of reduced respiratory Complex I subunits NuoEF from Aquifex aeolicus bound to reduced 3-acetylpyridine adenine dinucleotide
2XBQ	;	1.67	;	Crystal structure of reduced Schistosoma mansoni Thioredoxin pre- protein at 1.7 Angstrom
6VDZ	;	2.95	;	Crystal structure of reduced SfmD by soaking with sodium hydrosulfite
6VE0	;	3.15	;	Crystal structure of reduced SfmD by soaking with sodium hydrosulfite
5K0R	;	1.45	;	Crystal structure of reduced Shewanella Yellow Enzyme 4 (SYE4)
5K1U	;	1.551	;	Crystal structure of reduced Shewanella Yellow Enzyme 4 (SYE4) in complex with the hydride Meisenheimer complex of trinitrophenol
5E59	;	2.0	;	Crystal structure of reduced state of a novel disulfide oxidoreductase from Deinococcus radiodurans
6Q46	;	1.7	;	Crystal structure of reduced thioredoxin h1 from Chlamydomonas reinhardtii
1CL0	;	2.5	;	CRYSTAL STRUCTURE OF REDUCED THIOREDOXIN REDUCTASE FROM ESCHERICHIA COLI.
2YWO	;	1.9	;	Crystal structure of reduced thioredoxin-like protein from Thermus thermophilus HB8
3DHI	;	1.68	;	Crystal Structure of Reduced Toluene 4-Monoxygenase Hydroxylase Complexed with Effector Protein
4K1F	;	2.34	;	Crystal structure of reduced tryparedoxin peroxidase from leishmania major at 2.34 A resolution
4DSH	;	2.25	;	Crystal structure of reduced UDP-Galactopyranose mutase
1Z48	;	1.8	;	Crystal structure of reduced YqjM from Bacillus subtilis
1P7R	;	2.85	;	CRYSTAL STRUCTURE OF REDUCED, CO-EXPOSED COMPLEX OF CYTOCHROME P450CAM WITH (S)-(-)-NICOTINE
5YXT	;	1.88	;	Crystal structure of reducing end xylose-releasing exo-oligoxylanase
8IDP	;	1.8	;	Crystal structure of reducing-end xylose-releasing exoxylanase in GH30 from Talaromyces cellulolyticus
8IDQ	;	1.7	;	Crystal structure of reducing-end xylose-releasing exoxylanase in GH30 from Talaromyces cellulolyticus with xylose
1WU4	;	1.35	;	Crystal structure of reducing-end-xylose releasing exo-oligoxylanase
1WU5	;	2.2	;	Crystal structure of reducing-end-xylose releasing exo-oligoxylanase complexed with xylose
2DRO	;	1.7	;	Crystal structure of reducing-end-xylose releasing exo-oligoxylanase D263C mutant
2DRQ	;	2.1	;	Crystal structure of reducing-end-xylose releasing exo-oligoxylanase D263G mutant
2DRR	;	1.6	;	Crystal structure of reducing-end-xylose releasing exo-oligoxylanase D263N mutant
2DRS	;	2.1	;	Crystal structure of reducing-end-xylose releasing exo-oligoxylanase D263S mutant
1WU6	;	1.45	;	Crystal structure of reducing-end-xylose releasing exo-oligoxylanase E70A mutant complexed with xylobiose
3A3V	;	1.39	;	Crystal structure of reducing-end-xylose releasing exo-oligoxylanase Y198F mutant
4DQV	;	2.3	;	Crystal structure of reductase (R) domain of non-ribosomal peptide synthetase from Mycobacterium tuberculosis
7YIC	;	2.16	;	Crystal structure of reductase LSADH
6A48	;	2.0	;	Crystal structure of reelin N-terminal region
1S7D	;	2.17	;	Crystal structure of refined tetragonal crystal of YodA from Escherichia coli
3W9V	;	1.031	;	Crystal structure of refolded DING protein
1T8B	;	3.23	;	Crystal structure of refolded PHOU-like protein (gi 2983430) from Aquifex aeolicus
6MJ1	;	2.6	;	Crystal structure of RefZ (regulator of FtsZ) from Bacillus subtilis
3RRC	;	1.95	;	Crystal Structure of Region II from Plasmodium vivax Duffy Binding Protein
5H9V	;	2.75	;	Crystal structure of Regnase PIN domain, form I
5H9W	;	2.6	;	Crystal structure of Regnase PIN domain, form II
3ONQ	;	2.098	;	Crystal Structure of Regulator of Polyketide Synthase Expression BAD_0249 from Bifidobacterium adolescentis
6DQL	;	3.3	;	Crystal structure of Regulator of Proteinase B RopB complexed with SIP
1VI4	;	1.87	;	Crystal structure of Regulator of ribonuclease activity A protein 1
5OJX	;	2.1	;	Crystal structure of regulator protein 2 (PamR2) from the pamamycin biosynthetic gene cluster of Streptomyces alboniger
3D5L	;	2.35	;	Crystal structure of regulatory protein RecX
3BRU	;	2.3	;	Crystal structure of regulatory protein TetR from Rhodobacter sphaeroides
2DTJ	;	1.58	;	Crystal structure of regulatory subunit of aspartate kinase from Corynebacterium glutamicum
4JHB	;	2.44	;	Crystal structure of RelB double mutants: Y300F/I335F
4JGM	;	3.0	;	Crystal structure of RelB double mutants: Y300F/I335V
3BPQ	;	2.2	;	Crystal Structure of RelB-RelE antitoxin-toxin complex from Methanococcus jannaschii
4V89	;	3.7	;	Crystal Structure of Release Factor RF3 Trapped in the GTP State on a Rotated Conformation of the Ribosome (without viomycin)
4V85	;	3.2	;	Crystal Structure of Release Factor RF3 Trapped in the GTP State on a Rotated Conformation of the Ribosome.
6EWZ	;	2.24	;	Crystal structure of RelP (SAS2) from Staphylococcus aureus bound to AMPCPP and GTP in the pre-catalytic state
6EX0	;	2.78	;	Crystal structure of RelP (SAS2) from Staphylococcus aureus bound to pppGpp in the post-catalytic state
3Q85	;	1.757	;	Crystal Structure of Rem2 G-domain -GTP Analog Complex
3ID7	;	1.3	;	Crystal structure of renal dipeptidase from Streptomyces coelicolor A3(2)
3V42	;	2.0	;	Crystal structure of renal tumor suppressor protein, folliculin
6YN2	;	1.9	;	Crystal structure of Renilla reniformis luciferase variant RLuc8-W121F/E144Q in complex with a coelenteramide (the postcatalytic enzyme-product complex)
4PYV	;	2.65	;	Crystal structure of renin in complex with compound4
4GJ9	;	2.6	;	Crystal structure of renin in complex with GP055321 (compound 4)
4GJ5	;	2.4	;	Crystal structure of renin in complex with NVP-AMQ838 (compound 5)
4GJA	;	2.6	;	Crystal structure of renin in complex with NVP-AYL747 (compound 5)
4GJ6	;	2.58	;	Crystal structure of renin in complex with NVP-AYZ832 (compound 6a)
4GJB	;	2.75	;	Crystal structure of renin in complex with NVP-BBV031 (compound 6)
4GJ7	;	2.8	;	Crystal structure of renin in complex with NVP-BCA079 (compound 12a)
4GJC	;	2.4	;	Crystal structure of renin in complex with NVP-BCH965 (compound 9)
4GJD	;	2.65	;	Crystal structure of renin in complex with NVP-BGQ311 (compound 12)
4GJ8	;	2.5	;	Crystal structure of renin in complex with PKF909-724 (compound 3)
2V0Z	;	2.2	;	Crystal Structure of Renin with Inhibitor 10 (Aliskiren)
2V16	;	2.8	;	Crystal Structure of Renin with Inhibitor 3
2V11	;	3.1	;	Crystal Structure of Renin with Inhibitor 6
2V13	;	2.8	;	Crystal Structure of Renin with Inhibitor 7
2V12	;	3.2	;	Crystal Structure of Renin with Inhibitor 8
2V10	;	3.1	;	Crystal Structure of Renin with Inhibitor 9
2BKS	;	2.2	;	crystal structure of Renin-PF00074777 complex
2BKT	;	2.3	;	crystal structure of renin-pf00257567 complex
1KKE	;	2.6	;	Crystal Structure of Reovirus Attachment Protein Sigma1 Trimer
2OJ6	;	1.85	;	Crystal Structure of Reovirus T3D Attachment Protein Sigma1 head domain D345N mutant
2OJ5	;	1.75	;	Crystal Structure of Reovirus T3D Attachment Protein Sigma1 head domain wild-type at 1.75 A resolution
8H56	;	2.33	;	Crystal structure of Rep' of porcine circovirus type 2
5D50	;	2.49	;	Crystal structure of Rep-Ant complex from Salmonella-temperate phage
3EDV	;	1.951	;	Crystal Structure of Repeats 14-16 of Beta2-Spectrin
1U5P	;	2.0	;	Crystal Structure of Repeats 15 and 16 of Chicken Brain Alpha Spectrin
1U4Q	;	2.5	;	Crystal Structure of Repeats 15, 16 and 17 of Chicken Brain Alpha Spectrin
1CUN	;	2.0	;	CRYSTAL STRUCTURE OF REPEATS 16 AND 17 OF CHICKEN BRAIN ALPHA SPECTRIN
1S35	;	2.4	;	Crystal Structure of Repeats 8 and 9 of Human Erythroid Spectrin
3H15	;	2.72	;	Crystal structure of replication initiation factor MCM10-ID bound to ssDNA
1REP	;	2.6	;	CRYSTAL STRUCTURE OF REPLICATION INITIATOR PROTEIN REPE54 OF MINI-F PLASMID COMPLEXED WITH AN ITERON DNA
7F4Y	;	2.2	;	Crystal structure of replisomal dimer of DNA polymerase from bacteriophage RB69 with DNA duplexes
5D4Z	;	2.98	;	Crystal structure of Repressor from Salmonella-temperate phage
4RBR	;	1.7	;	Crystal structure of Repressor of Toxin (Rot), a central regulator of Staphylococcus aureus virulence
2H19	;	2.0	;	Crystal Structure of ResA Cys77Ala Variant
4ZK7	;	3.4	;	Crystal structure of rescued two-component self-assembling tetrahedral cage T33-31
4IT4	;	2.5	;	Crystal structure of residues 1-211 of CG17282
1RFX	;	2.002	;	Crystal Structure of resisitin
1RGX	;	1.787	;	Crystal Structure of resisitin
1RH7	;	3.106	;	Crystal Structure of Resistin-like beta
3M9S	;	4.5	;	Crystal structure of respiratory complex I from Thermus thermophilus
8QH7	;	1.85	;	Crystal structure of respiratory Complex I subunits NuoEF from Aquifex aeolicus bound to reduced 3-acetylpyridine adenine dinucleotide (without reducing agent)
4JHW	;	3.6	;	Crystal Structure of Respiratory Syncytial Virus Fusion Glycoprotein Stabilized in the Prefusion Conformation by Human Antibody D25
3LTE	;	2.0	;	CRYSTAL STRUCTURE OF RESPONSE REGULATOR (SIGNAL RECEIVER DOMAIN) FROM Bermanella marisrubri
5X5L	;	2.75	;	Crystal structure of response regulator AdeR DNA binding domain in complex with an intercistronic region
5X5J	;	1.401	;	Crystal structure of response regulator AdeR receiver domain
5XJP	;	1.597	;	Crystal structure of response regulator AdeR receiver domain with Mg
4YN8	;	1.8	;	Crystal Structure of Response Regulator ChrA in Heme-Sensing Two Component System
2ZAY	;	2.0	;	Crystal structure of response regulator from Desulfuromonas acetoxidans
3KHT	;	2.1	;	Crystal structure of response regulator from Hahella chejuensis
8IMW	;	1.6	;	Crystal structure of response regulator PmrA receiver domain
3A10	;	1.63	;	Crystal structure of response regulator protein TrrA (TM1360) from Thermotoga maritima in complex with Mg(2+)-BeF (SeMet, L89M)
3A0U	;	1.66	;	Crystal structure of response regulator protein TrrA (TM1360) from Thermotoga maritima in complex with Mg(2+)-BeF (wild type)
3HEB	;	2.4	;	Crystal Structure of Response regulator receiver domain from Rhodospirillum rubrum
3CG4	;	1.61	;	Crystal structure of response regulator receiver domain protein (CheY-like) from Methanospirillum hungatei JF-1
3CRN	;	1.58	;	Crystal structure of response regulator receiver domain protein (CheY-like) from Methanospirillum hungatei JF-1
3JTE	;	1.9	;	Crystal structure of response regulator receiver domain Protein from clostridium thermocellum
5TQJ	;	1.3	;	Crystal structure of response regulator receiver protein from Burkholderia phymatum
4XLT	;	2.3	;	Crystal structure of response regulator receiver protein from Dyadobacter fermentans DSM 18053
3KTO	;	1.98	;	Crystal structure of response regulator receiver protein from Pseudoalteromonas atlantica
3HDV	;	2.09	;	Crystal structure of response regulator receiver protein from Pseudomonas putida
2RDM	;	1.76	;	Crystal structure of response regulator receiver protein from Sinorhizobium medicae WSM419
4ZYL	;	1.8	;	Crystal structure of response regulator RPA3017 in red light signaling of R. palustris
3DHH	;	1.94	;	Crystal Structure of Resting State Toluene 4-Monoxygenase Hydroxylase Complexed with Effector Protein
4LG2	;	2.7	;	Crystal structure of Reston Ebola virus VP35 RNA binding domain bound to 12-bp dsRNA
3L2A	;	1.71	;	Crystal structure of Reston Ebola VP35 interferon inhibitory domain
3KS4	;	2.4	;	Crystal structure of Reston ebolavirus VP35 RNA binding domain
3KS8	;	2.401	;	Crystal structure of Reston ebolavirus VP35 RNA binding domain in complex with 18bp dsRNA
5DWC	;	2.5	;	Crystal structure of restriction endonuclease AgeI
3ZI5	;	3.2	;	Crystal STRUCTURE OF RESTRICTION ENDONUCLEASE BFII C-TERMINAL RECOGNITION DOMAIN IN COMPLEX WITH COGNATE DNA
1D2I	;	1.7	;	CRYSTAL STRUCTURE OF RESTRICTION ENDONUCLEASE BGLII COMPLEXED WITH DNA 16-MER
1DFM	;	1.5	;	Crystal structure of restriction endonuclease BGLII complexed with DNA 16-mer
2VLA	;	1.3	;	Crystal structure of restriction endonuclease BpuJI recognition domain in complex with cognate DNA
1SDO	;	1.85	;	Crystal Structure of Restriction Endonuclease BstYI
3HQG	;	2.6	;	Crystal structure of restriction endonuclease EcoRII catalytic C-terminal domain in complex with cognate DNA
1NA6	;	2.1	;	Crystal structure of restriction endonuclease EcoRII mutant R88A
3HQF	;	2.51	;	Crystal structure of restriction endonuclease EcoRII N-terminal effector-binding domain in complex with cognate DNA
1YNM	;	2.65	;	Crystal structure of restriction endonuclease HinP1I
1YFI	;	2.7	;	Crystal Structure of restriction endonuclease MspI in complex with its cognate DNA in P212121 space group
2DVY	;	3.0	;	Crystal structure of restriction endonucleases PabI
4OW1	;	1.9	;	Crystal Structure of Resuscitation Promoting Factor C
4Q93	;	2.1	;	Crystal structure of resveratrol bound human tyrosyl tRNA synthetase
4CKJ	;	1.65	;	Crystal structure of RET tyrosine kinase domain bound to adenosine
5DXV	;	1.55	;	Crystal structure of Rethreaded DHFR
6MKV	;	2.107	;	Crystal structure of Retinal-bound holo Q108K:K40L:T51W domain-swapped dimer of human cellular retinol binding protein 2
8PP0	;	1.9	;	Crystal structure of Retinoic Acid Receptor alpha (RXRA) in complexed with JP147
7B9O	;	2.05	;	Crystal structure of Retinoic Acid Receptor alpha (RXRA) in complexed with S169 inhibitor
7B88	;	2.38	;	Crystal structure of Retinoic Acid Receptor alpha (RXRA) in complexed with S99 inhibitor
5K38	;	2.05	;	Crystal structure of Retinoic acid receptor-related orphan receptor (ROR) gamma ligand binding domain
5K3L	;	2.75	;	Crystal structure of Retinoic acid receptor-related orphan receptor (ROR) gamma ligand binding domain complex with 444
5K3N	;	2.666	;	Crystal structure of Retinoic acid receptor-related orphan receptor (ROR) gamma ligand binding domain complex with ML209
5K6E	;	2.8	;	Crystal structure of Retinoic acid receptor-related orphan receptor (ROR) gamma ligand binding domain complex with SBI0654919
5K74	;	2.75	;	Crystal structure of Retinoic acid receptor-related orphan receptor (ROR) gamma ligand binding domain complex with SBI0655870
5K3M	;	2.894	;	Crystal structure of Retinoic acid receptor-related orphan receptor (ROR) gamma ligand binding domain complex with UUA
1FML	;	2.75	;	CRYSTAL STRUCTURE OF RETINOL DEHYDRATASE IN A COMPLEX WITH RETINOL AND PAP
1X8L	;	2.1	;	Crystal structure of retinol dehydratase in complex with all-trans-4-oxoretinol and inactive cofactor PAP
1X8J	;	2.35	;	Crystal structure of retinol dehydratase in complex with androsterone and inactive cofactor PAP
1X8K	;	2.75	;	Crystal structure of retinol dehydratase in complex with anhydroretinol and inactive cofactor PAP
4PSQ	;	2.4	;	Crystal Structure of Retinol-Binding Protein 4 (RBP4) in complex with a non-retinoid ligand
3FMZ	;	2.9	;	Crystal Structure of Retinol-Binding Protein 4 (RBP4) in complex with non-retinoid ligand
6QBA	;	1.8	;	Crystal Structure of Retinol-Binding Protein 4 (RBP4) in complex with non-retinoid ligand A1120 and engineered binding scaffold
4O9S	;	2.3	;	Crystal structure of Retinol-Binding Protein 4 (RBP4)in complex with a non-retinoid ligand
4CDL	;	2.5	;	Crystal Structure of Retro-aldolase RA110.4-6 Complexed with Inhibitor 1-(6-methoxy-2-naphthalenyl)-1,3-butanedione
7EFY	;	2.8	;	Crystal structure of retroviral protease-like domain of Ddi1 from Cryptosporidium hominis
5YQ8	;	2.25	;	Crystal structure of retroviral protease-like domain of Ddi1 from Leishmania major
5YS4	;	2.3	;	Crystal structure of retroviral protease-like domain of Ddi1 from Leishmania major
7D66	;	2.126	;	Crystal structure of retroviral protease-like domain of Ddi1 from Toxoplasma gondii
4PMI	;	3.2	;	Crystal structure of Rev and Rev-response-element RNA complex
2V0V	;	2.4	;	Crystal Structure of Rev-Erb beta
2V7C	;	2.4	;	Crystal Structure of Rev-Erb beta
3VU7	;	2.8	;	Crystal structure of REV1-REV7-REV3 ternary complex
6K07	;	2.24	;	Crystal structure of REV7(R124A) in complex with a Shieldin3 fragment
6K08	;	2.312	;	Crystal structure of REV7(R124A/A135D) in complex with a Shieldin3 fragment
6BCD	;	1.43	;	Crystal structure of Rev7-K44A/R124A/A135D in complex with Rev3-RBM2 (residues 1988-2014)
6BC8	;	1.68	;	Crystal structure of Rev7-R124A/Rev3-RBM2 (residues 1988-2014) complex
6BI7	;	2.8	;	Crystal structure of Rev7-WT/Rev3 as a monomer under high-salt conditions
8D8I	;	2.504	;	Crystal structure of Reverb alpha in complex with synthetic agonist
3CQV	;	1.9	;	Crystal structure of Reverb beta in complex with heme
8BGJ	;	1.63	;	Crystal structure of Reverse Transcriptase domain from Caloramator australicus CART-CAPP
6RCI	;	2.0	;	Crystal structure of REXO2
6RCL	;	1.97	;	Crystal structure of REXO2-D199A-AA
6RCN	;	2.25	;	Crystal structure of REXO2-D199A-dAdA
1MC3	;	2.6	;	CRYSTAL STRUCTURE OF RFFH
4IIL	;	1.3	;	Crystal Structure of RfuA (TP0298) of T. pallidum Bound to Riboflavin
5K8D	;	4.19	;	Crystal structure of rFVIIIFc
3UXG	;	1.85	;	Crystal structure of RFXANK
1M6R	;	1.54	;	Crystal structure of rGd(CGCGCG) forming hexamer Z-DNA duplex with 5'-(rG) overhang
4WPC	;	3.34	;	Crystal structure of Rgd1p F-BAR domain in complex with inositol phosphate
7VFT	;	1.45	;	Crystal structure of rGGGC(CAG)5GUCC oligo
2OJ4	;	2.3	;	Crystal structure of RGS3 RGS domain
6N9G	;	2.129	;	Crystal Structure of RGS7-Gbeta5 dimer
2ZUR	;	1.8	;	Crystal Structure of Rh(nbd)/apo-Fr
4DT5	;	1.15	;	Crystal Structure of Rhagium inquisitor Antifreeze Protein
6XNR	;	2.05	;	Crystal structure of Rhagium Mordax antifreeze protein
2Z8R	;	1.4	;	Crystal structure of rhamnogalacturonan lyase YesW at 1.40 A resolution
2Z8S	;	2.5	;	Crystal structure of rhamnogalacturonan lyase YesW complexed with digalacturonic acid
2ZUX	;	1.32	;	Crystal structure of rhamnogalacturonan lyase YesW complexed with rhamnose
3FXG	;	1.9	;	Crystal structure of rhamnonate dehydratase from Gibberella zeae complexed with Mg
2QLW	;	1.6	;	Crystal structure of rhamnose mutarotase RhaU of Rhizobium leguminosarum
2QLX	;	2.0	;	Crystal structure of rhamnose mutarotase RhaU of Rhizobium leguminosarum in complex with L-Rhamnose
4X1Z	;	1.36	;	Crystal structure of RHDVb P domain in complex with H type 2
4X1X	;	1.6	;	Crystal structure of RHDVb P domain in complex with Lewis Y
7BTA	;	2.6	;	Crystal structure of Rheb D60K mutant bound to GDP
6BSX	;	1.65	;	CRYSTAL STRUCTURE OF RHEB IN COMPLEX WITH COMPOUND 1 AT 1.65A RESOLUTION
6BT0	;	2.6	;	CRYSTAL STRUCTURE OF RHEB IN COMPLEX WITH COMPOUND NR1
7BTC	;	2.101	;	Crystal structure of Rheb Y35N mutant bound to GDP
7BTD	;	2.0	;	Crystal structure of Rheb Y35N mutant bound to GppNHp
6MJO	;	1.9	;	CRYSTAL STRUCTURE OF RHESUS MACAQUE (MACACA MULATTA) FC-GAMMA RECEPTOR III
7KCZ	;	3.15	;	CRYSTAL STRUCTURE OF RHESUS MACAQUE (MACACA MULATTA) IGG1 FC FRAGMENT- FC-GAMMA RECEPTOR III COMPLEX V158 MUTANT
6MJ3	;	3.8	;	CRYSTAL STRUCTURE OF RHESUS MACAQUE (MACACA MULATTA) IGG1 Fc Fragment-Fc-GAMMA RECEPTOR III complex
2Q3A	;	2.2	;	Crystal Structure of Rhesus Macaque CD8 Alpha-Alpha Homodimer
6IWH	;	1.95	;	Crystal structure of rhesus macaque MHC class I molecule Mamu-B*05104 complexed with C14-GGGI lipopeptide
6LT6	;	2.15	;	Crystal structure of rhesus macaque MHC class I molecule Mamu-B*05104 complexed with lysophosphatidylcholine
6IWG	;	1.8	;	Crystal structure of rhesus macaque MHC class I molecule Mamu-B*05104 complexed with N-myristoylated 4-mer lipopeptide derived from SIV nef protein
6LAH	;	1.87	;	Crystal structure of rhesus macaque MHC class I molecule Mamu-B*098 complexed with lysophosphatidylcholine
6LAM	;	1.8	;	Crystal structure of rhesus macaque MHC class I molecule Mamu-B*098 complexed with lysophosphatidylethanolamine
6LB2	;	1.69381	;	Crystal structure of rhesus macaque MHC class I molecule Mamu-B*098 complexed with mono-acyl glycerol
4ZFZ	;	1.763	;	Crystal structure of rhesus macaque MHC class I molecule Mamu-B*098 complexed with myristoylated 5-mer lipopeptide derived from SIV Nef protein
3RWC	;	2.502	;	Crystal structure of rhesus macaque MHC class I molecule Mamu-B*17-IW9
2P3K	;	1.56	;	Crystal structure of Rhesus rotavirus VP8* at 100K
2P3I	;	1.75	;	Crystal structure of Rhesus Rotavirus VP8* at 295K
3TB0	;	2.0	;	Crystal structure of Rhesus Rotavirus VP8* in complex with N-Glycolylneuraminic acid
4B3N	;	3.3	;	Crystal structure of rhesus TRIM5alpha PRY/SPRY domain
4U68	;	1.8	;	Crystal structure of Rhino chromodomain in complex with H3K9me3
3EW1	;	1.5	;	Crystal structure of rhizavidin
3EW2	;	2.3	;	Crystal structure of rhizavidin-biotin complex
8CLZ	;	1.501	;	Crystal structure of Rhizobium etli constitutive L-asparaginase ReAIV (monoclinic form R4mC-2)
8COL	;	2.0	;	Crystal structure of Rhizobium etli constitutive L-asparaginase ReAIV (orthorombic form R4oP-2)
8CLY	;	2.503	;	Crystal structure of Rhizobium etli constitutive L-asparaginase ReAIV (tetragonal form R4tP)
7OZ6	;	1.757	;	Crystal structure of Rhizobium etli inducible L-asparaginase ReAV (monoclinic form MC)
7OS6	;	1.43	;	Crystal structure of Rhizobium etli inducible L-asparaginase ReAV (monoclinic form MP1)
7OU1	;	1.65	;	Crystal structure of Rhizobium etli inducible L-asparaginase ReAV (monoclinic form MP2)
7OS5	;	1.293	;	Crystal structure of Rhizobium etli inducible L-asparaginase ReAV (orthorhombic form OP)
7OS3	;	2.177	;	Crystal structure of Rhizobium etli inducible L-asparaginase ReAV solved by S-SAD (orthorhombic form START)
8ORI	;	1.35	;	Crystal structure of Rhizobium etli L-asparaginase ReAIV (orthorhombic)
8OSW	;	1.3	;	Crystal structure of Rhizobium etli L-asparaginase ReAIV (R4mC-1)
1UH7	;	2.1	;	Crystal structure of rhizopuspepsin at pH 4.6
1UH9	;	2.0	;	Crystal structure of rhizopuspepsin at pH 7.0
1UH8	;	2.3	;	Crystal structure of rhizopuspepsin at pH 8.0
5EFX	;	2.451	;	Crystal structure of Rho GTPase regulator
3NDM	;	3.3	;	Crystal structure of Rho-Associated Protein Kinase (ROCK1) with a potent isoquinolone derivative
7JOU	;	3.318	;	CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK1) IN COMPLEX WITH A PHENYLPYRAZOLE AMIDE INHIBITOR
8GDS	;	2.71	;	CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE 2 (ROCK2) IN COMPLEX WITH 4-(4-(2-(2,3-DIHYDRO-1H- INDOL-1-YL)-2-OXOETHYL)PHENYL)-1(2H)-PHTHALAZINONE
7JOV	;	2.586	;	CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE 2 (ROCK2) IN COMPLEX WITH A PHENYLPYRAZOLE AMIDE INHIBITOR
7JNT	;	2.214	;	CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE 2 (ROCK2) IN COMPLEX WITH A POTENT AND SELECTIVE DUAL ROCK INHIBITOR
8GI3	;	1.52	;	Crystal structure of RhoA mutant L69P complexed with GDP
8GI6	;	1.4	;	Crystal structure of RhoA mutant L69R complexed with GDP
6KX3	;	1.981	;	Crystal structure of RhoA protein with covalent inhibitor DC-Rhoin
6V6U	;	1.16	;	Crystal structure of RhoA-GDP with novel Switch I conformation
6R3V	;	1.75	;	Crystal Structure of RhoA-GDP-Pi in Complex with RhoGAP
3MSX	;	1.65	;	Crystal structure of RhoA.GDP.MgF3 in complex with GAP domain of ArhGAP20
5HPY	;	2.4	;	Crystal Structure of RhoA.GDP.MgF3-in complex with human Myosin 9b RhoGAP domain
1OW3	;	1.8	;	Crystal Structure of RhoA.GDP.MgF3-in Complex with RhoGAP
1UAR	;	1.7	;	Crystal structure of Rhodanese from Thermus thermophilus HB8
1WV9	;	2.0	;	Crystal Structure of Rhodanese Homolog TT1651 from an Extremely Thermophilic Bacterium Thermus thermophilus HB8
3IWH	;	2.0	;	Crystal Structure of Rhodanese-like Domain Protein from Staphylococcus aureus
3MZZ	;	2.0	;	Crystal Structure of Rhodanese-like Domain Protein from Staphylococcus aureus
3GK5	;	2.4	;	Crystal structure of rhodanese-related protein (TVG0868615) from Thermoplasma volcanium, Northeast Structural Genomics Consortium Target TvR109A
6EX8	;	1.6	;	Crystal Structure of Rhodesain in complex with a Macrolactam Inhibitor
6EXO	;	1.9	;	Crystal Structure of Rhodesain in complex with a Macrolactam Inhibitor
6EXQ	;	2.5	;	Crystal Structure of Rhodesain in complex with a Macrolactam Inhibitor
6EEQ	;	2.60009	;	Crystal structure of Rhodiola rosea 4-hydroxyphenylacetaldehyde synthase
2QJY	;	2.4	;	Crystal structure of rhodobacter sphaeroides double mutant with stigmatellin and UQ2
4HIA	;	1.952	;	Crystal Structure of Rhodobacter Sphaeroides LOV protein
4HJ3	;	2.643	;	Crystal Structure of Rhodobacter Sphaeroides LOV protein
4HJ4	;	2.703	;	Crystal Structure of Rhodobacter Sphaeroides LOV protein
4HJ6	;	2.2	;	Crystal Structure of Rhodobacter Sphaeroides LOV protein
4HNB	;	2.34	;	Crystal Structure of Rhodobacter Sphaeroides LOV protein
4L9Y	;	2.102	;	Crystal Structure of Rhodobacter sphaeroides malyl-CoA lyase in complex with magnesium, glyoxylate, and propionyl-CoA
4L9Z	;	2.011	;	Crystal Structure of Rhodobacter sphaeroides malyl-CoA lyase in complex with magnesium, oxalate, and CoA
3FAC	;	2.5	;	Crystal structure of Rhodobacter sphaeroides protein RSP_2168. Northeast Structural Genomics target RhR83.
2Q1Z	;	2.4	;	Crystal Structure of Rhodobacter sphaeroides SigE in complex with the anti-sigma ChrR
2Z2S	;	2.7	;	Crystal Structure of Rhodobacter sphaeroides SigE in complex with the anti-sigma ChrR
1EG2	;	1.75	;	CRYSTAL STRUCTURE OF RHODOBACTER SPHEROIDES (N6 ADENOSINE) METHYLTRANSFERASE (M.RSRI)
3GPR	;	3.2	;	Crystal structure of rhodocetin
4CV7	;	1.4	;	Crystal structure of Rhodococcus equi VapB
6CO6	;	1.701	;	Crystal structure of Rhodococcus jostii RHA1 IpdAB
6CO9	;	1.602	;	Crystal structure of Rhodococcus jostii RHA1 IpdAB COCHEA-COA complex
6COJ	;	1.4	;	Crystal structure of Rhodococcus jostii RHA1 IpdAB E105A COCHEA-COA complex
4F5Z	;	1.2	;	Crystal structure of Rhodococcus rhodochrous haloalkane dehalogenase mutant (L95V, A172V).
4F60	;	1.45	;	Crystal structure of Rhodococcus rhodochrous haloalkane dehalogenase mutant (T148L, G171Q, A172V, C176F).
3A1I	;	2.32	;	Crystal structure of Rhodococcus sp. N-771 Amidase complexed with Benzamide
3A1K	;	2.17	;	Crystal structure of Rhodococcus sp. N771 Amidase
1HLQ	;	1.45	;	CRYSTAL STRUCTURE OF RHODOFERAX FERMENTANS HIGH POTENTIAL IRON-SULFUR PROTEIN REFINED TO 1.45 A
5JFN	;	1.9	;	Crystal structure of Rhodopseudomonas palustris propionaldehyde dehydrogenase with bound CoA and acylated Cys330
5JFL	;	2.3	;	Crystal structure of Rhodopseudomonas palustris propionaldehyde dehydrogenase with bound NAD+
5JFM	;	2.516	;	Crystal structure of Rhodopseudomonas palustris propionaldehyde dehydrogenase with bound propionyl-CoA
4ZWJ	;	3.302	;	Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser
5DGY	;	7.7	;	Crystal structure of rhodopsin bound to visual arrestin
5W0P	;	3.013	;	Crystal structure of rhodopsin bound to visual arrestin determined by X-ray free electron laser
5DA5	;	2.064	;	Crystal structure of Rhodospirillum rubrum Rru_A0973
6SUW	;	2.66	;	Crystal structure of Rhodospirillum rubrum Rru_A0973 E31A variant
6SV1	;	2.19	;	Crystal structure of Rhodospirillum rubrum Rru_A0973 E34A variant
5L89	;	2.59	;	Crystal structure of Rhodospirillum rubrum Rru_A0973 mutant E32A
5L8F	;	2.247	;	Crystal structure of Rhodospirillum rubrum Rru_A0973 mutant E32A, E62A, H65A.
5L8B	;	2.21	;	Crystal structure of Rhodospirillum rubrum Rru_A0973 mutant E62A
5L8G	;	2.974	;	Crystal structure of Rhodospirillum rubrum Rru_A0973 mutant H65A
4RQG	;	1.66	;	Crystal structure of Rhodostomin
7X4V	;	1.38	;	Crystal structure of Rhodostomin ARGDDP mutant
7X4S	;	1.8	;	Crystal structure of Rhodostomin ARGDMP mutant
4M4C	;	1.8	;	Crystal structure of Rhodostomin ARGDP mutant
7X4Z	;	1.48	;	Crystal structure of Rhodostomin ARGDWP mutant
3UCI	;	1.35	;	Crystal structure of Rhodostomin ARLDDL mutant
4R5R	;	0.96	;	Crystal structure of Rhodostomin KKKRT mutant
4R5U	;	1.81	;	Crystal structure of Rhodostomin R46E mutant
3QKY	;	2.15	;	Crystal structure of Rhodothermus marinus BamD
8WGK	;	1.75	;	Crystal structure of Rhodothermus marinus substrate-binding protein (Br soaking)
8WGL	;	2.3	;	Crystal structure of Rhodothermus marinus substrate-binding protein (Hg soaking)
6K1W	;	1.5	;	Crystal structure of Rhodothermus marinus substrate-binding protein at pH 5.5
6K1X	;	1.802	;	Crystal structure of Rhodothermus marinus substrate-binding protein at pH 6.0
6K1Y	;	1.9	;	Crystal structure of Rhodothermus marinus substrate-binding protein at pH 7.5
6UKA	;	2.4	;	Crystal structure of RHOG and ELMO complex
2JHU	;	1.65	;	CRYSTAL STRUCTURE OF RHOGDI E154A,E155A MUTANT
2JHV	;	2.07	;	CRYSTAL STRUCTURE OF RHOGDI E154A,E155A MUTANT
2JHW	;	2.5	;	CRYSTAL STRUCTURE OF RHOGDI E155A, E157A MUTANT
2JHX	;	1.6	;	CRYSTAL STRUCTURE OF RHOGDI E155H, E157H MUTANT
2JHY	;	1.9	;	CRYSTAL STRUCTURE OF RHOGDI E155H, E157H MUTANT
2JHZ	;	2.2	;	CRYSTAL STRUCTURE OF RHOGDI E155S, E157S MUTANT
1KMT	;	1.3	;	Crystal structure of RhoGDI Glu(154,155)Ala mutant
1QVY	;	1.6	;	Crystal structure of RhoGDI K(199,200)R double mutant
2JHS	;	1.95	;	CRYSTAL STRUCTURE OF RHOGDI K135H,K138H,K141H MUTANT
2JHT	;	1.88	;	CRYSTAL STRUCTURE OF RHOGDI K135T,K138T,K141T MUTANT
2JI0	;	2.1	;	CRYSTAL STRUCTURE OF RHOGDI K138Y, K141Y MUTANT
2BXW	;	2.4	;	CRYSTAL STRUCTURE OF RHOGDI Lys(135,138,141)Tyr MUTANT
2DX1	;	2.36	;	Crystal structure of RhoGEF protein Asef
2I35	;	3.8	;	Crystal structure of rhombohedral crystal form of ground-state rhodopsin
4QNZ	;	2.55	;	Crystal structure of rhomboid intramembrane protease GlpG F146I in complex with peptide derived inhibitor Ac-FATA-cmk
4QO0	;	2.9	;	Crystal structure of rhomboid intramembrane protease GlpG in complex with peptide derived inhibitor Ac-FATA-cmk
4QO2	;	2.1	;	Crystal structure of rhomboid intramembrane protease GlpG in complex with peptide derived inhibitor Ac-IATA-cmk
4JV4	;	2.952	;	Crystal Structure of RIalpha(91-379) bound to HE33, a N6 di-propyl substituted cAMP analog
6E31	;	2.4	;	Crystal structure of RIAM in an autoinhibited configuration.
4KVG	;	1.65	;	Crystal structure of RIAM RA-PH domains in complex with GTP bound Rap1
4W8P	;	1.5	;	Crystal structure of RIAM TBS1 in complex with talin R7R8 domains
5XUX	;	2.27	;	Crystal structure of Rib7 from Methanosarcina mazei
5XV2	;	2.0	;	Crystal structure of Rib7 mutant D33A from Methanosarcina mazei
5XV0	;	1.95	;	Crystal structure of Rib7 mutant D33N from Methanosarcina mazei
5XV5	;	2.5	;	Crystal structure of Rib7 mutant S88E from Methanosarcina mazei
6MNZ	;	2.66	;	Crystal structure of RibBX, a two domain 3,4-dihydroxy-2-butanone 4-phosphate synthase from A. baumannii.
6DKY	;	1.239	;	Crystal structure of ribifolin, an orbitide from Jatropha ribifolia
4JIS	;	1.772	;	Crystal structure of ribitol 5-phosphate cytidylyltransferase (TarI) from Bacillus subtilis
1T6Z	;	2.4	;	Crystal structure of riboflavin bound TM379
1NB9	;	1.7	;	Crystal Structure of Riboflavin Kinase
1P4M	;	1.8	;	CRYSTAL STRUCTURE OF RIBOFLAVIN KINASE
3CTA	;	2.2	;	Crystal structure of riboflavin kinase from Thermoplasma acidophilum
3BNW	;	2.4	;	Crystal structure of riboflavin kinase from Trypanosoma brucei
1Q9S	;	2.42	;	Crystal structure of riboflavin kinase with ternary product complex
5W48	;	1.9	;	Crystal Structure of Riboflavin Lyase (RcaE)
5W4Y	;	1.9	;	Crystal Structure of Riboflavin Lyase (RcaE) with cofactor FMN
5W4Z	;	1.75	;	Crystal Structure of Riboflavin Lyase (RcaE) with modified FMN and substrate Riboflavin
1I8D	;	2.0	;	CRYSTAL STRUCTURE OF RIBOFLAVIN SYNTHASE
1VM7	;	2.15	;	Crystal structure of Ribokinase (TM0960) from Thermotoga maritima at 2.15 A resolution
6CW5	;	1.8	;	Crystal structure of Ribokinase from Cryptococcus neoformans var. grubii serotype A
6XK2	;	2.5	;	Crystal structure of Ribokinase from Cryptococcus neoformans var. grubii serotype A in complex with ADP
3IKH	;	1.88	;	Crystal structure of Ribokinase in Complex with ATP and glycerol in the active site from Klebsiella pneumoniae
3I3Y	;	2.15	;	Crystal structure of Ribokinase in Complex with D-Ribose from Klebsiella pneumoniae
1WDY	;	1.8	;	Crystal structure of ribonuclease
1JVU	;	1.78	;	CRYSTAL STRUCTURE OF RIBONUCLEASE A (COMPLEXED FORM)
1JVT	;	2.05	;	CRYSTAL STRUCTURE OF RIBONUCLEASE A (LIGAND-FREE FORM)
1JVV	;	2.2	;	CRYSTAL STRUCTURE OF RIBONUCLEASE A (RETRO-SOAKED FORM)
1EOW	;	2.0	;	CRYSTAL STRUCTURE OF RIBONUCLEASE A COMPLEXED WITH URIDYLYL(2',5')GUANOSINE (NON-PRODUCTIVE BINDING)
1EOS	;	2.0	;	CRYSTAL STRUCTURE OF RIBONUCLEASE A COMPLEXED WITH URIDYLYL(2',5')GUANOSINE (PRODUCTIVE BINDING)
3EV5	;	1.68	;	Crystal Structure of Ribonuclease A in 1M Trimethylamine N-Oxide
3EUZ	;	1.84	;	Crystal Structure of Ribonuclease A in 50% Dimethylformamide
3EUY	;	1.95	;	Crystal Structure of Ribonuclease A in 50% Dioxane
3EV6	;	1.76	;	Crystal Structure of Ribonuclease A in 50% R,S,R-Bisfuranol
3EV4	;	1.93	;	Crystal Structure of Ribonuclease A in 50% Trifluoroethanol
3EV0	;	1.76	;	Crystal Structure of Ribonuclease A in 70% Dimethyl Sulfoxide
3EV1	;	2.0	;	Crystal Structure of Ribonuclease A in 70% Hexanediol
3EV2	;	2.02	;	Crystal Structure of Ribonuclease A in 70% Isopropanol
3EV3	;	1.68	;	Crystal Structure of Ribonuclease A in 70% t-Butanol
4J5Z	;	1.802	;	Crystal structure of Ribonuclease A in aqueous solution: One of twelve in MSCS set
1AFK	;	1.7	;	CRYSTAL STRUCTURE OF RIBONUCLEASE A IN COMPLEX WITH 5'-DIPHOSPHOADENOSINE-3'-PHOSPHATE
1QHC	;	1.7	;	CRYSTAL STRUCTURE OF RIBONUCLEASE A IN COMPLEX WITH 5'-PHOSPHO-2'-DEOXYURIDINE-3'-PYROPHOSPHATE ADENOSINE-3'-PHOSPHATE
4G8V	;	1.7	;	Crystal structure of Ribonuclease A in complex with 5a
4G8Y	;	1.8	;	Crystal structure of Ribonuclease A in complex with 5b
4G90	;	1.9	;	Crystal structure of Ribonuclease A in complex with 5e
4J60	;	1.69	;	Crystal structure of Ribonuclease A soaked in 25% Cyclopentanol: One of twelve in MSCS set
4J66	;	2.039	;	Crystal structure of Ribonuclease A soaked in 25% Dimethyl sulfoxide: One of twelve in MSCS set
4J6A	;	2.04	;	Crystal structure of Ribonuclease A soaked in 40% 2,2,2-Trifluoroethanol: One of twelve in MSCS set
4J62	;	2.039	;	Crystal structure of Ribonuclease A soaked in 40% Cyclohexanol: One of twelve in MSCS set
4J63	;	2.039	;	Crystal structure of Ribonuclease A soaked in 40% Cyclohexanone: One of twelve in MSCS set
4J61	;	1.69	;	Crystal structure of Ribonuclease A soaked in 40% Cyclopentanone: One of twelve in MSCS set
4J65	;	1.958	;	Crystal structure of Ribonuclease A soaked in 40% Dimethylformamide: One of twelve in MSCS set
4J64	;	1.781	;	Crystal structure of Ribonuclease A soaked in 40% Dioxane: One of twelve in MSCS set
4J68	;	1.779	;	Crystal structure of Ribonuclease A soaked in 40% Isopropanol: One of twelve in MSCS set
4J67	;	1.86	;	Crystal structure of Ribonuclease A soaked in 50% 1,6-Hexanediol: One of twelve in MSCS set
4J69	;	1.892	;	Crystal structure of Ribonuclease A soaked in 50% S,R,S-bisfuranol: One of twelve in MSCS set
6YO1	;	1.9	;	Crystal structure of ribonuclease A solved by vanadium SAD phasing
3MWQ	;	1.68	;	Crystal structure of ribonuclease A tandem enzymes and their interaction with the cytosolic ribonuclease inhibitor
3MWR	;	1.85	;	Crystal structure of ribonuclease A tandem enzymes and their interaction with the cytosolic ribonuclease inhibitor
3MX8	;	2.1	;	Crystal structure of ribonuclease A tandem enzymes and their interaction with the cytosolic ribonuclease inhibitor
3QL1	;	1.29	;	Crystal Structure of Ribonuclease A Variant A4C/D83E/V118C
3QL2	;	1.49	;	Crystal Structure of Ribonuclease A Variant A4C/D83E/V118C
1RIL	;	2.8	;	CRYSTAL STRUCTURE OF RIBONUCLEASE H FROM THERMUS THERMOPHILUS HB8 REFINED AT 2.8 ANGSTROMS RESOLUTION
2ETJ	;	1.74	;	Crystal structure of Ribonuclease HII (EC 3.1.26.4) (RNase HII) (tm0915) from THERMOTOGA MARITIMA at 1.74 A resolution
2EA1	;	1.8	;	Crystal structure of Ribonuclease I from Escherichia coli COMPLEXED WITH GUANYLYL-2(PRIME),5(PRIME)-GUANOSINE
2R7F	;	2.7	;	Crystal structure of ribonuclease II family protein from Deinococcus radiodurans, hexagonal crystal form. NorthEast Structural Genomics target DrR63
2R7D	;	1.8	;	Crystal structure of ribonuclease II family protein from Deinococcus radiodurans, triclinic crystal form. NorthEast Structural Genomics target DrR63
1O0W	;	2.0	;	Crystal structure of Ribonuclease III (TM1102) from Thermotoga maritima at 2.0 A resolution
2CX6	;	2.43	;	Crystal structure of ribonuclease inhibitor Barstar
5F4C	;	1.4	;	Crystal Structure of Ribonuclease Inhibitor Barstar from Salmonella Typhimurium
1UCD	;	1.3	;	Crystal structure of Ribonuclease MC1 from bitter gourd seeds complexed with 5'-UMP
1UCG	;	1.65	;	Crystal structure of Ribonuclease MC1 N71T mutant
1RDS	;	1.8	;	CRYSTAL STRUCTURE OF RIBONUCLEASE MS (AS RIBONUCLEASE T1 HOMOLOGUE) COMPLEXED WITH A GUANYLYL-3',5'-CYTIDINE ANALOGUE
1ZGX	;	1.13	;	Crystal structure of ribonuclease mutant
6MAX	;	1.42	;	Crystal structure of Ribonuclease P protein from Thermotoga maritima in complex with purpurin
1X0T	;	1.6	;	Crystal structure of ribonuclease P protein Ph1601p from Pyrococcus horikoshii OT3
1PY3	;	1.8	;	Crystal structure of Ribonuclease Sa2
1PYL	;	1.507	;	Crystal structure of Ribonuclease Sa2
3D4A	;	2.2	;	Crystal structure of ribonuclease Sa2 with 3'-GMP obtained by ligand diffusion
3D5I	;	2.2	;	Crystal structure of ribonuclease Sa2 with exo-2',3'-cyclophosphorotioate
3DGY	;	1.8	;	Crystal structure of ribonuclease Sa2 with guanosine-2'-cyclophosphate
3DH2	;	2.25	;	Crystal structure of ribonuclease Sa2 with guanosine-3'-cyclophosphate prepared by cocrystallization
6RNT	;	1.8	;	CRYSTAL STRUCTURE OF RIBONUCLEASE T1 COMPLEXED WITH ADENOSINE 2'-MONOPHOSPHATE AT 1.8-ANGSTROMS RESOLUTION
4BMQ	;	2.2	;	Crystal Structure of Ribonucleotide Reductase apo-NrdF from Bacillus cereus (space group C2)
4BMR	;	2.0	;	Crystal Structure of Ribonucleotide Reductase apo-NrdF from Bacillus cereus (space group P21)
4BMT	;	2.1	;	Crystal Structure of Ribonucleotide Reductase di-iron NrdF from Bacillus cereus
4BMU	;	1.9	;	Crystal Structure of Ribonucleotide Reductase di-manganese(II) NrdF from Bacillus cereus
6TQV	;	1.35001	;	Crystal structure of ribonucleotide reductase NrdF from Bacillus anthracis aerobically soaked with Fe(II) and Mn(II) ions
6QO7	;	1.628	;	Crystal structure of ribonucleotide reductase NrdF from Bacillus anthracis aerobically soaked with ferrous ions (photo-reduced)
6TQW	;	1.55	;	Crystal structure of ribonucleotide reductase NrdF from Bacillus anthracis anaerobically soaked with Fe(II) and Mn(II) ions
6QO8	;	1.31922	;	Crystal structure of ribonucleotide reductase NrdF from Bacillus anthracis anaerobically soaked with ferrous ions
6QO9	;	1.299	;	Crystal structure of ribonucleotide reductase NrdF from Bacillus anthracis soaked with manganese ions
6QOB	;	1.457	;	Crystal structure of ribonucleotide reductase NrdF from Bacillus anthracis with partially oxidised di-iron metallocofactor
6TQZ	;	2.09933	;	Crystal structure of ribonucleotide reductase NrdF L61G variant from Bacillus anthracis aerobically soaked with Fe(II) and Mn(II) ions
6TQY	;	1.77	;	Crystal structure of ribonucleotide reductase NrdF L61G variant from Bacillus anthracis anaerobically soaked with Fe(II) and Mn(II) ions
6L3R	;	2.0	;	Crystal structure of Ribonucleotide reductase R1 subunit, RRM1 in complex with 4-bromo-N-((1S,2R)-2-(naphthalen-1-yl)-1-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)propyl)benzenesulfonamide
6L7L	;	2.171	;	Crystal structure of Ribonucleotide reductase R1 subunit, RRM1 in complex with 5-chloro-2-(N-((1S,2R)-2-(2,3-dihydro-1H-inden-4-yl)-1-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)propyl)sulfamoyl)benzamide
6LKM	;	2.55	;	Crystal structure of Ribonucleotide reductase R1 subunit, RRM1 in complex with 5-chloro-N-((1S,2R)-2-(6-fluoro-2,3-dimethylphenyl)-1-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)propyl)-4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-sulfonamide
6Y2N	;	2.4	;	Crystal structure of ribonucleotide reductase R2 subunit solved by serial synchrotron crystallography
5UF2	;	1.4	;	Crystal Structure of ribose 5 phosphate isomerase A from Neisseria gonorrhoeae
4GMK	;	1.72	;	Crystal Structure of Ribose 5-Phosphate Isomerase from the Probiotic Bacterium Lactobacillus salivarius UCC118
4RY0	;	1.4	;	Crystal structure of ribose transporter solute binding protein RHE_PF00037 from Rhizobium etli CFN 42, TARGET EFI-511357, in complex with D-ribose
5YFJ	;	2.2	;	Crystal structure of ribose-1,5-bisphosphate isomerase from Pyrococcus horikoshii OT3 in complex with ribulose-1,5-bisphosphate
5YFU	;	2.35	;	Crystal structure of ribose-1,5-bisphosphate isomerase from Pyrococcus horikoshii OT3 in complex with ribulose-1,5-bisphosphate and AMP
5YG5	;	2.75	;	Crystal structure of ribose-1,5-bisphosphate isomerase from Pyrococcus horikoshii OT3 in complex with ribulose-1,5-bisphosphate and GMP
5YG8	;	2.8	;	Crystal structure of ribose-1,5-bisphosphate isomerase from Pyrococcus horikoshii OT3 in complex with ribulose-1,5-bisphosphate, AMP and GMP
3A11	;	2.5	;	Crystal structure of ribose-1,5-bisphosphate isomerase from Thermococcus kodakaraensis KOD1
3A9C	;	2.6	;	Crystal structure of ribose-1,5-bisphosphate isomerase from Thermococcus kodakaraensis KOD1 in complex with ribulose-1,5-bisphosphate
3VM6	;	2.85	;	Crystal structure of ribose-1,5-bisphosphate isomerase from Thermococcus kodakarensis KOD1 in complex with alpha-D-ribose-1,5-bisphosphate
5YFS	;	2.3	;	Crystal structure of ribose-1,5-bisphosphate isomerase mutant C135S from Pyrococcus horikoshii OT3 in complex with ribose-1,5-bisphosphate
5YFV	;	2.75	;	Crystal structure of ribose-1,5-bisphosphate isomerase mutant C135S from Pyrococcus horikoshii OT3 in complex with ribose-1,5-bisphosphate and AMP
5YG6	;	2.35	;	Crystal structure of ribose-1,5-bisphosphate isomerase mutant C135S from Pyrococcus horikoshii OT3 in complex with ribose-1,5-bisphosphate and GMP
5YG9	;	2.8	;	Crystal structure of ribose-1,5-bisphosphate isomerase mutant C135S from Pyrococcus horikoshii OT3 in complex with ribose-1,5-bisphosphate, AMP and GMP
5YFT	;	2.21	;	Crystal structure of ribose-1,5-bisphosphate isomerase mutant D204N from Pyrococcus horikoshii OT3 in complex with ribose-1,5-bisphosphate
5YFW	;	2.35	;	Crystal structure of ribose-1,5-bisphosphate isomerase mutant D204N from Pyrococcus horikoshii OT3 in complex with ribose-1,5-bisphosphate and AMP
5YFX	;	2.7	;	Crystal structure of ribose-1,5-bisphosphate isomerase mutant D204N from Pyrococcus horikoshii OT3 in complex with ribose-1,5-bisphosphate and AMP
5YG7	;	2.5	;	Crystal structure of ribose-1,5-bisphosphate isomerase mutant D204N from Pyrococcus horikoshii OT3 in complex with ribose-1,5-bisphosphate and GMP
5YGA	;	2.45	;	Crystal structure of ribose-1,5-bisphosphate isomerase mutant D204N from Pyrococcus horikoshii OT3 in complex with ribose-1,5-bisphosphate, AMP and GMP
3KWM	;	2.32	;	Crystal structure of ribose-5-isomerase A
4IO1	;	1.65	;	Crystal structure of ribose-5-isomerase A from Francisella Tularensis
3HHE	;	2.3	;	Crystal structure of ribose-5-phosphate isomerase A from Bartonella henselae
3U7J	;	2.1	;	Crystal structure of Ribose-5-phosphate isomerase A from Burkholderia thailandensis
3UW1	;	1.71	;	Crystal structure of ribose-5-phosphate isomerase a from burkholderia thailandensis with ribose-5-phosphate
6J1K	;	2.824	;	Crystal structure of ribose-5-phosphate isomerase A from Ochrobactrum sp. CSL1
4X84	;	1.25	;	Crystal structure of Ribose-5-phosphate isomerase A from Pseudomonas aeruginosa
3L7O	;	1.7	;	Crystal structure of Ribose-5-phosphate isomerase A from streptococcus mutans UA159
6MU0	;	1.1	;	Crystal Structure of Ribose-5-phosphate Isomerase B from Mycoplasma genitalium with bound Ribulose-5-phosphate
3SGW	;	1.7	;	Crystal structure of ribose-5-phosphate isomerase B RpiB from Coccidioides immitis semi-covalently bound to malonic acid
3S5P	;	2.3	;	Crystal structure of ribose-5-phosphate isomerase B RpiB from Giardia lamblia
5IFZ	;	1.6	;	Crystal Structure of Ribose-5-phosphate Isomerase from Brucella melitensis 16M
5JLA	;	1.45	;	Crystal Structure of Ribose-5-phosphate Isomerase from Brucella melitensis 16M
6EEP	;	1.85	;	Crystal Structure of Ribose-5-phosphate Isomerase from Legionella pneumophila
6MC0	;	2.0	;	Crystal Structure of Ribose-5-phosphate Isomerase from Legionella pneumophila with Bound Substrate Ribose-5-Phosphate and Product Ribulose-5-Phosphate
3ONO	;	1.75	;	Crystal Structure of Ribose-5-phosphate Isomerase LacAB_rpiB from Vibrio parahaemolyticus
6NFE	;	1.75	;	Crystal Structure of Ribose-phosphate Pyrophosphokinase from Legionella pneumophila with bound AMP, ADP, and Ribose-5-Phosphate
3ZZ0	;	2.8	;	Crystal structure of ribosomal elongation factor (EF)-G from Staphylococcus aureus with a fusidic acid hyper-sensitivity mutation M16I
7Y17	;	3.39	;	Crystal structure of ribosomal ITS2 pre-rRNA processing complex from Cyberlindnera jadinii
7Y18	;	3.69	;	Crystal structure of ribosomal ITS2 pre-rRNA processing complex from Saccharomyces cerevisiae
4Y4R	;	3.3	;	Crystal structure of ribosomal oxygenase NO66 dimer mutant
4Y3O	;	2.2	;	Crystal structure of Ribosomal oxygenase NO66 in complex with substrate Rpl8 peptide and Ni(II) and cofactor N-oxalyglycine
3QOY	;	2.1	;	Crystal structure of ribosomal protein L1 from Aquifex aeolicus
1CJS	;	2.3	;	CRYSTAL STRUCTURE OF RIBOSOMAL PROTEIN L1 FROM METHANOCOCCUS JANNASCHII
3GRZ	;	2.0	;	CRYSTAL STRUCTURE OF ribosomal protein L11 methylase FROM Lactobacillus delbrueckii subsp. bulgaricus
2ZBQ	;	2.4	;	Crystal structure of ribosomal protein L11 methyltransferase from Thermus thermophilus in complex with S-adenosyl-L-homocysteine
2ZBP	;	2.3	;	Crystal structure of ribosomal protein L11 methyltransferase from Thermus thermophilus in complex with S-adenosyl-L-methionine
2ZBR	;	1.9	;	Crystal structure of ribosomal protein L11 methyltransferase from Thermus thermophilus in complex with S-adenosyl-ornithine
1DD4	;	2.4	;	Crystal structure of ribosomal protein l12 from thermotoga maritim
1DD3	;	2.0	;	CRYSTAL STRUCTURE OF RIBOSOMAL PROTEIN L12 FROM THERMOTOGA MARITIMA
1J3A	;	1.6	;	Crystal structure of ribosomal protein L13 from Pyrococcus horikoshii
1V8Q	;	2.8	;	Crystal structure of ribosomal protein L27 from Thermus thermophilus HB8
1BXY	;	1.9	;	CRYSTAL STRUCTURE OF RIBOSOMAL PROTEIN L30 FROM THERMUS THERMOPHILUS AT 1.9 A RESOLUTION: CONFORMATIONAL FLEXIBILITY OF THE MOLECULE.
1DMG	;	1.7	;	CRYSTAL STRUCTURE OF RIBOSOMAL PROTEIN L4
1VI5	;	2.65	;	Crystal structure of ribosomal protein S2P
1VI6	;	1.95	;	Crystal structure of ribosomal protein S2P
1FEU	;	2.3	;	CRYSTAL STRUCTURE OF RIBOSOMAL PROTEIN TL5, ONE OF THE CTC FAMILY PROTEINS, COMPLEXED WITH A FRAGMENT OF 5S RRNA.
3U4M	;	2.0	;	Crystal structure of ribosomal protein tthl1 in complex with 80nt 23s rna from thermus thermophilus
4JXJ	;	2.0	;	Crystal Structure of Ribosomal RNA small subunit methyltransferase A from Rickettsia bellii Determined by Iodide SAD Phasing
4J3G	;	1.75	;	Crystal structure of Ribosomal-protein-alanine N-acetyltransferase from Brucella melitensis
7N1L	;	2.3	;	Crystal Structure of Ribosomal-protein-alanine N-acetyltransferase from Brucella melitensis biovar Abortus 2308
4JWP	;	2.0	;	Crystal structure of Ribosomal-protein-alanine N-acetyltransferase from Brucella melitensis in complex with Acetyl CoA
5YMA	;	3.295	;	Crystal structure of ribosome assembly factor Efg1
8BXA	;	2.22	;	Crystal structure of ribosome binding factor A (RbfA) from S. aureus
4KMK	;	1.65	;	Crystal structure of Ribosome Inactivating protein from Momordica balsamina at 1.65 A resolution
5GM7	;	1.78	;	Crystal structure of Ribosome inactivating protein from Momordica balsamina at 1.78 Angstrom resolution
4JTP	;	1.85	;	Crystal structure of Ribosome inactivating protein from Momordica balsamina complexed with Ascorbic acid at 1.85 Angstrom resolution
4JTB	;	1.71	;	Crystal structure of Ribosome inactivating protein from Momordica balsamina complexed with phosphate ion at 1.71 Angstrom resolution
4KL4	;	1.9	;	Crystal structure of Ribosome inactivating protein from Momordica balsamina complexed with Polyethylene glycol at 1.90 Angstrom resolution
3V2K	;	2.07	;	Crystal structure of ribosome inactivating protein from momordica balsamina complexed with the product of RNA substrate adenosine triphosphate at 2.0 A resolution
4L66	;	1.7	;	Crystal structure of Ribosome inactivating protein from Momordica balsamina with highly ordered water structure in the substrate binding site
5ILX	;	1.7	;	Crystal structure of Ribosome inactivating protein from Momordica balsamina with Uracil at 1.70 Angstrom resolution
1WQF	;	2.65	;	Crystal structure of Ribosome recycling factor from Mycobacterium Tuberculosis
1WQG	;	2.15	;	Crystal structure of ribosome recycling factor from Mycobacterium Tuberculosis
1WQH	;	2.9	;	Crystal structure of ribosome recycling factor from Mycobacterium tuberculosis
1IS1	;	2.2	;	Crystal structure of ribosome recycling factor from Vibrio parahaemolyticus
4KB2	;	2.3	;	Crystal structure of ribosome recycling factor mutant R109A from Mycobacterium tuberculosis
4KB4	;	2.25	;	Crystal structure of ribosome recycling factor mutant R31A from Mycobacterium tuberculosis
4KAW	;	2.5	;	Crystal structure of ribosome recycling factor mutant R39G from Mycobacterium tuberculosis
4V50	;	3.22	;	Crystal Structure of Ribosome with messenger RNA and the Anticodon stem-loop of P-site tRNA.
3KA5	;	1.8	;	Crystal structure of Ribosome-associated protein Y (PSrp-1) from Clostridium acetobutylicum. Northeast Structural Genomics Consortium target id CaR123A
2DYJ	;	1.84	;	Crystal structure of ribosome-binding factor A from Thermus thermophilus HB8
1T5J	;	2.7	;	Crystal structure of ribosylglycohydrolase MJ1187 from Methanococcus jannaschii
1JBS	;	1.97	;	Crystal structure of ribotoxin restrictocin and a 29-mer SRD RNA analog
1JBT	;	2.7	;	CRYSTAL STRUCTURE OF RIBOTOXIN RESTRICTOCIN COMPLEXED WITH A 29-MER SARCIN/RICIN DOMAIN RNA ANALOG
3CU2	;	1.91	;	Crystal structure of ribulose-5-phosphate 3-epimerase (YP_718263.1) from Haemophilus somnus 129PT at 1.91 A resolution
7U5Y	;	2.55	;	Crystal structure of ribulose-phosphate 3-epimerase from Pseudomonas aeruginosa
7SBJ	;	1.85	;	Crystal Structure of Ribulose-phosphate 3-epimerase from Stenotrophomonas maltophilia K279a
1UAS	;	1.5	;	Crystal structure of rice alpha-galactosidase
7XPJ	;	2.301	;	crystal structure of rice ASI1 BAH domain
7XPK	;	1.8	;	crystal structure of rice ASI1 BAH domain in complex with a rice SUVH6 peptide
6BRQ	;	2.99	;	Crystal structure of rice ASK1-D3 ubiquitin ligase complex crystal form 3
3AHT	;	2.8	;	Crystal structure of rice BGlu1 E176Q mutant in complex with laminaribiose
4QLK	;	1.83	;	Crystal structure of rice BGlu1 E176Q/Y341A mutant complexed with cellotetraose
4QLL	;	1.85	;	Crystal structure of rice BGlu1 E176Q/Y341A/Q187A mutant complexed with cellotetraose
3SCP	;	2.1	;	Crystal Structure of Rice BGlu1 E386A Mutant
3SCQ	;	2.1	;	Crystal Structure of Rice BGlu1 E386A Mutant Complexed with alpha-Glucosyl Fluoride
3SCN	;	2.2	;	Crystal Structure of Rice BGlu1 E386G Mutant
3SCO	;	1.95	;	Crystal Structure of Rice BGlu1 E386G Mutant Complexed with alpha-Glucosyl Fluoride
3SCU	;	1.58	;	Crystal Structure of Rice BGlu1 E386G Mutant Complexed with Cellopentaose
3SCT	;	1.6	;	Crystal Structure of Rice BGlu1 E386G Mutant Complexed with Cellotetraose
3SCV	;	2.11	;	Crystal Structure of Rice BGlu1 E386G/S334A Mutant Complexed with Cellotetraose
3SCW	;	1.9	;	Crystal Structure of Rice BGlu1 E386G/Y341A Mutant Complexed with Cellotetraose
4QLJ	;	1.95	;	Crystal structure of rice BGlu1 E386G/Y341A/Q187A mutant complexed with cellotetraose
3SCR	;	1.8	;	Crystal Structure of Rice BGlu1 E386S Mutant
3SCS	;	1.85	;	Crystal Structure of Rice BGlu1 E386S Mutant Complexed with alpha-Glucosyl Fluoride
6AP8	;	1.27	;	Crystal Structure of rice D14 bound to 2-(2-methyl-3-nitroanilino)benzoic acid
6LCQ	;	1.62	;	Crystal structure of rice defensin OsAFP1
5X70	;	3.3	;	Crystal structure of Rice Dwarf Virus P5 in complex with a ssRNA oligomer
5X6Z	;	2.1	;	Crystal structure of Rice Dwarf Virus P5 in complex with GTP and GDP
5X6Y	;	2.1	;	Crystal structure of Rice Dwarf Virus P5 in complex with S-adenosylmethionine
5X71	;	2.568	;	Crystal structure of Rice Dwarf Virus P5 in space group P212121
4IH9	;	1.55	;	Crystal structure of rice DWARF14 (D14)
4IHA	;	1.55	;	Crystal structure of rice DWARF14 (D14) in complex with a GR24 hydrolysis intermediate
5DJ5	;	2.4	;	Crystal structure of rice DWARF14 in complex with synthetic strigolactone GR24
3ED1	;	1.9	;	Crystal Structure of Rice GID1 complexed with GA3
3EBL	;	1.9	;	Crystal Structure of Rice GID1 complexed with GA4
3VUE	;	2.7	;	Crystal Structure of Rice Granule bound Starch Synthase I Catalytic Domain
3VUF	;	3.0	;	Crystal Structure of Rice Granule bound Starch Synthase I Catalytic Domain in Complex with ADP
7C9P	;	2.0	;	Crystal structure of rice histone-fold dimer GHD8/OsNF-YC2
7DVG	;	2.8	;	Crystal structure of rice immune receptor RGA5-HMA5 mutant.
7Y77	;	2.6	;	Crystal structure of rice NAL1
7BZM	;	2.3	;	Crystal structure of rice Os3BGlu7 with glucoimidazole
7XGT	;	1.7	;	Crystal structure of rice OsRNase ZS1
3HKM	;	1.9845	;	Crystal Structure of rice(Oryza sativa) Rrp46
5V5F	;	2.945	;	Crystal structure of RICE1 (PNT2)
5F9I	;	3.0	;	Crystal Structure of rich-AT DNA 20mer
7XZW	;	1.45	;	Crystal structure of Ricin A chain bound with (2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)-D-phenylalanine
7XZT	;	1.3	;	Crystal structure of Ricin A chain bound with (2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)-D-tyrosine
7XZU	;	1.6	;	Crystal structure of Ricin A chain bound with (2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)-L-phenylalanine
7XZS	;	1.5	;	Crystal structure of Ricin A chain bound with (2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)-L-tyrosine
7Y08	;	1.25	;	Crystal structure of Ricin A chain bound with (2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)glycyl-L-phenylalanine
7Y05	;	1.6	;	Crystal structure of Ricin A chain bound with (R)-2-(2-amino-4-oxo-3,4-dihydropteridine-7-carboxamido)-2-phenylacetic acid
7Y03	;	1.35	;	Crystal structure of Ricin A chain bound with (S)-2-(2-amino-4-oxo-3,4-dihydropteridine-7-carboxamido)-2-phenylacetic acid
7Y02	;	1.6	;	Crystal structure of Ricin A chain bound with (S)-2-(2-amino-4-oxo-3,4-dihydropteridine-7-carboxamido)-3-(4-fluorophenyl)propanoic acid
7Y06	;	1.35	;	Crystal structure of Ricin A chain bound with (S)-2-(2-amino-4-oxo-3,4-dihydropteridine-7-carboxamido)-4-phenylbutanoic acid
7Y07	;	1.25	;	Crystal structure of Ricin A chain bound with (S)-2-amino-N-(1-hydroxy-3-phenylpropan-2-yl)-4-oxo-3,4-dihydropteridine-7-carboxamide
7Y4M	;	1.45	;	Crystal structure of Ricin A chain bound with N2-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)glycyl-L-phenylalanyl-N6-((benzyloxy)carbonyl)-L-lysine
7Y4K	;	1.7	;	Crystal structure of Ricin A chain bound with N2-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)glycyl-L-phenylalanyl-N6-((benzyloxy)carbonyl)-L-ornitine
8I7P	;	1.6	;	Crystal structure of Ricin A chain bound with N2-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)glycyl-L-tyrosine
4Q2V	;	2.198	;	Crystal Structure of Ricin A chain complexed with Baicalin inhibitor
7MLP	;	1.78	;	Crystal structure of ricin A chain in complex with 5-(2,6-dimethylphenyl)thiophene-2-carboxylic acid
7MLT	;	1.8	;	Crystal structure of ricin A chain in complex with 5-(2-ethylphenyl)thiophene-2-carboxylic acid
7MLN	;	1.52	;	Crystal structure of ricin A chain in complex with 5-(o-tolyl)thiophene-2-carboxylic acid
7MLO	;	1.65	;	Crystal structure of ricin A chain in complex with 5-mesitylthiophene-2-carboxylic acid
6URW	;	2.4	;	Crystal structure of ricin A chain in complex with inhibitor 4-(2-thienylmethyl)benzoic acid
6URX	;	1.99	;	Crystal structure of ricin A chain in complex with inhibitor 5-phenyl-2-thiophenecarboxylic acid
6URY	;	1.54	;	Crystal structure of ricin A chain in complex with inhibitor 9-oxo-4-fluorenecarboxamide
3HIO	;	2.0	;	Crystal structure of Ricin A-chain in complex with the cyclic tetranucleotide inhibitor, a transition state analogue
3RTJ	;	3.0	;	Crystal structure of ricin bound with dinucleotide ApG
3RTI	;	2.8	;	Crystal structure of ricin bound with formycin monophosphate
4KUC	;	2.787	;	Crystal structure of ricin-A chain in complex with the antibody 6C2
6L8P	;	1.601	;	Crystal structure of RidA from Antarctic bacterium Psychrobacter sp. PAMC 21119
5WYH	;	2.46	;	Crystal structure of RidL(1-200) complexed with VPS29
4BJ5	;	3.29	;	Crystal structure of Rif2 in complex with the C-terminal domain of Rap1 (Rap1-RCT)
2HW2	;	1.45	;	Crystal structure of Rifampin ADP-ribosyl transferase in complex with Rifampin
5VQB	;	3.391	;	Crystal structure of rifampin monooxygenase from Streptomyces venezuelae, complex with FAD
6BRD	;	3.32	;	Crystal structure of rifampin monooxygenase from Streptomyces venezuelae, complexed with rifampin and FAD
5FBS	;	2.59	;	Crystal structure of rifampin phosphotransferase RPH-Lm from Listeria monocytogenes in complex with ADP and magnesium
5FBT	;	2.702	;	Crystal structure of rifampin phosphotransferase RPH-Lm from Listeria monocytogenes in complex with rifampin
5FBU	;	2.85	;	Crystal structure of rifampin phosphotransferase RPH-Lm from Listeria monocytogenes in complex with rifampin-phosphate
4H5M	;	3.1	;	Crystal Structure of Rift Valley Fever Virus Nucleocapsid Protein Hexamer
4H5Q	;	2.7	;	Crystal Structure of Rift Valley Fever Virus Nucleocapsid Protein Hexamer Bound to Single-stranded DNA
4V9E	;	3.4	;	Crystal Structure of Rift Valley Fever Virus Nucleocapsid Protein Hexamer Bound to Single-stranded RNA.
4H5O	;	3.9	;	Crystal Structure of Rift Valley Fever Virus Nucleocapsid Protein Pentamer Bound to Single-stranded RNA
4H5P	;	2.15	;	Crystal Structure of Rift Valley Fever Virus Nucleocapsid Protein Tetramer Bound to Single-stranded RNA
1YHU	;	3.15	;	Crystal structure of Riftia pachyptila C1 hemoglobin reveals novel assembly of 24 subunits.
6KYV	;	3.0	;	Crystal Structure of RIG-I and hairpin RNA with G-U wobble base pairs
5F9H	;	3.1	;	Crystal structure of RIG-I helicase-RD in complex with 24-mer 5' triphosphate hairpin RNA
5F9F	;	2.601	;	Crystal structure of RIG-I helicase-RD in complex with 24-mer blunt-end hairpin RNA
5F98	;	3.28	;	Crystal structure of RIG-I in complex with Cap-0 RNA
8A71	;	0.69	;	Crystal structure of right-handed Z-DNA containing 2'-deoxy-L-ribose in complex with the polyamine cadaverine and potassium cations at ultrahigh resolution
4PD3	;	2.84	;	Crystal Structure of Rigor-Like Human Nonmuscle Myosin-2B
3I5G	;	2.6	;	Crystal structure of rigor-like squid myosin S1
2HWN	;	1.6	;	Crystal Structure of RII alpha Dimerization/Docking domain of PKA bound to the D-AKAP2 peptide
4JVA	;	2.5	;	Crystal Structure of RIIbeta(108-402) bound to HE33, a N6 di-propyl substituted cAMP analog
5ZK6	;	3.15	;	Crystal structure of RimK complexed with RpsF
5I47	;	2.35	;	Crystal structure of RimK domain protein ATP-grasp from Sphaerobacter thermophilus DSM 20745
7QYR	;	2.4	;	Crystal structure of RimK from Pseudomonas aeruginosa PAO1
7QYS	;	2.9	;	Crystal structure of RimK from Pseudomonas syringae DC3000
5YWR	;	1.47	;	Crystal Structure of RING E3 ligase ZNRF1 in complex with Ube2N (Ubc13)
7VBT	;	2.54001	;	Crystal structure of RIOK2 in complex with CQ211
6C3E	;	2.6	;	CRYSTAL STRUCTURE OF RIP1 KINASE BOUND TO INHIBITOR
6OCQ	;	2.793	;	Crystal structure of RIP1 kinase in complex with a pyrrolidine
6R5F	;	3.25	;	Crystal structure of RIP1 kinase in complex with DHP77
6RLN	;	2.87	;	Crystal structure of RIP1 kinase in complex with GSK3145095
6HHO	;	3.49	;	Crystal structure of RIP1 kinase in complex with GSK547
4ITH	;	2.25	;	Crystal structure of RIP1 kinase in complex with necrostatin-1 analog
4ITI	;	2.86	;	Crystal structure of RIP1 kinase in complex with necrostatin-3 analog
4ITJ	;	1.8	;	Crystal structure of RIP1 kinase in complex with necrostatin-4
5HX6	;	2.23	;	Crystal structure of RIP1 kinase with a benzo[b][1,4]oxazepin-4-one
3QLI	;	1.9	;	Crystal Structure of RipA from Yersinia pestis
3QLK	;	3.0	;	Crystal Structure of RipA from Yersinia pestis
3S8D	;	2.31	;	Crystal Structure of RipA from Yersinia pestis
3QLL	;	2.45	;	Crystal Structure of RipC from Yersinia pestis
6AC5	;	1.451	;	Crystal structure of RIPK1 death domain GlcNAcylated by EPEC effector NleB
3TE8	;	1.7	;	Crystal structure of risS periplasmic domain at low pH dimer with N-termini ordered
7VE0	;	1.9	;	Crystal Structure of Ritonavir bound Plasmepsin II (PMII) from Plasmodium falciparum
2OSL	;	2.6	;	Crystal structure of Rituximab Fab in complex with an epitope peptide
1P91	;	2.8	;	Crystal Structure of RlmA(I) enzyme: 23S rRNA n1-G745 methyltransferase (NORTHEAST STRUCTURAL GENOMICS CONSORTIUM TARGET ER19)
5TWJ	;	2.299	;	Crystal Structure of RlmH in Complex with S-Adenosylmethionine
5TWK	;	2.1	;	Crystal Structure of RlmH in Complex with Sinefungin
6I05	;	1.213	;	Crystal structure of RlpA SPOR domain from Pseudomonas aeruginosa
6I0N	;	1.4	;	Crystal structure of RlpA SPOR domain from Pseudomonas aeruginosa in complex with denuded glycan ended in anhNAM
6I09	;	1.48	;	Crystal structure of RlpA SPOR domain from Pseudomonas aeruginosa in complex with denuded glycan obtained by soaking
6I0A	;	1.3	;	Crystal structure of RlpA SPOR domain from Pseudomonas aeruginosa in complex with nuded glycan obtained by co-crystallization
2IST	;	1.86	;	crystal structure of RluD from E. coli
3DH3	;	3.0	;	Crystal Structure of RluF in complex with a 22 nucleotide RNA substrate
4V8G	;	3.0	;	Crystal structure of RMF bound to the 70S ribosome.
5XTT	;	1.75	;	Crystal structure of RmMan134A-M3 complex
4KYY	;	2.35	;	Crystal Structure of RNA 17-mer UUCGGUUUUGAUCCGGA duplex
1IPA	;	2.4	;	CRYSTAL STRUCTURE OF RNA 2'-O RIBOSE METHYLTRANSFERASE
1QMH	;	2.1	;	Crystal structure of RNA 3'-terminal phosphate cyclase, an ubiquitous enzyme with unusual topology
1QMI	;	2.8	;	Crystal structure of RNA 3'-terminal phosphate cyclase, an ubiquitous enzyme with unusual topology
6VYO	;	1.7	;	Crystal structure of RNA binding domain of nucleocapsid phosphoprotein from SARS coronavirus 2
7JLY	;	1.73	;	Crystal Structure of RNA Binding Protein PG1
2HCS	;	2.5	;	Crystal structure of RNA dependant RNA polymerase domain of West Nile virus
2HCN	;	2.35	;	Crystal structure of RNA dependent RNA polymerase domain from west nile virus
2HFZ	;	3.0	;	Crystal structure of RNA dependent RNA polymerase domain from West Nile virus
6AKW	;	2.2	;	Crystal structure of RNA dioxygenase bound with an inhibitor
5AY2	;	1.3	;	Crystal structure of RNA duplex containing C-Ag(I)-C base pairs
5AY3	;	1.2	;	Crystal structure of RNA duplex containing C-C base pairs
5AY4	;	1.7	;	Crystal structure of RNA duplex containing C-C base pairs obtained in the presence of Hg(II)
7OUO	;	2.212	;	Crystal structure of RNA duplex [UCGUGCGA]2 in complex with Ba2+ cation
5GI0	;	2.044	;	Crystal structure of RNA editing factor MORF9/RIP9
5IWW	;	2.65	;	Crystal structure of RNA editing factor of designer PLS-type PPR/9R protein in complex with MORF9/RIP9
5IZW	;	1.738	;	Crystal structure of RNA editing specific factor of designer PLS-type PPR-9R protein
6UV1	;	2.307	;	Crystal structure of RNA helicase DDX17 in complex of rU10 RNA
8OHM	;	2.3	;	CRYSTAL STRUCTURE OF RNA HELICASE FROM GENOTYPE 1B HEPATITIS C VIRUS: MECHANISM OF UNWINDING DUPLEX RNA
7XT0	;	2.48	;	Crystal structure of RNA helicase from Saint Louis encephalitis virus and discovery of its inhibitors
5BXY	;	1.75	;	Crystal structure of RNA methyltransferase from Salinibacter ruber in complex with S-Adenosyl-L-homocysteine
2A0P	;	1.95	;	Crystal structure of RNA oligomer containing 4'-thioribose
3TJ1	;	2.85	;	Crystal Structure of RNA Polymerase I Transcription Initiation Factor Rrn3
3K1F	;	4.3	;	Crystal structure of RNA Polymerase II in complex with TFIIB
2ZTT	;	2.1	;	Crystal Structure of RNA polymerase PB1-PB2 subunits from Influenza A Virus
3U1U	;	1.8	;	Crystal structure of RNA polymerase-associated protein RTF1 homolog Plus-3 domain
5EMF	;	1.14	;	Crystal structure of RNA r(GCUGCUGC) with antisense PNA p(GCAGCAGC)
4JNX	;	1.95	;	Crystal structure of RNA silencing suppressor p19 complexed with double-helical RNA 20mer pG(CUG)6C
4JGN	;	1.86	;	Crystal structure of RNA silencing suppressor p19 with 1nt-5'-overhanging double-helical RNA 20mer pUUG(CUG)5CU
2CWO	;	3.3	;	Crystal structure of RNA silencing suppressor p21 from Beet Yellows Virus
4LK2	;	2.12	;	Crystal structure of RNA splicing effector Prp5
4LJY	;	1.95	;	Crystal structure of RNA splicing effector Prp5 in complex with ADP
6WY3	;	1.647	;	Crystal structure of RNA-10mer: CCGG(N4,N4-dimethyl-C)GCCGG; P212121 form
6Z18	;	1.81	;	Crystal structure of RNA-10mer: CCGG(N4,N4-dimethyl-C)GCCGG; R32 form
6WY2	;	1.928	;	Crystal structure of RNA-10mer: CCGG(N4-methyl-C)GCCGG
2Z0A	;	1.85	;	Crystal structure of RNA-binding domain of NS1 from influenza A virus A/crow/Kyoto/T1/2004(H5N1)
6WKP	;	2.67	;	Crystal structure of RNA-binding domain of nucleocapsid phosphoprotein from SARS CoV-2, monoclinic crystal form
2EK1	;	2.0	;	Crystal structure of RNA-binding motif of human rna-binding protein 12
1XR7	;	2.3	;	Crystal structure of RNA-dependent RNA Polymerase 3D from human rhinovirus serotype 16
1XR6	;	2.5	;	Crystal Structure of RNA-dependent RNA Polymerase 3D from human rhinovirus serotype 1B
1S49	;	3.0	;	Crystal Structure of RNA-dependent RNA polymerase construct 1 (residues 71-679) from bovine viral diarrhea virus complexed with GTP
1S48	;	3.0	;	Crystal structure of RNA-dependent RNA polymerase construct 1 (residues 71-679) from BVDV
1S4F	;	3.0	;	Crystal Structure of RNA-dependent RNA polymerase construct 2 from bovine viral diarrhea virus (BVDV)
8WU3	;	3.2	;	Crystal structure of RNA-dependent RNA polymerases from Alongshan virus
8WU2	;	2.6	;	Crystal structure of RNA-dependent RNA polymerases from Jingmen tick virus
4U7U	;	3.003	;	Crystal structure of RNA-guided immune Cascade complex from E.coli
3UGO	;	2.096	;	Crystal structure of RNA-polymerase sigma subunit domain 2 complexed with -10 promoter element ssDNA oligo (TACAAT)
3UGP	;	2.697	;	Crystal structure of RNA-polymerase sigma subunit domain 2 complexed with -10 promoter element ssDNA oligo (TATAAT)
3SSF	;	1.6	;	Crystal structure of RNA:DNA dodecamer corresponding to HIV-1 polypurine tract, at 1.6 A resolution.
6MV6	;	1.5	;	Crystal structure of RNAse 6
6MV7	;	2.59	;	Crystal structure of RNAse 6
7UG9	;	1.69	;	Crystal structure of RNase AM PHP domain
4OKJ	;	2.1	;	Crystal structure of RNase AS from M tuberculosis
4OKK	;	2.21	;	Crystal structure of RNase AS from M tuberculosis in complex with UMP
2OP2	;	1.6	;	Crystal structure of RNase double-mutant V43C R85C with extra disulphide bond
6VRD	;	1.299	;	Crystal structure of RNase H/RNA/PS-ASO complex at an atomic level
4E19	;	1.41	;	Crystal structure of RNase H1 from halophilic archaeon Halobacterium salinarum NRC-1
4NYN	;	1.41	;	Crystal structure of RNase H1 from halophilic archaeon Halobacterium salinarum NRC-1
3ALY	;	1.66	;	Crystal Structure of RNase HI from Sulfolobus tokodaii with C-terminal deletion
4M30	;	2.501	;	Crystal structure of RNASE III complexed with double-stranded RNA AND AMP (TYPE II CLEAVAGE)
4M2Z	;	2.85	;	Crystal structure of RNASE III complexed with double-stranded RNA and CMP (TYPE II CLEAVAGE)
1I4S	;	2.15	;	CRYSTAL STRUCTURE OF RNASE III ENDONUCLEASE DOMAIN FROM AQUIFEX AEOLICUS AT 2.15 ANGSTROM RESOLUTION
1YYW	;	2.8	;	Crystal structure of RNase III from Aquifex aeolicus complexed with double stranded RNA at 2.8-Angstrom Resolution
1YYK	;	2.5	;	Crystal structure of RNase III from Aquifex Aeolicus complexed with double-stranded RNA at 2.5-angstrom resolution
2NUG	;	1.7	;	Crystal structure of RNase III from Aquifex aeolicus complexed with ds-RNA at 1.7-Angstrom Resolution
2NUF	;	2.5	;	Crystal structure of RNase III from Aquifex aeolicus complexed with ds-RNA at 2.5-Angstrom Resolution
2NUE	;	2.9	;	Crystal structure of RNase III from Aquifex aeolicus complexed with ds-RNA at 2.9-Angstrom Resolution
1YYO	;	2.9	;	Crystal structure of RNase III mutant E110K from Aquifex aeolicus complexed with double-stranded RNA at 2.9-Angstrom Resolution
1RC7	;	2.15	;	Crystal structure of RNase III Mutant E110K from Aquifex Aeolicus complexed with ds-RNA at 2.15 Angstrom Resolution
1YZ9	;	2.1	;	Crystal structure of RNase III mutant E110Q from Aquifex aeolicus complexed with double stranded RNA at 2.1-Angstrom Resolution
4XWW	;	1.7	;	Crystal structure of RNase J complexed with RNA
4XWT	;	2.003	;	Crystal structure of RNase J complexed with UMP
4O1O	;	3.27	;	Crystal Structure of RNase L in complex with 2-5A
4O1P	;	2.5	;	Crystal Structure of RNase L in complex with 2-5A and AMP-PNP
7DTS	;	2.63	;	Crystal structure of RNase L in complex with AC40357
7DSY	;	2.651	;	Crystal Structure of RNase L in complex with KM05073
7ELW	;	3.55	;	Crystal structure of RNase L in complex with Myricetin
6M12	;	2.4	;	Crystal Structure of Rnase L in complex with SU11652
6M11	;	2.46	;	Crystal structure of Rnase L in complex with Sunitinib
6M13	;	2.56	;	Crystal structure of Rnase L in complex with Toceranib
1DIX	;	1.65	;	CRYSTAL STRUCTURE OF RNASE LE
1VD1	;	1.8	;	Crystal structure of RNase NT in complex with 5'-AMP
3IAB	;	2.7	;	Crystal structure of RNase P /RNase MRP proteins Pop6, Pop7 in a complex with the P3 domain of RNase MRP RNA
4K7L	;	1.38	;	Crystal structure of RNase S variant (K7C/Q11C)
4K7M	;	1.8	;	Crystal structure of RNase S variant (K7C/Q11C) with bound mercury ions
1I8V	;	1.25	;	CRYSTAL STRUCTURE OF RNASE SA Y80F MUTANT
1I70	;	1.7	;	CRYSTAL STRUCTURE OF RNASE SA Y86F MUTANT
1MGW	;	2.0	;	Crystal structure of RNase Sa3, cytotoxic microbial ribonuclease
1MGR	;	1.7	;	Crystal structure of RNase Sa3,cytotoxic microbial ribonuclease
3NGY	;	2.204	;	Crystal structure of RNase T (E92G mutant)
4KB0	;	2.004	;	Crystal structure of RNase T in complex with a bluge DNA (Two nucleotide insertion CC )
4KB1	;	1.8	;	Crystal structure of RNase T in complex with a bluge DNA (two nucleotide insertion CT )
3VA0	;	2.201	;	Crystal structure of RNase T in complex with a di-nucleotide product (GG) with one Mg in the active site
3VA3	;	2.714	;	Crystal structure of RNase T in complex with a duplex DNA product (stem loop DNA with 2 nucleotide 3' overhang)
3NH0	;	2.3	;	Crystal structure of RNase T in complex with a non-preferred ssDNA (AAC)
3NGZ	;	2.1	;	Crystal structure of RNase T in complex with a non-preferred ssDNA (GC) with one Mg in the active site
3V9X	;	1.9	;	Crystal structure of RNase T in complex with a preferred ssDNA (AAA) with two Mg in the active site
3V9U	;	2.298	;	Crystal structure of RNase T in complex with a preferred ssDNA (AAT) with two Mg in the active site
3NH1	;	2.107	;	Crystal structure of RNase T in complex with a preferred ssDNA (TAGG) with two Mg in the active site
3V9W	;	1.702	;	Crystal structure of RNase T in complex with a preferred ssDNA (TTA) with two Mg in the active site
3V9S	;	2.1	;	Crystal structure of RNase T in complex with a product ssDNA (AAC) with one Mg in the active site
3V9Z	;	1.8	;	Crystal structure of RNase T in complex with a product ssDNA (ACC) with one Mg in the active site
3NH2	;	2.3	;	Crystal structure of RNase T in complex with a stem DNA with a 3' overhang
4KAZ	;	1.9	;	Crystal structure of RNase T in complex with a Y structured DNA
1RLS	;	1.9	;	CRYSTAL STRUCTURE OF RNASE T1 COMPLEXED WITH THE PRODUCT NUCLEOTIDE 3'-GMP. STRUCTURAL EVIDENCE FOR DIRECT INTERACTION OF HISTIDINE 40 AND GLUTAMIC ACID 58 WITH THE 2'-HYDROXYL GROUP OF RIBOSE
1RGA	;	1.7	;	CRYSTAL STRUCTURE OF RNASE T1 WITH 3'-GMP AND GUANOSINE: A PRODUCT COMPLEX
1Y44	;	2.1	;	Crystal structure of RNase Z
4GCW	;	3.0	;	Crystal structure of RNase Z in complex with precursor tRNA(Thr)
2FK6	;	2.9	;	Crystal Structure of RNAse Z/tRNA(Thr) complex
4E89	;	2.6	;	Crystal Structure of RnaseH from gammaretrovirus
1M7B	;	2.0	;	Crystal structure of Rnd3/RhoE: functional implications
5ZC4	;	1.906	;	Crystal Structure of RNF13 RING domain
4QPL	;	1.9	;	Crystal structure of RNF146(RING-WWE)/UbcH5a/iso-ADPr complex
5ULK	;	2.38	;	Crystal Structure of RNF165 in complex with a UbcH5b~Ub conjugate
8UQA	;	2.049	;	Crystal structure of RNF168 (RING)-UbcH5c fused to H2A-H2B via a 12-residue linker
8UQ8	;	2.34	;	Crystal structure of RNF168 (RING)-UbcH5c fused to H2A-H2B via a 2-residue linker
8UQD	;	3.893	;	Crystal structure of RNF168 (RING)-UbcH5c fused to H2A-H2B via a 20-residue linker (condition 2. RING not modeled in density)
8UQB	;	2.484	;	Crystal structure of RNF168 (RING)-UbcH5c fused to H2A-H2B via a 20-residue linker (crystallization condition 1)
8UQC	;	2.61	;	Crystal structure of RNF168 (RING)-UbcH5c fused to H2A-H2B via a 20-residue linker (crystallization condition 2)
8UQE	;	3.562	;	Crystal structure of RNF168 (RING)-UbcH5c fused to H2A-H2B via a 26-residue linker (RING not modeled in density)
8UQ9	;	2.3	;	Crystal structure of RNF168 (RING)-UbcH5c fused to H2A-H2B via a 4-residue linker
5XIS	;	1.78	;	Crystal structure of RNF168 UDM1 in complex with Lys63-linked diubiquitin, form I
5XIT	;	2.25	;	Crystal structure of RNF168 UDM1 in complex with Lys63-linked diubiquitin, form II
5YDK	;	2.505	;	Crystal structure of RNF168 UDM1 in complex with Lys63-linked diubiquitin, tetrameric form
5XIU	;	1.8	;	Crystal structure of RNF168 UDM2 in complex with Lys63-linked diubiquitin
4ORH	;	4.802	;	Crystal structure of RNF8 bound to the UBC13/MMS2 heterodimer
7CRV	;	2.0	;	Crystal structure of rNLRP1-FIIND
5WTK	;	2.651	;	Crystal structure of RNP complex
1T4O	;	2.5	;	Crystal structure of rnt1p dsRBD
5IQ1	;	1.75	;	Crystal structure of RnTmm mutant Y207S
5IQ4	;	1.5	;	Crystal structure of RnTmm mutant Y207S soaking
3KYE	;	2.15	;	Crystal Structure of Roadblock/LC7 Domain from Streptomyces avermitilis
2ESM	;	3.2	;	Crystal Structure of ROCK 1 bound to fasudil
2ETK	;	2.96	;	Crystal Structure of ROCK 1 bound to hydroxyfasudil
4W7P	;	2.8	;	Crystal Structure of ROCK 1 bound to YB-15-QD37
3D9V	;	3.3	;	CRYSTAL STRUCTURE OF ROCK I BOUND TO H-1152P A DI-METHYLATED VARIANT OF FASUDIL
2ETR	;	2.6	;	Crystal Structure of ROCK I bound to Y-27632
5UZJ	;	3.3	;	Crystal Structure of ROCK1 bound to an aminopyridine inhibitor
6E9W	;	2.96	;	Crystal structure of Rock1 with a pyridinylbenzamide based inhibitor
6ED6	;	2.86	;	Crystal structure of Rock2 with a pyridinylbenzamide based inhibitor
7RHE	;	2.3	;	Crystal Structure of ROK family protein from Burkholderia vietnamiensis G4
3VOV	;	2.02	;	Crystal Structure of ROK Hexokinase from Thermus thermophilus
3AQT	;	2.5	;	CRYSTAL STRUCTURE OF RolR (NCGL1110) complex WITH ligand RESORCINOL
3AQS	;	3.6	;	Crystal structure of RolR (NCGL1110) without ligand
4QT8	;	3.0	;	Crystal Structure of RON Sema-PSI-IPT1 extracellular domains in complex with MSP beta-chain
8TGB	;	1.55	;	Crystal structure of root lateral formation protein (RLF) b5-domain from Oryza sativa
5DL2	;	3.5	;	Crystal Structure of RopB
5W7M	;	1.7	;	Crystal structure of RoqN
4WQP	;	1.99	;	Crystal structure of RORc in complex with a benzyl sulfonamide inverse agonist
4WLB	;	1.702	;	Crystal structure of RORc in complex with a partial inverse agonist compound
4WPF	;	2.202	;	Crystal structure of RORc in complex with a phenyl sulfonamide agonist
4QM0	;	2.195	;	Crystal structure of RORc in complex with a tertiary sulfonamide inverse agonist
5YP5	;	2.65	;	Crystal structure of RORgamma complexed with SRC2 and compound 5d
7W3P	;	1.77	;	Crystal structure of RORgamma in complex with natural inverse agonist
7W3Q	;	2.0	;	Crystal structure of RORgamma in complex with natural inverse agonist
6LO9	;	1.86005	;	Crystal structure of RORgammat with ligand C46D bound
6LOA	;	2.50003	;	Crystal structure of RORgammat with ligand C46D bound
6LOB	;	2.40007	;	Crystal structure of RORgammat with ligand C46D bound
6LOC	;	2.20015	;	Crystal structure of RORgammat with ligand C46D bound
6O3Z	;	2.4	;	Crystal structure of RORgt with 3-cyano-N-(3-{[(3S)-4-(cyclopentanecarbonyl)-3-methylpiperazin-1-yl]methyl}-5-fluoro-2-methylphenyl)benzamide (compound 1)
7JTW	;	1.9	;	Crystal structure of RORgt with compound (4R)-6-[(2,5-dichloro-3-{[(2R,4R)-1-(cyclopentanecarbonyl)-2-methylpiperidin-4-yl]oxy}phenyl)amino]-6-oxo-4-phenylhexanoic acid
5MLD	;	1.7	;	Crystal Structure of RosB with bound intermediate AFP (8-demethyl-8-aminoriboflavin-5'-phosphate)
5MJI	;	2.0	;	Crystal Structure of RosB with bound intermediate OHC-RP (8-demethyl-8-formylriboflavin-5'-phosphate)
4Q77	;	1.77	;	Crystal structure of Rot, a global regulator of virulence genes in Staphylococcus aureus
6AUK	;	2.603	;	Crystal structure of rotavirus Non Structural protein 2 (NSP2) mutant S313D
2R7J	;	2.6	;	Crystal Structure of rotavirus non structural protein NSP2 with H225A mutation
3MIW	;	2.5	;	Crystal Structure of Rotavirus NSP4
2R7S	;	3.24	;	Crystal Structure of Rotavirus SA11 VP1 / RNA (UGUGCC) complex
2R7U	;	3.1	;	Crystal Structure of Rotavirus SA11 VP1/RNA (AAAAGCC) Complex
2R7V	;	2.8	;	Crystal Structure of Rotavirus SA11 VP1/RNA (GGCUUU) Complex
2R7T	;	3.0	;	Crystal Structure of Rotavirus SA11 VP1/RNA (UGUGAACC) Complex
2R7R	;	2.6	;	Crystal Structure of Rotavirus SA11 VP1/RNA (UGUGACC) complex
2R7X	;	2.8	;	Crystal Structure of Rotavirus SA11 VP1/RNA (UGUGACC)/GTP complex
2R7W	;	2.6	;	Crystal Structure of Rotavirus SA11 VP1/RNA (UGUGACC)/mRNA 5'-CAP (m7GpppG) complex
2DB4	;	2.4	;	Crystal structure of rotor ring with DCCD of the V- ATPase from Enterococcus hirae
1BAI	;	2.4	;	Crystal structure of Rous sarcoma virus protease in complex with inhibitor
4AIJ	;	2.05	;	Crystal structure of RovA from Yersinia in complex with a rovA promoter fragment
4AIK	;	1.85	;	Crystal structure of RovA from Yersinia in complex with an invasin promoter fragment
4AIH	;	2.4	;	Crystal structure of RovA from Yersinia in its free form
1NE4	;	2.4	;	Crystal Structure of Rp-cAMP Binding R1a Subunit of cAMP-dependent Protein Kinase
4OU0	;	1.4	;	Crystal Structure of RPA32C
8DK0	;	1.55	;	Crystal structure of RPA3624, a beta-propeller lactonase from Rhodopseudomonas palustris, with active-site bound (S)gamma-valerolactone
7RIZ	;	1.71	;	Crystal structure of RPA3624, a beta-propeller lactonase from Rhodopseudomonas palustris, with active-site bound 2-hydroxyquinoline
7RIS	;	1.72	;	Crystal structure of RPA3624, a beta-propeller lactonase from Rhodopseudomonas palustris, with active-site bound phosphate
8DJZ	;	1.55	;	Crystal structure of RPA3624, a beta-propeller lactonase from Rhodopseudomonas palustris, with active-site bound product
8DJF	;	1.55	;	Crystal structure of RPA3624, a beta-propeller lactonase from Rhodopseudomonas palustris, with active-site bound tetrahedral intermediate
4R4Q	;	1.35	;	Crystal structure of RPA70N in complex with 5-(3-((N-(4-(5-carboxyfuran-2-yl)benzyl)acetamido)methyl)phenyl)-1-(3,4-dichlorophenyl)-1H-pyrazole-3-carboxylic acid
4R4O	;	1.33	;	Crystal structure of RPA70N in complex with 5-(4-((4-(5-carboxyfuran-2-yl)benzyl)carbamothioyl)phenyl)-1-(3,4-dichlorophenyl)-1H-pyrazole-3-carboxylic acid
4R4T	;	1.28	;	Crystal Structure of RPA70N in complex with 5-(4-((4-(5-carboxyfuran-2-yl)phenylthioamido)methyl)phenyl)-1-(3,4-dichlorophenyl)-1H-pyrazole-3-carboxylic acid
4NB3	;	1.35	;	Crystal structure of RPA70N in complex with a 3,4 dichlorophenylalanine ATRIP derived peptide
5E7N	;	1.21	;	Crystal Structure of RPA70N in complex with VU0085636
7XV4	;	1.6	;	Crystal structure of RPA70N-ATRIP fusion
7XV0	;	1.5	;	Crystal structure of RPA70N-BLMp1 fusion
7XUW	;	1.8	;	Crystal structure of RPA70N-BLMp2 fusion
7XV1	;	1.8	;	Crystal structure of RPA70N-HelB fusion
7XUV	;	1.6	;	Crystal structure of RPA70N-RMI1 fusion
7XUT	;	1.6	;	Crystal structure of RPA70N-WRN fusion
5AFQ	;	7.0	;	Crystal structure of RPC62 - RPC32 beta
3FSN	;	2.14	;	Crystal structure of RPE65 at 2.14 angstrom resolution
4F2Z	;	3.0	;	Crystal structure of RPE65 in a lipid environment
8DOC	;	2.1	;	Crystal structure of RPE65 in complex with compound 16e and palmitate
4RSC	;	1.8	;	Crystal structure of RPE65 in complex with emixustat and palmitate
4RYX	;	2.0	;	Crystal structure of RPE65 in complex with emixustat and palmitate, P6522 crystal form
4RSE	;	2.39	;	Crystal structure of RPE65 in complex with MB-001 and palmitate
4ZHK	;	2.09	;	Crystal structure of RPE65 in complex with MB-002
5UL5	;	2.2	;	Crystal structure of RPE65 in complex with MB-004 and palmitate
5ULG	;	2.1	;	Crystal structure of RPE65 in complex with MB-008 and palmitate
4RYY	;	2.3	;	Crystal structure of RPE65 in complex with R-emixustat and palmitate
4RYZ	;	2.5	;	Crystal structure of RPE65 in complex with S-emixustat and palmitate
4EMN	;	1.17	;	Crystal structure of RpfB catalytic domain in complex with benzamidine
3M6N	;	1.8	;	Crystal structure of RpfF
3M6M	;	2.5	;	Crystal structure of RpfF complexed with REC domain of RpfC
3DD6	;	1.702	;	Crystal structure of Rph, an exoribonuclease from Bacillus anthracis at 1.7 A resolution
4M8L	;	2.37	;	crystal structure of RpiA-R5P complex
3SHO	;	1.8	;	Crystal structure of RpiR transcription factor from Sphaerobacter thermophilus (sugar isomerase domain)
4OWP	;	2.35	;	Crystal structure of rpn11 in a heterodimer complex with rpn8, representing the active portion of the proteasome lid.
3TXM	;	3.0	;	Crystal structure of Rpn6 from Drosophila melanogaster, Gd(3+) complex
3TXN	;	2.496	;	Crystal structure of Rpn6 from Drosophila melanogaster, native data
7XOZ	;	2.52	;	Crystal structure of RPPT-TIR
6UZT	;	1.8	;	Crystal Structure of RPTP alpha
3BH8	;	1.65	;	Crystal Structure of RQA_M Phosphopeptide Bound to HUMAN Class I MHC HLA-A2
4NO2	;	2.0	;	Crystal structure of RQA_V phosphopeptide bound to HLA-A2
3Q9V	;	1.60174	;	Crystal structure of rra c-terminal domain(123-221) from Deinococcus radiodurans
3Q9S	;	2.4	;	Crystal structure of rra(1-215) from Deinococcus Radiodurans
7WEZ	;	1.9	;	Crystal structure of RRM domain of Cyclophilin 33-like protein of Plasmodium falciparum
2YWK	;	1.54	;	Crystal structure of RRM-domain derived from human putative RNA-binding protein 11
3B89	;	2.6	;	Crystal structure of rRNA methylase from Escherichia coli
7F8A	;	1.9	;	Crystal structure of rRNA methyltransferase Erm38
7F8B	;	2.248	;	Crystal structure of rRNA methyltransferase Erm38 in complex with SAM
7F8C	;	2.248	;	Crystal structure of rRNA methyltransferase Erm38 in complex with sinefungin
5KZK	;	2.28	;	Crystal Structure of rRNA methyltransferase from Sinorhizobium meliloti
2EGW	;	2.8	;	Crystal structure of rRNA methyltransferase with SAH ligand
2EGV	;	1.45	;	Crystal structure of rRNA methyltransferase with SAM ligand
7Y16	;	1.8	;	Crystal structure of rRNA-processing protein Las1
6EMF	;	2.65	;	Crystal structure of Rrp1 from Chaetomium thermophilum in space group C2
6EMG	;	2.24	;	Crystal structure of Rrp1 from Chaetomium thermophilum in space group P6322
4JXM	;	1.92	;	Crystal structure of RRP9 WD40 repeats
5W6L	;	3.45	;	Crystal Structure of RRSP, a MARTX Toxin Effector Domain from Vibrio vulnificus CMCP6
3JZV	;	2.3	;	Crystal structure of Rru_A2000 from Rhodospirillum rubrum: A cupin-2 domain.
2OIG	;	3.3	;	Crystal structure of RS21-C6 core segment and dm5CTP complex
2OIE	;	2.2	;	Crystal structure of RS21-C6 core segment RSCUT
4WJS	;	1.8	;	Crystal structure of Rsa4 from Chaetomium thermophilum
4WJU	;	2.8	;	Crystal structure of Rsa4 from Saccharomyces cerevisiae
4WJV	;	3.2	;	Crystal structure of Rsa4 in complex with the Nsa2 binding peptide
1WOM	;	2.5	;	Crystal structure of RsbQ
1WPR	;	2.6	;	Crystal structure of RsbQ inhibited by PMSF
3W45	;	1.7	;	Crystal structure of RsbX in complex with cobalt in space group P1
3W40	;	1.3	;	Crystal structure of RsbX in complex with magnesium in space group P1
3W41	;	1.42	;	Crystal structure of RsbX in complex with magnesium in space group P21
3W42	;	1.06	;	Crystal structure of RsbX in complex with manganese in space group P1
3W43	;	1.22	;	Crystal structure of RsbX in complex with manganese in space group P21
3W44	;	2.3	;	Crystal structure of RsbX, selenomethionine derivative
2V42	;	2.75	;	Crystal structure of RseB: a sensor for periplasmic stress response in E. coli
2V43	;	2.37	;	Crystal structure of RseB: a sensor for periplasmic stress response in E. coli
6T39	;	1.6	;	Crystal structure of rsEGFP2 in its off-state determined by SFX
5DTX	;	1.45	;	Crystal structure of rsEGFP2 in the fluorescent on-state
5O89	;	1.7	;	Crystal Structure of rsEGFP2 in the fluorescent on-state determined by SFX
5DTY	;	1.5	;	Crystal structure of rsEGFP2 in the non-fluorescent off-state
7O7U	;	1.7	;	Crystal structure of rsEGFP2 in the non-fluorescent off-state determined by serial femtosecond crystallography at room temperature
5O8A	;	1.7	;	Crystal Structure of rsEGFP2 in the non-fluorescent off-state determined by SFX
7O7V	;	1.9	;	Crystal structure of rsEGFP2 mutant V151A in the fluorescent on-state determined by serial femtosecond crystallography at room temperature
7O7D	;	1.4	;	Crystal structure of rsEGFP2 mutant V151A in the fluorescent on-state determined by synchrotron radiation at 100K
7O7X	;	1.95	;	Crystal structure of rsEGFP2 mutant V151A in the non-fluorescent off-state determined by serial femtosecond crystallography at room temperature
7O7C	;	1.55	;	Crystal structure of rsEGFP2 mutant V151A in the non-fluorescent off-state determined by synchrotron radiation at 100K
7O7E	;	1.8	;	Crystal structure of rsEGFP2 mutant V151L in the fluorescent on-state determined by synchrotron radiation at 100K
7O7H	;	1.7	;	Crystal structure of rsEGFP2 mutant V151L in the non-fluorescent off-state determined by synchrotron radiation at 100K
7O7W	;	2.1	;	Crystal structure of rsEGFP2 mutant V151L in the non-fluorescent off-state the determined by serial femtosecond crystallography at room temperature
7AMU	;	1.64	;	Crystal structure of rsEGFP2 T204A in its fluorescent on-state
6UN4	;	1.499	;	Crystal structure of rsEGFP2, Y67(3-ClY), Y107(3-ClY)
3ID1	;	1.67	;	Crystal Structure of RseP PDZ1 domain
3ID2	;	3.089	;	Crystal Structure of RseP PDZ2 domain
3ID4	;	1.604	;	Crystal Structure of RseP PDZ2 domain fused GKASPV peptide
3ID3	;	2.01	;	Crystal Structure of RseP PDZ2 I304A domain
5DTZ	;	1.5	;	Crystal structure of rsFolder in the fluorescent on-state
5DU0	;	2.35	;	Crystal structure of rsFolder in the non-fluorescent off-state
7AMB	;	1.63	;	Crystal structure of rsFolder2 in its fluorescent on-state
7AMF	;	1.63	;	Crystal structure of rsFolder2 in its non-fluorescent off-state
6H4D	;	2.9	;	Crystal structure of RsgA from Pseudomonas aeruginosa
6ZSN	;	2.6	;	Crystal structure of rsGCaMP double mutant Ile80His/Val116Ile in the OFF state (illuminated)
6ZSM	;	1.95	;	Crystal structure of rsGCaMP double mutant Ile80His/Val116Ile in the ON state (non-illuminated)
6TV7	;	2.9	;	Crystal structure of rsGCaMP in the OFF state (illuminated)
6YA9	;	2.15	;	Crystal structure of rsGCaMP in the ON state (non-illuminated)
7AUG	;	2.04	;	Crystal structure of rsGCamP1.3 in the ON state
7E7R	;	1.82	;	Crystal structure of RSL mutant in complex with Ligand
7E7T	;	1.98	;	Crystal structure of RSL mutant in complex with sugar Ligand
7E7U	;	2.1	;	Crystal structure of RSL mutant in complex with sugar Ligand
7E7V	;	1.61	;	Crystal structure of RSL mutant in complex with sugar Ligand
7E7W	;	4.1	;	Crystal structure of RSL mutant in complex with sugar Ligand
7E7N	;	1.55	;	Crystal structure of RSL mutant-R17A/R108A/R199A in complex with R3F
6M1C	;	2.401	;	Crystal structure of RsmD methyltransferase of M. tuberculosis in complex with sinefungin reveals key interactions
7CFE	;	2.02	;	Crystal structure of RsmG methyltransferase of M. tuberculosis
3WGG	;	2.1	;	Crystal structure of RSP in complex with alpha-NAD+
3WGI	;	3.25	;	Crystal structure of RSP in complex with beta-NAD+ and operator DNA
3WGH	;	2.05	;	Crystal structure of RSP in complex with beta-NADH
3WG9	;	1.97	;	Crystal structure of RSP, a Rex-family repressor
6Y42	;	4.3	;	Crystal Structure of RsrR complexed to a 39 basepair DNA fragment of the rsrR promoter
4OF8	;	1.902	;	Crystal Structure of Rst D1-D2
7D2T	;	2.2	;	Crystal structure of Rsu1/PINCH1_LIM45C complex
7D2U	;	3.15	;	Crystal structure of Rsu1/PINCH1_LIM45C complex
7D2S	;	1.653	;	Crystal structure of Rsu1/PINCH1_LIM5C complex
4L8I	;	2.0	;	Crystal structure of RSV epitope scaffold FFL_005
5UDC	;	3.45	;	Crystal Structure of RSV F A2 Bound to MEDI8897
5UDD	;	4.3	;	Crystal Structure of RSV F B9320 Bound to MEDI8897
5UDE	;	3.001	;	Crystal Structure of RSV F B9320 DS-Cav1
6APD	;	4.1	;	Crystal structure of RSV F bound by AM22 and the infant antibody ADI-19425
5W23	;	3.4	;	Crystal Structure of RSV F in complex with 5C4 Fab
5TPN	;	3.141	;	Crystal structure of RSV F in complex with human antibody hRSV90
6Q0S	;	1.94	;	Crystal Structure of RSV strain B18537 Prefusion-stabilized glycoprotein F Variant DS-Cav1
4FW2	;	2.65	;	Crystal structure of RSV three-domain integrase with disordered N-terminal domain
1C0M	;	2.53	;	CRYSTAL STRUCTURE OF RSV TWO-DOMAIN INTEGRASE
1C1A	;	3.1	;	CRYSTAL STRUCTURE OF RSV TWO-DOMAIN INTEGRASE
4JHA	;	1.6	;	Crystal Structure of RSV-Neutralizing Human Antibody D25
6NF7	;	2.9	;	Crystal Structure of RT1.Aa-Bu31-10
4O8J	;	2.04	;	Crystal structure of RtcA, the RNA 3'-terminal phosphate cyclase from Pyrococcus horikoshii, in complex with rACAAA3'phosphate and adenine.
4O89	;	1.9	;	Crystal structure of RtcA, the RNA 3'-terminal phosphate cyclase from Pyrococcus horikoshii.
3TV1	;	1.9	;	Crystal structure of RtcA.AMP product complex
3TUT	;	1.58	;	Crystal structure of RtcA.ATP binary complex
3TW3	;	2.1	;	Crystal structure of RtcA.ATP.Co ternary complex
3TUX	;	1.85	;	Crystal structure of RtcA.ATP.Mn ternary complex
4RAU	;	3.74	;	crystal structure of RTOFab in complex with human PF4
3T7J	;	2.042	;	Crystal structure of Rtt107p (residues 820-1070)
2RIM	;	2.2	;	Crystal structure of Rtt109
5ZB9	;	2.502	;	Crystal structure of Rtt109 from Aspergillus fumigatus
7BWZ	;	1.77	;	Crystal structure of RTT109 from CANDIDA ALBICANS
7BX0	;	1.5	;	Crystal structure of RTT109 from Candida albicans
7BX1	;	1.58	;	Crystal structure of RTT109 from Candida albicans
3QM0	;	3.1	;	Crystal structure of RTT109-AC-CoA complex
5ZBB	;	3.6	;	Crystal structure of Rtt109-Asf1-H3-H4 complex
5ZBA	;	3.5	;	Crystal structure of Rtt109-Asf1-H3-H4-CoA complex
5CVW	;	1.25	;	CRYSTAL STRUCTURE OF RTX DOMAIN BLOCK V OF ADENYLATE CYCLASE TOXIN FROM BORDETELLA PERTUSSIS
5CXL	;	1.45	;	CRYSTAL STRUCTURE OF RTX DOMAIN BLOCK V OF ADENYLATE CYCLASE TOXIN FROM BORDETELLA PERTUSSIS
6SUS	;	1.76	;	Crystal structure of RTX domain blocks IV and V of adenylate cyclase toxin from Bordetella pertussis
3BH9	;	1.7	;	Crystal Structure of RTY Phosphopeptide Bound to Human Class I MHC HLA-A2
3O7S	;	1.73	;	Crystal structure of Ru(p-cymene)/apo-Fr
3O7R	;	1.9	;	Crystal structure of Ru(p-cymene)/apo-H49AFr
7FAV	;	1.64	;	Crystal Structure of Rubella Protease
4HAR	;	2.663	;	Crystal Structure of Rubella virus capsid protein (residues 127-277)
4HBE	;	2.3	;	Crystal Structure of Rubella virus capsid protein (residues 127-277)
4HBO	;	3.241	;	Crystal Structure of Rubella virus capsid protein (residues 127-277)
6KKN	;	2.85	;	Crystal structure of RuBisCO accumulation factor Raf1 from Anabaena sp. PCC 7120
2V63	;	1.8	;	Crystal structure of Rubisco from Chlamydomonas reinhardtii with a large-subunit V331A mutation
6URA	;	2.17	;	Crystal structure of RUBISCO from Promineofilum breve
7T1J	;	1.96	;	Crystal structure of RUBISCO from Rhodospirillaceae bacterium BRH_c57
7T1C	;	1.73	;	Crystal structure of RUBISCO from Sulfurivirga caldicuralii
3WQP	;	2.25	;	Crystal structure of Rubisco T289D mutant from Thermococcus kodakarensis
3FK4	;	2.0	;	Crystal structure of RuBisCO-like protein from Bacillus Cereus ATCC 14579
3QFW	;	1.789	;	Crystal structure of Rubisco-like protein from Rhodopseudomonas palustris
7A9A	;	1.17	;	Crystal structure of rubredoxin B (Rv3250c) from Mycobacterium tuberculosis
2DSX	;	0.68	;	Crystal structure of rubredoxin from Desulfovibrio gigas to ultra-high 0.68 A resolution
2V3A	;	2.4	;	Crystal structure of rubredoxin reductase from Pseudomonas aeruginosa.
1JYB	;	2.2	;	Crystal structure of Rubrerythrin
3WVV	;	1.82	;	Crystal Structure of RuCO/apo-E45C_C48AFr
3WVU	;	1.92	;	Crystal Structure of RuCO/apo-R52CFr
3WVW	;	2.0	;	Crystal structure of RuCO/apo-WTFr
1UWV	;	1.95	;	Crystal Structure of RumA, the iron-sulfur cluster containing E. coli 23S Ribosomal RNA 5-Methyluridine Methyltransferase
5OGZ	;	1.6	;	Crystal structure of Ruminiclostridium Thermocellum beta-Glucosidase A
5AY9	;	2.5	;	Crystal structure of Ruminococcus albus 4-O-beta-D-mannosyl-D-glucose phosphorylase (RaMP1)
5AYC	;	1.9	;	Crystal structure of Ruminococcus albus 4-O-beta-D-mannosyl-D-glucose phosphorylase (RaMP1) in complexes with sulfate and 4-O-beta-D-mannosyl-D-glucose
5AYD	;	2.3	;	Crystal structure of Ruminococcus albus beta-(1,4)-mannooligosaccharide phosphorylase (RaMP2) in complexes with phosphate
5AYE	;	2.2	;	Crystal structure of Ruminococcus albus beta-(1,4)-mannooligosaccharide phosphorylase (RaMP2) in complexes with phosphate and beta-(1,4)-mannobiose
5LXV	;	2.4	;	Crystal structure of Ruminococcus flavefaciens scaffoldin C cohesin in complex with a dockerin from an uncharacterized CBM-containing protein
5N5P	;	1.98	;	Crystal structure of Ruminococcus flavefaciens' type III complex containing the fifth cohesin from scaffoldin B and the dockerin from scaffoldin A
7KPJ	;	2.1	;	Crystal structure of Ruminococcus gnavus immunoglobulin binding protein in complex with 338E6 Fab
1HJB	;	3.0	;	CRYSTAL STRUCTURE OF RUNX-1/AML1/CBFALPHA RUNT DOMAIN AND C/EBPBETA BZIP HOMODIMER BOUND TO A DNA FRAGMENT FROM THE CSF-1R PROMOTER
1HJC	;	2.65	;	CRYSTAL STRUCTURE OF RUNX-1/AML1/CBFALPHA RUNT DOMAIN BOUND TO A DNA FRAGMENT FROM THE CSF-1R PROMOTER
1IO4	;	3.0	;	CRYSTAL STRUCTURE OF RUNX-1/AML1/CBFALPHA RUNT DOMAIN-CBFBETA CORE DOMAIN HETERODIMER AND C/EBPBETA BZIP HOMODIMER BOUND TO A DNA FRAGMENT FROM THE CSF-1R PROMOTER
4L0Y	;	2.5	;	Crystal structure of Runx1 and Ets1 bound to TCR alpha promoter (crystal form 1)
4L0Z	;	2.7	;	Crystal structure of Runx1 and Ets1 bound to TCR alpha promoter (crystal form 2)
4L18	;	2.3	;	Crystal structure of Runx1 and Ets1 bound to TCR alpha promoter (crystal form 3)
4IDI	;	1.9	;	Crystal Structure of Rurm1-related protein from Plasmodium Yoelii, PY06420
2E3X	;	2.91	;	Crystal structure of Russell's viper venom metalloproteinase
1OYF	;	2.45	;	Crystal Structure of Russelles viper (Daboia russellii pulchella) phospholipase A2 in a complex with venom 6-methyl heptanol
1TK4	;	1.1	;	Crystal structure of russells viper phospholipase A2 in complex with a specifically designed tetrapeptide Ala-Ile-Arg-Ser at 1.1 A resolution
3V4D	;	1.95	;	Crystal structure of RutC protein a member of the YjgF family from E.coli
6I1A	;	1.27	;	Crystal structure of rutinosidase from Aspergillus niger
7X5B	;	2.16	;	Crystal structure of RuvB
7XHJ	;	1.6	;	Crystal structure of RuvC from Deinococcus radiodurans
6LW3	;	2.38	;	Crystal structure of RuvC from Pseudomonas aeruginosa
6EIC	;	1.8	;	Crystal structure of Rv0183, a Monoglyceride Lipase from Mycobacterium Tuberculosis
6LDZ	;	2.4	;	Crystal structure of Rv0222 from Mycobacterium tuberculosis
5XKL	;	2.392	;	Crystal structure of Rv0289/EspG3 from the ESX-3 type VII secretion system of M. tuberculosis
2YES	;	1.9	;	Crystal Structure of Rv0371C complex with Manganese from Mycobacterium Tuberculosis H37Rv
2WE9	;	2.1	;	Crystal structure of Rv0371c from Mycobacterium tuberculosis H37Rv
2WEE	;	1.65	;	Crystal structure of Rv0371c from Mycobacterium tuberculosis H37Rv
2FSX	;	1.8	;	Crystal structure of Rv0390 from M. tuberculosis
6ID6	;	1.63	;	Crystal structure of Rv0731c from Mycobacterium tuberculosis at 1.63 Angstroms.
2VZY	;	2.0	;	Crystal structure of Rv0802c from Mycobacterium tuberculosis in an unliganded form.
2VZZ	;	2.3	;	Crystal structure of Rv0802c from Mycobacterium tuberculosis in Complex with Succinyl-CoA
2HY1	;	1.932	;	Crystal structure of Rv0805
2HYP	;	2.05	;	Crystal structure of Rv0805 D66A mutant
2HYO	;	2.25	;	Crystal structure of Rv0805 N97A mutant
2FWV	;	1.7	;	Crystal Structure of Rv0813
1OZP	;	1.7	;	Crystal Structure of Rv0819 from Mycobacterium tuberculosis MshD-Mycothiol Synthase Acetyl-Coenzyme A Complex.
1P0H	;	1.6	;	Crystal Structure of Rv0819 from Mycobacterium Tuberculosis MshD-Mycothiol Synthase Coenzyme A Complex
4YIF	;	2.002	;	Crystal structure of Rv0880
1Y8T	;	2.0	;	Crystal Structure of RV0983 from Mycobacterium tuberculosis- Proteolytically active form
2Z9I	;	2.0	;	Crystal structure of RV0983 from Mycobacterium tuberculosis- Proteolytically active form
7C46	;	1.93	;	Crystal Structure of Rv1045 toxin point variant K189A
4ADM	;	1.65	;	Crystal structure of Rv1098c in complex with meso-tartrate
1W9A	;	1.8	;	Crystal structure of Rv1155 from Mycobacterium tuberculosis
1YLK	;	2.0	;	Crystal Structure of Rv1284 from Mycobacterium tuberculosis in Complex with Thiocyanate
4YF5	;	2.0	;	Crystal structure of Rv1284 in the presence of polycarpine at acidic pH
4YF4	;	1.8	;	Crystal structure of Rv1284 in the presence of polycarpine at mildly acidic pH
1YK3	;	2.2	;	Crystal structure of Rv1347c from Mycobacterium tuberculosis
2NYX	;	2.3	;	Crystal structure of RV1404 from Mycobacterium tuberculosis
4HQQ	;	2.4	;	Crystal structure of RV144-elicited antibody CH58
4HPO	;	1.694	;	Crystal structure of RV144-elicited antibody CH58 in complex with V2 peptide
4HPY	;	1.5	;	Crystal structure of RV144-elicited antibody CH59 in complex with V2 peptide
3OQT	;	2.88	;	Crystal structure of Rv1498A protein from mycobacterium tuberculosis
4RAE	;	2.59	;	Crystal structure of Rv1600 encoded aminotransferase from Mycobacterium tuberculosis
4R8D	;	2.05	;	Crystal structure of Rv1600 encoded aminotransferase in complex with PLP-MES from Mycobacterium tuberculosis
1SD5	;	1.68	;	Crystal structure of Rv1626
1S8N	;	1.482	;	Crystal structure of Rv1626 from Mycobacterium tuberculosis
2G9W	;	1.8	;	Crystal Structure of Rv1846c, a Putative Transcriptional Regulatory Protein of Mycobacterium Tuberculosis
2FVH	;	1.8	;	Crystal Structure of Rv1848, a Urease Gamma Subunit UreA (Urea amidohydrolase), from Mycobacterium Tuberculosis
8G8K	;	1.54	;	Crystal structure of Rv1916 (residues 233-398)
1NFF	;	1.8	;	Crystal structure of Rv2002 gene product from Mycobacterium tuberculosis
4ZIL	;	1.507	;	Crystal structure of Rv2466c and oxidoreductase from Mycobacterium tuberculosis in its reduced state
5XUR	;	1.996	;	Crystal Structure of Rv2466c C22S Mutant
4JDY	;	1.8	;	Crystal structure of Rv2606c
2FGG	;	2.3	;	Crystal Structure of Rv2632c
4XT4	;	1.891	;	Crystal structure of Rv2671 from Mycobacteirum tuberculosis in complex with dihydropteridine ring of dihydropteroic acid
4XRB	;	1.9	;	Crystal structure of Rv2671 from Mycobacterium tuberculosis
4XT5	;	2.13	;	Crystal structure of Rv2671 from Mycobacterium tuberculosis in complex with NADP+
4XT7	;	2.3	;	Crystal structure of Rv2671 from Mycobacterium tuberculosis in complex with NADP+ and trimethoprim
4XT8	;	1.95	;	Crystal structure of Rv2671 from Mycobacterium tuberculosis in complex with NADP+ and trimetrexate
4XT6	;	1.85	;	Crystal structure of Rv2671 from Mycobacterium tuberculosis in complex with the tetrahydropteridine ring of tetrahydrofolate (THF)
3I7T	;	1.93	;	Crystal structure of Rv2704, a member of highly conserved YjgF/YER057c/UK114 family, from Mycobacterium tuberculosis
2FR2	;	1.5	;	Crystal Structure of Rv2717c from M. tuberculosis
2VOE	;	2.6	;	Crystal structure of Rv2780 from M. tuberculosis H37Rv
1ZEL	;	1.93	;	Crystal structure of RV2827C protein from Mycobacterium tuberculosis
5CET	;	2.0	;	Crystal structure of Rv2837c
5JJU	;	2.312	;	Crystal structure of Rv2837c complexed with 5'-pApA and 5'-AMP
3H6P	;	1.91	;	Crystal structure of Rv3019c-Rv3020c from Mycobacterium tuberculosis
7F70	;	2.14	;	Crystal structure of Rv3094c
2WP4	;	2.49	;	crystal structure of Rv3119 from Mycobacterium tuberculosis
3ATS	;	1.67	;	Crystal structure of Rv3168
3ATT	;	2.0	;	Crystal structure of Rv3168 with ATP
5YX6	;	2.2	;	Crystal structure of Rv3272 from M. tuberculosis orthorhombic form
3LP6	;	1.702	;	Crystal Structure of Rv3275c-E60A from Mycobacterium tuberculosis at 1.7A resolution
4CMV	;	2.307	;	Crystal structure of Rv3378c
4CMW	;	2.209	;	Crystal structure of Rv3378c
4CMX	;	2.36	;	Crystal structure of Rv3378c
3WQM	;	2.1	;	Crystal structure of Rv3378c with inhibitor BPH-629
3WQL	;	2.1	;	Crystal structure of Rv3378c with Mg2+ and PPi
3WQK	;	2.3	;	Crystal structure of Rv3378c with PO4
3WQN	;	2.7	;	Crystal structure of Rv3378c_Y51F with TPP
8H5S	;	1.7	;	Crystal structure of Rv3400 from Mycobacterium tuberculosis
4W1U	;	1.875	;	Crystal structure of Rv3557c/KstR2, a transcriptional repressor involved in cholesterol metabolism in Mycobacterium tuberculosis
3LT3	;	2.1	;	Crystal structure of Rv3671c from M. tuberculosis H37Rv, Ser343Ala mutant, inactive form
3K6Y	;	1.3	;	Crystal structure of Rv3671c protease from M. tuberculosis, active form
3K6Z	;	1.75	;	Crystal structure of Rv3671c protease, inactive form
4LQ6	;	1.68	;	Crystal structure of Rv3717 reveals a novel amidase from M. tuberculosis
4R5Z	;	1.95	;	Crystal structure of Rv3772 encoded aminotransferase
4R2N	;	1.98	;	Crystal structure of Rv3772 in complex with its substrate
3OUK	;	3.402	;	Crystal structure of Rv3910 from Mycobacterium Tuberculosis
1OQS	;	1.9	;	Crystal Structure of RV4/RV7 Complex
3ZR8	;	0.9	;	Crystal structure of RxLR effector Avr3a11 from Phytophthora capsici
3ZRG	;	1.75	;	Crystal structure of RxLR effector PexRD2 from Phytophthora infestans
5L7S	;	2.9	;	Crystal structure of RXLR effector PexRD54 from Phytophthora infestans
7A77	;	1.5	;	Crystal structure of RXR alpha LBD in complexes with palmitic acid and GRIP-1 peptide
7A78	;	1.72	;	Crystal structure of RXR beta LBD in complexes with palmitic acid and GRIP-1 peptide
7A79	;	2.05	;	Crystal structure of RXR gamma LBD in complexes with palmitic acid and GRIP-1 peptide
5TBP	;	2.6	;	Crystal Structure of RXR-alpha ligand binding domain complexed with synthetic modulator K8003
8J54	;	2.72	;	Crystal structure of RXR/DR2 complex
4N8R	;	2.03	;	Crystal structure of RXRa LBD complexed with a synthetic modulator K-8008
4N5G	;	2.11	;	Crystal Structure of RXRa LBD complexed with a synthetic modulator K8012
6STI	;	1.892	;	Crystal structure of RXRalpha LBD in complex with LG 100754 and a coactivator peptide
7BK4	;	2.8	;	Crystal structure of RXRalpha ligand binding domain in complex with a fragment of the TIF2 coactivator
3E94	;	1.9	;	Crystal structure of RXRalpha ligand binding domain in complex with tributyltin and a coactivator fragment
3KWY	;	2.3	;	Crystal structure of RXRalpha ligand binding domain in complex with triphenyltin and a coactivator fragment
3R29	;	2.9	;	Crystal structure of RXRalpha ligand-binding domain complexed with corepressor SMRT2
3R2A	;	3.0	;	Crystal structure of RXRalpha ligand-binding domain complexed with corepressor SMRT2 and antagonist rhein
3R5M	;	2.8	;	Crystal structure of RXRalphaLBD complexed with the agonist magnolol
2IZW	;	2.9	;	Crystal structure of Ryegrass Mottle Virus
4GH5	;	1.6	;	Crystal structure of S-2-hydroxypropyl coenzyme M dehydrogenase (S-HPCDH)
4ITU	;	1.6	;	Crystal structure of S-2-HYDROXYPROPYL COENZYME M DEHYDROGENASE (S-HPCDH) bound to S-HPC AND NADH
3V06	;	1.53	;	Crystal structure of S-6'-Me-3'-fluoro hexitol nucleic acid
6UK3	;	1.4	;	Crystal Structure of S-adenosyl-L-homocysteine hydrolase from Acanthamoeba castellanii with bound NAD and Adenosine
5M65	;	1.945	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from Bradyrhizobium elkanii in complex with adenine
5M67	;	1.54	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from Bradyrhizobium elkanii in complex with adenine and 2'-deoxyadenosine
4LVC	;	1.74	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from Bradyrhizobium elkanii in complex with adenosine
5M66	;	1.951	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from Bradyrhizobium elkanii in complex with adenosine
3N58	;	2.39	;	Crystal structure of S-ADENOSYL-L-HOMOCYSTEINE hydrolase from brucella melitensis in ternary complex with NAD and adenosine, orthorhombic form
3D64	;	2.3	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from Burkholderia pseudomallei
3GLQ	;	2.3	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from Burkholderia pseudomallei in complex with 9-beta-D-arabino-furansyl-adenine
6GBN	;	2.09	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from Cytophaga hutchinsonii in complex with adenosine
7R3A	;	2.53	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from Methanococcus maripaludis in complex with inosine
8COD	;	2.48	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from Mus musculus in complex with inosine
5V96	;	2.0	;	Crystal Structure of S-adenosyl-l-homocysteine Hydrolase from Naegleria fowleri with bound NAD and Adenosine
8CFC	;	1.64	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from P. aeruginosa in complex with F2X-Entry library fragment A01
8CFD	;	1.88	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from P. aeruginosa in complex with F2X-Entry library fragment A07
8CFE	;	1.8	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from P. aeruginosa in complex with F2X-Entry library fragment B03
8CG2	;	1.37	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from P. aeruginosa in complex with F2X-Entry library fragment B07
8CFG	;	1.73	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from P. aeruginosa in complex with F2X-Entry library fragment C04
8CFH	;	1.6	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from P. aeruginosa in complex with F2X-Entry library fragment C08
8CFB	;	2.07	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from P. aeruginosa in complex with F2X-Entry library fragment D02
8CFI	;	2.02	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from P. aeruginosa in complex with F2X-Entry library fragment D07
8CFJ	;	1.64	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from P. aeruginosa in complex with F2X-Entry library fragment D10
8CFK	;	1.73	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from P. aeruginosa in complex with F2X-Entry library fragment E06
8CFL	;	1.73	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from P. aeruginosa in complex with F2X-Entry library fragment E07
8CFM	;	1.84	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from P. aeruginosa in complex with F2X-Entry library fragment E08
8CFN	;	1.34	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from P. aeruginosa in complex with F2X-Entry library fragment F03
8CFO	;	2.13	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from P. aeruginosa in complex with F2X-Entry library fragment F04
8CFP	;	1.61	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from P. aeruginosa in complex with F2X-Entry library fragment F09
8CFQ	;	1.73	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from P. aeruginosa in complex with F2X-Entry library fragment F11
8CFR	;	1.89	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from P. aeruginosa in complex with F2X-Entry library fragment G03
8CFS	;	1.64	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from P. aeruginosa in complex with F2X-Entry library fragment G11
8CFT	;	1.72	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from P. aeruginosa in complex with F2X-Entry library fragment G12
8CFU	;	1.5	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from P. aeruginosa in complex with F2X-Entry library fragment H02
8CFV	;	1.88	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from P. aeruginosa in complex with F2X-Entry library fragment H04
8CFW	;	1.61	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from P. aeruginosa in complex with F2X-Entry library fragment H05
8CFX	;	1.98	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from P. aeruginosa in complex with F2X-Entry library fragment H06
8CFY	;	1.88	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from P. aeruginosa in complex with F2X-Entry library fragment H08
8CG0	;	1.6	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from P. aeruginosa in complex with F2X-Entry library fragment H11
8CG1	;	2.02	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from P. aeruginosa in complex with F2X-Entry library fragment H12
6F3N	;	1.85	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from Pseudomonas aeruginosa cocrystallized with SAH in the presence of K+ and Zn2+ cations
6F3O	;	1.75	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from Pseudomonas aeruginosa complexed with adenine, K+ and Zn2+ cations
6F3M	;	1.6	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from Pseudomonas aeruginosa complexed with adenosine, K+ and Zn2+ cations
6F3P	;	1.35	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from Pseudomonas aeruginosa in complex with 3'-deoxyadenosine and K+ cation
6F3Q	;	1.45	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from Pseudomonas aeruginosa in complex with adenine and Rb+ cation
7R37	;	2.28	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from Pyrococcus furiosus in complex with inosine
7R38	;	2.05	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from Pyrococcus furiosus in complex with S-inosyl-L-homocysteine
7R39	;	2.5	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from Sulfolobus acidocaldarius in complex with adenosine
7O5M	;	2.2	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from Synechocystis sp. PCC 6803 cocrystallized with adenosine in the presence of Na+ cations
7O5L	;	1.74	;	Crystal structure of S-adenosyl-L-homocysteine hydrolase from Synechocystis sp. PCC 6803 cocrystallized with adenosine in the presence of Rb+ cations
3IHT	;	1.8	;	Crystal structure of S-adenosyl-L-methionine methyl transferase (YP_165822.1) from SILICIBACTER POMEROYI DSS-3 at 1.80 A resolution
4G41	;	1.45	;	Crystal structure of s-adenosylhomocysteine nucleosidase from streptococcus pyogenes in complex with 5-methylthiotubericidin
1MHM	;	2.3	;	Crystal structure of S-adenosylmethionine decarboxylase from potato
1VR7	;	1.2	;	Crystal structure of S-adenosylmethionine decarboxylase proenzyme (TM0655) from THERMOTOGA MARITIMA at 1.2 A resolution
3BKW	;	1.6	;	Crystal structure of S-adenosylmethionine dependent methyltransferase (NP_104914.1) from Mesorhizobium loti at 1.60 A resolution
4L7I	;	2.189	;	Crystal structure of S-Adenosylmethionine synthase from Sulfolobus solfataricus complexed with SAM and PPi
1XRA	;	3.0	;	CRYSTAL STRUCTURE OF S-ADENOSYLMETHIONINE SYNTHETASE
1XRC	;	3.0	;	CRYSTAL STRUCTURE OF S-ADENOSYLMETHIONINE SYNTHETASE
6C07	;	1.85	;	Crystal Structure of S-Adenosylmethionine synthetase (MetK/Mat) from Cryptosporidium parvum
3IML	;	2.35	;	Crystal Structure Of S-Adenosylmethionine Synthetase From Burkholderia Pseudomallei
3RV2	;	2.0	;	Crystal structure of S-adenosylmethionine synthetase from Mycobacterium marinum
4HPV	;	2.214	;	Crystal structure of S-Adenosylmethionine synthetase from Sulfolobus solfataricus
4L2Z	;	2.494	;	Crystal structure of S-Adenosylmethionine synthetase from Sulfolobus solfataricus complexed with SAE and PPi
4K0B	;	2.39	;	Crystal structure of S-Adenosylmethionine synthetase from Sulfolobus solfataricus complexed with SAM and PPi
3TDE	;	1.85	;	Crystal structure of S-adenosylmethionine synthetase Rv1392 from Mycobacterium tuberculosis
1VKY	;	2.0	;	Crystal structure of S-adenosylmethionine tRNA ribosyltransferase (TM0574) from Thermotoga maritima at 2.00 A resolution
2P8J	;	2.0	;	Crystal structure of S-adenosylmethionine-dependent methyltransferase (NP_349143.1) from Clostridium acetobutylicum at 2.00 A resolution
4HTF	;	1.6	;	Crystal structure of S-adenosylmethionine-dependent methyltransferase from Escherichia coli in complex with S-adenosylmethionine.
8K76	;	1.49	;	Crystal structure of S-adenosylmethionine-dependent methyltransferase from Fusobacterium nucleatum
4U1Q	;	2.085	;	Crystal structure of S-adenosylmethionine-dependent methyltransferase SibL in complex with 3HK and SAH
4X3Q	;	2.586	;	Crystal structure of S-adenosylmethionine-dependent methyltransferase SibL in complex with SAH
4QVG	;	2.9	;	Crystal structure of S-adenosylmethionine-dependent methyltransferase SibL in its apo form
8T1A	;	2.0	;	Crystal Structure of S-adenosylmethionine-dependent methyltransferase UmaA from Mycobacterium tuberculosis (P32 Twin)
7L9U	;	1.55	;	Crystal Structure of S-adenosylmethionine-dependent methyltransferase UmaA from Mycobacterium tuberculosis in complex with a 12-mer PEG
7MCJ	;	1.8	;	Crystal Structure of S-adenosylmethionine-dependent methyltransferase UmaA from Mycobacterium tuberculosis in complex with compound 8918
7LXI	;	1.95	;	Crystal structure of S-adenosylmethionine-dependent methyltransferase UmaA from Mycobacterium tuberculosis in complex with SAH
2PCN	;	1.9	;	Crystal structure of S-adenosylmethionine: 2-dimethylmenaquinone methyltransferase (gk_1813) from geobacillus kaustophilus HTA426
7L0A	;	1.6	;	Crystal structure of s-formylglutathione hydrolase (FrmB) from Staphylococcus aureus, apoenzyme
1FLJ	;	1.8	;	CRYSTAL STRUCTURE OF S-GLUTATHIOLATED CARBONIC ANHYDRASE III
4YK7	;	2.6	;	Crystal structure of S-hydroxynitrile lyase from Manihot esculenta (His103Leu)
7QLE	;	2.6	;	Crystal structure of S-layer protein SlpA from Lactobacillus acidophilus, domain I (aa 32-198)
7QLD	;	2.153	;	Crystal structure of S-layer protein SlpA from Lactobacillus acidophilus, domain I, Co-crystallization with HgCl2, Mutation Ser146Cys, (aa 32-198)
7QFL	;	1.4	;	Crystal structure of S-layer protein SlpA from Lactobacillus acidophilus, domain II (aa 199-308)
7QFG	;	1.65	;	Crystal structure of S-layer protein SlpA from Lactobacillus acidophilus, domain III (aa 309-444)
7QLH	;	2.3	;	Crystal structure of S-layer protein SlpA from Lactobacillus amylovorus, domain I (aa 48-213)
7QFI	;	1.5	;	Crystal structure of S-layer protein SlpX from Lactobacillus acidophilus, domain I (aa 31-182)
7QFJ	;	2.5	;	Crystal structure of S-layer protein SlpX from Lactobacillus acidophilus, domain II (aa 194-362)
7QFK	;	2.48	;	Crystal structure of S-layer protein SlpX from Lactobacillus acidophilus, domain II, Co-Crystallization with HgCl2, Mutation Ser316Cys (aa 194-362)
8AOL	;	2.4	;	Crystal structure of S-layer protein SlpX from Lactobacillus acidophilus, domain III (aa 363-499)
4OO5	;	1.54	;	Crystal Structure of S-nitrosated Human Thioredoxin Mutant
2HXK	;	1.65	;	Crystal structure of S-nitroso thioredoxin
2IFQ	;	1.2	;	Crystal structure of S-nitroso thioredoxin
2IIY	;	1.7	;	Crystal structure of S-nitroso thioredoxin
1BUW	;	1.9	;	CRYSTAL STRUCTURE OF S-NITROSO-NITROSYL HUMAN HEMOGLOBIN A
4DLA	;	2.14	;	Crystal structure of S-nitrosoglutathione reductase apoenzyme from tomato (Solanum lycopersicum)
4L0Q	;	1.95	;	Crystal structure of S-nitrosoglutathione reductase from Arabidopsis thaliana, C370A/C373A double mutant
3UKO	;	1.4	;	Crystal Structure of S-Nitrosoglutathione Reductase from Arabidopsis thaliana, complex with NADH
4JJI	;	1.8	;	Crystal structure of S-nitrosoglutathione reductase from Arabidopsis thalina, complex with NAD+
4DL9	;	1.85	;	Crystal structure of S-nitrosoglutathione reductase from tomato (Solanum lycopersicum) in complex with NAD+
7AV7	;	2.9	;	Crystal structure of S-nitrosylated nitrosoglutathione reductase(GSNOR)from Chlamydomonas reinhardtii, in complex with NAD+
1UHG	;	1.9	;	Crystal Structure of S-Ovalbumin At 1.9 Angstrom Resolution
4PIA	;	1.466	;	Crystal structure of S. Aureus Autolysin E
4PI7	;	1.6	;	Crystal structure of S. Aureus Autolysin E in complex with disaccharide NAM-NAG
4PI9	;	1.48	;	Crystal structure of S. Aureus Autolysin E in complex with muropeptide NAM-L-ALA-D-iGLU
6L4L	;	2.0	;	Crystal structure of S. aureus CntK in inactive state
6JIW	;	1.58	;	Crystal structure of S. aureus CntK with C72S mutation
7VHV	;	2.55	;	Crystal structure of S. aureus D-alanine alanyl carrier protein ligase
7O39	;	1.3	;	Crystal structure of S. aureus DivIVA N terminal domain
3IL7	;	2.6	;	Crystal structure of S. aureus FabH
1ZOW	;	2.0	;	Crystal Structure of S. aureus FabH, beta-ketoacyl carrier protein synthase III
4ALN	;	3.05	;	Crystal structure of S. aureus FabI (P32)
4ALM	;	2.45	;	Crystal structure of S. aureus FabI (P43212)
4BNL	;	2.15	;	Crystal structure of S. aureus FabI in complex with NADP and 2- phenoxy-5-(2-propenyl)phenol
4BNF	;	2.3	;	Crystal structure of S. aureus FabI in complex with NADP and 2- phenoxy-5-propylphenol
4BNI	;	2.2	;	Crystal structure of S. aureus FabI in complex with NADP and 2-(2- aminophenoxy)-5-hexylphenol
4D43	;	2.15	;	Crystal structure of S. aureus FabI in complex with NADP and 2-(2- chloro-4-nitrophenoxy)-5-ethyl-4-fluorophenol
4BNN	;	2.25	;	Crystal structure of S. aureus FabI in complex with NADP and 2-(2- cyanophenoxy)-5-hexylphenol
4D42	;	2.02	;	Crystal structure of S. aureus FabI in complex with NADP and 4-fluoro- 5-hexyl-2-phenoxyphenol
4D45	;	2.15	;	Crystal structure of S. aureus FabI in complex with NADP and 5-bromo- 2-(4-chloro-2-hydroxyphenoxy)benzonitrile
4ALJ	;	2.2	;	Crystal structure of S. aureus FabI in complex with NADP and 5-chloro- 2-phenoxyphenol
4ALK	;	1.9	;	Crystal structure of S. aureus FabI in complex with NADP and 5-ethyl- 2-phenoxyphenol
4D44	;	1.8	;	Crystal structure of S. aureus FabI in complex with NADP and 5-ethyl- 4-fluoro-2-((2-fluoropyridin-3-yl)oxy)phenol
4BNK	;	2.5	;	Crystal structure of S. aureus FabI in complex with NADP and 5-fluoro- 2-phenoxyphenol
4BNM	;	2.35	;	Crystal structure of S. aureus FabI in complex with NADP and 5-hexyl- 2-(2-methylphenoxy)phenol
4D41	;	2.3	;	Crystal structure of S. aureus FabI in complex with NADP and 5-hexyl- 2-(4-nitrophenoxy)phenol
4BNH	;	2.15	;	Crystal structure of S. aureus FabI in complex with NADP and 5-hexyl- 2-phenoxyphenol
4BNJ	;	2.4	;	Crystal structure of S. aureus FabI in complex with NADP and 5-methyl- 2-phenoxyphenol
4BNG	;	2.2	;	Crystal structure of S. aureus FabI in complex with NADP and 5-pentyl- 2-phenoxyphenol
4ALI	;	2.1	;	Crystal structure of S. aureus FabI in complex with NADP and triclosan (P1)
4ALL	;	2.8	;	Crystal structure of S. aureus FabI in complex with NADP and triclosan (P212121)
4CV1	;	1.95	;	Crystal structure of S. aureus FabI in complex with NADPH and CG400549
4CV0	;	2.2	;	Crystal structure of S. aureus FabI in complex with NADPH and CG400549 (small unit cell)
6TBB	;	2.45	;	Crystal structure of S. aureus FabI in complex with NADPH and kalimantacin A (batumin)
6TBC	;	2.55	;	Crystal structure of S. aureus FabI in complex with NADPH and kalimantacin B
4CUZ	;	3.1	;	Crystal structure of S. aureus FabI in complex with NADPH and PT173
6YUR	;	1.96	;	Crystal structure of S. aureus FabI inhibited by SKTS1
1RTR	;	2.5	;	Crystal Structure of S. Aureus Farnesyl Pyrophosphate Synthase
7TEA	;	2.35	;	Crystal structure of S. aureus GlnR-DNA complex
6FXP	;	2.03	;	Crystal structure of S. aureus glucosaminidase B
7TDV	;	2.92	;	Crystal structure of S. aureus glutamine synthetase in Met-Sox-P/ADP transition state complex
7FVS	;	2.16	;	Crystal Structure of S. aureus gyrase in complex with 4-[[1-[(1-chloro-6,7-dihydro-5H-cyclopenta[c]pyridin-6-yl)methyl]azetidin-3-yl]methylamino]-6-fluorochromen-2-one
7FVT	;	2.081	;	Crystal Structure of S. aureus gyrase in complex with 6-[5-[2-[(4-chloro-2,3-dihydro-1H-inden-2-yl)methylamino]ethyl]-2-oxo-1,3-oxazolidin-3-yl]-4H-pyrido[3,2-b][1,4]oxazin-3-one
4PG4	;	2.2	;	Crystal structure of S. aureus Homoserine Dehydrogenase at pH6.0
4PG5	;	2.2	;	Crystal structure of S. aureus Homoserine Dehydrogenase at pH6.5
4PG6	;	2.2	;	Crystal structure of S. aureus Homoserine Dehydrogenase at pH7.0
4PG7	;	2.1	;	Crystal structure of S. aureus Homoserine Dehydrogenase at pH7.5
4PG8	;	2.2	;	Crystal structure of S. aureus Homoserine Dehydrogenase at pH8.5
2Q8Q	;	2.15	;	Crystal Structure of S. aureus IsdE complexed with heme
6UEX	;	1.9	;	Crystal structure of S. aureus LcpA in complex with octaprenyl-pyrophosphate-GlcNAc
4L9J	;	3.45	;	Crystal structure of S. aureus MepR in DNA-binding conformation
4LLL	;	3.036	;	Crystal structure of S. aureus MepR-DNA complex
4LLN	;	2.842	;	Crystal structure of S. aureus MepR-DNA complex
1QXY	;	1.04	;	Crystal structure of S. aureus methionine aminopeptidase in complex with a ketoheterocycle 618
1QXZ	;	1.68	;	Crystal structure of S. aureus methionine aminopeptidase in complex with a ketoheterocycle inhibitor 119
1HSK	;	2.3	;	CRYSTAL STRUCTURE OF S. AUREUS MURB
5TW4	;	1.57	;	Crystal structure of S. aureus penicillin binding protein 4 (PBP4) mutant (E183A, F241R) in complex with ceftaroline
5TX9	;	1.68	;	Crystal structure of S. aureus penicillin binding protein 4 (PBP4) mutant (E183A, F241R) in complex with ceftobiprole
5TY2	;	1.7	;	Crystal structure of S. aureus penicillin binding protein 4 (PBP4) mutant (E183A, F241R) in complex with nafcillin
6DZ8	;	1.86	;	Crystal structure of S. aureus penicillin binding protein 4 (PBP4) mutant (S75C)
7KCV	;	1.6	;	Crystal structure of S. aureus penicillin-binding protein 4 (PBP4) mutant (R200L)
7KCX	;	1.62	;	Crystal structure of S. aureus penicillin-binding protein 4 (PBP4) mutant (R200L) in complex with cefoxitin
7KCW	;	1.73	;	Crystal structure of S. aureus penicillin-binding protein 4 (PBP4) mutant (R200L) in complex with nafcillin
7KCY	;	1.85	;	Crystal structure of S. aureus penicillin-binding protein 4 (PBP4) with cefoxitin
1LMH	;	1.9	;	Crystal Structure of S. aureus peptide deformylase
3HB9	;	2.9	;	Crystal Structure of S. aureus Pyruvate Carboxylase A610T Mutant
3HO8	;	2.9	;	Crystal Structure of S. aureus Pyruvate Carboxylase in complex with Coenzyme A
3HBL	;	2.71	;	Crystal Structure of S. aureus Pyruvate Carboxylase T908A Mutant
3T05	;	3.05	;	Crystal structure of S. aureus Pyruvate Kinase
3T0T	;	3.1	;	Crystal structure of S. aureus Pyruvate Kinase
3T07	;	3.3	;	Crystal structure of S. aureus Pyruvate Kinase in complex with a naturally occurring bis-indole alkaloid
6R1N	;	2.03	;	Crystal structure of S. aureus seryl-tRNA synthetase complexed to seryl sulfamoyl adenosine
6XHP	;	1.9	;	Crystal structure of S. aureus TarI (space group C121)
6XHR	;	2.1	;	Crystal structure of S. aureus TarI (space group P1211)
6XHQ	;	2.4	;	Crystal structure of S. aureus TarI in complex with CDP-ribitol (space group C121)
6XHT	;	1.8	;	Crystal structure of S. aureus TarI in complex with CDP-ribitol (space group P1211)
6XHS	;	2.9	;	Crystal structure of S. aureus TarI in complex with CTP (space group P1211)
6XH9	;	3.2	;	Crystal structure of S. aureus TarJ
6XHK	;	3.0	;	Crystal structure of S. aureus TarJ in complex with NADPH
8V34	;	3.0	;	Crystal structure of S. aureus TarK N-terminal domain
8V33	;	1.7	;	Crystal structure of S. aureus TarL N-terminal domain
4X7R	;	2.15	;	Crystal structure of S. aureus TarM G117R mutant in complex with Fondaparinux, alpha-GlcNAc-glycerol and UDP
4X7M	;	2.4	;	Crystal structure of S. aureus TarM G117R mutant in complex with UDP and UDP-GlcNAc
4X6L	;	3.19	;	Crystal structure of S. aureus TarM in complex with UDP
5TZ8	;	4.0	;	Crystal structure of S. aureus TarS
5TZI	;	2.3	;	Crystal structure of S. aureus TarS 1-349
5TZK	;	2.22	;	Crystal structure of S. aureus TarS 1-349 in complex with UDP
5TZJ	;	1.9	;	Crystal structure of S. aureus TarS 1-349 in complex with UDP-GlcNAc
5U02	;	2.301	;	Crystal structure of S. aureus TarS 217-571
5TZE	;	2.33	;	Crystal structure of S. aureus TarS in complex with UDP-GlcNAc
2CCJ	;	1.7	;	Crystal structure of S. aureus thymidylate kinase complexed with thymidine monophosphate
1JII	;	3.2	;	Crystal structure of S. aureus TyrRS in complex with SB-219383
1JIJ	;	3.2	;	Crystal structure of S. aureus TyrRS in complex with SB-239629
1JIK	;	2.8	;	Crystal structure of S. aureus TyrRS in complex with SB-243545
1JIL	;	2.2	;	Crystal structure of S. aureus TyrRS in complex with SB284485
2ODM	;	2.24	;	Crystal structure of S. aureus YlaN, an essential leucine rich protein involved in the control of cell shape
6R4L	;	3.5	;	Crystal structure of S. cerevisia Niemann-Pick type C protein NCR1
6R4M	;	2.8	;	Crystal structure of S. cerevisia Niemann-Pick type C protein NPC2
6R4N	;	2.9	;	Crystal structure of S. cerevisia Niemann-Pick type C protein NPC2 with ergosterol bound
6WY6	;	1.773	;	Crystal structure of S. cerevisiae Atg8 in complex with Ede1 (1220-1247)
5O7X	;	3.2	;	CRYSTAL STRUCTURE OF S. CEREVISIAE CORE FACTOR AT 3.2A RESOLUTION
3BQ3	;	1.9	;	Crystal structure of S. cerevisiae Dcn1
5OMD	;	2.1	;	Crystal structure of S. cerevisiae Ddc2 N-terminal coiled-coil domain
6H57	;	2.3	;	Crystal structure of S. cerevisiae DEAH-box RNA helicase Dhr1, essential for small ribosomal subunit biogenesis
7KKF	;	2.4	;	Crystal Structure of S. cerevisiae Ess1
3IDQ	;	3.701	;	Crystal structure of S. cerevisiae Get3 at 3.7 Angstrom resolution
3B2E	;	3.0	;	Crystal structure of S. cerevisiae Get3 in the open conformation in complex with Get1 cytosolic domain
3SJA	;	3.0	;	Crystal structure of S. cerevisiae Get3 in the open state in complex with Get1 cytosolic domain
3SJB	;	3.3	;	Crystal structure of S. cerevisiae Get3 in the open state in complex with Get1 cytosolic domain
3VLC	;	4.5	;	Crystal structure of S. cerevisiae Get3 in the semi open conformation in complex with Get1 cytosolic domain at 4.5 angstrom resolution
3SJD	;	4.6	;	Crystal structure of S. cerevisiae Get3 with bound ADP-Mg2+ in complex with Get2 cytosolic domain
3LKU	;	2.8	;	Crystal structure of S. cerevisiae Get4 in complex with an N-terminal fragment of Get5
2WPV	;	1.99	;	Crystal structure of S. cerevisiae Get4-Get5 complex
3P26	;	2.5	;	Crystal structure of S. cerevisiae Hbs1 protein (apo-form), a translational GTPase involved in RNA quality control pathways and interacting with Dom34/Pelota
3P27	;	2.95	;	Crystal structure of S. cerevisiae Hbs1 protein (GDP-bound form), a translational GTPase involved in RNA quality control pathways and interacting with Dom34/Pelota
7WJL	;	2.4	;	Crystal structure of S. cerevisiae Hos3
4N0H	;	1.952	;	Crystal structure of S. cerevisiae mitochondrial GatFAB
4N0I	;	2.001	;	Crystal structure of S. cerevisiae mitochondrial GatFAB in complex with glutamine
7RDN	;	2.49	;	Crystal structure of S. cerevisiae pre-mRNA leakage protein 39 (Pml39)
3OWT	;	2.0	;	Crystal structure of S. cerevisiae RAP1-Sir3 complex
5M1X	;	1.8	;	Crystal structure of S. cerevisiae Rfa1 N-OB domain mutant (K45E)
3ZCO	;	2.7	;	Crystal structure of S. cerevisiae Sir3 C-terminal domain
7Q83	;	2.19	;	Crystal structure of S. cerevisiae Sso2 in complex with the pleckstrin homology domain of Sec3
3KEY	;	2.1	;	Crystal structure of S. cerevisiae Stn1 C-terminal
3I2D	;	2.6	;	Crystal Structure of S. Cerevisiae SUMO E3 Ligase SIZ1
6U75	;	2.63	;	Crystal Structure of S. Cerevisiae SUMO E3 Ligase SIZ2
3KT0	;	2.1	;	Crystal structure of S. cerevisiae tryptophanyl-tRNA synthetase
3KT8	;	3.0	;	Crystal structure of S. cerevisiae tryptophanyl-tRNA synthetase in complex with L-tryptophanamide
3KT6	;	2.8	;	Crystal structure of S. cerevisiae tryptophanyl-tRNA synthetase in complex with Trp
3KT3	;	2.6	;	Crystal structure of S. cerevisiae tryptophanyl-tRNA synthetase in complex with TrpAMP
5DVB	;	2.2	;	Crystal Structure of S. cerevisiae TSA2
5EPT	;	5.0	;	Crystal Structure of S. cerevisiae TSA2 in the disulfide state
6NYD	;	1.65	;	Crystal Structure of S. cerevisiae Ubc3 (Cdc34)
1RD6	;	2.6	;	Crystal Structure of S. Marcescens Chitinase A Mutant W167A
1X6L	;	1.9	;	Crystal structure of S. marcescens chitinase A mutant W167A
1X6N	;	2.0	;	Crystal structure of S. marcescens chitinase A mutant W167A in complex with allosamidin
1W1P	;	2.1	;	Crystal structure of S. marcescens chitinase B in complex with the cyclic dipeptide inhibitor cyclo-(Gly-L-Pro) at 2.1 A resolution
1W1T	;	1.9	;	Crystal structure of S. marcescens chitinase B in complex with the cyclic dipeptide inhibitor cyclo-(His-L-Pro) at 1.9 A resolution
1W1V	;	1.85	;	Crystal structure of S. marcescens chitinase B in complex with the cyclic dipeptide inhibitor cyclo-(L-Arg-L-Pro) at 1.85 A resolution
1W1Y	;	1.85	;	Crystal structure of S. marcescens chitinase B in complex with the cyclic dipeptide inhibitor cyclo-(L-Tyr-L-Pro) at 1.85 A resolution
4IL3	;	3.102	;	Crystal Structure of S. mikatae Ste24p
3SR7	;	2.036	;	Crystal structure of S. mutans isopentenyl pyrophosphate isomerase
3QR0	;	2.0	;	Crystal Structure of S. officinalis PLC21
3ZH3	;	2.9	;	crystal structure of S. pneumoniae D39 native MurA1
2Z6I	;	1.7	;	Crystal Structure of S. pneumoniae Enoyl-Acyl Carrier Protein Reductase (FabK)
2Z6J	;	2.3	;	Crystal Structure of S. pneumoniae Enoyl-Acyl Carrier Protein Reductase (FabK) in Complex with an Inhibitor
3ZH4	;	1.8	;	crystal structure of S. pneumoniae Hungary 19A MurA1 in complex with citrate
1W3Y	;	1.65	;	Crystal structure of S. pneumoniae hyaluronate lyase in complex with palmitoyl-vitamin C
2BRP	;	2.0	;	Crystal structure of S. pneumoniae hyaluronate lyase in complex with W249b
4MSJ	;	1.8	;	Crystal structure of S. pombe AMSH-like protease SST2 catalytic domain from P212121 space group
6JPK	;	2.102	;	Crystal structure of S. pombe aspartate aminotransferase
4HDV	;	2.702	;	Crystal structure of S. pombe ATL1 in complex with damaged DNA containing 2,6-diaminopurine
4HDU	;	2.848	;	Crystal structure of S. pombe ATL1 in complex with damaged DNA containing 2-aminopurine
4ENM	;	2.8402	;	Crystal structure of S. pombe Atl1 in complex with damaged DNA containing O6-benzylguanine
4ENN	;	2.8448	;	Crystal structure of S. pombe Atl1 in complex with damaged DNA containing O6-carboxymethylguanine
4ENJ	;	3.0989	;	Crystal structure of S. pombe Atl1 in complex with damaged DNA containing O6-hydroxyethylguanine
4ENK	;	3.0445	;	Crystal structure of S. pombe Atl1 in complex with damaged DNA containing O6-propylguanine
3L40	;	1.55	;	Crystal Structure of S. pombe Brc1 BRCT5-BRCT6 domains
3L41	;	1.45	;	Crystal Structure of S. pombe Brc1 BRCT5-BRCT6 domains in complex with phosphorylated H2A
5JP4	;	2.043	;	Crystal structure of S. pombe Dcp1 in complex with the decapping enhancer EDC
5KQ1	;	3.002	;	Crystal structure of S. pombe Dcp1/Dcp2 in complex with H. sapiens PNRC2
5KQ4	;	2.56	;	Crystal structure of S. pombe Dcp1/Dcp2 in complex with H. sapiens PNRC2 and synthetic cap analog
5J3Q	;	1.87	;	Crystal structure of S. pombe Dcp1:Edc1 mRNA decapping complex
5J3Y	;	3.288	;	Crystal structure of S. pombe Dcp2:Dcp1 mRNA decapping complex
5J3T	;	1.6	;	Crystal structure of S. pombe Dcp2:Dcp1:Edc1 mRNA decapping complex
6FDF	;	1.697	;	Crystal structure of S. pombe Dnmt2 methyltransferase
4S3H	;	2.701	;	Crystal structure of S. pombe Mdb1 FHA domain
6YYL	;	1.89	;	Crystal structure of S. pombe Mei2 RRM3 domain
4Q2S	;	1.35	;	Crystal Structure of S. pombe Pdc1 Ge1 Domain
6WUG	;	1.9	;	Crystal Structure of S. pombe Rai1 in complex with 3'-FADP
4B0Z	;	1.585	;	Crystal structure of S. pombe Rpn12
4RG5	;	1.7	;	Crystal Structure of S. Pombe SMN YG-Dimer
3KF6	;	1.65	;	Crystal structure of S. pombe Stn1-ten1 complex
5UM6	;	2.794	;	Crystal Structure of S. pombe Uba1 in a closed conformation
4II3	;	2.9	;	Crystal structure of S. pombe Ubiquitin activating enzyme 1 (Uba1) in complex with ubiquitin and ATP/Mg
5KNL	;	2.5	;	Crystal structure of S. pombe ubiquitin E1 (Uba1) in complex with Ubc15 and ubiquitin
4CMP	;	2.62	;	Crystal structure of S. pyogenes Cas9
5IG0	;	1.75	;	Crystal structure of S. rosetta CaMKII hub
5IG1	;	2.9	;	Crystal structure of S. rosetta CaMKII kinase domain
5HMB	;	2.151	;	Crystal structure of S. sahachiroi AziG
5HMC	;	2.2	;	Crystal structure of S. sahachiroi AziG complexed with 5-methyl naphthoic acid
7BVU	;	2.5	;	Crystal structure of S. thermophilus NFeoB E66A.E67A bound to GDP.AlF4-
7BWV	;	2.35	;	Crystal structure of S. thermophilus NFeoB E67A bound to GDP.AlF4-
3AJE	;	1.8	;	Crystal structure of S. tokodaii Sua5 complexed with L-threonine and AMPPNP
1Z5U	;	2.3	;	Crystal structure of S. typhimurium AphA complexed with cyclic-AMP
3NR7	;	3.7	;	Crystal structure of S. typhimurium H-NS 1-83
4P7B	;	1.6	;	Crystal structure of S. typhimurium peptidyl-tRNA hydrolase
5BS3	;	2.65	;	Crystal Structure of S.A. gyrase in complex with Compound 7
4PLB	;	2.69	;	Crystal Structure of S.A. gyrase-AM8191 complex
5T73	;	2.599	;	Crystal structure of S.aureus glyceraldehyde-3-phosphate-dehydrogenase (Gap) containing oxidized Cys151
2EWS	;	2.05	;	Crystal structure of S.aureus pantothenate kinase
1LQW	;	1.87	;	Crystal Structure of S.aureus Peptide Deformylase
5XEX	;	2.2	;	Crystal structure of S.aureus PNPase catalytic domain
1G62	;	2.5	;	CRYSTAL STRUCTURE OF S.CEREVISIAE EIF6
3SJC	;	3.2	;	Crystal structure of S.cerevisiae Get3 in the semi-open state in complex with Get1 cytosolic domain
3GGY	;	1.7	;	Crystal Structure of S.cerevisiae Ist1 N-terminal domain
3GGZ	;	3.8	;	Crystal Structure of S.cerevisiae Ist1 N-terminal domain in complex with Did2 MIM motif
5AX2	;	2.4	;	Crystal structure of S.cerevisiae Kti11p
2QP9	;	2.9	;	Crystal Structure of S.cerevisiae Vps4
2QPA	;	3.2	;	Crystal Structure of S.cerevisiae Vps4 in the presence of ADP
3EIH	;	3.25	;	Crystal structure of S.cerevisiae Vps4 in the presence of ATPgammaS
3EIE	;	2.7	;	Crystal Structure of S.cerevisiae Vps4 in the SO4-bound state
2RKL	;	1.5	;	Crystal Structure of S.cerevisiae Vta1 C-terminal domain
2RKK	;	2.9	;	Crystal Structure of S.cerevisiae Vta1 N-terminal domain
4GQZ	;	1.799	;	Crystal Structure of S.CueP
1G95	;	2.33	;	CRYSTAL STRUCTURE OF S.PNEUMONIAE GLMU, APO FORM
1HM0	;	2.3	;	CRYSTAL STRUCTURE OF S.PNEUMONIAE N-ACETYLGLUCOSAMINE 1-PHOSPHATE URIDYLTRANSFERASE, GLMU
1HM8	;	2.5	;	CRYSTAL STRUCTURE OF S.PNEUMONIAE N-ACETYLGLUCOSAMINE-1-PHOSPHATE URIDYLTRANSFERASE, GLMU, BOUND TO ACETYL COENZYME A
1HM9	;	1.75	;	CRYSTAL STRUCTURE OF S.PNEUMONIAE N-ACETYLGLUCOSAMINE-1-PHOSPHATE URIDYLTRANSFERASE, GLMU, BOUND TO ACETYL COENZYME A AND UDP-N-ACETYLGLUCOSAMINE
3E20	;	3.5	;	Crystal structure of S.pombe eRF1/eRF3 complex
7P0J	;	1.48	;	Crystal structure of S.pombe Mdb1 BRCT domains
7P0L	;	1.97	;	Crystal structure of S.pombe Mdb1 BRCT domains in complex with a H2A phosphopeptide
2A6T	;	2.5	;	Crystal structure of S.pombe mRNA decapping enzyme Dcp2p
4BMC	;	1.982	;	Crystal structure of s.pombe Rad4 BRCT1,2
4BMD	;	2.5	;	Crystal structure of S.pombe Rad4 BRCT3,4
1V71	;	1.7	;	Crystal Structure of S.pombe Serine Racemase
1WTC	;	1.9	;	Crystal Structure of S.pombe Serine Racemase complex with AMPPCP
7Q52	;	2.35	;	Crystal structure of S/T protein kinase PknG from Mycobacterium tuberculosis in complex with inhibitor L2W
5EE8	;	1.54	;	Crystal structure of S02030 boronic acid inhibitor complexed to SHV-1 beta-lactamase
3NSL	;	1.5	;	Crystal Structure of S100A3 C30A+C68A double mutant expressed in insect cell
3NSO	;	1.45	;	Crystal Structure of S100A3 Protein Expressed in Insect Cell
7PSP	;	2.61	;	Crystal structure of S100A4 labeled with NU000846b.
7PSQ	;	1.91	;	Crystal structure of S100A4 labeled with NU074381b.
3D10	;	1.65	;	Crystal Structure of S100B in the Calcium and Zinc Loaded State at pH 10.0
3D0Y	;	1.5	;	Crystal Structure of S100B in the Calcium and Zinc Loaded State at pH 6.5
3CZT	;	1.4	;	Crystal Structure of S100B in the Calcium and Zinc Loaded State at pH 9
6LYL	;	2.1	;	Crystal structure of S1052D mutant of Formylglycinamidine synthetase
3RSM	;	2.1	;	Crystal structure of S108C mutant of PMM/PGM
6BG6	;	1.52	;	Crystal structure of S111A mutant of human macrophage migration inhibitory factor
2RI6	;	1.68	;	Crystal Structure of S112A mutant of a C-C hydrolase, BphD from Burkholderia xenovorans LB400
2PU7	;	2.07	;	Crystal Structure of S112A/H265A double mutant of a C-C hydrolase, BphD, from Burkholderia xenovorans LB400
2WUD	;	2.1	;	Crystal structure of S114A mutant of HsaD from Mycobacterium tuberculosis
2WUF	;	1.9	;	Crystal structure of S114A mutant of HsaD from Mycobacterium tuberculosis in complex with 4,9DSHA
2WUG	;	1.8	;	Crystal structure of S114A mutant of HsaD from Mycobacterium tuberculosis in complex with HOPDA
2WUE	;	1.8	;	Crystal structure of S114A mutant of HsaD from Mycobacterium tuberculosis in complex with HOPODA
5F5X	;	2.006	;	Crystal structure of S116A Ba3275 with AMP bound
7NNK	;	1.8	;	Crystal structure of S116A mutant of hydroxy ketone aldolase (SwHKA) from Sphingomonas wittichii RW1 in complex with hydroxypyruvate
3FAO	;	2.01	;	Crystal structure of S118A mutant 3CLSP of PRRSV
5JVY	;	2.36	;	Crystal structure of S121P murine COX-2 mutant
2BJH	;	2.54	;	Crystal Structure Of S133A AnFaeA-ferulic acid complex
3WO5	;	2.79	;	Crystal structure of S147Q of Rv2613c from Mycobacterium tuberculosis
2VI9	;	2.0	;	Crystal structure of S172AbsSHMT Glycine external aldimine
2VI8	;	1.67	;	Crystal structure of S172AbsSHMT internal aldimine
2VIA	;	1.67	;	Crystal structure of S172AbsSHMT L-Serine external aldimine
2VIB	;	1.85	;	Crystal structure of S172AbsSHMT obtained in the presence of L-allo- Thr
7CY0	;	1.32	;	Crystal structure of S185H mutant PET hydrolase from Ideonella sakaiensis
4DPX	;	1.948	;	Crystal structure of S192A Staphylococcus epidermidis mevalonate diphosphate decarboxylase
4PEM	;	2.5	;	Crystal Structure of S1G mutant of Penicillin G Acylase from Kluyvera citrophila
5H4Z	;	3.01	;	Crystal structure of S202G mutant of human SYT-5 C2A domain
4HSO	;	2.1	;	Crystal structure of S213G variant DAH7PS from Neisseria meningitidis
4IXX	;	2.4	;	Crystal structure of S213G variant DAH7PS without Tyr bound from Neisseria meningitidis
2R1W	;	1.7	;	Crystal structure of S25-2 Fab in complex with Kdo analogues
2R1X	;	1.6	;	Crystal structure of S25-2 Fab in complex with Kdo analogues
2R1Y	;	1.6	;	Crystal structure of S25-2 Fab in complex with Kdo analogues
2R23	;	1.65	;	Crystal structure of S25-2 Fab in complex with Kdo analogues
2R2B	;	1.6	;	Crystal structure of S25-2 Fab in complex with Kdo analogues
2R2E	;	2.4	;	Crystal structure of S25-2 Fab in complex with Kdo analogues
7T0J	;	2.15	;	Crystal structure of S25-2 Fab Unliganded 3
7T0K	;	2.0	;	Crystal structure of S25-2 Fab Unliganded 4
4HGW	;	1.65	;	Crystal structure of S25-2 in complex with a 5,6-dehydro-Kdo disaccharide
4M7J	;	1.95	;	Crystal structure of S25-26 in complex with Kdo(2.8)Kdo(2.4)Kdo trisaccharide
7T0F	;	2.0	;	Crystal structure of S25-39 Fab in complex with 4-MeO-KdoOAll
7T0G	;	1.53	;	Crystal structure of S25-39 Fab Unliganded 1
7T0H	;	1.3	;	Crystal structure of S25-39 Fab Unliganded 2
7T0I	;	2.1	;	Crystal structure of S25-39 Fab Unliganded 3
3OKD	;	1.8	;	Crystal structure of S25-39 in complex with Kdo
3OKK	;	1.95	;	Crystal structure of S25-39 in complex with Kdo(2.4)Kdo
3OKN	;	2.15	;	Crystal structure of S25-39 in complex with Kdo(2.4)Kdo(2.4)Kdo
3OKL	;	1.8	;	Crystal structure of S25-39 in complex with Kdo(2.8)Kdo
3OKO	;	2.45	;	Crystal structure of S25-39 in complex with Kdo(2.8)Kdo(2.4)Kdo
3OKE	;	2.4	;	Crystal structure of S25-39 in complex with Ko
1K7W	;	1.96	;	Crystal Structure of S283A Duck Delta 2 Crystallin Mutant
6YG0	;	2.0	;	Crystal structure of S287D,T291D MKK7 (MAP2K7), apo form
8GSK	;	2.271	;	Crystal Structure of S302G single mutant of O-acetyl-L-serine sulfhydrylase from Haemophilus influenzae at 2.2 A
5IMI	;	2.462	;	Crystal structure of S303A Aspergillus terreus aristolochene synthase complexed with (1S,8S,9aR)-1,9a-dimethyl-8-(prop-1-en-2-yl)decahydroquinolizin-5-ium
2ZRQ	;	2.16	;	Crystal structure of S324A-subtilisin
2PN6	;	1.44	;	Crystal Structure of S32A of ST1022-Gln complex from Sulfolobus tokodaii
7C08	;	3.35	;	Crystal structure of S34Y mutant of yeast U2AF1 complex bound to 3' splice site RNA, 5'-UAGGU.
3IDZ	;	2.5	;	Crystal Structure of S378Q mutant TTHA0252 from Thermus thermophilus HB8
3IE0	;	2.73	;	Crystal Structure of S378Y mutant TTHA0252 from Thermus thermophilus HB8
4RN0	;	1.761	;	Crystal structure of S39D HDAC8 in complex with a largazole analogue.
4RN1	;	2.18	;	Crystal structure of S39D HDAC8 in complex with a largazole analogue.
4RN2	;	2.39	;	Crystal structure of S39D HDAC8 in complex with a largazole analogue.
5BWZ	;	1.59	;	Crystal structure of S39E HDAC8 in complex with Droxinostat
5OPP	;	1.7	;	Crystal structure of S408R cN-II mutant
7WD2	;	2.69	;	Crystal structure of S43 bound to SARS-CoV-2 RBD
3I02	;	2.6	;	Crystal structure of S54-10 antibody in complex with antigen Kdo(2.4)Kdo(2.4)Kdo
7MRU	;	1.33	;	Crystal structure of S62A MIF2 mutant
5BSJ	;	2.0	;	Crystal structure of S63A mutant of human macrophage migration inhibitory factor
3PHQ	;	2.0	;	Crystal structure of S64-4 in complex with KDO
3PHO	;	2.6	;	Crystal structure of S64-4 in complex with PSBP
3WF7	;	1.85	;	Crystal structure of S6K1 kinase domain in complex with a purine derivative 1-(9H-purin-6-yl)-N-[3-(trifluoromethyl)phenyl]piperidine-4-carboxamide
3WF5	;	2.099	;	Crystal structure of S6K1 kinase domain in complex with a pyrazolopyrimidine derivative 4-[4-(1H-benzimidazol-2-yl)piperidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
3WF6	;	2.031	;	Crystal structure of S6K1 kinase domain in complex with a pyrazolopyrimidine derivative 4-[4-(1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]-1H-pyrazolo[3,4-d]pyrimidine
3WE4	;	1.995	;	Crystal structure of S6K1 kinase domain in complex with a pyrimidine derivative PF-4708671 2-{[4-(5-ethylpyrimidin-4-yl)piperazin-1-yl]methyl}-5-(trifluoromethyl)-1H-benzimidazole
3WF9	;	2.035	;	Crystal structure of S6K1 kinase domain in complex with a quinoline derivative 1-oxo-1-[(4-sulfamoylphenyl)amino]propan-2-yl-2-methyl-1,2,3,4-tetrahydroacridine-9-carboxylate
3WF8	;	1.975	;	Crystal structure of S6K1 kinase domain in complex with a quinoline derivative 2-oxo-2-[(4-sulfamoylphenyl)amino]ethyl 7,8,9,10-tetrahydro-6H-cyclohepta[b]quinoline-11-carboxylate
3HZM	;	1.8	;	Crystal structure of S73-2 antibody in complex with antigen Kdo
3HZK	;	2.15	;	Crystal structure of S73-2 antibody in complex with antigen Kdo(2.4)Kdo
3HZY	;	2.1	;	Crystal structure of S73-2 antibody in complex with antigen Kdo(2.4)Kdo(2.4)Kdo
3HZV	;	1.9	;	Crystal structure of S73-2 antibody in complex with antigen Kdo(2.8)Kdo(2.4)Kdo
8WT1	;	2.0	;	Crystal structure of S9 carboxypeptidase from Geobacillus sterothermophilus
5YZN	;	2.3	;	Crystal structure of S9 peptidase (active form) from Deinococcus radiodurans R1
5YZM	;	2.3	;	Crystal structure of S9 peptidase (inactive form) from Deinococcus radiodurans R1
6IGP	;	2.4	;	Crystal structure of S9 peptidase (inactive state)from Deinococcus radiodurans R1 in P212121
6IGR	;	2.6	;	Crystal structure of S9 peptidase (S514A mutant in inactive state) from Deinococcus radiodurans R1
5YZO	;	1.7	;	Crystal structure of S9 peptidase mutant (S514A) from Deinococcus radiodurans R1
6E3H	;	2.9	;	Crystal structure of S9-3-37 bound to H5 influenza hemagglutinin
3RY7	;	2.15	;	Crystal Structure of Sa239
5NWS	;	2.227	;	Crystal structure of saAcmM involved in actinomycin biosynthesis
4O5J	;	2.2	;	Crystal structure of SabA from Helicobacter pylori
4TRQ	;	3.1	;	Crystal structure of Sac3/Thp1/Sem1
2QFY	;	2.1	;	Crystal structure of Saccharomyces cerevesiae mitochondrial NADP(+)-dependent isocitrate dehydrogenase in complex with a-ketoglutarate
2QFW	;	2.6	;	Crystal structure of Saccharomyces cerevesiae mitochondrial NADP(+)-dependent isocitrate dehydrogenase in complex with isocitrate
2QFV	;	2.3	;	Crystal structure of Saccharomyces cerevesiae mitochondrial NADP(+)-dependent isocitrate dehydrogenase in complex with NADP(+)
2QFX	;	2.7	;	Crystal structure of Saccharomyces cerevesiae mitochondrial NADP(+)-dependent isocitrate dehydrogenase in complex with NADPH, a-ketoglutarate and Ca(2+)
4HBG	;	2.27	;	Crystal structure of Saccharomyces cerevisiae 3 oxoacyl-[acyl carrier protein]-reductase complexed with NADPH (form2)
4FDA	;	2.1	;	Crystal structure of Saccharomyces cerevisiae 3-oxoacyl-[acyl-carrier-protein] reductase complexed with NADP
8EW8	;	2.15	;	Crystal structure of Saccharomyces cerevisiae Altered Inheritance rate of Mitochondria protein 18 (AIM18p) R123A mutant
8EW9	;	2.0	;	Crystal structure of Saccharomyces cerevisiae Altered Inheritance rate of Mitochondria protein 46 (AIM46p)
7N3Z	;	1.99	;	Crystal Structure of Saccharomyces cerevisiae Apn2 Catalytic Domain
7N3Y	;	2.73	;	Crystal Structure of Saccharomyces cerevisiae Apn2 Catalytic Domain E59Q/D222N Mutant in Complex with DNA
4IJR	;	2.0	;	Crystal structure of Saccharomyces cerevisiae arabinose dehydrogenase Ara1 complexed with NADPH
3W1S	;	2.6	;	Crystal structure of Saccharomyces cerevisiae Atg12-Atg5 conjugate bound to the N-terminal domain of Atg16
3VH1	;	3.0	;	Crystal structure of Saccharomyces cerevisiae Atg7 (1-595)
3VH2	;	3.3	;	Crystal structure of Saccharomyces cerevisiae Atg7 (1-613)
3VXW	;	3.0	;	Crystal structure of Saccharomyces cerevisiae Atg8 complexed with Atg32 AIM
4KG4	;	1.8	;	Crystal structure of Saccharomyces cerevisiae Dcp2 Nudix domain (E198Q mutation)
4K6E	;	2.1	;	Crystal structure of Saccharomyces cerevisiae Dcp2 Nudix domain in complex with Mg
4KG3	;	1.7	;	Crystal structure of Saccharomyces cerevisiae Dcp2 Nudix domain in complex with Mg (E153Q mutation)
2AJ4	;	2.4	;	Crystal structure of Saccharomyces cerevisiae Galactokinase in complex with galactose and Mg:AMPPNP
6B4E	;	1.75	;	Crystal structure of Saccharomyces cerevisiae Gle1 CTD-Nup42 GBM complex
1I12	;	1.3	;	CRYSTAL STRUCTURE OF SACCHAROMYCES CEREVISIAE GNA1 COMPLEXED WITH ACCOA
3IBH	;	2.1	;	Crystal structure of Saccharomyces cerevisiae Gtt2 in complex with glutathione
7E29	;	2.303	;	Crystal Structure of Saccharomyces cerevisiae Ioc4 PWWP domain fused with MBP
5X6R	;	1.911	;	Crystal structure of Saccharomyces cerevisiae KMO in complex with Ro 61-8048
7F6W	;	2.607	;	Crystal structure of Saccharomyces cerevisiae lysyl-tRNA Synthetase
3QV0	;	2.1	;	Crystal structure of Saccharomyces cerevisiae Mam33
5AEX	;	3.2	;	Crystal structure of Saccharomyces cerevisiae Mep2
3V9R	;	2.4	;	Crystal structure of Saccharomyces cerevisiae MHF complex
3ZF8	;	1.98	;	Crystal structure of Saccharomyces cerevisiae Mnn9 in complex with GDP and Mn.
1IIC	;	2.2	;	Crystal Structure of Saccharomyces cerevisiae N-myristoyltransferase with Bound MyristoylCoA
1IID	;	2.5	;	Crystal Structure of Saccharomyces cerevisiae N-myristoyltransferase with Bound S-(2-oxo)pentadecylCoA and the Octapeptide GLYASKLA
7ROM	;	1.65	;	Crystal structure of Saccharomyces cerevisiae NADH-cytochrome b5 reductase 1 (Cbr1) fragment (residues 28-284) bound to FAD
3D8X	;	2.8	;	Crystal Structure of Saccharomyces cerevisiae NDPPH Dependent Thioredoxin Reductase 1
3OII	;	1.85	;	Crystal structure of Saccharomyces Cerevisiae Nep1/Emg1 bound to S-adenosylhomocysteine
3OIN	;	1.9	;	Crystal structure of Saccharomyces cerevisiae Nep1/Emg1 bound to S-adenosylhomocysteine and 1 molecule of cognate RNA
3OIJ	;	3.0	;	Crystal structure of Saccharomyces Cerevisiae Nep1/Emg1 bound to S-adenosylhomocysteine and 2 molecules of cognate RNA
1F89	;	2.4	;	Crystal structure of Saccharomyces cerevisiae Nit3, a member of branch 10 of the nitrilase superfamily
4IFQ	;	3.25	;	Crystal structure of Saccharomyces cerevisiae NUP192, residues 2 to 960 [ScNup192(2-960)]
4WML	;	1.73	;	Crystal structure of Saccharomyces cerevisiae OMP synthase in complex with PRP(CH2)P
4WN3	;	1.8	;	Crystal structure of Saccharomyces cerevisiae OMP synthase in complex with PRP(NH)P
5H2C	;	3.508	;	Crystal structure of Saccharomyces cerevisiae Osh1 ANK - Nvj1
4BJ1	;	2.94	;	Crystal structure of Saccharomyces cerevisiae RIF2
7WVT	;	1.5	;	Crystal structure of Saccharomyces cerevisiae Sfh2 complexed with phosphatidylinositol
7WWG	;	3.4	;	Crystal structure of Saccharomyces cerevisiae Sfh2 complexed with phosphatidylinositol in an open conformation
7WWD	;	2.39	;	Crystal structure of Saccharomyces cerevisiae Sfh2 complexed with squalene
7WWE	;	2.2	;	Crystal structure of Saccharomyces cerevisiae Sfh2 in an apo form
4J7P	;	2.0	;	Crystal structure of Saccharomyces cerevisiae Sfh3
4J7Q	;	1.55	;	Crystal structure of Saccharomyces cerevisiae Sfh3 complexed with phosphatidylinositol
6K6R	;	2.471	;	Crystal structure of Saccharomyces cerevisiae single domain sulfurtranferase RDL2
6J2P	;	2.85	;	Crystal structure of Saccharomyces cerevisiae Spp1 in complex with H3K4me3
3ITJ	;	2.4	;	Crystal structure of Saccharomyces cerevisiae thioredoxin reductase 1 (Trr1)
2EXU	;	2.23	;	Crystal Structure of Saccharomyces cerevisiae transcription elongation factors Spt4-Spt5NGN domain
3SBC	;	2.8	;	Crystal structure of Saccharomyces cerevisiae TSA1C47S mutant protein
1FZY	;	1.9	;	CRYSTAL STRUCTURE OF SACCHAROMYCES CEREVISIAE UBIQUITIN CONJUGATING ENZYME 1
4N9N	;	2.9	;	Crystal Structure of Saccharomyces cerevisiae Upc2 Transcription Factor fused with T4 Lysozyme
3GRE	;	1.8	;	Crystal structure of Saccharomyces cerevisiae Vps15 WD repeat domain
3FS5	;	1.9	;	Crystal structure of Saccharomyces cerevisiae Ygr203w, a homolog of single-domain rhodanese and Cdc25 phosphatase catalytic domain
1YGA	;	2.0	;	CRYSTAL STRUCTURE OF Saccharomyces cerevisiae YN9A PROTEIN, NEW YORK STRUCTURAL GENOMICS CONSORTIUM
3QWA	;	2.0	;	Crystal structure of Saccharomyces cerevisiae Zeta-crystallin-like quinone oxidoreductase Zta1
3QWB	;	1.59	;	Crystal structure of Saccharomyces cerevisiae Zeta-crystallin-like quinone oxidoreductase Zta1 complexed with NADPH
2Q99	;	1.64	;	Crystal Structure of Saccharopine Dehydrogenase from Saccharomyces cerevisiae
3UH1	;	2.17	;	Crystal Structure of Saccharopine Dehydrogenase from Saccharomyces cerevisiae with bound saccharopine and NADH
3UHA	;	2.3	;	Crystal Structure of Saccharopine Dehydrogenase from Saccharomyces cervisiae complexed with NAD.
3IB3	;	2.05	;	Crystal Structure of SACOL2612 - CocE/NonD family hydrolase from Staphylococcus aureus
3TC3	;	1.5	;	Crystal Structure of SacUVDE
8X7X	;	2.59	;	Crystal structure of SADS-CoV fusion core
5LHM	;	1.31	;	Crystal Structure of SafC from Myxococcus xanthus apo-Form
5LOG	;	2.01	;	Crystal Structure of SafC from Myxococcus xanthus bound to SAM
5Y9H	;	2.8	;	Crystal structure of SafDAA-dsc complex
8P2A	;	2.0	;	Crystal structure of SaFMN3 domain 2
3DUR	;	1.86	;	Crystal structure of SAG173-04
3DUS	;	1.95	;	Crystal structure of SAG506-01, orthorhombic, twinned, crystal 1
3DUU	;	1.95	;	Crystal structure of SAG506-01, orthorhombic, twinned, crystal 2
3DV4	;	1.95	;	Crystal structure of SAG506-01, tetragonal, crystal 1
3DV6	;	1.95	;	Crystal structure of SAG506-01, tetragonal, crystal 2
4X7C	;	2.0	;	Crystal structure of Saga-2006 GII.4 P domain in complex with Nano-85
7CT9	;	2.3	;	Crystal structure of SAH bound CmoB from Vibrio Vulnificus
8FT7	;	2.15	;	Crystal structure of SAH bound protein arginine N-methyltransferase 1 (PRMT1) from Naegleria fowleri
7E3Q	;	2.7	;	Crystal structure of SAH bound TrmL from Vibrio vulnificus
5IL2	;	1.606	;	Crystal structure of SAH-bound METTL3-METTL14 complex
7F4N	;	3.12	;	Crystal structure of SAH-bound MTA1-p1-p2 complex
7F4Q	;	3.42	;	Crystal structure of SAH-bound MTA1-p2 complex
4YMH	;	1.876	;	Crystal structure of SAH-bound Podospora anserina methyltransferase PaMTH1
4CE0	;	2.001	;	Crystal Structure of SAH-bound Spinosyn Rhamnosyl 4'-O- Methyltransferase SpnH from Saccharopolyspora spinosa
7WM6	;	2.54	;	Crystal structure of SAH-bound TrmM from Mycoplasma capricolum
6YVQ	;	1.48	;	Crystal structure of SAICAR Synthetase (PurC) from Mycobacterium abscessus in apo form
6YX3	;	1.22	;	Crystal structure of SAICAR Synthetase (PurC) from Mycobacterium abscessus in complex with ATP
6Z0R	;	1.308	;	Crystal structure of SAICAR Synthetase (PurC) from Mycobacterium abscessus in complex with fragment 1
6Z0Q	;	1.535	;	Crystal structure of SAICAR Synthetase (PurC) from Mycobacterium abscessus in complex with fragment 2
6YY6	;	1.499	;	Crystal structure of SAICAR Synthetase (PurC) from Mycobacterium abscessus in complex with inhibitor
6YY7	;	1.35	;	Crystal structure of SAICAR Synthetase (PurC) from Mycobacterium abscessus in complex with inhibitor
6YY8	;	1.3	;	Crystal structure of SAICAR Synthetase (PurC) from Mycobacterium abscessus in complex with inhibitor
6YY9	;	1.413	;	Crystal structure of SAICAR Synthetase (PurC) from Mycobacterium abscessus in complex with inhibitor
6YYA	;	1.41	;	Crystal structure of SAICAR Synthetase (PurC) from Mycobacterium abscessus in complex with inhibitor
6YYB	;	1.51	;	Crystal structure of SAICAR Synthetase (PurC) from Mycobacterium abscessus in complex with inhibitor
6YYC	;	1.274	;	Crystal structure of SAICAR Synthetase (PurC) from Mycobacterium abscessus in complex with inhibitor
6YYD	;	1.387	;	Crystal structure of SAICAR Synthetase (PurC) from Mycobacterium abscessus in complex with inhibitor
2YWV	;	1.75	;	Crystal structure of SAICAR synthetase from Geobacillus kaustophilus
3NL1	;	2.155	;	Crystal Structure of Salicylate 1,2-dioxygenase from Pseudoaminobacter salicylatoxidans Adducts with gentisate
3NKT	;	2.35	;	Crystal Structure of Salicylate 1,2-dioxygenase from Pseudoaminobacter salicylatoxidans Adducts with naphthoate
3NJZ	;	2.1	;	Crystal Structure of Salicylate 1,2-dioxygenase from Pseudoaminobacter salicylatoxidans Adducts with salicylate
3NST	;	2.4	;	Crystal Structure of Salicylate 1,2-dioxygenase G106A mutant from Pseudoaminobacter salicylatoxidans
3NW4	;	2.0	;	Crystal Structure of Salicylate 1,2-dioxygenase G106A mutant from Pseudoaminobacter salicylatoxidans in complex with gentisate
3NVC	;	2.45	;	Crystal Structure of Salicylate 1,2-dioxygenase G106A mutant from Pseudoaminobacter salicylatoxidans in complex with salicylate
7C8Z	;	2.6	;	Crystal structure of salicylate 5-hydroxylase NagGH (a Rieske non-heme iron-dependent monooxgenase)
1M6E	;	3.0	;	CRYSTAL STRUCTURE OF SALICYLIC ACID CARBOXYL METHYLTRANSFERASE (SAMT)
1XKL	;	2.0	;	Crystal Structure of Salicylic Acid-binding Protein 2 (SABP2) from Nicotiana tabacum, NESG Target AR2241
2FAK	;	2.8	;	Crystal structure of Salinosporamide A in complex with the yeast 20S proteasome
3L0R	;	2.45	;	Crystal Structure of Salivary Cystatin from the Soft Tick Ornithodoros moubata
8A4I	;	2.76	;	Crystal structure of SALL4 zinc finger cluster 4 with AT-rich DNA
5XWS	;	3.084	;	Crystal structure of SALM5 LRR-Ig
3OHT	;	2.7	;	Crystal Structure of Salmo Salar p38alpha
6TCC	;	1.05	;	Crystal structure of Salmo salar RidA-1
6TCD	;	1.36	;	Crystal structure of Salmo salar RidA-2
5AHI	;	1.999	;	Crystal structure of salmonalla enterica HisA mutant D7N with ProFAR
4U48	;	2.95	;	Crystal structure of Salmonella alpha-2-macroglobulin
4U4J	;	2.9	;	Crystal structure of Salmonella alpha-2-macroglobulin mutant Y1175G
4U59	;	3.09	;	Crystal structure of Salmonella alpha-2-macroglobulin reacted with methylamine
7DN9	;	3.29	;	Crystal structure of Salmonella effector in complex with NAD and host co-factor ARF1
4DID	;	2.3501	;	Crystal structure of Salmonella effector N-terminal domain SopB in complex with Cdc42
4MI7	;	1.65	;	Crystal Structure of Salmonella Effector Protein GtgE
2QYU	;	2.1	;	Crystal structure of Salmonella effector protein SopA
2QZA	;	2.8	;	Crystal structure of Salmonella effector protein SopA
7DN8	;	2.6084	;	Crystal structure of Salmonella effector SopF in complex with ARF1
5JRH	;	1.644	;	Crystal structure of Salmonella enterica acetyl-CoA synthetase (Acs) in complex with cAMP and Coenzyme A
5AHE	;	1.7	;	Crystal structure of Salmonella enterica HisA
5A5W	;	1.6	;	Crystal structure of Salmonella enterica HisA D7N D176A with ProFAR
5AHF	;	2.201	;	Crystal structure of Salmonella enterica HisA D7N with ProFAR
7EYL	;	1.2	;	Crystal structure of Salmonella enterica ppnP
3L9S	;	1.58	;	Crystal Structure of Salmonella enterica serovar Typhimurium DsbA
3L9U	;	1.568	;	Crystal Structure of Salmonella enterica serovar Typhimurium DsbL
3L9V	;	2.151	;	Crystal Structure of Salmonella enterica serovar Typhimurium SrgA
2XF4	;	2.3	;	Crystal structure of Salmonella enterica serovar typhimurium YcbL
6L3E	;	1.6	;	Crystal structure of Salmonella enterica sugar-binding protein MalE
7JVE	;	2.31	;	Crystal structure of Salmonella enterica Typhimurium BcfH
3TEE	;	1.95	;	Crystal Structure of Salmonella FlgA in open form
7DQG	;	2.21	;	Crystal structure of Salmonella phage acetyltransferase
5Y9G	;	2.2	;	Crystal structure of Salmonella SafD adhesin
3CGZ	;	1.9	;	Crystal Structure of Salmonella Sensor Kinase PhoQ catalytic domain
3CGY	;	2.6	;	Crystal Structure of Salmonella Sensor Kinase PhoQ catalytic domain in complex with radicicol
2QED	;	1.45	;	Crystal structure of Salmonella thyphimurium LT2 glyoxalase II
7EZZ	;	2.76	;	Crystal structure of Salmonella typhi outer membrane phospholipase (OMPLA) dimer with bound calcium
3SK3	;	1.9	;	Crystal structure of Salmonella typhimurium acetate kinase (AckA) with citrate bound at the dimeric interface
1TJY	;	1.3	;	Crystal Structure of Salmonella typhimurium AI-2 receptor LsrB in complex with R-THMF
1Z5G	;	2.0	;	Crystal structure of Salmonella typhimurium AphA protein
1EQW	;	2.3	;	CRYSTAL STRUCTURE OF SALMONELLA TYPHIMURIUM CU,ZN SUPEROXIDE DISMUTASE
5KDG	;	1.73	;	Crystal Structure of Salmonella Typhimurium Effector GtgE
6T7M	;	2.65	;	Crystal structure of Salmonella typhimurium FabG at 2.65 A resolution
6T5X	;	1.5	;	Crystal structure of Salmonella typhimurium FabG in complex with NADPH at 1.5 A resolution
4GVG	;	1.7	;	Crystal structure of Salmonella typhimurium family 3 glycoside hydrolase (NagZ)
4GVF	;	1.35	;	Crystal structure of Salmonella typhimurium family 3 glycoside hydrolase (NagZ) bound to GlcNAc
4HZM	;	1.45	;	Crystal structure of Salmonella typhimurium family 3 glycoside hydrolase (NagZ) bound to N-[(3S,4R,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)piperidin-3-yl]butanamide
4GVH	;	1.45	;	Crystal structure of Salmonella typhimurium family 3 glycoside hydrolase (NagZ) covalently bound to 5-fluoro-GlcNAc.
1LH0	;	2.0	;	Crystal Structure of Salmonella typhimurium OMP Synthase in Complex with MGPRPP and Orotate
4DY5	;	1.78	;	Crystal structure of Salmonella Typhimurium PliG, a periplasmic lysozyme inhibitor of g-type lysozyme
4FWN	;	3.0	;	Crystal structure of Salmonella typhimurium propionate kinase (TdcD) in complex with Adenosine Tetraphosphate (AP4)
4FWK	;	2.8	;	Crystal structure of Salmonella typhimurium propionate kinase (TdcD) in complex with AMP
4FWM	;	2.95	;	Crystal structure of Salmonella typhimurium propionate kinase (TdcD) in complex with ATP
4FWR	;	3.0	;	Crystal structure of Salmonella typhimurium propionate kinase (TdcD) in complex with CMP
4FWS	;	2.69	;	Crystal structure of Salmonella typhimurium propionate kinase (TdcD) in complex with CTP
2E20	;	2.4	;	Crystal structure of Salmonella typhimurium propionate kinase (TdcD) in complex with diadenosine tetraphosphate (Ap4A)
2E1Z	;	1.98	;	Crystal structure of Salmonella typhimurium propionate kinase (TdcD) in complex with diadenosine tetraphosphate (Ap4A) obtained after co-crystallization with ATP
4FWP	;	2.5	;	Crystal structure of Salmonella typhimurium propionate kinase (TdcD) in complex with GDP
4FWO	;	2.9	;	Crystal structure of Salmonella typhimurium propionate kinase (TdcD) in complex with GMP
4FWQ	;	2.65	;	Crystal structure of Salmonella typhimurium propionate kinase (TdcD) in complex with GTP
4FWL	;	2.4	;	Crystal structure of Salmonella typhimurium propionate kinase (TdcD) in complex with Phosphate (PO4)
4XH5	;	2.11	;	Crystal structure of Salmonella typhimurium propionate kinase A88G mutant, in complex with AMPPNP and propionate
4XH4	;	1.8	;	Crystal structure of Salmonella typhimurium propionate kinase A88V mutant, in complex with AMPPNP and propionate
4XH1	;	2.0	;	Crystal structure of Salmonella typhimurium propionate kinase in complex with AMPPNP and propionate
2V4N	;	1.7	;	Crystal structure of Salmonella typhimurium SurE at 1.7 angstrom resolution in orthorhombic form
2V4O	;	2.71	;	Crystal structure of Salmonella typhimurium SurE at 2.75 angstrom resolution in monoclinic form
6DZO	;	1.64	;	Crystal structure of Salmonella typhimurium Tryptophan Synthase mutant beta-Q114A with 2-({[4-(trifluoromethoxy)phenyl]sulfonyl}amino)ethyl dihydrogen phosphate (F9F) at the alpha-site, Cesium ion at the metal coordination site, and (E)-N-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methylidene)-L-serine at the beta-site
6DZ4	;	1.45	;	Crystal structure of Salmonella typhimurium Tryptophan Synthase with sodium ion at the metal coordination site and (E)-N-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methylidene)-L-serine at the beta-site
2P1R	;	2.5	;	Crystal structure of Salmonella typhimurium YegS, a putative lipid kinase homologous to eukaryotic sphingosine and diacylglycerol kinases.
6GGO	;	2.6	;	Crystal structure of Salmonella zinc metalloprotease effector GtgA
6GGR	;	2.097	;	Crystal structure of Salmonella zinc metalloprotease effector GtgA in complex with p65
5GVY	;	1.662	;	Crystal structure of SALT protein from Oryza sativa
8HD2	;	1.6	;	Crystal structure of SAM dependent methyltransferase encoded in type II fatty acid biosynthesis gene cluster from ladderane lipid producing anammox bacteria
5IL1	;	1.71	;	Crystal structure of SAM-bound METTL3-METTL14 complex
7F4M	;	3.58	;	Crystal structure of SAM-bound MTA1-p1-p2 complex
7F4P	;	2.98	;	Crystal structure of SAM-bound MTA1-p2 complex
4YMG	;	1.899	;	Crystal structure of SAM-bound Podospora anserina methyltransferase PaMTH1
6NM4	;	2.58	;	Crystal structure of SAM-bound PRDM9 in complex with MRK-740 inhibitor
7F4T	;	3.68	;	Crystal structure of SAM-bound TthMTA1-Ptep2 complex
3GGD	;	2.11	;	Crystal structure of SAM-dependent methyltransferase (YP_325210.1) from ANABAENA VARIABILIS ATCC 29413 at 2.11 A resolution
3D2L	;	1.9	;	Crystal structure of SAM-dependent methyltransferase (ZP_00538691.1) from EXIGUOBACTERIUM SP. 255-15 at 1.90 A resolution
5BP9	;	1.5	;	Crystal structure of SAM-dependent methyltransferase from Bacteroides fragilis in complex with S-Adenosyl-L-homocysteine
3DP7	;	2.33	;	CRYSTAL STRUCTURE OF SAM-dependent methyltransferase from Bacteroides vulgatus ATCC 8482
5BP7	;	2.1	;	Crystal structure of SAM-dependent methyltransferase from Geobacter sulfurreducens in complex with S-Adenosyl-L-homocysteine
5EPE	;	1.9	;	Crystal structure of SAM-dependent methyltransferase from Thiobacillus denitrificans in complex with S-Adenosyl-L-homocysteine
1VLM	;	2.2	;	Crystal structure of SAM-dependent methyltransferase, possible histamine N-methyltransferase (TM1293) from Thermotoga maritima at 2.20 A resolution
3SM3	;	2.197	;	Crystal Structure of SAM-dependent methyltransferases Q8PUK2_METMA from Methanosarcina mazei. Northeast Structural Genomics Consortium Target MaR262.
1O54	;	1.65	;	Crystal structure of SAM-dependent O-methyltransferase (TM0748) from Thermotoga maritima at 1.65 A resolution
2HNK	;	2.3	;	Crystal structure of SAM-dependent O-methyltransferase from pathogenic bacterium Leptospira interrogans
7EAF	;	2.85	;	Crystal structure of SAM-I riboswitch with the Actinomyces-1 k-turn
4G13	;	0.8	;	Crystal structure of samarosporin I at 100K
4G14	;	1.09	;	Crystal structure of samarosporin I at 293K
3CA5	;	1.55	;	Crystal structure of Sambucus nigra agglutinin II (SNA-II)-tetragonal crystal form- complexed to alpha1 methylgalactose
3CA3	;	1.55	;	Crystal structure of Sambucus Nigra Agglutinin II (SNA-II)-tetragonal crystal form- complexed to N-Acetylgalactosamine
4Q7H	;	2.587	;	Crystal structure of SAMHD1 catalytic core with GTP
8GB1	;	2.46	;	Crystal structure of SAMHD1 dimer bound to deoxyguanosine linked inhibitor
3PO0	;	1.55	;	Crystal structure of SAMP1 from Haloferax volcanii
1MJT	;	2.4	;	CRYSTAL STRUCTURE OF SANOS, A BACTERIAL NITRIC OXIDE SYNTHASE OXYGENASE PROTEIN, IN COMPLEX WITH NAD+ AND SEITU
1M27	;	2.5	;	Crystal structure of SAP/FynSH3/SLAM ternary complex
1JZL	;	1.5	;	Crystal structure of Sapharca inaequivalvis HbI, I114M mutant ligated to carbon monoxide.
3HIS	;	1.49	;	Crystal structure of Saporin-L1 from Saponaria officinalis
3HIW	;	1.8	;	Crystal structure of Saporin-L1 in complex with the cyclic tetranucleotide inhibitor, a transition state analogue
3HIT	;	2.29	;	Crystal structure of Saporin-L1 in complex with the dinucleotide inhibitor, a transition state analogue
3HIV	;	2.14	;	Crystal structure of Saporin-L1 in complex with the trinucleotide inhibitor, a transition state analogue
3HIQ	;	2.19	;	Crystal structure of Saporin-L1 mutant (Y73A) from Saponaria officinalis
4DDJ	;	1.9	;	Crystal structure of saposin A in complex with lauryldimethylamine-N-oxide (LDAO)
7E19	;	2.15	;	Crystal structure of SAR-CoV-2 3CL protease complex with inhibitor SH-5
7E18	;	1.65	;	Crystal structure of SAR-CoV-2 3CL protease complex with inhibitor YH-53
1F6B	;	1.7	;	CRYSTAL STRUCTURE OF SAR1-GDP COMPLEX
5KKW	;	1.88	;	Crystal structure of SAR11_1068 bound to a sulfobetaine (3-(1-methylpiperidinium-1-yl)propane-1-sulfonate)
2X4K	;	1.1	;	Crystal structure of SAR1376, a putative 4-oxalocrotonate tautomerase from the methicillin-resistant Staphylococcus aureus (MRSA)
2FNP	;	2.6	;	Crystal structure of SarA
2FRH	;	2.5	;	Crystal Structure of Sara, A Transcription Regulator From Staphylococcus Aureus
7ANK	;	3.204	;	Crystal structure of sarcomeric protein FATZ-1 (d91-FATZ-1 construct) in complex with half dimer of alpha-actinin-2
7A8U	;	3.802	;	Crystal structure of sarcomeric protein FATZ-1 (d91-FATZ-1 construct) in complex with rod domain of alpha-actinin-2
7A8T	;	2.69	;	Crystal structure of sarcomeric protein FATZ-1 (mini-FATZ-1 construct) in complex with rod domain of alpha-actinin-2
7WBO	;	1.6	;	Crystal structure of Sarcoplasmic Calcium-Binding Protein from Scylla paramamosain
6H18	;	1.85	;	Crystal structure of sarin surrogate NIMP inhibited recombinant human bile salt activated lipase
3M7A	;	1.22	;	Crystal structure of Saro_0823 (YP_496102.1) a protein of unknown function from NOVOSPHINGOBIUM AROMATICIVORANS DSM 12444 at 1.22 A resolution
5UUN	;	1.45	;	Crystal structure of SARO_2595 from Novosphingobium aromaticivorans
5UUO	;	1.25	;	Crystal structure of SARO_2595 from Novosphingobium aromaticivorans
7DQZ	;	1.99	;	Crystal structure of SARS 3C-like protease in apo form
1Z1J	;	2.8	;	Crystal structure of SARS 3CLpro C145A mutant
7F90	;	2.39	;	Crystal structure of SARS auxiliary protein in complex with human nuclear protein
2GX4	;	1.93	;	Crystal structure of SARS coronavirus 3CL protease inhibitor complex
2GT8	;	2.0	;	Crystal structure of SARS coronavirus main peptidase (with an additional Ala at the N-terminus of each protomer) in the space group P43212
2GTB	;	2.0	;	Crystal structure of SARS coronavirus main peptidase (with an additional Ala at the N-terminus of each protomer) inhibited by an aza-peptide epoxide in the space group P43212
2GT7	;	1.82	;	Crystal structure of SARS coronavirus main peptidase at pH 6.0 in the space group P21
3SNB	;	2.4	;	Crystal structure of SARS coronavirus main protease complexed with Ac-DSFDQ-H (soaking)
3SND	;	1.89	;	Crystal structure of SARS coronavirus main protease complexed with Ac-ESTLQ-H (cocrystallization)
3SNE	;	2.6	;	Crystal structure of SARS coronavirus main protease complexed with Ac-ESTLQ-H (Soaking)
3SNA	;	3.05	;	Crystal structure of SARS coronavirus main protease complexed with Ac-NSFSQ-H (soaking)
3SNC	;	2.58	;	Crystal structure of SARS coronavirus main protease complexed with Ac-NSTSQ-H (soaking)
3TNS	;	1.99	;	Crystal structure of SARS coronavirus main protease complexed with an alpha, beta-unsaturated ethyl ester inhibitor SG83
3TNT	;	1.59	;	Crystal structure of SARS coronavirus main protease complexed with an alpha, beta-unsaturated ethyl ester inhibitor SG85
3SZN	;	1.69	;	Crystal structure of SARS coronavirus main protease complexed with an alpha, beta-unsaturated ethyl ester SG75
3TIT	;	1.99	;	Crystal structure of SARS coronavirus main protease complexed with an alpha, beta-unsaturated ethyl ester SG81
3TIU	;	2.08	;	Crystal structure of SARS coronavirus main protease complexed with an alpha,beta-unsaturated ethyl ester inhibitor SG82
3SN8	;	1.99	;	Crystal structure of SARS coronavirus main protease complexed with Cm-FF-H (soaking)
7EO8	;	2.28085	;	Crystal structure of SARS coronavirus main protease in complex with an inhibitor Shikonin
7XAX	;	2.25	;	Crystal structure of SARS coronavirus main protease in complex with Baicalei
7WQI	;	1.93	;	Crystal structure of SARS coronavirus main protease in complex with PF07304814
7VLO	;	2.0227	;	Crystal structure of SARS coronavirus main protease in complex with PF07321332
1UJ1	;	1.9	;	Crystal structure of SARS Coronavirus Main Proteinase (3CLpro)
1UK3	;	2.4	;	Crystal structure of SARS Coronavirus Main Proteinase (3CLpro) At pH7.6
1UK2	;	2.2	;	Crystal structure of SARS Coronavirus Main Proteinase (3CLpro) At pH8.0
1UK4	;	2.5	;	Crystal structure of SARS Coronavirus Main Proteinase (3CLpro) Complexed With An Inhibitor
2BX4	;	2.79	;	Crystal Structure of SARS Coronavirus Main Proteinase (P21212)
2BX3	;	2.0	;	Crystal Structure of SARS Coronavirus Main Proteinase (P43212)
2DUC	;	1.7	;	Crystal structure of SARS coronavirus main proteinase(3CLPRO)
1QZ8	;	2.7	;	Crystal structure of SARS coronavirus NSP9
5Y3Q	;	1.65	;	Crystal structure of SARS coronavirus papain-like protease conjugated with beta-mercaptoethanol
5Y3E	;	1.65	;	Crystal structure of SARS coronavirus papain-like protease in complex with glycerol
8UHO	;	2.02	;	Crystal structure of SARS CoV-2 3CL protease in complex with GSK4365096A
8UIF	;	2.02	;	Crystal structure of SARS CoV-2 3CL protease in complex with GSK4365096A
8UIA	;	1.75	;	Crystal structure of SARS CoV-2 3CL protease in complex with GSK4365097A
7ZV5	;	1.999	;	Crystal structure of SARS Cov-2 main protease in complex with an inhibitor 4
7ZV7	;	1.336	;	Crystal structure of SARS Cov-2 main protease in complex with an inhibitor 57
7ZV8	;	1.937	;	Crystal structure of SARS Cov-2 main protease in complex with an inhibitor 58
8DT9	;	2.0	;	Crystal Structure of SARS CoV-2 Mpro mutant L141R with Pfizer Intravenous Inhibitor PF-00835231
8E5C	;	2.2	;	Crystal Structure of SARS CoV-2 Mpro mutant L50F with Nirmatrelvir captured in two conformational states
8E4W	;	2.75	;	Crystal Structure of SARS CoV-2 Mpro mutant N142P with Pfizer Intravenous Inhibitor PF-00835231
8DSU	;	1.86	;	Crystal Structure of SARS CoV-2 Mpro with Pfizer Intravenous Inhibitor PF-00835231
8D34	;	2.91	;	Crystal Structure of SARS CoV-2 NSP15 Endroribonuclease H250A
7S83	;	2.52	;	Crystal structure of SARS CoV-2 Spike Receptor Binding Domain in complex with shark neutralizing VNARs ShAb01 and ShAb02
7NTV	;	2.065	;	Crystal structure of SARS CoV2 main protease in complex with DN_EG_002 (modelled using PanDDA event map)
7NUK	;	2.19	;	Crystal structure of SARS CoV2 main protease in complex with EG009 (modelled using PanDDA event map)
7NT3	;	2.325	;	Crystal structure of SARS CoV2 main protease in complex with FSCU015
7NT2	;	2.145	;	Crystal structure of SARS CoV2 main protease in complex with FSP006
7NT1	;	2.85	;	Crystal structure of SARS CoV2 main protease in complex with FSP007
6ZRU	;	2.1	;	Crystal structure of SARS CoV2 main protease in complex with inhibitor Boceprevir
6ZRT	;	2.1	;	Crystal structure of SARS CoV2 main protease in complex with inhibitor Telaprevir
2FAV	;	1.8	;	Crystal structure of SARS macro domain in complex with ADP-ribose at 1.8 A resolution
8IG5	;	2.17	;	Crystal structure of SARS main protease in complex with GC376
7YGQ	;	2.04	;	Crystal structure of SARS main protease in complex with inhibitor YH-53
8HUS	;	1.97	;	Crystal structure of SARS main protease in complex with S217622
1P4X	;	2.2	;	Crystal structure of SarS protein from Staphylococcus Aureus
2GHV	;	2.2	;	Crystal structure of SARS spike protein receptor binding domain
2GHW	;	2.3	;	Crystal structure of SARS spike protein receptor binding domain in complex with a neutralizing antibody, 80R
3VB3	;	2.2	;	Crystal structure of SARS-CoV 3C-like protease in apo form
3VB4	;	2.2	;	Crystal structure of SARS-CoV 3C-like protease with B4Z
3VB5	;	1.95	;	Crystal structure of SARS-CoV 3C-like protease with C4Z
3VB6	;	2.5	;	Crystal structure of SARS-CoV 3C-like protease with C6Z
3VB7	;	1.95	;	Crystal structure of SARS-CoV 3C-like protease with M4Z
7END	;	1.99	;	Crystal structure of SARS-CoV 3CLpro in complex with the non-covalent inhibitor WU-04
6W7Y	;	3.3	;	Crystal structure of SARS-CoV and SARS-CoV-2 reactive human antibody CR3022
6YXJ	;	3.5	;	Crystal structure of SARS-CoV macrodomain II in complex with human Paip1
3M3S	;	2.3	;	Crystal structure of SARS-COV main protease Asn214Ala mutant with authorize N-terminus
2Q6G	;	2.5	;	Crystal structure of SARS-CoV main protease H41A mutant in complex with an N-terminal substrate
3EA9	;	2.4	;	Crystal structure of SARS-CoV main protease quadruple mutant STIF/A with one molecule in one asymmetric unit
3EAJ	;	2.7	;	Crystal structure of SARS-CoV main protease quadruple mutant STIF/A with two molecules in one asymmetric unit
3EA8	;	2.25	;	Crystal structure of SARS-CoV main protease triple mutant STI/A in space group C2
3EA7	;	2.65	;	Crystal structure of SARS-CoV main protease triple mutant STI/A in space group P21
2H2Z	;	1.6	;	Crystal structure of SARS-CoV main protease with authentic N and C-termini
2HOB	;	1.95	;	Crystal structure of SARS-CoV main protease with authentic N and C-termini in complex with a Michael acceptor N3
2D2D	;	2.7	;	Crystal Structure Of SARS-CoV Mpro in Complex with an Inhibitor I2
1WOF	;	2.0	;	Crystal Structure Of SARS-CoV Mpro in Complex with an Inhibitor N1
3E91	;	2.55	;	Crystal structure of SARS-CoV Mpro mutant in P21 at pH6.9
3EE7	;	2.6	;	Crystal Structure of SARS-CoV nsp9 G104E
4M0W	;	1.4	;	Crystal Structure of SARS-CoV papain-like protease C112S mutant in complex with ubiquitin
5TL7	;	2.44	;	Crystal structure of SARS-CoV papain-like protease in complex with C-terminal domain mouse ISG15
5TL6	;	2.618	;	Crystal structure of SARS-CoV papain-like protease in complex with the C-terminal domain of human ISG15
4MM3	;	2.752	;	Crystal structure of SARS-CoV papain-like protease PLpro in complex with ubiquitin aldehyde
7FC6	;	2.655	;	Crystal structure of SARS-CoV RBD and horse ACE2
7Y3N	;	2.97	;	Crystal structure of SARS-CoV receptor binding domain in complex with human antibody BIOLS56
7JN5	;	2.705	;	Crystal structure of SARS-CoV receptor binding domain in complex with human antibody CR3022
7LM9	;	1.53	;	Crystal structure of SARS-CoV spike protein receptor-binding domain in complex with a cross-neutralizing antibody CV38-142 Fab isolated from COVID-19 patient
2DD8	;	2.3	;	Crystal Structure of SARS-CoV Spike Receptor-Binding Domain Complexed with Neutralizing Antibody
7VMU	;	2.89	;	Crystal Structure of SARS-CoV Spike Receptor-Binding Domain Complexed with Neutralizing Antibody
2AHM	;	2.4	;	Crystal structure of SARS-CoV super complex of non-structural proteins: the hexadecamer
6YWL	;	2.5	;	Crystal structure of SARS-CoV-2 (Covid-19) NSP3 macrodomain in complex with ADP-ribose
6YWK	;	2.2	;	Crystal structure of SARS-CoV-2 (Covid-19) NSP3 macrodomain in complex with HEPES
6YWM	;	2.16	;	Crystal structure of SARS-CoV-2 (Covid-19) NSP3 macrodomain in complex with MES
8GIA	;	1.86	;	Crystal structure of SARS-CoV-2 (Covid-19) Nsp3 macrodomain in complex with TFMU-ADPr
8F4Y	;	2.13	;	Crystal Structure of SARS-CoV-2 2'-O-Methyltransferase in Complex with Compound 5a covalently bound to nsp16 and nsp10
7JST	;	1.85	;	Crystal structure of SARS-CoV-2 3CL in apo form
7TIU	;	1.65	;	Crystal structure of SARS-CoV-2 3CL in complex with inhibitor EB46
7TIV	;	2.08	;	Crystal structure of SARS-CoV-2 3CL in complex with inhibitor EB48
7TIW	;	1.68	;	Crystal structure of SARS-CoV-2 3CL in complex with inhibitor EB54
7TIX	;	2.0	;	Crystal structure of SARS-CoV-2 3CL in complex with inhibitor EB56
7TIA	;	1.64	;	Crystal structure of SARS-CoV-2 3CL in complex with inhibitor NK01-14
7TIY	;	1.79	;	Crystal structure of SARS-CoV-2 3CL in complex with inhibitor NK01-48
7TIZ	;	1.55	;	Crystal structure of SARS-CoV-2 3CL in complex with inhibitor NK01-63
7TJ0	;	2.17	;	Crystal structure of SARS-CoV-2 3CL in complex with inhibitor SL-4-241
7V7M	;	2.08	;	crystal structure of SARS-CoV-2 3CL protease
8E64	;	1.75	;	Crystal structure of SARS-CoV-2 3CL protease in complex with a benzimidazole dimethyl sulfane inhibitor
8F44	;	1.65	;	Crystal structure of SARS-CoV-2 3CL protease in complex with a dimethyl phenyl sulfane inhibitor
8F46	;	1.5	;	Crystal structure of SARS-CoV-2 3CL protease in complex with a dimethyl phenyl sulfane inhibitor (cyano warhead)
8E5X	;	1.7	;	Crystal structure of SARS-CoV-2 3CL protease in complex with a dimethyl sulfinyl benzene inhibitor
8E5Z	;	1.8	;	Crystal structure of SARS-CoV-2 3CL protease in complex with a dimethyl sulfonyl benzene inhibitor
8E61	;	1.85	;	Crystal structure of SARS-CoV-2 3CL protease in complex with a m-chlorophenyl dimethyl sulfane inhibitor
8E69	;	2.26	;	Crystal structure of SARS-CoV-2 3CL protease in complex with a m-fluorodimethyl oxybenzene inhibitor
8E65	;	1.8	;	Crystal structure of SARS-CoV-2 3CL protease in complex with a p-chlorodimethyl oxybenzene inhibitor
8E6A	;	2.05	;	Crystal structure of SARS-CoV-2 3CL protease in complex with a p-chlorophenylethanol based inhibitor
8E68	;	1.6	;	Crystal structure of SARS-CoV-2 3CL protease in complex with a p-fluorodimethyl oxybenzene inhibitor
8F45	;	1.65	;	Crystal structure of SARS-CoV-2 3CL protease in complex with a phenyl dimethyl sulfane inhibitor (cyclopropyl ketoamide warhead)
8E63	;	1.75	;	Crystal structure of SARS-CoV-2 3CL protease in complex with a phenyl sulfane inhibitor
7JT7	;	1.94	;	Crystal structure of SARS-CoV-2 3CL protease in complex with compound 4
7JW8	;	1.84	;	Crystal structure of SARS-CoV-2 3CL protease in complex with compound 4 in space group P1
7JSU	;	1.83	;	Crystal structure of SARS-CoV-2 3CL protease in complex with GC376
7JT0	;	1.73	;	Crystal structure of SARS-CoV-2 3CL protease in complex with MAC5576
7WHC	;	2.269	;	Crystal structure of SARS-CoV-2 3CLpro catalytic domain
7EN9	;	1.9	;	Crystal structure of SARS-CoV-2 3CLpro in complex with the non-covalent inhibitor WU-02
7EN8	;	1.83	;	Crystal structure of SARS-CoV-2 3CLpro in complex with the non-covalent inhibitor WU-04
7YTN	;	3.51	;	Crystal structure of SARS-CoV-2 Alpha RBD in complex with the D27LEY neutralizing antibody Fab fragment
7CHS	;	2.401	;	Crystal structure of SARS-CoV-2 antibody P22A-1D1 with RBD
7CDJ	;	3.396	;	Crystal structure of SARS-CoV-2 antibody P2C-1A3 with RBD
7E8M	;	2.09	;	Crystal structure of SARS-CoV-2 antibody P2C-1F11 with mutated RBD
7CDI	;	2.96	;	Crystal structure of SARS-CoV-2 antibody P2C-1F11 with RBD
7CHO	;	2.561	;	Crystal structure of SARS-CoV-2 antibody P5A-1D2 with RBD
7CHP	;	2.357	;	Crystal structure of SARS-CoV-2 antibody P5A-3C8 with RBD
7BWJ	;	2.85	;	crystal structure of SARS-CoV-2 antibody with RBD
7S5Q	;	2.88	;	Crystal structure of SARS-CoV-2 B.1.351 variant receptor binding domain in complex with neutralizing antibodies CS44 and COVA1-16
7S5P	;	2.86	;	Crystal structure of SARS-CoV-2 B.1.351 variant receptor binding domain in complex with neutralizing antibody CS23
8GB8	;	2.3	;	Crystal structure of SARS-CoV-2 BA.2 receptor binding domain in complex with neutralizing antibody 20A7
7FJC	;	2.96	;	Crystal structure of SARS-CoV-2 Beta RBD complexed with P36-5D2 Fab
7C6U	;	2.0	;	Crystal structure of SARS-CoV-2 complexed with GC376
8I5H	;	2.38	;	Crystal structure of SARS-CoV-2 delta variant spike receptor-binding domain (RBD) in complex with NCV2SG48 Fab
8I5I	;	3.06	;	Crystal structure of SARS-CoV-2 delta variant spike receptor-binding domain (RBD) in complex with NCV2SG53 Fab
8D36	;	1.45	;	Crystal structure of SARS-CoV-2 fusion peptide in complex with neutralizing antibody COV44-62
7C53	;	2.278	;	Crystal Structure of SARS-CoV-2 HR1 motif in complex with pan-CoVs inhibitor EK1
7BF3	;	2.0	;	Crystal structure of SARS-CoV-2 macrodomain in complex with adenosine
7BF5	;	2.05	;	Crystal structure of SARS-CoV-2 macrodomain in complex with ADP-ribose-phosphate (ADP-ribose-2'-phosphate, ADPRP)
7BF4	;	1.55	;	Crystal structure of SARS-CoV-2 macrodomain in complex with GMP
7BF6	;	2.15	;	Crystal structure of SARS-CoV-2 macrodomain in complex with remdesivir metabolite GS-441524
7K3T	;	1.2	;	Crystal Structure of SARS-CoV-2 Main Protease (3CLpro/Mpro) at 1.2 A Resolution and a Possible Capture of Zinc Binding Intermediate
7MLG	;	2.5	;	Crystal Structure of SARS-CoV-2 Main Protease (3CLpro/Mpro) Covalently Bound to Compound C63
7MLF	;	2.6	;	Crystal Structure of SARS-CoV-2 Main Protease (3CLpro/Mpro) Covalently Bound to Compound C7
7K40	;	1.35	;	Crystal Structure of SARS-CoV-2 Main Protease (3CLpro/Mpro) in Complex with Covalent Inhibitor Boceprevir at 1.35 A Resolution
7MRR	;	2.32	;	Crystal Structure of SARS-CoV-2 Main Protease (3CLpro/Mpro) in Complex with Covalent Inhibitor Leupeptin
7JYC	;	1.79	;	Crystal Structure of SARS-CoV-2 Main Protease (3CLpro/Mpro) in Complex with Covalent Inhibitor Narlaprevir
7MNG	;	1.7	;	Crystal Structure of SARS-CoV-2 Main Protease (3CLpro/Mpro) in Complex with Covalent Inhibitor VBY-825 (Partial Occupancy)
8H57	;	1.55	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) A193P Mutant in Complex with Inhibitor Nirmatrelvir
7MHF	;	1.55	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) at 100 K
7MHG	;	1.5302	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) at 240 K
7MHH	;	2.1908	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) at 277 K
7MHI	;	1.88	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) at 298 K
7MHJ	;	2.0005	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) at 298 K and High Humidity
8D35	;	1.9	;	Crystal structure of SARS-CoV-2 main protease (Mpro) C145A mutant in complex with peptide from human tRNA methyltransferase TRMT1
8H3K	;	1.8	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) Double Mutant (L50F and E166V) in Complex with Inhibitor Enstrelvir
8H5P	;	1.67	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) Double Mutant (L50F and E166V) in Complex with Inhibitor Nirmatrelvir
8H3L	;	2.3	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) Double Mutant (T21I and E166V) in Complex with Inhibitor Enstrelvir
8H51	;	2.18	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) Double Mutant (T21I and E166V) in Complex with Inhibitor Nirmatrelvir
8DDI	;	2.8	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) E166N Mutant
8D4N	;	2.7	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) E166Q Mutant
8DDM	;	2.78	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) E166R Mutant in Complex with Inhibitor GC376
8H3G	;	1.46	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) E166V Mutant in Complex with Inhibitor Enstrelvir
8H4Y	;	2.25	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) F140L Mutant in Complex with Inhibitor Nirmatrelvir
8INQ	;	1.77	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) G15S Mutant
8INX	;	1.66	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) G15S Mutant in Complex with Inhibitor ensitrelvir
8INU	;	1.69	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) G15S Mutant in Complex with Inhibitor nirmatrelvir
8SXO	;	2.76	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) H164I Mutant
8DFN	;	2.04	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) H164N Mutant
8EHJ	;	2.28	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) H172Q Mutant
8D4J	;	1.78	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) H172Y Mutant
8D4K	;	1.89	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) H172Y Mutant in Complex with Inhibitor GC376
7NBR	;	2.4	;	Crystal structure of SARS-CoV-2 main protease (Mpro) in complex with the HCV NS3/4A inhibitor boceprevir
7NBS	;	1.7	;	Crystal structure of SARS-CoV-2 main protease (Mpro) in complex with the HCV NS3/4A inhibitor telaprevir
8Q71	;	2.322	;	Crystal structure of SARS-CoV-2 main protease (MPro) in complex with the inhibitor GC-67
8B56	;	1.823	;	Crystal structure of SARS-CoV-2 main protease (MPro) in complex with the inhibitor GD-9
8ACD	;	1.39	;	Crystal structure of SARS-CoV-2 main protease (MPro) in complex with the non-covalent inhibitor GA-17S
8ACL	;	1.4	;	Crystal structure of SARS-CoV-2 main protease (MPro) in complex with the non-covalent inhibitor GC-14
8INT	;	1.66	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) K90R Mutant
8INY	;	1.59	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) K90R Mutant in Complex with Inhibitor ensitrelvir
8INW	;	2.4	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) K90R Mutant in Complex with Inhibitor nirmatrelvir
8H5F	;	1.79	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) L167F Mutant in Complex with Inhibitor Nirmatrelvir
8DCZ	;	2.38	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) M165Y Mutant in Complex with Nirmatrelvir
8H82	;	1.93	;	Crystal structure of SARS-CoV-2 main protease (Mpro) Mutant (E166V) in complex with protease inhibitor Nirmatrelvir
8H7W	;	1.6	;	Crystal structure of SARS-CoV-2 main protease (Mpro) Mutant (S144A) in complex with protease inhibitor Nirmatrelvir
8H6N	;	1.65	;	Crystal structure of SARS-CoV-2 main protease (Mpro) Mutant (T21I) in complex with protease inhibitor Nirmatrelvir
8SPJ	;	2.08	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) N28T Mutant
8DGB	;	2.87	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) Q192T Mutant in Complex with Inhibitor GC376
8D4L	;	1.7	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) S144A Mutant
8D4M	;	1.81	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) S144A Mutant in Complex with Inhibitor GC376
8EHM	;	1.84	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) S144F Mutant
8DFE	;	1.89	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) S144L Mutant
8DD9	;	2.04	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) S144L Mutant in Complex with Inhibitor GC376
8EHL	;	2.19	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) S144M Mutant
8EHK	;	2.18	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) T135I Mutant
7ZB6	;	2.12	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) variant C44S at 2.12 A resolution
7ZB8	;	2.48	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) variant K61A at 2.48 A resolution
7ZB7	;	1.63	;	Crystal Structure of SARS-CoV-2 Main Protease (Mpro) variant Y54F at 1.63 A resolution
7DJR	;	1.45	;	Crystal structure of SARS-CoV-2 main protease (no ligand)
7B2U	;	1.55	;	Crystal Structure of SARS-CoV-2 main protease (Nsp5) in complex with compound 1
7BIJ	;	1.47	;	Crystal Structure of SARS-CoV-2 main protease (Nsp5) in complex with compound 13
7NEO	;	1.64	;	Crystal Structure of SARS-CoV-2 main protease (Nsp5) in complex with compound 15
7O46	;	2.23	;	Crystal Structure of SARS-CoV-2 main protease (Nsp5) in complex with compound 17
7QBB	;	2.0	;	Crystal Structure of SARS-CoV-2 main protease (Nsp5) in complex with compound 18
7NBT	;	1.63	;	Crystal Structure of SARS-CoV-2 main protease (Nsp5) in complex with compound 21
7AU4	;	1.82	;	Crystal Structure of SARS-CoV-2 main protease (Nsp5) in complex with compound 3
7B2J	;	1.55	;	Crystal Structure of SARS-CoV-2 main protease (Nsp5) in complex with compound 5
7B5Z	;	1.65	;	Crystal Structure of SARS-CoV-2 main protease (Nsp5) in complex with compound 6
7B77	;	1.6	;	Crystal Structure of SARS-CoV-2 main protease (Nsp5) in complex with compound 8
8E1Y	;	2.48	;	Crystal Structure of SARS-CoV-2 Main protease A193S mutant in complex with Nirmatrelvir
8DZA	;	1.961	;	Crystal Structure of SARS-CoV-2 Main protease A193T mutant in complex with Nirmatrelvir
7Z3U	;	1.72	;	Crystal structure of SARS-CoV-2 Main Protease after incubation with Sulfo-Calpeptin
7XB3	;	2.08	;	Crystal structure of SARS-Cov-2 main protease D48N mutant
7XB4	;	2.07	;	Crystal structure of SARS-Cov-2 main protease D48N mutant in complex with PF07321332
8UH8	;	1.9	;	Crystal structure of SARS-CoV-2 main protease E166V (Apo structure)
8UH9	;	2.067	;	Crystal structure of SARS-CoV-2 main protease E166V mutant in complex with an inhibitor TKB-272
8DZ9	;	1.664	;	Crystal Structure of SARS-CoV-2 Main protease G143S mutant in complex with Nirmatrelvir
8IG7	;	1.69	;	Crystal structure of SARS-Cov-2 main protease G15S mutant in complex with GC376
8HQF	;	1.51	;	Crystal structure of SARS-Cov-2 main protease G15S mutant in complex with inhibitor YH-53
8HVU	;	2.29	;	Crystal structure of SARS-Cov-2 main protease G15S mutant in complex with PF07304814
8HVK	;	1.63	;	Crystal structure of SARS-Cov-2 main protease G15S mutant in complex with PF07321332
8HUV	;	1.97	;	Crystal structure of SARS-Cov-2 main protease G15S mutant in complex with S217622
7FAY	;	2.1	;	Crystal structure of SARS-CoV-2 main protease in complex with (R)-1a
7JKV	;	1.25	;	Crystal Structure of SARS-CoV-2 main protease in complex with an inhibitor GRL-2420
8DOY	;	1.59	;	Crystal structure of SARS-CoV-2 main protease in complex with an inhibitor TKB-198
8DOX	;	1.46	;	Crystal structure of SARS-CoV-2 main protease in complex with an inhibitor TKB-245
8UH5	;	1.74	;	Crystal structure of SARS-CoV-2 main protease in complex with an inhibitor TKB-272
7QKA	;	1.8	;	Crystal structure of SARS-CoV-2 Main Protease in complex with covalently bound GC376
7GRE	;	1.66	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-1
7GRN	;	1.92	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-10
7GRO	;	1.55	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-11
7GRP	;	1.56	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-12
7GRQ	;	1.67	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-13
7GRR	;	1.68	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-14
7GRS	;	1.47	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-15
7GRT	;	1.71	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-16
7GRU	;	1.81	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-17
7GRV	;	1.92	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-18
7GRW	;	1.92	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-19
7GRF	;	1.84	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-2
7GRX	;	1.55	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-20
7GRY	;	1.54	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-21
7GRZ	;	1.86	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-22
7GS0	;	1.69	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-23
7GS1	;	1.74	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-24
7GS2	;	1.77	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-25
7GS3	;	1.89	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-26
7GS4	;	1.86	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-27
7GS5	;	1.88	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-28
7GS6	;	1.62	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-29
7GRG	;	1.54	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-3
7GRH	;	1.87	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-4
7GRI	;	1.79	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-5
7GRJ	;	1.74	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-6
7GRK	;	1.8	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-7
7GRL	;	1.68	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-8
7GRM	;	1.7	;	Crystal structure of SARS-CoV-2 main protease in complex with cpd-9
8DZ0	;	2.29	;	Crystal Structure of SARS-CoV-2 Main protease in complex with Ensitrelvir
8IG4	;	1.8	;	Crystal structure of SARS-Cov-2 main protease in complex with GC376
8DPR	;	2.0	;	Crystal structure of SARS-CoV-2 main protease in complex with inhibitor TKB-248
7XRS	;	1.93	;	Crystal structure of SARS-Cov-2 main protease in complex with inhibitor YH-53
7NW2	;	2.1	;	Crystal Structure of SARS-CoV-2 main protease in complex with LON-WEI-adc59df6-47
7D3I	;	2.004	;	Crystal structure of SARS-CoV-2 main protease in complex with MI-23
8DZ2	;	2.129	;	Crystal Structure of SARS-CoV-2 Main protease in complex with Nirmatrelvir
7VVP	;	1.97	;	Crystal structure of SARS-Cov-2 main protease in complex with PF07304814
7VLP	;	1.50252	;	Crystal structure of SARS-Cov-2 main protease in complex with PF07321332 in spacegroup P1211
7VLQ	;	1.93911	;	Crystal structure of SARS-Cov-2 main protease in complex with PF07321332 in spacegroup P212121
7VH8	;	1.59	;	Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332
8IGN	;	2.02	;	Crystal structure of SARS-CoV-2 main protease in complex with RAY1216
8HUR	;	1.64	;	Crystal structure of SARS-Cov-2 main protease in complex with S217622
7DDC	;	2.175	;	Crystal structure of SARS-CoV-2 main protease in complex with Tafenoquine
7WQ8	;	2.2	;	Crystal structure of SARS-CoV-2 main protease in complex with Z-DEVD-FMK
7WQ9	;	2.054	;	Crystal structure of SARS-CoV-2 main protease in complex with Z-IETD-FMK
7Z2K	;	1.65	;	Crystal structure of SARS-CoV-2 Main Protease in orthorhombic space group p212121
8IGA	;	1.63	;	Crystal structure of SARS-Cov-2 main protease K90R mutant in complex with GC376
8HQG	;	1.88	;	Crystal structure of SARS-Cov-2 main protease K90R mutant in complex with inhibitor YH-53
8HVY	;	1.97	;	Crystal structure of SARS-Cov-2 main protease K90R mutant in complex with PF07304814
8HVM	;	1.48	;	Crystal structure of SARS-Cov-2 main protease K90R mutant in complex with PF07321332
8HUW	;	1.75	;	Crystal structure of SARS-Cov-2 main protease K90R mutant in complex with S217622
8IG9	;	1.68	;	Crystal structure of SARS-Cov-2 main protease M49I mutant in complex with GC376
8HQH	;	1.58	;	Crystal structure of SARS-Cov-2 main protease M49I mutant in complex with inhibitor YH-53
8E25	;	1.868	;	Crystal Structure of SARS-CoV-2 Main Protease M49I mutant in complex with Nirmatrelvir
8HVW	;	2.05	;	Crystal structure of SARS-Cov-2 main protease M49I mutant in complex with PF07304814
8HVL	;	1.45	;	Crystal structure of SARS-Cov-2 main protease M49I mutant in complex with PF07321332
8DZ1	;	2.08	;	Crystal Structure of SARS-CoV-2 Main protease mutant M49I in complex with Ensitrelvir
8DZ6	;	2.366	;	Crystal Structure of SARS-CoV-2 Main protease mutant Q189K in complex with Nirmatrelvir
8E26	;	1.845	;	Crystal Structure of SARS-CoV-2 Main Protease N142S mutant in complex with Nirmatrelvir
8IGB	;	1.72	;	Crystal structure of SARS-Cov-2 main protease P132H mutant in complex with GC376
8HQI	;	1.55	;	Crystal structure of SARS-Cov-2 main protease P132H mutant in complex with inhibitor YH-53
8HVN	;	1.9	;	Crystal structure of SARS-Cov-2 main protease P132H mutant in complex with PF07321332
8HUX	;	1.74	;	Crystal structure of SARS-Cov-2 main protease P132H mutant in complex with S217622
8IG8	;	1.73	;	Crystal structure of SARS-Cov-2 main protease S46F mutant in complex with GC376
8HVV	;	1.95	;	Crystal structure of SARS-Cov-2 main protease S46F mutant in complex with PF07304814
8HZR	;	1.92	;	Crystal structure of SARS-Cov-2 main protease S46F mutant in complex with PF07321332
7BAK	;	2.05	;	Crystal structure of SARS-CoV-2 main protease treated with ebselen
7BAL	;	1.85	;	Crystal structure of SARS-CoV-2 main protease treated with ebselen derivative of MR6-31-2
8HVZ	;	1.7	;	Crystal structure of SARS-Cov-2 main protease V186F mutant in complex with PF07304814
8HVO	;	1.65	;	Crystal structure of SARS-Cov-2 main protease V186F mutant in complex with PF07321332
7D1O	;	1.78	;	Crystal structure of SARS-Cov-2 main protease with narlaprevir
8HQJ	;	1.74	;	Crystal structure of SARS-Cov-2 main protease Y54C mutant in complex with inhibitor YH-53
8HVX	;	1.75	;	Crystal structure of SARS-Cov-2 main protease Y54C mutant in complex with PF07304814
7VJY	;	1.9	;	Crystal Structure of Sars-Cov-2 Mpro at 1.90 A resolution-1
7VJZ	;	1.9	;	Crystal Structure of SARS-CoV-2 Mpro at 1.90 A resolution-7
7VK1	;	1.93	;	Crystal Structure of SARS-CoV-2 Mpro at 1.93 A resolution-5
7VK2	;	2.0	;	Crystal Structure of SARS-CoV-2 Mpro at 2.0 A resolution -9
7VK3	;	2.1	;	Crystal Structure of SARS-CoV-2 Mpro at 2.10 A resolution-2
7VK4	;	2.1	;	Crystal Structure of SARS-CoV-2 Mpro at 2.10 A resolution-3
7VK0	;	2.1	;	Crystal Structure of SARS-CoV-2 Mpro at 2.10 A resolution-6
7VK5	;	2.17	;	Crystal Structure of SARS-CoV-2 Mpro at 2.10 A resolution-8
7VJW	;	2.2	;	Crystal Structure of SARS-CoV-2 Mpro at 2.20 A resolution-10
7VJX	;	2.2	;	Crystal Structure of SARS-CoV-2 Mpro at 2.20 A resolution-12
7VK6	;	2.25	;	Crystal Structure of SARS-CoV-2 Mpro at 2.25 A resolution-13
7VK8	;	2.4	;	Crystal structure of SARS-CoV-2 Mpro at 2.4 A Resolution
7VK7	;	2.4	;	Crystal Structure of SARS-CoV-2 Mpro at 2.4 A resolution-11
7Z4S	;	1.7	;	Crystal structure of SARS-CoV-2 Mpro in complex with cyclic peptide GM4 including unnatural amino acids.
6Z2E	;	1.7	;	Crystal structure of SARS-CoV-2 Mpro in complex with the activity-based probe, biotin-PEG(4)-Abu-Tle-Leu-Gln-vinylsulfone
8SXR	;	2.114	;	Crystal structure of SARS-CoV-2 Mpro with C5a
8CZ7	;	2.0	;	Crystal structure of SARS-CoV-2 Mpro with compound C2
8CZ4	;	2.1	;	Crystal structure of SARS-CoV-2 Mpro with compound C3
8CYZ	;	1.9	;	Crystal structure of SARS-CoV-2 Mpro with compound C4
8CYU	;	1.8	;	Crystal structure of SARS-CoV-2 Mpro with compound C5
8C9O	;	1.69	;	Crystal structure of SARS-CoV-2 Mpro-S144A mutant in complex with 13b-K
8C9L	;	1.7	;	Crystal structure of SARS-CoV-2 Mpro-S144A mutant, free enzyme
7O05	;	1.94	;	Crystal structure of SARS-CoV-2 N-CTD
7XWX	;	3.0	;	Crystal structure of SARS-CoV-2 N-CTD
7XXK	;	2.0	;	Crystal structure of SARS-CoV-2 N-CTD in complex with GMP
7O35	;	1.8	;	Crystal Structure of SARS-CoV-2 N-CTD in complex with GTP (I)
7O36	;	2.0	;	Crystal Structure of SARS-CoV-2 N-CTD in complex with GTP (II)
7XX1	;	1.9	;	Crystal structure of SARS-CoV-2 N-NTD
7XWZ	;	2.25	;	Crystal structure of SARS-CoV-2 N-NTD and dsRNA complex
7N7W	;	2.42	;	Crystal Structure of SARS-CoV-2 NendoU in complex with CSC000178569
7N7U	;	2.06	;	Crystal Structure of SARS-CoV-2 NendoU in complex with LIZA-7
7N7Y	;	2.09	;	Crystal Structure of SARS-CoV-2 NendoU in complex with Z18197050
7N83	;	1.91	;	Crystal Structure of SARS-CoV-2 NendoU in complex with Z2443429438
7N7R	;	2.01	;	Crystal Structure of SARS-CoV-2 NendoU in complex with Z2472938267
7TCQ	;	2.02	;	Crystal structure of SARS-CoV-2 neutralizing antibody WS6 in complex with spike S2 peptide
7DIY	;	2.693	;	Crystal structure of SARS-CoV-2 nsp10 bound to nsp14-exoribonuclease domain
8TYJ	;	1.9	;	Crystal structure of SARS-CoV-2 nsp10/nsp16 complex with bound SAH
7R1T	;	2.7	;	Crystal structure of SARS-CoV-2 nsp10/nsp16 in complex with the SS148 inhibitor
7R1U	;	2.5	;	Crystal structure of SARS-CoV-2 nsp10/nsp16 in complex with the WZ16 inhibitor
8A23	;	2.8	;	Crystal structure of SARS-CoV-2 nsp10/nsp16 methyltransferase in complex with TO383
7QIF	;	2.53	;	Crystal structure of SARS-CoV-2 NSP14 in complex with 7MeGpppG.
7QGI	;	1.65	;	Crystal structure of SARS-CoV-2 NSP14 in the absence of NSP10
8BWU	;	2.36	;	Crystal structure of SARS-CoV-2 nsp14 methyltransferase domain in complex with the SS148 inhibitor
7ULT	;	1.9	;	Crystal Structure of SARS-CoV-2 Nsp16/10 Heterodimer Apo-Form.
7JYY	;	2.05	;	Crystal Structure of SARS-CoV-2 Nsp16/10 Heterodimer in Complex with (m7GpppA)pUpUpApApA (Cap-0) and S-Adenosylmethionine (SAM).
7JZ0	;	2.15	;	Crystal Structure of SARS-CoV-2 Nsp16/10 Heterodimer in Complex with (m7GpppA2m)pUpUpApApA (Cap-1) and S-Adenosyl-L-homocysteine (SAH).
7L6R	;	1.98	;	Crystal Structure of SARS-CoV-2 Nsp16/10 Heterodimer in Complex with (m7GpppA2m)pUpUpApApA (Cap-1), S-Adenosyl-L-homocysteine (SAH) and Manganese (Mn).
7L6T	;	1.78	;	Crystal Structure of SARS-CoV-2 Nsp16/10 Heterodimer in Complex with (m7GpppA2m)pUpUpApApA (Cap-1), S-Adenosyl-L-homocysteine (SAH) and two Magnesium (Mg) ions.
7KR0	;	0.77	;	Crystal structure of SARS-CoV-2 NSP3 macrodomain (C2 crystal form, 100 K)
7KR1	;	1.55	;	Crystal structure of SARS-CoV-2 NSP3 macrodomain (C2 crystal form, 310 K)
7KQW	;	0.93	;	Crystal structure of SARS-CoV-2 NSP3 macrodomain (C2 crystal form, methylated)
7KQO	;	0.85	;	Crystal structure of SARS-CoV-2 NSP3 macrodomain (P43 crystal form)
7XC3	;	1.7	;	Crystal structure of SARS-CoV-2 NSP3 Macrodomain 3 (SARS-unique domain-M)
7XC4	;	2.1	;	Crystal structure of SARS-CoV-2 NSP3 Macrodomain 3 (SARS-unique domain-M) in complex with Oxaprozin
7TWG	;	1.1	;	Crystal structure of SARS-CoV-2 NSP3 macrodomain at 293 K (P43 crystal form, 153 kGy)
7TWH	;	1.1	;	Crystal structure of SARS-CoV-2 NSP3 macrodomain at 293 K (P43 crystal form, 290 kGy)
7TWI	;	1.1	;	Crystal structure of SARS-CoV-2 NSP3 macrodomain at 293 K (P43 crystal form, 539 kGy)
7TWF	;	1.1	;	Crystal structure of SARS-CoV-2 NSP3 macrodomain at 293 K (P43 crystal form, 73 kGy)
7TWS	;	0.9	;	Crystal structure of SARS-CoV-2 NSP3 macrodomain at pH 10 (P43 crystal form)
7TWJ	;	0.9	;	Crystal structure of SARS-CoV-2 NSP3 macrodomain at pH 4 (P43 crystal form)
7TWN	;	0.9	;	Crystal structure of SARS-CoV-2 NSP3 macrodomain at pH 5 (P43 crystal form)
7TWO	;	0.9	;	Crystal structure of SARS-CoV-2 NSP3 macrodomain at pH 6 (P43 crystal form)
7TWP	;	0.9	;	Crystal structure of SARS-CoV-2 NSP3 macrodomain at pH 7 (P43 crystal form)
7TWR	;	0.9	;	Crystal structure of SARS-CoV-2 NSP3 macrodomain at pH 8 (P43 crystal form)
7TWQ	;	0.9	;	Crystal structure of SARS-CoV-2 NSP3 macrodomain at pH 9 (P43 crystal form)
7KXB	;	1.55	;	Crystal structure of SARS-CoV-2 Nsp3 Macrodomain complex with PARG329
7KQP	;	0.88	;	Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ADP-ribose (P43 crystal form)
7TX1	;	0.9	;	Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ADP-ribose at pH 10 (P43 crystal form)
7TWT	;	0.9	;	Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ADP-ribose at pH 4 (P43 crystal form)
7TWV	;	0.9	;	Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ADP-ribose at pH 5 (P43 crystal form)
7TWW	;	0.9	;	Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ADP-ribose at pH 6 (P43 crystal form)
7TWX	;	0.9	;	Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ADP-ribose at pH 7 (P43 crystal form)
7TWY	;	0.9	;	Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ADP-ribose at pH 8 (P43 crystal form)
7TX0	;	0.84	;	Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ADP-ribose at pH 9 (P43 crystal form)
7JLT	;	2.7	;	Crystal Structure of SARS-CoV-2 NSP7-NSP8 complex.
7VBD	;	1.94	;	Crystal structure of SARS-Cov-2 nucleocapsid N-terminal domain (NTD) protein,pH8.0
7UXX	;	1.85	;	Crystal structure of SARS-CoV-2 nucleocapsid protein C-terminal domain
7UXZ	;	1.733	;	Crystal structure of SARS-CoV-2 nucleocapsid protein C-terminal domain complexed with Chicoric acid
7DE1	;	2.0	;	Crystal structure of SARS-CoV-2 nucleocapsid protein C-terminal RNA binding domain
7F2B	;	2.0	;	Crystal structure of SARS-CoV-2 nucleocapsid protein C-terminal RNA binding domain at 2.0A resolution
6M3M	;	2.7	;	Crystal structure of SARS-CoV-2 nucleocapsid protein N-terminal RNA binding domain
8HOL	;	1.82	;	Crystal Structure of SARS-CoV-2 Omicron Main Protease (Mpro)
8HOM	;	1.56	;	Crystal Structure of SARS-CoV-2 Omicron Main Protease (Mpro) in Complex with Ensitrelvir
8HOZ	;	2.83	;	Crystal Structure of SARS-CoV-2 Omicron Main Protease (Mpro) in Complex with Nirmatrelvir
7WHH	;	2.6	;	Crystal structure of SARS-CoV-2 omicron RBD and human ACE2
7WSK	;	3.3	;	Crystal structure of SARS-CoV-2 Omicron spike receptor-binding domain in complex with civet ACE2
7YOW	;	3.3	;	Crystal structure of SARS-CoV-2 omicron variant spike receptor-binding domain (RBD) in complex with NCV2SG48 Fab
7DHG	;	2.2	;	Crystal structure of SARS-CoV-2 Orf9b complex with human TOM70
8FWO	;	1.8	;	Crystal structure of SARS-CoV-2 papain-like protease
7D47	;	1.97	;	Crystal structure of SARS-CoV-2 Papain-like protease C111S
8FWN	;	1.5	;	Crystal structure of SARS-CoV-2 papain-like protease C111S mutant
7FC5	;	2.894	;	Crystal structure of SARS-CoV-2 RBD and horse ACE2
8HES	;	2.2	;	Crystal structure of SARS-CoV-2 RBD and NIV-10 complex
7E3J	;	2.99	;	Crystal structure of SARS-CoV-2 RBD binding to dog ACE2
7DHX	;	2.3	;	Crystal structure of SARS-CoV-2 RBD binding to pangolin ACE2
7KM5	;	3.19	;	Crystal structure of SARS-CoV-2 RBD complexed with Nanosota-1
7CJF	;	2.108	;	Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody Fab
7DEO	;	2.5	;	Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv
7DET	;	2.2	;	Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv
7DEU	;	2.1	;	Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv
7E5O	;	2.8	;	Crystal structure of SARS-CoV-2 RBD in complex with antibody NT-193
7VOA	;	1.8	;	Crystal structure of SARS-CoV-2 RBD in complex with aRBD5
7UL1	;	2.65	;	Crystal structure of SARS-CoV-2 RBD in complex with the neutralizing IGHV3-53-encoded antibody EH3 isolated from a nonvaccinated pediatric patient
7Q3R	;	1.92	;	Crystal structure of SARS-CoV-2 RBD in complex with the neutralizing nanobodies VHH-F04 and VHH-G09
7Q3Q	;	2.3	;	Crystal structure of SARS-CoV-2 RBD in complex with the neutralizing nanobody VHH-12
7UL0	;	2.49	;	Crystal structure of SARS-CoV-2 RBD in complex with the ridge-binding nAb EH8 isolated from a nonvaccinated pediatric patient
7P19	;	3.24	;	Crystal structure of SARS-CoV-2 RBD Q498Y complexed with human ACE2
8GX9	;	4.01	;	Crystal structure of SARS-CoV-2 RBD with P2C-1F11 and P2B-1G5
7LKA	;	1.981	;	Crystal structure of SARS-CoV-2 RBD-targeting antibody COV107-23
7LK9	;	3.4	;	Crystal structure of SARS-CoV-2 RBD-targeting antibody COV107-23 HC + COVD21-C8 LC
8BSE	;	1.9	;	CRYSTAL STRUCTURE OF SARS-COV-2 RECEPTOR BINDING DOMAIN (RBD) in complex with 1D1 Fab
8BSF	;	2.2	;	CRYSTAL STRUCTURE OF SARS-COV-2 RECEPTOR BINDING DOMAIN (RBD-beta variant) in complex with 3D2 Fab
7YCO	;	1.96	;	Crystal structure of SARS-CoV-2 Receptor Binding Domain bound to A6 repebody
7KN5	;	1.87	;	Crystal structure of SARS-CoV-2 receptor binding domain complexed with nanobodies VHH E and U
7KN6	;	2.55	;	Crystal structure of SARS-CoV-2 receptor binding domain complexed with nanobody VHH V and antibody Fab CC12.3
7KN7	;	2.73	;	Crystal structure of SARS-CoV-2 receptor binding domain complexed with nanobody VHH W and antibody Fab CC12.3
6XC3	;	2.698	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CC12.1 and CR3022
6XC7	;	2.883	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CC12.3 and CR3022
7LOP	;	2.246	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CV05-163 and CR3022
7LQ7	;	3.4	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CV503 and COVA1-16
8GF2	;	2.851	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies eCR3022.20 and CC12.3
7Y3O	;	2.1	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with human antibody BIOLS56
8F0I	;	3.7	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with human antibody COVA309-22
6W41	;	3.084	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with human antibody CR3022
7S5R	;	2.45	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibodies CV07-287 and COVA1-16
8GB7	;	2.57	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody 20A7
8GB6	;	1.75	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody 21B6
8GB5	;	3.35	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody 25F9
7MF1	;	2.092	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody 47D1
7U2D	;	2.76	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody ADG20
7U2E	;	2.85	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody ADI-55688
6XC2	;	3.112	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC12.1
6XC4	;	2.341	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC12.3
8SDF	;	1.79	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC25.4
8SDG	;	2.71	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC25.43
7JMO	;	2.359	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody COVA2-04
7JMP	;	1.712	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody COVA2-39
6XKQ	;	2.55	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CV07-250
6XKP	;	2.72	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CV07-270
7TP3	;	2.33	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody K288.2
7TP4	;	1.95	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody K398.22
7E3O	;	2.51	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody nCoV617
8FI9	;	4.2	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody WRAIR-5001
8EOO	;	2.77	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibodies WRAIR-2063 and WRAIR-2151
7N4I	;	2.284	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody WRAIR-2057.
7N4L	;	3.601	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody WRAIR-2125.
7N4M	;	3.79	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody WRAIR-2151.
7N4J	;	2.207	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody WRAIR-2173.
7FBJ	;	2.85	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing nanobody 17F6
8FAH	;	4.22	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with SARS-CoV-2 reactive human antibody CR3022
7K9Z	;	2.95	;	Crystal structure of SARS-CoV-2 receptor binding domain in complex with the Fab fragments of neutralizing antibodies 298 and 52
7WUE	;	3.2	;	Crystal structure of SARS-CoV-2 Receptor Binding Domain in complex with the monoclonal antibody m31A7
7FBK	;	1.9	;	Crystal structure of SARS-CoV-2 receptor binding domain N501Y mutant in complex with neutralizing nanobody 20G6
7XA7	;	3.31	;	Crystal structure of SARS-CoV-2 receptor-binding domain in complex with intermediate horseshoe bat ACE2
7YE8	;	3.01	;	Crystal structure of SARS-CoV-2 refolded dimeric ORF9b
7URQ	;	2.05	;	Crystal Structure of SARS-CoV-2 S delta variant receptor-binding domain (RBD) in complex CoV11 Fab crystal form 1
7URS	;	2.4	;	Crystal Structure of SARS-CoV-2 S delta variant receptor-binding domain (RBD) in complex CoV11 Fab crystal form 2
7LY3	;	3.0	;	Crystal structure of SARS-CoV-2 S NTD bound to S2M28 Fab
7Z8O	;	0.96	;	Crystal structure of SARS-CoV-2 S RBD in complex with a stapled peptide
8AAA	;	1.9	;	Crystal structure of SARS-CoV-2 S RBD in complex with a stapled peptide
7S4S	;	2.05	;	Crystal Structure of SARS-CoV-2 S receptor-binding domain (RBD) in complex CoV11 Fab
7YE7	;	2.95	;	Crystal structure of SARS-CoV-2 soluble dimeric ORF9b
7B62	;	1.82	;	Crystal structure of SARS-CoV-2 spike protein N-terminal domain in complex with biliverdin
7KN3	;	2.251	;	Crystal structure of SARS-CoV-2 spike protein receptor-binding domain complexed with a pre-pandemic antibody S-B8 Fab
7KN4	;	2.7	;	Crystal structure of SARS-CoV-2 spike protein receptor-binding domain complexed with a pre-pandemic antibody S-E6 Fab
7T7B	;	2.59	;	Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with a cross-neutralizing antibody ADI-62113 Fab
8CWU	;	1.71	;	Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with a cross-neutralizing nanobody 1-21
8CWV	;	2.51	;	Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with a cross-neutralizing nanobody 2-31 and a human antibody CC12.1 Fab
7SBU	;	2.53	;	Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with a highly potent antibody J08 Fab
8ELO	;	2.72	;	Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with antibody CC12.1 Fab and nanobody Nb-C4-225
8ELP	;	2.83	;	Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with antibody CC12.1 Fab and nanobody Nb-C4-240
8ELQ	;	2.21	;	Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with antibody CC12.1 Fab and nanobody Nb-C4-255
7JMW	;	2.89	;	Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with cross-neutralizing antibody COVA1-16 Fab
7LM8	;	1.936	;	Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with two cross-neutralizing antibodies CV38-142 and COVA1-16 Fabs isolated from COVID-19 patients
7YCK	;	2.6	;	Crystal structure of SARS-CoV-2 Spike RBD in complex with FP-12A Fab
7L7E	;	3.0	;	Crystal structure of SARS-CoV-2 spike RBD in complex with human monoclonal antibodies AZD8895 and AZD1061
7L7D	;	2.5	;	Crystal structure of SARS-CoV-2 spike RBD in complex with human monoclonal antibody AZD8895
7YCL	;	2.13	;	Crystal structure of SARS-CoV-2 Spike RBD in complex with IS-9A Fab
7YCN	;	2.85	;	Crystal structure of SARS-CoV-2 Spike RBD in complex with IY-2A Fab
7DJZ	;	2.397	;	Crystal structure of SARS-CoV-2 Spike RBD in complex with MW01 Fab
7DK0	;	3.199	;	Crystal structure of SARS-CoV-2 Spike RBD in complex with MW05 Fab
7DPM	;	3.304	;	Crystal structure of SARS-CoV-2 Spike RBD in complex with MW06 Fab
7DK2	;	3.0	;	Crystal structure of SARS-CoV-2 Spike RBD in complex with MW07 Fab
7VYR	;	2.2	;	Crystal structure of SARS-CoV-2 Spike RBD in complex with the D27 neutralizing antibody Fab fragment
7XSA	;	2.2	;	Crystal structure of SARS-CoV-2 spike receptor binding domain bound with P2S-2E9 Fab
7XS8	;	2.8	;	Crystal structure of SARS-CoV-2 spike receptor binding domain bound with P5S-1H1 Fab
7XSC	;	2.88	;	Crystal structure of SARS-CoV-2 spike receptor binding domain bound with P5S-2B10
7XSB	;	3.2	;	Crystal structure of SARS-CoV-2 spike receptor binding domain bound with P5S-3B11 Fab
7WNB	;	2.18	;	Crystal structure of SARS-CoV-2 spike receptor-binding domain (RBD) in complex with NCV2SG48 Fab
7WN2	;	2.35	;	Crystal structure of SARS-CoV-2 spike receptor-binding domain (RBD) in complex with NCV2SG53 Fab
7X2H	;	2.1	;	Crystal structure of SARS-CoV-2 spike receptor-binding domain bound with 6-2C Fab
6M0J	;	2.45	;	Crystal structure of SARS-CoV-2 spike receptor-binding domain bound with ACE2
8SIQ	;	2.5	;	Crystal structure of SARS-CoV-2 spike receptor-binding domain in complex with broadly neutralizing antibodies CC25.36 and CV38-142 Fab
8SIR	;	3.3	;	Crystal structure of SARS-CoV-2 spike receptor-binding domain in complex with broadly neutralizing antibody CC25.54 Fab
8SIS	;	3.08	;	Crystal structure of SARS-CoV-2 spike receptor-binding domain in complex with broadly neutralizing antibody CC84.2 Fab
8SIT	;	2.91	;	Crystal structure of SARS-CoV-2 spike receptor-binding domain in complex with broadly neutralizing antibody CC84.24 Fab
8H91	;	3.07	;	Crystal structure of SARS-CoV-2 spike receptor-binding domain in complex with nanobody N19
7W1S	;	1.997	;	Crystal structure of SARS-CoV-2 spike receptor-binding domain in complex with neutralizing nanobody Nb-007
8H5T	;	2.0	;	Crystal structure of SARS-CoV-2 spike receptor-binding domain in complex with neutralizing nanobody Nb-015
8H5U	;	2.401	;	Crystal structure of SARS-CoV-2 spike receptor-binding domain in complex with neutralizing nanobody Nb-021
8DAO	;	2.8	;	Crystal structure of SARS-CoV-2 spike stem fusion peptide in complex with neutralizing antibody COV44-79
8D6Z	;	2.3	;	Crystal structure of SARS-CoV-2 spike stem fusion peptide in complex with neutralizing antibody COV91-27
8DGU	;	1.89	;	Crystal structure of SARS-CoV-2 spike stem helix peptide in complex with Fab of broadly neutralizing antibody CC25.106 isolated from a vaccinated COVID-19 convalescent
7SJS	;	1.612	;	Crystal structure of SARS-CoV-2 spike stem helix peptide in complex with neutralizing antibody CC40.8
8DTR	;	1.5	;	Crystal structure of SARS-CoV-2 spike stem helix peptide in complex with neutralizing antibody COV30-14
8DTX	;	1.6	;	Crystal structure of SARS-CoV-2 spike stem helix peptide in complex with neutralizing antibody COV89-22
8DTT	;	1.75	;	Crystal structure of SARS-CoV-2 spike stem helix peptide in complex with neutralizing antibody COV93-03
7F5R	;	3.01	;	Crystal structure of SARS-CoV-2 Y453F-RBD bound to mink ACE2
8IQJ	;	2.3	;	Crystal structure of SARS-CoV2 N-NTD
8IV3	;	1.9	;	Crystal structure of SARS-CoV2 N-NTD complexed with 5-Benzyloxygramine
8J6X	;	2.7	;	Crystal structure of SARS-CoV2 N-NTD complexed with 5-Benzyloxygramine derivative (P3-8)
8UFL	;	2.51	;	Crystal Structure of SARS-Unique Domain (SUD) of Nsp3 from SARS coronavirus
2AMQ	;	2.3	;	Crystal Structure Of SARS_CoV Mpro in Complex with an Inhibitor N3
2AMD	;	1.85	;	Crystal Structure Of SARS_CoV Mpro in Complex with an Inhibitor N9
7F5M	;	2.4	;	Crystal structure of Sas5 YEATS domain in complex with H3K27bz peptide
8GW5	;	1.8	;	Crystal structure of SaSsbA complexed with glycerol
7E4N	;	1.94	;	Crystal structure of Sat1646
7XM0	;	2.6	;	Crystal structure of Sau3AI-C and DNA substrate complex
5AYS	;	2.09	;	Crystal structure of SAUGI/HSV UDG complex
5KIV	;	1.75	;	Crystal structure of SauMacro (SAV0325)
7XHZ	;	1.92	;	Crystal structure of SAV2152 from MRSA
6Y5S	;	0.95	;	Crystal structure of savinase at cryogenic conditions
6Y5T	;	1.1	;	Crystal structure of savinase at room temperature
3DEX	;	2.7	;	Crystal structure of SAV_2001 protein from Streptomyces avermitilis, Northeast Structural Genomics Consortium Target SvR107.
3S69	;	1.43	;	Crystal structure of saxthrombin
2AK4	;	2.5	;	Crystal Structure of SB27 TCR in complex with HLA-B*3508-13mer peptide
3KXF	;	3.1	;	Crystal Structure of SB27 TCR in complex with the 'restriction triad' mutant HLA-B*3508-13mer
4JRY	;	2.8	;	Crystal Structure of SB47 TCR-HLA B*3505-LPEP complex
6LG0	;	2.998	;	Crystal structure of SbCGTa in complex with UDP
6LFZ	;	2.866	;	Crystal structure of SbCGTb in complex with UDPG
7CBB	;	2.6	;	Crystal structure of SbnC in the biosynthesis of staphyloferrin B
6KNH	;	1.76	;	Crystal structure of SbnH in complex with citrate, a PLP-dependent decarboxylase in Staphyloferrin B biothesynthesis
6KNK	;	2.3	;	Crystal structure of SbnH in complex with citryl-diaminoethane
6KNI	;	1.97	;	Crystal structure of SbnH in complex with the cofactor PLP, a PLP-dependent decarboxylase in Staphyloferrin B biothesynthesis
8SVC	;	1.59	;	Crystal Structure of SBP from Klebsiella pneumoniae
2VNU	;	2.3	;	Crystal structure of Sc Rrp44
3CBT	;	1.7	;	Crystal structure of SC4828, a unique phosphatase from Streptomyces coelicolor
3H7T	;	2.0	;	Crystal structure of scabies mite inactivated protease paralogue S-D1 (SMIPP-S-D1)
3H7O	;	1.85	;	Crystal structure of scabies mite inactivated protease paralogue S-I1 (SMIPP-S-I1)
5DAZ	;	1.45	;	Crystal structure of Scabin, a mono-ADP-ribosyltransferase from Streptomyces scabies
2QDL	;	2.2	;	Crystal structure of scaffolding protein TtCheW from Thermoanaerobacter tengcongensis
1QVI	;	2.54	;	Crystal structure of scallop myosin S1 in the pre-power stroke state to 2.6 Angstrom resolution: flexibility and function in the head
1JZK	;	2.2	;	Crystal Structure of Scapharca inaequivalvis HbI, I114F mutant (deoxy)
1JWN	;	2.1	;	Crystal Structure of Scapharca inaequivalvis HbI, I114F Mutant Ligated to Carbon Monoxide.
1JZM	;	1.9	;	Crystal Structure of Scapharca inaequivalvis HbI, I114M Mutant in the Absence of ligand.
2GRF	;	2.1	;	Crystal structure of Scapharca inaequivalvis HBI, M37V mutant in the absence of ligand
3HRT	;	2.8	;	Crystal Structure of ScaR with bound Cd2+
3HRU	;	2.9	;	Crystal Structure of ScaR with bound Zn2+
4TW0	;	3.648	;	Crystal Structure of SCARB2 in Acidic Condition (pH4.8)
4TVZ	;	3.006	;	Crystal Structure of SCARB2 in Neural Condition (pH7.5)
4TW2	;	2.889	;	Crystal Structure of SCARB2 in Neural Condition (pH7.5)
4XDN	;	2.08	;	Crystal structure of Scc4 in complex with Scc2n
5W94	;	3.193	;	Crystal structure of Scc4 in complex with Scc2n and Ctf19n
4JQE	;	1.77	;	Crystal structure of scCK2 alpha in complex with AMPPN
4FI1	;	2.09	;	Crystal structure of scCK2 alpha in complex with ATP
4MWH	;	2.09	;	Crystal structure of scCK2 alpha in complex with ATP
4JR7	;	1.48	;	Crystal structure of scCK2 alpha in complex with GMPPNP
4LFI	;	1.85	;	Crystal structure of scCK2 alpha in complex with GMPPNP
3K41	;	1.9	;	Crystal structure of sCD-MPR mutant E19Q/K137M bound to Man-6-P
3K43	;	2.0	;	Crystal structure of sCD-MPR mutant E19Q/K137M pH 6.5
3K42	;	2.3	;	Crystal structure of sCD-MPR mutant E19Q/K137M pH 7.0
3MC6	;	3.15	;	Crystal structure of ScDPL1
1P4I	;	2.8	;	Crystal Structure of scFv against peptide GCN4
8JUH	;	2.21	;	Crystal structure of ScFv against the receptor binding domine of SARS-CoV-2 S-spike protein
8IA6	;	2.75	;	Crystal structure of scFv antibody against Phospholipase A2 of Echis carinatus venom
8OZ3	;	3.1	;	Crystal structure of scFv ATOR 1017 bound to human 4-1BB
8DY1	;	2.68	;	Crystal Structure of scFv CAT2200 LH in complex with IL-17A
8DGR	;	1.56	;	Crystal Structure of scFv(F8) Antibody Fragment
4H0I	;	2.4	;	Crystal Structure of Scfv-2D10 in Complex with Methyl Alpha-D-Mannopyranoside
5A2L	;	1.79	;	Crystal structure of scFv-SM3 in complex with APD-CGalNAc-RP
6FRJ	;	1.4	;	Crystal structure of scFv-SM3 in complex with APD-SeThrGalNAc-RP
5A2I	;	1.88	;	Crystal structure of scFv-SM3 in complex with APD-SGalNAc-RP
5A2K	;	1.7	;	Crystal structure of scFv-SM3 in complex with APD-TGalNAc-RP
6FZR	;	1.8	;	Crystal structure of scFv-SM3 in complex with compound 2
6FZQ	;	1.7	;	Crystal structure of scFv-SM3 in complex with compound 3
5A2J	;	1.65	;	Crystal structure of scFv-SM3 in complex with the naked peptide APDTRP
2ZNW	;	2.71	;	Crystal Structure of ScFv10 in Complex with Hen Egg Lysozyme
4RAV	;	2.5	;	Crystal structure of scFvC4 in complex with the first 17 AA of huntingtin
5O9Y	;	1.57	;	Crystal structure of ScGas2 in complex with compound 11
5OA6	;	1.94	;	Crystal structure of ScGas2 in complex with compound 12
5O9Q	;	1.4	;	Crystal structure of ScGas2 in complex with compound 6
5O9O	;	1.9	;	Crystal structure of ScGas2 in complex with compound 7.
5OA2	;	2.15	;	Crystal structure of ScGas2 in complex with compound 8
5O9R	;	1.7	;	Crystal structure of ScGas2 in complex with compound 9
5BTO	;	1.641	;	Crystal structure of Scheffersomyces stipitis Rai1
5ULJ	;	1.911	;	Crystal structure of Scheffersomyces stipitis Rai1 in complex with (3'-NADP)+ and calcium ion
1RMR	;	2.5	;	Crystal Structure of Schistatin, a Disintegrin Homodimer from saw-scaled Viper (Echis carinatus) at 2.5 A resolution
4Q3P	;	2.501	;	Crystal structure of Schistosoma mansoni arginase
4Q3Q	;	2.001	;	Crystal structure of Schistosoma mansoni arginase in complex with inhibitor ABH
4Q3R	;	2.169	;	Crystal structure of Schistosoma mansoni arginase in complex with inhibitor ABHDP
4Q3S	;	2.11	;	Crystal structure of Schistosoma mansoni arginase in complex with inhibitor ABHPE
4Q3V	;	2.7	;	Crystal structure of Schistosoma mansoni arginase in complex with inhibitor BEC
4Q3T	;	2.142	;	Crystal structure of Schistosoma mansoni arginase in complex with inhibitor NOHA
4Q3U	;	2.5	;	Crystal structure of Schistosoma mansoni arginase in complex with inhibitor nor-NOHA
4Q41	;	2.199	;	Crystal structure of Schistosoma mansoni arginase in complex with L-lysine
4Q42	;	2.051	;	Crystal structure of Schistosoma mansoni arginase in complex with L-ornithine
4Q40	;	1.831	;	Crystal structure of Schistosoma mansoni arginase in complex with L-valine
2V1M	;	1.0	;	Crystal structure of Schistosoma mansoni glutathione peroxidase
4BZ5	;	1.785	;	Crystal structure of Schistosoma mansoni HDAC8
5FUE	;	2.199	;	Crystal structure of Schistosoma mansoni HDAC8 complexed with 3- benzamido-benzohydroxamate
6HU1	;	1.996	;	Crystal structure of Schistosoma mansoni HDAC8 complexed with a benzohydroxamate inhibitor 10
6HU2	;	1.986	;	Crystal structure of Schistosoma mansoni HDAC8 complexed with a benzohydroxamate inhibitor 11
7P3S	;	1.546	;	Crystal structure of Schistosoma mansoni HDAC8 complexed with a benzohydroxamate inhibitor 12
6HSZ	;	2.374	;	Crystal structure of Schistosoma mansoni HDAC8 complexed with a benzohydroxamate inhibitor 2
6HT8	;	2.497	;	Crystal structure of Schistosoma mansoni HDAC8 complexed with a benzohydroxamate inhibitor 3
6HTG	;	1.939	;	Crystal structure of Schistosoma mansoni HDAC8 complexed with a benzohydroxamate inhibitor 4
6HTH	;	1.95	;	Crystal structure of Schistosoma mansoni HDAC8 complexed with a benzohydroxamate inhibitor 5
6HTI	;	1.693	;	Crystal structure of Schistosoma mansoni HDAC8 complexed with a benzohydroxamate inhibitor 6
6HTT	;	1.748	;	Crystal structure of Schistosoma mansoni HDAC8 complexed with a benzohydroxamate inhibitor 7
6HTZ	;	1.841	;	Crystal structure of Schistosoma mansoni HDAC8 complexed with a benzohydroxamate inhibitor 8
6HU0	;	1.746	;	Crystal structure of Schistosoma mansoni HDAC8 complexed with a benzohydroxamate inhibitor 9
4CQF	;	2.3	;	Crystal structure of Schistosoma mansoni HDAC8 complexed with a mercaptoacetamide inhibitor
6FU1	;	1.548	;	Crystal structure of Schistosoma mansoni HDAC8 complexed with a n-alkyl hydroxamate
6HU3	;	1.655	;	Crystal structure of Schistosoma mansoni HDAC8 complexed with a triazole hydroxamate inhibitor
6TLD	;	1.61	;	Crystal structure of Schistosoma mansoni HDAC8 complexed with a triazole hydroxamate inhibitor 2
6GX3	;	2.1	;	Crystal structure of Schistosoma mansoni HDAC8 complexed with an hydroxamate 1
6GXA	;	2.1	;	Crystal structure of Schistosoma mansoni HDAC8 complexed with an hydroxamate 2
6GXU	;	1.917	;	Crystal structure of Schistosoma mansoni HDAC8 complexed with an hydroxamate 3
6GXW	;	2.071	;	Crystal structure of Schistosoma mansoni HDAC8 complexed with an hydroxamate 4
4BZ8	;	2.21	;	Crystal structure of Schistosoma mansoni HDAC8 complexed with J1038
4BZ9	;	2.0	;	Crystal structure of Schistosoma mansoni HDAC8 complexed with J1075
4BZ7	;	1.65	;	Crystal structure of Schistosoma mansoni HDAC8 complexed with M344
6HRQ	;	1.845	;	Crystal structure of Schistosoma mansoni HDAC8 complexed with NCC-149
6HQY	;	2.501	;	Crystal structure of Schistosoma mansoni HDAC8 complexed with PCI-34051
6HSH	;	1.545	;	Crystal structure of Schistosoma mansoni HDAC8 complexed with Quisinostat
4BZ6	;	2.0	;	Crystal structure of Schistosoma mansoni HDAC8 complexed with SAHA
6HSG	;	1.846	;	Crystal structure of Schistosoma mansoni HDAC8 H292M mutant complexed with NCC-149
7P2U	;	1.8	;	Crystal structure of Schistosoma mansoni HDAC8 in complex with a 3-chlorophenyl-spiroindoline capped hydroxamate-based inhibitor, bound to a novel site
7P2V	;	2.25	;	Crystal structure of Schistosoma mansoni HDAC8 in complex with a 4-chlorophenyl-spiroindoline capped hydroxamate-based inhibitor, bound to a novel site
7ZW7	;	2.85	;	Crystal structure of Schistosoma mansoni HDAC8 in complex with a formate molecule in the active site
7P2S	;	2.2	;	Crystal structure of Schistosoma mansoni HDAC8 in complex with a tricyclic thieno[3,2-b]indole capped hydroxamate-based inhibitor, chlorine derivative
6HSF	;	1.899	;	Crystal structure of Schistosoma mansoni HDAC8 mutant H292M complexed with PCI-34051
7POZ	;	1.9	;	Crystal structure of Schistosoma mansoni HDAC8 with DMSO bound in the active site
3ZLP	;	3.515	;	Crystal structure of Schistosoma mansoni Peroxiredoxin 1 C48P mutant form with four decamers in the asymmetric unit
3ZL5	;	2.493	;	Crystal structure of Schistosoma mansoni Peroxiredoxin I C48S mutant with one decamer in the ASU
3E0Q	;	1.9	;	Crystal structure of Schistosoma mansoni purine nucleoside phosphorylase complexed with a novel monocyclic inhibitor
3DJF	;	2.302	;	Crystal Structure of Schistosoma mansoni Purine Nucleoside Phosphorylase in a complex with BCX-34
3F8W	;	2.3	;	Crystal structure of Schistosoma mansoni purine nucleoside phosphorylase in complex with adenosine
3FAZ	;	1.9	;	Crystal structure of Schistosoma mansoni purine nucleoside phosphorylase in complex with inosine
2XBI	;	1.6	;	Crystal structure of Schistosoma mansoni Thioredoxin at 1.6 Angstrom
3FNQ	;	1.85	;	Crystal structure of schistosoma purine nucleoside phosphorylase in complex with hypoxanthine
7JMT	;	2.75	;	Crystal structure of schistosome BCL-2 bound to ABT-737
3HXI	;	1.8	;	Crystal structure of Schistosome eIF4E complexed with m7GpppG and 4E-BP
3HXG	;	2.1	;	Crystal structure of Schistsome eIF4E complexed with m7GpppA and 4E-BP
7E4G	;	2.1	;	Crystal structure of schizorhodopsin 4
4MSQ	;	1.952	;	Crystal structure of Schizosaccharomyces pombe AMSH-like protease sst2 catalytic domain bound to ubiquitin
4MSM	;	1.74	;	Crystal structure of Schizosaccharomyces pombe AMSH-like protease sst2 E286A mutant bound to ubiquitin
4MSD	;	1.9	;	Crystal structure of Schizosaccharomyces pombe AMSH-like protein SST2 T319I mutant
5WJC	;	2.298	;	Crystal structure of Schizosaccharomyces pombe Mis16 in complex with Eic1
4HJA	;	2.1	;	Crystal Structure of Schizosaccharomyces pombe Pot1pC bound to ssDNA (ACGGTTACGGT)
4HJ9	;	1.85	;	Crystal Structure of Schizosaccharomyces pombe Pot1pC bound to ssDNA (CGGTTACGGT)
4HID	;	1.822	;	Crystal Structure of Schizosaccharomyces pombe Pot1pC bound to ssDNA (GCTTACGGT)
4HIM	;	1.75	;	Crystal Structure of Schizosaccharomyces pombe Pot1pC bound to ssDNA (GGATACGGT)
4HIO	;	1.753	;	Crystal Structure of Schizosaccharomyces pombe Pot1pC bound to ssDNA (GGTAACGGT)
4HJ8	;	2.043	;	Crystal Structure of Schizosaccharomyces pombe Pot1pC bound to ssDNA (GGTTACGCT)
4HIK	;	1.636	;	Crystal Structure of Schizosaccharomyces pombe Pot1pC bound to ssDNA (GGTTACGGT)
4HJ7	;	1.783	;	Crystal Structure of Schizosaccharomyces pombe Pot1pC bound to ssDNA (GGTTAGGGT)
4HJ5	;	2.04	;	Crystal Structure of Schizosaccharomyces pombe Pot1pC bound to ssDNA (GGTTTCGGT)
5USO	;	2.0	;	Crystal Structure of Schizosaccharomyces pombe Pot1pC bound to ssRNA/ssDNA chimera (GGTTACrGrGrU)
5USB	;	1.615	;	Crystal Structure of Schizosaccharomyces pombe Pot1pC bound to ssRNA/ssDNA chimera (rGGTTACGGT)
5USN	;	1.9	;	Crystal Structure of Schizosaccharomyces pombe Pot1pC bound to ssRNA/ssDNA chimera (rGrGrUTACGGT)
8ETD	;	2.78	;	Crystal Structure of Schizosaccharomyces pombe Rho1
1N05	;	2.1	;	Crystal Structure of Schizosaccharomyces pombe Riboflavin Kinase Reveals a Novel ATP and Riboflavin Binding Fold
1N06	;	2.0	;	Crystal Structure of Schizosaccharomyces pombe Riboflavin Kinase Reveals a Novel ATP and Riboflavin Binding Fold
1N07	;	2.45	;	Crystal Structure of Schizosaccharomyces pombe Riboflavin Kinase Reveals a Novel ATP and Riboflavin Binding Fold
1N08	;	1.6	;	Crystal Structure of Schizosaccharomyces pombe Riboflavin Kinase Reveals a Novel ATP and Riboflavin Binding Fold
4JXE	;	1.451	;	Crystal structure of Schizosaccharomyces pombe sst2 catalytic domain
4MS7	;	1.673	;	Crystal structure of Schizosaccharomyces pombe sst2 catalytic domain
4K1R	;	1.632	;	Crystal structure of Schizosaccharomyces pombe sst2 catalytic domain and Ubiquitin
5YD0	;	3.182	;	Crystal structure of Schlafen 13 (SLFN13) N'-domain
4IDU	;	3.08	;	crystal structure of Schmallenberg virus nucleoprotein
7XQ5	;	2.25	;	Crystal structure of ScIno2p-ScIno4p bound promoter DNA
6XRB	;	1.76	;	Crystal structure of SciW from Salmonella typhimurium
5HYZ	;	1.822	;	Crystal Structure of SCL7 in Oryza sativa
6XQG	;	2.15	;	Crystal structure of SCLam E144S mutant, a non-specific endo-beta-1,3(4)-glucanase from family GH16, co-crystallized with 1,3-beta-D-cellobiosyl-cellobiose, presenting a 1,3-beta-D-cellobiosyl-glucose at active site
6XQF	;	1.58	;	Crystal structure of SCLam E144S mutant, a non-specific endo-beta-1,3(4)-glucanase from family GH16, co-crystallized with 1,3-beta-D-cellotriosyl-glucose, presenting a 1,3-beta-D-cellobiosyl-glucose at active site
6XQL	;	1.97	;	Crystal structure of SCLam E144S mutant, a non-specific endo-beta-1,3(4)-glucanase from family GH16, co-crystallized with cellohexaose, presenting a 1,3-beta-D-cellobiosyl-glucose at active site
6XQH	;	1.57	;	Crystal structure of SCLam E144S mutant, a non-specific endo-beta-1,3(4)-glucanase from family GH16, co-crystallized with cellotriose, presenting a 1,3-beta-D-cellobiosyl-glucose and a cellobiose at active site
6XQM	;	1.85	;	Crystal structure of SCLam E144S mutant, a non-specific endo-beta-1,3(4)-glucanase from family GH16, co-crystallized with laminarihexaose, presenting a laminaribiose and a glucose at active site
6XOF	;	1.5	;	Crystal structure of SCLam, a non-specific endo-beta-1,3(4)-glucanase from family GH16
2X2S	;	1.6	;	Crystal structure of Sclerotinia sclerotiorum agglutinin SSA
2X2T	;	1.97	;	CRYSTAL STRUCTURE OF SCLEROTINIA SCLEROTIORUM AGGLUTININ SSA in complex with Gal-beta1,3-Galnac
2P0K	;	1.75	;	Crystal structure of SCMH1
2NM0	;	1.99	;	Crystal Structure of SCO1815: a Beta-Ketoacyl-Acyl Carrier Protein Reductase from Streptomyces coelicolor A3(2)
3ITC	;	1.7	;	Crystal structure of Sco3058 with bound citrate and glycerol
3ISI	;	2.2	;	Crystal structure of Sco3058 with bound inhibitor L-Ala-L-Asp Phosphinodipeptide
3ZPL	;	2.8	;	Crystal structure of Sco3205, a MarR family transcriptional regulator from Streptomyces coelicolor, in complex with DNA
2IAI	;	1.65	;	Crystal structure of SCO3833, a member of the TetR transcriptional regulator family from Streptomyces coelicolor A3
3G7R	;	1.38	;	Crystal structure of SCO4454, a TetR-family transcriptional regulator from Streptomyces coelicolor
2ZDS	;	2.3	;	Crystal Structure of SCO6571 from Streptomyces coelicolor A3(2)
3L0B	;	2.35	;	Crystal structure of SCP1 phosphatase D206A mutant phosphoryl-intermediate
3L0C	;	2.45	;	Crystal structure of SCP1 phosphatase D206A mutant with trapped inorganic phosphate
3L0Y	;	2.3	;	Crystal structure OF SCP1 phosphatase D98A mutant
5LNQ	;	1.98	;	Crystal structure of SCP2 thiolase from Leishmania mexicana. Complex of the C123A mutant with acetoacetyl-CoA.
5LOT	;	2.25	;	Crystal structure of SCP2 thiolase from Leishmania mexicana. Complex of the C123A mutant with acetyl-CoA.
3ZBN	;	2.45	;	Crystal structure of SCP2 thiolase from Leishmania mexicana. Complex of the C123A mutant with Coenzyme A.
3ZBK	;	1.9	;	Crystal structure of SCP2 thiolase from Leishmania mexicana: The C123A mutant.
3ZBL	;	1.9	;	Crystal structure of SCP2 thiolase from Leishmania mexicana: The C123S mutant.
4BIA	;	2.9	;	Crystal structure of SCP2 thiolase from Trypanosoma brucei: The C337A mutant.
3W6J	;	2.6	;	Crystal structure of ScpAB core complex
2Z99	;	2.3	;	Crystal Structure of ScpB from Mycobacterium tuberculosis
8B82	;	2.8	;	Crystal structure of Scribble PDZ1 with human papillomavirus strain 16 E6 peptide
8B87	;	2.0	;	Crystal structure of Scribble PDZ1 with human papillomavirus strain 16 E6 peptide
8B8O	;	2.9	;	Crystal structure of Scribble PDZ1 with human papillomavirus strain 16 E6 peptide
8B9T	;	2.5	;	Crystal structure of Scribble PDZ1 with human papillomavirus strain 16 E6 peptide
8BIA	;	2.4	;	Crystal structure of Scribble PDZ1 with PTHR
8BJ0	;	2.6	;	Crystal structure of Scribble PDZ1 with PTHR
4WYT	;	2.6	;	Crystal Structure of Scribble PDZ34 tandem at 2.6 Angstroms
4WYU	;	2.5	;	Crystal Structure of Scribble PDZ34 tandem in complex with its target peptide
1NEX	;	2.7	;	Crystal Structure of ScSkp1-ScCdc4-CPD peptide complex
3V7D	;	2.306	;	Crystal Structure of ScSkp1-ScCdc4-pSic1 peptide complex
4JWJ	;	1.76	;	Crystal structure of scTrm10(84)-SAH complex
8T2A	;	3.17	;	Crystal structure of SCV PTE G18A mutant RNA in complex with Fab BL3-6
8T2B	;	3.18	;	Crystal structure of SCV PTE G18C mutant RNA in complex with Fab BL3-6
8T2O	;	3.29	;	Crystal structure of SCV PTE G18U RNA in complex with Fab BL3-6
8T29	;	3.13	;	Crystal structure of SCV PTE RNA in complex with Fab BL3-6
5ZHQ	;	3.002	;	Crystal structure of Scylla paramamosain arginine kinase
4N54	;	2.05	;	Crystal structure of scyllo-inositol dehydrogenase from Lactobacillus casei with bound cofactor NAD(H) and scyllo-inositol
6KTJ	;	2.1	;	Crystal structure of scyllo-inositol dehydrogenase R178A mutant, apo-form, from Paracoccus laeviglucosivorans
6KTL	;	1.65	;	Crystal structure of scyllo-inositol dehydrogenase R178A mutant, complexed with NAD and myo-inositol, from Paracoccus laeviglucosivorans
6KTK	;	1.65	;	Crystal structure of scyllo-inositol dehydrogenase R178A mutant, complexed with NADH and L-glucono-1,5-lactone, from Paracoccus laeviglucosivorans
5YAB	;	1.75	;	Crystal structure of scyllo-inositol dehydrogenase with L-glucose dehydrogenase activity
5YAP	;	1.8	;	Crystal structure of scyllo-inositol dehydrogenase with L-glucose dehydrogenase activity complexed with L-glucono-1,5-lactone
5YA8	;	2.3	;	Crystal structure of scyllo-inositol dehydrogenase with L-glucose dehydrogenase activity complexed with myo-inositol
5YAQ	;	1.99	;	Crystal structure of scyllo-inositol dehydrogenase with L-glucose dehydrogenase activity complexed with scyllo-inosose
2IFR	;	1.95	;	Crystal structure of Scytalido-glutamic peptidase with a peptide based transition state analog
2IFW	;	2.3	;	Crystal structure of scytalido-glutamic peptidase with a transition state analog inhibitor
1IDP	;	1.45	;	Crystal structure of scytalone dehydratase F162A mutant in the unligated state
1STD	;	2.9	;	CRYSTAL STRUCTURE OF SCYTALONE DEHYDRATASE: A DISEASE DETERMINANT OF THE RICE PATHOGEN, MAGNAPORTHE GRISEA
7OXD	;	1.3	;	Crystal structure of Scytonema hofmanni transposition protein TniQ
6G0C	;	2.802	;	Crystal structure of SdeA catalytic core
5CRB	;	2.0	;	Crystal Structure of SdeA DUB
5M93	;	1.793	;	Crystal structure of SdeA-modified ubiquitin.
5YVX	;	1.591	;	Crystal structure of SDG8 CW domain in complex with H3K4me1 peptide
7EC6	;	1.9	;	Crystal structure of SdgB (complexed with peptides)
7EC7	;	3.2	;	Crystal structure of SdgB (complexed with phosphate ions)
7EC3	;	2.5	;	Crystal structure of SdgB (complexed with UDP, GlcNAc, and Glycosylated peptide)
7EC1	;	1.85	;	Crystal structure of SdgB (ligand-free form)
7VFK	;	1.84	;	Crystal structure of SdgB (ligand-free form)
7VFO	;	3.2	;	Crystal structure of SdgB (Phosphate-binding form)
7VFN	;	1.9	;	Crystal structure of SdgB (SD peptide-binding form)
7VFM	;	2.28	;	Crystal structure of SdgB (UDP and SD peptide-binding form)
7VFL	;	2.45	;	Crystal structure of SdgB (UDP, NAG, and O-glycosylated SD peptide-binding form)
4YSL	;	1.4618	;	Crystal structure of SdoA from Pseudomonas putida in complex with glutathione
7E24	;	2.7203	;	Crystal structure of SDR family NAD(P)-dependent oxidoreductase from Exiguobacterium
7E28	;	1.83	;	Crystal structure of SDR family NAD(P)-dependent oxidoreductase from Exiguobacterium
7E3X	;	2.58	;	Crystal structure of SDR family NAD(P)-dependent oxidoreductase from exiguobacterium
2CFU	;	1.9	;	Crystal structure of SdsA1, an alkylsulfatase from Pseudomonas aeruginosa, in complex with 1-decane-sulfonic-acid.
2CFZ	;	2.05	;	Crystal structure of SdsA1, an alkylsulfatase from Pseudomonas aeruginosa, in complex with 1-dodecanol
2CG2	;	2.1	;	Crystal structure of SdsA1, an alkylsulfatase from Pseudomonas aeruginosa, in complex with sulfate
2CG3	;	2.6	;	Crystal structure of SdsA1, an alkylsulfatase from Pseudomonas aeruginosa.
7Y8H	;	1.8	;	Crystal structure of sDscam FNIII1 domain, isoform alpha7
7Y8S	;	2.696	;	Crystal structure of sDscam FNIII1-3 domains, isoform beta2v6
7Y5R	;	1.562	;	Crystal structure of sDscam FNIII2 domain, isoform alpha7
7Y6E	;	3.034	;	Crystal structure of sDscam FNIII23 domains, isoform Beta2v6
7Y8I	;	1.9	;	Crystal structure of sDscam FNIII3 domain, isoform alpha7
7Y54	;	1.787	;	Crystal structure of sDscam Ig1 domain, isoform alpha1
7Y5J	;	1.6	;	Crystal structure of sDscam Ig1 domain, isoform alpha1v7
7Y4X	;	2.952	;	Crystal structure of sDscam Ig1 domain, isoform alpha7
7Y73	;	1.32	;	Crystal structure of sDscam Ig1 domain, isoform beta3v7
7Y95	;	1.55	;	Crystal structure of sDscam Ig1 domain, isoform beta6v2
7Y9A	;	2.51	;	Crystal structure of sDscam Ig1-2 domains, isoform beta2v6
7Y6O	;	3.102	;	Crystal structure of sDscam Ig1-3 domains, isoform alpha25
6K4L	;	2.949	;	Crystal structure of Se-labelled SidJ complex with CaM at 2.95 A
2Y28	;	1.8	;	crystal structure of Se-Met AmpD derivative
6LJ9	;	2.307	;	Crystal Structure of Se-Met ASFV pS273R protease
6JGF	;	2.15	;	Crystal structure of Se-Met CadR from P. putida with a 21 residue C-terminal truncation
4L9V	;	2.374	;	Crystal structure of Se-Met derivative MepR F27L mutant from multidrug resistant S. aureus clinical isolate
5Y27	;	1.9	;	Crystal structure of Se-Met Dpb4-Dpb3
2OCX	;	2.2	;	Crystal structure of Se-Met fucosyltransferase NodZ from Bradyrhizobium
4XO1	;	1.802	;	crystal structure of Se-Met GnsA with double mutations
4M8G	;	2.0	;	Crystal structure of Se-Met hN33/Tusc3
3ABZ	;	2.15	;	Crystal structure of Se-Met labeled Beta-glucosidase from Kluyveromyces marxianus
7AI2	;	3.61	;	Crystal structure of Se-Met labelled MCE domain of Mce4A from Mycobacterium tuberculosis H37Rv
1JC4	;	2.0	;	Crystal Structure of Se-Met Methylmalonyl-CoA Epimerase
5A5X	;	1.801	;	Crystal Structure of Se-Met MltF from Pseudomonas aeruginosa
3T7I	;	2.3	;	Crystal structure of Se-Met Rtt107p (residues 820-1070)
5ZBC	;	2.2	;	Crystal structure of Se-Met tryptophan oxidase (C395A mutant) from Chromobacterium violaceum
1T2O	;	2.3	;	Crystal structure of Se-SrtA, C184-Ala
4IUP	;	1.9	;	crystal structure of Se-substituted arabidopsis thaliana SHH1 SAWADEE domain L200M/L218M mutant
4FSX	;	3.2	;	crystal structure of Se-substituted Zea mays ZMET2 in complex with SAH
2QGS	;	2.0	;	Crystal structure of SE1688 protein from Staphylococcus epidermidis. Northeast Structural Genomics Consortium target SeR89
1SN2	;	1.75	;	Crystal Structure of Sea Bream Transthyretin at 1.90A Resolution
6GNM	;	2.24	;	Crystal Structure Of Sea Bream Transthyretin in complex with 2,2',4,4'-tetrahydroxybenzophenone (BP2)
6GNW	;	1.75	;	Crystal Structure Of Sea Bream Transthyretin in complex with 2,4,5-trichlorophenoxyacetic acid (2,4,5-T)
6GNR	;	1.4	;	Crystal Structure Of Sea Bream Transthyretin in complex with 2-(3-chloro-2-methylanilino)pyridine-3-carboxylic acid (Clonixin)
6GNP	;	2.019	;	Crystal Structure Of Sea Bream Transthyretin in complex with 3,5,6-trichloro-2-pyridinol (TC2P)
6GOO	;	1.8	;	Crystal Structure Of Sea Bream Transthyretin in complex with Perfluorooctanoic acid (PFOA). Crystallized in AmSO4
6GON	;	1.65	;	Crystal Structure Of Sea Bream Transthyretin in complex with Perfluorooctanoic acid (PFOA). Crystallized in PEG
6GNO	;	1.65	;	Crystal Structure Of Sea Bream Transthyretin in complex with Tetrabromobisphenol A (TBBPA)
1SN0	;	1.9	;	Crystal Structure Of Sea Bream Transthyretin in complex with thyroxine At 1.9A Resolution
1SN5	;	1.9	;	Crystal Structure of Sea Bream Transthyretin in complex with Triiodothyronine at 1.90A Resolution
2E7V	;	1.92	;	Crystal structure of SEA domain of transmembrane protease from Mus musculus
2JG7	;	2.83	;	Crystal structure of Seabream Antiquitin and Elucidation of its substrate specificity
8A2G	;	1.56	;	Crystal structure of Sebokelevirus 2A2 protein
4UYB	;	1.5	;	Crystal structure of SEC14-like protein 3
4TLG	;	1.77	;	Crystal structure of SEC14-like protein 4 (SEC14L4)
2A2F	;	2.5	;	Crystal Structure of Sec15 C-terminal domain
5KYX	;	3.516	;	crystal structure of Sec23 and TANGO1 peptide1 complex
5KYU	;	3.512	;	crystal structure of Sec23 and TANGO1 peptide2 complex
5KYW	;	3.2	;	crystal structure of Sec23 and TANGO1 peptide3 complex
5KYY	;	3.403	;	Crystal structure of Sec23 and TANGO1 peptide4 complex
5VNO	;	2.905	;	Crystal structure of Sec23a/Sec24a/Sec22
5VNM	;	2.765	;	Crystal structure of Sec23a/Sec24a/Sec22 complexed with 4-phenylbutyric acid (15mM soaking)
5VNL	;	2.394	;	Crystal structure of Sec23a/Sec24a/Sec22 complexed with 4-phenylbutyric acid (1mM soaking)
5VNN	;	2.501	;	Crystal structure of Sec23a/Sec24a/Sec22 complexed with 4-phenylbutyric acid (50mM soaking)
5VNI	;	2.788	;	Crystal structure of Sec23a/Sec24a/Sec22 complexed with a C-terminal FA sorting motif
5VNJ	;	2.806	;	Crystal structure of Sec23a/Sec24a/Sec22 complexed with a C-terminal FF sorting motif (ERGIC-53)
5VNG	;	2.6	;	Crystal structure of Sec23a/Sec24a/Sec22 complexed with a C-terminal II sorting motif
5VNK	;	2.55	;	Crystal structure of Sec23a/Sec24a/Sec22 complexed with a C-terminal LL sorting motif
5VNH	;	2.6	;	Crystal structure of Sec23a/Sec24a/Sec22 complexed with a C-terminal SV sorting motif
5VNF	;	2.407	;	Crystal structure of Sec23a/Sec24a/Sec22 complexed with a C-terminal VV sorting motif
5VNE	;	2.698	;	Crystal structure of Sec23a/Sec24a/Sec22 complexed with Emp24 sorting motif
3A58	;	2.6	;	Crystal structure of Sec3p - Rho1p complex from Saccharomyces cerevisiae
3CPH	;	2.9	;	Crystal structure of Sec4 in complex with Rab-GDI
1G16	;	1.8	;	CRYSTAL STRUCTURE OF SEC4-GDP
1G17	;	2.0	;	CRYSTAL STRUCTURE OF SEC4-GUANOSINE-5'-(BETA,GAMMA)-IMIDOTRIPHOSPHATE
6O62	;	1.88	;	Crystal structure of Sec4p, a Rab family GTPase from Candida albicans
7BRT	;	1.999	;	Crystal structure of Sec62 LIR fused to GABARAP
4OIY	;	1.5	;	Crystal structure of Sec7p catalytic domain
1TF5	;	2.18	;	Crystal structure of SecA in an open conformation from Bacillus Subtilis
1TF2	;	2.9	;	Crystal structure of SecA:ADP in an open conformation from Bacillus Subtilis
1OZB	;	2.8	;	Crystal Structure of SecB complexed with SecA C-terminus
1QYN	;	2.35	;	Crystal Structure of SecB from Escherichia coli
5XAP	;	2.605	;	Crystal structure of SecDF in I form (C2 space group)
5XAN	;	2.75	;	Crystal structure of SecDF in I form (P212121 space group)
5XAM	;	4.0	;	Crystal structure of SecDF in I form at 4 A resolution
5YHF	;	2.8	;	Crystal structure of SecDF in Super-membrane-facing form
3AQP	;	3.3	;	Crystal structure of SecDF, a translocon-associated membrane protein, from Thermus thrmophilus
7UTC	;	1.85	;	Crystal structure of secondary alcohol dehydrogenases from the Thermoanaerobacter ethanolicus with NADP and transition-state analogue inhibitor DMSO
2GBB	;	2.1	;	Crystal structure of secreted chorismate mutase from Yersinia pestis
8HX3	;	2.28	;	crystal structure of secreted coleopteran active protein (Sip)
1XJU	;	1.07	;	Crystal structure of secreted inactive form of P1 phage endolysin Lyz
4PWS	;	2.15	;	Crystal structure of secreted proline rich antigen MTC28 (Rv0040c) at 2.15 A with bound chloride from Mycobacterium tuberculosis
4OL4	;	2.8	;	Crystal structure of secreted proline rich antigen MTC28 (Rv0040c) from Mycobacterium tuberculosis
5YQ0	;	1.76	;	Crystal structure of secreted protein CofJ from ETEC.
5Z4G	;	1.5	;	Crystal structure of secretory abundant heat soluble protein 4 from Ramazzottius varieornatus
2ZQP	;	6.0	;	Crystal Structure of SecYE translocon from Thermus thermophilus
2ZJS	;	3.2	;	Crystal Structure of SecYE translocon from Thermus thermophilus with a Fab fragment
1H3Q	;	2.4	;	Crystal structure of SEDL at 2.4 Angstroms resolution
3UIZ	;	3.1	;	Crystal structure of SefD_dscA in D2O
3UIY	;	3.1	;	Crystal structure of SefD_dscA in H2O
7C5C	;	1.72	;	Crystal structure of SeFRS
2NTT	;	1.561	;	Crystal Structure of SEK
2NTS	;	2.4	;	Crystal Structure of SEK-hVb5.1
8SXQ	;	2.7	;	Crystal structure of Sel-1 repeat protein LceB from Legionella pneumophila
6OK0	;	2.174	;	Crystal structure of Sel1 repeat protein from Oxalobacter formigenes
6OK3	;	2.353	;	Crystal structure of Sel1 repeat protein from Oxalobacter formigenes
6ONW	;	2.951	;	Crystal structure of Sel1 repeat protein from Oxalobacter formigenes
6ORC	;	2.98	;	Crystal structure of Sel1 repeat protein from Oxalobacter formigenes
6ORK	;	3.0	;	Crystal structure of Sel1 repeat protein from Oxalobacter formigenes
6UR7	;	2.709	;	Crystal structure of Sel1 repeat protein from Oxalobacter formigenes
6DD2	;	2.9056	;	Crystal structure of Selaginella moellendorffii HCT
5V9T	;	3.05	;	Crystal structure of selective pyrrolidine amide KDM5a inhibitor N-{(3R)-1-[3-(propan-2-yl)-1H-pyrazole-5-carbonyl]pyrrolidin-3-yl}cyclopropanecarboxamide (compound 48)
4KJR	;	3.0	;	Crystal structure of selenium substituted Ca2+/H+ antiporter proteinYfkE
1YLS	;	3.0	;	Crystal structure of selenium-modified Diels-Alder ribozyme complexed with the product of the reaction between N-pentylmaleimide and covalently attached 9-hydroxymethylanthracene
6QIQ	;	2.519	;	Crystal structure of seleno-derivative CAG repeats with synthetic CMBL3a compound
6QIV	;	2.28	;	Crystal structure of seleno-derivative CAG repeats with synthetic CMBL4 compound
5AZZ	;	1.45	;	Crystal structure of seleno-insulin
4EQ4	;	2.074	;	Crystal structure of seleno-methionine derivatized GH3.12
4QKB	;	2.6	;	Crystal structure of seleno-methionine labelled human ALKBH7 in complex with alpha-ketoglutarate and Mn(II)
5N0O	;	1.44	;	Crystal structure of Seleno-OphA-DeltaC18 in complex with SAM
1JF9	;	2.0	;	Crystal Structure of selenocysteine lyase
6NDN	;	1.768	;	Crystal Structure of Selenocysteine Lyase from Escherichia coli
4GGP	;	2.05	;	Crystal Structure of Selenomethionine containing Trans-2-Enoyl-CoA Reductase from Treponema denticola
3R0X	;	1.93	;	Crystal structure of Selenomethionine incorporated apo D-serine deaminase from Salmonella tyhimurium
4D9G	;	2.45	;	Crystal structure of Selenomethionine incorporated holo Diaminopropionate ammonia lyase from Escherichia coli
7YN1	;	2.5	;	Crystal structure of selenomethionine labeled CcbD
4UA3	;	1.85	;	Crystal structure of selenomethionine labeled SpNatD
5XPB	;	2.996	;	Crystal Structure of Selenomethionine labelled Drep4 CIDE domain
5HWI	;	1.755	;	Crystal structure of selenomethionine labelled gama glutamyl cyclotransferease specific to glutathione from yeast
5XXR	;	2.647	;	Crystal structure of selenomethionine labelled RIBT from Bacillus subtilis
2Q8P	;	1.95	;	Crystal Structure of selenomethionine labelled S. aureus IsdE complexed with heme
3EIX	;	1.35	;	Crystal structure of selenomethionine labelled Staphylococcus aureus lipoprotein, HtsA
6O0T	;	2.8	;	Crystal structure of selenomethionine labelled tandem SAM domains (L446M:L505M:L523M mutant) from human SARM1
4WAL	;	2.2	;	Crystal structure of selenomethionine Msl5 protein in complex with RNA at 2.2 A
1IX2	;	1.55	;	Crystal Structure of Selenomethionine PcoC, a Copper Resistance Protein from Escherichia coli
3AJ3	;	1.577	;	Crystal structure of selenomethionine substituted 4-pyridoxolactonase from Mesorhizobium loti
3K4A	;	2.9	;	Crystal structure of selenomethionine substituted E. coli beta-glucuronidase
1ZHF	;	2.5	;	Crystal structure of selenomethionine substituted isoflavanone 4'-O-methyltransferase
2Z2N	;	1.65	;	Crystal Structure of selenomethionine substituted virginiamycin B lyase from Staphylococcus aureus
4YU5	;	2.9	;	Crystal structure of selenomethionine variant of Bacillus anthracis immune inhibitor A2 peptidase zymogen
3UD2	;	2.21	;	Crystal structure of Selenomethionine ZU5A-ZU5B protein domains of human erythrocyte ankyrin
6N8A	;	3.4011	;	Crystal structure of selenomethionine-containing AcaB from uropathogenic E. coli
7CCM	;	2.45	;	Crystal structure of selenomethionine-derived human BFK
5TTK	;	2.51	;	Crystal Structure of Selenomethionine-incorporated Nicotine Oxidoreductase from Pseudomonas putida
5D08	;	1.747	;	Crystal structure of selenomethionine-labeled epoxyqueuosine reductase
7F0O	;	2.2	;	Crystal structure of selenomethionine-labeled isomerase NsrQ
2Z44	;	2.5	;	Crystal Structure of Selenomethionine-labeled ORF134
2PEI	;	2.7	;	Crystal structure of selenomethionine-labeled RbcX
3WA7	;	1.7	;	Crystal structure of selenomethionine-labeled tannase from Lactobacillus plantarum in the orthorhombic crystal
7ED9	;	2.01764	;	Crystal structure of selenomethionine-labeled Thermus thermophilus FakA ATP-binding domain
1Q0H	;	2.2	;	Crystal structure of selenomethionine-labelled DXR in complex with fosmidomycin
5YK9	;	3.001	;	Crystal structure of selenomethionine-labelled indole prenyltransferase AmbP1
2HFB	;	2.9	;	Crystal structure of selenomethionine-labelled RafE from Streptococcus pneumoniae
1U24	;	2.0	;	Crystal structure of Selenomonas ruminantium phytase
1U26	;	2.5	;	Crystal structure of Selenomonas ruminantium phytase complexed with persulfated phytate
1U25	;	2.5	;	Crystal structure of Selenomonas ruminantium phytase complexed with persulfated phytate in the C2221 crystal form
2ZOD	;	1.98	;	Crystal structure of selenophosphate synthetase from Aquifex aeolicus
2YYE	;	2.1	;	Crystal structure of selenophosphate synthetase from Aquifex aeolicus complexed with AMPCPP
2P0G	;	2.3	;	Crystal structure of Selenoprotein W-related protein from Vibrio cholerae. Northeast Structural Genomics target VcR75
1SEL	;	2.0	;	CRYSTAL STRUCTURE OF SELENOSUBTILISIN AT 2.0-ANGSTROMS RESOLUTION
6FM5	;	1.47	;	Crystal structure of self-complemented CsuA/B major subunit from archaic chaperone-usher Csu pili of Acinetobacter baumannii
5LND	;	1.46	;	Crystal structure of self-complemented MyfA, the major subunit of Myf fimbriae from Yersinia enterocolitica
5LO7	;	1.9	;	Crystal structure of self-complemented MyfA, the major subunit of Myf fimbriae from Yersinia enterocolitica
5LN8	;	1.65	;	Crystal structure of self-complemented MyfA, the major subunit of Myf fimbriae from Yersinia enterocolitica, in complex with galactose
5LN4	;	2.36	;	Crystal structure of self-complemented PsaA, the major subunit of pH 6 antigen from Yersinia pests, in complex with choline
4YZJ	;	2.106	;	Crystal structure of selnomethionin-labeled indole prenyltransferase TleC
5GK0	;	2.331	;	Crystal structure of selnomethionin-labeled ketosynthase StlD
6I04	;	3.1	;	Crystal structure of Sema domain of the Met receptor in complex with FAB
4ZGM	;	1.8	;	Crystal structure of Semaglutide peptide backbone in complex with the GLP-1 receptor extracellular domain
6IXE	;	3.35	;	Crystal structure of SeMet apo SH3BP5 (I41)
6IXF	;	3.6	;	Crystal structure of SeMet apo SH3BP5 (P41)
2X46	;	1.0	;	Crystal Structure of SeMet Arg r 1
3S7T	;	2.808	;	Crystal structure of SeMet B. licheniformis CDPS YvmC-Blic
4M7S	;	2.022	;	Crystal structure of SeMet BtrN in an OPEN conformation
5T49	;	2.5	;	Crystal structure of SeMet derivative BhGH81
4Q5J	;	2.772	;	Crystal structure of SeMet derivative BRI1 in complex with BKI1
4H65	;	2.6	;	Crystal structure of SeMet derivative of HMP synthase Thi5 from S. cerevisiae
5TBF	;	3.003	;	Crystal structure of SeMet derivatives of domain2 and domain 3 of RctB
4OMY	;	3.062	;	Crystal Structure of SeMet NolR from Sinorhizobium fredii in complex with oligo AT DNA
5FF5	;	2.933	;	Crystal Structure of SeMet PaaA
6DWX	;	2.395	;	Crystal structure of SeMet phased viral OTU domain protease from Qalyub virus
6M9S	;	2.08	;	Crystal structure of SeMet SznF from Streptomyces achromogenes var. streptozoticus NRRL 2697
4F1I	;	2.5	;	Crystal structure of SeMet TDP2 from Caenorhabditis elegans
6O86	;	1.799	;	Crystal Structure of SeMet UDP-dependent glucosyltransferases (UGT) from Stevia rebaudiana in complex with UDP
3C9B	;	2.42	;	Crystal structure of SeMet Vps75
5H3B	;	1.492	;	Crystal Structure of SeMet-BioG from Haemophilus influenzae at 1.49 Angstroms resolution
5XF2	;	2.8	;	Crystal structure of SeMet-HldC from Burkholderia pseudomallei
6G43	;	2.4	;	Crystal structure of SeMet-labeled mavirus major capsid protein lacking the C-terminal domain
6G41	;	2.9	;	Crystal structure of SeMet-labeled mavirus penton protein
4RHI	;	2.55	;	Crystal structure of SeMet-labeled wild-type T. brucei arginase-like protein in P321 space group
3W91	;	2.1	;	crystal structure of SeMet-labeled yeast N-acetyltransferase Mpr1 L87M mutant
6KMD	;	2.2	;	Crystal structure of SeMet-phytochromobilin synthase from tomato in complex with biliverdin
2ZXK	;	2.5	;	Crystal structure of SeMet-Red chlorophyll catabolite reductase
3SBY	;	2.71	;	Crystal Structure of SeMet-Substituted Apo-MMACHC (1-244), a human B12 processing enzyme
5THY	;	2.087	;	Crystal structure of SeMet-Substituted CurJ carbon methyltransferase
5CUZ	;	2.31	;	Crystal structure of SeMet-substituted N-terminal truncated human B12-chaperone CblD (108-296)
6L6G	;	1.98	;	Crystal structure of SeMet_Lpg0189
4ZPZ	;	1.54	;	Crystal Structure of Semi-synthetic Ubiquitin with Phospho-Ser65 and Ala46Cys
6FSI	;	1.32	;	Crystal structure of semiquinone Flavodoxin 1 from Bacillus cereus (1.32 A resolution)
4X5N	;	3.0	;	Crystal structure of SemiSWEET in the inward-open and outward-open conformations
4X5M	;	2.0	;	Crystal structure of SemiSWEET in the inward-open conformation
6L0T	;	1.9	;	Crystal structure of senecavirus A 3C protease
3MR0	;	1.493	;	Crystal Structure of Sensory Box Histidine Kinase/Response Regulator from Burkholderia thailandensis E264
3MXQ	;	2.78	;	Crystal structure of sensory box sensor histidine kinase from Vibrio cholerae
1JGJ	;	2.4	;	CRYSTAL STRUCTURE OF SENSORY RHODOPSIN II AT 2.4 ANGSTROMS: INSIGHTS INTO COLOR TUNING AND TRANSDUCER INTERACTION
2E7I	;	3.0	;	Crystal Structure of Sep-tRNA:Cys-tRNA Synthase from Archaeoglobus fulgidus
2E7J	;	2.4	;	Crystal Structure of Sep-tRNA:Cys-tRNA Synthase from Archaeoglobus fulgidus
5X6B	;	2.596	;	Crystal structure of SepCysE-SepCysS in complex with tRNACys from Methanocaldococcus jannaschii
5X6C	;	3.101	;	Crystal structure of SepRS-SepCysE from Methanocaldococcus jannaschii
2QA5	;	3.4	;	Crystal structure of Sept2 G-domain
3FTQ	;	2.9	;	Crystal structure of Septin 2 in complex with GppNHp and Mg2+
3T5D	;	3.3	;	Crystal structure of Septin 7 in complex with GDP
5IRR	;	2.04	;	Crystal structure of Septin GTPase domain from Chlamydomonas reinhardtii
8DKT	;	2.38	;	Crystal Structure of Septin1 - Septin2 heterocomplex from Drosophila melanogaster
3FMT	;	2.983	;	Crystal structure of SeqA bound to DNA
2EFN	;	1.98	;	Crystal Structure of Ser 32 to Ala of ST1022 from Sulfolobus tokodaii 7
6L11	;	2.05	;	Crystal structure of Ser/Thr kinase Pim1 in complex with 10-DEBC derivatives
6L12	;	1.87	;	Crystal structure of Ser/Thr kinase Pim1 in complex with 10-DEBC derivatives
6L13	;	2.24	;	Crystal structure of Ser/Thr kinase Pim1 in complex with 10-DEBC derivatives
6L14	;	1.95	;	Crystal structure of Ser/Thr kinase Pim1 in complex with 10-DEBC derivatives
6L15	;	2.6	;	Crystal structure of Ser/Thr kinase Pim1 in complex with 10-DEBC derivatives
6L16	;	2.1	;	Crystal structure of Ser/Thr kinase Pim1 in complex with 10-DEBC derivatives
6L17	;	1.75	;	Crystal structure of Ser/Thr kinase Pim1 in complex with 10-DEBC derivatives
4RBL	;	2.55	;	Crystal structure of Ser/Thr kinase Pim1 in complex with Mitoxantrone derivatives
4RC2	;	2.096	;	Crystal structure of Ser/Thr kinase Pim1 in complex with Mitoxantrone derivatives
4RC3	;	2.338	;	Crystal structure of Ser/Thr kinase Pim1 in complex with Mitoxantrone derivatives
4RC4	;	2.651	;	Crystal structure of Ser/Thr kinase Pim1 in complex with Mitoxantrone derivatives
4IAA	;	2.85	;	Crystal structure of Ser/Thr kinase Pim1 in complex with thioridazine
6KZI	;	2.8	;	Crystal structure of Ser/Thr kinase Pim1 in complex with thioridazine derivatives
5MBZ	;	1.5	;	Crystal Structure of Ser202Phe mutant of Human Prolidase with Mn ions and GlyPro ligand
1II4	;	2.7	;	CRYSTAL STRUCTURE OF SER252TRP APERT MUTANT FGF RECEPTOR 2 (FGFR2) IN COMPLEX WITH FGF2
2QHE	;	2.0	;	Crystal structure of Ser49-PLA2 (ecarpholin S) from Echis carinatus sochureki snake venom
5OC3	;	2.153	;	Crystal structure of Ser67Cys/Pro121Cys Amadoriase I mutant from Aspergillus Fumigatus
5CUS	;	3.2	;	Crystal Structure of sErbB3-Fab3379 Complex
3GVD	;	2.4	;	Crystal Structure of Serine Acetyltransferase CysE from Yersinia pestis
4HZC	;	1.97	;	Crystal structure of Serine acetyltransferase from Brucella abortus strain S19
1T3D	;	2.2	;	Crystal structure of Serine Acetyltransferase from E.coli at 2.2A
6LCN	;	2.15	;	Crystal structure of Serine Acetyltransferase from Planctomyces limnophilus at 2.15A
8I09	;	1.8	;	Crystal structure of serine acetyltransferase from Salmonella typhimurium complexed with butyl gallate
8I06	;	2.5	;	Crystal structure of serine acetyltransferase from Salmonella typhimurium complexed with CoA
7E3Y	;	1.9	;	Crystal structure of serine acetyltransferase from Salmonella typhimurium complexed with cysteine
8I04	;	2.3	;	Crystal structure of serine acetyltransferase from Salmonella typhimurium complexed with serine
4H7O	;	2.17	;	Crystal structure of Serine acetyltransferase from Vibrio cholerae O1 biovar El Tor N16961
4HZD	;	1.87	;	Crystal structure of Serine acetyltransferase in complex with Coenzyme A from Brucella abortus strain S19
7BW9	;	2.131	;	Crystal structure of Serine acetyltransferase isoform 3 in complex with cysteine from Entamoeba histolytica
3DC2	;	2.7	;	Crystal structure of serine bound D-3-phosphoglycerate dehydrogenase from Mycobacterium tuberculosis
2P9C	;	2.46	;	Crystal structure of serine bound G336V mutant of E.coli phosphoglycerate dehydrogenase
2PA3	;	2.74	;	crystal structure of serine bound G336V mutant of E.coli phosphoglycerate dehydrogenase
2P9G	;	2.8	;	Crystal structure of serine bound G336V,G337V double mutant of E.coli phosphoglycerate dehydrogenase
3ASU	;	1.9	;	Crystal structure of serine dehydrogenase from Escherichia coli
4I3F	;	1.69	;	Crystal structure of serine hydrolase CCSP0084 from the polyaromatic hydrocarbon (PAH)-degrading bacterium Cycloclasticus zankles
1KL1	;	1.93	;	Crystal Structure of Serine Hydroxymethyltransferase Complexed with Glycine
1KL2	;	2.7	;	Crystal Structure of Serine Hydroxymethyltransferase Complexed with Glycine and 5-formyl tetrahydrofolate
1KKP	;	1.93	;	Crystal Structure of Serine Hydroxymethyltransferase complexed with Serine
6YMD	;	1.25	;	Crystal structure of serine hydroxymethyltransferase from Aphanothece halophytica in the covalent complex with malonate
6YME	;	1.77	;	Crystal structure of serine hydroxymethyltransferase from Aphanothece halophytica in the PLP-internal aldimine state
6YMF	;	1.63	;	Crystal structure of serine hydroxymethyltransferase from Aphanothece halophytica in the PLP-Serine external aldimine state
1KKJ	;	1.93	;	Crystal Structure of Serine Hydroxymethyltransferase from B.stearothermophilus
3ECD	;	1.6	;	Crystal structure of serine hydroxymethyltransferase from Burkholderia pseudomallei
3N0L	;	1.8	;	Crystal structure of serine hydroxymethyltransferase from Campylobacter jejuni
3H7F	;	1.5	;	Crystal structure of serine hydroxymethyltransferase from Mycobacterium tuberculosis
6ULD	;	1.5	;	Crystal structure of serine hydroxymethyltransferase from Mycobacterium tuberculosis with bound PLP forming a Schiff base with substrate Serine in one monomer and PLP forming a Schiff base with product Glycine in the other monomer
4P3M	;	1.85	;	Crystal structure of serine hydroxymethyltransferase from Psychromonas ingrahamii
4WXB	;	2.05	;	Crystal Structure of Serine Hydroxymethyltransferase from Streptococcus thermophilus
4O6Z	;	2.98	;	Crystal structure of serine hydroxymethyltransferase with covalently bound PLP Schiff-base from Plasmodium falciparum
7PZZ	;	1.65	;	Crystal structure of serine hydroxymethyltransferase, isoform 2 from Arabidopsis thaliana (SHM2)
7Q00	;	1.74	;	Crystal structure of serine hydroxymethyltransferase, isoform 4 from Arabidopsis thaliana (SHM4)
7QPE	;	2.18	;	Crystal structure of serine hydroxymethyltransferase, isoform 6 from Arabidopsis thaliana (SHM6)
7QX8	;	2.74	;	Crystal structure of serine hydroxymethyltransferase, isoform 7 from Arabidopsis thaliana (SHM7)
8IYT	;	1.7	;	Crystal Structure of Serine Palmitoyltransferase complexed with D-methylserine
3A2B	;	2.3	;	Crystal Structure of Serine Palmitoyltransferase from Sphingobacterium multivorum with substrate L-serine
8IYP	;	1.651	;	Crystal structure of serine palmitoyltransferase soaked in 190 mM D-serine solution
5CE1	;	2.5	;	Crystal Structure of Serine protease Hepsin in complex with Inhibitor
1V5I	;	1.5	;	Crystal structure of serine protease inhibitor POIA1 in complex with subtilisin BPN'
3HJR	;	1.65	;	Crystal structure of serine protease of Aeromonas sobria
6YV6	;	1.36	;	Crystal Structure of Serine protease SplB N2K/N3Q/S154R from Staphylococcus aureus
6YV5	;	1.1	;	Crystal Structure of Serine protease SplB N3Q/S154R from Staphylococcus aureus
3HMK	;	2.1	;	Crystal Structure of Serine Racemase
6LUT	;	1.35	;	Crystal structure of Serine Racemase from Dictyostelium discoideum.
2I44	;	2.04	;	Crystal structure of serine-threonine phosphatase 2C from Toxoplasma gondii
3PU9	;	1.55	;	Crystal structure of serine/threonine phosphatase Sphaerobacter thermophilus DSM 20745
5F1M	;	2.322	;	Crystal structure of Serine/threonine phosphatase Stp1 from Staphylococcus aureus
3WWS	;	2.01	;	Crystal structure of Serine/threonine-protein kinase 3
4JDK	;	2.4	;	Crystal structure of Serine/threonine-protein kinase PAK 4 F461V mutant in complex with Paktide S peptide substrate
4JDJ	;	2.3	;	Crystal structure of Serine/threonine-protein kinase PAK 4 F461V mutant in complex with Paktide T peptide substrate
4JDI	;	1.85	;	Crystal structure of Serine/threonine-protein kinase PAK 4 in complex with Paktide S peptide substrate
4JDH	;	2.0	;	Crystal structure of Serine/threonine-protein kinase PAK 4 in complex with Paktide T peptide substrate
7WC7	;	2.6	;	Crystal structure of serotonin 2A receptor in complex with lisuride
7WC6	;	2.6	;	Crystal structure of serotonin 2A receptor in complex with LSD
7WC8	;	2.45	;	Crystal structure of serotonin 2A receptor in complex with lumateperone
7WC9	;	2.5	;	Crystal structure of serotonin 2A receptor in complex with non-hallucinogenic psychedelic analog
7WC5	;	3.2	;	Crystal structure of serotonin 2A receptor in complex with psilocin
7WC4	;	3.2	;	Crystal structure of serotonin 2A receptor in complex with serotonin
3NDA	;	1.8	;	Crystal structure of serpin from tick Ixodes ricinus
3OZQ	;	1.9	;	Crystal structure of Serpin48, which is a highly specific serpin in the insect Tenebrio molitor
5D7W	;	1.1	;	Crystal structure of serralysin
4EQI	;	1.38	;	Crystal structure of serratia fonticola carbapenemase SFC-1
4EV4	;	1.3	;	Crystal structure of serratia fonticola carbapenemase SFC-1 E166A mutant with the acylenzyme intermediate of meropenem
4EUZ	;	1.08	;	Crystal structure of serratia fonticola carbapenemase SFC-1 S70A-Meropenem complex
3Q6V	;	1.37	;	Crystal Structure of Serratia fonticola Sfh-I: glycerol complex
3SD9	;	1.83	;	Crystal structure of serratia fonticola SFH-I: Source of the nucleophile in the catalytic mechanism of mono-zinc metallo-beta-lactamases
7C34	;	1.938	;	Crystal structure of Serratia marcescens Chitinase B complexed with Berberine
6JK9	;	2.312	;	Crystal structure of Serratia marcescens Chitinase B complexed with compound 2-8-14
6JKF	;	1.99	;	Crystal structure of Serratia marcescens Chitinase B complexed with compound 2-8-s2
5OQ1	;	1.34	;	Crystal structure of Serratia marcescens ChiX (used as MR model for superior PDB 5OPZ)
5OPZ	;	1.34	;	Crystal structure of Serratia marcescens L-Ala D-Glu endopeptidase ChiX
3HDM	;	2.6	;	Crystal structure of serum and glucocorticoid-regulated kinase 1 in complex with compound 1
3HDN	;	3.1	;	Crystal structure of serum and glucocorticoid-regulated kinase 1 in complex with compound 2
4C55	;	2.35	;	Crystal structure of serum-derived human IgG4 Fc
6OTE	;	2.95	;	Crystal Structure of Seryl-tRNA synthetase (SerRS) from Cryptosporidium parvum complexed with L-Serylsulfamoyl Adenosine
3QO8	;	2.0	;	Crystal Structure of seryl-tRNA synthetase from Candida albicans
3VBB	;	2.891	;	Crystal Structure of Seryl-tRNA Synthetase from Human at 2.9 angstroms
6S30	;	2.41	;	Crystal Structure of Seryl-tRNA Synthetase from Klebsiella pneumoniae
2ZR3	;	3.0	;	Crystal structure of seryl-tRNA synthetase from Pyrococcus horikoshii
2DQ0	;	2.6	;	Crystal structure of seryl-tRNA synthetase from Pyrococcus horikoshii complexed with a seryl-adenylate analog
2ZR2	;	2.8	;	Crystal structure of seryl-tRNA synthetase from Pyrococcus horikoshii complexed with ATP
6K16	;	2.2	;	Crystal Structure of Sesquisabinene B Synthase 1 from Santalum album
7E6W	;	3.1	;	Crystal structure of Sesquisabinene B Synthase 1 mutant G418A and F419N
7E9R	;	3.41	;	Crystal structure of Sesquisabinene B Synthase 1 mutant T313S
6J9J	;	1.78	;	crystal structure of SESTD2 in complex with H3.3S31phK36M peptide
6N0M	;	3.3	;	CRYSTAL STRUCTURE OF SESTRIN2 IN COMPLEX WITH NV-0005138
3QWP	;	1.53	;	Crystal structure of SET and MYND domain containing 3; Zinc finger MYND domain-containing protein 1
7MTO	;	1.791	;	Crystal Structure of SET/I2PP2A/TAF-1Beta core
2E50	;	2.3	;	Crystal structure of SET/TAF-1beta/INHAT
1M4V	;	1.9	;	Crystal structure of SET3, a superantigen-like protein from Staphylococcus aureus
5H6Z	;	2.0	;	Crystal structure of Set7, a novel histone methyltransferase in Schizossacharomyces pombe
5WW0	;	2.1	;	Crystal structure of Set7, a novel histone methyltransferase in Schizossacharomyces pombe
5YLT	;	1.69	;	Crystal structure of SET7/9 in complex with a cyproheptadine derivative
5AYF	;	2.005	;	Crystal structure of SET7/9 in complex with cyproheptadine
7TY2	;	2.438	;	Crystal Structure of SETD2 Bound to an Indole-based Inhibitor
7TY3	;	2.3	;	Crystal Structure of SETD2 Bound to an Indole-based Inhibitor
7LZB	;	2.28	;	Crystal Structure of SETD2 bound to Compound 2
7LZD	;	1.8	;	Crystal Structure of SETD2 bound to Compound 35
7LZF	;	2.47	;	Crystal Structure of SETD2 bound to Compound 57
5JLB	;	1.5	;	Crystal structure of SETD2 bound to histone H3.3 K36I peptide
5JJY	;	2.053	;	Crystal structure of SETD2 bound to histone H3.3 K36M peptide
5JLE	;	2.4	;	Crystal structure of SETD2 bound to SAH
6JAT	;	2.713	;	Crystal structure of SETD3 bound to Actin peptide and SFG
7W28	;	1.79	;	Crystal Structure of SETD3-SAH in complex with betaA-4PyrAla73 peptide
7W29	;	2.9	;	Crystal Structure of SETD3-SAH in complex with betaA-Orn73 peptide
5KE3	;	1.7	;	Crystal structure of SETDB1 Tudor domain in complex with fragment MRT0181a
5KE2	;	1.56	;	Crystal structure of SETDB1 Tudor domain in complex with inhibitor XST06472A
8UWP	;	1.77	;	Crystal structure of SETDB1 Tudor domain in complex with MR46747
8G5E	;	1.98	;	Crystal Structure of SETDB1 Tudor domain in complex with UNC6535
7CJT	;	2.474	;	Crystal Structure of SETDB1 Tudor domain in complexed with (R,R)-59
7C9N	;	2.472	;	Crystal structure of SETDB1 tudor domain in complexed with Compound 1.
7CAJ	;	2.198	;	Crystal structure of SETDB1 Tudor domain in complexed with Compound 2.
7CD9	;	1.6	;	Crystal Structure of SETDB1 tudor domain in complexed with Compound 6
6BPI	;	1.64	;	Crystal structure of SETDB1 Tudor domain with aryl triazole fragment peptide conjugates
6AU2	;	1.63	;	Crystal structure of SETDB1 Tudor domain with aryl triazole fragments
6AU3	;	1.8	;	Crystal structure of SETDB1 Tudor domain with aryl triazole fragments
6BHD	;	1.25	;	Crystal structure of SETDB1 with a modified H3 peptide
6BHE	;	1.35	;	Crystal structure of SETDB1 with a modified H3 peptide
6BHG	;	1.45	;	Crystal structure of SETDB1 with a modified H3 peptide
6BHH	;	1.85	;	Crystal structure of SETDB1 with a modified H3 peptide
6BHI	;	1.4	;	Crystal structure of SETDB1 with a modified H3 peptide
8ILC	;	2.2	;	Crystal structure of SetMet CoV-Y domain of Nsp3 in SARS-CoV-2
2QC2	;	2.7	;	Crystal structure of Severe Acute Respiratory Syndrome (SARS) 3C-like protease Asn214Ala mutant
3IB5	;	1.35	;	Crystal structure of Sex pheromone precursor (YP_536235.1) from LACTOBACILLUS SALIVARIUS SUBSP. SALIVARIUS UCC118 at 1.35 A resolution
3N2Q	;	2.55	;	Crystal structure of Sex pheromone staph-cAM373 precursor
7AGH	;	2.93	;	Crystal structure of SF kinase YihV from E. coli in complex with AMPPNP-Mg
7AG6	;	2.08	;	Crystal structure of SF kinase YihV from E. coli in complex with sulfofructose (SF), ADP-Mg
5H1N	;	1.47	;	Crystal structure of SF173 from Shigella flexneri
4KF4	;	1.994	;	Crystal Structure of sfCherry
7E53	;	2.21	;	Crystal structure of sfGFP complexed with the nanobody nb2 at 2.2 Angstron resolution
6KRG	;	1.4	;	Crystal structure of sfGFP Y182TMSiPhe
4JFG	;	3.001	;	Crystal structure of sfGFP-66-HqAla
4M8Z	;	1.928	;	Crystal Structure of SFH3, a phosphatidylinositol transfer protein that integrates phosphoinositide signaling with lipid droplet metabolism
6W32	;	2.9	;	Crystal structure of Sfh5
2DOQ	;	3.0	;	crystal structure of Sfi1p/Cdc31p complex
2GV5	;	3.0	;	crystal structure of Sfi1p/Cdc31p complex
6VDQ	;	1.78	;	Crystal structure of SfmD
6VDP	;	2.0	;	Crystal structure of SfmD truncated variant
7AG7	;	1.8	;	Crystal structure of SFP aldolase YihT from Salmonella enterica in complex with sulfate bound at the active site
7LRU	;	1.6	;	Crystal structure of SFPQ-NONO-SFPQ chimeric protein homodimer
6U22	;	1.42	;	Crystal structure of SFTI-triazole inhibitor in complex with beta-trypsin
6L02	;	1.799	;	Crystal Structure of sfYFP66BPAC203Y
4ZNM	;	1.998	;	Crystal structure of SgcC5 protein from Streptomyces globisporus (apo form)
4ZXW	;	2.187	;	Crystal structure of SgcC5 protein from Streptomyces globisporus (complex with (R)-(-)-1-(2-naphthyl)-1,2-ethanediol and sucrose)
4OVM	;	2.719	;	Crystal structure of SgcJ protein from Streptomyces carzinostaticus
3MET	;	2.0	;	Crystal structure of SGF29 in complex with H3K4me2
3ME9	;	1.37	;	Crystal structure of SGF29 in complex with H3K4me3 peptide
3MEU	;	1.28	;	Crystal structure of SGF29 in complex with H3R2me2sK4me3
3MEV	;	1.83	;	Crystal structure of SGF29 in complex with R2AK4me3
5C0M	;	1.6	;	Crystal structure of SGF29 tandem tudor domain in complex with a Carba containing peptide
3MP8	;	1.92	;	Crystal structure of Sgf29 tudor domain
6EDX	;	2.009	;	Crystal Structure of SGK3 PX domain
3Q2R	;	2.2	;	crystal structure of sGLIPR1 soaked with zinc chloride
1DS2	;	1.7	;	CRYSTAL STRUCTURE OF SGPB:OMTKY3-COO-LEU18I
2QVE	;	2.0	;	Crystal Structure of SgTAM bound to mechanism based inhibitor
3DEV	;	3.1	;	Crystal structure of SH1221 protein from Staphylococcus haemolyticus, Northeast Structural Genomics Consortium Target ShR87
3EAZ	;	1.31	;	Crystal structure of SH2 domain of Human Csk (carboxyl-terminal src kinase), C122S mutant.
3EAC	;	1.37	;	Crystal structure of SH2 domain of Human Csk (carboxyl-terminal src kinase), Oxidized form.
1O4G	;	1.55	;	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH DPI59.
1O4L	;	1.65	;	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH FRAGMENT2.
1O4J	;	1.7	;	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH ISO24.
1O4M	;	1.6	;	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH MALONICACID.
1O4N	;	1.6	;	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH OXALIC ACID.
1O4I	;	1.75	;	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH PAS219.
1O4K	;	1.57	;	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH PASBN.
1O4O	;	1.7	;	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH PHENYLPHOSPHATE.
1O4C	;	1.8	;	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH PHOSPHATE.
1O4D	;	1.85	;	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU78262.
1O4E	;	2.0	;	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU78299.
1O41	;	1.7	;	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU78300.
1O4R	;	1.5	;	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU78783.
1O4P	;	1.9	;	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU78791.
1O4H	;	2.25	;	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU79072.
1O4F	;	2.0	;	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU79073.
1O4Q	;	1.7	;	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU79256.
1O42	;	1.7	;	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU81843.
1O43	;	1.5	;	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU82129.
1O4A	;	1.5	;	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU82197.
1O47	;	1.8	;	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU82209.
1O4B	;	1.85	;	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU83876.
1O45	;	1.8	;	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU84687.
1O44	;	1.7	;	Crystal structure of sh2 in complex with ru85052
1O48	;	1.55	;	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU85053.
1O49	;	1.7	;	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU85493.
1O46	;	2.0	;	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU90395.
4HXJ	;	2.0	;	Crystal structure of SH3:RGT complex
6IXV	;	3.8	;	Crystal structure of SH3BP5-Rab11a
2YDL	;	2.05	;	Crystal structure of SH3C from CIN85
7W7I	;	3.59	;	Crystal Structure of shaft pilin PitB from pilus islet-2 of Streptococcus oralis
5F44	;	1.904	;	Crystal structure of shaft pilin spaA from Lactobacillus rhamnosus GG
5HTS	;	2.6	;	Crystal structure of shaft pilin spaA from Lactobacillus rhamnosus GG - D295N mutant
5HBB	;	2.47	;	Crystal structure of shaft pilin spaA from Lactobacillus rhamnosus GG - E139A mutant
5HDL	;	2.39	;	Crystal structure of shaft pilin spaA from Lactobacillus rhamnosus GG - E269A mutant
5J4M	;	1.99	;	Crystal structure of shaft pilin SpaA from Lactobacillus rhamnosus GG - E269A/D295N double mutant
5YU5	;	2.27	;	Crystal structure of shaft pilin spaD from Lactobacillus rhamnosus GG
5Z0Z	;	2.47	;	Crystal structure of shaft pilin spaD from Lactobacillus rhamnosus GG - D242A mutant
5Z24	;	2.4	;	Crystal structure of shaft pilin spaD from Lactobacillus rhamnosus GG - K365A mutant
5YXO	;	2.51	;	Crystal structure of shaft pilin spaD from Lactobacillus rhamnosus GG in bent conformation
7A9B	;	2.0	;	Crystal structure of Shank1 PDZ domain with ARAP3-derived peptide
6YWZ	;	2.12	;	Crystal structure of SHANK1 PDZ in complex with a peptide-small molecule hybrid
6YX0	;	1.57	;	Crystal structure of SHANK1 PDZ in complex with a peptide-small molecule hybrid
6YX1	;	1.8	;	Crystal structure of SHANK1 PDZ in complex with a peptide-small molecule hybrid
6YX2	;	1.62	;	Crystal structure of SHANK1 PDZ in complex with a peptide-small molecule hybrid
7A00	;	1.78	;	Crystal structure of Shank1 PDZ in complex with L6F mutant of the C-terminal hexapeptide from GKAP
8ATJ	;	2.117	;	Crystal Structure of Shank2-SAM domain
8B10	;	1.95	;	Crystal Structure of Shank2-SAM mutant domain - L1800W
6KYH	;	3.3	;	Crystal structure of Shank3 NTD-ANK A42K mutant in complex with HRas
6KYK	;	2.82	;	Crystal structure of Shank3 NTD-ANK mutant in complex with Rap1
7C7I	;	2.28	;	Crystal structure of SHANK3 SPN domain in complex with GTP-bound Rap1b(E30D,K31E)
7C7J	;	2.39	;	Crystal structure of SHANK3 SPN domain in complex with GTP-bound Rap1b(G12V,Q63E)
6LUP	;	2.302	;	Crystal structure of shark MHC CLASS I for 2.3 angstrom
3OPB	;	2.9	;	Crystal structure of She4p
4NLJ	;	1.4	;	Crystal structure of sheep beta-lactoglobulin (space group P1)
4NLI	;	1.9	;	Crystal structure of sheep beta-lactoglobulin (space group P3121)
2IKC	;	3.25	;	Crystal structure of sheep lactoperoxidase at 3.25 A resolution reveals the binding sites for formate
8UGZ	;	1.8	;	Crystal structure of Shewanella benthica Group 1 truncated hemoglobin C51S C71S variant
8VSH	;	2.0	;	Crystal structure of Shewanella benthica Group 1 truncated hemoglobin C51S C71S variant with trans heme D
8W3A	;	1.8	;	Crystal structure of Shewanella benthica Group 1 truncated hemoglobin C51S C71S variant with trans heme D
8TLS	;	1.7	;	Crystal structure of Shewanella benthica Group 1 truncated hemoglobin C51S C71S Y108A variant
7TT9	;	2.0	;	Crystal structure of Shewanella benthica Group 1 truncated hemoglobin C51S C71S Y34F variant
8UZU	;	1.9	;	Crystal structure of Shewanella benthica Group 1 truncated hemoglobin L80A C51S C71S variant
8VIJ	;	1.35	;	Crystal structure of Shewanella benthica Group 1 truncated hemoglobin Y34F C51S C71S variant (cyanomet)
4XHF	;	1.76	;	Crystal structure of Shewanella oneidensis NqrC
3GZ5	;	2.2	;	Crystal structure of Shewanella oneidensis NrtR
3GZ6	;	2.901	;	Crystal structure of Shewanella oneidensis NrtR complexed with a 27mer DNA
4IUQ	;	2.809	;	crystal structure of SHH1 SAWADEE domain
4IUV	;	2.8	;	crystal structure of SHH1 SAWADEE domain in complex with H3K4me1K9me1 peptide
4IUU	;	2.7	;	Crystal structure of SHH1 SAWADEE domain in complex with H3K9me1 peptide
4IUT	;	2.7	;	crystal structure of SHH1 SAWADEE domain in complex with H3K9me2 peptide
4IUR	;	2.501	;	crystal structure of SHH1 SAWADEE domain in complex with H3K9me3 peptide
3N1R	;	2.13	;	Crystal Structure of ShhN
7SNU	;	1.46	;	Crystal structure of ShHTL7 from Striga hermonthica in complex with strigolactone antagonist RG6
6U3U	;	2.287	;	Crystal Structure of Shiga Toxin 2K
3TND	;	2.7	;	Crystal structure of Shigella flexneri VapBC toxin-antitoxin complex
2EGG	;	2.25	;	Crystal Structure of Shikimate 5-Dehydrogenase (AroE) from Geobacillus kaustophilus
1WXD	;	2.1	;	Crystal Structure of Shikimate 5-Dehydrogenase (AroE) from Thermus Thermophilus HB8
2CY0	;	1.9	;	Crystal Structure of Shikimate 5-Dehydrogenase (AroE) from Thermus Thermophilus HB8 in complex with NADP
2EV9	;	1.9	;	Crystal Structure of Shikimate 5-Dehydrogenase (AroE) from Thermus Thermophilus HB8 in complex with NADP(H) and shikimate
2D5C	;	1.65	;	Crystal Structure of Shikimate 5-Dehydrogenase (AroE) from Thermus Thermophilus HB8 in complex with shikimate
1NVT	;	2.35	;	Crystal structure of Shikimate Dehydrogenase (AROE or MJ1084) in complex with NADP+
4FSH	;	2.85	;	Crystal Structure of Shikimate Dehydrogenase (aroE) Clinical Variant v2356 from Helicobacter pylori in Complex with Shikimate
1P74	;	2.4	;	CRYSTAL STRUCTURE OF SHIKIMATE DEHYDROGENASE (AROE) FROM HAEMOPHILUS INFLUENZAE
1P77	;	1.95	;	CRYSTAL STRUCTURE OF SHIKIMATE DEHYDROGENASE (AROE) FROM HAEMOPHILUS INFLUENZAE
4OMU	;	1.65	;	Crystal structure of shikimate dehydrogenase (AroE) from Pseudomonas putida
4FOS	;	1.72	;	Crystal Structure of Shikimate Dehydrogenase (aroE) Q237A Mutant from Helicobacter pylori in Complex with Shikimate
4FOO	;	2.55	;	Crystal Structure of Shikimate Dehydrogenase (aroE) Q237K Mutant from Helicobacter pylori
4FPX	;	2.4	;	Crystal Structure of Shikimate Dehydrogenase (aroE) Q237N Mutant from Helicobacter pylori
4FQ8	;	2.07	;	Crystal Structure of Shikimate Dehydrogenase (aroE) Y210A Mutant from Helicobacter pylori in Complex with Shikimate
4FR5	;	2.2	;	Crystal Structure of Shikimate Dehydrogenase (aroE) Y210S Mutant from Helicobacter pylori in Complex with Shikimate
2HK8	;	2.35	;	Crystal structure of shikimate dehydrogenase from aquifex aeolicus at 2.35 angstrom resolution
2HK7	;	2.5	;	Crystal structure of shikimate dehydrogenase from aquifex aeolicus in complex with mercury at 2.5 angstrom resolution
2HK9	;	2.2	;	Crystal structure of shikimate dehydrogenase from aquifex aeolicus in complex with shikimate and NADP+ at 2.2 angstrom resolution
3DON	;	2.1	;	Crystal structure of shikimate dehydrogenase from Staphylococcus epidermidis
3DOO	;	2.2	;	Crystal structure of shikimate dehydrogenase from Staphylococcus epidermidis complexed with shikimate
3U62	;	1.45	;	Crystal structure of shikimate dehydrogenase from Thermotoga maritima
1VIA	;	1.57	;	Crystal structure of shikimate kinase
2PT5	;	2.1	;	Crystal Structure Of Shikimate Kinase (aq_2177) From Aquifex Aeolicus vf5
3NWJ	;	2.35	;	Crystal structure of shikimate kinase from Arabidopsis thaliana (AtSK2)
3BAF	;	2.25	;	Crystal structure of shikimate kinase from Mycobacterium tuberculosis in complex with AMP-PNP
1L4U	;	1.8	;	CRYSTAL STRUCTURE OF SHIKIMATE KINASE FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MGADP AND PT(II) AT 1.8 ANGSTROM RESOLUTION
1WE2	;	2.3	;	Crystal structure of shikimate kinase from mycobacterium tuberculosis in complex with MGADP and shikimic acid
1L4Y	;	2.0	;	CRYSTAL STRUCTURE OF SHIKIMATE KINASE FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MGADP AT 2.0 ANGSTROM RESOLUTION
3MRS	;	2.4	;	Crystal structure of shikimate kinase mutant (R57A) from Helicobacter pylori
7TM6	;	1.26	;	Crystal structure of shikimate-3-phosphate and glyphosate bound 3-phosphoshikimate 1-carboxyvinyltransferase from Klebsiella pneumoniae
7TM5	;	1.41	;	Crystal structure of shikimate-3-phosphate bound 3-phosphoshikimate 1-carboxyvinyltransferase from Klebsiella pneumoniae
1VI2	;	2.1	;	Crystal structure of shikimate-5-dehydrogenase with NAD
6QRJ	;	2.65	;	Crystal structure of ShkA full-length in complex with AMPPNP
6QRL	;	1.84	;	Crystal structure of ShkA _Rec1 in complex with c-di-GMP
7SD1	;	3.19	;	Crystal structure of SHOC2
7TVG	;	2.4	;	Crystal Structure of SHOC2 to a resolution of 2.4 Angstrom
6HDT	;	1.54	;	crystal structure of short afifavidin - biotin complex
4ILK	;	2.003	;	Crystal structure of short chain alcohol dehydrogenase (rspB) from E. coli CFT073 (EFI TARGET EFI-506413) complexed with cofactor NADH
3IAH	;	1.83	;	Crystal Structure of Short Chain Dehydrogenase (yciK) from Salmonella enterica subsp. enterica serovar Typhimurium str. LT2 in Complex with NADP and Acetate.
6UH2	;	1.9	;	Crystal Structure of Short Chain Dehydrogenase from Leptospira borgpetersenii serovar Hardjo-bovis (Strain JB197) with bound NAD+
3G1T	;	1.7	;	CRYSTAL STRUCTURE OF short chain dehydrogenase from Salmonella enterica subsp. enterica serovar Typhi str. CT18
3TSC	;	2.05	;	Crystal structure of short chain dehydrogenase MAP_2410 from Mycobacterium paratuberculosis bound to NAD
3GRK	;	2.35	;	Crystal structure of short chain dehydrogenase reductase SDR glucose-ribitol dehydrogenase from Brucella melitensis
4Z28	;	1.66	;	Crystal structure of short hoefavidin biotin complex
4Z2V	;	1.39	;	Crystal structure of short hoefavidin-hoef-peptide complex
4Z2P	;	1.6	;	Crystal structure of short hoefavidin-hoef-peptide(L9F) complex
3TN7	;	1.68	;	Crystal structure of short-chain alcohol dehydrogenase from hyperthermophilic archaeon Thermococcus sibiricus complexed with 5-hydroxy-NADP
3KSU	;	2.3	;	Crystal structure of short-chain dehydrogenase from oenococcus oeni psu-1
3GEM	;	1.83	;	Crystal structure of short-chain dehydrogenase from Pseudomonas syringae
3H7A	;	1.87	;	CRYSTAL STRUCTURE OF SHORT-CHAIN DEHYDROGENASE FROM Rhodopseudomonas palustris
8BCI	;	1.7	;	Crystal structure of short-chain dehydrogenase PA3128 from Pseudomonas aeruginosa PAO1
8BCJ	;	1.15	;	Crystal structure of short-chain dehydrogenase PA3128 from Pseudomonas aeruginosa PAO1 in complex with NADP+
4IUY	;	2.385	;	Crystal structure of short-chain dehydrogenase/reductase (apo-form) from A. baumannii clinical strain WM99C
1XKQ	;	2.1	;	Crystal Structure of Short-Chain Dehydrogenase/Reductase of unknown Function from Caenorhabditis Elegans with Cofactor
5VA8	;	1.6	;	Crystal Structure of Short-chain dehydrogenase/reductase SDR from Burkholderia phymatum in complex with NADP
3PK0	;	1.75	;	Crystal structure of Short-chain dehydrogenase/reductase SDR from Mycobacterium smegmatis
5T5Q	;	1.95	;	Crystal structure of Short-chain dehydrogenase/reductase SDR:Glucose/ribitol dehydrogenase from Brucella melitensis
4NUF	;	2.8	;	Crystal Structure of SHP/EID1
4GS0	;	1.7961	;	Crystal structure of SHP1 catalytic domain with JAK1 activation loop peptide
4GRZ	;	1.3732	;	Crystal structure of SHP1 catalytic domain with PO4
4GRY	;	1.6998	;	Crystal structure of SHP1 catalytic domain with SO4
6CRG	;	2.75	;	Crystal Structure of Shp2 E76K GOF Mutant in complex with SHP099
6CRF	;	2.62	;	Crystal Structure of Shp2 E76K GOF Mutant in the Open Conformation
3MOW	;	2.3	;	Crystal structure of SHP2 in complex with a tautomycetin analog TTN D-1
5X7B	;	2.45	;	Crystal structure of SHP2_SH2-CagA EPIYA_C peptide complex
5X94	;	2.6	;	Crystal structure of SHP2_SH2-CagA EPIYA_D peptide complex
1K7H	;	1.92	;	CRYSTAL STRUCTURE OF SHRIMP ALKALINE PHOSPHATASE
1SHQ	;	2.0	;	Crystal structure of shrimp alkaline phosphatase with magnesium in M3
1SHN	;	2.15	;	Crystal structure of shrimp alkaline phosphatase with phosphate bound
5J45	;	2.758	;	Crystal structure of Shrub, fly ortholog of SNF7/CHMP4B
4R3B	;	1.366	;	Crystal structure of SHV-1 b-lactamase in complex with 6b-(hydroxymethyl)penicillanic acid sulfone PSR-283A
4ZAM	;	1.42	;	Crystal structure of SHV-1 beta-lactamase bound to avibactam
3T2W	;	1.5	;	Crystal structure of shwanavidin (F43A) - biotin complex
7WVI	;	2.48	;	Crystal structure of SIA28
4CA1	;	1.58	;	Crystal structure of Siah1 at 1.58 A resolution.
4C9Z	;	1.95	;	Crystal structure of Siah1 at 1.95 A resolution
8HEO	;	2.53	;	Crystal structure of SIAH1 SBD bound to Axin2 peptide
2A25	;	2.2	;	Crystal structure of Siah1 SBD bound to the peptide EKPAAVVAPITTG from SIP
4X3G	;	2.34	;	Crystal structure of SIAH1 SINA domain in complex with a USP19 peptide
5H9M	;	1.761	;	Crystal structure of siah2 SBD domain
6XPG	;	1.9	;	Crystal Structure of Sialate O-acetylesterase from Bacteroides vulgatus by Serial Crystallography
6XPM	;	2.3	;	Crystal Structure of Sialate O-acetylesterase from Bacteroides vulgatus with microfluidics crystals at room temperature
2WYP	;	1.5	;	Crystal structure of sialic acid binding protein
5ZA4	;	2.193	;	Crystal structure of Sialic acid Binding protein from Haemophilus ducreyi
5Z99	;	1.494	;	Crystal structure of Sialic acid Binding protein from Haemophilus ducreyi with Neu5Ac
5YYB	;	2.484	;	Crystal structure of Sialic acid Binding protein from Haemophilus ducreyi with Neu5Gc
1XUU	;	1.9	;	Crystal structure of sialic acid synthase (NeuB) in complex with Mn2+ and Malate from Neisseria meningitidis
2WQP	;	1.75	;	Crystal structure of sialic acid synthase NeuB-inhibitor complex
4ZM8	;	2.6762	;	Crystal Structure of Sialostatin L
3LH4	;	1.8	;	Crystal Structure of Sialostatin L2
4BYH	;	2.3	;	Crystal structure of sialylated IgG Fc
4R83	;	1.93	;	Crystal structure of Sialyltransferase from Photobacterium damsela
4R84	;	1.7	;	Crystal structure of Sialyltransferase from Photobacterium damsela with CMP-3F(a)Neu5Ac bound
4R9V	;	2.3	;	Crystal structure of sialyltransferase from photobacterium damselae, residues 113-497 corresponding to the gt-b domain
3K3L	;	2.62	;	Crystal structure of Siderocalin (NGAL, Lipocalin 2) complexed with apo Enterobactin
1X89	;	2.1	;	Crystal structure of Siderocalin (NGAL, Lipocalin 2) complexed with Carboxymycobactin S
1X8U	;	2.2	;	Crystal structure of Siderocalin (NGAL, Lipocalin 2) complexed with Carboxymycobactin T
3HWE	;	2.8	;	Crystal structure of Siderocalin (NGAL, Lipocalin 2) complexed with Fe-BisHaCam
3HWG	;	2.19	;	Crystal structure of Siderocalin (NGAL, Lipocalin 2) complexed with Fe-TrenCam-hopo2
3HWF	;	3.2	;	Crystal structure of Siderocalin (NGAL, Lipocalin 2) complexed with Fe-TrenCam2-hopo
3FW5	;	2.3	;	Crystal structure of Siderocalin (NGAL, Lipocalin 2) complexed with Ferric 4-methyl-catechol
3FW4	;	2.3	;	Crystal structure of Siderocalin (NGAL, Lipocalin 2) complexed with Ferric Catechol
1X71	;	2.1	;	Crystal structure of Siderocalin (NGAL, Lipocalin 2) complexed with TRENCAM-3,2-HOPO, a cepabactin analogue
3CMP	;	2.8	;	Crystal structure of Siderocalin (NGAL, Lipocalin 2) K125A mutant complexed with Ferric Enterobactin
3HWD	;	2.95	;	Crystal structure of Siderocalin (NGAL, Lipocalin 2) K125A-K134A mutant complexed with Ferric Enterobactin
3I0A	;	2.6	;	Crystal structure of Siderocalin (NGAL, Lipocalin 2) K134A mutant complexed with Ferric Enterobactin
3BY0	;	2.572	;	Crystal structure of Siderocalin (NGAL, Lipocalin 2) W79A-R81A complexed with Ferric Enterobactin
3CBC	;	2.17	;	Crystal structure of Siderocalin (NGAL, Lipocalin 2) Y106F complexed with Ferric Enterobactin
7SF6	;	1.46	;	Crystal Structure of Siderophore Binding Protein FatB from Desulfitobacterium hafniense
7W8F	;	1.9	;	Crystal structure of siderophore binding protein VatD from Vibrio vulnificus M2799 complexed with Desferal
7ABW	;	3.35	;	Crystal structure of siderophore reductase FoxB
6K4K	;	2.715	;	Crystal structure of SidJ-CaM binary complex at 2.71 A
6K4R	;	3.109	;	Crystal structure of SidJ-CaM-AMP ternary complex at 3.11 A
3CXB	;	2.6	;	Crystal Structure of sifa and skip
3VEP	;	2.5	;	Crystal structure of SigD4 in complex with its negative regulator RsdA
7ZOZ	;	2.104	;	Crystal structure of Siglec-15 in complex with Fab
2G5R	;	1.6	;	Crystal structure of Siglec-7 in complex with methyl-9-(aminooxalyl-amino)-9-deoxyNeu5Ac (oxamido-Neu5Ac)
1NY6	;	3.1	;	Crystal structure of sigm54 activator (AAA+ ATPase) in the active state
1NY5	;	2.4	;	Crystal structure of sigm54 activator (AAA+ ATPase) in the inactive state
3CO5	;	2.4	;	Crystal structure of sigma-54 interaction domain of putative transcriptional response regulator from Neisseria gonorrhoeae
3GDW	;	2.0	;	Crystal structure of sigma-54 interaction domain protein from Enterococcus faecalis
3DZD	;	2.4	;	Crystal structure of sigma54 activator NTRC4 in the inactive state
3E7L	;	2.252	;	Crystal structure of sigma54 activator NtrC4's DNA binding domain
3CNB	;	2.0	;	Crystal structure of signal receiver domain of DNA binding response regulator protein (merR) from Colwellia psychrerythraea 34H
3HV2	;	1.5	;	Crystal structure of signal receiver domain OF HD domain-containing protein FROM Pseudomonas fluorescens Pf-5
3CG0	;	2.15	;	Crystal structure of signal receiver domain of modulated diguanylate cyclase from Desulfovibrio desulfuricans G20, an example of alternate folding
3CFY	;	2.5	;	Crystal structure of signal receiver domain of putative Luxo repressor protein from Vibrio parahaemolyticus
3GT7	;	2.3	;	CRYSTAL STRUCTURE OF SIGNAL RECEIVER DOMAIN OF SIGNAL TRANSDUCTION HISTIDINE KINASE FROM Syntrophus aciditrophicus
7EPK	;	2.7	;	Crystal Structure of Signal Recognition Particle 54 kDa protein (SRP54) from Aeropyrum pernix K1 in Complex with GDP
6CY1	;	1.9	;	Crystal structure of Signal recognition particle receptor FtsY from Elizabethkingia anophelis
6CY5	;	1.7	;	Crystal structure of Signal recognition particle receptor FtsY from Elizabethkingia anophelis in complex with GDP
4I2X	;	2.48	;	Crystal structure of Signal Regulatory Protein gamma (SIRP-gamma) in complex with FabOX117
4D6V	;	2.2	;	Crystal structure of signal transducing protein
4MAV	;	2.79	;	Crystal structure of signaling protein SPB-40 complexed with 5-hydroxymethyl oxalanetriol at 2.80 A resolution
5Z05	;	1.49	;	Crystal structure of signalling protein from buffalo (SPB-40) with an acetone induced conformation of Trp78 at 1.49 A resolution
5Z4W	;	1.79	;	Crystal structure of signalling protein from buffalo (SPB-40) with an altered conformation of Trp78 at 1.79 A resolution
1SYT	;	2.6	;	Crystal structure of signalling protein from goat SPG-40 in the presense of N,N',N''-triacetyl-chitotriose at 2.6A resolution
1SR0	;	3.05	;	Crystal structure of signalling protein from sheep(SPS-40) at 3.0A resolution using crystal grown in the presence of polysaccharides
5WUQ	;	2.8	;	Crystal structure of SigW in complex with its anti-sigma RsiW, a zinc binding form
5WUR	;	2.6	;	Crystal structure of SigW in complex with its anti-sigma RsiW, an oxdized form
8BHU	;	1.7	;	Crystal Structure of SilF (Ag(I) form
8BBZ	;	2.2	;	Crystal Structure of SilF (apo form)
8BWV	;	2.2	;	Crystal Structure of SilF Cu(I)
6ZQ3	;	2.4	;	Crystal Structure of Silicatein Alpha from Marine Sponge Tethya aurantium
8IUI	;	1.56	;	Crystal structure of silkworm fibroinase complexed with E-64
5GUH	;	2.4	;	Crystal structure of silkworm PIWI-clade Argonaute Siwi bound to piRNA
1ED1	;	2.1	;	CRYSTAL STRUCTURE OF SIMIAN IMMUNODEFICIENCY VIRUS MATRIX ANTIGEN (SIV MA) AT 100K.
1ECW	;	2.2	;	CRYSTAL STRUCTURE OF SIMIAN IMMUNODEFICIENCY VIRUS MATRIX ANTIGEN (SIV MA) AT 293K.
5A9A	;	1.822	;	Crystal structure of Simulium ubiquitum CPV20 polyhedra
2Q79	;	1.8	;	Crystal Structure of single chain E2C from HPV16 with a 12aa linker for monomerization.
1IV7	;	1.82	;	Crystal Structure of Single Chain Monellin
1IV9	;	1.9	;	Crystal Structure of Single Chain Monellin
3KSK	;	2.35	;	Crystal Structure of single chain PvuII
3P8S	;	2.0	;	Crystal structure of single chain recombinant jacalin showing highly dynamic posttranslational excission loop that reduces binding affinity
5VF6	;	1.635	;	Crystal structure of single chain variable fragment (scFv45).
3BD3	;	1.6	;	Crystal structure of single domain VL of an anti-DNA binding antibody 3D8 scFv and its active site revealed by complex structures of a small molecule and metals
3BD4	;	2.4	;	Crystal structure of single domain VL of an anti-DNA binding antibody 3D8 scFv and its active site revealed by complex structures of a small molecule and metals
3BD5	;	2.0	;	Crystal structure of single domain VL of an anti-DNA binding antibody 3D8 scFv and its active site revealed by complex structures of a small molecule and metals
5E2J	;	2.1	;	Crystal structure of single mutant thermostable endoglucanase (D468A) from Alicyclobacillus acidocaldarius
4IG4	;	2.402	;	Crystal structure of single mutant thermostable NPPase (N86S) from Geobacillus stearothermophilus
2W2F	;	1.73	;	CRYSTAL STRUCTURE OF SINGLE POINT MUTANT ARG48GLN OF P-COUMARIC ACID DECARBOXYLASE FROM LACTOBACILLUS PLANTARUM STRUCTURAL INSIGHTS INTO THE ACTIVE SITE AND DECARBOXYLATION CATALYTIC MECHANISM
2WSJ	;	2.24	;	Crystal Structure of single point mutant Glu71Ser p-coumaric Acid Decarboxylase
2W2B	;	1.4	;	Crystal Structure of single point mutant Tyr20Phe p-coumaric Acid Decarboxylase from Lactobacillus plantarum: structural insights into the active site and decarboxylation catalytic mechanism
1Z9F	;	2.3	;	Crystal structure of single stranded DNA-binding protein (TM0604) from Thermotoga maritima at 2.60 A resolution
8KGZ	;	2.21	;	Crystal structure of single-chain Fv antibody against antigen peptide from SARS-CoV2 S-spike protein
8JPW	;	2.66	;	Crystal Structure of Single-chain L-Glutamate Oxidase Mutant from Streptomyces sp. X-119-6
3LGJ	;	2.5	;	Crystal structure of single-stranded binding protein (ssb) from Bartonella henselae
3EIV	;	2.141	;	Crystal Structure of Single-stranded DNA-binding protein from Streptomyces coelicolor
1DDG	;	2.01	;	CRYSTAL STRUCTURE OF SIR-FP60
1DDI	;	2.51	;	CRYSTAL STRUCTURE OF SIR-FP60
4IAO	;	2.901	;	Crystal structure of Sir2 C543S mutant in complex with SID domain of Sir4
4BV2	;	3.3	;	CRYSTAL STRUCTURE OF SIR2 IN COMPLEX WITH THE INHIBITOR EX-527, 2'-O-ACETYL-ADP-RIBOSE AND DEACETYLATED P53-PEPTIDE
3D4B	;	1.9	;	Crystal structure of Sir2Tm in complex with Acetyl p53 peptide and DADMe-NAD+
6L8X	;	1.55	;	Crystal structure of Siraitia grosvenorii ugt transferase mutant2
5BTR	;	3.2	;	Crystal structure of SIRT1 in complex with resveratrol and an AMC-containing peptide
5YQM	;	1.735	;	Crystal structure of Sirt2 in complex with selective inhibitor A29
5YQL	;	1.601	;	Crystal structure of Sirt2 in complex with selective inhibitor A2I
5YQN	;	1.6	;	Crystal structure of Sirt2 in complex with selective inhibitor L55
5YQO	;	1.483	;	Crystal structure of Sirt2 in complex with selective inhibitor L5C
4L3O	;	2.518	;	Crystal Structure of SIRT2 in complex with the macrocyclic peptide S2iL5
8TGP	;	1.76	;	Crystal structure of SIRT2 with FAM-PEG4-H4K16(myristoyl) peptide
5D7O	;	1.63	;	Crystal structure of Sirt2-ADPR at an improved resolution
5YTK	;	2.7	;	Crystal structure of SIRT3 bound to a leucylated AceCS2
4FZ3	;	2.1	;	Crystal structure of SIRT3 in complex with acetyl p53 peptide coupled with 4-amino-7-methylcoumarin
8HLY	;	2.0	;	Crystal structure of SIRT3 in complex with H3K23la peptide
5Z94	;	1.899	;	Crystal Structure of SIRT3 in complex with H3K4bhb peptide
5Z93	;	1.945	;	Crystal Structure of SIRT3 in complex with H3K9bhb peptide
5ZGC	;	2.9	;	Crystal Structure of SIRT3 in complex with H4K16bhb peptide
8HLW	;	2.5	;	Crystal structure of SIRT3 in complex with H4K16la peptide
4BV3	;	2.0	;	CRYSTAL STRUCTURE OF SIRT3 IN COMPLEX WITH THE INHIBITOR EX-527 AND NAD
5BWN	;	1.942	;	Crystal Structure of SIRT3 with a H3K9 Peptide Containing a Myristoyl Lysine
5XHS	;	2.19	;	Crystal structure of SIRT5 complexed with a fluorogenic small-molecule substrate SuBKA
5BWL	;	1.548	;	Crystal Structure of SIRT5 in Complex with a Coumarin-Labelled Succinyl Peptide
6ZX9	;	2.51973	;	Crystal structure of SIV Vpr,fused to T4 lysozyme, isolated from moustached monkey, bound to human DDB1 and human DCAF1 (amino acid residues 1046-1396)
8FBW	;	2.35	;	Crystal structure of SIV-1 V2 antibody NCI05 in complex with a V2 peptide
5NUH	;	2.78	;	Crystal structure of SIVmac239 Nef bound to an engineered Hck SH3 domain
5NUI	;	2.5	;	Crystal structure of SIVmac239 Nef in an ExxxLM endocytic sorting motif bound state
6K6N	;	2.0002	;	Crystal structure of SIVmac239 Nef protein
6P59	;	2.94221	;	Crystal structure of SIVrcm Vif-CBFbeta-ELOB-ELOC complex
8EBB	;	1.88	;	Crystal structure of SIX6 from Fusarium oxysporum f. sp. lycopersici
8EB9	;	1.28	;	Crystal structure of SIX8 from Fusarium oxysporum f. sp. lycopersici
7EL5	;	1.95	;	Crystal structure of Sizzled protein from Xenopus Laevis
6RWD	;	1.53	;	Crystal structure of SjGST in complex with GSH and ellagic acid at 1.53 Angstrom resolution
4LA1	;	2.348	;	Crystal structure of SjTGR (thioredoxin glutathione reductase from Schistosoma japonicumi)complex with FAD
1YTZ	;	3.0	;	Crystal structure of skeletal muscle troponin in the Ca2+-activated state
1YV0	;	7.0	;	Crystal structure of skeletal muscle troponin in the Ca2+-free state
1U2M	;	2.3	;	Crystal Structure of Skp
2AST	;	2.3	;	Crystal structure of Skp1-Skp2-Cks1 in complex with a p27 peptide
6SM7	;	1.88	;	Crystal structure of SLA Reductase YihU from E. Coli
6SMZ	;	1.75	;	Crystal structure of SLA Reductase YihU from E. Coli in complex with NADH
6SMY	;	2.45	;	Crystal structure of SLA Reductase YihU from E. Coli with NADH and product DHPS
3IDW	;	1.85	;	Crystal structure of Sla1 homology domain 2
5GKS	;	2.05	;	Crystal structure of SLE patient-derived anti-DNA antibody
5GKR	;	2.1	;	Crystal structure of SLE patient-derived anti-DNA antibody in complex with oligonucleotide
4GR4	;	2.44	;	Crystal structure of SlgN1deltaAsub
4GR5	;	1.92	;	Crystal structure of SlgN1deltaAsub in complex with AMPcPP
4RKI	;	2.05	;	Crystal structure of sliding beta clamp from Helicobacter pylori
7YBD	;	2.13	;	Crystal structure of sliding DNA clamp of Clostridioides difficile
2NT2	;	2.1	;	Crystal Structure of Slingshot phosphatase 2
3WMP	;	2.0	;	Crystal structure of SLL-2
4A6K	;	1.8	;	Crystal structure of Slm1-PH domain in complex with D-myo-Inositol-4- phosphate
4A6H	;	1.449	;	Crystal structure of Slm1-PH domain in complex with Inositol-4- phosphate
4A6F	;	1.68	;	Crystal structure of Slm1-PH domain in complex with Phosphoserine
6AKM	;	2.3	;	Crystal structure of SLMAP-SIKE1 complex
4XZV	;	3.58	;	Crystal Structure of SLMO1-TRIAP1 Complex
5J98	;	2.6	;	Crystal structure of Slow Bee Paralysis Virus at 2.6A resolution
5J96	;	3.41	;	Crystal structure of Slow Bee Paralysis Virus at 3.4A resolution
7QEC	;	1.95	;	Crystal structure of SlpA - domain II, domain that is involved in the self-assembly of the S-layer from Lactobacillus amylovorus
8BT9	;	2.1	;	Crystal structure of SlpA domain II (aa 201-310), domain that is involved in the self-assembly and dimerization of the S-layer from Lactobacillus acidophilus
4K00	;	1.9	;	Crystal structure of Slr0204, a 1,4-dihydroxy-2-naphthoyl-CoA thioesterase from Synechocystis
3K25	;	2.551	;	Crystal Structure of Slr1438 protein from Synechocystis sp. PCC 6803, Northeast Structural Genomics Consortium Target SgR112
5AO7	;	2.09	;	Crystal Structure of SltB3 from Pseudomonas aeruginosa in complex with NAG-anhNAM-pentapeptide
5AO8	;	2.23	;	Crystal Structure of SltB3 from Pseudomonas aeruginosa in complex with NAG-NAM-pentapeptide
5ANZ	;	1.614	;	Crystal Structure of SltB3 from Pseudomonas aeruginosa.
7CQ2	;	2.5	;	Crystal structure of Slx1-Slx4
7CQ3	;	1.449	;	Crystal structure of Slx1-Slx4
7CQ4	;	3.294	;	Crystal structure of Slx1-Slx4 in complex with 5'flap DNA
1MQS	;	3.0	;	Crystal structure of Sly1p in complex with an N-terminal peptide of Sed5p
3M3G	;	1.39	;	Crystal structure of Sm1, an elicitor of plant defence responses from Trichoderma virens.
5J7S	;	2.368	;	Crystal structure of SM1-71 bound to TAK1-TAB1
1G73	;	2.0	;	CRYSTAL STRUCTURE OF SMAC BOUND TO XIAP-BIR3 DOMAIN
4TX5	;	1.8	;	Crystal structure of Smac-DIABLO (in space group P65)
1FEW	;	2.2	;	CRYSTAL STRUCTURE OF SMAC/DIABLO
3KMP	;	2.7	;	Crystal Structure of SMAD1-MH1/DNA complex
6M64	;	1.45	;	Crystal structure of SMAD2 in complex with CBP
7CO1	;	3.3	;	Crystal structure of SMAD2 in complex with wild-type CBP
1DEV	;	2.2	;	CRYSTAL STRUCTURE OF SMAD2 MH2 DOMAIN BOUND TO THE SMAD-BINDING DOMAIN OF SARA
6H3R	;	2.75	;	Crystal structure of Smad2 without exon -MH1 bound to the CAGAC site.
1OZJ	;	2.4	;	Crystal structure of Smad3-MH1 bound to DNA at 2.4 A resolution
5OD6	;	2.0	;	Crystal structure of Smad3-MH1 bound to the GGCGC site.
5ODG	;	2.12	;	Crystal structure of Smad3-MH1 bound to the GGCT site.
5UWU	;	2.24	;	Crystal Structure of SMAD4 NES Peptide in complex with CRM1-Ran-RanBP1
5MF0	;	3.03	;	Crystal structure of Smad4-MH1 bound to the GGCCG site.
5MEY	;	2.05	;	Crystal structure of Smad4-MH1 bound to the GGCGC site.
5MEZ	;	2.98	;	Crystal structure of Smad4-MH1 bound to the GGCT site.
6FZS	;	2.31	;	Crystal structure of Smad5-MH1 bound to the GGCGC site.
5X6M	;	3.2	;	Crystal Structure of SMAD5-MH1 in complex with a composite DNA sequence
5X6H	;	3.1	;	Crystal Structure of SMAD5-MH1/GC-BRE DNA complex
5X6G	;	3.05	;	Crystal Structure of SMAD5-MH1/palindromic SBE DNA complex
6FZT	;	2.46	;	Crystal structure of Smad8_9-MH1 bound to the GGCGC site.
5HVZ	;	2.0	;	Crystal structure of smAKAP AKB domain bound RIa dimerization/docking (D/D) complex at 2.0 A resolution
4M3H	;	2.2	;	Crystal structure of small laccase Ssl1 from Streptomyces sviceus
7WMT	;	1.77	;	Crystal structure of small molecule 13 bound to human Nicotinamide N-methyltransferase
5V6S	;	1.7	;	Crystal structure of small molecule acrylamide 1 covalently bound to K-Ras G12C
4M21	;	1.94	;	Crystal Structure of small molecule acrylamide 11 covalently bound to K-Ras G12C
4M22	;	2.09	;	Crystal Structure of small molecule acrylamide 16 covalently bound to K-Ras G12C
8CX5	;	1.72	;	Crystal Structure of small molecule alpha,beta-ketoamide 4 covalently bound to K-Ras(G12R)
6CZ5	;	3.0	;	Crystal structure of small molecule AMP-acrylamide covalently bound to DDX3 S228C
6B0V	;	1.29	;	Crystal Structure of small molecule ARS-107 covalently bound to K-Ras G12C
5V9U	;	1.38	;	Crystal Structure of small molecule ARS-1620 covalently bound to K-Ras G12C
5F2E	;	1.4	;	Crystal Structure of small molecule ARS-853 covalently bound to K-Ras G12C
6B0Y	;	1.43	;	Crystal Structure of small molecule ARS-917 covalently bound to K-Ras G12C
5V6V	;	1.72	;	Crystal structure of small molecule aziridine 3 covalently bound to K-Ras G12C
7TLE	;	1.98717	;	Crystal Structure of small molecule beta-lactone 1 covalently bound to K-Ras(G12S)
7TLG	;	1.80001	;	Crystal Structure of small molecule beta-lactone 5 covalently bound to K-Ras(G12S)
5VBE	;	1.57	;	Crystal Structure of Small Molecule Disulfide 2C07 Bound to H-Ras M72C GDP
5VBZ	;	2.2	;	Crystal Structure of Small Molecule Disulfide 2C07 Bound to H-Ras M72C GppNHp
5VBM	;	1.49	;	Crystal Structure of Small Molecule Disulfide 2C07 Bound to K-Ras Cys Light M72C GDP
4LV6	;	1.5	;	Crystal Structure of small molecule disulfide 4 covalently bound to K-Ras G12C
4LUC	;	1.29	;	Crystal Structure of small molecule disulfide 6 bound to K-Ras G12C
7AQF	;	1.77	;	Crystal Structure of Small Molecule Inhibitor TM5484 Bound to Stabilized Active Plasminogen Activator Inhibitor-1 (PAI-1-stab)
7AQG	;	2.27	;	Crystal Structure of Small Molecule Inhibitor TM5484 Bound to Stabilized Active Plasminogen Activator Inhibitor-1 (PAI-1-W175F)
4M1S	;	1.552	;	Crystal Structure of small molecule vinylsulfonamide 13 covalently bound to K-Ras G12C
4M1T	;	1.703	;	Crystal Structure of small molecule vinylsulfonamide 14 covalently bound to K-Ras G12C
4M1Y	;	1.491	;	Crystal Structure of small molecule vinylsulfonamide 15 covalently bound to K-Ras G12C
4M1O	;	1.571	;	Crystal Structure of small molecule vinylsulfonamide 7 covalently bound to K-Ras G12C
4LYF	;	1.568	;	Crystal Structure of small molecule vinylsulfonamide 8 covalently bound to K-Ras G12C
4LYH	;	1.371	;	Crystal Structure of small molecule vinylsulfonamide 9 covalently bound to K-Ras G12C
4LYJ	;	1.927	;	Crystal Structure of small molecule vinylsulfonamide 9 covalently bound to K-Ras G12C, alternative space group
4M1W	;	1.58	;	Crystal Structure of small molecule vinylsulfonamide covalently bound to K-Ras G12C
3NIR	;	0.48	;	Crystal structure of small protein crambin at 0.48 A resolution
3HTX	;	3.1	;	Crystal structure of small RNA methyltransferase HEN1
4DAM	;	1.7	;	Crystal structure of small single-stranded DNA-binding protein from Streptomyces coelicolor
2P14	;	1.5	;	Crystal structure of small subunit (R.BspD6I2) of the heterodimeric restriction endonuclease R.BspD6I
5MKI	;	2.048	;	Crystal structure of SmAP (LSm) protein from Methanococcus vannielii
5MKN	;	2.55	;	Crystal structure of SmAP (LSm) protein from Methanococcus vannielii
5MKL	;	2.086	;	Crystal structure of SmAP (LSm) protein from Sulfolobus acidocaldarius
5EA1	;	2.0	;	Crystal Structure of SMARCA4 bromodomain in complex with MPD
4O66	;	1.9	;	Crystal Structure of SMARCAL1 HARP substrate recognition domain
4WS9	;	2.803	;	Crystal structure of sMAT N159G from Sulfolobus solfataricus
6K4X	;	1.17	;	Crystal structure of SMB-1 metallo-beta-lactamase in a complex with ASB
6K4T	;	1.39	;	Crystal structure of SMB-1 metallo-beta-lactamase in a complex with TSA
6GS8	;	2.8	;	Crystal structure of SmbA in complex with c-di-GMP
6GTM	;	3.3	;	Crystal structure of SmbA in complex with ppGpp.
7B0E	;	1.4	;	Crystal structure of SmbA loop deletion mutant
7FD6	;	1.79	;	Crystal structure of SmChiA in complex with 6a
1ZWX	;	1.9	;	Crystal Structure of SmcL
6WAH	;	2.55	;	Crystal Structure of SmcR L139R from Vibrio vulnificus
6WAI	;	2.583	;	Crystal Structure of SmcR N142D from Vibrio vulnificus
6WAF	;	3.381	;	Crystal Structure of SmcR N55I from Vibrio vulnificus
6WAG	;	2.575	;	Crystal Structure of SmcR S76A from Vibrio Vulnificus
4ZRE	;	2.0	;	Crystal structure of SMG1 F278D mutant
4ZRD	;	2.3	;	Crystal structure of SMG1 F278N mutant
7SPR	;	1.79	;	Crystal structure of SMG1 mutant (G28C/P206C/Q34P/A37P/M176V/G177A/M294R/F278N)
5XGC	;	2.1	;	Crystal structure of SmgGDS-558
5ZHX	;	3.5	;	Crystal structure of SmgGDS-558 and farnesylated RhoA complex
3W3D	;	1.8	;	Crystal structure of smooth muscle G actin DNase I complex
5KLX	;	2.45	;	Crystal Structure of SMT Fusion Peptidyl-Prolyl Cis-Trans Isomerase from Burkholderia Pseudomallei Complexed with SF110
6O49	;	1.85	;	CRYSTAL STRUCTURE OF SMT FUSION PEPTIDYL-PROLYL CIS-TRANS ISOMERASE FROM BURKHOLDERIA PSEUDOMALLEI COMPLEXED WITH SF339
5V8T	;	2.1	;	Crystal structure of SMT fusion Peptidyl-prolyl cis-trans isomerase from Burkholderia pseudomallei complexed with SF354
6O4A	;	2.1	;	CRYSTAL STRUCTURE OF SMT FUSION PEPTIDYL-PROLYL CIS-TRANS ISOMERASE FROM BURKHOLDERIA PSEUDOMALLEI COMPLEXED WITH SF355
3L7T	;	1.8	;	Crystal structure of SMU.1112c
3L7N	;	2.7	;	Crystal structure of SMU.1228c
2HCU	;	2.1	;	Crystal Structure Of Smu.1381 (or LeuD) from Streptococcus Mutans
4L9A	;	2.0	;	Crystal structure of Smu.1393c from cariogenic pathogen Streptococcus mutans
3LCM	;	1.799	;	Crystal structure of Smu.1420 from Streptococcus mutans UA159
3L7P	;	2.0	;	Crystal structure of SMU.1657c, Putative nitrogen regulatory protein PII from streptococcus mutans
3LBY	;	2.0	;	Crystal structure of SMU.1697c, a putative methyltransferase from streptococcus mutans in complex with SAH
3L8U	;	2.0	;	Crystal structure of SMU.1707c, a putative rRNA methyltransferase from streptococcus mutans UA159
3LDG	;	1.963	;	Crystal structure of SMU.472, a putative methyltransferase complexed with SAH
3LDF	;	2.23	;	Crystal structure of SMU.776, a putative methyltransferase complexed with SAH
2G0I	;	1.85	;	Crystal structure of SMU.848 from Streptococcus mutans
2G0J	;	2.8	;	Crystal structure of SMU.848 from Streptococcus mutans
5V3H	;	2.69	;	Crystal structure of SMYD2 with SAM and EPZ033294
6ZRB	;	1.55	;	Crystal structure of SMYD3 conjugate with piperidine-based covalent inhibitor EM127
5XXD	;	2.314	;	Crystal structure of SmyD3 in complex with covalent inhibitor 1
5XXG	;	2.14	;	Crystal structure of SmyD3 in complex with covalent inhibitor 2
5XXJ	;	1.689	;	Crystal structure of SmyD3 in complex with covalent inhibitor 3
5YJO	;	2.135	;	Crystal structure of SmyD3 in complex with covalent inhibitor 4
6IJL	;	2.351	;	Crystal structure of SmyD3 in complex with covalent inhibitor 5
3PDN	;	1.7	;	Crystal structure of SmyD3 in complex with methyltransferase inhibitor sinefungin
6YUH	;	1.93	;	Crystal structure of SMYD3 with diperodon R enantiomer bound to allosteric site
7BJ1	;	1.61	;	Crystal structure of SMYD3 with diperodon S enantiomer bound to allosteric site
6O9O	;	1.586	;	Crystal Structure of SMYD3 with Potent and Selective Isoxazole Amide Inhibitor 1
5V37	;	1.42	;	Crystal structure of SMYD3 with SAM and EPZ028862
5CCM	;	2.3	;	Crystal structure of SMYD3 with SAM and EPZ030456
5CCL	;	1.5	;	Crystal structure of SMYD3 with SAM and oxindole compound
6KX1	;	1.773	;	Crystal structure of SN-101 mAb in complex with MUC1 glycopeptide
6KX0	;	2.404	;	Crystal structure of SN-101 mAb non-liganded form
7BYD	;	2.80003	;	Crystal structure of SN45 TCR in complex with lipopeptide-bound Mamu-B*05104
3W5K	;	2.6	;	Crystal structure of Snail1 and importin beta complex
4HR6	;	2.25	;	Crystal structure of snake gourd (Trichosanthes anguina) seed lectin, a three chain homologue of type II RIPs
5Y97	;	3.05	;	Crystal structure of snake gourd seed lectin in complex with lactose
5GZ4	;	2.55	;	Crystal structure of snake venom phosphodiesterase (PDE) from Taiwan cobra (Naja atra atra)
5GZ5	;	2.093	;	Crystal structure of snake venom phosphodiesterase (PDE) from Taiwan cobra (Naja atra atra) in complex with AMP
7CBA	;	2.901	;	Crystal structure of snake venom phosphodiesterase (PDE) from Taiwan cobra (Naja atra atra) in complex with isorhamnetin and citrate
3KZY	;	1.9	;	Crystal structure of SNAP-tag
3KZZ	;	1.89	;	Crystal structure of SNAP-tag bound to its substrate benzylguanine
6Y8P	;	2.3	;	Crystal structure of SNAP-tag labeled with a benzyl-tetramethylrhodamine fluorophore
7V6Q	;	3.0	;	Crystal structure of sNASP-ASF1A-H3.1-H4 complex
7KNW	;	2.65	;	Crystal structure of SND1 in complex with C-26-A2
7KNX	;	2.7	;	Crystal structure of SND1 in complex with C-26-A6
5T8N	;	2.204	;	Crystal structure of Snf7 under 200 MPa
5T8L	;	2.2	;	Crystal structure of Snf7 under 350 MPa
3KG0	;	1.7	;	Crystal structure of SnoaB, a cofactor-independent oxygenase from Streptomyces nogalater, determined to 1.7 resolution
3KNG	;	1.9	;	Crystal structure of SnoaB, a cofactor-independent oxygenase from Streptomyces nogalater, determined to 1.9 resolution
3KG1	;	2.5	;	Crystal structure of SnoaB, a cofactor-independent oxygenase from Streptomyces nogalater, mutant N63A
2GEX	;	2.5	;	Crystal structure of SnoaL2 a putative hydroxylase from Streptomyces nogalater
3UDB	;	2.567	;	Crystal structure of SnRK2.6
3UJG	;	2.6	;	Crystal structure of SnRK2.6 in complex with HAB1
4IKB	;	1.78	;	Crystal structure of SNX11 PX domain
4IKD	;	1.6	;	Crystal structure of SNX11 PX domain
6KOJ	;	2.14	;	Crystal structure of SNX11-PXe domain in complex with PI(3,5)P2
6KOI	;	3.5	;	Crystal structure of SNX11-PXe domain in dimer form.
6KOK	;	2.0	;	Crystal Structure of SNX11/SNX10-PXe Chimera
7WF6	;	3.25	;	Crystal structure of SNX13 RGS domain
6ECM	;	2.353	;	Crystal Structure of SNX15 PX domain in domain swapped conformation
6MBI	;	2.834	;	Crystal Structure of SNX15 PX domain in domain swapped conformation form 2
5GW0	;	3.3	;	Crystal structure of SNX16 PX-Coiled coil
5GW1	;	3.35	;	Crystal structure of SNX16 PX-Coiled coil in space group P212121
6EE0	;	2.518	;	Crystal Structure of SNX23 PX domain
7CT1	;	1.947	;	Crystal structure of Snx27 FERM domain in complex with a DLF motif
3HPC	;	1.47	;	Crystal structure of SNX5-PX domain in P21 space group
3HPB	;	2.19	;	Crystal structure of SNX5-PX domain in P212121 space group
3DYT	;	2.08	;	Crystal structure of Snx9PX-BAR (230-595), C2221
3DYU	;	4.1	;	Crystal structure of Snx9PX-BAR (230-595), H32
3TEQ	;	1.9	;	Crystal structure of SOAR domain
3TER	;	2.551	;	Crystal structure of SOAR domain with Inhibition helix from C. elegans
2C9W	;	1.9	;	CRYSTAL STRUCTURE OF SOCS-2 IN COMPLEX WITH ELONGIN-B AND ELONGIN-C AT 1.9A RESOLUTION
2IZV	;	2.55	;	CRYSTAL STRUCTURE OF SOCS-4 IN COMPLEX WITH ELONGIN-B AND ELONGIN-C AT 2.55A RESOLUTION
6C5X	;	3.105	;	Crystal Structure of SOCS1 in complex with ElonginB and ElonginC
7M6T	;	3.194	;	Crystal structure of SOCS2/ElonginB/ElonginC bound to a non-canonical peptide that enhances phospho-peptide binding
6I4X	;	2.69	;	Crystal structure of SOCS2:Elongin C:Elongin B in complex with erythropoietin receptor peptide
6I5J	;	2.8	;	Crystal structure of SOCS2:Elongin C:Elongin B in complex with growth hormone receptor peptide
6I5N	;	1.98	;	Crystal structure of SOCS2:Elongin C:Elongin B in complex with growth hormone receptor peptide
7ZLN	;	2.6	;	Crystal structure of SOCS2:ElonginB:ElonginC in complex with compound 11
7ZLO	;	2.22	;	Crystal structure of SOCS2:ElonginB:ElonginC in complex with compound 12
7ZLR	;	2.01	;	Crystal structure of SOCS2:ElonginB:ElonginC in complex with compound 13
7ZLP	;	1.94	;	Crystal structure of SOCS2:ElonginB:ElonginC in complex with compound 9
7ZLM	;	1.79	;	Crystal structure of SOCS2:ElonginB:ElonginC in complex with compound MN551
2HMH	;	2.0	;	Crystal structure of SOCS3 in complex with gp130(pTyr757) phosphopeptide.
2VIF	;	1.45	;	Crystal structure of SOCS6 SH2 domain in complex with a c-KIT phosphopeptide
3LSU	;	1.896	;	Crystal Structure of SOD2 from Saccharomyces cerevisiae
1XUQ	;	1.8	;	Crystal Structure of SodA-1 (BA4499) from Bacillus anthracis at 1.8A Resolution.
1XRE	;	1.8	;	Crystal Structure of SodA-2 (BA5696) from Bacillus anthracis at 1.8A Resolution.
5BZ3	;	2.3	;	CRYSTAL STRUCTURE OF SODIUM PROTON ANTIPORTER NAPA IN OUTWARD-FACING CONFORMATION.
7KGV	;	3.4	;	Crystal structure of sodium-coupled neutral amino acid transporter SLC38A9 in the N-terminal plugged form
6CSF	;	3.3	;	Crystal structure of sodium/alanine symporter AgcS with D-alanine bound
6CSE	;	3.24	;	Crystal structure of sodium/alanine symporter AgcS with L-alanine bound
3DH4	;	2.7	;	Crystal Structure of Sodium/Sugar symporter with bound Galactose from vibrio parahaemolyticus
3FW3	;	1.72	;	Crystal Structure of soluble domain of CA4 in complex with Dorzolamide
3F7B	;	2.05	;	Crystal Structure of soluble domain of CA4 in complex with small molecule.
3F7U	;	2.0	;	Crystal Structure of soluble domain of CA4 in complex with small molecule.
7OKV	;	1.85	;	Crystal structure of soluble EPCR after exposure to the nonionic surfactant Polysorbate 20
3I1Y	;	2.469	;	Crystal Structure of soluble epoxide Hydrolase
3I28	;	1.95	;	Crystal Structure of soluble epoxide Hydrolase
3KOO	;	2.791	;	Crystal Structure of soluble epoxide Hydrolase
3WK4	;	2.11	;	Crystal structure of soluble epoxide hydrolase in complex with fragment inhibitor
3WK5	;	2.77	;	Crystal structure of soluble epoxide hydrolase in complex with fragment inhibitor
3WK6	;	2.1	;	Crystal structure of soluble epoxide hydrolase in complex with fragment inhibitor
3WK7	;	2.2	;	Crystal structure of soluble epoxide hydrolase in complex with fragment inhibitor
3WK8	;	2.2	;	Crystal structure of soluble epoxide hydrolase in complex with fragment inhibitor
3WK9	;	2.2	;	Crystal structure of soluble epoxide hydrolase in complex with fragment inhibitor
3WKA	;	2.01	;	Crystal structure of soluble epoxide hydrolase in complex with fragment inhibitor
3WKB	;	2.2	;	Crystal structure of soluble epoxide hydrolase in complex with fragment inhibitor
3WKC	;	2.2	;	Crystal structure of soluble epoxide hydrolase in complex with fragment inhibitor
3WKD	;	2.48	;	Crystal structure of soluble epoxide hydrolase in complex with fragment inhibitor
3WKE	;	2.75	;	Crystal structure of soluble epoxide hydrolase in complex with t-AUCB
2D2Z	;	2.2	;	Crystal structure of Soluble Form Of CLIC4
7LGK	;	2.2	;	Crystal structure of soluble guanylate cyclase activator runcaciguat (BAY 1101042) bound to nostoc H-NOX domain
1E4K	;	3.2	;	CRYSTAL STRUCTURE OF SOLUBLE HUMAN IGG1 FC FRAGMENT-FC-GAMMA RECEPTOR III COMPLEX
6CF9	;	2.29	;	Crystal structure of soluble lytic transglycosylase Cj0843 of Campylobacter jejuni at 2.3A resolution in I23 space group
8GFJ	;	2.2	;	Crystal structure of soluble lytic transglycosylase Cj0843 of Campylobacter jejuni dose-response soaking with 1 mM concentration Z7285 inhibitor (no inhibitor binding observed)
8GFL	;	2.36	;	Crystal structure of soluble lytic transglycosylase Cj0843 of Campylobacter jejuni in complex with 4-Nitrophenyl N,N' diacetyl-beta-D-chitobioside inhibitor
6CFC	;	2.04	;	Crystal structure of soluble lytic transglycosylase Cj0843 of Campylobacter jejuni in complex with Bulgecin A
8GFB	;	2.17	;	Crystal structure of soluble lytic transglycosylase Cj0843 of Campylobacter jejuni in complex with Fv16b inhibitor
8GFC	;	2.48	;	Crystal structure of soluble lytic transglycosylase Cj0843 of Campylobacter jejuni in complex with Fv17b inhibitor
8GFQ	;	2.3	;	Crystal structure of soluble lytic transglycosylase Cj0843 of Campylobacter jejuni in complex with Fv32r inhibitor
8GEZ	;	1.99	;	Crystal structure of soluble lytic transglycosylase Cj0843 of Campylobacter jejuni in complex with LV8036 inhibitor
8GF0	;	1.89	;	Crystal structure of soluble lytic transglycosylase Cj0843 of Campylobacter jejuni in complex with LV8044 inhibitor
8GF1	;	1.92	;	Crystal structure of soluble lytic transglycosylase Cj0843 of Campylobacter jejuni in complex with LV8060 inhibitor
8GFP	;	2.07	;	Crystal structure of soluble lytic transglycosylase Cj0843 of Campylobacter jejuni in complex with N-acetyl-2,3-dehydro-2-deoxyneuraminic acid inhibitor
8GFS	;	2.38	;	Crystal structure of soluble lytic transglycosylase Cj0843 of Campylobacter jejuni in complex with siastatin B inhibitor
8GFD	;	1.86	;	Crystal structure of soluble lytic transglycosylase Cj0843 of Campylobacter jejuni in complex with Z3252 inhibitor
8GFE	;	2.42	;	Crystal structure of soluble lytic transglycosylase Cj0843 of Campylobacter jejuni in complex with Z3261 inhibitor
8GFF	;	1.9	;	Crystal structure of soluble lytic transglycosylase Cj0843 of Campylobacter jejuni in complex with Z7146 inhibitor
8GFH	;	1.83	;	Crystal structure of soluble lytic transglycosylase Cj0843 of Campylobacter jejuni in complex with Z7285 inhibitor soaked at 10 mM concentration
8GFI	;	2.15	;	Crystal structure of soluble lytic transglycosylase Cj0843 of Campylobacter jejuni in complex with Z7285 inhibitor soaked at 3 mM concentration
8GFG	;	2.48	;	Crystal structure of soluble lytic transglycosylase Cj0843 of Campylobacter jejuni in complex with Z7912 inhibitor
8GFM	;	2.38	;	Crystal structure of soluble lytic transglycosylase Cj0843 of Campylobacter jejuni in complex with zanamivir amine inhibitor
4ANR	;	1.84	;	Crystal structure of soluble lytic Transglycosylase SltB1 from Pseudomonas aeruginosa
4WSG	;	3.0	;	Crystal Structure of Soluble WR PIV5 F-GCNt
4EYK	;	1.9	;	Crystal structure of solute binding protein of ABC transporter from Rhodopseudomonas palustris BisB5 in complex with 3,4-dihydroxy benzoic acid
4EYG	;	1.86	;	Crystal structure of solute binding protein of ABC transporter from Rhodopseudomonas palustris BisB5 in complex with vanillic acid
4EYQ	;	1.96	;	Crystal structure of solute binding protein of ABC transporter from Rhodopseudomonas palustris HaA2 in complex with caffeic acid/3-(4-HYDROXY-PHENYL)PYRUVIC ACID
4EYO	;	1.69	;	Crystal structure of solute binding protein of ABC transporter from Rhodopseudomonas palustris HaA2 in complex with p-coumaric acid
4F06	;	1.3	;	Crystal structure of solute binding protein of ABC transporter from Rhodopseudomonas palustris HaA2 RPB_2270 in complex with P-HYDROXYBENZOIC ACID
4EY3	;	2.22	;	Crystal structure of solute binding protein of ABC transporter in complex with p-hydroxybenzoic acid
5GUB	;	1.78	;	Crystal structure of solute-binding protein complexed with sulfate group-free unsaturated chondroitin disaccharide
5GX6	;	1.81	;	Crystal structure of solute-binding protein complexed with unsaturated chondroitin disaccharide with a sulfate group at C-4 position of GalNAc
5GX7	;	1.991	;	Crystal structure of solute-binding protein complexed with unsaturated chondroitin disaccharide with a sulfate group at C-6 position of GalNAc
5XS8	;	1.952	;	Crystal structure of solute-binding protein complexed with unsaturated chondroitin disaccharide with two sulfate groups at C-4 and C-6 positions of GalNAc
6INZ	;	2.289	;	Crystal structure of solute-binding protein complexed with unsaturated hyaluronan disaccharide
5EYF	;	1.52	;	Crystal Structure of Solute-binding Protein from Enterococcus faecium with Bound Glutamate
5GX8	;	1.778	;	Crystal structure of solute-binding protein related to glycosaminoglycans
4R6Y	;	1.22	;	Crystal structure of solute-binding protein stm0429 from salmonella enterica subsp. enterica serovar typhimurium str. lt2, target efi-510776, a closed conformation, in complex with glycerol and acetate
1P0Q	;	2.43	;	Crystal structure of soman-aged human butyryl cholinesterase
1P0P	;	2.3	;	Crystal structure of soman-aged human butyryl cholinesterase in complex with the substrate analog butyrylthiocholine
4AXB	;	2.4	;	Crystal structure of soman-aged human butyrylcholinesterase in complex with 2-PAM
4B0O	;	2.35	;	Crystal structure of soman-aged human butyrylcholinesterase in complex with benzyl pyridinium-4-methyltrichloroacetimidate
4B0P	;	2.5	;	Crystal structure of soman-aged human butyrylcholinesterase in complex with methyl 2-(pentafluorobenzyloxyimino)pyridinium
7XNA	;	2.65	;	Crystal structure of somatostatin receptor 2 (SSTR2) with peptide antagonist CYN 154806
3D1M	;	1.7	;	Crystal Structure of Sonic Hedgehog Bound to the third FNIII domain of CDO
5JW7	;	2.849	;	Crystal structure of SopA-Trim56 complex
5CPC	;	2.15	;	Crystal structure of SopD, a type III secreted virulence effector from Salmonella enterica
5CQ9	;	3.0	;	Crystal structure of SopD2, a type III secreted virulence effector from Salmonella enterica
3WLA	;	1.9	;	Crystal Structure of sOPH Native
1K2W	;	2.4	;	Crystal structure of sorbitol dehydrogenase from R. sphaeroides
5O3Z	;	1.84	;	Crystal structure of Sorbitol-6-Phosphate 2-dehydrogenase SrlD from Erwinia amylovora
5KVA	;	1.827	;	Crystal Structure of sorghum caffeoyl-CoA O-methyltransferase (CCoAOMT)
3FN5	;	1.5	;	Crystal structure of sortase A (Spy1154) from Streptococcus pyogenes serotype M1 strain SF370
3FN7	;	1.75	;	Crystal structure of sortase A (Spy1154) from Streptococcus pyogenes serotype M1 strain SF370
1T2P	;	2.0	;	Crystal structure of Sortase A from Staphylococcus aureus
7V6K	;	1.57	;	Crystal structure of Sortase A from Streptococcus pyogenes in complex with ML346
3FN6	;	1.9	;	Crystal structure of sortase A from Streptococcus pyogenes serotype M1 strain SF370 with the active site Cys in its sulphenic acid form
1T2W	;	1.8	;	Crystal Structure of Sortase A in Complex with a LPETG peptide
1QX6	;	2.7	;	Crystal structure of Sortase B complexed with E-64
1QXA	;	2.5	;	Crystal structure of Sortase B complexed with Gly3
1QWZ	;	1.75	;	Crystal structure of Sortase B from S. aureus complexed with MTSET
4Y4Q	;	2.162	;	Crystal structure of sortase B from Type II pilus of Streptococcus pneumoniae
2W1J	;	1.24	;	CRYSTAL STRUCTURE OF SORTASE C-1 (SRTC-1) from Streptococcus pneumoniae
2WTS	;	1.3	;	Crystal structure of sortase C-1 (SrtC-1) mutant H131D from S. pneumoniae
2XWG	;	2.4	;	Crystal structure of sortase C-1 from Actinomyces oris (formerly Actinomyces naeslundii)
2W1K	;	2.14	;	Crystal Structure of Sortase C-3 (SRTC-3) from Streptococcus pneumoniae
4D7W	;	1.95	;	Crystal structure of sortase C1 (SrtC1) from Streptococcus agalactiae
5CUW	;	1.887	;	Crystal structure of Sortase E1 from Streptomyces coelicolor with tripeptide in the active site
3RE9	;	2.4	;	Crystal structure of sortaseC1 from Streptococcus suis
7AVI	;	1.93	;	Crystal structure of SOS1 in complex with compound 2
7AVL	;	1.718	;	Crystal structure of SOS1 in complex with compound 4
7AVS	;	2.28	;	Crystal structure of SOS1 in complex with compound 6
7AVT	;	1.88	;	Crystal structure of SOS1 in complex with compound 7
7AVU	;	2.1	;	Crystal structure of SOS1 in complex with compound 8
7AVV	;	2.12	;	Crystal structure of SOS1 in complex with compound 9
7UKR	;	2.5	;	Crystal Structure of SOS1 with MRTX0902, a Potent and Selective Inhibitor of the SOS1:KRAS Protein-Protein Interaction
7UKS	;	2.29	;	Crystal structure of SOS1 with phthalazine inhibitor bound (compound 15)
8BEA	;	2.47	;	Crystal structure of SOS1-HRas-peptidomimetic10
8BE6	;	2.8988	;	Crystal structure of SOS1-HRas-peptidomimetic2
8BE7	;	3.0	;	Crystal structure of SOS1-HRas-peptidomimetic3
8BE8	;	2.4	;	Crystal structure of SOS1-HRas-peptidomimetic4
8BE9	;	2.51	;	Crystal structure of SOS1-HRas-peptidomimetic5
8BE4	;	1.9	;	Crystal structure of SOS1-KRasG12V-Nanobody14
8BE5	;	3.13	;	Crystal structure of SOS1-KRasG12V-Nanobody22-Nanobody75
8BE2	;	1.89794	;	Crystal structure of SOS1-Nanobody77
7JJK	;	1.4	;	Crystal structure of SOX30
2ZHH	;	3.2	;	Crystal structure of SoxR
2ZHG	;	2.8	;	Crystal structure of SoxR in complex with DNA
2C1D	;	1.92	;	Crystal structure of SoxXA from P. pantotrophus
2VNX	;	1.5	;	Crystal structure of soybean ascorbate peroxidase mutant W41A after exposure to a high dose of x-rays
2VO2	;	1.9	;	Crystal structure of soybean ascorbate peroxidase mutant W41A subjected to low dose X-rays
1Q6C	;	1.86	;	Crystal Structure of Soybean Beta-Amylase Complexed with Maltose
1Q6E	;	1.95	;	Crystal Structure of Soybean Beta-Amylase Mutant (E178Y) with Increased pH Optimum at pH 5.4
1Q6F	;	2.1	;	Crystal Structure of Soybean Beta-Amylase Mutant (E178Y) with Increased pH Optimum at pH 7.1
1Q6D	;	2.0	;	Crystal structure of Soybean Beta-Amylase Mutant (M51T) with Increased pH Optimum
1Q6G	;	2.0	;	Crystal Structure of Soybean Beta-Amylase Mutant (N340T) with Increased pH Optimum
1UKO	;	2.1	;	Crystal structure of soybean beta-amylase mutant substituted at surface region
1UKP	;	2.1	;	Crystal structure of soybean beta-amylase mutant substituted at surface region
1UIK	;	2.3	;	Crystal structure of soybean beta-conglycinin alpha prime homotrimer
1UIJ	;	2.5	;	Crystal Structure Of Soybean beta-Conglycinin Beta Homotrimer (I122M/K124W)
2IUJ	;	2.4	;	Crystal Structure of Soybean Lipoxygenase-B
2IUK	;	2.4	;	Crystal structure of Soybean Lipoxygenase-D
1FXZ	;	2.8	;	CRYSTAL STRUCTURE OF SOYBEAN PROGLYCININ A1AB1B HOMOTRIMER
7ETR	;	3.804	;	Crystal structure of SO_1444-SO_1445 complex from Shewanella oneidensis
5YEP	;	3.0	;	Crystal structure of SO_3166-SO_3165 from Shewanella oneidensis
4R5H	;	1.8	;	Crystal structure of sp-Aspartate-Semialdehyde-Dehydrogenase with Nicotinamide-Adenine-Dinucleotide-Phosphate and 3-carboxy-propenyl-phthalic acid
1NE6	;	2.3	;	Crystal structure of Sp-cAMP binding R1a subunit of cAMP-dependent protein kinase
5GOT	;	1.902	;	Crystal structure of SP-PTP, low molecular weight protein tyrosine phosphatase from Streptococcus pyogenes
4R01	;	2.4	;	Crystal structure of SP1627, a putative NADH-flavin reductase, from Streptococcus pneumoniae TIGR4
2OYS	;	2.0	;	Crystal Structure of SP1951 protein from Streptococcus pneumoniae in complex with FMN, Northeast Structural Genomics Target SpR27
6CWC	;	1.9	;	Crystal structure of SpaA-SLH
7SV4	;	2.06	;	Crystal structure of SpaA-SLH in complex with 4,6-Pyr-beta-D-ManNAc-(1->4)-beta-D-GlcNAc-(1->3)-4,6-Pyr-beta-D-ManNAcOMe
7SV3	;	1.7	;	Crystal structure of SpaA-SLH in complex with 4,6-Pyr-beta-D-ManNAc-(1->4)-beta-D-GlcNAcOMe
6CWF	;	2.25	;	Crystal structure of SpaA-SLH in complex with 4,6-Pyr-beta-D-ManNAcOMe
6CWI	;	2.16	;	Crystal structure of SpaA-SLH in complex with 4,6-Pyr-beta-D-ManNAcOMe (C2)
6CWH	;	2.0	;	Crystal structure of SpaA-SLH in complex with 4,6-Pyr-beta-D-ManNAcOMe (P1)
6CWL	;	2.15	;	Crystal structure of SpaA-SLH in complex with beta-D-GlcNAc-(1->3)-4,6-Pyr-beta-D-ManNAcOMe
6CWM	;	1.15	;	Crystal structure of SpaA-SLH/G109A
7SV5	;	1.72	;	Crystal structure of SpaA-SLH/G109A in complex with 4,6-Pyr-beta-D-ManNAc-(1->4)-beta-D-GlcNAcOMe
6CWN	;	1.53	;	Crystal structure of SpaA-SLH/G109A in complex with 4,6-Pyr-beta-D-ManNAcOMe
7SV6	;	1.85	;	Crystal structure of SpaA-SLH/G46A/G109A in complex with 4,6-Pyr-beta-D-ManNAc-(1->4)-beta-D-GlcNAcOMe
6CWR	;	1.24	;	Crystal structure of SpaA-SLH/G46A/G109A in complex with 4,6-Pyr-beta-D-ManNAcOMe
7CBS	;	2.39	;	Crystal structure of SpaB basal pilin from Lactobacillus rhamnosus GG
4E57	;	2.0	;	Crystal Structure of spacer 6aa-shortened cephalosporin acylase mutant
4E56	;	2.2	;	Crystal Structure of spacer 8aa-shortened cephalosporin acylase mutant
4E55	;	2.3	;	Crystal Structure of spacer removed cephalosporin acylase mutant
6JCH	;	1.536	;	Crystal structure of SpaE basal pilin from Lactobacillus rhamnosus GG - Orthorhombic form
6JBV	;	1.712	;	Crystal structure of SpaE basal pilin from Lactobacillus rhamnosus GG - Selenium derivative
6JK7	;	3.204	;	Crystal structure of SpaE basal pilin from Lactobacillus rhamnosus GG - Trigonal form
5D9H	;	3.1	;	Crystal structure of SPAK (STK39) dimer in the basal activity state
5XWK	;	1.901	;	Crystal Structure of SPAP, an alkaline phosphatase from Sphingomonas in complex with inorganic phosphate
5XWI	;	1.872	;	Crystal Structure of SPAP, an alkaline phosphatase from Sphingomonas showing covalent intermediate
3Q3Q	;	1.953	;	Crystal Structure of SPAP: an novel alkaline phosphatase from bacterium Sphingomonas sp. strain BSAR-1
3EAB	;	2.5	;	Crystal structure of Spastin MIT in complex with ESCRT III
3IPV	;	2.04	;	Crystal structure of Spatholobus parviflorus seed lectin
3E07	;	2.4	;	Crystal structure of spatzle cystine knot
6I5O	;	1.33	;	Crystal structure of SPBc2 prophage-derived protein YomS
2Q6Q	;	1.97	;	Crystal structure of Spc42p, a critical component of spindle pole body in budding yeast
7Z4D	;	3.1	;	Crystal structure of SpCas9 bound to a 10 nucleotide complementary DNA substrate
5FW2	;	2.676	;	Crystal structure of SpCas9 variant EQR bound to sgRNA and TGAG PAM target DNA
5FW3	;	2.7	;	Crystal structure of SpCas9 variant VRER bound to sgRNA and TGCG PAM target DNA
6AI6	;	2.7	;	Crystal structure of SpCas9-NG
2Z34	;	2.4	;	Crystal structure of SpCia1/Asf1 complex with Hip1
2Z3F	;	2.7	;	Crystal structure of spCia1/Asf1 complexed with Cac2 peptide
7F00	;	2.7	;	Crystal structure of SPD_0310
3LMO	;	2.0	;	Crystal Structure of specialized acyl carrier protein (RPA2022) from Rhodopseudomonas palustris, Northeast Structural Genomics Consortium Target RpR324
5LC8	;	1.8	;	Crystal Structure of specific mutant from Pseudomonas aeruginosa Lipoxygenase at 1.8A resolution
5DWB	;	2.4	;	Crystal structure of specific restriction endonuclease AgeI-DNA complex
6SXJ	;	2.1	;	Crystal structure of spectinomycin adenyltransferase AAD(9) from Enterococcus faecialis
6XXQ	;	3.0	;	Crystal structure of spectinomycin adenyltransferase AAD(9) from Enterococcus faecialis with ATP and spectinomycin
6XZ0	;	2.8	;	Crystal structure of spectinomycin adenyltransferase AAD(9) from Enterococcus faecialis with spectinomycin
3I0O	;	2.4	;	Crystal Structure of Spectinomycin Phosphotransferase, APH(9)-Ia, in complex with ADP and Spectinomcyin
3Q2M	;	2.9	;	Crystal Structure of Spectinomycin Phosphotransferase, APH(9)-Ia, Protein Kinase Inhibitor CKI-7 Complex
6VFM	;	2.67	;	Crystal structure of SpeG allosteric polyamine acetyltransferase from Bacillus thuringiensis
6VFN	;	2.5	;	Crystal structure of SpeG allosteric polyamine acetyltransferase from Bacillus thuringiensis in complex with spermine
3O89	;	1.1	;	Crystal Structure of Sperm Whale Myoglobin G65T
2W6Y	;	1.6	;	Crystal structure of Sperm Whale Myoglobin mutant YQR in complex with Xenon
2W6X	;	1.73	;	Crystal structure of Sperm Whale Myoglobin mutant YQRF in complex with Xenon
7SPH	;	1.3	;	Crystal structure of sperm whale myoglobin variant sMb13(pCaaF) in space group P21
7SPG	;	1.3	;	Crystal structure of sperm whale myoglobin variant sMb13(pCaaF) in space group P212121
7SPE	;	1.7	;	Crystal structure of sperm whale myoglobin variant sMb5(O2beY)
7SPF	;	1.17	;	Crystal structure of sperm whale myoglobin variant sMb5(pCaaF)
3WR7	;	2.5	;	Crystal Structure of Spermidine Acetyltransferase from Escherichia coli
4LRO	;	1.98	;	Crystal structure of spermidine inhibited Ribosome inactivating protein from Momordica balsamina
4R9M	;	2.9	;	Crystal structure of spermidine N-acetyltransferase from Escherichia coli
4R57	;	2.079	;	Crystal structure of spermidine N-acetyltransferase from Vibrio cholerae in complex with acetyl-CoA
4R87	;	2.61	;	Crystal structure of spermidine N-acetyltransferase from Vibrio cholerae in complex with CoA and spermine
4MJ8	;	2.04	;	Crystal structure of spermidine N-acetyltransferase from Vibrio cholerae in complex with polyamine
4MHD	;	2.32	;	Crystal structure of spermidine N-acetyltransferase from Vibrio cholerae in complex with spermidine
4MI4	;	1.848	;	Crystal structure of spermidine N-acetyltransferase from Vibrio cholerae in complex with spermine
1IY9	;	2.3	;	Crystal structure of spermidine synthase
3O4F	;	2.9	;	Crystal Structure of Spermidine Synthase from E. coli
2CMG	;	2.0	;	Crystal Structure of Spermidine Synthase from Helicobacter Pylori
2CMH	;	2.3	;	Crystal Structure of Spermidine Synthase from Helicobacter Pylori
2PWP	;	2.1	;	Crystal structure of spermidine synthase from Plasmodium falciparum in complex with spermidine
3B7P	;	2.0	;	Crystal structure of spermidine synthase from Plasmodium falciparum in complex with spermine
2E5W	;	2.0	;	Crystal structure of spermidine synthase from Pyrococcus horikoshii OT3
2ZSU	;	2.2	;	Crystal structure of spermidine synthase from Pyrococcus horikoshii OT3, P1 form
1INL	;	1.5	;	Crystal Structure of Spermidine Synthase from Thermotoga Maritima
3BWC	;	2.3	;	Crystal structure of spermidine synthase from Trypanosoma cruzi in complex with SAM at 2.3 A resolution
1JQ3	;	1.8	;	Crystal Structure of Spermidine Synthase in Complex with Transition State Analogue AdoDATO
6CY6	;	1.75	;	Crystal structure of spermidine/spermine N-acetyltransferase SpeG from Escherichia coli in complex with tris(hydroxymethyl)aminomethane.
6CX8	;	2.41	;	Crystal structure of spermidine/spermine N-acetyltransferase SpeG from Vibrio cholerae in complex with manganese ions.
5WIF	;	2.5	;	Crystal structure of spermidine/spermine N-acetyltransferase SpeG from Yersinia pestis
6D72	;	2.17	;	Crystal structure of spermidine/spermine N-acetyltransferase SpeG from Yersinia pestis in complex with calcium ions.
4OMJ	;	1.6	;	Crystal structure of SPF bound to 2,3-oxidosqualene
4OMK	;	1.75	;	Crystal structure of SPF bound to squalene
5LSO	;	2.22	;	Crystal structure of SPF45 UHM domain with cyclic peptide inhibitor
7XXE	;	4.202	;	Crystal structure of spFft3 C-terminal truncation
7XWY	;	2.25	;	Crystal structure of spFft3 N-terminal truncation
8DY4	;	2.4	;	Crystal Structure of spFv CAT2200 HL
8DY5	;	2.2	;	Crystal Structure of spFv CAT2200 LH in complex with IL-17A
8DY2	;	1.65	;	Crystal Structure of spFv GLK1
8DY0	;	2.1	;	Crystal Structure of spFv GLK1 HL
8DY3	;	1.509	;	Crystal Structure of spFv GLK2 HL
6OR4	;	2.1	;	Crystal structure of SpGH29
6ORF	;	1.7	;	Crystal structure of SpGH29
6ORG	;	1.72	;	Crystal structure of SpGH29
6ORH	;	1.62	;	Crystal structure of SpGH29
5SWI	;	2.15	;	Crystal structure of SpGH92 in complex with mannose
2UX8	;	2.65	;	Crystal Structure of Sphingomonas elodea ATCC 31461 Glucose-1- phosphate uridylyltransferase in Complex with glucose-1-phosphate.
5TL4	;	1.751	;	Crystal structure of Sphingomonas paucimobilis aryl O-demethylase LigM
6OJR	;	2.3	;	Crystal structure of Sphingomonas paucimobilis TMY1009 apo-LsdA
6OJW	;	2.6	;	Crystal structure of Sphingomonas paucimobilis TMY1009 holo-LsdA
6OJT	;	3.0	;	Crystal structure of Sphingomonas paucimobilis TMY1009 LsdA phenylazophenol complex
3VLW	;	2.0	;	Crystal structure of Sphingomonas sp. A1 alginate-binding protein AlgQ1 in complex with mannuronate-guluronate disaccharide
3VLU	;	1.55	;	Crystal structure of Sphingomonas sp. A1 alginate-binding protein AlgQ1 in complex with saturated trimannuronate
3A09	;	1.4	;	Crystal structure of Sphingomonas sp. A1 alginate-binding protein AlgQ1 in complex with unsaturated trimannuronate
3VLV	;	1.5	;	Crystal structure of Sphingomonas sp. A1 alginate-binding ptotein AlgQ1 in complex with unsaturated triguluronate
6JBN	;	2.3	;	Crystal structure of Sphingomonas sp. A1 peroxidase EfeB responsible for import of iron
7CNE	;	2.0	;	Crystal Structure of Sphingomyelinase C from Streptomyces griseocarneus
2DDR	;	1.4	;	Crystal structure of sphingomyelinase from Bacillus cereus with calcium ion
2DDS	;	1.8	;	Crystal structure of sphingomyelinase from Bacillus cereus with cobalt ion
2DDT	;	1.8	;	Crystal structure of sphingomyelinase from Bacillus cereus with magnesium ion
3VZB	;	2.0	;	Crystal structure of Sphingosine Kinase 1
3VZC	;	2.3	;	Crystal structure of Sphingosine Kinase 1 with inhibitor
3VZD	;	2.3	;	Crystal structure of Sphingosine Kinase 1 with inhibitor and ADP
4L02	;	2.75	;	Crystal Structure of SphK1 with inhibitor
5DFS	;	1.15	;	Crystal structure of Spider Monkey Cytochrome C at 1.15 Angstrom
7SN0	;	3.08	;	Crystal structure of spike protein receptor binding domain of escape mutant SARS-CoV-2 from immunocompromised patient (d146*) in complex with human receptor ACE2
3SCJ	;	3.0	;	Crystal structure of spike protein receptor-binding domain from a predicted SARS coronavirus civet strain complexed with human receptor ACE2
3SCK	;	3.0	;	Crystal structure of spike protein receptor-binding domain from a predicted SARS coronavirus civet strain complexed with human-civet chimeric receptor ACE2
3SCI	;	2.9	;	Crystal structure of spike protein receptor-binding domain from a predicted SARS coronavirus human strain complexed with human receptor ACE2
3SCL	;	3.0	;	Crystal structure of spike protein receptor-binding domain from SARS coronavirus epidemic strain complexed with human-civet chimeric receptor ACE2
3D0H	;	3.1	;	Crystal structure of spike protein receptor-binding domain from the 2002-2003 SARS coronavirus civet strain complexed with human-civet chimeric receptor ACE2
3D0G	;	2.8	;	Crystal structure of spike protein receptor-binding domain from the 2002-2003 SARS coronavirus human strain complexed with human-civet chimeric receptor ACE2
3D0I	;	2.9	;	Crystal structure of spike protein receptor-binding domain from the 2005-2006 SARS coronavirus civet strain complexed with human-civet chimeric receptor ACE2
1ZYT	;	1.7	;	Crystal structure of spin labeled T4 Lysozyme (A82R1)
3G3X	;	1.8	;	Crystal structure of spin labeled T4 Lysozyme (T151R1) at 100 K
3G3W	;	2.3	;	Crystal structure of spin labeled T4 Lysozyme (T151R1) at 291 K
2CUU	;	1.75	;	Crystal structure of spin labeled T4 Lysozyme (V131R1)
3G3V	;	2.1	;	Crystal structure of spin labeled T4 Lysozyme (V131R1) at 291 K
1ZWN	;	1.8	;	Crystal structure of spin labeled T4 Lysozyme (V131R1B)
1ZUR	;	1.6	;	Crystal structure of spin labeled T4 Lysozyme (V131R1F)
2A4T	;	1.7	;	Crystal structure of spin labeled T4 Lysozyme (V131R7)
3L2X	;	1.8	;	Crystal Structure of Spin Labeled T4 Lysozyme Mutant 115-119RX
3K2R	;	1.5	;	Crystal Structure of Spin Labeled T4 Lysozyme Mutant K65V1/R76V1
2W8H	;	2.76	;	Crystal structure of spin labeled Wza24-345.
4BWW	;	1.48	;	Crystal structure of spin labelled azurin T21R1.
7A5C	;	2.2	;	Crystal structure of spin labelled VcSiaP R125A bound to an artificial peptide ligand.
3RGM	;	2.6	;	Crystal structure of spin-labeled BtuB T156R1
3M8B	;	2.44	;	Crystal structure of spin-labeled BtuB V10R1 in the apo state
3M8D	;	2.44	;	Crystal structure of spin-labeled BtuB V10R1 with bound calcium and cyanocobalamin
3RGN	;	2.3	;	Crystal structure of spin-labeled BtuB W371R1
5UUI	;	1.4	;	Crystal Structure of Spin-Labeled T77C TNFa
1KMH	;	3.4	;	Crystal Structure of spinach chloroplast F1-ATPase complexed with tentoxin
1SPI	;	2.8	;	CRYSTAL STRUCTURE OF SPINACH CHLOROPLAST FRUCTOSE-1,6-BISPHOSPHATASE AT 2.8 ANGSTROMS RESOLUTION
1RWT	;	2.72	;	Crystal Structure of Spinach Major Light-harvesting complex at 2.72 Angstrom Resolution
3PL9	;	2.8	;	Crystal structure of spinach minor light-harvesting complex CP29 at 2.80 angstrom resolution
1IR1	;	1.8	;	Crystal Structure of Spinach Ribulose-1,5-Bisphosphate Carboxylase/Oxygenase (Rubisco) Complexed with CO2, Mg2+ and 2-Carboxyarabinitol-1,5-Bisphosphate
6B14	;	1.64	;	Crystal structure of Spinach RNA aptamer in complex with Fab BL3-6S97N
2NS2	;	2.2	;	Crystal Structure of Spindlin1
5JSG	;	2.5	;	Crystal structure of Spindlin1 bound to compound EML405
5JSJ	;	2.348	;	Crystal structure of Spindlin1 bound to compound EML631
7BQZ	;	3.101	;	Crystal Structure of Spindlin1 bound to H3(K4me3-K9me3) peptide
7EA1	;	2.7	;	Crystal Structure of Spindlin1 bound to SPINDOC Docpep2
7E9M	;	2.5	;	Crystal Structure of Spindlin1 bound to SPINDOC Docpep3
6QPL	;	1.6	;	Crystal structure of Spindlin1 in complex with the inhibitor MS31
6I8L	;	1.58	;	Crystal structure of Spindlin1 in complex with the inhibitor TD001851a
6I8B	;	1.76	;	Crystal structure of Spindlin1 in complex with the inhibitor VinSpinIn
7OCB	;	1.42	;	Crystal structure of Spindlin1 in complex with the inhibitor XY49-92B
6I8Y	;	1.52	;	Crystal structure of Spindlin1 in complex with the Methyltransferase inhibitor A366
7BU9	;	3.502	;	Crystal Structure of Spindlin1-H3(K4me3-K9me2) complex
7CNA	;	1.6	;	Crystal structure of Spindlin1/C11orf84 complex bound to histone H3K4me3K9me3 peptide
7Y4I	;	2.85	;	Crystal structure of SPINDLY in complex with GDP
4CDZ	;	2.503	;	Crystal Structure of Spinosyn Rhamnosyl 4'-O-Methyltransferase SpnH from Saccharopolyspora spinosa
5I10	;	2.0	;	Crystal structure of spinosyn rhamnosyl 4'-O-methyltransferase spnh mutant T242Q from Saccharopolyspora Spinosa
3RBW	;	3.2	;	Crystal structure of Spire KIND domain
3R7G	;	2.2	;	Crystal structure of Spire KIND domain in complex with the tail of FMN2
4INK	;	1.56	;	Crystal structure of SplD protease from Staphylococcus aureus at 1.56 A resolution
4INL	;	2.1	;	Crystal structure of SplD protease from Staphylococcus aureus at 2.1 A resolution
8ABV	;	1.683	;	Crystal structure of SpLdpA in complex with erythro-DGPD
8ABW	;	1.83	;	Crystal structure of SpLdpA in complex with threo-DGPD
6HM7	;	1.64	;	CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A 2-(PHENOXYMETHYL)PYRIDINE INHIBITOR
6HM6	;	2.1	;	CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A 2-(PYRIDINYLOXYMETHYL)PYRIDINE INHIBITOR
3SRV	;	1.95	;	Crystal structure of spleen tyrosine kinase (SYK) in complex with a diaminopyrimidine carboxamide inhibitor
4PV0	;	2.0	;	Crystal structure of spleen tyrosine kinase (Syk) in complex with an imidazopyrazine inhibitor
4PUZ	;	2.085	;	Crystal structure of spleen tyrosine kinase (Syk) in complex with GS-9973
4I0R	;	2.1	;	Crystal structure of spleen tyrosine kinase complexed with 2-(3,4,5-Trimethoxy-phenyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide
4I0T	;	1.7	;	Crystal structure of spleen tyrosine kinase complexed with 2-(5,6,7,8-Tetrahydro-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid tert-butylamide
4I0S	;	1.98	;	Crystal structure of spleen tyrosine kinase complexed with 2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide
4FYN	;	2.318	;	Crystal structure of spleen tyrosine kinase complexed with 3-(8-{4-[Ethyl-(2-hydroxy-ethyl)-amino]-phenylamino}-imidazo[1,2-a]pyrazin-5-yl)-phenol
4FZ7	;	1.75	;	Crystal structure of spleen tyrosine kinase complexed with 6-((1R,2S)-2-Amino-cyclohexylamino)-4-(6-ethyl-pyridin-2-ylamino)-pyridazine-3-carboxylic acid amide
3FQH	;	2.26	;	Crystal structure of spleen tyrosine kinase complexed with a 2-substituted 7-azaindole
4DFL	;	1.98	;	Crystal structure of spleen tyrosine kinase complexed with a sulfonamidopyrazine piperidine inhibitor
4DFN	;	2.48	;	Crystal structure of spleen tyrosine kinase complexed with an adamantylpyrazine inhibitor
4FYO	;	1.4	;	Crystal structure of spleen tyrosine kinase complexed with N-{(S)-1-[7-(3,4-Dimethoxy-phenylamino)-thiazolo[5,4-d]pyrimidin-5-yl]-pyrrolidin-3-yl}-terephthalamic acid
3FQS	;	2.1	;	Crystal structure of spleen tyrosine kinase complexed with R406
4GFG	;	2.35	;	Crystal structure of spleen tyrosine kinase complexed with r9021
3FQE	;	2.5	;	Crystal structure of spleen tyrosine kinase complexed with YM193306
4FZ6	;	1.85	;	Crystal structure of spleen tyrosine kinase complexed with [6-((S)-2-Methyl-pyrrolidin-1-yl)-pyridin-2-yl]-(6-phenyl-imidazo[1,2-b]pyridazin-8-yl)-amine
3VF8	;	2.08	;	Crystal Structure of Spleen Tyrosine Kinase Syk Catalytic Domain with Pyrazolylbenzimidazole Inhibitor 416
3VF9	;	2.3	;	Crystal Structure of Spleen Tyrosine Kinase Syk Catalytic Domain with Thienopyrazolylindole Inhibitor 027
4KF5	;	2.599	;	Crystal Structure of Split GFP complexed with engineered sfCherry with an insertion of GFP fragment
6OFO	;	2.603	;	Crystal structure of split green fluorescent protein (GFP); s10 circular permutant (194-195)
4EMG	;	2.7	;	Crystal structure of SpLsm3
4EMH	;	2.2	;	Crystal structure of SpLsm4
4EMK	;	2.3	;	Crystal structure of SpLsm5/6/7
5I7L	;	2.598	;	Crystal Structure of SPLUNC1 Disulfide Mutant M2 (A48C, V253C)
3O8Z	;	2.15	;	Crystal structure of Spn1 (Iws1) core domain
5CL2	;	2.3	;	Crystal structure of Spo0M, sporulation control protein, from Bacillus subtilis.
6Q2V	;	2.594	;	Crystal structure of SPOC domain of human PHD-finger protein 3 (PHF3)
5CG0	;	2.09	;	Crystal structure of Spodoptera frugiperda Beta-glycosidase
4H0N	;	2.712	;	Crystal structure of Spodoptera frugiperda DNMT2 E260A/E261A/K263A mutant
3UZ0	;	2.82	;	Crystal Structure of SpoIIIAH and SpoIIQ Complex
1IXM	;	2.6	;	CRYSTAL STRUCTURE OF SPOOB FROM BACILLUS SUBTILIS
1NAT	;	2.45	;	CRYSTAL STRUCTURE OF SPOOF FROM BACILLUS SUBTILIS
7D3D	;	1.45	;	Crystal structure of SPOP bound with a peptide
1VLI	;	2.38	;	Crystal structure of Spore coat polysaccharide biosynthesis protein spsE (BSU37870) from Bacillus subtilis at 2.38 A resolution
4L3K	;	1.88	;	Crystal structure of Sporosarcina pasteurii UreE bound to Ni2+ and Zn2+
2X8K	;	2.95	;	Crystal Structure of SPP1 Dit (gp 19.1) Protein, a Paradigm of Hub Adsorption Apparatus in Gram-positive Infecting Phages.
3GDB	;	1.87	;	Crystal structure of Spr0440 glycoside hydrolase domain, Endo-D from Streptococcus pneumoniae R6
7C5Z	;	1.5	;	Crystal structure of spring viremia of carp virus phosphoprotein central domain
5XJ1	;	1.753	;	Crystal structure of spRlmCD
5ZQ1	;	3.1	;	Crystal structure of spRlmCD with U1939loop RNA at 3.10 angstrom
5ZTH	;	3.24	;	Crystal structure of spRlmCD with U1939loop RNA at 3.24 angstrom
5ZQ8	;	2.18	;	Crystal structure of spRlmCD with U747 stemloop RNA
5ZQ0	;	2.0	;	Crystal structure of spRlmCD with U747loop RNA
7B2S	;	1.5	;	Crystal structure of SPRY domain of TRIM9
5XN3	;	1.34	;	Crystal structure of SPSB2 in complex with a rational designed RGD containing cyclic peptide inhibitor of SPSB2-iNOS interaction
3LPE	;	1.9	;	Crystal structure of Spt4/5NGN heterodimer complex from Methanococcus jannaschii
4JWG	;	2.5	;	Crystal structure of spTrm10(74)
4JWF	;	2.4	;	Crystal structure of spTrm10(74)-SAH complex
4JWH	;	2.04	;	Crystal structure of spTrm10(Full length)-SAH complex
3TTM	;	2.0	;	Crystal structure of SpuD in complex with putrescine
6IKM	;	3.398	;	Crystal structure of SpuE-Spermidine in complex with ScFv5
1Z3E	;	1.5	;	Crystal Structure of Spx in Complex with the C-terminal Domain of the RNA Polymerase Alpha Subunit
6GHO	;	1.79	;	Crystal structure of Spx in complex with YjbH
6GHB	;	3.104	;	Crystal structure of Spx in complex with YjbH (oxidized)
3O39	;	2.599	;	Crystal Structure of SPY
3PSQ	;	2.32	;	Crystal structure of Spy0129, a Streptococcus pyogenes class B sortase involved in pilus biogenesis
5FW1	;	2.499	;	Crystal structure of SpyCas9 variant VQR bound to sgRNA and TGAG PAM target DNA
5VW1	;	2.598	;	Crystal structure of SpyCas9-sgRNA-AcrIIA4 ternary complex
7OFY	;	1.7	;	Crystal structure of SQ binding protein from Agrobacterium tumefaciens in complex with sulfoquinovosyl glycerol (SQGro)
1QRR	;	1.6	;	CRYSTAL STRUCTURE OF SQD1 PROTEIN COMPLEX WITH NAD AND UDP-GLUCOSE
5AMS	;	3.35	;	Crystal structure of Sqt1
4ZN4	;	1.94	;	Crystal structure of Sqt1 from Chaetomium thermophilum solved by MR
4HD1	;	2.4	;	Crystal structure of squalene synthase HpnC from Alicyclobacillus acidocaldarius
7KVU	;	2.68	;	Crystal structure of Squash RNA aptamer in complex with DFHBI-1T
7KVV	;	2.85	;	Crystal structure of Squash RNA aptamer in complex with DFHBI-1T
7KVT	;	2.73	;	Crystal structure of Squash RNA aptamer in complex with DFHBI-1T with iridium (III) ions
6BK9	;	3.00006	;	Crystal Structure of Squid Arrestin
2IAX	;	1.1	;	Crystal structure of squid ganglion DFPase D232S mutant
2IAP	;	1.9	;	Crystal structure of squid ganglion DFPase E21Q mutant
2IAO	;	2.0	;	Crystal structure of squid ganglion DFPase E37Q mutant
2IAV	;	1.07	;	Crystal structure of squid ganglion DFPase H287A mutant
2IAW	;	1.74	;	Crystal structure of squid ganglion DFPase N175D mutant
2IAQ	;	2.1	;	Crystal structure of squid ganglion DFPase S271A mutant
2IAS	;	2.0	;	Crystal structure of squid ganglion DFPase W244F mutant
2IAR	;	1.9	;	Crystal structure of squid ganglion DFPase W244H mutant
2IAT	;	1.9	;	Crystal structure of squid ganglion DFPase W244L mutant
2IAU	;	2.0	;	Crystal structure of squid ganglion DFPase W244Y mutant
4YD9	;	3.0	;	Crystal structure of squid hemocyanin
3AYN	;	2.7	;	Crystal structure of squid isorhodopsin
3I5F	;	3.1	;	Crystal structure of squid MG.ADP myosin S1
2Z73	;	2.5	;	Crystal structure of squid rhodopsin
2ZIY	;	3.7	;	Crystal structure of squid rhodopsin
3BEG	;	2.9	;	Crystal structure of SR protein kinase 1 complexed to its substrate ASF/SF2
6XKB	;	1.6	;	Crystal structure of SR-related and CTD-associated factor 4(SCAF4-CID)with peptide S2,S5p-CTD
4R06	;	2.22	;	Crystal Structure of SR2067 bound to PPARgamma
1YOJ	;	1.95	;	Crystal structure of Src kinase domain
1YOL	;	2.3	;	Crystal structure of Src kinase domain in complex with CGP77675
2HWO	;	2.5	;	Crystal structure of Src kinase domain in complex with covalent inhibitor
2HWP	;	2.48	;	Crystal structure of Src kinase domain in complex with covalent inhibitor PD168393
1YOM	;	2.9	;	Crystal structure of Src kinase domain in complex with Purvalanol A
2QLQ	;	2.33	;	Crystal structure of SRC kinase domain with covalent inhibitor RL3
1NZL	;	1.9	;	Crystal Structure of Src SH2 domain bound to doubly phosphorylated peptide PQpYEpYIPI
1NZV	;	2.1	;	Crystal Structure of Src SH2 domain bound to doubly phosphorylated peptide PQpYIpYVPA
8J8D	;	1.51	;	Crystal structure of SRCR domain 11 of DMBT1
2GNC	;	1.8	;	Crystal structure of srGAP1 SH3 domain in the slit-robo signaling pathway
5I6J	;	2.7	;	Crystal Structure of SRGAP2 F-BARx
5I6R	;	2.15	;	Crystal Structure of srGAP2 F-BARx WT Form-1
5I7D	;	3.95	;	Crystal Structure of srGAP2 F-BARx WT Form-2
5GJP	;	2.5	;	Crystal structure of SrLDC in complex with PLP and Cadaverine
5GJO	;	1.8	;	Crystal structure of SrLDC mutant (A225C/T302C) in complex with PLP
2OAJ	;	2.4	;	Crystal structure of Sro7 from S. cerevisiae
1L9A	;	2.9	;	CRYSTAL STRUCTURE OF SRP19 IN COMPLEX WITH THE S DOMAIN OF SIGNAL RECOGNITION PARTICLE RNA
7DD1	;	2.05	;	Crystal structure of SRPK1 in complex with a peptide inhibitor
5MY8	;	1.7	;	Crystal structure of SRPK1 in complex with SPHINX31
5MYV	;	2.9	;	Crystal structure of SRPK2 in complex with compound 1
8DDP	;	1.591	;	Crystal structure of SRS57 from Toxoplasma gondii
7K1U	;	2.4	;	Crystal Structure of SrtB-anchored Collagen-binding Adhesin Fragment (residues 206-565) from Clostridioides difficile strain 630
6EDB	;	3.209	;	Crystal structure of SRY.hcGAS-21bp dsDNA complex
4NPH	;	2.09	;	Crystal structure of SsaN from Salmonella enterica
5D8F	;	2.35	;	crystal structure of SSB and ssDNA complex from homo sapiens
5YUN	;	2.67	;	Crystal structure of SSB complexed with myc
7VUM	;	2.319	;	Crystal structure of SSB complexed with que
5D8E	;	3.0	;	crystal structure of SSB from homo sapiens
7F2N	;	2.35	;	Crystal structure of SSB from Klebsiella pneumonia.
7F25	;	2.87	;	Crystal structure of SSB from Salmonella enterica serovar Typhimurium LT2.
5YUO	;	2.037	;	Crystal structure of SSB protein from Pseudomonas aeruginosa PAO1
3HP9	;	1.6	;	Crystal structure of SSB/Exonuclease I in complex with inhibitor CFAM
6S9R	;	2.4	;	Crystal structure of SSDP from D. melanogaster
4FZR	;	2.397	;	Crystal Structure of SsfS6, Streptomyces sp. SF2575 glycosyltransferase
3CM1	;	2.6	;	Crystal structure of SsgA-like sporulation-specific cell division protein (YP_290167.1) from Thermobifida fusca YX-ER1 at 2.60 A resolution
3KXI	;	2.65	;	crystal structure of SsGBP and GDP complex
3KXK	;	2.35	;	Crystal structure of SsGBP mutation variant G235P
3KXL	;	2.5	;	crystal structure of SsGBP mutation variant G235S
4BMH	;	1.5	;	Crystal structure of SsHAT
3WJ1	;	1.5	;	Crystal structure of SSHESTI
4P9N	;	1.8	;	Crystal structure of sshesti PE mutant
4XQ3	;	2.6	;	Crystal structure of Sso-SmAP2
4IC1	;	2.35	;	Crystal structure of SSO0001
4HW0	;	2.0	;	Crystal structure of Sso10a-2, a DNA-binding protein from Sulfolobus solfataricus
2W0M	;	2.0	;	Crystal Structure of sso2452 from Sulfolobus solfataricus P2
2X3D	;	2.7	;	Crystal Structure of SSo6206 from Sulfolobus solfataricus P2
5VSA	;	2.0	;	Crystal structure of SsoPox AsA1 mutant (C258L-I261F-W263A)
5VRI	;	2.15	;	Crystal structure of SsoPox AsA6 mutant (F46L-C258A-W263M-I280T) - closed form
5VRK	;	1.4	;	Crystal structure of SsoPox AsA6 mutant (F46L-C258A-W263M-I280T) - open form
5W3U	;	2.5	;	Crystal structure of SsoPox AsB5 mutant (V27A-I76T-Y97W-Y99F-L130P-L226V)
5W3Z	;	2.55	;	Crystal structure of SsoPox AsC6 mutant (L72I-Y99F-I122L-L228M-F229S-W263L)
5W3W	;	2.95	;	Crystal structure of SsoPox AsD6 mutant (V27A-Y97W-L228M-W263M) - open form
3UF9	;	2.68	;	Crystal structure of SsoPox in complex with the phosphotriester fensulfothion
4KEZ	;	1.85	;	Crystal structure of SsoPox W263F
4KET	;	2.0	;	Crystal structure of SsoPox W263I
4KF1	;	2.0	;	Crystal structure of SsoPox W263I in complex with C10HTL
4KEV	;	2.65	;	Crystal structure of SsoPox W263L
4KEU	;	2.2	;	Crystal structure of SsoPox W263M
4KES	;	2.1	;	Crystal structure of SsoPox W263T
4KER	;	2.6	;	Crystal structure of SsoPox W263V
6FRH	;	2.03	;	Crystal structure of Ssp DnaB Mini-Intein variant M86
3FOJ	;	1.6	;	Crystal Structure of SSP1007 From Staphylococcus saprophyticus subsp. saprophyticus. Northeast Structural Genomics Target SyR101A.
1OX8	;	2.2	;	Crystal structure of SspB
1OX9	;	2.9	;	Crystal structure of SspB-ssrA complex
4NKH	;	2.75	;	Crystal structure of SspH1 LRR domain
4NKG	;	2.9	;	Crystal structure of SspH1 LRR domain in complex PKN1 HR1b domain
7XN9	;	2.6	;	Crystal structure of SSTR2 and L-054,522 complex
3OMX	;	2.3366	;	Crystal structure of Ssu72 with vanadate complex
3OMW	;	2.8701	;	Crystal structure of Ssu72, an essential eukaryotic phosphatase specific for the C-terminal domain of RNA polymerase II
6DQP	;	1.546	;	Crystal structure of SsuE FMN reductase Delta118 mutant in apo form
6DQI	;	1.95	;	Crystal structure of SsuE FMN reductase Y118A mutant in apo form.
6DQO	;	1.705	;	Crystal structure of SsuE FMN reductase Y118A mutant in FMN bound form.
1TBX	;	2.7	;	Crystal structure of SSV1 F-93
5I8F	;	1.3	;	Crystal structure of St. John's wort Hyp-1 protein in complex with melatonin
1WSC	;	2.45	;	Crystal structure of ST0229, function unknown protein from Sulfolobus tokodaii
2DGD	;	2.9	;	Crystal structure of ST0656, a function unknown protein from Sulfolobus tokodaii
1WOL	;	1.62	;	Crystal Structure of ST0689, an archaeal HEPN homologue
3GFI	;	2.1	;	Crystal structure of ST1710 complexed with its promoter DNA
2D1H	;	2.05	;	Crystal structure of ST1889 protein from thermoacidophilic archaeon Sulfolobus tokodaii
2EF7	;	2.1	;	Crystal structure of ST2348, a hypothetical protein with CBS domains from Sulfolobus tokodaii strain7
3BXW	;	2.7	;	Crystal Structure of Stabilin-1 Interacting Chitinase-Like Protein, SI-CLP
3TRT	;	2.3	;	Crystal structure of stabilised vimentin coil2 fragment
5N2S	;	3.303	;	Crystal structure of stabilized A1 receptor in complex with PSB36 at 3.3A resolution
5MZP	;	2.1	;	Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with caffeine at 2.1A resolution
6ZDR	;	1.918	;	Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with Chromone 4d
6ZDV	;	2.13	;	Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with Chromone 5d
8CIC	;	2.102	;	Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with clinical candidate Etrumadenant
5IUA	;	2.2	;	Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with compound 12b at 2.2A resolution
5IU7	;	1.9	;	Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with compound 12c at 1.9A resolution
5IU8	;	2.002	;	Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with compound 12f at 2.0A resolution
5IUB	;	2.1	;	Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with compound 12x at 2.1A resolution
5N2R	;	2.8	;	Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with PSB36 at 2.8A resolution
5MZJ	;	2.0	;	Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with theophylline at 2.0A resolution
5IU4	;	1.72	;	Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with ZM241385 at 1.7A resolution
6GWQ	;	2.32	;	Crystal Structure of Stabilized Active Plasminogen Activator Inhibitor-1 (PAI-1-stab) in Complex with an Inhibitory Nanobody (VHH-2g-42)
6GWP	;	2.28	;	Crystal Structure of Stabilized Active Plasminogen Activator Inhibitor-1 (PAI-1-stab) in Complex with Two Inhibitory Nanobodies (VHH-2g-42, VHH-2w-64)
6ZRV	;	1.88	;	Crystal Structure of Stabilized Active Plasminogen Activator Inhibitor-1 (PAI-1-W175F) in Complex with an Inhibitory Nanobody (VHH-s-a93, Nb93)
6GWN	;	2.03	;	Crystal Structure of Stabilized Active Plasminogen Activator Inhibitor-1 (PAI-1-W175F) in Complex with Two Inhibitory Nanobodies (VHH-2g-42, VHH-2w-64)
6VKM	;	3.5	;	Crystal Structure of Stabilized GP from Makona Variant of Ebola Virus
7QA4	;	2.19	;	Crystal structure of stabilized H3N2 A/Hong Kong/1/1968 Hemagglutinin at 2.2 Angstrom
3U74	;	2.39	;	Crystal structure of stabilized human uPAR mutant
3U73	;	3.19	;	Crystal structure of stabilized human uPAR mutant in complex with ATF
6L6O	;	1.8	;	Crystal structure of stabilized Rab5a GTPase domain from Leishmania donovani
4IBX	;	2.68	;	Crystal structure of stabilized TEM-1 beta-lactamase variant v.13
4OPR	;	1.45	;	Crystal structure of stabilized TEM-1 beta-lactamase variant v.13 carrying G238S mutation
4OPZ	;	1.45	;	Crystal structure of stabilized TEM-1 beta-lactamase variant v.13 carrying G238S mutation in complex with boron-based inhibitor EC25
4IBR	;	2.2	;	Crystal structure of stabilized TEM-1 beta-lactamase variant v.13 carrying G238S/E104K mutations
4OP5	;	1.05	;	Crystal structure of stabilized TEM-1 beta-lactamase variant v.13 carrying R164S mutation
4OQH	;	1.7	;	Crystal structure of stabilized TEM-1 beta-lactamase variant v.13 carrying R164S mutation in complex with boron-based inhibitor EC25
4OQ0	;	1.42	;	Crystal structure of stabilized TEM-1 beta-lactamase variant v.13 carrying R164S/G238S mutation in complex with boron-based inhibitor EC25
4OQI	;	1.13	;	Crystal structure of stabilized TEM-1 beta-lactamase variant v.13 carrying R164S/G238S mutations
3AHP	;	2.7	;	Crystal structure of stable protein, CutA1, from a psychrotrophic bacterium Shewanella sp. SIB1
4QUQ	;	2.266	;	Crystal structure of stachydrine demethylase in complex with azide
4QUR	;	1.759	;	Crystal Structure of stachydrine demethylase in complex with cyanide, oxygen, and N-methyl proline in a new orientation
4QUP	;	1.7	;	Crystal structure of stachydrine demethylase with N-methyl proline from low X-ray dose composite datasets
3RNR	;	2.0	;	Crystal Structure of Stage II Sporulation E Family Protein from Thermanaerovibrio acidaminovorans
3LM6	;	2.5	;	Crystal Structure of Stage V sporulation protein AD (spoVAD) from Bacillus subtilis, Northeast Structural Genomics Consortium Target SR525
2OV8	;	2.58	;	Crystal Structure of StaL
2OVF	;	2.95	;	Crystal Structure of StaL-PAP complex
2OVB	;	2.61	;	Crystal Structure of StaL-sulfate complex
1OQD	;	2.6	;	Crystal structure of sTALL-1 and BCMA
1JH5	;	3.0	;	Crystal Structure of sTALL-1 of TNF family ligand
1OQE	;	2.5	;	Crystal structure of sTALL-1 with BAFF-R
1UJ0	;	1.7	;	Crystal Structure of STAM2 SH3 domain in complex with a UBPY-derived peptide
7L97	;	2.01	;	Crystal structure of STAMBPL1 in complex with an engineered binder
4URM	;	2.94	;	Crystal Structure of Staph GyraseB 24kDa in complex with Kibdelomycin
4URO	;	2.59	;	Crystal Structure of Staph GyraseB 24kDa in complex with Novobiocin
4URN	;	2.3	;	Crystal Structure of Staph ParE 24kDa in complex with Novobiocin
4URL	;	2.29	;	Crystal Structure of Staph ParE43kDa in complex with KBD
3FY8	;	2.2	;	Crystal Structure of Staph. aureus DHFR complexed with NADPH and AR-101
1XAH	;	2.2	;	CRYSTAL STRUCTURE OF STAPHLYOCOCCUS AUREUS 3-DEHYDROQUINATE SYNTHASE (DHQS) IN COMPLEX WITH ZN2+ AND NAD+
1XAG	;	2.45	;	CRYSTAL STRUCTURE OF STAPHLYOCOCCUS AUREUS 3-DEHYDROQUINATE SYNTHASE (DHQS) IN COMPLEX WITH ZN2+, NAD+ AND CARBAPHOSPHONATE
1XAI	;	2.3	;	CRYSTAL STRUCTURE OF STAPHLYOCOCCUS AUREUS 3-DEHYDROQUINATE SYNTHASE (DHQS) IN COMPLEX WITH ZN2+, NAD+ AND CARBAPHOSPHONATE
1XAJ	;	2.35	;	CRYSTAL STRUCTURE OF STAPHLYOCOCCUS AUREUS 3-DEHYDROQUINATE SYNTHASE (DHQS) IN COMPLEX WITH ZN2+, NAD+ AND CARBAPHOSPHONATE
1XAL	;	2.8	;	CRYSTAL STRUCTURE OF STAPHLYOCOCCUS AUREUS 3-DEHYDROQUINATE SYNTHASE (DHQS) IN COMPLEX WITH ZN2+, NAD+ AND CARBAPHOSPHONATE (SOAK)
8OIG	;	1.58	;	Crystal Structure of Staphopain C from Staphylococcus aureus
4YIJ	;	1.64	;	Crystal structure of Staphylcoccal nuclease variant Delta+PHS A109E at cryogenic temperature
4PMC	;	1.65	;	Crystal structure of Staphylcoccal nuclease variant Delta+PHS I72K V74K at cryogenic temperature
4TRD	;	1.6	;	Crystal structure of Staphylcoccal nuclease variant Delta+PHS I72K/V74K at pH 9.0 at cryogenic temperature
4PMB	;	1.8	;	Crystal structure of Staphylcoccal nuclease variant Delta+PHS I92S at cryogenic temperature
6EEG	;	1.95	;	Crystal structure of Staphylcoccal nuclease variant Delta+PHS T62E at cryogenic temperature
4WRD	;	1.65	;	Crystal structure of Staphylcoccal nulease variant Delta+PHS V66E L125E at cryogenic temperature
2RDF	;	2.01	;	Crystal Structure of staphyloccocal nuclease VIAGAN/E75A variant at cryogenic temperature
1QXW	;	1.67	;	Crystal structure of Staphyloccocus aureus in complex with an aminoketone inhibitor 54135.
2QFF	;	1.8	;	Crystal structure of Staphylococcal Complement Inhibitor
3T46	;	1.5	;	Crystal structure of Staphylococcal Complement Inhibitor D (SCIN-D) at 1.5 Angstrom
4H6I	;	3.091	;	Crystal Structure of Staphylococcal Complement Inhibitor SCIN-B
4H6H	;	2.5024	;	Crystal Structure of Staphylococcal Complement Inhibitor SCIN-B(4-85)
3W2D	;	3.1	;	Crystal Structure of Staphylococcal Eenterotoxin B in complex with a novel neutralization monoclonal antibody Fab fragment
5FK9	;	3.1	;	Crystal structure of staphylococcal enterotoxin A F47A mutant in complex with a T cell receptor
1I4G	;	2.1	;	Crystal structure of Staphylococcal enterotoxin A mutant H187A with reduced Zn2+ affinity
3R8B	;	2.95	;	Crystal structure of Staphylococcal Enterotoxin B in complex with an affinity matured mouse TCR VBeta8.2 protein, G5-8
1CQV	;	2.06	;	CRYSTAL STRUCTURE OF STAPHYLOCOCCAL ENTEROTOXIN C2 AT 100K CRYSTALLIZED AT PH 5.0
1I4P	;	2.0	;	CRYSTAL STRUCTURE OF STAPHYLOCOCCAL ENTEROTOXIN C2 AT 100K CRYSTALLIZED AT PH 5.5
1I4Q	;	2.2	;	CRYSTAL STRUCTURE OF STAPHYLOCOCCAL ENTEROTOXIN C2 AT 100K CRYSTALLIZED AT PH 6.0
1I4R	;	2.1	;	CRYSTAL STRUCTURE OF STAPHYLOCOCCAL ENTEROTOXIN C2 AT 100K CRYSTALLIZED AT PH 6.5
4UDU	;	2.5	;	Crystal structure of staphylococcal enterotoxin E in complex with a T cell receptor
5FKA	;	2.4	;	Crystal structure of staphylococcal enterotoxin E in complex with a T cell receptor
1XXG	;	2.2	;	Crystal Structure of Staphylococcal Enterotoxin G
3OWE	;	2.6	;	Crystal Structure of Staphylococcal Enterotoxin G (SEG) in Complex with a High Affinity Mutant Mouse T-cell Receptor Chain
3MC0	;	2.0	;	Crystal Structure of Staphylococcal Enterotoxin G (SEG) in Complex with a Mouse T-cell Receptor beta Chain
1ENF	;	1.69	;	CRYSTAL STRUCTURE OF STAPHYLOCOCCAL ENTEROTOXIN H DETERMINED TO 1.69 A RESOLUTION
1HXY	;	2.6	;	CRYSTAL STRUCTURE OF STAPHYLOCOCCAL ENTEROTOXIN H IN COMPLEX WITH HUMAN MHC CLASS II
2G9H	;	2.0	;	Crystal Structure of Staphylococcal Enterotoxin I (SEI) in Complex with a Human MHC class II Molecule
4P1Y	;	2.992	;	Crystal structure of staphylococcal gamma-hemolysin prepore
3VAZ	;	3.19	;	Crystal structure of Staphylococcal GAPDH1 in a hexagonal space group
4I3E	;	2.6	;	Crystal structure of Staphylococcal IMPase - I complexed with products.
4PTK	;	2.503	;	Crystal structure of Staphylococcal IMPase-I complex with 3Mg2+ and Phosphate
5I3S	;	2.2	;	Crystal structure of Staphylococcal IMPase-II
4I3Y	;	2.04	;	Crystal structure of Staphylococcal inositol monophosphatase-1: 100 mM LiCl soaked inhibitory complex
4I40	;	2.5	;	crystal structure of Staphylococcal inositol monophosphatase-1: 50mM LiCl inhibited complex
4P1X	;	2.4	;	Crystal structure of staphylococcal LUK prepore
2F0I	;	1.8	;	Crystal structure of Staphylococcal nuclease mutant I72L
2F0J	;	1.8	;	Crystal structure of Staphylococcal nuclease mutant I72V
4H7B	;	1.6	;	Crystal Structure of Staphylococcal nuclease mutant I72V/V99L
2F0D	;	2.5	;	Crystal structure of Staphylococcal nuclease mutant I92V
4K8I	;	2.1	;	Crystal Structure of Staphylococcal Nuclease mutant I92V/V99L
2F0F	;	2.15	;	Crystal structure of Staphylococcal nuclease mutant L25I
2F0N	;	1.7	;	Crystal structure of Staphylococcal nuclease mutant L25I/I72L
2EYM	;	1.8	;	Crystal structure of Staphylococcal nuclease mutant T120C
2EYO	;	1.7	;	Crystal structure of Staphylococcal nuclease mutant T120S
2EYP	;	1.8	;	Crystal structure of Staphylococcal nuclease mutant T120V
2EXZ	;	1.9	;	Crystal structure of Staphylococcal nuclease mutant T22C
2EY1	;	1.85	;	Crystal structure of Staphylococcal nuclease mutant T22V
2EY2	;	1.7	;	Crystal structure of Staphylococcal nuclease mutant T41C
2EY5	;	2.0	;	Crystal structure of Staphylococcal nuclease mutant T41S
2EY6	;	1.65	;	Crystal structure of Staphylococcal nuclease mutant T41V
2EYF	;	1.8	;	Crystal structure of Staphylococcal nuclease mutant T44V
2EYH	;	1.9	;	Crystal structure of Staphylococcal nuclease mutant T62S
2EYJ	;	1.85	;	Crystal structure of Staphylococcal nuclease mutant T62V
2EYL	;	1.7	;	Crystal structure of Staphylococcal nuclease mutant T82S
4ID6	;	1.898	;	Crystal Structure of Staphylococcal nuclease mutant V23I/I72L
2F0K	;	1.9	;	Crystal structure of Staphylococcal nuclease mutant V23I/L25I
2F0U	;	1.83	;	Crystal structure of Staphylococcal nuclease mutant V23I/L25I/I72V
2F0W	;	2.1	;	Crystal structure of Staphylococcal nuclease mutant V23I/L25I/V66L/I72L
4I65	;	1.61	;	Crystal Structure of Staphylococcal nuclease mutant V23I/L25V/I72V/I92V
2F0E	;	1.95	;	Crystal structure of Staphylococcal nuclease mutant V23L
2F0L	;	1.9	;	Crystal structure of Staphylococcal nuclease mutant V23L/I72L
2F0M	;	2.0	;	Crystal structure of Staphylococcal nuclease mutant V23L/I72V
4QB4	;	1.6	;	Crystal Structure of Staphylococcal Nuclease mutant V23L/L25V/V66L
4K8J	;	2.0	;	Crystal Structure of Staphylococcal nuclease mutant V23L/V66I
2F0V	;	2.0	;	Crystal structure of Staphylococcal nuclease mutant V23L/V66L/I72L
2OXP	;	2.0	;	Crystal Structure of Staphylococcal Nuclease mutant V66D/P117G/H124L/S128A
1U9R	;	2.1	;	Crystal Structure of Staphylococcal Nuclease mutant V66E/P117G/H124L/S128A at Room Temperature
2F0G	;	1.9	;	Crystal structure of Staphylococcal nuclease mutant V66I
2F0O	;	1.9	;	Crystal structure of Staphylococcal nuclease mutant V66I/I72V
2F0P	;	2.05	;	Crystal structure of Staphylococcal nuclease mutant V66I/V99I
4K14	;	1.601	;	Crystal Structure of Staphylococcal nuclease mutant V66I/V99L
2F0H	;	2.15	;	Crystal structure of Staphylococcal nuclease mutant V66L
2F0Q	;	1.95	;	Crystal structure of Staphylococcal nuclease mutant V66L/I92L
2F0S	;	1.75	;	Crystal structure of Staphylococcal nuclease mutant V66L/I92V
2F0T	;	1.7	;	Crystal structure of Staphylococcal nuclease mutant V66L/V99I
3QOL	;	1.9	;	Crystal structure of Staphylococcal nuclease variant D+PHS/V23E at pH 6 determined at 100 K
3HZX	;	2.0	;	Crystal Structure of Staphylococcal nuclease variant D+PHS/V66K at pH 9 determined at 100 K
3TME	;	1.4	;	Crystal structure of Staphylococcal nuclease variant Delta+NVIAGLA V23E at cryogenic temperature
3TP5	;	1.8	;	Crystal structure of Staphylococcal nuclease variant Delta+NVIAGLA V23E/L36E at cryogenic temperature
3SK6	;	1.8	;	Crystal structure of Staphylococcal nuclease variant Delta+NVIAGLA V23K/L36E at cryogenic temperature
3D4W	;	1.9	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS A109R at cryogenic temperature
6XSB	;	1.95	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS A132S at cryogenic temperature
5I6W	;	1.9	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS A58D at cryogenic temperature
3T13	;	1.8	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS A69G at cryogenic temperature
3SR1	;	1.45	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS A69G bound to Ca2+ and thymidine-5',3'-diphosphate at cryogenic temperature
5J1Z	;	1.73	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS A90D at cryogenic temperature
5I6Y	;	1.9	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS A90E at cryogenic temperature
3DHQ	;	2.15	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS A90R at cryogenic temperature
3BDC	;	1.8	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS at cryogenic temperature
3LX0	;	1.5	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS D21N at cryogenic temperature
3SK4	;	1.85	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS D21N/V23E at cryogenic temperature
3MVV	;	1.72	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS F34A at cryogenic temperature
3ITP	;	1.75	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS F34K at cryogenic temperature
6XSE	;	2.1	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS F34Y at cryogenic temperature
5E1F	;	1.9	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS G20E at cryogenic temperature
4IAL	;	1.595	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS H121E at cryogenic temperature
4J6H	;	1.6	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS H121Q at cryogenic temperature
4IZ8	;	1.7	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS H8E at cryogenic temperature
4EQP	;	1.35	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS I72D at cryogenic temperature
5C3X	;	1.95	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS I72D/N100E at cryogenic temperature
3ERO	;	1.85	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS I72E at cryogenic temperature
4PNY	;	1.68	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS I72H at cryogenic temperature
2RBM	;	1.9	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS I72K at cryogenic temperature
5K5P	;	1.83	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS I72K L103K at cryogenic temperature
3D8G	;	1.99	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS I72R at cryogenic temperature
3MEH	;	1.5	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS I92A at cryogenic temperature
4DGZ	;	1.47	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS I92A/L125A at cryogenic temperature
4F7X	;	1.7	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS I92A/L25A at cryogenic temperature
4DFA	;	1.404	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS I92A/L36A at cryogenic temperature
3VA5	;	1.55	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS I92A/V23A at cryogenic temperature
3V2T	;	1.8	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS I92A/V66A at cryogenic temperature
4DU9	;	1.63	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS I92A/V74A at cryogenic temperature
3SXH	;	1.4	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS I92AL103A at cryogenic temperature
5KIX	;	1.75	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS I92E at cryogenic temperature
5C4H	;	1.8	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS I92H at cryogenic temperature
5E3F	;	1.75	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS I92K at cryogenic temperature
4S3S	;	1.64	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS I92K/V23A at cryogenic temperature
3QB3	;	1.63	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS I92KL25A at cryogenic temperature
4NDX	;	1.496	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS I92N at cryogenic temperature
5F2D	;	1.7	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS I92N/V99T at cryogenic temperature
4K2L	;	1.55	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS I92Q at cryogenic temperature
4ZQ3	;	1.9	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS I92T at cryogenic temperature
6OK8	;	1.8	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS K127L at cryogenic temperature
6U0W	;	1.9	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS K133M at cryogenic temperature
5CV5	;	1.8	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS K64G/V66K/E67G at cryogenic temperature
3MZ5	;	1.58	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS L103A at cryogenic temperature
5J22	;	1.9	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS L103D at cryogenic temperature
3E5S	;	2.0	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS L103K at cryogenic temperature
3NXW	;	1.65	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS L125A at cryogenic temperature
3C1E	;	1.9	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS L125K at cryogenic temperature
3OSO	;	1.6	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS L25A at cryogenic temperature
4K2K	;	1.65	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS L25A/L36A/I92A at cryogenic temperature
4KD3	;	1.75	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS L25A/V66A/I92A at cryogenic temperature
4KY6	;	1.7	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS L25D at pH 6 and cryogenic temperature
5C6A	;	1.85	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS L25E / N100E at cryogenic temperature
3EVQ	;	2.0	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS L25E at cryogenic temperature
5C4Z	;	1.62	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS L25H at cryogenic temperature
5JOB	;	1.45	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS L25K/I92A at cryogenic temperature
5KEE	;	1.5	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS L25K/I92F at cryogenic temperature
5HGT	;	1.75	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS L25K/I92T at cryogenic temperature
5HUR	;	1.5	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS L25T/I92K at cryogenic temperature
3NP8	;	1.7	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS L36A at cryogenic temperature
4KJO	;	1.9	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS L36A/V66T/V99T at cryogenic temperature
4HMJ	;	1.35	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS L36D at cryogenic temperature
5IGB	;	1.8	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS L36D/V66H at cryogenic temperature
3TP8	;	1.6	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS L36E at cryogenic temperature
3TP6	;	1.8	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS L36E/L103K at cryogenic temperature
5CV9	;	1.62	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS L36E/V66H at cryogenic temperature
4LAA	;	1.58	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS L36H at cryogenic temperature
3EJI	;	1.9	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS L36K at cryogenic temperature
5I9O	;	1.95	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS L36K L103K at cryogenic temperature
3MHB	;	1.55	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS L38A at cryogenic temperature
5ISR	;	1.9	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS L38E at cryogenic temperature
3SK8	;	1.9	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS M98G apo protein at cryogenic temperature
3S9W	;	1.9	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS M98G bound to Ca2+ and thymidine-5',3'-diphosphate at cryogenic temperature
5DEH	;	1.7	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS N100D at cryogenic temperature
5KGU	;	1.9	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS N118D at cryogenic temperature
6U0X	;	1.86	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS Q123D at cryogenic temperature
4J1M	;	1.65	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS R105E at cryogenic temperature
4KTA	;	1.95	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS R105Q at cryogenic temperatures
4IUN	;	1.6	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS R126E at cryogenic temperature
4KV6	;	1.55	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS R126Q at cryogenic temperature
6XSF	;	1.6	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS T41V at cryogenic temperature
3MXP	;	1.61	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS T62A at cryogenic temperature
3R3O	;	1.9	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS T62A at cryogenic temperature and with high redundancy
5C5M	;	1.7	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS T62D / V104E at cryogenic temperature
5IIF	;	1.85	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS T62D at cryogenic temperature
5EKL	;	2.1	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS T62D/N100E at cryogenic temperature
5C5L	;	1.75	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS T62E / L125E at cryogenic temperature
5CC4	;	1.9	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS T62E/V66E at cryogenic temperature
5KRU	;	1.6	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS T62E/V66K at cryogenic temperature
5I9P	;	1.85	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS T62H at cryogenic temperature
5IGD	;	1.8	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS T62H/I92E at cryogenic temperature
5IGF	;	1.7	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS T62H/V66D at cryogenic temperature
5IGE	;	1.8	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS T62H/V99D at cryogenic temperature
5KYL	;	1.85	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS T62K/V66E pH 7 at cryogenic temperature
5KYI	;	1.7	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS T62K/V66E pH 9 at cryogenic temperature
3HEJ	;	1.8	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS T62R at cryogenic temperature
6XSH	;	2.0	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS T62V at cryogenic temperature
3P75	;	1.9	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V104D at cryogenic temperature
3H6M	;	1.7	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V104E at cryogenic temperature
5CR3	;	1.8	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V104E/L125E at cryogenic temperature
3C1F	;	2.0	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V104K at cryogenic temperature
6XSI	;	2.0	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V104T at cryogenic temperature
3PMF	;	1.6	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V23A at cryogenic temperature
4KY5	;	1.4	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V23D at pH 7 and cryogenic temperature
5CV8	;	1.58	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V23D/T62H at cryogenic temperature
5CV4	;	1.8	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V23D/V66H at cryogenic temperature
4EQN	;	1.8	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V23E/I72K at cryogenic temperature
5IGC	;	1.8	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V23E/V66H at cryogenic temperature
4ZUI	;	1.7	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V23H at cryogenic temperature
4F8M	;	1.6	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V23I/I92V at cryogenic temperature
3P1H	;	1.79	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V23K/I92A at cryogenic temperature
6AMF	;	1.85	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V23K/L36E at cryogenic temperature
6B8R	;	1.65	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V23K/L36Q at cryogenic temperature
4DF7	;	1.5	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V23L/V99I at cryogenic temperature
4NMZ	;	1.7	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V23Q/V66A at cryogenic temperature
4KHV	;	1.6	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V23S at cryogenic temperature
4ME5	;	1.8	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V23S/V66A at cryogenic temperature
6XSC	;	2.0	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V23T at cryogenic temperature
4N9P	;	1.4	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V23T/L25A/V99T at cryogenic temperature
4K5V	;	1.75	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V23T/L36A/V99T at cryogenic temperature
4KJN	;	1.55	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V23T/V66A/V99T at cryogenic temperature
4RKL	;	1.66	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V23T/V66T at cryogenic temperature
4MIU	;	1.67	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V23T/V99T at cryogenic temperature
3SK5	;	1.7	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V39D at cryogenic temperature
5EKK	;	2.1	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V39D/L125E at cryogenic temperature
5DAU	;	1.5	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V39E/V104E at cryogenic temperature
3NQT	;	1.9	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V66A at cryogenic temperature
4NP5	;	1.5	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V66A/I92N at cryogenic temperature
4NKL	;	1.6	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V66A/I92Q at cryogenic temperature
4N9T	;	1.6	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V66A/I92S at cryogenic temperature
5CGK	;	1.85	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V66D/N100E at cryogenic temperature
4OL7	;	1.67	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V66E A109E at cryogenic temperature
5EGT	;	1.85	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V66E at cryogenic temperature
5C3W	;	1.72	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V66H at cryogenic temperature
5IGG	;	1.7	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V66H/I72E at cryogenic temperature
5CV7	;	1.65	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V66H/I92D at cryogenic temperature
5CV6	;	1.95	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V66H/I92E at cryogenic temperature
5IOC	;	1.9	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V66H/V99D at cryogenic temperature
5IOD	;	1.6	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V66H/V99E at cryogenic temperature
3OWF	;	1.85	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V66R at cryogenic temperature
6XSG	;	2.0	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V66T at cryogenic temperature
4RKB	;	1.88	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V66T/V99T at cryogenic temperature
3NK9	;	1.65	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V74A at cryogenic temperature
4KY7	;	1.55	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V74D at cryogenic temperature
3RUZ	;	1.58	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V74K at cryogenic temperature
3SHL	;	1.48	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V74KL25A at cryogenic temperature
4EQO	;	1.697	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V99D at cryogenic temperature
3TP7	;	1.9	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V99E at cryogenic temperature
4HMI	;	1.75	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS V99K at cryogenic temperature
5JAV	;	1.895	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS Y91D at cryogenic temperature
3D4D	;	2.1	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS Y91E at cryogenic temperature
4ZUJ	;	1.72	;	Crystal structure of Staphylococcal nuclease variant Delta+PHS Y91H at cryogenic temperature
4HTH	;	1.75	;	Crystal structure of Staphylococcal nuclease variant Delta+VIAGLA at cryogenic temperature
2QDB	;	2.2	;	Crystal structure of staphylococcal nuclease variant E75Q/D21N/T33V/T41I/S59A/P117G/S128A at 100 K
3ERQ	;	2.1	;	Crystal structure of Staphylococcal nuclease variant L25K at cryogenic temperature
4E6I	;	2.0	;	Crystal structure of Staphylococcal nuclease variant NVIAGA V99G at cryogenic temperature
4EVO	;	1.95	;	Crystal structure of Staphylococcal nuclease variant NVIAGA/E122G at cryogenic temperature
3T16	;	1.8	;	Crystal structure of Staphylococcal nuclease variant NVIAGA/M98G at cryogenic temperature
3U9O	;	1.95	;	Crystal structure of Staphylococcal nuclease variant NVIAGA/N100G at cryogenic temperature
3D6C	;	2.0	;	Crystal structure of Staphylococcal nuclease variant PHS L38E at cryogenic temperature
2RKS	;	2.01	;	Crystal structure of Staphylococcal nuclease variant PHS L38K at cryogenic temperature
3DMU	;	1.8	;	Crystal structure of Staphylococcal nuclease variant PHS T62K at cryogenic temperature
3NHH	;	2.0	;	Crystal structure of Staphylococcal nuclease variant V23E-L36K at cryogenic temperature
4R8N	;	1.65	;	Crystal structure of Staphylococcal nuclease variant V23I/V66I/I72V/I92V at cryogenic temperature
4ODG	;	1.73	;	Crystal structure of Staphylococcal nuclease variant V23I/V66I/V74I/V99I at cryogenic temperature
4KD4	;	1.55	;	Crystal structure of Staphylococcal nuclease variant V23L/L25V/V66I/I72V at cryogenic temperature
4QF4	;	1.8	;	Crystal structure of Staphylococcal nuclease variant V23M at cryogenic temperature
4K5W	;	1.65	;	Crystal structure of Staphylococcal nuclease variant V23M/L25F/T62F at cryogenic temperature
4K5X	;	1.65	;	Crystal structure of Staphylococcal nuclease variant V23M/L36F at cryogenic temperature
4K6D	;	1.65	;	Crystal structure of Staphylococcal nuclease variant V23M/T62F at cryogenic temperature
2PZU	;	2.1	;	Crystal structure of Staphylococcal nuclease variant V66N/P117G/H124L/S128A at cryogenic temperature
2PZW	;	2.1	;	Crystal structure of Staphylococcal nuclease variant V66N/P117G/H124L/S128A at room temperature
2PZT	;	2.1	;	Crystal structure of Staphylococcal nuclease variant V66Q/P117G/H124L/S128A at 100 K
2PYK	;	2.1	;	Crystal structure of Staphylococcal nuclease variant V66Q/P117G/H124L/S128A at room temperature
2PW7	;	2.1	;	Crystal Structure of Staphylococcal nuclease variant V66Y/P117G/H124L/S128A at 100K
2PW5	;	2.1	;	Crystal Structure of Staphylococcal nuclease variant V66Y/P117G/H124L/S128A at room temperature
4DG5	;	2.3	;	Crystal structure of staphylococcal Phosphoglycerate kinase
6LWT	;	1.9	;	Crystal structure of Staphylococcal Superantigen-Like protein 10
2RDH	;	1.7	;	Crystal structure of Staphylococcal Superantigen-Like protein 11
2RDG	;	1.6	;	Crystal structure of Staphylococcal Superantigen-Like protein 11 in complex with Sialyl Lewis X
5D3D	;	1.94	;	Crystal structure of Staphylococcal Superantigen-Like protein 3
4DXF	;	1.7	;	Crystal structure of Staphylococcal Superantigen-Like protein 4
4DXG	;	2.5	;	Crystal structure of Staphylococcal Superantigen-Like protein 4 complexed with sialyl Lewis X
4O1N	;	2.5	;	Crystal structure of Staphylococcal superantigen-like protein SAOUHSC_00383
2UZF	;	2.9	;	Crystal structure of Staphylococcus aureus 1,4-dihydroxy-2-naphthoyl CoA synthase (MenB) in complex with acetoacetyl CoA
4GMH	;	2.0	;	Crystal structure of staphylococcus aureus 5'-methylthioadenosine/s-adenosylhomocysteine nucleosidase
3BL6	;	1.7	;	Crystal structure of Staphylococcus aureus 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase in complex with formycin A
3V8J	;	2.1	;	Crystal structure of Staphylococcus aureus biotin protein ligase
6NDL	;	2.0	;	Crystal structure of Staphylococcus aureus biotin protein ligase in complex with a sulfonamide inhibitor
3V8K	;	3.23	;	Crystal structure of Staphylococcus aureus biotin protein ligase in complex with biotin
3V8L	;	2.6	;	Crystal structure of Staphylococcus aureus biotin protein ligase in complex with biotinyl-5'-AMP
3V7R	;	2.61	;	Crystal structure of Staphylococcus aureus biotin protein ligase in complex with inhibitor
6APW	;	2.614	;	Crystal structure of Staphylococcus aureus biotin protein ligase in complex with inhibitor
6AQQ	;	2.71	;	Crystal structure of Staphylococcus aureus biotin protein ligase in complex with inhibitor
8ENI	;	2.4	;	Crystal structure of Staphylococcus aureus biotin protein ligase in complex with inhibitor
3V7S	;	3.1	;	Crystal structure of Staphylococcus aureus biotin protein ligase in complex with inhibitor 0364
6O9W	;	1.95	;	Crystal structure of Staphylococcus aureus BlaR1 antibiotic-sensor domain in complex with avibactam
4EMW	;	2.39	;	Crystal Structure of Staphylococcus aureus bound with the covalent inhibitor EtVC-CoA
4EM3	;	1.977	;	Crystal Structure of Staphylococcus aureus bound with the covalent inhibitor MeVS-CoA
4EM4	;	1.821	;	Crystal Structure of Staphylococcus aureus bound with the covalent inhibitor Pethyl-VS-CoA
5CZZ	;	2.6	;	Crystal structure of Staphylococcus aureus Cas9 in complex with sgRNA and target DNA (TTGAAT PAM)
5AXW	;	2.7	;	Crystal structure of Staphylococcus aureus Cas9 in complex with sgRNA and target DNA (TTGGGT PAM)
4EMM	;	2.4	;	Crystal structure of Staphylococcus aureus ClpP in compact conformation
7XBZ	;	2.15	;	Crystal structure of Staphylococcus aureus ClpP in complex with R-ZG197
7WID	;	1.9	;	Crystal structure of Staphylococcus aureus ClpP in complex with ZG180
3T8R	;	1.7	;	Crystal structure of Staphylococcus aureus CymR
3T8T	;	1.752	;	Crystal structure of Staphylococcus aureus CymR oxidized form
7MCB	;	2.14	;	Crystal structure of Staphylococcus aureus Cystathionine gamma lyase Holoenzyme
7MD0	;	2.12	;	Crystal structure of Staphylococcus aureus cystathionine gamma lyase holoenzyme in the presence of NL1F3
7MD9	;	1.8	;	Crystal structure of Staphylococcus aureus cystathionine gamma lyase holoenzyme Y103A mutant
7MDA	;	2.24	;	Crystal structure of Staphylococcus aureus cystathionine gamma lyase holoenzyme Y103A mutant co-crystallized with NL1
7MDB	;	1.8	;	Crystal structure of Staphylococcus aureus cystathionine gamma lyase holoenzyme Y103A mutant co-crystallized with NL2
7MD1	;	2.3	;	Crystal structure of Staphylococcus aureus cystathionine gamma lyase holoenzyme Y103N mutant
7MD6	;	2.2	;	Crystal structure of Staphylococcus aureus cystathionine gamma lyase holoenzyme Y103N mutant co-crystallized with NL1
7MD8	;	2.06	;	Crystal structure of Staphylococcus aureus cystathionine gamma lyase holoenzyme Y103N mutant co-crystallized with NL2
7MCQ	;	2.84	;	Crystal structure of Staphylococcus aureus Cystathionine gamma lyase, AOAA-bound enzyme in dimeric form
7MCT	;	1.6	;	Crystal structure of Staphylococcus aureus Cystathionine gamma lyase, Holoenzyme with bound NL1
7MCU	;	2.4	;	Crystal structure of Staphylococcus aureus Cystathionine gamma lyase, Holoenzyme with bound NL2
7MCY	;	1.72	;	Crystal structure of Staphylococcus aureus Cystathionine gamma lyase, Holoenzyme with bound NL3
7MCP	;	2.4	;	Crystal structure of Staphylococcus aureus Cystathionine gamma-lyase, Holoenzyme dimer
7MCN	;	2.52	;	Crystal structure of Staphylococcus aureus Cystathionine gamma-lyase, Holoenzyme with High HEPES
7MCL	;	2.4	;	Crystal structure of Staphylococcus aureus Cystathionine gamma-lyase, PLP bound
2H92	;	2.3	;	Crystal Structure of Staphylococcus aureus Cytidine Monophosphate Kinase in complex with cytidine-5'-monophosphate
3BCI	;	1.81	;	Crystal Structure of Staphylococcus aureus DsbA
3BD2	;	1.81	;	Crystal Structure of Staphylococcus aureus DsbA E96Q
3BCK	;	1.95	;	Crystal Structure of Staphylococcus aureus DsbA T153V
2XEX	;	1.9	;	crystal structure of Staphylococcus aureus elongation factor G
3ZZT	;	2.95	;	Crystal structure of Staphylococcus aureus elongation factor G with a fusidic-acid-resistant mutation F88L
3ZZU	;	2.98	;	Crystal structure of Staphylococcus aureus elongation factor G with mutations M16I and F88L
5BOF	;	2.45	;	Crystal Structure of Staphylococcus aureus Enolase
5BOE	;	1.6	;	Crystal structure of Staphylococcus aureus enolase in complex with PEP
4FS3	;	1.8	;	Crystal structure of Staphylococcus aureus enoyl-ACP reductase in complex with NADP and AFN-1252
2JFQ	;	2.15	;	Crystal structure of Staphylococcus aureus glutamate racemase in complex with D- Glutamate
2J41	;	1.9	;	Crystal structure of Staphylococcus aureus guanylate monophosphate kinase
3G75	;	2.3	;	Crystal structure of Staphylococcus aureus Gyrase B co-complexed with 4-METHYL-5-[3-(METHYLSULFANYL)-1H-PYRAZOL-5-YL]-2-THIOPHEN-2-YL-1,3-THIAZOLE inhibitor
1XPL	;	2.0	;	Crystal Structure of Staphylococcus aureus HMG-COA Synthase with Acetoacetyl-COA and Acetylated Cysteine
1XPM	;	1.6	;	Crystal Structure of Staphylococcus aureus HMG-COA Synthase with HMG-CoA and Acetoacetyl-COA and Acetylated Cysteine
1XPK	;	2.0	;	CRYSTAL STRUCTURE OF STAPHYLOCOCCUS AUREUS HMG-COA SYNTHASE WITH HMG-CoA AND WITH ACETOACETYL-COA AND ACETYLATED CYSTEINE
4KNK	;	1.124	;	Crystal structure of Staphylococcus aureus hydrolase AmiA
4KNL	;	1.55	;	Crystal structure of Staphylococcus aureus hydrolase AmiA in complex with its ligand
2NYD	;	2.0	;	Crystal structure of Staphylococcus aureus hypothetical protein SA1388
5W3K	;	1.589	;	Crystal structure of Staphylococcus aureus ketol-acid reductoisomerase in complex NADPH, Mg2+ and CPD
6VO2	;	1.59	;	Crystal structure of Staphylococcus aureus ketol-acid reductoisomerase in complex with Mg, NADPH and inhibitor.
7KE2	;	2.59	;	Crystal structure of Staphylococcus aureus ketol-acid reductoisomerase in complex with Mg2+ and NSC116565
7KH7	;	2.63	;	Crystal structure of Staphylococcus aureus ketol-acid reductoisomerase in complex with Mg2+, NADPH, and NSC116565
6C5N	;	1.673	;	Crystal structure of Staphylococcus aureus ketol-acid reductoisomerase with hydroxyoxamate inhibitor 1
6BUL	;	1.88	;	Crystal structure of Staphylococcus aureus ketol-acid reductoisomerase with hydroxyoxamate inhibitor 2
6C55	;	2.09	;	Crystal structure of Staphylococcus aureus Ketol-acid Reductosimerrase with hydroxyoxamate inhibitor 3
3EIW	;	1.6	;	Crystal structure of Staphylococcus aureus lipoprotein, HtsA
8GHH	;	2.1	;	Crystal structure of Staphylococcus aureus Lysophosphatidylglycerol phospholipase D
8GHI	;	2.4	;	Crystal structure of Staphylococcus aureus Lysophosphatidylglycerol phospholipase D
6O9S	;	1.59	;	Crystal structure of Staphylococcus aureus MecR1 antibiotic-sensor domain in complex with avibactam
3VMT	;	2.299	;	Crystal structure of Staphylococcus aureus membrane-bound transglycosylase in complex with a Lipid II analog
3VMR	;	3.688	;	Crystal structure of Staphylococcus aureus membrane-bound transglycosylase in complex with moenomycin
3VMS	;	3.202	;	Crystal structure of Staphylococcus aureus membrane-bound transglycosylase in complex with NBD-Lipid II
3VMQ	;	2.518	;	Crystal structure of Staphylococcus aureus membrane-bound transglycosylase: Apoenzyme
3KHX	;	2.3	;	Crystal structure of Staphylococcus aureus metallopeptidase (Sapep/DapE) in the apo-form
3KI9	;	2.9	;	Crystal structure of Staphylococcus aureus metallopeptidase (Sapep/DapE) in the Mn2+ bound form
3Q83	;	2.5	;	Crystal structure of Staphylococcus aureus nucleoside diphosphate kinase
3Q8U	;	2.22	;	Crystal structure of Staphylococcus aureus nucleoside diphosphate kinase complexed with ADP
3Q8Y	;	2.7	;	Crystal structure of Staphylococcus aureus nucleoside diphosphate kinase complexed with ADP and Vanadate
3Q89	;	2.9	;	Crystal structure of Staphylococcus aureus nucleoside diphosphate kinase complexed with CDP
3Q86	;	2.38	;	Crystal structure of Staphylococcus aureus nucleoside diphosphate kinase complexed with GTP
3Q8V	;	2.5	;	Crystal structure of Staphylococcus aureus nucleoside diphosphate kinase complexed with UDP
3LNL	;	2.0	;	Crystal structure of Staphylococcus aureus protein SA1388
3HSR	;	1.9	;	Crystal structure of Staphylococcus aureus protein SarZ in mixed disulfide form
3HSE	;	2.9	;	Crystal structure of Staphylococcus aureus protein SarZ in reduced form
3HRM	;	2.3	;	Crystal structure of Staphylococcus aureus protein SarZ in sulfenic acid form
4GXO	;	2.05	;	Crystal structure of Staphylococcus aureus protein SarZ mutant C13E
8DTQ	;	1.45	;	Crystal Structure of Staphylococcus aureus pSK41 Cop
4WK1	;	1.98	;	Crystal structure of Staphylococcus aureus PstA in complex with c-di-AMP
3BG5	;	2.8	;	Crystal Structure of Staphylococcus Aureus Pyruvate Carboxylase
6IS4	;	1.854	;	Crystal Structure of Staphylococcus aureus response regulator ArlR DNA binding domain
6KYX	;	2.0048	;	Crystal Structure of Staphylococcus aureus response regulator ArlR DNA binding domain with His tag cleaved
6IS3	;	1.549	;	Crystal Structure of Staphylococcus aureus response regulator ArlR receiver domain
6IS1	;	1.59	;	Crystal Structure of Staphylococcus aureus response regulator ArlR receiver domain in complex with BeF3 and Mg
6IS2	;	1.591	;	Crystal Structure of Staphylococcus aureus response regulator ArlR receiver domain in complex with Mg
6ZHM	;	2.15	;	Crystal Structure of Staphylococcus aureus RsgA bound to GDP.
6ZHL	;	1.94	;	Crystal Structure of Staphylococcus aureus RsgA bound to ppGpp.
6ZJO	;	2.01	;	Crystal Structure of Staphylococcus aureus RsgA.
5HS5	;	2.55	;	Crystal structure of Staphylococcus aureus SarX
3TIP	;	1.7009	;	Crystal structure of Staphylococcus aureus SasG E-G52 module
3TIQ	;	1.8739	;	Crystal structure of Staphylococcus aureus SasG G51-E-G52 module
5WTA	;	2.3	;	Crystal Structure of Staphylococcus aureus SdrE apo form
5YYU	;	2.984	;	Crystal structure of Staphylococcus aureus single-stranded DNA-binding protein SsbB
3MWG	;	2.1	;	Crystal structure of Staphylococcus aureus SirA
3MWF	;	1.7	;	Crystal structure of Staphylococcus aureus SirA complexed with staphyloferrin B
3UWV	;	2.07	;	Crystal structure of Staphylococcus Aureus triosephosphate isomerase complexed with 2-phosphoglyceric acid
3UWW	;	2.25	;	Crystal structure of Staphylococcus Aureus triosephosphate isomerase complexed with 3-phosphoglyceric acid
3UWZ	;	2.5	;	Crystal structure of Staphylococcus aureus triosephosphate isomerase complexed with glycerol-2-phosphate
3UWU	;	2.15	;	Crystal structure of Staphylococcus Aureus triosephosphate isomerase complexed with glycerol-3-phosphate
2B3J	;	2.0	;	Crystal Structure of Staphylococcus aureus tRNA Adenosine Deaminase, TadA, in Complex with RNA
3N8D	;	2.3	;	Crystal structure of Staphylococcus aureus VRSA-9 D-Ala:D-Ala ligase
5M94	;	3.101	;	Crystal structure of Staphylococcus capitis divalent metal ion transporter (DMT) in complex with nanobody
5TU7	;	3.34	;	Crystal structure of Staphylococcus epidermidis Aap G511-spacer-G513 (consensus G5-spacer-consensus G5)
5TU9	;	1.9	;	Crystal structure of Staphylococcus epidermidis Aap G58-spacer-G513 (variant G5-spacer-consensus G5)
5TU8	;	2.33	;	Crystal structure of Staphylococcus epidermidis Aap G58-spacer-G513* (variant G5-spacer-variant G5)
4DU8	;	2.1	;	Crystal structure of Staphylococcus epidermidis D283A mevalonate diphosphate decarboxylase complexed with inhibitor DPGP
4DPW	;	2.605	;	Crystal structure of Staphylococcus epidermidis D283A mevalonate diphosphate decarboxylase complexed with mevalonate diphosphate and ATPgS
3QT5	;	1.848	;	Crystal structure of Staphylococcus epidermidis mevalonate diphosphate decarboxylase
3QT7	;	2.199	;	Crystal structure of Staphylococcus epidermidis mevalonate diphosphate decarboxylase complexed with inhibitor 6-FMVAPP
4DPT	;	2.191	;	Crystal structure of Staphylococcus epidermidis mevalonate diphosphate decarboxylase complexed with inhibitor 6-FMVAPP and ATPgS
3QT6	;	2.047	;	Crystal structure of Staphylococcus epidermidis mevalonate diphosphate decarboxylase complexed with inhibitor DPGP
4DU7	;	2.201	;	Crystal structure of Staphylococcus epidermidis mevalonate diphosphate decarboxylase complexed with substrate mevalonate diphosphate
4DPU	;	1.9	;	Crystal structure of Staphylococcus epidermidis S192A mevalonate diphosphate decarboxylase complexed with inhibitor 6-FMVAPP and ATPgS
4DPY	;	2.14	;	Crystal structure of Staphylococcus epidermidis S192A mevalonate diphosphate decarboxylase complexed with inhibitor DPGP
2HIH	;	2.86	;	Crystal structure of Staphylococcus hyicus lipase
3LAT	;	1.7	;	Crystal structure of Staphylococcus peptidoglycan hydrolase AmiE
6NR6	;	1.9	;	Crystal Structure of Staphylococcus pseudintermedius SbnI in complex with ADP
5OEN	;	2.919	;	Crystal Structure of STAT2 in complex with IRF9
4ZIA	;	2.7	;	Crystal Structure of STAT3 N-terminal domain
4E6B	;	1.47	;	Crystal Structure of statistically disordered 19mer duplex p(CGG)3C(CUG)3
1NXK	;	2.7	;	Crystal structure of staurosporine bound to MAP KAP kinase 2
4YMK	;	2.605	;	Crystal Structure of Stearoyl-Coenzyme A Desaturase 1
3T6W	;	2.15	;	Crystal Structure of Steccherinum ochraceum Laccase obtained by multi-crystals composite data collection technique (10% dose)
3T6X	;	2.15	;	Crystal Structure of Steccherinum ochraceum Laccase obtained by multi-crystals composite data collection technique (20% dose)
3T6Z	;	2.15	;	Crystal Structure of Steccherinum ochraceum Laccase obtained by multi-crystals composite data collection technique (60% dose)
3T71	;	2.15	;	Crystal Structure of Steccherinum ochraceum Laccase obtained by multi-crystals composite data collection technique (90% dose)
1RC9	;	1.6	;	Crystal Structure of Stecrisp, a Member of CRISP Family from Trimeresurus Stejnegeri Refined at 1.6 Angstroms Resolution: Structual relationship of the two domains
1NB5	;	2.4	;	Crystal structure of stefin A in complex with cathepsin H
1NB3	;	2.8	;	Crystal structure of stefin A in complex with cathepsin H: N-terminal residues of inhibitors can adapt to the active sites of endo-and exopeptidases
7YJ5	;	1.701	;	Crystal structure of Stenoloma chusanum chalcone synthase 1 (ScCHS1)
7YJ6	;	1.704	;	Crystal structure of Stenoloma chusanum chalcone synthase 1 (ScCHS1) complex with CoA
7YJB	;	2.0	;	Crystal structure of Stenoloma chusanum chalcone synthase 1 (ScCHS1) complex with CoA and Eriodictyol
7YJ9	;	1.851	;	Crystal structure of Stenoloma chusanum chalcone synthase 1 (ScCHS1) complex with CoA and Naringenin
7YJA	;	2.17	;	Crystal structure of Stenoloma chusanum chalcone synthase 1 (ScCHS1) complex with CoA and Pinocembrin
7YJ7	;	1.997	;	Crystal structure of Stenoloma chusanum chalcone synthase 1 (ScCHS1) complex with Naringenin
7YJ8	;	2.2	;	Crystal structure of Stenoloma chusanum chalcone synthase 1 (ScCHS1) complex with Pinocembrin
3MHX	;	1.7	;	Crystal Structure of Stenotrophomonas maltophilia FeoA complexed with Zinc: A Unique Procaryotic SH3 Domain Protein Possibly Acting as a Bacterial Ferrous Iron Transport Activating Factor
5KH2	;	2.3	;	Crystal Structure of Steptococcus pneumoniae Undecaprenyl pyrophosphate Synthase (UPPS)
5KH5	;	2.63	;	Crystal Structure of Steptococcus pneumoniae Undecaprenyl pyrophosphate Synthase (UPPS) IN COMPLEX WITH ~{N}-(3-azanyl-3-oxidanylidene-propyl)-5-(1-benzothiophen-5-yl)-1-(phenylmethyl)-~{N}-[(4-propan-2-yloxyphenyl)methyl]pyrazole-4-carboxamide
5KH4	;	3.2	;	Crystal Structure of Steptococcus pneumoniae Undecaprenyl pyrophosphate Synthase (UPPS) with FARNESYL DIPHOSPHATE
3FVM	;	2.9	;	Crystal structure of Steptococcus suis mannonate dehydratase with metal Mn++
3CKW	;	1.96	;	Crystal structure of sterile 20-like kinase 3 (MST3, STK24)
3CKX	;	2.7	;	Crystal structure of sterile 20-like kinase 3 (MST3, STK24) in complex with staurosporine
7BW1	;	2.8	;	Crystal structure of Steroid 5-alpha-reductase 2 in complex with Finasteride
5FSA	;	2.86	;	Crystal structure of sterol 14-alpha demethylase (CYP51) from a pathogenic yeast Candida albicans in complex with the antifungal drug posaconazole
5TZ1	;	2.0	;	Crystal structure of sterol 14-alpha demethylase (CYP51) from Candida albicans in complex with the tetrazole-based antifungal drug candidate VT1161 (VT1)
3L4D	;	2.75	;	Crystal structure of sterol 14-alpha demethylase (CYP51) from Leishmania infantum in complex with fluconazole
3GW9	;	1.87	;	Crystal structure of sterol 14-alpha demethylase (CYP51) from Trypanosoma brucei bound to an inhibitor N-(1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxaziazol-2-yl)benzamide
3G1Q	;	1.89	;	Crystal structure of sterol 14-alpha demethylase (CYP51) from Trypanosoma brucei in ligand free state
3K1O	;	2.89	;	Crystal structure of sterol 14-alpha demethylase (CYP51) from Trypanosoma cruzi in complex with a potential antichagasic drug, posaconazole
5FRB	;	2.99	;	Crystal structure of sterol 14-alpha demethylase (CYP51B) from a pathogenic filamentous fungus Aspergillus fumigatus in complex with a tetrazole-based inhibitor VT-1598
4UYL	;	2.81	;	Crystal structure of sterol 14-alpha demethylase (CYP51B) from a pathogenic filamentous fungus Aspergillus fumigatus in complex with VNI
4UYM	;	2.55	;	Crystal structure of sterol 14-alpha demethylase (CYP51B) from a pathogenic filamentous fungus Aspergillus fumigatus in complex with voriconazole
6CR2	;	2.38	;	Crystal structure of sterol 14-alpha demethylase (CYP51B) from Aspergillus fumigatus in complex with the VNI derivative N-(1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethyl)-4-(5-(2-fluoro-4-(2,2,2-trifluoroethoxy)phenyl)-1,3,4-oxadiazol-2-yl)benzamide
3KSW	;	3.05	;	Crystal structure of sterol 14alpha-demethylase (CYP51) from Trypanosoma cruzi in complex with an inhibitor VNF ((4-(4-chlorophenyl)-N-[2-(1H-imidazol-1-yl)-1-phenylethyl]benzamide)
3KHM	;	2.85	;	Crystal structure of sterol 14alpha-demethylase (CYP51) from Trypanosoma cruzi in complex with inhibitor fluconazole
2CX7	;	1.75	;	Crystal structure of sterol carrier protein 2
2QZT	;	1.7	;	Crystal Structure of Sterol Carrier Protein 2 Like 2 (SCP2-L2) from Aedes Aegypti
3BKR	;	1.4	;	Crystal Structure of Sterol Carrier Protein-2 like-3 (SCP2-L3) from Aedes Aegypti
3BKS	;	2.1	;	Crystal Structure of Sterol Carrier Protein-2 like-3 (SCP2-L3) from Aedes Aegypti
6KMB	;	2.4	;	Crystal structure of Sth1 bromodomain
6KMJ	;	1.4	;	Crystal structure of Sth1 bromodomain in complex with H3K14Ac
7F3S	;	1.4	;	Crystal structure of Sth1 Bromodomain in complex with H3K14bz peptide
4O8O	;	1.21	;	Crystal structure of SthAraf62A, a GH62 family alpha-L-arabinofuranosidase from Streptomyces thermoviolaceus, bound to alpha-L-arabinose
4O8P	;	1.557	;	Crystal structure of SthAraf62A, a GH62 family alpha-L-arabinofuranosidase from Streptomyces thermoviolaceus, bound to xylotetraose
4O8N	;	1.6476	;	Crystal structure of SthAraf62A, a GH62 family alpha-L-arabinofuranosidase from Streptomyces thermoviolaceus, in the apoprotein form
1Z1E	;	2.4	;	Crystal structure of stilbene synthase from Arachis hypogaea
1Z1F	;	2.9	;	Crystal structure of stilbene synthase from Arachis hypogaea (resveratrol-bound form)
1XES	;	1.7	;	Crystal structure of stilbene synthase from Pinus sylvestris
1XET	;	2.0	;	Crystal structure of stilbene synthase from Pinus sylvestris, complexed with methylmalonyl CoA
6YQY	;	1.876	;	Crystal structure of sTIM11noCys, a de novo designed TIM barrel
4F9G	;	2.95	;	Crystal structure of STING complex with Cyclic di-GMP.
4EF5	;	2.45	;	Crystal structure of STING CTD
4EF4	;	2.147	;	Crystal structure of STING CTD complex with c-di-GMP
8T5L	;	2.01	;	Crystal structure of STING CTD in complex with 2'3'-cGAMP
8T5K	;	1.95	;	Crystal structure of STING CTD in complex with BDW-OH
6O8B	;	3.4	;	Crystal structure of STING CTD in complex with TBK1
6O8C	;	3.17	;	Crystal structure of STING CTT in complex with TBK1
4KSY	;	1.881	;	Crystal structure of STING in complex with cGAMP
6XF3	;	2.38	;	Crystal structure of STING in complex with E7766
6XF4	;	2.77	;	Crystal structure of STING REF variant in complex with E7766
6ZJF	;	1.75	;	Crystal structure of STK17B (DRAK2) in complex with AP-229
6Y6F	;	1.98	;	Crystal structure of STK17B (DRAK2) in complex with PKIS43
6Y6H	;	1.95	;	Crystal structure of STK17b (DRAK2) in complex with UNC-AP-194 probe
7AKG	;	2.08	;	Crystal structure of STK17B with bound dovitinib
4NZW	;	3.583	;	Crystal Structure of STK25-MO25 Complex
4L0N	;	1.4	;	Crystal structure of STK3 (MST2) SARAH domain
6YAT	;	2.58	;	Crystal structure of STK4 (MST1) in complex with compound 6
4NR2	;	2.0	;	Crystal structure of STK4 (MST1) SARAH domain
3EPU	;	2.5	;	Crystal Structure of STM2138, a novel virulence chaperone in Salmonella
3ERW	;	2.5	;	Crystal Structure of StoA from Bacillus subtilis
2GW3	;	1.4	;	Crystal structure of stony coral fluorescent protein Kaede, green form
2GW4	;	1.6	;	Crystal structure of stony coral fluorescent protein Kaede, red form
5D2S	;	2.2	;	Crystal structure of STPR from Bombyx mori in complex with 18-bp DNA containing four repetitive units of ATAC
5D2Q	;	2.4	;	Crystal structure of STPR from Bombyx Mori in complex with 20-bp DNA derived from +290 site of the fibroin gene
5T33	;	3.2092	;	Crystal structure of strain-specific glycan-dependent CD4 binding site-directed neutralizing antibody CAP257-RH1, in complex with HIV-1 strain RHPA gp120 core with an oligomannose N276 glycan.
5N8T	;	1.61	;	CRYSTAL STRUCTURE OF STREPTAVIDIN D-amino acid containing peptide Gdlwqheatwkkq
1MEP	;	1.65	;	Crystal Structure of Streptavidin Double Mutant S45A/D128A with Biotin: Cooperative Hydrogen-Bond Interactions in the Streptavidin-Biotin System.
1RXJ	;	1.14	;	Crystal structure of streptavidin mutant (M2) where the L3,4 loop was replace by that of avidin
1RXK	;	1.7	;	crystal structure of streptavidin mutant (M3) a combination of M1+M2
1RXH	;	2.9	;	Crystal structure of streptavidin mutant L124R (M1) complexed with biotinyl p-nitroanilide (BNI)
5N99	;	1.5	;	CRYSTAL STRUCTURE OF STREPTAVIDIN with cyclic peptide NQpWQ
5N8W	;	1.1	;	CRYSTAL STRUCTURE OF STREPTAVIDIN with D-amino acid containing peptide GGwhdeatwkpG
5TO2	;	1.65	;	Crystal structure of streptavidin with one wild type subunit and three mutated subunits (N23A/S27D/S45A)
5N8B	;	1.03	;	CRYSTAL STRUCTURE OF STREPTAVIDIN WITH PEPTIDE AFPDYLAEYHGG
5N8J	;	1.05	;	CRYSTAL STRUCTURE OF STREPTAVIDIN WITH PEPTIDE D-amino acid containing peptide GyGlanvdessG
5N7X	;	1.12	;	CRYSTAL STRUCTURE OF STREPTAVIDIN WITH PEPTIDE EWVHPQFEQKAK
5N89	;	1.27	;	CRYSTAL STRUCTURE OF STREPTAVIDIN WITH PEPTIDE GNSFDDWLASKG
5N8E	;	1.1	;	CRYSTAL STRUCTURE OF STREPTAVIDIN WITH PEPTIDE RDPAPAWAHGGG
7CPZ	;	2.5	;	Crystal structure of Streptoavidin-C1 from Streptomyces cinamonensis
7CQ0	;	2.03	;	Crystal structure of Streptoavidin-C1 from Streptomyces cinamonensis
3QFM	;	1.9	;	Crystal structure of Streptococcal asymmetric Ap4A hydrolase and phosphodiesterase Spr1479/SapH
3QFO	;	2.2	;	Crystal structure of Streptococcal asymmetric Ap4A hydrolase and phosphodiesterase Spr1479/SapH im complex with AMP
3QFN	;	2.31	;	Crystal structure of Streptococcal asymmetric Ap4A hydrolase and phosphodiesterase Spr1479/SapH in complex with inorganic phosphate
6WV2	;	2.21	;	Crystal Structure of Streptococcal Bacteriophage Hyaluronidase: Presence of a Prokaryotic Collagen and Elucidation of Catalytic Mechanism
4E8D	;	1.8	;	Crystal structure of streptococcal beta-galactosidase
4E8C	;	1.95	;	Crystal structure of streptococcal beta-galactosidase in complex with galactose
1FNW	;	3.9	;	CRYSTAL STRUCTURE OF STREPTOCOCCAL PYROGENIC EXOTOXIN A
2ICI	;	1.56	;	Crystal Structure of Streptococcal Pyrogenic Exotoxin I
4JKK	;	2.59	;	Crystal Structure of Streptococcus agalactiae beta-glucuronidase in space group I222
4JKL	;	2.288	;	Crystal Structure of Streptococcus agalactiae beta-glucuronidase in space group P21212
1F1S	;	2.1	;	CRYSTAL STRUCTURE OF STREPTOCOCCUS AGALACTIAE HYALURONATE LYASE AT 2.1 ANGSTROM RESOLUTION.
1I8Q	;	2.2	;	CRYSTAL STRUCTURE OF STREPTOCOCCUS AGALACTIAE HYALURONATE LYASE COMPLEXED WITH ENZYME PRODUCT, UNSATURATED DISACCHARIDE HYALURONAN
1LXM	;	2.2	;	Crystal Structure of Streptococcus agalactiae Hyaluronate Lyase Complexed with Hexasaccharide Unit of Hyaluronan
6W1A	;	2.8	;	Crystal structure of Streptococcus dysgalactiae SHP pheromone receptor Rgg2 bound to DNA
5W4M	;	2.388	;	Crystal structure of Streptococcus dysgalactiae SHP pheromone receptor Rgg2(C45S)
5W4N	;	2.198	;	Crystal structure of Streptococcus dysgalactiae SHP pheromone receptor Rgg2(C45S)
5C2O	;	2.35	;	Crystal structure of Streptococcus mutans Deoxycytidylate Deaminase complexed with dTTP
2ZIC	;	2.2	;	Crystal structure of Streptococcus mutans dextran glucosidase
3T0C	;	2.187	;	Crystal structure of Streptococcus mutans MetE complexed with Zinc
5BOD	;	2.2	;	Crystal structure of Streptococcus pneumonia ParE inhibitor
5YIG	;	2.8	;	Crystal structure of Streptococcus pneumonia ParE with inhibitor
1FTH	;	1.9	;	CRYSTAL STRUCTURE OF STREPTOCOCCUS PNEUMONIAE ACYL CARRIER PROTEIN SYNTHASE (3'5'-ADP COMPLEX)
1FTE	;	2.4	;	CRYSTAL STRUCTURE OF STREPTOCOCCUS PNEUMONIAE ACYL CARRIER PROTEIN SYNTHASE (NATIVE 1)
1FTF	;	2.05	;	CRYSTAL STRUCTURE OF STREPTOCOCCUS PNEUMONIAE ACYL CARRIER PROTEIN SYNTHASE (NATIVE 2)
3H71	;	1.7	;	Crystal structure of Streptococcus pneumoniae D39 neuraminidase A precursor (NanA)
3H73	;	1.7	;	Crystal structure of Streptococcus pneumoniae D39 neuraminidase A precursor (NanA) in complex with DANA
3H72	;	1.7	;	Crystal structure of Streptococcus pneumoniae D39 neuraminidase A precursor (NanA) in complex with NANA
3IX9	;	1.95	;	Crystal structure of Streptococcus pneumoniae dihydrofolate reductase - Sp9 mutant
6JBX	;	2.2	;	Crystal structure of Streptococcus pneumoniae FabT in complex with DNA
1EGU	;	1.56	;	CRYSTAL STRUCTURE OF STREPTOCOCCUS PNEUMONIAE HYALURONATE LYASE AT 1.56 A RESOLUTION
1F9G	;	2.0	;	CRYSTAL STRUCTURE OF STREPTOCOCCUS PNEUMONIAE HYALURONATE LYASE COCRYSTALLIZED WITH ASCORBIC ACID
2BRW	;	2.8	;	Crystal structure of Streptococcus Pneumoniae Hyaluronate Lyase from 30percent PEGMME.
2BRV	;	3.3	;	Crystal structure of Streptococcus Pneumoniae Hyaluronate Lyase from 70percent saturated malonate.
3MMS	;	1.6	;	Crystal structure of Streptococcus pneumoniae MTA/SAH nucleosidase in complex with 8-aminoadenine
2YA4	;	1.8	;	Crystal structure of Streptococcus pneumoniae NanA (TIGR4)
2YA6	;	2.0	;	Crystal structure of Streptococcus pneumoniae NanA (TIGR4) in complex with DANA
2YA8	;	1.75	;	Crystal structure of Streptococcus pneumoniae NanA (TIGR4) in complex with Oseltamivir carboxylate
2YA5	;	2.0	;	Crystal structure of Streptococcus pneumoniae NanA (TIGR4) in complex with sialic acid
2YA7	;	1.89	;	Crystal structure of Streptococcus pneumoniae NanA (TIGR4) in complex with Zanamivir
2JKB	;	1.54	;	Crystal structure of Streptococcus pneumoniae NanB in complex with 2, 7-anhydro-Neu5Ac
4YZ1	;	1.97	;	Crystal Structure of Streptococcus pneumoniae NanC, apo structure.
4YW2	;	2.0	;	Crystal Structure of Streptococcus pneumoniae NanC, complex 6'SL
4YW1	;	2.25	;	Crystal Structure of Streptococcus pneumoniae NanC, complex with Neu5Ac and Neu5Ac2en following soaking with 3'SL
4YW3	;	2.05	;	Crystal Structure of Streptococcus pneumoniae NanC, complex with Neu5Ac and Neu5Ac2en following soaking with Neu5Ac2en
4YW5	;	2.3	;	Crystal Structure of Streptococcus pneumoniae NanC, complex with oseltamivir carboxylate
5F9T	;	2.05	;	Crystal Structure of Streptococcus pneumoniae NanC, covalent complex with a fluorinated Neu5Ac derivative
4YZ2	;	2.06	;	Crystal Structure of Streptococcus pneumoniae NanC, in complex with 2-deoxy-2,3-didehydro-N-acetylneuraminic acid.
4YZ5	;	2.27	;	Crystal Structure of Streptococcus pneumoniae NanC, in complex with 3-Sialyllactose
4YZ4	;	2.15	;	Crystal Structure of Streptococcus pneumoniae NanC, in complex with N-Acetylneuraminic acid.
4YZ3	;	2.38	;	Crystal Structure of Streptococcus pneumoniae NanC, in complex with Oseltamivir.
8IAS	;	2.0	;	Crystal structure of Streptococcus pneumoniae pyruvate kinase
8IAV	;	2.59	;	Crystal structure of Streptococcus pneumoniae pyruvate kinase in complex with fructose 1,6-bisphosphate
8IAT	;	1.8	;	Crystal structure of Streptococcus pneumoniae pyruvate kinase in complex with oxalate
8IAU	;	2.0	;	Crystal structure of Streptococcus pneumoniae pyruvate kinase in complex with oxalate and fructose 1,6-bisphosphate
8IAW	;	2.89	;	Crystal structure of Streptococcus pneumoniae pyruvate kinase in complex with phosphoenolpyruvate
8IAX	;	1.8	;	Crystal structure of Streptococcus pneumoniae pyruvate kinase in complex with phosphoenolpyruvate and fructose 1,6-bisphosphate
3KR9	;	2.0	;	Crystal structure of Streptococcus pneumoniae Sp1610, a putative tRNA (m1A22) methyltransferase
3KU1	;	3.0	;	Crystal structure of Streptococcus pneumoniae Sp1610, a putative tRNA (m1A22) methyltransferase, in complex with S-adenosyl-L-methionine
5ZKL	;	1.951	;	Crystal structure of Streptococcus pneumoniae SP_0782 (residues 7-79) in complex with single-stranded DNA dT12
6JIP	;	1.659	;	Crystal structure of Streptococcus pneumoniae SP_0782 (residues 7-79) in complex with single-stranded DNA dT6
6JIQ	;	1.67	;	Crystal structure of Streptococcus pneumoniae SP_0782 (residues 7-79) in complex with single-stranded DNA dT6
5ZKM	;	1.65	;	Crystal structure of Streptococcus pneumoniae SP_0782 (residues 7-79) in complex with single-stranded DNA TCTTCC
4HMO	;	2.0	;	Crystal structure of streptococcus pneumoniae TIGR4 PiaA in complex with Bis-tris propane
4HMQ	;	2.1	;	Crystal structure of streptococcus pneumoniae TIGR4 PiaA in complex with ferrichrome
4QR0	;	2.4	;	Crystal structure of Streptococcus pyogenes Cas2 at pH 5.6
4QR1	;	2.193	;	Crystal structure of Streptococcus pyogenes Cas2 at pH 6.5
4QR2	;	1.8	;	Crystal structure of Streptococcus pyogenes Cas2 at pH 7.5
4OO8	;	2.5	;	Crystal structure of Streptococcus pyogenes Cas9 in complex with guide RNA and target DNA
3TOC	;	2.201	;	Crystal structure of Streptococcus pyogenes Csn2
3V7F	;	2.9	;	Crystal Structure of Streptococcus pyogenes Csn2
6E58	;	2.75	;	Crystal structure of Streptococcus pyogenes endo-beta-N-acetylglucosaminidase (EndoS2)
6MDS	;	2.5	;	Crystal structure of Streptococcus pyogenes endo-beta-N-acetylglucosaminidase (EndoS2) with complex biantennary glycan
6MDV	;	2.5	;	Crystal structure of Streptococcus pyogenes endo-beta-N-acetylglucosaminidase (EndoS2) with high-mannose glycan
5ZYF	;	1.76	;	Crystal structure of Streptococcus pyogenes type II-A Cas2
3QPB	;	1.82	;	Crystal Structure of Streptococcus Pyogenes Uridine Phosphorylase Reveals a Subclass of the NP-I Superfamily
2XJM	;	2.3	;	Crystal structure of Streptococcus suis Dpr with cobalt
2XJN	;	2.1	;	Crystal structure of Streptococcus suis Dpr with copper
2XKQ	;	2.4	;	Crystal structure of Streptococcus suis Dpr with manganese
2XJO	;	2.1	;	Crystal structure of Streptococcus suis Dpr with nickel
3BDK	;	2.5	;	Crystal Structure of Streptococcus suis mannonate dehydratase complexed with substrate analogue
5V1Q	;	2.5	;	Crystal structure of Streptococcus suis SuiB
5V1T	;	2.1	;	Crystal structure of Streptococcus suis SuiB bound to precursor peptide SuiA
5V1S	;	2.492	;	Crystal structure of Streptococcus suis SuiB bound to S-adenosylmethionine
6M0X	;	2.561	;	Crystal structure of Streptococcus thermophilus Cas9 in complex with AGGA PAM
6M0W	;	2.76	;	Crystal structure of Streptococcus thermophilus Cas9 in complex with the AGAA PAM
6W1E	;	2.202	;	Crystal structure of Streptococcus thermophilus SHP pheromone receptor Rgg3
6W1F	;	3.2	;	Crystal structure of Streptococcus thermophilus SHP pheromone receptor Rgg3 bound to DNA
5ZQH	;	2.4	;	Crystal structure of Streptococcus transcriptional regulator
1MR7	;	1.8	;	Crystal Structure of Streptogramin A Acetyltransferase
6X3J	;	2.7	;	Crystal structure of streptogramin A acetyltransferase VatA from Staphylococcus aureus in complex with streptogramin analog F0224 (46)
6X3C	;	3.05	;	Crystal structure of streptogramin A acetyltransferase VatA from Staphylococcus aureus in complex with streptogramin analog F1037 (47)
1MR9	;	3.0	;	Crystal structure of Streptogramin A Acetyltransferase with acetyl-CoA bound
1MRL	;	2.8	;	Crystal structure of streptogramin A acetyltransferase with dalfopristin
4MYO	;	2.696	;	Crystal structure of streptogramin group A antibiotic acetyltransferase VatA from Staphylococcus aureus
4HUR	;	2.15	;	Crystal structure of streptogramin group A antibiotic acetyltransferase VatA from Staphylococcus aureus in complex with acetyl coenzyme A
4HUS	;	2.36	;	Crystal structure of streptogramin group A antibiotic acetyltransferase VatA from Staphylococcus aureus in complex with virginiamycin M1
1QQR	;	2.3	;	CRYSTAL STRUCTURE OF STREPTOKINASE DOMAIN B
7CU1	;	1.91	;	CRYSTAL STRUCTURE OF STREPTOMYCES ALBOGRISEOLUS FLAVIN-DEPENDENT TRYPTOPHAN 6-HALOGENASE (THAL) IN COMPLEX WITH FAD and AMP
7CU2	;	2.4	;	CRYSTAL STRUCTURE OF STREPTOMYCES ALBOGRISEOLUS FLAVIN-DEPENDENT TRYPTOPHAN 6-HALOGENASE THAL IN COMPLEX WITH REDUCED FAD
7CU0	;	1.95	;	Crystal structure of Streptomyces albogriseolus flavin-dependent tryptophan 6-halogenase Thal in complex with tryptophan
3W5M	;	1.8	;	Crystal Structure of Streptomyces avermitilis alpha-L-rhamnosidase
3W5N	;	1.8	;	Crystal Structure of Streptomyces avermitilis alpha-L-rhamnosidase complexed with L-rhamnose
3A21	;	1.51	;	Crystal Structure of Streptomyces avermitilis beta-L-Arabinopyranosidase
4HWX	;	1.9	;	Crystal structure of Streptomyces caespitosus sermetstatin
4HX2	;	2.25	;	Crystal structure of Streptomyces caespitosus sermetstatin in complex with Bacillus licheniformis subtilisin
4HX3	;	2.7	;	Crystal structure of Streptomyces caespitosus sermetstatin in complex with S. caespitosus snapalysin
3B6D	;	1.2	;	Crystal Structure of Streptomyces Cholesterol Oxidase H447Q/E361Q mutant (1.2A)
3B3R	;	0.98	;	Crystal structure of Streptomyces cholesterol oxidase H447Q/E361Q mutant bound to glycerol (0.98A)
1S1F	;	1.5	;	Crystal Structure of Streptomyces Coelicolor A3(2) CYP158A2 from antibiotic biosynthetic pathways
1SE6	;	1.75	;	Crystal Structure of Streptomyces Coelicolor A3(2) CYP158A2 from antibiotic biosynthetic pathways
3WMY	;	1.4	;	Crystal Structure of Streptomyces coelicolor alpha-L-arabinofuranosidase
3WMZ	;	1.9	;	Crystal Structure of Streptomyces coelicolor alpha-L-arabinofuranosidase ethylmercury derivative
3WN0	;	1.9	;	Crystal Structure of Streptomyces coelicolor alpha-L-arabinofuranosidase in complex with L-arabinose
3WN2	;	2.1	;	Crystal Structure of Streptomyces coelicolor alpha-L-arabinofuranosidase in complex with xylohexaose
3WN1	;	2.0	;	Crystal Structure of Streptomyces coelicolor alpha-L-arabinofuranosidase in complex with xylotriose
7PMZ	;	2.03	;	Crystal structure of Streptomyces coelicolor guaB (IMP dehydrogenase) bound to ATP and ppGpp at 2.0 A resolution
3TVR	;	1.8	;	Crystal Structure of Streptomyces coelicolor Polyketide Aromatase/Cyclase whiE-ORFVI
5X15	;	3.094	;	Crystal structure of Streptomyces coelicolor RraAS2, an unusual member of the RNase ES inhibitor RraA protein family
1CLK	;	1.9	;	CRYSTAL STRUCTURE OF STREPTOMYCES DIASTATICUS NO.7 STRAIN M1033 XYLOSE ISOMERASE AT 1.9 A RESOLUTION WITH PSEUDO-I222 SPACE GROUP
5IVU	;	2.42	;	Crystal Structure of Streptomyces griseoflavus Cofilin
5T7D	;	1.4	;	Crystal structure of Streptomyces hygroscopicus bialaphos resistance (BAR) protein in complex with acetyl coenzyme A
5T7E	;	1.8	;	Crystal structure of Streptomyces hygroscopicus Bialaphos Resistance (BAR) protein in complex with Coenzyme A and L-phosphinothricin
1HP4	;	2.2	;	CRYSTAL STRUCTURE OF STREPTOMYCES PLICATUS BETA-N-ACETYLHEXOSAMINIDASE
1HVB	;	1.17	;	CRYSTAL STRUCTURE OF STREPTOMYCES R61 DD-PEPTIDASE COMPLEXED WITH A NOVEL CEPHALOSPORIN ANALOG OF CELL WALL PEPTIDOGLYCAN
6P2O	;	1.88	;	Crystal structure of Streptomyces rapamycinicus GH74 in complex with xyloglucan fragments XLLG and XXXG
4G2T	;	2.405	;	Crystal Structure of Streptomyces sp. SF2575 glycosyltransferase SsfS6, complexed with thymidine diphosphate
6XBC	;	2.863	;	Crystal structure of Streptomyces sviceus SsDesB
6XBB	;	2.366	;	Crystal structure of Streptomyces sviceus SsDesB in complex with NADP+
7KDX	;	1.791	;	Crystal structure of Streptomyces tokunonesis TokK with hydroxycobalamin, 5'-deoxyadenosine, and methionine
7KDY	;	1.939	;	Crystal structure of Streptomyces tokunonesis TokK with hydroxycobalamin, 5'-deoxyadenosine, methionine, and (2R)-pantetheinylated carbapenam
3AWX	;	1.25	;	Crystal structure of Streptomyces tyrosinase in a complex with caddie H82Q mutant soaked in a Cu(II)-containing solution for 80 hr
3AWZ	;	1.43	;	Crystal structure of Streptomyces tyrosinase in a complex with caddie H97Q mutant soaked in a Cu(II)-containing solution for 80 hr
3AWY	;	1.58	;	Crystal structure of Streptomyces tyrosinase in a complex with caddie M84L mutant soaked in a Cu(II)-containing solution for 80 hr
3AWT	;	1.35	;	Crystal structure of Streptomyces tyrosinase in a complex with caddie soaked in a Cu(II)-containing solution for 20 hr: occupancy of Cu(II) is high
3AWS	;	1.24	;	Crystal structure of Streptomyces tyrosinase in a complex with caddie soaked in a Cu(II)-containing solution for 20 hr: occupancy of Cu(II) is low
3AWU	;	1.16	;	Crystal structure of Streptomyces tyrosinase in a complex with caddie soaked in a Cu(II)-containing solution for 40 h
3AWW	;	1.35	;	Crystal structure of Streptomyces tyrosinase in a complex with caddie soaked in a Cu(II)-containing solution for 80 hr: occupancy of CuA is high
3AWV	;	1.4	;	Crystal structure of Streptomyces tyrosinase in a complex with caddie soaked in a Cu(II)-containing solution for 80 hr: occupancy of CuA is low
3AX0	;	1.4	;	Crystal structure of Streptomyces tyrosinase in a complex with caddie Y98F mutant soaked in a Cu(II)-containing solution for 80 hr
3BXO	;	2.0	;	Crystal Structure of Streptomyces venezuelae DesVI
3DNP	;	1.85	;	Crystal structure of Stress response protein yhaX from Bacillus subtilis
6AKL	;	1.75	;	Crystal structure of Striatin3 in complex with SIKE1 Coiled-coil domain
3ZJ7	;	2.5	;	Crystal structure of strictosidine glucosidase in complex with inhibitor-1
3ZJ8	;	3.01	;	Crystal structure of strictosidine glucosidase in complex with inhibitor-2
6N5V	;	2.549	;	Crystal Structure of Strictosidine in complex with 1H-indole-4-ethanamine
7T5I	;	2.94	;	Crystal Structure of Strictosidine Synthase in complex with R-IPA(2-(1H-indol-3-yl) propan-1-amine)
7T5J	;	2.86	;	Crystal Structure of Strictosidine Synthase in complex with S-IPA (2-(1H-indol-3-yl) propan-1-amine)
5Z7Z	;	1.978	;	Crystal structure of Striga hermonthica Dwarf14 (ShD14)
5Z7W	;	1.657	;	Crystal structure of Striga hermonthica HTL1 (ShHTL1)
5Z7X	;	2.055	;	Crystal structure of Striga hermonthica HTL4 (ShHTL4)
5Z7Y	;	1.9	;	Crystal structure of Striga hermonthica HTL7 (ShHTL7)
6J2R	;	1.4	;	Crystal structure of Striga hermonthica HTL8 (ShHTL8)
5DNU	;	1.2	;	Crystal structure of Striga KAI2-like protein in complex with karrikin
6V91	;	1.9	;	Crystal structure of Stringent starvation protein A (BTH_I2974) from Burkholderia thailandensis
1YY7	;	2.02	;	Crystal structure of stringent starvation protein A (SspA), an RNA polymerase-associated transcription factor
1QIA	;	2.0	;	CRYSTAL STRUCTURE OF STROMELYSIN CATALYTIC DOMAIN
1QIC	;	2.0	;	CRYSTAL STRUCTURE OF STROMELYSIN CATALYTIC DOMAIN
3HRP	;	1.7	;	Crystal structure of Structural genomics protein of unknown function (NP_812590.1) from Bacteroides thetaiotaomicron VPI-5482 at 1.70 A resolution
3LWC	;	1.4	;	Crystal structure of Structural Genomics, unknown function (YP_766765.1) from Rhizobium leguminosarum BV. viciae 3841 at 1.40 A resolution
4UXM	;	1.5	;	Crystal Structure of Struthiocalcin-1, a different crystal form.
2ZBC	;	1.9	;	Crystal structure of STS042, a stand-alone RAM module protein, from hyperthermophilic archaeon Sulfolobus tokodaii strain7.
3MAF	;	2.971	;	Crystal structure of StSPL (asymmetric form)
3MAD	;	2.0	;	Crystal structure of StSPL (symmetric form)
3MBB	;	2.051	;	Crystal structure of StSPL - apo form, after treatment with semicarbazide
3MAU	;	2.9	;	Crystal structure of StSPL in complex with phosphoethanolamine
3ZTH	;	2.4	;	Crystal structure of Stu0660 of Streptococcus thermophilus
7TB1	;	1.785	;	Crystal structure of STUB1 with a macrocyclic peptide
3N1H	;	2.201	;	Crystal Structure of StWhy2
3R9Y	;	2.35	;	Crystal Structure of StWhy2 K67A (form I)
3R9Z	;	1.755	;	Crystal Structure of StWhy2 K67A (form II)
7BV4	;	2.0	;	Crystal structure of STX17 LIR region in complex with GABARAP
7NBY	;	1.93	;	Crystal structure of SU3327 (halicin) covalently bound to the main protease (3CLpro/Mpro) of SARS-CoV-2.
2WEL	;	1.9	;	Crystal structure of SU6656-bound calcium/calmodulin-dependent protein kinase II delta in complex with calmodulin
4AXK	;	2.25	;	CRYSTAL STRUCTURE OF subHisA from the thermophile Corynebacterium efficiens
4KPT	;	1.4	;	Crystal structure of substrate binding domain 1 (SBD1) OF ABC transporter GLNPQ from lactococcus lactis
6FXG	;	1.7	;	Crystal structure of substrate binding domain 1 (SBD1) OF ABC transporter GLNPQ in complex with Asparagine
4ZEF	;	1.4	;	Crystal structure of substrate binding domain 2 (SBD2) OF ABC transporter GLNPQ from Enterococcus faecalis
7X0R	;	1.47	;	Crystal structure of substrate binding protein Lbp complexed wtih guanosine from Clostridium thermocellum
8IDU	;	2.0	;	Crystal structure of substrate bound-form dehydroquinate dehydratase from Corynebacterium glutamicum
1MXH	;	2.2	;	Crystal Structure of Substrate Complex of Putative Pteridine Reductase 2 (PTR2) from Trypanosoma cruzi
6W0S	;	1.7	;	Crystal structure of substrate free cytochrome P450 NasF5053 from Streptomyces sp. NRRL F-5053
2Z3T	;	1.9	;	Crystal Structure of Substrate Free Cytochrome P450 StaP (CYP245A1)
1MMF	;	2.5	;	Crystal structure of substrate free form of glycerol dehydratase
3LOP	;	1.55	;	Crystal structure of substrate-binding periplasmic protein (Pbp) from Ralstonia solanacearum
7KZ8	;	2.2	;	Crystal structure of substrate-binding protein Aapf from Pseudomonas sp. PDC86
8WXM	;	1.5	;	Crystal structure of substrate-binding protein from Rhodothermus marinus (Dose I)
8WXN	;	1.58	;	Crystal structure of substrate-binding protein from Rhodothermus marinus (Dose II)
8WXO	;	1.68	;	Crystal structure of substrate-binding protein from Rhodothermus marinus (Dose III)
8WXP	;	1.75	;	Crystal structure of substrate-binding protein from Rhodothermus marinus (Dose IV)
3K7Q	;	2.05	;	Crystal structure of substrate-bound 6-hydroxy-L-nicotine oxidase from Arthrobacter nicotinovorans
3UJH	;	2.1	;	Crystal structure of substrate-bound Glucose-6-phosphate isomerase from Toxoplasma gondii
5E9S	;	2.8	;	Crystal structure of substrate-bound glutamate transporter homologue GltTk
3NMU	;	2.729	;	Crystal Structure of substrate-bound halfmer box C/D RNP
4FMX	;	1.554	;	Crystal Structure of Substrate-Bound P450cin
6IKG	;	2.3	;	Crystal structure of substrate-bound S9 peptidase (S514A mutant) from Deinococcus radiodurans
5U8E	;	2.18	;	Crystal Structure of substrate-free arginine kinase from spider Polybetes pythagoricus
5OFQ	;	2.7	;	Crystal structure of substrate-free CYP109A2 from Bacillus megaterium
3A15	;	1.79	;	Crystal Structure of Substrate-Free Form of Aldoxime Dehydratase (OxdRE)
2DKE	;	2.5	;	Crystal structure of substrate-free form of PcyA
6SH1	;	2.1	;	Crystal structure of substrate-free human neprilysin E584D.
4L3T	;	2.03	;	Crystal Structure of Substrate-free Human Presequence Protease
3L61	;	1.5	;	Crystal structure of substrate-free P450cam at 200 mM [K+]
3L62	;	1.7	;	Crystal structure of substrate-free P450cam at low [K+]
4FB2	;	1.37	;	Crystal Structure of Substrate-Free P450cin
1PHC	;	1.6	;	CRYSTAL STRUCTURE OF SUBSTRATE-FREE PSEUDOMONAS PUTIDA CYTOCHROME P450
3ZFO	;	2.01	;	Crystal structure of substrate-like, unprocessed N-terminal protease Npro mutant S169P
3ZFU	;	1.76	;	Crystal structure of substrate-like, unprocessed N-terminal protease Npro mutant S169P with sulphate
1BFK	;	2.3	;	CRYSTAL STRUCTURE OF SUBTILISIN CARLSBERG IN 40% ACETONITRILE
1AF4	;	2.6	;	CRYSTAL STRUCTURE OF SUBTILISIN CARLSBERG IN ANHYDROUS DIOXANE
3VYV	;	1.36	;	Crystal structure of subtilisin NAT at 1.36
1SCJ	;	2.0	;	CRYSTAL STRUCTURE OF SUBTILISIN-PROPEPTIDE COMPLEX
4AFA	;	2.05	;	Crystal Structure of subtype-switched Epithelial Adhesin 1 to 2 A domain (Epa1to2A) from Candida glabrata in complex with glycerol
4AFB	;	1.9	;	Crystal Structure of subtype-switched Epithelial Adhesin 1 to 3 A domain (Epa1to3A) from Candida glabrata in complex with glycerol
4AFC	;	1.55	;	Crystal Structure of subtype-switched Epithelial Adhesin 1 to 6 A domain (Epa1to6A) from Candida glabrata in complex with Galb1-3Glc
6Y9J	;	1.1	;	Crystal Structure of subtype-switched Epithelial Adhesin 1 to 9 A domain (Epa1-CBL2Epa9) from Candida glabrata in complex with beta-lactose
6Y98	;	2.8	;	Crystal Structure of subtype-switched Epithelial Adhesin 9 to 1 A domain (Epa9-CBL2Epa1) from Candida glabrata in complex with beta-lactose
5X09	;	2.35	;	Crystal structure of subunit A mutant P235A/S238C of the A-ATP synthase from pyrococcus horikoshii OT3
3TGW	;	1.75	;	Crystal structure of subunit B mutant H156A of the A1AO ATP synthase
3TIV	;	1.75	;	Crystal structure of subunit B mutant N157A of the A1AO ATP synthase
3SSA	;	1.7	;	Crystal structure of subunit B mutant N157T of the A1AO ATP synthase
1U7L	;	1.75	;	Crystal Structure of subunit C (vma5p) of the yeast V-ATPase
1R5Z	;	1.95	;	Crystal Structure of Subunit C of V-ATPase
4IX9	;	2.33	;	Crystal structure of subunit F of V-ATPase from S. cerevisiae
1XB4	;	3.1	;	Crystal structure of subunit VPS25 of the endosomal trafficking complex ESCRT-II
6KM9	;	2.724	;	Crystal structure of SucA from Vibrio vulnificus
6KMA	;	2.282	;	Crystal structure of SucA with glycolaldehyde-1-13C from Vibrio vulnificus
3E4O	;	2.3	;	Crystal structure of succinate bound state DctB
5VBF	;	2.35	;	Crystal structure of succinate semialdehyde dehydrogenase from Burkholderia vietnamiensis
4V6H	;	2.7	;	Crystal structure of succinate-semialdehyde dehydrogenase from Burkholderia pseudomallei
4OGD	;	1.6	;	Crystal structure of succinic semialdehyde dehydrogenase from Streptococcus pyogenes in complex with NADP+ as the cofactor
4OHT	;	2.1	;	Crystal structure of succinic semialdehyde dehydrogenase from Streptococcus pyogenes in complex with NADP+ as the cofactor
2QGM	;	1.7	;	Crystal structure of succinoglycan biosynthesis protein at the resolution 1.7 A. Northeast Structural Genomics Consortium target BcR136.
1VGY	;	1.9	;	Crystal structure of succinyl diaminopimelate desuccinylase
2YV2	;	2.2	;	Crystal Structure of Succinyl-CoA Synthetase Alpha Chain from Aeropyrum pernix K1
2YV1	;	1.7	;	Crystal Structure of Succinyl-CoA Synthetase Alpha Chain from Methanocaldococcus jannaschii DSM 2661
4PQA	;	1.78	;	Crystal Structure of succinyl-diaminopimelate desuccinylase from Neisseria meningitidis MC58 in complex with the Inhibitor Captopril
1YW6	;	3.1	;	Crystal Structure of Succinylglutamate Desuccinylase from Escherichia coli, Northeast Structural Genomics Target ET72.
2G9D	;	3.0	;	Crystal Structure of Succinylglutamate desuccinylase from Vibrio cholerae, Northeast Structural Genomics Target VcR20
3CDX	;	2.1	;	Crystal structure of succinylglutamatedesuccinylase/aspartoacylase from Rhodobacter sphaeroides
3JU8	;	1.82	;	Crystal Structure of Succinylglutamic Semialdehyde Dehydrogenase from Pseudomonas aeruginosa.
6S9U	;	2.05	;	Crystal structure of sucrose 6F-phosphate phosphorylase from Ilumatobacter coccineus
6S9V	;	1.83	;	Crystal structure of sucrose 6F-phosphate phosphorylase from Thermoanaerobacter thermosaccharolyticum
5YKS	;	2.9	;	Crystal structure of sucrose nonfermenting-related kinase (SNRK)
3VE0	;	3.353	;	Crystal structure of Sudan Ebolavirus Glycoprotein (strain Boniface) bound to 16F6
3S88	;	3.351	;	Crystal structure of Sudan Ebolavirus Glycoprotein (strain Gulu) bound to 16F6
8B1O	;	1.75	;	Crystal structure of SUDV VP40 C314S mutant
8B1P	;	1.7	;	Crystal structure of SUDV VP40 CCS mutant
8B2U	;	1.8	;	Crystal structure of SUDV VP40 in complex with salicylic acid
8AYU	;	2.0	;	Crystal structure of SUDV VP40 L117A mutant
8AYT	;	1.9	;	Crystal structure of SUDV VP40 W95A mutant
5AWF	;	2.957	;	Crystal structure of SufB-SufC-SufD complex from Escherichia coli
2ZU0	;	2.2	;	Crystal structure of SufC-SufD complex involved in the iron-sulfur cluster biosynthesis
6JZV	;	2.0	;	Crystal structure of SufU from Bacillus subtilis
6JZW	;	2.64	;	Crystal structure of SufU from Bacillus subtilis with Cys persulfurated
4KM8	;	2.26	;	Crystal structure of Sufud60
4KMD	;	1.7	;	Crystal structure of Sufud60-Gli1p
5IX8	;	1.6	;	Crystal structure of sugar ABC transport system, substrate-binding protein from Bordetella parapertussis 12822
3G1W	;	2.02	;	Crystal structure of sugar ABC transporter (sugar-binding protein) from Bacillus halodurans
5ULB	;	1.28	;	Crystal structure of sugar ABC transporter from Yersinia enterocolitica subsp. enterocolitica 8081
2YYZ	;	2.11	;	Crystal structure of Sugar ABC transporter, ATP-binding protein
4ZAS	;	2.47	;	Crystal structure of sugar aminotransferase CalS13 from Micromonospora echinospora
4PIW	;	2.7	;	Crystal structure of sugar aminotransferase WecE from Escherichia coli K-12
4ZAH	;	2.24	;	Crystal structure of sugar aminotransferase WecE with External Aldimine VII from Escherichia coli K-12
7X0H	;	1.85	;	Crystal structure of sugar binding protein CbpA complexed wtih glucose from Clostridium thermocellum
7X0G	;	2.1	;	Crystal structure of sugar binding protein CbpA from Clostridium thermocellum
7X0J	;	1.7	;	Crystal structure of sugar binding protein CbpB complexed wtih cellobiose from Clostridium thermocellum
7X0M	;	2.0	;	Crystal structure of sugar binding protein CbpB complexed wtih cellopentaose from Clostridium thermocellum
7X0L	;	1.9	;	Crystal structure of sugar binding protein CbpB complexed wtih cellotetraose from Clostridium thermocellum
7X0K	;	1.7	;	Crystal structure of sugar binding protein CbpB complexed wtih cellotriose from Clostridium thermocellum
7X0N	;	1.68	;	Crystal structure of sugar binding protein CbpB complexed wtih laminaribiose from Clostridium thermocellum
7X0I	;	1.7	;	Crystal structure of sugar binding protein CbpB from Clostridium thermocellum
7X0O	;	2.0	;	Crystal structure of sugar binding protein CbpC from Clostridium thermocellum
7X0P	;	1.5	;	Crystal structure of sugar binding protein CbpD from Clostridium thermocellum
3VW5	;	2.6	;	Crystal structure of sugar epimerase from ruminal bacterium
3I7D	;	2.3	;	Crystal structure of sugar phosphate isomerase from a cupin superfamily SPO2919 from Silicibacter pomeroyi (YP_168127.1) from SILICIBACTER POMEROYI DSS-3 at 2.30 A resolution
3L23	;	1.7	;	Crystal structure of Sugar phosphate isomerase/epimerase (YP_001303399.1) from Parabacteroides distasonis ATCC 8503 at 1.70 A resolution
6BLG	;	2.102	;	Crystal Structure of Sugar Transaminase from Klebsiella pneumoniae Complexed with PLP
4R2F	;	2.0	;	Crystal structure of sugar transporter ACHL_0255 from Arthrobacter chlorophenolicus A6, target EFI-510633, with bound laminaribiose
4QRZ	;	1.34	;	Crystal structure of sugar transporter atu4361 from agrobacterium fabrum c58, target efi-510558, with bound maltotriose
4RK9	;	2.15	;	CRYSTAL STRUCTURE OF SUGAR TRANSPORTER BL01359 FROM Bacillus licheniformis, TARGET EFI-510856, IN COMPLEX WITH STACHYOSE
3BRS	;	2.0	;	Crystal structure of sugar transporter from Clostridium phytofermentans
4R2B	;	1.87	;	Crystal structure of sugar transporter Oant_3817 from Ochrobactrum anthropi, target EFI-510528, with bound glucose
4RK2	;	1.8	;	Crystal structure of sugar transporter RHE_PF00321 from Rhizobium etli, target EFI-510806, an open conformation
5Z6B	;	1.582	;	Crystal structure of sugar-binding protein YesO in complex with rhamnogalacturonan trisaccharide
3CS3	;	2.4	;	Crystal structure of sugar-binding transcriptional regulator (LacI family) from Enterococcus faecalis
3DBI	;	2.45	;	CRYSTAL STRUCTURE OF SUGAR-BINDING TRANSCRIPTIONAL REGULATOR (LACI FAMILY) FROM ESCHERICHIA COLI COMPLEXED WITH PHOSPHATE
7L16	;	3.15	;	Crystal structure of sugar-bound melibiose permease MelB
7L17	;	3.05	;	Crystal structure of sugar-bound melibiose permease MelB
1PVT	;	2.5	;	Crystal structure of sugar-phosphate aldolase from Thermotoga maritima
5WAX	;	2.0	;	Crystal Structure of Sugarcane SAPK10 (serine/threonine-protein kinase 10)
7KSN	;	1.51	;	Crystal Structure of Sugarwin
5VE6	;	2.953	;	Crystal structure of Sugen kinase 223
1OFT	;	2.9	;	Crystal structure of SulA from Pseudomonas aeruginosa
1OFU	;	2.1	;	Crystal structure of SulA:FtsZ from Pseudomonas aeruginosa
2A3U	;	1.34	;	Crystal structure of sulbactam bound to E166A variant of SHV-1 beta-lactamase
8GOL	;	1.6	;	crystal structure of SulE
8GP0	;	1.46	;	crystal structure of SulE
8IVE	;	1.44	;	crystal structure of SulE mutant
8IVH	;	1.45	;	crystal structure of SulE mutant
8IVM	;	1.32	;	crystal structure of SulE mutant
8IVN	;	1.5	;	crystal structure of SulE mutant
8IVS	;	1.52	;	crystal structure of SulE mutant
8IVT	;	1.42	;	crystal structure of SulE mutant
8IW3	;	1.56	;	crystal structure of SulE mutant
8IW6	;	1.44	;	crystal structure of SulE mutant
8IW8	;	1.57	;	crystal structure of SulE mutant
8J7G	;	1.63	;	crystal structure of SulE mutant
8J7J	;	1.54	;	crystal structure of SulE mutant
8J7K	;	1.36	;	crystal structure of SulE mutant
4MHX	;	2.0	;	Crystal Structure of Sulfamidase
4MIV	;	2.4	;	Crystal Structure of Sulfamidase, Crystal Form L
7STT	;	1.603	;	Crystal structure of sulfatase from Pedobacter yulinensis
7STU	;	2.23	;	Crystal structure of sulfatase from Pedobacter yulinensis
7STV	;	2.35	;	Crystal structure of sulfatase from Pedobacter yulinensis
4GXA	;	2.807	;	Crystal structure of Sulfate free form of CYSB, a member of LysR family from Salmonella typhimurium LT2
3OIR	;	1.85	;	Crystal structure of sulfate transporter family protein from Wolinella succinogenes
4XS5	;	2.9	;	Crystal structure of Sulfate transporter/antisigma-factor antagonist STAS from Dyadobacter fermentans DSM 18053
4PVQ	;	2.13	;	Crystal structure of sulfate-bound human l-asparaginase protein
2QRJ	;	1.6	;	Crystal Structure of Sulfate-bound Saccharopine Dehydrogenase (L-Lys Forming) from Saccharomyces cerevisiae
5YPQ	;	2.65	;	Crystal structure of sulfated dehydroquinate dehydratase from Acinetobacter baumannii at 2.65 A resolution
3SXI	;	2.1792	;	Crystal structure of sulfide:quinone oxidoreductase Cys128Ala variant from Acidithiobacillus ferrooxidans complexed with decylubiquinone
3T14	;	2.21	;	Crystal structure of sulfide:quinone oxidoreductase Cys128Ala variant from Acidithiobacillus ferrooxidans with bound disulfide
3T2K	;	2.3501	;	Crystal structure of sulfide:quinone oxidoreductase Cys128Ala variant from Acidithiobacillus ferrooxidans with bound trisulfane
3SZW	;	2.2	;	Crystal structure of sulfide:quinone oxidoreductase Cys128Ser variant from Acidithiobacillus ferrooxidans in complex with decylubiquinone
3SX6	;	1.7955	;	Crystal structure of sulfide:quinone oxidoreductase Cys356Ala variant from Acidithiobacillus ferrooxidans complexed with decylubiquinone
3T2Z	;	2.2994	;	Crystal structure of sulfide:quinone oxidoreductase from Acidithiobacillus ferrooxidans
3T31	;	2.3	;	Crystal structure of sulfide:quinone oxidoreductase from Acidithiobacillus ferrooxidans in complex with decylubiquinone
3SZC	;	2.2	;	Crystal structure of sulfide:quinone oxidoreductase from Acidithiobacillus ferrooxidans in complex with gold (I) cyanide
3SZ0	;	2.1501	;	Crystal structure of sulfide:quinone oxidoreductase from Acidithiobacillus ferrooxidans in complex with sodium selenide
3T0K	;	2.0	;	Crystal structure of sulfide:quinone oxidoreductase from Acidithiobacillus ferrooxidans with bound trisulfide and decylubiquinone
3KPK	;	2.05	;	Crystal structure of sulfide:quinone oxidoreductase from Acidithiobacillus ferrooxidans, C160A mutant
3SZF	;	2.0994	;	Crystal structure of sulfide:quinone oxidoreductase H198A variant from Acidithiobacillus ferrooxidans in complex with bound trisulfide and decylubiquinone
3T2Y	;	2.5001	;	Crystal structure of sulfide:quinone oxidoreductase His132Ala variant from Acidithiobacillus ferrooxidans with bound disulfide
3SY4	;	1.91	;	Crystal structure of sulfide:quinone oxidoreductase Ser126Ala variant from Acidithiobacillus ferrooxidans
3SYI	;	2.2001	;	Crystal structure of sulfide:quinone oxidoreductase Ser126Ala variant from Acidithiobacillus ferrooxidans using 7.0 keV diffraction data
6KY4	;	3.2	;	Crystal structure of Sulfiredoxin from Arabidopsis thaliana
3HY2	;	2.1	;	Crystal Structure of Sulfiredoxin in Complex with Peroxiredoxin I and ATP:Mg2+
7XCM	;	3.2	;	Crystal structure of sulfite MttB structure at 3.2 A resolution
2PW8	;	1.84	;	Crystal structure of sulfo-hirudin complexed to thrombin
6JKO	;	1.9	;	Crystal structure of sulfoacetaldehyde reductase from Bifidobacterium kashiwanohense
6JKP	;	3.008	;	Crystal structure of sulfoacetaldehyde reductase from Bifidobacterium kashiwanohense in complex with NAD+
5A7Z	;	2.1	;	Crystal structure of Sulfolobus acidocaldarius Trm10 at 2.1 angstrom resolution.
5A7T	;	2.4	;	Crystal structure of Sulfolobus acidocaldarius Trm10 at 2.4 angstrom resolution.
5A7Y	;	2.5	;	Crystal structure of Sulfolobus acidocaldarius Trm10 in complex with S-adenosylhomocysteine
4CNF	;	1.4	;	Crystal structure of Sulfolobus acidocaldarius TrmJ
4CNG	;	1.1	;	Crystal structure of Sulfolobus acidocaldarius TrmJ in complex with S-adenosyl-L-Homocysteine
3KXT	;	1.602	;	Crystal structure of Sulfolobus Cren7-dsDNA complex
4R56	;	2.3	;	Crystal structure of Sulfolobus Cren7-dsDNA(GTGATCAC) complex
2ZRU	;	2.0	;	Crystal structure of Sulfolobus shibatae isopentenyl diphosphate isomerase in complex with FMN
2ZRX	;	3.0	;	Crystal structure of Sulfolobus shibatae isopentenyl diphosphate isomerase in complex with FMN and DMAPP.
2ZRW	;	2.4	;	Crystal structure of Sulfolobus shibatae isopentenyl diphosphate isomerase in complex with FMN and IPP.
3B04	;	2.3	;	Crystal structure of Sulfolobus shibatae isopentenyl diphosphate isomerase in complex with oIPP.
2ZRZ	;	2.9	;	Crystal structure of Sulfolobus shibatae isopentenyl diphosphate isomerase in complex with reduced FMN and DMAPP
3B06	;	2.29	;	Crystal structure of Sulfolobus shibatae isopentenyl diphosphate isomerase in complex with reduced FMN and DMAPP.
3B05	;	2.2	;	Crystal structure of Sulfolobus shibatae isopentenyl diphosphate isomerase in complex with reduced FMN and IPP at 2.2A resolution.
2ZRY	;	2.64	;	Crystal structure of Sulfolobus shibatae isopentenyl diphosphate isomerase in complex with reduced FMN and IPP.
2ZRV	;	2.3	;	Crystal structure of Sulfolobus shibatae isopentenyl diphosphate isomerase in complex with reduced FMN.
3B03	;	2.2	;	Crystal structure of Sulfolobus shibatae isopentenyl diphosphate isomerase in complex with vIPP.
3VKJ	;	1.7	;	Crystal structure of Sulfolobus shibatae isopentenyl diphosphate isomerase, octameric form
2Y0S	;	3.8	;	Crystal structure of Sulfolobus shibatae RNA polymerase in P21 space group
2V78	;	2.0	;	Crystal structure of Sulfolobus solfataricus 2-keto-3-deoxygluconate kinase
2VAR	;	2.1	;	Crystal structure of Sulfolobus solfataricus 2-keto-3-deoxygluconate kinase complexed with 2-keto-3-deoxygluconate
3FHG	;	1.9	;	Crystal structure of Sulfolobus solfataricus 8-oxoguanine DNA glycosylase (SsOgg)
3I4C	;	2.0	;	Crystal structure of Sulfolobus Solfataricus ADH(SsADH) double mutant (W95L,N249Y)
3ID5	;	4.01	;	Crystal structure of Sulfolobus solfataricus C/D RNP assembled with Nop5, fibrillarin, L7Ae and a split half C/D RNA
5GME	;	1.7	;	Crystal structure of Sulfolobus solfataricus Diphosphomevalonate decarboxylase in complex with ADP
5GMD	;	1.5	;	Crystal structure of Sulfolobus solfataricus diphosphomevalonate decarboxylase in complex with ATP-gamma-S
1JNY	;	1.8	;	Crystal structure of Sulfolobus solfataricus elongation factor 1 alpha in complex with GDP
1EH9	;	3.0	;	CRYSTAL STRUCTURE OF SULFOLOBUS SOLFATARICUS GLYCOSYLTREHALOSE TREHALOHYDROLASE
4RZK	;	2.677	;	Crystal structure of Sulfolobus solfataricus Hsp20.1 ACD
6JD2	;	2.53	;	Crystal structure of Sulfolobus solfataricus ketol-acid reductoisomerase (Sso-KARI) in complex with Mg2+ at pH8.5
3ID6	;	2.6	;	Crystal structure of Sulfolobus solfataricus Nop5 (1-262) and fibrillarin complex
3ICX	;	3.1	;	Crystal structure of Sulfolobus solfataricus Nop5 (135-380)
4ZYE	;	1.85	;	Crystal structure of Sulfolobus solfataricus O6-methylguanine methyltransferase
5LLQ	;	2.7	;	Crystal structure of Sulfolobus solfataricus O6-methylguanine methyltransferase C119F variant
4ZYH	;	2.6	;	Crystal structure of Sulfolobus solfataricus O6-methylguanine methyltransferase C119L variant
4ZYD	;	2.682	;	Crystal structure of Sulfolobus solfataricus O6-methylguanine methyltransferase in complex with modified DNA
1XTY	;	1.8	;	Crystal structure of Sulfolobus solfataricus peptidyl-tRNA hydrolase
3F8R	;	1.95	;	Crystal structure of Sulfolobus solfataricus Thioredoxin reductase B3 in complex with two NADP molecules
4LGM	;	2.711	;	Crystal Structure of Sulfolobus solfataricus Vps4
2E2P	;	2.0	;	Crystal structure of Sulfolobus tokodaii hexokinase in complex with ADP
2E2O	;	1.65	;	Crystal structure of Sulfolobus tokodaii hexokinase in complex with glucose
2E2Q	;	2.0	;	Crystal structure of Sulfolobus tokodaii hexokinase in complex with xylose, Mg2+, and ADP
2E2N	;	1.9	;	Crystal structure of Sulfolobus tokodaii hexokinase in the apo form
3HJE	;	1.9	;	Crystal structure of sulfolobus tokodaii hypothetical maltooligosyl trehalose synthase
2F7L	;	2.8	;	Crystal structure of Sulfolobus tokodaii phosphomannomutase/phosphoglucomutase
7S2I	;	2.32	;	Crystal structure of sulfonamide resistance enzyme Sul1 in complex with 6-hydroxymethylpterin
7S2J	;	1.85	;	Crystal structure of sulfonamide resistance enzyme Sul2 apoenzyme
7S2K	;	1.74	;	Crystal structure of sulfonamide resistance enzyme Sul2 in complex with 7,8-dihydropteroate, magnesium, and pyrophosphate
7S2L	;	2.79	;	Crystal structure of sulfonamide resistance enzyme Sul3 apoenzyme
7S2M	;	2.42	;	Crystal structure of sulfonamide resistance enzyme Sul3 in complex with 6-hydroxymethylpterin
8SCD	;	2.06	;	Crystal structure of sulfonamide resistance enzyme Sul3 in complex with reaction intermediate
7BVV	;	2.12	;	Crystal structure of sulfonic peroxiredoxin Ahp1 in complex with thioredoxin Trx2
3RNL	;	1.752	;	Crystal Structure of Sulfotransferase from Alicyclobacillus acidocaldarius
2ZQ5	;	2.0	;	Crystal structure of sulfotransferase STF1 from Mycobacterium tuberculosis H37Rv (type1 form)
2Z6V	;	2.6	;	Crystal structure of sulfotransferase STF9 from Mycobacterium avium
6M35	;	1.73	;	Crystal structure of sulfur oxygenase reductase from Sulfurisphaera tokodaii
3IPP	;	2.4	;	crystal structure of sulfur-free YnjE
7DQR	;	1.74	;	Crystal structure of Sulfurisphaera tokodaii methylated O6-methylguanine methyltransferase
7DKN	;	1.79	;	Crystal structure of Sulfurisphaera tokodaii O6-methylguanine methyltransferase
7CSM	;	1.25	;	Crystal structure of Sulfurisphaera tokodaii O6-methylguanine methyltransferase C120S variant
7E1P	;	1.63	;	Crystal structure of Sulfurisphaera tokodaii O6-methylguanine methyltransferase C120S variant in complex with O6-methyldeoxyguanosine
7D4V	;	1.78	;	Crystal structure of Sulfurisphaera tokodaii O6-methylguanine methyltransferase Y91F/C120S variant
7DQQ	;	2.6	;	Crystal structure of Sulfurisphaera tokodaii O6-methylguanine methyltransferase Y91F/C120S variant in complex with O6-methyldeoxyguanosine
7SYB	;	1.45	;	Crystal Structure of sulfurtransferase (DsrC family protein) from Acinetobacter baumannii
4IFB	;	2.3	;	Crystal structure of SULT 2A1 LLGG mutant with PAPS
4GRA	;	2.56	;	Crystal structure of SULT1A1 bound with PAP
6CWY	;	2.462	;	Crystal structure of SUMO E1 in complex with an allosteric inhibitor
4MVT	;	2.3	;	Crystal structure of SUMO E3 Ligase PIAS3
2BF8	;	2.3	;	Crystal structure of SUMO modified ubiquitin conjugating enzyme E2- 25K
2D07	;	2.1	;	Crystal Structure of SUMO-3-modified Thymine-DNA Glycosylase
4WJQ	;	1.35	;	Crystal Structure of SUMO1 in complex with Daxx
4WJP	;	1.7	;	Crystal Structure of SUMO1 in complex with phosphorylated Daxx
6V7Q	;	1.35	;	Crystal structure of SUMO1 in complex with phosphorylated PIAS-SIM2
4WJN	;	1.5	;	Crystal structure of SUMO1 in complex with phosphorylated PML
6V7P	;	1.395	;	Crystal structure of SUMO1 in complex with PIAS-SIM2
4WJO	;	1.46	;	Crystal Structure of SUMO1 in complex with PML
1WYW	;	2.1	;	Crystal Structure of SUMO1-conjugated thymine DNA glycosylase
7E34	;	3.19	;	Crystal structure of SUN1-Speedy A-CDK2
4MO7	;	1.701	;	Crystal structure of superantigen PfiT
4MXM	;	1.95	;	Crystal structure of superantigen pfit
3URY	;	1.9	;	Crystal Structure of Superantigen-like Protein, Exotoxin from Staphylococcus aureus subsp. aureus NCTC 8325
3R2I	;	2.3	;	Crystal Structure of Superantigen-like Protein, Exotoxin SACOL0473 from Staphylococcus aureus subsp. aureus COL
2P6R	;	3.0	;	Crystal structure of superfamily 2 helicase Hel308 in complex with unwound DNA
6CYL	;	1.8	;	Crystal Structure of Superoxide Dismutase double mutant (G74Q+Q149G) from Trichoderma reesei
3H1S	;	1.9	;	Crystal structure of superoxide dismutase from Francisella tularensis subsp. tularensis SCHU S4
3CEI	;	2.4	;	Crystal Structure of Superoxide Dismutase from Helicobacter pylori
2Q2L	;	2.367	;	Crystal Structure of Superoxide Dismutase from P. atrosanguina
2CW2	;	1.86	;	Crystal structure of Superoxide dismutase from P. Marinus
1P7G	;	1.8	;	Crystal structure of superoxide dismutase from Pyrobaculum aerophilum
4RVP	;	2.6	;	Crystal structure of superoxide dismutase from sedum alfredii
1DQI	;	1.7	;	CRYSTAL STRUCTURE OF SUPEROXIDE REDUCTASE FROM P. FURIOSUS IN THE OXIDIZED STATE AT 1.7 ANGSTROMS RESOLUTION
1DO6	;	2.0	;	CRYSTAL STRUCTURE OF SUPEROXIDE REDUCTASE IN THE OXIDIZED STATE AT 2.0 ANGSTROM RESOLUTION
1DQK	;	2.0	;	CRYSTAL STRUCTURE OF SUPEROXIDE REDUCTASE IN THE REDUCED STATE AT 2.0 ANGSTROMS RESOLUTION
4KMH	;	3.04	;	Crystal structure of Suppressor of Fused d20
3RQ4	;	1.8	;	Crystal structure of suppressor of variegation 4-20 homolog 2
6KSU	;	2.2	;	Crystal structure of SurE
2WQK	;	1.5	;	Crystal Structure of Sure Protein from Aquifex aeolicus
1J9K	;	2.1	;	CRYSTAL STRUCTURE OF SURE PROTEIN FROM T.MARITIMA IN COMPLEX WITH TUNGSTATE
1J9L	;	1.9	;	CRYSTAL STRUCTURE OF SURE PROTEIN FROM T.MARITIMA IN COMPLEX WITH VANADATE
6KSV	;	2.42	;	Crystal structure of SurE with D-Leu
6HKI	;	3.3	;	Crystal structure of surface entropy mutant of human O-GlcNAc hydrolase
6D2Y	;	2.19	;	Crystal structure of surface glycan-binding protein PbSGBP-B from Prevotella bryantii
3HOE	;	2.303	;	Crystal Structure of Surface Lipoprotein
5FFR	;	2.2	;	Crystal Structure of Surfactant Protein-A complexed with phosphocholine
4WR9	;	2.301	;	Crystal Structure of Surfactant Protein-A DED Mutant (E171D/P175E/K203D)
4WUW	;	2.398	;	Crystal Structure of Surfactant Protein-A DED Mutant (E171D/P175E/K203D) Complexed with Inositol
4WUX	;	1.9	;	Crystal Structure of Surfactant Protein-A DED Mutant (E171D/P175E/K203D) Complexed with Mannose
4WRC	;	1.8	;	Crystal Structure of Surfactant Protein-A DEDN Mutant (E171D/P175E/R197N/K203D)
4WRE	;	1.751	;	Crystal Structure of Surfactant Protein-A DEDN Mutant (E171D/P175E/R197N/K203D) Complexed with Inositol
4WRF	;	1.901	;	Crystal Structure of Surfactant Protein-A DEDN Mutant (E171D/P175E/R197N/K203D) Complexed with Mannose
5FFS	;	1.8	;	Crystal Structure of Surfactant Protein-A Y164A Mutant
5FFT	;	2.2	;	Crystal Structure of Surfactant Protein-A Y221A Mutant
4M17	;	2.096	;	Crystal Structure of Surfactant Protein-D D325A/R343V mutant
4M18	;	3.203	;	Crystal Structure of Surfactant Protein-D D325A/R343V mutant in complex with trimannose (Man-a1,2Man-a1,2Man)
4A0I	;	2.605	;	Crystal structure of Survivin bound to the N-terminal tail of hSgo1
4A0J	;	2.803	;	Crystal structure of Survivin bound to the phosphorylated N-terminal tail of histone H3
4A0N	;	2.743	;	Crystal structure of Survivin bound to the phosphorylated N-terminal tail of histone H3
4I9A	;	2.096	;	Crystal Structure of Sus scrofa Quinolinate Phosphoribosyltransferase in Complex with Nicotinate Mononucleotide
7FEX	;	2.69	;	Crystal structure of Sus scrofa Schlafen11 N-terminal domain (2.69 A)
2ZQ0	;	1.6	;	Crystal structure of SusB complexed with acarbose
3IV0	;	1.35	;	Crystal structure of SusD homolog (NP_809186.1) from BACTEROIDES THETAIOTAOMICRON VPI-5482 at 1.35 A resolution
3IHV	;	1.7	;	Crystal structure of SusD homolog (NP_813570.1) from Bacteroides thetaiotaomicron VPI-5482 at 1.70 A resolution
3MCX	;	1.49	;	Crystal structure of SusD superfamily protein (BT_2365) from BACTEROIDES THETAIOTAOMICRON VPI-5482 at 1.49 A resolution
3HDX	;	1.5	;	Crystal structure of SusD superfamily protein (NP_809182.1) from BACTEROIDES THETAIOTAOMICRON VPI-5482 at 1.50 A resolution
3JQ1	;	1.55	;	Crystal structure of SusD superfamily protein (YP_001297730.1) from Bacteroides vulgatus ATCC 8482 at 1.55 A resolution
3JYS	;	2.0	;	Crystal structure of SusD superfamily protein (YP_001298690.1) from Bacteroides vulgatus ATCC 8482 at 2.00 A resolution
3JQ0	;	1.13	;	Crystal structure of SusD superfamily protein (YP_001299712.1) from Bacteroides vulgatus ATCC 8482 at 1.13 A resolution
3LEW	;	1.7	;	Crystal structure of SusD-like carbohydrate binding protein (YP_001298396.1) from Bacteroides vulgatus ATCC 8482 at 1.70 A resolution
4FE9	;	2.0	;	Crystal Structure of SusF from Bacteroides thetaiotaomicron
3K8K	;	2.2	;	Crystal structure of SusG
3K8M	;	2.5	;	Crystal structure of SusG with acarbose
3K8L	;	2.3	;	Crystal structure of SusG-D498N mutant with maltoheptaose
4YGI	;	2.6	;	Crystal Structure of SUVH5 SRA bound to fully hydroxymethylated CG DNA
3Q0B	;	2.2	;	Crystal structure of SUVH5 SRA- fully methylated CG DNA complex in space group P42212
3Q0D	;	2.3704	;	Crystal structure of SUVH5 SRA- hemi methylated CG DNA complex
3Q0F	;	2.75	;	Crystal structure of SUVH5 SRA- methylated CHH DNA complex
3Q0C	;	2.6567	;	Crystal structure of SUVH5 SRA-fully methylated CG DNA complex in space group P6122
4NJ5	;	2.4	;	Crystal structure of SUVH9
6KOS	;	2.0	;	Crystal structure of SUWA (Super WA20), a hyper-stable de novo protein with a dimeric bisecting topology
2NTC	;	2.4	;	Crystal Structure of sv40 large T antigen origin binding domain with DNA
2IF9	;	2.586	;	Crystal Structure of SV40 T-antigen origin binding domain disulfide-linked dimer
6J9H	;	2.31	;	Crystal structure of SVBP-VASH1 complex
6J8N	;	1.95	;	Crystal structure of SVBP-VASH1 complex, mutation C169A of VASH1
6J8F	;	2.283	;	Crystal structure of SVBP-VASH1 with peptide mimic the C-terminal of alpha-tubulin
5QU4	;	1.05	;	Crystal Structure of swapped human Nck SH3.1 domain, 1.05A, orthorhombic form I
5QU7	;	1.27	;	Crystal Structure of swapped human Nck SH3.1 domain, 1.3A, orthorhombic form III
5QUA	;	1.51	;	Crystal Structure of swapped human Nck SH3.1 domain, 1.5A, C2221
5QU6	;	1.816	;	Crystal Structure of swapped human Nck SH3.1 domain, 1.8A, triclinic
5WQU	;	2.49	;	Crystal structure of Sweet Potato Beta-Amylase complexed with Maltotetraose
3ALD	;	1.1	;	Crystal structure of sweet-tasting protein Thaumatin I at 1.10 A
3AOK	;	1.27	;	Crystal structure of sweet-tasting protein thaumatin II
3VIQ	;	2.2	;	Crystal structure of Swi5-Sfr1 complex from fission yeast
5EDX	;	1.801	;	Crystal structure of swine CD8aa homodimer
3M5R	;	2.0	;	Crystal Structure of Swine Flu Virus NS1 Effector Domain from H1N1 Influenza A/California/07/2009
3M8A	;	2.1	;	Crystal Structure of Swine Flu Virus NS1 N-Terminal RNA Binding Domain from H1N1 Influenza A/California/07/2009
1JSD	;	1.8	;	CRYSTAL STRUCTURE OF SWINE H9 HAEMAGGLUTININ
3QQ3	;	2.59	;	Crystal structure of swine major histocompatibility complex class I SLA-1 0401 and identification of 2009 pandemic swine-origin influenza A H1N1 virus cytotoxic T lymphocyte epitope peptides
3QQ4	;	2.097	;	Crystal structure of swine major histocompatibility complex class I SLA-1 0401 and identification of 2009 pandemic swine-origin influenza A H1N1 virus cytotoxic T lymphocyte epitope peptides
6A6H	;	2.31	;	Crystal Structure of Swine Major Histocompatibility Complex Class I SLA-2*040202 For 2.3 Angstrom
5H94	;	1.48	;	Crystal structure of Swine MHC CLASSI for 1.48 angstroms
7DC8	;	2.757	;	Crystal structure of Switch Ab Fab and hIL6R in complex with ATP
4PQZ	;	2.3	;	Crystal structure of swt1 C-terminal domain from yeast
5BQM	;	3.1	;	Crystal structure of SXN101959, a Clostridium botulinum neurotoxin type D derivative and targeted secretion inhibitor
1JYA	;	1.74	;	Crystal Structure of SycE
4R3Q	;	1.901	;	Crystal structure of SYCE3
4OF6	;	1.696	;	Crystal Structure of SYG-1 D1, Crystal form 1
4OF7	;	2.1	;	Crystal Structure of SYG-1 D1, Crystal Form 2
4OF3	;	2.5	;	Crystal Structure of SYG-1 D1-D2, Glycosylated
4OF0	;	2.3	;	Crystal Structure of SYG-1 D1-D2, refolded
4OFP	;	3.0	;	Crystal Structure of SYG-2 D3-D4
4OFK	;	1.802	;	Crystal Structure of SYG-2 D4
5T68	;	2.93	;	Crystal structure of Syk catalytic domain in complex with a furo[3,2-d]pyrimidine
5C26	;	1.95	;	Crystal structure of SYK in complex with compound 1
5C27	;	2.15	;	Crystal structure of SYK in complex with compound 2
6VOV	;	1.95	;	Crystal structure of Syk in complex with GS-9876
3TUB	;	2.23	;	Crystal structure of SYK kinase domain with 1-(5-(6,7-dimethoxyquinolin-4-yloxy)pyridin-2-yl)-3-((1R,2S)-2-phenylcyclopropyl)urea
3TUC	;	2.1	;	Crystal structure of SYK kinase domain with 1-benzyl-N-(5-(6,7-dimethoxyquinolin-4-yloxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide
5TIU	;	1.49	;	Crystal structure of SYK kinase domain with inhibitor
3TUD	;	2.33	;	Crystal structure of SYK kinase domain with N-(4-methyl-3-(8-methyl-7-oxo-2-(phenylamino)-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)phenyl)-3-(trifluoromethyl)benzamide
2POS	;	1.6	;	Crystal Structure of sylvaticin, a new secreted protein from pythium sylvaticum
2PR0	;	1.72	;	Crystal structure of Sylvaticin, a new secreted protein from Pythium Sylvaticum
3QHC	;	1.25	;	Crystal structure of Symerythrin from Cyanophora paradoxa, reduced with dithionite
3O49	;	1.45	;	Crystal structure of Symfoil-1: de novo designed beta-trefoil architecture with symmetric primary structure
3O4A	;	1.45	;	Crystal structure of Symfoil-2: de novo designed beta-trefoil architecture with symmetric primary structure
3Q7W	;	1.5	;	Crystal structure of Symfoil-4P/PV1: de novo designed beta-trefoil architecture with symmetric primary structure, primitive version 1
3Q7X	;	1.4	;	Crystal structure of Symfoil-4P/PV1: de novo designed beta-trefoil architecture with symmetric primary structure, primitive version 1
4D8H	;	1.901	;	Crystal structure of Symfoil-4P/PV2: de novo designed beta-trefoil architecture with symmetric primary structure, primitive version 2 (6xLeu / PV1)
3O4D	;	1.65	;	Crystal structure of Symfoil-4P: de novo designed beta-trefoil architecture with symmetric primary structure
3SNV	;	2.2	;	Crystal structure of Symfoil-4T Permutation #1: de novo designed beta-trefoil architecture with symmetric primary structure
3P6I	;	1.32	;	Crystal structure of Symfoil-4T Permutation #2: de novo designed beta-trefoil architecture with symmetric primary structure
3P6J	;	1.35	;	Crystal structure of Symfoil-4T Permutation #3: de novo designed beta-trefoil architecture with symmetric primary structure
3O4B	;	1.8	;	Crystal structure of Symfoil-4T: de novo designed beta-trefoil architecture with symmetric primary structure
3O4C	;	1.75	;	Crystal structure of Symfoil-4V: de novo designed beta-trefoil architecture with symmetric primary structure
4MD9	;	3.5	;	Crystal Structure of symmetric CK2 holoenzyme with mutated alpha subunit (F121E truncated at aa 336)
5QU8	;	0.93	;	Crystal Structure of symmetric swapped human Nck SH3.1 domain, 0.93A, orthorhombic form IV
4I9K	;	5.0003	;	Crystal structure of symmetric W-W-W ClpX Hexamer
2WQZ	;	3.9	;	Crystal structure of synaptic protein neuroligin-4 in complex with neurexin-beta 1: alternative refinement
3HN8	;	3.5	;	Crystal structure of synaptotagmin
3F04	;	1.35	;	Crystal Structure of Synaptotagmin I C2A domain
3F00	;	1.36	;	Crystal Structure of Synaptotagmin I C2A domain with Cu(II)
3F01	;	1.7	;	Crystal Structure of Synaptotagmin I C2A domain with Cu(II)
3F05	;	1.4	;	Crystal Structure of Synaptotagmin I C2A domain with Mn(II)
1DQV	;	3.2	;	CRYSTAL STRUCTURE OF SYNAPTOTAGMIN III C2A/C2B
6LCY	;	2.301	;	Crystal structure of Synaptotagmin-7 C2B in complex with IP6
2ZMV	;	2.8	;	Crystal structure of Synbindin
8H02	;	1.552	;	Crystal structure of Synechococcus elongatus PCC 7942 RNA polymerase SI3-tail
4MAX	;	1.444	;	Crystal structure of Synechococcus sp. PCC 7002 globin at cryogenic temperature with heme modification
2F1K	;	1.55	;	Crystal structure of Synechocystis arogenate dehydrogenase
6NTE	;	2.33	;	Crystal Structure of Synechocystis Dihydroxyacid Dehydratase (DHAD)
7ZOU	;	1.58	;	Crystal structure of Synechocystis halorhodopsin (SyHR), Cl-pumping mode, ground state
7ZOV	;	1.7	;	Crystal structure of Synechocystis halorhodopsin (SyHR), Cl-pumping mode, K state
7ZOW	;	1.6	;	Crystal structure of Synechocystis halorhodopsin (SyHR), Cl-pumping mode, O state
7ZOY	;	1.91	;	Crystal structure of Synechocystis halorhodopsin (SyHR), SO4-bound form, ground state
1RTX	;	1.8	;	Crystal Structure of Synechocystis Hemoglobin with a Covalent Heme Linkage
7OI1	;	1.9	;	Crystal structure of Synechocystis sp PCC6803 guanidinium hydrolase
7ESR	;	1.42	;	Crystal structure of Synechocystis sp PCC6803 guanidinium hydrolase (R32)
4LHC	;	1.899	;	Crystal structure of Synechocystis sp. PCC 6803 glycine decarboxylase (P-protein), holo form with pyridoxal-5'-phosphate and glycine
4LHD	;	1.7959	;	Crystal structure of Synechocystis sp. PCC 6803 glycine decarboxylase (P-protein), holo form with pyridoxal-5'-phosphate and glycine, closed flexible loop
6QMM	;	2.18	;	Crystal structure of Synecochoccus Spermidine Synthase in complex with putrescine, spermidine and MTA
6NHA	;	2.381	;	Crystal structure of SYNT001, a human FcRn blocking monoclonal antibody
4DND	;	1.4	;	Crystal structure of syntaxin 10 from Homo sapiens
3LRY	;	1.98	;	Crystal structure of synthetic HIV-1 capsid C-terminal domain (CCA)
4M0I	;	2.8	;	CRYSTAL STRUCTURE OF SYNTHETIC HIV-1 CAPSID C-TERMINAL DOMAIN (CTD) C198S mutant
7MFU	;	1.7	;	Crystal structure of synthetic nanobody (Sb14+Sb68) complexes with SARS-CoV-2 receptor binding domain
7MFV	;	1.9	;	Crystal structure of synthetic nanobody (Sb16)
7KGK	;	2.6	;	Crystal structure of synthetic nanobody (Sb16) complexes with SARS-CoV-2 receptor binding domain
7KGJ	;	2.3	;	Crystal structure of synthetic nanobody (Sb45) complexes with SARS-CoV-2 receptor binding domain
7KLW	;	2.6	;	Crystal structure of synthetic nanobody (Sb45+Sb68) complexes with SARS-CoV-2 receptor binding domain
4JMH	;	2.408	;	Crystal structure of synthetic protein in complex with double pY peptide
4GMO	;	2.1	;	Crystal structure of Syo1
4YXL	;	2.604	;	Crystal structure of Syrian hamster prion protein complexed with POM1 FAB
4FZN	;	3.12	;	Crystal structure of syringacin M mutant D232A from Pseudomonas syringae pv. tomato DC3000
3C2H	;	2.6	;	Crystal Structure of SYS-1 at 2.6A resolution
5CK6	;	2.5	;	Crystal structure of SZ348 in complex with cyclopentene oxide
5YNG	;	2.497	;	Crystal structure of SZ348 in complex with cyclopentene oxide
5CLK	;	2.701	;	Crystal structure of SZ348 in complex with S,S-cyclohexanediol
5GKW	;	2.01	;	crystal structure of SZ529 complex with (R,R)-cyclopentanediol
8E8W	;	2.5	;	Crystal structure of SznF from Streptomyces achromogenes var. streptozoticus NRRL 2697 mononuclear Fe(II) structure on the HDO cofactor assembly pathway
6M9R	;	1.69	;	Crystal structure of SznF from Streptomyces achromogenes var. streptozoticus NRRL 2697 with a bound N(delta)-hydroxy-N(omega)-methyl-L-arginine intermediate
6VZY	;	1.66	;	Crystal structure of SznF from Streptomyces achromogenes var. streptozoticus NRRL 2697 with a diiron(II) central domain cofactor
3W1Y	;	2.3	;	Crystal structure of T brucei ATG8.2 in complex with E coli S10
5H2Q	;	1.66	;	Crystal structure of T brucei phosphodiesterase B2 bound to compound 13e
5H2R	;	1.8	;	Crystal structure of T brucei phosphodiesterase B2 bound to compound 15b
4RWH	;	1.802	;	Crystal structure of T cell costimulatory ligand B7-1 (CD80)
4U6F	;	3.1	;	Crystal structure of T-2 toxin bound to the yeast 80S ribosome
4NXQ	;	2.1	;	Crystal Structure of T-cell Lymphoma Invasion and Metastasis-1 PDZ Domain Quadruple Mutant (QM) in Complex With Caspr4 Peptide
4NXR	;	1.9	;	Crystal Structure of T-cell Lymphoma Invasion and Metastasis-1 PDZ Domain Quadruple Mutant (QM) in Complex With Neurexin-1 Peptide
4GVC	;	1.54	;	Crystal Structure of T-cell Lymphoma Invasion and Metastasis-1 PDZ in complex with phosphorylated Syndecan1 Peptide
3KZE	;	1.8	;	Crystal Structure of T-cell Lymphoma Invasion and Metastasis-1 PDZ in Complex With SSRKEYYA Peptide
4GVD	;	1.85	;	Crystal Structure of T-cell Lymphoma Invasion and Metastasis-1 PDZ in complex with Syndecan1 Peptide
2AQ3	;	2.3	;	Crystal structure of T-cell receptor V beta domain variant complexed with superantigen SEC3
2AQ1	;	2.1	;	Crystal structure of T-cell receptor V beta domain variant complexed with superantigen SEC3 mutant
2AQ2	;	1.8	;	Crystal structure of T-cell receptor V beta domain variant complexed with superantigen SEC3 mutant
5WSR	;	1.5	;	Crystal structure of T-Hg-T pair containing DNA duplex
5WSS	;	1.45	;	Crystal structure of T-Hg-T pair containing DNA duplex in the presence Ba2+
1WOO	;	2.4	;	Crystal structure of T-protein of the Glycine Cleavage System
1WOP	;	2.0	;	Crystal Structure of T-protein of the Glycine Cleavage System
1WOR	;	1.95	;	Crystal Structure of T-protein of the Glycine Cleavage System
1WOS	;	1.84	;	Crystal Structure of T-protein of the Glycine Cleavage System
4IRO	;	2.2	;	Crystal structure of T-state carbonmonoxy hemoglobin from Trematomus bernacchii at pH 8.4
2D5Z	;	1.45	;	Crystal structure of T-state human hemoglobin complexed with three L35 molecules
4O5V	;	2.1	;	Crystal structure of T. acidophilum IdeR
3LL5	;	1.987	;	Crystal structure of T. acidophilum isopentenyl phosphate kinase product complex
3CTY	;	2.35	;	Crystal structure of T. acidophilum thioredoxin reductase
4XLN	;	4.0	;	Crystal structure of T. aquaticus transcription initiation complex containing bubble promoter and RNA
4XLS	;	4.01	;	Crystal structure of T. aquaticus transcription initiation complex with CarD containing upstream fork promoter.
4RHQ	;	2.18	;	Crystal structure of T. brucei arginase-like protein double mutant S149D/S153D
4RHK	;	2.38	;	Crystal structure of T. brucei arginase-like protein in an oxidized form
4RHM	;	1.95	;	Crystal structure of T. brucei arginase-like protein quadruple mutant S149D/R151H/S153D/S226D
4RHL	;	3.1	;	Crystal structure of T. brucei arginase-like protein triple mutant S149D/R151H/S226D bound with Mn2+
8UH1	;	1.898	;	Crystal structure of T. brucei EIF4E6 in complex with EIF4G5 peptide
4RYP	;	2.21	;	Crystal Structure of T. Brucei Farnesyl Diphosphate Synthase
7SB7	;	2.64717	;	Crystal structure of T. brucei hypoxanthine guanine phosphoribosyltransferase in complex with (4S,7S)-7-hydroxy-4-((guanin-9-yl)methyl)-2,5-dioxaheptan-1,7-diphosphonate
4YJ1	;	2.05	;	Crystal structure of T. brucei MRB1590-ADP bound to poly-U RNA
5G57	;	1.73	;	Crystal structure of T. brucei PDE-B1 catalytic domain with inhibitor NPD-001
6FV9	;	2.48	;	Crystal structure of T. brucei PDE-B1 catalytic domain with inhibitor NPD-007
5G2B	;	1.83	;	Crystal structure of T. brucei PDE-B1 catalytic domain with inhibitor NPD-008
5G5V	;	1.8	;	Crystal structure of T. brucei PDE-B1 catalytic domain with inhibitor NPD-038
5L8C	;	2.01	;	Crystal structure of T. brucei PDE-B1 catalytic domain with inhibitor NPD-039
6FTM	;	2.1	;	Crystal structure of T. brucei PDE-B1 catalytic domain with inhibitor NPD-048
6RB6	;	1.9	;	Crystal structure of T. brucei PDE-B1 catalytic domain with inhibitor NPD-053
6RGK	;	2.03	;	Crystal structure of T. brucei PDE-B1 catalytic domain with inhibitor NPD-055
6QGP	;	1.942	;	Crystal structure of T. brucei PDE-B1 catalytic domain with inhibitor NPD-0769
6RFN	;	2.29	;	Crystal structure of T. brucei PDE-B1 catalytic domain with inhibitor NPD-1018
6RFW	;	2.183	;	Crystal structure of T. brucei PDE-B1 catalytic domain with inhibitor NPD-1039
6FDX	;	2.31	;	Crystal structure of T. brucei PDE-B1 catalytic domain with inhibitor NPD-1086
6GXQ	;	1.96	;	Crystal structure of T. brucei PDE-B1 catalytic domain with inhibitor NPD-1335
6QGU	;	1.77	;	Crystal structure of T. brucei PDE-B1 catalytic domain with inhibitor NPD-1361
6FE3	;	1.62	;	Crystal structure of T. brucei PDE-B1 catalytic domain with inhibitor NPD-1439
6FDS	;	2.2	;	Crystal structure of T. brucei PDE-B1 catalytic domain with inhibitor NPD-226
5L9H	;	2.25	;	Crystal structure of T. brucei PDE-B1 catalytic domain with inhibitor NPD-340
6FDW	;	1.96	;	Crystal structure of T. brucei PDE-B1 catalytic domain with inhibitor NPD-356
7A28	;	1.89	;	Crystal structure of T. brucei PDE-B1 catalytic domain with inhibitor NPD-617
6FRD	;	2.2	;	Crystal structure of T. brucei PDE-B1 catalytic domain with inhibitor NPD-637
7A2F	;	2.0	;	Crystal structure of T. brucei PDE-B1 catalytic domain with inhibitor NPD-656
5L8Y	;	2.14	;	Crystal structure of T. brucei PDE-B1 catalytic domain with inhibitor NPD-937
3RA6	;	2.0	;	Crystal structure of T. celer L30e E62A/K46A variant
3RA5	;	1.8	;	Crystal structure of T. celer L30e E6A/R92A variant
3LFO	;	1.8	;	Crystal structure of T. celer L30e E90A/R92A variant
3KJS	;	2.5	;	Crystal Structure of T. cruzi DHFR-TS with 3 high affinity DHFR inhibitors: DQ1 inhibitor complex
5QQC	;	1.62	;	Crystal Structure of T. cruzi FPPS after initial refinement with no ligand modelled (structure $n)
3E0U	;	2.3	;	Crystal structure of T. cruzi GPX1
4YRE	;	2.25	;	Crystal structure of T. cruzi Histidyl-tRNA synthetase in complex with (2-bromophenyl)methanol (Chem 145)
4YRK	;	2.2	;	Crystal structure of T. cruzi Histidyl-tRNA synthetase in complex with (4-chlorophenyl)methanol (Chem 260)
4YRG	;	2.15	;	Crystal structure of T. cruzi Histidyl-tRNA synthetase in complex with (6-bromopyridin-2-yl)methanol (Chem 149)
4YRI	;	2.0	;	Crystal structure of T. cruzi Histidyl-tRNA synthetase in complex with 1-(3-bromophenyl)methanamine (Chem 166)
4YRP	;	2.2	;	Crystal structure of T. cruzi Histidyl-tRNA synthetase in complex with 1-(4-BROMOPHENYL)METHANAMINE (Chem 707)
4YRC	;	2.1	;	Crystal structure of T. cruzi Histidyl-tRNA synthetase in complex with 2-aminoquinolin-8-ol (Chem 89)
4YRM	;	2.3	;	Crystal structure of T. cruzi Histidyl-tRNA synthetase in complex with 3-methoxypyridine (Chem 443)
4YRL	;	2.3	;	Crystal structure of T. cruzi Histidyl-tRNA synthetase in complex with 4-(methylsulfanyl)aniline (Chem 262)
4YRJ	;	2.3	;	Crystal structure of T. cruzi Histidyl-tRNA synthetase in complex with 4-chlorobenzene-1,2-diamine (Chem 256)
4YP0	;	2.1	;	Crystal structure of T. cruzi Histidyl-tRNA synthetase in complex with 5-aminoisoquinoline (Chem 79)
4YRO	;	2.5	;	Crystal structure of T. cruzi Histidyl-tRNA synthetase in complex with 5-bromo-6-methylpyridin-2-amine (Chem 491)
4YRF	;	2.2	;	Crystal structure of T. cruzi Histidyl-tRNA synthetase in complex with 5-bromopyridin-2(1H)-one (Chem 148)
4YRQ	;	2.05	;	Crystal structure of T. cruzi Histidyl-tRNA synthetase in complex with 6-amino-2H-chromen-2-one (Chem 744)
4YRN	;	2.2	;	Crystal structure of T. cruzi Histidyl-tRNA synthetase in complex with 6-bromopyridin-3-amine (Chem 475)
4YRT	;	2.05	;	Crystal structure of T. cruzi Histidyl-tRNA synthetase in complex with N-(5-hydroxynaphthalen-2-yl)propanamide (Chem 1781)
4YRR	;	2.3	;	Crystal structure of T. cruzi Histidyl-tRNA synthetase in complex with N-(quinolin-3-yl)acetamide (Chem 1691)
4YRS	;	2.75	;	Crystal structure of T. cruzi Histidyl-tRNA synthetase in complex with N-(quinolin-3-yl)propanamide (Chem 1698)
4YPF	;	2.2	;	Crystal structure of T. cruzi Histidyl-tRNA synthetase in complex with quinolin-3-amine (Chem 84)
4O0M	;	2.84	;	Crystal structure of T. Elongatus BP-1 Clock Protein KaiC
4QQW	;	2.664	;	Crystal structure of T. fusca Cas3
4QQY	;	3.12	;	Crystal structure of T. fusca Cas3-ADP
4QQZ	;	2.93	;	Crystal structure of T. fusca Cas3-AMPPNP
4QQX	;	3.34	;	Crystal structure of T. fusca Cas3-ATP
2AA0	;	1.75	;	Crystal structure of T. gondii adenosine kinase complexed with 6-methylmercaptopurine riboside
2AB8	;	1.75	;	Crystal structure of T. gondii adenosine kinase complexed with 6-methylmercaptopurine riboside and AMP-PCP
2ABS	;	1.1	;	Crystal structure of T. gondii adenosine kinase complexed with AMP-PCP
2A9Y	;	1.35	;	Crystal structure of T. gondii adenosine kinase complexed with N6-dimethyladenosine
2A9Z	;	1.35	;	Crystal structure of T. gondii adenosine kinase complexed with N6-dimethyladenosine and AMP-PCP
3NJ8	;	2.7	;	Crystal structure of T. gondii enoyl acyl carrier protein reductase with bound triclosan like inhibitor
6A88	;	2.596	;	Crystal Structure of T. gondii prolyl tRNA synthetase with Febrifugine and ATP Analog
1LWH	;	2.6	;	CRYSTAL STRUCTURE OF T. MARITIMA 4-ALPHA-GLUCANOTRANSFERASE
1LWJ	;	2.5	;	CRYSTAL STRUCTURE OF T. MARITIMA 4-ALPHA-GLUCANOTRANSFERASE/ACARBOSE COMPLEX
3BQ6	;	2.1	;	Crystal Structure of T. maritima Cobalamin-Independent Methionine Synthase complexed with Zn2+ (Monoclinic)
1XDJ	;	2.2	;	Crystal Structure of T. maritima Cobalamin-Independent Methionine Synthase complexed with Zn2+ and Homocysteine
3BQ5	;	2.0	;	Crystal Structure of T. maritima Cobalamin-Independent Methionine Synthase complexed with Zn2+ and Homocysteine (Monoclinic)
1XPG	;	2.59	;	Crystal Structure of T. maritima Cobalamin-Independent Methionine Synthase complexed with Zn2+ and Methyltetrahydrofolate
2X5S	;	2.35	;	Crystal structure of T. maritima GDP-mannose pyrophosphorylase in apo state.
2X5Z	;	2.7	;	Crystal structure of T. maritima GDP-mannose pyrophosphorylase in complex with GDP-mannose.
2X60	;	2.8	;	Crystal structure of T. maritima GDP-mannose pyrophosphorylase in complex with GTP.
2X65	;	2.1	;	Crystal structure of T. maritima GDP-mannose pyrophosphorylase in complex with mannose-1-phosphate.
7FSF	;	2.77	;	CRYSTAL STRUCTURE OF T. MARITIMA REVERSE GYRASE ACTIVE SITE VARIANT Y851F
7FSE	;	2.89	;	Crystal Structure of T. maritima reverse gyrase with a minimal latch
8OFB	;	2.39	;	Crystal Structure of T. maritima reverse gyrase with a minimal latch, hexagonal form
7WB3	;	2.401	;	Crystal structure of T. maritima Rex in ternary complex
6N9L	;	2.01	;	Crystal structure of T. maritima UvrA d117-399 with ADP
6MLX	;	2.0	;	Crystal structure of T. pallidum Leucine Rich Repeat protein (TpLRR)
3GX5	;	2.402	;	Crystal structure of T. tencongensis SAM-I riboswitch variant A94G/U34 bound with SAM
3HM9	;	3.3	;	Crystal structure of T. thermophilus Argonaute complexed with DNA guide strand and 19-nt RNA target strand
3HVR	;	3.211	;	Crystal structure of T. thermophilus Argonaute complexed with DNA guide strand and 19-nt RNA target strand with two Mg2+ at the cleavage site
3HJF	;	3.056	;	Crystal structure of T. thermophilus Argonaute E546 mutant protein complexed with DNA guide strand and 15-nt RNA target strand
3HK2	;	2.8	;	Crystal structure of T. thermophilus Argonaute N478 mutant protein complexed with DNA guide strand and 19-nt RNA target strand
3HO1	;	2.6	;	Crystal structure of T. thermophilus Argonaute N546 mutant protein complexed with DNA guide strand and 12-nt RNA target strand
5XP8	;	3.1	;	Crystal structure of T. thermophilus Argonaute protein complexed with a bulge 4A5 on the guide strand
5XQ2	;	3.33	;	Crystal structure of T. thermophilus Argonaute protein complexed with a bulge 5A6 on the guide strand
5XOW	;	2.902	;	Crystal structure of T. thermophilus Argonaute protein complexed with a bulge 6'A7' on the target strand
5XPG	;	2.8	;	Crystal structure of T. thermophilus Argonaute protein complexed with a bulge 6'U7' on the target strand
5XOU	;	2.63	;	Crystal structure of T. thermophilus Argonaute protein complexed with a bulge 7T8 on the guide strand
5XPA	;	2.9	;	Crystal structure of T. thermophilus Argonaute protein complexed with a bulge 9'U10' on the target strand
6V6Y	;	2.15202	;	Crystal Structure of T. thermophilus methylenetetrahydrofolate dehydrogenase (MTHFD)
5D8B	;	3.63	;	Crystal structure of T. thermophilus ribosome containing a P-site wobble mismatch
5I2D	;	4.405	;	Crystal structure of T. thermophilus TTHB099 class II transcription activation complex: TAP-RPo
4XLQ	;	4.6	;	Crystal structure of T.aquaticus transcription initiation complex containing upstream fork (-11 base-paired) promoter
4XLP	;	4.0	;	Crystal structure of T.aquaticus transcription initiation complex containing upstream fork promoter
4XLR	;	4.3	;	Crystal structure of T.aquaticus transcription initiation complex with CarD containing bubble promoter and RNA
4G9I	;	4.5	;	Crystal structure of T.kodakarensis HypF
6LDN	;	2.6	;	Crystal structure of T.onnurineus Csm5
1V2D	;	1.9	;	Crystal Structure of T.th HB8 Glutamine Aminotransferase
1V2F	;	2.35	;	Crystal Structure of T.th HB8 Glutamine Aminotransferase complex with 3-phenylpropionate
1V2E	;	2.6	;	Crystal Structure of T.th HB8 Glutamine Aminotransferase complex with a-keto-g-methylthiobutyrate
1VCM	;	2.35	;	Crystal Structure of T.th. HB8 CTP synthetase
1VCO	;	2.15	;	Crystal Structure of T.th. HB8 CTP synthetase complex with Glutamine
1VCN	;	2.25	;	Crystal Structure of T.th. HB8 CTP synthetase complex with Sulfate anion
2EEO	;	1.6	;	Crystal Structure of T.th. HB8 L-Aspartate-alpha-Decarboxylase Complexed with Fumarate
1VE1	;	1.45	;	Crystal Structure of T.th. HB8 O-acetylserine sulfhydrylase
2ECQ	;	1.9	;	Crystal Structure of T.th. HB8 O-acetylserine sulfhydrylase Complexed with 3-Hydroxylactate
2EFY	;	2.35	;	Crystal Structure of T.th. HB8 O-acetylserine sulfhydrylase Complexed with 4-Acetylbutyric acid
2ECO	;	1.9	;	Crystal Structure of T.th. HB8 O-acetylserine sulfhydrylase Complexed with 4-methylvalerate
1VE5	;	2.15	;	Crystal Structure of T.th. HB8 Threonine deaminase
2E9F	;	2.8	;	Crystal Structure of T.th.HB8 Argininosuccinate lyase complexed with L-Arginine
1WRV	;	1.5	;	Crystal Structure of T.th.HB8 Branched-Chain Amino Acid Aminotransferase
2EIY	;	1.35	;	Crystal Structure of T.th.HB8 Branched-Chain Amino Acid Aminotransferase Complexed with 4-Methylvaleric Acid
2EJ3	;	2.2	;	Crystal Structure of T.th.HB8 Branched-Chain Amino Acid Aminotransferase Complexed with Gabapentin
2EJ2	;	2.0	;	Crystal Structure of T.th.HB8 Branched-Chain Amino Acid Aminotransferase Complexed with N-(5'-Phosphopyridoxyl)-L-Glutamate
2EJ0	;	1.6	;	Crystal Structure of T.th.HB8 Branched-Chain Amino Acid Aminotransferase with Pyridoxamine 5'-phosphate
2DKJ	;	1.15	;	Crystal Structure of T.th.HB8 Serine Hydroxymethyltransferase
2ALY	;	2.6	;	Crystal Structure of T.Thermophilus Phenylalanyl-tRNA synthetase complexed with 5'-O-[N-(L-tyrosyl)sulphamoyl]adenosine
2AKW	;	2.8	;	Crystal Structure of T.Thermophilus Phenylalanyl-tRNA synthetase complexed with p-Cl-Phenylalanine
2DSN	;	1.5	;	Crystal structure of T1 lipase
2Z5G	;	1.8	;	Crystal structure of T1 lipase F16L mutant
1R3H	;	2.5	;	Crystal Structure of T10
6BKI	;	2.94	;	Crystal structure of T101A variant mouse cathepsin K at 2.94 Angstrom resolution.
3NOR	;	1.9	;	Crystal Structure of T102S Isocyanide Hydratase from Pseudomonas fluorescens
2PLG	;	2.6	;	Crystal structure of T110839 protein from Synechococcus elongatus
6DNA	;	3.0	;	Crystal structure of T110A mutant human Glutamate oxaloacetate transaminase 1 (GOT1)
6DNB	;	1.7	;	Crystal structure of T110A:S256A mutant human Glutamate oxaloacetate transaminase 1 (GOT1)
5AIO	;	3.148	;	Crystal structure of t131 N-terminal TPR array
2YX4	;	2.0	;	Crystal Structure of T134A of ST1022 from Sulfolobus tokodaii
5AIM	;	1.401	;	Crystal structure of T138 central eWH domain
7T8Q	;	2.15	;	CRYSTAL STRUCTURE OF T151G CAO1
7T8P	;	1.9	;	CRYSTAL STRUCTURE OF T151V CAO1
2IPB	;	2.23	;	Crystal structure of T159D mutant of S. Typhimurium PhoN protein
1TJV	;	2.0	;	Crystal Structure of T161D Duck Delta 2 Crystallin Mutant
1TJW	;	2.0	;	Crystal Structure of T161D Duck Delta 2 Crystallin Mutant with bound argininosuccinate
1TJU	;	2.1	;	Crystal Structure of T161S Duck Delta 2 Crystallin Mutant
3VZR	;	2.901	;	Crystal structure of T173S mutant of PhaB from Ralstonia eutropha
1LW2	;	3.0	;	CRYSTAL STRUCTURE OF T215Y MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH 1051U91
1LW0	;	2.8	;	CRYSTAL STRUCTURE OF T215Y MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH NEVIRAPINE
5X1D	;	2.2	;	Crystal Structure of T246A-N247A Human CRMP-2 Mutant
7REH	;	1.545	;	Crystal structure of T252E CYP199A4 bound to 4-methoxybenzoic acid
8D1C	;	1.95	;	Crystal structure of T252E-CYP199A4 in complex with 4-(Trifluoromethoxy)benzoic acid
8GLY	;	2.03	;	Crystal structure of T252E-CYP199A4 in complex with 4-hydroxybenzoic acid
8GLZ	;	2.02	;	Crystal structure of T252E-CYP199A4 in complex with 4-hydroxybenzoic acid. Crystal was initially co-crystallised with 4-methoxybenzoic acid and soaked with 4 mM hydrogen peroxide
8GM1	;	1.85	;	Crystal structure of T252E-CYP199A4 in complex with 4-methoxybenzoic acid soaked with 1 mM hydrogen peroxide
8GM2	;	2.33	;	Crystal structure of T252E-CYP199A4 in complex with 4-methoxybenzoic acid soaked with 2 mM hydrogen peroxide
6FJA	;	2.2	;	Crystal structure of T2D three-domain heme-Cu nitrite reductase from Ralstonia pickettii
7OGN	;	2.2	;	Crystal structure of T2R-TTL -mebendazole complex
5XI7	;	2.99	;	Crystal structure of T2R-TTL bound with PO-7
5Z4U	;	3.18	;	Crystal Structure of T2R-TTL complex with 7a3
7CPD	;	2.506	;	Crystal structure of T2R-TTL-(+)-6-Br-JP18 complex
7CPQ	;	2.595	;	crystal structure of T2R-TTL-(+)-6-Cl-JP18 complex
7EXC	;	2.39	;	Crystal structure of T2R-TTL-1129A2 complex
5H74	;	2.6	;	Crystal structure of T2R-TTL-14b complex
7XQY	;	2.35	;	Crystal structure of T2R-TTL-15 complex
7XQX	;	3.36	;	Crystal structure of T2R-TTL-27a complex
7XR0	;	2.7	;	Crystal structure of T2R-TTL-27a complex
5YZ3	;	2.545	;	Crystal structure of T2R-TTL-28 complex
7XR1	;	2.81	;	Crystal structure of T2R-TTL-3a complex
8HUH	;	2.8	;	Crystal structure of T2R-TTL-3a complex
5YL4	;	2.64	;	CRYSTAL STRUCTURE OF T2R-TTL-8WR COMPLEX
7CBZ	;	2.61	;	Crystal structure of T2R-TTL-A31 complex
7EMJ	;	2.33	;	Crystal structure of T2R-TTL-Barbigerone complex
7CEK	;	2.696	;	Crystal structure of T2R-TTL-BML-284 complex
7CLD	;	2.611	;	Crystal structure of T2R-TTL-Cevipabulin complex
7DP8	;	2.446	;	Crystal structure of T2R-TTL-Cevipabulin-eribulin complex
5XKH	;	2.25	;	Crystal structure of T2R-TTL-CF1 complex
5XKG	;	2.2	;	Crystal structure of T2R-TTL-CH1 complex
5XIW	;	2.9	;	Crystal structure of T2R-TTL-Colchicine complex
7CE8	;	2.725	;	Crystal structure of T2R-TTL-Compound11 complex
7CE6	;	2.695	;	Crystal structure of T2R-TTL-Compound9 complex
5XKE	;	2.6	;	Crystal structure of T2R-TTL-Demecolcine complex
6KNZ	;	2.475	;	Crystal structure of T2R-TTL-KXO1 complex
5CA0	;	2.501	;	Crystal structure of T2R-TTL-Lexibulin complex
5YLJ	;	2.7	;	Crystal structure of T2R-TTL-Millepachine complex
5XKF	;	2.8	;	Crystal structure of T2R-TTL-MPC6827 complex
5CA1	;	2.401	;	Crystal structure of T2R-TTL-Nocodazole complex
7CDA	;	2.659	;	Crystal structure of T2R-TTL-PAC complex
5C8Y	;	2.594	;	Crystal structure of T2R-TTL-Plinabulin complex
7ZYW	;	2.45	;	Crystal structure of T2R-TTL-PM534 complex
5XHC	;	2.75	;	Crystal structure of T2R-TTL-PO10 complex
5XI5	;	2.81	;	Crystal structure of T2R-TTL-PO5 complex
5EZY	;	2.05	;	Crystal structure of T2R-TTL-taccalonolide AJ complex
5CB4	;	2.193	;	Crystal structure of T2R-TTL-Tivantinib complex
5YL2	;	2.09	;	Crystal structure of T2R-TTL-Y28 complex
5YLS	;	3.0	;	Crystal structure of T2R-TTL-Y50 complex
8JJB	;	2.68	;	Crystal structure of T2R-TTL-Y61 complex
3GWS	;	2.2	;	Crystal Structure of T3-Bound Thyroid Hormone Receptor
4QA3	;	2.876	;	Crystal structure of T311M HDAC8 in complex with Trichostatin A (TSA)
2JJE	;	2.2	;	Crystal structure of T330S mutant of Rv3290c from M. tuberculosis
3SVV	;	2.204	;	Crystal Structure of T338C c-Src covalently bound to vinylsulfonamide-pyrazolopyrimidine 9
3TU0	;	2.994	;	Crystal structure of T355V, S354A, K288A LeuT mutant in complex with alanine and sodium
4Y23	;	2.89	;	Crystal structure of T399A precursor mutant protein of gamma-glutamyl transpeptidase from Bacillus licheniformis
1KUQ	;	2.84	;	CRYSTAL STRUCTURE OF T3C MUTANT S15 RIBOSOMAL PROTEIN IN COMPLEX WITH 16S RRNA
2QNF	;	3.0	;	Crystal structure of T4 Endonuclease VII H43N mutant in complex with heteroduplex DNA containing base mismatches
2QNC	;	3.1	;	Crystal structure of T4 Endonuclease VII N62D mutant in complex with a DNA Holliday junction
3CPE	;	2.8	;	Crystal Structure of T4 gp17
3TBI	;	3.0	;	Crystal structure of T4 gp33 bound to E. coli RNAP beta-flap domain
2HUM	;	2.35	;	Crystal structure of T4 Lysozyme D72C synthetic dimer
3FI5	;	1.53	;	Crystal Structure of T4 Lysozyme Mutant R96W
1G0G	;	1.9	;	CRYSTAL STRUCTURE OF T4 LYSOZYME MUTANT T152A
1G0K	;	1.85	;	CRYSTAL STRUCTURE OF T4 LYSOZYME MUTANT T152C
1G0M	;	1.7	;	CRYSTAL STRUCTURE OF T4 LYSOZYME MUTANT T152I
1G0J	;	1.8	;	CRYSTAL STRUCTURE OF T4 LYSOZYME MUTANT T152S
1G0L	;	1.8	;	CRYSTAL STRUCTURE OF T4 LYSOZYME MUTANT T152V
1G07	;	1.7	;	CRYSTAL STRUCTURE OF T4 LYSOZYME MUTANT V149C
1G0P	;	1.8	;	CRYSTAL STRUCTURE OF T4 LYSOZYME MUTANT V149G
1G0Q	;	1.8	;	CRYSTAL STRUCTURE OF T4 LYSOZYME MUTANT V149I
1G06	;	1.85	;	CRYSTAL STRUCTURE OF T4 LYSOZYME MUTANT V149S
2HUL	;	1.8	;	Crystal structure of T4 Lysozyme S44C synthetic dimer
2HUK	;	2.0	;	Crystal structure of T4 Lysozyme V131C synthetic dimer
3HWL	;	1.8	;	Crystal Structure of T4 lysozyme with the unnatural amino acid p-Acetyl-L-Phenylalanine incorporated at position 131
4PJZ	;	1.87	;	CRYSTAL STRUCTURE OF T4 LYSOZYME-GSS-PEPTIDE IN COMPLEX WITH TEICOPLANIN-A2-2
4PK0	;	2.3	;	CRYSTAL STRUCTURE OF T4 LYSOZYME-PEPTIDE IN COMPLEX WITH TEICOPLANIN-A2-2
3WX4	;	1.9	;	CRYSTAL STRUCTURE of T4 PHAGE ARN PROTEIN
1J39	;	1.87	;	Crystal Structure of T4 phage BGT in complex with its UDP-glucose substrate
1LTQ	;	2.33	;	CRYSTAL STRUCTURE OF T4 POLYNUCLEOTIDE KINASE
6X6O	;	1.52	;	Crystal structure of T4 protein Spackle as determined by native SAD phasing
2FCC	;	2.3	;	Crystal Structure of T4 Pyrimidine Dimer Glycosylase (T4-Pdg) Covalently Complexed with a DNA Substrate Containing Abasic Site
1VQ2	;	2.2	;	CRYSTAL STRUCTURE OF T4-BACTERIOPHAGE DEOXYCYTIDYLATE DEAMINASE, MUTANT R115E
1LYD	;	2.0	;	CRYSTAL STRUCTURE OF T4-LYSOZYME GENERATED FROM SYNTHETIC CODING DNA EXPRESSED IN ESCHERICHIA COLI
6UP9	;	1.949	;	Crystal structure of T467A variant of cytosolic fumarate hydratase from Leishmania major in a complex with malonate
6UPM	;	2.03	;	Crystal structure of T467A variant of cytosolic fumarate hydratase from Leishmania major in a complex with S-malate
5HML	;	1.482	;	Crystal Structure of T5 D15 Protein Co-crystallized with Metal Ions
5HMM	;	1.5	;	Crystal Structure of T5 D15 Protein Co-crystallized with Metal Ions
3B86	;	2.0	;	Crystal structure of T57S substituted LUSH protein complexed with ethanol
5HNK	;	2.22	;	Crystal structure of T5Fen in complex intact substrate and metal ions.
7FJS	;	2.9	;	Crystal structure of T6 Fab bound to theSARS-CoV-2 RBD of B.1.351
4GIG	;	1.8	;	crystal structure of T69A mutant of trapped Dnae intein precursor
1XMQ	;	3.0	;	Crystal Structure of t6A37-ASLLysUUU AAA-mRNA Bound to the Decoding Center
7FCF	;	3.3	;	Crystal structure of T6SS Hcp protein
3U66	;	2.63	;	Crystal structure of T6SS SciP/TssL from Escherichia Coli Enteroaggregative 042
6QX5	;	3.6	;	Crystal structure of T7 bacteriophage portal protein, 12mer, closed valve
6QWP	;	3.4	;	Crystal structure of T7 bacteriophage portal protein, 13mer, closed valve
6TJP	;	3.74	;	Crystal structure of T7 bacteriophage portal protein, 13mer, closed valve - P212121
2PFJ	;	3.1	;	Crystal Structure of T7 Endo I resolvase in complex with a Holliday Junction
3VTW	;	2.52	;	Crystal structure of T7-tagged Optineurin LIR-fused human LC3B_2-119
5M6C	;	3.0	;	CRYSTAL STRUCTURE OF T71N MUTANT OF HUMAN HIPPOCALCIN
5BNK	;	1.8	;	Crystal structure of T75C mutant of Triosephosphate isomerase from Plasmodium falciparum
5BMX	;	1.8	;	Crystal structure of T75N mutant of Triosephosphate isomerase from Plasmodium falciparum
4ZZ9	;	1.81	;	Crystal structure of T75S mutant of Triosephosphate isomerase from Plasmodium falciparum
5BMW	;	1.86	;	Crystal structure of T75V mutant of Triosephosphate isomerase from Plasmodium falciparum
4OGH	;	2.98	;	Crystal structure of T877A-AR-LBD
4OH5	;	2.0	;	Crystal structure of T877A-AR-LBD bound with co-regulator peptide
4OH6	;	3.56	;	Crystal structure of T877A-AR-LBD bound with co-regulator peptide
4OHA	;	1.42	;	Crystal structure of T877A-AR-LBD bound with co-regulator peptide
4OIL	;	2.51	;	Crystal structure of T877A-AR-LBD bound with co-regulator peptide
4OIU	;	3.01	;	Crystal structure of T877A-AR-LBD bound with co-regulator peptide
4OJ9	;	3.31	;	Crystal structure of T877A-AR-LBD bound with co-regulator peptide
4JK0	;	2.3	;	Crystal structure of T89Q-mutant of RNA silencing suppressor p19 with 2nt-5'-overhanging double-helical RNA 21mer pUUUG(CUG)5CU
3COD	;	2.7	;	Crystal Structure of T90A/D115A mutant of Bacteriorhodopsin
5DYS	;	2.3	;	Crystal Structure of T94I rhodopsin mutant
5EN0	;	2.81	;	Crystal Structure of T94I rhodopsin mutant
2FSN	;	2.9	;	Crystal structure of Ta0583, an archaeal actin homolog, complex with ADP
2FSJ	;	1.9	;	Crystal structure of Ta0583, an archaeal actin homolog, native data
2FSK	;	2.1	;	Crystal structure of Ta0583, an archaeal actin homolog, SeMet data
1XPP	;	1.6	;	Crystal Structure of TA1416,DNA-directed RNA polymerase subunit L, from Thermoplasma acidophilum
3U3N	;	1.651	;	Crystal structure of tablysin-15
1J4J	;	2.55	;	Crystal Structure of Tabtoxin Resistance Protein (form II) complexed with an Acyl Coenzyme A
1GHE	;	1.55	;	CRYSTAL STRUCTURE OF TABTOXIN RESISTANCE PROTEIN COMPLEXED WITH AN ACYL COENZYME A
6H0V	;	2.2	;	Crystal structure of tabun surrogate NEDPA inhibited recombinant human bile salt activated lipase
2FV5	;	2.1	;	Crystal structure of TACE in complex with IK682
2FV9	;	2.02	;	Crystal structure of TACE in complex with JMV 390-1
2DDF	;	1.7	;	Crystal structure of TACE in complex with TAPI-2
3G42	;	2.1	;	Crystal Structure of TACE with Tryptophan Sulfonamide Derivative Inhibitor
7R2D	;	1.61	;	Crystal structure of TaCel5A E133A variant in complex with cellopentaose
7R29	;	1.28	;	Crystal structure of TaCel5A E133Q Y200F variant with covalently linked cellotriose
7R2C	;	1.48	;	Crystal structure of TaCel5A Y200F variant in complex with 2-chloro-4-nitrophenyl-glucose
5FVJ	;	1.7	;	Crystal structure of TacT (tRNA acetylating toxin) from Salmonella
6G96	;	1.47661	;	Crystal structure of TacT3 (tRNA acetylating toxin) from Salmonella
8E2P	;	2.72	;	Crystal structure of TadA*8.20 in a complex with ssDNA
8E2R	;	2.22	;	Crystal structure of TadAC-1.14
8E2Q	;	2.34	;	Crystal structure of TadAC-1.17 in a complex with ssDNA
8E2S	;	2.95	;	Crystal structure of TadAC-1.19
4YYM	;	1.5	;	Crystal structure of TAF1 BD2 Bromodomain bound to a butyryllysine peptide
4YYN	;	1.85	;	Crystal structure of TAF1 BD2 Bromodomain bound to a crotonyllysine peptide
4OY2	;	2.9	;	Crystal structure of TAF1-TAF7, a TFIID subcomplex
6MIP	;	2.0	;	Crystal structure of Taf14 YEATS domain G82A mutant
6MIN	;	1.9	;	Crystal structure of Taf14 YEATS domain G82A mutant in complex with histone H3K9cr
5D7E	;	1.9	;	Crystal structure of Taf14 YEATS domain in complex with H3K9ac
7F4A	;	2.0	;	Crystal structure of Taf14 YEATS domain in complex with H3K9bz peptide
6MIQ	;	1.75	;	Crystal structure of Taf14 YEATS domain in complex with histone H3K9bu
5IOK	;	2.22	;	Crystal structure of Taf14 YEATS domain in complex with histone H3K9cr
6MIO	;	1.85	;	Crystal structure of Taf14 YEATS domain in complex with histone H3K9pr
5WXH	;	1.297	;	Crystal structure of TAF3 PHD finger bound to H3K4me3
5XMY	;	1.699	;	Crystal structure of TAF3 PHD finger bound to H3K4me3Q5ser
5C13	;	2.101	;	Crystal Structure of TAF3 PHD finger bound to histone H3C4me3 peptide
7MPK	;	2.993	;	Crystal structure of TagA with UDP-GlcNAc
7N41	;	3.3	;	Crystal structure of TagA with UDP-ManNAc
3KAO	;	1.9	;	Crystal structure of tagatose 1,6-diphosphate aldolase from Staphylococcus aureus
3MYP	;	2.99	;	Crystal structure of tagatose-1,6-bisphosphate aldolase from Staphylococcus aureus
3MYO	;	2.5	;	Crystal structure of tagatose-1,6-bisphosphate aldolase from Streptococcus pyogenes
3C3J	;	1.8	;	Crystal structure of tagatose-6-phosphate ketose/aldose isomerase from Escherichia coli
3M24	;	2.2	;	Crystal structure of TagBFP fluorescent protein
6IZ8	;	2.7	;	Crystal Structure of TagF from Pseudomonas aeruginosa
3M22	;	2.2	;	Crystal structure of TagRFP fluorescent protein
4QNL	;	2.411	;	Crystal structure of tail fiber protein gp63.1 from E. coli phage G7C
5Z4C	;	1.65	;	Crystal structure of Tailor
8OQ0	;	2.59	;	Crystal structure of tailspike depolymerase (APK09_gp48) from Acinetobacter phage APK09
8OQ1	;	1.55	;	Crystal structure of tailspike depolymerase (APK14_gp49) from Acinetobacter phage vB_AbaP_APK14
8D9Y	;	2.2	;	Crystal structure of Taipan alpha-neurotoxin in complex with Centi-3FTX-D09 antibody
3VC0	;	2.15	;	Crystal structure of Taipoxin beta subunit isoform 1
3VBZ	;	1.76	;	Crystal structure of Taipoxin beta subunit isoform 2
7D0V	;	2.175	;	Crystal structure of Taiwan cobra 5'-nucleotidase
2BHI	;	2.31	;	Crystal structure of Taiwan cobra cardiotoxin A3 complexed with sulfogalactoceramide
5V5N	;	2.006	;	Crystal structure of Takinib bound to TAK1
4OSJ	;	2.79	;	Crystal structure of TAL effector reveals the recognition between asparagine and adenine
4OSK	;	2.398	;	Crystal structure of TAL effector reveals the recognition between asparagine and guanine
4OSL	;	2.447	;	Crystal structure of TAL effector reveals the recognition between histidine and guanine
3CQ0	;	1.9	;	Crystal Structure of TAL2_YEAST
7WVR	;	1.41	;	Crystal structure of Talaromyces leycettanus JCM12802 expansin
6FQQ	;	3.25	;	Crystal structure of TALE homeobox domain transcription factor TGIF1 double alanine mutant bound to its consensus DNA
6FQP	;	2.42	;	Crystal structure of TALE homeobox domain transcription factor TGIF1 with its consensus DNA
4F7G	;	2.05	;	Crystal structure of talin autoinhibition complex
8IVZ	;	2.8	;	Crystal structure of talin R7 in complex with KANK1 KN motif
7ZW4	;	2.72	;	Crystal structure of Talin R7R8 domains with Caskin-2 LD-peptide
1SJ7	;	2.5	;	Crystal Structure of Talin Rod 482-655
6TWN	;	2.28	;	Crystal structure of Talin1 R7R8 in complex with CDK1 (206-223)
3G9W	;	2.165	;	Crystal Structure of Talin2 F2-F3 in Complex with the Integrin Beta1D Cytoplasmic Tail
4HVM	;	2.704	;	Crystal structure of tallysomycin biosynthesis protein TlmII
7ECD	;	2.6	;	Crystal structure of Tam41 from Firmicutes bacterium, complex with CTP-Mg
4C00	;	2.25	;	Crystal structure of TamA from E. coli
4QAY	;	2.35	;	Crystal structure of TamA POTRA domains
4BZA	;	1.839	;	Crystal structure of TamA POTRA domains 1-3 from E. coli
2EGO	;	1.8	;	Crystal Structure of Tamalin PDZ Domain
2EGN	;	2.4	;	Crystal Structure of Tamalin PDZ Domain in Complex with mGluR5 C-terminal Peptide
2EGK	;	2.85	;	Crystal Structure of Tamalin PDZ-Intrinsic Ligand Fusion Protein
7MWS	;	1.8	;	Crystal structure of tamarin CD81 large extracellular loop
4B15	;	1.49	;	crystal structure of tamarind chitinase like lectin (TCLL)
4B16	;	1.61	;	crystal structure of tamarind chitinase like lectin (TCLL) complexed with N-acetyl glucosamine (GlcNAc)
7Q8A	;	2.05	;	Crystal structure of tandem domain RRM1-2 of FUBP-interacting repressor (FIR) bound to FUSE ssDNA fragment
3HFH	;	2.703	;	Crystal structure of tandem FF domains
5YYA	;	1.7	;	Crystal structure of Tandem Tudor Domain of human UHRF1
5YY9	;	2.653	;	Crystal structure of Tandem Tudor Domain of human UHRF1 in complex with LIG1-K126me3
4QQD	;	2.28	;	Crystal Structure of tandem tudor domains of UHRF1 in complex with a small organic molecule
1CFB	;	2.0	;	CRYSTAL STRUCTURE OF TANDEM TYPE III FIBRONECTIN DOMAINS FROM DROSOPHILA NEUROGLIAN AT 2.0 ANGSTROMS
7PB9	;	1.8	;	Crystal structure of tandem WH domains of Vps25 from Odinarchaeota
3NFI	;	1.9	;	Crystal structure of tandem winged helix domain of RNA polymerase I subunit A49
3NFH	;	2.17	;	Crystal structure of tandem winged helix domain of RNA polymerase I subunit A49 (P4)
5CQ2	;	1.4	;	Crystal Structure of tandem WW domains of ITCH in complex with TXNIP peptide
1P47	;	2.2	;	Crystal Structure of tandem Zif268 molecules complexed to DNA
2QKD	;	2.0	;	Crystal structure of tandem ZPR1 domains
4TOS	;	1.802	;	Crystal structure of Tankyrase 1 with 355
4MSG	;	1.8	;	Crystal structure of tankyrase 1 with compound 22
4I9I	;	2.4	;	Crystal structure of tankyrase 1 with compound 4
4TOR	;	1.501	;	Crystal structure of Tankyrase 1 with IWR-8
4DVI	;	1.9	;	Crystal structure of Tankyrase 1 with IWR2
4HLM	;	1.95	;	Crystal structure of Tankyrase 2 in complex with 3',4'-Dihydroxyflavone
4HLG	;	2.0	;	Crystal structure of Tankyrase 2 in complex with 3'-hydroxyflavone
4HLH	;	1.75	;	Crystal structure of Tankyrase 2 in complex with 4'-fluoroflavone
4HLK	;	2.0	;	Crystal structure of Tankyrase 2 in complex with 4'-methylflavone
4HLF	;	2.15	;	Crystal structure of Tankyrase 2 in complex with 7,3',4'-Trihydroxyflavone
4HMH	;	2.3	;	Crystal structure of tankyrase 2 in complex with 7,3-dihydroxyflavone
4OA7	;	2.301	;	Crystal structure of Tankyrase1 in complex with IWR1
4JUI	;	1.7	;	crystal structure of tannase from from Lactobacillus plantarum
3WA6	;	1.8	;	Crystal structure of tannase from Lactobacillus plantarum in the orthorhombic crystal
6EU8	;	1.47	;	Crystal structure of Tannerella forsythia Apo HmuY analog (TFO)
6QRO	;	2.1	;	Crystal structure of Tannerella forsythia glutaminyl cyclase
8OQW	;	2.05	;	Crystal structure of Tannerella forsythia MurNAc kinase MurK
8OW9	;	2.7	;	Crystal structure of Tannerella forsythia MurNAc kinase MurK in complex with N-acetylmuramic acid (MurNAc)
8OQX	;	2.12	;	Crystal structure of Tannerella forsythia MurNAc kinase MurK with a phosphate analogue
8OQK	;	2.0	;	Crystal structure of Tannerella forsythia sugar kinase K1058
8OW7	;	3.06	;	Crystal structure of Tannerella forsythia sugar kinase K1058 in complex with N-acetylmuramic acid (MurNAc)
7OW1	;	1.4	;	Crystal Structure of TAP01 in complex with amyloid beta peptide
7OXN	;	2.5	;	Crystal Structure of TAP01 in complex with cyclised amyloid beta peptide
7TUE	;	3.1	;	Crystal structure of Tapasin in complex with HLA-B*44:05 (T73C)
7TUF	;	2.8	;	Crystal structure of Tapasin in complex with PaSta1-Fab
7TUG	;	3.9	;	Crystal structure of Tapasin in complex with PaSta2-Fab
5WER	;	3.412	;	Crystal Structure of TAPBPR and H2-Dd complex
2DQA	;	1.6	;	Crystal Structure of Tapes japonica Lysozyme
1EWR	;	3.19	;	CRYSTAL STRUCTURE OF TAQ MUTS
5O0U	;	0.99	;	Crystal structure of tarantula venom peptide Protoxin-II
5T20	;	1.91	;	Crystal Structure of Tarin Lectin bound to Trimannose
4WAC	;	2.4	;	Crystal Structure of TarM
4WAD	;	2.8	;	Crystal Structure of TarM with UDP-GlcNAc
3FMX	;	2.95	;	Crystal structure of Tartrate dehydrogenase from Pseudomonas putida complexed with NADH
3FLK	;	2.0	;	Crystal Structure of Tartrate Dehydrogenase from Pseudomonas putida in complex with NADH, oxalate and metal ion
4P5U	;	2.0	;	Crystal structure of TatD
1XWY	;	2.0	;	Crystal structure of tatD deoxyribonuclease from Escherichia coli K12 at 2.0 A resolution
4PE8	;	2.894	;	Crystal structure of TatD in complex with trinucleotide DNA
1J6O	;	1.8	;	Crystal structure of TatD-related deoxyribonuclease (TM0667) from Thermotoga maritima at 1.8 A resolution
7EYC	;	2.49	;	Crystal structure of Tau and acetylated tau peptide antigen
1OS7	;	2.5	;	Crystal structure of TauD with iron, alpha-ketoglutarate and Taurine bound at pH 7.5
5VN6	;	2.1	;	Crystal structure of Taurine dioxygenase from Burkholderia ambifaria
2ZI0	;	2.82	;	Crystal structure of Tav2b/siRNA complex
3SFJ	;	1.24	;	Crystal Structure of Tax-Interacting Protein-1 (TIP-1) PDZ domain bound to iCAL36 inhibitor peptide
4E3B	;	1.5	;	Crystal structure of Tax-Interacting Protein-1 (TIP-1) PDZ domain bound to iCAL36-L (ANSRWPTSIL) peptide
5Z7G	;	2.301	;	Crystal structure of TAX1BP1 SKICH region in complex with NAP1
5YT6	;	1.501	;	Crystal structure of TAX1BP1 UBZ2 in complex with mono-ubiquitin
3P5P	;	1.816	;	Crystal Structure of Taxadiene Synthase from Pacific Yew (Taxus brevifolia) in complex with Mg2+ and 13-aza-13,14-dihydrocopalyl diphosphate
3P5R	;	2.247	;	Crystal Structure of Taxadiene Synthase from Pacific Yew (Taxus brevifolia) in complex with Mg2+ and 2-fluorogeranylgeranyl diphosphate
7R28	;	1.22	;	Crystal structure of Ta_Cel5A E133Q Y200F variant, apoform
7R2A	;	1.3	;	Crystal structure of Ta_Cel5A Y200F variant, apoform
6JM5	;	1.6	;	Crystal structure of TBC1D23 C terminal domain
6JL7	;	2.5	;	crystal structure of TBC1D23 N terminal domain
4LG9	;	2.28	;	Crystal structure of TBL1XR1 WD40 repeats
3OCI	;	1.899	;	Crystal structure of TBP (TATA box binding protein)
2CZR	;	2.3	;	Crystal structure of TBP-interacting protein (Tk-TIP26) and implications for its inhibition mechanism of the interaction between TBP and TATA-DNA
4I15	;	1.65	;	Crystal structure of TbrPDEB1
6IF4	;	1.934	;	Crystal structure of Tbtudor
5BQD	;	2.583	;	Crystal Structure of TBX5 (1-239) Dimer
6H12	;	2.2	;	Crystal structure of TcACHE complexed to 1-(6-Oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(4-(((1-(2-((1,2,3,4-tetrahydroacridin-9-yl)amino)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)methyl)pyridin-2-yl)urea
6H14	;	1.86	;	Crystal structure of TcACHE complexed to 1-(6-oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(4-(1-(2-((1,2,3,4-tetrahydroacridin-9-yl)amino)ethyl)-1H-1,2,3-triazol-4-yl)pyridin-2-yl)urea
6H13	;	2.8	;	Crystal structure of TcACHE complexed to1-(4-((Methyl((1-(2-((1,2,3,4-tetrahydroacridin-9-yl)amino)ethyl)-1H-1,2,3-triazol-4-yl)methyl)amino)methyl)pyridin-2-yl)-3-(6-oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)urea
6NEY	;	1.68	;	Crystal structure of TcBDF5, a bromodomain containing protein from Trypanosoma cruzi
6JTD	;	1.85	;	Crystal structure of TcCGT1 in complex with UDP
4NBZ	;	1.75	;	Crystal Structure of TcdA-A1 Bound to A26.8 VHH
4NC1	;	2.61	;	Crystal Structure of TcdA-A2 Bound to A20.1 VHH and A26.8 VHH
4NC0	;	2.3	;	Crystal Structure of TcdA-A2 Bound to A26.8 VHH
4NBY	;	2.08	;	Crystal Structure of TcdA-A2 Bound to Two Molecules of A20.1 VHH
4O9Y	;	3.502	;	Crystal Structure of TcdA1
4NC2	;	2.5	;	Crystal structure of TcdB-B1 bound to B39 VHH
4O9X	;	2.17	;	Crystal Structure of TcdB2-TccC3
6H6G	;	3.004	;	Crystal Structure of TcdB2-TccC3 without hypervariable C-terminal region
6SUP	;	2.0	;	Crystal Structure of TcdB2-TccC3-Cdc42
6SUQ	;	3.7	;	Crystal Structure of TcdB2-TccC3-TEV
5N12	;	1.38	;	Crystal structure of TCE treated rPPEP-1
6FSJ	;	1.2	;	Crystal structure of TCE-treated Lysozyme
6FSM	;	1.39	;	Crystal structure of TCE-treated Thermolysin
1JL2	;	1.76	;	Crystal structure of TCEO RNase H-a chimera combining the folding core from T. thermophilus RNase H and the remaining region of E. coli RNase H
3TVQ	;	1.67	;	Crystal structure of TCM Aro/Cyc complexed with trans-dihidroquercetin
3ATY	;	1.7	;	Crystal structure of TcOYE
3ATZ	;	2.04	;	Crystal structure of TcOYE with pHBA
5ZKT	;	1.74	;	Crystal structure of TCP domain of PCF6 in Oryza sativa
4MPZ	;	2.701	;	Crystal structure of TCP10c domain of Drosophila melanogaster Sas-4
3HRV	;	1.5	;	Crystal structure of TcpA, a Type IV pilin from Vibrio cholerae El Tor biotype
7F5N	;	1.93	;	Crystal structure of TCPTP catalytic domain
5D2L	;	3.511	;	Crystal structure of TCR C7 in complex with HCMV NLV epitope presented by HLA-A2
5E6I	;	4.0	;	Crystal structure of TCR PF8 in complex with flu MP(58-66) epitope presented by HLA-A2
7EA6	;	2.18	;	Crystal structure of TCR-017 ectodomain
6BNK	;	3.2	;	Crystal structure of TCR-MHC-like molecule
6BNL	;	2.6	;	Crystal structure of TCR-MHC-like molecule
4NQC	;	2.5	;	Crystal structure of TCR-MR1 ternary complex and covalently bound 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil
4NQD	;	2.2	;	Crystal structure of TCR-MR1 ternary complex and non-covalently bound 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil
4NQE	;	2.1	;	Crystal structure of TCR-MR1 ternary complex bound to 5-(2-oxoethylideneamino)-6-D-ribitylaminouracil
7F5K	;	3.00003	;	Crystal structure of TCR4-1 ectodomain
4MVE	;	2.11	;	Crystal structure of Tcur_1030 protein from Thermomonospora curvata
7ALR	;	1.93	;	Crystal structure of TD1-gatorbulin1 complex
7ODN	;	2.33	;	Crystal structure of TD1-mebendazole complex
5MDI	;	2.1	;	Crystal structure of TDP-43 N-terminal domain at 2.1 A resolution
1PN3	;	2.8	;	Crystal Structure of TDP-epi-Vancosaminyltransferase GtfA in complexes with TDP and the acceptor substrate DVV.
1PNV	;	2.8	;	Crystal Structure of TDP-epi-Vancosaminyltransferase GtfA in complexes with TDP and Vancomycin
2FS5	;	1.95	;	Crystal structure of TDP-fucosamine acetyltransferase (WecD)- apo form
2FT0	;	1.66	;	Crystal structure of TDP-fucosamine acetyltransferase (WecD)- complex with acetyl-CoA
6DJF	;	1.67	;	Crystal structure of Tdp1 catalytic domain in complex with compound XZ502
6DJG	;	1.88	;	Crystal structure of Tdp1 catalytic domain in complex with compound XZ503
6DJH	;	1.918	;	Crystal structure of Tdp1 catalytic domain in complex with compound XZ515
6MJ5	;	1.853	;	Crystal structure of Tdp1 catalytic domain in complex with compound XZ519
6MYZ	;	1.661	;	Crystal structure of Tdp1 catalytic domain in complex with compound XZ520
6DJI	;	1.75	;	Crystal structure of Tdp1 catalytic domain in complex with compound XZ522
6N0O	;	1.943	;	Crystal structure of Tdp1 catalytic domain in complex with compound XZ523
6MZ0	;	1.969	;	Crystal structure of Tdp1 catalytic domain in complex with compound XZ530
6DJJ	;	1.741	;	Crystal structure of Tdp1 catalytic domain in complex with compound XZ532
6N0R	;	1.544	;	Crystal structure of Tdp1 catalytic domain in complex with compound XZ572
6N0N	;	1.477	;	Crystal structure of Tdp1 catalytic domain in complex with compound XZ574
6N0D	;	1.453	;	Crystal structure of Tdp1 catalytic domain in complex with compound XZ575
6N17	;	1.639	;	Crystal structure of Tdp1 catalytic domain in complex with compound XZ577
6N19	;	1.501	;	Crystal structure of Tdp1 catalytic domain in complex with compound XZ578
6DJE	;	1.705	;	Crystal structure of Tdp1 catalytic domain in complex with Sigma Aldrich compound CDS010292
6DIH	;	1.78	;	Crystal structure of Tdp1 catalytic domain in complex with Sigma Aldrich compound PH004941
6DIE	;	1.78	;	Crystal structure of Tdp1 catalytic domain in complex with Zenobia fragment benzene-1,2,4-tricarboxylic acid from single soak
6DHU	;	1.63	;	Crystal structure of Tdp1 catalytic domain in complex with Zenobia fragment ZT0911 from cocktail soak
6DJD	;	1.777	;	Crystal structure of Tdp1 catalytic domain in complex with Zenobia fragment ZT1982 (single soak)
6DIM	;	1.81	;	Crystal structure of Tdp1 catalytic domain in complex with Zenobia fragment ZT1982 from cocktail soak
8CW2	;	1.811	;	Crystal structure of TDP1 complexed with compound XZ760
8CVQ	;	1.65	;	Crystal structure of TDP1 complexed with compound XZ761
7UFY	;	1.584	;	Crystal structure of TDP1 complexed with compound XZ766
7UFZ	;	1.559	;	Crystal structure of TDP1 complexed with compound XZ768
4GEW	;	2.35	;	Crystal structure of TDP2 from C. elegans
4F1H	;	1.662	;	Crystal structure of TDP2 from Danio rerio complexed with a single strand DNA
5GIJ	;	3.0	;	Crystal structure of TDR-TDIF complex
3FDR	;	1.75	;	Crystal structure of TDRD2
6LYH	;	3.15	;	Crystal structure of tea N9-methyltransferase CkTcS in complex with SAH and 1,3,7-trimethyluric acid
6CDY	;	2.32	;	Crystal structure of TEAD complexed with its inhibitor
8Q68	;	1.58	;	Crystal structure of TEAD1-YBD in complex with irreversible compound SWTX-143
7CMM	;	3.5	;	Crystal structure of TEAD1-YBD in complex with K-975
6UYB	;	1.543	;	Crystal structure of TEAD2 bound to Compound 1
6UYC	;	1.658	;	Crystal structure of TEAD2 bound to Compound 2
7T2J	;	2.7	;	Crystal Structure of TEAD2 in a covalent complex with TED-642
7T2K	;	2.34	;	Crystal Structure of TEAD2 in a covalent complex with TED-661
7T2L	;	2.15	;	Crystal Structure of TEAD2 in a covalent complex with TED-662
7T2M	;	2.81	;	Crystal Structure of TEAD2 in a covalent complex with TED-664
8A0V	;	2.699	;	Crystal structure of TEAD3 in complex with CPD2
8A0U	;	2.895	;	Crystal structure of TEAD3 in complex with CPD4
8P0M	;	1.961	;	Crystal structure of TEAD3 in complex with IAG933
7CNL	;	2.6	;	Crystal structure of TEAD3 in complex with VT105
6L9F	;	2.555	;	Crystal structure of TEAD4 in complex with a novel FAM181A peptide
8C17	;	2.25	;	Crystal structure of TEAD4 in complex with peptide 1
8A8R	;	1.696	;	Crystal structure of TEAD4 in complex with YAP peptide
8CAA	;	1.999	;	Crystal structure of TEAD4 in complex with YTP-13
1HXC	;	2.25	;	CRYSTAL STRUCTURE OF TEAS C440W
1HX9	;	3.5	;	CRYSTAL STRUCTURE OF TEAS W273S FORM 1
1HXA	;	2.32	;	CRYSTAL STRUCTURE OF TEAS W273S FORM 2
1HXG	;	2.9	;	CRYSTAL STRUCTURE OF TEAS W273S/C440W
3HFP	;	2.098	;	Crystal structure of teh complex between CA II and the activator MAI
3M70	;	1.95	;	Crystal Structure of TehB from Haemophilus influenzae
3CGG	;	2.0	;	Crystal structure of TehB-like SAM-dependent methyltransferase (NP_600671.1) from Corynebacterium glutamicum ATCC 13032 Kitasato at 2.00 A resolution
6TOV	;	0.767	;	Crystal Structure of Teicoplanin Aglycone
1JI7	;	1.45	;	Crystal Structure of TEL SAM Polymer
1YIJ	;	2.6	;	Crystal Structure Of Telithromycin Bound To The G2099A Mutant 50S Ribosomal Subunit Of Haloarcula Marismortui
3P06	;	2.1	;	Crystal structure of Tellina virus 1 VP4 protease in the form of an intra-molecular(cis)acyl-enzyme complex.
3FA1	;	1.5	;	Crystal Structure of Tellurium Derivatized DNA
3K10	;	2.5	;	Crystal structure of telomere capping protein Stn1 from Saccharomyces cerevisiae
3K0X	;	1.7	;	Crystal structure of telomere capping protein Ten1 from Saccharomyces pombe
1JTG	;	1.73	;	CRYSTAL STRUCTURE OF TEM-1 BETA-LACTAMASE / BETA-LACTAMASE INHIBITOR PROTEIN COMPLEX
4OQG	;	2.4	;	Crystal structure of TEM-1 beta-lactamase in complex with boron-based inhibitor EC25
6B2N	;	2.0	;	Crystal structure of TEM-1 beta-lactamase mutant M182N
1LHY	;	2.0	;	Crystal structure of TEM-30 beta-Lactamase at 2.0 Angstrom
1LI0	;	1.61	;	Crystal structure of TEM-32 beta-Lactamase at 1.6 Angstrom
1LI9	;	1.52	;	Crystal structure of TEM-34 beta-Lactamase at 1.5 Angstrom
1JWZ	;	1.8	;	Crystal structure of TEM-64 beta-lactamase in complex with a boronic acid inhibitor (105)
1YT4	;	1.4	;	Crystal structure of TEM-76 beta-lactamase at 1.4 Angstrom resolution
5HVI	;	1.64	;	Crystal structure of TEM1 beta-lactamase
5HW1	;	1.7	;	Crystal structure of TEM1 beta-lactamase in the presence of 1.2 MPa xenon
5HW5	;	1.41	;	Crystal structure of TEM1 beta-lactamase in the presence of 2.0 MPa xenon
5IQ8	;	2.06	;	Crystal structure of TEM1 beta-lactamase mutant A224C/G283C disulfide
6APA	;	1.86	;	Crystal structure of TEM1 beta-lactamase mutant I263A
6AYK	;	1.44	;	Crystal structure of TEM1 beta-lactamase mutant I263A in the presence of 1.2 MPa xenon
5KKF	;	1.82	;	Crystal structure of TEM1 beta-lactamase mutant I263L
5KPU	;	1.5	;	Crystal structure of TEM1 beta-lactamase mutant I263L in the presence of 1.2 MPa xenon
5I52	;	1.75	;	Crystal structure of TEM1 beta-lactamase mutant I263N
5I63	;	1.95	;	Crystal structure of TEM1 beta-lactamase mutant I263N in the presence of 1.2 MPa xenon
1HTZ	;	2.4	;	CRYSTAL STRUCTURE OF TEM52 BETA-LACTAMASE
2RD3	;	2.7	;	Crystal structure of TenA homologue (HP1287) from Helicobacter pylori
3TES	;	2.5	;	Crystal Structure of Tencon
4LPW	;	2.8	;	Crystal structure of TENCON variant A6
4LPX	;	1.9	;	Crystal structure of TENCON variant D4
4LPY	;	1.92	;	Crystal structure of TENCON variant G10
4LPU	;	3.4	;	Crystal structure of TENCON variant P40AR2-32R2
4LPV	;	1.8	;	Crystal structure of TENCON variant P41BR3-42
1OK0	;	0.93	;	Crystal Structure of Tendamistat
3QH2	;	2.231	;	Crystal structure of TenI from Bacillus subtilis complexed with product cThz-P
1WVH	;	1.5	;	Crystal structure of tensin1 PTB domain
2PN5	;	2.698	;	Crystal Structure of TEP1r
4D94	;	2.7	;	Crystal Structure of TEP1r
4LNV	;	3.7	;	Crystal Structure of TEP1s
8I98	;	2.54	;	Crystal structure of TePixD Y8F
6WF4	;	1.97	;	Crystal Structure of TerC Co-crystallized with Polyporic Acid
7VJU	;	2.27	;	Crystal Structure of terephthalate dioxygenase from Comamonas testosteroni KF1
4DYR	;	1.65	;	Crystal structure of terminase small subunit gp1 of the bacterial virus sf6 with CAPS PH10.5 buffer
1TMM	;	1.25	;	Crystal structure of ternary complex of E.coli HPPK(W89A) with MGAMPCPP and 6-Hydroxymethylpterin
4H4L	;	2.5	;	Crystal Structure of ternary complex of HutP(HutP-L-His-Zn)
6DF3	;	2.15	;	Crystal structure of ternary complex of IL-24 with soluble receptors IL-22RA and IL-20RB
4OYT	;	2.4	;	Crystal structure of ternary complex of Plasmodium vivax SHMT with D-serine and folinic acid
4TN4	;	2.2	;	Crystal structure of ternary complex of Plasmodium vivax SHMT with glycine and a novel pyrazolopyran 33G: (4S)-6-amino-4-(5-cyano-3'-fluorobiphenyl-3-yl)-4-cyclobutyl-3-methyl-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile
4TMR	;	2.7	;	Crystal structure of ternary complex of Plasmodium vivax SHMT with glycine and a novel pyrazolopyran 99S: methyl 5-{3-[(4S)-6-amino-5-cyano-3-methyl-4-(propan-2-yl)-2,4-dihydropyrano[2,3-c]pyrazol-4-yl]-5-cyanophenyl}thiophene-2-carboxylate .
7ZUS	;	2.26	;	Crystal structure of ternary complex of Pol theta polymerase domain
5MDH	;	2.4	;	CRYSTAL STRUCTURE OF TERNARY COMPLEX OF PORCINE CYTOPLASMIC MALATE DEHYDROGENASE ALPHA-KETOMALONATE AND TNAD AT 2.4 ANGSTROMS RESOLUTION
1MMK	;	2.0	;	Crystal structure of ternary complex of the catalytic domain of human phenylalanine hydroxylase ((FeII)) complexed with tetrahydrobiopterin and thienylalanine
1MMT	;	2.0	;	Crystal structure of ternary complex of the catalytic domain of human phenylalanine hydroxylase (Fe(II)) complexed with tetrahydrobiopterin and norleucine
4N90	;	3.3	;	Crystal structure of ternary complex of TRAIL, DR5, and Fab fragment from a DR5 agonist antibody
1LRT	;	2.2	;	CRYSTAL STRUCTURE OF TERNARY COMPLEX OF TRITRICHOMONAS FOETUS INOSINE-5'-MONOPHOSPHATE DEHYDROGENASE: STRUCTURAL CHARACTERIZATION OF NAD+ SITE IN MICROBIAL ENZYME
7DN7	;	1.7	;	Crystal structure of ternary complexes of lactoperoxidase with hydrogen peroxide at 1.70 A resolution
6P0U	;	3.3	;	Crystal structure of ternary DNA complex "" FX(1-2)-2Xis"" containing E. coli Fis and phage lambda Xis
6P0T	;	3.603	;	Crystal structure of ternary DNA complex ""FX(1-2)-1Xis"" containing E. coli Fis and phage lambda Xis
6P0S	;	2.7	;	Crystal structure of ternary DNA complex ""FX2"" containing E. coli Fis and phage lambda Xis
1H88	;	2.8	;	CRYSTAL STRUCTURE OF TERNARY PROTEIN-DNA COMPLEX1
1H89	;	2.45	;	CRYSTAL STRUCTURE OF TERNARY PROTEIN-DNA COMPLEX2
1H8A	;	2.23	;	CRYSTAL STRUCTURE OF TERNARY PROTEIN-DNA COMPLEX3
8T8U	;	2.01	;	Crystal structure of Terrestrivirus full-length Inositol pyrophosphate kinase in complex with ADP
8T8Z	;	2.6	;	Crystal structure of Terrestrivirus Inositol pyrophosphatase kinase in complex with ADP and myo-(1OH)IP5
8T90	;	2.3	;	Crystal structure of Terrestrivirus Inositol pyrophosphatase kinase in complex with ADP and myo-(3OH)IP5
8T91	;	2.56	;	Crystal structure of Terrestrivirus Inositol pyrophosphatase kinase in complex with ADP and myo-IP6
8T95	;	2.61	;	Crystal structure of Terrestrivirus Inositol pyrophosphatase kinase in complex with ADP and scyllo-(1,2,4,5)-IP4
8T92	;	2.3	;	Crystal structure of Terrestrivirus Inositol pyrophosphatase kinase in complex with ADP and scyllo-D-(1,2,3,4)-IP4
8T96	;	2.36	;	Crystal structure of Terrestrivirus Inositol pyrophosphatase kinase in complex with ADP and scyllo-IP5
8T97	;	2.46	;	Crystal structure of Terrestrivirus Inositol pyrophosphatase kinase in complex with ADP and scyllo-IP6
8T93	;	1.95	;	Crystal structure of Terrestrivirus Inositol pyrophosphatase kinase in complex with ADP and scyllo-L-(1,2,3,4)-IP4
8T8W	;	2.0	;	Crystal structure of Terrestrivirus Inositol pyrophosphatase kinase in complex with ATP
8T8V	;	1.96	;	Crystal structure of Terrestrivirus inositol pyrophosphate kinase in complex with ADP
8T8Y	;	2.5	;	Crystal structure of Terrestrivirus inositol pyrophosphate kinase in complex with ADP and 1,4,5-InsP3
8T8X	;	2.59	;	Crystal structure of Terrestrivirus inositol pyrophosphate kinase in complex with AMP-PNP
5HJ5	;	1.7	;	Crystal structure of tertiary complex of glucosamine-6-phosphate deaminase from Vibrio cholerae with BETA-D-GLUCOSE-6-PHOSPHATE and FRUCTOSE-6-PHOSPHATE
5XDE	;	1.6	;	Crystal structure of tertiary complex of TdsC from Paenibacillus sp. A11-2 with FMN and dibenzothiophene
5XDG	;	1.747	;	Crystal structure of tertiary complex of TdsC from Paenibacillus sp. A11-2 with FMN and dibenzothiophene sulfoxide
5XDD	;	1.9	;	Crystal structure of tertiary complex of TdsC from Paenibacillus sp. A11-2 with FMN and Indole
4JGG	;	1.9	;	Crystal Structure of TesA
5DS0	;	2.8	;	Crystal structure of TET aminopeptidase from marine sediment archaeon Thaumarchaeota archaeon SCGC AB-539-E09
5D9Y	;	1.971	;	Crystal structure of TET2-5fC complex
5DEU	;	1.801	;	Crystal structure of TET2-5hmC complex
4NM6	;	2.026	;	Crystal structure of TET2-DNA complex
4HP3	;	2.05	;	Crystal structure of Tet3 in complex with a CpG dsDNA
4HP1	;	2.25	;	Crystal structure of Tet3 in complex with a non-CpG dsDNA
6C31	;	3.0	;	Crystal structure of TetR family protein Rv0078 in complex with DNA
5WM9	;	1.85	;	Crystal Structure of TetR family regulator Rv0078 from Mycobacterium tuberculosis
5YDP	;	3.091	;	Crystal Structure of TetR Family Repressor AlkX from Dietzia sp. Strain DQ12-45-1b Implicated in Biodegradation of n-Alkanes
1T56	;	1.7	;	Crystal structure of TetR family repressor M. tuberculosis EthR
2ZB9	;	2.25	;	Crystal structure of TetR family transcription regulator SCO0332
2ZCX	;	2.22	;	Crystal structure of TetR family transcriptional regulator SCO7815
6RX9	;	1.8	;	Crystal structure of TetR from Acinetobacter baumannii AYE
3C2B	;	2.1	;	Crystal structure of TetR transcriptional regulator from Agrobacterium tumefaciens
3ON4	;	1.85	;	Crystal structure of TetR transcriptional regulator from Legionella pneumophila
2Q24	;	1.8	;	Crystal structure of TetR transcriptional regulator SCO0520 from Streptomyces coelicolor
3FK6	;	2.1	;	Crystal structure of TetR triple mutant (H64K, S135L, S138I)
3FK7	;	2.06	;	Crystal structure of TetR triple mutant (H64K, S135L, S138I) in complex with 4-ddma-atc
2NP3	;	2.35	;	Crystal structure of TetR-family regulator (SCO0857) from Streptomyces coelicolor A3.
2REK	;	1.86	;	Crystal structure of tetR-family transcriptional regulator
2QIB	;	1.7	;	Crystal structure of tetR-family transcriptional regulator from Streptomyces coelicolor
3BNI	;	2.3	;	Crystal structure of TetR-family transcriptional regulator from Streptomyces coelicolor
6RXB	;	2.25	;	Crystal structure of TetR-Q116A from Acinetobacter baumannii AYE in complex with minocycline
8KE8	;	2.05	;	Crystal structure of TetR-type transcriptional factor NalC from P. aeruginosa
7YOL	;	2.4	;	Crystal structure of tetra mutant (D67E, A68P, L98I, A301S) of O-acetylserine sulfhydrylase from Haemophilus influenzae in complex with high-affinity inhibitory peptide of serine acetyltransferase from Haemophilus influenzae at 2.4 A
7YOK	;	2.799	;	Crystal Structure of Tetra mutant (D67E, A68P, L98I, A301S) tetra mutant of O-acetyl-L-serine sulfhydrylase from Haemophilus influenzae at 2.8 A
7YOM	;	2.8	;	Crystal structure of tetra mutant (D67E,A68P,L98I,A301S) of O-acetylserine sulfhydrylase from Salmonella typhimurium in complex with high-affinity inhibitory peptide from serine acetyltransferase of Salmonella typhimurium at 2.8 A
6XI3	;	2.0	;	Crystal structure of tetra-tandem repeat in extending region of large adhesion protein
6XI1	;	1.75	;	Crystal structure of tetra-tandem repeat in extending RTX adhesin from Aeromonas hydrophila
5TUE	;	2.1	;	Crystal structure of tetracycline destructase Tet(50)
5TUF	;	2.25	;	Crystal structure of tetracycline destructase Tet(50) in complex with anhydrotetracycline
5TUI	;	1.75	;	Crystal structure of tetracycline destructase Tet(50) in complex with chlortetracycline
5TUK	;	1.85	;	Crystal structure of tetracycline destructase Tet(51)
5TUL	;	2.0	;	Crystal structure of tetracycline destructase Tet(55)
5TUM	;	3.299	;	Crystal structure of tetracycline destructase Tet(56)
6WG9	;	2.55	;	Crystal structure of tetracycline destructase Tet(X7)
1QPI	;	2.5	;	CRYSTAL STRUCTURE OF TETRACYCLINE REPRESSOR/OPERATOR COMPLEX
3FYG	;	2.2	;	CRYSTAL STRUCTURE OF TETRADECA-(3-FLUOROTYROSYL)-GLUTATHIONE S-TRANSFERASE
3AW7	;	2.1	;	Crystal structure of tetragonal hen egg white lysozyme at 71.9% relative humidity
3AW6	;	2.1	;	Crystal structure of tetragonal hen egg white lysozyme at 84.2% relative humidity
1JIS	;	1.9	;	CRYSTAL STRUCTURE OF TETRAGONAL LYSOZYME GROWN AT PH 4.6
1JIY	;	1.9	;	CRYSTAL STRUCTURE OF TETRAGONAL LYSOZYME GROWN IN PRESENCE 20% SORBITOL
1JIT	;	1.9	;	CRYSTAL STRUCTURE OF TETRAGONAL LYSOZYME GROWN IN PRESENCE 30% TREHALOSE
1JJ0	;	1.9	;	CRYSTAL STRUCTURE OF TETRAGONAL LYSOZYME GROWN IN PRESENCE of 30% SUCROSE
1Y0Y	;	1.6	;	Crystal structure of tetrahedral aminopeptidase from P. horikoshii in complex with amastatin
3VTE	;	2.75	;	Crystal structure of tetrahydrocannabinolic acid synthase from Cannabis sativa
3BXY	;	2.0	;	Crystal structure of tetrahydrodipicolinate N-succinyltransferase from E. coli
1KGQ	;	2.0	;	Crystal Structure of Tetrahydrodipicolinate N-Succinyltransferase in Complex with L-2-aminopimelate and Succinamide-CoA
1KGT	;	2.3	;	Crystal Structure of Tetrahydrodipicolinate N-Succinyltransferase in Complex with Pimelate and Succinyl-CoA
1QST	;	1.7	;	CRYSTAL STRUCTURE OF TETRAHYMENA GCN5
1QSR	;	2.0	;	CRYSTAL STRUCTURE OF TETRAHYMENA GCN5 WITH BOUND ACETYL-COENZYME A
1PU9	;	2.3	;	Crystal Structure of Tetrahymena GCN5 with Bound Coenzyme A and a 19-residue Histone H3 Peptide
1Q2C	;	2.25	;	Crystal Structure of Tetrahymena GCN5 With Bound Coenzyme A and a 19-residue Histone H4 Peptide
1Q2D	;	2.25	;	Crystal Structure of Tetrahymena GCN5 With Bound Coenzyme A and a 19-residue p53 peptide
1PUA	;	2.3	;	Crystal Structure of Tetrahymena GCN5 with Bound Coenzyme A and a Phosphorylated, 19-residue Histone H3 peptide
1QSN	;	2.2	;	CRYSTAL STRUCTURE OF TETRAHYMENA GCN5 WITH BOUND COENZYME A AND HISTONE H3 PEPTIDE
5DOF	;	1.7	;	Crystal structure of Tetrahymena p19
5DOK	;	2.3	;	Crystal structure of Tetrahymena p45C
5DOI	;	2.2	;	Crystal structure of Tetrahymena p45N and p19
8G2N	;	1.33	;	Crystal structure of Tetrahymena thermophila G-rich DNA with novel ligand PyDH2
6TZZ	;	3.0	;	Crystal Structure of Tetrahymena Thermophila Lipin Phosphatidic Acid Phosphatase with Magnesium
4BHH	;	3.4	;	Crystal structure of tetramer of La Crosse virus nucleoprotein in complex with ssRNA
7AFV	;	2.4	;	Crystal structure of tetrameric beta-2-microglobulin deltaN6 S52C stabilized by a covalent ligand
2GN2	;	2.5	;	Crystal structure of tetrameric biodegradative threonine deaminase (TdcB) from Salmonella typhimurium in complex with CMP at 2.5A resolution (Hexagonal form)
8RKG	;	2.9	;	Crystal structure of tetrameric collagenase-cleaved Xenopus ZP2-N2N3 (cleaved xZP2-N2N3)
4M7H	;	2.0	;	Crystal structure of tetrameric fibrinogen-like recognition domain of FIBCD1
6ZR4	;	2.0	;	Crystal structure of tetrameric fibrinogen-like recognition domain of FIBCD1
4M7F	;	2.1	;	Crystal structure of tetrameric fibrinogen-like recognition domain of FIBCD1 with bound ManNAc
6ZQR	;	1.93	;	Crystal structure of tetrameric fibrinogen-like recognition domain of FIBCD1 with GlcNAc ligand bound
6ZQX	;	1.84	;	Crystal structure of tetrameric fibrinogen-like recognition domain of FIBCD1 with N,N'-diacetyl chitobiose ligand bound
6ZR3	;	1.97	;	Crystal structure of tetrameric fibrinogen-like recognition domain of FIBCD1 with N-acetyl-galactosamine-4-sulfate ligand bound
6ZR0	;	1.94	;	Crystal structure of tetrameric fibrinogen-like recognition domain of FIBCD1 with N-acetylalanine ligand bound
6ZQY	;	1.85	;	Crystal structure of tetrameric fibrinogen-like recognition domain of FIBCD1 with Neu5Ac ligand bound
3BJU	;	2.31	;	Crystal Structure of tetrameric form of human lysyl-tRNA synthetase
1X0L	;	1.85	;	Crystal structure of tetrameric homoisocitrate dehydrogenase from an extreme thermophile, Thermus thermophilus
6TX0	;	2.01	;	Crystal structure of tetrameric human D137N-SAMHD1 (residues 109-626) with XTP, dAMPNPP and Mg
6TXF	;	2.25	;	Crystal structure of tetrameric human D137N-SAMHD1 (residues 109-626) with XTP, dAMPNPP and Mn
6YOM	;	3.25	;	Crystal structure of tetrameric human D137N-SAMHD1 (residues 109-626) with XTP, dATP, dCMPNPP, Mn and Mg
6TXA	;	2.853	;	Crystal structure of tetrameric human D137N-SAMHD1 (residues 109-626) with XTP, dGMPNPP and Mg
6XU1	;	2.2	;	Crystal structure of tetrameric human H215A-SAMHD1 (residues 109-626) with GTP, dAMPNPP and Mg
7A5Y	;	2.29	;	Crystal structure of tetrameric human H215A-SAMHD1 (residues 109-626) with Rp-dGTP-alphaS (T8T) and Mg
6F6P	;	2.45	;	Crystal structure of tetrameric human Rabin8 GEF domain
6TXC	;	2.84	;	Crystal structure of tetrameric human wt-SAMHD1 (residues 109-626) with GTP, dATP, dCMPNPP and Mg
6TXE	;	3.19	;	Crystal structure of tetrameric human wt-SAMHD1 (residues 109-626) with GTP, dATP, dTMPNPP and Mg
8IQE	;	2.17	;	Crystal structure of tetrameric K2-2 TSP
1VGL	;	2.6	;	Crystal structure of tetrameric KaiB from T.elongatus BP-1
5YIH	;	1.98	;	Crystal structure of tetrameric Nucleoside diphosphate kinase at 1.98 A resolution from Acinetobacter baumannii
6JKD	;	3.9	;	Crystal structure of tetrameric PepTSo2 in I4 space group
6JKC	;	3.5	;	Crystal structure of tetrameric PepTSo2 in P4212 space group
3NDR	;	2.88	;	Crystal structure of tetrameric pyridoxal 4-dehydrogenase from Mesorhizobium loti
2EZV	;	2.4	;	Crystal structure of tetrameric restriction endonuclease SfiI bound to cognate DNA.
2F03	;	3.05	;	Crystal structure of tetrameric restriction endonuclease SfiI in complex with cognate DNA (partial bound form)
3NSP	;	2.9	;	Crystal structure of tetrameric RXRalpha-LBD
3NSQ	;	2.6	;	Crystal structure of tetrameric RXRalpha-LBD complexed with antagonist danthron
5ZQU	;	2.60039	;	Crystal structure of tetrameric RXRalpha-LBD complexed with partial agonist CBt-PMN
1UB3	;	1.4	;	Crystal Structure of Tetrameric Structure of Aldolase from thermus thermophilus HB8
1HG3	;	2.7	;	Crystal structure of tetrameric TIM from Pyrococcus woesei.
7LVY	;	1.85	;	Crystal Structure of Tetur04g02350
7MCO	;	2.0	;	Crystal Structure of Tetur04g02350
3P9U	;	2.81	;	Crystal structure of TetX2 from Bacteroides thetaiotaomicron with substrate analogue
3V3N	;	2.703	;	Crystal structure of TetX2 T280A: an adaptive mutant in complex with minocycline
3V3O	;	2.9	;	Crystal structure of TetX2 T280A: an adaptive mutant in complex with tigecycline
2OCE	;	3.1	;	Crystal structure of Tex family protein PA5201 from Pseudomonas aeruginosa
6HK8	;	2.111	;	Crystal structure of TEX12 delta-Ctip
6HK9	;	1.454	;	Crystal structure of TEX12 F102A F109E V116A
6R2F	;	2.29	;	Crystal structure of TEX12 F102A F109E V116A in an alternative conformation
3BYB	;	1.63	;	Crystal structure of Textilinin-1, a Kunitz-type serine protease inhibitor from the Australian Common Brown snake venom
3D65	;	1.64	;	Crystal structure of Textilinin-1, a Kunitz-type serine protease inhibitor from the Australian Common Brown snake venom, in complex with trypsin
7LBW	;	2.84	;	Crystal structure of TFAM (mitochondrial transcription factor A) bridging two non-sequence specific DNA substrates
7LBX	;	2.7	;	Crystal structure of TFAM (mitochondrial transcription factor A) in complex with LSP
6AJK	;	3.001	;	Crystal structure of TFB1M and h45 in homo sapiens
6AAX	;	2.994	;	Crystal structure of TFB1M and h45 with SAM in homo sapiens
4WFQ	;	2.4	;	Crystal structure of TFIIH subunit
6TRS	;	2.68	;	Crystal structure of TFIIH subunit p52 in complex with p8
6S9J	;	2.698	;	Crystal structure of TfR1 mimicry in complex with GP1 from MACV
4JSB	;	1.87	;	Crystal structure of Tfu_1878, a putative enoyl-CoA hydratase from Thermobifida fusca YX
4OMR	;	1.85	;	Crystal structure of Tfu_1878, a putative enoyl-CoA hydratase from Thermobifida fusca YX in complex with acetoacetyl-CoA
4JVT	;	1.65	;	Crystal structure of Tfu_1878, a putative enoyl-CoA hydratase fromThermobifida fusca YX in complex with CoA
7OU3	;	1.49	;	Crystal structure of Tga-AGOG, an 8-oxoguanine DNA glycosylase from Thermococcus gammatolerans
5JMS	;	2.3	;	Crystal structure of TgCDPK1 bound to CGP060476
5JN2	;	2.2	;	Crystal structure of TgCDPK1 bound to NVPACU106
5T6A	;	2.05	;	Crystal Structure of TgCDPK1 from toxoplasma gondii complexed with 5GA
5T6I	;	2.05	;	CRYSTAL STRUCTURE OF TGCDPK1 FROM TOXOPLASMA GONDII COMPLEXED WITH 5GB
5DVR	;	2.4	;	Crystal Structure of TgCDPK1 From Toxoplasma Gondii complexed with GW780159X
5T6K	;	2.4	;	Crystal Structure of TgCDPK1 From Toxoplasma Gondii complexed with GW780159X
4IFG	;	2.11	;	Crystal structure of TgCDPK1 with inhibitor bound
4IH8	;	2.877	;	Crystal structure of TgCDPK1 with inhibitor bound
4IHP	;	2.27	;	Crystal structure of TgCDPK1 with inhibitor bound
1RW8	;	2.4	;	Crystal Structure of TGF-beta receptor I kinase with ATP site inhibitor
1PY5	;	2.3	;	Crystal Structure of TGF-beta receptor I kinase with inhibitor
4KXZ	;	2.83	;	crystal structure of tgfb2 in complex with GC2008.
3FAA	;	3.35	;	Crystal structure of TGFbRI complexed with a 2-aminoimidazole inhibitor
3KCF	;	2.8	;	Crystal structure of TGFbRI complexed with a pyrazolone inhibitor
2X7O	;	3.7	;	Crystal structure of TGFbRI complexed with an indolinone inhibitor
1Q4W	;	1.93	;	CRYSTAL STRUCTURE OF TGT IN COMPLEX WITH 2,6-DIAMINO-3H-QUINAZOLIN-4-ONE
1R5Y	;	1.2	;	Crystal Structure of TGT in complex with 2,6-Diamino-3H-Quinazolin-4-one Crystallized at PH 5.5
1Q63	;	1.85	;	CRYSTAL STRUCTURE OF TGT IN COMPLEX WITH 2,6-Diamino-8-(1H-imidazol-2-ylsulfanylmethyl)-3H-quinazoline-4-one crystallized at pH 5.5
1Q65	;	2.1	;	CRYSTAL STRUCTURE OF TGT IN COMPLEX WITH 2,6-DIAMINO-8-(2-dimethylaminoethylsulfanylmethyl)-3H-QUINAZOLIN-4-ONE crystallized at pH 5.5
5UTJ	;	1.549	;	Crystal Structure of TGT in complex with 2,6-dioxy-8-azapurine, 2,6-dioxy-8-azapurine, 2,6-dioxy-8-azapurine
1Q66	;	1.75	;	CRYSTAL STRUCTURE OF TGT IN COMPLEX WITH 2-AMINO-6-AMINOMETHYL-8-phenylsulfanylmethyl-3H-QUINAZOLIN-4-ONE crystallized at pH 5.5
1S38	;	1.81	;	CRYSTAL STRUCTURE OF TGT IN COMPLEX WITH 2-AMINO-8-METHYLQUINAZOLIN-4(3H)-ONE
1S39	;	1.95	;	CRYSTAL STRUCTURE OF TGT IN COMPLEX WITH 2-aminoquinazolin-4(3H)-one
1N2V	;	2.1	;	Crystal Structure of TGT in complex with 2-Butyl-5,6-dihydro-1H-imidazo[4,5-d]pyridazine-4,7-dione
5SW3	;	1.38	;	Crystal Structure of TGT in complex with 3-Pyridinecarboxylic acid, 6-(dimethylamino)
5V3C	;	1.419	;	Crystal structure of TGT in complex with 4-(aminomethane)cyclohexane-1-carboxylic acid
5UTI	;	1.36	;	Crystal Structure of TGT in complex with fragment in preQ1 pocket
5N6F	;	1.1191	;	Crystal structure of TGT in complex with guanine fragment
6FSO	;	1.449	;	Crystal Structure of TGT in complex with methyl({[5-(pyridin-3-yloxy)furan-2-yl]methyl})amine
6RKT	;	1.746	;	Crystal Structure of TGT in complex with N2-methyl-1H,7H,8H-imidazo[4,5-g]quinazoline-2,6-diamine
6RKQ	;	1.665	;	Crystal Structure of TGT in complex with N2-methyl-8-(prop-1-yn-1-yl)-3H,7H,8H-imidazo[4,5-g]quinazoline-2,6-diamine
4N2S	;	3.0	;	Crystal Structure of THA8 in complex with Zm1a-6 RNA
4N2Q	;	2.8	;	Crystal structure of THA8 in complex with Zm4 RNA
4ME2	;	1.6	;	Crystal Structure of THA8 protein from Brachypodium distachyon
4LEU	;	2.0	;	Crystal Structure of THA8-like protein from Arabidopsis thaliana
8HVE	;	1.13	;	Crystal structure of Thaumatin (1 s)
8HVF	;	1.13	;	Crystal structure of Thaumatin (100 ms)
1LR2	;	1.8	;	Crystal structure of thaumatin at high hydrostatic pressure
1LR3	;	1.8	;	Crystal structure of thaumatin at high hydrostatic pressure
4DC6	;	1.48	;	Crystal Structure of Thaumatin Exposed to Excessive SONICC Imaging Laser Dose.
4AXR	;	1.38	;	CRYSTAL STRUCTURE OF thaumatin FROM A AUTO-HARVESTED CRYSTAL
4AXU	;	1.38	;	CRYSTAL STRUCTURE OF THAUMATIN FROM AN AUTO-HARVESTED CRYSTAL, control experiment
6C5Y	;	2.5	;	Crystal structure of thaumatin from microcrystals
5AMZ	;	1.4	;	Crystal Structure of Thaumatin processed with the CrystalDirect automated mounting and cryo-cooling technology
4DC5	;	1.48	;	Crystal Structure of Thaumatin Unexposed to Excessive SONICC Imaging Laser Dose.
2O8X	;	3.0	;	Crystal structure of the ""-35 element"" promoter recognition domain of Mycobacterium tuberculosis SigC
4GXX	;	1.799	;	Crystal structure of the ""avianized"" 1918 influenza virus hemagglutinin
4CHD	;	2.4	;	Crystal structure of the '627' domain of the PB2 subunit of Thogoto virus polymerase
1G5C	;	2.1	;	CRYSTAL STRUCTURE OF THE 'CAB' TYPE BETA CLASS CARBONIC ANHYDRASE FROM METHANOBACTERIUM THERMOAUTOTROPHICUM
3KWW	;	2.18	;	Crystal structure of the 'restriction triad' mutant of HLA B*3508, beta-2-microglobulin and EBV peptide
4DMO	;	2.14	;	Crystal structure of the (BACCR)NAT3 arylamine N-acetyltransferase from Bacillus cereus reveals a unique Cys-His-Glu catalytic triad
2EW8	;	2.1	;	Crystal Structure of the (S)-Specific 1-Phenylethanol Dehydrogenase of the Denitrifying Bacterium Strain EbN1
2EWM	;	2.4	;	Crystal Structure of the (S)-Specific 1-Phenylethanol Dehydrogenase of the Denitrifying Bacterium Strain EbN1
6YSO	;	3.13	;	Crystal structure of the (SR) Ca2+-ATPase solved by vanadium SAD phasing
5A3Q	;	3.05	;	Crystal structure of the (SR) Calcium ATPase E2-vanadate complex bound to thapsigargin and TNP-AMPPCP
5A3S	;	3.3	;	Crystal structure of the (SR) Calcium ATPase E2-vanadate complex bound to thapsigargin and TNP-ATP
5A3R	;	3.05	;	Crystal structure of the (SR) Calcium ATPase E2.BeF3- complex bound to TNP-AMPPCP
5KYM	;	2.8	;	Crystal Structure of the 1-acyl-sn-glycerophosphate (LPA) acyltransferase, PlsC, from Thermotoga maritima
5B0W	;	1.7	;	Crystal structure of the 11-cis isomer of pharaonis halorhodopsin in the absence of halide ions
7Z2M	;	1.899	;	Crystal Structure of the 11.003 Fab in complex with human IL-17A
6DFK	;	3.1	;	Crystal structure of the 11S subunit of the Plasmodium falciparum proteasome, PA28
2QG1	;	1.4	;	Crystal structure of the 11th PDZ domain of MPDZ (MUPP1)
1X0S	;	2.5	;	Crystal structure of the 13-cis isomer of bacteriorhodopsin
6MQY	;	1.9	;	Crystal Structure of the 13-cis Product of All-trans Retinal-Bound R111K:Y134F:T54V:R132Q:P39Y:R59Y:L121E Mutant of Human Cellular Retinoic Acid Binding Protein II Irradiated with 400 nm Laser (30 seconds) at 1.9 Angstrom
6MQZ	;	2.07	;	Crystal Structure of the 13-cis Product of the All-trans Retinal-Bound R111K:Y134F:T54V:R132Q:P39Y:R59Y:L121E Mutant of Human Cellular Retinoic Acid Binding Protein II Irradiated with 400 nm Laser (5 minutes) at 2.07 Angstrom
6MPK	;	1.58	;	Crystal Structure of the 13-cis Retinal-Bound R111K:Y134F:T54V:R132Q:P39Y:R59Y:L121E:A32Y Mutant of Human Cellular Retinoic Acid Binding Protein II in the Dark at 1.58 Angstrom Resolution
8P6I	;	2.5	;	Crystal structure of the 139H2 Fab fragment bound to Muc1 peptide epitope
2QHR	;	2.0	;	Crystal structure of the 13F6-1-2 Fab fragment bound to its Ebola virus glycoprotein peptide epitope.
1IB1	;	2.7	;	CRYSTAL STRUCTURE OF THE 14-3-3 ZETA:SEROTONIN N-ACETYLTRANSFERASE COMPLEX
5N6N	;	2.29	;	CRYSTAL STRUCTURE OF THE 14-3-3:NEUTRAL TREHALASE NTH1 COMPLEX
5KVJ	;	2.261	;	Crystal structure of the 16-mer doublestranded RNA. Northeast Structural Genomics Consortium (NESG) target RNA1
6BGB	;	1.65	;	Crystal Structure of the 16mer GCAGNCUUAAGUCUGC containing BrPh 7-triazolyl-8-aza-7-deazaadenosine
5BW5	;	2.5	;	Crystal structure of the 16S rRNA (adenine(1408)-N(1))-methyltransferase D21A mutant from Catenulisporales acidiphilia
4X1O	;	1.7	;	Crystal structure of the 16S rRNA (adenine(1408)-N(1))-methyltransferase from Catenulisporales acidiphilia
5D1H	;	2.803	;	Crystal structure of the 16S rRNA (adenine(1408)-N(1))-methyltransferase W203A mutant from Catenulisporales acidiphilia
5BW4	;	2.1	;	Crystal structure of the 16S rRNA (adenine(1408)-N(1))-methyltransferase W203A mutant with cosubstrate SAM from Catenulisporales acidiphilia
5D1N	;	2.713	;	Crystal structure of the 16S rRNA (adenine(1408)-N(1))-methyltransferase with its reaction by-product SAH from Catenulisporales acidiphilia
3QWF	;	1.88	;	Crystal structure of the 17beta-hydroxysteroid dehydrogenase from Cochliobolus lunatus
3QWH	;	2.62	;	Crystal structure of the 17beta-hydroxysteroid dehydrogenase from Cochliobolus lunatus in complex with NADPH and kaempferol
1RD8	;	3.0	;	Crystal Structure of the 1918 Human H1 Hemagglutinin Precursor (HA0)
6RJ7	;	1.73002	;	Crystal structure of the 19F labelled OXA-48
1DVL	;	2.4	;	CRYSTAL STRUCTURE OF THE 1:1 NETROPSIN-DECAMER D(CCIICICCII)2 COMPLEX WITH ONLY ONE DRUG BOUND AT ONE END
2O5Z	;	2.4	;	Crystal structure of the 1E9 LeuH47Trp/ArgH100Trp Fab 5-beta-androstane-3,17-dione complex
2O5Y	;	2.85	;	Crystal structure of the 1E9 LeuH47Trp/ArgH100Trp Fab progesterone complex
3O2W	;	2.55	;	Crystal structure of the 1E9 PheL89Ser/LeuH47Trp/MetH100bPhe Fab in complex with a 39A11 transition state analog
1P1J	;	1.7	;	Crystal structure of the 1L-myo-inositol 1-phosphate synthase complexed with NADH
1P1K	;	2.1	;	Crystal structure of the 1L-myo-inositol 1-phosphate synthase complexed with NADH in the presence of EDTA
1P1H	;	1.95	;	Crystal structure of the 1L-myo-inositol/NAD+ complex
4NOB	;	1.51	;	Crystal structure of the 1st Ig domain from mouse Polymeric Immunoglobulin receptor [PSI-NYSGRC-006220]
2I1N	;	1.85	;	Crystal structure of the 1st PDZ domain of Human DLG3
4WCI	;	1.65	;	Crystal structure of the 1st SH3 domain from human CD2AP (CMS) in complex with a proline-rich peptide (aa 378-393) from human RIN3
7VW7	;	3.818	;	Crystal structure of the 2 ADP-AlF4-bound V1 complex
5KNB	;	3.251	;	Crystal structure of the 2 ADP-bound V1 complex
3SKW	;	2.95	;	Crystal structure of the 2'- Deoxyguanosine riboswitch bound to 2'- Deoxyguanosine, cesium soak
3SKR	;	3.1	;	Crystal structure of the 2'- Deoxyguanosine riboswitch bound to 2'- Deoxyguanosine, cobalt Hexammine soak
3SKT	;	3.1	;	Crystal structure of the 2'- Deoxyguanosine riboswitch bound to 2'- Deoxyguanosine, manganese Soak
3SKI	;	2.3	;	Crystal structure of the 2'- Deoxyguanosine riboswitch bound to 2'-deoxyguanosine
3SKL	;	2.9	;	Crystal structure of the 2'- deoxyguanosine riboswitch bound to 2'-deoxyguanosine, iridium hexammine soak
3SLM	;	2.7	;	Crystal structure of the 2'- Deoxyguanosine riboswitch bound to 2'-deoxyguanosine-5'-monophosphate
3SKZ	;	2.605	;	Crystal structure of the 2'- deoxyguanosine riboswitch bound to guanosine
3SLQ	;	2.5	;	Crystal structure of the 2'- Deoxyguanosine riboswitch bound to guanosine-5'-monophosphate
1PX5	;	1.74	;	Crystal structure of the 2'-specific and double-stranded RNA-activated interferon-induced antiviral protein 2'-5'-oligoadenylate synthetase
2JBW	;	2.1	;	Crystal Structure of the 2,6-dihydroxy-pseudo-oxynicotine Hydrolase.
7TXY	;	1.75	;	Crystal structure of the 2-Aminophenol 1,6-dioxygenase from the ARO bacterial microcompartment of Micromonospora rosaria
2C11	;	2.9	;	Crystal structure of the 2-hydrazinopyridine of semicarbazide- sensitive amine oxidase
2DFU	;	2.2	;	Crystal structure of the 2-hydroxyhepta-2,4-diene-1,7-dioate isomerase from Thermus Thermophilus HB8
7CD0	;	2.31	;	Crystal structure of the 2-iodoporphobilinogen-bound ES2 intermediate form of human hydroxymethylbilane synthase
7CCY	;	2.4	;	Crystal structure of the 2-iodoporphobilinogen-bound holo form of human hydroxymethylbilane synthase
5XSE	;	1.799	;	Crystal structure of the 2-keto-3-deoxy-6-phosphogluconate aldolase of Zymomonas mobilis ZM4
5XSF	;	1.962	;	Crystal structure of the 2-keto-3-deoxy-6-phosphogluconate aldolase of Zymomonas mobilis ZM4 with 3-phosphoglycerate
1OQF	;	1.93	;	Crystal structure of the 2-methylisocitrate lyase
4D8L	;	2.0	;	Crystal structure of the 2-pyrone-4,6-dicarboxylic acid hydrolase from sphingomonas paucimobilis
4L2M	;	2.25	;	Crystal structure of the 2/2 hemoglobin from Synechococcus sp. PCC 7002 in the cyanomet state and with covalently attached heme
3MLH	;	2.09	;	Crystal structure of the 2009 H1N1 influenza virus hemagglutinin receptor-binding domain
4QNP	;	2.8	;	Crystal structure of the 2009 pandemic H1N1 influenza virus neuraminidase with a neutralizing antibody
7BRO	;	2.0	;	Crystal structure of the 2019-nCoV main protease
7BRP	;	1.8	;	Crystal structure of the 2019-nCoV main protease complexed with Boceprevir
1RYP	;	1.9	;	CRYSTAL STRUCTURE OF THE 20S PROTEASOME FROM YEAST AT 2.4 ANGSTROMS RESOLUTION
1FNT	;	3.2	;	CRYSTAL STRUCTURE OF THE 20S PROTEASOME FROM YEAST IN COMPLEX WITH THE PROTEASOME ACTIVATOR PA26 FROM TRYPANOSOME BRUCEI AT 3.2 ANGSTROMS RESOLUTION
1Z7Q	;	3.22	;	Crystal structure of the 20s proteasome from yeast in complex with the proteasome activator PA26 from Trypanosome brucei at 3.2 angstroms resolution
3QIW	;	3.3	;	Crystal structure of the 226 TCR in complex with MCC-p5E/I-Ek
3QIU	;	2.7	;	Crystal structure of the 226 TCR in complex with MCC/I-Ek
1YA9	;	2.09	;	Crystal Structure of the 22kDa N-Terminal Fragment of Mouse Apolipoprotein E
3BAP	;	1.85	;	Crystal Structure of the 25 kDa Subunit of Human Cleavage Factor Im
3MDI	;	2.07	;	Crystal Structure of the 25kDa Subunit of Human Cleavage factor Im in complex with RNA UGUAAA
3MDG	;	2.22	;	Crystal Structure of the 25kDa Subunit of Human Cleavage factor Im in complex with RNA UUGUAU
3BHO	;	1.8	;	Crystal Structure of the 25kDa Subunit of Human Cleavage factor Im with Ap4A
1M9B	;	2.6	;	Crystal structure of the 26 kDa glutathione S-transferase from Schistosoma japonicum complexed with gamma-glutamyl[S-(2-iodobenzyl)cysteinyl]glycine
1M99	;	2.3	;	Crystal structure of the 26 kDa glutathione S-transferase from Schistosoma japonicum complexed with glutathione sulfonic acid
1M9A	;	2.1	;	Crystal structure of the 26 kDa glutathione S-transferase from Schistosoma japonicum complexed with S-hexylglutathione
1U87	;	3.5	;	Crystal Structure Of The 26 Kda Glutathione S-Transferase Y7F mutant From Schistosoma Japonicum Complexed With Glutathione
1U88	;	3.5	;	Crystal Structure Of The 26 Kda Glutathione S-Transferase Y7F mutant From Schistosoma Japonicum Complexed With S-Octyl Glutathione
358D	;	2.5	;	CRYSTAL STRUCTURE OF THE 2:1 NETROPSIN-DNA DECAMER D(CBRCCCCIIIII) COMPLEX WITH END-TO-END BINDING
4WZN	;	2.7	;	CRYSTAL STRUCTURE OF THE 2B PROTEIN SOLUBLE DOMAIN FROM HEPATITIS A VIRUS
3QJF	;	2.4	;	Crystal structure of the 2B4 TCR
4P2O	;	2.603	;	Crystal structure of the 2B4 TCR in complex with 2A/I-Ek
3QIB	;	2.7	;	Crystal structure of the 2B4 TCR in complex with MCC/I-Ek
3BQU	;	3.0	;	Crystal Structure of the 2F5 Fab'-3H6 Fab Complex
3AB5	;	1.18	;	Crystal structure of the 2Fe 2S Ferredoxin from Cyanidioschyzon merolae
3D4I	;	1.95	;	Crystal structure of the 2H-phosphatase domain of Sts-2
3DB1	;	2.77	;	Crystal structure of the 2H-phosphatase domain of Sts-2 in complex with phosphate
3D6A	;	2.25	;	Crystal structure of the 2H-phosphatase domain of Sts-2 in complex with tungstate.
2Z0W	;	2.5	;	Crystal structure of the 2nd CAP-Gly domain in human Restin-like protein 2 reveals a swapped-dimer
4X1V	;	1.58	;	Crystal structure of the 2nd SH3 domain from human CD2AP (CMS) in complex with a proline-rich peptide (aa 76-91) from human ARAP1
3EUN	;	1.05	;	Crystal structure of the 2[4Fe-4S] C57A ferredoxin variant from allochromatium vinosum
2ZVS	;	1.65	;	Crystal structure of the 2[4FE-4S] ferredoxin from escherichia coli
3EXY	;	1.48	;	Crystal structure of the 2[4Fe-4S] ferredoxin V13G variant from allochromatium vinosum
5KNC	;	3.015	;	Crystal structure of the 3 ADP-bound V1 complex
3JXV	;	2.08	;	Crystal Structure of the 3 FKBP domains of wheat FKBP73
3JYM	;	2.28	;	Crystal Structure of the 3 FKBP domains of wheat FKBP73
1RY7	;	3.2	;	Crystal Structure of the 3 Ig form of FGFR3c in complex with FGF1
5OLC	;	2.79	;	Crystal structure of the 3,6-anhydro-D-galactonate cycloisomerase from Zobellia galactanivorans
2DKN	;	1.8	;	Crystal structure of the 3-alpha-hydroxysteroid dehydrogenase from Pseudomonas sp. B-0831 complexed with NADH
3S42	;	1.45	;	Crystal Structure of the 3-Dehydroquinate Dehydratase (aroD) from Salmonella enterica Typhimurium LT2 with Malonate and Boric Acid at the Active Site
3LB0	;	1.65	;	Crystal Structure of the 3-Dehydroquinate Dehydratase (aroD) from Salmonella typhimurium LT2 with Citrate Bound to the Active Site.
2EGZ	;	1.75	;	Crystal structure of the 3-dehydroquinate dehydratase from Aquifex aeolicus VF5
2YSW	;	2.25	;	Crystal Structure of the 3-dehydroquinate dehydratase from Aquifex aeolicus VF5
3QBE	;	2.07	;	Crystal structure of the 3-Dehydroquinate Synthase (aroB) from Mycobacterium tuberculosis
6C5C	;	1.85	;	Crystal structure of the 3-dehydroquinate synthase (DHQS) domain of Aro1 from Candida albicans SC5314 in complex with NADH
1ZEJ	;	2.0	;	Crystal structure of the 3-hydroxyacyl-coa dehydrogenase (hbd-9, af2017) from archaeoglobus fulgidus dsm 4304 at 2.00 A resolution
2Y7G	;	1.4	;	Crystal structure of the 3-keto-5-aminohexanoate cleavage enzyme (Kce) from C. Cloacamonas acidaminovorans in complex with the product acetoacetate
2Y7F	;	1.75	;	Crystal structure of the 3-keto-5-aminohexanoate cleavage enzyme (Kce) from C. Cloacamonas acidaminovorans in complex with the substrate 3- keto-5-aminohexanoate
2Y7D	;	1.59	;	Crystal structure of the 3-keto-5-aminohexanoate cleavage enzyme (Kce) from Candidatus Cloacamonas acidaminovorans (orthorombic form)
2Y7E	;	1.28	;	Crystal structure of the 3-keto-5-aminohexanoate cleavage enzyme (Kce) from Candidatus Cloacamonas acidaminovorans (tetragonal form)
8JAT	;	3.2	;	Crystal structure of the 3-ketodihydrosphingosine reductase TSC10 from Cryptococcus neoformans
2RHI	;	1.66	;	Crystal structure of the 3-MBT domain from human L3MBTL1 in complex with H1.5K27me2 at 1.66 angstrom
3OQ5	;	2.5005	;	Crystal structure of the 3-MBT domain from human L3MBTL1 in complex with p53K382me1
3UT1	;	2.05	;	Crystal structure of the 3-MBT repeat domain of L3MBTL3
4L59	;	2.29	;	Crystal structure of the 3-MBT repeat domain of L3MBTL3 and UNC2533 complex
2RHX	;	2.1	;	Crystal structure of the 3-MBT repeats from human L3MBTL1 bound to dimethyl-lysine
2RHU	;	1.9	;	Crystal structure of the 3-MBT repeats from human L3MBTL1 bound to dimethyl-lysine and in chimera with histone H3.3(28-34)
2RHY	;	1.9	;	Crystal structure of the 3-MBT repeats from human L3MBTL1 bound to monomethyl-lysine
2RI2	;	2.2	;	Crystal structure of the 3-MBT repeats from human L3MBTL1 with D355A point mutation
2RHZ	;	2.2	;	Crystal structure of the 3-MBT repeats from human L3MBTL1 with D355N point mutation
2RI5	;	2.0	;	Crystal structure of the 3-MBT repeats from human L3MBTL1 with N358A point mutation
2RI3	;	2.0	;	Crystal structure of the 3-MBT repeats from human L3MBTL1 with N358Q point mutation
3MQG	;	1.43	;	crystal structure of the 3-N-acetyl transferase WlbB from Bordetella petrii in complex with acetyl-CoA
3MQH	;	1.43	;	crystal structure of the 3-N-acetyl transferase WlbB from Bordetella petrii in complex with CoA and UDP-3-amino-2-acetamido-2,3-dideoxy glucuronic acid
3OSU	;	1.9	;	Crystal structure of the 3-oxoacyl-acyl carrier protein reductase, FabG, from Staphylococcus aureus
1CYY	;	2.15	;	CRYSTAL STRUCTURE OF THE 30 KDA FRAGMENT OF E. COLI DNA TOPOISOMERASE I. HEXAGONAL FORM
1CY9	;	1.8	;	CRYSTAL STRUCTURE OF THE 30 KDA FRAGMENT OF E. COLI DNA TOPOISOMERASE I. MONOCLINIC FORM
3KBG	;	1.75	;	Crystal structure of the 30S ribosomal protein S4e from Thermoplasma acidophilum. Northeast Structural Genomics Consortium Target TaR28.
4NXM	;	3.65	;	Crystal Structure of the 30S ribosomal subunit from a GidB (RsmG) mutant of Thermus thermophilus (HB8)
4NXN	;	3.544	;	Crystal Structure of the 30S ribosomal subunit from a GidB (RsmG) mutant of Thermus thermophilus (HB8), bound with streptomycin
3OTO	;	3.69	;	Crystal Structure of the 30S ribosomal subunit from a KsgA mutant of Thermus thermophilus (HB8)
1I95	;	4.5	;	CRYSTAL STRUCTURE OF THE 30S RIBOSOMAL SUBUNIT FROM THERMUS THERMOPHILUS IN COMPLEX WITH EDEINE
1I97	;	4.5	;	CRYSTAL STRUCTURE OF THE 30S RIBOSOMAL SUBUNIT FROM THERMUS THERMOPHILUS IN COMPLEX WITH TETRACYCLINE
5IWA	;	3.5	;	Crystal structure of the 30S ribosomal subunit from Thermus thermophilus in complex with the GE81112 peptide antibiotic
1I96	;	4.2	;	CRYSTAL STRUCTURE OF THE 30S RIBOSOMAL SUBUNIT FROM THERMUS THERMOPHILUS IN COMPLEX WITH THE TRANSLATION INITIATION FACTOR IF3 (C-TERMINAL DOMAIN)
4YHH	;	3.417	;	Crystal structure of the 30S ribosomal subunit from Thermus thermophilus in complex with tigecycline
4B3M	;	2.9	;	Crystal structure of the 30S ribosome in complex with compound 1
4B3R	;	3.0	;	Crystal structure of the 30S ribosome in complex with compound 30
4B3S	;	3.15	;	Crystal structure of the 30S ribosome in complex with compound 37
4B3T	;	3.0	;	Crystal structure of the 30S ribosome in complex with compound 39
2YZ8	;	2.0	;	Crystal structure of the 32th Ig-like domain of human obscurin (KIAA1556)
2GBM	;	1.55	;	Crystal Structure of the 35-36 8 Glycine Insertion Mutant of Ubiquitin
2GBN	;	1.6	;	Crystal Structure of the 35-36 8 Glycine Insertion Mutant of Ubiquitin
2GBR	;	2.0	;	Crystal Structure of the 35-36 MoaD Insertion Mutant of Ubiquitin
8FG0	;	2.36	;	Crystal structure of the 3764 Fab in complex with the C-terminal PfCSP linker, PfCSP281-294.
3SJ8	;	2.199	;	Crystal structure of the 3C protease from coxsackievirus A16
5HM2	;	3.2	;	Crystal structure of the 3C protease from South African Territories type 2 foot-and-mouth disease virus
7N08	;	2.0	;	Crystal structure of the 3D6 antibody fragment bound to the HIV-1 gp41 immunodominant region
3K2J	;	2.2	;	Crystal Structure of the 3rd Bromodomain of Human Poly-bromodomain containing protein 1 (PB1)
2HE2	;	1.5	;	Crystal structure of the 3rd PDZ domain of human discs large homologue 2, DLG2
3BPU	;	1.6	;	Crystal structure of the 3rd PDZ domain of human membrane associated guanylate kinase, C677S and C709S double mutant
2V90	;	2.0	;	Crystal structure of the 3rd PDZ domain of intestine- and kidney- enriched PDZ domain IKEPP (PDZD3)
3SOE	;	1.6	;	Crystal Structure of the 3rd PDZ domain of the human Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 3 (MAGI3)
5KDL	;	2.665	;	Crystal structure of the 4 alanine insertion variant of the Gi alpha1 subunit bound to GTPgammaS
1QR0	;	1.9	;	CRYSTAL STRUCTURE OF THE 4'-PHOSPHOPANTETHEINYL TRANSFERASE SFP-COENZYME A COMPLEX
8GYE	;	2.3	;	Crystal Structure of the 4-1BB in complex with ZG033 Fab
6BWV	;	2.4	;	Crystal Structure of the 4-1BB/4-1BBL Complex
5O7W	;	1.35	;	Crystal structure of the 4-FLUORO RSL lectin in complex with Lewis x tetrasaccharide
3R4A	;	2.0701	;	Crystal structure of the 4-helix coiled coil CC-tet
3R4H	;	2.7003	;	Crystal structure of the 4-helix coiled coil CC-Tet-phi22
2ORM	;	2.1	;	Crystal Structure of the 4-Oxalocrotonate Tautomerase Homologue DmpI from Helicobacter pylori.
6ENG	;	2.3	;	Crystal structure of the 43K ATPase domain of Escherichia coli gyrase B in complex with an aminocoumarin
6ENH	;	1.94	;	Crystal structure of the 43K ATPase domain of Thermus thermophilus gyrase B in complex with an aminocoumarin
1KIJ	;	2.3	;	Crystal structure of the 43K ATPase domain of Thermus thermophilus gyrase B in complex with novobiocin
1J1D	;	2.61	;	Crystal structure of the 46kDa domain of human cardiac troponin in the Ca2+ saturated form
6SU4	;	1.5	;	Crystal structure of the 48C12 heliorhodopsin in the blue form at pH 4.3
6SU3	;	1.5	;	Crystal structure of the 48C12 heliorhodopsin in the violet form at pH 8.8
6X2R	;	2.299	;	Crystal Structure of the 4E-TNES peptide bound to CRM1
3Q36	;	2.5	;	Crystal structure of the 4Fe-4S cluster domain of human DNA primase large subunit
4N5U	;	1.456	;	Crystal structure of the 4th FN3 domain of human Protein Tyrosine phosphatase, receptor type F [PSI-NYSGRC-006240]
3PIE	;	2.9	;	Crystal structure of the 5'->3' exoribonuclease Xrn1, E178Q mutant
3PIF	;	2.92	;	Crystal structure of the 5'->3' exoribonuclease Xrn1, E178Q mutant in Complex with Manganese
2PAQ	;	2.1	;	Crystal structure of the 5'-deoxynucleotidase YfbR
2PAU	;	2.1	;	Crystal structure of the 5'-deoxynucleotidase YfbR mutant E72A complexed with Co(2+) and dAMP
2PAR	;	2.1	;	Crystal structure of the 5'-deoxynucleotidase YfbR mutant E72A complexed with Co(2+) and TMP
7QRH	;	2.36	;	Crystal structure of the 5-(aminomethyl)furan-3-yl methyl phosphate kinase MfnE from Methanococcus vannielii.
6JYY	;	2.0	;	Crystal structure of the 5-(Hydroxyethyl)-methylthiazole Kinase ThiM from Klebsiella pneumonia
6K28	;	2.002	;	Crystal structure of the 5-(Hydroxyethyl)-methylthiazole Kinase ThiM from Klebsiella pneumonia in complex with TZE
4HI4	;	2.304	;	Crystal structure of the 5-coordinate ferric heme-binding PAS domain of Aer2 from P. aeruginosa
7TBU	;	1.85	;	Crystal structure of the 5-enolpyruvate-shikimate-3-phosphate synthase (EPSPS) domain of Aro1 from Candida albicans in complex with shikimate-3-phosphate
4NC3	;	2.8	;	Crystal structure of the 5-HT2B receptor solved using serial femtosecond crystallography in lipidic cubic phase.
7A17	;	2.73	;	Crystal structure of the 5-phosphatase domain of Synaptojanin1 bound to its substrate diC8-PI(3,4,5)P3 in complex with a nanobody
7A0V	;	2.3	;	Crystal structure of the 5-phosphatase domain of Synaptojanin1 in complex with a nanobody
5D3U	;	1.45	;	Crystal structure of the 5-selective H176F mutant of Cytochrome TxtE
5D40	;	1.51	;	Crystal structure of the 5-selective H176Y mutant of Cytochrome TxtE
1SAT	;	1.75	;	CRYSTAL STRUCTURE OF THE 50 KDA METALLO PROTEASE FROM S. MARCESCENS
5CSL	;	3.2	;	Crystal structure of the 500 kD yeast acetyl-CoA carboxylase holoenzyme dimer
5DM6	;	2.9	;	Crystal structure of the 50S ribosomal subunit from Deinococcus radiodurans
5DM7	;	3.0	;	Crystal structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with hygromycin A
1J1E	;	3.3	;	Crystal structure of the 52kDa domain of human cardiac troponin in the Ca2+ saturated form
1KZY	;	2.5	;	Crystal Structure of the 53bp1 BRCT Region Complexed to Tumor Suppressor P53
3LGF	;	1.5	;	Crystal structure of the 53BP1 tandem tudor domain in complex with p53K370me2
3LH0	;	1.9	;	Crystal structure of the 53BP1 tandem tudor domain in complex with p53K372me2
4X34	;	1.801	;	Crystal structure of the 53BP1 tandem tudor domain in complex with p53K381acK382me2
3LGL	;	1.6	;	Crystal structure of the 53BP1 tandem tudor domain in complex with p53K382me2
6AZM	;	1.6	;	Crystal structure of the 580 germline antibody bound to circumsporozoite protein NANP 5-mer
4P2R	;	3.295	;	Crystal structure of the 5cc7 TCR in complex with 5c1/I-Ek
4P2Q	;	3.3	;	Crystal structure of the 5cc7 TCR in complex with 5c2/I-Ek
7T2B	;	2.8	;	Crystal structure of the 5F TCR in complex with HLA-DP4-Ply
5O7V	;	1.28	;	Crystal structure of the 5F-tryptophan RSL lectin in complex with Lewis x tetrasaccharide
2QKT	;	2.05	;	Crystal Structure of the 5th PDZ domain of InaD
5FLL	;	2.34	;	Crystal structure of the 6-carboxyhexanoate-CoA ligase (BioW) from Bacillus subtilis in complex with a Pimeloyl-adenylate
5FM0	;	2.44	;	Crystal structure of the 6-carboxyhexanoate-CoA ligase (BioW)from Bacillus subtilis (PtCl4 derivative)
5FLG	;	2.04	;	Crystal structure of the 6-carboxyhexanoate-CoA ligase (BioW)from Bacillus subtilis in complex with AMPPNP
5G1F	;	2.25	;	Crystal structure of the 6-carboxyhexanoate-CoA ligase (BioW)from Bacillus subtilis in complex with coenzyme A
3MCM	;	2.2	;	Crystal Structure of the 6-hyroxymethyl-7,8-dihydropterin pyrophosphokinase dihydropteroate synthase bifunctional enzyme from Francisella tularensis
3MCN	;	2.2	;	Crystal Structure of the 6-hyroxymethyl-7,8-dihydropterin pyrophosphokinase dihydropteroate synthase bifunctional enzyme from Francisella tularensis
3MCO	;	2.3	;	Crystal Structure of the 6-hyroxymethyl-7,8-dihydropterin pyrophosphokinase dihydropteroate synthase bifunctional enzyme from Francisella tularensis
6OZW	;	2.063	;	Crystal structure of the 65-kilodalton amino-terminal fragment of DNA topoisomerase I from Streptococcus mutans
5O7U	;	1.15	;	Crystal structure of the 7-Fluorotryptophan RSL lectin in complex with Lewis x tetrasaccharide
1QSA	;	1.65	;	CRYSTAL STRUCTURE OF THE 70 KDA SOLUBLE LYTIC TRANSGLYCOSYLASE SLT70 FROM ESCHERICHIA COLI AT 1.65 ANGSTROMS RESOLUTION
1QTE	;	1.9	;	CRYSTAL STRUCTURE OF THE 70 KDA SOLUBLE LYTIC TRANSGLYCOSYLASE SLT70 FROM ESCHERICHIA COLI AT 1.90 A RESOLUTION IN COMPLEX WITH A 1,6-ANHYDROMUROTRIPEPTIDE
2V7Z	;	3.5	;	Crystal structure of the 70-kDa heat shock cognate protein from Rattus norvegicus in post-ATP hydrolysis state
4V9N	;	3.4	;	Crystal structure of the 70S ribosome bound with the Q253P mutant of release factor RF2.
4V9A	;	3.2999	;	Crystal Structure of the 70S ribosome with tetracycline.
4V9B	;	3.1	;	Crystal Structure of the 70S ribosome with tigecycline.
4V4X	;	5.0	;	Crystal structure of the 70S Thermus thermophilus ribosome showing how the 16S 3'-end mimicks mRNA E and P codons.
4V4Y	;	5.5	;	Crystal structure of the 70S Thermus thermophilus ribosome with translocated and rotated Shine-Dalgarno Duplex.
7X9E	;	2.6	;	Crystal structure of the 76E1 Fab in complex with a SARS-CoV-2 spike peptide
2GBJ	;	1.35	;	Crystal Structure of the 9-10 8 Glycine Insertion Mutant of Ubiquitin.
2GBK	;	1.99	;	Crystal Structure of the 9-10 MoaD Insertion Mutant of Ubiquitin
1U07	;	1.13	;	Crystal Structure of the 92-residue C-term. part of TonB with significant structural changes compared to shorter fragments
7VKB	;	1.82	;	Crystal structure of the a bacterial kinase complex
3N8I	;	1.5	;	Crystal structure of the A isoform of human cytoplasmic protein tyrosine phosphatase (HCPTP-A) in complex with 1-naphtylacetic acid
3APU	;	2.1	;	Crystal structure of the A variant of human alpha1-acid glycoprotein
3APV	;	2.15	;	Crystal structure of the A variant of human alpha1-acid glycoprotein and amitriptyline complex
3APX	;	2.2	;	Crystal structure of the A variant of human alpha1-acid glycoprotein and chlorpromazine complex
3APW	;	2.2	;	Crystal structure of the A variant of human alpha1-acid glycoprotein and disopyramide complex
1QNC	;	2.3	;	Crystal structure of the A(-31) Adenovirus major late promoter TATA box variant bound to wild-type TBP (Arabidopsis thaliana TBP isoform 2). TATA element recognition by the TATA box-binding protein has been conserved throughout evolution.
6BBL	;	1.68	;	Crystal structure of the a-96Gln MoFe protein variant in the presence of the substrate acetylene
1YI5	;	4.2	;	Crystal structure of the a-cobratoxin-AChBP complex
213D	;	1.6	;	CRYSTAL STRUCTURE OF THE A-DNA DECAMER D(CCIGGCCM5CGG) AT 1.6 ANGSTROMS SHOWING THE UNEXPECTED WOBBLE I.M5C BASE PAIR
1QPH	;	2.5	;	CRYSTAL STRUCTURE OF THE A-DNA DODECAMER GACCACGTGGTC
1Y9F	;	1.6	;	Crystal structure of the A-DNA GCGTAT*CGC with a 2'-O-allyl Thymidine (T*)
1Y9S	;	1.55	;	Crystal structure of the A-DNA GCGTAT*CGC with a 2'-O-propargyl Thymidine (T*)
1Y8V	;	1.5	;	Crystal structure of the A-DNA GCGTAT*CGC with a 2'-O-propyl Thymidine (T*)
1YBC	;	1.8	;	Crystal structure of the A-DNA GCGTAT*CGC with a 2'-O-[2-(benzyloxy)ethyl] Thymidine (T*)
1Y86	;	1.7	;	Crystal structure of the A-DNA GCGTAT*CGC with a 2'-O-[2-(fluoro)ethyl] Thymidine (T*)
1Y84	;	1.6	;	Crystal structure of the A-DNA GCGTAT*CGC with a 2'-O-[2-(imidazolyl)ethyl] Thymidine (T*)
1YB9	;	1.65	;	Crystal structure of the A-DNA GCGTAT*CGC with a 2'-O-[2-(N,N-dimethylaminooxy)ethyl] Thymidine (T*)
1Y8L	;	1.5	;	Crystal structure of the A-DNA GCGTAT*CGC with a 2'-O-[2-(trifluoro)ethyl] Thymidine (T*)
1Y7F	;	1.6	;	Crystal structure of the A-DNA GCGTAT*CGC with a 2'-O-[2-[hydroxy(methyleneamino)oxy]ethyl] Thymidine (T*)
1F6E	;	2.0	;	CRYSTAL STRUCTURE OF THE A-DNA HEXAMER GGCGM5CC
281D	;	2.38	;	CRYSTAL STRUCTURE OF THE A-DNA OCTAMER D(GGCATGCC)
2IY9	;	1.8	;	Crystal structure of the A-subunit of the AB5 toxin from E. coli
3DWQ	;	2.1	;	Crystal structure of the A-subunit of the AB5 toxin from E. coli with Neu5Gc-2,3Gal-1,3GlcNAc
2O7Q	;	2.2	;	Crystal Structure of the A. thaliana DHQ-dehydroshikimate-SDH-shikimate-NADP(H)
2O7S	;	1.78	;	Crystal Structure of the A. thaliana DHQ-dehydroshikimate-SDH-shikimate-NADP(H)
5ADP	;	2.13	;	Crystal structure of the A.17 antibody FAB fragment - Light chain S35R mutant
4X4N	;	2.953	;	Crystal structure of the A.fulgidus CCA-adding enzyme in complex with a G70A arginyl-tRNA minihelix
4X4O	;	3.201	;	Crystal structure of the A.fulgidus CCA-adding enzyme in complex with a G70A arginyl-tRNA minihelix and CTP
4X4P	;	3.0	;	Crystal structure of the A.fulgidus CCA-adding enzyme in complex with a G70A arginyl-tRNA minihelix ending in CCAC
4X4Q	;	3.15	;	Crystal structure of the A.fulgidus CCA-adding enzyme in complex with a G70A arginyl-tRNA minihelix ending in CCAC and CTP
4X4R	;	3.202	;	Crystal structure of the A.fulgidus CCA-adding enzyme in complex with a G70A arginyl-tRNA minihelix ending in CCACC and AMPcPP
4X4S	;	3.25	;	Crystal structure of the A.fulgidus CCA-adding enzyme in complex with a G70A arginyl-tRNA minihelix ending in CCACC and CTP
4X4T	;	2.5	;	Crystal structure of the A.fulgidus CCA-adding enzyme in complex with a G70A arginyl-tRNA minihelix ending in CCACCA
4X4U	;	2.7	;	Crystal structure of the A.fulgidus CCA-adding enzyme in complex with a human MenBeta minihelix ending in CCACC
4X4V	;	2.6	;	Crystal structure of the A.fulgidus CCA-adding enzyme in complex with a human MenBeta minihelix ending in CCACC and AMPcPP
8TJ4	;	1.95	;	CRYSTAL STRUCTURE OF THE A/Bangkok/1/1979(H3N2) INFLUENZA VIRUS HEMAGGLUTININ WITH HUMAN RECEPTOR ANALOG 6'-SLNLN
8TJ6	;	2.85	;	CRYSTAL STRUCTURE OF THE A/Beijing/353/1989(H3N2) INFLUENZA VIRUS HEMAGGLUTININ WITH HUMAN RECEPTOR ANALOG 6'-SLN
6AOQ	;	2.35	;	Crystal structure of the A/Brisbane/10/2007 (H3N2) influenza virus hemagglutinin apo form
6AOR	;	1.7	;	Crystal structure of the A/Brisbane/10/2007 (H3N2) influenza virus hemagglutinin apo form
6NSC	;	2.25	;	Crystal structure of the A/Brisbane/10/2007 (H3N2) influenza virus hemagglutinin G186V/L194P mutant apo form
6NSF	;	2.1	;	Crystal structure of the A/Brisbane/10/2007 (H3N2) influenza virus hemagglutinin G186V/L194P mutant in complex with 3'-SLNLN
6NSG	;	2.4	;	Crystal structure of the A/Brisbane/10/2007 (H3N2) influenza virus hemagglutinin G186V/L194P mutant in complex with 6'-SLNLN
6AOU	;	1.75	;	Crystal structure of the A/Brisbane/10/2007 (H3N2) influenza virus hemagglutinin in complex with 3'-SLNLN
6AOV	;	1.75	;	Crystal structure of the A/Brisbane/10/2007 (H3N2) influenza virus hemagglutinin in complex with 6'-SLNLN
6AOP	;	2.3	;	Crystal structure of the A/Brisbane/10/2007 (H3N2) influenza virus hemagglutinin L194P mutant apo form
6AOS	;	2.3	;	Crystal structure of the A/Brisbane/10/2007 (H3N2) influenza virus hemagglutinin L194P mutant in complex with 3'-SLNLN
6AOT	;	1.95	;	Crystal structure of the A/Brisbane/10/2007 (H3N2) influenza virus hemagglutinin L194P mutant in complex with 6'-SLNLN
8TJA	;	2.05	;	CRYSTAL STRUCTURE OF THE A/Ecuador/1374/2016(H3N2) INFLUENZA VIRUS HEMAGGLUTININ WITH HUMAN RECEPTOR ANALOG 6'-SLNLN
4FNK	;	1.901	;	Crystal structure of the A/Hong Kong/1/1968 (H3N2) influenza virus hemagglutinin
6BKM	;	2.2	;	Crystal structure of the A/Hong Kong/1/1968 (H3N2) influenza virus hemagglutinin E190D mutant apo form
6BKQ	;	2.25	;	Crystal structure of the A/Hong Kong/1/1968 (H3N2) influenza virus hemagglutinin E190D mutant in complex with 6'-SLN
5VTU	;	2.45	;	Crystal structure of the A/Hong Kong/1/1968 (H3N2) influenza virus hemagglutinin G225L/L226S mutant apo form
5VTQ	;	2.95	;	Crystal structure of the A/Hong Kong/1/1968 (H3N2) influenza virus hemagglutinin G225L/L226S mutant in complex with 3'-SLN
5VTR	;	2.5	;	Crystal structure of the A/Hong Kong/1/1968 (H3N2) influenza virus hemagglutinin G225L/L226S mutant in complex with 6'-SLN
5VTX	;	2.65	;	Crystal structure of the A/Hong Kong/1/1968 (H3N2) influenza virus hemagglutinin G225M/L226T/S228A mutant apo form
5VTV	;	2.25	;	Crystal structure of the A/Hong Kong/1/1968 (H3N2) influenza virus hemagglutinin G225M/L226T/S228A mutant in complex with 3'-SLN
5VTW	;	2.35	;	Crystal structure of the A/Hong Kong/1/1968 (H3N2) influenza virus hemagglutinin G225M/L226T/S228A mutant in complex with 6'-SLN
5VTZ	;	2.15	;	Crystal structure of the A/Hong Kong/1/1968 (H3N2) influenza virus hemagglutinin G225Q/L226A mutant apo form
5VTY	;	2.36	;	Crystal structure of the A/Hong Kong/1/1968 (H3N2) influenza virus hemagglutinin G225Q/L226A mutant in complex with 3'-SLN
5VU4	;	2.25	;	Crystal structure of the A/Hong Kong/1/1968 (H3N2) influenza virus hemagglutinin G225Q/L226A mutant in complex with 6'-SLN
4ZCJ	;	3.0	;	Crystal structure of the A/Hong Kong/1/1968 (H3N2) influenza virus hemagglutinin HA1 Cys30, HA2 Cys47 mutant
6NHR	;	2.1	;	Crystal structure of the A/Hong Kong/1/1968 (H3N2) influenza virus hemagglutinin HA2 I45F mutant
6NHQ	;	2.5	;	Crystal structure of the A/Hong Kong/1/1968 (H3N2) influenza virus hemagglutinin HA2 I45M mutant
6NHP	;	2.25	;	Crystal structure of the A/Hong Kong/1/1968 (H3N2) influenza virus hemagglutinin HA2 I45T mutant
6TZB	;	2.243	;	Crystal structure of the A/Hong Kong/1/1968 (H3N2) influenza virus hemagglutinin in complex with 6'-SLNLN
6CEX	;	2.57	;	Crystal structure of the A/Hong Kong/1/1968 (H3N2) influenza virus hemagglutinin in complex with small molecule N-Cyclohexyltaurine
5T6N	;	2.541	;	Crystal structure of the A/Hong Kong/1/1968 (H3N2) influenza virus hemagglutinin in complex with the antiviral drug arbidol
6BKP	;	2.05	;	Crystal structure of the A/Michigan/15/2014 (H3N2) influenza virus hemagglutinin apo form
6BKT	;	1.8	;	Crystal structure of the A/Michigan/15/2014 (H3N2) influenza virus hemagglutinin in complex with 6'-SLN
8TJ9	;	1.9	;	CRYSTAL STRUCTURE OF THE A/Michigan/15/2014(H3N2) INFLUENZA VIRUS HEMAGGLUTININ WITH HUMAN RECEPTOR ANALOG 6'-SLNLN
8TJ8	;	2.56	;	CRYSTAL STRUCTURE OF THE A/Moscow/10/1999(H3N2) INFLUENZA VIRUS HEMAGGLUTININ WITH HUMAN RECEPTOR ANALOG 6'-SLNLN
5W6U	;	2.878	;	Crystal structure of the A/Puerto Rico/8/1934 (H1N1) influenza virus hemagglutinin in complex with cyclic peptide CP121068 (P2)
5W5S	;	2.284	;	Crystal structure of the A/Puerto Rico/8/1934 (H1N1) influenza virus hemagglutinin in complex with cyclic peptide CP141019 (P5)
5W5U	;	2.461	;	Crystal structure of the A/Puerto Rico/8/1934 (H1N1) influenza virus hemagglutinin in complex with cyclic peptide CP141037 (P4)
5W6I	;	3.104	;	Crystal structure of the A/Puerto Rico/8/1934 (H1N1) influenza virus hemagglutinin in complex with cyclic peptide CP141046 (P3)
5W6R	;	2.731	;	Crystal structure of the A/Puerto Rico/8/1934 (H1N1) influenza virus hemagglutinin in complex with cyclic peptide CP141099 (P6)
5W6T	;	2.59	;	Crystal structure of the A/Puerto Rico/8/1934 (H1N1) influenza virus hemagglutinin in complex with cyclic peptide CP151070 (P7)
6WCR	;	2.68	;	Crystal structure of the A/Puerto Rico/8/1934 (H1N1) influenza virus hemagglutinin in complex with small molecule F0045(S)
8TJ7	;	2.85	;	CRYSTAL STRUCTURE OF THE A/Shandong/9/1993(H3N2) INFLUENZA VIRUS HEMAGGLUTININ WITH HUMAN RECEPTOR ANALOG 6'-SLNLN
5T6S	;	2.36	;	Crystal structure of the A/Shanghai/2/2013 (H7N9) influenza virus hemagglutinin in complex with the antiviral drug arbidol
6CF7	;	2.719	;	Crystal structure of the A/Solomon Islands/3/2006(H1N1) influenza virus hemagglutinin in complex with small molecule JNJ4796
8TJB	;	2.45	;	CRYSTAL STRUCTURE OF THE A/Texas/73/2017(H3N2) INFLUENZA VIRUS HEMAGGLUTININ WITH HUMAN RECEPTOR ANALOG 6'-SLNLN
6CF5	;	2.04	;	Crystal structure of the A/Viet Nam/1203/2004(H5N1) influenza virus hemagglutinin in complex with small molecule N-Cyclohexyltaurine
6CFG	;	2.32	;	Crystal structure of the A/Vietnam/1203/2004 (H5N1) influenza virus hemagglutinin in complex with small molecule JNJ4796
6BKN	;	1.85	;	Crystal structure of the A/Wyoming/3/2003 (H3N2) influenza virus hemagglutinin apo form
6BKO	;	1.85	;	Crystal structure of the A/Wyoming/3/2003 (H3N2) influenza virus hemagglutinin D190E mutant apo form
6BKS	;	1.8	;	Crystal structure of the A/Wyoming/3/2003 (H3N2) influenza virus hemagglutinin D190E mutant in complex with 6'-SLN
6BKR	;	1.76	;	Crystal structure of the A/Wyoming/3/2003 (H3N2) influenza virus hemagglutinin in complex with 6'-SLN
3IDV	;	1.95	;	Crystal structure of the a0a fragment of ERp72
8AU0	;	2.07	;	Crystal structure of the a1 luminal coiled-coil domain of SUN1
5TXQ	;	1.9	;	Crystal structure of the A143D variant of catalase-peroxidase from B. pseudomallei
3BF2	;	2.6	;	Crystal structure of the A1KSW9_NEIMF protein from Neisseria meningitidis. Northeast Structural Genomics Consortium target MR36a
3OJ3	;	2.5	;	Crystal structure of the A20 ZnF4 and ubiquitin complex
3OJ4	;	3.4	;	Crystal structure of the A20 ZnF4, ubiquitin and UbcH5A complex
7RQ9	;	2.6	;	Crystal structure of the A2058-dimethylated Thermus thermophilus 70S ribosome in complex with iboxamycin, mRNA, deacylated A- and E-site tRNAs, and aminoacylated P-site tRNA at 2.60A resolution
6XHV	;	2.4	;	Crystal structure of the A2058-dimethylated Thermus thermophilus 70S ribosome in complex with mRNA, aminoacylated A- and P-site tRNAs, and deacylated E-site tRNA at 2.40A resolution
8UD7	;	2.55	;	Crystal structure of the A2058-N6-dimethylated Thermus thermophilus 70S ribosome in complex with cresomycin, mRNA, deacylated A-site tRNAphe, aminoacylated P-site fMet-tRNAmet, and deacylated E-site tRNAphe at 2.70A resolution
8FC5	;	2.65	;	Crystal structure of the A2058-N6-dimethylated Thermus thermophilus 70S ribosome in complex with protein Y, hygromycin A, and azithromycin at 2.65A resolution
8FC4	;	2.45	;	Crystal structure of the A2058-N6-dimethylated Thermus thermophilus 70S ribosome in complex with protein Y, hygromycin A, and erythromycin at 2.45A resolution
8FC6	;	2.35	;	Crystal structure of the A2058-N6-dimethylated Thermus thermophilus 70S ribosome in complex with protein Y, hygromycin A, and telithromycin at 2.35A resolution
6XHX	;	2.55	;	Crystal structure of the A2058-unmethylated Thermus thermophilus 70S ribosome in complex with erythromycin and protein Y (YfiA) at 2.55A resolution
6XHW	;	2.5	;	Crystal structure of the A2058-unmethylated Thermus thermophilus 70S ribosome in complex with mRNA, aminoacylated A- and P-site tRNAs, and deacylated E-site tRNA at 2.50A resolution
4FEJ	;	1.5	;	Crystal structure of the A24U mutant xpt-pbuX guanine riboswitch aptamer domain in complex with hypoxanthine
4FEN	;	1.35	;	Crystal structure of the A24U/U25A/A46G mutant xpt-pbuX guanine riboswitch aptamer domain in complex with hypoxanthine
4FEP	;	1.65	;	Crystal structure of the A24U/U25A/A46G/C74U mutant xpt-pbuX guanine riboswitch aptamer domain in complex with 2,6-diaminopurine
8UD8	;	2.6	;	Crystal structure of the A2503-C2,C8-dimethylated Thermus thermophilus 70S ribosome in complex with cresomycin, mRNA, deacylated A-site tRNAphe, aminoacylated P-site fMet-tRNAmet, and deacylated E-site tRNAphe at 2.70A resolution
8G2B	;	2.55	;	Crystal structure of the A2503-C2,C8-dimethylated Thermus thermophilus 70S ribosome in complex with iboxamycin, mRNA, deacylated A- and E-site tRNAphe, and aminoacylated P-site fMet-tRNAmet at 2.55A resolution
8G29	;	2.55	;	Crystal structure of the A2503-C2,C8-dimethylated Thermus thermophilus 70S ribosome in complex with mRNA, aminoacylated A-site Phe-tRNAphe, aminoacylated P-site fMet-tRNAmet, and deacylated E-site tRNAphe at 2.55A resolution
8G2A	;	2.45	;	Crystal structure of the A2503-C2,C8-dimethylated Thermus thermophilus 70S ribosome in complex with mRNA, aminoacylated A-site Phe-tRNAphe, peptidyl P-site fMTHSMRC-tRNAmet, and deacylated E-site tRNAphe at 2.45A resolution
8G2C	;	2.65	;	Crystal structure of the A2503-C2,C8-dimethylated Thermus thermophilus 70S ribosome in complex with tylosin, mRNA, aminoacylated A-site Phe-tRNAphe, aminoacylated P-site fMet-tRNAmet, and deacylated E-site tRNAphe at 2.65A resolution
3EKB	;	2.3	;	Crystal structure of the A264C mutant heme domain of cytochrome P450 BM3
3EKD	;	2.5	;	Crystal structure of the A264M heme domain of cytochrome P450 BM3
3EKF	;	2.1	;	Crystal structure of the A264Q heme domain of cytochrome P450 BM3
3DL5	;	2.74	;	Crystal Structure of the A287F Active Site Mutant of TS-DHFR from Cryptosporidium hominis
3DL6	;	3.25	;	Crystal Structure of the A287F/S290G Active Site Mutant of TS-DHFR from Cryptosporidium hominis
5KQ0	;	1.8	;	Crystal structure of the A290D variant of catalase-peroxidase from B. pseudomallei
6GT3	;	2.0	;	Crystal Structure of the A2A-StaR2-bRIL562 in complex with AZD4635 at 2.0A resolution
2QQM	;	2.0	;	Crystal Structure of the a2b1b2 Domains from Human Neuropilin-1
2QQO	;	2.3	;	Crystal Structure of the a2b1b2 Domains from Human Neuropilin-2
4K1W	;	1.646	;	Crystal structure of the A314P mutant of mannonate dehydratase from novosphingobium aromaticivorans complexed with mg and d-mannonate
3M4V	;	1.9	;	Crystal structure of the A330P mutant of cytochrome P450 BM3
5KQ2	;	1.9	;	Crystal structure of the A357D variant of catalase-peroxidase from B. pseudomallei
5KQ6	;	1.62	;	Crystal structure of the A359D variant of catalase-peroxidase from B. pseudomallei
3GQB	;	2.8	;	Crystal Structure of the A3B3 complex from V-ATPase
3A54	;	1.502	;	Crystal structure of the A47Q1 mutant of pro-protein-glutaminase
3A55	;	1.5	;	Crystal structure of the A47Q2 mutant of pro- protein-glutaminase
2HL3	;	2.03	;	Crystal structure of the A49M mutant CAP-Gly domain of human Dynactin-1 (p150-Glued) in complex with human EB1 C-terminal hexapeptide
2APF	;	1.8	;	Crystal Structure of the A52V/S54N/K66E variant of the murine T cell receptor V beta 8.2 domain
2XSU	;	1.6	;	Crystal structure of the A72G mutant of Acinetobacter radioresistens catechol 1,2 dioxygenase
2D7G	;	3.3	;	Crystal structure of the aa complex of the N-terminal domain of PriA
1LV7	;	1.5	;	Crystal Structure of the AAA domain of FtsH
6Z1E	;	2.454	;	Crystal structure of the AAA domain of Rubisco Activase from Nostoc sp. (strain PCC 7120)
6Z1D	;	2.705	;	Crystal structure of the AAA domain of Rubisco Activase from Nostoc sp. (strain PCC 7120), Gadolinium complex
3SYL	;	3.0	;	Crystal structure of the AAA+ protein CbbX, native structure
3SYK	;	3.08	;	Crystal structure of the AAA+ protein CbbX, selenomethionine structure
4AEI	;	2.3	;	Crystal structure of the AaHII-Fab4C1 complex
7Z3W	;	2.0	;	Crystal structure of the AAL160 Fab
2YZ2	;	2.3	;	Crystal structure of the ABC transporter in the cobalt transport system
5UVE	;	2.5	;	Crystal Structure of the ABC Transporter Substrate-binding protein BAB1_0226 from Brucella abortus
2FGK	;	2.7	;	Crystal structure of the ABC-cassette E631Q mutant of HlyB with bound ATP
2FGJ	;	2.6	;	Crystal structure of the ABC-cassette H662A mutant of HlyB with bound ATP
1EHK	;	2.4	;	CRYSTAL STRUCTURE OF THE ABERRANT BA3-CYTOCHROME-C OXIDASE FROM THERMUS THERMOPHILUS
7N9G	;	2.2	;	Crystal structure of the Abl 1b Kinase domain in complex with Dasatinib and Imatinib
7PVV	;	1.82	;	Crystal structure of the Abl SH3 domain G92N-Y93N-N94T-H95E mutant
7PW2	;	1.1	;	Crystal structure of the Abl SH3 domain V73E-A74S-S75R-G76T-D77E mutant
7PVS	;	1.05	;	Crystal structure of the Abl SH3 domain V73E-A74S-S75R-G76T-D77E-G92N-Y93N-N94T-H95E mutant in presence of PEG 200
7PVQ	;	1.55	;	Crystal structure of the Abl SH3 domain V73E-A74S-S75R-G76T-D77E-G92N-Y93N-N94T-H95E mutant in the space group P21221
7PVR	;	1.65	;	Crystal structure of the Abl SH3 domain V73E-A74S-S75R-G76T-D77E-G92N-Y93N-N94T-H95E mutant in the space group P41
5OAZ	;	1.03	;	Crystal structure of the Abl-SH3 domain at pH 7.5
4JJB	;	1.65	;	Crystal structure of the Abl-SH3 domain at pH3
4JJC	;	1.6	;	Crystal structure of the Abl-SH3 domain at pH5
1BBZ	;	1.65	;	CRYSTAL STRUCTURE OF THE ABL-SH3 DOMAIN COMPLEXED WITH A DESIGNED HIGH-AFFINITY PEPTIDE LIGAND: IMPLICATIONS FOR SH3-LIGAND INTERACTIONS
4J9I	;	2.2	;	Crystal structure of the ABL-SH3 domain complexed with the designed high-affinity peptide ligand P17
4J9H	;	1.7	;	Crystal structure of the ABL-SH3 domain complexed with the designed high-affinity peptide ligand P7 at pH 8
4J9G	;	1.8	;	Crystal structure of the ABL-SH3 domain complexed with the designed high-affinity peptide ligand P7 at pH7
4J9F	;	1.094	;	Crystal structure of the Abl-SH3 domain complexed with the high affinity peptide P0
4J9B	;	1.702	;	Crystal structure of the Abl-SH3 domain H59Q-N96T mutant
4J9C	;	1.051	;	Crystal structure of the Abl-SH3 domain H59Q-N96T mutant complexed with the designed high-affinity peptide ligand P17
2X8S	;	1.5	;	Crystal Structure of the Abn2 D171A mutant in complex with arabinotriose
2X8T	;	1.79	;	Crystal Structure of the Abn2 H318A mutant
5YGV	;	2.5	;	Crystal structure of the abscisic acid receptor PYR1 in complex with an antagonist
3WG8	;	2.3	;	Crystal structure of the abscisic acid receptor PYR1 in complex with an antagonist AS6
3NMH	;	1.85	;	Crystal structure of the abscisic receptor PYL2 in complex with pyrabactin
3NMP	;	2.1	;	Crystal structure of the abscisic receptor PYL2 mutant A93F in complex with pyrabactin
1G5H	;	1.95	;	CRYSTAL STRUCTURE OF THE ACCESSORY SUBUNIT OF MURINE MITOCHONDRIAL POLYMERASE GAMMA
1G5I	;	2.3	;	CRYSTAL STRUCTURE OF THE ACCESSORY SUBUNIT OF MURINE MITOCHONDRIAL POLYMERASE GAMMA
6SXH	;	2.3	;	Crystal structure of the accessory translocation ATPase, SecA2, from Clostridium difficile
6T4H	;	2.9	;	Crystal structure of the accessory translocation ATPase, SecA2, from Clostridium difficile, in complex with adenosine-5'-(gamma-thio)-triphosphate
4UAQ	;	2.8	;	Crystal structure of the accessory translocation ATPase, SecA2, from Mycobacterium tuberculosis
3U8J	;	2.35	;	Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3531 (1-(pyridin-3-yl)-1,4-diazepane)
3U8L	;	2.32	;	Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3570 (1-(5-phenylpyridin-3-yl)-1,4-diazepane)
3U8K	;	2.47	;	Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3573 (1-(5-ethoxypyridin-3-yl)-1,4-diazepane)
3U8M	;	2.7	;	Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3920 (1-(6-bromopyridin-3-yl)-1,4-diazepane)
3U8N	;	2.35	;	Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3950 (1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane)
2FSR	;	1.52	;	Crystal Structure of the Acetyltransferase from Agrobacterium tumefaciens str. C58
3JVN	;	2.61	;	Crystal Structure of the acetyltransferase VF_1542 from Vibrio fischeri, Northeast Structural Genomics Consortium Target VfR136
1X0I	;	2.3	;	Crystal Structure of the Acid Blue Form of Bacteriorhodopsin
6BYI	;	2.2	;	Crystal structure of the acid-base mutant (E477A) of the GH2 exo-beta-mannanase from Xanthomonas axonopodis pv. citri
1HUX	;	3.0	;	CRYSTAL STRUCTURE OF THE ACIDAMINOCOCCUS FERMENTANS (R)-2-HYDROXYGLUTARYL-COA DEHYDRATASE COMPONENT A
5XH7	;	2.0	;	Crystal structure of the Acidaminococcus sp. BV3L6 Cpf1 RR variant in complex with crRNA and target DNA (TCCA PAM)
5XH6	;	2.0	;	Crystal structure of the Acidaminococcus sp. BV3L6 Cpf1 RVR variant in complex with crRNA and target DNA (TATA PAM)
6GIE	;	2.1	;	Crystal structure of the Acinetobacter baumannii outer membrane protein Omp33
6E1R	;	2.693	;	Crystal structure of the Acinetobacter phage vB_ApiP_P1 tailspike protein
5MXR	;	1.75	;	Crystal Structure of the Acquired VIM-2 Metallo-beta-Lactamase in Complex with ANT-330 Inhibitor
6HF5	;	1.8	;	Crystal Structure of the Acquired VIM-2 Metallo-beta-Lactamase in Complex with ANT-431 Inhibitor
5MXQ	;	2.0	;	Crystal Structure of the Acquired VIM-2 Metallo-beta-Lactamase in Complex with ANT-90 Inhibitor
3IBW	;	1.93	;	Crystal Structure of the ACT domain from GTP pyrophosphokinase of Chlorobium tepidum. Northeast Structural Genomics Consortium Target CtR148A
5V0S	;	2.01	;	Crystal structure of the ACT domain of prephenate dehydrogenase tyrA from Bacillus anthracis
1MB8	;	2.15	;	Crystal Structure of the actin binding domain of plectin
1PEV	;	2.0	;	Crystal Structure of the Actin Interacting Protein from Caenorhabditis Elegans
2EYI	;	1.7	;	Crystal structure of the actin-binding domain of human alpha-actinin 1 at 1.7 Angstrom resolution
2EYN	;	1.8	;	Crystal structure of the actin-binding domain of human alpha-actinin 1 at 1.8 Angstrom resolution
6O31	;	1.51	;	CRYSTAL STRUCTURE OF THE ACTIN-BINDING DOMAIN OF HUMAN ALPHA-ACTININ-4
6OA6	;	1.37	;	CRYSTAL STRUCTURE OF THE ACTIN-BINDING DOMAIN OF HUMAN ALPHA-ACTININ-4
2R0O	;	2.2	;	Crystal structure of the actin-binding domain of human alpha-actinin-4 mutant(K255E)
1PXY	;	2.4	;	Crystal structure of the actin-crosslinking core of Arabidopsis fimbrin
1RT8	;	2.0	;	CRYSTAL STRUCTURE OF THE ACTIN-CROSSLINKING CORE OF SCHIZOSACCHAROMYCES POMBE FIMBRIN
3Q3E	;	2.1	;	Crystal structure of the Actinobacillus pleuropneumoniae HMW1C glycosyltransferase
3Q3H	;	2.25	;	Crystal structure of the Actinobacillus pleuropneumoniae HMW1C glycosyltransferase in complex with UDP-GLC
3Q3I	;	2.45	;	Crystal structure of the Actinobacillus pleuropneumoniae HMW1C glycosyltransferase in the presence of peptide N1131
2WKE	;	2.2	;	Crystal structure of the Actinomadura R39 DD-peptidase inhibited by 6- beta-iodopenicillanate.
3G4N	;	2.1	;	Crystal structure of the activated aerolysin mutant H132D
3G4O	;	2.3	;	Crystal structure of the activated aerolysin mutant H132N
5EG3	;	2.606	;	Crystal Structure of the Activated FGF Receptor 2 (FGFR2) Kinase Domain in complex with the cSH2 domain of Phospholipase C gamma (PLCgamma)
4XLV	;	2.3	;	Crystal structure of the activated insulin receptor tyrosine kinase dimer
2X1V	;	1.7	;	Crystal Structure of the activating H-Ras I163F mutant in Costello Syndrome, bound to MG-GDP
2QUZ	;	1.49	;	Crystal Structure of the activating H-RasK117R mutant in Costello Syndrome, bound to Mg-GDP
4JO8	;	3.2	;	Crystal structure of the activating Ly49H receptor in complex with m157 (G1F strain)
2O2K	;	1.6	;	Crystal Structure of the Activation Domain of Human Methionine Synthase Isoform/Mutant D963E/K1071N
5E7I	;	2.223	;	Crystal structure of the active catalytic core of the human DEAD-box protein DDX3
5E7J	;	2.23	;	Crystal structure of the active catalytic core of the human DEAD-box protein DDX3 bound to AMP
5E7M	;	2.304	;	Crystal structure of the active catalytic core of the human DEAD-box protein DDX3 bound to AMPPNP
6PT2	;	2.8	;	Crystal structure of the active delta opioid receptor in complex with the peptide agonist KGCHM07
6PT3	;	3.3	;	Crystal structure of the active delta opioid receptor in complex with the small molecule agonist DPI-287
4M8M	;	3.307	;	Crystal structure of the active dimer of zebrafish PlexinC1 cytoplasmic region
2GS2	;	2.8	;	Crystal Structure of the active EGFR kinase domain
2GS6	;	2.6	;	Crystal Structure of the active EGFR kinase domain in complex with an ATP analog-peptide conjugate
2CLT	;	2.67	;	Crystal structure of the active form (full-length) of human fibroblast collagenase.
5AJP	;	1.65	;	Crystal structure of the active form of GalNAc-T2 in complex with UDP and the glycopeptide MUC5AC-13
5K5S	;	2.6	;	Crystal structure of the active form of human calcium-sensing receptor extracellular domain
5DZK	;	3.07	;	Crystal structure of the active form of the proteolytic complex clpP1 and clpP2
5E0S	;	2.9	;	crystal structure of the active form of the proteolytic complex clpP1 and clpP2
3DQB	;	3.2	;	Crystal structure of the active G-protein-coupled receptor opsin in complex with a C-terminal peptide derived from the Galpha subunit of transducin
4PXF	;	2.75	;	Crystal structure of the active G-protein-coupled receptor opsin in complex with the finger-loop peptide derived from the full-length arrestin-1
4F76	;	1.85	;	Crystal Structure of the active HIV-1 Protease in Complex with the products of p1-p6 substrate
1LFD	;	2.1	;	CRYSTAL STRUCTURE OF THE ACTIVE RAS PROTEIN COMPLEXED WITH THE RAS-INTERACTING DOMAIN OF RALGDS
1JGI	;	2.0	;	Crystal Structure of the Active Site Mutant Glu328Gln of Amylosucrase from Neisseria polysaccharea in Complex with the Natural Substrate Sucrose
1AXE	;	2.0	;	CRYSTAL STRUCTURE OF THE ACTIVE-SITE MUTANT PHE93->TRP OF HORSE LIVER ALCOHOL DEHYDROGENASE IN COMPLEX WITH NAD AND INHIBITOR TRIFLUOROETHANOL
7U5P	;	3.14	;	CRYSTAL STRUCTURE OF THE ACTIVIN RECEPTOR TYPE-2A LIGAND BINDING DOMAIN IN COMPLEX WITH ACTIVIN-A
5NH3	;	2.35	;	CRYSTAL STRUCTURE OF THE Activin receptor type-2A LIGAND BINDING DOMAIN IN COMPLEX WITH BIMAGRUMAB FV
5NHR	;	3.35	;	CRYSTAL STRUCTURE OF THE Activin receptor type-2B LIGAND BINDING DOMAIN IN COMPLEX WITH BIMAGRUMAB FV, CUBIC CRYSTAL FORM
5NGV	;	2.0	;	CRYSTAL STRUCTURE OF THE Activin receptor type-2B LIGAND BINDING DOMAIN IN COMPLEX WITH BIMAGRUMAB FV, ORTHORHOMBIC CRYSTAL FORM
1S4Y	;	2.3	;	Crystal structure of the activin/actrIIb extracellular domain
6GIP	;	2.17	;	Crystal structure of the ACVR1 (ALK2) kinase in complex with a Quinazolinone based ALK2 inhibitor with a 2, 5-dimethyl core.
6GI6	;	1.98	;	Crystal structure of the ACVR1 (ALK2) kinase in complex with a Quinazolinone based ALK2 inhibitor with a 5-methyl core.
6GIN	;	2.2	;	Crystal structure of the ACVR1 (ALK2) kinase in complex with an Quinazolinone based ALK2 inhibitor with a 4-morpholinophenyl solvent accessible group.
5OY6	;	2.56	;	Crystal structure of the ACVR1 (ALK2) kinase in complex with cyclical inhibitor OD36.
6I1S	;	1.52	;	Crystal structure of the ACVR1 (ALK2) kinase in complex with FKBP12 and the inhibitor E6201
5OXG	;	2.13	;	Crystal structure of the ACVR1 (ALK2) kinase in complex with LDN-212854
6TN8	;	1.63	;	Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound BI-9564
6SZM	;	1.42	;	Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound M4K2009
6SRH	;	1.25	;	Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound M4K2117
6Z36	;	1.37	;	Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound M4K2118
6T6D	;	2.56	;	Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound M4K2149
7A21	;	2.14	;	Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound M4K2158
8C7W	;	2.26	;	Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound M4K2304
8C7Z	;	2.23	;	Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound M4K2308
6T8N	;	1.77	;	Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound M4K3007
7NNS	;	2.14	;	Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound Momelotinib
6ZGC	;	2.67	;	Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound Saracatinib (AZD0530)
3Q4U	;	1.82	;	Crystal structure of the ACVR1 kinase domain in complex with LDN-193189
4DYM	;	2.42	;	Crystal structure of the ACVR1 kinase domain in complex with the imidazo[1,2-b]pyridazine inhibitor K00135
3OOM	;	2.0	;	Crystal structure of the ACVR1 kinase domain in complex with the imidazo[1,2-b]pyridazine inhibitor K00507
3MTF	;	2.15	;	Crystal structure of the ACVR1 kinase in complex with a 2-aminopyridine inhibitor
4BGG	;	2.56	;	Crystal structure of the ACVR1 kinase in complex with LDN-213844
3MY0	;	2.65	;	Crystal structure of the ACVRL1 (ALK1) kinase domain bound to LDN-193189
1X3O	;	1.5	;	Crystal structure of the acyl carrier protein from thermus thermophilus HB8
6OSS	;	2.19	;	Crystal Structure of the Acyl-Carrier-Protein UDP-N-Acetylglucosamine O-Acyltransferase LpxA from Proteus mirabilis
2A7S	;	2.9	;	Crystal Structure of the Acyl-CoA Carboxylase, AccD5, from Mycobacterium tuberculosis
2WKH	;	1.791	;	Crystal structure of the acyl-enzyme OXA-10 K70C-Ampicillin at pH 7
2WGI	;	2.85	;	Crystal structure of the acyl-enzyme OXA-10 W154A-benzylpenicillin at pH 6
1KZF	;	1.8	;	Crystal Structure of the Acyl-homoserine Lactone Synthase, EsaI
1K4J	;	2.5	;	Crystal Structure of the Acyl-homoserinelactone Synthase EsaI Complexed with Rhenate
1XKZ	;	1.75	;	Crystal structure of the acylated beta-lactam sensor domain of Blar1 from S. aureus
6IYR	;	2.05	;	Crystal Structure of the acyltransferase domain from module 8 of the salinomycin polyketide synthase
6IYT	;	1.78	;	Crystal Structure of the acyltransferase domain from second module 14 of salinomycin polyketide synthase
6IYO	;	2.2	;	Crystal Structure of the acyltransferase domain from the second module of the salinomycin polyketide synthase
6J0U	;	1.79	;	Crystal Structure of the acyltransferase domain from the third module of the ansamitocin polyketide synthase
6L3M	;	1.77	;	Crystal Structure of the acyltransferase domain from the third module of the ansamitocin polyketide synthase
6L3N	;	1.83	;	Crystal Structure of the acyltransferase domain from the third module of the ansamitocin polyketide synthase
4AMM	;	1.4	;	Crystal Structure of the Acyltransferase Domain of the Iterative Polyketide Synthase in Enediyne Biosynthesis Reveals the Molecular Basis of Substrate Specificity
4AMN	;	1.5	;	Crystal Structure of the Acyltransferase Domain of the Iterative Polyketide Synthase in Enediyne Biosynthesis Reveals the Molecular Basis of Substrate Specificity
4AMO	;	1.9	;	Crystal Structure of the Acyltransferase Domain of the Iterative Polyketide Synthase in Enediyne Biosynthesis Reveals the Molecular Basis of Substrate Specificity
4AMP	;	1.65	;	Crystal Structure of the Acyltransferase Domain of the Iterative Polyketide Synthase in Enediyne Biosynthesis Reveals the Molecular Basis of Substrate Specificity
6MFJ	;	2.62	;	Crystal structure of the ADCC potent antibody DH677.3 Fab elicited in the RV305 vaccine trial.
4RFO	;	3.2	;	Crystal structure of the ADCC-Potent Antibody N60-I3 Fab in complex with HIV-1 Clade A/E gp120 and M48u1
5KJR	;	2.98	;	Crystal structure of the ADCC-potent antibody N60-i3 Fab in complex with HIV-1 Clade A/E gp120 W69A/S115W mutant and M48U1.
6W4M	;	3.2	;	CRYSTAL STRUCTURE OF THE ADCC-POTENT, WEAKLY NEUTRALIZING HIV ENV CO-RECEPTOR BINDING SITE ANTIBODY N12-I2 FAB IN COMPLEX WITH HIV-1 CLADE A/E GP120 AND M48U1
8BRC	;	3.17	;	Crystal structure of the adduct between human serum transferrin and cisplatin
3CJK	;	1.8	;	Crystal structure of the adduct HAH1-Cd(II)-MNK1.
2IBS	;	2.4	;	Crystal structure of the adenine-specific DNA methyltransferase M.TaqI complexed with the cofactor analog AETA and a 10 bp DNA containing 2-aminopurine at the target position
2IBT	;	1.7	;	Crystal structure of the adenine-specific DNA methyltransferase M.TaqI complexed with the cofactor analog AETA and a 10 bp DNA containing 2-aminopurine at the target position and an abasic site analog at the target base partner position
2IH2	;	1.61	;	Crystal structure of the adenine-specific DNA methyltransferase M.TaqI complexed with the cofactor analog AETA and a 10 bp DNA containing 5-methylpyrimidin-2(1H)-one at the target base partner position
2IH5	;	1.8	;	Crystal structure of the adenine-specific DNA methyltransferase M.TaqI complexed with the cofactor analog AETA and a 10 bp DNA containing an abasic site analog at the target base partner position
2NP6	;	2.1	;	Crystal structure of the adenine-specific DNA methyltransferase M.TaqI complexed with the cofactor analog AETA and a 10 bp DNA containing an abasic site analog at the target position
2NP7	;	1.9	;	Crystal structure of the adenine-specific DNA methyltransferase M.TaqI complexed with the cofactor analog AETA and a 10 bp DNA containing an abasic site analog at the target position and pyrrolo-dC at the target base partner position
2IH4	;	2.1	;	Crystal structure of the adenine-specific DNA methyltransferase M.TaqI complexed with the cofactor analog AETA and a 10 bp DNA containing pyrrolo-dC at the target base partner position
7PX4	;	2.25	;	Crystal structure of the adenosine A2A receptor (A2A-PSB1-bRIL) in complex with preladenant conjugate PSB-2113
7PYR	;	2.6	;	Crystal structure of the adenosine A2A receptor (A2A-PSB1-bRIL) in complex with preladenant conjugate PSB-2115
8C9W	;	2.114	;	Crystal structure of the adenosine A2A receptor (construct A2A-PSB2-bRIL) complexed with Etrumadenant at the orthosteric pocket
5KB5	;	1.8	;	Crystal structure of the adenosine kinase from Mus musculus in complex with adenosine and adenosine-diphosphate
4GMA	;	3.94	;	Crystal structure of the adenosylcobalamin riboswitch
8FW4	;	4.3	;	Crystal structure of the adenosylcobalamin riboswitch holo conformation in absence of ligand
2III	;	2.3	;	Crystal structure of the adenosylmethionine decarboxylase (aq_254) from aquifex aeolicus vf5
1QNE	;	1.9	;	Crystal structure of the Adenovirus major late promoter TATA box bound to wild-type TBP (Arabidopsis thaliana TBP isoform 2).
6HF7	;	1.96	;	Crystal structure of the adenylate kinase from Methanothermococcus thermolithotrophicus co-crystallized with Tb-Xo4
2OOX	;	2.6	;	Crystal structure of the adenylate sensor from AMP-activated protein kinase complexed with AMP
2OOY	;	2.88	;	Crystal structure of the adenylate sensor from AMP-activated protein kinase complexed with ATP
2QRE	;	3.01	;	Crystal structure of the adenylate sensor from AMP-activated protein kinase in complex with 5-aminoimidazole-4-carboxamide 1-beta-D-ribofuranotide (ZMP)
2QR1	;	2.7	;	Crystal structure of the adenylate sensor from AMP-activated protein kinase in complex with ADP
2QRC	;	2.7	;	Crystal structure of the adenylate sensor from AMP-activated protein kinase in complex with ADP and AMP
2QRD	;	2.41	;	Crystal Structure of the Adenylate Sensor from AMP-activated Protein Kinase in complex with ADP and ATP
6OZ1	;	1.97	;	Crystal structure of the adenylation (A) domain of the carboxylate reductase (CAR) GR01_22995 from Mycobacterium chelonae
7XBS	;	1.64	;	Crystal structure of the adenylation domain of CmnG
7XBT	;	1.84	;	Crystal structure of the adenylation domain of CmnG in complex with AMP
7XBV	;	1.94	;	Crystal structure of the adenylation domain of CmnG in complex with AMPCPP
7XBU	;	2.35	;	Crystal structure of the adenylation domain of CmnG in complex with capreomycidine
3JSL	;	1.8	;	Crystal structure of the adenylation domain of NAD+-dependent DNA ligase from Staphylococcus aureus
3JSN	;	1.9	;	Crystal structure of the adenylation domain of NAD+-dependent DNA ligase from Staphylococcus aureus
3R5G	;	1.5	;	Crystal structure of the adenylyl cyclase CyaB from P. aeruginosa
1K8T	;	2.6	;	Crystal structure of the adenylyl cyclase domain of anthrax edema factor (EF)
1K93	;	2.95	;	Crystal structure of the adenylyl cyclase domain of anthrax edema factor (EF) in complex with calmodulin
1LVC	;	3.6	;	Crystal structure of the adenylyl cyclase domain of anthrax edema factor (EF) in complex with calmodulin and 2' deoxy, 3' anthraniloyl ATP
1K90	;	2.75	;	Crystal structure of the adenylyl cyclase domain of anthrax edema factor (EF) in complex with calmodulin and 3' deoxy-ATP
1SK6	;	3.2	;	Crystal structure of the adenylyl cyclase domain of anthrax edema factor (EF) in complex with calmodulin, 3',5' cyclic AMP (cAMP), and pyrophosphate
4ES9	;	2.0	;	Crystal Structure of the adhesin domain of Epf from Streptococcus pyogenes in P21
4ES8	;	1.58	;	Crystal Structure of the adhesin domain of Epf from Streptococcus pyogenes in P212121
1G6H	;	1.6	;	CRYSTAL STRUCTURE OF THE ADP CONFORMATION OF MJ1267, AN ATP-BINDING CASSETTE OF AN ABC TRANSPORTER
6TFG	;	2.45	;	Crystal structure of the ADP-binding domain of the NAD+ riboswitch with Adenosine 3-phosphate 5-phosphosulfate (APPS)
6TF2	;	2.55	;	Crystal structure of the ADP-binding domain of the NAD+ riboswitch with Adenosine 5-triphosphate (ATP)
6TF1	;	2.4	;	Crystal structure of the ADP-binding domain of the NAD+ riboswitch with Adenosine diphosphate (ADP)
6TB7	;	2.53	;	Crystal structure of the ADP-binding domain of the NAD+ riboswitch with Adenosine monophosphate (AMP)
6TF3	;	2.66	;	Crystal structure of the ADP-binding domain of the NAD+ riboswitch with Cordycepin 5-triphosphate (3-dATP)
6TFE	;	2.3	;	Crystal structure of the ADP-binding domain of the NAD+ riboswitch with N6-Methyl-adenosine-5'-triphosphate (m6ATP)
6TFF	;	2.52	;	Crystal structure of the ADP-binding domain of the NAD+ riboswitch with Nicotinamide adenine dinucleotide (NAD+)
6TF0	;	2.1	;	Crystal structure of the ADP-binding domain of the NAD+ riboswitch with Nicotinamide adenine dinucleotide, reduced (NADH)
6TFH	;	2.95	;	Crystal structure of the ADP-binding domain of the NAD+ riboswitch with Nicotinamide adenine dinucleotide, reduced (NADH); soaking with Manganese(II) (Mn2+)
6YXT	;	2.2	;	Crystal structure of the ADP-bound form of choline kinase from Plasmodium falciparum
7DQE	;	2.694	;	Crystal structure of the ADP-bound mutant A(S23C)3B(N64C)3 complex from enterococcus hirae V-ATPase
2AWO	;	2.8	;	Crystal structure of the ADP-Mg-bound E. Coli MALK (Crystallized with ADP-Mg)
2AWN	;	2.3	;	Crystal structure of the ADP-Mg-bound E. Coli MALK (Crystallized with ATP-Mg)
1GA7	;	2.71	;	CRYSTAL STRUCTURE OF THE ADP-RIBOSE PYROPHOSPHATASE IN COMPLEX WITH GD+3
5A3A	;	1.54	;	Crystal structure of the ADP-ribosylating sirtuin (SirTM) from Streptococcus pyogenes (Apo form)
5A3B	;	1.9	;	Crystal structure of the ADP-ribosylating sirtuin (SirTM) from Streptococcus pyogenes in complex with ADP-ribose
5A3C	;	2.03	;	Crystal structure of the ADP-ribosylating sirtuin (SirTM) from Streptococcus pyogenes in complex with NAD
1D6Z	;	2.1	;	CRYSTAL STRUCTURE OF THE AEROBICALLY FREEZE TRAPPED RATE-DETERMINING CATALYTIC INTERMEDIATE OF E. COLI COPPER-CONTAINING AMINE OXIDASE.
6AMB	;	2.5	;	Crystal Structure of the Afadin RA1 domain in complex with HRAS
7CP2	;	2.19	;	Crystal structure of the African swine fever virus core shell protein p15
8I6G	;	1.79	;	Crystal structure of the African swine fever virus DNA sliding clamp (native form)
8I6H	;	2.292	;	Crystal structure of the African swine fever virus DNA sliding clamp (selenomethionine form)
8WWO	;	2.2	;	Crystal structure of the AFSV topoisomerase ATPase domain in complex with AMPPNP
4WLW	;	2.8	;	CRYSTAL STRUCTURE OF THE AG(I) (ACTIVATOR) FORM OF E. COLI CUER, A COPPER EFFLUX REGULATOR, BOUND TO COPA PROMOTER DNA
1Q06	;	2.07	;	Crystal structure of the Ag(I) form of E. coli CueR, a copper efflux regulator
7DNM	;	2.3	;	Crystal structure of the AgCarB2-C2 complex
7DNN	;	2.25	;	Crystal structure of the AgCarB2-C2 complex with homoorientin
1P93	;	2.7	;	CRYSTAL STRUCTURE OF THE AGONIST FORM OF GLUCOCORTICOID RECEPTOR
3MNO	;	1.55	;	Crystal structure of the agonist form of mouse glucocorticoid receptor stabilized by (A611V, F608S) mutations at 1.55A
3MNP	;	1.5	;	Crystal structure of the agonist form of mouse glucocorticoid receptor stabilized by (A611V, V708A, E711G) mutations at 1.50A
3MNE	;	1.96	;	Crystal structure of the agonist form of mouse glucocorticoid receptor stabilized by F608S mutation at 1.96A
1XIU	;	2.5	;	Crystal structure of the agonist-bound ligand-binding domain of Biomphalaria glabrata RXR
1RO5	;	2.3	;	Crystal Structure of the AHL Synthase LasI
5V0L	;	4.0	;	Crystal structure of the AHR-ARNT heterodimer in complex with the DRE
3ELI	;	2.8	;	Crystal structure of the AHSA1 (SPO3351) protein from Silicibacter pomeroyi, Northeast Structural Genomics Consortium Target SiR160
4BVY	;	1.992	;	Crystal structure of the AIMP3-MRS N-terminal domain complex
4BL7	;	1.892	;	Crystal structure of the AIMP3-MRS N-terminal domain complex in different space group
4BVX	;	1.6	;	Crystal structure of the AIMP3-MRS N-terminal domain complex with I3C
4XKH	;	3.0	;	CRYSTAL STRUCTURE OF THE AIRAPL TANDEM UIMS IN COMPLEX WITH A LYS48-LINKED TRI-UBIQUITIN
4K9N	;	1.7	;	Crystal Structure of the Ala460Ile mutant of Benzoylformate Decarboxylase from Pseudomonas putida
1FEV	;	2.25	;	CRYSTAL STRUCTURE OF THE ALA4AIB MUTATION IN RNASE S
5IRP	;	2.1	;	Crystal structure of the alanine racemase Bsu17640 from Bacillus subtilis
6Q71	;	1.92	;	Crystal structure of the alanine racemase Bsu17640 from Bacillus subtilis in the presence of Bis-Tris propane
6Q70	;	2.05	;	Crystal structure of the alanine racemase Bsu17640 from Bacillus subtilis in the presence of HEPES
6Q72	;	3.0	;	Crystal structure of the alanine racemase from Bacillus subtilis in the presence of only PEG 4000 and Magnesium chloride in the crystallization condition
2E1B	;	2.7	;	Crystal structure of the AlaX-M trans-editing enzyme from Pyrococcus horikoshii
2BKY	;	1.7	;	Crystal structure of the Alba1:Alba2 heterodimer from sulfolobus solfataricus
7R3W	;	3.6	;	Crystal structure of the albicidin resistance protein STM3175 from Salmonella typhimurium
4R0C	;	2.963	;	Crystal structure of the Alcanivorax borkumensis YdaH transporter reveals an unusual topology
1H2B	;	1.62	;	Crystal Structure of the Alcohol Dehydrogenase from the Hyperthermophilic Archaeon Aeropyrum pernix at 1.65A Resolution
1SIJ	;	2.3	;	Crystal structure of the Aldehyde Dehydrogenase (a.k.a. AOR or MOP) of Desulfovibrio gigas covalently bound to [AsO3]-
3L4P	;	1.45	;	Crystal structure of the Aldehyde Dehydrogenase (a.k.a. AOR or MOP) of Desulfovibrio gigas covalently bound to [AsO3]-
1DGJ	;	2.8	;	CRYSTAL STRUCTURE OF THE ALDEHYDE OXIDOREDUCTASE FROM DESULFOVIBRIO DESULFURICANS ATCC 27774
7QK9	;	1.782	;	Crystal structure of the ALDH1A3-ATP complex
7QK8	;	1.893	;	Crystal structure of the ALDH1A3-NAD+ complex
4JN6	;	1.93	;	Crystal Structure of the Aldolase-Dehydrogenase Complex from Mycobacterium tuberculosis HRv37
1UAI	;	1.2	;	Crystal Structure of the Alginate Lyase from Corynebacterium sp.
4OZX	;	1.88	;	Crystal Structure of the alginate lyase from Klebsiella pneumoniae
5FTQ	;	1.7	;	Crystal structure of the ALK kinase domain in complex with Cmpd 17
5FTO	;	2.22	;	Crystal structure of the ALK kinase domain in complex with Entrectinib
3E4R	;	2.01	;	Crystal structure of the alkanesulfonate binding protein (SsuA) from the phytopathogenic bacteria Xanthomonas axonopodis pv. citri bound to HEPES
4O5Q	;	2.0	;	Crystal Structure of the Alkylhydroperoxide Reductase AhpF from Escherichia coli
4YKG	;	2.4	;	Crystal Structure of the Alkylhydroperoxide Reductase subunit F (AhpF) with NAD+ from Escherichia coli
4YKF	;	2.5	;	Crystal Structure of the Alkylhydroperoxide Reductase subunit F (AhpF) with NADH from Escherichia coli
1OIH	;	1.89	;	Crystal structure of the alkylsulfatase AtsK, a non-heme Fe(II) alphaketoglutarate dependent Dioxygenase
1OIJ	;	2.1	;	Crystal structure of the alkylsulfatase AtsK, a non-heme Fe(II) alphaketoglutarate dependent Dioxygenase in complex with alphaketoglutarate
1OIK	;	2.06	;	Crystal structure of the alkylsulfatase AtsK, a non-heme Fe(II) alphaketoglutarate dependent Dioxygenase in complex with fe, alphaketoglutarate and 2-ethyl-1-hexanesulfuric acid
1OII	;	2.19	;	Crystal structure of the alkylsulfatase AtsK, a non-heme Fe(II) alphaketoglutarate dependent Dioxygenase in complex with iron and alphaketoglutarate
6MR0	;	2.649	;	Crystal Structure of the All-trans Retinal Bound R111K:Y134F:T54V:R132Q:P39Q:R59Y:L121E Human Cellular Retinoic Acid Binding Protein II Mutant After 5 Minutes UV irradiation at 2.6 Angstrom Resolution
6MOV	;	1.752	;	Crystal Structure of the All-trans Retinal bound R111K:Y134F:T54V:R132Q:P39Y:R59Y:L121Q Human Cellular Retinoic Acid Binding Protein II in the Dark at 1.75 Angstrom Resolution
6MQI	;	1.87	;	Crystal Structure of the All-trans Retinal bound R111K:Y134F:T54V:R132Q:P39Y:R59Y:L121Q mutant of Human Cellular Retinoic Acid Binding Protein II Irradiated with 400 nm Laser for 5 minutes at 1.87 Angstrom Resolution
6MQJ	;	2.125	;	Crystal Structure of the All-Trans Retinal bound R111K:Y134F:T54V:R132Q:P39Y:R59Y:L121Q mutant of Human Cellular Retinoic Acid Binding Protein II Irradiated with 532 nm Laser for 10 minutes at 2.1 Angstrom Resolution
6NNY	;	1.668	;	Crystal Structure of the All-Trans Retinal-Bound R111K:Y134F:T54V:R132Q:P39E:R59Y:L121E Mutant of Human Cellular Retinoic Acid Binding Protein II in the Dark at 1.67 Angstrom Resolution
6MOX	;	2.18	;	Crystal Structure of the All-trans Retinal-Bound R111K:Y134F:T54V:R132Q:P39Q:R59Y:L121E Human Cellular Retinoic Acid Binding Protein II Mutant in the Dark at 2.18 Angstrom Resolution
6MOP	;	1.9	;	Crystal Structure of the All-trans Retinal-Bound R111K:Y134F:T54V:R132Q:P39Y:R59Y:L121E Mutant of Human Cellular Retinoic Acid Binding Protein II in the Dark at 1.9 Angstrom Resolution
6NOE	;	1.969	;	Crystal Structure of the All-Trans Retinal-Bound R111K:Y134F:T54V:R132Q:P39Y:R59Y:L121E:I63D Mutant of Human Cellular Retinoic Acid Binding Protein II in the Dark at 1.97 Angstrom Resolution
6NNX	;	1.87	;	Crystal Structure of the All-Trans Retinal-Bound R111K:Y134F:T54V:R132Q:P39Y:R59Y:L121M Mutant of Human Cellular Retinoic Acid Binding Protein II in the Dark at 1.87 Angstrom Resolution
6MOQ	;	2.198	;	Crystal Structure of the All-trans Retinal-Bound R111K:Y134F:T54V:R132Q:P39Y:R59Y:L121W Mutant of Human Cellular Retinoic Acid Binding Protein II in the Dark at 2.2 Angstrom Resolution
6MOR	;	1.79	;	Crystal Structure of the All-Trans Retinal-Bound R111K:Y134F:T54V:R132Q:P39Y:R59Y:L121Y Mutant of Human Cellular Retinoic Acid Binding Protein II in the Dark at 1.79 Angstrom Resolution
3IGF	;	2.0	;	Crystal Structure of the All4481 protein from Nostoc sp. PCC 7120, Northeast Structural Genomics Consortium Target NsR300
4H6C	;	1.35	;	Crystal Structure of the Allene Oxide Cyclase 1 from Physcomitrella patens
4H6A	;	1.95	;	Crystal Structure of the Allene Oxide Cyclase 2 from Physcomitrella patens
4H69	;	2.0	;	Crystal Structure of the Allene Oxide Cyclase 2 from Physcomitrella patens complexed with substrate analog
2DIO	;	1.7	;	Crystal Structure of the Allene Oxide Cyclase 2 with bound inhibitor vernolic acid
5FEF	;	2.2	;	Crystal structure of the allergen profilin (Zea m 12)
7FEE	;	2.7	;	Crystal structure of the allosteric modulator ZCZ011 binding to CP55940-bound cannabinoid receptor 1
2YEY	;	4.5	;	Crystal structure of the allosteric-defective chaperonin GroEL E434K mutant
4EX6	;	1.25	;	Crystal structure of the alnumycin P phosphatase AlnB
4EX7	;	1.5	;	Crystal structure of the alnumycin P phosphatase in complex with free phosphate
6KDY	;	3.02	;	Crystal structure of the alpha bata heterodimer of human IDH3 in complex with NAD.
6KE3	;	3.307	;	Crystal structure of the alpha bata heterodimer of human IDH3 in complex with NADH
6KDF	;	3.05	;	Crystal structure of the alpha beta heterodimer of human IDH3 in APO form.
6KDE	;	2.999	;	Crystal structure of the alpha beta heterodimer of human IDH3 in complex with Ca(2+)
6QQM	;	1.75	;	Crystal structure of the alpha carbonic anhydrase from Schistosoma mansoni
6L57	;	2.302	;	Crystal structure of the alpha gamma heterodimer of human IDH3 in complex with CIT , Mg and ATP binding at allosteric site.
6L59	;	2.254	;	Crystal structure of the alpha gamma heterodimer of human IDH3 in complex with CIT, Mg and ATP binding at allosteric site and Mg, ATP binding at active site.
5GRH	;	2.8	;	Crystal structure of the alpha gamma heterodimer of human IDH3 in complex with Mg(2+)
5GRI	;	2.31	;	Crystal structure of the alpha gamma heterodimer of human IDH3 in complex with Mg(2+) and citrate
5YVT	;	2.4	;	Crystal structure of the alpha gamma heterodimer of human IDH3 in complex with Mg(2+) and NADH
5GRE	;	2.65	;	Crystal structure of the alpha gamma heterodimer of human IDH3 in complex with Mg(2+), citrate and ADP
5GRL	;	2.79	;	Crystal structure of the alpha gamma heterodimer of human IDH3 in complex with Mg(2+), isocitrate and ADP
5GRF	;	2.5	;	Crystal structure of the alpha gamma mutant (gamma-K151A) of human IDH3 in complex with Mg(2+), citrate and ADP
4F16	;	1.93	;	Crystal Structure of the alpha spectrin SH3 domain at pH 5
4F17	;	1.55	;	Crystal Structure of the alpha spectrin SH3 domain at pH 9
5IHI	;	1.45	;	Crystal Structure of the alpha spectrin SH3 domain double mutant V46G-D48G
5IHK	;	1.35	;	Crystal Structure of the alpha spectrin SH3 domain mutant N47A
5IHN	;	1.5	;	Crystal Structure of the alpha spectrin SH3 domain mutant N47G
5F5W	;	2.81	;	Crystal structure of the alpha subunit of glycyl tRNA synthetase (GlyRS) from Aquifex aeolicus in complex with an analog of glycyl adenylate (Gly-SA)
5LTE	;	1.65	;	Crystal structure of the alpha subunit of heme dependent oxidative N-demethylase (HODM)
5LTH	;	1.76	;	Crystal structure of the alpha subunit of heme dependent oxidative N-demethylase (HODM) in complex with the dimethylamine substrate
5LTI	;	1.9	;	Crystal structure of the alpha subunit of heme dependent oxidative N-demethylase (HODM) in complex with the dimethylamine substrate
2P02	;	1.21	;	Crystal structure of the alpha subunit of human S-adenosylmethionine synthetase 2
1F0Q	;	2.63	;	CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT OF PROTEIN KINASE CK2 IN COMPLEX WITH THE NUCLEOTIDE COMPETITIVE INHIBITOR EMODIN
1W80	;	1.9	;	Crystal structure of the alpha-adaptin appendage domain, from the AP2 adaptor complex, bound to 2 peptides from Synaptojanin170
2VJ0	;	1.6	;	Crystal structure of the alpha-adaptin appendage domain, from the AP2 adaptor complex, in complex with an FXDNF peptide from amphiphysin1 and a WVXF peptide from synaptojanin P170
1DOV	;	3.0	;	CRYSTAL STRUCTURE OF THE ALPHA-CATENIN DIMERIZATION DOMAIN
6DV1	;	2.2	;	Crystal structure of the alpha-E-catenin actin-binding domain
5IKX	;	2.19	;	Crystal structure of the alpha-esterase-7 carboxyl esterase (dimer), E3, from Lucilia cuprina
3MI6	;	2.704	;	Crystal structure of the alpha-galactosidase from Lactobacillus brevis, Northeast Structural Genomics Consortium Target LbR11.
3G08	;	1.6	;	Crystal structure of the alpha-galactosylceramide analog OCH in complex with mouse CD1d
1FP4	;	2.5	;	CRYSTAL STRUCTURE OF THE ALPHA-H195Q MUTANT OF NITROGENASE
3LMH	;	2.0	;	Crystal Structure of the Alpha-kinase Domain of Myosin Heavy Chain Kinase A Complex with ADP
3LLA	;	2.11	;	Crystal Structure of the Alpha-kinase Domain of Myosin Heavy Chain Kinase A Complex with AMPPCP
4ZME	;	1.98	;	Crystal Structure of the Alpha-kinase Domain of Myosin-II Heavy Chain Kinase A in Complex with Adenosine
5E9E	;	2.4	;	Crystal Structure of the Alpha-kinase Domain of Myosin-II Heavy Chain Kinase A in Complex with AMP-PNP
4N4B	;	1.44	;	Crystal Structure of the alpha-L-arabinofuranosidase PaAbf62A from Podospora anserina
4N2Z	;	1.8	;	Crystal Structure of the alpha-L-arabinofuranosidase PaAbf62A from Podospora anserina in complex with cellotriose
4N1I	;	1.0	;	Crystal Structure of the alpha-L-arabinofuranosidase UmAbf62A from Ustilago maidys
4N2R	;	1.2	;	Crystal Structure of the alpha-L-arabinofuranosidase UmAbf62A from Ustilago maydis in complex with L-arabinofuranose
6DUW	;	2.2	;	Crystal structure of the alpha-N-catenin actin-binding domain H1 mutant
6DUY	;	2.81	;	Crystal structure of the alpha-N-catenin actin-binding domain H1 mutant
3POY	;	3.02	;	Crystal Structure of the alpha-Neurexin-1 ectodomain, LNS 2-6
6NRU	;	2.505	;	Crystal Structure of the Alpha-ribazole Phosphatase from Shigella flexneri
1N3Y	;	1.65	;	Crystal structure of the alpha-X beta2 integrin I domain
4IZI	;	2.4	;	Crystal Structure of the Alpha1 dimer of Thermus thermophilus Transhydrogenase in P4(3)
4IZH	;	1.8	;	Crystal Structure of the Alpha1 dimer of Thermus thermophilus Transhydrogenase in P6
6KUY	;	3.2	;	Crystal structure of the alpha2A adrenergic receptor in complex with a partial agonist
4K1O	;	2.603	;	Crystal structure of the alphaN-catenin actin-binding domain
3F2I	;	2.0	;	Crystal structure of the alr0221 protein from Nostoc, Northeast Structural Genomics Consortium Target NsR422.
3ILM	;	2.262	;	Crystal Structure of the Alr3790 protein from Anabaena sp. Northeast Structural Genomics Consortium Target NsR437h
6E12	;	2.4	;	Crystal Structure of the Alr8543 protein in complex with Oleic Acid and magnesium ion from Nostoc sp. PCC 7120, Northeast Structural Genomics Consortium Target NsR141
3ECV	;	1.9	;	Crystal structure of the ALS-related pathological mutant I113T of human apo Cu,Zn Superoxide Dismutase (SOD1)
3ECW	;	2.15	;	Crystal structure of the ALS-related pathological mutant T54R of human apo Cu,Zn Superoxide Dismutase (SOD1)
3S7N	;	2.451	;	Crystal Structure of the alternate His 207 conformation of the Infrared Fluorescent D207H variant of Deinococcus Bacteriophytochrome chromophore binding domain at 2.45 angstrom resolution
3HYU	;	1.67	;	Crystal structure of the altitude adapted hemoglobin of guinea pig.
7YX8	;	1.5	;	Crystal structure of the AM0627 (E326A) inactive mutant in complex with PSGL-1-like bis-T glycopeptide and Zn2+
2PLQ	;	1.9	;	Crystal structure of the amidase from geobacillus pallidus RAPc8
3ZZF	;	2.2	;	Crystal structure of the amino acid kinase domain from Saccharomyces cerevisiae acetylglutamate kinase complexed with its substrate N- acetylglutamate
3ZZH	;	2.1	;	Crystal structure of the amino acid kinase domain from Saccharomyces cerevisiae acetylglutamate kinase in complex with its feed- back inhibitor L-arginine
3ZZG	;	2.95	;	Crystal structure of the amino acid kinase domain from Saccharomyces cerevisiae acetylglutamate kinase without ligands
3M9B	;	3.94	;	Crystal structure of the amino terminal coiled coil domain and the inter domain of the Mycobacterium tuberculosis proteasomal ATPase Mpa
3M9H	;	2.0	;	Crystal structure of the amino terminal coiled coil domain of the Mycobacterium tuberculosis proteasomal ATPase Mpa
5KC9	;	2.3	;	Crystal structure of the amino-terminal domain (ATD) of iGluR Delta-1 (GluD1)
5KC8	;	1.751	;	Crystal structure of the amino-terminal domain (ATD) of iGluR Delta-2 (GluD2)
3Q5L	;	2.65	;	Crystal structure of the amino-terminal domain of HSP90 from Leishmania major, LMJF33.0312:M1-K 213 in the presence of 17-AEP-geldanamycin
3H80	;	2.0	;	Crystal structure of the amino-terminal domain of HSP90 from Leishmania major, LmjF33.0312:M1-K213
3Q5J	;	2.1	;	Crystal structure of the amino-terminal domain of HSP90 from Leishmania major, LMJF33.0312:M1-K213 in the presence of 17-DMAP-geldanamycin
3Q5K	;	2.35	;	Crystal structure of the amino-terminal domain of HSP90 from Leishmania major, LMJF33.0312:M1-K213 in the presence of an inhibitor
3SD6	;	1.37	;	Crystal structure of the amino-terminal domain of human cardiac troponin C in complex with cadmium at 1.4 resolution.
3SWB	;	1.67	;	Crystal structure of the amino-terminal domain of human cardiac troponin C in complex with cadmium at 1.7 A resolution
4GJG	;	2.0	;	Crystal structure of the amino-terminal domain of human cardiac troponin C mutant D2N/V28I/L29Q/G30D (NIQD) in complex with cadmium.
4GJF	;	1.9	;	Crystal structure of the amino-terminal domain of human cardiac troponin C mutant L29Q in complex with cadmium
2W21	;	2.95	;	Crystal structure of the aminoacid kinase domain of the glutamate 5 kinase of Escherichia coli.
1O5T	;	2.5	;	Crystal structure of the aminoacylation catalytic fragment of human tryptophanyl-tRNA synthetase
7BXZ	;	2.502	;	Crystal structure of the aminoglycoside 6'-N-acetyltransferase from Enterococcus faecium
4EJ7	;	2.29	;	Crystal structure of the aminoglycoside phosphotransferase APH(3')-Ia, ATP-bound
4GKH	;	1.863	;	Crystal structure of the aminoglycoside phosphotransferase APH(3')-Ia, with substrate kanamycin and small molecule inhibitor 1-NA-PP1
4GKI	;	1.88	;	Crystal structure of the aminoglycoside phosphotransferase APH(3')-Ia, with substrate kanamycin and small molecule inhibitor 1-NM-PP1
4FEU	;	2.37	;	Crystal structure of the aminoglycoside phosphotransferase APH(3')-Ia, with substrate kanamycin and small molecule inhibitor anthrapyrazolone SP600125
4FEV	;	1.89	;	Crystal structure of the aminoglycoside phosphotransferase APH(3')-Ia, with substrate kanamycin and small molecule inhibitor pyrazolopyrimidine PP1
4FEW	;	1.98	;	Crystal structure of the aminoglycoside phosphotransferase APH(3')-Ia, with substrate kanamycin and small molecule inhibitor pyrazolopyrimidine PP2
4FEX	;	2.71	;	Crystal structure of the aminoglycoside phosphotransferase APH(3')-Ia, with substrate kanamycin and small molecule inhibitor tyrphostin AG1478
4OX9	;	3.8035	;	Crystal structure of the aminoglycoside resistance methyltransferase NpmA bound to the 30S ribosomal subunit
7EHF	;	1.5	;	Crystal structure of the aminoglycoside resistance methyltransferase NpmB1
2IQ6	;	2.0	;	Crystal Structure of the Aminopeptidase from Vibrio proteolyticus in Complexation with Leucyl-leucyl-leucine.
4FGM	;	2.394	;	Crystal structure of the aminopeptidase N family protein Q5QTY1 from Idiomarina loihiensis. Northeast Structural Genomics Consortium Target IlR60.
2DEA	;	1.24	;	Crystal Structure of the Aminopeptidase of Aeromonas proteolytica at pH 4.7
7XII	;	2.25	;	Crystal structure of the aminopropyltransferase, SpeE from hyperthermophilic crenarchaeon, Pyrobaculum calidifontis in complex with 5'-methylthioadenosine (MTA) & aminopropylagmatine
7XIF	;	2.14	;	Crystal structure of the aminopropyltransferase, SpeE from hyperthermophilic crenarchaeon, Pyrobaculum calidifontis in complex with 5'-methylthioadenosine (MTA) alone or together with spermidine or thermospermine
7XIH	;	1.2	;	Crystal structure of the aminopropyltransferase, SpeE from hyperthermophilic crenarchaeon, Pyrobaculum calidifontis in complex with 5'-methylthioadenosine (MTA) and spermidine
7XIG	;	2.25	;	Crystal structure of the aminopropyltransferase, SpeE from hyperthermophilic crenarchaeon, Pyrobaculum calidifontis in complex with 5'-methylthioadenosine (MTA) and spermine
6HNU	;	1.8	;	Crystal structure of the aminotransferase Aro8 from C. Albicans with ligands
3I0Q	;	2.8	;	Crystal Structure of the AMP-bound complex of Spectinomycin Phosphotransferase, APH(9)-Ia
7DQD	;	3.383	;	Crystal structure of the AMP-PNP-bound mutant A(S23C)3B(N64C)3 complex from enterococcus hirae V-ATPase
8QEZ	;	1.55	;	Crystal structure of the AMPA receptor GluA2-L504Y-N775S ligand binding domain in complex with L-glutamate and positive allosteric modulator BPAM395 at 1.55A resolution
5FWY	;	2.12	;	Crystal structure of the AMPA receptor GluA2/A3 N-terminal domain heterodimer
5FWX	;	2.5	;	Crystal structure of the AMPA receptor GluA2/A4 N-terminal domain heterodimer
3IJO	;	2.003	;	Crystal structure of the AMPA subunit GluR2 bound to the allosteric modulator, althiazide
3IK6	;	2.101	;	Crystal structure of the AMPA subunit GluR2 bound to the allosteric modulator, chlorothiazide
3IJX	;	2.881	;	Crystal structure of the AMPA subunit GluR2 bound to the allosteric modulator, hydrochlorothiazide
3ILU	;	2.003	;	Crystal structure of the AMPA subunit GluR2 bound to the allosteric modulator, hydroflumethiazide
3IL1	;	1.998	;	Crystal structure of the AMPA subunit GluR2 bound to the allosteric modulator, IDRA-21
3ILT	;	2.107	;	Crystal structure of the AMPA subunit GluR2 bound to the allosteric modulator, trichlormethiazide
6I30	;	2.21	;	Crystal structure of the AmpC from Pseudomonas aeruginosa with 1C
4ZBP	;	2.6	;	Crystal structure of the AMPCPR-bound AtNUDT7
2ONV	;	1.61	;	Crystal Structure of the amyloid-fibril forming peptide GGVVIA derived from the Alzheimer's amyloid Abeta (Abeta37-42).
4E0K	;	0.97	;	Crystal Structure of the amyloid-fibril forming peptide KDWSFY derived from human Beta 2 Microglobulin (58-63)
4K07	;	2.83	;	Crystal structure of the amyloid-forming immunoglobulin AL-103 cis-proline 95 mutant
6FHC	;	1.51	;	Crystal Structure of the Amyloid-like hexametric polymorph of the LFKFFK segment from the S. aureus PSMalpha3
6RHB	;	1.26	;	Crystal structure of the amyloid-like IATLYV segment from the Candida albicans Agglutinin-like protein (Adhesin) 5
6FGR	;	1.5	;	Crystal Structure of the Amyloid-like IIKIIK Segment from the S. aureus Biofilm-associated PSMalpha4
6FG4	;	1.1	;	Crystal Structure of the Amyloid-like IIKVIK Segment from the S. aureus Biofilm-associated PSMalpha1
6G8C	;	1.65	;	Crystal Structure of the Amyloid-like IYQYGG segment from the R1 repeat of the E. coli Biofilm-associated CsgA Curli protein
6G8D	;	1.85	;	Crystal Structure of the Amyloid-like LNIYQY segment from the R1 repeat of the E. coli Biofilm-associated CsgA Curli protein
6RHA	;	1.6	;	Crystal structure of the amyloid-like NTVTFN segment from the Candida albicans Agglutinin-like protein (Adhesin) 5
6RHD	;	1.2	;	Crystal structure of the amyloid-like TSYVGV segment from the Candida albicans Agglutinin-like protein (Adhesin) 5
6G8E	;	1.7	;	Crystal Structure of the Amyloid-like VTQVGF segment from the R5 repeat of the E. coli Biofilm-associated CsgA Curli protein
6FHD	;	1.85	;	Crystal Structure of the Amyloid-like, out-of-register beta-sheets, polymorph of the LFKFFK segment from the S. aureus PSMalpha3
3OK4	;	1.149	;	Crystal structure of the ANA:RNA decamer suffering from lattice translocation defects
3OK2	;	1.963	;	Crystal structure of the ANA:RNA decamer without lattice translocation defects
3WKU	;	2.7	;	Crystal structure of the anaerobic DesB-gallate complex
3WR3	;	2.5	;	Crystal structure of the anaerobic DesB-gallate complex
3WR4	;	2.4	;	Crystal structure of the anaerobic DesB-gallate complex
3WR9	;	2.4	;	Crystal structure of the Anaerobic DesB-Gallate complex
3WPM	;	2.5	;	Crystal structure of the anaerobic DesB-gallate complex by co-crystallization
3WRC	;	2.4	;	Crystal structure of the anaerobic DesB-Protocatechuate (PCA) complex
3WRB	;	2.1	;	Crystal structure of the anaerobic H124F DESb-Gallate complex
4COJ	;	2.48	;	Crystal structure of the anaerobic ribonucleotide reductase from Thermotoga maritima in complex with dATP and CTP
4CON	;	2.12	;	Crystal structure of the anaerobic ribonucleotide reductase from Thermotoga maritima with citrate in the active site
4COL	;	1.96	;	Crystal structure of the anaerobic ribonucleotide reductase from Thermotoga maritima with dATP bound in the specificity site
4COI	;	1.94	;	Crystal structure of the anaerobic ribonucleotide reductase from Thermotoga maritima with glycerol in the active site
4COM	;	1.92	;	Crystal structure of the anaerobic ribonucleotide reductase from Thermotoga maritima with MES in the active site
5IUH	;	2.1	;	Crystal Structure of the Anaplastic Lymphoma Kinase (ALK) in complex with 5d
3L9P	;	1.8	;	Crystal Structure of the Anaplastic Lymphoma Kinase Catalytic Domain
3LCS	;	1.95	;	Crystal Structure of the Anaplastic Lymphoma Kinase Catalytic Domain
3LCT	;	2.1	;	Crystal Structure of the Anaplastic Lymphoma Kinase Catalytic Domain
5T0W	;	2.59	;	Crystal structure of the ancestral amino acid-binding protein AncCDT-1, a precursor of cyclohexadienyl dehydratase
8HNE	;	1.13	;	Crystal structure of the ancestral GH19 chitinase Anc4
8HNF	;	1.57	;	Crystal structure of the ancestral GH19 chitinase Anc5
8X2V	;	1.29	;	Crystal structure of the ancestral GH19 chitinase, Anc4+LoopII (P12K/N13H mutant)
8X2W	;	1.4	;	Crystal structure of the ancestral GH19 chitinase, Anc4+LoopII (P12K/N13H/S58T/N193G/Y194F/D197R)
4M1V	;	1.3	;	Crystal structure of the ancestral soluble variant of the Human Phosphate Binding Protein (HPBP)
1T5Z	;	2.3	;	Crystal Structure of the Androgen Receptor Ligand Binding Domain (LBD) with DHT and a peptide derived from its physiological coactivator ARA70
5VO4	;	2.35	;	Crystal Structure Of The Androgen Receptor Ligand Binding Domain In Complex With 5-(2-fluoro-4-hydroxyphenyl)-1-methyl-1H-pyrrole-2-carbonitrile
1T7T	;	1.7	;	Crystal structure of the androgen receptor ligand binding domain in complex with 5-alpha dihydrotestosterone
1T73	;	2.2	;	Crystal structure of the androgen receptor ligand binding domain in complex with a FxxFF motif
1T7R	;	1.4	;	Crystal structure of the androgen receptor ligand binding domain in complex with a FxxLF motif
1T79	;	1.8	;	Crystal structure of the androgen receptor ligand binding domain in complex with a FxxLW motif
1T7M	;	1.6	;	Crystal structure of the androgen receptor ligand binding domain in complex with a FxxYF motif
1T7F	;	1.6	;	Crystal structure of the androgen receptor ligand binding domain in complex with a LxxLL motif
1T74	;	2.0	;	Crystal structure of the androgen receptor ligand binding domain in complex with a WxxLF motif
1T76	;	2.1	;	Crystal structure of the androgen receptor ligand binding domain in complex with a WxxVW motif
4K7A	;	2.44	;	Crystal structure of the androgen receptor ligand binding domain in complex with minoxidil
2AX9	;	1.65	;	Crystal Structure Of The Androgen Receptor Ligand Binding Domain In Complex With R-3
2AXA	;	1.8	;	Crystal Structure Of The Androgen Receptor Ligand Binding Domain In Complex With S-1
3B67	;	1.9	;	Crystal structure of the androgen receptor ligand binding domain in complex with SARM C-23
3B5R	;	1.8	;	Crystal structure of the androgen receptor ligand binding domain in complex with SARM C-31
3B66	;	1.65	;	Crystal structure of the androgen receptor ligand binding domain in complex with SARM S-21
3RLJ	;	1.9	;	Crystal structure of the androgen receptor ligand binding domain in complex with SARM S-22
3B65	;	1.8	;	Crystal structure of the androgen receptor ligand binding domain in complex with SARM S-24
3B68	;	1.9	;	Crystal structure of the androgen receptor ligand binding domain in complex with SARM S-4
2AX6	;	1.5	;	Crystal Structure Of The Androgen Receptor Ligand Binding Domain T877A Mutant In Complex With Hydroxyflutamide
2AX7	;	1.9	;	Crystal Structure Of The Androgen Receptor Ligand Binding Domain T877A Mutant In Complex With S-1
2AX8	;	1.7	;	Crystal Structure Of The Androgen Receptor Ligand Binding Domain W741L Mutant In Complex With S-1
1T65	;	1.66	;	Crystal structure of the androgen receptor ligand binding domain with DHT and a peptide derived form its physiological coactivator GRIP1 NR box 2 bound in a non-helical conformation
1T63	;	2.07	;	Crystal Structure of the Androgen Receptor Ligand Binding Domain with DHT and a peptide derived from its physiological coactivator GRIP1 NR box3
1Z95	;	1.8	;	Crystal Structure of the Androgen Receptor Ligand-binding Domain W741L Mutant Complex with R-bicalutamide
7JNI	;	3.0	;	Crystal structure of the angiotensin II type 2 receptoror (AT2R) in complex with EMA401
4BXK	;	2.2	;	Crystal structure of the Angiotensin-1 converting enzyme N-domain in complex with a domain-specific inhibitor
4UFA	;	1.8	;	Crystal structure of the Angiotensin-1 converting enzyme N-domain in complex with Ac-SD
5AMA	;	1.8	;	Crystal structure of the Angiotensin-1 converting enzyme N-domain in complex with amyloid-beta 1-16
5AM9	;	1.8	;	Crystal structure of the Angiotensin-1 converting enzyme N-domain in complex with amyloid-beta 10-16
5AMB	;	1.55	;	Crystal structure of the Angiotensin-1 converting enzyme N-domain in complex with amyloid-beta 35-42
5AM8	;	1.9	;	Crystal structure of the Angiotensin-1 converting enzyme N-domain in complex with amyloid-beta 4-10
5AMC	;	1.65	;	Crystal structure of the Angiotensin-1 converting enzyme N-domain in complex with amyloid-beta fluorogenic fragment 4-10
4UFB	;	1.8	;	Crystal structure of the Angiotensin-1 converting enzyme N-domain in complex with Lys-Pro
4YZF	;	3.5	;	Crystal structure of the anion exchanger domain of human erythrocyte Band 3
7XC5	;	2.1	;	Crystal structure of the ANK domain of CLPB
5YAZ	;	1.9	;	Crystal structure of the ANKRD domain of KANK1
1BG5	;	2.6	;	CRYSTAL STRUCTURE OF THE ANKYRIN BINDING DOMAIN OF ALPHA-NA,K-ATPASE AS A FUSION PROTEIN WITH GLUTATHIONE S-TRANSFERASE
3KBT	;	2.75	;	Crystal structure of the ankyrin binding domain of human erythroid beta spectrin (repeats 13-15) in complex with the spectrin binding domain of human erythroid ankyrin (ZU5-ANK)
3KBU	;	2.75	;	Crystal structure of the ankyrin binding domain of human erythroid beta spectrin (repeats 13-15) in complex with the spectrin binding domain of human erythroid ankyrin (ZU5-ANK), EMTS derivative
1K1A	;	1.86	;	Crystal structure of the ankyrin repeat domain of Bcl-3: a unique member of the IkappaB protein family
1K1B	;	1.9	;	Crystal structure of the ankyrin repeat domain of Bcl-3: a unique member of the IkappaB protein family
3W9G	;	2.0	;	Crystal structure of the ankyrin repeat domain of chicken TRPV4
3W9F	;	1.9	;	Crystal structure of the ankyrin repeat domain of chicken TRPV4 in complex with IP3
2F37	;	1.7	;	Crystal structure of the ankyrin repeat domain of human TRPV2
2ETA	;	2.2	;	Crystal structure of the ankyrin repeat domain of the TRPV2
2NYJ	;	3.2	;	Crystal structure of the ankyrin repeat domain of TRPV1
2PNN	;	2.7	;	Crystal Structure of the Ankyrin Repeat Domain of Trpv1
2ETB	;	1.65	;	Crystal structure of the ankyrin repeat domain of TRPV2
2ETC	;	3.1	;	Crystal structure of the ankyrin repeat domain of TRPV2
4D8O	;	2.203	;	Crystal Structure of the ankyrin-B ZU5-ZU5-UPA-DD tandem
3EDU	;	2.1	;	Crystal structure of the ankyrin-binding domain of human erythroid spectrin
1AEI	;	2.8	;	CRYSTAL STRUCTURE OF THE ANNEXIN XII HEXAMER
7U1N	;	2.4	;	Crystal structure of the Anopheles darlingi AD-118 long form D7 salivary protein
3L47	;	2.506	;	Crystal Structure of the Anopheles gambiae Odorant-binding Protein 22a
3NHI	;	1.43	;	Crystal structure of the AnSt-D7L1-leukotriene C4 complex
3NHT	;	1.45	;	Crystal structure of the AnSt-D7L1-U46619 complex
1NHZ	;	2.3	;	Crystal Structure of the Antagonist Form of Glucocorticoid Receptor
3H52	;	2.8	;	Crystal structure of the antagonist form of human glucocorticoid receptor
4WV3	;	2.599	;	Crystal structure of the anthranilate CoA ligase AuaEII in complex with anthranoyl-AMP
2QK8	;	2.4	;	Crystal structure of the anthrax drug target, Bacillus anthracis dihydrofolate reductase
1JKY	;	3.9	;	Crystal Structure of the Anthrax Lethal Factor (LF): Wild-type LF Complexed with the N-terminal Sequence of MAPKK2
1PWP	;	2.9	;	Crystal Structure of the Anthrax Lethal Factor complexed with Small Molecule Inhibitor NSC 12155
1TZO	;	3.6	;	Crystal Structure of the Anthrax Toxin Protective Antigen Heptameric Prepore
1TZN	;	4.3	;	Crystal Structure of the Anthrax Toxin Protective Antigen Heptameric Prepore bound to the VWA domain of CMG2, an anthrax toxin receptor
4AEH	;	1.6	;	Crystal structure of the anti-AaHI Fab9C2 antibody
3ULQ	;	2.3	;	Crystal Structure of the Anti-Activator RapF Complexed with the Response Regulator ComA DNA Binding Domain
2G5B	;	2.3	;	Crystal Structure of the anti-Bax monoclonal antibody 6A7 and a Bax peptide.
7T0R	;	3.65	;	Crystal structure of the anti-CD4 adnectin 6940_B01 as a complex with the extracellular domains of CD4 and ibalizumab fAb
6B0W	;	1.9	;	Crystal structure of the anti-circumsporozoite protein 1710 antibody
5BK5	;	3.0	;	Crystal structure of the anti-circumsporozoite protein 663 germline antibody
5YHR	;	1.34	;	Crystal structure of the anti-CRISPR protein, AcrF2
5Y6A	;	2.0	;	Crystal structure of the anti-CRISPR protein, AcrIIA1
7N6P	;	2.15	;	Crystal structure of the anti-EBOV and SUDV monoclonal antibody 1C3 Fab
1L7I	;	1.8	;	Crystal Structure of the anti-ErbB2 Fab2C4
1JHK	;	2.51	;	Crystal structure of the anti-estradiol antibody 57-2
4O4Y	;	1.85	;	Crystal structure of the anti-hinge rabbit antibody 2095-2 in complex with IDES hinge peptide
1KTR	;	2.7	;	Crystal Structure of the Anti-His Tag Antibody 3D5 Single-Chain Fragment (scFv) in Complex with a Oligohistidine peptide
6P3B	;	2.02	;	Crystal structure of the anti-HIV antibody DH501 unmutated common ancestor (UCA)
3RPT	;	1.303	;	Crystal structure of the anti-HIV b12 scaffold protein
4R4B	;	2.199	;	Crystal structure of the anti-hiv-1 antibody 2.2c
4R4N	;	3.56	;	Crystal structure of the anti-hiv-1 antibody 2.2c in complex with hiv-1 93ug037 gp120
4NWT	;	1.75	;	Crystal structure of the anti-human NGF Fab APE1531
6ZTF	;	1.55	;	Crystal Structure of the anti-human P-Cadherin Fab CQY684
6ZTR	;	2.1	;	Crystal Structure of the anti-human P-Cadherin Fab CQY684 in complex with human P-Cadherin(108-324)
7C95	;	2.13	;	Crystal structure of the anti-human podoplanin antibody Fab fragment
7C94	;	2.84	;	Crystal structure of the anti-human podoplanin antibody Fab fragment complex with glycopeptide
5YFI	;	1.848	;	Crystal structure of the anti-human prostaglandin E receptor EP4 antibody Fab fragment
1DQJ	;	2.0	;	CRYSTAL STRUCTURE OF THE ANTI-LYSOZYME ANTIBODY HYHEL-63 COMPLEXED WITH HEN EGG WHITE LYSOZYME
7O30	;	2.65	;	Crystal structure of the anti-PAS Fab 1.1 in complex with its epitope peptide
7O31	;	1.55	;	Crystal structure of the anti-PAS Fab 1.2 in complex with its epitope peptide and the anti-Kappa VHH domain
7O2Z	;	2.55	;	Crystal structure of the anti-PAS Fab 2.2 in complex with its epitope peptide
7O33	;	1.85	;	Crystal structure of the anti-PAS Fab 3.1 in complex with its epitope peptide
1CR9	;	2.0	;	CRYSTAL STRUCTURE OF THE ANTI-PRION FAB 3F4
1CU4	;	2.9	;	CRYSTAL STRUCTURE OF THE ANTI-PRION FAB 3F4 IN COMPLEX WITH ITS PEPTIDE EPITOPE
5ITB	;	2.0	;	Crystal structure of the anti-RSV F Fab 14N4
7QH3	;	2.3	;	Crystal structure of the anti-sigma factor RsfG from Streptomyces tsukubaensis NRRL18488
5JEN	;	2.3	;	Crystal structure of the anti-sigma factor RsiV bound to lysozyme
3IQS	;	2.3	;	Crystal structure of the anti-viral APOBEC3G catalytic domain
4PL0	;	2.7	;	Crystal structure of the antibacterial peptide ABC transporter McjD in an outward occluded state
4RWZ	;	1.801	;	Crystal structure of the antibiotic-resistance methyltransferase Kmr
4NZR	;	1.65	;	Crystal structure of the antibody-binding region of Protein M (Protein M TD) in complex with anti-HIV antibody PGT135 Fab
4NZT	;	2.497	;	Crystal structure of the antibody-binding region of Protein M (Protein M TD) in complex with anti-infleunza hemagglutinin antibody CR9114 Fab
1MH0	;	2.8	;	Crystal structure of the anticoagulant slow form of thrombin
1SGI	;	2.3	;	Crystal structure of the anticoagulant slow form of thrombin
1TQ7	;	2.4	;	Crystal structure of the anticoagulant thrombin mutant W215A/E217A bound to PPACK
1UYW	;	2.0	;	Crystal Structure of the antiflavivirus Fab4g2
7X9R	;	2.25	;	Crystal structure of the antirepressor GmaR
3KCG	;	1.7	;	Crystal structure of the antithrombin-factor IXa-pentasaccharide complex
2GD4	;	3.3	;	Crystal Structure of the Antithrombin-S195A Factor Xa-Pentasaccharide Complex
6UVU	;	2.1	;	Crystal structure of the AntR antimony-specific transcriptional repressor
6FIG	;	1.48	;	Crystal structure of the ANX1 ectodomain from Arabidopsis thaliana
6FIH	;	1.08	;	Crystal structure of the ANX2 ectodomain from Arabidopsis thaliana
1QTP	;	1.6	;	CRYSTAL STRUCTURE OF THE AP-2 CLATHRIN ADAPTOR ALPHA-APPENDAGE
1QTS	;	1.4	;	CRYSTAL STRUCTURE OF THE AP-2 CLATHRIN ADAPTOR ALPHA-APPENDAGE
7DXS	;	2.102	;	Crystal structure of the ap1h peptide homodimer.
1CY5	;	1.3	;	CRYSTAL STRUCTURE OF THE APAF-1 CARD
1VRM	;	1.58	;	Crystal structure of the apbe protein (tm1553) from thermotoga maritima msb8 at 1.58 A resolution
5L9W	;	2.9	;	Crystal structure of the Apc core complex
1JHJ	;	1.6	;	Crystal structure of the APC10/Doc1 subunit of the human anaphase-promoting complex
3P1Z	;	2.8	;	Crystal structure of the Aperopyrum pernix RNA splicing endonuclease
7A4D	;	2.694	;	Crystal structure of the APH coiled-coil in complex with nanobodies Nb28 and Nb30
7A50	;	1.999	;	Crystal structure of the APH coiled-coil in complex with nanobody Nb26
7A48	;	1.547	;	Crystal structure of the APH coiled-coil in complex with Nb49
4DR1	;	3.6	;	Crystal structure of the apo 30S ribosomal subunit from Thermus thermophilus (HB8)
7N07	;	2.4	;	Crystal structure of the apo 3D6 antibody fragment
5VZ1	;	2.112	;	Crystal structure of the Apo Antibody fragment (Fab) raised against C-terminal domain of Ebola nucleoprotein (EBOV, TAFV, BDBV strains)
6B6Z	;	2.112	;	Crystal structure of the Apo Antibody fragment (Fab) raised against C-terminal domain of Ebola nucleoprotein (EBOV, TAFV, BDBV strains)
4ZB3	;	2.3	;	Crystal structure of the apo AtNUDT7
3U39	;	2.7921	;	Crystal Structure of the apo Bacillus Stearothermophilus phosphofructokinase
7WRU	;	2.5	;	Crystal structure of the apo chicken glutamyl-tRNA synthetase 1 (EARS1)
3FWE	;	2.3	;	Crystal Structure of the Apo D138L CAP mutant
6E50	;	1.965	;	Crystal structure of the apo domain-swapped dimer Q108K:K40L:T51F mutant of human Cellular Retinol Binding Protein II
6E51	;	2.256	;	Crystal structure of the apo domain-swapped dimer Q108K:K40L:T51W mutant of human cellular retinol binding protein II
6E5E	;	1.696	;	Crystal structure of the apo domain-swapped dimer Q108K:T51D mutant of human cellular retinol binding protein II
6E5R	;	2.592	;	Crystal structure of the apo domain-swapped dimer Q108K:T51D:A28C mutant of human Cellular Retinol Binding Protein II
6E5Q	;	1.99	;	Crystal structure of the apo domain-swapped dimer Q108K:T51D:A28H mutant of human Cellular Retinol Binding Protein II
2NLX	;	2.7	;	Crystal structure of the apo E. coli xylulose kinase
4NMI	;	1.78	;	Crystal Structure of the Apo ectoine hydroxylase ECTD from Salibacillus salexigens
7FC8	;	2.377	;	Crystal structure of the Apo enoyl-ACP-reductase (FabI) from Moraxella catarrhalis
4IC8	;	2.8	;	Crystal structure of the apo ERK5 kinase domain
4FNW	;	1.75	;	Crystal structure of the apo F1174L anaplastic lymphoma kinase catalytic domain
7N04	;	1.70001	;	Crystal structure of the apo F240 antibody fragment
6F2E	;	1.9	;	Crystal structure of the APO Fe(II)/alpha-ketoglutarate dependent dioxygenase KDO1
1FA8	;	1.7	;	CRYSTAL STRUCTURE OF THE APO FORM GLYOXALASE I OF ESCHERICHIA COLI
1INJ	;	1.55	;	CRYSTAL STRUCTURE OF THE APO FORM OF 4-DIPHOSPHOCYTIDYL-2-C-METHYLERYTHRITOL (CDP-ME) SYNTHETASE (YGBP) INVOLVED IN MEVALONATE INDEPENDENT ISOPRENOID BIOSYNTHESIS
4IS2	;	1.9	;	Crystal structure of the apo form of a 3alpha-hydroxysteroid dehydrogenase (BaiA2) associated with secondary bile acid synthesis from Clostridium scindens VPI12708 at 1.90 A resolution
6IZ9	;	2.199	;	Crystal structure of the apo form of a beta-transaminase from Mesorhizobium sp. strain LUK
4ADZ	;	1.7	;	Crystal Structure of the apo form of a Copper-sensitive operon Regulator (CsoR) protein from Streptomyces lividans
1O62	;	2.1	;	Crystal structure of the apo form of a PLP-dependent enzyme
6Y8J	;	2.05	;	Crystal structure of the apo form of a quaternary ammonium Rieske monooxygenase CntA
5JH1	;	1.45	;	Crystal structure of the apo form of AKR4C7 from maize
7QK7	;	2.289	;	Crystal structure of the APO form of ALDH1A3
2JIJ	;	2.9	;	Crystal structure of the apo form of Chlamydomonas reinhardtii prolyl- 4 hydroxylase type I
6YXS	;	2.0	;	Crystal structure of the apo form of choline kinase from Plasmodium falciparum
6IFI	;	2.8	;	Crystal Structure of the Apo form of CMP-N-acetylneuraminate Synthetase from Vibrio cholerae
5JUF	;	1.946	;	Crystal structure of the apo form of ComR from S. thermophilus.
4QUW	;	2.26	;	Crystal structure of the apo form of cyanobacterial aldehyde-deformylating oxygenase
2FB9	;	1.9	;	Crystal structure of the Apo form of D-alanine: D-alanine ligase (Ddl) from Thermus caldophilus: a basis for the substrate-induced conformational changes
3K3P	;	2.23	;	Crystal Structure of the Apo Form of D-Alanine:D-Alanine Ligase (DDl) from Streptococcus mutans
2OQX	;	1.9	;	Crystal Structure of the apo form of E. coli tryptophanase at 1.9 A resolution
2PWZ	;	2.2	;	Crystal structure of the apo form of E.Coli malate dehydrogenase
3RHB	;	1.2	;	Crystal structure of the apo form of glutaredoxin C5 from Arabidopsis thaliana
5H9A	;	1.381	;	Crystal structure of the Apo form of human cellular retinol binding protein 1
4DYZ	;	2.3	;	Crystal Structure of the apo form of Human H-Ferritin variant MIC1
7M3X	;	1.46	;	Crystal Structure of the Apo Form of Human RBBP7
3CFM	;	1.6	;	Crystal structure of the apo form of human wild-type transthyretin
4BV8	;	2.3	;	Crystal structure of the apo form of mouse Mu-crystallin.
4BT8	;	2.198	;	CRYSTAL STRUCTURE OF THE APO FORM OF N-TERMINAL DOMAIN AND PEPTIDE SUBSTRATE BINDING DOMAIN OF PROLYL-4 HYDROXYLASE TYPE I FROM HUMAN
7JMA	;	1.7	;	Crystal structure of the apo form of Nitrogenase iron-molybdenum cofactor biosynthesis enzyme NifB from Methanothermobacter thermautotrophicus
4I1A	;	2.443	;	Crystal Structure of the Apo Form of RapI
8BVB	;	1.8	;	Crystal structure of the apo form of SmbA loop deletion mutant.
3BWB	;	2.5	;	Crystal structure of the apo form of spermidine synthase from Trypanosoma cruzi at 2.5 A resolution
2C4U	;	2.5	;	Crystal structure of the apo form of the 5'-Fluoro-5'-deoxyadenosine synthase enzyme from Streptomyces cattleya
3SL3	;	2.1	;	Crystal structure of the apo form of the catalytic domain of PDE4D2
1UR3	;	2.57	;	Crystal structure of the apo form of the E.coli ydhF protein
4FJW	;	2.2	;	Crystal Structure of the apo form of the E131Q Mtb crotonase
4JCA	;	2.411	;	Crystal Structure of the apo form of the evolved variant of the computationally designed serine hydrolase, OSH55.4_H1. Northeast Structural Genomics Consortium (NESG) Target OR273
4P2B	;	2.8	;	Crystal structure of the apo form of the glutaminyl-tRNA synthetase catalytic domain from Toxoplasma gondii.
8BZ4	;	2.52	;	Crystal structure of the apo form of the L. monocytogenes RmlT
7AGL	;	1.6	;	crystal structure of the apo form of the N-acetylmuramyl-L-alanine amidase, Ami1, from Mycobacterium abscessus.
1TM2	;	1.9	;	Crystal Structure of the apo form of the Salmonella typhimurium AI-2 receptor LsrB
5A6O	;	1.6	;	Crystal structure of the apo form of the unphosphorylated human death associated protein kinase 3 (DAPK3)
3UGQ	;	2.1	;	Crystal structure of the apo form of the yeast mitochondrial threonyl-tRNA synthetase determined at 2.1 Angstrom resolution
4KDE	;	1.798	;	Crystal Structure of the Apo Form of Thermus thermophilus Malate Dehydrogenase
5V3W	;	1.723	;	Crystal Structure of the Apo form of Thioesterase domain of Mtb Pks13
1ZHH	;	1.94	;	Crystal Structure of the Apo Form of Vibrio Harveyi LUXP Complexed with the Periplasmic Domain of LUXQ
2V1P	;	1.9	;	Crystal Structure of the apo form of Y74F mutant E. coli tryptophanase
6IPX	;	2.634	;	Crystal structure of the apo form transcription factor
2W2K	;	1.85	;	Crystal structure of the apo forms of Rhodotorula graminis D- mandelate dehydrogenase at 1.8A.
8ASN	;	2.571	;	Crystal structure of the apo human TTL in complex with tubulin-stathmin
4L00	;	1.8	;	Crystal structure of the apo Jak1 pseudokinase domain
4Z99	;	2.3	;	Crystal structure of the apo Low Molecular Weight Protein Tyrosine Phosphatase isoform A
3RP9	;	2.4	;	Crystal Structure of the apo MapK from Toxoplasma Gondii, 25.m01780 or TGME49_007820
1FMV	;	2.1	;	CRYSTAL STRUCTURE OF THE APO MOTOR DOMAIN OF DICTYOSTELLIUM MYOSIN II
6YGA	;	2.397	;	Crystal structure of the apo NatC complex
4BA4	;	1.73	;	Crystal structure of the apo omega-transaminase from Chromobacterium violaceum
8BFU	;	2.41	;	Crystal structure of the apo p110alpha catalytic subunit from homo sapiens
5WLF	;	1.4	;	Crystal structure of the apo PPS PHD finger
6MOW	;	2.354	;	Crystal Structure of the apo R111K:Y134F:T54V:R132Q:P39Y:R59Y:L121Q mutant of Human Cellular Retinoic Acid Binding Protein II at 2.3 Angstrom Resolution
4FNX	;	1.7	;	Crystal structure of the apo R1275Q anaplastic lymphoma kinase catalytic domain
3I17	;	1.68	;	Crystal structure of the apo R132K:L121E mutant of cellular retinoic acid-binding protein II at 1.68 angstrom resolution
3FA7	;	1.9	;	Crystal structure of the apo R132K:R111L:L121E:R59E mutant of cellular retinoic acid-binding protein II at 1.90 angstrom resolution
3FA9	;	1.94	;	Crystal structure of the apo R132K:Y134F:R111L:L121D mutant of cellular retinoic acid-binding protein II at 1.94 angstrom resolution
3FA8	;	1.78	;	Crystal structure of the apo R132K:Y134F:R111L:L121E mutant of cellular retinoic acid-binding protein II at 1.78 angstrom resolution
7SA7	;	3.2	;	Crystal structure of the apo SH2 domains of Syk
1M61	;	2.5	;	Crystal structure of the apo SH2 domains of ZAP-70
5XOE	;	2.98	;	Crystal Structure of the apo Staphylococcus aureus phosphofructokinase
5C6Q	;	3.251	;	Crystal structure of the apo TOPLESS related protein 2 (TPR2) N-terminal domain (1-209) from rice
5LPW	;	2.431	;	Crystal structure of the apo-BRI1 kinase domain (865-1160)
5GVW	;	2.4	;	Crystal structure of the apo-form glycosyltransferase GlyE in Streptococcus pneumoniae TIGR4
2CBM	;	2.03	;	Crystal structure of the apo-form of a neocarzinostatin mutant evolved to bind testosterone.
3QA0	;	2.5	;	Crystal structure of the apo-form of human CK2 alpha at pH 6.5
3Q04	;	1.8	;	Crystal structure of the apo-form of human CK2 alpha at pH 8.5
2ZA2	;	2.7	;	Crystal Structure of the apo-form of orotidine-5'-monophosphate decarboxylase from P.falciparum
5N76	;	1.9	;	Crystal structure of the apo-form of the CO dehydrogenase accessory protein CooT from Rhodospirillum rubrum
1PT7	;	1.8	;	Crystal structure of the apo-form of the yfdW gene product of E. coli
5KYB	;	2.2	;	Crystal structure of the apo-form of USP7 catalytic domain [V302K] mutant
8H3I	;	1.9	;	Crystal Structure of the apo-form Pathogenesis-related Protein HcPR10 from Halostachys caspica
4FZO	;	1.3	;	Crystal Structure of the apo-form uranyl binding protein
3UJ4	;	3.0	;	Crystal structure of the apo-inositol 1,4,5-trisphosphate receptor
4J5W	;	2.8	;	Crystal Structure of the apo-PXR/RXRalpha LBD Heterotetramer Complex
4RWQ	;	3.1	;	Crystal structure of the apo-state of porcine OAS1
1FFL	;	2.94	;	CRYSTAL STRUCTURE OF THE APO-THYMIDYLATE SYNTHASE R166Q MUTANT
1SUL	;	2.0	;	Crystal Structure of the apo-YsxC
5J6X	;	2.493	;	Crystal structure of the apo-Zalpha of Zebrafish PKZ
6B8L	;	2.3	;	Crystal Structure of the Apo/CaM:Kv7.4 (KCNQ4) AB Domain Complex
7EG2	;	2.22	;	Crystal structure of the apoAequorin complex with (S)-daCTZ
7EG3	;	2.09	;	Crystal structure of the apoAequorin complex with (S)-HM-daCTZ
4J4J	;	3.1	;	Crystal structure of the APOBEC3F Vif binding domain
3IR2	;	2.25	;	Crystal structure of the APOBEC3G catalytic domain
5B4X	;	3.2	;	Crystal structure of the ApoER2 ectodomain in complex with the Reelin R56 fragment
2X5J	;	2.3	;	Crystal structure of the Apoform of the D-Erythrose-4-phosphate dehydrogenase from E. coli
2XCX	;	2.3	;	Crystal structure of the apoform of the D52N variant of cytosolic 5'- nucleotidase II
1SIW	;	2.2	;	Crystal structure of the apomolybdo-NarGHI
1JIW	;	1.74	;	Crystal structure of the APR-APRin complex
2OFW	;	2.05	;	Crystal structure of the APSK domain of human PAPSS1 complexed with 2 APS molecules
2OFX	;	1.9	;	crystal structure of the APSK domain of human PAPSS1 in complex with ADPMg and PAPS
4M4O	;	2.0	;	Crystal structure of the aptamer minE-lysozyme complex
4M6D	;	2.68	;	Crystal structure of the aptamer minF-lysozyme complex.
5ZHZ	;	1.18	;	Crystal structure of the apurinic/apyrimidinic endonuclease IV from Mycobacterium tuberculosis
1J4N	;	2.2	;	Crystal Structure of the AQP1 water channel
3P3C	;	1.25	;	Crystal Structure of the Aquifex aeolicus LpxC/LPC-009 complex
2AU3	;	2.0	;	Crystal Structure of the Aquifex aeolicus primase (Zinc Binding and RNA Polymerase Domains)
6O14	;	2.65	;	Crystal structure of the Aquifex aeolicus Wzt Carbohydrate Binding Domain
8DKY	;	1.61	;	Crystal structure of the Aquifex aeolicus Wzt Carbohydrate Binding Domain bound to 3-O-methyl-D-mannose
4BJH	;	2.2	;	Crystal Structure of the Aquifex Reactor Complex Formed by Dihydroorotase (H180A, H232A) with Dihydroorotate and Aspartate Transcarbamoylase with N-(phosphonacetyl)-L-aspartate (PALA)
4RL5	;	3.1	;	Crystal structure of the Arabidopsis exocyst subunit exo70 family protein A1
5IYX	;	2.43	;	Crystal structure of the Arabidopsis receptor kinase HAESA in complex with the peptide hormone IDA and the co-receptor SERK1
5IXO	;	1.74	;	Crystal structure of the Arabidopsis receptor kinase HAESA LRR ectdomain (apo form).
5IXQ	;	1.86	;	Crystal structure of the Arabidopsis receptor kinase HAESA LRR ectdomain in complex with the peptide hormone IDA.
5IYV	;	2.56	;	Crystal structure of the Arabidopsis receptor kinase HAESA LRR ectdomain in complex with the peptide hormone IDL1.
8F8N	;	1.798	;	Crystal structure of the Arabidopsis SPIRAL2 C-terminal domain
5EWU	;	1.25	;	Crystal structure of the Arabidopsis thaliana C-terminal Chlh at 1.25A
5YDG	;	2.405	;	Crystal structure of the Arabidopsis thaliana chloroplast RNA editing factors 2(MORF2)
4AEC	;	2.4	;	Crystal Structure of the Arabidopsis thaliana O-Acetyl-Serine-(Thiol)- Lyase C
1Z7Y	;	2.7	;	Crystal Structure of the Arabidopsis thaliana O-Acetylserine Sulfhydrylase K46A mutant
5WBI	;	3.0	;	Crystal structure of the Arabidopsis thaliana Raptor
5WBJ	;	3.0	;	Crystal structure of the arabidopsis thaliana Raptor in complex with the TOS peptide of human 4EBP1
5WBL	;	3.35	;	Crystal structure of the Arabidopsis thaliana Raptor in complex with the TOS peptide of human PRAS40
5WBK	;	3.11	;	Crystal structure of the arabidopsis thaliana Raptor in complex with the TOS peptide of human S6K1
7OVV	;	1.45	;	Crystal structure of the Arabidopsis thaliana thialysine acetyltransferase AtNATA2
4PUT	;	3.0	;	Crystal structure of the Arabidopsis thaliana TOP2 oligopeptidase
5G49	;	2.3	;	Crystal structure of the Arabodopsis thaliana histone-fold dimer L1L NF-YC3
5NLA	;	2.7	;	Crystal structure of the AraC-like transcriptional activator CuxR
2H9U	;	2.0	;	Crystal structure of the archaea specific DNA binding protein
3P8T	;	1.78	;	Crystal structure of the archaeal asparagine synthetase A
3REX	;	1.8	;	Crystal structure of the archaeal asparagine synthetase A complexed with Adenosine monophosphate
3P8Y	;	1.8	;	Crystal structure of the archaeal asparagine synthetase A complexed with L-Asparagine
3RL6	;	2.0	;	Crystal structure of the archaeal asparagine synthetase A complexed with L-Asparagine and Adenosine monophosphate
3P8V	;	1.8	;	Crystal structure of the archaeal asparagine synthetase A complexed with L-Aspartic acid
3REU	;	1.9	;	Crystal structure of the archaeal asparagine synthetase A complexed with L-Aspartic acid and Adenosine triphosphate
2AUS	;	2.1	;	Crystal structure of the archaeal box H/ACA sRNP Nop10-Cbf5 complex
7CSL	;	2.0	;	Crystal structure of the archaeal EF1A-EF1B complex
5YVS	;	2.345	;	Crystal Structure of the archaeal halo-thermophilic Red Sea brine pool alcohol dehydrogenase ADH/D1 bound to NADP
5YVM	;	2.12	;	Crystal Structure of the archaeal halo-thermophilic Red Sea brine pool alcohol dehydrogenase ADH/D1 bound to NZQ
4L7M	;	2.002	;	Crystal structure of the archaeal HEAT-like repeats protein TON_1937 from Thermococcus onnurineus NA1
1GEF	;	2.0	;	Crystal structure of the archaeal holliday junction resolvase HJC
1IPI	;	2.16	;	CRYSTAL STRUCTURE OF THE ARCHAEAL HOLLIDAY JUNCTION RESOLVASE HJC FROM PYROCOCCUS FURIOSUS FORM II
1TS9	;	1.7	;	Crystal Structure of the Archaeal Homolog of Human RNase P Protein Rpp29 from Archaeoglobus fulgidus
1TSF	;	1.7	;	Crystal Structure of the Archaeal homolog of Human RNase P Protein Rpp29 from Archaeoglobus fulgidus
2OAP	;	2.95	;	Crystal structure of the archaeal secretion ATPase GspE in complex with AMP-PNP
2OAQ	;	3.15	;	Crystal structure of the archaeal secretion ATPase GspE in complex with phosphate
5E71	;	1.7	;	Crystal structure of the archaeal tRNA m2G/m22G10 methyltransferase (aTrm11) from Thermococcus kodakarensis
5E72	;	1.739	;	Crystal structure of the archaeal tRNA m2G/m22G10 methyltransferase (aTrm11) in complex with S-adenosyl-L-methionine (SAM) from Thermococcus kodakarensis
3WAJ	;	2.501	;	Crystal structure of the Archaeoglobus fulgidus oligosaccharyltransferase (O29867_ARCFU) complex with Zn and sulfate
3WAK	;	3.413	;	Crystal structure of the Archaeoglobus fulgidus oligosaccharyltransferase (O29867_ARCFU) in the apo form
5GMY	;	3.5	;	Crystal structure of the Archaeoglobus fulgidus oligosaccharyltransferase (O29867_ARCFU) tethered with an acceptor peptide containing the NVT sequon via a disulfide bond
5K0P	;	1.94	;	Crystal structure of the archaeosine synthase QueF-Like in the apo form
6PTA	;	2.5	;	Crystal structure of the ARF family small GTPase ARF1 from Candida albicans in complex with GDP
5UF8	;	1.872	;	Crystal structure of the ARF family small GTPase ARF2 from Candida albicans in complex with GDP
1DCQ	;	2.1	;	CRYSTAL STRUCTURE OF THE ARF-GAP DOMAIN AND ANKYRIN REPEATS OF PAPBETA.
2J59	;	2.1	;	Crystal structure of the ARF1:ARHGAP21-ArfBD complex
4CHK	;	2.85	;	Crystal Structure of the ARF5 oligomerization domain
2W83	;	1.93	;	Crystal structure of the ARF6 GTPase in complex with a specific effector, JIP4
3DWD	;	2.4	;	Crystal structure of the ArfGAP domain of human ARFGAP1
1CVR	;	2.0	;	Crystal structure of the Arg specific cysteine proteinase gingipain R (RGPB)
2P3J	;	1.9	;	Crystal structure of the Arg101Ala mutant protein of Rhesus rotavirus VP8*
2EF4	;	2.3	;	Crystal structure of the arginase from thermus thermophilus
2EF5	;	2.0	;	Crystal structure of the arginase from thermus thermophilus
2EIV	;	2.91	;	Crystal Structure of the arginase from Thermus thermophilus
3FHZ	;	3.27	;	Crystal structure of the arginine repressor from Mycobacterium tuberculosis bound with its DNA operator and co-repressor, L-arginine
5JVO	;	1.9	;	Crystal structure of the Arginine Repressor from the pathogenic bacterium Corynebacterium pseudotuberculosis
3ERE	;	2.5	;	Crystal structure of the arginine repressor protein from Mycobacterium tuberculosis in complex with the DNA operator
8HQR	;	1.32	;	Crystal structure of the arginine-/lysine-binding protein SAR11_1210 from 'Candidatus Pelagibacter ubique' HTCC1062 bound to arginine
6GPC	;	1.75	;	Crystal structure of the arginine-bound form of domain 1 from TmArgBP
1F7U	;	2.2	;	CRYSTAL STRUCTURE OF THE ARGINYL-TRNA SYNTHETASE COMPLEXED WITH THE TRNA(ARG) AND L-ARG
7RTC	;	3.31	;	Crystal structure of the ARM domain from Drosophila SARM1 in complex with NaMN
7LCZ	;	1.65	;	Crystal structure of the ARM domain from Drosophila SARM1 in complex with NMN
7M6K	;	1.69	;	Crystal structure of the ARM domain from Drosophila SARM1 in complex with VMN
7VPS	;	2.29	;	Crystal structure of the ARM domain of C. glabrata importin alpha
5A8J	;	1.46	;	Crystal structure of the ArnB paralog VWA2 from Sulfolobus acidocaldarius
4EQ1	;	1.6	;	Crystal Structure of the ARNT PAS-B homodimer
2RER	;	1.9	;	Crystal structure of the aromatase/cyclase domain of TcmN from Streptomyces glaucescens
4MY5	;	2.194	;	Crystal structure of the aromatic amino acid aminotransferase from Streptococcus mutants
4JE5	;	1.909	;	Crystal structure of the aromatic aminotransferase Aro8, a putative alpha-aminoadipate aminotransferase in Saccharomyces cerevisiae
6HND	;	2.23	;	Crystal structure of the aromatic aminotransferase Aro9 from C. Albicans
5KCG	;	1.9	;	Crystal structure of the aromatic prenyltransferase AtaPT (apo state) from Aspergillus terreus A8-4
5KCL	;	2.1	;	Crystal structure of the aromatic prenyltransferase AtaPT from Aspergillus terreus A8-4 in complex with dimethylallyl S-thiolodiphosphate
5KD6	;	1.84	;	Crystal structure of the aromatic prenyltransferase AtaPT from Aspergillus terreus A8-4 in complex with dimethylallyl S-thiolodiphosphate and (-)-butyrolactone II
5KDA	;	2.0	;	Crystal structure of the aromatic prenyltransferase AtaPT from Aspergillus terreus A8-4 in complex with dimethylallyl S-thiolodiphosphate and genistein
5KCQ	;	2.0	;	Crystal structure of the aromatic prenyltransferase AtaPT from Aspergillus terreus A8-4 in complex with geranyl S-thiolodiphosphate
5KCY	;	2.3	;	Crystal structure of the aromatic prenyltransferase AtaPT from Aspergillus terreus A8-4 in complex with geranyl S-thiolodiphosphate and (+)-butyrolactone II
5KD0	;	2.82	;	Crystal structure of the aromatic prenyltransferase AtaPT(E91A) mutant from Aspergillus terreus A8-4 in complex with geranyl S-thiolodiphosphate and (+)-butyrolactone II
5KBH	;	2.55	;	CRYSTAL STRUCTURE OF THE AROMATIC SENSOR DOMAIN OF MOPR IN COMPLEX WITH 3-CHLORO-PHENOL
5KBI	;	2.9	;	CRYSTAL STRUCTURE OF THE AROMATIC SENSOR DOMAIN OF MOPR IN COMPLEX WITH CATACHOL
5KBG	;	2.8	;	CRYSTAL STRUCTURE OF THE AROMATIC SENSOR DOMAIN OF MOPR IN COMPLEX WITH OCRESOL
5KBE	;	2.5	;	CRYSTAL STRUCTURE OF THE AROMATIC SENSOR DOMAIN OF MOPR IN COMPLEX WITH PHENOL
5NBL	;	2.8	;	Crystal structure of the Arp4-N-actin(APO-state) heterodimer bound by a nanobody
5NBM	;	3.4	;	Crystal structure of the Arp4-N-actin(ATP-state) heterodimer bound by a nanobody
5NBN	;	4.0	;	Crystal structure of the Arp4-N-actin-Arp8-Ino80HSA module of INO80
4AAY	;	2.7	;	Crystal Structure of the arsenite oxidase protein complex from Rhizobium species strain NT-26
4BKL	;	3.25	;	Crystal structure of the arthritogenic antibody M2139 (Fab fragment) in complex with the triple-helical J1 peptide
1RW9	;	1.35	;	Crystal structure of the Arthrobacter aurescens chondroitin AC lyase
4ZV6	;	2.22	;	Crystal structure of the artificial alpharep-7 octarellinV.1 complex
5BOP	;	1.95	;	Crystal structure of the artificial nanobody octarellinV.1 complex
3WKN	;	2.9	;	Crystal structure of the artificial protein AFFinger p17 (AF.p17) complexed with Fc fragment of human IgG
6E97	;	1.8	;	Crystal structure of the aryl acid adenylating enzyme FscC from Fuscachelin NRPS in complex with DHB-adenylate
2JD6	;	2.75	;	Crystal Structure of the as isolated Ferritin from the Hyperthermophilic Archaeal Anaerobe Pyrococcus furiosus
5H9C	;	1.783	;	Crystal structure of the ASLV fusion protein core
1Z9A	;	2.4	;	Crystal Structure Of The Asn-309 To Asp Mutant Of Candida Tenuis Xylose Reductase (Akr2B5) Bound To Nad+
5DNE	;	2.39	;	Crystal structure of the Asn-bound guinea pig L-asparaginase 1 catalytic domain active site mutant K188M
5DND	;	2.29	;	Crystal structure of the Asn-bound guinea pig L-asparaginase 1 catalytic domain active site mutant T116A
5DNC	;	2.01	;	Crystal structure of the Asn-bound guinea pig L-asparaginase 1 catalytic domain active site mutant T19A
3S4X	;	1.95	;	Crystal structure of the Asn152Gly mutant of P99 beta-lactamase
2CLA	;	2.35	;	CRYSTAL STRUCTURE OF THE ASP-199-ASN MUTANT OF CHLORAMPHENICOL ACETYLTRANSFERASE TO 2.35 ANGSTROMS RESOLUTION. STRUCTURAL CONSEQUENCES OF DISRUPTION OF A BURIED SALT-BRIDGE
4R8L	;	2.41	;	Crystal structure of the Asp-bound guinea pig L-asparaginase 1 catalytic domain
4WJ3	;	3.705	;	Crystal structure of the asparagine transamidosome from Pseudomonas aeruginosa
6F35	;	1.9	;	Crystal structure of the aspartate aminotranferase from Rhizobium meliloti
2WCD	;	3.29	;	Crystal structure of the assembled cytolysin A pore
1AON	;	3.0	;	CRYSTAL STRUCTURE OF THE ASYMMETRIC CHAPERONIN COMPLEX GROEL/GROES/(ADP)7
4CSA	;	2.28	;	Crystal structure of the asymmetric human metapneumovirus M2-1 tetramer bound to a DNA 4-mer
4CS9	;	2.01	;	Crystal structure of the asymmetric human metapneumovirus M2-1 tetramer bound to adenosine monophosphate
4CS7	;	2.47	;	Crystal structure of the asymmetric human metapneumovirus M2-1 tetramer, form 1
4CS8	;	2.1	;	Crystal structure of the asymmetric human metapneumovirus M2-1 tetramer, form 2
2PNR	;	2.5	;	Crystal Structure of the asymmetric Pdk3-l2 Complex
4YK8	;	3.0	;	Crystal structure of the Atg101-Atg13 complex from fission yeast
4HPQ	;	3.06	;	Crystal Structure of the Atg17-Atg31-Atg29 Complex
3SKX	;	1.59	;	Crystal structure of the ATP binding domain of Archaeoglobus fulgidus COPB
1YS3	;	1.9	;	Crystal Structure of the ATP binding domain of PrrB from Mycobacterium Tuberculosis
5CPH	;	1.2	;	Crystal structure of the ATP binding domain of S. aureus GyrB complexed with a fragment
5CTU	;	1.45	;	Crystal structure of the ATP binding domain of S. aureus GyrB complexed with a fragment
5CTW	;	1.48	;	Crystal structure of the ATP binding domain of S. aureus GyrB complexed with a fragment
5CTX	;	1.6	;	Crystal structure of the ATP binding domain of S. aureus GyrB complexed with a fragment
5CTY	;	1.6	;	Crystal structure of the ATP binding domain of S. aureus GyrB complexed with a fragment
5D6P	;	2.05	;	Crystal structure of the ATP binding domain of S. aureus GyrB complexed with a ligand
5D6Q	;	1.5	;	Crystal structure of the ATP binding domain of S. aureus GyrB complexed with a ligand
5D7C	;	1.55	;	Crystal structure of the ATP binding domain of S. aureus GyrB complexed with a ligand
5D7D	;	1.6	;	Crystal structure of the ATP binding domain of S. aureus GyrB complexed with a ligand
5D7R	;	1.55	;	Crystal structure of the ATP binding domain of S. aureus GyrB complexed with a ligand
6TTG	;	1.7	;	Crystal structure of the ATP binding domain of S. aureus GyrB complexed with LMD62
6TCK	;	1.6	;	Crystal structure of the ATP binding domain of S. aureus GyrB complexed with ULD-2
3LF0	;	2.4	;	Crystal structure of the ATP bound Mycobacterium tuberculosis nitrogen regulatory PII protein
7FH3	;	1.8	;	Crystal structure of the ATP sulfurylase domain of human PAPSS2
7FHA	;	2.0	;	Crystal structure of the ATP sulfurylase domain of human PAPSS2 in complex with APS
1VCI	;	2.9	;	Crystal structure of the ATP-binding cassette of multisugar transporter from Pyrococcus horikoshii OT3 complexed with ATP
3EHG	;	1.74	;	Crystal structure of the ATP-binding domain of DesK in complex with ATP
3ZXQ	;	1.9	;	CRYSTAL STRUCTURE OF THE ATP-BINDING DOMAIN OF MYCOBACTERIUM TUBERCULOSIS DOST
2PP6	;	2.7	;	Crystal structure of the ATP-binding sugar transporter-like protein from Salmonella typhimurium
1Q12	;	2.6	;	Crystal Structure of the ATP-bound E. coli MalK
3M0E	;	2.63	;	Crystal structure of the ATP-bound state of Walker B mutant of NtrC1 ATPase domain
5OLK	;	2.45	;	Crystal structure of the ATP-cone-containing NrdB from Leeuwenhoekiella blandensis
3FES	;	1.82	;	Crystal Structure of the ATP-dependent Clp Protease ClpC from Clostridium difficile
2CBY	;	2.6	;	Crystal structure of the ATP-dependent Clp Protease proteolytic subunit 1 (ClpP1) from Mycobacterium tuberculosis
2CE3	;	2.6	;	CRYSTAL STRUCTURE OF THE ATP-DEPENDENT CLP PROTEASE PROTEOLYTIC SUBUNIT 1 (CLPP1) FROM MYCOBACTERIUM TUBERCULOSIS
7CLG	;	3.1	;	Crystal structure of the ATP-dependent restriction endonuclease SauUSI
5SVM	;	3.093	;	Crystal structure of the ATP-gated human P2X3 ion channel bound to agonist 2-methylthio-ATP in the desensitized state
5SVR	;	3.13	;	Crystal structure of the ATP-gated human P2X3 ion channel bound to competitive antagonist A-317491
5SVQ	;	3.25	;	Crystal structure of the ATP-gated human P2X3 ion channel bound to competitive antagonist TNP-ATP
5SVL	;	2.9	;	Crystal structure of the ATP-gated human P2X3 ion channel in the ATP-bound, closed (desensitized) state
5SVK	;	2.773	;	Crystal structure of the ATP-gated human P2X3 ion channel in the ATP-bound, open state
5SVJ	;	2.984	;	Crystal structure of the ATP-gated human P2X3 ion channel in the closed, apo state
4DW1	;	2.8	;	Crystal structure of the ATP-gated P2X4 ion channel in the ATP-bound, open state at 2.8 Angstroms
4DW0	;	2.9	;	Crystal structure of the ATP-gated P2X4 ion channel in the closed, apo state at 2.9 Angstroms
3H9V	;	3.1	;	Crystal structure of the ATP-gated P2X4 ion channel in the closed, apo state at 3.1 Angstroms
3I5D	;	3.46	;	Crystal structure of the ATP-gated P2X4 ion channel in the closed, apo state at 3.5 Angstroms (R3)
5U1U	;	3.604	;	Crystal structure of the ATP-gated P2X7 ion channel bound to allosteric antagonist A740003
5U1V	;	3.4	;	Crystal structure of the ATP-gated P2X7 ion channel bound to allosteric antagonist A804598
5U1W	;	3.501	;	Crystal structure of the ATP-gated P2X7 ion channel bound to allosteric antagonist AZ10606120
5U1Y	;	3.3	;	Crystal structure of the ATP-gated P2X7 ion channel bound to allosteric antagonist GW791343
5U1X	;	3.201	;	Crystal structure of the ATP-gated P2X7 ion channel bound to allosteric antagonist JNJ47965567
5U2H	;	3.903	;	Crystal structure of the ATP-gated P2X7 ion channel bound to ATP and allosteric antagonist A804598
5U1L	;	3.4	;	Crystal structure of the ATP-gated P2X7 ion channel in the closed, apo state
1XEF	;	2.5	;	Crystal structure of the ATP/Mg2+ bound composite dimer of HlyB-NBD
7L6S	;	1.95	;	Crystal structure of the ATPase and transducer domains of DNA topoisomerase II from Balamuthia mandrillaris CDC:V039: baboon/San Diego/1986
5X9Y	;	3.443	;	Crystal structure of the ATPase domain from bacterial mismatch repair endonuclease Aquifex aeolicus MutL.
5EQT	;	1.943	;	crystal structure of the ATPase domain of PAN from Pyrococcus horikoshii
2IXE	;	2.0	;	Crystal structure of the ATPase domain of TAP1 with ATP (D645N mutant)
4K8O	;	2.65	;	CRYSTAL STRUCTURE OF THE ATPASE DOMAIN OF TAP1 WITH ATP (D645N, D651A MUTANT)
2IXF	;	2.0	;	Crystal structure of the ATPase domain of TAP1 with ATP (D645Q, Q678H mutant)
2IXG	;	2.7	;	Crystal structure of the ATPase domain of TAP1 with ATP (S621A, G622V, D645N mutant)
1QDE	;	2.0	;	CRYSTAL STRUCTURE OF THE ATPASE DOMAIN OF TRANSLATION INITIATION FACTOR 4A FROM SACCHAROMYCES CEREVISIAE-THE PROTOTYPE OF THE DEAD BOX PROTEIN FAMILY
3ZM7	;	3.3	;	CRYSTAL STRUCTURE OF THE ATPASE REGION OF Mycobacterium tuberculosis GyrB WITH AMPPCP
3ZKB	;	2.9	;	CRYSTAL STRUCTURE OF THE ATPASE REGION OF Mycobacterium tuberculosis GyrB WITH AMPPNP
3ZKD	;	2.95	;	CRYSTAL STRUCTURE OF THE ATPASE REGION OF Mycobacterium tuberculosis GyrB WITH AMPPNP
1PVG	;	1.8	;	Crystal Structure of the ATPase region of Saccharomyces Cerevisiae topoisomerase II
1QZR	;	1.9	;	CRYSTAL STRUCTURE OF THE ATPASE REGION OF SACCHAROMYCES CEREVISIAE TOPOISOMERASE II BOUND TO ICRF-187 (DEXRAZOXANE)
5XG3	;	3.5	;	Crystal structure of the ATPgS-engaged Smc head domain with an extended coiled coil bound to the C-terminal domain of ScpA derived from Bacillus subtilis
5A68	;	1.67	;	Crystal structure of the AtTTM3 product complex with two orthophosphates and manganese ions (form B)
6J4E	;	3.126	;	Crystal structure of the AtWRKY1 domain
6J4F	;	2.4	;	Crystal structure of the AtWRKY2 domain
6J4G	;	3.0	;	Crystal structure of the AtWRKY33 domain
1CC7	;	1.2	;	CRYSTAL STRUCTURE OF THE ATX1 METALLOCHAPERONE PROTEIN
1CC8	;	1.02	;	CRYSTAL STRUCTURE OF THE ATX1 METALLOCHAPERONE PROTEIN
4EZA	;	1.5	;	Crystal structure of the atypical phosphoinositide (aPI) binding domain of IQGAP2
5NYN	;	1.6	;	Crystal structure of the atypical poplar thioredoxin-like2.1 in complex with gluathione
5NYK	;	1.05	;	Crystal structure of the atypical poplar thioredoxin-like2.1 in oxidized state
5NYM	;	1.4	;	Crystal structure of the atypical poplar thioredoxin-like2.1 in reduced state
1IAH	;	2.4	;	CRYSTAL STRUCTURE OF THE ATYPICAL PROTEIN KINASE DOMAIN OF A TRP CA-CHANNEL, CHAK (ADP-MG COMPLEX)
1IA9	;	2.0	;	CRYSTAL STRUCTURE OF THE ATYPICAL PROTEIN KINASE DOMAIN OF A TRP CA-CHANNEL, CHAK (AMPPNP COMPLEX)
1IAJ	;	2.8	;	CRYSTAL STRUCTURE OF THE ATYPICAL PROTEIN KINASE DOMAIN OF A TRP CA-CHANNEL, CHAK (APO)
5NII	;	2.0	;	Crystal structure of the atypical thioredoxin reductase TRi from Desulfovibrio vulgaris Hildenborough
1Q07	;	2.5	;	Crystal structure of the Au(I) form of E. coli CueR, a copper efflux regulator
4FEO	;	1.6	;	Crystal structure of the AU25A/A46G/C74U mutant xpt-pbuX guanine riboswitch aptamer domain in complex with 2,6-diaminopurine
1N8N	;	1.69	;	Crystal structure of the Au3+ complex of AphA class B acid phosphatase/phosphotransferase from E. coli at 1.69 A resolution
4FTB	;	2.7	;	Crystal structure of the authentic Flock House virus particle
2BDW	;	1.8	;	Crystal Structure of the Auto-Inhibited Kinase Domain of Calcium/Calmodulin Activated Kinase II
5XMC	;	2.6	;	Crystal structure of the auto-inhibited Nedd4 family E3 ligase Itch
1K2D	;	2.2	;	Crystal structure of the autoimmune MHC class II I-Au complexed with myelin basic protein 1-11 at 2.2A
2HJ9	;	2.34	;	Crystal structure of the Autoinducer-2-bound form of Vibrio harveyi LuxP complexed with the periplasmic domain of LuxQ
4S0O	;	1.9	;	Crystal Structure of the Autoinhibited Dimer of Pro-apoptotic BAX (I)
4S0P	;	3.252	;	Crystal Structure of the Autoinhibited Dimer of Pro-apoptotic BAX (II)
2YA9	;	2.3	;	Crystal structure of the autoinhibited form of mouse DAPK2
2YAB	;	1.9	;	Crystal structure of the autoinhibited form of mouse DAPK2 in complex with AMP
2YAA	;	2.3	;	Crystal structure of the autoinhibited form of mouse DAPK2 in complex with ATP
2OGV	;	2.7	;	Crystal Structure of the Autoinhibited Human c-Fms Kinase Domain
2F31	;	2.1	;	Crystal structure of the autoinhibitory switch in Formin mDia1; the DID/DAD complex
3FI7	;	2.35	;	Crystal Structure of the autolysin Auto (Lmo1076) from Listeria monocytogenes, catalytic domain
4X36	;	2.101	;	Crystal structure of the autolysin LytA from Streptococcus pneumoniae TIGR4
7BV6	;	3.05	;	Crystal structure of the autophagic STX17/SNAP29/VAMP8 SNARE complex
3NQY	;	2.6	;	Crystal structure of the autoprocessed complex of Vibriolysin MCP-02 with a single point mutation E346A
3NQZ	;	2.05	;	Crystal structure of the autoprocessed Vibriolysin MCP-02 with E369A mutation
3KEP	;	1.82	;	Crystal structure of the autoproteolytic domain from the nuclear pore complex component NUP145 from Saccharomyces cerevisiae
3KES	;	2.1	;	Crystal structure of the autoproteolytic domain from the nuclear pore complex component NUP145 from Saccharomyces cerevisiae in the Hexagonal, P61 space group
8E7F	;	2.0	;	Crystal structure of the autotransporter Ssp from Serratia marcescens.
6BEA	;	1.97	;	Crystal structure of the autotransporter UpaB from E. coli strain CFT073
7NUV	;	1.76	;	Crystal structure of the Aux2pLS20 tetramerization domain
4IO5	;	1.721	;	Crystal Structure of the AvGluR1 ligand binding domain complex with alanine at 1.72 Angstrom resolution
4IO3	;	1.66	;	Crystal Structure of the AvGluR1 ligand binding domain complex with aspartate at 1.66 Angstrom resolution
4IO2	;	1.37	;	Crystal Structure of the AvGluR1 ligand binding domain complex with glutamate at 1.37 Angstrom resolution
4IO6	;	1.6	;	Crystal Structure of the AvGluR1 ligand binding domain complex with methionine at 1.6 Angstrom resolution
4IO7	;	1.92	;	Crystal Structure of the AvGluR1 ligand binding domain complex with phenylalanine at 1.9 Angstrom resolution
4IO4	;	1.941	;	Crystal Structure of the AvGluR1 ligand binding domain complex with serine at 1.94 Angstrom resolution
2VAK	;	2.34	;	Crystal structure of the avian reovirus inner capsid protein sigmaA
7O9Q	;	1.85	;	Crystal structure of the Awp1 (adhesin-like wall protein 1) A-domain from Candida glabrata
7O9O	;	1.55	;	Crystal structure of the Awp3b (adhesin-like wall protein 3b) A-domain from Candida glabrata
7O9P	;	1.99	;	Crystal structure of the Awp3b (adhesin-like wall protein 3b) A-domain from Candida glabrata showing a gadolinium cluster
4JYY	;	2.101	;	Crystal structure of the azide and iron substituted Clostrium difficile SOD2 complex
1SOF	;	2.6	;	Crystal structure of the azotobacter vinelandii bacterioferritin at 2.6 A resolution
4UII	;	2.827	;	Crystal structure of the Azotobacter vinelandii globin-coupled oxygen sensor in the aquo-met form
1NZR	;	2.2	;	CRYSTAL STRUCTURE OF THE AZURIN MUTANT NICKEL-TRP48MET FROM PSEUDOMONAS AERUGINOSA AT 2.2 ANGSTROMS RESOLUTION
1AZN	;	2.6	;	CRYSTAL STRUCTURE OF THE AZURIN MUTANT PHE114ALA FROM PSEUDOMONAS AERUGINOSA AT 2.6 ANGSTROMS RESOLUTION
7PRP	;	2.3	;	Crystal Structure of the B subunit of heat labile enterotoxin LT-IIc from Escherichia coli in apo form
7PRS	;	2.0	;	Crystal Structure of the B subunit of heat labile enterotoxin LT-IIc from Escherichia coli in complex with Sialyl-lacto-N-neotetraose d
1B44	;	3.3	;	CRYSTAL STRUCTURE OF THE B SUBUNIT OF HEAT-LABILE ENTEROTOXIN FROM E. COLI CARRYING A PEPTIDE WITH ANTI-HSV ACTIVITY
1LTR	;	3.04	;	CRYSTAL STRUCTURE OF THE B SUBUNIT OF HUMAN HEAT-LABILE ENTEROTOXIN FROM E. COLI CARRYING A PEPTIDE WITH ANTI-HSV ACTIVITY
4NWY	;	2.0	;	Crystal structure of the b' domain of human protein disulfide isomerase-like protein of the testis (PDILT)
5CRW	;	1.6	;	Crystal structure of the b'-a' domain of oxidized protein disulfide isomerase complexed with alpha-synuclein peptide (31-41)
3WT2	;	3.3	;	Crystal structure of the b'-a' domain of thermophilic fungal protein disulfide isomerase (oxidized form)
3WT1	;	1.85	;	Crystal structure of the b'-a' domain of thermophilic fungal protein disulfide isomerase (reduced form)
7COI	;	1.8	;	Crystal structure of the b-carbonic anhydrase CafA of the fungal pathogen Aspergillus fumigatus
7COJ	;	2.0	;	Crystal structure of the b-carbonic anhydrase CafA of the fungal pathogen Aspergillus fumigatus
1R29	;	1.3	;	Crystal Structure of the B-Cell Lymphoma 6 (BCL6) BTB Domain to 1.3 Angstrom
1R28	;	2.2	;	Crystal Structure of the B-Cell Lymphoma 6 (BCL6) BTB domain to 2.2 Angstrom
252D	;	2.3	;	CRYSTAL STRUCTURE OF THE B-DNA DECAMER D(CGCAATTGCG)2; SEQUENCE-DEPENDENT CROSSED HELIX PACKING
478D	;	2.2	;	CRYSTAL STRUCTURE OF THE B-DNA DODECAMER 5'-D(CGCGAA(TAF)TCGCG), WHERE TAF IS 2'-DEOXY-2'-FLUORO-ARABINO-FURANOSYL THYMINE
1JO2	;	1.5	;	Crystal Structure of the B-DNA Hexamer (CgATCG).Daunomycin Complex Containing a Ribose at the Intercalation Site
1F69	;	2.6	;	CRYSTAL STRUCTURE OF THE B-DNA HEXAMER GGCGCC WITH COBALT HEXAMINE
1IH1	;	2.0	;	Crystal Structure of the B-DNA Hexamer GGCGCC with Cobalt Hexamine Resolved to 2.0 Angstroms
1F6C	;	2.7	;	CRYSTAL STRUCTURE OF THE B-DNA HEXAMER GGCGCC WITH SPERMINE
253D	;	2.2	;	CRYSTAL STRUCTURE OF THE B-DNA NONAMER D(GCGTACGCG) WITH A NOVEL D[G*(G.C)] BASE-TRIPLET INVOLVING THE MINOR GROOVE
3V58	;	1.85	;	Crystal Structure of the B-phycoerythrin from the red algae Porphyridium Cruentum at pH5
3V57	;	1.7	;	Crystal Structure of the B-phycoerythrin from the red algae Porphyridium Cruentum at pH8
3U0X	;	1.85	;	Crystal structure of the B-specific-1,3-galactosyltransferase (GTB) in complex with compound 382
3DWA	;	2.084	;	Crystal structure of the B-subunit of the AB5 toxin from E. coli
3DWP	;	2.2	;	Crystal structure of the B-subunit of the AB5 toxin from E. Coli with Neu5Gc
5B12	;	1.721	;	Crystal structure of the B-type halohydrin hydrogen-halide-lyase mutant F71W/Q125T/D199H from Corynebacterium sp. N-1074
3LB9	;	3.0	;	Crystal structure of the B. circulans cpA123 circular permutant
6Q56	;	2.0	;	Crystal structure of the B. subtilis M1A22 tRNA methyltransferase TrmK
1Y7M	;	2.05	;	Crystal Structure of the B. subtilis YkuD protein at 2 A resolution
2ACJ	;	2.6	;	Crystal structure of the B/Z junction containing DNA bound to Z-DNA binding proteins
1KEX	;	1.9	;	Crystal Structure of the b1 Domain of Human Neuropilin-1
5C7G	;	1.45	;	Crystal Structure of the b1 Domain of Human Neuropilin-1 in complex with a bicine molecule
7T2D	;	3.4	;	Crystal structure of the B1 TCR in complex with HLA-DP4-Ply
2QQI	;	1.8	;	Crystal Structure of the b1b2 Domains from Human Neuropilin-1
2QQJ	;	1.95	;	Crystal Structure of the b1b2 Domains from Human Neuropilin-2
4N6C	;	1.548	;	Crystal Structure of the B1RZQ2 protein from Streptococcus pneumoniae. Northeast Structural Genomics Consortium (NESG) Target SpR36.
3DDT	;	1.9	;	Crystal structure of the B2 box from MuRF1 in dimeric state
3ZI3	;	1.7	;	Crystal structure of the B24His-insulin - human analogue
7O0O	;	1.45	;	Crystal structure of the B3 metallo-beta-lactamase L1 with hydrolysed ertapenem
2IHS	;	2.2	;	Crystal structure of the B30.2/SPRY domain of GUSTAVUS in complex with a 20-residue VASA peptide
6MCO	;	3.526	;	Crystal structure of the B41 SOSIP.664 Env trimer with PGT124 and 35O22 Fabs, in P23 space group
6MDT	;	3.816	;	Crystal structure of the B41 SOSIP.664 Env trimer with PGT124 and 35O22 Fabs, in P63 space group
7T2C	;	3.1	;	Crystal structure of the B5 TCR in complex with HLA-DP4-Ply
4U87	;	3.8	;	Crystal structure of the Ba-soaked C2 crystal form of pMV158 replication initiator RepB (P3221 space group)
5B5N	;	3.3	;	Crystal structure of the Ba-substituted LH1-RC complex from Tch. tepidum
5ANP	;	1.4	;	CRYSTAL STRUCTURE OF THE BA41 PROTEIN FROM BIZIONIA ARGENTINENSIS
4OA3	;	1.39	;	Crystal structure of the BA42 protein from BIZIONIA ARGENTINENSIS
5F8K	;	2.8	;	Crystal structure of the Bac7(1-16) antimicrobial peptide bound to the Thermus thermophilus 70S ribosome
2F3E	;	2.11	;	Crystal Structure of the Bace complex with AXQ093, a macrocyclic inhibitor
2F3F	;	2.3	;	Crystal Structure of the Bace complex with BDF488, a macrocyclic inhibitor
1YVK	;	3.01	;	Crystal Structure of the Bacillis subtilis Acetyltransferase in complex with CoA, Northeast Structural Genomics Target SR237.
1YDO	;	2.71	;	Crystal Structure of the Bacillis subtilis HMG-CoA Lyase, Northeast Structural Genomics Target SR181.
5WK0	;	1.335	;	Crystal structure of the bacillithiol transferase BstA from Staphylococcus aureus.
3SS6	;	1.7	;	Crystal structure of the Bacillus anthracis acetyl-CoA acetyltransferase
3L3C	;	2.85	;	Crystal structure of the Bacillus anthracis glmS ribozyme bound to Glc6P
3G96	;	3.01	;	Crystal structure of the Bacillus anthracis glmS ribozyme bound to MaN6P
4YMP	;	3.15	;	Crystal structure of the Bacillus anthracis Hal NEAT domain in complex with heme
3SIK	;	2.149	;	Crystal structure of the Bacillus anthracis hemophore IsdX1 complexed with heme
3EDN	;	1.5	;	Crystal structure of the Bacillus anthracis phenazine biosynthesis protein, PhzF family
2H1I	;	2.8	;	Crystal Structure of the Bacillus cereus Carboxylesterase
3OJE	;	3.02	;	Crystal Structure of the Bacillus cereus Enoyl-Acyl Carrier Protein Reductase (Apo form)
3OJF	;	2.2	;	Crystal Structure of the Bacillus cereus Enoyl-Acyl Carrier Protein Reductase with NADP+ and indole naphthyridinone (Complex form)
4S3J	;	1.6	;	Crystal structure of the Bacillus cereus spore cortex-lytic enzyme SleL
3VZJ	;	2.406	;	Crystal structure of the Bacillus circulans endo-beta-(1,4)-xylanase (BcX) E172H mutant
3VZM	;	1.86	;	Crystal structure of the Bacillus circulans endo-beta-(1,4)-xylanase (BcX) E172H mutant with Glu78 covalently bonded to 2-deoxy-2-fluoro-xylobiose
3VZK	;	1.55	;	Crystal structure of the Bacillus circulans endo-beta-(1,4)-xylanase (BcX) N35E mutant
3VZN	;	1.67	;	Crystal structure of the Bacillus circulans endo-beta-(1,4)-xylanase (BcX) N35E mutant with Glu78 covalently bonded to 2-deoxy-2-fluoro-xylobiose
3VZL	;	2.0	;	Crystal structure of the Bacillus circulans endo-beta-(1,4)-xylanase (BcX) N35H mutant
3VZO	;	1.73	;	Crystal structure of the Bacillus circulans endo-beta-(1,4)-xylanase (BcX) N35H mutant with Glu78 covalently bonded to 2-deoxy-2-fluoro-xylobiose
4S3K	;	1.7	;	Crystal structure of the Bacillus megaterium QM B1551 spore cortex-lytic enzyme SleL
1L0O	;	2.9	;	Crystal Structure of the Bacillus stearothermophilus Anti-Sigma Factor SpoIIAB with the Sporulation Sigma Factor SigmaF
4I36	;	2.3	;	Crystal Structure of the Bacillus stearothermophilus Phosphofructokinase Mutant D12A
4I7E	;	2.0	;	Crystal Structure of the Bacillus stearothermophilus Phosphofructokinase Mutant D12A in Complex with PEP
5GUJ	;	2.5	;	Crystal structure of the Bacillus subtilis DnaG RNA Polymerase Domain, natural degradation of full length DnaG
1VZY	;	1.97	;	Crystal structure of the Bacillus subtilis HSP33
1CSP	;	2.45	;	CRYSTAL STRUCTURE OF THE BACILLUS SUBTILIS MAJOR COLD SHOCK PROTEIN, CSPB: A UNIVERSAL NUCLEIC-ACID BINDING DOMAIN
1CSQ	;	2.7	;	CRYSTAL STRUCTURE OF THE BACILLUS SUBTILIS MAJOR COLD SHOCK PROTEIN, CSPB: A UNIVERSAL NUCLEIC-ACID BINDING DOMAIN
2PR1	;	3.2	;	Crystal structure of the Bacillus subtilis N-acetyltransferase YlbP protein in complex with Coenzyme-A
2J9P	;	2.8	;	Crystal structure of the Bacillus subtilis PBP4a, and its complex with a peptidoglycan mimetic peptide.
4JZS	;	2.2	;	Crystal structure of the Bacillus subtilis pyrophosphohydrolase BsRppH (E68A mutant)
4JZT	;	2.9	;	Crystal structure of the Bacillus subtilis pyrophosphohydrolase BsRppH (E68A mutant) bound to GTP
4JZU	;	1.7	;	Crystal structure of the Bacillus subtilis pyrophosphohydrolase BsRppH bound to a non-hydrolysable triphosphorylated dinucleotide RNA (pcp-pGpG) - first guanosine residue in guanosine binding pocket
4JZV	;	2.2	;	Crystal structure of the Bacillus subtilis pyrophosphohydrolase BsRppH bound to a non-hydrolysable triphosphorylated dinucleotide RNA (pcp-pGpG) - second guanosine residue in guanosine binding pocket
1FSE	;	2.05	;	CRYSTAL STRUCTURE OF THE BACILLUS SUBTILIS REGULATORY PROTEIN GERE
6E8D	;	2.34	;	Crystal structure of the Bacillus subtilis sliding clamp-MutL complex.
5H66	;	1.82195	;	Crystal structure of the Bacillus subtilis SMC head domain complexed with the cognate ScpA C-terminal domain
5H67	;	2.07204	;	Crystal structure of the Bacillus subtilis SMC head domain complexed with the cognate ScpA C-terminal domain and soaked ATP
2RCV	;	1.6	;	Crystal structure of the Bacillus subtilis superoxide dismutase
2W27	;	2.8	;	CRYSTAL STRUCTURE OF THE BACILLUS SUBTILIS YKUI PROTEIN, WITH AN EAL DOMAIN, IN COMPLEX WITH SUBSTRATE C-DI-GMP AND CALCIUM
2BAS	;	2.61	;	Crystal Structure of the Bacillus subtilis YkuI Protein, with an EAL Domain.
5IE9	;	2.8	;	Crystal structure of the Bacillus-conserved MazG protein, a nucleotide pyrophosphohydrolase
4P3T	;	1.6	;	Crystal structure of the bacterial A1408C-mutant ribosomal decoding site
4P3S	;	2.3	;	Crystal structure of the bacterial A1408C-mutant ribosomal decoding site in complex with geneticin
3TD0	;	1.6	;	Crystal structure of the bacterial A1408G-mutant and the protozoa cytoplasmic ribosomal decoding site
3TD1	;	2.1	;	Crystal structure of the bacterial A1408G-mutant and the protozoa cytoplasmic ribosomal decoding site in complex with geneticin
5ZEG	;	2.4	;	Crystal structure of the bacterial A1408me1A-mutant ribosomal decoding site
5ZEI	;	2.1	;	Crystal structure of the bacterial A1408me1A-mutant ribosomal decoding site in complex with geneticin
5ZEJ	;	3.5	;	Crystal structure of the bacterial A1408me1A-mutant ribosomal decoding site in complex with paromomycin
5ZEM	;	3.103	;	Crystal structure of the bacterial A1408me1A-mutant ribosomal decoding site in the presence of gentamicin
4P3U	;	3.0	;	Crystal structure of the bacterial A1408U-mutant ribosomal decoding site (C2 form 1)
4P43	;	2.0	;	Crystal structure of the bacterial A1408U-mutant ribosomal decoding site (C2 form 2)
2ICP	;	1.88	;	Crystal structure of the bacterial antitoxin HigA from Escherichia coli at pH 4.0. Northeast Structural Genomics Consortium TARGET ER390.
2ICT	;	1.63	;	Crystal structure of the bacterial antitoxin HigA from Escherichia coli at pH 8.5. Northeast Structural Genomics TARGET ER390.
5Z2W	;	3.0	;	Crystal structure of the bacterial cell division protein FtsQ and FtsB
1HF2	;	2.2	;	Crystal structure of the bacterial cell-division inhibitor MinC from T. maritima
6TJ0	;	2.2	;	Crystal structure of the bacterial cellulose secretion regulator BcsE, residues 217-523, with bound c-di-GMP.
6PCZ	;	1.44	;	Crystal structure of the bacterial cellulose synthase subunit G (BcsG) catalytic domain from Escherichia coli, selenomethionine variant
6PD0	;	1.75	;	Crystal structure of the bacterial cellulose synthase subunit G (BcsG) from Escherichia coli, catalytic domain
6IA6	;	2.7	;	Crystal structure of the bacterial Dehalococcoides mccartyi Elp3 with desulfo-CoA
4OMG	;	1.64	;	Crystal structure of the bacterial diterpene cyclase COTB2
4OMH	;	1.64	;	Crystal structure of the bacterial diterpene cyclase COTB2 variant F149L
1T16	;	2.6	;	Crystal structure of the bacterial fatty acid transporter FadL from Escherichia coli
3FGC	;	2.3	;	Crystal Structure of the Bacterial Luciferase:Flavin Complex Reveals the Basis of Intersubunit Communication
1JFX	;	1.65	;	Crystal structure of the bacterial lysozyme from Streptomyces coelicolor at 1.65 A resolution
4US3	;	2.098	;	Crystal Structure of the bacterial NSS member MhsT in an Occluded Inward-Facing State
4US4	;	2.6	;	Crystal Structure of the Bacterial NSS Member MhsT in an Occluded Inward-Facing State (lipidic cubic phase form)
8HPJ	;	3.3	;	Crystal structure of the bacterial oxalate transporter OxlT in a ligand-free outward-facing form
8HPK	;	3.0	;	Crystal structure of the bacterial oxalate transporter OxlT in an oxalate-bound occluded form
5LFJ	;	2.6	;	Crystal Structure of the Bacterial Proteasome Activator Bpa of Mycobacterium tuberculosis
5LFQ	;	3.503	;	Crystal Structure of the Bacterial Proteasome Activator Bpa of Mycobacterium tuberculosis (space group P3)
5LFP	;	3.303	;	Crystal Structure of the Bacterial Proteasome Activator Bpa of Mycobacterium tuberculosis (space group P6322, SeMet)
3BNL	;	2.602	;	Crystal structure of the bacterial ribosomal decoding A site in the presence of [Co(NH3)6]Cl3
2PWT	;	1.8	;	Crystal structure of the bacterial ribosomal decoding site complexed with aminoglycoside containing the L-HABA group
3S4P	;	2.56	;	Crystal structure of the bacterial ribosomal decoding site complexed with an amphiphilic paromomycin O2''-ether analogue
6JBF	;	2.6	;	Crystal structure of the bacterial ribosomal decoding site in complex with 4'-deoxy-4'-fluoro neamine analog (axial 4'-F)
6JBG	;	3.1	;	Crystal structure of the bacterial ribosomal decoding site in complex with 4'-deoxy-4'-fluoro neamine analog (equatorial 4'-F)
4PDQ	;	3.0	;	Crystal structure of the bacterial ribosomal decoding site in complex with 4'-deoxy-4'-fluoro neomycin analog
5Z1H	;	2.4	;	Crystal structure of the bacterial ribosomal decoding site in complex with 6'-fluoro sisomicin
4GPY	;	2.8	;	Crystal structure of the bacterial ribosomal decoding site in complex with 6'-hydroxysisomicin
7EDL	;	2.6	;	Crystal structure of the bacterial ribosomal decoding site in complex with G418 and Hg(II)
4F8U	;	2.0	;	Crystal structure of the bacterial ribosomal decoding site in complex with sisomicin (C2 form)
4F8V	;	2.8	;	Crystal structure of the bacterial ribosomal decoding site in complex with sisomicin (P21212 form)
3WRU	;	2.3	;	Crystal structure of the bacterial ribosomal decoding site in complex with synthetic aminoglycoside with F-HABA group
4V4Q	;	3.46	;	Crystal structure of the bacterial ribosome from Escherichia coli at 3.5 A resolution.
4V55	;	4.0	;	Crystal structure of the bacterial ribosome from Escherichia coli in complex with gentamicin and ribosome recycling factor (RRF).
4V53	;	3.54	;	Crystal structure of the bacterial ribosome from Escherichia coli in complex with gentamicin.
4V64	;	3.5	;	Crystal structure of the bacterial ribosome from Escherichia coli in complex with hygromycin B.
4V52	;	3.21	;	Crystal structure of the bacterial ribosome from Escherichia coli in complex with neomycin.
4V5Y	;	4.45	;	Crystal structure of the bacterial ribosome from Escherichia coli in complex with paromomycin and ribosome recycling factor (RRF).
4V54	;	3.3	;	Crystal structure of the bacterial ribosome from Escherichia coli in complex with ribosome recycling factor (RRF).
4V57	;	3.5	;	Crystal structure of the bacterial ribosome from Escherichia coli in complex with spectinomycin and neomycin.
4V56	;	3.93	;	Crystal structure of the bacterial ribosome from Escherichia coli in complex with spectinomycin.
4V4H	;	3.46	;	Crystal structure of the bacterial ribosome from Escherichia coli in complex with the antibiotic kasugamyin at 3.5A resolution.
4V97	;	3.516	;	Crystal structure of the bacterial ribosome ram mutation G299A.
4V8J	;	3.9	;	Crystal structure of the bacterial ribosome ram mutation G347U.
3M7H	;	2.2	;	Crystal structure of the bacteriocin LLPA from Pseudomonas sp.
4GC2	;	2.1201	;	Crystal structure of the bacteriocin LLPA from pseudomonas sp. in complex with GlcNAc beta(1-2)Man alpha(1-3)[GlcNAc beta(1-2)Man alpha(1-6)]Man
4GC1	;	2.0801	;	Crystal structure of the bacteriocin LLPA from pseudomonas sp. in complex with Man alpha(1-2)Man
3M7J	;	2.26	;	Crystal structure of the bacteriocin LLPA from pseudomonas sp. in complex with Met-mannose
4FZM	;	2.83	;	Crystal structure of the bacteriocin syringacin M from Pseudomonas syringae pv. tomato DC3000
4ZJN	;	1.98	;	Crystal structure of the bacteriophage G20C portal protein
4FCY	;	3.706	;	Crystal structure of the bacteriophage Mu transpososome
3QR8	;	2.03	;	Crystal structure of the bacteriophage P2 membrane-piercing protein gpV
3GQH	;	1.8	;	Crystal Structure of the Bacteriophage phi29 gene product 12 C-terminal fragment
3GQK	;	2.5	;	Crystal Structure of the Bacteriophage phi29 gene product 12 C-terminal fragment in complex with ATP
3GQ7	;	2.05	;	Crystal Structure of the Bacteriophage Phi29 Gene Product 12 N-terminal Fragment
3GQ9	;	2.0	;	Crystal Structure of the Bacteriophage phi29 gene product 12 N-terminal fragment in an apo form
3GQ8	;	2.0	;	Crystal Structure of the Bacteriophage phi29 gene product 12 N-terminal fragment in complex with 2-(N-cyclohexylamino)ethane sulfonic acid (CHES)
3GQA	;	2.1	;	Crystal Structure of the Bacteriophage phi29 gene product 12 N-terminal fragment in complex with cobalt ions
5FB5	;	3.5	;	Crystal structure of the bacteriophage phi29 tail knob protein gp9
5FB4	;	2.039	;	Crystal structure of the bacteriophage phi29 tail knob protein gp9 truncation variant
5FEI	;	2.604	;	Crystal structure of the bacteriophage phi29 tail knob protein gp9 truncation variant
3PQI	;	2.642	;	Crystal structure of the bacteriophage phi92 membrane-piercing protein gp138
3BKH	;	2.5	;	Crystal structure of the bacteriophage phiKZ lytic transglycosylase, gp144
3HEF	;	1.65	;	Crystal structure of the bacteriophage Sf6 terminase small subunit
4ZWQ	;	2.351	;	Crystal Structure of the Bacteriophage T4 recombination mediator protein UvsY, Lattice Type I
4ZWR	;	3.3857	;	Crystal Structure of the Bacteriophage T4 recombination mediator protein UvsY, Lattice Type II
4ZWS	;	2.6	;	Crystal Structure of the Bacteriophage T4 recombination mediator protein UvsY, Lattice Type III
4ZWT	;	4.2	;	Crystal Structure of the Bacteriophage T4 recombination mediator protein UvsY, Lattice Type IV
3FOA	;	3.5	;	Crystal structure of the bacteriophage T4 tail sheath protein, deletion mutant gp18M
3FO8	;	1.8	;	Crystal structure of the bacteriophage T4 tail sheath protein, protease resistant fragment gp18PR
1ZMA	;	1.25	;	Crystal Structure of the Bacterocin Transport Accessory Protein from Streptococcus pneumoniae
4V46	;	3.3	;	Crystal structure of the BAFF-BAFF-R complex
8JIX	;	1.71	;	Crystal structure of the Bagaza virus helicase and structure-based discovery of a novel inhibitor
3SOG	;	2.3	;	Crystal structure of the BAR domain of human Amphiphysin, isoform 1
4ATM	;	1.783	;	Crystal structure of the BAR domain of human Amphiphysin, isoform 1 at 1.8 Angstrom resolution featuring increased order at the N- terminus.
4NSW	;	2.2	;	Crystal structure of the BAR-PH domain of ACAP1
2ELB	;	2.6	;	Crystal Structure of the BAR-PH domain of human APPL1
3C5R	;	2.0	;	Crystal Structure of the BARD1 Ankyrin Repeat Domain and Its Functional Consequences
2NTE	;	1.9	;	Crystal Structure of the BARD1 BRCT Domains
6M14	;	1.88002	;	Crystal Structure of the BARD1 BRCT Mutant
2R1Z	;	2.1	;	Crystal Structure of the BARD1 BRCT Repeat
5DAR	;	2.9	;	CRYSTAL STRUCTURE OF THE BASE OF THE RIBOSOMAL P STALK FROM METHANOCOCCUS JANNASCHII
5D8H	;	2.8	;	CRYSTAL STRUCTURE OF THE BASE OF THE RIBOSOMAL P STALK FROM METHANOCOCCUS JANNASCHII WITH ANTIBIOTIC THIOSTREPTON
3TI9	;	1.8	;	Crystal structure of the basic protease BprB from the ovine footrot pathogen, Dichelobacter nodosus
3TI7	;	2.0	;	Crystal structure of the basic protease BprV from the ovine footrot pathogen, Dichelobacter nodosus
2QL2	;	2.5	;	Crystal Structure of the basic-helix-loop-helix domains of the heterodimer E47/NeuroD1 bound to DNA
4P1G	;	2.603	;	Crystal structure of the Bateman domain of murine magnesium transporter CNNM2 bound to AMP
4P1O	;	3.06	;	Crystal structure of the Bateman domain of murine magnesium transporter CNNM2 bound to ATP-Mg
2NYC	;	1.9	;	Crystal structure of the Bateman2 domain of yeast Snf4
2NYE	;	2.5	;	Crystal structure of the Bateman2 domain of yeast Snf4
3AYM	;	2.8	;	Crystal structure of the batho intermediate of squid rhodopsin
3EC3	;	1.92	;	Crystal structure of the bb fragment of ERp72
2H8L	;	2.0	;	Crystal structure of the bb' fragment of ERp57
2HJW	;	2.5	;	Crystal Structure of the BC domain of ACC2
3JRX	;	2.5	;	Crystal structure of the BC domain of ACC2 in complex with soraphen A
4L1G	;	2.336	;	Crystal structure of the Bc1960 peptidoglycan N-acetylglucosamine deacetylase from Bacillus cereus
5O6Y	;	2.498	;	Crystal structure of the Bc1960 peptidoglycan N-acetylglucosamine deacetylase in complex with 4-naphthalen-1-yl-~{N}-oxidanyl-benzamide
8DV4	;	2.4	;	Crystal structure of the BC8B TCR-CD1b-PI complex
1R2B	;	2.2	;	Crystal structure of the BCL6 BTB domain complexed with a SMRT co-repressor peptide
3LBZ	;	2.3	;	Crystal Structure of the BCL6 BTB domain complexed with the small molecule inhibitor 79-6
3BIM	;	2.6	;	Crystal structure of the BCL6 BTB domain dimer in complex with the BCOR BBD corepressor peptide
6TCJ	;	2.13	;	Crystal structure of the BCL6 BTB domain in complex with a hybrid BTB-binding (HBP) peptide
6TBT	;	1.63	;	Crystal structure of the BCL6 BTB domain in complex with an Apt48 peptide
6EW6	;	1.39	;	Crystal structure of the BCL6 BTB domain in complex with anilinopyrimidine ligand
6EW7	;	1.6	;	Crystal structure of the BCL6 BTB domain in complex with anilinopyrimidine ligand
6EW8	;	1.84	;	Crystal structure of the BCL6 BTB domain in complex with anilinopyrimidine ligand
5X4M	;	1.65	;	Crystal structure of the BCL6 BTB domain in complex with Compound 1
5X9O	;	1.58	;	Crystal structure of the BCL6 BTB domain in complex with Compound 1a
5X4N	;	1.94	;	Crystal structure of the BCL6 BTB domain in complex with Compound 4
5X4O	;	2.05	;	Crystal structure of the BCL6 BTB domain in complex with Compound 5
5X9P	;	1.86	;	Crystal structure of the BCL6 BTB domain in complex with Compound 5
5X4P	;	2.06	;	Crystal structure of the BCL6 BTB domain in complex with Compound 6
5X4Q	;	2.0	;	Crystal structure of the BCL6 BTB domain in complex with Compound 7
5H7G	;	1.85	;	Crystal structure of the BCL6 BTB domain in complex with F1324
5H7H	;	1.95	;	Crystal structure of the BCL6 BTB domain in complex with F1324(10-13)
7LZR	;	1.34	;	Crystal structure of the BCL6 BTB domain in complex with OICR-10256
7RV8	;	1.25	;	Crystal structure of the BCL6 BTB domain in complex with OICR-10268
7RV9	;	1.5	;	Crystal structure of the BCL6 BTB domain in complex with OICR-10269
7T0T	;	2.0	;	Crystal structure of the BCL6 BTB domain in complex with OICR-10562
7LZS	;	1.49	;	Crystal structure of the BCL6 BTB domain in complex with OICR-11029
7T0S	;	1.86	;	Crystal structure of the BCL6 BTB domain in complex with OICR-11864
7T0U	;	1.49	;	Crystal structure of the BCL6 BTB domain in complex with OICR-12387
7LWG	;	1.3	;	Crystal structure of the BCL6 BTB domain in complex with OICR-12694
7LZQ	;	1.71	;	Crystal structure of the BCL6 BTB domain in complex with OICR-4425
7LWE	;	1.17	;	Crystal structure of the BCL6 BTB domain in complex with OICR-7629
7RUW	;	1.3	;	Crystal structure of the BCL6 BTB domain in complex with OICR-7859
7RUX	;	1.3	;	Crystal structure of the BCL6 BTB domain in complex with OICR-8311
7RUY	;	1.27	;	Crystal structure of the BCL6 BTB domain in complex with OICR-8388
7RUZ	;	1.62	;	Crystal structure of the BCL6 BTB domain in complex with OICR-8445
7RV0	;	1.45	;	Crystal structure of the BCL6 BTB domain in complex with OICR-8446
7RV1	;	1.17	;	Crystal structure of the BCL6 BTB domain in complex with OICR-8826
7RV2	;	1.29	;	Crystal structure of the BCL6 BTB domain in complex with OICR-8828
7RV3	;	1.35	;	Crystal structure of the BCL6 BTB domain in complex with OICR-9124
7RV4	;	1.25	;	Crystal structure of the BCL6 BTB domain in complex with OICR-9153
7RV5	;	2.21	;	Crystal structure of the BCL6 BTB domain in complex with OICR-9287
7RV6	;	1.683	;	Crystal structure of the BCL6 BTB domain in complex with OICR-9288
7LWF	;	1.22	;	Crystal structure of the BCL6 BTB domain in complex with OICR-9320
7RV7	;	1.63	;	Crystal structure of the BCL6 BTB domain in complex with OICR-9322
5N1X	;	1.72	;	Crystal structure of the BCL6 BTB domain in complex with pyrazolo-pyrimidine ligand
5N20	;	1.38	;	Crystal structure of the BCL6 BTB domain in complex with pyrazolo-pyrimidine ligand
5N21	;	1.58	;	Crystal structure of the BCL6 BTB domain in complex with pyrazolo-pyrimidine ligand
5N1Z	;	1.81	;	Crystal structure of the BCL6 BTB domain in complex with pyrazolo-pyrimidine macrocyclic ligand
6XYX	;	1.44	;	Crystal structure of the BCL6 BTB domain in complex with the NCoR1 BBD corepressor peptide
6XZZ	;	1.39	;	Crystal structure of the BCL6 BTB domain in complex with the NCoR1 BBD2 peptide
5MW6	;	1.65	;	Crystal structure of the BCL6 BTB-domain with compound 1
5MWD	;	1.85	;	Crystal structure of the BCL6 BTB-domain with compound 2
6ZTD	;	3.43	;	Crystal structure of the BCR Fab fragment from subset #169 case P6540
5IFH	;	2.293	;	Crystal structure of the BCR Fab fragment from subset #2 case P11475
5DRW	;	2.27	;	Crystal structure of the BCR Fab fragment from subset #4 case CLL183
5DRX	;	2.104	;	Crystal structure of the BCR Fab fragment from subset #4 case CLL240
3P04	;	2.2	;	Crystal Structure of the BCR protein from Corynebacterium glutamicum. Northeast Structural Genomics Consortium Target CgR8
7UXS	;	1.57	;	Crystal structure of the BcThsA SLOG domain in complex with 3'cADPR
5JNO	;	2.2	;	Crystal structure of the BD1-NTPR complex from BEND3 and PICH
5C7Q	;	1.52	;	Crystal Structure of the Bdellovibrio bacteriovorus Nucleoside Diphosphate Sugar Hydrolase
5C8L	;	1.8	;	Crystal Structure of the Bdellovibrio bacteriovorus Nucleoside Diphosphate Sugar Hydrolase
5C7T	;	2.06	;	Crystal Structure of the Bdellovibrio bacteriovorus Nucleoside Diphosphate Sugar Hydrolase in complex with ADP-ribose
6FMB	;	1.3	;	Crystal structure of the BEC1054 RNase-like effector from the fungal pathogen Blumeria graminis
1XHF	;	2.152	;	Crystal structure of the bef3-activated receiver domain of redox response regulator arca
2V3W	;	2.2	;	Crystal structure of the benzoylformate decarboxylase variant L461A from Pseudomonas putida
2HXC	;	1.45	;	Crystal structure of the benzylamine complex of aromatic amine dehydrogenase in N-semiquinone form
1XA7	;	2.4	;	Crystal structure of the benzylpenicillin-acylated BlaR1 sensor domain from Staphylococcus aureus
2GVR	;	1.65	;	Crystal structure of the berenil-D(CGCGAATTCGCG)2 complex at 1.65 A resolution.
5HEV	;	3.192	;	Crystal Structure of the beryllofluoride-activated LiaR from Enterococcus faecium
2C0J	;	2.2	;	Crystal structure of the bet3-trs33 heterodimer
4RXY	;	1.901	;	Crystal Structure of the Beta Carbonic Anhydrase psCA3 isolated from Pseudomonas aeruginosa
5JJ8	;	2.585	;	Crystal Structure of the Beta Carbonic Anhydrase psCA3 isolated from Pseudomonas aeruginosa - alternate crystal packing form
3QQ2	;	3.0	;	Crystal Structure of the Beta Domain of the Bordetella Autotransporter Brka
2H6J	;	3.2	;	Crystal Structure of the Beta F145A Rhodococcus Proteasome
2DTU	;	2.37	;	Crystal structure of the beta hairpin loop deletion variant of RB69 gp43 in complex with DNA containing an abasic site analog
6NI1	;	1.9	;	Crystal Structure of the Beta Lactamase Class A penP from Bacillus subtilis
6W2Z	;	1.5	;	Crystal Structure of the Beta Lactamase Class A PenP from Bacillus subtilis in the Complex with the Non-beta- lactam Beta-lactamase Inhibitor Avibactam
7K3M	;	1.8	;	Crystal Structure of the Beta Lactamase Class D from Chitinophaga pinensis by Serial Crystallography
6NHU	;	2.3	;	Crystal Structure of the Beta Lactamase Class D YbxI from Agrobacterium fabrum
6NI0	;	2.3	;	Crystal Structure of the Beta Lactamase Class D YbxI from Burkholderia thailandensis
6NHS	;	2.0	;	Crystal Structure of the Beta Lactamase Class D YbXI from Nostoc
2AVT	;	2.0	;	Crystal structure of the beta subunit from DNA polymerase of Streptococcus pyogenes
3EBY	;	1.75	;	Crystal structure of the beta subunit of a putative aromatic-ring-hydroxylating dioxygenase (YP_001165631.1) from NOVOSPHINGOBIUM AROMATICIVORANS DSM 12444 at 1.75 A resolution
6P57	;	3.16	;	Crystal Structure of the Beta Subunit of Luteinizing Hormone
3E99	;	1.9	;	Crystal structure of the beta subunit of the benzoate 1,2-dioxygenase (benb, bmaa0186) from burkholderia mallei atcc 23344 at 1.90 A resolution
3TM6	;	2.7	;	Crystal structure of the beta-2 microglobulin DIMC50 disulphide-linked homodimer mutant
3VP7	;	2.3	;	Crystal structure of the beta-alpha repeated, autophagy-specific (BARA) domain of Vps30/Atg6
3FC3	;	1.75	;	Crystal structure of the beta-beta-alpha-Me type II restriction endonuclease Hpy99I
3GOX	;	1.5	;	Crystal structure of the beta-beta-alpha-Me type II restriction endonuclease Hpy99I in the absence of EDTA
1LUJ	;	2.5	;	Crystal Structure of the Beta-catenin/ICAT Complex
2ASU	;	1.85	;	Crystal Structure of the beta-chain of HGFl/MSP
3E66	;	2.05	;	Crystal structure of the beta-finger domain of yeast Prp8
6JFP	;	2.7	;	Crystal structure of the beta-glucosidase Bgl15
5BWF	;	2.6	;	Crystal structure of the beta-glucosidase from Trichoderma harzianum
1QVB	;	2.4	;	CRYSTAL STRUCTURE OF THE BETA-GLYCOSIDASE FROM THE HYPERTHERMOPHILE THERMOSPHAERA AGGREGANS
6QKB	;	1.701	;	Crystal structure of the beta-hydroxyaspartate aldolase of Paracoccus denitrificans
3O04	;	1.85	;	Crystal structure of the beta-keto-acyl carrier protein synthase II (lmo2201) from Listeria monocytogenes
8EP6	;	1.5	;	Crystal Structure of the Beta-lactamase Class D from Chitinophaga pinensis in complex with Avibactam
5ODZ	;	2.07	;	CRYSTAL STRUCTURE OF THE BETA-LACTAMASE OXA-163
5OE0	;	2.05001	;	CRYSTAL STRUCTURE OF THE BETA-LACTAMASE OXA-181
5OE2	;	2.2	;	CRYSTAL STRUCTURE OF THE BETA-LACTAMASE OXA-245
3WO8	;	2.43	;	Crystal structure of the beta-N-acetylglucosaminidase from Thermotoga maritima
4AWD	;	2.4	;	Crystal structure of the beta-porphyranase BpGH16B (BACPLE_01689) from the human gut bacterium Bacteroides plebeius
1K7X	;	1.7	;	CRYSTAL STRUCTURE OF THE BETA-SER178PRO MUTANT OF TRYPTOPHAN SYNTHASE
5MU7	;	2.57	;	Crystal Structure of the beta/delta-COPI Core Complex
3SN6	;	3.2	;	Crystal structure of the beta2 adrenergic receptor-Gs protein complex
8A5U	;	2.4	;	Crystal structure of the beta3 subunit extracellular domain of nicotinic acetylcholine receptor
5CEZ	;	3.031	;	Crystal Structure of the BG505 SOSIP gp140 HIV-1 Env trimer in Complex with an early putative precursor of the PGT121 family at 3.0 Angstrom
4NCO	;	4.7	;	Crystal Structure of the BG505 SOSIP gp140 HIV-1 Env trimer in Complex with the Broadly Neutralizing Fab PGT122
5D9Q	;	4.4	;	Crystal Structure of the BG505 SOSIP gp140 HIV-1 Env trimer in Complex with the Broadly Neutralizing Fab PGT122 and scFv NIH45-46
1F7C	;	2.4	;	CRYSTAL STRUCTURE OF THE BH DOMAIN FROM GRAF, THE GTPASE REGULATOR ASSOCIATED WITH FOCAL ADHESION KINASE
2PUY	;	1.43	;	Crystal Structure of the BHC80 PHD finger
2GKS	;	2.31	;	Crystal Structure of the Bi-functional ATP Sulfurylase-APS Kinase from Aquifex aeolicus, a Chemolithotrophic Thermophile
4YK1	;	2.1	;	Crystal Structure of the BID Domain of Bep6 from Bartonella rochalimae
4YK2	;	2.05	;	Crystal Structure of the BID Domain of Bep9 from Bartonella clarridgeiae
4YK3	;	2.2	;	Crystal Structure of the BID Domain of BepE from Bartonella henselae
1VJ7	;	2.1	;	Crystal structure of the bifunctional catalytic fragment of RelSeq, the RelA/SpoT homolog from Streptococcus equisimilis.
1R52	;	2.89	;	Crystal structure of the bifunctional chorismate synthase from Saccharomyces cerevisiae
1R53	;	2.2	;	Crystal structure of the bifunctional chorismate synthase from Saccharomyces cerevisiae
1B1U	;	2.2	;	CRYSTAL STRUCTURE OF THE BIFUNCTIONAL INHIBITOR RAGI
7OCN	;	2.6	;	Crystal structure of the bifunctional mannitol-1-phosphate dehydrogenase/phosphatase MtlD from Acinetobacter baumannii
1VZW	;	1.8	;	Crystal structure of the bifunctional protein Pria
1K9B	;	2.8	;	Crystal structure of the bifunctional soybean Bowman-Birk inhibitor at 0.28 nm resolution. Structural peculiarities in a folded protein conformation
2FT3	;	3.4	;	Crystal structure of the biglycan dimer core protein
7A1I	;	1.87	;	Crystal structure of the BILBO2/FPC4 complex
4XXI	;	2.2	;	Crystal structure of the Bilin-binding domain of phycobilisome core-membrane linker ApcE
5NHW	;	1.78	;	CRYSTAL STRUCTURE OF THE BIMAGRUMAB Fab
4FIZ	;	1.9	;	Crystal structure of the binary complex between a fungal 17beta-hydroxysteroid dehydrogenase (Apo form) and coumestrol
2PUK	;	3.0	;	Crystal structure of the binary complex between ferredoxin: thioredoxin reductase and thioredoxin m
3GSO	;	1.6	;	Crystal structure of the binary complex between HLA-A2 and HCMV NLV peptide
3GSV	;	1.9	;	Crystal structure of the binary complex between HLA-A2 and HCMV NLV-M5Q peptide variant
3GSQ	;	2.12	;	Crystal structure of the binary complex between HLA-A2 and HCMV NLV-M5S peptide variant
3GSU	;	1.8	;	Crystal structure of the binary complex between HLA-A2 and HCMV NLV-M5T peptide variant
3GSR	;	1.95	;	Crystal structure of the binary complex between HLA-A2 and HCMV NLV-M5V peptide variant
3GSW	;	1.81	;	Crystal structure of the binary complex between HLA-A2 and HCMV NLV-T8A peptide variant
3GSX	;	2.1	;	Crystal structure of the binary complex between HLA-A2 and HCMV NLV-T8V peptide variant
6LRH	;	2.7051	;	Crystal Structure of the Binary Complex of AgrE C264A mutant with L-arginine
2FZE	;	1.9	;	Crystal structure of the binary complex of human glutathione-dependent formaldehyde dehydrogenase with ADP-ribose
4HDO	;	1.67	;	Crystal structure of the binary Complex of KRIT1 bound to the Rap1 GTPase
3QV1	;	2.0	;	Crystal structure of the binary complex of photosyntetic A4 glyceraldehyde 3-phosphate dehydrogenase (GAPDH) with cp12-2, both from Arabidopsis thaliana.
3GP8	;	2.5	;	Crystal structure of the binary complex of RecD2 with DNA
1RUS	;	2.9	;	CRYSTAL STRUCTURE OF THE BINARY COMPLEX OF RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE AND ITS PRODUCT, 3-PHOSPHO-D-GLYCERATE
3RVD	;	2.7	;	Crystal structure of the binary complex, obtained by soaking, of photosyntetic a4 glyceraldehyde 3-phosphate dehydrogenase (gapdh) with cp12-2, both from arabidopsis thaliana.
1P0F	;	1.8	;	Crystal Structure of the Binary Complex: NADP(H)-Dependent Vertebrate Alcohol Dehydrogenase (ADH8) with the cofactor NADP
6ES1	;	2.0	;	Crystal structure of the binding domain from botulinum neurotoxin A2 bound to extracellular domain of human receptor SV2C
6G5K	;	2.0	;	Crystal structure of the binding domain of Botulinum Neurotoxin type B in complex with human synaptotagmin 1
6QNS	;	2.4	;	Crystal structure of the binding domain of Botulinum Neurotoxin type B mutant I1248W/V1249W in complex with human synaptotagmin 1 and GD1a receptors
6HOX	;	1.95	;	Crystal structure of the binding domain of Paraclostridial Mosquitocidal Protein 1
5GPD	;	3.501	;	Crystal structure of the binding domain of SREBP from fission yeast
3DP6	;	1.55	;	Crystal structure of the binding domain of the AMPA subunit GluR2 bound to glutamate
3H06	;	2.8	;	Crystal structure of the binding domain of the AMPA subunit GluR2 bound to the willardiine antagonist, UBP282
3H03	;	1.9	;	Crystal structure of the binding domain of the AMPA subunit GluR2 bound to UBP277
3DP4	;	2.11	;	Crystal structure of the binding domain of the AMPA subunit GluR3 bound to AMPA
3DLN	;	1.91	;	Crystal structure of the binding domain of the AMPA subunit GluR3 bound to glutamate
2B4L	;	2.0	;	Crystal structure of the binding protein OpuAC in complex with glycine betaine
2B4M	;	2.8	;	Crystal structure of the binding protein OpuAC in complex with proline betaine
1D3V	;	1.7	;	CRYSTAL STRUCTURE OF THE BINUCLEAR MANGANESE METALLOENZYME ARGINASE COMPLEXED WITH 2(S)-AMINO-6-BORONOHEXANOIC ACID, AN L-ARGININE ANALOG
1HQF	;	2.9	;	CRYSTAL STRUCTURE OF THE BINUCLEAR MANGANESE METALLOENZYME ARGINASE COMPLEXED WITH N-HYDROXY-L-ARGININE
1HQH	;	2.8	;	CRYSTAL STRUCTURE OF THE BINUCLEAR MANGANESE METALLOENZYME ARGINASE COMPLEXED WITH NOR-N-HYDROXY-L-ARGININE
1HQ5	;	2.3	;	CRYSTAL STRUCTURE OF THE BINUCLEAR MANGANESE METALLOENZYME ARGINASE COMPLEXED WITH S-(2-BORONOETHYL)-L-CYSTEINE, AN L-ARGININE ANALOGUE
3QS3	;	2.1	;	Crystal structure of the biofilm forming subunit of the E. coli common pilus: donor strand complemented (DSC) EcpA
3QS2	;	1.78	;	Crystal structure of the biofilm forming subunit of the E. coli common pilus: full length domain swapped dimer of EcpA
3NZP	;	3.0	;	Crystal Structure of the Biosynthetic Arginine decarboxylase SpeA from Campylobacter jejuni, Northeast Structural Genomics Consortium Target BR53
2DZD	;	2.4	;	Crystal structure of the biotin carboxylase domain of pyruvate carboxylase
1ULZ	;	2.2	;	Crystal structure of the biotin carboxylase subunit of pyruvate carboxylase
2GPS	;	2.8	;	Crystal Structure of the Biotin Carboxylase Subunit, E23R mutant, of Acetyl-CoA Carboxylase from Escherichia coli.
3G8D	;	1.9	;	Crystal structure of the biotin carboxylase subunit, E296A mutant, of acetyl-COA carboxylase from Escherichia coli
2GPW	;	2.2	;	Crystal Structure of the Biotin Carboxylase Subunit, F363A Mutant, of Acetyl-CoA Carboxylase from Escherichia coli.
2EJG	;	2.71	;	Crystal Structure Of The Biotin Protein Ligase (Mutation R48A) and Biotin Carboxyl Carrier Protein Complex From Pyrococcus Horikoshii OT3
2EJF	;	2.0	;	Crystal Structure Of The Biotin Protein Ligase (Mutations R48A and K111A) and Biotin Carboxyl Carrier Protein Complex From Pyrococcus Horikoshii OT3
6HA7	;	2.49	;	Crystal structure of the BiP NBD and MANF complex
6H9U	;	1.57	;	Crystal structure of the BiP NBD and MANF SAP complex
3GZY	;	1.62	;	Crystal Structure of the Biphenyl Dioxygenase from Comamonas testosteroni Sp. Strain B-356
3GZX	;	1.58	;	Crystal Structure of the Biphenyl Dioxygenase in complex with Biphenyl from Comamonas testosteroni Sp. Strain B-356
1HAN	;	1.9	;	CRYSTAL STRUCTURE OF THE BIPHENYL-CLEAVING EXTRADIOL DIOXYGENASE FROM A PCB-DEGRADING PSEUDOMONAD
8PEI	;	3.0	;	Crystal structure of the biphotochromic fluorescent protein SAASoti (C21N/V127T variant) in its green on-state
6Q82	;	2.994	;	Crystal structure of the biportin Pdr6 in complex with RanGTP
6Q83	;	4.53	;	Crystal structure of the biportin Pdr6 in complex with UBC9
3UW5	;	1.71	;	Crystal structure of the BIR domain of MLIAP bound to GDC0152
6FG7	;	1.9	;	Crystal structure of the BIR2 ectodomain from Arabidopsis thaliana.
6FG8	;	1.25	;	Crystal structure of the BIR3 - SERK1 complex from Arabidopsis thaliana.
6G3W	;	2.2	;	Crystal structure of the BIR3 - SERK2 complex from Arabidopsis thaliana.
1FM4	;	1.97	;	CRYSTAL STRUCTURE OF THE BIRCH POLLEN ALLERGEN BET V 1L
1XSD	;	2.7	;	Crystal structure of the BlaI repressor in complex with DNA
7KW6	;	1.68	;	Crystal structure of the BlCel48B from Bacillus licheniformis
4CGZ	;	3.2	;	Crystal structure of the Bloom's syndrome helicase BLM in complex with DNA
4CDG	;	2.794	;	Crystal structure of the Bloom's syndrome helicase BLM in complex with Nanobody
1FL3	;	2.45	;	CRYSTAL STRUCTURE OF THE BLUE FLUORESCENT ANTIBODY (19G2) IN COMPLEX WITH STILBENE HAPTEN AT 277K
6JC5	;	2.051	;	Crystal structure of the blue fluorescent protein with a Leu-Leu-Gly tri-peptide chromophore derived from the purple chromoprotein of Stichodactyla haddoni
4FOF	;	2.416	;	Crystal Structure of the blue-light absorbing form of the Thermosynechococcus elongatus PixJ GAF-domain
4GLQ	;	1.772	;	Crystal Structure of the blue-light absorbing form of the Thermosynechococcus elongatus PixJ GAF-domain
1LX5	;	3.3	;	Crystal Structure of the BMP7/ActRII Extracellular Domain Complex
3PUB	;	1.91	;	Crystal structure of the Bombyx mori low molecular weight lipoprotein 7 (Bmlp7)
4D25	;	1.9	;	Crystal structure of the Bombyx mori Vasa helicase (E339Q) in complex with RNA and AMPPNP
4D26	;	2.1	;	Crystal structure of the Bombyx mori Vasa helicase (E339Q) in complex with RNA,ADP and Pi
7U5O	;	3.45	;	CRYSTAL STRUCTURE OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE 2 LIGAND BINDING DOMAIN IN COMPLEX WITH ACTIVIN-B
5MOY	;	2.302	;	Crystal structure of the BoNT/A2 receptor-binding domain in complex with the luminal domain of its neuronal receptor SV2C
2PZJ	;	1.9	;	Crystal structure of the Bordetella bronchiseptica enzyme WbmF in complex with NAD+
2Q1T	;	1.75	;	Crystal structure of the Bordetella bronchiseptica enzyme WbmF in complex with NAD+ and UDP
2Q1U	;	1.7	;	Crystal structure of the Bordetella bronchiseptica enzyme WbmF in complex with NAD+ and UDP
2Q1S	;	1.5	;	Crystal structure of the Bordetella bronchiseptica enzyme WbmF in complex with NADH
2PZK	;	2.1	;	Crystal structure of the Bordetella bronchiseptica enzyme WbmG in complex with NAD
2PZL	;	2.39	;	Crystal structure of the Bordetella bronchiseptica enzyme WbmG in complex with NAD and UDP
2PZM	;	2.0	;	Crystal structure of the Bordetella bronchiseptica enzyme WbmG in complex with NAD and UDP
2Q1W	;	2.19	;	Crystal structure of the Bordetella bronchiseptica enzyme WbmH in complex with NAD+
2RAW	;	2.4	;	Crystal structure of the Borealin-Survivin complex
3F1J	;	2.65	;	Crystal structure of the Borna disease virus matrix protein (BDV-M) reveals RNA binding properties
1N93	;	1.76	;	Crystal Structure of the Borna Disease Virus Nucleoprotein
1PP1	;	1.9	;	Crystal structure of the Borna Disease Virus Nucleoprotein
7MIE	;	1.6	;	Crystal structure of the Borreliella burgdorferi PlzA protein in complex with c-di-GMP
2H8I	;	1.9	;	Crystal Structure of the Bothropstoxin-I complexed with polyethylene glycol
4JRA	;	2.3	;	CRYSTAL STRUCTURE OF THE BOTULINUM NEUROTOXIN A RECEPTOR-BINDING DOMAIN IN COMPLEX WITH THE LUMINAL DOMAIN Of SV2C
2VUA	;	1.7	;	Crystal Structure of the Botulinum Neurotoxin Serotype A binding domain
2VXR	;	1.9	;	Crystal Structure of the Botulinum Neurotoxin serotype G binding domain
2NP0	;	2.62	;	Crystal structure of the Botulinum neurotoxin type B complexed with synaptotagamin-II ectodomain
1FGX	;	2.4	;	CRYSTAL STRUCTURE OF THE BOVINE BETA 1,4 GALACTOSYLTRANSFERASE (B4GALT1) CATALYTIC DOMAIN COMPLEXED WITH UMP
1FR8	;	2.4	;	CRYSTAL STRUCTURE OF THE BOVINE BETA 1,4 GALACTOSYLTRANSFERASE (B4GALT1) CATALYTIC DOMAIN COMPLEXED WITH URIDINE DIPHOSPHOGALACTOSE
1G93	;	2.5	;	CRYSTAL STRUCTURE OF THE BOVINE CATALYTIC DOMAIN OF ALPHA-1,3-GALACTOSYLTRANSFERASE IN THE PRESENCE OF UDP-GALACTOSE
4YB9	;	3.2	;	Crystal structure of the Bovine Fructose transporter GLUT5 in an open inward-facing conformation
2PQS	;	2.4	;	Crystal Structure of the Bovine Lactadherin C2 Domain
3A7U	;	3.44	;	Crystal structure of the bovine lipoyltransferase in its unliganded form
1G4I	;	0.97	;	Crystal structure of the bovine pancreatic phospholipase A2 at 0.97A
1OX1	;	2.0	;	crystal structure of the bovine trypsin complex with a synthetic 11 peptide inhibitor
2ILN	;	2.0	;	Crystal structure of the Bowman-Birk inhibitor from snail medic seeds in complex with bovine trypsin
2G81	;	1.55	;	Crystal Structure of the Bowman-Birk Inhibitor from Vigna unguiculata Seeds in Complex with Beta-trypsin at 1.55 Angstrons Resolution
3RU4	;	1.68	;	Crystal structure of the Bowman-Birk serine protease inhibitor BTCI in complex with trypsin and chymotrypsin
8AG2	;	1.025	;	Crystal structure of the BPTF bromodomain in complex with BI-7190
6AZE	;	2.451	;	Crystal Structure of the BPTF PHD-bromodomain module bound to H3KC4me3 methyl lysine analog
1EJM	;	1.85	;	CRYSTAL STRUCTURE OF THE BPTI ALA16LEU MUTANT IN COMPLEX WITH BOVINE TRYPSIN
4RZV	;	2.994	;	Crystal structure of the BRAF (R509H) kinase domain monomer bound to Vemurafenib
4MNE	;	2.8483	;	Crystal structure of the BRAF:MEK1 complex
6V2W	;	3.12	;	Crystal structure of the BRAF:MEK1 kinases in complex with AMPPNP
7M0U	;	3.09	;	Crystal structure of the BRAF:MEK1 kinases in complex with AMPPNP and Binimetinib
7M0Z	;	3.12	;	Crystal structure of the BRAF:MEK1 kinases in complex with AMPPNP and CH5126766
7M0V	;	3.16	;	Crystal structure of the BRAF:MEK1 kinases in complex with AMPPNP and Cobimetinib
7M0X	;	2.47	;	Crystal structure of the BRAF:MEK1 kinases in complex with AMPPNP and PD0325901
7M0W	;	3.09	;	Crystal structure of the BRAF:MEK1 kinases in complex with AMPPNP and Pimasertib
7M0T	;	3.19	;	Crystal structure of the BRAF:MEK1 kinases in complex with AMPPNP and Selumetinib
7M0Y	;	3.45	;	Crystal structure of the BRAF:MEK1 kinases in complex with AMPPNP and Trametinib
4DQN	;	1.97	;	Crystal structure of the branched-chain aminotransferase from Streptococcus mutans
5XNF	;	1.9	;	Crystal structure of the branched-chain polyamine synthase (BpsA) from Thermococcus kodakarensis
5XNC	;	1.84	;	Crystal structure of the branched-chain polyamine synthase (BpsA) in complex with N4-aminopropylspermidine and 5-methylthioadenosine
5XNH	;	1.95	;	Crystal structure of the branched-chain polyamine synthase (BpsA) in complex with spermidine
6J28	;	1.9	;	Crystal structure of the branched-chain polyamine synthase C9 mutein from Thermus thermophilus (Tth-BpsA C9) in complex with N4-aminopropylspermidine and 5'-methylthioadenosine
6J26	;	2.0	;	Crystal structure of the branched-chain polyamine synthase from Thermococcus kodakarensis (Tk-BpsA) in complex with N4-bis(aminopropyl)spermidine and 5'-methylthioadenosine
6J27	;	1.66	;	Crystal structure of the branched-chain polyamine synthase from Thermus thermophilus (Tth-BpsA) in complex with N4-aminopropylspermidine and 5'-methylthioadenosine
6H65	;	2.35	;	Crystal structure of the branched-chain-amino-acid aminotransferase from Haliangium ochraceum
3FA2	;	2.2	;	Crystal Structure of the BRCA1 Associated Ring Domain (BARD1) Tandem BRCT Domains
1T15	;	1.85	;	Crystal Structure of the Brca1 BRCT Domains in Complex with the Phosphorylated Interacting Region from Bach1 Helicase
1T29	;	2.3	;	Crystal structure of the BRCA1 BRCT repeats bound to a phosphorylated BACH1 peptide
6GVW	;	3.75	;	Crystal structure of the BRCA1-A complex
4ID3	;	1.9669	;	Crystal Structure of the BRCT domain of S. Cerevisiae Rev1
5UMV	;	1.75	;	Crystal structure of the BRCT domain of S. cerevisiae Rev1
5ECG	;	3.0	;	Crystal structure of the BRCT domains of 53BP1 in complex with p53 and H2AX-pSer139 (gammaH2AX)
1GZH	;	2.6	;	Crystal structure of the BRCT domains of human 53BP1 bound to the p53 tumor supressor
3COJ	;	3.21	;	Crystal Structure of the BRCT Domains of Human BRCA1 in Complex with a Phosphorylated Peptide from Human Acetyl-CoA Carboxylase 1
1JNX	;	2.5	;	Crystal structure of the BRCT repeat region from the breast cancer associated protein, BRCA1
2ADO	;	1.45	;	Crystal Structure Of The Brct Repeat Region From The Mediator of DNA damage checkpoint protein 1, MDC1
7UU0	;	1.3	;	Crystal structure of the BRD2-BD2 in complex with a ligand
5XHK	;	1.28	;	Crystal structure of the BRD2-BD2 in complex with phenanthridinone
4ZC9	;	0.99	;	Crystal Structure of the BRD4a/DB-2-190 complex
5MQ1	;	1.5	;	Crystal structure of the BRD7 bromodomain in complex with BI-9564
5F1H	;	1.82	;	Crystal structure of the BRD9 bromodamian in complex with BI-9564.
5JI8	;	1.42	;	Crystal structure of the BRD9 bromodomain and hit 1
5F2P	;	1.8	;	Crystal structure of the BRD9 bromodomain in complex with compound 3.
5F25	;	1.68	;	Crystal structure of the BRD9 bromodomain in complex with compound 4.
8AHC	;	1.504	;	Crystal structure of the BRD9 bromodomain with BI-7189
3O24	;	2.5	;	Crystal structure of the brevianamide F prenyltransferase FtmPT1 from Aspergillus fumigatus
6FIF	;	2.54	;	Crystal structure of the BRI1 Gly644-Asp (bri1-6) mutant from Arabidopsis thaliana.
5LPB	;	1.98	;	Crystal structure of the BRI1 kinase domain (865-1160) in complex with ADP from Arabidopsis thaliana
5LPV	;	2.7	;	Crystal structure of the BRI1 kinase domain (865-1160) in complex with AMPPNP and Mn from Arabidopsis thaliana
5LPY	;	2.3	;	Crystal structure of the BRI1 kinase domain (865-1160) in complex with ATP from Arabidopsis thaliana
5LPZ	;	2.48	;	Crystal structure of the BRI1 kinase domain (865-1196) in complex with ADP from Arabidopsis thaliana
2IHC	;	2.44	;	Crystal structure of the bric-a-brac (BTB) domain of human BACH1
6XW2	;	1.75	;	Crystal structure of the bright genetically encoded calcium indicator NCaMP7 based on mNeonGreen fluorescent protein
2XUS	;	1.912	;	Crystal Structure of the BRMS1 N-terminal region
4AUV	;	1.999	;	Crystal Structure of the BRMS1 N-terminal region
5CRU	;	2.4	;	Crystal structure of the Bro domain of HD-PTP
5CRV	;	2.001	;	Crystal structure of the Bro domain of HD-PTP in a complex with the core region of STAM2
4WB0	;	1.91	;	Crystal structure of the broad specificity aminotransferase from Leishmania mexicana
1RHH	;	1.9	;	Crystal Structure of the Broadly HIV-1 Neutralizing Fab X5 at 1.90 Angstrom Resolution
1U6A	;	2.81	;	Crystal Structure of the Broadly Neutralizing Anti-HIV Fab F105
1TJH	;	2.1	;	Crystal Structure of the broadly neutralizing anti-HIV-1 antibody 2F5 in complex with a gp41 11mer epitope
1TJI	;	2.2	;	Crystal Structure of the broadly neutralizing anti-HIV-1 antibody 2F5 in complex with a gp41 17mer epitope
1TJG	;	2.0	;	Crystal Structure of the broadly neutralizing anti-HIV-1 antibody 2F5 in complex with a gp41 7mer epitope
6OZ2	;	2.55	;	Crystal structure of the broadly neutralizing antibody N49P6 Fab in complex with HIV-1 Clade A/E strain 93TH057 gp120 core.
5WCC	;	2.461	;	Crystal structure of the broadly neutralizing Influenza A antibody VRC 315 02-1F07 Fab.
5WCD	;	1.814	;	Crystal structure of the broadly neutralizing Influenza A antibody VRC 315 04-1D02 Fab.
5TY6	;	1.361	;	Crystal structure of the broadly neutralizing Influenza A antibody VRC 315 13-1b02 Fab.
5WCA	;	1.369	;	Crystal structure of the broadly neutralizing Influenza A antibody VRC 315 27-1C08 Fab.
5U4R	;	1.762	;	Crystal structure of the broadly neutralizing Influenza A antibody VRC 315 53-1A09 Fab.
2XA3	;	1.5	;	crystal structure of the broadly neutralizing llama VHH D7 and its mode of HIV-1 gp120 interaction
3SVH	;	1.8	;	Crystal Structure of the bromdomain of human CREBBP in complex with a 3,5-dimethylisoxazol ligand
1N9K	;	2.2	;	Crystal structure of the bromide adduct of AphA class B acid phosphatase/phosphotransferase from E. coli at 2.2 A resolution
3QXR	;	1.62	;	Crystal structure of the brominated CKIT-1 proto-oncogene promoter quadruplex DNA
2OSS	;	1.35	;	Crystal structure of the Bromo domain 1 in human Bromodomain Containing Protein 4 (BRD4)
2RFJ	;	2.05	;	Crystal structure of the bromo domain 1 in human bromodomain containing protein, testis specific (BRDT)
2OUO	;	1.89	;	Crystal Structure of the Bromo domain 2 in human Bromodomain Containing Protein 4 (BRD4)
2OO1	;	1.7	;	Crystal structure of the Bromo domain 2 of human Bromodomain containing protein 3 (BRD3)
4N4G	;	1.947	;	Crystal structure of the Bromo-PWWP of the mouse zinc finger MYND-type containing 11 isoform alpha
4N4H	;	2.302	;	Crystal structure of the Bromo-PWWP of the mouse zinc finger MYND-type containing 11 isoform alpha in complex with histone H3.1K36me3
4N4I	;	1.999	;	Crystal structure of the Bromo-PWWP of the mouse zinc finger MYND-type containing 11 isoform alpha in complex with histone H3.3K36me3
7K6S	;	1.23	;	Crystal structure of the bromodomain (BD) of human Bromodomain and PHD finger-containing Transcription Factor (BPTF) bound to Compound 4 (SKT1174)
7KDW	;	1.71	;	Crystal structure of the bromodomain (BD) of human Bromodomain and PHD finger-containing Transcription Factor (BPTF) bound to Compound 6 (HZ01052)
7K6R	;	1.6	;	Crystal structure of the bromodomain (BD) of human Bromodomain and PHD finger-containing Transcription Factor (BPTF) bound to GSK4027
7KDZ	;	1.54	;	Crystal structure of the bromodomain (BD) of human Bromodomain and PHD finger-containing Transcription Factor (BPTF) bound to TP-238
3JVJ	;	1.55	;	Crystal structure of the bromodomain 1 in mouse Brd4
7M97	;	2.0	;	Crystal structure of the bromodomain from Plasmodium falciparum bromodomain protein 1
7Q6T	;	2.05	;	Crystal structure of the bromodomain of ATAD2 with AZ13824374
7Q6U	;	1.95	;	Crystal structure of the bromodomain of ATAD2 with phenol HTS hit (cpd 6)
7Q6W	;	1.96	;	Crystal structure of the bromodomain of ATAD2 with triazolopyridazine (cpd 22)
7Q6V	;	1.96	;	Crystal structure of the bromodomain of ATAD2 with triazolopyridine (cpd 14)
4XY8	;	1.7	;	Crystal Structure of the bromodomain of BRD9 in complex with a 2-amine-9H-purine ligand
5F1L	;	2.3	;	Crystal structure of the bromodomain of BRD9 in complex with compound 9.
5CUA	;	1.89	;	Crystal structure of the bromodomain of bromodomain adjacent to zinc finger domain protein 2B (BAZ2B) in complex with 1-Acetyl-4-(4-hydroxyphenyl)piperazine (SGC - Diamond I04-1 fragment screening)
5CQ5	;	1.961	;	Crystal structure of the bromodomain of bromodomain adjacent to zinc finger domain protein 2B (BAZ2B) in complex with 2,3-Ethylenedioxybenzoic Acid (SGC - Diamond I04-1 fragment screening)
5CQ6	;	1.97	;	Crystal structure of the bromodomain of bromodomain adjacent to zinc finger domain protein 2B (BAZ2B) in complex with 2,6-Pyridinedicarboxylic acid (SGC - Diamond I04-1 fragment screening)
5CU8	;	2.05	;	Crystal structure of the bromodomain of bromodomain adjacent to zinc finger domain protein 2B (BAZ2B) in complex with 2-Amino-6-chlorobenzothiazole (SGC - Diamond I04-1 fragment screening)
5CQ4	;	1.782	;	Crystal structure of the bromodomain of bromodomain adjacent to zinc finger domain protein 2B (BAZ2B) in complex with 3'-Hydroxyacetophenone (SGC - Diamond I04-1 fragment screening)
5CUB	;	2.1	;	Crystal structure of the bromodomain of bromodomain adjacent to zinc finger domain protein 2B (BAZ2B) in complex with 314268-40-1 (SGC - Diamond I04-1 fragment screening)
5CQ8	;	1.651	;	Crystal structure of the bromodomain of bromodomain adjacent to zinc finger domain protein 2B (BAZ2B) in complex with 4'-Hydroxyacetophenone (SGC - Diamond I04-1 fragment screening)
5CUG	;	1.78	;	Crystal structure of the bromodomain of bromodomain adjacent to zinc finger domain protein 2B (BAZ2B) in complex with 4-Acetamidobenzoic acid (SGC - Diamond I04-1 fragment screening)
5CUD	;	1.75	;	Crystal structure of the bromodomain of bromodomain adjacent to zinc finger domain protein 2B (BAZ2B) in complex with 6-CHLOROPURINE (SGC - Diamond I04-1 fragment screening)
5CQ3	;	1.925	;	Crystal structure of the bromodomain of bromodomain adjacent to zinc finger domain protein 2B (BAZ2B) in complex with 6-Hydroxypicolinic acid (SGC - Diamond I04-1 fragment screening)
5CUE	;	2.08	;	Crystal structure of the bromodomain of bromodomain adjacent to zinc finger domain protein 2B (BAZ2B) in complex with AGN-PC-04G0SS (SGC - Diamond I04-1 fragment screening)
5CQ7	;	1.86	;	Crystal structure of the bromodomain of bromodomain adjacent to zinc finger domain protein 2B (BAZ2B) in complex with N,N-dimethylquinoxaline-6-carboxamide (SGC - Diamond I04-1 fragment screening)
5CUC	;	1.85	;	Crystal structure of the bromodomain of bromodomain adjacent to zinc finger domain protein 2B (BAZ2B) in complex with N-Acetyl-2-phenylethylamine (SGC - Diamond I04-1 fragment screening)
5CQA	;	2.13	;	Crystal structure of the bromodomain of bromodomain adjacent to zinc finger domain protein 2B (BAZ2B) in complex with N-methyl-2,3-dihydrothieno[3,4-b][1,4]dioxine-5-carboxamide (SGC - Diamond I04-1 fragment screening)
3LXJ	;	2.33	;	Crystal Structure of the Bromodomain of Human AAA domain containing 2B (ATAD2B)
3MQM	;	2.54	;	Crystal Structure of the Bromodomain of human ASH1L
5EPB	;	1.5	;	Crystal structure of the bromodomain of human ATAD2 in complex with Compound 49
5F36	;	1.5	;	Crystal structure of the bromodomain of human ATAD2 in complex with Compound A12
5F3A	;	1.599	;	Crystal structure of the bromodomain of human ATAD2 in complex with Compound A14
6CPS	;	1.93	;	Crystal structure of the bromodomain of human ATAD2 with a disulfide bridge
4LZ2	;	1.76	;	Crystal structure of the bromodomain of human BAZ2A
4IR4	;	2.05	;	Crystal Structure of the bromodomain of human BAZ2B in complex with 1-[7-(morpholin-4-yl)-1-(pyridin-2-yl)indolizin-3-yl]ethanone (GSK2834113A)
4IR3	;	2.0	;	Crystal Structure of the bromodomain of human BAZ2B in complex with 1-[7-amino-1-(pyrimidin-2-yl)indolizin-3-yl]ethanone (GSK2833282A)
4IR5	;	1.7	;	Crystal Structure of the bromodomain of human BAZ2B in complex with 1-{1-[2-(hydroxymethyl)phenyl]-7-phenoxyindolizin-3-yl}ethanone (GSK2847449A)
4IR6	;	1.8	;	Crystal Structure of the bromodomain of human BAZ2B in complex with 1-{1-[2-(METHYLSULFONYL)PHENYL]-7-PHENOXYINDOLIZIN-3-YL}ETHANONE (GSK2838097A)
3Q2F	;	2.06	;	Crystal Structure of the bromodomain of human BAZ2B in complex with a triazolo ligand
4NR9	;	1.98	;	Crystal Structure of the bromodomain of human BAZ2B in complex with acetylated lysine
4XUB	;	1.98	;	Crystal Structure of the bromodomain of human BAZ2B in complex with BAZ2-ICR chemical probe
4NRB	;	2.08	;	Crystal Structure of the bromodomain of human BAZ2B in complex with compound-1 N01197
4NRC	;	1.86	;	Crystal Structure of the bromodomain of human BAZ2B in complex with compound-3 N01186
4NRA	;	1.85	;	Crystal Structure of the bromodomain of human BAZ2B in complex with compound-6 E11322
4XUA	;	1.75	;	Crystal Structure of the bromodomain of human BAZ2B in complex with E11919 BAZ2-ICR analogue
4RVR	;	1.98	;	Crystal Structure of the bromodomain of human BAZ2B in complex WITH GSK2801
3RCW	;	2.21	;	Crystal Structure of the bromodomain of human BRD1
5FG6	;	1.1	;	Crystal structure of the bromodomain of human BRD1 (BRPF2) in complex with OF-1 chemical probe
6V1E	;	2.3	;	Crystal structure of the bromodomain of human BRD7 bound to BI7273
6V1F	;	2.0	;	Crystal structure of the bromodomain of human BRD7 bound to BI9564
6V1H	;	1.93	;	Crystal structure of the bromodomain of human BRD7 bound to bromosporine
6V17	;	2.05	;	Crystal structure of the bromodomain of human BRD7 bound to I-BRD9
6V0Q	;	1.69	;	Crystal structure of the bromodomain of human BRD7 bound to TG003
6V16	;	1.9	;	Crystal structure of the bromodomain of human BRD7 bound to TP472
6V1B	;	1.35	;	Crystal structure of the bromodomain of human BRD9 bound to I-BRD9
6V0X	;	1.5	;	Crystal structure of the bromodomain of human BRD9 bound to sunitinib
6V0S	;	2.4	;	Crystal structure of the bromodomain of human BRD9 bound to TG003
6V14	;	1.7	;	Crystal structure of the bromodomain of human BRD9 bound to TP472
4NQN	;	1.73	;	Crystal Structure of the bromodomain of human BRD9 in complex with a triazolo-phthalazine ligand
5IGM	;	1.6	;	Crystal structure of the bromodomain of human BRD9 in complex with bromosporine (BSP)
5DKD	;	2.0	;	Crystal structure of the bromodomain of human BRG1 (SMARCA4) in complex with PFI-3 chemical probe
5DKH	;	1.7	;	Crystal structure of the bromodomain of human BRM (SMARCA2) in complex with a hydroxyphenyl propenone inhibitor 17
5DKC	;	1.6	;	Crystal structure of the bromodomain of human BRM (SMARCA2) in complex with PFI-3 chemical probe
5FFY	;	1.55	;	Crystal structure of the bromodomain of human BRPF1 in complex with a benzimidazole ligand
5T4U	;	1.5	;	Crystal structure of the bromodomain of human BRPF1 in complex with a quinolinone ligand
5FFV	;	1.3	;	Crystal structure of the bromodomain of human BRPF1 in complex with H3K14ac histone peptide
5FFW	;	1.5	;	Crystal structure of the bromodomain of human BRPF1 in complex with H4K5acK8ac histone peptide
5T4V	;	1.65	;	Crystal structure of the bromodomain of human BRPF1 in complex with NI-48 ligand
5MYG	;	2.3	;	Crystal structure of the bromodomain of human BRPF1 in complex with NI-57 chemical probe
5FG4	;	1.65	;	Crystal structure of the bromodomain of human BRPF1 in complex with OF-1 chemical probe
5FG5	;	1.5	;	Crystal structure of the bromodomain of human BRPF1 in complex with PFI-4 chemical probe
4LC2	;	1.65	;	Crystal structure of the bromodomain of human BRPF1B
3NXB	;	1.83	;	Crystal Structure of the Bromodomain of human CECR2
3DWY	;	1.98	;	Crystal Structure of the Bromodomain of Human CREBBP
5KTU	;	1.38	;	Crystal structure of the bromodomain of human CREBBP bound to pyrazolopiperidine scaffold
5I83	;	1.35	;	Crystal structure of the bromodomain of human CREBBP bound to the benzodiazepinone G02773986
5I86	;	1.05	;	Crystal structure of the bromodomain of human CREBBP bound to the benzodiazepinone G02778174
5I89	;	1.07	;	Crystal structure of the bromodomain of human CREBBP bound to the benzodiazepinone G02857790
5LPJ	;	1.65	;	Crystal structure of the bromodomain of human CREBBP bound to the inhibitor XDM1
5LPL	;	1.65	;	Crystal structure of the bromodomain of human CREBBP bound to the inhibitor XDM3c
5J0D	;	1.05	;	Crystal structure of the bromodomain of human CREBBP in complex with a benzoxazepine compound
4NYW	;	1.43	;	Crystal Structure of the Bromodomain of human CREBBP in complex with a dihydroquinoxalinone ligand
4NYX	;	1.1	;	Crystal Structure of the Bromodomain of human CREBBP in complex with a dihydroquinoxalinone ligand
3P1F	;	1.63	;	Crystal structure of the bromodomain of human CREBBP in complex with a hydroquinazolin ligand
4NYV	;	1.83	;	Crystal Structure of the Bromodomain of human CREBBP in complex with a quinazolin-one ligand
6SXX	;	2.01	;	Crystal structure of the bromodomain of human CREBBP in complex with ACA007
3P1C	;	1.82	;	Crystal structure of the bromodomain of human CREBBP in complex with acetylated lysine
4NR4	;	1.69	;	Crystal structure of the bromodomain of human CREBBP in complex with an isoxazolyl-benzimidazole ligand
4NR5	;	1.66	;	Crystal structure of the bromodomain of human CREBBP in complex with an isoxazolyl-benzimidazole ligand
4NR7	;	1.2	;	Crystal structure of the bromodomain of human CREBBP in complex with an isoxazolyl-benzimidazole ligand
4NR6	;	1.66	;	Crystal structure of the bromodomain of human CREBBP in complex with an oxazepin ligand
5EIC	;	1.5	;	Crystal structure of the bromodomain of human CREBBP in complex with AYC
3P1E	;	1.8	;	Crystal structure of the bromodomain of human CREBBP in complex with dimethyl sulfoxide (DMSO)
3P1D	;	1.86	;	Crystal structure of the bromodomain of human CREBBP in complex with N-Methyl-2-pyrrolidone (NMP)
4TQN	;	1.7	;	Crystal structure of the bromodomain of human CREBBP in complex with UL04
5EP7	;	1.198	;	Crystal structure of the bromodomain of human CREBBP in complex with UN32
5H85	;	1.701	;	Crystal structure of the bromodomain of human CREBBP in complex with UO37D
5ENG	;	1.3	;	Crystal structure of the bromodomain of human CREBBP in complex with UP39
4TS8	;	2.0	;	Crystal structure of the bromodomain of human CREBBP in complex with XZ08
3I3J	;	2.33	;	Crystal Structure of the Bromodomain of Human EP300
5LPK	;	2.1	;	Crystal structure of the bromodomain of human EP300 bound to the inhibitor XDM1
5LPM	;	1.5	;	Crystal structure of the bromodomain of human Ep300 bound to the inhibitor XDM3d
3D7C	;	2.06	;	Crystal structure of the bromodomain of human GCN5, the general control of amino-acid synthesis protein 5-like 2
3UV2	;	1.58	;	Crystal structure of the bromodomain of human nucleosome-remodeling factor subunit BPTF
3GG3	;	2.25	;	Crystal Structure of the Bromodomain of Human PCAF
4QY4	;	1.97	;	Crystal structure of the bromodomain of human SMARCA2
6HAZ	;	1.31	;	Crystal structure of the bromodomain of human SMARCA2 in complex with SMARCA-BD ligand
5AME	;	1.578	;	Crystal structure of the bromodomain of human surface epitope engineered BRD1A in complex with 3D Consortium fragment 4-acetyl- piperazin-2-one (SGC - Diamond I04-1 fragment screening)
5AMF	;	1.75	;	Crystal structure of the bromodomain of human surface epitope engineered BRD1A in complex with 3D Consortium fragment Ethyl 4,5,6,7- tetrahydro-1H-indazole-5-carboxylate (SGC - Diamond I04-1 fragment screening)
6ZS2	;	1.57	;	Crystal Structure of the bromodomain of human transcription activator BRG1 (SMARCA4) in complex with 2-(6-amino-5-(piperazin-1-yl)pyridazin-3-yl)phenol
3UVD	;	1.85	;	Crystal Structure of the bromodomain of human Transcription activator BRG1 (SMARCA4) in complex with N-Methyl-2-pyrrolidone
3DAI	;	1.95	;	Crystal structure of the bromodomain of the human ATAD2
4N3W	;	1.9	;	Crystal Structure of the Bromodomain-PHD Finger Module of Human Transcriptional Co-Activator CBP in complex with Acetylated Histone 4 Peptide (H4K20ac).
4N4F	;	1.83	;	Crystal Structure of the Bromodomain-PHD Finger Module of Human Transcriptional Co-Activator CBP in complex with di-Acetylated Histone 4 Peptide (H412acK16ac).
7RE6	;	1.53	;	Crystal Structure of the brown dog tick (Rhipicephalus sanguineus) Arginine Kinase in absence of substrate or ligands
3R9M	;	1.95	;	Crystal structure of the Brox Bro1 domain
3UM3	;	3.8	;	Crystal structure of the Brox Bro1 domain in complex with the C-terminal tail of CHMP4B
3UM0	;	3.102	;	Crystal structure of the Brox Bro1 domain in complex with the C-terminal tail of CHMP5
3UM1	;	2.708	;	Crystal structure of the Brox Bro1 domain in complex with the C-terminal tail of CHMP5
3UM2	;	2.589	;	Crystal structure of the Brox Bro1 domain in complex with the C-terminal tail of CHMP5
5VR3	;	2.102	;	Crystal structure of the BRS domain of BRAF
5VYK	;	1.749	;	Crystal structure of the BRS domain of BRAF in complex with the CC-SAM domain of KSR1
3UPL	;	1.5	;	Crystal structure of the Brucella abortus enzyme catalyzing the first committed step of the methylerythritol 4-phosphate pathway.
3UPY	;	1.8	;	Crystal structure of the Brucella abortus enzyme catalyzing the first committed step of the methylerythritol 4-phosphate pathway.
5HDA	;	2.3899	;	Crystal Structure of the BS69 coiled coil-MYND domains bound to an EBNA2 PXLXP motif
6EKB	;	1.9	;	Crystal structure of the BSD2 homolog of Arabidopsis thaliana
6EKC	;	2.63	;	Crystal structure of the BSD2 homolog of Arabidopsis thaliana bound to the octameric assembly of RbcL from Thermosynechococcus elongatus
1Q0U	;	1.85	;	Crystal Structure of the BstDEAD N-terminal Domain
3M5B	;	2.0	;	Crystal structure of the BTB domain from FAZF/ZBTB32
3M4T	;	2.05	;	Crystal structure of the BTB domain from Kaiso/ZBTB33, form I
3M8V	;	2.7	;	Crystal structure of the BTB domain from Kaiso/ZBTB33, form II
2NN2	;	2.1	;	Crystal structure of the BTB domain from the LRF/ZBTB7 transcriptional regulator
3M52	;	2.59	;	Crystal structure of the BTB domain from the Miz-1/ZBTB17 transcription regulator
7EXI	;	1.82	;	Crystal structure of the BTB domain human Keap1
5A15	;	2.76	;	Crystal structure of the BTB domain of human KCTD16
5A6R	;	2.85	;	Crystal structure of the BTB domain of human KCTD17
2VPK	;	2.0	;	Crystal structure of the BTB domain of human myoneurin
6N34	;	2.8	;	Crystal structure of the BTB domain of Human NS1-BP
4UYI	;	1.86	;	Crystal structure of the BTB domain of human SLX4 (BTBD12)
4UIJ	;	2.7	;	Crystal structure of the BTB domain of KCTD13
4ZOU	;	2.15	;	Crystal structure of the BTB domain of SLX4
3I3N	;	2.6	;	Crystal structure of the BTB-BACK domains of human KLHL11
4CRH	;	1.72	;	Crystal structure of the BTB-T1 domain of human SHKBP1
7UXR	;	1.42	;	Crystal structure of the BtTir TIR domain
2O9O	;	2.8	;	Crystal Structure of the buffalo Secretory Signalling Glycoprotein at 2.8 A resolution
2ES4	;	1.85	;	Crystal structure of the Burkholderia glumae lipase-specific foldase in complex with its cognate lipase
3TU8	;	1.04	;	Crystal Structure of the Burkholderia Lethal Factor 1 (BLF1)
6RVU	;	0.99	;	Crystal structure of the Burkholderia Lethal Factor 1 (BLF1)
7PPZ	;	2.52	;	Crystal structure of the Burkholderia Lethal Factor 1 (BLF1) C94S inactive mutant in complex with human eIF4A - Crystal form A
7PQ0	;	3.0	;	Crystal structure of the Burkholderia Lethal Factor 1 (BLF1) C94S inactive mutant in complex with human eIF4A - Crystal form B
3TUA	;	1.09	;	Crystal Structure of the Burkholderia Lethal Factor 1 (BLF1) C94S mutant
6G1N	;	1.85	;	Crystal structure of the Burkholderia Pseudomallei antitoxin HicB
2WT7	;	2.3	;	Crystal structure of the bZIP heterodimeric complex MafB:cFos bound to DNA
4AUW	;	2.9	;	CRYSTAL STRUCTURE OF THE BZIP HOMODIMERIC MAFB IN COMPLEX WITH THE C- MARE BINDING SITE
4RS6	;	2.6	;	Crystal structure of the C domain of Polo like Kinase II in Homo Sapiens
4WWI	;	2.307	;	Crystal structure of the C domain of staphylococcal protein A in complex with the Fc fragment of human IgG at 2.3 Angstrom resolution
1V9M	;	1.85	;	Crystal structure of the C subunit of V-type ATPase from Thermus thermophilus
2NRW	;	2.3	;	Crystal structure of the C terminal half of UvrC
1QN3	;	1.95	;	Crystal structure of the C(-25) Adenovirus major late promoter TATA box variant bound to wild-type TBP (Arabidopsis thaliana TBP isoform 2). TATA element recognition by the TATA box-binding protein has been conserved throughout evolution.
1QN9	;	1.9	;	Crystal structure of the C(-29) Adenovirus major late promoter TATA box variant bound to wild-type TBP (Arabidopsis thaliana TBP isoform 2). TATA element recognition by the TATA box-binding protein has been conserved throughout evolution.
3NRI	;	2.85	;	Crystal structure of the C(30) carotenoid dehydrosqualene synthase from S. aureus complexed with dehydrosqualene (DHS)
3NPR	;	2.0	;	Crystal structure of the C(30) carotenoid dehydrosqualene synthase from S. aureus complexed with Presqualene diphosphate (PSPP)
2ZCO	;	1.58	;	Crystal structure of the C(30) carotenoid dehydrosqualene synthase from Staphylococcus aureus
2ZCQ	;	2.38	;	Crystal structure of the C(30) carotenoid dehydrosqualene synthase from Staphylococcus aureus complexed with bisphosphonate BPH-652
2ZCR	;	1.92	;	Crystal structure of the C(30) carotenoid dehydrosqualene synthase from Staphylococcus aureus complexed with bisphosphonate BPH-698
2ZCS	;	2.03	;	Crystal structure of the C(30) carotenoid dehydrosqualene synthase from Staphylococcus aureus complexed with bisphosphonate BPH-700
2ZY1	;	1.78	;	Crystal structure of the C(30) carotenoid dehydrosqualene synthase from Staphylococcus aureus complexed with bisphosphonate BPH-830
3ACW	;	1.63	;	Crystal structure of the C(30) carotenoid dehydrosqualene synthase from Staphylococcus aureus complexed with BPH-651
3ACX	;	1.31	;	Crystal structure of the C(30) carotenoid dehydrosqualene synthase from Staphylococcus aureus complexed with BPH-673
3ACY	;	1.84	;	Crystal structure of the C(30) carotenoid dehydrosqualene synthase from Staphylococcus aureus complexed with BPH-702
3W7F	;	2.25	;	Crystal structure of the C(30) carotenoid dehydrosqualene synthase from staphylococcus aureus complexed with farnesyl thiopyrophosphate
3AE0	;	2.37	;	Crystal structure of the C(30) carotenoid dehydrosqualene synthase from Staphylococcus aureus complexed with geranylgeranyl thiopyrophosphate
3ADZ	;	1.89	;	Crystal structure of the C(30) carotenoid dehydrosqualene synthase from Staphylococcus aureus complexed with intermediate PSPP
2E2B	;	2.2	;	Crystal structure of the c-Abl kinase domain in complex with INNO-406
1M52	;	2.6	;	Crystal Structure of the c-Abl Kinase domain in complex with PD173955
1IEP	;	2.1	;	CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
3G98	;	1.85	;	Crystal Structure of the C-Ala domain from Aquifex aeolicus alanyl-tRNA synthetase
1U2E	;	2.1	;	Crystal Structure of the C-C bond hydrolase MhpC
1YVH	;	2.05	;	Crystal Structure of the c-Cbl TKB Domain in Complex with the APS pTyr-618 Phosphopeptide
4RLE	;	1.3	;	Crystal structure of the c-di-AMP binding PII-like protein DarA
5EUH	;	2.989	;	Crystal structure of the c-di-GMP-bound GGDEF domain of P. fluorescens GcbC
1Q89	;	2.75	;	Crystal structure of the C-domain of the T.vaginalis Inr binding protein, IBP39 (cubic crystal form)
1Q88	;	2.42	;	Crystal structure of the C-domain of the T.vaginalis Inr binding protein, IBP39 (monoclinic form)
1Q87	;	2.32	;	Crystal structure of the C-domain of the T.vaginalis Inr binding protein, IBP39 (tetragonal form)
1IOZ	;	2.0	;	Crystal Structure of the C-HA-RAS Protein Prepared by the Cell-Free Synthesis
6SID	;	1.05	;	Crystal structure of the C-lobe of drosophila Arc 1 at atomic resolution
6SIE	;	2.8	;	Crystal structure of the C-lobe of drosophila Arc 2
7EQU	;	2.743	;	Crystal structure of the C-lobe of lactoferrin produced by limited proteolysis using pepsin at 2.74A resolution
5T3Q	;	2.0	;	Crystal structure of the c-Met kinase domain in complex with a pyrazolone inhibitor
7PVY	;	1.4	;	Crystal structure of the c-Src SH3 domain E93V-S94A-R95S-T96G mutant
6XX3	;	1.36	;	Crystal structure of the c-Src SH3 domain H122R-Q128E mutant in complex with Cu(II) at pH 6.5 co-crystallized with methyl beta-cyclodextrin
6XX4	;	1.05	;	Crystal structure of the c-Src SH3 domain H122R-Q128E mutant in complex with Ni(II) at pH 7.5 co-crystallized with methyl beta-cyclodextrin
6XX2	;	1.25	;	Crystal structure of the c-Src SH3 domain H122R-Q128K mutant in complex with Cu(II) at pH 7.5 co-crystallized with methyl beta-cyclodextrin
6XX5	;	1.3	;	Crystal structure of the c-Src SH3 domain H122R-Q128K mutant in complex with Ni(II) at pH 7.5 co-crystallized with methyl beta-cyclodextrin
4QT7	;	1.55	;	Crystal structure of the c-Src SH3 domain in complex with a peptide from the Hepatitis C virus NS5A-protein
7PVX	;	1.43	;	Crystal structure of the c-Src SH3 domain mutant E93V-S94A-R95S-T96G-N112G-N113Y-T114N-E115H in complex with the synthetic peptide VSL12
7A3C	;	1.8	;	Crystal structure of the c-Src SH3 domain mutant L100I at pH 3.0
7A33	;	0.96	;	Crystal structure of the c-Src SH3 domain mutant S94A-T98D-V111L-N113S-T114S at pH 3.0
7A31	;	0.94	;	Crystal structure of the c-Src SH3 domain mutant S94A-T98D-V111L-N113S-T114S at pH 4.5
7A32	;	1.15	;	Crystal structure of the c-Src SH3 domain mutant S94A-T98D-V111L-N113S-T114S at pH 7.0
7A35	;	1.314	;	Crystal structure of the c-Src SH3 domain mutant V111L-N113S-T114S at pH 7.0
7A37	;	1.52	;	Crystal structure of the c-Src SH3 domain mutant V111L-N113S-T114S in 3 M urea
7A36	;	1.5	;	Crystal structure of the c-Src SH3 domain mutant V111L-N113S-T114S in 7 M urea
7A38	;	1.62	;	Crystal structure of the c-Src SH3 domain mutant V111L-N113S-T114S-Q128E at pH 6.0
7A39	;	1.65	;	Crystal structure of the c-Src SH3 domain mutant V111L-N113S-T114S-Q128E at pH 7.0
7PW0	;	1.7	;	Crystal structure of the c-Src SH3 domain N112G-N113Y-T114N-E115H mutant
4OMO	;	1.04	;	Crystal structure of the c-Src tyrosine kinase SH3 domain mutant Q128E
3FJ5	;	1.65	;	Crystal structure of the c-src-SH3 domain
4RTW	;	1.24	;	Crystal structure of the c-Src-SH3 domain E93V/Q128R mutant in complex with the high affinity peptide APP12
5OB2	;	1.8	;	Crystal structure of the c-Src-SH3 domain E97T mutant in complex with the high affinity peptide APP12
4RTY	;	1.279	;	Crystal structure of the c-Src-SH3 domain in complex with the high affinity peptide APP12
4RTZ	;	0.979	;	Crystal structure of the c-Src-SH3 domain in complex with the high affinity peptide VSL12
5OB0	;	1.172	;	Crystal structure of the c-Src-SH3 domain Q128E mutant in complex with the high affinity peptide APP12
5OB1	;	1.172	;	Crystal structure of the c-Src-SH3 domain Q128R mutant in complex with the high affinity peptide APP12
4IWT	;	2.6	;	Crystal structure of the C-teminal choline-binding domain of the Streptococcus pneumoniae prophage LytA
2P32	;	3.2	;	Crystal structure of the C-terminal 10 kDa subdomain from C. elegans Hsp70
1UD0	;	3.45	;	CRYSTAL STRUCTURE OF THE C-TERMINAL 10-kDA SUBDOMAIN OF HSC70
5AF2	;	1.39	;	Crystal structure of the C-terminal 2',5'-phosphodiesterase domain of group A rotavirus protein VP3
1Q5Z	;	1.8	;	Crystal Structure of the C-terminal Actin Binding Domain of Salmonella Invasion Protein A (SipA)
4XKZ	;	1.95	;	Crystal structure of the C-terminal anticodon loop binding domain of a valyl-tRNA synthetase from Pseudomonas aeruginosa
6DED	;	2.204	;	Crystal structure of the C-terminal ARM domain of Homo sapiens SPIN90 (SH3-protein interacting with Nck), residues 351-722
1JJ7	;	2.4	;	Crystal Structure of the C-terminal ATPase domain of human TAP1
2VZC	;	1.05	;	Crystal structure of the C-terminal calponin homology domain of alpha parvin
2VZD	;	2.1	;	Crystal structure of the C-terminal calponin homology domain of alpha parvin in complex with paxillin LD1 motif
2VZG	;	1.8	;	Crystal structure of the C-terminal calponin homology domain of alpha- parvin in complex with paxillin LD2 motif
2VZI	;	2.2	;	Crystal structure of the C-terminal calponin homology domain of alpha- parvin in complex with paxillin LD4 motif
6DGB	;	2.52	;	Crystal structure of the C-terminal catalytic domain of IS1535 TnpA, an IS607-like serine recombinase
6DGC	;	2.92	;	Crystal structure of the C-terminal catalytic domain of ISC1926 TnpA, an IS607-like serine recombinase
4ZCT	;	2.22	;	Crystal structure of the C-terminal catalytic domain of Plasmodium falciparum CTP:phosphocholine cytidylyltransferase
4ZCS	;	2.45	;	Crystal structure of the C-terminal catalytic domain of Plasmodium falciparum CTP:phosphocholine cytidylyltransferase in complex with CDP-choline
4ZCQ	;	1.92	;	Crystal structure of the C-terminal catalytic domain of Plasmodium falciparum CTP:phosphocholine cytidylyltransferase in complex with choline
4ZCP	;	1.98	;	Crystal structure of the C-terminal catalytic domain of Plasmodium falciparum CTP:phosphocholine cytidylyltransferase in complex with CMP
4ZCR	;	1.8	;	Crystal structure of the C-terminal catalytic domain of Plasmodium falciparum CTP:phosphocholine cytidylyltransferase in complex with phosphocholine
7PY9	;	2.03	;	Crystal structure of the C-terminal catalytic domain of Plasmodium falciparum CTP:phosphocholine cytidylyltransferase with (pyrrolidin-2-yl)methanol
7Q3W	;	1.75	;	Crystal structure of the C-terminal catalytic domain of Plasmodium falciparum CTP:phosphocholine cytidylyltransferase with (R)-2-Aminobutanamide hydrochloride
7Z9V	;	1.9	;	Crystal structure of the C-terminal catalytic domain of Plasmodium falciparum CTP:phosphocholine cytidylyltransferase with 1,4-Anhydroerythritol
7QAD	;	2.11	;	Crystal structure of the C-terminal catalytic domain of Plasmodium falciparum CTP:phosphocholine cytidylyltransferase with 1,4-Oxazepane hydrochloride
7Q9V	;	1.5	;	Crystal structure of the C-terminal catalytic domain of Plasmodium falciparum CTP:phosphocholine cytidylyltransferase with 1-(1,3-oxazol-4-yl)methanamine
7Q2V	;	1.96	;	Crystal structure of the C-terminal catalytic domain of Plasmodium falciparum CTP:phosphocholine cytidylyltransferase with 1-methylpyrrolidin-3-ol
7PYC	;	2.36	;	Crystal structure of the C-terminal catalytic domain of Plasmodium falciparum CTP:phosphocholine cytidylyltransferase with 2-Aminopyridine
7PYB	;	2.03	;	Crystal structure of the C-terminal catalytic domain of Plasmodium falciparum CTP:phosphocholine cytidylyltransferase with 2-Hydroxypyridine
7PUI	;	2.08	;	Crystal structure of the C-terminal catalytic domain of Plasmodium falciparum CTP:phosphocholine cytidylyltransferase with 2-pyridineboronic acid
7Q2K	;	1.94	;	Crystal structure of the C-terminal catalytic domain of Plasmodium falciparum CTP:phosphocholine cytidylyltransferase with 2-pyrrolidinone
7Q2L	;	2.12	;	Crystal structure of the C-terminal catalytic domain of Plasmodium falciparum CTP:phosphocholine cytidylyltransferase with 3-Aminopyrrolidin-2-one hydrochloride
7PVF	;	2.33	;	Crystal structure of the C-terminal catalytic domain of Plasmodium falciparum CTP:phosphocholine cytidylyltransferase with 3-hydroxy-1lambda6-thietane-1,1-dione
7PYA	;	2.2	;	Crystal structure of the C-terminal catalytic domain of Plasmodium falciparum CTP:phosphocholine cytidylyltransferase with 3-Hydroxyazetidine hydrochloride
7Q3M	;	2.2	;	Crystal structure of the C-terminal catalytic domain of Plasmodium falciparum CTP:phosphocholine cytidylyltransferase with 3-hydroxypiperidine
7Q9W	;	1.8	;	Crystal structure of the C-terminal catalytic domain of Plasmodium falciparum CTP:phosphocholine cytidylyltransferase with 4-(aminomethyl)pyridin-2-amine
7PVE	;	2.39	;	Crystal structure of the C-terminal catalytic domain of Plasmodium falciparum CTP:phosphocholine cytidylyltransferase with 4-bromo-1H-imidazole
7Q2M	;	2.08	;	Crystal structure of the C-terminal catalytic domain of Plasmodium falciparum CTP:phosphocholine cytidylyltransferase with but-3-yn-2-amine hydrochloride
7QA7	;	2.36	;	Crystal structure of the C-terminal catalytic domain of Plasmodium falciparum CTP:phosphocholine cytidylyltransferase with Cyclopropanemethylamine
7QVO	;	1.62	;	Crystal structure of the C-terminal catalytic domain of Plasmodium falciparum CTP:phosphocholine cytidylyltransferase with guanidine
7PVG	;	2.27	;	Crystal structure of the C-terminal catalytic domain of Plasmodium falciparum CTP:phosphocholine cytidylyltransferase with isonicotinic acid
7QD3	;	2.43	;	Crystal structure of the C-terminal catalytic domain of Plasmodium falciparum CTP:phosphocholine cytidylyltransferase with morpholine
7Q2I	;	1.87	;	Crystal structure of the C-terminal catalytic domain of Plasmodium falciparum CTP:phosphocholine cytidylyltransferase with Tetrahydrofurfurylamine
7QVN	;	2.21	;	Crystal structure of the C-terminal catalytic domain of Plasmodium falciparum CTP:phosphocholine cytidylyltransferase with(1H-pyrazol-5-yl)methanol
5FUI	;	1.4	;	Crystal structure of the C-terminal CBM6 of LamC a marine laminarianse from Zobellia galactanivorans
4BFC	;	1.7	;	Crystal structure of the C-terminal CMP-Kdo binding domain of WaaA from Acinetobacter baumannii
4YTD	;	1.5	;	Crystal structure of the C-terminal Coiled Coil of mouse Bicaudal D1
5ABS	;	1.74	;	CRYSTAL STRUCTURE OF THE C-TERMINAL COILED-COIL DOMAIN OF CIN85 IN SPACE GROUP P321
4QJI	;	2.65	;	Crystal Structure of the C-terminal CTP-binding domain of a Phosphopantothenoylcysteine decarboxylase/phosphopantothenate-cysteine ligase with bound CTP from Mycobacterium smegmatis
3VC8	;	2.0	;	Crystal structure of the C-terminal cytoplasmic domain of non-structural protein 4 from mouse hepatitis virus A59
3C5A	;	1.23	;	Crystal structure of the C-terminal deleted mutant of the class A carbapenemase KPC-2 at 1.23 angstrom
6RO6	;	1.41	;	Crystal structure of the C-terminal dimerization domain of the essential repressor DdrO from radiation-resistant Deinococcus bacteria (Deinococcus deserti)
3LRX	;	2.6	;	Crystal Structure of the C-terminal domain (residues 78-226) of PF1911 hydrogenase from Pyrococcus furiosus, Northeast Structural Genomics Consortium Target PfR246A
3LYU	;	2.3	;	Crystal Structure of the C-terminal domain (residues 83-215) of PF1911 hydrogenase from Pyrococcus furiosus, Northeast Structural Genomics Consortium Target PfR246A
6Y3P	;	2.3	;	Crystal structure of the C-terminal domain from K. lactis Pby1, an ATP-grasp enzyme interacting with the mRNA decapping enzyme Dcp2
1U2K	;	2.0	;	Crystal structure of the C-terminal domain from the catalase-peroxidase KatG of Escherichia coli (I41)
1U2L	;	2.3	;	Crystal structure of the C-terminal domain from the catalase-peroxidase KatG of Escherichia coli (P1)
1U2J	;	2.3	;	Crystal structure of the C-terminal domain from the catalase-peroxidase KatG of Escherichia coli (P21 21 21)
3KFO	;	1.9	;	Crystal structure of the C-terminal domain from the nuclear pore complex component NUP133 from Saccharomyces cerevisiae
3G1G	;	2.01	;	Crystal structure of the C-terminal domain from the Rous Sarcoma Virus capsid protein: High pH
3G0V	;	2.0	;	Crystal structure of the C-terminal domain from the Rous Sarcoma Virus capsid protein: mutant D179A
4OTM	;	1.95	;	Crystal structure of the C-terminal domain from yeast GCN2
3BUE	;	2.15	;	Crystal structure of the C-terminal domain hexamer of ArgR from Mycobacterium tuberculosis
2ZFZ	;	1.85	;	Crystal structure of the C-terminal domain hexamer of ArgR from Mycobacterium tuberculosis in complex with arginine
4GO2	;	2.28	;	Crystal structure of the c-terminal domain of 10'formyltetrahydrofolate dehydrogenase in complex with Thio-NADP
3F2Z	;	1.3	;	Crystal structure of the C-terminal domain of a chitobiase (BF3579) from Bacteroides fragilis, Northeast Structural Genomics Consortium Target BfR260B
3BJO	;	2.05	;	Crystal structure of the C-terminal domain of a possible ATP-binding protein from Methanocaldococcus jannaschii DSM 2661
2QL3	;	2.05	;	Crystal structure of the C-terminal domain of a probable LysR family transcriptional regulator from Rhodococcus sp. RHA1
4Q6G	;	2.25	;	Crystal Structure of the C-terminal domain of AcKRS-1 bound with N-acetyl-lysine and ADPNP
2QZ5	;	2.6	;	Crystal Structure of the C-terminal domain of Aida
2QW6	;	2.3	;	Crystal structure of the C-terminal domain of an AAA ATPase from Enterococcus faecium DO
4TYZ	;	1.6	;	Crystal structure of the C-terminal domain of an unknown protein from Leishmania infantum
3LKL	;	2.15	;	Crystal structure of the C-terminal domain of Anti-Sigma factor antagonist STAS from Rhodobacter sphaeroides
1IU9	;	2.04	;	Crystal structure of the C-terminal domain of aspartate racemase from Pyrococcus horikoshii OT3
2W1R	;	1.5	;	Crystal Structure of the C-terminal Domain of B. subtilis SpoVT
5X03	;	2.0	;	Crystal structure of the C-terminal domain of Bacillus subtilis GabR reveals a closed conformation by the binding of gamma-aminobutyric acid, inducing the transcriptional activation
2FKD	;	2.7	;	Crystal Structure of the C-terminal domain of Bacteriophage 186 repressor
1WCK	;	1.36	;	Crystal structure of the C-terminal domain of BclA, the major antigen of the exosporium of the Bacillus anthracis spore.
7XTM	;	1.47	;	Crystal structure of the C-terminal domain of Bombyx mori N-acetylglucosaminyltransferase IV
7XTN	;	1.15	;	Crystal structure of the C-terminal domain of Bombyx mori N-acetylglucosaminyltransferase IV in complex with N-acetylglucosamine
2P87	;	2.3	;	Crystal structure of the C-terminal domain of C. elegans pre-mRNA splicing factor Prp8
2P8R	;	2.1	;	Crystal structure of the C-terminal domain of C. elegans pre-mRNA splicing factor Prp8 carrying R2303K mutant
5XLX	;	1.969	;	Crystal structure of the C-terminal domain of CheR1 containing SAH
4FCT	;	4.0	;	Crystal structure of the C-terminal domain of ClpB
4FCV	;	3.4	;	Crystal structure of the C-terminal domain of ClpB
4FCW	;	2.35	;	Crystal structure of the C-terminal domain of ClpB
4FD2	;	3.0	;	Crystal structure of the C-terminal domain of ClpB
6YHM	;	1.13	;	Crystal structure of the C-terminal domain of CNFy from Yersinia pseudotuberculosis
5INT	;	2.15	;	Crystal structure of the C-terminal Domain of Coenzyme A biosynthesis bifunctional protein CoaBC
4NAD	;	2.8	;	Crystal Structure of the C-terminal Domain of CREPT
3A9F	;	1.3	;	Crystal structure of the C-terminal domain of cytochrome cz from Chlorobium tepidum
6VPQ	;	1.74	;	Crystal structure of the C-terminal domain of DENR
6VPR	;	2.2	;	Crystal structure of the C-terminal domain of DENR
1WP5	;	1.79	;	Crystal structure of the C-terminal domain of DNA topoisomerase IV
6B4A	;	2.0	;	Crystal structure of the C-Terminal Domain of Doublecortin (TgDCX) from Toxoplasma gondii ME49
4H4A	;	2.2	;	Crystal structure of the C-terminal domain of Drosophila melanogaster Zucchini
3EYW	;	2.4	;	Crystal structure of the C-terminal domain of E. coli KefC in complex with KefF
1YSP	;	1.8	;	Crystal structure of the C-terminal domain of E. coli transcriptional regulator KdgR.
2I8B	;	2.0	;	Crystal structure of the C-terminal domain of Ebola virus VP30
3V7O	;	2.25	;	Crystal structure of the C-terminal domain of Ebola virus VP30 (strain Reston-89)
6VU0	;	3.5	;	CRYSTAL STRUCTURE OF THE C-TERMINAL DOMAIN OF ENZYME I OF THE BACTERIAL PHOSPHOTRANSFERASE SYSTEM FROM THE ESCHERICHIA COLI ENZYME
3SNS	;	1.5	;	Crystal structure of the C-terminal domain of Escherichia coli lipoprotein BamC
7ZC8	;	2.08	;	Crystal structure of the C-terminal domain of FusB, a TonB homologue
4HE6	;	1.1	;	Crystal structure of the C-terminal domain of Geobacillus thermoleovorans putative U32 peptidase
4GBF	;	1.949	;	Crystal structure of the C-terminal domain of gp131 from bacteriophage phiKZ
2Q5X	;	1.9	;	Crystal Structure of the C-terminal domain of hNup98
2Q5Y	;	2.3	;	Crystal Structure of the C-terminal domain of hNup98
6JSA	;	1.3	;	Crystal structure of the C-terminal domain of HtaA from Corynebacterium glutamicum
8AXR	;	1.5	;	Crystal structure of the C-terminal domain of human CFAP410
2HL5	;	1.93	;	Crystal structure of the C-terminal domain of human EB1 in complex with the A49M mutant CAP-Gly domain of human Dynactin-1 (p150-Glued)
2HKQ	;	1.86	;	Crystal structure of the C-terminal domain of human EB1 in complex with the CAP-Gly domain of human Dynactin-1 (p150-Glued)
5W2F	;	1.4	;	Crystal Structure of the C-terminal Domain of Human eIF2D at 1.4 A resolution
5CBL	;	1.781	;	Crystal structure of the C-terminal domain of human galectin-4 with lactose
3GA3	;	1.45	;	Crystal structure of the C-terminal domain of human MDA5
7XTL	;	1.972	;	Crystal structure of the C-terminal domain of human N-acetylglucosaminyltransferase IVa
3JUI	;	2.0	;	Crystal Structure of the C-terminal Domain of Human Translation Initiation Factor eIF2B epsilon Subunit
4ERN	;	1.8	;	Crystal structure of the C-terminal domain of human XPB/ERCC-3 excision repair protein at 1.80 A
4TQF	;	2.7143	;	Crystal Structure of the C-terminal domain of IFRS bound with 2-(5-bromothienyl)-L-Ala and ATP
4TQD	;	2.1429	;	Crystal Structure of the C-terminal domain of IFRS bound with 3-iodo-L-Phe and ATP
2X49	;	1.5	;	Crystal structure of the C-terminal domain of InvA
2X4A	;	2.54	;	Crystal structure of the C-terminal domain of InvA
3JTP	;	2.17	;	crystal structure of the C-terminal domain of MecA
5H34	;	1.748	;	Crystal structure of the C-terminal domain of methionyl-tRNA synthetase (MetRS-C) in Nanoarchaeum equitans
5D7U	;	1.5	;	Crystal structure of the C-terminal domain of MMTV integrase
2Q2B	;	2.5	;	Crystal structure of the C-terminal domain of mouse acyl-CoA thioesterase 7
2OGB	;	1.95	;	Crystal structure of the C-terminal domain of mouse Nrdp1
4QDH	;	2.399	;	Crystal Structure of the C-terminal Domain of Mouse TLR9
6CUJ	;	1.805	;	Crystal structure of the C-terminal domain of neisserial heparin binding antigen (NHBA)
4HTE	;	3.0	;	Crystal Structure of the C-terminal domain of Nicking Enzyme from Staphylococcus aureus
3NF5	;	1.94	;	Crystal structure of the C-terminal domain of nuclear pore complex component NUP116 from Candida glabrata
5WTP	;	2.15	;	Crystal structure of the C-terminal domain of outer membrane protein A (OmpA) from Capnocytophaga gingivalis
4OT9	;	3.35	;	crystal structure of the C-terminal domain of p100/NF-kB2
7D8U	;	2.7	;	Crystal structure of the C-terminal domain of pNP868R from African swine fever virus
2PHP	;	2.03	;	Crystal structure of the C-terminal domain of protein MJ0236 (Y236_METJA)
4ZIB	;	2.054	;	Crystal Structure of the C-terminal domain of PylRS mutant bound with 3-benzothienyl-l-alanine and ATP
4S36	;	1.46	;	Crystal structure of the C-terminal domain of R2 pyocin membrane-piercing spike
2O2P	;	1.7	;	Crystal structure of the C-terminal domain of rat 10'formyltetrahydrofolate dehydrogenase
2O2Q	;	2.0	;	Crystal structure of the C-terminal domain of rat 10'formyltetrahydrofolate dehydrogenase in complex with NADP
2O2R	;	2.2	;	Crystal structure of the C-terminal domain of rat 10'formyltetrahydrofolate dehydrogenase in complex with NADPH
5C9S	;	2.7	;	Crystal Structure of the C-terminal domain of Rrp5
4EHC	;	1.98	;	Crystal structure of the C-terminal domain of Rv0977 of Mycobacterium tuberculosis
2FUL	;	1.5	;	Crystal Structure of the C-terminal Domain of S. cerevisiae eIF5
7C22	;	2.0	;	Crystal structure of the C-terminal domain of SARS-CoV-2 nucleocapsid protein
3AO9	;	2.1	;	Crystal structure of the C-terminal domain of sequence-specific ribonuclease
3L3P	;	3.2	;	Crystal structure of the C-terminal domain of Shigella type III effector IpaH9.8, with a novel domain swap
3X38	;	1.801	;	Crystal structure of the C-terminal domain of Sld7
2WOY	;	1.5	;	Crystal structure of the C-terminal domain of Streptococcus gordonii surface protein SspB
2WQS	;	1.7	;	Crystal structure of the C-terminal domain of Streptococcus gordonii surface protein SspB
3OPU	;	2.181	;	Crystal structure of the C-terminal domain of Streptococcus mutans surface protein SpaP
5BND	;	2.68	;	Crystal structure of the C-terminal domain of TagH
4EYT	;	2.5	;	Crystal structure of the C-terminal domain of Tetrahymena telomerase protein p65
4ERD	;	2.589	;	Crystal structure of the C-terminal domain of Tetrahymena telomerase protein p65 in complex with stem IV of telomerase RNA
2FKK	;	1.2	;	Crystal structure of the C-terminal domain of the bacteriophage T4 gene product 10
2FWE	;	1.65	;	crystal structure of the C-terminal domain of the electron transfer catalyst DsbD (oxidized form)
1WU9	;	1.54	;	Crystal structure of the C-terminal domain of the end-binding protein 1 (EB1)
2FJI	;	2.4	;	Crystal structure of the C-terminal domain of the exocyst subunit Sec6p
6T6E	;	1.302	;	Crystal Structure of the C-terminal domain of the HIV-1 Integrase (PNL4-3)
6T6I	;	2.203	;	Crystal Structure of the C-terminal domain of the HIV-1 Integrase (subtype A2)
6T6J	;	2.003	;	Crystal Structure of the C-terminal domain of the HIV-1 Integrase (subtype A2, mutant N254K, K340Q)
1O9Y	;	2.29	;	Crystal structure of the C-terminal domain of the HrcQb protein from Pseudomonas syringae pv. phaseolicola
2GIY	;	1.78	;	Crystal Structure of the C-terminal domain of the HSV-1 gE ectodomain
5IKF	;	2.8	;	Crystal structure of the C-terminal domain of the Mit1 nucleosome remodeler in complex with Clr1
3L48	;	2.1	;	Crystal structure of the C-terminal domain of the PapC usher
7T88	;	2.1	;	Crystal Structure of the C-terminal Domain of the Phosphate Acetyltransferase from Escherichia coli
1I27	;	1.02	;	CRYSTAL STRUCTURE OF THE C-TERMINAL DOMAIN OF THE RAP74 SUBUNIT OF HUMAN TRANSCRIPTION FACTOR IIF (TFIIF)
3G29	;	2.5	;	Crystal structure of the C-terminal domain of the Rous Sarcoma Virus capsid protein: D179N mutant, neutral pH
3G1I	;	2.1	;	Crystal structure of the C-terminal domain of the Rous Sarcoma Virus capsid protein: Intermediate pH
3G21	;	0.9	;	Crystal structure of the C-terminal domain of the Rous Sarcoma Virus capsid protein: Low pH
3G26	;	1.55	;	Crystal structure of the C-terminal domain of the Rous Sarcoma Virus capsid protein: Mutant A184C
3G28	;	1.64	;	Crystal structure of the C-terminal domain of the Rous Sarcoma Virus capsid protein: mutant D179N, low pH
3CKD	;	2.65	;	Crystal structure of the C-terminal domain of the Shigella type III effector IpaH
1R62	;	1.6	;	Crystal structure of the C-terminal Domain of the Two-Component System Transmitter Protein NRII (NtrB)
3OC8	;	2.1	;	Crystal Structure of the C-terminal Domain of the Vibrio cholerae soluble colonization factor TcpF
3QQZ	;	2.55	;	Crystal structure of the C-terminal domain of the yjiK protein from Escherichia coli CFT073
3WHP	;	2.52	;	Crystal structure of the C-terminal domain of Themus thermophilus LitR in complex with cobalamin
1V2Z	;	1.8	;	Crystal structure of the C-terminal domain of Thermosynechococcus elongatus BP-1 KaiA
1QXX	;	2.7	;	CRYSTAL STRUCTURE OF THE C-TERMINAL DOMAIN OF TONB
8AXO	;	1.29	;	Crystal structure of the C-terminal domain of Trypanosoma brucei CFAP410
1T5I	;	1.9	;	Crystal structure of the C-terminal domain of UAP56
3EUR	;	1.3	;	Crystal structure of the C-terminal domain of uncharacterized protein from Bacteroides fragilis NCTC 9343
2G3K	;	3.05	;	Crystal structure of the C-terminal domain of Vps28
2R5O	;	1.3	;	Crystal structure of the C-terminal domain of wzt
3JTN	;	2.09	;	Crystal Structure of the c-terminal domain of YpbH
3JTO	;	2.4	;	Crystal structure of the c-terminal domain of YpbH
3U2G	;	2.3	;	Crystal structure of the C-terminal DUF1608 domain of the Methanosarcina acetivorans S-layer (MA0829) protein
3U2H	;	2.36	;	Crystal structure of the C-terminal DUF1608 domain of the Methanosarcina acetivorans S-layer (MA0829) protein
5B42	;	1.35	;	Crystal structure of the C-terminal endonuclease domain of Aquifex aeolicus MutL.
3PTY	;	2.0	;	Crystal structure of the C-terminal extracellular domain of Mycobacterium tuberculosis EmbC
8FNB	;	1.8	;	Crystal structure of the C-terminal Fg domain of human TNC with the mutations Y2140H and S2164H
8FNA	;	1.75	;	Crystal structure of the C-terminal Fg domain of human TNR
8FN8	;	1.89	;	Crystal structure of the C-terminal Fg domain of TNC with the single FN domain of PTPRZ
8FN9	;	1.8	;	Crystal structure of the C-terminal Fg domain of TNR with the single FN domain of PTPRZ
3JT0	;	2.392	;	Crystal Structure of the C-terminal fragment (426-558) Lamin-B1 from Homo sapiens, Northeast Structural Genomics Consortium Target HR5546A
8WAG	;	3.003	;	Crystal structure of the C-terminal fragment (residues 716-982) of Arabidopsis thaliana CHUP1
8WAF	;	2.8	;	Crystal structure of the C-terminal fragment (residues 756-982 with the C864S mutation) of Arabidopsis thaliana CHUP1
2R9G	;	2.09	;	Crystal structure of the C-terminal fragment of AAA ATPase from Enterococcus faecium
8G28	;	1.3	;	Crystal Structure of the C-terminal Fragment of AAA ATPase from Streptococcus pneumoniae.
3BGE	;	1.85	;	Crystal structure of the C-terminal fragment of AAA+ATPase from Haemophilus influenzae
5YXA	;	2.1	;	Crystal structure of the C-terminal fragment of NS1 protein from yellow fever virus
2D3E	;	2.6	;	Crystal structure of the C-Terminal fragment of rabbit skeletal alpha-tropomyosin
3QR7	;	0.94	;	Crystal structure of the C-terminal fragment of the bacteriophage P2 membrane-piercing protein gpV
3PQH	;	1.295	;	Crystal structure of the C-terminal fragment of the bacteriophage phi92 membrane-piercing protein gp138
2ZMF	;	2.1	;	Crystal structure of the C-terminal GAF domain of human phosphodiesterase 10A
3WAI	;	1.897	;	Crystal structure of the C-terminal globular domain of oligosaccharyltransferase (AfAglB-L, O29867_ARCFU) from Archaeoglobus fulgidus as a MBP fusion
3VU0	;	1.94	;	Crystal structure of the C-terminal globular domain of oligosaccharyltransferase (AfAglB-S2, AF_0040, O30195_ARCFU) from Archaeoglobus fulgidus
3VGP	;	1.75	;	Crystal structure of the C-terminal globular domain of oligosaccharyltransferase (AF_0329) from Archaeoglobus fulgidus
3WOV	;	3.11	;	Crystal structure of the C-terminal globular domain of oligosaccharyltransferase (PaAglB-L, Q9V250_PYRAB, PAB2202) from Pyrococcus abyssi
3VU1	;	2.7	;	Crystal structure of the C-terminal globular domain of oligosaccharyltransferase (PhAglB-L, O74088_PYRHO) from Pyrococcus horikoshii
6D8Z	;	2.65	;	Crystal Structure of the C-terminal Guanine Nucleotide Exchange Factor Module of Human Trio
6MIC	;	1.531	;	Crystal Structure of the C-terminal half of the Vibrio cholerae minor pilin TcpB
2NRT	;	1.5	;	Crystal structure of the C-terminal half of UvrC
2NRV	;	1.8	;	Crystal structure of the C-terminal half of UvrC
2NRZ	;	2.0	;	Crystal structure of the C-terminal half of UvrC bound to its catalytic divalent cation
2NRX	;	1.9	;	Crystal structure of the C-terminal half of UvrC, in the presence of sulfate molecules
3HM8	;	2.8	;	Crystal structure of the C-terminal Hexokinase domain of human HK3
3KN6	;	2.0	;	Crystal structure of the C-terminal kinase domain of MSK1
3KN5	;	2.4	;	Crystal structure of the C-terminal kinase domain of msk1 in complex with AMP-PNP
7TRW	;	2.28	;	Crystal Structure of the C-terminal Ligand-Binding Domain of the LysR family Transcriptional Regulator YfbA from Yersinia pestis
5THE	;	2.097	;	Crystal structure of the C-terminal lobe of a budding yeast Argonaute
2P1S	;	1.93	;	Crystal structure of the C-terminal lobe of bovine lactoferrin complexed with O-alpha-D-Glucopyranosyl-(1 3)-alpha-D-fructofuranosyl- (2 1)- alpha-D-glucopyranoside at 1.93 A resolution
5W87	;	2.199	;	Crystal structure of the C-terminal lobe of the human HERC6 HECT domain
3PT3	;	1.97	;	Crystal structure of the C-terminal lobe of the human UBR5 HECT domain
5H45	;	2.7	;	Crystal structure of the C-terminal Lon protease-like domain of Thermus thermophilus RadA/Sms
2IOL	;	2.0	;	Crystal structure of the C-terminal MA3 domain of Pdcd4 (mouse); form 1
2IOS	;	1.76	;	Crystal structure of the C-terminal MA3 domain of Pdcd4 (mouse); form 3
2ION	;	1.57	;	Crystal structure of the C-terminal MA3 domain of Pdcd4 (mouse); form2
1L1D	;	1.85	;	Crystal structure of the C-terminal methionine sulfoxide reductase domain (MsrB) of N. gonorrhoeae pilB
3G9H	;	2.8	;	Crystal structure of the C-terminal mu homology domain of Syp1
3CED	;	2.15	;	Crystal structure of the C-terminal NIL domain of an ABC transporter protein homologue from Staphylococcus aureus
2REU	;	1.9	;	Crystal Structure of the C-terminal of Sau3AI fragment
5GN1	;	1.95	;	Crystal structure of the C-terminal part of Fun30 ATPase domain
8AY2	;	2.5	;	Crystal structure of the C-terminal part of rat Sec8
4KC5	;	2.14	;	Crystal structure of the C-terminal part of RhiE from Burkholderia rhizoxinica
3LG8	;	4.1	;	Crystal structure of the C-terminal part of subunit E (E101-206) from Methanocaldococcus jannaschii of A1AO ATP synthase
3U4T	;	2.282	;	Crystal Structure of the C-terminal part of the TPR repeat-containing protein Q11TI6_CYTH3 from Cytophaga hutchinsonii. Northeast Structural Genomics Consortium Target ChR11B.
7O61	;	1.78	;	Crystal structure of the C-terminal PASTA domains of Staphylococcus aureus PBP1
5U1H	;	1.5	;	Crystal structure of the C-terminal peptidoglycan binding domain of OprF (PA1777) from Pseudomonas aeruginosa
1SK3	;	2.8	;	Crystal structure of the C-terminal peptidoglycan-binding domain of human peptidoglycan recognition protein Ialpha
1SK4	;	1.65	;	crystal structure of the C-terminal peptidoglycan-binding domain of human peptidoglycan recognition protein Ialpha
2EAV	;	2.2	;	Crystal structure of the C-terminal peptidoglycan-binding domain of human peptidoglycan recognition protein Ibeta
4WN5	;	1.15	;	Crystal structure of the C-terminal Per-Arnt-Sim (PASb) of human HIF-3alpha9 bound to 18:1-1-monoacylglycerol
6A82	;	2.1	;	Crystal structure of the C-terminal periplasmic domain of EcEptC from Escherichia coli
6A83	;	2.602	;	Crystal structure of the C-terminal periplasmic domain of EcEptC from Escherichia coli complex with Zn
5ZZU	;	2.1	;	Crystal structure of the C-terminal periplasmic domain of EcEptC from Escherichia coli- complex with Zn
4TN0	;	2.4	;	Crystal Structure of the C-terminal Periplasmic Domain of Phosphoethanolamine Transferase EptC from Campylobacter jejuni
1TWQ	;	2.3	;	Crystal structure of the C-terminal PGN-binding domain of human PGRP-Ialpha in complex with PGN analog muramyl tripeptide
2I5C	;	1.75	;	Crystal structure of the C-terminal PH domain of pleckstrin in complex with D-myo-Ins(1,2,3,4,5)P5
2I5F	;	1.35	;	Crystal structure of the C-terminal PH domain of pleckstrin in complex with D-myo-Ins(1,2,3,5,6)P5
2DYQ	;	3.1	;	Crystal Structure of the C-terminal Phophotyrosine Interaction Domain of Human APBB3
6F9S	;	3.03	;	Crystal structure of the C-terminal RecA domain of DDX6 in complex with a conserved peptide from LSM14
2VGE	;	2.1	;	Crystal structure of the C-terminal region of human iASPP
3L6A	;	2.0	;	Crystal structure of the C-terminal region of Human p97
4BKW	;	2.53	;	Crystal structure of the C-terminal region of human ZFYVE9
1KQL	;	2.7	;	Crystal structure of the C-terminal region of striated muscle alpha-tropomyosin at 2.7 angstrom resolution
3WIT	;	1.95	;	Crystal structure of the C-terminal region of VgrG1 from E. coli O157 EDL933
4C8S	;	3.0	;	Crystal structure of the C-terminal region of yeast Ctf4
4C8H	;	2.691	;	Crystal structure of the C-terminal region of yeast Ctf4, selenomethionine protein.
4OTN	;	1.9	;	Crystal structure of the C-terminal regulatory domain of murine GCN2
2EB1	;	2.0	;	Crystal Structure of the C-Terminal RNase III Domain of Human Dicer
2NRR	;	1.2	;	Crystal structure of the C-terminal RNAseH endonuclase domain of UvrC
4M6W	;	2.9	;	Crystal structure of the C-terminal segment of FANCM in complex with FAAP24
1QAD	;	1.8	;	Crystal Structure of the C-Terminal SH2 Domain of the P85 alpha Regulatory Subunit of Phosphoinositide 3-Kinase: An SH2 domain mimicking its own substrate
2D0N	;	1.57	;	Crystal structure of the C-terminal SH3 domain of the adaptor protein GADS in complex with SLP-76 motif peptide reveals a unique SH3-SH3 interaction
1DXS	;	2.54	;	Crystal structure of the C-terminal sterile alpha motif (SAM) domain of human p73 alpha splice variant
4N4C	;	2.48	;	Crystal structure of the C-terminal swapped dimer of a Bovine seminal ribonuclease mutant
7VPG	;	2.49	;	Crystal structure of the C-terminal tail of SARS-CoV-1 Orf6 complex with human nucleoporin pair Rae1-Nup98
7VPH	;	2.8	;	Crystal structure of the C-terminal tail of SARS-CoV-2 Orf6 complex with human nucleoporin pair Rae1-Nup98
6AQK	;	1.8	;	Crystal structure of the C-terminal toxin domain of RHS2 from Yersinia entomophaga
2EFR	;	1.8	;	Crystal structure of the c-terminal tropomyosin fragment with N- and C-terminal extensions of the leucine zipper at 1.8 angstroms resolution
2EFS	;	2.0	;	Crystal structure of the C-terminal tropomyosin fragment with N- and C-terminal extensions of the leucine zipper at 2.0 angstroms resolution
3PDT	;	1.8	;	Crystal Structure of the C-terminal Truncated Alpha-Kinase Domain of Myosin Heavy chain Kinase
5C3O	;	2.3	;	Crystal structure of the C-terminal truncated Neurospora crassa T7H (NcT7HdeltaC) in apo form
2H84	;	2.9	;	Crystal Structure of the C-terminal Type III Polyketide Synthase (PKS III) Domain of 'Steely1' (a Type I/III PKS Hybrid from Dictyostelium)
2W18	;	1.9	;	Crystal structure of the C-terminal WD40 domain of human PALB2
1R5M	;	1.55	;	Crystal Structure Of The C-Terminal WD40 Domain Of Sif2
1ERJ	;	2.3	;	CRYSTAL STRUCTURE OF THE C-TERMINAL WD40 DOMAIN OF TUP1
2AYD	;	1.6	;	Crystal Structure of the C-terminal WRKY domainof AtWRKY1, an SA-induced and partially NPR1-dependent transcription factor
5J4G	;	2.6	;	Crystal structure of the C-terminally His6-tagged HP0902, an uncharacterized protein from Helicobacter pylori 26695
6T1F	;	2.9	;	Crystal structure of the C-terminally truncated chromosome-partitioning protein ParB from Caulobacter crescentus complexed to the centromeric parS site
7BM8	;	2.73	;	Crystal structure of the C-terminally truncated chromosome-partitioning protein ParB from Caulobacter crescentus complexed with CTP-gamma-S
8QA8	;	2.3	;	Crystal structure of the C-terminally truncated transcriptional repressor protein KorB from the RK2 plasmid complexed with CTP-gamma-S
6DEE	;	3.04	;	Crystal structure of the C-terminus of Homo sapiens SPIN90 (SH3-protein interacting with Nck), residues 306-722
1SZI	;	2.8	;	Crystal Structure of the C-terminus of TIP47
4DCK	;	2.2	;	Crystal structure of the C-terminus of voltage-gated sodium channel in complex with FGF13 and CaM
4PWA	;	2.19	;	Crystal structure of the c-type cytochrome SorU from Sinorhizobium meliloti
1Q40	;	1.95	;	Crystal structure of the C. albicans Mtr2-Mex67 M domain complex
8Q66	;	2.03	;	Crystal Structure of the C. elegans MUT-7 MUT-8 CTD complex
1EMS	;	2.8	;	CRYSTAL STRUCTURE OF THE C. ELEGANS NITFHIT PROTEIN
8AY1	;	2.13	;	Crystal structure of the C. elegans POFUT2 (CePoFUT2) triple mutant (R298K-R299K-A418C) in complex with the Rattus norvegicus TSR4 single mutant (E10C) from F-spondin
5FOE	;	1.98	;	Crystal structure of the C. elegans Protein O-fucosyltransferase 2 (CePOFUT2) double mutant (R298K-R299K) in complex with GDP and the human TSR1 from thrombospondin 1
6GBS	;	1.946	;	Crystal Structure of the C. themophilum Scavenger Decapping Enzyme DcpS apo form
6QJ0	;	2.0	;	Crystal structure of the C. thermophilum condensin Smc2 ATPase head (crystal form II)
6QJ1	;	2.56	;	Crystal structure of the C. thermophilum condensin Smc2 ATPase head (crystal from I)
6QJ2	;	3.0	;	Crystal structure of the C. thermophilum condensin Smc4 ATPase head in complex with the C-terminal domain of Brn1
6QJ3	;	3.3	;	Crystal structure of the C. thermophilum condensin Ycs4-Brn1 subcomplex
6QJ4	;	5.8	;	Crystal structure of the C. thermophilum condensin Ycs4-Brn1 subcomplex bound to the Smc4 ATPase head in complex with the C-terminal domain of Brn1
3CX2	;	1.3	;	Crystal structure of the C1 domain of cardiac isoform of myosin binding protein-C at 1.3A
2V6H	;	1.55	;	Crystal structure of the C1 domain of cardiac myosin binding protein-C
1DLG	;	1.9	;	CRYSTAL STRUCTURE OF THE C115S ENTEROBACTER CLOACAE MURA IN THE UN-LIGANDED STATE
1Y55	;	1.0	;	Crystal structure of the C122S mutant of E. Coli expressed avidin related protein 4 (AVR4)-biotin complex
1XG4	;	1.6	;	Crystal Structure of the C123S 2-Methylisocitrate Lyase Mutant from Escherichia coli in complex with the inhibitor isocitrate
1XG3	;	1.9	;	Crystal structure of the C123S 2-methylisocitrate lyase mutant from Escherichia coli in complex with the reaction product, Mg(II)-pyruvate and succinate
1GGV	;	2.5	;	CRYSTAL STRUCTURE OF THE C123S MUTANT OF DIENELACTONE HYDROLASE (DLH) BOUND WITH THE PMS MOIETY OF THE PROTEASE INHIBITOR, PHENYLMETHYLSULFONYL FLUORIDE (PMSF)
2BO0	;	1.35	;	Crystal structure of the C130A mutant of nitrite reductase from Alcaligenes xylosoxidans
4K7Z	;	1.5	;	Crystal structure of the C136(42)A/C141(47)A double mutant of Tn501 MerA in complex with NADP and Hg2+
4FBE	;	1.88	;	Crystal structure of the C136A/C164A variant of mitochondrial isoform of glutaminyl cyclase from Drosophila melanogaster
1PQP	;	2.06	;	Crystal Structure of the C136S Mutant of Aspartate Semialdehyde Dehydrogenase from Haemophilus influenzae Bound with Aspartate Semialdehyde and Phosphate
4IAM	;	1.99	;	Crystal Structure of the C139A mutant of nostoc H-NOX domain
6TQJ	;	2.3	;	Crystal structure of the c14 ring of the F1FO ATP synthase from spinach chloroplast
3NVJ	;	3.2	;	Crystal structure of the C143A/C166A mutant of Ero1p
3SJK	;	2.096	;	Crystal structure of the C147A mutant 3C from enterovirus 71
3SJ9	;	2.399	;	crystal structure of the C147A mutant 3C of CVA16 in complex with FAGLRQAVTQ peptide
3AYH	;	2.193	;	Crystal structure of the C17/25 subcomplex from S. pombe RNA Polymerase III
3ML5	;	2.05	;	Crystal structure of the C183S/C217S mutant of human CA VII in complex with acetazolamide
3RZP	;	2.0	;	Crystal Structure of the C194A mutant of 7-cyano-7-deazaguanine reductase, QueF from Vibrio cholerae complexed with preQ1
8POW	;	1.61	;	Crystal Structure of the C19G variant of the membrane-bound [NiFe]-Hydrogenase from Cupriavidus necator in the air-oxidized state at 1.61 A Resolution.
8POU	;	1.65	;	Crystal Structure of the C19G/C120G variant of the membrane-bound [NiFe]-Hydrogenase from Cupriavidus necator in the air-oxidized state at 1.65 A Resolution.
8POV	;	1.92	;	Crystal Structure of the C19G/C120G variant of the membrane-bound [NiFe]-Hydrogenase from Cupriavidus necator in the H2-reduced state at 1.92 A Resolution.
4NN0	;	1.42	;	Crystal structure of the C1QTNF5 globular domain in space group P63
3BN6	;	1.67	;	Crystal Structure of the C2 Domain of Bovine Lactadherin at 1.67 Angstrom Resolution
2B3R	;	2.3	;	Crystal structure of the C2 domain of class II phosphatidylinositide 3-kinase C2
1CZT	;	1.87	;	CRYSTAL STRUCTURE OF THE C2 DOMAIN OF HUMAN COAGULATION FACTOR V
1CZS	;	1.9	;	CRYSTAL STRUCTURE OF THE C2 DOMAIN OF HUMAN COAGULATION FACTOR V: COMPLEX WITH PHENYLMERCURY
1CZV	;	2.4	;	CRYSTAL STRUCTURE OF THE C2 DOMAIN OF HUMAN COAGULATION FACTOR V: DIMERIC CRYSTAL FORM
1D7P	;	1.5	;	Crystal structure of the c2 domain of human factor viii at 1.5 a resolution at 1.5 A
2NQ3	;	1.8	;	Crystal structure of the C2 Domain of Human Itchy Homolog E3 Ubiquitin Protein Ligase
2UZP	;	2.0	;	Crystal structure of the C2 domain of human protein kinase C gamma.
3B7Y	;	1.8	;	Crystal structure of the C2 Domain of the E3 Ubiquitin-Protein Ligase NEDD4
2NSQ	;	1.85	;	Crystal structure of the C2 domain of the human E3 ubiquitin-protein ligase NEDD4-like protein
3FBK	;	2.0	;	Crystal structure of the C2 domain of the human regulator of G-protein signaling 3 isoform 6 (RGP3), Northeast Structural Genomics Consortium Target HR5550A
2I1L	;	2.5	;	Crystal structure of the C2 form of FAD synthetase from Thermotoga maritima
1FCC	;	3.2	;	CRYSTAL STRUCTURE OF THE C2 FRAGMENT OF STREPTOCOCCAL PROTEIN G IN COMPLEX WITH THE FC DOMAIN OF HUMAN IGG
3BXJ	;	3.0	;	Crystal Structure of the C2-GAP Fragment of synGAP
1PA1	;	1.6	;	Crystal structure of the C215D mutant of protein tyrosine phosphatase 1B
2Q9J	;	2.2	;	Crystal structure of the C217S mutant of diaminopimelate epimerase
6GEU	;	1.55	;	Crystal structure of the C230A mutant of human IBA57
4A5B	;	2.48	;	Crystal structure of the C258S/C268S variant of Toxoplasma gondii nucleoside triphosphate diphosphohydrolase 1 (NTPDase1)
4A5A	;	2.85	;	Crystal structure of the C258S/C268S variant of Toxoplasma gondii nucleoside triphosphate diphosphohydrolase 3 (NTPDase3) in complex with magnesium and AMPPNP
5Y8U	;	2.92	;	Crystal structure of the C276S mutant of MAP2K7
4MJJ	;	2.0	;	Crystal structure of the C2A domain of DOC2A
2CHD	;	1.92	;	Crystal structure of the C2A domain of Rabphilin-3A
4LT7	;	2.5	;	Crystal structure of the c2a domain of rabphilin-3a in complex with a calcium
2CM5	;	1.28	;	crystal structure of the C2B domain of rabphilin
2CM6	;	1.85	;	crystal structure of the C2B domain of rabphilin3A
7A1R	;	1.5	;	Crystal structure of the C2B domain of Trypanosoma brucei extended synaptotagmin (E-Syt)
3IUF	;	1.8	;	Crystal structure of the C2H2-type zinc finger domain of human ubi-d4
4E0I	;	3.0	;	Crystal structure of the C30S/C133S mutant of Erv1 from Saccharomyces cerevisiae
2A9K	;	1.73	;	Crystal structure of the C3bot-NAD-RalA complex reveals a novel type of action of a bacterial exoenzyme
2A78	;	1.81	;	Crystal structure of the C3bot-RalA complex reveals a novel type of action of a bacterial exoenzyme
1FF2	;	2.3	;	CRYSTAL STRUCTURE OF THE C42D MUTANT OF AZOTOBACTER VINELANDII 7FE FERREDOXIN (FDI)
4EQX	;	1.7	;	Crystal Structure of the C43S Mutant of Staphylococcus aureus CoADR
2V2G	;	1.6	;	Crystal Structure of the C45S mutant of the Peroxiredoxin 6 of Arenicola Marina. Monoclinic form
2V32	;	2.0	;	Crystal Structure of the C45S mutant of the Peroxiredoxin 6 of Arenicola Marina. Monoclinic form 2
2V41	;	2.4	;	Crystal Structure of the C45S mutant of the Peroxiredoxin 6 of Arenicola Marina. Orthorhombic form
2CJZ	;	1.7	;	crystal structure of the c472s mutant of human protein tyrosine phosphatase ptpn5 (step, striatum enriched phosphatase) in complex with phosphotyrosine
3NPM	;	2.1	;	Crystal Structure of the C47A/A241C disulfide-linked C6 Aspartate Transcarbamoylase enzyme
3MPU	;	2.855	;	Crystal structure of the C47A/A241C disulfide-linked E. coli Aspartate Transcarbamoylase holoenzyme
5H8Z	;	1.8	;	Crystal structure of the C49A C353A mutant Fenna-Matthews-Olson Protein from Chlorobaculum Tepidum
4K8D	;	1.86	;	Crystal structure of the C558(464)A/C559(465)A double mutant of Tn501 MerA in complex with NADPH and Hg2+
2QKV	;	1.55	;	Crystal Structure of the C645S Mutant of the 5th PDZ Domain of InaD
3RHQ	;	2.1	;	Crystal structure of the C707A mutant of C-Terminal domain of 10'FORMYLTETRAHYDROFOLATE DEHYDROGENASE in complex with NADP
3RHP	;	2.5	;	Crystal structure of the C707A mutant of the C-Terminal domain of 10'FORMYLTETRAHYDROFOLATE DEHYDROGENASE
3RHR	;	2.3	;	Crystal structure of the C707A mutant of the C-Terminal domain of 10'FORMYLTETRAHYDROFOLATE DEHYDROGENASE in complex with NADPH
4GNZ	;	2.3	;	Crystal structure of the c707s mutant of c-terminal domain of 10'formyltetrahydrofolate dehydrogenase in complex with NADP
4GO0	;	3.38	;	Crystal structure of the c707s mutant of c-terminal domain of 10'formyltetrahydrofolate dehydrogenase in complex with NADPH
1O77	;	3.2	;	CRYSTAL STRUCTURE OF THE C713S MUTANT OF THE TIR DOMAIN OF HUMAN TLR2
2Q9H	;	2.3	;	Crystal structure of the C73S mutant of diaminopimelate epimerase
5VOK	;	2.89	;	Crystal structure of the C7orf59-HBXIP dimer
7CVS	;	3.01	;	Crystal structure of the C85A/L194A mutant CLC-ec1 with Fab fragment
7CVT	;	2.9	;	Crystal structure of the C85A/L194A/H234C mutant CLC-ec1 with Fab fragment
2Q9V	;	2.0	;	Crystal structure of the C890S mutant of the 4th PDZ domain of human membrane associated guanylate kinase
4WIO	;	3.15	;	Crystal structure of the C89A GMP synthetase inactive mutant from Plasmodium falciparum in complex with glutamine
7ZU9	;	2.8	;	CRYSTAL STRUCTURE OF THE C89A_C113A GMP SYNTHETASE INACTIVE DOUBLE MUTANT FROM PLASMODIUM FALCIPARUM
4BPY	;	1.4	;	Crystal structure of the C90A mutant of the Sco copper chaperone protein from Streptomyces lividans
3MUR	;	3.0	;	Crystal Structure of the C92U mutant c-di-GMP riboswith bound to c-di-GMP
7YGV	;	2.8	;	Crystal structure of the Ca2+-bound EFhd1/Swiprosin-2
6LB7	;	2.101	;	Crystal structure of the Ca2+-free and Ca2+-bound MICU1-MICU2 complex
6LB8	;	3.283	;	Crystal structure of the Ca2+-free T4L-MICU1-MICU2 complex
3TZ1	;	1.8	;	Crystal structure of the Ca2+-saturated C-terminal domain of Akazara scallop troponin C in complex with a troponin I fragment
6N5W	;	2.15	;	Crystal structure of the Ca2+/CaM complex with independent peptides of Kv7.4 (KCNQ4) A & B domains
6B8M	;	2.3	;	Crystal Structure of the Ca2+/CaM:Kv7.4 (KCNQ4) AB Domain Complex, 1 mM CaCl2 soak
6B8N	;	2.201	;	Crystal Structure of the Ca2+/CaM:Kv7.4 (KCNQ4) AB Domain Complex, 10 uM CaCl2 soak
3VHQ	;	2.15	;	Crystal structure of the Ca6 site mutant of Pro-SA-subtilisin
4B0E	;	2.0	;	Crystal structure of the Caf1A usher protein N-terminal domain from Yersinia pestis
4JWQ	;	2.15	;	Crystal Structure of the Calcium Binding Domain of CDPK3 from Plasmodium Berghei, PB000947.00
4AQO	;	0.99	;	CRYSTAL STRUCTURE OF THE CALCIUM BOUND PKD-like DOMAIN OF COLLAGENASE G FROM CLOSTRIDIUM HISTOLYTICUM AT 0.99 ANGSTROM RESOLUTION.
3ONR	;	1.8	;	Crystal structure of the calcium chelating immunodominant antigen, calcium dodecin (Rv0379),from Mycobacterium tuberculosis with a novel calcium-binding site
3W5A	;	3.01	;	Crystal structure of the calcium pump and sarcolipin from rabbit fast twitch skeletal muscle in the E1.Mg2+ state
3W5C	;	2.5	;	Crystal structure of the calcium pump in the E2 state free from exogenous inhibitors
3W5D	;	2.45	;	Crystal structure of the calcium pump in the E2+Pi state
2DQS	;	2.5	;	Crystal structure of the calcium pump with amppcp in the absence of calcium
4YCN	;	3.5	;	Crystal structure of the calcium pump with bound marine macrolide BLLB
4YCM	;	3.2	;	Crystal structure of the calcium pump with bound marine macrolide BLS
3OX5	;	2.9	;	Crystal Structure of the calcium sensor calcium-binding protein 1 (CaBP1)
3OX6	;	2.4	;	Crystal Structure of the calcium sensor calcium-binding protein 1 (CaBP1)
2OPO	;	1.75	;	Crystal structure of the calcium-binding pollen allergen Che a 3
1K9U	;	1.75	;	Crystal Structure of the Calcium-Binding Pollen Allergen Phl p 7 (Polcalcin) at 1.75 Angstroem
1ZH2	;	2.0	;	Crystal Structure Of The Calcium-Bound Receiver Domain Of Kdp Potassium Transport System Response Regulator KdpE
3DXN	;	2.17	;	Crystal structure of the calcium-dependent kinase from toxoplasma gondii, 541.m00134, kinase domain.
3KHE	;	1.95	;	Crystal structure of the calcium-loaded calmodulin-like domain of the CDPK, 541.m00134 from toxoplasma gondii
4GKO	;	3.3	;	Crystal structure of the calcium2+-bound human IgE-Fc(epsilon)3-4 bound to its B cell receptor derCD23
6P2M	;	1.98	;	Crystal structure of the Caldicellulosiruptor lactoaceticus GH74 (ClGH74a) enzyme in complex with LLG xyloglucan
3G43	;	2.1	;	Crystal structure of the calmodulin-bound Cav1.2 C-terminal regulatory domain dimer
1GGZ	;	1.5	;	CRYSTAL STRUCTURE OF THE CALMODULIN-LIKE PROTEIN (HCLP) FROM HUMAN EPITHELIAL CELLS
3I6X	;	2.5	;	Crystal structure of the calponin homology domain of IQGAP1
1P2X	;	2.21	;	CRYSTAL STRUCTURE OF THE CALPONIN-HOMOLOGY DOMAIN OF RNG2 FROM SCHIZOSACCHAROMYCES POMBE
3O0V	;	2.3	;	Crystal structure of the calreticulin lectin domain
3FQ4	;	1.487	;	Crystal structure of the Calx-beta domain of integrin beta4
3FSO	;	1.405	;	Crystal structure of the Calx-beta domain of integrin beta4, calcium soak
1RI8	;	1.85	;	Crystal Structure of the Camelid Single Domain Antibody 1D2L19 in complex with Hen Egg White Lysozyme
1RJC	;	1.4	;	Crystal structure of the camelid single domain antibody cAb-Lys2 in complex with hen egg white lysozyme
6Y2O	;	2.01	;	Crystal structure of the cAMP-dependent protein kinase A cocrystallized with 1,7-Naphthyridin-8-amine and PKI (5-24)
7AXW	;	1.69	;	Crystal structure of the cAMP-dependent protein kinase A cocrystallized with 1-aminoisoquinoline and PKI (5-24)
7AXV	;	1.79	;	Crystal structure of the cAMP-dependent protein kinase A cocrystallized with 5-isoquinolinesulfonic acid and PKI (5-24)
7BAQ	;	1.54	;	Crystal structure of the cAMP-dependent protein kinase A cocrystallized with a chiral ligand (S- and E-configuration) and PKI (5-24)
6Y05	;	1.7	;	Crystal structure of the cAMP-dependent protein kinase A cocrystallized with adenine and PKI (5-24)
6Y2U	;	1.93	;	Crystal structure of the cAMP-dependent protein kinase A cocrystallized with aminofasudil and PKI (5-24)
6Y8C	;	1.76	;	Crystal structure of the cAMP-dependent protein kinase A cocrystallized with ATP and PKI (5-24)
6F14	;	1.867	;	Crystal structure of the cAMP-dependent protein kinase A cocrystallized with isoquinoline and PKI (5-24)
7AXT	;	1.86	;	Crystal structure of the cAMP-dependent protein kinase A cocrystallized with isoquinoline-5-carboxylic acid and PKI (5-24)
6Y89	;	1.56	;	Crystal structure of the cAMP-dependent protein kinase A cocrystallized with Methyl 5-isoquinolinecarboxylate and PKI (5-24)
6YOT	;	1.96	;	Crystal structure of the cAMP-dependent protein kinase A cocrystallized with N,N-dimethylisoquinoline-5-sulfonamide and PKI (5-24)
7BB0	;	1.75	;	Crystal structure of the cAMP-dependent protein kinase A cocrystallized with NAT22-366511 and PKI (5-24)
6YPP	;	1.75	;	Crystal structure of the cAMP-dependent protein kinase A cocrystallized with PKI (5-24). Soaking of aminofasudil and displacing it with the fragment isoquinoline.
6Y0B	;	1.71	;	Crystal structure of the cAMP-dependent protein kinase A cocrystallized with quinazolin-4-amine and PKI (5-24)
6YNR	;	1.9	;	Crystal structure of the cAMP-dependent protein kinase A in complex with 1,7-Naphthyridin-8-amine (soaked) and PKI (5-24)
6YPS	;	1.35	;	Crystal structure of the cAMP-dependent protein kinase A in complex with 4-hydroxybenzamidine
6YNT	;	1.52	;	Crystal structure of the cAMP-dependent protein kinase A in complex with aminofasudil and PKI (5-24)
6Z44	;	1.38	;	Crystal structure of the cAMP-dependent protein kinase A in complex with phenol
6YOU	;	1.73	;	Crystal structure of the cAMP-dependent protein kinase A in complex with Pyrido[3,2-d]pyrimidin-4-amine (soaked)
7BAR	;	1.37	;	Crystal structure of the cAMP-dependent protein kinase A with a chiral ligand (S- and E-configuration, soaked)
4MT4	;	2.373	;	Crystal structure of the Campylobacter jejuni CmeC outer membrane channel
5CQD	;	2.08	;	Crystal Structure of the Cancer Genomic DNA Mutator APOBEC3B
5CQH	;	1.73	;	Crystal Structure of the Cancer Genomic DNA Mutator APOBEC3B
5CQI	;	1.68	;	Crystal Structure of the Cancer Genomic DNA Mutator APOBEC3B
5CQK	;	1.88	;	Crystal Structure of the Cancer Genomic DNA Mutator APOBEC3B
5SXG	;	1.93	;	Crystal Structure of the Cancer Genomic DNA Mutator APOBEC3B
5SXH	;	1.78	;	Crystal Structure of the Cancer Genomic DNA Mutator APOBEC3B
6NFM	;	2.53	;	Crystal Structure of the Cancer Genomic DNA Mutator APOBEC3B with loop 7 from APOBEC3G
6NFK	;	1.86	;	Crystal Structure of the Cancer Genomic DNA Mutator APOBEC3B with loop 7 from APOBEC3G bound to iodide
6NFL	;	1.731	;	Crystal Structure of the Cancer Genomic DNA Mutator APOBEC3B with loop 7 from APOBEC3G complexed with 2-HP
1U6G	;	3.1	;	Crystal Structure of The Cand1-Cul1-Roc1 Complex
7LFF	;	2.01	;	Crystal structure of the Candida albicans kinesin-8 motor domain
3PPG	;	1.98	;	Crystal structure of the Candida albicans methionine synthase by surface entropy reduction, alanine variant with zinc
3PPF	;	2.3	;	Crystal structure of the Candida albicans methionine synthase by surface entropy reduction, alanine variant without zinc
3PPH	;	2.8	;	Crystal structure of the Candida albicans methionine synthase by surface entropy reduction, threonine variant
3PPC	;	2.2	;	Crystal structure of the Candida albicans methionine synthase by surface entropy reduction, tyrosine variant with zinc
4L64	;	2.18	;	Crystal structure of the Candida albicans Methionine Synthase in complex with 5-Methyl-Tetrahydrofolate
4L65	;	2.31	;	Crystal structure of the Candida albicans Methionine Synthase in complex with 5-Methyl-Tetrahydrofolate and Methionine
4L6O	;	1.88	;	Crystal structure of the Candida albicans Methionine Synthase in complex with Glutamine
4L5Z	;	2.18	;	Crystal structure of the Candida albicans Methionine Synthase in complex with Homocysteine
4L61	;	2.13	;	Crystal structure of the Candida albicans Methionine Synthase in complex with Methionine
4L6H	;	1.75	;	Crystal structure of the Candida albicans Methionine Synthase in complex with Methotrexate and Homocysteine
5D06	;	3.1	;	Crystal Structure of the Candida Glabrata Glycogen Debranching Enzyme
7EKW	;	3.1	;	Crystal Structure of the Candida Glabrata Glycogen Debranching Enzyme (D535N) in complex with maltotetrose
5D0F	;	3.3	;	Crystal Structure of the Candida Glabrata Glycogen Debranching Enzyme (E564Q) in complex with maltopentaose
7EKX	;	3.4	;	Crystal Structure of the Candida Glabrata Glycogen Debranching Enzyme (W470A E564Q) in complex with maltononaose
7EJT	;	3.2	;	Crystal Structure of the Candida Glabrata Glycogen Debranching Enzyme (W470A) in complex with maltoheptaose
7EJP	;	3.1	;	Crystal Structure of the Candida Glabrata Glycogen Debranching Enzyme (W470A) in complex with maltohexaose
7EIM	;	3.1	;	Crystal Structure of the Candida Glabrata Glycogen Debranching Enzyme (W470A) in complex with maltopentaose
7EKU	;	3.1	;	Crystal Structure of the Candida Glabrata Glycogen Debranching Enzyme (W958A)
6WSK	;	1.55	;	Crystal Structure of the Cannabinoid Receptor 1 Interacting Protein 1a (CRIP1a)
3TF2	;	2.1	;	Crystal structure of the cap free human translation initiation factor eIF4E
4ES5	;	1.8	;	Crystal structure of the cap-binding domain of polymerase basic protein 2 from influenza virus A/Bar-headed Gs/Qinghai/15c/2005 (h5n1) with bound m7GTP
4EQK	;	1.95	;	Crystal structure of the cap-binding domain of polymerase basic protein 2 from influenza virus A/Hong Kong/1/68 (h3n2) with bound m7GTP
4ENF	;	1.32	;	Crystal structure of the cap-binding domain of polymerase basic protein 2 from influenza virus A/Puerto Rico/8/34(h1n1)
6EUW	;	1.0	;	Crystal structure of the cap-binding domain of the PB2 subunit of influenza A/H5N1 polymerase bound to an azaindazole inhibitor
2HKN	;	1.87	;	Crystal structure of the CAP-Gly domain of human Dynactin-1 (p150-Glued)
6S5V	;	1.35	;	Crystal structure of the Cap-Midlink region of the H5N1 Influenza A virus polymerase in complex with a Cap-domain binding analogue
4I1T	;	2.8	;	Crystal structure of the cap-snatching endonuclease from Pichinde virus
5X6X	;	2.1	;	Crystal structure of the capping enzyme P5 from Rice Dwarf Virus
7NY6	;	1.34	;	Crystal structure of the Capsaspora owczarzaki macroH2A macrodomain
7NY7	;	2.0	;	Crystal structure of the Capsaspora owczarzaki macroH2A macrodomain in complex with ADP-ribose
3R6J	;	1.75	;	Crystal Structure of the Capsid P Domain from Norwalk Virus Strain Hiroshima/1999
3R6K	;	1.6	;	Crystal Structure of the Capsid P Domain from Norwalk Virus Strain Hiroshima/1999 in complex with HBGA type B (triglycan)
4AGJ	;	1.98	;	Crystal structure of the capsid protein (110-267) from Aura virus in complex with dioxane
5YGH	;	1.884	;	Crystal Structure of the Capsid Protein from Zika Virus
8CRV	;	1.6	;	Crystal Structure of the Carbamate Kinase from Pseudomonas aeruginosa
1C3O	;	2.1	;	CRYSTAL STRUCTURE OF THE CARBAMOYL PHOSPHATE SYNTHETASE: SMALL SUBUNIT MUTANT C269S WITH BOUND GLUTAMINE
2AGZ	;	1.6	;	Crystal structure of the carbinolamine intermediate in the reductive half-reaction of aromatic amine dehydrogenase (AADH) with tryptamine. F222 form
2AH0	;	1.45	;	Crystal structure of the carbinolamine intermediate in the reductive half-reaction of aromatic amine dehydrogenase (AADH) with tryptamine. Monoclinic form
3C22	;	1.5	;	Crystal structure of the carbohydrate recognition domain of human Langerin
3LCP	;	2.45	;	Crystal structure of the carbohydrate recognition domain of LMAN1 in complex with MCFD2
1DV8	;	2.3	;	CRYSTAL STRUCTURE OF THE CARBOHYDRATE RECOGNITION DOMAIN OF THE H1 SUBUNIT OF THE ASIALOGLYCOPROTEIN RECEPTOR
6PUV	;	1.2	;	Crystal Structure of the Carbohydrate Recognition Domain of the Human Macrophage Galactose C-Type Lectin
6PY1	;	1.701	;	Crystal Structure of the Carbohydrate Recognition Domain of the Human Macrophage Galactose C-Type Lectin Bound to GalNAc
6XIY	;	2.307	;	Crystal Structure of the Carbohydrate Recognition Domain of the Human Macrophage Galactose C-Type Lectin Bound to methyl 2-(acetylamino)-2-deoxy-1-thio-alpha-D-galactopyranose
6W12	;	2.0	;	Crystal Structure of the Carbohydrate Recognition Domain of the Human Macrophage Galactose C-Type Lectin Bound to the Tumor-Associated Tn Antigen
6UT9	;	1.21	;	Crystal structure of the carbohydrate-binding domain VP8* of human P[4] rotavirus strain BM5265
7KHU	;	2.54	;	Crystal structure of the carbohydrate-binding domain VP8* of human P[4] rotavirus strain BM5265 in complex with LNDFH I
6VKX	;	1.71	;	Crystal structure of the carbohydrate-binding domain VP8* of human P[8] rotavirus strain BM13851
7JHZ	;	2.68	;	Crystal structure of the carbohydrate-binding domain VP8* of human P[8] rotavirus strain BM13851 in complex with LNDFH I
3CPP	;	1.9	;	CRYSTAL STRUCTURE OF THE CARBON MONOXY-SUBSTRATE-CYTOCHROME P450-CAM TERNARY COMPLEX
2O4Z	;	2.1	;	Crystal structure of the Carbonic Anhydrase II complexed with hydroxysulfamide inhibitor
7O4Z	;	1.67	;	Crystal structure of the carbonic anhydrase-like domain of CcmM from Synechococcus elongatus (strain PCC 7942)
7O54	;	1.63	;	Crystal structure of the carbonic anhydrase-like domain of CcmM in complex with the C-terminal 17 residues of CcaA from Synechococcus elongatus (strain PCC 7942)
2DFX	;	1.9	;	Crystal structure of the carboxy terminal domain of colicin E5 complexed with its inhibitor
1FUK	;	1.75	;	CRYSTAL STRUCTURE OF THE CARBOXY TERMINAL DOMAIN OF YEAST EIF4A
3CVE	;	1.75	;	Crystal Structure of the carboxy terminus of Homer1
3CVF	;	2.9	;	Crystal Structure of the carboxy terminus of Homer3
8IOM	;	3.0	;	Crystal structure of the carboxy-terminal channel-forming domain of Colicin Ib
7Y96	;	3.415	;	Crystal structure of the carboxy-terminal domain of a coronavirus M protein fused with a split GFP
3HJC	;	2.5	;	Crystal structure of the carboxy-terminal domain of HSP90 from Leishmania major, LmjF33.0312
1SF8	;	2.6	;	Crystal structure of the carboxy-terminal domain of htpG, the E. coli Hsp90
5NXQ	;	2.413	;	Crystal structure of the carboxy-terminal domain of yeast Ctf4 bound to a stapled Sld5 CIP
5HOG	;	3.092	;	Crystal structure of the carboxy-terminal domain of yeast Ctf4 bound to Dna2.
4C93	;	2.694	;	Crystal structure of the carboxy-terminal domain of yeast Ctf4 bound to Pol alpha.
4C95	;	2.694	;	Crystal structure of the carboxy-terminal domain of yeast Ctf4 bound to Sld5
5HOI	;	3.3	;	Crystal structure of the carboxy-terminal domain of yeast Ctf4 bound to Tof2.
4UXF	;	2.0	;	Crystal structure of the carboxy-terminal region of the bacteriophage T4 proximal long tail fibre protein gp34, P21 native crystal
4UXE	;	2.0	;	Crystal structure of the carboxy-terminal region of the bacteriophage T4 proximal long tail fibre protein gp34, P21 selenomethionine crystal
4UXG	;	3.0	;	Crystal structure of the carboxy-terminal region of the bacteriophage T4 proximal long tail fibre protein gp34, R32 native crystal
5NXH	;	2.89	;	Crystal structure of the carboxy-terminal region of the bacteriophage T4 proximal long tail fibre protein gp34, residues 744-1289 at 2.9 Angstrom resolution
5NXF	;	1.9	;	Crystal structure of the carboxy-terminal region of the bacteriophage T4 proximal long tail fibre protein gp34, residues 795 to 1289, at 1.9 Angstrom.
2DJH	;	1.9	;	Crystal structure of the carboxy-terminal ribonuclease domain of Colicin E5
3VJ7	;	2.3	;	Crystal structure of the carboxy-terminal ribonuclease domain of Colicin E5 R33Q mutant
1ZM0	;	2.1	;	Crystal Structure of the Carboxyl Terminal PH Domain of Pleckstrin To 2.1 Angstroms
1X0U	;	2.2	;	Crystal Structure of the carboxyl transferase subunit of putative PCC of Sulfolobus tokodaii
3FLO	;	2.5	;	Crystal structure of the carboxyl-terminal domain of yeast DNA polymerase alpha in complex with its B subunit
1W2X	;	2.8	;	Crystal structure of the carboxyltransferase domain of acetyl- coenzyme A carboxylase in complex with CP-640186
3H0J	;	2.8	;	Crystal structure of the carboxyltransferase domain of acetyl-coenzyme A carboxylase in complex with compound 2
3H0Q	;	2.5	;	Crystal structure of the carboxyltransferase domain of acetyl-coenzyme A carboxylase in complex with compound 3
3H0S	;	2.43	;	Crystal structure of the carboxyltransferase domain of acetyl-coenzyme A carboxylase in complex with compound 7
3K8X	;	2.3	;	Crystal structure of the carboxyltransferase domain of acetyl-coenzyme A carboxylase in complex with tepraloxydim
3PGQ	;	2.8	;	Crystal Structure of the Carboxyltransferase Domain of S. cerevisiae Acetyl CoA Carboxylase in Complex with Pinoxaden
2NX9	;	1.7	;	Crystal structure of the carboxyltransferase domain of the oxaloacetate decarboxylase Na+ pump from Vibrio cholerae
4G2R	;	2.28	;	Crystal Structure of the carboxyltransferase subunit of ACC (AccD6) in complex with inhibitor haloxyfop from Mycobacterium tuberculosis
6TZV	;	2.388	;	Crystal Structure of the carboxyltransferase subunit of ACC (AccD6) in complex with inhibitor Phenyl-Cyclodiaone from Mycobacterium tuberculosis
6PK2	;	2.402	;	CRYSTAL STRUCTURE OF THE CARBOXYLTRANSFERASE SUBUNIT OF ACC (ACCD6) IN COMPLEX WITH INHIBITOR QUIZALOFOP-P derivative FROM MYCOBACTERIUM TUBERCULOSIS
6PRW	;	2.609	;	CRYSTAL STRUCTURE OF THE CARBOXYLTRANSFERASE SUBUNIT OF ACC (ACCD6) IN COMPLEX WITH INHIBITOR QUIZALOFOP-P DERIVATIVE FROM MYCOBACTERIUM TUBERCULOSIS
6P7U	;	2.198	;	CRYSTAL STRUCTURE OF THE CARBOXYLTRANSFERASE SUBUNIT OF ACC (ACCD6) IN COMPLEX WITH INHIBITOR QUIZALOFOP-P FROM MYCOBACTERIUM TUBERCULOSIS
2F9I	;	1.98	;	Crystal Structure of the carboxyltransferase subunit of ACC from Staphylococcus aureus
1PIX	;	2.2	;	Crystal structure of the carboxyltransferase subunit of the bacterial ion pump glutaconyl-coenzyme A decarboxylase
1JQG	;	2.5	;	Crystal Structure of the Carboxypeptidase A from Helicoverpa Armigera
3KAT	;	3.1	;	Crystal Structure of the CARD domain of the human NLRP1 protein, Northeast Structural Genomics Consortium Target HR3486E
3IDU	;	1.7	;	Crystal Structure of the CARDB domain of the PF1109 protein in complex with di-metal ions from Pyrococcus furiosus, Northeast Structural Genomics Consortium Target PfR193A
7KFL	;	2.35	;	Crystal structure of the cargo-binding domain from the plant class XI myosin (MyoXIk)
3IOQ	;	1.87	;	Crystal structure of the Carica candamarcensis cysteine protease CMS1MS2 in complex with E-64.
8FTY	;	1.95	;	Crystal structure of the carotenoid isomerooxygenase, NinaB
7ZVR	;	2.0	;	Crystal structure of the carotenoid-binding protein domain from silkworm Bombyx mori (BmCBP) complexed with zeaxanthin
7ZTQ	;	1.45	;	Crystal structure of the carotenoid-binding protein domain from silkworm Bombyx mori (BmCBP) in the apoform
7ZTU	;	1.9	;	Crystal structure of the carotenoid-binding protein domain from silkworm Bombyx mori (BmCBP) in the apoform, D162L mutant
7ZVQ	;	2.5	;	Crystal structure of the carotenoid-binding protein domain from silkworm Bombyx mori (BmCBP) in the apoform, S206V mutant
7ZTR	;	1.75	;	Crystal structure of the carotenoid-binding protein domain from silkworm Bombyx mori (BmCBP) in the apoform, W232F mutant
8AAQ	;	1.8	;	Crystal structure of the carotenoid-binding protein domain from silkworm Bombyx mori (BmCBP), CRT-416 form
4P6I	;	2.3	;	Crystal structure of the Cas1-Cas2 complex from Escherichia coli
7D3J	;	2.45	;	Crystal structure of the Cas12i1 R-loop complex after target DNA cleavage
7D2L	;	2.75	;	Crystal structure of the Cas12i1 R-loop complex before target DNA cleavage
7D8C	;	3.6	;	Crystal structure of the Cas12i1-crRNA binary complex
7VTI	;	1.89	;	Crystal structure of the Cas13bt3-crRNA binary complex
5G4D	;	1.701	;	Crystal structure of the Cas2 in T.onnurineus
6DD5	;	2.85	;	Crystal Structure of the Cas6 Domain of Marinomonas mediterranea MMB-1 Cas6-RT-Cas1 Fusion Protein
4IS7	;	2.751	;	Crystal Structure of the CASKIN2 SAM Domain Tandem
1KMC	;	2.9	;	Crystal Structure of the Caspase-7 / XIAP-BIR2 Complex
1I4E	;	3.0	;	CRYSTAL STRUCTURE OF THE CASPASE-8/P35 COMPLEX
1SY7	;	1.75	;	Crystal structure of the catalase-1 from Neurospora crassa, native structure at 1.75A resolution.
2CCA	;	2.0	;	Crystal structure of the catalase-peroxidase (KatG) and S315T mutant from Mycobacterium tuberculosis
2CCD	;	2.1	;	Crystal structure of the catalase-peroxidase (KatG) and S315T mutant from Mycobacterium tuberculosis
4C50	;	2.5	;	Crystal Structure of the Catalase-Peroxidase (KatG) D137S mutant from Mycobacterium Tuberculosis
4C51	;	3.1	;	Crystal Structure of the Catalase-Peroxidase (KatG) R418L mutant from Mycobacterium Tuberculosis
5KSK	;	1.69	;	Crystal structure of the catalase-peroxidase from B. pseudomallei treated with acetate
5KT9	;	1.88	;	Crystal structure of the catalase-peroxidase from B. pseudomallei treated with hydrogen peroxide and carbon monoxide
6B9B	;	1.8	;	Crystal structure of the catalase-peroxidase from B. pseudomallei with maltose bound
5WHS	;	2.6	;	Crystal structure of the catalase-peroxidase from Neurospora crassa at 2.6 A
5WHQ	;	2.9	;	Crystal structure of the catalase-peroxidase from Neurospora crassa at 2.9 A
5SX3	;	2.0	;	Crystal structure of the catalase-peroxidase KatG of B. pseudomaallei at pH 4.5
5SX6	;	1.9	;	Crystal structure of the catalase-peroxidase KatG of B. pseudomallei at pH 6.5
3X16	;	2.65	;	Crystal structure of the catalase-peroxidase KatG W78F mutant from Synechococcus elongatus PCC7942
6ZZI	;	1.932	;	Crystal structure of the catalyic domain of Corynebacterium glutamicum acetyltransferase AceF (E2p).
2HNH	;	2.3	;	Crystal structure of the catalytic alpha subunit of E. coli replicative DNA polymerase III
2HQA	;	2.6	;	Crystal structure of the catalytic alpha subunit of E. Coli replicative DNA polymerase III
4GT8	;	1.51	;	Crystal Structure of the Catalytic and ATP-binding Domain from VraS in Complex with ADP
2AQX	;	2.5	;	Crystal Structure of the Catalytic and CaM-Binding domains of Inositol 1,4,5-Trisphosphate 3-Kinase B
8H70	;	1.88	;	Crystal structure of the catalytic ATP-binding domain of the PhoR sensor histidine kinase from Vibrio cholera
3DLR	;	2.2	;	Crystal structure of the catalytic core domain from PFV integrase
3K3N	;	2.4	;	Crystal structure of the catalytic core domain of human PHF8
3K3O	;	2.1	;	Crystal structure of the catalytic core domain of human PHF8 complexed with alpha-ketoglutarate
2GP3	;	2.35	;	Crystal structure of the catalytic core domain of jmjd2a
3DXT	;	1.8	;	Crystal structure of the catalytic core domain of JMJD2D
5CZ1	;	1.7	;	Crystal structure of the catalytic core domain of MMTV integrase
5OYH	;	2.249	;	crystal structure of the catalytic core of a rhodopsin-guanylyl cyclase with converted specificity in complex with ATPalphaS
3IVK	;	3.1	;	Crystal Structure of the Catalytic Core of an RNA Polymerase Ribozyme Complexed with an Antigen Binding Antibody Fragment
5U7G	;	2.401	;	Crystal Structure of the Catalytic Core of CBP
4LJQ	;	2.45	;	Crystal structure of the catalytic core of E3 ligase HOIP
6AS7	;	2.95	;	CRYSTAL STRUCTURE OF THE CATALYTIC CORE OF HUMAN DNA POLYMERASE ALPHA IN TERNARY COMPLEX WITH AN DNA-PRIMED DNA TEMPLATE AND DCTP
4Q5V	;	2.52	;	Crystal structure of the catalytic core of human DNA polymerase alpha in ternary complex with an RNA-primed DNA template and aphidicolin
4QCL	;	2.2	;	Crystal structure of the catalytic core of human DNA polymerase alpha in ternary complex with an RNA-primed DNA template and dCTP
1T94	;	2.4	;	Crystal structure of the catalytic core of human DNA polymerase kappa
1TZD	;	2.2	;	CRYSTAL STRUCTURE OF THE CATALYTIC CORE OF INOSITOL 1,4,5-TRISPHOSPHATE 3-KINASE
1JMS	;	2.36	;	Crystal Structure of the Catalytic Core of Murine Terminal Deoxynucleotidyl Transferase
4NLB	;	2.4	;	Crystal structure of the catalytic core of RRP6 from Trypanosoma brucei
4NLC	;	2.15	;	Crystal structure of the catalytic core of RRP6 from Trypanosoma brucei, mutant C496S
3RQC	;	4.01	;	Crystal structure of the catalytic core of the 2-oxoacid dehydrogenase multienzyme complex from Thermoplasma acidophilum
4I4N	;	1.84	;	Crystal Structure of the catalytic Cys to Ala mutant of VcHsp31 from Vibrio cholerae
6MGJ	;	2.0	;	Crystal structure of the catalytic domain from GH74 enzyme PoGH74 from Paenibacillus odorifer, apoenzyme
6MGL	;	1.5	;	Crystal structure of the catalytic domain from GH74 enzyme PoGH74 from Paenibacillus odorifer, D60A mutant in complex with XXLG and XGXXLG xyloglucan
6MGK	;	2.1	;	Crystal structure of the catalytic domain from GH74 enzyme PoGH74 from Paenibacillus odorifer, in complex with XLX xyloglucan
8OW8	;	2.0	;	Crystal Structure of the Catalytic Domain of a Botulinum Neurotoxin Homologue from Enterococcus faecium
4RL3	;	1.57	;	Crystal Structure of the Catalytic Domain of a family GH18 Chitinase from fern, Peteris ryukyuensis
7V91	;	1.6	;	Crystal Structure of the Catalytic Domain of a Family GH19 Chitinase from Gazyumaru, Ficus microcarpa
6JP4	;	2.069	;	Crystal structure of the catalytic domain of a multi-domain alginate lyase Dp0100 from thermophilic bacterium Defluviitalea phaphyphila
6JPH	;	2.759	;	Crystal structure of the catalytic domain of a multi-domain alginate lyase Dp0100 from thermophilic bacterium Defluviitalea phaphyphila
6JPN	;	2.85	;	Crystal structure of the catalytic domain of a multi-domain alginate lyase Dp0100 from thermophilic bacterium Defluviitalea phaphyphila
1GH2	;	2.22	;	Crystal structure of the catalytic domain of a new human thioredoxin-like protein
1TML	;	1.8	;	CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF A THERMOPHILIC ENDOCELLULASE
3HY9	;	2.02	;	Crystal Structure of the Catalytic Domain of ADAMTS-5 in Complex with an Amino-2-indanol compound
3HYG	;	1.4	;	Crystal Structure of the Catalytic Domain of ADAMTS-5 in Complex with an Amino-2-indanol compound
3LJT	;	1.6	;	Crystal Structure of the Catalytic Domain of ADAMTS-5 in Complex with an Amino-2-indanol compound
3HY7	;	1.69	;	Crystal Structure of the Catalytic Domain of ADAMTS-5 in Complex with Marimastat
6YJM	;	2.25	;	Crystal Structure of the Catalytic Domain of ADAMTS-5 in Complex with the Inhibitor GLPG1972
2VK9	;	2.85	;	CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF ALPHA-TOXIN FROM CLOSTRIDIUM NOVYI
1ZY7	;	1.7	;	Crystal structure of the catalytic domain of an adenosine deaminase that acts on RNA (hADAR2) bound to inositol hexakisphosphate (IHP)
7WME	;	1.7	;	Crystal Structure of the catalytic domain of At-HIGLE
1ZRZ	;	3.0	;	Crystal Structure of the Catalytic Domain of Atypical Protein Kinase C-iota
4ASM	;	1.5	;	Crystal structure of the catalytic domain of beta-agarase D from Zobellia galactanivorans
3VOC	;	1.95	;	Crystal structure of the catalytic domain of beta-amylase from paenibacillus polymyxa
4ELC	;	1.8	;	Crystal structure of the catalytic domain of botulinum neurotoxin BoNT/A C134 mutant with MTSEA modified Cys-165
4KUF	;	1.697	;	Crystal structure of the catalytic domain of botulinum neurotoxin BoNT/A C134 mutant with MTSEA modified Cys-165 causing stretch disorder
4KS6	;	1.93	;	Crystal structure of the catalytic domain of botulinum neurotoxin BoNT/A C134S mutant with covalent inhibitor that modifies Cys-165 causing disorder in 166-174 stretch
4KTX	;	2.59	;	Crystal structure of the catalytic domain of botulinum neurotoxin BoNT/A C134S mutant with covalent inhibitor that modifies Cys-165 causing disorder in 167-174 stretch
4EL4	;	1.2	;	Crystal structure of the catalytic domain of botulinum neurotoxin BoNT/A C134S/C165S double mutant
4EJ5	;	1.87	;	Crystal structure of the catalytic domain of botulinum neurotoxin BoNT/A wild-type
4ZJX	;	1.94	;	Crystal structure of the catalytic domain of botulinum neurotoxin serotype A with a Novel Cyclic Peptide Inhibitor
3DDA	;	1.5	;	Crystal structure of the catalytic domain of Botulinum neurotoxin serotype a with a snap-25 peptide
3DDB	;	1.6	;	Crystal structure of the catalytic domain of Botulinum neurotoxin serotype a with a substrate analog peptide
3BWI	;	1.7	;	Crystal structure of the catalytic domain of botulinum neurotoxin serotype A with an acetate ion bound at the active site
3C88	;	1.6	;	Crystal structure of the catalytic domain of botulinum neurotoxin serotype A with inhibitory peptide RRGC
3C8B	;	1.47	;	Crystal structure of the catalytic domain of botulinum neurotoxin serotype A with inhibitory peptide RRGI
3C8A	;	1.52	;	Crystal structure of the catalytic domain of botulinum neurotoxin serotype A with inhibitory peptide RRGL
3C89	;	1.58	;	Crystal structure of the catalytic domain of botulinum neurotoxin serotype A with inhibitory peptide RRGM
7DVL	;	2.006	;	Crystal Structure of the Catalytic Domain of Botulinum Neurotoxin Subtype A3
6F47	;	1.35	;	Crystal structure of the catalytic domain of botulinum neurotoxin X
1O0R	;	2.3	;	Crystal structure of the catalytic domain of bovine beta1,4-galactosyltransferase complex with UDP-galactose
2FYC	;	2.0	;	Crystal structure of the catalytic domain of bovine beta1,4-galactosyltransferase-I in complex with alpha-lactalbumin, Ca and UDP-galactose
3RHK	;	1.94	;	Crystal structure of the catalytic domain of c-Met kinase in complex with ARQ 197
6ZZK	;	2.09	;	Crystal structure of the catalytic domain of C. glutamicum AceF (E2p) in ternary complex with CoA and dihydrolipoamide.
6KST	;	1.25	;	Crystal structure of the catalytic domain of chitinase ChiL from Chitiniphilus shinanonensis (CsChiL)
6KXL	;	1.35	;	Crystal structure of the catalytic domain of Chitiniphilus shinanonensis chitinase ChiL (CsChiL) complexed with N,N'-diacetylchitobiose
3QHP	;	1.5	;	Crystal structure of the catalytic domain of cholesterol-alpha-glucosyltransferase from Helicobacter pylori
5TSP	;	1.24	;	Crystal structure of the catalytic domain of Clostridium perfringens neuraminidase (NanI) in complex with a CHES
1ZMN	;	2.05	;	Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with (R)-1-(4-(4-(hydroxymethyl)-1,3,2-dioxaborolan-2-yl)phenyl)guanidine
1ZTK	;	2.5	;	Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 2-(5-Amino-6-oxo-2-m-tolyl-6H-pyrimidin-1-yl)-N-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-acetamide
1ZTJ	;	2.05	;	Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 2-(5-Benzylamino-2-methylsulfanyl-6-oxo-6H-pyrimidin-1-yl)-N-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-acetamide
1ZPC	;	2.6	;	Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 2-[2-(3-Chloro-phenyl)-2-hydroxy-acetylamino]-N-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-3-methyl-butyramide
1ZPB	;	2.1	;	Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 4-Methyl-pentanoic acid {1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-methyl-propyl}-amide
1ZSK	;	1.9	;	Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 6-Carbamimidoyl-4-(3-hydroxy-2-methyl-benzoylamino)-naphthalene-2-carboxylic acid methyl ester
1ZOM	;	2.25	;	Crystal Structure of the Catalytic Domain of Coagulation Factor XI in complex with a peptidomimetic Inhibitor
1ZHR	;	1.73	;	Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with Benzamidine (S434A-T475A-C482S-K437A Mutant)
1ZHP	;	2.7	;	Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with Benzamidine (S434A-T475A-K505 Mutant)
1ZJD	;	2.6	;	Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with Kunitz Protease Inhibitor Domain of Protease Nexin II
1ZSJ	;	1.9	;	Crystal Structure of the Catalytic Domain of Coagulation Factor XI in complex with N-(7-Carbamimidoyl-naphthalen-1-yl)-3-hydroxy-2-methyl-benzamide
1ZTL	;	2.6	;	Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with N-[4-Guanidino-1-(thiazole-2-carbonyl)-butyl]-2-{6-oxo-5-[(quinolin-8-ylmethyl)-amino]-2-m-tolyl-6H-pyrimidin-1-yl}-acetamide
6TWB	;	2.91	;	Crystal Structure of the Catalytic Domain of Coagulation Factor XIa in Complex with Double Bridged Peptide F19
6ZZJ	;	1.35	;	Crystal structure of the catalytic domain of Corynebacterium glutamicum acetyltransferase AceF (E2p) in complex with oxidized CoA.
6ZZM	;	2.5	;	Crystal structure of the catalytic domain of Corynebacterium mustelae predicted acetyltransferase AceF (E2p).
4ONW	;	1.65	;	Crystal structure of the catalytic domain of DapE protein from V.cholerea
4OP4	;	1.651	;	Crystal structure of the catalytic domain of DapE protein from V.cholerea in the Zn bound form
1XPI	;	2.2	;	Crystal structure of the catalytic domain of E. coli pseudouridine synthase RluC
1HQ0	;	1.83	;	CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF E.COLI CYTOTOXIC NECROTIZING FACTOR TYPE 1
1ZML	;	2.25	;	Crystal Structure of the Catalytic Domain of Factor XI in complex with (R)-1-(4-(4-(hydroxymethyl)-1,3,2-dioxaborolan-2-yl)phenethyl)guanidine
1ZMJ	;	2.0	;	Crystal Structure of the Catalytic Domain of Factor XI in complex with 4-(guanidinomethyl)-phenylboronic acid
3RHX	;	2.01	;	Crystal structure of the catalytic domain of FGFR1 kinase in complex with ARQ 069
3RI1	;	2.1	;	Crystal structure of the catalytic domain of FGFR2 kinase in complex with ARQ 069
2XDV	;	2.57	;	Crystal Structure of the Catalytic Domain of FLJ14393
8AKP	;	1.9	;	Crystal structure of the catalytic domain of G7048 from Penicillium sumatraense
1ITG	;	2.3	;	CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HIV-1 INTEGRASE: SIMILARITY TO OTHER POLYNUCLEOTIDYL TRANSFERASES
1R55	;	1.58	;	Crystal structure of the catalytic domain of human ADAM 33
1R54	;	1.85	;	Crystal structure of the catalytic domain of human ADAM33
2FDA	;	2.0	;	Crystal Structure of the Catalytic Domain of Human Coagulation Factor XIa in Complex with alpha-Ketothiazole Arginine Derived Ligand
1ELV	;	1.7	;	CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN COMPLEMENT C1S PROTEASE
5BYB	;	2.3	;	Crystal structure of the catalytic domain of human diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) in complex with ADP and 1,5-(PA)2-IP4
5BYA	;	1.9	;	Crystal structure of the catalytic domain of human diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) in complex with ADP and 1,5-(PCP)2-IP4
3T9F	;	2.0	;	Crystal structure of the catalytic domain of human diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) in complex with ADP and 1,5-(PP)2-IP4 (1,5-IP8)
5DGI	;	1.85	;	Crystal structure of the catalytic domain of human diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) in complex with ADP and 3,5-(PCP)2-IP4
3T99	;	2.1	;	Crystal structure of the catalytic domain of human diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) in complex with ADP and in the absence of cadmium at pH 7.0
4Q4C	;	1.9	;	Crystal structure of the catalytic domain of human diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) in complex with ADP and synthetic 1,5-(PP)2-IP4 (1,5-IP8)
3T7A	;	1.7	;	Crystal structure of the catalytic domain of human diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) in complex with ADP at pH 5.2
3T9E	;	1.9	;	Crystal structure of the catalytic domain of human diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) in complex with ADP, 5-(PP)-IP5 (5-IP7) and MgF3 (transition state mimic)
8G9E	;	1.75	;	Crystal structure of the catalytic domain of human diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) in complex with AMP-PNP and 5-(PCF2P)-IP5, an analog of 5-IP7
5DGH	;	2.1	;	Crystal structure of the catalytic domain of human diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) in complex with AMP-PNP and 5-(PCP)-IP5
4Q4D	;	1.85	;	Crystal structure of the catalytic domain of human diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) in complex with AMP-PNP and synthetic 3,5-(PP)2-IP4 (3,5-IP8)
3T9D	;	1.85	;	Crystal structure of the catalytic domain of human diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) in complex with AMPPNP and 5-(PP)-IP5 (5-IP7)
4HN2	;	1.9	;	Crystal structure of the catalytic domain of human diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) in complex with AMPPNP and a substrate analog 5PA-IP5
3T9C	;	1.9	;	Crystal structure of the catalytic domain of human diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) in complex with AMPPNP and inositol hexakisphosphate (IP6)
3T9B	;	1.85	;	Crystal structure of the catalytic domain of human diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) in complex with AMPPNP at pH 5.2
3T9A	;	1.8	;	Crystal structure of the catalytic domain of human diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) in complex with AMPPNP at pH 7.0
3T54	;	1.9	;	Crystal structure of the catalytic domain of human diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) in complex with ATP and Cadmium
1ZWS	;	2.9	;	Crystal structure of the catalytic domain of human DRP-1 kinase
4Y2E	;	1.67	;	Crystal structure of the catalytic domain of human dual-specificity phosphatase 7 (C232S)
4JNB	;	3.0	;	Crystal structure of the Catalytic Domain of Human DUSP12
4KI9	;	2.0	;	Crystal structure of the catalytic domain of human DUSP12 at 2.0 A resolution
4B04	;	2.205	;	Crystal structure of the Catalytic Domain of Human DUSP26 (C152S)
6OZE	;	1.5	;	Crystal structure of the catalytic domain of human Endonuclease V (C140S/C225S/C226A/C228S)
1SLN	;	2.27	;	CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN FIBROBLAST STROMELYSIN-1 INHIBITED WITH THE N-CARBOXY-ALKYL INHIBITOR L-702,842
1HFS	;	1.7	;	CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN FIBROBLAST STROMELYSIN-1 INHIBITED WITH THE N-CARBOXY-ALKYL INHIBITOR L-764,004
2USN	;	2.2	;	CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN FIBROBLAST STROMELYSIN-1 INHIBITED WITH THIADIAZOLE INHIBITOR PNU-141803
1USN	;	1.8	;	CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN FIBROBLAST STROMELYSIN-1 INHIBITED WITH THIADIAZOLE INHIBITOR PNU-142372
3PB4	;	1.13	;	Crystal structure of the catalytic domain of human Golgi-resident glutaminyl cyclase at pH 6.0
3PB6	;	1.05	;	Crystal structure of the catalytic domain of human Golgi-resident glutaminyl cyclase at pH 6.5
3PB9	;	1.12	;	Crystal structure of the catalytic domain of human Golgi-resident glutaminyl cyclase in complex with 1-benzylimidazole
3PB8	;	1.13	;	Crystal structure of the catalytic domain of human Golgi-resident glutaminyl cyclase in complex with N-acetylhistamine
3PB7	;	1.4	;	Crystal structure of the catalytic domain of human Golgi-resident glutaminyl cyclase in complex with PBD150
3KVO	;	2.25	;	Crystal structure of the catalytic domain of human Hydroxysteroid dehydrogenase like 2 (HSDL2)
2A98	;	2.6	;	Crystal structure of the catalytic domain of human inositol 1,4,5-trisphosphate 3-kinase C
5FZ0	;	2.42	;	Crystal structure of the catalytic domain of human JARID1B in complex with 2,5-dichloro-N-(pyridin-3-yl)thiophene-3-carboxamide (N08137b) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)
5FZ4	;	2.07	;	Crystal structure of the catalytic domain of human JARID1B in complex with 3D fragment (3R)-1-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]pyrrolidin-3-ol (N10057a) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)
5FYT	;	1.87	;	Crystal structure of the catalytic domain of human JARID1B in complex with 3D fragment (5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-yl)acetic acid (N09996a)
5FYZ	;	1.75	;	Crystal structure of the catalytic domain of human JARID1B in complex with 3D fragment 2-(2-oxo-2,3-dihydro-1H-indol-3-yl)acetonitrile (N10063a)
5FZA	;	2.099	;	Crystal structure of the catalytic domain of human JARID1B in complex with 3D fragment 2-piperidin-4-yloxy-5-(trifluoromethyl)pyridine (N10072a) (ligand modelled based on PANDDA event map)
5FYU	;	2.06	;	Crystal structure of the catalytic domain of human JARID1B in complex with 3D fragment 3-Amino-4-methyl-1,3-dihydro-2H-indol-2-one (N10042a)
5FZL	;	2.55	;	Crystal structure of the catalytic domain of human JARID1B in complex with 3D fragment 3-methyl-N-pyridin-4-yl-1,2-oxazole-5-carboxamide (N09954a) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)
5FZM	;	2.49	;	Crystal structure of the catalytic domain of human JARID1B in complex with 3D fragment 5-(2-fluorophenyl)-1,3-oxazole-4-carboxylic acid (N09989b) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)
5FZK	;	2.05	;	Crystal structure of the catalytic domain of human JARID1B in complex with 3D fragment N,3-dimethyl-N-(pyridin-3-ylmethyl)-1,2-oxazole-5- carboxamide (N10051a) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)
5FYS	;	1.89	;	Crystal structure of the catalytic domain of human JARID1B in complex with D-2-hydroxyglutarate
5FY5	;	2.47	;	Crystal structure of the catalytic domain of human JARID1B in complex with fumarate
5FZD	;	2.05	;	Crystal structure of the catalytic domain of human JARID1B in complex with L-2-hydroxyglutarate
5FZ8	;	1.86	;	Crystal structure of the catalytic domain of human JARID1B in complex with malate
5FZ1	;	2.39	;	Crystal structure of the catalytic domain of human JARID1B in complex with Maybridge fragment 2,4-dichloro-N-pyridin-3-ylbenzamide (E48115b) (ligand modelled based on PANDDA event map)
5FZ3	;	2.5	;	Crystal structure of the catalytic domain of human JARID1B in complex with Maybridge fragment 3,6-Dihydroxybenzonorbornane (N08776b) (ligand modelled based on PANDDA event map)
5FYY	;	2.18	;	Crystal structure of the catalytic domain of human JARID1B in complex with Maybridge fragment 3-pyridin-3-ylaniline (N05798a) (ligand modelled based on PANDDA event map)
5FZC	;	2.05	;	Crystal structure of the catalytic domain of human JARID1B in complex with Maybridge fragment 4,5-dihydronaphtho(1,2-b)thiophene-2- carboxylicacid (N11181a) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)
5FZH	;	2.09	;	Crystal structure of the catalytic domain of human JARID1B in complex with Maybridge fragment 4,5-dihydronaphtho(1,2-b)thiophene-2- carboxylicacid (N11181a) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)
5FZB	;	2.18	;	Crystal structure of the catalytic domain of human JARID1B in complex with Maybridge fragment 4-Pyridylthiourea (N06275b) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)
5FZ7	;	2.3	;	Crystal structure of the catalytic domain of human JARID1B in complex with Maybridge fragment ethyl 2-amino-4-thiophen-2-ylthiophene-3- carboxylate (N06131b) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)
5FZ6	;	2.33	;	Crystal structure of the catalytic domain of human JARID1B in complex with Maybridge fragment N05859b (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)
5FZ9	;	2.06	;	Crystal structure of the catalytic domain of human JARID1B in complex with Maybridge fragment thieno(3,2-b)thiophene-5-carboxylic acid (N06263b) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)
5FYB	;	1.87	;	Crystal structure of the catalytic domain of human JARID1B in complex with MC1648
5FZI	;	1.95	;	Crystal structure of the catalytic domain of human JARID1B in complex with MC3095
5FZG	;	1.96	;	Crystal structure of the catalytic domain of human JARID1B in complex with MC3948
5FZE	;	2.02	;	Crystal structure of the catalytic domain of human JARID1B in complex with MC3960
5FZF	;	1.97	;	Crystal structure of the catalytic domain of human JARID1B in complex with MC3962
5FYV	;	1.87	;	Crystal structure of the catalytic domain of human JARID1B in complex with oxaloacetate
5FY9	;	2.03	;	Crystal structure of the catalytic domain of human JARID1B in complex with pyruvate
5FY4	;	2.1	;	Crystal structure of the catalytic domain of human JARID1B in complex with succinate
5FZO	;	1.84	;	Crystal structure of the catalytic domain of human JmjD1C
4ARK	;	2.6	;	CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN MAP KINASE KINASE 1 (MEK1) IN COMPLEX WITH A SMALL MOLECULE INHIBITOR AND ADP
1Q3A	;	2.1	;	Crystal structure of the catalytic domain of human matrix metalloproteinase 10
2OUD	;	2.8	;	Crystal structure of the catalytic domain of human MKP5
1Y93	;	1.03	;	Crystal structure of the catalytic domain of human MMP12 complexed with acetohydroxamic acid at atomic resolution
3EHY	;	1.9	;	Crystal structure of the catalytic domain of human MMP12 complexed with the inhibitor (R)-2-(4-methoxyphenylsulfonamido)propanoic acid
3EHX	;	1.9	;	Crystal structure of the catalytic domain of human MMP12 complexed with the inhibitor (R)-2-(biphenyl-4-ylsulfonamido)-4-methylpentanoic acid
3F16	;	1.16	;	Crystal structure of the catalytic domain of human MMP12 complexed with the inhibitor (R)-N-(3-hydroxy-1-nitroso-1-oxopropan-2-yl)-4-methoxybenzenesulfonamide
3F15	;	1.7	;	Crystal structure of the catalytic domain of human mmp12 complexed with the inhibitor (S)-N-(2,3-dihydroxypropyl)-4-methoxy-N-(2-nitroso-2-oxoethyl)benzenesulfonamide
3F18	;	1.13	;	Crystal structure of the catalytic domain of human MMP12 complexed with the inhibitor 4-fluoro-N-(2-hydroxyethyl)-N-(2-nitroso-2-oxoethyl)benzenesulfonamide
3F19	;	1.13	;	Crystal structure of the catalytic domain of human MMP12 complexed with the inhibitor 4-fluoro-N-(2-nitroso-2-oxoethyl)benzenesulfonamide
3F1A	;	1.25	;	Crystal structure of the catalytic domain of human MMP12 complexed with the inhibitor N-(2-nitroso-2-oxoethyl)benzenesulfonamide
3F17	;	1.1	;	Crystal structure of the catalytic domain of human MMP12 complexed with the inhibitor N-(2-nitroso-2-oxoethyl)biphenyl-4-sulfonamide
3N2U	;	1.81	;	Crystal structure of the catalytic domain of human MMP12 complexed with the inhibitor N-hydroxy-2-(4-methoxy-N(2-(3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)ethyl)phenylsulfonamido)acetamide
3NX7	;	1.8	;	Crystal structure of the catalytic domain of human MMP12 complexed with the inhibitor N-Hydroxy-2-(N-(2-hydroxyethyl)4-methoxyphenylsulfonamido)acetamide
3N2V	;	1.55	;	Crystal structure of the catalytic domain of human MMP12 complexed with the inhibitor N-hydroxy-2-(N-hydroxyethyl)biphenyl-4-ylsulfonamido)acetamide
5LAB	;	1.34	;	Crystal structure of the catalytic domain of human MMP12 complexed with the inhibitor NNGH
1RMZ	;	1.34	;	Crystal structure of the catalytic domain of human MMP12 complexed with the inhibitor NNGH at 1.3 A resolution
3LK8	;	1.8	;	Crystal structure of the catalytic domain of human MMP12 complexed with the inhibitor paramethoxy-sulfonyl-glycine hydroxamate
4H76	;	1.5	;	Crystal structure of the catalytic domain of Human MMP12 in complex with a broad spectrum hydroxamate inhibitor
5CXA	;	1.3	;	Crystal structure of the catalytic domain of Human MMP12 in complex with a carboxylate inhibitor related to RXP470
4H84	;	1.592	;	Crystal structure of the catalytic domain of Human MMP12 in complex with a selective carboxylate based inhibitor.
4GQL	;	1.15	;	Crystal structure of the catalytic domain of Human MMP12 in complex with selective phosphinic inhibitor RXP470.1
4GR3	;	1.494	;	Crystal structure of the catalytic domain of Human MMP12 in complex with selective phosphinic inhibitor RXP470A
4GR0	;	1.497	;	Crystal structure of the catalytic domain of Human MMP12 in complex with selective phosphinic inhibitor RXP470B
4GR8	;	1.299	;	Crystal structure of the catalytic domain of Human MMP12 in complex with selective phosphinic inhibitor RXP470C
6SCX	;	2.92	;	Crystal structure of the catalytic domain of human NUDT12 in complex with 7-methyl-guanosine-5'-triphosphate
7AAA	;	1.74	;	Crystal structure of the catalytic domain of human PARP1 (apo)
7AAB	;	2.8	;	Crystal structure of the catalytic domain of human PARP1 in complex with inhibitor EB-47
7AAD	;	2.21	;	Crystal structure of the catalytic domain of human PARP1 in complex with olaparib
7AAC	;	1.593	;	Crystal structure of the catalytic domain of human PARP1 in complex with veliparib
5B4L	;	2.4	;	Crystal structure of the catalytic domain of human PDE10A complexed with 1-(cyclopropylmethyl)-5-(2-(2,3-dihydro-1H-imidazo[1,2-a]benzimidazol-1-yl)ethoxy)-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one
5B4K	;	2.9	;	Crystal structure of the catalytic domain of human PDE10A complexed with N-(4-((5-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)oxy)phenyl)-1H-benzimidazol-2-amine
7L27	;	1.7	;	Crystal structure of the catalytic domain of human PDE3A
7L29	;	2.08	;	Crystal structure of the catalytic domain of human PDE3A bound to AMP
7KWE	;	2.0	;	Crystal structure of the catalytic domain of human PDE3A bound to DNMDP
7L28	;	2.2	;	Crystal structure of the catalytic domain of human PDE3A bound to Trequinsin
8UAK	;	2.82	;	Crystal structure of the catalytic domain of human PKC alpha (D463N, V568I, S657E) in complex with Darovasertib (NVP-LXS196) at 2.82-A resolution
8U37	;	2.48	;	Crystal structure of the catalytic domain of human PKC alpha (D463N, V568I, S657E) in complex with NVP-CJL037 at 2.48-A resolution
5A3P	;	2.008	;	Crystal structure of the catalytic domain of human PLU1 (JARID1B).
5J8R	;	2.043	;	Crystal Structure of the Catalytic Domain of Human Protein Tyrosine Phosphatase non-receptor Type 12 - K61R mutant
2OC3	;	1.5	;	Crystal Structure of the Catalytic Domain of Human Protein Tyrosine Phosphatase non-receptor Type 18
4IQM	;	1.8	;	Crystal structure of the catalytic domain of human Pus1
4J37	;	1.75	;	Crystal structure of the catalytic domain of human Pus1
4ITS	;	1.85	;	Crystal structure of the catalytic domain of human Pus1 with MES in the active site
4HNE	;	2.95	;	Crystal structure of the catalytic domain of human type II alpha Phosphatidylinositol 4-kinase (PI4KIIalpha) in complex with ADP
2A8B	;	2.3	;	Crystal Structure of the Catalytic Domain of Human Tyrosine Phosphatase Receptor, Type R
2AHS	;	2.1	;	Crystal Structure of the Catalytic Domain of Human Tyrosine Receptor Phosphatase Beta
5J3P	;	3.1	;	Crystal structure of the catalytic domain of human tyrosyl DNA phosphodiesterase 2
5J3S	;	3.4	;	Crystal structure of the catalytic domain of human tyrosyl DNA phosphodiesterase 2 in complex with a small molecule inhibitor
6LOH	;	3.207	;	Crystal structure of the catalytic domain of human ubiquitin ligase AREL1
5WCH	;	2.5	;	Crystal structure of the catalytic domain of human USP9X
7XLO	;	2.6	;	Crystal Structure of the Catalytic Domain of Inosine Monophosphate Dehydrogenase (IMPDH) from Methanocaldococcus jannaschii
2VL8	;	2.31	;	CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF LETHAL TOXIN FROM CLOSTRIDIUM SORDELLII IN COMPLEX WITH UDP, CASTANOSPERMINE AND CALCIUM ION
2VKH	;	2.3	;	CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF LETHAL TOXIN FROM CLOSTRIDIUM SORDELLII IN COMPLEX WITH UDP-GLC AND CALCIUM ION
2VKD	;	2.53	;	CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF LETHAL TOXIN FROM CLOSTRIDIUM SORDELLII IN COMPLEX WITH UDP-GLC AND MANGANESE ION
3BLE	;	2.0	;	Crystal structure of the catalytic domain of LiCMS in complexed with malonate
3BLF	;	2.6	;	Crystal structure of the catalytic domain of LiCMS in complexed with pyruvate
3BLI	;	2.5	;	Crystal structure of the catalytic domain of LiCMS in complexed with pyruvate and acetyl-CoA
5ZJV	;	1.82	;	Crystal structure of the catalytic domain of MCR-1 (cMCR-1) in complex with xylose
5H0U	;	2.239	;	Crystal structure of the catalytic domain of membrane type 1 matrix metalloproteinase
5K7W	;	1.65	;	Crystal structure of the catalytic domain of Mettl3/Mettl14 complex with SAH
3QTC	;	1.75	;	Crystal structure of the catalytic domain of MmOmeRS, an O-methyl tyrosyl-tRNA synthetase evolved from Methanosarcina mazei PylRS, complexed with O-methyl tyrosine and AMP-PNP
2J0T	;	2.54	;	Crystal Structure of the Catalytic Domain of MMP-1 in Complex with the Inhibitory Domain of TIMP-1
5I0L	;	2.45	;	Crystal structure of the catalytic domain of MMP-12 in complex with a selective sugar-conjugated arylsulfonamide carboxylate water-soluble inhibitor (DC27).
5I3M	;	2.17	;	Crystal structure of the catalytic domain of MMP-12 in complex with a selective sugar-conjugated thiourea-linked carboxylate zinc-chelator water-soluble inhibitor (DC31).
5I2Z	;	2.3	;	Crystal structure of the catalytic domain of MMP-12 in complex with a selective sugar-conjugated triazole-linked carboxylate chelating water-soluble inhibitor (DC24).
5I43	;	1.95	;	Crystal structure of the catalytic domain of MMP-12 in complex with a selective sugar-conjugated triazole-linked carboxylate chelator water-soluble inhibitor (DC32).
5I4O	;	2.05	;	Crystal structure of the catalytic domain of MMP-12 in complex with a selective sugar-conjugated triazole-linked carboxylate zinc-chelator water-soluble inhibitor (DC28).
4H30	;	1.43	;	Crystal structure of the catalytic domain of MMP-12 in complex with a twin inhibitor.
4H49	;	2.16	;	Crystal structure of the catalytic domain of MMP-12 in complex with a twin inhibitor.
3WV1	;	1.98	;	Crystal structure of the catalytic domain of MMP-13 complexed with 4-(2-((6-fluoro-2-((3-methoxybenzyl)carbamoyl)-4-oxo-3,4-dihydroquinazolin-5-yl)oxy)ethyl)benzoic acid
5B5P	;	1.6	;	Crystal structure of the catalytic domain of MMP-13 complexed with 4-oxo-N-(3-(2-(1H-1,2,4-triazol-3-ylsulfanyl)ethoxy)benzyl)-3,4-dihydroquinazoline-2-carboxamide
1YOU	;	2.3	;	Crystal structure of the catalytic domain of MMP-13 complexed with a potent pyrimidinetrione inhibitor
3WV2	;	2.3	;	Crystal structure of the catalytic domain of MMP-13 complexed with N-(3-methoxybenzyl)-4-oxo-3,4-dihydroquinazoline-2-carboxamide
3WV3	;	1.6	;	Crystal structure of the catalytic domain of MMP-13 complexed with N-(3-methoxybenzyl)-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-2-carboxamide
5B5O	;	1.2	;	Crystal structure of the catalytic domain of MMP-13 complexed with N-phenyl-4-((4H-1,2,4-triazol-3-ylsulfanyl)methyl)-1,3-thiazol-2-amine
1ZTQ	;	2.0	;	Crystal structure of the catalytic domain of MMP-13 complexed with WAY-033
2PJT	;	2.8	;	Crystal structure of the catalytic domain of MMP-13 complexed with WAY-344
1RM8	;	1.8	;	Crystal structure of the catalytic domain of MMP-16/MT3-MMP: Characterization of MT-MMP specific features
5I12	;	1.59	;	Crystal structure of the catalytic domain of MMP-9 in complex with a selective sugar-conjugated arylsulfonamide carboxylate water-soluble inhibitor (DC27).
2F7T	;	2.25	;	Crystal structure of the catalytic domain of Mos1 mariner transposase
6O3P	;	1.6	;	Crystal structure of the catalytic domain of mouse Nudt12 in complex with AMP and 3 Mg2+ ions
5FOH	;	1.6	;	Crystal structure of the catalytic domain of NcLPMO9A
4ONJ	;	2.807	;	Crystal structure of the catalytic domain of ntDRM
6XQZ	;	2.04	;	Crystal structure of the catalytic domain of PBP2 S310A from Neisseria gonorrhoeae at pH 7.5
6XQY	;	1.9	;	Crystal structure of the catalytic domain of PBP2 S310A from Neisseria gonorrhoeae at pH 9.5
6XQV	;	2.05	;	Crystal structure of the catalytic domain of PBP2 S310A from Neisseria gonorrhoeae in a pre-acylation complex with ceftriaxone
6XQX	;	2.15	;	Crystal structure of the catalytic domain of PBP2 S310A from Neisseria gonorrhoeae with the H514A mutation at pH 7.5
3WYM	;	2.0	;	Crystal structure of the catalytic domain of PDE10A complexed with 1-(2-fluoro-4-(1H-pyrazol-1-yl)phenyl)-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one
5AXP	;	1.95	;	Crystal structure of the catalytic domain of PDE10A complexed with 1-(2-fluoro-4-(2-oxo-1,3-oxazolidin-3-yl)phenyl)-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one
3WYK	;	2.5	;	Crystal structure of the catalytic domain of PDE10A complexed with 3-(1-phenyl-1H-pyrazol-5-yl)-1-(3-(trifluoromethyl)phenyl)pyridazin-4(1H)-one
3WYL	;	2.68	;	Crystal structure of the catalytic domain of PDE10A complexed with 5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)-1-(3-(trifluoromethyl)phenyl)pyridazin-4(1H)-one
5AXQ	;	1.77	;	Crystal structure of the catalytic domain of PDE10A complexed with highly potent and brain-penetrant PDE10A Inhibitor with 2-oxindole scaffold
3SL5	;	2.65	;	Crystal structure of the catalytic domain of PDE4D2 complexed with compound 10d
3V9B	;	2.1	;	Crystal structure of the catalytic domain of PDE4D2 with (S)-N-(3-{1-[1-(3-Cyclopropylmethoxy-4-difluoromethoxyphenyl)-2-(1-oxypyridin-4-yl)-ethyl]-1H-pyrazl-3-yl}phenyl)acetamide
3SL4	;	1.9	;	Crystal structure of the catalytic domain of PDE4D2 with compound 10D
3SL8	;	2.6	;	Crystal structure of the catalytic domain of PDE4D2 with compound 10o
3SL6	;	2.44	;	Crystal structure of the catalytic domain of PDE4D2 with compound 12c
4OGB	;	2.032	;	Crystal structure of the catalytic domain of PDE4D2 with compound 2
3B90	;	2.11	;	Crystal Structure of the Catalytic Domain of Pectate Lyase PelI from Erwinia chrysanthemi
2WWU	;	2.15	;	Crystal structure of the catalytic domain of PHD finger protein 8
3SUB	;	2.4	;	Crystal structure of the catalytic domain of Plasmodium falciparum ARF GTPase activating protein
5A1F	;	2.1	;	Crystal structure of the catalytic domain of PLU1 in complex with N-oxalylglycine.
3RDE	;	1.892	;	Crystal structure of the catalytic domain of porcine leukocyte 12-lipoxygenase
4NZO	;	1.9	;	Crystal structure of the catalytic domain of PPIP5K2 in complex with AMPPNP and 2,5-DI-O-BN-INSP4
4NZN	;	1.75	;	Crystal structure of the catalytic domain of PPIP5K2 in complex with AMPPNP and 2-O-BN-5-PA-INSP4
4NZM	;	2.0	;	Crystal structure of the catalytic domain of PPIP5K2 in complex with AMPPNP and 5-PA-InsP5
6N5C	;	1.95	;	Crystal structure of the catalytic domain of PPIP5K2 in complex with AMPPNP and 5-PCF2Am-InsP5
3H25	;	2.7	;	Crystal structure of the catalytic domain of primase Repb' in complex with initiator DNA
2G59	;	2.19	;	Crystal Structure of the Catalytic Domain of Protein Tyrosine Phosphatase from Homo sapiens
1JLN	;	1.81	;	Crystal structure of the catalytic domain of protein tyrosine phosphatase PTP-SL/BR7
2B49	;	1.54	;	Crystal Structure of the Catalytic Domain of Protein Tyrosine Phosphatase, non-receptor Type 3
3S3E	;	2.4	;	Crystal structure of the catalytic domain of PTP10D from Drosophila melanogaster
3S3H	;	2.8	;	Crystal structure of the catalytic domain of PTP10D from Drosophila melanogaster with a phosphopeptide substrate GP4
3S3K	;	3.2	;	Crystal structure of the catalytic domain of PTP10D from Drosophila melanogaster with a small molecular inhibitor para-NitroCatechol Sulphate
3S3F	;	2.7	;	Crystal Structure of the catalytic domain of PTP10D from Drosophila melanogaster with a small molecule inhibitor Vanadate
2E3C	;	2.65	;	Crystal structure of the catalytic domain of pyrrolysyl-tRNA synthetase
2ZIO	;	2.06	;	Crystal structure of the catalytic domain of pyrrolysyl-tRNA synthetase in complex with AlocLys-AMP and PNP
3VQV	;	1.9	;	Crystal structure of the catalytic domain of pyrrolysyl-tRNA synthetase in complex with AMPPNP (re-refined)
3VQY	;	2.4	;	Crystal structure of the catalytic domain of pyrrolysyl-tRNA synthetase in complex with BocLys and AMPPNP (form 2)
2ZIN	;	1.79	;	Crystal structure of the catalytic domain of pyrrolysyl-tRNA synthetase in complex with BocLys and an ATP analogue
2ZCE	;	1.8	;	Crystal structure of the catalytic domain of pyrrolysyl-tRNA synthetase in complex with pyrrolysine and an ATP analogue
3VQX	;	2.3	;	Crystal structure of the catalytic domain of pyrrolysyl-tRNA synthetase in triclinic crystal form
2O8H	;	1.8	;	Crystal structure of the catalytic domain of rat phosphodiesterase 10A
2OVV	;	2.0	;	Crystal structure of the catalytic domain of rat phosphodiesterase 10A
2OVY	;	1.8	;	Crystal structure of the catalytic domain of rat phosphodiesterase 10A
3UEK	;	1.95	;	Crystal structure of the catalytic domain of rat poly (ADP-ribose) glycohydrolase
3UEL	;	3.0	;	Crystal structure of the catalytic domain of rat poly (ADP-ribose) glycohydrolase bound to ADP-HPD
4LAB	;	2.5043	;	Crystal structure of the catalytic domain of RluB
4LGT	;	1.3	;	Crystal structure of the catalytic domain of RluB in complex with a 21-nucleotide RNA substrate
4KL7	;	1.45	;	Crystal structure of the catalytic domain of RpfB from Mycobacterium tuberculosis
4KPM	;	1.33	;	Crystal structure of the catalytic domain of RpfB from Mycobacterium tuberculosis in complex with triNAG
4HND	;	3.2	;	Crystal structure of the catalytic domain of Selenomethionine substituted human PI4KIIalpha in complex with ADP
2CM1	;	2.0	;	Crystal structure of the catalytic domain of serine threonine protein phosphatase PstP in complex with 2 Manganese ions.
4H2K	;	1.84	;	Crystal structure of the catalytic domain of succinyl-diaminopimelate desuccinylase from Haemophilus influenzae
3LE9	;	1.85	;	Crystal structure of the catalytic domain of TACE with Indazolinone-phenyl-hydantoin inhibitor
3LEA	;	2.0	;	Crystal structure of the catalytic domain of TACE with Isoindolinone-biphenyl-hydantoin inhibitor
4F55	;	1.85	;	Crystal Structure of the Catalytic Domain of the Bacillus cereus SleB Protein
2EXO	;	1.8	;	CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE BETA-1,4-GLYCANASE CEX FROM CELLULOMONAS FIMI
1ZHM	;	1.96	;	Crystal Structure of the Catalytic Domain of the Coagulation Factor XIa in Complex with Benzamidine (S434A-T475A-K437 Mutant)
6TWC	;	2.86	;	Crystal Structure of the Catalytic Domain of the Coagulation Factor XIa in Complex with Double Bridged Peptide F21
3W9A	;	1.99	;	Crystal structure of the catalytic domain of the glycoside hydrolase family 131 protein from Coprinopsis cinerea
3UVJ	;	2.08	;	Crystal structure of the catalytic domain of the heterodimeric human soluble guanylate cyclase 1.
2FYA	;	1.9	;	Crystal structure of the catalytic domain of the human beta1, 4-galactosyltransferase mutant M339H complex with manganese
2FY7	;	1.7	;	Crystal structure of the catalytic domain of the human beta1,4-galactosyltransferase mutant M339H in apo form
2FYB	;	1.9	;	Crystal structure of the catalytic domain of the human beta1,4-galactosyltransferase mutant M339H in complex with Mn and UDP-galactose in open conformation
4OTP	;	2.7	;	Crystal structure of the catalytic domain of the human RioK1 atypical protein kinase in complex with ADP/Mg2+
5UUV	;	2.75	;	Crystal Structure of the Catalytic Domain of the Inosine Monophosphate Dehydrogenase from Bacillus anthracis in the complex with a product IMP and the inhibitor P182
7MTX	;	2.44	;	Crystal Structure of the Catalytic Domain of the Inosine Monophosphate Dehydrogenase from Bacillus anthracis in the complex with IMP and the inhibitor P176
5URS	;	2.388	;	Crystal Structure of the Catalytic Domain of the Inosine Monophosphate Dehydrogenase from Bacillus anthracis in the complex with IMP and the inhibitor P178
5UUZ	;	2.496	;	Crystal Structure of the Catalytic Domain of the Inosine Monophosphate Dehydrogenase from Bacillus anthracis in the complex with IMP and the inhibitor P200
7MTU	;	2.34	;	Crystal Structure of the Catalytic Domain of the Inosine Monophosphate Dehydrogenase from Bacillus anthracis in the complex with IMP and the inhibitor P221
6MGU	;	1.54	;	Crystal Structure of the Catalytic Domain of the Inosine Monophosphate Dehydrogenase from Bacillus Anthracis in the complex with inhibitor Oxanosine monophosphate
5UQF	;	2.73	;	Crystal Structure of the Catalytic Domain of the Inosine Monophosphate Dehydrogenase from Campylobacter jejuni in the complex with IMP and the inhibitor P225
6MGR	;	1.97	;	Crystal Structure of the Catalytic Domain of the Inosine Monophosphate Dehydrogenase from Campylobacter jejuni in the complex with inhibitor Oxanosine monophosphate
5URQ	;	2.7	;	Crystal Structure of the Catalytic Domain of the Inosine Monophosphate Dehydrogenase from Campylobacter jejuni in the complex with inhibitor p176
5UQH	;	2.201	;	Crystal Structure of the Catalytic Domain of the Inosine Monophosphate Dehydrogenase from Campylobacter jejuni in the complex with inhibitor p182
5UQG	;	2.03	;	Crystal Structure of the Catalytic Domain of the Inosine Monophosphate Dehydrogenase from Campylobacter jejuni in the complex with inhibitor p200
4IXH	;	2.105	;	Crystal Structure of the Catalytic Domain of the Inosine Monophosphate Dehydrogenase from Cryptosporidium parvum
8EBC	;	2.5	;	Crystal Structure of the Catalytic Domain of the Inosine Monophosphate Dehydrogenase from Listeria monocytogenes in the complex with IMP
5UPY	;	2.35	;	Crystal Structure of the Catalytic Domain of the Inosine Monophosphate Dehydrogenase from Listeria Monocytogenes in the complex with IMP and Q21
5UPX	;	1.855	;	Crystal Structure of the Catalytic Domain of the Inosine Monophosphate Dehydrogenase from Listeria Monocytogenes in the presence of Xanthosine Monophosphate
4ZQR	;	1.692	;	Crystal Structure of the Catalytic Domain of the Inosine Monophosphate Dehydrogenase from Mycobacterium tuberculosis
4ZQP	;	1.9	;	Crystal Structure of the Catalytic Domain of the Inosine Monophosphate Dehydrogenase from Mycobacterium tuberculosis in the complex with IMP and the inhibitor MAD1
4ZQN	;	2.0	;	Crystal Structure of the Catalytic Domain of the Inosine Monophosphate Dehydrogenase from Mycobacterium tuberculosis in the complex with IMP and the inhibitor P41
4ZQO	;	1.76	;	Crystal Structure of the Catalytic Domain of the Inosine Monophosphate Dehydrogenase from Mycobacterium tuberculosis in the complex with IMP and the inhibitor Q67
4ZQM	;	1.602	;	Crystal Structure of the Catalytic Domain of the Inosine Monophosphate Dehydrogenase from Mycobacterium tuberculosis in the complex with XMP and NAD
5UPV	;	1.63	;	Crystal Structure of the Catalytic Domain of the Inosine Monophosphate Dehydrogenase from Mycobacterium tuberculosis In the presence of G36
5UPU	;	2.905	;	Crystal Structure of the Catalytic Domain of the Inosine Monophosphate Dehydrogenase from Mycobacterium tuberculosis in the presence of TBK6
4CRQ	;	1.5	;	Crystal structure of the catalytic domain of the modular laminarinase ZgLamC mutant E142S
4CTE	;	1.8	;	Crystal structure of the catalytic domain of the modular laminarinase ZgLamC mutant E142S in complex with a thio-oligosaccharide
2CB6	;	3.0	;	Crystal structure of the catalytic domain of the mosquitocidal toxin from Bacillus sphaericus, mutant E195Q
2CB4	;	2.5	;	Crystal structure of the catalytic domain of the mosquitocidal toxin from Bacillus sphaericus, mutant E197Q
1GWZ	;	2.5	;	CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTEIN TYROSINE PHOSPHATASE SHP-1
7CQE	;	2.69	;	Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with AZD-7762
4MHA	;	2.59	;	Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with inhibitor UNC1817
4MH7	;	2.51	;	Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with inhibitor UNC1896
4M3Q	;	2.718	;	Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with inhibitor UNC1917
5K0K	;	2.545	;	Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with inhibitor UNC2434
5K0X	;	2.231	;	Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with inhibitor UNC2541
6MEP	;	2.893	;	Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with inhibitor UNC3437
3TCP	;	2.69	;	Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with inhibitor UNC569
3IAI	;	2.2	;	Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX
6RIM	;	1.6	;	Crystal structure of the catalytic domain of the Weissela oryzae botulinum like toxin
2BVL	;	2.2	;	Crystal structure of the catalytic domain of toxin B from Clostridium difficile in complex with UDP, Glc and manganese ion
2BVM	;	2.55	;	Crystal structure of the catalytic domain of toxin B from Clostridium difficile in complex with UDP, Glc and manganese ion
6S96	;	2.18	;	Crystal structure of the catalytic domain of UBE2S C118A.
6S98	;	1.55	;	Crystal structure of the catalytic domain of UBE2S WT.
3RII	;	2.0008	;	Crystal structure of the catalytic domain of UCHL5, a proteasome-associated human deubiquitinating enzyme, reveals an unproductive form of the enzyme
3RIS	;	2.398	;	Crystal structure of the catalytic domain of UCHL5, a proteasome-associated human deubiquitinating enzyme, reveals an unproductive form of the enzyme
2H40	;	1.85	;	Crystal structure of the catalytic domain of unliganded PDE5
1NQ6	;	1.78	;	Crystal Structure of the catalytic domain of xylanase A from Streptomyces halstedii JM8
3RO8	;	1.34	;	Crystal structure of the catalytic domain of XynA1 from Paenibacillus sp. JDR-2
1HY5	;	2.25	;	CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF YOPE-YERSINIA PESTIS GAP EFFECTOR PROTEIN.
6ZZL	;	2.229	;	Crystal structure of the catalytic domain plus N-terminal linker of the acetyltransferase AceF (E2p) from Corynebacterium glutamicum.
5K7M	;	1.65	;	Crystal structure of the catalytic domains of Mettl3/Mettl14 complex
5K7U	;	1.7	;	Crystal structure of the catalytic domains of Mettl3/Mettl14 complex with SAM
1YGB	;	2.48	;	Crystal Structure of the catalytic fragment of alanyl-tRNA synthetase in complex with L-serine
3HTZ	;	2.5	;	Crystal Structure of the catalytic fragment of alanyl-tRNA synthetase in complex with L-serine: Re-refined
1PAQ	;	2.3	;	CRYSTAL STRUCTURE OF THE CATALYTIC FRAGMENT OF EUKARYOTIC INITIATION FACTOR 2B EPSILON
7ARX	;	2.42	;	Crystal structure of the catalytic fragment of masp-1 in complex with SFMI1
1GS0	;	2.8	;	Crystal structure of the catalytic fragment of murine poly(ADP-ribose) polymerase-2
1EFY	;	2.2	;	CRYSTAL STRUCTURE OF THE CATALYTIC FRAGMENT OF POLY (ADP-RIBOSE) POLYMERASE COMPLEXED WITH A BENZIMIDAZOLE INHIBITOR
2WMK	;	1.9	;	Crystal structure of the catalytic module of a family 98 glycoside hydrolase from Streptococcus pneumoniae SP3-BS71 (Sp3GH98) in complex with the A-LewisY pentasaccharide blood group antigen.
2WMJ	;	2.0	;	Crystal structure of the catalytic module of a family 98 glycoside hydrolase from Streptococcus pneumoniae SP3-BS71 (Sp3GH98) in complex with the B-trisaccharide blood group antigen.
2WMI	;	1.9	;	Crystal structure of the catalytic module of a family 98 glycoside hydrolase from Streptococcus pneumoniae SP3-BS71 in complex with the A-trisaccharide blood group antigen.
2WMG	;	2.3	;	Crystal structure of the catalytic module of a family 98 glycoside hydrolase from Streptococcus pneumoniae TIGR4 (Sp4GH98) in complex with the LewisY pentasaccharide blood group antigen.
2WMF	;	1.5	;	Crystal structure of the catalytic module of a family 98 glycoside hydrolase from Streptococcus pneumoniae TIGR4 (Sp4GH98) in its native form.
2WMH	;	1.7	;	Crystal structure of the catalytic module of a family 98 glycoside hydrolase from Streptococcus pneumoniae TIGR4 in complex with the H- disaccharide blood group antigen.
4RHH	;	2.15	;	Crystal structure of the catalytic mutant Xyn52B2-E335G, a GH52 Beta-D-xylosidase from Geobacillus stearothermophilus T6
5SV8	;	1.588	;	Crystal Structure of the catalytic nucleophile and surface cysteine mutant of VvEG16 in complex with a xyloglucan oligosaccharide
5DZF	;	1.65	;	Crystal Structure of the catalytic nucleophile mutant of VvEG16 in complex with a mixed-linkage glucan octasaccharide
5DZG	;	1.79	;	Crystal Structure of the catalytic nucleophile mutant of VvEG16 in complex with a xyloglucan tetradecasaccharide
5DZE	;	0.97	;	Crystal Structure of the catalytic nucleophile mutant of VvEG16 in complex with cellotetraose
3GOV	;	2.55	;	Crystal structure of the catalytic region of human MASP-1
1Q3X	;	2.23	;	Crystal structure of the catalytic region of human MASP-2
1IEC	;	2.2	;	CRYSTAL STRUCTURE OF THE CATALYTIC SITE MUTANT (H157A) OF THE HUMAN CYTOMEGALOVIRUS PROTEASE
1IED	;	2.0	;	CRYSTAL STRUCTURE OF THE CATALYTIC SITE MUTANT (H157E) OF THE HUMAN CYTOMEGALOVIRUS PROTEASE
1ID4	;	2.2	;	CRYSTAL STRUCTURE OF THE CATALYTIC SITE MUTANT (H157Q) OF THE HUMAN CYTOMEGALOVIRUS PROTEASE
1IEF	;	2.3	;	CRYSTAL STRUCTURE OF THE CATALYTIC SITE MUTANT S134A OF THE HUMAN CYTOMEGALOVIRUS PROTEASE
1IEG	;	2.0	;	CRYSTAL STRUCTURE OF THE CATALYTIC SITE MUTANT S134A/H157A OF THE HUMAN CYTOMEGALOVIRUS PROTEASE
1O4V	;	1.77	;	Crystal structure of the catalytic subunit of a phosphoribosylaminoimidazole mutase (tm0446) from thermotoga maritima at 1.77 A resolution
1JLU	;	2.25	;	Crystal Structure of the Catalytic Subunit of cAMP-dependent Protein Kinase Complexed with a Phosphorylated Substrate Peptide and Detergent
1JBP	;	2.2	;	Crystal Structure of the Catalytic Subunit of cAMP-dependent Protein Kinase Complexed with a Substrate Peptide, ADP and Detergent
4HPT	;	2.15	;	Crystal structure of the catalytic subunit of cAMP-dependent protein kinase displaying complete phosphoryl transfer of AMP-PNP onto a substrate peptide
4HPU	;	1.55	;	Crystal structure of the catalytic subunit of cAMP-dependent protein kinase displaying partial phosphoryl transfer of AMP-PNP onto a substrate peptide
2CPK	;	2.7	;	CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CYCLIC ADENOSINE MONOPHOSPHATE-DEPENDENT PROTEIN KINASE
4LIK	;	1.7	;	Crystal structure of the catalytic subunit of human primase
4LIL	;	2.6	;	Crystal structure of the catalytic subunit of human primase bound to UTP and Mn
1NA7	;	2.4	;	Crystal structure of the catalytic subunit of human protein kinase CK2
3H30	;	1.56	;	Crystal structure of the catalytic subunit of human protein kinase CK2 with 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole
4ZHJ	;	2.502	;	Crystal Structure of the Catalytic Subunit of Magnesium Chelatase
2PVR	;	1.605	;	Crystal structure of the catalytic subunit of protein kinase CK2 (C-terminal deletion mutant 1-335) in complex with two sulfate ions
1JSC	;	2.6	;	Crystal Structure of the Catalytic Subunit of Yeast Acetohydroxyacid Synthase: A target for Herbicidal Inhibitors
4LIM	;	1.63	;	Crystal structure of the catalytic subunit of yeast primase
7C7D	;	1.16	;	Crystal structure of the catalytic unit of thermostable GH87 alpha-1,3-glucanase from Streptomyces thermodiastaticus strain HF3-3
5DVX	;	1.598	;	Crystal structure of the catalytic-domain of human carbonic anhydrase IX at 1.6 angstrom resolution
2OTN	;	2.4	;	Crystal structure of the catalytically active form of diaminopimelate epimerase from Bacillus anthracis
3KEX	;	2.797	;	Crystal structure of the catalytically inactive kinase domain of the human epidermal growth factor receptor 3 (HER3)
4JGF	;	2.5	;	Crystal Structure of the Cataract-Causing P23T gamma D-Crystallin Mutant
1LXE	;	2.5	;	CRYSTAL STRUCTURE OF THE CATHELICIDIN MOTIF OF PROTEGRINS
4EYC	;	1.9	;	Crystal structure of the cathelin-like domain of human cathelicidin LL-37 (hCLD)
3C9E	;	1.8	;	Crystal structure of the cathepsin K : chondroitin sulfate complex.
2AA1	;	1.8	;	Crystal structure of the cathodic hemoglobin isolated from the Antarctic fish Trematomus Newnesi
5KLB	;	2.7	;	Crystal structure of the CavAb voltage-gated calcium channel(wild-type, 2.7A)
3FEX	;	3.549	;	Crystal structure of the CBC-importin alpha complex.
3FEY	;	2.2	;	Crystal structure of the CBC-importin alpha complex.
4LQQ	;	3.6	;	Crystal structure of the Cbk1(T743E)-Mob2 kinase-coactivator complex in crystal form B
4LQP	;	4.5	;	Crystal structure of the Cbk1(T743E)-Mob2 kinase-coactivator complex, in crystal form A
4LQS	;	3.3	;	Crystal structure of the Cbk1-Mob2 kinase-coactivator complex
5NCL	;	3.15	;	Crystal structure of the Cbk1-Mob2 kinase-coactivator complex with an SSD1 peptide
5KC5	;	2.351	;	Crystal structure of the Cbln1 C1q domain trimer
5KCA	;	3.1	;	Crystal structure of the Cbln1 C1q domain trimer in complex with the amino-terminal domain (ATD) of iGluR Delta-2 (GluD2)
7TOK	;	2.45	;	Crystal structure of the CBM domain of carbohydrate esterase FjoAcXE
6UFV	;	1.06	;	Crystal structure of the CBM3 from Bacillus subtilis at 1.06 angstrom resolution
6UFW	;	1.28	;	Crystal structure of the CBM3 from Bacillus subtilis at 1.28 angstrom resolution
7AY3	;	2.00002	;	Crystal structure of the CBM36-1 domain of a multidomain xylanase from the hindgut metagenome of Trinervitermes trinervoides
4YK0	;	1.65	;	Crystal structure of the CBP bromodomain in complex with CPI098
5DBM	;	1.86	;	Crystal structure of the CBP bromodomain in complex with CPI703
6LQX	;	2.46	;	Crystal structure of the CBP bromodomain in complex with small molecule LC-CPin7
7XM7	;	2.36	;	Crystal Structure of the CBP in complex with the Y08188
6RWT	;	1.42	;	Crystal structure of the Cbp3 homolog from Brucella abortus
3L2B	;	2.27	;	Crystal structure of the CBS and DRTGG domains of the regulatory region of Clostridium perfringens pyrophosphatase complexed with activator, diadenosine tetraphosphate
3L31	;	2.3	;	Crystal structure of the CBS and DRTGG domains of the regulatory region of Clostridium perfringens pyrophosphatase complexed with the inhibitor, AMP
4ESY	;	2.011	;	Crystal Structure of the CBS Domain of CBS Domain Containing Membrane Protein from Sphaerobacter thermophilus
3KPC	;	1.79	;	Crystal Structure of the CBS domain pair of protein MJ0100 in complex with 5 -methylthioadenosine and S-adenosyl-L-methionine
3KPB	;	1.6	;	Crystal Structure of the CBS domain pair of protein MJ0100 in complex with 5 -methylthioadenosine and S-adenosyl-L-methionine.
3KPD	;	2.91	;	Crystal Structure of the CBS domain pair of protein MJ0100 in complex with 5 -methylthioadenosine and S-adenosyl-L-methionine.
3FV6	;	1.95	;	Crystal Structure of the CBS domains from the Bacillus subtilis CcpN repressor
3FWR	;	2.45	;	Crystal Structure of the CBS domains from the Bacillus subtilis CcpN repressor complexed with ADP
3FWS	;	2.03	;	Crystal Structure of the CBS domains from the Bacillus subtilis CcpN repressor complexed with AppNp, phosphate and magnesium ions
4O9K	;	1.85	;	Crystal structure of the CBS pair of a putative D-arabinose 5-phosphate isomerase from Methylococcus capsulatus in complex with CMP-Kdo
3FNA	;	2.1	;	Crystal structure of the CBS pair of possible D-arabinose 5-phosphate isomerase yrbH from Escherichia coli CFT073
3FHM	;	2.7	;	Crystal structure of the CBS-domain containing protein ATU1752 from Agrobacterium tumefaciens
3KUP	;	1.77	;	Crystal Structure of the CBX3 Chromo Shadow Domain
2Q8T	;	2.23	;	Crystal Structure of the CC chemokine CCL14
6STK	;	1.52	;	Crystal structure of the CC-chemokine 5 (CCL5) E66S mutation
5DJO	;	1.74	;	Crystal structure of the CC1-FHA tandem of Kinesin-3 KIF13A
6QY6	;	1.8	;	Crystal structure of the CCA-adding enzyme of a psychrophilic organism
6QXN	;	1.849	;	Crystal structure of the CCA-adding enzyme of a psychrophilic organism in complex with CTP
2D7H	;	3.0	;	Crystal structure of the ccc complex of the N-terminal domain of PriA
4FQN	;	1.9	;	Crystal structure of the CCM2 C-terminal Harmonin Homology Domain (HHD)
7U0L	;	3.3	;	Crystal structure of the CCoV-HuPn-2018 RBD (domain B) in complex with canine APN
5Y9Q	;	1.953	;	Crystal structure of the CcpE regulatory domain at 1.95 Angstrom from Staphylococcus aureus
4MBS	;	2.71	;	Crystal Structure of the CCR5 Chemokine Receptor
1CCZ	;	1.8	;	CRYSTAL STRUCTURE OF THE CD2-BINDING DOMAIN OF CD58 (LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN 3) AT 1.8-A RESOLUTION
7KX0	;	2.69	;	Crystal structure of the CD27:CD70 co-stimulatory complex
3QD6	;	3.5	;	Crystal structure of the CD40 and CD154 (CD40L) complex
3DMM	;	2.6	;	Crystal structure of the CD8 alpha beta/H-2Dd complex
3QXL	;	2.237	;	Crystal structure of the CDC25 Domain from Ral-specific Guanine-nucleotide Exchange Factor RalGPS1a
2IJE	;	2.2	;	Crystal Structure of the Cdc25 domain of RasGRF1
1YMK	;	1.7	;	Crystal Structure of the CDC25B phosphatase catalytic domain in the apo form
1YS0	;	2.0	;	Crystal Structure of the CDC25B phosphatase catalytic domain with the active site cysteine in the disulfide form
1YML	;	1.7	;	Crystal Structure of the CDC25B phosphatase catalytic domain with the active site cysteine in the sulfenic form
1YM9	;	2.0	;	Crystal structure of the CDC25B phosphatase catalytic domain with the active site cysteine in the sulfinic form
1YMD	;	1.7	;	Crystal Structure of the CDC25B phosphatase catalytic domain with the active site cysteine in the sulfonic form
2DFK	;	2.15	;	Crystal structure of the CDC42-Collybistin II complex
1GRN	;	2.1	;	CRYSTAL STRUCTURE OF THE CDC42/CDC42GAP/ALF3 COMPLEX.
4EK4	;	1.26	;	Crystal structure of the cdk2 in complex with aminopyrazole inhibitor
4EK5	;	1.6	;	Crystal structure of the cdk2 in complex with aminopyrazole inhibitor
4EK6	;	1.52	;	Crystal structure of the cdk2 in complex with aminopyrazole inhibitor
4FKG	;	1.51	;	Crystal structure of the cdk2 in complex with aminopyrazole inhibitor
4FKI	;	1.6	;	Crystal Structure of the Cdk2 in Complex with Aminopyrazole Inhibitor
4FKJ	;	1.63	;	Crystal structure of the cdk2 in complex with aminopyrazole inhibitor
4FKP	;	1.6	;	Crystal structure of the cdk2 in complex with oxindole inhibitor
4FKQ	;	1.75	;	Crystal structure of the cdk2 in complex with oxindole inhibitor
4FKR	;	1.9	;	Crystal structure of the cdk2 in complex with oxindole inhibitor
4FKS	;	1.55	;	Crystal structure of the cdk2 in complex with oxindole inhibitor
4FKT	;	1.6	;	Crystal structure of the cdk2 in complex with oxindole inhibitor
4FKU	;	1.47	;	Crystal structure of the cdk2 in complex with oxindole inhibitor
4FKV	;	1.7	;	Crystal structure of the cdk2 in complex with oxindole inhibitor
4FKW	;	1.8	;	Crystal structure of the cdk2 in complex with oxindole inhibitor
3SW4	;	1.7	;	Crystal Structure of the CDK2 in complex with thiazolylpyrimidine inhibitor
3SW7	;	1.8	;	Crystal Structure of the CDK2 in complex with thiazolylpyrimidine inhibitor
4EK8	;	1.7	;	Crystal structure of the cdk2 in complex with thiazolylpyrimidine inhibitor
4FKL	;	1.26	;	Crystal structure of the cdk2 in complex with thiazolylpyrimidine inhibitor
4FKO	;	1.55	;	Crystal structure of the cdk2 in complex with thiazolylpyrimidine inhibitor
4FX3	;	2.75	;	Crystal Structure of the CDK2/Cyclin A complex with oxindole inhibitor
1XFP	;	1.5	;	Crystal structure of the CDR2 germline reversion mutant of cAb-Lys3 in complex with hen egg white lysozyme
4HAE	;	2.0	;	Crystal structure of the CDYL2-chromodomain
6P72	;	3.283	;	Crystal Structure of the Cedar henipavirus Attachment G Glycoprotein global domain
6P7S	;	3.49	;	Crystal Structure of the Cedar henipavirus Attachment G Glycoprotein globular domain in complex with the receptor ephrin-B1
6P7Y	;	2.844	;	Crystal Structure of the Cedar henipavirus Attachment G Glycoprotein globular domain in complex with the receptor ephrin-B2
1QB3	;	3.0	;	CRYSTAL STRUCTURE OF THE CELL CYCLE REGULATORY PROTEIN CKS1
1SCE	;	2.2	;	CRYSTAL STRUCTURE OF THE CELL CYCLE REGULATORY PROTEIN SUC1 REVEALS A NOVEL BETA-HINGE CONFORMATIONAL SWITCH
4RU3	;	1.172	;	Crystal structure of the cell puncturing protein Orf41 from Pseudomonas phage SN
2Q7A	;	2.1	;	Crystal structure of the cell surface heme transfer protein Shp
1R77	;	1.75	;	Crystal structure of the cell wall targeting domain of peptidylglycan hydrolase ALE-1
2XSC	;	2.052	;	Crystal structure of the cell-binding B oligomer of verotoxin-1 from E. coli
1FSZ	;	2.8	;	CRYSTAL STRUCTURE OF THE CELL-DIVISION PROTEIN FTSZ AT 2.8A RESOLUTION
5AX0	;	1.521	;	Crystal Structure of the Cell-Free Synthesized Membrane Protein, Acetabularia Rhodopsin I, at 1.52 angstrom
5AWZ	;	1.57	;	Crystal Structure of the Cell-Free Synthesized Membrane Protein, Acetabularia Rhodopsin I, at 1.57 angstrom
5AX1	;	1.803	;	Crystal Structure of the Cell-Free Synthesized Membrane Protein, Acetabularia Rhodopsin I, at 1.80 angstrom
6L00	;	1.75	;	Crystal structure of the cell-wall binding domain (CBD) of endolysin LysIME-EF1
1FBO	;	2.3	;	Crystal structure of the cellulase CEL48F from C. cellulolyticum in complex with cellobiitol
1FAE	;	2.0	;	Crystal structure of the cellulase CEL48F from C. cellulolyticum in complex with cellobiose
1FBW	;	2.0	;	Crystal structure of the cellulase CEL48F from C. cellulolyticum in complex with cellohexaose
1F9D	;	2.3	;	Crystal structure of the cellulase CEL48F from C. cellulolyticum in complex with cellotetraose
1F9O	;	2.5	;	Crystal structure of the cellulase Cel48F from C. Cellulolyticum with the thiooligosaccharide inhibitor PIPS-IG3
1IA7	;	2.0	;	CRYSTAL STRUCTURE OF THE CELLULASE CEL9M OF C. CELLULOLYTICIUM IN COMPLEX WITH CELLOBIOSE
1IA6	;	1.8	;	CRYSTAL STRUCTURE OF THE CELLULASE CEL9M OF C. CELLULOLYTICUM
3K4Z	;	2.11	;	Crystal Structure of the Cellulosomal CBM4 from Clostridium thermocellum Cellulase CbhA
7UNP	;	2.0	;	Crystal structure of the CelR catalytic domain and CBM3c
3KNC	;	2.5	;	Crystal structure of the CeNA-RNA hybrid octamer ce(GCGTAGCG):r(CGCUACGC)
7PB8	;	3.68	;	Crystal structure of the CENP-OPQUR complex
3AON	;	2.0	;	Crystal structure of the central axis (NtpD-NtpG) in the catalytic portion of Enterococcus hirae V-type sodium ATPase
5JJ2	;	1.25	;	Crystal structure of the central domain of human AKAP18 gamma/delta in complex with malonate
2A1I	;	1.9	;	Crystal Structure of the Central Domain of Human ERCC1
5I6E	;	3.0	;	Crystal structure of the central domain of yeast acetyl-CoA carboxylase
5M0H	;	2.65	;	Crystal structure of the central flexible region of ASH1 mRNA E3-localization element
1JY2	;	1.4	;	Crystal Structure of the Central Region of Bovine Fibrinogen (E5 fragment) at 1.4 Angstroms Resolution
1JY3	;	1.6	;	Crystal Structure of the Central Region of Bovine Fibrinogen (E5 Fragment) at 1.4 Angstroms Resolution
6R7O	;	2.31	;	Crystal structure of the central region of human cohesin subunit STAG1
6RRK	;	3.17	;	Crystal structure of the central region of human cohesin subunit STAG1 in complex with RAD21 peptide
4CVD	;	1.666	;	Crystal structure of the central repeat of cell wall binding module of Cpl7
3NO7	;	1.4	;	Crystal structure of the centromere-binding protein ParB from plasmid pCXC100
5JJD	;	2.403	;	crystal structure of the ceramide transfer protein PH and START domain complex
8A14	;	1.9	;	Crystal structure of the cerato-platanin-like protein Cpl1 from Ustilago maydis
3PUT	;	1.828	;	Crystal Structure of the CERT START domain (mutant V151E) from Rhizobium etli at the resolution 1.8A, Northeast Structural Genomics Consortium Target ReR239.
3H3Q	;	2.0	;	Crystal structure of the CERT START domain in complex with HPA-13
3H3R	;	1.85	;	Crystal structure of the CERT START domain in complex with HPA-14
3H3S	;	1.66	;	Crystal structure of the CERT START domain in complex with HPA-15
3H3T	;	2.4	;	Crystal structure of the CERT START domain in complex with HPA-16
1XOU	;	2.8	;	Crystal structure of the CesA-EspA complex
3VAC	;	2.6	;	Crystal Structure of the CFA/I Enterotoxigenic E. coli adhesin CfaE mutant G168D
4Y7S	;	2.0	;	Crystal Structure of the CFEM protein Csa2
3KD2	;	1.8	;	Crystal structure of the CFTR inhibitory factor Cif
4EUS	;	1.65	;	Crystal structure of the CFTR inhibitory factor Cif bound to 1,2-hexanediol
5HK9	;	1.8	;	Crystal structure of the CFTR inhibitory factor Cif bound to a urea inhibitor
5HKA	;	2.05	;	Crystal structure of the CFTR inhibitory factor Cif bound to an amide inhibitor
5HKB	;	1.65	;	Crystal structure of the CFTR inhibitory factor Cif bound to the inhibitor KB2115
4YX9	;	1.75	;	Crystal structure of the CFTR inhibitory factor Cif bound to tiratricol
4DLN	;	1.55	;	Crystal structure of the CFTR inhibitory factor Cif with the D129S mutation
4EHB	;	1.85	;	Crystal structure of the CFTR inhibitory factor Cif with the D129S mutation bound to epoxyhexane
4DM7	;	1.36	;	Crystal structure of the CFTR inhibitory factor Cif with the E153D mutation
4DMC	;	1.66	;	Crystal structure of the CFTR inhibitory factor Cif with the E153Q mutation
4DNO	;	1.95	;	Crystal structure of the CFTR inhibitory factor Cif with the E153Q mutation adducted with the 1,2-epoxyhexane hydrolysis intermediate
4DNF	;	1.8	;	Crystal structure of the CFTR inhibitory factor Cif with the E153Q mutation adducted with the epibromohydrin hydrolysis intermediate
4DMF	;	2.12	;	Crystal structure of the CFTR inhibitory factor Cif with the H177A mutation
3PI6	;	1.5	;	Crystal structure of the CFTR inhibitory factor Cif with the H177Y mutation
4DMH	;	1.9	;	Crystal structure of the CFTR inhibitory factor Cif with the H207A mutation
3KDA	;	1.5	;	Crystal structure of the CFTR inhibitory factor Cif with the H269A mutation
4DMK	;	1.5	;	Crystal structure of the CFTR inhibitory factor Cif with the Y239F mutation
3ZZR	;	1.45	;	Crystal structure of the CG11501 protein in P21212 spacegroup
3ZZO	;	1.15	;	Crystal structure of the CG11501 protein in P212121 spacegroup
3DBA	;	2.57	;	Crystal structure of the cGMP-bound GAF a domain from the photoreceptor phosphodiesterase 6C
5DYK	;	2.45	;	Crystal structure of the cGMP-dependent protein kinase PKG from Plasmodium falciparum - Apo form
5DZC	;	2.3	;	Crystal structure of the cGMP-dependent protein kinase PKG from Plasmodium Vivax - AMPPNP bound
5DYL	;	2.4	;	Crystal structure of the cGMP-dependent protein kinase PKG from Plasmodium Vivax - Apo form
7PT5	;	2.3	;	Crystal structure of the CH domain of human CEP44
1CQK	;	2.2	;	CRYSTAL STRUCTURE OF THE CH3 DOMAIN FROM THE MAK33 ANTIBODY
6QV5	;	2.3	;	Crystal structure of the CHAD domain from the plant Ricinus communis
5CWW	;	2.2	;	Crystal structure of the Chaetomium thermophilum heterotrimeric Nup82 NTD-Nup159 TAIL-Nup145N APD complex
7MVX	;	4.35	;	Crystal structure of the Chaetomium thermophilum Nup188-Nic96 complex (Nup188 residues 1-1858; Nic96 residues 240-301)
7MVT	;	3.6	;	Crystal structure of the Chaetomium thermophilum Nup192-Nic96 complex (Nup192 residues 185-1756; Nic96 residues 187-301)
5M5G	;	2.27	;	Crystal structure of the Chaetomium Thermophilum polycomb repressive complex 2 (PRC2)
4ZOY	;	1.5	;	Crystal structure of the Chaetomium thermophilum Sqt1
4ZOZ	;	1.7	;	Crystal structure of the Chaetomium thermophilum Sqt1 bound to the N-terminus of the ribosomal protein L10
2I88	;	2.5	;	Crystal structure of the Channel-forming Domain of Colicin E1
4V4O	;	2.8	;	Crystal Structure of the Chaperonin Complex Cpn60/Cpn10/(ADP)7 from Thermus Thermophilus
1Q3S	;	3.0	;	Crystal structure of the chaperonin from Thermococcus strain KS-1 (FormIII crystal complexed with ADP)
1Q3R	;	2.9	;	Crystal structure of the chaperonin from Thermococcus strain KS-1 (nucleotide-free form of single mutant)
1Q2V	;	2.4	;	Crystal structure of the chaperonin from Thermococcus strain KS-1 (nucleotide-free form)
1Q3Q	;	2.3	;	Crystal structure of the chaperonin from Thermococcus strain KS-1 (two-point mutant complexed with AMP-PNP)
6TMT	;	4.03	;	Crystal structure of the chaperonin gp146 from the bacteriophage EL 2 (Pseudomonas aeruginosa) in presence of ATP-BeFx, crystal form I
6TMU	;	3.54	;	Crystal structure of the chaperonin gp146 from the bacteriophage EL 2 (Pseudomonas aeruginosa) in presence of ATP-BeFx, crystal form II
2EU1	;	3.29	;	Crystal structure of the chaperonin GroEL-E461K
3TED	;	2.0	;	Crystal structure of the Chd1 DNA-binding domain in complex with a DNA duplex
7DXT	;	1.8	;	Crystal structure of the chemically synthesized mk2h peptide homodimer
7DXY	;	1.4	;	Crystal structure of the chemically synthesized mk2h_deltaMILPS peptide homodimer
7DYC	;	2.3	;	Crystal structure of the chemically synthesized mk2h_deltaMILPYS peptide homodimer in complex with malate
7DXZ	;	1.9	;	Crystal structure of the chemically synthesized mk2h_deltaMILPYS peptide homodimer in complex with malonate
4P5I	;	2.25	;	Crystal structure of the chemokine binding protein from orf virus
3OE9	;	3.1	;	Crystal structure of the chemokine CXCR4 receptor in complex with a small molecule antagonist IT1t in P1 spacegroup
4JL7	;	1.16	;	Crystal Structure of the Chemokine Receptor CXCR2 in Complex with the First PDZ Domain of NHERF1
4N6X	;	1.051	;	Crystal Structure of the Chemokine Receptor CXCR2 in Complex with the First PDZ Domain of NHERF1
7OVP	;	2.9	;	Crystal structure of the chemotactic adaptor protein CheF
3HZH	;	1.96	;	Crystal structure of the CheX-CheY-BeF3-Mg+2 complex from Borrelia burgdorferi
6TG7	;	1.65	;	Crystal structure of the CheY in presence of magnesium
1MDU	;	2.2	;	Crystal structure of the chicken actin trimer complexed with human gelsolin segment 1 (GS-1)
5XW6	;	3.1	;	Crystal structure of the chicken ATP-gated P2X7 receptor channel in the presence of competitive antagonist TNP-ATP at 3.1 Angstroms
4JZ3	;	1.852	;	Crystal structure of the chicken c-Src-SH3 domain intertwined dimer
3B0B	;	2.15	;	Crystal structure of the chicken CENP-S/CENP-X complex
3B0C	;	2.201	;	Crystal structure of the chicken CENP-T histone fold/CENP-W complex, crystal form I
3B0D	;	2.197	;	Crystal structure of the chicken CENP-T histone fold/CENP-W complex, crystal form II
3VH5	;	2.402	;	Crystal structure of the chicken CENP-T histone fold/CENP-W/CENP-S/CENP-X heterotetrameric complex, crystal form I
3VH6	;	3.351	;	Crystal structure of the chicken CENP-T histone fold/CENP-W/CENP-S/CENP-X heterotetrameric complex, crystal form II
7WRS	;	2.4	;	Crystal structure of the chicken isoleucyl-tRNA synthetase 1 (IARS1) UNE-I complexed with glutamyl-tRNA synthetase 1 (EARS1)
5OJ2	;	3.2	;	Crystal structure of the chicken MDGA1 ectodomain
5OJ6	;	3.3	;	Crystal structure of the chicken MDGA1 ectodomain in complex with the human neuroligin 1 (NL1(-A-B)) cholinesterase domain.
7DA1	;	2.01	;	Crystal structure of the chicken MHF complex
3VZ9	;	1.03	;	Crystal structure of the chicken Spc24-Spc25 globular domain
3VZA	;	1.898	;	Crystal structure of the chicken Spc24-Spc25 globular domain in complex with CENP-T peptide
7YLF	;	1.9	;	Crystal structure of the chicken Toll-like receptor 15 TIR domain (2-mercaptoethanol adduct)
7YLG	;	1.8	;	Crystal structure of the chicken Toll-like receptor 15 TIR domain (glutathione adduct)
3JXI	;	2.3	;	Crystal structure of the chicken TRPV4 ankyrin repeat domain
3JXJ	;	2.8	;	Crystal structure of the chicken TRPV4 ankyrin repeat domain
7OAW	;	2.95	;	Crystal structure of the Chili RNA aptamer in complex with DMHBI+
7OAX	;	2.24	;	Crystal structure of the Chili RNA aptamer in complex with DMHBO+
8P1H	;	1.95	;	Crystal structure of the chimera of human 14-3-3 zeta and phosphorylated cytoplasmic loop fragment of the alpha7 acetylcholine receptor
3P1Y	;	2.05	;	Crystal structure of the chimeric Archaeoglobus fulgidus RNA splicing endonuclease with the broadest substrate specificity
3FEV	;	1.3	;	Crystal structure of the chimeric muscarinic toxin MT7 with loop 1 from MT1.
3NEQ	;	1.25	;	Crystal structure of the chimeric muscarinic toxin MT7 with loop 3 from MT1
4IAQ	;	2.8	;	Crystal structure of the chimeric protein of 5-HT1B-BRIL in complex with dihydroergotamine (PSI Community Target)
4IAR	;	2.7	;	Crystal structure of the chimeric protein of 5-HT1B-BRIL in complex with ergotamine (PSI Community Target)
4IB4	;	2.7	;	Crystal structure of the chimeric protein of 5-HT2B-BRIL in complex with ergotamine
4EIY	;	1.8	;	Crystal structure of the chimeric protein of A2aAR-BRIL in complex with ZM241385 at 1.8A resolution
5JTB	;	2.8	;	Crystal structure of the chimeric protein of A2aAR-BRIL with bound iodide ions
1EVP	;	1.8	;	CRYSTAL STRUCTURE OF THE CHIMERICAL DECAMER D(CCACTAGTG)R(G)
2VED	;	2.6	;	crystal structure of the chimerical mutant CapABK55M protein
4JLV	;	2.2	;	Crystal structure of the chimerical protein CapA1B1 in complex with ADP-Mg
4JMP	;	1.3	;	Crystal structure of the chimerical protein CapA2B2
3BFV	;	1.8	;	crystal structure of the chimerical protein CapAB
2C2L	;	3.3	;	Crystal structure of the CHIP U-box E3 ubiquitin ligase
2C2V	;	2.9	;	Crystal structure of the CHIP-UBC13-UEV1a complex
1ZTY	;	2.3	;	Crystal Structure of the Chitin Oligasaccharide Binding Protein
4GF8	;	2.3	;	Crystal Structure of the Chitin Oligasaccharide Binding Protein
4MPI	;	1.602	;	Crystal structure of the chitin-binding module (CBM18) of a chitinase-like protein from Hevea brasiliensis
4A5Q	;	17.0	;	Crystal structure of the chitinase Chi1 fitted into the 3D structure of the Yersinia entomophaga toxin complex
6T9M	;	1.3	;	Crystal structure of the Chitinase Domain of the Spore Coat Protein CotE from Clostridium difficile
6TSB	;	2.1	;	Crystal structure of the Chitinase Domain of the Spore Coat Protein CotE from Clostridium difficile
4FSM	;	2.3	;	Crystal Structure of the CHK1
4FSN	;	2.1	;	Crystal Structure of the CHK1
4FSQ	;	2.4	;	Crystal Structure of the CHK1
4FSR	;	2.5	;	Crystal Structure of the CHK1
4FST	;	1.9	;	Crystal Structure of the CHK1
4FSU	;	2.1	;	Crystal Structure of the CHK1
4FSW	;	2.3	;	Crystal Structure of the CHK1
4FSY	;	2.3	;	Crystal Structure of the CHK1
4FSZ	;	2.3	;	Crystal Structure of the CHK1
4FT0	;	2.3	;	Crystal Structure of the CHK1
4FT3	;	2.5	;	Crystal Structure of the CHK1
4FT5	;	2.4	;	Crystal Structure of the CHK1
4FT7	;	2.2	;	Crystal Structure of the CHK1
4FT9	;	2.2	;	Crystal Structure of the CHK1
4FTA	;	2.4	;	Crystal Structure of the CHK1
4FTC	;	2.0	;	Crystal Structure of the CHK1
4FTI	;	2.2	;	Crystal Structure of the CHK1
4FTJ	;	2.2	;	Crystal Structure of the CHK1
4FTK	;	2.3	;	Crystal Structure of the CHK1
4FTL	;	2.5	;	Crystal Structure of the CHK1
4FTM	;	1.9	;	Crystal Structure of the CHK1
4FTN	;	2.02	;	Crystal Structure of the CHK1
4FTO	;	2.1	;	Crystal Structure of the CHK1
4FTQ	;	2.0	;	Crystal Structure of the CHK1
4FTR	;	2.25	;	Crystal Structure of the CHK1
4FTT	;	2.3	;	Crystal Structure of the CHK1
4FTU	;	2.1	;	Crystal Structure of the CHK1
4GH2	;	2.03	;	Crystal Structure of the CHK1
4P17	;	1.7941	;	Crystal structure of the Chlamydomonas flagellar RabGAP TBC domain.
4UZY	;	2.477	;	Crystal structure of the Chlamydomonas IFT70 and IFT52 complex
6BHP	;	3.209	;	Crystal structure of the Chlamydomonas reinhardtii LCI1 channel
8B7S	;	2.1	;	Crystal structure of the Chloramphenicol-inactivating oxidoreductase from Novosphingobium sp
3RK8	;	1.8	;	Crystal structure of the chloride inhibited dihydrodipicolinate synthase from Acinetobacter baumannii complexed with pyruvate at 1.8 A resolution
5B1K	;	1.35	;	Crystal structure of the chloride-bound form of blue copper nitrite reductase
6HJW	;	2.5	;	Crystal structure of the chloroplast chorismate mutase from Zea mays
1FX0	;	3.2	;	Crystal structure of the chloroplast F1-ATPase from spinach
1RYB	;	1.7	;	Crystal Structure of the Chloroplast Group II Intron Splicing Factor CRS2
7BJK	;	2.25	;	Crystal structure of the chloroplastic Fe superoxide dismutase PAP9 from Arabidopsis thaliana.
5A3V	;	2.34	;	Crystal structure of the chloroplastic gamma-ketol reductase from Arabidopsis thaliana
5A3J	;	2.776	;	Crystal structure of the chloroplastic gamma-ketol reductase from Arabidopsis thaliana bound to 13-Oxo-9(Z),11(E),15(Z)- octadecatrienoic acid.
5A4D	;	2.807	;	Crystal structure of the chloroplastic gamma-ketol reductase from Arabidopsis thaliana bound to 13KOTE and NADP
7F8Y	;	2.5	;	Crystal structure of the cholecystokinin receptor CCKAR in complex with devazepide
7F8U	;	2.8	;	Crystal structure of the cholecystokinin receptor CCKAR in complex with lintitript
7F8X	;	3.0	;	Crystal structure of the cholecystokinin receptor CCKAR in complex with NN9056
2WV6	;	1.895	;	Crystal structure of the cholera toxin-like B-subunit from Citrobacter freundii to 1.9 angstrom
6KO8	;	1.55	;	Crystal structure of the Cholic acid bound RamR determined with XtaLAB Synergy
3HIA	;	2.38	;	Crystal structure of the choline binding domain of Spr1274 in Streptococcus pneumoniae
4CNL	;	1.7	;	Crystal structure of the Choline-binding domain of CbpL from Streptococcus pneumoniae
1SQ1	;	2.8	;	Crystal Structure of the Chorismate Synthase from Campylobacter jejuni, Northeast Structural Genomics Target BR19
3TIX	;	2.9001	;	Crystal structure of the Chp1-Tas3 complex core
6FTO	;	1.6	;	Crystal structure of the Chp2 chromoshadow domain in complex with N-terminal domain of chromatin remodeler Mit1
3MVD	;	2.9	;	Crystal structure of the chromatin factor RCC1 in complex with the nucleosome core particle
5E5A	;	2.809	;	Crystal structure of the chromatin-tethering domain of Human cytomegalovirus IE1 protein bound to the nucleosome core particle
2F5K	;	2.2	;	Crystal structure of the chromo domain of human MRG15
3R93	;	2.057	;	Crystal structure of the chromo domain of M-phase phosphoprotein 8 bound to H3K9Me3 peptide
7VYW	;	1.6	;	Crystal structure of the chromodomain of Arabidopsis LHP1 in complex with methylated histone H3K9 peptide
6BPH	;	1.85	;	Crystal structure of the chromodomain of RBBP1
3MWY	;	3.7	;	Crystal structure of the chromodomain-ATPase portion of the yeast Chd1 chromatin remodeler
2OOL	;	2.2	;	Crystal structure of the chromophore-binding domain of an unusual bacteriophytochrome RpBphP3 from R. palustris
4RQ9	;	2.5	;	Crystal structure of the chromophore-binding domain of Stigmatella aurantiaca bacteriophytochrome (Thr289His mutant) in the Pr state
7SWS	;	1.642	;	Crystal structure of the chromoprotein amilCP
7SWT	;	2.005	;	Crystal structure of the chromoprotein eforRED
7SWR	;	1.388	;	Crystal structure of the chromoprotein gfasPurple
7SWU	;	1.444	;	Crystal structure of the chromoprotein spisPINK
6IZD	;	1.6	;	Crystal structure of the chromosome-encoded beta-lactamase mutant R168H/M221I of Vibrio parahaemolyticus
6IZC	;	1.55	;	Crystal structure of the chromosome-encoded beta-lactamase of Vibrio parahaemolyticus
4CG4	;	2.4	;	Crystal structure of the CHS-B30.2 domains of TRIM20
4IN3	;	2.936	;	Crystal Structure of the Chs5-Bch1 Exomer Cargo Adaptor Complex
4YG8	;	2.75	;	CRYSTAL STRUCTURE OF THE CHS5-CHS6 EXOMER CARGO ADAPTOR COMPLEX
4WJW	;	2.59	;	Crystal Structure of the Chs5-Chs6 Exomer Cargo Adaptor Complex Bound to portion of Chs3
4X28	;	1.99	;	Crystal structure of the ChsE4-ChsE5 complex from Mycobacterium tuberculosis
4W78	;	1.541	;	Crystal structure of the ChsH1-ChsH2 complex from Mycobacterium tuberculosis
4WNB	;	1.76	;	Crystal structure of the ChsH1-ChsH2 complex from Mycobacterium tuberculosis bound to 3-OPC-CoA
3HJ3	;	2.7	;	Crystal Structure of the ChTS-DHFR F207A Non-Active Site Mutant
2IO5	;	2.7	;	Crystal structure of the CIA- histone H3-H4 complex
4MEA	;	1.95	;	Crystal structure of the Cif epoxide hydrolase from Acinetobacter nosocomialis
2DQL	;	1.7	;	Crystal structure of the circadian clock associated protein Pex from anabaena
5XTF	;	2.095	;	Crystal structure of the cis-dihydrodiol naphthalene dehydrogenase NahB from Pseudomonas sp. MC1
5XTG	;	2.318	;	Crystal structure of the cis-dihydrodiol naphthalene dehydrogenase NahB from Pseudomonas sp. MC1 in the presence of NAD+ and 2,3-dihydroxybiphenyl
6ZSQ	;	2.004	;	Crystal structure of the Cisplatin beta-Lactoglobulin adduct formed after 18 h of soaking
6ZSR	;	2.005	;	Crystal structure of the Cisplatin beta-Lactoglobulin adduct formed after 72 h of soaking
2VRB	;	2.0	;	Crystal structure of the Citrobacter sp. triphenylmethane reductase complexed with NADP(H)
2VRC	;	2.5	;	Crystal structure of the Citrobacter sp. triphenylmethane reductase complexed with NADP(H)
4DGL	;	3.0	;	Crystal Structure of the CK2 Tetrameric Holoenzyme
5B0X	;	2.3	;	Crystal structure of the CK2a/benzoic acid derivative complex
6A1C	;	1.68	;	Crystal structure of the CK2a1-go289 complex
3WIK	;	1.995	;	Crystal structure of the CK2alpha/compound10 complex
3WIL	;	2.9	;	Crystal structure of the CK2alpha/compound3 complex
6ME1	;	1.97	;	Crystal structure of the clade B isolate B41 mutant fusion peptide (residues 512-521) in complex with VRC34.01
1IQP	;	2.8	;	Crystal Structure of the Clamp Loader Small Subunit from Pyrococcus furiosus
2WK0	;	1.65	;	Crystal structure of the class A beta-lactamase BS3 inhibited by 6- beta-iodopenicillanate.
1W7F	;	1.8	;	Crystal structure of the class A beta-lactamase BS3 inhibited with isocitrate
2CC1	;	2.13	;	Crystal structure of the class A beta-lactamase from Mycobacterium fortuitum
1N4O	;	1.85	;	Crystal structure of the Class A beta-lactamase L2 from Stenotrophomonas maltophilia
5GL9	;	1.5	;	Crystal structure of the class A beta-lactamase PenL
5GLA	;	1.5	;	Crystal structure of the class A beta-lactamase PenL-tTR10 containing 10 residues insertion in omega-loop
5GLB	;	1.6	;	Crystal structure of the class A beta-lactamase PenL-tTR10 in complex with CBA
5GLC	;	1.601	;	Crystal structure of the class A beta-lactamase PenL-tTR11 containing 20 residues insertion in omega-loop
5GLD	;	1.7	;	Crystal structure of the class A beta-lactamase PenL-tTR11 in complex with CBA
8EO5	;	1.8	;	Crystal structure of the class A beta-lactamase precursor LRA-5 from an Alaskan soil metagenome at 1.8 Angstrom resolution
3BFE	;	2.4	;	Crystal Structure of the Class A beta-lactamase SED-1 from Citrobacter sedlakii
3BFD	;	2.0	;	Crystal Structure of the Class A beta-lactamase SED-G238C mutant from Citrobacter sedlakii
1O7E	;	1.51	;	Crystal structure of the class A beta-lactamse L2 from Stenotrophomonas maltophilia at 1.51 angstrom
8EK9	;	1.4	;	Crystal structure of the class A carbapenemase CRH-1 in complex with avibactam at 1.4 Angstrom resolution
3DW0	;	1.6	;	Crystal structure of the class A carbapenemase KPC-2 at 1.6 angstrom resolution
3ZNY	;	1.2	;	Crystal structure of the class A extended-spectrum beta-lactamase CTX- M-96, a natural D240G mutant derived from CTX-M-12
8EHH	;	1.03	;	Crystal structure of the class A extended-spectrum beta-lactamase CTX-M-96 in complex with relebactam at 1.03 Angstrom resolution
4D2O	;	2.2	;	Crystal structure of the class A extended-spectrum beta-lactamase PER- 2
5AEB	;	2.1	;	Crystal structure of the class B3 di-zinc metallo-beta-lactamase LRA- 12 from an Alaskan soil metagenome.
6FM6	;	1.05	;	Crystal structure of the class C beta-lactamase TRU-1 from Aeromonas enteropelogenes
6FM7	;	1.04	;	Crystal structure of the class C beta-lactamase TRU-1 from Aeromonas enteropelogenes in complex with avibactam
1FOF	;	2.0	;	CRYSTAL STRUCTURE OF THE CLASS D BETA-LACTAMASE OXA-10
2X02	;	1.35	;	CRYSTAL STRUCTURE OF THE CLASS D BETA-LACTAMASE OXA-10 AT 1.35 A RESOLUTION
1K4F	;	1.6	;	CRYSTAL STRUCTURE OF THE CLASS D BETA-LACTAMASE OXA-10 AT 1.6 A RESOLUTION
1H8Z	;	1.8	;	Crystal structure of the class D beta-lactamase OXA-13
1H5X	;	1.9	;	CRYSTAL STRUCTURE OF THE CLASS D BETA-LACTAMASE OXA-13 COMPLEXED WITH IMIPENEM
1H8Y	;	2.0	;	Crystal structure of the class D beta-lactamase OXA-13 in complex with meropenem
1K38	;	1.5	;	CRYSTAL STRUCTURE OF THE CLASS D BETA-LACTAMASE OXA-2
7L5V	;	1.3	;	Crystal Structure of the Class D Beta-lactamase OXA-935 from Pseudomonas aeruginosa, Monoclinic Crystal Form
7N1M	;	1.96	;	Crystal Structure of the Class D Beta-lactamase OXA-935 from Pseudomonas aeruginosa, Orthorhombic Crystal Form
1K4E	;	2.0	;	CRYSTAL STRUCTURE OF THE CLASS D BETA-LACTAMASES OXA-10 DETERMINED BY MAD PHASING WITH SELENOMETHIONINE
5KIJ	;	1.649	;	Crystal structure of the class I human endoplasmic reticulum 1,2-alpha-mannosidase and Man9GlcNAc2-PA complex
5KK7	;	1.7324	;	Crystal structure of the class I human endoplasmic reticulum 1,2-alpha-mannosidase T688A mutant and Thio-disaccharide substrate analog complex
3R1H	;	3.15	;	Crystal structure of the Class I ligase ribozyme-substrate preligation complex, C47U mutant, Ca2+ bound
3R1L	;	3.125	;	Crystal structure of the Class I ligase ribozyme-substrate preligation complex, C47U mutant, Mg2+ bound
3FOM	;	2.1	;	Crystal structure of the Class I MHC Molecule H-2Kwm7 with a Single Self Peptide IQQSIERL
3FON	;	2.03	;	Crystal structure of the Class I MHC Molecule H-2Kwm7 with a Single Self Peptide VNDIFEAI
3FOL	;	2.5	;	Crystal structure of the Class I MHC Molecule H-2Kwm7 with a Single Self Peptide VNDIFERI
5IM3	;	2.298	;	Crystal structure of the class I ribonucleotide reductase from Pseudomonas aeruginosa in complex with dATP
1UZR	;	2.2	;	Crystal Structure of the Class Ib Ribonucleotide Reductase R2F-2 subunit from Mycobacterium tuberculosis
7MMP	;	2.15	;	Crystal Structure of the Class Ie Ribonucleotide Reductase
7MMW	;	1.55	;	Crystal Structure of the Class Ie Ribonucleotide Reductase Beta Subunit from Aerococcus urinae (in alternate conformation)
6EBP	;	1.59	;	Crystal Structure of the Class Ie Ribonucleotide Reductase Beta Subunit from Aerococcus urinae in Activated Form
6EBZ	;	1.66	;	Crystal Structure of the Class Ie Ribonucleotide Reductase Beta Subunit from Aerococcus urinae in Activated Form with Thiocyanate Bound
6EBO	;	1.58	;	Crystal Structure of the Class Ie Ribonucleotide Reductase Beta Subunit from Aerococcus urinae in Unactivated Form
7MMU	;	2.08	;	Crystal Structure of the Class Ie Ribonucleotide Reductase Beta Subunit from Aerococcus urinae with Cu(I) bound (Cu acetonitrile soak)
7MMT	;	1.54	;	Crystal Structure of the Class Ie Ribonucleotide Reductase Beta Subunit from Aerococcus urinae with Cu(I) bound (Cu chloride soak)
7MMV	;	1.78	;	Crystal Structure of the Class Ie Ribonucleotide Reductase Beta Subunit from Aerococcus urinae with Cu(I) bound (Cu sulfate soak)
7MMR	;	2.0	;	Crystal Structure of the Class Ie Ribonucleotide Reductase Beta-NrdI complex from Aerococcus urinae in Oxidized Form with Cu(I) bound
7MMQ	;	2.4	;	Crystal Structure of the Class Ie Ribonucleotide Reductase Beta-NrdI complex from Aerococcus urinae in Reduced Hydroquinone Form
7MMS	;	1.91	;	Crystal Structure of the Class Ie Ribonucleotide Reductase Beta-NrdI complex from Aerococcus urinae in Semiquinone Form with Cu(I) bound
1KPK	;	3.5	;	Crystal Structure of the ClC Chloride Channel from E. coli
1KPL	;	3.0	;	Crystal Structure of the ClC Chloride Channel from S. typhimurium
6K5F	;	3.203	;	Crystal structure of the CLC-ec1 deltaNC in presence of 200 mM NaBr
6B0N	;	3.4	;	Crystal structure of the cleavage-independent prefusion HIV Env glycoprotein trimer of the clade A BG505 isolate (NFL construct) in complex with Fabs PGT122 and PGV19 at 3.39 A
2YV7	;	1.7	;	Crystal structure of the CLIC homolog from drosophila melanogaster
2YV9	;	1.6	;	Crystal structure of the CLIC homologue EXC-4 from c. elegans
2E3I	;	2.0	;	Crystal structure of the CLIP-170 CAP-Gly domain 1
2E3H	;	1.45	;	Crystal structure of the CLIP-170 CAP-Gly domain 2
5VJI	;	1.86	;	Crystal structure of the CLOCK Transcription Domain Exon19 in Complex with a Repressor
5VJX	;	2.695	;	Crystal structure of the CLOCK Transcription Domain Exon19 in Complex with a Repressor
1LV5	;	1.95	;	Crystal Structure of the Closed Conformation of Bacillus DNA Polymerase I Fragment Bound to DNA and dCTP
2CST	;	1.9	;	CRYSTAL STRUCTURE OF THE CLOSED FORM OF CHICKEN CYTOSOLIC ASPARTATE AMINOTRANSFERASE AT 1.9 ANGSTROMS RESOLUTION
4BP0	;	2.24	;	Crystal structure of the closed form of Pseudomonas aeruginosa SPM-1
3WFW	;	1.65	;	Crystal Structure of the Closed Form of the HGbRL's Globin Domain
3UG9	;	2.3	;	Crystal Structure of the Closed State of Channelrhodopsin
1GZ7	;	1.97	;	Crystal structure of the closed state of lipase 2 from Candida rugosa
6UJE	;	1.75	;	Crystal structure of the Clostridial cellulose synthase subunit Z (CcsZ) from Clostridioides difficile
6UJF	;	2.0	;	Crystal structure of the Clostridial cellulose synthase subunit Z (CcsZ) from Clostridioides difficile
6UWI	;	3.7	;	Crystal structure of the Clostridium difficile translocase CDTb
4U6T	;	1.76	;	Crystal structure of the Clostridium histolyticum colH collagenase polycystic kidney disease-like domain 2a at 1.76 Angstrom resolution
4U7K	;	1.91	;	Crystal structure of the Clostridium histolyticum colH collagenase polycystic kidney disease-like domain 2a in the presence of calcium at 1.9 Angstrom resolution
3BW8	;	1.8	;	Crystal structure of the Clostridium limosum C3 exoenzyme
4H56	;	3.9	;	Crystal structure of the Clostridium perfringens NetB toxin in the membrane inserted form
5JIP	;	1.8	;	Crystal structure of the Clostridium perfringens spore cortex lytic enzyme SleM
3F52	;	1.75	;	Crystal structure of the clp gene regulator ClgR from C. glutamicum
3F51	;	2.05	;	Crystal Structure of the clp gene regulator ClgR from Corynebacterium glutamicum
2F6I	;	2.45	;	Crystal structure of the ClpP protease catalytic domain from Plasmodium falciparum
4RWG	;	2.44	;	Crystal structure of the CLR:RAMP1 extracellular domain heterodimer with bound high affinity CGRP analog
4RWF	;	1.76	;	Crystal structure of the CLR:RAMP2 extracellular domain heterodimer with bound adrenomedullin
3P30	;	3.3	;	crystal structure of the cluster II Fab 1281 in complex with HIV-1 gp41 ectodomain
3W2V	;	2.6	;	Crystal structure of the Cmr2dHD-Cmr3 subcomplex bound to 3'-AMP
3W2W	;	2.5	;	Crystal structure of the Cmr2dHD-Cmr3 subcomplex bound to ATP
1LT0	;	2.4	;	Crystal structure of the CN-bound BjFixL heme domain
2E39	;	1.3	;	Crystal structure of the CN-bound form of Arthromyces ramosus peroxidase at 1.3 Angstroms resolution
6G52	;	3.691	;	CRYSTAL STRUCTURE OF THE CNMP BINDING DOMAIN OF THE MAGNESIUM TRANSPORTER CNNM4
8F6D	;	3.2	;	Crystal structure of the CNNM2 CBS-pair domain in complex with ARL15
1FA6	;	1.9	;	CRYSTAL STRUCTURE OF THE CO(II)-BOUND GLYOXALASE I OF ESCHERICHIA COLI
1LSV	;	2.4	;	Crystal structure of the CO-bound BjFixL heme domain
5VTD	;	1.95	;	Crystal Structure of the Co-bound Human Heavy-Chain Ferritin variant 122H-delta C-star
8U5G	;	3.2	;	Crystal structure of the co-expressed SDS22:PP1:I3 complex
3CDK	;	2.59	;	Crystal structure of the co-expressed succinyl-CoA transferase A and B complex from Bacillus subtilis
6WIQ	;	2.85	;	Crystal structure of the co-factor complex of NSP7 and the C-terminal domain of NSP8 from SARS CoV-2
5TKY	;	2.6	;	Crystal structure of the co-translational Hsp70 chaperone Ssb in the ATP-bound, open conformation
3THH	;	1.85	;	Crystal structure of the Co2+2-HAI-ABH complex
3THJ	;	1.5	;	Crystal structure of the Co2+2-HAI-L-Orn complex
4FCK	;	1.9	;	Crystal Structure of the Co2+2-Human Arginase I-AGPA Complex
4FRG	;	2.95	;	Crystal structure of the cobalamin riboswitch aptamer domain
4FRN	;	3.43	;	Crystal structure of the cobalamin riboswitch regulatory element
4QQU	;	2.98	;	Crystal structure of the cobalamin-independent methionine synthase enzyme in a closed conformation
4RXW	;	1.73	;	Crystal Structure of the cobalt human insulin derivative
1C0W	;	3.2	;	CRYSTAL STRUCTURE OF THE COBALT-ACTIVATED DIPHTHERIA TOXIN REPRESSOR-DNA COMPLEX REVEALS A METAL BINDING SH-LIKE DOMAIN
7NP8	;	2.3	;	Crystal structure of the Coenzyme F420-dependent sulfite reductase from Methanocaldococcus jannaschii at 2.3-A resolution
7NPA	;	1.55	;	Crystal structure of the Coenzyme F420-dependent sulfite reductase from Methanothermococcus thermolithotrophicus at 1.55-A resolution
3JXP	;	2.2	;	Crystal Structure of the Coenzyme PQQ Synthesis Protein (PqqB) from Pseudomonas putida
1XTO	;	2.8	;	Crystal Structure of the Coenzyme PQQ Synthesis Protein (PqqB) from Pseudomonas putida, Northeast Structural Genomics Target PpR6
3S0T	;	1.26	;	Crystal structure of the CofA Type IV pilin subunit from enterotoxigenic E. coli
2FYI	;	2.8	;	Crystal Structure of the Cofactor-Binding Domain of the Cbl Transcriptional Regulator
6IPB	;	1.78	;	Crystal Structure of the Cofactor-binding Domain of the Human Phase II Drug Metabolism Enzyme UGT2B15
7OKZ	;	2.101	;	CRYSTAL STRUCTURE OF THE COFACTOR-DEVOID 1-H-3-HYDROXY-4- OXOQUINALDINE 2,4-DIOXYGENASE (HOD) CATALYTICALLY INACTIVE H251A VARIANT COMPLEXED WITH 2-METHYL- QUINOLIN-4(1H)-ONE UNDER HYPEROXIC CONDITIONS
7OJM	;	2.001	;	CRYSTAL STRUCTURE OF THE COFACTOR-DEVOID 1-H-3-HYDROXY-4- OXOQUINALDINE 2,4-DIOXYGENASE (HOD) CATALYTICALLY INACTIVE H251A VARIANT COMPLEXED WITH 2-METHYL-QUINOLIN-4(1H)-ONE UNDER NORMOXIC CONDITIONS
4CFS	;	1.94	;	CRYSTAL STRUCTURE OF THE COFACTOR-DEVOID 1-H-3-HYDROXY-4- OXOQUINALDINE 2,4-DIOXYGENASE (HOD) CATALYTICALLY INACTIVE H251A VARIANT COMPLEXED WITH ITS NATURAL SUBSTRATE 1-H-3-HYDROXY-4- OXOQUINALDINE
2WJ3	;	2.09	;	CRYSTAL STRUCTURE OF THE COFACTOR-DEVOID 1-H-3-HYDROXY-4- OXOQUINALDINE 2,4-DIOXYGENASE (HOD) FROM ARTHROBACTER NITROGUAJACOLICUS RU61A
2WJ4	;	2.1	;	CRYSTAL STRUCTURE OF THE COFACTOR-DEVOID 1-H-3-HYDROXY-4- OXOQUINALDINE 2,4-DIOXYGENASE (HOD) FROM ARTHROBACTER NITROGUAJACOLICUS RU61A ANAEROBICALLY COMPLEXED WITH ITS NATURAL SUBSTRATE 1-H-3-HYDROXY-4-OXOQUINALDINE
2WJ6	;	2.0	;	CRYSTAL STRUCTURE OF THE COFACTOR-DEVOID 1-H-3-HYDROXY-4- OXOQUINALDINE 2,4-DIOXYGENASE (HOD) FROM ARTHROBACTER NITROGUAJACOLICUS RU61A COMPLEXED WITH ITS NATURAL PRODUCT N- ACETYLANTHRANILATE
2WM2	;	2.7	;	CRYSTAL STRUCTURE OF THE COFACTOR-DEVOID 1-H-3-HYDROXY-4- OXOQUINALDINE 2,4-DIOXYGENASE (HOD) FROM ARTHROBACTER NITROGUAJACOLICUS RU61A IN COMPLEX WITH CHLORIDE
8OXT	;	2.003	;	CRYSTAL STRUCTURE OF THE COFACTOR-DEVOID 1-H-3-HYDROXY-4- OXOQUINALDINE 2,4-DIOXYGENASE (HOD) H251A VARIANT COMPLEXED WITH N-ACETYLANTHRANILATE AS RESULT OF IN CRYSTALLO TURNOVER OF ITS NATURAL SUBSTRATE 1-H-3-HYDROXY-4- OXOQUINALDINE UNDER HYPEROXIC CONDITIONS
8ORO	;	2.0	;	CRYSTAL STRUCTURE OF THE COFACTOR-DEVOID 1-H-3-HYDROXY-4- OXOQUINALDINE 2,4-DIOXYGENASE (HOD) S101A VARIANT COMPLEXED WITH 2-METHYL-QUINOLIN-4(1H)-ONE UNDER HYPEROXYC CONDITIONS
8OXN	;	2.0	;	CRYSTAL STRUCTURE OF THE COFACTOR-DEVOID 1-H-3-HYDROXY-4- OXOQUINALDINE 2,4-DIOXYGENASE (HOD) S101A VARIANT COMPLEXED WITH 2-METHYL-QUINOLIN-4(1H)-ONE UNDER NORMOXYC CONDITIONS
6RGT	;	1.6	;	Crystal structure of the cofactor-free Aspergillus flavus urate oxidase T57A variant anaerobically complexed with 9-methyl uric acid
4RL8	;	2.3	;	Crystal structure of the COG4313 outer membrane channel from Pseudomonas putida F1
4U6U	;	3.0	;	Crystal Structure of the Cog5-Cog7 complex from Kluyveromyces lactis
5M0Y	;	1.5	;	Crystal Structure of the CohScaA-XDocCipB type II complex from Clostridium thermocellum at 1.5Angstrom resolution
5G5D	;	3.0	;	Crystal Structure of the CohScaC2-XDocCipA type II complex from Clostridium thermocellum
6TTR	;	2.85	;	Crystal Structure of the coiled coil and GGDEF domain of DgcB from Caulobacter crescentus in complex with c-di-GMP
3Q8T	;	1.9	;	Crystal structure of the coiled coil domain of Beclin 1, an essential autophagy protein
4M3L	;	2.1	;	Crystal Structure of the coiled coil domain of MuRF1
5CJ1	;	2.1	;	Crystal structure of the coiled coil of MYH7 residues 1526 to 1571 fused to Gp7
1M5I	;	2.0	;	Crystal Structure of the coiled coil region 129-250 of the tumor suppressor gene product APC
4DJG	;	1.9	;	Crystal structure of the coiled-coil 1 domain of actin-binding protein SCAB1
1T6F	;	1.47	;	Crystal Structure of the Coiled-coil Dimerization Motif of Geminin
1NYH	;	3.1	;	Crystal Structure of the Coiled-coil Dimerization Motif of Sir4
5U96	;	1.95	;	Crystal structure of the coiled-coil domain from Listeria Innocua (Tetragonal Form)
5UDO	;	2.541	;	Crystal structure of the coiled-coil domain from Listeria Innocua Phage Integrase (Tetragonal Form II)
5UAE	;	2.75	;	Crystal structure of the coiled-coil domain from Listeria Innocua Phage Integrase (Trigonal Form)
4GKW	;	3.3	;	Crystal Structure of the Coiled-coil Domain of C. elegans SAS-6
2AKF	;	1.2	;	Crystal structure of the coiled-coil domain of coronin 1
5N7H	;	2.2	;	Crystal structure of the coiled-coil domain of human tricellulin
5N7I	;	2.88	;	Crystal structure of the coiled-coil domain of human tricellulin
5N7K	;	2.81	;	Crystal structure of the coiled-coil domain of human tricellulin
2V66	;	2.1	;	Crystal Structure of the coiled-coil domain of Ndel1 (a.a. 58 to 169) C
3VVI	;	1.25	;	Crystal structure of the coiled-coil domain of the transient receptor potential channel from Gibberella zeae (TRPGz)
8FXF	;	2.8	;	Crystal structure of the coiled-coil domain of TRIM56
7UG2	;	2.052	;	Crystal structure of the coiled-coil domain of TRIM75
6JN2	;	3.6	;	Crystal structure of the coiled-coil domains of human DOT1L in complex with AF10
4XA1	;	3.2	;	Crystal Structure of the coiled-coil surrounding Skip 1 of MYH7
4XA3	;	2.548	;	Crystal structure of the coiled-coil surrounding Skip 2 of MYH7
4XA4	;	2.327	;	Crystal Structure of the coiled-coil surrounding Skip 3 of MYH7
4XA6	;	3.42	;	Crystal Structure of the coiled-coil surrounding Skip 4 of MYH7
4GMV	;	2.403	;	Crystal Structure of the coiled-coil, RA and PH domains of Lamellipodin
6E0W	;	1.803	;	Crystal structure of the colanidase tailspike protein gp150 of Phage Phi92 complexed with one repeating unit of colanic acid
6A6L	;	1.78	;	Crystal structure of the cold shock domain of YB-1 in complex with m5C RNA
3CAM	;	2.6	;	Crystal structure of the cold shock domain protein from Neisseria meningitidis
3U43	;	1.72	;	Crystal structure of the colicin E2 DNase-Im2 complex
1V14	;	2.9	;	Crystal Structure of the Colicin E9, mutant His103Ala, in complex with Mg+2 and dsDNA (resolution 2.9A)
1V15	;	2.4	;	CRYSTAL STRUCTURE OF THE COLICIN E9, MUTANT HIS103ALA, IN COMPLEX WITH ZN+2 AND DSDNA (RESOLUTION 2.4A)
2HDF	;	2.65	;	Crystal structure of the Colicin I receptor Cir from E.coli
2HDI	;	2.5	;	Crystal structure of the Colicin I receptor Cir from E.coli in complex with receptor binding domain of Colicin Ia.
1XWR	;	2.56	;	Crystal structure of the coliphage lambda transcription activator protein CII
8JL8	;	1.81	;	Crystal structure of the collagen binding domain of Cnm from Streptococcus mutans
3V10	;	1.75	;	Crystal structure of the collagen binding domain of Erysipelothrix rhusiopathiae surface protein RspB
1K6F	;	1.3	;	Crystal Structure of the Collagen Triple Helix Model [(Pro-Pro-Gly)10]3
1WZB	;	1.5	;	Crystal structure of the collagen triple helix model [{HYP(R)-HYP(R)-GLY}10]3
3B2C	;	1.36	;	Crystal structure of the collagen triple helix model [{PRO-HYP(R)-GLY}4-{HYP(S)-Pro-GLY}2-{PRO-HYP(R)-GLY}4]3
6SNK	;	2.2	;	Crystal structure of the Collagen VI alpha3 N2 domain
4IGI	;	1.2	;	Crystal structure of the Collagen VI alpha3 N5 domain
4IHK	;	1.2	;	Crystal structure of the Collagen VI alpha3 N5 domain R1061Q
1P9H	;	1.55	;	CRYSTAL STRUCTURE OF THE COLLAGEN-BINDING DOMAIN OF YERSINIA ADHESIN YadA
7VLZ	;	1.6	;	Crystal structure of the collagenase unit of a Vibrio collagenase from Vibrio harveyi VHJR7
7ESI	;	1.8	;	Crystal structure of the collagenase unit of a Vibrio collagenase from Vibrio harveyi VHJR7 at 1. 8 angstrom resolution.
4ARE	;	2.19	;	Crystal structure of the collagenase Unit of collagenase G from Clostridium histolyticum at 2.19 angstrom resolution.
6G75	;	1.391	;	Crystal structure of the common ancestor of haloalkane dehalogenases and Renilla luciferase (AncHLD-RLuc)
1Y2T	;	1.5	;	Crystal structure of the common edible mushroom (Agaricus bisporus) lectin
1Y2U	;	1.85	;	Crystal structure of the common edible mushroom (Agaricus bisporus) lectin in complex with Lacto-N-biose
1Y2V	;	1.9	;	Crystal structure of the common edible mushroom (Agaricus bisporus) lectin in complex with T-antigen
5V01	;	1.3	;	Crystal structure of the competence damage-inducible protein A (ComA) from Klebsiella pneumoniae subsp. pneumoniae MGH 78578
5KOL	;	1.91	;	Crystal structure of the competence-damaged protein (CinA) superfamily protein ECK1530/EC0983 from Escherichia coli
5VU3	;	1.868	;	Crystal structure of the competence-damaged protein (CinA) superfamily protein ECL_02051 from Enterobacter cloacae
6MR3	;	2.05	;	Crystal structure of the competence-damaged protein (CinA) superfamily protein from Streptococcus mutans
5KVK	;	1.66	;	Crystal structure of the Competence-Damaged Protein (CinA) Superfamily Protein KP700603 from Klebsiella pneumoniae 700603
1QZW	;	4.1	;	Crystal structure of the complete core of archaeal SRP and implications for inter-domain communication
1QZX	;	4.0	;	Crystal structure of the complete core of archaeal SRP and implications for inter-domain communication
2X10	;	3.0	;	Crystal structure of the complete EphA2 ectodomain
2X11	;	4.83	;	Crystal structure of the complete EphA2 ectodomain in complex with ephrin A5 receptor binding domain
1GH7	;	3.0	;	CRYSTAL STRUCTURE OF THE COMPLETE EXTRACELLULAR DOMAIN OF THE BETA-COMMON RECEPTOR OF IL-3, IL-5, AND GM-CSF
3K70	;	3.59	;	Crystal structure of the complete initiation complex of RecBCD
3IJE	;	2.9	;	Crystal structure of the complete integrin alhaVbeta3 ectodomain plus an Alpha/beta transmembrane fragment
2BIB	;	1.92	;	Crystal structure of the complete modular teichioic acid phosphorylcholine esterase Pce (CbpE) from Streptococcus pneumoniae
8RKE	;	2.7	;	Crystal structure of the complete N-terminal region of human ZP2 (hZP2-N1N2N3)
1DTO	;	1.9	;	CRYSTAL STRUCTURE OF THE COMPLETE TRANSACTIVATION DOMAIN OF E2 PROTEIN FROM THE HUMAN PAPILLOMAVIRUS TYPE 16
6MJ0	;	3.1	;	Crystal structure of the complete turnip yellow mosaic virus 3'UTR
5L0Q	;	2.759	;	Crystal structure of the complex between ADAM10 D+C domain and a conformation specific mAb 8C7.
3GRV	;	1.9	;	Crystal Structure of the Complex between Adenosine and Methanocaldococcus jannaschi Dim1
5VU0	;	2.26	;	Crystal structure of the complex between afucosylated/galactosylated human IgG1 Fc and Fc gamma receptor IIIa (CD16A) with Man5 N-glycans
3GRU	;	1.6	;	Crystal Structure of the Complex between AMP and Methanocaldococcus jannaschi Dim1
1KXH	;	2.3	;	Crystal structure of the complex between an inactive mutant of psychrophilic alpha-amylase (D174N) and acarbose
2G1A	;	2.0	;	Crystal structure of the complex between Apha class B acid phosphatase/phosphotransferase
2FOT	;	2.45	;	Crystal structure of the complex between calmodulin and alphaII-spectrin
1IT6	;	2.0	;	CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN CALYCULIN A AND THE CATALYTIC SUBUNIT OF PROTEIN PHOSPHATASE 1
3EFT	;	1.85	;	Crystal structure of the complex between Carbonic Anhydrase II and a spin-labeled sulfonamide incorporating TEMPO moiety
3K7K	;	1.9	;	Crystal structure of the complex between Carbonic Anhydrase II and anions
5E5R	;	2.6	;	Crystal structure of the complex between Carbonic anhydrase-like domain of PTPRG and Immunoglobulin domains 2-3 of CNTN3
5E5U	;	2.0	;	Crystal structure of the complex between Carbonic anhydrase-like domain of PTPRG and Immunoglobulin domains 2-3 of CNTN6
1CBX	;	2.0	;	CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN CARBOXYPEPTIDASE A AND THE BIPRODUCT ANALOG INHIBITOR L-BENZYLSUCCINATE AT 2.0 ANGSTROMS RESOLUTION
3UCS	;	1.87	;	Crystal structure of the complex between CBPA J-domain and CBPM
5WK3	;	1.9	;	CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN CCL17 AND M116 FAB
5WCM	;	1.2	;	Crystal structure of the complex between class B3 beta-lactamase BJP-1 and 4-nitrobenzene-sulfonamide - new refinement
3G6D	;	3.2	;	Crystal structure of the complex between CNTO607 Fab and IL-13
4DN4	;	2.8	;	Crystal structure of the complex between cnto888 fab and mcp-1 mutant p8a
2Y0M	;	2.7	;	CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN DOSAGE COMPENSATION FACTORS MSL1 AND MOF
2Y0N	;	3.0	;	CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN DOSAGE COMPENSATION FACTORS MSL1 AND MSL3
1BO5	;	3.2	;	CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN ESCHERICHIA COLI GLYCEROL KINASE AND THE ALLOSTERIC REGULATOR FRUCTOSE 1,6-BISPHOSPHATE.
1BOT	;	3.05	;	CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN ESCHERICHIA COLI GLYCEROL KINASE AND THE ALLOSTERIC REGULATOR FRUCTOSE 1,6-BISPHOSPHATE.
1GAQ	;	2.59	;	CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN FERREDOXIN AND FERREDOXIN-NADP+ REDUCTASE
1OMW	;	2.5	;	Crystal Structure of the complex between G Protein-Coupled Receptor Kinase 2 and Heterotrimeric G Protein beta 1 and gamma 2 subunits
2ZZO	;	2.2	;	Crystal structure of the complex between GP41 fragment N36 and fusion inhibitor C34/S138A
2Z2T	;	2.1	;	Crystal structure of the complex between gp41 fragment N36 and fusion inhibitor SC34EK
3AHA	;	1.7	;	Crystal structure of the complex between gp41 fragments N36 and C34 mutant N126K/E137Q
6D07	;	2.1	;	Crystal structure of the complex between human chromobox homolog 1 (CBX1) and H3K9me3 peptide
3TJS	;	2.25	;	Crystal Structure of the complex between human cytochrome P450 3A4 and desthiazolylmethyloxycarbonyl ritonavir
5DEA	;	2.7973	;	Crystal structure of the complex between human FMRP RGG motif and G-quadruplex RNA, cesium bound form.
5DE8	;	3.1003	;	Crystal structure of the complex between human FMRP RGG motif and G-quadruplex RNA, iridium hexammine bound form.
5DE5	;	3.0011	;	Crystal structure of the complex between human FMRP RGG motif and G-quadruplex RNA.
2WG3	;	2.6	;	Crystal structure of the complex between human hedgehog-interacting protein HIP and desert hedgehog without calcium
2WFX	;	3.2	;	Crystal structure of the complex between human hedgehog-interacting protein HIP and Sonic Hedgehog in the presence of calcium
2WG4	;	3.15	;	Crystal structure of the complex between human hedgehog-interacting protein HIP and sonic hedgehog without calcium
2WJV	;	2.85	;	Crystal structure of the complex between human nonsense mediated decay factors UPF1 and UPF2
2WJY	;	2.5	;	Crystal structure of the complex between human nonsense mediated decay factors UPF1 and UPF2 Orthorhombic form
5K23	;	2.96	;	Crystal structure of the complex between human phosphatase PRL-2 in the oxidized state with the Bateman domain of human magnesium transporter CNNM3
5K22	;	3.0	;	Crystal structure of the complex between human PRL-2 phosphatase in reduced state and Bateman domain of human CNNM3
2XNA	;	2.1	;	Crystal structure of the complex between human T cell receptor and staphylococcal enterotoxin
4M7L	;	3.4	;	Crystal structure of the complex between human tissue factor extracellular domain and antibody 10H10 FAB fragment
3L5W	;	2.0	;	Crystal structure of the complex between IL-13 and C836 FAB
3L5X	;	1.9	;	Crystal structure of the complex between IL-13 and H2L6 FAB
4PS4	;	2.8	;	Crystal structure of the complex between IL-13 and M1295 FAB
1S6C	;	2.0	;	Crystal structure of the complex between KChIP1 and Kv4.2 N1-30
2NLI	;	1.59	;	Crystal Structure of the complex between L-lactate oxidase and a substrate analogue at 1.59 angstrom resolution
4WZ3	;	2.7	;	Crystal structure of the complex between LubX/LegU2/Lpp2887 U-box 1 and Homo sapiens UBE2D2
1NYY	;	1.9	;	Crystal Structure of the complex between M182T mutant of TEM-1 and a boronic acid inhibitor (105)
1NYM	;	1.2	;	Crystal Structure of the complex between M182T mutant of TEM-1 and a boronic acid inhibitor (CXB)
1NY0	;	1.75	;	Crystal Structure of the complex between M182T mutant of TEM-1 and a boronic acid inhibitor (NBF)
1NXY	;	1.6	;	Crystal Structure of the complex between M182T mutant of TEM-1 and a boronic acid inhibitor (SM2)
5H8V	;	2.2	;	Crystal structure of the complex between maize Sulfite Reductase and ferredoxin in the form-1 crystal
5H8Y	;	2.2	;	Crystal structure of the complex between maize sulfite reductase and ferredoxin in the form-2 crystal
5H92	;	2.08	;	Crystal structure of the complex between maize Sulfite Reductase and ferredoxin in the form-3 crystal
1ZP5	;	1.8	;	Crystal structure of the complex between MMP-8 and a N-hydroxyurea inhibitor
3DNG	;	2.0	;	Crystal structure of the complex between MMP-8 and a non-zinc chelating inhibitor
3DPE	;	1.6	;	Crystal structure of the complex between MMP-8 and a non-zinc chelating inhibitor
3DPF	;	2.1	;	Crystal structure of the complex between MMP-8 and a non-zinc chelating inhibitor
1ZVX	;	1.87	;	Crystal structure of the complex between MMP-8 and a phosphonate inhibitor (R-enantiomer)
1ZS0	;	1.56	;	Crystal structure of the complex between MMP-8 and a phosphonate inhibitor (S-enantiomer)
3RNK	;	1.74	;	Crystal structure of the complex between mouse PD-1 mutant and PD-L2 IgV domain
7CEG	;	3.85	;	Crystal structure of the complex between mouse PTP delta and neuroligin-3
2QX1	;	2.6	;	Crystal structure of the complex between mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthase III (FABH) and decyl-COA disulfide
1U6S	;	2.3	;	Crystal Structure of the Complex Between Mycobacterium Tuberculosis Beta-Ketoacyl-Acyl Carrier Protein Synthase III and Lauroyl Coenzyme A
5O0W	;	2.57	;	Crystal structure of the complex between Nb474 and Trypanosoma congolense fructose-1,6-bisphosphate aldolase
2HEV	;	2.41	;	Crystal structure of the complex between OX40L and OX40
1XG2	;	1.9	;	Crystal structure of the complex between pectin methylesterase and its inhibitor protein
6PX4	;	1.65	;	Crystal structure of the complex between periplasmic domains of antiholin RI and holin T from T4 phage, in H32
6PXE	;	2.3	;	Crystal structure of the complex between periplasmic domains of antiholin RI and holin T from T4 phage, in P21
6PSK	;	2.2	;	Crystal structure of the complex between periplasmic domains of antiholin RI and holin T from T4 phage, in P6522
5K24	;	3.1	;	Crystal structure of the complex between phosphatase PRL-2 in the oxidized state with the Bateman domain of murine magnesium transporter CNNM3
3CDS	;	2.65	;	Crystal structure of the complex between PPAR-gamma and the agonist LT248 (clofibric acid analogue)
2I4J	;	2.1	;	Crystal structure of the complex between PPARgamma and the agonist LT160 (ureidofibrate derivative)
3B3K	;	2.6	;	Crystal structure of the complex between PPARgamma and the full agonist LT175
2I4P	;	2.1	;	Crystal structure of the complex between PPARgamma and the partial agonist LT127 (ureidofibrate derivative). Structure obtained from crystals of the apo-form soaked for 30 days.
2I4Z	;	2.25	;	Crystal structure of the complex between PPARgamma and the partial agonist LT127 (ureidofibrate derivative). This structure has been obtained from crystals soaked for 6 hours.
6AN1	;	2.687	;	Crystal structure of the complex between PPARgamma LBD and the ligand AM-879
4JL4	;	2.5	;	Crystal structure of the complex between PPARgamma LBD and the ligand LJ570 [(2S)-3-(biphenyl-4-yl)-2-(biphenyl-4-yloxy)propanoic acid]
6F2L	;	2.1	;	Crystal structure of the complex between PPARgamma LBD and the ligand LJ570: structure obtained from crystals of the apo-form soaked for 15 days.
6T9C	;	1.95	;	Crystal structure of the complex between PPARgamma LBD and the ligand NV1346 (3a)
6ZLY	;	1.79	;	Crystal structure of the complex between PPARgamma LBD and the ligand NV1362 (7a)
3D6D	;	2.4	;	Crystal Structure of the complex between PPARgamma LBD and the LT175(R-enantiomer)
4JAZ	;	2.85	;	Crystal structure of the complex between PPARgamma LBD and trans-resveratrol
4O8F	;	2.6	;	Crystal Structure of the complex between PPARgamma mutant R357A and rosiglitazone
4PVU	;	2.6	;	Crystal structure of the complex between PPARgamma-LBD and the R enantiomer of Mbx-102 (Metaglidasen)
4PWL	;	2.6	;	Crystal structure of the complex between PPARgamma-LBD and the S enantiomer of Mbx-102 (Metaglidasen)
4BJR	;	2.8	;	Crystal structure of the complex between Prokaryotic Ubiquitin-like Protein Pup and its Ligase PafA
2PDA	;	3.0	;	CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PYRUVATE-FERREDOXIN OXIDOREDUCTASE FROM DESULFOVIBRIO AFRICANUS AND PYRUVATE.
1O07	;	1.71	;	Crystal Structure of the complex between Q120L/Y150E mutant of AmpC and a beta-lactam inhibitor (MXG)
1LS3	;	2.7	;	Crystal Structure of the Complex between Rabbit Cytosolic Serine Hydroxymethyltransferase and TriGlu-5-formyl-tetrahydrofolate
1DP2	;	2.01	;	CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN RHODANESE AND LIPOATE
6THL	;	2.8	;	Crystal structure of the complex between RTT106 and BCD1
3GRR	;	1.8	;	Crystal Structure of the complex between S-Adenosyl Homocysteine and Methanocaldococcus jannaschi Dim1.
3GRY	;	2.2	;	Crystal Structure of the complex between S-Adenosyl Methionine and Methanocaldococcus jannaschi Dim1.
4OAJ	;	2.3	;	Crystal structure of the complex between SAP97 PDZ2 and 5HT2A receptor peptide
4I98	;	2.8	;	Crystal structure of the complex between ScpA(residues 1-160)-ScpB(residues 1-183)
6FE4	;	3.0	;	Crystal structure of the complex between Shiga toxin Stx2 B subunit and neutralising Nb113
4Y61	;	3.358	;	Crystal structure of the complex between Slitrk2 LRR1 and PTP delta Ig1-Fn1
3WMQ	;	1.6	;	Crystal structure of the complex between SLL-2 and GalNAc.
4NUT	;	1.55	;	Crystal structure of the complex between Snu13p and the PEP domain of Rsa1
3DGP	;	1.8	;	Crystal Structure of the complex between Tfb5 and the C-terminal domain of Tfb2
3DOM	;	2.6	;	Crystal Structure of the complex between Tfb5 and the C-terminal domain of Tfb2
3N9U	;	1.92	;	Crystal Structure of the Complex between the 25 kDa Subunit and the 59 kDa Subunit (RRM domain) of Human Cleavage Factor Im
2QO0	;	1.85	;	Crystal structure of the complex between the A246F mutant of mycobacterium beta-ketoacyl-acyl carrier protein synthase III (FABH) and 11-(decyldithiocarbonyloxy)-undecanoic acid
2QNY	;	2.15	;	Crystal structure of the complex between the A246F mutant of mycobacterium beta-ketoacyl-acyl carrier protein synthase III (FABH) and SS-(2-hydroxyethyl) O-decyl ester carbono(dithioperoxoic) acid
3QHE	;	2.4	;	Crystal structure of the complex between the armadillo repeat domain of adenomatous polyposis coli and the tyrosine-rich domain of Sam68
6L4P	;	1.703	;	Crystal structure of the complex between the axonemal outer-arm dynein light chain-1 and microtubule binding domain of gamma heavy chain
3A8Y	;	2.3	;	Crystal structure of the complex between the BAG5 BD5 and Hsp70 NBD
7EFA	;	2.7	;	Crystal structure of the complex between the C-terminal domain of mouse MUTYH and human PCNA
2A1J	;	2.7	;	Crystal Structure of the Complex between the C-Terminal Domains of Human XPF and ERCC1
1IOD	;	2.3	;	CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE COAGULATION FACTOR X BINDING PROTEIN FROM SNAKE VENOM AND THE GLA DOMAIN OF FACTOR X
3SF4	;	2.6	;	Crystal structure of the complex between the conserved cell polarity proteins Inscuteable and LGN
5FT8	;	2.5	;	Crystal structure of the complex between the cysteine desulfurase CsdA and the sulfur-acceptor CsdE in the persulfurated state at 2.50 Angstroem resolution
2RF9	;	3.5	;	Crystal structure of the complex between the EGFR kinase domain and a Mig6 peptide
2RFD	;	3.6	;	Crystal structure of the complex between the EGFR kinase domain and a Mig6 peptide
2RFE	;	2.9	;	Crystal structure of the complex between the EGFR kinase domain and a Mig6 peptide
3SBW	;	2.28	;	Crystal structure of the complex between the extracellular domains of mouse PD-1 mutant and human PD-L1
3RNQ	;	1.6	;	Crystal structure of the complex between the extracellular domains of mouse PD-1 mutant and PD-L2
4FHR	;	1.931	;	Crystal structure of the complex between the flagellar motor proteins FliG and FliM.
1HE1	;	2.0	;	Crystal structure of the complex between the GAP domain of the Pseudomonas aeruginosa ExoS toxin and human Rac
1GZS	;	2.3	;	CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE GEF DOMAIN OF THE SALMONELLA TYPHIMURIUM SOPE TOXIN AND HUMAN Cdc42
4U5Y	;	1.926	;	Crystal Structure of the complex between the GNAT domain of S. lividans PAT and the acetyl-CoA synthetase C-terminal domain of S. enterica
1S1C	;	2.6	;	Crystal structure of the complex between the human RhoA and Rho-binding domain of human ROCKI
5JHG	;	2.5	;	Crystal structure of the complex between the human RhoA and the DH/PH domain of human ARHGEF11
6H0S	;	1.75	;	Crystal structure of the complex between the Lactococcus lactis FPG mutant G226P and a Fapy-dG containing DNA
6FL1	;	1.6	;	Crystal structure of the complex between the Lactococcus lactis FPG mutant T221P and a Fapy-dG containing DNA
1DTD	;	1.65	;	CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE LEECH CARBOXYPEPTIDASE INHIBITOR AND THE HUMAN CARBOXYPEPTIDASE A2 (LCI-CPA2)
2QNX	;	2.7	;	Crystal structure of the complex between the mycobacterium beta-ketoacyl-acyl carrier protein synthase III (FABH) and 11-[(decyloxycarbonyl)dithio]-undecanoic acid
2QNZ	;	2.3	;	Crystal structure of the complex between the mycobacterium beta-ketoacyl-acyl carrier protein synthase III (FABH) and SS-(2-hydroxyethyl)-O-decyl ester carbono(dithioperoxoic) acid
4XA9	;	2.0	;	Crystal structure of the complex between the N-terminal domain of RavJ and LegL1 from Legionella pneumophila str. Philadelphia
1F3V	;	2.0	;	Crystal structure of the complex between the N-terminal domain of TRADD and the TRAF domain of TRAF2
5L23	;	1.77	;	Crystal structure of the complex between the N-terminal SH3 domain of CrkII and a proline-rich ligand
1N83	;	1.63	;	Crystal Structure of the complex between the Orphan Nuclear Hormone Receptor ROR(alpha)-LBD and Cholesterol
1DVA	;	3.0	;	Crystal Structure of the Complex Between the Peptide Exosite Inhibitor E-76 and Coagulation Factor VIIA
1CZY	;	2.0	;	CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE TRAF DOMAIN OF HUMAN TRAF2 AND AN LMP1 BINDING PEPTIDE
6OX6	;	2.17	;	Crystal structure of the complex between the Type VI effector Tas1 and its immunity protein
5Y04	;	2.85	;	Crystal Structure of the complex between the vinculin D1 domain and alphaE-catenin
2A45	;	3.65	;	Crystal structure of the complex between thrombin and the central ""E"" region of fibrin
6LHR	;	2.62	;	Crystal structure of the complex between Vesicle Amine Transport-1 and NADP
3WTU	;	2.7	;	Crystal structure of the complex comprised of ETS1 (V170A), RUNX1, CBFBETA, and the tcralpha gene enhancer DNA
3WTY	;	2.7	;	Crystal structure of the complex comprised of ETS1(G333P), RUNX1, CBFBETA, and the tcralpha gene enhancer DNA
3WTW	;	2.9	;	Crystal structure of the complex comprised of ETS1(K167A), RUNX1, CBFBETA, and the tcralpha gene enhancer DNA
3WTV	;	2.7	;	Crystal structure of the complex comprised of ETS1(V170G), RUNX1, CBFBETA, and the tcralpha gene enhancer DNA
3WTX	;	2.8	;	Crystal structure of the complex comprised of ETS1(Y329A), RUNX1, CBFBETA, and the tcralpha gene enhancer DNA
3WTS	;	2.35	;	Crystal structure of the complex comprised of ETS1, RUNX1, CBFBETA, and the tcralpha gene enhancer DNA
3WTT	;	2.35	;	Crystal structure of the complex comprised of phosphorylated ETS1, RUNX1, CBFBETA, and the tcralpha gene enhancer DNA
8AMQ	;	1.6	;	Crystal structure of the complex CYP143-FdxE from M. tuberculosis
2HKF	;	2.01	;	Crystal structure of the Complex Fab M75- Peptide
6F2B	;	2.0	;	Crystal structure of the complex Fe(II)/alpha-ketoglutarate dependent dioxygenase KDO1 with Fe(II)/alpha-ketoglutarate
6F2A	;	2.0	;	Crystal structure of the complex Fe(II)/alpha-ketoglutarate dependent dioxygenase KDO1 with Fe(II)/Lysine
6EUR	;	2.3	;	Crystal structure of the complex Fe(II)/alpha-ketoglutarate dependent dioxygenase KDO5 with Fe(II)/alpha-ketoglutarate
6EXF	;	1.95	;	Crystal structure of the complex Fe(II)/alpha-ketoglutarate dependent dioxygenase KDO5 with Fe(II)/Lysine
6EXH	;	2.6	;	Crystal structure of the complex Fe(II)/alpha-ketoglutarate dependent dioxygenase KDO5 with Fe(II)/succinate/(4R)-4-hydroxy-L-lysine
2OLI	;	2.21	;	Crystal structure of the complex formed between a group II phospholipase A2 and an indole derivative at 2.2 A resolution
3G8F	;	1.25	;	Crystal structure of the complex formed between a group II phospholipase A2 and designed peptide inhibitor carbobenzoxy-dehydro-val-ala-arg-ser at 1.2 A resolution
3GCI	;	2.04	;	Crystal Structure of the Complex Formed Between a New Isoform of Phospholipase A2 with C-terminal Amyloid Beta Heptapeptide at 2 A Resolution
1TK2	;	1.54	;	Crystal Structure of the Complex formed between Alkaline Proteinase Savinase and Gramicidin S at 1.5A Resolution
1F2S	;	1.79	;	CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN BOVINE BETA-TRYPSIN AND MCTI-A, A TRYPSIN INHIBITOR OF SQUASH FAMILY AT 1.8 A RESOLUTION
2OTV	;	1.56	;	Crystal structure of the complex formed between bovine trypsin and nicotinamide at 1.56 A resolution
3CFL	;	2.25	;	Crystal structure of the complex formed between C-lobe of bovine lactoferrin and 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine at 2.25 A resolution
2DWI	;	2.2	;	Crystal structure of the complex formed between C-terminal half of bovine lactoferrin and cellobiose at 2.2 A resolution
2DXR	;	2.85	;	Crystal structure of the complex formed between C-terminal half of bovine lactoferrin and sorbitol at 2.85 A resolution
2DT3	;	2.28	;	Crystal structure of the complex formed between goat signalling protein and the hexasaccharide at 2.28 A resolution
2DT2	;	2.9	;	Crystal structure of the complex formed between goat signalling protein with pentasaccharide at 2.9A resolution
2B31	;	3.1	;	Crystal structure of the complex formed between goat signalling protein with pentasaccharide at 3.1 A resolution reveals large scale conformational changes in the residues of TIM barrel
1ZR8	;	2.03	;	Crystal Structure of the complex formed between group II phospholipase A2 and a plant alkaloid ajmaline at 2.0A resolution
1TJK	;	1.25	;	Crystal structure of the complex formed between group II phospholipase A2 with a designed pentapeptide, Phe- Leu- Ser- Thr- Lys at 1.2 A resolution
1SV9	;	2.71	;	Crystal structure of the complex formed between groupII phospholipase A2 and anti-inflammatory agent 2-[(2,6-Dichlorophenyl)amino] benzeneacetic acid at 2.7A resolution
2PMJ	;	2.4	;	Crystal structure of the complex formed between phospholipase A2 and 1, 2 benzopyrone at 2.4 A resolution
2PWS	;	2.21	;	Crystal structure of the complex formed between phospholipase A2 and 2-(4-isobutyl-phenyl)-propionic acid at 2.2 A resolution
3JQL	;	1.2	;	Crystal Structure of the Complex Formed Between Phospholipase A2 and a Hexapeptide Fragment of Amyloid Beta Peptide, Lys-Leu-Val-Phe-Phe-Ala at 1.2 A Resolution
2OTF	;	1.95	;	Crystal structure of the complex formed between phospholipase A2 and atenolol at 1.95 A resolution
2OUB	;	2.75	;	Crystal structure of the complex formed between phospholipase A2 and atenolol at 2.75 A resolution
2PB8	;	2.0	;	Crystal structure of the complex formed between phospholipase A2 and peptide Ala-Val-Tyr-Ser at 2.0 A resolution
1Y38	;	2.44	;	Crystal structure of the complex formed between phospholipase A2 dimer and glycerophosphate at 2.4 A resolution
3JTI	;	1.8	;	Crystal structure of the complex formed between Phospholipase A2 with beta-amyloid fragment, Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met at 1.8 A resolution
2DP4	;	2.9	;	Crystal structure of the complex formed between proteinase K and a human lactoferrin fragment at 2.9 A resolution
2DUJ	;	1.67	;	Crystal structure of the complex formed between proteinase K and a synthetic peptide Leu-Leu-Phe-Asn-Asp at 1.67 A resolution
1Q7A	;	1.6	;	Crystal structure of the complex formed between russell's viper phospholipase A2 and an antiinflammatory agent oxyphenbutazone at 1.6A resolution
1TG1	;	1.25	;	Crystal Structure of the complex formed between russells viper phospholipase A2 and a designed peptide inhibitor PHQ-Leu-Val-Arg-Tyr at 1.2A resolution
1ZBW	;	2.8	;	Crystal structure of the complex formed between signalling protein from goat mammary gland (SPG-40) and a tripeptide Trp-Pro-Trp at 2.8A resolution
1FPR	;	2.5	;	CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN THE CATALYTIC DOMAIN OF SHP-1 AND AN IN VITRO PEPTIDE SUBSTRATE PY469 DERIVED FROM SHPS-1.
2AYW	;	0.97	;	Crystal Structure of the complex formed between trypsin and a designed synthetic highly potent inhibitor in the presence of benzamidine at 0.97 A resolution
3U6Z	;	1.7	;	Crystal structure of the complex formed between type 1 ribosome inactivating protein and adenine at 1.7A resolution
4O4Q	;	1.81	;	Crystal structure of the complex formed between type 1 ribosome inactivating protein and uridine diphosphate at 1.81 A resolution
3N3X	;	1.7	;	Crystal Structure of the complex formed between type I ribosome inactivating protein and hexapeptide Ser-Asp-Asp-Asp-Met-Gly at 1.7 A resolution
3NJS	;	2.1	;	Crystal structure of the complex formed between typeI ribosome inactivating protein and lactose at 2.1A resolution
1ZM6	;	2.6	;	Crystal structure of the complex formed beween a group I phospholipase A2 and designed penta peptide Leu-Ala-Ile-Tyr-Ser at 2.6A resolution
4LUP	;	1.2	;	Crystal structure of the complex formed by region of E. coli sigmaE bound to its -10 element non template strand
7ESY	;	2.297	;	Crystal structure of the complex formed by Wolbachia cytoplasmic incompatibility factors CidA and CidBND1-ND2 from wPip
7FIV	;	2.59	;	Crystal structure of the complex formed by Wolbachia cytoplasmic incompatibility factors CidA and CidBND1-ND2 from wPip(Tunis)
7FIW	;	2.16	;	Crystal structure of the complex formed by Wolbachia cytoplasmic incompatibility factors CidAwMel(ST) and CidBND1-ND2 from wPip(Pel)
7ET0	;	2.2	;	Crystal structure of the complex formed by Wolbachia cytoplasmic incompatibility factors CinA and CinB from wPip
7ESZ	;	2.476	;	Crystal structure of the complex formed by Wolbachia cytoplasmic incompatibility factors CinA and CinB with Mn2+ from wPip
5H8X	;	1.3	;	Crystal structure of the complex MMP-8/BF471 (catechol inhibitor)
5XWD	;	2.894	;	Crystal structure of the complex of 059-152-Fv and EGFR-ECD
5SY8	;	1.62	;	Crystal structure of the complex of 10E8 Fab light chain mutant1 and T117v2 HIV-1 MPER scaffold
5T5B	;	2.07	;	CRYSTAL STRUCTURE OF THE COMPLEX OF 10E8 FAB LIGHT CHAIN MUTANT5 AND T117V2 HIV-1 MPER SCAFFOLD
1D7R	;	2.0	;	CRYSTAL STRUCTURE OF THE COMPLEX OF 2,2-DIALKYLGLYCINE DECARBOXYLASE WITH 5PA
1D7S	;	2.05	;	CRYSTAL STRUCTURE OF THE COMPLEX OF 2,2-DIALKYLGLYCINE DECARBOXYLASE WITH DCS
1D7U	;	1.95	;	Crystal structure of the complex of 2,2-dialkylglycine decarboxylase with LCS
1D7V	;	2.8	;	CRYSTAL STRUCTURE OF THE COMPLEX OF 2,2-DIALKYLGLYCINE DECARBOXYLASE WITH NMA
1A05	;	2.0	;	CRYSTAL STRUCTURE OF THE COMPLEX OF 3-ISOPROPYLMALATE DEHYDROGENASE FROM THIOBACILLUS FERROOXIDANS WITH 3-ISOPROPYLMALATE
4N7H	;	1.698	;	Crystal Structure of the Complex of 3rd WW domain of Human Nedd4 and 1st PPXY Motif of ARRDC3
1KNO	;	3.2	;	CRYSTAL STRUCTURE OF THE COMPLEX OF A CATALYTIC ANTIBODY FAB WITH A TRANSITION STATE ANALOG: STRUCTURAL SIMILARITIES IN ESTERASE-LIKE ABZYMES
6GND	;	2.889	;	Crystal structure of the complex of a Ferredoxin-Flavin Thioredoxin Reductase and a Thioredoxin from Clostridium acetobutylicum at 2.9 A resolution
1ZYX	;	1.95	;	Crystal structure of the complex of a group IIA phospholipase A2 with a synthetic anti-inflammatory agent licofelone at 1.9A resolution
4FXM	;	1.651	;	Crystal structure of the complex of a human telomeric repeat G-quadruplex and N-methyl mesoporphyrin IX (P21212)
4G0F	;	2.15	;	Crystal structure of the complex of a human telomeric repeat G-quadruplex and N-methyl mesoporphyrin IX (P6)
4J9W	;	1.6	;	Crystal structure of the complex of a hydroxyproline epimerase (TARGET EFI-506499, PSEUDOMONAS FLUORESCENS PF-5) with the inhibitor pyrrole-2-carboxylate
4J9X	;	1.7	;	Crystal structure of the complex of a hydroxyproline epimerase (TARGET EFI-506499, PSEUDOMONAS FLUORESCENS PF-5) with trans-4-hydroxy-l-proline
3PMZ	;	2.44	;	Crystal Structure of the Complex of Acetylcholine Binding Protein and d-tubocurarine
1LOT	;	2.5	;	CRYSTAL STRUCTURE OF THE COMPLEX OF ACTIN WITH VITAMIN D-BINDING PROTEIN
1CQI	;	3.3	;	Crystal Structure of the Complex of ADP and MG2+ with Dephosphorylated E. Coli Succinyl-CoA Synthetase
5XC1	;	2.26	;	Crystal structure of the complex of an aromatic mutant (W6A) of an alkali thermostable GH10 Xylanase from Bacillus sp. NG-27 with S-1,2-Propanediol
2NR6	;	2.81	;	Crystal structure of the complex of antibody and the allergen Bla g 2
1PAU	;	2.5	;	Crystal structure of the complex of apopain with the tetrapeptide aldehyde inhibitor AC-DEVD-CHO
1CP3	;	2.3	;	CRYSTAL STRUCTURE OF THE COMPLEX OF APOPAIN WITH THE TETRAPEPTIDE INHIBITOR ACE-DVAD-FMC
5YV5	;	2.1	;	Crystal structure of the complex of archaeal ribosomal stalk protein aP1 and archaeal ribosome recycling factor aABCE1.
5YT0	;	1.89	;	Crystal structure of the complex of archaeal ribosomal stalk protein aP1 and archaeal translation initiation factor aIF5B
1CX9	;	2.3	;	CRYSTAL STRUCTURE OF THE COMPLEX OF BACTERIAL TRYPTOPHAN SYNTHASE WITH THE TRANSITION STATE ANALOGUE INHIBITOR 4-(2-AMINOPHENYLTHIO)-BUTYLPHOSPHONIC ACID
1C9D	;	2.3	;	CRYSTAL STRUCTURE OF THE COMPLEX OF BACTERIAL TRYPTOPHAN SYNTHASE WITH THE TRANSITION STATE ANALOGUE INHIBITOR 4-(2-HYDROXY-4-FLUOROPHENYLTHIO)-BUTYLPHOSPHONIC ACID
1CW2	;	2.0	;	CRYSTAL STRUCTURE OF THE COMPLEX OF BACTERIAL TRYPTOPHAN SYNTHASE WITH THE TRANSITION STATE ANALOGUE INHIBITOR 4-(2-HYDROXYPHENYLSULFINYL)-BUTYLPHOSPHONIC ACID
1C29	;	2.3	;	CRYSTAL STRUCTURE OF THE COMPLEX OF BACTERIAL TRYPTOPHAN SYNTHASE WITH THE TRANSITION STATE ANALOGUE INHIBITOR 4-(2-HYDROXYPHENYLTHIO)-1-BUTENYLPHOSPHONIC ACID
1C8V	;	2.2	;	CRYSTAL STRUCTURE OF THE COMPLEX OF BACTERIAL TRYPTOPHAN SYNTHASE WITH THE TRANSITION STATE ANALOGUE INHIBITOR 4-(2-HYDROXYPHENYLTHIO)-BUTYLPHOSPHONIC ACID
3BK3	;	2.7	;	Crystal structure of the complex of BMP-2 and the first Von Willebrand domain type C of Crossveinless-2
2QJE	;	2.3	;	Crystal structure of the complex of Bovine C-lobe with Amygdalin at 2.3A resolution
2R71	;	2.07	;	Crystal structure of the complex of bovine C-lobe with inositol at 2.1A resolution
2FA7	;	2.38	;	Crystal structure of the complex of bovine lactoferrin C-lobe with a pentasaccharide at 2.38 A resolution
2PX1	;	2.5	;	crystal structure of the complex of bovine lactoferrin C-lobe with Ribose at 2.5 A resolution
3R5O	;	2.6	;	Crystal structure of the complex of bovine lactoperoxidase with 4-allyl-2-methoxyphenol at 2.6 A resolution
2QQT	;	2.5	;	Crystal structure of the complex of bovine lactoperoxidase with acetyl salicylic acid at 2.5 A resolution
3TGY	;	2.35	;	Crystal structure of the complex of Bovine Lactoperoxidase with Ascorbic acid at 2.35 A resolution
3V6Q	;	2.0	;	Crystal structure of the complex of bovine lactoperoxidase with Carbon monoxide at 2.0 A resolution
5GH0	;	2.3	;	Crystal structure of the complex of bovine lactoperoxidase with mercaptoimidazole at 2.3 A resolution
5ZGS	;	2.2	;	Crystal structure of the complex of bovine lactoperoxidase with multiple SCN and OSCN ions in the distal heme cavity
6L9T	;	1.89	;	Crystal structure of the complex of bovine lactoperoxidase with OSCN at 1.89 A resolution
3UBA	;	2.65	;	Crystal structure of the complex of bovine lactoperoxidase with p-hydroxycinnamic acid at 2.6 A resolution
2QPK	;	2.34	;	Crystal structure of the complex of bovine lactoperoxidase with salicylhydroxamic acid at 2.34 A resolution
2Z5Z	;	3.5	;	Crystal structure of the complex of buffalo Lactoperoxidase with fluoride ion at 3.5A resolution
3FNL	;	2.48	;	Crystal Structure of the Complex of Buffalo Lactoperoxidase with Salicylhydroxamic Acid at 2.48 A Resolution
2QF8	;	2.8	;	Crystal structure of the complex of Buffalo Secretory Glycoprotein with tetrasaccharide at 2.8A resolution
4MPK	;	2.65	;	Crystal structure of the complex of buffalo signaling protein SPB-40 with N-acetylglucosamine at 2.65 A resolution
4MTV	;	2.8	;	Crystal structure of the complex of Buffalo Signalling Glycoprotein with pentasaccharide at 2.8A resolution
4Q7N	;	1.79	;	Crystal structure of the complex of Buffalo Signalling protein SPB-40 with 4-N-trimethylaminobutyraldehyde at 1.79 Angstrom Resolution
3KJ7	;	1.91	;	Crystal Structure of the Complex of C-lobe of Bovine Lactoferrin with Dextrin at 1.9 A Resolution
2B65	;	1.5	;	Crystal structure of the complex of C-lobe of bovine lactoferrin with maltose at 1.5A resolution
2Q8J	;	2.71	;	Crystal Structure of the complex of C-lobe of bovine lactoferrin with Mannitol and Mannose at 2.7 A resolution
3CRB	;	2.6	;	Crystal structure of the complex of C-lobe of lactoferrin with 2-chromenone at 2.6 A resolution
3O97	;	2.68	;	Crystal Structure of the complex of C-lobe of lactoferrin with indole acetic acid at 2.68 A Resolution
3MJN	;	2.38	;	Crystal Structure of the complex of C-lobe of lactoferrin with isopropylamino-3-(1-naphthyloxy)propan-2-ol at 2.38 A Resolution
3E9X	;	2.7	;	Crystal Structure of the Complex of C-lobe of Lactoferrin with Nimesulide at 2.7 A Resolution
3CI8	;	2.4	;	Crystal structure of the complex of C-lobe of lactoferrin with vitamin B3 (niacin) at 2.4 A resolution
2E1S	;	2.7	;	Crystal structure of the complex of C-terminal half of bovine lactoferrin and arabinose at 2.7 A resolution
2DOJ	;	2.4	;	Crystal structure of the complex of C-terminal lobe of bovine lactoferrin with adenosine at 2.4 A resolution
2NUV	;	2.25	;	Crystal structure of the complex of C-terminal lobe of bovine lactoferrin with atenolol at 2.25 A resolution
2ZMB	;	2.9	;	Crystal structure of the complex of C-terminal lobe of bovine lactoferrin with parecoxib at 2.9 A resolution
5E0A	;	2.6	;	Crystal Structure of the complex of Camel Peptidoglycan Recognition Protein (CPGRP-S) and N-Acetylglucosamine at 2.6 A
2R2K	;	3.25	;	Crystal structure of the complex of camel peptidoglycan recognition protein with disaccharide at 3.2A resolution
3T39	;	2.7	;	Crystal structure of the complex of camel peptidoglycan recognition protein(CPGRP-S) with a mycobacterium metabolite shikimate at 2.7 A resolution
3QF1	;	2.6	;	Crystal structure of the complex of caprine lactoperoxidase with diethylenediamine at 2.6A resolution
6CPA	;	2.0	;	CRYSTAL STRUCTURE OF THE COMPLEX OF CARBOXYPEPTIDASE A WITH A STRONGLY BOUND PHOSPHONATE IN A NEW CRYSTALLINE FORM: COMPARISON WITH STRUCTURES OF OTHER COMPLEXES
1RHU	;	2.51	;	CRYSTAL STRUCTURE OF THE COMPLEX OF CASPASE-3 WITH A 5,6,7 TRICYCLIC PEPTIDOMIMETIC INHIBITOR
1RHQ	;	3.0	;	CRYSTAL STRUCTURE OF THE COMPLEX OF CASPASE-3 WITH A BROMOMETHOXYPHENYL INHIBITOR
1RHR	;	3.0	;	CRYSTAL STRUCTURE OF THE COMPLEX OF CASPASE-3 WITH A CINNAMIC ACID METHYL ESTER INHIBITOR
1RHM	;	2.5	;	CRYSTAL STRUCTURE OF THE COMPLEX OF CASPASE-3 WITH A NICOTINIC ACID ALDEHYDE INHIBITOR
1RHK	;	2.5	;	Crystal structure of the complex of caspase-3 with a phenyl-propyl-ketone inhibitor
1RHJ	;	2.2	;	CRYSTAL STRUCTURE OF THE COMPLEX OF CASPASE-3 WITH A PRYAZINONE INHIBITOR
1QTN	;	1.2	;	CRYSTAL STRUCTURE OF THE COMPLEX OF CASPASE-8 WITH THE TETRAPEPTIDE INHIBITOR ACE-IETD-ALDEHYDE
1QDU	;	2.8	;	CRYSTAL STRUCTURE OF THE COMPLEX OF CASPASE-8 WITH THE TRIPEPTIDE KETONE INHIBITOR ZEVD-DCBMK
7SEG	;	2.156	;	Crystal structure of the complex of CD16A bound by an anti-CD16A Fab
1JW6	;	1.93	;	Crystal Structure of the Complex of Concanavalin A and Hexapeptide
1HQW	;	2.4	;	CRYSTAL STRUCTURE OF THE COMPLEX OF CONCANAVALIN A WITH A TRIPEPTIDE YPY
4FNN	;	2.24	;	Crystal structure of the complex of CPGRP-S with stearic acid at 2.2 A RESOLUTION
1K9G	;	1.4	;	Crystal Structure of the Complex of Cryptolepine-d(CCTAGG)2
3T1U	;	2.0	;	Crystal Structure of the complex of Cyclophilin-A enzyme from Azotobacter vinelandii with sucAFPFpNA peptide
3BR2	;	2.9	;	Crystal Structure of the Complex of Dequalinium Bound to QacR(E120Q), a Mutant of a Multidrug Binding Transcriptional Repressor
3BR1	;	3.31	;	Crystal Structure of the Complex of Dequalinium Bound to QacR(E90Q), a Mutant of a Multidrug Binding Transcriptional Repressor
3TAK	;	1.42	;	Crystal structure of the complex of DHDPS from Acinetobacter baumannii with Pyruvate at 1.4 A resolution
3PUL	;	2.3	;	Crystal structure of the complex of Dhydrodipicolinate synthase from Acinetobacter baumannii with lysine at 2.3A resolution
3PUE	;	2.6	;	Crystal structure of the complex of Dhydrodipicolinate synthase from Acinetobacter baumannii with lysine at 2.6A resolution
5YE4	;	1.799	;	Crystal structure of the complex of di-acetylated histone H4 and 1A9D7 Fab fragment
5YE3	;	1.7	;	Crystal structure of the complex of di-acetylated histone H4 and 2A7D9 Fab fragment
3TDF	;	1.99	;	Crystal structure of the complex of Dihydrodipicolinate synthase from Acinetobacter baumannii with 2-Ketobutanoic acid at 1.99 A resolution
3TCE	;	2.6	;	Crystal structure of the complex of Dihydrodipicolinate synthase from Acinetobacter baumannii with 5-Hydroxylysine at 2.6 A resolution
3U8G	;	1.8	;	Crystal structure of the complex of Dihydrodipicolinate synthase from Acinetobacter baumannii with Oxalic acid at 1.80 A resolution
3NIU	;	2.94	;	Crystal structure of the complex of dimeric goat lactoperoxidase with diethylene glycol at 2.9 A resolution
4L5K	;	2.71	;	Crystal structure of the complex of DNA hexamer d(CGATCG) with Coptisine
1D8Y	;	2.08	;	CRYSTAL STRUCTURE OF THE COMPLEX OF DNA POLYMERASE I KLENOW FRAGMENT WITH DNA
1D9F	;	3.0	;	CRYSTAL STRUCTURE OF THE COMPLEX OF DNA POLYMERASE I KLENOW FRAGMENT WITH DNA TETRAMER CARRYING 2'-O-(3-AMINOPROPYL)-RNA MODIFICATION 5'-D(TT)-AP(U)-D(T)-3'
7NXV	;	2.55	;	Crystal structure of the complex of DNase I/G-actin/PPP1R15A_582-621
5EO9	;	2.2988	;	Crystal Structure of the complex of Dpr6 Domain 1 bound to DIP-alpha Domain 1+2
1EOM	;	2.1	;	CRYSTAL STRUCTURE OF THE COMPLEX OF ENDO-BETA-N-ACETYLGLUCOSAMINIDASE F3 WITH A BIANTENNARY COMPLEX OCTASACCHARIDE
1XEY	;	2.05	;	Crystal structure of the complex of Escherichia coli GADA with glutarate at 2.05 A resolution
3BR3	;	2.8	;	Crystal Structure of the Complex of Ethidium Bound to QacR(E90Q), a Mutant of a Multidrug Binding Transcriptional Repressor
4L98	;	2.28	;	Crystal structure of the complex of F360L PPARgamma mutant with the ligand LT175
4GHW	;	2.6	;	Crystal structure of the complex of Fungal lipase from Thermomyces lanuginosa with decanoic acid at 2.6 A resolution
1M10	;	3.1	;	Crystal structure of the complex of Glycoprotein Ib alpha and the von Willebrand Factor A1 Domain
4MSF	;	1.98	;	Crystal structure of the complex of goat lactoperoxidase with 3-hydroxymethyl phenol at 1.98 Angstrom resolution
3SXV	;	2.1	;	Crystal structure of the complex of goat lactoperoxidase with amitrole at 2.1 A resolution
6LF7	;	1.794	;	Crystal structure of the complex of goat lactoperoxidase with hypothiocyanite and hydrogen peroxide at 1.79 A resolution.
3NAK	;	3.3	;	Crystal structure of the complex of goat lactoperoxidase with hypothiocyanite at 3.3 A resolution
2E9E	;	3.25	;	Crystal structure of the complex of goat lactoperoxidase with Nitrate at 3.25 A resolution
4OEK	;	2.47	;	Crystal Structure of the Complex of goat Lactoperoxidase with Phenylethylamine at 2.47 A Resolution
2EFB	;	2.94	;	Crystal structure of the complex of goat lactoperoxidase with phosphate at 2.94 A resolution
3R55	;	2.1	;	Crystal structure of the complex of goat lactoperoxidase with Pyrazinamide at 2.1 A resolution
3N8F	;	3.25	;	Crystal structure of the complex of goat lactoperoxidase with thiocyanate at 3.2 A resolution
2DT1	;	2.09	;	Crystal Structure Of The Complex Of Goat Signalling Protein With Tetrasaccharide At 2.09 A Resolution
2DT0	;	2.45	;	Crystal structure of the complex of goat signalling protein with the trimer of N-acetylglucosamine at 2.45A resolution
3OSH	;	1.5	;	Crystal Structure of The Complex of Group 1 Phospholipase A2 With Atropin At 1.5 A Resolution
3NJU	;	1.4	;	Crystal structure of the complex of group I phospholipase A2 with 4-Methoxy-benzoicacid at 1.4A resolution
4HMB	;	2.21	;	Crystal Structure of the complex of group II phospholipase A2 with a 3-{3-[(Dimethylamino)methyl]-1H-indol-7-yl}propan-1-ol at 2.21 A Resolution
2QU9	;	2.08	;	Crystal structure of the complex of group II phospholipase A2 with Eugenol
1TP2	;	2.4	;	Crystal structure of the complex of group II phospholipaseA2 dimer with a fatty acid tridecanoic acid at 2.4 A resolution
2QO8	;	1.4	;	Crystal structure of the complex of hcaii with an indane-sulfonamide inhibitor
2QOA	;	1.6	;	Crystal structure of the complex of hcaii with an indane-sulfonamide inhibitor
5TV3	;	2.9	;	Crystal structure of the complex of Helicobacter pylori alpha-carbonic anhydrase with (E)-5-(((4-(tert-butyl)phenyl)sulfonyl)imino)-4-methyl-4,5-dihydro-1,3,4-thiadiazole-2-sulfonamide
5TUO	;	2.5	;	Crystal structure of the complex of Helicobacter pylori alpha-carbonic anhydrase with 5-amino-1,3,4-thiadiazole-2-sulfonamide inhibitor.
4YGF	;	2.0	;	Crystal structure of the complex of Helicobacter pylori alpha-Carbonic Anhydrase with acetazolamide
5TT8	;	2.4	;	Crystal structure of the complex of Helicobacter pylori alpha-carbonic anhydrase with benzolamide
5TT3	;	2.2	;	Crystal structure of the complex of Helicobacter pylori alpha-carbonic anhydrase with ethoxzolamide
4YHA	;	2.2	;	Crystal structure of the complex of Helicobacter pylori alpha-Carbonic Anhydrase with methazolamide
1FQX	;	3.1	;	CRYSTAL STRUCTURE OF THE COMPLEX OF HIV-1 PROTEASE WITH A PEPTIDOMIMETIC INHIBITOR
1QRV	;	2.2	;	CRYSTAL STRUCTURE OF THE COMPLEX OF HMG-D AND DNA
7AMP	;	2.64	;	Crystal structure of the complex of HuJovi-1 Fab with the human A6 T-cell receptor TRBC1
7AMQ	;	2.353	;	Crystal structure of the complex of HuJovi-1 Fab with the human TRBC2
1IHS	;	2.0	;	CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN ALPHA-THROMBIN AND NON-HYDROLYZABLE BIFUNCTIONAL INHIBITORS, HIRUTONIN-2 AND HIRUTONIN-6
1IHT	;	2.1	;	CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN ALPHA-THROMBIN AND NON-HYDROLYZABLE BIFUNCTIONAL INHIBITORS, HIRUTONIN-2 AND HIRUTONIN-6
6I3F	;	2.55	;	Crystal structure of the complex of human angiotensinogen and renin at 2.55 Angstrom
5C50	;	1.63	;	Crystal structure of the complex of human Atg101-Atg13 HORMA domain
3H91	;	1.5	;	Crystal structure of the complex of human chromobox homolog 2 (CBX2) and H3K27 peptide
3TZD	;	1.81	;	Crystal structure of the complex of Human Chromobox Homolog 3 (CBX3)
3DM1	;	2.4	;	Crystal structure of the complex of human chromobox homolog 3 (CBX3) with peptide
3FDT	;	2.0	;	Crystal structure of the complex of human chromobox homolog 5 (CBX5) with H3K9(me)3 peptide
1IVO	;	3.3	;	Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains.
3DI3	;	2.9	;	Crystal structure of the complex of human interleukin-7 with glycosylated human interleukin-7 receptor alpha ectodomain
3DI2	;	2.7	;	Crystal structure of the complex of human interleukin-7 with unglycosylated human interleukin-7 receptor alpha ectodomain
2PMS	;	2.91	;	Crystal structure of the complex of human lactoferrin N-lobe and lactoferrin-binding domain of pneumococcal surface protein A
2NPT	;	1.75	;	Crystal Structure of the complex of human mitogen activated protein kinase kinase 5 phox domain (MAP2K5-phox) with human mitogen activated protein kinase kinase kinase 2 phox domain (MAP3K2-phox)
2O2V	;	1.83	;	Crystal Structure of the Complex of Human Mitogen Activated Protein Kinase Kinase 5 Phox Domain (MAP2K5-phox) with Human Mitogen Activated Protein Kinase Kinase Kinase 3 (MAP3K3B-phox)
2Z7F	;	1.7	;	Crystal structure of the complex of human neutrophil elastase with 1/2SLPI
1MA9	;	2.4	;	Crystal structure of the complex of human vitamin D binding protein and rabbit muscle actin
2EH8	;	2.6	;	Crystal structure of the complex of humanized KR127 fab and PRES1 peptide epitope
3EKA	;	3.1	;	Crystal structure of the complex of hyaluranidase trimer with ascorbic acid at 3.1 A resolution reveals the locations of three binding sites
1BMQ	;	2.5	;	CRYSTAL STRUCTURE OF THE COMPLEX OF INTERLEUKIN-1BETA CONVERTING ENZYME (ICE) WITH A PEPTIDE BASED INHIBITOR, (3S )-N-METHANESULFONYL-3-({1-[N-(2-NAPHTOYL)-L-VALYL]-L-PROLYL }AMINO)-4-OXOBUTANAMIDE
1PXD	;	1.8	;	Crystal structure of the complex of jacalin with meso-tetrasulphonatophenylporphyrin.
3MJ7	;	2.8	;	Crystal structure of the complex of JAML and Coxsackie and Adenovirus receptor, CAR
3CR9	;	3.49	;	Crystal structure of the complex of Lactoferrin with 6-(Hydroxymethyl)oxane-2,3,4,5-tetrol at 3.49 A resolution
4NJB	;	2.31	;	Crystal structure of the complex of lactoperoxidase from bovine with 3,3-oxydipyridine at 2.31 A resolution
3KRQ	;	2.25	;	Crystal structure of the complex of lactoperoxidase with a potent inhibitor amino-triazole at 2.2a resolution
4PNX	;	2.41	;	Crystal structure of the complex of lactoperoxidase with bromo methane at 2.41 angstrom resolution
8Y9X	;	2.0	;	Crystal structure of the complex of lactoperoxidase with four inorganic substrates, SCN, I, Br and Cl
7DLQ	;	1.773	;	CRYSTAL STRUCTURE OF THE COMPLEX OF LACTOPEROXIDASE WITH HYDROGEN PEROXIDE AT 1.77A RESOLUTION
7Y3U	;	2.5	;	Crystal structure of the complex of Lactoperoxidase with Nitric oxide at 2.50A resolution
3P71	;	2.7	;	Crystal structure of the complex of LCMT-1 and PP2A
7K9M	;	2.5	;	Crystal structure of the complex of M. tuberculosis PheRS with cognate precursor tRNA and 5'-O-(N-phenylalanyl)sulfamoyl-adenosine
7KA0	;	2.4	;	Crystal structure of the complex of M. tuberculosis PheRS with cognate precursor tRNA and phenylalanine
3BR0	;	2.42	;	Crystal Structure of the Complex of Malachite Green Bound to QacR(E120Q), a Mutant of a Multidrug Binding Transcriptional Repressor
3BQZ	;	2.17	;	Crystal Structure of the Complex of Malachite Green Bound to QacR(E90Q), a Mutant of a Multidrug Binding Transcriptional Repressor
4MI8	;	2.1	;	Crystal structure of the complex of murine gamma-herpesvirus 68 Bcl-2 homolog M11 and a Beclin 1 BH3 domain-derived peptide
3DVU	;	2.5	;	Crystal structure of the complex of murine gamma-herpesvirus 68 Bcl-2 homolog M11 and the Beclin 1 BH3 domain
1ZPK	;	1.65	;	Crystal structure of the complex of mutant HIV-1 protease (A71V, V82T, I84V) with a hydroxyethylamine peptidomimetic inhibitor BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2
1LZQ	;	2.2	;	Crystal structure of the complex of mutant HIV-1 protease (A71V, V82T, I84V) with an ethylenamine peptidomimetic inhibitor BOC-PHE-PSI[CH2CH2NH]-PHE-GLU-PHE-NH2
1Z8C	;	2.2	;	Crystal structure of the complex of mutant HIV-1 protease (l63P, A71V, V82T, I84V) with a hydroxyethylamine peptidomimetic inhibitor BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2
3NP1	;	2.3	;	CRYSTAL STRUCTURE OF THE COMPLEX OF NITROPHORIN 1 FROM RHODNIUS PROLIXUS WITH CYANIDE
1NP1	;	2.0	;	CRYSTAL STRUCTURE OF THE COMPLEX OF NITROPHORIN 1 FROM RHODNIUS PROLIXUS WITH HISTAMINE
2XKO	;	2.25	;	Crystal structure of the complex of NtcA with its transcriptional co- activator PipX
3KZ1	;	2.7	;	Crystal Structure of the Complex of PDZ-RhoGEF DH/PH domains with GTP-gamma-S Activated RhoA
1OBY	;	1.85	;	Crystal structure of the complex of PDZ2 of syntenin with a syndecan-4 peptide.
1OBX	;	1.35	;	Crystal structure of the complex of PDZ2 of syntenin with an interleukin 5 receptor alpha peptide.
3O4K	;	2.11	;	Crystal structure of the complex of peptidoglycan recognition protein (PGRP-S) and lipoteichoic acid at 2.1 A resolution
3QS0	;	2.5	;	Crystal structure of the complex of peptidoglycan recognition protein (PGRP-S) with a bound N-acetylglucosamine in the diffusion channel at 2.5 A resolution
3NNO	;	2.9	;	Crystal structure of the complex of peptidoglycan recognition protein (PGRP-S) with Alpha-Rhamnose at 2.9 A resolution
3QV4	;	2.7	;	Crystal structure of the complex of peptidoglycan recognition protein (PGRP-S) with dipeptide L-ALA D-GLU at 2.7 A resolution
3OGX	;	2.8	;	Crystal structure of the complex of Peptidoglycan Recognition protein (PGRP-s) with Heparin-Dissacharide at 2.8 A resolution
3COR	;	3.1	;	Crystal structure of the complex of peptidoglycan recognition protein (PGRP-S) with N-acetylgalactosamine at 3.1 A resolution
3NW3	;	2.5	;	Crystal structure of the complex of peptidoglycan recognition protein (PGRP-S) with the PGN Fragment at 2.5 A resolution
5E0B	;	2.6	;	Crystal structure of the complex of Peptidoglycan recognition protein PGRP-S with N-Acetyl Muramic acid at 2.6 A resolution
3CXA	;	3.4	;	Crystal structure of the complex of peptidoglycan recognition protein with alpha-D-glucopyranosyl alpha-D-glucopyranoside at 3.4 A resolution
3TRU	;	3.2	;	Crystal structure of the complex of peptidoglycan recognition protein with cellular metabolite chorismate at 3.2 A resolution
3CG9	;	2.9	;	Crystal structure of the complex of peptidoglycan recognition protein with methyloxane-2,3,4,5-tetrol at 2.9 A resolution
5DWF	;	1.83	;	Crystal structure of the complex of Peptidoglycan recognition protein, PGRP-S from camel with ethylene glycol at 1.83 A resolution
3T2V	;	2.51	;	Crystal structure of the complex of peptidoglycan recognition protein-short (CPGRP-S) with mycolic acid at 2.5 A resolution
4JX9	;	1.4	;	Crystal structure of the complex of peptidyl t-RNA hydrolase from Acinetobacter baumannii with uridine at 1.4A resolution
5Y9A	;	1.1	;	Crystal structure of the complex of peptidyl tRNA hydrolase with a phosphate ion at the substrate binding site and cytarabine at a new ligand binding site at 1.1 A resolution
4JWK	;	1.87	;	Crystal structure of the complex of peptidyl-tRNA hydrolase from Acinetobacter baumannii with cytidine at 1.87 A resolution
4QBK	;	1.77	;	Crystal structure of the complex of Peptidyl-tRNA hydrolase from Pseudomonas aeruginosa with amino acyl-tRNA analogue at 1.77 Angstrom resolution
4ERX	;	2.5	;	Crystal structure of the complex of peptidyl-tRNA hydrolase from Pseudomonas aeruginosa with diethylene glycol at 2.5 Angstrom resolution
4DJJ	;	2.94	;	Crystal structure of the complex of Peptidyl-tRNA hydrolase from Pseudomonas aeruginosa with Pimelic acid at 2.9 Angstrom resolution
6IX6	;	1.43	;	Crystal structure of the complex of peptidyl-tRNA hydrolase with N-propanol at 1.43 A resolution
2XDE	;	1.4	;	Crystal structure of the complex of PF-3450074 with an engineered HIV capsid N terminal domain
3UIL	;	2.2	;	Crystal Structure of the complex of PGRP-S with lauric acid at 2.2 A resolution
6JOG	;	2.3	;	Crystal structure of the complex of phospho pantetheine adenylyl transferase from Acinetobacter baumannii with two ascorbic acid (Vitamin-C) molecules.
1PFK	;	2.4	;	CRYSTAL STRUCTURE OF THE COMPLEX OF PHOSPHOFRUCTOKINASE FROM ESCHERICHIA COLI WITH ITS REACTION PRODUCTS
2ARM	;	1.23	;	Crystal Structure of the Complex of Phospholipase A2 with a natural compound atropine at 1.2 A resolution
2ZBH	;	2.6	;	Crystal structure of the complex of phospholipase A2 with Bavachalcone from Aerva lanata at 2.6 A resolution
4QF7	;	1.48	;	Crystal Structure of the Complex of Phospholipase A2 with Corticosterone at 1.48 A Resolution
4QGD	;	1.8	;	Crystal Structure of the Complex of Phospholipase A2 with Gramine derivative at 1.80 A Resolution
2OYF	;	1.2	;	Crystal Structure of the complex of phospholipase A2 with indole acetic acid at 1.2 A resolution
4QEM	;	1.2	;	Crystal structure of the complex of Phospholipase A2 With P-Coumaric Acid At 1.2 A Resolution
4QER	;	1.2	;	Crystal Structure of the Complex of Phospholipase A2 with Resveratrol at 1.20 A Resolution
4QF8	;	1.65	;	Crystal Structure of the Complex of Phospholipase A2 with Spermidine at 1.65 A Resolution
6KKW	;	3.202	;	Crystal structure of the complex of phosphopantetheine adenylyl transferase from Acinetobacter baumannii with Dephospho Coenzyme at 3.2 A resolution.
5H7X	;	1.76	;	Crystal structure of the complex of Phosphopantetheine adenylyltransferase from Acinetobacter baumannii with 2-hydroxy-1,2,3-propane tricarboxylate at 1.76 A resolution
5H16	;	2.3	;	Crystal structure of the complex of Phosphopantetheine adenylyltransferase from Acinetobacter baumannii with citrate at 2.3 A resolution.
5YH7	;	2.03	;	Crystal structure of the complex of Phosphopantetheine adenylyltransferase from Acinetobacter baumannii with Coenzyme A at 2.0 A resolution
5ZZC	;	1.96	;	Crystal structure of the complex of Phosphopantetheine adenylyltransferase from Acinetobacter baumannii with Dephospho Coenzyme A at 1.94A resolution
6A7D	;	2.74	;	Crystal structure of the complex of Phosphopantetheine adenylyltransferase from Acinetobacter baumannii with Dephospho Coenzyme A at 2.74 A resolution
6A75	;	2.75	;	Crystal structure of the complex of Phosphopantetheine adenylyltransferase from Acinetobacter baumannii with Dephospho Coenzyme A at 2.75 A resolution
6A6D	;	2.9	;	Crystal structure of the complex of Phosphopantetheine adenylyltransferase from Acinetobacter baumannii with Dephospho Coenzyme A at 2.90A resolution
8I8P	;	2.19	;	Crystal structure of the complex of phosphopantetheine adenylyltransferase from Acinetobacter baumannii with Dephosphocoenzyme-A at 2.19 A resolution.
6J3M	;	2.3	;	Crystal structure of the complex of Phosphopantetheine adenylyltransferase from Acinetobacter baumannii with Pyrophosphate at 2.30A resolution
6JNH	;	2.0	;	Crystal structure of the complex of Phosphopantetheine adenylyltransferasefrom Acinetobacter baumannii with Ascorbic acid (Vitamin-C) at 2.0A resolution
1P8V	;	2.6	;	CRYSTAL STRUCTURE OF THE COMPLEX OF PLATELET RECEPTOR GPIB-ALPHA AND ALPHA-THROMBIN AT 2.6A
1OOK	;	2.3	;	Crystal Structure of the Complex of Platelet Receptor GPIb-alpha and Human alpha-Thrombin
4DOQ	;	2.0	;	Crystal structure of the complex of Porcine Pancreatic Trypsin with 1/2SLPI
7WP3	;	2.954	;	Crystal structure of the complex of proliferating cell nuclear antigen (PCNA) from Leishmania donovani with 1,5-Bis (4-amidinophenoxy) pentane (PNT) at 2.95 A resolution
6K2M	;	3.19	;	Crystal structure of the complex of Proliferating Cell Nuclear Antigen from Leishmania donovani with arginine at 3.19 A resolution.
1P7W	;	1.02	;	Crystal structure of the complex of Proteinase K with a designed heptapeptide inhibitor Pro-Ala-Pro-Phe-Ala-Ser-Ala at atomic resolution
2DQK	;	1.93	;	Crystal structure of the complex of proteinase K with a specific lactoferrin peptide Val-Leu-Leu-His at 1.93 A resolution
2PWA	;	0.83	;	Crystal Structure of the complex of Proteinase K with Alanine Boronic acid at 0.83A resolution
3OSZ	;	2.26	;	Crystal Structure of the complex of proteinase K with an antimicrobial nonapeptide, at 2.26 A resolution
2PYZ	;	1.79	;	Crystal structure of the complex of proteinase K with auramine at 1.8A resolution
2PWB	;	1.9	;	Crystal structure of the complex of proteinase K with coumarin at 1.9 A resolution
2H4I	;	2.55	;	Crystal structure of the complex of proteolytically produced C-terminal half of bovine lactoferrin with lactose at 2.55 A resolution
1FRT	;	4.5	;	CRYSTAL STRUCTURE OF THE COMPLEX OF RAT NEONATAL FC RECEPTOR WITH FC
1RL8	;	2.0	;	Crystal structure of the complex of resistant strain of hiv-1 protease(v82a mutant) with ritonavir
3BR6	;	3.2	;	Crystal Structure of the Complex of Rhodamine 6G Bound to QacR(E120Q), a Mutant of a Multidrug Binding Transcriptional Repressor
3BR5	;	2.9	;	Crystal Structure of the Complex of Rhodamine 6G Bound to QacR(E90Q), a Mutant of a Multidrug Binding Transcriptional Repressor
4M5A	;	1.7	;	Crystal structure of the complex of Ribosome inactivating protein from Momordica balsamina inhibited by asymmetric dimethyl arginine at 1.70 A resolution
4FZ9	;	1.7	;	Crystal structure of the complex of Ribosome inactivating protein from Momordica Balsamina with disaccharide, N-Acetylglucosamine (beta-1, 4) Mannose at 1.7 A resolution
4FXA	;	1.7	;	Crystal structure of the complex of Ribosome inactivating protein from Momordica balsamina with N-acetyl arginine at 1.7 Angstrom resolution
4H0Z	;	2.0	;	Crystal structure of the complex of Ribosome inactivating protein from Momordica balsamina with N-acetyl muramic acid at 2.0 Angstrom resolution
4XY7	;	2.5	;	Crystal structure of the complex of ribosome inactivating protein from Momordica balsamina with N-acetylglucosamine at 2.5 A resolution
4LWX	;	1.78	;	Crystal structure of the complex of Ribosome inactivating protein from Momordica Balsamina with peptidoglycan fragment at 1.78 A resolution
4KPV	;	2.57	;	Crystal structure of the complex of ribosome inactivating protein from Momordica balsamina with Pyrimidine-2,4(1H,3H)-dione at 2.57 A resolution
5Y48	;	1.7	;	Crystal structure of the complex of Ribosome inactivating protein from Momordica balsamina with Pyrimidine-2,4-dione at 1.70 Angstrom resolution
5WV1	;	1.9	;	Crystal structure of the complex of Ribosome inactivating protein from Momordica balsamina with ribose sugar at 1.90 A resolution.
5GZ7	;	1.95	;	Crystal Structure of the complex of Ribosome Inactivating Protein with 1,2-ethanediol at 1.95 Angstrom resolution
3QJI	;	1.75	;	Crystal structure of the complex of ribosome inactivating protein with 7-methylguanosine triphosphate at 1.75A resolution
4IJ8	;	2.0	;	Crystal structure of the complex of SETD8 with SAM
2G41	;	3.0	;	Crystal structure of the complex of sheep signalling glycoprotein with chitin trimer at 3.0A resolution
4ML4	;	2.5	;	Crystal structure of the complex of signaling glycoprotein from buffalo (SPB-40) with tetrahydropyran at 2.5 A resolution
4NSB	;	3.05	;	Crystal structure of the complex of signaling glycoprotein, SPB-40 and N-acetyl salicylic acid at 3.05 A resolution
1ZL1	;	3.5	;	Crystal structure of the complex of signalling protein from sheep (SPS-40) with a designed peptide Trp-His-Trp reveals significance of Asn79 and Trp191 in the complex formation
1TM1	;	1.7	;	CRYSTAL STRUCTURE OF THE COMPLEX OF SUBTILISIN BPN' WITH CHYMOTRYPSIN INHIBITOR 2
1LW6	;	1.5	;	Crystal Structure of the Complex of Subtilisin BPN' with Chymotrypsin Inhibitor 2 at 1.5 Angstrom Resolution
1Y34	;	1.55	;	Crystal structure of the complex of subtilisin BPN' with chymotrypsin inhibitor 2 E60A mutant
1Y3B	;	1.8	;	Crystal structure of the complex of subtilisin BPN' with chymotrypsin inhibitor 2 E60S mutant
1Y3F	;	1.72	;	Crystal structure of the complex of subtilisin BPN' with chymotrypsin inhibitor 2 F69A mutant
1TM5	;	1.45	;	crystal structure of the complex of subtilisin BPN' with chymotrypsin inhibitor 2 M59A mutant
1TMG	;	1.67	;	crystal structure of the complex of subtilisin BPN' with chymotrypsin inhibitor 2 M59F mutant
1TM3	;	1.57	;	crystal structure of the complex of subtilisin BPN' with chymotrypsin inhibitor 2 M59k mutant
1TO2	;	1.3	;	crystal structure of the complex of subtilisin BPN' with chymotrypsin inhibitor 2 M59K, in pH 9 cryosoak
1Y4A	;	1.6	;	Crystal structure of the complex of subtilisin BPN' with chymotrypsin inhibitor 2 M59R/E60S mutant
1Y4D	;	2.0	;	Crystal structure of the complex of subtilisin BPN' with chymotrypsin inhibitor 2 M59R/E60S mutant
1TM7	;	1.59	;	crystal structure of the complex of subtilisin BPN' with chymotrypsin inhibitor 2 M59Y mutant
1Y3C	;	1.69	;	Crystal structure of the complex of subtilisin BPN' with chymotrypsin inhibitor 2 R62A mutant
1Y48	;	1.84	;	Crystal structure of the complex of subtilisin BPN' with chymotrypsin inhibitor 2 R65A mutant
1Y3D	;	1.8	;	Crystal structure of the complex of subtilisin BPN' with chymotrypsin inhibitor 2 R67A mutant
1Y1K	;	1.56	;	Crystal structure of the complex of subtilisin BPN' with chymotrypsin inhibitor 2 T58A mutant
1Y33	;	1.8	;	Crystal structure of the complex of subtilisin BPN' with chymotrypsin inhibitor 2 T58P mutant
1TO1	;	1.68	;	crystal structure of the complex of subtilisin BPN' with chymotrypsin inhibitor 2 Y61A mutant
1TM4	;	1.7	;	crystal structure of the complex of subtilsin BPN'with chymotrypsin inhibitor 2 M59G mutant
2D69	;	1.9	;	Crystal structure of the complex of sulfate ion and octameric ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco) from Pyrococcus horikoshii OT3 (form-2 crystal)
4OFY	;	3.3	;	Crystal Structure of the Complex of SYG-1 D1-D2 and SYG-2 D1-D4
5M4Z	;	1.179	;	Crystal structure of the complex of T.spiralis thymidylate synthase with N(4)-hydroxy-2'-deoxycytidine-5'-monophosphate, crystallized in the presence of N(5,10)-methylenetetrahydrofolate
5NW9	;	2.04	;	Crystal structure of the complex of Tdp1 with duplex DNA
5NWA	;	3.2	;	Crystal structure of the complex of Tdp1 with duplex DNA
4FL6	;	2.55	;	Crystal structure of the complex of the 3-MBT repeat domain of L3MBTL3 and UNC1215
1ABO	;	2.0	;	CRYSTAL STRUCTURE OF THE COMPLEX OF THE ABL TYROSINE KINASE SH3 DOMAIN WITH 3BP-1 SYNTHETIC PEPTIDE
2I6J	;	1.66	;	Crystal structure of the complex of the archaeal sulfolobus PTP-fold phosphatase with phosphate ion
2DXP	;	2.1	;	Crystal structure of the complex of the archaeal sulfolobus PTP-fold phosphatase with phosphopeptides A-(p)Y-R
2I6O	;	1.9	;	Crystal structure of the complex of the archaeal sulfolobus PTP-fold phosphatase with phosphopeptides N-G-(p)Y-K-N
2I6P	;	2.5	;	Crystal structure of the complex of the archaeal sulfolobus PTP-fold phosphatase with pNPP
3RO1	;	1.9	;	Crystal structure of the complex of the archaeal sulfolobus PTP-fold phosphatase with terpyridine platinum(II)
3DPB	;	2.2	;	Crystal structure of the complex of the Caf1M chaperone with the mini-fiber of two Caf1 subunits (Caf1:Caf1), carrying the Ala9Val, Ala11Val, and Leu13Val mutations in the Gd donor strand
3DOS	;	2.4	;	Crystal structure of the complex of the Caf1M chaperone with the mini-fiber of two Caf1 subunits (Caf1:Caf1), carrying the Thr7Phe and Ala9Val mutations in the Gd donor strand
3DSN	;	2.2	;	Crystal structure of the complex of the Caf1M chaperone with the mini-fiber of two Caf1 subunits (Caf1:Caf1), carrying the Thr7Phe mutation in the Gd donor strand
4AZ8	;	2.65	;	Crystal structure of the complex of the Caf1M:Caf1 chaperone:subunit preassembly complex carrying the KDKDTN insertion at the F1G1 loop region
4AYF	;	2.07	;	Crystal structure of the complex of the Caf1M:Caf1 chaperone:subunit preassembly complex carrying the Tyr40Ala mutation in the Caf1M chaperone
2XR5	;	1.42	;	Crystal structure of the complex of the carbohydrate recognition domain of human DC-SIGN with pseudo dimannoside mimic.
2XR6	;	1.35	;	Crystal structure of the complex of the carbohydrate recognition domain of human DC-SIGN with pseudo trimannoside mimic.
4CJ6	;	1.896	;	Crystal structure of the complex of the Cellular Retinal Binding Protein Mutant R234W with 9-cis-retinal
4CIZ	;	3.403	;	Crystal structure of the complex of the Cellular Retinal Binding Protein with 9-cis-retinal
2GYK	;	1.6	;	Crystal structure of the complex of the Colicin E9 DNase domain with a mutant immunity protein, IMME9 (D51A)
3GIB	;	2.4	;	Crystal Structure of the Complex of the E. coli Hfq with Poly(A)
4UY2	;	2.697	;	Crystal structure of the complex of the extracellular domain of human alpha9 nAChR with alpha-bungarotoxin.
1MJ7	;	2.25	;	Crystal Structure Of The Complex Of The Fab fragment of Esterolytic Antibody MS5-393 and A Transition-State Analog
6A9K	;	1.9	;	Crystal structure of the complex of the hydrolytic antibody Fab 9C10 with a transition-state analog
3A98	;	2.1	;	Crystal structure of the complex of the interacting regions of DOCK2 and ELMO1
6KZA	;	3.1	;	Crystal structure of the complex of the interaction domains of E. coli DnaB helicase and DnaC helicase loader
5OCQ	;	1.7	;	Crystal structure of the complex of the kappa-carrageenase from Pseudoalteromonas carrageenovora with an oligotetrasaccharide of kappa-carrageenan
7AMS	;	2.419	;	Crystal structure of the complex of the KFN mutant of HuJovi-1 Fab with human TRBC2
7AMR	;	1.949	;	Crystal structure of the complex of the KFN mutant of Jovi-1 Fab with human TRBC1
7TXW	;	2.17	;	Crystal structure of the complex of the malaria sexual stage protein and vaccine target Pfs25 with the Fab fragment of a transmission blocking antibody 1G2
1JWS	;	2.6	;	Crystal Structure of the Complex of the MHC Class II Molecule HLA-DR1 (HA peptide 306-318) with the Superantigen SEC3 Variant 3B1
1JWU	;	2.3	;	Crystal Structure of the Complex of the MHC Class II Molecule HLA-DR1 (HA peptide 306-318) with the superantigen SEC3 Variant 3B2
1JWM	;	2.7	;	Crystal Structure of the Complex of the MHC Class II Molecule HLA-DR1(HA peptide 306-318) with the Superantigen SEC3
4CF6	;	2.694	;	Crystal structure of the complex of the P187S variant of human NAD(P) H:quinone oxidoreductase with Cibacron blue at 2.7 A resolution
4CET	;	2.2	;	Crystal structure of the complex of the P187S variant of human NAD(P) H:quinone oxidoreductase with dicoumarol at 2.2 A resolution
1OBZ	;	1.7	;	Crystal structure of the complex of the PDZ tandem of syntenin with an interleukin 5 receptor alpha peptide.
5XE9	;	3.101	;	Crystal Structure of the Complex of the Peptidase Domain of Streptococcus mutans ComA with a Small Molecule Inhibitor.
7A6O	;	2.117	;	Crystal Structure of the Complex of the Recombinant Von Willebrand Factor AIM-A1 domain and VHH81 at 2.1 Angstrom resolution
1SQ0	;	2.6	;	Crystal Structure of the Complex of the Wild-type Von Willebrand Factor A1 domain and Glycoprotein Ib alpha at 2.6 Angstrom Resolution
4KJX	;	2.1	;	Crystal Structure of the complex of three phase partition treated lipase from Thermomyces lanuginosa with Lauric acid and P-nitrobenzaldehyde (PNB) at 2.1 resolution
5GS0	;	3.275	;	Crystal structure of the complex of TLR3 and bi-specific diabody
1QD2	;	1.86	;	CRYSTAL STRUCTURE OF THE COMPLEX OF TRICHOSANTHIN WITH ADENINE, OBTAINED FROM TRICHOSANTHIN COMPLEXED WITH THE DINUCLEOTIDE APG
3U5N	;	1.95	;	Crystal structure of the complex of TRIM33 PHD-Bromo and H3(1-20)K9me3K14ac histone peptide
3U5O	;	2.7	;	Crystal structure of the complex of TRIM33 PHD-Bromo and H3(1-22)K9me3K14acK18ac histone peptide
3U5P	;	2.8	;	Crystal structure of the complex of TRIM33 PHD-Bromo and H3(1-28)K9me3K14acK18acK23ac histone peptide
5Z1M	;	1.87	;	Crystal structure of the complex of trimeric Phosphopantetheine adenylyltransferase from Acinetobacter baumannii with citrate ion at 1.87 A resolution
3IBA	;	2.4	;	Crystal structure of the complex of Trypanosoma cruzi farnesyl diphosphate synthase with zoledronate, IPP and Mg2+
4O0O	;	2.59	;	Crystal structure of the complex of type 1 Ribosome inactivating protein from Momordica balsamina with 5-fluorouracil at 2.59 A resolution
4HOA	;	2.0	;	Crystal structure of the complex of type 1 ribosome inactivating protein from Momordica Balsamina with B-D-galactopyranosyl-(1-4)-D-glucose at 2.0 A resolution
5ILW	;	1.98	;	Crystal structure of the complex of type 1 Ribosome inactivating protein from Momordica balsamina with Uridine at 1.97 Angstrom resolution
3MY6	;	2.65	;	Crystal Structure of the complex of type 1 ribosome inactivating protein with 7-methylguanine at 2.65 A resolution
3V14	;	1.7	;	Crystal structure of the complex of type I Ribosome inactivating protein complexed with Trehalose at 1.70 A resolution
3SJ6	;	1.6	;	Crystal Structure of the complex of type I ribosome inactivating protein from momordica balsamina with 5-(hydroxymethyl)oxalane-2,3,4-triol at 1.6 A resolution
4K2Z	;	1.8	;	Crystal structure of the complex of type I Ribosome inactivating protein from Momordica balsamina with Methylethylamine at 1.80 A resolution
4F9N	;	2.65	;	Crystal structure of the complex of type I Ribosome inactivating protein from Momordica balsamina with N7-methylated guanine at 2.65 A resolution
4O8E	;	2.0	;	Crystal structure of the complex of type I ribosome inactivating protein from Momordica balsamina with uridine triphosphate at 2.0 A resolution
4EMF	;	1.77	;	Crystal structure of the complex of type I Ribosome inactivating protein in complex with 7n-methyl-8-hydroguanosine-5-p-diphosphate at 1.77 A
3U6T	;	1.85	;	Crystal structure of the complex of type I Ribosome inactivating protein in complex with Kanamycin at 1.85 A
3U8F	;	1.8	;	Crystal structure of the complex of type I Ribosome inactivating protein in complex with Mycolic acid at 1.8 A resolution
3Q4P	;	1.8	;	Crystal structure of the complex of type I ribosome inactivating protein with 7n-methyl -8-hydroguanosine-5-p-diphosphate at 1.8 A resolution
3NFM	;	2.5	;	Crystal Structure of the complex of type I ribosome inactivating protein with fructose at 2.5A resolution
3N31	;	2.11	;	Crystal Structure of the complex of type I ribosome inactivating protein with fucose at 2.1A resolution
3N5D	;	1.9	;	Crystal structure of the complex of type I ribosome inactivating protein with glucose at 1.9A resolution
3N1N	;	2.23	;	Crystal structure of the complex of type I ribosome inactivating protein with guanine at 2.2A resolution
3N2D	;	2.22	;	Crystal Structure of the Complex of type I Ribosome inactivating protein with hexapeptide Ser-Asp-Asp-Asp-Met-Gly at 2.2 A resolution
4DWM	;	1.62	;	Crystal structure of the complex of type I Ribosome inactivating protein with N-acetylglucosamine at 1.62 A resolution
3N1D	;	1.7	;	Crystal structure of the complex of type I ribosome inactivating protein with ribose at 1.7A resolution
3RL9	;	1.9	;	Crystal Structure of the complex of type I RIP with the hydrolyzed product of dATP, adenine at 1.9 A resolution
5YDB	;	1.76	;	Crystal structure of the complex of type II dehydroquinate dehydratase from Acinetobacter baumannii with dehydroquinic acid at 1.76 Angstrom resolution
4GLD	;	1.69	;	Crystal Structure of the complex of type II phospholipase A2 with a designed peptide inhibitor Phe - Leu - Ala - Tyr - Lys at 1.69 A resolution
1I3O	;	2.7	;	CRYSTAL STRUCTURE OF THE COMPLEX OF XIAP-BIR2 AND CASPASE 3
3M7S	;	2.4	;	Crystal structure of the complex of xylanase GH-11 and alpha amylase inhibitor protein with cellobiose at 2.4 A resolution
3OIH	;	1.87	;	Crystal Structure of the complex of xylanase-alpha-amylase inhibitor Protein (XAIP-I) with trehalose at 1.87 A resolution
5HYK	;	1.83	;	Crystal structure of the complex PPARalpha/AL26-29
5HZC	;	2.0	;	Crystal structure of the complex PPARgamma/AL26-29
3BC1	;	1.8	;	Crystal Structure of the complex Rab27a-Slp2a
6Y7M	;	1.9	;	Crystal structure of the complex resulting from the reaction between the SARS-CoV main protease and tert-butyl (1-((S)-3-cyclohexyl-1-(((S)-4-(cyclopropylamino)-3,4-dioxo-1-((S)-2-oxopyrrolidin-3-yl)butan-2-yl)amino)-1-oxopropan-2-yl)-2-oxo-1,2-dihydropyridin-3-yl)carbamate
2I6M	;	1.9	;	Crystal structure of the complexes of the archaeal sulfolobus PTP-fold phosphatase with Tungstate
6J67	;	2.05	;	Crystal structure of the compound 34 in a complex with TRF2
6TJI	;	2.2	;	Crystal structure of the computationally designed Cake10 protein
6TJB	;	2.3	;	Crystal structure of the computationally designed Cake2 protein
6TJC	;	1.9	;	Crystal structure of the computationally designed Cake3 protein
6TJD	;	2.1	;	Crystal structure of the computationally designed Cake4 protein
6TJE	;	3.15	;	Crystal structure of the computationally designed Cake5 protein
6TJF	;	2.4	;	Crystal structure of the computationally designed Cake6 protein
6TJG	;	1.8	;	Crystal structure of the computationally designed Cake8 protein
6TJH	;	1.43	;	Crystal structure of the computationally designed Cake9 protein
7AYE	;	2.95	;	Crystal structure of the computationally designed chemically disruptable heterodimer LD6-MDM2
6G6Q	;	2.5	;	Crystal structure of the computationally designed Ika4 protein
6G6O	;	2.05	;	Crystal structure of the computationally designed Ika8 protein: crystal packing No.1 in P63
6G6P	;	2.4	;	Crystal structure of the computationally designed Ika8 protein: crystal packing No.2 in P63
7DWW	;	1.802	;	Crystal structure of the computationally designed msDPBB_sym2 protein
4HOP	;	2.29	;	Crystal structure of the computationally designed NNOS-Syntrophin complex
3WW7	;	1.697	;	Crystal structure of the computationally designed Pizza2 protein
3WWB	;	1.7	;	Crystal structure of the computationally designed Pizza2-SR protein
3WWF	;	1.601	;	Crystal structure of the computationally designed Pizza2-SR protein
3WW8	;	1.402	;	Crystal structure of the computationally designed Pizza3 protein
3WW9	;	1.33	;	Crystal structure of the computationally designed Pizza6 protein
3WWA	;	1.988	;	Crystal structure of the computationally designed Pizza7 protein after heat treatment
7DVC	;	1.705	;	Crystal structure of the computationally designed reDPBB_sym1 protein
7DVF	;	1.209	;	Crystal structure of the computationally designed reDPBB_sym2 protein
7DVH	;	1.698	;	Crystal structure of the computationally designed reDPBB_sym4 protein
7ONA	;	1.45	;	Crystal structure of the computationally designed SAKe6AC protein
7ON6	;	1.35	;	Crystal structure of the computationally designed SAKe6AE protein
7ON8	;	1.5	;	Crystal structure of the computationally designed SAKe6AR protein
7ONC	;	1.49	;	Crystal structure of the computationally designed SAKe6BE protein
7OP4	;	1.52	;	Crystal structure of the computationally designed SAKe6BE-3HH protein
7OPV	;	1.95	;	Crystal structure of the computationally designed SAKe6BE-3HH protein, alternative packing
7ONG	;	1.95	;	Crystal structure of the computationally designed SAKe6BE-L1 protein
7ON7	;	1.95	;	Crystal structure of the computationally designed SAKe6BE-L2 protein
7ONH	;	1.65	;	Crystal structure of the computationally designed SAKe6BE-L3 protein
7AWZ	;	1.6	;	Crystal structure of the computationally designed Scone-E protein
7AX0	;	2.2	;	Crystal structure of the computationally designed Scone-E protein co-crystallized with STA form a
7AX2	;	2.1	;	Crystal structure of the computationally designed Scone-E protein co-crystallized with STA, form b
7AWY	;	1.5	;	Crystal structure of the computationally designed Scone-R protein
4JBC	;	2.005	;	Crystal Structure of the computationally designed serine hydrolase 3mmj_2, Northeast Structural Genomics Consortium (NESG) Target OR318
4K0C	;	3.002	;	Crystal Structure of the computationally designed serine hydrolase. Northeast Structural Genomics Consortium (NESG) Target OR317
6G6N	;	2.001	;	Crystal structure of the computationally designed Tako8 protein in C2
6G6M	;	1.7	;	Crystal structure of the computationally designed Tako8 protein in P42212
4P6L	;	2.803	;	Crystal Structure of the Computationally Designed Transmembrane Metallotransporter in Octyl Glucoside
4P6K	;	2.704	;	Crystal Structure of the Computationally Designed Transmembrane Metallotransporter with 4-bromophenylalanine in Lipidic Cubic Phase
4P6J	;	2.8	;	Crystal Structure of the Computationally Designed Transmembrane Metallotransporter with 4-bromophenylalanine in Octyl Glucoside
7UYI	;	3.0	;	Crystal structure of the computationally optimized broadly reactive H1 influenza hemagglutinin P1
6OU1	;	1.878	;	Crystal Structure of the Computationally-derived 21-Variant of the Myocilin Olfactomedin Domain
2RLC	;	1.8	;	Crystal Structure of the Conjugated Bile Acid Hydrolase from Clostridium perfringens in Complex with Reaction Products Glycine and Cholate
3C0B	;	2.4	;	Crystal structure of the conserved archaeal protein Q6M145. Northeast Structural Genomics Consortium target MrR63
2VXG	;	1.9	;	Crystal structure of the conserved C-terminal region of Ge-1
3NFQ	;	1.85	;	Crystal structure of the conserved central domain of yeast Spn1/Iws1
1EP5	;	2.3	;	CRYSTAL STRUCTURE OF THE CONSERVED CORE DOMAIN OF VENEZUALAN EQUINE ENCEPHALITIS CAPSID PROTEIN
1EP6	;	2.45	;	CRYSTAL STRUCTURE OF THE CONSERVED CORE DOMAIN OF VENEZUALAN EQUINE ENCEPHALITIS CAPSID PROTEIN
4XAL	;	1.869	;	Crystal structure of the conserved core domain of VP22 from HSV-1
1F3L	;	2.03	;	CRYSTAL STRUCTURE OF THE CONSERVED CORE OF PROTEIN ARGININE METHYLTRANSFERASE PRMT3
1DUH	;	2.7	;	CRYSTAL STRUCTURE OF THE CONSERVED DOMAIN IV OF E. COLI 4.5S RNA
3M1C	;	3.0	;	Crystal structure of the conserved herpesvirus fusion regulator complex gH-gL
2GSC	;	2.45	;	Crystal Structure of the Conserved Hypothetical Cytosolic Protein Xcc0516 from Xanthomonas campestris
1WDE	;	2.0	;	Crystal structure of the conserved hypothetical protein APE0931 from Aeropyrum pernix K1
4EZB	;	2.1	;	CRYSTAL STRUCTURE OF the Conserved hypothetical protein from Sinorhizobium meliloti 1021
4IWG	;	2.472	;	Crystal Structure of the Conserved Hypothetical Protein MJ0927 from Methanocaldococcus jannaschii (in C2221 form)
4IWM	;	2.7	;	Crystal Structure of the Conserved Hypothetical Protein MJ0927 from Methanocaldococcus jannaschii (in P21 form)
1TD6	;	2.5	;	Crystal structure of the conserved hypothetical protein MP506/MPN330 (gi: 1674200)from Mycoplasma pneumoniae
2JEK	;	1.38	;	Crystal structure of the conserved hypothetical protein Rv1873 from Mycobacterium tuberculosis at 1.38 A
2ASF	;	1.6	;	Crystal structure of the conserved hypothetical protein Rv2074 from Mycobacterium tuberculosis 1.6 A
1WEK	;	2.2	;	Crystal structure of the conserved hypothetical protein TT1465 from Thermus thermophilus HB8
2CU5	;	1.84	;	Crystal Structure Of The Conserved Hypothetical Protein TT1486 From Thermus Thermophilus HB8
1V8D	;	2.16	;	Crystal structure of the conserved hypothetical protein TT1679 from Thermus thermophilus
1J3M	;	2.0	;	Crystal structure of the conserved hypothetical protein TT1751 from Thermus thermophilus HB8
1WEH	;	1.8	;	Crystal structure of the conserved hypothetical protein TT1887 from Thermus thermophilus HB8
1VGG	;	1.75	;	Crystal Structure of the Conserved Hypothetical Protein TTHA1091 from Thermus Thermophilus HB8
1YZH	;	2.02	;	Crystal Structure of the Conserved Hypothetical Protein, Methyltransferase from Streptococcus pneumoniae TIGR4
5AON	;	1.646	;	Crystal structure of the conserved N-terminal domain of Pex14 from Trypanosoma brucei
3ESL	;	1.74	;	Crystal structure of the conserved N-terminal domain of the mitotic checkpoint component BUB1
3FF5	;	1.8	;	Crystal structure of the conserved N-terminal domain of the peroxisomal matrix-protein-import receptor, Pex14p
1T57	;	2.3	;	Crystal Structure of the Conserved Protein MTH1675 from Methanobacterium thermoautotrophicum
3CEX	;	2.0	;	Crystal structure of the conserved protein of locus EF_3021 from Enterococcus faecalis
2FDO	;	2.4	;	Crystal Structure of the Conserved Protein of Unknown Function AF2331 from Archaeoglobus fulgidus DSM 4304 Reveals a New Type of Alpha/Beta Fold
2FSQ	;	1.4	;	Crystal Structure of the Conserved Protein of Unknown Function ATU0111 from Agrobacterium tumefaciens str. C58
2FIU	;	2.0	;	Crystal Structure of the Conserved Protein of Unknown Function ATU0297 from Agrobacterium tumefaciens
2GUK	;	1.91	;	Crystal Structure of the Conserved Protein of Unknown Function from Porphyromonas gingivalis
1YLL	;	1.64	;	Crystal Structure of the Conserved Protein of Unknown Function PA5104 from Pseudomonas aeruginosa PAO1
3C5O	;	2.2	;	Crystal structure of the conserved protein of unknown function RPA1785 from Rhodopseudomonas palustris
1UDX	;	2.07	;	Crystal structure of the conserved protein TT1381 from Thermus thermophilus HB8
1UAN	;	2.0	;	Crystal structure of the conserved protein TT1542 from Thermus thermophilus HB8
4BIH	;	2.459	;	Crystal structure of the conserved staphylococcal antigen 1A, Csa1A
4BIG	;	2.274	;	Crystal structure of the conserved staphylococcal antigen 1B, Csa1B
1QB2	;	2.1	;	CRYSTAL STRUCTURE OF THE CONSERVED SUBDOMAIN OF HUMAN PROTEIN SRP54M AT 2.1A RESOLUTION: EVIDENCE FOR THE MECHANISM OF SIGNAL PEPTIDE BINDING
2X72	;	3.0	;	CRYSTAL STRUCTURE OF THE CONSTITUTIVELY ACTIVE E113Q,D2C,D282C RHODOPSIN MUTANT WITH BOUND GALPHACT PEPTIDE.
8OMV	;	4.16	;	Crystal structure of the constitutively active S117E/S181E mutant of human IKK2
4D10	;	3.8	;	Crystal structure of the COP9 signalosome
4D18	;	4.08	;	Crystal structure of the COP9 signalosome
4WSN	;	5.5	;	Crystal structure of the COP9 signalosome, a P1 crystal form
3FRY	;	2.0	;	Crystal structure of the CopA C-terminal metal binding domain
1PD1	;	2.6	;	Crystal structure of the COPII coat subunit, Sec24, complexed with a peptide containing the DxE cargo sorting signal of yeast Sys1 protein
1PCX	;	2.5	;	Crystal structure of the COPII coat subunit, Sec24, complexed with a peptide from the SNARE protein Bet1
1PD0	;	2.6	;	Crystal structure of the COPII coat subunit, Sec24, complexed with a peptide from the SNARE protein Sed5 (yeast syntaxin-5)
1QUP	;	1.8	;	CRYSTAL STRUCTURE OF THE COPPER CHAPERONE FOR SUPEROXIDE DISMUTASE
7OG7	;	1.85	;	Crystal structure of the copper chaperone NosL from Shewanella denitrificans
5C0U	;	1.87	;	Crystal structure of the copper-bound form of MerB mutant D99S
2ZWG	;	1.32	;	Crystal structure of the copper-bound tyrosinase in complex with a caddie protein from streptomyces castaneoglobisporus obtained by soaking the deoxy-form crystal in dioxygen-saturated solution for 12 hours
2ZWE	;	1.32	;	Crystal structure of the copper-bound tyrosinase in complex with a caddie protein from streptomyces castaneoglobisporus obtained by soaking the deoxy-form crystal in dioxygen-saturated solution for 40 minutes
2ZWD	;	1.35	;	Crystal structure of the copper-bound tyrosinase in complex with a caddie protein from streptomyces castaneoglobisporus obtained by soaking the deoxy-form crystal in dioxygen-saturated solution for 5 minutes
2ZWF	;	1.4	;	Crystal structure of the copper-bound tyrosinase in complex with a caddie protein from streptomyces castaneoglobisporus obtained by soaking the deoxy-form crystal in dioxygen-saturated solution for 80 minutes
1WXC	;	1.2	;	Crystal Structure of the copper-free Streptomyces castaneoglobisporus tyrosinase complexed with a caddie protein
1WX5	;	2.02	;	Crystal Structure of the copper-free Streptomyces castaneoglobisporus tyrosinase complexed with a caddie protein in the monoclinic crystal
4M1P	;	2.564	;	Crystal structure of the copper-sensing repressor CsoR with Cu(I) from Geobacillus thermodenitrificans NG80-2
2BBJ	;	3.9	;	Crystal structure of the CorA Mg2+ transporter
2HN2	;	3.7	;	Crystal structure of the CorA Mg2+ transporter homologue from T. maritima in complex with divalent cations
2P3H	;	1.8	;	Crystal structure of the CorC_HlyC domain of a putative Corynebacterium glutamicum hemolysin
5W2G	;	1.8	;	Crystal structure of the core catalytic domain of human inositol phosphate multikinase
6M8D	;	2.0	;	Crystal structure of the core catalytic domain of human inositol phosphate multikinase in complex with diosmetin
5W2H	;	1.9	;	Crystal structure of the core catalytic domain of human inositol phosphate multikinase in complex with Ins(1,4,5)P3 and ADP
6M8C	;	1.8	;	Crystal structure of the core catalytic domain of human inositol phosphate multikinase in complex with isorhamnetin
6M8B	;	1.8	;	Crystal structure of the core catalytic domain of human inositol phosphate multikinase in complex with kaempferol
6M8A	;	1.75	;	Crystal structure of the core catalytic domain of human inositol phosphate multikinase in complex with luteolin
6M88	;	1.9	;	Crystal structure of the core catalytic domain of human inositol phosphate multikinase in complex with myricetin
6M89	;	1.85	;	Crystal structure of the core catalytic domain of human inositol phosphate multikinase in complex with quercetin
6M8E	;	2.0	;	Crystal structure of the core catalytic domain of human inositol phosphate multikinase in complex with rhamnetin
5W2I	;	1.6	;	Crystal structure of the core catalytic domain of human inositol phosphate multikinase soaked with C4-analogue of PtdIns(4,5)P2 and ADP
5UHK	;	2.97	;	Crystal structure of the core catalytic domain of Human O-GlcNAcase
5UHP	;	2.79	;	Crystal structure of the core catalytic domain of human O-GlcNAcase
6PM9	;	2.86	;	Crystal structure of the core catalytic domain of human O-GlcNAcase bound to MK-8719
5UHO	;	3.21	;	Crystal structure of the core catalytic domain of human O-GlcNAcase complexed with PUGNAc
5UHL	;	3.14	;	Crystal structure of the core catalytic domain of human O-GlcNAcase complexed with Thiamet G
6BYF	;	2.35	;	Crystal structure of the core catalytic domain of PP-IP phosphatase SIW14 from S. cerevisiae in complex with citrate
6UIH	;	2.826	;	Crystal structure of the core domain from the GST-like protein GDAP1
6LAF	;	3.001	;	Crystal structure of the core domain of Amuc_1100 from Akkermansia muciniphila
6UV2	;	1.894	;	Crystal structure of the core domain of RNA helicase DDX17 with RNA pri-125a-oligo1
6UV3	;	1.597	;	Crystal structure of the core domain of RNA helicase DDX17 with RNA pri-125a-oligo2
6UV4	;	1.7	;	Crystal structure of the core domain of RNA helicase DDX17 with RNA pri-18a-oligo1
1Z21	;	1.499	;	Crystal structure of the core domain of Yersinia pestis virulence factor YopR
1V9D	;	2.6	;	Crystal structure of the core FH2 domain of mouse mDia1
1KG2	;	1.2	;	Crystal structure of the core fragment of MutY from E.coli at 1.2A resolution
1KG3	;	1.55	;	Crystal structure of the core fragment of MutY from E.coli at 1.55A resolution
2XB2	;	3.4	;	Crystal structure of the core Mago-Y14-eIF4AIII-Barentsz-UPF3b assembly shows how the EJC is bridged to the NMD machinery
4WWX	;	3.2001	;	Crystal structure of the core RAG1/2 recombinase
7VUK	;	3.38	;	Crystal Structure of the core region of Thermus thermophilus MutS2 complexed with ADP.
7VUF	;	3.11	;	Crystal Structure of the core region of Thermus thermophilus MutS2.
3WZN	;	1.3	;	Crystal structure of the core streptavidin mutant V21 (Y22S/N23D/S27D/Y83S/R84K/E101D/R103K/E116N) complexed with biotin at 1.3 A resolution
3WZO	;	1.5	;	Crystal structure of the core streptavidin mutant V21 (Y22S/N23D/S27D/Y83S/R84K/E101D/R103K/E116N) complexed with biotin long tail (BTNtail) at 1.5 A resolution
3WZP	;	1.2	;	Crystal structure of the core streptavidin mutant V21 (Y22S/N23D/S27D/Y83S/R84K/E101D/R103K/E116N) complexed with iminobiotin long tail (IMNtail) at 1.2 A resolution
3X00	;	1.3	;	Crystal structure of the core streptavidin mutant V212 (Y22S/N23D/S27D/S45N/Y83S/R84K/E101D/R103K/E116N) complexed with bis iminobiotin long tail (Bis-IMNtail) at 1.3 A resolution
3WZQ	;	1.7	;	Crystal structure of the core streptavidin mutant V212 (Y22S/N23D/S27D/S45N/Y83S/R84K/E101D/R103K/E116N) complexed with iminobiotin long tail (IMNtail) at 1.7 A resolution
1TZY	;	1.9	;	Crystal Structure of the Core-Histone Octamer to 1.90 Angstrom Resolution
6E81	;	2.721	;	Crystal structure of the Corn aptamer in complex with ThT
6E84	;	2.901	;	Crystal structure of the Corn aptamer in complex with TO
6E80	;	2.901	;	Crystal structure of the Corn aptamer in unliganded state
6E82	;	3.101	;	Crystal structure of the Corn aptamer mutant A14U in complex with ThT
5BJP	;	2.51	;	Crystal structure of the Corn RNA aptamer in complex with DFHO, iridium hexammine soak
5BJO	;	2.35	;	Crystal structure of the Corn RNA aptamer in complex with DFHO, site-specific 5-iodo-U
8OWI	;	2.14	;	Crystal structure of the corona-targeting domain of CENP-E
4Q89	;	2.31	;	Crystal Structure of the CotA native enzyme
8F2E	;	2.43	;	Crystal Structure of the CoV-Y domain of SARS-CoV-2 Nonstructural Protein 3
4B55	;	2.7	;	Crystal Structure of the Covalent Adduct Formed between Mycobacterium marinum Aryalamine N-acetyltransferase and Phenyl vinyl ketone a derivative of Piperidinols
3CG5	;	1.7	;	Crystal Structure of the Covalent Adduct Formed between TB B-lactamase and Clavulanate
6EI1	;	1.732	;	Crystal structure of the covalent complex between deubiquitinase ZUFSP (ZUP1) and Ubiquitin-PA
3BRM	;	2.29	;	Crystal structure of the covalent complex between the Bacillus subtilis glutaminase YbgJ and 5-oxo-L-norleucine formed by reaction of the protein with 6-diazo-5-oxo-L-norleucine
7OJE	;	2.05	;	Crystal structure of the covalent complex between Tribolium castaneum deubiquitinase ZUP and Ubiquitin-PA
4EST	;	1.78	;	CRYSTAL STRUCTURE OF THE COVALENT COMPLEX FORMED BY A PEPTIDYL ALPHA,ALPHA-DIFLUORO-BETA-KETO AMIDE WITH PORCINE PANCREATIC ELASTASE AT 1.78-ANGSTROMS RESOLUTION
2ZOX	;	1.9	;	Crystal Structure of the Covalent Intermediate of Human Cytosolic beta-Glucosidase
3VKK	;	2.0	;	Crystal Structure Of The Covalent Intermediate Of Human Cytosolic Beta-Glucosidase-mannose complex
3LB8	;	2.6	;	Crystal structure of the covalent putidaredoxin reductase-putidaredoxin complex
5JYX	;	2.74	;	Crystal structure of the covalent thioimide intermediate of the archaeosine synthase QueF-Like
4F8B	;	2.502	;	Crystal Structure of the Covalent Thioimide Intermediate of Unimodular Nitrile Reductase QueF
7L5P	;	2.14	;	Crystal structure of the covalently bonded complex of rilzabrutinib with BTK
6PWS	;	1.0	;	Crystal structure of the cow C-type carbohydrate-recognition domain of CD23 in the presence of alpha-methyl mannoside
6PWR	;	1.2	;	Crystal structure of the cow C-type carbohydrate-recognition domain of CD23 in the presence of GlcNAc-beta1-2-Man
6PWT	;	2.701	;	Crystal structure of the cow C-type carbohydrate-recognition domain of CD23 in the presence of GlcNAc2Man3 oligosaccharide
5Y6Z	;	2.5	;	Crystal structure of the coxsackievirus A16 polymerase elongation complex
1WNR	;	2.9	;	Crystal structure of the Cpn10 from Thermus thermophilus HB8
4QN0	;	2.74	;	Crystal structure of the CPS-6 mutant Q130K
3UI2	;	3.178	;	Crystal structure of the cpSRP54 tail bound to cpSRP43
4RMO	;	2.2	;	Crystal Structure of the CptIN Type III Toxin-Antitoxin System from Eubacterium rectale
2Z4H	;	2.8	;	Crystal structure of the Cpx pathway activator NlpE from Escherichia coli
2Z4I	;	2.6	;	Crystal structure of the Cpx pathway activator NlpE from Escherichia coli
4V0K	;	1.438	;	Crystal structure of the CrARL6DN in the GDP bound form
4V0L	;	2.197	;	Crystal structure of the CrARL6DN in the GTP bound form
6H64	;	1.8	;	Crystal structure of the CRD-SAT
6YIJ	;	2.2	;	Crystal structure of the CREBBP bromodomain in complex with a benzo-diazepine ligand
6YIM	;	1.23	;	Crystal structure of the CREBBP bromodomain in complex with a benzo-diazepine ligand
6YIK	;	1.7	;	Crystal structure of the CREBBP bromodomain in complex with a tetrahydroquinoxaline ligand
6YIL	;	1.22	;	Crystal structure of the CREBBP bromodomain in complex with a tetrahydroquinoxaline ligand
3THG	;	1.88	;	Crystal structure of the creosote Rubisco activase C-domain
7A0J	;	1.95	;	Crystal structure of the CRINKLY WD40 ectodomain from the Arabidopsis thaliana receptor kinase ACR4
4DZD	;	1.999	;	Crystal structure of the CRISPR-associated protein Cas6e from Escherichia coli str. K-12
5WTI	;	2.682	;	Crystal structure of the CRISPR-associated protein in complex with crRNA and DNA
3QYF	;	1.9	;	Crystal structure of the CRISPR-associated protein SSO1393 from Sulfolobus solfataricus
3X1L	;	2.096	;	Crystal Structure of the CRISPR-Cas RNA Silencing Cmr Complex Bound to a Target Analog
3NC1	;	3.35	;	Crystal structure of the CRM1-RanGTP complex
7DZN	;	2.63	;	Crystal Structure of the cross-restricted T18A TCR and HLAB4201 bound to HIV-1 Gag TL9 peptide
7DZM	;	2.25	;	Crystal Structure of the cross-restricted T18A TCR and HLAB8101 bound to HIV-1 Gag TL9 peptide
7T8O	;	2.71	;	Crystal Structure of the Crp/Fnr Family Transcriptional Regulator from Listeria monocytogenes
5ZK1	;	3.05	;	Crystal Structure of the CRTC2(SeMet)-CREB-CRE complex
5ZKO	;	3.05	;	Crystal structure of the CRTC2-CREB-CRE complex
4YL8	;	1.5	;	Crystal structure of the Crumbs/Moesin complex
6OF7	;	3.11	;	Crystal structure of the CRY1-PER2 complex
4NKB	;	2.3	;	Crystal Structure of the cryptic polo box (CPB)of ZYG-1
6N46	;	3.708	;	Crystal structure of the cryptic polo box domain of a human activated Plk4
6N45	;	2.64	;	Crystal structure of the cryptic polo box domain of human activated Plk4 variant 1
4N9J	;	2.601	;	Crystal structure of the cryptic polo box domain of human Plk4
5FON	;	2.7	;	Crystal structure of the Cryptosporidium muris cytosolic leucyl-tRNA synthetase editing domain (apo structure)
5FOL	;	1.77	;	Crystal structure of the Cryptosporidium muris cytosolic leucyl-tRNA synthetase editing domain complex with a post-transfer editing analogue of isoeucine (Ile2AA)
5FOM	;	2.1	;	Crystal structure of the Cryptosporidium muris cytosolic leucyl-tRNA synthetase editing domain complex with the adduct AMP-AN6426
7D5G	;	1.6	;	Crystal structure of the CsCE with ligand to have a insight into the catalytic mechanism
6T2W	;	1.7	;	Crystal structure of the CSF1R kinase domain with a dihydropurinone inhibitor (compound 4)
6GPE	;	2.2	;	Crystal Structure of the CsiD Glutarate Hydroxylase
6HL8	;	2.4	;	Crystal Structure of the CsiD Glutarate Hydroxylase in complex with Glutarate
6GPN	;	2.2	;	Crystal Structure of the CsiD Glutarate Hydroxylase in complex with N-Oxalylglycine
6HL9	;	2.3	;	Crystal Structure of the CsiD Glutarate Hydroxylase in complex with Succinate
2FO1	;	3.12	;	Crystal Structure of the CSL-Notch-Mastermind ternary complex bound to DNA
8JBB	;	1.81	;	Crystal Structure of the Csm6 from Thermus thermophilus HB8 in complex with A2>p
8JBC	;	2.41	;	Crystal Structure of the Csm6 K137A mutant from Thermus thermophilus HB8 in its apo form
8JH1	;	2.89	;	Crystal Structure of the Csm6 Y161A mutant from Thermus thermophilus HB8 in complex with cyclic-tetraadenylate (cA4)
6FQ0	;	2.5	;	Crystal structure of the CsuC-CsuA/B chaperone-subunit preassembly complex of the archaic chaperone-usher Csu pili of Acinetobacter baumannii
6FQA	;	2.85	;	Crystal structure of the CsuC-CsuA/B chaperone-subunit preassembly complex of the archaic chaperone-usher Csu pili of Acinetobacter baumannii
2XLJ	;	2.6	;	Crystal structure of the Csy4-crRNA complex, hexagonal form
2XLI	;	2.33	;	Crystal structure of the Csy4-crRNA complex, monoclinic form
2XLK	;	1.805	;	Crystal structure of the Csy4-crRNA complex, orthorhombic form
4AL5	;	2.0	;	Crystal structure of the Csy4-crRNA product complex
4AL7	;	2.32	;	Crystal structure of the Csy4-minimal crRNA complex
7XGB	;	2.7	;	Crystal structure of the ctcP from Streptomyces aureofaciens
5CD9	;	2.102	;	Crystal structure of the CTD of Drosophila Oskar protein
5OKC	;	2.3	;	Crystal structure of the Ctf18-1-8 module from Ctf18-RFC
5OKI	;	4.5	;	Crystal structure of the Ctf18-1-8 module from Ctf18-RFC in complex with a 63 kDa fragment of DNA Polymerase epsilon
3ZXU	;	3.7	;	Crystal structure of the Ctf19-Mcm21 kinetochore heterodimer from yeast
1I85	;	3.2	;	CRYSTAL STRUCTURE OF THE CTLA-4/B7-2 COMPLEX
2BE9	;	2.6	;	Crystal structure of the CTP-liganded (T-State) aspartate transcarbamoylase from the extremely thermophilic archaeon Sulfolobus acidocaldarius
5A6S	;	1.9	;	Crystal structure of the CTP1L endolysin reveals how its activity is regulated by a secondary translation product
4C2F	;	2.4	;	Crystal structure of the CtpB R168A mutant present in an active conformation
4C2H	;	1.95	;	Crystal structure of the CtpB(V118Y) mutant
7DKH	;	2.9	;	Crystal structure of the Ctr9/Paf1/Cdc73/Rtf1 quaternary complex
1Q05	;	2.2	;	Crystal structure of the Cu(I) form of E. coli CueR, a copper efflux regulator
1N63	;	1.21	;	Crystal Structure of the Cu,Mo-CO Dehydrogenase (CODH); Carbon monoxide reduced state
1N60	;	1.19	;	Crystal Structure of the Cu,Mo-CO Dehydrogenase (CODH); Cyanide-inactivated Form
1N61	;	1.3	;	Crystal Structure of the Cu,Mo-CO Dehydrogenase (CODH); Dithionite reduced state
1N5W	;	1.5	;	Crystal Structure of the Cu,Mo-CO Dehydrogenase (CODH); Oxidized form
4DYX	;	1.85	;	Crystal Structure of the Cu-adduct of Human H-Ferritin variant 4His-delta C-star
4DYY	;	1.9	;	Crystal Structure of the Cu-adduct of Human H-Ferritin variant MIC1
4DZ0	;	2.5	;	Crystal structure of the Cu-adduct of human H-Ferritin variant MIC1 labeled with a dansyl fluorophore
3HNL	;	2.2	;	Crystal structure of the Cu-induced dimer of the engineered cyt cb562 variant RIDC-1
3CE1	;	1.2	;	Crystal Structure of the Cu/Zn Superoxide Dismutase from Cryptococcus liquefaciens Strain N6
1NZI	;	1.5	;	Crystal Structure of the CUB1-EGF Interaction Domain of Complement Protease C1s
1NT0	;	2.7	;	Crystal structure of the CUB1-EGF-CUB2 region of MASP2
6ZZN	;	1.5	;	Crystal structure of the cubic catalytic core of the Mycobacterium tuberculosis branched-chain alphaketoacid acyltransferase component (E2b).
4G3O	;	1.6	;	Crystal structure of the CUE domain of the E3 ubiquitin ligase AMFR (gp78)
3NNH	;	2.7501	;	Crystal Structure of the CUGBP1 RRM1 with GUUGUUUUGUUU RNA
5N4W	;	3.9	;	Crystal structure of the Cul2-Rbx1-EloBC-VHL ubiquitin ligase complex
5CYL	;	2.77	;	Crystal structure of the CupB6 tip adhesin from Pseudomonas aeruginosa
7Z3G	;	2.1	;	Crystal structure of the cupredoxin AcoP from Acidithiobacillus ferrooxidans, H166A mutant
7Z3I	;	1.82	;	Crystal structure of the cupredoxin AcoP from Acidithiobacillus ferrooxidans, M171A mutant
7Z3F	;	1.7	;	Crystal structure of the cupredoxin AcoP from Acidithiobacillus ferrooxidans, oxidized form
7Z3B	;	1.65	;	Crystal structure of the cupredoxin AcoP from Acidithiobacillus ferrooxidans, reduced form
4O65	;	1.796	;	Crystal structure of the cupredoxin domain of amoB from Nitrosocaldus yellowstonii
5KP5	;	2.1	;	Crystal Structure of the Curacin Biosynthetic Pathway HMG Synthase
5KP8	;	1.9	;	Crystal Structure of the Curacin Biosynthetic Pathway HMG Synthase in Complex with Acetyl Donor-ACP
5KP6	;	2.05	;	Crystal Structure of the Curacin Biosynthetic Pathway HMG Synthase in Complex with Apo Donor-ACP
5KP7	;	1.6	;	Crystal Structure of the Curacin Biosynthetic Pathway HMG Synthase in Complex with Holo Donor-ACP
3NE5	;	2.898	;	Crystal structure of the CusBA heavy-metal efflux complex from Escherichia coli
4DNR	;	3.68	;	Crystal structure of the CusBA heavy-metal efflux complex from Escherichia coli, E716F mutant
4DNT	;	3.1	;	Crystal structure of the CusBA heavy-metal efflux complex from Escherichia coli, mutant
4DOP	;	4.2	;	Crystal structure of the CusBA heavy-metal efflux complex from Escherichia coli, R mutant
4Z0R	;	1.75	;	Crystal Structure of the CW domain of ZCWPW2 mutant F78R in complex with histone H3 peptide
3OE0	;	2.9	;	Crystal structure of the CXCR4 chemokine receptor in complex with a cyclic peptide antagonist CVX15
3OE6	;	3.2	;	Crystal structure of the CXCR4 chemokine receptor in complex with a small molecule antagonist IT1t in I222 spacegroup
3OE8	;	3.1	;	Crystal structure of the CXCR4 chemokine receptor in complex with a small molecule antagonist IT1t in P1 spacegroup
4BBQ	;	2.24	;	Crystal structure of the CXXC and PHD domain of Human Lysine-specific Demethylase 2A (KDM2A)(FBXL11)
5J2O	;	1.5	;	Crystal structure of the cyan fluorescence protein Cerulean S175G mutant
5B82	;	2.0	;	Crystal structure of the cyanobacterial heme-protein Tll0287
1R22	;	2.3	;	Crystal structure of the cyanobacterial metallothionein repressor SmtB (C14S/C61S/C121S mutant) in the Zn2alpha5-form
1R1T	;	1.7	;	Crystal structure of the cyanobacterial metallothionein repressor SmtB in the apo-form
1R23	;	2.0	;	Crystal structure of the cyanobacterial metallothionein repressor SmtB in the Zn1-form (one Zn(II) per dimer)
1K66	;	1.75	;	Crystal Structure of the Cyanobacterial Phytochrome Response Regulator, RcpB
5CXM	;	1.7	;	Crystal structure of the cyanobacterial plasma membrane Rieske protein PetC3 from Synechocystis PCC 6803
3W2Z	;	1.8	;	Crystal structure of the cyanobacterial protein
2E1N	;	1.8	;	Crystal structure of the Cyanobacterium circadian clock modifier Pex
6SYG	;	1.5	;	Crystal structure of the Cyclic Nucleotide-Binding Homology Domain of the human KCNH2 channel
6P3W	;	2.54	;	Crystal structure of the Cyclin A-CDK2-ORC1 complex
1QYQ	;	1.8	;	Crystal Structure of the cyclized S65G Y66G GFP variant
5WJP	;	1.57	;	Crystal structure of the cyclohexadienyl dehydratase-like solute-binding protein SAR11_1068 from Candidatus Pelagibacter ubique.
1C5F	;	2.47	;	CRYSTAL STRUCTURE OF THE CYCLOPHILIN-LIKE DOMAIN FROM BRUGIA MALAYI COMPLEXED WITH CYCLOSPORIN A
1ZKC	;	1.65	;	Crystal Structure of the cyclophiln_RING domain of human peptidylprolyl isomerase (cyclophilin)-like 2 isoform b
3E4H	;	1.8	;	Crystal structure of the cyclotide varv F
7W97	;	1.4	;	Crystal Structure of the CYP102A1 (P450BM3) Heme Domain with N-Hexadecanoyl-L-Homoserine
8HKJ	;	2.8	;	Crystal structure of the CYP102A5 haem Domain isolated from Bacillus cereus
8HGD	;	1.53	;	Crystal structure of the CYP153A mutant V456A from Marinobacter aquaeolei
8HGT	;	2.06	;	Crystal structure of the CYP153A mutant V456A from Marinobacter aquaeolei
8HGE	;	1.53	;	Crystal structure of the CYP153A mutant V456A from Marinobacter aquaeolei in complex with 12-hydroxydodecanoic acid
8HGB	;	1.54	;	Crystal structure of the CYP199A4 mutant F182G in complex with 3-hydroxy-4-methoxybenzoic acid
8HGC	;	1.72	;	Crystal structure of the CYP199A4 mutant F182T in complex with 4-methoxybenzoic acid
6JDD	;	2.6	;	Crystal structure of the cypemycin decarboxylase CypD.
6XFT	;	1.78	;	Crystal Structure of the Cys-NO Modified YopH Tyrosine Phosphatase
6ZUI	;	2.20008	;	Crystal structure of the Cys-Ser mutant of the cpYFP-based biosensor for hypochlorous acid
5XTW	;	3.2	;	Crystal structure of the CysR-CTLD2 fragment of human MR at acidic pH
6INV	;	3.3	;	Crystal structure of the CysR-CTLD2 fragment of human MR at acidic pH (pH 4.0)
6INO	;	3.054	;	Crystal structure of the CysR-CTLD2 fragment of human MR at acidic pH (pH 4.6)
6INU	;	2.65	;	Crystal structure of the CysR-CTLD2 fragment of human MR at acidic pH (pH 4.6)
6IOE	;	2.9	;	Crystal structure of the CysR-CTLD2 fragment of human MR at basic pH (pH 8.5)
8HBC	;	3.35	;	Crystal structure of the CysR-CTLD3 fragment of human DEC205
8K8H	;	2.79	;	Crystal structure of the CysR-CTLD3 fragment of human DEC205
6INN	;	3.001	;	Crystal structure of the CysR-CTLD3 fragment of human MR at acidic pH (pH 5.6)
5XTS	;	2.0	;	Crystal structure of the CysR-CTLD3 fragment of human MR at basic/neutral pH
6QB2	;	2.5	;	Crystal structure of the cystatin-based engineered protein scaffold SQT-1C
2QO5	;	1.5	;	Crystal structure of the cysteine 91 threonine mutant of zebrafish liver bile acid-binding protein complexed with cholic acid
5VCG	;	2.2	;	Crystal structure of the cysteine depleted CYP3A4 bound to bromoergocryptine
5VCD	;	1.95	;	Crystal structure of the cysteine depleted CYP3A4 bound to glycerol
5VCE	;	2.2	;	Crystal structure of the cysteine depleted CYP3A4 bound to ritonavir
5FT5	;	2.384	;	Crystal structure of the cysteine desulfurase CsdA (persulfurated) from Escherichia coli at 2.384 Angstroem resolution
5FT6	;	2.049	;	Crystal structure of the cysteine desulfurase CsdA (S-sulfonic acid) from Escherichia coli at 2.050 Angstroem resolution
5FT4	;	1.996	;	Crystal structure of the cysteine desulfurase CsdA from Escherichia coli at 1.996 Angstroem resolution
5J8Q	;	1.702	;	Crystal Structure of the Cysteine Desulfurase SufS of Bacillus subtilis
1NL6	;	2.8	;	Crystal Structure Of The Cysteine Protease Human Cathepsin K In Complex With A Covalent Azepanone Inhibitor
1NLJ	;	2.4	;	CRYSTAL STRUCTURE OF THE CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT AZEPANONE INHIBITOR
1AU2	;	2.6	;	CRYSTAL STRUCTURE OF THE CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT PROPANONE INHIBITOR
1AU3	;	2.5	;	CRYSTAL STRUCTURE OF THE CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT PYRROLIDINONE INHIBITOR
1AU4	;	2.3	;	CRYSTAL STRUCTURE OF THE CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT PYRROLIDINONE INHIBITOR
1AU0	;	2.6	;	CRYSTAL STRUCTURE OF THE CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT SYMMETRIC DIACYLAMINOMETHYL KETONE INHIBITOR
1ATK	;	2.2	;	CRYSTAL STRUCTURE OF THE CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH THE COVALENT INHIBITOR E-64
1U9V	;	2.2	;	Crystal Structure of the Cysteine Protease Human Cathepsin K in Complex with the Covalent Inhibitor NVP-ABE854
1U9W	;	2.3	;	Crystal Structure of the Cysteine Protease Human Cathepsin K in Complex with the Covalent Inhibitor NVP-ABI491
1U9X	;	2.1	;	Crystal Structure of the Cysteine Protease Human Cathepsin K in Complex with the Covalent Inhibitor NVP-ABJ688
3M86	;	1.65	;	Crystal structure of the cysteine protease inhibitor, EhICP2, from Entamoeba histolytica
3M88	;	1.9	;	Crystal structure of the cysteine protease inhibitor, EhICP2, from Entamoeba histolytica
1DQG	;	1.7	;	CRYSTAL STRUCTURE OF THE CYSTEINE RICH DOMAIN OF MANNOSE RECEPTOR
1DQO	;	2.2	;	Crystal structure of the cysteine rich domain of mannose receptor complexed with Acetylgalactosamine-4-sulfate
5BPB	;	2.2	;	Crystal structure of the cysteine-rich domain of human Frizzled 4 - Crystal Form I
5BPQ	;	2.4	;	Crystal structure of the cysteine-rich domain of human Frizzled 4 - Crystal Form II
1FWV	;	2.2	;	CRYSTAL STRUCTURE OF THE CYSTEINE-RICH DOMAIN OF MANNOSE RECEPTOR COMPLEXED WITH 3-SO4-LEWIS(A)
1FWU	;	1.9	;	CRYSTAL STRUCTURE OF THE CYSTEINE-RICH DOMAIN OF MANNOSE RECEPTOR COMPLEXED WITH 3-SO4-LEWIS(X)
1IJY	;	1.35	;	CRYSTAL STRUCTURE OF THE CYSTEINE-RICH DOMAIN OF MOUSE FRIZZLED 8 (MFZ8)
1IJX	;	1.9	;	CRYSTAL STRUCTURE OF THE CYSTEINE-RICH DOMAIN OF SECRETED FRIZZLED-RELATED PROTEIN 3 (SFRP-3;FZB)
8OIH	;	1.86	;	Crystal structure of the cysteine-rich Gallus gallus urate oxidase in complex with the 8-azaxanthine inhibitor under oxidising conditions (space group C 2 2 21)
8OIW	;	1.89	;	Crystal structure of the cysteine-rich Gallus gallus urate oxidase in complex with the 8-azaxanthine inhibitor under oxidising conditions (space group P 21 21 21)
8OFK	;	1.713	;	Crystal structure of the cysteine-rich Gallus gallus urate oxidase in complex with the 8-azaxanthine inhibitor under reducing conditions (space group C 2 2 21)
8OH8	;	2.12	;	Crystal structure of the cysteine-rich Gallus gallus urate oxidase in complex with the 8-azaxanthine inhibitor under reducing conditions (space group P 21 21 21)
1ELQ	;	1.8	;	CRYSTAL STRUCTURE OF THE CYSTINE C-S LYASE C-DES
3B8F	;	1.9	;	Crystal structure of the cytidine deaminase from Bacillus anthracis
5YLY	;	1.76	;	Crystal structure of the cytochrome b5 reductase domain of Ulva prolifera nitrate reductase
2E74	;	3.0	;	Crystal Structure of the Cytochrome b6f Complex from M.laminosus
4H13	;	3.07	;	Crystal Structure of the Cytochrome b6f Complex from Mastigocladus laminosus with TDS
2ZT9	;	3.0	;	Crystal Structure of the Cytochrome b6f Complex from Nostoc sp. PCC 7120
2E75	;	3.55	;	Crystal Structure of the Cytochrome b6f Complex with 2-nonyl-4-hydroxyquinoline N-oxide (NQNO) from M.laminosus
2E76	;	3.41	;	Crystal Structure of the Cytochrome b6f Complex with tridecyl-stigmatellin (TDS) from M.laminosus
1YNR	;	2.0	;	Crystal structure of the cytochrome c-552 from Hydrogenobacter thermophilus at 2.0 resolution
2D0S	;	2.2	;	Crystal structure of the Cytochrome C552 from moderate thermophilic bacterium, hydrogenophilus thermoluteolus
3CXV	;	1.7	;	Crystal structure of the Cytochrome P450 CYP121 A233G mutant from Mycobacterium tuberculosis
3CXY	;	1.45	;	Crystal structure of the cytochrome P450 CYP121 P346L mutant from M. tuberculosis
3CY1	;	1.75	;	Crystal structure of the cytochrome P450 CYP121 S279A mutant from M. tuberculosis
8SPC	;	1.871	;	Crystal structure of the cytochrome P450 enzyme RufO
4L36	;	2.104	;	Crystal structure of the cytochrome P450 enzyme TxtE
3P3X	;	2.3	;	Crystal Structure of the Cytochrome P450 Monooxygenase AurH (nterm-AurH-I) from Streptomyces Thioluteus
3P3O	;	1.54	;	Crystal Structure of the Cytochrome P450 Monooxygenase AurH (ntermII) from Streptomyces Thioluteus
3P3L	;	2.1	;	Crystal Structure of the Cytochrome P450 monooxygenase AurH (wildtype) from Streptomyces Thioluteus
3P3Z	;	2.3	;	Crystal Structure of the Cytochrome P450 Monooxygenase AurH from Streptomyces Thioluteus in Complex with Ancymidol
2CP4	;	2.1	;	CRYSTAL STRUCTURE OF THE CYTOCHROME P450-CAM ACTIVE SITE MUTANT THR252ALA
3CP4	;	2.3	;	CRYSTAL STRUCTURE OF THE CYTOCHROME P450-CAM ACTIVE SITE MUTANT THR252ALA
4CP4	;	2.1	;	CRYSTAL STRUCTURE OF THE CYTOCHROME P450-CAM ACTIVE SITE MUTANT THR252ALA
3UA1	;	2.15	;	Crystal structure of the cytochrome P4503A4-bromoergocryptine complex
4AKR	;	2.2	;	Crystal Structure of the cytoplasmic actin capping protein Cap32_34 from Dictyostelium discoideum
6H3P	;	2.7	;	Crystal structure of the cytoplasmic chorismate mutase from Zea mays
5M0J	;	2.8	;	Crystal structure of the cytoplasmic complex with She2p, She3p, and the ASH1 mRNA E3-localization element
1XAW	;	1.45	;	crystal structure of the cytoplasmic distal C-terminal domain of occludin
2CH7	;	2.5	;	Crystal structure of the cytoplasmic domain of a bacterial chemoreceptor from Thermotoga maritima
3G40	;	1.9	;	Crystal structure of the cytoplasmic domain of a prokaryotic cation chloride cotransporter
3VHJ	;	1.9	;	Crystal structure of the cytoplasmic domain of BfpC
6CH3	;	2.68	;	Crystal structure of the cytoplasmic domain of FlhA and FliS-FliC complex
6CH2	;	2.7	;	Crystal structure of the cytoplasmic domain of FlhA and FliT-FliD complex
6CH1	;	1.9	;	Crystal structure of the cytoplasmic domain of FlhA in monomeric form
3B1S	;	2.55	;	Crystal structure of the cytoplasmic domain of FlhB from Aquifex aeolicus
6Z0W	;	2.1	;	Crystal structure of the cytoplasmic domain of FlhB from Shewanella putrefaciens
1N9P	;	1.8	;	Crystal Structure of the Cytoplasmic Domain of G-protein Activated Inward Rectifier Potassium Channel 1
2E4F	;	2.302	;	Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2
3VSQ	;	2.0	;	Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2 E236R Mutant in the presence of ethanol
3AGW	;	2.2	;	Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2 in the absence of Na+
1HYN	;	2.6	;	CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF HUMAN ERYTHROCYTE BAND-3 PROTEIN
3HM6	;	2.402	;	Crystal structure of the cytoplasmic domain of human plexin B1
2VT1	;	2.0	;	Crystal structure of the cytoplasmic domain of Spa40, the specificity switch for the Shigella flexneri Type III Secretion System
3MDY	;	2.05	;	Crystal structure of the cytoplasmic domain of the bone morphogenetic protein receptor type-1B (BMPR1B) in complex with FKBP12 and LDN-193189
2D4Z	;	3.1	;	Crystal structure of the cytoplasmic domain of the chloride channel ClC-0
2PFI	;	1.6	;	Crystal structure of the cytoplasmic domain of the human chloride channel ClC-Ka
5COS	;	2.019	;	Crystal Structure of the Cytoplasmic Domain of the Pseudomonas putida Anti-sigma Factor PupR
5CAM	;	2.171	;	Crystal Structure of the Cytoplasmic Domain of the Pseudomonas putida Anti-sigma Factor PupR (SeMet)
1B6C	;	2.6	;	CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
4ECL	;	2.017	;	Crystal structure of the cytoplasmic domain of vancomycin resistance serine racemase VanTg
2JLH	;	1.53	;	Crystal Structure of the Cytoplasmic domain of Yersinia Pestis YscU N263A mutant
2JLJ	;	1.3	;	Crystal Structure of the cytoplasmic domain of Yersinia pestis YscU N263A P264A mutant
3QMZ	;	6.0	;	Crystal structure of the cytoplasmic dynein heavy chain motor domain
3RRK	;	2.64	;	Crystal structure of the cytoplasmic N-terminal domain of subunit I, homolog of subunit a, of V-ATPase
4A0E	;	2.042	;	Crystal structure of the cytoplasmic N-terminal domain of Yersinia pestis YscD
3LBS	;	2.15	;	Crystal structure of the cytoplasmic tail of (pro)renin receptor as a MBP fusion (Maltose-bound form)
3LC8	;	2.0	;	Crystal structure of the cytoplasmic tail of (pro)renin receptor as a MBP fusion (Maltose-free form)
3G3O	;	2.1	;	Crystal structure of the cytoplasmic tunnel domain in yeast Vtc2p
3MIX	;	2.3	;	Crystal structure of the cytosolic domain of B. subtilis FlhA
3QNU	;	2.8	;	Crystal structure of the cytosolic domain of human atlastin-1 in complex with GDP, hexagonal form
3QOF	;	2.802	;	Crystal structure of the cytosolic domain of human atlastin-1 in complex with GDP, orthorhombic form
6N7E	;	3.5	;	Crystal structure of the cytosolic domain of human CNNM2 in complex with AMP-PNP and Mg2+
6MN6	;	3.36	;	Crystal structure of the cytosolic domain of human CNNM3
4NXT	;	2.12	;	Crystal structure of the cytosolic domain of human MiD51
4NXU	;	2.3	;	Crystal structure of the cytosolic domain of human MiD51
4NXV	;	2.3	;	Crystal structure of the cytosolic domain of human MiD51
4NXW	;	2.55	;	Crystal structure of the cytosolic domain of human MiD51
4NXX	;	2.55	;	Crystal structure of the cytosolic domain of human MiD51
5X9B	;	2.7	;	Crystal structure of the cytosolic domain of human MiD51
5X9C	;	1.85	;	Crystal structure of the cytosolic domain of human MiD51
4OAF	;	2.2	;	Crystal structure of the cytosolic domain of mouse MiD51
4OAG	;	2.0	;	Crystal structure of the cytosolic domain of mouse MiD51 bound to ADP
4OAI	;	2.0	;	Crystal structure of the cytosolic domain of mouse MiD51 dimer mutant
4OAH	;	2.0	;	Crystal structure of the cytosolic domain of mouse MiD51 H201A mutant
2ZZT	;	2.842	;	Crystal structure of the cytosolic domain of the cation diffusion facilitator family protein
5N77	;	2.8	;	Crystal structure of the cytosolic domain of the CorA magnesium channel from Escherichia coli in complex with magnesium
5N78	;	2.85	;	Crystal structure of the cytosolic domain of the CorA Mg2+ channel from Escherichia coli in complex with magnesium and cobalt hexammine
5X9G	;	3.0	;	Crystal structure of the cytosolic domain of the Mg2+ channel MgtE in complex with ATP
7MP8	;	3.0	;	Crystal structure of the cytosolic domain of Tribolium castaneum PINK1 in the non-phosphorylated state
7MP9	;	2.8	;	Crystal structure of the cytosolic domain of Tribolium castaneum PINK1 phosphorylated at Ser205 in complex with ADP analog
2BDE	;	2.9	;	Crystal Structure of the cytosolic IMP-GMP specific 5'-nucleotidase (lpg0095) from Legionella pneumophila, Northeast Structural Genomics Target LgR1
1RH1	;	2.5	;	crystal structure of the cytotoxic bacterial protein colicin B at 2.5 A resolution
6OSU	;	2.44	;	Crystal Structure of the D-alanyl-D-alanine carboxypeptidase DacD from Francisella tularensis
2H6E	;	1.8	;	Crystal structure of the D-arabinose dehydrogenase from Sulfolobus solfataricus
5T47	;	2.2	;	Crystal structure of the D. melanogaster eIF4E-eIF4G complex
5T48	;	2.19	;	Crystal structure of the D. melanogaster eIF4E-eIF4G complex without lateral contact
4NK7	;	3.233	;	Crystal Structure of the D. melanogaster Plk4 cryptic polo box (CPB)
6XQK	;	2.56	;	Crystal structure of the D/D domain of PKA from S. cerevisiae
4JJH	;	2.25	;	Crystal structure of the D1 domain from human Nectin-4 extracellular fragment [PSI-NYSGRC-005624]
2QEP	;	2.5	;	Crystal structure of the D1 domain of PTPRN2 (IA2beta)
1CZQ	;	1.5	;	CRYSTAL STRUCTURE OF THE D10-P1/IQN17 COMPLEX: A D-PEPTIDE INHIBITOR OF HIV-1 ENTRY BOUND TO THE GP41 COILED-COIL POCKET.
2Q3I	;	1.5	;	Crystal structure of the D10-P3/IQN17 complex: a D-peptide inhibitor of HIV-1 entry bound to the GP41 coiled-coil pocket
3K7J	;	1.9	;	Crystal structure of the D100E mutant of the Indian Hedgehog N-terminal signalling domain
6VWE	;	2.5	;	Crystal structure of the D100R multidrug binding transcriptional regulator LmrR in complex with Rhodium Bis-diphosphine Complex
5N4H	;	1.701	;	Crystal structure of the D109N mutant of the mouse alpha-Dystroglycan N-terminal region
6YBY	;	1.8	;	Crystal structure of the D116N mutant of the light-driven sodium pump KR2 in the monomeric form, pH 4.6
6YBZ	;	2.35	;	Crystal structure of the D116N mutant of the light-driven sodium pump KR2 in the pentameric form, pH 8.0
3B3T	;	1.17	;	Crystal structure of the D118N mutant of the aminopeptidase from Vibrio proteolyticus
5TNS	;	1.75	;	Crystal structure of the D129S mutant of the CFTR inhibitory factor Cif containing 1,2-Epoxycyclohexane
1SWV	;	2.3	;	Crystal structure of the D12A mutant of phosphonoacetaldehyde hydrolase complexed with magnesium
1GOI	;	1.45	;	Crystal structure of the D140N mutant of chitinase B from Serratia marcescens at 1.45 A resolution
5SYJ	;	1.88	;	Crystal structure of the D141A variant of B. pseudomallei KatGin complex with isoniazid
5KSF	;	1.75	;	Crystal structure of the D141A variant of the catalase-peroxidase from B. pseudomallei treated with acetate
5KQ3	;	1.85	;	Crystal structure of the D141A/Q233E variant of catalase-peroxidase from B. pseudomallei
5V4O	;	1.95	;	Crystal structure of the D141A/Q233E/N240D variant of catalase-peroxidase from B. pseudomallei
5V53	;	1.7	;	Crystal structure of the D141A/Q233E/N240D variant of catalase-peroxidase from B. pseudomallei with acetate bound
5SX2	;	2.15	;	Crystal structure of the D141E mutant of B. pseudomallei KatG at pH 8.0.
6CEK	;	1.8	;	Crystal structure of the D141N variant of catalase-peroxidase from B. pseudomallei
6CFQ	;	1.72	;	Crystal structure of the D141N variant of catalase-peroxidase from B. pseudomallei with INH bound
1S08	;	2.1	;	Crystal Structure of the D147N Mutant of 7,8-Diaminopelargonic Acid Synthase
3PPW	;	1.9	;	Crystal structure of the D1596A mutant of an engineered VWF A2 domain (N1493C and C1670S)
3PPY	;	2.0	;	Crystal structure of the D1596A/N1602A double mutant of an engineered VWF A2 domain (N1493C and C1670S)
5V3Z	;	1.881	;	Crystal Structure of the D1607N mutant form of Thioesterase domain of Mtb Pks13
1P7Y	;	2.4	;	Crystal structure of the D181A variant of catalase HPII from E. coli
1P81	;	1.81	;	Crystal structure of the D181E variant of catalase HPII from E. coli
1P80	;	1.65	;	Crystal structure of the D181Q variant of catalase HPII from E. coli
1P7Z	;	2.21	;	Crystal structure of the D181S variant of catalase HPII from E. coli
5LUC	;	1.8	;	Crystal structure of the D183N variant of human Alanine:Glyoxylate Aminotransferase major allele (AGT-Ma) at 1.8 Angstrom; internal aldimine with PLP in the active site
5OFY	;	2.8	;	Crystal structure of the D183N variant of human Alanine:Glyoxylate Aminotransferase major allele (AGT-Ma) at pH 9.0. 2.8 Ang; internal aldimine with PLP in the active site
1B34	;	2.5	;	CRYSTAL STRUCTURE OF THE D1D2 SUB-COMPLEX FROM THE HUMAN SNRNP CORE DOMAIN
1P15	;	2.0	;	Crystal structure of the D2 domain of RPTPa
1EJR	;	2.0	;	CRYSTAL STRUCTURE OF THE D221A VARIANT OF KLEBSIELLA AEROGENES UREASE
1LO5	;	3.2	;	Crystal structure of the D227A variant of Staphylococcal enterotoxin A in complex with human MHC class II
4DI9	;	1.35	;	CRYSTAL STRUCTURE OF THE D248A mutant of 2-PYRONE-4,6-DICARBOXYLIC ACID HYDROLASE FROM SPHINGOMONAS PAUCIMOBILIS complexed with substrate at pH 6.5
4DI8	;	1.81	;	CRYSTAL STRUCTURE OF THE D248A mutant of 2-PYRONE-4,6-DICARBOXYLIC ACID HYDROLASE FROM SPHINGOMONAS PAUCIMOBILIS complexed with substrate at pH 8.5
4DIA	;	2.0	;	CRYSTAL STRUCTURE OF THE D248N mutant of 2-PYRONE-4,6-DICARBOXYLIC ACID HYDROLASE FROM SPHINGOMONAS PAUCIMOBILIS complexed with substrate at pH 4.6
5TR2	;	2.5	;	Crystal structure of the D263G missense variant of human PGM1
5JN5	;	1.75	;	Crystal structure of the D263Y missense variant of human PGM1
1X09	;	1.87	;	Crystal structure of the D26A mutant UPPs in complex with magnesium and isopentenyl pyrophosphate
2VHV	;	2.8	;	Crystal structure of the D270A mutant of L-alanine dehydrogenase from Mycobacterium tuberculosis in complex with NADH.
6OU0	;	1.799	;	Crystal Structure of the D380A/D478S Variant of the Myocilin Olfactomedin Domain
3R77	;	1.9	;	Crystal structure of the D38A mutant of isochorismatase PhzD from Pseudomonas fluorescens 2-79 in complex with 2-amino-2-desoxyisochorismate ADIC
4RMR	;	1.529	;	Crystal structure of the D38N Beta-2 Microglobulin mutant
1D3B	;	2.0	;	CRYSTAL STRUCTURE OF THE D3B SUBCOMPLEX OF THE HUMAN CORE SNRNP DOMAIN AT 2.0A RESOLUTION
5J5Z	;	1.84	;	Crystal structure of the D444V disease-causing mutant of the human dihydrolipoamide dehydrogenase
6OU2	;	1.963	;	Crystal Structure of the D478N Variant of the Myocilin Olfactomedin Domain
6OU3	;	1.796	;	Crystal Structure of the D478S Variant of the Myocilin Olfactomedin Domain
1GMZ	;	2.4	;	Crystal structure of the D49 phospholipase A2 piratoxin III from Bothrops pirajai.
2XJB	;	2.3	;	Crystal structure of the D52N variant of cytosolic 5'-nucleotidase II in complex with deoxyguanosine monophosphate and deoxyadenosine triphosphate
2XJC	;	2.0	;	Crystal structure of the D52N variant of cytosolic 5'-nucleotidase II in complex with guanosine monophosphate and diadenosine tetraphosphate
2XJD	;	2.0	;	Crystal structure of the D52N variant of cytosolic 5'-nucleotidase II in complex with inorganic phosphate and deoxyadenosine triphosphate
2XCV	;	2.3	;	Crystal structure of the D52N variant of cytosolic 5'-nucleotidase II in complex with inosine monophosphate and 2,3-bisphosphoglycerate
2XCW	;	1.9	;	Crystal structure of the D52N variant of cytosolic 5'-nucleotidase II in complex with inosine monophosphate and ATP
2XJE	;	2.3	;	Crystal structure of the D52N variant of cytosolic 5'-nucleotidase II in complex with uridine 5'-monophosphate and adenosine triphosphate
2XJF	;	2.1	;	Crystal structure of the D52N variant of cytosolic 5'-nucleotidase II with a covalently modified Asn52
4RMS	;	1.7	;	Crystal structure of the D53N Beta-2 Microglobulin mutant
2VUH	;	2.5	;	Crystal structure of the D55E mutant of the HupR receiver domain
1S2U	;	2.0	;	Crystal structure of the D58A phosphoenolpyruvate mutase mutant protein
4RMQ	;	1.461	;	Crystal structure of the D59N Beta-2 Microglobulin mutant
1OQG	;	1.9	;	Crystal structure of the D63E mutant of the N-lobe human transferrin
4I9L	;	2.6	;	Crystal structure of the D714A mutant of RB69 DNA polymerase
4FTE	;	3.5	;	Crystal structure of the D75N mutant capsid of Flock House virus
4RMW	;	1.4	;	Crystal structure of the D76A Beta-2 Microglobulin mutant
4RMU	;	1.4	;	Crystal structure of the D76E Beta-2 Microglobulin mutant
4RMV	;	1.463	;	Crystal structure of the D76H Beta-2 Microglobulin mutant
4FXL	;	1.4	;	Crystal structure of the D76N Beta-2 Microglobulin mutant
3GDR	;	1.9	;	Crystal structure of the D91N mutant of the orotidine 5'-monophosphate decarboxylase from Saccharomyces cerevisiae
3GDT	;	1.6	;	Crystal structure of the D91N mutant of the orotidine 5'-monophosphate decarboxylase from Saccharomyces cerevisiae complexed with 6-azauridine 5'-monophosphate
3VBN	;	2.5	;	Crystal Structure of the D94A mutant of AntD, an N-acyltransferase from Bacillus cereus in complex with dTDP and Coenzyme A
3VBP	;	2.3	;	Crystal Structure of the D94N mutant of AntD, an N-acyltransferase from Bacillus cereus in complex with dTDP and Coenzyme A
2WOE	;	1.9	;	Crystal Structure of the D97N variant of dinitrogenase reductase- activating glycohydrolase (DRAG) from Rhodospirillum rubrum in complex with ADP-ribose
4RMT	;	1.242	;	Crystal structure of the D98N Beta-2 Microglobulin mutant
1SBX	;	1.65	;	Crystal structure of the Dachshund-homology domain of human SKI
7BJI	;	2.58	;	Crystal structure of the Danio rerio centrosomal protein Cep135 coiled-coil fragment 64-190
3WOJ	;	2.2	;	Crystal structure of the DAP BII
4Y06	;	2.18	;	Crystal structure of the DAP BII (G675R) dipeptide complex
3WOI	;	2.1	;	Crystal structure of the DAP BII (S657A)
3WOK	;	1.95	;	Crystal structure of the DAP BII (Space)
3WOL	;	1.74	;	Crystal structure of the DAP BII dipeptide complex I
3WOM	;	1.86	;	Crystal structure of the DAP BII dipeptide complex II
3WON	;	1.75	;	Crystal structure of the DAP BII dipeptide complex III
3WOO	;	1.8	;	Crystal structure of the DAP BII hexapeptide complex I
3WOP	;	1.95	;	Crystal structure of the DAP BII hexapeptide complex II
3WOQ	;	1.82	;	Crystal structure of the DAP BII hexapeptide complex III
3WOR	;	2.1	;	Crystal structure of the DAP BII octapeptide complex
4WO1	;	2.14	;	Crystal structure of the DAP12 transmembrane domain in lipid cubic phase
4WOL	;	1.77	;	Crystal Structure of the DAP12 transmembrane domain in lipidic cubic phase
6E20	;	2.0	;	Crystal structure of the Dario rerio galectin-1-L2
1XMZ	;	1.38	;	Crystal structure of the dark state of kindling fluorescent protein kfp from anemonia sulcata
5AKP	;	3.25	;	Crystal structure of the dark-adapted full-length bacteriophytochrome XccBphP from Xanthomonas campestris bound to BV chromophore
6PL0	;	2.96	;	Crystal structure of the dark-adapted full-length bacteriophytochrome XccBphP from Xanthomonas campestris in the Pr state bound to BV chromophore
5UYR	;	3.45	;	Crystal structure of the dark-adapted full-length bacteriophytochrome XccBphP mutant D199A from Xanthomonas campestris
6NDO	;	3.58	;	Crystal structure of the dark-adapted full-length bacteriophytochrome XccBphP mutant L193N from Xanthomonas campestris
6NDP	;	3.89	;	Crystal structure of the dark-adapted full-length bacteriophytochrome XccBphP mutant L193Q from Xanthomonas campestris
7L59	;	2.68	;	Crystal structure of the dark-adapted full-length bacteriophytochrome XccBphP-G454E variant from Xanthomonas campestris in the Pfr state
5H76	;	2.6	;	Crystal structure of the DARPin-Protein A fusion protein
3UUS	;	5.65	;	Crystal structure of the dATP inhibited E. coli class Ia ribonucleotide reductase complex
4ERM	;	3.95	;	Crystal structure of the dATP inhibited E. coli class Ia ribonucleotide reductase complex at 4 Angstroms resolution
5CNU	;	3.4	;	Crystal structure of the dATP inhibited E. coli class Ia ribonucleotide reductase complex bound to ADP and dGTP at 3.40 Angstroms resolution
5CNS	;	2.975	;	Crystal structure of the dATP inhibited E. coli class Ia ribonucleotide reductase complex bound to CDP and dATP at 2.97 Angstroms resolution
5CNV	;	3.2	;	Crystal structure of the dATP inhibited E. coli class Ia ribonucleotide reductase complex bound to GDP and TTP at 3.20 Angstroms resolution
5CNT	;	3.25	;	Crystal structure of the dATP inhibited E. coli class Ia ribonucleotide reductase complex bound to UDP and dATP at 3.25 Angstroms resolution
2NLM	;	2.05	;	Crystal structure of the DB 911- D(CGCGAATTCGCG)2 complex at 2.05 A resolution.
4AH1	;	1.42	;	CRYSTAL STRUCTURE OF THE DB 921-D(CGCAAATTTGCG)2 COMPLEX AT 1.42 A RESOLUTION
4AH0	;	1.2	;	CRYSTAL STRUCTURE OF THE DB 985-D(CGCAAATTTGCG)2 COMPLEX AT 1.20 A RESOLUTION
4AGZ	;	1.25	;	CRYSTAL STRUCTURE OF THE DB 985-D(CGCGAATTCGCG)2 COMPLEX AT 1.25 A RESOLUTION.
3OIE	;	1.9	;	Crystal structure of the DB1880-D(CGCGAATTCGCG)2 complex
3U0U	;	1.24	;	Crystal structure of the DB1883-D(CGCGAATTCGCG)2 complex at 1.24 A resolution
2I2I	;	1.63	;	Crystal structure of the DB293-D(CGCGAATTCGCG)2 complex.
2B0K	;	1.64	;	Crystal structure of the DB921-D(CGCGAATTCGCG)2 complex.
4HTO	;	2.8068	;	Crystal structure of the DBD domain of human DNA ligase IV Apo form
4HTP	;	2.2502	;	Crystal structure of the DBD domain of human DNA ligase IV bound to Artemis peptide
5MR7	;	2.5	;	Crystal structure of the DBD domain of human Grhl2
1LB1	;	2.81	;	Crystal Structure of the Dbl and Pleckstrin homology domains of Dbs in complex with RhoA
5N7E	;	1.647	;	Crystal structure of the Dbl-homology domain of Bcr-Abl in complex with monobody Mb(Bcr-DH_4).
3CML	;	1.9	;	Crystal Structure of the DBL3x domain of the Plasmodium falcipurum VAR2CSA protein
4P1T	;	2.9	;	Crystal structure of the DBL3X-DBL4epsilon double domain from the extracellular part of VAR2CSA PfEMP1 from Plasmodium falciparum
8BW8	;	2.1	;	Crystal structure of the dCNK-SAM-CRIC-PDZ/dHYP-SAM complex
1W79	;	1.8	;	Crystal structure of the DD-transpeptidase-carboxypeptidase from Actinomadura R39
1W8Q	;	2.85	;	Crystal Structure of the DD-Transpeptidase-carboxypeptidase from Actinomadura R39
2B5N	;	2.8	;	Crystal Structure of the DDB1 BPB Domain
2HYE	;	3.1	;	Crystal Structure of the DDB1-Cul4A-Rbx1-SV5V Complex
2WUH	;	1.6	;	Crystal structure of the DDR2 discoidin domain bound to a triple- helical collagen peptide
5GVR	;	1.5	;	Crystal structure of the DDX41 DEAD domain in an apo closed form
5GVS	;	2.2	;	Crystal structure of the DDX41 DEAD domain in an apo open form
5H1Y	;	2.26	;	Crystal structure of the DDX41 DEAD domain in complex with SO42- and Mg2+
7RDH	;	2.75	;	Crystal structure of the de novo designed binding protein H3mb in complex with the 1968 influenza A virus hemagglutinin
3R2X	;	3.1	;	Crystal structure of the de novo designed binding protein HB36.3 in complex the the 1918 influenza virus hemagglutinin
4G4M	;	1.48	;	Crystal structure of the de novo designed fluorinated peptide alpha4F3(6-13)
3TWF	;	1.54	;	Crystal structure of the de novo designed fluorinated peptide alpha4F3a
3TWG	;	1.72	;	Crystal structure of the de novo designed fluorinated peptide alpha4F3af3d
4G3B	;	1.19	;	Crystal structure of the de novo designed fluorinated peptide alpha4F3d
3TWE	;	1.36	;	Crystal Structure of the de novo designed peptide alpha4H
4G4L	;	1.54	;	Crystal structure of the de novo designed peptide alpha4tbA6
7AH0	;	1.91	;	Crystal structure of the de novo designed two-heme binding protein, 4D2
5JG9	;	2.09	;	Crystal structure of the de novo mini protein gEHEE_06
5LNB	;	2.3	;	Crystal structure of the de-sumoylating protease
7LJK	;	1.81	;	Crystal structure of the deacylation deficient KPC-2 F72Y mutant
1S2M	;	2.1	;	Crystal Structure of the DEAD box protein Dhh1p
5ZBZ	;	1.3086	;	Crystal structure of the DEAD domain of Human eIF4A with sanguinarine
3BOR	;	1.85	;	Crystal structure of the DEADc domain of human translation initiation factor 4A-2
6ZM2	;	2.1	;	Crystal structure of the DEAH-box ATPase Prp2 in complex with ADP-BeF3 and ssRNA
6RM8	;	1.95	;	Crystal structure of the DEAH-box ATPase Prp2 in complex with Spp2 and ADP
6RM9	;	1.85	;	Crystal structure of the DEAH-box ATPase Prp2 in complex with Spp2 and ADP
6RMA	;	2.1	;	Crystal structure of the DEAH-box ATPase Prp2 in complex with Spp2 and ADP
6RMB	;	2.5	;	Crystal structure of the DEAH-box ATPase Prp2 in complex with Spp2 and ADP
6RMC	;	2.6	;	Crystal structure of the DEAH-box ATPase Prp2 in complex with Spp2 and ADP
6FA9	;	2.6	;	CRYSTAL STRUCTURE OF THE DEAH-BOX HELICASE PRP2
6FA5	;	2.303	;	CRYSTAL STRUCTURE OF THE DEAH-BOX HELICASE PRP2 IN COMPLEX WITH ADP
6FAA	;	1.97	;	CRYSTAL STRUCTURE OF THE DEAH-BOX HELICASE PRP2 IN COMPLEX WITH ADP
6FAC	;	2.05	;	CRYSTAL STRUCTURE OF THE DEAH-BOX HELICASE PRP2 IN COMPLEX WITH ADP
5YM9	;	2.5	;	Crystal Structure of the Deamidase from Legionella pneumophila
3F5U	;	2.0	;	Crystal structure of the death associated protein kinase in complex with AMPPNP and Mg2+
6OHI	;	2.27	;	Crystal Structure of the Debrominase Bmp8 (Apo)
6OHJ	;	3.19	;	Crystal Structure of the Debrominase Bmp8 C82A in Complex with 2,3,4-tribromopyrrole
3HQE	;	2.94	;	Crystal Structure of the decamer CGGGCGCCCG forming a Holliday junction
3TCI	;	2.421	;	Crystal structure of the decameric sequence d(CGGGCGCCCG) as Z type duplex
5MZW	;	1.52	;	Crystal structure of the decarboxylase AibA/AibB
5N00	;	1.9	;	Crystal structure of the decarboxylase AibA/AibB C56A variant
5N01	;	1.95	;	Crystal structure of the decarboxylase AibA/AibB C56N variant
5N02	;	1.9	;	Crystal structure of the decarboxylase AibA/AibB C56S variant
5N03	;	2.1	;	Crystal structure of the decarboxylase AibA/AibB C56V variant
5MZZ	;	2.3	;	Crystal structure of the decarboxylase AibA/AibB in complex with 3-methylglutaconate
5MZX	;	2.0	;	Crystal structure of the decarboxylase AibA/AibB in complex with 4'-diphospho pantetheine
5MZY	;	1.6	;	Crystal structure of the decarboxylase AibA/AibB in complex with a possible transition state analog
8PNK	;	2.2	;	Crystal structure of the Ded1p RecA1 domain
3UM9	;	2.19	;	Crystal Structure of the Defluorinating L-2-Haloacid Dehalogenase Bpro0530
3UMG	;	2.25	;	Crystal Structure of the Defluorinating L-2-Haloacid Dehalogenase Rha0230
2DTS	;	2.2	;	Crystal Structure of the Defucosylated Fc Fragment from Human Immunoglobulin G1
3DJD	;	1.75	;	Crystal structure of the deglycating enzyme fructosamine oxidase from Aspergillus fumigatus (Amadoriase II)
3DJE	;	1.6	;	Crystal structure of the deglycating enzyme fructosamine oxidase from Aspergillus fumigatus (Amadoriase II) in complex with FSA
3OTP	;	3.76	;	Crystal structure of the DegP dodecamer with a model substrate
6JJK	;	3.6	;	Crystal structure of the DegP dodecamer with a modulator
6JJL	;	4.2	;	Crystal structure of the DegP dodecamer with a modulator
6JJO	;	4.157	;	Crystal structure of the DegP dodecamer with a modulator
2R3Y	;	2.5	;	Crystal structure of the DegS protease in complex with the YWF activating peptide
1SOT	;	2.3	;	Crystal Structure of the DegS stress sensor
4LN9	;	1.82	;	Crystal structure of the dehydratase domain from the terminal module of the rifamycin polyketide synthase
5HST	;	2.1	;	Crystal structure of the dehydratase domain of MlnB from Bacillus amyloliquefaciens
5IL5	;	2.91	;	Crystal structure of the dehydratase domain of MlnD from Bacillus amyloliquefaciens
5IL6	;	1.9	;	Crystal structure of the dehydratase domain of RzxB from Pseudomonas fluorescens
3K6J	;	2.2	;	Crystal structure of the dehydrogenase part of multifuctional enzyme 1 from C.elegans
5OJG	;	1.9	;	Crystal structure of the dehydrogenase/reductase SDR family member 4 (DHRS4) from Caenorhabditis elegans
5OJI	;	1.6	;	Crystal structure of the dehydrogenase/reductase SDR family member 4 (DHRS4) from Caenorhabditis elegans
6C3I	;	2.95013	;	Crystal structure of the Deinococcus radiodurans Nramp/MntH divalent transition metal transporter G45R mutant in an inward occluded state
6D91	;	2.356	;	Crystal structure of the Deinococcus radiodurans Nramp/MntH divalent transition metal transporter in the outward-open, apo conformation
1A5T	;	2.2	;	CRYSTAL STRUCTURE OF THE DELTA PRIME SUBUNIT OF THE CLAMP-LOADER COMPLEX OF ESCHERICHIA COLI DNA POLYMERASE III
5ZWP	;	1.4	;	Crystal structure of the delta-class glutathione transferase from Musca domestica
4IDM	;	2.5	;	Crystal structure of the Delta-pyrroline-5-carboxylate dehydrogenase from Mycobacterium tuberculosis
4IDS	;	2.04	;	Crystal structure of the Delta-pyrroline-5-carboxylate dehydrogenase from Mycobacterium tuberculosis
4JDC	;	1.6	;	Crystal structure of the Delta-pyrroline-5-carboxylate dehydrogenase from Mycobacterium tuberculosis
4LEM	;	2.27	;	Crystal structure of the Delta-pyrroline-5-carboxylate dehydrogenase from Mycobacterium tuberculosis
4IHI	;	2.25	;	Crystal structure of the Delta-pyrroline-5-carboxylate dehydrogenase from Mycobacterium tuberculosis bound with NAD
4NS3	;	2.38	;	Crystal structure of the Delta-pyrroline-5-carboxylate dehydrogenase from Mycobacterium tuberculosis bound with NAD and cobalamin
1FY8	;	1.7	;	CRYSTAL STRUCTURE OF THE DELTAILE16VAL17 RAT ANIONIC TRYPSINOGEN-BPTI COMPLEX
1OK8	;	2.0	;	Crystal structure of the dengue 2 virus envelope glycoprotein in the postfusion conformation
1OAN	;	2.75	;	Crystal structure of the dengue 2 virus envelope protein
1OKE	;	2.4	;	Crystal structure of the dengue 2 virus envelope protein in complex with n-octyl-beta-D-glucoside
1UZG	;	3.5	;	CRYSTAL STRUCTURE OF THE DENGUE TYPE 3 VIRUS ENVELOPE PROTEIN
2XBM	;	2.9	;	Crystal structure of the dengue virus methyltransferase bound to a 5'- capped octameric RNA
3UZQ	;	1.6	;	Crystal structure of the dengue virus serotype 1 envelope protein domain III in complex with the variable domains of Mab 4E11
3UZV	;	2.1	;	Crystal structure of the dengue virus serotype 2 envelope protein domain III in complex with the variable domains of Mab 4E11
3UZE	;	2.04	;	Crystal structure of the dengue virus serotype 3 envelope protein domain III in complex with the variable domains of Mab 4E11
3UYP	;	2.0	;	Crystal structure of the dengue virus serotype 4 envelope protein domain III in complex with the variable domains of Mab 4E11
6MS4	;	2.001	;	Crystal structure of the DENR-MCT-1 complex
3WCO	;	2.4	;	Crystal structure of the depentamerized mutant of N-terminal truncated selenocysteine synthase SelA
3WCN	;	3.35	;	Crystal structure of the depentamerized mutant of selenocysteine synthase SelA
4JN9	;	1.9	;	Crystal structure of the DepH
4JNA	;	2.0	;	Crystal structure of the DepH complex with dimethyl-FK228
3VW0	;	2.6	;	Crystal Structure of The Dequalinum-bound Form of RamR (Transcriptional Regulator of TetR Family) From Salmonella Typhimurium
3WRA	;	2.1	;	Crystal structure of the desB-Gallate complex exposed to Aerobic Atomosphere
6Z3X	;	1.74	;	Crystal structure of the designed antibody DesAb-anti-HSA-P1
4EEF	;	2.704	;	Crystal structure of the designed inhibitor protein F-HB80.4 in complex with the 1918 influenza virus hemagglutinin.
6CSO	;	3.2	;	Crystal structure of the designed light-gated anion channel iC++ at pH6.5
6CSN	;	2.9	;	Crystal structure of the designed light-gated anion channel iC++ at pH8.5
6N4N	;	2.29	;	Crystal structure of the designed protein DNCR2/danoprevir/NS3a complex
7SSJ	;	2.52	;	Crystal structure of the DesK-DesR complex in the phosphatase state
5IUK	;	2.9	;	Crystal structure of the DesK-DesR complex in the phosphotransfer state with high Mg2+ (150 mM)
5IUL	;	3.153	;	Crystal structure of the DesK-DesR complex in the phosphotransfer state with high Mg2+ (150 mM) and BeF3
5IUJ	;	3.2	;	Crystal structure of the DesK-DesR complex in the phosphotransfer state with low Mg2+ (20 mM)
7SSI	;	3.41	;	CRYSTAL STRUCTURE OF THE DESK:DESR-Q10A COMPLEX IN THE PHOSPHOTRANSFER STATE
3ME1	;	3.862	;	Crystal Structure of the Desulfovibro vulgaris Urea Transporter in the P3(1) Space Group at 3.86
6UPS	;	2.0	;	Crystal structure of the deubiquitylase domain from the Orientia tsutsugamushi protein OTT_1962 (OtDUB)
3LE4	;	1.701	;	Crystal structure of the DGCR8 dimerization domain
4ZWE	;	2.81	;	Crystal structure of the dGTP-bound catalytic core of SAMHD1 T592V mutant
3MPX	;	2.8	;	Crystal structure of the DH and PH-1 domains of human FGD5
4GYV	;	2.9	;	Crystal structure of the DH domain of FARP2
1XD4	;	3.64	;	Crystal structure of the DH-PH-cat module of Son of Sevenless (SOS)
4H6Y	;	4.09	;	Crystal structure of the DH-PH-PH domain of FARP1
4GZU	;	3.2	;	Crystal structure of the DH-PH-PH domain of FARP2
1TXD	;	2.13	;	Crystal Structure of the DH/PH domains of Leukemia-associated RhoGEF
1X86	;	3.22	;	Crystal Structure of the DH/PH domains of Leukemia-associated RhoGEF in complex with RhoA
3ODO	;	2.9	;	Crystal Structure of the DH/PH Domains of p115-RhoGEF
3P6A	;	2.5	;	Crystal Structure of the DH/PH domains of p115-RhoGEF (R399E mutant)
1RJ2	;	3.0	;	Crystal structure of the DH/PH fragment of Dbs without bound GTPase
1KZ7	;	2.4	;	Crystal Structure of the DH/PH Fragment of Murine Dbs in Complex with the Placental Isoform of Human Cdc42
3T06	;	2.84	;	Crystal Structure of the DH/PH fragment of PDZRHOGEF with N-terminal regulatory elements in complex with Human RhoA
5UIX	;	2.501	;	Crystal Structure of the DH576 CD4bs Fab (unliganded) from the RV305 HIV Vaccine Trial
8I5F	;	2.8	;	Crystal structure of the DHR-2 domain of DOCK10 in complex with Cdc42 (T17N mutant)
8I5W	;	2.432	;	Crystal structure of the DHR-2 domain of DOCK10 in complex with Rac1
3B13	;	3.006	;	Crystal structure of the DHR-2 domain of DOCK2 in complex with Rac1 (T17N mutant)
6AJ4	;	3.256	;	Crystal structure of the DHR-2 domain of DOCK7 in complex with Cdc42
3VHL	;	2.085	;	Crystal structure of the DHR-2 domain of DOCK8 in complex with Cdc42 (T17N mutant)
6TKY	;	2.55	;	Crystal structure of the DHR2 domain of DOCK10 in complex with CDC42
6TKZ	;	2.64	;	Crystal structure of the DHR2 domain of DOCK10 in complex with CDC42
6TM1	;	3.71	;	Crystal structure of the DHR2 domain of DOCK10 in complex with RAC3
4XRW	;	1.79	;	Crystal structure of the di-domain ARO/CYC BexL from the BE-7585A biosynthetic pathway
4XRT	;	1.952	;	Crystal structure of the di-domain ARO/CYC StfQ from the steffimycin biosynthetic pathway
2C1V	;	1.2	;	CRYSTAL STRUCTURE OF THE DI-HAEM CYTOCHROME C PEROXIDASE FROM PARACOCCUS PANTOTROPHUS - Mixed VALENCE FORM
2C1U	;	1.95	;	CRYSTAL STRUCTURE OF THE DI-HAEM CYTOCHROME C PEROXIDASE FROM PARACOCCUS PANTOTROPHUS - OXIDISED FORM
1EB7	;	2.4	;	Crystal structure of the di-haem cytochrome c peroxidase from Pseudomonas aeruginosa
2VHD	;	2.3	;	Crystal Structure Of The Di-Haem Cytochrome C Peroxidase From Pseudomonas aeruginosa - Mixed Valence Form
1GYO	;	1.2	;	Crystal structure of the di-tetraheme cytochrome c3 from Desulfovibrio gigas at 1.2 Angstrom resolution
3F9O	;	2.03	;	Crystal Structure of the Di-Zinc Carbapenemase CphA from Aeromonas Hydrophila
2WHG	;	1.9	;	Crystal Structure of the Di-Zinc Metallo-beta-lactamase VIM-4 from Pseudomonas aeruginosa
2DFJ	;	2.72	;	Crystal Structure of the Diadenosine Tetraphosphate Hydrolase from Shigella flexneri 2a
5HS8	;	2.0	;	Crystal structure of the diamide-treated YodB from B. subtilis
7L5K	;	1.86	;	Crystal structure of the DiB-RM protein
7L5L	;	2.01	;	Crystal structure of the DiB-RM protein
7L5M	;	2.33	;	Crystal Structure of the DiB-RM-split Protein
4WYQ	;	3.2	;	Crystal structure of the Dicer-TRBP interface
4L7X	;	1.35	;	Crystal structure of the DIDO PHD finger in complex with H3K4me3
6YMN	;	2.05	;	Crystal structure of the Diels Alderase AbmU from Streptomyces koyangensis
1YKV	;	3.3	;	Crystal structure of the Diels-Alder ribozyme complexed with the product of the reaction between N-pentylmaleimide and covalently attached 9-hydroxymethylanthracene
4H54	;	3.9	;	Crystal structure of the diguanylate cyclase DgcZ
6NX0	;	1.54	;	Crystal structure of the diheme peroxidase BthA from Burkholderia thailandensis E264
6V59	;	1.593	;	Crystal structure of the diheme peroxidase BthA Y463M variant from Burkholderia thailandensis E264
2F60	;	1.55	;	Crystal Structure of the Dihydrolipoamide Dehydrogenase (E3)-Binding Domain of Human E3-Binding Protein
5YNZ	;	2.774	;	Crystal structure of the dihydroorotase domain (K1556A) of human CAD
4C6E	;	1.263	;	Crystal structure of the dihydroorotase domain of human CAD bound to substrate at pH 5.5
4C6D	;	1.298	;	Crystal structure of the dihydroorotase domain of human CAD bound to substrate at pH 6.0
4C6F	;	1.261	;	Crystal structure of the dihydroorotase domain of human CAD bound to substrate at pH 6.5
4C6I	;	1.35	;	Crystal structure of the dihydroorotase domain of human CAD bound to substrate at pH 7.0
4C6J	;	1.299	;	Crystal structure of the dihydroorotase domain of human CAD bound to substrate at pH 7.5
4C6K	;	1.478	;	Crystal structure of the dihydroorotase domain of human CAD bound to substrate at pH 8.0
4C6L	;	1.55	;	Crystal structure of the dihydroorotase domain of human CAD bound to the inhibitor fluoroorotate at pH 6.0
4C6M	;	1.62	;	Crystal structure of the dihydroorotase domain of human CAD bound to the inhibitor fluoroorotate at pH 7.0
4C6Q	;	1.659	;	Crystal structure of the dihydroorotase domain of human CAD C1613S mutant bound to substrate at pH 7.0
4C6O	;	1.65	;	Crystal structure of the dihydroorotase domain of human CAD C1613S mutant in apo-form at pH 6.0
4C6P	;	1.518	;	Crystal structure of the dihydroorotase domain of human CAD C1613S mutant in apo-form at pH 7.0
4C6N	;	1.899	;	Crystal structure of the dihydroorotase domain of human CAD E1637T mutant bound to substrate at pH 6.0
4BY3	;	1.73	;	Crystal structure of the dihydroorotase domain of human CAD in apo- form obtained recombinantly from E. coli.
4C6C	;	1.451	;	Crystal structure of the dihydroorotase domain of human CAD in apo- form obtained recombinantly from HEK293 cells.
4C6B	;	1.656	;	Crystal structure of the dihydroorotase domain of human CAD with incomplete active site, obtained recombinantly from E. coli.
1UN9	;	3.1	;	Crystal structure of the dihydroxyacetone kinase from C. freundii in complex with AMP-PNP and Mg2+
1UOD	;	1.9	;	Crystal structure of the dihydroxyacetone kinase from E. coli in complex with dihydroxyacetone-phosphate
1UOE	;	2.0	;	Crystal structure of the dihydroxyacetone kinase from E. coli in complex with glyceraldehyde
1UN8	;	2.5	;	Crystal structure of the dihydroxyacetone kinase of C. freundii (native form)
8H7A	;	1.92	;	Crystal structure of the dimer form KAT6A WH domain with its bound double stranded DNA
3GQ2	;	2.18	;	Crystal Structure of the Dimer of the p115 Tether Globular Head Domain
7PU4	;	1.69	;	Crystal structure of the dimer RBP-N and RBP-Trunc from Thermotoga maritima Ribose Binding Protein
5FEG	;	2.802	;	Crystal structure of the dimeric allergen profilin (Hev b 8)
3HNK	;	2.1	;	Crystal structure of the dimeric assembly of the cyt cb562 variant RIDC-1
2YH9	;	1.8	;	Crystal structure of the dimeric BamE from E. coli
6MY5	;	1.73	;	Crystal structure of the dimeric bH1-Fab variant [HC-Y33W,HC-D98F,HC-G99M,LC-S30bR]
6MXS	;	1.95	;	Crystal structure of the dimeric bH1-Fab variant [HC-Y33W,HC-D98F,HC-G99M]
6MY4	;	1.69	;	Crystal structure of the dimeric bH1-Fab variant [HC-Y33W,HC-D98M,HC-G99M,LC-S30bR]
6MXR	;	2.04	;	Crystal structure of the dimeric bH1-Fab variant [HC-Y33W,HC-D98M,HC-G99M]
7XRC	;	1.89	;	Crystal Structure of the dimeric Brn2 (Pou3f2) POU domain bound to palindromic MORE DNA
7R3T	;	2.109	;	Crystal structure of the Dimeric C-terminal Big_2-CBM56 domains from Paenibacillus illinoisensis (Bacillus circulans IAM1165) beta-1,3-glucanase H
1IHR	;	1.55	;	Crystal structure of the dimeric C-terminal domain of TonB
4H22	;	2.89	;	Crystal structure of the dimeric coiled-coil domain of the cytosolic nucleic acid sensor LRRFIP1
7V98	;	2.35	;	Crystal Structure of the Dimeric EcHsp60
2Z9O	;	3.14	;	Crystal structure of the dimeric form of RepE in complex with the repE operator DNA
4JU5	;	2.28	;	Crystal structure of the dimeric form of the bb' domains of human protein disulfide isomerase
5ZF6	;	2.796	;	Crystal structure of the dimeric human PNPase
4AEQ	;	1.892	;	Crystal structure of the dimeric immunity protein Cmi solved by direct methods (Arcimboldo)
7PV1	;	2.497	;	Crystal structure of the dimeric mitofilin domain of Mic60 in complex with the CHCH domain of Mic19
2XSD	;	2.049	;	Crystal Structure of the dimeric Oct-6 (Pou3f1) POU domain bound to palindromic MORE DNA
1XKU	;	2.15	;	Crystal structure of the dimeric protein core of decorin, the archetypal small leucine-rich repeat proteoglycan
2BNX	;	2.4	;	Crystal structure of the dimeric regulatory domain of mouse diaphaneous-related formin (DRF), mDia1
1RPY	;	2.3	;	CRYSTAL STRUCTURE OF THE DIMERIC SH2 DOMAIN OF APS
1N1C	;	2.4	;	Crystal Structure Of The Dimeric TorD Chaperone From Shewanella Massilia
1R3M	;	2.2	;	Crystal structure of the dimeric unswapped form of bovine seminal ribonuclease
4N3D	;	1.34	;	Crystal structure of the dimeric variant EGFP-K162Q in P61 space group
1ZV1	;	1.6	;	Crystal structure of the dimerization domain of doublesex protein from D. melanogaster
6RNQ	;	1.95	;	Crystal structure of the dimerization domain of Gemin5 at 1.95 A
6RNS	;	2.69	;	Crystal structure of the dimerization domain of Gemin5 at 2.7 A
4J8C	;	1.1	;	Crystal structure of the dimerization domain of Hsc70-interacting protein
1UFI	;	1.65	;	Crystal structure of the dimerization domain of human CENP-B
3CNK	;	1.65	;	Crystal Structure of the dimerization domain of human filamin A
4E1P	;	1.728	;	Crystal structure of the dimerization domain of Lsr2 from Mycobacterium tuberculosis in the P 1 21 1 space group
4E1R	;	2.041	;	Crystal structure of the dimerization domain of Lsr2 from Mycobacterium tuberculosis in the P 31 2 1 space group
4ZMK	;	1.5	;	Crystal structure of the dimerization domain of S. pombe Taz1
7EQB	;	2.103	;	Crystal structure of the dimerization domain of ZEN-4
3JV4	;	3.15	;	Crystal structure of the dimerization domains p50 and RelB
3JV6	;	2.78	;	Crystal structure of the dimerization domains p52 and RelB
3JV5	;	2.65	;	Crystal structure of the dimerization domains p52 homodimer
2D2Q	;	2.8	;	Crystal structure of the dimerized radixin FERM domain
3I4Z	;	1.76	;	Crystal structure of the dimethylallyl tryptophan synthase FgaPT2 from Aspergillus fumigatus
3I4X	;	2.1	;	Crystal structure of the dimethylallyl tryptophan synthase FgaPT2 from Aspergillus fumigatus in complex with Trp and DMSPP
3RHY	;	2.18	;	Crystal structure of the dimethylarginine dimethylaminohydrolase adduct with 4-chloro-2-hydroxymethylpyridine
6DGE	;	1.91	;	Crystal structure of the dimethylarginine dimethylaminohydrolase adduct with N5-(1-imino-2-chloroethyl)-L-lysine
3BPB	;	2.81	;	Crystal structure of the dimethylarginine dimethylaminohydrolase H162G adduct with S-methyl-L-thiocitrulline
5TG0	;	1.44	;	Crystal structure of the dimethylsulfoniopropionate (DMSP) lyase DddK complexed with iron and zinc
5TFZ	;	2.2	;	Crystal structure of the dimethylsulfoniopropionate (DMSP) lyase DddK complexed with nickel and diacrylate
2WOC	;	2.2	;	Crystal Structure of the dinitrogenase reductase-activating glycohydrolase (DRAG) from Rhodospirillum rubrum
2WOD	;	2.25	;	Crystal Structure of the dinitrogenase reductase-activating glycohydrolase (DRAG) from Rhodospirillum rubrum in complex with ADP- ribsoyllysine
1EGV	;	1.75	;	CRYSTAL STRUCTURE OF THE DIOL DEHYDRATASE-ADENINYLPENTYLCOBALAMIN COMPLEX FROM KLEBSELLA OXYTOCA UNDER THE ILLUMINATED CONDITION.
1EEX	;	1.7	;	CRYSTAL STRUCTURE OF THE DIOL DEHYDRATASE-ADENINYLPENTYLCOBALAMIN COMPLEX FROM KLEBSIELLA OXYTOCA
1V8X	;	1.85	;	Crystal Structure of the Dioxygen-bound Heme Oxygenase from Corynebacterium diphtheriae
8JKK	;	2.3	;	Crystal Structure of the dioxygenase CcTet from Coprinopsis cinerea bound to 12bp 5-methylcytosine (5mC) containing duplex DNA
7W5P	;	2.3	;	Crystal Structure of the dioxygenase CcTet from Coprinopsis cinereain bound to 12bp N6-methyldeoxyadenine (6mA) containing duplex DNA
7VPN	;	2.6	;	Crystal Structure of the dioxygenase CcTet from Coprinopsis cinereain in complex with Mn(II) and N-Oxalylglycine
3LMM	;	3.0	;	Crystal Structure of the DIP2311 protein from Corynebacterium diphtheriae, Northeast Structural Genomics Consortium Target CdR35
3MCU	;	2.303	;	Crystal structure of the dipicolinate synthase chain B from Bacillus cereus. Northeast Structural Genomics Consortium Target BcR215.
1NTV	;	1.5	;	Crystal Structure of the Disabled-1 (Dab1) PTB domain-ApoER2 peptide complex
6O5O	;	1.75	;	Crystal Structure of the Disabled-2 (Dab2) Dab Homology Domain in Complex with Peptide STA02
6OVF	;	1.95	;	Crystal Structure of the Disabled-2 (Dab2) Dab Homology Domain in Complex with Peptide STA03
1ZGP	;	1.9	;	Crystal Structure of the Discosoma Red Fluorescent Protein (DsRed) Variant K70M
1ZGQ	;	1.9	;	Crystal Structure of the Discosoma Red Fluorescent Protein (DsRed) Variant Q66M
6I4P	;	1.6	;	Crystal structure of the disease-causing G194C mutant of the human dihydrolipoamide dehydrogenase
6I4U	;	1.84	;	Crystal structure of the disease-causing G426E mutant of the human dihydrolipoamide dehydrogenase
7PSC	;	2.436	;	Crystal structure of the disease-causing I358T mutant of the human dihydrolipoamide dehydrogenase
6I4T	;	1.823	;	Crystal structure of the disease-causing I445M mutant of the human dihydrolipoamide dehydrogenase
6I4Z	;	2.342	;	Crystal structure of the disease-causing P453L mutant of the human dihydrolipoamide dehydrogenase
6I4S	;	1.75	;	Crystal structure of the disease-causing R447G mutant of the human dihydrolipoamide dehydrogenase
6I4R	;	1.439	;	Crystal structure of the disease-causing R460G mutant of the human dihydrolipoamide dehydrogenase at 1.44 Angstrom resolution
7XCC	;	1.75	;	Crystal Structure of the Disease-Specific Protein of Rice Stripe Virus
7XCD	;	1.71	;	Crystal Structure of the Disease-Specific Protein of Rice Stripe Virus
1J2L	;	1.7	;	Crystal structure of the disintegrin, trimestatin
1V57	;	2.0	;	Crystal Structure of the Disulfide Bond Isomerase DsbG
6TDR	;	1.75	;	Crystal structure of the disulfide engineered HLA-A0201 molecule devoid of peptide (annealed)
6TDP	;	1.4	;	Crystal structure of the disulfide engineered HLA-A0201 molecule in complex with one GL dipeptide in the A pocket.
6TDQ	;	1.6	;	Crystal structure of the disulfide engineered HLA-A0201 molecule in complex with one GM dipeptide in the A pocket and one GM dipeptide in the F pocket.
6TDO	;	1.65	;	Crystal structure of the disulfide engineered HLA-A0201 molecule in complex with one GM dipeptide in the A pocket.
6TDS	;	1.7	;	Crystal structure of the disulfide engineered HLA-A0201 molecule without peptide bound after NaCl wash
6XRJ	;	3.15	;	Crystal structure of the disulfide linked DH717.1 Fab dimer, derived from a macaque HIV-1 vaccine-induced Env glycan-reactive neutralizing antibody B cell lineage
4OCF	;	1.979	;	Crystal structure of the disulfide oxidoreductase DsbA (S30XXC33) active site mutant from Proteus mirabilis
4OCE	;	1.768	;	Crystal structure of the disulfide oxidoreductase DsbA from Proteus mirabilis
8AJJ	;	2.4	;	Crystal structure of the disulfide reductase MerA from Staphylococcus aureus
1VRS	;	2.85	;	Crystal structure of the disulfide-linked complex between the N-terminal and C-terminal domain of the electron transfer catalyst DsbD
1Z5Y	;	1.94	;	Crystal Structure Of The Disulfide-Linked Complex Between The N-Terminal Domain Of The Electron Transfer Catalyst DsbD and The Cytochrome c Biogenesis Protein CcmG
4UWQ	;	3.28	;	Crystal structure of the disulfide-linked complex of the thiosulfodyrolase SoxB with the carrier-protein SoxYZ from Thermus thermophilus
1EZL	;	2.0	;	CRYSTAL STRUCTURE OF THE DISULPHIDE BOND-DEFICIENT AZURIN MUTANT C3A/C26A: HOW IMPORTANT IS THE S-S BOND FOR FOLDING AND STABILITY?
4DVD	;	3.0	;	Crystal structure of the disulphide linked knotted homodimer of Psu
3KUQ	;	2.3	;	Crystal structure of the DLC1 RhoGAP domain
2NO2	;	2.8	;	Crystal structure of the DLLRKN-containing coiled-coil domain of Huntingtin-interacting protein 1
4YJ0	;	3.814	;	Crystal structure of the DM domain of human DMRT1 bound to 25mer target DNA
3DX9	;	2.75	;	Crystal Structure of the DM1 TCR at 2.75A
3DXA	;	3.5	;	Crystal Structure of the DM1 TCR in complex with HLA-B*4405 and decamer EBV antigen
3CSP	;	1.7	;	Crystal structure of the DM2 mutant of myelin oligodendrocyte glycoprotein
6VGD	;	4.2	;	Crystal structure of the DNA binding domain (DBD) of human FLI1 and the complex of the DBD of human Runx2 with core binding factor beta (Cbfb), in complex with 16mer DNA CAGAGGATGTGGCTTC
4LDV	;	1.45	;	Crystal structure of the DNA binding domain of A. thailana auxin response factor 1
4LDX	;	2.9	;	Crystal structure of the DNA binding domain of arabidopsis thaliana auxin response factor 1 (ARF1) in complex with protomor-like sequence ER7
6YCQ	;	1.65	;	Crystal structure of the DNA binding domain of Arabidopsis thaliana Auxin Response Factor 1 (AtARF1) in complex with High Affinity DNA
4LDW	;	2.67	;	Crystal structure of the DNA Binding Domain of arabidopsis thaliana auxin response factor 1, P21 structure
4LDU	;	2.15	;	Crystal structure of the DNA binding domain of Arabidopsis thaliana auxin response factor 5
3RJP	;	1.5	;	Crystal structure of the DNA binding domain of CovR from Streptococcus pyogenes
4UHT	;	1.15	;	Crystal structure of the DNA binding domain of CpxR from E. coli
2FU4	;	1.8	;	Crystal Structure of the DNA binding domain of E.coli FUR (Ferric Uptake Regulator)
6EXT	;	1.5	;	Crystal structure of the DNA binding domain of fission yeast Sap1
6EXU	;	1.409	;	Crystal structure of the DNA binding domain of fission yeast Sap1
3L2C	;	1.868	;	Crystal Structure of the DNA Binding Domain of FOXO4 Bound to DNA
2CMP	;	1.58	;	crystal structure of the DNA binding domain of G1P SMALL TERMINASE SUBUNIT from bacteriophage SF6
2XWC	;	1.82	;	Crystal structure of the DNA binding domain of human TP73 refined at 1.8 A resolution
7JSL	;	4.51	;	Crystal structure of the DNA binding domain of human transcription factor ERF in the oxidized form, in complex with double-stranded DNA ACCGGAAGTG
7JSA	;	2.85	;	Crystal structure of the DNA binding domain of human transcription factor ERF in the reduced form, in complex with double-stranded DNA ACCGGAAGTG
5E8G	;	2.7	;	Crystal structure of the DNA binding domain of human transcription factor FLI1
6VG2	;	3.9	;	Crystal structure of the DNA binding domain of human transcription factor FLI1 in complex with 16-mer DNA CAGAGGATGTGGCTTC
5E8I	;	3.45	;	Crystal structure of the DNA binding domain of human transcription factor FLI1 in complex with a 10-mer DNA ACCGGAAGTG
1R71	;	2.2	;	Crystal Structure of the DNA binding domain of KorB in complex with the operator DNA
6SDG	;	2.96	;	Crystal structure of the DNA binding domain of M. polymorpha Auxin Response Factor 2 (MpARF2) in complex with High Affinity DNA
8OJ1	;	2.57	;	Crystal structure of the DNA binding domain of M. polymorpha Auxin Response Factor 2 (MpARF2) in complex with High Affinity DNA
5JDK	;	0.998	;	Crystal structure of the DNA binding domain of Sap1 in fission yeast S.pombe
6S6H	;	2.4	;	Crystal structure of the DNA binding domain of the chromosome-partitioning protein ParB complexed to the centromeric parS site
4LDY	;	2.3	;	Crystal structure of the DNA binding domain of the G245A mutant of arabidopsis thaliana auxin reponse factor 1
2HTS	;	1.83	;	CRYSTAL STRUCTURE OF THE DNA BINDING DOMAIN OF THE HEAT SHOCK TRANSCRIPTION FACTOR
5JVT	;	3.1	;	Crystal structure of the DNA binding domain of transcription factor FLI1 in complex with an 11-mer DNA GACCGGAAGTG
6VG8	;	4.31	;	Crystal structure of the DNA binding domains of human FLI1 and Runx2 in complex with 16-mer DNA CAGAGGATGTGGCTTC
6VGG	;	4.31	;	Crystal structure of the DNA binding domains of human transcription factor ERG, human Runx2 bound to core binding factor beta (Cbfb), and mithramycin, in complex with 16mer DNA CAGAGGATGTGGCTTC
6VGE	;	4.25	;	Crystal structure of the DNA binding domains of human transcription factor ERG, human Runx2 bound to core binding factor beta (Cbfb), in complex with 16mer DNA CAGAGGATGTGGCTTC
4WT0	;	1.8	;	Crystal structure of the DNA binding domains of LiaRD191N from E. faecalis
4WSZ	;	1.769	;	Crystal structure of the DNA binding domains of wild type LiaR from E. faecalis
2YPR	;	2.64	;	Crystal structure of the DNA binding ETS domain of human protein FEV
3ZP5	;	2.0	;	Crystal structure of the DNA binding ETS domain of the human protein FEV in complex with DNA
6K2J	;	2.4	;	Crystal Structure of the DNA Complex of C. crescentus GapR
238D	;	2.0	;	CRYSTAL STRUCTURE OF THE DNA DECAMER D(AGG(BR)CATGCCT): COMPARISON WITH D(AGGCATGCCT) AND IMPLICATIONS FOR COBALT HEXAMMINE BINDING TO DNA
261D	;	2.4	;	CRYSTAL STRUCTURE OF THE DNA DECAMER D(CGCAATTGCG) COMPLEXED WITH THE MINOR GROOVE BINDING DRUG NETROPSIN
3VJZ	;	1.8	;	Crystal structure of the DNA mimic protein DMP19
1BGT	;	2.2	;	CRYSTAL STRUCTURE OF THE DNA MODIFYING ENZYME BETA-GLUCOSYLTRANSFERASE IN THE PRESENCE AND ABSENCE OF THE SUBSTRATE URIDINE DIPHOSPHOGLUCOSE
1BGU	;	2.2	;	CRYSTAL STRUCTURE OF THE DNA MODIFYING ENZYME BETA-GLUCOSYLTRANSFERASE IN THE PRESENCE AND ABSENCE OF THE SUBSTRATE URIDINE DIPHOSPHOGLUCOSE
2BGT	;	2.2	;	CRYSTAL STRUCTURE OF THE DNA MODIFYING ENZYME BETA-GLUCOSYLTRANSFERASE IN THE PRESENCE AND ABSENCE OF THE SUBSTRATE URIDINE DIPHOSPHOGLUCOSE
2BGU	;	2.2	;	CRYSTAL STRUCTURE OF THE DNA MODIFYING ENZYME BETA-GLUCOSYLTRANSFERASE IN THE PRESENCE AND ABSENCE OF THE SUBSTRATE URIDINE DIPHOSPHOGLUCOSE
1C4O	;	1.5	;	CRYSTAL STRUCTURE OF THE DNA NUCLEOTIDE EXCISION REPAIR ENZYME UVRB FROM THERMUS THERMOPHILUS
6AP4	;	2.95	;	Crystal structure of the DNA polymerase III subunit beta from Acinetobacter baumannii
6AMQ	;	2.67	;	Crystal structure of the DNA polymerase III subunit beta from Enterobacter cloacae
6AMS	;	2.39	;	Crystal structure of the DNA polymerase III subunit beta from Pseudomonas aeruginosa
5IIO	;	2.08	;	Crystal structure of the DNA polymerase lambda binary complex
7UI4	;	2.51	;	Crystal structure of the DNA preQ0 insertase DpdA
2OQ4	;	2.6	;	Crystal structure of the DNA repair enzyme endonuclease-VIII (Nei) from E. coli (E2Q) in complex with AP-site containing DNA substrate
6FBU	;	2.0	;	Crystal structure of the DNA repair enzyme endonuclease-VIII (Nei) from E. coli (E2Q) in complex with AP-site containing DNA substrate
2OPF	;	1.85	;	Crystal structure of the DNA repair enzyme endonuclease-VIII (Nei) from E. coli (R252A) in complex with AP-site containing DNA substrate
2EA0	;	1.4	;	Crystal structure of the DNA repair enzyme endonuclease-VIII (Nei) from E. coli in complex with AP-site containing DNA substrate
1Q3C	;	2.3	;	Crystal structure of the DNA repair enzyme endonuclease-VIII (Nei) from E. coli: The E2A mutant at 2.3 resolution.
1Q3B	;	2.05	;	Crystal structure of the DNA repair enzyme endonuclease-VIII (Nei) from E. coli: The R252A mutant at 2.05 resolution.
1Q39	;	2.8	;	Crystal structure of the DNA repair enzyme endonuclease-VIII (Nei) from E. coli: The WT enzyme at 2.8 resolution.
2J6V	;	1.55	;	Crystal structure of the DNA repair enzyme UV Damage Endonuclease
1D9X	;	2.6	;	CRYSTAL STRUCTURE OF THE DNA REPAIR PROTEIN UVRB
1D9Z	;	3.15	;	CRYSTAL STRUCTURE OF THE DNA REPAIR PROTEIN UVRB IN COMPLEX WITH ATP
1T5L	;	2.6	;	Crystal structure of the DNA repair protein UvrB point mutant Y96A revealing a novel fold for domain 2
3W6V	;	2.95	;	Crystal structure of the DNA-binding domain of AdpA, the global transcriptional factor, in complex with a target DNA
7CX5	;	1.07	;	Crystal structure of the DNA-binding domain of Bacillus subtilis CssR
2EWT	;	1.81	;	Crystal structure of the DNA-binding domain of BldD
3VW4	;	2.7	;	Crystal structure of the DNA-binding domain of ColE2-P9 Rep in complex with the replication origin
3V6P	;	2.401	;	Crystal structure of the DNA-binding domain of dHax3, a TAL effector
6K5X	;	2.086	;	Crystal Structure of the DNA-Binding Domain of GapR
4B4C	;	1.62	;	Crystal structure of the DNA-binding domain of human CHD1.
4BNC	;	2.9	;	Crystal structure of the DNA-binding domain of human ETV1 complexed with DNA
4AVP	;	1.82	;	Crystal structure of the DNA-binding domain of human ETV1.
5YHU	;	1.85	;	Crystal structure of the DNA-binding domain of human myelin-gene regulatory factor
5ZHU	;	2.202	;	Crystal structure of the DNA-binding domain of human myelin-gene regulatory factor
2XWR	;	1.68	;	Crystal structure of the DNA-binding domain of human p53 with extended N terminus
6LAE	;	2.81	;	Crystal structure of the DNA-binding domain of human XPA in complex with DNA
1I3J	;	2.2	;	CRYSTAL STRUCTURE OF THE DNA-BINDING DOMAIN OF INTRON ENDONUCLEASE I-TEVI WITH ITS SUBSTRATE
1T2T	;	2.5	;	Crystal structure of the DNA-binding domain of intron endonuclease I-TevI with operator site
1HF0	;	2.7	;	Crystal structure of the DNA-binding domain of Oct-1 bound to DNA as a dimer
2PMU	;	1.779	;	Crystal structure of the DNA-binding domain of PhoP
1R9W	;	1.8	;	Crystal Structure of the DNA-binding domain of the human papillomavirus type 18 (HPV-18) replication initiation protein E1
7TRV	;	1.8	;	Crystal Structure of the DNA-Binding Domain of the LysR family Transcriptional Regulator YfbA from Yersinia pestis
6Y93	;	2.23	;	Crystal structure of the DNA-binding domain of the Nucleoid Occlusion Factor (Noc) complexed to the Noc-binding site (NBS)
1F08	;	1.9	;	CRYSTAL STRUCTURE OF THE DNA-BINDING DOMAIN OF THE REPLICATION INITIATION PROTEIN E1 FROM PAPILLOMAVIRUS
4QWQ	;	2.501	;	Crystal structure of the DNA-binding domain of the response regulator SaeR from Staphylococcus aureus
7E92	;	1.8	;	Crystal structure of the DNA-binding domain of the response regulator VbrR from Vibrio parahaemolyticus
1J75	;	1.85	;	Crystal Structure of the DNA-Binding Domain Zalpha of DLM-1 Bound to Z-DNA
4U0Y	;	1.91	;	Crystal structure of the DNA-binding domains of YvoA in complex with palindromic operator DNA
7QVB	;	2.5	;	Crystal structure of the DNA-binding protein DdrC from Deinococcus radiodurans
7BM2	;	2.29	;	Crystal structure of the DNA-binding protein RemA from Geobacillus thermodenitrificans
1R7J	;	1.47	;	Crystal structure of the DNA-binding protein Sso10a from Sulfolobus solfataricus
8B6E	;	1.2	;	crystal structure of the DNA-binding short chromatophore-targeted protein sCTP-23166 from Paulinella chromatophora
7L6L	;	1.75	;	Crystal Structure of the DNA-binding Transcriptional Repressor DeoR from Escherichia coli str. K-12
3V6T	;	1.85	;	Crystal structure of the DNA-bound dHax3, a TAL effector, at 1.85 angstrom
6CFN	;	2.5	;	Crystal Structure of the DNA-free Glucocorticoid Receptor DNA Binding Domain
2VYF	;	3.6	;	Crystal Structure of the DnaC
3EC2	;	2.7	;	Crystal structure of the DnaC helicase loader
3ECC	;	2.7	;	Crystal structure of the DnaC helicase loader in complex with ADP-BeF3
2VYE	;	4.1	;	Crystal Structure of the DnaC-ssDNA complex
2W58	;	2.5	;	Crystal Structure of the DnaI
4R5J	;	2.361	;	Crystal structure of the DnaK C-terminus (Dnak-SBD-A)
4R5K	;	1.7469	;	Crystal structure of the DnaK C-terminus (Dnak-SBD-B)
4R5L	;	2.9701	;	Crystal structure of the DnaK C-terminus (Dnak-SBD-C)
4R5G	;	3.4501	;	Crystal structure of the DnaK C-terminus with the inhibitor PET-16
4R5I	;	1.9702	;	Crystal structure of the DnaK C-terminus with the substrate peptide NRLLLTG
3A1A	;	2.3	;	Crystal Structure of the DNMT3A ADD domain
8BA5	;	1.45	;	Crystal structure of the DNMT3A ADD domain
3A1B	;	2.292	;	Crystal structure of the DNMT3A ADD domain in complex with histone H3
7W1F	;	2.9	;	Crystal structure of the dNTP triphosphohydrolase PA1124 from Pseudomonas aeruginosa
7CLX	;	1.5	;	Crystal structure of the DOCK8 DHR-1 domain
2CHP	;	2.0	;	Crystal structure of the dodecameric ferritin MrgA from B. subtilis 168
7DRU	;	2.5	;	Crystal Structure of the Dog Lipocalin Allergen Can f 1
3L4R	;	1.45	;	Crystal structure of the dog lipocalin allergen Can f 2 and implications for cross-reactivity to the cat allergen Fel d 4
5X7Y	;	2.35	;	Crystal Structure of the Dog Lipocalin Allergen Can f 6
6FKR	;	3.2	;	Crystal structure of the dolphin proline-rich antimicrobial peptide Tur1A bound to the Thermus thermophilus 70S ribosome
2R6H	;	2.95	;	Crystal structure of the domain comprising the NAD binding and the FAD binding regions of the NADH:ubiquinone oxidoreductase, Na translocating, F subunit from Porphyromonas gingivalis
2P7J	;	2.25	;	Crystal structure of the domain of putative sensory box/GGDEF family protein from Vibrio parahaemolyticus
4YMR	;	2.4	;	Crystal structure of the domain swapped PXB/TPR domain of mouse SNX21
3OP8	;	1.9	;	Crystal structure of the domain V from beta2-glycoprotein I
6JSD	;	2.042	;	Crystal structure of the domain-swapped dimer H434A variant of the C-terminal domain of HtaA from Corynebacterium glutamicum
4ZR2	;	1.8024	;	Crystal Structure of the Domain-Swapped Dimer K40L:Q108K:Y60W mutant of Human Cellular Retinol Binding Protein II
4ZH9	;	2.66	;	Crystal Structure of the Domain-Swapped Dimer Wild-Type of Human Cellular Retinol Binding Protein II
4ZH6	;	1.5497	;	Crystal Structure of the Domain-Swapped Dimer Y60L mutant of Human Cellular Retinol Binding Protein II
6SIB	;	1.9	;	Crystal structure of the domain-swapped N-lobe dimer of drosophila Arc 2
7D7X	;	2.631	;	Crystal Structure of the Domain1 of NAD+ Riboswitch with adenosine diphosphate (ADP)
7D7Y	;	2.8	;	Crystal Structure of the Domain1 of NAD+ Riboswitch with adenosine triphosphate (ATP)
7D7W	;	2.391	;	Crystal Structure of the Domain1 of NAD+ Riboswitch with nicotinamide adenine dinucleotide (NAD+)
7D7V	;	2.8	;	Crystal Structure of the Domain1 of NAD+ Riboswitch with nicotinamide adenine dinucleotide (NAD+) and U1A protein
7D7Z	;	2.6	;	Crystal Structure of the Domain1 of NAD+ Riboswitch with nicotinamide adenine dinucleotide (NAD+), soaked in Mn2+
7D81	;	2.1	;	Crystal Structure of the Domain2 of NAD+ Riboswitch with nicotinamide adenine dinucleotide (NAD+)
7D82	;	2.489	;	Crystal Structure of the Domain2 of NAD+ Riboswitch with nicotinamide adenine dinucleotide (NAD+), soaked in Mn2+
3LO5	;	2.568	;	Crystal Structure of the dominant negative S17N mutant of Ras
1EQF	;	2.1	;	CRYSTAL STRUCTURE OF THE DOUBLE BROMODOMAIN MODULE FROM HUMAN TAFII250
6U81	;	2.34	;	Crystal Structure of the Double Homeodomain of DUX4 in Complex with a DNA aptamer
6U82	;	3.21	;	Crystal Structure of the Double Homeodomain of DUX4 in Complex with a DNA aptamer containing bulge and loop
6E8C	;	2.12	;	Crystal structure of the double homeodomain of DUX4 in complex with DNA
5NAV	;	2.3	;	Crystal structure of the double mutant (Cys211Ser/Cys292Ser) 6-phospho-b-D-glucosidase from Lactobacillus plantarum
6DD3	;	1.98	;	Crystal structure of the double mutant (D52N/D407A) of NT5C2-537X in the active state
6DDY	;	1.803	;	Crystal structure of the double mutant (D52N/K359Q) of NT5C2-537X in the active state, Northeast Structural Genomics Target
6DDX	;	2.901	;	Crystal structure of the double mutant (D52N/L375F) of NT5C2-537X in the active state, Northeast Structural Genomics Target
6DE2	;	2.1	;	Crystal structure of the double mutant (D52N/L375F) of the full-length NT5C2 in the active state
6DDZ	;	1.97	;	Crystal structure of the double mutant (D52N/R238W) of NT5C2-537X in the active state, Northeast Structural Genomics Target
6DDH	;	2.35	;	Crystal structure of the double mutant (D52N/R367Q) of NT5C2-537X in the active state, Northeast Structural Genomics Target
6DDB	;	2.8	;	Crystal structure of the double mutant (D52N/R367Q) of NT5C2-537X in the basal state, Northeast Structural Genomics Consortium Target
6DDK	;	2.5	;	Crystal structure of the double mutant (D52N/R367Q) of the full-length NT5C2 in the basal state
6DE3	;	3.06	;	Crystal structure of the double mutant (R39Q/D52N) of the full-length NT5C2 in the active state
6DDQ	;	2.31	;	Crystal structure of the double mutant (R39Q/D52N) of the full-length NT5C2 in the basal state
4MJX	;	1.4	;	Crystal structure of the double mutant (S112A, H303A) of B.anthracis mycrocine immunity protein (MccF)
4JVO	;	1.3	;	Crystal structure of the double mutant (S112A, H303A) of B.anthracis mycrocine immunity protein (MccF) with alanyl sulfamoyl adenylates
4MI1	;	1.4	;	Crystal structure of the double mutant (S112A, H303A) of B.anthracis mycrocine immunity protein (MccF) with aspartyl sulfamoyl adenylates
1GR7	;	1.8	;	Crystal structure of the double mutant Cys3Ser/Ser100Pro from Pseudomonas Aeruginosa at 1.8 A resolution
3BQV	;	1.5	;	Crystal Structure of the double mutant D44A D45A Plastocyanin from Phormidium laminosum
3KOF	;	1.9	;	Crystal structure of the double mutant F178Y/R181E of E.coli transaldolase B
6Y2V	;	2.0	;	Crystal structure of the double mutant L13R I16K of Low Molecular Weight Protein Tyrosine Phosphatase (LMW-PTP)
6EFU	;	2.2	;	Crystal structure of the double mutant L167W / P172L of the beta-glucosidase from Trichoderma harzianum
5HPF	;	2.309	;	Crystal Structure of the Double Mutant of PobR Transcription Factor Inducer Binding Domain from Acinetobacter
5HPI	;	2.963	;	Crystal Structure of the Double Mutant of PobR Transcription Factor Inducer Binding Domain-3-Hydroxy Benzoic Acid complex from Acinetobacter
1XTM	;	1.6	;	Crystal structure of the double mutant Y88H-P104H of a SOD-like protein from Bacillus subtilis.
2C2J	;	2.05	;	Crystal Structure Of The Dps92 From Deinococcus Radiodurans
7U1Z	;	3.18	;	Crystal structure of the DRBD and CROPs of TcdA
7L4N	;	2.247	;	Crystal structure of the DRM2 (C397R)-CCG DNA complex
7L4F	;	2.55	;	Crystal structure of the DRM2-CAT DNA complex
7L4K	;	2.61	;	Crystal structure of the DRM2-CCG DNA complex
7L4M	;	2.805	;	Crystal structure of the DRM2-CCT DNA complex
8T1U	;	2.91	;	Crystal structure of the DRM2-CTA DNA complex
7L4H	;	2.56	;	Crystal structure of the DRM2-CTG DNA complex
7L4C	;	2.11	;	Crystal structure of the DRM2-CTT DNA complex
4LW3	;	2.0	;	Crystal structure of the Drosophila beta1,4galactosyltransferase7 catalytic domain D211N single mutant enzyme complex with manganese and UDP-galactose
5EHS	;	1.749	;	Crystal structure of the Drosophila CG3822 KaiR1D ligand binding domain complex with D-AP5
5DTB	;	1.843	;	Crystal structure of the Drosophila CG3822 KaiR1D ligand binding domain complex with glutamate
5EHM	;	1.281	;	Crystal structure of the Drosophila CG3822 KaiR1D ligand binding domain complex with NMDA
3LTG	;	3.4	;	Crystal structure of the Drosophila Epidermal Growth Factor Receptor ectodomain complexed with a low affinity Spitz mutant
3LTF	;	3.2	;	Crystal Structure of the Drosophila Epidermal Growth Factor Receptor ectodomain in complex with Spitz
5DT6	;	1.598	;	Crystal structure of the Drosophila GluR1A ligand binding domain complex with glutamate
5ICT	;	1.68	;	Crystal structure of the Drosophila GluR1A ligand binding domain Y792T mutant complex with glutamate
1M0U	;	1.75	;	Crystal Structure of the Drosophila Glutathione S-transferase-2 in Complex with Glutathione
2FP3	;	2.5	;	Crystal structure of the Drosophila initiator caspase Dronc
3PXN	;	2.6	;	Crystal structure of the Drosophila kinesin family member Kin10/NOD in complex with divalent manganese and ADP
3DC4	;	1.9	;	Crystal structure of the Drosophila kinesin family member NOD in complex with ADP
3DCB	;	2.5	;	Crystal structure of the Drosophila kinesin family member NOD in complex with AMPPNP
1OO0	;	1.85	;	Crystal structure of the Drosophila Mago nashi-Y14 complex
4KG0	;	2.1	;	Crystal structure of the drosophila melanogaster neuralized-nhr1 domain
6E4Q	;	2.799	;	Crystal Structure of the Drosophila Melanogaster Polypeptide N-Acetylgalactosaminyl Transferase PGANT9A in Complex with UDP and Mn2+
6E4R	;	2.061	;	Crystal Structure of the Drosophila Melanogaster Polypeptide N-Acetylgalactosaminyl Transferase PGANT9B
6F4H	;	2.0	;	Crystal structure of the Drosophila melanogaster SNF/U1-SL2 complex
3P9Y	;	2.1	;	Crystal structure of the Drosophila melanogaster Ssu72-pCTD complex
3UV0	;	1.9	;	Crystal structure of the drosophila MU2 FHA domain
1S2J	;	2.2	;	Crystal structure of the Drosophila pattern-recognition receptor PGRP-SA
5KLA	;	1.14	;	Crystal structure of the drosophila Pumilio RNA-binding domain in complex with hunchback RNA
5CQQ	;	3.1	;	Crystal structure of the Drosophila Zeste DNA binding domain in complex with DNA
4M4K	;	2.2	;	Crystal structure of the Drosphila beta,14galactosyltransferase 7 mutant D211N complex with manganese, UDP-Gal and xylobiose
1WP1	;	2.56	;	Crystal structure of the drug-discharge outer membrane protein, OprM
1DSB	;	2.0	;	CRYSTAL STRUCTURE OF THE DSBA PROTEIN REQUIRED FOR DISULPHIDE BOND FORMATION IN VIVO
8B02	;	1.676	;	Crystal structure of the dsRBD domain of tRNA-dihydrouridine(20) synthase from Amphimedon queenslandica
8G22	;	1.0	;	Crystal Structure of the dTDP-4-dehydrorhamnose Reductase from Streptococcus pneumoniae.
2CU6	;	2.0	;	Crystal Structure Of The dTDP-4-keto-L-rhamnose reductase-related Protein From Thermus Thermophilus HB8
7N7A	;	1.8	;	crystal structure of the dTDP-Qui3N N-formyltransferase from Helicobacter canadensis, apo form
6JO0	;	1.651	;	Crystal structure of the DTS-motif rhodopsin from Phaeocystis globosa virus 12T
8PYR	;	2.15	;	Crystal structure of the dual T-loop phosphorylated Cdk7/CycH/Mat1 complex
4J40	;	2.99	;	Crystal structure of the dual-domain GGDEF-EAL module of FimX from Pseudomonas aeruginosa
2ZNR	;	1.2	;	Crystal structure of the DUB domain of human AMSH-LP
7FIU	;	1.84	;	Crystal structure of the DUB domain of Wolbachia cytoplasmic incompatibility factor CidB from wMel
2BA2	;	1.8	;	Crystal structure of the DUF16 domain of MPN010 from Mycoplasma pneumoniae
8IEV	;	2.08	;	Crystal structure of the DUF2891 family protein CJ0554 from Campylobacter jejuni in space group C2
8IEU	;	2.3	;	Crystal structure of the DUF2891 family protein CJ0554 from Campylobacter jejuni in space group P41212
3EOP	;	2.3	;	Crystal Structure of the DUF55 domain of human thymocyte nuclear protein 1
2OIY	;	1.6	;	Crystal structure of the duplex form of the HIV-1(LAI) RNA dimerization initiation site
2OJ0	;	2.6	;	Crystal structure of the duplex form of the HIV-1(LAI) RNA dimerization initiation site MN soaked
5ZJL	;	1.7	;	Crystal Structure of the dust mite allergen Der f 23 from Dermatophagoides farinae
4ZCE	;	1.55	;	Crystal Structure of the dust mite allergen Der p 23 from Dermatophagoides pteronyssinus
5Y5P	;	2.03	;	Crystal structure of the dUTPase of white spot syndrome virus in complex with dU,PPi and Mg2+
5Y5O	;	2.4	;	Crystal structure of the dUTPase of white spot syndrome virus in the apo state
4RFX	;	2.9	;	Crystal Structure of the Dynactin DCTN1 Fragment involved in Dynein Interaction
3L43	;	2.27	;	Crystal structure of the dynamin 3 GTPase domain bound with GDP
1JWY	;	2.3	;	CRYSTAL STRUCTURE OF THE DYNAMIN A GTPASE DOMAIN COMPLEXED WITH GDP, DETERMINED AS MYOSIN FUSION
5A3F	;	3.7	;	Crystal structure of the dynamin tetramer
4W7G	;	2.1	;	Crystal Structure of the Dynein Light Intermediate Chain's Conserved Domain
4W8F	;	3.541	;	Crystal structure of the dynein motor domain in the AMPPNP-bound state
7W86	;	1.8	;	Crystal structure of the DYW domain of DYW1
5MV2	;	2.1	;	Crystal structure of the E protein of the Japanese encephalitis live attenuated vaccine virus
5MV1	;	2.25	;	Crystal structure of the E protein of the Japanese encephalitis virulent virus
1F6J	;	2.25	;	CRYSTAL STRUCTURE OF THE E-DNA HEXAMER GGCGBR5CC
1F6I	;	2.2	;	CRYSTAL STRUCTURE OF THE E-DNA HEXAMER GGCGM5CC
4V6C	;	3.19	;	Crystal structure of the E. coli 70S ribosome in an intermediate state of ratcheting
4V6D	;	3.814	;	Crystal structure of the E. coli 70S ribosome in an intermediate state of ratcheting
4V6E	;	3.712	;	Crystal structure of the E. coli 70S ribosome in an intermediate state of ratcheting
3U33	;	2.8	;	Crystal Structure of the E. coli adaptive response protein AidB in the space group P3(2)
2NS1	;	1.962	;	Crystal structure of the e. coli ammonia channel AMTB complexed with the signal transduction protein GLNK
1FCO	;	2.2	;	CRYSTAL STRUCTURE OF THE E. COLI AMPC BETA-LACTAMASE COVALENTLY ACYLATED WITH THE INHIBITORY BETA-LACTAM, MOXALACTAM
1I5Q	;	1.83	;	CRYSTAL STRUCTURE OF THE E. COLI AMPC BETA-LACTAMASE MUTANT N152A COVALENTLY ACYLATED WITH THE INHIBITORY BETA-LACTAM, MOXALACTAM
1FCN	;	2.35	;	Crystal Structure of the E. Coli AMPC Beta-Lactamase Mutant Q120L/Y150E Covalently Acylated with the Substrate Beta-Lactam LORACARBEF
1C0A	;	2.4	;	CRYSTAL STRUCTURE OF THE E. COLI ASPARTYL-TRNA SYNTHETASE : TRNAASP : ASPARTYL-ADENYLATE COMPLEX
1IL2	;	2.6	;	Crystal Structure of the E. coli Aspartyl-tRNA Synthetase:Yeast tRNAasp:aspartyl-Adenylate Complex
3TGO	;	2.9	;	Crystal structure of the E. coli BamCD complex
3PWE	;	2.199	;	Crystal structure of the E. coli beta clamp mutant R103C, I305C, C260S, C333S at 2.2A resolution
4DJM	;	2.52	;	Crystal structure of the E. coli chaperone DraB
3GLI	;	3.5	;	Crystal Structure of the E. coli clamp loader bound to Primer-Template DNA and Psi Peptide
3GLH	;	3.891	;	Crystal Structure of the E. coli clamp loader bound to Psi Peptide
4TVX	;	3.24	;	Crystal structure of the E. coli CRISPR RNA-guided surveillance complex, Cascade
4Q2U	;	1.8	;	Crystal structure of the E. coli DinJ-YafQ toxin-antitoxin complex
1RYA	;	1.3	;	Crystal Structure of the E. coli GDP-mannose mannosyl hydrolase in complex with GDP and MG
1LDF	;	2.1	;	CRYSTAL STRUCTURE OF THE E. COLI GLYCEROL FACILITATOR (GLPF) MUTATION W48F, F200T
1FX8	;	2.2	;	CRYSTAL STRUCTURE OF THE E. COLI GLYCEROL FACILITATOR (GLPF) WITH SUBSTRATE GLYCEROL
1LDA	;	2.8	;	CRYSTAL STRUCTURE OF THE E. COLI GLYCEROL FACILITATOR (GLPF) WITHOUT SUBSTRATE GLYCEROL
1LDI	;	2.7	;	CRYSTAL STRUCTURE OF THE E. COLI GLYCEROL FACILITATOR (GLPF) WITHOUT SUBSTRATE GLYCEROL
1TF1	;	1.8	;	Crystal Structure of the E. coli Glyoxylate Regulatory Protein Ligand Binding Domain
5D55	;	2.0	;	Crystal structure of the E. coli Hda pilus minor tip subunit, HdaB
3EZH	;	1.7	;	Crystal Structure of the E. coli Histidine Kinase NarX Sensor Domain in Complex with Nitrate
3EZI	;	1.7	;	Crystal Structure of the E. coli Histidine Kinase NarX Sensor Domain without Ligand
3I9W	;	2.7	;	Crystal structure of the E. coli histidine kinase sensor TorS sensor domain
1MUL	;	2.3	;	Crystal structure of the E. coli HU alpha2 protein
4P3V	;	1.25	;	Crystal structure of the E. coli HU beta2 protein
3CDJ	;	2.8	;	Crystal structure of the E. coli KH/S1 domain truncated PNPase
8GAL	;	1.8	;	Crystal Structure of the E. coli LptA in complex with Murgantia histrionica Thanatin
8C8F	;	1.15	;	Crystal structure of the E. coli maltodextrin-binding protein
1IX9	;	0.9	;	Crystal Structure of the E. coli Manganase(III) superoxide dismutase mutant Y174F at 0.90 angstroms resolution.
1I0H	;	1.35	;	CRYSTAL STRUCTURE OF THE E. COLI MANGANESE SUPEROXIDE DISMUTASE MUTANT Y174F AT 1.35 ANGSTROMS RESOLUTION.
1IXB	;	0.9	;	CRYSTAL STRUCTURE OF THE E. COLI MANGANESE(II) SUPEROXIDE DISMUTASE MUTANT Y174F AT 0.90 ANGSTROMS RESOLUTION.
4BIN	;	2.49	;	Crystal structure of the E. coli N-acetylmuramoyl-L-alanine amidase AmiC
2Y1B	;	2.0	;	Crystal structure of the E. coli outer membrane lipoprotein RcsF
1ZMR	;	2.4	;	Crystal Structure of the E. coli Phosphoglycerate Kinase
8Q2C	;	3.21	;	Crystal structure of the E. coli PqiC Lipoprotein
8Q2D	;	2.08	;	Crystal structure of the E. coli PqiC Lipoprotein residues 17-187
1K8W	;	1.85	;	Crystal structure of the E. coli pseudouridine synthase TruB bound to a T stem-loop RNA
3MKN	;	2.0	;	Crystal structure of the E. coli pyrimidine nucleosidase YeiK bound to a competitive inhibitor
3MKM	;	2.2	;	Crystal structure of the E. coli pyrimidine nucleoside hydrolase YeiK (Apo-form)
3B9X	;	2.3	;	Crystal structure of the E. coli pyrimidine nucleoside hydrolase YeiK in complex with inosine
4WWW	;	3.1	;	Crystal structure of the E. coli ribosome bound to CEM-101
4V7T	;	3.1942	;	Crystal structure of the E. coli ribosome bound to chloramphenicol.
4V7V	;	3.2891	;	Crystal structure of the E. coli ribosome bound to clindamycin.
4U26	;	2.8	;	Crystal structure of the E. coli ribosome bound to dalfopristin and quinupristin.
4U24	;	2.9	;	Crystal structure of the E. coli ribosome bound to dalfopristin.
4V7U	;	3.1	;	Crystal structure of the E. coli ribosome bound to erythromycin.
4U27	;	2.8	;	Crystal structure of the E. coli ribosome bound to flopristin and linopristin.
4U20	;	2.9	;	Crystal structure of the E. coli ribosome bound to flopristin.
4U1V	;	3.0	;	Crystal structure of the E. coli ribosome bound to linopristin.
4WF1	;	3.09	;	Crystal structure of the E. coli ribosome bound to negamycin.
4U1U	;	2.95	;	Crystal structure of the E. coli ribosome bound to quinupristin.
4V7S	;	3.2547	;	Crystal structure of the E. coli ribosome bound to telithromycin.
4U25	;	2.9	;	Crystal structure of the E. coli ribosome bound to virginiamycin M1.
1D5Y	;	2.7	;	CRYSTAL STRUCTURE OF THE E. COLI ROB TRANSCRIPTION FACTOR IN COMPLEX WITH DNA
2WP9	;	2.7	;	Crystal structure of the E. coli succinate:quinone oxidoreductase (SQR) SdhB His207Thr mutant
2WU2	;	2.5	;	Crystal structure of the E. coli succinate:quinone oxidoreductase (SQR) SdhC His84Met mutant
2WU5	;	2.803	;	Crystal structure of the E. coli succinate:quinone oxidoreductase (SQR) SdhD His71Met mutant
2WS3	;	3.2	;	Crystal structure of the E. coli succinate:quinone oxidoreductase (SQR) SdhD Tyr83Phe mutant
7TZU	;	2.87	;	Crystal structure of the E. coli thiM riboswitch bound to 1-(4-(piperazin-1-yl)pyridin-3-yl)-N-(quinoxalin-6-ylmethyl)methanamine (linked compound 38)
7TZR	;	2.7	;	Crystal structure of the E. coli thiM riboswitch bound to N-methyl-1-(quinoxalin-6-yl)methanamine (compound 16)
4NYB	;	3.1	;	Crystal structure of the E. coli thiM riboswitch in complex with (4-(1,2,3-thiadiazol-4-yl)phenyl)methanamine
4NYA	;	2.65	;	Crystal structure of the E. coli thiM riboswitch in complex with 5-(azidomethyl)-2-methylpyrimidin-4-amine
4NYD	;	2.9	;	Crystal structure of the E. coli thiM riboswitch in complex with hypoxanthine
7TZT	;	2.96	;	Crystal structure of the E. coli thiM riboswitch in complex with N1,N1-dimethyl-N2-(quinoxalin-6-ylmethyl)ethane-1,2-diamine (linked compound 37)
7TZS	;	2.21	;	Crystal structure of the E. coli thiM riboswitch in complex with quinoxalin-6-ylmethanamine (compound 17)
4NYG	;	3.05	;	Crystal structure of the E. coli thiM riboswitch in complex with thiamine
7TDC	;	2.46	;	Crystal structure of the E. coli thiM riboswitch in complex with thiamine bisphosphonate, calcium ions
7TDB	;	2.56	;	Crystal structure of the E. coli thiM riboswitch in complex with thiamine bisphosphonate, manganese ions
3K0J	;	3.1	;	Crystal structure of the E. coli ThiM riboswitch in complex with thiamine pyrophosphate and the U1A crystallization module
7TDA	;	2.25	;	Crystal structure of the E. coli thiM riboswitch in complex with thiamine pyrophosphate, manganese ions
4NYC	;	3.15	;	Crystal structure of the E. coli thiM riboswitch in complex with thieno[2,3-b]pyrazin-7-amine
1CRZ	;	1.95	;	CRYSTAL STRUCTURE OF THE E. COLI TOLB PROTEIN
6WA8	;	3.3	;	Crystal structure of the E. coli transcription termination factor Rho
7X2R	;	4.4	;	Crystal structure of the E. coli transcription termination factor Rho
7B0W	;	1.75	;	Crystal structure of the E. coli type 1 pilus assembly inhibitor FimI bound to FimC
5IQN	;	1.0	;	Crystal structure of the E. coli type 1 pilus subunit FimG (engineered variant with substitution Q134E; N-terminal FimG residues 1-12 truncated) in complex with the donor strand peptide DsF_SRIRIRGYVR
5IQM	;	1.5	;	Crystal structure of the E. coli type 1 pilus subunit FimG (engineered variant with substitution Q134E; N-terminal FimG residues 1-12 truncated) in complex with the donor strand peptide DsF_T4R-T6R-D13N
5IQO	;	1.302	;	Crystal structure of the E. coli type 1 pilus subunit FimG (engineered variant with substitutions Q134E and S138E; N-terminal FimG residues 1-12 truncated) in complex with the donor strand peptide DsF_T4R-T6R-D13N
2ITM	;	2.1	;	Crystal structure of the E. coli xylulose kinase complexed with xylulose
1FCM	;	2.46	;	CRYSTAL STRUCTURE OF THE E.COLI AMPC BETA-LACTAMASE MUTANT Q120L/Y150E COVALENTLY ACYLATED WITH THE INHIBITORY BETA-LACTAM, CLOXACILLIN
2GZW	;	2.21	;	Crystal structure of the E.coli CRP-cAMP complex
3BY8	;	1.45	;	Crystal Structure of the E.coli DcuS Sensor Domain
4LRX	;	3.25	;	Crystal Structure of the E.coli DhaR(N)-DhaK complex
4LRY	;	2.83	;	Crystal Structure of the E.coli DhaR(N)-DhaK(T79L) complex
4LRZ	;	2.32	;	Crystal Structure of the E.coli DhaR(N)-DhaL complex
1Y79	;	2.0	;	Crystal Structure of the E.coli Dipeptidyl Carboxypeptidase Dcp in Complex with a Peptidic Inhibitor
1T3W	;	2.8	;	Crystal Structure of the E.coli DnaG C-terminal domain (residues 434 to 581)
1EUM	;	2.05	;	CRYSTAL STRUCTURE OF THE E.COLI FERRITIN ECFTNA
3O7P	;	3.196	;	Crystal structure of the E.coli Fucose:proton symporter, FucP (N162A)
6HPB	;	2.28	;	Crystal structure of the E.coli HicAB toxin-antitoxin complex
4CQN	;	2.5	;	Crystal structure of the E.coli LeuRS-tRNA complex with the non- cognate isoleucyl adenylate analogue
1F4L	;	1.85	;	CRYSTAL STRUCTURE OF THE E.COLI METHIONYL-TRNA SYNTHETASE COMPLEXED WITH METHIONINE
3BQ8	;	2.5	;	Crystal Structure of the E.coli PhoQ Sensor Domain
1XDP	;	2.5	;	Crystal Structure of the E.coli Polyphosphate Kinase in complex with AMPPNP
1SB7	;	2.2	;	Crystal structure of the E.coli pseudouridine synthase TruD
1Q8F	;	1.7	;	Crystal Structure of the E.coli pyrimidine nucleoside hydrolase yeiK
3G5I	;	2.1	;	Crystal Structure of the E.coli RihA pyrimidine nucleosidase bound to a iminoribitol-based inhibitor
1IU3	;	3.0	;	CRYSTAL STRUCTURE OF THE E.COLI SEQA PROTEIN COMPLEXED WITH HEMIMETHYLATED DNA
1J3E	;	2.5	;	Crystal Structure of the E.coli SeqA protein complexed with N6-methyladenine- guanine mismatch DNA
1C8U	;	1.9	;	CRYSTAL STRUCTURE OF THE E.COLI THIOESTERASE II, A HOMOLOGUE OF THE HUMAN NEF-BINDING ENZYME
2W89	;	2.0	;	Crystal structure of the E.coli tRNAArg aminoacyl stem issoacceptor RR-1660 at 2.0 Angstroem resolution
7S2Z	;	2.35	;	Crystal structure of the E100A mutant TIR domain from the grapevine disease resistance protein RUN1 bound to NAD
1LSJ	;	2.5	;	Crystal Structure of the E110Q Mutant of L-3-Hydroxyacyl-CoA Dehydrogenase in Complex with NAD
4L1Q	;	1.92	;	Crystal Structure of the E113Q-MauG/pre-Methylamine Dehydrogenase Complex
4L3H	;	1.79	;	Crystal Structure of the E113Q-MauG/pre-Methylamine Dehydrogenase Complex After Treatment with Hydrogen Peroxide
4L3G	;	2.05	;	Crystal Structure of the E113Q-MauG/pre-Methylamine Dehydrogenase Complex Aged 120 Days
1L5Z	;	2.0	;	CRYSTAL STRUCTURE OF THE E121K SUBSTITUTION OF THE RECEIVER DOMAIN OF SINORHIZOBIUM MELILOTI DCTD
2H2U	;	2.4	;	Crystal structure of the E130Y mutant of human soluble calcium-activated nucleotidase (SCAN) with calcium ion
3K7I	;	1.438	;	Crystal structure of the E131K mutant of the Indian Hedgehog N-terminal signalling domain
6ADC	;	3.055	;	Crystal structure of the E148A mutant CLC-ec1 in the presence of 50mM bromoacetate
6AD7	;	2.95	;	Crystal structure of the E148D mutant CLC-ec1 in 20 mM bromide
6ADA	;	3.153	;	Crystal structure of the E148D mutant CLC-ec1 in 200mM bromide
6AD8	;	3.3	;	Crystal structure of the E148D mutant CLC-ec1 in 50 mM bromide
6K5I	;	3.022	;	Crystal structure of the E148D/R147A/F317A mutant CLC-ec1 in the presence of 20 mM NaBr
6K5A	;	3.162	;	Crystal structure of the E148D/R147A/F317A mutant in presence of 200 mM NaBr
6ADB	;	2.692	;	Crystal structure of the E148N mutant CLC-ec1 in 20mM bromide
6K5D	;	3.203	;	Crystal structure of the E148N mutant CLC-ec1 in presence of 200 mM NaBr
2EXY	;	3.1	;	Crystal structure of the E148Q Mutant of EcClC, Fab complexed in absence of bound ions
5TNM	;	1.7	;	Crystal structure of the E153Q mutant of the CFTR inhibitory factor Cif containing the adducted (R)-1,2-Epoxyoctane hydrolysis intermediate
5TNQ	;	1.5	;	Crystal structure of the E153Q mutant of the CFTR inhibitory factor Cif containing the adducted (R)-Styrene oxide hydrolysis intermediate
5TNL	;	1.8	;	Crystal structure of the E153Q mutant of the CFTR inhibitory factor Cif containing the adducted (S)-1,2-Epoxyhexane hydrolysis intermediate
5TNN	;	1.95	;	Crystal structure of the E153Q mutant of the CFTR inhibitory factor Cif containing the adducted (S)-1,2-Epoxyoctane hydrolysis intermediate
5TND	;	1.55	;	Crystal structure of the E153Q mutant of the CFTR inhibitory factor Cif containing the adducted 1,2-Epoxycyclohexane hydrolysis intermediate
5TNK	;	1.65	;	Crystal structure of the E153Q mutant of the CFTR inhibitory factor Cif containing the adducted 1,2-Epoxyoctane hydrolysis intermediate
5JYC	;	2.0	;	Crystal structure of the E153Q mutant of the CFTR inhibitory factor Cif containing the adducted 14,15-EET hydrolysis intermediate
5TNG	;	1.75	;	Crystal structure of the E153Q mutant of the CFTR inhibitory factor Cif containing the adducted 14,15-EpETE hydrolysis intermediate
5TNR	;	1.8	;	Crystal structure of the E153Q mutant of the CFTR inhibitory factor Cif containing the adducted 16,17-EpDPE hydrolysis intermediate
5TNH	;	2.1	;	Crystal structure of the E153Q mutant of the CFTR inhibitory factor Cif containing the adducted 17,18-EpETE hydrolysis intermediate
5TNF	;	1.75	;	Crystal structure of the E153Q mutant of the CFTR inhibitory factor Cif containing the adducted 19,20-EpDPE hydrolysis intermediate
5TNJ	;	1.65	;	Crystal structure of the E153Q mutant of the CFTR inhibitory factor Cif containing the adducted 4-Vinyl-1-cyclohexene 1,2-epoxide hydrolysis intermediate
5TNE	;	1.75	;	Crystal structure of the E153Q mutant of the CFTR inhibitory factor Cif containing the adducted cis-Stilbene Oxide hydrolysis intermediate
5TNI	;	1.8	;	Crystal structure of the E153Q mutant of the CFTR inhibitory factor Cif containing the adducted S-Styrene oxide hydrolysis intermediate
5TNP	;	1.85	;	Crystal structure of the E153Q mutant of the CFTR inhibitory factor Cif containing the adducted Styrene oxide hydrolysis intermediate
8GHY	;	1.8	;	Crystal Structure of the E154D mutant CelD Cellulase from the Anaerobic Fungus Piromyces finnis in the complex with cellotriose.
1KG7	;	1.5	;	Crystal Structure of the E161A mutant of E.coli MutY (core fragment)
2OFJ	;	2.3	;	Crystal structure of the E190A mutant of o-succinylbenzoate synthase from Escherichia coli
2WPB	;	2.05	;	Crystal structure of the E192N mutant of E. Coli N-acetylneuraminic acid lyase in complex with pyruvate and the inhibitor (2R,3R)-2,3,4- trihydroxy-N,N-dipropylbutanamide in space group P21 crystal form I
2WKJ	;	1.45	;	Crystal structure of the E192N mutant of E. Coli N-acetylneuraminic acid lyase in complex with pyruvate at 1.45A resolution in space group P212121
5SXX	;	1.7	;	Crystal structure of the E198A variant of Burkholderia pseudomallei catalase-peroxidase KatG with INH
5SXW	;	1.6	;	Crystal structure of the E198A variant of catalase-peroxidase KatG of Burkholderia pseudomallei
1BY9	;	2.2	;	CRYSTAL STRUCTURE OF THE E2 DNA-BINDING DOMAIN FROM HUMAN PAPILLOMAVIRUS TYPE-16: IMPLICATIONS FOR ITS DNA BINDING-SITE SELECTION MECHANISM
3Q7L	;	2.2	;	Crystal structure of the E2 domain of amyloid precursor-like protein 1
3QMK	;	2.21	;	Crystal structure of the E2 domain of APLP1 in complex with heparin hexasaccharide
3FGO	;	2.5	;	Crystal Structure of the E2 magnesium fluoride complex of the (SR) Ca2+-ATPase with bound CPA and AMPPCP
1Q2X	;	2.05	;	Crystal Structure of the E243D Mutant of Aspartate Semialdehyde Dehydrogenase from Haemophilus influenzae bound with substrate aspartate semialdehyde
6MOY	;	2.5	;	Crystal structure of the E257A mutant of BlMan5B in complex with GlcNAc (co-crystallization)
6MP7	;	1.75	;	Crystal structure of the E257A mutant of BlMan5B in complex with GlcNAc (soaking)
8A0H	;	1.73	;	Crystal structure of the E25A mutant of the Orange Carotenoid Protein X from Gloeobacter kilaueensis JS1 complexed with echinenone
2GFT	;	2.3	;	Crystal structure of the E263A nucleophile mutant of Bacillus licheniformis endo-beta-1,4-galactanase in complex with galactotriose
2HLP	;	2.59	;	CRYSTAL STRUCTURE OF THE E267R MUTANT OF A HALOPHILIC MALATE DEHYDROGENASE IN THE APO FORM
4RSN	;	2.701	;	Crystal structure of the E267V mutant of cytochrome P450 BM3
3GJC	;	2.8	;	Crystal Structure of the E290S mutant of LeuT with bound OG
2HS6	;	1.9	;	Crystal structure of the E291K mutant of 12-oxophytodienoate reductase 3 (OPR3) from tomato
5TUU	;	2.251	;	Crystal structure of the E2F4-DP1 coiled coil and marked-box domains
5TUV	;	2.9	;	Crystal structure of the E2F5-DP1-p107 ternary complex
8B5W	;	1.8	;	Crystal structure of the E3 module from UBR4
4FO9	;	2.39	;	Crystal structure of the E3 SUMO Ligase PIAS2
8QNI	;	2.483	;	Crystal structure of the E3 ubiquitin ligase Cbl-b with an allosteric inhibitor (benzodiazepine compound 25)
8QNG	;	2.197	;	Crystal structure of the E3 ubiquitin ligase Cbl-b with an allosteric inhibitor (benzodiazepine HTS hit compound 1)
8QNH	;	2.001	;	Crystal structure of the E3 ubiquitin ligase Cbl-b with an allosteric inhibitor (WO2020264398 Ex23)
5MIY	;	1.717	;	Crystal structure of the E3 ubiquitin ligase RavN from Legionella pneumophila
5ZMV	;	3.3	;	Crystal structure of the E309A mutant of SR Ca2+-ATPase in E2(TG)
5ZMW	;	2.5	;	Crystal structure of the E309Q mutant of SR Ca2+-ATPase in E2(TG)
7ZD9	;	1.89	;	Crystal structure of the E352T mutant of S-adenosyl-L-homocysteine hydrolase from Synechocystis sp. PCC 6803 cocrystallized with adenosine in the presence of Rb+ cations
8CZ9	;	1.65	;	Crystal Structure of the E372K LNK SH2 Domain mutant in Complex with a JAK2 pY813 Phosphopeptide
4WXS	;	1.9	;	Crystal Structure of the E396D SNP Variant of the Myocilin Olfactomedin Domain
5FMH	;	1.8	;	Crystal structure of the E405K mutant of human apoptosis inducing factor
1WBH	;	1.55	;	Crystal structure of the E45N mutant from KDPG aldolase from Escherichia coli
4FDC	;	2.4	;	Crystal structure of the E493V mutant of human apoptosis inducing factor (AIF)
6M4F	;	2.2	;	Crystal structure of the E496A mutant of HsBglA
6M55	;	3.0	;	Crystal structure of the E496A mutant of HsBglA in complex with 4-galactosyllactose
5I4N	;	1.54	;	Crystal Structure of the E596A V617F Mutant JAK2 Pseudokinase Domain Bound to Mg-ATP
3RHJ	;	1.89	;	Crystal structure of the E673A mutant of the C-terminal domain of RAT 10'FORMYLTETRAHYDROFOLATE DEHYDROGENASE in complex with co-purified NADP
3RHL	;	2.0	;	Crystal structure of the E673A/C707A double mutant of the C-Terminal domain of RAT 10'FORMYLTETRAHYDROFOLATE DEHYDROGENASE in complex with co-purified NADP
3RHM	;	2.38	;	Crystal structure of the E673Q mutant oF C-Terminal domain of 10'FORMYLTETRAHYDROFOLATE DEHYDROGENASE
3RHO	;	2.26	;	Crystal structure of the E673Q MUTANT OF C-Terminal domain of 10'FORMYLTETRAHYDROFOLATE DEHYDROGENASE in complex with NADP
1UJZ	;	2.1	;	Crystal structure of the E7_C/Im7_C complex; a computationally designed interface between the colicin E7 DNase and the Im7 Immunity protein
2ERH	;	2.0	;	Crystal Structure of the E7_G/Im7_G complex; a designed interface between the colicin E7 DNAse and the Im7 immunity protein
1FSJ	;	1.8	;	CRYSTAL STRUCTURE OF THE E9 DNASE DOMAIN
2GZJ	;	1.6	;	Crystal Structure of the E9 DNase Domain with a Mutant Immunity Protein IM9 (D51A)
2GZI	;	1.7	;	Crystal Structure of the E9 DNase Domain with a Mutant Immunity Protein IM9 (V34A)
2GZF	;	1.75	;	Crystal structure of the E9 DNase domain with a mutant immunity protein IM9 (Y54F)
2GZE	;	1.8	;	Crystal structure of the E9 DNase domain with a mutant immunity protein IM9 (Y55A)
2GZG	;	1.7	;	Crystal Structure of the E9 DNase Domain with a Mutant Immunity Protein IM9 (Y55F)
1FR2	;	1.6	;	CRYSTAL STRUCTURE OF THE E9 DNASE DOMAIN WITH A MUTANT IMMUNITY PROTEIN IM9(E41A)
3K7H	;	1.5	;	Crystal structure of the E95K mutant of the Indian Hedgehog N-terminal signalling domain
4KIE	;	1.7	;	Crystal structure of the EAL domain of c-di-GMP specific phosphodiesterase YahA
4LYK	;	2.4	;	Crystal structure of the EAL domain of c-di-GMP specific phosphodiesterase YahA in complex with activating cofactor Mg++
4LJ3	;	1.7	;	Crystal structure of the EAL domain of c-di-GMP specific phosphodiesterase YahA in complex with substrate c-di-GMP and Ca++
5YRP	;	2.99	;	Crystal structure of the EAL domain of Mycobacterium smegmatis DcpA
2NPS	;	2.5	;	Crystal Structure of the Early Endosomal SNARE Complex
2DRY	;	1.8	;	Crystal structure of the earthworm lectin C-terminal domain mutant
2DS0	;	1.8	;	Crystal structure of the earthworm lectin C-terminal domain mutant in complex with 6'-sialyllactose
2DRZ	;	2.19	;	Crystal structure of the earthworm lectin C-terminal domain mutant in complex with lactose
2ZQO	;	1.8	;	Crystal structure of the earthworm R-type lectin C-half in complex with GalNAc
2ZQN	;	1.9	;	Crystal structure of the earthworm R-type lectin C-half in complex with Lactose
1TXQ	;	1.8	;	Crystal structure of the EB1 C-terminal domain complexed with the CAP-Gly domain of p150Glued
4E61	;	2.45	;	Crystal structure of the EB1-like motif of Bim1p
1EBO	;	3.0	;	CRYSTAL STRUCTURE OF THE EBOLA VIRUS MEMBRANE-FUSION SUBUNIT, GP2, FROM THE ENVELOPE GLYCOPROTEIN ECTODOMAIN
3C7T	;	1.76	;	Crystal structure of the ecdysone phosphate phosphatase, EPPase, from Bombix mori in complex with tungstate
3IXP	;	2.85	;	Crystal structure of the ecdysone receptor bound to BYI08346
2Q2X	;	2.0	;	Crystal Structure of the ECH2 decarboxylase domain of CurF from Lyngbya majuscula
2Q34	;	1.85	;	Crystal Structure of the ECH2 decarboxylase domain of CurF from Lyngbya majuscula, rhombohedral crystal form
3GLF	;	3.388	;	Crystal Structure of the Ecoli Clamp Loader Bound to Primer-Template DNA
3N7P	;	2.8	;	Crystal structure of the ectodomain complex of the CGRP receptor, a Class-B GPCR, reveals the site of drug antagonism
3N7R	;	2.9	;	Crystal structure of the ectodomain complex of the CGRP receptor, a Class-B GPCR, reveals the site of drug antagonism
3N7S	;	2.1	;	Crystal structure of the ectodomain complex of the CGRP receptor, a Class-B GPCR, reveals the site of drug antagonism
4EBY	;	1.65	;	Crystal structure of the ectodomain of a receptor like kinase
4EBZ	;	1.792	;	Crystal structure of the ectodomain of a receptor like kinase
3X0G	;	1.899	;	Crystal structure of the ectodomain of African green monkey CD81 large extracellular loop (agmCD81-LEL)
4JNT	;	4.09	;	Crystal structure of the ectodomain of Bovine viral diarrhea virus 1 E2 envelope protein
1Z6I	;	2.5	;	Crystal structure of the ectodomain of Drosophila transmembrane receptor PGRP-LCa
3X0E	;	1.844	;	Crystal structure of the ectodomain of human CD81 large extracellular loop (hCD81-LEL)
1CX8	;	3.2	;	CRYSTAL STRUCTURE OF THE ECTODOMAIN OF HUMAN TRANSFERRIN RECEPTOR
2NSU	;	27.0	;	Crystal structure of the ectodomain of human transferrin receptor fitted into a cryo-EM reconstruction of canine parvovirus and feline transferrin receptor complex
1FJR	;	2.3	;	CRYSTAL STRUCTURE OF THE ECTODOMAIN OF METHUSELAH
3X0F	;	1.471	;	Crystal structure of the ectodomain of mouse CD81 large extracellular loop (mCD81-LEL)
8PAG	;	3.5	;	Crystal structure of the ectodomain of Norway rat pestivirus E2 glycoprotein
7VS7	;	2.015	;	Crystal structure of the ectodomain of OsCERK1 in complex with chitin hexamer
8HQA	;	3.2	;	Crystal structure of the ectodomain of the MlaD protein from Escherichia coli in the resting state
5BXX	;	2.0	;	Crystal structure of the ectoine synthase from the cold-adapted marine bacterium Sphingopyxis alaskensis
3FXB	;	2.9	;	Crystal structure of the ectoine-binding protein UehA
2AJG	;	2.0	;	Crystal structure of the editing domain of E. coli leucyl-tRNA synthetase
2AJI	;	3.2	;	Crystal structure of the editing domain of E. coli leucyl-tRNA synthetase complexes with isoleucine
2AJH	;	2.4	;	Crystal structure of the editing domain of E. coli leucyl-tRNA synthetase complexes with methionine
1TJE	;	1.5	;	Crystal structure of the editing domain of threonyl-tRNA synthetase
1TKG	;	1.5	;	Crystal structure of the editing domain of threonyl-tRNA synthetase complexed with an analog of seryladenylate
1TKE	;	1.46	;	Crystal structure of the editing domain of threonyl-tRNA synthetase complexed with serine
1TKY	;	1.48	;	Crystal structure of the editing domain of threonyl-tRNA synthetase complexed with seryl-3'-aminoadenosine
1Y2Q	;	1.95	;	Crystal structure of the editing domain of threonyl-tRNA synthetase from Pyrococcus abyssi
2HL2	;	2.6	;	Crystal structure of the editing domain of threonyl-tRNA synthetase from Pyrococcus abyssi in complex with an analog of seryladenylate
3PD5	;	2.29	;	Crystal structure of the editing domain of threonyl-tRNA synthetase from Pyrococcus abyssi in complex with an analog of threonyl-adenylate
3PD4	;	2.4	;	Crystal structure of the editing domain of threonyl-tRNA synthetase from Pyrococcus abyssi in complex with glycyl-3'-aminoadenosine
2HKZ	;	2.1	;	Crystal structure of the editing domain of threonyl-tRNA synthetase from Pyrococcus abyssi in complex with L-serine
2HL0	;	1.86	;	Crystal structure of the editing domain of threonyl-tRNA synthetase from Pyrococcus abyssi in complex with seryl-3'-aminoadenosine
2HL1	;	2.25	;	Crystal structure of the editing domain of threonyl-tRNA synthetase from Pyrococcus abyssi in complex with seryl-3'-aminoadenosine
3PD2	;	1.86	;	Crystal structure of the editing domain of threonyl-tRNA synthetase from Pyrococcus abyssi in complex with seryl-3'-aminoadenosine
3PD3	;	1.86	;	Crystal structure of the editing domain of threonyl-tRNA synthetase from Pyrococcus abyssi in complex with threonyl-3'-aminoadenosine
1PK0	;	3.3	;	Crystal Structure of the EF3-CaM complexed with PMEApp
2EFK	;	2.3	;	Crystal structure of the EFC domain of Cdc42-interacting protein 4
2EFL	;	2.61	;	Crystal structure of the EFC domain of formin-binding protein 17
3ABH	;	2.0	;	Crystal structure of the EFC/F-BAR domain of human PACSIN2/Syndapin II (2.0 A)
3ACO	;	2.7	;	Crystal structure of the EFC/F-BAR domain of human PACSIN2/Syndapin II (2.7 A)
7AD5	;	2.14	;	Crystal structure of the effector AvrLm5-9 from Leptosphaeria maculans
7B76	;	2.7	;	Crystal structure of the effector AvrLm5-9 from Leptosphaeria maculans
2H9B	;	1.8	;	Crystal structure of the effector binding domain of a BenM variant (BenM R156H/T157S)
2H99	;	1.85	;	Crystal structure of the effector binding domain of a BenM variant (R156H,T157S)
3GLB	;	2.8	;	Crystal structure of the effector binding domain of a CATM variant (R156H)
2H98	;	1.8	;	Crystal structure of the effector binding domain of a CatM variant, CatM(V158M)
5VVH	;	2.5	;	Crystal Structure of the Effector Binding Domain of LysR-type Transcriptional Regulator, OccR from Agrobacterium tumefaciens
2R2O	;	2.0	;	Crystal structure of the effector domain of human Plexin B1
3F8L	;	1.9	;	Crystal Structure of the Effector Domain of PhnF from Mycobacterium smegmatis
2REX	;	2.3	;	Crystal structure of the effector domain of PLXNB1 bound with Rnd1 GTPase
5DIL	;	2.01	;	Crystal structure of the effector domain of the NS1 protein from influenza virus B
3D3O	;	2.46	;	Crystal structure of the effector domain of the putative transcriptional regulator IclR from Acinetobacter sp. ADP1
5XN7	;	2.7	;	Crystal structure of the effector domain RID of Vibrio vulnificus MARTX toxin
6ZUQ	;	1.94	;	Crystal structure of the effector Ecp11-1 from Fulvia fulva
6ZUS	;	1.62	;	Crystal structure of the effector Ecp11-1 from Fulvia fulva
4KL0	;	1.598	;	Crystal structure of the effector protein XOO4466
6WES	;	1.36	;	Crystal structure of the effector SnTox3 from Parastagonospora nodorum
4JUR	;	2.5	;	Crystal structure of the effector Tae4 from Salmonella typhimurium in complex with the immunity Tai4 from Enterobacter cloacae
4ZSI	;	1.652	;	Crystal structure of the effector-binding domain of DasR (DasR-EBD) in complex with glucosamine-6-phosphate
4ZSK	;	1.85	;	Crystal structure of the effector-binding domain of DasR (DasR-EBD) in complex with N-acetylglucosamine-6-phosphate
4QBA	;	2.21	;	Crystal structure of the effector-binding domain of S. aureus CcpE
5Z49	;	2.148	;	Crystal structure of the effector-binding domain of Synechococcus elongatus CmpR in complex with ribulose-1,5-bisphosphate
8H3Z	;	2.35	;	Crystal structure of the effector-binding domain of the LysR-type trasncription factor NtcB from Anabaena PCC 7120
4NSO	;	2.4	;	Crystal structure of the effector-immunity protein complex
7CLT	;	2.07381	;	Crystal structure of the EFhd1/Swiprosin-2, a mitochondrial actin-binding protein
3GOP	;	2.8	;	Crystal structure of the EGF receptor juxtamembrane and kinase domains
5UGA	;	1.82	;	Crystal structure of the EGFR kinase domain (L858R, T790M, V948R) in complex with 4-(4-{[2-{[(3S)-1-acetylpyrrolidin-3-yl]amino}-9-(propan-2-yl)-9H-purin-6-yl]amino}phenyl)-1-methylpiperazin-1-ium
5UG8	;	1.46	;	Crystal structure of the EGFR kinase domain (L858R, T790M, V948R) in complex with a covalent inhibitor N-[(3R,4R)-4-fluoro-1-{6-[(1-methyl-1H-pyrazol-4-yl)amino]-9-(propan-2-yl)-9H-purin-2-yl}pyrrolidin-3-yl]propanamide
5UG9	;	1.33	;	Crystal structure of the EGFR kinase domain (L858R, T790M, V948R) in complex with a covalent inhibitor N-[(3R,4R)-4-fluoro-1-{6-[(3-methoxy-1-methyl-1H-pyrazol-4-yl)amino]-9-(propan-2-yl)-9H-purin-2-yl}pyrrolidin-3-yl]propanamide
5UGC	;	1.58	;	Crystal structure of the EGFR kinase domain (L858R, T790M, V948R) in complex with a covalent inhibitor N-[(3R,4R)-4-fluoro-1-{6-[(3-methoxy-1-methyl-1H-pyrazol-4-yl)amino]-9-methyl-9H-purin-2-yl}pyrrolidin-3-yl]propanamide
5UGB	;	2.53	;	Crystal structure of the EGFR kinase domain in complex with 4-(4-{[2-{[(3S)-1-acetylpyrrolidin-3-yl]amino}-9-(propan-2-yl)-9H-purin-6-yl]amino}phenyl)-1-methylpiperazin-1-ium
5CNN	;	1.9	;	Crystal structure of the EGFR kinase domain mutant I682Q
5CNO	;	1.55	;	Crystal structure of the EGFR kinase domain mutant V924R
3FIA	;	1.45	;	Crystal structure of the EH 1 domain from human intersectin-1 protein. Northeast Structural Genomics Consortium target HR3646e.
1Q46	;	2.86	;	crystal structure of the eIF2 alpha subunit from saccharomyces cerevisia
4U1C	;	3.5	;	Crystal structure of the eIF3a/eIF3c PCI-domain heterodimer
4U1E	;	2.0	;	Crystal structure of the eIF3b-CTD/eIF3i/eIF3g-NTD translation initiation complex
2ZU6	;	2.8	;	crystal structure of the eIF4A-PDCD4 complex
6FC2	;	1.92	;	Crystal structure of the eIF4E-Eap1p complex from Saccharomyces cerevisiae
6FC1	;	1.35	;	Crystal structure of the eIF4E-Eap1p complex from Saccharomyces cerevisiae in the cap-bound state
6FC0	;	1.293	;	Crystal structure of the eIF4E-eIF4G complex from Chaetomium thermophilum
6FBZ	;	1.496	;	Crystal structure of the eIF4E-eIF4G complex from Chaetomium thermophilum in the cap-bound state
6FC3	;	1.75	;	Crystal structure of the eIF4E-p20 complex from Saccharomyces cerevisiae
6ZT0	;	2.02	;	Crystal structure of the Eiger TNF domain/Grindelwald extracellular domain complex
6ZZB	;	1.322	;	Crystal structure of the Eimeria tenella surface antigen protein SAG19
2DE5	;	1.9	;	Crystal structure of the electron transfer complex between oxygenase and ferredoxin in carbazole 1,9a-dioxygenase
3W9C	;	2.5	;	Crystal structure of the electron transfer complex of cytochrome p450cam with putidaredoxin
2V3B	;	2.45	;	Crystal structure of the electron transfer complex rubredoxin - rubredoxin reductase from Pseudomonas aeruginosa.
3FET	;	2.05	;	Crystal Structure of the Electron Transfer Flavoprotein Subunit Alpha related Protein Ta0212 from Thermoplasma acidophilum
4PW9	;	2.49	;	Crystal structure of the electron-transfer complex formed between a sulfite dehydrogenase and a c-type cytochrome from Sinorhizobium meliloti
5B1J	;	3.0	;	Crystal structure of the electron-transfer complex of copper nitrite reductase with a cupredoxin
8IJ9	;	2.04	;	Crystal structure of the ELKS1/Rab6B complex
2VSZ	;	2.3	;	Crystal Structure of the ELMO1 PH domain
7LY7	;	3.8	;	Crystal structure of the elongation module of the bacillamide NRPS, BmdB, in complex with the oxidase BmdC
4A8J	;	2.1	;	Crystal Structure of the Elongator subcomplex Elp456
1NTG	;	2.21	;	Crystal Structure of the EMAP II-like Cytokine Released from human tyrosyl-tRNA Synthetase
1E7Z	;	2.05	;	Crystal structure of the EMAP2/RNA binding domain of the p43 protein from human aminoacyl-tRNA synthetase complex
1FL0	;	1.5	;	CRYSTAL STRUCTURE OF THE EMAP2/RNA-BINDING DOMAIN OF THE P43 PROTEIN FROM HUMAN AMINOACYL-TRNA SYNTHETASE COMPLEX
5F1W	;	2.161	;	Crystal structure of the enantiomer of a macrocyclic peptide containing fragments from alpha synuclein 36-55
5LJF	;	1.7344	;	Crystal structure of the endo-1,4-glucanase RBcel1 E135A with cellotriose
4M24	;	1.386	;	Crystal structure of the endo-1,4-glucanase, RBcel1, in complex with cellobiose
3O5S	;	2.2	;	Crystal Structure of the endo-beta-1,3-1,4 glucanase from Bacillus subtilis (strain 168)
5HNN	;	1.63	;	Crystal structure of the endo-beta-1,4-glucanase (Xac0030) from Xanthomonas axonopodis pv. citri with the triple mutation His174Trp, Tyr211Ala and Lys227Arg.
5HOS	;	1.6	;	Crystal structure of the endo-beta-1,4-glucanase Xac0029 from Xanthomonas axonopodis pv. citri
3CIV	;	1.9	;	Crystal structure of the endo-beta-1,4-mannanase from Alicyclobacillus acidocaldarius
4QDN	;	1.7	;	Crystal Structure of the endo-beta-N-acetylglucosaminidase from Thermotoga maritima
5GKP	;	2.3	;	Crystal structure of the EndoG worm homologue CPS-6 H148A/F122A in complex with DNA
3ISM	;	2.2	;	Crystal structure of the EndoG/EndoGI complex: Mechanism of EndoG inhibition
7P6G	;	1.49	;	Crystal structure of the endoglucanase RBcel1 E135Q
7P6H	;	1.73	;	Crystal structure of the endoglucanase RBcel1 E135Q in complex with cellotriose
7P6I	;	1.47	;	Crystal structure of the endoglucanase RBcel1 Y201F
5FML	;	1.7	;	Crystal structure of the endonuclease from the PA subunit of influenza B virus bound to the PB2 subunit NLS peptide
3GOC	;	1.6	;	Crystal structure of the Endonuclease V (SAV1684) from Streptomyces avermitilis. Northeast Structural Genomics Consortium Target SvR196
3G6S	;	2.5	;	Crystal structure of the endonuclease/exonuclease/phosphatase (BVU_0621) from Bacteroides vulgatus. Northeast Structural Genomics Consortium Target BvR56D
3GA2	;	2.1	;	Crystal structure of the Endonuclease_V (BSU36170) from Bacillus subtilis, Northeast Structural Genomics Consortium Target SR624
2D4C	;	2.4	;	Crystal structure of the endophilin BAR domain mutant
1L8J	;	2.0	;	Crystal Structure of the Endothelial Protein C Receptor and Bound Phospholipid Molecule
1LQV	;	1.6	;	Crystal structure of the Endothelial protein C receptor with phospholipid in the groove in complex with Gla domain of protein C.
3P22	;	2.501	;	Crystal structure of the ENE, a viral RNA stability element, in complex with A9 RNA
3D6E	;	2.4	;	Crystal structure of the engineered 1,3-1,4-beta-glucanase protein from Bacillus licheniformis
6S6E	;	2.001	;	Crystal structure of the engineered ancestor of haloalkane dehalogenases and Renilla luciferase (AncHLD-RLuc I161_F162PinsL)
1U0A	;	1.64	;	Crystal structure of the engineered beta-1,3-1,4-endoglucanase H(A16-M) in complex with beta-glucan tetrasaccharide
5LOC	;	2.04	;	Crystal structure of the engineered D-Amino Acid Dehydrogenase (DAADH)
5LOA	;	1.84	;	Crystal structure of the engineered D-Amino Acid Dehydrogenase (DAADH) bound to NADP+
3U0L	;	1.25	;	Crystal structure of the engineered fluorescent protein mRuby, crystal form 1, pH 4.5
3U0M	;	1.65	;	Crystal structure of the engineered fluorescent protein mRuby, crystal form 1, pH 8.5
3U0N	;	1.6	;	Crystal structure of the engineered fluorescent protein mRuby, crystal form 2
4DXC	;	2.3	;	Crystal structure of the engineered MBP TEM-1 fusion protein RG13, C2 space group
3ET9	;	2.8	;	Crystal structure of the engineered neutralizing antibody 1H
3ESV	;	2.0	;	Crystal structure of the engineered neutralizing antibody M18
3ETB	;	3.8	;	Crystal structure of the engineered neutralizing antibody M18 complexed with anthrax protective antigen domain 4
5YKH	;	2.457	;	Crystal structure of the engineered nine-repeat PUF domain
5YKI	;	2.25	;	Crystal structure of the engineered nine-repeat PUF domain in complex with cognate 9nt-RNA
8SO5	;	2.35	;	Crystal structure of the engineered quorum quenching acylase MacQ variant M1 - acylated form
7SO0	;	1.74	;	Crystal Structure of the Engineered Tick Evasin EVA-P974(F31A) Complexed to Human Chemokine CCL2
2XUA	;	1.9	;	Crystal structure of the enol-lactonase from Burkholderia xenovorans LB400
4FQD	;	2.5	;	Crystal structure of the enolpyruvyl transferase NikO from Streptomyces tendae
4CW5	;	2.3	;	Crystal structure of the enoyl reductase domain of DfnA from Bacillus amyloliquefaciens
3C8D	;	1.8	;	Crystal structure of the enterobactin esterase FES from Shigella flexneri in the presence of 2,3-Di-hydroxy-N-benzoyl-glycine
3C8H	;	2.48	;	Crystal structure of the enterobactin esterase FES from Shigella flexneri in the presence of 2,3-Di-hydroxy-N-benzoyl-serine
3C87	;	2.17	;	Crystal structure of the enterobactin esterase FES from Shigella flexneri in the presence of enterobactin
3IPR	;	2.5	;	Crystal structure of the Enterococcus faecalis gluconate specific EIIA phosphotransferase system component
3TB5	;	2.3	;	Crystal Structure of the Enterococcus faecalis Methionine aminopeptidase apo form
6LSG	;	2.14	;	Crystal structure of the enterovirus 71 polymerase elongation complex (C0S6M form)
7W9S	;	2.53	;	Crystal structure of the enterovirus 71 polymerase elongation complex (C1S3 form)
6LSH	;	2.231	;	Crystal structure of the enterovirus 71 polymerase elongation complex (C2S6M form)
6LSF	;	2.152	;	Crystal structure of the enterovirus 71 polymerase elongation complex (C2S6RA/C2S6RB form)
6LSE	;	2.25	;	Crystal structure of the enterovirus 71 polymerase elongation complex (C3S6A/C3S6B form)
5UCC	;	1.83	;	Crystal structure of the ENTH domain of ENT2 from Candida albicans
1EDU	;	1.8	;	CRYSTAL STRUCTURE OF THE ENTH DOMAIN OF RAT EPSIN 1
7A0K	;	2.7	;	Crystal structure of the entire ectodomain from the Physcomitrella patens receptor kinase CR4
4HEA	;	3.3027	;	Crystal structure of the entire respiratory complex I from Thermus thermophilus
6Y5W	;	2.55	;	Crystal structure of the envelope glycoprotein complex of Andes virus in a near postfusion conformation
6Y62	;	2.2	;	Crystal structure of the envelope glycoprotein complex of Maporal virus in a prefusion conformation
7QQB	;	2.6	;	Crystal structure of the envelope glycoprotein complex of Puumala virus in complex with the scFv fragment of the broadly neutralizing human antibody ADI-42898
3UAJ	;	3.232	;	Crystal structure of the envelope glycoprotein ectodomain from dengue virus serotype 4 in complex with the fab fragment of the chimpanzee monoclonal antibody 5H2
6Y5F	;	3.2	;	Crystal structure of the envelope glycoprotein prefusion complex of Andes virus - Mutant H953F
8EHU	;	1.1	;	Crystal structure of the environmental CRH-1 class A carbapenemase at 1.1 Angstrom resolution
5XGA	;	1.951	;	Crystal structure of the EnvZ periplasmic domain with CHAPS
2J3V	;	2.11	;	Crystal structure of the enzymatic component C2-I of the C2-toxin from Clostridium botulinum at pH 3.0
2J3X	;	1.75	;	Crystal structure of the enzymatic component C2-I of the C2-toxin from Clostridium botulinum at pH 3.0 (mut-S361R)
2J3Z	;	2.3	;	Crystal structure of the enzymatic component C2-I of the C2-toxin from Clostridium botulinum at pH 6.1
1GIQ	;	1.8	;	Crystal Structure of the Enzymatic Componet of Iota-Toxin from Clostridium Perfringens with NADH
1GIR	;	2.1	;	CRYSTAL STRUCTURE OF THE ENZYMATIC COMPONET OF IOTA-TOXIN FROM CLOSTRIDIUM PERFRINGENS WITH NADPH
2VO9	;	1.8	;	CRYSTAL STRUCTURE OF THE ENZYMATICALLY ACTIVE DOMAIN OF THE LISTERIA MONOCYTOGENES BACTERIOPHAGE 500 ENDOLYSIN PLY500
3ESF	;	2.01	;	Crystal Structure of the enzyme Fe-superoxide dismutase TbSODB2 from Trypanosoma brucei
1H8U	;	1.8	;	Crystal Structure of the Eosinophil Major Basic Protein at 1.8A: An Atypical Lectin with a Paradigm Shift in Specificity
7KJA	;	1.75	;	Crystal structure of the EphA2 intracellular KD-SAM domains
7KJB	;	2.8	;	Crystal structure of the EphA2 S897E/S901E mutant intracellular KD-SAM domains
7KJC	;	2.3	;	Crystal structure of the EphA2 S901E mutant intracellular KD-SAM domains
5JR2	;	1.75	;	Crystal structure of the EphA4 LBD in complex with APYd3 peptide inhibitor
2WO1	;	1.85	;	Crystal Structure of the EphA4 Ligand Binding Domain
2WO3	;	2.35	;	Crystal Structure of the EphA4-ephrinA2 complex
2WO2	;	2.45	;	Crystal Structure of the EphA4-ephrinB2 complex
7S7K	;	3.15	;	Crystal structure of the EphB2 extracellular domain
2HEN	;	2.6	;	Crystal Structure of the EphB2 Receptor Kinase domain in complex with ADP
1KGY	;	2.7	;	Crystal Structure of the EphB2-ephrinB2 complex
5WB8	;	3.0	;	Crystal structure of the epidermal growth factor receptor extracellular region in complex with epigen
5WB7	;	2.941	;	Crystal structure of the epidermal growth factor receptor extracellular region in complex with epiregulin
7LFS	;	3.5	;	Crystal structure of the epidermal growth factor receptor extracellular region with A265V mutation in complex with epiregulin
7LFR	;	3.2	;	Crystal structure of the epidermal growth factor receptor extracellular region with R84K mutation in complex with epiregulin crystallized with spermine
7LEN	;	2.9	;	Crystal structure of the epidermal growth factor receptor extracellular region with R84K mutation in complex with epiregulin crystallized with trehalose
5EQU	;	2.2	;	Crystal structure of the epimerase SnoN in complex with Fe3+, alpha ketoglutarate and nogalamycin RO
5ERL	;	2.85	;	Crystal structure of the epimerase SnoN in complex with Ni2+, succinate and nogalamycin RO
2XHG	;	1.5	;	Crystal Structure of the Epimerization Domain from the Initiation Module of Tyrocidine Biosynthesis
6TA8	;	2.4	;	Crystal structure of the epimerization domain from the third module of tyrocidine synthetase B, TycB3(E)
6L30	;	2.8	;	Crystal structure of the epithelial cell transforming 2 (ECT2)
5GQ0	;	2.31	;	Crystal structure of the Epithiospecifier Protein, ESP from Arabidopsis thaliana
1EYH	;	1.56	;	CRYSTAL STRUCTURE OF THE EPSIN N-TERMINAL HOMOLOGY (ENTH) DOMAIN AT 1.56 ANGSTROM RESOLUTION
3PHF	;	3.58	;	Crystal Structure of the Epstein-Barr virus gH and gL complex
7NX5	;	2.5	;	Crystal structure of the Epstein-Barr Virus protein ZEBRA (BZLF1, Zta) bound to a methylated DNA duplex
1TZQ	;	2.3	;	Crystal structure of the equinatoxin II 8-69 double cysteine mutant
2P15	;	1.94	;	Crystal structure of the ER alpha ligand binding domain with the agonist ortho-trifluoromethylphenylvinyl estradiol
7RS8	;	1.64	;	Crystal Structure of the ER-alpha Ligand-binding Domain (L372S, L536S) in complex with DMERI-16
7RS0	;	1.67	;	Crystal Structure of the ER-alpha Ligand-binding Domain (L372S, L536S) in complex with DMERI-18
7RRX	;	1.78	;	Crystal Structure of the ER-alpha Ligand-binding Domain (L372S, L536S) in complex with DMERI-19
7RRY	;	1.87	;	Crystal Structure of the ER-alpha Ligand-binding Domain (L372S, L536S) in complex with DMERI-20
7RS1	;	1.59	;	Crystal Structure of the ER-alpha Ligand-binding Domain (L372S, L536S) in complex with DMERI-21
7RS2	;	1.72	;	Crystal Structure of the ER-alpha Ligand-binding Domain (L372S, L536S) in complex with DMERI-23
7RS9	;	1.7	;	Crystal Structure of the ER-alpha Ligand-binding Domain (L372S, L536S) in complex with DMERI-25
7RS3	;	1.84	;	Crystal Structure of the ER-alpha Ligand-binding Domain (L372S, L536S) in complex with DMERI-29
7RRZ	;	1.83	;	Crystal Structure of the ER-alpha Ligand-binding Domain (L372S, L536S) in complex with DMERI-30
7RS7	;	1.58	;	Crystal Structure of the ER-alpha Ligand-binding Domain (L372S, L536S) in complex with DMERI-30
7RS4	;	1.78	;	Crystal Structure of the ER-alpha Ligand-binding Domain (L372S, L536S) in complex with DMERI-8
5TN9	;	2.253	;	Crystal Structure of the ER-alpha Ligand-binding Domain (L372S,L536S) in Complex with the OBHS-BSC, 4-bromophenyl (1R,2R,4S)-5-(4-hydroxyphenyl)-6-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonate
5TNB	;	2.08	;	Crystal Structure of the ER-alpha Ligand-binding Domain (L372S,L536S) in Complex with the OBHS-BSC, 4-bromophenyl (1R,2R,4S)-6-(4-(2-(dimethylamino)ethoxy)phenyl)-5-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonate
5EGV	;	2.863	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex the 3,4-diaryl-furan derivative 3-chloranyl-4-[4-(2-chloranyl-4-oxidanyl-phenyl)furan-3-yl]phenol
5TLL	;	2.423	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with (E)-2-chloro-4'-hydroxy-4-((hydroxyiminio)methyl)-[1,1'-biphenyl]-3-olate
5TN7	;	2.238	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with (E)-3'-fluoro-4'-hydroxy-3-((hydroxyiminio)methyl)-[1,1'-biphenyl]-4-olate
5TN8	;	2.652	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with (E)-4'-hydroxy-3-((hydroxyiminio)methyl)-[1,1'-biphenyl]-4-olate
5TLG	;	2.228	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with (E)-4,4''-dihydroxy-3'-((hydroxyiminio)methyl)-[1,1':2',1''-terphenyl]-4'-olate
5KRH	;	2.243	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with 16-benzylidene estrone
5KRI	;	2.247	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with 16b-benzyl 17b-estradiol
5TM3	;	2.194	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with 2,3-bis(2-chloro-4-hydroxyphenyl)thiophene 1-oxide
5TM2	;	2.603	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with 2,5-bis(2-chloro-4-hydroxyphenyl)thiophene 1-oxide
5TM1	;	2.231	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with 2,5-bis(2-fluoro-4-hydroxyphenyl)thiophene 1-oxide
5TLY	;	2.143	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with 3,4-bis(2-fluoro-4-hydroxyphenyl)thiophene 1,1-dioxide
5TLX	;	2.103	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with 3,4-bis(4-hydroxyphenyl)thiophene 1,1-dioxide
5TLM	;	2.497	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with 4,4',4''-(thiophene-2,3,5-triyl)triphenol
5TMT	;	2.051	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with 4,4'-((1,3-dihydro-2H-inden-2-ylidene)methylene)diphenol
5KRK	;	2.391	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with 4,4'-((5-bromo-2,3-dihydro-1H-inden-1-ylidene)methylene)diphenol
5TMU	;	2.429	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with 4,4'-(cycloheptylidenemethylene)diphenol
5TLV	;	2.323	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with 4,4'-(thiophene-2,3-diyl)bis(3-fluorophenol)
4ZNH	;	1.933	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in complex with a 2-Fluoro-substituted OBHS derivative
4ZNV	;	1.771	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in complex with a 2-Methoxy-substituted OBHS derivative
4ZNU	;	2.4	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in complex with a 2-Methyl-substituted OBHS derivative
4ZNT	;	1.903	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in complex with a 3-Bromo-substituted OBHS derivative
4ZNS	;	1.86	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in complex with a 3-Fluoro-substituted OBHS derivative
4ZNW	;	2.31	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in complex with a 4-Bromo-substituted OBHS derivative
5TLO	;	2.28	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with a Squaric Acid-linked Dimeric Estrogen
5KRJ	;	2.7	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with an a-naphthyl Substituted OBHS derivative
5KCT	;	1.6	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with an N-ethyl, 4-chlorobenzyl OBHS-N derivative
5KCF	;	2.07	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with an N-ethyl, 4-methoxybenzyl OBHS-N derivative
5KCU	;	2.03	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with an N-ethyl, alpha-naphthyl OBHS-N derivative
5KCD	;	1.82	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with an N-methyl Substituted OBHS-N derivative
5KCE	;	1.847	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with an N-methyl, 2-chlorobenzyl OBHS-N derivative
5KD9	;	1.78	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with an N-trifluoroethyl 4-chlorobenzyl OBHS-N derivative
5KCW	;	1.905	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with an N-trifluoroethyl OBHS-N derivative
5KR9	;	2.25	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with Coumestrol
5KRA	;	2.401	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with DDT and DDE
4ZN7	;	1.934	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in complex with Diethylstilbestrol
5TLT	;	1.903	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with octane-1,8-diyl bis(2,3-bis(4-hydroxyphenyl)pentanoate)
5KCC	;	2.386	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with Oxabicyclic Heptene Sulfonamide (OBHS-N)
4ZN9	;	2.215	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in complex with Oxabicyclic Heptene Sulfonate (OBHS)
5U2D	;	1.86	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in complex with Oxabicyclic Heptene Sulfonate (OBHS)
5KRM	;	2.24	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the A-CD ring estrogen, (1S,7aS)-5-(2,5-difluoro-4-hydroxyphenyl)-7a-methyl-2,3,3a,4,7,7a-hexahydro-1H-inden-1-ol
5KRL	;	2.4	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the A-CD ring estrogen, (1S,7aS)-5-(2-chloro-4-hydroxyphenyl)-7a-methyl-2,3,3a,4,7,7a-hexahydro-1H-inden-1-ol
5TN5	;	1.892	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the AC-ring estrogen, (1S,3aS,5S,7aS)-5-(4-hydroxyphenyl)-7a-methyloctahydro-1H-inden-1-ol
5TN4	;	1.857	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the ACD-ring estrogen, (S)-5-(4-hydroxy-3,5-dimethylphenyl)-2,3-dihydro-1H-inden-1-ol
5TMQ	;	2.24	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the Arene Core OBHS derivative, 4-bromophenyl 4,4''-dihydroxy-[1,1':2',1''-terphenyl]-4'-sulfonate
5TMO	;	2.172	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the Arene Core OBHS derivative, phenyl 4,4''-dihydroxy-[1,1':2',1''-terphenyl]-4'-sulfonate
5TLF	;	2.204	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the Constrained WAY Derivative, 4-(2-(3-methylbut-2-en-1-yl)-7-(trifluoromethyl)-2H-indazol-3-yl)benzene-1,3-diol
5TMS	;	2.24	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the Cyclofenil-ASC derivative, ethyl (E)-3-(4-(bicyclo[3.3.1]nonan-9-ylidene(4-hydroxyphenyl)methyl)phenyl)acrylate
5TMR	;	2.296	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the Cyclofenil-ASC derivative, ethyl (E)-3-(4-(cyclohexylidene(4-hydroxyphenyl)methyl)phenyl)acrylate
5KRF	;	2.193	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the Dynamic WAY derivative, 1a
5TN3	;	2.543	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the estradiol derivative, (8S,9S,13S,14S)-17-((4-isopropylphenyl)amino)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-ol
5TMZ	;	2.207	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the estradiol derivative, (8S,9S,13S,14S,17S)-16-(3-methoxybenzyl)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
5TN1	;	2.055	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the estradiol derivative, (8S,9S,13S,14S,E)-17-((4-isopropylphenyl)imino)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-ol
5EIT	;	2.68	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the imidazopyridine derivative 2-(4-hydroxyphenyl)-3-(trifluoromethyl)imidazo[1,2-a]pyridin-6-ol
5EI1	;	2.4	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the imidazopyridine derivative 2-(4-hydroxyphenyl)-3-iodanyl-imidazo[1,2-a]pyridin-6-ol
5KRO	;	2.1	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the Methyl(phenyl)amino-substituted Estrogen, (8R,9S,13S,14S,17S)-13-methyl-17-(methyl(phenyl)amino)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-ol
5TMV	;	2.38	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the OBHS analog, 4-iodophenyl (1S,2R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonate
5TMW	;	2.286	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the OBHS derivative, 4-acetamidophenyl (1S,2R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonate
5TM9	;	2.5	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the OBHS-ASC Analog, (E)-3-(4-((1R,4S,6R)-6-((3-chlorophenoxy)sulfonyl)-3-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenyl)acrylic acid
5TMM	;	2.2	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the OBHS-ASC analog, (E)-6-(4-((1R,4S,6R)-6-((4-bromophenoxy)sulfonyl)-3-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenyl)hex-5-enoic acid
5TM4	;	2.25	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the OBHS-ASC Analog, 5-(4-((1R,4S,6R)-6-((3-chlorophenoxy)sulfonyl)-3-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenoxy)pentanoic acid
5TML	;	2.25	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the OBHS-ASC compound, (E)-6-(4-((1R,4S,6R)-6-((3-chlorophenoxy)sulfonyl)-3-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenyl)hex-5-enoic acid
5TM5	;	2.24	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the OBHS-ASC compound, 5-(4-((1R,4S,6R)-6-((4-bromophenoxy)sulfonyl)-3-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenoxy)pentanoic acid
5TM6	;	2.542	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the OBHS-ASC compound, 6-(4-((1R,4S,6R)-6-((4-bromophenoxy)sulfonyl)-3-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenoxy)hexanoic acid
5TM7	;	2.4	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the OBHS-ASC compound, 7-(4-((1R,4S,6R)-6-((3-chlorophenoxy)sulfonyl)-3-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenoxy)heptanoic acid
5TM8	;	1.99	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the OBHS-ASC compound, 7-(4-((1R,4S,6R)-6-((4-bromophenoxy)sulfonyl)-3-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenoxy)heptanoic acid
5TLP	;	2.08	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the OBHS-BSC Analog, 3-fluorophenyl (1R,2R,4S)-5-(4-hydroxyphenyl)-6-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonate and 3-methyl-6-phenyl-3H-imidazo[4,5-b]pyridin-2-amine
5TLU	;	2.223	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the PEG-linked Dimeric Estrogen, EE2-(eg)6-EE2-amine
5TLD	;	2.375	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the phenylamino-substituted estrogen, (8R,9S,13S,14S,17S)-13-methyl-17-(phenylamino)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-ol
5U2B	;	2.22	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the phenylamino-substituted estrogen, (8R,9S,13S,14S,17S)-13-methyl-17-(phenylamino)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-ol, without a coactivator peptide
5TN6	;	2.091	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with the Spiro BC-estradiol, (1S,1'S,3a'S,7a'S)-7a'-methyl-1',2,2',3,3',3a',4',6',7',7a'-decahydro-1,5'-spirobi[indene]-1',5-diol
5KRC	;	2.4	;	Crystal Structure of the ER-alpha Ligand-binding Domain (Y537S) in Complex with Zearalenone
5DWE	;	1.92	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with a 2-Chloro-substituted Triaryl-imine analog 4,4'-[(2-chlorophenyl)carbonimidoyl]diphenol
5DVS	;	2.28	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with a 2-Methyl-substituted Triaryl-imine 4,4'-[(2-methylphenyl)carbonimidoyl]diphenol
5DKS	;	2.6	;	Crystal Structure of the ER-alpha Ligand-binding Domain in complex with a 2-naphthylamino-substituted, ethyl, triaryl-ethylene derivative 4,4'-{2-[3-(naphthalen-1-ylamino)phenyl]but-1-ene-1,1-diyl}diphenol
5DKB	;	2.4	;	Crystal Structure of the ER-alpha Ligand-binding Domain in complex with a 3-methylphenylamino-substituted ethyl triaryl-ethylene derivative 4,4'-(2-{3-[(3-methylphenyl)amino]phenyl}but-1-ene-1,1-diyl)diphenol
5DKE	;	2.6	;	Crystal Structure of the ER-alpha Ligand-binding Domain in complex with a 3-naphthyl-substituted, methyl, cis-diaryl-ethylene compound 4,4'-[2-(naphthalen-2-yl)prop-1-ene-1,1-diyl]diphenol
5DP0	;	2.382	;	Crystal Structure of the ER-alpha Ligand-binding Domain in complex with a 4-fluorophenylamino-substituted triaryl-ethylene derivative 4,4'-(2-{3-[(4-fluorophenyl)amino]phenyl}ethene-1,1-diyl)diphenol
5DMF	;	2.4	;	Crystal Structure of the ER-alpha Ligand-binding Domain in complex with a 4-fluorophenylamino-substituted, methyl triaryl-ethylene derivative 4,4'-(2-{3-[(4-fluorophenyl)amino]phenyl}prop-1-ene-1,1-diyl)diphenol
5DRM	;	2.241	;	Crystal Structure of the ER-alpha Ligand-binding Domain in complex with a dichloro-substituted, 2,5-diarylthiophene-core ligand 4,4'-thiene-2,5-diylbis(3-chlorophenol)
5DU5	;	2.195	;	Crystal Structure of the ER-alpha Ligand-binding Domain in complex with a dichloro-substituted, 3,4-diarylthiophene dioxide core ligand
5DRJ	;	2.07	;	Crystal Structure of the ER-alpha Ligand-binding Domain in complex with a dichloro-substituted, 3-methyl 2,5-diarylthiophene-core ligand 4,4'-(3-methylthiene-2,5-diyl)bis(3-chlorophenol)
5DID	;	2.24	;	Crystal Structure of the ER-alpha Ligand-binding Domain in complex with a difluoro-substituted A-CD ring estrogen derivative (1S,3aR,5S,7aS)-5-(2,3-difluoro-4-hydroxyphenyl)-7a-methyloctahydro-1H-inden-1-ol
5DTV	;	2.295	;	Crystal Structure of the ER-alpha Ligand-binding Domain in complex with a dimethyl-substituted, 3,4-diarylthiophene dioxide core ligand
5DMC	;	2.403	;	Crystal Structure of the ER-alpha Ligand-binding Domain in complex with a nitrile-substituted triaryl-ethylene derivative 3,3-bis(4-hydroxyphenyl)-2-phenylprop-2-enenitrile
5DUE	;	2.09	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with a para-Hydroxyl-substituted, Sulfoxide-bridged Oxabicyclic Heptene Sulfonate (SOBHS)-2 Analog 4-hydroxyphenyl (1S,2S,4S,5S,6R,7S)-5,6-bis(4-hydroxy-2-methylphenyl)-7-thiabicyclo[2.2.1]heptane-2-sulfonate 7-oxide
5DK9	;	2.28	;	Crystal Structure of the ER-alpha Ligand-binding Domain in complex with a phenylamino-substituted ethyl triaryl-ethylene derivative 4,4'-{2-[3-(phenylamino)phenyl]but-1-ene-1,1-diyl}diphenol
5DL4	;	2.1	;	Crystal Structure of the ER-alpha Ligand-binding Domain in complex with a phenylamino-substituted, methyl, triaryl-ethylene derivative 4,4'-{2-[3-(phenylamino)phenyl]prop-1-ene-1,1-diyl}diphenol
5DWI	;	2.43	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with a Resorcinyl 2-Chloro-substituted Diaryl-imine analog 4-[(E)-[(2-chlorophenyl)imino](4-hydroxyphenyl)methyl]benzene-1,3-diol
5DWJ	;	2.001	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with a Resorcinyl 4-Fluoro-substituted Diaryl-imine analog 4-[(E)-[(4-fluorophenyl)imino](4-hydroxyphenyl)methyl]benzene-1,3-diol
5DUG	;	2.252	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with a Sulfoxide-bridged Oxabicyclic Heptene Sulfonate (SOBHS)-2 analog phenyl (1S,2S,4S,7S)-5,6-bis(4-hydroxy-2-methylphenyl)-7-thiabicyclo[2.2.1]hept-5-ene-2-sulfonate 7-oxide
5DUH	;	2.24	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with a Sulfoxide-bridged Oxabicyclic Heptene Sulfonate (SOBHS)-3 analog phenyl (1S,2S,4S,7S)-5,6-bis(4-hydroxy-3-methylphenyl)-7-thiabicyclo[2.2.1]hept-5-ene-2-sulfonate 7-oxide
5DKG	;	2.15	;	Crystal Structure of the ER-alpha Ligand-binding Domain in complex with a t-butyl-substituted, methyl, triaryl-ethylene derivative 4,4'-[2-(4-tert-butylphenyl)prop-1-ene-1,1-diyl]diphenol
5DLR	;	2.26	;	Crystal Structure of the ER-alpha Ligand-binding Domain in complex with a triaryl-ethylene compound 4,4'-(2-phenylethene-1,1-diyl)diphenol
5DVV	;	2.505	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with a Triaryl-imine analog 4,4'-(phenylcarbonimidoyl)diphenol
5DIE	;	2.24	;	Crystal Structure of the ER-alpha Ligand-binding Domain in complex with a trifluoro-substituted A-CD ring estrogen derivative (1S,3aR,5S,7aS)-7a-methyl-5-(2,3,5-trifluoro-4-hydroxyphenyl)octahydro-1H-inden-1-ol
5DIG	;	2.24	;	Crystal Structure of the ER-alpha Ligand-binding Domain in complex with a trifluoromethyl-substituted A-CD ring estrogen derivative (1S,3aR,5S,7aS)-5-[4-hydroxy-2-(trifluoromethyl)phenyl]-7a-methyloctahydro-1H-inden-1-ol
5DI7	;	2.241	;	Crystal Structure of the ER-alpha Ligand-binding Domain in complex with an methyl-substituted A-CD ring estrogen derivative (1S,3aR,5S,7aS)-5-(4-hydroxy-2-methylphenyl)-7a-methyloctahydro-1H-inden-1-ol
5DXM	;	2.37	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with the Cyclofenil Derivative 3-[(E)-(1s,5s)-bicyclo[3.3.1]non-9-ylidene(4-hydroxyphenyl)methyl]phenol
5DYB	;	2.27	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with the Cyclofenil Derivative 4,4'-(3,4-dihydronaphthalen-2(1H)-ylidenemethanediyl)diphenol
5DXQ	;	2.4	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with the Cyclofenil Derivative 4,4'-[(1s,5s)-bicyclo[3.3.1]non-9-ylidenemethanediyl]diphenol
5DZ1	;	2.2	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with the Cyclofenil Derivative 4,4'-[(4-ethylcyclohexylidene)methanediyl]diphenol
5DZ0	;	2.24	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with the Cyclofenil Derivative 4,4'-[(4-methylcyclohexylidene)methanediyl]diphenol
5EHJ	;	2.5	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with the Cyclofenil Derivative 4,4'-[(4aR,8aR)-octahydronaphthalen-2(1H)-ylidenemethanediyl]diphenol
5DXK	;	2.226	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with the Cyclofenil Derivative 4,4'-[(9s)-bicyclo[3.3.1]non-9-ylmethanediyl]diphenol
5DXR	;	2.28	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with the Cyclofenil Derivative 4,4'-{[(3R)-3-methylcyclohexylidene]methanediyl}diphenol
5E14	;	2.22	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with the Cyclofenil Derivative 4,4'-{[(3R)-3-phenylcyclohexylidene]methanediyl}diphenol
5DZI	;	1.9	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with the Cyclofenil Derivative 4,4'-{[(3S)-3-(2-hydroxyethyl)cyclohexylidene]methanediyl}diphenol
5E0W	;	2.0	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with the Cyclofenil Derivative 4,4'-{[(3S)-3-(4-hydroxyphenyl)cyclohexylidene]methanediyl}diphenol
5E0X	;	2.014	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with the Cyclofenil Derivative 4,4'-{[(3S)-3-(4-methoxyphenyl)cyclohexylidene]methanediyl}diphenol
5DYD	;	2.485	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with the Cyclofenil Derivative 4,4'-{[(3S)-3-(methylsulfanyl)cyclohexylidene]methanediyl}diphenol
5DY8	;	2.031	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with the Cyclofenil Derivative 4,4'-{[(3S)-3-ethylcyclohexylidene]methanediyl}diphenol
5DZH	;	2.11	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with the Cyclofenil Derivative 4,4'-{[4-(2-hydroxyethyl)cyclohexylidene]methanediyl}diphenol
5E15	;	2.1	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with the Cyclofenil Derivative 4,4'-{[4-(2-hydroxyethyl)cyclohexylidene]methanediyl}diphenol
5DZ3	;	2.15	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with the Cyclofenil Derivative 4,4'-{[4-(fluoromethyl)cyclohexylidene]methanediyl}diphenol
5DXP	;	2.201	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with the Cyclofenil Derivative 4-[(E)-(1s,5s)-bicyclo[3.3.1]non-9-ylidene(phenyl)methyl]phenol
5E1C	;	1.98	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with the Cyclofenil Derivative dimethyl {(1S)-3-[bis(4-hydroxyphenyl)methylidene]cyclohexyl}propanedioate
5E19	;	2.24	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with the Cyclofenil Derivative methyl {4-[bis(4-hydroxyphenyl)methylidene]cyclohexyl}acetate
5DWG	;	2.3	;	Crystal Structure of the ER-alpha Ligand-binding Domain in Complex with the Triaryl-substituted Imine Analog, 4-{(E)-(4-hydroxyphenyl)[(2-methylphenyl)imino]methyl}benzene-1,3-diol
5EM2	;	2.67	;	Crystal structure of the Erb1-Ytm1 complex
3LMG	;	2.8	;	Crystal structure of the ERBB3 kinase domain in complex with AMP-PNP
3BCE	;	2.5	;	Crystal structure of the ErbB4 kinase
3BBT	;	2.8	;	crystal structure of the ErbB4 kinase in complex with lapatinib
3BBW	;	4.0	;	crystal structure of the ErbB4 kinase in its inactive conformation
4G6N	;	2.0	;	Crystal Structure of the ERK2
4G6O	;	2.2	;	Crystal Structure of the ERK2
4FV6	;	2.5	;	Crystal Structure of the ERK2 complexed with E57
4FV8	;	2.0	;	Crystal Structure of the ERK2 complexed with E63
4FV9	;	2.11	;	Crystal Structure of the ERK2 complexed with E71
4FUX	;	2.2	;	Crystal Structure of the ERK2 complexed with E75
4FV7	;	1.9	;	Crystal Structure of the ERK2 complexed with E94
4FUY	;	2.0	;	Crystal Structure of the ERK2 complexed with EK2
4FV0	;	2.1	;	Crystal Structure of the ERK2 complexed with EK3
4FV1	;	1.99	;	Crystal Structure of the ERK2 complexed with EK4
4FV2	;	2.0	;	Crystal Structure of the ERK2 complexed with EK5
4FV3	;	2.2	;	Crystal Structure of the ERK2 complexed with EK6
4FV4	;	2.5	;	Crystal Structure of the ERK2 complexed with EK7
4FV5	;	2.4	;	Crystal Structure of the ERK2 complexed with EK9
4IC7	;	2.6	;	Crystal structure of the ERK5 kinase domain in complex with an MKK5 binding fragment
5HQP	;	2.6	;	Crystal structure of the ERp44-peroxiredoxin 4 complex
3M6B	;	1.3	;	Crystal Structure of the Ertapenem Pre-isomerized Covalent Adduct with TB B-lactamase
3LBX	;	2.8	;	Crystal Structure of the Erythrocyte Spectrin Tetramerization Domain Complex
4Z8N	;	2.124	;	Crystal structure of the erythrocyte-binding domain from Plasmodium vivax reticulocyte-binding protein 2a (PvRBP2a)
5W53	;	1.71	;	Crystal structure of the erythrocyte-binding domain from Plasmodium vivax reticulocyte-binding protein 2b (PvRBP2b)
3EL6	;	1.85	;	Crystal Structure of the Erythromycin Dehydratase
7CCZ	;	1.79	;	Crystal structure of the ES2 intermediate form of human hydroxymethylbilane synthase
7Y6C	;	1.4	;	Crystal structure of the EscE/EsaG/EsaH complex
7Y6B	;	1.8	;	Crystal structure of the EscE/EsaH complex
4PTY	;	2.1	;	Crystal structure of the Escherichia coli alkanesulfonate FMN reductase SsuE in apo form
4PTZ	;	1.9007	;	Crystal structure of the Escherichia coli alkanesulfonate FMN reductase SsuE in FMN-bound form
4PU0	;	2.3018	;	Crystal structure of the Escherichia coli alkanesulfonate FMN reductase SsuE in FMNH2-bound form
1F48	;	2.3	;	CRYSTAL STRUCTURE OF THE ESCHERICHIA COLI ARSENITE-TRANSLOCATING ATPASE
1II0	;	2.4	;	CRYSTAL STRUCTURE OF THE ESCHERICHIA COLI ARSENITE-TRANSLOCATING ATPASE
1II9	;	2.6	;	CRYSTAL STRUCTURE OF THE ESCHERICHIA COLI ARSENITE-TRANSLOCATING ATPASE IN COMPLEX WITH AMP-PNP
1IHU	;	2.15	;	CRYSTAL STRUCTURE OF THE ESCHERICHIA COLI ARSENITE-TRANSLOCATING ATPASE IN COMPLEX WITH MG-ADP-ALF3
6CVL	;	2.953	;	Crystal structure of the Escherichia coli ATPgS-bound MetNI methionine ABC transporter in complex with its MetQ binding protein
1BXI	;	2.05	;	CRYSTAL STRUCTURE OF THE ESCHERICHIA COLI COLICIN E9 DNASE DOMAIN WITH ITS COGNATE IMMUNITY PROTEIN IM9
5DFK	;	2.4	;	Crystal Structure of the Escherichia coli Common Pilus Chaperone, EcpB
1JSX	;	2.4	;	Crystal Structure of the Escherichia coli Glucose-Inhibited Division Protein B (GidB)
4ISA	;	1.8	;	Crystal Structure of the Escherichia coli LpxC/BB-78485 complex
4IS9	;	2.13	;	Crystal Structure of the Escherichia coli LpxC/L-161,240 complex
3P3G	;	1.65	;	Crystal Structure of the Escherichia coli LpxC/LPC-009 complex
3PS1	;	1.85	;	Crystal structure of the Escherichia Coli LPXC/LPC-011 complex
3PS2	;	2.3	;	Crystal structure of the Escherichia Coli LPXC/LPC-012 complex
3PS3	;	2.1	;	Crystal structure of the Escherichia Coli LPXC/LPC-053 complex
4MQY	;	2.005	;	Crystal Structure of the Escherichia coli LpxC/LPC-138 complex
5NHI	;	2.6	;	Crystal structure of the Escherichia coli N-terminal domain of DsbD (nDsbD) without the cap-loop region
2RF7	;	2.04	;	Crystal structure of the escherichia coli nrfa mutant Q263E
6GFL	;	2.48	;	Crystal structure of the Escherichia coli nucleosidase PpnN (apo form)
6GFM	;	2.77	;	Crystal structure of the Escherichia coli nucleosidase PpnN (pppGpp-form)
2P7V	;	2.6	;	Crystal structure of the Escherichia coli regulator of sigma 70, Rsd, in complex with sigma 70 domain 4
3LTI	;	1.6	;	Crystal structure of the Escherichia coli RNA polymerase beta subunit beta2-betai4 domains
1JYH	;	1.8	;	Crystal Structure of the Escherichia coli SbmC protein (AKA Gyrase Inhibitory Protein GyrI, AKA YeeB)
1KAG	;	2.05	;	Crystal Structure of the Escherichia coli Shikimate Kinase I (AroK)
6E8E	;	2.25	;	Crystal structure of the Escherichia coli sliding clamp-MutL complex.
7AB5	;	2.9	;	Crystal structure of the Escherichia coli toxin-antitoxin system HipBST (HipT D233Q)
7AB3	;	2.4	;	Crystal structure of the Escherichia coli toxin-antitoxin system HipBST (HipT S57A)
7AB4	;	3.34	;	Crystal structure of the Escherichia coli toxin-antitoxin system HipBST (HipT S59A)
3BRQ	;	2.0	;	Crystal structure of the Escherichia coli transcriptional repressor ascG
3EFP	;	2.01	;	Crystal structure of the Escherichia coli twin arginine leader peptide binding protein DmsD in a monomeric form
1VBM	;	2.7	;	Crystal structure of the Escherichia coli tyrosyl-tRNA synthetase complexed with Tyr-AMS
1Y0G	;	2.2	;	CRYSTAL STRUCTURE OF THE ESCHERICHIA COLI YCEI PROTEIN, STRUCTURAL GENOMICS
3C03	;	1.9	;	Crystal structure of the EscU C-terminal domain with P263A mutation,space group P 1 21 1
7JPJ	;	2.78	;	Crystal Structure of the essential dimeric LYSA from Phaeodactylum tricornutum
1OKJ	;	2.28	;	crystal structure of the essential E. coli YeaZ protein by MAD method using the gadolinium complex ""DOTMA""
2QUQ	;	2.8	;	Crystal Structure of the Essential Inner Kinetochore Protein Cep3p
4QVH	;	1.75	;	Crystal structure of the essential Mycobacterium tuberculosis phosphopantetheinyl transferase PptT, solved as a fusion protein with maltose binding protein
4CGK	;	2.55	;	Crystal structure of the essential protein PcsB from Streptococcus pneumoniae
6RNX	;	2.84	;	Crystal structure of the essential repressor DdrO from radiation-resistant Deinococcus bacteria (Deinococcus deserti)
5CML	;	1.56	;	Crystal structure of the Esterase domain from Rhodothermus marinus Rmar_1206 protein
4FLE	;	2.1	;	Crystal structure of the esterase YqiA (YE3661) from Yersinia enterocolitica, Northeast Structural Genomics Consortium Target YeR85
2QGT	;	2.15	;	Crystal Structure of the Estrogen Receptor Alpha Ligand Binding Domain Complexed to an Ether Estradiol Compound
2QXM	;	2.3	;	Crystal Structure of the Estrogen Receptor Alpha Ligand Binding Domain Complexed to Burned Meat Compound PhIP
2QGW	;	2.39	;	Crystal Structure of the Estrogen Receptor Alpha Ligand Binding Domain Complexed with a Chloro-Indazole Compound
2QR9	;	2.0	;	Crystal Structure of the Estrogen Receptor Alpha Ligand Binding Domain Complexed with an Oxabicyclic Derivative Compound
2QH6	;	2.7	;	Crystal Structure of the Estrogen Receptor Alpha Ligand Binding Domain Complexed with an Oxabicyclic diarylethylene Compound
2QSE	;	1.85	;	Crystal Structure of the Estrogen Receptor Alpha Ligand Binding Domain complexed with Burned Meat Compound 4-OH-PhIP
2QZO	;	1.72	;	Crystal Structure of the Estrogen Receptor Alpha Ligand Binding Domain Complexed with WAY-169916
2QA8	;	1.85	;	Crystal Structure of the Estrogen Receptor Alpha Ligand Binding Domain Mutant 537S Complexed with Genistein
4IWF	;	1.932	;	Crystal Structure of the Estrogen Receptor alpha Ligand-binding Domain in Complex with a Dynamic Oxime-derivative
4IWC	;	2.24	;	Crystal Structure of the Estrogen Receptor alpha Ligand-binding Domain in Complex with a Dynamic Thiophene-derivative
4PPS	;	1.929	;	Crystal Structure of the Estrogen Receptor alpha Ligand-binding Domain in Complex with an A-CD ring estrogen derivative
4IU7	;	2.29	;	Crystal Structure of the Estrogen Receptor alpha Ligand-binding Domain in Complex with Constrained WAY-derivative, 2b
4IV4	;	2.3	;	Crystal Structure of the Estrogen Receptor alpha Ligand-binding Domain in Complex with Constrained WAY-derivative, 5b
4IVW	;	2.06	;	Crystal Structure of the Estrogen Receptor alpha Ligand-binding Domain in Complex with Constrained WAY-derivative, 6b
4IW6	;	1.98	;	Crystal Structure of the Estrogen Receptor alpha Ligand-binding Domain in Complex with Constrained WAY-derivative, 7b
4IUI	;	2.3	;	Crystal Structure of the Estrogen Receptor alpha Ligand-binding Domain in Complex with Dynamic WAY derivative, 4a
4IV2	;	2.14	;	Crystal Structure of the Estrogen Receptor alpha Ligand-binding Domain in Complex with Dynamic WAY-derivative, 5a
4IVY	;	1.95	;	Crystal Structure of the Estrogen Receptor alpha Ligand-binding Domain in Complex with Dynamic WAY-derivative, 7a
4IW8	;	2.0375	;	Crystal Structure of the Estrogen Receptor alpha Ligand-binding Domain in Complex with Dynamic WAY-derivative, 9a
4PPP	;	2.686	;	Crystal Structure of the Estrogen Receptor alpha Ligand-binding Domain in Complex with Fluoro-Resveratrol
4PP6	;	2.201	;	Crystal Structure of the Estrogen Receptor alpha Ligand-binding Domain in Complex with Resveratrol
7E2E	;	2.7	;	Crystal structure of the Estrogen-Related Receptor alpha (ERRalpha) ligand-binding domain (LBD) in complex with an agonist DS45500853 and a PGC-1alpha peptide
4IJY	;	2.6	;	Crystal Structure of the ETEC Secreted Protein CofJ
2HD3	;	2.4	;	Crystal Structure of the Ethanolamine Utilization Protein EutN from Escherichia coli, NESG Target ER316
6KO7	;	1.7	;	Crystal structure of the Ethidium bound RamR determined with XtaLAB Synergy
2ZOZ	;	1.95	;	Crystal structure of the ethidium-bound form of the multi-drug binding transcriptional repressor CgmR
7B1S	;	0.992	;	Crystal structure of the ethyl-coenzyme M reductase from Candidatus Ethanoperedens thermophilum at 0.994-A resolution
7B2C	;	1.8	;	Crystal structure of the ethyl-coenzyme M reductase from Candidatus Ethanoperedens thermophilum gassed with xenon
4BQA	;	2.5	;	Crystal structure of the ETS domain of human ETS2 in complex with DNA
4UNO	;	1.95	;	Crystal structure of the ETS domain of human ETV5 in complex with DNA
2NNY	;	2.58	;	Crystal structure of the Ets1 dimer DNA complex.
3WU1	;	2.4	;	Crystal structure of the ETS1-RUNX1-DNA ternary complex
1OG1	;	2.0	;	CRYSTAL STRUCTURE OF THE EUCARYOTIC MONO-ADP-RIBOSYLTRANSFERASE ART2.2 IN COMPLEX WITH TAD
1OG4	;	2.6	;	Crystal Structure of the Eucaryotic Mono-ADP-Ribosyltransferase ART2.2 Mutant E189A in Complex with NADH
1GXY	;	1.71	;	crystal structure of the eucaryotic mono-ADP-ribosyltransferase ART2.2; CRYSTAL FORM A (P21)
1GY0	;	2.08	;	crystal structure of the eucaryotic mono-ADP-ribosyltransferase ART2.2; CRYSTAL FORM C (P3121)
4V5O	;	3.93	;	CRYSTAL STRUCTURE OF THE EUKARYOTIC 40S RIBOSOMAL SUBUNIT IN COMPLEX WITH INITIATION FACTOR 1.
1SXJ	;	2.85	;	Crystal Structure of the Eukaryotic Clamp Loader (Replication Factor C, RFC) Bound to the DNA Sliding Clamp (Proliferating Cell Nuclear Antigen, PCNA)
7EDN	;	2.6	;	Crystal structure of the eukaryotic decoding site in complex with Ag(I)
1PLQ	;	2.3	;	CRYSTAL STRUCTURE OF THE EUKARYOTIC DNA POLYMERASE PROCESSIVITY FACTOR PCNA
1PLR	;	3.0	;	CRYSTAL STRUCTURE OF THE EUKARYOTIC DNA POLYMERASE PROCESSIVITY FACTOR PCNA
3WJ9	;	2.506	;	Crystal structure of the eukaryotic initiation factor
2A0U	;	2.1	;	Crystal structure of the eukaryotic initiation factor 2B from Leishmania major at 2.1 A resolution
1OG3	;	2.6	;	Crystal structure of the eukaryotic mono-ADP-ribosyltransferase ART2.2 mutant E189I in complex with NAD
1GXZ	;	2.1	;	crystal structure of the eukaryotic mono-ADP-ribosyltransferase ART2.2; Crystal form B (P212121)
4XGC	;	3.5	;	Crystal structure of the eukaryotic origin recognition complex
7EDM	;	2.81	;	Crystal structure of the eukaryotic ribosomal decoding site in complex with G418 and Hg(II)
5MB9	;	3.2	;	Crystal structure of the eukaryotic ribosome associated complex (RAC), a unique Hsp70/Hsp40 pair
3JYC	;	3.11	;	Crystal structure of the eukaryotic strong inward-rectifier K+ channel Kir2.2 at 3.1 Angstrom resolution
5B04	;	2.994	;	Crystal structure of the eukaryotic translation initiation factor 2B from Schizosaccharomyces pombe
4U6I	;	2.1	;	Crystal Structure of the EutL Microcompartment Shell Protein from Clostridium Perfringens Bound to Vitamin B12
4JGK	;	1.883	;	Crystal Structure of the evolved variant of the computationally designed serine hydrolase, Northeast Structural Genomics Consortium (NESG) Target OR275
4JLL	;	1.36	;	Crystal Structure of the evolved variant of the computationally designed serine hydrolase, OSH55.4_H1 covalently bound with FP-alkyne, Northeast Structural Genomics Consortium (NESG) Target OR273
4JVV	;	2.288	;	Crystal structure of the evolved variant of the computationally designed serine hydrolase, OSH55.4_H1, covalently bound with diisopropyl fluorophosphate (DFP), Northeast Structural Genomics Consortium (NESG) Target OR273
2EC8	;	3.0	;	Crystal structure of the exctracellular domain of the receptor tyrosine kinase, Kit
2D2S	;	2.85	;	Crystal Structure of the Exo84p C-terminal Domains
1KFI	;	2.4	;	Crystal Structure of the Exocytosis-Sensitive Phosphoprotein, pp63/Parafusin (phosphoglucomutase) from Paramecium
4BE3	;	1.75	;	crystal structure of the exolytic PL7 alginate lyase AlyA5 from Zobellia galactanivorans
4WBQ	;	2.693	;	Crystal structure of the exonuclease domain of QIP (QDE-2 interacting protein) solved by native-SAD phasing.
3CER	;	2.4	;	Crystal structure of the exopolyphosphatase-like protein Q8G5J2. Northeast Structural Genomics Consortium target BlR13
7TUV	;	2.225	;	Crystal structure of the exoribonucleolytic module of T. brucei RRP44
3GHM	;	2.6	;	Crystal structure of the exosite-containing fragment of human ADAMTS13 (form-1)
3GHN	;	2.8	;	Crystal structure of the exosite-containing fragment of human ADAMTS13 (form-2)
3VN4	;	2.8	;	Crystal structure of the exosite-containing fragment of human ADAMTS13 (P475S mutant)
4ZUA	;	2.5	;	Crystal structure of the ExsA regulatory domain
3KXY	;	2.804	;	Crystal Structure of the ExsC-ExsE Complex
5VQG	;	2.6	;	Crystal structure of the extended Tudor domain from BmPAPI
5VY1	;	3.05	;	Crystal structure of the extended Tudor domain from BmPAPI
5VQH	;	2.4	;	Crystal structure of the extended Tudor domain from BmPAPI in complex with sDMA
5J39	;	1.95	;	Crystal Structure of the extended TUDOR domain from TDRD2
4YIN	;	2.3	;	Crystal structure of the extended-spectrum beta-lactamase OXA-145
7CIN	;	1.79006	;	Crystal structure of the extended-spectrum class C beta-lactamase AmpC BER with the ordered R2 loop
3OAI	;	2.1	;	Crystal structure of the extra-cellular domain of human myelin protein zero
1N26	;	2.4	;	Crystal Structure of the extra-cellular domains of Human Interleukin-6 Receptor alpha chain
3IGQ	;	2.3	;	Crystal structure of the extracellular domain of a bacterial pentameric ligand-gated ion channel
1FNL	;	1.8	;	CRYSTAL STRUCTURE OF THE EXTRACELLULAR DOMAIN OF A HUMAN FCGRIII
5FJV	;	3.2	;	Crystal structure of the extracellular domain of alpha2 nicotinic acetylcholine receptor in pentameric assembly
2GUM	;	2.1	;	Crystal structure of the extracellular domain of glycoprotein B from Herpes Simplex Virus type I
5CXF	;	3.602	;	Crystal structure of the extracellular domain of glycoprotein B from Human Cytomegalovirus
5FBK	;	2.1	;	Crystal structure of the extracellular domain of human calcium sensing receptor
5FBH	;	2.7	;	Crystal structure of the extracellular domain of human calcium sensing receptor with bound Gd3+
1JCZ	;	1.55	;	CRYSTAL STRUCTURE OF THE EXTRACELLULAR DOMAIN OF HUMAN CARBONIC ANHYDRASE XII
1JD0	;	1.5	;	CRYSTAL STRUCTURE OF THE EXTRACELLULAR DOMAIN OF HUMAN CARBONIC ANHYDRASE XII COMPLEXED WITH ACETAZOLAMIDE
2EF1	;	2.4	;	Crystal structure of the extracellular domain of human CD38
3EHS	;	2.76	;	Crystal structure of the extracellular domain of human corticotropin releasing factor receptor type 1 (CRFR1)
3EHT	;	3.4	;	Crystal structure of the extracellular domain of human corticotropin releasing factor receptor type 1 (CRFR1) in complex with CRF
3EHU	;	1.96	;	Crystal structure of the extracellular domain of human corticotropin releasing factor receptor type 1 (CRFR1) in complex with CRF
4MS4	;	1.9	;	Crystal structure of the extracellular domain of human GABA(B) receptor bound to the agonist baclofen
4MQF	;	2.22	;	Crystal structure of the extracellular domain of human GABA(B) receptor bound to the antagonist 2-hydroxysaclofen
4MR8	;	2.15	;	Crystal structure of the extracellular domain of human GABA(B) receptor bound to the antagonist CGP35348
4MS1	;	2.25	;	Crystal structure of the extracellular domain of human GABA(B) receptor bound to the antagonist CGP46381
4MR7	;	2.15	;	Crystal structure of the extracellular domain of human GABA(B) receptor bound to the antagonist CGP54626
4MRM	;	2.86	;	Crystal structure of the extracellular domain of human GABA(B) receptor bound to the antagonist phaclofen
4MR9	;	2.35	;	Crystal structure of the extracellular domain of human GABA(B) receptor bound to the antagonist SCH50911
4MS3	;	2.5	;	Crystal structure of the extracellular domain of human GABA(B) receptor bound to the endogenous agonist GABA
4F11	;	2.38	;	Crystal structure of the extracellular domain of human GABA(B) receptor GBR2
4F12	;	3.02	;	Crystal structure of the extracellular domain of human GABA(B) receptor GBR2
4MQE	;	2.35	;	Crystal structure of the extracellular domain of human GABA(B) receptor in the apo form
2QKH	;	1.9	;	Crystal structure of the extracellular domain of human GIP receptor in complex with the hormone GIP
2XDG	;	1.95	;	Crystal structure of the extracellular domain of human growth hormone releasing hormone receptor.
3RRQ	;	2.1	;	Crystal structure of the extracellular domain of human PD-1
2YX8	;	2.4	;	Crystal structure of the extracellular domain of human RAMP1
3AQE	;	2.0	;	Crystal structure of the extracellular domain of human RAMP2
2X57	;	2.1	;	Crystal structure of the extracellular domain of human Vasoactive intestinal polypeptide receptor 2
2E9W	;	3.5	;	Crystal structure of the extracellular domain of Kit in complex with stem cell factor (SCF)
1IQA	;	2.2	;	CRYSTAL STRUCTURE OF THE EXTRACELLULAR DOMAIN OF MOUSE RANK LIGAND
6KD5	;	2.6	;	Crystal structure of the extracellular domain of MSPL/TMPRSS13 in complex with dec-RVKR-cmk inhibitor
1RJ5	;	2.81	;	Crystal Structure of the Extracellular Domain of Murine Carbonic Anhydrase XIV
1RJ6	;	2.9	;	Crystal Structure of the Extracellular Domain of Murine Carbonic Anhydrase XIV in Complex with Acetazolamide
1NPU	;	2.0	;	CRYSTAL STRUCTURE OF THE EXTRACELLULAR DOMAIN OF MURINE PD-1
3BL8	;	3.3	;	Crystal structure of the extracellular domain of neuroligin 2A from mouse
5F9Q	;	2.044	;	Crystal structure of the extracellular domain of noncanonic ABC-type transporter YknZ from Gram-positive bacteria
5A9D	;	2.1	;	Crystal structure of the extracellular domain of PepT1
5A9H	;	2.06	;	Crystal structure of the extracellular domain of PepT2
5A9I	;	2.84	;	Crystal structure of the extracellular domain of PepT2
4ESQ	;	1.7	;	Crystal structure of the extracellular domain of PknH from Mycobacterium tuberculosis
5IS1	;	1.998	;	Crystal structure of the extracellular domain of sensor histidine kinase YycG from Staphylococcus aureus at 2.0 Angstrom resolution
3QWQ	;	2.75	;	Crystal structure of the extracellular domain of the epidermal growth factor receptor in complex with an adnectin
4D01	;	1.795	;	Crystal Structure of the Extracellular Domain of the Human Alpha9 Nicotinic Acetylcholine Receptor
4UXU	;	1.71	;	Crystal Structure of the Extracellular Domain of the Human Alpha9 Nicotinic Acetylcholine Receptor In Complex with Methyllycaconitine
3H3G	;	1.94	;	Crystal structure of the extracellular domain of the human parathyroid hormone receptor (PTH1R) in complex with parathyroid hormone-related protein (PTHrP)
2QC1	;	1.94	;	Crystal structure of the extracellular domain of the nicotinic acetylcholine receptor 1 subunit bound to alpha-bungarotoxin at 1.9 A resolution
3LI8	;	1.75	;	Crystal Structure of the extracellular domain of the putative histidine kinase mmHK1S-Z2
3LI9	;	1.7	;	Crystal Structure of the extracellular domain of the putative histidine kinase mmHK1S-Z2
3LIA	;	1.99	;	Crystal Structure of the extracellular domain of the putative histidine kinase mmHK1S-Z2
3LIB	;	2.99	;	Crystal Structure of the extracellular domain of the putative histidine kinase mmHK1S-Z3
3LIF	;	2.7	;	Crystal Structure of the extracellular domain of the putative histidine kinase rpHK1S-Z16
3LIC	;	2.3	;	Crystal Structure of the extracellular domain of the putative histidine kinase soHK1S-Z6
3LID	;	1.76	;	Crystal Structure of the extracellular domain of the putative histidine kinase vpHK1S-Z8
3LIE	;	2.59	;	Crystal Structure of the extracellular domain of the putative histidine kinase vpHK1S-Z8
3V9F	;	3.3	;	Crystal Structure of the extracellular domain of the putative hybrid two component system BT3049 from B. thetaiotaomicron
3VA6	;	2.8	;	Crystal Structure of the extracellular domain of the putative hybrid two component system BT4673 from B. thetaiotaomicron
3OTT	;	2.3	;	Crystal Structure of the extracellular domain of the putative one component system BT4673 from B. thetaiotaomicron
1BTE	;	1.5	;	CRYSTAL STRUCTURE OF THE EXTRACELLULAR DOMAIN OF THE TYPE II ACTIVIN RECEPTOR
2HLQ	;	1.45	;	Crystal Structure of the Extracellular Domain of the Type II BMP Receptor
2HLR	;	1.2	;	Crystal Structure of the Extracellular Domain of the Type II BMP Receptor
4X82	;	2.76	;	Crystal Structure of the Extracellular Domain of ZIP4
3JZ7	;	2.19	;	Crystal structure of the extracellular domains of coxsackie & adenovirus receptor from mouse (mCAR)
8HC0	;	2.9	;	Crystal structure of the extracellular domains of GPR110
3BIX	;	1.8	;	Crystal structure of the extracellular esterase domain of Neuroligin-1
1UCT	;	2.1	;	Crystal structure of the extracellular fragment of Fc alpha Receptor I (CD89)
5EH1	;	1.8	;	Crystal structure of the extracellular part of receptor 2 of human interferon gamma
1PC3	;	2.16	;	Crystal structure of the extracellular phosphate ABC transport receptor (PstS-1) and immunodominant antigen of M. tuberculosis.
3B5H	;	2.8	;	Crystal structure of the extracellular portion of HAb18G/CD147
4YWZ	;	1.7	;	Crystal structure of the extracellular receptor domain of the essential sensor kinase WalK from Staphylococcus aureus
1N8Y	;	2.4	;	Crystal structure of the extracellular region of rat HER2
3B2V	;	3.3	;	Crystal structure of the extracellular region of the epidermal growth factor receptor in complex with the Fab fragment of IMC-11F8
2E4X	;	2.75	;	Crystal structure of the extracellular region of the group II metabotropic glutamate receptor complexed with 1S,3R-ACPD
2E4W	;	2.4	;	Crystal structure of the extracellular region of the group II metabotropic glutamate receptor complexed with 1S,3S-ACPD
2E4Y	;	3.4	;	Crystal structure of the extracellular region of the group II metabotropic glutamate receptor complexed with 2R,4R-APDC
2E4V	;	2.4	;	Crystal structure of the extracellular region of the group II metabotropic glutamate receptor complexed with DCG-IV
2E4U	;	2.35	;	Crystal structure of the extracellular region of the group II metabotropic glutamate receptor complexed with L-glutamate
1HNF	;	2.5	;	CRYSTAL STRUCTURE OF THE EXTRACELLULAR REGION OF THE HUMAN CELL ADHESION MOLECULE CD2 AT 2.5 ANGSTROMS RESOLUTION
1Z8G	;	1.55	;	Crystal structure of the extracellular region of the transmembrane serine protease hepsin with covalently bound preferred substrate.
1M1X	;	3.3	;	CRYSTAL STRUCTURE OF THE EXTRACELLULAR SEGMENT OF INTEGRIN ALPHA VBETA3 BOUND TO MN2+
1JV2	;	3.1	;	CRYSTAL STRUCTURE OF THE EXTRACELLULAR SEGMENT OF INTEGRIN ALPHAVBETA3
1L5G	;	3.2	;	CRYSTAL STRUCTURE OF THE EXTRACELLULAR SEGMENT OF INTEGRIN AVB3 IN COMPLEX WITH AN ARG-GLY-ASP LIGAND
1R85	;	1.45	;	Crystal structure of the extracellular xylanase from Geobacillus stearothermophilus T-6 (XT6): The WT enzyme (monoclinic form) at 1.45A resolution
1R87	;	1.67	;	Crystal structure of the extracellular xylanase from Geobacillus stearothermophilus T-6 (XT6, monoclinic form): The complex of the WT enzyme with xylopentaose at 1.67A resolution
1R86	;	1.8	;	Crystal structure of the extracellular xylanase from Geobacillus stearothermophilus T-6 (XT6, monoclinic form): The E159A/E265A mutant at 1.8A resolution
4CZN	;	1.199	;	Crystal structure of the extralong fungal manganese peroxidase from Ceriporiopsis subvermispora
4CZQ	;	1.198	;	Crystal structure of the extralong fungal manganese peroxidase from Ceriporiopsis subvermispora in complex with cadmium
4CZR	;	1.984	;	Crystal structure of the extralong fungal manganese peroxidase from Ceriporiopsis subvermispora in complex with cadmium (anomalous data)
4CZO	;	1.199	;	Crystal structure of the extralong fungal manganese peroxidase from Ceriporiopsis subvermispora in complex with manganese
4CZP	;	1.898	;	Crystal structure of the extralong fungal manganese peroxidase from ceriporiopsis subvermispora in complex with manganese (anomalous data)
5OJH	;	1.55	;	Crystal structure of the extramembrane domain of the cellulose biosynthetic protein BcsG from Salmonella typhimurium
5OLT	;	1.45	;	Crystal structure of the extramembrane domain of the cellulose biosynthetic protein BcsG from Salmonella typhimurium
2FC3	;	1.56	;	Crystal structure of the extremely thermostable Aeropyrum pernix L7Ae multifunctional protein
4MI5	;	2.0	;	Crystal structure of the EZH2 SET domain
2Q7T	;	2.42	;	Crystal Structure of the F plasmid TraI Relaxase Domain with the Scissile Thymidine Base
2Q7U	;	3.0	;	Crystal Structure of the F plasmid TraI Relaxase Domain with the Scissile Thymidine Base and Imidodiphosphate
5ES7	;	2.805	;	Crystal structure of the F-A domains of the LgrA initiation module soaked with FON, AMPcPP, and valine.
7AAN	;	2.14	;	Crystal structure of the F-BAR domain of PSTIPIP1
7AAM	;	2.15	;	Crystal structure of the F-BAR domain of PSTIPIP1 bound to the CTH domain of the phosphatase LYP
7AAL	;	1.97	;	Crystal structure of the F-BAR domain of PSTIPIP1, G258A mutant
4BEM	;	2.1	;	Crystal structure of the F-type ATP synthase c-ring from Acetobacterium woodii.
2QE7	;	3.06	;	Crystal structure of the f1-atpase from the thermoalkaliphilic bacterium bacillus sp. ta2.a1
3IN0	;	2.35	;	Crystal structure of the F114P/M121Q variant of Pseudomonas aeruginosa azurin in the Cu(II) state
2ANI	;	2.0	;	Crystal structure of the F127Y mutant of Ribonucleotide Reductase R2 from Chlamydia trachomatis
3F9F	;	2.3	;	Crystal Structure of the F140A mutant of SARS-Coronovirus 3C-like Protease at pH 6.0
3F9G	;	2.6	;	Crystal Structure of the F140A mutant of SARS-Coronovirus 3C-like Protease at pH 6.5
3F9H	;	2.9	;	Crystal Structure of the F140A mutant of SARS-Coronovirus 3C-like Protease at pH 7.6
2FRS	;	1.51	;	Crystal structure of the f15w mutant of apo-cellular retinoic acid binding protein type ii at 1.51 angstroms resolution
3TYX	;	2.04	;	Crystal structure of the F177S mutant of mycrocine immunity protein (MccF) with AMP
7Z97	;	1.46	;	Crystal structure of the F191M variant of Variovorax paradoxus indole monooxygenase (VpIndA1) in complex with 6-bromoindole
7ZCA	;	1.68	;	Crystal structure of the F191M/F201A variant of Variovorax paradoxus indole monooxygenase (VpIndA1) in complex with benzyl phenyl sulfoxide
6CPH	;	1.7	;	Crystal structure of the F24 TCR
7N05	;	1.7	;	Crystal structure of the F240 antibody fragment bound to the HIV-1 gp41 immunodominant region
5UM4	;	2.5	;	Crystal structure of the F255A mutant Kir3.1 cytoplasmic pore domain
5V45	;	1.91	;	Crystal structure of the F270M, K291M, L318M mutant of SR1 domain of human sacsin
4O7Q	;	1.82	;	Crystal Structure of the F27G AIM2 Pyrin Domain Mutant and Similarities of its Self-association to DED/DED Interactions
6VMW	;	1.99	;	Crystal structure of the F316A mutant of GoxA soaked with glycine
8AJS	;	1.68	;	Crystal structure of the F324A mutant of S-adenosyl-L-homocysteine hydrolase from Pseudomonas aeruginosa cocrystallized with adenosine in the presence of K+ cations
8STX	;	2.4	;	Crystal structure of the F337A mutation of Trypanosoma cruzi glucokinase in the apo form (open conformation)
7S2P	;	2.35	;	Crystal structure of the F337L mutation of Trypanosoma cruzi glucokinase in complex with inhibitor CBZ-GlcN
7S2N	;	1.75	;	Crystal structure of the F337L mutation of Trypanosoma cruzi glucokinase in the apo form (open conformation)
5VY2	;	2.3	;	Crystal structure of the F36A mutant of HsNUDT16
3P3F	;	2.3	;	Crystal structure of the F36A mutant of the fluoroacetyl-CoA-specific thioesterase FlK
3P3I	;	2.0	;	Crystal structure of the F36A mutant of the fluoroacetyl-CoA-specific thioesterase FlK in complex with fluoroacetate and CoA
5C04	;	1.45	;	Crystal structure of the F37H mutant AhpE from Mycobacterium tuberculosis
4WEI	;	2.3	;	Crystal structure of the F4 fimbrial adhesin FaeG in complex with lactose
6FHM	;	2.39	;	Crystal structure of the F47E mutant of the lipoprotein localization factor, LolA
4IC3	;	1.783	;	Crystal structure of the F495L mutant XIAP RING domain
3NNG	;	2.177	;	Crystal structure of the F5/8 type C domain of Q5LFR2_BACFN protein from Bacteroides fragilis. Northeast Structural Genomics Consortium Target BfR258E
1T7Q	;	1.8	;	Crystal structure of the F565A mutant of murine carnitine acetyltransferase in complex with carnitine and CoA
5WJI	;	2.3	;	Crystal structure of the F61S mutant of HsNUDT16
3HGO	;	2.3	;	Crystal structure of the F74Y/H244Y OPR3 double mutant from tomato
2EXV	;	1.86	;	Crystal structure of the F7A mutant of the cytochrome c551 from Pseudomonas aeruginosa
3DGD	;	1.383	;	Crystal structure of the F87M/L110M mutant of human transthyretin at pH 4.6
3DID	;	1.78	;	Crystal structure of the F87M/L110M mutant of human transthyretin at pH 4.6 soaked
3GPS	;	1.78	;	Crystal structure of the F87M/L110M mutant of human transthyretin at pH 5.5
3GRB	;	1.75	;	Crystal structure of the F87M/L110M mutant of human transthyretin at pH 6.5
3GRG	;	1.9	;	Crystal structure of the F87M/L110M mutant of human transthyretin at pH 7.5
2HNW	;	2.9	;	Crystal Structure of the F91STOP mutant of des1-6 Bovine Neurophysin-I, unliganded state
2VFF	;	1.7	;	Crystal structure of the F96H mutant of Plasmodium falciparum triosephosphate isomerase
2VFG	;	1.95	;	Crystal structure of the F96H mutant of Plasmodium falciparum triosephosphate isomerase with 3-phosphoglycerate bound at the dimer interface
2VFD	;	1.4	;	Crystal structure of the F96S mutant of Plasmodium falciparum triosephosphate isomerase
2VFH	;	2.0	;	Crystal structure of the F96W mutant of Plasmodium falciparum triosephosphate isomerase complexed with 3-phosphoglycerate
6JGJ	;	0.78	;	Crystal structure of the F99S/M153T/V163A/E222Q variant of GFP at 0.78 A
6JGH	;	0.94	;	Crystal structure of the F99S/M153T/V163A/T203I variant of GFP at 0.94 A
7CJ2	;	2.7	;	Crystal structure of the Fab antibody complexed with human YKL-40
4RRP	;	2.79	;	Crystal Structure of the Fab complexed with antigen Asf1p, Northeast Structural Genomics Consortium (NESG) Target PdR16
2XA8	;	2.42	;	Crystal structure of the Fab domain of omalizumab at 2.41A
5NBW	;	2.4	;	Crystal structure of the Fab fragment 22F12 in complex with 3-hydroxybenzo[a]pyrene
8FAB	;	1.8	;	CRYSTAL STRUCTURE OF THE FAB FRAGMENT FROM THE HUMAN MYELOMA IMMUNOGLOBULIN IGG HIL AT 1.8 ANGSTROMS RESOLUTION
1YY8	;	2.0	;	Crystal structure of the Fab fragment from the monoclonal antibody cetuximab/Erbitux/IMC-C225
4ISV	;	1.497	;	Crystal structure of the Fab FRAGMENT OF 1C2, A MONOCLONAL ANTIBODY SPECIFIC FOR POLY-GLUTAMINE
4JJ5	;	2.445	;	CRYSTAL STRUCTURE OF THE Fab FRAGMENT OF 1C2, A MONOCLONAL ANTIBODY SPECIFIC for POLY-GLUTAMINE
4DCQ	;	1.94	;	Crystal Structure of the Fab Fragment of 3B5H10, an Antibody-Specific for Extended Polyglutamine Repeats (orthorhombic form)
5AZ2	;	1.603	;	Crystal structure of the Fab fragment of 9E5, a murine monoclonal antibody specific for human epiregulin
6ZEC	;	1.65	;	Crystal Structure of the Fab Fragment of a Glycosylated Lymphoma Antibody
7ARN	;	1.57	;	Crystal Structure of the Fab Fragment of a Glycosylated Lymphoma Antibody
1QLR	;	2.83	;	CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF A HUMAN MONOCLONAL IgM COLD AGGLUTININ
6L8T	;	1.766	;	Crystal structure of the Fab fragment of a humanized HBV therapeutic antibody
2DDQ	;	2.35	;	Crystal Structure of the Fab fragment of a R310 antibody complexed with (R)-HNE-histidine adduct
4OD2	;	3.2	;	Crystal structure of the Fab fragment of an anti-DR5 antibody bound to DR5
3D69	;	3.77	;	Crystal Structure of the Fab Fragment of an Anti-Factor IX Antibody 10C12
5B6F	;	2.1	;	Crystal structure of the Fab fragment of an anti-Leukotriene C4 monoclonal antibody complexed with LTC4
3GIZ	;	2.2	;	Crystal structure of the Fab fragment of anti-CD20 antibody Ofatumumab
2Z91	;	2.6	;	Crystal structure of the Fab fragment of anti-ciguatoxin antibody 10C9
2Z92	;	2.3	;	Crystal structure of the Fab fragment of anti-ciguatoxin antibody 10C9 in complex with CTX3C_ABCDE
5WTG	;	2.907	;	Crystal structure of the Fab fragment of anti-HAV antibody R10
5TDN	;	1.63	;	Crystal structure of the Fab fragment of anti-HER2 antibody 4D5 with redesigned heavy and light chain interfaces
5TDO	;	1.61	;	Crystal structure of the Fab fragment of anti-HER2 antibody 4D5 with redesigned heavy and light chain interfaces
5TDP	;	1.716	;	Crystal structure of the Fab fragment of anti-HER2 antibody 4D5 with redesigned heavy and light chain interfaces
4Z0B	;	3.2	;	Crystal Structure of the Fab Fragment of Anti-ofloxacin Antibody and Exploration Its Receptor Binding Site
5X5X	;	1.9	;	Crystal structure of the Fab fragment of anti-osteocalcin C-terminal peptide antibody KTM219
6UGU	;	2.2	;	Crystal structure of the Fab fragment of anti-TNFa antibody infliximab (Remicade) in a C-centered orthorhombic crystal form, Lot C
6UGV	;	2.4	;	Crystal structure of the Fab fragment of anti-TNFa antibody infliximab (Remicade) in a I-centered orthorhombic crystal form, Lot C
3WII	;	1.6	;	Crystal structure of the Fab fragment of B2212A, a murine monoclonal antibody specific for the third fibronectin domain (Fn3) of human ROBO1.
6A76	;	1.5	;	Crystal structure of the Fab fragment of B5209B, a murine monoclonal antibody specific for the fifth immunoglobulin domain (Ig5) of human ROBO1
1MIE	;	1.95	;	Crystal Structure Of The Fab Fragment of Esterolytic Antibody MS5-393
5YUP	;	1.81	;	Crystal Structure of the Fab fragment of FVIIa antibody mAb4F5
6W4W	;	1.77	;	Crystal Structure of the Fab fragment of humanized 5c8 antibody
6BJZ	;	1.45	;	Crystal Structure of the Fab fragment of humanized 5c8 antibody containing the fluorescent non-canonical amino acid L-(7-hydroxycoumarin-4-yl)ethylglycine at pH 5.5
6W5A	;	1.75	;	Crystal Structure of the Fab fragment of humanized 5c8 antibody containing the fluorescent non-canonical amino acid L-(7-hydroxycoumarin-4-yl)ethylglycine at pH 9.7
6W9G	;	1.82	;	Crystal Structure of the Fab fragment of humanized 5c8 antibody containing the fluorescent non-canonical amino acid L-(7-hydroxycoumarin-4-yl)ethylglycine in complex with CD40L at pH 6.8
6JC2	;	2.65	;	Crystal structure of the Fab fragment of ipilimumab
4R97	;	2.2	;	Crystal structure of the Fab fragment of KKO
6LKT	;	1.8	;	Crystal structure of the Fab fragment of murine monoclonal antibody KH-1 against Human herpesvirus 6B
6LTG	;	1.63	;	Crystal structure of the Fab fragment of murine monoclonal antibody OHV-3 against Human herpesvirus 6B
6B3S	;	2.8	;	Crystal structure of the Fab fragment of necitumumab (Fab11F8) in complex with domain III from a cetuximab resistant variant of EGFR (sEGFRd3-S468R)
3GKW	;	2.5	;	Crystal structure of the Fab fragment of Nimotuzumab. An anti-epidermal growth factor receptor antibody
6UGS	;	1.95	;	Crystal structure of the Fab fragment of PF06438179/GP1111 an infliximab biosimilar in a C-centered orthorhombic crystal form, Lot A
6UGT	;	2.15	;	Crystal structure of the Fab fragment of PF06438179/GP1111 an infliximab biosimilar in a I-centered orthorhombic crystal form, Lot A
2XKN	;	1.4	;	Crystal structure of the Fab fragment of the anti-EGFR antibody 7A7
6O3J	;	3.416	;	Crystal structure of the Fab fragment of the human HIV-1 neutralizing antibody PGZL1 in complex with its MPER peptide epitope (region 671-683 of HIV-1 gp41) and phosphatidic acid (06:0 PA)
6O3G	;	3.645	;	Crystal structure of the Fab fragment of the human HIV-1 neutralizing antibody PGZL1 in complex with its MPER peptide epitope (region 671-683 of HIV-1 gp41).
6O3U	;	3.105	;	Crystal structure of the Fab fragment of the human HIV-1 neutralizing antibody PGZL1.H4K3 in complex with 06:0 PA
6O3L	;	1.98	;	Crystal structure of the Fab fragment of the human HIV-1 neutralizing antibody PGZL1.H4K3 in complex with its MPER peptide epitope (region 671-683 of HIV-1 gp41).
3N9G	;	1.434	;	Crystal structure of the Fab fragment of the human neutralizing anti-West Nile Virus MAb CR4354
1FH5	;	2.9	;	CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF THE MONOCLONAL ANTIBODY MAK33
1IQW	;	2.5	;	CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF THE MOUSE ANTI-HUMAN FAS ANTIBODY HFE7A
3IU3	;	2.9	;	Crystal structure of the Fab fragment of therapeutic antibody Basiliximab in complex with IL-2Ra (CD25) ectodomain
3NFP	;	2.86	;	Crystal structure of the Fab fragment of therapeutic antibody daclizumab in complex with IL-2Ra (CD25) ectodomain
2HKH	;	2.1	;	Crystal structure of the Fab M75
6WGB	;	1.99	;	Crystal structure of the fab portion of dupilumab
4CNI	;	2.2	;	Crystal structure of the Fab portion of Olokizumab in complex with IL- 6
5ZMJ	;	1.81	;	Crystal structure of the Fab region of a neutralizing fully human antibody against GM-CSF
1TZH	;	2.6	;	Crystal Structure of the Fab YADS1 Complexed with h-VEGF
1TZI	;	2.8	;	Crystal Structure of the Fab YADS2 Complexed with h-VEGF
4QWW	;	2.7	;	Crystal structure of the Fab410-BfAChE complex
1FIA	;	2.0	;	CRYSTAL STRUCTURE OF THE FACTOR FOR INVERSION STIMULATION FIS AT 2.0 ANGSTROMS RESOLUTION
2P3F	;	3.1	;	Crystal structure of the factor Xa/NAP5 complex
8OS5	;	3.4	;	Crystal structure of the Factor XII heavy chain reveals an interlocking dimer with a FnII to kringle domain interaction
3GWN	;	1.78	;	Crystal structure of the FAD binding domain from mimivirus sulfhydryl oxidase R596
4DQK	;	2.4	;	Crystal structure of the FAD binding domain of cytochrome P450 BM3
4DQL	;	2.15	;	Crystal structure of the FAD binding domain of cytochrome P450 BM3 in complex with NADP+
5EZ7	;	2.4	;	Crystal structure of the FAD dependent oxidoreductase PA4991 from Pseudomonas aeruginosa
2QTL	;	1.9	;	Crystal Structure of the FAD-containing FNR-like Module of Human Methionine Synthase Reductase
2GJ3	;	1.04	;	Crystal structure of the FAD-containing PAS domain of the protein NifL from Azotobacter vinelandii.
3R3M	;	3.0	;	Crystal structure of the FAF1 UBX domain
6CB0	;	1.97	;	Crystal Structure of the FAK FERM domain
6W38	;	4.48	;	Crystal structure of the FAM46C/Plk4 complex
6W3J	;	4.385	;	Crystal structure of the FAM46C/Plk4/Cep192 complex
4NPR	;	2.5	;	Crystal Structure of the Family 12 Xyloglucanase from Aspergillus niveus
6HHM	;	1.23	;	Crystal structure of the family S1_7 ulvan-specific sulfatase FA22070 from Formosa agariphila
5O67	;	2.84	;	Crystal structure of the FapF polypeptide transporter - F103A mutant
3RCP	;	1.9	;	Crystal structure of the FAPP1 pleckstrin homology domain
3EZQ	;	2.73	;	Crystal Structure of the Fas/FADD Death Domain Complex
1K40	;	2.25	;	crystal structure of the FAT domain of focal adhesion kinase
3LFM	;	2.5	;	Crystal structure of the fat mass and obesity associated (FTO) protein reveals basis for its substrate specificity
1U7N	;	2.26	;	Crystal Structure of the fatty acid/phospholipid synthesis protein PlsX from Enterococcus faecalis V583
6UGY	;	2.1	;	Crystal structure of the Fc fragment of anti-TNFa antibody infliximab (Remicade) in a primative orthorhombic crystal form, Lot C
6UGW	;	2.0	;	Crystal structure of the Fc fragment of PF06438179/GP1111 an infliximab biosimilar in a C-centered orthorhombic crystal form, Lot A
6UGX	;	2.1	;	Crystal structure of the Fc fragment of PF06438179/GP1111 an infliximab biosimilar in a primative orthorhombic crystal form, Lot A
6F6J	;	2.0	;	Crystal structure of the Fe(II)/alpha-ketoglutarate dependent dioxygenase KDO1 with Fe(II)/succinate/(3S)-3-hydroxy-L-lysine
6F9P	;	2.4	;	Crystal structure of the Fe(II)/alpha-ketoglutarate dependent dioxygenase KDO5 with Re(II)
7QTG	;	2.695	;	Crystal Structure of the Fe(II)/alpha-ketoglutarate dependent dioxygenase PlaO1
7QTE	;	1.81	;	Crystal Structure of the Fe(II)/alpha-ketoglutarate dependent dioxygenase PlaO1 in complex with cobalt and succinate
7QTD	;	1.75	;	Crystal Structure of the Fe(II)/alpha-ketoglutarate dependent dioxygenase PlaO1 in complex with iron and alpha-ketoglutarate
7QTF	;	1.55	;	Crystal Structure of the Fe(II)/alpha-ketoglutarate dependent dioxygenase PlaO1 in complex with sodium succinate
3PVJ	;	1.85	;	Crystal structure of the Fe(II)/alpha-ketoglutarate dependent taurine dioxygenase from Pseudomonas putida KT2440
3V15	;	2.6	;	Crystal structure of the Fe(II)/alpha-ketoglutarate dependent taurine dioxygenase from Pseudomonas putida KT2440
3V17	;	2.57	;	Crystal structure of the Fe(II)/alpha-ketoglutarate dependent taurine dioxygenase from Pseudomonas putida KT2440
3LGB	;	1.54	;	Crystal Structure of the Fe-S Domain of the yeast DNA primase
2JD7	;	2.8	;	Crystal Structure of the Fe-soaked Ferritin from the Hyperthermophilic Archaeal Anaerobe Pyrococcus furiosus
3ENI	;	2.2	;	Crystal structure of the Fenna-Matthews-Olson Protein from Chlorobaculum Tepidum
7BYJ	;	2.49	;	Crystal structure of the FERM domain of FRMPD4
4RMA	;	1.75	;	Crystal structure of the FERM domain of human ezrin
1H4R	;	1.8	;	Crystal Structure of the FERM domain of Merlin, the Neurofibromatosis 2 Tumor Suppressor Protein.
6D2K	;	1.55	;	Crystal structure of the FERM domain of mouse FARP2
6D2Q	;	2.99	;	Crystal structure of the FERM domain of zebrafish FARP1
6D21	;	1.999	;	Crystal structure of the FERM domain of zebrafish FARP2
4Z32	;	3.04	;	Crystal Structure of the FERM-SH2 Domains of Jak2
1RGV	;	2.9	;	Crystal Structure of the Ferredoxin from Thauera aromatica
1FXR	;	2.3	;	CRYSTAL STRUCTURE OF THE FERREDOXIN I FROM DESULFOVIBRIO AFRICANUS AT 2.3 ANGSTROMS RESOLUTION
2YVJ	;	1.9	;	Crystal structure of the ferredoxin-ferredoxin reductase (BPHA3-BPHA4)complex
1JB9	;	1.7	;	Crystal Structure of The Ferredoxin:NADP+ Reductase From Maize Root AT 1.7 Angstroms
3LVB	;	1.7	;	Crystal structure of the Ferredoxin:NADP+ reductase from maize root at 1.7 angstroms - Test Set Withheld
6GI0	;	2.0	;	Crystal structure of the ferric enterobactin esterase (PfeE) from Pseudomonas aeruginosa
6GI5	;	3.11	;	Crystal structure of the ferric enterobactin esterase (PfeE) from Pseudomonas aeruginosa in complex with the tris-catechol vector
6GI2	;	1.49	;	Crystal structure of the ferric enterobactin esterase (pfeE) mutant(S157A) from Pseudomonas aeruginosa in complex with Tris-catechol vector
6GI1	;	1.66	;	Crystal structure of the ferric enterobactin esterase (pfeE) mutant(S157A) from Pseudomonas aeruginosa in presence of enterobactin
5M9B	;	2.12	;	Crystal structure of the ferric enterobactin receptor (PfeA) from Pseudomonas aeruginosa
5NR2	;	2.78	;	Crystal structure of the ferric enterobactin receptor (PfeA) from Pseudomonas aeruginosa in complex with azotochelin
7OBW	;	2.66	;	Crystal structure of the ferric enterobactin receptor (PfeA) from Pseudomonas aeruginosa in complex with TCV-L6
5NC3	;	2.57	;	Crystal structure of the ferric enterobactin receptor (PfeA) from Pseudomonas aeruginosa in complex with the tris-catechol vector
6Z33	;	2.711	;	Crystal structure of the ferric enterobactin receptor (PfeA) in complex with BCV
6Y47	;	3.04	;	Crystal structure of the ferric enterobactin receptor (PfeA) in complex with BCV-L5
6Z2N	;	3.029	;	Crystal structure of the ferric enterobactin receptor (PfeA) in complex with BCV-L6
5NC4	;	2.8	;	Crystal structure of the ferric enterobactin receptor (PfeA) in complex with protochelin from Pseudomonas aeruginosa
6YY5	;	2.717	;	Crystal structure of the ferric enterobactin receptor (PfeA) in complex with TCV_L5
5OUT	;	2.9	;	CRYSTAL STRUCTURE OF THE FERRIC ENTEROBACTIN RECEPTOR (PFEA) MUTANT (G324V) FROM PSEUDOMONAS AERUGINOSA
5MZS	;	2.67	;	Crystal structure of the ferric enterobactin receptor (PfeA) mutant (R480A_Q482A) from Pseudomonas aeruginosa
6Q5E	;	2.7	;	Crystal structure of the ferric enterobactin receptor from Pseudomonas aeruginosa (PfeA) in complex with enterobactin
6I2J	;	2.96	;	Crystal structure of the ferric enterobactin receptor mutant (Q482A) from Pseudomonas aeruginosa (PfeA) in complex with enterobactin
6R1F	;	3.11	;	Crystal structure of the ferric enterobactin receptor mutant R480A from Pseudomonas aeruginosa (PfeA) in complex with enterobactin
8GEX	;	2.55	;	Crystal structure of the ferric enterobactin transporter (XusB) from Bacteroides thetaiotaomicron
2Z6T	;	1.2	;	Crystal structure of the ferric peroxo myoglobin
2IAH	;	2.73	;	Crystal structure of the ferripyoverdine receptor of the outer membrane of Pseudomonas aeruginosa bound to ferripyoverdine.
1LSW	;	2.2	;	Crystal structure of the ferrous BjFixL heme domain
1T87	;	1.8	;	Crystal Structure of the Ferrous CO-bound Cytochrome P450cam (C334A)
1T85	;	1.8	;	Crystal Structure of the Ferrous CO-bound Cytochrome P450cam Mutant (L358P/C334A)
1T88	;	1.9	;	Crystal Structure of the Ferrous Cytochrome P450cam (C334A)
1T86	;	1.9	;	Crystal Structure of the Ferrous Cytochrome P450cam Mutant (L358P/C334A)
2ZNY	;	2.59	;	Crystal structure of the FFRP
3EUU	;	2.34	;	Crystal structure of the FGFR2 D2 domain
4WV1	;	2.362	;	Crystal structure of the FGFR2 D2 domain in complex with Fab 2B.1.3
5A8I	;	1.75	;	Crystal structure of the FHA domain of ArnA from Sulfolobus acidocaldarius
3GQS	;	2.2	;	Crystal structure of the FHA domain of CT664 protein from Chlamydia trachomatis
6A8W	;	1.844	;	Crystal structure of the FHA domain of Far9
2G1L	;	2.602	;	Crystal structure of the FHA domain of human kinesin family member C
2BRF	;	1.4	;	Crystal Structure of the FHA Domain of Human Polynucleotide Kinase 3' Phosphatase
1YJM	;	2.2	;	Crystal structure of the FHA domain of mouse polynucleotide kinase in complex with an XRCC4-derived phosphopeptide.
2PIE	;	1.35	;	Crystal structure of the FHA domain of RNF8 in complex with its optimal phosphopeptide
1LGQ	;	2.1	;	Crystal structure of the FHA domain of the Chfr mitotic checkpoint protein
1LGP	;	2.0	;	Crystal structure of the FHA domain of the Chfr mitotic checkpoint protein complexed with tungstate
3OUN	;	2.705	;	Crystal structure of the FhaA FHA domain complexed with the intracellular domain of Rv3910
3HXP	;	3.2	;	Crystal structure of the FhuD fold-family BSU3320, a periplasmic binding protein component of a Fep/Fec-like ferrichrome ABC transporter from Bacillus subtilis. Northeast Structural Genomics Consortium Target SR577
3G9Q	;	2.6	;	Crystal structure of the FhuD fold-family BSU3320, a periplasmic binding protein component of a Fep/Fec-like ferrichrome ABC transporter from Bacillus subtilis. Northeast Structural Genomics Consortium Target SR577A
4UMI	;	1.33	;	Crystal structure of the fiber head domain of the Atadenovirus snake adenovirus 1, native, F23 crystal form
4D1F	;	2.7	;	Crystal structure of the fiber head domain of the Atadenovirus snake adenovirus 1, native, first P212121 crystal form
4D0V	;	1.7	;	Crystal structure of the fiber head domain of the Atadenovirus snake adenovirus 1, native, I213 crystal form
4D1G	;	1.9	;	Crystal structure of the fiber head domain of the Atadenovirus snake adenovirus 1, native, second P212121 crystal form
4D0U	;	1.6	;	Crystal structure of the fiber head domain of the Atadenovirus snake adenovirus 1, selenomethionine-derivative
3LN9	;	1.8	;	Crystal structure of the fibril-specific B10 antibody fragment
3MQL	;	3.004	;	Crystal structure of the fibronectin 6FnI1-2FnII7FnI fragment
3EJH	;	2.1	;	Crystal Structure of the Fibronectin 8-9FnI Domain Pair in Complex with a Type-I Collagen Peptide
4XI8	;	2.95	;	Crystal Structure of the FIC domain of Bep5 protein (VirB-translocated Bartonella effector protein) from Bartonella clarridgeiae
5HRX	;	1.73	;	Crystal structure of the fifth bromodomain of human PB1 in complex with 1-butylisochromeno[3,4-c]pyrazol-5(2H)-one) compound
5HRV	;	1.7	;	Crystal structure of the fifth bromodomain of human PB1 in complex with 1-ethylisochromeno[3,4-c]pyrazol-5(2H)-one) compound
5HRW	;	1.8	;	Crystal structure of the fifth bromodomain of human PB1 in complex with 1-propylisochromeno[3,4-c]pyrazol-5(2H)-one) compound
5E7D	;	1.87	;	Crystal Structure of the fifth bromodomain of human PB1 in complex with a hydroxyphenyl ligand
5FH6	;	2.3	;	Crystal structure of the fifth bromodomain of human PB1 in complex with compound 10
5FH7	;	1.47	;	Crystal structure of the fifth bromodomain of human PB1 in complex with compound 18
5FH8	;	1.55	;	Crystal structure of the fifth bromodomain of human PB1 in complex with compound 28
4Y03	;	1.94	;	Crystal Structure of the fifth bromodomain of human PB1 in complex with salicylic acid
3G0J	;	1.78	;	Crystal Structure of the fifth Bromodomain of Human Poly-bromodomain containing protein 1 (PB1)
4Q0N	;	1.78	;	Crystal Structure of the fifth bromodomain of Human Poly-bromodomain containing protein 1 (PB1) in complex with a hydroxyphenyl-propenone ligand
4Q0O	;	1.83	;	Crystal Structure of the fifth bromodomain of Human Poly-bromodomain containing protein 1 (PB1) in complex with a hydroxyphenyl-propenone ligand
3MB4	;	1.66	;	Crystal Structure of the fifth Bromodomain of Human Poly-bromodomain containing protein 1 (PB1) with NMP
5II1	;	2.02	;	Crystal Structure of the fifth bromodomain of human polybromo (PB1) in complex with 1-methylisochromeno[3,4-c]pyrazol-5(3H)-one
5II2	;	2.1	;	Crystal Structure of the fifth bromodomain of human polybromo (PB1) in complex with 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one
5IID	;	2.4	;	Crystal Structure of the fifth bromodomain of human polybromo (PB1) in complex with 2-(3,4-dihydroxyphenyl)-5-hydroxy-4H-chromen-4-one
6ZS3	;	1.67	;	Crystal structure of the fifth bromodomain of human protein polybromo-1 in complex with 2-(6-amino-5-(piperazin-1-yl)pyridazin-3-yl)phenol
6ZS4	;	2.0	;	Crystal structure of the fifth bromodomain of human protein polybromo-1 in complex with tert-butyl 4-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]piperazine-1-carboxylate
6A77	;	2.0	;	Crystal structure of the fifth immunoglobulin domain (Ig5) of human Robo1 in complex with the Fab fragment of murine monoclonal antibody B5209B
6A79	;	2.31	;	Crystal structure of the fifth immunoglobulin domain (Ig5) of human Robo1 in complex with the mutant scFv fragment (P103A) of murine monoclonal antibody B5209B
6A78	;	2.1	;	Crystal structure of the fifth immunoglobulin domain (Ig5) of human Robo1 in complex with the scFv fragment of murine monoclonal antibody B5209B
1QU0	;	2.35	;	CRYSTAL STRUCTURE OF THE FIFTH LAMININ G-LIKE MODULE OF THE MOUSE LAMININ ALPHA2 CHAIN
6EW1	;	2.30701	;	Crystal structure of the Filamin A Ig-like domains 3-5 mutant P637Q
2JF1	;	2.2	;	CRYSTAL STRUCTURE OF THE FILAMIN A REPEAT 21 COMPLEXED WITH THE INTEGRIN BETA2 CYTOPLASMIC TAIL PEPTIDE
2BRQ	;	2.1	;	Crystal structure of the filamin A repeat 21 complexed with the integrin beta7 cytoplasmic tail peptide
2W0P	;	1.9	;	Crystal structure of the filamin A repeat 21 complexed with the migfilin peptide
2VCO	;	2.1	;	Crystal structure of the fimbrial adhesin FimH in complex with its high-mannose epitope
5DHM	;	1.9	;	Crystal structure of the fimbrial protein Mfa4 from Porphyromonas gingivalis
3OHN	;	3.011	;	Crystal structure of the FimD translocation domain
3RFZ	;	2.8	;	Crystal structure of the FimD usher bound to its cognate FimC:FimH substrate
4J3O	;	3.8	;	Crystal structure of the FimD usher traversed by the pilus tip complex assembly composed of FimC:FimF:FimG:FimH
4XOC	;	1.42	;	Crystal structure of the FimH lectin domain from E.coli F18 in complex with heptyl alpha-D-mannopyrannoside
6GTW	;	2.5	;	Crystal structure of the FimH lectin domain from E.coli F18 in complex with trimannose
4XO8	;	1.698	;	Crystal structure of the FimH lectin domain from E.coli K12 in complex with heptyl alpha-D-mannopyrannoside
5JCQ	;	1.602	;	Crystal structure of the FimH lectin domain from E.coli K12 in complex with methyl alpha-D-mannopyrannoside in spacegroup P21
5JCR	;	1.701	;	Crystal structure of the FimH lectin domain from E.coli K12 in complex with methyl alpha-D-mannopyrannoside in spacegroup P212121
6GTX	;	2.5	;	Crystal structure of the FimH lectin domain from E.coli K12 in complex with the dimannoside Man(alpha1-2)Man
6GTY	;	1.9	;	Crystal structure of the FimH lectin domain from E.coli K12 in complex with the dimannoside Man(alpha1-6)Man
5MUC	;	2.6	;	Crystal structure of the FimH lectin domain in complex with 1,5-Anhydromannitol
7P6R	;	1.9	;	Crystal structure of the FimH-binding decoy module of human glycoprotein 2 (GP2) (crystal form I)
7P6S	;	1.35	;	Crystal structure of the FimH-binding decoy module of human glycoprotein 2 (GP2) (crystal form II)
7P6T	;	1.4	;	Crystal structure of the FimH-binding decoy module of human glycoprotein 2 (GP2) (crystal form III)
4AFY	;	2.01	;	Crystal structure of the FimX EAL domain in complex with reaction product pGpG
6GMA	;	3.2	;	Crystal structure of the FIP200 C-terminal region
1AKS	;	1.8	;	CRYSTAL STRUCTURE OF THE FIRST ACTIVE AUTOLYSATE FORM OF THE PORCINE ALPHA TRYPSIN
2IBB	;	2.4	;	Crystal Structure of the First and Second FNIII Domains of Ihog
4CIT	;	1.8	;	Crystal structure of the first bacterial vanadium dependant iodoperoxidase
4USZ	;	2.0	;	Crystal structure of the first bacterial vanadium dependant iodoperoxidase
7LAI	;	1.85	;	Crystal structure of the first bromodomain (BD1) of human BRD2 bound to BI2536
7LAH	;	1.6	;	Crystal structure of the first bromodomain (BD1) of human BRD2 bound to bromosporine
7LAU	;	2.4	;	Crystal structure of the first bromodomain (BD1) of human BRD2 bound to ERK5-IN-1
7LAJ	;	1.854	;	Crystal structure of the first bromodomain (BD1) of human BRD2 bound to Ro3280
7LAK	;	1.831	;	Crystal structure of the first bromodomain (BD1) of human BRD2 bound to volasertib
7LAZ	;	2.302	;	Crystal structure of the first bromodomain (BD1) of human BRD3 bound to ERK5-IN-1
7LAY	;	1.45	;	Crystal structure of the first bromodomain (BD1) of human BRD3 bound to SG3-179
7LA9	;	2.2	;	Crystal structure of the first bromodomain (BD1) of human BRD4 (BRD4-1) in complex with bivalent inhibitor NC-III-49-1
6V1K	;	1.75	;	Crystal structure of the first bromodomain (BD1) of human BRD4 bound to BI7273
6V1L	;	2.1	;	Crystal structure of the first bromodomain (BD1) of human BRD4 bound to BI9564
6V0U	;	1.4	;	Crystal structure of the first bromodomain (BD1) of human BRD4 bound to bromosporine
7K6G	;	1.7	;	Crystal structure of the first bromodomain (BD1) of human BRD4 bound to ERK5-IN-1
7MR5	;	1.82	;	Crystal structure of the first bromodomain (BD1) of human BRD4 bound to GXH-II-052
7MR7	;	1.4	;	Crystal structure of the first bromodomain (BD1) of human BRD4 bound to GXH-II-075
7MR8	;	1.2	;	Crystal structure of the first bromodomain (BD1) of human BRD4 bound to GXH-II-076
7MR6	;	1.85	;	Crystal structure of the first bromodomain (BD1) of human BRD4 bound to GXH-II-082
7MR9	;	1.19	;	Crystal structure of the first bromodomain (BD1) of human BRD4 bound to NC-II-153
7MRA	;	1.16	;	Crystal structure of the first bromodomain (BD1) of human BRD4 bound to NC-II-259
7MRB	;	1.2	;	Crystal structure of the first bromodomain (BD1) of human BRD4 bound to NC-III-53
6V1U	;	1.73	;	Crystal structure of the first bromodomain (BD1) of human BRD4 bound to TP-472
7K6H	;	1.5	;	Crystal structure of the first bromodomain (BD1) of human BRD4 bound to XMD8-92
7L9M	;	1.45	;	Crystal structure of the first bromodomain (BD1) of human BRD4 in complex with bivalent inhibitor GXH-II-083
7REL	;	1.55	;	Crystal structure of the first bromodomain (BD1) of human BRD4 in complex with dual BRD4-JAK2 inhibitor MA9-060
7REK	;	1.2	;	Crystal structure of the first bromodomain (BD1) of human BRD4 in complex with dual BRD4-JAK2 inhibitor MA9-086
8EAD	;	1.65	;	Crystal structure of the first bromodomain (BD1) of human BRD4 in complex with dual BRD4-JAK2 inhibitor MA9-177
7REM	;	1.8	;	Crystal structure of the first bromodomain (BD1) of human BRD4 in complex with dual BRD4-JAK2 inhibitor PN1-050
7L73	;	1.46	;	Crystal structure of the first bromodomain (BD1) of human BRDT bound to ERK5-IN-1
7MRC	;	1.55	;	Crystal structure of the first bromodomain (BD1) of human BRDT bound to GXH-II-052
7MRD	;	1.39	;	Crystal structure of the first bromodomain (BD1) of human BRDT bound to GXH-II-082
8CZA	;	2.96	;	Crystal structure of the first bromodomain (BD1) of human BRDT bound to GXH-IV-075
7LEM	;	1.89	;	Crystal structure of the first bromodomain (BD1) of human BRDT bound to LRRK2-IN-1
7MRG	;	1.99	;	Crystal structure of the first bromodomain (BD1) of human BRDT bound to NC-II-153
7MRH	;	1.98	;	Crystal structure of the first bromodomain (BD1) of human BRDT bound to NC-II-259
7BJY	;	2.22	;	Crystal structure of the first bromodomain (BD1) of human BRDT bound to Ro3280
7FH2	;	2.492	;	Crystal structure of the first bromodomain of BRD4 in complex with 16D10
6IN1	;	1.5	;	Crystal structure of the first bromodomain of BRD4 in complex with 18-Crown-6
6YIN	;	1.53	;	Crystal structure of the first bromodomain of BRD4 in complex with a benzo-diazepine ligand
6S25	;	1.1	;	Crystal Structure of the first bromodomain of BRD4 in complex with a benzodiazepine ligand
7AJN	;	1.48	;	Crystal Structure of the first bromodomain of BRD4 in complex with a BzD ligand
5E0R	;	1.352	;	Crystal Structure of the first bromodomain of BRD4 in complex with AYC
4PCI	;	1.25	;	Crystal Structure of the first bromodomain of BRD4 in complex with B16
5HCL	;	1.5	;	Crystal Structure of the first bromodomain of BRD4 in complex with DMA
4IOR	;	1.4	;	Crystal Structure of the first bromodomain of BRD4 in complex with DMSO
4IOO	;	1.25	;	Crystal Structure of the first bromodomain of BRD4 in complex with N-methyltrimethylacetamide
4IOQ	;	1.5	;	Crystal Structure of the first bromodomain of BRD4 in complex with pyrrolidin-2-one
6I7X	;	1.2	;	Crystal Structure of the first bromodomain of BRD4 in complex with RT53
6I7Y	;	1.0	;	Crystal Structure of the first bromodomain of BRD4 in complex with RT56
4QZS	;	1.45	;	Crystal structure of the first bromodomain of human 3-fluoro tyrosine-labeled brd4 in complex with jq1
2YEK	;	1.98	;	Crystal Structure of the First Bromodomain of Human Brd2 with the inhibitor GSK525762 (IBET)
2YDW	;	1.9	;	Crystal Structure of the First Bromodomain of Human Brd2 with the inhibitor GW841819X
3S91	;	2.06	;	Crystal Structure of the first bromodomain of human BRD3 in complex with the inhibitor JQ1
5HM0	;	1.395	;	Crystal structure of the first bromodomain of human BRD4 bound to benzoisoxazoloazepine 3
4Z1Q	;	1.399	;	Crystal structure of the first bromodomain of human BRD4 bound to benzotriazolo-diazepine scaffold
5HLS	;	2.182	;	Crystal structure of the first bromodomain of human BRD4 bound to CPI-0610
6SE4	;	1.38	;	Crystal Structure of the first bromodomain of human BRD4 in complex with (+)-JD1, an Organometallic BET Bromodomain Inhibitor
5S9Q	;	1.85	;	CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX WITH 2-(3,5-dimethyl-1,2-oxazol-4-yl)-7-(2-hydroxypropan-2-yl)-9-[(S)-(oxan-4-yl)(phenyl)methyl]-9H-carbazole-4-carboxamide
7MCE	;	1.76	;	CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX WITH 2-{(7P)-7-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)-8-fluoro-5-[(S)-(oxan-4-yl)(phenyl)methyl]-5H-pyrido[3,2-b]indol-3-yl}propan-2-ol
7MCF	;	2.19	;	CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX WITH 2-{3-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)-6-fluoro-5-[(S)-(3-fluoropyridin-2-yl)(oxan-4-yl)methyl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol
6AFR	;	1.998	;	Crystal Structure of the first bromodomain of human BRD4 in complex with 5-((4-fluoro-1H-imidazol-1-yl)methyl)quinolin-8-ol
5S9P	;	2.1	;	CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX WITH 9-benzyl-2-(3,5-dimethyl-1,2-oxazol-4-yl)-7-(2-hydroxypropan-2-yl)-9H-carbazole-4-carboxamide
4XY9	;	1.83	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a 2-amine-9H-purine ligand
4XYA	;	2.05	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a 2-amine-9H-purine ligand
4MEO	;	1.72	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a 2-methyl-quinoline ligand
3SVG	;	1.68	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a 3,5-dimethylisoxazol ligand
4J0R	;	1.72	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a 3,5-dimethylisoxazol ligand
4J0S	;	1.84	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a 3,5-dimethylisoxazol ligand
6FSY	;	1.34	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a 3,5-dimethylisoxazol ligand
6FT3	;	1.28	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a 3,5-dimethylisoxazol ligand
6FT4	;	1.34	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a 3,5-dimethylisoxazol ligand
4MEP	;	1.85	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a 3-chloro-pyridone ligand
4MEN	;	1.81	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a 5-methyl-triazolopyrimidine ligand
4MEQ	;	1.77	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a 5-methyl-triazolopyrimidine ligand
3U5L	;	1.39	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a benzo-triazepine ligand (BzT-7)
5NNC	;	2.22	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a diacetylated histone 4 peptide (H3K9ac/K14ac)
5NND	;	1.82	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a diacetylated histone 4 peptide (H3K9ac/K14ac)
3UVX	;	1.91	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a diacetylated histone 4 peptide (H4K12acK16ac)
3UVY	;	2.02	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a diacetylated histone 4 peptide (H4K16acK20ac)
3UVW	;	1.37	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a diacetylated histone 4 peptide (H4K5acK8ac)
3UW9	;	2.3	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a diacetylated histone 4 peptide (H4K8acK12ac)
5NNE	;	1.15	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a diacetylated TOP2A peptide (K1201ac/K1204ac)
3SVF	;	1.975	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a dihydro-quinazolin ligand
5KDH	;	1.5	;	CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX WITH A DIHYDROPYRIDOPYRIMIDINE SCAFFOLD INHIBITOR
4GPJ	;	1.6	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a isoxazolylbenzimidazole ligand
4WIV	;	1.56	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a novel inhibitor UMB32 (N-TERT-BUTYL-2-[4-(3,5-DIMETHYL-1,2-OXAZOL-4-YL) PHENYL]IMIDAZO[1,2-A]PYRAZIN-3-AMINE)
4HBV	;	1.63	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a quinazolin ligand
4HBX	;	1.62	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a quinazolin ligand
4HBY	;	1.59	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a quinazolin ligand
4HBW	;	1.69	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a quinazoline ligand
4MR4	;	1.66	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a quinazolinone ligand (RVX-208)
4MR3	;	1.68	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a quinazolinone ligand (RVX-OH)
5N2M	;	1.54	;	Crystal structure of the first bromodomain of human BRD4 in complex with a tetrahydroquinoline analogue
4NQM	;	1.58	;	Crystal Structure of the first bromodomain of human BRD4 in complex with a triazolo-phthalazine ligand
3U5J	;	1.6	;	Crystal Structure of the first bromodomain of human BRD4 in complex with Alprazolam
6G0O	;	1.4	;	Crystal Structure of the first bromodomain of human BRD4 in complex with an acetylated ATRX peptide (K1030ac/K1033ac)
5NNF	;	1.15	;	Crystal Structure of the first bromodomain of human BRD4 in complex with an acetylated BAZ1B peptide (K221ac)
6G0P	;	1.3	;	Crystal Structure of the first bromodomain of human BRD4 in complex with an acetylated E2F1 peptide (K117ac/K120ac)
6G0Q	;	1.4	;	Crystal Structure of the first bromodomain of human BRD4 in complex with an acetylated GATA1 peptide (K312ac/K315ac)
6G0R	;	1.25	;	Crystal Structure of the first bromodomain of human BRD4 in complex with an acetylated POLR2A peptide (K775ac/K778ac)
6G0S	;	1.48	;	Crystal Structure of the first bromodomain of human BRD4 in complex with an acetylated SIRT7 peptide (K272ac/K275ac)
5NNG	;	1.2	;	Crystal Structure of the first bromodomain of human BRD4 in complex with an acetylated SRPK1 peptide (K585ac)
4NR8	;	1.635	;	Crystal structure of the first bromodomain of human BRD4 in complex with an isoxazolyl-benzimidazole ligand
5COI	;	1.62	;	Crystal Structure of the first bromodomain of human BRD4 in complex with benzo[cd]indol-2(1H)-one ligand
5CP5	;	1.79	;	Crystal Structure of the first bromodomain of human BRD4 in complex with benzo[cd]indol-2(1H)-one ligand
5CPE	;	1.62	;	Crystal Structure of the first bromodomain of human BRD4 in complex with benzo[cd]indol-2(1H)-one ligand
5CQT	;	1.6	;	Crystal Structure of the first bromodomain of human BRD4 in complex with benzo[cd]indol-2(1H)-one ligand
5CRM	;	1.99	;	Crystal Structure of the first bromodomain of human BRD4 in complex with benzo[cd]indol-2(1H)-one ligand
5CRZ	;	2.12	;	Crystal Structure of the first bromodomain of human BRD4 in complex with benzo[cd]indol-2(1H)-one ligand
5CS8	;	1.62	;	Crystal Structure of the first bromodomain of human BRD4 in complex with benzo[cd]indol-2(1H)-one ligand
5CTL	;	2.51	;	Crystal Structure of the first bromodomain of human BRD4 in complex with benzo[cd]indol-2(1H)-one ligand
5CY9	;	1.55	;	Crystal Structure of the first bromodomain of human BRD4 in complex with benzo[cd]indol-2(1H)-one ligand
5D0C	;	1.49	;	Crystal Structure of the first bromodomain of human BRD4 in complex with benzo[cd]indol-2(1H)-one ligand
5DX4	;	2.3	;	Crystal Structure of the first bromodomain of human BRD4 in complex with benzo[cd]indol-2(1H)-one ligand
4O74	;	1.45	;	Crystal structure of the first bromodomain of human BRD4 in complex with BI 2536
5S9R	;	1.85	;	CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX WITH BMS-986158, 2-{3-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)-5-[(S)-(oxan-4-yl)(phenyl)methyl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol
7UZN	;	1.685	;	CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX WITH BMT-206059 AKA 2-{(3M)-3-(1,4-DIMETHYL-1H-1,2,3-TRIAZOL-5-YL)-8-FLUORO-5-[(S)-(OXAN-4-YL)(PHENYL)METHYL]-5H-PYRIDO[3,2-b]INDOL-7-YL}PROPAN-2-OL, TRIPLY DEUTERATED ON THE 4-METHYL GROUP
5IGK	;	1.7	;	Crystal structure of the first bromodomain of human BRD4 in complex with bromosporine (BSP)
4PCE	;	1.293	;	Crystal Structure of the first bromodomain of human BRD4 in complex with compound B13
6LG6	;	1.98	;	Crystal Structure of the first bromodomain of human BRD4 in complex with compound BDF-1021
6LG4	;	1.85	;	crystal structure of the first bromodomain of human BRD4 in complex with compound BDF-1024
6LG5	;	1.83	;	Crystal Structure of the first bromodomain of human BRD4 in complex with compound BDF-1038
6LG7	;	1.83	;	Crystal Structure of the first bromodomain of human BRD4 in complex with compound BDF-2030
6LG8	;	1.58	;	crystal structure of the first bromodomain of human BRD4 in complex with compound BDF-2138
6LG9	;	1.81	;	crystal structure of the first bromodomain of human BRD4 in complex with compound BDF-2143
6ZED	;	1.08	;	CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX with compound F1
6ZEL	;	1.12	;	CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX with compound F5
6ZF9	;	1.2	;	CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX with compound SSR4
5ULA	;	1.5	;	Crystal Structure of the First Bromodomain of Human BRD4 in Complex With Cyclic Vinylogous Amide Inhibitor MS402
5KJ0	;	1.51	;	CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX WITH DB-1-264-2
4O70	;	1.55	;	Crystal structure of the first bromodomain of human BRD4 in complex with DINACICLIB
4O71	;	1.36	;	Crystal structure of the first bromodomain of human BRD4 in complex with FLAVOPIRIDOL
4O75	;	1.55	;	Crystal structure of the first bromodomain of human BRD4 in complex with FOSTAMATINIB
4O78	;	1.34	;	Crystal structure of the first bromodomain of human BRD4 in complex with GW612286X
6MH1	;	1.6	;	CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX WITH HU-10, A 1,4,5-Trisubstituted Imidazole Analogue
3ZYU	;	1.5	;	Crystal Structure of the first bromodomain of human BRD4 in complex with I-BET151(GSK1210151A)
3P5O	;	1.6	;	Crystal Structure of the First Bromodomain of Human Brd4 in complex with IBET inhibitor
5TI3	;	1.703	;	CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX WITH INHIBITOR 17503468
5TI7	;	1.65	;	CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX WITH INHIBITOR 17528462
5TI2	;	1.65	;	CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX WITH INHIBITOR 7635936
5TI4	;	1.62	;	CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX WITH INHIBITOR 8841871
5TI5	;	1.83	;	CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX WITH INHIBITOR 8841880
5TI6	;	1.704	;	CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX WITH INHIBITOR 8841881
7LH8	;	1.75	;	CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX WITH INHIBITOR JJ-II-131
5VBO	;	1.3	;	CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX WITH LRRK2-IN-1
5F5Z	;	1.76	;	Crystal structure of the first bromodomain of human BRD4 in complex with MA2-014
5F61	;	1.45	;	Crystal structure of the first bromodomain of human BRD4 in complex with MA4-022-1
5F62	;	1.35	;	Crystal structure of the first bromodomain of human BRD4 in complex with MA4-022-2
3U5K	;	1.8	;	Crystal Structure of the first bromodomain of human BRD4 in complex with Midazolam
4NUE	;	1.3	;	Crystal structure of the first bromodomain of human BRD4 in complex with MS267 inhibitor
4F3I	;	1.4	;	Crystal structure of the first bromodomain of human BRD4 in complex with MS417 inhibitor
4NUC	;	1.4	;	Crystal structure of the first bromodomain of human BRD4 in complex with MS435 inhibitor
4NUD	;	1.2	;	Crystal structure of the first bromodomain of human BRD4 in complex with MS436 inhibitor
4O72	;	1.4	;	Crystal structure of the first bromodomain of human BRD4 in complex with NU7441
4QB3	;	0.94	;	Crystal structure of the first bromodomain of human BRD4 in complex with Olinone
5FBX	;	1.85	;	Crystal structure of the first bromodomain of human BRD4 in complex with PNZ5 isoxazole inhibitor
5VBP	;	1.83	;	CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX WITH RO3280
4O77	;	2.0	;	Crystal structure of the first bromodomain of human BRD4 in complex with SB 202190
4O7F	;	1.8	;	Crystal structure of the first bromodomain of human BRD4 in complex with SB-251527
4O7B	;	1.5	;	Crystal structure of the first bromodomain of human BRD4 in complex with SB-284847-BT
4O7A	;	1.34	;	Crystal structure of the first bromodomain of human BRD4 in complex with SB-409514
4O7E	;	1.85	;	Crystal structure of the first bromodomain of human BRD4 in complex with SB-610251-B
4O7C	;	1.55	;	Crystal structure of the first bromodomain of human BRD4 in complex with SB-614067-R
5F60	;	1.35	;	Crystal structure of the first bromodomain of human BRD4 in complex with SG3-014
5F63	;	1.45	;	Crystal structure of the first bromodomain of human BRD4 in complex with SG3-179
7RN2	;	1.05	;	Crystal structure of the first bromodomain of human BRD4 in complex with SJ001010551-2
7RMD	;	1.18	;	Crystal structure of the first bromodomain of human BRD4 in complex with SJ001011461-1
6MH7	;	1.74	;	Crystal structure of the first bromodomain of human BRD4 in complex with SKT-68, a 1,4,5-trisubstituted imidazole analogue
4O76	;	1.7	;	Crystal structure of the first bromodomain of human BRD4 in complex with TG101209
4PS5	;	1.4	;	Crystal structure of the first bromodomain of human BRD4 in complex with TG101348
8P9F	;	1.3	;	Crystal structure of the first bromodomain of human BRD4 in complex with the dual BET/HDAC inhibitor NB161
8P9G	;	1.1	;	Crystal structure of the first bromodomain of human BRD4 in complex with the dual BET/HDAC inhibitor NB390
8P9H	;	1.19	;	Crystal structure of the first bromodomain of human BRD4 in complex with the dual BET/HDAC inhibitor NB437
8P9I	;	1.23	;	Crystal structure of the first bromodomain of human BRD4 in complex with the dual BET/HDAC inhibitor NB462
8P9J	;	1.42	;	Crystal structure of the first bromodomain of human BRD4 in complex with the dual BET/HDAC inhibitor NB500
8P9K	;	1.25	;	Crystal structure of the first bromodomain of human BRD4 in complex with the dual BET/HDAC inhibitor NB503
8P9L	;	1.29	;	Crystal structure of the first bromodomain of human BRD4 in complex with the dual BET/HDAC inhibitor NB512
6YQO	;	1.07	;	Crystal structure of the first bromodomain of human BRD4 in complex with the dual inhibitor TW12
6YQP	;	1.25	;	Crystal structure of the first bromodomain of human BRD4 in complex with the dual inhibitor TW22
6YQN	;	1.05	;	Crystal structure of the first bromodomain of human BRD4 in complex with the dual inhibitor TW9
6Q3Y	;	1.2	;	Crystal structure of the first bromodomain of human BRD4 in complex with the inhibitor 16i
6Q3Z	;	2.0	;	Crystal structure of the first bromodomain of human BRD4 in complex with the inhibitor 16k
8WY3	;	2.78	;	Crystal Structure of the first bromodomain of human BRD4 in complex with the inhibitor 21
8WY7	;	2.83	;	Crystal Structure of the first bromodomain of human BRD4 in complex with the inhibitor 22
8WXY	;	2.87	;	Crystal Structure of the first bromodomain of human BRD4 in complex with the inhibitor 23
7V2J	;	2.24	;	Crystal Structure of the first bromodomain of human BRD4 in complex with the inhibitor 33
4OGI	;	1.73	;	Crystal Structure of the first bromodomain of human BRD4 in complex with the inhibitor BI-2536
3MXF	;	1.6	;	Crystal Structure of the first bromodomain of human BRD4 in complex with the inhibitor JQ1
6CD4	;	1.23	;	Crystal Structure of the first bromodomain of human BRD4 in complex with the inhibitor JWG046
6CIS	;	1.51	;	Crystal Structure of the first bromodomain of human BRD4 in complex with the inhibitor JWG047
5W55	;	1.354	;	Crystal Structure of the first bromodomain of human BRD4 in complex with the inhibitor JWG048
6CJ2	;	1.47	;	Crystal Structure of the first bromodomain of human BRD4 in complex with the inhibitor JWG056
6CIY	;	1.68	;	Crystal Structure of the first bromodomain of human BRD4 in complex with the inhibitor JWG069
6CJ1	;	1.53	;	Crystal Structure of the first bromodomain of human BRD4 in complex with the inhibitor JWG071
4E96	;	1.92	;	Crystal Structure of the first bromodomain of human BRD4 in complex with the inhibitor PFi-1
7WL4	;	1.82	;	Crystal Structure of the first bromodomain of human BRD4 in complex with the inhibitor SLP-50
4OGJ	;	1.65	;	Crystal Structure of the first bromodomain of human BRD4 in complex with the inhibitor TG-101348
5WA5	;	1.172	;	Crystal Structure of the first bromodomain of human BRD4 in complex with the inhibitor XMD11-50
6CD5	;	1.58	;	Crystal Structure of the first bromodomain of human BRD4 in complex with the inhibitor XMD17-26
7YL2	;	1.62	;	Crystal Structure of the first bromodomain of human BRD4 in complex with the inhibitor Y07004
7WKY	;	2.83	;	Crystal Structure of the first bromodomain of human BRD4 in complex with the inhibitor Y13153
7WJS	;	2.73	;	Crystal Structure of the first bromodomain of human BRD4 in complex with the inhibitor Y13157
7V1U	;	1.82	;	Crystal Structure of the first bromodomain of human BRD4 in complex with the inhibitor ZJ12
6UWU	;	2.0	;	Crystal Structure of the first bromodomain of human BRD4 in complex with the inhibitor ZL0516
6U0D	;	1.43	;	Crystal Structure of the first bromodomain of human BRD4 in complex with the inhibitor ZL0590
8Q34	;	1.48	;	Crystal structure of the first bromodomain of human BRD4 in complex with the ligand ZZ001229a
5V67	;	1.78	;	CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX WITH Volasertib
8CKF	;	1.88	;	Crystal Structure of the first bromodomain of human BRD4 L94C variant in complex with racemic 3,5-dimethylisoxazol ligand
6WVX	;	1.55	;	Crystal structure of the first bromodomain of human BRD4 with benzodiazepine inhibitor
4Z1S	;	1.06	;	Crystal structure of the first bromodomain of human BRD4 with benzotriazolo-diazepine scaffold
2YEL	;	1.65	;	Crystal Structure of the First Bromodomain of Human Brd4 with the inhibitor GW841819X
5VBQ	;	1.65	;	CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRDT IN COMPLEX WITH BI2536
7UBO	;	1.82	;	Crystal Structure of the first bromodomain of human BRDT in complex with the inhibitor CCD-956
4FLP	;	2.23	;	Crystal Structure of the first bromodomain of human BRDT in complex with the inhibitor JQ1
5VBR	;	1.9	;	CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRDT IN COMPLEX WITH Volasertib
3IU5	;	1.63	;	Crystal structure of the first bromodomain of human poly-bromodomain containing protein 1 (PB1)
4EF0	;	1.5	;	Crystal Structure of the first catalytic domain of protein disulfide isomerase P5
1ZVS	;	2.8	;	Crystal structure of the first class MHC mamu and Tat-Tl8 complex
1NTY	;	1.7	;	Crystal structure of the first DH/PH domain of Trio to 1.7 A
3LLH	;	2.14	;	Crystal structure of the first dsRBD of TAR RNA-binding protein 2
2HAZ	;	1.7	;	Crystal structure of the first fibronectin domain of human NCAM1
2E3V	;	1.95	;	Crystal structure of the first fibronectin type III domain of neural cell adhesion molecule splicing isoform from human muscle culture lambda-4.4
2IC2	;	1.3	;	Crystal Structure of the First FNIII Domain of Ihog
3RPM	;	2.1	;	Crystal structure of the first GH20 domain of a novel Beta-N-acetyl-hexosaminidase StrH from Streptococcus pneumoniae R6
3ZYW	;	1.84	;	Crystal structure of the first glutaredoxin domain of human glutaredoxin 3 (GLRX3)
2OQ0	;	2.0	;	Crystal Structure of the First HIN-200 Domain of Interferon-Inducible Protein 16
4CEM	;	2.6	;	Crystal structure of the first MIF4G domain of human nonsense mediated decay factor UPF2
1JBK	;	1.8	;	Crystal Structure of the First Nucelotide Binding Domain of ClpB
3V4Y	;	2.098	;	Crystal Structure of the first Nuclear PP1 holoenzyme
2P65	;	1.7	;	Crystal Structure of the first nucleotide binding domain of chaperone ClpB1, putative, (Pv089580) from Plasmodium Vivax
3IFZ	;	2.7	;	crystal structure of the first part of the Mycobacterium tuberculosis DNA gyrase reaction core: the breakage and reunion domain at 2.7 A resolution
2W4F	;	1.3	;	CRYSTAL STRUCTURE OF THE FIRST PDZ DOMAIN OF HUMAN SCRIB1
3QIK	;	2.285	;	Crystal structure of the first PDZ domain of PREX1
3GBW	;	1.32	;	Crystal structure of the first PHR domain of the Mouse Myc-binding protein 2 (MYCBP-2)
3LA4	;	2.05	;	Crystal structure of the first plant urease from Jack bean (Canavalia ensiformis)
3WWH	;	1.65	;	Crystal structure of the first R-stereoselective -transaminase identified from Arthrobacter sp. KNK168 (FERM-BP-5228)
1R3O	;	1.9	;	Crystal structure of the first RNA duplex in L-conformation at 1.9A resolution
3R27	;	2.04	;	Crystal structure of the first RRM domain of heterogeneous nuclear ribonucleoprotein L (HnRNP L)
6SXW	;	2.751	;	Crystal structure of the first RRM domain of human Zinc finger protein 638 (ZNF638)
5YQI	;	1.6	;	Crystal structure of the first StARkin domain of Lam2
5YQJ	;	1.5	;	Crystal structure of the first StARkin domain of Lam4
6CAY	;	2.0	;	Crystal structure of the first StART-like domain of Ysp2p/Lam2p in its apo and ergosterol-bound state.
1JI3	;	2.2	;	CRYSTAL STRUCTURE OF THE FIRST THERMOSTABLE BACTERIAL LIPASE FROM BACILLUS STEAROTHERMOPHILUS
5JKI	;	2.25	;	Crystal structure of the first transmembrane PAP2 type phosphatidylglycerolphosphate phosphatase from Bacillus subtilis
3SD4	;	1.928	;	Crystal structure of the first Tudor domain of human PHF20
5ES6	;	2.46	;	Crystal structure of the first two domains of the initiation module of LgrA
3MD3	;	2.7	;	Crystal Structure of the First Two RRM Domains of Yeast Poly(U) Binding Protein (Pub1)
4PYZ	;	2.84	;	Crystal structure of the first two Ubl domains of Deubiquitylase USP7
4REX	;	1.6	;	Crystal structure of the first WW domain of human YAP2 isoform
8J0H	;	3.383	;	Crystal structure of the fission yeast Rex1BD protein(C4H3.06)
3NI6	;	1.42	;	Crystal structure of the FK506 binding domain of Plasmodium vivax FKBP35
4ITZ	;	1.65	;	Crystal structure of the FK506 binding domain of Plasmodium vivax FKBP35 in complex with a tetrapeptide substrate
3IHZ	;	1.67	;	Crystal structure of the FK506 binding domain of Plasmodium vivax FKBP35 in complex with FK506
3EY6	;	1.05	;	Crystal structure of the FK506-binding domain of human FKBP38
2VN1	;	2.35	;	Crystal structure of the FK506-binding domain of Plasmodium falciparum FKBP35 in complex with FK506
4QT2	;	1.44	;	Crystal Structure of the FK506-Binding Domain of Plasmodium Falciparum FKBP35 in complex with Rapamycin
5U9A	;	2.7	;	Crystal structure of the FKBP domain of human aryl hydrocarbon receptor-interacting protein-like 1 (AIPL1)
5U9J	;	2.1	;	Crystal structure of the FKBP domain of human aryl hydrocarbon receptor-interacting protein-like 1 (AIPL1) complexed with geranyl geranyl pyrophoshate
5U9I	;	2.3	;	Crystal structure of the FKBP domain of human aryl hydrocarbon receptor-interacting protein-like 1 (AIPL1) complexed with S-farnesyl-L-cysteine methyl ester
5DMD	;	1.45	;	Crystal structure of the flagellar assembly factor FliW
5JAK	;	1.801	;	Crystal structure of the flagellar assembly factor FliW
5H5V	;	3.0	;	Crystal structure of the flagellar cap protein FliD D1-D2-D3 domains from Escherichia coli
5H5W	;	2.15	;	Crystal structure of the flagellar cap protein FliD D2-D3 domains from Escherichia coli
5H5T	;	2.5	;	Crystal structure of the flagellar cap protein FliD D2-D3 domains from Salmonella Typhimurium
5XLK	;	3.05	;	Crystal structure of the flagellar cap protein FliD D2-D3 domains from Serratia marcescens in Space group I422
5XLJ	;	1.9	;	Crystal structure of the flagellar cap protein flid D2-D3 domains from serratia marcescens in Space group P432
6KTY	;	1.99	;	Crystal structure of the flagellar cap protein FliD from Bdellovibrio bacteriovorus
6IWY	;	2.6	;	Crystal structure of the flagellar cap protein FliD from Helicobacter pylori
7X1K	;	2.39	;	Crystal structure of the flagellar expression regulator DegU from Listeria monocytogenes
7EH9	;	2.2	;	Crystal structure of the flagellar hook cap fragment from Salmonella enterica serovar Typhimurium
7EHA	;	3.3	;	Crystal structure of the flagellar hook cap from Salmonella enterica serovar Typhimurium
7C7Z	;	3.06	;	Crystal structure of the flagellar junction protein FlgL from Legionella pneumophila
2DPY	;	2.4	;	Crystal structure of the flagellar type III ATPase FliI
5MAW	;	1.5	;	Crystal structure of the flagellin-FliS complex from Bacillus subtilis
6GOW	;	2.1	;	Crystal structure of the flagellin-FliS complex from Bacillus subtilis crystallized in spacegroup P22121
1KDG	;	1.5	;	Crystal structure of the flavin domain of cellobiose dehydrogenase
6V43	;	1.77	;	Crystal structure of the flavin oxygenase with cofactor and substrate bound involved in folate catabolism
6V42	;	1.45	;	Crystal structure of the flavin oxygenase with cofactor bound involved in folate catabolism
3C96	;	1.9	;	Crystal structure of the flavin-containing monooxygenase phzS from Pseudomonas aeruginosa. Northeast Structural Genomics Consortium target PaR240
6U0S	;	2.52	;	Crystal structure of the flavin-dependent monooxygenase PieE in complex with FAD and substrate
1D4E	;	2.8	;	CRYSTAL STRUCTURE OF THE FLAVOCYTOCHROME C FUMARATE REDUCTASE OF SHEWANELLA PUTREFACIENS STRAIN MR-1 COMPLEXED WITH FUMARATE
2Q9U	;	1.9	;	Crystal structure of the flavodiiron protein from Giardia intestinalis
3HLY	;	2.403	;	Crystal Structure of the Flavodoxin-like domain from Synechococcus sp Q5MZP6_SYNP6 protein. Northeast Structural Genomics Consortium Target SnR135d.
4EH1	;	2.2	;	Crystal Structure of the Flavohem-like-FAD/NAD Binding Domain of Nitric Oxide Dioxygenase from Vibrio cholerae O1 biovar El Tor
1CQX	;	1.75	;	Crystal structure of the flavohemoglobin from Alcaligenes eutrophus at 1.75 A resolution
7XP7	;	1.95	;	Crystal Structure of the Flavoprotein ColB1 Catalyzing Assembly Line-Tethered Cysteine Dehydrogenation
7OUC	;	1.75	;	Crystal structure of the flavoprotein monooxygenase GrhO5 from griseorhodin A biosynthesis
7OUJ	;	1.573	;	Crystal structure of the flavoprotein monooxygenase RubL from rubromycin biosynthesis
6EBQ	;	1.95	;	Crystal Structure of the Flavoprotein NrdI from Aerococcus urinae in Oxidized Form
4BJM	;	2.6	;	Crystal structure of the flax-rust effector avrM
4BJN	;	2.9	;	Crystal structure of the flax-rust effector AvrM-A
5VJJ	;	2.52	;	Crystal structure of the flax-rust effector AvrP
8H5V	;	2.0	;	Crystal structure of the FleQ domain of Vibrio cholerae FlrA
5XW7	;	3.272	;	Crystal structure of the flexible tandem repeat domain of bacterial cellulose synthase subunit C
8J56	;	3.5	;	Crystal structure of the FlhDC complex from Cupriavidus necator
6IL3	;	2.5	;	Crystal structure of the FLT3 kinase bound to a small molecule inhibitor
5X02	;	2.401	;	Crystal structure of the FLT3 kinase domain bound to the inhibitor FF-10101
4XUF	;	3.2	;	Crystal structure of the FLT3 kinase domain bound to the inhibitor quizartinib (AC220)
1ETE	;	2.2	;	CRYSTAL STRUCTURE OF THE FLT3 LIGAND
3B12	;	1.2	;	Crystal Structure of the Fluoroacetate Dehalogenase D104 mutant from Burkholderia sp. FA1 in complex with fluoroacetate
5T4T	;	1.511	;	Crystal Structure of the Fluoroacetate Dehalogenase RPA1163 - Asp110Asn - Apo No Halide
3R40	;	1.05	;	Crystal Structure of the Fluoroacetate Dehalogenase RPA1163 - Asp110Asn/apo
3R3X	;	1.8	;	Crystal Structure of the Fluoroacetate Dehalogenase RPA1163 - Asp110Asn/Bromoacetate
3R3W	;	1.6	;	Crystal Structure of the Fluoroacetate Dehalogenase RPA1163 - Asp110Asn/Chloroacetate
5K3B	;	1.58	;	Crystal Structure of the Fluoroacetate Dehalogenase RPA1163 - Asp110Asn/Chloroacetate - Cocrystallized
3R3V	;	1.5	;	Crystal Structure of the Fluoroacetate Dehalogenase RPA1163 - Asp110Asn/Fluoroacetate
5SWN	;	1.541	;	Crystal Structure of the Fluoroacetate Dehalogenase RPA1163 - Asp110Asn/Fluoroacetate - Cocrystallized
5K3E	;	1.54	;	Crystal Structure of the Fluoroacetate Dehalogenase RPA1163 - Asp110Asn/Glycolate - Cocrystallized
3R41	;	1.05	;	Crystal Structure of the Fluoroacetate Dehalogenase RPA1163 - His280Asn/apo
3R3Y	;	1.15	;	Crystal Structure of the Fluoroacetate Dehalogenase RPA1163 - His280Asn/Fluoroacetate
5K3A	;	1.511	;	Crystal Structure of the Fluoroacetate Dehalogenase RPA1163 - His280Asn/Fluoroacetate - Cocrystallized - Both Protomers Reacted with Ligand
5K3F	;	1.54	;	Crystal Structure of the Fluoroacetate Dehalogenase RPA1163 - His280Asn/Fluoroacetate - Cocrystallized - Single Protomer Reacted with Ligand
6QKS	;	1.6	;	Crystal Structure of the Fluoroacetate Dehalogenase RPA1163 - Tyr219Phe - Apo
6QKU	;	1.511	;	Crystal Structure of the Fluoroacetate Dehalogenase RPA1163 - Tyr219Phe - Chloroacetate soaked 2hr
6QKT	;	1.512	;	Crystal Structure of the Fluoroacetate Dehalogenase RPA1163 - Tyr219Phe - Fluoroacetate soaked 24hr - Glycolate bound
6QKW	;	1.512	;	Crystal Structure of the Fluoroacetate Dehalogenase RPA1163 - Tyr219Phe - Fluoroacetate soaked 2hr
5K3C	;	1.541	;	Crystal Structure of the Fluoroacetate Dehalogenase RPA1163 - WT/5-Fluorotryptophan
3R3U	;	1.6	;	Crystal Structure of the Fluoroacetate Dehalogenase RPA1163 - WT/apo
5K3D	;	1.45	;	Crystal Structure of the Fluoroacetate Dehalogenase RPA1163 - WT/Apo - No Halide
3R3Z	;	1.7	;	Crystal Structure of the Fluoroacetate Dehalogenase RPA1163 - WT/Glycolate
3P2S	;	1.95	;	Crystal structure of the fluoroacetyl-CoA-specific thioesterase FlK in an open conformation
3P2R	;	2.46	;	Crystal structure of the fluoroacetyl-CoA-specific thioesterase FlK in complex with fluoroacetate
3P2Q	;	1.85	;	Crystal structure of the fluoroacetyl-CoA-specific thioesterase, FlK
6DN1	;	3.03	;	CRYSTAL STRUCTURE OF THE FMN RIBOSWITCH BOUND TO BRX1151 SPLIT RNA
6DN2	;	2.88	;	CRYSTAL STRUCTURE OF THE FMN RIBOSWITCH BOUND TO BRX1354 SPLIT RNA
6DN3	;	2.8	;	CRYSTAL STRUCTURE OF THE FMN RIBOSWITCH BOUND TO BRX1555 SPLIT RNA
3F2Q	;	2.95	;	Crystal structure of the FMN riboswitch bound to FMN
3F2W	;	3.45	;	Crystal structure of the FMn riboswitch bound to FMN, Ba2+ soak.
3F30	;	3.15	;	Crystal structure of the FMN riboswitch bound to FMN, cobalt hexammine soak.
3F2X	;	3.11	;	Crystal structure of the FMN riboswitch bound to FMN, Cs+ soak.
3F2T	;	3.0	;	Crystal structure of the FMN riboswitch bound to FMN, iridium hexamine soak.
3F2Y	;	3.2	;	Crystal structure of the FMN riboswitch bound to FMN, Mn2+ soak.
3F4E	;	3.05	;	Crystal structure of the FMN riboswitch bound to FMN, split RNA.
3F4G	;	3.01	;	Crystal structure of the FMN riboswitch bound to riboflavin.
3F4H	;	3.0	;	Crystal structure of the FMN riboswitch bound to roseoflavin
1B1C	;	1.93	;	CRYSTAL STRUCTURE OF THE FMN-BINDING DOMAIN OF HUMAN CYTOCHROME P450 REDUCTASE AT 1.93A RESOLUTION
2WZV	;	1.75	;	Crystal structure of the FMN-dependent nitroreductase NfnB from Mycobacterium smegmatis
2WZW	;	1.8	;	Crystal structure of the FMN-dependent nitroreductase NfnB from Mycobacterium smegmatis in complex with NADPH
4C76	;	1.96	;	Crystal Structure of the FMN-reductase Msue from Pseudomonas putida KT2440.
6X3A	;	1.77	;	Crystal structure of the FN4-FN6 domains of human PTPRD
4BQC	;	3.2	;	Crystal structure of the FN5 and FN6 domains of NEO1 bound to SOS
4BQ9	;	2.91	;	Crystal structure of the FN5 and FN6 domains of NEO1, form 1
4BQB	;	2.7	;	Crystal structure of the FN5 and FN6 domains of NEO1, form 2
6X38	;	1.3	;	Crystal structure of the FN5 domain of Drosophila Lar
6X39	;	1.7	;	Crystal structure of the FN5 domain of Mouse Lar
3LPW	;	1.65	;	Crystal structure of the FnIII-tandem A77-A78 from the A-band of titin
8BNQ	;	2.3	;	Crystal structure of the FnIII-tandem A84-A86 from the A-band of titin
3GM2	;	2.71	;	Crystal Structure of the Focal Adhesion Targeting (FAT) Domain of Pyk2
3GM3	;	2.6	;	Crystal Structure of the Focal Adhesion Targeting (FAT) Domain of Pyk2
3GM1	;	2.95	;	Crystal Structure of the Focal Adhesion Targeting (FAT) Domain of Pyk2 in Complex with Paxillin LD4 Motif-Derived Peptides
1K04	;	1.95	;	Crystal Structure of the Focal Adhesion Targeting Domain of Focal Adhesion Kinase
1K05	;	2.9	;	Crystal structure of the Focal Adhesion Targeting Domain of Focal Adhesion Kinase
7PVH	;	2.0	;	Crystal structure of the folded domain of PorN
3WVL	;	3.788	;	Crystal structure of the football-shaped GroEL-GroES complex (GroEL: GroES2:ATP14) from Escherichia coli
4PKO	;	3.84	;	Crystal structure of the Football-shaped GroEL-GroES2-(ADPBeFx)14 complex
4PKN	;	3.66	;	Crystal structure of the football-shaped GroEL-GroES2-(ADPBeFx)14 complex containing substrate Rubisco
5XFL	;	2.45	;	Crystal structure of the force-sensing device region of alpha N-catenin
7RJ3	;	1.68	;	Crystal Structure of the Forkhead Associated (FHA) Domain of the Glycogen Accumulation Regulator (GarA) from Mycobacterium tuberculosis
5OCN	;	2.7	;	Crystal structure of the forkhead domain of human FOXN1
6EL8	;	1.61	;	Crystal structure of the Forkhead domain of human FOXN1 in complex with DNA
4EAH	;	3.4	;	Crystal structure of the formin homology 2 domain of FMNL3 bound to actin
4QQ8	;	2.88	;	Crystal structure of the formolase FLS in space group P 43 21 2
4QPZ	;	3.0	;	Crystal structure of the formolase FLS_v2 in space group P 21
6CI2	;	1.96	;	Crystal structure of the formyltransferase PseJ from Anoxybacillus kamchatkensis
6CI5	;	2.00003	;	Crystal structure of the formyltransferase PseJ from Anoxybacillus kamchatkensis in complex with UDP-4,6-dideoxy-4-formamido-L-AltNAc and tetrahydrofolate
6CI4	;	1.82407	;	Crystal structure of the formyltransferase PseJ from Anoxybacillus kamchatkensis soaked with UDP-4-amino-4,6-dideoxy-L-AltNAc
6EDK	;	1.8	;	Crystal structure of the formyltransferase PseJ from Anoxybacillus kamchatkensis with N10-formyltetrahydrofolate
1LQP	;	1.19	;	CRYSTAL STRUCTURE OF THE FOSFOMYCIN RESISTANCE PROTEIN (FOSA) CONTAINING BOUND SUBSTRATE
1NKI	;	0.95	;	CRYSTAL STRUCTURE OF THE FOSFOMYCIN RESISTANCE PROTEIN A (FOSA) CONTAINING BOUND PHOSPHONOFORMATE
1NPB	;	2.5	;	Crystal structure of the fosfomycin resistance protein from transposon Tn2921
6AED	;	3.797	;	Crystal Structure of the four Ig-like domain of LILRB2(LIR2/ILT4/CD85d)
6AEE	;	3.303	;	Crystal structure of the four Ig-like domains of LILRB1 complexed with HLA-G
3H6Z	;	2.8	;	Crystal Structure of the Four MBT Repeats of Drosophila melanogaster Sfmbt in Complex with Peptide RHR (me)K VLR
5XWX	;	1.55	;	Crystal structure of the four N-terminal immunoglogulin domains of Sidekick-1 protein
5XX0	;	2.4	;	Crystal structure of the four N-terminal immunoglogulin domains of Sidekick-2 protein
2RKY	;	1.8	;	Crystal structure of the fourth and fifth fibronectin F1 modules in complex with a fragment of staphylococcus aureus fnbpa-1
2RL0	;	2.0	;	Crystal structure of the fourth and fifth fibronectin F1 modules in complex with a fragment of staphylococcus aureus fnbpa-5
3TLP	;	2.13	;	Crystal structure of the fourth bromodomain of human poly-bromodomain containing protein 1 (PB1)
4WTX	;	1.5	;	Crystal structure of the fourth FnIII domain of integrin beta4
2VSP	;	2.41	;	Crystal structure of the fourth PDZ domain of PDZ domain-containing protein 1
4FZ2	;	2.252	;	Crystal structure of the fourth type of archaeal tRNA splicing endonuclease from Candidatus Micrarchaeum acidiphilum ARMAN-2
6P7A	;	3.081	;	CRYSTAL STRUCTURE OF THE FOWLPOX VIRUS HOLLIDAY JUNCTION RESOLVASE
4L9C	;	2.1	;	Crystal structure of the FP domain of human F-box protein Fbxo7 (native)
4L9H	;	2.0	;	Crystal structure of the FP domain of human F-box protein Fbxo7(SeMet)
4OUH	;	2.0	;	Crystal structure of the FP domain of Human PI31 Proteasome Inhibitor
6RU3	;	1.26	;	Crystal structure of the FP specific nanobody hFPNb1
6Y3X	;	3.4	;	Crystal structure of the Francisella novicida lysine decarboxylase LdcF
3NRC	;	2.101	;	Crystal Structure of the Francisella tularensis enoyl-acyl carrier protein reductase (FabI) in complex with NAD+ and triclosan
1W7Z	;	1.67	;	Crystal structure of the free (uncomplexed) Ecballium elaterium trypsin inhibitor (EETI-II)
2I9A	;	1.9	;	Crystal structure of the free aminoterminal fragment of urokinase type plasminogen activator (ATF)
6Y2E	;	1.75	;	Crystal structure of the free enzyme of the SARS-CoV-2 (2019-nCoV) main protease
4MNA	;	3.998	;	Crystal structure of the free FLS2 ectodomains
1MPU	;	2.5	;	Crystal Structure of the free human NKG2D immunoreceptor
1KEK	;	1.9	;	Crystal Structure of the Free Radical Intermediate of Pyruvate:Ferredoxin Oxidoreductase
2C3O	;	2.7	;	CRYSTAL STRUCTURE OF THE FREE RADICAL INTERMEDIATE OF PYRUVATE:FERREDOXIN OXIDOREDUCTASE FROM Desulfovibrio africanus
2C3P	;	2.33	;	CRYSTAL STRUCTURE OF THE FREE RADICAL INTERMEDIATE OF PYRUVATE:FERREDOXIN OXIDOREDUCTASE FROM Desulfovibrio africanus
2UZA	;	2.42	;	CRYSTAL STRUCTURE OF THE FREE RADICAL INTERMEDIATE OF PYRUVATE:FERREDOXIN OXIDOREDUCTASE FROM DESULFOVIBRIO AFRICANUS
7RON	;	1.68	;	Crystal structure of the Friedel-Crafts alkylating enzyme CylK from Cylindospermum licheniforme
3HKL	;	2.1	;	Crystal Structure of the Frizzled-like Cysteine-rich Domain of MuSK
2R8T	;	2.3	;	Crystal structure of the fructose 1,6-bisphosphatase GlpX from E.coli in the complex with fructose 1,6-bisphosphate
2R48	;	1.8	;	Crystal structure of the fructose specific IIB subunit of PTS system from Bacillus subtilis subsp. subtilis str. 168
3BIG	;	1.85	;	Crystal structure of the fructose-1,6-bisphosphatase GlpX from E.coli in complex with inorganic phosphate
1IXZ	;	2.2	;	Crystal structure of the FtsH ATPase domain from Thermus thermophilus
1IY2	;	3.2	;	Crystal structure of the FtsH ATPase domain from Thermus thermophilus
1IY1	;	2.8	;	Crystal structure of the FtsH ATPase domain with ADP from Thermus thermophilus
1IY0	;	2.95	;	Crystal structure of the FtsH ATPase domain with AMP-PNP from Thermus thermophilus
2DI4	;	2.79	;	Crystal structure of the FtsH protease domain
4A34	;	2.5	;	Crystal structure of the fucose mutarotase in complex with L-fucose from Streptococcus pneumoniae
3AVE	;	2.0	;	Crystal Structure of the Fucosylated Fc Fragment from Human Immunoglobulin G1
4C2S	;	2.48	;	Crystal structure of the fucosylgalactoside alpha N- acetylgalactosaminyltransferase (GTA P156L mutant) in complex with UDP and deoxy-H-antigen acceptor
3ZGF	;	1.701	;	Crystal structure of the Fucosylgalactoside alpha N- acetylgalactosaminyltransferase (GTA, cisAB mutant L266G, G268A) in complex with in complex with NPE caged UDP-Gal (P2(1)2(1)2(1) space group)
3ZGG	;	1.9	;	Crystal structure of the Fucosylgalactoside alpha N- acetylgalactosaminyltransferase (GTA, cisAB mutant L266G, G268A) in complex with NPE caged UDP-Gal (C222(1) space group)
3IOH	;	1.25	;	Crystal structure of the Fucosylgalactoside alpha N-acetylgalactosaminyltransferase (GTA, cisAB mutant L266G, G268A)
3IOI	;	1.45	;	Crystal structure of the Fucosylgalactoside alpha N-acetylgalactosaminyltransferase (GTA, cisAB mutant L266G, G268A) in complex with a novel UDP-Gal derived inhibitor (1GW)
3V0L	;	1.75	;	Crystal structure of the Fucosylgalactoside alpha N-acetylgalactosaminyltransferase (GTA, cisAB mutant L266G, G268A) in complex with a novel UDP-Gal derived inhibitor (2GW)
3V0P	;	1.9	;	Crystal structure of the Fucosylgalactoside alpha N-acetylgalactosaminyltransferase (GTA, cisAB mutant L266G, G268A) in complex with a novel UDP-Gal derived inhibitor (4GW) and H-antigen acceptor
3V0M	;	1.68	;	Crystal structure of the Fucosylgalactoside alpha N-acetylgalactosaminyltransferase (GTA, cisAB mutant L266G, G268A) in complex with a novel UDP-Gal derived inhibitor (5GW) and H-antigen acceptor
3V0N	;	1.75	;	Crystal structure of the Fucosylgalactoside alpha N-acetylgalactosaminyltransferase (GTA, cisAB mutant L266G, G268A) in complex with a novel UDP-GalNAc derived inhibitor (3GW and 4GW)
3V0O	;	1.65	;	Crystal structure of the Fucosylgalactoside alpha N-acetylgalactosaminyltransferase (GTA, cisAB mutant L266G, G268A) in complex with a novel UDP-GalNAc derived inhibitor (4GW) and H-antigen acceptor
3U0Y	;	1.6	;	Crystal structure of the Fucosylgalactoside alpha N-acetylgalactosaminyltransferase (GTA, cisAB mutant L266G, G268A) in complex with compound 382 and UDP
3IOJ	;	1.651	;	Crystal structure of the Fucosylgalactoside alpha N-acetylgalactosaminyltransferase (GTA, cisAB mutant L266G, G268A) in complex with UDP
3V0Q	;	1.8	;	Crystal structure of the Fucosylgalactoside alpha N-acetylgalactosaminyltransferase (GTA, cisAB mutant L266G, G268A) in complex with UDP and H-antigen acceptor
4HC7	;	2.65	;	Crystal structure of the full DNA binding domain of GATA3-complex 2
3L5H	;	3.6	;	Crystal structure of the full ectodomain of human gp130: New insights into the molecular assembly of receptor complexes
2VEP	;	1.8	;	Crystal Structure Of The Full Length Bifunctional Enzyme Pria
3ER0	;	3.35	;	Crystal structure of the full length eIF5A from Saccharomyces cerevisiae
2O5P	;	2.77	;	Crystal structure of the full length ferric pyoverdine outer membrane receptor FpvA of Pseudomonas aeruginosa in its apo form
3CVR	;	2.8	;	Crystal structure of the full length IpaH3
5XHB	;	1.9	;	Crystal structure of the full length of NisI in a lipid free form, the nisin immunity protein, from Lactococcus lactis
5DYE	;	3.5	;	CRYSTAL STRUCTURE OF THE FULL LENGTH S156E MUTANT OF HUMAN AQUAPORIN 5
3T1B	;	2.7	;	Crystal structure of the full-length AphB N100E variant
3KVN	;	2.499	;	Crystal structure of the full-length autotransporter EstA from Pseudomonas aeruginosa
8GMB	;	3.4	;	Crystal structure of the full-length Bruton's tyrosine kinase (PH-TH domain not visible)
5I8L	;	2.801	;	Crystal structure of the full-length cell wall-binding module of Cpl7 mutant R223A
8OFW	;	3.8	;	Crystal structure of the full-length dihydroorotate dehydrogenase from Mycobacterium tuberculosis
5NA2	;	1.67	;	Crystal structure of the full-length Feline Immunodeficiency Virus capsid protein unveils original features
4X4W	;	1.9	;	Crystal structure of the full-length human mitochondrial CCA-adding enzyme
3PS5	;	3.1	;	Crystal structure of the full-length Human Protein Tyrosine Phosphatase SHP-1
4LP5	;	3.8	;	Crystal structure of the full-length human RAGE extracellular domain (VC1C2 fragment)
4K6M	;	2.6	;	Crystal Structure of the full-length Japanese encephalitis virus NS5
3FNJ	;	2.7	;	Crystal structure of the full-length lp_1913 protein from Lactobacillus plantarum, Northeast Structural Genomics Consortium Target LpR140
4IC9	;	2.0	;	Crystal structure of the full-length matrix subunit (p15) of the Feline Immunodeficiency Virus (FIV) Gag polyprotein
5C3P	;	2.1	;	Crystal structure of the full-length Neurospora crassa T7H in complex with alpha-KG
5C3S	;	2.15	;	Crystal structure of the full-length Neurospora crassa T7H in complex with alpha-KG and 5-formyluracil (5fU)
5C3R	;	2.35	;	Crystal structure of the full-length Neurospora crassa T7H in complex with alpha-KG and 5-hydroxymethyluracil (5hmU)
5C3Q	;	2.05	;	Crystal structure of the full-length Neurospora crassa T7H in complex with alpha-KG and thymine (T)
4LDZ	;	2.31	;	Crystal structure of the full-length response regulator DesR in the active state
7R5N	;	3.45	;	Crystal structure of the full-length short LOV protein PF5-LOV from Pseudomonas fluorescens (dark state)
7YX0	;	1.6	;	Crystal structure of the full-length short LOV protein SBW25-LOV from Pseudomonas fluorescens (light state)
2PF4	;	3.1	;	Crystal structure of the full-length simian virus 40 small t antigen complexed with the protein phosphatase 2A Aalpha subunit
3ZQQ	;	4.0	;	Crystal structure of the full-length small terminase from a SPP1-like bacteriophage
2W48	;	3.2	;	Crystal structure of the Full-length Sorbitol Operon Regulator SorC from Klebsiella pneumoniae
3FWL	;	3.086	;	Crystal Structure of the Full-Length Transglycosylase PBP1b from Escherichia coli
3VMA	;	2.161	;	Crystal Structure of the Full-Length Transglycosylase PBP1b from Escherichia coli
3EXA	;	2.3	;	Crystal structure of the full-length tRNA isopentenylpyrophosphate transferase (BH2366) from Bacillus halodurans, Northeast Structural Genomics Consortium target BhR41.
6NO7	;	3.55	;	Crystal Structure of the full-length wild-type PKA RIa Holoenzyme
5M2X	;	4.991	;	Crystal structure of the full-length Zika virus NS5 protein (Human isolate Z1106033)
5M2Z	;	4.8	;	Crystal structure of the full-length Zika virus NS5 protein (Human isolate Z1106033)
6I7P	;	3.975	;	Crystal structure of the full-length Zika virus NS5 protein (Human isolate Z1106033)
1L3P	;	1.98	;	CRYSTAL STRUCTURE OF THE FUNCTIONAL DOMAIN OF THE MAJOR GRASS POLLEN ALLERGEN Phl p 5b
1DVK	;	2.15	;	CRYSTAL STRUCTURE OF THE FUNCTIONAL DOMAIN OF THE SPLICING FACTOR PRP18
3IEY	;	2.11	;	Crystal Structure of the functional Nanoarchaeum equitans tRNA splicing endonuclease
6ZRW	;	1.35	;	Crystal structure of the fungal lectin CML1
1ARP	;	1.9	;	Crystal structure of the fungal peroxidase from Arthromyces ramosus at 1.9 angstroms resolution: structural comparisons with the lignin and cytochrome C peroxidases
1I9W	;	3.0	;	CRYSTAL STRUCTURE OF THE FUSION GLYCOPROTEIN E1 FROM SEMLIKI FOREST VIRUS
5C2K	;	1.42	;	Crystal structure of the fusion protein linked by RhoA and the GAP domain of MgcRacGAP
1WZ1	;	1.85	;	Crystal structure of the Fv fragment complexed with dansyl-lysine
2GSG	;	2.1	;	Crystal structure of the Fv fragment of a monoclonal antibody specific for poly-glutamine
1XXF	;	2.6	;	Crystal Structure of the FXIa Catalytic Domain in Complex with Ecotin Mutant (EcotinP)
1XX9	;	2.2	;	Crystal Structure of the FXIa Catalytic Domain in Complex with EcotinM84R
1XXD	;	2.91	;	Crystal Structure of the FXIa Catalytic Domain in Complex with mutated Ecotin
7A2M	;	1.5	;	Crystal structure of the Fyn SH3 domain A95S-D99T mutant in C21 space group
7A2N	;	1.4	;	Crystal structure of the Fyn SH3 domain A95S-D99T mutant in space group P21
7A2J	;	1.5	;	Crystal structure of the Fyn SH3 domain in space group C21 at pH 7.5
7A2K	;	1.5	;	Crystal structure of the Fyn SH3 domain in space group P1 at pH 7.5
7A2U	;	1.7	;	Crystal structure of the Fyn SH3 domain L112V-S114N-S115T at pH 4.5
7A2Q	;	0.94	;	Crystal structure of the Fyn SH3 domain L112V-S114N-S115T-E121L-R123H mutant at pH 3.0 with PEG
7A2T	;	1.22	;	Crystal structure of the Fyn SH3 domain L112V-S114N-S115T-E121L-R123H mutant at pH 4.0
7A2O	;	0.94	;	Crystal structure of the Fyn SH3 domain L112V-S114N-S115T-E121L-R123H mutant at pH 4.5
7A2S	;	1.02	;	Crystal structure of the Fyn SH3 domain L112V-S114N-S115T-E121L-R123H mutant at pH 5.0
7A2P	;	0.9	;	Crystal structure of the Fyn SH3 domain L112V-S114N-S115T-E121L-R123H mutant at pH 5.0 with PEG
7A2R	;	1.05	;	Crystal structure of the Fyn SH3 domain L112V-S114N-S115T-E121L-R123H mutant at pH 6.0
7A2W	;	0.99	;	Crystal structure of the Fyn SH3 domain L112V-S114N-S115T-E121L-R123H mutant in complex with VSL12 at pH 3.0
7A2Y	;	0.97	;	Crystal structure of the Fyn SH3 domain L112V-S114N-S115T-E121L-R123H mutant in complex with VSL12 at pH 4.0
7A2X	;	0.92	;	Crystal structure of the Fyn SH3 domain L112V-S114N-S115T-E121L-R123H mutant in complex with VSL12 at pH 5.0
7A2Z	;	1.14	;	Crystal structure of the Fyn SH3 domain L112V-S114N-S115T-E121L-R123H mutant in complex with VSL12 at pH 6.0
7A2V	;	1.81	;	Crystal structure of the Fyn SH3 domain L112V-S114N-S115T-E129Q at pH 4.0
7A2L	;	1.9	;	Crystal structure of the Fyn SH3 domain mutant E129Q in space group C21 at pH 4.0
4ZNX	;	2.1	;	Crystal structure of the Fyn-SH3 domain in complex with the high affinity peptide APP12
3T7L	;	1.09	;	Crystal structure of the FYVE domain of endofin (ZFYVE16) at 1.1A resolution
2XTZ	;	2.34	;	Crystal structure of the G alpha protein AtGPA1 from Arabidopsis thaliana
6VKJ	;	2.105	;	Crystal structure of the G domain of human guanylate-binding protein 2 (hGBP2) in complex with GDP
3D7M	;	2.9	;	Crystal Structure of the G Protein Fast-Exchange Double Mutant I56C/Q333C
3SYC	;	3.41	;	Crystal structure of the G protein-gated inward rectifier K+ channel GIRK2 (Kir3.2) D228N mutant
3SYO	;	3.54	;	Crystal structure of the G protein-gated inward rectifier K+ channel GIRK2 (Kir3.2) in complex with sodium
3SYA	;	2.98	;	Crystal structure of the G protein-gated inward rectifier K+ channel GIRK2 (Kir3.2) in complex with sodium and PIP2
4KFM	;	3.45	;	Crystal structure of the G protein-gated inward rectifier K+ channel GIRK2 (Kir3.2) in complex with the beta-gamma G protein subunits
3SYP	;	3.12	;	Crystal structure of the G protein-gated inward rectifier K+ channel GIRK2 (Kir3.2) R201A mutant
3SYQ	;	3.44	;	Crystal structure of the G protein-gated inward rectifier K+ channel GIRK2 (Kir3.2) R201A mutant in complex with PIP2
1QN5	;	1.93	;	Crystal structure of the G(-26) Adenovirus major late promoter TATA box variant bound to wild-type TBP (Arabidopsis thaliana TBP isoform 2). TATA element recognition by the TATA box-binding protein has been conserved throughout evolution.
6PNK	;	2.39	;	Crystal structure of the G-quadruplex formed by (GGGTT)3GGG in complex with N-methylmesoporphryin IX
6P45	;	2.339	;	Crystal structure of the G-quadruplex formed by (TGGGT)4 in complex with N-methylmesoporphryin IX
2VVG	;	1.6	;	Crystal Structure of the G.intestinalis Kinesin 2 GiKIN2a Motor Domain
4F1M	;	2.04	;	Crystal Structure of the G1179S Roco4 Kinase Domain bound to AppCp from D. discoideum.
5F9C	;	2.5	;	Crystal structure of the G121R mutant of human phosphoglucomutase 1
1OBI	;	2.2	;	Crystal structure of the G130A mutant of Malonamidase E2 from Bradyrhizobium japonicum
3WWI	;	2.27	;	Crystal structure of the G136F mutant of the first R-stereoselective -transaminase identified from Arthrobacter sp. KNK168 (FERM-BP-5228)
1Y94	;	2.2	;	Crystal structure of the G16S/N17T/P19A/S20A/N67D Variant Of Bovine seminal Ribonuclease
2APW	;	2.0	;	Crystal Structure of the G17E/A52V/S54N/K66E/E80V/L81S/T87S/G96V variant of the murine T cell receptor V beta 8.2 domain
2APX	;	1.8	;	Crystal Structure of the G17E/A52V/S54N/K66E/Q72H/E80V/L81S/T87S/G96V variant of the murine T cell receptor V beta 8.2 domain
2APV	;	1.9	;	Crystal Structure of the G17E/A52V/S54N/Q72H/E80V/L81S/T87S/G96V variant of the murine T cell receptor V beta 8.2 domain
2APT	;	2.0	;	Crystal Structure of the G17E/S54N/K66E/Q72H/E80V/L81S/T87S/G96V variant of the murine T cell receptor V beta 8.2 domain
3PVE	;	1.4	;	Crystal structure of the G2 domain of Agrin from Mus Musculus
3UMS	;	2.343	;	Crystal structure of the G202A mutant of human G-alpha-i1
3UMR	;	2.04	;	Crystal structure of the G202D mutant of human G-alpha-i1
3MUM	;	2.9	;	Crystal Structure of the G20A mutant c-di-GMP riboswith bound to c-di-GMP
3MUV	;	3.2	;	Crystal Structure of the G20A/C92U mutant c-di-GMP riboswith bound to c-di-AMP
3MUT	;	3.0	;	Crystal Structure of the G20A/C92U mutant c-di-GMP riboswith bound to c-di-GMP
6DMM	;	1.67	;	Crystal structure of the G23A mutant of human alpha defensin HNP4.
2WGY	;	1.5	;	Crystal structure of the G243A mutant of CYP130 from M. tuberculosis
5FS7	;	1.85	;	Crystal structure of the G262S mutant of human apoptosis inducing factor
7DJ1	;	3.528	;	Crystal structure of the G26C mutant of LeuT
7DJ2	;	2.4	;	Crystal structure of the G26C/E290S mutant of LeuT
7DJC	;	2.701	;	Crystal structure of the G26C/Q250A mutant of LeuT
5HSH	;	2.65	;	Crystal structure of the G291R mutant of human phosphoglucomutase 1
2WBN	;	1.9	;	Crystal structure of the g2p (large terminase) nuclease domain from the bacteriophage SPP1
2WC9	;	2.5	;	Crystal structure of the g2p (large terminase) nuclease domain from the bacteriophage SPP1 with bound Mn
5FS8	;	1.4	;	Crystal structure of the G308E mutant of human apoptosis inducing factor
5FS9	;	1.75	;	Crystal structure of the G338E mutant of human apoptosis inducing factor
3G8T	;	3.0	;	Crystal structure of the G33A mutant Bacillus anthracis glmS ribozyme bound to GlcN6P
6EJH	;	1.71	;	Crystal structure of the G343C mutant of Candida albicans Mep2
1M6V	;	2.1	;	Crystal Structure of the G359F (small subunit) Point Mutant of Carbamoyl Phosphate Synthetase
7S77	;	2.8	;	Crystal structure of the G391V variant of human PGM-1
8TH7	;	2.88	;	Crystal Structure of the G3BP1 NTF2-like domain bound to the Caprin1 peptide
7SUO	;	2.35	;	Crystal Structure of the G3BP1 NTF2-like domain bound to the IDR1 of SARS-CoV-2 nucleocapsid protein
8TH1	;	1.8	;	Crystal Structure of the G3BP1 NTF2-like domain bound to the IDR1 of SARS-CoV-2 nucleocapsid protein D3L mutant
8TH5	;	2.62	;	Crystal Structure of the G3BP1 NTF2-like domain bound to the IDR1 of SARS-CoV-2 nucleocapsid protein P13L mutant
8TH6	;	2.34	;	Crystal Structure of the G3BP1 NTF2-like domain bound to USP10 peptide
5DRV	;	2.75	;	Crystal structure of the G3BP2 NTF2-like domain in complex with a peptide
2A7N	;	1.8	;	Crystal Structure of the G81A mutant of the Active Chimera of (S)-Mandelate Dehydrogenase
2A85	;	2.5	;	Crystal Structure of the G81A mutant of the Active Chimera of (S)-Mandelate Dehydrogenase in complex with its substrate 2-hydroxyoctanoate
2A7P	;	2.2	;	Crystal Structure of the G81A mutant of the Active Chimera of (S)-Mandelate Dehydrogenase in complex with its substrate 3-indolelactate
2D03	;	1.97	;	Crystal structure of the G91S mutant of the NNA7 Fab
1TF0	;	2.7	;	Crystal structure of the GA module complexed with human serum albumin
2J5Y	;	1.4	;	Crystal structure of the GA module from F.magna
5AUK	;	1.62	;	Crystal structure of the Ga-substituted Ferredoxin
1KJT	;	2.0	;	Crystal Structure of the GABA(A) Receptor Associated Protein, GABARAP
6HB9	;	1.3	;	Crystal structure of the GABARAP in complex with the UBA5 LIR motif
3CI6	;	1.55	;	Crystal structure of the GAF domain from Acinetobacter phosphoenolpyruvate-protein phosphotransferase
3CIT	;	1.9	;	Crystal structure of the GAF domain of a putative sensor histidine kinase from Pseudomonas syringae pv. tomato
2QYB	;	2.4	;	Crystal structure of the GAF domain region of putative membrane protein from Geobacter sulfurreducens PCA
4DLO	;	2.3	;	Crystal structure of the GAIN and HormR domains of brain angiogenesis inhibitor 3 (BAI3)
4DLQ	;	1.85	;	Crystal structure of the GAIN and HormR domains of CIRL 1/Latrophilin 1 (CL1)
1Z45	;	1.85	;	Crystal structure of the gal10 fusion protein galactose mutarotase/UDP-galactose 4-epimerase from Saccharomyces cerevisiae complexed with NAD, UDP-glucose, and galactose
3FTT	;	1.6	;	Crystal Structure of the galactoside O-acetyltransferase from Staphylococcus aureus
3V4E	;	1.95	;	Crystal Structure of the galactoside O-acetyltransferase in complex with CoA
3AP5	;	1.92	;	Crystal structure of the galectin-8 N-terminal carbohydrate recognition domain
3APB	;	1.95	;	Crystal structure of the galectin-8 N-terminal carbohydrate recognition domain in complex with iodide
3AP9	;	1.33	;	Crystal structure of the galectin-8 N-terminal carbohydrate recognition domain in complex with Lacto-N-fucopentaose III
3AP4	;	2.33	;	Crystal structure of the galectin-8 N-terminal carbohydrate recognition domain in complex with lactose
3AP6	;	1.58	;	Crystal structure of the galectin-8 N-terminal carbohydrate recognition domain in complex with lactose 3'-sulfate
3AP7	;	1.53	;	Crystal structure of the galectin-8 N-terminal carbohydrate recognition domain in complex with lactose sialic acid
1LUR	;	1.85	;	Crystal Structure of the GalM/aldose Epimerase Homologue from C. elegans, Northeast Structural Genomics Target WR66
6EGS	;	2.7	;	Crystal structure of the GalNAc-T2 F104S mutant in complex with UDP-GalNAc
5ZWL	;	1.98	;	Crystal structure of the gamma - epsilon complex of photosynthetic cyanobacterial F1-ATPase
3OUP	;	1.65	;	Crystal structure of the gamma-carbonic anhydrase W19N mutant from Methanosarcina thermophila
2AF7	;	2.81	;	Crystal structure of the gamma-carboxymuconolactone decarboxylase from Methanobacterium thermoautotrophicum. Northeast Structural Genomics Consortium target TT747.
4OTU	;	3.022	;	Crystal structure of the gamma-glutamyltranspeptidase from Bacillus licheniformis in complex with L-Glutamate
4OTT	;	2.98	;	Crystal structure of the gamma-glutamyltranspeptidase from Bacillus licheniformis.
4R12	;	1.95	;	Crystal structure of the gamma-secretase component Nicastrin
3MJ6	;	2.19	;	Crystal structure of the gammadelta T cell costimulatory receptor Junctional Adhesion Molecule-Like Protein, JAML
3W6R	;	1.9	;	Crystal structure of the GAP domain of human MgcRacGAP
3WPQ	;	1.84	;	crystal structure of the GAP domain of MgcRacGAP(S387A)
3WPS	;	2.7	;	crystal structure of the GAP domain of MgcRacGAP(S387D)
2IQJ	;	1.9	;	Crystal structure of the GAP domain of SMAP1L (LOC64744) stromal membrane-associated protein 1-like
1HE9	;	2.4	;	Crystal structure of the GAP domain of the Pseudomonas aeruginosa ExoS toxin
3FAY	;	2.2	;	Crystal structure of the GAP-related domain of IQGAP1
6L5D	;	2.55	;	Crystal structure of the gas vesicle protein GvpF from Anabaena sp. PCC7120
4MCE	;	2.205	;	Crystal structure of the Gas5 GRE Mimic
4MCF	;	1.899	;	Crystal structure of the Gas5 GRE Mimic
6IKN	;	3.0	;	Crystal structure of the GAS7 F-BAR domain
7W48	;	3.5	;	Crystal structure of the gastric proton pump complexed with PF-03716556
5YLV	;	2.79978	;	Crystal structure of the gastric proton pump complexed with SCH28080
7W49	;	3.1	;	Crystal structure of the gastric proton pump complexed with soraprazan
7W47	;	3.0	;	Crystal structure of the gastric proton pump complexed with tegoprazan
5YLU	;	2.79989	;	Crystal structure of the gastric proton pump complexed with vonoprazan
7EFL	;	3.4	;	Crystal structure of the gastric proton pump K791S in (BYK)E2BeF state
7EFM	;	3.2	;	Crystal structure of the gastric proton pump K791S/E820D/Y340N in (BYK)E2BeF state
7EFN	;	3.2	;	Crystal structure of the gastric proton pump K791S/E820D/Y340N/E936V in (BYK)E2BeF state
4WIN	;	2.6	;	Crystal structure of the GATase domain from Plasmodium falciparum GMP synthetase
6GS2	;	2.04	;	Crystal Structure of the GatD/MurT Enzyme Complex from Staphylococcus aureus
6H5E	;	2.139	;	Crystal Structure of the GatD/MurT Enzyme Complex from Staphylococcus aureus with bound AMPPNP
7AS7	;	2.65	;	Crystal structure of the GCD-associated TGFBIp mutant R124H
7A4T	;	2.124	;	Crystal structure of the GCN coiled-coil in complex with nanobody Nb39
2FIW	;	2.35	;	Crystal Structure of the GCN5-Related N-acetyltransferase: Aminotransferase, Class-II from Rhodopseudomonas palustris
3EVS	;	2.1	;	Crystal structure of the GDF-5:BMP receptor IB complex.
5JHW	;	2.35	;	Crystal Structure of the GDF11:Follistatin 288 complex
5C1S	;	3.1	;	Crystal structure of the GDP-bound fast hydrolyzing mutant (V71A/K73Q) of EhRabX3 from Entamoeba histolytica
1XJ0	;	1.7	;	Crystal Structure of the GDP-bound form of the RasG60A mutant
3SFV	;	1.73	;	Crystal structure of the GDP-bound Rab1a S25N mutant in complex with the coiled-coil domain of LidA from Legionella pneumophila
8DB5	;	1.9	;	Crystal structure of the GDP-D-glycero-4-keto-d-lyxo-heptose-3,5-epimerase from Campylobacter jejuni, serotype HS:15
8DCO	;	1.9	;	Crystal structure of the GDP-D-glycero-4-keto-D-lyxo-heptose-3,5-epimerase from Campylobacter jejuni, serotype HS:42
8DCL	;	1.55	;	Crystal structure of the GDP-D-glycero-4-keto-D-lyxo-heptose-3-epimerase from campylobacter jejuni, serotype HS:23/36
8DAK	;	1.5	;	Crystal structure of the GDP-D-glycero-4-keto-d-lyxo-heptose-3-epimerase from Campylobacter jejuni, serotype HS:3
1N7G	;	2.2	;	Crystal Structure of the GDP-mannose 4,6-dehydratase ternary complex with NADPH and GDP-rhamnose.
8GR2	;	1.65	;	Crystal structure of the GDSL-family esterase CJ0610C from Campylobacter jejuni
3N6O	;	2.5	;	Crystal structure of the GEF and P4M domain of DrrA/SidM from Legionella pneumophila
3JZ9	;	1.8	;	Crystal structure of the GEF domain of DrrA/SidM from Legionella pneumophila
6KO9	;	2.2	;	Crystal structure of the Gefitinib Intermediate 1 bound RamR determined with XtaLAB Synergy
5XJT	;	2.92	;	Crystal Structure of the Gemin2-binding domain of SMN, Gemin2 in Complex with SmD1(1-82)/D2.R61A/F/E/G from Human
5XJQ	;	3.28	;	Crystal Structure of the Gemin2-binding domain of SMN, Gemin2 in Complex with SmD1(1-82)/D2/F/E/G from Human
5XJL	;	2.5	;	Crystal Structure of the Gemin2-binding domain of SMN, Gemin2 in Complex with SmD1/D2/F/E/G from Human
5XJU	;	2.58	;	Crystal Structure of the Gemin2-binding domain of SMN, Gemin2dN39 in Complex with SmD1(1-82)/D2.R61A/F/E/G from Human
5XJS	;	3.38	;	Crystal Structure of the Gemin2-binding domain of SMN, Gemin2dN39 in Complex with SmD1(1-82)/D2/F/E from Human
5XJR	;	3.12	;	Crystal Structure of the Gemin2-binding domain of SMN, Gemin2dN39 in Complex with SmD1(1-82)/D2/F/E/G from Human
1Y96	;	2.002	;	crystal structure of the Gemin6/Gemin7 heterodimer from the human SMN complex
2XC8	;	2.35	;	Crystal structure of the gene 22 product of the Bacillus subtilis SPP1 phage
3U34	;	2.8	;	Crystal structure of the general stress FMN/FAD binding protein from the phytopathogen Xanthomonas citri
3U35	;	2.5	;	Crystal structure of the general stress FMN/FAD binding protein from the phytopathogen Xanthomonas citri
3F2V	;	2.0	;	Crystal structure of the general stress protein 14 (TDE0354) in complex with FMN from Treponema denticola, Northeast Structural Genomics Consortium Target TdR58.
3EC6	;	1.6	;	Crystal structure of the General Stress Protein 26 from Bacillus anthracis str. Sterne
2AFS	;	2.22	;	Crystal structure of the genetic mutant R54W of human glutaminyl cyclase
5UKG	;	2.36	;	Crystal Structure of the genetically encoded calcium indicator K-GECO
3U0K	;	2.1	;	Crystal Structure of the genetically encoded calcium indicator RCaMP
4I2Y	;	2.2	;	Crystal Structure of the genetically encoded calcium indicator RGECO1
6XU4	;	3.18	;	Crystal structure of the genetically-encoded FGCaMP calcium indicator in its calcium-bound state
5MWC	;	2.45	;	Crystal structure of the genetically-encoded green calcium indicator NTnC in its calcium bound state
2OGS	;	2.02	;	Crystal Structure of the GEOBACILLUS STEAROTHERMOPHILUS Carboxylesterase EST55 at pH 6.2
2OGT	;	1.58	;	Crystal Structure of the Geobacillus Stearothermophilus Carboxylesterase EST55 at pH 6.8
7WWH	;	1.92	;	Crystal structure of the Geobacillus thermoglucosidasius feruloyl esterase GthFAE
3N54	;	2.3	;	Crystal Structure of the GerBC protein
4O8W	;	2.293	;	Crystal Structure of the GerD spore germination protein
6O42	;	2.6	;	Crystal structure of the germline PGZL1 (PGZL1_gVmDmJ) Fab in complex with MPER peptide epitope.
6ZMU	;	1.95	;	Crystal structure of the germline-specific thioredoxin protein Deadhead (Thioredoxin-1) from Drospohila melanogaster, P43212
4JPK	;	2.4	;	Crystal structure of the germline-targeting HIV-1 gp120 engineered outer domain eOD-GT6 in complex with a putative VRC01 germline precursor Fab
4JPJ	;	2.5	;	Crystal structure of the germline-targeting HIV-1 gp120 engineered outer domain, eOD-GT6
5IDL	;	2.9	;	Crystal structure of the germline-targeting HIV-1 gp120 engineered outer domain, eOD-GT8
4GOG	;	1.1	;	Crystal structure of the GES-1 imipenem acyl-enzyme complex
3VEJ	;	1.23	;	Crystal structure of the Get5 carboxyl domain from S. cerevisiae
4GOC	;	2.4	;	Crystal structure of the Get5 ubiquitin-like domain
6TCE	;	2.92	;	Crystal structure of the GGCT site-bound MH1 domain of Smad5 containing a GGGS insertion in the Loop1
3IGN	;	1.83	;	Crystal Structure of the GGDEF domain from Marinobacter aquaeolei diguanylate cyclase complexed with c-di-GMP - Northeast Structural Genomics Consortium Target MqR89a
6TTS	;	2.5	;	Crystal structure of the GGDEF domain of DgcB from Caulobacter crescentus in complex with c-di-GMP
4IOB	;	2.78	;	Crystal structure of the GGDEF domain of PA1120 (YfiN or TpbB) from Pseudomonas aeruginosa at 2.7 Ang.
3HVW	;	1.7	;	Crystal Structure of the GGDEF domain of the PA2567 protein from Pseudomonas aeruginosa, Northeast Structural Genomics Consortium Target PaR365C
5DT7	;	2.15	;	Crystal structure of the GH1 beta-glucosidase from Exiguobacterium antarcticum B7 in space group C2221
5DT5	;	2.24	;	Crystal structure of the GH1 beta-glucosidase from Exiguobacterium antarcticum B7 in space group P21
7ZSZ	;	1.5	;	Crystal structure of the GH11 domain of a multidomain xylanase from the hindgut metagenome of Trinervitermes trinervoides
7MKR	;	1.5	;	Crystal structure of the GH12 domain from Acidothermus cellulolyticus GuxA
7MKS	;	1.85	;	Crystal structure of the GH12 domain from Acidothermus cellulolyticus GuxA bound to cellobiose
6XYZ	;	1.63	;	Crystal structure of the GH18 chitinase ChiB from the chitin utilization locus of Flavobacterium johnsoniae
6BYC	;	1.897	;	Crystal structure of the GH2 exo-beta-mannanase from Xanthomonas axonopodis pv. citri
6BYE	;	2.126	;	Crystal structure of the GH2 exo-beta-mannanase from Xanthomonas axonopodis pv. citri in complex with mannose
6D2X	;	1.72	;	Crystal structure of the GH26 domain from PbGH26-GH5A endo-beta-mannanase/endo-beta-glucanase from Prevotella bryantii
7KMP	;	1.556	;	Crystal structure of the GH31 alpha-xylosidase (Xac1773) from Xanthomonas citri
7KNC	;	1.873	;	Crystal structure of the GH31 alpha-xylosidase (Xac1773) from Xanthomonas citri
7KMO	;	1.753	;	Crystal structure of the GH35 beta-galactosidase (Xac1772) from Xanthomonas citri in complex with galactose
6UQJ	;	1.707	;	Crystal structure of the GH39 enzyme from Xanthomonas axonopodis pv. citri
6MS2	;	2.494	;	Crystal structure of the GH43 BlXynB protein from Bacillus licheniformis
6MS3	;	1.95	;	Crystal structure of the GH43 protein BlXynB mutant (K247S) from Bacillus licheniformis
6XN1	;	1.8	;	Crystal structure of the GH43_1 enzyme from Xanthomonas citri complexed with xylose
6XN2	;	1.652	;	Crystal structure of the GH43_1 enzyme from Xanthomonas citri complexed with xylotriose
4NF7	;	2.111	;	Crystal structure of the GH5 family catalytic domain of Endo-1,4-beta-glucanase Cel5C from Butyrivibrio proteoclasticus.
6D25	;	1.91	;	Crystal structure of the GH51 arabinofuranosidase from Xanthomonas axonopodis pv. citri
7KN8	;	1.95	;	Crystal structure of the GH74 xyloglucanase from Xanthomonas campestris (Xcc1752)
7KMQ	;	2.045	;	Crystal structure of the GH95 alpha-L-1,2-fucosidase (Xac1774) from Xanthomonas citri
4UFC	;	2.81	;	Crystal structure of the GH95 enzyme BACOVA_03438
2CUL	;	1.65	;	Crystal structure of the GidA-related protein from Thermus thermophilus HB8
1YD6	;	2.0	;	Crystal structure of the GIY-YIG N-terminal endonuclease domain of UvrC from Bacillus caldotenax
1YCZ	;	1.8	;	Crystal structure of the GIY-YIG N-terminal endonuclease domain of UvrC from Thermotoga maritima
1YD1	;	1.8	;	Crystal structure of the GIY-YIG N-terminal endonuclease domain of UvrC from Thermotoga maritima bound to its catalytic divalent cation: magnesium
1YD0	;	1.5	;	Crystal structure of the GIY-YIG N-terminal endonuclease domain of UvrC from Thermotoga maritima bound to its catalytic divalent cation: manganese
1YD5	;	1.8	;	Crystal structure of the GIY-YIG N-terminal endonuclease domain of UvrC from Thermotoga maritima: Point mutant N88A bound to its catalytic divalent cation
1YD2	;	1.6	;	Crystal structure of the GIY-YIG N-terminal endonuclease domain of UvrC from Thermotoga maritima: Point mutant Y19F bound to the catalytic divalent cation
1YD4	;	1.9	;	Crystal structure of the GIY-YIG N-terminal endonuclease domain of UvrC from Thermotoga maritima: Point mutant Y29F bound to its catalytic divalent cation
1YD3	;	1.6	;	Crystal structure of the GIY-YIG N-terminal endonuclease domain of UvrC from Thermotoga maritima: Point mutant Y43F bound to its catalytic divalent cation
3K6T	;	2.04	;	Crystal structure of the GLD-1 homodimerization domain from Caenorhabditis elegans at 2.04 A resolution
3KBL	;	2.28	;	Crystal structure of the GLD-1 homodimerization domain from Caenorhabditis elegans N169A mutant at 2.28 A resolution
8H17	;	2.15	;	Crystal structure of the Globin domain of Thermosynechococcus elongatus BP-1
3POS	;	1.65	;	Crystal structure of the globular domain of human calreticulin
3POW	;	1.55	;	Crystal structure of the globular domain of human calreticulin
5LK5	;	2.3	;	Crystal structure of the globular domain of human calreticulin mutant D71K
1G6W	;	2.5	;	CRYSTAL STRUCTURE OF THE GLOBULAR REGION OF THE PRION PROTEIN URE2 FROM THE YEAST SACCAROMYCES CEREVISIAE
1G6Y	;	2.8	;	CRYSTAL STRUCTURE OF THE GLOBULAR REGION OF THE PRION PROTEIN URE2 FROM YEAST SACCHAROMYCES CEREVISIAE
3MMI	;	2.3	;	Crystal structure of the globular tail of Myo4p
6GB1	;	2.73	;	Crystal structure of the GLP1 receptor ECD with Peptide 11
6X01	;	3.65	;	Crystal structure of the GltPh V216C-A391C mutant cross-linked in outward-facing state
6WZB	;	3.45	;	Crystal structure of the GltPh V216C-G388C mutant cross-linked with divalent mercury
5FTI	;	1.35	;	Crystal structure of the GluA2 K738M-T744K LBD in complex with glutamate (lithium form)
5FTH	;	2.9	;	Crystal structure of the GluA2 K738M-T744K LBD in complex with glutamate (zinc form)
5NS9	;	1.44	;	Crystal structure of the GluA2 LBD (L483Y-N754S-L758V) in complex with glutamate
5JEI	;	1.229	;	Crystal structure of the GluA2 LBD in complex with FW
5BUU	;	2.07	;	Crystal structure of the GluA2 ligand-binding domain (L483Y-N754S) in complex with glutamate and BPAM-321 at 2.07 A resolution
5FHM	;	1.55	;	Crystal structure of the GluA2 ligand-binding domain (S1S2J) in complex with (S)-2-Amino-3-(5-(2-(3-(aminomethyl)benzyl)-2H-tetrazol-5-yl)-3-hydroxyisoxazol-4-yl)propanoic acid at resolution 1.55 A resolution
5FHO	;	2.3	;	Crystal structure of the GluA2 ligand-binding domain (S1S2J) in complex with (S)-2-Amino-3-(5-(2-(3-chlorobenzyl)-2H-tetrazol-5-yl)-3-hydroxyisoxazol-4-yl)propanoic acid at 2.3 A resolution
5FHN	;	1.6	;	Crystal structure of the GluA2 ligand-binding domain (S1S2J) in complex with (S)-2-Amino-3-(5-(2-(3-methylbenzyl)-2H-tetrazol-5-yl)-3-hydroxyisoxazol-4-yl)propanoic acid at 1.6 A resolution
5NG9	;	1.15	;	Crystal structure of the GluA2 ligand-binding domain (S1S2J) in complex with agonist CIP-AS at 1.15 A resolution.
5NIH	;	1.3	;	Crystal structure of the GluA2 ligand-binding domain (S1S2J) in complex with agonist LM-12b at 1.3 A resolution.
5OEW	;	2.0	;	Crystal structure of the GluA2 ligand-binding domain (S1S2J) in complex with glutamate and positive allosteric modulator BPAM538
4G8M	;	2.05	;	Crystal structure of the GluA2 ligand-binding domain (S1S2J) in complex with the agonist CBG-IV at 2.05A resolution
4IGT	;	1.24	;	Crystal structure of the GluA2 ligand-binding domain (S1S2J) in complex with the agonist ZA302 at 1.24A resolution
4ISU	;	2.3	;	Crystal structure of the GluA2 ligand-binding domain (S1S2J) in complex with the antagonist (2R)-IKM-159 at 2.3A resolution.
5CBS	;	1.801	;	Crystal structure of the GluA2 ligand-binding domain (S1S2J) in complex with the antagonist (R)-2-amino-3-(3'-hydroxybiphenyl-3-yl)propanoic acid at 1.8A resolution
3TZA	;	1.9	;	Crystal structure of the GluA2 ligand-binding domain (S1S2J) in complex with the antagonist (S)-2-amino-3-(2-(2-carboxyethyl)-5-chloro-4-nitrophenyl)propionic acid at 1.9A resolution
5CBR	;	1.996	;	Crystal structure of the GluA2 ligand-binding domain (S1S2J) in complex with the antagonist (S)-2-amino-3-(3,4-dichloro-5-(5-hydroxypyridin-3-yl)phenyl)propanoic acid at 2.0A resolution
6FAZ	;	1.4	;	Crystal structure of the GluA2 ligand-binding domain (S1S2J) in complex with the positive allosteric modulator TDPAM01 at 1.4 A resolution.
4N07	;	1.87	;	Crystal structure of the GluA2 ligand-binding domain (S1S2J-L483Y-N754S) in complex with glutamate and BPAM-344 at 1.87 A resolution
3TDJ	;	1.95	;	Crystal structure of the GluA2 ligand-binding domain (S1S2J-L483Y-N754S) in complex with glutamate and BPAM-97 at 1.95 A resolution
4U4S	;	1.9	;	Crystal structure of the GluA2 ligand-binding domain (S1S2J-L483Y-N754S) in complex with glutamate and BPAM25 at 1.90 A resolution.
4U4X	;	1.56	;	Crystal structure of the GluA2 ligand-binding domain (S1S2J-L483Y-N754S) in complex with glutamate and BPAM37 at 1.56 A resolution.
4IY5	;	2.0	;	Crystal structure of the glua2 ligand-binding domain (S1S2J-L483Y-N754S) in complex with glutamate and CX516 at 2.0 A resolution
3TKD	;	1.45	;	Crystal structure of the GluA2 ligand-binding domain (S1S2J-L483Y-N754S) in complex with glutamate and cyclothiazide at 1.45 A resolution
4IY6	;	1.72	;	Crystal structure of the GLUA2 ligand-binding domain (S1S2J-L483Y-N754S) in complex with glutamate and ME-CX516 at 1.72 A resolution
5ELV	;	1.92	;	Crystal structure of the GluA2 ligand-binding domain (S1S2J-L504-N775) in complex with glutamate and BPAM-521 at 1.92 A resolution
5O9A	;	1.78	;	Crystal structure of the GluA2 ligand-binding domain (S1S2J-L504Y-N775S) in complex with glutamate and BPAM121 at 1.78 A resolution
4O3C	;	1.5	;	Crystal structure of the GLUA2 ligand-binding domain in complex with L-aspartate at 1.50 A resolution
4O3A	;	1.8	;	Crystal structure of the glua2 ligand-binding domain in complex with L-aspartate at 1.80 a resolution
5ZG0	;	1.58	;	Crystal structure of the GluA2o LBD in complex with glutamate and Compound-1
5ZG1	;	1.32	;	Crystal structure of the GluA2o LBD in complex with glutamate and Compound-2
5YBF	;	1.5	;	Crystal structure of the GluA2o LBD in complex with glutamate and HBT1
5YBG	;	1.52	;	Crystal structure of the GluA2o LBD in complex with glutamate and LY451395
5ZG3	;	1.65	;	Crystal structure of the GluA2o LBD in complex with glutamate and TAK-137
7F3O	;	1.44	;	Crystal structure of the GluA2o LBD in complex with glutamate and TAK-653
5ZG2	;	1.25	;	Crystal structure of the GluA2o LBD in complex with ZK200775 and Compound-2
3KEI	;	1.9	;	Crystal Structure of the GluA4 Ligand-Binding domain L651V mutant in complex with glutamate
3KFM	;	2.2	;	Crystal Structure of the GluA4 Ligand-Binding domain L651V mutant in complex with kainate
4MDD	;	2.4	;	Crystal Structure of the Glucocorticoid Receptor Bound to a Non-steroidal Antagonist Reveals Repositioning and Partial Disordering of Activation Function Helix 12
4LSJ	;	2.35	;	Crystal Structure of the Glucocorticoid Receptor Ligand Binding Domain Bound to a Dibenzoxapine Sulfonamide
8HQQ	;	1.86	;	Crystal structure of the glucose-binding protein SAR11_0769 from ""Candidatus Pelagibacter ubique"" HTCC1062 bound to glucose
3KL0	;	1.64	;	Crystal structure of the glucuronoxylan xylanohydrolase XynC from Bacillus subtilis
4DLD	;	2.0	;	Crystal structure of the GluK1 ligand-binding domain (S1S2) in complex with the antagonist (S)-2-amino-3-(2-(2-carboxyethyl)-5-chloro-4-nitrophenyl)propionic acid at 2.0 A resolution
5MFW	;	2.1	;	Crystal structure of the GluK1 ligand-binding domain in complex with kainate and BPAM-121 at 2.10 A resolution
5MFQ	;	1.9	;	Crystal structure of the GluK1 ligand-binding domain in complex with kainate and BPAM-344 at 1.90 A resolution
5MFV	;	2.181	;	Crystal structure of the GluK1 ligand-binding domain in complex with kainate and BPAM-521 at 2.18 A resolution
2XXW	;	2.3	;	Crystal structure of the GluK2 (GluR6) D776K LBD dimer in complex with glutamate
2XXX	;	2.098	;	Crystal structure of the GluK2 (GluR6) D776K LBD dimer in complex with glutamate (P21 21 21)
2XXY	;	3.0	;	Crystal structure of the GluK2 (GluR6) D776K LBD dimer in complex with kainate
2XXU	;	1.5	;	Crystal structure of the GluK2 (GluR6) M770K LBD dimer in complex with glutamate
2XXV	;	1.7	;	Crystal structure of the GluK2 (GluR6) M770K LBD dimer in complex with kainate
2XXR	;	1.6	;	Crystal structure of the GluK2 (GluR6) wild-type LBD dimer in complex with glutamate
2XXT	;	1.9	;	Crystal structure of the GluK2 (GluR6) wild-type LBD dimer in complex with kainate
4BDL	;	1.75	;	Crystal structure of the GluK2 K531A LBD dimer in complex with glutamate
4BDM	;	3.4	;	Crystal structure of the GluK2 K531A LBD dimer in complex with kainate
4BDN	;	2.5	;	Crystal structure of the GluK2 K531A-T779G LBD dimer in complex with glutamate
4BDO	;	2.55	;	Crystal structure of the GluK2 K531A-T779G LBD dimer in complex with kainate
4BDQ	;	1.9	;	Crystal structure of the GluK2 R775A LBD dimer in complex with glutamate
4BDR	;	1.65	;	Crystal structure of the GluK2 R775A LBD dimer in complex with kainate
3QLU	;	2.906	;	Crystal structure of the GluK2/GluK5 (GluR6/KA2) ATD dimer assembly
3QLV	;	3.94	;	Crystal structure of the GluK2/GluK5 (GluR6/KA2) ATD tetramer assembly
5CMM	;	1.271	;	Crystal structure of the GluK2EM LBD dimer assembly complex with 2S,4R-4-methylglutamate
5CMK	;	1.801	;	Crystal structure of the GluK2EM LBD dimer assembly complex with glutamate and LY466195
3OLZ	;	2.75	;	Crystal structure of the GluK3 (GluR7) ATD dimer at 2.75 Angstrom resolution
3U94	;	1.962	;	Crystal structure of the GluK3 ligand binding domain complex with glutamate and zinc: P21212 form
3U93	;	1.881	;	Crystal structure of the GluK3 ligand binding domain complex with glutamate and zinc: P2221 form
3U92	;	1.9	;	Crystal structure of the GluK3 ligand binding domain complex with kainate and zinc: P2221 form
6JMV	;	1.832	;	Crystal structure of the GluK3 ligand binding domain complex with SYM and zinc
4NWC	;	2.012	;	Crystal structure of the GluK3 ligand-binding domain (S1S2) in complex with the agonist (2S,4R)-4-(3-Methoxy-3-oxopropyl)glutamic acid at 2.01 A resolution.
3OM0	;	1.401	;	Crystal structure of the GluK5 (KA2) ATD crystallographic dimer at 1.4 Angstrom resolution
3OM1	;	1.677	;	Crystal structure of the GluK5 (KA2) ATD dimer at 1.7 Angstrom Resolution
3Q41	;	3.4	;	Crystal structure of the GluN1 N-terminal domain (NTD)
1II5	;	1.6	;	CRYSTAL STRUCTURE OF THE GLUR0 LIGAND BINDING CORE COMPLEX WITH L-GLUTAMATE
2PYY	;	2.1	;	Crystal Structure of the GluR0 ligand-binding core from Nostoc punctiforme in complex with (L)-glutamate
2GFE	;	1.54	;	Crystal structure of the GluR2 A476E S673D Ligand Binding Core Mutant at 1.54 Angstroms Resolution
3B7D	;	2.5	;	Crystal structure of the GLUR2 ligand binding core (HS1S2J) in complex with CNQX at 2.5 A resolution
1FTK	;	1.6	;	CRYSTAL STRUCTURE OF THE GLUR2 LIGAND BINDING CORE (S1S2I) IN COMPLEX WITH KAINATE AT 1.6 A RESOLUTION
1FTM	;	1.7	;	CRYSTAL STRUCTURE OF THE GLUR2 LIGAND BINDING CORE (S1S2J) IN COMPLEX WITH AMPA AT 1.7 RESOLUTION
1MXU	;	1.8	;	CRYSTAL STRUCTURE OF THE GLUR2 LIGAND BINDING CORE (S1S2J) in complex with bromo-willardiine (Control for the crystal titration experiments)
1MQH	;	1.8	;	Crystal Structure of the GluR2 Ligand Binding Core (S1S2J) in Complex with Bromo-Willardiine at 1.8 Angstroms Resolution
2AL5	;	1.65	;	Crystal structure of the GluR2 ligand binding core (S1S2J) in complex with fluoro-willardiine and aniracetam
1MQI	;	1.35	;	Crystal Structure of the GluR2 Ligand Binding Core (S1S2J) in Complex with Fluoro-Willardiine at 1.35 Angstroms Resolution
3BKI	;	1.87	;	Crystal Structure of the GluR2 ligand binding core (S1S2J) in complex with FQX at 1.87 Angstroms
1FTJ	;	1.9	;	CRYSTAL STRUCTURE OF THE GLUR2 LIGAND BINDING CORE (S1S2J) IN COMPLEX WITH GLUTAMATE AT 1.9 RESOLUTION
1MQG	;	2.15	;	Crystal Structure of the GluR2 Ligand Binding Core (S1S2J) in Complex with Iodo-Willardiine at 2.15 Angstroms Resolution
1FW0	;	1.9	;	CRYSTAL STRUCTURE OF THE GLUR2 LIGAND BINDING CORE (S1S2J) IN COMPLEX WITH KAINATE AT 2.0 A RESOLUTION
2AL4	;	1.7	;	CRYSTAL STRUCTURE OF THE GLUR2 LIGAND BINDING CORE (S1S2J) IN COMPLEX WITH quisqualate and CX614.
1MM6	;	2.15	;	crystal structure of the GluR2 ligand binding core (S1S2J) in complex with quisqualate in a non zinc crystal form at 2.15 angstroms resolution
1MM7	;	1.65	;	Crystal Structure of the GluR2 Ligand Binding Core (S1S2J) in Complex with Quisqualate in a Zinc Crystal Form at 1.65 Angstroms Resolution
1FTL	;	1.8	;	CRYSTAL STRUCTURE OF THE GLUR2 LIGAND BINDING CORE (S1S2J) IN COMPLEX WITH THE ANTAGONIST DNQX AT 1.8 A RESOLUTION
1MQJ	;	1.65	;	Crystal structure of the GluR2 ligand binding core (S1S2J) in complex with willardiine at 1.65 angstroms resolution
1FTO	;	2.0	;	CRYSTAL STRUCTURE OF THE GLUR2 LIGAND BINDING CORE (S1S2J) IN THE APO STATE AT 2.0 A RESOLUTION
1P1Q	;	2.0	;	Crystal structure of the GluR2 ligand binding core (S1S2J) L650T mutant in complex with AMPA
3B6Q	;	2.0	;	Crystal Structure of the GLUR2 Ligand Binding Core (S1S2J) Mutant T686A in Complex with Glutamate at 2.0 Resolution
3B6T	;	2.1	;	Crystal Structure of the GLUR2 Ligand Binding Core (S1S2J) T686A Mutant in Complex with Quisqualate at 2.1 Resolution
3B6W	;	1.7	;	Crystal Structure of the GLUR2 Ligand Binding Core (S1S2J) T686S Mutant in Complex with Glutamate at 1.7 Resolution
4U2R	;	1.4114	;	Crystal structure of the GLUR2 ligand binding core (S1S2J, flip variant) in the apo state
2ANJ	;	2.1	;	Crystal Structure of the Glur2 Ligand Binding Core (S1S2J-Y450W) Mutant in Complex With the Partial Agonist Kainic Acid at 2.1 A Resolution
1LBB	;	2.1	;	Crystal structure of the GluR2 ligand binding domain mutant (S1S2J-N754D) in complex with kainate at 2.1 A resolution
1P1U	;	2.0	;	Crystal structure of the GluR2 ligand-binding core (S1S2J) L650T mutant in complex with AMPA (ammonium sulfate crystal form)
1P1O	;	1.6	;	Crystal structure of the GluR2 ligand-binding core (S1S2J) mutant L650T in complex with quisqualate
1P1W	;	1.8	;	Crystal structure of the GluR2 ligand-binding core (S1S2J) with the L483Y and L650T mutations and in complex with AMPA
3H5V	;	2.33	;	Crystal structure of the GluR2-ATD
3H5W	;	2.686	;	Crystal structure of the GluR2-ATD in space group P212121 without solvent
2UXA	;	2.38	;	Crystal structure of the GluR2-flip ligand binding domain, r/g unedited.
3EPE	;	1.85	;	Crystal Structure of the GluR4 Ligand-Binding domain in complex with glutamate
3EN3	;	2.43	;	Crystal Structure of the GluR4 Ligand-Binding domain in complex with kainate
2QS4	;	1.58	;	Crystal structure of the GluR5 ligand binding core dimer in complex with LY466195 at 1.58 Angstroms resolution
2QS1	;	1.8	;	Crystal structure of the GluR5 ligand binding core dimer in complex with UBP315 at 1.80 Angstroms resolution
2QS3	;	1.76	;	Crystal structure of the GluR5 ligand binding core dimer in complex with UBP316 at 1.76 Angstroms resolution
2QS2	;	1.8	;	Crystal structure of the GluR5 ligand binding core dimer in complex with UBP318 at 1.80 Angstroms resolution
2F36	;	2.11	;	Crystal Structure of the GluR5 Ligand Binding Core Dimer with Glutamate At 2.1 Angstroms Resolution
2F34	;	1.74	;	Crystal Structure of the GluR5 Ligand Binding Core Dimer with UBP310 At 1.74 Angstroms Resolution
1TXF	;	2.1	;	CRYSTAL STRUCTURE OF THE GLUR5 LIGAND BINDING CORE IN COMPLEX WITH GLUTAMATE AT 2.1 ANGSTROM RESOLUTION
2F35	;	1.87	;	Crystal Structure of the GluR5 Ligand Binding Core with UBP302 At 1.87 Angstroms Resolution
3H6G	;	2.697	;	Crystal structure of the GluR6 amino terminal domain dimer assembly
3H6H	;	2.901	;	Crystal structure of the GluR6 amino terminal domain dimer assembly MPD form
2I0C	;	2.25	;	Crystal structure of the GluR6 ligand binding core dimer crosslinked by disulfide bonds between Y490C and L752C at 2.25 Angstroms Resolution
2I0B	;	1.96	;	Crystal structure of the GluR6 ligand binding core ELKQ mutant dimer at 1.96 Angstroms Resolution
1SD3	;	1.8	;	Crystal structure of the GLUR6 ligand binding core in complex with 2S,4R-4-methylglutamate at 1.8 Angstrom resolution
1S7Y	;	1.75	;	Crystal structure of the GluR6 ligand binding core in complex with glutamate at 1.75 A resolution orthorhombic form
1TT1	;	1.93	;	CRYSTAL STRUCTURE OF THE GLUR6 LIGAND BINDING CORE IN COMPLEX WITH KAINATE 1.93 A RESOLUTION
1S9T	;	1.8	;	Crystal structure of the GLUR6 ligand binding core in complex with quisqualate at 1.8A resolution
3G3I	;	1.371	;	Crystal structure of the GluR6 ligand binding domain dimer I442H K494E I749L Q753K mutant with glutamate and NaCl at 1.37 Angstrom resolution
3G3K	;	1.24	;	Crystal structure of the GluR6 ligand binding domain dimer I442H K494E K665R I749L Q753K E757Q mutant with glutamate and NaCl at 1.24 Angstrom resolution
3G3J	;	1.321	;	Crystal structure of the GluR6 ligand binding domain dimer I442H K494E K665R I749L Q753K mutant with glutamate and NaCl at 1.32 Angstrom resolution
3G3H	;	1.5	;	Crystal structure of the GluR6 ligand binding domain dimer K665R I749L Q753K mutant with glutamate and NaCl at 1.5 Angstrom resolution
3G3G	;	1.303	;	Crystal structure of the GluR6 ligand binding domain dimer K665R mutant with glutamate and NaCl at 1.3 Angstrom resolution
3G3F	;	1.377	;	Crystal structure of the GluR6 ligand binding domain dimer with glutamate and NaCl at 1.38 Angstrom resolution
2GZM	;	1.99	;	Crystal Structure of the Glutamate Racemase from Bacillus anthracis
6R7R	;	2.8	;	Crystal structure of the glutamate transporter homologue GltTk in complex with D-aspartate
3FKY	;	2.95	;	Crystal structure of the glutamine synthetase Gln1deltaN18 from the yeast Saccharomyces cerevisiae
3AL0	;	3.368	;	Crystal structure of the glutamine transamidosome from Thermotoga maritima in the glutamylation state.
3MBR	;	1.44	;	Crystal Structure of the Glutaminyl Cyclase from Xanthomonas campestris
2HZ7	;	2.3	;	Crystal structure of the Glutaminyl-tRNA synthetase from Deinococcus radiodurans
4A91	;	1.75	;	Crystal structure of the glutamyl-queuosine tRNAAsp synthetase from E. coli complexed with L-glutamate
7TBS	;	1.96	;	Crystal Structure of the Glutaredoxin 2 from Francisella tularensis
1T1V	;	1.6	;	Crystal Structure of the Glutaredoxin-like Protein SH3BGRL3 at 1.6 A resolution
7PWE	;	2.077	;	Crystal structure of the glutaredoxin/ferredoxin disulfide reductase fusion protein from Desulfotalea psychrophila Lsv54
1GHD	;	2.4	;	Crystal structure of the glutaryl-7-aminocephalosporanic acid acylase by mad phasing
4Q5Q	;	1.931	;	Crystal Structure of the Glutathione S-transferase Der p 8
4Q5F	;	2.448	;	Crystal Structure of the Glutathione S-transferase from Ascaris lumbricoides
6J3F	;	2.5	;	Crystal structure of the glutathione S-transferase, CsGST63524, of Ceriporiopsis subvermispora in complex with glutathione
6J3H	;	2.19	;	Crystal structure of the glutathione S-transferase, CsGST83044, of Ceriporiopsis subvermispora in complex with glutathione
4F03	;	1.8	;	Crystal structure of the glutathione transferase GTE1 from Phanerochaete chrysosporium
4G19	;	2.0	;	Crystal structure of the glutathione transferase GTE1 from Phanerochaete chrysosporium in complex with glutathione
3CSI	;	1.9	;	Crystal Structure of the Glutathione Transferase Pi allelic variant*C, I104V/A113V, in complex with the Chlorambucil-Glutathione Conjugate
3DD3	;	2.25	;	Crystal Structure of the Glutathione Transferase Pi enzyme in complex with the bifunctional inhibitor, Etharapta
3DGQ	;	1.6	;	Crystal structure of the glutathione transferase PI enzyme in complex with the bifunctional inhibitor, etharapta
1ZGN	;	2.1	;	Crystal Structure of the Glutathione Transferase Pi in Complex with Dinitrosyl-diglutathionyl Iron Complex
4F0B	;	1.45	;	Crystal structure of the glutathione transferase URE2P1 from Phanerochaete chrysosporium.
4F0C	;	1.901	;	Crystal structure of the glutathione transferase URE2P5 from Phanerochaete chrysosporium
4ZBD	;	1.12	;	Crystal structure of the glutathione transferase URE2P6 from Phanerochaete chrysosporium in complex with glutathione reduced by X-ray irradiation at 100K
4ZB8	;	2.0	;	Crystal structure of the glutathione transferase URE2P6 from Phanerochaete chrysosporium in complex with oxidized glutathione.
4ZBB	;	1.8	;	Crystal structure of the glutathione transferase URE2P8 from Phanerochaete chrysosporium complexed with glutathionyl-S-dinitrobenzene.
4ZBA	;	1.501	;	Crystal structure of the glutathione transferase URE2P8 from Phanerochaete chrysosporium with oxidized glutathione.
4ZB9	;	2.403	;	Crystal structure of the glutathione transferase URE2P8 from Phanerochaete chrysosporium, with one glutathione disulfide bound per dimer.
1X6M	;	2.35	;	Crystal structure of the glutathione-dependent formaldehyde-activating enzyme (Gfa)
3PPU	;	2.3	;	Crystal structure of the glutathione-S-transferase Xi from Phanerochaete chrysosporium
4Q5N	;	2.55	;	Crystal structure of the gluthatione S-transferase Blo t 8
3IXL	;	1.45	;	Crystal structure of the Gly74Cys-Cys188Ser mutant of arylmalonate decarboxylase in the liganded form
2DPN	;	2.8	;	Crystal Structure of the glycerol kinase from Thermus thermophilus HB8
1PW4	;	3.3	;	Crystal Structure of the Glycerol-3-Phosphate Transporter from E.Coli
2QO6	;	1.9	;	Crystal structure of the glycine 55 arginine mutant of zebrafish liver bile acid-binding protein complexed with cholic acid
2FTS	;	2.41	;	Crystal structure of the glycine receptor-gephyrin complex
3OWI	;	2.845	;	Crystal structure of the glycine riboswitch bound to glycine
3OWW	;	2.802	;	Crystal structure of the glycine riboswitch bound to glycine
2F3S	;	1.96	;	Crystal Structure of the glycogen phosphorylase B / ethyl-N-(beta-D-glucopyranosyl)oxamate complex
2F3Q	;	1.96	;	Crystal structure of the glycogen phosphorylase B / methyl-N-(beta-D-glucopyranosyl)oxamate complex
2F3U	;	1.93	;	Crystal Structure of the glycogen phosphorylase B / N-(beta-D-glucopyranosyl)-N'-cyclopropyl oxalamide complex
2F3P	;	1.94	;	Crystal Structure of the glycogen phosphorylase B / N-(beta-D-glucopyranosyl)oxamic acid complex
1RZU	;	2.3	;	Crystal structure of the glycogen synthase from A. tumefaciens in complex with ADP
1RZV	;	2.3	;	Crystal structure of the glycogen synthase from Agrobacterium tumefaciens (non-complexed form)
4EEC	;	2.7	;	Crystal Structure of the glycopeptide antibiotic sulfotransferase StaL complexed with A3P and desulfo-A47934.
3G2M	;	2.0	;	Crystal Structure of the Glycopeptide N-methyltransferase MtfA
3G2P	;	2.95	;	Crystal Structure of the Glycopeptide N-methyltransferase MtfA complexed with (S)-adenosyl-L-homocysteine (SAH)
3G2O	;	2.1	;	Crystal Structure of the Glycopeptide N-methyltransferase MtfA complexed with (S)-adenosyl-L-methionine (SAM)
3G2Q	;	2.18	;	Crystal Structure of the Glycopeptide N-methyltransferase MtfA complexed with sinefungin
5EH4	;	2.81	;	Crystal Structure of the Glycophorin A Transmembrane Dimer in Lipidic Cubic Phase
5EH6	;	1.918	;	Crystal Structure of the Glycophorin A Transmembrane Monomer in Lipidic Cubic Phase
4DVL	;	2.75	;	Crystal structure of the glycoprotein Erns from the pestivirus BVDV-1 in complex with 2'-3'-cyclo-UMP
4DVN	;	2.38	;	Crystal structure of the glycoprotein Erns from the pestivirus BVDV-1 in complex with 2'-UMP
4DW3	;	2.35	;	Crystal structure of the glycoprotein Erns from the pestivirus BVDV-1 in complex with 5'-CMP
4DW4	;	2.23	;	Crystal structure of the glycoprotein Erns from the pestivirus BVDV-1 in complex with 5'-UMP
4DW5	;	2.21	;	Crystal structure of the glycoprotein Erns from the pestivirus BVDV-1 in complex with a non-cleavable CpU dinucleotide
4DWC	;	2.89	;	Crystal structure of the glycoprotein Erns from the pestivirus BVDV-1 in complex with Zn ions
4DVK	;	2.21	;	Crystal structure of the glycoprotein Erns from the pestivirus BVDV-1 strain NCP-7
5OU7	;	1.9	;	Crystal structure of the Glycoprotein VI loop truncation mutant PAVS-PAPYKN
8U01	;	3.0	;	Crystal Structure of the Glycoside Hydrolase Family 2 TIM Barrel-domain Containing Protein from Phocaeicola plebeius
6JHP	;	2.559	;	Crystal structure of the glycoside hydrolase family 36 alpha-galactosidase from Paecilomyces thermophila
3LV4	;	1.695	;	Crystal structure of the glycoside hydrolase, family 43 YxiA protein from Bacillus licheniformis. Northeast Structural Genomics Consortium Target BiR14.
1P4K	;	1.9	;	CRYSTAL STRUCTURE OF THE GLYCOSYLASPARAGINASE PRECURSOR D151N MUTANT
1P4V	;	1.9	;	CRYSTAL STRUCTURE OF THE GLYCOSYLASPARAGINASE PRECURSOR D151N MUTANT WITH GLYCINE
3LJQ	;	1.9	;	Crystal Structure of the Glycosylasparaginase T152C apo-precursor
1QUB	;	2.7	;	CRYSTAL STRUCTURE OF THE GLYCOSYLATED FIVE-DOMAIN HUMAN BETA2-GLYCOPROTEIN I PURIFIED FROM BLOOD PLASMA
3MBO	;	3.307	;	Crystal Structure of the Glycosyltransferase BaBshA bound with UDP and L-malate
5GVV	;	1.95	;	Crystal structure of the glycosyltransferase GlyE in Streptococcus pneumoniae TIGR4
4AMB	;	2.62	;	Crystal structure of the glycosyltransferase SnogD from Streptomyces nogalater
4AMG	;	2.59	;	Crystal structure of the glycosyltransferase SnogD from Streptomyces nogalater
4AN4	;	2.7	;	Crystal structure of the glycosyltransferase SnogD from Streptomyces nogalater
5CA3	;	1.8	;	Crystal structure of the glycosynthase mutant D324N of Escherichia coli GH63 glycosidase in complex with glucose and lactose
5GW7	;	2.2	;	Crystal structure of the glycosynthase mutant E727A of Escherichia coli GH63 glycosidase in complex with glucose and lactose
5Z5E	;	2.098	;	Crystal structure of the Glycyl-tRNA synthetase (GlyRS) in Nanoarchaeum equitans
1SS4	;	1.84	;	Crystal Structure of the Glyoxalase Family Protein APC24694 from Bacillus cereus
1JXM	;	2.0	;	CRYSTAL STRUCTURE OF THE GMP BOUND SH3-HOOK-GK FRAGMENT OF PSD-95
2DPL	;	1.43	;	Crystal Structure of the GMP synthase from Pyrococcus horikoshii OT3
4WIM	;	3.6	;	Crystal Structure of the GMP Synthetase from Plasmodium falciparum
2XC6	;	1.83	;	Crystal structure of the GNA 3'-CTC(Br)UAGAG-2'
2WNA	;	0.97	;	Crystal structure of the GNA 3'-G(Br)CGCGC-2'
4NXY	;	1.449	;	Crystal Structure of the GNAT domain of S. lividans PAT
2WV0	;	2.4	;	Crystal structure of the GntR-HutC family member YvoA from Bacillus subtilis
6ON4	;	2.1	;	Crystal structure of the GntR-type sialoregulator NanR from Escherichia coli, in complex with sialic acid
1ZBV	;	3.21	;	Crystal Structure of the goat signalling protein (SPG-40) complexed with a designed peptide Trp-Pro-Trp at 3.2A resolution
1ZU8	;	3.05	;	Crystal structure of the goat signalling protein with a bound trisaccharide reveals that Trp78 reduces the carbohydrate binding site to half
5TDQ	;	2.493	;	Crystal Structure of the GOLD domain of ACBD3
4KQA	;	2.603	;	Crystal structure of the golgi casein kinase
4KQB	;	3.045	;	crystal structure of the Golgi casein kinase with Mn/ADP bound
6S6N	;	1.1	;	Crystal structure of the Gorilla LL37(17-29) antimicrobial peptide
5KG9	;	2.3	;	Crystal structure of the gp120 v2 antibody RE505-22 Fab from IGH- and IGK-humanized mouse
4N21	;	1.99	;	Crystal structure of the GP2 Core Domain from the California Academy of Science Virus
4N23	;	2.0	;	Crystal structure of the GP2 Core Domain from the California Academy of Science Virus, monoclinic symmetry
8S9I	;	3.53	;	Crystal structure of the gp32 C-terminal peptide/Dda/dT8
8GME	;	4.98	;	Crystal structure of the gp32-Dda-dT17 complex
6F45	;	1.70356	;	Crystal structure of the gp37-gp38 adhesin tip complex of the bacteriophage S16 long tail fiber
3TW5	;	2.95	;	Crystal structure of the GP42 transglutaminase from Phytophthora sojae
1XCM	;	1.84	;	Crystal structure of the GppNHp-bound H-Ras G60A mutant
7R58	;	1.902	;	Crystal structure of the GPVI-glenzocimab complex
2X2J	;	2.35	;	Crystal structure of the Gracilariopsis lemaneiformis alpha- 1,4-glucan lyase with deoxynojirimycin
2X2H	;	2.06	;	Crystal structure of the Gracilariopsis lemaneiformis alpha-1,4- glucan lyase
4AMX	;	2.1	;	CRYSTAL STRUCTURE OF THE GRACILARIOPSIS LEMANEIFORMIS ALPHA-1,4- GLUCAN LYASE Covalent Intermediate Complex with 5-fluoro-glucosyl- fluoride
4AMW	;	1.9	;	CRYSTAL STRUCTURE OF THE GRACILARIOPSIS LEMANEIFORMIS ALPHA-1,4- GLUCAN LYASE Covalent Intermediate Complex with 5-fluoro-idosyl- fluoride
2X2I	;	2.6	;	Crystal structure of the Gracilariopsis lemaneiformis alpha-1,4- glucan lyase with acarbose
7C31	;	1.3	;	Crystal structure of the grapevine defensin VvK1
4EDJ	;	1.901	;	Crystal structure of the GRASP55 GRASP Domain with a phosphomimetic mutation (S189D)
4REY	;	1.96	;	Crystal Structure of the GRASP65-GM130 C-terminal peptide complex
2AUH	;	3.2	;	Crystal structure of the Grb14 BPS region in complex with the insulin receptor tyrosine kinase
4K81	;	2.4	;	Crystal structure of the Grb14 RA and PH domains in complex with GTP-loaded H-Ras
2AUG	;	2.3	;	Crystal structure of the Grb14 SH2 domain
3N7Y	;	2.02	;	Crystal Structure of the Grb2 SH2 Domain in Complex with a 20-Membered Macrocyclic Ligand Having the Sequence pYVNV
3N84	;	2.0	;	Crystal Structure of the Grb2 SH2 Domain in Complex with a 23-Membered Macrocyclic Ligand Having the Sequence pYVNVP
3IMJ	;	2.02	;	Crystal Structure of the Grb2 SH2 Domain in Complex with a Cyclopropyl-constrained Ac-pTyr-Ile-Asn-NH2 Tripeptide Mimic
3IN7	;	2.0	;	Crystal Structure of the Grb2 SH2 Domain in Complex with a Cyclopropyl-constrained Ac-pY-Q-N-NH2 Tripeptide Mimic
3IN8	;	1.7	;	Crystal Structure of the Grb2 SH2 Domain in Complex with a Flexible Ac-pTyr-Ile-Asn-NH2 Tripeptide Mimic
3KFJ	;	2.02	;	Crystal Structure of the Grb2 SH2 Domain in Complex with a Flexible Ac-pY-E-N-NH2 Tripeptide Mimic
3IMD	;	2.0	;	Crystal Structure of the Grb2 SH2 Domain in Complex with a Flexible Ac-pY-Q-N-NH2 Tripeptide Mimic
3OV1	;	1.6	;	Crystal Structure of the Grb2 SH2 Domain in Complex with a pYXN-Derived Tripeptide
3OVE	;	1.82	;	Crystal Structure of the Grb2 SH2 Domain in Complex with a pYXN-Derived Tripeptide
3S8N	;	1.71	;	Crystal Structure of the Grb2 SH2 Domain in Complex with a pYXN-Derived Tripeptide
3S8O	;	1.85	;	Crystal Structure of the Grb2 SH2 Domain in Complex with a pYXN-Derived Tripeptide
6WO2	;	2.0	;	Crystal Structure of the Grb2 SH2 Domain in Complex with a Tripeptide: Ac-pY-Ac6c-N-isohexyl
6WM1	;	1.8	;	Crystal structure of the Grb2 SH2 domain in complex with a tripeptide: Ac-pY-Ac6c-N-phenylpropyl
3N8M	;	2.0	;	Crystal Structure of the Grb2 SH2 Domain in Complex with An Acyclic Ligand Having the Sequence pYVNVP
1F0B	;	2.1	;	CRYSTAL STRUCTURE OF THE GREEN FLUORESCENT PROTEIN (GFP) VARIANT YFP-H148Q
1F09	;	2.14	;	CRYSTAL STRUCTURE OF THE GREEN FLUORESCENT PROTEIN (GFP) VARIANT YFP-H148Q WITH TWO BOUND IODIDES
5WJ2	;	2.409	;	Crystal structure of the green fluorescent protein Clover
4RYS	;	1.18	;	Crystal structure of the green fluorescent rotein NowGFP (the variant of cyan Cerulean) at pH 4.8
4RTC	;	1.35	;	Crystal structure of the green fluorescent variant, nowGFP, of the cyan Cerulean at pH 9.0
6ZSY	;	0.926	;	Crystal structure of the Grindelwald extracellular domain complex
6ZSZ	;	1.92	;	Crystal structure of the Grindelwald extracellular domain complex
5OPW	;	3.19	;	Crystal structure of the GroEL mutant A109C
5OPX	;	3.64	;	Crystal structure of the GroEL mutant A109C in complex with GroES and ADP BeF2
1IW6	;	2.3	;	Crystal Structure of the Ground State of Bacteriorhodopsin
7Z09	;	1.05	;	Crystal structure of the ground state of bacteriorhodopsin at 1.05 Angstrom resolution
7Z0A	;	1.22	;	Crystal structure of the ground state of bacteriorhodopsin at 1.22 Angstrom resolution
3FAW	;	2.1	;	Crystal Structure of the Group B Streptococcus Pullulanase SAP
5W74	;	3.65	;	Crystal Structure of the Group II Chaperonin from Methanococcus Maripaludis D386ADeltaLid Mutant in the Open, ADP-Bound State
5W79	;	3.122	;	Crystal Structure of the Group II Chaperonin from Methanococcus Maripaludis, Cysteine-less mutant in the Apo State
5V3T	;	1.899	;	Crystal Structure of the Group II Truncated Hemoglobin from Bacillus Anthracis
5V3U	;	2.5	;	Crystal Structure of the Group II Truncated Hemoglobin from Bacillus Anthracis: Trp90Leu mutant
5V3V	;	2.14	;	Crystal Structure of the Group II Truncated Hemoglobin from Bacillus Anthracis: Tyr26Ala Mutant
4KAX	;	1.85	;	Crystal structure of the Grp1 PH domain in complex with Arf6-GTP
5IUC	;	1.253	;	Crystal structure of the GspB siglec domain with sialyl T antigen bound
1NHY	;	3.0	;	Crystal Structure of the GST-like Domain of Elongation Factor 1-gamma from Saccharomyces cerevisiae.
4GX1	;	2.8	;	Crystal structure of the GsuK bound to ADP
4GX0	;	2.601	;	Crystal structure of the GsuK L97D mutant
4GVL	;	3.0	;	Crystal Structure of the GsuK RCK domain
4DMV	;	1.5	;	Crystal structure of the GT domain of Clostridium difficile Toxin A
4DMW	;	2.5	;	Crystal structure of the GT domain of Clostridium difficile toxin A (TcdA) in complex with UDP and Manganese
2DBY	;	1.76	;	Crystal structure of the GTP-binding protein YchF in complexed with GDP
1SVI	;	1.95	;	Crystal Structure of the GTP-binding protein YsxC complexed with GDP
1ZW6	;	1.5	;	Crystal Structure of the GTP-bound form of RasQ61G
3TKL	;	2.183	;	Crystal structure of the GTP-bound Rab1a in complex with the coiled-coil domain of LidA from Legionella pneumophila
5C1T	;	2.801	;	Crystal structure of the GTP-bound wild type EhRabX3 from Entamoeba histolytica
4ZWG	;	2.3	;	Crystal structure of the GTP-dATP-bound catalytic core of SAMHD1 phosphomimetic T592E mutant
4H5I	;	1.36	;	Crystal Structure of the Guanine Nucleotide Exchange Factor Sec12 (P1 form)
4H5J	;	2.601	;	Crystal Structure of the Guanine Nucleotide Exchange Factor Sec12 (P64 form)
3GAO	;	1.9	;	Crystal structure of the guanine riboswitch bound to xanthine.
3GES	;	2.15	;	Crystal structure of the guanine riboswitch C74U mutant bound to 6-O-methylguanine
6SIR	;	1.7	;	Crystal structure of the guanylate cyclase domain of RhGC from Catenaria anguillulae in complex with GTP
1KGD	;	1.314	;	Crystal Structure of the Guanylate Kinase-like Domain of Human CASK
2W01	;	2.31	;	Crystal structure of the guanylyl cyclase Cya2
3DLB	;	2.7	;	Crystal structure of the guide-strand-containing Argonaute protein silencing complex
3DLH	;	3.0	;	Crystal structure of the guide-strand-containing Argonaute protein silencing complex
3DWF	;	2.2	;	Crystal Structure of the Guinea Pig 11beta-Hydroxysteroid Dehydrogenase Type 1 Mutant F278E
4R8K	;	2.2	;	Crystal structure of the guinea pig L-asparaginase 1 catalytic domain
6ITU	;	2.17	;	Crystal Structure of the GULP1 PTB domain-APP peptide complex
3FMA	;	2.5	;	Crystal structure of the GYF domain of Smy2 in complex with a proline-rich peptide from BBP/ScSF1
2O09	;	2.1	;	Crystal structure of the H-NOX domain from Nostoc sp. PCC 7120
2O0G	;	2.51	;	Crystal structure of the H-NOX domain from Nostoc sp. PCC 7120 complexed to CO
2O0C	;	2.6	;	Crystal structure of the H-NOX domain from Nostoc sp. PCC 7120 complexed to NO
4A01	;	2.35	;	Crystal Structure of the H-Translocating Pyrophosphatase
1G3K	;	1.9	;	CRYSTAL STRUCTURE OF THE H. INFLUENZAE PROTEASE HSLV AT 1.9 A RESOLUTION
6ZN8	;	3.211	;	Crystal structure of the H. influenzae VapXD toxin-antitoxin complex
3PG7	;	2.189	;	Crystal structure of the H. sapiens NF1 SEC-PH domain (del1750 mutant)
3N1T	;	1.716	;	Crystal structure of the H101A mutant ecHint GMP complex
8APY	;	2.34	;	Crystal structure of the H12A variant of the KDEL receptor bound to sybody
1HQG	;	2.0	;	CRYSTAL STRUCTURE OF THE H141C ARGINASE VARIANT COMPLEXED WITH PRODUCTS ORNITHINE AND UREA
1EJS	;	2.0	;	Crystal Structure of the H219N Variant of Klebsiella Aerogenes Urease
1EJT	;	2.0	;	CRYSTAL STRUCTURE OF THE H219Q VARIANT OF KLEBSIELLA AEROGENES UREASE
4GHM	;	1.618	;	Crystal Structure of the H233A mutant of 7-cyano-7-deazaguanine reductase, QueF from Vibrio cholerae complexed with preQ0
5W6Z	;	2.61	;	Crystal structure of the H24W mutant of HsNUDT16
5LWX	;	1.49	;	Crystal structure of the H253D mutant of McoG from Aspergillus niger
3V1N	;	1.59	;	Crystal Structure of the H265Q mutant of a C-C hydrolase, BphD from Burkholderia xenovorans LB400, after exposure to its substrate HOPDA
3V1K	;	2.13	;	Crystal Structure of the H265Q mutant of a C-C hydrolase, BphD from Burkholderia xenovorans LB400.
5YVR	;	1.896	;	Crystal Structure of the H277A mutant of ADH/D1, an archaeal halo-thermophilic Red Sea brine pool alcohol dehydrogenase
1PQU	;	1.92	;	Crystal Structure of the H277N Mutant of Aspartate Semialdehyde Dehydrogenase from Haemophilus influenzae Bound with NADP, S-methyl cysteine sulfoxide and cacodylate
3JQQ	;	2.2	;	Crystal structure of the H286K mutant of Ferredoxin-NADP+ reductase from Plasmodium falciparum in complex with 2'P-AMP
3JQR	;	2.3	;	Crystal structure of the H286L mutant of Ferredoxin-NADP+ reductase from Plasmodium falciparum
3JQP	;	3.0	;	Crystal structure of the H286L mutant of Ferredoxin-NADP+ reductase from Plasmodium falciparum with 2'P-AMP
4L8C	;	2.8	;	Crystal structure of the H2Db in complex with the NP-N3D peptide
4L8D	;	1.9	;	Crystal structure of the H2Db in complex with the NP-N5D peptide
4L8B	;	2.2	;	Crystal structure of the H2Db in complex with the NP-N5H peptide
6YC1	;	2.2	;	Crystal structure of the H30A mutant of the light-driven sodium pump KR2 in the pentameric form, pH 8.0
6RFA	;	2.2	;	Crystal structure of the H30K mutant of the light-driven sodium pump KR2 in the monomeric form, pH 8.0
1EJU	;	2.0	;	CRYSTAL STRUCTURE OF THE H320N VARIANT OF KLEBSIELLA AEROGENES UREASE
1EJV	;	2.4	;	CRYSTAL STRUCTURE OF THE H320Q VARIANT OF KLEBSIELLA AEROGENES UREASE
8AJT	;	1.499	;	Crystal structure of the H323A mutant of S-adenosyl-L-homocysteine hydrolase from Pseudomonas aeruginosa cocrystallized with adenosine in the presence of K+ cations
6Y45	;	1.68	;	Crystal Structure of the H33A variant of RsrR
5KQN	;	1.75	;	Crystal structure of the H381S variant of catalase-peroxidase from B. pseudomallei
2RJV	;	1.45	;	Crystal structure of the H41Y mutant of villin headpiece, P 21 21 21 space group
7XL5	;	2.604	;	Crystal structure of the H42T/A85G/I86A mutant of a nadp-dependent alcohol dehydrogenase
6JSC	;	1.4	;	Crystal structure of the H434A variant of the C-terminal domain of HtaA from Corynebacterium glutamicum
4UDR	;	1.6	;	Crystal structure of the H467A mutant of 5-hydroxymethylfurfural oxidase (HMFO)
2NNX	;	2.3	;	Crystal Structure of the H46R, H48Q double mutant of human [Cu-Zn] Superoxide Dismutase
1N28	;	1.5	;	Crystal structure of the H48Q mutant of human group IIA phospholipase A2
4O9G	;	1.9	;	Crystal structure of the H51N mutant of the 3,4-ketoisomerase QdtA from Thermoanaerobacterium thermosaccharolyticum in complex with TDP-4-keto-6-deoxyglucose
6VL7	;	2.14	;	Crystal structure of the H583C mutant of GoxA soaked with glycine
3ZHQ	;	2.5	;	Crystal structure of the H747A mutant of the SucA domain of Mycobacterium smegmatis KGD
3ZHR	;	2.1	;	Crystal structure of the H747A mutant of the SucA domain of Mycobacterium smegmatis KGD showing the active site lid closed
6VMV	;	2.2	;	Crystal structure of the H767A mutant of GoxA soaked with glycine
5FUQ	;	2.04	;	CRYSTAL STRUCTURE OF THE H80R VARIANT OF NQO1 BOUND TO DICOUMAROL
2VVR	;	2.1	;	Crystal structure of the H99N mutant of ribose-5-phosphate isomerase B from E. coli soaked with ribose 5-phosphate
2E3B	;	1.3	;	Crystal structure of the HA-bound form of Arthromyces ramosus peroxidase at 1.3 Angstroms resolution
3QQI	;	1.65	;	Crystal structure of the HA1 receptor binding domain of H2 hemagglutinin
1S94	;	3.34	;	Crystal structure of the Habc domain of neuronal syntaxin from the squid Loligo pealei
4BSA	;	2.3	;	Crystal Structure of the Haemagglutinin (with Asn-133 Glycosylation) from an H7N9 Influenza Virus Isolated from Humans
6TVD	;	2.7	;	Crystal structure of the haemagglutinin from a H10N7 seal influenza virus isolated in Germany in complex with avian receptor analogue, 3'-SLN
6TVF	;	2.6	;	Crystal structure of the haemagglutinin from a H10N7 seal influenza virus isolated in Germany in complex with human receptor analogue, 6'-SLN
6TVC	;	1.84	;	Crystal structure of the haemagglutinin from a transmissible H10N7 seal influenza virus isolated in Netherland
6TVA	;	1.74	;	Crystal structure of the haemagglutinin from a transmissible H10N7 seal influenza virus isolated in Netherland in complex with avian receptor analogue, 3'-SLN
6TVB	;	1.65	;	Crystal structure of the haemagglutinin from a transmissible H10N7 seal influenza virus isolated in Netherland in complex with human receptor analogue 6'-SLN
4BH2	;	2.12	;	Crystal Structure of the Haemagglutinin from a Transmissible Mutant H5 Influenza Virus
6TVR	;	2.63	;	Crystal structure of the haemagglutinin mutant (Gln226Leu) from an H10N7 seal influenza virus isolated in Germany
6TVS	;	1.9	;	Crystal structure of the haemagglutinin mutant (Gln226Leu) from an H10N7 seal influenza virus isolated in Germany in complex with avian receptor analogue 3'-SLN
6TWV	;	2.55	;	Crystal structure of the haemagglutinin mutant (Gln226Leu) from an H10N7 seal influenza virus isolated in Germany with human receptor analogue, 6'SLN
6TJW	;	2.31	;	Crystal structure of the haemagglutinin mutant (Gln226Leu, Del228) from an H10N7 seal influenza virus isolated in Germany
6TXO	;	2.4	;	Crystal structure of the haemagglutinin mutant (Gln226Leu, Del228) from an H10N7 seal influenza virus isolated in Germany in complex with avian receptor analogue 3'-SLN
6TVT	;	2.2	;	Crystal structure of the haemagglutinin mutant (Gln226Leu, Del228) from an H10N7 seal influenza virus isolated in Germany in complex with human receptor analogue 6'-SLN
6TWH	;	2.68	;	Crystal structure of the haemagglutinin mutant (Gln226Leu, Gly228Ser) from an H10N7 seal influenza virus isolated in Germany
6TWI	;	2.27	;	Crystal structure of the haemagglutinin mutant (Gln226Leu, Gly228Ser) from an H10N7 seal influenza virus isolated in Germany in complex with avian receptor analogue 3'-SLN
6TY1	;	3.2	;	Crystal structure of the haemagglutinin mutant (Gln226Leu, Gly228Ser) from an H10N7 seal influenza virus isolated in Germany in complex with human receptor analogue 6'-SLN
6TWS	;	2.0	;	Crystal structure of the haemagglutinin mutant (Gln226Leu, Gly228Ser) from an H10N7 seal influenza virus isolated in Germany with 2mM EDTA
1SR4	;	2.0	;	Crystal Structure of the Haemophilus ducreyi cytolethal distending toxin
2O6A	;	1.8	;	Crystal structure of the Haemophilus influenzae E57A mutant FbpA
3SYJ	;	2.2	;	Crystal structure of the Haemophilus influenzae Hap adhesin
3I2U	;	2.8	;	Crystal structure of the haiprin ribozyme with a 2',5'-linked substrate and N1-deazaadenosine at position A10
3I2Q	;	2.9	;	Crystal structure of the hairpin ribozyme with 2'OMe substrate strand and N1-deazaadenosine at position A9
3I2R	;	2.8	;	Crystal structure of the hairpin ribozyme with a 2',5'-linked substrate with N1-deazaadenosine at position A9
3I2S	;	2.75	;	Crystal structure of the hairpin ribozyme with a 2'OMe substrate and N1-deazaadenosine at position A10
1PWZ	;	2.5	;	Crystal structure of the haloalcohol dehalogenase HheC complexed with (R)-styrene oxide and chloride
1PWX	;	1.8	;	Crystal structure of the haloalcohol dehalogenase HheC complexed with bromide
1PX0	;	1.9	;	Crystal structure of the haloalcohol dehalogenase HheC complexed with the haloalcohol mimic (R)-1-para-nitro-phenyl-2-azido-ethanol
3IFV	;	2.0	;	Crystal structure of the Haloferax volcanii proliferating cell nuclear antigen
7QY3	;	2.72	;	Crystal structure of the halohydrin dehalogenase HheG D114C mutant cross-linked with BMOE
6I9V	;	2.8	;	Crystal structure of the halohydrin dehalogenase HheG T123G mutant
6I9W	;	1.55	;	Crystal structure of the halohydrin dehalogenase HheG T123G mutant
6I9U	;	2.4	;	Crystal structure of the halohydrin dehalogenase HheG T123W mutant
4KAA	;	2.276	;	Crystal structure of the halotag2 protein at the resolution 2.3A, Northeast Structural Genomics Consortium (NESG) target OR150
7EMS	;	1.85	;	Crystal Structure of the HasAp L85A Mutant Capturing Iron Tetraphenylporphyrin
7EMT	;	1.8	;	Crystal Structure of the HasAp V37G Mutant Capturing Iron Tetraphenylporphyrin
7EMV	;	1.45	;	Crystal Structure of the HasAp V37G Mutant Capturing Iron-5,10,15-Triphenylporphyrin
7EMU	;	1.35	;	Crystal Structure of the HasAp V37G Mutant Capturing Manganese Tetraphenylporphyrin
7EMW	;	1.12	;	Crystal Structure of the HasAp V37G/K59Q Mutant Capturing Iron Tetraphenylporphyrin
4E6H	;	2.3	;	CRYSTAL STRUCTURE OF THE HAT domain of k. lactis RNA14
5JJX	;	2.0	;	Crystal structure of the HAT domain of sart3
5JJW	;	3.01	;	Crystal structure of the HAT domain of sart3 in complex with USP15 DUSP-UBL domain
2RC4	;	3.0	;	Crystal Structure of the HAT domain of the human MOZ protein
2OND	;	2.8	;	Crystal Structure of the HAT-C domain of murine CstF-77
3LQB	;	1.1	;	Crystal structure of the hatching enzyme ZHE1 from the zebrafish Danio rerio
5IKU	;	1.9	;	Crystal structure of the Hathewaya histolytica ColG tandem collagen-binding domain s3as3b in the presence of calcium at 1.9 Angstrom resolution
2CXY	;	1.6	;	Crystal structure of the hBAF250b AT-rich interaction domain (ARID)
2EH9	;	2.0	;	Crystal structure of the HBAF250B at-rich interaction domain (ARID)
5E0I	;	1.95	;	Crystal structure of the HBV capsid Y132A mutant (VCID 8772) in complex with NVR10-001E2 at 1.95A resolution
8PMU	;	1.75	;	Crystal structure of the HC7 apo form
8PN3	;	1.44	;	Crystal structure of the HC7-Glu200Ala mutant complexed to a tetraglycopeptide.
8PN5	;	1.72	;	Crystal structure of the HC7-Glu200Ala mutant complexed to a triglycopeptide
6H23	;	3.089	;	Crystal structure of the hClpP Y118A mutant with an activating small molecule
7LYV	;	1.9	;	Crystal structure of the HCMV pentamer-specific antibody 1-103
7M1C	;	2.1	;	Crystal structure of the HCMV pentamer-specific antibody 1-32
7LYW	;	2.51	;	Crystal structure of the HCMV pentamer-specific antibody 2-25
7KBA	;	2.8	;	Crystal structure of the HCMV pentamer-specific Fab 2-18
3T4B	;	3.55	;	Crystal Structure of the HCV IRES pseudoknot domain
3RAU	;	1.95	;	Crystal structure of the HD-PTP Bro1 domain
6HXY	;	2.9	;	Crystal structure of the head and coiled-coil domains of zebrafish CCDC61
6HXV	;	1.97	;	Crystal structure of the head and coiled-coil domains of zebrafish CCDC61 (F129E/D130A)
6HXT	;	2.55	;	Crystal structure of the head domain of human CCDC61
1LKT	;	2.6	;	CRYSTAL STRUCTURE OF THE HEAD-BINDING DOMAIN OF PHAGE P22 TAILSPIKE PROTEIN
2Z5I	;	2.1	;	Crystal structure of the head-to-tail junction of tropomyosin
2Z5H	;	2.89	;	Crystal structure of the head-to-tail junction of tropomyosin complexed with a fragment of TnT
1YU5	;	1.4	;	Crystal Structure of the Headpiece Domain of Chicken Villin
2RJX	;	1.7	;	Crystal structure of the headpiece domain of chicken villin, P61 space group
4Y07	;	2.507	;	Crystal structure of the HECT domain of human WWP2
3TUG	;	2.27	;	Crystal structure of the HECT domain of ITCH E3 ubiquitin ligase
3DKM	;	1.6	;	Crystal structure of the HECTD1 CPH domain
6XJ7	;	1.85	;	Crystal structure of the helical cell shape determining protein Pgp2 (K307A mutant) from Campylobacter jejuni
6XJ6	;	1.497	;	Crystal structure of the helical cell shape determining protein Pgp2 from Campylobacter jejuni
4W8C	;	1.7568	;	Crystal structure of the helical domain deleted form MsrA from Clostridium oremlandii
4ZMI	;	2.3	;	Crystal structure of the Helical domain of S. pombe Taz1
6K5S	;	1.904	;	Crystal structure of the Helical domain of S. pombe Tbf1
2RB4	;	2.8	;	Crystal structure of the Helicase domain of human DDX25 RNA helicase
5A9F	;	3.2	;	Crystal structure of the Helicase domain of human DNA polymerase theta in complex with ADP
5AGA	;	2.9	;	Crystal structure of the Helicase domain of human DNA polymerase theta in complex with AMPPNP
5A9J	;	3.55	;	Crystal structure of the Helicase domain of human DNA polymerase theta, apo-form
1CR2	;	2.3	;	CRYSTAL STRUCTURE OF THE HELICASE DOMAIN OF THE GENE 4 PROTEIN OF BACTERIOPHAGE T7: COMPLEX WITH DATP
1CR4	;	2.5	;	CRYSTAL STRUCTURE OF THE HELICASE DOMAIN OF THE GENE 4 PROTEIN OF BACTERIOPHAGE T7: COMPLEX WITH DTDP
1CR1	;	2.3	;	CRYSTAL STRUCTURE OF THE HELICASE DOMAIN OF THE GENE 4 PROTEIN OF BACTERIOPHAGE T7: COMPLEX WITH DTTP
1CR0	;	2.3	;	CRYSTAL STRUCTURE OF THE HELICASE DOMAIN OF THE GENE4 PROTEIN OF BACTERIOPHAGE T7
1G6O	;	2.5	;	CRYSTAL STRUCTURE OF THE HELICOBACTER PYLORI ATPASE, HP0525, IN COMPLEX WITH ADP
4DVY	;	3.3	;	Crystal structure of the Helicobacter pylori CagA oncoprotein
4DVZ	;	3.19	;	Crystal structure of the Helicobacter pylori CagA oncoprotein
2PD3	;	2.5	;	Crystal Structure of the Helicobacter pylori Enoyl-Acyl Carrier Protein Reductase in Complex with Hydroxydiphenyl Ether Compounds, Triclosan and Diclosan
2PD4	;	2.3	;	Crystal Structure of the Helicobacter pylori Enoyl-Acyl Carrier Protein Reductase in Complex with Hydroxydiphenyl Ether Compounds, Triclosan and Diclosan
4P54	;	1.65	;	Crystal Structure of the Helicobacter pylori MTAN-D198N mutant with 5'-methylthioadenosine in the active site.
4OY3	;	1.2	;	Crystal Structure of the Helicobacter pylori MTAN-D198N mutant with S-Adenosylhomocysteine in the active site
2QV3	;	2.401	;	Crystal Structure of the Helicobacter pylori Vacuolating Toxin p55 Domain
4LXV	;	3.0	;	Crystal Structure of the Hemagglutinin from a H1N1pdm A/WASHINGTON/5/2011 virus
4KDQ	;	2.604	;	Crystal structure of the hemagglutinin of A/Xinjiang/1/2006 virus
4KDM	;	2.496	;	Crystal structure of the hemagglutinin of ferret-transmissible H5N1 virus
4KDN	;	2.483	;	Crystal structure of the hemagglutinin of ferret-transmissible H5N1 virus in complex with avian receptor analog LSTa
4KDO	;	2.396	;	Crystal structure of the hemagglutinin of ferret-transmissible H5N1 virus in complex with human receptor analog LSTc
6CPB	;	1.155	;	Crystal structure of the heme domain of CooA from Carboxydothermus hydrogenoformans
3KS0	;	2.7	;	Crystal structure of the heme domain of flavocytochrome b2 in complex with Fab B2B4
3I8R	;	1.5	;	Crystal structure of the heme oxygenase from Corynebacterium diphtheriae (HmuO) in complex with heme binding ditiothreitol (DTT)
1V9Y	;	1.32	;	Crystal Structure of the heme PAS sensor domain of Ec DOS (ferric form)
1V9Z	;	1.9	;	Crystal Structure of the heme PAS sensor domain of Ec DOS (Ferrous Form)
1VB6	;	1.56	;	Crystal Structure of the heme PAS sensor domain of Ec DOS (oxygen-bound form)
7W81	;	1.8	;	Crystal structure of the heme-bound form of the linker-NEAT3 region of IsdH from Staphylococcus aureus
2O6P	;	1.5	;	Crystal Structure of the heme-IsdC complex
3FHH	;	2.6	;	Crystal structure of the heme/hemoglobin outer membrane transporter ShuA from Shigella dysenteriae
1W3F	;	2.58	;	Crystal structure of the hemolytic lectin from the mushroom Laetiporus sulphureus complexed with N-acetyllactosamine in the gamma motif
8KI0	;	1.45	;	Crystal structure of the hemophore HasA from Pseudomonas protegens Pf-5 capturing Fe-tetraphenylporphyrin
1DK0	;	1.77	;	CRYSTAL STRUCTURE OF THE HEMOPHORE HASA FROM SERRATIA MARCESCENS CRYSTAL FORM P2(1), PH8
1DKH	;	3.2	;	CRYSTAL STRUCTURE OF THE HEMOPHORE HASA, PH 6.5
7YRK	;	0.92	;	Crystal structure of the hen egg lysozyme-2-oxidobenzylidene-threoninato-copper (II) complex
6CMG	;	2.7	;	Crystal Structure of the Hendra Virus Attachment G Glycoprotein Bound to a Potent Cross-Reactive Neutralizing Human Monoclonal Antibody m102.3
6CMI	;	2.72	;	Crystal Structure of the Hendra Virus Attachment G Glycoprotein Bound to a Potent Cross-Reactive Neutralizing Human Monoclonal Antibody m102.3
1JMO	;	2.2	;	Crystal Structure of the Heparin Cofactor II-S195A Thrombin Complex
5TWM	;	1.97	;	CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS GENOTYPE 2A STRAIN JFH1 L30S NS5B RNA-DEPENDENT RNA POLYMERASE IN COMPLEX WITH 5-[3-(tert-butylcarbamoyl)phenyl]-6-(ethylamino)-2-(4-fluorophenyl)-N-methylfuro[2,3-b]pyridine-3-carboxamide
5QJ1	;	2.17	;	CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS GENOTYPE 2A STRAIN JFH1 L30S NS5B RNA-DEPENDENT RNA POLYMERASE IN COMPLEX WITH 6-(ethylamino)-2-(4-fluorophenyl)-5-(3-{[1-(5-fluoropyrimidin-2-yl)cyclopropyl]carbamoyl}-4-methoxyphenyl)-N-methyl-1-benzofuran-3-carboxamide
5QJ0	;	2.08	;	CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS GENOTYPE 2A STRAIN JFH1 NS5B RNA-DEPENDENT RNA POLYMERASE IN COMPLEX WITH 6-[ethyl(methylsulfonyl)amino]-2-(4-fluorophenyl)-N-methyl-5-(3-{[1-(pyrimidin-2-yl)cyclopropyl]carbamoyl}phenyl)-1-benzofuran-3-carboxamide
1W3C	;	2.3	;	Crystal structure of the Hepatitis C Virus NS3 Protease in complex with a peptidomimetic inhibitor
5TWN	;	3.04	;	CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS5B RNA- DEPENDENT RNA POLYMERASE IN COMPLEX WITH 5-[3-(tert-butylcarbamoyl)phenyl]-6-(ethylamino)-2-(4-fluorophenyl)-N-methylfuro[2,3-b]pyridine-3-carboxamide
5TRK	;	2.06	;	CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS5B RNA- DEPENDENT RNA POLYMERASE IN COMPLEX WITH N-{3-[(benzenecarbonyl)amino]-4-[(4-chlorophenyl)methoxy]benzene-1-carbonyl}glycine
5PZO	;	2.8	;	CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS5B RNA-DEPENDENT RNA POLYMERASE C316N IN COMPLEX WITH 2-(4-FLUOROPHENYL)-N-METHYL-5-[3-({2-METHYL-1-OXO-1-[(1,3,4-THIADIAZOL-2-YL)AMINO]PROPAN-2-YL}CARBAMOYL)PHENYL]-1-BENZOFURAN-3-CARBOXAMIDE
3Q0Z	;	2.29	;	Crystal structure of the hepatitis C virus NS5B RNA-dependent RNA polymerase complex with (2E)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5h-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl]amino}cyclopentyl)carbonyl]amino}phenyl)prop-2-enoic acid
3QGD	;	2.6	;	Crystal structure of the hepatitis C virus NS5B RNA-dependent RNA polymerase complex with (2E)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl]amino}cyclopentyl)carbonyl]amino}phenyl)prop-2-enoic acid and (2R)-4-(2,6-dimethoxypyrimidin-4-yl)-1-[(4-ethylphenyl)sulfonyl]-N-(4-methoxybenzyl)piperazine-2-carboxamide
3QGE	;	3.0	;	Crystal structure of the hepatitis C virus NS5B RNA-dependent RNA polymerase complex with (2E)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl]amino}cyclopentyl)carbonyl]amino}phenyl)prop-2-enoic acid and (2R)-4-(2,6-dimethoxypyrimidin-4-yl)-N-(4-methoxybenzyl)-1-{[4-(trifluoromethoxy)phenyl]sulfonyl}piperazine-2-carboxamide
3QGF	;	2.45	;	Crystal structure of the hepatitis C virus NS5B RNA-dependent RNA polymerase complex with (2E)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl]amino}cyclopentyl)carbonyl]amino}phenyl)prop-2-enoic acid and (2R)-4-(6-chloropyridazin-3-yl)-N-(4-methoxybenzyl)-1-{[4-(trifluoromethoxy)phenyl]sulfonyl}piperazine-2-carboxamide
3QGG	;	3.22	;	Crystal structure of the hepatitis C virus NS5B RNA-dependent RNA polymerase complex with (2E)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl]amino}cyclopentyl)carbonyl]amino}phenyl)prop-2-enoic acid and N-cyclopropyl-6-[(3R)-3-{[4-(trifluoromethoxy)benzyl]carbamoyl}-4-{[4-(trifluoromethoxy)phenyl]sulfonyl}piperazin-1-yl]pyridazine-3-carboxamide
4NLD	;	2.75	;	Crystal structure of the hepatitis C virus NS5B RNA-dependent RNA polymerase complex with BMS-791325 also known as (1aR,12bS)-8-cyclohexyl-n-(dimethylsulfamoyl)-11-methoxy-1a-{[(1R,5S)-3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl]carbonyl}-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide and 2-(4-fluorophenyl)-n-methyl-6-[(methylsulfonyl)amino]-5-(propan-2-yloxy)-1-benzofuran-3-carboxamide
3QGH	;	2.14	;	Crystal structure of the hepatitis C virus NS5B RNA-dependent RNA polymerase genotype 1a complex with N-cyclopropyl-6-[(3R)-3-{[4-(trifluoromethoxy)benzyl]carbamoyl}-4-{[4-(trifluoromethoxy)phenyl]sulfonyl}piperazin-1-yl]pyridazine-3-carboxamide
3QGI	;	1.8	;	Crystal structure of the hepatitis C virus NS5B RNA-dependent RNA polymerase genotype 1a complex with N-[(2S)-butan-2-yl]-6-[(3R)-3-{[4-(trifluoromethoxy)benzyl]carbamoyl}-4-{[4-(trifluoromethoxy)phenyl]sulfonyl}piperazin-1-yl]pyridazine-3-carboxamide
5PZK	;	2.2	;	CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS5B RNA-DEPENDENT RNA POLYMERASE IN COMPLEX WITH 2-(4-FLUOROPHENYL)-N-METHYL-6-[(METHYLSULFONYL)AMINO]-5-(PROPAN-2-YLOXY)-1-BENZOFURAN-3-CARBOXAMIDE
5PZL	;	2.06	;	CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS5B RNA-DEPENDENT RNA POLYMERASE IN COMPLEX WITH 2-({3-[1-(2-CYCLOPROPYLETHYL)-6-FLUORO-4-HYDROXY-2-OXO-1,2-DIHYDROQUINOLIN-3-YL]-1,1-DIOXO-1,4-DIHYDRO-1LAMBDA~6~,2,4-BENZOTHIADIAZIN-7-YL}OXY)ACETAMIDE
5TRH	;	2.7	;	CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS5B RNA-DEPENDENT RNA POLYMERASE IN COMPLEX WITH 2-[(benzenecarbonyl)amino]-3-[(4-chlorophenyl)methoxy]benzoic acid
5TRJ	;	2.57	;	CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS5B RNA-DEPENDENT RNA POLYMERASE IN COMPLEX WITH 2-{[2-(carboxymethoxy)benzene-1-carbonyl]amino}-3-[(4-chlorophenyl)methoxy]benzoic acid
5TRI	;	2.3	;	CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS5B RNA-DEPENDENT RNA POLYMERASE IN COMPLEX WITH 3-[(4-chlorophenyl)methoxy]-2-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)benzoic acid
5PZM	;	2.54	;	CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS5B RNA-DEPENDENT RNA POLYMERASE IN COMPLEX WITH 3-[2-(4-FLUOROPHENYL)-3-(METHYLCARBAMOYL)-1-BENZOFURAN-5-YL]BENZOIC ACID
5PZP	;	2.95	;	CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS5B RNA-DEPENDENT RNA POLYMERASE IN COMPLEX WITH 4-FLUORO-2-(4-FLUOROPHENYL)-N-METHYL-5-(2-METHYL-5-{[1-(PYRIMIDIN-2-YL)CYCLOPROPYL]CARBAMOYL}PHENYL)-1-BENZOFURAN-3-CARBOXAMIDE (BMS-929075)
5PZN	;	2.25	;	CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS5B RNA-DEPENDENT RNA POLYMERASE IN COMPLEX WITH 5-[3-(TERT-BUTYLCARBAMOYL)PHENYL]-2-(4-FLUOROPHENYL)-N-METHYL-1-BENZOFURAN-3-CARBOXAMIDE
1VBY	;	2.9	;	Crystal Structure of the Hepatitis Delta Virus Gemonic Ribozyme Precursor, with C75U mutaion, and Mn2+ bound
1VBZ	;	2.8	;	Crystal Structure of the Hepatitis Delta Virus Gemonic Ribozyme Precursor, with C75U mutaion, in Ba2+ solution
1SJF	;	2.75	;	Crystal Structure of the Hepatitis Delta Virus Gemonic Ribozyme Precursor, with C75U mutaion, in Cobalt Hexammine solution
1VBX	;	2.7	;	Crystal Structure of the Hepatitis Delta Virus Gemonic Ribozyme Precursor, with C75U mutaion, in EDTA solution
1VC0	;	2.5	;	Crystal Structure of the Hepatitis Delta Virus Gemonic Ribozyme Precursor, with C75U mutaion, in Imidazole and Sr2+ solution
1VC6	;	2.8	;	Crystal Structure of the Hepatitis Delta Virus Gemonic Ribozyme Product with C75U Mutaion, cleaved in Imidazole and Mg2+ solutions
3HAG	;	3.5	;	Crystal structure of the Hepatitis E Virus-like Particle
3O10	;	1.9	;	Crystal structure of the HEPN domain from human sacsin
7V9R	;	3.5	;	Crystal Structure of the heptameric EcHsp60
2HVL	;	2.4	;	Crystal structure of the HePTP catalytic domain C270S mutant
2QDP	;	2.72	;	Crystal structure of the HePTP catalytic domain C270S mutant crystallized in ammonium acetate
2QDM	;	2.05	;	Crystal structure of the HePTP catalytic domain C270S/D236A/Q314A mutant
2QDC	;	2.0	;	Crystal structure of the HePTP catalytic domain D236A mutant
4D2I	;	2.841	;	Crystal structure of the HerA hexameric DNA translocase from Sulfolobus solfataricus bound to AMP-PNP
1JMA	;	2.65	;	CRYSTAL STRUCTURE OF THE HERPES SIMPLEX VIRUS GLYCOPROTEIN D BOUND TO THE CELLULAR RECEPTOR HVEA/HVEM
2GV9	;	2.68	;	Crystal structure of the Herpes Simplex virus type 1 DNA polymerase
8ONW	;	2.29	;	Crystal structure of the hetero-dimeric complex from Archaeoglobus fulgidus PRC1 and PRC2 domains
4ZRY	;	3.30013	;	Crystal structure of the heterocomplex between coil 2B domains of human intermediate filament proteins keratin 1 (KRT1) and keratin 10 (KRT10)
6UUI	;	2.069	;	Crystal structure of the heterocomplex between coil 2B domains of wild-type keratin 1 (KRT1) and keratin 10 (KRT10) containing mutation Cys401Ala
6E2J	;	2.386	;	Crystal structure of the heterocomplex between human keratin 1 coil 1B containing S233L mutation and wild-type human keratin 10 coil 1B
7BGG	;	1.04	;	Crystal structure of the heterocyclic toxin methyltransferase from Mycobacterium tuberculosis
7NOY	;	1.8	;	Crystal structure of the heterocyclic toxin methyltransferase from Mycobacterium tuberculosis in complex with substrate 1-hydroxyquinolin-4(1H)-one
7NMK	;	1.204	;	Crystal structure of the heterocyclic toxin methyltransferase from Mycobacterium tuberculosis with bound methylation product 1-methoxyquinolin-4(1H)-one
7NDM	;	1.35	;	Crystal structure of the heterocyclic toxin methyltransferase from Mycobacterium tuberculosis with bound substrate 4-hydroxyisoquinolin-1(2H)-one
5MKK	;	2.7	;	Crystal structure of the heterodimeric ABC transporter TmrAB, a homolog of the antigen translocation complex TAP
4NI2	;	1.9	;	Crystal structure of the heterodimeric catalytic domain of wild-type human soluble guanylate cyclase
4F3L	;	2.268	;	Crystal Structure of the Heterodimeric CLOCK:BMAL1 Transcriptional Activator Complex
2GTP	;	2.55	;	Crystal structure of the heterodimeric complex of human RGS1 and activated Gi alpha 1
2IHB	;	2.71	;	Crystal structure of the heterodimeric complex of human RGS10 and activated Gi alpha 3
2IK8	;	2.71	;	Crystal structure of the heterodimeric complex of human RGS16 and activated Gi alpha 1
2ODE	;	1.9	;	Crystal structure of the heterodimeric complex of human RGS8 and activated Gi alpha 3
1FQK	;	2.3	;	CRYSTAL STRUCTURE OF THE HETERODIMERIC COMPLEX OF THE RGS DOMAIN OF RGS9, AND THE GT/I1 CHIMERA ALPHA SUBUNIT [(RGS9)-(GT/I1ALPHA)-(GDP)-(ALF4-)-(MG2+)]
1R0O	;	2.24	;	Crystal Structure of the Heterodimeric Ecdysone Receptor DNA-binding Complex
5LDD	;	2.496	;	Crystal structure of the heterodimeric GEF Mon1-Ccz1 in complex with Ypt7
4ZPR	;	3.902	;	Crystal Structure of the Heterodimeric HIF-1a:ARNT Complex with HRE DNA
6E3U	;	2.85	;	Crystal Structure of the Heterodimeric HIF-2 Complex with Agonist M1001
6E3S	;	3.0	;	Crystal Structure of the Heterodimeric HIF-2 Complex with Antagonist PT2385
6E3T	;	3.0	;	Crystal Structure of the Heterodimeric HIF-2 Complex with Antagonist T1001
7W80	;	2.754	;	Crystal Structure of the Heterodimeric HIF-2 in Complex with Antagonist Belzutifan
4ZP4	;	2.355	;	Crystal Structure of the Heterodimeric HIF-2a:ARNT Complex
4ZPK	;	3.6	;	Crystal Structure of the Heterodimeric HIF-2a:ARNT Complex with HRE DNA
4ZPH	;	2.8	;	Crystal Structure of the Heterodimeric HIF-2a:ARNT Complex with Proflavine
4ZQD	;	2.87	;	Crystal Structure of the Heterodimeric HIF-2a:ARNT Complex with the Benzoxadiazole Antagonist 0X3
7V7L	;	2.3	;	Crystal Structure of the Heterodimeric HIF-3a:ARNT Complex
7V7W	;	2.507	;	Crystal Structure of the Heterodimeric HIF-3a:ARNT Complex with oleoylethanolamide (OEA)
7ZSC	;	3.85	;	Crystal structure of the heterodimeric human C-P4H-II with truncated alpha subunit (C-P4H-II delta281)
1OGY	;	3.2	;	Crystal structure of the heterodimeric nitrate reductase from Rhodobacter sphaeroides
5SY5	;	3.201	;	Crystal Structure of the Heterodimeric NPAS1-ARNT Complex
5SY7	;	4.2	;	Crystal Structure of the Heterodimeric NPAS3-ARNT Complex with HRE DNA
3ER8	;	3.18	;	Crystal structure of the heterodimeric vaccinia virus mRNA polyadenylate polymerase complex with two fragments of RNA
3ER9	;	2.06	;	Crystal structure of the heterodimeric vaccinia virus mRNA polyadenylate polymerase complex with UU and 3'-deoxy ATP
3ERC	;	3.21	;	Crystal structure of the heterodimeric vaccinia virus mRNA polyadenylate polymerase with three fragments of RNA and 3'-deoxy ATP
2GA9	;	2.3	;	Crystal Structure of the Heterodimeric Vaccinia Virus Polyadenylate Polymerase with Bound ATP-gamma-S
3PH0	;	2.4	;	Crystal structure of the heteromolecular chaperone, AscE-AscG, from the type III secretion system in Aeromonas hydrophila
4GYP	;	2.1	;	Crystal structure of the heterotetrameric complex of GlucD and GlucDRP from E. coli K-12 MG1655 (EFI TARGET EFI-506058)
2QLV	;	2.6	;	Crystal structure of the heterotrimer core of the S. cerevisiae AMPK homolog SNF1
4BWS	;	2.5	;	Crystal structure of the heterotrimer of PQBP1, U5-15kD and U5-52kD.
1FQJ	;	2.02	;	CRYSTAL STRUCTURE OF THE HETEROTRIMERIC COMPLEX OF THE RGS DOMAIN OF RGS9, THE GAMMA SUBUNIT OF PHOSPHODIESTERASE AND THE GT/I1 CHIMERA ALPHA SUBUNIT [(RGS9)-(PDEGAMMA)-(GT/I1ALPHA)-(GDP)-(ALF4-)-(MG2+)]
4DL0	;	2.905	;	Crystal Structure of the heterotrimeric EGChead Peripheral Stalk Complex of the Yeast Vacuolar ATPase
4EFA	;	2.8163	;	Crystal Structure of the Heterotrimeric EGChead Peripheral Stalk Complex of the Yeast Vacuolar ATPase - second conformation
5MC9	;	2.13	;	Crystal structure of the heterotrimeric integrin-binding region of laminin-111
2ERJ	;	3.0	;	Crystal structure of the heterotrimeric interleukin-2 receptor in complex with interleukin-2
2IX2	;	2.2	;	Crystal structure of the heterotrimeric PCNA from Sulfolobus solfataricus
5OF3	;	2.906	;	Crystal structure of the heterotrimeric PriSLX primase from S. solfataricus.
5OFN	;	3.005	;	Crystal structure of the heterotrimeric PriSLX primase from S. solfataricus.
3IKO	;	3.2	;	Crystal structure of the heterotrimeric Sec13-Nup145C-Nup84 nucleoporin complex
3WTP	;	2.67	;	Crystal Structure of the heterotypic nucleosome containing human CENP-A and H3.3
1FY9	;	2.2	;	CRYSTAL STRUCTURE OF THE HEXA-SUBSTITUTED MUTANT OF THE MOLECULAR CHAPERONIN GROEL APICAL DOMAIN
1FYA	;	2.2	;	CRYSTAL STRUCTURE OF THE HEXA-SUBSTITUTED MUTANT OF THE MOLECULAR CHAPERONIN GROEL APICAL DOMAIN
7RUR	;	1.8	;	Crystal structure of the hexadecameric form of Rv3208A
2YMK	;	2.49	;	Crystal structure of the hexameric anti-microbial peptide channel dermcidin
2W37	;	2.1	;	CRYSTAL STRUCTURE OF THE HEXAMERIC CATABOLIC ORNITHINE TRANSCARBAMYLASE FROM Lactobacillus hilgardii
1P9M	;	3.65	;	Crystal structure of the hexameric human IL-6/IL-6 alpha receptor/gp130 complex
4D8V	;	2.35	;	Crystal structure of the hexameric purine nucleoside phosphorylase from Bacillus subtilis at pH 4.2
4DA0	;	2.95	;	Crystal structure of the hexameric purine nucleoside phosphorylase from Bacillus subtilis in complex with 2'-deoxyguanosine
4DAN	;	2.56	;	Crystal structure of the hexameric purine nucleoside phosphorylase from Bacillus subtilis in complex with 2-fluoroadenosine
4DAE	;	2.35	;	Crystal structure of the hexameric purine nucleoside phosphorylase from Bacillus subtilis in complex with 6-chloroguanosine
4DA8	;	2.6	;	Crystal structure of the hexameric purine nucleoside phosphorylase from Bacillus subtilis in complex with 8-bromoguanosine
4DA7	;	2.05	;	Crystal structure of the hexameric purine nucleoside phosphorylase from Bacillus subtilis in complex with aciclovir
4DAO	;	2.22	;	Crystal structure of the hexameric purine nucleoside phosphorylase from Bacillus subtilis in complex with adenine
4D9H	;	1.91	;	Crystal structure of the hexameric purine nucleoside phosphorylase from Bacillus subtilis in complex with adenosine
4DA6	;	1.7	;	Crystal structure of the hexameric purine nucleoside phosphorylase from Bacillus subtilis in complex with ganciclovir
4DAB	;	1.85	;	Crystal structure of the hexameric purine nucleoside phosphorylase from Bacillus subtilis in complex with hypoxanthine
4DAR	;	3.15	;	Crystal structure of the hexameric purine nucleoside phosphorylase from Bacillus subtilis in complex with tubercidin
4D98	;	1.7	;	Crystal structure of the hexameric purine nucleoside phosphorylase from Bacillus subtilis in space group H32 at pH 7.5
4D8Y	;	1.61	;	Crystal structure of the hexameric purine nucleoside phosphorylase from Bacillus subtilis in space group P212121 at pH 5.6
4D8X	;	2.65	;	Crystal structure of the hexameric purine nucleoside phosphorylase from Bacillus subtilis in space group P6322 at pH 4.6
1G8Y	;	2.4	;	CRYSTAL STRUCTURE OF THE HEXAMERIC REPLICATIVE HELICASE REPA OF PLASMID RSF1010
5WMF	;	1.9	;	Crystal structure of the Hexameric Ring of Epstein-Barr Virus Nuclear Antigen-1, EBNA1
5DM5	;	2.7	;	Crystal structure of the hexameric thioesterase y2039 from Yersinia pestis
3ECT	;	2.51	;	Crystal Structure of the Hexapeptide-Repeat Containing-Acetyltransferase VCA0836 from Vibrio cholerae
3VU3	;	2.85	;	Crystal structure of the Hfq and catalase HPII complex
1HK9	;	2.15	;	Crystal structure of the Hfq protein from Escherichia coli
1HMY	;	2.5	;	CRYSTAL STRUCTURE OF THE HHAI DNA METHYLTRANSFERASE COMPLEXED WITH S-ADENOSYL-L-METHIONINE
6FDD	;	1.75	;	Crystal Structure of the HHD2 Domain of Whirlin
6FDE	;	1.85	;	Crystal Structure of the HHD2 Domain of Whirlin : 3-helix conformation
6HPC	;	2.26	;	Crystal structure of the HicB antitoxin from E. coli
5J9I	;	1.797	;	Crystal structure of the HigA2 antitoxin C-terminal domain
8A0W	;	2.334	;	Crystal structure of the HigA2 antitoxin in complex with operator DNA
7AWK	;	1.91	;	Crystal structure of the HigB1 toxin mutant K95A from Mycobacterium tuberculosis (Rv1955)
5JA8	;	2.49	;	Crystal structure of the HigB2 toxin in complex with Nb2
5JA9	;	1.849	;	Crystal structure of the HigB2 toxin in complex with Nb6
5MJE	;	2.599	;	Crystal structure of the HigB2 toxin in complex with Nb8
8A0X	;	3.296	;	Crystal structure of the HigB2-HigA2 tetramer in complex with operator DNA
5JAA	;	2.993	;	Crystal structure of the HigBA2 toxin-antitoxin complex
3N23	;	4.6	;	Crystal structure of the high affinity complex between ouabain and the E2P form of the sodium-potassium pump
4GHI	;	1.5	;	Crystal structure of the high affinity heterodimer of HIF2 alpha and ARNT C-terminal PAS domains in complex with a benzoxadiazole antagonist
4XT2	;	1.698	;	Crystal structure of the high affinity heterodimer of HIF2 alpha and ARNT C-terminal PAS domains in complex with a tetrazole-containing antagonist
4GS9	;	1.72	;	Crystal structure of the high affinity heterodimer of HIF2 alpha and ARNT C-terminal PAS domains in complex with an inactive benzoxadiazole antagonist
3H7W	;	1.65	;	Crystal structure of the high affinity heterodimer of HIF2 alpha and ARNT C-terminal PAS domains with the artificial ligand THS017
3H82	;	1.5	;	Crystal structure of the high affinity heterodimer of HIF2 alpha and ARNT C-terminal PAS domains with the artificial ligand THS020
3F1O	;	1.598	;	Crystal structure of the high affinity heterodimer of HIF2 alpha and ARNT C-terminal PAS domains, with an internally-bound artificial ligand
7Q9U	;	2.238	;	Crystal structure of the high affinity KRas mutant PDE6D complex
3W9R	;	1.9	;	Crystal structure of the high-affinity abscisic acid receptor PYL9/RCAR9 bound to ABA
6M97	;	3.03	;	Crystal structure of the high-affinity copper transporter Ctr1
6M98	;	3.21	;	Crystal structure of the high-affinity copper transporter Ctr1 in complex with Cu(I)
1G1O	;	2.3	;	CRYSTAL STRUCTURE OF THE HIGHLY AMYLOIDOGENIC TRANSTHYRETIN MUTANT TTR G53S/E54D/L55S
2QEL	;	2.29	;	Crystal structure of the highly amyloidogenic transthyretin mutant TTR G53S/E54D/L55S- heated protein
1LNT	;	1.7	;	Crystal Structure of the Highly Conserved RNA Internal Loop of SRP
100D	;	1.9	;	CRYSTAL STRUCTURE OF THE HIGHLY DISTORTED CHIMERIC DECAMER R(C)D(CGGCGCCG)R(G)-SPERMINE COMPLEX-SPERMINE BINDING TO PHOSPHATE ONLY AND MINOR GROOVE TERTIARY BASE-PAIRING
5V6N	;	3.355	;	Crystal Structure of the highly open channel-stabilized mutant C27S + K33C + I9'A + N21'C of GLIC under reducing conditions.
5V6O	;	3.121	;	Crystal Structure of the highly open channel-stabilized mutant G-2'I + I9'A of GLIC
2WMM	;	2.3	;	Crystal structure of the hinge domain of MukB
8EZR	;	1.95	;	Crystal structure of the HipS(Lp)-HipT(Lp) complex from Legionella pneumophila, native protein
8EZS	;	2.47	;	Crystal structure of the HipS(Lp)-HipT(Lp) complex from Legionella pneumophila, Sel-met protein
5MK3	;	2.0	;	Crystal structure of the His Domain Protein Tyrosine Phosphatase (HD-PTP/PTPN23) Bro 1 domain (CHMP4C peptide complex structure)
5MJZ	;	1.867	;	Crystal structure of the His Domain Protein Tyrosine Phosphatase (HD-PTP/PTPN23) Bro1 domain (Apo structure)
5MK1	;	2.5	;	Crystal structure of the His Domain Protein Tyrosine Phosphatase (HD-PTP/PTPN23) Bro1 domain (CHMP4A peptide complex structure)
5MK2	;	1.7	;	Crystal structure of the His Domain Protein Tyrosine Phosphatase (HD-PTP/PTPN23) Bro1 domain (CHMP4B peptide complex structure)
5MK0	;	1.765	;	Crystal structure of the His Domain Protein Tyrosine Phosphatase (HD-PTP/PTPN23) Bro1 domain (Endofin peptide complex)
5MJY	;	2.25	;	Crystal structure of the His Domain Protein Tyrosine Phosphatase (HD-PTP/PTPN23) Bro1 domain (SARA complex structure)
3FLC	;	1.85	;	Crystal structure of the His-tagged H232R mutant of glycerol kinase from Enterococcus casseliflavus with glycerol
1KWB	;	2.0	;	Crystal structure of the His145Ala mutant of 2,3-dihydroxybipheny dioxygenase (BphC)
2H1W	;	2.6	;	Crystal structure of the His183Ala mutant variant of Bacillus subtilis ferrochelatase
2Q3J	;	2.39	;	Crystal structure of the His183Ala variant of Bacillus subtilis ferrochelatase in complex with N-Methyl Mesoporphyrin
2AC4	;	2.1	;	Crystal structure of the His183Cys mutant variant of Bacillus subtilis Ferrochelatase
4K9M	;	1.15	;	Crystal Structure of the His281Asn mutant of Benzoylformate Decarboxylase from Pseudomonas putida
4K9L	;	1.649	;	Crystal Structure of the His281Thr mutant of Benzoylformate Decarboxylase from Pseudomonas putida
4K9K	;	1.301	;	Crystal Structure of the His281Tyr mutant of Benzoylformate Decarboxylase from Pseudomonas putida
4K9P	;	2.244	;	Crystal Structure of the His281Tyr/Ala460Ile Double Mutant of Benzoylformate Decarboxylase from Pseudomonas putida
4JU9	;	1.124	;	Crystal Structure of the His70Leu mutant of Benzoylformate Decarboxylase from Pseudomonas putida
4JU8	;	1.251	;	Crystal Structure of the His70Phe mutant of Benzoylformate Decarboxylase from Pseudomonas putida
4JUA	;	1.15	;	Crystal Structure of the His70Ser mutant of Benzoylformate Decarboxylase from Pseudomonas putida
4JUB	;	1.901	;	Crystal Structure of the His70Thr mutant of Benzoylformate Decarboxylase from Pseudomonas putida
8F71	;	3.19	;	Crystal structure of the histidine kinase domain of bacteriophytochrome RpBphP2
6JIS	;	1.82	;	Crystal structure of the histidine racemase CntK in cobalt and nickel transporter system of staphylococcus aureus
1ROC	;	1.5	;	Crystal structure of the histone deposition protein Asf1
1Q9C	;	3.21	;	Crystal Structure of the Histone domain of Son of Sevenless
3KSY	;	3.178	;	Crystal structure of the Histone domain, DH-PH unit, and catalytic unit of the Ras activator Son of Sevenless (SOS)
1F1E	;	1.37	;	CRYSTAL STRUCTURE OF THE HISTONE FROM METHANOPYRUS KANDLERI
1B67	;	1.48	;	CRYSTAL STRUCTURE OF THE HISTONE HMFA FROM METHANOTHERMUS FERVIDUS
1HTA	;	1.55	;	CRYSTAL STRUCTURE OF THE HISTONE HMFA FROM METHANOTHERMUS FERVIDUS
1A7W	;	1.55	;	CRYSTAL STRUCTURE OF THE HISTONE HMFB FROM METHANOTHERMUS FERVIDUS
1H3I	;	2.1	;	Crystal structure of the Histone Methyltransferase SET7/9
4QOZ	;	2.304	;	Crystal structure of the histone mRNA stem-loop, stem-loop binding protein (phosphorylated), and 3'hExo ternary complex
1HQ3	;	2.15	;	CRYSTAL STRUCTURE OF THE HISTONE-CORE-OCTAMER IN KCL/PHOSPHATE
6V2F	;	2.0	;	Crystal structure of the HIV capsid hexamer bound to the small molecule long-acting inhibitor, GS-6207
2OT5	;	1.8	;	Crystal structure of the HIV gp41 core with the enfuvirtide resistance mutation N43D
3DCG	;	2.4	;	Crystal Structure of the HIV Vif BC-box in Complex with Human ElonginB and ElonginC
4TVP	;	3.1	;	Crystal Structure of the HIV-1 BG505 SOSIP.664 Env Trimer Ectodomain, Comprising Atomic-Level Definition of Pre-Fusion gp120 and gp41, in Complex with Human Antibodies PGT122 and 35O22
3D0L	;	2.35	;	Crystal structure of the HIV-1 broadly neutralizing antibody 2F5 in complex with the gp41 FP-MPER Hyb3K construct 514GIGALFLGFLGAAGS528KK-Ahx-655KNEQELLELDKWASLWN671
3DRQ	;	2.0	;	Crystal structure of the HIV-1 broadly neutralizing antibody 2F5 in complex with the gp41 FP-MPER Hyb3K construct 514GIGALFLGFLGAAGS528KK-Ahx-655KNEQELLELDKWASLWN671 soaked in PEG/2-propanol solution
3DRT	;	3.3	;	Crystal structure of the HIV-1 broadly neutralizing antibody 2F5 in complex with the gp41 scrambledFP-MPER scrHyb3K construct GIGAFGLLGFLAAGSKK-Ahx-K656NEQELLELDKWASLWN671
3EGS	;	3.6	;	Crystal structure of the HIV-1 broadly neutralizing antibody 2F5 in complex with the gp41 scrambledFP-MPER scrHyb3K construct GIGAFGLLGFLAAGSKK-Ahx-K656NEQELLELDKWASLWN671 soaked in ammonium sulfate
2XV6	;	1.89	;	Crystal structure of the HIV-1 capsid protein C-terminal domain (146- 220) in complex with a camelid VHH.
2XT1	;	1.32	;	Crystal structure of the HIV-1 capsid protein C-terminal domain (146- 231) in complex with a camelid VHH.
2XXM	;	1.65	;	Crystal structure of the HIV-1 capsid protein C-terminal domain in complex with a camelid VHH and the CAI peptide.
3DRO	;	3.9	;	Crystal structure of the HIV-1 Cross Neutralizing Antibody 2F5 in complex with gp41 Peptide ELLELDKWASLWN grown in ammonium sulfate
3IDI	;	2.1	;	Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 Fab' fragment in complex with gp41 Peptide ALDKWNQ
3IDM	;	2.24	;	Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 Fab' fragment in complex with gp41 Peptide analog ELD(Nrg)WAS
3IDJ	;	2.24	;	Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 Fab' fragment in complex with gp41 Peptide analog ELD(Orn)WAS
3IDN	;	2.25	;	Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 Fab' fragment in complex with gp41 Peptide analog ELD(Paf)WAS
1U8H	;	2.1	;	Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ALDKWAS
3IDG	;	1.86	;	Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ALDKWD
1U92	;	2.24	;	Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide Analog E-[Dap]-DKWQS (cyclic)
1U91	;	2.24	;	Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide Analog ENDKW-[Dap]-S (cyclic)
1U93	;	2.37	;	Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide Analog EQDKW-[Dap]-S (cyclic)
1U8L	;	2.6	;	Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide DLDRWAS
1U8P	;	3.23	;	Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ECDKWCS
1U95	;	2.24	;	Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ELDHWAS
1U8N	;	2.56	;	Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ELDKFAS
1U8O	;	3.02	;	Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ELDKHAS
1U8J	;	2.24	;	Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ELDKWAG
1U8I	;	2.0	;	Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ELDKWAN
2PW2	;	2.55	;	Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ELDKWKSL
2PW1	;	2.6	;	Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ELDKWNSL
1U8M	;	2.4	;	Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ELDKYAS
1U8Q	;	2.24	;	Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ELEKWAS
2P8L	;	2.44	;	Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ELLELDKWASLWN
2P8M	;	2.7	;	Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ELLELDKWASLWN in new crystal form
1U8K	;	2.24	;	Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide LELDKWASL
2P8P	;	2.7	;	Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide LELDKWASLW[N-Ac]
3D0V	;	2.05	;	Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide LLELDKWASLW
462D	;	2.3	;	CRYSTAL STRUCTURE OF THE HIV-1 GENOMIC RNA DIMERIZATION INITIATION SITE
4B50	;	1.3	;	Crystal structure of the HIV-1 gp41 MPER-specific llama VHH 2H10
1EXQ	;	1.6	;	CRYSTAL STRUCTURE OF THE HIV-1 INTEGRASE CATALYTIC CORE DOMAIN
4OJR	;	1.82	;	Crystal Structure of the HIV-1 Integrase catalytic domain with GSK1264
3L3U	;	1.4	;	Crystal structure of the HIV-1 integrase core domain to 1.4A
2XI1	;	3.5	;	Crystal structure of the HIV-1 Nef sequenced from a patient's sample
4NGH	;	2.68	;	Crystal structure of the HIV-1 neutralizing antibody 4E10 Fab fragment in complex with a hydrocarbon-stapled peptide containing the 4e10 epitope on gp41 and a tethered phosphate moiety.
4NHC	;	2.912	;	Crystal structure of the HIV-1 neutralizing antibody 4E10 Fab fragment in complex with a hydrocarbon-stapled peptide containing the 4e10 epitope on gp41.
2CMR	;	2.0	;	Crystal structure of the HIV-1 neutralizing antibody D5 Fab bound to the gp41 inner-core mimetic 5-helix
3LPH	;	2.5	;	Crystal structure of the HIV-1 Rev dimer
3NBZ	;	2.8	;	Crystal structure of the HIV-1 Rev NES-CRM1-RanGTP nuclear export complex (crystal I)
3NC0	;	2.9	;	Crystal structure of the HIV-1 Rev NES-CRM1-RanGTP nuclear export complex (crystal II)
3IS9	;	2.55	;	Crystal structure of the HIV-1 reverse transcriptase (RT) in complex with the alkenyldiarylmethane (ADAM) Non-nucleoside RT Inhibitor dimethyl 3,3'-(6-methoxy-6-oxohex-1-ene-1,1-diyl)bis(5-cyano-6-methoxybenzoate).
3ITH	;	2.8	;	Crystal structure of the HIV-1 reverse transcriptase bound to a 6-vinylpyrimidine inhibitor
4IOU	;	2.751	;	Crystal structure of the HIV-1 Vif binding, catalytically active domain of APOBEC3F
3NZ8	;	2.7	;	Crystal structure of the HIV-2 neutralizing Fab fragment 7C8
2XRA	;	2.3	;	crystal structure of the HK20 Fab in complex with a gp41 mimetic 5- Helix
6Z6D	;	2.2	;	Crystal structure of the HK97 bacteriophage large terminase
6Z6E	;	1.4	;	Crystal structure of the HK97 bacteriophage small terminase
3SKO	;	1.6	;	Crystal structure of the HLA-B8-A66-FLR, mutant A66 of the HLA B8
3SKM	;	1.8	;	Crystal structure of the HLA-B8FLRGRAYVL, mutant G8V of the FLR peptide
7F09	;	2.6	;	Crystal structure of the HLH-Lz domain of human TFE3
5BNH	;	1.7	;	Crystal structure of the HLTF HIRAN domain with a ssDNA fragment
2WV1	;	2.3	;	CRYSTAL STRUCTURE OF THE HLYIIR MUTANT PROTEIN WITH RESIDUES 169-186 SUBSTITUTED BY A LINKER CONTAINING TWO THROMBIN SITES
2JK3	;	2.2	;	CRYSTAL STRUCTURE OF THE HLYIIR MUTANT PROTEIN WITH RESIDUES 169-186 SUBSTITUTED BY GSSGSSG LINKER
2JJ7	;	2.1	;	Crystal structure of the HlyIIR mutant protein with residues 170-185 substituted by alanine
6L34	;	1.996	;	Crystal structure of the HMG domain of human FACT complex subunit SSRP1
7M5W	;	2.95	;	Crystal structure of the HMG-C1 domain of human capicua bound to DNA
1YDN	;	2.3	;	Crystal Structure of the HMG-CoA Lyase from Brucella melitensis, Northeast Structural Genomics Target LR35.
4E44	;	2.1	;	Crystal structure of the hMHF1/hMHF2 Histone-Fold Tetramer
4E45	;	2.0	;	Crystal structure of the hMHF1/hMHF2 Histone-Fold Tetramer in Complex with Fanconi Anemia Associated Helicase hFANCM
3MOO	;	1.71	;	Crystal structure of the HmuO, heme oxygenase from Corynebacterium diphtheriae, in complex with azide-bound verdoheme
2ODL	;	1.92	;	Crystal structure of the HMW1 secretion domain from Haemophilus influenzae
5CO8	;	2.4	;	Crystal structure of the Holliday junction-resolving enzyme GEN1 (WT) in complex with product DNA and Mg2+ ion
5CNQ	;	2.602	;	Crystal structure of the Holliday junction-resolving enzyme GEN1 (WT) in complex with product DNA, Mg2+ and Mn2+ ions
5U6G	;	2.6	;	Crystal Structure of the holo Domain-Swapped Dimer mutant Q108K:K40D Human Cellular Retinol Binding Protein II bound with all trans retinal
5JH2	;	1.72	;	Crystal structure of the holo form of AKR4C7 from maize
2E7P	;	2.1	;	Crystal structure of the holo form of glutaredoxin C1 from populus tremula x tremuloides
3RHC	;	2.4	;	Crystal structure of the holo form of glutaredoxin C5 from Arabidopsis thaliana
7CCX	;	1.84	;	Crystal structure of the holo form of human hydroxymethylbilane synthase
8KI1	;	1.9	;	Crystal structure of the holo form of the hemophore HasA from Pseudomonas protegens Pf-5
2W2L	;	2.5	;	Crystal structure of the holo forms of Rhodotorula graminis D- mandelate dehydrogenase at 2.5A.
4AH3	;	1.57	;	Crystal structure of the holo omega-transaminase from Chromobacterium violaceum
6MLB	;	2.15	;	Crystal structure of the holo retinal-bound domain-swapped dimer Q108K:K40L:T51F mutant of human cellular retinol binding protein II
6E6L	;	2.08	;	Crystal structure of the holo retinal-bound domain-swapped dimer Q108K:K40L:T51F:Y60A mutant of human cellular retinol binding protein II
6E7M	;	2.7	;	Crystal structure of the holo retinal-bound domain-swapped dimer Q108K:T51D:A28C mutant of human Cellular Retinol Binding Protein II
6MCU	;	2.572	;	Crystal structure of the holo retinal-bound domain-swapped dimer Q108K:T51D:A28H mutant of human Cellular Retinol Binding Protein II
7PDI	;	1.69	;	Crystal structure of the holo-acyl carrier protein (holo-AcpP) from Pseudomonas putida KT2440. Produced as an apo/holo mixture.
3GWM	;	1.7	;	Crystal structure of the holo-[Acyl-Carrier-Protein] Synthase (ACPS) from Mycobacterium smegmatis
3H7Q	;	2.25	;	Crystal structure of the holo-[Acyl-Carrier-Protein] Synthase (ACPS) from Mycobacterium tuberculosis
3N6R	;	3.2	;	CRYSTAL STRUCTURE OF the holoenzyme of PROPIONYL-COA CARBOXYLASE (PCC)
1MIJ	;	2.05	;	Crystal Structure of the Homeo-prospero Domain of D. melanogaster Prospero
3K2A	;	1.95	;	Crystal structure of the homeobox domain of human homeobox protein Meis2
8EJO	;	2.67	;	Crystal structure of the homeodomain of Platypus sDUX in complex with DNA
8EJP	;	2.174	;	Crystal structure of the homeodomain of Platypus sDUX in complex with DNA containing 5-Bromouracil
1DDV	;	1.9	;	CRYSTAL STRUCTURE OF THE HOMER EVH1 DOMAIN WITH BOUND MGLUR PEPTIDE
5A77	;	2.5	;	Crystal structure of the homing endonuclease I-CvuI in complex with I- CreI target (C1221) in the presence of 2 mM Mg revealing DNA cleaved
5A78	;	2.5	;	Crystal structure of the homing endonuclease I-CvuI in complex with I- CreI target (C1221) in the presence of 2 mM Mg revealing DNA not cleaved
5A72	;	2.6	;	Crystal structure of the homing endonuclease I-CvuI in complex with its target (Sro1.3) in the presence of 2 mM Ca
5A74	;	2.5	;	Crystal structure of the homing endonuclease I-CvuI in complex with its target (Sro1.3) in the presence of 2 mM Mn
1M5X	;	2.25	;	Crystal structure of the homing endonuclease I-MsoI bound to its DNA substrate
2FQN	;	2.3	;	Crystal structure of the Homo sapiens cytoplasmic ribosomal decoding A site
2G5K	;	2.8	;	Crystal Structure of the Homo sapiens Cytoplasmic Ribosomal Decoding Site complexed with Apramycin
2O3V	;	2.8	;	Crystal Structure of the Homo sapiens Cytoplasmic Ribosomal Decoding Site complexed with paromamine derivative NB33
5XZ1	;	3.008	;	Crystal structure of the Homo Sapiens cytoplasmic ribosomal decoding site in complex with G418
5Z71	;	2.5	;	Crystal structure of the Homo Sapiens cytoplasmic ribosomal decoding site in complex with G418 (P21212 form)
2O3Y	;	2.7	;	Crystal Structure of the Homo sapiens Cytoplasmic Ribosomal Decoding Site in Presence of Paromamine Derivative NB30
2O3W	;	2.8	;	Crystal Structure of the Homo sapiens Cytoplasmic Ribosomal Decoding Site in presence of paromomycin
3BNN	;	2.0	;	Crystal Structure of the Homo sapiens Mitochondrial Ribosomal Decoding Site
3BNP	;	2.7	;	Crystal Structure of the Homo sapiens Mitochondrial Ribosomal Decoding Site (A1555G Mutant)
3BNS	;	1.9	;	Crystal Structure of the Homo sapiens Mitochondrial Ribosomal Decoding Site (A1555G mutant, Br-derivative)
3BNO	;	2.35	;	Crystal Structure of the Homo sapiens Mitochondrial Ribosomal Decoding Site (Br-derivative)
3BNR	;	2.1	;	Crystal Structure of the Homo sapiens Mitochondrial Ribosomal Decoding Site in the presence of nonspecifically bound paromomycin (A1555G mutant, Br-derivative)
3BNQ	;	2.0	;	Crystal Structure of the Homo sapiens Mitochondrial Ribosomal Decoding Site in the Presence of SrCl2 (A1555G mutant, Br-derivative)
3BNT	;	2.3	;	Crystal Structure of the Homo sapiens Mitochondrial Ribosomal Decoding Site in the Presence of [Co(NH3)6]Cl3 (A1555G mutant, Br-derivative)
7MW1	;	3.4	;	Crystal structure of the Homo sapiens NUP93-NUP53 complex (NUP93 residues 174-819; NUP53 residues 84-150)
5DMN	;	2.892	;	Crystal Structure of the Homocysteine Methyltransferase MmuM from Escherichia coli, Apo form
5DMM	;	1.779	;	Crystal Structure of the Homocysteine Methyltransferase MmuM from Escherichia coli, Metallated form
5DML	;	2.452	;	Crystal Structure of the Homocysteine Methyltransferase MmuM from Escherichia coli, Oxidized form
8DPA	;	1.84	;	Crystal structure of the homodimeric AvrM14-B Nudix hydrolase effector from Melampsora lini
1OZ0	;	2.5	;	CRYSTAL STRUCTURE OF THE HOMODIMERIC BIFUNCTIONAL TRANSFORMYLASE AND CYCLOHYDROLASE ENZYME AVIAN ATIC IN COMPLEX WITH A MULTISUBSTRATE ADDUCT INHIBITOR BETA-DADF.
1M9N	;	1.93	;	CRYSTAL STRUCTURE OF THE HOMODIMERIC BIFUNCTIONAL TRANSFORMYLASE AND CYCLOHYDROLASE ENZYME AVIAN ATIC IN COMPLEX WITH AICAR AND XMP AT 1.93 ANGSTROMS.
2WTY	;	2.9	;	Crystal structure of the homodimeric MafB in complex with the T-MARE binding site
8P5S	;	2.459	;	Crystal structure of the homohexameric 2-oxoglutarate dehydrogenase OdhA from Corynebacterium glutamicum
2PPQ	;	2.0	;	Crystal structure of the homoserine kinase from Agrobacterium tumefaciens
4PLP	;	1.49	;	Crystal Structure of the Homospermidine Synthase (HSS) from Blastochloris viridis in Complex with NAD
4XQ9	;	1.6	;	Crystal Structure of the Homospermidine Synthase (HSS) from Blastochloris viridis in Complex with NAD
4XQC	;	1.27	;	Crystal Structure of the Homospermidine Synthase (HSS) from Blastochloris viridis in Complex with NAD and 1,3-diaminopropane.
4XR4	;	1.626	;	Crystal Structure of the Homospermidine Synthase (HSS) from Blastochloris viridis in Complex with NAD and Agmatine
4TVB	;	1.689	;	Crystal Structure of the Homospermidine Synthase (HSS) from Blastochloris viridis in Complex with NAD, Putrescine and sym-Homospermidine
6Y87	;	2.15	;	Crystal Structure of the Homospermidine Synthase (HSS) from Pseudomonas aeruginosa in Complex with NAD and PUT
6S6G	;	1.6	;	Crystal Structure of the Homospermidine Synthase (HSS) variant E117Q from Blastochloris viridis in Complex with NAD
6S49	;	1.69	;	Crystal Structure of the Homospermidine Synthase (HSS) variant E210A from Blastochloris viridis in Complex with NAD
6S3X	;	1.72	;	Crystal Structure of the Homospermidine Synthase (HSS) variant E210Q from Blastochloris viridis in Complex with NAD
4XQG	;	1.417	;	Crystal Structure of the Homospermidine Synthase (HSS) variant E237Q from Blastochloris viridis in Complex with NAD.
4XQE	;	1.3	;	Crystal Structure of the Homospermidine Synthase (HSS) variant H296S from Blastochloris viridis in Complex with NAD and Agmatine
4XRG	;	1.3	;	Crystal Structure of the Homospermidine Synthase (HSS) variant H296S from Blastochloris viridis in Complex with NAD, Putrescine and Agmatine
6S65	;	1.75	;	Crystal Structure of the Homospermidine Synthase (HSS) variant N135F from Blastochloris viridis in Complex with NAD
6S72	;	1.87	;	Crystal Structure of the Homospermidine Synthase (HSS) variant W229A from Blastochloris viridis in Complex with NAD and PUT
6SEP	;	2.2	;	Crystal Structure of the Homospermidine Synthase (HSS) variant W229E from Blastochloris viridis in Complex with NAD
6S4D	;	1.8	;	Crystal Structure of the Homospermidine Synthase (HSS) variant W229F from Blastochloris viridis in Complex with NAD
2PH5	;	2.5	;	Crystal structure of the homospermidine synthase hss from Legionella pneumophila in complex with NAD, Northeast Structural Genomics Target LgR54
1RER	;	3.2	;	Crystal structure of the homotrimer of fusion glycoprotein E1 from Semliki Forest Virus.
4YNL	;	2.1	;	Crystal structure of the hood domain of Anabaena HetR in complex with the hexapeptide ERGSGR derived from PatS
6AW2	;	2.68	;	Crystal structure of the HopQ-CEACAM1 complex
6AW3	;	2.66	;	Crystal structure of the HopQ-CEACAM3 L44Q complex
6AVZ	;	2.05	;	Crystal structure of the HopQ-CEACAM3 WT complex
8OEK	;	2.22	;	Crystal structure of the HormR-GAIN domains of adhesion GPCR ADGRB2 (BAI2) in the uncleaved state
6VC0	;	2.746	;	Crystal structure of the horse MLKL pseudokinase domain
2D4E	;	2.1	;	Crystal Structure of the HpcC from Thermus Thermophilus HB8
1WZO	;	1.9	;	Crystal Structure of the HpcE from Thermus Thermophilus HB8
1J7J	;	2.3	;	Crystal Structure of the HPRT from Salmonella typhimurium
1F9F	;	1.9	;	CRYSTAL STRUCTURE OF THE HPV-18 E2 DNA-BINDING DOMAIN
4XR8	;	2.25	;	Crystal structure of the HPV16 E6/E6AP/p53 ternary complex at 2.25 A resolution
7AX8	;	2.15	;	Crystal structure of the hPXR-LBD in apo form (P43212 SG)
7AXH	;	2.55	;	Crystal structure of the hPXR-LBD in complex with alpha-zearalanol
7AX9	;	2.25	;	Crystal structure of the hPXR-LBD in complex with cis-chlordane
7AXA	;	2.26	;	Crystal structure of the hPXR-LBD in complex with clotrimazole
7AXB	;	2.55	;	Crystal structure of the hPXR-LBD in complex with endosulfan
7AXI	;	2.15	;	Crystal structure of the hPXR-LBD in complex with estradiol and cis-chlordane
7AXJ	;	2.3	;	Crystal structure of the hPXR-LBD in complex with estradiol and clotrimazole
7AXK	;	2.0	;	Crystal structure of the hPXR-LBD in complex with estradiol and endosulfan
7AXL	;	2.5	;	Crystal structure of the hPXR-LBD in complex with estradiol and heptachlor endo-epoxide
7AXC	;	2.05	;	Crystal structure of the hPXR-LBD in complex with ferutinine
7AXD	;	2.65	;	Crystal structure of the hPXR-LBD in complex with fipronil
7AXE	;	1.9	;	Crystal structure of the hPXR-LBD in complex with oxadiazon
7AXF	;	2.45	;	Crystal structure of the hPXR-LBD in complex with pretilachlor
4X1F	;	2.0	;	Crystal structure of the hPXR-LBD in complex with the synthetic estrogen 17alpha-ethinylestradiol
4X1G	;	2.25	;	Crystal structure of the hPXR-LBD in complex with the synthetic estrogen 17alpha-ethinylestradiol and the pesticide trans-nonachlor
7AXG	;	2.7	;	Crystal structure of the hPXR-LBD in complex with tributyltin
4XAO	;	2.58	;	Crystal structure of the hPXR-LBD obtained in presence of the pesticide trans-nonachlor
6BK4	;	1.8	;	Crystal structure of the HR-1 domain of Drosophila caprin in the P212121 space group
4WBE	;	2.05	;	Crystal structure of the HR-1 domain of human caprin-1 in the C121 space group
4WBP	;	2.5	;	Crystal structure of the HR-1 domain of human caprin-1 in the P3121 space group
2E1E	;	2.3	;	Crystal structure of the HRDC Domain of Human Werner Syndrome Protein, WRN
2E1F	;	2.0	;	Crystal structure of the HRDC Domain of Human Werner Syndrome Protein, WRN
7WKZ	;	2.992	;	Crystal structure of the HSA complex with mycophenolate and aripiprazole
7WLF	;	2.4	;	Crystal structure of the HSA Fe complex
3AFF	;	2.0	;	Crystal structure of the HsaA monooxygenase from M. tuberculosis
3AFE	;	2.5	;	Crystal structure of the HsaA monooxygenase from M.tuberculosis
2ZYQ	;	2.0	;	Crystal structure of the HsaC extradiol dioxygenase from M. tuberculosis
2ZI8	;	2.2	;	Crystal structure of the HsaC extradiol dioxygenase from M. tuberculosis in complex with 3,4-dihydroxy-9,10-seconandrost-1,3,5(10)-triene-9,17-dione (DHSA)
3DXF	;	2.2	;	Crystal structure of the HSCARG R37A mutant
3E5M	;	2.7	;	Crystal structure of the HSCARG Y81A mutant
2W00	;	2.6	;	Crystal structure of the HsdR subunit of the EcoR124I restriction enzyme in complex with ATP
6H2J	;	2.6	;	Crystal structure of the HsdR subunit of the EcoR124I restriction enzyme with the C-terminal domain
1G3I	;	3.41	;	CRYSTAL STRUCTURE OF THE HSLUV PROTEASE-CHAPERONE COMPLEX
5W6X	;	2.1	;	Crystal structure of the HsNUDT16 in complex with Mg+2 and ADP-ribose
5U2L	;	1.6555	;	Crystal structure of the Hsp104 N-terminal domain from Candida albicans
5U2U	;	2.541	;	Crystal structure of the Hsp104 N-terminal domain from Saccharomyces cerevisiae
1I7F	;	2.7	;	CRYSTAL STRUCTURE OF THE HSP33 DOMAIN WITH CONSTITUTIVE CHAPERONE ACTIVITY
8OXU	;	2.94	;	Crystal Structure of the Hsp90-LA1011 Complex
3GLA	;	1.64	;	Crystal Structure of the hspA from Xanthomonas axonopodis
3GT6	;	2.15	;	Crystal Structure of the hspA from Xanthomonas axonopodis
3GUF	;	2.28	;	Crystal Structure of the hspA from Xanthomonas axonopodis
1XQR	;	2.1	;	Crystal structure of the HspBP1 core domain
1XQS	;	2.9	;	Crystal structure of the HspBP1 core domain complexed with the fragment of Hsp70 ATPase domain
4IFS	;	1.93	;	Crystal structure of the hSSRP1 Middle domain
7BCA	;	2.8	;	Crystal structure of the HTH DNA binding protein ArdK from R388 plasmid bound to a direct-repeat DNA element
7BCB	;	2.8	;	Crystal structure of the HTH DNA binding protein ArdK from R388 plasmid bound to IR3 DNA
7BBQ	;	3.0	;	Crystal structure of the HTH DNA binding protein ArdK from R388 plasmid. Apo form.
2PZD	;	2.75	;	Crystal Structure of the HtrA2/Omi PDZ Domain Bound to a Phage-Derived Ligand (WTMFWV)
2P3W	;	1.7	;	Crystal Structure of the HtrA3 PDZ Domain Bound to a Phage-Derived Ligand (FGRWV)
2J2I	;	1.9	;	Crystal Structure of the humab PIM1 in complex with LY333531
6SY1	;	1.87	;	Crystal structure of the human 2-oxoadipate dehydrogenase DHTKD1 (E1)
2W2I	;	2.1	;	Crystal structure of the human 2-oxoglutarate oxygenase LOC390245
5VYC	;	6.0	;	Crystal structure of the human 40S ribosomal subunit in complex with DENR-MCT-1.
5NVN	;	1.9	;	Crystal structure of the human 4EHP-4E-BP1 complex
5NVK	;	2.9	;	Crystal structure of the human 4EHP-GIGYF1 complex
5NVL	;	2.3	;	Crystal structure of the human 4EHP-GIGYF2 complex
5NVM	;	2.0	;	Crystal structure of the human 4EHP-GIGYF2 complex lacking the auxiliary sequences
3GDQ	;	1.8	;	Crystal structure of the human 70kDa heat shock protein 1-like ATPase domain in complex with ADP and inorganic phosphate
3JXU	;	2.14	;	Crystal structure of the human 70kDa heat shock protein 1A (Hsp70-1) ATPase domain in complex with ADP and inorganic phosphate
3I33	;	1.3	;	Crystal structure of the human 70kDa heat shock protein 2 (Hsp70-2) ATPase domain in complex with ADP and inorganic phosphate
3IUC	;	2.4	;	Crystal structure of the human 70kDa heat shock protein 5 (BiP/GRP78) ATPase domain in complex with ADP
3FE1	;	2.2	;	Crystal structure of the human 70kDa heat shock protein 6 (Hsp70B') ATPase domain in complex with ADP and inorganic phosphate
1EBM	;	2.1	;	CRYSTAL STRUCTURE OF THE HUMAN 8-OXOGUANINE GLYCOSYLASE (HOGG1) BOUND TO A SUBSTRATE OLIGONUCLEOTIDE
5AN4	;	1.6	;	Crystal structure of the human 8-oxoguanine glycosylase (OGG1) processed with the CrystalDirect automated mounting and cryo-cooling technology
1EWN	;	2.1	;	CRYSTAL STRUCTURE OF THE HUMAN AAG DNA REPAIR GLYCOSYLASE COMPLEXED WITH 1,N6-ETHENOADENINE-DNA
1F4R	;	2.4	;	CRYSTAL STRUCTURE OF THE HUMAN AAG DNA REPAIR GLYCOSYLASE COMPLEXED WITH 1,N6-ETHENOADENINE-DNA
1F6O	;	2.4	;	CRYSTAL STRUCTURE OF THE HUMAN AAG DNA REPAIR GLYCOSYLASE COMPLEXED WITH DNA
1FJ2	;	1.5	;	Crystal structure of the human acyl protein thioesterase 1 at 1.5 A resolution
5UEN	;	3.2	;	Crystal structure of the human adenosine A1 receptor A1AR-bRIL in complex with the covalent antagonist DU172 at 3.2A resolution
8WDT	;	3.34	;	Crystal structure of the human adenosine A2A receptor in complex with photoresponsive ligand photoNECA(blue)
7RTG	;	2.591	;	Crystal Structure of the Human Adenosine Deaminase 1
3EXV	;	1.45	;	Crystal structure of the human Adenovirus type 11 fiber knob
3F0Y	;	1.8	;	Crystal structure of the human Adenovirus type 14 fiber knob
3L88	;	2.5	;	Crystal structure of the human Adenovirus type 21 fiber knob
3EXW	;	1.75	;	Crystal structure of the human Adenovirus type 7 fiber knob
6KS0	;	2.79	;	Crystal structure of the human adiponectin receptor 1
6KRZ	;	3.05	;	Crystal structure of the human adiponectin receptor 1 D208A mutant
6KS1	;	2.4	;	Crystal structure of the human adiponectin receptor 2
1E0F	;	3.1	;	Crystal structure of the human alpha-thrombin-haemadin complex: an exosite II-binding inhibitor
7B6W	;	2.873	;	Crystal structure of the human alpha1B adrenergic receptor in complex with inverse agonist (+)-cyclazosin
1XOW	;	1.8	;	Crystal structure of the human androgen receptor ligand binding domain bound with an androgen receptor NH2-terminal peptide, AR20-30, and R1881
1XQ3	;	2.25	;	Crystal structure of the human androgen receptor ligand binding domain bound with R1881
2AO6	;	1.89	;	Crystal structure of the human androgen receptor ligand binding domain bound with TIF2(iii) 740-753 peptide and R1881
2OZ7	;	1.8	;	Crystal structure of the human androgen receptor T877A mutant ligand-binding domain with cyproterone acetate
4NJ8	;	1.6	;	Crystal structure of the human ANKS3 SAM Domain L52A mutant
4NL9	;	1.5	;	Crystal structure of the human Anks3-SAM/Anks6-SAM heterodimer
3PH9	;	1.83	;	Crystal structure of the human anterior gradient protein 3
3KMN	;	1.8	;	Crystal Structure of the Human Apo GST Pi C47S/Y108V Double Mutant
3VM8	;	3.0	;	Crystal structure of the human APOBEC3C having HIV-1 Vif-binding interface
3VOW	;	2.15	;	Crystal Structure of the Human APOBEC3C having HIV-1 Vif-binding Interface
6TN7	;	1.67	;	Crystal structure of the human Arc C-lobe
6TNQ	;	1.3	;	Crystal structure of the human Arc N-lobe bound to repeat 4 from GKAP
6TQ0	;	1.95	;	Crystal structure of the human Arc N-lobe bound to repeat peptide 5 from GKAP
6TNO	;	1.9	;	Crystal structure of the human Arc N-lobe bound to stargazin
1K62	;	2.65	;	Crystal Structure of the Human Argininosuccinate Lyase Q286R Mutant
5EWN	;	2.602	;	Crystal structure of the human astrovirus 1 capsid protein core domain at 2.6 A resolution
5EWO	;	0.95	;	Crystal structure of the human astrovirus 1 capsid protein spike domain at 0.95-A resolution
5KOU	;	1.867	;	Crystal structure of the human astrovirus 2 capsid protein spike domain at 1.87-A resolution
5KOV	;	3.245	;	Crystal structure of the human astrovirus 2 capsid protein spike in complex with a single chain variable fragment of an astrovirus neutralizing antibody at 3.24-A resolution
5I30	;	1.9	;	Crystal structure of the human astrovirus 2 neutralizing monoclonal antibody PL-2 Fab fragment at 1.9 A resolution
5W1N	;	1.348	;	Crystal structure of the human astrovirus 2 Oxford serotype capsid protein spike at 1.35-A resolution
7UZT	;	1.86	;	Crystal structure of the human astrovirus MLB1 capsid protein spike domain at 1.86-A resolution
7RK2	;	2.65	;	Crystal structure of the human astrovirus serotype 8 capsid spike in complex with scFv 2D9, an astrovirus-neutralizing antibody, at 2.65-A resolution
7RK1	;	2.05	;	Crystal structure of the human astrovirus serotype 8 capsid spike in complex with scFv 3E8, an astrovirus-neutralizing antibody, at 2.05-A resolution
2ZJJ	;	2.2	;	Crystal structure of the human BACE1 catalytic domain in complex with 4-(4-fluoro-benzyl)-piperazine-2-carboxylic acid (2-mercapto-ethyl)-amide
2ZJK	;	3.0	;	Crystal structure of the human BACE1 catalytic domain in complex with 4-(4-fluoro-benzyl)-piperazine-2-carboxylic acid(3-mercapto-propyl)-amide
2ZJH	;	2.6	;	Crystal structure of the human BACE1 catalytic domain in complex with N-(1-benzyl-piperidin-4-yl)-4-mercapto-butyramide
2ZJI	;	2.3	;	Crystal structure of the human BACE1 catalytic domain in complex with N-[1-(2,6-dimethoxy-benzyl)-piperidin-4-yl]-4-mercapto-butyramide
2ZJL	;	2.1	;	Crystal structure of the human BACE1 catalytic domain in complex with N-[1-(5-bromo-2,3-dimethoxy-benzyl)-piperidin-4-yl]-4-mercapto-butyramide
2ZJN	;	2.7	;	Crystal structure of the human BACE1 catalytic domain in complex with N-[1-(5-chloro-2-isopropoxy-3-methoxy-benzyl)-piperidin-4-yl]-2-(2-methyl-4-sulfamoyl-phenoxy)-acetamide
2ZJM	;	1.9	;	Crystal structure of the human BACE1 catalytic domain in complex with N-[1-(5-chloro-2-isopropoxy-3-methoxy-benzyl)-piperidin-4-yl]-2-(4-sulfamoyl-phenoxy)-acetamide
3OHU	;	2.1	;	Crystal structure of the human Bach2 POZ domain, form I
3OHV	;	2.2	;	Crystal structure of the human Bach2 POZ domain, form II
2Z9T	;	1.8	;	Crystal structure of the human beta-2 microglobulin mutant W60G
2VRF	;	2.0	;	CRYSTAL STRUCTURE OF THE HUMAN BETA-2-SYNTROPHIN PDZ DOMAIN
3NY9	;	2.84	;	Crystal structure of the human beta2 adrenergic receptor in complex with a novel inverse agonist
3NY8	;	2.84	;	Crystal structure of the human beta2 adrenergic receptor in complex with the inverse agonist ICI 118,551
3NYA	;	3.16	;	Crystal structure of the human beta2 adrenergic receptor in complex with the neutral antagonist alprenolol
2R4R	;	3.4	;	Crystal structure of the human beta2 adrenoceptor
2R4S	;	3.4	;	Crystal structure of the human beta2 adrenoceptor
1XA6	;	3.2	;	Crystal Structure of the Human Beta2-Chimaerin
6V5A	;	2.0	;	Crystal structure of the human BK channel gating ring L390P mutant
3MT5	;	3.0	;	Crystal Structure of the Human BK Gating Apparatus
3FB2	;	2.3	;	Crystal structure of the human brain alpha spectrin repeats 15 and 16. Northeast Structural Genomics Consortium target HR5563a.
5S9O	;	2.49	;	CRYSTAL STRUCTURE OF THE HUMAN BRD2 BD1 BROMODOMAIN IN COMPLEX WITH 9-(cyclopropylmethyl)-7-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-3-(3,5-dimethyl-1,2-oxazol-4-yl)-9H-carbazole-1-carboxamide
3AQA	;	2.3	;	Crystal structure of the human BRD2 BD1 bromodomain in complex with a BRD2-interactive compound, BIC1
6DDI	;	1.5	;	Crystal Structure of the human BRD2 BD1 bromodomain in complex with a Tetrahydroquinoline analogue
6DDJ	;	1.05	;	Crystal Structure of the human BRD2 BD2 bromodimain in complex with a Tetrahydroquinoline analogue
2E3K	;	2.3	;	Crystal structure of the human Brd2 second bromodomain in complexed with the acetylated histone H4 peptide
8B96	;	1.338	;	Crystal structure of the human BRD4-BD1 bromodomain in complex with the inhibitor CRCM5464
8B98	;	1.495	;	Crystal structure of the human BRD4-BD1 bromodomain in complex with the inhibitor CRCM5483
3MAZ	;	1.9	;	Crystal Structure of the Human BRDG1/STAP-1 SH2 Domain in Complex with the NTAL pTyr136 Peptide
5NU3	;	1.75	;	Crystal structure of the human bromodomain of CREBBP bound to the inhibitor XDM-CBP
5NRW	;	1.7	;	Crystal structure of the human bromodomain of CREBBP bound to the inhibitor XDM4
5NU5	;	1.6	;	Crystal structure of the human bromodomain of EP300 bound to the inhibitor XDM-CBP
6EKQ	;	1.65	;	Crystal structure of the human BRPF1 bromodomain complexed with BZ054 in space group C2
5C89	;	1.65	;	Crystal structure of the human BRPF1 bromodomain in complex with 917
4QYL	;	1.8	;	Crystal Structure of the human BRPF1 bromodomain in complex with a histone H2AK5ac peptide
4QYD	;	1.94	;	Crystal Structure of the human BRPF1 bromodomain in complex with a histone H4K12ac peptide
5C7N	;	1.75	;	Crystal structure of the human BRPF1 bromodomain in complex with Bromosporine
5O5A	;	1.6	;	Crystal structure of the human BRPF1 bromodomain in complex with BZ032
5O5F	;	1.302	;	Crystal structure of the human BRPF1 bromodomain in complex with BZ038
5O55	;	1.45	;	Crystal structure of the human BRPF1 bromodomain in complex with BZ047
5O5H	;	1.85	;	Crystal structure of the human BRPF1 bromodomain in complex with BZ053
5OWA	;	1.95	;	Crystal structure of the human BRPF1 bromodomain in complex with BZ054
5O4T	;	1.5	;	Crystal structure of the human BRPF1 bromodomain in complex with BZ061
5MWZ	;	1.25	;	Crystal structure of the human BRPF1 bromodomain in complex with BZ073
5MWH	;	1.65	;	Crystal structure of the human BRPF1 bromodomain in complex with BZ089
5MWG	;	1.5	;	Crystal structure of the human BRPF1 bromodomain in complex with BZ091
5OV8	;	1.8	;	Crystal structure of the human BRPF1 bromodomain in complex with BZ097
5O4S	;	1.75	;	Crystal structure of the human BRPF1 bromodomain in complex with BZ135
5OWB	;	1.65	;	Crystal structure of the human BRPF1 bromodomain in complex with DSPBP1004
5OWE	;	1.7	;	Crystal structure of the human BRPF1 bromodomain in complex with DSPBP1010
5C85	;	1.7	;	Crystal structure of the human BRPF1 bromodomain in complex with SEED1
5EPS	;	1.47	;	Crystal structure of the human BRPF1 bromodomain in complex with SEED10
5EPR	;	1.65	;	Crystal structure of the human BRPF1 bromodomain in complex with SEED11
5EQ1	;	1.55	;	Crystal structure of the human BRPF1 bromodomain in complex with SEED12
5ETB	;	1.33	;	Crystal structure of the human BRPF1 bromodomain in complex with SEED13
5ETD	;	1.4	;	Crystal structure of the human BRPF1 bromodomain in complex with SEED14
5EV9	;	1.45	;	Crystal structure of the human BRPF1 bromodomain in complex with SEED15
5EVA	;	1.45	;	Crystal structure of the human BRPF1 bromodomain in complex with SEED16
5EWC	;	1.75	;	Crystal structure of the human BRPF1 bromodomain in complex with SEED17
5EWD	;	1.58	;	Crystal structure of the human BRPF1 bromodomain in complex with SEED18
5EWH	;	1.63	;	Crystal structure of the human BRPF1 bromodomain in complex with SEED19
5C87	;	1.55	;	Crystal structure of the human BRPF1 bromodomain in complex with SEED2
5EWV	;	1.67	;	Crystal structure of the human BRPF1 bromodomain in complex with SEED20
5EWW	;	1.73	;	Crystal structure of the human BRPF1 bromodomain in complex with SEED21
5DY7	;	1.69	;	Crystal structure of the human BRPF1 bromodomain in complex with SEED4
5DYA	;	1.65	;	Crystal structure of the human BRPF1 bromodomain in complex with SEED5
5DYC	;	1.65	;	Crystal structure of the human BRPF1 bromodomain in complex with SEED6
5E3D	;	1.71	;	Crystal structure of the human BRPF1 bromodomain in complex with SEED7
5E3G	;	1.65	;	Crystal structure of the human BRPF1 bromodomain in complex with SEED8
5EM3	;	1.4	;	Crystal structure of the human BRPF1 bromodomain in complex with SEED9
5D7X	;	1.35	;	Crystal structure of the human BRPF1 bromodomain in complex with XZ08
4P6Z	;	3.0	;	Crystal structure of the human BST2 cytoplasmic domain and the HIV-1 Vpu cytoplasmic domain bound to the clathrin adaptor protein complex 1 (AP1) core
3B84	;	1.74	;	Crystal structure of the human BTB domain of the Krueppel related Zinc Finger Protein 3 (HKR3)
3P08	;	2.3	;	Crystal structure of the human BTK kinase domain
2AW2	;	2.8	;	Crystal structure of the human BTLA-HVEM complex
4F80	;	1.944	;	Crystal Structure of the human BTN3A1 ectodomain
4F9P	;	3.519	;	Crystal Structure of the Human BTN3A1 Ectodomain in Complex with the 103.2 Single Chain Antibody
4F9L	;	3.1404	;	Crystal Structure of the Human BTN3A1 Ectodomain in Complex with the 20.1 Single Chain Antibody
6XLQ	;	3.0	;	Crystal Structure of the Human BTN3A1 Ectodomain in Complex with the CTX-2026 Fab
4F8Q	;	2.3789	;	Crystal Structure of the Human BTN3A2 Ectodomain
4F8T	;	2.382	;	Crystal Structure of the Human BTN3A3 Ectodomain
6F7B	;	2.0	;	Crystal structure of the human Bub1 kinase domain in complex with BAY 1816032
1K8F	;	2.8	;	CRYSTAL STRUCTURE OF THE HUMAN C-TERMINAL CAP1-ADENYLYL CYCLASE ASSOCIATED PROTEIN
4HW5	;	2.25	;	Crystal Structure of the Human C3a anaphylatoxin
4HWJ	;	2.6	;	Crystal Structure of the Human C3a desArg anaphylatoxin
4UU9	;	2.12	;	Crystal structure of the human c5a in complex with MEDI7814 a neutralising antibody
4P39	;	2.401	;	Crystal structure of the human C5aR antagonist C5a-A8
2O3H	;	1.9	;	Crystal structure of the human C65A Ape
5II0	;	2.097	;	Crystal structure of the human calcitonin receptor ectodomain in complex with a truncated salmon calcitonin analogue
5IG3	;	2.75	;	Crystal structure of the human CaMKII-alpha hub
6CD6	;	2.2	;	Crystal Structure of the Human CAMKK1A in complex with GSK650394
6CCF	;	2.1	;	Crystal Structure of the Human CAMKK1A in complex with Hesperadin
5UY6	;	1.7	;	Crystal Structure of the Human CAMKK2B
5UYJ	;	1.6	;	Crystal Structure of the Human CAMKK2B
5VT1	;	1.9	;	Crystal Structure of the Human CAMKK2B bound to a thiadiazinone benzamide inhibitor
6BKU	;	2.0	;	Crystal Structure of the Human CAMKK2B bound to GSK650394
6BRC	;	2.2	;	Crystal Structure of the Human CAMKK2B in complex with AP26113-analog (ALK-IN-1)
6BQQ	;	1.8	;	Crystal Structure of the Human CAMKK2B in complex with BI2526
6BLE	;	1.9	;	Crystal Structure of the Human CAMKK2B in complex with CP673451
6BQP	;	1.95	;	Crystal Structure of the Human CAMKK2B in complex with Crenolanib
6BQL	;	2.0	;	Crystal Structure of the Human CAMKK2B in complex with TAE-226
5TGZ	;	2.8	;	Crystal Structure of the Human Cannabinoid Receptor CB1
6IRV	;	2.7	;	Crystal structure of the human cap-specific adenosine methyltransferase
6IRW	;	2.9	;	Crystal structure of the human cap-specific adenosine methyltransferase bound to SAH
2HD6	;	1.8	;	Crystal structure of the human carbonic anhydrase II in complex with a hypoxia-activatable sulfonamide.
3CAJ	;	1.8	;	Crystal structure of the human carbonic anhydrase II in complex with ethoxzolamide
3T5U	;	1.75	;	Crystal structure of the human carbonic anhydrase II in complex with N-hydroxy benzenesulfonamide
3T5Z	;	1.65	;	Crystal structure of the human carbonic anhydrase II in complex with N-methoxy-benzenesulfonamide
3BET	;	1.85	;	Crystal structure of the human carbonic anhydrase II in complex with STX 641 at 1.85 angstroms resolution
2HOC	;	2.1	;	Crystal structure of the human carbonic anhydrase II in complex with the 5-(4-amino-3-chloro-5-fluorophenylsulfonamido)-1,3,4-thiadiazole-2-sulfonamide inhibitor
2HNC	;	1.55	;	Crystal structure of the human carbonic anhydrase II in complex with the 5-amino-1,3,4-thiadiazole-2-sulfonamide inhibitor.
2W2J	;	1.6	;	Crystal structure of the human carbonic anhydrase related protein VIII
3CZV	;	2.0	;	Crystal structure of the human carbonic anhydrase XIII in complex with acetazolamide
5OM9	;	1.8	;	Crystal structure of the human CARBOXYPEPTIDASE A1 in complex with a thiirane mechanism-based inhibitor
4UEE	;	2.27	;	Crystal structure of the human CARBOXYPEPTIDASE A1 in complex with the PHOSPHINIC INHIBITOR Acetyl-Leu-Ala-Y(PO2CH2)-homoPhe-OH
4UEZ	;	2.29	;	Crystal structure of the human CARBOXYPEPTIDASE A1 in complex with the PHOSPHINIC INHIBITOR Acetyl-Leu-Phe-Y(PO2CH2)-Phe-OH
6I6Z	;	1.72	;	Crystal structure of the human CARBOXYPEPTIDASE A1 in complex with the PHOSPHINIC INHIBITOR Acetyl-Tyr-Ala-Y(PO2CH2)-homoPhe-OH
2NSM	;	2.1	;	Crystal structure of the human carboxypeptidase N (Kininase I) catalytic domain
1SC4	;	2.1	;	Crystal structure of the human caspase-1 C285A mutant after removal of malonate
1SC3	;	1.8	;	Crystal structure of the human caspase-1 C285A mutant in complex with malonate
5XRA	;	2.8	;	Crystal structure of the human CB1 in complex with agonist AM11542
5XR8	;	2.95	;	Crystal structure of the human CB1 in complex with agonist AM841
5LWE	;	2.8	;	Crystal structure of the human CC chemokine receptor type 9 (CCR9) in complex with vercirnon
1IMJ	;	2.2	;	CRYSTAL STRUCTURE OF THE HUMAN CCG1/TAFII250-INTERACTING FACTOR B (CIB)
7AX1	;	3.3	;	Crystal structure of the human CCR4-CAF1 complex
2H2R	;	1.5	;	Crystal structure of the human CD23 Lectin domain, apo form
1JL4	;	4.3	;	CRYSTAL STRUCTURE OF THE HUMAN CD4 N-TERMINAL TWO DOMAIN FRAGMENT COMPLEXED TO A CLASS II MHC MOLECULE
4CXA	;	3.15	;	Crystal structure of the human CDK12-cyclin K complex bound to AMPPNP
4UN0	;	3.15	;	Crystal structure of the human CDK12-cyclinK complex
5ACB	;	2.7	;	Crystal Structure of the Human Cdk12-Cyclink Complex
2C68	;	1.95	;	Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor
2C69	;	2.1	;	Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor
2C6I	;	1.8	;	Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor
2C6K	;	1.9	;	Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor
2C6L	;	2.3	;	Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor
2C6M	;	1.9	;	Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor
2C6O	;	2.1	;	Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor
2C6T	;	2.61	;	Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor
1BUH	;	2.6	;	CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITH CELL CYCLE-REGULATORY PROTEIN CKSHS1
8P4Z	;	2.75	;	Crystal structure of the human CDK7 kinase domain in complex with LDC4297
4AGU	;	2.4	;	CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
4AAA	;	1.53	;	Crystal structure of the human CDKL2 kinase domain
4BBM	;	2.0	;	CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
3ZDU	;	2.2	;	Crystal structure of the human CDKL3 kinase domain
4BGQ	;	2.0	;	Crystal structure of the human CDKL5 kinase domain
8CIE	;	2.2	;	Crystal structure of the human CDKL5 kinase domain with compound YL-354
4QXW	;	2.04	;	Crystal structure of the human CEACAM1 membrane distal amino terminal (N)-domain
6N8R	;	1.91	;	Crystal structure of the human cell polarity protein Lethal Giant Larvae 2 (Lgl2). aPKC phosphorylated, crystal form 2.
6N8S	;	3.9	;	Crystal structure of the human cell polarity protein Lethal Giant Larvae 2 (Lgl2). aPKC phosphorylated, crystal form 3.
6N8P	;	3.193	;	Crystal structure of the human cell polarity protein Lethal Giant Larvae 2 (Lgl2). Unphosphorylated, crystal form 1.
6N8Q	;	2.2	;	Crystal structure of the human cell polarity protein Lethal Giant Larvae 2 (Lgl2). Unphosphorylated, crystal form 2.
7F1T	;	2.6	;	Crystal structure of the human chemokine receptor CCR5 in complex with MIP-1a
6EFK	;	1.5	;	Crystal structure of the human CHIP TPR domain in complex with a 5mer acetylated HSP70 peptide
6NSV	;	1.305	;	Crystal structure of the human CHIP TPR domain in complex with a 5mer acetylated optimized peptide
8FYU	;	1.84839	;	Crystal structure of the human CHIP-TPR domain in complex with a 10mer acetylated tau peptide
8GCK	;	1.36824	;	Crystal structure of the human CHIP-TPR domain in complex with a 6mer acetylated tau peptide
4KP0	;	2.8	;	Crystal Structure of the human Chymase with TJK002
1DLH	;	2.8	;	CRYSTAL STRUCTURE OF THE HUMAN CLASS II MHC PROTEIN HLA-DR1 COMPLEXED WITH AN INFLUENZA VIRUS PEPTIDE
3VPP	;	1.642	;	Crystal Structure of the Human CLEC9A C-type Lectin-Like Domain
2WU6	;	1.92	;	Crystal Structure of the Human CLK3 in complex with DKI
2WU7	;	2.25	;	Crystal Structure of the Human CLK3 in complex with V25
2PKT	;	1.5	;	Crystal structure of the human CLP-36 (PDLIM1) bound to the C-terminal peptide of human alpha-actinin-1
6D1U	;	2.05	;	Crystal structure of the human CLR:RAMP1 extracellular domain heterodimer in complex with adrenomedullin 2/intermedin
5V6Y	;	2.8	;	Crystal structure of the human CLR:RAMP1 extracellular domain heterodimer with bound high-affinity and altered selectivity adrenomedullin variant
6V2E	;	1.83	;	Crystal structure of the human CLR:RAMP2 extracellular domain heterodimer with bound high-affinity adrenomedullin S45R/K46L/S48G/Q50W variant
3NGQ	;	1.8	;	Crystal structure of the human CNOT6L nuclease domain
3NGN	;	2.4	;	Crystal structure of the human CNOT6L nuclease domain in complex with AMP
3NGO	;	2.2	;	Crystal structure of the human CNOT6L nuclease domain in complex with poly(A) DNA
1EJF	;	2.49	;	CRYSTAL STRUCTURE OF THE HUMAN CO-CHAPERONE P23
2Y4T	;	3.0	;	Crystal structure of the human co-chaperone P58(IPK)
3N3F	;	2.005	;	Crystal Structure of the Human Collagen XV Trimerization Domain: A Potent Trimerizing Unit Common to Multiplexin Collagens
3UF2	;	2.75	;	Crystal structure of the human Colony-Stimulating Factor 1 (hCSF-1) cytokine
3UEZ	;	3.414	;	Crystal structure of the human Colony-Stimulating Factor 1 (hCSF-1) cytokine in complex with the viral receptor BARF1
4ADF	;	4.4	;	CRYSTAL STRUCTURE OF THE HUMAN COLONY-STIMULATING FACTOR 1 (hCSF-1) CYTOKINE IN COMPLEX WITH THE VIRAL RECEPTOR BARF1
6ODD	;	2.0	;	Crystal structure of the human complex ACP-ISD11
6ZBK	;	1.49	;	Crystal structure of the human complex between RPAP3 and TRBP
4U4P	;	1.89	;	Crystal structure of the human condensin SMC hinge domain heterodimer with short coiled coils
8D41	;	2.0	;	Crystal structure of the human COPB2 WD-domain in complex with OICR-6254
8D30	;	2.4	;	Crystal structure of the human COPB2 WD-domains
3EH1	;	1.8	;	Crystal structure of the human COPII-coat protein Sec24b
3EH2	;	2.35	;	Crystal structure of the human COPII-coat protein Sec24c
5ZUV	;	2.21	;	Crystal Structure of the Human Coronavirus 229E HR1 motif in complex with pan-CoVs inhibitor EK1
6ATK	;	3.505	;	Crystal structure of the human coronavirus 229E spike protein receptor binding domain in complex with human aminopeptidase N
5ZVK	;	3.31	;	Crystal Structure of the Human Coronavirus MERS HR1 motif in complex with pan-CoVs inhibitor EK1
5ZVM	;	3.3	;	Crystal Structure of the Human Coronavirus SARS HR1 motif in complex with pan-CoVs inhibitor EK1
3CJW	;	1.48	;	Crystal structure of the human COUP-TFII ligand binding domain
6F9N	;	2.5	;	CRYSTAL STRUCTURE OF THE HUMAN CPSF160-WDR33 COMPLEX
3AQF	;	2.6	;	Crystal structure of the human CRLR/RAMP2 extracellular complex
1PTZ	;	1.8	;	Crystal structure of the human CU, Zn Superoxide Dismutase, Familial Amyotrophic Lateral Sclerosis (FALS) Mutant H43R
4O38	;	2.097	;	Crystal structure of the human cyclin G associated kinase (GAK)
6RZ8	;	2.7	;	Crystal structure of the human cysteinyl leukotriene receptor 2 in complex with ONO-2080365
6RZ6	;	2.43	;	Crystal structure of the human cysteinyl leukotriene receptor 2 in complex with ONO-2570366 (C2221 space group)
6RZ7	;	2.43	;	Crystal structure of the human cysteinyl leukotriene receptor 2 in complex with ONO-2570366 (F222 space group)
6RZ9	;	2.73	;	Crystal structure of the human cysteinyl leukotriene receptor 2 in complex with ONO-2770372
7RL2	;	2.23	;	Crystal Structure of the Human Cytochrome P450 2C9*8 (CYP2C9*8) Genetic Variant in Complex with the Drug Losartan
1T6L	;	1.85	;	Crystal Structure of the Human Cytomegalovirus DNA Polymerase Subunit, UL44
5DOB	;	2.47	;	Crystal structure of the Human Cytomegalovirus Nuclear Egress Complex (NEC)
1IM3	;	2.2	;	Crystal Structure of the human cytomegalovirus protein US2 bound to the MHC class I molecule HLA-A2/tax
5D5N	;	2.44	;	Crystal Structure of the Human Cytomegalovirus pUL50-pUL53 Complex
5DOE	;	3.0	;	Crystal structure of the Human Cytomegalovirus UL53 (residues 72-292)
5DOC	;	1.94	;	Crystal structure of the Human Cytomegalovirus UL53 subunit of the NEC
4CKR	;	2.2	;	Crystal structure of the human DDR1 kinase domain in complex with DDR1-IN-1
4BKJ	;	1.7	;	Crystal structure of the human DDR1 kinase domain in complex with imatinib
6SH7	;	2.21	;	Crystal structure of the human DEAH-helicase DHX15 in complex with the NKRF G-patch
6SH6	;	1.85	;	Crystal structure of the human DEAH-helicase DHX15 in complex with the NKRF G-patch bound to ADP
2YBR	;	2.55	;	Crystal structure of the human derived single chain antibody fragment (scFv) 9004G in complex with Cn2 toxin from the scorpion Centruroides noxius Hoffmann
2YC1	;	1.9	;	Crystal structure of the human derived single chain antibody fragment (scFv) 9004G in complex with Cn2 toxin from the scorpion Centruroides noxius Hoffmann
5NHG	;	2.27	;	Crystal structure of the human dihydrolipoamide dehydrogenase
6I4Q	;	1.75	;	Crystal structure of the human dihydrolipoamide dehydrogenase at 1.75 Angstrom resolution
8GW0	;	1.64	;	Crystal structure of the human dihydroorotase domain in complex with malic acid
8GVZ	;	1.97	;	Crystal structure of the human dihydroorotase domain in complex with the anticancer drug 5-fluorouracil
3W9Y	;	2.2	;	Crystal structure of the human DLG1 guanylate kinase domain
1V5W	;	3.2	;	Crystal structure of the human Dmc1 protein
2ZJB	;	3.5	;	Crystal structure of the human Dmc1-M200V polymorphic variant
8QHR	;	1.65	;	Crystal structure of the human DNPH1 glycosyl-enzyme intermediate
2V76	;	1.6	;	Crystal structure of the human dok1 PTB domain
5VDC	;	1.6	;	Crystal structure of the human DPF2 tandem PHD finger domain
3G36	;	1.2	;	Crystal structure of the human DPY-30-like C-terminal domain
6D66	;	2.226	;	Crystal structure of the human dual specificity 1 catalytic domain (C258S) as a maltose binding protein fusion in complex with the designed AR protein mbp3_16
6D67	;	2.55	;	Crystal structure of the human dual specificity phosphatase 1 catalytic domain (C258S) as a maltose binding protein fusion (maltose bound form) in complex with the designed AR protein mbp3_16
6D65	;	2.348	;	Crystal structure of the human dual specificity phosphatase 1 catalytic domain (C258S) as a maltose binding protein fusion in complex with the designed AR protein off7
2VX3	;	2.4	;	Crystal structure of the human dual specificity tyrosine- phosphorylation-regulated kinase 1A
7O7K	;	1.82	;	Crystal structure of the human DYRK1A kinase domain bound to abemaciclib
3EVX	;	2.54	;	Crystal structure of the human E2-like ubiquitin-fold modifier conjugating enzyme 1 (Ufc1). Northeast Structural Genomics Consortium target HR41
1YIB	;	1.8	;	Crystal Structure of the Human EB1 C-terminal Dimerization Domain
1YIG	;	2.0	;	Crystal Structure of the Human EB1 C-terminal Dimerization Domain
5F4Q	;	1.8	;	Crystal structure of the human egg surface protein Juno
5ZC9	;	2.0	;	Crystal structure of the human eIF4A1-ATP analog-RocA-polypurine RNA complex
3U7X	;	2.1	;	Crystal structure of the human eIF4E-4EBP1 peptide complex without cap
5T46	;	1.53	;	Crystal structure of the human eIF4E-eIF4G complex
3SE6	;	3.08	;	Crystal structure of the human Endoplasmic Reticulum Aminopeptidase 2
4JBS	;	2.789	;	Crystal structure of the human Endoplasmic Reticulum Aminopeptidase 2 in complex with PHOSPHINIC PSEUDOTRIPEPTIDE inhibitor.
4E36	;	3.22	;	Crystal structure of the human Endoplasmic Reticulum Aminopeptidase 2 variant N392K
4BK4	;	3.65	;	crystal structure of the human EphA4 ectodomain
4BKA	;	5.3	;	crystal structure of the human EphA4 ectodomain in complex with human ephrin A5
4BK5	;	4.0	;	crystal structure of the human EphA4 ectodomain in complex with human ephrin A5 (amine-methylated sample)
4BKF	;	4.65	;	crystal structure of the human EphA4 ectodomain in complex with human ephrinB3
3FL7	;	2.5	;	Crystal structure of the human ephrin A2 ectodomain
3MBW	;	2.81	;	Crystal structure of the human ephrin A2 LBD and CRD domains in complex with ephrin A1
3CZU	;	2.65	;	Crystal structure of the human ephrin A2- ephrin A1 complex
2A1U	;	2.11	;	Crystal structure of the human ETF E165betaA mutant
5EWI	;	1.5996	;	Crystal Structure of the Human Fab VRC38.01, an HIV-1 V1V2-Directed Neutralizing Antibody Isolated from Donor N90
5VGJ	;	3.456	;	Crystal Structure of the Human Fab VRC38.01, an HIV-1 V1V2-Directed Neutralizing Antibody Isolated from Donor N90, bound to a scaffolded WITO V1V2 domain
4XZU	;	2.61	;	Crystal Structure of the Human Factor VIII C2 Domain in Complex with Murine 3E6 Inhibitory Antibody
4IE4	;	2.5048	;	Crystal structure of the human fat mass and obesity associated protein (FTO) in complex with 5-carboxy-8-hydroxyquinoline (IOX1)
4QHO	;	2.37	;	Crystal structure of the human fat mass and obesity associated protein (FTO) in complex with CCO10
4IE7	;	2.6004	;	Crystal structure of the human fat mass and obesity associated protein (FTO) in complex with citrate and rhein (RHN)
4IDZ	;	2.46	;	Crystal structure of the human fat mass and obesity associated protein (FTO) in complex with N-oxalylglycine (NOG)
4IE6	;	2.5036	;	Crystal structure of the human fat mass and obesity associated protein (FTO) in complex with N-[(1-chloro-4-hydroxyisoquinolin-3-yl)carbonyl]glycine (IOX3/UN9)
4IE5	;	1.95	;	Crystal structure of the human fat mass and obesity associated protein (FTO) in complex with N-[(3-hydroxypyridin-2-yl)carbonyl]glycine (MD6)
4IE0	;	2.53	;	Crystal structure of the human fat mass and obesity associated protein (FTO) in complex with pyridine-2,4-dicarboxylate (2,4-PDCA)
7E8Z	;	2.55	;	Crystal structure of the human fat mass and obesity associated protein (FTO) in complex with SS81
3TJM	;	1.48	;	Crystal Structure of the Human Fatty Acid Synthase Thioesterase Domain with an Activate Site-Specific Polyunsaturated Fatty Acyl Adduct
3D8D	;	2.2	;	Crystal structure of the human Fe65-PTB1 domain
3D8E	;	2.8	;	Crystal structure of the human Fe65-PTB1 domain (trigonal crystal form)
3D8F	;	2.7	;	Crystal structure of the human Fe65-PTB1 domain with bound phosphate (trigonal crystal form)
1UL1	;	2.9	;	Crystal structure of the human FEN1-PCNA complex
2J3S	;	2.5	;	Crystal structure of the human filamin A Ig domains 19 to 21
4P3W	;	2.0	;	Crystal structure of the human filamin A Ig-like domains 20-21 in complex with migfilin peptide
4M9P	;	1.72	;	Crystal structure of the human filamin A Ig-like domains 3-5
5DCP	;	2.49	;	Crystal structure of the human filamin B Ig-like domains 16-17
6LW5	;	2.8	;	Crystal structure of the human formyl peptide receptor 2 in complex with WKYMVm
7YZE	;	1.99	;	Crystal structure of the human FoxA2 bound to the TGTTTACT site (forkhead motif GTAAACA)
7YZF	;	2.18	;	Crystal structure of the human FoxA2 bound to the TGTTTATT site (forkhead motif ATAAACA)
7YZB	;	1.47	;	Crystal structure of the human FoxH1 bound to the TGTGGATT site
6NCE	;	2.598	;	Crystal structure of the human FOXN3 DNA binding domain in complex with a forkhead DNA sequence
6NCM	;	2.704	;	Crystal structure of the human FOXN3 DNA binding domain in complex with a forkhead-like (FHL) DNA sequence
2UZK	;	2.7	;	Crystal structure of the human FOXO3a-DBD bound to DNA
6XAT	;	2.2	;	Crystal structure of the human FoxP4 DNA binding Domain
6TKV	;	1.95	;	Crystal structure of the human FUT8 in complex with GDP and a biantennary complex N-glycan
3UA6	;	1.85	;	Crystal Structure of the Human Fyn SH3 domain
3UA7	;	1.5	;	Crystal Structure of the Human Fyn SH3 domain in complex with a peptide from the Hepatitis C virus NS5A-protein
4EIK	;	1.6	;	Crystal Structure of the Human Fyn SH3 domain in complex with the synthetic peptide VSL12
3H0F	;	2.61	;	Crystal structure of the human Fyn SH3 R96W mutant
1KJR	;	1.55	;	Crystal Structure of the human galectin-3 CRD in complex with a 3'-derivative of N-Acetyllactosamine
4YM1	;	2.0	;	Crystal structure of the human galectin-4 C-terminal carbohydrate recognition domain in complex with 2'-fucosyllactose
4YLZ	;	2.1	;	Crystal structure of the human galectin-4 C-terminal carbohydrate recognition domain in complex with lacto-N-neotetraose (LNnT)
4YM0	;	2.3	;	Crystal structure of the human galectin-4 C-terminal carbohydrate recognition domain in complex with lacto-N-tetraose (LNT)
4YM3	;	1.89	;	Crystal structure of the human galectin-4 C-terminal carbohydrate recognition domain in complex with lactose
4YM2	;	2.1	;	Crystal structure of the human galectin-4 C-terminal carbohydrate recognition domain in complex with lactose-3'-sulfate
5DUX	;	1.85	;	Crystal structure of the human galectin-4 N-terminal carbohydrate recognition domain in complex with 2'-fucosyllactose
5DUU	;	2.0	;	Crystal structure of the human galectin-4 N-terminal carbohydrate recognition domain in complex with glycerol
5DUV	;	1.9	;	Crystal structure of the human galectin-4 N-terminal carbohydrate recognition domain in complex with lactose
5DUW	;	1.7	;	Crystal structure of the human galectin-4 N-terminal carbohydrate recognition domain in complex with lactose-3'-sulfate
6H0B	;	1.8	;	Crystal structure of the human GalNAc-T4 in complex with UDP, manganese and the diglycopeptide 6.
6AO4	;	2.901	;	Crystal structure of the human gasdermin D C-terminal domain
6J3P	;	1.598	;	Crystal structure of the human GCN5 bromodomain in complex with compound (R,R)-36n
2D9Q	;	2.8	;	Crystal Structure of the Human GCSF-Receptor Signaling Complex
7Q6J	;	2.2	;	Crystal structure of the human GDAP1 CMT2 mutant-H123R
7Q6K	;	3.41	;	Crystal structure of the human GDAP1 CMT2 mutant-R120W
1NAF	;	2.8	;	Crystal structure of the human GGA1 GAT domain
1OXZ	;	2.8	;	Crystal Structure of the Human GGA1 GAT domain
4HJ0	;	3.0	;	Crystal structure of the human GIPr ECD in complex with Gipg013 Fab at 3-A resolution
6A9P	;	2.51	;	Crystal structure of the human glial fibrillary acidic protein 1B domain
5EE7	;	2.5	;	Crystal structure of the human glucagon receptor (GCGR) in complex with the antagonist MK-0893
4PYP	;	3.166	;	Crystal structure of the human glucose transporter GLUT1
6G2U	;	2.93429	;	Crystal structure of the human glutamate dehydrogenase 2 (hGDH2)
3FVK	;	1.5	;	Crystal structure of the human glutamate receptor, GluR5, ligand-binding core in complex with 8-deoxy-neodysiherbaine A in space group P1
3FVO	;	1.5	;	Crystal structure of the human glutamate receptor, GluR5, ligand-binding core in complex with 8-epi-neodysiherbaine A in space group P1
3FVN	;	1.5	;	Crystal structure of the human glutamate receptor, GluR5, ligand-binding core in complex with 9-deoxy-neodysiherbaine A in space group P1
3FV1	;	1.5	;	Crystal Structure of the human glutamate receptor, GluR5, ligand-binding core in complex with dysiherbaine in space group P1
3FUZ	;	1.65	;	Crystal structure of the human glutamate receptor, GluR5, ligand-binding core in complex with L-glutamate in space group P1
3FVG	;	1.5	;	Crystal structure of the human glutamate receptor, GluR5, ligand-binding core in complex with MSVIII-19 in space group P1
3FV2	;	1.5	;	Crystal structure of the human glutamate receptor, GluR5, ligand-binding core in complex with neodysiherbaine A in space group P1
2ZEL	;	1.97	;	Crystal structure of the human glutaminyl cyclase mutant D248A at 1.97 angstrom resolution
2ZEM	;	2.18	;	Crystal structure of the human glutaminyl cyclase mutant D248Q at 2.18 angstrom resolution
2ZEN	;	1.78	;	Crystal structure of the human glutaminyl cyclase mutant D305A at 1.78 angstrom resolution
2ZEO	;	1.66	;	Crystal structure of the human glutaminyl cyclase mutant D305E at 1.66 angstrom resolution
2ZEF	;	1.67	;	Crystal structure of the human glutaminyl cyclase mutant E201D at 1.67 angstrom resolution
2ZEG	;	2.08	;	Crystal structure of the human glutaminyl cyclase mutant E201L at 2.08 angstrom resolution
2ZEH	;	1.8	;	Crystal structure of the human glutaminyl cyclase mutant E201Q at 1.8 angstrom resolution
2ZEP	;	2.1	;	Crystal structure of the human glutaminyl cyclase mutant H319L at 2.1 angstrom resolution
2ZED	;	1.7	;	Crystal structure of the human glutaminyl cyclase mutant S160A at 1.7 angstrom resolution
2ZEE	;	1.99	;	Crystal structure of the human glutaminyl cyclase mutant S160G at 1.99 angstrom resolution
2WUL	;	2.4	;	CRYSTAL STRUCTURE OF THE HUMAN GLUTAREDOXIN 5 WITH BOUND GLUTATHIONE IN AN FES CLUSTER
3ZW5	;	1.6	;	Crystal structure of the human Glyoxalase domain-containing protein 5
3KM6	;	2.1	;	Crystal Structure of the Human GST Pi C47S/Y108V Double Mutant in Complex with the Ethacrynic Acid-Glutathione Conjugate
3KMO	;	2.6	;	Crystal Structure of the Human GST Pi C47S/Y108V Double Mutant in Complex with the Ethacrynic Acid-Glutathione Conjugate (Grown in the Absence of the Reducing Agent DTT)
4HBN	;	2.6	;	Crystal structure of the human HCN4 channel C-terminus carrying the S672R mutation
4G93	;	4.2	;	CRYSTAL STRUCTURE OF THE HUMAN HEPATITIS B VIRUS T = 4 CAPSID, ADYW STRAIN, in COMPLEX WITH THE PHENYLPROPENAMIDE ASSEMBLY ACCELERATOR AT-130
1F2Q	;	2.4	;	CRYSTAL STRUCTURE OF THE HUMAN HIGH-AFFINITY IGE RECEPTOR
2WFT	;	2.8	;	Crystal structure of the human HIP ectodomain
7O7I	;	2.5	;	Crystal structure of the human HIPK3 kinase domain
7O7J	;	2.81	;	Crystal structure of the human HIPK3 kinase domain bound to abemaciclib
5W6M	;	3.696	;	Crystal structure of the human histidyl-tRNA synthetase mutant D175E
3CI9	;	1.8	;	Crystal Structure of the human HSBP1
7NDX	;	2.541	;	Crystal structure of the human HSP40 DNAJB1-CTDs in complex with a peptide of NudC
2E8A	;	1.77	;	Crystal structure of the human Hsp70 ATPase domain in complex with AMP-PNP
2E88	;	1.8	;	Crystal structure of the human Hsp70 ATPase domain in the apo form
4HY6	;	1.649	;	Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ1
4LWE	;	1.5	;	Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ2
4LWF	;	1.75	;	Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ3
4LWG	;	1.599	;	Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ4
4LWH	;	1.7	;	Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ5
5XRB	;	1.65	;	Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ5
4LWI	;	1.7	;	Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ6
5CF0	;	1.8	;	Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ6
5XRD	;	1.3	;	Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FS7
5XRE	;	1.497	;	Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor JX1
1EFH	;	2.4	;	CRYSTAL STRUCTURE OF THE HUMAN HYDROXYSTEROID SULFOTRANSFERASE IN THE PRESENCE OF PAP
8OJS	;	2.75	;	Crystal structure of the human IgD Fab - structure Fab1
8OJT	;	1.55	;	Crystal structure of the human IgD Fab - structure Fab2
8OJU	;	1.45	;	Crystal structure of the human IgD Fab - structure Fab3
8OJV	;	2.1	;	Crystal structure of the human IgD Fab - structure Fab4
5LGK	;	3.5	;	Crystal structure of the human IgE-Fc bound to its B cell receptor derCD23
4EZM	;	3.1	;	Crystal structure of the human IgE-Fc(epsilon)3-4 bound to its B cell receptor derCD23
1H3X	;	2.44	;	CRYSTAL STRUCTURE OF THE HUMAN IGG1 FC-FRAGMENT,GLYCOFORM (G0F)2
1H3V	;	3.1	;	CRYSTAL STRUCTURE OF THE HUMAN IGG1 FC-FRAGMENT,GLYCOFORM (G2F)2,SG P212121
1H3U	;	2.4	;	CRYSTAL STRUCTURE OF THE HUMAN IGG1 FC-FRAGMENT,GLYCOFORM (M3N2F)2
1H3T	;	2.4	;	Crystal structure of the human igg1 fc-fragment,glycoform (mn2f)2
6HGA	;	2.6	;	Crystal Structure of the human IL-17RC D2-D3-D4 domains in complex with an anti-APP tag Fab
6HG4	;	3.32	;	Crystal Structure of the human IL-17RC ECD in complex with human IL-17F
6HG9	;	3.62	;	Crystal Structure of the human IL-17RC ECD in complex with human IL-17F, Crystal form II
6VHI	;	2.46	;	Crystal structure of the human ILRUN Fw domain
2AXN	;	2.1	;	Crystal structure of the human inducible form 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase
6SN1	;	2.54	;	Crystal structure of the human INTS13-INTS14 complex
2WJW	;	1.8	;	Crystal structure of the human ionotropic glutamate receptor GluR2 ATD region at 1.8 A resolution
2WJX	;	4.1	;	Crystal structure of the human ionotropic glutamate receptor GluR2 ATD region at 4.1 A resolution
2XXZ	;	1.8	;	Crystal structure of the human JMJD3 jumonji domain
8A46	;	1.323	;	Crystal structure of the human Kelch domain of Keap1 in complex with compound S217879
2GRY	;	2.35	;	Crystal structure of the human KIF2 motor domain in complex with ADP
3NWN	;	2.0	;	Crystal structure of the human KIF9 motor domain in complex with ADP
1B6U	;	3.0	;	CRYSTAL STRUCTURE OF THE HUMAN KILLER CELL INHIBITORY RECEPTOR (KIR2DL3) SPECIFIC FOR HLA-CW3 RELATED ALLELES
3P23	;	2.7	;	Crystal structure of the Human kinase and RNase domains in complex with ADP
5LSK	;	3.502	;	CRYSTAL STRUCTURE OF THE HUMAN KINETOCHORE MIS12-CENP-C COMPLEX
5LSJ	;	3.25	;	CRYSTAL STRUCTURE OF THE HUMAN KINETOCHORE MIS12-CENP-C delta-HEAD2 COMPLEX
6EQT	;	2.735	;	CRYSTAL STRUCTURE OF THE HUMAN KINETOCHORE PROTEIN CENP-N
4AP2	;	2.8	;	Crystal structure of the human KLHL11-Cul3 complex at 2.8A resolution
4APF	;	3.1	;	Crystal structure of the human KLHL11-Cul3 complex at 3.1A resolution
4CHB	;	1.56	;	Crystal structure of the human KLHL2 Kelch domain in complex with a WNK4 peptide
5NKP	;	2.8	;	Crystal structure of the human KLHL3 Kelch domain in complex with a WNK3 peptide
4CH9	;	1.84	;	Crystal structure of the human KLHL3 Kelch domain in complex with a WNK4 peptide
4O0D	;	1.95	;	Crystal structure of the human L-asparaginase protein T168S mutant
4O0E	;	1.71	;	Crystal structure of the human L-asparaginase protein T186V mutant
4O0F	;	1.92	;	Crystal structure of the human L-asparaginase protein T219A mutant
4O0G	;	2.1	;	Crystal structure of the human L-asparaginase protein T219V mutant
3BCH	;	2.15	;	Crystal Structure of the Human Laminin Receptor Precursor
7Z3Q	;	3.617	;	Crystal structure of the human leptin:LepR-CRH2 encounter complex to 3.6 A resolution.
3KGR	;	1.8	;	Crystal structure of the human leukocyte-associated Ig-like receptor-1 (LAIR-1)
7K15	;	2.88	;	Crystal structure of the Human Leukotriene B4 Receptor 1 in Complex with Selective Antagonist MK-D-046
3S95	;	1.65	;	Crystal structure of the human LIMK1 kinase domain in complex with staurosporine
4TPT	;	2.6	;	Crystal Structure of the Human LIMK2 Kinase Domain In Complex With a Non-ATP Competitive Inhibitor
4A4I	;	1.95	;	Crystal structure of the human Lin28b cold shock domain
2XST	;	1.63	;	Crystal Structure of the Human Lipocalin 15
2WWP	;	2.0	;	Crystal structure of the human lipocalin-type prostaglandin D synthase
1UPV	;	2.1	;	Crystal structure of the human Liver X receptor beta ligand binding domain in complex with a synthetic agonist
1UPW	;	2.4	;	Crystal structure of the human Liver X receptor beta ligand binding domain in complex with a synthetic agonist
6S6M	;	1.35	;	Crystal structure of the human LL37(17-29) antimicrobial peptide
7NPQ	;	1.5	;	Crystal structure of the human LL37(17-29) I24C mutant antimicrobial peptide
3H2X	;	2.2	;	Crystal Structure of The Human Lymphoid Tyrosine Phosphatase Catalytic Domain
6NMW	;	1.199	;	Crystal structure of the human Lyn SH3 domain
4AKM	;	2.687	;	Crystal structure of the human lysosome-associated membrane protein LAMP-3 (aka DC-LAMP)
5LXF	;	2.0	;	Crystal structure of the human Macrophage Colony Stimulating Factor M- CSF_C31S variant
2WA0	;	2.3	;	Crystal structure of the human MAGEA4
1SZB	;	2.5	;	Crystal structure of the human MBL-associated protein 19 (MAp19)
3UMZ	;	1.65	;	Crystal Structure of the human MDC1 FHA Domain
3UNM	;	1.8	;	Crystal Structure of The Human MDC1 FHA Domain
4LP7	;	2.83	;	Crystal structure of the human metapneumovirus matrix protein
4BXT	;	3.13	;	Crystal structure of the human metapneumovirus phosphoprotein tetramerization domain
8H0N	;	1.8	;	Crystal structure of the human METTL1-WDR4 complex
6TTP	;	2.0	;	Crystal structure of the human METTL3-METTL14 complex bound to Compound 1/Adenosine (DHU_M3M_023)
7O0P	;	2.7	;	Crystal structure of the human METTL3-METTL14 complex bound to Compound 10 (ADO_AD_022)
7O0Q	;	2.49	;	Crystal structure of the human METTL3-METTL14 complex bound to Compound 12 (ADO_AD_066)
7O2H	;	2.5	;	Crystal structure of the human METTL3-METTL14 complex bound to Compound 13 (ADO_AD_091)
7O0R	;	2.3	;	Crystal structure of the human METTL3-METTL14 complex bound to Compound 15 (ADO_AE_026)
7O27	;	2.4	;	Crystal structure of the human METTL3-METTL14 complex bound to Compound 17 (ADO_AE_005)
7O28	;	2.47	;	Crystal structure of the human METTL3-METTL14 complex bound to Compound 19 (ADO_AE_009)
6TTT	;	2.3	;	Crystal structure of the human METTL3-METTL14 complex bound to Compound 2 (ASI_M3M_140)
7O29	;	2.75	;	Crystal structure of the human METTL3-METTL14 complex bound to Compound 20 (ADO_AD_044)
7O2E	;	2.5	;	Crystal structure of the human METTL3-METTL14 complex bound to Compound 21 (ADO_AD_089)
7O2F	;	2.1	;	Crystal structure of the human METTL3-METTL14 complex bound to Compound 22 (UZH2)
6TTV	;	2.14	;	Crystal structure of the human METTL3-METTL14 complex bound to Compound 3 (ASI_M3M_138)
6TTW	;	2.2	;	Crystal structure of the human METTL3-METTL14 complex bound to Compound 4 (ASI_M3M_047)
7O08	;	2.0	;	Crystal structure of the human METTL3-METTL14 complex bound to Compound 5 (ADO_AB_075)
6TTX	;	2.0	;	Crystal structure of the human METTL3-METTL14 complex bound to Compound 5 (ASI_M3M_051)
7O09	;	1.8	;	Crystal structure of the human METTL3-METTL14 complex bound to Compound 7 (ADO_AC_074)
7O0L	;	1.9	;	Crystal structure of the human METTL3-METTL14 complex bound to Compound 8 (ADO_AC_093)
6TU1	;	2.31	;	Crystal structure of the human METTL3-METTL14 complex bound to Compound 8 (ASI_M3M_091)
7O0M	;	2.39	;	Crystal structure of the human METTL3-METTL14 complex bound to Compound 9 (ADO_AD_023)
5L6D	;	1.852	;	Crystal structure of the human METTL3-METTL14 complex bound to SAH
5L6E	;	1.901	;	Crystal structure of the human METTL3-METTL14 complex bound to SAM
6Y4G	;	1.9	;	Crystal structure of the human METTL3-METTL14 complex bound to Sinefungin
7NHG	;	2.5	;	Crystal structure of the human METTL3-METTL14 complex with compound ASI_M3M_041
7NHJ	;	2.16	;	Crystal structure of the human METTL3-METTL14 complex with compound DHU_M3M_154
7O2X	;	2.8	;	Crystal structure of the human METTL3-METTL14 complex with compound T180
7ACD	;	2.5	;	Crystal structure of the human METTL3-METTL14 complex with compound T30 (UZH1a)
7NHH	;	2.1	;	Crystal structure of the human METTL3-METTL14 complex with compound UOZ002
7NHI	;	1.85	;	Crystal structure of the human METTL3-METTL14 complex with compound UOZ004
7NHV	;	1.91	;	Crystal structure of the human METTL3-METTL14 complex with compound UOZ016
7OED	;	2.0	;	Crystal structure of the human METTL3-METTL14 complex with compound UOZ019a
7OEE	;	2.7	;	Crystal structure of the human METTL3-METTL14 complex with compound UOZ019b
7NI7	;	2.5	;	Crystal structure of the human METTL3-METTL14 complex with compound UOZ031
7OEF	;	2.03	;	Crystal structure of the human METTL3-METTL14 complex with compound UOZ038
7NI8	;	2.2	;	Crystal structure of the human METTL3-METTL14 complex with compound UOZ040a
7OEG	;	2.79	;	Crystal structure of the human METTL3-METTL14 complex with compound UOZ040b
7NI9	;	2.2	;	Crystal structure of the human METTL3-METTL14 complex with compound UOZ058
7NIA	;	2.3	;	Crystal structure of the human METTL3-METTL14 complex with compound UOZ059a
7OEH	;	2.01	;	Crystal structure of the human METTL3-METTL14 complex with compound UOZ059b
7NID	;	2.3	;	Crystal structure of the human METTL3-METTL14 complex with compound UOZ078
7OEI	;	2.48	;	Crystal structure of the human METTL3-METTL14 complex with compound UOZ083
7OEJ	;	2.3	;	Crystal structure of the human METTL3-METTL14 complex with compound UOZ090
7OEK	;	1.9	;	Crystal structure of the human METTL3-METTL14 complex with compound UOZ091
7OQL	;	2.5	;	Crystal structure of the human METTL3-METTL14 complex with compound UOZ094
7OEL	;	1.86	;	Crystal structure of the human METTL3-METTL14 complex with compound UOZ097
7OQO	;	3.35	;	Crystal structure of the human METTL3-METTL14 complex with compound UOZ111
7OQP	;	2.0	;	Crystal structure of the human METTL3-METTL14 complex with compound UOZ113
7OEM	;	2.2	;	Crystal structure of the human METTL3-METTL14 complex with compound UOZ120
8PW9	;	2.3	;	Crystal structure of the human METTL3-METTL14 in complex with a bisubstrate analogue (BA1)
8PW8	;	2.3	;	Crystal structure of the human METTL3-METTL14 in complex with a bisubstrate analogue (BA2)
8PWA	;	2.1	;	Crystal structure of the human METTL3-METTL14 in complex with a bisubstrate analogue (BA4)
8PWB	;	2.5	;	Crystal structure of the human METTL3-METTL14 in complex with a bisubstrate analogue (BA6)
7ZEJ	;	1.79	;	Crystal structure of the human MGC45594 gene product in complex with celecoxib.
2WEK	;	1.9	;	Crystal structure of the human MGC45594 gene product in complex with diclofenac
2X7H	;	1.6	;	Crystal structure of the human MGC45594 gene product in complex with fenoprofen
2X1H	;	1.75	;	Crystal structure of the human MGC45594 gene product in complex with raloxifene
1EXU	;	2.7	;	CRYSTAL STRUCTURE OF THE HUMAN MHC-RELATED FC RECEPTOR
2ABI	;	2.33	;	Crystal structure of the human mineralocorticoid receptor ligand-binding domain bound to deoxycorticosterone
1Y9R	;	1.96	;	Crystal structure of the human mineralocorticoid receptor ligand-binding domain bound to deoxycorticosterone and harboring the S810L mutation responsible for a severe form of hypertension
1YA3	;	2.34	;	Crystal structure of the human mineralocorticoid receptor ligand-binding domain bound to progesterone and harboring the S810L mutation responsible for a severe form of hypertension
6D71	;	1.71808	;	Crystal Structure of the Human Miro1 N-terminal GTPase bound to GTP
1U5B	;	1.83	;	Crystal structure of the human mitochondrial branched-chain alpha-ketoacid dehydrogenase
1X7W	;	1.73	;	Crystal structure of the human mitochondrial branched-chain alpha-ketoacid dehydrogenase
1X7X	;	2.1	;	Crystal structure of the human mitochondrial branched-chain alpha-ketoacid dehydrogenase
1X7Y	;	1.57	;	Crystal structure of the human mitochondrial branched-chain alpha-ketoacid dehydrogenase
1X7Z	;	1.72	;	Crystal structure of the human mitochondrial branched-chain alpha-ketoacid dehydrogenase
1X80	;	2.0	;	Crystal structure of the human mitochondrial branched-chain alpha-ketoacid dehydrogenase
4PJ1	;	3.15	;	Crystal structure of the human mitochondrial chaperonin symmetrical 'football' complex
5WGB	;	2.75	;	Crystal Structure of the Human mitochondrial Cysteine Desulfurase in complex with ISD11 and E. coli ACP1 protein at 2.75A
5WKP	;	3.15	;	Crystal Structure of the Human mitochondrial Cysteine Desulfurase in complex with ISD11 and Iron-Sulfur Cluster Scaffold Protein ISCU1, and E. coli ACP1 protein at 3.15A
5WLW	;	3.317	;	Crystal Structure of the Human Mitochondrial Cysteine Desulfurase with active Cysteine Loop within ISCU1 active site, coordinating Zn ion. Complexed with human ISD11 and E. coli ACP1 at 3.3A.
6I3Y	;	2.98	;	Crystal structure of the human mitochondrial PRELID1K58V-TRIAP1 complex with PS
7TZB	;	2.95	;	Crystal structure of the human mitochondrial seryl-tRNA synthetase (mt SerRS) bound with a seryl-adenylate analogue
3MBL	;	2.6	;	Crystal Structure of the human mitogen-activated protein kinase kinase 1 (MEK 1) in complex with ligand and MgADP
3PP1	;	2.7	;	Crystal Structure of the Human Mitogen-activated protein kinase kinase 1 (MEK 1) in complex with ligand and MgATP
4M67	;	1.9	;	Crystal structure of the human MLKL kinase-like domain
4MWI	;	1.7	;	Crystal structure of the human MLKL pseudokinase domain
6O5Z	;	2.285	;	Crystal Structure of the human MLKL pseudokinase domain bound to compound 2
6BWK	;	2.79	;	Crystal structure of the human MLKL pseudokinase domain T357E/S358E mutant
4KBO	;	2.8	;	Crystal structure of the human Mortalin (GRP75) ATPase domain in the apo form
4OH8	;	2.281	;	Crystal Structure of the human MST1-RASSF5 SARAH heterodimer
4OH9	;	1.699	;	Crystal Structure of the human MST2 SARAH homodimer
4FZV	;	1.9996	;	Crystal structure of the human MTERF4:NSUN4:SAM ternary complex
1Q8M	;	2.6	;	Crystal structure of the human myeloid cell activating receptor TREM-1
6T3O	;	1.8	;	Crystal structure of the human myomesin domain 10
4XWH	;	2.32	;	Crystal structure of the human N-acetyl-alpha-glucosaminidase
3GA1	;	2.1	;	Crystal Structure of the Human Nac1 POZ Domain
1M4K	;	2.3	;	Crystal structure of the human natural killer cell activator receptor KIR2DS2 (CD158j)
1IM9	;	2.8	;	Crystal structure of the human natural killer cell inhibitory receptor KIR2DL1 bound to its MHC ligand HLA-Cw4
7OBP	;	1.8	;	Crystal structure of the human NCOA7-AS TLDc domain
8G0P	;	2.0	;	Crystal structure of the human Ndc80:Nuf2 loop region
6POL	;	1.8	;	Crystal structure of the human NELL1 EGF1-3-Robo3 FN1 complex
5OJK	;	2.55	;	Crystal structure of the human neuroligin 1 cholinesterase domain containing spliced sequence B (SSB) (NL1(-A+B))
6YPE	;	1.45	;	Crystal structure of the human neuronal pentraxin 1 (NP1) pentraxin (PTX) domain.
5UVG	;	1.849	;	Crystal structure of the human neutral sphingomyelinase 2 (nSMase2) catalytic domain with insertion deleted and calcium bound
7LSE	;	2.35	;	Crystal structure of the human neutralizing antibody Fab fragment T025 bound to TBEV EDIII (Far Eastern Subtype)
7LSG	;	1.86	;	Crystal structure of the human neutralizing antibody Fab fragment T025 bound to TBEV EDIII (Siberian Subtype)
7LSF	;	2.24	;	Crystal structure of the human neutralizing antibody Fab fragment T025 bound to TBEV EDIII (Western Subtype)
6J20	;	2.7	;	Crystal structure of the human NK1 substance P receptor
6J21	;	3.2	;	Crystal structure of the human NK1 substance P receptor
6E59	;	3.4	;	Crystal structure of the human NK1 tachykinin receptor
7BSO	;	2.08	;	Crystal structure of the human NLRP9 pyrin domain
1YYH	;	1.901	;	Crystal structure of the human Notch 1 ankyrin domain
3L95	;	2.19	;	Crystal structure of the human Notch1 Negative Regulatory Region (NRR) bound to the fab fragment of an antagonist antibody
3CON	;	1.649	;	Crystal structure of the human NRAS GTPase bound with GDP
4AW6	;	3.4	;	Crystal structure of the human nuclear membrane zinc metalloprotease ZMPSTE24 (FACE1)
2YPT	;	3.8	;	Crystal structure of the human nuclear membrane zinc metalloprotease ZMPSTE24 mutant (E336A) in complex with a synthetic CSIM tetrapeptide from the C-terminus of prelamin A
8PYW	;	1.553	;	Crystal structure of the human Nucleoside-diphosphate kinase B domain bound to compound diphosphate form of AT-9052-Sp.
5Y0C	;	2.087	;	Crystal Structure of the human nucleosome at 2.09 angstrom resolution
4YM5	;	4.005	;	Crystal structure of the human nucleosome containing 6-4PP (inside)
4YM6	;	3.514	;	Crystal structure of the human nucleosome containing 6-4PP (outside)
6JOU	;	2.17	;	Crystal structure of the human nucleosome containing H2A.Z.1 S42R
5Y0D	;	1.99	;	Crystal Structure of the human nucleosome containing the H2B E76K mutant
6JR0	;	2.5	;	Crystal structure of the human nucleosome phased with 12 selenium atoms
6JR1	;	2.4	;	Crystal structure of the human nucleosome phased with 16 selenium atoms
6X7V	;	2.3	;	Crystal Structure of the Human Nudix Hydrolase Nudt16
6X7U	;	2.7	;	Crystal Structure of the Human Nudix Hydrolase Nudt16 in complex with FAD
4JQ5	;	2.195	;	Crystal structure of the human Nup49CCS2+3* coiled-coil segment
4JO9	;	2.499	;	Crystal structure of the human Nup49CCS2+3* Nup57CCS3* complex 1:2 stoichiometry
4JO7	;	1.752	;	Crystal structure of the human Nup49CCS2+3* Nup57CCS3* complex with 2:2 stoichiometry
4JNV	;	1.85	;	Crystal structure of the human Nup57CCS3* coiled-coil segment, space group C2
4JNU	;	1.445	;	Crystal structure of the human Nup57CCS3* coiled-coil segment, space group P21
3V3E	;	2.06	;	Crystal Structure of the Human Nur77 Ligand-binding Domain
6S4M	;	2.4	;	Crystal structure of the human organic anion transporter MFSD10 (TETRAN)
4S0V	;	2.5	;	Crystal structure of the human OX2 orexin receptor bound to the insomnia drug Suvorexant
7XRR	;	2.89	;	Crystal structure of the human OX2R bound to the insomnia drug lemborexant.
6TPK	;	3.2	;	Crystal structure of the human oxytocin receptor
2BVA	;	2.3	;	Crystal structure of the human P21-activated kinase 4
2J0I	;	1.6	;	CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
4APP	;	2.2	;	Crystal Structure of the Human p21-Activated Kinase 4 in Complex with (S)-N-(5-(3-benzyl-1-methylpiperazine-4-carbonyl)-6,6-dimethyl-1,4,5, 6-tetrahydropyrrolo(3,4-c)pyrazol-3-yl)-3-phenoxybenzamide
2CDZ	;	2.3	;	CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH CGP74514A
2X4Z	;	2.1	;	Crystal Structure of the Human p21-Activated Kinase 4 in Complex with PF-03758309
2F57	;	1.8	;	Crystal Structure Of The Human P21-Activated Kinase 5
2C30	;	1.6	;	Crystal Structure Of The Human P21-Activated Kinase 6
1UOL	;	1.9	;	Crystal structure of the human p53 core domain mutant M133L/V203A/N239Y/N268D at 1.9 A resolution.
8UQR	;	1.22	;	Crystal structure of the human p53 tetramerization domain
3ZY1	;	2.15	;	Crystal structure of the human p63 tetramerization domain
2WQI	;	1.7	;	Crystal structure of the human p73 tetramerization domain
4AV1	;	3.1	;	Crystal structure of the human PARP-1 DNA binding domain in complex with DNA
6PAX	;	2.5	;	CRYSTAL STRUCTURE OF THE HUMAN PAX-6 PAIRED DOMAIN-DNA COMPLEX REVEALS A GENERAL MODEL FOR PAX PROTEIN-DNA INTERACTIONS
6J3O	;	2.11	;	Crystal structure of the human PCAF bromodomain in complex with compound 12
8GDY	;	2.05	;	Crystal structure of the human PDI first domain with 9 mutations
3KIJ	;	1.8	;	Crystal structure of the human PDI-peroxidase
2HXP	;	1.83	;	Crystal Structure of the human phosphatase (DUSP9)
2YY2	;	2.8	;	Crystal structure of the human Phosphodiesterase 9A catalytic domain complexed with IBMX
8A5W	;	2.78	;	Crystal structure of the human phosphoserine aminotransferase (PSAT) in complex with O-phosphoserine
8A5V	;	2.46	;	Crystal structure of the human phosposerine aminotransferase (PSAT)
2BZH	;	1.9	;	CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
2BZI	;	1.9	;	CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU2
2BZJ	;	2.05	;	CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU3
2BZK	;	2.45	;	CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AMPPNP AND PIMTIDE
3BWF	;	2.35	;	Crystal structure of the human Pim1 in complex with an osmium compound
1XWS	;	1.8	;	Crystal Structure of the human PIM1 kinase domain
2IWI	;	2.8	;	CRYSTAL STRUCTURE OF THE HUMAN PIM2 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
5ZKQ	;	2.9	;	Crystal structure of the human platelet-activating factor receptor in complex with ABT-491
5ZKP	;	2.81	;	Crystal structure of the human platelet-activating factor receptor in complex with SR 27417
2W3O	;	1.85	;	Crystal structure of the human PNKP FHA domain in complex with an XRCC1-derived phosphopeptide
5D4K	;	2.599	;	Crystal structure of the human polymeric Ig receptor (pIgR) ectodomain
1KKQ	;	3.0	;	Crystal structure of the human PPAR-alpha ligand-binding domain in complex with an antagonist GW6471 and a SMRT corepressor motif
4XLD	;	2.45	;	Crystal structure of the human PPARg-LBD/rosiglitazone complex obtained by dry co-crystallization and in situ diffraction
1M13	;	2.15	;	Crystal Structure of the Human Pregane X Receptor Ligand Binding Domain in Complex with Hyperforin, a Constituent of St. John's Wort
2O9I	;	2.8	;	Crystal Structure of the Human Pregnane X Receptor LBD in complex with an SRC-1 coactivator peptide and T0901317
1I4M	;	2.0	;	Crystal structure of the human prion protein reveals a mechanism for oligomerization
4GQB	;	2.06	;	Crystal Structure of the human PRMT5:MEP50 Complex
6RLL	;	2.22	;	CRYSTAL STRUCTURE OF THE HUMAN PRMT5:MEP50 COMPLEX with JNJ44064146
6RLQ	;	2.53	;	CRYSTAL STRUCTURE OF THE HUMAN PRMT5:MEP50 COMPLEX with JNJ45031882
7BO7	;	2.83	;	CRYSTAL STRUCTURE OF THE HUMAN PRMT5:MEP50 COMPLEX with JNJB44355437
3D90	;	2.26	;	Crystal structure of the human progesterone receptor ligand-binding domain bound to levonorgestrel
7OBM	;	3.1	;	Crystal structure of the human Prolyl Endopeptidase-Like protein short form (residues 90-727)
6AK3	;	2.9	;	Crystal structure of the human prostaglandin E receptor EP3 bound to prostaglandin E2
5YHL	;	4.2	;	Crystal structure of the human prostaglandin E receptor EP4 in complex with Fab and an antagonist Br-derivative
5YWY	;	3.2	;	Crystal structure of the human prostaglandin E receptor EP4 in complex with Fab and ONO-AE3-208
2BZL	;	1.65	;	CRYSTAL STRUCTURE OF THE HUMAN PROTEIN TYROSINE PHOSPHATASE N14 AT 1. 65 A RESOLUTION
6H8R	;	1.66	;	CRYSTAL STRUCTURE OF THE HUMAN PROTEIN TYROSINE PHOSPHATASE PTPN5 (STEP) IN COMPLEX WITH COMPOUND 2
2BIJ	;	2.05	;	Crystal structure of the human protein tyrosine phosphatase PTPN5 (STEP, striatum enriched enriched Phosphatase)
2BV5	;	1.8	;	CRYSTAL STRUCTURE OF THE HUMAN PROTEIN TYROSINE PHOSPHATASE PTPN5 AT 1.8A RESOLUTION
2VPH	;	1.9	;	Crystal structure of the human protein tyrosine phosphatase, non- receptor type 4, PDZ domain
2A3K	;	2.55	;	Crystal Structure of the Human Protein Tyrosine Phosphatase, PTPN7 (HePTP, Hematopoietic Protein Tyrosine Phosphatase)
4IQY	;	1.55	;	Crystal structure of the human protein-proximal ADP-ribosyl-hydrolase MacroD2
8CCT	;	2.9	;	Crystal structure of the human PXR ligand-binding domain in complex with 2,2'-dichloro bisphenol A
8CH8	;	2.15	;	Crystal structure of the human PXR ligand-binding domain in complex with liranaftate
8CF9	;	2.0	;	Crystal structure of the human PXR ligand-binding domain in complex with sclareol
1NRL	;	2.0	;	Crystal Structure of the human PXR-LBD in complex with an SRC-1 coactivator peptide and SR12813
4NY9	;	2.8	;	Crystal Structure Of the Human PXR-LBD In Complex With N-{(2R)-1-[(4S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl]-3-methyl-1-oxobutan-2-yl}-3-hydroxy-3-methylbutanamide
2XB1	;	1.9	;	Crystal structure of the human Pygo2 PHD finger in complex with the B9L HD1 domain
8DL3	;	2.26	;	Crystal structure of the human queuine salvage enzyme DUF2419, complexed with queuine
7UGK	;	1.78	;	Crystal structure of the human queuine salvage enzyme DUF2419, wild-type apo form
2C2H	;	1.85	;	CRYSTAL STRUCTURE OF THE HUMAN RAC3 IN COMPLEX WITH GDP
4AOW	;	2.45	;	Crystal structure of the human Rack1 protein at a resolution of 2.45 angstrom
1KN0	;	2.85	;	Crystal Structure of the human Rad52 protein
3A1J	;	2.5	;	Crystal structure of the human Rad9-Hus1-Rad1 complex
3GGR	;	3.2	;	Crystal Structure of the Human Rad9-Hus1-Rad1 complex
6J8Y	;	2.4	;	Crystal structure of the human RAD9-HUS1-RAD1-RHINO complex
8WU8	;	2.81	;	Crystal structure of the human RAD9-RAD1(F64A/M256A/F266A)-HUS1-RHINO(88-99) complex
3G65	;	2.9	;	Crystal Structure of the Human Rad9-Rad1-Hus1 DNA Damage Checkpoint Complex
8GNN	;	2.119	;	Crystal structure of the human RAD9-RAD1-HUS1-RAD17 complex
4P2Y	;	2.3	;	Crystal structure of the human RAGE ectodomain (fragment VC1C2) in complex with mouse S100A6
4YBH	;	2.4	;	Crystal structure of the human RAGE ectodomain (VC1C2 fragment) in complex with human S100A6
4LP4	;	2.4	;	Crystal structure of the human RAGE VC1 fragment in space group P62
5IQQ	;	2.52	;	Crystal structure of the human RBM7 RRM domain
2GJT	;	2.15	;	Crystal structure of the human receptor phosphatase PTPRO
2OOQ	;	1.8	;	Crystal Structure of the Human Receptor Phosphatase PTPRT
5LST	;	2.75	;	Crystal structure of the human RecQL4 helicase.
3CBQ	;	1.82	;	Crystal structure of the human REM2 GTPase with bound GDP
3GQQ	;	1.945	;	Crystal structure of the human retinal protein 4 (unc-119 homolog A). Northeast Structural Genomics Consortium target HR3066a
2BX6	;	2.1	;	Crystal Structure of the human Retinitis Pigmentosa protein 2 (RP2)
2QS9	;	1.72	;	Crystal structure of the human retinoblastoma-binding protein 9 (RBBP-9). NESG target HR2978
4CN7	;	2.34	;	Crystal Structure of the Human Retinoid X Receptor DNA-Binding Domain Bound to an idealized DR1 Response Element
4CN3	;	2.35	;	Crystal Structure of the Human Retinoid X Receptor DNA-Binding Domain Bound to the Human Gde1SpA Response Element
6FBR	;	2.1	;	Crystal Structure of the Human Retinoid X Receptor DNA-Binding Domain Bound to the Human MEp DR1 Response Element, pH 4.2
6FBQ	;	1.6	;	Crystal Structure of the Human Retinoid X Receptor DNA-Binding Domain Bound to the Human MEp DR1 Response Element, pH 7.0
4CN5	;	2.0	;	Crystal Structure of the Human Retinoid X Receptor DNA-Binding Domain Bound to the Human Nr1d1 Response Element
4CN2	;	2.069	;	Crystal Structure of the Human Retinoid X Receptor DNA-Binding Domain Bound to the Human Ramp2 Response Element
4UHY	;	3.2	;	Crystal structure of the human RGMA-BMP2 complex
4UHZ	;	2.85	;	Crystal structure of the human RGMB-BMP2 complex, crystal form 1
4UI0	;	2.8	;	Crystal structure of the human RGMB-BMP2 complex, crystal form 2
4UI1	;	2.35	;	Crystal structure of the human RGMC-BMP2 complex
3HD6	;	2.1	;	Crystal Structure of the Human Rhesus Glycoprotein RhCG
1FTN	;	2.1	;	CRYSTAL STRUCTURE OF THE HUMAN RHOA/GDP COMPLEX
2GCN	;	1.85	;	Crystal structure of the human RhoC-GDP complex
2GCO	;	1.4	;	Crystal structure of the human RhoC-GppNHp complex
2GCP	;	2.15	;	Crystal structure of the human RhoC-GSP complex
2WNT	;	2.4	;	Crystal Structure of the Human Ribosomal protein S6 kinase
2C46	;	1.6	;	CRYSTAL STRUCTURE OF THE HUMAN RNA guanylyltransferase and 5'- phosphatase
5AYG	;	2.6	;	Crystal Structure of the Human ROR gamma Ligand Binding Domain With 3g
1S0X	;	2.2	;	Crystal structure of the human RORalpha ligand binding domain in complex with cholesterol sulfate at 2.2A
6GXZ	;	2.965	;	Crystal structure of the human RPAP3(TPR2)-PIH1D1(CS) complex
3SAF	;	2.5	;	Crystal structure of the human RRP6 catalytic domain with D313N mutation in the active site
3SAG	;	2.7	;	Crystal structure of the human RRP6 catalytic domain with D313N mutation in the active site
3SAH	;	2.65	;	Crystal structure of the human RRP6 catalytic domain with Y436A mutation in the catalytic site
1FBY	;	2.25	;	CRYSTAL STRUCTURE OF THE HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO 9-CIS RETINOIC ACID
2ZXZ	;	3.0	;	Crystal structure of the human RXR alpha ligand binding domain bound to a synthetic agonist compound and a coactivator peptide
2ZY0	;	2.9	;	Crystal structure of the human RXR alpha ligand binding domain bound to a synthetic agonist compound and a coactivator peptide
1MV9	;	1.9	;	Crystal Structure of the human RXR alpha ligand binding domain bound to the eicosanoid DHA (Docosa Hexaenoic Acid) and a coactivator peptide
1MVC	;	1.9	;	Crystal structure of the human RXR alpha ligand binding domain bound to the synthetic agonist compound BMS 649 and a coactivator peptide
6XWH	;	2.1	;	Crystal Structure of the Human RXR DNA-Binding Domain Homodimer Bound to the Human Hoxb13 DR0 Response Element
6XWG	;	2.4	;	Crystal Structure of the Human RXR/RAR DNA-Binding Domain Heterodimer Bound to the Human RARb2 DR5 Response Element
6SW5	;	2.35	;	Crystal structure of the human S-adenosylmethionine synthetase 1 (ligand-free form)
8SWA	;	1.999	;	Crystal structure of the human S-adenosylmethionine synthetase 1 in complex with SAM and PPNP
2OBV	;	2.05	;	Crystal structure of the human S-adenosylmethionine synthetase 1 in complex with the product
6MS1	;	1.35	;	Crystal structure of the human Scribble PDZ1 domain bound to the PDZ-binding motif of APC
2NUP	;	2.8	;	Crystal Structure of the human Sec23a/24a heterodimer, complexed with the SNARE protein Sec22b
2NUT	;	2.3	;	Crystal Structure of the human Sec23a/24a heterodimer, complexed with the SNARE protein Sec22b
5AEK	;	3.0	;	Crystal structure of the human SENP2 C548S in complex with the human SUMO1 K48M F66W
3EAY	;	2.4	;	Crystal structure of the human SENP7 catalytic domain
2BUJ	;	2.6	;	Crystal structure of the human Serine-threonine Kinase 16 in complex with staurosporine
4L87	;	2.897	;	Crystal structure of the human seryl-tRNA synthetase in complex with Ser-SA at 2.9 Angstrom resolution
5IFE	;	3.1	;	Crystal structure of the human SF3b core complex
1U6T	;	1.9	;	Crystal structure of the human SH3 binding glutamic-rich protein like
2F24	;	1.76	;	Crystal Structure of the Human Sialidase Neu2 E111Q Mutant
2F25	;	1.95	;	Crystal Structure of the Human Sialidase Neu2 E111Q Mutant in Complex with DANA Inhibitor
2F26	;	1.58	;	Crystal Structure of the Human Sialidase Neu2 E111Q-Q112E Double Mutant
2F27	;	2.15	;	Crystal Structure of the Human Sialidase Neu2 E111Q-Q112E Double Mutant in Complex with DANA Inhibitor
2F13	;	2.26	;	Crystal Structure of the Human Sialidase Neu2 in Complex with 2',3'- dihydroxypropyl ether mimetic Inhibitor
2F12	;	2.27	;	Crystal Structure of the Human Sialidase Neu2 in Complex with 3- hydroxypropyl ether mimetic Inhibitor
2F11	;	2.57	;	Crystal Structure of the Human Sialidase Neu2 in Complex with isobutyl ether mimetic Inhibitor
2F10	;	2.9	;	Crystal Structure of the Human Sialidase Neu2 in Complex with Peramivir inhibitor
2F0Z	;	2.8	;	Crystal Structure of the Human Sialidase Neu2 in Complex with Zanamivir inhibitor
2F28	;	1.67	;	Crystal Structure of the Human Sialidase Neu2 Q116E Mutant
2F29	;	2.921	;	Crystal Structure of the Human Sialidase Neu2 Q116E Mutant in Complex with DANA Inhibitor
1YWT	;	2.4	;	Crystal structure of the human sigma isoform of 14-3-3 in complex with a mode-1 phosphopeptide
4RJF	;	2.0072	;	Crystal structure of the human sliding clamp at 2.0 angstrom resolution
8FR5	;	1.33	;	Crystal structure of the Human Smacovirus 1 Rep domain
2HHL	;	2.1	;	Crystal structure of the human small CTD phosphatase 3 isoform 1
2G3Y	;	2.4	;	Crystal structure of the human small GTPase GEM
3APM	;	2.5	;	Crystal structure of the human SNP PAD4 protein
7SR1	;	2.4	;	Crystal structure of the human SNX25 regulator of G-protein signalling (RGS) domain
7SR2	;	2.42	;	Crystal structure of the human SNX25 regulator of G-protein signalling (RGS) domain
5IV4	;	1.79	;	Crystal structure of the human soluble adenylyl cyclase in complex with the allosteric inhibitor LRE1
5F4E	;	2.4	;	Crystal structure of the human sperm Izumo1 and egg Juno complex
5F4T	;	3.083	;	Crystal structure of the human sperm Izumo1 residues 22-254
5F4V	;	2.9	;	Crystal structure of the human sperm Izumo1 residues 22-268
7TA2	;	2.25	;	Crystal structure of the human sperm-expressed surface protein SPACA6
2YLF	;	2.05	;	Crystal structure of the human Spir-1 KIND domain
2YLE	;	1.8	;	Crystal structure of the human Spir-1 KIND FSI domain in complex with the FSI peptide
7PJH	;	2.35	;	Crystal structure of the human spliceosomal maturation factor AAR2 bound to the RNAse H domain of PRPF8
4J8Z	;	2.42	;	Crystal Structure of the Human SPOP BTB Domain
4HS2	;	1.53	;	Crystal Structure of the Human SPOP C-terminal Domain
3VJ8	;	1.52	;	Crystal structure of the human squalene synthase
3VJ9	;	1.52	;	Crystal structure of the human squalene synthase
3VJA	;	1.76	;	Crystal structure of the human squalene synthase
3VJB	;	2.05	;	Crystal structure of the human squalene synthase
3LEE	;	3.2	;	Crystal structure of the human squalene synthase complexed with BPH-652
3WEJ	;	2.0	;	Crystal structure of the human squalene synthase F288A mutant in complex with presqualene pyrophosphate
3WEK	;	1.85	;	Crystal structure of the human squalene synthase F288L mutant in complex with presqualene pyrophosphate
3WEF	;	2.35	;	Crystal structure of the human squalene synthase in complex with farnesyl thiopyrophosphate
3WEG	;	1.75	;	Crystal structure of the human squalene synthase in complex with farnesyl thiopyrophosphate and magnesium ion
3WEH	;	1.87	;	Crystal structure of the human squalene synthase in complex with presqualene pyrophosphate
3VJC	;	1.89	;	Crystal structure of the human squalene synthase in complex with zaragozic acid A
3WEI	;	1.79	;	Crystal structure of the human squalene synthase Y73A mutant in complex with presqualene pyrophosphate
3KTV	;	3.8	;	Crystal structure of the human SRP19/S-domain SRP RNA complex
5DO7	;	3.93	;	Crystal Structure of the Human Sterol Transporter ABCG5/ABCG8
3O2S	;	2.5	;	Crystal structure of the human symplekin-Ssu72 complex
3O2Q	;	2.4	;	Crystal structure of the human symplekin-Ssu72-CTD phosphopeptide complex
8F0L	;	1.81	;	Crystal Structure of the Human T cell Receptor CD3(EPSILON) N-Terminal Peptide Complexed with ADI-26906 FAB
1H3O	;	2.3	;	Crystal Structure of the Human TAF4-TAF12 (TAFII135-TAFII20) Complex
6F3T	;	2.5	;	Crystal structure of the human TAF5-TAF6-TAF9 complex
5JU5	;	2.5	;	Crystal structure of the human Tankyrase 1 (TNKS) SAM domain (D1055R), crystal form 1
5JTI	;	2.9	;	Crystal structure of the human Tankyrase 1 (TNKS) SAM domain (D1055R), crystal form 2
5JRT	;	1.53	;	Crystal structure of the human Tankyrase 2 (TNKS2) SAM domain (DH902/924RE)
2Y1H	;	2.5	;	Crystal structure of the human TatD-domain protein 3 (TATDN3)
4HL4	;	2.2	;	Crystal structure of the human TBC1D20 RabGAP domain
4JOI	;	2.05	;	Crystal structure of the human telomeric Stn1-Ten1 complex
5GPY	;	2.1	;	Crystal structure of the human TFIIE complex
1YDL	;	2.3	;	Crystal Structure of the Human TFIIH, Northeast Structural Genomics Target HR2045.
1KTZ	;	2.15	;	Crystal Structure of the Human TGF-beta Type II Receptor Extracellular Domain in Complex with TGF-beta3
6H42	;	2.45	;	crystal structure of the human TGT catalytic subunit QTRT1
6H45	;	2.4	;	crystal structure of the human TGT catalytic subunit QTRT1 in complex with queuine
3QFA	;	2.2	;	Crystal structure of the human thioredoxin reductase-thioredoxin complex
3QFB	;	2.6	;	Crystal structure of the human thioredoxin reductase-thioredoxin complex
3QDZ	;	2.8	;	Crystal structure of the human thrombin mutant D102N in complex with the extracellular fragment of human PAR4.
6IIV	;	3.0	;	Crystal structure of the human thromboxane A2 receptor bound to daltroban
6IIU	;	2.5	;	Crystal structure of the human thromboxane A2 receptor bound to ramatroban
6R2E	;	2.55	;	Crystal structure of the human thymidylate synthase (hTS) interface variant Q62R
6DHB	;	1.7	;	Crystal structure of the human TIM-3 with bound Calcium
5XYF	;	2.202	;	Crystal structure of the human TIN2-TPP1-TRF2 telomeric complex
6NIG	;	2.35	;	Crystal structure of the human TLR2-Diprovocim complex
2Z65	;	2.7	;	Crystal structure of the human TLR4 TV3 hybrid-MD-2-Eritoran complex
3FXI	;	3.1	;	Crystal structure of the human TLR4-human MD-2-E.coli LPS Ra complex
4CGY	;	2.85	;	Crystal structure of the human topoisomerase III alpha-RMI1 complex
4CHT	;	3.25	;	Crystal structure of the human topoisomerase III alpha-RMI1 complex with bound calcium ion
7XV9	;	1.599	;	Crystal structure of the Human TR4 DNA-Binding Domain
7XV8	;	3.199	;	Crystal structure of the Human TR4 DNA-Binding Domain Homodimer Bound to DR1 Response Element
7XV6	;	2.3	;	Crystal structure of the Human TR4 DNA-Binding Domain with C-terminal extension (DBD-CTE) Homodimer Bound to DR1 Response Element
7XVA	;	1.856	;	Crystal structure of the Human TR4 Ligand Binding Domain in complex with the JAZF1 corepressor fragment
2C62	;	1.74	;	Crystal Structure of the Human Transcription Cofactor PC4 in Complex with Single-Stranded DNA
3H7H	;	1.55	;	Crystal structure of the human transcription elongation factor DSIF, hSpt4/hSpt5 (176-273)
2XZZ	;	2.3	;	Crystal structure of the human transglutaminase 1 beta-barrel domain
6FLN	;	3.6	;	Crystal structure of the human TRIM25 coiled-coil and PRYSPRY domains
6FLM	;	2.009	;	Crystal structure of the human TRIM25 PRYSPRY domain
7UW7	;	1.17	;	Crystal structure of the Human TRIP12 WWE domain (isoform 2) in complex with ADP
8TRE	;	1.4	;	Crystal structure of the Human TRIP12 WWE domain (isoform 2) in complex with ATP
4DX1	;	2.85	;	Crystal structure of the human TRPV4 ankyrin repeat domain
4DX2	;	2.95	;	Crystal structure of the human TRPV4 ankyrin repeat domain
2PF5	;	1.9	;	Crystal Structure of the Human TSG-6 Link Module
6N6O	;	2.6	;	Crystal structure of the human TTK in complex with an inhibitor
5YOY	;	2.727	;	Crystal structure of the human tumor necrosis factor in complex with golimumab Fv
3UM7	;	3.31	;	Crystal structure of the human two pore domain K+ ion channel TRAAK (K2P4.1)
3UKM	;	3.4	;	Crystal structure of the human two pore domain potassium ion channel K2P1 (TWIK-1)
6RV2	;	3.0	;	Crystal structure of the human two pore domain potassium ion channel TASK-1 (K2P3.1) in a closed conformation
6RV3	;	2.9	;	Crystal structure of the human two pore domain potassium ion channel TASK-1 (K2P3.1) in a closed conformation with a bound inhibitor BAY 1000493
6RV4	;	3.1	;	Crystal structure of the human two pore domain potassium ion channel TASK-1 (K2P3.1) in a closed conformation with a bound inhibitor BAY 2341237
4PO6	;	1.99	;	Crystal structure of the human TYK2 FERM and SH2 domains with an IFNAR1 intracellular peptide
3B7O	;	1.6	;	Crystal structure of the human tyrosine phosphatase SHP2 (PTPN11) with an accessible active site
2H4V	;	1.55	;	Crystal Structure of the Human Tyrosine Receptor Phosphatase Gamma
2PBN	;	1.7	;	Crystal structure of the human tyrosine receptor phosphate gamma
2HY3	;	2.6	;	Crystal structure of the human tyrosine receptor phosphate gamma in complex with vanadate
5THL	;	1.6	;	Crystal structure of the human tyrosyl-tRNA synthetase mutant G41R
3TGD	;	1.8	;	Crystal structure of the human ubiquitin-conjugating enzyme (E2) UbcH5b
5TDC	;	1.607	;	Crystal structure of the human UBR-box domain from UBR1 in complex with monomethylated arginine peptide.
5TDB	;	1.101	;	Crystal structure of the human UBR-box domain from UBR2 in complex with asymmetrically double methylated arginine peptide
1TEV	;	2.1	;	Crystal structure of the human UMP/CMP kinase in open conformation
4MEL	;	2.899	;	Crystal Structure of the human USP11 DUSP-UBL domains
6CNX	;	2.0	;	Crystal Structure of the Human vaccinia-related kinase 1 (VRK1) bound to an N-propynyl-N-isopentyl-dihydropteridin inhibitor
6BP0	;	1.9	;	Crystal Structure of the Human vaccinia-related kinase 1 bound to (R)-2-phenylaminopteridinone inhibitor
5UKF	;	2.4	;	Crystal Structure of the Human Vaccinia-related Kinase 1 Bound to an Oxindole Inhibitor
6BRU	;	1.8	;	Crystal Structure of the Human vaccinia-related kinase bound to a (S)-2-phenylaminopteridinone inhibitor
6BU6	;	1.8	;	Crystal Structure of the Human vaccinia-related kinase bound to a bis-difluorophenol-aminopyridine inhibitor
6DD4	;	2.1	;	Crystal Structure of the Human vaccinia-related kinase bound to a N,N-dipropyl-dihydropteridine inhibitor
6CMM	;	2.1	;	Crystal Structure of the Human vaccinia-related kinase bound to a N,N-dipropynyl-dihydropteridine inhibitor
6NPN	;	2.2	;	Crystal Structure of the Human vaccinia-related kinase bound to a N,N-dipropynyl-dihydropteridine-3-hydroxyindazole inhibitor
6CSW	;	2.25	;	Crystal Structure of the Human vaccinia-related kinase bound to a N-methyl-N-propyl-dihydropteridine inhibitor
6CQH	;	2.15	;	Crystal Structure of the Human vaccinia-related kinase bound to a N-propynyl-N-ethyl-dihydropteridine inhibitor
6BTW	;	1.9	;	Crystal Structure of the Human vaccinia-related kinase bound to a phenyl-pteridinone inhibitor
6CFM	;	2.45	;	Crystal Structure of the Human vaccinia-related kinase bound to a propynyl-pteridinone inhibitor
5UVF	;	2.0	;	Crystal Structure of the Human vaccinia-related kinase bound to BI-D1870
3A78	;	1.9	;	Crystal structure of the human VDR ligand binding domain bound to the natural metabolite 1alpha,25-dihydroxy-3-epi-vitamin D3
3A3Z	;	1.72	;	Crystal structure of the human VDR ligand binding domain bound to the synthetic agonist compound 2alpha-methyl-AMCR277A(C23S)
3A40	;	1.45	;	Crystal structure of the human VDR ligand binding domain bound to the synthetic agonist compound 2alpha-methyl-AMCR277B(C23R)
7OBF	;	2.699	;	Crystal structure of the human VH antibody domain HEL4
3A2I	;	3.27	;	Crystal structure of the human vitamin D receptor (H305F) ligand binding domain complexed with TEI-9647
3A2J	;	2.7	;	Crystal structure of the human vitamin D receptor (H305F/H397F) ligand binding domain complexed with TEI-9647
5YSY	;	2.0	;	Crystal structure of the human vitamin D receptor ligand binding domain complexed with (1R,2R,3R)-5-[(E)-2-{(1R,3aS,7aR)-1-[(R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,6,7,7a-hexahydro-1H-inden-4-yl}vinyl]-2-(3-hydroxypropyl)cyclohex-4-ene-1,3-diol
5YT2	;	2.0	;	Crystal structure of the human vitamin D receptor ligand binding domain complexed with (1R,2S,3R)-5-[(E)-2-{(1R,3aS,7aR)-1-[(R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,6,7,7a-hexahydro-1H-inden-4-yl}vinyl]-2-(3-hydroxypropyl)cyclohex-4-ene-1,3-diol
5GT4	;	1.83	;	Crystal structure of the human vitamin D receptor ligand binding domain complexed with (1R,2S,3R,5Z,7E,14beta,17alpha)-2-cyanopropoxy-9,10-secocholesta-5,7,10-triene-1,3,25-triol
8IQT	;	1.745	;	Crystal structure of the human vitamin D receptor ligand binding domain complexed with (23R)-F-25(OH)D3
3WWR	;	3.18	;	Crystal structure of the human vitamin D receptor ligand binding domain complexed with 1-((((1S,2R,6R,Z)-2,6-dihydroxy-4-((E)-2-((1R,3aS,7aR)-1-((R)-6-hydroxy-6-methylheptan-2-yl)-7a-methylhexahydro-1H-inden-4(2H)-ylidene)ethylidene)-3-methylenecyclohexyl)oxy)methyl)cyclopropanecarbonitrile
3AX8	;	2.6	;	Crystal structure of the human vitamin D receptor ligand binding domain complexed with 15alpha-methoxy-1alpha,25-dihydroxyvitamin D3
4ITF	;	2.84	;	Crystal structure of the human vitamin D receptor ligand binding domain complexed with 1alpha,25-Dihydroxy-2alpha-[2-(1H-tetrazole-1-yl)ethyl]vitamin D3
4ITE	;	2.49	;	Crystal structure of the human vitamin D receptor ligand binding domain complexed with 1alpha,25-Dihydroxy-2alpha-[2-(2H-tetrazol-2-yl)ethyl]vitamin D3
8IQN	;	1.639	;	Crystal structure of the human vitamin D receptor ligand binding domain complexed with 24,24-F2-25(OH)D3
3VHW	;	2.43	;	Crystal structure of the human vitamin D receptor ligand binding domain complexed with 4-MP
3X31	;	2.11	;	Crystal structure of the human vitamin D receptor ligand binding domain complexed with 7,8-cis-14-epi-1a,25-Dihydroxy-19-norvitamin D3
3X36	;	1.93	;	Crystal structure of the human vitamin D receptor ligand binding domain complexed with 7,8-cis-1a,25-Dihydroxy-19-norvitamin D3
3AUQ	;	2.64	;	Crystal structure of the human vitamin D receptor ligand binding domain complexed with Yne-diene type analog of active 14-epi-2alpha-methyl-19-norvitamin D3
3AUR	;	2.21	;	Crystal structure of the human vitamin D receptor ligand binding domain complexed with Yne-diene type analog of active 14-epi-2beta-methyl-19-norvitamin D3
3HTU	;	2.0	;	Crystal structure of the human VPS25-VPS20 subcomplex
2DWR	;	2.5	;	Crystal structure of the human Wa rotavirus VP8* carbohydrate-recognising domain
3APN	;	2.7	;	Crystal structure of the human wild-type PAD4 protein
6FBK	;	1.743	;	Crystal structure of the human WNK2 CCT-like 1 domain in complex with a WNK1 RFXV peptide
6ELM	;	1.14	;	Crystal structure of the human WNK2 CCT1 domain
3RWR	;	3.943	;	Crystal structure of the human XRCC4-XLF complex
1P27	;	2.0	;	Crystal Structure of the Human Y14/Magoh complex
6K6U	;	2.27	;	Crystal structure of the human YTHDC2 YTH domain
5MKW	;	2.0	;	Crystal structure of the human ZRANB3 HNH domain
1S3R	;	2.6	;	Crystal structure of the human-specific toxin intermedilysin
3QCT	;	2.1493	;	Crystal structure of the humanized apo LT3015 anti-lysophosphatidic acid antibody Fab fragment
3TV5	;	2.8	;	Crystal Structure of the humanized carboxyltransferase domain of yeast Acetyl-coA caroxylase in complex with compound 1
3TZ3	;	2.7	;	Crystal Structure of the humanized carboxyltransferase domain of yeast Acetyl-coA caroxylase in complex with compound 2
3TVU	;	2.4	;	Crystal Structure of the humanized carboxyltransferase domain of yeast Acetyl-coA caroxylase in complex with compound 3
3TVW	;	2.8	;	Crystal Structure of the humanized carboxyltransferase domain of yeast Acetyl-coA caroxylase in complex with compound 4
8GKK	;	1.75	;	Crystal Structure of the Humanized MUC16 Specific Antibody huAR9.6
8GKL	;	2.6	;	Crystal Structure of the Humanized MUC16 Specific Antibody huAR9.6
3AAZ	;	2.2	;	Crystal structure of the humanized recombinant Fab fragment of a murine; antibody
3I00	;	2.3	;	Crystal Structure of the huntingtin interacting protein 1 coiled coil domain
3AWJ	;	2.2	;	Crystal structure of the Huperzia serrata polyketide synthase 1 complexed with CoA-SH
2VUI	;	2.9	;	Crystal structure of the HupR receiver domain in inhibitory phospho- state
1WPU	;	1.48	;	Crystal Structure of the HutP antitermination complex bound to a single stranded region of hut mRNA
3BOY	;	1.7	;	Crystal structure of the HutP antitermination complex bound to the HUT mRNA
4ELK	;	2.1	;	Crystal structure of the Hy19.3 type II NKT TCR
6QSG	;	1.15	;	Crystal structure of the hybrid bioinorganic complex of Pizza6S and Keggin (STA)
6QSH	;	2.5	;	Crystal structure of the hybrid bioinorganic complex of Pizza6S linked by the 1:2 Ce-substituted Keggin
6V9K	;	1.9	;	CRYSTAL STRUCTURE OF THE HYBRID C-TERMINAL DOMAIN OF ENZYME I OF THE BACTERIAL PHOSPHOTRANSFERASE SYSTEM FORMED BY HYBRIDIZING THE SCAFFOLD OF THE ESCHERICHIA COLI ENZYME WITH THE ACTIVE SITE LOOPS FROM THE THERMOANAEROBACTER TENGCONGENSIS ENZYME
6VBJ	;	2.0	;	CRYSTAL STRUCTURE OF THE HYBRID C-TERMINAL DOMAIN OF ENZYME I OF THE BACTERIAL PHOSPHOTRANSFERASE SYSTEM FORMED BY HYBRIDIZING THE SCAFFOLD OF THE THERMOANAEROBACTER TENGCONGENSIS ENZYME WITH THE ACTIVE SITE LOOPS FROM THE ESCHERICHIA COLI ENZYME
4V8O	;	3.8	;	Crystal structure of the hybrid state of ribosome in complex with the guanosine triphosphatase release factor 3
2E85	;	1.7	;	Crystal Structure of the Hydrogenase 3 Maturation protease
3D3R	;	1.85	;	Crystal structure of the hydrogenase assembly chaperone HypC/HupF family protein from Shewanella oneidensis MR-1
7KCT	;	2.02	;	Crystal Structure of the Hydrogenobacter thermophilus 2-Oxoglutarate Carboxylase (OGC) Biotin Carboxylase (BC) Domain Dimer in Complex with Adenosine 5'-Diphosphate Magnesium Salt (MgADP), Adenosine 5'-Diphosphate (ADP, and Bicarbonate Anion (Hydrogen Carbonate/HCO3-)
4TT8	;	2.301	;	Crystal structure of the hydrolase domain of 10-formyltetrahydrofolate dehydrogenase (wild-type) complex with 10-formyl-5,8-dideazafolate
4R8V	;	2.197	;	Crystal structure of the hydrolase domain of 10-formyltetrahydrofolate dehydrogenase (wild-type) complex with formate
4QPD	;	2.1	;	Crystal structure of the hydrolase domain of 10-formyltetrahydrofolate dehydrogenase (wild-type) complex with tetrahydrofolate
4TS4	;	1.75	;	Crystal structure of the hydrolase domain of 10-formyltetrahydrofolate dehydrogenase (wild-type) from zebrafish
4TTS	;	2.0	;	Crystal structure of the hydrolase domain of 10-formyltetrahydrofolate dehydrogenase (Y200A) complex with 10-formyl-5,8-dideazafolate
4QPC	;	1.902	;	Crystal structure of the hydrolase domain of 10-formyltetrahydrofolate dehydrogenase (Y200A) from zebrafish
2BW0	;	1.7	;	Crystal Structure of the hydrolase domain of Human 10-Formyltetrahydrofolate 2 dehydrogenase
6IGU	;	2.11	;	Crystal structure of the hydrolytic antibody Fab 9C10
2FUG	;	3.3	;	Crystal structure of the hydrophilic domain of respiratory complex I from Thermus thermophilus
3I9V	;	3.1	;	Crystal structure of the hydrophilic domain of respiratory complex I from Thermus thermophilus, oxidized, 2 mol/ASU
3IAS	;	3.15	;	Crystal structure of the hydrophilic domain of respiratory complex I from Thermus thermophilus, oxidized, 4 mol/ASU, re-refined to 3.15 angstrom resolution
3IAM	;	3.1	;	Crystal structure of the hydrophilic domain of respiratory complex I from Thermus thermophilus, reduced, 2 mol/ASU, with bound NADH
6W1G	;	1.14	;	Crystal structure of the hydroxyglutarate synthase from Pseudomonas putida
6W1K	;	1.85	;	Crystal structure of the hydroxyglutarate synthase in complex with 2-oxoadipate from Oryza sativa
6W1H	;	1.42	;	Crystal structure of the hydroxyglutarate synthase in complex with 2-oxoadipate from Pseudomonas putida
1TV2	;	2.0	;	Crystal structure of the hydroxylamine MtmB complex
2AHL	;	1.6	;	Crystal structure of the hydroxylamine-induced deoxy-form of the copper-bound Streptomyces castaneoglobisporus tyrosinase in complex with a caddie protein
5XW2	;	1.298	;	Crystal structure of the Hydroxylase HmtN in C 1 2 1 crystal form
1JU2	;	1.47	;	Crystal structure of the hydroxynitrile lyase from almond
5YXY	;	3.299	;	Crystal structure of the HyhL-HypA complex (form I)
5YY0	;	3.243	;	Crystal structure of the HyhL-HypA complex (form II)
5AUP	;	3.102	;	Crystal structure of the HypAB complex
5AUN	;	1.63	;	Crystal structure of the HypAB-Ni complex
5AUO	;	1.8	;	Crystal structure of the HypAB-Ni complex (AMPPCP)
3VYR	;	2.55	;	Crystal structure of the HypC-HypD complex
3VYT	;	2.25	;	Crystal structure of the HypC-HypD-HypE complex (form I inward)
3VYS	;	2.35	;	Crystal structure of the HypC-HypD-HypE complex (form I)
3VYU	;	2.75	;	Crystal structure of the HypC-HypD-HypE complex (form II)
3WJP	;	1.533	;	Crystal structure of the HypE CA form
3WJQ	;	1.645	;	Crystal structure of the HypE CN form
4KE2	;	1.8	;	Crystal structure of the hyperactive Type I antifreeze from winter flounder
1UDV	;	1.85	;	Crystal structure of the hyperthermophilic archaeal dna-binding protein Sso10b2 at 1.85 A
4G2D	;	2.7	;	Crystal structure of the hyperthermophilic Sulfolobus islandicus PLL SisLac
3GEZ	;	2.0	;	Crystal Structure of the hypothetical egulator from Sulfolobus tokodaii 7
2IN5	;	2.3	;	Crystal Structure of the hypothetical lipoprotein YmcC from Escherichia coli (K12), Northeast Structural Genomics target ER552.
7SUA	;	1.65	;	Crystal Structure of the Hypothetical Protein (ACX60_00475) from Acinetobacter baumannii
2QYH	;	2.6	;	Crystal structure of the hypothetical protein (gk1056) from geobacillus kaustophilus HTA426
4Z8Z	;	2.55	;	Crystal structure of the hypothetical protein from Ruminiclostridium thermocellum ATCC 27405
2NMU	;	1.8	;	Crystal structure of the hypothetical protein from Salmonella typhimurium LT2. Northeast Structural Genomics Consortium target StR127.
1JEO	;	2.0	;	Crystal Structure of the Hypothetical Protein MJ1247 from Methanococcus jannaschii at 2.0 A Resolution Infers a Molecular Function of 3-Hexulose-6-Phosphate isomerase.
2X3G	;	1.8	;	Crystal Structure of the hypothetical protein ORF119 from Sulfolobus islandicus rod-shaped virus 1
2X5R	;	2.0	;	Crystal Structure of the hypothetical protein ORF126 from Pyrobaculum spherical virus
2X3O	;	2.9	;	Crystal Structure of the Hypothetical Protein PA0856 from Pseudomonas aeruginosa
7AL6	;	2.1	;	Crystal structure of the hypothetical protein PA1622 from Pseudomonas aeruginosa PAO1
4AVR	;	1.08	;	Crystal structure of the hypothetical protein Pa4485 from Pseudomonas aeruginosa
2XU2	;	2.3	;	Crystal Structure of the hypothetical protein PA4511 from Pseudomonas aeruginosa
2X4H	;	2.3	;	Crystal Structure of the hypothetical protein SSo2273 from Sulfolobus solfataricus
2EJX	;	1.79	;	Crystal structure of the hypothetical protein STK_08120 from Sulfolobus tokodaii
4Q37	;	3.19	;	Crystal structure of the hypothetical protein TM0182 Thermotoga maritima, N-terminal domain.
1WN9	;	1.58	;	Crystal structure of the hypothetical protein TT1805 from Thermus thermophillus HB8
1WNA	;	1.58	;	Crystal structure of the hypothetical protein TT1805 from Thermus thermophillus HB8
2E67	;	2.9	;	Crystal structure of the hypothetical protein TTHB029 from Thermus thermophilus HB8
2YR2	;	2.01	;	Crystal Structure of the Hypothetical regulator from Sulfolobus tokodaii
2EB7	;	1.8	;	Crystal structure of the hypothetical regulator from Sulfolobus tokodaii 7
3GF2	;	1.8	;	Crystal structure of the hypothetical regulator ST1710 complexed with sodium salicylate
2EQA	;	1.8	;	Crystal Structure of the hypothetical Sua5 protein from Sulfolobus tokodaii
3AB8	;	1.7	;	Crystal Structure of the Hypothetical Tandem-type Universal Stress Protein TTHA0350 complexed with ATPs.
3AB7	;	2.52	;	Crystal Structure of the Hypothetical Tandem-type Universal Stress Protein TTHA0350 from Thermus thermophilus HB8
1ZXJ	;	2.8	;	Crystal structure of the hypthetical Mycoplasma protein, MPN555
2GTC	;	2.3	;	Crystal structure of the hypthetical protein from Bacillus cereus (ATCC 14579). Northeast structural genomics Target BcR11
2YKT	;	2.11	;	Crystal structure of the I-BAR domain of IRSp53 (BAIAP2) in complex with an EHEC derived Tir peptide
6FB8	;	2.45	;	Crystal Structure of the I-CreI Homing Endonuclease D75N variant in complex with an altered version of its target DNA at 5NNN region in the presence of Magnesium
6FB9	;	2.95	;	Crystal Structure of the I-CreI Homing Endonuclease D75N variant in complex with an altered version of its target DNA at 5NNN region in the presence of Manganese
6FB7	;	2.689	;	Crystal Structure of the I-CreI Homing Endonuclease D75N variant in complex with its target DNA in the presence of Manganese
4LQ0	;	2.68	;	Crystal structure of the I-LtrWI LAGLIDADG homing endonuclease bound to target DNA.
4LOX	;	1.98	;	Crystal structure of the I-SmaMI LAGLIDADG homing endonuclease bound to cleaved DNA
5V46	;	1.8	;	Crystal structure of the I113M, F270M, K291M, L308M mutant of SR1 domain of human sacsin
1YDK	;	1.95	;	Crystal structure of the I219A mutant of human glutathione transferase A1-1 with S-hexylglutathione
1L9Q	;	1.7	;	CRYSTAL STRUCTURE OF THE I257L VARIANT OF THE COPPER-CONTAINING NITRITE REDUCTASE FROM ALCALIGENES FAECALIS S-6
1L9R	;	1.78	;	CRYSTAL STRUCTURE OF THE I257M VARIANT OF THE COPPER-CONTAINING NITRITE REDUCTASE FROM ALCALIGENES FAECALIS S-6
1L9S	;	1.78	;	CRYSTAL STRUCTURE OF THE I257T VARIANT OF THE COPPER-CONTAINING NITRITE REDUCTASE FROM ALCALIGENES FAECALIS S-6
1L9T	;	1.75	;	CRYSTAL STRUCTURE OF THE I257V VARIANT OF THE COPPER-CONTAINING NITRITE REDUCTASE FROM ALCALIGENES FAECALIS S-6
7ZYT	;	2.892	;	Crystal structure of the I318T pathogenic variant of the human dihydrolipoamide dehydrogenase
3HF2	;	2.2	;	Crystal structure of the I401P mutant of cytochrome P450 BM3
7VIV	;	2.0	;	Crystal structure of the I73R from African Swine Fever Virus
3ZFB	;	1.86	;	Crystal structure of the I75A mutant of human class alpha glutathione transferase in the apo form
5CF2	;	3.0	;	Crystal Structure of the I80Y/L114V/I116V mutant of LEH
3KVF	;	2.8	;	Crystal structure of the I93M mutant of ubiquitin carboxy terminal hydrolase L1 bound to ubiquitin vinylmethylester
3IRT	;	2.799	;	Crystal Structure of the I93M Mutant of Ubiquitin Carboxy-terminal Hydrolase L1
2FPF	;	3.0	;	Crystal structure of the ib1 sh3 dimer at low resolution
8BVL	;	2.24	;	Crystal structure of the IBR-RING2 domain of HOIL-1
2CA1	;	2.6	;	Crystal structure of the IBV coronavirus nucleocapsid
4EYY	;	2.4	;	Crystal Structure of the IcmR-IcmQ complex from Legionella pneumophila
5XNB	;	2.594	;	Crystal structure of the IcmS-IcmW-DotL complex of the Legionella type IVb secretion system
3ML3	;	2.0	;	Crystal structure of the IcsA autochaperone region
1QZ1	;	2.0	;	Crystal Structure of the Ig 1-2-3 fragment of NCAM
3WUZ	;	1.3	;	Crystal structure of the Ig V-set domain of human paired immunoglobulin-like type 2 receptor alpha
4HWU	;	2.903	;	Crystal structure of the Ig-C2 type 1 domain from mouse Fibroblast growth factor receptor 2 (FGFR2) [NYSGRC-005912]
4JGJ	;	2.6508	;	Crystal structure of the Ig-like D1 domain from mouse Carcinoembryogenic antigen-related cell adhesion molecule 15 (CEACAM15) [PSI-NYSGRC-005691]
4DIX	;	1.7	;	Crystal structure of the Ig-PH domain of actin-binding protein SCAB1
3MTR	;	1.8	;	Crystal structure of the Ig5-FN1 tandem of human NCAM
3H9Y	;	2.23	;	Crystal structure of the IgE-Fc3-4 domains
3H9Z	;	2.45	;	Crystal structure of the IgE-Fc3-4 domains
3HA0	;	2.8	;	Crystal structure of the IgE-Fc3-4 domains
4C83	;	2.69	;	Crystal Structure of the IgG2a LPT3 in complex with an 8-sugar inner core analogue of Neisseria meningitidis
3BBR	;	2.25	;	Crystal structure of the iGluR2 ligand binding core (S1S2J-N775S) in complex with a dimeric positive modulator as well as glutamate at 2.25 A resolution
3H6T	;	2.25	;	Crystal structure of the iGluR2 ligand-binding core (S1S2J-N754S) in complex with glutamate and cyclothiazide at 2.25 A resolution
3H6U	;	1.85	;	Crystal structure of the iGluR2 ligand-binding core (S1S2J-N754S) in complex with glutamate and NS1493 at 1.85 A resolution
3H6V	;	2.1	;	Crystal structure of the iGluR2 ligand-binding core (S1S2J-N754S) in complex with glutamate and NS5206 at 2.10 A resolution
3H6W	;	1.49	;	Crystal structure of the iGluR2 ligand-binding core (S1S2J-N754S) in complex with glutamate and NS5217 at 1.50 A resolution
1NRZ	;	1.75	;	Crystal structure of the IIBSor domain of the sorbose permease from Klebsiella pneumoniae solved to 1.75A resolution
2Z3Q	;	1.85	;	Crystal structure of the IL-15/IL-15Ra complex
2Z3R	;	2.0	;	Crystal structure of the IL-15/IL-15Ra complex
3WO4	;	3.1	;	Crystal structure of the IL-18 signaling ternary complex
3DLQ	;	1.9	;	Crystal structure of the IL-22/IL-22R1 complex
3BPO	;	3.0	;	Crystal structure of the IL13-IL4R-IL13Ra ternary complex
3BPL	;	2.93	;	Crystal structure of the IL4-IL4R-Common Gamma ternary complex
3BPN	;	3.02	;	Crystal structure of the IL4-IL4R-IL13Ra ternary complex
7WD4	;	1.75	;	Crystal structure of the Ilheus virus helicase: implications for enzyme function and drug design
6MIB	;	1.8	;	Crystal structure of the ILK ATP-binding deficient mutant (L207W)/alpha-parvin core complex
3KMU	;	1.8	;	Crystal structure of the ILK/alpha-parvin core complex (apo)
3KMW	;	2.0	;	Crystal structure of the ILK/alpha-parvin core complex (MgATP)
3REP	;	1.8	;	Crystal structure of the ILK/alpha-parvin core complex (MnATP)
3WFX	;	1.94	;	Crystal Structure of the Imidazole-Bound Form of the HGbRL's Globin Domain
2GOK	;	1.87	;	Crystal structure of the imidazolonepropionase from Agrobacterium tumefaciens at 1.87 A resolution
6RQA	;	2.56	;	Crystal structure of the iminosuccinate reductase of Paracoccus denitrificans in complex with NAD+
1BT5	;	1.8	;	CRYSTAL STRUCTURE OF THE IMIPENEM INHIBITED TEM-1 BETA-LACTAMASE FROM ESCHERICHIA COLI
3N40	;	2.17	;	Crystal structure of the immature envelope glycoprotein complex of Chikungunya virus.
7YR9	;	1.7	;	Crystal structure of the immature form of TtPetA
4WID	;	2.31	;	Crystal structure of the immediate-early 1 protein (IE1) at 2.31 angstrom (tetragonal form after crystal dehydration)
7T8I	;	2.1	;	Crystal structure of the ImmR transcriptional regulator DNA-binding domain of Bacillus subtilis
4NSR	;	2.795	;	Crystal structure of the Immunity protein
3R0N	;	1.3	;	Crystal Structure of the Immunoglobulin variable domain of Nectin-2
4HZA	;	1.7	;	Crystal Structure of the Immunoglobulin variable domain of Nectin-2 in monoclinic form
3UCR	;	2.627	;	Crystal structure of the immunoreceptor TIGIT IgV domain
3UDW	;	2.903	;	Crystal structure of the immunoreceptor TIGIT in complex with Poliovirus receptor (PVR/CD155/necl-5) D1 domain
5WXM	;	2.304	;	Crystal structure of the Imp3 and Mpp10 complex
5O9E	;	1.884	;	Crystal structure of the Imp4-Mpp10 complex from Chaetomium thermophilum
1IQ1	;	2.8	;	CRYSTAL STRUCTURE OF THE IMPORTIN-ALPHA(44-54)-IMPORTIN-ALPHA(70-529) COMPLEX
4J4Z	;	1.26	;	Crystal structure of the improved variant of the evolved serine hydrolase, OSH55.4_H1.2, bond with sulfate ion in the active site, Northeast Structural Genomics Consortium (NESG) Target OR301
8P6G	;	1.95	;	Crystal structure of the improved version of the Genetically Encoded Green Calcium Indicator YTnC2-5
4MGM	;	3.2	;	Crystal structure of the in vitro transcribed G. kaustophilus tRNA-Gly
8W7N	;	3.6	;	Crystal structure of the in-cell Cry1Aa purified from Bacillus thuringiensis
4RGE	;	2.89	;	Crystal structure of the in-line aligned env22 twister ribozyme
4RGF	;	3.2008	;	Crystal structure of the in-line aligned env22 twister ribozyme soaked with Mn2+
3LMI	;	2.2	;	Crystal Structure of the Inactive Alpha-kinase Domain of Myosin Heavy Chain Kinase A (D766A) complex with ATP
4ZS4	;	2.4	;	Crystal Structure of the Inactive Alpha-kinase Domain of Myosin-II Heavy Chain Kinase A (D756A) Complexed with ATP
1HZG	;	1.86	;	CRYSTAL STRUCTURE OF THE INACTIVE C866S MUTANT OF THE CATALYTIC DOMAIN OF E. COLI CYTOTOXIC NECROTIZING FACTOR 1
1H49	;	1.9	;	CRYSTAL STRUCTURE OF THE INACTIVE DOUBLE MUTANT OF THE MAIZE BETA-GLUCOSIDASE ZMGLU1-E191D-F198V IN COMPLEX WITH DIMBOA-GLUCOSIDE
2GS7	;	2.6	;	Crystal Structure of the inactive EGFR kinase domain in complex with AMP-PNP
3GT8	;	2.955	;	Crystal structure of the inactive EGFR kinase domain in complex with AMP-PNP
4HJO	;	2.75	;	Crystal structure of the inactive EGFR tyrosine kinase domain with erlotinib
5AJO	;	1.48	;	Crystal structure of the inactive form of GalNAc-T2 in complex with the glycopeptide MUC5AC-3,13
5AJN	;	1.67	;	Crystal structure of the inactive form of GalNAc-T2 in complex with the glycopeptide MUC5AC-Cys13
5K5T	;	3.1	;	Crystal structure of the inactive form of human calcium-sensing receptor extracellular domain
5TOV	;	1.9	;	Crystal structure of the inactive form of S-adenosyl-L-homocysteine hydrolase from Thermotoga maritima in binary complex with NADH
5TOW	;	1.75	;	Crystal structure of the inactive form of S-adenosyl-L-homocysteine hydrolase from Thermotoga maritima in ternary complex with NADH and Adenosine
4ISL	;	2.29	;	Crystal Structure of the inactive Matriptase in complex with its inhibitor HAI-1
1E4L	;	2.2	;	Crystal structure of the inactive mutant Monocot (Maize ZMGlu1) beta-glucosidase ZM Glu191Asp
1E55	;	2.0	;	Crystal structure of the inactive mutant Monocot (Maize ZMGlu1) beta-glucosidase ZMGluE191D in complex with the competitive inhibitor dhurrin
1E4N	;	2.1	;	Crystal structure of the inactive mutant Monocot (Maize ZMGlu1) beta-glucosidase ZMGluE191D in complex with the natural aglycone DIMBOA
1E56	;	2.1	;	Crystal structure of the inactive mutant Monocot (Maize ZMGlu1) beta-glucosidase ZMGluE191D in complex with the natural substrate DIMBOA-beta-D-glucoside
4ELJ	;	2.7	;	Crystal structure of the inactive retinoblastoma protein phosphorylated at T373
2F9R	;	1.85	;	Crystal structure of the inactive state of the Smase I, a sphingomyelinase D from Loxosceles laeta venom
4GT5	;	2.398	;	Crystal structure of the inactive TrkA kinase domain
6EGF	;	2.61	;	Crystal structure of the inactive unphosphorylated IRAK4 kinase domain bound to AMP-PNP
3K7G	;	1.5	;	Crystal structure of the Indian Hedgehog N-terminal signalling domain
4YLA	;	1.4	;	Crystal structure of the indole prenyltransferase MpnD complexed with indolactam V and DMSPP
4YL7	;	1.601	;	Crystal structure of the indole prenyltransferase MpnD from Marinactinospora thermotolerans
4YZK	;	1.95	;	Crystal structure of the indole prenyltransferase TleC apo structure
4YZL	;	2.096	;	Crystal structure of the indole prenyltransferase TleC complexed with indolactam V and DMSPP
4PK5	;	2.79	;	Crystal structure of the indoleamine 2,3-dioxygenagse 1 (IDO1) complexed with Amg-1
7M63	;	3.1	;	Crystal structure of the indoleamine 2,3-dioxygenagse 1 (IDO1) complexed with IACS-70099
7M7D	;	2.6	;	Crystal structure of the indoleamine 2,3-dioxygenagse 1 (IDO1) complexed with IACS-8968
4PK6	;	3.45	;	Crystal structure of the indoleamine 2,3-dioxygenagse 1 (IDO1) complexed with imidazothiazole derivative
5XE1	;	3.2	;	Crystal structure of the indoleamine 2,3-dioxygenagse 1 (IDO1) complexed with INCB14943
5EK2	;	2.68	;	Crystal structure of the indoleamine 2,3-dioxygenagse 1 (IDO1) complexed with NLG919 analogue
5EK3	;	2.209	;	Crystal structure of the indoleamine 2,3-dioxygenagse 1 (IDO1) complexed with NLG919 analogue
5EK4	;	2.64	;	Crystal structure of the indoleamine 2,3-dioxygenagse 1 (IDO1) complexed with NLG919 analogue
5ETW	;	2.7	;	Crystal structure of the indoleamine 2,3-dioxygenagse 1 (IDO1) complexed with NLG919 analogue
7B1O	;	2.58	;	Crystal structure of the indoleamine 2,3-dioxygenase 1 (IDO1) in complex with compound 22
6E40	;	2.306	;	Crystal structure of the indoleamine 2,3-dioxygenase 1 (IDO1) in complexed with ferric heme and Epacadostat
1IIZ	;	2.4	;	Crystal Structure of the Induced Antibacterial Protein from Tasar Silkworm, Antheraea mylitta
5T96	;	2.0	;	Crystal structure of the infectious salmon anemia virus (ISAV) HE viral receptor complex
5T9Y	;	1.8	;	Crystal structure of the infectious salmon anemia virus (ISAV) hemagglutinin-esterase protein
4EWC	;	2.7	;	Crystal Structure of the Infectious Salmon Anemia Virus Nucleoprotein
5WFM	;	2.251	;	Crystal structure of the influenza virus PA endonuclease (E119D mutant) in complex with inhibitor 10e (SRI-30024)
5WFW	;	2.292	;	Crystal structure of the influenza virus PA endonuclease (E119D mutant) in complex with inhibitor 10j (SRI-30026)
5WEI	;	2.25	;	Crystal structure of the influenza virus PA endonuclease (E119D mutant) in complex with inhibitor 7a (SRI-29770)
5WFZ	;	2.35	;	Crystal structure of the influenza virus PA endonuclease (E119D mutant) in complex with inhibitor 8e (SRI-30049)
5WG9	;	2.3	;	Crystal structure of the influenza virus PA endonuclease (E119D mutant) in complex with inhibitor 9b (SRI-30101)
5WF3	;	2.251	;	Crystal structure of the influenza virus PA endonuclease (E119D mutant) in complex with inhibitor 9k (SRI-30023)
5WEF	;	2.0	;	Crystal structure of the influenza virus PA endonuclease (F105S mutant) in complex with inhibitor 7a (SRI-29770)
5WE7	;	2.12	;	Crystal structure of the influenza virus PA endonuclease in complex with an inhibitor - SRI-29782
5WA6	;	2.25	;	Crystal structure of the influenza virus PA endonuclease in complex with an inhibitor - SRI-30007
5W92	;	2.3	;	Crystal structure of the influenza virus PA endonuclease in complex with an inhibitor - SRI-30049
5WEB	;	2.254	;	Crystal structure of the influenza virus PA endonuclease in complex with inhibitor 10e (SRI-30024)
5WAP	;	2.201	;	Crystal structure of the influenza virus PA endonuclease in complex with inhibitor 10i (SRI-30025)
5WB3	;	2.203	;	Crystal structure of the influenza virus PA endonuclease in complex with inhibitor 10j (SRI-30026)
5WDW	;	2.3	;	Crystal structure of the influenza virus PA endonuclease in complex with inhibitor 10k (SRI-30027)
5WCS	;	2.525	;	Crystal structure of the influenza virus PA endonuclease in complex with inhibitor 6b (SRI-29789)
5WCT	;	2.3	;	Crystal structure of the influenza virus PA endonuclease in complex with inhibitor 6c (SRI-29775)
5WDN	;	2.1	;	Crystal structure of the influenza virus PA endonuclease in complex with inhibitor 6d (SRI-29680)
5W3I	;	1.95	;	Crystal structure of the influenza virus PA endonuclease in complex with inhibitor 6e (SRI-29685)
5W44	;	2.1	;	Crystal structure of the influenza virus PA endonuclease in complex with inhibitor 7a (SRI-29770)
5WE9	;	1.804	;	Crystal structure of the influenza virus PA endonuclease in complex with inhibitor 7b (SRI-29731)
5W7U	;	2.2	;	Crystal structure of the influenza virus PA endonuclease in complex with inhibitor 8f (SRI-29928)
5WA7	;	2.204	;	Crystal structure of the influenza virus PA endonuclease in complex with inhibitor 9b (SRI-30101)
5WDC	;	2.1	;	Crystal structure of the influenza virus PA endonuclease in complex with inhibitor 9e (SRI-29843)
5W73	;	2.202	;	Crystal structure of the influenza virus PA endonuclease in complex with inhibitor 9f (SRI-29835)
5W9G	;	2.1	;	Crystal structure of the influenza virus PA endonuclease in complex with inhibitor 9k (SRI-30023)
3S7O	;	1.24	;	Crystal Structure of the Infrared Fluorescent D207H variant of Deinococcus Bacteriophytochrome chromophore binding domain at 1.24 angstrom resolution
3S7P	;	1.722	;	Crystal Structure of the Infrared Fluorescent D207H variant of Deinococcus Bacteriophytochrome chromophore binding domain at 1.72 angstrom resolution
2QIC	;	2.1	;	Crystal Structure of the ING1 PHD Finger in complex with a Histone H3K4ME3 peptide
3C6W	;	1.75	;	Crystal structure of the ING5 PHD finger in complex with H3K4me3 peptide
5VRL	;	2.65	;	CRYSTAL STRUCTURE OF THE INHA FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH AN12855, EBSI 4333.
5VRM	;	2.5	;	CRYSTAL STRUCTURE OF THE INHA FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH AN12855, EBSI 4333.
5VRN	;	2.55	;	CRYSTAL STRUCTURE OF THE INHA FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH AN12855, EBSI 4333.
5W07	;	2.65	;	CRYSTAL STRUCTURE OF THE INHA FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH AN12855, EBSI 4333.
4QXM	;	2.196	;	Crystal structure of the InhA:GSK_SB713 complex
5NQ6	;	2.4	;	Crystal structure of the inhibited form of the redox-sensitive SufE-like sulfur acceptor CsdE from Escherichia coli at 2.40 Angstrom Resolution
3EKP	;	2.15	;	Crystal Structure of the inhibitor Amprenavir (APV) in complex with a multi-drug resistant HIV-1 protease variant (L10I/G48V/I54V/V64I/V82A)Refer: FLAP+ in citation
3EKW	;	1.6	;	Crystal structure of the inhibitor Atazanavir (ATV) in complex with a multi-drug resistance HIV-1 protease variant (L10I/G48V/I54V/V64I/V82A) Refer: FLAP+ in citation.
3EKT	;	1.97	;	Crystal Structure of the inhibitor Darunavir (DRV) in complex with a multi-drug resistant HIV-1 protease variant (L10F/G48V/I54V/V64I/V82A) (Refer: FLAP+ in citation.)
3EL0	;	2.0	;	Crystal structure of the inhibitor Nelfinavir (NFV) in complex with a multi-drug resistant HIV-1 protease variant (L10I/G48V/I54V/V64I/V82A) (Refer: FLAP+ in citation)
4DF6	;	2.29	;	Crystal Structure of the inhibitor NXL104 Covalent Adduct with TB B-lactamase
1FJS	;	1.92	;	CRYSTAL STRUCTURE OF THE INHIBITOR ZK-807834 (CI-1031) COMPLEXED WITH FACTOR XA
6NVB	;	1.636	;	Crystal structure of the inhibitor-free form of the serine protease kallikrein-4
1WPL	;	2.8	;	Crystal structure of the inhibitory form of rat GTP cyclohydrolase I/GFRP complex
5ES5	;	2.8	;	Crystal structure of the initiation module of LgrA in the ""open"" and ""closed "" adenylation states
5ES8	;	2.547	;	Crystal structure of the initiation module of LgrA in the thiolation state
5FCU	;	1.85	;	CRYSTAL STRUCTURE OF THE INNER DOMAIN OF CLADE A/E HIV-1 GP120 IN COMPLEX WITH THE ADCC-POTENT RHESUS MACAQUE ANTIBODY JR4
1UDE	;	2.66	;	Crystal structure of the Inorganic pyrophosphatase from the hyperthermophilic archaeon Pyrococcus horikoshii OT3
4MYA	;	1.8997	;	Crystal Structure of the Inosine 5'-monophosphate Dehydrogenase with an Internal Deletion of the CBS Domain from Bacillus anthracis str. Ames complexed with inhibitor A110
4MY9	;	2.5893	;	Crystal Structure of the Inosine 5'-monophosphate Dehydrogenase with an Internal Deletion of the CBS Domain from Bacillus anthracis str. Ames complexed with inhibitor C91
4QM1	;	2.7964	;	Crystal Structure of the Inosine 5'-monophosphate Dehydrogenase with an Internal Deletion of the CBS Domain from Bacillus anthracis str. Ames complexed with inhibitor D67
4MY8	;	2.2924	;	Crystal Structure of the Inosine 5'-monophosphate Dehydrogenase with an Internal Deletion of the CBS Domain from Bacillus anthracis str. Ames complexed with inhibitor Q21
4MYX	;	2.701	;	Crystal Structure of the Inosine 5'-monophosphate Dehydrogenase, with a Internal Deletion of CBS Domain from Bacillus anthracis str. Ame complexed with P32
4MY1	;	2.5997	;	Crystal Structure of the Inosine 5'-monophosphate Dehydrogenase, with a Internal Deletion of CBS Domain from Bacillus anthracis str. Ames complexed with P68
4MZ1	;	2.3991	;	Crystal Structure of the Inosine 5'-monophosphate Dehydrogenase, with a Internal Deletion of CBS Domain from Campylobacter jejuni complexed with inhibitor compound P12
4MJM	;	2.2544	;	Crystal Structure of the Inosine 5'-monophosphate Dehydrogenase, with a Short Internal Deletion of CBS Domain from Bacillus anthracis str. Ames
4MZ8	;	2.5004	;	Crystal Structure of the Inosine 5'-monophosphate Dehydrogenase, with an Internal Deletion of CBS Domain from Campylobacter jejuni complexed with inhibitor compound C91
1N4K	;	2.2	;	Crystal structure of the inositol 1,4,5-trisphosphate receptor binding core in complex with IP3
3UJ0	;	3.6	;	Crystal structure of the inositol 1,4,5-trisphosphate receptor with ligand bound form.
8OMI	;	1.77	;	Crystal structure of the inositol hexakisphosphate kinase EhIP6KA M85 variant in complex with ATP and Mg2+
6V2U	;	3.78	;	Crystal structure of the insect cell-expressed WT-BRAF kinase in complex with Dabrafenib
1BIH	;	3.1	;	CRYSTAL STRUCTURE OF THE INSECT IMMUNE PROTEIN HEMOLIN: A NEW DOMAIN ARRANGEMENT WITH IMPLICATIONS FOR HOMOPHILIC ADHESION
1JI6	;	2.4	;	CRYSTAL STRUCTURE OF THE INSECTICIDAL BACTERIAL DEL ENDOTOXIN CRY3Bb1 BACILLUS THURINGIENSIS
5I62	;	2.001	;	Crystal structure of the insertion loop deletion mutant of the RNA-dependent RNA polymerase of a human picorbirnavirus
1GAG	;	2.7	;	CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH A BISUBSTRATE INHIBITOR
3BU3	;	1.65	;	Crystal structure of the insulin receptor kinase in complex with IRS2 KRLB peptide
3BU5	;	2.1	;	Crystal structure of the insulin receptor kinase in complex with IRS2 KRLB peptide and ATP
3BU6	;	1.95	;	Crystal structure of the insulin receptor kinase in complex with IRS2 KRLB phosphopeptide
1RQQ	;	2.6	;	Crystal Structure of the Insulin Receptor Kinase in Complex with the SH2 Domain of APS
3D94	;	2.3	;	Crystal structure of the insulin-like growth factor-1 receptor kinase in complex with PQIP
4IX7	;	1.581	;	Crystal Structure of the insv-BEN domain complexed to its DNA target site
3CW2	;	2.8	;	Crystal structure of the intact archaeal translation initiation factor 2 from Sulfolobus solfataricus .
5CWS	;	3.77	;	Crystal structure of the intact Chaetomium thermophilum Nsp1-Nup49-Nup57 channel nucleoporin heterotrimer bound to its Nic96 nuclear pore complex attachment site
4FXE	;	2.7503	;	Crystal structure of the intact E. coli RelBE toxin-antitoxin complex
1HZH	;	2.7	;	CRYSTAL STRUCTURE OF THE INTACT HUMAN IGG B12 WITH BROAD AND POTENT ACTIVITY AGAINST PRIMARY HIV-1 ISOLATES: A TEMPLATE FOR HIV VACCINE DESIGN
7EEW	;	2.896	;	Crystal structure of the intact MTase from Vibrio vulnificus YJ016 in complex with the DNA-mimicking Ocr protein and the S-adenosyl-L-homocysteine (SAH)
4BRR	;	2.44	;	Crystal structure of the integral membrane diacylglycerol kinase - delta 7.79
3ZE5	;	3.101	;	Crystal structure of the integral membrane diacylglycerol kinase - delta4
3ZE3	;	2.05	;	Crystal structure of the integral membrane diacylglycerol kinase - delta7
4CK0	;	2.924	;	Crystal structure of the integral membrane diacylglycerol kinase - form 2
3ZE4	;	3.702	;	Crystal structure of the integral membrane diacylglycerol kinase - wild-type
4CJZ	;	3.25	;	Crystal structure of the integral membrane diacylglycerol kinase DgkA- 9.9, delta 4
4BRB	;	2.55	;	Crystal structure of the integral membrane enzyme DgkA-ref, delta 7
1LWS	;	3.5	;	Crystal structure of the intein homing endonuclease PI-SceI bound to its recognition sequence
1LWT	;	3.2	;	Crystal structure of the intein homing endonuclease PI-SceI bound to its substrate DNA (Ca2+ free)
1XU9	;	1.55	;	Crystal Structure of the Interface Closed Conformation of 11b-hydroxysteroid dehydrogenase isozyme 1
1XU7	;	1.8	;	Crystal Structure of the Interface Open Conformation of Tetrameric 11b-HSD1
1ILR	;	2.1	;	CRYSTAL STRUCTURE OF THE INTERLEUKIN-1 RECEPTOR ANTAGONIST
2B8X	;	1.7	;	Crystal structure of the interleukin-4 variant F82D
2B91	;	2.0	;	Crystal structure of the interleukin-4 variant F82DR85A
2B8Z	;	2.5	;	Crystal structure of the interleukin-4 variant R85A
2D48	;	1.65	;	Crystal structure of the Interleukin-4 variant T13D
2B8Y	;	1.8	;	Crystal structure of the interleukin-4 variant T13DF82D
2B90	;	2.1	;	Crystal structure of the interleukin-4 variant T13DR85A
1MJN	;	1.3	;	Crystal Structure of the intermediate affinity aL I domain mutant
5U9L	;	2.516	;	Crystal structure of the intermembrane space region of the plastid division protein PARC6
6W2H	;	1.6	;	Crystal Structure of the Internal UBA Domain of HHR23A
7PVZ	;	2.0	;	Crystal structure of the intertwined dimer of the c-Src SH3 domain E93V-S94A-R95S-T96G mutant
7PVW	;	1.5	;	Crystal structure of the intertwined dimer of the c-Src SH3 domain E93V-S94A-R95S-T96G-N112G-N113Y-T114N-E115H mutant
6XVO	;	1.7	;	Crystal structure of the intertwined dimer of the c-Src SH3 domain without ATCUN motif
4OMM	;	1.9	;	Crystal structure of the intertwined dimer of the c-Src tyrosine kinase SH3 domain mutant N113S
4OMN	;	1.5	;	Crystal structure of the intertwined dimer of the c-Src tyrosine kinase SH3 domain mutant Q128E
4OMP	;	2.0	;	Crystal structure of the intertwined dimer of the c-Src tyrosine kinase SH3 domain mutant Q128K
4OML	;	1.6	;	Crystal structure of the intertwined dimer of the c-Src tyrosine kinase SH3 domain mutant Q128R
4OMQ	;	2.0	;	Crystal structure of the intertwined dimer of the c-Src tyrosine kinase SH3 domain mutant S94A
4Y92	;	2.1	;	Crystal structure of the intertwined form of the Src tyrosine kinase SH3 domain E97T-Q128R mutant
5I11	;	1.95	;	Crystal structure of the intertwined form of the Src tyrosine kinase SH3 domain T114S-Q128R mutant
4RTU	;	2.453	;	Crystal structure of the intertwined form of the Src tyrosine kinase SH3 domain T96G/Q128R mutant
3DXE	;	2.0	;	Crystal structure of the intracellular domain of human APP (T668A mutant) in complex with Fe65-PTB2
3DXD	;	2.2	;	Crystal structure of the intracellular domain of human APP (T668E mutant) in complex with Fe65-PTB2
3DXC	;	2.1	;	Crystal structure of the intracellular domain of human APP in complex with Fe65-PTB2
3SUA	;	4.39	;	Crystal structure of the intracellular domain of Plexin-B1 in complex with Rac1
3OTV	;	3.094	;	Crystal structure of the intracellular domain of Rv3910 from Mycobacterium tuberculosis
4X3F	;	2.9	;	Crystal structure of the intracellular domain of the M. tuberculosis Ser/Thr kinase PknA
4X4A	;	1.71	;	Crystal structure of the intramolecular trans-sialidase from Ruminococcus gnavus in complex with 2,7-Anhydro-Neu5Ac
4X47	;	2.0	;	Crystal structure of the intramolecular trans-sialidase from Ruminococcus gnavus in complex with Neu5Ac2en
4X49	;	2.01	;	Crystal structure of the intramolecular trans-sialidase from Ruminococcus gnavus in complex with oseltamivir carboxylate
4X6K	;	1.94	;	Crystal structure of the intramolecular trans-sialidase from Ruminococcus gnavus in complex with Siastatin B
6BNF	;	2.33	;	Crystal structure of the intrinsic colistin resistance enzyme ICR(Mc) from Moraxella catarrhalis, catalytic domain, mono-zinc complex
6BNE	;	2.61	;	Crystal structure of the intrinsic colistin resistance enzyme ICR(Mc) from Moraxella catarrhalis, catalytic domain, phosphate-bound complex
6BNC	;	1.5	;	Crystal structure of the intrinsic colistin resistance enzyme ICR(Mc) from Moraxella catarrhalis, catalytic domain, Thr315Ala mutant di-zinc and PEG complex
6BND	;	1.66	;	Crystal structure of the intrinsic colistin resistance enzyme ICR(Mc) from Moraxella catarrhalis, catalytic domain, Thr315Ala mutant mono-zinc and phosphoethanolamine complex
4JA0	;	2.8	;	Crystal structure of the invertebrate bi-functional purine biosynthesis enzyme PAICS at 2.8 A resolution
6EYU	;	2.5	;	Crystal structure of the inward H(+) pump xenorhodopsin
7C5V	;	2.65	;	Crystal structure of the iota-carbonic anhydrase from cyanobacterium complexed with bicarbonate
7C5W	;	2.3	;	Crystal structure of the iota-carbonic anhydrase from cyanobacterium complexed with iodide
7C5X	;	2.55	;	Crystal structure of the iota-carbonic anhydrase from eukaryotic microalga complexed with bicarbonate
7C5Y	;	2.2	;	Crystal structure of the iota-carbonic anhydrase from eukaryotic microalga complexed with iodide
7SBH	;	1.34	;	Crystal structure of the iron superoxide dismutase from Acinetobacter sp. Ver3
1FX7	;	2.0	;	CRYSTAL STRUCTURE OF THE IRON-DEPENDENT REGULATOR (IDER) FROM MYCOBACTERIUM TUBERCULOSIS
7AZQ	;	2.0	;	Crystal structure of the iron/manganese cambialistic superoxide dismutase from Rhodobacter capsulatus complex with Fe
7AZR	;	2.1	;	Crystal structure of the iron/manganese cambialistic superoxide dismutase from Rhodobacter capsulatus complex with Mn
3DTE	;	2.6	;	Crystal structure of the IRRE protein, a central regulator of DNA damage repair in deinococcaceae
3DTI	;	3.5	;	Crystal structure of the IRRE protein, a central regulator of DNA damage repair in deinococcaceae
3DTK	;	3.24	;	Crystal structure of the IRRE protein, a central regulator of DNA damage repair in deinococcaceae
2VIH	;	2.1	;	CRYSTAL STRUCTURE OF THE IS608 TRANSPOSASE IN COMPLEX WITH Left END 26-MER DNA
2VJV	;	1.9	;	Crystal structure of the IS608 transposase in complex with left end 26-mer DNA hairpin and a 6-mer DNA representing the left end cleavage site
6FI8	;	2.598	;	Crystal structure of the IS608 transposase in complex with left end 29-mer DNA hairpin and a 6-mer DNA representing the intact target site: pre-cleavage target capture complex
2VJU	;	2.4	;	Crystal structure of the IS608 transposase in complex with the complete Right end 35-mer DNA and manganese
3TB4	;	1.35	;	Crystal structure of the ISC domain of VibB
3TG2	;	1.101	;	Crystal structure of the ISC domain of VibB in complex with isochorismate
3AH7	;	1.9	;	Crystal structure of the ISC-like [2Fe-2S] ferredoxin (FdxB) from Pseudomonas putida JCM 20004
2ITE	;	1.6	;	Crystal structure of the IsdA NEAT domain from Staphylococcus aureus
2A6M	;	2.4	;	Crystal Structure of the ISHp608 Transposase
2VIC	;	2.35	;	CRYSTAL STRUCTURE OF THE ISHP608 TRANSPOSASE IN COMPLEX with Left end 26- mer DNA and manganese
2VHG	;	2.9	;	Crystal Structure of the ISHp608 Transposase in Complex with Right End 31-mer DNA
2A6O	;	2.6	;	Crystal Structure of the ISHp608 Transposase in Complex with Stem-loop DNA
5XO0	;	1.85	;	Crystal structure of the isochorismatase domain of AngB from Vibrio anguillarum 775
5XO1	;	2.23	;	Crystal structure of the isochorismatase domain of VabB from Vibrio anguillarum 775
1DQU	;	2.8	;	CRYSTAL STRUCTURE OF THE ISOCITRATE LYASE FROM ASPERGILLUS NIDULANS
1IGW	;	2.1	;	Crystal Structure of the Isocitrate Lyase from the A219C mutant of Escherichia coli
1ZG3	;	2.35	;	Crystal structure of the isoflavanone 4'-O-methyltransferase complexed with SAH and 2,7,4'-trihydroxyisoflavanone
3BXZ	;	3.0	;	Crystal structure of the isolated DEAD motor domains from Escherichia coli SecA
4FXI	;	1.8003	;	Crystal structure of the isolated E. coli RelE toxin, P21 form
4FXH	;	2.4	;	Crystal structure of the isolated E. coli RelE toxin, P212121 form
3I5B	;	2.043	;	Crystal structure of the isolated GGDEF domain of WpsR from Pseudomonas aeruginosa
6ZI1	;	2.2	;	Crystal structure of the isolated H. influenzae VapD toxin (D7N mutant)
6ZI0	;	2.5	;	Crystal structure of the isolated H. influenzae VapD toxin (wildtype)
4B53	;	1.8	;	Crystal structure of the isolated IgG4 CH3 domain
2OGU	;	3.23	;	Crystal structure of the isolated MthK RCK domain
3GBD	;	1.95	;	Crystal structure of the isomaltulose synthase SmuA from Protaminobacter rubrum
3GBE	;	1.7	;	Crystal structure of the isomaltulose synthase SmuA from Protaminobacter rubrum in complex with the inhibitor deoxynojirimycin
3LKK	;	2.001	;	Crystal structure of the isopentenyl phosphate kinase substrate complex
4QQ1	;	3.33	;	Crystal structure of the isotype 1 Transferrin binding protein B (TbpB) from serogroup B Neisseria meningitidis
5BQ5	;	2.1	;	Crystal structure of the IstB AAA+ domain bound to ADP-BeF3
3S9K	;	2.354	;	Crystal structure of the Itk SH2 domain.
7YW5	;	2.77	;	Crystal Structure of the ITS1 processing by human ribonuclease ISG20L2 with mutation D327A
6NS9	;	1.95	;	Crystal structure of the IVR-165 (H3N2) influenza virus hemagglutinin apo form
6NSA	;	1.95	;	Crystal structure of the IVR-165 (H3N2) influenza virus hemagglutinin in complex with 3'-SLNLN
6NSB	;	1.75	;	Crystal structure of the IVR-165 (H3N2) influenza virus hemagglutinin in complex with 6'-SLNLN
4FVP	;	2.01	;	Crystal structure of the Jak2 pseudokinase domain (apo form)
4FVQ	;	1.75	;	Crystal structure of the Jak2 pseudokinase domain (Mg-ATP-bound form)
4FVR	;	2.0	;	Crystal structure of the Jak2 pseudokinase domain mutant V617F (Mg-ATP-bound form)
4Z16	;	2.9	;	Crystal Structure of the Jak3 Kinase Domain Covalently Bound to N-(3-(((5-chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)methyl)phenyl)acrylamide
1YVJ	;	2.55	;	Crystal structure of the Jak3 kinase domain in complex with a staurosporine analogue
3P54	;	2.097	;	Crystal Structure of the Japanese Encephalitis Virus Envelope Protein, strain SA-14-14-2.
4LIF	;	2.6	;	Crystal structure of the JCV large T-antigen origin binding domain
4LMD	;	1.5	;	Crystal structure of the JCV large t-antigen origin binding domain
4NBP	;	1.315	;	Crystal structure of the JCV large T-antigen origin binding domain
5HHM	;	2.5	;	Crystal Structure of the JM22 TCR in complex with HLA-A*0201 in complex with M1-F5L
5HHO	;	2.95	;	Crystal Structure of the JM22 TCR in complex with HLA-A*0201 in complex with M1-G4E
6YDV	;	2.07	;	Crystal Structure of the Jmjc Domain of Human JMJD1B in complex with FM001511a from the DSPL fragment library
2YPD	;	2.1	;	Crystal structure of the Jumonji domain of human Jumonji domain containing 1C protein
2H7H	;	2.3	;	Crystal structure of the JUN BZIP homodimer complexed with AP-1 DNA
1JNM	;	2.2	;	Crystal Structure of the Jun/CRE Complex
1IXF	;	2.6	;	Crystal Structure of the K intermediate of bacteriorhodopsin
7Z0C	;	1.53	;	Crystal structure of the K state of bacteriorhodopsin at 1.53 Angstrom resolution
7W75	;	3.2	;	Crystal structure of the K. lactis Bre1 RBD in complex with Rad6, crystal form I
7W76	;	3.05	;	Crystal structure of the K. lactis Bre1 RBD in complex with Rad6, crystal form II
6L8N	;	3.6	;	Crystal structure of the K. lactis Rad5
6L8O	;	3.3	;	Crystal structure of the K. lactis Rad5 (Hg-derivative)
5I8I	;	6.5	;	Crystal Structure of the K. lactis Urea Amidolyase
6WII	;	1.85	;	Crystal structure of the K. pneumoniae LpxH/JH-LPH-41 complex
3RC9	;	1.91	;	Crystal Structure of the K102A mutant of KijD10, a 3-ketoreductase from Actinomadura kijaniata in complex with TDP-benzene and NADP
3RCB	;	2.49	;	Crystal structure of the K102E mutant of KijD10, a 3-ketoreductase from Actinomadura kijaniata in complex with TDP-benzene and NADP
3VSD	;	2.09	;	Crystal Structure of the K127A Mutant of O-Phosphoserine Sulfhydrylase Complexed with External Schiff Base of Pyridoxal 5'-Phosphate with O-Acetyl-L-Serine
3VSC	;	2.07	;	Crystal Structure of the K127A Mutant of O-Phosphoserine Sulfhydrylase Complexed with External Schiff Base of Pyridoxal 5'-Phosphate with O-Phospho-L-Serine
1PE0	;	1.7	;	Crystal structure of the K130R mutant of human DJ-1
3SM4	;	1.88	;	Crystal Structure of the K131A Mutant of Lambda Exonuclease in Complex with a 5'-Phosphorylated 14-mer/12-mer Duplex and Magnesium
1R6W	;	1.62	;	Crystal structure of the K133R mutant of o-Succinylbenzoate synthase (OSBS) from Escherichia coli. Complex with SHCHC
1KG4	;	1.6	;	Crystal structure of the K142A mutant of E. coli MutY (core fragment)
1KG5	;	1.35	;	Crystal structure of the K142Q mutant of E.coli MutY (core fragment)
1KG6	;	1.5	;	Crystal structure of the K142R mutant of E.coli MutY (core fragment)
4F6E	;	1.6	;	Crystal Structure of the K182R, A183P mutant manganese superoxide dismutase from Sacchromyces cerevisiae
4GUN	;	1.94	;	Crystal Structure of the K184R, L185P mutant manganese superoxide dismutase from Candida albicans cytosol
3ODS	;	1.9	;	Crystal structure of the K185A mutant of the N-terminal domain of human Symplekin
1PU2	;	2.06	;	Crystal Structure of the K246R Mutant of Aspartate Semialdehyde Dehydrogenase from Haemophilus influenzae
2QJM	;	2.2	;	Crystal structure of the K271E mutant of Mannonate dehydratase from Novosphingobium aromaticivorans complexed with Mg and D-mannonate
7X5D	;	1.82	;	Crystal Structure of the K316C mutant of Human Lamin A/C Coil 2 (residues 244-340)
4N0E	;	2.1	;	Crystal structure of the K345L variant of the Gi alpha1 subunit bound to GDP
4N0D	;	1.55	;	Crystal structure of the K345L variant of the Gi alpha1 subunit bound to GTPgammaS
1LUZ	;	1.8	;	Crystal Structure of the K3L Protein From Vaccinia Virus (Wisconsin Strain)
7NX7	;	2.3	;	Crystal structure of the K417N mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and EY6A Fabs
7NX8	;	1.95	;	Crystal structure of the K417T mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and EY6A Fabs
1D6S	;	2.3	;	CRYSTAL STRUCTURE OF THE K41A MUTANT OF O-ACETYLSERINE SULFHYDRYLASE COMPLEXED IN EXTERNAL ALDIMINE LINKAGE WITH METHIONINE
4I69	;	1.79	;	Crystal structure of the K463A mutant of the RRM domain of RNA helicase HERA from T. thermophilus
4XMI	;	1.97	;	Crystal structure of the K499G mutant of NanB sialidase from Streptococcus pneumoniae
4XMA	;	2.09	;	Crystal structure of the K499G mutant of NanB sialidase from streptococcus pneumoniae in complex with Optactin
1O9N	;	2.0	;	Crystal structure of the K62A mutant of Malonamidase E2 from Bradyrhizobium japonicum
3PAE	;	2.1	;	Crystal structure of the K84D mutant of OXA-24/40 in complex with doripenem
8H28	;	2.06	;	Crystal structure of the K87V mutant of cytochrome c' from Shewanella benthica DB6705
3GDM	;	1.6	;	Crystal structure of the K93R mutant of the orotidine 5'-monophosphate decarboxylase from Saccharomyces cerevisiae
5WI2	;	2.495	;	Crystal structure of the KA1 domain from human Chk1
4E0X	;	2.0	;	Crystal structure of the kainate receptor GluK1 ligand-binding domain in complex with kainate in the absence of glycerol
6F28	;	2.4	;	Crystal structure of the kainate receptor GluK3 ligand binding domain in complex with (S)-1-[2'-Amino-2'-carboxyethyl]-6-methyl-5,7-dihydropyrrolo[3,4-d]pyrimidin-2,4(1H,3H)-dione at resolution 2.4A
6F29	;	2.6	;	Crystal structure of the kainate receptor GluK3 ligand binding domain in complex with (S)-1-[2-Amino-2-carboxyethyl]-5,7-dihydrothieno[3,4-d]pyrimidin-2,4(1H,3H)-dione at resolution 2.6A
3S9E	;	1.6	;	Crystal structure of the kainate receptor GluK3 ligand binding domain in complex with (S)-glutamate
4MH5	;	1.65	;	Crystal structure of the kainate receptor GluK3 ligand binding domain in complex with (S)-glutamate
4E0W	;	2.3501	;	Crystal structure of the kainate receptor GluK3 ligand binding domain in complex with kainate
4NWD	;	2.6	;	Crystal structure of the kainate receptor GluK3 ligand-binding domain in complex with the agonist (2S,4R)-4-(3-Methylamino-3-oxopropyl)glutamic acid at 2.6 A resolution
4G8N	;	2.3	;	Crystal structure of the kainate receptor GluK3 ligand-binding domain in complex with the agonist G8M
4IGR	;	2.65	;	Crystal structure of the kainate receptor GluK3 ligand-binding domain in complex with the agonist ZA302
8BSU	;	2.9	;	Crystal structure of the kainate receptor GluK3-H523A ligand binding domain in complex with kainate and the positive allosteric modulator BPAM344 at 2.9A resolution
8BST	;	2.7	;	Crystal structure of the kainate receptor GluK3-H523A ligand binding domain in complex with kainate at 2.7A resolution
5IKB	;	2.05	;	Crystal structure of the kainate receptor GluK4 ligand binding domain in complex with kainate
1YCJ	;	1.95	;	Crystal structure of the kainate receptor GluR5 ligand-binding core in complex with (S)-glutamate
8IW0	;	2.1	;	Crystal structure of the KANK1/liprin-beta1 complex
4CY1	;	1.5	;	Crystal structure of the KANSL1-WDR5 complex.
4CY2	;	2.0	;	Crystal structure of the KANSL1-WDR5-KANSL2 complex.
6QU1	;	3.7	;	Crystal structure of the KAP1 RBCC domain in complex with the SMARCAD1 CUE1 domain at 3.7 angstrom resolution.
6H3A	;	5.505	;	Crystal structure of the KAP1 RBCC domain in complex with the SMARCAD1 CUE1 domain.
7Z36	;	2.8	;	Crystal structure of the KAP1 tripartite motif in complex with the ZNF93 KRAB domain
5OCR	;	1.66	;	Crystal structure of the kappa-carrageenase zobellia_236 from Zobellia galactanivorans
4ZJ7	;	2.4	;	Crystal structure of the karyopherin Kap121p bound to the extreme C-terminus of the protein phosphatase Cdc14p
5H2V	;	2.8	;	Crystal structure of the karyopherin Kap121p bound to the SUMO protease Ulp1p
5H2X	;	2.2	;	Crystal structure of the karyopherin Kap60p bound to the SUMO protease Ulp1p (150-172)
5H2W	;	2.5	;	Crystal structure of the karyopherin Kap60p bound to the SUMO protease Ulp1p (150-340)
7Y43	;	1.5	;	Crystal structure of the KAT6A WH domain and its bound double stranded DNA
6D42	;	1.75014	;	Crystal structure of the KCa3.1 C-terminal four-helix bundle (with copper)
2I2R	;	3.35	;	Crystal structure of the KChIP1/Kv4.3 T1 complex
2HVK	;	1.9	;	crystal structure of the KcsA-Fab-TBA complex in high K+
6M8S	;	3.71	;	Crystal structure of the KCTD12 H1 domain in complex with Gbeta1gamma2 subunits
6M8R	;	3.2	;	Crystal structure of the KCTD16 BTB domain in complex with GABAB2 peptide
7OXE	;	2.283	;	Crystal structure of the KDEL receptor bound to HDEF peptide at pH 6.0
6Y7V	;	2.241	;	Crystal structure of the KDEL receptor bound to HDEL peptide at pH 6.0
7OYE	;	2.62	;	Crystal structure of the KDEL receptor bound to HDEL peptide at pH 7.0
6ZXR	;	2.31	;	Crystal structure of the KDEL receptor bound to RDEL peptide at pH 6.0
6I6J	;	2.23	;	Crystal structure of the KDEL receptor bound to synthetic nanobody.
6I6H	;	2.0	;	Crystal structure of the KDEL receptor in the peptide bound state
6I6B	;	2.59	;	Crystal structure of the KDEL receptor in the peptide free state.
5Y9X	;	1.39	;	Crystal structure of the Kdo hydroxylase KdoO, a non-heme Fe(II) alphaketoglutarate dependent dioxygenase in complex with alphaketoglutarate and coblat(II)
5YVZ	;	1.6	;	Crystal structure of the Kdo hydroxylase KdoO, a non-heme Fe(II) alphaketoglutarate dependent dioxygenase in complex with alphaketoglutarate and Fe(III)
5Y9I	;	1.901	;	Crystal structure of the Kdo hydroxylase KdoO, a non-heme Fe(II) alphaketoglutarate dependent dioxygenase in complex with Co(II)
5YKA	;	1.448	;	Crystal structure of the Kdo hydroxylase KdoO, a non-heme Fe(II) alphaketoglutarate dependent dioxygenase in complex with cobalt(II)
5Y9Y	;	1.599	;	Crystal structure of the Kdo hydroxylase KdoO, a non-heme Fe(II) alphaketoglutarate dependent dioxygenase in complex with succinate and Co(II)
5YW0	;	1.49	;	Crystal structure of the Kdo hydroxylase KdoO, a non-heme Fe(II) alphaketoglutarate dependent dioxygenase in complex with succinate and Fe(III)
6XVJ	;	1.78	;	Crystal structure of the KDR (VEGFR2) kinase domain in complex with a type-II inhibitor
6XVK	;	1.99	;	Crystal structure of the KDR (VEGFR2) kinase domain in complex with a type-II inhibitor bearing an acrylamide
7ECA	;	2.00006	;	Crystal structure of the Keap1 complex with a peptide base on ETGE motif.
5X54	;	2.3	;	Crystal structure of the Keap1 Kelch domain in complex with a tetrapeptide
7YEN	;	2.8	;	Crystal structure of the Keap1 Kelch domain in complex with Caffeic acid
2DYH	;	1.9	;	Crystal structure of the Keap1 protein in complexed with the N-terminal region of the Nrf2 transcription factor
3ZGC	;	2.2	;	crystal structure of the KEAP1-NEH2 complex
6TG8	;	2.75	;	Crystal structure of the Kelch domain in complex with 11 amino acid peptide (model of the ETGE loop)
7QZQ	;	1.88	;	Crystal structure of the kelch domain of human KBTBD12
4ASC	;	1.78	;	Crystal structure of the Kelch domain of human KBTBD5
1U6D	;	1.85	;	Crystal structure of the Kelch domain of human Keap1
6ROG	;	2.16	;	Crystal Structure of the KELCH domain of human KEAP1
2VPJ	;	1.85	;	Crystal structure of the Kelch domain of human KLHL12
6TTK	;	2.383	;	Crystal structure of the kelch domain of human KLHL12 in complex with DVL1 peptide
8OIO	;	1.954	;	Crystal structure of the kelch domain of human KLHL12 in complex with PLEKHA4 peptide
6HRL	;	2.6	;	Crystal structure of the Kelch domain of human KLHL17
2XN4	;	1.99	;	Crystal structure of the kelch domain of human KLHL2 (Mayven)
8CIA	;	3.72	;	Crystal structure of the kelch domain of human KLHL20
6GY5	;	1.086	;	Crystal structure of the kelch domain of human KLHL20 in complex with DAPK1 peptide
3II7	;	1.63	;	Crystal structure of the kelch domain of human KLHL7
5YY8	;	1.979	;	Crystal structure of the Kelch domain of human NS1-BP
2FLU	;	1.5	;	Crystal Structure of the Kelch-Neh2 Complex
4OX0	;	2.49	;	Crystal structure of the keratin-like domain from the MADS transcription factor Sepallata 3
8UJW	;	1.72	;	Crystal structure of the KETc7 antigen from Taenia solium
8EP7	;	2.2	;	Crystal Structure of the Ketol-acid Reductoisomerase from Bacillus anthracis in complex with NADP
5X8H	;	1.85	;	Crystal structure of the ketone reductase ChKRED20 from the genome of Chryseobacterium sp. CA49
6IXM	;	1.601	;	Crystal structure of the ketone reductase ChKRED20 from the genome of Chryseobacterium sp. CA49 complexed with NAD
5GK1	;	1.83	;	Crystal structure of the ketosynthase StlD complexed with substrate
6AVG	;	2.6	;	Crystal structure of the KFJ37 TCR-NY-ESO-1-HLA-B*07:02 complex
6AT6	;	1.417	;	Crystal structure of the KFJ5 TCR
6AVF	;	2.028	;	Crystal structure of the KFJ5 TCR-NY-ESO-1-HLA-B*07:02 complex
5WWW	;	1.798	;	Crystal structure of the KH1 domain of human RNA-binding E3 ubiquitin-protein ligase MEX-3C complex with RNA
2QND	;	1.9	;	Crystal Structure of the KH1-KH2 domains from human Fragile X Mental Retardation Protein
5WWZ	;	2.5	;	Crystal structure of the KH2 domain of human RNA-binding E3 ubiquitin-protein ligase MEX-3C
5WWX	;	2.0	;	Crystal structure of the KH2 domain of human RNA-binding E3 ubiquitin-protein ligase MEX-3C complex with RNA
5GSZ	;	2.72	;	Crystal Structure of the KIF19A Motor Domain Complexed with Mg-ADP
2ZFM	;	2.31	;	Crystal Structure of the Kif1A Motor Domain After Mg Release
2ZFI	;	1.55	;	Crystal Structure of the Kif1A Motor Domain Before Mg Release
1VFX	;	2.55	;	Crystal Structure of the Kif1A Motor Domain Complexed With ADP-Mg-AlFx
1VFZ	;	2.24	;	Crystal Structure of the Kif1A Motor Domain Complexed With ADP-Mg-VO4
1I5S	;	2.2	;	CRYSTAL STRUCTURE OF THE KIF1A MOTOR DOMAIN COMPLEXED WITH MG-ADP
1I6I	;	2.0	;	CRYSTAL STRUCTURE OF THE KIF1A MOTOR DOMAIN COMPLEXED WITH MG-AMPPCP
1VFV	;	1.85	;	Crystal Structure of the Kif1A Motor Domain Complexed With Mg-AMPPNP
1VFW	;	2.3	;	Crystal Structure of the Kif1A Motor Domain Complexed With Mg-AMPPNP
2ZFJ	;	3.2	;	Crystal Structure of the Kif1A Motor Domain during Mg release: Mg-releasing Transition-1
2ZFK	;	3.61	;	Crystal Structure of the Kif1A Motor Domain during Mg release: Mg-releasing Transition-2
2ZFL	;	2.7	;	Crystal Structure of the Kif1A Motor Domain during Mg release: Mg-releasing Transition-3
2HEH	;	2.15	;	Crystal Structure of the KIF2C motor domain
3ZFC	;	1.8	;	Crystal Structure of the Kif4 Motor Domain Complexed With Mg-AMPPNP
3ZFD	;	1.71	;	Crystal Structure of the Kif4 Motor Domain Complexed With Mg-AMPPNP
3X2T	;	2.7	;	Crystal Structure of the KIF5C Motor Domain With ADP
3WRD	;	2.86	;	Crystal Structure of the KIF5C Motor Domain Without Any Nucleotide
5WDE	;	1.85	;	Crystal structure of the KIFC3 motor domain in complex with ADP
7WJ6	;	2.55	;	Crystal Structure of the Kinase Domain of a Class III Lanthipeptide Synthetase CurKC
8R7G	;	2.09	;	Crystal structure of the kinase domain of ACVR1 (ALK2) with M4K2234
6UNP	;	2.3	;	Crystal structure of the kinase domain of BMPR2-D485G
3G2F	;	2.35	;	Crystal structure of the kinase domain of bone morphogenetic protein receptor type II (BMPR2) at 2.35 A resolution
8S9F	;	2.6	;	Crystal structure of the kinase domain of Bruton's Tyrosine Kinase bound to dasatinib
4OTF	;	1.95	;	Crystal structure of the kinase domain of Bruton's Tyrosine kinase with GDC0834
4Y95	;	1.599	;	Crystal structure of the kinase domain of Bruton's tyrosine kinase with mutations in the activation loop
4CZT	;	2.3	;	Crystal structure of the kinase domain of CIPK23
4CZU	;	1.9	;	Crystal structure of the kinase domain of CIPK23 T190D mutant
4D28	;	3.3	;	Crystal structure of the kinase domain of CIPK24/SOS2
2WEI	;	1.65	;	Crystal structure of the kinase domain of Cryptosporidium parvum calcium dependent protein kinase in complex with 3-MB-PP1
7TVD	;	2.96	;	Crystal structure of the kinase domain of EGFR exon-19 (del-747-749) mutant
4NT4	;	2.86	;	Crystal structure of the kinase domain of Gilgamesh isoform I from Drosophila melanogaster
2AX4	;	2.5	;	Crystal structure of the kinase domain of human 3'-phosphoadenosine 5'-phosphosulphate synthetase 2
4DBN	;	3.15	;	Crystal Structure of the Kinase domain of Human B-raf with a [1,3]thiazolo[5,4-b]pyridine derivative
6XV9	;	3.38	;	Crystal structure of the kinase domain of human c-KIT in complex with a type-II inhibitor
6XVA	;	2.3	;	Crystal structure of the kinase domain of human c-KIT in complex with a type-II inhibitor bearing an acrylamide
6XVB	;	2.15	;	Crystal structure of the kinase domain of human c-KIT with a cyclic imidate inhibitor covalently bound to Cys788
3PP0	;	2.25	;	Crystal Structure of the Kinase domain of Human HER2 (erbB2).
4P90	;	2.49	;	Crystal structure of the kinase domain of human PAK1 in complex with compound 15
6ES0	;	2.38	;	Crystal structure of the kinase domain of human RIPK2 in complex with the activation loop targeting inhibitor CS-R35
5CWZ	;	2.9	;	Crystal structure of the kinase domain of human TRAF2 and NCK-interacting protein kinase
5AX9	;	2.4	;	Crystal structure of the kinase domain of human TRAF2 and NCK-interacting protein kinase in complex with compund 9
2X7F	;	2.8	;	Crystal structure of the kinase domain of human Traf2- and Nck- interacting Kinase with Wee1Chk1 inhibitor
3VNT	;	1.64	;	Crystal Structure of the Kinase domain of Human VEGFR2 with a [1,3]thiazolo[5,4-b]pyridine derivative
3VO3	;	1.52	;	Crystal Structure of the Kinase domain of Human VEGFR2 with imidazo[1,2-b]pyridazine derivative
3NEY	;	2.26	;	Crystal structure of the kinase domain of MPP1/p55
3ZZW	;	2.9	;	Crystal structure of the kinase domain of ROR2
8E4T	;	1.95	;	Crystal structure of the kinase domain of RTKC8 from the choanoflagellate Monosiga brevicollis
6EIX	;	2.3	;	Crystal structure of the kinase domain of the Q207E mutant of ACVR1 (ALK2) in complex with a 2-aminopyridine inhibitor K02288
5D7A	;	2.9	;	Crystal structure of the kinase domain of TRAF2 and NCK-interacting protein kinase with NCB-0846
3H9R	;	2.35	;	Crystal structure of the kinase domain of type I activin receptor (ACVR1) in complex with FKBP12 and dorsomorphin
6CN9	;	1.8	;	Crystal structure of the Kinase domain of WNK1
7WJ7	;	2.55	;	Crystal Structure of the Kinase Domain with Adenosine of a Class III Lanthipeptide Synthetase CurKC
3FE3	;	1.9	;	Crystal structure of the kinase MARK3/Par-1: T211A-S215A double mutant
7WCF	;	1.3636	;	Crystal structure of the kinase with AMP-PNP
3U06	;	2.35	;	Crystal structure of the kinesin-14 NcdG347D
5DJN	;	2.82	;	Crystal structure of the Kinesin-3 KIF13A NC-CC1 mutant - Deletion of P390
4KR1	;	2.5	;	Crystal structure of the kinetechore protein Iml3 from budding yeast
5LSI	;	2.002	;	CRYSTAL STRUCTURE OF THE KINETOCHORE MIS12 COMPLEX HEAD2 SUBDOMAIN CONTAINING DSN1 AND NSL1 FRAGMENTS
6YPC	;	2.9	;	Crystal structure of the kinetochore subunits H/I/K/T/W penta-complex from S. cerevisiae at 2.9 angstroms
8QOH	;	2.2	;	Crystal structure of the kinetoplastid kinetochore protein KKT14 C-terminal domain from Apiculatamorpha spiralis
8A0K	;	2.92	;	crystal structure of the kinetoplastid kinetochore protein Trypanosoma brucei KKT3 Divergent Polo-Box domain
8A0J	;	2.2	;	Crystal structure of the kinetoplastid kinetochore protein Trypanosoma congolense KKT2 divergent polo-box domain
3AT9	;	3.3	;	Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride and 10 mM magnesium chloride)
3ATA	;	3.49	;	Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride and 10 mM Spermine)
3AT8	;	3.3	;	Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride)
3ATD	;	3.01	;	Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM Gadolinium chloride and 10 mM magnesium chloride)
3ATB	;	3.51	;	Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM Gadolinium chloride)
3ATE	;	3.2	;	Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM praseodymium (III) acetate)
3ATF	;	2.95	;	Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 200 mM Cesium chloride)
4X9U	;	2.1	;	Crystal structure of the kiwifruit allergen Act d 5
5SVH	;	2.05	;	Crystal structure of the KIX domain of CBP in complex with a MLL/c-Myb chimera
4BK0	;	1.9	;	Crystal structure of the KIX domain of human RECQL5 (domain-swapped dimer)
5OJ8	;	2.247	;	Crystal structure of the KLC1-TPR domain ([A1-B5] fragment)
7AI4	;	2.795	;	Crystal structure of the KLC1-TPR domain truncated from its nonTPR region ([A1-B6]-Delta-nonTPR fragment)
8BKE	;	2.0	;	Crystal structure of the Klebsiella phage KP34p57 capsular depolymerase
6PH9	;	1.92	;	Crystal Structure of the Klebsiella pneumoniae LpxH-lipid X complex
6PJ3	;	2.25	;	Crystal structure of the Klebsiella pneumoniae LpxH/JH-LPH-33 complex
3ZGX	;	3.4	;	Crystal structure of the kleisin-N SMC interface in prokaryotic condensin
3VA7	;	2.6	;	Crystal structure of the Kluyveromyces lactis Urea Carboxylase
4LEJ	;	2.402	;	Crystal Structure of the Korean pine (Pinus koraiensis) vicilin
5OHQ	;	1.098	;	Crystal structure of the KOW6-KOW7 domain of human DSIF
5OHO	;	1.601	;	Crystal structure of the KOWx-KOW4 domain of human DSIF
5UJ3	;	1.45	;	Crystal structure of the KPC-2 beta-lactamase complexed with hydrolyzed cefotaxime
5UJ4	;	1.4	;	Crystal structure of the KPC-2 beta-lactamase complexed with hydrolyzed faropenem
3E2K	;	2.1	;	Crystal Structure of the KPC-2 Beta-lactamase/Beta-lactamase inhibitor protein (BLIP)
3E2L	;	1.87	;	Crystal Structure of the KPC-2 Beta-lactamase/Beta-lactamase inhibitor protein (BLIP)
2OV5	;	1.85	;	Crystal structure of the KPC-2 carbapenemase
8G2R	;	1.28	;	CRYSTAL STRUCTURE OF THE KPC-2 D179N VARIANT IN COMPLEX WITH AVIBACTAM
8G2T	;	1.26	;	CRYSTAL STRUCTURE OF THE KPC-2 D179N VARIANT IN COMPLEX WITH RELEBACTAM (IMINE HYDROLYSIS INTERMEDIATE)
1TPK	;	2.4	;	CRYSTAL STRUCTURE OF THE KRINGLE-2 DOMAIN OF TISSUE PLASMINOGEN ACTIVATOR AT 2.4-ANGSTROMS RESOLUTION
3U7D	;	2.49	;	Crystal structure of the KRIT1/CCM1 FERM domain in complex with the heart of glass (HEG1) cytoplasmic tail
3ZGH	;	2.0	;	Crystal structure of the KRT10-binding region domain of the pneumococcal serine rich repeat protein PsrP
3ZGI	;	2.25	;	Crystal structure of the KRT10-binding region domain of the pneumococcal serine rich repeat protein PsrP
3PSX	;	1.9	;	Crystal structure of the KT2 mutant of cytochrome P450 BM3
4D4O	;	2.897	;	Crystal Structure of the Kti11 Kti13 heterodimer Spacegroup P64
4D4P	;	2.999	;	Crystal Structure of the Kti11 Kti13 heterodimer Spacegroup P65
1JEQ	;	2.7	;	Crystal Structure of the Ku Heterodimer
1JEY	;	2.5	;	Crystal Structure of the Ku heterodimer bound to DNA
3UOU	;	2.0	;	Crystal structure of the Kunitz-type protease inhibitor ShPI-1 Lys13Leu mutant in complex with pancreatic elastase
7VVH	;	2.296	;	Crystal Structure of the Kv7.1 C-terminal Domain in Complex with Calmodulin disease mutation E140G
7VUO	;	2.679	;	Crystal Structure of the Kv7.1 C-terminal Domain in Complex with Calmodulin disease mutation F141L
7VVD	;	3.134	;	Crystal Structure of the Kv7.1 C-terminal Domain in Complex with Calmodulin disease mutation Q135P
4UMO	;	3.0	;	Crystal Structure of the Kv7.1 proximal C-terminal Domain in Complex with Calmodulin
4V0C	;	2.86	;	Crystal Structure of the Kv7.1 proximal C-terminal Domain in Complex with Calmodulin
1UCQ	;	2.4	;	Crystal structure of the L intermediate of bacteriorhodopsin
3FWY	;	1.63	;	Crystal structure of the L protein of Rhodobacter sphaeroides light-independent protochlorophyllide reductase (BchL) with MgADP bound: a homologue of the nitrogenase Fe protein
7Z0D	;	1.2	;	Crystal structure of the L state of bacteriorhodopsin at 1.20 Angstrom resolution
4LPQ	;	1.37	;	Crystal structure of the L,D-transpeptidase (residues 123-326) from Xylanimonas cellulosilytica DSM 15894
3UMC	;	2.15	;	Crystal Structure of the L-2-Haloacid Dehalogenase PA0810
3UMB	;	2.2	;	Crystal Structure of the L-2-Haloacid Dehalogenase RSc1362
5J4N	;	2.594	;	Crystal structure of the L-arginine/agmatine antiporter AdiC in complex with agmatine at 2.6 Angstroem resolution
5J4I	;	2.207	;	Crystal Structure of the L-arginine/agmatine antiporter from E. coli at 2.2 Angstroem resolution
2YLN	;	1.12	;	Crystal structure of the L-cystine solute receptor of Neisseria gonorrhoeae in the closed conformation
3ZSF	;	2.32	;	Crystal structure of the L-cystine solute receptor of Neisseria gonorrhoeae in the unliganded open conformation
6K1F	;	2.5	;	Crystal structure of the L-fucose isomerase from Raoultella sp.
6K1G	;	2.96	;	Crystal structure of the L-fucose isomerase soaked with Mn2+ from Raoultella sp.
2IRP	;	2.4	;	Crystal structure of the l-fuculose-1-phosphate aldolase (aq_1979) from aquifex aeolicus VF5
3WEU	;	1.93	;	Crystal structure of the L-Lys epsilon-oxidase from Marinomonas mediterranea
7PD1	;	1.27	;	Crystal structure of the L-tyrosine-bound radical SAM tyrosine lyase ThiH (2-iminoacetate synthase) from Thermosinus carboxydivorans
8BZ8	;	2.52	;	Crystal structure of the L. monocytogenes RmlT D198A variant in complex with TDP-rhamnose
8BZ5	;	2.3	;	Crystal structure of the L. monocytogenes RmlT in complex with HEPES
8BZ7	;	2.2	;	Crystal structure of the L. monocytogenes RmlT in complex with TDP-rhamnose
8BZ6	;	2.4	;	Crystal structure of the L. monocytogenes RmlT in complex with UDP-glucose
7R49	;	1.88	;	Crystal structure of the L. plantarum acyl carrier protein synthase (AcpS)in complex with D-alanyl carrier protein (DltC1)
7R27	;	2.01	;	Crystal structure of the L. plantarum D-alanine ligase DltA
6CB3	;	1.891	;	Crystal structure of the L.Lactis YkoY riboswitch bound to cadmium
4F1O	;	2.3	;	Crystal Structure of the L1180T mutant Roco4 Kinase Domain from D. discoideum bound to AppCp
7MFQ	;	1.95	;	crystal structure of the L136 aminotransferase from acanthamoeba polyphaga mimivirus in complex with the TDP-viosamine external aldimine
7MFP	;	1.85	;	crystal structure of the L136 aminotransferase K185A from acanthamoeba polyphaga mimivirus in the presence of the UDP-viosamine external aldimine
4RP5	;	1.65	;	Crystal Structure of the L27 domain of Discs Large 1 (target ID NYSGRC-010766) from Drosophila melanogaster (space group P21)
4RP4	;	1.42	;	Crystal Structure of the L27 domain of Discs Large 1 (target ID NYSGRC-010766) from Drosophila melanogaster (space group P212121)
4RP3	;	1.36	;	Crystal Structure of the L27 Domain of Discs Large 1 (target ID NYSGRC-010766) from Drosophila melanogaster bound to a potassium ion (space group P212121)
3QLG	;	2.75	;	Crystal structure of the L317I mutant of the C-src tyrosine kinase domain complexed with dasatinib
3QLF	;	2.75	;	Crystal structure of the L317I mutant of the C-src tyrosine kinase domain complexed with pyrazolopyrimidine 5
3OF0	;	2.7	;	crystal structure of the L317I mutant of the chicken c-Src tyrosine kinase domain
3OEZ	;	2.4	;	crystal structure of the L317I mutant of the chicken c-Src tyrosine kinase domain complexed with imatinib
5KQI	;	1.87	;	Crystal structure of the L326D variant of catalase-peroxidase from B. pseudomallei
8DWR	;	2.1	;	Crystal structure of the L333V variant of catalase-peroxidase from Mycobacterium tuberculosis
1GAO	;	2.2	;	CRYSTAL STRUCTURE OF THE L44S MUTANT OF FERREDOXIN I
7ORB	;	2.5	;	Crystal structure of the L452R mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-75 and COVOX-253 Fabs
5Y69	;	1.85	;	Crystal structure of the L52M mutant of AcrIIA1
3WJT	;	1.55	;	Crystal structure of the L68D variant of mLolB
3WJU	;	2.5	;	Crystal structure of the L68D variant of mLolB from Escherichia coli
3WJV	;	2.4	;	Crystal structure of the L68E variant of mLolB
4XBX	;	1.53	;	Crystal Structure of the L74F/M78F/L103V/L114V/I116V/F139V/L147V mutant of LEH
4XBT	;	1.7	;	Crystal Structure of the L74F/M78F/L103V/L114V/I116V/F139V/L147V mutant of LEH complexed with (S,S)-cyclohexanediol
4XDW	;	2.05	;	Crystal Structure of the L74F/M78V/I80V/L114F mutant of LEH
4XDV	;	2.25	;	Crystal Structure of the L74F/M78V/I80V/L114F mutant of LEH complexed with cyclohexanediol
4XBY	;	2.3	;	Crystal Structure of the L74F/M78V/I80V/L114F mutant of LEH complexed with cyclopentene oxide
5YQT	;	2.3	;	Crystal Structure of the L74F/M78V/I80V/L114F mutant of LEH complexed with cyclopentene oxide
7JID	;	1.45	;	Crystal structure of the L780 UDP-rhamnose synthase from Acanthamoeba polyphaga mimivirus
4G4E	;	2.888	;	Crystal structure of the L88A mutant of HslV from Escherichia coli
5B4Y	;	1.9	;	Crystal structure of the LA12 fragment of ApoER2
2PE5	;	3.5	;	Crystal Structure of the Lac Repressor bound to ONPG in repressed state
1EFA	;	2.6	;	CRYSTAL STRUCTURE OF THE LAC REPRESSOR DIMER BOUND TO OPERATOR AND THE ANTI-INDUCER ONPF
2PUA	;	2.9	;	CRYSTAL STRUCTURE OF THE LACI FAMILY MEMBER, PURR, BOUND TO DNA: MINOR GROOVE BINDING BY ALPHA HELICES
2PUB	;	2.7	;	CRYSTAL STRUCTURE OF THE LACI FAMILY MEMBER, PURR, BOUND TO DNA: MINOR GROOVE BINDING BY ALPHA HELICES
2PUC	;	2.6	;	CRYSTAL STRUCTURE OF THE LACI FAMILY MEMBER, PURR, BOUND TO DNA: MINOR GROOVE BINDING BY ALPHA HELICES
2PUD	;	2.6	;	CRYSTAL STRUCTURE OF THE LACI FAMILY MEMBER, PURR, BOUND TO DNA: MINOR GROOVE BINDING BY ALPHA HELICES
2PUE	;	2.7	;	CRYSTAL STRUCTURE OF THE LACI FAMILY MEMBER, PURR, BOUND TO DNA: MINOR GROOVE BINDING BY ALPHA HELICES
2PUF	;	3.0	;	CRYSTAL STRUCTURE OF THE LACI FAMILY MEMBER, PURR, BOUND TO DNA: MINOR GROOVE BINDING BY ALPHA HELICES
2PUG	;	2.7	;	CRYSTAL STRUCTURE OF THE LACI FAMILY MEMBER, PURR, BOUND TO DNA: MINOR GROOVE BINDING BY ALPHA HELICES
4ND5	;	2.1	;	Crystal structure of the lactate dehydrogenase from cryptosporidium parvum
4ND1	;	2.15	;	Crystal structure of the lactate dehydrogenase from cryptosporidium parvum complexed with cofactor (b-nicotinamide adenine dinucleotide) and inhibitor (oxamic acid)
4ND3	;	2.05	;	Crystal structure of the lactate dehydrogenase from cryptosporidium parvum complexed with substrate (l-lactic acid) and cofactor (b-nicotinamide adenine dinucleotide)
2FN7	;	2.3	;	Crystal structure of the lactate dehydrogenase from cryptosporidium parvum complexed with substrate (lactic acid) and cofactor (b-nicotinamide adenine dinucleotide)
4ND4	;	2.2	;	Crystal structure of the lactate dehydrogenase from cryptosporidium parvum complexed with substrate (pyruvic acid) and cofactor (b-nicotinamide adenine dinucleotide)
4ND2	;	2.0	;	Crystal structure of the lactate dehydrogenase from cryptosporidium parvum complexed with substrate (pyruvic acid) and cofactor analog (3-acetylpyridine adenine dinucleotide)
8AB3	;	2.616	;	Crystal Structure of the Lactate Dehydrogenase of Cyanobacterium Aponinum in complex with oxamate, NADH and FBP.
8AB2	;	2.1	;	Crystal Structure of the Lactate Dehydrogenase of Cyanobacterium Aponinum in its apo form.
3PF8	;	2.34	;	Crystal structure of the Lactobacillus johnsonii cinnamoyl esterase LJ0536
3PF9	;	1.75	;	Crystal structure of the Lactobacillus johnsonii cinnamoyl esterase LJ0536 S106A mutant
3S2Z	;	1.76	;	Crystal structure of the Lactobacillus johnsonii cinnamoyl esterase LJ0536 S106A mutant in complex with caffeic acid
3PFB	;	1.58	;	Crystal structure of the Lactobacillus johnsonii cinnamoyl esterase LJ0536 S106A mutant in complex with ethylferulate
3QM1	;	1.817	;	CRYSTAL STRUCTURE OF THE LACTOBACILLUS JOHNSONII CINNAMOYL ESTERASE LJ0536 S106A MUTANT IN COMPLEX WITH ETHYLFERULATE, Form II
3PFC	;	1.75	;	Crystal structure of the Lactobacillus johnsonii cinnamoyl esterase LJ0536 S106A mutant in complex with ferulic acid
3PNZ	;	1.5983	;	Crystal structure of the lactonase Lmo2620 from Listeria monocytogenes
2PAF	;	3.5	;	Crystal Structure of the Lactose Repressor bound to anti-inducer ONPF in induced state
1P7D	;	2.95	;	Crystal structure of the Lambda Integrase (residues 75-356) bound to DNA
5LM7	;	3.35	;	Crystal structure of the lambda N-Nus factor complex
3BDN	;	3.909	;	Crystal Structure of the Lambda Repressor
1F39	;	1.9	;	CRYSTAL STRUCTURE OF THE LAMBDA REPRESSOR C-TERMINAL DOMAIN
1KCA	;	2.91	;	Crystal Structure of the lambda Repressor C-terminal Domain Octamer
2OG0	;	1.9	;	Crystal Structure of the Lambda Xis-DNA complex
3AZX	;	1.8	;	Crystal structure of the laminarinase catalytic domain from Thermotoga maritima MSB8
3AZY	;	1.65	;	Crystal structure of the laminarinase catalytic domain from Thermotoga maritima MSB8
3B01	;	1.87	;	Crystal structure of the laminarinase catalytic domain from Thermotoga maritima MSB8
3B00	;	1.74	;	Crystal structure of the laminarinase catalytic domain from Thermotoga maritima MSB8 in complex with cetyltrimethylammonium bromide
3AZZ	;	1.81	;	Crystal structure of the laminarinase catalytic domain from Thermotoga maritima MSB8 in complex with gluconolactone
3GI1	;	2.45	;	Crystal Structure of the laminin-binding protein Lbp of Streptococcus pyogenes
3WO9	;	2.3	;	Crystal structure of the lamprey variable lymphocyte receptor C
7V9N	;	1.9	;	Crystal structure of the lanthipeptide zinc-metallopeptidase EryP from saccharopolyspora erythraea in closed state
7V9P	;	1.8	;	Crystal structure of the lanthipeptide zinc-metallopeptidase EryP from saccharopolyspora erythraea in intermediate state
7V9Q	;	2.67	;	Crystal structure of the lanthipeptide zinc-metallopeptidase EryP from saccharopolyspora erythraea in open state
7V9O	;	1.77	;	Crystal structure of the lanthipeptide zinc-metallopeptidase EryP mutant E802R from saccharopolyspora erythraea
3KHW	;	2.1	;	Crystal structure of the large c-terminal domain of polymerase basic protein 2 from influenza virus a/mexico/indre4487/2009(h1n1)
3KC6	;	2.05	;	Crystal structure of the large c-terminal domain of polymerase basic protein 2 from influenza virus a/viet nam/1203/2004 (h5n1)
3L56	;	2.3	;	Crystal structure of the large c-terminal domain of polymerase basic protein 2 from influenza virus a/viet nam/1203/2004 (h5n1)
4DFP	;	2.0	;	Crystal structure of the large fragment of DNA Polymerase I from Thermus aqauticus in a ternary complex with 7-(aminopentinyl)-7-deaza-dGTP
4DFJ	;	1.9	;	Crystal structure of the large fragment of DNA Polymerase I from Thermus aquaticus in a closed ternary complex with 5-(aminopentinyl)-dTTP
5E41	;	1.8	;	Crystal structure of the large fragment of DNA Polymerase I from Thermus aquaticus in a closed ternary complex with 5-(N-(10-hydroxydecanoyl)-aminopentenyl)-2'-deoxyuridine-triphosphate
5SZT	;	1.8	;	Crystal structure of the large fragment of DNA Polymerase I from Thermus aquaticus in a closed ternary complex with 7-(N-(10-hydroxydecanoyl)-aminopentenyl)-7-deaza-2'-dATP
4DF4	;	2.2	;	Crystal structure of the large fragment of DNA Polymerase I from Thermus aquaticus in a closed ternary complex with 7-(N-(10-hydroxydecanoyl)-aminopentinyl)-7-deaza-2 -dATP
4DF8	;	2.0	;	Crystal structure of the large fragment of DNA Polymerase I from Thermus aquaticus in a closed ternary complex with aminopentinyl-7-deaza-2-dATP
3RTV	;	1.9	;	Crystal structure of the large fragment of DNA polymerase I from Thermus Aquaticus in a closed ternary complex with natural primer/template DNA
5NKL	;	1.7	;	Crystal structure of the large fragment of DNA polymerase I from Thermus Aquaticus in a closed ternary complex with the artificial base pair dDs-dPxTP
3SV3	;	2.1	;	Crystal structure of the large fragment of DNA polymerase I from Thermus Aquaticus in a closed ternary complex with the artificial base pair dNaM-d5SICSTP
3M8R	;	2.0	;	Crystal structure of the large fragment of DNA polymerase I from Thermus aquaticus in a closed ternary complex with trapped 4'-ethylated dTTP
3M8S	;	2.2	;	Crystal structure of the large fragment of DNA polymerase I from Thermus aquaticus in a closed ternary complex with trapped 4'-methylated dTTP
4C8K	;	2.17	;	Crystal structure of the large fragment of DNA polymerase I from Thermus Aquaticus in a partially closed complex with the artificial base pair d5SICS-dNaMTP
4CCH	;	2.55	;	Crystal structure of the large fragment of DNA polymerase I from Thermus Aquaticus in an open binary complex with d5SICS as templating nucleotide
3SZ2	;	2.15	;	Crystal structure of the large fragment of DNA polymerase I from Thermus Aquaticus in an open binary complex with dG as templating nucleobase
3SYZ	;	1.952	;	Crystal structure of the large fragment of DNA polymerase I from Thermus Aquaticus in an open binary complex with dNaM as templating nucleobase
3SV4	;	1.99	;	Crystal structure of the large fragment of DNA polymerase I from Thermus Aquaticus in an open binary complex with dT as templating nucleobase
4DFM	;	1.886	;	Crystal structure of the large fragment of DNA polymerase I from Thermus aquaticus in ternary complex with 5-(aminopentinyl)-2-dCTP
7JSR	;	6.27	;	Crystal structure of the large glutamate dehydrogenase composed of 180 kDa subunits from Mycobacterium smegmatis
4U67	;	3.65	;	Crystal structure of the large ribosomal subunit (50S) of Deinococcus radiodurans containing a three residue insertion in L22
4WFN	;	3.54	;	Crystal structure of the large ribosomal subunit (50S) of Deinococcus radiodurans containing a three residue insertion in L22 in complex with erythromycin
1NKW	;	3.1	;	Crystal Structure Of The Large Ribosomal Subunit From Deinococcus Radiodurans
1FFK	;	2.4	;	CRYSTAL STRUCTURE OF THE LARGE RIBOSOMAL SUBUNIT FROM HALOARCULA MARISMORTUI AT 2.4 ANGSTROM RESOLUTION
5M1F	;	2.15	;	Crystal structure of the large terminase nuclease from thermophilic phage G20c
5M1P	;	1.1	;	Crystal structure of the large terminase nuclease from thermophilic phage G20c with bound Calcium
5M1O	;	1.6	;	Crystal structure of the large terminase nuclease from thermophilic phage G20c with bound Cobalt
5M1K	;	1.2	;	Crystal structure of the large terminase nuclease from thermophilic phage G20c with bound Magnesium
5M1N	;	1.2	;	Crystal structure of the large terminase nuclease from thermophilic phage G20c with bound Manganese
5M1Q	;	1.45	;	Crystal structure of the large terminase nuclease from thermophilic phage G20c with bound Zinc
4IDH	;	1.69	;	Crystal Structure of the large terminase subunit gp2 of bacterial virus Sf6
4IEI	;	2.09	;	Crystal Structure of the large terminase subunit gp2 of bacterial virus Sf6 complexed with ADP
4IFE	;	3.05	;	Crystal Structure of the large terminase subunit gp2 of bacterial virus Sf6 complexed with ATP
4IEE	;	1.89	;	Crystal Structure of the large terminase subunit gp2 of bacterial virus Sf6 complexed with ATP-r-S
3IT5	;	2.0	;	Crystal Structure of the LasA Virulence Factor from Pseudomonas aeruginosa
3IT7	;	2.14	;	Crystal Structure of the LasA virulence factor from Pseudomonas aeruginosa
5OQZ	;	0.806	;	Crystal structure of the lasso peptide rubrivinodin
5JQF	;	0.85	;	Crystal structure of the lasso peptide Sphingopyxin I (SpI)
5AFB	;	2.16	;	Crystal structure of the Latrophilin3 Lectin and Olfactomedin Domains
2HC4	;	2.2	;	Crystal structure of the LBD of VDR of Danio rerio in complex with calcitriol
8HKH	;	2.7	;	Crystal structure of the LC/A1-DARPin18 complex
3KPR	;	2.6	;	Crystal Structure of the LC13 TCR in complex with HLA B*4405 bound to EEYLKAWTF a mimotope
3KPS	;	2.7	;	Crystal Structure of the LC13 TCR in complex with HLA B*4405 bound to EEYLQAFTY a self peptide from the ABCD3 protein
3TID	;	1.65	;	Crystal structure of the LCMV derived peptide GP34 in complex with the murine mhc class I H-2 Kb
1JPF	;	2.18	;	Crystal Structure Of The LCMV Peptidic Epitope Gp276 In Complex With The Murine Class I Mhc Molecule H-2Db
1FG2	;	2.754	;	CRYSTAL STRUCTURE OF THE LCMV PEPTIDIC EPITOPE GP33 IN COMPLEX WITH THE MURINE CLASS I MHC MOLECULE H-2DB
1JPG	;	2.2	;	Crystal Structure Of The LCMV Peptidic Epitope Np396 In Complex With The Murine Class I Mhc Molecule H-2Db
3SO6	;	1.37	;	Crystal structure of the LDL receptor tail in complex with autosomal recessive hypercholesterolemia PTB domain
1IJQ	;	1.5	;	Crystal Structure of the LDL Receptor YWTD-EGF Domain Pair
5U7C	;	1.75	;	Crystal structure of the lead-bound form of MerB formed from diethyllead.
3ZDV	;	1.41	;	Crystal structure of the LecB lectin from Pseudomonas aeruginosa in complex with Methyl 6-(2,4,6-trimethylphenylsulfonylamido)-6-deoxy-alpha-D-mannopyranoside
5A3O	;	1.6	;	Crystal structure of the LecB lectin from Pseudomonas aeruginosa in complex with Methyl 6-(cinnamido)-6-deoxy-alpha-D-mannopyranoside at 1.6 ansgtrom
4UT5	;	1.75	;	Crystal structure of the LecB lectin from Pseudomonas aeruginosa strain PA7 in complex with lewis a tetrasaccharide
5NWP	;	1.05	;	Crystal Structure of the Lectin Domain From the F17-like Adhesin, UclD
5VQ5	;	1.6	;	Crystal Structure of the Lectin Domain From the F17-like Adhesin, UclD
4B4Q	;	2.0	;	Crystal Structure of the lectin domain of F18 fimbrial adhesin FedF in complex with blood group A type 1 hexasaccharide
4B4R	;	1.8	;	Crystal Structure of the lectin domain of F18 fimbrial adhesin FedF in complex with blood group B type 1 hexasaccharide
4B4P	;	1.8	;	Crystal Structure of the lectin domain of F18 fimbrial adhesin FedF.
4Z3H	;	1.5	;	Crystal structure of the lectin domain of PapG from E. coli BI47 in complex with 4-methoxyphenyl beta-D-galabiose in space group P21
4Z3G	;	1.45	;	Crystal structure of the lectin domain of PapG from E. coli BI47 in complex with 4-methoxyphenyl beta-D-galabiose in space group P212121
4Z3F	;	1.8	;	Crystal structure of the lectin domain of PapG from E. coli BI47 in complex with SSEA4 in space group P21
4Z3E	;	1.8	;	Crystal structure of the lectin domain of PapG from E. coli BI47 in complex with SSEA4 in space group P212121
4Z3J	;	2.5	;	Crystal structure of the lectin domain of PapG from E. coli BI47 in space group P1
4Z3I	;	1.739	;	Crystal structure of the lectin domain of PapG from E. coli BI47 in spacegroup P21212
7AYN	;	1.42	;	Crystal structure of the lectin domain of the FimH variant Arg98Ala, in complex with Methyl 3-chloro-4-D-mannopyranosyloxy-3-biphenylcarboxylate
1JXN	;	2.3	;	Crystal Structure of the Lectin I from Ulex europaeus in complex with the methyl glycoside of alpha-L-fucose
5MIH	;	1.8	;	Crystal structure of the lectin LecA from Pseudomonas aeruginosa in complex with a phenyl-epoxy-galactopyranoside
4AL9	;	1.75	;	Crystal structure of the lectin PA-IL from Pseudomonas aeruginoas in complex with melibiose
6PIR	;	1.65	;	Crystal structure of the Legionella effector protein MavE
6OMI	;	2.643	;	Crystal structure of the Legionella effector protein MavL
8IPJ	;	2.003	;	Crystal structure of the Legionella effector protein MavL with ADPR-Ub
5N6X	;	1.75	;	Crystal structure of the Legionella effector WipA
5N72	;	1.842	;	Crystal structure of the Legionella effector WipA shorter construct
6S2X	;	1.71	;	Crystal structure of the Legionella pneumophila ChiA C-terminal domain
5CQC	;	2.985	;	Crystal structure of the legionella pneumophila effector protein RavZ
5IZV	;	2.814	;	Crystal structure of the legionella pneumophila effector protein RavZ - F222
5IO3	;	2.74	;	Crystal structure of the legionella pneumophila effector protein RavZ - I422
5HZY	;	2.548	;	Crystal structure of the legionella pneumophila effector protein RavZ - P6322
5MS2	;	2.47	;	Crystal structure of the Legionella pneumophila effector protein RavZ in complex with human LC3B
5MS8	;	2.85	;	Crystal structure of the legionella pneumophila effector protein RavZ_1-487
5MS7	;	2.8	;	Crystal structure of the legionella pneumophila effector protein RavZ_20-502
4BEP	;	3.14	;	Crystal structure of the Legionella pneumophila FIC domain-containing effector AnkX protein (apo-form)
4BET	;	2.55	;	Crystal structure of the Legionella pneumophila FIC domain-containing effector AnkX protein (inactive H229A mutant) in complex with cytidine-diphosphate-choline
4BER	;	2.6	;	Crystal structure of the Legionella pneumophila FIC domain-containing effector AnkX protein in complex with cytidine monophosphate
4BES	;	2.54	;	Crystal structure of the Legionella pneumophila FIC domain-containing effector AnkX protein in complex with cytidine monophosphate and phosphocholine
4I1M	;	2.804	;	Crystal structure of the Legionella pneumophila GAP domain of LepB
4I1O	;	2.701	;	Crystal structure of the Legionella pneumophila GAP domain of LepB in complex with Rab1b bound to GDP and BeF3
7BYK	;	2.65	;	Crystal structure of the Legionella pneumophila LegK7 effector kinase
6SJT	;	3.103	;	Crystal structure of the Legionella pneumophila type II secretion system substrate NttC
6SKW	;	2.2	;	Crystal structure of the Legionella pneumophila type II secretion system substrate NttE
6ESL	;	1.87	;	Crystal structure of the Legionella pneumoppila LapA
2P18	;	1.8	;	Crystal structure of the Leishmania infantum glyoxalase II
2P1E	;	1.9	;	Crystal structure of the Leishmania infantum glyoxalase II with D-Lactate at the active site
4GED	;	1.84	;	Crystal Structure of the Leishmania Major Peroxidase-Cytochrome C Complex
4HZI	;	1.85	;	Crystal structure of the Leptospira interrogans ATPase subunit of an orphan ABC transporter
3BWS	;	1.99	;	Crystal structure of the leptospiral antigen Lp49
3NMD	;	2.272	;	Crystal structure of the leucine zipper domain of cGMP dependent protein kinase I beta
2PNV	;	2.1	;	Crystal Structure of the leucine zipper domain of small-conductance Ca2+-activated K+ (SKCa) channel from Rattus norvegicus
5MQ4	;	2.7	;	Crystal Structure of the leucine zipper of human PRKCBP1
3GOZ	;	2.099	;	Crystal structure of the leucine-rich repeat-containing protein LegL7 from Legionella pneumophila. Northeast Structural Genomics Consortium target LgR148
6GZ0	;	1.52	;	Crystal Structure of the LeuO Effector Binding Domain
6GZ1	;	1.74	;	Crystal Structure of the LeuO Effector Binding Domain
6GZ2	;	1.94	;	Crystal Structure of the LeuO Effector Binding Domain
5AGJ	;	2.0	;	Crystal structure of the LeuRS editing domain of Candida albicans in complex with the adduct AN2690-AMP
5AGH	;	1.81	;	Crystal structure of the LeuRS editing domain of Candida albicans Mutant K510A
5AGI	;	1.47	;	Crystal structure of the LeuRS editing domain of Candida albicans Mutant K510A in complex with the adduct formed by AN2690-AMP
5AGT	;	1.45	;	Crystal structure of the LeuRS editing domain of Mycobacterium tuberculosis in complex with the adduct (S)-3-(Aminomethyl)-4-chloro-7-ethoxybenzo[c][1,2]oxaborol-1(3H)-ol-AMP
5AGR	;	1.3	;	Crystal structure of the LeuRS editing domain of Mycobacterium tuberculosis in complex with the adduct (S)-3-(Aminomethyl)-7-ethoxybenzo[c][1,2]oxaborol-1(3H)-ol-AMP
5AGS	;	1.47	;	Crystal structure of the LeuRS editing domain of Mycobacterium tuberculosis in complex with the adduct 3-(Aminomethyl)-4-bromo-7-ethoxybenzo[c][1,2]oxaborol-1(3H)-ol-AMP
2XZ8	;	1.94	;	CRYSTAL STRUCTURE OF THE LFW ECTODOMAIN OF THE PEPTIDOGLYCAN RECOGNITION PROTEIN LF
2XZ4	;	1.72	;	Crystal structure of the LFZ ectodomain of the peptidoglycan recognition protein LF
2WJS	;	2.8	;	Crystal structure of the LG1-3 region of the laminin alpha2 chain
5JNF	;	2.75	;	Crystal structure of the LgrA initiation module excluding the Asub domain: F-A-delta-sub
5ES9	;	3.77	;	Crystal structure of the LgrA initiation module in the formylation state
3WMM	;	3.008	;	Crystal structure of the LH1-RC complex from Thermochromatium tepidum in C2 form
4V8K	;	3.006	;	Crystal structure of the LH1-RC complex from Thermochromatium tepidum in P21 form
5BQN	;	2.3	;	Crystal structure of the LHn fragment of botulinum neurotoxin type D, mutant H233Y E230Q
3RBJ	;	2.3	;	Crystal Structure of the lid-mutant of Streptococcus agalactiae Sortase C1
4N73	;	1.8662	;	Crystal structure of the ligand binding domain (LBD) of REV-ERB beta bound to Cobalt Protoporphyrin IX
1I7G	;	2.2	;	CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN FROM HUMAN PPAR-ALPHA IN COMPLEX WITH THE AGONIST AZ 242
3HFU	;	2.6	;	Crystal structure of the ligand binding domain of E. coli CynR with its specific effector azide
1TD5	;	2.3	;	Crystal Structure of the Ligand Binding Domain of E. coli IclR.
2XHS	;	2.8	;	Crystal structure of the ligand binding domain of Fushi tarazu factor 1 of Drosophila melanogaster.
3S2V	;	2.5	;	Crystal Structure of the Ligand Binding Domain of GluK1 in Complex with an Antagonist (S)-1-(2'-Amino-2'-carboxyethyl)-3-[(2-carboxythien-3-yl)methyl]thieno[3,4-d]pyrimidin-2,4-dione at 2.5 A Resolution
3C8X	;	1.95	;	Crystal structure of the ligand binding domain of human Ephrin A2 (Epha2) receptor protein kinase
2ATH	;	2.28	;	Crystal structure of the ligand binding domain of human PPAR-gamma im complex with an agonist
2F4B	;	2.07	;	Crystal structure of the ligand binding domain of human PPAR-gamma in complex with an agonist
1I7I	;	2.35	;	CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST AZ 242
3P0U	;	3.0	;	Crystal Structure of the ligand binding domain of human testicular receptor 4
1G0X	;	2.1	;	CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF LIR-1 (ILT2)
5VVI	;	2.28	;	Crystal Structure of the Ligand Binding Domain of LysR-type Transcriptional Regulator, OccR from Agrobacterium tumefaciens in the Complex with Octopine
2Q60	;	2.9	;	Crystal structure of the ligand binding domain of polyandrocarpa misakiensis rxr in tetramer in absence of ligand
4NB6	;	2.85	;	Crystal structure of the ligand binding domain of RORC with T0901317
2D4U	;	1.95	;	Crystal Structure of the ligand binding domain of the bacterial serine chemoreceptor Tsr
2P1U	;	2.2	;	Crystal structure of the ligand binding domain of the retinoid X receptor alpha in complex with 3-(2'-ethoxy)-tetrahydronaphtyl cinnamic acid and a fragment of the coactivator TIF-2
2P1T	;	1.8	;	Crystal structure of the ligand binding domain of the retinoid X receptor alpha in complex with 3-(2'-methoxy)-tetrahydronaphtyl cinnamic acid and a fragment of the coactivator TIF-2
2P1V	;	2.2	;	Crystal structure of the ligand binding domain of the retinoid X receptor alpha in complex with 3-(2'-propoxy)-tetrahydronaphtyl cinnamic acid and a fragment of the coactivator TIF-2
1G2N	;	1.65	;	CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF THE ULTRASPIRACLE PROTEIN USP, THE ORTHOLOG OF RXRS IN INSECTS
2HCD	;	2.6	;	Crystal structure of the ligand binding domain of the Vitamin D nuclear receptor in complex with Gemini and a coactivator peptide
4OZR	;	2.7	;	Crystal structure of the ligand binding domains of the Bovicola ovis ecdysone receptor EcR/USP heterodimer (methylene lactam crystal)
4OZT	;	2.7	;	crystal structure of the ligand binding domains of the Bovicola ovis ecdysone receptor EcR/USP heterodimer (PonA crystal)
3UVV	;	2.95	;	Crystal Structure of the ligand binding domains of the thyroid receptor:retinoid X receptor complexed with 3,3',5 triiodo-L-thyronine and 9-cis retinoic acid
4M00	;	2.05	;	Crystal structure of the ligand binding region of staphylococcal adhesion SraP
1XZZ	;	1.8	;	Crystal structure of the ligand binding suppressor domain of type 1 inositol 1,4,5-trisphosphate receptor
3JRR	;	1.9	;	Crystal structure of the ligand binding suppressor domain of type 3 inositol 1,4,5-trisphosphate receptor
1DRM	;	2.4	;	CRYSTAL STRUCTURE OF THE LIGAND FREE BJFIXL HEME DOMAIN
2WKY	;	2.2	;	Crystal structure of the ligand-binding core of GluR5 in complex with the agonist 4-AHCP
1VSO	;	1.85	;	Crystal Structure of the Ligand-Binding Core of iGluR5 in Complex With the Antagonist (S)-ATPO at 1.85 A resolution
2PBW	;	2.5	;	Crystal Structure of the Ligand-Binding Core of iGluR5 in Complex with the Partial agonist Domoic Acid at 2.5 A Resolution
2ZNT	;	1.6	;	Crystal structure of the ligand-binding core of the human ionotropic glutamate receptor, GluR5, in complex with a novel selective agonist, dysiherbaine
2ZNU	;	1.8	;	Crystal structure of the ligand-binding core of the human ionotropic glutamate receptor, GluR5, in complex with a novel selective agonist, neodysiherbaine A
2ZNS	;	2.0	;	Crystal structure of the ligand-binding core of the human ionotropic glutamate receptor, GluR5, in complex with glutamate
8BN2	;	1.63	;	Crystal structure of the ligand-binding domain (LBD) of human iGluR Delta-1 (GluD1) in complex with D-Serine
8BN5	;	1.9	;	Crystal structure of the ligand-binding domain (LBD) of human iGluR Delta-1 (GluD1) in complex with GABA
8BLJ	;	2.18	;	Crystal structure of the ligand-binding domain (LBD) of human iGluR Delta-1 (GluD1), apo state
3CNV	;	2.0	;	Crystal structure of the ligand-binding domain of a putative GntR-family transcriptional regulator from Bordetella bronchiseptica
7VPR	;	2.59	;	Crystal structure of the ligand-binding domain of C. glabrata Upc2 in complex with ergosterol
7VPU	;	2.59	;	Crystal structure of the ligand-binding domain of L. thermotolerans Upc2 in complex with ergosterol
2YZ1	;	1.4	;	Crystal structure of the ligand-binding domain of murine SHPS-1/SIRP alpha
1NUK	;	2.9	;	CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE EPHB2 RECEPTOR TYROSINE KINASE
1S9Q	;	2.2	;	crystal structure of the ligand-binding domain of the estrogen-related receptor gamma in complex with 4-hydroxytamoxifen
1VJB	;	3.2	;	crystal structure of the ligand-binding domain of the estrogen-related receptor gamma in complex with 4-hydroxytamoxifen
1TFC	;	2.4	;	CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH A STEROID RECEPTOR COACTIVATOR-1 PEPTIDE
1S9P	;	2.13	;	crystal structure of the ligand-binding domain of the estrogen-related receptor gamma in complex with diethylstilbestrol
1R1K	;	2.9	;	Crystal structure of the ligand-binding domains of the heterodimer EcR/USP bound to ponasterone A
1R20	;	3.0	;	Crystal structure of the ligand-binding domains of the heterodimer EcR/USP bound to the synthetic agonist BYI06830
7BJU	;	2.85	;	Crystal structure of the ligand-binding domains of the heterodimer EcR/USP bound to the synthetic agonist BYI08346
7BJV	;	3.05	;	Crystal structure of the ligand-binding domains of the heterodimer EcR/USP bound to the synthetic agonist BYI09181
2NXX	;	2.75	;	Crystal Structure of the Ligand-Binding Domains of the T.castaneum (Coleoptera) Heterodimer EcrUSP Bound to Ponasterone A
2E4Z	;	3.3	;	Crystal structure of the ligand-binding region of the group III metabotropic glutamate receptor
3C59	;	2.3	;	Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain
3C5T	;	2.1	;	Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain
7LCY	;	3.35	;	Crystal structure of the ligand-free ARM domain from Drosophila SARM1
4ZSB	;	2.004	;	Crystal structure of the ligand-free effector-binding domain of DasR (DasR-EBD)
6GPD	;	1.75	;	Crystal structure of the ligand-free form of domain 1 from TmArgBP
2ECR	;	1.6	;	Crystal structure of the ligand-free form of the flavin reductase component (HpaC) of 4-hydroxyphenylacetate 3-monooxygenase
6RTH	;	3.4	;	Crystal structure of the ligand-free glycosyltransferase domain from the YGT toxin
4IS5	;	1.48	;	Crystal Structure of the ligand-free inactive Matriptase
1ZU0	;	2.2	;	Crystal Structure of the liganded Chitin Oligasaccharide Binding Protein
4GFR	;	2.2	;	Crystal Structure of the liganded Chitin Oligasaccharide Binding Protein
2H3H	;	1.7	;	Crystal structure of the liganded form of Thermotoga maritima glucose binding protein
1VS0	;	2.4	;	Crystal Structure of the Ligase Domain from M. tuberculosis LigD at 2.4A
6N67	;	1.9	;	Crystal structure of the ligase domain of fungal tRNA ligase Trl1
6DT1	;	2.75	;	Crystal structure of the ligase from bacteriophage T4 complexed with DNA intermediate
4RSU	;	2.3	;	Crystal structure of the light and hvem complex
6GRZ	;	2.1	;	Crystal structure of the light chain dimer mH6
6G8U	;	1.308	;	Crystal structure of the light chain of botulinum neurotoxin X (residues 2-427)
6G8V	;	1.45	;	Crystal structure of the light chain of botulinum neurotoxin X (residues 2-442)
4A4M	;	3.3	;	Crystal structure of the light-activated constitutively active N2C, M257Y,D282C rhodopsin mutant in complex with a peptide resembling the C-terminus of the Galpha-protein subunit (GaCT)
5B2N	;	1.581	;	Crystal structure of the light-driven chloride ion-pumping rhodopsin, ClP, from Nonlabens marinus
7ZNH	;	2.3	;	Crystal structure of the light-driven inward proton pump xenorhodopsin BcXeR in the activated state at pH 8.2 at room temperature, 250-750-mks-snapshot
7ZNI	;	2.2	;	Crystal structure of the light-driven inward proton pump xenorhodopsin BcXeR in the activated state at pH 8.2 at room temperature, 7.5-15-ms-snapshot
7ZNA	;	1.8	;	Crystal structure of the light-driven inward proton pump xenorhodopsin BcXeR in the ground state at pH 5.2 in the presence of sodium at 100K
7ZN8	;	2.2	;	Crystal structure of the light-driven inward proton pump xenorhodopsin BcXeR in the ground state at pH 7.0 in the presence of sodium at 100K
7ZNC	;	1.7	;	Crystal structure of the light-driven inward proton pump xenorhodopsin BcXeR in the ground state at pH 7.6 in the absence of sodium at 100K
7ZNG	;	2.3	;	Crystal structure of the light-driven inward proton pump xenorhodopsin BcXeR in the ground state at pH 8.2 at room temperature, 500-mks-long snapshots
7ZNE	;	2.1	;	Crystal structure of the light-driven inward proton pump xenorhodopsin BcXeR in the ground state at pH 8.2 at room temperature, 7.5-ms-long snapshots
7ZMY	;	1.7	;	Crystal structure of the light-driven inward proton pump xenorhodopsin BcXeR in the ground state at pH 8.2 in the presence of sodium at 100K
7ZN3	;	1.6	;	Crystal structure of the light-driven inward proton pump xenorhodopsin BcXeR in the L state at pH 8.2 in the presence of sodium at 100K
7ZNB	;	1.9	;	Crystal structure of the light-driven inward proton pump xenorhodopsin BcXeR in the M state at pH 5.2 in the presence of sodium at 100K
7ZN9	;	2.3	;	Crystal structure of the light-driven inward proton pump xenorhodopsin BcXeR in the M state at pH 7.0 in the presence of sodium at 100K
7ZND	;	1.985	;	Crystal structure of the light-driven inward proton pump xenorhodopsin BcXeR in the M state at pH 7.6 in the absence of sodium at 100K
7ZN0	;	1.7	;	Crystal structure of the light-driven inward proton pump xenorhodopsin BcXeR in the M state at pH 8.2 in the presence of sodium at 100K
6GYH	;	2.0	;	Crystal structure of the light-driven proton pump Coccomyxa subellipsoidea Rhodopsin CsR
8JH0	;	2.79	;	Crystal structure of the light-driven sodium pump IaNaR
5JRF	;	2.5	;	Crystal structure of the light-driven sodium pump KR2 bound with iodide ions
3X3B	;	2.3	;	Crystal structure of the light-driven sodium pump KR2 in acidic state
3X3C	;	2.3	;	Crystal structure of the light-driven sodium pump KR2 in neutral state
4XTL	;	1.45	;	Crystal structure of the light-driven sodium pump KR2 in the monomeric blue form, pH 4.3
6RF5	;	2.3	;	Crystal structure of the light-driven sodium pump KR2 in the monomeric form, pH 6.0
6RF6	;	1.8	;	Crystal structure of the light-driven sodium pump KR2 in the monomeric form, pH 8.0
6RF7	;	2.6	;	Crystal structure of the light-driven sodium pump KR2 in the monomeric form, pH 8.9
6RF0	;	3.0	;	Crystal structure of the light-driven sodium pump KR2 in the pentameric ""dry"" form
6RF1	;	2.8	;	Crystal structure of the light-driven sodium pump KR2 in the pentameric ""wet"" form
6YC2	;	2.5	;	Crystal structure of the light-driven sodium pump KR2 in the pentameric form at room temperature, pH 8.0
6REZ	;	2.6	;	Crystal structure of the light-driven sodium pump KR2 in the pentameric form, pH 5.0
6REX	;	2.7	;	Crystal structure of the light-driven sodium pump KR2 in the pentameric form, pH 6.0
6YC3	;	2.0	;	Crystal structure of the light-driven sodium pump KR2 in the pentameric form, pH 8.0
4XTN	;	2.2	;	Crystal structure of the light-driven sodium pump KR2 in the pentameric red form, pH 4.9
4XTO	;	2.8	;	Crystal structure of the light-driven sodium pump KR2 in the pentameric red form, pH 5.6
6EDQ	;	2.9	;	Crystal Structure of the Light-Gated Anion Channelrhodopsin GtACR1
6Q53	;	3.701	;	CRYSTAL STRUCTURE OF THE LIGHT-HARVESTING COMPLEX II (B800-850) FROM Ectothiorhodospira haloalkaliphila
1LGH	;	2.4	;	CRYSTAL STRUCTURE OF THE LIGHT-HARVESTING COMPLEX II (B800-850) FROM RHODOSPIRILLUM MOLISCHIANUM
3RH8	;	2.75	;	Crystal Structure of the Light-state Dimer of Fungal Blue-Light Photoreceptor Vivid
6DXS	;	1.65	;	Crystal structure of the LigJ hydratase E284Q mutant substrate complex with (3Z)-2-keto-4-carboxy-3-hexenedioate
6DWV	;	2.2	;	Crystal structure of the LigJ Hydratase in the Apo state
6DXQ	;	2.02	;	Crystal structure of the LigJ Hydratase product complex with 4-carboxy-4-hydroxy-2-oxoadipate
7OO5	;	1.85	;	Crystal structure of the lignin peroxidase (ApeLiP) from Agrocybe pediades
4UMG	;	1.68	;	Crystal structure of the Lin-41 filamin domain
3LD7	;	1.547	;	Crystal structure of the Lin0431 protein from Listeria innocua, Northeast Structural Genomics Consortium Target LkR112
3K7X	;	1.889	;	Crystal structure of the Lin0763 protein from Listeria innocua. Northeast Structural Genomics Consortium Target LkR23.
3B57	;	3.0	;	Crystal structure of the Lin1889 protein (Q92AN1) from Listeria innocua. Northeast Structural Consortium target LkR65
6IW6	;	2.402	;	Crystal structure of the Lin28-interacting module of human TUT4
2ID5	;	2.698	;	Crystal Structure of the Lingo-1 Ectodomain
3ODW	;	3.2	;	Crystal Structure of the Linker-DH/PH domains of p115-RhoGEF
4GW3	;	2.0	;	Crystal Structure of the Lipase from Proteus mirabilis
6NKC	;	1.631	;	Crystal Structure of the Lipase Lip_vut1 from Goat Rumen metagenome.
6NKD	;	2.8	;	Crystal Structure of the Lipase Lip_vut3 from Goat Rumen metagenome.
6NKF	;	2.232	;	Crystal Structure of the Lipase Lip_vut4 from Goat Rumen metagenome.
6NKG	;	2.15	;	Crystal Structure of the Lipase Lip_vut5 from Goat Rumen metagenome.
8OIM	;	1.994	;	Crystal structure of the lipase SpL from Sphingomonas sp. HXN-200
1YZF	;	1.9	;	Crystal structure of the lipase/acylhydrolase from Enterococcus faecalis
4WIS	;	3.3	;	Crystal structure of the lipid scramblase nhTMEM16 in crystal form 1
3CQR	;	2.0	;	Crystal Structure of the Lipocalin domain of Violaxanthin de-epoxidase (VDE) at pH5
3CQN	;	2.0	;	Crystal Structure of the Lipocalin domain of Violaxanthin de-epoxidase (VDE) at pH7
4RHB	;	3.355	;	Crystal structure of the lipopolysaccharide assembly complex LptD-LptE from the Escherichia coli outer membrane
3GLV	;	1.99	;	Crystal structure of the lipopolysaccharide core biosynthesis protein from Thermoplasma volcanium GSS1
3PRW	;	1.8	;	Crystal structure of the lipoprotein BamB
5FQ3	;	3.1	;	Crystal structure of the lipoprotein BT2262 from Bacteroides thetaiotaomicron
5FQ4	;	1.9	;	Crystal structure of the lipoprotein BT2263 from Bacteroides thetaiotaomicron
3UAU	;	2.7	;	Crystal structure of the lipoprotein JlpA
1IWL	;	1.65	;	Crystal Structure of the Lipoprotein Localization Factor, LolA
1UA8	;	1.9	;	Crystal structure of the lipoprotein localization factor, LolA
3KSN	;	1.65	;	Crystal structure of the lipoprotein localization factor, LolA
3JVC	;	2.69	;	Crystal Structure of the Lipoprotein_17 domain from Q9PRA0_UREPA protein of Ureaplasma parvum. Northeast Structural Genomics Consortium Target UuR17a.
4UOP	;	1.75	;	Crystal structure of the lipoteichoic acid synthase LtaP from Listeria monocytogenes
3TAC	;	2.2	;	Crystal Structure of the Liprin-alpha/CASK complex
3TAD	;	2.9	;	Crystal Structure of the Liprin-alpha/Liprin-beta complex
6KR4	;	2.85	;	Crystal structure of the liprin-alpha3_SAM123/LAR_D1D2 complex
7TEN	;	3.5	;	Crystal structure of the Listeria monocytogenes GS-Met-Sox-P- ADP complex to 3.5 Angstrom
6O7C	;	1.85	;	Crystal structure of the LjCASTOR gating ring in the Ca2+ and K+ state
6O6J	;	1.6	;	Crystal structure of the LjCASTOR gating ring in the Ca2+ and Na+ condition
6O7A	;	3.3	;	Crystal structure of the LjCASTOR gating ring in the Ca2+-free state
6WW1	;	2.05	;	Crystal structure of the LmFPPS mutant E97Y
3EW7	;	2.73	;	Crystal structure of the Lmo0794 protein from Listeria monocytogenes. Northeast Structural Genomics Consortium target LmR162.
2XJZ	;	2.8	;	Crystal structure of the LMO2:LDB1-LID complex, C2 crystal form
2XJY	;	2.4	;	Crystal structure of the LMO2:LDB1-LID complex, P21 crystal form
7R8W	;	1.9	;	Crystal Structure of the LNK SH2 Domain in Complex with a JAK2 pY813 Phosphopeptide
7R8X	;	2.3	;	Crystal Structure of the LNK SH2 Domain in Complex with an EPOR pY454 Phosphopeptide
4Z5P	;	1.9	;	Crystal structure of the LnmA cytochrome P450 hydroxylase from the leinamycin biosynthetic pathway of Streptomyces atroolivaceus S-140 at 1.9 A resolution
4Z5Q	;	1.801	;	Crystal structure of the LnmZ cytochrome P450 hydroxylase from the leinamycin biosynthetic pathway of Streptomyces atroolivaceus S-140 at 1.8 A resolution
2REE	;	1.95	;	Crystal structure of the loading GNATL domain of CurA from Lyngbya majuscula
2REF	;	2.75	;	Crystal structure of the loading GNATL domain of CurA from Lyngbya majuscula soaked with malonyl-CoA
4FW9	;	2.0	;	Crystal structure of the Lon-like protease MtaLonC
4FWD	;	2.03	;	Crystal structure of the Lon-like protease MtaLonC in complex with bortezomib
4FWG	;	1.99	;	Crystal structure of the Lon-like protease MtaLonC in complex with lactacystin
4FWH	;	2.19	;	Crystal structure of the Lon-like protease MtaLonC in complex with MG262
7EV6	;	2.1	;	Crystal structure of the Lon-like protease MtaLonC with D581A mutation in complex with F-b20-Q
7EUX	;	2.25	;	Crystal structure of the Lon-like protease MtaLonC with D581A mutation in complex with substrate polypeptide
7EUY	;	2.2	;	Crystal structure of the Lon-like protease MtaLonC with D582A mutation in complex with substrate polypeptide
7EV4	;	2.12	;	Crystal structure of the Lon-like protease MtaLonC with S582A mutation in complex with F-b20-Q
1T1L	;	2.8	;	Crystal structure of the long-chain fatty acid transporter FadL
3DWN	;	2.5	;	Crystal structure of the long-chain fatty acid transporter FadL mutant A77E/S100R
2R89	;	3.4	;	Crystal structure of the long-chain fatty acid transporter FadL mutant delta N3
2R8A	;	3.0	;	Crystal structure of the long-chain fatty acid transporter FadL mutant delta N8
2R4O	;	3.6	;	Crystal structure of the long-chain fatty acid transporter FadL mutant delta NPA
2R88	;	2.6	;	Crystal structure of the long-chain fatty acid transporter FadL mutant delta S3 kink
2R4P	;	2.9	;	Crystal structure of the long-chain fatty acid transporter FadL mutant G212E
2R4N	;	3.2	;	Crystal structure of the long-chain fatty acid transporter FadL mutant N33A
2R4L	;	3.3	;	Crystal structure of the long-chain fatty acid transporter FadL mutant P34A
3BW6	;	2.5	;	Crystal structure of the longin domain of yeast Ykt6
3WI5	;	2.4	;	Crystal structure of the Loop 7 mutant PorB from Neisseria meningitidis serogroup B
4EIL	;	2.1971	;	Crystal Structure of the loop truncated Toxoplasma gondii TS-DHFR
5A49	;	2.098	;	Crystal structure of the LOTUS domain (aa 139-222) of Drosophila Oskar in C222
5A48	;	2.35	;	Crystal structure of the LOTUS domain (aa 139-240) of Drosophila Oskar in P65
8IL9	;	2.16	;	Crystal structure of the LOV1 Q122N mutant of Klebsormidium nitens phototropin
7URU	;	2.4	;	Crystal structure of the low affinity Fc gamma receptor IIIA variant in complex with the Fc of IgG1.
4D6W	;	3.6	;	Crystal Structure of the low pH conformation of Chandipura Virus glycoprotein G ectodomain
3WYQ	;	1.0	;	Crystal structure of the low-immunogenic core streptavidin mutant LISA-314 (Y22S/Y83S/R84K/E101D/R103K/E116N) at 1.0 A resolution
4P29	;	1.95006	;	Crystal structure of the LpoA N-terminal domain from Haemophilus influenzae
3D0K	;	1.83	;	Crystal structure of the LpqC, poly(3-hydroxybutyrate) depolymerase from Bordetella parapertussis
4FW5	;	1.99	;	Crystal Structure of the LpxC in complex with 4'-BROMO-N-[(2S,3R)-3-HYDROXY-1-(HYDROXYAMINO)-1-OXOBUTAN-2-YL]BIPHENYL-4-CARBOXAMIDE inhibitor
4FW4	;	2.19	;	Crystal Structure of the LpxC in complex with N-[(1S,2R)-2-HYDROXY-1-(HYDROXYCARBAMOYL)PROPYL]-4-(4-PHENYLBUTA-1,3-DIYN-1-YL)BENZAMIDE inhibitor
4FW3	;	2.35	;	Crystal Structure of the LpxC in complex with N-[(2S)-3-AMINO-1-(HYDROXYAMINO)-1-OXOPROPAN-2-YL]-4-(4-PHENYLBUTA-1,3-DIYN-1-YL)BENZAMIDE inhibitor
4FW6	;	1.83	;	Crystal Structure of the LpxC in complex with N-[(2S,3R)-3-HYDROXY-1-(HYDROXYAMINO)-1-OXOBUTAN-2-YL]-4-(PHENYLETHYNYL)BENZAMIDE inhibitor
4FW7	;	1.7	;	Crystal Structure of the LpxC in complex with N-[(2S,3R)-3-HYDROXY-1-(HYDROXYAMINO)-1-OXOBUTAN-2-YL]BIPHENYL-4-CARBOXAMIDE inhibitor
3CQ9	;	2.2	;	Crystal structure of the lp_1622 protein from Lactobacillus plantarum. Northeast Structural Genomics Consortium target LpR114
3HFQ	;	1.963	;	Crystal structure of the lp_2219 protein from Lactobacillus plantarum. Northeast Structural Genomics Consortium Target LpR118.
1I1G	;	2.9	;	CRYSTAL STRUCTURE OF THE LRP-LIKE TRANSCRIPTIONAL REGULATOR FROM THE ARCHAEON PYROCOCCUS FURIOSUS
2E7W	;	1.82	;	Crystal structure of the Lrp/AsnC like transcriptional regulators from Sulfolobus tokodaii 7
6S6Q	;	2.95	;	Crystal structure of the LRR ectodomain of the plant membrane receptor kinase GASSHO1/SCHENGEN3 from Arabidopsis thaliana in complex with CASPARIAN STRIP INTEGRITY FACTOR 2.
6R1H	;	1.55	;	Crystal structure of the LRR ectodomain of the receptor kinase SOBIR1 from Arabidopsis thaliana.
6HLU	;	3.29	;	Crystal structure of the LRR-Roc-COR domain of the Chlorobium tepidum Roco protein
5TVN	;	2.9	;	Crystal structure of the LSD-bound 5-HT2B receptor
6VYP	;	4.99	;	Crystal structure of the LSD1/CoREST histone demethylase bound to its nucleosome substrate
4RZM	;	2.33	;	Crystal structure of the Lsd19-lasalocid A complex
2VC8	;	1.31	;	Crystal structure of the LSm domain of human EDC3 (enhancer of decapping 3)
6F9W	;	2.623	;	Crystal structure of the LSM domain of LSM14 in complex with a C-terminal peptide of 4E-T
3I9G	;	1.9	;	Crystal structure of the LT1009 (SONEPCIZUMAB) antibody Fab fragment in complex with sphingosine-1-phosphate
3QCU	;	1.979	;	Crystal structure of the LT3015 antibody Fab fragment in complex with lysophosphatidic acid (14:0)
3QCV	;	2.51	;	Crystal structure of the LT3015 antibody Fab fragment in complex with lysophosphatidic acid (18:2)
5HA0	;	1.441	;	Crystal structure of the LTBP1 leukotriene d4 complex
5DV9	;	2.4	;	Crystal structure of the Luciferase
5DWV	;	2.3	;	Crystal structure of the Luciferase complexed with substrate analogue
2B81	;	2.5	;	Crystal Structure of the Luciferase-like Monooxygenase from Bacillus cereus
3RAO	;	2.3	;	Crystal Structure of the Luciferase-like Monooxygenase from Bacillus cereus ATCC 10987.
1JHN	;	2.9	;	Crystal Structure of the Lumenal Domain of Calnexin
4WW3	;	2.8	;	Crystal structure of the lumi intermediate of squid rhodopsin
1UHL	;	2.9	;	Crystal structure of the LXRalfa-RXRbeta LBD heterodimer
1QPJ	;	2.2	;	CRYSTAL STRUCTURE OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH STAUROSPORINE.
3MKO	;	1.8	;	Crystal Structure of the Lymphocytic Choriomeningitis Virus Membrane Fusion Glycoprotein GP2 in its Postfusion Conformation
1YE4	;	2.4	;	Crystal structure of the Lys-274 to Arg mutant of Candida tenuis xylose reductase (AKR2B5) bound to NAD+
1YE6	;	2.3	;	Crystal structure of the Lys-274 to Arg mutant of Candida tenuis xylose reductase (AKR2B5) bound to NADP+
3M13	;	2.1	;	Crystal Structure of the Lys265Arg PEG-crystallized mutant of monomeric sarcosine oxidase
3M12	;	1.6	;	Crystal Structure of the Lys265Arg phosphate-crytsallized mutant of monomeric sarcosine oxidase
3M0O	;	1.6	;	Crystal Structure of the Lys265Met mutant of monomeric sarcosine oxidase
3ZRH	;	2.23	;	Crystal structure of the Lys29, Lys33-linkage-specific TRABID OTU deubiquitinase domain reveals an Ankyrin-repeat ubiquitin binding domain (AnkUBD)
2H1V	;	1.2	;	Crystal structure of the Lys87Ala mutant variant of Bacillus subtilis ferrochelatase
4ERJ	;	3.0	;	Crystal structure of the lysine riboswitch bound to a 6-aminocaproic acid
4ERL	;	3.0	;	Crystal structure of the lysine riboswitch bound to a lysine-glycine dipeptide
3FBX	;	2.4	;	Crystal structure of the lysosomal 66.3 kDa protein from mouse solved by S-SAD
6SWR	;	3.2	;	Crystal structure of the lysosomal potassium channel MtTMEM175 T38A mutant soaked with zinc
6SYD	;	1.1	;	Crystal structure of the lysozyme in presence of bromophenol blue at pH 5.5
6SYC	;	1.38	;	Crystal structure of the lysozyme in presence of bromophenol blue at pH 6.5
3FXQ	;	1.85	;	Crystal structure of the LysR-type transcriptional regulator TsaR
1IW9	;	2.5	;	Crystal Structure of the M Intermediate of Bacteriorhodopsin
7Z0E	;	1.22	;	Crystal structure of the M state of bacteriorhodopsin at 1.22 Angstrom resolution
7N11	;	2.1	;	Crystal structure of the M. abscessus LeuRS editing domain in complex with epetraborole-AMP adduct
7N12	;	1.7	;	Crystal structure of the M. abscessus LeuRS editing domain in complex with epetraborole-AMP adduct
4PBS	;	2.011	;	Crystal structure of the M. jannaschii F9 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF)
4PBR	;	1.9	;	Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF)
4PBT	;	1.9	;	Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-trans-cyclooctene-amidopheylalanine (Tco-amF)
3RB9	;	3.0	;	Crystal structure of the M. tuberculosis beta clamp
4ZDI	;	3.52	;	Crystal structure of the M. tuberculosis CTP synthase PyrG (apo form)
4ZDJ	;	1.99	;	Crystal structure of the M. tuberculosis CTP synthase PyrG in complex with two UTP molecules
4ZDK	;	3.49	;	Crystal structure of the M. tuberculosis CTP synthase PyrG in complex with UTP, AMP-PCP and oxonorleucine
2JJG	;	2.4	;	Crystal structure of the M. tuberculosis Lysine-epsilon aminotransferase (Rv3290c) complexed to an inhibitor
4BHC	;	2.8	;	CRYSTAL STRUCTURE OF THE M. TUBERCULOSIS O6-METHYLGUANINE METHYLTRANSFERASE R37L VARIANT
7DM2	;	2.4	;	crystal structure of the M. tuberculosis phosphate ABC transport receptor PstS-1 in complex with Fab p4-170
4LVQ	;	2.3	;	Crystal structure of the M. tuberculosis phosphate binding protein PstS3
4CVY	;	2.0	;	Crystal structure of the M. tuberculosis sulfate ester dioxygenase Rv3406 in complex with iron.
6FKG	;	1.8	;	Crystal structure of the M.tuberculosis MbcT-MbcA toxin-antitoxin complex.
7DM1	;	2.1	;	crystal structure of the M.tuberculosis phosphate ABC transport receptor PstS-1 in complex with Fab p4-36
2Y9R	;	1.9	;	Crystal structure of the M10 domain of Titin
3M3R	;	2.2	;	Crystal structure of the M113F alpha-hemolysin mutant complexed with beta-cyclodextrin
3M2L	;	2.1	;	Crystal structure of the M113F mutant of alpha-hemolysin
3M4D	;	1.9	;	Crystal structure of the M113N mutant of alpha-hemolysin
3M4E	;	2.3	;	Crystal structure of the M113N mutant of alpha-hemolysin bound to beta-cyclodextrin
1WA4	;	2.1	;	Crystal structure of the M131F L135A EvaD double mutant
3B35	;	1.1	;	Crystal structure of the M180A mutant of the aminopeptidase from Vibrio proteolyticus
3B3S	;	1.18	;	Crystal structure of the M180A mutant of the aminopeptidase from Vibrio proteolyticus in complex with leucine
3B3C	;	1.46	;	Crystal structure of the M180A mutant of the aminopeptidase from Vibrio proteolyticus in complex with leucine phosphonic acid
6YZD	;	1.41	;	Crystal structure of the M295A variant of Ssl1
6YO5	;	1.5	;	Crystal structure of the M295F variant of Ssl1
6Y4A	;	1.785	;	Crystal structure of the M295I variant of Ssl1
6YZY	;	2.282	;	Crystal structure of the M295V variant of Ssl1
6YZF	;	1.684	;	Crystal structure of the M295Y variant of Ssl1
5CF1	;	2.242	;	Crystal Structure of the M32V/M78V/I80V/L114F mutant of LEH
1XK5	;	2.4	;	Crystal structure of the m3G-cap-binding domain of snurportin1 in complex with a m3GpppG-cap dinucleotide
4P6Y	;	2.2	;	Crystal structure of the M42 aminopeptidase TmPep1050 from Thermotoga maritima
1PF3	;	1.5	;	Crystal Structure of the M441L mutant of the multicopper oxidase CueO
1T7O	;	2.3	;	Crystal structure of the M564G mutant of murine carnitine acetyltransferase in complex with carnitine
1T7N	;	1.9	;	Crystal structure of the M564G mutant of murine CrAT
2H0T	;	1.6	;	Crystal structure of the M69V E166A double mutant of SHV-1 b-lactamase complexed to clavulanic acid
2H0Y	;	1.7	;	Crystal structure of the M69V E166A double mutant of SHV-1 b-lactamase complexed to sulbactam
2H10	;	1.75	;	Crystal structure of the M69V E166A double mutant of SHV-1 b-lactamase complexed to tazobactam
6SF6	;	1.9	;	Crystal structure of the mAb 15A in complex with COMP-epitope P6
3TOW	;	1.34	;	Crystal Structure of the MABP Domain of MVB12B of Human ESCRT-I Complex
2XUQ	;	2.7	;	CRYSTAL STRUCTURE OF the MACHE-Y337A mutant in complex with soaked TZ2PA6 ANTI-SYN inhibitors
2XUP	;	2.7	;	CRYSTAL STRUCTURE OF the MACHE-Y337A mutant in complex with soaked TZ2PA6 SYN inhibitor
5HIH	;	1.66	;	Crystal structure of the macro domain in Middle-East Respiratory Syndrome Coronavirus
2XD7	;	2.09	;	Crystal structure of the macro domain of human core histone H2A
3IID	;	1.9	;	Crystal structure of the macro domain of human histone macroH2A1.1 in complex with ADP-ribose (form A)
3IIF	;	2.1	;	Crystal structure of the macro domain of human histone macroH2A1.1 in complex with ADP-ribose (form B)
6FY5	;	1.65	;	Crystal structure of the macro domain of human macroh2a2
2FXK	;	2.54	;	Crystal structure of the macro-domain of human core histone variant macroH2A1.1 (form A)
1ZR3	;	1.66	;	Crystal structure of the macro-domain of human core histone variant macroH2A1.1 (form B)
1ZR5	;	2.92	;	Crystal structure of the macro-domain of human core histone variant macroH2A1.2
7V0E	;	3.27016	;	Crystal structure of the macro-oligomeric form of DNMT3B methyltransferase domain.
1KEZ	;	2.8	;	Crystal Structure of the Macrocycle-forming Thioesterase Domain of Erythromycin Polyketide Synthase (DEBS TE)
1FD9	;	2.41	;	CRYSTAL STRUCTURE OF THE MACROPHAGE INFECTIVITY POTENTIATOR PROTEIN (MIP) A MAJOR VIRULENCE FACTOR FROM LEGIONELLA PNEUMOPHILA
3GMH	;	3.95	;	Crystal Structure of the Mad2 Dimer
2QYF	;	2.3	;	Crystal structure of the Mad2/p31(comet)/Mad2-binding peptide ternary complex
4YBG	;	1.602	;	Crystal structure of the MAEL domain of Drosophila melanogaster Maelstrom
4EOT	;	2.855	;	Crystal structure of the MafA homodimer bound to the consensus MARE
8HHJ	;	1.5	;	Crystal structure of the MafB2-CTMGI-2B16B6/MafI2MGI-2B16B6 complex
4V0P	;	2.07	;	Crystal structure of the MAGE homology domain of human MAGE-A3
4IF4	;	2.35	;	Crystal Structure of the Magnesium and beryllofluoride-activated VraR from Staphylococcus aureus
4Z29	;	2.03	;	Crystal structure of the magnetobacterial protein MtxA C-terminal domain
3Q3X	;	1.9	;	Crystal structure of the main protease (3C) from human enterovirus B EV93
7ALH	;	1.65	;	Crystal structure of the main protease (3CLpro/Mpro) of SARS-CoV-2 at 1.65A resolution (spacegroup C2).
7ALI	;	1.65	;	Crystal structure of the main protease (3CLpro/Mpro) of SARS-CoV-2 at 1.65A resolution (spacegroup P2(1)).
7BB2	;	1.6	;	Crystal structure of the main protease (3CLpro/Mpro) of SARS-CoV-2 at 1.6A resolution (spacegroup P2(1)2(1)2(1))
2YNA	;	1.5	;	Crystal structure of the main protease of coronavirus HKU4
2YNB	;	1.96	;	Crystal structure of the main protease of coronavirus HKU4 in complex with a Michael acceptor SG85
2D3A	;	2.63	;	Crystal Structure of the Maize Glutamine Synthetase complexed with ADP and Methionine sulfoximine Phosphate
2D3C	;	3.81	;	Crystal Structure of the Maize Glutamine Synthetase complexed with ADP and Phosphinothricin Phosphate
2D3B	;	3.5	;	Crystal Structure of the Maize Glutamine Synthetase complexed with AMPPNP and Methionine sulfoximine
1HXJ	;	2.05	;	CRYSTAL STRUCTURE OF THE MAIZE ZM-P60.1 BETA-GLUCOSIDASE
6GNY	;	1.85	;	Crystal structure of the MAJIN-TERB2 heterotetrameric complex
6GNX	;	2.9	;	Crystal structure of the MAJIN-TERB2 heterotetrameric complex - selenomethionine derivative
2VZN	;	3.05	;	Crystal structure of the major allergen from fire ant venom, Sol i 3
4B9R	;	1.76	;	Crystal structure of the Major Birch Pollen Allergen Bet v 1.0101 (isoform a) nitrated in vitro with tetranitromethan.
2VVF	;	2.5	;	Crystal structure of the major capsid protein P2 from Bacteriophage PM2
2WQL	;	2.7	;	CRYSTAL STRUCTURE OF THE MAJOR CARROT ALLERGEN DAU C 1
1ZKR	;	1.64	;	Crystal structure of the major cat allergen Fel d 1 (1+2)
2BK0	;	2.9	;	Crystal structure of the major celery allergen Api G 1
2VXQ	;	1.9	;	Crystal structure of the major grass pollen allergen Phl p 2 in complex with its specific IgE-Fab
8A0D	;	3.685	;	Crystal structure of the major guinea pig allergen Cav p 1.0101 part of the lipocalin family
2MHA	;	2.5	;	CRYSTAL STRUCTURE OF THE MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I H-2KB MOLECULE CONTAINING A SINGLE VIRAL PEPTIDE: IMPLICATIONS FOR PEPTIDE BINDING AND T-CELL RECEPTOR RECOGNITION
1EW3	;	2.3	;	CRYSTAL STRUCTURE OF THE MAJOR HORSE ALLERGEN EQU C 1
1XKG	;	1.61	;	Crystal structure of the major house dust mite allergen Der p 1 in its pro form at 1.61 A resolution
2P9W	;	1.35	;	Crystal Structure of the Major Malassezia sympodialis Allergen Mala s 1
3B2M	;	2.22	;	Crystal Structure of the Major Pilin from Streptococcus pyogenes
3GLD	;	2.03	;	Crystal Structure of the Major Pilin from Streptococcus pyogenes E117A mutant
3GLE	;	2.19	;	Crystal Structure of the Major Pilin from Streptococcus pyogenes N168A mutant
4Z8W	;	1.98	;	Crystal Structure of the Major Plantain Pollen Allergen Pla l 1
4MNS	;	1.2	;	Crystal structure of the major pollen allergen Bet v 1-A in complex with P303
3G20	;	1.78	;	Crystal structure of the major pseudopilin from the type 2 secretion system of enterohaemorrhagic Escherichia coli
3FU1	;	1.9	;	Crystal structure of the major pseudopilin from the type 2 secretion system of Vibrio cholerae
3GN9	;	1.86	;	Crystal structure of the major pseudopilin from the type 2 secretion system of Vibrio vulnificus
6AU4	;	2.35	;	Crystal structure of the major quadruplex formed in the human c-MYC promoter
8HQU	;	2.0	;	Crystal structure of the major sperm protein domain of SCS2 from saccharomyces cerevisiae
6II0	;	2.36	;	Crystal structure of the Makes Caterpillars Floppy (MCF)-Like effector of Vibrio vulnificus MO6-24/O
6II6	;	2.1	;	Crystal structure of the Makes Caterpillars Floppy (MCF)-Like effector of Vibrio vulnificus MO6-24/O in complex with a human ADP-ribosylation factor 3 (ARF3)
1F1T	;	2.8	;	CRYSTAL STRUCTURE OF THE MALACHITE GREEN APTAMER COMPLEXED WITH TETRAMETHYL-ROSAMINE
4L07	;	1.75	;	Crystal structure of the maleamate amidase Ami from Pseudomonas putida S16
4L08	;	2.66	;	Crystal structure of the maleamate amidase Ami(C149A) in complex with maleate from Pseudomonas putida S16
4FQ7	;	3.0	;	Crystal structure of the maleate isomerase Iso from Pseudomonas putida S16
4FQ5	;	2.1	;	Crystal structure of the maleate isomerase Iso(C200A) from Pseudomonas putida S16 with maleate
8AYV	;	1.044	;	Crystal structure of the Malonyl-ACP Decarboxylase MadB from Pseudomonas putida
3UO8	;	1.9	;	Crystal structure of the MALT1 paracaspase (P1 form)
3UOA	;	1.75	;	Crystal structure of the MALT1 paracaspase (P21 form)
1L5V	;	2.0	;	Crystal Structure of the Maltodextrin Phosphorylase complexed with Glucose-1-phosphate
1L6I	;	2.2	;	Crystal Structure of the Maltodextrin Phosphorylase complexed with the products of the enzymatic reaction between glucose-1-phosphate and maltopentaose
1L5W	;	1.8	;	Crystal Structure of the Maltodextrin Phosphorylase Complexed with the Products of the Enzymatic Reaction between Glucose-1-phosphate and Maltotetraose
4KI0	;	2.38	;	Crystal structure of the maltose-binding protein/maltose transporter complex in an outward-facing conformation bound to maltohexaose
3RLF	;	2.2	;	Crystal structure of the maltose-binding protein/maltose transporter complex in an outward-facing conformation bound to MgAMPPNP
4KHZ	;	2.9	;	Crystal structure of the maltose-binding protein/maltose transporter complex in an pre-translocation conformation bound to maltoheptaose
2C9A	;	2.7	;	Crystal structure of the MAM-Ig module of receptor protein tyrosine phosphatase mu
1R5I	;	2.6	;	Crystal structure of the MAM-MHC complex
1IRU	;	2.75	;	Crystal Structure of the mammalian 20S proteasome at 2.75 A resolution
2AR5	;	1.8	;	Crystal structure of the mammalian C2alpha-PI3 Kinase PX-domain
3EG9	;	3.0	;	Crystal structure of the mammalian COPII-coat protein Sec23/24 bound to the transport signal sequence of membrin
3EFO	;	2.7	;	Crystal Structure of the mammalian COPII-coat protein Sec23/24 bound to the transport signal sequence of syntaxin 5
3EGD	;	2.7	;	Crystal structure of the mammalian COPII-coat protein Sec23a/24a complexed with the SNARE protein Sec22 and bound to the transport signal sequence of vesicular stomatitis virus glycoprotein
3EGX	;	3.3	;	Crystal structure of the mammalian COPII-coat protein Sec23a/24a complexed with the SNARE protein Sec22b and bound to the transport signal sequence of the SNARE protein Bet1
2XSM	;	5.5	;	Crystal structure of the mammalian cytosolic chaperonin CCT in complex with tubulin
3VA1	;	1.74	;	Crystal structure of the mammalian MDC1 FHA domain
3VA4	;	1.54	;	Crystal structure of the mammalian MDC1 FHA domain complexed with CHK2 pThr68 peptide
1NQ3	;	2.2	;	Crystal structure of the mammalian tumor associated antigen UK114
3HRS	;	2.7	;	Crystal Structure of the Manganese-activated Repressor ScaR: apo form
6C63	;	2.90003	;	Crystal Structure of the Mango-II Fluorescent Aptamer Bound to TO1-Biotin
6C64	;	3.00015	;	Crystal Structure of the Mango-II Fluorescent Aptamer Bound to TO3-Biotin
6C65	;	2.80005	;	Crystal Structure of the Mango-II-A22U Fluorescent Aptamer Bound to TO1-Biotin
3X3H	;	2.88	;	Crystal Structure of the Manihot esculenta Hydroxynitrile Lyase (MeHNL) 3KP (K176P, K199P, K224P) triple mutant
3RKS	;	2.5	;	Crystal Structure of the Manihot esculenta Hydroxynitrile Lyase (MeHNL) K176P mutant
3EXZ	;	2.3	;	Crystal structure of the MaoC-like dehydratase from Rhodospirillum rubrum. Northeast Structural Genomics Consortium target RrR103a.
2OUC	;	2.2	;	Crystal structure of the MAP kinase binding domain of MKP5
3TG3	;	2.675	;	Crystal structure of the MAPK binding domain of MKP7
4G2K	;	1.9	;	Crystal structure of the Marburg Virus GP2 ectodomain in its post-fusion conformation
5XSQ	;	2.6	;	Crystal Structure of the Marburg Virus Nucleoprotein Core Domain Chaperoned by a VP35 Peptide
5TOH	;	2.01	;	Crystal Structure of the Marburg Virus VP35 Oligomerization Domain I2
5TOI	;	2.19	;	Crystal Structure of the Marburg Virus VP35 Oligomerization Domain P4222
4AM1	;	1.25	;	Crystal structure of the marine crustacean decapod shrimp (Litopenaeus vannamei) arginine kinase in the absence of substrate or ligands.
5GMT	;	1.77	;	Crystal structure of the marine PL-14 alginate lyase from Aplysia kurodai
3ZPY	;	1.43	;	Crystal structure of the marine PL7 alginate lyase AlyA1 from Zobellia galactanivorans
3HOS	;	3.5	;	Crystal structure of the mariner Mos1 paired end complex with Mg
7L1I	;	2.35	;	Crystal structure of the MarR family transcriptional regulator from Acineotobacter baumannii bound to Indole 3 acetic acid
7KYM	;	1.5	;	Crystal structure of the MarR family transcriptional regulator from Bradyrhizobium japonicum
7L19	;	2.77	;	Crystal structure of the MarR family transcriptional regulator from Enterobacter soli strain LF7 bound to Indole 3 acetic acid
7KUA	;	1.89	;	Crystal structure of the MarR family transcriptional regulator from Pseudomonas putida bound to Indole 3 acetic acid
7KFQ	;	1.35	;	Crystal structure of the MarR family transcriptional regulator from Variovorax paradoxus bound to 1H-Indole-3-Carboxylic Acid
7KKI	;	1.6	;	Crystal structure of the MarR family transcriptional regulator from Variovorax paradoxus bound to 2,4-Dichlorophenoxyacetic acid
7KKC	;	1.5	;	Crystal structure of the MarR family transcriptional regulator from Variovorax paradoxus bound to 5-Hydroxyindoleacetic acid
7KFS	;	1.5	;	Crystal structure of the MarR family transcriptional regulator from Variovorax paradoxus bound to Benzoic Acid
7KK0	;	1.5	;	Crystal structure of the MarR family transcriptional regulator from Variovorax paradoxus bound to Catechol
7KFO	;	1.3	;	Crystal structure of the MarR family transcriptional regulator from Variovorax paradoxus bound to Indole 3 acetic acid
7KH3	;	1.5	;	Crystal structure of the MarR family transcriptional regulator from Variovorax paradoxus bound to Indole 3 propionic acid
7KIG	;	1.4	;	Crystal structure of the MarR family transcriptional regulator from Variovorax paradoxus bound to Indole-3-butyric acid
7KJQ	;	1.35	;	Crystal structure of the MarR family transcriptional regulator from Variovorax paradoxus bound to Picloram
7KJL	;	1.6	;	Crystal structure of the MarR family transcriptional regulator from Variovorax paradoxus bound to Salicylic acid
7KRH	;	1.5	;	Crystal structure of the MarR family transcriptional regulator from Variovorax paradoxus with S28A and R46A mutations
3CDH	;	2.69	;	Crystal structure of the MarR family transcriptional regulator SPO1453 from Silicibacter pomeroyi DSS-3
3POE	;	1.501	;	Crystal structure of the MASP-1 CUB2 domain bound to Ca2+
3POG	;	2.749	;	Crystal structure of the MASP-1 CUB2 domain bound to Ca2+
3ZKC	;	3.0	;	Crystal structure of the master regulator for biofilm formation SinR in complex with DNA.
3KZ9	;	2.1	;	Crystal structure of the master transcriptional regulator, SmcR, in Vibrio vulnificus provides insight into its DNA recognition mechanism
6H8O	;	1.15	;	Crystal structure of the Master-Rep protein nuclease domain from the Faba Bean Necrotic Yellows Virus
1YRN	;	2.5	;	CRYSTAL STRUCTURE OF THE MATA1/MATALPHA2 HOMEODOMAIN HETERODIMER BOUND TO DNA
1LE8	;	2.3	;	Crystal Structure of the MATa1/MATalpha2-3A Heterodimer Bound to DNA Complex
4Z3N	;	2.7	;	Crystal structure of the MATE transporter ClbM
3MD2	;	2.2	;	Crystal structure of the matrix protein 1 from influenza A virus (A/California/04/2009 (H1N1))
1ES6	;	2.0	;	CRYSTAL STRUCTURE OF THE MATRIX PROTEIN OF EBOLA VIRUS
3N41	;	3.01	;	Crystal structure of the mature envelope glycoprotein complex (spontaneous cleavage) of Chikungunya virus.
3N44	;	2.35	;	Crystal structure of the mature envelope glycoprotein complex (trypsin cleavage; Osmium soak) of Chikungunya virus.
4NOJ	;	2.8	;	Crystal structure of the mature form of asparaginyl endopeptidase (AEP)/Legumain activated at pH 3.5
4P9S	;	2.32	;	Crystal structure of the mature form of rat DMGDH
4PAA	;	2.26	;	Crystal structure of the mature form of rat DMGDH complexed with tetrahydrofolate
7ZVB	;	2.35	;	Crystal Structure of the mature form of the glutamic-class prolyl-endopeptidase neprosin at 2.35 A resolution.
2UZJ	;	1.55	;	Crystal structure of the mature streptococcal cysteine protease, mSpeB
3L4O	;	2.046	;	Crystal Structure of the MauG/pre-Methylamine Dehydrogenase Complex After Treatment with Hydrogen Peroxide
3L4M	;	2.02	;	Crystal Structure of the MauG/pre-Methylamine Dehydrogenase Complex.
4Z8M	;	2.95	;	Crystal structure of the MAVS-TRAF6 complex
4N4X	;	2.501	;	Crystal Structure of the MBP fused human SPLUNC1 (native form)
5LOF	;	2.2	;	Crystal structure of the MBP-MCL1 complex with highly selective and potent inhibitor of MCL1
1OI1	;	1.78	;	Crystal Structure of the MBT domains of Human SCML2
6EBY	;	1.85	;	Crystal structure of the MbtH-like protein FscK bound to the interface forming region of FscH adenylation domain from Thermobifida fusca
4Y2D	;	3.05	;	Crystal structure of the mCD1d/7DW8-5/iNKTCR ternary complex
4ZAK	;	2.824	;	Crystal structure of the mCD1d/DB06-1/iNKTCR ternary complex
4Y4K	;	2.9	;	Crystal structure of the mCD1d/EF77/iNKTCR ternary complex
4Y4F	;	3.19	;	Crystal structure of the mCD1d/GCK127/iNKTCR ternary complex
4Y4H	;	3.1	;	Crystal structure of the mCD1d/GCK152/iNKTCR ternary complex
4Y16	;	2.6	;	Crystal structure of the mCD1d/NC-aGC/iNKTCR ternary complex
6MIY	;	2.75	;	Crystal structure of the mCD1d/xxa (JJ239)/iNKTCR ternary complex
6MJJ	;	1.93	;	Crystal structure of the mCD1d/xxm (JJ290) /iNKTCR ternary complex
6MJA	;	2.35	;	Crystal structure of the mCD1d/xxo (JJ294) /iNKTCR ternary complex
6MJQ	;	3.0	;	Crystal structure of the mCD1d/xxp (JJ295) /iNKTCR ternary complex
6MIV	;	2.05	;	Crystal structure of the mCD1d/xxq (JJ300)/iNKTCR ternary complex
6MJI	;	2.3	;	Crystal structure of the mCD1d/xxs (JJ304) /iNKTCR ternary complex
6MJ6	;	2.45	;	Crystal structure of the mCD1d/xxx (JJ166) /iNKTCR ternary complex
2NL9	;	1.55	;	Crystal structure of the Mcl-1:Bim BH3 complex
2NLA	;	2.8	;	Crystal structure of the Mcl-1:mNoxaB BH3 complex
3TS9	;	2.003	;	Crystal Structure of the MDA5 Helicase Insert Domain
2AZM	;	2.41	;	Crystal structure of the MDC1 brct repeat in complex with the histone tail of gamma-H2AX
2VJE	;	2.2	;	Crystal Structure of the MDM2-MDMX RING Domain Heterodimer
2VJF	;	2.3	;	Crystal Structure of the MDM2-MDMX RING Domain Heterodimer
2RKC	;	2.7	;	Crystal structure of the measles virus hemagglutinin
2ZB5	;	3.0	;	Crystal structure of the measles virus hemagglutinin (complex-sugar-type)
2ZB6	;	2.6	;	Crystal structure of the measles virus hemagglutinin (oligo-sugar type)
3ALZ	;	4.515	;	Crystal structure of the measles virus hemagglutinin bound to its cellular receptor SLAM (Form I)
3ALW	;	3.55	;	Crystal structure of the measles virus hemagglutinin bound to its cellular receptor SLAM (Form I, MV-H-SLAM(N102H/R108Y) fusion)
3ALX	;	3.15	;	Crystal structure of the measles virus hemagglutinin bound to its cellular receptor SLAM (MV-H(L482R)-SLAM(N102H/R108Y) fusion)
1OKS	;	1.8	;	Crystal structure of the measles virus phosphoprotein XD domain
2D45	;	3.8	;	Crystal structure of the MecI-mecA repressor-operator complex
5X2Q	;	2.6	;	Crystal structure of the medaka fish taste receptor T1r2a-T1r3 ligand binding domains in complex with glycine
5X2N	;	2.2	;	Crystal structure of the medaka fish taste receptor T1r2a-T1r3 ligand binding domains in complex with L-alanine
5X2O	;	2.6	;	Crystal structure of the medaka fish taste receptor T1r2a-T1r3 ligand binding domains in complex with L-arginine
5X2P	;	2.608	;	Crystal structure of the medaka fish taste receptor T1r2a-T1r3 ligand binding domains in complex with L-glutamate
5X2M	;	2.206	;	Crystal structure of the medaka fish taste receptor T1r2a-T1r3 ligand binding domains in complex with L-glutamine
6HHE	;	1.516	;	Crystal structure of the medfly Odorant Binding Protein CcapOBP22/CcapOBP69a
4LDQ	;	2.496	;	Crystal Structure of the Mediator of Rho Dependent Invasion
4P37	;	2.24	;	Crystal structure of the Megavirus polyadenylate synthase
7NYQ	;	1.6	;	Crystal structure of the Mei-P26 NHL domain
7LDG	;	2.56	;	Crystal structure of the MEILB2-BRCA2 complex
7Z8Z	;	1.5	;	Crystal structure of the MEILB2-BRME1 2:2 core complex
5YYX	;	1.684	;	Crystal Structure of the MEK1 FHA domain
5YYZ	;	1.798	;	Crystal structure of the MEK1 FHA domain in complex with the HOP1 pThr318 peptide.
6X2P	;	2.401	;	Crystal Structure of the Mek1NES peptide bound to CRM1
6W25	;	2.75	;	Crystal structure of the Melanocortin-4 Receptor (MC4R) in complex with SHU9119
7Y9B	;	3.214	;	Crystal structure of the membrane (M) protein of a SARS-COV-2-related coronavirus
6FL0	;	2.9	;	Crystal structure of the membrane attack complex assembly inhibitor BGA71 from Lyme disease agent Borreliella bavariensis
6FMH	;	2.8	;	Crystal structure of the membrane attack complex assembly inhibitor BGA71 from Lyme disease agent Borreliella bavariensis (Native data)
3RKO	;	3.0	;	Crystal structure of the membrane domain of respiratory complex I from E. coli at 3.0 angstrom resolution
3M9C	;	3.9	;	Crystal structure of the membrane domain of respiratory complex I from Escherichia coli
4HE8	;	3.3	;	Crystal structure of the membrane domain of respiratory complex I from Thermus thermophilus
3H94	;	3.84	;	Crystal structure of the membrane fusion protein CusB from Escherichia coli
3OOC	;	3.404	;	Crystal structure of the membrane fusion protein CusB from Escherichia coli
3OPO	;	3.848	;	Crystal structure of the membrane fusion protein CusB from Escherichia coli
3OW7	;	3.78	;	Crystal structure of the membrane fusion protein CusB from Escherichia coli.
1VF7	;	2.4	;	Crystal structure of the membrane fusion protein, MexA of the multidrug transporter
2VNS	;	2.0	;	Crystal Structure of the Membrane Proximal Oxidoreductase Domain of Human Steap3, the Dominant Ferric Reductase of the Erythroid Transferrin Cycle
2VQ3	;	2.0	;	Crystal Structure of the Membrane Proximal Oxidoreductase Domain of Human Steap3, the Dominant Ferric Reductase of the Erythroid Transferrin Cycle
5UTK	;	2.5	;	Crystal structure of the membrane proximal three fibronectin type III (FNIII) domains of Tie2 (Tie2[FNIIIa-c])
6Z0F	;	2.553	;	Crystal structure of the membrane pseudokinase YukC/EssB from Bacillus subtilis T7SS
5GV3	;	2.096	;	Crystal structure of the membrane-distal domain of mouse lysosome-associated membrane protein 2 (LAMP-2)
5GV0	;	1.5	;	Crystal structure of the membrane-proximal domain of mouse lysosome-associated membrane protein 1 (LAMP-1)
6LUS	;	1.4	;	Crystal structure of the Mengla Virus VP30 C-terminal domain
5BOB	;	1.5	;	Crystal Structure of the Meningitis Pathogen Streptococcus suis adhesion Fhb
5BOA	;	2.708	;	Crystal Structure of the Meningitis Pathogen Streptococcus suis adhesion Fhb bound to the disaccharide receptor Gb2
2YPV	;	1.8	;	Crystal structure of the Meningococcal vaccine antigen factor H binding protein in complex with a bactericidal antibody
6XZW	;	2.4	;	Crystal structure of the meningococcal vaccine antigen fHbp in complex with a cross-reactive human Fab.
5AID	;	3.4	;	Crystal structure of the Mep2 mutant delta442 from Candida albicans
5AH3	;	2.4	;	Crystal structure of the Mep2 mutant R452D,S453D from Candida albicans
5FUF	;	2.066	;	Crystal structure of the Mep2 mutant S453D from Candida albicans
5U6C	;	2.1	;	Crystal structure of the Mer kinase domain in complex with a macrocyclic inhibitor
3F2H	;	2.0	;	Crystal structure of the mercury-bound form of MerB mutant C160S, the Organomercurial Lyase involved in a bacterial mercury resistance system
5C0T	;	1.96	;	Crystal structure of the mercury-bound form of MerB mutant D99S
5DSF	;	1.954	;	Crystal structure of the mercury-bound form of MerB mutant D99S
3F0P	;	1.64	;	Crystal structure of the mercury-bound form of MerB, the Organomercurial Lyase involved in a bacterial mercury resistance system
3F2F	;	1.98	;	Crystal structure of the mercury-bound form of MerB, the Organomercurial Lyase involved in a bacterial mercury resistance system
5C17	;	1.24	;	Crystal structure of the mercury-bound form of MerB2
4P7I	;	2.6	;	Crystal structure of the Merlin FERM/DCAF1 complex
3VUU	;	2.093	;	Crystal structure of the merozoite surface protein MSPDBL2 from P. falciparum
3VUV	;	2.114	;	Crystal structure of the merozoite surface protein MSPDBL2 from P. falciparum bound to zinc
6WAR	;	3.4	;	Crystal structure of the MERS-CoV RBD bound by the neutralizing single-domain antibody MERS VHH-55
7M5Z	;	3.06	;	Crystal Structure of the MerTK Kinase Domain in Complex with Inhibitor MIPS15692
2AHK	;	1.71	;	Crystal structure of the met-form of the copper-bound Streptomyces castaneoglobisporus tyrosinase in complex with a caddie protein obtained by soking in cupric sulfate for 6 months
2ZMX	;	1.33	;	Crystal structure of the met1-form of the copper-bound tyrosinase in complex with a caddie protein from Streptomyces castaneoglobisporus obtained by soaking in cupric sulfate solution for 36 hours
1E30	;	1.5	;	Crystal structure of the Met148Gln mutant of rusticyanin at 1.5 Angstrom resolution
2ZMY	;	1.45	;	Crystal structure of the met2-form of the copper-bound tyrosinase in complex with a caddie protein from Streptomyces castaneoglobisporus obtained by soaking in cupric sulfate solution for 80 hours
5D8M	;	1.95	;	Crystal structure of the metagenomic carboxyl esterase MGS0156
4F2F	;	1.5	;	Crystal structure of the metal binding domain (MBD) of the Streptococcus pneumoniae D39 Cu(I) exporting P-type ATPase CopA with Cu(I)
3EVK	;	1.85	;	Crystal structure of the metal-bound superoxide dismutase from Pyrobaculum aerophilum
3DTO	;	3.3	;	Crystal structure of the metal-dependent HD domain-containing hydrolase BH2835 from Bacillus halodurans, Northeast Structural Genomics Consortium Target BhR130.
2O1E	;	2.6	;	Crystal Structure of the Metal-dependent Lipoprotein YcdH from Bacillus subtilis, Northeast Structural Genomics Target SR583
4WLS	;	2.105	;	Crystal structure of the metal-free (repressor) form of E. Coli CUER, a copper efflux regulator, bound to COPA promoter DNA
2O96	;	3.0	;	Crystal Structure of the Metal-Free Dimeric Human Mov34 MPN domain (residues 1-177)
2O95	;	1.95	;	Crystal Structure of the Metal-Free Dimeric Human Mov34 MPN domain (residues 1-186)
1R1U	;	2.0	;	Crystal structure of the metal-sensing transcriptional repressor CzrA from Staphylococcus aureus in the apo-form
1R1V	;	2.3	;	Crystal structure of the metal-sensing transcriptional repressor CzrA from Staphylococcus aureus in the Zn2-form
7L52	;	1.85	;	Crystal Structure of the Metallo Beta Lactamase L1 from Stenotrophomonas maltophilia Determined by Serial Crystallography
1KR3	;	2.5	;	Crystal Structure of the Metallo beta-Lactamase from Bacteroides fragilis (CfiA) in Complex with the Tricyclic Inhibitor SB-236050.
4C09	;	1.2	;	Crystal structure of the metallo-beta-lactamase BCII
4C1C	;	1.18	;	Crystal structure of the metallo-beta-lactamase BCII with D-captopril
4C1H	;	1.1	;	Crystal structure of the metallo-beta-lactamase BCII with L-captopril
1M2X	;	1.5	;	Crystal Structure of the metallo-beta-lactamase BlaB of Chryseobacterium meningosepticum in complex with the inhibitor D-captopril
6V3Q	;	2.4	;	Crystal Structure of the Metallo-beta-Lactamase FIM-1 from Pseudomonas aeruginosa in the Mono-Zinc Form
6KNS	;	2.15	;	Crystal structure of the metallo-beta-lactamase fold protein YhfI from Bacillus subtilis (space group I4122)
6KNT	;	2.5	;	Crystal structure of the metallo-beta-lactamase fold protein YhfI from Bacillus subtilis (space group P4332)
5K0W	;	2.61	;	Crystal structure of the metallo-beta-lactamase GOB-18 from Elizabethkingia meningoseptica
5EV8	;	2.3	;	Crystal structure of the metallo-beta-lactamase IMP-1 in complex with the bisthiazolidine inhibitor D-CS319
5EWA	;	2.3	;	Crystal structure of the metallo-beta-lactamase IMP-1 in complex with the bisthiazolidine inhibitor L-VC26
4C1G	;	1.714	;	Crystal structure of the metallo-beta-lactamase IMP-1 with D-captopril
4C1F	;	2.01	;	Crystal structure of the metallo-beta-lactamase IMP-1 with L-captopril
6U0Y	;	1.7	;	Crystal Structure of the metallo-beta-lactamase L1 from Stenotrophomonas maltophilia
6UAC	;	1.6	;	Crystal Structure of the metallo-beta-lactamase L1 from Stenotrophomonas maltophilia in the complex with cadmium and hydrolyzed moxolactam
6UAF	;	1.9	;	Crystal Structure of the Metallo-beta-lactamase L1 from Stenotrophomonas maltophilia in the Complex with Hydrolyzed Imipnem
6UAH	;	1.98	;	Crystal Structure of the Metallo-beta-Lactamase L1 from Stenotrophomonas maltophilia in the Complex with Hydrolyzed Meropenem
6U13	;	1.52	;	Crystal Structure of the metallo-beta-lactamase L1 from Stenotrophomonas maltophilia in the complex with the hydrolyzed antibiotic moxalactam
6U2Z	;	2.38	;	Crystal Structure of the metallo-beta-lactamase L1 from Stenotrophomonas maltophilia in the complex with the hydrolyzed moxalactam and two copper ions
6U2Y	;	1.5	;	Crystal Structure of the metallo-beta-lactamase L1 from Stenotrophomonas maltophilia in the complex with the hydrolyzed moxalactam and two Ni ions
6U0Z	;	1.65	;	Crystal Structure of the metallo-beta-lactamase L1 from Stenotrophomonas maltophilia in the complex with the hydrolyzed penicillin G
6U10	;	1.4	;	Crystal Structure of the metallo-beta-lactamase L1 from Stenotrophomonas maltophilia in the complex with the inhibitor captopril
6UA1	;	1.8	;	Crystal Structure of the metallo-beta-lactamase L1 from Stenotrophomonas maltophilia in the no-metal bound form
5EVB	;	1.841	;	Crystal structure of the metallo-beta-lactamase L1 in complex with the bisthiazolidine inhibitor D-CS319
5EVD	;	1.8	;	Crystal structure of the metallo-beta-lactamase L1 in complex with the bisthiazolidine inhibitor D-VC26
5EVK	;	1.627	;	Crystal structure of the metallo-beta-lactamase L1 in complex with the bisthiazolidine inhibitor L-CS319
4U4L	;	1.9	;	Crystal structure of the metallo-beta-lactamase NDM-1 in complex with a bisthiazolidine inhibitor
7AEZ	;	1.018	;	Crystal structure of the metallo-beta-lactamase NDM-7 with 407
5EW0	;	1.3	;	Crystal structure of the metallo-beta-lactamase Sfh-I in complex with the bisthiazolidine inhibitor L-CS319
4BZ3	;	1.294	;	Crystal structure of the metallo-beta-lactamase VIM-2
5FQC	;	1.449	;	Crystal structure of the metallo-beta-lactamase VIM-2 with 2C
4C1E	;	1.399	;	Crystal structure of the metallo-beta-lactamase VIM-2 with D-captopril
4C1D	;	1.198	;	Crystal structure of the metallo-beta-lactamase VIM-2 with L-captopril
6EW3	;	2.14	;	Crystal structure of the metallo-beta-lactamase VIM-2 with ML302F
4FSB	;	1.88	;	Crystal structure of the metallo-beta-lactamase VIM-31 in its oxidized form at 1.88 A
4FR7	;	1.61	;	Crystal structure of the metallo-beta-lactamase VIM-31 in its reduced form at 1.61 A
5A87	;	1.5	;	Crystal structure of the metallo-beta-lactamase VIM-5
7AFY	;	1.105	;	Crystal structure of the metallo-beta-lactamase VIM1 with 1306
7AFX	;	1.636	;	Crystal structure of the metallo-beta-lactamase VIM2 with 139
4JIX	;	2.0	;	Crystal structure of the metallopeptidase zymogen of Methanocaldococcus jannaschii jannalysin
4JIU	;	1.15	;	Crystal structure of the metallopeptidase zymogen of Pyrococcus abyssi abylysin
6FZW	;	2.78	;	Crystal structure of the metalloproteinase enhancer PCPE-1 bound to the procollagen C propeptide trimer (long)
6FZV	;	2.7	;	Crystal structure of the metalloproteinase enhancer PCPE-1 bound to the procollagen C propeptide trimer (short)
5FDU	;	2.9	;	Crystal structure of the Metalnikowin I antimicrobial peptide bound to the Thermus thermophilus 70S ribosome
6BM6	;	1.504	;	Crystal Structure of the MetH Reactivation Domain bound to AdoHcy
6BM5	;	1.5	;	Crystal Structure of the MetH Reactivation Domain bound to AdoMet
6BDY	;	1.512	;	Crystal Structure of the MetH Reactivation Domain bound to Sinefungin
4RGV	;	2.45	;	Crystal structure of the Methanocaldococcus jannaschii G1PDH
4RGQ	;	2.23	;	Crystal structure of the Methanocaldococcus jannaschii G1PDH with NADPH and DHAP
2APO	;	1.95	;	Crystal Structure of the Methanococcus jannaschii Cbf5 Nop10 Complex
1RA4	;	1.86	;	Crystal structure of the Methanococcus jannaschii L7Ae protein
1KKH	;	2.4	;	Crystal Structure of the Methanococcus jannaschii Mevalonate Kinase
1L2Q	;	1.7	;	Crystal Structure of the Methanosarcina barkeri Monomethylamine Methyltransferase (MtmB)
1NTH	;	1.55	;	Crystal structure of the methanosarcina barkeri monomethylamine methyltransferase (MTMB)
8TGE	;	2.3	;	Crystal structure of the Methanosarcina mazei glutamine synthetase in complex with GlnK1
2X5F	;	1.8	;	Crystal structure of the methicillin-resistant Staphylococcus aureus Sar2028, an aspartate_tyrosine_phenylalanine pyridoxal-5'-phosphate dependent aminotransferase
2X3F	;	1.95	;	Crystal Structure of the Methicillin-Resistant Staphylococcus aureus Sar2676, a Pantothenate Synthetase.
4YAH	;	1.6	;	Crystal Structure of the Methionine Binding Protein, MetQ
3VYQ	;	2.525	;	Crystal structure of the methyl CpG Binding Domain of MBD4 in complex with the 5mCG/TG sequence in space group P1
7B2H	;	2.12	;	Crystal structure of the methyl-coenzyme M reductase from Methanothermobacter Marburgensis derivatized with xenon
8HFP	;	1.82	;	Crystal structure of the methyl-CpG-binding domain of SETDB2 in complex with the cysteine-rich domain of C11orf46 protein
4XZN	;	1.7	;	Crystal structure of the methylated K125R/V301L AKR1B10 Holoenzyme
1U8B	;	2.1	;	Crystal structure of the methylated N-ADA/DNA complex
4XZM	;	1.75	;	Crystal structure of the methylated wild-type AKR1B10 holoenzyme
2YVE	;	1.4	;	Crystal structure of the methylene blue-bound form of the multi-drug binding transcriptional repressor CgmR
1LSX	;	2.7	;	Crystal structure of the methylimidazole-bound BjFixL heme domain
2YXB	;	1.8	;	Crystal structure of the methylmalonyl-CoA mutase alpha-subunit from Aeropyrum pernix
5WY0	;	2.001	;	Crystal structure of the methyltranferase domain of human HEN1 in complex with AdoMet
3GU3	;	2.3	;	Crystal Structure of the methyltransferase BC_2162 in complex with S-Adenosyl-L-Homocysteine from Bacillus cereus, Northeast Structural Genomics Consortium Target BcR20
3NUT	;	2.22	;	Crystal structure of the methyltransferase CobJ
8TDR	;	3.32	;	Crystal structure of the methyltransferase domain of DNMT3A homotetramer
8TE3	;	3.2	;	Crystal structure of the methyltransferase domain of R882C/R676K DNMT3A homotetramer
8TE4	;	2.65	;	Crystal structure of the methyltransferase domain of R882H/N879A DNMT3A homotetramer
8TE1	;	2.48	;	Crystal structure of the methyltransferase domain of R882H/R676K DNMT3A homotetramer
3MER	;	2.2	;	Crystal Structure of the methyltransferase Slr1183 from Synechocystis sp. PCC 6803, Northeast Structural Genomics Consortium Target SgR145
5NFJ	;	1.96	;	Crystal structure of the methyltransferase subunit of human mitochondrial Ribonuclease P (MRPP1) bound to S-adenosyl-methionine (SAM)
1K3R	;	2.3	;	Crystal Structure of the Methyltransferase with a Knot from Methanobacterium thermoautotrophicum
7Q7Y	;	2.9	;	Crystal structure of the methyltransferase-ribozyme 1 (1-benzyl-adenosine derivative)
7Q7Z	;	3.26	;	Crystal structure of the methyltransferase-ribozyme 1 (with 1-benzylamine-adenosine)
7Q7X	;	2.8	;	Crystal structure of the methyltransferase-ribozyme 1 (with 1-methyl-adenosine)
7Q81	;	2.85	;	Crystal structure of the methyltransferase-ribozyme 1, 2'-Selenomethyl-Uridine modified (with 1-methyl-adenosine)
7Q80	;	3.14	;	Crystal structure of the methyltransferase-ribozyme 1, no Magnesium condition (with 1-methyl-adenosine)
7Q82	;	2.95	;	Crystal structure of the methyltransferase-ribozyme 1, Thallium derivative (with 1-methyl-adenosine)
6W61	;	2.0	;	Crystal Structure of the methyltransferase-stimulatory factor complex of NSP16 and NSP10 from SARS CoV-2.
8BVI	;	3.1	;	Crystal structure of the METTL9-like histidine methyltransferase from Ostreococcus tauri
6FZ0	;	2.499	;	Crystal structure of the metY SAM V riboswitch
4HAC	;	1.92	;	Crystal Structure of the Mevalonate Kinase from an Archaeon Methanosarcina mazei
1LNW	;	2.1	;	CRYSTAL STRUCTURE OF THE MEXR REPRESSOR OF THE MEXAB-OPRM MULTIDRUG EFFLUX OPERON OF PSEUDOMONAS AERUGINOSA
1ZH4	;	2.2	;	Crystal Structure Of The Mg+2/BeF3-Bound Receiver Domain Of Kdp Potassium Transport System Response Regulator KdpE
5X9H	;	3.598	;	Crystal structure of the Mg2+ channel MgtE in complex with ATP
4F1K	;	1.87	;	Crystal structure of the MG2+ free VWA domain of plasmodium falciparum trap protein
4F1J	;	1.73	;	Crystal structure of the MG2+ loaded VWA domain of plasmodium falciparum trap protein
1VAQ	;	2.0	;	Crystal structure of the Mg2+-(chromomycin A3)2-d(TTGGCCAA)2 complex reveals GGCC binding specificity of the drug dimer chelated by metal ion
6B8P	;	2.2	;	Crystal Structure of the Mg2+/CaM:Kv7.4 (KCNQ4) AB domain complex
6B8Q	;	2.6	;	Crystal Structure of the Mg2+/CaM:Kv7.5 (KCNQ5) AB domain complex
1FMW	;	2.15	;	CRYSTAL STRUCTURE OF THE MGATP COMPLEX FOR THE MOTOR DOMAIN OF DICTYOSTELIUM MYOSIN II
8H5E	;	2.5	;	Crystal structure of the MgtE TM domain in complex with Ca2+ ions at 2.5 angstrom resolution
6TBZ	;	1.782	;	Crystal structure of the MH1 domain of Smad5-Smad3 chimera construct bound to the GGCGC site
2IPK	;	2.3	;	Crystal Structure of the MHC Class II Molecule HLA-DR1 in Complex with the Fluorogenic Peptide, AcPKXVKQNTLKLAT (X=3-[5-(dimethylamino)-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl]-L-alanine) and the Superantigen, SEC3 Variant 3B2
3CUP	;	3.09	;	Crystal structure of the MHC class II molecule I-Ag7 in complex with the peptide GAD221-235
4TSE	;	2.057	;	Crystal Structure of the Mib Repeat Domain of Mind bomb 1
7PUZ	;	2.842	;	Crystal structure of the Mic60 coiled coil domain
8ANQ	;	2.8	;	Crystal structure of the microbial rhodopsin from Sphingomonas paucimobilis (SpaR)
5FMM	;	2.4	;	crystal structure of the mid, cap-binding, mid-link and 627 domains from avian influenza a virus polymerase PB2 subunit bound to M7GTP
5FMQ	;	3.1	;	Crystal structure of the mid, cap-binding, mid-link and 627 domains from avian influenza A virus polymerase PB2 subunit bound to M7GTP H32 crystal form
5TE8	;	2.7	;	Crystal structure of the midazolam-bound human CYP3A4
1LKV	;	2.8	;	Crystal Structure of the Middle and C-terminal Domains of the Flagellar Rotor Protein FliG
2GQ0	;	1.9	;	Crystal Structure of the Middle Domain of HtpG, the E. coli Hsp90
3PRY	;	2.28	;	Crystal structure of the middle domain of human HSP90-beta refined at 2.3 A resolution
3RK6	;	2.0	;	Crystal structure of the middle domain of human Paip1
5UMU	;	1.903	;	Crystal structure of the middle double PH domain of human FACT complex subunit SPT16
5V6A	;	2.7	;	Crystal structure of the Middle East respiratory syndrome coronavirus papain-like protease bound to ubiquitin variant ME.2
5V69	;	2.55	;	Crystal structure of the Middle East respiratory syndrome coronavirus papain-like protease bound to ubiquitin variant ME.4
1RR7	;	2.2	;	Crystal structure of the Middle Operon Regulator protein of Bacteriophage Mu
4REZ	;	2.8	;	Crystal structure of the Middle-East respiratory syndrome coronavirus papain-like protease
4RF1	;	2.15	;	Crystal structure of the Middle-East respiratory syndrome coronavirus papain-like protease in complex with ubiquitin (space group P63)
4RF0	;	2.8	;	Crystal structure of the Middle-East respiratory syndrome coronavirus papain-like protease in complex with ubiquitin (space group P6522)
6OZU	;	2.4	;	Crystal structure of the MIF4G domain of Trypanosoma cruzi translation initiation factor EIF4G5
2OSE	;	2.04	;	Crystal Structure of the Mimivirus Cyclophilin
3EVO	;	1.5	;	Crystal structure of the Mimivirus NDK +Kpn mutant complexed with dTDP
3EJM	;	1.95	;	Crystal structure of the mimivirus NDK +Kpn mutant complexed with GDP
3FC9	;	2.8	;	Crystal structure of the Mimivirus NDK +Kpn-N62L double mutant complexed with CDP
3EM1	;	1.5	;	Crystal structure of the mimivirus NDK +Kpn-N62L double mutant complexed with dTDP
3ETM	;	1.9	;	Crystal structure of the mimivirus NDK +KPN-N62L-R107G triple mutant complexed with CDP
3EVM	;	1.8	;	Crystal structure of the Mimivirus NDK +Kpn-N62L-R107G triple mutant complexed with dCDP
3ENA	;	1.6	;	Crystal structure of the mimivirus NDK +Kpn-N62L-R107G triple mutant complexed with dGDP
3FCV	;	2.4	;	Crystal structure of the Mimivirus NDK +Kpn-N62L-R107G triple mutant complexed with dUDP
3DKD	;	1.9	;	Crystal structure of the mimivirus NDK +Kpn-N62L-R107G triple mutant complexed with GDP
3DDI	;	1.9	;	Crystal structure of the mimivirus NDK +Kpn-N62L-R107G triple mutant complexed with TDP
3EMT	;	1.6	;	Crystal structure of the mimivirus NDK +Kpn-R107G double mutant complexed with dGDP
3GP9	;	1.8	;	Crystal structure of the Mimivirus NDK complexed with GDP
3GPA	;	2.0	;	Crystal structure of the Mimivirus NDK N62L mutant complexed with CDP
3FBF	;	2.6	;	Crystal structure of the Mimivirus NDK N62L mutant complexed with dTDP
3FCW	;	2.4	;	Crystal structure of the Mimivirus NDK N62L mutant complexed with UDP
3FBC	;	2.6	;	Crystal structure of the Mimivirus NDK N62L-R107G double mutant complexed with dTDP
3FBE	;	2.4	;	Crystal structure of the Mimivirus NDK N62L-R107G double mutant complexed with GDP
3FBB	;	2.4	;	Crystal structure of the Mimivirus NDK N62L-R107G double mutant complexed with UDP
3EVW	;	2.6	;	Crystal structure of the Mimivirus NDK R107G mutant complexed with dTDP
4WSE	;	2.84	;	Crystal structure of the Mimivirus polyadenylate synthase
4RZ2	;	2.8	;	Crystal structure of the MinD-like ATPase FlhG
4RZ3	;	1.9	;	Crystal structure of the MinD-like ATPase FlhG
7EQC	;	2.5	;	Crystal structure of the mini-centralspindlin complex
5ONS	;	2.14	;	Crystal structure of the minimal DENR-MCTS1 complex
6YGU	;	1.99	;	Crystal structure of the minimal Mtr4-Red1 complex (single chain) from Chaetomium thermophilum
4C5E	;	1.951	;	Crystal structure of the minimal Pho-Sfmbt complex (P21 spacegroup)
4C5H	;	3.2	;	Crystal structure of the minimal Pho-Sfmbt complex (P3121 spacegroup)
4C5G	;	2.1	;	Crystal structure of the minimal Pho-Sfmbt complex (P6122 spacegroup)
2NS6	;	2.1	;	Crystal Structure of the Minimal Relaxase Domain of MobA from Plasmid R1162
6IRI	;	1.38	;	Crystal structure of the minor ferredoxin from Thermosynechococcus elongatus
3FT4	;	1.9	;	Crystal Structure of the minor histocompatibility peptide HA-1Arg in complex with HLA-A2
3FT3	;	1.95	;	Crystal Structure of the minor histocompatibility peptide HA-1His in complex with HLA-A2
3KLQ	;	1.9	;	Crystal Structure of the Minor Pilin FctB from Streptococcus pyogenes 90/306S
4DQ9	;	1.59	;	Crystal structure of the minor pseudopilin EPSH from the type II secretion system of Vibrio cholerae
6P28	;	1.35	;	Crystal structure of the MIR domain (aa 337-532) of the S. cerevisiae mannosyltransferase Pmt2
4GLU	;	1.9	;	Crystal structure of the mirror image form of VEGF-A
4WB2	;	1.8	;	Crystal structure of the mirror-image L-RNA/L-DNA aptamer NOX-D20 in complex with mouse C5a complement anaphylatoxin
4WB3	;	2.0	;	Crystal structure of the mirror-image L-RNA/L-DNA aptamer NOX-D20 in complex with mouse C5a-desArg complement anaphylatoxin
6C5W	;	3.1001	;	Crystal structure of the mitochondrial calcium uniporter
6LE5	;	3.1	;	Crystal structure of the mitochondrial calcium uptake 1 and 2 heterodimer (MICU1-MICU2 heterodimer) in an apo state
5JH0	;	2.18	;	Crystal structure of the mitochondrial DNA packaging protein Abf2p in complex with DNA at 2.18 Angstrom resolution
5JGH	;	2.6	;	Crystal structure of the mitochondrial DNA packaging protein Abf2p in complex with DNA at 2.6 Angstrom resolution
7TOC	;	2.43	;	Crystal Structure of the Mitochondrial Ketol-acid Reductoisomerase IlvC from Candida auris
4KB3	;	2.93	;	Crystal structure of the mitochondrial peroxiredoxin from Leishmania braziliensis in the decameric form
4KCE	;	2.79	;	Crystal structure of the mitochondrial peroxiredoxin from Leishmania braziliensis in the dimeric form
1LCY	;	2.0	;	Crystal Structure of the Mitochondrial Serine Protease HtrA2
2FME	;	2.1	;	Crystal structure of the mitotic kinesin eg5 (ksp) in complex with mg-adp and (r)-4-(3-hydroxyphenyl)-n,n,7,8-tetramethyl-3,4-dihydroisoquinoline-2(1h)-carboxamide
2GM1	;	2.3	;	Crystal structure of the mitotic kinesin eg5 in complex with mg-adp and n-(3-aminopropyl)-n-((3-benzyl-5-chloro-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)(cyclopropyl)methyl)-4-methylbenzamide
1II6	;	2.1	;	Crystal Structure of the Mitotic Kinesin Eg5 in Complex with Mg-ADP.
4TXO	;	2.2	;	Crystal structure of the mixed disulfide complex of thioredoxin-like TlpAs(C110S) and copper chaperone ScoIs(C74S)
4TXV	;	2.0	;	Crystal structure of the mixed disulfide intermediate between thioredoxin-like TlpAs(C110S) and subunit II of cytochrome c oxidase CoxBPD (C233S)
7U5V	;	2.59	;	Crystal structure of the Mixed Lineage Leukaemia (MLL1) SET Domain with the cofactor product S-Adenosylhomocysteine and Borealin peptide
2Q81	;	2.1	;	Crystal Structure of the Miz-1 BTB/POZ domain
7AZW	;	2.1	;	Crystal structure of the MIZ1-BTB-domain
7AZX	;	2.25	;	Crystal structure of the MIZ1-BTB-domain in complex with a HUWE1-derived peptide
1HYE	;	1.9	;	CRYSTAL STRUCTURE OF THE MJ0490 GENE PRODUCT, THE FAMILY OF LACTATE/MALATE DEHYDROGENASE, DIMERIC STRUCTURE
7DXR	;	1.6	;	Crystal structure of the mk2h peptide homodimer.
7DXW	;	1.509	;	Crystal structure of the mk2h_deltaMIL peptide homodimer
7DXX	;	1.403	;	Crystal structure of the mk2h_deltaMILPS peptide homodimer
7DXU	;	2.314	;	Crystal structure of the mk2h_deltaP peptide homodimer
7DXV	;	2.301	;	Crystal structure of the mk2h_deltaY peptide homodimer
8HPZ	;	2.3	;	Crystal structure of the MlaD domain of the MlaD protein from Escherichia coli (Form I)
8HQ9	;	2.7	;	Crystal structure of the MlaD domain of the MlaD protein from Escherichia coli (Form II)
7W6A	;	2.21	;	Crystal structure of the MLL1 (N3861I/Q3867L/C3882SS)-RBBP5-ASH2L complex
5F6K	;	2.411	;	Crystal structure of the MLL3-Ash2L-RbBP5 complex
4L58	;	1.48	;	Crystal structure of the MLL5 PHD finger in complex with H3K4me3
3KUR	;	2.5	;	Crystal structure of the MLLE domain of poly(A)-binding protein
3KUS	;	1.4	;	Crystal structure of the MLLE domain of poly(A)-binding protein in complex with the binding region of Paip2
3KUT	;	1.5	;	Crystal structure of the MLLE domain of poly(A)-binding protein in complex with the binding region of Paip2
5O8M	;	1.45	;	Crystal structure of the MmI1 YTH domain
1JLK	;	2.3	;	Crystal structure of the Mn(2+)-bound form of response regulator Rcp1
3B59	;	2.53	;	Crystal structure of the Mn(II)-bound glyoxalase from Novosphingobium aromaticivorans
4GWD	;	1.53	;	Crystal Structure of the Mn2+2,Zn2+-Human Arginase I-ABH Complex
4FCI	;	1.82	;	Crystal Structure of the Mn2+2-Human Arginase I-AGPA Complex
1N62	;	1.09	;	Crystal Structure of the Mo,Cu-CO Dehydrogenase (CODH), n-butylisocyanide-bound state
5G2R	;	2.45	;	Crystal structure of the Mo-insertase domain Cnx1E from Arabidopsis thaliana
5G2S	;	2.838	;	Crystal structure of the Mo-insertase domain Cnx1E from Arabidopsis thaliana in complex with molybdate
4AWY	;	1.6	;	Crystal Structure of the Mobile Metallo-beta-Lactamase AIM-1 from Pseudomonas aeruginosa: Insights into Antibiotic Binding and the role of Gln157
4AWZ	;	1.8	;	Crystal Structure of the Mobile Metallo-beta-Lactamase AIM-1 from Pseudomonas aeruginosa: Insights into Antibiotic Binding and the role of Gln157
6A6S	;	1.851	;	Crystal structure of the modified fructosyl peptide oxidase from Aspergillus nidulans in complex with FSA, Seleno-methionine Derivative
6A6V	;	2.9	;	Crystal structure of the modified fructosyl peptide oxidase from Aspergillus nidulans with 7 additional mutations, in complex with FSA
6A6T	;	1.901	;	Crystal structure of the modified fructosyl peptide oxidase from Aspergillus nidulans with R61G mutation
6A6U	;	1.945	;	Crystal structure of the modified fructosyl peptide oxidase from Aspergillus nidulans with R61G mutation, in complex with FSA
6A6R	;	2.609	;	Crystal structure of the modified fructosyl peptide oxidase from Aspergillus nidulans, Seleno-methionine Derivative
2J8F	;	1.84	;	Crystal structure of the modular Cpl-1 endolysin complexed with a peptidoglycan analogue (E94Q mutant in complex with a disaccharide- pentapeptide)
2J8G	;	1.69	;	Crystal structure of the modular Cpl-1 endolysin complexed with a peptidoglycan analogue (E94Q mutant in complex with a tetrasaccharide- pentapeptide)
2IXV	;	1.96	;	Crystal structure of the modular Cpl-1 endolysin complexed with a peptidoglycan analogue (E94Q mutant)
2IXU	;	2.28	;	Crystal structure of the modular Cpl-1 endolysin complexed with a peptidoglycan analogue (wild-type endolysin)
1EF1	;	1.9	;	CRYSTAL STRUCTURE OF THE MOESIN FERM DOMAIN/TAIL DOMAIN COMPLEX
2V7Y	;	2.37	;	Crystal structure of the molecular chaperone DnaK from Geobacillus kaustophilus HTA426 in post-ATP hydrolysis state
2HB5	;	1.59	;	Crystal Structure of the Moloney Murine Leukemia Virus RNase H Domain
6NIO	;	1.37	;	Crystal Structure of the Molybdate Transporter Periplasmic Protein ModA from Yersinia pestis
7T50	;	1.9	;	Crystal structure of the molybdate-binding periplasmic protein ModA from the bacteria Pseudomonsa aeruginosa in chromate-bound form
7T4Z	;	1.78	;	Crystal structure of the molybdate-binding periplasmic protein ModA from the bacteria Pseudomonsa aeruginosa in ligand-free form
7T51	;	2.5	;	Crystal structure of the molybdate-binding periplasmic protein ModA from the bacteria Pseudomonsa aeruginosa in molybdate-bound form
7T5A	;	2.16	;	Crystal structure of the molybdate-binding periplasmic protein ModA from the bacteria Pseudomonsa aeruginosa in tungstate-bound form
2IDE	;	1.9	;	Crystal Structure of the molybdenum cofactor biosynthesis protein C (TTHA1789) from Thermus Theromophilus HB8
3JQJ	;	1.9	;	Crystal structure of the molybdenum cofactor biosynthesis protein C (TTHA1789) from Thermus Theromophilus HB8
2IIH	;	1.75	;	Crystal structure of the molybdenum cofactor biosynthesis protein C (TTHA1789) from thermus theromophilus HB8 (H32 form)
3JQK	;	1.75	;	Crystal structure of the molybdenum cofactor biosynthesis protein C (TTHA1789) from Thermus Theromophilus HB8 (H32 FORM)
1E5K	;	1.35	;	CRYSTAL STRUCTURE OF THE MOLYBDENUM COFACTOR BIOSYNTHESIS PROTEIN MOBA (PROTEIN FA) FROM ESCHERICHIA COLI AT NEAR ATOMIC RESOLUTION
2BIH	;	2.6	;	crystal structure of the Molybdenum-containing nitrate reducing fragment of Pichia angusta assimilatory nitrate reductase
2IS8	;	1.64	;	Crystal structure of the Molybdopterin biosynthesis enzyme MoaB (TTHA0341) from thermus theromophilus HB8
3MCH	;	1.64	;	Crystal structure of the molybdopterin biosynthesis enzyme MoaB (TTHA0341) from thermus theromophilus HB8
1X8G	;	1.7	;	Crystal Structure of the Mono-Zinc Carbapenemase CphA from Aeromonas Hydrophyla
2WRS	;	2.79	;	Crystal Structure of the Mono-Zinc Metallo-beta-lactamase VIM-4 from Pseudomonas aeruginosa
3SFP	;	2.27	;	Crystal Structure of the Mono-Zinc-boundform of New Delhi Metallo-beta-Lactamase-1 from Klebsiella pneumoniae
3QHT	;	2.4	;	Crystal Structure of the Monobody ySMB-1 bound to yeast SUMO
3RZW	;	2.15	;	Crystal Structure of the Monobody ySMB-9 bound to human SUMO1
4XFW	;	1.517	;	Crystal structure of the monoclinic form of alpha-carbonic anhydrase from the human pathogen Helicobacter pylori
5FDF	;	1.76	;	Crystal structure of the monoclinic form of Thermotoga maritima Acetyl Esterase TM0077 (apo structure) at 1.76 Angstrom resolution
3GRL	;	2.0	;	Crystal Structure of the Monomer of the p115 Tether Globular Head Domain
4I1Z	;	3.0	;	Crystal structure of the monomeric (V948R) form of the gefitinib/erlotinib resistant EGFR kinase domain L858R+T790M
1RU3	;	2.2	;	Crystal Structure of the monomeric acetyl-CoA synthase from Carboxydothermus hydrogenoformans
5FDS	;	1.9	;	Crystal structure of the monomeric allergen profilin (Hev b 8)
8DP8	;	2.30001	;	Crystal structure of the monomeric AvrM14-A Nudix hydrolase effector from Melampsora lini
8DP9	;	1.76	;	Crystal structure of the monomeric AvrM14-B Nudix hydrolase effector from Melampsora lini
7JU2	;	1.85002	;	Crystal structure of the monomeric ETV6 PNT domain
5QU1	;	1.08	;	Crystal Structure of the monomeric human Nck SH3.1 domain, triclinic, 1.08A
1ITW	;	1.95	;	Crystal structure of the monomeric isocitrate dehydrogenase in complex with isocitrate and Mn
1J1W	;	3.2	;	Crystal Structure Of The Monomeric Isocitrate Dehydrogenase In Complex With NADP+
2F1C	;	2.3	;	Crystal structure of the monomeric porin OmpG
8PI6	;	2.14	;	Crystal structure of the monomeric zinc free human insulin A22K, B3E, B26E, B29R, desB30 precursor with a Ser-Glu-Asp-Trp-Trp-Arg C-peptide and a Glu-Glu-Gly-Glu-Pro-Arg N-terminal extension
4MKO	;	1.7	;	Crystal structure of the monomeric, cleaved form of the Pore-Forming Toxin Monalysin
5T77	;	2.0	;	Crystal structure of the MOP flippase MurJ
4ZQG	;	2.5	;	Crystal structure of the Moraxella catarrhalis DOX-P Reductoisomerase in complex with NADH, fosmidomycin and magnesium
3HOT	;	3.25	;	Crystal structure of the Mos1 mariner paired end complex with Mn
5HOO	;	3.3	;	Crystal structure of the Mos1 Strand Transfer Complex
6XRX	;	1.95	;	Crystal structure of the mosquito protein AZ1 as an MBP fusion
3OC3	;	3.1	;	Crystal structure of the Mot1 N-terminal domain in complex with TBP
4WZS	;	3.78	;	Crystal structure of the Mot1 N-terminal domain in complex with TBP and NC2 bound to a promoter DNA fragment
6NJE	;	2.2	;	Crystal structure of the motor domain of human kinesin family member 22
3B6U	;	1.8	;	Crystal structure of the motor domain of human kinesin family member 3B in complex with ADP
3B6V	;	2.7	;	Crystal structure of the motor domain of human kinesin family member 3C in complex with ADP
1T5C	;	2.5	;	Crystal structure of the motor domain of human kinetochore protein CENP-E
3GBJ	;	2.102	;	Crystal structure of the motor domain of kinesin KIF13B bound with ADP
1Q0B	;	1.9	;	Crystal structure of the motor protein KSP in complex with ADP and monastrol
1J07	;	2.35	;	Crystal structure of the mouse acetylcholinesterase-decidium complex
1N5M	;	2.2	;	Crystal structure of the mouse acetylcholinesterase-gallamine complex
1N5R	;	2.25	;	Crystal structure of the mouse acetylcholinesterase-propidium complex
1Q84	;	2.45	;	Crystal structure of the mouse acetylcholinesterase-TZ2PA6 anti complex
1Q83	;	2.65	;	Crystal structure of the mouse acetylcholinesterase-TZ2PA6 syn complex
3DJ7	;	2.8	;	Crystal structure of the mouse Aurora-A catalytic domain (Asn186->Gly, Lys240->Arg, Met302->Leu) in complex with Compound 130.
3DJ5	;	1.8	;	Crystal structure of the mouse Aurora-A catalytic domain (Asn186->Gly, Lys240->Arg, Met302->Leu) in complex with Compound 290.
3DJ6	;	1.7	;	Crystal structure of the mouse Aurora-A catalytic domain (Asn186->Gly, Lys240->Arg, Met302->Leu) in complex with Compound 823.
4P3A	;	1.4	;	Crystal structure of the mouse C5a anaphylatoxin
4P3B	;	2.1	;	Crystal structure of the mouse C5a-desArg anaphylatoxin
1XLS	;	2.96	;	Crystal structure of the mouse CAR/RXR LBD heterodimer bound to TCPOBOP and 9cRA and a TIF2 peptide containg the third LXXLL motifs
4QKV	;	3.0	;	Crystal structure of the mouse cavin1 HR1 domain
1GN1	;	2.8	;	crystal structure of the mouse CCT gamma apical domain (monoclinic)
1GML	;	2.2	;	crystal structure of the mouse CCT gamma apical domain (triclinic)
5FKP	;	1.8	;	Crystal structure of the mouse CD1d in complex with the p99 peptide
3UBX	;	3.1	;	Crystal structure of the mouse CD1d-C20:2-aGalCer-L363 mAb Fab complex
3T1F	;	1.7	;	Crystal structure of the mouse CD1d-Glc-DAG-s2 complex
4ELM	;	3.48	;	Crystal structure of the mouse CD1d-lysosulfatide-Hy19.3 TCR complex
3UF5	;	2.8	;	Crystal structure of the mouse Colony-Stimulating Factor 1 (mCSF-1) cytokine
4ADQ	;	4.5	;	CRYSTAL STRUCTURE OF THE MOUSE COLONY-STIMULATING FACTOR 1 (MCSF-1) CYTOKINE IN COMPLEX WITH THE VIRAL RECEPTOR BARF1
3L51	;	1.506	;	Crystal Structure of the Mouse Condensin Hinge Domain
3FQI	;	2.013	;	Crystal Structure of the Mouse Dom3Z
3FQJ	;	2.623	;	Crystal Structure of the Mouse Dom3Z in Complex with GDP
6M3U	;	2.32	;	Crystal structure of the mouse endonuclease EndoG(H138A/C100A), space group C2
6M3F	;	1.96	;	Crystal structure of the mouse endonuclease EndoG(H138A/C110A), space group P212121
6M3T	;	2.38	;	Crystal structure of the mouse endonuclease EndoG(H138A/C110A), space group P41212
6LYF	;	2.8	;	Crystal structure of the mouse endonuclease EndoG(H138A/Se-Met)
3B08	;	1.701	;	Crystal structure of the mouse HOIL1-L-NZF in complex with linear di-ubiquitin
3B0A	;	1.9	;	Crystal structure of the mouse HOIL1-L-NZF in complex with linear di-ubiquitin
7XCB	;	3.4	;	Crystal structure of the mouse interleukin-9
4OZQ	;	2.71	;	Crystal structure of the mouse Kif14 motor domain
7LTW	;	1.8	;	Crystal structure of the mouse Kirrel2 D1 homodimer
7LU6	;	1.95	;	Crystal structure of the mouse Kirrel3 D1 homodimer
7Z3P	;	1.943	;	Crystal structure of the mouse leptin:LepR-CRH2 encounter complex to 1.95 A resolution.
7Z3R	;	2.951	;	Crystal structure of the mouse leptin:LepR-IgCRH2 complex to 2.95 A resolution.
7KIH	;	1.467	;	Crystal structure of the mouse lipin-1 M-Lip domain
7KIL	;	1.898	;	Crystal structure of the mouse lipin-1 M-Lip domain with zinc
7KIQ	;	2.523	;	Crystal structure of the mouse lipin-2 M-Lip domain
3ZYV	;	2.545	;	Crystal structure of the mouse liver Aldehyde Oxidase 3 (mAOX3)
3SGD	;	2.31	;	Crystal structure of the mouse mAb 17.2
4M68	;	1.696	;	Crystal structure of the mouse MLKL kinase-like domain
1HU8	;	2.7	;	CRYSTAL STRUCTURE OF THE MOUSE P53 CORE DNA-BINDING DOMAIN AT 2.7A RESOLUTION
2IOO	;	2.02	;	Crystal structure of the mouse p53 core domain
2IOI	;	1.55	;	Crystal structure of the mouse p53 core domain at 1.55 A
2HPL	;	1.8	;	Crystal structure of the mouse p97/PNGase complex
3BP5	;	1.8	;	Crystal structure of the mouse PD-1 and PD-L2 complex
3BP6	;	1.6	;	Crystal structure of the mouse PD-1 Mutant and PD-L2 complex
6H8S	;	1.771	;	CRYSTAL STRUCTURE OF THE MOUSE PROTEIN TYROSINE PHOSPHATASE PTPN5 (STEP) IN COMPLEX WITH COMPOUND BI-0314
2ZPY	;	2.1	;	Crystal structure of the mouse radxin FERM domain complexed with the mouse CD44 cytoplasmic peptide
3A1Q	;	2.2	;	Crystal structure of the mouse RAP80 UIMs in complex with Lys63-linked di-ubiquitin
4M66	;	2.401	;	Crystal structure of the mouse RIP3 kinase domain
4M69	;	2.497	;	Crystal structure of the mouse RIP3-MLKL complex
4P2I	;	1.9	;	Crystal structure of the mouse SNX19 PX domain
4P2J	;	2.4	;	Crystal structure of the mouse SNX19 PX domain with bound sulphate ion
3A9J	;	1.18	;	Crystal structure of the mouse TAB2-NZF in complex with Lys63-linked di-ubiquitin
3A9K	;	1.4	;	Crystal structure of the mouse TAB3-NZF in complex with Lys63-linked di-ubiquitin
2RFA	;	1.7	;	Crystal structure of the mouse TRPV6 ankyrin repeat domain
4ZW2	;	1.86	;	Crystal structure of the Mouse voltage gated calcium channel beta subunit isoform 1a in complex with Alpha Interaction Domain peptide.
7WEK	;	3.21	;	Crystal structure of the mouse Wdr47 NTD in complex with the WBR motif form Camsap3.
7WEJ	;	3.09	;	Crystal structure of the mouse Wdr47 NTD.
1LOO	;	2.2	;	Crystal Structure of the Mouse-Muscle Adenylosuccinate Synthetase Ligated with GTP
4JF3	;	1.7	;	Crystal structure of the mpmv tm retroviral fusion core
7YDW	;	2.47	;	Crystal structure of the MPND-DNA complex
1WWH	;	2.7	;	Crystal structure of the MPPN domain of mouse Nup35
2AQL	;	2.3	;	Crystal Structure of the MRG15 MRG domain
5IN1	;	1.4	;	Crystal Structure of the MRG701 chromodomain
4XQM	;	1.625	;	Crystal structure of the MRH domain of Glucosidase II beta bound to mannose
5E9J	;	3.47	;	Crystal structure of the mRNA cap guanine-N7 methyltransferase - modular lobe (416-456) deletion
6E5U	;	3.8	;	Crystal structure of the mRNA export receptor NXF1/NXT1 in complex with influenza virus NS1 protein
1IRJ	;	2.1	;	Crystal Structure of the MRP14 complexed with CHAPS
5H75	;	2.738	;	Crystal structure of the MrsD-Protein A fusion protein
6OQM	;	2.2	;	crystal structure of the MSH6 PWWP domain
4B7Y	;	3.25	;	Crystal structure of the MSL1-MSL2 complex
4B86	;	3.5	;	Crystal structure of the MSL1-MSL2 complex (3.5A)
4V12	;	1.5	;	Crystal structure of the MSMEG_6754 dehydratase from Mycobacterium smegmatis
1BQQ	;	2.75	;	CRYSTAL STRUCTURE OF THE MT1-MMP--TIMP-2 COMPLEX
1BUV	;	2.75	;	CRYSTAL STRUCTURE OF THE MT1-MMP-TIMP-2 COMPLEX
3BSF	;	2.9	;	Crystal Structure of the MTA/SAH nucleosidase
4FNB	;	1.8	;	Crystal structure of the Mtb enoyl CoA isomerase (Rv0632c) in complex with hydroxybutyrl CoA
4FN8	;	1.831	;	Crystal structure of the Mtb enoyl CoA isomerase (Rv0632c)in complex with acetoacetyl CoA
4FND	;	1.85	;	Crystal structure of the Mtb enoyl CoA isomerase in complex with hydroxyhexanoyl CoA
4FOA	;	2.253	;	Crystal Structure of the Mtb ThyA in Complex with 5-fluoro-dUMP
7VM8	;	3.034	;	Crystal structure of the MtDMI1 gating ring
5CRK	;	2.48	;	Crystal Structure of the MTERF1 F243A substitution bound to the termination sequence.
5CRJ	;	2.59	;	Crystal Structure of the MTERF1 F322A substitution bound to the termination sequence.
5CKY	;	2.62	;	Crystal Structure of the MTERF1 R162A substitution bound to the termination sequence.
5CO0	;	2.65	;	Crystal Structure of the MTERF1 Y288A substitution bound to the termination sequence.
2RAQ	;	3.11	;	Crystal structure of the MTH889 protein from Methanothermobacter thermautotrophicus. Northeast Structural Genomics Consortium target TT205
3KXD	;	2.2	;	Crystal structure of the mthk rck in complex with cadmium
3MXJ	;	1.95	;	Crystal Structure of the mTREX1 Apoprotein
1EAW	;	2.93	;	Crystal structure of the MTSP1 (matriptase)-BPTI (aprotinin) complex
7XCN	;	2.7	;	Crystal structure of the MttB-MttC complex at 2.7 A resolution
4DKL	;	2.8	;	Crystal structure of the mu-opioid receptor bound to a morphinan antagonist
3LYY	;	1.9	;	Crystal structure of the MucBP domain of the adhesion protein PEPE_0118 from Pediococcus pentosaceus. Northeast Structural Genomics Consortium target id PtR41A
6BSC	;	1.303	;	Crystal structure of the Mucin-1 SEA domain
6BSB	;	1.6	;	Crystal structure of the Mucin-1 SEA domain, L1105M mutant, Selenium-derivative
3NZ3	;	2.0	;	Crystal structure of the mucin-binding domain of Spr1345 from Streptococcus pneumoniae
1Z96	;	1.8	;	Crystal structure of the Mud1 UBA domain
7V8P	;	2.44	;	Crystal Structure of the MukE dimer
3EUH	;	2.9	;	Crystal Structure of the MukE-MukF Complex
3RPU	;	3.6	;	Crystal structure of the MukE-MukF complex
2P3A	;	1.75	;	Crystal Structure of the multi-drug resistant mutant subtype B HIV protease complexed with TL-3 inhibitor
2P3D	;	2.8	;	Crystal Structure of the multi-drug resistant mutant subtype F HIV protease complexed with TL-3 inhibitor
1JT6	;	2.54	;	Crystal structure of the multidrug binding protein QacR bound to dequalinium
1RPW	;	2.9	;	Crystal Structure Of The Multidrug Binding Protein Qacr Bound To The Diamidine Hexamidine
7Q34	;	2.6	;	Crystal structure of the multidrug binding transcriptional regulator LmrR in complex squaraine dye
6DO0	;	2.798	;	Crystal structure of the multidrug binding transcriptional regulator LmrR in complex with Rhodium Bis-diphosphine Complex
3F8B	;	2.0	;	Crystal structure of the multidrug binding transcriptional regulator LmrR in drug free state
1JTX	;	2.85	;	Crystal structure of the multidrug binding transcriptional regulator QacR bound to crystal violet
1JTY	;	2.97	;	Crystal structure of the multidrug binding transcriptional regulator QacR bound to ethidium
1JUP	;	2.95	;	Crystal structure of the multidrug binding transcriptional repressor QacR bound to malachite green
1RKW	;	2.62	;	CRYSTAL STRUCTURE OF THE MULTIDRUG BINDING TRANSCRIPTIONAL REPRESSOR QACR BOUND TO PENTAMADINE
1JUS	;	2.84	;	Crystal structure of the multidrug binding transcriptional repressor QacR bound to rhodamine 6G
1QVT	;	2.89	;	CRYSTAL STRUCTURE OF THE MULTIDRUG BINDING TRANSCRIPTIONAL REPRESSOR QACR BOUND TO THE DRUG PROFLAVINE
1JUM	;	2.98	;	Crystal structure of the multidrug binding transcriptional repressor QacR bound to the natural drug berberine
1QVU	;	2.96	;	Crystal structure of the multidrug binding transcriptional repressor QacR bound to two drugs: ethidium and proflavine
2I6W	;	3.1	;	Crystal structure of the multidrug efflux transporter AcrB
7WLS	;	2.94	;	Crystal structure of the multidrug efflux transporter BpeB from Burkholderia pseudomallei
7WLV	;	3.0	;	Crystal Structure of the Multidrug effulx transporter BpeF from Burkholderia pseudomallei.
1EZJ	;	1.9	;	CRYSTAL STRUCTURE OF THE MULTIMERIZATION DOMAIN OF THE PHOSPHOPROTEIN FROM SENDAI VIRUS
3PUJ	;	3.313	;	Crystal structure of the MUNC18-1 and SYNTAXIN4 N-Peptide complex
8TN8	;	1.75	;	Crystal structure of the murine astrovirus capsid spike at 1.75 A
4BKM	;	2.65	;	Crystal structure of the murine AUM (phosphoglycolate phosphatase) capping domain as a fusion protein with the catalytic core domain of murine chronophin (pyridoxal phosphate phosphatase)
6I8C	;	1.92	;	Crystal structure of the murine beta-2-microglobulin.
4MRD	;	2.55	;	Crystal structure of the murine cd44 hyaluronan binding domain complex with a small molecule
4MRE	;	1.58	;	Crystal structure of the murine CD44 hyaluronan binding domain complex with a small molecule
4MRF	;	1.55	;	Crystal structure of the murine cd44 hyaluronan binding domain complex with a small molecule
4MRG	;	1.69	;	Crystal structure of the murine cd44 hyaluronan binding domain complex with a small molecule
4MRH	;	1.12	;	Crystal structure of the murine CD44 hyaluronan binding domain complex with a small molecule
4NP2	;	1.75	;	Crystal structure of the murine CD44 hyaluronan binding domain complex with a small molecule
4NP3	;	1.61	;	Crystal structure of the murine cd44 hyaluronan binding domain complex with a small molecule
5BZC	;	1.95	;	Crystal structure of the murine CD44 hyaluronan binding domain complex with a small molecule
5BZE	;	1.31	;	Crystal structure of the murine CD44 hyaluronan binding domain complex with a small molecule
5BZF	;	2.77	;	Crystal structure of the murine CD44 hyaluronan binding domain complex with a small molecule
5BZG	;	2.19	;	Crystal structure of the murine CD44 hyaluronan binding domain complex with a small molecule
5BZH	;	1.95	;	Crystal structure of the murine CD44 hyaluronan binding domain complex with a small molecule
5BZI	;	1.32	;	Crystal structure of the murine cd44 hyaluronan binding domain complex with a small molecule
5BZJ	;	1.4	;	Crystal structure of the murine cd44 hyaluronan binding domain complex with a small molecule
5BZK	;	1.4	;	Crystal structure of the murine cd44 hyaluronan binding domain complex with a small molecule
5BZL	;	1.23	;	Crystal structure of the murine cd44 hyaluronan binding domain complex with a small molecule
5BZM	;	1.25	;	Crystal structure of the murine cd44 hyaluronan binding domain complex with a small molecule
5BZN	;	1.23	;	Crystal structure of the murine cd44 hyaluronan binding domain complex with a small molecule
5BZO	;	1.22	;	Crystal structure of the murine cd44 hyaluronan binding domain complex with a small molecule
5BZP	;	1.23	;	Crystal structure of the murine cd44 hyaluronan binding domain complex with a small molecule
5BZQ	;	1.2	;	Crystal structure of the murine cd44 hyaluronan binding domain complex with a small molecule
5BZR	;	1.15	;	Crystal structure of the murine cd44 hyaluronan binding domain complex with a small molecule
5BZS	;	1.5	;	Crystal structure of the murine cd44 hyaluronan binding domain complex with a small molecule
5BZT	;	1.25	;	Crystal structure of the murine cd44 hyaluronan binding domain complex with a small molecule
3TBS	;	2.49	;	CRYSTAL STRUCTURE OF THE MURINE CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX H-2DB IN COMPLEX THE WITH LCMV-DERIVED GP33 ALTERED PEPTIDE ligand (V3P,Y4A)
4NSK	;	2.6	;	CRYSTAL STRUCTURE OF THE MURINE CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX H-2DB IN COMPLEX WITH LCMV-DERIVED GP33 ALTERED PEPTIDE ligand V3P
7P0T	;	2.605	;	CRYSTAL STRUCTURE OF THE MURINE CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX H-2DB IN COMPLEX WITH LCMV-DERIVED GP33 PEPTIDE with D-AMINOACID
7P0A	;	2.429	;	CRYSTAL STRUCTURE OF THE MURINE CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX H-2DB IN COMPLEX WITH LCMV-DERIVED GP33 PEPTIDE with D-AMINOACID (p3P6f)
3TBW	;	2.15	;	CRYSTAL STRUCTURE OF THE MURINE CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX H-2DB IN COMPLEX WITH THE LCMV-DERIVED GP33 ALTERED PEPTIDE ligand (A2G, V3P, Y4S)
3TBV	;	2.1	;	CRYSTAL STRUCTURE OF THE MURINE CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX H-2DB IN COMPLEX WITH THE LCMV-DERIVED GP33 ALTERED PEPTIDE ligand (A2G,V3P,Y4A)
3TBY	;	2.5	;	CRYSTAL STRUCTURE OF THE MURINE CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX H-2DB IN COMPLEX WITH THE LCMV-DERIVED GP33 ALTERED PEPTIDE ligand (V3P, Y4F)
3TBT	;	2.3	;	CRYSTAL STRUCTURE OF THE MURINE CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX H-2DB IN COMPLEX WITH THE LCMV-DERIVED GP33 ALTERED PEPTIDE ligand (V3P, Y4S)
1N5A	;	2.85	;	Crystal structure of the Murine class I Major Histocompatibility Complex of H-2DB, B2-Microglobulin, and A 9-Residue immunodominant peptide epitope gp33 derived from LCMV
1ZHB	;	2.7	;	Crystal Structure Of The Murine Class I Major Histocompatibility Complex Of H-2Db, B2-Microglobulin, and a 9-Residue Peptide Derived from rat dopamine beta-monooxigenase
1N59	;	2.95	;	Crystal structure of the Murine class I Major Histocompatibility Complex of H-2KB, B2-Microglobulin, and A 9-Residue immunodominant peptide epitope gp33 derived from LCMV
1ES0	;	2.6	;	CRYSTAL STRUCTURE OF THE MURINE CLASS II ALLELE I-A(G7) COMPLEXED WITH THE GLUTAMIC ACID DECARBOXYLASE (GAD65) PEPTIDE 207-220
1U58	;	1.9	;	Crystal structure of the murine cytomegalovirus MHC-I homolog m144
4G59	;	2.44	;	Crystal structure of the murine cytomegalovirus MHC-I homolog m152 with ligand RAE-1 gamma
6UP2	;	1.97	;	Crystal structure of the murine DHX36 helicase
6UP4	;	2.4	;	Crystal structure of the murine DHX36 helicase in complex with ADP
6UP3	;	2.691	;	Crystal structure of the murine DHX36 helicase in complex with ANP
1NU2	;	1.9	;	Crystal structure of the murine Disabled-1 (Dab1) PTB domain-ApoER2 peptide-PI-4,5P2 ternary complex
1IKO	;	1.92	;	CRYSTAL STRUCTURE OF THE MURINE EPHRIN-B2 ECTODOMAIN
6AO3	;	1.76	;	Crystal structure of the murine gasdermin D C-terminal domain
3MC2	;	2.4	;	Crystal Structure of the Murine Inhibitor of Carbonic Anhydrase
1ZS8	;	3.0	;	Crystal Structure of the Murine MHC Class Ib Molecule M10.5
8GKJ	;	1.9	;	Crystal Structure of the Murine MUC16 Specific Antibody AR9.6
1JA3	;	3.0	;	Crystal Structure of the Murine NK Cell Inhibitory Receptor Ly-49I
1HQ8	;	1.95	;	CRYSTAL STRUCTURE OF THE MURINE NK CELL-ACTIVATING RECEPTOR NKG2D AT 1.95 A
4X2V	;	2.3	;	Crystal structure of the Murine Norovirus NS6 protease (inactive C139A mutant) with a C-terminal extension to include residue P1 prime of NS7
4X2W	;	2.7	;	Crystal structure of the Murine Norovirus NS6 protease (inactive C139A mutant) with a C-terminal extension to include residues P1 prime - P2 prime of NS7
4X2X	;	2.472	;	Crystal structure of the Murine Norovirus NS6 protease (inactive C139A mutant) with a C-terminal extension to include residues P1 prime - P4 prime of NS7
6C6Q	;	2.0	;	Crystal Structure of the Murine Norovirus VP1 P Domain in complex with the CD300lf Receptor
6E47	;	1.95	;	Crystal Structure of the Murine Norovirus VP1 P domain in complex with the CD300lf Receptor and Glycochenodeoxycholic Acid
6E48	;	1.801	;	Crystal Structure of the Murine Norovirus VP1 P domain in complex with the CD300lf Receptor and Lithocholic Acid
2PX2	;	2.0	;	Crystal structure of the Murray Valley Encephalitis Virus NS5 2'-O Methyltransferase domain in complex with SAH (Monoclinic form 1)
2PX4	;	2.2	;	Crystal structure of the Murray Valley Encephalitis Virus NS5 2'-O Methyltransferase domain in complex with SAH (Monoclinic form 2)
2PX5	;	2.3	;	Crystal structure of the Murray Valley Encephalitis Virus NS5 2'-O Methyltransferase domain in complex with SAH (Orthorhombic crystal form)
2PX8	;	2.2	;	Crystal structure of the Murray Valley Encephalitis Virus NS5 2'-O Methyltransferase domain in complex with SAH and 7M-GTP
2PXA	;	2.3	;	Crystal structure of the Murray Valley Encephalitis Virus NS5 2'-O Methyltransferase domain in complex with SAH and GTPG
2PXC	;	2.8	;	Crystal structure of the Murray Valley Encephalitis Virus NS5 2'-O Methyltransferase domain in complex with SAM and GTPA
7Q8E	;	2.90002	;	Crystal Structure of the MurT-GatD Enzyme Complex from Staphylococcus aureus COL strain
1JSS	;	2.2	;	Crystal structure of the Mus musculus cholesterol-regulated START protein 4 (StarD4).
2ZIU	;	2.7	;	Crystal structure of the Mus81-Eme1 complex
2ZIV	;	2.7	;	Crystal structure of the Mus81-Eme1 complex
2ZIW	;	2.8	;	Crystal structure of the Mus81-Eme1 complex
2ZIX	;	3.5	;	Crystal structure of the Mus81-Eme1 complex
4DO8	;	1.802	;	Crystal structure of the muscarinic toxin MT1
2VLW	;	1.39	;	Crystal structure of the muscarinic toxin MT7 diiodoTYR51 derivative.
1LUF	;	2.05	;	Crystal Structure of the MuSK Tyrosine Kinase: Insights into Receptor Autoregulation
3KAV	;	2.5	;	Crystal Structure of THE MUTANT (L80M) PA2107 PROTEIN from Pseudomonas aeruginosa, Northeast Structural Genomics Consortium Target PaR198
1YJ9	;	2.8	;	Crystal Structure Of The Mutant 50S Ribosomal Subunit Of Haloarcula Marismortui Containing a three residue deletion in L22
3HUI	;	2.01	;	Crystal Structure of the mutant A105R of [2Fe-2S] Ferredoxin in the Class I CYP199A2 System from Rhodopseudomonas palustris
3ZXO	;	1.9	;	CRYSTAL STRUCTURE OF THE MUTANT ATP-BINDING DOMAIN OF MYCOBACTERIUM TUBERCULOSIS DOSS
2XVI	;	2.48	;	Crystal structure of the mutant bacterial flavin containing monooxygenase (Y207S)
2XVJ	;	2.48	;	Crystal structure of the mutant bacterial flavin containing monooxygenase in complex with indole
7Q38	;	1.65	;	Crystal structure of the mutant bacteriorhodopsin pressurized with argon
7Q35	;	2.0	;	Crystal structure of the mutant bacteriorhodopsin pressurized with krypton
4UP3	;	1.44	;	Crystal structure of the mutant C140S,C286Q thioredoxin reductase from Entamoeba histolytica
2RF8	;	2.9	;	Crystal Structure of the mutant C2A conjugated bile acid hydrolase from Clostridium perfringens
4XPR	;	2.01	;	Crystal structure of the mutant D365A of Pedobacter saltans GH31 alpha-galactosidase
4XPS	;	2.1	;	Crystal structure of the mutant D365A of Pedobacter saltans GH31 alpha-galactosidase complexed with p-nitrophenyl-alpha-galactopyranoside
1LSY	;	1.9	;	CRYSTAL STRUCTURE OF THE MUTANT D52S HEN EGG WHITE LYSOZYME WITH AN OLIGOSACCHARIDE PRODUCT
1LSZ	;	2.0	;	CRYSTAL STRUCTURE OF THE MUTANT D52S HEN EGG WHITE LYSOZYME WITH AN OLIGOSACCHARIDE PRODUCT
3G1S	;	1.4	;	Crystal structure of the mutant D70G of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum
3G1V	;	1.3	;	Crystal structure of the mutant D70G of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with 5-fluorouridine 5'-monophosphate
3G1X	;	1.55	;	Crystal structure of the mutant D70G of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with uridine 5'-monophosphate
3G24	;	1.5	;	Crystal structure of the mutant D70N of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with 6-azauridine 5'-monophosphate
3G1Y	;	1.4	;	Crystal structure of the mutant D70N of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with sulfate
3G22	;	1.5	;	Crystal structure of the mutant D70N of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with uridine 5'-monophosphate
4AAE	;	2.6	;	Crystal structure of the mutant D75N I-CreI in complex with an altered target (The four central bases, 2NN region, are composed by AGCG from 5' to 3')
4AAF	;	2.5	;	Crystal structure of the mutant D75N I-CreI in complex with an altered target (The four central bases, 2NN region, are composed by TGCA from 5' to 3')
4AAB	;	2.5	;	Crystal structure of the mutant D75N I-CreI in complex with its wild- type target (The four central bases, 2NN region, are composed by GTAC from 5' to 3')
4AAD	;	3.1	;	Crystal structure of the mutant D75N I-CreI in complex with its wild- type target in absence of metal ions at the active site (The four central bases, 2NN region, are composed by GTAC from 5' to 3')
4AAG	;	2.8	;	Crystal structure of the mutant D75N I-CreI in complex with its wild- type target in presence of Ca at the active site (The four central bases, 2NN region, are composed by GTAC from 5' to 3')
3V5C	;	1.53	;	Crystal structure of the mutant E234A of Galacturonate Dehydratase from GEOBACILLUS SP. complexed with Mg
3V5F	;	2.0	;	Crystal structure of the mutant E234A of Galacturonate Dehydratase from GEOBACILLUS SP. complexed with Mg
3LSB	;	1.932	;	Crystal structure of the mutant E241Q of atrazine chlorohydrolase TrzN from Arthrobacter aurescens TC1 complexed with zinc and ametrin
3LSC	;	1.64	;	Crystal structure of the mutant E241Q of atrazine chlorohydrolase TrzN from Arthrobacter aurescens TC1 complexed with zinc and atraton
7FE2	;	1.75	;	Crystal structure of the mutant E494Q of GH92 alpha-1,2-mannosidase from Enterococcus faecalis ATCC 10100 in complex with alpha-1,2-mannobiose
2QNO	;	2.0	;	Crystal Structure of the Mutant E55Q of the Cellulase CEL48F in Complex with a Thio-Oligosaccharide
3NQA	;	1.395	;	Crystal structure of the mutant F100A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
4E0A	;	1.801	;	Crystal Structure of the mutant F44R BH1408 protein from Bacillus halodurans, Northeast Structural Genomics Consortium (NESG) Target BhR182
3NQ7	;	1.443	;	Crystal structure of the mutant F71A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
1OG0	;	2.7	;	CRYSTAL STRUCTURE OF THE MUTANT G226S OF THE TYROSINE-REGULATED 3-DEOXY-D-ARABINO-HEPTULOSONATE-7-PHOSPHATE SYNTHASE FROM SACCHAROMYCES CEREVISIAE COMPLEXED WITH PHENYLALANINE AND MANGANESE
4LC8	;	1.318	;	Crystal structure of the mutant H128N of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with the inhibitor BMP
4LC6	;	1.32	;	Crystal structure of the mutant H128Q of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with the inhibitor BMP
4LW7	;	1.423	;	Crystal structure of the mutant H128S of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with the inhibitor BMP
2JB0	;	1.91	;	CRYSTAL STRUCTURE OF THE MUTANT H573A OF THE NUCLEASE DOMAIN OF COLE7 IN COMPLEX WITH IM7
2W0L	;	2.2	;	CRYSTAL STRUCTURE OF THE MUTANT H8P FROM THE RECOMBINANT VARIABLE DOMAIN 6JAL2
1V13	;	2.0	;	CRYSTAL STRUCTURE OF THE MUTANT HIS103ALA OF THE COLICIN E9 DNASE DOMAIN IN COMPLEX WITH ZN+2 (2.0 ANGSTROMS)
5X8X	;	2.6	;	Crystal Structure of the mutant Human ROR gamma Ligand Binding Domain With Compound A.
5X8Q	;	2.2	;	Crystal Structure of the mutant Human ROR gamma Ligand Binding Domain With rockogenin.
5X8S	;	2.2	;	Crystal Structure of the mutant Human ROR gamma Ligand Binding Domain With Ursolic acid.
5X8W	;	2.3	;	Crystal Structure of the mutant Human ROR gamma Ligand Binding Domain.
3M43	;	1.3	;	Crystal structure of the mutant I199A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum
3LHY	;	1.4	;	Crystal structure of the mutant I199A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
3LV5	;	1.444	;	Crystal structure of the mutant I199E of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
3LHU	;	1.6	;	Crystal structure of the mutant I199F of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
3M47	;	1.2	;	Crystal structure of the mutant I218A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum
3LI1	;	1.35	;	Crystal structure of the mutant I218A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
3LV6	;	1.451	;	Crystal structure of the mutant I218F of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
4S1T	;	2.504	;	Crystal structure of the mutant I26A/N52A of the endoribonuclease from human coronavirus 229E
3PBU	;	1.299	;	Crystal structure of the mutant I96S of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with 6-azauridine 5'-monophosphate
3NQC	;	1.531	;	Crystal structure of the mutant I96S of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
3PBV	;	1.3	;	Crystal structure of the mutant I96T of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with 6-azauridine 5'-monophosphate
3NQD	;	1.423	;	Crystal structure of the mutant I96T of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
2DW6	;	2.3	;	Crystal structure of the mutant K184A of D-Tartrate Dehydratase from Bradyrhizobium japonicum complexed with Mg++ and D-tartrate
3RLU	;	1.49	;	Crystal structure of the mutant K82A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with the inhibitor BMP
3PBW	;	1.3	;	Crystal structure of the mutant L123N of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with 6-azauridine 5'-monophosphate
3NQE	;	1.421	;	Crystal structure of the mutant L123N of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
3PBY	;	1.3	;	Crystal structure of the mutant L123S of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with 6-azauridine 5'-monophosphate
3NQF	;	1.312	;	Crystal structure of the mutant L123S of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
5GMR	;	1.8	;	Crystal structure of the mutant M3+S202W/I203F of the esterase E40
2JBG	;	2.2	;	crystal structure of the mutant N560A of the nuclease domain of ColE7 in complex with Im7
2JAZ	;	2.03	;	CRYSTAL STRUCTURE OF THE MUTANT N560D OF THE NUCLEASE DOMAIN OF COLE7 IN COMPLEX WITH IM7
4EMP	;	2.7	;	Crystal structure of the mutant of ClpP E137A from Staphylococcus aureus
2YYK	;	1.6	;	Crystal structure of the mutant of HpaB (T198I, A276G, and R466H)
2YYL	;	1.75	;	Crystal structure of the mutant of HpaB (T198I, A276G, and R466H) complexed with FAD
2YYM	;	1.7	;	Crystal structure of the mutant of HpaB (T198I, A276G, and R466H) complexed with FAD and 4-hydroxyphenylacetate
3NQ6	;	1.494	;	Crystal structure of the mutant P180A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor 6-azaUMP
3SBF	;	1.5	;	Crystal structure of the mutant P311A of enolase superfamily member from VIBRIONALES BACTERIUM complexed with Mg and D-Arabinonate
4K2S	;	1.699	;	Crystal structure of the mutant P317A of d-mannonate dehydratase from chromohalobacter salexigens complexed with mg and d-gluconate
3PWI	;	2.2296	;	Crystal structure of the mutant P34A of D-Glucarate dehydratase from Escherichia coli complexed with product 5-keto-4-deoxy-D-Glucarate
3V1P	;	1.37	;	Crystal structure of the mutant Q185A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with the inhibitor BMP
4FX8	;	1.9411	;	Crystal structure of the mutant Q185A.R203A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
4HNQ	;	2.4	;	Crystal Structure of the mutant Q97A of Vibrio cholerae CheY3
3P61	;	1.396	;	Crystal structure of the mutant R160A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
3QMR	;	1.3213	;	Crystal structure of the mutant R160A,V182A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with the inhibitor BMP
4GC4	;	1.4204	;	Crystal structure of the mutant R160A.R203A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
3SJ3	;	1.26	;	Crystal structure of the mutant R160A.Y206F of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with the inhibitor BMP
3LI0	;	1.5	;	Crystal structure of the mutant R203A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
3SY5	;	1.321	;	Crystal structure of the mutant S127A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with the inhibitor 6azaUMP
3SIZ	;	1.321	;	Crystal structure of the mutant S127A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with the inhibitor BMP
3LLD	;	1.45	;	Crystal structure of the mutant S127G of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with 6-azauridine 5'-monophosphate
3LLF	;	1.3	;	Crystal structure of the mutant S127P of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with 6-azauridine 5'-monophosphate
5GMS	;	1.7	;	Crystal structure of the mutant S202W/I203F of the esterase E40
3PWG	;	2.0	;	Crystal structure of the mutant S29G.P34A of D-Glucarate dehydratase from Escherichia coli complexed with product 5-keto-4-deoxy-D-Glucarate
3P5Y	;	1.6	;	Crystal structure of the mutant T159A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
3P5Z	;	1.3	;	Crystal structure of the mutant T159S of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
3P60	;	1.4	;	Crystal structure of the mutant T159V of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
3QEZ	;	1.5431	;	Crystal structure of the mutant T159V,V182A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with the inhibitor BMP
3QMS	;	1.32	;	Crystal structure of the mutant T159V,V182A,Y206F of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with the inhibitor BMP
3QF0	;	1.34	;	Crystal structure of the mutant T159V,Y206F of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with the inhibitor BMP
4FXR	;	1.708	;	Crystal structure of the mutant T159V.R203A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
3NQG	;	1.421	;	Crystal structure of the mutant V155D of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
3PC0	;	1.298	;	Crystal structure of the mutant V155S of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with 6-azauridine 5'-monophosphate
3NQM	;	1.32	;	Crystal structure of the mutant V155S of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
3M41	;	1.4	;	Crystal structure of the mutant V182A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum
3LHW	;	1.35	;	Crystal structure of the mutant V182A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
3M5X	;	1.4	;	Crystal structure of the mutant V182A,I199A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum
3LTS	;	1.428	;	Crystal structure of the mutant V182A,I199A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
3M5Z	;	1.35	;	Crystal structure of the mutant V182A,I218A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum
3LTY	;	1.5	;	Crystal structure of the mutant V182A,I218A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
3M5Y	;	1.455	;	Crystal structure of the mutant V182A,V201A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum
3QMT	;	1.3202	;	Crystal structure of the mutant V182A,Y206F of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with the inhibitor BMP
3LHV	;	1.35	;	Crystal structure of the mutant V182A.I199A.V201A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
4FX6	;	1.531	;	Crystal structure of the mutant V182A.R203A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
3M1Z	;	1.42	;	Crystal structure of the mutant V182A.V201A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
3M44	;	1.4	;	Crystal structure of the mutant V201A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum
3LHZ	;	1.4	;	Crystal structure of the mutant V201A of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
3LHT	;	1.35	;	Crystal structure of the mutant V201F of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with inhibitor BMP
1MKQ	;	1.64	;	Crystal Structure of the Mutant Variant of Cytochrome c Peroxidase in the 'Open' Uncross-linked form
3PBE	;	1.95	;	Crystal structure of the mutant W207F of human secretory glutaminyl cyclase
3RLV	;	1.421	;	Crystal structure of the mutant Y206F of orotidine 5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with the inhibitor BMP
3HPF	;	1.8	;	Crystal structure of the mutant Y90F of divergent galactarate dehydratase from Oceanobacillus iheyensis complexed with Mg and galactarate
5B0U	;	1.71	;	Crystal structure of the mutated 19 kDa protein of Oplophorus luciferase (nanoKAZ)
3VJN	;	2.34	;	Crystal structure of the mutated EGFR kinase domain (G719S/T790M) in complex with AMPPNP.
3UG2	;	2.5	;	Crystal structure of the mutated EGFR kinase domain (G719S/T790M) in complex with gefitinib
3UG1	;	2.75	;	Crystal structure of the mutated EGFR kinase domain (G719S/T790M) in the apo form
3BZX	;	1.6	;	Crystal structure of the mutated H265A EscU C-terminal domain
2V5G	;	2.0	;	Crystal structure of the mutated N263A YscU C-terminal domain
2W0R	;	1.55	;	Crystal structure of the mutated N263D YscU C-terminal domain
3EDT	;	2.7	;	Crystal structure of the mutated S328N hKLC2 TPR domain
1PXG	;	1.7	;	Crystal structure of the mutated tRNA-guanine transglycosylase (TGT) D280E complexed with preQ1
1OZQ	;	1.9	;	CRYSTAL STRUCTURE OF THE MUTATED TRNA-GUANINE TRANSGLYCOSYLASE (TGT)Y106F COMPLEXED WITH PREQ1
3BZY	;	1.2	;	Crystal structure of the mutated Y316D EscU C-terminal domain
2PWF	;	1.8	;	Crystal structure of the MutB D200A mutant in complex with glucose
2PWE	;	2.0	;	Crystal structure of the MutB E254Q mutant in complex with the substrate sucrose
4GIA	;	2.01	;	Crystal structure of the MUTB F164L mutant from crystals soaked with isomaltulose
4GI8	;	1.95	;	Crystal structure of the MUTB F164L mutant from crystals soaked with the substrate sucrose
4GI9	;	2.15	;	Crystal structure of the MUTB F164L mutant from crystals soaked with Trehalulose
4GI6	;	2.15	;	Crystal structure of the MUTB F164L mutant in complex with glucose
4GIN	;	1.9	;	Crystal structure of the MUTB R284C mutant from crystals soaked with the inhibitor deoxynojirimycin
1X9Z	;	2.1	;	Crystal structure of the MutL C-terminal domain
1NNE	;	3.11	;	Crystal Structure of the MutS-ADPBeF3-DNA complex
3A6S	;	1.8	;	Crystal structure of the MutT protein
3A6V	;	2.0	;	Crystal structure of the MutT protein in MN(II) bound holo form
2AZW	;	1.9	;	Crystal structure of the MutT/nudix family protein from Enterococcus faecalis
2B06	;	1.4	;	Crystal structure of the MutT/nudix family protein from Streptococcus pneumoniae
6K5U	;	2.079	;	Crystal structure of the myb domain of S. pombe Tbf1
2CJJ	;	1.9	;	Crystal Structure of the MYB domain of the RAD transcription factor from Antirrhinum majus
5T0F	;	2.4	;	Crystal structure of the Myc3 N-terminal domain [44-242] in complex with JAZ10 CMID domain [16-58] from arabidopsis
5T0Q	;	2.15	;	Crystal structure of the Myc3 N-terminal domain [44-242] in complex with JAZ10 Jas domain [166-192] from arabidopsis
6T84	;	1.4	;	crystal structure of the mycobacterial trehalose monomycolate transport factor A, TtfA
3Q4H	;	2.7	;	Crystal structure of the Mycobacterium smegmatis EsxGH complex (MSMEG_0620-MSMEG_0621)
1SFR	;	2.7	;	Crystal Structure of the Mycobacterium tuberculosis Antigen 85A Protein
2GDN	;	1.72	;	Crystal structure of the Mycobacterium tuberculosis beta-lactamase
1P3H	;	2.8	;	Crystal Structure of the Mycobacterium tuberculosis chaperonin 10 tetradecamer
3Q0G	;	2.38	;	Crystal Structure of the Mycobacterium tuberculosis Crotonase Bound to a Reaction Intermediate Derived from Crotonyl CoA
3PZK	;	2.2303	;	Crystal Structure of the Mycobacterium tuberculosis crotonase in apo form
3Q0J	;	2.4	;	Crystal Structure of the Mycobacterium tuberculosis Crotonase in complex with the Inhibitor AcetoacetylCoA
4GZR	;	2.553	;	Crystal structure of the Mycobacterium tuberculosis H37Rv EsxOP (Rv2346c-Rv2347c) complex in space group C2221
3OGI	;	2.549	;	Crystal structure of the Mycobacterium tuberculosis H37Rv EsxOP complex (Rv2346c-Rv2347c)
3C3W	;	2.2	;	Crystal Structure of the Mycobacterium tuberculosis Hypoxic Response Regulator DosR
1ZLJ	;	2.0	;	Crystal Structure of the Mycobacterium tuberculosis Hypoxic Response Regulator DosR C-terminal Domain
3C57	;	1.7	;	Crystal Structure of the Mycobacterium tuberculosis Hypoxic Response Regulator DosR C-terminal Domain Crystal Form II
1ZLK	;	3.1	;	Crystal Structure of the Mycobacterium tuberculosis Hypoxic Response Regulator DosR C-terminal Domain-DNA Complex
3QJA	;	1.29	;	Crystal Structure of the Mycobacterium tuberculosis Indole-3-glycerol phosphate synthase (TrpC) in apo form
5LBG	;	1.54	;	Crystal structure of the Mycobacterium tuberculosis L,D-transpeptidase-2 (LdtMt2) BC-module with faropenem-derived adduct at the active site cysteine-354
5LB1	;	1.55	;	Crystal structure of the Mycobacterium tuberculosis L,D-transpeptidase-2 (LdtMt2) BC-module with thionitrobenzoate (TNB) adduct at the active site cysteine-354
7F8P	;	1.7	;	Crystal structure of the Mycobacterium tuberculosis L,D-transpeptidase-2 (LdtMt2) with new carbapenem drug T203
7F71	;	1.58	;	Crystal structure of the Mycobacterium tuberculosis L,D-transpeptidase-2 (LdtMt2) with peptidoglycan sugar moiety and glutamate
5U94	;	2.2	;	Crystal structure of the Mycobacterium tuberculosis PASTA kinase PknB in complex with the potential theraputic kinase inhibitor GSK690693.
6I2P	;	2.37	;	Crystal structure of the Mycobacterium tuberculosis PknB kinase domain (L33E mutant) in complex with its substrate GarA
3F69	;	2.8	;	Crystal structure of the Mycobacterium tuberculosis PknB mutant kinase domain in complex with KT5720
8RCW	;	1.692	;	Crystal structure of the Mycobacterium tuberculosis regulator VirS (N-terminal fragment 4-208) in complex with the lead compound SMARt751
1TXO	;	1.95	;	Crystal structure of the Mycobacterium tuberculosis serine/threonine phosphatase PstP/Ppp at 1.95 A.
4PMR	;	1.81	;	Crystal structure of the Mycobacterium tuberculosis Tat-secreted protein Rv2525c in complex with HEPES (monoclinic crystal form II)
4PMQ	;	1.61	;	Crystal structure of the Mycobacterium tuberculosis Tat-secreted protein Rv2525c in complex with L-tartrate (orthorhombic crystal form)
4PMN	;	1.44	;	Crystal structure of the Mycobacterium tuberculosis Tat-secreted protein Rv2525c in complex with MES (monoclinic crystal form I)
4PMO	;	1.33	;	Crystal structure of the Mycobacterium tuberculosis Tat-secreted protein Rv2525c, monoclinic crystal form I
3QJ7	;	2.504	;	Crystal Structure of the Mycobacterium tuberculosis Thymidylate synthase (ThyA) bound to dUMP
5ICJ	;	2.4	;	Crystal structure of the Mycobacterium tuberculosis transcriptional repressor EthR2 in complex with BDM41420
4I0X	;	1.956	;	Crystal structure of the Mycobacterum abscessus EsxEF (Mab_3112-Mab_3113) complex
2NSF	;	1.75	;	Crystal structure of the mycothiol-dependent maleylpyruvate isomerase
2NSG	;	2.05	;	Crystal structure of the mycothiol-dependent maleylpyruvate isomerase H52A mutant
3EA2	;	1.95	;	Crystal Structure of the Myo-inositol bound Y247S/Y251S Mutant of Phosphatidylinositol-Specific Phospholipase C from Bacillus Thuringiensis
1HZP	;	2.1	;	Crystal Structure of the Myobacterium Tuberculosis Beta-Ketoacyl-Acyl Carrier Protein Synthase III
4WXQ	;	2.15	;	Crystal Structure of the Myocilin Olfactomedin Domain
3RBS	;	1.85	;	Crystal structure of the myomesin domains 10 and 11
2R15	;	2.24	;	Crystal structure of the myomesin domains 12 and 13
2Y25	;	3.5	;	Crystal structure of the myomesin domains My11-My13
2Y23	;	2.5	;	CRYSTAL STRUCTURE OF THE MYOMESIN DOMAINS MY9-MY11
5FM5	;	3.1	;	Crystal structure of the myomesin:obscurin-like-1 complex
5MZU	;	3.8	;	Crystal structure of the myosin chaperone UNC-45 from C. elegans (alternative conformation)
4I2W	;	3.6	;	Crystal structure of the myosin chaperone UNC-45 from C.elegans in complex with a Hsp70 peptide
4I2Z	;	2.9	;	Crystal structure of the myosin chaperone UNC-45 from C.elegans in complex with a Hsp90 peptide
3HH2	;	2.15	;	Crystal structure of the myostatin:follistatin 288 complex
3SEK	;	2.401	;	Crystal Structure of the Myostatin:Follistatin-like 3 Complex
2AOZ	;	2.08	;	Crystal structure of the myotoxin-II from Atropoides nummifer venom
7DC3	;	2.4	;	Crystal structure of the MyRF ICA domain
4FBR	;	1.6	;	Crystal structure of the Myxococcus Xanthus hemagglutinin (MBHA)
4FBV	;	1.76	;	Crystal structure of the Myxococcus Xanthus hemagglutinin in complex with a3,a6-mannopentaose
2JBX	;	2.73	;	Crystal Structure of the myxoma virus anti-apoptotic protein M11L
4XI6	;	2.04	;	Crystal structure of the MZM-REP domains of Mind bomb 1
4XIB	;	2.147	;	Crystal structure of the MZM-REP domains of Mind bomb 1 in complex with fly Delta N-box peptide
4XI7	;	2.051	;	Crystal structure of the MZM-REP domains of Mind bomb 1 in complex with Jagged1 N-box peptide
2GK2	;	2.2	;	Crystal structure of the N terminal domain of human CEACAM1
4BMB	;	1.351	;	Crystal structure of the N terminal domain of human Galectin 8
4BME	;	2.0	;	Crystal structure of the N terminal domain of human Galectin 8, F19Y mutant
4BSX	;	2.229	;	Crystal Structure of the N terminal domain of TRIF (TIR-domain- containing adapter-inducing interferon-beta)
4C0M	;	2.8	;	Crystal Structure of the N terminal domain of wild type TRIF (TIR- domain-containing adapter-inducing interferon-beta)
1S3I	;	2.3	;	Crystal structure of the N terminal hydrolase domain of 10-formyltetrahydrofolate dehydrogenase
4ZV3	;	3.1	;	Crystal structure of the N- and C-terminal domains of mouse acyl-CoA thioesterase 7
1BG6	;	1.8	;	CRYSTAL STRUCTURE OF THE N-(1-D-CARBOXYLETHYL)-L-NORVALINE DEHYDROGENASE FROM ARTHROBACTER SP. STRAIN 1C
4CR7	;	2.15	;	Crystal structure of the N-acetyl-D-mannosamine dehydrogenase with n-acetylmannosamine
4CR8	;	2.2	;	Crystal structure of the N-acetyl-D-mannosamine dehydrogenase with NAD
4CR6	;	1.9	;	Crystal structure of the N-acetyl-D-mannosamine dehydrogenase without substrates
1YMY	;	2.6	;	Crystal Structure of the N-Acetylglucosamine-6-phosphate deacetylase from Escherichia coli K12
1YRR	;	2.0	;	Crystal Structure Of The N-Acetylglucosamine-6-Phosphate Deacetylase From Escherichia Coli K12 at 2.0 A Resolution
3EO3	;	2.84	;	Crystal structure of the N-acetylmannosamine kinase domain of human GNE protein
7AGO	;	1.7	;	crystal structure of the N-acetylmuramyl-L-alanine amidase, Ami1, from Mycobacterium abscessus bound to L-Alanine-D-isoglutamine
7AGM	;	1.35	;	Crystal structure of the N-acetylmuramyl-L-alanine amidase, Ami1, from Mycobacterium smegmatis
4AVM	;	1.91	;	Crystal structure of the N-BAR domain of human bridging integrator 2.
7SC3	;	2.229	;	CRYSTAL STRUCTURE OF THE N-DOMAIN OF CARDIAC MUSCLE TROPONIN C TETHERED TO THE SWITCH REGION OF CARDIAC MUSCLE TROPONIN I (ORTHORHOMBIC FORM)
7SC2	;	1.814	;	CRYSTAL STRUCTURE OF THE N-DOMAIN OF CARDIAC MUSCLE TROPONIN C TETHERED TO THE SWITCH REGION OF CARDIAC MUSCLE TROPONIN I (TETRAGONAL FORM)
3B09	;	1.9	;	Crystal structure of the N-domain of FKBP22 from Shewanella sp. SIB1
1U2O	;	2.1	;	Crystal Structure Of The N-Domain Of Grp94 Lacking The Charged Domain In Complex With Neca
5LBD	;	1.5	;	Crystal structure of the N-domain of HMA6, a copper-transporting P-type ATPase
5LBK	;	1.75	;	Crystal structure of the N-domain of HMA8, a copper-transporting P-type ATPase
1QYE	;	2.1	;	Crystal Structure of the N-domain of the ER Hsp90 chaperone GRP94 in complex with 2-chlorodideoxyadenosine
1QY8	;	1.85	;	Crystal Structure of the N-domain of the ER Hsp90 chaperone GRP94 in complex with Radicicol
6D28	;	1.75	;	Crystal Structure of the N-domain of the ER Hsp90 chaperone GRP94 in complex with the specific ligand NECA
4L0C	;	1.65	;	Crystal structure of the N-Fopmylmaleamic acid deformylase Nfo(S94A) from Pseudomonas putida S16
7N7C	;	2.0	;	crystal structure of the N-formyltransferase HCAN_0200 from helicobacter canadensis in complex with folinic acid and dTDP-3-aminoquinovose
5VYQ	;	1.6	;	Crystal structure of the N-formyltransferase Rv3404c from mycobacterium tuberculosis in complex with YDP-Qui4N and folinic acid
7N7B	;	2.0	;	crystal structure of the N-formyltrasferase HCAN_0200 from Helicobacter canadensis on complex with folinic acid and dTDP-3-aminofucose
3WWG	;	2.2	;	Crystal structure of the N-glycan-deficient variant N448A of isopullulanase complexed with isopanose
3UAQ	;	2.9318	;	Crystal Structure of the N-lobe Domain of Lactoferrin Binding Protein B (LbpB) of Moraxella bovis
1TV3	;	2.2	;	Crystal structure of the N-methyl-hydroxylamine MtmB complex
6VKZ	;	2.1	;	Crystal Structure of the N-prenyltransferase DabA in Complex with GSPP and Mg2+
6VL0	;	2.2	;	Crystal Structure of the N-prenyltransferase DabA in Complex with GSPP and Mn2+
6VL1	;	2.1	;	Crystal Structure of the N-prenyltransferase DabA in Complex with NGG and Mg2+
3WIA	;	1.77	;	Crystal structure of the N-terminal 1-37 residues deleted mutant of Geobacillus copper nitrite reductase
2GHP	;	2.7	;	Crystal structure of the N-terminal 3 RNA binding domains of the yeast splicing factor Prp24
2X7B	;	1.95	;	Crystal structure of the N-terminal acetylase Ard1 from Sulfolobus solfataricus P2
1M4J	;	1.6	;	CRYSTAL STRUCTURE OF THE N-TERMINAL ADF-H DOMAIN OF MOUSE TWINFILIN ISOFORM-1
3RV1	;	1.975	;	Crystal structure of the N-terminal and RNase III domains of K. polysporus Dcr1 E224Q mutant
4N5Q	;	1.946	;	Crystal structure of the N-terminal ankyrin repeat domain of TRPV3
5GRO	;	2.0	;	Crystal structure of the N-terminal anticodon-binding domain of non-discriminating aspartyl-tRNA synthetase from Helicobacter pylori
1M4Z	;	2.2	;	Crystal structure of the N-terminal BAH domain of Orc1p
3N2W	;	1.45	;	Crystal structure of the N-terminal beta-aminopeptidase BapA from Sphingosinicella xenopeptidilytica
3NDV	;	1.7	;	Crystal structure of the N-terminal beta-aminopeptidase BapA in complex with ampicillin
3NFB	;	1.85	;	Crystal structure of the N-terminal beta-aminopeptidase BapA in complex with hydrolyzed ampicillin
3N33	;	1.8	;	Crystal structure of the N-terminal beta-aminopeptidase BapA in complex with pefabloc SC (AEBSF)
4RLC	;	1.6	;	Crystal structure of the N-terminal beta-barrel domain of Pseudomonas aeruginosa OprF
5FTA	;	2.64	;	Crystal structure of the N-terminal BTB domain of human KCTD10
6RZN	;	1.907	;	Crystal structure of the N-terminal carbohydrate binding module family 48 and ferulic acid esterase from the multi-enzyme CE1-GH62-GH10
6RZO	;	1.632	;	Crystal structure of the N-terminal carbohydrate binding module family 48 and ferulic acid esterase from the multi-enzyme CE1-GH62-GH10
3BVP	;	2.1	;	Crystal Structure of the N-terminal Catalytic Domain of TP901-1 Integrase
1DEB	;	2.4	;	CRYSTAL STRUCTURE OF THE N-TERMINAL COILED COIL DOMAIN FROM APC
4CVO	;	1.85	;	Crystal structure of the N-terminal colied-coil domain of human DNA excision repair protein ERCC-6
1WPN	;	1.3	;	Crystal structure of the N-terminal core of Bacillus subtilis inorganic pyrophosphatase
4PBD	;	1.68	;	Crystal structure of the N-terminal CS domain of human Shq1
2O49	;	2.0	;	Crystal Structure of the N-terminal CUT domain of SATB1 Bound to Matrix Attachment Region DNA
2O4A	;	1.75	;	Crystal Structure of the N-terminal CUT Domain of SATB1 Bound to Matrix Attachment Region DNA
5HAS	;	2.653	;	Crystal structure of the N-terminal DCB-HUS domain of T. terrestris Sec7
7EVT	;	2.95	;	Crystal structure of the N-terminal degron-truncated human glutamine synthetase
2IYJ	;	2.0	;	Crystal structure of the N-terminal dimer domain of E.coli DsbC
2IY2	;	1.9	;	Crystal structure of the N-terminal dimer domain of E.coli DsbG
7BGF	;	2.802	;	CRYSTAL STRUCTURE OF THE N-TERMINAL DIMERIC COILED COIL OF THE HUMAN CTIP PROTEIN
1OV9	;	2.3	;	Crystal structure of the N-terminal dimerisation domain of VicH, the H-NS protein from Vibrio cholerae
5UBE	;	2.0	;	Crystal structure of the N-terminal domain (domain 1) of RctB
5UBD	;	2.002	;	Crystal structure of the N-terminal domain (domain 1) of RctB, RctB-1-124-L48M
3DXI	;	2.04	;	Crystal structure of the N-terminal domain of a putative aldolase (BVU_2661) from Bacteroides vulgatus
3H5I	;	1.9	;	Crystal structure of the N-terminal domain of a response regulator/sensory box/GGDEF 3-domain protein from Carboxydothermus hydrogenoformans
2P5K	;	1.0	;	Crystal structure of the N-terminal domain of AhrC
3PEH	;	2.75	;	Crystal Structure of the N-terminal domain of an HSP90 from Plasmodium Falciparum, PFL1070c in the presence of a thienopyrimidine derivative
3PEJ	;	2.81	;	Crystal Structure of the N-terminal domain of an HSP90 from Plasmodium Falciparum, PFL1070c in the presence of Macbecin
3OPD	;	2.6	;	Crystal Structure of the N-terminal domain of an HSP90 from Trypanosoma Brucei, Tb10.26.1080 in the presence of a benzamide derivative
3OMU	;	2.15	;	Crystal Structure of the N-terminal domain of an HSP90 from Trypanosoma Brucei, Tb10.26.1080 in the presence of a thienopyrimidine derivative
3O6O	;	2.0	;	Crystal Structure of the N-terminal domain of an HSP90 from Trypanosoma Brucei, Tb10.26.1080 in the presence of an the inhibitor BIIB021
3TUH	;	1.8	;	Crystal Structure of the N-terminal domain of an HSP90 in the presence of an the inhibitor ganetespib
3HDG	;	2.27	;	Crystal structure of the N-terminal domain of an uncharacterized protein (WS1339) from Wolinella succinogenes
3FFL	;	2.5	;	Crystal Structure of the N-terminal Domain of Anaphase-Promoting Complex Subunit 7
6A9E	;	3.205	;	Crystal structure of the N-terminal domain of Atg2
5YBX	;	2.501	;	Crystal structure of the N-terminal domain of Bqt4 in S.pombe
2WVI	;	1.8	;	Crystal Structure of the N-terminal Domain of BubR1
6G1C	;	1.56	;	Crystal structure of the N-terminal domain of Burkholderia Pseudomallei antitoxin HicB
2QSQ	;	1.95	;	Crystal structure of the N-terminal domain of carcinoembryonic antigen (CEA)
5GUI	;	1.2	;	Crystal structure of the N-terminal Domain of Caseinolytic protease associated chaperone ClpC1 from Arabidopsis thaliana
5GKM	;	1.6	;	Crystal structure of the N-terminal Domain of Caseinolytic protease associated chaperone ClpD from Arabidopsis thaliana
4Y8A	;	1.83	;	Crystal Structure of the N-terminal domain of CEACAM6
4Y89	;	1.47	;	Crystal structure of the N-terminal domain of CEACAM7
4Y88	;	1.45	;	Crystal structure of the N-terminal domain of CEACAM8
7O06	;	1.6	;	Crystal structure of the N-terminal domain of CEP164(1-109) bound to camelid nanobody 10Z
7O0S	;	1.7	;	Crystal structure of the N-terminal domain of CEP164(1-109) bound to camelid nanobody 36Z
2OQB	;	1.69	;	Crystal structure of the N-terminal domain of coactivator-associated methyltransferase 1 (CARM1)
8EI1	;	2.89	;	Crystal structure of the N-terminal domain of CUL4B in complex with H316, a Helicon Polypeptide
8EI2	;	2.8	;	Crystal structure of the N-terminal domain of CUL5 in complex with H314, a Helicon Polypeptide
3H9W	;	1.9	;	Crystal Structure of the N-terminal domain of Diguanylate cyclase with PAS/PAC sensor (Maqu_2914) from Marinobacter aquaeolei, Northeast Structural Genomics Consortium Target MqR66C
3NZL	;	1.199	;	Crystal Structure of the N-terminal domain of DNA-binding protein SATB1 from Homo sapiens, Northeast Structural Genomics Consortium Target HR4435B
2R5U	;	1.9	;	Crystal structure of the N-terminal domain of DnaB helicase from Mycobacterium tuberculosis
2V79	;	2.0	;	Crystal Structure of the N-terminal domain of DnaD from Bacillus Subtilis
2VN2	;	2.3	;	Crystal structure of the N-terminal domain of DnaD protein from Geobacillus kaustophilus HTA426
4ARN	;	2.41	;	Crystal structure of the N-terminal domain of Drosophila Toll receptor
4ARR	;	3.0	;	Crystal structure of the N-terminal domain of Drosophila Toll receptor with the magic triangle I3C
3NKU	;	2.1	;	Crystal structure of the N-terminal domain of DrrA/SidM from Legionella pneumophila
2FPS	;	2.2	;	Crystal structure of the N-terminal domain of E.coli HisB- Apo Ca model.
2FPU	;	1.8	;	Crystal Structure of the N-terminal domain of E.coli HisB- Complex with histidinol
2FPW	;	1.75	;	Crystal Structure of the N-terminal Domain of E.coli HisB- Phosphoaspartate intermediate.
2FPX	;	1.8	;	Crystal Structure of the N-terminal Domain of E.coli HisB- Sulfate complex.
2WZ7	;	2.48	;	Crystal structure of the N-terminal domain of E.coli YbgF
2XDJ	;	1.82	;	Crystal structure of the N-terminal domain of E.coli YbgF
4MU6	;	2.082	;	Crystal Structure of the N-terminal domain of Effector Protein LegC3 from Legionella pneumophila
5T39	;	1.1004	;	Crystal Structure of the N-terminal domain of EvdMO1 in the presence of SAH and D-fucose
5T38	;	1.1502	;	Crystal Structure of the N-terminal domain of EvdMO1 with SAH bound
6PON	;	2.395	;	CRYSTAL STRUCTURE OF THE N-TERMINAL DOMAIN OF FIBRONECTIN- BINDING PROTEIN PAVA FROM STREPTOCOCCUS PNEUMONIAE
1YWM	;	1.86	;	Crystal structure of the N-terminal domain of group B Streptococcus alpha C protein
5B52	;	2.3	;	Crystal structure of the N-terminal domain of H-NS family protein TurB
8H8H	;	2.7	;	Crystal structure of the N-terminal domain of H-NS family protein TurB (TurB_nt50)
4FI5	;	2.2	;	Crystal structure of the N-terminal domain of Hantaan virus strain 76-118 nucleoprotein
4G0H	;	3.6	;	Crystal structure of the N-terminal domain of Helicobacter pylori CagA protein
4INB	;	1.8	;	Crystal Structure of the N-Terminal Domain of HIV-1 Capsid in Complex With benzodiazepine Inhibitor
4E91	;	1.7	;	Crystal Structure of the N-Terminal Domain of HIV-1 Capsid in Complex With Inhibitor BD3
4J93	;	1.74	;	Crystal Structure of the N-Terminal Domain of HIV-1 Capsid in Complex With Inhibitor BI-1
4E92	;	1.8	;	Crystal Structure of the N-Terminal Domain of HIV-1 Capsid in Complex With Inhibitor BM4
3L4I	;	2.2	;	CRYSTAL STRUCTURE OF THE N-TERMINAL DOMAIN OF HSP70 (CGD2_20) FROM Cryptosporidium PARVUM IN COMPLEX WITH ADP and inorganic phosphate
3KVG	;	2.15	;	Crystal structure of the N-terminal domain of Hsp70 (cgd2_20) from Cryptosporidium parvum in complex with AMPPNP
3L6Q	;	2.29	;	Crystal structure of the N-terminal domain of HSP70 from Cryptosporidium parvum (CGD2_20)
3U67	;	1.77	;	Crystal structure of the N-terminal domain of Hsp90 from Leishmania major(LmjF33.0312)in complex with ADP
6JS9	;	2.0	;	Crystal structure of the N-terminal domain of HtaA from Corynebacterium glutamicum
2IOR	;	1.65	;	Crystal Structure of the N-terminal Domain of HtpG, the Escherichia coli Hsp90, Bound to ADP
1WRL	;	2.6	;	Crystal structure of the N-terminal domain of human cardiac troponin C in complex with trifluoperazine (monoclinic crystal form)
1WRK	;	2.15	;	Crystal structure of the N-terminal domain of human cardiac troponin C in complex with trifluoperazine (orthrombic crystal form)
4A64	;	2.57	;	Crystal structure of the N-terminal domain of human Cul4B at 2.57A resolution
1N1A	;	2.4	;	Crystal Structure of the N-terminal domain of human FKBP52
4XZP	;	1.48	;	Crystal structure of the N-terminal domain of human galectin-4
7C3Y	;	1.632	;	Crystal structure of the N-terminal domain of human MdmX protein in complex with Nutlin3a
6B91	;	1.94	;	Crystal structure of the N-terminal domain of human METTL16
6B92	;	2.1	;	Crystal Structure of the N-terminal domain of human METTL16 in complex with SAH
3FXT	;	2.3	;	Crystal structure of the N-terminal domain of human NUDT6
4PCW	;	2.2	;	Crystal Structure of the N-terminal Domain of Human Profilaggrin at 2.2 A Resolution
1YA0	;	2.55	;	Crystal structure of the N-terminal domain of human SMG7
3O2T	;	1.4	;	Crystal structure of the N-terminal domain of human Symplekin
3ODR	;	2.2	;	Crystal Structure of the N-terminal Domain of Human Symplekin
5MQI	;	1.847	;	Crystal structure of the N-terminal domain of human Timeless
1T6N	;	1.94	;	Crystal structure of the N-terminal domain of human UAP56
4RXX	;	2.06	;	Crystal Structure of the N-terminal Domain of Human Ubiquitin Specific Protease 38
2BTL	;	1.95	;	Crystal structure of the N-terminal domain of IBV coronavirus nucleocapsid
2BXX	;	1.85	;	Crystal structure of the N-terminal domain of IBV coronavirus nucleocapsid. Native crystal form
6RJX	;	2.35	;	Crystal structure of the N-terminal domain of Lyme disease agent Borrelia burgdorferi major virulence factor BB0323 (native data)
6RJW	;	2.85	;	Crystal structure of the N-terminal domain of Lyme disease agent Borrelia burgdorferi major virulence factor BB0323 (Se-Met data)
3NNQ	;	2.693	;	Crystal Structure of the N-terminal domain of Moloney murine leukemia virus integrase, Northeast Structural Genomics Consortium Target OR3
4NZG	;	2.152	;	Crystal Structure of the N-terminal domain of Moloney murine leukemia virus integrase, Northeast Structural Genomics Consortium Target OR3
2DYC	;	2.4	;	Crystal structure of the N-terminal domain of mouse galectin-4
1QHL	;	2.2	;	CRYSTAL STRUCTURE OF THE N-TERMINAL DOMAIN OF MUKB AT 2.2A RESOLUTION
7FCR	;	1.4	;	Crystal structure of the N-terminal domain of mutants of Human Apolipoprotein-E (ApoE)
7FCS	;	1.6	;	Crystal structure of the N-terminal domain of mutants of Human Apolipoprotein-E (ApoE)
1XIP	;	2.5	;	Crystal Structure of the N-terminal Domain of Nup159
7MNO	;	6.73	;	Crystal structure of the N-terminal domain of NUP358/RanBP2 (residues 1-752) I656V mutant in complex with Fab fragment
7MNL	;	3.95	;	Crystal structure of the N-terminal domain of NUP358/RanBP2 (residues 1-752) in complex with Fab fragment
7MNM	;	4.7	;	Crystal structure of the N-terminal domain of NUP358/RanBP2 (residues 1-752) T585M mutant in complex with Fab fragment
7MNN	;	6.7	;	Crystal structure of the N-terminal domain of NUP358/RanBP2 (residues 1-752) T653I mutant in complex with Fab fragment
7MNJ	;	3.8	;	Crystal structure of the N-terminal domain of NUP358/RanBP2 (residues 145-673)
7MNI	;	2.0	;	Crystal structure of the N-terminal domain of NUP88 in complex with NUP98 C-terminal Autoproteolytic Domain
3EWG	;	2.04	;	Crystal structure of the N-terminal domain of NusG (NGN) from Methanocaldococcus jannaschii
1K8G	;	2.6	;	Crystal Structure of the N-terminal domain of Oxytricha nova telomere end binding protein alpha subunit both uncomplexed and complexed with telomeric ssDNA
4NAC	;	2.002	;	Crystal Structure of the N-terminal Domain of p15RS
3NRW	;	1.7	;	Crystal Structure of the N-terminal domain of Phage integrase/site-specific recombinase (tnp) from Haloarcula marismortui, Northeast Structural Genomics Consortium Target HmR208A
2H30	;	1.6	;	Crystal structure of the N-terminal domain of PilB from Neisseria gonorrhoeae
5OE6	;	1.67	;	Crystal structure of the N-terminal domain of PqsA in complex with 6-fluoroanthraniloyl-AMP (crystal form 1)
5OE3	;	1.43	;	Crystal structure of the N-terminal domain of PqsA in complex with anthraniloyl-AMP (crystal form 1)
5OE4	;	1.904	;	Crystal structure of the N-terminal domain of PqsA in complex with anthraniloyl-AMP (crystal form 2)
5OE5	;	1.74	;	Crystal structure of the N-terminal domain of PqsA in complex with anthraniloyl-AMP (crystal form 3)
1VEC	;	2.01	;	Crystal structure of the N-terminal domain of rck/p54, a human DEAD-box protein
3WRW	;	2.71	;	Crystal structure of the N-terminal domain of resistance protein
3C3M	;	1.7	;	Crystal structure of the N-terminal domain of response regulator receiver protein from Methanoculleus marisnigri JR1
2HBB	;	1.9	;	Crystal Structure of the N-terminal Domain of Ribosomal Protein L9 (NTL9)
7Q0I	;	2.39	;	Crystal structure of the N-terminal domain of SARS-CoV-2 beta variant spike glycoprotein in complex with Beta-43
7VNU	;	1.95	;	Crystal structure of the N-terminal domain of SARS-CoV-2 nucleocapsid protein
6IVH	;	2.5	;	Crystal structure of the N-terminal domain of ScpA derived from Thermococcus onnurineus
7QU6	;	2.34	;	Crystal structure of the N-terminal domain of Siglec-8
7QUI	;	3.352	;	Crystal structure of the N-terminal domain of Siglec-8 in complex with sulfonamide sialoside analogue
3X37	;	2.35	;	Crystal structure of the N-terminal domain of Sld7 in complex with Sld3
5XGT	;	1.82	;	Crystal structure of the N-terminal domain of Staphylococcus aureus single-stranded DNA-binding protein SsbA at 1.82 angstrom resolution
3LPO	;	3.2	;	Crystal structure of the N-terminal domain of sucrase-isomaltase
7DD0	;	2.7	;	Crystal structure of the N-terminal domain of TagH from Bacillus subtilis
3BV8	;	1.75	;	Crystal structure of the N-terminal domain of tetrahydrodipicolinate acetyltransferase from Staphylococcus aureus
6O59	;	2.79	;	Crystal structure of the N-terminal domain of the A subunit of the Bacillus megaterium spore germinant receptor GerK3
8SMQ	;	2.0	;	Crystal Structure of the N-terminal Domain of the Cryptic Surface Protein (CD630_25440) from Clostridium difficile.
5HD9	;	1.941	;	Crystal Structure of the N-terminal domain of the DNA packaging ATPase from bacteriophage phi29
3QWE	;	2.4	;	Crystal structure of the N-terminal domain of the GEM interacting protein
4A4D	;	2.7	;	Crystal structure of the N-terminal domain of the Human DEAD-BOX RNA helicase DDX5 (P68)
4XTB	;	1.5	;	Crystal structure of the N-terminal domain of the human mitochondrial calcium uniporter
4XSJ	;	1.8	;	Crystal structure of the N-terminal domain of the human mitochondrial calcium uniporter fused with T4 lysozyme
2OIT	;	1.65	;	Crystal Structure of the N-terminal Domain of the Human Proto-oncogene Nup214/CAN
4OOJ	;	2.4	;	Crystal structure of the N-terminal domain of the Legionella pneumophila protein SidC at 2.4A resolution
4FWV	;	2.4	;	Crystal structure of the N-terminal domain of the Lon-like protease MtaLonC
3JSB	;	2.13	;	Crystal structure of the N-terminal domain of the Lymphocytic Choriomeningitis Virus L protein
4G7W	;	2.9	;	Crystal structure of the N-terminal domain of the minor coat protein pIII from CTXphi
4CGS	;	1.3	;	Crystal structure of the N-terminal domain of the PA subunit of Dhori virus polymerase
4CGX	;	2.7	;	Crystal structure of the N-terminal domain of the PA subunit of Thogoto virus polymerase (form 1)
4CHC	;	2.77	;	Crystal structure of the N-terminal domain of the PA subunit of Thogoto virus polymerase (form 2)
7T85	;	2.0	;	Crystal Structure of the N-terminal Domain of the Phosphate Acetyltransferase from Escherichia coli
3LYS	;	2.8	;	Crystal Structure of the N-terminal domain of the Prophage pi2 protein 01 (integrase) from Lactococcus lactis, Northeast Structural Genomics Consortium Target KR124F
3EZJ	;	2.8	;	Crystal structure of the N-terminal domain of the secretin GspD from ETEC determined with the assistance of a nanobody
4E9J	;	2.03	;	Crystal structure of the N-terminal domain of the secretin XcpQ from Pseudomonas aeruginosa
4IGB	;	2.09	;	Crystal structure of the N-terminal domain of the Streptococcus gordonii adhesin Sgo0707
1HUF	;	2.0	;	CRYSTAL STRUCTURE OF THE N-TERMINAL DOMAIN OF THE TYROSINE PHOSPHATASE YOPH FROM YERSINIA PESTIS.
6S9Y	;	1.64	;	Crystal structure of the N-terminal domain of the wild type parasitic PEX14
3VP8	;	1.91	;	Crystal structure of the N-terminal domain of the yeast general corepressor Tup1p
3VP9	;	1.799	;	Crystal structure of the N-terminal domain of the yeast general corepressor Tup1p mutant
3NWS	;	2.5	;	Crystal structure of the N-terminal domain of the yeast telomere-binding and telomerase regulatory protein Cdc13
3NWT	;	2.7	;	Crystal structure of the N-terminal domain of the yeast telomere-binding and telomerase regulatory protein Cdc13
3HCS	;	2.2	;	Crystal structure of the N-terminal domain of TRAF6
8AXJ	;	1.0	;	Crystal structure of the N-terminal domain of Trypanosoma brucei CFAP410
4GFX	;	1.6	;	Crystal structure of the N-terminal domain of TXNIP
2QY6	;	2.0	;	Crystal structure of the N-terminal domain of UPF0209 protein yfcK from Escherichia coli O157:H7
1YZE	;	2.0	;	Crystal structure of the N-terminal domain of USP7/HAUSP.
5EZU	;	1.55	;	Crystal structure of the N-terminal domain of vaccinia virus immunomodulator A46 in complex with myristic acid.
8Q0E	;	3.15	;	Crystal Structure of the N-terminal Domain of Variant Surface Glycoprotein 545 (VSG545) of Trypanosome brucei brucei Lister 427
6KVX	;	2.85	;	Crystal structure of the N-terminal domain single mutant (D119A) of the human mitochondrial calcium uniporter fused with T4 lysozyme
5BZ6	;	2.75	;	Crystal structure of the N-terminal domain single mutant (S92A) of the human mitochondrial calcium uniporter fused with T4 lysozyme
6JG0	;	2.5	;	Crystal structure of the N-terminal domain single mutant (S92E) of the human mitochondrial calcium uniporter fused with T4 lysozyme
1G3P	;	1.46	;	CRYSTAL STRUCTURE OF THE N-TERMINAL DOMAINS OF BACTERIOPHAGE MINOR COAT PROTEIN G3P
4OYU	;	1.8	;	Crystal structure of the N-terminal domains of muskelin
3JYU	;	2.37	;	Crystal structure of the N-terminal domains of the ubiquitin specific peptidase 4 (USP4)
2Z13	;	1.84	;	Crystal structure of the N-terminal DUF1126 in human EF-hand domain
2Z14	;	1.68	;	Crystal structure of the N-terminal DUF1126 in human ef-hand domain containing 2 protein
6YIG	;	1.55	;	Crystal structure of the N-terminal EF-hand domain of Arabidopsis thaliana AtEH1/Pan1
3G9G	;	2.4	;	Crystal Structure of the N-terminal EFC/F-BAR domain of Syp1
7PLR	;	2.64	;	Crystal structure of the N-terminal endonuclease domain of La Crosse virus L-protein bound to compound Baloxavir
7OA4	;	2.9	;	Crystal structure of the N-terminal endonuclease domain of La Crosse virus L-protein bound to compound L-742,001
4LU4	;	2.0	;	Crystal Structure of the N-terminal Fic Domain of a Putative Cell Filamentation protein (VirB-translocated Bep effector protein) from Bartonella quintana
4N67	;	1.55	;	Crystal Structure of the N-terminal Fic Domain of a Putative Cell Filamentation protein (VirB-translocated Bep effector protein) with bound ADP from Bartonella quintana
4M16	;	1.85	;	Crystal Structure of the N-terminal Fic Domain of Bartonella effector protein (Bep); substrate of VirB T4SS (VirB-translocated Bep effector protein) from Bartonella sp. AR 15-3
4PY3	;	2.35	;	Crystal Structure of the N-terminal FIC domain of Bep8 protein (VirB-translocated Bartonella effector protein) from Bartonella sp. 1-1C
3HMT	;	2.0	;	Crystal structure of the N-terminal fragment (28-126) of the human hepatocyte growth factor/scatter factor, trigonal crystal form
3HMR	;	2.0	;	Crystal structure of the N-terminal fragment (31-127) of the mouse hepatocyte growth factor/scatter factor
7CR9	;	2.095	;	Crystal structure of the N-terminal fragment (residue 1-206) of LonA protease from Meiothermus taiwanensis
7CRA	;	1.7	;	Crystal structure of the N-terminal fragment (residue 1-291) of LonA protease from Meiothermus taiwanensis
3VGO	;	3.1	;	Crystal structure of the N-terminal fragment of Cbl-b
5KHT	;	1.4964	;	Crystal structure of the N-terminal fragment of tropomyosin isoform Tpm1.1 at 1.5 A resolution
3V44	;	2.83	;	Crystal structure of the N-terminal fragment of zebrafish TLR5
3V47	;	2.47	;	Crystal structure of the N-terminal fragment of zebrafish TLR5 in complex with Salmonella flagellin
1F5F	;	1.7	;	CRYSTAL STRUCTURE OF THE N-TERMINAL G-DOMAIN OF SHBG IN COMPLEX WITH ZINC
2FZ4	;	2.4	;	Crystal Structure of the N-terminal half of Archaeoglobus Fulgidus XPB
6TRU	;	2.8	;	Crystal structure of the N-terminal half of the TFIIH subunit p52
6RNZ	;	1.35	;	Crystal structure of the N-terminal HTH DNA-binding domain of the essential repressor DdrO from radiation-resistant Deinococcus bacteria (Deinococcus deserti)
2YD4	;	1.65	;	Crystal structure of the N-terminal Ig1-2 module of Chicken Receptor Protein Tyrosine Phosphatase Sigma
2YD1	;	1.8	;	Crystal structure of the N-terminal Ig1-2 module of Drosophila Receptor Protein Tyrosine Phosphatase DLAR
2YD6	;	1.35	;	Crystal structure of the N-terminal Ig1-2 module of Human Receptor Protein Tyrosine Phosphatase Delta
2YD7	;	1.98	;	Crystal structure of the N-terminal Ig1-2 module of Human Receptor Protein Tyrosine Phosphatase Delta
2YD5	;	2.2	;	Crystal structure of the N-terminal Ig1-2 module of Human Receptor Protein Tyrosine Phosphatase LAR
2YD8	;	2.05	;	Crystal structure of the N-terminal Ig1-2 module of Human Receptor Protein Tyrosine Phosphatase LAR in complex with sucrose octasulphate
2YD2	;	2.552	;	Crystal structure of the N-terminal Ig1-2 module of Human Receptor Protein Tyrosine Phosphatase Sigma
2YD3	;	2.3	;	Crystal structure of the N-terminal Ig1-2 module of Human Receptor Protein Tyrosine Phosphatase Sigma
2YD9	;	2.6	;	Crystal structure of the N-terminal Ig1-3 module of Human Receptor Protein Tyrosine Phosphatase Sigma
6GY4	;	1.986	;	Crystal structure of the N-terminal KH domain of human BICC1
2Z7Q	;	2.0	;	Crystal structure of the N-terminal kinase domain of human RSK-1 bound to AMP-PCP
2Z7S	;	2.1	;	Crystal Structure of the N-terminal Kinase Domain of Human RSK1 bound to Purvalnol A
2Z7R	;	2.0	;	Crystal Structure of the N-terminal Kinase Domain of Human RSK1 bound to Staurosporine
8EQ5	;	1.8	;	Crystal structure of the N-terminal kinase domain of RSK2 in complex with SPRED2 (131-160)
3HYJ	;	2.6	;	Crystal structure of the N-terminal LAGLIDADG domain of DUF199/WhiA
1D2S	;	1.55	;	CRYSTAL STRUCTURE OF THE N-TERMINAL LAMININ G-LIKE DOMAIN OF SHBG IN COMPLEX WITH DIHYDROTESTOSTERONE
3ZYO	;	3.1	;	Crystal structure of the N-terminal leucine rich repeats and immunoglobulin domain of netrin-G ligand-3
3ZYN	;	3.2	;	Crystal structure of the N-terminal leucine rich repeats of Netrin-G Ligand-3
1LHW	;	1.75	;	CRYSTAL STRUCTURE OF THE N-TERMINAL LG-DOMAIN OF SHBG IN COMPLEX WITH 2-METHOXYESTRADIOL
1LHN	;	2.0	;	CRYSTAL STRUCTURE OF THE N-TERMINAL LG-DOMAIN OF SHBG IN COMPLEX WITH 5ALPHA-ANDROSTANE-3BETA,17ALPHA-DIOL
1LHO	;	2.0	;	CRYSTAL STRUCTURE OF THE N-TERMINAL LG-DOMAIN OF SHBG IN COMPLEX WITH 5ALPHA-ANDROSTANE-3BETA,17BETA-DIOL
1LHU	;	1.8	;	CRYSTAL STRUCTURE OF THE N-TERMINAL LG-DOMAIN OF SHBG IN COMPLEX WITH ESTRADIOL
1LHV	;	2.0	;	CRYSTAL STRUCTURE OF THE N-TERMINAL LG-DOMAIN OF SHBG IN COMPLEX WITH NORGESTREL
4UZ2	;	2.5	;	Crystal structure of the N-terminal LysM domains from the putative NlpC/P60 D,L endopeptidase from T. thermophilus
4UZ3	;	1.75	;	Crystal structure of the N-terminal LysM domains from the putative NlpC/P60 D,L endopeptidase from T. thermophilus bound to N-acetyl-chitohexaose
2BAP	;	3.3	;	Crystal structure of the N-terminal mDia1 Armadillo Repeat Region and Dimerisation Domain in complex with the mDia1 autoregulatory domain (DAD)
4M7R	;	1.801	;	Crystal structure of the N-terminal methyltransferase-like domain of anamorsin
5J63	;	2.5	;	Crystal Structure of the N-terminal N-formyltransferase Domain (residues 1-306) of Escherichia coli Arna in Complex with UDP-Ara4N and Folinic Acid
8ARF	;	2.8	;	Crystal structure of the N-terminal parallel dimeric coiled-coil region of the human kinetochore associated protein Spindly
2RA1	;	2.406	;	Crystal structure of the N-terminal part of the bacterial S-layer protein SbsC
6Y7Q	;	1.39	;	Crystal Structure of the N-terminal PAS domain from the hERG3 Potassium Channel
1IHJ	;	1.8	;	Crystal Structure of the N-terminal PDZ domain of InaD in complex with a NorpA C-terminal peptide
3B79	;	1.37	;	Crystal structure of the N-terminal peptidase C39 like domain of the toxin secretion ATP-binding protein from Vibrio parahaemolyticus
6C29	;	1.538	;	Crystal structure of the N-terminal periplasmic domain of ScsB from Proteus mirabilis
1WRB	;	2.4	;	Crystal structure of the N-terminal RecA-like domain of DjVLGB, a pranarian Vasa-like RNA helicase
2R8R	;	2.3	;	Crystal structure of the N-terminal region (19..243) of sensor protein KdpD from Pseudomonas syringae pv. tomato str. DC3000
3F31	;	2.3	;	Crystal Structure of the N-terminal region of AlphaII-spectrin Tetramerization Domain
3RSN	;	2.1	;	Crystal Structure of the N-terminal region of Human Ash2L
6QB5	;	2.02	;	Crystal structure of the N-terminal region of human cohesin subunit STAG1
6RRC	;	2.37	;	Crystal structure of the N-terminal region of human cohesin subunit STAG1 in complex with RAD21 peptide
5EN8	;	2.23	;	Crystal structure of the N-terminal region of Smu1
2JKU	;	1.5	;	Crystal structure of the N-terminal region of the biotin acceptor domain of human propionyl-CoA carboxylase
4JKQ	;	2.39	;	Crystal structure of the N-terminal region of the human ryanodine receptor 2
3BAS	;	2.3	;	Crystal structure of the N-terminal region of the scallop myosin rod, monoclinic (C2) form
3BAT	;	2.3	;	Crystal structure of the N-terminal region of the scallop myosin rod, monoclinic (P21) form
3OLC	;	2.4	;	Crystal structure of the N-terminal region of TopBP1
3DAD	;	2.3	;	Crystal structure of the N-terminal regulatory domains of the formin FHOD1
5BJR	;	2.6	;	Crystal structure of the N-terminal RRM domain from MEC-8
2HZC	;	1.47	;	Crystal structure of the N-terminal RRM of the U2AF large subunit
1KL9	;	1.9	;	Crystal structure of the N-terminal segment of Human eukaryotic initiation factor 2alpha
2DX0	;	2.5	;	Crystal structure of the N-terminal SH2 domain of mouse phospholipase C-gamma 2
2QR3	;	1.8	;	Crystal structure of the N-terminal signal receiver domain of two-component system response regulator from Bacteroides fragilis
2WFR	;	1.95	;	Crystal structure of the N-terminal signalling domain of human Dhh with calcium
2WFQ	;	1.85	;	Crystal structure of the N-terminal signalling domain of human Dhh without calcium
7X8U	;	2.89	;	Crystal structure of the N-terminal Solanaceae domain of the Sw-5b NLR immune receptor
7CSX	;	2.5	;	Crystal structure of the N-terminal tandem RRM domains of RBM45
7CSZ	;	1.8	;	Crystal structure of the N-terminal tandem RRM domains of RBM45 in complex with single-stranded DNA
6X61	;	3.2	;	Crystal structure of the N-terminal thioredoxin domain of SasA in complex with the N-terminal CI domain of KaiC from Thermosynchococcus elongatus
2XOA	;	2.5	;	Crystal Structure of the N-terminal three domains of the skeletal muscle Ryanodine Receptor (RyR1)
1WM5	;	1.95	;	Crystal structure of the N-terminal TPR domain (1-203) of p67phox
4HP9	;	2.12	;	Crystal structure of the N-terminal truncated PAS domain from the hERG potassium channel
3W1I	;	3.192	;	Crystal structure of the N-terminal truncated selenocysteine synthase SelA
3W1J	;	3.252	;	Crystal structure of the N-terminal truncated selenocysteine synthase SelA in complex with thiosulfate
4I96	;	2.73	;	Crystal structure of the N-terminal two domains of the skeletal muscle ryanodine receptor (rabbit RyR1) residues 217-536
2A26	;	1.2	;	Crystal structure of the N-terminal, dimerization domain of Siah Interacting Protein
4JFN	;	1.75	;	Crystal structure of the N-terminal, growth factor-like domain of the amyloid precursor protein bound to copper
4LD9	;	3.306	;	Crystal structure of the N-terminally acetylated BAH domain of Sir3 bound to the nucleosome core particle
5J4F	;	1.4	;	Crystal structure of the N-terminally His6-tagged HP0902, an uncharacterized protein from Helicobacter pylori 26695
2GKR	;	1.16	;	Crystal structure of the N-terminally truncated OMTKY3-del(1-5)
5HEM	;	1.65	;	Crystal structure of the N-terminus D161Y bromodomain mutant of human BRD2
7EQ4	;	1.25	;	Crystal Structure of the N-terminus of Nonstructural protein 1 from SARS-CoV-2
2A38	;	2.0	;	Crystal structure of the N-Terminus of titin
5HEN	;	1.79	;	Crystal structure of the N-terminus R100L bromodomain mutant of human BRD2
5HEL	;	1.45	;	Crystal structure of the N-terminus Y153H bromodomain mutant of human BRD2
5IZ2	;	2.02	;	Crystal structure of the N. clavipes spidroin NTD at pH 6.5
2XDY	;	2.2	;	Crystal structure of the N. crassa QDE-2 AGO MID domain
2YHA	;	1.85	;	Crystal Structure of the N. crassa QDE-2 AGO MID-PIWI Domains
2YHB	;	3.65	;	Crystal Structure of the N. crassa QDE-2 AGO MID-PIWI Domains
6DZX	;	1.678	;	Crystal structure of the N. meningitides methionine-binding protein in its D-methionine bound conformation.
6OJA	;	1.55	;	Crystal structure of the N. meningitides methionine-binding protein in its L-methionine bound conformation
6CVA	;	1.559	;	Crystal structure of the N. meningitides methionine-binding protein in its substrate-free conformation
6YT4	;	2.4	;	Crystal structure of the N112A mutant of the light-driven sodium pump KR2 in the pentameric form, pH 8.0
4JJD	;	1.6	;	Crystal structure of the N114A Abl-SH3 domain mutant at pH4
3EG3	;	1.4	;	Crystal structure of the N114A mutant of ABL-SH3 domain
3EGU	;	2.25	;	Crystal structure of the N114A mutant of ABL-SH3 domain
2O88	;	1.75	;	Crystal structure of the N114A mutant of ABL-SH3 domain complexed with a designed high-affinity peptide ligand: implications for SH3-ligand interactions
4J9D	;	1.5	;	Crystal structure of the N114A mutant of the Abl-SH3 domain complexed with the high affinity peptide P0
4J9E	;	1.4	;	Crystal structure of the N114A mutant of the Abl-SH3 domain complexed with the high affinity peptide P17
3EG2	;	1.8	;	Crystal structure of the N114Q mutant of ABL-SH3 domain
3EG1	;	1.85	;	Crystal structure of the N114Q mutant of ABL-SH3 domain complexed with a designed high-affinity peptide ligand: implications for SH3-ligand interactions
3EG0	;	2.3	;	Crystal structure of the N114T mutant of ABL-SH3 domain
1EOF	;	2.38	;	CRYSTAL STRUCTURE OF THE N136A MUTANT OF A SHAKER T1 DOMAIN
1EOD	;	2.45	;	CRYSTAL STRUCTURE OF THE N136D MUTANT OF A SHAKER T1 DOMAIN
3PPX	;	1.91	;	Crystal structure of the N1602A mutant of an engineered VWF A2 domain (N1493C and C1670S)
1N29	;	2.6	;	Crystal structure of the N1A mutant of human group IIA phospholipase A2
1M75	;	2.3	;	Crystal Structure of the N208S Mutant of L-3-Hydroxyacyl-COA Dehydrogenase in Complex with NAD and Acetoacetyl-COA
6EJ6	;	1.65	;	Crystal structure of the N240A mutant of Candida albicans Mep2
4FTS	;	3.2	;	Crystal structure of the N363T mutant of the Flock House virus capsid
3IN2	;	2.6	;	Crystal structure of the N47S/M121L variant of Pseudomonas aeruginosa azurin in the Cu(II) state
7NX9	;	2.4	;	Crystal structure of the N501Y mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and EY6A Fabs
7NEG	;	2.19	;	Crystal structure of the N501Y mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-269 Fab
3QPZ	;	1.75	;	Crystal structure of the N59A mutant of the 3-deoxy-d-manno-octulosonate 8-phosphate synthase (KDO8PS) from Neisseria meningitidis
7D91	;	3.35	;	Crystal Structure of the Na+,K+-ATPase in the E2P state with bound Mg2+ (P4(3)2(1)2 symmetry)
7D93	;	3.65	;	Crystal Structure of the Na+,K+-ATPase in the E2P state with bound Mg2+ and anthroylouabain (P2(1)2(1)2(1) symmetry)
7D92	;	3.9	;	Crystal Structure of the Na+,K+-ATPase in the E2P state with bound Mg2+ and anthroylouabain (P4(3)2(1)2 symmetry)
7D94	;	3.5	;	Crystal Structure of the Na+,K+-ATPase in the E2P state with bound one Mg2+ and one Rb+ in the presence of bufalin
1ZCD	;	3.45	;	Crystal structure of the Na+/H+ antiporter NhaA
7S24	;	2.2	;	Crystal structure of the Na+/H+ antiporter NhaA at pH 6.5
4RES	;	3.408	;	Crystal structure of the Na,K-ATPase E2P-bufalin complex with bound potassium
4RET	;	4.0	;	Crystal structure of the Na,K-ATPase E2P-digoxin complex with bound magnesium
4XE5	;	3.901	;	Crystal structure of the Na,K-ATPase from bovine
3MCE	;	2.396	;	Crystal structure of the NAC domain of alpha subunit of nascent polypeptide-associated complex(NAC)
1DHS	;	2.2	;	CRYSTAL STRUCTURE OF THE NAD COMPLEX OF HUMAN DEOXYHYPUSINE SYNTHASE
1P1I	;	2.4	;	Crystal structure of the NAD+-bound 1L-myo-inositol 1-phosphate synthase
1EE9	;	3.0	;	CRYSTAL STRUCTURE OF THE NAD-DEPENDENT 5,10-METHYLENETETRAHYDROFOLATE DEHYDROGENASE FROM SACCHAROMYCES CEREVISIAE COMPLEXED WITH NAD
1PS0	;	3.01	;	Crystal Structure of the NADP(H)-Dependent Cinnamyl Alcohol Dehydrogenase from Saccharomyces cerevisiae
1P0C	;	2.2	;	Crystal Structure of the NADP(H)-Dependent Vertebrate Alcohol Dehydrogenase (ADH8)
8HI5	;	2.3	;	Crystal structure of the NADP+ and MSA bound C terminal domain of bi-functional malonyl-CoA reductase from Roseiflexus castenholzii
8HI6	;	2.0	;	Crystal structure of the NADP+ and MSA bound N terminal domain of bi-functional malonyl-CoA reductase from Roseiflexus castenholzii
5XVH	;	1.57	;	Crystal structure of the NADP+ and tartrate-bound complex of L-serine 3-dehydrogenase from the hyperthermophilic archaeon Pyrobaculum calidifontis
1EYY	;	2.5	;	CRYSTAL STRUCTURE OF THE NADP+ DEPENDENT ALDEHYDE DEHYDROGENASE FROM VIBRIO HARVEYI.
1EZ0	;	2.1	;	CRYSTAL STRUCTURE OF THE NADP+ DEPENDENT ALDEHYDE DEHYDROGENASE FROM VIBRIO HARVEYI.
2QTZ	;	1.9	;	Crystal Structure of the NADP+-bound FAD-containing FNR-like Module of Human Methionine Synthase Reductase
3GDF	;	2.5	;	Crystal structure of the NADP-dependent mannitol dehydrogenase from Cladosporium herbarum.
3GDG	;	2.3	;	Crystal structure of the NADP-dependent mannitol dehydrogenase from Cladosporium herbarum.
4BV9	;	2.193	;	Crystal structure of the NADPH form of mouse Mu-crystallin.
4BVA	;	1.75	;	Crystal structure of the NADPH-T3 form of mouse Mu-crystallin.
2C4C	;	2.9	;	Crystal structure of the NADPH-treated monooxygenase domain of MICAL
2VW0	;	2.3	;	Crystal structure of the NanB sialidase from Streptococcus pneumoniae
2VW1	;	2.39	;	Crystal structure of the NanB sialidase from Streptococcus pneumoniae
2VW2	;	1.7	;	Crystal structure of the NanB sialidase from Streptococcus pneumoniae
4FOY	;	1.843	;	Crystal structure of the NanB sialidase from streptococcus pneumoniae in complex with 2-(Benzylammonio)ethanesulfonate
4FOQ	;	1.99	;	Crystal structure of the NanB sialidase from streptococcus pneumoniae in complex with 2-aminoethanesulfonic acid
4FPL	;	2.1	;	Crystal structure of the NanB sialidase from streptococcus pneumoniae in complex with 2-[(3,4-dichlorobenzyl)ammonio]ethanesulfonate
4FPY	;	2.18	;	Crystal structure of the NanB sialidase from streptococcus pneumoniae in complex with 2-[(3-Bromobenzyl)ammonio]ethanesulfonate
4FPO	;	2.591	;	Crystal structure of the NanB sialidase from streptococcus pneumoniae in complex with 2-[(3-chloro-4-methoxybenzyl)ammonio]ethanesulfonate
4FPF	;	2.23	;	Crystal structure of the NanB sialidase from streptococcus pneumoniae in complex with 2-[(3-Chlorobenzyl)ammonio]ethanesulfonate
4FPH	;	1.938	;	Crystal structure of the NanB sialidase from streptococcus pneumoniae in complex with 2-[(3-Fluorobenzyl)ammonio]ethanesulfonate
4FPG	;	2.576	;	Crystal structure of the NanB sialidase from streptococcus pneumoniae in complex with 2-[(3-Hydroxybenzyl)ammonio]ethanesulfonate
4FPJ	;	1.981	;	Crystal structure of the NanB sialidase from streptococcus pneumoniae in complex with 2-[(3-Methoxybenzyl)ammonio]ethanesulfonate
4FPK	;	2.4	;	Crystal structure of the NanB sialidase from streptococcus pneumoniae in complex with 2-[(3-methylbenzyl)ammonio]ethanesulfonate
4FPC	;	2.32	;	Crystal structure of the NanB sialidase from streptococcus pneumoniae in complex with 2-[(4-Chlorobenzyl)ammonio]ethanesulfonate
4FQ4	;	1.843	;	Crystal structure of the NanB sialidase from streptococcus pneumoniae in complex with 2-[(4-Fluoro-3-methylbenzyl)ammonio]ethanesulfonate
4FPE	;	2.181	;	Crystal structure of the NanB sialidase from streptococcus pneumoniae in complex with 2-[(4-Methoxybenzyl)ammonio]ethanesulfonate
4FP3	;	2.743	;	Crystal structure of the NanB sialidase from streptococcus pneumoniae in complex with 2-[(Furan-2-ylmethyl)ammonio]sulfonate
4FP2	;	2.05	;	Crystal structure of the NanB sialidase from streptococcus pneumoniae in complex with 2[(Cyclohexylmethyl)ammonio]sulfonate
4FOW	;	2.1	;	Crystal structure of the NanB sialidase from streptococcus pneumoniae in complex with 3-ammoniopropane-1-sulfonate
4FOV	;	2.29	;	Crystal structure of the NanB sialidase from streptococcus pneumoniae in complex with 3-Cyclohexyl-1-propylsulfonic acid
4XJU	;	1.94	;	Crystal structure of the NanB sialidase from streptococcus pneumoniae in complex with 4-acetamido-2-fluoro-3-hydroxy-6-[1,2-dihydroxyethyl]-7,8-dioxabicyclo[3.2.1]octane-1-carboxylic acid
4XJA	;	1.98	;	Crystal structure of the NanB sialidase from streptococcus pneumoniae in complex with 5-acetamido-2,3-difluoro-3-hydroxy-6-[1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
4XE9	;	1.84	;	Crystal structure of the NanB sialidase from Streptococcus pneumoniae in complex with Optactin
4XHX	;	2.1	;	Crystal structure of the NanB sialidase from streptococcus pneumoniae in complex with Optactin and 2-[(3-Chlorobenzyl)ammonio]ethanesulfonate
4XOG	;	2.09	;	CRYSTAL STRUCTURE OF THE NANB SIALIDASE FROM STREPTOCOCCUS PNEUMONIAE IN COMPLEX WITH Optactin and DANA
4XJ9	;	1.98	;	Crystal structure of the NanB sialidase from streptococcus pneumoniae in complex with Optactin at pH 5.0 in 50mM Sodium Acetate with DMSO as the cryoprotectant
4XJW	;	1.53	;	Crystal structure of the NanB sialidase from streptococcus pneumoniae in complex with Optactin at pH 7.4 in PBS with DMSO as the cryoprotectant
4XIL	;	1.9	;	Crystal structure of the NanB sialidase from streptococcus pneumoniae in complex with Optactin at pH 7.4 in PBS with MPD as the cryoprotectant
4XHB	;	1.88	;	Crystal structure of the NanB sialidase from streptococcus pneumoniae in complex with pentanediol and CHES
3IF0	;	2.2	;	Crystal Structure of the Nanoarchaeum equitans tRNA splicing endonuclease structural subunit
2VI6	;	2.6	;	Crystal Structure of the Nanog Homeodomain
2HMN	;	1.7	;	Crystal Structure of the Naphthalene 1,2-Dioxygenase F352V Mutant Bound to Anthracene.
2HML	;	1.8	;	Crystal Structure of the Naphthalene 1,2-Dioxygenase F352V Mutant Bound to Phenanthrene.
2HMJ	;	1.5	;	Crystal Structure of the Naphthalene 1,2-Dioxygenase Phe-352-Val Mutant.
2VZM	;	1.85	;	Crystal structure of the narbomycin-bound PikC D50N mutant
2UWB	;	2.0	;	Crystal structure of the Nasturtium seedling mutant xyloglucanase isoform NXG1-delta-YNIIG
2UWA	;	1.8	;	Crystal structure of the Nasturtium seedling xyloglucanase isoform NXG1
6YGC	;	2.994	;	Crystal structure of the NatC complex bound to Arl3 peptide and CoA
6YGB	;	2.451	;	Crystal structure of the NatC complex bound to CoA
6YGD	;	2.752	;	Crystal structure of the NatC complex bound to Gag peptide and CoA
7Q1K	;	1.36	;	Crystal structure of the native AA9A LPMO from Thermoascus aurantiacus
4RQN	;	2.0	;	Crystal structure of the native BICC1 SAM Domain R924E mutant
1Z9S	;	2.2	;	Crystal Structure of the native chaperone:subunit:subunit Caf1M:Caf1:Caf1 complex
1Y54	;	2.1	;	Crystal structure of the native class C beta-lactamase from Enterobacter cloacae 908R complexed with BRL42715
1X7I	;	1.7	;	Crystal structure of the native copper homeostasis protein (cutCm) with calcium binding from Shigella flexneri 2a str. 301
2WKX	;	1.8	;	Crystal structure of the native E. coli zinc amidase AmiD
5A8N	;	2.05	;	Crystal structure of the native form of beta-glucanase SdGluc5_26A from Saccharophagus degradans
1VA0	;	1.97	;	Crystal Structure of the Native Form of Uroporphyrin III C-methyl transferase from Thermus thermophilus
2ARO	;	2.1	;	Crystal Structure Of The Native Histone Octamer To 2.1 Angstrom Resolution, Crystalised In The Presence Of S-Nitrosoglutathione
2BRY	;	1.45	;	Crystal structure of the native monooxygenase domain of MICAL at 1.45 A resolution
3P1B	;	1.77	;	Crystal structure of the native serine acetyltransferase 1 from Entamoeba histolytica
2F3N	;	2.1	;	Crystal Structure of the native Shank SAM domain.
8OEX	;	1.07	;	Crystal structure of the native Z-DNA duplex d(CGCGCG) before soaking of CuCl2
7ZVA	;	1.8	;	Crystal Structure of the native zymogen form of the glutamic-class prolyl-endopeptidase neprosin at 1.80 A resolution.
5EV6	;	1.984	;	Crystal structure of the native, di-zinc metallo-beta-lactamase IMP-1
4RQP	;	3.151	;	Crystal structure of the natually occurring empty particle of a clinical C4 strain EV71
6CSM	;	2.9	;	Crystal structure of the natural light-gated anion channel GtACR1
3RVY	;	2.7	;	Crystal structure of the NavAb voltage-gated sodium channel (Ile217Cys, 2.7 A)
3RVZ	;	2.8	;	Crystal structure of the NavAb voltage-gated sodium channel (Ile217Cys, 2.8 A)
3RW0	;	2.95	;	Crystal structure of the NavAb voltage-gated sodium channel (Met221Cys, 2.95 A)
4EKW	;	3.21	;	Crystal structure of the NavAb voltage-gated sodium channel (wild-type, 3.2 A)
5VB2	;	3.2	;	Crystal structure of the NavAb voltage-gated sodium channel in a closed conformation
5VB8	;	2.85	;	Crystal structure of the NavAb voltage-gated sodium channel in an open state
1JFI	;	2.62	;	Crystal Structure of the NC2-TBP-DNA Ternary Complex
1OJ5	;	2.21	;	Crystal structure of the Nco-A1 PAS-B domain bound to the STAT6 transactivation domain LXXLL motif
5Y7W	;	2.25	;	Crystal structure of the Nco-A1 PAS-B domain with YL-2
3US9	;	2.68	;	Crystal Structure of the NCX1 Intracellular Tandem Calcium Binding Domains(CBD12)
6V3U	;	2.0	;	Crystal Structure of the NDM_FIM-1 like Metallo-beta-Lactamase from Erythrobacter litoralis in the Mono-Zinc Form
3M7F	;	2.0	;	Crystal structure of the Nedd4 C2/Grb10 SH2 complex
5JKK	;	1.6	;	Crystal structure of the negatively supercharged variant Ftn(neg) of human heavy chain ferritin
4MT1	;	3.54	;	Crystal Structure of the Neisseria gonorrhoeae MtrD Inner Membrane Multidrug Efflux Pump
3KVD	;	2.0	;	Crystal structure of the Neisseria meningitidis Factor H binding protein, fHbp (GNA1870) at 2.0 A resolution
5EDJ	;	2.3	;	Crystal structure of the Neisseria meningitidis iron-regulated outer membrane lipoprotein FrpD
2OPE	;	2.4	;	Crystal structure of the Neisseria meningitidis minor Type IV pilin, PilX, in space group P43
6POG	;	2.755	;	Crystal structure of the NELL2 EGF1-6-Robo3 FN1 complex
2BJQ	;	1.75	;	Crystal structure of the nematode sperm cell motility protein MFP2
2BJR	;	1.8	;	Crystal structure of the nematode sperm cell motility protein MFP2B
4OWF	;	2.0	;	Crystal structure of the NEMO CoZi in complex with HOIP NZF1 domain
2CBQ	;	2.6	;	Crystal structure of the neocarzinostatin 1Tes15 mutant bound to testosterone hemisuccinate.
2CBO	;	1.7	;	Crystal structure of the neocarzinostatin 3Tes24 mutant bound to testosterone hemisuccinate.
2CBT	;	2.2	;	Crystal structure of the neocarzinostatin 4Tes1 mutant bound testosterone hemisuccinate.
1I1A	;	2.8	;	CRYSTAL STRUCTURE OF THE NEONATAL FC RECEPTOR COMPLEXED WITH A HETERODIMERIC FC
3L24	;	2.3	;	Crystal Structure of the Nerve Agent Degrading Organophosphate Anhydrolase/Prolidase in Complex with Inhibitors
1KR7	;	1.5	;	Crystal structure of the nerve tissue mini-hemoglobin from the nemertean worm Cerebratulus lacteus
6PZD	;	1.12	;	Crystal structure of the neuraminidase stabilization mutant Y169aH from A/Shanghai/2/2013 (H7N9)
3P7Z	;	2.65	;	Crystal structure of the Neurofibromin Sec14-PH module containing the patient derived mutation I1584V
4B4Y	;	2.3	;	crystal structure of the neuroglobin from the photosymbiotic marine acoel Symsagittifera roscoffensis
6HLO	;	2.4	;	Crystal structure of the Neurokinin 1 receptor in complex with the small molecule antagonist Aprepitant
6HLL	;	3.27	;	Crystal structure of the Neurokinin 1 receptor in complex with the small molecule antagonist CP-99,994
6HLP	;	2.2	;	Crystal structure of the Neurokinin 1 receptor in complex with the small molecule antagonist Netupitant
3BIW	;	3.5	;	Crystal structure of the Neuroligin-1/Neurexin-1beta synaptic adhesion complex
4CQ1	;	1.69	;	Crystal structure of the neuronal isoform of PTB
1EZ3	;	1.9	;	CRYSTAL STRUCTURE OF THE NEURONAL T-SNARE SYNTAXIN-1A
6Z4V	;	2.595	;	Crystal structure of the neurotensin receptor 1 (NTSR1-H4bmx) in complex with NTS8-13
6Z4S	;	2.707	;	Crystal structure of the neurotensin receptor 1 (NTSR1-H4bmx) in complex with the small molecule inverse agonist SR48692
6YVR	;	2.458	;	Crystal structure of the neurotensin receptor 1 in complex with the peptide full agonist NTS8-13
6ZIN	;	2.639	;	Crystal structure of the neurotensin receptor 1 in complex with the small molecule inverse agonist SR48692
6Z8N	;	2.803	;	Crystal structure of the neurotensin receptor 1 in complex with the small-molecule full agonist SRI-9829
6Z4Q	;	2.923	;	Crystal structure of the neurotensin receptor 1 in complex with the small-molecule inverse agonist SR142948A
6ZA8	;	2.72	;	Crystal structure of the neurotensin receptor 1 in complex with the small-molecule partial agonist RTI-3a
3BUK	;	2.6	;	Crystal Structure of the Neurotrophin-3 and p75NTR Symmetrical Complex
1FPB	;	2.6	;	CRYSTAL STRUCTURE OF THE NEUTRAL FORM OF FRUCTOSE 1,6-BISPHOSPHATASE COMPLEXED WITH REGULATORY INHIBITOR FRUCTOSE 2,6-BISPHOSPHATE AT 2.6-ANGSTROMS RESOLUTION
5FBP	;	2.1	;	CRYSTAL STRUCTURE OF THE NEUTRAL FORM OF FRUCTOSE-1,6-BISPHOSPHATASE COMPLEXED WITH THE PRODUCT FRUCTOSE 6-PHOSPHATE AT 2.1-ANGSTROMS RESOLUTION
5BK3	;	2.8	;	Crystal structure of the neutralizing anti-circumsporozoite protein 580 antibody
6AZX	;	2.1	;	Crystal structure of the neutralizing anti-circumsporozoite protein 663 antibody
3NH7	;	2.7	;	Crystal structure of the neutralizing Fab fragment AbD1556 bound to the BMP type I receptor IA
3MOB	;	2.6	;	Crystal structure of the neutralizing HIV antibody 2F5 Fab fragment (recombinantly produced Fab) with 11 aa gp41 MPER-derived peptide
3MOA	;	2.3	;	Crystal structure of the neutralizing HIV antibody 2F5 Fab fragment (recombinantly produced Fab) with 17 aa gp41 MPER-derived peptide
3MOD	;	2.2	;	Crystal structure of the neutralizing HIV antibody 2F5 Fab fragment (recombinantly produced IgG) with 11 aa gp41 MPER-derived peptide
7VPY	;	1.6	;	Crystal structure of the neutralizing nanobody P86 against SARS-CoV-2
8D4O	;	1.45	;	Crystal Structure of the Neutrophil Serine Protease Inhibitor Eap1 from S. aureus
6OVZ	;	2.017	;	Crystal structure of the New Delhi metallo-beta-lactamase-1 adduct with a lysine-targeted affinity label
6MH0	;	1.65	;	Crystal Structure of the New Deli Metallo Beta Lactamase Variant 3 from Klebsiella pneumoniae
6MGZ	;	1.647	;	Crystal Structure of the New Deli Metallo Beta Lactamase Variant 4 from Klebsiella pneumoniae
6MGY	;	1.6	;	Crystal Structure of the New Deli Metallo Beta Lactamase Variant 5 from Klebsiella pneumoniae
6MGX	;	2.6	;	Crystal Structure of the New Deli Metallo Beta Lactamase Variant 6 Klebsiella pneumoniae
1USX	;	2.7	;	Crystal structure of the Newcastle disease virus hemagglutinin-neuraminidase complexed with thiosialoside
1N1J	;	1.67	;	Crystal structure of the NF-YB/NF-YC histone pair
4AT7	;	1.902	;	Crystal structure of the NF90-NF45 dimerisation domain complex
4AT8	;	2.692	;	Crystal structure of the NF90-NF45 dimerisation domain complex with ATP
4ATB	;	3.1	;	Crystal structure of the NF90-NF45 dimerisation domain complex with CTP
4AT9	;	2.803	;	Crystal structure of the NF90-NF45 dimerisation domain complex with UTP
1VKX	;	2.9	;	CRYSTAL STRUCTURE OF THE NFKB P50/P65 HETERODIMER COMPLEXED TO THE IMMUNOGLOBULIN KB DNA
6D69	;	2.601	;	Crystal Structure of the NHL Repeat Region of D. melanogaster Thin
6L76	;	2.94	;	Crystal structure of the Ni(II)(Chro)2-d(TTGGGCCGAA/TTCGGCCCAA) complex at 2.94 angstrom resolution
1F9Z	;	1.5	;	CRYSTAL STRUCTURE OF THE NI(II)-BOUND GLYOXALASE I FROM ESCHERICHIA COLI
3HDP	;	2.06	;	Crystal structure of the NI(II)-bound Glyoxalase-I from Clostridium acetobutylicum
5UP7	;	1.79	;	Crystal Structure of the Ni-bound Human Heavy-Chain Ferritin 122H-delta C-star variant
7JGP	;	6.42	;	Crystal Structure of the Ni-bound Human Heavy-chain variant 122H-delta C-star with 2,5-furandihyrdoxamate at 318K
7JGK	;	2.68	;	Crystal Structure of the Ni-bound Human Heavy-chain variant 122H-delta C-star with 2,5-furandihyrdoxamate collected at 100K
7JGO	;	3.08	;	Crystal Structure of the Ni-bound Human Heavy-chain variant 122H-delta C-star with 2,5-furandihyrdoxamate collected at 278K
7JGQ	;	3.01	;	Crystal Structure of the Ni-bound Human Heavy-chain variant 122H-delta C-star with 2,5-furandihyrdoxamate collected at 278K after one heating/cooling cycle
7JGM	;	2.31	;	Crystal Structure of the Ni-bound Human Heavy-chain variant 122H-delta C-star with meta-benzenedihyrdoxamate
1FRF	;	2.7	;	CRYSTAL STRUCTURE OF THE NI-FE HYDROGENASE FROM DESULFOVIBRIO FRUCTOSOVORANS
4GSV	;	1.48	;	Crystal Structure of the Ni2+2-Human Arginase I-ABH complex
2ISY	;	1.955	;	Crystal structure of the nickel-activated two-domain iron-dependent regulator (IdeR)
4RUM	;	2.6426	;	Crystal structure of the NiCo transition-metal riboswitch bound to cobalt
1IYB	;	1.5	;	Crystal Structure of the Nicotiana glutinosa Ribonuclease NW
6KUA	;	2.104	;	Crystal structure of the nicotinamidase SaPncA from Staphylococcus aureus
6EB9	;	1.9	;	Crystal Structure of the Nipah Virus Phosphoprotein Multimerization Domain Delta 542-544
6EB8	;	2.5	;	Crystal Structure of the Nipah Virus Phosphoprotein Multimerization Domain G519N
4N5B	;	2.2	;	Crystal structure of the Nipah virus phosphoprotein tetramerization domain
4CO6	;	2.498	;	Crystal structure of the Nipah virus RNA free nucleoprotein- phosphoprotein complex
5A2O	;	3.71	;	Crystal structure of the nitrate transporter NRT1.1 from Arabidopsis thaliana in complex with nitrate.
5A2N	;	3.7	;	Crystal structure of the nitrate transporter NRT1.1 from Arabidopsis thaliana.
5JGP	;	2.7	;	Crystal structure of the nitrate/nitrite sensor NarQ fragment bound with iodide ions
1DP8	;	2.5	;	CRYSTAL STRUCTURE OF THE NITRIC OXIDE BOUND FIXL HEME DOMAIN
1W8Y	;	2.4	;	Crystal structure of the nitrocefin acyl-DD-peptidase from Actinomadura R39.
1HQO	;	2.3	;	CRYSTAL STRUCTURE OF THE NITROGEN REGULATION FRAGMENT OF THE YEAST PRION PROTEIN URE2P
1XDB	;	2.8	;	Crystal Structure of the Nitrogenase Fe protein Asp129Glu
1XD8	;	2.7	;	Crystal Structure of the Nitrogenase Fe protein Asp39Asn
1XD9	;	2.8	;	Crystal Structure of the Nitrogenase Fe protein Asp39Asn with MgADP bound
1XCP	;	3.2	;	Crystal Structure of the Nitrogenase Fe protein Phe135Trp with MgADP bound
2WQF	;	1.35	;	Crystal Structure of the Nitroreductase CinD from Lactococcus lactis in Complex with FMN
2B67	;	2.05	;	Crystal structure of the Nitroreductase Family Protein from Streptococcus pneumoniae TIGR4
2I7H	;	2.3	;	Crystal Structure of the Nitroreductase-like Family Protein from Bacillus cereus
3B9Y	;	1.85	;	Crystal structure of the Nitrosomonas europaea Rh protein
3B9Z	;	1.85	;	Crystal structure of the Nitrosomonas europaea Rh protein complexed with carbon dioxide
4D3C	;	2.62	;	Crystal structure of the NK1 domain of HGF in complex with anti-HGF monoclonal antibody SFN68.
3HN4	;	2.6	;	Crystal structure of the NK2 fragment (28-289) of human hepatocyte growth factor/scatter factor
4IUA	;	3.05	;	Crystal Structure of the NK2 Fragment (31-290) of the mouse Hepatocyte Growth Factor/Scatter Factor
5VGC	;	2.6	;	Crystal structure of the NleG5-1 effector (C200A) from Escherichia coli O157:H7 str. Sakai
4EWI	;	2.28	;	Crystal structure of the NLRP4 Pyrin domain
3BBB	;	1.3	;	Crystal structure of the NM23-H2 transcription factor complex with dinucleotide d(AG)
3BBF	;	1.7	;	Crystal structure of the NM23-H2 transcription factor complex with GDP
3BID	;	2.7	;	Crystal structure of the NMB1088 protein from Neisseria meningitidis. Northeast Structural Genomics Consortium target MR91
4KCC	;	1.894	;	Crystal Structure of the NMDA Receptor GluN1 Ligand Binding Domain Apo State
4KFQ	;	2.2	;	Crystal structure of the NMDA receptor GluN1 ligand binding domain in complex with 1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one
4KCD	;	1.68	;	Crystal Structure of the NMDA Receptor GluN3A Ligand Binding Domain Apo State
2E3A	;	1.3	;	Crystal structure of the NO-bound form of Arthromyces ramosus peroxidase at 1.3 Angstroms resolution
6LYC	;	1.36	;	Crystal structure of the NOD SIRPa complex with D4-2
4P91	;	2.1	;	Crystal structure of the nogo-receptor-2 (27-330)
8OE3	;	1.08	;	Crystal structure of the non-canonical quadruplex d(GCATGCT) before soaking
2C61	;	1.5	;	Crystal structure of the non-catalytic B subunit of A-type ATPase from M. mazei Go1
1K8D	;	2.3	;	crystal structure of the non-classical MHC class Ib Qa-2 complexed with a self peptide
1LB8	;	2.3	;	Crystal structure of the Non-desensitizing GluR2 ligand binding core mutant (S1S2J-L483Y) in complex with AMPA at 2.3 resolution
1LB9	;	2.3	;	Crystal structure of the Non-desensitizing GluR2 ligand binding core mutant (S1S2J-L483Y) in complex with antagonist DNQX at 2.3 A resolution
1N9W	;	2.3	;	Crystal structure of the non-discriminating and archaeal-type aspartyl-tRNA synthetase from Thermus thermophilus
5EP9	;	2.13	;	Crystal structure of the non-heme alpha ketoglutarate dependent epimerase SnoN from nogalamycin biosynthesis
8SDW	;	1.75	;	Crystal structure of the non-myristoylated mutant [L8K]Arf1 in complex with a GDP analogue
6OEJ	;	3.45	;	CRYSTAL STRUCTURE OF THE NON-NEUTRALIZING AND ADCC-POTENT ANTIBODY C11 IN COMPLEX WITH HIV-1 CLADE A/E GP120
5W4L	;	2.92	;	Crystal structure of the non-neutralizing and ADCC-potent C11-like antibody N12-i3 in complex with HIV-1 clade A/E gp120, the CD4 mimetic M48U1, and the antibody N5-i5.
3MNV	;	2.4	;	Crystal structure of the non-neutralizing HIV antibody 13H11 Fab fragment
3MO1	;	1.8	;	Crystal structure of the non-neutralizing HIV antibody 13H11 Fab fragment
3MNZ	;	1.8	;	Crystal structure of the non-neutralizing HIV antibody 13H11 Fab fragment with a gp41 MPER-derived peptide bearing Ala substitutions in a helical conformation
3MNW	;	2.2	;	Crystal structure of the non-neutralizing HIV antibody 13H11 Fab fragment with a gp41 MPER-derived peptide in a helical conformation
4REW	;	4.58	;	Crystal structure of the non-phosphorylated human alpha1 beta2 gamma1 holo-AMPK complex
1KY8	;	2.4	;	Crystal Structure of the Non-phosphorylating glyceraldehyde-3-phosphate Dehydrogenase
1JN0	;	3.0	;	Crystal structure of the non-regulatory A4 isoform of spinach chloroplast glyceraldehyde-3-phosphate dehydrogenase complexed with NADP
7ARO	;	3.119	;	Crystal structure of the non-ribose partial agonist LUF5833 bound to the adenosine A2A receptor
6DGK	;	1.9	;	Crystal Structure of the Non-Structural Protein 1 (NS1) effector domain W187A mutant from the A/Brevig Mission/1/1918 (H1N1) strain of Influenza A Virus
4KW3	;	2.7	;	Crystal structure of the non-structural protein 1 N-terminal origin-recognition/nickase domain from the emerging human bocavirus
4CW4	;	1.349	;	Crystal structure of the noncanonical ketosynthase FabY from P. aeruginosa
7L5O	;	1.21	;	Crystal structure of the noncovalently bonded complex of rilzabrutinib with BTK
3UB0	;	2.6	;	Crystal structure of the nonstructural protein 7 and 8 complex of Feline Coronavirus
2FYQ	;	1.5	;	Crystal Structure of the Norwalk Virus Protease
2B43	;	2.3	;	Crystal structure of the Norwalk virus RNA dependent RNA polymerase from strain Hu/NLV/Dresden174/1997/GE
2B5D	;	2.2	;	Crystal structure of the novel alpha-amylase AmyC from Thermotoga maritima
3ES6	;	3.23	;	Crystal structure of the novel complex formed between Zinc 2-glycoprotein (ZAG) and Prolactin inducible protein (PIP) from human seminal plasma
2G6Y	;	1.6	;	Crystal structure of the novel green fluorescent protein from marine copepod Pontellina plumata
3WI7	;	1.7	;	Crystal Structure of the Novel Haloalkane Dehalogenase DatA from Agrobacterium tumefaciens C58
5O30	;	2.3	;	Crystal structure of the novel halohydrin dehalogenase HheG
5ZB8	;	2.5	;	Crystal structure of the novel lesion-specific endonuclease PfuEndoQ from Pyrococcus furiosus
4EE6	;	1.33	;	Crystal Structure of the Novel Phenazine Prenyltransferase EpzP (methylated)
4EE8	;	1.93	;	Crystal structure of the Novel Phenazine Prenyltransferase EpzP (wildtype)
4EE7	;	1.67	;	Crystal Structure of the Novel Phenazine Prenyltransferase EpzP in complex with S-thiolodiphosphate (methylated)
4MER	;	2.41	;	Crystal structure of the novel protein and virulence factor sHIP (Q99XU0) from Streptococcus pyogenes
1XRV	;	2.1	;	Crystal Structure of the novel secretory signalling protein from Porcine (SPP-40) at 2.1A resolution.
2ZWN	;	1.7	;	Crystal structure of the novel two-domain type laccase from a metagenome
7XHV	;	3.996	;	Crystal Structure of the NPAS4-ARNT heterodimer in complex with DNA
7XI4	;	4.707	;	Crystal Structure of the NPAS4-ARNT heterodimer in complex with DNA
7XI3	;	4.274	;	Crystal Structure of the NPAS4-ARNT2 heterodimer in complex with DNA
7TAE	;	1.5	;	Crystal Structure of the NPR1-Interacting Domain of TGA3
1PBQ	;	1.9	;	CRYSTAL STRUCTURE OF THE NR1 LIGAND BINDING CORE IN COMPLEX WITH 5,7-DICHLOROKYNURENIC ACID (DCKA) AT 1.90 ANGSTROMS RESOLUTION
1Y1Z	;	1.5	;	Crystal structure of the NR1 ligand binding core in complex with ACBC
1Y1M	;	1.8	;	Crystal structure of the NR1 ligand binding core in complex with cycloleucine
1PB9	;	1.6	;	CRYSTAL STRUCTURE OF THE NR1 LIGAND BINDING CORE IN COMPLEX WITH D-CYCLOSERINE AT 1.60 ANGSTROMS RESOLUTION
1PB8	;	1.45	;	CRYSTAL STRUCTURE OF THE NR1 LIGAND BINDING CORE IN COMPLEX WITH D-SERINE AT 1.45 ANGSTROMS RESOLUTION
1PB7	;	1.35	;	CRYSTAL STRUCTURE OF THE NR1 LIGAND BINDING CORE IN COMPLEX WITH GLYCINE AT 1.35 ANGSTROMS RESOLUTION
1Y20	;	1.4	;	Crystal structure of the NR1 ligand-binding core in complex with ACPC
2A5T	;	2.0	;	Crystal Structure Of The NR1/NR2A ligand-binding cores complex
2A5S	;	1.7	;	Crystal Structure Of The NR2A Ligand Binding Core In Complex With Glutamate
2RC9	;	1.96	;	Crystal structure of the NR3A ligand binding core complex with ACPC at 1.96 Angstrom resolution
2RC8	;	1.45	;	Crystal structure of the NR3A ligand binding core complex with D-serine at 1.45 Angstrom resolution
2RC7	;	1.58	;	Crystal structure of the NR3A ligand binding core complex with glycine at 1.58 Angstrom resolution
2RCB	;	1.62	;	Crystal structure of the NR3B ligand binding core complex with D-serine at 1.62 Angstrom resolution
2RCA	;	1.58	;	Crystal structure of the NR3B ligand binding core complex with glycine at 1.58 Angstrom resolution
6SW8	;	1.933	;	Crystal structure of the NS1 (H7N1) RNA-binding domain
3P31	;	2.45	;	Crystal structure of the NS1 effector domain from influenza A/Vietnam/1203/2004 (H5N1) virus
3P38	;	2.76	;	Crystal structure of the NS1 effector domain W182A mutant from influenza A/Vietnam/1203/2004 (H5N1) virus
3P39	;	3.14	;	Crystal structure of the NS1 effector domain W182A mutant from influenza A/Vietnam/1203/2004 (H5N1) virus
2VBC	;	3.15	;	Crystal structure of the NS3 protease-helicase from Dengue virus
2WV9	;	2.75	;	Crystal Structure of the NS3 protease-helicase from Murray Valley encephalitis virus
6M40	;	2.89	;	Crystal structure of the NS3-like helicase from Alongshan virus
3I5K	;	2.2	;	Crystal structure of the NS5B polymerase from Hepatitis C Virus (HCV) strain JFH1
4ASH	;	1.578	;	Crystal structure of the NS6 protease from murine norovirus 1
4CY3	;	1.4	;	Crystal structure of the NSL1-WDS complex.
4CY5	;	2.3	;	Crystal structure of the NSL1-WDS-NSL2 complex.
2XYQ	;	2.0	;	Crystal structure of the nsp16 nsp10 SARS coronavirus complex
2XYR	;	2.5	;	Crystal structure of the nsp16 nsp10 SARS coronavirus complex
2XYV	;	2.06	;	Crystal structure of the nsp16 nsp10 SARS coronavirus complex
7T9W	;	2.2	;	Crystal structure of the Nsp3 bSM (Betacoronavirus-Specific Marker) domain from SARS-CoV-2
7RQG	;	2.17	;	Crystal structure of the Nsp3 Y3 domain from SARS-CoV-2
6YHU	;	2.0	;	Crystal structure of the nsp7-nsp8 complex of SARS-CoV-2
5CD7	;	2.502	;	Crystal structure of the NTD L199M of Drosophila Oskar protein
5CD8	;	3.001	;	Crystal structure of the NTD of Drosophila Oskar protein
5H29	;	2.3	;	Crystal Structure of the NTD_N/C domain of Alkylhydroperoxide Reductase AhpF from Enterococcus Faecalis (V583)
3Q90	;	1.7	;	Crystal structure of the NTF2 domain of Ras GTPase-activating protein-binding protein 1
4FCJ	;	1.62	;	Crystal structure of the NTF2-like domain of human G3BP1
4FCM	;	2.69	;	Crystal structure of the NTF2-like domain of human G3BP1 in complex with a peptide
3UJM	;	2.741	;	Crystal structure of the NTF2-like domain of the Drosophila melanogaster Rasputin protein
8V1L	;	2.68	;	Crystal structure of the NTF2L domain of human G3BP1 in complex with small molecule
7XHG	;	2.46	;	Crystal structure of the NTF2L domain of human G3BP1 in complex with the Caprin-1 derived peptide
7XHF	;	2.68	;	Crystal structure of the NTF2L domain of human G3BP1 in complex with the USP10 derived peptide
2XU0	;	2.06	;	Crystal structure of the NTS-DBL1(alpha-1) domain of the Plasmodium falciparum membrane protein 1 (PfEMP1) from the varO strain.
5J9Q	;	3.25	;	Crystal structure of the NuA4 core complex
5J9T	;	2.7	;	Crystal structure of the NuA4 core complex
5J9U	;	2.95	;	Crystal structure of the NuA4 core complex
5J9W	;	2.8	;	Crystal structure of the NuA4 core complex
6AN5	;	3.512	;	Crystal Structure of The Nucelotide Binding Domain of an O-antigen polysaccharide ABC-transporter
5M0I	;	2.41	;	Crystal structure of the nuclear complex with She2p and the ASH1 mRNA E3-localization element
3GJX	;	2.5	;	Crystal Structure of the Nuclear Export Complex CRM1-Snurportin1-RanGTP
4BSN	;	4.1	;	Crystal structure of the Nuclear Export Receptor CRM1 (exportin-1) lacking the C-terminal helical extension at 4.1A
4BSM	;	4.5	;	Crystal structure of the Nuclear Export Receptor CRM1 (exportin-1) lacking the C-terminal helical extension at 4.5A
1DB1	;	1.8	;	CRYSTAL STRUCTURE OF THE NUCLEAR RECEPTOR FOR VITAMIN D COMPLEXED TO VITAMIN D
1IE8	;	1.52	;	Crystal Structure Of The Nuclear Receptor For Vitamin D Ligand Binding Domain Bound to KH1060
1IE9	;	1.4	;	Crystal Structure Of The Nuclear Receptor For Vitamin D Ligand Binding Domain Bound to MC1288
2IVH	;	2.8	;	Crystal structure of the nuclease domain of ColE7 (H545Q mutant) in complex with an 18-bp duplex DNA
3FBD	;	2.9	;	Crystal structure of the nuclease domain of COLE7(D493Q mutant) in complex with an 18-BP duplex DNA
8GUO	;	2.59395	;	Crystal structure of the nuclease domain of EsaD in complex with EsaG from Staphylococcus aureus
7LGO	;	2.45	;	Crystal structure of the nucleic acid binding domain (NAB) of Nsp3 from SARS-CoV-2
3ZLA	;	3.2	;	Crystal structure of the nucleocapsid protein from Bunyamwera virus bound to RNA
3ZL9	;	2.75	;	Crystal structure of the nucleocapsid protein from Schmallenberg virus
1P65	;	2.6	;	Crystal structure of the nucleocapsid protein of porcine reproductive and respiratory syndrome virus (PRRSV)
6BYG	;	1.999	;	Crystal structure of the nucleophile mutant (E575A) of the GH2 exo-beta-mannanase from Xanthomonas axonopodis pv. citri
3FMO	;	2.51	;	Crystal structure of the nucleoporin Nup214 in complex with the DEAD-box helicase Ddx19
3FMP	;	3.19	;	Crystal structure of the nucleoporin Nup214 in complex with the DEAD-box helicase Ddx19
3F3F	;	2.9	;	Crystal structure of the nucleoporin pair Nup85-Seh1, space group P21
3F3P	;	3.2	;	Crystal structure of the nucleoporin pair Nup85-Seh1, space group P21212
3F3G	;	3.75	;	Crystal structure of the nucleoporin pair Nup85-Seh1, space group P212121
4KPC	;	2.7	;	Crystal structure of the nucleoside diphosphate kinase b from Leishmania braziliensis
8CTM	;	1.73	;	Crystal structure of the nucleoside hydrolase from Leishmania donovani.
3OH8	;	1.997	;	Crystal structure of the nucleoside-diphosphate sugar epimerase from Corynebacterium glutamicum. Northeast Structural Genomics Consortium Target CgR91
4EVW	;	1.9	;	Crystal Structure of the nucleoside-diphosphate-sugar pyrophosphorylase from Vibrio cholerae RC9. Northeast Structural Genomics Consortium (NESG) Target VcR193.
5Z23	;	2.73	;	Crystal structure of the nucleosome containing a chimeric histone H3/CENP-A CATD
5B0Y	;	2.557	;	Crystal structure of the nucleosome containing histone H3 with the crotonylated lysine 122
5JRG	;	2.5	;	Crystal structure of the nucleosome containing the DNA with tetrahydrofuran (THF)
3X1S	;	2.805	;	Crystal structure of the nucleosome core particle
1U35	;	3.0	;	Crystal structure of the nucleosome core particle containing the histone domain of macroH2A
3FVQ	;	1.9	;	Crystal structure of the nucleotide binding domain FbpC complexed with ATP
1ID0	;	1.6	;	CRYSTAL STRUCTURE OF THE NUCLEOTIDE BOND CONFORMATION OF PHOQ KINASE DOMAIN
1DKG	;	2.8	;	CRYSTAL STRUCTURE OF THE NUCLEOTIDE EXCHANGE FACTOR GRPE BOUND TO THE ATPASE DOMAIN OF THE MOLECULAR CHAPERONE DNAK
1SKY	;	3.2	;	CRYSTAL STRUCTURE OF THE NUCLEOTIDE FREE ALPHA3BETA3 SUB-COMPLEX OF F1-ATPASE FROM THE THERMOPHILIC BACILLUS PS3
5X7K	;	2.65	;	Crystal structure of the nucleotide-binding domain (NBD) of LipB, a ABC transporter subunit of a type I secretion system
4FWI	;	2.892	;	Crystal structure of the nucleotide-binding domain of a dipeptide ABC transporter
3LLU	;	1.4	;	Crystal structure of the nucleotide-binding domain of Ras-related GTP-binding protein C
3VX4	;	2.69	;	Crystal Structure of the Nucleotide-Binding Domain of S. mutans ComA, a Bifunctional ATP-binding Cassette Transporter Involved in the Quorum-sensing Pathway
3KB1	;	2.9	;	Crystal Structure of the Nucleotide-binding protein AF_226 in complex with ADP from Archaeoglobus fulgidus, Northeast Structural Genomics Consortium Target GR157
1JX2	;	2.3	;	CRYSTAL STRUCTURE OF THE NUCLEOTIDE-FREE DYNAMIN A GTPASE DOMAIN, DETERMINED AS MYOSIN FUSION
5ZEA	;	3.384	;	Crystal structure of the nucleotide-free mutant A3B3
3GG6	;	2.1	;	Crystal structure of the NUDIX domain of human NUDT18
3H95	;	1.7	;	Crystal structure of the NUDIX domain of NUDT6
1SU2	;	1.6	;	CRYSTAL STRUCTURE OF THE NUDIX HYDROLASE DR1025 IN COMPLEX WITH ATP
3P3D	;	2.35	;	Crystal structure of the Nup53 RRM domain from Pichia guilliermondii
3EWE	;	3.5	;	Crystal Structure of the Nup85/Seh1 Complex
5E0Q	;	1.9	;	Crystal structure of the Nup98 C-terminal domain bound to nanobody TP377
2YGK	;	2.5	;	Crystal structure of the NurA nuclease from Sulfolobus solfataricus
3IMQ	;	2.5	;	Crystal structure of the NusB101-S10(delta loop) complex
6FDL	;	1.75	;	Crystal structure of the NYN domain of human MARF1
3VI0	;	2.3	;	Crystal structure of the O intermediate of the L93A mutant of bacteriorhodopsin
3VEN	;	1.57	;	Crystal structure of the O-carbamoyltransferase TobZ
3VEX	;	1.9	;	Crystal structure of the O-carbamoyltransferase TobZ H14N variant in complex with carbamoyl adenylate intermediate
3VEW	;	2.352	;	Crystal structure of the O-carbamoyltransferase TobZ in complex with ADP
3VES	;	2.23	;	Crystal structure of the O-carbamoyltransferase TobZ in complex with AMPCPP and carbamoyl phosphate
3VER	;	2.34	;	Crystal structure of the O-carbamoyltransferase TobZ in complex with carbamoyl adenylate intermediate
3VEO	;	2.187	;	Crystal structure of the O-carbamoyltransferase TobZ in complex with carbamoyl phosphate
3VET	;	2.2	;	Crystal structure of the O-carbamoyltransferase TobZ in complex with Tobramycin, carbamoyl phosphate and ADP
3VEZ	;	2.4	;	Crystal structure of the O-carbamoyltransferase TobZ K443A variant in complex with ATP, ADP and carbamoyl phosphate
3VF2	;	2.9	;	Crystal structure of the O-carbamoyltransferase TobZ M473I variant in complex with carbamoyl phosphate and ADP
3VF4	;	2.4	;	Crystal structure of the O-carbamoyltransferase TobZ S530A variant in complex with carbamoyl phosphate and ADP
7XB6	;	2.901	;	Crystal structure of the O-carbamoyltransferase VtdB in complex with carbamoyl adenylate intermediate
7YYK	;	2.6	;	Crystal structure of the O-fucosylated form of TSRs1-3 from the human thrombospondin 1
6Q4M	;	2.2	;	Crystal structure of the O-GlcNAc transferase Asn648Tyr mutation
6HP1	;	1.9	;	Crystal Structure of the O-Methyltransferase from the trans-AT PKS multienzyme C0ZGQ3 of Brevibacillus brevis
6HP2	;	1.9	;	Crystal Structure of the O-Methyltransferase from the trans-AT PKS multienzyme C0ZGQ3 of Brevibacillus brevis in complex with S-Adenosyl-L-homocysteine
5N5D	;	1.55	;	Crystal Structure of the O-Methyltransferase TomG from Streptomyces achromogenes involved in Tomaymycin synthesis in complex with SAM
5B36	;	2.15	;	Crystal Structure of the O-Phosphoserine Sulfhydrylase from Aeropyrum pernix Complexed with Cysteine
6L0S	;	1.96	;	Crystal Structure of the O-Phosphoserine Sulfhydrylase from Aeropyrum pernix Complexed with L-Cysteine
6L0R	;	1.79	;	Crystal Structure of the O-Phosphoserine Sulfhydrylase from Aeropyrum pernix Complexed with O-Acetylserine
6L0P	;	1.79	;	Crystal Structure of the O-Phosphoserine Sulfhydrylase from Aeropyrum pernix Complexed with O-Phosphoserine
6L0Q	;	1.58	;	Crystal Structure of the O-Phosphoserine Sulfhydrylase from Aeropyrum pernix Complexed with O-Phosphoserine
6XYT	;	2.1	;	Crystal structure of the O-state of the light-driven sodium pump KR2 in the pentameric form, pH 8.0
7ODH	;	1.34	;	Crystal structure of the O2-tolerant MBH-P242C from Ralstonia eutropha in its as-isolated state
7ODG	;	1.62	;	Crystal structure of the O2-tolerant MBH-P242C from Ralstonia eutropha in its reduced state
1OCT	;	3.0	;	CRYSTAL STRUCTURE OF THE OCT-1 POU DOMAIN BOUND TO AN OCTAMER SITE: DNA RECOGNITION WITH TETHERED DNA-BINDING MODULES
7RUS	;	2.87	;	Crystal structure of the octameric form of Rv3208A
4TW1	;	2.8	;	Crystal structure of the octameric pore complex of the Staphylococcus aureus Bi-component Toxin LukGH
4N9X	;	2.503	;	Crystal Structure of the OCTAPRENYL-METHYL-METHOXY-BENZQ MOLECULE from Erwina carotovora subsp. atroseptica strain SCRI 1043 / ATCC BAA-672, Northeast Structural Genomics Consortium (NESG) Target EwR161
5ODO	;	2.64	;	Crystal Structure of the Oleate hydratase of Rhodococcus erythropolis
4XAT	;	2.113	;	Crystal structure of the olfactomedin domain from noelin/pancortin/olfactomedin-1
4RML	;	1.601	;	Crystal structure of the Olfactomedin domain of latrophilin 3 in C2221 crystal form
4RMK	;	1.606	;	Crystal structure of the Olfactomedin domain of latrophilin 3 in P65 crystal form
3FBV	;	3.2	;	Crystal structure of the oligomer formed by the kinase-ribonuclease domain of Ire1
3TPK	;	1.3	;	Crystal structure of the oligomer-specific KW1 antibody fragment
5I72	;	2.9	;	Crystal structure of the oligomeric form of the Lassa virus matrix protein Z
4MJT	;	2.85	;	Crystal structure of the oligomeric pore-forming toxin pro-Monalysin
8IIA	;	2.09	;	Crystal structure of the oligomeric state of the extracellular domain of human myelin protein zero(MPZ/P0)
2YF2	;	2.24	;	Crystal structure of the oligomerisation domain of C4b-binding protein from Gallus gallus
6TO9	;	2.45	;	Crystal structure of the oligomerisation domain of the transcription factor PHOSPHATE STARVATION RESPONSE 1 from Arabidopsis (crystal form 2)
6TOC	;	1.853	;	Crystal structure of the oligomerisation domain of the transcription factor PHOSPHATE STARVATION RESPONSE 1 from Arabidopsis (crystal form 3).
6TO5	;	2.38	;	Crystal structure of the oligomerisation domain of the transcription factor PHOSPHATE STARVATION RESPONSE 1 from Arabidopsis.
1G1I	;	2.0	;	CRYSTAL STRUCTURE OF THE OLIGOMERIZATION DOMAIN FROM ROTAVIRUS NSP4
1G1J	;	1.86	;	CRYSTAL STRUCTURE OF THE OLIGOMERIZATION DOMAIN FROM ROTAVIRUS NSP4
3CAG	;	1.9	;	Crystal structure of the oligomerization domain hexamer of the arginine repressor protein from Mycobacterium tuberculosis in complex with 9 arginines.
5Y2J	;	2.55	;	Crystal structure of the oligomerization domain of NSP4 from rotavirus strain MF66
5Y9R	;	2.2	;	Crystal structure of the oligomerization domain of NSP4 from rotavirus strain MF66
5Y2H	;	2.6	;	Crystal structure of the oligomerization domain of NSP4 from the rotavirus strain MF66
5Y2E	;	2.7	;	Crystal structure of the oligomerization domain of NSP4 from the rotavirus strain NCDV
6VAG	;	1.4	;	Crystal structure of the oligomerization domain of phosphoprotein from parainfluenza virus 5
2FQM	;	2.3	;	Crystal structure of the oligomerization domain of the phosphoprotein of vesicular stomatitis virus
6GBO	;	2.1	;	Crystal Structure of the oligomerization domain of Vp35 from Ebola virus
6GBP	;	3.49	;	Crystal Structure of the oligomerization domain of VP35 from Ebola virus, mercury derivative
6GBQ	;	2.43	;	Crystal Structure of the oligomerization domain of Vp35 from Reston virus
6GBR	;	3.15	;	Crystal Structure of the oligomerization domain of VP35 from Reston virus, mercury derivative
6TCM	;	1.85	;	Crystal structure of the omalizumab Fab - crystal form I
6TCN	;	2.3	;	Crystal structure of the omalizumab Fab - crystal form II
6TCO	;	1.8	;	Crystal structure of the omalizumab Fab Leu158Pro light chain mutant - crystal form I
6TCP	;	2.5	;	Crystal structure of the omalizumab Fab Leu158Pro light chain mutant - crystal form II
6TCQ	;	2.05	;	Crystal structure of the omalizumab Fab Ser81Arg and Gln83Arg light chain mutant
6TCR	;	1.45	;	Crystal structure of the omalizumab Fab Ser81Arg, Gln83Arg and Leu158Pro light chain mutant
6TCS	;	2.3	;	Crystal structure of the omalizumab scFv
1OME	;	2.3	;	CRYSTAL STRUCTURE OF THE OMEGA LOOP DELETION MUTANT (RESIDUES 163-178 DELETED) OF BETA-LACTAMASE FROM STAPHYLOCOCCUS AUREUS PC1
4A72	;	2.4	;	Crystal structure of the omega transaminase from Chromobacterium violaceum in a mixture of apo and PLP-bound states
4A6T	;	1.8	;	Crystal structure of the omega transaminase from Chromobacterium violaceum in complex with PLP
6S4G	;	1.67	;	Crystal structure of the omega transaminase from Chromobacterium violaceum in complex with PMP
4A6U	;	1.687	;	Crystal structure of the omega transaminase from Chromobacterium violaceum in the apo form, crystallised from PEG 3350
4A6R	;	1.349	;	Crystal structure of the omega transaminase from Chromobacterium violaceum in the apo form, crystallised from polyacrylic acid
6G4D	;	2.15	;	Crystal structure of the omega TRANSAMINASE FROM PSEUDOMONAS Jessenii in complex with PLP
6G4E	;	2.45	;	Crystal structure of the omega TRANSAMINASE FROM PSEUDOMONAS Jessenii in complex with PLP and 6-aminohexanoate (6-ACA)
6G4F	;	2.5	;	Crystal structure of the omega TRANSAMINASE FROM PSEUDOMONAS Jessenii in complex with PMP
6G4C	;	1.87	;	Crystal structure of the omega transaminase from Pseudomonas jessenii in the apo form, crystallized from ammonium phosphate
6G4B	;	1.8	;	Crystal structure of the omega transaminase from Pseudomonas jessenii in the apo form, crystallized from succinate
6RCP	;	3.231	;	Crystal structure of the OmpK36 clinical isolate ST258 from Klebsiella pneumonia
7Q3T	;	1.788	;	Crystal structure of the OmpK36 D insertion chimera from Klebsiella pneumonia
6RCK	;	2.029	;	Crystal structure of the OmpK36 GD insertion chimera from Klebsiella pneumonia
7PZF	;	1.499	;	Crystal structure of the OmpK36 TD insertion chimera from Klebsiella pneumonia
1CSO	;	1.9	;	CRYSTAL STRUCTURE OF THE OMTKY3 P1 VARIANT OMTKY3-ILE18I IN COMPLEX WITH SGPB
1CT0	;	1.8	;	CRYSTAL STRUCTURE OF THE OMTKY3 P1 VARIANT OMTKY3-SER18I IN COMPLEX WITH SGPB
1CT2	;	1.65	;	CRYSTAL STRUCTURE OF THE OMTKY3 P1 VARIANT OMTKY3-THR18I IN COMPLEX WITH SGPB
1CT4	;	1.6	;	CRYSTAL STRUCTURE OF THE OMTKY3 P1 VARIANT OMTKY3-VAL18I IN COMPLEX WITH SGPB
4ZER	;	3.1	;	Crystal structure of the Onc112 antimicrobial peptide bound to the Thermus thermophilus 70S ribosome
3O5X	;	2.0	;	Crystal structure of the oncogenic tyrosine phosphatase SHP2 complexed with a salicylic acid-based small molecule inhibitor
3E3H	;	2.15	;	Crystal structure of the OP hydrolase mutant from Brevundimonas diminuta
1K24	;	2.03	;	Crystal Structure of the OpcA Outer Membrane Adhesin/Invasin from Neisseria meningitidis
6ZPQ	;	1.85	;	Crystal structure of the open conformation of Angiotensin-1 converting enzyme N-domain.
6ZPT	;	2.8	;	Crystal structure of the open conformation of S2_S'-mutant human Angiotensin-1 converting enzyme N-domain.
3QNF	;	3.0	;	Crystal structure of the open state of human endoplasmic reticulum aminopeptidase 1 ERAP1
4MT0	;	3.292	;	Crystal Structure of the Open State of the Neisseria gonorrhoeae MtrE Outer Membrane Channel
2VDD	;	3.3	;	Crystal Structure of the Open State of TolC Outer Membrane Component of Mutlidrug Efflux Pumps
2VDE	;	3.2	;	Crystal Structure of the Open State of TolC Outer Membrane Component of Mutlidrug Efflux Pumps
2YVH	;	2.5	;	Crystal structure of the operator-binding form of the multi-drug binding transcriptional repressor CgmR
8UQS	;	1.35	;	Crystal structure of the Opossum p53 tetramerization domain
3D5K	;	2.4	;	Crystal structure of the OprM channel in a non-symmetrical space group
4RJX	;	1.54	;	Crystal structure of the OprO mutant protein F62Y/D114Y
8PYH	;	2.2	;	Crystal structure of the Orange Carotenoid Protein 2 (OCP2) from Crinalium epipsammum PCC 9333
8PZK	;	1.8	;	Crystal structure of the Orange Carotenoid Protein 2 (OCP2) from Gloeocapsa sp. PCC 7428
3MG1	;	1.649	;	Crystal structure of the orange carotenoid protein from cyanobacteria Synechocystis sp. PCC 6803
3MG3	;	1.702	;	Crystal structure of the orange carotenoid protein R155L mutant from cyanobacteria synechocystis sp. PCC 6803
3MG2	;	2.653	;	Crystal structure of the orange carotenoid protein Y44S mutant from cyanobacteria synechocystis sp. PCC 6803
6OM3	;	3.3	;	Crystal structure of the Orc1 BAH domain in complex with a nucleosome core particle
8P7A	;	2.56	;	Crystal structure of the ORD domain of human ORP8
6TP4	;	3.011	;	Crystal structure of the Orexin-1 receptor in complex with ACT-462206
6TQ6	;	2.546	;	Crystal structure of the Orexin-1 receptor in complex with Compound 14
6TQ4	;	2.299	;	Crystal structure of the Orexin-1 receptor in complex with Compound 16
6TP3	;	3.04	;	Crystal structure of the Orexin-1 receptor in complex with daridorexant
6TOD	;	2.11	;	Crystal structure of the Orexin-1 receptor in complex with EMPA
6TP6	;	2.338	;	Crystal structure of the Orexin-1 receptor in complex with filorexant
6TOS	;	2.13	;	Crystal structure of the Orexin-1 receptor in complex with GSK1059865
6TOT	;	2.22	;	Crystal structure of the Orexin-1 receptor in complex with lemborexant
6TQ7	;	2.6636	;	Crystal structure of the Orexin-1 receptor in complex with SB-334867
6TQ9	;	2.655	;	Crystal structure of the Orexin-1 receptor in complex with SB-408124
6TO7	;	2.26	;	Crystal structure of the Orexin-1 receptor in complex with suvorexant at 2.29 A resolution
6TPG	;	2.741	;	Crystal structure of the Orexin-2 receptor in complex with EMPA at 2.74 A resolution
6TPN	;	2.608	;	Crystal structure of the Orexin-2 receptor in complex with HTL6641 at 2.61 A resolution
6TPJ	;	2.74	;	Crystal structure of the Orexin-2 receptor in complex with suvorexant at 2.76 A resolution
2GNN	;	2.3	;	Crystal Structure of the Orf Virus NZ2 Variant of VEGF-E
2X5H	;	1.8	;	Crystal structure of the ORF131 L26M L51M double mutant from Sulfolobus islandicus rudivirus 1
2X5G	;	2.0	;	Crystal structure of the ORF131L51M mutant from Sulfolobus islandicus rudivirus 1
3OO3	;	2.2	;	Crystal Structure of the Orf6* (CYP165D3) Monooxygenase Involved in Teicoplanin Biosynthesis
8BGM	;	2.7	;	Crystal structure of the OrfX1-OrfX3 complex from the PMP1 neurotoxin gene cluster
2BJO	;	2.1	;	Crystal Structure of the Organic Hydroperoxide Resistance Protein OhrB of Bacillus subtilis
5E20	;	1.97	;	Crystal structure of the organohalide sensing RdhR-CbdbA1625 transcriptional regulator in the 2,3-dichlorophenol bound form
5E1Z	;	1.66	;	Crystal structure of the organohalide sensing RdhR-CbdbA1625 transcriptional regulator in the 2,4-dichlorophenol bound form
5E1X	;	1.46	;	Crystal structure of the organohalide sensing RdhR-CbdbA1625 transcriptional regulator in the 3,4-dichlorophenol bound form
5E1W	;	1.392	;	Crystal structure of the organohalide sensing RdhR-CbdbA1625 transcriptional regulator in the ligand free form
6UPU	;	2.2	;	Crystal structure of the Orientia tsutsugamushi OtDUB in complex with three molecules of ubiquitin
5E3K	;	1.7	;	Crystal structure of the ornithine aminotransferase from Toxoplasma gondii ME49 in a complex with (S)-4-amino-5-fluoropentanoic acid
5DJ9	;	1.55	;	Crystal structure of the ornithine aminotransferase from Toxoplasma gondii ME49 in a complex with gabaculine
4ZLV	;	1.8	;	Crystal structure of the ornithine aminotransferase from Toxoplasma gondii ME49 in a complex with the Schiff base between PLP and Lys286
3RUY	;	2.65	;	Crystal Structure of the Ornithine-oxo acid transaminase RocD from Bacillus anthracis
2X3L	;	2.0	;	Crystal Structure of the Orn_Lys_Arg decarboxylase family protein SAR0482 from Methicillin-resistant Staphylococcus aureus
8U0Z	;	1.399	;	CRYSTAL STRUCTURE OF THE OROTIDINE 5'-MONOPHOSPHATE DECARBOXYLASE DOMAIN OF Coffea arabica UMP SYNTHASE
3GDK	;	2.0	;	Crystal structure of the orotidine 5'-monophosphate decarboxylase from Saccharomyces cerevisiae
3GDL	;	1.65	;	Crystal structure of the orotidine 5'-monophosphate decarboxylase from Saccharomyces cerevisiae complexed with 6-azauridine 5'-monophosphate
2QCF	;	1.22	;	Crystal structure of the orotidine-5'-monophosphate decarboxylase domain (Asp312Asn mutant) of human UMP synthase bound to 5-fluoro-UMP
2QCM	;	1.67	;	Crystal structure of the orotidine-5'-monophosphate decarboxylase domain (Asp312Asn mutant) of human UMP synthase bound to 6-hydroxymethyl-UMP
2QCL	;	1.85	;	Crystal structure of the orotidine-5'-monophosphate decarboxylase domain (Asp312Asn mutant) of human UMP synthase bound to OMP
2QCG	;	1.75	;	Crystal structure of the orotidine-5'-monophosphate decarboxylase domain of human UMP synthase bound to 5-bromo-UMP
2QCH	;	1.95	;	Crystal structure of the orotidine-5'-monophosphate decarboxylase domain of human UMP synthase bound to 5-iodo-UMP
2QCE	;	1.43	;	Crystal structure of the orotidine-5'-monophosphate decarboxylase domain of human UMP synthase bound to sulfate, glycerol, and chloride
2QCD	;	2.03	;	Crystal structure of the orotidine-5'-monophosphate decarboxylase domain of human UMP synthase bound to UMP
2QCC	;	1.85	;	Crystal structure of the orotidine-5'-monophosphate decarboxylase domain of human UMP synthase, apo form
1PK5	;	2.4	;	Crystal structure of the orphan nuclear receptor LRH-1
1GA5	;	2.4	;	CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR REV-ERB(ALPHA) DNA-BINDING DOMAIN BOUND TO ITS COGNATE RESPONSE ELEMENT
1HLZ	;	2.8	;	CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR REV-ERB(ALPHA) DNA-BINDING DOMAIN BOUND TO ITS COGNATE RESPONSE ELEMENT
3B0W	;	2.2	;	Crystal structure of the orphan nuclear receptor ROR(gamma)t ligand-binding domain in complex with digoxin
4NIE	;	2.01	;	Crystal structure of the orphan nuclear receptor ROR(gamma)t ligand-binding domain in complex with small molecule ligand
4S15	;	1.897	;	Crystal structure of the orphan nuclear receptor RORalpha ligand-binding domain in complex with 4alpha-caboxyl, 4beta-methyl-zymosterol (4ACD8)
4S14	;	3.542	;	Crystal structure of the orphan nuclear receptor RORgamma ligand-binding domain in complex with 4alpha-caboxyl, 4beta-methyl-zymosterol (4ACD8)
5I04	;	2.42	;	Crystal structure of the orphan region of human endoglin/CD105
5HZW	;	4.451	;	Crystal structure of the orphan region of human endoglin/CD105 in complex with BMP9
5JIE	;	2.1374	;	Crystal structure of the Orsay virus delta protein N-terminal fragment (aa 1~66)
1Y2W	;	1.74	;	Crystal structure of the orthorhombic form of the common edible mushroom (Agaricus bisporus) lectin in complex with T-antigen and N-acetylglucosamine
5A4A	;	1.699	;	Crystal structure of the OSK domain of Drosophila Oskar
7D3Y	;	3.11	;	Crystal structure of the osPHR2-osSPX2 complex
3WKZ	;	2.001	;	Crystal Structure of the Ostrinia furnacalis Group I Chitinase catalytic domain E148Q mutant
4KSJ	;	1.6	;	Crystal structure of the OTU domain of Gumby/Fam105B at 1.6 angstrom
3ZNV	;	1.3	;	Crystal structure of the OTU domain of OTULIN at 1.3 Angstroms.
3ZNX	;	1.35	;	Crystal structure of the OTU domain of OTULIN D336A mutant
4I3S	;	2.85	;	Crystal structure of the outer domain of HIV-1 gp120 in complex with VRC-PG04 space group P21
4I3R	;	3.0	;	Crystal structure of the outer domain of HIV-1 gp120 in complex with VRC-PG04 space group P3221
6EUS	;	2.2	;	Crystal structure of the outer membrane channel DcaP of Acinetobacter baumannii
3JQO	;	2.6	;	Crystal structure of the outer membrane complex of a type IV secretion system
4LM8	;	1.8	;	Crystal structure of the outer membrane decaheme cytochrome MtrC
3PMQ	;	3.2	;	Crystal structure of the outer membrane decaheme cytochrome MtrF
4LMH	;	2.7	;	Crystal structure of the outer membrane decaheme cytochrome OmcA
2ERV	;	2.0	;	Crystal structure of the outer membrane enzyme PagL
4NHR	;	2.34	;	Crystal structure of the outer membrane lipopolysaccharide transport protein LptE (RlpB)
4RH8	;	2.2	;	Crystal structure of the outer membrane lipopolysaccharide transport protein LptE (RlpB) from Escherichia coli in the tetragonal crystal form
1IWN	;	2.2	;	Crystal Structure of the Outer Membrane Lipoprotein Receptor LolB Complexed with PEGMME2000
1IWM	;	1.9	;	Crystal Structure of the Outer Membrane Lipoprotein Receptor, LolB
8QXP	;	3.2	;	Crystal structure of the outer membrane porin OmpW from Klebsiella pneumoniae
1QJ8	;	1.9	;	CRYSTAL STRUCTURE OF THE OUTER MEMBRANE PROTEIN OMPX FROM ESCHERICHIA COLI
1QJ9	;	2.1	;	CRYSTAL STRUCTURE OF THE OUTER MEMBRANE PROTEIN OMPX FROM ESCHERICHIA COLI
2QTK	;	2.8	;	Crystal Structure of the outer membrane protein opdK from Pseudomonas aeruginosa
2ODJ	;	2.9	;	Crystal structure of the outer membrane protein OprD from Pseudomonas aeruginosa
2X27	;	2.4	;	Crystal structure of the outer membrane protein OprG from Pseudomonas aeruginosa
1KMO	;	2.0	;	Crystal structure of the Outer Membrane Transporter FecA
1KMP	;	2.5	;	Crystal structure of the Outer Membrane Transporter FecA Complexed with Ferric Citrate
7AHK	;	2.5	;	Crystal structure of the outward-facing state of the substrate-free Na+-only bound glutamate transporter homolog GltPh
5HLH	;	3.0	;	Crystal structure of the overoxidized AbfR bound to DNA
1GZ2	;	1.5	;	Crystal structure of the Ovocleidin-17 a major protein of the Gallus gallus eggshell calcified layer.
1EWZ	;	2.4	;	CRYSTAL STRUCTURE OF THE OXA-10 BETA-LACTAMASE FROM PSEUDOMONAS AERUGINOSA
2WKI	;	2.1	;	Crystal structure of the OXA-10 K70C mutant at pH 7.0
2X01	;	1.9	;	CRYSTAL STRUCTURE OF THE OXA-10 S67A MUTANT AT PH 7
2WGV	;	1.8	;	Crystal structure of the OXA-10 V117T mutant at pH 6.5 inhibited by a chloride ion
2WGW	;	1.8	;	Crystal structure of the OXA-10 V117T mutant at pH 8.0
2HP9	;	2.5	;	Crystal Structure of the OXA-10 W154A mutant at pH 6.0
2HP6	;	2.2	;	Crystal structure of the OXA-10 W154A mutant at pH 7.5
2HPB	;	2.05	;	Crystal structure of the OXA-10 W154A mutant at pH 9.0
2HP5	;	2.7	;	Crystal Structure of the OXA-10 W154G mutant at pH 7.0
2RL3	;	1.9	;	Crystal structure of the OXA-10 W154H mutant at pH 7
6ZXI	;	1.85	;	Crystal Structure of the OXA-48 Carbapenem-Hydrolyzing Class D beta-Lactamase in Complex with the DBO inhibitor ANT3310
5FQ9	;	1.5	;	Crystal structure of the OXA10 with 1C
7L5R	;	1.65	;	Crystal Structure of the Oxacillin-hydrolyzing Class D Extended-spectrum Beta-lactamase OXA-14 from Pseudomonas aeruginosa
7L5T	;	1.88	;	Crystal Structure of the Oxacillin-hydrolyzing Class D Extended-spectrum Beta-lactamase OXA-14 from Pseudomonas aeruginosa in Complex with Covalently Bound Clavulanic Acid
6KKH	;	2.64	;	Crystal structure of the oxalate bound malyl-CoA lyase from Roseiflexus castenholzii
3F3Q	;	1.76	;	Crystal structure of the oxidised form of thioredoxin 1 from saccharomyces cerevisiae
3DUI	;	2.1	;	Crystal structure of the oxidized CG-1B: an adhesion/growth-regulatory lectin from chicken
3LO8	;	1.05	;	Crystal Structure of The Oxidized Form of Ferredoxin:NADP+ Reductase From Maize Root at 1.05 Angstroms
4JBA	;	2.5	;	Crystal Structure of the Oxidized Form of MarR from E.coli
1FRV	;	2.85	;	CRYSTAL STRUCTURE OF THE OXIDIZED FORM OF NI-FE HYDROGENASE
2FRV	;	2.54	;	CRYSTAL STRUCTURE OF THE OXIDIZED FORM OF NI-FE HYDROGENASE
1I6A	;	2.3	;	CRYSTAL STRUCTURE OF THE OXIDIZED FORM OF OXYR
3X32	;	0.83	;	Crystal structure of the oxidized form of the solubilized domain of porcine cytochrome b5 in form 1 crystal
3X33	;	0.93	;	Crystal structure of the oxidized form of the solubilized domain of porcine cytochrome b5 in form 2 crystal
6HSD	;	1.6	;	Crystal structure of the oxidized form of the transcription regulator RsrR
2A5W	;	2.1	;	Crystal structure of the oxidized gamma-subunit of the dissimilatory sulfite reductase (DsrC) from Archaeoglobus fulgidus
4I2T	;	1.4	;	Crystal structure of the oxidized glutaredoxin from Chlorella sorokiniana T-89
1I9T	;	1.7	;	CRYSTAL STRUCTURE OF THE OXIDIZED RNA TRIPHOSPHATASE DOMAIN OF MOUSE MRNA CAPPING ENZYME
4AWS	;	1.0	;	Crystal structure of the oxidized Shewanella Yellow Enzyme 1 (SYE1) M25L mutant
4AWU	;	1.69	;	Crystal structure of the oxidized Shewanella Yellow Enzyme 1 (SYE1) M25L mutant in complex with para-chlorophenol
1FT5	;	1.6	;	CRYSTAL STRUCTURE OF THE OXIDIZED STATE OF CYTOCHROME C554 FROM NITROSOMONAS EUROPAEA
3HZ8	;	1.45	;	Crystal structure of the oxidized T176V DsbA1 mutant
4WNF	;	2.9	;	Crystal structure of the oxidized TPR domain of LGN in complex with Frmpd4/Preso1 at 2.9 Angstrom resolution
3DQP	;	1.4	;	Crystal structure of the oxidoreductase ylbE from Lactococcus lactis, Northeast Structural Genomics Consortium Target KR121.
7W9J	;	1.75	;	Crystal Structure of the Oxomolybdenum Mesoporphyrin IX-Reconstituted CYP102A1 (P450BM3) Heme Domain with N-Dodecanoyl-L-Homoserine Lactone
7W9D	;	1.55	;	Crystal Structure of the Oxomolybdenum Mesoporphyrin IX-Reconstituted CYP102A1 (P450BM3) Heme Domain with N-Hexadecanoyl-L-Homoserine
2Z6S	;	1.25	;	Crystal structure of the oxy myoglobin free from X-ray-induced photoreduction
1WX4	;	1.5	;	Crystal structure of the oxy-form of the copper-bound Streptomyces castaneoglobisporus tyrosinase complexed with a caddie protein prepared by the addition of dithiothreitol
1WX2	;	1.8	;	Crystal Structure of the oxy-form of the copper-bound Streptomyces castaneoglobisporus tyrosinase complexed with a caddie protein prepared by the addition of hydrogenperoxide
2YYG	;	2.0	;	Crystal structure of the oxygenase component (HpaB) of 4-hydroxyphenylacetate 3-monooxygenase
2YYI	;	1.66	;	Crystal structure of the oxygenase component (HpaB) of 4-hydroxyphenylacetate 3-monooxygenase complexed with FAD
2YYJ	;	1.66	;	Crystal structure of the oxygenase component (HpaB) of 4-hydroxyphenylacetate 3-monooxygenase complexed with FAD and 4-hydroxyphenylacetate
7L4S	;	2.4	;	Crystal structure of the OxyR regulatory domain of Shewanella oneidensis MR-1, reduced form
1PHJ	;	2.5	;	CRYSTAL STRUCTURE OF THE OXYTRICHA NOVA TELOMERE END-BINDING PROTEIN COMPLEXED WITH NONCOGNATE SSDNA GG(3DR)GTTTTGGGG
1PH2	;	3.1	;	CRYSTAL STRUCTURE OF THE OXYTRICHA NOVA TELOMERE END-BINDING PROTEIN COMPLEXED WITH NONCOGNATE SSDNA GGGGTTTTG
1PH5	;	2.3	;	CRYSTAL STRUCTURE OF THE OXYTRICHA NOVA TELOMERE END-BINDING PROTEIN COMPLEXED WITH NONCOGNATE SSDNA GGGGTTTTG(3DR)GG
1PA6	;	2.45	;	Crystal structure of the OXYTRICHA nova telomere end-binding protein complexed with noncognate ssDNA GGGGTTTTGAGG
1PH9	;	2.5	;	CRYSTAL STRUCTURE OF THE OXYTRICHA NOVA TELOMERE END-BINDING PROTEIN COMPLEXED WITH NONCOGNATE SSDNA GGGGTTTTGAGG
1PH8	;	2.36	;	CRYSTAL STRUCTURE OF THE OXYTRICHA NOVA TELOMERE END-BINDING PROTEIN COMPLEXED WITH NONCOGNATE SSDNA GGGGTTTTGCGG
1PH4	;	2.3	;	CRYSTAL STRUCTURE OF THE OXYTRICHA NOVA TELOMERE END-BINDING PROTEIN COMPLEXED WITH NONCOGNATE SSDNA GGGGTTTTGGCG
1PH1	;	2.51	;	CRYSTAL STRUCTURE OF THE OXYTRICHA NOVA TELOMERE END-BINDING PROTEIN COMPLEXED WITH NONCOGNATE SSDNA GGGGTTTTGGGGT
1PH3	;	2.3	;	CRYSTAL STRUCTURE OF THE OXYTRICHA NOVA TELOMERE END-BINDING PROTEIN COMPLEXED WITH NONCOGNATE SSDNA GGGGTTTTGGTG
1PH7	;	2.9	;	CRYSTAL STRUCTURE OF THE OXYTRICHA NOVA TELOMERE END-BINDING PROTEIN COMPLEXED WITH NONCOGNATE SSDNA GGGGTTTTGIGG
1PH6	;	2.1	;	Crystal Structure of THE OXYTRICHA NOVA TELOMERE END-BINDING PROTEIN COMPLEXED WITH NONCOGNATE SSDNA GGGGTTTTGTGG
1JPQ	;	1.6	;	Crystal Structure of the Oxytricha Telomeric DNA at 1.6A
2UY6	;	2.5	;	Crystal structure of the P pilus rod subunit PapA
2UY7	;	2.6	;	Crystal structure of the P pilus rod subunit PapA
3A1D	;	1.85	;	Crystal structure of the P- and N-domains of CopA, a copper-transporting P-type ATPase, bound with ADP-Mg
3A1C	;	1.85	;	crystal structure of the P- and N-domains of CopA, a copper-transporting P-type ATPase, bound with AMPPCP-Mg
3A1E	;	1.95	;	Crystal structure of the P- and N-domains of His462Gln mutant CopA, a copper-transporting P-type ATPase, bound with AMPPCP-Mg
1PBE	;	1.9	;	CRYSTAL STRUCTURE OF THE P-HYDROXYBENZOATE HYDROXYLASE-SUBSTRATE COMPLEX REFINED AT 1.9 ANGSTROMS RESOLUTION. ANALYSIS OF THE ENZYME-SUBSTRATE AND ENZYME-PRODUCT COMPLEXES
6VSK	;	3.12	;	Crystal structure of the P-Rex1 DEP1 domain
5FI1	;	3.203	;	Crystal Structure of the P-Rex1 DH/PH tandem in complex with Cdc42
5FI0	;	3.282	;	Crystal Structure of the P-Rex1 DH/PH tandem in complex with Rac1
5D27	;	1.92	;	Crystal Structure of the P-Rex1 PH domain
5D3V	;	1.852	;	Crystal Structure of the P-Rex1 PH domain with Citrate Bound
5D3X	;	1.69	;	Crystal Structure of the P-Rex1 PH domain with Inositol-(1,3,4,5)-Tetrakisphosphate Bound
5D3Y	;	1.95	;	Crystal Structure of the P-Rex1 PH domain with Inositol-(1,3,4,5)-Tetrakisphosphate Bound
5D3W	;	1.852	;	Crystal Structure of the P-Rex1 PH domain with Sulfate Bound
6BNM	;	1.9	;	Crystal Structure of the P-Rex2 PH domain
2PO1	;	1.94	;	Crystal structure of the P. abyssi exosome RNase PH ring complexed with a single stranded 10-mer poly(A) RNA
2PO0	;	2.3	;	Crystal structure of the P. abyssi exosome RNase PH ring complexed with ADP in double conformation
2PO2	;	2.41	;	Crystal structure of the P. abyssi exosome RNase PH ring complexed with CDP
2PNZ	;	2.14	;	Crystal structure of the P. abyssi exosome RNase PH ring complexed with UDP and GMP
3N9B	;	1.92	;	Crystal Structure of the P. aeruginosa LigD phosphoesterase domain
1II8	;	3.02	;	Crystal structure of the P. furiosus Rad50 ATPase domain
3BS0	;	2.6	;	Crystal structure of the P. putida toluene transporter TodX
1QS8	;	2.5	;	Crystal structure of the P. vivax aspartic proteinase plasmepsin complexed with the inhibitor pepstatin A
1LNX	;	2.05	;	Crystal structure of the P.aerophilum SmAP1 heptamer in a new crystal form (C2221)
5FO4	;	1.85	;	Crystal structure of the P.falciparum cytosolic leucyl-tRNA synthetase editing domain (space group P1)
5FOD	;	1.7	;	Crystal structure of the P.falciparum cytosolic leucyl-tRNA synthetase editing domain (space group P1) containing deletions of insertions 1 and 3
5FOC	;	1.5	;	Crystal structure of the P.falciparum cytosolic leucyl-tRNA synthetase editing domain (space group P21)
5FOF	;	2.4	;	Crystal structure of the P.knowlesi cytosolic leucyl-tRNA synthetase editing domain
3BXK	;	2.55	;	Crystal structure of the P/Q-type calcium channel (CaV2.1) IQ domain and CA2+calmodulin complex
7QIQ	;	1.85	;	CRYSTAL STRUCTURE OF THE P1 aminobutanoic acid (ABU) BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
3KH2	;	2.71	;	Crystal structure of the P1 bacteriophage Doc toxin (F68S) in complex with the Phd antitoxin (L17M/V39A). Northeast Structural Genomics targets ER385-ER386
7QIS	;	1.83	;	CRYSTAL STRUCTURE OF THE P1 difluoroethylglycine (DfeGly) BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
1I5N	;	2.14	;	Crystal structure of the P1 domain of CheA from Salmonella typhimurium
3KYJ	;	1.4	;	Crystal structure of the P1 domain of CheA3 in complex with CheY6 from R. sphaeroides
1T7C	;	1.85	;	CRYSTAL STRUCTURE OF THE P1 GLU BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
1T8M	;	1.8	;	CRYSTAL STRUCTURE OF THE P1 HIS BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
1T8L	;	1.75	;	CRYSTAL STRUCTURE OF THE P1 MET BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
7QIR	;	1.9	;	CRYSTAL STRUCTURE OF THE P1 monofluorethylglycine(MfeGly) BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
1T8N	;	1.75	;	CRYSTAL STRUCTURE OF THE P1 THR BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
7QIT	;	1.99	;	CRYSTAL STRUCTURE OF THE P1 trifluoroethylglycine (TfeGly) BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
1T8O	;	1.7	;	CRYSTAL STRUCTURE OF THE P1 TRP BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
3SLE	;	2.52	;	Crystal Structure of the P107C-MauG/pre-Methylamine Dehydrogenase Complex
3SJL	;	1.63	;	Crystal Structure of the P107S-MauG/pre-Methylamine Dehydrogenase Complex
3SVW	;	1.86	;	Crystal Structure of the P107V-MauG/pre-Methylamine Dehydrogenase Complex
8OW2	;	2.57	;	Crystal structure of the p110alpha catalytic subunit from homo sapiens in complex with activator 1938
1SHZ	;	2.85	;	Crystal Structure of the p115RhoGEF rgRGS Domain in A Complex with Galpha(13):Galpha(i1) Chimera
2GKT	;	1.23	;	Crystal structure of the P14'-Ala32 variant of the N-terminally truncated OMTKY3-del(1-5)
1VEU	;	2.15	;	Crystal structure of the p14/MP1 complex at 2.15 A resolution
1Y92	;	2.2	;	Crystal structure of the P19A/N67D Variant Of Bovine seminal Ribonuclease
3GF5	;	2.5	;	Crystal structure of the P21 R1-R7 N-terminal domain of murine MVP
3JXB	;	1.67	;	Crystal structure of the P22 c2 repressor protein in complex with synthetic operator 9C
3JXD	;	2.1	;	Crystal structure of the P22 c2 repressor protein in complex with synthetic operator 9C in the presence of Rb+
3JXC	;	1.9	;	Crystal structure of the P22 c2 repressor protein in complex with synthetic operator 9T in the presence of Tl+
2R1J	;	1.53	;	Crystal Structure of the P22 c2 Repressor protein in complex with the synthetic operator 9T
5GMA	;	2.1	;	Crystal structure of the P228A variant of Thermotoga maritima acetyl esterase
4PCK	;	2.401	;	Crystal structure of the P22S mutant of N-terminal CS domain of human Shq1
6SVF	;	1.6	;	Crystal structure of the P235GK mutant of ArgBP from T. maritima
5WZY	;	2.799	;	Crystal structure of the P2X4 receptor from zebrafish in the presence of CTP at 2.8 Angstroms
7PP1	;	2.78	;	Crystal structure of the P2Y12 receptor in complex with the inverse agonist selatogrel.
5LKT	;	2.04	;	Crystal structure of the p300 acetyltransferase catalytic core with butyryl-coenzyme A.
5LKU	;	3.5	;	Crystal structure of the p300 acetyltransferase catalytic core with coenzyme A.
5LKZ	;	2.5	;	Crystal structure of the p300 acetyltransferase catalytic core with crotonyl-coenzyme A.
5LKX	;	2.52	;	Crystal structure of the p300 acetyltransferase catalytic core with propionyl-coenzyme A.
6V8B	;	3.13	;	Crystal structure of the p300 acetyltransferase domain with AcCoA competitive inhibitor 1
6V90	;	2.04	;	Crystal structure of the p300 acetyltransferase domain with AcCoA competitive inhibitor 12
6V8N	;	2.3	;	Crystal structure of the p300 acetyltransferase domain with AcCoA competitive inhibitor 17
6PGU	;	1.72	;	Crystal structure of the p300 acetyltransferase domain with allosteric inhibitor CPI-076 and CoA
6PF1	;	2.32	;	Crystal structure of the p300 acetyltransferase domain with allosteric inhibitor CPI-090 and CoA
6V8K	;	1.84	;	Crystal structure of the p300 acetyltransferase domain with peptide-competitive inhibitor 2
3P57	;	2.1921	;	Crystal structure of the p300 TAZ2 domain bound to MEF2 on DNA
2AN0	;	2.6	;	Crystal Structure of the P332G mutant of the Bacillus subtilis NOS
2OKR	;	2.0	;	Crystal Structure of the P38a-MAPKAP kinase 2 Heterodimer
2ONL	;	4.0	;	Crystal Structure of the p38a-MAPKAP kinase 2 Heterodimer
8HOP	;	1.86	;	Crystal structure of the P450 BM3 heme domain mutant F87A in complex with Im-C6-Nap-Tyr
8HOQ	;	1.94	;	Crystal structure of the P450 BM3 heme domain mutant F87A in complex with Im-C6-Phe(4CF3)-Tyr
8HOR	;	1.95	;	Crystal structure of the P450 BM3 heme domain mutant F87A in complex with Im-C6-Phe(4CH3)-Tyr
8HOS	;	1.82	;	Crystal structure of the P450 BM3 heme domain mutant F87A in complex with Im-C6-Phe(4NO2)-Tyr
8HOO	;	1.86	;	Crystal structure of the P450 BM3 heme domain mutant F87A in complex with Im-C6-Tyr-Nap
8HON	;	2.01	;	Crystal structure of the P450 BM3 heme domain mutant F87A in complex with Im-C6-Tyr-Tyr
7EGN	;	2.7	;	Crystal structure of the P450 BM3 heme domain mutant F87A in complex with N-imidazolyl-hexanoyl-L-phenylalanine and hydroxylamine
7YJD	;	1.9	;	Crystal structure of the P450 BM3 heme domain mutant F87A in complex with N-imidazolyl-hexanoyl-L-phenylalanine and hydroxylamine
7WDH	;	1.68	;	Crystal structure of the P450 BM3 heme domain mutant F87A in complex with N-imidazolyl-hexanoyl-L-phenylalanine, phenol and hydroxylamine
7Y0T	;	1.89	;	Crystal structure of the P450 BM3 heme domain mutant F87A in complex with N-imidazolyl-hexanoyl-L-phenylalanyl-L-phenylalanine
7Y0U	;	2.0	;	Crystal structure of the P450 BM3 heme domain mutant F87A in complex with N-imidazolyl-hexanoyl-L-phenylalanyl-L-phenylalanine and hydroxylamine
7Y0S	;	2.06	;	Crystal structure of the P450 BM3 heme domain mutant F87A in complex with N-imidazolyl-hexanoyl-L-tyrosyl-L-tyrosine and hydroxylamine
8HOT	;	1.96	;	Crystal structure of the P450 BM3 heme domain mutant F87A in complex with NH2-C7-Phe-Phe
8HOU	;	1.75	;	Crystal structure of the P450 BM3 heme domain mutant F87A-T268V in complex with Im-N-C4-Phe-Phe
8JC3	;	1.82	;	Crystal structure of the P450 BM3 heme domain mutant F87A-T268V in complex with Pyd-N-C4-Phe and hydroxylamine
8JC4	;	2.64	;	Crystal structure of the P450 BM3 heme domain mutant F87A-T268V in complex with Pyd-Pid-Phe and hydroxylamine
7YDL	;	1.58	;	Crystal structure of the P450 BM3 heme domain mutant F87A/T268I/A184V/A82T in complex with N-imidazolyl-hexanoyl-L-phenylalanine
7YJF	;	1.515	;	Crystal structure of the P450 BM3 heme domain mutant F87A/T268P/V78I in complex with N-imidazolyl-pentanoyl-L-phenylalanine and hydroxylamine
7YDD	;	1.663	;	Crystal structure of the P450 BM3 heme domain mutant F87A/T268P/V78I in complex with N-imidazolyl-pentanoyl-L-phenylalanine,propylbenzene and hydroxylamine
7YJG	;	1.684	;	Crystal structure of the P450 BM3 heme domain mutant F87A/T268V/A82C/L181M in complex with N-imidazolyl-pentanoyl-L-phenylalanine and hydroxylamine
7YFT	;	2.0	;	Crystal structure of the P450 BM3 heme domain mutant F87A/T268V/A82C/L181M in complex with N-imidazolyl-pentanoyl-L-phenylalanine, indane and hydroxylamine
7Y0P	;	1.99	;	Crystal structure of the P450 BM3 heme domain mutant F87A/T268V/A82T/I263L in complex with N-imidazolyl-hexanoyl-L-phenylalanine, p-cresol and hydroxylamine
7Y0Q	;	2.31	;	Crystal structure of the P450 BM3 heme domain mutant F87A/T268V/A82T/I263L in complex with p-toluidine
7YJE	;	1.85	;	Crystal structure of the P450 BM3 heme domain mutant F87G/T268V/A184V/A328V in complex with N-imidazolyl-hexanoyl-L-phenylalanine and acetate ion
7YD9	;	1.748	;	Crystal structure of the P450 BM3 heme domain mutant F87G/T268V/A184V/A328V in complex with N-imidazolyl-hexanoyl-L-phenylalanine,methylbenzene and hydroxylamine
7WDI	;	2.1	;	Crystal structure of the P450 BM3 heme domain mutant F87K in complex with N-imidazolyl-hexanoyl-L-phenylalanine and hydroxylamine
7WDD	;	2.21	;	Crystal structure of the P450 BM3 heme domain mutant F87K in complex with N-imidazolyl-hexanoyl-L-phenylalanine, styrene and hydroxylamine
7WDG	;	2.07	;	Crystal structure of the P450 BM3 heme domain mutant F87L in complex with N-imidazolyl-hexanoyl-L-phenylalanine, phenol and hydroxylamine
7WDE	;	2.11	;	Crystal structure of the P450 BM3 heme domain mutant F87L in complex with N-imidazolyl-hexanoyl-L-phenylalanine, styrene and hydroxylamine
7YDC	;	1.609	;	Crystal structure of the P450 BM3 heme domain mutant F87L/T268V/V78C in complex with N-imidazolyl-pentanoyl-L-phenylalanine and hydroxylamine
7Y0R	;	2.09	;	Crystal structure of the P450 BM3 heme domain mutant F87L/V78S/A184V in complex with N-imidazolyl-hexanoyl-L-phenylalanine, p-toluidine and hydroxylamine
7YDE	;	1.789	;	Crystal structure of the P450 BM3 heme domain mutant F87T/T268V/I263V in complex with N-imidazolyl-hexanoyl-L-phenylalanine and hydroxylamine
7YJH	;	1.792	;	Crystal structure of the P450 BM3 heme domain mutant F87V/T268I in complex with N-imidazolyl-pentanoyl-L-phenylalanine and hydroxylamine
7YDB	;	1.472	;	Crystal structure of the P450 BM3 heme domain mutant F87V/T268I in complex with N-imidazolyl-pentanoyl-L-phenylalanine,ethylbenzene and hydroxylamine
7YDA	;	1.557	;	Crystal structure of the P450 BM3 heme domain mutant F87V/T268V/A184V in complex with N-imidazolyl-pentanoyl-L-phenylalanine and hydroxylamine
6MCW	;	2.4	;	Crystal structure of the P450 domain of the CYP51-ferredoxin fusion protein from Methylococcus capsulatus, complex with the detergent Anapoe-X-114
6MI0	;	2.73	;	Crystal structure of the P450 domain of the CYP51-ferredoxin fusion protein from Methylococcus capsulatus, ligand-free state
2QBM	;	1.8	;	Crystal structure of the P450cam G248T mutant in the cyanide bound state
2QBO	;	1.9	;	Crystal structure of the P450cam G248V mutant in the cyanide bound state
1PC4	;	1.65	;	Crystal Structure of the P50A mutant of ferredoxin I at 1.65 A Resolution
1PC5	;	1.8	;	Crystal Structure of the P50G Mutant of Ferredoxin I at 1.8 A Resolution
8E7B	;	2.5	;	Crystal structure of the p53 (Y107H) core domain monoclinic P form
8E7A	;	1.3	;	Crystal structure of the p53 (Y107H) core domain orthorhombic P form
5G4N	;	1.35	;	Crystal structure of the p53 cancer mutant Y220C in complex with a difluorinated derivative of the small molecule stabilizer Phikan083
5G4M	;	1.38	;	Crystal structure of the p53 cancer mutant Y220C in complex with a monofluorinated derivative of the small molecule stabilizer Phikan083
5G4O	;	1.48	;	Crystal structure of the p53 cancer mutant Y220C in complex with a trifluorinated derivative of the small molecule stabilizer Phikan083
3KMD	;	2.15	;	Crystal structure of the p53 core domain bound to a full consensus site as a self-assembled tetramer
7C44	;	1.65	;	Crystal structure of the p53-binding domain of human MdmX protein in complex with Nutlin3a
7A4Y	;	2.157	;	Crystal structure of the P5P6 coiled-coil in complex with nanobody Nb34.
3GT2	;	1.75	;	Crystal Structure of the P60 Domain from M. avium paratuberculosis Antigen MAP1272c
3I86	;	2.4	;	Crystal structure of the P60 Domain from M. avium subspecies paratuberculosis antigen MAP1204
3BB6	;	2.3	;	Crystal structure of the P64488 protein from E.coli (strain K12). Northeast Structural Genomics Consortium target ER596
1D7E	;	1.39	;	CRYSTAL STRUCTURE OF THE P65 CRYSTAL FORM OF PHOTOACTIVE YELLOW PROTEIN
1GSV	;	1.75	;	Crystal structure of the P65 crystal form of photoactive yellow protein G47S mutant
1GSX	;	1.79	;	CRYSTAL STRUCTURE OF THE P65 CRYSTAL FORM OF PHOTOACTIVE YELLOW PROTEIN G47S/G51S MUTANT
1GSW	;	1.85	;	CRYSTAL STRUCTURE OF THE P65 CRYSTAL FORM OF PHOTOACTIVE YELLOW PROTEIN G51S MUTANT
4A63	;	2.27	;	Crystal structure of the p73-ASPP2 complex at 2.6A resolution
3QY2	;	2.59	;	Crystal structure of the P93A monomer mutant of S. cerevisiae Cks1
2Q00	;	2.4	;	Crystal structure of the P95883_SULSO protein from Sulfolobus solfataricus. NESG target SsR10.
6G2V	;	1.903	;	Crystal structure of the p97 D2 domain in a helical split-washer conformation
6G2W	;	2.678	;	Crystal structure of the p97 D2 domain in a helical split-washer conformation
6G2X	;	2.078	;	Crystal structure of the p97 D2 domain in a helical split-washer conformation
6G2Y	;	2.153	;	Crystal structure of the p97 D2 domain in a helical split-washer conformation
6G2Z	;	1.923	;	Crystal structure of the p97 D2 domain in a helical split-washer conformation
6G30	;	2.418	;	Crystal structure of the p97 D2 domain in a helical split-washer conformation
3QQ7	;	2.65	;	Crystal Structure of the p97 N-terminal domain
8HRZ	;	2.7	;	Crystal structure of the p97-N/D1 hexamer in complex with six p47-UBX domains
4EXA	;	2.8	;	Crystal structure of the PA4992, the putative aldo-keto reductase from Pseudomona aeruginosa
2O6B	;	3.21	;	Crystal structure of the PA5185 protein from Pseudomonas Aeruginosa strain PAO1- new crystal form.
2O6U	;	3.01	;	Crystal structure of the PA5185 protein from Pseudomonas Aeruginosa strain PAO1- new crystal form.
2O5U	;	1.91	;	Crystal structure of the PA5185 protein from Pseudomonas Aeruginosa strain PAO1- orthorhombic form (C222).
2O6T	;	2.55	;	Crystal structure of the PA5185 protein from Pseudomonas Aeruginosa strain PAO1- orthorhombic form (P2221).
2AV9	;	2.4	;	Crystal Structure of the PA5185 protein from Pseudomonas Aeruginosa Strain PAO1.
5CW7	;	2.827	;	Crystal structure of the PaaA2-ParE2 antitoxin-toxin complex
5CZE	;	3.82	;	Crystal structure of the PaaA2-ParE2 antitoxin-toxin complex
5CZF	;	2.671	;	Crystal structure of the PaaA2-ParE2 antitoxin-toxin complex
4FZW	;	2.55	;	Crystal Structure of the PaaF-PaaG Hydratase-Isomerase Complex from E.coli
2X04	;	1.49	;	Crystal structure of the PABC-TNRC6C complex
4F02	;	2.0	;	Crystal structure of the PABP-binding site of eIF4G in complex with RRM1-2 of PABP and poly(A)
4N1Y	;	2.605	;	Crystal Structure of the Pacific Oyster Estrogen Receptor Ligand Binding Domain
5ZHC	;	1.97	;	Crystal structure of the PadR-family transcriptional regulator Rv3488 of Mycobacterium tuberculosis H37Rv
5ZI8	;	2.2	;	Crystal structure of the PadR-family transcriptional regulator Rv3488 of Mycobacterium tuberculosis H37Rv in complex with cadmium ion
7WH4	;	2.8	;	Crystal structure of the PadR-family transcriptional regulator Rv3488 of Mycobacterium tuberculosis H37Rv in complex with Manganese ion
5ZHV	;	2.4	;	Crystal structure of the PadR-family transcriptional regulator Rv3488 of Mycobacterium tuberculosis H37Rv in complex with zinc ion
6JYI	;	1.92	;	Crystal structure of the PadR-like transcriptional regulator BC1756 from Bacillus cereus
5EMV	;	2.0	;	Crystal structure of the palmitoylated human TEAD2 transcription factor
5EMW	;	2.55	;	Crystal structure of the palmitoylated human TEAD3 transcription factor
3CET	;	1.8	;	Crystal structure of the pantheonate kinase-like protein Q6M145 at the resolution 1.8 A. Northeast Structural Genomics Consortium target MrR63
4P16	;	2.5	;	Crystal structure of the papain-like protease of Middle-East Respiratory Syndrome coronavirus
6CD2	;	3.7	;	Crystal structure of the PapC usher bound to the chaperone-adhesin PapD-PapG
1N0L	;	2.3	;	Crystal structure of the PapD chaperone (C-terminally 6x histidine-tagged) bound to the PapE pilus subunit (N-terminal-deleted) from uropathogenic E. coli
1N12	;	1.87	;	Crystal structure of the PapE (N-terminal-deleted) pilus subunit bound to a peptide corresponding to the N-terminal extension of the PapK pilus subunit (residues 1-11) from uropathogenic E. coli
2NNU	;	1.59	;	Crystal Structure of the Papillomavirus DNA Tethering Complex E2:Brd4
5WKN	;	2.653	;	Crystal structure of the parainfluenza virus 5 nucleoprotein-phosphoprotein complex
4JRD	;	1.0	;	Crystal structure of the parallel double-stranded helix of poly(A) RNA
1Y4J	;	1.864	;	Crystal structure of the paralogue of the human formylglycine generating enzyme
6Y1M	;	2.0	;	Crystal structure of the paraoxon-modified A.17 antibody FAB fragment - L47K mutant
6Y1L	;	1.4	;	Crystal structure of the paraoxon-modified A.17 antibody FAB fragment - L47R mutant
5ADO	;	1.55	;	Crystal structure of the paraoxon-modified A.17 antibody FAB fragment - Light chain S35R mutant
6Y49	;	1.65	;	Crystal structure of the paraoxon-modified A.17kappa antibody FAB fragment
3E1Z	;	1.86	;	Crystal structure of the parasite protesase inhibitor chagasin in complex with papain
2ZTB	;	2.38	;	Crystal structure of the parasporin-2 Bacillus thuringiensis toxin that recognizes cancer cells
6RYK	;	1.7	;	Crystal structure of the ParB-like protein PadC
1ZGR	;	2.5	;	Crystal structure of the Parkia platycephala seed lectin
5NGO	;	2.5	;	Crystal structure of the PARP domain of Arabidopsis RADICAL-INDUCED CELL DEATH1
7PLQ	;	2.13	;	Crystal structure of the PARP domain of wheat SRO1
3B33	;	1.83	;	Crystal structure of the PAS domain of nitrogen regulation protein NR(II) from Vibrio parahaemolyticus
3MJQ	;	2.601	;	Crystal structure of the PAS domain of Q24QT8_DESHY protein from Desulfitobacterium hafniense. Northeast Structural Genomics Consortium Target DhR85c.
3KX0	;	2.3	;	Crystal Structure of the PAS domain of Rv1364c
3LYX	;	2.0	;	Crystal structure of the PAS domain of the protein CPS_1291 from Colwellia psychrerythraea. Northeast Structural Genomics Consortium target id CsR222B
1WA9	;	3.15	;	Crystal Structure of the PAS repeat region of the Drosophila clock protein PERIOD
5XGB	;	2.28	;	Crystal structure of the PAS-GGDEF-EAL domain of PA0861 from Pseudomonas aeruginosa
5XGE	;	3.31	;	Crystal structure of the PAS-GGDEF-EAL domain of PA0861 from Pseudomonas aeruginosa in complex with cyclic di-GMP
5XGD	;	2.8	;	Crystal structure of the PAS-GGDEF-EAL domain of PA0861 from Pseudomonas aeruginosa in complex with GTP
3SZE	;	2.5	;	Crystal structure of the passenger domain of the E. coli autotransporter EspP
6RTY	;	2.1	;	Crystal structure of the Patched ectodomain in complex with nanobody NB64
6RTX	;	1.95	;	Crystal structure of the Patched-1 (PTCH1) ectodomain 1
6RTW	;	1.9	;	Crystal structure of the Patched-1 (PTCH1) ectodomain in complex with nanobody NB64 and cholesterol-hemisuccinate
2Y5T	;	2.2	;	Crystal structure of the pathogenic autoantibody CIIC1 in complex with the triple-helical C1 peptide
2P7N	;	2.8	;	Crystal structure of the Pathogenicity island 1 effector protein from Chromobacterium violaceum. Northeast Structural Genomics Consortium (NESGC) target CvR69.
6QBF	;	3.499	;	Crystal structure of the pathological D187N variant of calcium-free human gelsolin.
6Q9Z	;	3.8	;	Crystal structure of the pathological G167R variant of calcium-free human gelsolin,
6Q9R	;	2.73	;	Crystal structure of the pathological N184K variant of calcium-free human gelsolin
1SI3	;	2.6	;	Crystal structure of the PAZ domain of human eIF2c1 in complex with a 9-mer siRNA-like duplex
1SI2	;	2.6	;	Crystal structure of the PAZ domain of human eIF2c1 in complex with a 9-mer siRNA-like duplex of deoxynucleotide overhang
5L9P	;	2.54	;	Crystal structure of the PBP MotA from A. tumefaciens B6
5L9L	;	1.8	;	Crystal structure of the PBP MotA from A. tumefaciens B6 in complex with glucopine
5L9G	;	1.75	;	Crystal Structure of the PBP MotA in complex with mannopine from A. tumefaciens B6
5LOM	;	1.5	;	Crystal structure of the PBP SocA from Agrobacterium tumefaciens C58 in complex with DFG at 1.5 A resolution
6TG3	;	1.85	;	Crystal Structure of the PBP/SBP MotA in complex with glucopinic acid from A. tumefaciens B6/R10
7TAV	;	2.75	;	Crystal Structure of the PBP2_YvgL_like protein Lmo1041 from Listeria monocytogene
6Y3Z	;	3.49	;	Crystal structure of the Pby1 ATP-grasp enzyme bound to the S. cerevisiae mRNA decapping complex (Dcp1-Dcp2-Edc3)
1CM0	;	2.3	;	CRYSTAL STRUCTURE OF THE PCAF/COENZYME-A COMPLEX
4G9Y	;	2.051	;	Crystal Structure of the PcaV transcriptional regulator from Streptomyces coelicolor
4FHT	;	2.15	;	Crystal Structure of the PcaV transcriptional regulator from Streptomyces coelicolor in complex with its natural ligand
4UR1	;	1.649	;	Crystal structure of the PCE reductive dehalogenase from S. multivorans in complex with dibromoethene
4UR2	;	2.096	;	Crystal structure of the PCE reductive dehalogenase from S. multivorans in complex with iodide
4UR0	;	1.798	;	Crystal structure of the PCE reductive dehalogenase from S. multivorans in complex with trichloroethene
4UR3	;	2.235	;	Crystal structure of the PCE reductive dehalogenase from S. multivorans P2(1) crystal form
4K51	;	2.65	;	Crystal Structure of the PCI domain of eIF3a
8VR2	;	1.8	;	Crystal structure of the Pcryo_0617 oxidoreductase/decarboxylase from Psychrobacter cryohalolentis K5 in the presence of NAD and UDP
8VR3	;	2.0	;	crystal structure of the Pcryo_0618 aminotransferase from Psychrobacter cryohalolentis K5 in the presence of its internal aldimine
8VR5	;	2.2	;	crystal structure of the Pcryo_0618 aminotransferase from Psychrobacter cryohalolentis K5 in the presence of PMP and glutamate
8VR6	;	1.9	;	crystal structure of the Pcryo_0619 N-acetryltransferase from Psychrobacter cryohalolentis K5 in the presence of CoA-disulfide
8VRM	;	1.75	;	Crystal structure of the Pcryo_0619 N-acetyltransferase from Psychrobacter cryohalolentis K5
8VR7	;	1.9	;	crystal structure of the Pcryo_0619 N-acetyltransferase from Psychrobacter cryohalolentis K5 int he presence of acetyl coenzyme A
3MTL	;	2.4	;	Crystal structure of the PCTAIRE1 kinase in complex with Indirubin E804
5G6V	;	2.2	;	Crystal structure of the PCTAIRE1 kinase in complex with inhibitor
3BIK	;	2.65	;	Crystal Structure of the PD-1/PD-L1 Complex
3BIS	;	2.64	;	Crystal Structure of the PD-L1
6NJJ	;	2.3	;	Crystal Structure of the PDE4D Catalytic Domain and UCR2 Regulatory Helix with BPN14770
6BOJ	;	1.7	;	Crystal Structure of the PDE4D Catalytic Domain and UCR2 Regulatory Helix with BPN5004
6NJH	;	2.15	;	Crystal Structure of the PDE4D Catalytic Domain and UCR2 Regulatory Helix with T-48
6NJI	;	2.45	;	Crystal Structure of the PDE4D Catalytic Domain and UCR2 Regulatory Helix with T-49
6F8W	;	1.601	;	Crystal structure of the PDE4D catalytic domain in complex with GEBR-18a
6F8V	;	1.85	;	Crystal structure of the PDE4D catalytic domain in complex with GEBR-18b
6F8U	;	2.1	;	Crystal structure of the PDE4D catalytic domain in complex with GEBR-20b
6F8X	;	1.95	;	Crystal structure of the PDE4D catalytic domain in complex with GEBR-26g
6FDC	;	1.45	;	Crystal structure of the PDE4D catalytic domain in complex with GEBR-32a
7AY6	;	1.66	;	Crystal structure of the PDE4D catalytic domain in complex with GEBR-41b
7B9H	;	1.5	;	Crystal structure of the PDE4D catalytic domain in complex with GEBR-42a
6F8T	;	1.8	;	Crystal structure of the PDE4D catalytic domain in complex with GEBR-4a
6F8R	;	1.826	;	Crystal structure of the PDE4D catalytic domain in complex with GEBR-54
6F6U	;	1.828	;	Crystal structure of the PDE4D catalytic domain in complex with GEBR-7b
6AKR	;	2.326	;	Crystal structure of the PDE4D catalytic domain in complex with osthole
5WH5	;	1.8	;	Crystal structure of the PDE4D2 catalytic domain in complex with inhibitor (R)-Zl-n-91
3BJC	;	2.0	;	Crystal structure of the PDE5A catalytic domain in complex with a novel inhibitor
3SHY	;	2.647	;	Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors
3SHZ	;	2.449	;	Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors
3SIE	;	1.93	;	Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors
4I9Z	;	2.08	;	Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors
4IA0	;	2.17	;	Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors
4OEW	;	2.44	;	Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors
4OEX	;	2.14	;	Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors
6A3N	;	2.6	;	Crystal structure of the PDE9 catalytic domain in complex with inhibitor 2
6LZZ	;	2.40004	;	Crystal structure of the PDE9 catalytic domain in complex with inhibitor 4a
3K3E	;	2.7	;	Crystal structure of the PDE9A catalytic domain in complex with (R)-BAY73-6691
3K3H	;	2.5	;	Crystal structure of the PDE9A catalytic domain in complex with (S)-BAY73-6691
4GH6	;	2.7	;	Crystal structure of the PDE9A catalytic domain in complex with inhibitor 28
3CRK	;	2.3	;	Crystal structure of the PDHK2-L2 complex.
3CRL	;	2.61	;	Crystal structure of the PDHK2-L2 complex.
1W1H	;	1.45	;	Crystal Structure of the PDK1 Pleckstrin Homology (PH) domain
1W1G	;	1.45	;	Crystal Structure of the PDK1 Pleckstrin Homology (PH) domain bound to DiC4-phosphatidylinositol (3,4,5)-trisphosphate
1W1D	;	1.5	;	Crystal Structure of the PDK1 Pleckstrin Homology (PH) domain bound to Inositol (1,3,4,5)-tetrakisphosphate
1Y8N	;	2.6	;	Crystal structure of the PDK3-L2 complex
1Y8O	;	2.48	;	Crystal structure of the PDK3-L2 complex
1Y8P	;	2.63	;	Crystal structure of the PDK3-L2 complex
3CGI	;	1.8	;	Crystal structure of the PduU shell protein from the Pdu microcompartment
2H1K	;	2.42	;	Crystal structure of the Pdx1 homeodomain in complex with DNA
1TD2	;	2.22	;	Crystal Structure of the PdxY Protein from Escherichia coli
2R3U	;	2.6	;	Crystal structure of the PDZ deletion mutant of DegS
2F5Y	;	2.39	;	Crystal Structure of the PDZ Domain from Human RGS-3
2REY	;	1.55	;	Crystal structure of the PDZ domain of human dishevelled 2 (homologous to Drosophila dsh)
6XNJ	;	1.85	;	Crystal structure of the PDZ domain of human GOPC in complex with a peptide of E. coli O157:H7 str. Sakai effector NleG8
2PNT	;	2.148	;	Crystal structure of the PDZ domain of human GRASP (GRP1) in complex with the C-terminal peptide of the metabotropic glutamate receptor type 1
2VSV	;	1.82	;	Crystal structure of the PDZ domain of human rhophilin-2
3O46	;	1.3	;	Crystal structure of the PDZ domain of MPP7
4UU6	;	1.8	;	CRYSTAL STRUCTURE OF THE PDZ DOMAIN OF PALS1
4UU5	;	1.23	;	CRYSTAL STRUCTURE OF THE PDZ DOMAIN OF PALS1 IN COMPLEX WITH THE CRB PEPTIDE
3GGE	;	2.6	;	Crystal structure of the PDZ domain of PDZ domain-containing protein GIPC2
5TYT	;	2.398	;	Crystal Structure of the PDZ domain of RhoGEF bound to CXCR2 C-terminal peptide
3I1E	;	2.91	;	Crystal Structure of the PDZ domain of the SdrC-like Protein (Lin2157) from Listeria innocua, Northeast Structural Genomics Consortium Target LkR136C
3I18	;	1.7	;	Crystal Structure of the PDZ domain of the SdrC-like protein (Lmo2051) from Listeria monocytogenes, Northeast Structural Genomics Consortium Target LmR166B
7L71	;	0.97	;	Crystal Structure of the PDZ Domain of the Serine Peptidase HtrA from Streptococcus agalactiae.
1N99	;	1.94	;	CRYSTAL STRUCTURE OF THE PDZ TANDEM OF HUMAN SYNTENIN
1W9Q	;	1.7	;	Crystal structure of the PDZ tandem of human syntenin in complex with TNEFAF peptide
1W9E	;	1.56	;	Crystal structure of the PDZ tandem of human syntenin in complex with TNEFYF peptide
1V1T	;	1.8	;	Crystal structure of the PDZ tandem of human syntenin in complex with TNEYKV peptide
1W9O	;	2.25	;	Crystal structure of the PDZ tandem of human syntenin in complex with TNEYYV peptide
1YBO	;	2.3	;	Crystal structure of the PDZ tandem of human syntenin with syndecan peptide
8AAK	;	2.554	;	Crystal structure of the PDZ tandem of syntenin in complex with compound 29
8AAO	;	2.469	;	Crystal structure of the PDZ tandem of syntenin in complex with compound 95
8AAP	;	2.174	;	Crystal structure of the PDZ tandem of syntenin in complex with compound SYNTi
6R9H	;	2.0	;	Crystal structure of the PDZ tandem of syntenin in complex with fragment C58
8AAI	;	2.76	;	Crystal structure of the PDZ tandem of syntenin in complex with fragment E5
6RLC	;	2.2	;	Crystal structure of the PDZ tandem of syntenin in complex with fragment F13
7W70	;	1.15	;	Crystal structure of the PDZ-C domain fragment of Kangiella koreensis RseP orthologue
7W71	;	3.2	;	Crystal structure of the PDZ-C domain of E. coli RseP in complex with 12C7 Fab
3TSW	;	2.847	;	crystal structure of the PDZ3-SH3-GUK core module of Human ZO-1
7F6J	;	2.1	;	Crystal structure of the PDZD8 coiled-coil domain - Rab7 complex
6A9J	;	2.7	;	Crystal structure of the PE-bound N-terminal domain of Atg2
7JMR	;	1.67	;	Crystal structure of the pea pathogenicity protein 2 from Madurella mycetomatis
7JMV	;	1.57	;	Crystal structure of the pea pathogenicity protein 2 from Madurella mycetomatis complexed with 4-nitrocatechol
8G4P	;	2.25	;	Crystal structure of the peanut allergen Ara h 2 bound by two neutralizing antibodies 13T1 and 13T5
8DB4	;	2.3	;	Crystal structure of the peanut allergen Ara h 2 bound by two neutralizing antibodies 22S1 and 13T1
2EVV	;	2.59	;	Crystal Structure of the PEBP-like Protein of Unknown Function HP0218 from Helicobacter pylori
5C1C	;	1.8	;	Crystal Structure of the Pectin Methylesterase from Aspergillus niger in Deglycosylated Form
5C1E	;	1.75	;	Crystal Structure of the Pectin Methylesterase from Aspergillus niger in Penultimately Deglycosylated Form (N-acetylglucosamine Stub at Asn84)
3OMY	;	1.3	;	Crystal structure of the pED208 TraM N-terminal domain
3ON0	;	2.874	;	Crystal structure of the pED208 TraM-sbmA complex
4OE1	;	2.8	;	Crystal structure of the pentatricopeptide repeat protein PPR10 (C256S/C430S/C449S) in complex with an 18-nt PSAJ rna element
4M57	;	2.86	;	Crystal structure of the pentatricopeptide repeat protein PPR10 from maize
4M59	;	2.46	;	Crystal structure of the pentatricopeptide repeat protein PPR10 in complex with an 18-nt psaJ RNA element
1UPR	;	2.27	;	Crystal structure of the PEPP1 pleckstrin homology domain in complex with Inositol 1,3,4,5-tetrakisphosphate
7EOH	;	1.637	;	Crystal structure of the Pepper aptamer in complex with HBC
7EOJ	;	1.77	;	Crystal structure of the Pepper aptamer in complex with HBC, cesium soak
7EOG	;	1.5	;	Crystal structure of the Pepper aptamer in complex with HBC, iridium hexammine soak
7EOI	;	1.92	;	Crystal structure of the Pepper aptamer in complex with HBC, manganese soak
7EOK	;	2.7	;	Crystal structure of the Pepper aptamer in complex with HBC485
7EOL	;	2.309	;	Crystal structure of the Pepper aptamer in complex with HBC497
7EOM	;	2.703	;	Crystal structure of the Pepper aptamer in complex with HBC508
7EON	;	2.3	;	Crystal structure of the Pepper aptamer in complex with HBC514
7EOO	;	2.23	;	Crystal structure of the Pepper aptamer in complex with HBC525
7EOP	;	1.8	;	Crystal structure of the Pepper aptamer in complex with HBC620
7ZBV	;	1.95	;	Crystal structure of the peptidase domain of collagenase G from Clostridium histolyticum in complex with a diphosphonate-based inhibitor
7Z5U	;	1.8	;	Crystal structure of the peptidase domain of collagenase G from Clostridium histolyticum in complex with a hydroxamate-based inhibitor
4AR1	;	2.01	;	Crystal Structure of the Peptidase Domain of Collagenase H from Clostridium histolyticum at 2.01 Angstrom resolution.
5O7E	;	1.87	;	Crystal structure of the peptidase domain of collagenase H from Clostridium histolyticum in complex with N-aryl mercaptoacetamide-based inhibitor
7ZOC	;	1.91	;	Crystal structure of the peptidase domain of collagenase H from Clostridium histolyticum in complex with N-aryl-2-alkylmercaptoacetamide-based inhibitor
4ARF	;	1.77	;	CRYSTAL STRUCTURE OF THE PEPTIDASE DOMAIN OF COLLAGENASE H FROM CLOSTRIDIUM HISTOLYTICUM IN COMPLEX WITH THE PEPTIDIC INHIBITOR ISOAMYLPHOSPHONYL-GLY-PRO-ALA AT 1.77 ANGSTROM RESOLUTION.
4AR9	;	1.69	;	Crystal structure of the peptidase domain of collagenase T from Clostridium tetani at 1.69 angstrom resolution.
4AR8	;	2.05	;	Crystal structure of the peptidase domain of collagenase T from Clostridium tetani complexed with the peptidic inhibitor isoamyl- phosphonyl-Gly-Pro-Ala at 2.05 angstrom resolution.
3K8U	;	1.9	;	Crystal Structure of the Peptidase Domain of Streptococcus ComA, a Bi-functional ABC Transporter Involved in Quorum Sensing Pathway
5XE8	;	3.1	;	Crystal Structure of the Peptidase Domain of Streptococcus mutans ComA
4RY2	;	3.611	;	Crystal structure of the peptidase-containing ABC transporter PCAT1
4S0F	;	5.515	;	Crystal structure of the peptidase-containing ABC transporter PCAT1 E648Q mutant complexed with ATPgS in an occluded conformation
8AY0	;	1.51	;	Crystal Structure of the peptide binding protein DppE from Bacillus subtilis in complex with murein tripeptide
8AZB	;	1.4	;	Crystal Structure of the peptide binding protein DppE from Bacillus subtilis in the unliganded state
8ARE	;	1.9	;	Crystal structure of the peptide binding protein, OppA, from Bacillus subtilis in complex with a PhrE-derived pentapeptide
8ARN	;	1.5	;	Crystal structure of the peptide binding protein, OppA, from Bacillus subtilis in complex with an endogenous tetrapeptide
3V2O	;	1.89	;	Crystal Structure of the Peptide Bound Complex of the Ankyrin Repeat Domains of Human ANKRA2
3V2X	;	1.85	;	Crystal Structure of the Peptide Bound Complex of the Ankyrin Repeat Domains of Human ANKRA2
3V31	;	1.57	;	Crystal Structure of the Peptide Bound Complex of the Ankyrin Repeat Domains of Human ANKRA2
3V30	;	1.57	;	Crystal Structure of the Peptide Bound Complex of the Ankyrin Repeat Domains of Human RFXANK
7Q0L	;	2.71	;	Crystal structure of the peptide transporter YePEPT-K314A at 2.93 A
7Q0M	;	2.54	;	Crystal structure of the peptide transporter YePEPT-K314A in complex with LZNV at 2.66 A
4BTB	;	1.899	;	CRYSTAL STRUCTURE OF THE PEPTIDE(PRO)9 BOUND COMPLEX OF N-TERMINAL DOMAIN AND PEPTIDE SUBSTRATE BINDING DOMAIN OF PROLYL-4 HYDROXYLASE (RESIDUES 1-238) TYPE I FROM HUMAN
4BT9	;	1.9	;	CRYSTAL STRUCTURE OF THE PEPTIDE(PRO-PRO-GLY)3 BOUND COMPLEX OF N- TERMINAL DOMAIN AND PEPTIDE SUBSTRATE BINDING DOMAIN OF PROLYL-4 HYDROXYLASE (RESIDUES 1-238) TYPE I FROM HUMAN
4BTA	;	2.95	;	CRYSTAL STRUCTURE OF THE PEPTIDE(PRO-PRO-GLY)3 BOUND COMPLEX OF N- TERMINAL DOMAIN AND PEPTIDE SUBSTRATE BINDING DOMAIN OF PROLYL-4 HYDROXYLASE (RESIDUES 1-244) TYPE I FROM HUMAN
7RJJ	;	1.88	;	Crystal Structure of the Peptidoglycan Binding Domain of the Outer Membrane Protein (OmpA) from Klebsiella pneumoniae with bound D-alanine
8GLD	;	2.3	;	Crystal structure of the peptidoglycan O-acetylesterase Ape1 (amino acids 22-392) from Campylobacter jejuni
8GKD	;	1.8	;	Crystal structure of the peptidoglycan O-acetylesterase Ape1 (amino acids 41-392) from Campylobacter jejuni
5LKW	;	2.0	;	Crystal structure of the peptidoglycan-associated lipoprotein (Pal) from Burkholderia cepacia in complex with DAP
5N2C	;	1.8	;	Crystal structure of the peptidoglycan-associated lipoprotein from Burkholderia cenocepacia
4B5C	;	2.3	;	Crystal structure of the peptidoglycan-associated lipoprotein from Burkholderia pseudomallei
6QVP	;	1.9	;	Crystal structure of the peptidoglycan-binding domain of SiiA from Salmonella enterica
7L6Y	;	1.28	;	Crystal Structure of the Peptidyl-Prolyl Cis-Trans Isomerase (PpiB) from Streptococcus pyogenes.
2GW2	;	1.8	;	Crystal structure of the peptidyl-prolyl isomerase domain of human cyclophilin G
3ERJ	;	1.8	;	Crystal structure of the peptidyl-tRNA hydrolase AF2095 from Archaeglobus fulgidis. Northeast Structural Genomics Consortium target GR4
5IVP	;	2.01	;	Crystal structure of the Peptidyl-tRNA hydrolase from Vibrio cholerae in the C121 space group at pH 6.5
6LKB	;	1.651	;	Crystal Structure of the peptidylprolyl isomerase domain of Arabidopsis thaliana CYP71.
2A2N	;	1.65	;	Crystal Structure of the peptidylprolyl isomerase domain of Human PPWD1
4P6F	;	3.6	;	Crystal structure of the peptolide 12C bound to bacterial ribosome
5CH7	;	2.2	;	Crystal structure of the perchlorate reductase PcrAB - Phe164 gate switch intermediate - from Azospira suillum PS
5CHC	;	2.38	;	Crystal structure of the perchlorate reductase PcrAB - substrate analog SeO3 bound - from Azospira suillum PS
4YDD	;	1.86	;	Crystal structure of the perchlorate reductase PcrAB from Azospira suillum PS
5E7O	;	2.4	;	Crystal structure of the perchlorate reductase PcrAB mutant W461E of PcrA from Azospira suillum PS
3K5B	;	3.1	;	Crystal structure of the peripheral stalk of Thermus thermophilus H+-ATPase/synthase
3V6I	;	2.25	;	Crystal structure of the peripheral stalk of Thermus thermophilus H+-ATPase/synthase at 2.25 A resolution
4NK6	;	2.0974	;	Crystal Structure of the periplasmic alginate epimerase AlgG
4NK8	;	2.2924	;	Crystal Structure of the periplasmic alginate epimerase AlgG D317A mutant
4OZY	;	2.9	;	Crystal Structure of the periplasmic alginate epimerase AlgG T265N mutant
4OZZ	;	2.9	;	Crystal Structure of the periplasmic alginate epimerase AlgG T265N T268M double mutant
4OZV	;	1.642	;	Crystal Structure of the periplasmic alginate lyase AlgL
4OZW	;	1.64	;	Crystal Structure of the periplasmic alginate lyase AlgL H202A mutant
2X26	;	1.75	;	Crystal structure of the periplasmic aliphatic sulphonate binding protein SsuA from Escherichia coli
5L9I	;	1.9	;	Crystal structure of the periplasmic binding protein MotA in complex with DFG from A. tumefaciens B6
3TEF	;	1.698	;	Crystal Structure of the Periplasmic Catecholate-Siderophore Binding Protein VctP from Vibrio Cholerae
1L4I	;	2.2	;	Crystal Structure of the Periplasmic Chaperone SfaE
1SG2	;	2.35	;	Crystal structure of the periplasmic chaperone Skp
3LY7	;	1.8	;	Crystal structure of the periplasmic domain of CadC
3LYA	;	2.3	;	Crystal structure of the periplasmic domain of CadC in the presence of K2ReCl6
2HL7	;	1.7	;	Crystal structure of the periplasmic domain of CcmH from Pseudomonas aeruginosa
4G08	;	1.801	;	Crystal structure of the periplasmic domain of InvG
4E2L	;	2.8	;	Crystal Structure of the periplasmic domain of mutant FepE LPS O-antigen chain length regulator protein
4E2H	;	2.36	;	Crystal structure of the periplasmic domain of Shigella flexneri WzzB
4W9Z	;	1.3	;	Crystal structure of the periplasmic domain of subunit II of cytochrome oxidase (CoxB) of Bradyrhizobium japonicum
6G49	;	1.6	;	Crystal structure of the periplasmic domain of TgpA from Pseudomonas aeruginosa
6G4H	;	1.8	;	Crystal structure of the periplasmic domain of TgpA from Pseudomonas aeruginosa bound to ethylmercury
4E2C	;	2.8	;	Crystal Structure of the periplasmic domain of the chimeric LPS O-antigen chain length regulator protein
3BLC	;	2.5	;	Crystal structure of the periplasmic domain of the Escherichia Coli YIDC
5Y82	;	2.517	;	Crystal structure of the periplasmic domain of the Thermotoga maritima YidC
3C38	;	2.3	;	Crystal structure of the periplasmic domain of Vibrio Cholerae LuxQ
6GHU	;	2.0	;	Crystal structure of the periplasmic domain of XcpY, oP crystal form.
5N7L	;	2.501	;	Crystal structure of the periplasmic domain of XcpY, tI crystal form.
1OUO	;	2.3	;	Crystal structure of the periplasmic endonuclease Vvn
2IVK	;	2.9	;	Crystal structure of the periplasmic endonuclease Vvn complexed with a 16-bp DNA
1OUP	;	2.3	;	Crystal structure of the periplasmic endonuclease Vvn complexed with octamer double stranded DNA
2R19	;	2.16	;	Crystal structure of the periplasmic lipopolysaccharide transport protein LptA (YhbN), orthorhombic form
2R1A	;	3.26	;	Crystal structure of the periplasmic lipopolysaccharide transport protein LptA (YhbN), trigonal form
7SA8	;	2.5	;	Crystal Structure of the periplasmic lyase AlgL K66A Mutant
6MKU	;	1.727	;	Crystal structure of the periplasmic Lysine-, Arginine-, Ornithine-binding protein (LAO) D11A mutant from Salmonella typhimurium complexed with arginine
6MKW	;	2.32	;	Crystal structure of the periplasmic Lysine-, Arginine-, Ornithine-binding protein (LAO) D11A mutant from Salmonella typhimurium complexed with histidine
6MLA	;	1.582	;	Crystal structure of the periplasmic Lysine-, Arginine-, Ornithine-binding protein (LAO) D161A mutant from Salmonella typhimurium complexed with arginine
6ML9	;	1.687	;	Crystal structure of the periplasmic Lysine-, Arginine-, Ornithine-binding protein (LAO) D30A mutant from Salmonella typhimurium complexed with arginine
6MLD	;	1.66	;	Crystal structure of the periplasmic Lysine-, Arginine-, Ornithine-binding protein (LAO) F52A mutant from Salmonella typhimurium
6MLE	;	1.858	;	Crystal structure of the periplasmic Lysine-, Arginine-, Ornithine-binding protein (LAO) from Salmonella typhimurium complexed with arginine
6MKX	;	2.284	;	Crystal structure of the periplasmic Lysine-, Arginine-, Ornithine-binding protein (LAO) R77A mutant from Salmonella typhimurium
6MLG	;	1.892	;	Crystal structure of the periplasmic Lysine-, Arginine-, Ornithine-binding protein (LAO) R77A mutant from Salmonella typhimurium complexed with arginine
6MLI	;	1.883	;	Crystal structure of the periplasmic Lysine-, Arginine-, Ornithine-binding protein (LAO) R77A mutant from Salmonella typhimurium complexed with histidine
6ML0	;	1.68	;	Crystal structure of the periplasmic Lysine-, Arginine-, Ornithine-binding protein (LAO) S69A mutant from Salmonella typhimurium
6MLJ	;	1.6	;	Crystal structure of the periplasmic Lysine-, Arginine-, Ornithine-binding protein (LAO) S70A mutant from Salmonella typhimurium complexed with arginine
6MLN	;	1.721	;	Crystal structure of the periplasmic Lysine-, Arginine-, Ornithine-binding protein (LAO) S72A mutant from Salmonella typhimurium complexed with arginine
6MLV	;	2.082	;	Crystal structure of the periplasmic Lysine-, Arginine-, Ornithine-binding protein (LAO) Y14A mutant from Salmonella typhimurium
6MLO	;	1.717	;	Crystal structure of the periplasmic Lysine-, Arginine-, Ornithine-binding protein (LAO) Y14A mutant from Salmonella typhimurium complexed with arginine
6MLP	;	1.485	;	Crystal structure of the periplasmic Lysine-, Arginine-, Ornithine-binding protein (LAO) Y14A mutant from Salmonella typhimurium complexed with histidine
5MWU	;	1.8	;	Crystal structure of the periplasmic nickel-binding protein NikA from Escherichia coli in complex with Ru(bpza)(CO)2Cl
6R4Q	;	1.9	;	Crystal structure of the periplasmic nickel-binding protein NikA from Escherichia coli in complex with Ru(bpza)CO H2O Cl
2NYA	;	2.5	;	Crystal structure of the periplasmic nitrate reductase (NAP) from Escherichia coli
3ML1	;	1.6	;	Crystal Structure of the Periplasmic Nitrate Reductase from Cupriavidus necator
2G29	;	1.5	;	crystal structure of the periplasmic nitrate-binding protein NrtA from Synechocystis PCC 6803
5WTL	;	2.298	;	Crystal structure of the periplasmic portion of outer membrane protein A (OmpA) from Capnocytophaga gingivalis
6EYS	;	2.091	;	Crystal structure of the periplasmic pyoverdine maturation protein PvdP
3FTJ	;	1.999	;	Crystal structure of the periplasmic region of MacB from Actinobacillus actinomycetemcomitans
5C59	;	3.0	;	Crystal structure of the periplasmic region of MacB from E. coli
4WY9	;	1.4	;	Crystal structure of the periplasmic sensory domain of the Campylobacter jejuni chemoreceptor Tlp1
4MAG	;	1.45	;	Crystal structure of the Periplasmic Sialic Acid Binding Protein from Vibrio Cholerea
3KH9	;	2.2	;	Crystal structure of the periplasmic soluble domain of oxidized CcmG from Pseudomonas aeruginosa
3KH7	;	1.75	;	Crystal structure of the periplasmic soluble domain of reduced CcmG from Pseudomonas aeruginosa
3URM	;	1.801	;	Crystal structure of the periplasmic sugar binding protein ChvE
3UUG	;	1.75	;	Crystal structure of the periplasmic sugar binding protein ChvE
3D4T	;	2.05	;	Crystal structure of the periplasmic thioredoxin SoxS from Paracoccus pantotrophus (oxidized form)
3DML	;	1.9	;	Crystal structure of the periplasmic thioredoxin SoxS from Paracoccus pantotrophus (reduced form)
1IDU	;	2.24	;	CRYSTAL STRUCTURE OF THE PEROXIDE FORM OF THE VANADIUM-CONTAINING CHLOROPEROXIDASE FROM CURVULARIA INAEQUALIS
3K9S	;	1.55	;	Crystal structure of the peroxide-bound manganese superoxide dismutase.
5OVQ	;	1.8	;	Crystal Structure of the peroxiredoxin (AhpC2) from the Hyperthermophilic bacteria Aquifex aeolicus VF
7DBI	;	1.99	;	Crystal structure of the peroxisomal acyl-CoA hydrolase MpaH
6BHF	;	2.09	;	Crystal structure of the petidylprolyl cis,trans-isomerase from Helicobacter pylori
6XOD	;	2.01	;	Crystal structure of the PEX4-PEX22 protein complex from Arabidopsis thaliana
3NPH	;	1.849	;	Crystal structure of the pfam00427 domain from Synechocystis sp. PCC 6803
5MLU	;	2.8	;	Crystal structure of the PFV GAG CBS bound to a mononucleosome
3OYN	;	2.68	;	Crystal structure of the PFV N224H mutant intasome bound to magnesium and the INSTI MK2048
3OYM	;	2.02	;	Crystal structure of the PFV N224H mutant intasome bound to manganese
3OYL	;	2.54	;	Crystal structure of the PFV S217H mutant intasome bound to magnesium and the INSTI MK2048
3OYK	;	2.72	;	Crystal structure of the PFV S217H mutant intasome bound to manganese
3OYJ	;	2.68	;	Crystal structure of the PFV S217Q mutant intasome in complex with magnesium and the INSTI MK2048
3OYI	;	2.72	;	Crystal structure of the PFV S217Q mutant intasome in complex with manganese
2H0Q	;	1.82	;	Crystal Structure of the PGM domain of the Suppressor of T-Cell receptor (Sts-1)
7MYX	;	1.39	;	Crystal structure of the PH domain (R86A) of Akt1
3VIA	;	1.75	;	Crystal structure of the PH domain of Evectin-2 from human
3AJ4	;	1.0	;	Crystal structure of the PH domain of Evectin-2 from human complexed with O-phospho-L-serine
2Y7B	;	1.9	;	Crystal structure of the PH domain of human Actin-binding protein anillin ANLN
5L81	;	2.23	;	Crystal structure of the PH domain of murine kindlin-3
1UNR	;	1.25	;	Crystal structure of the PH domain of PKB alpha in complex with a sulfate molecule
4EMO	;	2.0	;	Crystal structure of the PH domain of SHARPIN
1U5G	;	2.1	;	Crystal Structure of the PH Domain of SKAP-Hom
1U5F	;	1.9	;	Crystal Structure of the PH Domain of SKAP-Hom with 8 Vector-derived N-terminal Residues
1U5D	;	1.7	;	Crystal Structure of the PH domain of SKAP55
1MI1	;	2.9	;	Crystal Structure of the PH-BEACH Domain of Human Neurobeachin
1T77	;	2.4	;	Crystal structure of the PH-BEACH domains of human LRBA/BGL
6B3Y	;	1.852	;	Crystal structure of the PH-like domain from DENND3
5YQR	;	2.402	;	Crystal structure of the PH-like domain of Lam6
1QQG	;	2.3	;	CRYSTAL STRUCTURE OF THE PH-PTB TARGETING REGION OF IRS-1
4Y94	;	2.4	;	Crystal structure of the PH-TH module of Bruton's tyrosine kinase bound to inositol hexakisphosphate
4Y93	;	1.695	;	Crystal structure of the PH-TH-kinase construct of Bruton's tyrosine kinase (Btk)
8S93	;	2.1	;	Crystal structure of the PH-TH/kinase complex of Bruton's tyrosine kinase
2DRH	;	2.1	;	Crystal structure of the PH0078 protein from Pyrococcus horikoshii OT3
1X3L	;	2.1	;	Crystal structure of the PH0495 protein from pyrococccus horikoshii OT3
2DEC	;	1.7	;	Crystal Structure of the PH0510 protein from Pyrococcus horikoshii OT3
2DF8	;	1.5	;	Crystal Structure of the PH0510 protein from Pyrococcus horikoshii OT3 in complex with beta-D-Fructopyranose-1-phosphate
2E5F	;	1.35	;	Crystal Structure of the PH0510 protein from Pyrococcus horikoshii OT3 in complex with phosphate ion
1WY1	;	1.8	;	Crystal Structure of the PH0671 protein from Pyrococcus horikoshii OT3
2DR1	;	1.9	;	Crystal structure of the PH1308 protein from Pyrococcus horikoshii OT3
1V77	;	1.8	;	Crystal structure of the PH1877 protein
8BV8	;	2.03	;	Crystal structure of the phage Mu protein Mom inactive mutant S124A
1KA8	;	2.95	;	Crystal Structure of the Phage P4 Origin-Binding Domain
7DWM	;	2.65	;	Crystal structure of the phage VqmA-DPO complex
5TAB	;	1.25	;	Crystal Structure of the PHD Finger of PHF20
4COS	;	1.67	;	Crystal structure of the PHD-Bromo-PWWP cassette of human PRKCBP1
3K33	;	2.4	;	Crystal structure of the Phd-Doc complex
4K9O	;	1.888	;	Crystal Structure of the Phe397Ala mutant of Benzoylformate Decarboxylase from Pseudomonas putida
7A99	;	1.79	;	Crystal structure of the Phe57Trp mutant of the arginine-bound form of domain 1 from TmArgBP
3NMI	;	2.01	;	Crystal structure of the phenanthroline-modified cytochrome cb562 variant, MBP-Phen2
5FRU	;	1.85	;	crystal structure of the phenol-responsive sensory domain of the transcription activator PoxR
5FRV	;	1.9	;	crystal structure of the phenol-responsive sensory domain of the transcription activator PoxR in complex with 4-methylphenol (Cresol)
5FRX	;	2.4	;	crystal structure of the phenol-responsive sensory domain of the transcription activator PoxR in complex with 4-nitrophenol
5FS0	;	2.4	;	crystal structure of the phenol-responsive sensory domain of the transcription activator PoxR with 2,4-dichlorophenol
5FRZ	;	2.1	;	crystal structure of the phenol-responsive sensory domain of the transcription activator PoxR with 3,4-dimethylphenol
5FRY	;	1.792	;	crystal structure of the phenol-responsive sensory domain of the transcription activator PoxR with 3,5-dimethylphenol
5FRW	;	2.1	;	crystal structure of the phenol-responsive sensory domain of the transcription activator PoxR with Phenol
7YKC	;	3.3	;	crystal structure of the Phenylalanine-regulated 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase (ARO3) from Saccharomyces cerevisiae
2AGL	;	1.4	;	Crystal structure of the phenylhydrazine adduct of aromatic amine dehydrogenase from Alcaligenes faecalis
3B73	;	2.12	;	Crystal structure of the PhiH1 repressor-like protein from Haloarcula marismortui
2FSU	;	1.7	;	Crystal Structure of the PhnH Protein from Escherichia Coli
4RCM	;	1.8	;	Crystal structure of the Pho92 YTH domain in complex with m6A
1GXQ	;	2.0	;	Crystal structure of the PhoB effector domain
1MVO	;	1.6	;	Crystal structure of the PhoP receiver domain from Bacillus subtilis
5NNY	;	1.7	;	Crystal structure of the phosphatase domain from the Legionella effector WipB
4J6O	;	1.6	;	Crystal Structure of the Phosphatase Domain of C. thermocellum (Bacterial) PnkP
2I1Y	;	2.23	;	Crystal structure of the phosphatase domain of human PTP IA-2
2FH7	;	2.0	;	Crystal structure of the phosphatase domains of human PTP SIGMA
3EXM	;	1.65	;	Crystal structure of the phosphatase SC4828 with the non-hydrolyzable nucleotide GPCP
2I0M	;	2.4	;	Crystal structure of the phosphate transport system regulatory protein PhoU from Streptococcus pneumoniae
4WTV	;	1.9	;	Crystal structure of the phosphatidylinositol 4-kinase IIbeta
7D7P	;	2.1	;	Crystal structure of the phosphodiesterase domain of Salpingoeca rosetta rhodopsin phosphodiesterase
2XZ7	;	1.83	;	CRYSTAL STRUCTURE OF THE PHOSPHOENOLPYRUVATE-BINDING DOMAIN OF ENZYME I IN COMPLEX WITH PHOSPHOENOLPYRUVATE FROM THE THERMOANAEROBACTER TENGCONGENSIS PEP-SUGAR PHOSPHOTRANSFERASE SYSTEM (PTS)
2BG5	;	1.82	;	Crystal Structure of the Phosphoenolpyruvate-binding Enzyme I-Domain from the Thermoanaerobacter tengcongensis PEP: Sugar Phosphotransferase System (PTS)
3UMP	;	1.849	;	Crystal structure of the Phosphofructokinase-2 from Escherichia coli in complex with Cesium and ATP
3N1C	;	2.0	;	Crystal structure of the phosphofructokinase-2 from Escherichia coli in complex with fructose-6-phosphate
3UMO	;	1.696	;	Crystal structure of the Phosphofructokinase-2 from Escherichia coli in complex with Potassium
3UQD	;	2.14	;	Crystal structure of the Phosphofructokinase-2 from Escherichia coli in complex with substrates and products
3UQE	;	2.2	;	Crystal structure of the Phosphofructokinase-2 mutant Y23D from Escherichia coli
2YY6	;	2.3	;	Crystal Structure of the phosphoglycolate phosphatase from Aquifex aeolicus VF5
2R7B	;	2.7	;	Crystal Structure of the Phosphoinositide-dependent Kinase-1 (PDK-1)Catalytic Domain bound to a dibenzonaphthyridine inhibitor
1EAZ	;	1.4	;	Crystal structure of the phosphoinositol (3,4)-bisphosphate binding PH domain of TAPP1 from human.
4KYI	;	3.075	;	Crystal structure of the phospholipase VipD from Legionella pneumophila in complex with the human GTPase Rab5
5UE7	;	1.95	;	Crystal structure of the phosphomannomutase PMM1 from Candida albicans, apoenzyme state
3QUJ	;	2.2	;	Crystal structure of the phosphonate binding protein, PhnD, from Escherichia coli
6Y1N	;	2.2	;	Crystal structure of the phosphonate-modified A.5 antibody FAB fragment
1SWW	;	2.3	;	Crystal structure of the phosphonoacetaldehyde hydrolase D12A mutant complexed with magnesium and substrate phosphonoacetaldehyde
3LRT	;	1.534	;	Crystal structure of the phosphoribosyl pyrophosphate (PRPP) synthetase from Thermoplasma volcanium in complex with ADP.
3NAG	;	1.75	;	Crystal structure of the phosphoribosylpyrophosphate (PRPP) synthetase from Thermoplasma Volcanium in complex with ADP
3MBI	;	1.8	;	Crystal structure of the phosphoribosylpyrophosphate (PRPP) synthetase from Thermoplasma volcanium in complex with ADP-Mg2+ and ribose 5-phosphate
3LPN	;	1.8	;	Crystal structure of the phosphoribosylpyrophosphate (PRPP) synthetase from Thermoplasma volcanium in complex with an ATP analog (AMPCPP).
1OYP	;	2.76	;	Crystal Structure of the phosphorolytic exoribonuclease RNase PH from Bacillus subtilis
1OYR	;	3.1	;	Crystal structure of the phosphorolytic exoribonuclease RNase PH from Bacillus subtilis
1OYS	;	2.4	;	Crystal Structure of the Phosphorolytic Exoribonuclease RNase PH from Bacillus subtilis
4S2U	;	2.71	;	Crystal structure of the Phosphorybosylpyrophosphate synthetase from E. Coli
5T3O	;	2.2	;	Crystal structure of the Phosphorybosylpyrophosphate synthetase II from Thermus thermophilus
7PN0	;	1.85	;	Crystal structure of the Phosphorybosylpyrophosphate synthetase II from Thermus thermophilus at R32 space group
3SR0	;	1.565	;	Crystal Structure of the Phosphoryl Transfer Transition State Mimic in the Adenylate Kinase: ADP/AlF4/AMP in the active site
6ZWK	;	1.55	;	Crystal structure of the phosphorylated C-terminal tail of histone H2AX in complex with a specific nanobody (C6 gammaXbody)
2EXE	;	2.35	;	Crystal structure of the phosphorylated CLK3
1K68	;	1.9	;	Crystal Structure of the Phosphorylated Cyanobacterial Phytochrome Response Regulator RcpA
4RER	;	4.047	;	Crystal structure of the phosphorylated human alpha1 beta2 gamma1 holo-AMPK complex bound to AMP and cyclodextrin
1SM2	;	2.3	;	Crystal structure of the phosphorylated Interleukin-2 tyrosine kinase catalytic domain
3KYI	;	2.8	;	Crystal structure of the phosphorylated P1 domain of CheA3 in complex with CheY6 from R. sphaeroides
1ZY2	;	3.03	;	Crystal structure of the phosphorylated receiver domain of the transcription regulator NtrC1 from Aquifex aeolicus
1U7V	;	2.7	;	Crystal Structure of the phosphorylated Smad2/Smad4 heterotrimeric complex
1U7F	;	2.6	;	Crystal Structure of the phosphorylated Smad3/Smad4 heterotrimeric complex
3K0C	;	3.3	;	Crystal structure of the phosphorylation-site double mutant S431A/T432E of the KaiC circadian clock protein
3S1A	;	3.0	;	Crystal structure of the phosphorylation-site double mutant S431E/T432E of the KaiC circadian clock protein
3K0F	;	3.0	;	Crystal structure of the phosphorylation-site double mutant T426A/T432A of the KaiC circadian clock protein
3K0A	;	3.0	;	Crystal structure of the phosphorylation-site mutant S431A of the KaiC circadian clock protein
3K09	;	3.2	;	Crystal structure of the phosphorylation-site mutant S431D of the KaiC circadian clock protein
3K0E	;	3.2	;	Crystal structure of the phosphorylation-site mutant T426N of the KaiC circadian clock protein
3JZM	;	2.9	;	Crystal structure of the phosphorylation-site mutant T432A of the KaiC circadian clock protein
4ORK	;	2.3	;	Crystal Structure of the Phosphotransferase Domain of the Bifunctional Aminoglycoside Resistance Enzyme AAC(6')-Ie-APH(2'')-Ia
4LE6	;	2.1	;	Crystal structure of the phosphotriesterase OPHC2 from Pseudomonas pseudoalcaligenes
1P3R	;	2.1	;	Crystal structure of the phosphotyrosin binding domain(PTB) of mouse Disabled 1(Dab1)
1OQN	;	2.3	;	Crystal structure of the phosphotyrosine binding domain (PTB) of mouse Disabled 1 (Dab1)
1M7E	;	2.45	;	Crystal structure of the phosphotyrosine binding domain(PTB) of mouse Disabled 2(Dab2):implications for Reeling signaling
1SHA	;	1.5	;	CRYSTAL STRUCTURE OF THE PHOSPHOTYROSINE RECOGNITION DOMAIN SH2 OF V-SRC COMPLEXED WITH TYROSINE-PHOSPHORYLATED PEPTIDES
1SHB	;	2.0	;	CRYSTAL STRUCTURE OF THE PHOSPHOTYROSINE RECOGNITION DOMAIN SH2 OF V-SRC COMPLEXED WITH TYROSINE-PHOSPHORYLATED PEPTIDES
2HV6	;	1.9	;	Crystal structure of the phosphotyrosyl phosphatase activator
1N9O	;	2.8	;	Crystal structure of the Phot-LOV1 domain from Chlamydomonas reinhardtii in illuminated state. Composite data set.
1N9N	;	2.3	;	Crystal structure of the Phot-LOV1 domain from Chlamydomonas reinhardtii in illuminated state. Data set of a single crystal.
1N9L	;	1.9	;	Crystal structure of the Phot-LOV1 domain from Chlamydomonas reinhardtii in the dark state.
1MZU	;	2.0	;	Crystal Structure of the Photoactive Yellow Protein Domain from the Sensor Histidine Kinase Ppr from Rhodospirillum centenum
1F98	;	1.15	;	CRYSTAL STRUCTURE OF THE PHOTOACTIVE YELLOW PROTEIN MUTANT T50V
1F9I	;	1.1	;	CRYSTAL STRUCTURE OF THE PHOTOACTIVE YELLOW PROTEIN MUTANT Y42F
1KOU	;	1.16	;	Crystal Structure of the Photoactive Yellow Protein Reconstituted with Caffeic Acid at 1.16 A Resolution
4RYW	;	2.5	;	Crystal structure of the photoconverted green fluorescent protein NowGFP_conv (the variant of cyan Cerulean) at pH 7.0
4RI2	;	2.35	;	Crystal structure of the photoprotective protein PsbS from spinach
3C2W	;	2.9	;	Crystal structure of the photosensory core domain of P. aeruginosa bacteriophytochrome PaBphP in the Pfr state
6G1Y	;	2.5	;	Crystal structure of the photosensory core module (PCM) of a bathy phytochrome from Agrobacterium fabrum in the Pfr state.
4S21	;	3.25	;	Crystal structure of the photosensory core module of bacteriophytochrome RPA3015 from R. palustris
7L5A	;	2.95	;	Crystal structure of the photosensory module from Xanthomonas campestris bacteriophytochrome XccBphP in the Pfr state
2PKQ	;	3.6	;	Crystal structure of the photosynthetic A2B2-glyceraldehyde-3-phosphate dehydrogenase, complexed with NADP
5VYJ	;	3.3	;	Crystal structure of the photosynthetic phosphoenolpyruvate carboxylase isoenzyme from maize in complex with Gly
2WWE	;	1.25	;	Crystal structure of the phox homology domain of human phosphoinositide-3-kinase-C2-gamma
4BGJ	;	2.55	;	Crystal structure of the phox-homology domain of human sorting nexin 14
3NO8	;	2.2	;	Crystal structure of the PHR domain from human BTBD2 Protein
1U3C	;	2.6	;	Crystal Structure of the PHR domain of Cryptochrome 1 from Arabidopsis thaliana
1U3D	;	2.45	;	Crystal Structure of the PHR domain of Cryptochrome 1 from Arabidopsis thaliana with AMPPNP bound
6OZA	;	3.002	;	Crystal structure of the phycocyanobilin-bound GAF domain from a cyanobacterial phytochrome
6OZB	;	1.8	;	Crystal structure of the phycoerythrobilin-bound GAF domain from a cyanobacterial phytochrome
2GFI	;	2.29	;	Crystal structure of the phytase from D. castellii at 2.3 A
5KND	;	2.888	;	Crystal structure of the Pi-bound V1 complex
2IUG	;	1.89	;	Crystal structure of the PI3-kinase p85 N-terminal SH2 domain
2IUH	;	2.0	;	Crystal structure of the PI3-kinase p85 N-terminal SH2 domain in complex with c-Kit phosphotyrosyl peptide
2IUI	;	2.4	;	Crystal structure of the PI3-kinase p85 N-terminal SH2 domain in complex with PDGFR phosphotyrosyl peptide
6BU0	;	2.427	;	Crystal structure of the PI3KC2alpha C2 domain in complex with IP6
6BTZ	;	1.85	;	Crystal structure of the PI3KC2alpha C2 domain in space group C121
6BTY	;	1.678	;	Crystal structure of the PI3KC2alpha C2 domain in space group P41212
6BUB	;	2.604	;	Crystal structure of the PI3KC2alpha PX domain in space group P432
7EM4	;	2.8	;	Crystal structure of the PI5P4Kbeta F205L-ITP complex
7EM5	;	2.8	;	Crystal structure of the PI5P4Kbeta F205L-XTP complex
7EM6	;	2.95	;	Crystal structure of the PI5P4Kbeta N203D-ITP complex
7EM7	;	3.45	;	Crystal structure of the PI5P4Kbeta N203D-XTP complex
7EM8	;	3.05	;	Crystal structure of the PI5P4Kbeta T201M-2a-ATP complex
7EM3	;	3.1	;	Crystal structure of the PI5P4Kbeta-2a-ATP complex
6K4H	;	2.55	;	Crystal structure of the PI5P4Kbeta-AMPPNP complex
6K4G	;	2.7	;	Crystal structure of the PI5P4Kbeta-GMPPNP complex
7EM1	;	2.65	;	Crystal structure of the PI5P4Kbeta-ITP complex
7EM2	;	2.6	;	Crystal structure of the PI5P4Kbeta-XTP complex
7OCZ	;	1.82	;	Crystal Structure of the PID-3 RRM domain
7OCX	;	1.7	;	Crystal Structure of the PID-3 TOFU-6 RRM domain complex
1UA3	;	2.01	;	Crystal structure of the pig pancreatic a-amylase complexed with malto-oligosaccharides
1WO2	;	2.01	;	Crystal structure of the pig pancreatic alpha-amylase complexed with malto-oligosaacharides under the effect of the chloride ion
1VAH	;	2.4	;	Crystal structure of the pig pancreatic-amylase complexed with r-nitrophenyl-a-D-maltoside
7O4X	;	1.65	;	Crystal structure of the PII-like protein PotN from Lentilactobacillus hilgardii
4EO0	;	1.61	;	crystal structure of the pilus binding domain of the filamentous phage IKe
2EWV	;	2.8	;	Crystal Structure of the Pilus Retraction Motor PilT and Bound ADP
2EWW	;	3.2	;	Crystal Structure of the Pilus Retraction Motor PilT and Bound ATP
2DOK	;	1.8	;	Crystal structure of the PIN domain of human EST1A
4MJ7	;	2.51	;	Crystal structure of the PIN domain of Saccharomyces cerevisiae Utp23
7TFQ	;	1.75	;	Crystal Structure of the Pirin Family Protein Redox-sensitive Bicupin YhaK Bound to Copper Ion from Yersinia pestis
7TE5	;	1.85	;	Crystal Structure of the Pirin Family Protein Redox-sensitive Bicupin YhaK from Yersinia pestis
7TG5	;	1.72	;	Crystal Structure of the Pirin Family Protein Redox-sensitive Bicupin YhaK in the Presence of Fe Ion from Yersinia pestis
5H78	;	2.002	;	Crystal structure of the PKA-DHR14 fusion protein
5H77	;	3.197	;	Crystal structure of the PKA-protein A fusion protein
5XBY	;	3.25	;	Crystal structure of the PKA-Protein A fusion protein (end-to-end fusion)
2Y72	;	1.18	;	Crystal structure of the PKD Domain of Collagenase G from Clostridium Histolyticum at 1.18 Angstrom Resolution.
4L9D	;	1.1	;	Crystal structure of the PKD1 domain from Vibrio cholerae metalloprotease PrtV
6AEM	;	1.272	;	Crystal structure of the PKD1 domain of Vibrio anguillarum Epp
3NBY	;	3.42	;	Crystal structure of the PKI NES-CRM1-RanGTP nuclear export complex
5NM9	;	2.43	;	Crystal structure of the placozoa Trichoplax adhaerens Smad4-MH1 bound to the GGCGC site.
6B55	;	2.5	;	Crystal structure of the Plant Defensin NaD1 complexed with phosphatidic acid
5KK4	;	1.7	;	Crystal Structure of the Plant Defensin NsD7 bound to Phosphatidic Acid
5VYP	;	2.6	;	Crystal structure of the Plant Defensin NsD7 bound to PIP2
7ZMX	;	1.2	;	Crystal structure of the Plant Homeodomain (PHD) of human ING3
3BWD	;	1.53	;	Crystal structure of the plant Rho protein ROP5
3RIZ	;	2.523	;	Crystal structure of the plant steroid receptor BRI1 ectodomain
3H7R	;	1.4	;	Crystal structure of the plant stress-response enzyme AKR4C8
3H7U	;	1.25	;	Crystal structure of the plant stress-response enzyme AKR4C9
3I6S	;	2.5	;	Crystal Structure of the plant subtilisin-like protease SBT3
3I74	;	2.6	;	Crystal Structure of the plant subtilisin-like protease SBT3 in complex with a chloromethylketone inhibitor
5DLY	;	1.5	;	Crystal structure of the plantazolicin methyltransferase BamL in complex with monoazolic desmethylPZN analog and SAH
4KVZ	;	1.75	;	Crystal structure of the plantazolicin methyltransferase BamL in complex with SAH
5DM0	;	1.75	;	Crystal structure of the plantazolicin methyltransferase BamL in complex with triazolic desmethylPZN analog and SAH
5DM1	;	1.8	;	Crystal structure of the plantazolicin methyltransferase BpumL in complex with monoazolic desmethylPZN analog and SAH
5DM4	;	1.75	;	Crystal structure of the plantazolicin methyltransferase BpumL in complex with pentazolic desmethylPZN analog and SAH
5DM2	;	1.5	;	Crystal structure of the plantazolicin methyltransferase BpumL in complex with triazolic desmethylPZN analog and SAH
1GVN	;	1.95	;	Crystal Structure of the Plasmid Maintenance System epsilon/zeta: Meachnism of toxin inactivation and toxin function
3L57	;	2.293	;	Crystal Structure of the Plasmid pCU1 TraI Relaxase Domain
3UIR	;	2.777	;	Crystal structure of the plasmin-textilinin-1 complex
2BSX	;	2.0	;	Crystal structure of the Plasmodium falciparum purine nucleoside phosphorylase complexed with inosine
2VFI	;	2.25	;	Crystal structure of the Plasmodium falciparum triosephosphate isomerase in the loop closed state with 3-phosphoglycerate bound at the active site and interface
3E95	;	2.5	;	Crystal Structure of the Plasmodium Falciparum ubiquitin conjugating enzyme complex, PfUBC13-PfUev1a
1UMR	;	2.4	;	Crystal structure of the platelet activator convulxin, a disulfide linked a4b4 cyclic tetramer from the venom of Crotalus durissus terrificus
1UPQ	;	1.48	;	Crystal structure of the pleckstrin homology (PH) domain of PEPP1
3PP2	;	1.421	;	Crystal structure of the pleckstrin homology domain of ArhGAP27
3VOQ	;	2.0	;	Crystal structure of the pleckstrin homology domain of human Sin1, a TORC2 subunit
5MR1	;	1.2	;	Crystal structure of the Pleckstrin homology domain of Interactor protein for cytohesin exchange factors 1 (IPCEF1)
1UNP	;	1.65	;	Crystal structure of the pleckstrin homology domain of PKB alpha
3ULB	;	1.9	;	Crystal structure of the pleckstrin homology domain of Saccharomyces cerevisiae Avo1, a TORC2 subunit, in the P212121 crystal form
3ULC	;	2.8	;	Crystal structure of the pleckstrin homology domain of Saccharomyces cerevisiae Avo1, a TORC2 subunit, in the P3121 crystal form
5OC7	;	1.652	;	Crystal structure of the pleckstrin-homology domain of Bcr-Abl in complex with monobody Mb(Bcr-PH_4).
4Q28	;	2.64	;	Crystal Structure of the Plectin 1 and 2 Repeats of the Human Periplakin. Northeast Structural Genomics Consortium (NESG) Target HR9083A
4Q58	;	4.001	;	Crystal structure of the plectin 1a actin-binding domain/integrin beta 4 fragment complex
4Q57	;	1.8	;	Crystal structure of the plectin 1a actin-binding domain/N-terminal domain of calmodulin complex
6QP3	;	2.3	;	Crystal structure of the PLP-bound C-S lyase from Bacillus subtilis (strain 168)
6QP2	;	1.6	;	Crystal structure of the PLP-bound C-S lyase from Staphylococcus hominis
6QP1	;	1.42	;	Crystal structure of the PLP-bound C-S lyase in the external aldimine form from Staphylococcus hominis complexed with an inhibitor, L-cycloserine.
1DJE	;	1.71	;	CRYSTAL STRUCTURE OF THE PLP-BOUND FORM OF 8-AMINO-7-OXONANOATE SYNTHASE
2C7T	;	2.1	;	CRYSTAL STRUCTURE OF THE PLP-BOUND FORM OF BTRR, A DUAL FUNCTIONAL AMINOTRANSFERASE INVOLVED IN BUTIROSIN BIOSYNTHESIS.
4ZMC	;	1.9	;	Crystal structure of the PmFTN variant E130A soaked in iron (5 min)
4ZLW	;	2.0	;	Crystal structure of the PmFTN variant E130A soaked in iron (overnight)
4ZL6	;	1.9	;	Crystal structure of the PmFTN variant E44H soaked in iron (3 h)
4ZL5	;	1.85	;	Crystal structure of the PmFTN variant E44H soaked in iron (45 min)
4ZKW	;	1.8	;	Crystal structure of the PmFTN variant E44Q soaked in iron (45 min)
4ZKX	;	1.8	;	Crystal structure of the PmFTN variant E44Q soaked in iron (5 min)
4ZKH	;	1.9	;	Crystal structure of the PmFTN variant E44Q soaked in iron (overnight)
6QLA	;	1.43	;	CRYSTAL STRUCTURE OF THE PMGL2 ESTERASE (point mutant 1) FROM PERMAFROST METAGENOMIC LIBRARY
6QIN	;	1.6	;	CRYSTAL STRUCTURE OF THE PMGL2 ESTERASE FROM PERMAFROST METAGENOMIC LIBRARY
2CBG	;	2.5	;	Crystal structure of the PMSF-inhibited thioesterase domain of the fengycin biosynthesis cluster
7T8N	;	2.85	;	Crystal structure of the PNAG binding module PgaA-TPR 220-359
4HQS	;	1.48	;	Crystal structure of the pneumoccocal exposed lipoprotein thioredoxin sp_0659 (Etrx1) from Streptococcus pneumoniae strain TIGR4
4HQZ	;	1.22	;	Crystal structure of the pneumoccocal exposed lipoprotein thioredoxin sp_1000 (Etrx2) from Streptococcus pneumoniae strain TIGR4 in complex with 2-hydroxyethyl disulfide
2YP6	;	1.767	;	Crystal structure of the pneumoccocal exposed lipoprotein thioredoxin sp_1000 (Etrx2) from Streptococcus pneumoniae strain TIGR4 in complex with Cyclofos 3 TM
4PQG	;	2.0	;	Crystal structure of the pneumococcal O-GlcNAc transferase GtfA in complex with UDP and GlcNAc
8A42	;	1.5	;	Crystal structure of the pneumococcal Substrate-binding protein AmiA in complex with an unknown peptide
7LUG	;	1.95	;	Crystal structure of the pnRFP B30Y mutant
4MHV	;	2.45	;	Crystal structure of the PNT domain of human ETS2
2GCJ	;	2.55	;	Crystal Structure of the Pob3 middle domain
8CPN	;	1.85	;	Crystal structure of the PolB16_OarG intein variant S1A, N183A
8CPO	;	2.6	;	Crystal structure of the PolB16_OarG intein variant S1A, N183A, C111A, C165A
2IJD	;	3.4	;	Crystal Structure of the Poliovirus Precursor Protein 3CD
2IJF	;	3.0	;	Crystal Structure of the Poliovirus RNA-Dependent RNA Polymerase Fidelity Mutant 3Dpol G64S
4R0E	;	3.0	;	Crystal Structure of the Poliovirus RNA-Dependent RNA Polymerase Low-Fidelity Mutant 3Dpol H273R
6MF4	;	1.8	;	Crystal structure of the polo-box domain of Cdc5 from budding yeast.
1RSG	;	1.9	;	Crystal structure of the polyamine oxidase Fms1 from yeast
2IQ7	;	1.94	;	Crystal structure of the polygalacturonase from Colletotrichum lupini and its implications for the interaction with polygalacturonase-inhibiting proteins
1WUB	;	1.65	;	Crystal structure of the polyisoprenoid-binding protein, TT1927b, from Thermus thermophilus HB8
2F98	;	2.1	;	Crystal structure of the polyketide cyclase AknH with bound substrate and product analogue: implications for catalytic mechanism and product stereoselectivity.
2F99	;	1.9	;	Crystal structure of the polyketide cyclase AknH with bound substrate and product analogue: implications for catalytic mechanism and product stereoselectivity.
3AWK	;	2.0	;	Crystal structure of the polyketide synthase 1 from huperzia serrata
2IRU	;	1.65	;	Crystal Structure of the Polymerase Domain from Mycobacterium tuberculosis Ligase D
2IRY	;	1.78	;	Crystal Structure of the Polymerase Domain from Mycobacterium tuberculosis Ligase D with dGTP and Manganese.
2IRX	;	1.8	;	Crystal Structure of the Polymerase Domain from Mycobacterium tuberculosis Ligase D with GTP and Manganese.
7OQV	;	2.4	;	Crystal structure of the polymerising VEL domain of VIN3 (I575D mutant)
7O6T	;	2.02	;	Crystal structure of the polymerising VEL domain of VIN3 (R556D I575D mutant)
4WRN	;	3.2	;	Crystal structure of the polymerization region of human uromodulin/Tamm-Horsfall protein
5N1J	;	1.8	;	Crystal structure of the polysaccharide deacetylase Bc1974 from Bacillus cereus
5NC9	;	2.44	;	Crystal structure of the polysaccharide deacetylase Bc1974 from Bacillus cereus in complex with (2S)-2,6-diamino-N-hydroxyhexanamide
5NCD	;	2.447	;	Crystal structure of the polysaccharide deacetylase Bc1974 from Bacillus cereus in complex with (2S)-2-amino-5-(diaminomethylideneamino)-N-hydroxypentanamide
5NC6	;	2.8	;	Crystal structure of the polysaccharide deacetylase Bc1974 from Bacillus cereus in complex with (E)-N-hydroxy-3-(naphthalen-1-yl)prop-2-enamide
5NEK	;	3.057	;	Crystal structure of the polysaccharide deacetylase Bc1974 from Bacillus cereus in complex with acetazolamide
5N1P	;	1.448	;	Crystal structure of the polysaccharide deacetylase Bc1974 from Bacillus cereus in complex with N-hydroxynaphthalene-1-carboxamide
5NEL	;	2.734	;	Crystal structure of the polysaccharide deacetylase Bc1974 from Bacillus cereus in complex with ThiametG
3JQY	;	1.699	;	Crystal Structure of the polySia specific acetyltransferase NeuO
2P5R	;	2.45	;	Crystal structure of the poplar glutathione peroxidase 5 in the oxidized form
2P5Q	;	2.0	;	Crystal structure of the poplar glutathione peroxidase 5 in the reduced form
7XCA	;	2.5	;	Crystal structure of the porcine astrovirus capsid spike domain
5LRG	;	2.02	;	Crystal structure of the porcine carboxypeptidase B - Anabaenopeptin B complex
5LRJ	;	2.2	;	Crystal structure of the porcine carboxypeptidase B - Anabaenopeptin C complex
5LRK	;	2.3	;	Crystal structure of the porcine carboxypeptidase B - Anabaenopeptin F complex
2I2S	;	2.3	;	Crystal Structure of the porcine CRW-8 rotavirus VP8* carbohydrate-recognising domain
4RWO	;	2.2	;	Crystal structure of the porcine OAS1 L149R mutant in complex with dsRNA and ApCpp in the AMP donor position
1ZBC	;	2.29	;	Crystal Structure of the porcine signalling protein liganded with the peptide Trp-Pro-Trp (WPW) at 2.3 A resolution
3LIM	;	1.8	;	Crystal structure of the pore forming toxin frac from sea anemone actinia fragacea
3ZWG	;	3.0	;	Crystal structure of the pore-forming toxin FraC from Actinia fragacea (form 2)
3ZWJ	;	2.37	;	CRYSTAL STRUCTURE OF THE PORE-FORMING TOXIN FRAC FROM ACTINIA FRAGACEA (Form 3)
4MKQ	;	2.65	;	Crystal structure of the Pore-Forming Toxin Monalysin mutant deleted of the membrane-spanning domain
2R74	;	1.9	;	Crystal Structure of the Possum Milk Whey Lipocalin Trichosurin at pH 4.6
2RA6	;	1.5	;	Crystal Structure of the Possum Milk Whey Lipocalin Trichosurin at pH 4.6 with Bound 4-ethylphenol
2R73	;	2.5	;	Crystal Structure of the Possum Milk Whey Lipocalin Trichosurin at pH 8.2
5IIL	;	1.96	;	Crystal structure of the post-catalytic nick complex of DNA polymerase lambda with a templating 8-oxo-dG and incorporated dA
5IIK	;	1.982	;	Crystal structure of the post-catalytic nick complex of DNA polymerase lambda with a templating 8-oxo-dG and incorporated dC
4X5V	;	2.15	;	Crystal structure of the post-catalytic nick complex of DNA polymerase lambda with a templating A and incorporated 8-oxo-dGMP
3UQ0	;	2.14	;	Crystal structure of the post-catalytic product complex of polymerase lambda with an rAMP at the primer terminus.
3UQ2	;	2.25	;	Crystal structure of the post-catalytic product complex of polymerase lambda with an rCMP inserted opposite a templating G and dAMP inserted opposite a templating T at the primer terminus.
3NSI	;	2.15	;	Crystal Structure of the Post-Refolded S100A3 Protein Expressed in Insect Cell
3NSK	;	1.55	;	Crystal Structure of the Post-Refolded S100A3 R51A Mutant Expressed in Insect Cell
3DUZ	;	2.95	;	Crystal structure of the postfusion form of baculovirus fusion protein GP64
6HD8	;	2.4	;	Crystal structure of the potassium channel MtTMEM175 in complex with a Nanobody-MBP fusion protein
6HDC	;	3.4	;	Crystal structure of the potassium channel MtTMEM175 T38A variant in complex with a Nanobody-MBP fusion protein
6HDA	;	3.8	;	Crystal structure of the potassium channel MtTMEM175 with cesium
6HD9	;	3.5	;	Crystal structure of the potassium channel MtTMEM175 with rubidium
6HDB	;	2.9	;	Crystal structure of the potassium channel MtTMEM175 with zinc
3PJZ	;	3.506	;	Crystal Structure of the Potassium Transporter TrkH from Vibrio parahaemolyticus
6RFC	;	2.0	;	Crystal structure of the potassium-pumping G263F mutant of the light-driven sodium pump KR2 in the monomeric form, pH 4.3
6RF3	;	2.4	;	Crystal structure of the potassium-pumping G263F mutant of the light-driven sodium pump KR2 in the pentameric form, pH 8.0
6RFB	;	2.1	;	Crystal structure of the potassium-pumping S254A mutant of the light-driven sodium pump KR2 in the monomeric form, pH 4.3
6RF4	;	2.4	;	Crystal structure of the potassium-pumping S254A mutant of the light-driven sodium pump KR2 in the pentameric form, pH 8.0
3OBL	;	1.2	;	Crystal structure of the potent anti-HIV cyanobacterial lectin from Oscillatoria Agardhii
1TQ0	;	2.8	;	Crystal structure of the potent anticoagulant thrombin mutant W215A/E217A in free form
1BX6	;	2.1	;	CRYSTAL STRUCTURE OF THE POTENT NATURAL PRODUCT INHIBITOR BALANOL IN COMPLEX WITH THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
4HIC	;	3.001	;	Crystal structure of the potential transfer protein TraK from Gram-positive conjugative plasmid pIP501
7QM2	;	2.685	;	Crystal structure of the PP1/PTG/beta-cyclodextrin ternary complex
2IXO	;	2.6	;	CRYSTAL STRUCTURE OF THE PP2A PHOSPHATASE ACTIVATOR Ypa1 PTPA1
2IXP	;	2.8	;	Crystal structure of the Pp2A phosphatase activator Ypa1 PTPA1 in complex with model substrate
2IXN	;	2.8	;	CRYSTAL STRUCTURE OF THE PP2A PHOSPHATASE ACTIVATOR Ypa2 PTPA2
3LMP	;	1.9	;	Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator
3V9T	;	1.65	;	Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator
3V9V	;	1.6	;	Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator
3V9Y	;	2.1	;	Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator
4F9M	;	1.9	;	Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator
3B1M	;	1.6	;	Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator Cerco-A
3HO0	;	2.6	;	Crystal structure of the PPARgamma-LBD complexed with a new aryloxy-3phenylpropanoic acid
3HOD	;	2.1	;	Crystal structure of the PPARgamma-LBD complexed with a new aryloxy-3phenylpropanoic acid
5Z5S	;	1.8	;	Crystal structure of the PPARgamma-LBD complexed with compound 13ab
6IZM	;	1.8	;	Crystal structure of the PPARgamma-LBD complexed with compound 1l
6IZN	;	1.75	;	Crystal structure of the PPARgamma-LBD complexed with compound 3g
5Z6S	;	1.8	;	Crystal structure of the PPARgamma-LBD complexed with compound DS-6930
6GMP	;	1.35	;	CRYSTAL STRUCTURE OF THE PPIASE DOMAIN OF TBPAR42
4DT4	;	1.35	;	Crystal structure of the PPIase-chaperone SlpA with the chaperone binding site occupied by the linker of the purification tag
2V06	;	1.05	;	Crystal structure of the PPM Ser-Thr phosphatase MsPP from Mycobacterium smegmatis at pH 5.5
2JFS	;	1.45	;	Crystal structure of the PPM Ser-Thr phosphatase MsPP from Mycobacterium smegmatis in complex with cacodylate
2JFR	;	0.83	;	Crystal structure of the PPM Ser-Thr phosphatase MsPP from Mycobacterium smegmatis in complex with phosphate at 0.83 A resolution
2JFT	;	1.08	;	Crystal structure of the PPM Ser-Thr phosphatase MsPP from Mycobacterium smegmatis in complex with sulfate
6LVR	;	2.85	;	Crystal structure of the PPR domain of Arabidopsis thaliana protein-only RNase P 1 (PRORP1) in complex with tRNA
5WLE	;	1.952	;	Crystal structure of the PPS PHD finger in complex with H3K4me3
4C1Q	;	2.3	;	Crystal structure of the PRDM9 SET domain in complex with H3K4me2 and AdoHcy.
1NO4	;	2.2	;	Crystal Structure of the pre-assembly scaffolding protein gp7 from the double-stranded DNA bacteriophage phi29
2H32	;	2.7	;	Crystal structure of the pre-B cell receptor
5III	;	1.8	;	Crystal structure of the pre-catalytic ternary complex of DNA polymerase lambda with a templating 8-oxo-dG and an incoming dATP
5IIJ	;	1.724	;	Crystal structure of the pre-catalytic ternary complex of DNA polymerase lambda with a templating 8-oxo-dG and an incoming dCTP
4XA5	;	1.9	;	Crystal structure of the pre-catalytic ternary complex of DNA polymerase lambda with a templating A and an incoming 8-oxo-dGTP
4XUS	;	2.4	;	Crystal structure of the pre-catalytic ternary complex of DNA polymerase lambda with a templating A and an incoming dTTP
4FO6	;	2.007	;	Crystal structure of the pre-catalytic ternary complex of polymerase lambda with a dATP analog opposite a templating T and an rCMP at the primer terminus.
3UPQ	;	1.95	;	Crystal structure of the pre-catalytic ternary complex of polymerase lambda with an rATP analog opposite a templating T.
5IIM	;	1.941	;	Crystal structure of the pre-catalytic ternary extension complex of DNA polymerase lambda with an 8-oxo-dG:dA base-pair
5IIN	;	2.15	;	Crystal structure of the pre-catalytic ternary extension complex of DNA polymerase lambda with an 8-oxo-dG:dC base-pair
2HOF	;	2.4	;	Crystal structure of the pre-cleavage synaptic complex in the cre-loxp site-specific recombination
3G8S	;	3.1	;	Crystal structure of the pre-cleaved Bacillus anthracis glmS ribozyme
3T56	;	3.42	;	Crystal structure of the pre-extrusion state of the CusBA adaptor-transporter complex
3SUC	;	2.15	;	Crystal structure of the pre-mature bacteriophage phi29 gene product 12
4RWN	;	2.0	;	Crystal structure of the pre-reactive state of porcine OAS1
4EX8	;	2.1	;	Crystal structure of the prealnumycin C-glycosynthase AlnA
4EX9	;	3.15	;	Crystal structure of the prealnumycin C-glycosynthase AlnA in complex with ribulose 5-phosphate
3TP1	;	1.6	;	Crystal Structure of the precatalytic M-PMV dUTPase - substrate (dUPNPP) complex
3N5I	;	1.8	;	Crystal structure of the precursor (S250A mutant) of the N-terminal beta-aminopeptidase BapA
3EDY	;	1.85	;	Crystal Structure of the Precursor Form of Human Tripeptidyl-Peptidase 1
4PAB	;	1.85	;	Crystal structure of the precursor form of rat DMGDH complexed with tetrahydrofolate
3C5X	;	2.2	;	Crystal structure of the precursor membrane protein- envelope protein heterodimer from the dengue 2 virus at low pH
3C6E	;	2.6	;	Crystal structure of the precursor membrane protein- envelope protein heterodimer from the dengue 2 virus at neutral pH
6EPK	;	2.7	;	CRYSTAL STRUCTURE OF THE PRECURSOR MEMBRANE PROTEIN-ENVELOPE PROTEIN HETERODIMER FROM THE YELLOW FEVER VIRUS
1K3I	;	1.4	;	Crystal Structure of the Precursor of Galactose Oxidase
3CNU	;	1.9	;	Crystal structure of the predicted coding region AF_1534 from Archaeoglobus fulgidus
3CUO	;	2.0	;	Crystal structure of the predicted DNA-binding transcriptional regulator from E. coli
2ZQM	;	1.9	;	Crystal structure of the prefoldin beta subunit from Thermococcus strain KS-1
3AEI	;	1.7	;	Crystal structure of the prefoldin beta2 subunit from Thermococcus strain KS-1
5YXW	;	2.776	;	Crystal structure of the prefusion form of measles virus fusion protein
5YZC	;	2.334	;	Crystal structure of the prefusion form of measles virus fusion protein in complex with a fusion inhibitor compound (AS-48)
5YZD	;	2.636	;	Crystal structure of the prefusion form of measles virus fusion protein in complex with a fusion inhibitor peptide (FIP)
5INE	;	3.5	;	Crystal structure of the prefusion glycoprotein of LCMV
7MMN	;	3.57	;	Crystal Structure of the Prefusion RSV F Glycoprotein bound by human antibody AM14
2QNV	;	2.8	;	Crystal Structure of the Pregnane X Receptor bound to Colupulone
6F5V	;	1.7	;	Crystal structure of the prephenate aminotransferase from Arabidopsis thaliana
6F77	;	1.794	;	Crystal structure of the prephenate aminotransferase from Rhizobium meliloti
4OYC	;	2.6	;	Crystal structure of the PrgK periplasmic domain 2
6RB4	;	1.5	;	Crystal structure of the Pri1 subunit of human primase
6R5E	;	1.85	;	Crystal structure of the Pri1 subunit of human primase bound to 2F-ATP
6R4S	;	2.75	;	Crystal structure of the Pri1 subunit of human primase bound to ATP
6R5D	;	1.95	;	Crystal structure of the Pri1 subunit of human primase bound to dATP
6R4U	;	2.2	;	Crystal structure of the Pri1 subunit of human primase bound to fludarabine triphosphate
6R4T	;	2.35	;	Crystal structure of the Pri1 subunit of human primase bound to vidarabine triphosphate
2DWL	;	3.2	;	Crystal structure of the PriA protein complexed with oligonucleotides
2DWM	;	3.15	;	Crystal structure of the PriA protein complexed with oligonucleotides
2DWN	;	3.35	;	Crystal structure of the PriA protein complexed with oligonucleotides
2O7G	;	2.7	;	Crystal structure of the Pribnow Box recognition region of SigC from Mycobacterium tuberculosis
4NZU	;	1.2	;	Crystal structure of the primary monoclonal antibody 13PL Fab' from a multiple myeloma patient
1NUI	;	2.9	;	Crystal Structure of the primase fragment of Bacteriophage T7 primase-helicase protein
3M1M	;	1.85	;	Crystal structure of the primase-polymerase from Sulfolobus islandicus
5Z98	;	2.2	;	Crystal Structure of the Primate APOBEC3H Dimer mediated by RNA Duplex
5W5C	;	1.85	;	Crystal structure of the primed SNARE-Complexin-Synaptotagmin-1 C2AB complex
5W5D	;	2.496	;	Crystal structure of the primed SNARE-Complexin-Synaptotagmin-1 C2B complex
1MZJ	;	2.1	;	Crystal Structure of the Priming beta-Ketosynthase from the R1128 Polyketide Biosynthetic Pathway
1ACY	;	3.0	;	CRYSTAL STRUCTURE OF THE PRINCIPAL NEUTRALIZING SITE OF HIV-1
7BOC	;	2.55	;	Crystal structure of the PRMT5 TIM barrel domain in complex with RioK1 peptide
3C0M	;	2.88	;	Crystal structure of the proaerolysin mutant Y221G
3C0N	;	2.2	;	Crystal structure of the proaerolysin mutant Y221G at 2.2 A
3C0O	;	2.5	;	Crystal structure of the proaerolysin mutant Y221G complexed with mannose-6-phosphate
3DX5	;	2.12	;	Crystal structure of the probable 3-DHS dehydratase AsbF involved in the petrobactin synthesis from Bacillus anthracis
2O1M	;	2.0	;	Crystal structure of the probable amino-acid ABC transporter extracellular-binding protein ytmK from Bacillus subtilis. Northeast Structural Genomics Consortium target SR572
1YX2	;	2.08	;	Crystal Structure of the Probable Aminomethyltransferase from Bacillus subtilis
3B40	;	2.0	;	Crystal structure of the probable dipeptidase PvdM from Pseudomonas aeruginosa
8EBG	;	1.43	;	Crystal structure of the probable FhuD FeIII-dicitrate-binding domain protein FecB from Mycobacterium tuberculosis
2HOQ	;	1.7	;	Crystal structure of the probable haloacid dehalogenase (PH1655) from pyrococcus horikoshii OT3
6DRT	;	2.117	;	Crystal structure of the processivity clamp GP45 complexed with recognition peptide of ligase from bacteriophage T4
1CZD	;	2.45	;	CRYSTAL STRUCTURE OF THE PROCESSIVITY CLAMP GP45 FROM BACTERIOPHAGE T4
1JR3	;	2.7	;	Crystal Structure of the Processivity Clamp Loader Gamma Complex of E. coli DNA Polymerase III
6VJV	;	1.59	;	Crystal structure of the Prochlorococcus phage (myovirus P-SSM2) ferredoxin at 1.6 Angstroms
1SG8	;	2.3	;	Crystal structure of the procoagulant fast form of thrombin
3G9C	;	2.9	;	Crystal structure of the product Bacillus anthracis glmS ribozyme
3C28	;	2.6	;	Crystal structure of the product synapse complex
4ZKT	;	3.05	;	Crystal structure of the progenitor M complex of Clostridium botulinum type E neurotoxin
3QSQ	;	1.8	;	Crystal structure of the projection domain of the human astrovirus capsid protein
3TS3	;	1.49	;	Crystal structure of the projection domain of the turkey astrovirus capsid protein at 1.5 angstrom resolution
2O3X	;	2.9	;	Crystal Structure of the Prokaryotic Ribosomal Decoding Site Complexed with Paromamine Derivative NB30
3M9D	;	4.5	;	Crystal structure of the prokaryotic ubiquintin-like protein Pup complexed with the hexameric proteasomal ATPase Mpa which includes the amino terminal coiled coil domain and the inter domain
3M91	;	1.8	;	Crystal structure of the prokaryotic ubiquitin-like protein (Pup) complexed with the amino terminal coiled coil of the Mycobacterium tuberculosis proteasomal ATPase Mpa
1WY2	;	1.7	;	Crystal Structure of the Prolidase from Pyrococcus horikoshii OT3
2YYS	;	2.2	;	Crystal structure of the proline iminopeptidase-related protein TTHA1809 from Thermus thermophilus HB8
5D9E	;	0.859	;	Crystal Structure of the Proline-rich Lasso Peptide Caulosegnin II
4IRN	;	2.8	;	Crystal Structure of the Prolyl Acyl Carrier Protein Oxidase AnaB
7WAB	;	1.75	;	Crystal structure of the prolyl endoprotease, PEP, from Aspergillus niger
3B7H	;	2.0	;	Crystal structure of the prophage Lp1 protein 11
7LBU	;	2.11	;	Crystal structure of the Propionibacterium acnes surface sialidase
7LBV	;	1.7	;	Crystal structure of the Propionibacterium acnes surface sialidase in complex with Neu5Ac2en
1P8J	;	2.6	;	CRYSTAL STRUCTURE OF THE PROPROTEIN CONVERTASE FURIN
6D27	;	2.738	;	Crystal structure of the prostaglandin D2 receptor CRTH2 with CAY10471
6D26	;	2.798	;	Crystal structure of the prostaglandin D2 receptor CRTH2 with fevipiprant
3STJ	;	2.6	;	Crystal structure of the protease + PDZ1 domain of DegQ from Escherichia coli
6HF6	;	2.0	;	Crystal structure of the Protease 1 (E29A,E60A,E80A) from Pyrococcus horikoshii co-crystallized with Tb-Xo4.
4C2C	;	1.9	;	Crystal structure of the protease CtpB in an active state
4C2D	;	2.7	;	Crystal structure of the protease CtpB in an active state
4C2E	;	1.8	;	Crystal structure of the protease CtpB(S309A) present in a resting state
1L1J	;	2.8	;	Crystal structure of the protease domain of an ATP-independent heat shock protease HtrA
3QW8	;	1.6	;	Crystal structure of the protease domain of Botulinum Neurotoxin Serotype A with a peptide inhibitor CRGC
3QW7	;	1.5	;	Crystal structure of the protease domain of Botulinum Neurotoxin Serotype A with a peptide inhibitor RRFC
3QW5	;	1.6	;	Crystal structure of the protease domain of Botulinum Neurotoxin Serotype A with a peptide inhibitor RRGF
3QW6	;	1.6	;	Crystal structure of the protease domain of Botulinum Neurotoxin Serotype A with a peptide inhibitor RYGC
3STI	;	2.6	;	Crystal structure of the protease domain of DegQ from Escherichia coli
7MHW	;	2.55	;	Crystal structure of the protease inhibitor U-Omp19 from Brucella abortus fused to Maltose-binding protein
2R2Y	;	1.7	;	Crystal structure of the proteasomal Rpn13 PRU-domain
5IRS	;	1.796	;	crystal structure of the proteasomal Rpn13 PRU-domain
7BR3	;	2.79	;	Crystal structure of the protein 1
1GG3	;	2.8	;	CRYSTAL STRUCTURE OF THE PROTEIN 4.1R MEMBRANE BINDING DOMAIN
3D01	;	1.7	;	Crystal structure of the protein Atu1372 with unknown function from Agrobacterium tumefaciens
2Q08	;	2.0	;	Crystal structure of the protein BH0493 from Bacillus halodurans C-125 complexed with ZN
3GVZ	;	2.8	;	Crystal structure of the protein CV2077 from Chromobacterium violaceum. Northeast Structural Genomics Consortium Target CvR62
1EEJ	;	1.9	;	CRYSTAL STRUCTURE OF THE PROTEIN DISULFIDE BOND ISOMERASE, DSBC, FROM ESCHERICHIA COLI
5FID	;	1.809	;	Crystal structure of the protein elicitor MoHrip2 from Magnaporthe oryzae
4I4C	;	1.95	;	Crystal structure of the protein frsA complexed with unknown ligand
5DZL	;	3.4006	;	Crystal structure of the protein human CEACAM1
5XVU	;	3.0	;	Crystal structure of the protein kinase CK2 catalytic domain from Plasmodium falciparum bound to ATP
5N1V	;	2.52	;	Crystal structure of the protein kinase CK2 catalytic subunit in complex with pyrazolo-pyrimidine macrocyclic ligand
3HYH	;	2.2	;	Crystal structure of the protein kinase domain of yeast AMP-activated protein kinase Snf1
1TZZ	;	1.86	;	Crystal structure of the protein L1841, unknown member of enolase superfamily from Bradyrhizobium japonicum
3NEH	;	1.642	;	Crystal structure of the protein LMO2462 from Listeria monocytogenes complexed with ZN and phosphonate mimic of dipeptide L-Leu-D-Ala
3BEY	;	2.4	;	Crystal structure of the protein O27018 from Methanobacterium thermoautotrophicum. Northeast Structural Genomics Consortium target TT217
2R41	;	2.9	;	Crystal structure of the protein of unknown function from Enterococcus faecalis
2IGS	;	2.17	;	Crystal Structure of the Protein of Unknown Function from Pseudomonas aeruginosa
5V4D	;	1.6	;	Crystal Structure of the Protein of Unknown Function of the Conserved Rid Protein Family YyfA from Yersinia pestis
5V4F	;	3.001	;	Crystal Structure of the Protein of Unknown Function of the Conserved Rid Protein Family YyfB from Yersinia pestis
1Z0P	;	1.7	;	Crystal structure of the Protein of Unknown Function SPY1572 from Streptococcus pyogenes
7TMU	;	2.55	;	Crystal Structure of the Protein of Unknown Function YPO0625 from Yersinia pestis
3FHW	;	1.9	;	Crystal structure of the protein priB from Bordetella parapertussis. Northeast Structural Genomics Consortium target BpR162.
3DC7	;	2.12	;	Crystal structure of the protein Q88SR8 from Lactobacillus plantarum. Northeast Structural Genomics consortium target LpR109.
3E8P	;	2.3	;	Crystal structure of the protein Q8E9M7 from Shewanella oneidensis related to thioesterase superfamily. Northeast Structural Genomics Consortium target SoR246.
4FJ4	;	2.1	;	Crystal structure of the protein Q9HRE7 complexed with mercury from Halobacterium salinarium at the resolution 2.1A, Northeast Structural Genomics Consortium target HsR50
4DLH	;	1.9	;	Crystal Structure of the protein Q9HRE7 from Halobacterium salinarium at the resolution 1.9A, Northeast Structural Genomics Consortium (NESG) Target HsR50
2I9C	;	2.0	;	Crystal Structure of the Protein RPA1889 from Rhodopseudomonas palustris CGA009
2Q2H	;	1.65	;	Crystal structure of the protein secretion chaperone CsaA from Agrobacterium tumefaciens with a genetically fused phage-display derived peptide substrate at the N-terminus.
2Q2I	;	1.55	;	Crystal structure of the protein secretion chaperone CsaA from Agrobacterium tumefaciens.
1A6Q	;	2.0	;	CRYSTAL STRUCTURE OF THE PROTEIN SERINE/THREONINE PHOSPHATASE 2C AT 2 A RESOLUTION
2PLM	;	2.1	;	Crystal structure of the protein TM0936 from Thermotoga maritima complexed with ZN and S-inosylhomocysteine
3G7G	;	1.99	;	Crystal structure of the protein with unknown function from Clostridium acetobutylicum ATCC 824
1Q2Y	;	2.0	;	Crystal structure of the protein YJCF from Bacillus subtilis: a member of the GCN5-related N-acetyltransferase superfamily fold
3KLU	;	2.2	;	Crystal structure of the protein yqbn. northeast structural genomics consortium target sr445.
2QC7	;	2.9	;	Crystal structure of the protein-disulfide isomerase related chaperone ERp29
6I2A	;	1.75	;	Crystal Structure of the Protein-Kinase A catalytic subunit from Cricetulus Griseus in complex with compounds RKp153 and Fasudil
6I2B	;	1.97	;	Crystal Structure of the Protein-Kinase A catalytic subunit from Cricetulus Griseus in complex with compounds RKp153 and RKp117
6I2C	;	1.82	;	Crystal Structure of the Protein-Kinase A catalytic subunit from Cricetulus Griseus in complex with compounds RKp182 and Fasudil
6I2D	;	1.91	;	Crystal Structure of the Protein-Kinase A catalytic subunit from Cricetulus Griseus in complex with compounds RKp182 and RKp117
6I2H	;	1.68	;	Crystal Structure of the Protein-Kinase A catalytic subunit from Cricetulus Griseus in complex with compounds RKp182 and RKp190
5OUA	;	1.67	;	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compound RKp017
5NTJ	;	1.56	;	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compound RKp032
6ERU	;	2.15	;	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compound RKp120
6ERV	;	2.06	;	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp013
6ERW	;	1.89	;	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp013 and Fasudil
5OL3	;	1.58	;	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp013 and RKp117
5OTG	;	1.73	;	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp013 and RKp190
6EGW	;	1.74	;	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp017 and RKp117
6EM6	;	1.64	;	Crystal structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp032 and ADP
6EH2	;	1.76	;	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp032 and AMP
5NW8	;	2.086	;	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp032 and Fasudil
6EM7	;	1.238	;	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp120 and ADP
6ESA	;	1.307	;	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp120 and AMP
6EMA	;	1.88	;	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp120 and ATP
5O0E	;	1.5	;	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp120 and Fasudil
5O5M	;	1.583	;	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp120 and RKp117
6EH3	;	1.95	;	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp120 and RKp190
5OT3	;	2.04	;	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp191 and RKp117
5OUC	;	1.46	;	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp191 and RKp190
5OUS	;	2.21	;	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp193
6ERT	;	1.8	;	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp193 and RKp117
5OK3	;	1.588	;	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp241 and Fasudil
6EM2	;	1.3	;	Crystal structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with Fasudil
2B0Z	;	2.7	;	Crystal structure of the protein-protein complex between F82I cytochrome c and cytochrome c peroxidase
2B10	;	2.8	;	Crystal Structure of the Protein-Protein Complex between F82S cytochrome c and cytochrome c peroxidase
2B11	;	2.3	;	Crystal structure of the protein-protein complex between F82W cytochrome c and cytochrome c peroxidase
2B12	;	3.02	;	Crystal structure of the protein-protein complex between F82Y cytochrome c and cytochrome c peroxidase
3DIN	;	4.5	;	Crystal structure of the protein-translocation complex formed by the SecY channel and the SecA ATPase
4BXS	;	3.32	;	Crystal Structure of the Prothrombinase Complex from the Venom of Pseudonaja Textilis
4BXW	;	2.71	;	Crystal Structure of the Prothrombinase Complex from the Venom of Pseudonaja Textilis
6E6B	;	4.52	;	Crystal structure of the Protocadherin GammaB4 extracellular domain
3AM6	;	3.2	;	Crystal structure of the proton pumping rhodopsin AR2 from marine alga Acetabularia acetabulum
3L2Q	;	3.25	;	Crystal structure of the Prototype Foamy Virus (PFV) intasome in apo form
3L2R	;	2.88	;	Crystal structure of the Prototype Foamy Virus (PFV) intasome in complex with magnesium
3S3M	;	2.49	;	Crystal structure of the Prototype Foamy Virus (PFV) intasome in complex with magnesium and Dolutegravir (S/GSK1349572)
3L2U	;	3.15	;	Crystal structure of the Prototype Foamy Virus (PFV) intasome in complex with magnesium and GS9137 (Elvitegravir)
3OYA	;	2.65	;	Crystal structure of the Prototype Foamy Virus (PFV) intasome in complex with magnesium and raltegravir at 2.65 resolution
3OYG	;	2.56	;	Crystal structure of the Prototype Foamy Virus (PFV) intasome in complex with magnesium and the INSTI Compound1 (CompoundG)
3OYE	;	2.74	;	Crystal structure of the Prototype Foamy Virus (PFV) intasome in complex with magnesium and the INSTI Compound2
3OYD	;	2.54	;	Crystal structure of the Prototype Foamy Virus (PFV) intasome in complex with magnesium and the INSTI GS9160
3OYF	;	2.51	;	Crystal structure of the Prototype Foamy Virus (PFV) intasome in complex with magnesium and the INSTI L-870,810
3OYH	;	2.74	;	Crystal structure of the Prototype Foamy Virus (PFV) intasome in complex with magnesium and the INSTI MK0536
3OYB	;	2.54	;	Crystal structure of the Prototype Foamy Virus (PFV) intasome in complex with magnesium and the INSTI MK2048
3OYC	;	2.66	;	Crystal structure of the Prototype Foamy Virus (PFV) intasome in complex with magnesium and the INSTI PICA
5MMA	;	2.55	;	Crystal structure of the Prototype Foamy Virus (PFV) intasome in complex with magnesium and the INSTI XZ379 (compound 5'g)
5FRM	;	2.58	;	Crystal structure of the Prototype Foamy Virus (PFV) intasome in complex with magnesium and the INSTI XZ384 (compound 4a)
5NO1	;	2.6	;	Crystal structure of the Prototype Foamy Virus (PFV) intasome in complex with magnesium and the INSTI XZ407 (compound 5g)
5FRN	;	2.85	;	Crystal structure of the Prototype Foamy Virus (PFV) intasome in complex with magnesium and the INSTI XZ419 (compound 4c)
5MMB	;	2.77	;	Crystal structure of the Prototype Foamy Virus (PFV) intasome in complex with magnesium and the INSTI XZ434 (compound 6p)
7ADU	;	2.62	;	Crystal structure of the Prototype Foamy Virus (PFV) intasome in complex with magnesium and the INSTI XZ440 (compound 5j)
5FRO	;	2.67	;	Crystal structure of the Prototype Foamy Virus (PFV) intasome in complex with magnesium and the INSTI XZ446 (compound 4f)
7ADV	;	2.65	;	Crystal structure of the Prototype Foamy Virus (PFV) intasome in complex with magnesium and the INSTI XZ447 (compound 6v)
3L2W	;	3.2	;	Crystal structure of the Prototype Foamy Virus (PFV) intasome in complex with manganese and GS9137 (Elvitegravir)
3L2V	;	3.2	;	Crystal structure of the Prototype Foamy Virus (PFV) intasome in complex with manganese and MK0518 (Raltegravir)
3OY9	;	2.55	;	Crystal structure of the Prototype Foamy Virus (PFV) intasome in complex with manganese at 2.55 resolution
3S3O	;	2.55	;	Crystal structure of the Prototype Foamy Virus (PFV) N224H mutant intasome in complex with magnesium and Dolutegravir (S/GSK1349572)
3S3N	;	2.49	;	Crystal structure of the Prototype Foamy Virus (PFV) S217H mutant intasome in complex with magnesium and Dolutegravir (S/GSK1349572)
5UOP	;	2.85	;	CRYSTAL STRUCTURE OF THE PROTOTYPE FOAMY VIRUS INTASOME WITH A 2- PYRIDINONE AMINAL INHIBITOR (COMPOUND 18)
5UOQ	;	2.61	;	CRYSTAL STRUCTURE OF THE PROTOTYPE FOAMY VIRUS INTASOME WITH A 2- PYRIDINONE AMINAL INHIBITOR (COMPOUND 31)
4ZTF	;	2.7	;	Crystal Structure of the Prototype Foamy Virus Intasome with a 2-Pyridinone Aminal Inhibitor
4ZTJ	;	2.67	;	Crystal Structure of the Prototype Foamy Virus Intasome with a 2-Pyridinone Aminal Inhibitor
5Z1I	;	1.903	;	Crystal structure of the protozoal cytoplasmic ribosomal decoding site in complex with 6'-fluoro sisomicin
4GPW	;	3.0	;	Crystal structure of the protozoal cytoplasmic ribosomal decoding site in complex with 6'-hydroxysisomicin (P21212 form)
4GPX	;	2.6	;	Crystal structure of the protozoal cytoplasmic ribosomal decoding site in complex with 6'-hydroxysisomicin (P212121 form)
1W4S	;	1.55	;	Crystal structure of the proximal BAH domain of polybromo
2BAY	;	1.5	;	Crystal structure of the Prp19 U-box dimer
5F5T	;	2.55	;	Crystal structure of the Prp38-MFAP1 complex of Chaetomium thermophilum
5F5S	;	2.4	;	Crystal structure of the Prp38-MFAP1 complex of Homo sapiens
5LTK	;	3.241	;	Crystal structure of the Prp43-ADP-BeF3 complex (in hexagonal space group)
5LTJ	;	1.78	;	Crystal structure of the Prp43-ADP-BeF3 complex (in orthorhombic space group)
5LTA	;	2.621	;	Crystal structure of the Prp43-ADP-BeF3-U7-RNA complex
2XAU	;	1.9	;	Crystal structure of the Prp43p DEAH-box RNA helicase in complex with ADP
5JPT	;	2.935	;	CRYSTAL STRUCTURE OF THE PRP43P DEAH-BOX RNA HELICASE IN COMPLEX WITH CDP
2FBE	;	2.52	;	Crystal Structure of the PRYSPRY-domain
8C7I	;	2.12	;	Crystal structure of the PS2 assembly factor Psb32 from the cyanobactium Thermosyncechococcus vestitus (formerly elongatus)
5MB4	;	2.0	;	Crystal Structure of the Psathyrella asperospora lectin PAL in complex with GlcNAc
5H2F	;	2.2	;	Crystal structure of the PsbM-deletion mutant of photosystem II
5CUK	;	2.1	;	Crystal structure of the PscP SS domain
5CUL	;	2.9	;	crystal structure of the PscU C-terminal domain
2WL7	;	2.028	;	Crystal structure of the PSD93 PDZ1 domain
8H2C	;	2.9	;	Crystal structure of the pseudaminic acid synthase PseI from Campylobacter jejuni
2W38	;	1.9	;	Crystal structure of the pseudaminidase from Pseudomonas aeruginosa
4HHW	;	2.0	;	Crystal structure of the Pseudomonas aeruginosa azurin, H124NO YOH122
4HIP	;	1.9	;	Crystal structure of the Pseudomonas aeruginosa azurin, H126NO YOH109
4HHG	;	1.6	;	Crystal structure of the Pseudomonas aeruginosa azurin, RuH107NO YOH109
7E3U	;	2.159	;	Crystal structure of the Pseudomonas aeruginosa dihydropyrimidinase complexed with 5-AU
6KLK	;	1.759	;	Crystal structure of the Pseudomonas aeruginosa dihydropyrimidinase complexed with 5-FU
4NQZ	;	2.604	;	Crystal Structure of the Pseudomonas aeruginosa Enoyl-Acyl Carrier Protein Reductase (FabI) in apo form
4NR0	;	1.799	;	Crystal structure of the Pseudomonas aeruginosa Enoyl-Acyl Carrier Protein Reductase (FabI) in complex with NAD+ and triclosan
1EX9	;	2.54	;	CRYSTAL STRUCTURE OF THE PSEUDOMONAS AERUGINOSA LIPASE COMPLEXED WITH RC-(RP,SP)-1,2-DIOCTYLCARBAMOYL-GLYCERO-3-O-OCTYLPHOSPHONATE
3P3E	;	1.28	;	Crystal Structure of the PSEUDOMONAS AERUGINOSA LpxC/LPC-009 complex
4LCF	;	1.599	;	Crystal structure of the Pseudomonas aeruginosa LPXC/LPC-014 complex
5DRQ	;	1.63	;	Crystal structure of the Pseudomonas aeruginosa LpxC/LPC-040 complex
4LCG	;	1.568	;	Crystal structure of the Pseudomonas aeruginosa LPXC/LPC-050 complex
4LCH	;	1.596	;	Crystal structure of the Pseudomonas aeruginosa LPXC/LPC-051 complex
5DRR	;	1.59	;	Crystal structure of the Pseudomonas aeruginosa LpxC/LPC-058 complex
3S2U	;	2.23	;	Crystal structure of the Pseudomonas aeruginosa MurG:UDP-GlcNAc substrate complex
6OVK	;	1.761	;	Crystal Structure of the Pseudomonas capeferrum Anti-sigma Regulator PupR C-terminal Cell-surface Signaling Domain in Complex with the Outer Membrane Transporter PupB N-terminal Signaling Domain
6OVM	;	1.6	;	Crystal Structure of the Pseudomonas capeferrum Anti-sigma Regulator PupR C-terminal Cell-surface Signaling Domain in Complex with the Outer Membrane Transporter PupB N-terminal Signaling Domain (SeMet)
4FBO	;	1.7	;	Crystal structure of the Pseudomonas fluorescens agglutinin (PFA)
5O65	;	2.5	;	Crystal Structure of the Pseudomonas functional amyloid secretion protein FapF
5O68	;	3.08	;	Crystal Structure of the Pseudomonas functional amyloid secretion protein FapF - R157A mutant
4RU5	;	1.52	;	Crystal Structure of the Pseudomonas phage phi297 tailspike gp61
3BRZ	;	3.2	;	Crystal structure of the Pseudomonas putida toluene transporter TodX
4FU6	;	2.1	;	Crystal structure of the PSIP1 PWWP domain
6GQC	;	1.4	;	Crystal Structure of the PSMalpha3 Peptide Mutant G16A Forming Cross-Alpha Amyloid-like Fibril
6GQ2	;	1.54	;	Crystal Structure of the PSMalpha3 Peptide Mutant K12A Forming Cross-Alpha Amyloid-like Fibril
6GQ5	;	1.5	;	Crystal Structure of the PSMalpha3 Peptide Mutant L15A Forming Cross-Alpha Amyloid-like Fibril
3H9X	;	2.51	;	Crystal Structure of the PSPTO_3016 protein from Pseudomonas syringae, Northeast Structural Genomics Consortium Target PsR293
4DT1	;	1.899	;	Crystal structure of the Psy3-Csm2 complex
2ELA	;	2.0	;	Crystal Structure of the PTB domain of human APPL1
4XWX	;	1.87	;	Crystal structure of the PTB domain of SHC
1D5R	;	2.1	;	Crystal Structure of the PTEN Tumor Suppressor
6D4D	;	1.765	;	Crystal structure of the PTP epsilon D1 domain
6D3F	;	2.271	;	Crystal Structure of the PTP epsilon D2 domain
1NWL	;	2.4	;	Crystal structure of the PTP1B complexed with SP7343-SP7964, a pTyr mimetic
6XE8	;	1.952	;	Crystal Structure of the PTP1B YopH WPD loop Chimera 3 apo form
6XED	;	1.795	;	Crystal Structure of the PTP1B YopH WPD loop Chimera 3 bound to tungstate
6XEA	;	1.549	;	Crystal Structure of the PTP1B YopH WPD loop Chimera 3 bound to vanadate
6XEE	;	2.501	;	Crystal Structure of the PTP1B YopH WPD loop Chimera 4 apo form
6XEG	;	2.549	;	Crystal structure of the PTP1B YopH WPD loop Chimera 4 bound to tungstate
6XEF	;	2.048	;	Crystal structure of the PTP1B YopH WPD loop Chimera 4 bound to vanadate
6ZZ4	;	2.43	;	Crystal structure of the PTPN2 C216G mutant
4QUN	;	1.86	;	Crystal structure of the PTPN3 (PTPH1) catalytic domain C842S mutant
6T36	;	1.86	;	Crystal structure of the PTPN3 PDZ domain bound to the HBV core protein C-terminal peptide
6HKS	;	2.19441	;	Crystal structure of the PTPN3 PDZ domain bound to the HPV16 E6 oncoprotein C-terminal peptide
8OEP	;	1.87	;	Crystal structure of the PTPN3 PDZ domain bound to the HPV18 E6 oncoprotein C-terminal peptide
8CQY	;	1.7	;	Crystal structure of the PTPN3 PDZ domain bound to the PBM TACE C-terminal peptide
3NFK	;	1.43	;	Crystal structure of the PTPN4 PDZ domain complexed with the C-terminus of a rabies virus G protein
3NFL	;	1.91	;	Crystal structure of the PTPN4 PDZ domain complexed with the C-terminus of the GluN2A NMDA receptor subunit
5EZ0	;	2.35	;	CRYSTAL STRUCTURE OF THE PTPN4 PDZ DOMAIN COMPLEXED WITH THE PDZ BINDING MOTIF OF THE MITOGEN ACTIVATED PROTEIN KINASE P38GAMMA.
5EYZ	;	2.09	;	CRYSTAL STRUCTURE OF THE PTPN4 PDZ DOMAIN COMPLEXED WITH THE TAILORED PEPTIDE CYTO8-RETEV
2NZ6	;	2.3	;	Crystal structure of the PTPRJ inactivating mutant C1239S
3K1S	;	2.3	;	Crystal Structure of the PTS Cellobiose Specific Enzyme IIA from Bacillus anthracis
5T3U	;	2.15	;	Crystal Structure of the PTS IIA protein associated with the fucose utilization operon from Streptococcus pneumoniae
5T5D	;	2.5	;	Crystal Structure of the PTS IIB protein associated with the fucose utilization operon from Streptococcus pneumoniae
1FCH	;	2.2	;	CRYSTAL STRUCTURE OF THE PTS1 COMPLEXED TO THE TPR REGION OF HUMAN PEX5
4JUY	;	2.4	;	Crystal structure of the PUB domain of E3 ubiquitin ligase RNF31
2HPJ	;	1.7	;	Crystal structure of the PUB domain of mouse PNGase
3GSN	;	2.8	;	Crystal structure of the public RA14 TCR in complex with the HCMV dominant NLV/HLA-A2 epitope
8AB1	;	2.77	;	Crystal structure of the PulL-PulM C-terminal domain heterocomplex
6NY5	;	3.002	;	Crystal structure of the PUM-HD domain of S. pombe Puf1 in complex with RNA
3Q0N	;	2.4	;	Crystal structure of the PUMILIO-homology domain from Human PUMILIO1 in complex with erk2 NRE
3Q0O	;	2.804	;	Crystal structure of the PUMILIO-homology domain from Human PUMILIO1 in complex with erk2 NRE
3Q0P	;	2.6	;	Crystal structure of the PUMILIO-homology domain from Human PUMILIO1 in complex with hunchback NRE
1M8X	;	2.2	;	CRYSTAL STRUCTURE OF THE PUMILIO-HOMOLOGY DOMAIN FROM HUMAN PUMILIO1 IN COMPLEX WITH NRE1-14 RNA
1M8W	;	2.2	;	CRYSTAL STRUCTURE OF THE PUMILIO-HOMOLOGY DOMAIN FROM HUMAN PUMILIO1 IN COMPLEX WITH NRE1-19 RNA
1M8Y	;	2.6	;	CRYSTAL STRUCTURE OF THE PUMILIO-HOMOLOGY DOMAIN FROM HUMAN PUMILIO1 IN COMPLEX WITH NRE2-10 RNA
3Q0L	;	2.503	;	Crystal structure of the PUMILIO-homology domain from Human PUMILIO1 in complex with p38alpha NREa
3Q0M	;	2.705	;	Crystal structure of the PUMILIO-homology domain from Human PUMILIO1 in complex with p38alpha NREb
3Q0S	;	2.0	;	Crystal structure of the PUMILIO-homology domain from Human PUMILIO2 in complex with erk2 NRE
3Q0Q	;	2.0	;	Crystal structure of the PUMILIO-homology domain from Human PUMILIO2 in complex with p38alpha NREa
3Q0R	;	2.0	;	Crystal structure of the PUMILIO-homology domain from Human PUMILIO2 in complex with p38alpha NREb
5KL8	;	4.0	;	Crystal structure of the Pumilio-Nos-CyclinB RNA complex
5KL1	;	3.701	;	Crystal structure of the Pumilio-Nos-hunchback RNA complex
1TD1	;	1.9	;	Crystal Structure of the Purine Nucleoside Phosphorylase from Schistosoma mansoni in complex with acetate
1TCV	;	1.75	;	Crystal Structure of the Purine Nucleoside Phosphorylase from Schistosoma mansoni in complex with Non-detergent Sulfobetaine 195 and acetate
1TCU	;	2.0	;	Crystal Structure of the Purine Nucleoside Phosphorylase from Schistosoma mansoni in complex with phosphate and acetate
1O57	;	2.2	;	CRYSTAL STRUCTURE OF THE PURINE OPERON REPRESSOR OF BACILLUS SUBTILIS
6JC6	;	1.9	;	Crystal structure of the purple chromoprotein of Stichodactyla haddoni with a Glu-Tyr-Gly tri-peptide chromophore
1P4A	;	2.22	;	Crystal Structure of the PurR complexed with cPRPP
2EW2	;	2.0	;	Crystal Structure of the Putative 2-Dehydropantoate 2-Reductase from Enterococcus faecalis
2NVV	;	2.7	;	Crystal Structure of the Putative Acetyl-CoA hydrolase/transferase PG1013 from Porphyromonas gingivalis, Northeast Structural Genomics Target PgR16.
3U6U	;	1.92	;	Crystal structure of the putative acetylglutamate kinase from thermus thermophilus
4E2A	;	2.0	;	Crystal Structure of the Putative acetyltransferase from Streptococcus mutans
2PDO	;	2.0	;	Crystal Structure of the Putative Acetyltransferase of GNAT Family from Shigella flexneri
1ZMB	;	2.61	;	Crystal Structure of the Putative Acetylxylan Esterase from Clostridium acetobutylicum, Northeast Structural Genomics Target CaR6
2HJ0	;	2.7	;	Crystal Structure of the Putative Alfa Subunit of Citrate Lyase in Complex with Citrate from Streptococcus mutans, Northeast Structural Genomics Target SmR12 .
4RPC	;	2.1	;	Crystal structure of the putative alpha/beta hydrolase family protein from Desulfitobacterium hafniense
3V48	;	2.1	;	Crystal Structure of the putative alpha/beta hydrolase RutD from E.coli
6A8S	;	2.05	;	Crystal Structure of the putative amino acid-binding periplasmic ABC transporter protein from Candidatus Liberibacter asiaticus in complex with Cysteine
1XQ4	;	2.7	;	Crystal Structure of the Putative ApaA Protein from Bordetella pertussis, Northeast Structural Genomics Target BeR40
1ZBR	;	2.6	;	Crystal Structure of the Putative Arginine Deiminase from Porphyromonas gingivalis, Northeast Structural Genomics Target PgR3
1Y0U	;	1.6	;	Crystal Structure of the putative arsenical resistance operon repressor from Archaeoglobus fulgidus
7R6S	;	1.9	;	Crystal Structure of the Putative Bacteriophage Protein from Stenotrophomonas maltophilia
4CHE	;	1.8	;	Crystal structure of the putative cap-binding domain of the PB2 subunit of Thogoto virus polymerase
4CHF	;	3.0	;	Crystal structure of the putative cap-binding domain of the PB2 subunit of Thogoto virus polymerase (form 2)
3BQW	;	2.2	;	Crystal structure of the putative capsid protein of prophage (E.coli CFT073)
2JJ6	;	2.0	;	Crystal structure of the putative carbohydrate recognition domain of the human galectin-related protein
1YO6	;	2.6	;	Crystal Structure of the putative Carbonyl Reductase Sniffer of Caenorhabditis elegans
6NIQ	;	1.353	;	Crystal Structure of the Putative Class A Beta-Lactamase PenP from Rhodopseudomonas palustris
1TWD	;	1.7	;	Crystal Structure of the Putative Copper Homeostasis Protein (CutC) from Shigella flexneri, Northeast Structural Genomics Target SfR33
2BDQ	;	2.3	;	Crystal Structure of the Putative Copper Homeostasis Protein CutC from Streptococcus agalactiae, Northeast Strucural Genomics Target SaR15.
2IXD	;	1.8	;	Crystal structure of the putative deacetylase BC1534 from Bacillus cereus
2IF2	;	3.0	;	Crystal Structure of the Putative Dephospho-CoA Kinase from Aquifex aeolicus, Northeast Structural Genomics Target QR72.
3OIX	;	2.399	;	Crystal structure of the putative dihydroorotate dehydrogenase from Streptococcus mutans
3DHN	;	2.0	;	Crystal structure of the putative epimerase Q89Z24_BACTN from Bacteroides thetaiotaomicron. Northeast Structural Genomics Consortium target BtR310.
7TEM	;	1.65	;	Crystal Structure of the Putative Exported Protein YPO2471 from Yersinia pestis
7TJ1	;	2.1	;	Crystal Structure of the Putative Fluoride Ion Transporter CrcB Bab1_1389 from Brucella abortus
2BDT	;	2.4	;	Crystal Structure of the Putative Gluconate Kinase from Bacillus halodurans, Northeast Structural Genomics Target BhR61
2EBA	;	2.21	;	Crystal structure of the putative glutaryl-CoA dehydrogenase from thermus thermophilus
1SQ4	;	2.7	;	Crystal Structure of the Putative Glyoxylate Induced Protein from Pseudomonas aeruginosa, Northeast Structural Genomics Target PaR14
6NLR	;	2.1	;	Crystal structure of the putative histidinol phosphatase hisK from Listeria monocytogenes with trinuclear metals determined by PIXE revealing sulphate ion in active site. Based on PIXE analysis and original date from 3DCP
3DCP	;	2.1	;	Crystal structure of the putative histidinol phosphatase hisK from Listeria monocytogenes. Northeast Structural Genomics Consortium target LmR141.
7L6J	;	1.78	;	Crystal Structure of the Putative Hydrolase from Stenotrophomonas maltophilia
2V7S	;	1.96	;	Crystal structure of the putative lipoprotein LppA from Mycobacterium tuberculosis
1TZ9	;	2.9	;	Crystal Structure of the Putative Mannonate Dehydratase from Enterococcus faecalis, Northeast Structural Genomics Target EfR41
2F9F	;	1.8	;	Crystal Structure of the Putative Mannosyl Transferase (wbaZ-1)from Archaeoglobus fulgidus, Northeast Structural Genomics Target GR29A.
1ZBS	;	2.3	;	Crystal Structure of the Putative N-acetylglucosamine Kinase (PG1100) from Porphyromonas gingivalis, Northeast Structural Genomics Target PgR18
2GSW	;	2.92	;	Crystal Structure of the Putative NADPH-dependent Azobenzene FMN-Reductase YhdA from Bacillus subtilis, Northeast Structural Genomics Target SR135
3C0D	;	2.4	;	Crystal structure of the putative nitrite reductase NADPH (small subunit) oxidoreductase protein Q87HB1. Northeast Structural Genomics Consortium target VpR162
2IFA	;	2.3	;	Crystal Structure of the PUTATIVE NITROREDUCTASE (SMU.260) IN COMPLEX WITH FMN FROM STREPTOCOCCUS MUTANS, NORTHEAST STRUCTURAL GENOMICS TARGET SMR5.
4XCM	;	2.65	;	Crystal structure of the putative NlpC/P60 D,L endopeptidase from T. thermophilus
2ISM	;	1.9	;	Crystal structure of the putative oxidoreductase (glucose dehydrogenase) (TTHA0570) from thermus theromophilus HB8
2CSG	;	2.9	;	Crystal Structure of the Putative Oxidoreductase from Salmonella typhimurium LT2
7TWE	;	2.41	;	Crystal Structure of the Putative Oxidoreductase of DUF1479-containing Protein Family YPO2976 from Yersinia pestis Bound to 2-oxo-glutaric acid
7TWC	;	1.85	;	Crystal Structure of the Putative Oxidoreductase of DUF1479-containing Protein Family YPO2976 from Yersinia pestis Bound to CAPS
1XKN	;	1.6	;	Crystal Structure of the Putative Peptidyl-arginine Deiminase from Chlorobium tepidum, NESG Target CtR21
5T1P	;	2.0	;	Crystal structure of the putative periplasmic solute-binding protein from Campylobacter jejuni
1SPV	;	2.0	;	Crystal Structure of the Putative Phosphatase of Escherichia coli, Northeast Structural Genomoics Target ER58
2RFL	;	2.35	;	Crystal structure of the putative phosphohistidine phosphatase SixA from Agrobacterium tumefaciens
4V33	;	1.48	;	Crystal structure of the putative polysaccharide deacetylase BA0330 from bacillus anthracis
1TM0	;	2.8	;	Crystal Structure of the putative proline racemase from Brucella melitensis, Northeast Structural Genomics Target LR31
3CNE	;	1.99	;	Crystal structure of the putative protease I from Bacteroides thetaiotaomicron
2E8B	;	1.61	;	Crystal structure of the putative protein (Aq1419) from Aquifex aeolicus VF5
2GTA	;	2.9	;	Crystal Structure of the putative pyrophosphatase YPJD from Bacillus subtilis. Northeast Structural Genomics Consortium Target SR428.
2QQ8	;	2.0	;	Crystal structure of the putative RabGAP domain of human TBC1 domain family member 14
2AP1	;	1.9	;	Crystal structure of the putative regulatory protein
2GH1	;	2.5	;	Crystal Structure of the putative SAM-dependent methyltransferase BC2162 from Bacillus cereus, Northeast Structural Genomics Target BcR20.
2FA8	;	1.9	;	Crystal Structure of the Putative Selenoprotein W-related family Protein from Agrobacterium tumefaciens
2QZU	;	1.7	;	Crystal structure of the putative sulfatase yidJ from Bacteroides fragilis. Northeast Structural Genomics Consortium target BfR123
2GUH	;	1.52	;	Crystal Structure of the Putative TetR-family Transcriptional Regulator from Rhodococcus sp. RHA1
2HF1	;	1.9	;	Crystal structure of the putative Tetraacyldisaccharide-1-P 4-kinase from Chromobacterium violaceum. NESG target CvR39.
1T82	;	1.7	;	Crystal Structure of the putative thioesterase from Shewanella oneidensis, Northeast Structural Genomics Target SoR51
5V10	;	1.9	;	Crystal structure of the putative tol-pal system-associated acyl-CoA thioesterase from Pseudomonas aeruginosa PAO1
2FSW	;	2.16	;	Crystal Structure of the Putative Transcriptional Regualator, MarR family from Porphyromonas gingivalis W83
2RA5	;	2.4	;	Crystal structure of the putative transcriptional regulator from Streptomyces coelicolor
2DG7	;	2.3	;	Crystal structure of the putative transcriptional regulator SCO0337 from Streptomyces coelicolor A3(2)
2DG6	;	2.2	;	Crystal structure of the putative transcriptional regulator SCO5550 from Streptomyces coelicolor A3(2)
2DG8	;	2.21	;	Crystal structure of the putative trasncriptional regulator SCO7518 from Streptomyces coelicolor A3(2)
1Z2Z	;	2.6	;	Crystal Structure of the Putative tRNA pseudouridine synthase D (TruD) from Methanosarcina mazei, Northeast Structural Genomics Target MaR1
2R0J	;	1.85	;	Crystal structure of the putative ubiquitin conjugating enzyme, PFE1350c, from Plasmodium falciparum
3F08	;	2.2	;	Crystal structure of the putative uncharacterized protein Q6HG14 from Bacilllus thuringiensis. Northeast Structural Genomics Consortium target BuR153.
2BDR	;	1.6	;	Crystal Structure of the Putative Ureidoglycolate hydrolase PP4288 from Pseudomonas putida, Northeast Structural Genomics Target PpR49
1YPX	;	2.6	;	Crystal Structure of the Putative Vitamin-B12 Independent Methionine Synthase from Listeria monocytogenes, Northeast Structural Genomics Target LmR13
1Z7U	;	2.2	;	Crystal Structure of the Putitive Transcriptional Regulator of MarR Family from Enterococcus faecalis V583
3E59	;	2.1	;	Crystal structure of the PvcA (PA2254) protein from Pseudomonas aeruginosa
3EAT	;	2.5	;	Crystal structure of the PvcB (PA2255) protein from Pseudomonas aeruginosa
1K0Z	;	2.05	;	Crystal Structure of the PvuII endonuclease with Pr3+ and SO4 ions bound in the active site at 2.05A.
3LLR	;	2.3	;	Crystal structure of the PWWP domain of Human DNA (cytosine-5-)-methyltransferase 3 alpha
5XSL	;	3.3	;	Crystal structure of the PWWP domain of human hepatoma-derived growth factor
3QBY	;	1.95	;	Crystal structure of the PWWP domain of human Hepatoma-derived growth factor 2
1KHC	;	1.8	;	Crystal Structure of the PWWP Domain of Mammalian DNA Methyltransferase Dnmt3b
7V8N	;	2.05	;	Crystal structure of the PWWP-ARID domain of ARID4A
2YPS	;	2.6	;	Crystal structure of the PX domain of human sorting nexin 3
3FOG	;	2.8	;	Crystal structure of the PX domain of sorting nexin-17 (SNX17)
4UP5	;	1.65	;	Crystal structure of the Pygo2 PHD finger in complex with the B9L HD1 domain and a chemical fragment
4UHQ	;	1.5	;	Crystal structure of the pyocin AP41 DNase
4UHP	;	2.0	;	Crystal structure of the pyocin AP41 DNase-Immunity complex
6EYV	;	2.704	;	Crystal structure of the pyoverdine maturation protein PvdP in complex with the mock substrates L-tyrosine and zinc.
3QN1	;	1.8	;	Crystal structure of the PYR1 Abscisic Acid receptor in complex with the HAB1 type 2C phosphatase catalytic domain
1GC0	;	1.7	;	CRYSTAL STRUCTURE OF THE PYRIDOXAL-5'-PHOSPHATE DEPENDENT L-METHIONINE GAMMA-LYASE FROM PSEUDOMONAS PUTIDA
1GC2	;	2.0	;	CRYSTAL STRUCTURE OF THE PYRIDOXAL-5'-PHOSPHATE DEPENDENT L-METHIONINE GAMMA-LYASE FROM PSEUDOMONAS PUTIDA
4J8L	;	1.651	;	CRYSTAL STRUCTURE OF THE PYRIDOXAL-5'-PHOSPHATE DEPENDENT protein YhfS from Escherichia coli
4KBX	;	1.599	;	Crystal structure of the pyridoxal-5'-phosphate dependent protein yhfx from escherichia coli
8AAJ	;	3.7	;	Crystal structure of the Pyrococcus abyssi RPA (apo form)
8AAS	;	3.2	;	Crystal structure of the Pyrococcus abyssi RPA trimerization core bound to poly-dT20 ssDNA
4DHV	;	1.95	;	Crystal structure of the Pyrococcus furiosus ferredoxin D14C variant containing the heterometallic [AgFe3S4] cluster
3NWC	;	1.6961	;	Crystal Structure of the Pyrococcus furiosus SMC Protein Hinge Domain
1AUG	;	2.0	;	CRYSTAL STRUCTURE OF THE PYROGLUTAMYL PEPTIDASE I FROM BACILLUS AMYLOLIQUEFACIENS
5FDV	;	2.8	;	Crystal structure of the Pyrrhocoricin antimicrobial peptide bound to the Thermus thermophilus 70S ribosome
5NMW	;	1.89	;	Crystal Structure of the pyrrolizidine alkaloid N-oxygenase from Zonocerus variegatus in complex with FAD
5NMX	;	1.6	;	Crystal Structure of the pyrrolizidine alkaloid N-oxygenase from Zonocerus variegatus in complex with FAD and NADP+
3EXE	;	1.979	;	Crystal structure of the pyruvate dehydrogenase (E1p) component of human pyruvate dehydrogenase complex
3EXF	;	2.998	;	Crystal structure of the pyruvate dehydrogenase (E1p) component of human pyruvate dehydrogenase complex
3EXG	;	3.011	;	Crystal structure of the pyruvate dehydrogenase (E1p) component of human pyruvate dehydrogenase complex
3EXH	;	2.444	;	Crystal structure of the pyruvate dehydrogenase (E1p) component of human pyruvate dehydrogenase complex
3EXI	;	2.2	;	Crystal structure of the pyruvate dehydrogenase (E1p) component of human pyruvate dehydrogenase complex with the subunit-binding domain (SBD) of E2p, but SBD cannot be modeled into the electron density
6DU6	;	3.513	;	Crystal structure of the pyruvate kinase (PK1) from the mosquito Aedes aegypti
3H2S	;	1.78	;	Crystal Structure of the Q03B84 Protein from Lactobacillus casei. Northeast Structural Genomics Consortium Target LcR19.
4RL6	;	2.79	;	Crystal Structure of the Q04L03_STRP2 protein from Streptococcus pneumoniae. Northeast Structural Genomics Consortium Target SpR105
4O1Q	;	2.59	;	Crystal Structure of the Q103N-MauG/pre-Methylamine Dehydrogenase Complex
4EXZ	;	1.608	;	Crystal Structure of the Q108K:K40L Mutant of Cellular Retinol Binding Protein Type II in Complex with All-trans-Retinal at 1.7 Angstrom Resolution
4RUU	;	1.4	;	Crystal structure of the Q108K:K40L mutant of human Cellular Retinol Binding ProteinII in complex with All-trans-Retinal after 24 hour incubation at 1.4 Angstrom Resolution
5FAZ	;	1.4	;	Crystal structure of the Q108K:K40L:T51V mutant of human Cellular Retinol Binding Protein II in complex with All-trans-Retinal after 24 hours of incubation at 1.4 Angstrom Resolution
5F58	;	1.54	;	Crystal structure of the Q108K:K40L:T51V:R58F mutant of human Cellular Retinol Binding Protein II in complex with All-trans-Retinal after 24 hours of incubation at 1.54 Angstrom Resolution
6C7Z	;	1.42	;	Crystal structure of the Q108K:K40L:T51V:R58F mutant of human Cellular Retinol Binding Protein II in complex with synthetic Ligand Julolidine
5FFH	;	1.68	;	Crystal structure of the Q108K:K40L:T51V:R58W:Y19W mutant of human Cellular Retinol Binding Protein II in complex with All-trans-Retinal at 1.68 Angstrom Resolution
5F6B	;	1.31	;	Crystal structure of the Q108K:K40L:T51V:R58Y:Y19W mutant of human Cellular Retinol Binding Protein II in complex with All-trans-Retinal at 1.3 Angstrom Resolution
5F7G	;	1.48	;	Crystal structure of the Q108K:K40L:T51V:R58Y:Y19W:Q38L mutant of human Cellular Retinol Binding Protein II in complex with All-trans-Retinal at 1.48 Angstrom Resolution
4EFG	;	1.58	;	Crystal Structure of the Q108K:K40L:T51V:T53C:Y19W:R58W:T29L Mutant of Cellular Retinol Binding Protein Type II in Complex with All-trans-Retinal at 1.58 Angstrom Resolution
4EDE	;	1.4	;	Crystal Structure of the Q108K:K40L:T51V:T53C:Y19W:R58W:T29L:A33W Mutant of Cellular Retinol Binding Protein Type II in Complex with All-trans-Retinal at 1.4 Angstrom Resolution
4EEJ	;	1.501	;	Crystal Structure of the Q108K:K40L:T51V:T53C:Y19W:R58W:T29L:Q4R Mutant of Cellular Retinol Binding Protein Type II in Complex with All-trans-Retinal at 1.5 Angstrom Resolution
5FEN	;	1.55	;	Crystal structure of the Q108K:K40L:T53C mutant of human Cellular Retinol Binding Protein II in complex with All-trans-Retinal after 24 hours of incubation at 1.55 Angstrom Resolution
3OEB	;	1.55	;	Crystal structure of the Q121E mutant of C.polysaccharolyticus CBM16-1 bound to mannopentaose
3OEA	;	1.35	;	Crystal structure of the Q121E mutants of C.polysaccharolyticus CBM16-1 bound to cellopentaose
4NVS	;	2.385	;	Crystal Structure of the Q18CP6_CLOD6 protein from glyoxalase family. Northeast Structural Genomics Consortium Target CfR3
1MQV	;	1.78	;	Crystal Structure of the Q1A/F32W/W72F mutant of Rhodopseudomonas palustris cytochrome c' (prime) expressed in E. coli
5KQK	;	1.75	;	Crystal structure of the Q233E/N240D variant of the catalase-peroxidase from B. pseudomallei
3IPF	;	1.988	;	Crystal structure of the Q251Q8_DESHY protein from Desulfitobacterium hafniense. Northeast Structural Genomics Consortium Target DhR8c.
3USH	;	1.692	;	Crystal Structure of the Q2S0R5 protein from Salinibacter ruber, Northeast Structural Genomics Consortium Target SrR207
3PU2	;	2.606	;	Crystal Structure of the Q3J4M4_RHOS4 protein from Rhodobacter sphaeroides. Northeast Structural Genomics Consortium Target RhR263.
2PK7	;	2.2	;	Crystal structure of the Q4KFT4_PSEF5 protein from Pseudomonas fluorescens. NESG target PlR1
3KKZ	;	1.677	;	Crystal structure of the Q5LES9_BACFN protein from Bacteroides fragilis. Northeast Structural Genomics Consortium Target BfR250.
2RA8	;	1.95	;	Crystal structure of the Q64V53_BACFR protein from Bacteroides fragilis. Northeast Structural Genomics Consortium target BfR43
8AJU	;	1.645	;	Crystal structure of the Q65A mutant of S-adenosyl-L-homocysteine hydrolase from Pseudomonas aeruginosa cocrystallized with adenosine in the presence of K+ cations
8AJW	;	1.819	;	Crystal structure of the Q65N mutant of S-adenosyl-L-homocysteine hydrolase from Pseudomonas aeruginosa cocrystallized with adenosine in the presence of K+ cations
8AJV	;	1.9	;	Crystal structure of the Q65N mutant of S-adenosyl-L-homocysteine hydrolase from Pseudomonas aeruginosa crystallized in the presence of K+ cations
2PH0	;	1.85	;	Crystal structure of the Q6D2T7_ERWCT protein from Erwinia carotovora. NESG target EwR41.
4INA	;	2.488	;	Crystal Structure of the Q7MSS8_WOLSU protein from Wolinella succinogenes. Northeast Structural Genomics Consortium Target WsR35
4RMM	;	2.2	;	Crystal Structure of the Q7NVP2_CHRVO protein from Chromobacterium violaceum. Northeast Structural Genomics Consortium Target CvR191
6UN9	;	2.8	;	Crystal Structure of the Q7VLF5_HAEDU protein from Haemophilus ducreyi. Northeast Structural Genomics Consortium Target Hdr25
3CPK	;	2.5	;	Crystal structure of the Q7W7N7_BORPA protein from Bordetella parapertussis. Northeast Structural Genomics Consortium target BeR31
3DKZ	;	2.4	;	Crystal structure of the Q7W9W5_BORPA protein from Bordetella parapertussis. Northeast Structural Genomics Consortium target BpR208C.
3HT4	;	2.9	;	Crystal Structure of the Q81A77_BACCR Protein from Bacillus cereus. Northeast Structural Genomics Consortium Target BcR213
3B55	;	2.3	;	Crystal structure of the Q81BN2_BACCR protein from Bacillus cereus. NESG target BcR135
3FGB	;	2.0	;	Crystal structure of the Q89ZH8_BACTN protein from Bacteroides thetaiotaomicron. Northeast Structural Genomics Consortium target BtR289b.
3FVW	;	2.3	;	Crystal structure of the Q8DWD8_STRMU protein from Streptococcus mutans. Northeast Structural Genomics Consortium target SmR99.
3DR5	;	2.25	;	Crystal structure of the Q8NRD3_CORGL protein from Corynebacterium glutamicum. Northeast Structural Genomics Consortium target CgR117.
3D5N	;	2.8	;	Crystal structure of the Q97W15_SULSO protein from Sulfolobus solfataricus. NESG target SsR125.
3F1T	;	2.2	;	Crystal structure of the Q9I3C8_PSEAE protein from Pseudomonas aeruginosa. Northeast Structural Genomics Consortium target PaR319a.
4NAR	;	2.388	;	Crystal Structure of the Q9WYS3 protein from Thermotoga maritima. Northeast Structural Genomics Consortium Target VR152
4O51	;	2.204	;	Crystal structure of the QAA variant of anti-hinge rabbit antibody 2095-2 in complex with IDES hinge peptide
4ZU5	;	1.8	;	Crystal structure of the QdtA 3,4-Ketoisomerase from Thermoanaerobacterium thermosaccharolyticum, apo form
3FYP	;	1.85	;	Crystal structure of the quadruple mutant (N23C/C246S/D247E/P249A) of 3-deoxy-D-manno-octulosonate 8-phosphate synthase (KDO8PS) from Neisseria meningitidis
1L1H	;	1.75	;	Crystal Structure of the Quadruplex DNA-Drug Complex
4DNN	;	2.1	;	Crystal structure of the Quaking Qua1 homodimerization domain
6ZGP	;	2.01	;	Crystal structure of the quaternary ammonium Rieske monooxygenase CntA in complex with inhibitor MMV12 (MMV020670)
6Y8S	;	1.629	;	Crystal structure of the quaternary ammonium Rieske monooxygenase CntA in complex with substrate gamma-butyrobetaine
6Y9D	;	1.97	;	Crystal structure of the quaternary ammonium Rieske monooxygenase CntA in complex with substrate L-Carnitine
5C3I	;	3.5	;	Crystal structure of the quaternary complex of histone H3-H4 heterodimer with chaperone ASF1 and the replicative helicase subunit MCM2
3AU9	;	1.9	;	Crystal structure of the quaternary complex-1 of an isomerase
3AUA	;	2.15	;	Crystal structure of the quaternary complex-2 of an isomerase
2NLO	;	1.643	;	Crystal Structure of the Quinate Dehydrogenase from Corynebacterium glutamicum
3SXT	;	1.81	;	Crystal Structure of the Quinol Form of Methylamine Dehydrogenase in Complex with the Diferrous Form of MauG
4K3I	;	2.0	;	Crystal Structure of the Quinol Form of Methylamine Dehydrogenase in Complex with the Diferrous Form of MauG, C2 Space Group
3C2F	;	2.35	;	Crystal structure of the quinolinate phosphoribosyl transferase (BNA6) from Saccharomyces cerevisiae complexed with PRPP
3C2V	;	2.29	;	Crystal structure of the quinolinate phosphoribosyl transferase (BNA6) from Saccharomyces cerevisiae complexed with PRPP and the inhibitor phthalate
3C2O	;	2.3	;	Crystal structure of the quinolinate phosphoribosyl transferase (BNA6) from Sachharomyces cerevisiae complexed with quinolinate
3C2R	;	2.4	;	Crystal structure of the quinolinate phosphoribosyl transferase (BNA6) from Sachharomyces cerevisiae complexed with the inhibitor phthalate
3SWS	;	1.86	;	Crystal Structure of the Quinone Form of Methylamine Dehydrogenase in Complex with the Diferric Form of MauG
5HS9	;	2.1	;	Crystal structure of the quinone-bound YodB from B. subtilis
1FLG	;	2.6	;	CRYSTAL STRUCTURE OF THE QUINOPROTEIN ETHANOL DEHYDROGENASE FROM PSEUDOMONAS AERUGINOSA
2BBK	;	1.75	;	CRYSTAL STRUCTURE OF THE QUINOPROTEIN METHYLAMINE DEHYDROGENASE FROM PARACOCCUS DENITRIFICANS AT 1.75 ANGSTROMS
5CCJ	;	1.65	;	Crystal structure of the quintuple mutant of the synaptotagmin-1 C2B domain
1UPG	;	1.8	;	Crystal structure of the quorum-sensing protein TraM from Agrobacterium tumefaciens
1US6	;	1.65	;	Crystal structure of the quorum-sensing protein TraM from Agrobacterium tumefaciens at 1.65 Ang. resolution
3S8Q	;	2.1	;	Crystal structure of the R-M controller protein C.Esp1396I OL operator complex
4OAQ	;	1.858	;	Crystal structure of the R-specific Carbonyl Reductase from Candida parapsilosis ATCC 7330
7C2O	;	2.9	;	Crystal structure of the R-specific Carbonyl Reductase from Candida parapsilosis ATCC 7330 without DTT
6GKW	;	1.9	;	Crystal structure of the R-type bacteriocin sheath protein CD1363 from Clostridium difficile in the pre-assembled state
6GKX	;	1.5	;	Crystal structure of the R-type bacteriocin tube protein CD1364 from Clostridium difficile in the pre-assembled state
3BXL	;	2.3	;	Crystal structure of the R-type calcium channeL (CaV2.3) IQ domain and CA2+calmodulin complex
6L2N	;	2.45	;	Crystal structure of the R.PabI(Y68F-K154A)-dsDNA(GTAC-3bp-GTAC) complex
6L2O	;	2.2	;	Crystal structure of the R.PabI(Y68F-K154A)-dsDNA(GTAC-5bp-GTAC) complex
6M3L	;	2.75	;	Crystal structure of the R.PabI(Y68F-K154A)-dsDNA(nonspecific) complex
1PR3	;	2.15	;	Crystal Structure of the R103K Mutant of Aspartate Semialdehyde dehydrogenase from Haemophilus influenzae
1OZA	;	2.06	;	Crystal Structure of the R103L Mutant of Aspartate Semialdehyde Dehydrogenase from Haemophilus influenzae
4I9S	;	2.58	;	Crystal Structure of the R111K:R132L:Y134F:T54V:R59W Mutant of the Cellular Retinoic Acid Binding Protein Type II in Complex with All-Trans Retinal at 2.58 Angstrom Resolution
4I9R	;	2.6	;	Crystal Structure of the R111K:R132L:Y134F:T54V:R59W:A32W Mutant of the Cellular Retinoic Acid Binding Protein Type II in Complex with All-Trans Retinal at 2.6 Angstrom Resolution
4M7M	;	2.571	;	Crystal structure of the R111K:R132Q:Y134F:T54V:R59W:A32W mutant of the Cellular Retinoic Acid Binding Protein Type II in complex with All-Trans Retinal at 2.57 Angstrom Resolution
4M6S	;	2.47	;	Crystal structure of the R111K:R132Y:Y134F:T54V:R59W:A32W mutant of the Cellular Retinoic Acid Binding Protein Type II in complex with All-Trans Retinal at 2.38 Angstrom Resolution
4YDB	;	2.03	;	Crystal structure of the R111K:Y134F:T54V:R132Q:P39Q:R59Y mutant of human Cellular Retinoic Acid Binding Protein II in complex with Retinal at 2.03 angstrom -UV irradiated crystal- 3rd cycle
4YBU	;	1.924	;	Crystal structure of the R111K:Y134F:T54V:R132Q:P39Q:R59Y mutant of human Cellular Retinoic Acid Binding ProteinII in complex with Retinal after 24 h incubation and 1 hour UV irradiation at 1.92 angstrom - 1st cycle
4YBP	;	1.831	;	Crystal structure of the R111K:Y134F:T54V:R132Q:P39Q:R59Y mutant of human cellular retinoic acid binding proteinii with retinal after 24 hour incubation at 1.83 angstrom resolution - thermodynamic product - 1st cycle
4YCE	;	1.953	;	Crystal structure of the R111K:Y134F:T54V:R132Q:P39Q:R59Y mutant of human cellular retinoic acid binding proteinii with retinal at 1.95 angstrom- visible light irradiated crystal for 1 hour - 2nd cycle
4YKM	;	1.58	;	Crystal structure of the R111K:Y134F:T54V:R132Q:P39Q:R59Y:A32W:F3Q mutant of human Cellular Retinoic Acid Binding Protein II with Retinal at 1.58 angstrom resolution
4YKO	;	1.57	;	Crystal structure of the R111K:Y134F:T54V:R132Q:P39Q:R59Y:A32Y:F3Q mutant of human Cellular Retinoic Acid Binding Protein II with Retinal at 1.58 angstrom resolution
4YH0	;	2.144	;	Crystal structure of the R111K:Y134F:T54V:R132Q:P39Y:R59Y mutant of human Cellular Retinoic Acid Binding Protein II in complex with Retinal at 2.14 angstrom resolution - UV irradiated crystal - 3rd cycle
4YFP	;	1.951	;	CRYSTAL STRUCTURE OF THE R111K:Y134F:T54V:R132Q:P39Y:R59Y MUTANT OF HUMAN CELLULAR RETINOIC ACID BINDING PROTEIN II WITH RETINAL AFTER 20 MINUTES INCUBATION AT 1.95 ANGSTROM RESOLUTION-Kinetic Product
4YFR	;	1.952	;	Crystal structure of the R111K:Y134F:T54V:R132Q:P39Y:R59Y mutant of human Cellular Retinoic Acid Binding Protein II with Retinal at 1.95 Angstrom Resolution - UV irradiated crystal for 30 minutes - 1st Cycle
4YGZ	;	2.06	;	CRYSTAL STRUCTURE OF THE R111K:Y134F:T54V:R132Q:P39Y:R59Y MUTANT OF HUMAN CELLULAR RETINOIC ACID BINDING PROTEIN II WITH RETINAL AT 2.06 ANGSTROM RESOLUTION - VISIBLE LIGHT IRRADIATED CRYSTAL -3RD CYCLE
4YFQ	;	1.62	;	CRYSTAL STRUCTURE OF THE R111K:Y134F:T54V:R132Q:P39Y:R59Y MUTANT OF HUMAN CELLULAR RETINOIC ACID BINDING PROTEINII WITH RETINAL AFTER 24 HOURS INCUBATION AT 1.62 ANGSTROM RESOLUTION - Thermodynamic product - 1st cycle
4XIH	;	2.25	;	Crystal structure of the R116A mutant AhpE from Mycobacterium tuberculosis
3DYJ	;	1.85	;	Crystal Structure of the R11R12 Domains of Talin
1OQH	;	2.4	;	Crystal Structure of the R124A mutant of the N-lobe human transferrin
4FNY	;	2.45	;	Crystal structure of the R1275Q anaplastic lymphoma kinase catalytic domain in complex with a benzoxazole inhibitor
4QGV	;	1.73	;	Crystal structure of the R132K:R111L mutant of Cellular Retinoic Acid Binding ProteinII complexed with a synthetic ligand (Merocyanine) at 1.73 angstrom resolution.
3CR6	;	1.22	;	Crystal Structure of the R132K:R111L:A32E Mutant of Cellular Retinoic Acid Binding Protein Type II Complexed with C15-aldehyde (a retinal analog) at 1.22 Angstrom resolution.
3FEN	;	1.56	;	Crystal structure of the R132K:R111L:A32E mutant of cellular retinoic acid-binding protein II at 1.56 angstrom resolution
3D97	;	1.5	;	Crystal Structure of the R132K:R111L:L121E Mutant of Apo-Cellular Retinoic Acid Binding Protein Type II At 1.50 Angstroms Resolution
2G7B	;	1.18	;	Crystal Structure of the R132K:R111L:L121E mutant of Cellular Retinoic Acid Binding Protein Type II In Complex With All-Trans-Retinal At 1.18 Angstroms Resolution
4QGX	;	1.471	;	Crystal structure of the R132K:R111L:L121E mutant of Cellular Retinoic Acid Binding ProteinII complexed with a synthetic ligand (Merocyanine) at 1.47 angstrom resolution
3F8A	;	1.95	;	Crystal Structure of the R132K:R111L:L121E:R59W Mutant of Cellular Retinoic Acid-Binding Protein Type II Complexed with C15-aldehyde (a retinal analog) at 1.95 Angstrom resolution.
3FEP	;	2.6	;	Crystal structure of the R132K:R111L:L121E:R59W-CRABPII mutant complexed with a synthetic ligand (merocyanin) at 2.60 angstrom resolution.
3FEL	;	1.85	;	Crystal structure of the R132K:R111L:T54E mutant of cellular retinoic acid-binding protein II at 1.85 angstrom resolution
3F9D	;	2.0	;	Crystal structure of the R132K:R111L:T54E mutant of cellular retinoic acid-binding protein II complexed with C15-aldehyde (a retinal analog) at 2.00 angstrom resolution
3D96	;	1.71	;	Crystal Structure of the R132K:Y134F Mutant of Apo-Cellular Retinoic Acid Binding Protein Type II at 1.71 Angstroms Resolution
2G79	;	1.69	;	Crystal Structure of the R132K:Y134F Mutant of Cellular Retinoic Acid Binding Protein Type II in Complex with All-Trans-Retinal at 1.69 Angstroms Resolution
2G78	;	1.7	;	Crystal Structure of the R132K:Y134F Mutant of Cellular Retinoic Acid Binding Protein Type II in Complex with All-Trans-Retinoic Acid at 1.70 Angstroms Resolution
3FEK	;	1.51	;	Crystal structure of the R132K:Y134F:R111L:L121D:T54V mutant of cellular retinoic acid-binding protein II at 1.51 angstrom resolution
3FA6	;	1.54	;	Crystal structure of the R132K:Y134F:R111L:L121D:T54V mutant of cellular retinoic acid-binding protein II complexed with C15-aldehyde (a retinal analog) at 1.54 angstrom resolution
3D95	;	1.2	;	Crystal Structure of the R132K:Y134F:R111L:L121E:T54V Mutant of Apo-Cellular Retinoic Acid Binding Protein Type II at 1.20 Angstroms Resolution
3CWK	;	1.6	;	Crystal Structure of the R132K:Y134F:R111L:T54V:L121E Mutant of Cellular Retinoic Acid Binding Protein Type II in Complex with All-trans-Retinoic Acid at 1.57 Angstroms Resolution
2X30	;	1.95	;	Crystal structure of the r139n mutant of a bifunctional enzyme pria
5A4K	;	2.093	;	Crystal structure of the R139W variant of human NAD(P)H:quinone oxidoreductase
1OBK	;	2.2	;	crystal structure of the R158Q mutant of Malonamidase E2 from Bradyrhizobium japonicum
8OIY	;	2.1	;	Crystal structure of the R15908H missense variant of titin domain Fn3-3
8DY8	;	2.1	;	Crystal structure of the R178Q mutant of ubiquitin carboxy terminal hydrolase L1 (UCH-L1)
2O0I	;	3.1	;	crystal structure of the R185A mutant of the N-terminal domain of the Group B Streptococcus Alpha C protein
1SYY	;	1.7	;	Crystal structure of the R2 subunit of ribonucleotide reductase from Chlamydia trachomatis
6M8H	;	2.07	;	Crystal Structure of the R208Q mutant of G(i) subunit alpha-1
3M0P	;	2.6	;	Crystal Structure of the R21D mutant of alpha-spectrin SH3 domain. Crystal obtained in ammonium sulphate at pH 4.
3M0Q	;	1.75	;	Crystal Structure of the R21D mutant of alpha-spectrin SH3 domain. Crystal obtained in ammonium sulphate at pH 5.
3M0R	;	1.1	;	Crystal Structure of the R21D mutant of alpha-spectrin SH3 domain. Crystal obtained in ammonium sulphate at pH 6.
3M0S	;	1.6	;	Crystal Structure of the R21D mutant of alpha-spectrin SH3 domain. Crystal obtained in ammonium sulphate at pH 7
3M0T	;	1.7	;	Crystal Structure of the R21D mutant of alpha-spectrin SH3 domain. Crystal obtained in ammonium sulphate at pH 9.
3M0U	;	1.1	;	Crystal Structure of the R21D mutant of alpha-spectrin SH3 domain. Hexagonal crystal obtained in sodium formate at pH 6.5.
1Y28	;	2.1	;	Crystal structure of the R220A metBJFIXL HEME domain
3CLR	;	1.9	;	Crystal structure of the R236A ETF mutant from M. methylotrophus
3CLS	;	1.65	;	Crystal structure of the R236C mutant of ETF from Methylophilus methylotrophus
3CLT	;	2.0	;	Crystal structure of the R236E mutant of Methylophilus methylotrophus ETF
3CLU	;	1.8	;	Crystal structure of the R236K mutant from Methylophilus methylotrophus ETF
7ZD8	;	2.03	;	Crystal structure of the R24E mutant of S-adenosyl-L-homocysteine hydrolase from Synechocystis sp. PCC 6803 cocrystallized with adenosine in the presence of Rb+ cations
7ZD7	;	1.9	;	Crystal structure of the R24E/E352T double mutant of S-adenosyl-L-homocysteine hydrolase from Synechocystis sp. PCC 6803 cocrystallized with adenosine in the presence of Rb+ cations
1S07	;	2.42	;	Crystal Structure of the R253A Mutant of 7,8-Diaminopelargonic Acid Synthase
1S06	;	2.2	;	Crystal Structure of the R253K Mutant of 7,8-Diaminopelargonic Acid Synthase
3S19	;	1.5009	;	Crystal Structure of the R262L mutant of 7-cyano-7-deazaguanine reductase, QueF from Vibrio cholerae complexed with preQ0
3SHF	;	3.55	;	Crystal structure of the R265S mutant of full-length murine Apaf-1
1PS8	;	2.4	;	Crystal Structure of the R270K Mutant of Aspartate Semialdehyde dehydrogenase from Haemophilus influenzae
1JRG	;	2.1	;	Crystal Structure of the R3 form of Pectate Lyase A, Erwinia chrysanthemi
7LQK	;	2.1	;	Crystal structure of the R375A mutant of LeuT
7LQL	;	2.6	;	Crystal structure of the R375D mutant of LeuT
1YU8	;	1.45	;	Crystal Structure of the R37A Mutant of Villin Headpiece
1MGV	;	2.1	;	Crystal Structure of the R391A Mutant of 7,8-Diaminopelargonic Acid Synthase
7A9J	;	1.72	;	Crystal structure of the R395G mutant form of Coronafacic Acid Ligase from Pectobacterium brasiliense
5J5N	;	2.629	;	Crystal structure of the R39W mutant of Populus trichocarpa glutathione transferase PtGSTU30 in complex with glutathione
6UO6	;	2.15	;	Crystal Structure of the R422Q missense variant of human PGM1
2ZPC	;	2.35	;	Crystal structure of the R43L mutant of LolA in the closed form
2ZPD	;	1.85	;	Crystal structure of the R43L mutant of LolA in the open form
4I68	;	1.63	;	Crystal structure of the R444A / R449A double mutant of the HERA RNA helicase RRM domain
3NJT	;	3.5	;	Crystal structure of the R450A mutant of the membrane protein FhaC
6HG8	;	1.76	;	Crystal structure of the R460G disease-causing mutant of the human dihydrolipoamide dehydrogenase.
1NR1	;	3.3	;	Crystal structure of the R463A mutant of human Glutamate dehydrogenase
3GEF	;	1.5	;	Crystal structure of the R482W mutant of lamin A/C
5VG7	;	1.95	;	Crystal Structure of the R503Q missense variant of human PGM1
5VEC	;	2.20002	;	Crystal Structure of the R515L missense variant of human PGM1
5VIN	;	2.60004	;	Crystal Structure of the R515Q missense variant of human PGM1
5VBI	;	1.75	;	Crystal Structure of the R515W missense variant of human PGM1
4AM8	;	1.99	;	Crystal structure of the R54G mutant of putrescine transcarbamylase from Enterococcus faecalis bound to a curing guanidinium ion
6WVW	;	2.11	;	Crystal structure of the R59P-SNAP25 containing SNARE complex
7JQK	;	1.33	;	Crystal structure of the R64A mutant of Bauhinia Bauhinioides Kallikrein Inhibitor complexed with Human Kallikrein 4
7JQO	;	1.6	;	Crystal structure of the R64D mutant of Bauhinia Bauhinioides Kallikrein Inhibitor complexed with Human Kallikrein 4
7JRX	;	1.77	;	Crystal structure of the R64F mutant of Bauhinia Bauhinioides complexed with Bovine Chymotrypsin
7JR1	;	2.05	;	Crystal structure of the R64F mutant of Bauhinia Bauhinioides Kallikrein Inhibitor complexed with Bovine Trypsin
7JQV	;	2.1	;	Crystal structure of the R64F mutant of Bauhinia Bauhinioides Kallikrein Inhibitor complexed with Human Kallikrein 4
7JR2	;	1.851	;	Crystal structure of the R64M mutant of Bauhinia Bauhinioides Kallikrein Inhibitor complexed with Bovine Trypsin
7JQN	;	1.5	;	Crystal structure of the R64M mutant of Bauhinia Bauhinioides Kallikrein Inhibitor complexed with Human Kallikrein 4
2X0C	;	2.0	;	Crystal Structure of the R7R8 domains of Talin
3HK0	;	2.6	;	Crystal Structure of the RA and PH Domains of Grb10
4GN1	;	2.4	;	Crystal Structure of the RA and PH domains of Lamellipodin
5OD8	;	2.2	;	Crystal structure of the RA-associated mAb B2 (Fab fragment)
5ODB	;	1.53	;	Crystal structure of the RA-associated mAb D10 (chimeric Fab fragment)
4DKX	;	1.9	;	Crystal Structure of the Rab 6A'(Q72L)
1LV0	;	2.0	;	Crystal structure of the Rab effector guanine nucleotide dissociation inhibitor (GDI) in complex with a geranylgeranyl (GG) peptide
4ZDW	;	2.9	;	Crystal structure of the Rab GTPase Sec4p mutant - S29V in complex with Sec2p and GDP
2EQB	;	2.7	;	Crystal structure of the Rab GTPase Sec4p, the Sec2p GEF domain, and phosphate complex
6S8X	;	2.29	;	Crystal structure of the Rab-binding domain of FIP2
6DJL	;	3.10001	;	Crystal structure of the Rab11 GEF SH3BP5 bound to nucleotide free Rab11A
7OPP	;	2.32	;	Crystal structure of the Rab27a fusion with Slp2a-RBDa1 effector for SF4 pocket drug targeting
4Q9U	;	4.618	;	Crystal structure of the Rab5, Rabex-5delta and Rabaptin-5C21 complex
4QXA	;	2.3	;	Crystal structure of the Rab9A-RUTBC2 RBD complex
2VUO	;	1.95	;	Crystal structure of the rabbit IgG Fc fragment
3ADO	;	1.7	;	Crystal Structure of the Rabbit L-Gulonate 3-Dehydrogenase
3ADP	;	1.85	;	Crystal Structure of the Rabbit L-Gulonate 3-Dehydrogenase (NADH Form)
1J0X	;	2.4	;	Crystal structure of the rabbit muscle glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
3HZJ	;	2.3	;	Crystal structure of the RabGAP domain of the RABGAP1L protein
2GTT	;	3.49	;	Crystal structure of the rabies virus nucleoprotein-RNA complex
8B8V	;	2.3	;	Crystal structure of the Rabies virus RNA free nucleoprotein- phosphoprotein complex
6SR6	;	2.5	;	Crystal structure of the RAC core with a pseudo substrate bound to Ssz1 SBD
2QSF	;	2.35	;	Crystal structure of the Rad4-Rad23 complex
3QBZ	;	2.692	;	Crystal structure of the Rad53-recognition domain of Saccharomyces cerevisiae Dbf4
2CVF	;	2.6	;	Crystal structure of the RadB recombinase
2CVH	;	2.2	;	Crystal structure of the RadB recombinase
2C3Y	;	1.93	;	CRYSTAL STRUCTURE OF THE RADICAL FORM OF PYRUVATE:FERREDOXIN OXIDOREDUCTASE FROM Desulfovibrio africanus
1GC7	;	2.8	;	CRYSTAL STRUCTURE OF THE RADIXIN FERM DOMAIN
1GC6	;	2.9	;	CRYSTAL STRUCTURE OF THE RADIXIN FERM DOMAIN COMPLEXED WITH INOSITOL-(1,4,5)-TRIPHOSPHATE
2YVC	;	3.2	;	Crystal structure of the Radixin FERM domain complexed with the NEP cytoplasmic tail
2D10	;	2.5	;	Crystal structure of the Radixin FERM domain complexed with the NHERF-1 C-terminal tail peptide
2D11	;	2.81	;	Crystal structure of the Radixin FERM domain complexed with the NHERF-2 C-terminal tail peptide
1J19	;	2.4	;	Crystal structure of the radxin FERM domain complexed with the ICAM-2 cytoplasmic peptide
3GNA	;	2.4	;	Crystal structure of the RAG1 nonamer-binding domain with DNA
3GNB	;	3.0	;	Crystal structure of the RAG1 nonamer-binding domain with DNA
7EAG	;	2.5	;	Crystal structure of the RAGATH-18 k-turn
1ZC3	;	2.0	;	Crystal structure of the Ral-binding domain of Exo84 in complex with the active RalA
1ZC4	;	2.5	;	Crystal structure of the Ral-binding domain of Exo84 in complex with the active RalA
1UAD	;	2.1	;	Crystal structure of the RalA-GppNHp-Sec5 Ral-binding domain complex
3BRY	;	3.2	;	Crystal structure of the Ralstonia pickettii toluene transporter TbuX
3OAN	;	2.3	;	Crystal structure of the Ran Binding Domain From The Nuclear Complex Component Nup2 From Ashbya Gossypii
3N7C	;	2.26	;	Crystal structure of the RAN binding domain from the nuclear pore complex component NUP2 from Ashbya gossypii
4L6E	;	2.496	;	Crystal Structure of the RanBD1 fourth domain of E3 SUMO-protein ligase RanBP2. Northeast Structural Genomics Consortium (NESG) Target HR9193b
4BJT	;	1.61	;	Crystal structure of the Rap1 C-terminal domain (Rap1-RCT) in complex with the Rap1 binding module of Rif1 (Rif1-RBM)
3CZ6	;	1.85	;	Crystal Structure of the Rap1 C-terminus
1SRQ	;	2.9	;	Crystal Structure of the Rap1GAP catalytic domain
1F3U	;	1.7	;	CRYSTAL STRUCTURE OF THE RAP30/74 INTERACTION DOMAINS OF HUMAN TFIIF
5K13	;	1.85	;	Crystal structure of the RAR alpha ligand-binding domain in complex with an antagonist
7AOS	;	2.55	;	crystal structure of the RARalpha/RXRalpha ligand binding domain heterodimer in complex with a fragment of SRC1 coactivator
1XDK	;	2.9	;	Crystal Structure of the RARbeta/RXRalpha Ligand Binding Domain Heterodimer in Complex with 9-cis Retinoic Acid and a Fragment of the TRAP220 Coactivator
2R76	;	2.6	;	Crystal structure of the rare lipoprotein B (SO_1173) from Shewanella oneidensis, Northeast Structural Genomics Consortium Target SoR91A
3C5H	;	1.8	;	Crystal structure of the Ras homolog domain of human GRLF1 (p190RhoGAP)
1LXD	;	2.4	;	CRYSTAL STRUCTURE OF THE RAS INTERACTING DOMAIN OF RALGDS, A GUANINE NUCLEOTIDE DISSOCIATION STIMULATOR OF RAL PROTEIN
3TCA	;	2.35	;	Crystal structure of the Ras-associating and pleckstrin-homology domains of RIAM
3KH0	;	2.1	;	Crystal structure of the Ras-association (RA) domain of RALGDS
3IHW	;	1.92	;	Crystal structure of the Ras-like domain of CENTG3
3IEZ	;	1.5	;	Crystal structure of the RasGAP C-terminal (RGC) domain of IQGAP2
2J05	;	1.5	;	Crystal structure of the RasGAP SH3 domain at 1.5 Angstrom resolution
2J06	;	1.8	;	Crystal structure of the RasGAP SH3 domain at 1.8 Angstrom resolution
3G0W	;	1.95	;	Crystal structure of the rat androgen receptor ligand binding domain complex with an n-aryl-oxazolidin 2-imine inhibitor
2NW4	;	3.0	;	Crystal Structure of the Rat Androgen Receptor Ligand Binding Domain Complex with BMS-564929
1I37	;	2.0	;	CRYSTAL STRUCTURE OF THE RAT ANDROGEN RECEPTOR LIGAND BINDING DOMAIN COMPLEX WITH DIHYDROTESTOSTERONE
1XNN	;	2.2	;	CRYSTAL STRUCTURE OF THE RAT ANDROGEN RECEPTOR LIGAND BINDING DOMAIN T877A MUTANT COMPLEX WITH (3A-ALPHA-,4-ALPHA 7-ALPHA-,7A-ALPHA-)-3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE.
1I38	;	2.0	;	CRYSTAL STRUCTURE OF THE RAT ANDROGEN RECEPTOR LIGAND BINDING DOMAIN T877A MUTANT COMPLEX WITH DIHYDROTESTOSTERONE
2IHQ	;	2.0	;	Crystal Structure of the Rat Androgen Receptor Ligand Binding Domian Complex with an N-Aryl-Hydroxybicyclohydantoin
4IL1	;	3.0	;	Crystal Structure of the Rat Calcineurin
6YI9	;	1.75	;	Crystal structure of the rat cytosolic PCK1, acetylated on Lys244
3IQL	;	1.4	;	Crystal structure of the rat endophilin-A1 SH3 domain
2UUS	;	2.2	;	Crystal structure of the rat FGF1-sucrose octasulfate (SOS) complex.
3I9U	;	2.25	;	Crystal structure of the rat heme oxygenase (HO-1) in complex with heme binding dithioerythritol (DTE)
3I9T	;	2.15	;	Crystal structure of the rat heme oxygenase (HO-1) in complex with heme binding dithiothreitol (DTT)
6IBB	;	2.12	;	Crystal structure of the rat isoform of the succinate receptor SUCNR1 (GPR91) in complex with a nanobody
6VBZ	;	2.192	;	Crystal structure of the rat MLKL pseudokinase domain
4AII	;	2.66	;	Crystal structure of the rat REM2 GTPase - G domain bound to GDP
4MEM	;	2.34	;	Crystal Structure of the rat USP11 DUSP-UBL domains
1RK3	;	2.2	;	crystal structure of the rat vitamin D receptor ligand binding domain complexed with 1,25-dihydroxyvitamin D3 and a synthetic peptide containing the NR2 box of DRIP 205
1RKH	;	2.28	;	crystal structure of the rat vitamin D receptor ligand binding domain complexed with 2AM20R and a synthetic peptide containing the NR2 box of DRIP 205
1RKG	;	1.9	;	crystal structure of the rat vitamin D receptor ligand binding domain complexed with 2MbisP and a synthetic peptide containing the NR2 box of DRIP 205
1RJK	;	1.99	;	crystal structure of the rat vitamin D receptor ligand binding domain complexed with 2MD and a synthetic peptide containing the NR2 box of DRIP 205
3A2H	;	2.5	;	Crystal structure of the rat vitamin D receptor ligand binding domain complexed with TEI-9647 and a synthetic peptide containing the NR2 box of DRIP 205
2ZFX	;	1.99	;	Crystal structure of the rat vitamin D receptor ligand binding domain complexed with YR301 and a synthetic peptide containing the NR2 box of DRIP 205
3AUN	;	1.81	;	Crystal structure of the rat vitamin D receptor ligand binding domain complexed with YR335 and a synthetic peptide containing the NR2 box of DRIP 205
1GPO	;	1.95	;	CRYSTAL STRUCTURE OF THE RATIONALLY DESIGNED ANTIBODY M41 AS A FAB FRAGMENT
7DI0	;	1.6	;	Crystal structure of the rationally designed apDPBB_sym_79 protein
7DU7	;	1.201	;	Crystal structure of the rationally designed mkDPBB_sym1 protein
7DU6	;	1.6	;	Crystal structure of the rationally designed mkDPBB_sym2 protein
7DI1	;	2.097	;	Crystal structure of the rationally designed mkDPBB_sym_86 protein
1T0H	;	1.97	;	Crystal structure of the Rattus norvegicus voltage gated calcium channel beta subunit isoform 2a
3C6A	;	1.16	;	Crystal Structure of the RB49 gp17 nuclease domain
3C6H	;	2.8	;	Crystal Structure of the RB49 gp17 nuclease domain
4EE9	;	1.381	;	Crystal structure of the RBcel1 endo-1,4-glucanase
3NY5	;	1.993	;	Crystal structure of the RBD domain of serine/threonine-protein kinase B-raf from Homo sapiens. Northeast Structural Genomics Consortium Target HR4694F
6PY8	;	3.75	;	Crystal structure of the RBPJ-NOTCH1-NRARP ternary complex bound to DNA
4Z31	;	2.5	;	Crystal structure of the RC3H2 ROQ domain in complex with stem-loop and double-stranded forms of RNA
1ID1	;	2.4	;	CRYSTAL STRUCTURE OF THE RCK DOMAIN FROM E.COLI POTASSIUM CHANNEL
5UBF	;	2.6	;	Crystal structure of the RctB domains 2-3, RctB-155-483
8DGL	;	2.45	;	Crystal Structure of the RdfS Excisionase
3T6D	;	1.95	;	Crystal Structure of the Reaction Centre from Blastochloris viridis strain DSM 133 (ATCC 19567) substrain-08
3T6E	;	1.92	;	Crystal Structure of the Reaction Centre from Blastochloris viridis strain DSM 133 (ATCC 19567) substrain-94
1V5G	;	1.96	;	Crystal Structure of the Reaction Intermediate between Pyruvate oxidase containing FAD and TPP, and Substrate Pyruvate
1ZRM	;	2.0	;	CRYSTAL STRUCTURE OF THE REACTION INTERMEDIATE OF L-2-HALOACID DEHALOGENASE WITH 2-CHLORO-N-BUTYRATE
2VDX	;	1.84	;	Crystal Structure of the reactive loop Cleaved Corticosteroid Binding Globulin
2VDY	;	2.3	;	Crystal structure of the reactive loop cleaved Corticosteroid Binding Globulin complexed with Cortisol
2RIV	;	1.5	;	Crystal structure of the reactive loop cleaved human Thyroxine Binding Globulin
4AFX	;	2.09	;	Crystal structure of the reactive loop cleaved ZPI in I2 space group
4AJU	;	2.65	;	Crystal structure of the reactive loop cleaved ZPI in P41 space group
3RLC	;	2.9	;	Crystal structure of the read-through domain from bacteriophage Qbeta A1 protein, hexagonal crystal form
3RLK	;	1.76	;	Crystal structure of the read-through domain from bacteriophage Qbeta A1 protein, monoclinic crystal form
3AKO	;	2.1	;	Crystal Structure of the Reassembled Venus
7QWV	;	2.26	;	Crystal structure of the REC114-TOPOVIBL complex.
7DTK	;	1.849	;	Crystal structure of the RecA1 domain of RNA helicase CGH-1 in C. elegans
7DTJ	;	2.402	;	Crystal structure of the RecA2 domain of RNA helicase CGH-1 in C. elegans
7E90	;	2.25	;	Crystal structure of the receiver domain (D51E) of the response regulator VbrR from Vibrio parahaemolyticus
1QKK	;	1.7	;	Crystal structure of the receiver domain and linker region of DctD from Sinorhizobium meliloti
7P8C	;	2.15	;	Crystal structure of the Receiver domain of A. thaliana cytokinin receptor AtCRE1 in complex with K+
7P8D	;	1.7	;	Crystal structure of the Receiver domain of A. thaliana cytokinin receptor AtCRE1 in complex with Mg2+
4UHJ	;	1.9	;	Crystal structure of the receiver domain of CpxR from E. coli (orthorhombic form)
4UHK	;	2.6	;	Crystal structure of the receiver domain of CpxR from E. coli (phosphorylated)
4UHS	;	5.0	;	Crystal structure of the receiver domain of CpxR from E. coli (tetragonal form)
4LE0	;	2.27	;	Crystal structure of the receiver domain of DesR in complex with beryllofluoride and magnesium
4LE1	;	1.951	;	Crystal structure of the receiver domain of DesR in the inactive state
6M8O	;	2.5	;	Crystal structure of the receiver domain of LytR from Staphylococcus aureus
7P8E	;	2.5	;	Crystal structure of the Receiver domain of M. truncatula cytokinin receptor MtCRE1
4D6X	;	2.11	;	Crystal structure of the receiver domain of NtrX from Brucella abortus
4D6Y	;	1.7	;	Crystal structure of the receiver domain of NtrX from Brucella abortus in complex with beryllofluoride and magnesium
1XHE	;	2.5	;	Crystal structure of the receiver domain of redox response regulator arca
7CFW	;	1.31	;	Crystal structure of the receiver domain of sensor histidine kinase PA1611 (PA1611REC) from Pseudomonas aeruginosa PAO1 with calcium ion coordinated in the active site cleft
7C1J	;	1.35	;	Crystal structure of the receiver domain of sensor histidine kinase PA1611 (PA1611REC) from Pseudomonas aeruginosa PAO1 with magnesium ion coordinated in the active site cleft
1DCF	;	2.5	;	CRYSTAL STRUCTURE OF THE RECEIVER DOMAIN OF THE ETHYLENE RECEPTOR OF ARABIDOPSIS THALIANA
3MM4	;	2.0	;	Crystal structure of the receiver domain of the histidine kinase CKI1 from Arabidopsis thaliana
3MMN	;	2.2	;	Crystal structure of the receiver domain of the histidine kinase CKI1 from Arabidopsis thaliana complexed with Mg2+
5N2N	;	2.05	;	Crystal structure of the receiver domain of the histidine kinase CKI1 from Arabidopsis thaliana complexed with Mg2+ and BeF3-
7W9H	;	2.28	;	Crystal structure of the receiver domain of the transcription regulator FleR from Pseudomonas aeruginosa
1ZGZ	;	1.8	;	Crystal Structure Of The Receiver Domain Of TMAO Respiratory System Response Regulator TorR
3AZV	;	3.1	;	Crystal structure of the receptor binding domain
3AZW	;	2.99	;	Crystal structure of the receptor binding domain
3PME	;	1.56	;	Crystal structure of the receptor binding domain of botulinum neurotoxin C/D mosaic serotype
3OGG	;	1.651	;	Crystal structure of the receptor binding domain of botulinum neurotoxin D
4F83	;	1.7	;	Crystal structure of the receptor binding domain of botulinum neurotoxin mosaic serotype C/D with a tetraethylene glycol molecule bound on the Hcn sub-domain and a sulfate ion at the putative active site
3BOV	;	1.77	;	Crystal structure of the receptor binding domain of mouse PD-L2
3U4K	;	3.0	;	Crystal structure of the receptor binding domain of plasmid-born adhesin MrkD1P of Klebsiella pneumoniae
7NXA	;	2.5	;	Crystal structure of the receptor binding domain of SARS-CoV-2 B.1.351 variant Spike glycoprotein in complex with COVOX-222 and EY6A Fabs
7PRZ	;	3.2	;	Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in complex with beta-22 Fabs
7PS0	;	2.92	;	Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in complex with beta-24 Fabs
7PS1	;	2.4	;	Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in complex with Beta-27 Fab
7PS2	;	2.99	;	Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in complex with Beta-29 and Beta-53 Fabs
7PS4	;	1.94	;	Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in complex with Beta-38
7PS7	;	3.9	;	Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in complex with Beta-40 Fab
7PS6	;	2.26	;	Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in complex with Beta-44 and Beta-54 Fabs
7PS5	;	3.14	;	Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in complex with Beta-47 Fab
7Q0G	;	1.82	;	Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in complex with Beta-49 and FI-3A Fabs
7Q0H	;	3.65	;	Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in complex with Beta-50 and Beta-54
7PRY	;	3.1	;	Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in complex with COVOX-45 and beta-6 Fabs
8HRD	;	2.86	;	Crystal structure of the receptor binding domain of SARS-CoV-2 Delta variant in complex with IMCAS74 Fab and W14 Fab
7WBQ	;	3.34	;	Crystal structure of the receptor binding domain of SARS-CoV-2 Delta variant spike glycoprotein in complex with its receptor human ACE2
7XWA	;	3.36	;	Crystal structure of the receptor binding domain of SARS-CoV-2 Omicron BA.4/5 variant spike protein in complex with its receptor ACE2
8IF2	;	2.78	;	Crystal structure of the receptor binding domain of SARS-CoV-2 Omicron BQ.1.1 variant spike protein in complex with its receptor ACE2
7WBP	;	3.0	;	Crystal structure of the receptor binding domain of SARS-CoV-2 Omicron variant spike glycoprotein in complex with its receptor human ACE2
7NXC	;	3.14	;	Crystal structure of the receptor binding domain of SARS-CoV-2 P.1 variant Spike glycoprotein in complex with ACE2
7NXB	;	2.67	;	Crystal structure of the receptor binding domain of SARS-CoV-2 P.1 variant Spike glycoprotein in complex with COVOX-222 and EY6A Fabs
7BEN	;	2.5	;	Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-253 and COVOX-75 Fabs
7BEO	;	3.19	;	Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-253H55L and COVOX-75 Fabs
7BEP	;	2.61	;	Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-384 and S309 Fabs
7BEL	;	2.53	;	Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-88 and COVOX-45 Fabs
7BEI	;	2.3	;	Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-150 Fab
7BEJ	;	2.42	;	Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-158 Fab (crystal form 1)
7BEK	;	2.04	;	Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-158 Fab (crystal form 2)
7OR9	;	2.34	;	Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and COVOX-278 Fabs
7NX6	;	2.25	;	Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and EY6A Fabs
7NEH	;	1.77	;	Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-269 Fab
7BEM	;	2.52	;	Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-269 scFv
7BEH	;	2.3	;	Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-316 Fab
7PR0	;	2.92	;	Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with FD-5D Fab
7PQZ	;	3.2	;	Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with FI-3A and FD-11A Fabs
7PQY	;	3.0	;	Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with FI-3A Fab
5KWB	;	1.91	;	Crystal Structure of the Receptor Binding Domain of the Spike Glycoprotein of Human Betacoronavirus HKU1 (HKU1 1A-CTD, 1.9 angstrom, molecular replacement)
5GNB	;	2.3	;	Crystal Structure of the Receptor Binding Domain of the Spike Glycoprotein of Human Betacoronavirus HKU1 (HKU1 1A-CTD, 2.3 angstrom, native-SAD phasing)
2VVD	;	2.26	;	Crystal structure of the receptor binding domain of the spike protein P1 from bacteriophage PM2
6R5W	;	1.7	;	Crystal structure of the receptor binding protein (gp15) of Listeria phage PSA
2V5Y	;	3.1	;	Crystal structure of the receptor protein tyrosine phosphatase mu ectodomain
4L3N	;	2.13	;	Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus
1KNB	;	1.7	;	CRYSTAL STRUCTURE OF THE RECEPTOR-BINDING DOMAIN OF ADENOVIRUS TYPE 5 FIBER PROTEIN AT 1.7 ANGSTROMS RESOLUTION
5MK6	;	1.45	;	Crystal structure of the receptor-binding domain of botulinum neurotoxin A1 (crystal form 1)
5MK7	;	1.8	;	Crystal structure of the receptor-binding domain of botulinum neurotoxin A1 (crystal form 2)
5V38	;	1.8	;	Crystal Structure of The Receptor-binding Domain of Botulinum Neurotoxin Type HA
5MK8	;	1.95	;	Crystal structure of the receptor-binding domain of the FA hybrid Clostridium botulinum neurotoxin
1SG1	;	2.4	;	Crystal Structure of the Receptor-Ligand Complex between Nerve Growth Factor and the Common Neurotrophin Receptor p75
2ATM	;	2.0	;	Crystal structure of the recombinant allergen Ves v 2
1FXW	;	2.1	;	CRYSTAL STRUCTURE OF THE RECOMBINANT ALPHA1/ALPHA2 CATALYTIC HETERODIMER OF BOVINE BRAIN PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE IB.
6ZVF	;	1.9	;	Crystal structure of the recombinant Fab fragment derived from the hybridoma M3/38 in complex with a human Galectin-3 peptide
5IR3	;	1.7	;	Crystal structure of the recombinant highest fibrillogenic natural mutant (obtained from patient AR) derived from lambda 6 light chain variable domain
2F9O	;	2.1	;	Crystal Structure of the Recombinant Human Alpha I Tryptase Mutant D216G
2F9P	;	2.3	;	Crystal Structure of the Recombinant Human Alpha I Tryptase Mutant D216G in Complex with Leupeptin
2F9N	;	1.6	;	Crystal Structure of the Recombinant Human Alpha I Tryptase Mutant K192Q/D216G in Complex with Leupeptin
1LON	;	2.1	;	Crystal Structure of the Recombinant Mouse-Muscle Adenylosuccinate Synthetase Complexed with 6-phosphoryl-IMP, GDP and Hadacidin
1LNY	;	2.2	;	Crystal structure of the recombinant mouse-muscle adenylosuccinate synthetase complexed with 6-phosphoryl-IMP, GDP and Mg
3HG6	;	1.7	;	Crystal Structure of the Recombinant Onconase from Rana pipiens
7WXZ	;	2.41	;	Crystal structure of the recombinant protein HR121 from the S2 protein of SARS-CoV-2
3W5B	;	3.2	;	Crystal structure of the recombinant SERCA1a (calcium pump of fast twitch skeletal muscle) in the E1.Mg2+ state
3WOU	;	0.99	;	Crystal Structure of The Recombinant Thaumatin II at 0.99 A
2W0K	;	2.35	;	Crystal structure of the recombinant variable domain 6JAL2
7YMO	;	1.8	;	Crystal structure of the recombination mediator protein RecO from Campylobacter jejuni
8K3F	;	2.603	;	Crystal structure of the recombination mediator protein RecR from Campylobacter jejuni
2X87	;	2.0	;	Crystal Structure of the reconstituted CotA
4JCV	;	3.34	;	Crystal structure of the RecOR complex in an open conformation
8C0N	;	2.9	;	Crystal structure of the red form of the mTagFT fluorescent timer
5ZIH	;	2.6	;	Crystal structure of the red light-activated channelrhodopsin Chrimson.
6J44	;	2.06	;	Crystal structure of the redefined DNA-binding domain of human XPA
1MI0	;	1.85	;	Crystal Structure of the redesigned protein G variant NuG2
4G86	;	2.387	;	Crystal structure of the redox-active cofactor DBMIB bound to the full length circadian clock protein KaiA from Synechococcus elongatus
6ON8	;	2.395	;	Crystal Structure of the Reduced Form of Apo Domain-Swapped Dimer Q108K:T51D:A28C:L36C:F57H Mutant of Human Cellular Retinol Binding Protein II
1OAE	;	1.95	;	Crystal structure of the reduced form of cytochrome c"" from Methylophilus methylotrophus
5AVO	;	1.8	;	Crystal structure of the reduced form of homoserine dehydrogenase from Sulfolobus tokodaii.
3VB2	;	2.6	;	Crystal Structure of the Reduced Form of MarR from E.coli
1ZNZ	;	2.5	;	Crystal Structure Of The Reduced Form Of Mycobacterium tuberculosis Guanylate Kinase In Complex With GDP
1I69	;	2.7	;	CRYSTAL STRUCTURE OF THE REDUCED FORM OF OXYR
3X34	;	0.76	;	Crystal structure of the reduced form of the solubilized domain of porcine cytochrome b5 in form 1 crystal
3X35	;	0.95	;	Crystal structure of the reduced form of the solubilized domain of porcine cytochrome b5 in form 2 crystal
4I2U	;	1.3	;	Crystal structure of the reduced glutaredoxin from Chlorella sorokiniana T-89 in complex with glutathione
6MWS	;	1.22	;	crystal structure of the reduced Grx1 from Saccharomyces cerevisiae
4BUR	;	2.88	;	Crystal structure of the reduced human Apoptosis inducing factor complexed with NAD
1V58	;	1.7	;	Crystal Structure Of the Reduced Protein Disulfide Bond Isomerase DsbG
4AWT	;	0.98	;	Crystal structure of the reduced Shewanella Yellow Enzyme 1 (SYE1) M25L mutant
5UM7	;	1.62	;	Crystal structure of the reduced state of the thiol-disulfide reductase SdbA from Streptococcus gordonii
3GE3	;	1.52	;	Crystal Structure of the reduced Toluene 4-Monooxygenase HD T201A mutant complex
3GD4	;	2.24	;	Crystal structure of the reduced, NAD-bound form of murine apoptosis inducing factor
5ZYR	;	2.20001	;	Crystal structure of the reductase (C1) component of p-hydroxyphenylacetate 3-hydroxylase (HPAH) from Acinetobacter baumannii
1T1R	;	2.3	;	Crystal Structure of the Reductoisomerase Complexed with a Bisphosphonate
1T1S	;	2.4	;	Crystal Structure of the Reductoisomerase Complexed with a Bisphosphonate
4GJE	;	1.6	;	Crystal structure of the refolded amino-terminal domain of human cardiac troponin C in complex with cadmium
4R05	;	2.1	;	Crystal structure of the refolded DENV3 methyltransferase
7RCR	;	1.6	;	Crystal Structure of the refolded Hemagglutinin head domain of Influenza A virus A/Ohio/09/2015
4LH9	;	2.049	;	Crystal structure of the refolded hood domain (Asp256-Gly295) of HetR
8F67	;	3.59	;	Crystal structure of the refolded Penicillin Binding Protein 5 (PBP5) of Enterococcus faecium
3RDS	;	1.5	;	Crystal structure of the refolded R7-2 streptavidin
7FIB	;	2.1	;	Crystal structure of the regulatory domain of AceR in Acinetobacter baumannii
4O1H	;	2.8	;	Crystal Structure of the regulatory domain of AmeGlnR
1O7F	;	2.5	;	CRYSTAL STRUCTURE OF THE REGULATORY DOMAIN OF EPAC2
2W4R	;	2.6	;	Crystal structure of the regulatory domain of human LGP2
2QFD	;	2.7	;	Crystal structure of the regulatory domain of human RIG-I with bound Hg
2QFB	;	3.0	;	Crystal structure of the regulatory domain of human RIG-I with bound Zn
3F6G	;	2.0	;	Crystal structure of the regulatory domain of LiCMS in complexed with isoleucine - type II
3F6H	;	2.7	;	Crystal structure of the regulatory domain of LiCMS in complexed with isoleucine - type III
6L33	;	2.0	;	Crystal structure of the regulatory domain of MexT, a transcriptional activator in Pseudomonas aeruginosa
4O1I	;	2.8	;	Crystal Structure of the regulatory domain of MtbGlnR
5JHO	;	2.801	;	Crystal structure of the regulatory domain of the sodium driven chloride bicarbonate exchanger.
2V8Q	;	2.1	;	Crystal structure of the regulatory fragment of mammalian AMPK in complexes with AMP
2V92	;	2.4	;	Crystal structure of the regulatory fragment of mammalian AMPK in complexes with ATP-AMP
2V9J	;	2.53	;	Crystal structure of the regulatory fragment of mammalian AMPK in complexes with Mg.ATP-AMP
1HO8	;	2.95	;	CRYSTAL STRUCTURE OF THE REGULATORY SUBUNIT H OF THE V-TYPE ATPASE OF SACCHAROMYCES CEREVISIAE
2F1F	;	1.75	;	Crystal structure of the regulatory subunit of acetohydroxyacid synthase isozyme III from E. coli
2DT9	;	2.15	;	Crystal structure of the regulatory subunit of aspartate kinase from Thermus flavus
2ZHO	;	2.98	;	Crystal structure of the regulatory subunit of aspartate kinase from Thermus thermophilus (ligand free form)
1JMU	;	2.8	;	Crystal Structure of the Reovirus mu1/sigma3 Complex
1FN9	;	1.8	;	CRYSTAL STRUCTURE OF THE REOVIRUS OUTER CAPSID PROTEIN SIGMA 3
2SPC	;	1.8	;	CRYSTAL STRUCTURE OF THE REPETITIVE SEGMENTS OF SPECTRIN
3DKY	;	3.6	;	Crystal Structure of the replication initiator protein encoded on plasmid pMV158 (RepB), tetragonal form, to 3.6 Ang resolution
3DKX	;	2.7	;	Crystal Structure of the replication initiator protein encoded on plasmid pMV158 (RepB), trigonal form, to 2.7 Ang resolution
2DPU	;	3.1	;	Crystal structure of the replication termination protein in complex with a pseudosymmetric 21mer B-site DNA
2DPD	;	3.17	;	Crystal structure of the Replication Termination Protein in complex with a pseudosymmetric B-site
1J0R	;	2.5	;	Crystal structure of the replication termination protein mutant C110S
2DQR	;	3.01	;	Crystal structure of the replication terminator protein mutant RTP.E39K.R42Q
1F4K	;	2.5	;	CRYSTAL STRUCTURE OF THE REPLICATION TERMINATOR PROTEIN/B-SITE DNA COMPLEX
1M5T	;	1.6	;	CRYSTAL STRUCTURE OF THE RESPONSE REGULATOR DIVK
1MAV	;	1.6	;	CRYSTAL STRUCTURE OF THE RESPONSE REGULATOR DIVK AT PH 6.0 IN COMPLEX WITH MN2+
1MB0	;	2.0	;	CRYSTAL STRUCTURE OF THE RESPONSE REGULATOR DIVK AT PH 8.0 IN COMPLEX WITH MN2+
1MB3	;	1.41	;	CRYSTAL STRUCTURE OF THE RESPONSE REGULATOR DIVK AT PH 8.5 IN COMPLEX WITH MG2+
1M5U	;	1.87	;	CRYSTAL STRUCTURE OF THE RESPONSE REGULATOR DIVK. STRUCTURE AT PH 8.0 IN THE APO-FORM
3T8Y	;	1.9	;	Crystal structure of the response regulator domain of Thermotoga maritima CheB
4KNY	;	2.945	;	Crystal structure of the response regulator KdpE complexed to DNA in an active-like conformation
4G97	;	2.05	;	Crystal structure of the response regulator PhyR from Brucella abortus
2GWR	;	2.1	;	Crystal structure of the response regulator protein mtrA from Mycobacterium Tuberculosis
1YS7	;	1.58	;	Crystal structure of the response regulator protein prrA complexed with Mg2+
4GVP	;	2.03	;	Crystal Structure of the Response Regulator Protein VraR from Staphylococcus aureus
3C97	;	1.7	;	Crystal structure of the response regulator receiver domain of a signal transduction histidine kinase from Aspergillus oryzae
3SY8	;	2.5	;	Crystal structure of the response regulator RocR
1PEY	;	2.25	;	Crystal structure of the Response Regulator Spo0F complexed with Mn2+
2QV0	;	2.4	;	Crystal structure of the response regulatory domain of protein mrkE from Klebsiella pneumoniae
1YS6	;	1.77	;	Crystal structure of the response regulatory protein PrrA from Mycobacterium Tuberculosis
3FH6	;	4.5	;	Crystal structure of the resting state maltose transporter from E. coli
4NM9	;	1.898	;	Crystal structure of the resting state of proline utilization A (PutA) from Geobacter sulfurreducens PCA
7CFA	;	2.355	;	Crystal structure of the restriction DNA glycosylase R.CcoLI
1DMU	;	2.2	;	Crystal structure of the restriction endonuclease BglI (e.c.3.1.21.4) bound to its dna recognition sequence
1VRR	;	2.7	;	Crystal structure of the restriction endonuclease BstYI complex with DNA
3LFP	;	2.0	;	Crystal Structure of the Restriction-Modification Controller Protein C.Csp231I
3LIS	;	2.0	;	Crystal Structure of the Restriction-Modification Controller Protein C.Csp231I (Monoclinic form)
4JCX	;	2.3	;	Crystal structure of the Restriction-Modification Controller Protein C.Csp231I OL operator complex
4JQD	;	2.75	;	Crystal structure of the Restriction-Modification Controller Protein C.Csp231I OL operator complex
4JCY	;	1.8	;	Crystal structure of the Restriction-Modification Controller Protein C.Csp231I OR operator complex
3CLC	;	2.8	;	Crystal Structure of the Restriction-Modification Controller Protein C.Esp1396I Tetramer in Complex with its Natural 35 Base-Pair Operator
3RY9	;	1.95	;	Crystal Structure of the Resurrected Ancestral Glucocorticoid Receptor 1 in complex with DOC
3EO5	;	1.83	;	Crystal structure of the resuscitation promoting factor RpfB
2QDJ	;	2.0	;	Crystal structure of the Retinoblastoma protein N-domain provides insight into tumor suppression, ligand interaction and holoprotein architecture
1O9K	;	2.6	;	Crystal structure of the retinoblastoma tumour suppressor protein bound to E2F peptide
5LYQ	;	2.17	;	Crystal structure of the Retinoic Acid Receptor alpha in complex with a synthetic spiroketal agonist and a fragment of the TIF2 co-activator.
6SJM	;	2.52	;	Crystal structure of the Retinoic Acid Receptor alpha in complex with compound 24 (JP175)
5MKU	;	1.78	;	Crystal structure of the Retinoid X Receptor alpha in complex with synthetic honokiol derivative 4 and a fragment of the TIF2 co-activator.
5MMW	;	2.7	;	Crystal structure of the Retinoid X Receptor alpha in complex with synthetic honokiol derivative 6 and a fragment of the TIF2 co-activator.
5MK4	;	2.0	;	Crystal structure of the Retinoid X Receptor alpha in complex with synthetic honokiol derivative 7 and a fragment of the TIF2 co-activator.
5MKJ	;	2.5	;	Crystal structure of the Retinoid X Receptor alpha in complex with synthetic honokiol derivative 9 and a fragment of the TIF2 co-activator.
5MJ5	;	1.9	;	Crystal structure of the Retinoid X Receptor alpha in complex with synthetichonokiol derivative 3 and a fragment of the TIF2 co-activator.
3FUG	;	2.0	;	Crystal Structure of the Retinoid X Receptor Ligand Binding Domain Bound to the Synthetic Agonist 3-[4-Hydroxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-phenyl]acrylic Acid
8R02	;	2.5	;	Crystal structure of the retromer complex VPS29/VPS35 with the ligand bis-1,3-phenyl guanylhydrazone, 2a
8R0J	;	2.4	;	Crystal structure of the retromer complex VPS29/VPS35 with the ligand bis-1,3-phenyl guanylhydrazone, 2a
3JYB	;	2.04	;	Crystal Structure of the RetS periplasmic domain
1DUQ	;	2.1	;	CRYSTAL STRUCTURE OF THE REV BINDING ELEMENT OF HIV-1
5EB6	;	1.65008	;	Crystal Structure of the Reversibly photoswitching chromoprotein Dathail, Ground State
5EB7	;	1.65	;	Crystal Structure of the Reversibly photoswitching chromoprotein Dathail, Metastable State
2OUG	;	2.1	;	Crystal structure of the RfaH transcription factor at 2.1A resolution
3ISU	;	1.88	;	Crystal structure of the RGC domain of IQGAP3
4BQ6	;	2.3	;	Crystal structure of the RGMB-NEO1 complex form 1
4BQ7	;	6.601	;	Crystal structure of the RGMB-Neo1 complex form 2
4BQ8	;	2.8	;	Crystal structure of the RGMB-NEO1 complex form 3
4IGU	;	1.9	;	Crystal structure of the RGS domain of CG5036
1DK8	;	1.57	;	CRYSTAL STRUCTURE OF THE RGS-HOMOLOGOUS DOMAIN OF AXIN
7Y1P	;	2.602	;	CRYSTAL STRUCTURE OF THE RGS-HOMOLOGOUS DOMAIN OF AXIN IN COMPLEX WITH LZ-22Na
1KQR	;	1.4	;	Crystal Structure of the Rhesus Rotavirus VP4 Sialic Acid Binding Domain in Complex with 2-O-methyl-alpha-D-N-acetyl neuraminic acid
2B4H	;	1.6	;	Crystal Structure of the Rhesus Rotavirus VP5 Antigen Domain Dimer
2B4I	;	2.0	;	Crystal Structure of the Rhesus Rotavirus VP5 Antigen Domain Trimer
4G9M	;	1.601	;	Crystal structure of the Rhizoctonia solani agglutinin
4G9N	;	2.2	;	Crystal structure of the Rhizoctonia solani agglutinin in complex with N'-acetyl-galactosamine
4E74	;	1.58	;	Crystal structure of the RHO GTPASE BINDING DOMAIN of Plexin A4A
4E71	;	2.26	;	Crystal structure of the RHO GTPASE binding domain of Plexin B2
2H7O	;	2.0	;	Crystal structure of the Rho-GTPase binding domain of YpkA
2F2U	;	2.4	;	crystal structure of the Rho-kinase kinase domain
1CC0	;	5.0	;	CRYSTAL STRUCTURE OF THE RHOA.GDP-RHOGDI COMPLEX
8TFS	;	1.95	;	Crystal structure of the Rhodanese-like domain of Vretifemale_1082 from Volvox reticuliferus
3HIX	;	1.92	;	Crystal Structure of the Rhodanese_3 like domain from Anabaena sp Alr3790 protein. Northeast Structural Genomics Consortium Target NsR437i
3VA9	;	2.3	;	Crystal structure of the Rhodopseudomonas palustris histidine kinase HK9 sensor domain
6FUF	;	3.117	;	Crystal structure of the rhodopsin-mini-Go complex
3EAP	;	2.3	;	Crystal structure of the RhoGAP domain of ARHGAP11A
3FK2	;	2.8	;	Crystal structure of the RhoGAP domain of human glucocorticoid receptor DNA-binding factor 1
2XS6	;	2.09	;	CRYSTAL STRUCTURE OF THE RHOGAP DOMAIN OF HUMAN PIK3R2
5MY3	;	2.19	;	Crystal structure of the RhoGAP domain of Rgd1p at 2.19 Angstroms resolution
3IUG	;	1.77	;	Crystal structure of the RhoGAP domain of RICS
3EO2	;	2.6	;	Crystal structure of the RhoGEF domain of human neuroepithelial cell-transforming gene 1 protein
7RT7	;	2.49	;	Crystal structure of the RhsP2 C-terminal toxin domain in complex with its immunity protein, RhsI2
8BD1	;	1.26	;	Crystal structure of the RhsPWHH-RhsPI toxin-immunity pair
5A88	;	2.08	;	Crystal structure of the riboflavin kinase module of FAD synthetase from Corynebacterium ammoniagenes in complex with ADP
5A8A	;	1.8	;	Crystal structure of the riboflavin kinase module of FAD synthetase from Corynebacterium ammoniagenes in complex with FMN and ADP (P3 2 21)
5A89	;	1.65	;	Crystal structure of the riboflavin kinase module of FAD synthetase from Corynebacterium ammoniagenes in complex with FMN and ADP(P 21 21 21)
1RCN	;	2.32	;	CRYSTAL STRUCTURE OF THE RIBONUCLEASE A D(APTPAPAPG) COMPLEX : DIRECT EVIDENCE FOR EXTENDED SUBSTRATE RECOGNITION
6ZDW	;	1.65	;	Crystal structure of the ribonuclease core of R3B2
1HRH	;	2.4	;	CRYSTAL STRUCTURE OF THE RIBONUCLEASE H DOMAIN OF HIV-1 REVERSE TRANSCRIPTASE
3H08	;	1.6	;	Crystal structure of the Ribonuclease H1 from Chlorobium tepidum
1UAX	;	2.0	;	Crystal structure of the ribonuclease H2 from Pyrococcus horikoshii OT3
1UCA	;	1.48	;	Crystal structure of the Ribonuclease MC1 from bitter gourd seeds complexed with 2'-UMP
1UCC	;	1.77	;	Crystal structure of the Ribonuclease MC1 from bitter gourd seeds complexed with 3'-UMP.
8QND	;	1.9	;	Crystal structure of the ribonucleoside hydrolase C from Lactobacillus reuteri
2RCN	;	2.25	;	Crystal Structure of the Ribosomal interacting GTPase YjeQ from the Enterobacterial species Salmonella Typhimurium.
1MMS	;	2.57	;	Crystal structure of the ribosomal PROTEIN L11-RNA complex
1RIS	;	2.0	;	CRYSTAL STRUCTURE OF THE RIBOSOMAL PROTEIN S6 FROM THERMUS THERMOPHILUS
5ISV	;	1.35	;	Crystal structure of the ribosomal-protein-S18-alanine N-acetyltransferase from Escherichia coli
6EN7	;	2.403	;	Crystal structure of the ribosome assembly factor Nsa1
4V42	;	5.5	;	Crystal structure of the ribosome at 5.5 A resolution.
4V9H	;	2.857	;	Crystal structure of the ribosome bound to elongation factor G in the guanosine triphosphatase state
4I47	;	2.65	;	Crystal structure of the Ribosome inactivating protein complexed with methylated guanine
3H5K	;	1.45	;	Crystal structure of the ribosome inactivating protein PDL1
2QES	;	1.24	;	Crystal structure of the ribosome inactivating protein PDL4 from P. dioica leaves in complex with adenine
3H9N	;	2.7	;	Crystal structure of the ribosome maturation factor rimm (hi0203) from h.influenzae. northeast structural genomics consortium target IR66.
1EK8	;	2.3	;	CRYSTAL STRUCTURE OF THE RIBOSOME RECYCLING FACTOR (RRF) FROM ESCHERICHIA COLI
1JBR	;	2.15	;	Crystal Structure of the Ribotoxin Restrictocin and a 31-mer SRD RNA Inhibitor
3H2J	;	1.89	;	Crystal structure of the rice cell wall degrading esterase LipA from Xanthomonas oryzae
5C7F	;	2.7	;	Crystal structure of the rice Topless related protein 2 (TPR2) N-terminal domain (1-209) in complex with Arabidopsis IAA1 peptide
5C7E	;	3.1	;	Crystal structure of the rice Topless related protein 2 (TPR2) N-terminal domain (1-209) in complex with Arabidopsis IAA10 peptide
5C6V	;	3.1	;	Crystal structure of the rice Topless related protein 2 (TPR2) N-terminal domain (1-209) in complex with Arabidopsis NINJA peptide
5J9K	;	2.55	;	Crystal structure of the rice Topless related protein 2 (TPR2) N-terminal topless domain (1-209) in complex with rice D53 repressor EAR peptide motif
5JA5	;	2.0	;	Crystal structure of the rice Topless related protein 2 (TPR2) N-terminal topless domain (1-209) L111A and L130A mutant in complex with rice D53 repressor EAR peptide motif
5JGC	;	2.08	;	Crystal structure of the rice Topless related protein 2 (TPR2) N-terminal topless domain (1-209) L111A, L130A, L179A and I195A mutant
5JHP	;	3.15	;	Crystal structure of the rice Topless related protein 2 (TPR2) N-terminal topless domain (1-209) L179A and I195A mutant in complex with rice D53 repressor EAR peptide motif
1NYK	;	1.31	;	Crystal Structure of the Rieske protein from Thermus thermophilus
1FQT	;	1.6	;	CRYSTAL STRUCTURE OF THE RIESKE-TYPE FERREDOXIN ASSOCIATED WITH BIPHENYL DIOXYGENASE
4BJS	;	1.94	;	Crystal structure of the Rif1 C-terminal domain (Rif1-CTD) from Saccharomyces cerevisiae
5NVR	;	3.95	;	Crystal structure of the Rif1 N-terminal domain (RIF1-NTD) from Saccharomyces cerevisiae
5NW5	;	6.502	;	Crystal structure of the Rif1 N-terminal domain (RIF1-NTD) from Saccharomyces cerevisiae in complex with DNA
3LYF	;	1.93	;	Crystal Structure of the Rift Valley Fever Virus Nucleocapsid Protein
6ON6	;	1.423	;	Crystal Structure of the RIG-5 IG1 homodimer
4TS6	;	1.92	;	Crystal structure of the RIM C2A domain from Drosophila.
2BWQ	;	1.41	;	Crystal Structure of the RIM2 C2A-domain at 1.4 angstrom Resolution
3KNV	;	1.9	;	Crystal structure of the RING and first zinc finger domains of TRAF2
8CH4	;	2.1	;	Crystal structure of the ring cleaving dioxygenase 5-nitrosalicylate 1,2-dioxygenase from Bradyrhizobium sp.
8W5A	;	1.65	;	Crystal structure of the RING domain of human XIAP
8W59	;	1.339	;	Crystal structure of the RING domain of human XIAP treated with arsenic trioxide
3L11	;	2.12	;	Crystal Structure of the Ring Domain of RNF168
4GB0	;	2.6	;	Crystal Structure of the RING domain of RNF168
3FL2	;	1.75	;	Crystal structure of the ring domain of the E3 ubiquitin-protein ligase UHRF1
4ZDT	;	2.0	;	Crystal structure of the RING finger domain of Slx1 in complex with the C-terminal domain of Slx4
7Z55	;	1.664	;	Crystal Structure of the Ring Nuclease 0455 from Sulfolobus islandicus (Sis0455) in complex with its substrate
7Z56	;	2.27	;	Crystal Structure of the Ring Nuclease 0455 from Sulfolobus islandicus (Sis0455) in its apo form
7PQ3	;	2.85	;	Crystal Structure of the Ring Nuclease 0811 from Sulfolobus islandicus (Sis0811) in complex with its post-catalytic reaction product
7PQ2	;	2.38	;	Crystal Structure of the Ring Nuclease 0811 from Sulfolobus islandicus (Sis0811) in its apo form
7PQ6	;	2.67	;	Crystal Structure of the Ring Nuclease 0811 mutant-S12A from Sulfolobus islandicus (Sis0811)
7PQA	;	2.04	;	Crystal Structure of the Ring Nuclease 0811 mutant-S12G/K169G from Sulfolobus islandicus (Sis0811)
7YGL	;	2.5	;	Crystal Structure of the ring nuclease Sso2081 from Saccharolobus solfataricus in complex with A4>p cleavage intermediate
7YGH	;	3.11	;	Crystal Structure of the ring nuclease Sso2081 from Saccharolobus solfataricus in complex with cyclic-tetraadenylate (cA4)
7YHL	;	2.7	;	Crystal Structure of the ring nuclease Sso2081 from Saccharolobus solfataricus in complex with free phosphate
8HTW	;	2.0	;	Crystal Structure of the ring nuclease Sso2081 Y133F mutant from Saccharolobus solfataricus in its apo form
7BVW	;	2.1	;	Crystal structure of the RING-H2 domain of Arabidopsis RMR1
4R8P	;	3.2846	;	Crystal structure of the Ring1B/Bmi1/UbcH5c PRC1 ubiquitylation module bound to the nucleosome core particle
4GYG	;	2.482	;	Crystal structure of the Rio2 kinase from Chaetomium thermophilum
4GYI	;	2.2	;	Crystal structure of the Rio2 kinase-ADP/Mg2+-phosphoaspartate complex from Chaetomium thermophilum
8QA9	;	2.7	;	Crystal structure of the RK2 plasmid encoded co-complex of the C-terminally truncated transcriptional repressor protein KorB complexed with the partner repressor protein KorA bound to OA-DNA
3SJV	;	3.1	;	Crystal structure of the RL42 TCR in complex with HLA-B8-FLR
3SKN	;	2.9	;	Crystal structure of the RL42 TCR unliganded
6ZQT	;	1.51	;	Crystal structure of the RLIP76 Ral binding domain mutant (E427H/Q433L/K440R) in complex with RalB-GMPPNP
6ZRN	;	1.482	;	Crystal structure of the RLIP76 Ral binding domain mutant (E427S/L429M/Q433L/K440R) in complex with RalB-GMPPNP
3MXN	;	1.55	;	Crystal structure of the RMI core complex
4DAY	;	3.3	;	Crystal structure of the RMI core complex with MM2 peptide from FANCM
1UTY	;	2.4	;	Crystal structure of the RNA binding domain of Bluetongue virus non-structural protein 2(NS2)
3BWT	;	2.69	;	Crystal structure of the RNA binding domain of Puf4 from Saccharomyces cerevisiae
7L3O	;	2.1	;	Crystal Structure of the RNA binding domain of Threonyl-tRNA synthetase from Cryptosporidium parvum Iowa II
2D3D	;	1.6	;	crystal structure of the RNA binding SAM domain of saccharomyces cerevisiae Vts1
3SB2	;	2.6301	;	Crystal Structure of the RNA chaperone Hfq from Herbaspirillum seropedicae SMR1
1QUV	;	2.5	;	CRYSTAL STRUCTURE OF THE RNA DIRECTED RNA POLYMERASE OF HEPATITIS C VIRUS
1SA9	;	2.86	;	Crystal Structure of the RNA octamer GGCGAGCC
1SAQ	;	2.7	;	Crystal Structure of the RNA octamer GIC(GA)GCC
5W33	;	2.85	;	Crystal structure of the RNA polymerase domain (RPD) of Mycobacterium tuberculosis primase DnaG
5W35	;	3.31	;	Crystal structure of the RNA polymerase domain (RPD) of Mycobacterium tuberculosis primase DnaG in complex with a double-stranded DNA oligomer with a 1-nucleotide overhang
5W36	;	2.46	;	Crystal structure of the RNA polymerase domain (RPD) of Mycobacterium tuberculosis primase DnaG in complex with a double-stranded DNA oligomer with a 6-nucleotide overhang
5W34	;	2.95	;	Crystal structure of the RNA polymerase domain (RPD) of Mycobacterium tuberculosis primase DnaG in complex with double-stranded DNA GACCGGAAGTGG
1IW7	;	2.6	;	Crystal structure of the RNA polymerase holoenzyme from Thermus thermophilus at 2.6A resolution
2RF4	;	3.1	;	Crystal structure of the RNA Polymerase I subcomplex A14/43
5IM0	;	1.7	;	Crystal structure of the RNA recognition motif of mRNA decay regulator AUF1
3NS5	;	2.598	;	Crystal structure of the RNA recognition motif of yeast eIF3b residues 76-161
2A2E	;	3.85	;	Crystal structure of the RNA subunit of Ribonuclease P. Bacterial A-type.
1I9S	;	1.65	;	CRYSTAL STRUCTURE OF THE RNA TRIPHOSPHATASE DOMAIN OF MOUSE MRNA CAPPING ENZYME
1FO1	;	2.9	;	CRYSTAL STRUCTURE OF THE RNA-BINDING DOMAIN OF THE MRNA EXPORT FACTOR TAP
1FT8	;	3.15	;	CRYSTAL STRUCTURE OF THE RNA-BINDING DOMAIN OF THE MRNA EXPORT FACTOR TAP
1A62	;	1.55	;	CRYSTAL STRUCTURE OF THE RNA-BINDING DOMAIN OF THE TRANSCRIPTIONAL TERMINATOR PROTEIN RHO
5BZU	;	2.501	;	Crystal structure of the RNA-binding domain of yeast Puf5p bound to AAT2 RNA
5BZ5	;	2.8	;	Crystal structure of the RNA-binding domain of yeast Puf5p bound to AMN1 RNA
5BZ1	;	2.15	;	Crystal structure of the RNA-binding domain of yeast Puf5p bound to MFA2 RNA
5BYM	;	2.708	;	Crystal structure of the RNA-binding domain of yeast Puf5p bound to SMX2 RNA
5BZV	;	2.354	;	Crystal structure of the RNA-binding domain of yeast Puf5p bound to SMX2 RNA
1XR5	;	2.8	;	Crystal Structure of the RNA-dependent RNA Polymerase 3D from human rhinovirus serotype 14
1TP7	;	2.4	;	Crystal Structure of the RNA-dependent RNA Polymerase from Human Rhinovirus 16
5I61	;	2.4	;	Crystal structure of the RNA-dependent RNA polymerase of a human picorbirnavirus
1CSJ	;	2.8	;	CRYSTAL STRUCTURE OF THE RNA-DEPENDENT RNA POLYMERASE OF HEPATITIS C VIRUS
5DTU	;	3.199	;	Crystal structure of the RNA-helicase Prp28 from Chaetomium thermophilum bound to ADP
5D0U	;	2.919	;	Crystal structure of the RNA-helicase Prp43 from Chaetomium thermophilum bound to ADP
404D	;	2.5	;	CRYSTAL STRUCTURE OF THE RNA/DNA HYBRID R(GAAGAGAAGC). D(GCTTCTCTTC)
4EBA	;	3.3	;	Crystal structure of the Rna14-Rna15 complex
1J1G	;	1.6	;	Crystal structure of the RNase MC1 mutant N71S in complex with 5'-GMP
1J1F	;	1.6	;	Crystal structure of the RNase MC1 mutant N71T in complex with 5'-GMP
1V9H	;	2.0	;	Crystal structure of the RNase MC1 mutant Y101A in complex with 5'-UMP
1VCZ	;	1.8	;	Crystal structure of the RNase NT in complex with 5'-GMP
1TTO	;	2.1	;	Crystal structure of the Rnase T1 variant R2
5TRB	;	1.8	;	Crystal structure of the RNF20 RING domain
3NG2	;	1.8	;	Crystal structure of the RNF4 ring domain dimer
1YJE	;	2.4	;	Crystal structure of the rNGFI-B ligand-binding domain
6POK	;	1.796	;	Crystal structure of the Robo3 FN2-3 domains
4F0F	;	1.8	;	Crystal Structure of the Roco4 Kinase Domain bound to AppCp from D. discoideum
4F0G	;	2.0	;	Crystal Structure of the Roco4 Kinase Domain from D. discoideum
4F1T	;	2.3	;	Crystal Structure of the Roco4 Kinase Domain from D. discoideum bound to the ROCK Inhibitor H1152
1HCI	;	2.8	;	CRYSTAL STRUCTURE OF THE ROD DOMAIN OF ALPHA-ACTININ
1Z05	;	2.0	;	Crystal structure of the ROK family transcriptional regulator, homolog of E.coli MLC protein.
4DO2	;	1.401	;	Crystal Structure of the Rop protein mutant D30P/A31G at resolution 1.4 resolution.
3X1O	;	2.201	;	Crystal structure of the ROQ domain of human Roquin
4QIL	;	2.9	;	Crystal structure of the ROQ domain of human Roquin in complex with the Hmg19 stem-loop RNA
4QIK	;	1.9	;	Crystal structure of the ROQ domain of human Roquin in complex with the TNF23 RNA duplex
4YWQ	;	1.7	;	Crystal structure of the ROQ domain of human Roquin-1
4Z30	;	2.71	;	Crystal structure of the ROQ domain of human Roquin-2
4ZLC	;	2.7	;	Crystal structure of the ROQ domain of human Roquin-2
4ULW	;	1.91	;	Crystal structure of the ROQ-domain of human ROQUIN1
4YPQ	;	2.32	;	Crystal structure of the ROR(gamma)t ligand binding domain in complex with 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)benzoic acid
3KZ4	;	3.8	;	Crystal Structure of the Rotavirus Double Layered Particle
2AEN	;	1.604	;	Crystal structure of the rotavirus strain DS-1 VP8* core
3O4Q	;	1.55	;	Crystal structure of the Rous Associated Virus Integrase catalytic domain A182T in citrate buffer pH 6.2
3O4N	;	1.8	;	Crystal structure of the Rous Associated Virus Integrase catalytic domain in MES buffer pH 6.0
5EJK	;	3.8	;	Crystal structure of the Rous sarcoma virus intasome
5KZA	;	1.86	;	Crystal structure of the Rous sarcoma virus matrix protein (aa 2-102). Space group I41
5KZB	;	3.2	;	Crystal structure of the Rous sarcoma virus matrix protein (aa 2-102). Space group I4122
5KZ9	;	2.85	;	Crystal structure of the Rous sarcoma virus matrix protein.
3RG1	;	2.91	;	Crystal structure of the RP105/MD-1 complex
3BH7	;	1.9	;	Crystal structure of the RP2-Arl3 complex bound to GDP-AlF4
3BH6	;	2.6	;	Crystal structure of the RP2-Arl3 complex bound to GppNHp
3DCA	;	3.35	;	Crystal structure of the RPA0582- protein of unknown function from Rhodopseudomonas palustris- a structural genomics target
8AA9	;	1.8	;	Crystal structure of the Rpa1 AROD-OB-1 domains
3E23	;	1.6	;	Crystal structure of the RPA2492 protein in complex with SAM from Rhodopseudomonas palustris, Northeast Structural Genomics Consortium Target RpR299
5A53	;	2.401	;	Crystal Structure of the Rpf2-Rrs1 complex
4QAM	;	1.83	;	Crystal Structure of the RPGR RCC1-like domain in complex with the RPGR-interacting domain of RPGRIP1
3OPW	;	2.5	;	Crystal Structure of the Rph1 catalytic core
3OPT	;	2.2	;	Crystal structure of the Rph1 catalytic core with a-ketoglutarate
5V1Z	;	2.0	;	Crystal structure of the RPN13 PRU-RPN2 (932-953)-ubiquitin complex
4OCL	;	2.4	;	Crystal Structure of the Rpn8-Rpn11 MPN domain heterodimer, crystal form Ia
4OCM	;	1.99	;	Crystal Structure of the Rpn8-Rpn11 MPN domain heterodimer, crystal form Ib
4OCN	;	2.25	;	Crystal Structure of the Rpn8-Rpn11 MPN domain heterodimer, crystal form II
2BF0	;	2.3	;	crystal structure of the rpr of pcf11
4C6T	;	2.65	;	Crystal structure of the RPS4 and RRS1 TIR domain heterodimer
1CSL	;	1.6	;	CRYSTAL STRUCTURE OF THE RRE HIGH AFFINITY SITE
5MKC	;	2.04	;	Crystal structure of the RrgA Jo.In complex
3MDF	;	1.85	;	Crystal structure of the RRM domain of Cyclophilin 33
3LPY	;	2.0	;	Crystal structure of the RRM domain of CyP33
3S8S	;	1.3	;	Crystal structure of the RRM domain of human SETD1A
8ILY	;	1.7	;	Crystal structure of the RRM domain of human SETD1A
8ILZ	;	1.77	;	Crystal structure of the RRM domain of human SETD1B
2XSF	;	1.7	;	Crystal structure of the RRM domain of mouse Deleted in azoospermia- like
2XS5	;	1.6	;	Crystal structure of the RRM domain of mouse Deleted in azoospermia- like in complex with Mvh RNA, UGUUC
2XS7	;	1.45	;	Crystal structure of the RRM domain of mouse Deleted in azoospermia- like in complex with Sycp3 RNA, UUGUUU
2XS2	;	1.35	;	Crystal structure of the RRM domain of mouse Deleted in azoospermia-like in complex with RNA, UUGUUCUU
4I67	;	2.33	;	Crystal structure of the RRM domain of RNA helicase HERA from T. thermophilus in complex with GGGC RNA
6NX5	;	1.554	;	Crystal structure of the RRM domain of S. pombe Puf1 in the P21 space group
6NWW	;	2.06	;	Crystal structure of the RRM domain of S. pombe Puf1 in the P212121 space group
6KOR	;	2.602	;	Crystal structure of the RRM domain of SYNCRIP
3CTR	;	2.1	;	Crystal structure of the RRM-domain of the poly(A)-specific ribonuclease PARN bound to m7GTP
6FQ1	;	1.31	;	Crystal structure of the RRM12 domain of IMP3
5C0Y	;	2.1	;	Crystal structure of the Rrp6 catalytic domain bound to poly(U) RNA
5WXL	;	1.9	;	Crystal structure of the Rrs1 and Rpf2 complex
2R0S	;	1.8	;	Crystal Structure of the Rsc4 tandem bromodomain
5TOJ	;	3.3	;	Crystal structure of the RSV F glycoprotein in complex with the neutralizing single-domain antibody F-VHH-4
5TOK	;	3.8	;	Crystal structure of the RSV F glycoprotein in complex with the neutralizing single-domain antibody F-VHH-L66
5TP3	;	1.874	;	Crystal structure of the RSV-neutralizing single-domain antibody F-VHH-4
5DDZ	;	1.5	;	Crystal structure of the RTA-c10-P2 complex
2EFW	;	2.5	;	Crystal structure of the RTP:nRB complex from Bacillus subtilis
5JTD	;	1.5	;	Crystal structure of the Ru(bpy)2PhenA functionalized P450 BM3 L407C heme domain mutant in complex with DMSO.
5JQ2	;	2.0	;	Crystal structure of the Ru(bpy)2PhenA functionalized P450 BM3 L407C heme domain mutant in complex with N-palmitoylglycine
4ADI	;	1.8	;	Crystal structure of the Rubella virus envelope glycoprotein E1 in post-fusion form (crystal form I)
4ADG	;	2.18	;	Crystal structure of the Rubella virus envelope Glycoprotein E1 in post-fusion form (crystal form II)
4ADJ	;	1.94	;	Crystal structure of the Rubella virus glycoprotein E1 in its post-fusion form crystallized in presence of 1mM of calcium acetate
4B3V	;	1.98	;	Crystal structure of the Rubella virus glycoprotein E1 in its post-fusion form crystallized in presence of 20mM of Calcium Acetate
4GIW	;	2.0	;	Crystal structure of the RUN domain of human NESCA
2DWK	;	2.0	;	Crystal structure of the RUN domain of mouse Rap2 interacting protein x
6MG7	;	2.91	;	Crystal structure of the RV144 C1-C2 specific antibody CH54 Fab in complex with HIV-1 CLADE A/E GP120 and M48U1
6OED	;	2.461	;	CRYSTAL STRUCTURE OF THE RV144 C1-C2 SPECIFIC ANTIBODY CH55 FAB
6OFI	;	3.85	;	CRYSTAL STRUCTURE OF the RV144 C1-C2 SPECIFIC ANTIBODY CH55 FAB IN COMPLEX WITH HIV-1 CLADE A/E GP120
5I8U	;	2.0	;	Crystal Structure of the RV1700 (MT ADPRASE) E142Q mutant
6MFP	;	3.0	;	Crystal Structure of the RV305 C1-C2 specific ADCC potent antibody DH677.3 Fab in complex with HIV-1 clade A/E gp120 and M48U1
7E2K	;	2.041	;	Crystal structure of the RWD domain of human GCN2 - 1
7E2M	;	2.35	;	Crystal structure of the RWD domain of human GCN2 - 2
1QCP	;	1.8	;	CRYSTAL STRUCTURE OF THE RWJ-51084 BOVINE PANCREATIC BETA-TRYPSIN AT 1.8 A
3RQR	;	2.16	;	Crystal structure of the RYR domain of the rabbit ryanodine receptor
3EMP	;	4.0	;	Crystal Structure of the S-acetanilide modified form of C165S AhpC
4GKG	;	1.695	;	Crystal structure of the S-Helix Linker
4UIC	;	2.9	;	Crystal structure of the S-layer protein rSbsC(31-844)
4UID	;	2.8	;	Crystal structure of the S-layer protein SbsC domains 4 and 5
4UIE	;	3.1	;	Crystal structure of the S-layer protein SbsC, domains 7, 8 and 9
5EGP	;	1.5	;	Crystal structure of the S-methyltransferase TmtA
3EU0	;	2.7	;	Crystal structure of the S-nitrosylated Cys215 of PTP1B
3MFB	;	2.2	;	Crystal Structure of the S-type Pyocin domain of ECA1669 protein from Erwinia carotovora, Northeast Structural Genomics Consortium Target EwR82C
3ROF	;	1.03	;	Crystal Structure of the S. aureus Protein Tyrosine Phosphatase PtpA
5OQQ	;	2.79	;	Crystal structure of the S. cerevisiae condensin Ycg1-Brn1 subcomplex
5OQP	;	2.98	;	Crystal structure of the S. cerevisiae condensin Ycg1-Brn1 subcomplex bound to DNA (crystal form I)
5OQO	;	3.25	;	Crystal structure of the S. cerevisiae condensin Ycg1-Brn1 subcomplex bound to DNA (crystal form II)
5OQN	;	3.15	;	Crystal structure of the S. cerevisiae condensin Ycg1-Brn1 subcomplex bound to DNA (short kleisin loop)
1XTZ	;	2.1	;	Crystal structure of the S. cerevisiae D-ribose-5-phosphate isomerase: comparison with the archeal and bacterial enzymes
4A4Z	;	2.4	;	CRYSTAL STRUCTURE OF THE S. CEREVISIAE DEXH HELICASE SKI2 BOUND TO AMPPNP
2B7M	;	3.5	;	Crystal Structure of the S. cerevisiae Exocyst Component Exo70p
6P4X	;	3.59	;	Crystal Structure of the S. cerevisiae glucokinase, Glk1
5EMX	;	1.399	;	Crystal structure of the S. cerevisiae Rtf1 histone modification domain mutant R124A R126A R128A
5E8B	;	1.62	;	Crystal structure of the S. cerevisiae Rtf1 histone modification domain mutant R126A
3TE6	;	2.8001	;	Crystal Structure of the S. cerevisiae Sir3 AAA+ domain
4A4K	;	3.25	;	Crystal structure of the S. cerevisiae Ski2 insertion domain
4BUJ	;	3.7	;	Crystal structure of the S. cerevisiae Ski2-3-8 complex
4ZKD	;	2.181	;	Crystal structure of the S. cerevisiae Ski7 GTPase-like domain, bound to GDP and inorganic phosphate.
4ZKE	;	2.251	;	Crystal structure of the S. cerevisiae Ski7 GTPase-like domain, bound to GTP.
1QVV	;	2.35	;	Crystal structure of the S. cerevisiae YDR533c protein
1QVW	;	1.9	;	Crystal structure of the S. cerevisiae YDR533c protein
1QVZ	;	1.85	;	Crystal structure of the S. cerevisiae YDR533c protein
2WDO	;	1.56	;	Crystal structure of the S. coelicolor AcpS in complex with acetyl- CoA at 1.5 A
5OQR	;	2.61	;	Crystal structure of the S. pombe condensin Cnd3-Cnd2 subcomplex
3CB5	;	2.05	;	Crystal Structure of the S. pombe Peptidase Homology Domain of FACT complex subunit Spt16 (form A)
3CB6	;	1.84	;	Crystal Structure of the S. pombe Peptidase Homology Domain of FACT complex subunit Spt16 (form B)
2P51	;	1.4	;	Crystal structure of the S. pombe Pop2p deadenylation subunit
3FQG	;	2.0	;	Crystal Structure of the S. pombe Rai1
3FQD	;	2.2	;	Crystal Structure of the S. pombe Rat1-Rai1 Complex
3L7Z	;	2.41	;	Crystal structure of the S. solfataricus archaeal exosome
6IVA	;	4.403	;	Crystal structure of the S. typhimurium oxaloacetate decarboxylase beta-gamma sub-complex
5TGA	;	3.3	;	Crystal structure of the S.cerevisiae 80S ribosome in complex with the A-site bound aminoacyl-tRNA analog ACCA-Pro
5TGM	;	3.5	;	Crystal structure of the S.cerevisiae 80S ribosome in complex with the A-site bound aminoacyl-tRNA analog ACCA-Pro
5LYB	;	3.25	;	Crystal structure of the S.cerevisiae 80S ribosome in complex with the A-site bound aminoacyl-tRNA analog ACCPmn
1GPP	;	1.35	;	Crystal structure of the S.cerevisiae Homing Endonuclease PI-SceI Domain I
7QY5	;	2.77	;	Crystal structure of the S.pombe Ars2-Red1 complex.
5MG8	;	2.75	;	Crystal structure of the S.pombe Smc5/6 hinge domain
7MXJ	;	1.92	;	Crystal structure of the S/T protein kinase PknG from Corynebacterium glutamicum (residues 130-433) in complex with AMP-PNP, isoform 1
7MXK	;	1.99	;	Crystal structure of the S/T protein kinase PknG from Corynebacterium glutamicum (residues 130-433) in complex with AMP-PNP, isoform 2
7MXB	;	2.2	;	Crystal structure of the S/T protein kinase PknG from Corynebacterium glutamicum in complex with AMP-PNP
4Y0X	;	1.74	;	Crystal structure of the S/T protein kinase PknG from Mycobacterium tuberculosis in complex with ADP
4Y12	;	1.9	;	Crystal structure of the S/T protein kinase PknG from Mycobacterium tuberculosis in complex with AGS
1SMX	;	1.8	;	Crystal structure of the S1 domain of RNase E from E. coli (native)
1SN8	;	2.0	;	Crystal structure of the S1 domain of RNase E from E. coli (Pb derivative)
6JHY	;	2.5	;	Crystal Structure of the S1 subunit N-terminal domain from DcCoV UAE-HKU23 spike protein
3I08	;	3.2	;	Crystal structure of the S1-cleaved Notch1 Negative Regulatory Region (NRR)
7CD2	;	2.7	;	Crystal structure of the S103F mutant of Bacillus subtilis (natto) YabJ protein.
7CD3	;	2.1	;	Crystal structure of the S103F mutant of Bacillus subtilis (natto) YabJ protein.
7CD4	;	2.1	;	Crystal structure of the S103F mutant of Bacillus subtilis (natto) YabJ protein.
4LYD	;	2.26	;	Crystal structure of the S105A mutant of a C-C hydrolase, DxnB2 from Sphingomonas wittichii RW1
4LYE	;	2.33	;	Crystal structure of the S105A mutant of a C-C hydrolase, DxnB2 from Sphingomonas wittichii RW1, in complex with substrate HOPDA
4LXH	;	2.02	;	Crystal Structure of the S105A mutant of a carbon-carbon bond hydrolase, DxnB2 from Sphingomonas wittichii RW1, in complex with 3-Cl HOPDA
4LXI	;	2.17	;	Crystal Structure of the S105A mutant of a carbon-carbon bond hydrolase, DxnB2 from Sphingomonas wittichii RW1, in complex with 5,8-diF HOPDA
2EZ0	;	3.54	;	Crystal structure of the S107A/E148Q/Y445A mutant of EcClC, in complex with a FaB fragment
4INJ	;	2.4	;	Crystal structure of the S111A mutant of member of MccF clade from Listeria monocytogenes EGD-e with product
2RHW	;	1.57	;	Crystal Structure of the S112A mutant of a C-C hydrolase, BphD from Burkholderia xenovorans LB400, in complex with 3,10-Di-Fluoro HOPDA
2RHT	;	1.7	;	Crystal Structure of the S112A mutant of a C-C hydrolase, BphD from Burkholderia xenovorans LB400, in complex with 3-Cl HOPDA
2PUH	;	1.82	;	Crystal Structure of the S112A mutant of a C-C hydrolase, BphD from Burkholderia xenovorans LB400, in complex with its substrate HOPDA
3T5M	;	1.749	;	Crystal structure of the S112A mutant of mycrocine immunity protein (MccF) with AMP
2PUJ	;	1.57	;	Crystal Structure of the S112A/H265A double mutant of a C-C hydrolase, BphD from Burkholderia xenovorans LB400, in complex with its substrate HOPDA
3V1L	;	2.11	;	Crystal Structure of the S112A/H265Q mutant of a C-C hydrolase, BphD from Burkholderia xenovorans LB400
3V1M	;	1.92	;	Crystal Structure of the S112A/H265Q mutant of a C-C hydrolase, BphD from Burkholderia xenovorans LB400, after exposure to its substrate HOPDA
1O9O	;	2.3	;	Crystal structure of the S131A mutant of Malonamidase E2 complexed with malonamate from Bradyrhizobium japonicum
1O9P	;	1.8	;	Crystal structure of the S131A mutant of Malonamidase E2 complexed with malonate from Bradyrhizobium japonicum
1OBL	;	2.0	;	crystal structure of the S133A mutant of Malonamidase E2 complexed with malonate from Bradyrhizobium japonicum
1LSO	;	2.6	;	Crystal Structure of the S137A mutant of L-3-Hydroxyacyl-CoA Dehydrogenase in Complex with NAD
1M76	;	2.15	;	Crystal Structure of the S137C Mutant of L-3-HYDROXYACYL-COA Dehydrogenase in Complex with NAD and Acetoacetyl-COA
2O8M	;	2.0	;	Crystal structure of the S139A mutant of Hepatitis C Virus NS3/4A protease
3F9E	;	2.5	;	Crystal Structure of the S139A mutant of SARS-Coronovirus 3C-like Protease
4AL6	;	2.63	;	Crystal structure of the S148ACsy4-crRNA complex
1O9Q	;	1.8	;	Crystal structure of the S155C mutant of Malonamidase E2 from Bradyrhizobium japonicum
1OCH	;	1.8	;	Crystal structure of the S155C mutant of malonamidase E2 from Bradyrhizobium japonicum
5C5X	;	2.6	;	CRYSTAL STRUCTURE OF THE S156E MUTANT OF HUMAN AQUAPORIN 5
3IFW	;	2.4	;	Crystal structure of the S18Y variant of ubiquitin carboxy terminal hydrolase L1 bound to ubiquitin vinylmethylester.
4JKJ	;	2.151	;	Crystal Structure of the S18Y Variant of Ubiquitin Carboxy-terminal Hydrolase L1
4EC5	;	2.197	;	Crystal structure of the S210C (dimer) mutant from the N-terminal domain of the secretin XcpQ from Pseudomonas aeruginosa
2Z53	;	1.29	;	Crystal structure of the S211A mutant of the ribosome inactivating protein PDL4 from P. dioica leaves
3K6N	;	2.0	;	Crystal structure of the S225E mutant Kir3.1 cytoplasmic pore domain
3B3V	;	1.22	;	Crystal structure of the S228A mutant of the aminopeptidase from Vibrio proteolyticus
3B3W	;	1.75	;	Crystal structure of the S228A mutant of the aminopeptidase from Vibrio proteolyticus in complex with leucine
3B7I	;	1.75	;	Crystal structure of the S228A mutant of the aminopeptidase from Vibrio proteolyticus in complex with leucine phosphonic acid
8ORL	;	1.43	;	Crystal structure of the S23226G missense variant of titin domain Fn3-56
3U1B	;	1.604	;	Crystal structure of the S238R mutant of mycrocine immunity protein (MccF) with AMP
2OIP	;	2.8	;	Crystal Structure of the S290G Active Site Mutant of TS-DHFR from Cryptosporidium hominis
5SYY	;	1.85	;	Crystal structure of the S324G variant of catalase-peroxidase from B. pseudomallei
5KSN	;	1.87	;	Crystal structure of the S324G variant of catalase-peroxidase from B. pseudomallei with INH bound
5SXT	;	1.9	;	Crystal structure of the S324T variant of Burkholderia pseudomallei KatG with isonicotinic acid hydrazide bound
5ZWT	;	2.0	;	Crystal structure of the S37A mutant of apo-acyl carrier protein from Leishmania major
4OST	;	1.996	;	Crystal structure of the S505C mutant of TAL effector dHax3
4OSW	;	2.302	;	Crystal structure of the S505E mutant of TAL effector dHax3
4OSM	;	2.454	;	Crystal structure of the S505H mutant of TAL effector dHax3
4OSR	;	1.944	;	Crystal structure of the S505K mutant of TAL effector dHax3
4OT3	;	1.944	;	Crystal structure of the S505L mutant of TAL effector dHax3
4OSV	;	1.996	;	Crystal structure of the S505M mutant of TAL effector dHax3
4OSZ	;	2.614	;	Crystal structure of the S505P mutant of TAL effector dHax3
4OSS	;	2.397	;	Crystal structure of the S505Q mutant of TAL effector dHax3
4OSQ	;	2.256	;	Crystal structure of the S505R mutant of TAL effector dHax3
4OT0	;	2.491	;	Crystal structure of the S505T mutant of TAL effector dHax3
4OTO	;	2.588	;	Crystal structure of the S505W mutant of TAL effector dHax3
2APB	;	1.8	;	Crystal Structure of the S54N variant of murine T cell receptor Vbeta 8.2 domain
2H3W	;	2.1	;	Crystal structure of the S554A/M564G mutant of murine carnitine acetyltransferase in complex with hexanoylcarnitine and CoA
5JOC	;	1.75	;	Crystal structure of the S61A mutant of AmpC BER
1O99	;	2.65	;	CRYSTAL STRUCTURE OF THE S62A MUTANT OF PHOSPHOGLYCERATE MUTASE FROM BACILLUS STEAROTHERMOPHILUS COMPLEXED WITH 2-PHOSPHOGLYCERATE
6JGI	;	0.85	;	Crystal structure of the S65T/F99S/M153T/V163A variant of GFP at 0.85 A
6KL1	;	0.851	;	Crystal structure of the S65T/F99S/M153T/V163A variant of non-deuterated GFP at pD 8.5
6KL0	;	0.798	;	Crystal structure of the S65T/F99S/M153T/V163A variant of perdeuterated GFP at pD 7.0
6KKZ	;	0.9	;	Crystal structure of the S65T/F99S/M153T/V163A variant of perdeuterated GFP at pD 8.5
2OAX	;	2.29	;	Crystal structure of the S810L mutant mineralocorticoid receptor associated with SC9420
3VBK	;	2.2	;	Crystal Structure of the S84A mutant of AntD, an N-acyltransferase from Bacillus cereus in complex with dTDP-4-amino-4,6-dideoxyglucose and Coenzyme A
3VBL	;	1.9	;	Crystal Structure of the S84C mutant of AntD, an N-acyltransferase from Bacillus cereus in complex with dTDP-4-amino-4,6-dideoxyglucose and Coenzyme A
3VBM	;	1.9	;	Crystal Structure of the S84T mutant of AntD, an N-acyltransferase from Bacillus cereus in complex with dTDP and Coenzyme A
5ITZ	;	2.2	;	Crystal structure of the SAC domain of CPAP in a complex with Tubulin and Darpin
2XIW	;	1.5	;	Crystal structure of the Sac7d-derived IgG1-binder C3-C24S
2VK1	;	1.71	;	Crystal structure of the Saccharomyces cerevisiae pyruvate decarboxylase variant D28A in complex with its substrate
2VK8	;	1.42	;	Crystal structure of the Saccharomyces cerevisiae pyruvate decarboxylase variant E477Q in complex with its substrate
2W93	;	1.6	;	Crystal structure of the Saccharomyces cerevisiae pyruvate decarboxylase variant E477Q in complex with the surrogate pyruvamide
5C2Y	;	2.6	;	Crystal structure of the Saccharomyces cerevisiae Rtr1 (regulator of transcription)
5U1T	;	2.6	;	Crystal structure of the Saccharomyces cerevisiae separase-securin complex at 2.6 angstrom resolution
5U1S	;	3.002	;	Crystal structure of the Saccharomyces cerevisiae separase-securin complex at 3.0 angstrom resolution
4ZOV	;	2.0	;	Crystal structure of the Saccharomyces cerevisiae Sqt1
4ZOX	;	1.6	;	Crystal structure of the Saccharomyces cerevisiae Sqt1 bound to the N-terminus of the ribosomal protein L10
1Q99	;	2.11	;	Crystal structure of the Saccharomyces cerevisiae SR protein kinsae, Sky1p, complexed with the non-hydrolyzable ATP analogue, AMP-PNP
1AYZ	;	2.6	;	CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE UBIQUITIN-CONJUGATING ENZYME RAD6 (UBC2) AT 2.6A RESOLUTION
3MGJ	;	2.703	;	Crystal structure of the Saccharop_dh_N domain of MJ1480 protein from Methanococcus jannaschii. Northeast Structural Genomics Consortium Target MjR83a.
7PVP	;	1.8	;	Crystal structure of the SAKe6BC designer protein
7Q58	;	1.3	;	Crystal structure of the SAKe6BR designer protein
4FAH	;	2.5	;	Crystal Structure of the Salicylate 1,2-dioxygenase from Pseudoaminobacter salicylatoxidans A85H mutant
4FBF	;	2.7	;	Crystal Structure of the Salicylate 1,2-dioxygenase from Pseudoaminobacter salicylatoxidans W104Y mutant
4FAG	;	2.5	;	Crystal Structure of the Salicylate 1,2-dioxygenase from Pseudoaminobacter salicylatoxidans W104Y mutant in complex with gentisate
3SY2	;	3.27	;	Crystal structure of the Salmonella E3 ubiquitin ligase SopA in complex with the human E2 UbcH7
7YM5	;	3.45	;	Crystal structure of the Salmonella effector SseK1
7YM7	;	2.2	;	Crystal structure of the Salmonella effector SseK1 F187A mutant
6EYR	;	2.2	;	Crystal structure of the salmonella effector SseK3
6EYT	;	2.21	;	Crystal structure of the Salmonella effector SseK3 in complex with UDP-GlcNAc and Manganese
2FM8	;	2.2	;	Crystal Structure of the Salmonella Secretion Chaperone InvB in Complex with SipA
2GWM	;	1.5	;	Crystal structure of the Salmonella SpvB ATR Domain
2GWL	;	1.9	;	Crystal structure of the Salmonella SpvB ATR Domain in complex with NADH
3QPT	;	2.4	;	Crystal structure of the Salmonella transcriptional regulator SlyA
3Q5F	;	2.96	;	Crystal structure of the Salmonella transcriptional regulator SlyA in complex with DNA
3NZZ	;	1.65	;	Crystal Structure of the Salmonella Type III Secretion System Tip Protein SipD
3O00	;	1.85	;	Crystal Structure of the Salmonella Type III Secretion System Tip Protein SipD-C244S
3GOA	;	1.7	;	Crystal structure of the Salmonella typhimurium FadA 3-ketoacyl-CoA thiolase
1G4W	;	2.2	;	CRYSTAL STRUCTURE OF THE SALMONELLA TYROSINE PHOSPHATASE AND GTPASE ACTIVATING PROTEIN SPTP
1G4U	;	2.3	;	CRYSTAL STRUCTURE OF THE SALMONELLA TYROSINE PHOSPHATASE AND GTPASE ACTIVATING PROTEIN SPTP BOUND TO RAC1
2IGT	;	1.89	;	Crystal Structure of the SAM Dependent Methyltransferase from Agrobacterium tumefaciens
6FXF	;	2.05	;	Crystal structure of the SAM domain of murine SLy1
3H2B	;	2.0	;	Crystal structure of the SAM-dependent methyltransferase cg3271 from Corynebacterium glutamicum in complex with S-adenosyl-L-homocysteine and pyrophosphate. Northeast Structural Genomics Consortium Target CgR113A
1WZN	;	1.9	;	Crystal Structure of the SAM-dependent methyltransferase from Pyrococcus horikoshii OT3
2R6Z	;	1.8	;	Crystal structure of the SAM-dependent methyltransferase NGO1261 from Neisseria gonorrhoeae, Northeast Structural Genomics Consortium Target NgR48
2YDH	;	2.9	;	Crystal structure of the SAM-I riboswitch A94G U34 G18U G19U variant in complex with SAM
6YMJ	;	2.04	;	Crystal structure of the SAM-SAH riboswitch with adenosine.
6YMK	;	2.03	;	Crystal structure of the SAM-SAH riboswitch with AMP
6YMI	;	2.5	;	Crystal structure of the SAM-SAH riboswitch with AMP.
6YML	;	2.17	;	Crystal structure of the SAM-SAH riboswitch with decarboxylated SAH
6YL5	;	1.7	;	Crystal structure of the SAM-SAH riboswitch with SAH
6YLB	;	2.12	;	Crystal structure of the SAM-SAH riboswitch with SAM
6YMM	;	2.2	;	Crystal structure of the SAM-SAH riboswitch with SAM from space group P312
2E0Y	;	2.02	;	Crystal structure of the samarium derivative of mature gamma-glutamyltranspeptidase from Escherichia coli
6LUJ	;	1.12	;	Crystal structure of the SAMD1 SAM domain
6LUK	;	2.054	;	Crystal structure of the SAMD1 SAM domain in another crystal form
6LUI	;	1.781	;	Crystal structure of the SAMD1 WH domain and DNA complex
1OQJ	;	1.55	;	Crystal structure of the SAND domain from glucocorticoid modulatory element binding protein-1 (GMEB1)
2X7Z	;	2.0	;	Crystal Structure of the SAP97 PDZ2 I342W C378A mutant protein domain
3RFI	;	1.9	;	Crystal structure of the saposin-like domain of plant aspartic protease from Solanum tuberosum
6O2U	;	1.8	;	Crystal structure of the SARAF luminal domain
6O2W	;	2.101	;	Crystal structure of the SARAF luminal domain Cys-lock mutant dimer
6O2V	;	1.58	;	Crystal structure of the SARAF luminal domain Cys-lock mutant monomer
3DVZ	;	1.0	;	Crystal Structure of the Sarcin/Ricin Domain from E. coli 23 S rRNA
480D	;	1.5	;	CRYSTAL STRUCTURE OF THE SARCIN/RICIN DOMAIN FROM E. COLI 23 S RRNA
483D	;	1.11	;	CRYSTAL STRUCTURE OF THE SARCIN/RICIN DOMAIN FROM E. COLI 23 S RRNA
3DW4	;	0.97	;	Crystal Structure of the Sarcin/Ricin Domain from E. COLI 23 S rRNA, U2650-OCH3 modified
3DW6	;	1.0	;	Crystal Structure of the Sarcin/Ricin Domain from E. COLI 23 S rRNA, U2650-SECH3 modified
3DW7	;	1.0	;	Crystal Structure of the Sarcin/Ricin Domain from E. COLI 23 S rRNA, U2656-SeCH3 modified
3DW5	;	0.96	;	Crystal Structure of the Sarcin/Ricin Domain from E. COLI 23S rRNA, U2656-OCH3 modified
1Q9A	;	1.04	;	Crystal structure of the sarcin/ricin domain from E.coli 23S rRNA at 1.04 resolution
2G9T	;	2.1	;	Crystal structure of the SARS coronavirus nsp10 at 2.1A
5C8U	;	3.401	;	Crystal structure of the SARS coronavirus nsp14-nsp10 complex
5C8T	;	3.2	;	Crystal structure of the SARS coronavirus nsp14-nsp10 complex with functional ligand SAM
5C8S	;	3.326	;	Crystal structure of the SARS coronavirus nsp14-nsp10 complex with functional ligands SAH and GpppA
2GIB	;	1.75	;	Crystal structure of the SARS coronavirus nucleocapsid protein dimerization domain
7LFU	;	2.29	;	Crystal structure of the SARS CoV-1 Papain-like protease in complex with peptide inhibitor VIR250
7LFV	;	2.23	;	Crystal structure of the SARS CoV-1 Papain-like protease in complex with peptide inhibitor VIR251
6WUU	;	2.79	;	Crystal structure of the SARS CoV-2 Papain-like protease in complex with peptide inhibitor VIR250
6WX4	;	1.655	;	Crystal structure of the SARS CoV-2 Papain-like protease in complex with peptide inhibitor VIR251
1WNC	;	2.8	;	Crystal structure of the SARS-CoV Spike protein fusion core
6WAQ	;	2.2	;	Crystal structure of the SARS-CoV-1 RBD bound by the cross-reactive single-domain antibody SARS VHH-72
7N44	;	1.94	;	Crystal structure of the SARS-CoV-2 (2019-NCoV) main protease in complex with 5-(3-{3-chloro-5-[(5-methyl-1,3-thiazol-4-yl)methoxy]phenyl}-2-oxo-2H-[1,3'-bipyridin]-5-yl)pyrimidine-2,4(1H,3H)-dione (compound 13)
7L10	;	1.63	;	CRYSTAL STRUCTURE OF THE SARS-COV-2 (2019-NCOV) MAIN PROTEASE IN COMPLEX WITH COMPOUND 4
8FTL	;	2.08	;	Crystal structure of the SARS-CoV-2 (COVID-19) main protease (Mpro) in complex with inhibitor Jun89-3-C1
8DZB	;	1.85	;	Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with inhibitor 11
8DZC	;	2.2	;	Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with inhibitor 17
8D4P	;	2.04	;	Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with inhibitor Jun10-90-3-C1
8FIW	;	2.54	;	Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with inhibitor Jun10221
8FIV	;	2.51	;	Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with inhibitor Jun10541R
7RN0	;	2.25	;	Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with inhibitor Jun9-57-3R
7RN1	;	2.3	;	Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with inhibitor Jun9-62-2R
6XBG	;	1.45	;	Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with inhibitor UAW246
6XBH	;	1.6	;	Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with inhibitor UAW247
6XBI	;	1.7	;	Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with inhibitor UAW248
7LYH	;	1.9	;	Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with inhibitor UAWJ9-36-1
7LYI	;	1.9	;	Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with inhibitor UAWJ9-36-3
7CUU	;	1.68	;	Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with MG132
7KX5	;	2.6	;	Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with noncovalent inhibitor Jun8-76-3A
6XA4	;	1.65	;	Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with UAW241
6XFN	;	1.7	;	Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with UAW243
7CUT	;	1.82	;	Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with Z-VAD-FMK
8F4S	;	2.15	;	Crystal Structure of the SARS-CoV-2 2'-O-Methyltransferase with Compound 5a bound to the Cryptic Pocket of nsp16
8Q95	;	1.6	;	Crystal structure of the SARS-CoV-2 BA.1 RBD with neutralizing-VHHs Ma16B06 and Ma3F05
8Q94	;	2.5	;	Crystal structure of The SARS-COV-2 BA.2.75 RBD with neutralizing-VHHs Re32D03 and Ma3B12
7MC5	;	1.64	;	Crystal structure of the SARS-CoV-2 ExoN-nsp10 complex
7MC6	;	2.1	;	Crystal structure of the SARS-CoV-2 ExoN-nsp10 complex containing Mg2+ ion
7NIO	;	2.2	;	Crystal structure of the SARS-CoV-2 helicase APO form
6ZSL	;	1.94	;	Crystal structure of the SARS-CoV-2 helicase at 1.94 Angstrom resolution
7NN0	;	3.04	;	Crystal structure of the SARS-CoV-2 helicase in complex with AMP-PNP
7NNG	;	2.38	;	Crystal structure of the SARS-CoV-2 helicase in complex with Z2327226104
7NTT	;	1.743	;	Crystal structure of the SARS-CoV-2 Main Protease
7C6S	;	1.6	;	Crystal structure of the SARS-CoV-2 main protease complexed with Boceprevir
7P51	;	1.474	;	CRYSTAL STRUCTURE OF THE SARS-COV-2 MAIN PROTEASE COMPLEXED WITH FRAGMENT F01
7D1M	;	1.35	;	CRYSTAL STRUCTURE OF THE SARS-CoV-2 MAIN PROTEASE COMPLEXED WITH GC376
7NTQ	;	1.495	;	Crystal structure of the SARS-CoV-2 Main Protease complexed with N-(pyridin-3-ylmethyl)thioformamide
8JOP	;	2.7	;	Crystal structure of the SARS-CoV-2 main protease in complex with 11a
8I30	;	2.0	;	Crystal structure of the SARS-CoV-2 main protease in complex with 32j
7COM	;	2.25	;	Crystal structure of the SARS-CoV-2 main protease in complex with Boceprevir (space group P212121)
8HHT	;	1.95	;	Crystal structure of the SARS-CoV-2 main protease in complex with Hit-1
7CX9	;	1.73	;	Crystal structure of the SARS-CoV-2 main protease in complex with INZ-1
8HHU	;	2.258	;	Crystal structure of the SARS-CoV-2 main protease in complex with SY110
7C7P	;	1.74	;	Crystal structure of the SARS-CoV-2 main protease in complex with Telaprevir
7FAZ	;	2.1	;	Crystal structure of the SARS-CoV-2 main protease in complex with Y180
7C8B	;	2.2	;	Crystal structure of the SARS-CoV-2 main protease in complex with Z-VAD(OMe)-FMK
7JPY	;	1.6	;	Crystal structure of the SARS-CoV-2 main protease in its apo-form
7UU6	;	1.85	;	Crystal structure of the SARS-CoV-2 main protease in its apo-form
7UU7	;	2.49	;	Crystal structure of the SARS-CoV-2 main protease in its apo-form
7UU8	;	2.5	;	Crystal structure of the SARS-CoV-2 main protease in its apo-form
7UU9	;	2.47	;	Crystal structure of the SARS-CoV-2 main protease in its apo-form
7NTW	;	1.815	;	Crystal structure of the SARS-CoV-2 Main Protease with a Zinc ion coordinated in the active site
7NTS	;	1.477	;	Crystal structure of the SARS-CoV-2 Main Protease with oxidized C145
7ON5	;	1.25	;	Crystal structure of the SARS-CoV-2 neutralizing nanobody Re5D06
8SK5	;	2.011	;	Crystal structure of the SARS-CoV-2 neutralizing VHH 7A9 bound to the spike receptor binding domain
7WZO	;	2.64	;	Crystal structure of the SARS-CoV-2 nucleocapsid protein N-terminal domain in complex with Ubl1
7TOB	;	2.05	;	Crystal structure of the SARS-CoV-2 Omicron main protease (Mpro) in complex with inhibitor GC376
7MX9	;	2.6	;	Crystal structure of the SARS-CoV-2 ORF8 accessory protein
7YBG	;	1.9	;	Crystal structure of the SARS-CoV-2 papain-like protease (C111S mutant)
7D6H	;	1.6	;	Crystal structure of the SARS-CoV-2 papain-like protease (PLPro) C112S mutant
7E35	;	2.4	;	Crystal structure of the SARS-CoV-2 papain-like protease (PLPro) C112S mutant bound to compound S43
7CJD	;	2.501	;	Crystal structure of the SARS-CoV-2 PLpro C111S mutant
7CMD	;	2.59	;	Crystal structure of the SARS-CoV-2 PLpro with GRL0617
8Q7S	;	2.7	;	Crystal structure of the SARS-CoV-2 RBD (Wuhan) with neutralizing VHHs Ma6F06 and Re21H01
7VNB	;	2.27	;	Crystal structure of the SARS-CoV-2 RBD in complex with a human single domain antibody n3113
7CHB	;	2.4	;	Crystal structure of the SARS-CoV-2 RBD in complex with BD-236 Fab
7CHE	;	3.416	;	Crystal structure of the SARS-CoV-2 RBD in complex with BD-236 Fab and BD-368-2 Fab
7CHF	;	2.674	;	Crystal structure of the SARS-CoV-2 RBD in complex with BD-604 Fab and BD-368-2 Fab
7WBZ	;	2.42	;	Crystal structure of the SARS-Cov-2 RBD in complex with Fab 2303
7B3O	;	2.0	;	Crystal structure of the SARS-CoV-2 RBD in complex with STE90-C11 Fab
7QF0	;	2.3	;	Crystal structure of the SARS-CoV-2 RBD in complex with the human antibody CV2.2325
7QF1	;	2.8	;	Crystal structure of the SARS-CoV-2 RBD in complex with the human antibody CV2.6264
7QEZ	;	2.89	;	Crystal structure of the SARS-CoV-2 RBD in complex with the ultrapotent antibody CV2.1169 and CR3022
8Q93	;	3.1	;	Crystal structure of the SARS-COV-2 RBD with neutralizing-VHHs Re30H02 and Re21D01
7OLZ	;	1.75	;	Crystal structure of the SARS-CoV-2 RBD with neutralizing-VHHs Re5D06 and Re9F06
8SGU	;	1.95	;	Crystal structure of the SARS-CoV-2 receptor binding domain
7BNV	;	2.35	;	Crystal Structure of the SARS-CoV-2 Receptor Binding Domain in Complex with Antibody ION-300
7NP1	;	2.8	;	Crystal Structure of the SARS-CoV-2 Receptor Binding Domain in Complex with Antibody ION-360
6YLA	;	2.42	;	Crystal structure of the SARS-CoV-2 receptor binding domain in complex with CR3022 Fab
6YM0	;	4.36	;	Crystal structure of the SARS-CoV-2 receptor binding domain in complex with CR3022 Fab (crystal form 1)
8FHY	;	2.53	;	Crystal structure of the SARS-CoV-2 receptor binding domain in complex with neutralizing antibody WRAIR-5021
7N3I	;	2.03	;	Crystal structure of the SARS-CoV-2 receptor binding domain in complex with the human neutralizing antibody Fab fragment C098
7SPP	;	1.96	;	Crystal structure of the SARS-CoV-2 receptor binding domain in complex with VNAR 2C02
7SPO	;	1.92	;	Crystal structure of the SARS-CoV-2 receptor binding domain in complex with VNAR 3B4
7E86	;	2.9	;	Crystal structure of the SARS-CoV-2 S RBD in complex with BD-508 Fab
7E88	;	3.14	;	Crystal structure of the SARS-CoV-2 S RBD in complex with BD-515 Fab
7CH4	;	3.15	;	Crystal structure of the SARS-CoV-2 S RBD in complex with BD-604 Fab
7E7Y	;	2.41	;	Crystal structure of the SARS-CoV-2 S RBD in complex with BD-623 Fab
7CH5	;	2.7	;	Crystal structure of the SARS-CoV-2 S RBD in complex with BD-629 Fab
7CHC	;	2.71	;	Crystal structure of the SARS-CoV-2 S RBD in complex with BD-629 Fab and BD-368-2 Fab
8BEC	;	1.7	;	Crystal structure of the SARS-CoV-2 S RBD in complex with pT1375 scFV
8BG1	;	2.88	;	Crystal structure of the SARS-CoV-2 S RBD in complex with pT1511 scFV
8BG2	;	2.1	;	Crystal structure of the SARS-CoV-2 S RBD in complex with pT1580 scFV
8BG3	;	1.9	;	Crystal structure of the SARS-CoV-2 S RBD in complex with pT1610 scFV
8BG4	;	1.6	;	Crystal structure of the SARS-CoV-2 S RBD in complex with pT1611 scFV
8BG5	;	2.05	;	Crystal structure of the SARS-CoV-2 S RBD in complex with pT1631 scFV
7JVB	;	3.287	;	Crystal structure of the SARS-CoV-2 spike receptor-binding domain (RBD) with nanobody Nb20
7M8M	;	1.78	;	CRYSTAL STRUCTURE OF THE SARS-COV-2(2019-NCOV) MAIN PROTEASE IN COMPLEX WITH COMPOUND 11
7L12	;	1.8	;	CRYSTAL STRUCTURE OF THE SARS-COV-2(2019-NCOV) MAIN PROTEASE IN COMPLEX WITH COMPOUND 14
7M8Y	;	1.75	;	CRYSTAL STRUCTURE OF THE SARS-COV-2(2019-NCOV) MAIN PROTEASE IN COMPLEX WITH COMPOUND 15
7M8N	;	1.96	;	CRYSTAL STRUCTURE OF THE SARS-COV-2(2019-NCOV) MAIN PROTEASE IN COMPLEX WITH COMPOUND 16
7M8O	;	2.44	;	CRYSTAL STRUCTURE OF THE SARS-COV-2(2019-NCOV) MAIN PROTEASE IN COMPLEX WITH COMPOUND 19
7L13	;	2.17	;	CRYSTAL STRUCTURE OF THE SARS-COV-2(2019-NCOV) MAIN PROTEASE IN COMPLEX WITH COMPOUND 21
7M8P	;	2.23	;	CRYSTAL STRUCTURE OF THE SARS-COV-2(2019-NCOV) MAIN PROTEASE IN COMPLEX WITH COMPOUND 23
7M91	;	1.95	;	CRYSTAL STRUCTURE OF THE SARS-COV-2(2019-NCOV) MAIN PROTEASE IN COMPLEX WITH COMPOUND 25
7L14	;	1.8	;	CRYSTAL STRUCTURE OF THE SARS-COV-2(2019-NCOV) MAIN PROTEASE IN COMPLEX WITH COMPOUND 26
7M8Z	;	1.79	;	CRYSTAL STRUCTURE OF THE SARS-COV-2(2019-NCOV) MAIN PROTEASE IN COMPLEX WITH COMPOUND 29
7L11	;	1.8	;	CRYSTAL STRUCTURE OF THE SARS-COV-2(2019-NCOV) MAIN PROTEASE IN COMPLEX WITH COMPOUND 5
7M90	;	2.19	;	CRYSTAL STRUCTURE OF THE SARS-COV-2(2019-NCOV) MAIN PROTEASE IN COMPLEX WITH COMPOUND 50
7M8X	;	1.74	;	CRYSTAL STRUCTURE OF THE SARS-COV-2(2019-NCOV) MAIN PROTEASE IN COMPLEX WITH COMPOUND 6
8GQC	;	1.35	;	Crystal structure of the SARS-unique domain (SUD) of SARS-CoV-2 (1.35 angstrom resolution)
8HBL	;	1.58	;	Crystal structure of the SARS-unique domain (SUD) of SARS-CoV-2 (1.58 angstrom resolution)
4RO5	;	1.6	;	Crystal structure of the SAT domain from the non-reducing fungal polyketide synthase CazM
4RPM	;	1.4	;	Crystal structure of the SAT domain from the non-reducing fungal polyketide synthase CazM with bound hexanoyl
4BHX	;	1.95	;	Crystal structure of the SCAN domain from human paternally expressed gene 3 protein
3LHR	;	1.9	;	Crystal structure of the SCAN domain from Human ZNF24
4E6S	;	1.85	;	Crystal structure of the SCAN domain from mouse Zfp206
5HRJ	;	1.8	;	Crystal structure of the scavenger receptor cysteine-rich domain 5 (SRCR5) from porcine CD163
5JFB	;	2.0	;	Crystal structure of the scavenger receptor cysteine-rich domain 5 (SRCR5) from porcine CD163
5YD3	;	1.35	;	Crystal structure of the scFv antibody 4B08 with epitope peptide
5YD5	;	1.96	;	Crystal structure of the scFv antibody 4B08 with epitope peptide (mutation N3A)
5YD4	;	1.35	;	Crystal structure of the scFv antibody 4B08 with epitope peptide (mutation T6A)
5YY4	;	1.59	;	Crystal structure of the scFv antibody 4B08 with sulfated epitope peptide
4UT7	;	1.7	;	CRYSTAL STRUCTURE OF THE SCFV FRAGMENT OF THE BROADLY NEUTRALIZING HUMAN ANTIBODY EDE2 A11
6TNP	;	3.0	;	Crystal structure of the ScFv-5E5 in complex with a Tn glycopeptide
2HKM	;	1.5	;	Crystal structure of the Schiff base intermediate in the reductive half-reaction of aromatic amine dehydrogenase (AADH) with phenylethylamine.
2AGY	;	1.1	;	Crystal structure of the Schiff base intermediate in the reductive half-reaction of aromatic amine dehydrogenase (AADH) with tryptamine. Monoclinic form
2AGX	;	2.2	;	Crystal structure of the Schiff base intermediate in the reductive half-reaction of aromatic amine dehydrogenase (AADH) with tryptamine. P212121 form
3WEV	;	1.98	;	Crystal structure of the Schiff base intermediate of L-Lys epsilon-oxidase from Marinomonas mediterranea with L-Lys
7ZVS	;	3.07	;	Crystal structure of the Schistosoma mansoni VKR2 kinase domain in an active-like state (ADP-bound)
5WWL	;	2.4	;	Crystal structure of the Schizogenesis pombe kinetochore Mis12C subcomplex
5DR5	;	1.85	;	Crystal structure of the sclerostin-neutralizing Fab AbD09097
5J8Y	;	1.98	;	Crystal structure of the Scm-SAM and Sfmbt-SAM heterodimer
1R1G	;	1.72	;	Crystal Structure of the Scorpion Toxin BmBKTtx1
3THF	;	2.6951	;	Crystal structure of the SD2 domain from Drosophila Shroom
3KF9	;	2.6	;	Crystal structure of the SdCen/skMLCK complex
3MAL	;	1.95	;	Crystal structure of the SDF2-like protein from Arabidopsis thaliana
4ZQA	;	1.65	;	Crystal Structure of the Sds3 Dimerization Domain
2D4Q	;	2.3	;	Crystal structure of the Sec-PH domain of the human neurofibromatosis type 1 protein
4L9O	;	1.6	;	Crystal Structure of the Sec13-Sec16 blade-inserted complex from Pichia pastoris
7UR2	;	1.89	;	Crystal structure of the Sec14 domain of the RhoGEF Kalirin
1M2O	;	2.5	;	Crystal Structure of the Sec23-Sar1 complex
5M4Y	;	2.2	;	Crystal structure of the Sec3/Sso2 complex at 2.20 angstrom resolution
5LG4	;	2.9	;	Crystal structure of the Sec3/Sso2 complex at 2.9 angstrom resolution
4A4P	;	2.0	;	crystal structure of the Sec7 domain from human cytohesin1
1KU1	;	1.93	;	Crystal Structure of the Sec7 Domain of Yeast GEA2
1NKT	;	2.601	;	CRYSTAL STRUCTURE OF THE SECA PROTEIN TRANSLOCATION ATPASE FROM MYCOBACTERIUM TUBERCULOSIS COMPLEX WITH ADPBS
1NL3	;	2.8	;	CRYSTAL STRUCTURE OF THE SECA PROTEIN TRANSLOCATION ATPASE FROM MYCOBACTERIUM TUBERCULOSIS in APO FORM
1M6N	;	2.7	;	Crystal structure of the SecA translocation ATPase from Bacillus subtilis
4PZ5	;	1.96	;	Crystal structure of the second and third fibronectin F1 modules in complex with a fragment of BBK32 from Borrelia burgdorferi
2RKZ	;	2.0	;	Crystal structure of the second and third fibronectin f1 modules in complex with a fragment of staphylococcus aureus fnbpa-1
3CAL	;	1.7	;	Crystal structure of the second and third fibronectin F1 modules in complex with a fragment of staphylococcus aureus fnbpa-5
3ZRZ	;	1.7	;	Crystal structure of the second and third fibronectin F1 modules in complex with a fragment of Streptococcus pyogenes SfbI-5
5V6C	;	2.2	;	Crystal Structure of the Second beta-Prism Domain of RbmC from V. cholerae
5V6F	;	1.5	;	Crystal Structure of the Second beta-Prism Domain of RbmC from V. cholerae bound to Mannotriose
5V6K	;	1.8	;	Crystal Structure of the Second beta-Prism Domain of RbmC from V. cholerae Bound to N-acetylglucosaminyl-beta-1,2-mannose
3L46	;	1.482	;	Crystal structure of the second BRCT domain of epithelial cell transforming 2 (ECT2)
7L9G	;	1.36	;	Crystal structure of the second bromodomain (BD2) of human BRD2 bound to BI2536
7L6D	;	1.55	;	Crystal structure of the second bromodomain (BD2) of human BRD2 bound to bromosporine
7L9K	;	1.95	;	Crystal structure of the second bromodomain (BD2) of human BRD2 bound to LRRK2-IN-1
7L9J	;	1.85	;	Crystal structure of the second bromodomain (BD2) of human BRD2 bound to Ro3280
7L9L	;	1.55	;	Crystal structure of the second bromodomain (BD2) of human BRD3 bound to BI2536
7LB4	;	2.004	;	Crystal structure of the second bromodomain (BD2) of human BRD3 bound to bromosporine
7LBT	;	2.7	;	Crystal structure of the second bromodomain (BD2) of human BRD3 bound to ERK5-IN-1
7L72	;	1.5	;	Crystal structure of the second bromodomain (BD2) of human BRD3 bound to Ro3280
7KO0	;	1.9	;	Crystal structure of the second bromodomain (BD2) of human BRD4 bound to SG3-179
7LEL	;	2.15	;	Crystal structure of the second bromodomain (BD2) of human BRDT bound to Bromosporine
7LEK	;	2.75	;	Crystal structure of the second bromodomain (BD2) of human BRDT bound to ERK5-IN-1
7LEJ	;	1.73	;	Crystal structure of the second bromodomain (BD2) of human BRDT bound to Volasertib
7JJG	;	1.6	;	Crystal structure of the second bromodomain (BD2) of human TAF1 bound to ATR kinase inhibitor AZ20
7JSP	;	1.7	;	Crystal structure of the second bromodomain (BD2) of human TAF1 bound to ATR kinase inhibitor AZD6738
7K1P	;	2.45	;	Crystal structure of the second bromodomain (BD2) of human TAF1 bound to bromosporine
7K42	;	1.7	;	Crystal structure of the second bromodomain (BD2) of human TAF1 bound to dioxane
7K0U	;	2.52	;	Crystal structure of the second bromodomain (BD2) of human TAF1 bound to PLK1 kinase inhibitor BI2536
7JTC	;	2.05	;	Crystal structure of the second bromodomain (BD2) of human TAF1 bound to ZS1-322
7LB3	;	1.9	;	Crystal structure of the second bromodomain (BD2) of human TAF1 bound to ZS1-580
5HFR	;	1.7	;	Crystal structure of the second bromodomain H395R mutant of human BRD3
6I80	;	1.14	;	Crystal Structure of the second bromodomain of BRD2 in complex with RT53
6I81	;	1.74	;	Crystal Structure of the second bromodomain of BRD2 in complex with RT56
8BPT	;	1.6	;	Crystal structure of the second bromodomain of BRD5 from Leishmania donovani
4MR6	;	1.67	;	Crystal Structure of the second bromodomain of human BRD2 in complex with a quinazolinone ligand (RVX-208)
4MR5	;	1.63	;	Crystal Structure of the second bromodomain of human BRD2 in complex with a quinazolinone ligand (RVX-OH)
5N2L	;	1.89	;	Crystal structure of the second bromodomain of human BRD2 in complex with a tetrahydroquinoline analogue
5EK9	;	2.08	;	Crystal structure of the second bromodomain of human BRD2 in complex with a tetrahydroquinoline inhibitor
6WWB	;	1.31	;	Crystal Structure of the second bromodomain of human BRD2 in complex with the compound 3b
8WYG	;	3.13	;	Crystal Structure of the second bromodomain of human BRD2 in complex with the inhibitor 22
3ONI	;	1.61	;	Crystal Structure of the second bromodomain of human BRD2 in complex with the inhibitor JQ1
7WNA	;	2.6	;	Crystal Structure of the second bromodomain of human BRD2 in complex with the inhibitor Y13120
7WN5	;	1.7	;	Crystal Structure of the second bromodomain of human BRD2 in complex with the inhibitor Y13142
7WMU	;	1.73	;	Crystal Structure of the second bromodomain of human BRD2 in complex with the inhibitor Y13146
7WLN	;	2.85	;	Crystal Structure of the second bromodomain of human BRD2 in complex with the inhibitor Y13153
7WMQ	;	2.37	;	Crystal Structure of the second bromodomain of human BRD2 in complex with the inhibitor Y13157
7WNI	;	3.12	;	Crystal Structure of the second bromodomain of human BRD2 in complex with the inhibitor Y13158
5A7C	;	1.9	;	Crystal structure of the second bromodomain of human BRD3 in complex with compound
3S92	;	1.36	;	Crystal Structure of the second bromodomain of human BRD3 in complex with the inhibitor JQ1
6DUV	;	1.8	;	Crystal structure of the second bromodomain of human BRD4 in complex with MS417 inhibitor
2YEM	;	2.3	;	Crystal Structure of the Second Bromodomain of Human Brd4 with the inhibitor GW841819X
3Q2E	;	1.74	;	Crystal structure of the second bromodomain of human bromodomain and WD repeat-containing protein 1 isoform A (WDR9)
3HMF	;	1.63	;	Crystal Structure of the second Bromodomain of Human Poly-bromodomain containing protein 1 (PB1)
3LJW	;	1.501	;	Crystal Structure of the Second Bromodomain of Human Polybromo
8FTA	;	1.78	;	Crystal Structure of the second bromodomain of human Polybromo-1 (PB1) in complex with compound 16
5MG2	;	1.75	;	Crystal structure of the second bromodomain of human TAF1 in complex with BAY-299 chemical probe
5IGL	;	2.1	;	Crystal structure of the second bromodomain of human TAF1L in complex with bromosporine (BSP)
3HMH	;	2.05	;	Crystal structure of the second bromodomain of human TBP-associated factor RNA polymerase 1-like (TAF1L)
3UV4	;	1.89	;	Crystal Structure of the second bromodomain of human Transcription initiation factor TFIID subunit 1 (TAF1)
3MB3	;	2.25	;	Crystal Structure of the second bromodomain of Pleckstrin homology domain interacting protein (PHIP)
5ENE	;	1.49	;	Crystal structure of the second bromodomain of Pleckstrin homology domain interacting protein (PHIP) in complex with 5-Amino-2-benzyl-1,3-oxazole-4-carbonitrile (SGC - Diamond I04-1 fragment screening)
5ENH	;	1.95	;	Crystal structure of the second bromodomain of Pleckstrin homology domain interacting protein (PHIP) in complex with compound-12 N11528 (SGC - Diamond I04-1 fragment screening)
5ENI	;	1.69	;	Crystal structure of the second bromodomain of Pleckstrin homology domain interacting protein (PHIP) in complex with compound-13 N11537 (SGC - Diamond I04-1 fragment screening)
5ENJ	;	1.63	;	Crystal structure of the second bromodomain of Pleckstrin homology domain interacting protein (PHIP) in complex with compound-14 N11530 (SGC - Diamond I04-1 fragment screening)
5ENF	;	1.37	;	Crystal structure of the second bromodomain of Pleckstrin homology domain interacting protein (PHIP) in complex with fragment-4 N10142 (SGC - Diamond I04-1 fragment screening)
7BBP	;	1.99	;	Crystal Structure of the second bromodomain of Pleckstrin homology domain interacting protein (PHIP) in complex with H4K5acK8ac
5ENC	;	1.59	;	Crystal structure of the second bromodomain of Pleckstrin homology domain interacting protein (PHIP) in complex with N-(2,6-Dichlorobenzyl)acetamide (SGC - Diamond I04-1 fragment screening)
5ENB	;	1.73	;	Crystal structure of the second bromodomain of Pleckstrin homology domain interacting protein (PHIP) in complex with o-Tolylthiourea (SGC - Diamond I04-1 fragment screening)
7AV9	;	1.23	;	Crystal Structure of the second bromodomain of Pleckstrin homology domain interacting protein (PHIP) in space group C2
7AV8	;	1.63	;	Crystal Structure of the second bromodomain of Pleckstrin homology domain interacting protein (PHIP) in space group P21212
7BBO	;	1.32	;	Crystal Structure of the second bromodomain of Pleckstrin homology domain interacting protein (PHIP) in space group P212121
2DVV	;	1.8	;	Crystal structure of the second bromodomain of the human Brd2 protein
5HFQ	;	1.4	;	Crystal structure of the second bromodomain Q443H mutant of human BRD2
4GWR	;	1.81	;	Crystal Structure of the second catalytic domain of protein disulfide isomerase P5
6AKK	;	1.5	;	Crystal structure of the second Coiled-coil domain of SIKE1
5WW5	;	2.04	;	Crystal structure of the second DNA-Binding protein under starvation from Mycobacterium smegmatis soaked with iron in the ratio of 100 iron atoms per dodecamer
5WW3	;	2.05	;	Crystal structure of the second DNA-Binding protein under starvation from Mycobacterium smegmatis soaked with iron in the ratio of 24 iron atoms per dodecamer
5WW6	;	2.04	;	Crystal structure of the second DNA-Binding protein under starvation from Mycobacterium smegmatis soaked with iron in the ratio of 240 iron atoms per dodecamer
5WW7	;	2.05	;	Crystal structure of the second DNA-Binding protein under starvation from Mycobacterium smegmatis soaked with iron in the ratio of 360 iron atoms per dodecamer
5WW4	;	2.05	;	Crystal structure of the second DNA-Binding protein under starvation from Mycobacterium smegmatis soaked with iron in the ratio of 48 iron atoms per dodecamer
5WW8	;	2.04	;	Crystal structure of the second DNA-Binding protein under starvation from Mycobacterium smegmatis soaked with iron in the ratio of 480 iron atoms per dodecamer
2Z90	;	2.4	;	Crystal Structure of the Second Dps from Mycobacterium smegmatis
6WTC	;	1.85	;	Crystal Structure of the Second Form of the Co-factor Complex of NSP7 and the C-terminal Domain of NSP8 from SARS CoV-2
2VJW	;	2.0	;	crystal structure of the second GAF domain of DevS from Mycobacterium smegmatis
2YAN	;	1.9	;	Crystal structure of the second glutaredoxin domain of human TXNL2
7JTJ	;	1.94	;	Crystal structure of the second heterocyclization domain of yersiniabactin synthetase
7JUA	;	2.35	;	Crystal structure of the second heterocyclization domain of yersiniabactin synthetase at 2.35 A resolution
3B6Y	;	2.35	;	Crystal Structure of the Second HIN-200 Domain of Interferon-Inducible Protein 16
4NOF	;	1.65	;	Crystal structure of the second Ig domain from mouse Polymeric Immunoglobulin receptor [PSI-NYSGRC-006220]
4HWN	;	2.006	;	Crystal structure of the second Ig-C2 domain of human Fc-receptor like A (FCRLA), Isoform 9 [NYSGRC-005836]
4NA1	;	1.95	;	Crystal Structure of the second ketosynthase from the bacillaene polyketide synthase
4NA3	;	2.89	;	Crystal Structure of the second ketosynthase from the bacillaene polyketide synthase bound to a hexanoyl substrate mimic
4NA2	;	2.3	;	Crystal Structure of the second ketosynthase from the bacillaene polyketide synthase bound to its natural intermediate
6Y2D	;	1.9	;	Crystal structure of the second KH domain of FUBP1
2H0B	;	2.1	;	Crystal Structure of the second LNS/LG domain from Neurexin 1 alpha
4CEK	;	2.35	;	Crystal structure of the second MIF4G domain of human nonsense mediated decay factor UPF2
3M4I	;	1.95	;	Crystal structure of the second part of the Mycobacterium tuberculosis DNA gyrase reaction core: the TOPRIM domain at 1.95 A resolution
3IG0	;	2.1	;	crystal structure of the second part of the Mycobacterium tuberculosis DNA gyrase reaction core: the TOPRIM domain at 2.1 A resolution
7XTY	;	2.1	;	Crystal Structure of the second PDZ domain from human PTPN13 in complex with APC peptide
3E17	;	1.75	;	Crystal structure of the second PDZ domain from human Zona Occludens-2
5ZDS	;	1.8	;	Crystal structure of the second PDZ domain of Frmpd2
2VWR	;	1.3	;	Crystal structure of the second pdz domain of numb-binding protein 2
2G2L	;	2.35	;	Crystal Structure of the Second PDZ Domain of SAP97 in Complex with a GluR-A C-terminal Peptide
3HWJ	;	2.25	;	Crystal structure of the second PHR domain of Mouse Myc-binding protein 2 (MYCBP-2)
4F26	;	2.0	;	Crystal structure of the second RRM domain of human PABPC1 a pH 9.0
4F25	;	1.9	;	Crystal structure of the second RRM domain of human PABPC1 at pH 6.0
3MD1	;	1.6	;	Crystal Structure of the Second RRM Domain of Yeast Poly(U)-Binding Protein (Pub1)
3HIB	;	2.0	;	Crystal structure of the second Sec63 domain of yeast Brr2
2O31	;	1.5	;	Crystal structure of the second SH3 domain from ponsin
6GBU	;	3.44	;	Crystal structure of the second SH3 domain of FCHSD2 (SH3-2) in complex with the fourth SH3 domain of ITSN1 (SH3d)
4IIM	;	1.8	;	Crystal structure of the Second SH3 Domain of ITSN1 bound with a synthetic peptide
4IIO	;	1.7	;	Crystal Structure of the Second SH3 Domain of ITSN2 Bound with a Synthetic Peptide
6B29	;	1.3	;	Crystal structure of the second SH3 domain of STAC3 (309-364)
5YS0	;	2.601	;	Crystal structure of the second StARkin domain of Lam2 in complex with ergosterol
5YQP	;	1.7	;	Crystal structure of the second StARkin domain of Lam4
6BYD	;	2.195	;	Crystal structure of the second StART domain of yeast Lam4
4OEN	;	1.65	;	Crystal structure of the second substrate binding domain of a putative amino acid ABC transporter from Streptococcus pneumoniae Canada MDR_19A
2QA9	;	1.18	;	Crystal structure of the second tetrahedral intermediates of SGPB at pH 4.2
2QAA	;	1.23	;	Crystal structure of the second tetrahedral intermediates of SGPB at pH 7.3
3P8D	;	2.0	;	Crystal structure of the second Tudor domain of human PHF20 (homodimer form)
3FNK	;	1.99	;	Crystal structure of the second type II cohesin module from the cellulosomal adaptor ScaA scaffoldin of Acetivibrio cellulolyticus
3G9Y	;	1.4	;	Crystal structure of the second zinc finger from ZRANB2/ZNF265 bound to 6 nt ssRNA sequence AGGUAA
6T9Q	;	1.15	;	Crystal structure of the second, C-terminal repeat of the DNA-binding domain of human TImeless
5J44	;	2.912	;	Crystal structure of the Secreted Extracellular protein A (SepA) from Shigella flexneri
4KZS	;	2.7	;	Crystal structure of the secreted protein HP1454 from the human pathogen Helicobacter pylori
5WIQ	;	1.25	;	Crystal structure of the segment, GFNGGFG, from the low complexity domain of TDP-43, residues 396-402
5WKD	;	1.8	;	Crystal structure of the segment, GNNQGSN, from the low complexity domain of TDP-43, residues 300-306
5WIA	;	1.002	;	Crystal structure of the segment, GNNSYS, from the low complexity domain of TDP-43, residues 370-375
5W50	;	1.4	;	Crystal structure of the segment, LIIKGI, from the RRM2 of TDP-43, residues 248-253
5WHN	;	1.1	;	Crystal structure of the segment, NFGAFS, from the low complexity domain of TDP-43, residues 312-317
5WHP	;	1.0	;	Crystal structure of the segment, NFGTFS, from the A315T familial variant of the low complexity domain of TDP-43, residues 312-317
6FJH	;	3.15	;	Crystal structure of the seleniated LkcE from Streptomyces rochei
3W1K	;	7.5	;	Crystal structure of the selenocysteine synthase SelA and tRNASec complex
3W1H	;	3.893	;	Crystal structure of the selenocysteine synthase SelA from Aquifex aeolicus
2HE3	;	2.1	;	Crystal structure of the selenocysteine to cysteine mutant of human glutathionine peroxidase 2 (GPX2)
2OBI	;	1.55	;	Crystal structure of the Selenocysteine to Cysteine Mutant of human phospholipid hydroperoxide glutathione peroxidase (GPx4)
2F8A	;	1.5	;	Crystal structure of the selenocysteine to glycine mutant of human glutathione peroxidase 1
2GS3	;	1.9	;	Crystal structure of the selenocysteine to glycine mutant of human glutathione peroxidase 4(GPX4)
8I16	;	2.24	;	Crystal structure of the selenomethionine (SeMet)-derived Cas12g (D513A) mutant
5A8M	;	1.86	;	Crystal structure of the selenomethionine derivative of beta-glucanase SdGluc5_26A from Saccharophagus degradans
3U3L	;	1.57	;	Crystal structure of the selenomethionine derivative of tablysin-15
3MWZ	;	1.52	;	Crystal structure of the selenomethionine derivative of the L 22,47,100 M mutant of sialostatin L2
7AL5	;	2.42	;	Crystal structure of the selenomethionine substituted hypothetical protein PA1622 from Pseudomonas aeruginosa PAO1
1B6W	;	2.05	;	CRYSTAL STRUCTURE OF THE SELENOMETHIONINE VARIANT OF HISTONE HMFB FROM METHANOTHERMUS FERVIDUS
4HE5	;	1.15	;	Crystal structure of the selenomethionine variant of the C-terminal domain of Geobacillus thermoleovorans putative U32 peptidase
7VYX	;	3.2	;	Crystal structure of the selenomethionine(SeMet)-derived Cas12c1 (D969A) ternary complex
7EU9	;	2.35	;	Crystal structure of the selenomethionine(SeMet)-derived Cas12i1 R-loop complex before target DNA cleavage
6MO6	;	2.59	;	Crystal structure of the selenomethionine-substituted human sulfide:quinone oxidoreductase
5EDF	;	1.4	;	Crystal structure of the selenomethionine-substituted iron-regulated protein FrpD from Neisseria meningitidis
4WXU	;	2.092	;	Crystal Structure of the Selenomthionine Incorporated Myocilin Olfactomedin Domain E396D Variant.
5JHC	;	3.4	;	Crystal structure of the self-assembled propeptides from Ape1
7ONE	;	1.3	;	Crystal structure of the self-assembled SAKe6BE designer protein
260D	;	1.9	;	CRYSTAL STRUCTURE OF THE SELF-COMPLEMENTARY 5'-PURINE START DECAMER D(GCACGCGTGC) IN THE A-DNA CONFORMATION-PART II
279D	;	1.9	;	CRYSTAL STRUCTURE OF THE SELF-COMPLEMENTARY 5'-PURINE START DECAMER D(GCGCGCGCGC) IN THE Z-DNA CONFORMATION-PART I
1QC1	;	2.5	;	CRYSTAL STRUCTURE OF THE SELF-FITTED B-DNA DECAMER D(CCGCCGGCGG)
4FWW	;	1.85	;	Crystal structure of the Sema-PSI extracellular domains of human RON receptor tyrosine kinase
4RQM	;	1.75	;	Crystal structure of the SeMET BICC1 SAM Domain R924E mutant
7QUZ	;	2.156	;	Crystal structure of the SeMet octameric C-terminal Big_2-CBM56 domains from Paenibacillus illinoisensis (Bacillus circulans IAM1165) beta-1,3-glucanase H
3VQW	;	2.4	;	Crystal structure of the SeMet substituted catalytic domain of pyrrolysyl-tRNA synthetase
4ZHE	;	2.5	;	Crystal structure of the SeMet substituted Topless related protein 2 (TPR2) N-terminal domain (1-209) from rice
1X8C	;	2.1	;	Crystal structure of the SeMet-derivative copper homeostasis protein (cutCm) with calcium binding from Shigella flexneri 2a str. 301
4XXK	;	2.97	;	Crystal structure of the Semet-derivative of the Bilin-binding domain of phycobilisome core-membrane linker ApcE
2YQ8	;	2.987	;	Crystal structure of the SeMet-labeled N-terminal domain and peptide substrate binding domain of alpha subunit of prolyl-4 hydroxylase type I from human.
2V4A	;	1.93	;	Crystal structure of the SeMet-labeled prolyl-4 hydroxylase (P4H) type I from green algae Chlamydomonas reinhardtii.
2ZAG	;	3.0	;	Crystal structure of the SeMet-substituted soluble domain of STT3 from P. furiosus
2ALA	;	3.0	;	Crystal structure of the Semliki Forest Virus envelope protein E1 in its monomeric conformation.
1XA1	;	1.8	;	Crystal structure of the sensor domain of BlaR1 from Staphylococcus aureus in its apo form
2Z69	;	2.1	;	Crystal Structure of the sensor domain of the transcriptional regulator DNR from Pseudomonas aeruginosa
5V30	;	3.15	;	Crystal structure of the sensor domain of the transcriptional regulator HcpR from Porphyromonas Gingivalis
6NP6	;	2.6	;	Crystal structure of the sensor domain of the transcriptional regulator HcpR from Porphyromonas Gingivalis
7CUS	;	1.65	;	Crystal structure of the sensor domain of VbrK from Vibrio parahaemolyticus
7F2G	;	1.9	;	Crystal structure of the sensor domain of VbrK from Vibrio rotiferianus (crystal type 1)
7F2H	;	2.25	;	Crystal structure of the sensor domain of VbrK from Vibrio rotiferianus (crystal type 2)
2O3O	;	2.89	;	Crystal Structure of the sensor histidine kinase regulator YycI from Bacillus subtitlis
3MFX	;	2.4	;	Crystal Structure of the sensory box domain of the sensory-box/GGDEF protein SO_1695 from Shewanella oneidensis, Northeast Structural Genomics Consortium Target SoR288B
4XMQ	;	1.5	;	Crystal structure of the sensory domain of the Campylobacter jejuni chemoreceptor Tlp3 (CcmL)
4XMR	;	1.3	;	Crystal structure of the sensory domain of the Campylobacter jejuni chemoreceptor Tlp3 (CcmL) with isoleucine bound.
3AK8	;	1.25	;	Crystal structure of the SEp22 dodecamer, a Dps-like protein from Salmonella enterica subsp. enterica serovar Enteritidis
3AK9	;	1.3	;	Crystal structure of the SEp22 dodecamer, a Dps-like protein from Salmonella enterica subsp. enterica serovar Enteritidis, FE-soaked form
3WKR	;	2.803	;	Crystal structure of the SepCysS-SepCysE complex from Methanocaldococcus jannaschii
3WKS	;	3.029	;	Crystal structure of the SepCysS-SepCysE N-terminal domain complex from
3GHF	;	2.2	;	Crystal structure of the septum site-determining protein minC from Salmonella typhimurium
4JUC	;	2.303	;	Crystal Structure of the Ser26Met mutant of Benzoylformate Decarboxylase from Pseudomonas putida
4JUD	;	1.65	;	Crystal Structure of the Ser26Thr mutant of Benzoylformate Decarboxylase from Pseudomonas putida
7BT2	;	3.00003	;	Crystal structure of the SERCA2a in the E2.ATP state
5JD8	;	1.85	;	Crystal structure of the serine endoprotease from Yersinia pestis
3FMV	;	3.31	;	Crystal structure of the serine phosphatase of RNA polymerase II CTD (SSU72 superfamily) from Drosophila melanogaster. Monoclinic crystal form. Northeast Structural Genomics Consortium target FR253.
3FDF	;	3.2	;	Crystal structure of the serine phosphatase of RNA polymerase II CTD (SSU72 superfamily) from Drosophila melanogaster. Orthorhombic crystal form. Northeast Structural Genomics Consortium target FR253.
4IW4	;	3.2	;	Crystal structure of the serine protease domain of MASP-3 in complex with ecotin
2OLG	;	1.7	;	Crystal structure of the serine protease domain of prophenoloxidase activating factor-I in a zymogen form
1ZYO	;	2.4	;	Crystal Structure of the Serine Protease Domain of Sesbania Mosaic Virus polyprotein
2P8E	;	1.816	;	Crystal structure of the serine/threonine phosphatase domain of human PPM1B
2BEM	;	1.55	;	Crystal structure of the Serratia marcescens chitin-binding protein CBP21
2BEN	;	1.8	;	Crystal structure of the Serratia marcescens chitin-binding protein CBP21 Y54A mutant.
3QO5	;	2.3	;	Crystal Structure of the seryl-tRNA synthetase from Candida albicans
3QO7	;	2.55	;	Crystal structure of the seryl-tRNA synthetase from Candida albicans
7OFL	;	1.83	;	Crystal structure of the sesquiterpene synthase Copu9 from coniophora puteana in complex with alendronate
3S8P	;	1.85	;	Crystal Structure of the SET Domain of Human Histone-Lysine N-Methyltransferase SUV420H1 In Complex With S-Adenosyl-L-Methionine
5WBV	;	2.3	;	Crystal Structure of the SET Domain of Human SUV420H1 In Complex With Inhibitor
1OZV	;	2.65	;	Crystal structure of the SET domain of LSMT bound to Lysine and AdoHcy
1P0Y	;	2.55	;	Crystal structure of the SET domain of LSMT bound to MeLysine and AdoHcy
5HT6	;	2.093	;	Crystal structure of the SET domain of the human MLL5 methyltransferase
5TFP	;	2.0	;	Crystal Structure of the SETDB2 Amino Terminal Domain
6OKQ	;	3.2	;	Crystal structure of the SF12 Fab
4DGW	;	3.112	;	Crystal Structure of the SF3a splicing factor complex of U2 snRNP
3MEA	;	1.26	;	Crystal structure of the SGF29 in complex with H3K4me3
5AWT	;	2.702	;	Crystal structure of the SGIP1 mu homology domain in complex with an Eps15 fragment containing two DPF motifs (YDPFGGDPFKG)
5AWU	;	2.7	;	Crystal structure of the SGIP1 mu homology domain in complex with an Eps15 fragment containing two DPF motifs (YDPFKGSDPFA)
5AWS	;	2.001	;	Crystal structure of the SGIP1 mu homology domain in the P1 space group
5AWR	;	2.502	;	Crystal structure of the SGIP1 mu homology domain in the P4212 space group
2GKV	;	1.7	;	Crystal structure of the SGPB:P14'-Ala32 OMTKY3-del(1-5) complex
3ZDM	;	1.803	;	Crystal structure of the Sgt2 N domain and the Get5 UBL domain complex
3SZ7	;	1.72	;	Crystal structure of the Sgt2 TPR domain from Aspergillus fumigatus
4GOD	;	1.4	;	Crystal structure of the SGTA homodimerization domain
4GOE	;	1.45	;	Crystal structure of the SGTA homodimerization domain with a covalent modification of a single C38
4GOF	;	1.35	;	Crystal structure of the SGTA homodimerization domain with covalent modifications to both C38
6DM4	;	1.9	;	Crystal structure of the SH2 domain from RavO (Lpg1129) from Legionella pneumophila in complex with Homo sapiens Shc1 phospho-Tyr317 peptide
6DM3	;	1.95	;	Crystal structure of the SH2 domain from RavO (Lpg1129) from Legionella pneumophila, apoprotein
1NRV	;	1.65	;	Crystal structure of the SH2 domain of Grb10
1OOT	;	1.39	;	Crystal structure of the SH3 domain from a S. cerevisiae hypothetical 40.4 kDa protein at 1.39 A resolution
1SSH	;	1.4	;	Crystal structure of the SH3 domain from a S. cerevisiae hypothetical 40.4 kDa protein in complex with a peptide
3RNJ	;	1.5	;	Crystal structure of the SH3 domain from IRSp53 (BAIAP2)
3O5Z	;	2.01	;	Crystal structure of the SH3 domain from p85beta subunit of phosphoinositide 3-kinase (PI3K)
1BB9	;	2.2	;	CRYSTAL STRUCTURE OF THE SH3 DOMAIN FROM RAT AMPHIPHYSIN 2
1RUW	;	1.8	;	Crystal structure of the SH3 domain from S. cerevisiae Myo3
1SHF	;	1.9	;	CRYSTAL STRUCTURE OF THE SH3 DOMAIN IN HUMAN FYN; COMPARISON OF THE THREE-DIMENSIONAL STRUCTURES OF SH3 DOMAINS IN TYROSINE KINASES AND SPECTRIN
2DF6	;	1.3	;	Crystal Structure of the SH3 Domain of betaPIX in Complex with a High Affinity Peptide from PAK2
2G6F	;	0.92	;	Crystal Structure of the SH3 Domain of betaPIX in Complex with a High Affinity Peptide from PAK2
4GLM	;	1.9	;	Crystal structure of the SH3 Domain of DNMBP protein [Homo sapiens]
1ZLM	;	1.07	;	Crystal structure of the SH3 domain of human osteoclast stimulating factor
5VEI	;	1.33	;	Crystal structure of the SH3 domain of human sorbin and SH3 domain-containing protein 2
3LH5	;	2.6	;	Crystal Structure of the SH3-Guanylate kinase core domain of ZO-1
1JXO	;	2.3	;	Crystal Structure of the SH3-HOOK-GK Fragment of PSD-95
3KFV	;	2.8	;	Crystal structure of the SH3-kinase fragment of tight junction protein 3 (TJP3) in apo-form
1Q3O	;	1.8	;	Crystal structure of the Shank PDZ-ligand complex reveals a class I PDZ interaction and a novel PDZ-PDZ dimerization
1Q3P	;	2.25	;	Crystal structure of the Shank PDZ-ligand complex reveals a class I PDZ interaction and a novel PDZ-PDZ dimerization
5TUB	;	2.85	;	Crystal Structure of the Shark TBC1D15 GAP Domain
3HXL	;	1.9	;	Crystal Structure of the sheath tail protein (DSY3957) from Desulfitobacterium hafniense, Northeast Structural Genomics Consortium Target DhR18
3LML	;	3.3	;	Crystal Structure of the sheath tail protein Lin1278 from Listeria innocua, Northeast Structural Genomics Consortium Target LkR115
2PI6	;	1.65	;	Crystal structure of the sheep signalling glycoprotein (SPS-40) complex with 2-methyl-2-4-pentanediol at 1.65A resolution reveals specific binding characteristics of SPS-40
5Z4V	;	1.65	;	Crystal structure of the sheep signalling glycoprotein (SPS-40) complex with 2-methyl-2-4-pentanediol at 1.65A resolution reveals specific binding characteristics of SPS-40
7QTH	;	1.9	;	Crystal structure of the Shewanella oneidensis MR1 MtrC mutant C453A
7O7G	;	1.6	;	Crystal structure of the Shewanella oneidensis MR1 MtrC mutant H561M
1RYE	;	2.3	;	Crystal Structure of the Shifted Form of the Glucose-Fructose Oxidoreductase from Zymomonas mobilis
2FOR	;	2.0	;	Crystal Structure of the Shigella flexneri Farnesyl Pyrophosphate Synthase Complex with an Isopentenyl Pyrophosphate
3PHG	;	1.57	;	Crystal structure of the Shikimate 5-Dehydrogenase (aroE) from Helicobacter pylori
7TBV	;	2.3	;	Crystal structure of the shikimate kinase + 3-dehydroquinate dehydratase + 3-dehydroshikimate dehydrogenase domains of Aro1 from Candida albicans
3HR7	;	1.8	;	Crystal structure of the shikimate kinase-sulfate complex from Helicobacter pylori
7TVF	;	2.17	;	Crystal structure of the SHOC2-MRAS-PP1CA (SMP) complex to a resolution of 2.17 Angstrom
3E9Q	;	1.7	;	Crystal Structure of the Short Chain Dehydrogenase from Shigella flexneri
2WDZ	;	1.95	;	Crystal structure of the short chain dehydrogenase Galactitol- Dehydrogenase (GatDH) of Rhodobacter sphaeroides in complex with NAD+ and 1,2-Pentandiol
2WSB	;	1.25	;	Crystal structure of the short-chain dehydrogenase Galactitol- Dehydrogenase (GatDH) of Rhodobacter sphaeroides in complex with NAD
3LQF	;	1.8	;	Crystal structure of the short-chain dehydrogenase Galactitol-Dehydrogenase (GatDH) of Rhodobacter sphaeroides in complex with NAD and erythritol
6DKQ	;	1.5	;	Crystal structure of the Shr Hemoglobin Interacting Domain 2
8DOV	;	2.1	;	Crystal structure of the Shr Hemoglobin Interacting Domain 2 (HID2) in complex with Hemoglobin
4L2W	;	2.49	;	Crystal structure of the Shroom-Binding domain of human Rock1
3FHD	;	1.85	;	Crystal structure of the Shutoff and Exonuclease Protein from Kaposis Sarcoma Associated Herpesvirus
2G2W	;	1.8	;	Crystal Structure of the SHV D104K Beta-lactamase/Beta-lactamase inhibitor protein (BLIP) complex
2G2U	;	1.6	;	Crystal Structure of the SHV-1 Beta-lactamase/Beta-lactamase inhibitor protein (BLIP) complex
3C4P	;	1.75	;	Crystal Structure of the SHV-1 Beta-lactamase/Beta-lactamase inhibitor protein (BLIP) E73M complex
3C4O	;	1.7	;	Crystal Structure of the SHV-1 Beta-lactamase/Beta-lactamase inhibitor protein (BLIP) E73M/S130K/S146M complex
3N4I	;	1.56	;	Crystal structure of the SHV-1 D104E beta-lactamase/beta-lactamase inhibitor protein (BLIP) complex
1T95	;	1.9	;	Crystal Structure of the Shwachman-Bodian-Diamond Syndrome Protein Orthologue from Archaeoglobus fulgidus
6NJC	;	1.9	;	Crystal Structure of the Sialate O-acetylesterase from Bacteroides vulgatus
2WX9	;	1.37	;	Crystal structure of the sialic acid binding periplasmic protein SiaP
2X61	;	1.95	;	Crystal structure of the sialyltransferase CST-II in complex with trisaccharide acceptor and CMP
2X63	;	2.0	;	Crystal structure of the sialyltransferase CST-II N51A in complex with CMP
2X62	;	2.2	;	CRYSTAL STRUCTURE OF THE SIALYLTRANSFERASE CST-II Y81F IN COMPLEX WITH CMP
2C83	;	1.9	;	CRYSTAL STRUCTURE OF THE SIALYLTRANSFERASE PM0188
2C84	;	2.31	;	CRYSTAL STRUCTURE OF THE SIALYLTRANSFERASE PM0188 WITH CMP
2IY7	;	1.85	;	crystal structure of the sialyltransferase PM0188 with CMP-3FNeuAc
2IY8	;	2.5	;	Crystal structure of the sialyltransferase PM0188 with CMP-3FNeuAc and lactose
5FR8	;	2.83	;	Crystal structure of the siderophore receptor PirA from Acinetobacter baumannii
5FP2	;	2.97	;	Crystal structure of the siderophore receptor PirA from Pseudomonas aeruginosa
5FP1	;	1.94	;	Crystal structure of the siderophore receptor PiuA from Acinetobacter baumannii
5FOK	;	1.9	;	Crystal structure of the siderophore receptor PiuA from Pseudomonas aeruginosa
5NEC	;	2.3	;	Crystal structure of the siderophore receptor PiuD from Pseudomonas aeruginosa
6K2L	;	2.5	;	Crystal structure of the Siderophore-interacting protein SipS from Aeromonas hydrophila
2WWX	;	1.5	;	Crystal structure of the SidM/DrrA(GEF/GDF domain)-Rab1(GTPase domain) complex
3HW2	;	3.3	;	Crystal structure of the SifA-SKIP(PH) complex
6MFV	;	3.4	;	Crystal structure of the Signal Transduction ATPase with Numerous Domains (STAND) protein with a tetratricopeptide repeat sensor PH0952 from Pyrococcus horikoshii
3HLS	;	2.15	;	Crystal structure of the signaling helix coiled-coil doimain of the BETA-1 subunit of the soluble guanylyl cyclase
5IXV	;	2.3	;	Crystal structure of the signaling protein complex 2
5IXW	;	2.46	;	Crystal structure of the signaling protein complex 3
5IXX	;	2.35	;	Crystal structure of the signaling protein complex 4
5IXZ	;	2.4	;	Crystal structure of the signaling protein complex 5
3MUU	;	3.29	;	Crystal structure of the Sindbis virus E2-E1 heterodimer at low pH
6CBP	;	2.17	;	Crystal structure of the single chain variable fragment of the DH270.6 bnAb in complex with the Man9-V3 glycopeptide
5I0Z	;	1.9	;	Crystal structure of the single domain catalytic antibody 3D8-VH
6DDC	;	2.91	;	Crystal structure of the single mutant (D52N) of NT5C2-537X in the basal state, Northeast Structural Genomics Consortium Target
6DE0	;	2.05	;	Crystal structure of the single mutant (D52N) of NT5C2-Q523X in the active state
6DDL	;	2.26	;	Crystal structure of the single mutant (D52N) of NT5C2-Q523X in the basal state
6DE1	;	2.151	;	Crystal structure of the single mutant (D52N) of the full-length NT5C2 in the active state
6DDO	;	2.48	;	Crystal structure of the single mutant (D52N) of the full-length NT5C2 in the basal state
6Y2W	;	1.77	;	Crystal structure of the single mutant I16K of Low Molecular Weight Protein Tyrosine Phosphatase (LMW-PTP)
3H3B	;	2.45	;	Crystal structure of the single-chain Fv (scFv) fragment of an anti-ErbB2 antibody chA21 in complex with residues 1-192 of ErbB2 extracellular domain
1JP5	;	2.7	;	Crystal structure of the single-chain Fv fragment 1696 in complex with the epitope peptide corresponding to N-terminus of HIV-1 protease
1SVZ	;	1.89	;	Crystal structure of the single-chain Fv fragment 1696 in complex with the epitope peptide corresponding to N-terminus of HIV-2 protease
3AFP	;	2.05	;	Crystal structure of the single-stranded DNA binding protein from Mycobacterium leprae (Form I)
3AFQ	;	2.8	;	Crystal structure of the single-stranded DNA binding protein from Mycobacterium leprae (Form II)
2CWA	;	1.96	;	Crystal Structure Of The Single-stranded DNA Binding Protein From Thermus Thermophilus HB8
1X3E	;	2.15	;	Crystal structure of the single-stranded DNA-binding protein from Mycobacterium smegmatis
1X3F	;	2.7	;	Crystal structure of the single-stranded DNA-binding protein from Mycobacterium SMEGMATIS
1X3G	;	3.0	;	Crystal structure of the single-stranded DNA-binding protein from Mycobacterium SMEGMATIS
1UE1	;	2.5	;	Crystal structure of the single-stranded dna-binding protein from mycobacterium tuberculosis
1UE5	;	2.6	;	Crystal structure of the single-stranded dna-binding protein from mycobacterium tuberculosis
1UE6	;	2.7	;	Crystal structure of the single-stranded dna-binding protein from mycobacterium tuberculosis
1UE7	;	3.2	;	Crystal structure of the single-stranded dna-binding protein from mycobacterium tuberculosis
7F5Y	;	1.92	;	Crystal structure of the single-stranded dna-binding protein from Mycobacterium tuberculosis- Form III
7F5Z	;	3.0	;	Crystal structure of the single-stranded dna-binding protein from Mycobacterium tuberculosis- Form III
4OK9	;	1.91	;	Crystal structure of the single-stranded RNA binding protein HutP from Geobacillus thermodenitrificans
4OKQ	;	2.5	;	Crystal structure of the single-stranded RNA binding protein HutP from Geobacillus thermodenitrificans
3EJW	;	1.8	;	Crystal Structure of the Sinorhizobium meliloti AI-2 receptor, SmLsrB
2HJH	;	1.85	;	Crystal Structure of the Sir2 deacetylase
3TU4	;	3.0	;	Crystal structure of the Sir3 BAH domain in complex with a nucleosome core particle.
6RRV	;	1.1	;	Crystal structure of the Sir4 H-BRCT domain
6QSZ	;	2.5	;	Crystal structure of the Sir4 H-BRCT domain in complex with Esc1 pS1450 peptide
6QTM	;	3.0	;	Crystal structure of the Sir4 H-BRCT domain in complex with Ty5 pS1095 peptide
6RR0	;	2.18	;	Crystal structure of the Sir4 H-BRCT domain in complex with Ubp10 pT123 peptide
3HZ7	;	2.0	;	Crystal Structure of the SirA-like protein (DSY4693) from Desulfitobacterium hafniense, Northeast Structural Genomics Consortium Target DhR2A
4CH7	;	2.002	;	Crystal structure of the siroheme decarboxylase NirDL
4CZC	;	2.9	;	Crystal structure of the siroheme decarboxylase NirDL in co-complex with iron-uroporphyrin III analogue
6JV6	;	2.15	;	Crystal structure of the sirohydrochlorin chelatase SirB from Bacillus subtilis subspecies spizizenii in complex with cobalt
4I5I	;	2.5	;	Crystal structure of the SIRT1 catalytic domain bound to NAD and an EX527 analog
6EXP	;	1.93	;	Crystal structure of the SIRV3 AcrID1 (gp02) anti-CRISPR protein
2EWF	;	1.84	;	Crystal structure of the site-specific DNA nickase N.BspD6I
6QNZ	;	2.45	;	Crystal structure of the site-specific DNA nickase N.BspD6I E418A Mutant
4PBX	;	3.15	;	Crystal structure of the six N-terminal domains of human receptor protein tyrosine phosphatase sigma
1Z1N	;	2.1	;	Crystal Structure of the sixteen heme cytochrome from Desulfovibrio gigas
3PD7	;	1.26	;	Crystal Structure of the Sixth BRCT Domain of Human TopBP1
3JVE	;	1.34	;	Crystal Structure of the Sixth BRCT Domain of TopBP1
3IU6	;	1.79	;	Crystal structure of the sixth bromodomain of human poly-bromodomain containing protein 1 (PB1)
5NRK	;	1.45	;	Crystal structure of the sixth cohesin from Acetivibrio cellulolyticus' scaffoldin B in complex with Cel5 dockerin S15I, I16N mutant
5NRM	;	1.4	;	Crystal structure of the sixth cohesin from Acetivibrio cellulolyticus' scaffoldin B in complex with Cel5 dockerin S51I, L52N mutant
4CC7	;	1.97	;	Crystal structure of the sixth or C-terminal SH3 domain of human Tuba in complex with proline-rich peptides of N-WASP. Space group P41
1N7E	;	1.5	;	Crystal structure of the sixth PDZ domain of GRIP1
1N7F	;	1.8	;	Crystal structure of the sixth PDZ domain of GRIP1 in complex with liprin C-terminal peptide
4AJ5	;	3.32	;	Crystal structure of the Ska core complex
6QV3	;	2.9	;	Crystal structure of the Ski2 RNA-helicase Brr2 from Chaetomium thermophilum bound to ADP
6QV4	;	2.8	;	Crystal structure of the Ski2 RNA-helicase Brr2 from Chaetomium thermophilum bound to ATP-gamma-S
6QWS	;	3.3	;	Crystal structure of the Ski2 RNA-helicase Brr2 from Chaetomium thermophilum in the apo state
3WSO	;	2.6	;	Crystal structure of the Skp1-FBG3 complex
5VZT	;	2.7	;	Crystal structure of the Skp1-FBXO31 complex
5VZU	;	2.7	;	Crystal structure of the Skp1-FBXO31-cyclin D1 complex
5V4B	;	2.6	;	Crystal structure of the Skp1-FBXW7-DISC1 complex
2ASS	;	3.0	;	Crystal structure of the Skp1-Skp2-Cks1 complex
3WI3	;	2.4	;	Crystal Structure of the Sld3/Treslin domain from yeast Sld3
5CR4	;	1.4	;	Crystal structure of the Sleeping Beauty transposase catalytic domain
8IR4	;	1.62	;	Crystal structure of the SLF1 BRCT domain in complex with a Rad18 peptide containing pS442
8IR2	;	1.75	;	Crystal structure of the SLF1 BRCT domain in complex with a Rad18 peptide containing pS442 and pS444
6BT4	;	2.306	;	Crystal structure of the SLH domain of Sap from Bacillus anthracis in complex with a pyruvylated SCWP unit
2GP9	;	1.87	;	Crystal structure of the slow form of thrombin in a self-inhibited conformation
3BEI	;	1.55	;	Crystal structure of the slow form of thrombin in a self_inhibited conformation
5O7B	;	2.281	;	CRYSTAL STRUCTURE OF THE SLR0328 TYROSINE PHOSPHATASE WZB FROM SYNECHOCYSTIS SP. PCC 6803
3HX1	;	2.5	;	Crystal structure of the Slr1951 protein from Synechocystis sp. Northeast Structural Genomics Consortium Target SgR167A
1H64	;	1.9	;	CRYSTAL STRUCTURE OF THE SM-RELATED PROTEIN OF P. ABYSSI: THE BIOLOGICAL UNIT IS A HEPTAMER
6ZMN	;	2.333	;	Crystal structure of the Smad3-Smad5 MH1 domain chimera bound to the GGCGC site
1YGS	;	2.1	;	CRYSTAL STRUCTURE OF THE SMAD4 TUMOR SUPPRESSOR C-TERMINAL DOMAIN
6YVC	;	1.85	;	Crystal structure of the small alarmone hydrolase (SAH) of Pseudomonas aeruginosa
5DEC	;	2.0	;	Crystal structure of the small alarmone synthetase 1 from Bacillus subtilis
5F2V	;	2.8	;	Crystal structure of the small alarmone synthethase 1 from Bacillus subtilis bound to AMPCPP
5DED	;	2.942	;	Crystal structure of the small alarmone synthethase 1 from Bacillus subtilis bound to its product pppGpp
6FGK	;	3.2	;	Crystal structure of the small alarmone synthethase 2 from Bacillus subtilis
6FGJ	;	2.251	;	Crystal structure of the small alarmone synthethase 2 from Staphylococcus aureus
6FGX	;	2.9	;	Crystal structure of the small alarmone synthethase 2 from Staphylococcus aureus bound to AMPCPP
1KAO	;	1.7	;	CRYSTAL STRUCTURE OF THE SMALL G PROTEIN RAP2A WITH GDP
2CJW	;	2.1	;	Crystal structure of the small GTPase Gem (GemDNDCaM) in complex to Mg.GDP
2ZET	;	3.0	;	Crystal structure of the small GTPase Rab27B complexed with the Slp homology domain of Slac2-a/melanophilin
3OES	;	2.301	;	Crystal structure of the small GTPase RhebL1
6HBB	;	1.2	;	Crystal Structure of the small subunit-like domain 1 of CcmM from Synechococcus elongatus (strain PCC 7942)
6HBA	;	1.65	;	Crystal Structure of the small subunit-like domain 1 of CcmM from Synechococcus elongatus (strain PCC 7942), thiol-oxidized form
6HAS	;	1.38	;	Crystal Structure of the small subunit-like domain of Rubisco activase from Nostoc sp. (strain PCC 7120)
4XVN	;	2.6	;	Crystal structure of the small terminase from thermophilic phage G20C
3ZQM	;	1.85	;	Crystal structure of the small terminase oligomerization core domain from a SPP1-like bacteriophage (crystal form 1)
3ZQN	;	2.2	;	Crystal structure of the small terminase oligomerization core domain from a SPP1-like bacteriophage (crystal form 2)
3ZQO	;	1.68	;	Crystal structure of the small terminase oligomerization core domain from a SPP1-like bacteriophage (crystal form 3)
3ZQP	;	3.0	;	Crystal structure of the small terminase oligomerization domain from a SPP1-like bacteriophage
7UQA	;	2.802	;	Crystal structure of the small Ultra-Red Fluorescent Protein (smURFP)
6KAG	;	2.601	;	Crystal structure of the SMARCB1/SMARCC2 subcomplex
1OXJ	;	1.8	;	Crystal structure of the Smaug RNA binding domain
5XEI	;	2.599	;	Crystal structure of the Smc head domain with a coiled coil and joint derived from Pyrococcus yayanosii
5XNS	;	2.01	;	Crystal structure of the Smc head domain with an extended coiled coil bound to the C-terminal domain of ScpA derived from Pyrococcus furiosus
4I99	;	2.3	;	Crystal structure of the SmcHead bound to the C-winged helix domain of ScpA
5X3R	;	2.1	;	Crystal structure of the SmcR complexed with QStatin
2UYD	;	2.7	;	Crystal structure of the SmHasA mutant H83A
3E5C	;	2.25	;	Crystal Structure of the SMK box (SAM-III) Riboswitch with SAM
4C79	;	2.604	;	Crystal structure of the Smoothened CRD, native
4C7A	;	2.3	;	Crystal structure of the Smoothened CRD, selenomethionine-labeled
2ZQE	;	1.7	;	Crystal structure of the Smr domain of Thermus thermophilus MutS2
5EN7	;	2.936	;	Crystal structure of the Smu1-RED complex (native) of Caenorhabditis elegans.
5EN6	;	3.103	;	Crystal structure of the Smu1-RED complex (SeMet) of Caenorhabditis elegans
3BX4	;	1.7	;	Crystal structure of the snake venom toxin aggretin
6WC3	;	3.203	;	Crystal structure of the SNARE Sec20 bound to Dsl1 complex subunit Tip20
8FTU	;	5.73	;	Crystal structure of the SNARE Use1 bound to Dsl1 complex subunits Sec39 and Dsl1, Revised Use1 structure
2PNE	;	0.98	;	Crystal Structure of the Snow Flea Antifreeze Protein
5F5U	;	2.748	;	Crystal structure of the Snu23-Prp38-MFAP1(217-258) complex of Chaetomium thermophilum
5F5V	;	3.1	;	Crystal structure of the Snu23-Prp38-MFAP1(217-296) complex of Chaetomium thermophilum
3LUI	;	1.8	;	Crystal structure of the SNX17 PX domain with bound sulphate
5ELQ	;	1.1	;	Crystal structure of the SNX27 PDZ domain bound to the C-terminal DGKzeta PDZ binding motif
5EMB	;	0.85	;	Crystal structure of the SNX27 PDZ domain bound to the C-terminal phosphorylated PTHR PDZ binding motif
4Z8J	;	0.95	;	Crystal structure of the SNX27 PDZ domain bound to the C-terminal PTHR PDZ binding motif
5EM9	;	1.6	;	Crystal structure of the SNX27 PDZ domain bound to the phosphorylated C-terminal 5HT4(a)R PDZ binding motif
5EMA	;	1.32	;	Crystal structure of the SNX27 PDZ domain bound to the phosphorylated C-terminal LRRC3B PDZ binding motif
6N5X	;	2.051	;	Crystal structure of the SNX5 PX domain in complex with the CI-MPR (space group P212121 - Form 1)
6N5Y	;	2.26	;	Crystal structure of the SNX5 PX domain in complex with the CI-MPR (space group P212121 - Form 1)
6N5Z	;	2.45	;	Crystal structure of the SNX5 PX domain in complex with the Sema4C
2ZXE	;	2.4	;	Crystal structure of the sodium - potassium pump in the E2.2K+.Pi state
4N7W	;	1.951	;	Crystal Structure of the sodium bile acid symporter from Yersinia frederiksenii
3ZK1	;	2.2	;	Crystal structure of the sodium binding rotor ring at pH 5.3
3ZK2	;	2.63	;	Crystal structure of the sodium binding rotor ring at pH 8.7
5BZ2	;	3.7	;	CRYSTAL STRUCTURE OF THE SODIUM PROTON ANTIPORTER NAPA IN INWARD-FACING CONFORMATION
4BWZ	;	2.984	;	Crystal structure of the sodium proton antiporter, NapA
2WIT	;	3.35	;	CRYSTAL STRUCTURE OF THE SODIUM-COUPLED GLYCINE BETAINE SYMPORTER BETP FROM CORYNEBACTERIUM GLUTAMICUM WITH BOUND SUBSTRATE
5A1S	;	2.5	;	Crystal structure of the sodium-dependent citrate symporter SeCitS form Salmonella enterica.
3B8E	;	3.5	;	Crystal structure of the sodium-potassium pump
3KDP	;	3.5	;	Crystal structure of the sodium-potassium pump
3A3Y	;	2.8	;	Crystal structure of the sodium-potassium pump with bound potassium and ouabain
2G8S	;	1.5	;	Crystal structure of the soluble Aldose sugar dehydrogenase (Asd) from Escherichia coli in the apo-form
6Q10	;	1.6	;	Crystal structure of the soluble domain (residues 71-217) of a conserved hypothetical secreted protein (Rv2700 ortholog) from Mycobacterium marinum
4LSO	;	1.7	;	Crystal structure of the soluble domain of a Type IV secretion system protein VirB8 from Bartonella quintana Toulouse
1KBW	;	2.4	;	CRYSTAL STRUCTURE OF THE SOLUBLE DOMAIN OF ANIA FROM NEISSERIA GONORRHOEAE
2YD0	;	2.7	;	Crystal structure of the soluble domain of human endoplasmic reticulum aminopeptidase 1 ERAP1
5NEN	;	2.901	;	Crystal structure of the soluble domain of LipC, a membrane fusion protein of a type I secretion system
4KAV	;	1.433	;	Crystal Structure of the soluble domain of Lipooligosaccharide phosphoethanolamine transferase A from Neisseria meningitidis
3CP0	;	1.65	;	Crystal structure of the soluble domain of membrane protein implicated in regulation of membrane protease activity from Corynebacterium glutamicum
2ZAI	;	2.7	;	Crystal structure of the soluble domain of STT3 from P. furiosus
2QRR	;	1.71	;	Crystal structure of the soluble domain of the ABC transporter, ATP-binding protein from Vibrio parahaemolyticus
6C5R	;	3.09608	;	Crystal structure of the soluble domain of the mitochondrial calcium uniporter
6LV0	;	1.998	;	Crystal structure of the soluble domain of the multiple peptide resistance factor (MprF) from Rhizobium tropici
7THW	;	2.2	;	Crystal Structure of the Soluble Domain of the Putative OmpA -Family Membrane Protein YPO0514 from Yersinia pestis
1JM1	;	1.11	;	Crystal structure of the soluble domain of the Rieske protein II (soxF) from Sulfolobus acidocaldarius
7CU9	;	1.55	;	Crystal structure of the soluble domain of TiME protein from Mycobacterium smegmatis
7CU8	;	3.3	;	Crystal structure of the soluble domain of TiME protein from Mycobacterium tuberculosis
1JFU	;	1.6	;	CRYSTAL STRUCTURE OF THE SOLUBLE DOMAIN OF TLPA FROM BRADYRHIZOBIUM JAPONICUM
4NHF	;	2.0	;	Crystal structure of the soluble domain of TrwG Type IV secretion machinery from Bartonella grahamii
4KZ1	;	2.55	;	Crystal structure of the soluble domain of VirB8 from Bartonella grahamii
1TNR	;	2.85	;	CRYSTAL STRUCTURE OF THE SOLUBLE HUMAN 55 KD TNF RECEPTOR-HUMAN TNF-BETA COMPLEX: IMPLICATIONS FOR TNF RECEPTOR ACTIVATION
1E4J	;	2.5	;	Crystal structure of the soluble human Fc-gamma Receptor III
2OUX	;	2.16	;	Crystal structure of the soluble part of a magnesium transporter
3AZC	;	2.0	;	Crystal structure of the soluble part of cytochrome b6f complex iron-sulfur subunit from Thermosynechococcus elongatus BP-1
1C9U	;	2.2	;	CRYSTAL STRUCTURE OF THE SOLUBLE QUINOPROTEIN GLUCOSE DEHYDROGENASE IN COMPLEX WITH PQQ
2YJP	;	2.26	;	Crystal structure of the solute receptors for L-cysteine of Neisseria gonorrhoeae
4C4M	;	1.74	;	Crystal structure of the Sonic Hedgehog-chondroitin-4-sulphate complex
4C4N	;	2.36	;	Crystal structure of the Sonic Hedgehog-heparin complex
1V02	;	1.8	;	Crystal structure of the Sorghum bicolor dhurrinase 1
1V03	;	2.0	;	Crystal structure of the Sorghum bicolor dhurrinase 1
1G9F	;	2.5	;	CRYSTAL STRUCTURE OF THE SOYBEAN AGGLUTININ IN A COMPLEX WITH A BIANTENNARY BLOOD GROUP ANTIGEN ANALOG
7MY4	;	1.72	;	Crystal Structure of the SPA17 Docking and Dimerization Domain from Danio rerio
4GEQ	;	2.01	;	Crystal structure of the Spc24-Spc25/Cnn1 binding interface
7PTB	;	2.08	;	Crystal structure of the SPD-2 domain of human CEP192
1U9S	;	2.9	;	Crystal structure of the specificity domain of Ribonuclease P of the A-type
1NBS	;	3.15	;	Crystal structure of the specificity domain of Ribonuclease P RNA
1DTM	;	2.13	;	CRYSTAL STRUCTURE OF THE SPERM-WHALE MYOGLOBIN MUTANT H93G COMPLEXED WITH 4-METHYLIMIDAZOLE, METAQUO FORM
5IOJ	;	1.76	;	Crystal structure of the Sphingobium sp. TCM1 phosphotriesterase without the binuclear manganese center
5JRL	;	3.2	;	Crystal Structure of the Sphingopyxin I Lasso Peptide Isopeptidase SpI-IsoP (Native)
5JRK	;	3.0	;	Crystal Structure of the Sphingopyxin I Lasso Peptide Isopeptidase SpI-IsoP (SeMet-derived)
4F5C	;	3.2	;	Crystal structure of the spike receptor binding domain of a porcine respiratory coronavirus in complex with the pig aminopeptidase N ectodomain
3IFX	;	3.56	;	Crystal structure of the Spin-labeled KcsA mutant V48R1
1Z98	;	2.1	;	Crystal structure of the spinach aquaporin SoPIP2;1 in a closed conformation
2B5F	;	3.9	;	Crystal structure of the spinach aquaporin SoPIP2;1 in an open conformation to 3.9 resolution
3CLL	;	2.3	;	Crystal structure of the Spinach Aquaporin SoPIP2;1 S115E mutant
3CN5	;	2.05	;	Crystal structure of the Spinach Aquaporin SoPIP2;1 S115E, S274E mutant
3CN6	;	2.95	;	Crystal structure of the Spinach Aquaporin SoPIP2;1 S274E mutant
1TEF	;	1.9	;	Crystal structure of the spinach plastocyanin mutants G8D/K30C/T69C and K30C/T69C- a study of the effect on crystal packing and thermostability from the introduction of a novel disulfide bond
1TEG	;	1.96	;	Crystal structure of the spinach plastocyanin mutants G8D/K30C/T69C and K30C/T69C- a study of the effect on crystal packing and thermostability from the introduction of a novel disulfide bond
4TS0	;	2.8	;	Crystal structure of the Spinach RNA aptamer in complex with DFHBI, barium ions
4TS2	;	2.884	;	Crystal structure of the Spinach RNA aptamer in complex with DFHBI, magnesium ions
6PNP	;	1.94	;	Crystal structure of the splice insert-free neurexin-1 LNS2 domain in complex with neurexophilin-1
3D9H	;	2.2	;	Crystal Structure of the Splice Variant of Human ASB9 (hASB9-2), an Ankyrin Repeat Protein
1E7K	;	2.9	;	Crystal structure of the spliceosomal 15.5kD protein bound to a U4 snRNA fragment
1A9N	;	2.38	;	CRYSTAL STRUCTURE OF THE SPLICEOSOMAL U2B''-U2A' PROTEIN COMPLEX BOUND TO A FRAGMENT OF U2 SMALL NUCLEAR RNA
3TP2	;	2.4	;	Crystal Structure of the Splicing Factor Cwc2 from yeast
7V6H	;	3.054	;	Crystal Structure of the SpnL
6IC8	;	1.929	;	Crystal structure of the SPOC domain of human PHF3 in complex with RNA polymerase II CTD diheptapeptide phosphorylated on Ser2
6Q5Y	;	2.85	;	Crystal structure of the SPOC domain of human PHF3 in complex with RNA polymerase II CTD diheptapeptide phosphorylated on Ser2Ser5
6IC9	;	1.748	;	Crystal structure of the SPOC domain of human PHF3 in complex with RNA polymerase II CTD diheptapeptide phosphorylated on Ser2Ser7
7Z27	;	1.45	;	Crystal structure of the SPOC domain of human RBM15
7Z1K	;	1.55	;	Crystal structure of the SPOC domain of human SHARP (SPEN) in complex with RNA polymerase II CTD heptapeptide phosphorylated on Ser5
8OU1	;	1.7	;	Crystal structure of the SPOC domain of mouse SPOCD1
5KXF	;	2.7	;	Crystal structure of the SPOC domain of the Arabidopsis flowering regulator FPA
1OW1	;	1.8	;	Crystal structure of the SPOC domain of the human transcriptional corepressor, SHARP.
4EOZ	;	2.4	;	Crystal structure of the SPOP BTB domain complexed with the Cul3 N-terminal domain
7KPI	;	1.7	;	Crystal structure of the SPOP MATH domain
7KPK	;	1.71	;	Crystal structure of the SPOP MATH domain in complex with a fragment of Pdx1
3FYR	;	1.97	;	Crystal structure of the sporulation histidine kinase inhibitor Sda from Bacillus subtilis
3PMD	;	1.76	;	Crystal structure of the sporulation inhibitor pXO1-118 from Bacillus anthracis
3PMC	;	1.49	;	Crystal structure of the sporulation inhibitor pXO2-61 from Bacillus anthracis
1X7O	;	2.37	;	Crystal structure of the SpoU Methyltransferase AviRb from Streptomyces viridochromogenes
1X7P	;	2.55	;	Crystal structure of the SpoU Methyltransferase AviRb from Streptomyces viridochromogenes in complex with the cofactor AdoMet
2X5N	;	1.3	;	Crystal Structure of the SpRpn10 VWA domain
4QT6	;	1.64	;	Crystal structure of the SPRY domain of human HERC1
6JWM	;	1.23	;	Crystal structure of the SPRY domain of SPSB2 in complex with cR7, a potent cyclic peptide inhibitor of SPSB2-iNOS interaction
6JWN	;	1.61	;	Crystal structure of the SPRY domain of SPSB2 in complex with cR9, a cyclic peptide inhibitor of SPSB-iNOS interaction
4XW3	;	2.0	;	Crystal structure of the SPRY domain of the human DEAD-box protein DDX1
7CCB	;	1.62	;	Crystal structure of the SPRY domain-containing protein 7 (SPRY7)
3PSF	;	2.59	;	Crystal Structure of the Spt6 core domain from Saccharomyces cerevisiae, Form Spt6(236-1259)
3PSI	;	3.3	;	Crystal Structure of the Spt6 core domain from Saccharomyces cerevisiae, Form Spt6(239-1451)
3PSK	;	2.1	;	Crystal Structure of the Spt6 Tandem SH2 Domain from Saccharomyces cerevisiae, Form Native Spt6 (1247-1451)
3PSJ	;	2.702	;	Crystal Structure of the Spt6 Tandem SH2 Domain from Saccharomyces cerevisiae, Form Se-Spt6 (1247-1451)
5IJP	;	2.75	;	Crystal structure of the SPX domain of Chaetomium thermophilum Vtc4 in complex with inositol hexakisphosphate (InsP6).
4MLS	;	1.984	;	Crystal structure of the SpyTag and SpyCatcher-deltaN1 complex
4MLI	;	2.1	;	Crystal structure of the SpyTag/SpyCatcher complex
1IWO	;	3.1	;	Crystal structure of the SR Ca2+-ATPase in the absence of Ca2+
4XOU	;	2.8	;	Crystal structure of the SR Ca2+-ATPase in the Ca2-E1-MgAMPPCP form determined by serial femtosecond crystallography using an X-ray free-electron laser.
2AGV	;	2.4	;	Crystal structure of the SR CA2+-ATPASE with BHQ and TG
1VFP	;	2.9	;	Crystal structure of the SR CA2+-ATPase with bound AMPPCP
4YCL	;	3.25	;	Crystal structure of the SR CA2+-ATPASE with bound CPA
2EAT	;	2.9	;	Crystal structure of the SR CA2+-ATPASE with bound CPA and TG
2EAU	;	2.8	;	Crystal structure of the SR CA2+-ATPASE with bound CPA in the presence of curcumin
1WPG	;	2.3	;	Crystal structure of the SR CA2+-ATPase with MGF4
2ZBD	;	2.4	;	Crystal Structure of the SR Calcium Pump with Bound Aluminium Fluoride, ADP and Calcium
5B5M	;	3.3	;	Crystal structure of the Sr-substituted LH1-RC complex from Tch. tepidum
5V44	;	1.56	;	Crystal structure of the SR1 domain of human sacsin
5V47	;	1.84	;	Crystal structure of the SR1 domain of lizard sacsin
4J5X	;	2.8	;	Crystal Structure of the SR12813-bound PXR/RXRalpha LBD Heterotetramer Complex
3BI7	;	1.7	;	Crystal structure of the SRA domain of E3 ubiquitin-protein ligase UHRF1
3OLN	;	2.3	;	Crystal structure of the SRA domain of E3 ubiquitin-protein ligase UHRF2
2ZKD	;	1.6	;	Crystal structure of the SRA domain of mouse Np95 in complex with hemi-methylated CpG DNA
2ZKE	;	2.6	;	Crystal structure of the SRA domain of mouse Np95 in complex with hemi-methylated CpG DNA
2ZKF	;	2.55	;	Crystal structure of the SRA domain of mouse Np95 in complex with hemi-methylated CpG DNA
2PB7	;	1.9	;	Crystal Structure of the SRA domain of the human UHRF1 protein
5KO9	;	1.5	;	Crystal Structure of the SRAP Domain of Human HMCES Protein
2HDX	;	2.35	;	Crystal structure of the Src homology-2 domain of SH2-B in complex with Jak2 pTyr813 phosphopeptide
2HDV	;	2.0	;	Crystal structure of the Src Homology-2 domain of the adapter protein SH2-B
1P13	;	1.63	;	Crystal Structure of the Src SH2 Domain Complexed with Peptide (SDpYANFK)
4RTV	;	1.37	;	Crystal structure of the Src tyrosine kinase SH3 domain S94A/Q128R mutant in complex with the high affinity synthetic peptide APP12
4RTX	;	1.32	;	Crystal structure of the Src tyrosine kinase SH3 domain T96G/Q128R mutant
3NHN	;	2.61	;	Crystal structure of the SRC-family kinase HCK SH3-SH2-linker regulatory region
7DPX	;	2.002	;	Crystal structure of the SRCR domain of human SCARA1/CD204
7C00	;	1.7	;	Crystal structure of the SRCR domain of human SCARA5.
6J02	;	1.803	;	Crystal structure of the SRCR domain of mouse SCARA1
7BZZ	;	2.501	;	Crystal structure of the SRCR domain of mouse SCARA5
1LNG	;	2.3	;	Crystal Structure of the SRP19-7S.S SRP RNA Complex of M. jannaschii
3KTW	;	3.2	;	Crystal structure of the SRP19/S-domain SRP RNA complex of Sulfolobus solfataricus
2V3C	;	2.5	;	Crystal structure of the SRP54-SRP19-7S.S SRP RNA complex of M. jannaschii
5EQ2	;	1.8	;	Crystal Structure of the SrpA Adhesin from Streptococcus sanguinis
5EQ3	;	2.0	;	Crystal structure of the SrpA adhesin from Streptococcus sanguinis with a sialyl galactose disaccharide bound
5EQ4	;	2.3	;	Crystal structure of the SrpA adhesin R347E mutant from Streptococcus sanguinis
6PNQ	;	1.947	;	Crystal structure of the SS2A splice insert-containing neurexin-1 LNS2 domain in complex with neurexophilin-1
3KOJ	;	1.895	;	Crystal structure of the SSB domain of Q5N255_SYNP6 protein from Synechococcus sp. Northeast Structural Genomics Consortium Target SnR59a.
6AEQ	;	2.25181	;	Crystal structure of the ssDNA-binding domain of DnaT from Salmonella enterica Serovar Typhimurium LT2
6AEP	;	1.844	;	Crystal structure of the ssDNA-binding domain of DnaT from Salmonella enterica Serovar Typhimurium LT2 at 1.84 angstrom resolution
3C4S	;	1.7	;	Crystal structure of the Ssl0352 protein from Synechocystis sp. Northeast Structural Genomics Consortium target SgR42
5D3I	;	3.2	;	Crystal structure of the SSL3-TLR2 complex
3GFM	;	2.1	;	Crystal structure of the ST1710 mutant (K91A) protein
3GFJ	;	2.2	;	Crystal structure of the ST1710 mutant (R89A) protein
3GFL	;	1.9	;	Crystal structure of the ST1710 mutant (R90A) protein
4YC2	;	3.02	;	Crystal structure of the stabilized inner domain of clade A/E HIV-1 gp120 from E. coli in complex with the antibody A32.
4YBL	;	3.1	;	Crystal structure of the stabilized inner domain of clade A/E HIV-1 gp120 in complex with the ADCC mediating ANTI-HIV-1 antibody A32
3TT9	;	1.55	;	Crystal structure of the stable degradation fragment of human plakophilin 2 isoform a (PKP2a) C752R variant
6UY7	;	2.105	;	Crystal structure of the STAC3 tandem SH3 domains - P269R
6UY8	;	1.649	;	Crystal structure of the STAC3 tandem SH3 domains - P269R, K329N
6UY9	;	1.6	;	Crystal structure of the STAC3 tandem SH3 domains - P269R, W284S
3LMA	;	1.993	;	Crystal structure of the stage V sporulation protein AD (SpoVAD) from Bacillus licheniformis. Northeast Structural Genomics Consortium Target BiR6.
3UFA	;	1.8	;	Crystal structure of the staphylococcal serine protease SplA in complex with a specific phosphonate inhibitor
4MVN	;	1.7	;	Crystal structure of the staphylococcal serine protease SplA in complex with a specific phosphonate inhibitor
2Z8L	;	1.65	;	Crystal Structure of the Staphylococcal superantigen-like protein SSL5 at pH 4.6 complexed with sialyl Lewis X
2R61	;	2.75	;	Crystal structure of the Staphylococcal superantigen-like protein SSL5 in complex with sialyl-Lewis X at pH 7.4
3DI1	;	2.2	;	Crystal structure of the Staphylococcus aureus Dihydrodipicolinate synthase-pyruvate complex
3GNS	;	2.706	;	Crystal Structure of the Staphylococcus aureus Enoyl-Acyl Carrier Protein Reductase (FabI) in apo form (one molecule in AU)
3GNT	;	2.75	;	Crystal Structure of the Staphylococcus aureus Enoyl-Acyl Carrier Protein Reductase (FabI) in apo form (two molecules in AU)
3GR6	;	2.28	;	Crystal structure of the staphylococcus aureus enoyl-acyl carrier protein reductase (fabI) in complex with NADP and triclosan
1U2W	;	1.9	;	Crystal Structure of the Staphylococcus aureus pI258 CadC
3F72	;	2.31	;	Crystal Structure of the Staphylococcus aureus pI258 CadC Metal Binding Site 2 Mutant
4KJM	;	2.0	;	Crystal structure of the Staphylococcus aureus protein (NP_646141.1, domain 3912-4037) similar to streptococcal adhesins emb and ebhA/ebhB
5DBL	;	1.6	;	Crystal structure of the Staphylococcus aureus SasG E1-G52 Y625W mutant
4WVE	;	1.6	;	Crystal structure of the Staphylococcus aureus SasG G52-E2-G53 module
3QSZ	;	2.389	;	Crystal Structure of the STAR-related lipid transfer protein (fragment 25-204) from Xanthomonas axonopodis at the resolution 2.4A, Northeast Structural Genomics Consortium Target XaR342
4AIO	;	1.9	;	Crystal structure of the starch debranching enzyme barley limit dextrinase
4BFN	;	1.32	;	Crystal Structure of the Starch-Binding Domain from Rhizopus oryzae Glucoamylase in Complex with isomaltotetraose
4BFO	;	1.175	;	Crystal Structure of the Starch-Binding Domain from Rhizopus oryzae Glucoamylase in Complex with isomaltotriose
7C1H	;	2.3	;	Crystal structure of the starter condensation domain of rhizomide synthetase RzmA
7C1R	;	1.698	;	Crystal structure of the starter condensation domain of rhizomide synthetase RzmA mutant H140A/R148A in complex with C8-CoA
7C1S	;	2.586	;	Crystal structure of the starter condensation domain of rhizomide synthetase RzmA mutant H140A/R148A in complex with C8-CoA and Leu-SNAC
7C1U	;	1.4	;	Crystal structure of the starter condensation domain of rhizomide synthetase RzmA mutant H140V/R148A in a ""product-released"" conformation
7C1K	;	2.755	;	Crystal structure of the starter condensation domain of rhizomide synthetase RzmA mutant R148A
7C1L	;	1.85	;	Crystal structure of the starter condensation domain of rhizomide synthetase RzmA mutant R148A in complex with C8-CoA
7C1P	;	2.6	;	Crystal structure of the starter condensation domain of the rhizomide synthetase RzmA mutant H140V, R148A
3LLO	;	1.57	;	Crystal structure of the STAS domain of motor protein prestin (anion transporter SLC26A5)
2E6E	;	2.5	;	Crystal structure of the stationary phase survival protein SurE from Thermus thermophilus HB8
2E6C	;	2.05	;	Crystal structure of the stationary phase survival protein SurE from Thermus thermophilus HB8 cocrystallized with manganese and AMP
2E6B	;	2.5	;	Crystal structure of the stationary phase survival protein SurE from Thermus thermophilus HB8 in complex with magnesium and tungstate
2E6G	;	2.6	;	Crystal structure of the stationary phase survival protein SurE from Thermus thermophilus HB8 in complex with phosphate
2E69	;	2.2	;	Crystal structure of the stationary phase survival protein SurE from Thermus thermophilus HB8 in complex with sulfate
6YC4	;	2.6	;	Crystal structure of the steady-state activated state of the light-driven sodium pump KR2 in the pentameric form at room temperature, pH 8.0
6YC0	;	2.7	;	Crystal structure of the steady-state-SMX activated state of the light-driven sodium pump KR2 in the pentameric form at room temperature, pH 8.0
2VVE	;	1.77	;	Crystal structure of the stem and receptor binding domain of the spike protein P1 from bacteriophage PM2
3BS7	;	1.9	;	Crystal structure of the Sterile Alpha Motif (SAM) domain of Hyphen/Aveugle
7JJ1	;	3.0	;	Crystal structure of the sterol 14alpha-demethylase-ferredoxin (CYP51-fx) heme domain and architectural comparison to the whole fusion protein
6BYM	;	2.2	;	Crystal structure of the sterol-bound second StART domain of yeast Lam4
6MR4	;	2.71	;	Crystal structure of the Sth1 bromodomain from S.cerevisiae
6UY1	;	2.21	;	Crystal structure of the Sth1 bromodomain from Saccharomyces cerevisiae at 2.2 Angstrom resolution
2BBD	;	2.04	;	Crystal Structure of the STIV MCP
6ST8	;	2.04	;	Crystal structure of the strawberry pathogenesis-related 10 (PR-10) Fra a 1.02 protein
6ST9	;	1.97	;	Crystal structure of the strawberry pathogenesis-related 10 (PR-10) Fra a 1.02 protein, D48R mutant
6STA	;	2.19	;	Crystal structure of the strawberry pathogenesis-related 10 (PR-10) Fra a 1.02 protein, E46A D48A mutant
6STB	;	2.27	;	Crystal structure of the strawberry pathogenesis-related 10 (PR-10) Fra a 1.02 protein, Q64W mutant
4C9C	;	2.2	;	Crystal Structure of the Strawberry Pathogenesis-Related 10 (PR-10) Fra a 1E protein (Form A)
4C9I	;	3.1	;	Crystal Structure of the Strawberry Pathogenesis-Related 10 (PR-10) Fra a 1E protein (Form B)
5AMW	;	1.9	;	Crystal Structure of the Strawberry Pathogenesis-Related 10 (PR-10) Fra a 2 protein (A141F) processed with the CrystalDirect automated mounting and cryo-cooling technology
4C94	;	3.0	;	Crystal Structure of the Strawberry Pathogenesis-Related 10 (PR-10) Fra a 3 protein in complex with Catechin
3DBN	;	2.9	;	Crystal structure of the Streptoccocus suis serotype2 D-mannonate dehydratase in complex with its substrate
4NSM	;	1.6	;	crystal structure of the streptococcal collagen-like protein 2 globular domain from invasive M3-type group A Streptococcus
1PVJ	;	3.0	;	Crystal structure of the Streptococcal pyrogenic exotoxin B (SpeB)- inhibitor complex
1TY0	;	1.75	;	Crystal structure of the streptococcal pyrogenic exotoxin J (SPE-J)
1TY2	;	2.0	;	Crystal structure of the streptococcal pyrogenic exotoxin J (SPE-J)
1AN8	;	2.4	;	CRYSTAL STRUCTURE OF THE STREPTOCOCCAL SUPERANTIGEN SPE-C
3RCC	;	3.1	;	Crystal Structure of the Streptococcus agalactiae Sortase A
4F2E	;	1.449	;	Crystal structure of the Streptococcus pneumoniae D39 copper chaperone CupA with Cu(I)
1K47	;	2.42	;	Crystal Structure of the Streptococcus pneumoniae Phosphomevalonate Kinase (PMK)
5B2S	;	2.2	;	Crystal structure of the Streptococcus pyogenes Cas9 EQR variant in complex with sgRNA and target DNA (TGAG PAM)
5B2R	;	2.0	;	Crystal structure of the Streptococcus pyogenes Cas9 VQR variant in complex with sgRNA and target DNA (TGA PAM)
5B2T	;	2.2	;	Crystal structure of the Streptococcus pyogenes Cas9 VRER variant in complex with sgRNA and target DNA (TGCG PAM)
2X5P	;	1.6	;	Crystal structure of the Streptococcus pyogenes fibronectin binding protein Fbab-B
3PNT	;	2.8	;	Crystal Structure of the Streptococcus pyogenes NAD+ glycohydrolase SPN in complex with IFS, the Immunity Factor for SPN
2WDY	;	1.4	;	Crystal structure of the Streptomyces coelicolor D111A AcpS mutant in complex with cofactor CoA at 1.4 A
2WDS	;	1.35	;	Crystal structure of the Streptomyces coelicolor H110A AcpS mutant in complex with cofactor CoA at 1.3 A
2JCA	;	1.98	;	Crystal structure of the streptomyces coelicolor holo- [Acyl-carrier-protein] Synthase (AcpS) at 2 A.
2JBZ	;	1.62	;	Crystal structure of the Streptomyces coelicolor holo-[Acyl-carrier-protein] Synthase (AcpS) in complex with coenzyme A at 1.6 A
3B6C	;	2.3	;	Crystal structure of the Streptomyces coelicolor TetR family protein ActR in complex with (S)-DNPA
3B6A	;	3.05	;	Crystal structure of the Streptomyces coelicolor TetR family protein ActR in complex with actinorhodin
3TL1	;	1.8	;	Crystal structure of the Streptomyces coelicolor WhiE ORFVI polyketide aromatase/cyclase
1JFR	;	1.9	;	CRYSTAL STRUCTURE OF THE STREPTOMYCES EXFOLIATUS LIPASE AT 1.9A RESOLUTION: A MODEL FOR A FAMILY OF PLATELET-ACTIVATING FACTOR ACETYLHYDROLASES
1F2O	;	1.7	;	CRYSTAL STRUCTURE OF THE STREPTOMYCES GRISEUS AMINOPEPTIDASE COMPLEXED WITH L-LEUCINE
1F2P	;	1.8	;	CRYSTAL STRUCTURE OF THE STREPTOMYCES GRISEUS AMINOPEPTIDASE COMPLEXED WITH L-PHENYLALANINE
1SKF	;	2.0	;	CRYSTAL STRUCTURE OF THE STREPTOMYCES K15 DD-TRANSPEPTIDASE
4BMW	;	1.99	;	Crystal structure of the Streptomyces reticuli HbpS E78D, E81D double mutant
4PO2	;	2.0	;	Crystal Structure of the Stress-Inducible Human Heat Shock Protein HSP70 Substrate-Binding Domain in Complex with Peptide Substrate
5CBK	;	2.462	;	Crystal structure of the strigolactone receptor ShHTL5 from Striga hermonthica
6A9D	;	2.302	;	Crystal structure of the strigolactone receptor ShHTL7 from Striga hermonthica
1CQR	;	2.0	;	CRYSTAL STRUCTURE OF THE STROMELYSIN CATALYTIC DOMAIN AT 2.0 A RESOLUTION
1HV5	;	2.6	;	CRYSTAL STRUCTURE OF THE STROMELYSIN-3 (MMP-11) CATALYTIC DOMAIN COMPLEXED WITH A PHOSPHINIC INHIBITOR
8EHZ	;	2.06	;	Crystal structure of the STUB1 TPR domain in complex with H317, a Helicon Polypeptide
8EI0	;	1.47	;	Crystal structure of the STUB1 TPR domain in complex with H318, a Helicon Polypeptide
7D6Q	;	1.8	;	Crystal structure of the Stx2a
7VHC	;	1.8	;	Crystal structure of the STX2a complexed with AR4A peptide
7D6R	;	1.6	;	Crystal structure of the Stx2a complexed with MMA betaAla peptide
7VHD	;	1.8	;	Crystal structure of the STX2a complexed with R4A peptide
7VHF	;	1.75	;	Crystal structure of the STX2a complexed with RRA peptide
7VHE	;	1.9	;	Crystal structure of the STX2a complexed with RRRA peptide
5SUP	;	2.6	;	Crystal structure of the Sub2-Yra1 complex in association with RNA
5NGG	;	1.18	;	Crystal structure of the subclass B3 metallo-beta-lactamase BJP-1 in complex with acetate anion
6FMO	;	3.18	;	Crystal structure of the substrate (obtusifoliol)-bound and ligand-free I105F mutant of sterol 14-alpha demethylase (CYP51) from Trypanosoma cruzi
3DPP	;	2.5	;	Crystal structure of the substrate binding domain of E. coli DnaK in complex with a long pyrrhocoricin-derived inhibitor peptide (form A)
3DPQ	;	2.6	;	Crystal structure of the substrate binding domain of E. coli DnaK in complex with a long pyrrhocoricin-derived inhibitor peptide (form B)
3DPO	;	2.1	;	Crystal structure of the substrate binding domain of E. coli DnaK in complex with a short pyrrhocoricin-derived inhibitor peptide
4E81	;	1.9	;	Crystal structure of the substrate binding domain of E.coli DnaK in complex with a short apidaecin peptide
4EZP	;	1.65	;	Crystal structure of the substrate binding domain of E.coli DnaK in complex with A3-APO(residues 1 to 20)
4F00	;	1.95	;	Crystal structure of the substrate binding domain of E.coli DnaK in complex with an apidaecin fragment from the bumblebee (residues 3 to 11)
4JWC	;	1.8	;	Crystal structure of the substrate binding domain of E.coli DnaK in complex with bovine Bac7(1-16)
4JWD	;	1.95	;	Crystal structure of the substrate binding domain of E.coli DnaK in complex with bovine Bac7(15-28)
4EZT	;	2.0	;	Crystal structure of the substrate binding domain of E.coli DnaK in complex with heliocin (residues 14 to 21)
4EZS	;	1.9	;	Crystal structure of the substrate binding domain of E.coli DnaK in complex with metchnikowin (residues 20 to 26)
4EZO	;	1.9	;	Crystal structure of the substrate binding domain of E.coli DnaK in complex with PR-39 (residues 1 to 15)
4EZU	;	1.9	;	Crystal structure of the substrate binding domain of E.coli DnaK in complex with PR-bombesin in space group I222
4EZV	;	2.1	;	Crystal structure of the substrate binding domain of E.coli DnaK in complex with PR-bombesin in space group P21212
4EZN	;	1.8	;	Crystal structure of the substrate binding domain of E.coli DnaK in complex with pyrrhocoricin
4HYB	;	1.7	;	Crystal structure of the substrate binding domain of E.coli DnaK in complex with pyrrhocoricin_LYZI (residues 1 to 10)
4HY9	;	1.55	;	Crystal structure of the substrate binding domain of E.coli DnaK in complex with pyrrhocoricin_LYZZ (residues 1 to 11)
4JWE	;	1.95	;	Crystal structure of the substrate binding domain of E.coli DnaK in complex with sheep Bac7(1-21)
4JWI	;	1.9	;	Crystal structure of the substrate binding domain of E.coli DnaK in complex with sheep Bac7(35-43)
3QNJ	;	2.28	;	Crystal structure of the substrate binding domain of E.coli DnaK in complex with the antimicrobial peptide oncocin
4EZR	;	1.9	;	Crystal structure of the substrate binding domain of E.coli DnaK in complex with the C-terminal part of drosocin (residues 12 to 19)
4EZQ	;	2.0	;	Crystal structure of the substrate binding domain of E.coli DnaK in complex with the C-terminal part of pyrrhocoricin (residues 12 to 20)
4EZZ	;	2.05	;	Crystal structure of the substrate binding domain of E.coli DnaK in complex with the designer peptide ELPLVKI
4EZY	;	1.85	;	Crystal structure of the substrate binding domain of E.coli DnaK in complex with the designer peptide NRLILTG
4EZW	;	1.8	;	Crystal structure of the substrate binding domain of E.coli DnaK in complex with the designer peptide NRLLLTG
4EZX	;	1.7	;	Crystal structure of the substrate binding domain of E.coli DnaK in complex with the designer peptide NRLMLTG
6LU4	;	2.8	;	Crystal structure of the substrate binding protein from Microbacterium hydrocarbonoxydans complexed with propylparaben
6JF1	;	1.95	;	Crystal structure of the substrate binding protein of a methionine transporter from Streptococcus pneumoniae
4YMX	;	1.481	;	Crystal structure of the substrate binding protein of an amino acid ABC transporter
3C9H	;	1.9	;	Crystal structure of the substrate binding protein of the ABC transporter from Agrobacterium tumefaciens
7N6L	;	2.4	;	Crystal structure of the substrate-binding domain of E. coli DnaK in complex with the peptide EANQQKPLLGLFADG
7JN9	;	2.4	;	Crystal structure of the substrate-binding domain of E. coli DnaK in complex with the peptide QEHTGSQLRIAAYGP
7JMM	;	2.56	;	Crystal structure of the substrate-binding domain of E. coli DnaK in complex with the peptide RAKNIILLSR
7N6K	;	2.55	;	Crystal structure of the substrate-binding domain of E. coli DnaK in complex with the peptide RALALLPLSR
7JN8	;	3.09	;	Crystal structure of the substrate-binding domain of E. coli DnaK in complex with the peptide RGNTLVIVSR
7JNE	;	2.54	;	Crystal structure of the substrate-binding domain of E. coli DnaK in complex with the peptide RGSQLRIASR
7N6J	;	2.0	;	Crystal structure of the substrate-binding domain of E. coli DnaK in complex with the peptide RKQSTIALALLPLLFTPRR
7N6M	;	1.82	;	Crystal structure of the substrate-binding domain of E. coli DnaK in complex with the peptide RQKPLLGLSR
7Z8E	;	1.58	;	Crystal structure of the substrate-binding protein YejA from S. meliloti in complex with peptide fragment
7Z6F	;	1.65	;	Crystal structure of the substrate-binding protein YejA in complex with peptide fragment
7PD2	;	1.99	;	Crystal structure of the substrate-free radical SAM tyrosine lyase ThiH (2-iminoacetate synthase) from Thermosinus carboxydivorans
1YU6	;	1.55	;	Crystal Structure of the Subtilisin Carlsberg:OMTKY3 Complex
2P3B	;	2.1	;	Crystal Structure of the subtype B wild type HIV protease complexed with TL-3 inhibitor
2P3C	;	2.1	;	Crystal Structure of the subtype F wild type HIV protease complexed with TL-3 inhibitor
4RND	;	3.18	;	Crystal Structure of the subunit DF-assembly of the eukaryotic V-ATPase.
2YIC	;	1.96	;	Crystal structure of the SucA domain of Mycobacterium smegmatis alpha- ketoglutarate decarboxylase (triclinic form)
2XTA	;	2.2	;	Crystal structure of the SucA domain of Mycobacterium smegmatis alpha- ketoglutarate decarboxylase in complex with acetyl-CoA (triclinic form)
2YID	;	2.25	;	Crystal structure of the SucA domain of Mycobacterium smegmatis alpha- ketoglutarate decarboxylase in complex with the enamine-ThDP intermediate
2Y0P	;	2.4	;	Crystal structure of the SucA domain of Mycobacterium smegmatis alpha- ketoglutarate decarboxylase in complex with the enamine-ThDP intermediate and acetyl-CoA
6I2R	;	2.2	;	Crystal structure of the SucA domain of Mycobacterium smegmatis KGD (alpha-ketoglutarate decarboxylase), mutant R802A, in complex with GarA
6I2S	;	2.4	;	Crystal structure of the SucA domain of Mycobacterium smegmatis KGD (R802A) in complex with GarA, following 2-oxoglutarate soak
6R2B	;	1.96	;	Crystal structure of the SucA domain of Mycobacterium smegmatis KGD after soaking with succinylphosphonate
6R2C	;	2.09	;	Crystal structure of the SucA domain of Mycobacterium smegmatis KGD after soaking with succinylphosphonate phosphonoethyl ester (PESP)
6R2D	;	2.3	;	Crystal structure of the SucA domain of Mycobacterium smegmatis KGD after soaking with succinylphosphonate phosphonoethyl ester, followed by temperature increase
6R29	;	1.67	;	Crystal structure of the SucA domain of Mycobacterium smegmatis KGD cocrystallized with succinylphosphonate
6R2A	;	1.7	;	Crystal structure of the SucA domain of Mycobacterium smegmatis KGD cocrystallized with succinylphosphonate phosphonoethyl ester (PESP)
3ZHT	;	2.15	;	Crystal structure of the SucA domain of Mycobacterium smegmatis KGD, first post-decarboxylation intermediate from 2-oxoadipate
3ZHS	;	2.1	;	Crystal structure of the SucA domain of Mycobacterium smegmatis KGD, first post-decarboxylation intermediate from alpha-ketoglutarate
3ZHV	;	2.3	;	Crystal structure of the SucA domain of Mycobacterium smegmatis KGD, post-decarboxylation intermediate from pyruvate (2-hydroxyethyl-ThDP)
3ZHU	;	2.3	;	Crystal structure of the SucA domain of Mycobacterium smegmatis KGD, second post-decarboxylation intermediate from 2-oxoadipate
1D4D	;	2.5	;	CRYSTAL STRUCTURE OF THE SUCCINATE COMPLEXED FORM OF THE FLAVOCYTOCHROME C FUMARATE REDUCTASE OF SHEWANELLA PUTREFACIENS STRAIN MR-1
2RAD	;	2.75	;	Crystal structure of the succinoglycan biosynthesis protein. Northeast structural Genomics Consortium target BcR135
7T1Q	;	2.25	;	Crystal Structure of the Succinyl-diaminopimelate Desuccinylase (DapE) from Acinetobacter baumannii in complex with Succinic Acid
8F8O	;	2.1	;	Crystal Structure of the Succinyl-diaminopimelate Desuccinylase (DapE) from Acinetobacter baumannii in complex with Succinic and L-Lactic Acids
1YW4	;	2.0	;	Crystal Structure of the Succinylglutamate Desuccinylase from Chromobacterium violaceum, Northeast Structural Genomics Target CvR22.
7BBR	;	1.3	;	Crystal structure of the sugar acid binding protein DctPAm from Advenella mimigardefordensis strain DPN7T
7BCO	;	2.0	;	Crystal structure of the sugar acid binding protein DctPAm from Advenella mimigardefordensis strain DPN7T in complex with D-foconate
7BCR	;	2.0	;	Crystal structure of the sugar acid binding protein DctPAm from Advenella mimigardefordensis strain DPN7T in complex with galactonate
7BCP	;	2.0	;	Crystal structure of the sugar acid binding protein DctPAm from Advenella mimigardefordensis strain DPN7T in complex with gluconate
7BCN	;	1.7	;	Crystal structure of the sugar acid binding protein DctPAm from Advenella mimigardefordensis strain DPN7T in complex with Xylonic acid
6NDI	;	2.6	;	Crystal Structure of the Sugar Binding Domain of LacI Family Protein from Klebsiella pneumoniae
2F5T	;	1.45	;	Crystal Structure of the sugar binding domain of the archaeal transcriptional regulator TrmB
4QJB	;	2.05	;	Crystal structure of the sugar phosphatase PfHAD1 from Plasmodium falciparum
2RJ2	;	1.7	;	Crystal Structure of the Sugar Recognizing SCF Ubiquitin Ligase at 1.7 Resolution
2XTS	;	1.33	;	Crystal Structure of the Sulfane Dehydrogenase SoxCD from Paracoccus pantotrophus
6PTK	;	1.75	;	Crystal structure of the sulfatase PsS1_NC C84A with bound sulfate ion
4PW3	;	2.35	;	Crystal structure of the sulfite dehydrogenase SorT from Sinorhizobium meliloti
5K3X	;	1.6	;	Crystal Structure of the sulfite dehydrogenase, SorT R78K mutant from Sinorhizobium meliloti
5WA0	;	2.1	;	Crystal Structure of the sulfite dehydrogenase, SorT R78Q mutant from Sinorhizobium meliloti
1TV4	;	1.8	;	Crystal structure of the sulfite MtmB complex
2G3M	;	2.55	;	Crystal structure of the Sulfolobus solfataricus alpha-glucosidase MalA
2G3N	;	2.55	;	Crystal structure of the Sulfolobus solfataricus alpha-glucosidase MalA in complex with beta-octyl-glucopyranoside
6K8N	;	2.1	;	Crystal structure of the Sulfolobus solfataricus topoisomerase III
6K8O	;	2.5	;	Crystal structure of the Sulfolobus solfataricus topoisomerase III in complex with DNA
7YZU	;	1.59	;	Crystal structure of the sulfoquinovosyl binding protein SmoF complexed with SQMe
7YZS	;	1.8	;	Crystal structure of the sulfoquinovosyl binding protein SmoF complexed with sulfoquinovose
7QHV	;	2.14	;	Crystal structure of the sulfoquinovosyl binding protein SmoF complexed with sulfoquinovosyl diacylglycerol
6R15	;	1.82	;	Crystal structure of the SUN1-KASH1 6:6 complex
6R16	;	2.75	;	Crystal structure of the SUN1-KASH4 6:6 complex
6R2I	;	1.541	;	Crystal structure of the SUN1-KASH5 6:6 complex
7Z8Y	;	2.29	;	Crystal structure of the SUN1-KASH6 9:6 complex
8B5X	;	1.98	;	Crystal structure of the SUN1-KASH6 9:6 complex
8B46	;	1.67	;	Crystal structure of the SUN1-KASH6 9:9 complex
6R2W	;	1.25	;	Crystal structure of the super-active FVIIa variant VYT in complex with tissue factor
3BTV	;	2.1	;	Crystal structure of the super-repressor mutant of Gal80p from Saccharomyces cerevisiae; Gal80(S0)-[G301R]
3BTU	;	2.85	;	Crystal structure of the super-repressor mutant of Gal80p from Saccharomyces cerevisiae; Gal80(S2) [E351K]
1EU3	;	1.68	;	CRYSTAL STRUCTURE OF THE SUPERANTIGEN SMEZ-2 (ZINC BOUND) FROM STREPTOCOCCUS PYOGENES
1ET6	;	1.9	;	CRYSTAL STRUCTURE OF THE SUPERANTIGEN SMEZ-2 FROM STREPTOCOCCUS PYOGENES
1EU4	;	2.5	;	CRYSTAL STRUCTURE OF THE SUPERANTIGEN SPE-H (ZINC BOUND) FROM STREPTOCOCCUS PYOGENES
1ET9	;	1.9	;	CRYSTAL STRUCTURE OF THE SUPERANTIGEN SPE-H FROM STREPTOCOCCUS PYOGENES
3VKW	;	1.9	;	Crystal Structure of the Superfamily 1 Helicase from Tomato Mosaic Virus
1Y07	;	1.55	;	Crystal structure of the superoxide reductase from Treponema pallidum
3DSM	;	1.9	;	Crystal structure of the surface layer protein BACUNI_02894 from Bacteroides uniformis, Northeast Structural Genomics Consortium Target BtR193D.
3BJ9	;	2.0	;	Crystal structure of the Surrogate Light Chain Variable Domain VpreBJ
5TUC	;	2.5	;	Crystal Structure of the Sus TBC1D15 GAP Domain
5FQ6	;	2.8	;	Crystal structure of the SusCD complex BT2261-2264 from Bacteroides thetaiotaomicron
5FQ7	;	3.4	;	Crystal structure of the SusCD complex BT2261-2264 from Bacteroides thetaiotaomicron
5FQ8	;	2.75	;	Crystal structure of the SusCD complex BT2261-2264 from Bacteroides thetaiotaomicron
1N25	;	2.8	;	Crystal structure of the SV40 Large T antigen helicase domain
2FUF	;	1.45	;	Crystal structure of the SV40 large T antigen origin-binding domain
4FGN	;	3.2	;	Crystal structure of the SV40 large T-antigen origin bining domain bound to Site I DNA
6TIV	;	2.38	;	Crystal structure of the SVS_A2 protein (205-DREMH-209 /205-AQDLE-209 mutant) from ancestral sequence reconstruction at 2.38 A resolution
6THU	;	2.6	;	Crystal structure of the SVS_A2 protein (A224I mutant) from ancestral sequence reconstruction at 2.6 A resolution
6TJZ	;	2.4	;	Crystal structure of the SVS_A2 protein (W156Y mutant) from ancestral sequence reconstruction at 2.4 A resolution
6TJA	;	2.27	;	Crystal structure of the SVS_A2 protein (W79F,G83L mutant) from ancestral sequence reconstruction at 2.27 A resolution
6TBD	;	2.3	;	Crystal structure of the SVS_A2 protein from ancestral sequence reconstruction at 2.30 A resolution
3BCO	;	2.25	;	Crystal Structure of The Swapped FOrm of P19A/L28Q/N67D BS-RNase
3BCP	;	2.57	;	Crystal Structure of The Swapped non covalent form of P19A/L28Q/N67D BS-RNase
3AL4	;	2.872	;	Crystal structure of the swine-origin A (H1N1)-2009 influenza A virus hemagglutinin (HA) reveals similar antigenicity to that of the 1918 pandemic virus
6E1F	;	1.16	;	Crystal structure of the SWIRM domain of human histone lysine-specific demethylase LSD1
6R17	;	2.424	;	Crystal structure of the SYCE2-TEX12 delta-Ctip 2:2 complex
6YQF	;	3.33	;	Crystal structure of the SYCE2-TEX12 delta-Ctip complex in a 4:4 assembly
6F63	;	2.154	;	Crystal structure of the SYCP1 C-terminal back-to-back assembly
6F64	;	2.493	;	Crystal structure of the SYCP1 C-terminal back-to-back assembly
6F5X	;	1.91	;	Crystal structure of the SYCP1 N-terminal head-to-head assembly in closed conformation
6F62	;	2.066	;	Crystal structure of the SYCP1 N-terminal head-to-head assembly in open conformation
1XBB	;	1.57	;	Crystal structure of the syk tyrosine kinase domain with Gleevec
1XBC	;	2.0	;	Crystal structure of the syk tyrosine kinase domain with Staurosporin
3BE8	;	2.2	;	Crystal structure of the synaptic protein neuroligin 4
3UJ3	;	3.51	;	Crystal Structure of the synaptic tetramer of the G-Segment Invertase (Gin)
3PIO	;	3.2473	;	Crystal structure of the synergistic antibiotic pair lankamycin and lankacidin in complex with the large ribosomal subunit
3PIP	;	3.45	;	Crystal structure of the synergistic antibiotic pair lankamycin and lankacidin in complex with the large ribosomal subunit
4Z33	;	2.45	;	Crystal structure of the syntenin PDZ1 and PDZ2 tandem in complex with the Frizzled 7 C-terminal fragment and PIP2
6AK2	;	1.868	;	Crystal structure of the syntenin PDZ1 domain in complex with the peptide inhibitor KSL-128018
2VO1	;	2.8	;	CRYSTAL STRUCTURE OF THE SYNTHETASE DOMAIN OF HUMAN CTP SYNTHETASE
4C7N	;	2.1	;	Crystal Structure of the synthetic peptide iM10 in complex with the coiled-coil region of MITF
4JMG	;	1.403	;	Crystal structure of the synthetic protein in complex with pY peptide
1QN4	;	1.86	;	Crystal structure of the T(-24) Adenovirus major late promoter TATA box variant bound to wild-type TBP (Arabidopsis thaliana TBP isoform 2). TATA element recognition by the TATA box-binding protein has been conserved throughout evolution.
1QNB	;	2.23	;	Crystal structure of the T(-25) Adenovirus major late promoter TATA box variant bound to wild-type TBP (Arabidopsis thaliana TBP isoform 2). TATA element recognition by the TATA box-binding protein has been conserved throughout evolution.
1QN6	;	2.1	;	Crystal structure of the T(-26) Adenovirus major late promoter TATA box variant bound to wild-type TBP (Arabidopsis thaliana TBP isoform 2). TATA element recognition by the TATA box-binding protein has been conserved throughout evolution.
1QN7	;	2.3	;	Crystal structure of the T(-27) Adenovirus major late promoter TATA box variant bound to wild-type TBP (Arabidopsis thaliana TBP isoform 2). TATA element recognition by the TATA box-binding protein has been conserved throughout evolution.
1QN8	;	2.1	;	Crystal structure of the T(-28) Adenovirus major late promoter TATA box variant bound to wild-type TBP (Arabidopsis thaliana TBP isoform 2). TATA element recognition by the TATA box-binding protein has been conserved throughout evolution.
1QNA	;	1.8	;	Crystal structure of the T(-30) Adenovirus major late promoter TATA box variant bound to wild-type TBP (Arabidopsis thaliana TBP isoform 2). TATA element recognition by the TATA box-binding protein has been conserved throughout evolution.
6TRO	;	3.0	;	Crystal structure of the T-cell receptor GVY01 bound to HLA A2*01-GVYDGREHTV
6RPB	;	2.5	;	Crystal structure of the T-cell receptor NYE_S1 bound to HLA A2*01-SLLMWITQV
6RPA	;	2.56	;	Crystal structure of the T-cell receptor NYE_S2 bound to HLA A2*01-SLLMWITQV
6RP9	;	3.12	;	Crystal structure of the T-cell receptor NYE_S3 bound to HLA A2*01-SLLMWITQV
6V3O	;	2.909	;	Crystal structure of the T-state of maize C4-phosphoenolpyruvate carboxylase in complex with citrate
6U2T	;	2.8	;	Crystal structure of the T-state of maize C4-phosphoenolpyruvate carboxylase in complex with malate
2PU1	;	1.8	;	Crystal Structure of the T. brucei enolase complexed with Fluoro-phosphonoacetohydroxamate (FPAH)
2PTY	;	2.0	;	Crystal Structure of the T. brucei enolase complexed with PEP
2PU0	;	1.9	;	Crystal Structure of the T. brucei enolase complexed with phosphonoacetohydroxamate (PAH), His156-in conformation
2PTZ	;	1.65	;	Crystal Structure of the T. brucei enolase complexed with phosphonoacetohydroxamate (PAH), His156-out conformation
2PTX	;	1.9	;	Crystal Structure of the T. brucei enolase complexed with sulphate in closed conformation
2PTW	;	1.9	;	Crystal Structure of the T. brucei enolase complexed with sulphate, identification of a metal binding site IV
3GX3	;	2.7	;	Crystal structure of the T. tengcongensis SAM-I riboswitch variant U34C/A94G bound with SAH
3GX6	;	2.8	;	Crystal structure of the T. tengcongensis SAM-I riboswitch variant U34C/A94G bound with SAM in manganese chloride
3GX7	;	2.95	;	Crystal structure of the T. tengcongensis SAM-I riboswitch variant U34C/A94G mutant A6C/U7G/A87C/U88G bound with SAM
2V18	;	2.59	;	Crystal structure of the T. thermophilus dodecin
2V21	;	2.4	;	Crystal structure of the T. thermophilus dodecin in complex with prebound FMN
2V19	;	2.59	;	Crystal structure of the T. thermophilus dodecin R45A mutant
2UX9	;	1.4	;	Crystal structure of the T. thermophilus dodecin R65A mutant
2VYX	;	1.5	;	Crystal structure of the T. thermophilus dodecin W38F mutant
2O5I	;	2.5	;	Crystal structure of the T. thermophilus RNA polymerase elongation complex
2A6E	;	2.8	;	Crystal structure of the T. Thermophilus RNA polymerase holoenzyme
3EQL	;	2.7	;	Crystal structure of the T. Thermophilus RNA polymerase holoenzyme in complex with antibiotic myxopyronin
2A68	;	2.5	;	Crystal structure of the T. thermophilus RNA polymerase holoenzyme in complex with antibiotic rifabutin
2A69	;	2.5	;	Crystal structure of the T. Thermophilus RNA polymerase holoenzyme in complex with antibiotic rifapentin
2A6H	;	2.4	;	Crystal structure of the T. thermophilus RNA polymerase holoenzyme in complex with antibiotic sterptolydigin
2BE5	;	2.4	;	Crystal structure of the T. Thermophilus RNA polymerase holoenzyme in complex with inhibitor tagetitoxin
2O5J	;	3.0	;	Crystal structure of the T. thermophilus RNAP polymerase elongation complex with the NTP substrate analog
2PPB	;	3.0	;	Crystal structure of the T. thermophilus RNAP polymerase elongation complex with the ntp substrate analog and antibiotic streptolydigin
1PP8	;	3.05	;	crystal structure of the T. vaginalis IBP39 Initiator binding domain (IBD) bound to the alpha-SCS Inr element
1PP7	;	2.45	;	Crystal structure of the T. vaginalis Initiator binding protein bound to the ferredoxin Inr
1WCE	;	7.0	;	Crystal structure of the T13 IBDV viral particle reveals a missing link in icosahedral viruses evolution
1OBJ	;	1.9	;	Crystal structure of the T150A mutant of Malonamidase E2 from Bradyrhizobium japonicum
1V0B	;	2.2	;	Crystal structure of the t198a mutant of pfpk5
8CCR	;	2.1	;	Crystal structure of the T19D mutant of the de novo diheme binding 4D2
4XC5	;	2.2	;	CRYSTAL STRUCTURE OF THE T1L REOVIRUS ATTACHMENT PROTEIN SIGMA1
4GU4	;	3.5	;	Crystal structure of the T1L reovirus attachment protein sigma1 in complex with alpha-2,3-sialyllactose
4ODB	;	3.2	;	Crystal structure of the T1L reovirus attachment protein sigma1 in complex with Junctional Adhesion Molecule-A
4GU3	;	3.6	;	Crystal structure of the T1L reovirus attachment protein sigma1 in complex with the GM2 glycan
6GAK	;	1.43	;	Crystal structure of the T1L reovirus sigma1 coiled coil tail (chloride)
6GAJ	;	1.35	;	Crystal structure of the T1L reovirus sigma1 coiled coil tail (iodide)
6GAO	;	2.101	;	Crystal structure of the T1L reovirus sigma1 coiled coil tail and body
4WNI	;	2.3	;	Crystal structure of the T229K mutant of human GAPDH at 2.3 angstroems resolution
6AZR	;	3.628	;	Crystal structure of the T264A HK853cp-BeF3-RR468 complex
6DMQ	;	1.7	;	Crystal structure of the T27A mutant of human alpha defensin HNP4.
4ZO1	;	3.221	;	Crystal Structure of the T3-bound TR-beta Ligand-binding Domain in complex with RXR-alpha
2V7A	;	2.5	;	Crystal structure of the T315I Abl mutant in complex with the inhibitor PHA-739358
2Z60	;	1.95	;	Crystal Structure of the T315I Mutant of Abl kinase bound with PPY-A
5CY5	;	3.4	;	Crystal structure of the T33-51H designed self-assembling protein tetrahedron
7S0W	;	2.5	;	Crystal structure of the T337M variant of human PGM-1
6GAP	;	2.15	;	Crystal structure of the T3D reovirus sigma1 coiled coil tail and body
3UPU	;	3.299	;	Crystal structure of the T4 Phage SF1B Helicase Dda
1REG	;	1.9	;	CRYSTAL STRUCTURE OF THE T4 REGA TRANSLATIONAL REGULATOR PROTEIN AT 1.9 ANGSTROMS RESOLUTION
7ORA	;	2.6	;	Crystal structure of the T478K mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-45 and COVOX-253 Fabs
3ZHN	;	1.4	;	Crystal structure of the T6SS lipoprotein TssJ1 from Pseudomonas aeruginosa
5IKN	;	4.802	;	Crystal Structure of the T7 Replisome in the Absence of DNA
2J7K	;	2.9	;	Crystal structure of the T84A mutant EF-G:GDPCP complex
3RLL	;	1.7	;	Crystal structure of the T877A androgen receptor ligand binding domain in complex with (S)-N-(4-Cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanonaphthalen-1-yloxy)-2-hydroxy-2-methylpropanamide
4HVU	;	0.98	;	Crystal structure of the T98D c-Src-SH3 domain mutant in complex with the high affinity peptide APP12
4HVV	;	1.1	;	Crystal structure of the T98E c-Src-SH3 domain mutant in complex with the high affinity peptide APP12
4HVW	;	0.98	;	Crystal structure of the T98E c-Src-SH3 domain mutant in complex with the high affinity peptide VSL12
3U3U	;	2.5	;	Crystal structure of the tablysin-15-leukotriene E4 complex
3CKI	;	2.3	;	Crystal structure of the TACE-N-TIMP-3 complex
3QRL	;	1.7	;	Crystal Structure of the Taf14 YEATS domain
4MTM	;	1.368	;	Crystal structure of the tail fiber gp53 from Acinetobacter baumannii bacteriophage AP22
3SPE	;	2.3996	;	Crystal structure of the tail sheath protein protease resistant fragment from bacteriophage phiKZ
3FZ2	;	2.7	;	Crystal structure of the tail terminator protein from phage lambda (gpU-D74A)
3FZB	;	2.8	;	Crystal structure of the tail terminator protein from phage lambda (gpU-WT)
4RU4	;	1.903	;	Crystal structure of the tailspike protein gp49 from Pseudomonas phage LKA1
4GJP	;	1.94	;	Crystal structure of the TAL effector dHax3 bound to dsDNA containing repetitive methyl-CpG
4GJR	;	1.85	;	Crystal structure of the TAL effector dHax3 bound to methylated dsDNA
4GG4	;	2.501	;	Crystal structure of the TAL effector dHax3 bound to specific DNA-RNA hybrid
4OSH	;	2.201	;	Crystal structure of the TAL effector dHax3 with NI RVD at 2.2 angstrom resolution
4OSI	;	2.849	;	Crystal structure of the TAL effector dHax3 with NI RVD at 2.8 angstrom resolution
2QDQ	;	2.2	;	Crystal structure of the talin dimerisation domain
3IVF	;	1.94	;	Crystal structure of the talin head FERM domain
8AS9	;	3.4	;	Crystal structure of the talin-KANK1 complex
4CI8	;	2.6	;	Crystal structure of the tandem atypical beta-propeller domain of EML1
7WSJ	;	2.4	;	Crystal structure of the tandem B-box domain of Arabidopsis thaliana CONSTANS
7K03	;	1.6	;	Crystal structure of the tandem bromodomain (BD1 and BD2) of human TAF1 bound to ATR kinase inhibitor AZD6738
7T36	;	1.65	;	Crystal structure of the tandem bromodomain (BD1 and BD2) of human TAF1 bound to ZS1-322
7K27	;	1.5	;	Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound to ATR inhibitor AZ20
7L6X	;	2.75	;	Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound to GNE-371
7K0D	;	2.2	;	Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound to mTORC1/2 inhibitor AZD3147
7LB0	;	2.33	;	Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound to ZS1-295
7LB1	;	1.35	;	Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound to ZS1-585
7T2I	;	1.89	;	Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound to ZS1-588
7LB2	;	1.7	;	Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound to ZS1-589
7K6F	;	1.86	;	Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 in complex with MES (2-(N-morpholino)ethanesulfonic acid)
7N42	;	1.9	;	Crystal structure of the tandem bromodomain of human TAF1 (TAF1-T) bound to ZS1-681
3UV5	;	2.03	;	Crystal Structure of the tandem bromodomains of human Transcription initiation factor TFIID subunit 1 (TAF1)
7DKL	;	1.5	;	Crystal structure of the tandem DEP domains of DEPTOR
6GRE	;	1.29	;	Crystal structure of the tandem DUF26 ectodomain from the Arabidopsis thaliana cysteine-rich receptor-like protein PDLP5.
6GRF	;	1.95	;	Crystal structure of the tandem DUF26 ectodomain from the Arabidopsis thaliana cysteine-rich receptor-like protein PDLP8.
1YKD	;	1.9	;	Crystal Structure of the Tandem GAF Domains from a Cyanobacterial Adenylyl Cyclase: Novel Modes of Ligand-Binding and Dimerization
3K0W	;	2.8	;	Crystal structure of the tandem IG-like C2-type 2 domains of the human mucosa-associated lymphoid tissue lymphoma translocation protein 1
7Z67	;	2.65	;	Crystal structure of the tandem kinase & triphosphate tunnel metalloenzyme domain module of the TTM1 protein from Arabidoposis thaliana in complex with a adenosine nucleotide analog.
7Z66	;	2.7	;	Crystal structure of the tandem kinase & triphosphate tunnel metalloenzyme domain module of the TTM1 protein from Arabidoposis thaliana in complex with inorganic phosphate and citric acid.
1YGR	;	2.9	;	Crystal structure of the tandem phosphatase domain of RPTP CD45
1YGU	;	2.9	;	Crystal structure of the tandem phosphatase domains of RPTP CD45 with a pTyr peptide
1LAR	;	2.0	;	CRYSTAL STRUCTURE OF THE TANDEM PHOSPHATASE DOMAINS OF RPTP LAR
6FSF	;	2.2	;	Crystal structure of the tandem PX-PH-domains of Bem3 from Saccharomyces cerevisiae
6O0S	;	2.7	;	Crystal structure of the tandem SAM domains from human SARM1
1A81	;	3.0	;	CRYSTAL STRUCTURE OF THE TANDEM SH2 DOMAIN OF THE SYK KINASE BOUND TO A DUALLY TYROSINE-PHOSPHORYLATED ITAM
4GY5	;	2.956	;	Crystal structure of the tandem tudor domain and plant homeodomain of UHRF1 with Histone H3K9me3
3DB4	;	2.4	;	Crystal structure of the tandem tudor domains of the E3 ubiquitin-protein ligase UHRF1
3DB3	;	2.4	;	Crystal structure of the tandem tudor domains of the E3 ubiquitin-protein ligase UHRF1 in complex with trimethylated histone H3-K9 peptide
3ZYQ	;	1.48	;	Crystal structure of the tandem VHS and FYVE domains of Hepatocyte growth factor-regulated tyrosine kinase substrate (HGS-Hrs) at 1.48 A resolution
2A90	;	2.15	;	Crystal Structure of the tandem WWE domain of Drosophila Deltex
1U5Q	;	2.1	;	Crystal Structure of the TAO2 Kinase Domain: Activation and Specifity of a Ste20p MAP3K
1U5R	;	2.1	;	Crystal Structure of the TAO2 Kinase Domain: Activation and Specifity of a Ste20p MAP3K
5OPI	;	3.3	;	Crystal structure of the TAPBPR-MHC I peptide editing complex
5WB4	;	2.0	;	Crystal structure of the TarA wall teichoic acid glycosyltransferase
5WFG	;	2.9	;	Crystal structure of the TarA wall teichoic acid glycosyltransferase bound to UDP
1YB4	;	2.4	;	Crystal Structure of the Tartronic Semialdehyde Reductase from Salmonella typhimurium LT2
6G9G	;	1.6	;	Crystal Structure of the TASNSS segment from the R4-R5 loop of the E. coli Biofilm-associated CsgA Curli protein
6TL1	;	2.03	;	Crystal structure of the TASOR pseudo-PARP domain
6SWG	;	2.51	;	Crystal structure of the TASOR-Periphilin core complex
2GZX	;	2.2	;	Crystal Structure of the TatD deoxyribonuclease MW0446 from Staphylococcus aureus. Northeast Structural Genomics Consortium Target ZR237.
3GUW	;	3.2	;	Crystal Structure of the TatD-like Protein (AF1765) from Archaeoglobus fulgidus, Northeast Structural Genomics Consortium Target GR121
3SWT	;	2.05	;	Crystal Structure of the Taurine catabolism dioxygenase, TauD from Mycobacterium marinum
3IO2	;	2.5	;	Crystal structure of the Taz2 domain of p300
3T92	;	1.5	;	Crystal structure of the Taz2:C/EBPepsilon-TAD chimera protein
5HJN	;	2.501	;	Crystal structure of the TBC domain of Skywalker/TBC1D24 from Drosophila melanogaster
5HJQ	;	2.3	;	Crystal structure of the TBC domain of Skywalker/TBC1D24 from Drosophila melanogaster in complex with inositol(1,4,5)triphosphate
5T1J	;	2.947	;	Crystal Structure of the Tbox DNA binding domain of the transcription factor T-bet
2ATX	;	2.65	;	Crystal Structure of the TC10 GppNHp complex
4FQG	;	2.0	;	Crystal structure of the TCERG1 FF4-6 tandem repeat domain
6PI7	;	2.8	;	Crystal structure of the TDRD2 extended Tudor domain in complex with an antibody fragment and the PIWIL1 peptide
8QDO	;	2.7	;	Crystal structure of the tegument protein UL82 (pp71) from Human Cytomegalovirus
8ALU	;	2.09	;	Crystal structure of the teichoic acid binding domain of SlpA, S-layer protein from Lactobacillus acidophilus (aa. 314-444)
5F1S	;	1.749	;	Crystal structure of the teleost fish polymeric Ig receptor (pIgR) ectodomain
2XVM	;	1.48	;	Crystal structure of the tellurite detoxification protein TehB from E. coli in complex with SAH
2XVA	;	1.9	;	Crystal structure of the tellurite detoxification protein TehB from E. coli in complex with sinefungin
3DL3	;	2.3	;	Crystal structure of the tellurite resistance protein TehB. Northeast Structural Genomics Consortium target VfR98 .
4HCE	;	2.3	;	Crystal structure of the telomeric Saccharomyces cerevisiae Cdc13 OB2 domain
2B2A	;	2.22	;	Crystal Structure of the TEN domain of the Telomerase Reverse Transcriptase
1FNA	;	1.8	;	CRYSTAL STRUCTURE OF THE TENTH TYPE III CELL ADHESION MODULE OF HUMAN FIBRONECTIN
2UUD	;	2.9	;	Crystal structure of the TEPC15-Vk45.1 anti-2-phenyl-5-oxazolone NQ10- 1.12 scFv in complex with the hapten
2CJU	;	2.5	;	Crystal structure of the TEPC15-Vk45.1 anti-2-phenyl-5-oxazolone NQ16- 113.8 scFv in complex with phOxGABA
2CKF	;	1.85	;	Crystal Structure of the Terminal Component of the PAH-hydroxylating Dioxygenase from Sphingomonas sp CHY-1
1WW9	;	1.95	;	Crystal structure of the terminal oxygenase component of carbazole 1,9a-dioxygenase, a non-heme iron oxygenase system catalyzing the novel angular dioxygenation for carbazole and dioxin
4DYC	;	1.8	;	Crystal Structure of the terminase small subunit gp1 with D19R mutation of the bacterial virus sf6
4DZJ	;	1.9	;	Crystal structure of the terminase small subunit gp1 with K59E mutation of the bacterial virus sf6
4DZP	;	1.8	;	Crystal structure of the terminase small subunit gp1 with R48A mutation of the bacterial virus sf6
4FJ0	;	2.2	;	Crystal structure of the ternary complex between a fungal 17beta-hydroxysteroid dehydrogenase (Holo form) and 3,7-dihydroxy flavone
4FJ2	;	2.5	;	Crystal structure of the ternary complex between a fungal 17beta-hydroxysteroid dehydrogenase (Holo form) and biochanin A
4FJ1	;	2.3	;	Crystal Structure of the ternary complex between a fungal 17beta-hydroxysteroid dehydrogenase (Holo form) and genistein
2XN9	;	2.3	;	Crystal structure of the ternary complex between human T cell receptor, staphylococcal enterotoxin H and human major histocompatibility complex class II
1F6F	;	2.3	;	CRYSTAL STRUCTURE OF THE TERNARY COMPLEX BETWEEN OVINE PLACENTAL LACTOGEN AND THE EXTRACELLULAR DOMAIN OF THE RAT PROLACTIN RECEPTOR
4DRW	;	3.5	;	Crystal Structure of the Ternary Complex between S100A10, an Annexin A2 N-terminal Peptide and an AHNAK Peptide
5JHH	;	2.3	;	Crystal structure of the ternary complex between the human RhoA, its inhibitor and the DH/PH domain of human ARHGEF11
6SWH	;	2.8	;	Crystal structure of the ternary complex between the type 1 pilus proteins FimC, FimI and FimA from E. coli
6LRG	;	2.41218	;	Crystal Structure of the Ternary Complex of AgrE with Ornithine and NAD+
5AH5	;	2.1	;	Crystal structure of the ternary complex of Agrobacterium radiobacter K84 agnB2 LeuRS-tRNA-LeuAMS
3AU8	;	1.86	;	Crystal structure of the ternary complex of an isomerase
4OPP	;	2.3	;	Crystal structure of the ternary complex of camel peptidoglycan recognition protein PGRP-S with 11-cyclohexylundecanoic acid and N- acetylglucosamine at 2.30 A resolution
4ORV	;	2.5	;	Crystal structure of the ternary complex of camel peptidoglycan recognition protein PGRP-S with 7- phenylheptanoic acid and N- acetylglucosamine at 2.50 A resolution
4OUG	;	2.46	;	Crystal structure of the ternary complex of camel peptidoglycan recognition protein, PGRP-S with lipopolysaccharide and palmitic acid at 2.46 A resolution
1F9H	;	1.5	;	CRYSTAL STRUCTURE OF THE TERNARY COMPLEX OF E. COLI HPPK(R92A) WITH MGAMPCPP AND 6-HYDROXYMETHYL-7,8-DIHYDROPTERIN AT 1.50 ANGSTROM RESOLUTION
1WKW	;	2.1	;	Crystal structure of the ternary complex of eIF4E-m7GpppA-4EBP1 peptide
3AM7	;	2.2	;	Crystal structure of the ternary complex of eIF4E-M7GTP-4EBP2 peptide
1ZE3	;	1.84	;	Crystal Structure of the Ternary Complex of FIMD (N-Terminal Domain) with FIMC and the Pilin Domain of FIMH
3BWU	;	1.76	;	Crystal structure of the ternary complex of FimD (N-Terminal Domain, FimDN) with FimC and the N-terminally truncated pilus subunit FimF (FimFt)
3MDB	;	2.952	;	Crystal structure of the ternary complex of full length centaurin alpha-1, KIF13B FHA domain, and IP4
6HSN	;	1.55	;	Crystal structure of the ternary complex of GephE-ADP-GABA(A) receptor derived peptide
6HSO	;	1.95	;	Crystal structure of the ternary complex of GephE-ADP-Glycine receptor derived peptide
6OQ4	;	1.754	;	Crystal Structure of the Ternary Complex of KRIT1 bound to both the Rap1 GTPase and HKi1
6OQ3	;	1.85	;	Crystal Structure of the Ternary Complex of KRIT1 bound to both the Rap1 GTPase and HKi2
6UZK	;	1.924	;	Crystal Structure of the Ternary Complex of KRIT1 bound to both the Rap1 GTPase and HKi6
4HDQ	;	1.95	;	Crystal Structure of the Ternary Complex of KRIT1 bound to both the Rap1 GTPase and the Heart of Glass (HEG1) cytoplasmic tail
2VHX	;	2.0	;	Crystal structure of the ternary complex of L-alanine dehydrogenase from Mycobacterium tuberculosis with NAD+ and pyruvate
4N8S	;	2.3	;	Crystal Structure of the ternary complex of lipase from Thermomyces lanuginosa with Ethylacetoacetate and P-nitrobenzaldehyde at 2.3 A resolution
6A89	;	2.11	;	Crystal structure of the ternary complex of peptidoglycan recognition protein (PGRP-S) with Tartaric acid, Ribose and 2,6-DIAMINOPIMELIC ACID at 2.11 A resolution
7XFW	;	2.07	;	Crystal structure of the ternary complex of Peptidoglycan recognition protein, PGRP-S with hexanoic and tartaric acids at 2.07 A resolution.
7XFX	;	2.28	;	Crystal structure of the ternary complex of Peptidoglycan recognition protein, PGRP-S with hexanoic and tartaric acids at 2.28 A resolution.
7XFY	;	2.67	;	Crystal structure of the ternary complex of Peptidoglycan recognition protein, PGRP-S with hexanoic and tartaric acids at 2.67 A resolution.
3CBI	;	3.15	;	Crystal structure of the ternary complex of phospholipase A2 with ajmaline and anisic acid at 3.1 A resolution
8I8J	;	2.07	;	Crystal structure of the ternary complex of Phosphopantetheine adenylyltransferase (PPAT) from Enterobacter sp. with Coenzyme-A and Phosphonoacetic acid at 2.07 A resolution.
8I8K	;	2.127	;	Crystal structure of the ternary complex of Phosphopantetheine adenylyltransferase (PPAT) from Enterobacter sp. with Coenzyme-A and Phosphonoacetic acid at 2.13 A resolution.
8I8L	;	2.23	;	Crystal structure of the ternary complex of Phosphopantetheine adenylyltransferase (PPAT) from Enterobacter sp. with Coenzyme-A and Phosphonoacetic acid at 2.23 A resolution.
8I8M	;	2.651	;	Crystal structure of the ternary complex of Phosphopantetheine adenylyltransferase (PPAT) from Enterobacter sp. with Coenzyme-A and Phosphonoacetic acid at 2.65 A resolution.
8I8N	;	2.22	;	Crystal structure of the ternary complex of Phosphopantetheine adenylyltransferase (PPAT) from Enterobacter sp. with Dephosphocoenzyme-A and Phosphonoacetic acid at 2.22 A resolution.
8I8O	;	2.408	;	Crystal structure of the ternary complex of Phosphopantetheine adenylyltransferase (PPAT) from Enterobacter sp. with Dephosphocoenzyme-A and Phosphonoacetic acid at 2.41 A resolution.
3GPL	;	2.5	;	Crystal structure of the ternary complex of RecD2 with DNA and ADPNP
2RUS	;	2.3	;	CRYSTAL STRUCTURE OF THE TERNARY COMPLEX OF RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE, MG(II), AND ACTIVATOR CO2 AT 2.3-ANGSTROMS RESOLUTION
2FDM	;	3.0	;	Crystal structure of the ternary complex of signalling glycoprotein frm sheep (SPS-40)with hexasaccharide (NAG6) and peptide Trp-Pro-Trp at 3.0A resolution
2G8Z	;	2.5	;	Crystal structure of the ternary complex of signalling protein from sheep (SPS-40) with trimer and designed peptide at 2.5A resolution
4R3N	;	1.35	;	Crystal structure of the ternary complex of sp-ASADH with NADP and 1,2,3-Benzenetricarboxylic acid
8GMH	;	2.6	;	Crystal Structure of the ternary complex of TelA-LXG, LapA3, and LapA4
4I9Q	;	2.3	;	Crystal structure of the ternary complex of the D714A mutant of RB69 DNA polymerase
4KHN	;	2.55	;	Crystal structure of the ternary complex of the D714A mutant of RB69 DNA polymerase
7B0X	;	1.7	;	Crystal structure of the ternary complex of the E. coli type 1 pilus proteins FimC, FimI and the N-terminal domain of FimD
2DLC	;	2.4	;	Crystal structure of the ternary complex of yeast tyrosyl-tRNA synthetase
5HLK	;	2.0	;	Crystal structure of the ternary EcoRV-DNA-Lu complex with cleaved DNA substrate.
5F8A	;	1.76	;	Crystal structure of the ternary EcoRV-DNA-Lu complex with uncleaved DNA substrate. Lanthanide binding to EcoRV-DNA complex inhibits cleavage.
4EN4	;	2.15	;	Crystal Structure of the Ternary Human PL Kinase-Ginkgotoxin-MgATP Complex
3DAT	;	2.3	;	Crystal structure of the ternary MTX NADPH complex of Bacillus anthracis dihydrofolate reductase
3DAU	;	1.5	;	Crystal structure of the ternary MTX NADPH complex of Escherichia coli dihydrofolate reductase
4UI2	;	3.15	;	Crystal structure of the ternary RGMB-BMP2-NEO1 complex
5V1Y	;	1.421	;	Crystal structure of the ternary RPN13 PRU-RPN2 (940-953)-ubiquitin complex
5N0B	;	2.6	;	Crystal structure of the tetanus neurotoxin in complex with GD1a
5N0C	;	2.6	;	Crystal structure of the tetanus neurotoxin in complex with GM1a
2QWT	;	2.3	;	Crystal structure of the TetR transcription regulatory protein from Mycobacterium vanbaalenii
3NI7	;	2.78	;	Crystal structure of the TetR transcriptional regulator from Nitrosomonas europaea ATCC 19718
2WGB	;	2.0	;	Crystal structure of the TetR-like transcriptional regulator LfrR from Mycobacterium smegmatis
2V57	;	1.9	;	Crystal structure of the TetR-like transcriptional regulator LfrR from Mycobacterium smegmatis in complex with proflavine
2GL2	;	2.5	;	Crystal structure of the tetra mutant (T66G,R67G,F68G,Y69G) of bacterial adhesin FadA
3V9D	;	2.5	;	Crystal structure of the tetra-decanucleotide d(CCCCGGTACCGGGG)2 as an A-DNA duplex
4UQU	;	1.595	;	Crystal structure of the tetrachloroethene reductive dehalogenase from Sulfurospirillum multivorans
2IPP	;	2.15	;	Crystal Structure of the tetragonal form of human liver cathepsin B
1Y2X	;	2.36	;	Crystal structure of the tetragonal form of the common edible mushroom (Agaricus bisporus) lectin in complex with T-antigen and N-acetylglucosamine
1Y0R	;	1.75	;	Crystal structure of the tetrahedral aminopeptidase from P. horikoshii
3U58	;	2.613	;	Crystal Structure of the Tetrahymena telomerase processivity factor Teb1 AB
3U4V	;	1.8	;	Crystal Structure of the Tetrahymena telomerase processivity factor Teb1 OB-A
3U4Z	;	2.3	;	Crystal Structure of the Tetrahymena telomerase processivity factor Teb1 OB-B
3U50	;	2.5	;	Crystal Structure of the Tetrahymena telomerase processivity factor Teb1 OB-C
7XQ3	;	1.77	;	Crystal structure of the tetramer of thioredoxin domain containing-protein of Oncomelania hupensis(OhTRP14)
6XEQ	;	3.2	;	Crystal structure of the tetrameric 6-phosphogluconate dehydrogenase from Gluconobacter oxidans
3TLR	;	2.45	;	Crystal Structure of the tetrameric Beta-2 microglobulin DIMC20 mutant
7R1N	;	2.072	;	Crystal structure of the Tetrameric C-terminal Big_2-CBM56 domains from Paenibacillus illinoisensis (Bacillus circulans IAM1165) beta-1,3-glucanase H
4BZB	;	1.83	;	Crystal structure of the tetrameric dGTP-bound SAMHD1 mutant catalytic core
4BZC	;	2.88	;	Crystal structure of the tetrameric dGTP-bound wild type SAMHD1 catalytic core
4QFX	;	2.2	;	Crystal structure of the tetrameric dGTP/dATP-bound SAMHD1 (RN206) mutant catalytic core
4QFY	;	2.1	;	Crystal structure of the tetrameric dGTP/dCTP-bound SAMHD1 (RN206) mutant catalytic core
4QFZ	;	2.3	;	Crystal structure of the tetrameric dGTP/dTTP-bound SAMHD1 (RN206) mutant catalytic core
4QG0	;	2.3	;	Crystal structure of the tetrameric dGTP/dUTP-bound SAMHD1 (RN206) mutant catalytic core
5DBO	;	3.0	;	Crystal structure of the tetrameric eIF2B-beta2-delta2 complex from C. thermophilum
4QG1	;	2.2	;	Crystal structure of the tetrameric GTP/dATP-bound SAMHD1 (RN206) mutant catalytic core
4QG4	;	2.1	;	Crystal structure of the tetrameric GTP/dATP/ATP-bound SAMHD1 (H210A) mutant catalytic core
4QG2	;	2.25	;	Crystal structure of the tetrameric GTP/dATP/ATP-bound SAMHD1 (RN206) mutant catalytic core
4L5T	;	3.405	;	Crystal structure of the tetrameric p202 HIN2
2HOI	;	2.601	;	Crystal structure of the tetrameric pre-cleavage synaptic complex in the cre-loxp site-specific recombination
4D2H	;	1.9	;	Crystal structure of the tetramerisation domain of human CtIP
7SPD	;	2.7	;	Crystal Structure of The Tetramerization Domain (29-147) From Human Voltage-gated Potassium Channel Kv2.1 in C 2 2 21 Space Group
7RE5	;	2.5	;	Crystal Structure of The Tetramerization Domain (29-147) From Human Voltage-gated Potassium Channel Kv2.1 in P 41 21 2 Space Group
6YRQ	;	1.902	;	Crystal structure of the tetramerization domain of the glycoprotein Gn (Andes virus) at pH 4.6
6YRB	;	2.351	;	Crystal structure of the tetramerization domain of the glycoprotein Gn (Andes virus) at pH 7.5
1A68	;	1.8	;	CRYSTAL STRUCTURE OF THE TETRAMERIZATION DOMAIN OF THE SHAKER POTASSIUM CHANNEL
1T1D	;	1.51	;	CRYSTAL STRUCTURE OF THE TETRAMERIZATION DOMAIN OF THE SHAKER POTASSIUM CHANNEL
1NN7	;	2.1	;	Crystal Structure Of The Tetramerization Domain Of The Shal Voltage-Gated Potassium Channel
7MNK	;	1.1	;	Crystal structure of the tetramerization element of NUP358/RanBP2 (residues 805-832)
4H7X	;	2.6	;	Crystal structure of the tetratricopeptide repeat (TPR) motif of human dual specificity protein kinase Mps1
4H7Y	;	1.8	;	Crystal structure of the tetratricopeptide repeat (TPR) motif of human dual specificity protein kinase Mps1
3MA5	;	2.8	;	Crystal structure of the tetratricopeptide repeat domain protein Q2S6C5_SALRD from Salinibacter ruber. Northeast Structural Genomics Consortium Target SrR115c.
3BZK	;	2.3	;	Crystal Structure of the Tex protein from Pseudomonas aeruginosa, crystal form 2
3BZC	;	2.27	;	Crystal Structure of the Tex protein from Pseudomonas aeruginosa, crystal form I
4PN7	;	2.801	;	Crystal Structure of the TFIIH p34 N-terminal Domain
7NX4	;	3.0	;	Crystal structure of the TG and EGF-like domains of ALK
6S22	;	1.96	;	Crystal structure of the TgGalNAc-T3 in complex with UDP, manganese and FGF23c
6S24	;	2.12	;	Crystal structure of the TgGalNAc-T3 in complex with UDP, manganese and the peptide 3
3HVZ	;	2.2	;	Crystal Structure of the TGS domain of the CLOLEP_03100 protein from Clostridium leptum, Northeast Structural Genomics Consortium Target QlR13A
3KDE	;	1.74	;	Crystal structure of the THAP domain from D. melanogaster P-element transposase in complex with its natural DNA binding site
2JKS	;	1.9	;	Crystal structure of the the bradyzoite specific antigen BSR4 from toxoplasma gondii.
2OBZ	;	1.1	;	Crystal structure of the The brominated Z-DNA duplex d(CGCG[BrU]G)
6K4J	;	2.701	;	Crystal Structure of the the CD9
3E83	;	1.8	;	Crystal Structure of the the open NaK channel pore
3E8F	;	2.0	;	Crystal Structure of the the open NaK channel- K+/Ba2+
3E8B	;	1.7	;	Crystal Structure of the the open NaK channel- Rb+ complex
3E8H	;	1.8	;	Crystal Structure of the the open NaK channel-K+ complex
3E89	;	1.8	;	Crystal Structure of the the open NaK channel-low Na+ complex
3E8G	;	2.0	;	Crystal Structure of the the open NaK channel-Na+/Ca2+ complex
4G6K	;	1.9	;	Crystal structure of the therapeutic antibody binding fragment of gevokizumab in its unbound state
4G5Z	;	1.83	;	Crystal structure of the therapeutical antibody fragment of canakinumab in its unbound state
2GEB	;	1.7	;	Crystal structure of the Thermoanaerobacter tengcongensis hypoxanthine-guanine phosphoribosyltransferase L160I mutant: insights into the inhibitor design
2QI2	;	2.9	;	Crystal structure of the Thermoplasma acidophilum Pelota protein
5M86	;	2.4	;	Crystal Structure of the Thermoplasma acidophilum Protein Ta1207
4CSI	;	1.8	;	Crystal structure of the thermostable Cellobiohydrolase Cel7A from the fungus Humicola grisea var. thermoidea.
2D1S	;	1.3	;	Crystal structure of the thermostable Japanese Firefly Luciferase complexed with High-energy intermediate analogue
2D1Q	;	2.3	;	Crystal structure of the thermostable Japanese Firefly Luciferase complexed with MgATP
2D1R	;	1.6	;	Crystal structure of the thermostable Japanese firefly Luciferase complexed with OXYLUCIFERIN and AMP
2D1T	;	1.45	;	Crystal structure of the thermostable Japanese Firefly Luciferase red-color emission S286N mutant complexed with High-energy intermediate analogue
3KRZ	;	1.8	;	Crystal Structure of the Thermostable NADH4-bound old yellow enzyme from Thermoanaerobacter pseudethanolicus E39
3KRU	;	1.6	;	Crystal Structure of the Thermostable Old Yellow Enzyme from Thermoanaerobacter pseudethanolicus E39
1GTJ	;	1.75	;	Crystal structure of the thermostable serine-carboxyl type proteinase, kumamolisin (KSCP) - complex with Ac-Ile-Ala-Phe-cho
1GTG	;	2.3	;	Crystal structure of the thermostable serine-carboxyl type proteinase, kumamolysin (kscp)
5JIB	;	1.86	;	Crystal structure of the Thermotoga maritima acetyl esterase (TM0077) complex with a substrate analog
1MKM	;	2.2	;	CRYSTAL STRUCTURE OF THE THERMOTOGA MARITIMA ICLR
3DIL	;	1.9	;	Crystal structure of the Thermotoga maritima lysine riboswitch bound to lysine
3DIG	;	2.8	;	CRYSTAL STRUCTURE OF THE THERMOTOGA MARITIMA LYSINE RIBOSWITCH BOUND TO S-(2-aminoethyl)-L-cysteine
3DCM	;	2.0	;	Crystal structure of the Thermotoga maritima SPOUT family RNA-methyltransferase protein Tm1570 in complex with S-adenosyl-L-methionine
2Q6T	;	2.9	;	Crystal structure of the Thermus aquaticus DnaB monomer
4DR4	;	3.969	;	Crystal structure of the Thermus thermophilus (HB8) 30S ribosomal subunit with codon, cognate transfer RNA anticodon stem-loop and multiple copies of paromomycin molecules bound
4DR5	;	3.45	;	Crystal structure of the Thermus thermophilus (HB8) 30S ribosomal subunit with codon, crystallographically disordered cognate transfer RNA anticodon stem-loop and streptomycin bound
4DR7	;	3.75	;	Crystal structure of the Thermus thermophilus (HB8) 30S ribosomal subunit with codon, crystallographically disordered near-cognate transfer RNA anticodon stem-loop mismatched at the second codon position, and streptomycin bound
4DR6	;	3.3	;	Crystal structure of the Thermus thermophilus (HB8) 30S ribosomal subunit with codon, near-cognate transfer RNA anticodon stem-loop mismatched at the first codon position and streptomycin bound
7DUH	;	3.75	;	Crystal structure of the Thermus thermophilus (HB8) 30S ribosomal subunit with mRNA and cognate transfer RNA anticodon stem-loop and sisomicin derivative N1''AC bound
7DUI	;	3.62	;	Crystal structure of the Thermus thermophilus (HB8) 30S ribosomal subunit with mRNA and cognate transfer RNA anticodon stem-loop and sisomicin derivative N1''PyrS bound
7DUG	;	3.75	;	Crystal structure of the Thermus thermophilus (HB8) 30S ribosomal subunit with mRNA and cognate transfer RNA anticodon stem-loop and sisomicin derivative N1''TFMS bound
7DUJ	;	3.75	;	Crystal structure of the Thermus thermophilus (HB8) 30S ribosomal subunit with mRNA and cognate transfer RNA anticodon stem-loop and sisomicin derivative N1,3''Bz bound
7DUK	;	3.6	;	Crystal structure of the Thermus thermophilus (HB8) 30S ribosomal subunit with mRNA and cognate transfer RNA anticodon stem-loop and sisomicin derivative N1,3''MS bound
7DUL	;	3.62	;	Crystal structure of the Thermus thermophilus (HB8) 30S ribosomal subunit with mRNA and cognate transfer RNA anticodon stem-loop and sisomicin derivative N3''MS bound
4DR2	;	3.249	;	Crystal structure of the Thermus thermophilus (HB8) 30S ribosomal subunit with multiple copies of paromomycin molecules bound
4DR3	;	3.348	;	Crystal structure of the Thermus thermophilus (HB8) 30S ribosomal subunit with streptomycin bound
2ZM6	;	3.3	;	Crystal structure of the Thermus thermophilus 30S ribosomal subunit
4K0K	;	3.4	;	Crystal structure of the Thermus thermophilus 30S ribosomal subunit complexed with a serine-ASL and mRNA containing a stop codon
4DV4	;	3.651	;	Crystal structure of the Thermus thermophilus 30S ribosomal subunit with a 16S rRNA mutation, A914G
4DV5	;	3.683	;	Crystal structure of the Thermus thermophilus 30S ribosomal subunit with a 16S rRNA mutation, A914G, bound with streptomycin
4DV6	;	3.297	;	Crystal structure of the Thermus thermophilus 30S ribosomal subunit with a 16S rRNA mutation, A915G
4DV7	;	3.294	;	Crystal structure of the Thermus thermophilus 30S ribosomal subunit with a 16S rRNA mutation, A915G, bound with streptomycin
4DV2	;	3.646	;	Crystal structure of the Thermus thermophilus 30S ribosomal subunit with a 16S rRNA mutation, C912A
4DV3	;	3.547	;	Crystal structure of the Thermus thermophilus 30S ribosomal subunit with a 16S rRNA mutation, C912A, bound with streptomycin
4DUY	;	3.386	;	Crystal structure of the Thermus thermophilus 30S ribosomal subunit with a 16S rRNA mutation, U13C
4DUZ	;	3.651	;	Crystal structure of the Thermus thermophilus 30S ribosomal subunit with a 16S rRNA mutation, U13C, bound with streptomycin
4DV0	;	3.853	;	Crystal structure of the Thermus thermophilus 30S ribosomal subunit with a 16S rRNA mutation, U20G
4DV1	;	3.849	;	Crystal structure of the Thermus thermophilus 30S ribosomal subunit with a 16S rRNA mutation, U20G, bound with streptomycin
4Z8C	;	2.9	;	Crystal structure of the Thermus thermophilus 70S ribosome bound to translation inhibitor oncocin
6N9F	;	3.7	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with a short substrate mimic ACCA-DPhe and bound to mRNA and P-site tRNA at 3.7A resolution
6N9E	;	3.7	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with a short substrate mimic CC-Pmn and bound to mRNA and P-site tRNA at 3.7A resolution
4W2F	;	2.4	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with amicoumacin, mRNA and three deacylated tRNAs in the A, P and E sites
8EV6	;	2.946	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with amikacin, mRNA, and A-, P-, and E-site tRNAs
4Z3S	;	2.65	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with antibiotic A201A, mRNA and three tRNAs in the A, P and E sites at 2.65A resolution
5DOY	;	2.6	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with antibiotic Hygromycin A, mRNA and three tRNAs in the A, P and E sites at 2.6A resolution
7JQL	;	3.0	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with Bac7-001, mRNA, and deacylated P-site tRNA at 3.00A resolution
7JQM	;	3.05	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with Bac7-002, mRNA, and deacylated P-site tRNA at 3.05A resolution
6ND5	;	2.6	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with chloramphenicol and bound to mRNA and A-, P-, and E-site tRNAs at 2.60A resolution
5J4B	;	2.6	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with cisplatin (co-crystallized) and bound to mRNA and A-, P- and E-site tRNAs at 2.6A resolution
5J4C	;	2.8	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with cisplatin (soaked) and bound to mRNA and A-, P- and E-site tRNAs at 2.8A resolution
6CFK	;	2.7	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with D-histidyl-CAM and bound to protein Y (YfiA) at 2.7A resolution
6OF1	;	2.8	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with dirithromycin and bound to mRNA and A-, P-, and E-site tRNAs at 2.80A resolution
4WQF	;	2.8	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with elongation factor G and fusidic acid in the post-translocational state
4WQY	;	2.8	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with elongation factor G in the post-translocational state (without fusitic acid)
4WPO	;	2.8	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with elongation factor G in the pre-translocational state
4WQU	;	2.8	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with elongation factor G trapped by the antibiotic dityromycin
6ND6	;	2.85	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with erythromycin and bound to mRNA and A-, P-, and E-site tRNAs at 2.85A resolution
6CFJ	;	2.8	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with histidyl-CAM and bound to mRNA and A-, P-, and E-site tRNAs at 2.8A resolution
5DOX	;	3.1	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with Hygromycin-A at 3.1A resolution
8EV7	;	2.89	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with kanamycin, mRNA, and A-, P-, and E-site tRNAs
5W4K	;	2.7	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with Klebsazolicin and bound to mRNA and A-, P- and E-site tRNAs at 2.7A resolution
6CFL	;	2.6	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with lysyl-CAM and bound to protein Y (YfiA) at 2.6A resolution
5VP2	;	2.8	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with madumycin II and bound to mRNA and A-, P- and E-site tRNAs at 2.8A resolution
5WIS	;	2.703	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with methymycin and bound to mRNA and A-, P- and E-site tRNAs at 2.7A resolution
6UO1	;	2.95	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with mRNA (containing pseudouridine at the first position of the codon) and deacylated A-, P-, and E-site tRNAs at 2.95A resolution
7U2H	;	2.55	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with mRNA, aminoacylated A-site Gly-NH-tRNAgly, aminoacylated P-site fMet-NH-tRNAmet, and deacylated E-site tRNAgly at 2.55A resolution
7U2I	;	2.55	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with mRNA, aminoacylated A-site Gly-NH-tRNAgly, aminoacylated P-site fMet-NH-tRNAmet, deacylated E-site tRNAgly, and chloramphenicol at 2.55A resolution
7U2J	;	2.55	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with mRNA, aminoacylated A-site Gly-NH-tRNAgly, peptidyl P-site fMAC-NH-tRNAmet, deacylated E-site tRNAgly, and chloramphenicol at 2.55A resolution
8CVK	;	2.5	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with mRNA, aminoacylated A-site Phe-NH-tRNAphe, peptidyl P-site fMRC-NH-tRNAmet, and deacylated E-site tRNAphe at 2.50A resolution
8CVJ	;	2.4	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with mRNA, aminoacylated A-site Phe-NH-tRNAphe, peptidyl P-site fMSEAC-NH-tRNAmet, and deacylated E-site tRNAphe at 2.40A resolution
8CVL	;	2.3	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with mRNA, aminoacylated A-site Phe-NH-tRNAphe, peptidyl P-site fMTHSMRC-NH-tRNAmet, and deacylated E-site tRNAphe at 2.30A resolution
8EKB	;	2.7	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with mRNA, deacylated P-site tRNAmet, and thermorubin at 2.70A resolution
4W2I	;	2.7	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with negamycin, mRNA and three deacylated tRNAs in the A, P and E sites
6CAE	;	2.6	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with NOSO-95179 antibiotic and bound to mRNA and A-, P- and E-site tRNAs at 2.6A resolution
4W2H	;	2.7	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with pactamycin (co-crystallized), mRNA and deacylated tRNA in the P site
4W2G	;	2.55	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with pactamycin (soaked), mRNA and three deacylated tRNAs in the A, P and E sites
5WIT	;	2.6	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with pikromycin and bound to mRNA and A-, P- and E-site tRNAs at 2.6A resolution
7LH5	;	3.27	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with plazomicin, mRNA and tRNAs
6O97	;	2.75	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with propylamycin and bound to mRNA and A-, P-, and E-site tRNAs at 2.75A resolution
8T8B	;	2.65	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with protein Y, A-site aminoacyl-tRNA analog ACC-PMN, and P-site formyl-MAI-tripeptidyl-tRNA analog ACCA-IAMf at 2.65A resolution
8T8C	;	2.6	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with protein Y, A-site aminoacyl-tRNA analog ACC-PMN, and P-site formyl-MFI-tripeptidyl-tRNA analog ACCA-IFMf at 2.60A resolution
7RQB	;	2.45	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with protein Y, A-site aminoacyl-tRNA analog ACC-PMN, and P-site MAI-tripeptidyl-tRNA analog ACCA-IAM at 2.45A resolution
7RQC	;	2.5	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with protein Y, A-site aminoacyl-tRNA analog ACC-PMN, and P-site MFI-tripeptidyl-tRNA analog ACCA-IFM at 2.50A resolution
7RQA	;	2.4	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with protein Y, A-site aminoacyl-tRNA analog ACC-PMN, and P-site MTI-tripeptidyl-tRNA analog ACCA-ITM at 2.40A resolution
7RQE	;	2.4	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with protein Y, A-site deacylated tRNA analog CACCA, P-site MAI-tripeptidyl-tRNA analog ACCA-IAM, and chloramphenicol at 2.40A resolution
7RQD	;	2.5	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with protein Y, A-site deacylated tRNA analog CACCA, P-site MTI-tripeptidyl-tRNA analog ACCA-ITM, and chloramphenicol at 2.50A resolution
8FC2	;	2.5	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with protein Y, hygromycin A, and azithromycin at 2.50A resolution
8FC1	;	2.5	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with protein Y, hygromycin A, and erythromycin at 2.50A resolution
8FC3	;	2.6	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with protein Y, hygromycin A, and telithromycin at 2.60A resolution
6XQE	;	3.0	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with sarecycline, UAA-mRNA, and deacylated P-site tRNA at 3.00A resolution
6XQD	;	2.8	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with sarecycline, UUC-mRNA, and deacylated P-site tRNA at 2.80A resolution
6XHY	;	2.6	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with telithromycin, mRNA, aminoacylated A- and P-site tRNAs, and deacylated E-site tRNA at 2.60A resolution
7MD7	;	2.8	;	Crystal structure of the Thermus thermophilus 70S ribosome in complex with triphenylphosphonium analog of chloramphenicol CAM-C4-TPP and protein Y (YfiA) at 2.80A resolution
1VY5	;	2.55	;	Crystal structure of the Thermus thermophilus 70S ribosome in the post-catalysis state of peptide bond formation containing dipeptydil-tRNA in the A site and deacylated tRNA in the P site.
1VY4	;	2.6	;	Crystal structure of the Thermus thermophilus 70S ribosome in the pre-attack state of peptide bond formation containing acylated tRNA-substrates in the A and P sites.
1VY7	;	2.8	;	Crystal structure of the Thermus thermophilus 70S ribosome in the pre-attack state of peptide bond formation containing short substrate-mimic Cytidine-Cytidine-Puromycin in the A site and acylated tRNA in the P site.
1VY6	;	2.9	;	Crystal structure of the Thermus thermophilus 70S ribosome in the pre-attack state of peptide bond formation containing short substrate-mimic Cytidine-Puromycin in the A site and acylated tRNA in the P site.
6UCQ	;	3.5	;	Crystal structure of the Thermus thermophilus 70S ribosome recycling complex
4Y4P	;	2.5	;	Crystal structure of the Thermus thermophilus 70S ribosome with rRNA modifications and bound to mRNA and A-, P- and E-site tRNAs at 2.5A resolution
4Y4O	;	2.3	;	Crystal structure of the Thermus thermophilus 70S ribosome with rRNA modifications and bound to protein Y (YfiA) at 2.3A resolution
3SK9	;	1.8	;	Crystal structure of the Thermus thermophilus cas3 HD domain
3SKD	;	2.0	;	Crystal structure of the Thermus thermophilus cas3 HD domain in the presence of Ni2+
2CWZ	;	1.85	;	Crystal structure of the Thermus thermophilus hypothetical protein TTHA0967, a thioesterase superfamily member
3HOA	;	2.1	;	Crystal structure of the Thermus thermophilus M32 carboxypeptidase
3MLQ	;	2.91	;	Crystal structure of the Thermus thermophilus transcription-repair coupling factor RNA polymerase interacting domain with the Thermus aquaticus RNA polymerase beta1 domain
6NV6	;	2.65	;	Crystal structure of the theta class glutathione S-transferase from the citrus canker pathogen Xanthomonas axonopodis pv. citri with glutathione bound
6NXV	;	2.75	;	Crystal structure of the theta class glutathione S-transferase from the citrus canker pathogen Xanthomonas axonopodis pv. citri, apo form
1PVD	;	2.3	;	CRYSTAL STRUCTURE OF THE THIAMIN DIPHOSPHATE DEPENDENT ENZYME PYRUVATE DECARBOXYLASE FROM THE YEAST SACCHAROMYCES CEREVISIAE AT 2.3 ANGSTROMS RESOLUTION
4NMY	;	1.896	;	Crystal Structure of the Thiamin-bound form of Substrate-binding Protein of ABC Transporter from Clostridium difficile
6HK1	;	2.55	;	Crystal structure of the Thiazole synthase from Methanothermococcus thermolithotrophicus co-crystallized with Tb-Xo4
5D3K	;	1.7	;	Crystal structure of the thioesterase domain of deoxyerythronolide B synthase
5D3Z	;	2.1	;	Crystal structure of the thioesterase domain of deoxyerythronolide B synthase in complex with a small phosphonate inhibitor
2PX6	;	2.3	;	Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by Orlistat
2CB9	;	1.8	;	Crystal structure of the thioesterase domain of the fengycin biosynthesis cluster
6EEZ	;	2.25	;	Crystal Structure of the thiol-disulfide exchange protein alpha-DsbA2 from Wolbachia pipientis
2WZ9	;	1.55	;	Crystal structure of the thioredoxin domain of human TXNL2
4CCR	;	2.28	;	Crystal structure of the thioredoxin reductase apoenzyme from Entamoeba histolytica in the absence of the NADP cofactor
4A5L	;	1.66	;	Crystal structure of the thioredoxin reductase from Entamoeba histolytica
4A65	;	1.7	;	Crystal structure of the thioredoxin reductase from Entamoeba histolytica with AuCN
4CBQ	;	1.94	;	Crystal structure of the thioredoxin reductase from Entamoeba histolytica with auranofin Au(I) bound to Cys286
4CCQ	;	1.5	;	Crystal structure of the thioredoxin reductase from Entamoeba histolytica with NADP
3EVI	;	2.7	;	Crystal structure of the thioredoxin-fold domain of human phosducin-like protein 2
3ZIJ	;	1.4	;	Crystal structure of the thioredoxin-like protein BC3987
3ZIT	;	1.18	;	Crystal structure of the thioredoxin-like protein BC3987 mutant T8A
7TKV	;	2.8	;	Crystal Structure of the Thioredox_DsbH Domain-Containing Uncharacterized Protein Bab1_2064 from Brucella abortus
4V2K	;	1.29	;	Crystal structure of the thiosulfate dehydrogenase TsdA in complex with thiosulfate
4FD9	;	1.86	;	Crystal structure of the third beta-gamma-crystallin domain of Crybg3 (betagamma-crystallin domain-containing protein 3) from Mus musculus
3UVT	;	2.0	;	Crystal structure of the third catalytic domain of ERp46
3WIH	;	1.701	;	Crystal structure of the third fibronectin domain (Fn3) of human ROBO1 in complex with the Fab fragment of murine monoclonal antibody B2212A.
6HYF	;	1.6	;	Crystal structure of the third FNIII domain from rat beta4 integrin, a binding site for periaxin
4WTW	;	1.606	;	Crystal structure of the third FnIII domain of integrin beta4
6Y2C	;	2.0	;	Crystal structure of the third KH domain of FUBP1
1ZZK	;	0.95	;	Crystal Structure of the third KH domain of hnRNP K at 0.95A resolution
2P2R	;	1.6	;	Crystal structure of the third KH domain of human Poly(C)-Binding Protein-2 in complex with C-rich strand of human telomeric DNA
1PDR	;	2.8	;	CRYSTAL STRUCTURE OF THE THIRD PDZ DOMAIN FROM THE HUMAN HOMOLOG OF DISCS LARGE PROTEIN
5MZ7	;	1.53	;	Crystal Structure of the third PDZ domain from the synaptic protein PSD-95 with incorporated Azidohomoalanine
3B76	;	1.75	;	Crystal structure of the third PDZ domain of human ligand-of-numb protein-X (LNX1) in complex with the C-terminal peptide from the coxsackievirus and adenovirus receptor
3I4W	;	1.35	;	Crystal Structure of the third PDZ domain of PSD-95
3K82	;	1.4	;	Crystal Structure of the third PDZ domain of PSD-95
6QJN	;	1.8	;	Crystal Structure of the third PDZ domain of PSD-95 protein D332G mutant: space group I4122
6QJL	;	1.043	;	Crystal Structure of the third PDZ domain of PSD-95 protein D332G mutant: space group P21
6QJK	;	1.046	;	Crystal Structure of the third PDZ domain of PSD-95 protein D332G mutant: space group P43
6QJF	;	1.5	;	Crystal Structure of the third PDZ domain of PSD-95 protein D332P mutant: space group C121, structure 1
6QJG	;	2.003	;	Crystal Structure of the third PDZ domain of PSD-95 protein D332P mutant: space group C121, structure 2
8AH6	;	1.63	;	Crystal Structure of the third PDZ domain of PSD-95 protein in the space group P21 at pH 4.0
8AH7	;	1.25	;	Crystal Structure of the third PDZ domain of PSD-95 protein in the space group P212121 at pH 4.0
8AH5	;	1.25	;	Crystal Structure of the third PDZ domain of PSD-95 protein in the space group P212121 at pH 4.6
8AH4	;	1.48	;	Crystal Structure of the third PDZ domain of PSD-95 protein in the space group P3112 at pH 4.0
8AH8	;	1.5	;	Crystal Structure of the third PDZ domain of PSD-95 protein in the space group P3121 at pH 3.7
6QJI	;	1.5	;	Crystal Structure of the third PDZ domain of PSD-95 protein: space group P3112
6QJJ	;	1.7	;	Crystal Structure of the third PDZ domain of PSD-95 protein: space group P3221
3JXT	;	1.5	;	Crystal structure of the third PDZ domain of SAP-102 in complex with a fluorogenic peptide-based ligand
3TSV	;	1.989	;	crystal structure of the third PDZ domain of the human ZO-1 MAGUK protein
4O2W	;	2.0	;	Crystal structure of the third RCC1-like domain of HERC1
2DDU	;	2.05	;	Crystal structure of the third repeat domain of reelin
6H8M	;	1.7	;	Crystal structure of the third SRCR domain of Murine Neurotrypsin.
3UJ1	;	2.651	;	Crystal structure of the third thioredoxin domain of human ERp46
7OC3	;	2.25	;	Crystal structure of the third tudor domain of Qin
2RIQ	;	1.7	;	Crystal Structure of the Third Zinc-binding domain of human PARP-1
5SUQ	;	6.0	;	Crystal structure of the THO-Sub2 complex
7C2G	;	1.71	;	Crystal Structure of the Thorarchaeota 2DGel/rabbit actin complex
7C2H	;	2.352	;	Crystal Structure of the Thorarchaeota 2DGel3/rabbit actin complex
7C2F	;	2.03	;	Crystal Structure of the Thorarchaeota ProGel/rabbit actin complex
6WNU	;	1.88	;	Crystal structure of the three-domain cyclomaltodextrin glucanotransferase CldA in the monomeric form
3M9G	;	2.9	;	Crystal structure of the three-PASTA-domain of a Ser/Thr kinase from Staphylococcus aureus
8G1Y	;	1.43	;	Crystal Structure of the Threonine Synthase from Streptococcus pneumoniae in complex with Pyridoxal 5-phosphate.
1TWX	;	2.4	;	Crystal structure of the thrombin mutant D221A/D222K
1Z8I	;	2.0	;	Crystal structure of the thrombin mutant G193A bound to PPACK
1Z8J	;	2.0	;	Crystal structure of the thrombin mutant G193P bound to PPACK
1DX5	;	2.3	;	Crystal structure of the thrombin-thrombomodulin complex
1Z78	;	1.8	;	Crystal Structure of the Thrombospondin-1 N-terminal domain
2ERF	;	1.45	;	Crystal Structure of the Thrombospondin-1 N-terminal Domain at 1.45A Resolution
1ZA4	;	1.9	;	Crystal Structure of the Thrombospondin-1 N-terminal Domain in Complex with Arixtra
2OUH	;	2.4	;	Crystal structure of the Thrombospondin-1 N-terminal domain in complex with fractionated Heparin DP10
1LSL	;	1.9	;	Crystal Structure of the Thrombospondin-1 Type 1 Repeats
3B5B	;	2.7	;	Crystal structure of the thymidylate synthase k48q
2VF0	;	3.0	;	CRYSTAL STRUCTURE OF THE THYMIDYLATE SYNTHASE K48Q COMPLEXED WITH 5NO2DUMP AND BW1843U89
2VET	;	2.2	;	CRYSTAL STRUCTURE OF THE THYMIDYLATE SYNTHASE K48Q COMPLEXED WITH DUMP
1FWM	;	2.2	;	Crystal structure of the thymidylate synthase R166Q mutant
1R6G	;	3.0	;	Crystal structure of the thyroid hormone receptor beta ligand binding domain in complex with a beta selective compound
3A8N	;	4.5	;	Crystal structure of the Tiam1 PHCCEx domain
3A8P	;	2.1	;	Crystal structure of the Tiam2 PHCCEx domain
3AMU	;	3.1	;	Crystal structure of the TiaS-tRNA(Ile2)-AMPCPP-agmatine complex
3AMT	;	2.9	;	Crystal structure of the TiaS-tRNA(Ile2)-ATP complex
1ZLH	;	1.7	;	Crystal structure of the tick carboxypeptidase inhibitor in complex with bovine carboxypeptidase A
1ZLI	;	2.09	;	Crystal structure of the tick carboxypeptidase inhibitor in complex with human carboxypeptidase B
6I31	;	1.79	;	Crystal structure of the tick chemokine-binding protein Evasin-3
6ST4	;	1.29	;	Crystal structure of the tick chemokine-binding protein Evasin-4 (SG 1)
6STC	;	1.69	;	Crystal structure of the tick chemokine-binding protein Evasin-4 (SG 2)
6STE	;	1.79	;	Crystal structure of the tick chemokine-binding protein Evasin-4 (SG 3)
7SCS	;	1.51	;	Crystal Structure of the Tick Evasin EVA-AAM1001 Complexed to Human Chemokine CCL11
7SCT	;	1.84	;	Crystal Structure of the Tick Evasin EVA-AAM1001 Complexed to Human Chemokine CCL16
7SCV	;	2.01	;	Crystal Structure of the Tick Evasin EVA-AAM1001 Complexed to Human Chemokine CCL17
7SCU	;	1.86	;	Crystal Structure of the Tick Evasin EVA-AAM1001 Complexed to Human Chemokine CCL7
8FJ3	;	2.07	;	Crystal Structure of the Tick Evasin EVA-AAM1001 Complexed to Human Chemokine CCL7(Y13A)
8FJ2	;	2.07	;	Crystal Structure of the Tick Evasin EVA-AAM1001(C8) Complexed to Human Chemokine CCL17
8SKK	;	2.1	;	Crystal Structure of the Tick Evasin EVA-AAM1001(L39P) Complexed to Human Chemokine CCL17
8FK8	;	1.96	;	Crystal Structure of the Tick Evasin EVA-AAM1001(L39P) Complexed to Human Chemokine CCL7
8FJ0	;	2.91	;	Crystal Structure of the Tick Evasin EVA-AAM1001(Y44A) Complexed to Human Chemokine CCL2
8FK6	;	1.74	;	Crystal Structure of the Tick Evasin EVA-AAM1001(Y44A) Complexed to Human Chemokine CCL7
8FK9	;	2.7	;	Crystal Structure of the Tick Evasin EVA-ACA1001 Complexed to Human Chemokine CCL16
7S59	;	2.39	;	Crystal structure of the tick evasin EVA-P974 complexed to a chimera made of human chemokines CCL7 and CCL8
7S4N	;	1.65	;	Crystal structure of the tick evasin EVA-P974 complexed to human chemokine CCL17
7S58	;	1.82	;	Crystal Structure of the tick evasin EVA-P974 complexed to human chemokine CCL7
7BLV	;	2.099	;	Crystal structure of the tick-borne encephalitis virus NS3 helicase in complex with ADP
7NXU	;	2.1	;	Crystal structure of the tick-borne encephalitis virus NS3 helicase in complex with ADP-Pi
7BM0	;	1.9	;	Crystal structure of the tick-borne encephalitis virus NS3 helicase in complex with AMPPNP
2CXK	;	1.85	;	Crystal structure of the TIG domain of human calmodulin-binding transcription activator 1 (CAMTA1)
2BSK	;	3.3	;	Crystal structure of the TIM9 Tim10 hexameric complex
3UK6	;	2.95	;	Crystal Structure of the Tip48 (Tip49b) hexamer
7NAG	;	1.72	;	Crystal structure of the TIR domain from human SARM1 in complex with 1AD
7NAH	;	1.79	;	Crystal structure of the TIR domain from human SARM1 in complex with 2AD
7NAI	;	1.74	;	Crystal structure of the TIR domain from human SARM1 in complex with 3AD
7NAJ	;	1.6	;	Crystal structure of the TIR domain from human SARM1 in complex with ara-2'F-ADPR
6O0R	;	1.8	;	Crystal structure of the TIR domain from human SARM1 in complex with glycerol
6O0Q	;	1.8	;	Crystal structure of the TIR domain from human SARM1 in complex with ribose
5TEB	;	2.796	;	Crystal Structure of the TIR domain from the Arabidopsis Thaliana disease resistance protein RPP1
4C6R	;	2.05	;	Crystal structure of the TIR domain from the Arabidopsis Thaliana disease resistance protein RPS4
4C6S	;	1.751	;	Crystal structure of the TIR domain from the Arabidopsis Thaliana disease resistance protein RRS1
5TEC	;	2.2	;	Crystal structure of the TIR domain from the Arabidopsis thaliana NLR protein SNC1
3OZI	;	2.3	;	Crystal structure of the TIR domain from the flax disease resistance protein L6
7RX1	;	1.89	;	Crystal structure of the TIR domain from the grapevine disease resistance protein RUN1
6O0W	;	1.75	;	Crystal structure of the TIR domain from the grapevine disease resistance protein RUN1 in complex with NADP+ and Bis-Tris
7RTS	;	1.74	;	Crystal structure of the TIR domain from the grapevine disease resistance protein RUN1 without the AE interface
5KU7	;	2.3	;	Crystal structure of the TIR domain from the Muscadinia rotundifolia disease resistance protein RPV1
6O1B	;	1.67	;	Crystal structure of the TIR domain G601P mutant from human SARM1, crystal form 1
6O0V	;	2.07	;	Crystal structure of the TIR domain G601P mutant from human SARM1, crystal form 2
6O0U	;	3.03	;	Crystal structure of the TIR domain H685A mutant from human SARM1
4EO7	;	1.449	;	Crystal structure of the TIR domain of human myeloid differentiation primary response protein 88.
1FYV	;	2.9	;	CRYSTAL STRUCTURE OF THE TIR DOMAIN OF HUMAN TLR1
7NUW	;	1.9	;	Crystal structure of the TIR domain of human TLR1 (crystallised with Zn2+ ions)
7NUX	;	2.47	;	Crystal structure of the TIR domain of human TLR1 (crystallised without ZN2+ ions)
1FYW	;	3.0	;	CRYSTAL STRUCTURE OF THE TIR DOMAIN OF HUMAN TLR2
4W8G	;	1.95	;	Crystal structure of the TIR domain of the Toll-related Receptor TRR-2 from the lower metazoan Hydra magnipapillata (crystal form I)
4W8H	;	1.14	;	Crystal structure of the TIR domain of the Toll-related Receptor TRR-2 from the lower metazoan Hydra magnipapillata (crystal form II)
4DOM	;	1.798	;	Crystal Structure of the TIR-domain of Human Myeloid Differentiation Primary Response protein (MyD88)
4O00	;	1.853	;	Crystal structure of the Titin A-band domain A3
3KNB	;	1.4	;	Crystal structure of the titin C-terminus in complex with obscurin-like 1
8OS3	;	1.68	;	Crystal structure of the titin domain Fn3-11
8OMW	;	1.05	;	Crystal structure of the titin domain Fn3-20
8OSD	;	1.7	;	Crystal structure of the titin domain Fn3-49
8OQ9	;	1.65	;	Crystal structure of the titin domain Fn3-56
8OT5	;	1.56	;	Crystal structure of the titin domain Fn3-85
8OTY	;	1.9	;	Crystal structure of the titin domain Fn3-90
1YA5	;	2.445	;	Crystal structure of the titin domains z1z2 in complex with telethonin
4C4K	;	1.95	;	Crystal structure of the titin M10-Obscurin Ig domain 1 complex
4UOW	;	3.3	;	Crystal structure of the titin M10-Obscurin Ig domain 1 complex
2WP3	;	1.48	;	Crystal structure of the Titin M10-Obscurin like 1 Ig complex
2WWM	;	2.3	;	Crystal structure of the Titin M10-Obscurin like 1 Ig complex in space group P1
2WWK	;	1.7	;	Crystal structure of the Titin M10-Obscurin like 1 Ig F17R mutant complex
5HEE	;	1.41	;	Crystal structure of the TK2203 protein
3MV7	;	2.0	;	Crystal Structure of the TK3 TCR in complex with HLA-B*3501/HPVG
3MV9	;	2.7	;	Crystal Structure of the TK3-Gln55Ala TCR in complex with HLA-B*3501/HPVG
3MV8	;	2.1	;	Crystal Structure of the TK3-Gln55His TCR in complex with HLA-B*3501/HPVG
3RRW	;	2.5	;	Crystal structure of the TL29 protein from Arabidopsis thaliana
4ACJ	;	0.97	;	Crystal structure of the TLDC domain of Oxidation resistance protein 2 from zebrafish
6R82	;	2.046	;	Crystal structure of the TLDc domain of Skywalker/TBC1D24 from Drosophila melanogaster
4IOH	;	2.53	;	Crystal Structure of the Tll1086 protein from Thermosynechococcus elongatus, Northeast Structural Genomics Consortium Target TeR258
2Z7X	;	2.1	;	Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide
2Z80	;	1.8	;	Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide
2Z81	;	1.8	;	Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide
2Z82	;	2.6	;	Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide
1VC1	;	2.0	;	Crystal structure of the TM1442 protein from Thermotoga maritima, a homolog of the Bacillus subtilis general stress response anti-anti-sigma factor RsbV
4OV8	;	2.15	;	Crystal Structure of the TMH1-lock mutant of the mature form of pleurotolysin B
7BRC	;	2.06	;	Crystal structure of the TMK3 LRR domain
3GIO	;	2.4	;	Crystal structure of the TNF-alpha inducing protein (Tip alpha) from Helicobacter pylori
6GX9	;	2.7	;	Crystal structure of the TNPO3 - CPSF6 RSLD complex
1T0F	;	1.85	;	Crystal Structure of the TnsA/TnsC(504-555) complex
1Q31	;	2.7	;	Crystal Structure of the Tobacco Etch Virus Protease C151A mutant
6XWX	;	3.1	;	Crystal structure of the Tof1-Csm3 complex
4EO1	;	1.8	;	crystal structure of the TolA binding domain from the filamentous phage IKe
4JML	;	2.0	;	Crystal structure of the TolB(P201C)-ColicinE9 TBE peptide(A33C) complex.
1T3G	;	2.3	;	Crystal structure of the Toll/interleukin-1 receptor (TIR) domain of human IL-1RAPL
7SZL	;	2.3	;	Crystal structure of the Toll/interleukin-1 receptor domain of human IL-1R10 (IL-1RAPL2)
4P1B	;	2.05	;	CRYSTAL STRUCTURE OF THE TOLUENE 4-MONOOXYGENASE HYDROXYLASE-FERREDOXIN C7S E16C C84A C85A VARIANT ELECTRON-TRANSFER COMPLEX
4P1C	;	2.4	;	CRYSTAL STRUCTURE OF THE TOLUENE 4-MONOOXYGENASE HYDROXYLASE-FERREDOXIN C7S, C84A, C85A VARIANT ELECTRON-TRANSFER COMPLEX
1T0R	;	2.3	;	Crystal Structure of the Toluene/o-xylene Monooxygenase Hydroxuylase from Pseudomonas stutzeri-azide bound
4UJ0	;	1.7	;	Crystal structure of the tomato defensin TPP3
1AHS	;	2.3	;	CRYSTAL STRUCTURE OF THE TOP DOMAIN OF AFRICAN HORSE SICKNESS VIRUS VP7
2Q2E	;	4.0	;	Crystal structure of the topoisomerase VI holoenzyme from Methanosarcina mazei
3O1J	;	2.95	;	Crystal Structure of the TorS sensor domain - TorT complex in the absence of isopropanol
3O1I	;	2.8	;	Crystal Structure of the TorS sensor domain - TorT complex in the absence of ligand
3O1H	;	3.1	;	Crystal Structure of the TorS sensor domain - TorT complex in the presence of TMAO
4I8O	;	2.104	;	Crystal structure of the toxin RnlA from Escherichia coli
7BXO	;	2.77	;	Crystal structure of the toxin-antitoxin with AMP-PNP
7NJC	;	1.38	;	Crystal structure of the Toxoplasma CPSF4 YTH-domain in complex with a 7 mer m6A-modified RNA
3BKP	;	1.8	;	Crystal structure of the Toxoplasma gondii cyclophilin, 49.m03261
3GG8	;	2.21	;	Crystal structure of the Toxoplasma gondii Pyruvate Kinase N terminal truncated
4ECK	;	3.516	;	Crystal Structure of the Toxoplasma gondii TS-DHFR
2V84	;	1.78	;	Crystal Structure of the Tp0655 (TpPotD) Lipoprotein of Treponema pallidum
7TBR	;	1.1	;	Crystal structure of the TPM domain from the Rhodothermus marinus protein Rhom172_1776
4YVO	;	1.45	;	Crystal Structure of the TPR Domain of Arabidopsis FLU (FLU-TPR)
3Q49	;	1.543	;	Crystal structure of the TPR domain of CHIP complexed with Hsp70-C peptide
3Q4A	;	1.542	;	Crystal structure of the TPR domain of CHIP complexed with phosphorylated Smad1 peptide
6PX0	;	1.55	;	Crystal structure of the TPR domain of human aryl hydrocarbon receptor-interacting protein-like 1 (AIPL1)
2VYI	;	2.4	;	Crystal Structure of the TPR domain of Human SGT
3NF1	;	2.8	;	Crystal structure of the TPR domain of kinesin light chain 1
3ZFW	;	2.9	;	Crystal structure of the TPR domain of kinesin light chain 2 in complex with a tryptophan-acidic cargo peptide
6SWU	;	2.849	;	Crystal structure of the TPR domain of KLC1 in complex with an engineered high-affinity cargo peptide.
6FUZ	;	2.7	;	Crystal structure of the TPR domain of KLC1 in complex with the C-terminal peptide of JIP1
6FV0	;	2.29	;	Crystal structure of the TPR domain of KLC1 in complex with the C-terminal peptide of torsinA
4WND	;	1.5	;	Crystal structure of the TPR domain of LGN in complex with Frmpd4/Preso1 at 1.5 Angstrom resolution
4WNE	;	2.0	;	Crystal structure of the TPR domain of LGN in complex with Frmpd4/Preso1 at 2.0 Angstrom resolution
4WNG	;	2.11	;	Crystal structure of the TPR domain of LGN in complex with Frmpd4/Preso1 at 2.1 Angstrom resolution
5WWM	;	2.809	;	Crystal structure of the TPR domain of Rrp5
5LYP	;	1.55	;	Crystal structure of the Tpr Domain of Sgt2.
4UM2	;	2.1	;	Crystal structure of the TPR domain of SMG6
2XEV	;	1.57	;	Crystal structure of the TPR domain of Xanthomonas campestris ybgF
1ELW	;	1.6	;	Crystal structure of the TPR1 domain of HOP in complex with a HSC70 peptide
1ELR	;	1.9	;	Crystal structure of the TPR2A domain of HOP in complex with the HSP90 peptide MEEVD
1QSC	;	2.4	;	CRYSTAL STRUCTURE OF THE TRAF DOMAIN OF TRAF2 IN A COMPLEX WITH A PEPTIDE FROM THE CD40 RECEPTOR
4GJH	;	2.805	;	Crystal Structure of the TRAF domain of TRAF5
2F1W	;	1.65	;	Crystal structure of the TRAF-like domain of HAUSP/USP7
2F1Y	;	1.7	;	Crystal structure of the TRAF-like domain of HAUSP/USP7 bound to a MDM2 peptide
2F1X	;	2.3	;	Crystal structure of the TRAF-like domain of HAUSP/USP7 bound to a p53 peptide
3M0D	;	2.8	;	Crystal structure of the TRAF1:TRAF2:cIAP2 complex
1OPX	;	2.8	;	Crystal structure of the traffic ATPase (HP0525) of the Helicobacter pylori type IV secretion system bound by sulfate
1NLY	;	2.8	;	Crystal structure of the traffic ATPase of the Helicobacter pylori type IV secretion system in complex with ATPgammaS
3FLD	;	2.4	;	Crystal structure of the trai c-terminal domain
3VHZ	;	2.3	;	Crystal structure of the trans isomer of the L93A mutant of bacteriorhodopsin
4U3V	;	1.73	;	Crystal structure of the trans-acyltransferase polyketide synthase enoyl-isomerase
5HU7	;	2.4	;	Crystal structure of the trans-AT PKS dehydratase domain of C0ZGQ4 from Brevibacillus brevis
3KFU	;	3.0	;	Crystal structure of the transamidosome
2P4V	;	2.6	;	Crystal structure of the transcript cleavage factor, GreB at 2.6A resolution
5CRL	;	2.8	;	Crystal Structure of the Transcription Activator Tn501 MerR in Complex with Mercury (II)
3QOQ	;	3.1	;	Crystal Structure of the Transcription Factor AmrZ in Complex with the 18 Base Pair amrZ1 Binding Site
6JYW	;	2.95	;	Crystal structure of the transcription regulator CadR N81M mutant from P. putida in complex with Cadmium(II) and DNA
3BRO	;	2.04	;	Crystal structure of the transcription regulator MarR from Oenococcus oeni PSU-1
5GPE	;	2.01	;	Crystal structure of the transcription regulator PbrR691 from Ralstonia metallidurans CH34 in complex with Lead(II)
3FD9	;	2.6	;	Crystal Structure of the transcriptional anti-activator ExsD from Pseudomonas aeruginosa
2DI3	;	2.05	;	Crystal structure of the transcriptional factor CGL2915 from Corynebacterium glutamicum
2DU9	;	2.28	;	crystal structure of the transcriptional factor from C.glutamicum
2EK5	;	2.2	;	Crystal structure of the transcriptional factor from C.glutamicum at 2.2 angstrom resolution
2QOP	;	2.55	;	Crystal structure of the transcriptional regulator AcrR from Escherichia coli
3F3X	;	1.9	;	Crystal structure of the transcriptional regulator BldR from Sulfolobus Solfataricus
6JGV	;	2.2	;	Crystal structure of the transcriptional regulator CadR from P. putida
6JGX	;	2.71	;	Crystal structure of the transcriptional regulator CadR from P. putida in complex with Cadmium(II) and DNA
6JGW	;	2.8	;	Crystal structure of the transcriptional regulator CadR from P. putida in complex with DNA
6JNI	;	2.9	;	Crystal structure of the transcriptional regulator CadR from P. putida in complex with Zinc(II) and DNA
2QCO	;	2.25	;	Crystal structure of the transcriptional regulator CmeR from Campylobacter jejuni
1U9O	;	3.3	;	Crystal structure of the transcriptional regulator EthR in a ligand bound conformation
1U9N	;	2.3	;	Crystal structure of the transcriptional regulator EthR in a ligand bound conformation opens therapeutic perspectives against tuberculosis and leprosy
7CBV	;	2.3	;	Crystal structure of the transcriptional regulator PadR from Bacillus subtilis (space group H32)
4I6Z	;	3.2	;	Crystal structure of the transcriptional regulator TM1030 with 24bp DNA oligonucleotide
3NXH	;	2.584	;	Crystal Structure of the transcriptional regulator yvhJ from Bacillus subtilis. Northeast Structural Genomics Consortium Target SR735.
3PQJ	;	2.48	;	Crystal Structure of the transcriptional repressor BigR from Xylella fastidiosa
3PQK	;	2.09	;	Crystal Structure of the transcriptional repressor BigR from Xylella fastidiosa
2ZKZ	;	2.0	;	Crystal structure of the transcriptional repressor PagR of Bacillus anthracis
1T5O	;	1.9	;	Crystal structure of the translation initiation factor eIF-2B, subunit delta, from A. fulgidus
6HTJ	;	1.65	;	Crystal structure of the translation recovery factor Trf from Sulfolobus solfataricus
2IPC	;	2.8	;	Crystal structure of the translocation ATPase SecA from Thermus thermophilus reveals a parallel, head-to-head dimer
7D7Q	;	3.5	;	Crystal structure of the transmembrane domain and linker region of Salpingoeca rosetta rhodopsin phosphodiesterase
7CJ3	;	2.6	;	Crystal structure of the transmembrane domain of Salpingoeca rosetta rhodopsin phosphodiesterase
8VBZ	;	1.9	;	Crystal structure of the transpeptidase domain of a S310A mutant of PBP2 from Neisseria gonorrhoeae strain H041
6P56	;	1.92	;	Crystal structure of the transpeptidase domain of a T498A mutant of PBP2 from Neisseria gonorrhoeae
4U3T	;	2.2	;	Crystal structure of the transpeptidase domain of Neisseria gonorrhoeae penicillin-binding protein 2 derived from the penicillin-resistant strain 6140
6P53	;	1.92	;	Crystal structure of the transpeptidase domain of PBP2 from Neisseria gonorrhoeae in apo form
6VBL	;	1.93	;	Crystal structure of the transpeptidase domain of PBP2 from the Neisseria gonorrhoeae cephalosporin decreased susceptibility strain 35/02
8A1O	;	1.95	;	Crystal structure of the transpeptidase LdtMt2 from Mycobacterium tuberculosis in complex with acrylamide analogue 8
8A1L	;	2.3	;	Crystal structure of the transpeptidase LdtMt2 from Mycobacterium tuberculosis in complex with alpha-chloro ketone 2
8AHO	;	2.3	;	Crystal structure of the transpeptidase LdtMt2 from Mycobacterium tuberculosis in complex with cyanamide analogue 31
8BK3	;	2.15	;	Crystal structure of the transpeptidase LdtMt2 from Mycobacterium tuberculosis in complex with diepoxide ketone 1
8A1K	;	1.75	;	Crystal structure of the transpeptidase LdtMt2 from Mycobacterium tuberculosis in complex with ebsulfur analogue 15
8A1N	;	2.05	;	Crystal structure of the transpeptidase LdtMt2 from Mycobacterium tuberculosis in complex with fumaryl amide analogue 13
8A1J	;	2.55	;	Crystal structure of the transpeptidase LdtMt2 from Mycobacterium tuberculosis in complex with maleimide analogue 3
8A1M	;	2.3	;	Crystal structure of the transpeptidase LdtMt2 from Mycobacterium tuberculosis in complex with maleimide analogue 4
4MEE	;	3.0	;	Crystal structure of the transport unit of the autotransporter AIDA-I from Escherichia coli
3QNQ	;	3.295	;	Crystal structure of the transporter ChbC, the IIC component from the N,N'-diacetylchitobiose-specific phosphotransferase system
5IWS	;	2.551	;	Crystal structure of the transporter MalT, the EIIC domain from the maltose-specific phosphotransferase system
6V9P	;	1.93	;	Crystal structure of the transposition protein TniQ
1SOQ	;	2.1	;	Crystal structure of the transthyretin mutant A108Y/L110E solved in space group C2
1SOK	;	1.6	;	Crystal structure of the transthyretin mutant A108Y/L110E solved in space group p21212
1IJN	;	1.7	;	Crystal structure of the transthyretin mutant TTR C10A/Y114C
1IIK	;	2.0	;	CRYSTAL STRUCTURE OF THE TRANSTHYRETIN MUTANT TTR Y114C-DATA COLLECTED AT CRYO TEMPERATURE
1III	;	2.0	;	CRYSTAL STRUCTURE OF THE TRANSTHYRETIN MUTANT TTR Y114C-DATA COLLECTED AT ROOM TEMPERATURE
3BSZ	;	3.38	;	Crystal structure of the transthyretin-retinol binding protein-Fab complex
7Z5A	;	2.28	;	Crystal structure of the trapped complex of mouse Endonuclease VIII-LIKE 3 (mNEIL3) and hairpin DNA with 5'overhang
4O26	;	3.001	;	Crystal structure of the TRBD domain of TERT and the CR4/5 of TR
8UQT	;	1.16	;	Crystal structure of the Tree Shrew p53 tetramerization domain
4GO9	;	2.2	;	CRYSTAL STRUCTURE of the TREHALULOSE SYNTHASE MUTANT, MUTB D415N, in COMPLEX with TRIS
2PWH	;	2.0	;	Crystal structure of the trehalulose synthase MutB from Pseudomonas mesoacidophila MX-45
1ZJB	;	1.8	;	Crystal structure of the trehalulose synthase MutB from Pseudomonas mesoacidophila MX-45 (monoclinic form)
1ZJA	;	1.6	;	Crystal structure of the trehalulose synthase MutB from Pseudomonas mesoacidophila MX-45 (triclinic form)
2PWG	;	2.2	;	Crystal Structure of the Trehalulose Synthase MutB From Pseudomonas Mesoacidophila MX-45 Complexed to the Inhibitor Castanospermine
2PWD	;	1.8	;	Crystal Structure of the Trehalulose Synthase MUTB from Pseudomonas Mesoacidophila MX-45 Complexed to the Inhibitor Deoxynojirmycin
4H8V	;	1.95	;	Crystal structure of the trehalulose synthase MUTB in complex with trehalulose
4GO8	;	2.15	;	Crystal Structure of the TREHALULOSE SYNTHASE MUTB, MUTANT A258V, in complex with TRIS
4M7C	;	2.05	;	Crystal structure of the TRF2-binding motif of SLX4 in complex with the TRFH domain of TRF2
6KIN	;	2.527	;	Crystal structure of the tri-functional malyl-CoA lyase from Roseiflexus castenholzii
8BV7	;	1.8	;	Crystal structure of the Trichoplax Scribble PDZ1 domain in complex with the Trichoplax phosphorylated Vangl peptide
1MTZ	;	1.8	;	Crystal Structure of the Tricorn Interacting Factor F1
1MU0	;	2.4	;	Crystal Structure of the Tricorn Interacting Factor F1 Complex with PCK
1MT3	;	2.0	;	Crystal Structure of the Tricorn Interacting Factor Selenomethionine-F1
1K32	;	2.0	;	Crystal structure of the tricorn protease
1BRP	;	2.5	;	CRYSTAL STRUCTURE OF THE TRIGONAL FORM OF HUMAN PLASMA RETINOL-BINDING PROTEIN AT 2.5 ANGSTROMS RESOLUTION
1BRQ	;	2.5	;	CRYSTAL STRUCTURE OF THE TRIGONAL FORM OF HUMAN PLASMA RETINOL-BINDING PROTEIN AT 2.5 ANGSTROMS RESOLUTION
6JBM	;	2.1	;	Crystal structure of the TRIM14 PRYSPRY domain
8PD6	;	1.3	;	Crystal structure of the TRIM58 PRY-SPRY domain in complex with TRIM-473
6UMA	;	1.6	;	Crystal structure of the TRIM7 B30.2 domain at 1.6 angstrom resolution
2GGX	;	1.9	;	Crystal structure of the trimer neck and carbohydrate recognition domain of human surfactant protein D in complex with p-nitrophenyl maltoside
3LAA	;	1.35	;	Crystal structure of the trimeric autotransporter adhesin head domain BpaA from Burkholderia pseudomallei
3LA9	;	2.05	;	Crystal structure of the trimeric autotransporter adhesin head domain BpaA from Burkholderia pseudomallei, iodide phased
2W6B	;	2.8	;	Crystal Structure of the Trimeric beta-PIX Coiled-Coil Domain
7P4L	;	2.3	;	Crystal structure of the trimeric ectodomain of archaeal Fusexin1 (Fsx1)
7JPD	;	2.95	;	Crystal structure of the trimeric full length mature hemagglutinin from influenza A virus A/Fort Monmouth/1/1947
2RIE	;	1.6	;	Crystal structure of the trimeric neck and carbohydrate recognition domain of human surfactant protein D in complex with 2-deoxy-L-glycero-D-manno-heptose
2RID	;	1.8	;	Crystal structure of the trimeric neck and carbohydrate recognition domain of human surfactant protein D in complex with Allyl 7-O-carbamoyl-L-glycero-D-manno-heptopyranoside
3G83	;	1.9	;	Crystal structure of the trimeric neck and carbohydrate recognition domain of human surfactant protein D in complex with alpha 1,2 dimannose.
3G81	;	1.8	;	Crystal structure of the trimeric neck and carbohydrate recognition domain of human surfactant protein D in complex with alpha methyl mannoside
2RIA	;	1.8	;	Crystal structure of the trimeric neck and carbohydrate recognition domain of human surfactant protein D in complex with D-glycero-D-manno-heptose
2ORK	;	1.89	;	crystal structure of the trimeric neck and carbohydrate recognition domain of human surfactant protein D in complex with inositol-1-phosphate
2RIC	;	1.8	;	Crystal structure of the trimeric neck and carbohydrate recognition domain of human surfactant protein D in complex with L-glycero-D-manno-heptopyranosyl-(1-3)-L-glycero-D-manno-heptopyranose
2RIB	;	1.8	;	Crystal structure of the trimeric neck and carbohydrate recognition domain of human surfactant protein D in complex with L-glycero-D-manno-heptose
2GGU	;	1.9	;	crystal structure of the trimeric neck and carbohydrate recognition domain of human surfactant protein D in complex with maltotriose
2OS9	;	1.7	;	crystal structure of the trimeric neck and carbohydrate recognition domain of human surfactant protein D in complex with myoinositol
2ORJ	;	1.8	;	crystal structure of the trimeric neck and carbohydrate recognition domain of human surfactant protein D in complex with N-acetyl mannosamine
3G84	;	2.3	;	Crystal structure of the trimeric neck and carbohydrate recognition domain of R343V mutant of human surfactant protein D in complex with alpha 1,2 dimannose.
3CSY	;	3.4	;	Crystal structure of the trimeric prefusion Ebola virus glycoprotein in complex with a neutralizing antibody from a human survivor
1SLQ	;	3.2	;	Crystal structure of the trimeric state of the rhesus rotavirus VP4 membrane interaction domain, VP5CT
4CGB	;	2.154	;	Crystal structure of the trimerization domain of EML2
4CGC	;	2.901	;	Crystal structure of the trimerization domain of human EML4
5Y79	;	2.2	;	Crystal structure of the triose-phosphate/phosphate translocator in complex with 3-phosphoglycerate
5Y78	;	2.1	;	Crystal structure of the triose-phosphate/phosphate translocator in complex with inorganic phosphate
3FYO	;	1.9	;	Crystal structure of the triple mutant (N23C/D247E/P249A) of 3-deoxy-D-manno-octulosonate 8-phosphate synthase (KDO8PS) from Neisseria meningitidis
7YHE	;	1.67	;	Crystal structure of the triple mutant CmnC-L136Q,S138G,D249Y in complex with alpha-KG
7YW9	;	1.76	;	Crystal structure of the triple mutant CmnC-L136Q,S138G,D249Y in complex with alpha-KG
3I9Q	;	1.45	;	Crystal Structure of the triple mutant S19G-P20D-R21S of alpha spectrin SH3 domain
1QSU	;	1.75	;	CRYSTAL STRUCTURE OF THE TRIPLE-HELICAL COLLAGEN-LIKE PEPTIDE, (PRO-HYP-GLY)4-GLU-LYS-GLY(PRO-HYP-GLY)5
4PLX	;	3.1	;	Crystal structure of the triple-helical stability element at the 3' end of MALAT1
3SYW	;	1.57	;	Crystal Structure of the Triplet Repeat in Myotonic Dystrophy Reveals Heterogeneous 1x1 Nucleotide UU Internal Loop Conformations
3SZX	;	2.204	;	Crystal Structure of the Triplet Repeat in Myotonic Dystrophy Reveals Heterogeneous 1x1 Nucleotide UU Internal Loop Conformations
2WI8	;	1.55	;	Crystal structure of the triscatecholate siderophore binding protein FeuA from Bacillus subtilis
2WHY	;	1.7	;	Crystal structure of the triscatecholate siderophore binding protein FeuA from Bacillus subtilis complexed with Ferri-Bacillibactin
2XUZ	;	1.9	;	Crystal structure of the triscatecholate siderophore binding protein FeuA from Bacillus subtilis complexed with Ferri-Enterobactin
2XV1	;	2.15	;	Crystal structure of the triscatecholate siderophore binding protein FeuA from Bacillus subtilis complexed with Ferric MECAM
1T6E	;	1.7	;	Crystal Structure of the Triticum aestivum xylanase inhibitor I
1T6G	;	1.8	;	Crystal structure of the Triticum aestivum xylanase inhibitor-I in complex with aspergillus niger xylanase-I
3HD8	;	2.39	;	Crystal structure of the Triticum aestivum xylanase inhibitor-IIA in complex with bacillus subtilis xylanase
2B42	;	2.5	;	Crystal structure of the Triticum xylanse inhibitor-I in complex with bacillus subtilis xylanase
4J9V	;	3.051	;	Crystal Structure of the TrkA Gating ring bound to ATP-gamma-S
4J9U	;	3.8	;	Crystal Structure of the TrkH/TrkA potassium transport complex
3TL4	;	2.3	;	Crystal Structure of the tRNA Binding Domain of Glutaminyl-tRNA Synthetase from Saccharomyces cerevisiae
5UD5	;	2.347	;	Crystal structure of the tRNA binding domain of Pyrrolysyl-tRNA synthetase bound to tRNA(Pyl)
5V6X	;	2.76	;	Crystal structure of the tRNA binding domain of Pyrrolysyl-tRNA synthetase mutant (32A NTD) bound to tRNA(Pyl)
2CZJ	;	3.01	;	Crystal structure of the tRNA domain of tmRNA from Thermus thermophilus HB8
1P6V	;	3.2	;	Crystal structure of the tRNA domain of transfer-messenger RNA in complex with SmpB
3U02	;	2.399	;	Crystal Structure of the tRNA modifier TiaS from Pyrococcus furiosus, Northeast Structural Genomics Consortium Target PfR225
1UDN	;	2.3	;	Crystal structure of the tRNA processing enzyme RNase PH from Aquifex aeolicus
1R6L	;	1.9	;	Crystal Structure Of The tRNA Processing Enzyme Rnase pH From Pseudomonas Aeruginosa
1R6M	;	2.0	;	Crystal Structure Of The tRNA Processing Enzyme Rnase pH From Pseudomonas Aeruginosa In Complex With Phosphate
1UDS	;	2.3	;	Crystal structure of the tRNA processing enzyme RNase PH R126A mutant from Aquifex aeolicus
1UDO	;	2.3	;	Crystal structure of the tRNA processing enzyme RNase PH R86A mutant from Aquifex aeolicus
1UDQ	;	2.3	;	Crystal structure of the tRNA processing enzyme RNase PH T125A mutant from Aquifex aeolicus
1VS3	;	2.25	;	Crystal Structure of the tRNA Pseudouridine Synthase TruA From Thermus thermophilus HB8
1A79	;	2.28	;	CRYSTAL STRUCTURE OF THE TRNA SPLICING ENDONUCLEASE FROM METHANOCOCCUS JANNASCHII
4P5J	;	1.9912	;	Crystal structure of the tRNA-like structure from Turnip Yellow Mosaic Virus (TYMV), a tRNA mimicking RNA
3ZTE	;	2.41	;	Crystal Structure of the TRP RNA-Binding Attenuation Protein (TRAP) from Bacillus Licheniformis.
6BWM	;	3.9	;	Crystal structure of the TRPV2 ion channel
6BWJ	;	3.1	;	Crystal structure of the TRPV2 ion channel in complex with RTx
5XLN	;	1.9	;	Crystal structure of the TRS_UNE-T and 4EHP complex
6T3Z	;	1.55863	;	Crystal structure of the truncated EBV BFRF1-BFLF2 nuclear egress complex
2EG9	;	2.8	;	Crystal structure of the truncated extracellular domain of mouse CD38
2XRH	;	1.5	;	Crystal structure of the truncated form of HP0721
6QJD	;	1.551	;	Crystal Structure of the truncated form of the third PDZ domain of PSD-95: residues 302-392
2BKM	;	1.5	;	Crystal structure of the truncated hemoglobin from Geobacillus stearothermophilus
6T3X	;	1.48	;	Crystal structure of the truncated human cytomegalovirus pUL50-pUL53 complex
1QVE	;	1.54	;	Crystal structure of the truncated K122-4 pilin from Pseudomonas aeruginosa
1IDR	;	1.9	;	CRYSTAL STRUCTURE OF THE TRUNCATED-HEMOGLOBIN-N FROM MYCOBACTERIUM TUBERCULOSIS
8FJN	;	2.1	;	Crystal Structure of the Trypanosoma brucei DOT1A histone H3K76 methyltransferase in complex with AdoHcy - C2221 space group
8FJM	;	1.9	;	Crystal Structure of the Trypanosoma brucei DOT1A histone H3K76 methyltransferase in complex with AdoHcy - P212121 space group
4I70	;	1.6	;	Crystal structure of the Trypanosoma brucei Inosine-Adenosine-Guanosine nucleoside hydrolase
4I71	;	1.28	;	Crystal structure of the Trypanosoma brucei Inosine-Adenosine-Guanosine nucleoside hydrolase in complex with a trypanocidal compound
4I73	;	2.18	;	Crystal structure of the Trypanosoma brucei Inosine-Adenosine-Guanosine nucleoside hydrolase in complex with compound UAMC-00312
4I74	;	1.68	;	Crystal structure of the Trypanosoma brucei Inosine-Adenosine-Guanosine nucleoside hydrolase in complex with compound UAMC-00312 and allosterically inhibited by a Ni2+ ion
4I72	;	2.05	;	Crystal structure of the Trypanosoma brucei Inosine-Adenosine-Guanosine nucleoside hydrolase in complex with Immucillin A
4I75	;	1.8	;	Crystal structure of the Trypanosoma brucei Inosine-Adenosine-Guanosine nucleoside hydrolase in complex with the NiTris metalorganic complex
3JV1	;	2.0	;	Crystal structure of the Trypanosoma brucei p22 protein
8FX1	;	1.8	;	Crystal structure of the Trypanosoma cruzi hypoxanthine-guanine-xanthine phosphoribosyltransferase (HGXPRT), isoform D, bound to (R)-SerMe-ImmH Phosphonate
8FX0	;	1.52	;	Crystal structure of the Trypanosoma cruzi hypoxanthine-guanine-xanthine phosphoribosyltransferase (HGXPRT), isoform D, bound to (S)-SerMe-ImmH Phosphonate
8FWZ	;	1.65	;	Crystal structure of the Trypanosoma cruzi hypoxanthine-guanine-xanthine phosphoribosyltransferase (HGXPRT), isoform D, bound to Hydroxypropyl-Lin-ImmH Phosphonate
8FX3	;	1.31	;	Crystal structure of the Trypanosoma cruzi hypoxanthine-guanine-xanthine phosphoribosyltransferase (HGXPRT), isoform D, bound to Immucillin-GP, showing the structure of the complete active site in its open conformation
8FX2	;	1.54	;	Crystal structure of the Trypanosoma cruzi hypoxanthine-guanine-xanthine phosphoribosyltransferase (HGXPRT), isoform D, bound to Immucillin-HP
8FWY	;	1.54	;	Crystal structure of the Trypanosoma cruzi hypoxanthine-guanine-xanthine phosphoribosyltransferase (HGXPRT), isoform D, bound to the dead-end complex xanthine and pyrophosphate
4AZ1	;	2.181	;	Crystal structure of the Trypanosoma cruzi protein tyrosine phosphatase TcPTP1, a potential therapeutic target for Chagas' disease
2OXS	;	1.32	;	Crystal Structure of the trypsin complex with benzamidine at high temperature (35 C)
2OIZ	;	1.05	;	Crystal Structure of the Tryptamine-Derived (Indol-3-Acetamide)-TTQ Adduct of Aromatic Amine Dehydrogenase
4OQO	;	2.42	;	Crystal structure of the tryptic generated iron-free C-lobe of bovine Lactoferrin at 2.42 Angstrom resolution
1YW0	;	2.7	;	Crystal structure of the tryptophan 2,3-dioxygenase from Xanthomonas campestris. Northeast Structural Genomics Target XcR13.
1K8Y	;	1.5	;	CRYSTAL STRUCTURE OF THE TRYPTOPHAN SYNTHASE BETA-SER178PRO MUTANT COMPLEXED WITH D,L-ALPHA-GLYCEROL-3-PHOSPHATE
1K8Z	;	1.7	;	CRYSTAL STRUCTURE OF THE TRYPTOPHAN SYNTHASE BETA-SER178PRO MUTANT COMPLEXED WITH N-[1H-INDOL-3-YL-ACETYL]GLYCINE ACID
6FHG	;	1.95	;	Crystal structure of the Ts2631 endolysin from Thermus scotoductus phage with the unique N-terminal moiety responsible for peptidoglycan anchoring
3OBX	;	1.6	;	Crystal structure of the Tsg101 UEV domain in complex with a HIV-1 Gag P7A mutant peptide
3OBU	;	1.6	;	Crystal structure of the Tsg101 UEV domain in complex with a HIV-1 PTAP peptide
3OBQ	;	1.4	;	Crystal Structure of the Tsg101 UEV domain in complex with a human HRS PSAP peptide
3P9H	;	1.8	;	Crystal structure of the TSG101 UEV domain in complex with FA258 peptide
3P9G	;	1.8	;	Crystal structure of the TSG101 UEV domain in complex with FA459 peptide
7ZLX	;	2.25	;	Crystal Structure of the TSG101-UEV domain:space group P21
2XWT	;	1.9	;	CRYSTAL STRUCTURE OF THE TSH RECEPTOR IN COMPLEX WITH A BLOCKING TYPE TSHR AUTOANTIBODY
3G04	;	2.55	;	Crystal structure of the TSH receptor in complex with a thyroid-stimulating autoantibody
2DCT	;	1.45	;	Crystal structure of the TT1209 from Thermus thermophilus HB8
7O3B	;	2.4	;	Crystal structure of the TTBK2-CEP164 complex bound to a camelid nanobody
5DSE	;	2.9	;	Crystal Structure of the TTC7B/Hyccin Complex
4UZZ	;	2.318	;	Crystal structure of the TtIFT52-46 complex
6DA7	;	1.83	;	Crystal structure of the TtnD decarboxylase from the tautomycetin biosynthesis pathway of Streptomyces griseochromogenes with apo form at 1.83 A resolution (I222)
6DA9	;	2.05	;	Crystal structure of the TtnD decarboxylase from the tautomycetin biosynthesis pathway of Streptomyces griseochromogenes with FMN bound at 2.05 A resolution
6DA6	;	2.59	;	Crystal structure of the TtnD decarboxylase from the tautomycetin biosynthesis pathway of Streptomyces griseochromogenes, apo form at 2.6 A resolution (P212121)
4AUT	;	2.1	;	Crystal structure of the tuberculosis drug target Decaprenyl- Phosphoryl-beta-D-Ribofuranose-2-oxidoreductase (DprE1) from Mycobacterium smegmatis
6HQ9	;	1.982	;	Crystal structure of the Tudor domain of human ERCC6-L2
2XDP	;	1.56	;	Crystal structure of the tudor domain of human JMJD2C
3PNW	;	2.05	;	Crystal Structure of the tudor domain of human TDRD3 in complex with an anti-TDRD3 FAB
3PMT	;	1.8	;	Crystal structure of the Tudor domain of human Tudor domain-containing protein 3
3O8V	;	2.5	;	Crystal Structure of the Tudor Domains from FXR1
1SM3	;	1.95	;	CRYSTAL STRUCTURE OF THE TUMOR SPECIFIC ANTIBODY SM3 COMPLEX WITH ITS PEPTIDE EPITOPE
1JK7	;	1.9	;	CRYSTAL STRUCTURE OF THE TUMOR-PROMOTER OKADAIC ACID BOUND TO PROTEIN PHOSPHATASE-1
2Z62	;	1.7	;	Crystal structure of the TV3 hybrid of human TLR4 and hagfish VLRB.61
3UL7	;	2.37	;	Crystal structure of the TV3 mutant F63W
3ULA	;	3.6	;	Crystal structure of the TV3 mutant F63W-MD-2-Eritoran complex
3UL8	;	2.5	;	Crystal structure of the TV3 mutant V134L
2Z63	;	2.0	;	Crystal structure of the TV8 hybrid of human TLR4 and hagfish VLRB.61
4QJH	;	3.88	;	Crystal Structure of the Twister Ribozyme with the Nucleotide 5'- to the Cleavage Site Ordered at 4.1 A Resolution
5T5A	;	2.0	;	Crystal Structure of the Twister Sister (TS) Ribozyme at 2.0 Angstrom
3TO8	;	1.82	;	Crystal structure of the two C-terminal RRM domains of heterogeneous nuclear ribonucleoprotein L (hnRNP L)
2R57	;	2.2	;	Crystal Structure of the two MBT repeats from Sex-Comb on Midleg (SCM)
2R58	;	2.0	;	Crystal Structure of the two MBT repeats from Sex-Comb on Midleg (SCM) in Complex with Di-Methyl Lysine
2R5A	;	2.3	;	Crystal Structure of the two MBT repeats from Sex-Comb on Midleg (SCM) in complex with methyl lysine
2R5M	;	2.65	;	Crystal Structure of the two MBT repeats from Sex-Comb on Midleg (SCM) in complex with peptide R-(me)K-S
1EPF	;	1.85	;	CRYSTAL STRUCTURE OF THE TWO N-TERMINAL IMMUNOGLOBULIN DOMAINS OF THE NEURAL CELL ADHESION MOLECULE (NCAM)
4ED5	;	2.0	;	Crystal structure of the two N-terminal RRM domains of HuR complexed with RNA
5KW1	;	2.1	;	Crystal Structure of the Two Tandem RRM Domains of PUF60 Bound to a Modified AdML Pre-mRNA 3' Splice Site Analogue
5KVY	;	1.95	;	CRYSTAL STRUCTURE OF THE TWO TANDEM RRM DOMAINS OF PUF60 BOUND TO A PORTION OF AN ADML PRE-MRNA 3' SPLICE SITE ANALOG
2FBO	;	1.85	;	Crystal Structure of the Two Tandem V-type Regions of VCBP3 (v-region-containing chitin binding protein) to 1.85 A
7A73	;	1.14	;	Crystal structure of the two-domain cyclophilinA from Anabaena sp.
2FQ1	;	2.3	;	Crystal structure of the two-domain non-ribosomal peptide synthetase EntB containing isochorismate lyase and aryl-carrier protein domains
5EQJ	;	2.2	;	Crystal structure of the two-subunit tRNA m1A58 methyltransferase from Saccharomyces cerevisiae
5ERG	;	2.202	;	Crystal structure of the two-subunit tRNA m1A58 methyltransferase TRM6-TRM61 in complex with SAM
8S99	;	1.71	;	Crystal structure of the TYK2 pseudokinase domain in complex with compound 11
8S98	;	1.87	;	Crystal structure of the TYK2 pseudokinase domain in complex with compound 8
8S9A	;	1.83	;	Crystal structure of the TYK2 pseudokinase domain in complex with TAK-279
4OQE	;	2.2	;	Crystal structure of the tylM1 N,N-dimethyltransferase in complex with SAH and TDP-Fuc3NMe
4OQD	;	1.6	;	Crystal structure of the tylM1 N,N-dimethyltransferase in complex with SAH and TDP-Qui3NMe2
3CTK	;	1.8	;	Crystal structure of the type 1 RIP bouganin
4A56	;	1.24	;	Crystal structure of the type 2 secretion system pilotin from Klebsiella Oxytoca
3SOL	;	1.9	;	Crystal structure of the type 2 secretion system pilotin GspS
2RJZ	;	2.2	;	Crystal structure of the type 4 fimbrial biogenesis protein PilO from Pseudomonas aeruginosa
6PUB	;	2.43	;	Crystal Structure of the Type B Chloramphenicol Acetyltransferase from Vibrio cholerae in the Complex with Crystal Violet
6PU9	;	1.7	;	Crystal Structure of the Type B Chloramphenicol O-Acetyltransferase from Vibrio vulnificus
3LKD	;	2.25	;	Crystal Structure of the type I restriction-modification system methyltransferase subunit from Streptococcus thermophilus, Northeast Structural Genomics Consortium Target SuR80
7XZ3	;	1.889	;	Crystal structure of the Type I-B CRISPR-associated protein, Csh2 from Thermobaculum terrenum
1J2Y	;	2.6	;	Crystal structure of the type II 3-dehydroquinase
3BWZ	;	1.2	;	Crystal structure of the type II cohesin module from the cellulosome of Acetivibrio cellulolyticus with an extended linker conformation
4L8L	;	1.74	;	Crystal Structure of the Type II Dehydroquinase from Pseudomonas aeruginosa
4RC9	;	2.05	;	Crystal Structure of the type II Dehydroquinate dehydratase from Acinetobacter baumannii at 2.03A Resolution
4OGC	;	2.8	;	Crystal structure of the Type II-C Cas9 enzyme from Actinomyces naeslundii
4OGE	;	2.201	;	Crystal structure of the Type II-C Cas9 enzyme from Actinomyces naeslundii
1NH1	;	2.2	;	Crystal Structure of the Type III Effector AvrB from Pseudomonas syringae.
6HQZ	;	1.8	;	Crystal structure of the type III effector protein AvrRpt2 from Erwinia amylovora, a C70 family cysteine protease
6K94	;	2.26	;	Crystal structure of the type III effector XopAI from Xanthomonas axonopodis pv. citri - a 70 residue N-terminal truncation
6K93	;	1.53	;	Crystal structure of the type III effector XopAI from Xanthomonas axonopodis pv. citri in space group P41212
6KLY	;	2.01	;	Crystal structure of the type III effector XopAI from Xanthomonas axonopodis pv. citri in space group P43212
3O6X	;	3.5	;	Crystal Structure of the type III Glutamine Synthetase from Bacteroides fragilis
2BSI	;	2.01	;	Crystal structure of the type III secretion chaperone SycT from Yersinia enterocolitica (crystal form 1)
2BSH	;	1.9	;	Crystal structure of the type III secretion chaperone SycT from Yersinia enterocolitica (crystal form 2)
6XFJ	;	1.2	;	Crystal structure of the type III secretion pilotin InvH
6XFK	;	1.85	;	Crystal structure of the type III secretion system pilotin-secretin complex InvH-InvG
1K46	;	2.2	;	Crystal Structure of the Type III Secretory Domain of Yersinia YopH Reveals a Domain-Swapped Dimer
5JW8	;	1.439	;	Crystal structure of the Type IV pilin subunit PilE from Neisseria meningitidis
5CVB	;	2.249	;	Crystal structure of the type IX collagen NC2 hetero-trimerization domain with a guest fragment a1a1a1 of type I collagen
5CVA	;	2.098	;	Crystal structure of the type IX collagen NC2 hetero-trimerization domain with a guest fragment a1a2a1 of type I collagen
5CTD	;	1.5991	;	Crystal structure of the type IX collagen NC2 hetero-trimerization domain with a guest fragment a2a1a1 of type I collagen
5CTI	;	1.8994	;	Crystal structure of the type IX collagen NC2 hetero-trimerization domain with a guest fragment a2a1a1 of type I collagen (native form)
3HA4	;	2.4	;	Crystal structure of the type one membrane protein MIX1 from Leishmania
6IJE	;	1.55	;	Crystal structure of the type VI amidase immunity (Tai4) from Agrobacterium tumefaciens
4HFL	;	2.002	;	Crystal structure of the type VI effector Tae4 from Enterobacter cloacae
6IJF	;	1.9	;	Crystal structure of the type VI effector-immunity complex (Tae4-Tai4) from Agrobacterium tumefaciens
4BI8	;	2.0	;	Crystal structure of the type VI effector-immunity complex Ssp1-Rap1a from Serratia marcescens
4HFK	;	2.1	;	Crystal structure of the type VI effector-immunity complex Tae4-Tai4 from Enterobacter cloacae
4HFF	;	2.398	;	Crystal structure of the type VI effector-immunity complex Tae4-Tai4 from Salmonella Typhimurium
4HZ9	;	2.4	;	Crystal structure of the type VI native effector-immunity complex Tae3-Tai3 from Ralstonia pickettii
4HZB	;	2.6	;	Crystal structure of the type VI SeMet effector-immunity complex Tae3-Tai3 from Ralstonia pickettii
4WVH	;	2.1	;	Crystal structure of the Type-I signal peptidase from Staphylococcus aureus (SpsB) in complex with a substrate peptide (pep1).
4WVI	;	1.9	;	Crystal structure of the Type-I signal peptidase from Staphylococcus aureus (SpsB) in complex with a substrate peptide (pep2).
4WVJ	;	1.95	;	Crystal structure of the Type-I signal peptidase from Staphylococcus aureus (SpsB) in complex with an inhibitor peptide (pep3).
4WVG	;	2.05	;	Crystal structure of the Type-I signal peptidase from Staphylococcus aureus (SpsB).
3GOQ	;	1.6	;	Crystal structure of the Tyr13Met variant of Bacillus subtilis ferrochelatase
2AC2	;	2.5	;	Crystal structure of the Tyr13Phe mutant variant of Bacillus subtilis Ferrochelatase with Zn(2+) bound at the active site
7RNT	;	1.9	;	CRYSTAL STRUCTURE OF THE TYR45TRP MUTANT OF RIBONUCLEASE T1 IN A COMPLEX WITH 2'-ADENYLIC ACID
6RRR	;	2.11	;	Crystal structure of the tyrosinase PvdP from Pseudomonas aeruginosa
3VRN	;	1.64	;	Crystal structure of the tyrosine kinase binding domain of Cbl-c
3VRQ	;	2.39	;	Crystal structure of the tyrosine kinase binding domain of Cbl-c (PL mutant)
3VRR	;	2.0	;	Crystal structure of the tyrosine kinase binding domain of Cbl-c (PL mutant) in complex with phospho-EGFR peptide
3VRP	;	1.52	;	Crystal structure of the tyrosine kinase binding domain of Cbl-c in complex with phospho-EGFR peptide
3VRO	;	1.8	;	Crystal structure of the tyrosine kinase binding domain of Cbl-c in complex with phospho-Src peptide
2FGI	;	2.5	;	CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
5UGX	;	2.349	;	Crystal Structure of the Tyrosine Kinase Domain of FGF Receptor 2 Harboring a E565A/D650V double Gain-of-Function Mutation
5UHN	;	2.909	;	Crystal Structure of the Tyrosine Kinase Domain of FGF Receptor 2 harboring a N549H/E565A Double Gain-of-Function Mutation
5UI0	;	2.05	;	Crystal Structure of the Tyrosine Kinase Domain of FGF Receptor 2 harboring an E565A/K659M Double Gain-of-Function Mutation
4QRC	;	1.901	;	Crystal Structure of the Tyrosine Kinase Domain of FGF Receptor 4 in Complex with Ponatinib
1FGK	;	2.0	;	CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
1AGW	;	2.4	;	CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
1FGI	;	2.5	;	CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
1R1W	;	1.8	;	CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET
3CTH	;	2.3	;	Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-met in complex with a aminopyridine based inhibitor
3CTJ	;	2.5	;	Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-met in complex with a aminopyridine based inhibitor
3L8V	;	2.4	;	Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-MET in complex with a biarylamine based inhibitor
3CE3	;	2.4	;	Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-MET in complex with a Pyrrolopyridinepyridone based inhibitor
3C1X	;	2.17	;	Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-MET in complex with a Pyrrolotriazine based inhibitor
5DG5	;	2.6	;	CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP-4157
3F82	;	2.5	;	Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-MET in complex with N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide
1R0P	;	1.8	;	Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met in complex with the microbial alkaloid K-252a
1IRK	;	2.1	;	CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HUMAN INSULIN RECEPTOR
2WJF	;	2.22	;	Crystal structure of the tyrosine phosphatase Cps4B from Steptococcus pneumoniae TIGR4 in complex with phosphate.
2WJD	;	2.799	;	Crystal structure of the tyrosine phosphatase Cps4B from Steptococcus pneumoniae TIGR4.
2WJE	;	1.899	;	Crystal structure of the tyrosine phosphatase Cps4B from Steptococcus pneumoniae TIGR4.
4H1O	;	2.2	;	Crystal structure of the tyrosine phosphatase SHP-2 with D61G mutation
4NWG	;	2.45	;	Crystal structure of the tyrosine phosphatase SHP-2 with E139D mutation
4NWF	;	2.1	;	Crystal structure of the tyrosine phosphatase SHP-2 with N308D mutation
4H34	;	2.7	;	Crystal structure of the tyrosine phosphatase SHP-2 with Q506P mutation
4GWF	;	2.1	;	Crystal structure of the tyrosine phosphatase SHP-2 with Y279C mutation
2WJA	;	2.5	;	Crystal structure of the tyrosine phosphatase Wzb from Escherichia coli K30 in complex with phosphate.
2WMY	;	2.211	;	Crystal structure of the tyrosine phosphatase Wzb from Escherichia coli K30 in complex with sulphate.
1OFO	;	1.86	;	Crystal Structure of the Tyrosine Regulated 3-Deoxy-D-Arabino-Heptulosonate-7-Phosphate Synthase from Saccharomyces Cerevisiae in Complex with 2-Phosphoglycolate
1OAB	;	1.9	;	CRYSTAL STRUCTURE OF THE TYROSINE REGULATED 3-DEOXY-D-ARABINO-HEPTULOSONATE-7-PHOSPHATE SYNTHASE FROM SACCHAROMYCES CEREVISIAE IN COMPLEX WITH PHOSPHOENOLPYRUVATE AND MANGANESE(II)
1OFP	;	2.1	;	CRYSTAL STRUCTURE OF THE TYROSINE-REGULATED 3-DEOXY-D-ARABINO-HEPTULOSONATE-7-PHOSPHATE SYNTHASE FROM SACCHAROMYCES CEREVISIAE
1OFR	;	2.7	;	CRYSTAL STRUCTURE OF THE TYROSINE-REGULATED 3-DEOXY-D-ARABINO-HEPTULOSONATE-7-PHOSPHATE SYNTHASE FROM SACCHAROMYCES CEREVISIAE COMPLEXED WITH PHENYLALANINE AND MANGANESE
1HFB	;	1.9	;	Crystal structure of the tyrosine-regulated 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase from Saccharomyces cerevisiae complexed with phosphoenolpyruvate
1OF6	;	2.1	;	crystal structure of the tyrosine-regulated 3-deoxy-d-arabino-heptulosonate-7-phosphate synthase from saccharomyces cerevisiae complexed with tyrosine and manganese
1OFB	;	2.01	;	CRYSTAL STRUCTURE OF THE TYROSINE-REGULATED 3-DEOXY-D-ARABINO-HEPTULOSONATE-7-PHOSPHATE SYNTHASE FROM SACCHAROMYCES CEREVISIAE IN COMPLEX WITH MANGANESE(II)
1OFQ	;	2.7	;	CRYSTAL STRUCTURE OF THE TYROSINE-REGULATED 3-DEOXY-D-ARABINO-HEPTULOSONATE-7-PHOSPHATE SYNTHASE FROM SACCHAROMYCES CEREVISIAE IN COMPLEX WITH MANGANESE(II)
1OFA	;	2.02	;	Crystal structure of the tyrosine-regulated 3-deoxy-d-arabino-heptulosonate-7-phosphate synthase from saccharomyces cerevisiae in complex with phosphoenolpyruvate and cobalt(ii)
7FG6	;	2.8	;	Crystal structure of the Tyrosyl-tRNA synthetase (TyrRS) in Nanoarchaeum equitans
3L1Z	;	3.17	;	Crystal structure of the U-BOX domain of human E4B ubiquitin ligase in complex with UBCH5C E2 ubiquitin conjugating enzyme
3LRQ	;	2.292	;	Crystal structure of the U-box domain of human ubiquitin-protein ligase (E3), NORTHEAST STRUCTURAL GENOMICS CONSORTIUM TARGET HR4604D.
4FEL	;	1.6	;	Crystal structure of the U25A/A46G mutant of the xpt-pbuX guanine riboswitch aptamer domain in complex with hypoxanthine
5K1A	;	2.3	;	Crystal structure of the UAF1-USP12 complex in C2 space group
5K1B	;	3.3	;	Crystal structure of the UAF1/USP12 complex in F222 space group
5K1C	;	3.0	;	Crystal structure of the UAF1/WDR20/USP12 complex
2OOA	;	1.56	;	crystal structure of the UBA domain from Cbl-b ubiquitin ligase
2OOB	;	1.9	;	crystal structure of the UBA domain from Cbl-b ubiquitin ligase in complex with ubiquitin
2QHO	;	1.85	;	Crystal structure of the UBA domain from EDD ubiquitin ligase in complex with ubiquitin
2OO9	;	2.1	;	crystal structure of the UBA domain from human c-Cbl ubiquitin ligase
2BWB	;	2.3	;	Crystal structure of the UBA domain of Dsk2 from S. cerevisiae
4UN2	;	1.51	;	Crystal structure of the UBA domain of Dsk2 in complex with Ubiquitin
3B0F	;	1.4	;	Crystal structure of the UBA domain of p62 and its interaction with ubiquitin
3CMM	;	2.7	;	Crystal Structure of the Uba1-Ubiquitin Complex
7R70	;	2.499	;	Crystal Structure of the UbArk2C fusion protein
7R71	;	2.8	;	Crystal Structure of the UbArk2C-UbcH5b~Ub complex
3CEG	;	2.008	;	Crystal structure of the UBC domain of baculoviral IAP repeat-containing protein 6
6CYR	;	2.2	;	Crystal structure of the UBE2A variant Q93E
4LAD	;	2.3	;	Crystal Structure of the Ube2g2:RING-G2BR complex
3FSH	;	2.76	;	Crystal structure of the ubiquitin conjugating enzyme Ube2g2 bound to the G2BR domain of ubiquitin ligase gp78
4PIG	;	1.952	;	Crystal structure of the ubiquitin K11S mutant
3KUZ	;	2.3	;	Crystal structure of the ubiquitin like domain of PLXNC1
3WUP	;	1.6	;	Crystal Structure of the Ubiquitin-Binding Zinc Finger (UBZ) Domain of the Human DNA Polymerase Eta
7KAG	;	3.21	;	Crystal structure of the ubiquitin-like domain 1 (Ubl1) of Nsp3 from SARS-CoV-2
7TI9	;	2.73	;	Crystal structure of the ubiquitin-like domain 1 (Ubl1) of Nsp3 from SARS-CoV-2, form 2
8ID2	;	1.8	;	Crystal structure of the ubiquitin-like domain in the SF3A1 subunit of human U2 snRNP complexed with the stem-loop 4 of U1 snRNA
4EFO	;	1.769	;	Crystal structure of the ubiquitin-like domain of human TBK1
3H6N	;	2.004	;	Crystal Structure of the ubiquitin-like domain of plexin D1
2J7Q	;	1.8	;	Crystal structure of the ubiquitin-specific protease encoded by murine cytomegalovirus tegument protein M48 in complex with a ubquitin-based suicide substrate
4EEW	;	1.3	;	Crystal structure of the Ubl domain of BAG6
2BWF	;	1.15	;	Crystal structure of the UBL domain of Dsk2 from S. cerevisiae
6WAJ	;	1.9	;	Crystal structure of the UBL domain of human NLE1
4A20	;	1.78	;	Crystal structure of the Ubl domain of Mdy2 (Get5) at 1.78A
6JL3	;	1.303	;	Crystal Structure of the UBL domain of Plasmodium Falciparum Dsk2
5TDA	;	0.79	;	Crystal structure of the UBR-box domain from UBR2 in complex with RLWS N-degron
5X3P	;	1.999	;	Crystal structure of the UBX domain of human UBXD7
5X4L	;	2.402	;	Crystal structure of the UBX domain of human UBXD7 in complex with p97 N domain
7MZO	;	1.62	;	Crystal structure of the UcaD lectin-binding domain
7MZQ	;	1.5	;	Crystal structure of the UcaD lectin-binding domain in complex with fucose
7MZS	;	1.72	;	Crystal structure of the UcaD lectin-binding domain in complex with galactose
7MZR	;	1.78	;	Crystal structure of the UcaD lectin-binding domain in complex with glucose
3TB3	;	2.3	;	Crystal structure of the UCH domain of UCH-L5 with 6 residues deleted
7MZP	;	2.2	;	Crystal structure of the UclD lectin-binding domain
6RTG	;	1.9	;	Crystal structure of the UDP-bound glycosyltransferase domain from the YGT toxin
4M2A	;	1.66	;	Crystal structure of the udp-glucose pyrophosphorylase from Leishmania major in the post-reactive state
2O6L	;	1.8	;	Crystal Structure of the UDP-Glucuronic Acid Binding Domain of the Human Drug Metabolizing UDP-Glucuronosyltransferase 2B7
7YF5	;	1.527	;	Crystal Structure of the UDPGA Binding Domain of the Human Phase II Metabolizing Enzyme UDP-Glucuronosyltransferase 2B10
2Z6O	;	1.6	;	Crystal Structure of the Ufc1, Ufm1 conjugating enzyme 1
2Z6P	;	1.8	;	Crystal Structure of the Ufc1, Ufm1 conjugating enzyme 1
2PE8	;	2.0	;	Crystal structure of the UHM domain of human SPF45 (free form)
2PEH	;	2.11	;	Crystal structure of the UHM domain of human SPF45 in complex with SF3b155-ULM5
6SJ5	;	2.26687	;	Crystal structure of the uL14-RsfS complex from Staphylococcus aureus
4UUT	;	2.8	;	Crystal structure of the Ultrabithorax protein
3RUB	;	2.0	;	CRYSTAL STRUCTURE OF THE UNACTIVATED FORM OF RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE(SLASH)OXYGENASE FROM TOBACCO REFINED AT 2.0-ANGSTROMS RESOLUTION
1RLC	;	2.7	;	CRYSTAL STRUCTURE OF THE UNACTIVATED RIBULOSE 1, 5-BISPHOSPHATE CARBOXYLASE(SLASH)OXYGENASE COMPLEXED WITH A TRANSITION STATE ANALOG, 2-CARBOXY-D-ARABINITOL 1,5-BISPHOSPHATE
6O3D	;	1.402	;	Crystal structure of the unbound Fab fragment of the human HIV-1 neutralizing antibody PGZL1.
6O3K	;	1.451	;	Crystal structure of the unbound Fab fragment of the human HIV-1 neutralizing antibody PGZL1.H4K3
3D0X	;	2.95	;	Crystal Structure of the unbound lysine riboswitch
1M08	;	2.1	;	Crystal structure of the unbound nuclease domain of ColE7
6O41	;	2.465	;	Crystal structure of the unbound PGZL1 germline Fab fragment (PGZL1_gVmDmJ)
7OK7	;	3.15	;	Crystal structure of the UNC119B ARL3 complex
2XHE	;	2.8	;	Crystal structure of the Unc18-syntaxin 1 complex from Monosiga brevicollis
1WMG	;	2.1	;	Crystal structure of the UNC5H2 death domain
3C9Q	;	1.5	;	Crystal structure of the uncharacterized human protein C8orf32 with bound peptide
3L6I	;	2.011	;	Crystal structure of the uncharacterized lipoprotein yceb from e. coli at the resolution 2.0a. northeast structural genomics consortium target er542
4JHC	;	1.85	;	Crystal structure of the uncharacterized Maf protein YceF from E. coli
4LU1	;	1.92	;	Crystal structure of the uncharacterized Maf protein YceF from E. coli, mutant D69A
2QYZ	;	2.04	;	Crystal structure of the uncharacterized protein CTC02137 from Clostridium tetani E88
2RG4	;	1.9	;	Crystal structure of the uncharacterized protein Q2CBJ1_9RHOB from Oceanicola granulosus HTCC2516
2QZB	;	2.1	;	Crystal structure of the uncharacterized protein yfeY from Escherichia coli
1D4C	;	2.9	;	CRYSTAL STRUCTURE OF THE UNCOMPLEXED FORM OF THE FLAVOCYTOCHROME C FUMARATE REDUCTASE OF SHEWANELLA PUTREFACIENS STRAIN MR-1
1IK7	;	2.3	;	Crystal Structure of the Uncomplexed Pelle Death Domain
6TLY	;	1.8	;	Crystal structure of the unconventional kinetochore protein Bodo saltans KKT2 central domain
6ZPJ	;	1.9	;	Crystal structure of the unconventional kinetochore protein Leishmania mexicana KKT4 coiled coil domain
6TLX	;	2.87	;	Crystal structure of the unconventional kinetochore protein Perkinsela sp. KKT2a central domain
6ZPK	;	1.57	;	Crystal structure of the unconventional kinetochore protein Trypanosoma brucei KKT4 BRCT domain
7QRO	;	1.8	;	Crystal structure of the unconventional kinetochore protein Trypanosoma brucei KKT4 BRCT domain K543A mutant
6ZPM	;	1.9	;	Crystal structure of the unconventional kinetochore protein Trypanosoma cruzi KKT4 coiled coil domain
5PAL	;	1.54	;	CRYSTAL STRUCTURE OF THE UNIQUE PARVALBUMIN COMPONENT FROM MUSCLE OF THE LEOPARD SHARK (TRIAKIS SEMIFASCIATA). THE FIRST X-RAY STUDY OF AN ALPHA-PARVALBUMIN
2BE7	;	2.85	;	Crystal structure of the unliganded (T-state) aspartate transcarbamoylase of the psychrophilic bacterium Moritella profunda
1ABQ	;	2.8	;	CRYSTAL STRUCTURE OF THE UNLIGANDED ABL TYROSINE KINASE SH3 DOMAIN
6CUH	;	2.01	;	Crystal structure of the unliganded BC8B TCR
6PPA	;	1.77	;	Crystal structure of the unliganded bromodomain of human BRD7
6UZF	;	1.75	;	Crystal structure of the unliganded bromodomain of human BRD9
6OVN	;	1.77	;	Crystal structure of the unliganded Clone 2 TCR
5TRP	;	2.692	;	Crystal Structure of the Unliganded DH270 Cooperating Lineage Member DH272
3I2T	;	2.7	;	Crystal structure of the unliganded Drosophila Epidermal Growth Factor Receptor ectodomain
2AYE	;	2.3	;	Crystal structure of the unliganded E2 DNA Binding Domain from HPV6a
3V5R	;	2.099	;	Crystal structure of the unliganded form of Gal3p
1YT2	;	3.25	;	Crystal Structure of the Unliganded Form of GRP94, the ER Hsp90: Basis for Nucleotide-Induced Conformational Change, GRP94N APO CRYSTAL
1YT1	;	2.2	;	Crystal Structure of the Unliganded Form of GRP94, the ER Hsp90: Basis for Nucleotide-Induced Conformational Change, GRP94N(DELTA)41 APO CRYSTAL
1YT0	;	2.4	;	Crystal Structure of the Unliganded Form of GRP94, the ER Hsp90: Basis for Nucleotide-Induced Conformational Change, GRP94N(DELTA)41 APO CRYSTAL SOAKED WITH ADP
1YSZ	;	2.65	;	Crystal Structure of the Unliganded Form of GRP94, the ER Hsp90: Basis for Nucleotide-Induced Conformational Change, GRP94N(DELTA)41 APO CRYSTAL SOAKED WITH NECA
5JON	;	2.042	;	Crystal structure of the unliganded form of HCN2 CNBD
1MQK	;	1.28	;	Crystal structure of the unliganded Fv-fragment of the anti-cytochrome C oxidase antibody 7E2
5DW7	;	3.202	;	Crystal structure of the unliganded geosmin synthase N-terminal domain from Streptomyces coelicolor
3UP1	;	2.15	;	Crystal structure of the unliganded human interleukin-7 receptor extracellular domain
3ECM	;	1.9	;	Crystal structure of the unliganded PDE8A catalytic domain
6OVO	;	2.49	;	Crystal structure of the unliganded PG10 TCR
5WJO	;	2.5	;	Crystal structure of the unliganded PG90 TCR
3POM	;	2.5	;	Crystal Structure of the Unliganded Retinoblastoma Protein Pocket Domain
7K3O	;	1.7	;	Crystal structure of the unliganded second bromodomain (BD2) of human TAF1
7JJH	;	2.1	;	Crystal structure of the unliganded tandem bromodomain (BD1, BD2) of human TAF1
1PG5	;	2.6	;	CRYSTAL STRUCTURE OF THE UNLIGATED (T-STATE) ASPARTATE TRANSCARBAMOYLASE FROM THE EXTREMELY THERMOPHILIC ARCHAEON SULFOLOBUS ACIDOCALDARIUS
6Y1K	;	1.65	;	Crystal structure of the unmodified A.17 antibody FAB fragment - L47R mutant
8GC1	;	3.19	;	Crystal structure of the unmutated common ancestor (UCA) of the PC39-1 anti-HIV broadly neutralizing antibody lineage
1SNU	;	2.5	;	CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
6EGD	;	2.1	;	Crystal structure of the unphosphorylated IRAK4 kinase domain Bound to a type I inhibitor
6EGE	;	1.401	;	Crystal structure of the unphosphorylated IRAK4 kinase domain Bound to a type I inhibitor
1U46	;	2.0	;	Crystal Structure of the Unphosphorylated Kinase Domain of the Tyrosine Kinase ACK1
4LE2	;	2.54	;	Crystal structure of the unphosphorylated receiver domain of DesR in the active state
3B5G	;	1.9	;	Crystal Structure of the Unstable and Highly Fibrillogenic PRO7SER Mutant of the Recombinant Variable Domain 6AJL2
3BDX	;	2.3	;	Crystal structure of the unstable and highly fibrillogenic Pro7Ser mutant of the Recombinant variable domain 6AJL2
3BCM	;	2.25	;	Crystal Structure of The Unswapped Form of P19A/L28Q/N67D BS-RNase
6GS3	;	1.45	;	Crystal Structure of the Uperin-3.5 peptide from Uperoleia mjobergii forming cross-alpha fibril
2OTA	;	2.2	;	Crystal structure of the UPF0352 protein CPS_2611 from Colwellia psychrerythraea. NESG target CsR4.
2QTI	;	2.3	;	Crystal structure of the UPF0352 protein SO_2176 from Shewanella oneidensis. NESG target SoR77.
2IYK	;	2.95	;	Crystal structure of the UPF2-interacting domain of nonsense mediated mRNA decay factor UPF1
4FZP	;	1.29	;	Crystal Structure of the uranyl binding protein complexed with uranyl
3UX4	;	3.26	;	Crystal structure of the urea channel from the human gastric pathogen Helicobacter pylori
3K3F	;	2.3	;	Crystal Structure of the Urea Transporter from Desulfovibrio Vulgaris
3K3G	;	2.4	;	Crystal Structure of the Urea Transporter from Desulfovibrio Vulgaris Bound to 1,3-dimethylurea
6JC4	;	2.3	;	Crystal structure of the urease accessory protein UreF from Klebsiella pneumoniae
4BQH	;	1.75	;	Crystal structure of the uridine diphosphate N-acetylglucosamine pyrophosphorylase from Trypanosoma brucei in complex with inhibitor
1Y1T	;	1.77	;	Crystal Structure of the Uridine Phosphorylase from Salmonella Typhimurium at 1.77A Resolution
1SJ9	;	2.5	;	Crystal structure of the uridine phosphorylase from Salmonella typhimurium at 2.5A resolution
1ZL2	;	1.85	;	Crystal structure of the uridine phosphorylase from Salmonella typhimurium in complex with 2,2'-anhydrouridine and phosphate ion at 1.85A resolution
2OEC	;	2.194	;	Crystal structure of the uridine phosphorylase from Salmonella typhimurium in complex with 2,2'-anhydrouridine and potassium ion at 2.194A resolution
1Y1R	;	2.11	;	Crystal Structure of the Uridine Phosphorylase from Salmonella Typhimurium in Complex with Inhibitor and Phosphate Ion at 2.11A Resolution
2HRD	;	1.7	;	Crystal structure of the uridine phosphorylase from Salmonella typhimurium in complex with thymine and phosphate ion at 1.70A resolution
2HN9	;	2.12	;	Crystal structure of the uridine phosphorylase from Salmonella typhimurium in complex with thymine and phosphate ion at 2.12A resolution
2RJ3	;	2.51	;	Crystal Structure of the Uridine Phosphorylase from Salmonella Typhimurium in Complex with Uracil and Phosphate Ion at 2.49A Resolution
1Y1S	;	2.55	;	Crystal Structure of the Uridine Phosphorylase from Salmonella Typhimurium in Complex with Uracil and Sulfate Ion at 2.55A Resolution
2HWU	;	2.91	;	Crystal structure of the uridine phosphorylase from Salmonella typhimurium in complex with uridine and phosphate ion at 2.91A resolution
1Y1Q	;	2.35	;	Crystal Structure of the Uridine Phosphorylase from Salmonella Typhimurium in Complex with Uridine-5p-monophosphate and Sulfate Ion at 2.35A Resolution
2HSW	;	1.99	;	Crystal structure of the uridine phosphorylase from Salmonella typhimurium in unliganded state at 1.99A resolution
4FU7	;	2.0	;	Crystal Structure of the Urokinase
4FU8	;	2.2	;	Crystal Structure of the Urokinase
4FU9	;	1.6	;	Crystal Structure of the Urokinase
4FUB	;	1.9	;	Crystal Structure of the Urokinase
4FUC	;	1.72	;	Crystal Structure of the Urokinase
4FUD	;	2.0	;	Crystal Structure of the Urokinase
4FUE	;	2.0	;	Crystal Structure of the Urokinase
4FUF	;	2.0	;	Crystal Structure of the Urokinase
4FUG	;	1.8	;	Crystal Structure of the Urokinase
4FUH	;	1.6	;	Crystal Structure of the Urokinase
4FUI	;	2.0	;	Crystal Structure of the Urokinase
4FUJ	;	2.05	;	Crystal Structure of the Urokinase
3PV1	;	2.6	;	Crystal structure of the USP15 DUSP-UBL domains
4A3O	;	2.2	;	Crystal structure of the USP15 DUSP-UBL monomer
4M5W	;	2.244	;	Crystal structure of the USP7/HAUSP catalytic domain
4M5X	;	2.187	;	Crystal structure of the USP7/HAUSP catalytic domain
3MQS	;	2.4	;	Crystal Structure of the USP7:Hdm2(PSTS) complex
3MQR	;	1.8	;	Crystal Structure of the USP7:HdmX(AHSS) complex
2FZP	;	1.87	;	Crystal structure of the USP8 interaction domain of human NRDP1
8A4O	;	1.35	;	Crystal structure of the Ustilago hordei effector protein Uvi2
4EZC	;	2.36	;	Crystal Structure of the UT-B Urea Transporter from Bos Taurus
4EZD	;	2.5	;	Crystal Structure of the UT-B Urea Transporter from Bos Taurus Bound to Selenourea
4NSX	;	2.1	;	Crystal Structure of the Utp21 tandem WD Domain
4M5D	;	1.97	;	Crystal structure of the Utp22 and Rrp7 complex from Saccharomyces cerevisiae
1RIF	;	2.0	;	Crystal structure of the UvsW helicase from Bacteriophage T4
1JMM	;	2.4	;	Crystal structure of the V-region of Streptococcus mutans antigen I/II
7NES	;	1.35	;	Crystal structure of the v-Src SH3 domain N117D-V124L mutant
7NER	;	1.55	;	Crystal structure of the v-Src SH3 domain Q128R mutant
7PVT	;	1.6	;	Crystal structure of the v-Src SH3 domain Q128R mutant in complex with the synthetic peptide VSL12
7NET	;	1.5	;	Crystal structure of the v-Src SH3 domain W95R-I96T mutant
2I4R	;	2.8	;	Crystal structure of the V-type ATP synthase subunit F from Archaeoglobus fulgidus. NESG target GR52A.
2QAI	;	2.4	;	Crystal structure of the V-type ATP synthase subunit F from Pyrococcus furiosus. NESG target PfR7.
6MLT	;	1.9	;	Crystal structure of the V. cholerae biofilm matrix protein Bap1
3BY9	;	1.7	;	Crystal structure of the V. cholerae Histidine Kinase DctB Sensor Domain
3I9Y	;	2.16	;	Crystal structure of the V. parahaemolyticus histidine kinase sensor TorS sensor domain
5UM3	;	1.198	;	Crystal structure of the V122L mutant of human UBR-box domain from UBR2
3PAG	;	2.25	;	Crystal structure of the V130D mutant of OXA-24/40 in complex with doripenem
1EOE	;	1.704	;	CRYSTAL STRUCTURE OF THE V135R MUTANT OF A SHAKER T1 DOMAIN
3U7C	;	0.93	;	crystal structure of the V143I mutant of human carbonic anhydrase II
5FS6	;	1.9	;	Crystal structure of the V243L mutant of human apoptosis inducing factor
5KQH	;	1.82	;	Crystal structure of the V293D variant of catalase-peroxidase from B. pseudomallei
5NGD	;	1.9	;	Crystal structure of the V325G mutant of the bacteriophage G20C portal protein
2QST	;	2.9	;	Crystal structure of the V39C mutant of the N-terminal domain of carcinoembryonic antigen (CEA)
6F97	;	1.9	;	Crystal structure of the V465T mutant of 5-(Hydroxymethyl)furfural Oxidase (HMFO)
3ZFL	;	1.88	;	Crystal structure of the V58A mutant of human class alpha glutathione transferase in the apo form
4L01	;	1.9	;	Crystal structure of the V658F apo Jak1 pseudokinase domain
5N30	;	1.8	;	Crystal structure of the V72I mutant of the mouse alpha-Dystroglycan N-terminal region
4O4X	;	2.9	;	Crystal structure of the vaccine antigen Transferrin Binding Protein B (TbpB) double mutant Tyr-167-Ala and Trp-176-Ala from Haemophilus parasuis Hp5
4O3Y	;	2.6	;	Crystal structure of the vaccine antigen Transferrin Binding Protein B (TbpB) mutant Arg-179-Glu from Actinobacillus pleuropneumoniae H87
4O3X	;	2.5	;	Crystal structure of the vaccine antigen Transferrin Binding Protein B (TbpB) mutant Phe-171-Ala from Actinobacillus pleuropneumoniae H49
4O4U	;	2.64	;	Crystal structure of the vaccine antigen Transferrin Binding Protein B (TbpB) mutant Trp-176-Ala from Haemophilus parasuis Hp5
4O49	;	2.5	;	Crystal structure of the vaccine antigen Transferrin Binding Protein B (TbpB) mutant Tyr-174-Ala from Actinobacillus pleuropneumoniae H87
4O3W	;	2.1	;	Crystal structure of the vaccine antigen Transferrin Binding Protein B (TbpB) mutant Tyr-63-Ala from Actinobacillus suis H57
4O3Z	;	2.9	;	Crystal structure of the vaccine antigen Transferrin Binding Protein B (TbpB) mutant Tyr-95-Ala from Actinobacillus pleuropneumoniae H87
3TIE	;	2.25	;	Crystal structure of the vaccinia derived peptide A11R in complex with the murine MHC CLASS I H-2 KB
2GAF	;	2.4	;	Crystal Structure of the Vaccinia Polyadenylate Polymerase Heterodimer (apo form)
4OD8	;	1.85	;	Crystal structure of the vaccinia virus DNA polymerase holoenzyme subunit D4 in complex with the A20 N-terminus
4ODA	;	2.2	;	Crystal structure of the vaccinia virus DNA polymerase holoenzyme subunit D4 in complex with the A20 N-terminus
2RF6	;	1.95	;	Crystal Structure of the Vaccinia Virus Dual-Specificity Phosphatase VH1
1AXG	;	2.5	;	CRYSTAL STRUCTURE OF THE VAL203->ALA MUTANT OF LIVER ALCOHOL DEHYDROGENASE COMPLEXED WITH COFACTOR NAD AND INHIBITOR TRIFLUOROETHANOL SOLVED TO 2.5 ANGSTROM RESOLUTION
5Z7B	;	2.1	;	Crystal structure of the VanR transcription factor in complex with vanillate
1ZV5	;	2.0	;	Crystal structure of the variable domain of the camelid heavy-chain antibody D2-L29 in complex with hen egg white lysozyme
2WD6	;	2.3	;	Crystal structure of the Variable Domain of the Streptococcus gordonii Surface Protein SspB
7F9N	;	3.0	;	Crystal structure of the variable region of Plasmodium RIFIN #4 (PF3D7_1000500) in complex with LAIR1
7F9M	;	2.9	;	Crystal structure of the variable region of Plasmodium RIFIN #4 (PF3D7_1000500) in complex with LAIR1 (with T67L, N69S and A77T mutations)
7F9L	;	2.7	;	Crystal structure of the variable region of Plasmodium RIFIN #6 (PF3D7_1400600) in complex with LAIR1 (with T67L, N69S and A77T mutations)
7F9K	;	2.18	;	Crystal structure of the variable region of Plasmodium RIFIN #6(PF3D7_1400600)
6NVQ	;	2.1	;	Crystal structure of the VASH1-SVBP complex
7WFY	;	2.449	;	Crystal Structure of the VAV2 SH2 domain in complex with APP phosphorylated peptide
4ROJ	;	1.95	;	Crystal Structure of the VAV2 SH2 domain in complex with TXNIP phosphorylated peptide
8P0F	;	1.98	;	Crystal structure of the VCB complex with compound 1.
1S0Z	;	2.5	;	Crystal structure of the VDR LBD complexed to seocalcitol.
1TXI	;	1.9	;	Crystal structure of the vdr ligand binding domain complexed to TX522
2RL5	;	2.65	;	Crystal structure of the VEGFR2 kinase domain in complex with a 2,3-dihydro-1,4-benzoxazine inhibitor
3VHK	;	2.49	;	Crystal structure of the VEGFR2 kinase domain in complex with a back pocket binder
3BE2	;	1.75	;	Crystal structure of the VEGFR2 kinase domain in complex with a benzamide inhibitor
2QU5	;	2.95	;	Crystal structure of the VEGFR2 kinase domain in complex with a benzimidazole inhibitor
3DTW	;	2.9	;	Crystal structure of the VEGFR2 kinase domain in complex with a benzisoxazole inhibitor
2QU6	;	2.1	;	Crystal structure of the VEGFR2 kinase domain in complex with a benzoxazole inhibitor
3CPB	;	2.7	;	Crystal structure of the VEGFR2 kinase domain in complex with a bisamide inhibitor
3B8Q	;	2.75	;	Crystal structure of the VEGFR2 kinase domain in complex with a naphthamide inhibitor
3B8R	;	2.7	;	Crystal structure of the VEGFR2 kinase domain in complex with a naphthamide inhibitor
2P2I	;	2.4	;	Crystal structure of the VEGFR2 kinase domain in complex with a nicotinamide inhibitor
3U6J	;	2.15	;	Crystal structure of the VEGFR2 kinase domain in complex with a pyrazolone inhibitor
2P2H	;	1.95	;	Crystal structure of the VEGFR2 kinase domain in complex with a pyridinyl-triazine inhibitor
3CP9	;	2.5	;	Crystal structure of the VEGFR2 kinase domain in complex with a pyridone inhibitor
3CPC	;	2.4	;	Crystal structure of the VEGFR2 kinase domain in complex with a pyridone inhibitor
3EWH	;	1.6	;	Crystal structure of the VEGFR2 kinase domain in complex with a pyridyl-pyrimidine benzimidazole inhibitor
4AG8	;	1.95	;	CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH AXITINIB (AG-013736) (N-Methyl-2-(3-((E)-2-pyridin-2-yl-vinyl)-1H- indazol-6-ylsulfanyl)-benzamide)
3EFL	;	2.2	;	Crystal structure of the VEGFR2 kinase domain in complex with motesanib
2XIR	;	1.5	;	Crystal structure of the VEGFR2 kinase domain in complex with PF- 00337210 (N,2-dimethyl-6-(7-(2-morpholinoethoxy)quinolin-4-yloxy) benzofuran-3-carboxamide)
7O6V	;	2.5	;	Crystal structure of the VEL1 VEL polymerising domain (R643A K645D I664D mutant)
6M1U	;	2.791	;	Crystal structure of the vertebrate conserved region (VCR) of human METTL16
3PMK	;	3.03	;	Crystal structure of the Vesicular Stomatitis Virus RNA free nucleoprotein/phosphoprotein complex
1QQE	;	2.9	;	CRYSTAL STRUCTURE OF THE VESICULAR TRANSPORT PROTEIN SEC17
4LN0	;	2.896	;	Crystal structure of the VGLL4-TEAD4 complex
1ZVY	;	1.63	;	Crystal structure of the VHH D3-L11 in complex with hen egg white lysozyme
1ZVH	;	1.5	;	Crystal structure of the VHH domain D2-L24 in complex with hen egg white lysozyme
6RBB	;	2.45	;	CRYSTAL STRUCTURE OF the VhH-domain of anti-IL-17A antibody netakimab
1DVP	;	2.0	;	CRYSTAL STRUCTURE OF THE VHS AND FYVE TANDEM DOMAINS OF HRS, A PROTEIN INVOLVED IN MEMBRANE TRAFFICKING AND SIGNAL TRANSDUCTION
6IDE	;	2.51	;	Crystal structure of the Vibrio cholera VqmA-Ligand-DNA complex provides molecular mechanisms for drug design
4KSR	;	4.2	;	Crystal Structure of the Vibrio cholerae ATPase GspE Hexamer
3O44	;	2.88	;	Crystal Structure of the Vibrio cholerae Cytolysin (HlyA) Heptameric Pore
1XEZ	;	2.3	;	Crystal Structure Of The Vibrio Cholerae Cytolysin (HlyA) Pro-Toxin With Octylglucoside Bound
2W57	;	2.6	;	Crystal structure of the Vibrio cholerae ferric uptake regulator (Fur) reveals structural rearrangement of the DNA-binding domains
3C30	;	2.8	;	Crystal structure of the Vibrio Cholerae LuxQ periplasmic domain (SeMet)
7QXM	;	3.8	;	Crystal structure of the Vibrio cholerae replicative helicase (DnaB)
6T66	;	3.9	;	Crystal structure of the Vibrio cholerae replicative helicase (DnaB) with GDP-AlF4
8A3V	;	2.9	;	Crystal structure of the Vibrio cholerae replicative helicase (VcDnaB) in complex with its loader protein (VcDciA)
3OC5	;	2.4	;	Crystal Structure of the vibrio cholerae secreted colonization factor TcpF
4OWJ	;	2.0	;	Crystal Structure of the Vibrio vulnificus Hemolysin/Cytolysin Beta-Trefoil Lectin
4OWK	;	2.0	;	Crystal Structure of the Vibrio vulnificus Hemolysin/Cytolysin Beta-Trefoil Lectin with N-Acetyl-D-Galactosamine Bound
4OWL	;	2.1	;	Crystal Structure of the Vibrio vulnificus Hemolysin/Cytolysin Beta-Trefoil Lectin with N-Acetyl-D-Lactosamine Bound
5CAD	;	1.49	;	Crystal structure of the vicilin from Solanum melongena revealed existence of different anionic ligands in structurally similar pockets
5VF5	;	1.49	;	Crystal structure of the vicilin from Solanum melongena, re-refinement
3WUS	;	2.54	;	Crystal Structure of the Vif-Binding Domain of Human APOBEC3F
4N9F	;	3.3	;	Crystal structure of the Vif-CBFbeta-CUL5-ElOB-ElOC pentameric complex
7OVE	;	1.92	;	Crystal structure of the VIM-2 acquired metallo-beta-Lactamase in Complex with compound 10 (JMV-7210)
7OVH	;	1.8	;	Crystal structure of the VIM-2 acquired metallo-beta-Lactamase in Complex with compound 14 (JMV-6931)
7PP0	;	1.73	;	Crystal structure of the VIM-2 acquired metallo-beta-Lactamase in complex with compound 28 (JMV-7038)
8A4M	;	1.98	;	Crystal structure of the VIM-2 acquired metallo-beta-Lactamase in complex with compound 8 (JMV-7061)
7OVF	;	1.9	;	Crystal structure of the VIM-2 acquired metallo-beta-Lactamase in Complex with compound 8 (JMV-7207)
6YRP	;	1.95	;	Crystal Structure of the VIM-2 Acquired Metallo-beta-Lactamase in Complex with JMV-4690 (Cpd 31)
6SP7	;	1.8	;	Crystal Structure of the VIM-2 Acquired Metallo-beta-Lactamase in Complex with Taniborbactam (VNRX-5133)
6ZGM	;	1.65	;	Crystal Structure of the VIM-2 Acquired Metallo-beta-Lactamase in Complex with the thiazolecarboxylate inhibitor ANT2681
7O6U	;	1.84	;	Crystal structure of the VIN3 VEL polymerising domain (R554A R556D mutant)
1QKR	;	1.8	;	Crystal structure of the vinculin tail and a pathway for activation
8R2C	;	1.8	;	Crystal structure of the Vint domain from Tetrahymena thermophila
6DX2	;	1.614	;	Crystal structure of the viral OTU domain protease from Dera Ghazi Khan virus
6DX5	;	2.224	;	Crystal structure of the viral OTU domain protease from Farallon virus
6DX1	;	1.652	;	Crystal structure of the viral OTU domain protease from Qalyub virus
6DX3	;	2.052	;	Crystal structure of the viral OTU domain protease from Taggert virus
7AKX	;	1.6	;	Crystal structure of the viral rhodopsin OLPVR1 in P1 space group
7AKY	;	1.4	;	Crystal structure of the viral rhodopsin OLPVR1 in P21212 space group
7AKW	;	1.96	;	Crystal structure of the viral rhodopsins chimera O1O2
1SFU	;	2.0	;	Crystal structure of the viral Zalpha domain bound to left-handed Z-DNA
4GVB	;	1.8	;	Crystal structure of the virally encoded antifungal protein, KP6, heterodimer
2GZA	;	2.6	;	Crystal structure of the VirB11 ATPase from the Brucella Suis type IV secretion system in complex with sulphate
3F6N	;	3.1	;	Crystal structure of the virion-associated protein P3 from Caulimovirus
3K4T	;	2.59	;	Crystal structure of the virion-associated protein P3 from caulimovirus
1XKP	;	1.7	;	Crystal structure of the virulence factor YopN in complex with its heterodimeric chaperone SycN-YscB
5I55	;	1.45	;	Crystal Structure of the Virulent PSM-alpha3 Peptide Forming a Cross-alpha amyloid-like Fibril
4FSJ	;	3.5	;	Crystal structure of the virus like particle of Flock House virus
4YVS	;	3.65	;	crystal structure of the virus-like particle of a c4 strain EV71
2DJ5	;	2.55	;	Crystal Structure of the vitamin B12 biosynthetic cobaltochelatase, CbiXS, from Archaeoglobus fulgidus
4QTN	;	2.8	;	Crystal structure of the Vitamin B3 transporter PnuC
6O5E	;	1.9	;	Crystal structure of the Vitronectin hemopexin-like domain
7RJ9	;	1.7	;	Crystal structure of the Vitronectin hemopexin-like domain binding Calcium
7TXR	;	2.0	;	Crystal structure of the Vitronectin hemopexin-like domain binding Calcium-2
7U68	;	2.0	;	Crystal structure of the Vitronectin hemopexin-like domain binding Sodium-2
1JVA	;	2.1	;	CRYSTAL STRUCTURE OF THE VMA1-DERIVED ENDONUCLEASE BEARING THE N AND C EXTEIN PROPEPTIDES
1UM2	;	2.9	;	Crystal Structure of the Vma1-Derived Endonuclease with the Ligated Extein Segment
4BUM	;	2.801	;	Crystal structure of the Voltage Dependant Anion Channel 2 from zebrafish.
4DEY	;	1.95	;	Crystal structure of the Voltage Dependent Calcium Channel beta-2 Subunit in Complex With The CaV1.2 I-II Linker.
4DEX	;	2.0	;	Crystal structure of the Voltage Dependent Calcium Channel beta-2 Subunit in Complex With The CaV2.2 I-II Linker.
5FEB	;	1.35	;	Crystal structure of the Voltage-gated Sodium Channel Beta 2 subunit extracellular domain
5FDY	;	1.85	;	Crystal structure of the Voltage-gated Sodium Channel Beta 2 subunit extracellular domain, C72A/C75A mutant
4MZ2	;	1.722	;	Crystal structure of the voltage-gated sodium channel beta 4 subunit extracellular domain
4MZ3	;	1.741	;	Crystal structure of the voltage-gated sodium channel beta 4 subunit extracellular domain, C131W mutant
6SX7	;	2.5	;	Crystal Structure of the Voltage-Gated Sodium Channel NavMs (F208L) (2.2 Angstrom resolution)
6SXC	;	2.5	;	Crystal structure of the Voltage-Gated Sodium Channel NavMs (F208L) in complex with 4-hydroxytamoxifen (2.5 Angstrom resolution)
6SXE	;	2.6	;	Crystal Structure of the Voltage-Gated Sodium Channel NavMs (F208L) in complex with Endoxifen (2.6 Angstrom resolution)
6Z8C	;	3.2	;	Crystal Structure of the Voltage-Gated Sodium Channel NavMs (F208L) in complex with N-desmethyltamoxifen (3.2 A resolution)
6SXF	;	2.839	;	Crystal Structure of the Voltage-Gated Sodium Channel NavMs (F208L) in complex with Tamoxifen (2.8 Angstrom resolution)
6SXG	;	2.4	;	Crystal Structure of the Voltage-Gated Sodium Channel NavMs in complex with 4-hydroxytamoxifen (2.4 Angstrom resolution)
1FNS	;	2.0	;	CRYSTAL STRUCTURE OF THE VON WILLEBRAND FACTOR (VWF) A1 DOMAIN I546V MUTANT IN COMPLEX WITH THE FUNCTION BLOCKING FAB NMC4
1OAK	;	2.2	;	CRYSTAL STRUCTURE OF THE VON WILLEBRAND FACTOR (VWF) A1 DOMAIN IN COMPLEX WITH THE FUNCTION BLOCKING NMC-4 FAB
1SHT	;	1.81	;	Crystal Structure of the von Willebrand factor A domain of human capillary morphogenesis protein 2: an anthrax toxin receptor
1SHU	;	1.5	;	Crystal Structure of the von Willebrand factor A domain of human capillary morphogenesis protein 2: an anthrax toxin receptor
4DMU	;	2.8	;	Crystal structure of the von Willebrand factor A3 domain in complex with a collagen III derived triple-helical peptide
1FE8	;	2.03	;	CRYSTAL STRUCTURE OF THE VON WILLEBRAND FACTOR A3 DOMAIN IN COMPLEX WITH A FAB FRAGMENT OF IGG RU5 THAT INHIBITS COLLAGEN BINDING
1M0Z	;	1.85	;	Crystal Structure of the von Willebrand Factor Binding Domain of Glycoprotein Ib alpha
3NLC	;	2.15	;	Crystal structure of the VP0956 protein from Vibrio parahaemolyticus. Northeast Structural Genomics Consortium Target VpR147
3U07	;	2.083	;	Crystal Structure of the VPA0106 protein from Vibrio parahaemolyticus. Northeast Structural Genomics Consortium Target VpR106.
4N7E	;	2.7	;	Crystal structure of the Vps10p domain of human sortilin/NTS3 in complex with AF38469
4MSL	;	2.7	;	Crystal structure of the Vps10p domain of human sortilin/NTS3 in complex with AF40431
3F6K	;	2.0	;	Crystal structure of the Vps10p domain of human sortilin/NTS3 in complex with neurotensin
5MRH	;	2.5	;	Crystal structure of the Vps10p domain of human sortilin/NTS3 in complex with Triazolone 1
5MRI	;	2.0	;	Crystal structure of the Vps10p domain of human sortilin/NTS3 in complex with Triazolone 18
1O06	;	1.45	;	Crystal structure of the Vps27p Ubiquitin Interacting Motif (UIM)
4KMO	;	2.6	;	Crystal Structure of the Vps33-Vps16 HOPS subcomplex from Chaetomium thermophilum
2RKO	;	3.35	;	Crystal Structure of the Vps4p-dimer
3DM7	;	2.0	;	Crystal Structure of the Vps75 Histone Chaperone
1TXU	;	2.35	;	Crystal Structure of the Vps9 Domain of Rabex-5
4R4V	;	3.07	;	Crystal structure of the VS ribozyme - G638A mutant
5V3I	;	3.293	;	Crystal structure of the VS ribozyme - wild-type C634
4R4P	;	3.07	;	Crystal Structure of the VS ribozyme-A756G mutant
2Z66	;	1.9	;	Crystal structure of the VT3 hybrid of human TLR4 and hagfish VLRB.61
6TNJ	;	1.85	;	Crystal structure of the vWF domain of the type V pili tip protein Mfa5 from Porphyromonas gingivalis
6S4C	;	2.0	;	Crystal Structure of the vWFA2 subdomain of type VII collagen
5KT8	;	2.0	;	Crystal structure of the W139F variant of the catalase-peroxidase from B. pseudomallei treated with isoniazid
3VLG	;	2.3	;	Crystal structure of the W150A mutant LOX-1 CTLD showing impaired OxLDL binding
5KQQ	;	1.87	;	Crystal structure of the W153F variant of catalase-peroxidase from B. pseudomallei treated
5KSG	;	1.62	;	Crystal structure of the W153F variant of catalase-peroxidase from B. pseudomallei treated with isoniazid
3SR3	;	1.495	;	Crystal structure of the w180a mutant of microcin immunity protein mccf from Bacillus anthracis shows the active site loop in the open conformation.
6D7M	;	2.187	;	Crystal structure of the W184R/W231R Importin alpha mutant
3RN1	;	1.93	;	Crystal Structure of the W199E-MauG/pre-Methylamine Dehydrogenase Complex
3RMZ	;	1.72	;	Crystal Structure of the W199F-MauG/pre-Methylamine Dehydrogenase Complex
3RN0	;	1.91	;	Crystal Structure of the W199K-MauG/pre-Methylamine Dehydrogenase Complex
6CC6	;	1.8	;	Crystal structure of the W202F variant of catalase-peroxidase from B. pseudomallei
6CDQ	;	1.92	;	Crystal structure of the W202F variant of catalase-peroxidase from B. pseudomallei with INH bound.
3EE0	;	2.75	;	Crystal Structure of the W215A/E217A Mutant of Human Thrombin (space group P2(1)2(1)2(1))
3EDX	;	2.4	;	Crystal structure of the W215A/E217A mutant of murine thrombin
3MMD	;	1.7	;	Crystal structure of the W241A mutant of xylanase from Geobacillus stearothermophilus T-6 (XT6) complexed with hydrolyzed xylopentaose
4DNU	;	1.764	;	Crystal structure of the W285A mutant of UVB-resistance protein UVR8
8GQE	;	2.0	;	Crystal structure of the W285A mutant of UVR8 in complex with RUP2
4DNV	;	1.999	;	Crystal structure of the W285F mutant of UVB-resistance protein UVR8
6D7N	;	2.3	;	Crystal structure of the W357R/W399R Importin alpha mutant
3RG3	;	1.903	;	Crystal structure of the W5E mutant of human carbonic anhydrase II
3RG4	;	1.5	;	Crystal structure of the W5F mutant of human carbonic anhydrase II
3RGE	;	2.096	;	Crystal structure of the W5H mutant of human carbonic anhydrase II
6SNU	;	2.0	;	Crystal structure of the W60C mutant of the (S)-selective transaminase from Chromobacterium violaceum
1YU7	;	1.5	;	Crystal Structure of the W64Y mutant of Villin Headpiece
6CAW	;	1.95	;	Crystal structure of the W95F variant of catalase-peroxidase from B. pseudomallei
5BPG	;	2.14	;	Crystal structure of the water-soluble FraC purified starting from the trans-membrane pore
1GWY	;	1.71	;	Crystal structure of the water-soluble state of the pore-forming cytolysin Sticholysin II
1O71	;	2.26	;	Crystal structure of the water-soluble state of the pore-forming cytolysin Sticholysin II complexed with glycerol
1O72	;	2.41	;	Crystal structure of the water-soluble state of the pore-forming cytolysin Sticholysin II complexed with phosphorylcholine
5VYR	;	1.7	;	Crystal structure of the WbkC formyl transferase from Brucella melitensis
5VYS	;	2.2	;	Crystal structure of the WbkC N-formyltransferase (C47S variant) from Brucella melitensis
5VYT	;	2.2	;	Crystal structure of the WbkC N-formyltransferase (F142A variant) from Brucella melitensis
5VYU	;	2.2	;	Crystal structure of the WbkC N-formyltransferase from Brucella melitensis in complex with GDP-perosaminea and N-10-formyltetrahydrofolate
3OW8	;	2.3	;	Crystal Structure of the WD repeat-containing protein 61
7KLJ	;	1.52	;	Crystal structure of the WD-repeat domain of human KIF21A
7SUL	;	2.4	;	Crystal structure of the WD-repeat domain of human SEC31A
8SHJ	;	2.21	;	Crystal structure of the WD-repeat domain of human WDR91 in complex with MR45279
4YHC	;	2.05	;	Crystal structure of the WD40 domain of SCAP from fission yeast
5TF2	;	2.8	;	CRYSTAL STRUCTURE OF THE WD40 DOMAIN OF THE HUMAN PROLACTIN REGULATORY ELEMENT-BINDING PROTEIN
6CVZ	;	1.8	;	Crystal structure of the WD40-repeat of RFWD3
7SSE	;	1.62	;	Crystal structure of the WDR domain of human DCAF1 in complex with CYCA-117-70
7UFV	;	1.9	;	Crystal structure of the WDR domain of human DCAF1 in complex with OICR-6766
8F8E	;	1.55	;	Crystal structure of the WDR domain of human DCAF1 in complex with OICR-8268 compound
2I69	;	3.11	;	Crystal structure of the West Nile virus envelope glycoprotein
3I50	;	3.0	;	Crystal structure of the West Nile Virus envelope glycoprotein in complex with the E53 antibody Fab
2OY0	;	2.8	;	Crystal structure of the West Nile virus methyltransferase
2IJO	;	2.3	;	Crystal Structure of the West Nile virus NS2B-NS3 protease complexed with bovine pancreatic trypsin inhibitor
2GGV	;	1.8	;	Crystal structure of the West Nile virus NS2B-NS3 protease, His51Ala mutant
3SYX	;	2.453	;	Crystal Structure of the WH1 domain from human sprouty-related, EVH1 domain-containing protein. Northeast Structural Genomics Consortium Target HR5538B.
6Q1M	;	1.24	;	Crystal structure of the wheat dwarf virus Rep domain
4V4T	;	6.46	;	Crystal structure of the whole ribosomal complex with a stop codon in the A-site.
4V4R	;	5.9	;	Crystal structure of the whole ribosomal complex.
4V4S	;	6.76	;	Crystal structure of the whole ribosomal complex.
5VC8	;	1.8	;	Crystal structure of the WHSC1 PWWP1 domain
5X8U	;	2.0	;	Crystal Structure of the wild Human ROR gamma Ligand Binding Domain.
3O0A	;	1.77	;	Crystal structure of the wild type CP1 hydrolitic domain from Aquifex Aeolicus leucyl-trna
6NDW	;	1.725	;	Crystal structure of the wild type D2 domain (A168-T344) of the flagellar hook protein FlgE from Treponema denticola
7U9C	;	2.1	;	Crystal Structure of the wild type Escherichia coli Pyridoxal 5'-phosphate homeostasis protein (YGGS)
1D3A	;	2.94	;	CRYSTAL STRUCTURE OF THE WILD TYPE HALOPHILIC MALATE DEHYDROGENASE IN THE APO FORM
1ZO9	;	1.7	;	Crystal Structure Of The Wild Type Heme Domain Of P450BM-3 with N-palmitoylmethionine
1VC5	;	3.4	;	Crystal Structure of the Wild Type Hepatitis Delta Virus Gemonic Ribozyme Precursor, in EDTA solution
3EKV	;	1.75	;	Crystal structure of the wild type HIV-1 protease with the inhibitor, Amprenavir
6RD3	;	1.98	;	Crystal structure of the wild type OmpK36 from Klebsiella pneumonia
4JF9	;	2.33	;	Crystal structure of the wild type red fluorescent protein lanRFP (Branchiostoma Lanceolatum)
4V4A	;	9.5	;	Crystal Structure of the Wild Type Ribosome from E. Coli 70S Ribosome.
7JRN	;	2.48	;	Crystal structure of the wild type SARS-CoV-2 papain-like protease (PLPro) with inhibitor GRL0617
3H4K	;	2.55	;	Crystal structure of the wild type Thioredoxin glutatione reductase from Schistosoma mansoni in complex with auranofin
4DER	;	1.9	;	Crystal Structure of the Wild Type TTR Binding Apigenin (TTRwt:API)
4DES	;	1.75	;	Crystal Structure of the Wild Type TTR Binding Chrysin (TTRwt:CHR)
4DET	;	2.05	;	Crystal Structure of the Wild Type TTR Binding Kaempferol (TTRwt:KAE)
4DEW	;	1.899	;	Crystal Structure of the Wild Type TTR Binding Luteolin (TTRwt:LUT)
4DEU	;	1.599	;	Crystal Structure of the Wild Type TTR Binding Naringenin (TTRwt:NAR)
8SBM	;	1.47	;	Crystal structure of the wild-type Catalytic ATP-binding domain of Mtb DosS
4UP6	;	3.801	;	Crystal structure of the wild-type diacylglycerol kinase refolded in the lipid cubic phase
3VJO	;	2.64	;	Crystal structure of the wild-type EGFR kinase domain in complex with AMPPNP.
4I23	;	2.8	;	Crystal structure of the wild-type EGFR kinase domain in complex with dacomitinib (soaked)
3NTE	;	1.95	;	Crystal Structure of the Wild-type Full-Length HIV-1 Capsid Protein
4OJC	;	2.93	;	Crystal structure of the wild-type full-length trimeric ectodomain of the C. elegans fusion protein EFF-1
6EC0	;	2.983	;	Crystal structure of the wild-type heterocomplex between coil 1B domains of human intermediate filament proteins keratin 1 (KRT1) and keratin 10 (KRT10)
3EKX	;	1.97	;	Crystal structure of the wild-type HIV-1 protease with the inhibitor, Nelfinavir
3E4U	;	2.1	;	Crystal Structure of the Wild-Type Human BCL6 BTB/POZ Domain
2JK1	;	2.1	;	Crystal structure of the wild-type HupR receiver domain
7TI6	;	2.64	;	Crystal structure of the wild-type least mutated common ancestor (LMCA) of the HIV-targeting PCT64 antibody lineage
2BIV	;	1.7	;	Crystal structure of the wild-type MBT domains of Human SCML2
3G5G	;	2.8	;	Crystal Structure of the Wild-Type Restriction-Modification Controller Protein C.Esp1396I
5KNI	;	2.5	;	Crystal Structure of the wild-type SAM domain of human Tankyrase-1
5A8G	;	1.72	;	Crystal structure of the wild-type Staphylococcus aureus N- acetylneurminic acid lyase in complex with fluoropyruvate
6I2Q	;	2.15	;	Crystal structure of the wild-type SucA domain of Mycobacterium smegmatis KGD (alpha-ketoglutarate decarboxylase), in complex with GarA
8UD6	;	2.7	;	Crystal structure of the wild-type Thermus thermophilus 70S ribosome in complex with cresomycin, mRNA, deacylated A-site tRNAphe, aminoacylated P-site fMet-tRNAmet, and deacylated E-site tRNAphe at 2.70A resolution
7RQ8	;	2.5	;	Crystal structure of the wild-type Thermus thermophilus 70S ribosome in complex with iboxamycin, mRNA, deacylated A- and E-site tRNAs, and aminoacylated P-site tRNA at 2.50A resolution
8G2D	;	2.7	;	Crystal structure of the wild-type Thermus thermophilus 70S ribosome in complex with tylosin, mRNA, deacylated A- and E-site tRNAphe, and deacylated P-site tRNAmet at 2.70A resolution
2GTH	;	2.7	;	crystal structure of the wildtype MHV coronavirus non-structural protein nsp15
5EJO	;	2.75	;	Crystal structure of the winged helix domain in Chromatin assembly factor 1 subunit p90
6A6I	;	2.6	;	Crystal structure of the winged-helix domain of Cockayne syndrome group B protein in complex with ubiquitin
3OA2	;	1.5	;	Crystal structure of the WlbA (WbpB) dehydrogenase from Pseudomonas aeruginosa in complex with NAD at 1.5 angstrom resolution
3O9Z	;	1.449	;	Crystal structure of the WlbA (WbpB) dehydrogenase from Thermus thermophilus in complex with NAD and alpha-ketoglutarate at 1.45 angstrom resolution
3OA0	;	2.0	;	Crystal structure of the WlbA (WbpB) Dehydrogenase from Thermus thermophilus in complex with NAD and UDP-GlcNAcA
3Q2K	;	2.13	;	Crystal structure of the WlbA dehydrogenase from Bordetella pertussis in complex with NADH and UDP-GlcNAcA
3Q2I	;	1.5	;	Crystal structure of the WlbA dehydrognase from Chromobactrium violaceum in complex with NADH and UDP-GlcNAcA at 1.50 A resolution
5LN5	;	1.75	;	Crystal structure of the Wss1 E203Q mutant from S. pombe
5Y5Q	;	1.56	;	Crystal structure of the WSSV dUTPase D88N/R158E mutant in complex with dUTP
6HT7	;	3.7	;	Crystal structure of the WT human mitochondrial chaperonin (ADP:BeF3)14 complex
6VRI	;	1.94	;	Crystal Structure of the wtBlc-split Protein
8EI4	;	2.43	;	Crystal structure of the WWP1 HECT domain in complex with H302, a Helicon Polypeptide
8EI5	;	2.6	;	Crystal structure of the WWP2 HECT domain in complex with H301, a Helicon Polypeptide
8EI7	;	2.22	;	Crystal structure of the WWP2 HECT domain in complex with H304, a Helicon Polypeptide
8EI6	;	3.62	;	Crystal structure of the WWP2 HECT domain in complex with H305, a Helicon Polypeptide
8EI8	;	2.9	;	Crystal structure of the WWP2 HECT domain in complex with H308, a Helicon Polypeptide
4TX2	;	2.9	;	Crystal structure of the X-domain from teicoplanin biosynthesis
3GZG	;	1.55	;	Crystal structure of the Xanthomonas axonopodis pv. citri molybdate-binding protein (ModA) mutant (K127S)
3L6V	;	2.19	;	Crystal Structure of the Xanthomonas campestris Gyrase A C-terminal Domain
7YZG	;	2.82	;	Crystal structure of the Xenopus FoxH1 bound to the TGTGGATT site
5KZV	;	1.616	;	Crystal structure of the xenopus Smoothened cysteine-rich domain (CRD) in complex with 20(S)-hydroxycholesterol
5KZY	;	2.484	;	Crystal structure of the xenopus Smoothened cysteine-rich domain (CRD) in complex with cyclopamine
5KZZ	;	1.332	;	Crystal structure of the xenopus Smoothened cysteine-rich domain (CRD) in its apo-form
1TJ6	;	1.65	;	Crystal structure of the Xenopus tropicalis Spred1 EVH-1 domain
3P1G	;	1.5	;	Crystal Structure of the Xenotropic Murine Leukemia Virus-Related Virus (XMRV) RNase H Domain
8CDS	;	1.53	;	Crystal structure of the xhNup93-Nb4i VHH antibody
5LKB	;	1.45	;	Crystal structure of the Xi glutathione transferase ECM4 from Saccharomyces cerevisiae
5LKD	;	1.68	;	Crystal structure of the Xi glutathione transferase ECM4 from Saccharomyces cerevisiae in complex with glutathione
4IC2	;	2.2	;	Crystal structure of the XIAP RING domain
1I4O	;	2.4	;	CRYSTAL STRUCTURE OF THE XIAP/CASPASE-7 COMPLEX
1D1Z	;	1.4	;	CRYSTAL STRUCTURE OF THE XLP PROTEIN SAP
1D4T	;	1.1	;	CRYSTAL STRUCTURE OF THE XLP PROTEIN SAP IN COMPLEX WITH A SLAM PEPTIDE
1D4W	;	1.8	;	CRYSTAL STRUCTURE OF THE XLP PROTEIN SAP IN COMPLEX WITH SLAM PHOSPHOPEPTIDE
4JGS	;	2.2	;	Crystal structure of the xmrv tm retroviral fusion core
8CDT	;	1.41	;	Crystal structure of the xNup93-Nb2t VHH antibody
6P4F	;	3.55	;	Crystal structure of the XPB-Bax1-forked DNA ternary complex
4EP6	;	2.3	;	Crystal structure of the XplA heme domain in complex with imidazole and PEG
4FE5	;	1.32	;	Crystal structure of the xpt-pbuX guanine riboswitch aptamer domain in complex with hypoxanthine
1G3J	;	2.1	;	CRYSTAL STRUCTURE OF THE XTCF3-CBD/BETA-CATENIN ARMADILLO REPEAT COMPLEX
7AX7	;	2.05	;	Crystal structure of the Xyl-CE4 domain of a multidomain xylanase from the hindgut metagenome of Trinervitermes trinervoides
3MU7	;	1.29	;	Crystal structure of the xylanase and alpha-amylase inhibitor protein (XAIP-II) from scadoxus multiflorus at 1.2 A resolution
1FHD	;	1.9	;	CRYSTAL STRUCTURE OF THE XYLANASE CEX WITH XYLOBIOSE-DERIVED IMIDAZOLE INHIBITOR
1FH7	;	1.82	;	CRYSTAL STRUCTURE OF THE XYLANASE CEX WITH XYLOBIOSE-DERIVED INHIBITOR DEOXYNOJIRIMYCIN
1J01	;	2.0	;	Crystal Structure Of The Xylanase Cex With Xylobiose-Derived Inhibitor Isofagomine lactam
1FH8	;	1.95	;	CRYSTAL STRUCTURE OF THE XYLANASE CEX WITH XYLOBIOSE-DERIVED ISOFAGOMINE INHIBITOR
1FH9	;	1.72	;	CRYSTAL STRUCTURE OF THE XYLANASE CEX WITH XYLOBIOSE-DERIVED LACTAM OXIME INHIBITOR
2GT4	;	2.3	;	Crystal Structure of the Y103F mutant of the GDP-mannose mannosyl hydrolase in complex with GDP-mannose and MG+2
2F8F	;	2.1	;	Crystal structure of the Y10F mutant of the gluathione s-transferase from schistosoma haematobium
1YFD	;	1.9	;	Crystal structure of the Y122H mutant of ribonucleotide reductase R2 protein from E. coli
2AG9	;	2.2	;	Crystal Structure of the Y137S mutant of GM2-Activator Protein
5C55	;	1.7	;	Crystal structure of the Y138F mutant of C.glutamicum N-acetylneuraminic acid lyase in complex with pyruvate
1S09	;	1.83	;	Crystal Structure of the Y144F Mutant of 7,8-Diaminopelargonic Acid Synthase
6RF9	;	1.8	;	Crystal structure of the Y154F mutant of the light-driven sodium pump KR2 in the monomeric form, pH 8.0
1S0A	;	1.71	;	Crystal Structure of the Y17F Mutant of 7,8-Diaminopelargonic Acid Synthase
6VDG	;	2.79	;	Crystal Structure of the Y182A HisF Mutant from Thermotoga maritima
3RC7	;	2.0	;	Crystal Structure of the Y186F mutant of KijD10, a 3-ketoreductase from Actinomadura kijaniata in complex with TDP-benzene and NADP
3OW5	;	1.801	;	Crystal structure of the Y200A mutant of gamma carbonic anhydrase from Methanosarcina thermophila
3EA3	;	1.78	;	Crystal Structure of the Y246S/Y247S/Y248S/Y251S Mutant of Phosphatidylinositol-Specific Phospholipase C from Bacillus Thuringiensis
3EA1	;	1.75	;	Crystal Structure of the Y247S/Y251S Mutant of Phosphatidylinositol-Specific Phospholipase C from Bacillus Thuringiensis
3VJD	;	1.48	;	Crystal structure of the Y248A mutant of C(30) carotenoid dehydrosqualene synthase from Staphylococcus aureus
3VJE	;	2.12	;	Crystal structure of the Y248A mutant of C(30) carotenoid dehydrosqualene synthase from Staphylococcus aureus in complex with zaragozic acid A
3ORV	;	1.91	;	Crystal Structure of the Y294H-MauG/pre-Methylamine Dehydrogenase Complex
2XUD	;	2.65	;	Crystal structure of the Y337A mutant of mouse acetylcholinesterase
4E4E	;	1.88	;	Crystal Structure of the Y34F mutant of Saccharomyces cerevisiae Manganese Superoxide Dismutase
4EQR	;	1.8	;	Crystal structure of the Y361F mutant of Staphylococcus aureus CoADR
4EQW	;	1.5	;	Crystal Structure of the Y361F, Y419F Mutant of Staphylococcus aureus CoADR
2HS8	;	1.9	;	Crystal structure of the Y364F mutant of 12-oxophytodienoate reductase 3 from tomato
3WWT	;	2.0	;	Crystal Structure of the Y3:STAT1ND complex
4EQS	;	1.5	;	Crystal structure of the Y419F mutant of Staphylococcus aureus CoADR
1O9I	;	1.33	;	Crystal structure of the Y42F mutant of manganese catalase from Lactobacillus plantarum at 1.33A resolution
7VWD	;	2.153	;	Crystal Structure of the Y53F/N55A mutant of LEH
7XEF	;	1.816	;	Crystal Structure of the Y53F/N55A mutant of LEH complexed with (R)-(1-benzyl-3-phenylpyrrolidin-3-yl)methanol
7XEE	;	1.877	;	Crystal Structure of the Y53F/N55A mutant of LEH complexed with 2-(3-phenyloxetan-3-yl)ethanamine
7VWM	;	1.98	;	Crystal Structure of the Y53F/N55A/I116V mutant of LEH
7VX2	;	2.485	;	Crystal Structure of the Y53F/N55A/I80F/L114V/I116V mutant of LEH
1AQE	;	2.2	;	CRYSTAL STRUCTURE OF THE Y73E MUTANT OF CYTOCHROME C OF CLASS III (AMBLER) 26 KD
6VMF	;	2.24	;	Crystal structure of the Y766F mutant of GoxA soaked with glycine
3RLD	;	1.5	;	Crystal structure of the Y7I mutant of human carbonic anhydrase II
2Q35	;	1.65	;	Crystal Structure of the Y82F variant of ECH2 decarboxylase domain of CurF from Lyngbya majuscula
7TCB	;	2.7	;	Crystal Structure of the YaeQ Family Protein VPA0551 from Vibrio parahaemolyticus
6AXJ	;	2.379	;	Crystal structure of the Yaf9 YEATS domain bound to H3K27ac
5B7W	;	2.08	;	Crystal structure of the YajQ-family protein XC_3703 from Xanthomonas campestris pv.campestris
2VZ7	;	3.2	;	Crystal structure of the YC-17-bound PikC D50N mutant
4FIB	;	1.997	;	Crystal structure of the ydhK protein from Bacillus subtilis. Northeast Structural Genomics Consortium Target SR518A.
3CBW	;	1.269	;	Crystal structure of the YdhT protein from Bacillus subtilis
3NZW	;	2.5	;	Crystal structure of the yeast 20S proteasome in complex with 2b
2F16	;	2.8	;	Crystal structure of the yeast 20S proteasome in complex with bortezomib
3E47	;	3.0	;	Crystal Structure of the Yeast 20S Proteasome in Complex with Homobelactosin C
3NZX	;	2.7	;	Crystal structure of the yeast 20S proteasome in complex with ligand 2c
3GPW	;	2.5	;	Crystal structure of the yeast 20S proteasome in complex with Salinosporamide derivatives: irreversible inhibitor ligand
3GPT	;	2.41	;	Crystal structure of the yeast 20S proteasome in complex with Salinosporamide derivatives: slow substrate ligand
3GPJ	;	2.7	;	Crystal structure of the yeast 20S proteasome in complex with syringolin B
1JD2	;	3.0	;	Crystal Structure of the yeast 20S Proteasome:TMC-95A complex: A non-covalent Proteasome Inhibitor
1G6I	;	1.59	;	Crystal structure of the yeast alpha-1,2-mannosidase with bound 1-deoxymannojirimycin at 1.59 A resolution
1ZUU	;	0.97	;	Crystal structure of the yeast Bzz1 first SH3 domain at 0.97-A resolution
6CHG	;	2.985	;	Crystal structure of the yeast COMPASS catalytic module
2BPO	;	2.9	;	Crystal structure of the yeast CPR triple mutant: D74G, Y75F, K78A.
4W7S	;	2.542	;	Crystal structure of the yeast DEAD-box splicing factor Prp28 at 2.54 Angstroms resolution
4BRU	;	3.245	;	Crystal structure of the yeast Dhh1-Edc3 complex
4BRW	;	2.795	;	Crystal structure of the yeast Dhh1-Pat1 complex
3ED3	;	2.0	;	Crystal Structure of the Yeast Dithiol/Disulfide Oxidoreductase Mpd1p
1F60	;	1.67	;	CRYSTAL STRUCTURE OF THE YEAST ELONGATION FACTOR COMPLEX EEF1A:EEF1BA
3V2U	;	2.105	;	Crystal structure of the yeast GAL regulon complex of the repressor, Gal80p, and the transducer, Gal3p, with galactose and ATP
7BV5	;	2.8	;	Crystal structure of the yeast heterodimeric ADAT2/3
3DXR	;	2.5	;	Crystal structure of the yeast inter-membrane space chaperone assembly TIM9.10
2FTX	;	1.9	;	Crystal structure of the yeast kinetochore Spc24/Spc25 globular domain
4C92	;	2.299	;	Crystal structure of the yeast Lsm1-7 complex
4C8Q	;	3.698	;	Crystal structure of the yeast Lsm1-7-Pat1 complex
4F6O	;	1.681	;	Crystal structure of the yeast metacaspase Yca1
4F6P	;	1.619	;	Crystal structure of the yeast metacaspase Yca1 C276A mutant
1KCF	;	2.3	;	Crystal Structure of the Yeast Mitochondrial Holliday Junction Resolvase, Ydc2
4EO4	;	2.87	;	Crystal structure of the yeast mitochondrial threonyl-tRNA synthetase (MST1) in complex with seryl sulfamoyl adenylate
4YYE	;	2.301	;	Crystal structure of the yeast mitochondrial threonyl-tRNA synthetase (MST1) in complex with the canonical tRNAThr and threonyl sulfamoyl adenylate
3UH0	;	2.0	;	Crystal structure of the yeast mitochondrial threonyl-tRNA synthetase (MST1) in complex with threonyl sulfamoyl adenylate
3UGT	;	3.6	;	Crystal structure of the yeast mitochondrial threonyl-tRNA synthetase - orthorhombic crystal form
8G0Q	;	3.22	;	Crystal structure of the yeast Ndc80:Nuf2 head region with a bound Dam1 segment
3V8E	;	2.71	;	Crystal structure of the yeast nicotinamidase Pnc1p bound to the inhibitor nicotinaldehyde
5UAZ	;	1.753	;	Crystal structure of the yeast nucleoporin
1ID3	;	3.1	;	CRYSTAL STRUCTURE OF THE YEAST NUCLEOSOME CORE PARTICLE REVEALS FUNDAMENTAL DIFFERENCES IN INTER-NUCLEOSOME INTERACTIONS
3FRX	;	2.13	;	Crystal Structure of the Yeast Orthologue of RACK1, Asc1.
1QSP	;	2.7	;	CRYSTAL STRUCTURE OF THE YEAST PHOSPHORELAY PROTEIN YPD1
1OCS	;	2.03	;	Crystal structure of the yeast PX-doamin protein Grd19p (sorting nexin3) complexed to phosphatidylinosytol-3-phosphate.
1OCU	;	2.3	;	Crystal structure of the yeast PX-domain protein Grd19p (sorting nexin 3) complexed to phosphatidylinosytol-3-phosphate.
3RFH	;	2.9	;	Crystal structure of the yeast RACK1 dimer in space group P21
3RFG	;	3.9	;	Crystal structure of the yeast RACK1 dimer in space group P63
4BSZ	;	2.842	;	Crystal Structure of the Yeast Ribosomal Protein Rps3 in Complex with its Chaperone Yar1
7JV7	;	1.85055	;	Crystal Structure of the yeast RNA Pol II CTD kinase CTDK-1 complex
4BB7	;	2.4	;	Crystal structure of the yeast Rsc2 BAH domain
3LWT	;	1.956	;	Crystal structure of the Yeast Sac1: Implications for its phosphoinositide phosphatase function
1M2V	;	2.75	;	Crystal Structure of the yeast Sec23/24 heterodimer
2E7S	;	3.0	;	Crystal structure of the yeast Sec2p GEF domain
8PFH	;	3.24	;	Crystal structure of the yeast septin complex Shs1-Cdc12-Cdc3-Cdc10
8QRY	;	1.87	;	Crystal structure of the yeast spindle body component Spc98
2GW1	;	3.0	;	Crystal Structure of the Yeast Tom70
3R3Q	;	1.45	;	Crystal structure of the yeast Vps23 UEV domain
3R42	;	1.866	;	Crystal structure of the yeast vps23 UEV domain in complex with a vps27 PSDP peptide
4HE4	;	2.05	;	Crystal structure of the yellow fluorescent protein phiYFP (Phialidium sp.)
1N5B	;	2.0	;	Crystal Structure Of The Yersinia enterocolitica Molecular Chaperone Syce
4AM9	;	2.5	;	CRYSTAL STRUCTURE OF THE YERSINIA ENTEROCOLITICA TYPE III SECRETION CHAPERONE SYCD IN COMPLEX WITH A PEPTIDE OF THE TRANSLOCATOR YOPD
2BHO	;	2.6	;	Crystal structure of the Yersinia enterocolitica type III secretion chaperone SycT
2VGY	;	2.6	;	Crystal structure of the Yersinia enterocolitica Type III Secretion Translocator Chaperone SycD (alternative dimer)
3TZF	;	2.1	;	Crystal Structure of the Yersinia pestis Dihydropteroate Synthase with Sulfonamide Drug Complex.
3TZN	;	2.083	;	Crystal Structure of the Yersinia pestis Dihydropteroate synthase.
3TYZ	;	2.07	;	Crystal Structure of the Yersinia pestis Dihydropteroate synthetase with substrate transition state complex.
1QZ0	;	1.5	;	Crystal Structure of the Yersinia Pestis Phosphatase YopH in Complex with a Phosphotyrosyl Mimetic-Containing Hexapeptide
1TTW	;	2.38	;	Crystal structure of the Yersinia Pestis type III secretion chaperone SycH in complex with a stable fragment of YscM2
1K6Z	;	2.0	;	Crystal Structure of the Yersinia Secretion Chaperone SycE
1ZW0	;	1.8	;	Crystal structure of the Yersinia Type III Secretion protein YscE
1L2W	;	2.0	;	Crystal Structure of the Yersinia Virulence Effector YopE Chaperone-binding Domain in Complex with its Secretion Chaperone, SycE
1PT8	;	2.2	;	Crystal structure of the yfdW gene product of E. coli, in complex with oxalate and acetyl-CoA
6HR1	;	1.901	;	Crystal structure of the YFPnano fusion protein
3FIF	;	2.7	;	Crystal structure of the ygdR protein from E.coli. Northeast Structural Genomics target ER382A.
5H7D	;	2.57	;	Crystal structure of the YgjG-protein A-Zpa963-calmodulin complex
5X3F	;	3.38	;	Crystal structure of the YgjG-Protein A-Zpa963-PKA catalytic domain
3NX4	;	1.9	;	Crystal structure of the yhdH oxidoreductase from Salmonella enterica in complex with NADP
3CFU	;	2.4	;	Crystal structure of the yjhA protein from Bacillus subtilis. Northeast Structural Genomics Consortium target SR562
1XE7	;	1.75	;	Crystal structure of the YML079w protein from Saccharomyces cerevisiae reveals a new sequence family of the jelly roll fold
1XE8	;	2.8	;	Crystal structure of the YML079w protein from Saccharomyces cerevisiae reveals a new sequence family of the jelly roll fold.
6DR9	;	1.945	;	Crystal Structure of the YopH PTP1B Chimera 3 PTPase apo form
6DT6	;	2.101	;	Crystal Structure of the YopH PTP1B Chimera 3 PTPase bound to vanadate
6DRB	;	2.745	;	Crystal Structure of the YopH PTP1B WPD loop Chimera 3 PTPase bound to tungstate
1FKM	;	1.9	;	CRYSTAL STRUCTURE OF THE YPT/RAB-GAP DOMAIN OF GYP1P
3NJC	;	1.693	;	Crystal structure of the yslB protein from Bacillus subtilis. Northeast Structural Genomics Consortium Target SR460.
3EQE	;	2.82	;	Crystal structure of the YubC protein from Bacillus subtilis. Northeast Structural Genomics Consortium target SR112.
2OHW	;	1.4	;	Crystal structure of the YueI protein from Bacillus subtilis
8OEB	;	1.8	;	Crystal structure of the Z-DNA duplex d(CGCGCG) containing ordered copper(II) and soaked in hydrogen peroxide for 30 minutes, second collection at room temperature
8OE7	;	1.25	;	Crystal structure of the Z-DNA duplex d(CGCGCG) containing ordered copper(II) and soaked in hydrogen peroxide for 5 minutes
8OE8	;	1.3	;	Crystal structure of the Z-DNA duplex d(CGCGCG) containing ordered copper(II) and soaked in hydrogen peroxide for an hour
8OEC	;	2.1	;	Crystal structure of the Z-DNA duplex d(CGCGCG) containing ordered copper(II) and soaked in hydrogen peroxide for another 30 minutes, third collection at room temperature
8OE9	;	1.04	;	Crystal structure of the Z-DNA duplex d(CGCGCG) soaked in copper(II) chloride and hydrogen peroxide
8OEA	;	1.5	;	Crystal structure of the Z-DNA duplex d(CGCGCG) soaked in copper(II) chloride, in preparation to hydrogen peroxide soaking, first collection at room temperature
4FS6	;	1.3	;	Crystal structure of the Z-DNA hexamer CGCGCG at 500 mM CaCl2
4FS5	;	1.3	;	Crystal structure of the Z-DNA hexamer CGCGCG at 500 mM MgCl2
8OEZ	;	1.64	;	Crystal structure of the Z-DNA hexamer d(CGCGCG) with Iron(II) chloride
2GXB	;	2.25	;	Crystal Structure of The Za Domain bound to Z-RNA
4IJF	;	2.506	;	Crystal structure of the Zaire ebolavirus VP35 interferon inhibitory domain K222A/R225A/K248A/K251A mutant
4IJE	;	1.899	;	Crystal structure of the Zaire ebolavirus VP35 interferon inhibitory domain R312A/K319A/R322A mutant
1QBJ	;	2.1	;	CRYSTAL STRUCTURE OF THE ZALPHA Z-DNA COMPLEX
1U59	;	2.3	;	Crystal Structure of the ZAP-70 Kinase Domain in Complex with Staurosporine
6KLG	;	2.1	;	Crystal Structure of the Zea Mays laccase 3
6KLJ	;	1.998	;	Crystal Structure of the Zea Mays laccase 3 complexed with coniferyl
6KLI	;	1.8	;	Crystal Structure of the Zea Mays laccase 3 complexed with sinapyl
1V08	;	1.9	;	Crystal structure of the Zea maze beta-glucosidase-1 in complex with gluco-tetrazole
5LP0	;	1.41	;	CRYSTAL STRUCTURE OF THE ZEBRA FISH ENTH DOMAIN FROM EPSIN1 IN 1.41 ANGSTROM RESOLUTION
6IRX	;	2.0	;	Crystal structure of the zebrafish cap-specific adenosine methyltransferase
6IRY	;	1.8	;	Crystal structure of the zebrafish cap-specific adenosine methyltransferase bound to SAH
6IRZ	;	2.0	;	Crystal structure of the zebrafish cap-specific adenosine methyltransferase bound to SAH and m7G-capped RNA
6IS0	;	1.8	;	Crystal structure of the zebrafish cap-specific adenosine methyltransferase bound to SAH and m7G-capped RNA
4QKW	;	1.7	;	Crystal structure of the zebrafish cavin4a HR1 domain
7YZ7	;	0.98	;	Crystal structure of the zebrafish FoxH1 bound to the TGTGGATT site
7YZA	;	1.18	;	Crystal structure of the zebrafish FoxH1 bound to the TGTGTATT site
7YZD	;	2.13	;	Crystal structure of the zebrafish FoxH1 bound to the TGTTTACT site (fkh motif GTAAACA)
7YZC	;	2.17	;	Crystal structure of the zebrafish FoxH1 bound to the TGTTTATT site
6HRV	;	1.95	;	Crystal structure of the zebrafish peroxisomal SCP2-thiolase (type-1)
6HSJ	;	1.46	;	Crystal structure of the zebrafish peroxisomal SCP2-thiolase (type-1) in complex with CoA
6HSP	;	1.73	;	Crystal structure of the zebrafish peroxisomal SCP2-thiolase (type-1) in complex with CoA and octanoyl-CoA
6WLE	;	3.0	;	Crystal structure of the Zeitlupe light-state mimic G46A
6PLL	;	2.693	;	Crystal structure of the ZIG-8 IG1 homodimer
6ONB	;	1.696	;	Crystal Structure of the ZIG-8-RIG-5 IG1-IG1 heterodimer, monoclinic form
6ON9	;	1.995	;	Crystal Structure of the ZIG-8-RIG-5 IG1-IG1 heterodimer, tetragonal form
5TFN	;	3.0	;	CRYSTAL STRUCTURE OF THE ZIKA VIRUS NS2B-NS3 PROTEASE in super-open conformation
5TFO	;	2.51	;	CRYSTAL STRUCTURE OF THE ZIKA VIRUS NS2B-NS3 PROTEASE with a deletion V76-L86 in NS2b
5VI7	;	2.005	;	Crystal structure of the Zika virus NS3 helicase
6ADX	;	1.752	;	Crystal structure of the Zika virus NS3 helicase (ADP-Mn2+ complex, form 1)
6ADY	;	1.9	;	Crystal structure of the Zika virus NS3 helicase (ADP-Mn2+ complex, form 2)
6ADW	;	2.2	;	Crystal structure of the Zika virus NS3 helicase (apo form)
5Y4Z	;	1.3	;	Crystal structure of the Zika virus NS3 helicase complex with AMPPNP
5TXG	;	2.05	;	Crystal structure of the Zika virus NS3 helicase.
5VIM	;	2.1	;	Crystal structure of the Zika virus NS5 methyltransferase.
8TQX	;	2.09	;	Crystal structure of the Zika virus stem-loop A (SLA) bottom stem
8TSV	;	1.51	;	Crystal structure of the Zika virus stem-loop A (SLA) top stem
1X8I	;	1.9	;	Crystal Structure of the Zinc Carbapenemase CphA in Complex with the Antibiotic Biapenem
2QDS	;	1.66	;	Crystal Structure of the Zinc Carbapenemase CPHA in Complex with the Inhibitor D-Captopril
2GKL	;	1.86	;	Crystal structure of the zinc carbapenemase CPHA in complex with the inhibitor pyridine-2,4-dicarboxylate
3U9G	;	1.801	;	Crystal structure of the Zinc finger antiviral protein
1PZW	;	2.0	;	Crystal structure of the zinc finger associated domain of the Drosophila transcription factor Grauzone
2WBS	;	1.7	;	Crystal structure of the zinc finger domain of Klf4 bound to its target DNA
2WBU	;	2.5	;	CRYSTAL STRUCTURE OF THE ZINC FINGER DOMAIN OF KLF4 BOUND TO ITS TARGET DNA
4II1	;	2.65	;	Crystal structure of the zinc finger of ZGPAT
1C7K	;	1.0	;	CRYSTAL STRUCTURE OF THE ZINC PROTEASE
1SDX	;	2.06	;	Crystal structure of the zinc saturated C-terminal half of bovine lactoferrin at 2.0 A resolution reveals two additional zinc binding sites
2GFJ	;	1.8	;	Crystal structure of the zinc-beta-lactamase L1 from stenotrophomonas maltophilia (inhibitor 1)
2GFK	;	1.9	;	Crystal structure of the zinc-beta-lactamase l1 from stenotrophomonas maltophilia (inhibitor 2)
2HB9	;	1.75	;	Crystal Structure of the Zinc-Beta-Lactamase L1 from Stenotrophomonas Maltophilia (Inhibitor 3)
2H6A	;	1.8	;	Crystal structure of the zinc-beta-lactamase L1 from Stenotrophomonas maltophilia (mono zinc form)
3JPY	;	3.209	;	Crystal structure of the zinc-bound amino terminal domain of the NMDA receptor subunit NR2B
2F44	;	2.4	;	Crystal Structure of the Zinc-bound Shank SAM domain
3TGN	;	2.0	;	Crystal Structure of the zinc-dependent MarR Family Transcriptional Regulator AdcR in the Zn(II)-bound State
6F4E	;	2.4	;	Crystal structure of the zinc-free catalytic domain of botulinum neurotoxin X
3E2U	;	2.6	;	Crystal structure of the zink-knuckle 2 domain of human CLIP-170 in complex with CAP-Gly domain of human dynactin-1 (p150-GLUED)
7JJA	;	1.01	;	Crystal structure of the ZinT-like domain of Streptococcus pneumoniae AdcA in the apo form
4XWF	;	1.8	;	Crystal structure of the ZMP riboswitch at 1.80 angstrom
4XW7	;	2.5	;	Crystal structure of the ZMP riboswitch at 2.50 angstrom
1Q0A	;	2.0	;	Crystal structure of the Zn(II) form of E. coli ZntR, a zinc-sensing transcriptional regulator (space group C222)
1Q09	;	2.5	;	Crystal structure of the Zn(II) form of E. coli ZntR, a zinc-sensing transcriptional regulator (space group I4122)
1Q08	;	1.9	;	Crystal structure of the Zn(II) form of E. coli ZntR, a zinc-sensing transcriptional regulator, at 1.9 A resolution (space group P212121)
7LM7	;	3.12	;	Crystal structure of the Zn(II)-bound AdcAII E280Q mutant variant of Streptococcus pneumoniae
7LM6	;	3.367	;	Crystal structure of the Zn(II)-bound AdcAII H205L mutant variant of Streptococcus pneumoniae
7LM5	;	2.4	;	Crystal structure of the Zn(II)-bound AdcAII H65A mutant variant of Streptococcus pneumoniae
1FA5	;	1.8	;	CRYSTAL STRUCTURE OF THE ZN(II)-BOUND GLYOXALASE I OF ESCHERICHIA COLI
7JJ8	;	2.03	;	Crystal structure of the Zn(II)-bound ZnuA-like domain of Streptococcus pneumoniae AdcA
6ON5	;	1.638	;	Crystal Structure of the Zn-bound Domain-Swapped Dimer Q108K:T51D:A28C:L36C:F57H Mutant of Human Cellular Retinol Binding Protein II
7JGL	;	2.34	;	Crystal Structure of the Zn-bound Human Heavy-chain variant 122H-delta C-star with 2,5-furandihyrdoxamate collected at 100K
7JGN	;	2.07	;	Crystal Structure of the Zn-bound Human Heavy-chain variant 122H-delta C-star with meta-benzenedihyrdoxamate collected at 100K
5UP8	;	2.631	;	Crystal Structure of the Zn-bound Human Heavy-Chain variant 122H-delta C-star with para-benzenedihydroxamate
5OJJ	;	1.85	;	Crystal structure of the Zn-bound ubiquitin-conjugating enzyme Ube2T
6LDG	;	1.98	;	Crystal structure of the Zn-directed tetramer of the engineered cyt cb 562 variant, C96I AB5
7DCL	;	2.45	;	Crystal structure of the Zn-directed tetramer of the engineered cyt cb 562 variant, C96I/A38S AB5
6LDF	;	2.35	;	Crystal structure of the Zn-directed tetramer of the engineered cyt cb 562 variant, C96K AB5
6LDE	;	2.0	;	Crystal structure of the Zn-directed tetramer of the engineered cyt cb 562 variant, C96V AB5
4U9E	;	2.8	;	Crystal structure of the Zn-directed tetramer of the engineered cyt cb562 variant, A104/57G AB3
4U9D	;	2.5	;	Crystal Structure of the Zn-directed tetramer of the engineered cyt cb562 variant, AB3
5XZI	;	2.65	;	Crystal structure of the Zn-directed tetramer of the engineered cyt cb562 variant, AB5
5XZJ	;	1.98	;	Crystal structure of the Zn-directed tetramer of the engineered cyt cb562 variant, C96T/AB5
3HNI	;	2.35	;	Crystal structure of the Zn-induced tetramer of the engineered cyt cb562 variant RIDC-1
3HNJ	;	2.0	;	Crystal structure of the Zn-induced tetramer of the engineered cyt cb562 variant RIDC-2
5L32	;	2.1	;	Crystal structure of the Zn-RIDC1 complex bearing six interfacial disulfide bonds
3QW0	;	1.84	;	Crystal structure of the Zn-RIDC1 complex stabilized by BMB crosslinks
3QW1	;	2.7	;	Crystal structure of the Zn-RIDC1 complex stabilized by BMH crosslinks
3QVY	;	2.3	;	Crystal structure of the Zn-RIDC1 complex stabilized by BMOE crosslinks
3QVZ	;	2.64	;	Crystal structure of the Zn-RIDC1 complex stabilized by BMOE crosslinks cocrystallized in the presence of Cu(II)
2JD8	;	2.8	;	Crystal Structure of the Zn-soaked Ferritin from the Hyperthermophilic Archaeal Anaerobe Pyrococcus furiosus
7YGW	;	1.72	;	Crystal structure of the Zn2+-bound EFhd1/Swiprosin-2
7YGY	;	2.6	;	Crystal structure of the Zn2+-bound EFhd2/Swiprosin-1
4GSZ	;	2.2	;	Crystal Structure of the Zn2+5-Human Arginase I-ABH Complex
7MO1	;	1.6	;	Crystal Structure of the ZnF1 of Nucleoporin NUP153 in complex with Ran-GDP
7MO2	;	1.65	;	Crystal Structure of the ZnF2 of Nucleoporin NUP153 in complex with Ran-GDP
7MNP	;	2.05	;	Crystal Structure of the ZnF2 of Nucleoporin NUP358/RanBP2 in complex with Ran-GDP
7MNQ	;	2.05	;	Crystal Structure of the ZnF2 of Nucleoporin NUP358/RanBP2 in complex with Ran-GDP
7MO3	;	2.05	;	Crystal Structure of the ZnF3 of Nucleoporin NUP153 in complex with Ran-GDP, resolution 2.05 Angstrom
7MO4	;	2.4	;	Crystal Structure of the ZnF3 of Nucleoporin NUP153 in complex with Ran-GDP, resolution 2.4 Angstrom
7MNR	;	1.8	;	Crystal Structure of the ZnF3 of Nucleoporin NUP358/RanBP2 in complex with Ran-GDP
7MO5	;	1.55	;	Crystal Structure of the ZnF4 of Nucleoporin NUP153 in complex with Ran-GDP
7MNS	;	2.1	;	Crystal Structure of the ZnF4 of Nucleoporin NUP358/RanBP2 in complex with Ran-GDP
7MNT	;	2.45	;	Crystal Structure of the ZnF5 or ZnF6 of Nucleoporin NUP358/RanBP2 in complex with Ran-GDP
7MNU	;	2.0	;	Crystal Structure of the ZnF7 of Nucleoporin NUP358/RanBP2 in complex with Ran-GDP
7MNV	;	1.8	;	Crystal Structure of the ZnF8 of Nucleoporin NUP358/RanBP2 in complex with Ran-GDP
4OEP	;	2.35	;	Crystal structure of the ZO-1 PDZ1 domain in complex with the 7-mer Claudin1 C-terminal tail
4YYX	;	1.79	;	Crystal structure of the ZO-1 PDZ1 domain in complex with the 7-mer Claudin2 C-terminal tail
5HZV	;	2.7	;	Crystal structure of the zona pellucida module of human endoglin/CD105
5CJ3	;	1.6499	;	Crystal structure of the zorbamycin binding protein (ZbmA) from Streptomyces flavoviridis with zorbamycin
5BUP	;	2.251	;	Crystal structure of the ZP-C domain of mouse ZP2
8RKF	;	3.2	;	Crystal structure of the ZP-N1 and ZP-N2 domains of human ZP2 (hZP2-N1N2)
5II6	;	0.95	;	Crystal structure of the ZP-N1 domain of mouse sperm receptor ZP2 at 0.95 A resolution
8RKH	;	1.9	;	Crystal structure of the ZP-N2 and ZP-N3 domains of mouse ZP2 (mZP2-N2N3)
3AU7	;	2.6	;	Crystal structure of the ZRD-deleted mutant of TiaS in complex with agmatine
5TSB	;	2.7	;	Crystal structure of the Zrt-/Irt-like protein from Bordetella bronchiseptica with bound Cd2+
5TSA	;	2.4	;	Crystal structure of the Zrt-/Irt-like protein from Bordetella bronchiseptica with bound Zn2+
6WLP	;	3.0	;	Crystal Structure of the ZTL light-state mimic G46S
7OIY	;	2.05	;	Crystal structure of the ZUFSP family member Mug105
5DJE	;	1.85	;	Crystal structure of the zuotin homology domain (ZHD) from yeast Zuo1
4IGD	;	2.5	;	Crystal structure of the zymogen catalytic region of Human MASP-1
1ZJK	;	2.18	;	Crystal structure of the zymogen catalytic region of human MASP-2
1DKI	;	1.6	;	CRYSTAL STRUCTURE OF THE ZYMOGEN FORM OF STREPTOCOCCAL PYROGENIC EXOTOXIN B ACTIVE SITE (C47S) MUTANT
7ZU8	;	2.05	;	Crystal Structure of the zymogen form of the glutamic-class prolyl-endopeptidase neprosin at 2.05 A resolution in presence of the crystallophore Lu-Xo4.
5LYO	;	2.498	;	Crystal structure of the zymogen matriptase catalytic domain
4PNE	;	1.5	;	Crystal Structure of the [4+2]-Cyclase SpnF
5XJW	;	2.097	;	Crystal Structure of the [Co2+-(Chromomycin A3)2]-CCG repeats Complex
5YZE	;	1.87	;	Crystal structure of the [Co2+-(chromomycin A3)2]-d(CCG)3 complex
1SIZ	;	2.25	;	Crystal structure of the [Fe3S4]-ferredoxin from the hyperthermophilic archaeon Pyrococcus furiosus
3QQ5	;	2.99	;	Crystal structure of the [FeFe]-hydrogenase maturation protein HydF
5XEW	;	1.751	;	Crystal structure of the [Ni2+-(chromomycin A3)2]-CCG repeats complex
1N3Z	;	1.65	;	Crystal structure of the [S-carboxyamidomethyl-Cys31, S-carboxyamidomethyl-Cys32] monomeric derivative of the bovine seminal ribonuclease in the liganded state
8D29	;	1.81	;	Crystal structure of theophylline aptamer - apo form
8D5L	;	1.64	;	Crystal structure of theophylline aptamer in complex with TAL1
8D2B	;	1.44	;	Crystal structure of theophylline aptamer in complex with TAL2
8D2A	;	2.17	;	Crystal structure of theophylline aptamer in complex with TAL3
8D5O	;	2.7	;	Crystal structure of theophylline aptamer in complex with TAL4
8D28	;	1.42	;	Crystal structure of theophylline aptamer in complex with theophylline
8DK7	;	2.46	;	Crystal structure of theophylline aptamer soaked with TAL2
1YE8	;	1.4	;	Crystal Structure of THEP1 from the hyperthermophile Aquifex aeolicus
4F33	;	1.749	;	Crystal Structure of therapeutic antibody MORAb-009
5T6P	;	1.97	;	Crystal structure of therapeutic mAB AR20.5 in complex with MUC1 peptide
5T78	;	2.2	;	Crystal structure of therapeutic mAB AR20.5 in complex with MUC1 peptide
7AOB	;	2.12	;	Crystal structure of Thermaerobacter marianensis malate dehydrogenase
1THM	;	1.37	;	CRYSTAL STRUCTURE OF THERMITASE AT 1.4 ANGSTROMS RESOLUTION
3W9K	;	1.8	;	Crystal structure of thermoacidophile-specific protein STK_08120 complexed with myristic acid
2D0F	;	2.08	;	Crystal Structure of Thermoactinomyces vulgaris R-47 Alpha-Amylase 1 (TVAI) Mutant D356N complexed with P2, a pullulan model oligosaccharide
2D0H	;	2.1	;	Crystal Structure of Thermoactinomyces vulgaris R-47 Alpha-Amylase 1 (TVAI) Mutant D356N/E396Q complexed with P2, a pullulan model oligosaccharide
2D0G	;	2.6	;	Crystal Structure of Thermoactinomyces vulgaris R-47 Alpha-Amylase 1 (TVAI) Mutant D356N/E396Q complexed with P5, a pullulan model oligosaccharide
1JF5	;	3.2	;	CRYSTAL STRUCTURE OF THERMOACTINOMYCES VULGARIS R-47 ALPHA-AMYLASE 2 MUTANT F286A
3A6O	;	2.8	;	Crystal structure of Thermoactinomyces vulgaris R-47 alpha-amylase 2/acarbose complex
1VFM	;	2.9	;	Crystal structure of Thermoactinomyces vulgaris R-47 alpha-amylase 2/alpha-cyclodextrin complex
1VFO	;	2.81	;	Crystal structure of Thermoactinomyces vulgaris R-47 alpha-amylase 2/beta-cyclodextrin complex
1VB9	;	2.2	;	Crystal structure of Thermoactinomyces vulgaris R-47 alpha-amylase II (TVA II) complexed with transglycosylated product
1JF6	;	3.2	;	Crystal structure of thermoactinomyces vulgaris r-47 alpha-amylase mutant F286Y
1VFU	;	3.1	;	Crystal structure of Thermoactinomyces vulgaris R-47 amylase 2/gamma-cyclodextrin complex
2IOY	;	1.9	;	Crystal structure of Thermoanaerobacter tengcongensis ribose binding protein
5BX2	;	1.61	;	Crystal structure of Thermoanaerobacterium xylanolyticum GH116 beta-glucosidase with 2-deoxy-2-fluoroglucoside
8R06	;	1.7	;	CRYSTAL STRUCTURE OF THERMOANAEROBACTERIUM XYLANOLYTICUM GH116 BETA-GLUCOSIDASE WITH A COVALENTLY BOUND CYCLOPHELLITOL AZIRIDINE
5BX3	;	1.96	;	Crystal structure of Thermoanaerobacterium xylanolyticum GH116 beta-glucosidase with deoxynojirimycin
5BX4	;	1.65	;	Crystal structure of Thermoanaerobacterium xylanolyticum GH116 beta-glucosidase with Glucoimidazole
5BX5	;	1.85	;	Crystal structure of Thermoanaerobacterium xylanolyticum GH116 beta-glucosidase with glucose
5BVU	;	1.61	;	Crystal structure of Thermoanaerobacterium xylolyticum GH116 beta-glucosidase
3WVO	;	3.31	;	Crystal structure of Thermobifida fusca Cse1
2PFE	;	1.436	;	Crystal Structure of Thermobifida fusca Protease A (TFPA)
7CNR	;	3.39	;	Crystal structure of Thermococcus kodakaraensis aconitase X (apo-form)
7CNS	;	1.902	;	Crystal structure of Thermococcus kodakaraensis aconitase X (holo-form)
1K1Y	;	2.4	;	Crystal structure of thermococcus litoralis 4-alpha-glucanotransferase complexed with acarbose
4B8R	;	2.05	;	Crystal Structure of Thermococcus litoralis ADP-dependent Glucokinase (GK)
4B8S	;	2.58	;	Crystal Structure of Thermococcus litoralis ADP-dependent Glucokinase (GK)
5O5X	;	2.148	;	Crystal structure of Thermococcus litoralis ADP-dependent glucokinase (GK)
5O5Y	;	1.915	;	Crystal structure of Thermococcus litoralis ADP-dependent glucokinase (GK)
5O5Z	;	2.441	;	CRYSTAL STRUCTURE OF THERMOCOCCUS LITORALIS ADP-DEPENDENT GLUCOKINASE (GK)
1J3P	;	2.02	;	Crystal structure of Thermococcus litoralis phosphoglucose isomerase
1J3R	;	2.18	;	Crystal structure of Thermococcus litoralis phosphogrucose isomerase complexed with gluconate-6-phosphate
1J3Q	;	1.85	;	Crystal structure of Thermococcus litoralis phosphogrucose isomerase soaked with FeSO4
4TXD	;	1.818	;	Crystal structure of Thermofilum pendens Csc2
7DIH	;	1.5	;	Crystal structure of Thermoglobin Y29F mutant in complex with imidazole
2YY7	;	2.061	;	Crystal structure of thermolabile L-threonine dehydrogenase from Flavobacterium frigidimaris KUC-1
6IG7	;	1.8	;	Crystal structure of thermolysin delivered in polyacrylamide using x-ray free electron laser
3NN7	;	2.05	;	Crystal structure of Thermolysin in complex with 2-bromoacetate
3MSA	;	1.66	;	Crystal structure of Thermolysin in complex with 3-Bromophenol
3MS3	;	1.54	;	Crystal structure of Thermolysin in complex with Aniline
3MSN	;	1.97	;	Crystal structure of Thermolysin in complex with N-methylurea
3N21	;	1.87	;	Crystal structure of Thermolysin in complex with S-1,2-Propandiol
3MSF	;	2.09	;	Crystal structure of Thermolysin in complex with Urea
3LS7	;	1.98	;	Crystal structure of Thermolysin in complex with Xenon
1UE8	;	3.0	;	Crystal Structure of Thermophilic Cytochrome P450 from Sulfolobus tokodaii
5AXG	;	1.85	;	Crystal structure of thermophilic dextranase from Thermoanaerobacter pseudethanolicus
5AXH	;	2.2	;	Crystal structure of thermophilic dextranase from Thermoanaerobacter pseudethanolicus, D312G mutant in complex with isomaltohexaose
4R1O	;	2.401	;	Crystal Structure of Thermophilic Geobacillus kaustophilus L-Arabinose isomerase
4R1Q	;	2.248	;	Crystal Structure of Thermophilic Geobacillus kaustophilus L-Arabinose isomerase in complex with L-arabitol
4R1P	;	2.297	;	Crystal Structure of Thermophilic Geobacillus kaustophilus L-Arabinose isomerase with Mn2+
3ORW	;	2.4	;	Crystal structure of thermophilic phosphotriesterase from Geobacillus kaustophilus HTA426
6KFQ	;	1.84	;	Crystal structure of thermophilic rhodopsin from Rubrobacter xylanophilus
5AZD	;	2.8	;	Crystal structure of thermophilic rhodopsin.
3CGM	;	2.41	;	Crystal structure of thermophilic SlyD
3CGN	;	2.7	;	Crystal Structure of thermophilic SlyD
5LV9	;	2.33	;	Crystal structure of thermophilic tryptophan halogenase (Th-Hal) enzyme from Streptomycin violaceusniger.
5LVA	;	2.53	;	Crystal structure of thermophilic tryptophan halogenase (Th-Hal) enzyme from Streptomycin violaceusniger.
1L6R	;	1.4	;	Crystal Structure of Thermoplasma acidophilum 0175 (APC0014)
1KYT	;	1.7	;	Crystal Structure of Thermoplasma acidophilum 0175 (APC014)
1NE2	;	1.75	;	Crystal Structure of Thermoplasma acidophilum 1320 (APC5513)
6IS6	;	2.4	;	Crystal structure of Thermoplasmatales archaeon heliorhodopsin
7U55	;	1.97	;	Crystal structure of Thermoplasmatales archaeon heliorhodopsin at pH 4.5
7CLJ	;	2.6	;	Crystal structure of Thermoplasmatales archaeon heliorhodopsin E108D mutant
5NX2	;	3.7	;	Crystal structure of thermostabilised full-length GLP-1R in complex with a truncated peptide agonist at 3.7 A resolution
5O9H	;	2.7	;	Crystal structure of thermostabilised human C5a anaphylatoxin chemotactic receptor 1 (C5aR) in complex with NDT9513727
7ET8	;	1.9	;	Crystal structure of thermostable AbHpaI, a class II metal dependent pyruvate aldolase, HpaI from Acinetobacter baumannii
8HAP	;	2.2	;	Crystal structure of thermostable acetaldehyde dehydrogenase from hyperthermophilic archaeon Sulfolobus tokodaii
4NUR	;	1.761	;	Crystal structure of thermostable alkylsulfatase SdsAP from Pseudomonas sp. S9
2DPP	;	2.52	;	Crystal structure of thermostable Bacillus sp. RAPc8 nitrile hydratase
1NP2	;	2.4	;	Crystal structure of thermostable beta-glycosidase from thermophilic eubacterium Thermus nonproteolyticus HG102
5E3X	;	2.197	;	Crystal structure of thermostable Carboxypeptidase (FisCP) from Fervidobacterium Islandicum AW-1
6A6E	;	2.09	;	Crystal structure of thermostable Cysteine desulfurase (FiSufS) from thermophilic Fervidobacterium Islandicum AW-1
3A57	;	1.5	;	Crystal structure of Thermostable Direct Hemolysin
6A6G	;	2.49	;	Crystal structure of thermostable FiSufS-SufU complex from thermophilic Fervidobacterium Islandicum AW-1
6TB0	;	1.95	;	Crystal structure of thermostable omega transaminase 4-fold mutant from Pseudomonas jessenii
6TB1	;	1.85	;	Crystal structure of thermostable omega transaminase 6-fold mutant from Pseudomonas jessenii
4FMP	;	2.3	;	Crystal structure of thermostable, organic-solvent tolerant lipase from Geobacillus sp. strain ARM
4U0O	;	1.6	;	Crystal structure of Thermosynechococcus elongatus Lipoyl Synthase 2 complexed with MTA and DTT
6OZF	;	1.8	;	Crystal structure of Thermotoga maritima (Tm) Endonuclease V (D110N) in complex with a 12mer DNA containing an inosine followed by a ribo-adenosine
6OZG	;	1.93	;	Crystal structure of Thermotoga maritima (Tm) Endonuclease V (E89Q) in complex with a 12mer DNA containing an inosine followed by a ribo-adenosine
1NC7	;	1.55	;	Crystal Structure of Thermotoga maritima 1070
6TXJ	;	2.17	;	Crystal structure of thermotoga maritima A42V E65D Ferritin
1HL8	;	2.4	;	CRYSTAL STRUCTURE OF THERMOTOGA MARITIMA ALPHA-FUCOSIDASE
1HL9	;	2.25	;	CRYSTAL STRUCTURE OF THERMOTOGA MARITIMA ALPHA-FUCOSIDASE IN COMPLEX WITH A MECHANISM BASED INHIBITOR
1ODU	;	2.8	;	CRYSTAL STRUCTURE OF THERMOTOGA MARITIMA ALPHA-FUCOSIDASE IN COMPLEX WITH FUCOSE
7CTM	;	1.85	;	Crystal structure of Thermotoga maritima alpha-glucuronidase (TM0752) in complex with NADH and D-glucuronic acid
3SFT	;	2.15	;	Crystal structure of Thermotoga maritima CheB methylesterase catalytic domain
5AN6	;	2.403	;	Crystal structure of Thermotoga maritima Csm2
6TXI	;	1.759	;	Crystal structure of thermotoga maritima E65A Ferritin
6TXK	;	2.359	;	Crystal structure of thermotoga maritima E65K Ferritin
6TXL	;	2.099	;	Crystal structure of thermotoga maritima E65Q Ferritin
6TXM	;	2.198	;	Crystal structure of thermotoga maritima E65R Ferritin
3DKT	;	3.104	;	Crystal structure of Thermotoga maritima encapsulin
2X7W	;	2.36	;	Crystal structure of Thermotoga maritima endonuclease IV in the presence of cadmium and zinc
2X7V	;	2.3	;	Crystal structure of Thermotoga maritima endonuclease IV in the presence of zinc
6TXH	;	2.198	;	Crystal structure of thermotoga maritima Ferritin in apo form
6TXN	;	2.01	;	Crystal structure of thermotoga maritima Ferritin in apo form
7DL5	;	2.3	;	Crystal structure of Thermotoga Maritima ferritin mutant at 2.3 Angstrom resolution
4M8A	;	1.502	;	Crystal Structure of Thermotoga maritima FtsH Periplasmic Domain
4Q0F	;	1.948	;	Crystal Structure of Thermotoga maritima FtsH Periplasmic domain
4JC0	;	3.3	;	Crystal structure of Thermotoga maritima holo RimO in complex with pentasulfide, Northeast Structural Genomics Consortium Target VR77
5XUM	;	2.1	;	Crystal structure of Thermotoga maritima holo-[acyl-carrier-protein] synthase (AcpS)
5JTG	;	3.05	;	Crystal structure of Thermotoga maritima mutant D89K/D253K
5JRW	;	3.3	;	Crystal structure of Thermotoga maritima mutant D89R/D253R
2XHC	;	2.45	;	Crystal Structure of Thermotoga maritima N-utilization Substance G (NusG)
3AFH	;	2.0	;	Crystal structure of Thermotoga maritima nondiscriminating glutamyl-tRNA synthetase in complex with a glutamyl-AMP analog
3AKZ	;	2.9	;	Crystal structure of Thermotoga maritima nondiscriminating glutamyl-tRNA synthetase in complex with tRNAGln and a glutamyl-AMP analog
1SG9	;	2.3	;	Crystal structure of Thermotoga maritima protein HEMK, an N5-glutamine methyltransferase
3HR8	;	1.95	;	Crystal Structure of Thermotoga maritima RecA
3PQC	;	1.9	;	Crystal structure of Thermotoga maritima ribosome biogenesis GTP-binding protein EngB (YsxC/YihA) in complex with GDP
1DD5	;	2.55	;	CRYSTAL STRUCTURE OF THERMOTOGA MARITIMA RIBOSOME RECYCLING FACTOR, RRF
1TLU	;	1.55	;	Crystal Structure of Thermotoga maritima S-adenosylmethionine decarboxylase
4AV6	;	4.0	;	Crystal structure of Thermotoga maritima sodium pumping membrane integral pyrophosphatase at 4 A in complex with phosphate and magnesium
5LZQ	;	3.495	;	Crystal structure of Thermotoga maritima sodium pumping membrane integral pyrophosphatase in complex with imidodiphosphate and magnesium, and with bound sodium ion
5LZR	;	4.0	;	Crystal structure of Thermotoga maritima sodium pumping membrane integral pyrophosphatase in complex with tungstate and magnesium
4AV3	;	2.6	;	Crystal structure of Thermotoga Maritima sodium pumping membrane integral pyrophosphatase with metal ions in active site
6N9A	;	2.5	;	Crystal Structure of Thermotoga maritima threonylcarbamoyladenosine biosynthesis complex TsaB2D2E2 bound to ATP and carboxy-AMP
5Y0R	;	3.11	;	Crystal structure of Thermotoga maritima TmcAL (apo, form I)
5Y0T	;	1.9	;	Crystal structure of Thermotoga maritima TmcAL bound with alpha-thio ATP(Form II)
7RK0	;	2.28	;	Crystal structure of Thermovibrio ammonificans THI4
1KU7	;	2.4	;	Crystal Structure of Thermus aquatics RNA Polymerase SigmaA Subunit Region 4 Bound to-35 Element DNA
5JIW	;	1.73	;	Crystal structure of Thermus aquaticus amylomaltase (GH77) in complex with a 34-meric cycloamylose
1HQM	;	3.3	;	CRYSTAL STRUCTURE OF THERMUS AQUATICUS CORE RNA POLYMERASE-INCLUDES COMPLETE STRUCTURE WITH SIDE-CHAINS (EXCEPT FOR DISORDERED REGIONS)-FURTHER REFINED FROM ORIGINAL DEPOSITION-CONTAINS ADDITIONAL SEQUENCE INFORMATION
2ETN	;	3.3	;	Crystal structure of Thermus aquaticus Gfh1
1KU2	;	2.9	;	Crystal Structure of Thermus aquaticus RNA Polymerase Sigma Subunit Fragment Containing Regions 1.2 to 3.1
1KU3	;	1.8	;	Crystal Structure of Thermus aquaticus RNA Polymerase Sigma Subunit Fragment, Region 4
2IE8	;	1.8	;	Crystal structure of Thermus caldophilus phosphoglycerate kinase in the open conformation
4O93	;	2.77	;	Crystal structure of Thermus thermophilis transhydrogeanse domain II dimer
4O9P	;	2.89	;	Crystal structure of Thermus thermophilis transhydrogeanse domain II dimer SeMet derivative
2ZWV	;	2.0	;	Crystal structure of Thermus thermophilus 16S rRNA methyltransferase RsmC (TTHA0533)
2ZUL	;	1.8	;	Crystal structure of Thermus thermophilus 16S rRNA methyltransferase RsmC (TTHA0533) in complex with cofactor S-adenosyl-L-Methionine
4V9I	;	3.3	;	Crystal structure of thermus thermophilus 70S in complex with tRNAs and mRNA containing a pseudouridine in a stop codon
1KWG	;	1.6	;	Crystal structure of Thermus thermophilus A4 beta-galactosidase
1KWK	;	2.2	;	Crystal structure of Thermus thermophilus A4 beta-galactosidase in complex with galactose
7KWD	;	2.1	;	Crystal structure of Thermus thermophilus alkaline phosphatase
5GQ9	;	2.7	;	Crystal structure of Thermus thermophilus Argonaute in complex with g1C siDNA and DNA target
4L5G	;	2.3902	;	Crystal structure of Thermus thermophilus CarD
4XAX	;	2.404	;	Crystal structure of Thermus thermophilus CarD in complex with the Thermus aquaticus RNA polymerase beta1 domain
5C8E	;	3.89	;	Crystal structure of Thermus thermophilus CarH bound to adenosylcobalamin and a 26-bp DNA segment
4EV0	;	2.402	;	Crystal Structure of Thermus thermophilus Catabolite Activator Protein
5FSH	;	2.301	;	Crystal structure of Thermus thermophilus Csm6
1EXM	;	1.7	;	CRYSTAL STRUCTURE OF THERMUS THERMOPHILUS ELONGATION FACTOR TU (EF-TU) IN COMPLEX WITH THE GTP ANALOGUE GPPNHP.
3ANG	;	2.25	;	Crystal structure of Thermus thermophilus FadR in complex with E. coli-derived dodecyl-CoA
3ANP	;	1.95	;	Crystal structure of Thermus thermophilus FadR, a TetR familly transcriptional repressor, in complex with lauroyl-CoA.
7ED6	;	1.9285	;	Crystal structure of Thermus thermophilus FakA ATP-binding domain
1J09	;	1.8	;	Crystal structure of Thermus thermophilus glutamyl-tRNA synthetase complexed with ATP and Glu
1N75	;	1.9	;	Crystal structure of Thermus thermophilus glutamyl-tRNA synthetase complexed with ATP.
1N77	;	2.4	;	Crystal structure of Thermus thermophilus glutamyl-tRNA synthetase complexed with tRNA(Glu) and ATP.
1N78	;	2.1	;	Crystal structure of Thermus thermophilus glutamyl-tRNA synthetase complexed with tRNA(Glu) and glutamol-AMP.
1KH1	;	2.3	;	Crystal Structure of Thermus thermophilus HB8 Argininosuccinate Synthetase
1KH2	;	2.3	;	Crystal Structure of Thermus thermophilus HB8 Argininosuccinate Synthetase in complex with ATP
1J21	;	2.2	;	Crystal Structure of Thermus thermophilus HB8 Argininosuccinate Synthetase in complex with ATP and citrulline
1KH3	;	2.15	;	Crystal Structure of Thermus thermophilus HB8 Argininosuccinate Synthetase in complex with inhibitor
1KOR	;	1.95	;	Crystal Structure of Thermus thermophilus HB8 Argininosuccinate Synthetase in complex with inhibitors
1J20	;	2.0	;	Crystal Structure of Thermus thermophilus HB8 Argininosuccinate Synthetase in complex with product
1J1Z	;	2.1	;	Crystal Structure of Thermus thermophilus HB8 Argininosuccinate Synthetase in complex with substrate
4F3E	;	2.4	;	Crystal Structure of Thermus thermophilus HB8 CasA
1ONL	;	2.5	;	Crystal structure of Thermus thermophilus HB8 H-protein of the glycine cleavage system
2P5U	;	2.37	;	Crystal structure of Thermus thermophilus HB8 UDP-glucose 4-epimerase complex with NAD
2P5Y	;	1.92	;	Crystal structure of Thermus thermophilus HB8 UDP-glucose 4-epimerase complex with NAD
4KJZ	;	2.8	;	Crystal Structure of Thermus Thermophilus IF2, Apo and GDP-bound Forms (2-474)
4KDF	;	2.356	;	Crystal Structure of Thermus thermophilus Malate Dehydrogenase in Complex with NAD
2D5B	;	1.8	;	Crystal Structure of Thermus Thermophilus Methionyl tRNA synthetase Y225F Mutant obtained in the presence of PEG6000
3TEH	;	2.8524	;	Crystal structure of Thermus thermophilus Phenylalanyl-tRNA synthetase complexed with L-dopa
3HFZ	;	2.9	;	Crystal structure of Thermus thermophilus Phenylalanyl-tRNA synthetase complexed with m-tyrosine
4OIO	;	3.1	;	Crystal structure of Thermus thermophilus pre-insertion substrate complex for de novo transcription initiation
5D4E	;	3.08	;	Crystal structure of Thermus thermophilus product complex for transcription initiation with 3'-dephosphate-CoA and CTP
5D4C	;	3.28	;	Crystal structure of Thermus thermophilus product complex for transcription initiation with ATP and CTP
5D4D	;	3.0	;	Crystal structure of Thermus thermophilus product complex for transcription initiation with NAD and CTP
2YWQ	;	2.64	;	Crystal structure of Thermus thermophilus Protein Y N-terminal domain
2CUW	;	2.3	;	Crystal Structure of Thermus thermophilus PurS, one of the subunits of Formylglycinamide Ribonucleotide Amidotransferase in the purine biosynthetic pathway
7MLJ	;	3.75	;	Crystal structure of Thermus thermophilus reiterative transcription complex with 4nt oligo-G RNA
7MLI	;	3.6	;	Crystal structure of Thermus thermophilus reiterative transcription complex with 5nt oligo-C RNA
1UJ4	;	1.8	;	Crystal structure of Thermus thermophilus ribose-5-phosphate isomerase
1UJ6	;	1.74	;	Crystal structure of Thermus thermophilus ribose-5-phosphate isomerase complexed with arabinose-5-phosphate
1UJ5	;	2.0	;	Crystal structure of Thermus thermophilus ribose-5-phosphate isomerase complexed with ribose-5-phosphate
6ASG	;	3.8	;	Crystal structure of Thermus thermophilus RNA polymerase core enzyme
2CW0	;	3.3	;	Crystal structure of Thermus thermophilus RNA polymerase holoenzyme at 3.3 angstroms resolution
4MQ9	;	3.35	;	Crystal structure of Thermus thermophilus RNA polymerase holoenzyme in complex with GE23077
3DXJ	;	3.0	;	Crystal structure of thermus thermophilus rna polymerase holoenzyme in complex with the antibiotic myxopyronin
4OIR	;	3.105	;	Crystal structure of Thermus thermophilus RNA polymerase transcription initiation complex soaked with GE23077 and rifamycin SV
6BAR	;	2.908	;	Crystal structure of Thermus thermophilus Rod shape determining protein RodA (Q5SIX3_THET8)
6BAS	;	3.194	;	Crystal structure of Thermus thermophilus Rod shape determining protein RodA D255A mutant (Q5SIX3_THET8)
2CVK	;	2.0	;	Crystal Structure of Thermus thermophilus Thioredoxin
4TN8	;	2.15	;	Crystal structure of Thermus Thermophilus thioredoxin solved by sulfur SAD using Swiss Light Source data
4G7H	;	2.9	;	Crystal structure of Thermus thermophilus transcription initiation complex
6LTS	;	3.45	;	Crystal structure of Thermus thermophilus transcription initiation complex comprising a truncated sigma finger
4G7O	;	2.993	;	Crystal structure of Thermus thermophilus transcription initiation complex containing 2 nt of RNA
4G7Z	;	3.815	;	Crystal structure of Thermus thermophilus transcription initiation complex containing 5-BrU at template-strand position +1
4OIN	;	2.8	;	Crystal structure of Thermus thermophilus transcription initiation complex soaked with GE23077
4OIQ	;	3.624	;	Crystal structure of Thermus thermophilus transcription initiation complex soaked with GE23077 and rifampicin
4OIP	;	3.4	;	Crystal structure of Thermus thermophilus transcription initiation complex soaked with GE23077, ATP, and CMPcPP
7MLB	;	3.6	;	Crystal structure of Thermus thermophilus transcription initiation complex with 5nt RNA
5X22	;	3.35	;	Crystal structure of Thermus thermophilus transcription initiation complex with GpA and CMPcPP
5X21	;	3.323	;	Crystal structure of Thermus thermophilus transcription initiation complex with GpA and pseudouridimycin (PUM)
4J16	;	2.41	;	Crystal structure of Thermus thermophilus transhydrogenase heterotrimeric complex of the Alpha1 subunit dimer with the NADP binding domain (domain III) of the Beta subunit
4J1T	;	2.37	;	Crystal structure of Thermus thermophilus transhydrogenase heterotrimeric complex of the Alpha1 subunit dimer with the NADP binding domain (domain III) of the Beta subunit in P2(1)
3G5Q	;	2.102	;	Crystal structure of Thermus thermophilus TrmFO
3G5S	;	1.05	;	Crystal structure of Thermus thermophilus TrmFO in complex with glutathione
3G5R	;	1.6	;	Crystal structure of Thermus thermophilus TrmFO in complex with tetrahydrofolate
2CWW	;	2.6	;	Crystal structure of Thermus thermophilus TTHA1280, a putative SAM-dependent RNA methyltransferase, in complex with S-adenosyl-L-homocysteine
1GAX	;	2.9	;	CRYSTAL STRUCTURE OF THERMUS THERMOPHILUS VALYL-TRNA SYNTHETASE COMPLEXED WITH TRNA(VAL) AND VALYL-ADENYLATE ANALOGUE
1IVS	;	2.9	;	CRYSTAL STRUCTURE OF THERMUS THERMOPHILUS VALYL-TRNA SYNTHETASE COMPLEXED WITH TRNA(VAL) AND VALYL-ADENYLATE ANALOGUE
3SUH	;	2.65	;	Crystal structure of THF riboswitch, bound with 5-formyl-THF
3SUX	;	2.9	;	Crystal structure of THF riboswitch, bound with THF
3SUY	;	3.21	;	Crystal structure of THF riboswitch, unbound status
5AXK	;	2.29	;	Crystal structure of Thg1 like protein (TLP)
5AXL	;	2.998	;	Crystal structure of Thg1 like protein (TLP) with GTP
5AXM	;	2.21	;	Crystal structure of Thg1 like protein (TLP) with tRNA(Phe)
5AXN	;	2.703	;	Crystal structure of Thg1 like protein (TLP) with tRNA(Phe) and GDPNP
1TO9	;	2.4	;	Crystal structure of THI-4 protein from Bacillus subtilis
1RP0	;	1.6	;	Crystal Structure of Thi1 protein from Arabidopsis thaliana
3O63	;	2.35	;	Crystal Structure of Thiamin Phosphate Synthase from Mycobacterium tuberculosis
3MEL	;	2.788	;	Crystal Structure of Thiamin pyrophosphokinase family protein from Enterococcus faecalis, Northeast Structural Genomics Consortium Target EfR150
3K94	;	2.101	;	Crystal Structure of Thiamin pyrophosphokinase from Geobacillus thermodenitrificans, Northeast Structural Genomics Consortium Target GtR2
3IHK	;	3.0	;	Crystal Structure of thiamin pyrophosphokinase from S.mutans, Northeast Structural Genomics Consortium Target SmR83
3CWI	;	1.9	;	Crystal structure of thiamine biosynthesis protein (ThiS) from Geobacter metallireducens. Northeast Structural Genomics Consortium Target GmR137
1WV2	;	2.9	;	Crystal structure of thiamine biosynthesis protein from Pseudomonas Aeruginosa
1VQV	;	2.65	;	Crystal Structure of Thiamine Monophosphate Kinase (thil) from Aquifex Aeolicus
3CEU	;	2.3	;	Crystal structure of thiamine phosphate pyrophosphorylase (BT_0647) from Bacteroides thetaiotaomicron. Northeast Structural Genomics Consortium target BtR268
2GDI	;	2.05	;	Crystal structure of thiamine pyrophosphate-specific riboswitch in complex with thiamine pyrophosphate
3LM8	;	2.6	;	Crystal Structure of Thiamine pyrophosphokinase from Bacillus subtilis, Northeast Structural Genomics Consortium Target SR677
3MCQ	;	1.91	;	Crystal structure of Thiamine-monophosphate kinase (Mfla_0573) from METHYLOBACILLUS FLAGELLATUS KT at 1.91 A resolution
6XEP	;	1.8	;	Crystal structure of Thiamine-monophosphate kinase from Stenotrophomonas maltophilia K279a
1ESJ	;	1.8	;	CRYSTAL STRUCTURE OF THIAZOLE KINASE MUTANT (C198S)
1ESQ	;	2.5	;	CRYSTAL STRUCTURE OF THIAZOLE KINASE MUTANT (C198S) WITH ATP AND THIAZOLE PHOSPHATE.
4HCJ	;	1.12	;	Crystal Structure of ThiJ/PfpI Domain Protein from Brachyspira murdochii
3IA1	;	1.76	;	Crystal structure of thio-disulfide isomerase from Thermus thermophilus
5KLO	;	1.79	;	Crystal structure of thioacyl intermediate in 2-aminomuconate 6-semialdehyde dehydrogenase N169A
7C7K	;	1.77	;	Crystal Structure of Thioacyl-Glyceraldehyde-3-phosphate dehydrogenase 1(GAPDH 1) from Escherichia coli at 1.77 Angstrom resolution
3LC2	;	2.8	;	Crystal Structure of Thioacyl-Glyceraldehyde-3-phosphate dehydrogenase 1(GAPDH 1) from methicillin resistant Staphylococcus aureus MRSA252
2ESD	;	2.55	;	Crystal Structure of thioacylenzyme intermediate of an Nadp Dependent Aldehyde Dehydrogenase
3VYG	;	1.72	;	Crystal structure of Thiocyanate hydrolase mutant R136W
2CYE	;	1.9	;	Crystal structure of Thioesterase complexed with coenzyme A and Zn from Thermus thermophilus HB8
3LZ7	;	2.191	;	Crystal Structure of thioesterase HI1161 EC3.1.2.- from Haemophilus influenzae. Orthorombic crystal form. Northeast Structural Genomics Consortium Target IR63
4QD7	;	1.765	;	Crystal structure of Thioesterase PA1618 from Pseudomonas aeruginosa
4QD9	;	1.767	;	Crystal structure of Thioesterase PA1618 from Pseudomonas aeruginosa in complex with benzoyl-dO-CoA
4QD8	;	1.616	;	Crystal structure of Thioesterase PA1618 from Pseudomonas aeruginosa in complex with phenacyl-CoA
2OAF	;	2.0	;	Crystal structure of thioesterase superfamily (YP_508616.1) from Jannaschia sp. CCS1 at 2.00 A resolution
2NUJ	;	2.0	;	Crystal structure of thioesterase superfamily (YP_509914.1) from Jannaschia Sp. CCS1 at 2.00 A resolution
2CY9	;	2.72	;	Crystal structure of thioesterase superfamily member2 from Mus musculus
2PRX	;	1.5	;	Crystal structure of Thioesterase superfamily protein (ZP_00837258.1) from Shewanella loihica PV-4 at 1.65 A resolution
4TLF	;	2.137	;	Crystal structure of Thiol dioxygenase from Pseudomonas aeruginosa
4JE1	;	1.4	;	Crystal structure of thiol peroxidase from BURKHOLDERIA CENOCEPACIA J2315
1XVQ	;	1.75	;	Crystal structure of thiol peroxidase from Mycobacterium tuberculosis
4NMU	;	1.35	;	Crystal Structure of Thiol-disulfide Oxidoreductase from Bacillus str. 'Ames Ancestor'
3OR5	;	1.66	;	Crystal structure of thiol:disulfide interchange protein, thioredoxin family protein from Chlorobium tepidum TLS
8GQF	;	1.8	;	Crystal structure of Thiolase
8GQM	;	1.45	;	Crystal structure of Thiolase complexed with acetyl coenzyme A
4XL4	;	1.9	;	Crystal structure of thiolase from Clostridium acetobutylicum in complex with CoA
4WYS	;	2.1	;	Crystal structure of thiolase from Escherichia coli
8GQK	;	2.15	;	Crystal structure of Thiolase from Pseudomonas aeruginosa PAO1
4WYR	;	2.3	;	Crystal structure of thiolase mutation (V77Q,N153Y,A286K) from Clostridium acetobutylicum
7YVY	;	2.7	;	Crystal structure of thiolase PFC_04095 from Pyrococcus furiosus
8GQG	;	1.8	;	Crystal structure of Thioloase from Pseudomonas aeruginosa PAO1
1KTE	;	2.2	;	CRYSTAL STRUCTURE OF THIOLTRANSFERASE AT 2.2 ANGSTROM RESOLUTION
8H8P	;	2.5	;	Crystal structure of thiomorpholine-carboxylate dehydrogenase from Candida parapsilosis.
2GB4	;	1.25	;	Crystal structure of Thiopurine methyltransferase (18204406) from Mus musculus at 1.35 A resolution
2BZG	;	1.58	;	Crystal structure of thiopurine S-methyltransferase.
7XAO	;	1.45	;	Crystal structure of thioredoxin 1
5JY5	;	1.8	;	Crystal structure of Thioredoxin 1 from Cryptococcus neoformans at 1.8 Angstroms resolution
7YSI	;	1.202	;	Crystal structure of thioredoxin 2
4RUV	;	1.93	;	Crystal structure of thioredoxin 2 from Staphylococcus aureus NCTC8325
3P2A	;	2.195	;	Crystal Structure of Thioredoxin 2 from Yersinia pestis
4GRF	;	1.76	;	Crystal structure of thioredoxin domain of thiol-disulfide oxidoreductase BVU-2223 (Target EFI-501010) from Bacteroides vulgatus
5HR0	;	1.31	;	Crystal structure of thioredoxin E101G mutant
1FAA	;	1.85	;	CRYSTAL STRUCTURE OF THIOREDOXIN F FROM SPINACH CHLOROPLAST (LONG FORM)
1F9M	;	1.86	;	CRYSTAL STRUCTURE OF THIOREDOXIN F FROM SPINACH CHLOROPLAST (SHORT FORM)
3EMX	;	2.25	;	Crystal structure of thioredoxin from Aeropyrum pernix
2TRX	;	1.68	;	CRYSTAL STRUCTURE OF THIOREDOXIN FROM ESCHERICHIA COLI AT 1.68 ANGSTROMS RESOLUTION
6BKV	;	2.35	;	Crystal structure of Thioredoxin from Helicobacter pylori (strain G27)
3HZ4	;	2.3	;	Crystal Structure of Thioredoxin from Methanosarcina mazei
4I8B	;	2.0	;	Crystal Structure of Thioredoxin from Schistosoma Japonicum
2I4A	;	1.0	;	Crystal structure of thioredoxin from the acidophile Acetobacter aceti
1R26	;	1.4	;	Crystal structure of thioredoxin from Trypanosoma brucei brucei
4FYU	;	2.0	;	Crystal structure of Thioredoxin from Wuchereria bancrofti at 2.0 Angstrom
5HR1	;	2.144	;	Crystal structure of thioredoxin L107A mutant
5HR2	;	1.2	;	Crystal structure of thioredoxin L94A mutant
1FB6	;	2.1	;	CRYSTAL STRUCTURE OF THIOREDOXIN M FROM SPINACH CHLOROPLAST (OXIDIZED FORM)
1FB0	;	2.26	;	CRYSTAL STRUCTURE OF THIOREDOXIN M FROM SPINACH CHLOROPLAST (REDUCED FORM)
7C65	;	1.1	;	Crystal structure of thioredoxin m1
2H76	;	2.25	;	Crystal Structure of Thioredoxin Mutant D10E in Hexagonal (p61) Space Group
2H75	;	2.2	;	Crystal Structure of Thioredoxin Mutant D13E in Hexagonal (p61) Space Group
2H74	;	2.4	;	Crystal Structure of Thioredoxin Mutant D2E in Hexagonal (p61) Space Group
2H73	;	2.45	;	Crystal Structure of Thioredoxin Mutant D43E in Hexagonal (p61) Space Group
2H71	;	2.2	;	Crystal Structure of Thioredoxin Mutant D47E in Hexagonal (p61) Space Group
2H70	;	2.7	;	Crystal Structure of Thioredoxin Mutant D9E in Hexagonal (p61) Space Group
2H6Z	;	2.25	;	Crystal Structure of Thioredoxin Mutant E44D in Hexagonal (p61) Space Group
2H6Y	;	2.4	;	Crystal Structure of Thioredoxin Mutant E48D in Hexagonal (p61) Space Group
2H72	;	2.25	;	Crystal Structure of Thioredoxin mutant E85D in Hexagonal (p61) Space Group
2FCH	;	2.6	;	Crystal Structure of Thioredoxin Mutant G74S
1ZZY	;	2.5	;	Crystal Structure of Thioredoxin Mutant L7V
2FD3	;	2.45	;	Crystal Structure of Thioredoxin Mutant P34H
5HR3	;	1.101	;	Crystal structure of thioredoxin N106A mutant
6X0B	;	1.702	;	Crystal Structure of Thioredoxin NaTrxh from Nicotiana alata
6G61	;	1.8	;	Crystal structure of thioredoxin O1 from Arabidopsis thaliana in oxidized state
6G62	;	1.5	;	Crystal structure of thioredoxin O2 from Arabidopsis thaliana in oxidized state
6A4J	;	3.4	;	Crystal structure of Thioredoxin reductase 2 from Staphylococcus aureus
7P0X	;	2.55	;	Crystal structure of Thioredoxin reductase from Brugia Malayi
7PVJ	;	3.1	;	Crystal structure of Thioredoxin Reductase from Brugia Malayi in complex with auranofin
7PUT	;	2.8	;	Crystal structure of Thioredoxin Reductase from Brugia Malayi in complex with NADP(H)
5W4C	;	2.255	;	Crystal structure of thioredoxin reductase from Cryptococcus neoformans in complex with FAD (FO conformation)
2NVK	;	2.4	;	Crystal Structure of Thioredoxin Reductase from Drosophila melanogaster
5UTH	;	1.95	;	Crystal structure of thioredoxin reductase from Mycobacterium smegmatis in complex with FAD
2ZBW	;	2.1	;	Crystal structure of thioredoxin reductase-like protein from Thermus thermophilus HB8
2CVJ	;	2.0	;	Crystal Structure of thioredoxin reductase-related protein TTHA0370 from Thermus thermophilus HB8
2YWL	;	1.6	;	Crystal structure of thioredoxin reductase-related protein TTHA0370 from Thermus thermophilus HB8
6Z7O	;	2.33	;	Crystal structure of Thioredoxin T from Drosophila melanogaster
2H6X	;	2.6	;	Crystal Structure of Thioredoxin Wild Type in Hexagonal (p61) Space Group
2PPT	;	1.92	;	Crystal structure of thioredoxin-2
5UTX	;	2.46	;	Crystal structure of thioredoxin-disulfide reductase from Vibrio vulnificus CMCP6 - apo form
5USX	;	2.603	;	Crystal structure of thioredoxin-disulfide reductase from Vibrio vulnificus CMCP6 in complex with NADP and FAD
4EUY	;	2.9	;	Crystal structure of thioredoxin-like protein BCE_0499 from Bacillus cereus ATCC 10987
3EYT	;	1.95	;	Crystal structure of Thioredoxin-like superfamily protein SPOA0173
1YT8	;	1.9	;	Crystal Structure of Thiosulfate sulfurtransferase from Pseudomonas aeruginosa
6LEO	;	2.52	;	Crystal structure of thiosulfate transporter YeeE from Spirochaeta thermophila
6LEP	;	2.6	;	Crystal structure of thiosulfate transporter YeeE inactive mutant - C91A
4MES	;	2.0	;	Crystal structure of ThiT complexed with LMG116
4MHW	;	2.5	;	Crystal structure of ThiT with small molecule BAT-25
5CYR	;	3.504	;	Crystal structure of Thosea asigna virus RNA-dependent RNA polymerase (RdRP) complexed with ATP and ssRNA
5CX6	;	2.1	;	Crystal structure of Thosea asigna virus RNA-dependent RNA polymerase (RdRP) complexed with CDP
4XHA	;	3.0	;	Crystal structure of Thosea asigna virus RNA-dependent RNA polymerase (RdRP) complexed with Lu3+
2PMH	;	1.9	;	Crystal structure of Thr132Ala of ST1022 from Sulfolobus tokodaii
2EFQ	;	2.3	;	Crystal Structure of Thr134 to Ala of ST1022-Glutamine Complex from Sulfolobus tokodaii 7
2EHL	;	1.6	;	Crystal structure of Thr146 to Arg mutant of Diphthine synthase
7LM3	;	2.7	;	Crystal Structure of Thr316Ala mutant of JAMM domain of S. pombe
6K2U	;	2.554	;	Crystal structure of Thr66 ADP-ribosylated ubiquitin
1V07	;	1.7	;	CRYSTAL STRUCTURE OF ThrE11Val mutant of THE NERVE TISSUE MINI-HEMOGLOBIN FROM THE NEMERTEAN WORM CEREBRATULUS LACTEUS
1KLO	;	2.1	;	CRYSTAL STRUCTURE OF THREE CONSECUTIVE LAMININ-TYPE EPIDERMAL GROWTH FACTOR-LIKE (LE) MODULES OF LAMININ GAMMA1 CHAIN HARBORING THE NIDOGEN BINDING SITE
6LN0	;	2.455	;	Crystal structure of three main domains of nonstructural protein 3 from Coronavirus
6TO1	;	1.8	;	Crystal structure of three N-terminal domains of the type V pili tip protein Mfa5 from Porphyromonas gingivalis
6F1Q	;	2.3	;	Crystal structure of three-domain heme-Cu nitrite reductase from Ralstonia pickettii in I213 space group
2DQ4	;	2.5	;	Crystal structure of threonine 3-dehydrogenase
2EJV	;	2.55	;	Crystal structure of threonine 3-dehydrogenase complexed with NAD+
1M6S	;	1.8	;	Crystal Structure Of Threonine Aldolase
1JG8	;	1.8	;	Crystal Structure of Threonine Aldolase (Low-specificity)
7W0I	;	1.75	;	Crystal structure of threonine aldolase from Mycobacterium vanbaalenii
3V7N	;	1.4	;	Crystal structure of Threonine synthase (thrC) from from Burkholderia thailandensis
2ZSJ	;	1.8	;	Crystal structure of threonine synthase from Aquifex aeolicus VF5
2C2G	;	2.61	;	Crystal structure of Threonine Synthase from Arabidopsis thaliana in complex with its cofactor pyridoxal phosphate
1VB3	;	2.2	;	Crystal Structure of Threonine Synthase from Escherichia coli
1V7C	;	2.0	;	Crystal structure of threonine synthase from thermus thermophilus hb8 in complex with a substrate analogue
1UIM	;	2.15	;	Crystal Structure of Threonine Synthase from Thermus Thermophilus HB8, Orthorhombic Crystal Form
1UIN	;	2.25	;	Crystal Structure of Threonine Synthase from Thermus Thermophilus HB8, Trigonal Crystal Form
1KL7	;	2.7	;	Crystal Structure of Threonine Synthase from Yeast
3C20	;	2.7	;	Crystal Structure of Threonine-sensitive Aspartokinase from Methanococcus jannaschii with L-aspartate
7CBG	;	2.5	;	Crystal structure of threonyl-tRNA synthetase (ThrRS) from Salmonella enterica in complex with an inhibitor
7CBH	;	1.95	;	Crystal structure of threonyl-tRNA synthetase (ThrRS) from Salmonella enterica in complex with an inhibitor
7CBI	;	1.59	;	Crystal structure of threonyl-tRNA synthetase (ThrRS) from Salmonella enterica in complex with an inhibitor
6VU9	;	2.2	;	Crystal structure of threonyl-tRNA synthetase (ThrRS) from Stenotrophomonas maltophilia K279a
1RKU	;	1.47	;	Crystal Structure of ThrH gene product of Pseudomonas Aeruginosa
3DGV	;	2.5	;	Crystal structure of thrombin activatable fibrinolysis inhibitor (TAFI)
5E8E	;	1.9	;	Crystal structure of thrombin bound to an exosite 1-specific IgA Fab
1XMN	;	1.85	;	Crystal structure of thrombin bound to heparin
6GWE	;	2.3	;	Crystal structure of Thrombin bound to P2 macrocycle
4DT7	;	1.9	;	Crystal structure of thrombin bound to the activation domain QEDQVDPRLIDGKMTRRGDS of protein C
3BEF	;	2.2	;	Crystal structure of thrombin bound to the extracellular fragment of PAR1
1QBV	;	1.8	;	CRYSTAL STRUCTURE OF THROMBIN COMPLEXED WITH AN GUANIDINE-MIMETIC INHIBITOR
1JWT	;	2.5	;	CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH A NOVEL BICYCLIC LACTAM INHIBITOR
6EO8	;	1.94	;	Crystal structure of thrombin in complex with a novel glucose-conjugated potent inhibitor
6EO9	;	1.84	;	Crystal structure of thrombin in complex with a novel glucose-conjugated potent inhibitor
1TA2	;	2.3	;	Crystal structure of thrombin in complex with compound 1
1TA6	;	1.9	;	Crystal structure of thrombin in complex with compound 14b
6ZUG	;	1.8	;	Crystal Structure of Thrombin in complex with compound10
6ZUH	;	1.7	;	Crystal Structure of Thrombin in complex with compound17
6ZUN	;	1.793	;	Crystal Structure of Thrombin in complex with compound20a
6ZUU	;	1.94	;	Crystal structure of Thrombin in complex with compound30
6ZUW	;	2.0	;	Crystal Structure of Thrombin in complex with compound40
6ZUX	;	1.94	;	Crystal Structure of Thrombin in complex with compound42a
6ZV7	;	1.94	;	Crystal Structure of Thrombin in complex with compound42b
6ZV8	;	1.7	;	Crystal Structure of Thrombin in complex with compound51
2HWL	;	2.4	;	Crystal structure of thrombin in complex with fibrinogen gamma' peptide
3DA9	;	1.8	;	Crystal structure of thrombin in complex with inhibitor
3C1K	;	1.84	;	Crystal structure of thrombin in complex with inhibitor 15
1MU6	;	1.99	;	Crystal Structure of Thrombin in Complex with L-378,622
6T7H	;	2.32	;	Crystal structure of Thrombin in complex with macrocycle N14-PR4-A
8ASF	;	2.58	;	Crystal structure of Thrombin in complex with macrocycle T1
8ASE	;	2.55	;	Crystal structure of Thrombin in complex with macrocycle T3
6Z48	;	2.27	;	Crystal structure of Thrombin in complex with macrocycle X1vE
4H6S	;	2.19	;	Crystal structure of thrombin mutant E14eA/D14lA/E18A/S195A
4RKJ	;	1.7	;	Crystal structure of thrombin mutant S195T (free form)
4RKO	;	1.84	;	Crystal structure of thrombin mutant S195T bound with PPACK
5TO3	;	2.34	;	Crystal structure of thrombin mutant W215A/E217A fused to EGF456 of thrombomodulin via a 31-residue linker and bound to PPACK
3D66	;	3.1	;	Crystal structure of Thrombin-Activatable Fibrinolysis Inhibitor (TAFI)
3D67	;	3.4	;	Crystal structure of Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) in complex with 2-guanidino-ethyl-mercaptosuccinic acid (GEMSA)
5HVG	;	3.05	;	Crystal Structure of Thrombin-activatable Fibrinolysis Inhibitor in Complex with an Inhibitory Nanobody (VHH-a204)
5HVF	;	2.85	;	Crystal Structure of Thrombin-activatable Fibrinolysis Inhibitor in Complex with an Inhibitory Nanobody (VHH-i83)
5HVH	;	3.0	;	Crystal Structure of Thrombin-activatable Fibrinolysis Inhibitor in Complex with two Inhibitory Nanobodies
5GIM	;	2.09	;	Crystal structure of thrombin-avathrin complex
3B23	;	2.4	;	Crystal structure of thrombin-variegin complex: Insights of a novel mechanism of inhibition and design of tunable thrombin inhibitors
2ES3	;	1.85	;	Crystal Structure of Thrombospondin-1 N-terminal Domain in P1 Form at 1.85A Resolution
3R6B	;	2.4	;	Crystal Structure of Thrombospondin-1 TSR Domains 2 and 3
6LHX	;	2.501	;	Crystal structure of ThsA
6LHY	;	1.796	;	Crystal structure of ThsB
4OQL	;	2.1	;	Crystal structure of thymidine kinase from herpes simplex virus type 1 in complex with dF-EdU
4OQN	;	2.3	;	Crystal structure of thymidine kinase from herpes simplex virus type 1 in complex with EdU
4OQM	;	2.2	;	Crystal structure of thymidine kinase from herpes simplex virus type 1 in complex with F-ARA-EdU
4JBY	;	2.0	;	Crystal structure of thymidine kinase from Herpes simplex virus type 1 in complex with F-SK78
4IVQ	;	1.9	;	Crystal structure of thymidine kinase from Herpes simplex virus type 1 in complex with IN43/5
4IVP	;	2.1	;	Crystal structure of thymidine kinase from herpes simplex virus type 1 in complex with IN51/20
4IVR	;	2.4	;	Crystal structure of thymidine kinase from herpes simplex virus type 1 in complex with IN52/10
4OQX	;	2.5	;	Crystal structure of thymidine kinase from herpes simplex virus type 1 in complex with Me-ARA-EdU
3F0T	;	2.0	;	Crystal structure of thymidine kinase from Herpes simplex virus type 1 in complex with N-methyl-DHBT
3RDP	;	2.8	;	Crystal structure of thymidine kinase from herpes simplex virus type 1 in complex with N-METHYL-FHBT
4JBX	;	2.1	;	Crystal structure of thymidine kinase from Herpes simplex virus type 1 in complex with SK-78
1KI4	;	2.34	;	CRYSTAL STRUCTURE OF THYMIDINE KINASE FROM HERPES SIMPLEX VIRUS TYPE I COMPLEXED WITH 5-BROMOTHIENYLDEOXYURIDINE
1KI8	;	2.2	;	CRYSTAL STRUCTURE OF THYMIDINE KINASE FROM HERPES SIMPLEX VIRUS TYPE I COMPLEXED WITH 5-BROMOVINYLDEOXYURIDINE
1KI7	;	2.2	;	CRYSTAL STRUCTURE OF THYMIDINE KINASE FROM HERPES SIMPLEX VIRUS TYPE I COMPLEXED WITH 5-IODODEOXYURIDINE
1KI6	;	2.37	;	CRYSTAL STRUCTURE OF THYMIDINE KINASE FROM HERPES SIMPLEX VIRUS TYPE I COMPLEXED WITH A 5-IODOURACIL ANHYDROHEXITOL NUCLEOSIDE
1KIM	;	2.14	;	CRYSTAL STRUCTURE OF THYMIDINE KINASE FROM HERPES SIMPLEX VIRUS TYPE I COMPLEXED WITH DEOXYTHYMIDINE
1KI2	;	2.2	;	CRYSTAL STRUCTURE OF THYMIDINE KINASE FROM HERPES SIMPLEX VIRUS TYPE I COMPLEXED WITH GANCICLOVIR
1KI3	;	2.37	;	CRYSTAL STRUCTURE OF THYMIDINE KINASE FROM HERPES SIMPLEX VIRUS TYPE I COMPLEXED WITH PENCICLOVIR
3E2I	;	2.01	;	Crystal structure of Thymidine Kinase from S. aureus
2B8T	;	2.0	;	Crystal structure of Thymidine Kinase from U.urealyticum in complex with thymidine
2UZ3	;	2.5	;	Crystal Structure of Thymidine Kinase with dTTP from U. urealyticum
2PBR	;	1.96	;	Crystal structure of thymidylate kinase (aq_969) from Aquifex Aeolicus VF5
3V9P	;	1.9	;	Crystal structure of Thymidylate kinase from Burkholderia thailandensis
3LD9	;	2.15	;	Crystal structure of thymidylate kinase from Ehrlichia chaffeensis at 2.15A resolution
4GSY	;	1.71	;	Crystal structure of thymidylate kinase from Staphylococcus aureus bound to inhibitor.
4F4I	;	2.45	;	Crystal structure of Thymidylate Kinase from Staphylococcus aureus in apo-form
4MQB	;	1.55	;	Crystal structure of thymidylate kinase from Staphylococcus aureus in complex with 2-(N-morpholino)ethanesulfonic acid
4EAQ	;	1.85	;	Crystal structure of Thymidylate Kinase from Staphylococcus aureus in complex with 3'-Azido-3'-Deoxythymidine-5'-Monophosphate
4DWJ	;	2.74	;	Crystal structure of Thymidylate Kinase from Staphylococcus aureus in complex with Thymidine Monophosphate
5X7J	;	1.84	;	Crystal structure of thymidylate kinase from thermus thermophilus HB8
5ZB0	;	1.19	;	Crystal structure of thymidylate kinase in complex with ADP and TDP from thermus thermophilus HB8
5ZB4	;	1.92	;	Crystal structure of thymidylate kinase in complex with ADP and TMP from thermus thermophilus HB8
5ZAX	;	2.36	;	Crystal structure of thymidylate kinase in complex with ADP, TDP and TMP from thermus thermophilus HB8
3HJN	;	2.1	;	Crystal structure of thymidylate kinase in complex with dTDP and ADP from Thermotoga maritima
7FGQ	;	1.91	;	Crystal structure of Thymidylate kinase with TMP and its low-resolution (SAXS) solution structure from Brugia malayi
3KGB	;	2.2	;	Crystal structure of thymidylate synthase 1/2 from Encephalitozoon cuniculi at 2.2 A resolution
1B02	;	2.5	;	CRYSTAL STRUCTURE OF THYMIDYLATE SYNTHASE A FROM BACILLUS SUBTILIS
1O24	;	2.0	;	Crystal structure of Thymidylate Synthase Complementing Protein (TM0449) from Thermotoga maritima at 2.0 A resolution
1O25	;	2.4	;	Crystal structure of Thymidylate Synthase Complementing Protein (TM0449) from Thermotoga maritima with dUMP at 2.4 A resolution
1O27	;	2.3	;	Crystal structure of Thymidylate Synthase Complementing Protein (TM0449) from Thermotoga maritima with FAD and BrdUMP at 2.3 A resolution
1O26	;	1.6	;	Crystal structure of Thymidylate Synthase Complementing Protein (TM0449) from Thermotoga maritima with FAD and dUMP at 1.6 A resolution
1O29	;	2.0	;	Crystal structure of Thymidylate Synthase Complementing Protein (TM0449) from Thermotoga maritima with FAD and FdUMP at 2.0 A resolution
1O2B	;	2.45	;	Crystal structure of Thymidylate Synthase Complementing Protein (TM0449) from Thermotoga maritima with FAD and PO4 at 2.45 A resolution
1O2A	;	1.8	;	Crystal structure of Thymidylate Synthase Complementing Protein (TM0449) from Thermotoga maritima with FAD at 1.8 A resolution
1O28	;	2.1	;	Crystal structure of Thymidylate Synthase Complementing Protein (TM0449) from Thermotoga maritima with FdUMP at 2.1 A resolution
7TA9	;	1.5	;	Crystal Structure of thymidylate synthase from Acinetobacter baumannii
3V8H	;	1.65	;	Crystal structure of Thymidylate Synthase from Burkholderia thailandensis
4H0R	;	2.3	;	Crystal structure of thymidylate synthase from Corynebacterium glutamicum
4H0U	;	2.75	;	Crystal structure of thymidylate synthase from Corynebacterium glutamicum in complex with dUMP
6AUJ	;	1.7	;	Crystal structure of thymidylate synthase from Elizabethkingia anophelis NUHP1
1F28	;	1.9	;	CRYSTAL STRUCTURE OF THYMIDYLATE SYNTHASE FROM PNEUMOCYSTIS CARINII BOUND TO DUMP AND BW1843U89
6K7Q	;	2.27	;	Crystal structure of thymidylate synthase from shrimp
6K7R	;	1.54	;	Crystal structure of thymidylate synthase from shrimp
6K7S	;	1.56	;	Crystal structure of thymidylate synthase from shrimp
1TIS	;	2.7	;	CRYSTAL STRUCTURE OF THYMIDYLATE SYNTHASE FROM T4 PHAGE
1AIQ	;	2.2	;	CRYSTAL STRUCTURE OF THYMIDYLATE SYNTHASE R126E MUTANT
1AJM	;	2.4	;	CRYSTAL STRUCTURE OF THYMIDYLATE SYNTHASE R126E MUTANT
3BNZ	;	2.6	;	Crystal structure of Thymidylate Synthase ternary complex with dUMP and 8A inhibitor
3IX6	;	2.2	;	Crystal structure of Thymidylate synthase thyA from Brucella melitensis
3N3Y	;	2.307	;	Crystal structure of Thymidylate Synthase X (ThyX) from Helicobacter pylori with FAD and dUMP at 2.31A resolution
6J61	;	2.5	;	Crystal Structure of Thymidylate Synthase, Thy1, from Thermus thermophilus having an Extra C Terminal Domain
5OX2	;	2.24	;	Crystal structure of thymoligase, a substrate-tailored peptiligase variant
2XN5	;	1.7	;	Crystal structure of thyroxine-binding globulin complexed with Furosemide
2XN3	;	2.09	;	Crystal structure of thyroxine-binding globulin complexed with mefenamic acid
2XN6	;	1.29	;	Crystal structure of thyroxine-binding globulin complexed with thyroxine-fluoresein
2XN7	;	1.43	;	Crystal structure of thyroxine-binding globulin complexed with thyroxine-fluoresein (T405-CF)
6ELD	;	2.485	;	Crystal structure of TIA-1 RRM1 in complex with U1C
5O3J	;	2.97	;	Crystal structure of TIA-1 RRM2 in complex with RNA
4Q1Q	;	2.11	;	Crystal structure of TibC-catalyzed hyper-glycosylated TibA55-350 fragment
1D0D	;	1.62	;	CRYSTAL STRUCTURE OF TICK ANTICOAGULANT PROTEIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR
8W5Z	;	1.55	;	Crystal structure of tick tyrosylprotein sulfotransferase reveals the activation mechanism of tick anticoagulant protein madanin
7D6M	;	1.894	;	Crystal structure of tick-borne encephalitis virus methyltransferase
7D6N	;	3.168	;	Crystal structure of tick-borne encephalitis virus RNA-dependent RNA polymerase
5N06	;	2.501	;	Crystal structure of Tie1 Fibronectin-like domain 3
6MWE	;	2.05	;	CRYSTAL STRUCTURE OF TIE2 IN COMPLEX WITH DECIPERA COMPOUND DP1919
7E72	;	2.094	;	Crystal structure of Tie2-agonistic antibody in complex with human Tie2 Fn2-3
5F6H	;	2.66	;	Crystal Structure of Tier 2 Neutralizing Antibody DH427 from a Rhesus Macaque
5F6J	;	6.63	;	Crystal Structure of Tier 2 Neutralizing Antibody DH427 from a Rhesus Macaque in Complex with HIV-1 gp120 Core
5F6I	;	2.32	;	Crystal Structure of Tier 2 Neutralizing Antibody DH428 from a Rhesus Macaque
5M3Q	;	1.5	;	Crystal structure of Tif6 from Chaetomium thermophilum
7EPV	;	1.78	;	Crystal structure of tigecycline degrading monooxygenase Tet(X4)
8JEL	;	2.45	;	Crystal structure of TIGIT in complexed with Ociperlimab, crystal form I
8JEN	;	2.71	;	Crystal structure of TIGIT in complexed with Ociperlimab, crystal form II
8JEO	;	2.06	;	Crystal structure of TIGIT in complexed with Tiragolumab
3HJ7	;	2.2	;	Crystal structure of TILS C-terminal domain
3A2K	;	3.65	;	Crystal structure of TilS complexed with tRNA
2E21	;	2.7	;	Crystal structure of TilS in a complex with AMPPNP from Aquifex aeolicus.
5TQL	;	1.9	;	Crystal structure of TIM-Barrel protein HisF-C9S
3A3C	;	2.5	;	Crystal structure of TIM40/MIA40 fusing MBP, C296S and C298S mutant
2ZXT	;	3.0	;	Crystal structure of Tim40/MIA40, a disulfide relay system in mitochondria, solved as MBP fusion protein
4XHW	;	2.85	;	Crystal structure of Timeless_PAB domain in SeMet-labelled form
4XHT	;	1.651	;	Crystal structure of Timeless_PAB domain native form
7KYW	;	2.3	;	Crystal structure of timothy grass allergen Phl p 12.0101 reveals an unusual profilin dimer
3ITW	;	2.15	;	Crystal structure of TioX from Micromonospora sp. ML1
3GJ9	;	2.8	;	crystal structure of TIP-1 in complex with c-terminal of Kir2.3
3DJ1	;	1.8	;	crystal structure of TIP-1 wild type
3VNC	;	2.6	;	Crystal Structure of TIP-alpha N25 from Helicobacter Pylori in its natural dimeric form
2WCQ	;	1.9	;	Crystal Structure of Tip-Alpha N34 (HP0596) from Helicobacter pylori at pH4
2WCR	;	1.7	;	Crystal Structure of Tip-Alpha N34 (HP0596) from Helicobacter pylori at pH8
3F4M	;	1.696	;	Crystal structure of TIPE2
4Q9V	;	2.3	;	Crystal structure of TIPE3
5D9G	;	2.15	;	Crystal structure of TIPRL, TOR signaling pathway regulator-like, in complex with peptide
3JRN	;	2.0	;	Crystal structure of TIR domain from Arabidopsis Thaliana
4OM7	;	2.204	;	Crystal structure of TIR domain of TLR6
8JEQ	;	1.96	;	Crystal structure of Tiragolumab
1JPS	;	1.85	;	Crystal structure of tissue factor in complex with humanized Fab D3h44
1J9C	;	2.9	;	Crystal Structure of tissue factor-factor VIIa complex
3QP3	;	1.997	;	Crystal structure of titin domain M4, tetragonal form
6HCI	;	2.12	;	Crystal structure of titin M3 domain
5Z5A	;	1.8	;	Crystal structure of Tk-PTP in the active form
5Z5B	;	2.3	;	Crystal structure of Tk-PTP in the G95A mutant form
5Z59	;	1.703	;	Crystal structure of Tk-PTP in the inactive form
1X1P	;	2.8	;	Crystal structure of Tk-RNase HII(1-197)-A(28-42)
2DFE	;	2.4	;	Crystal structure of Tk-RNase HII(1-200)-C
2DFF	;	2.7	;	Crystal structure of Tk-RNase HII(1-204)-C
2DFH	;	2.27	;	Crystal structure of Tk-RNase HII(1-212)-C
3N92	;	2.89	;	Crystal structure of TK1436, a GH57 branching enzyme from hyperthermophilic archaeon Thermococcus kodakaraensis, in complex with glucose
3N98	;	1.87	;	Crystal structure of TK1436, a GH57 branching enzyme from hyperthermophilic archaeon Thermococcus kodakaraensis, in complex with glucose and additives
4PRP	;	2.5	;	Crystal structure of TK3 TCR-HLA-B*35:01-HPVG-Q5 complex
4PRI	;	2.4	;	Crystal structure of TK3 TCR-HLA-B*35:08-HPVG complex
4PRH	;	2.5	;	Crystal structure of TK3 TCR-HLA-B*35:08-HPVG-D5 complex
7VNX	;	1.801	;	Crystal structure of TkArkI
5E7R	;	2.11	;	Crystal structure of TL10-81 bound to TAK1-TAB1
5JH6	;	2.365	;	Crystal structure of TL10-92 bound to TAK1-TAB1
5J8I	;	2.404	;	Crystal structure of TL11-113 bound to TAK1-TAB1
5JK3	;	2.371	;	Crystal structure of TL11-128 bound to TAK1-TAB1
2O0O	;	3.0	;	Crystal structure of TL1A
2RE9	;	2.1	;	Crystal structure of TL1A at 2.1 A
6NVT	;	2.2	;	Crystal structure of TLA-1 extended spectrum Beta-lactamase
6NVU	;	2.5	;	Crystal structure of TLA-1 extended spectrum Beta-lactamase in complex with Clavulanic Acid
6PQ9	;	2.191	;	Crystal Structure of TLA-1 S70G extended spectrum Beta-lactamase
6PQ8	;	2.2	;	Crystal structure of TLA-1 S70G extended spectrum Beta-lactamase in complex with clavulanic acid
5GS8	;	1.59	;	Crystal structure of TLA-3 extended-spectrum beta-lactamase
5GWA	;	1.59	;	Crystal structure of TLA-3 extended-spectrum beta-lactamase in a complex with avibactam
5X5G	;	2.0	;	Crystal structure of TLA-3 extended-spectrum beta-lactamase in a complex with OP0595
6J6A	;	2.353	;	Crystal structure of TldE from Thermococcus kodakarensis
7UMA	;	1.6	;	Crystal structure of Tlde1a from Salmonella Typhimurium
4OM2	;	4.0	;	Crystal structure of TLE1 N-terminal Q-domain residues 1-156
6J82	;	2.202	;	Crystal structure of TleB apo
6J84	;	2.0	;	Crystal structure of TleB with hydroxyl analog
6J83	;	1.9	;	Crystal structure of TleB with NMVT
6XZ4	;	2.3	;	Crystal structure of TLNRD1
6XZ3	;	2.19	;	Crystal structure of TLNRD1 4-helix bundle
4Z0C	;	2.3	;	Crystal structure of TLR13-ssRNA13 complex
3A7C	;	2.4	;	Crystal structure of TLR2-PE-DTPA complex
3A7B	;	2.53	;	Crystal structure of TLR2-Streptococcus Pneumoniae lipoteichoic acid complex
3A79	;	2.9	;	Crystal structure of TLR2-TLR6-Pam2CSK4 complex
6LVX	;	2.77	;	Crystal structure of TLR7/Cpd-1 (SM-374527) complex
6LVY	;	2.6	;	Crystal structure of TLR7/Cpd-2 (SM-360320) complex
6LVZ	;	2.83	;	Crystal structure of TLR7/Cpd-3 (SM-394830) complex
6LW0	;	2.6	;	Crystal structure of TLR7/Cpd-6 (DSR-139293) complex
7YTX	;	2.9	;	Crystal structure of TLR8 in complex with its antagonist
4J4M	;	1.8	;	Crystal structure of TM-1, a Trimeresurus mucrosquamatus venom metalloproteinase
3S86	;	2.15	;	Crystal Structure of TM0159 with bound IMP
3FMS	;	2.2	;	Crystal structure of TM0439, a GntR transcriptional regulator
3RRE	;	2.15	;	Crystal Structure of tm0922, a fusion of a domain of unknown function and ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Thermotoga maritima in complex with ADP
3RT7	;	2.1	;	Crystal structure of tm0922, a fusion of a domain of unknown function and ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Thermotoga maritima in complex with ADP-glucose
3RS8	;	2.1	;	Crystal structure of tm0922, a fusion of a domain of unknown function and ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Thermotoga maritima in complex with ADP-ribose
3RRB	;	2.4	;	Crystal structure of tm0922, a fusion of a domain of unknown function and ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Thermotoga maritima in complex with AMP
3RRF	;	2.1	;	Crystal structure of tm0922, a fusion of a domain of unknown function and ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Thermotoga maritima in complex with ATP
3RS9	;	2.103	;	Crystal structure of tm0922, a fusion of a domain of unknown function and ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Thermotoga maritima in complex with P1,P3-Di(adenosine-5') triphosphate
3RSF	;	2.3	;	Crystal structure of tm0922, a fusion of a domain of unknown function and ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Thermotoga maritima in complex with P1,P4-Di(adenosine-5') tetraphosphate
3RRJ	;	2.5	;	Crystal structure of tm0922, a fusion of a domain of unknown function and ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Thermotoga maritima in complex with P1,P5-Di(adenosine-5') pentaphosphate
3RTA	;	1.95	;	Crystal structure of tm0922, a fusion of a domain of unknown function and ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Thermotoga maritima soaked with Acetyl Coenzyme A
3RTB	;	2.1	;	Crystal structure of tm0922, a fusion of a domain of unknown function and ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Thermotoga maritima soaked with Adenosine-3'-5'-Diphosphate
3RT9	;	1.952	;	Crystal structure of tm0922, a fusion of a domain of unknown function and ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Thermotoga maritima soaked with Coenzyme A
3RTG	;	2.052	;	Crystal structure of tm0922, a fusion of a domain of unknown function and ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Thermotoga maritima soaked with Coenzyme A and ATP
3RTC	;	2.101	;	Crystal structure of tm0922, a fusion of a domain of unknown function and ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Thermotoga maritima soaked with NAD and ATP.
3RSG	;	2.1	;	Crystal structure of tm0922, a fusion of a domain of unknown function and ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Thermotoga maritima soaked with NAD.
3RSQ	;	2.054	;	Crystal structure of tm0922, a fusion of a domain of unknown function and ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Thermotoga maritima soaked with NADH
3RTD	;	2.3	;	Crystal structure of tm0922, a fusion of a domain of unknown function and ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Thermotoga maritima soaked with NADH and ADP.
3RSS	;	1.953	;	Crystal structure of tm0922, a fusion of a domain of unknown function and ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Thermotoga maritima soaked with NADP
3RTE	;	2.1	;	Crystal structure of tm0922, a fusion of a domain of unknown function and ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Thermotoga maritima soaked with NADP and ATP.
3RU3	;	2.605	;	Crystal structure of tm0922, a fusion of a domain of unknown function and ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Thermotoga maritima soaked with NADPH and ATP.
3RU2	;	2.2	;	Crystal structure of tm0922, a fusion of a domain of unknown function and ADP/ATP-dependent NAD(P)H-hydrate dehydratase from Thermotoga maritima soaked with NADPH.
3DCL	;	2.25	;	Crystal structure of TM1086
3N99	;	2.38	;	Crystal structure of TM1086
3E57	;	1.89	;	Crystal structure of Tm1382, a putative Nudix hydrolase
1S12	;	2.0	;	Crystal structure of TM1457
8RI0	;	1.95	;	Crystal structure of Tm1570 domain from Calditerrivibrio nitroreducens in complex with S-adenosyl-L-methionine
5TVD	;	1.734	;	Crystal structure of Tm16
1P8C	;	2.3	;	Crystal structure of TM1620 (APC4843) from Thermotoga maritima
1H2H	;	2.6	;	Crystal structure of TM1643
3H3E	;	2.749	;	Crystal structure of Tm1679, A METAL-DEPENDENT HYDROLASE OF THE BETA-LACTAMASE SUPERFAMILY
3N0U	;	1.5	;	Crystal structure of Tm1821, the 8-oxoguanine DNA glycosylase of Thermotoga maritima
3HD0	;	2.7	;	Crystal structure of Tm1865, an Endonuclease V from Thermotoga Maritima
6Y16	;	1.7	;	CRYSTAL STRUCTURE OF TMARGBP DOMAIN 1 IN COMPLEX WITH THE GUANIDINIUM ION
2GWO	;	2.4	;	crystal structure of TMDP
7DYA	;	2.197	;	Crystal structure of TmFtn with calcium ions
6KBW	;	1.686	;	Crystal structure of Tmm from Myroides profundi D25
7D4K	;	1.8	;	Crystal structure of Tmm from Pelagibacter sp. strain HTCC7211
7D4N	;	1.999	;	Crystal structure of Tmm from strain HTCC7211 soaked with DMS for 20 min
7D4M	;	1.786	;	Crystal structure of Tmm from strain HTCC7211 soaked with DMS for 5 min
5X86	;	1.19	;	Crystal structure of TMP bound thymidylate kinase from thermus thermophilus HB8
6NW5	;	1.7	;	Crystal structure of TmPep1050 aminopeptidase with its metal cofactors
8HD8	;	2.4	;	Crystal structure of TMPRSS2 in complex with 212-148
7Y0E	;	2.39	;	Crystal structure of TMPRSS2 in complex with Camostat
7XYD	;	2.58	;	Crystal structure of TMPRSS2 in complex with Nafamostat
7Y0F	;	2.6	;	Crystal structure of TMPRSS2 in complex with UK-371804
5KC0	;	3.2001	;	Crystal structure of TmRibU, hexagonal crystal form
5KBW	;	2.6093	;	Crystal structure of TmRibU, the riboflavin-binding S subunit from the Thermotoga maritima ECF transporter
7CKH	;	1.79493	;	Crystal structure of TMSiPheRS
7CKG	;	2.053	;	Crystal structure of TMSiPheRS complexed with TMSiPhe
2QGQ	;	2.0	;	Crystal structure of TM_1862 from Thermotoga maritima. Northeast Structural Genomics Consortium target VR77
4RV0	;	1.998	;	Crystal structure of TN complex
3ECP	;	2.5	;	Crystal Structure Of Tn5 Transposase Complexed With 5' Phosphorylated Transposon End DNA
1MM8	;	2.8	;	Crystal structure of Tn5 Transposase complexed with ME DNA
1MUS	;	1.9	;	crystal structure of Tn5 transposase complexed with resolved outside end DNA
1MUH	;	2.3	;	CRYSTAL STRUCTURE OF TN5 TRANSPOSASE COMPLEXED WITH TRANSPOSON END DNA
1ZK7	;	1.6	;	Crystal Structure of Tn501 MerA
1ZX9	;	1.9	;	Crystal Structure of Tn501 MerA
3IT8	;	2.8	;	Crystal structure of TNF alpha complexed with a poxvirus MHC-related TNF binding protein
4G3Y	;	2.6	;	Crystal structure of TNF-alpha in complex with Infliximab Fab fragment
2AZ5	;	2.1	;	Crystal Structure of TNF-alpha with a small molecule inhibitor
3ALQ	;	3.0	;	Crystal structure of TNF-TNFR2 complex
3WD5	;	3.101	;	Crystal structure of TNFalpha in complex with Adalimumab Fab fragment
6X83	;	2.83	;	Crystal Structure of TNFalpha with fragment compound 6
6X86	;	2.93	;	Crystal Structure of TNFalpha with indolinone compound 11
6X85	;	2.85	;	Crystal Structure of TNFalpha with indolinone compound 9
6X81	;	2.81	;	Crystal Structure of TNFalpha with isoquinoline compound 2
6X82	;	2.75	;	Crystal Structure of TNFalpha with isoquinoline compound 4
7XZR	;	2.26	;	Crystal structure of TNIK-AMPPNP-thiopeptide TP15 complex
7XZQ	;	2.09	;	Crystal structure of TNIK-thiopeptide TP1 complex
8WM0	;	2.8	;	Crystal structure of TNIK-thiopeptide wTP3 complex
4PNL	;	1.5	;	Crystal structure of TNKS-2 in complex with DR2313.
5OWT	;	2.2	;	Crystal structure of TNKS2 in complex with (5S)-5-methyl-5-[4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenyl]imidazolidine-2,4-dione
5NSX	;	1.8	;	Crystal structure of TNKS2 in complex with 2-(1H-indazol-5-yl)-3,4-dihydroquinazolin-4-one
5AL3	;	1.75	;	Crystal structure of TNKS2 in complex with 2-(2,4-dichlorophenyl)-1- methyl-1H,2H,3H,4H-pyrido(2,3-d)pyrimidin-4-one
5NWC	;	1.5	;	Crystal structure of TNKS2 in complex with 2-(2-aminophenyl)-3,4-dihydroquinazolin-4-one
5NT0	;	1.75	;	Crystal structure of TNKS2 in complex with 2-(3-aminophenyl)-3,4-dihydroquinazolin-4-one
5NVC	;	1.6	;	Crystal structure of TNKS2 in complex with 2-(3-hydroxyphenyl)-3,4-dihydroquinazolin-4-one
5AL5	;	2.05	;	Crystal structure of TNKS2 in complex with 2-(4-((pyridin-4-yl)methyl) piperazin-1-yl)-3,4,5,6,7,8-hexahydroquinazolin-4-one
5AL2	;	1.9	;	Crystal structure of TNKS2 in complex with 2-(4-(propan-2-yl)phenyl)- 1H,2H,3H,4H-pyrido(2,3-d)pyrimidin-4-one
5AKW	;	2.07	;	Crystal structure of TNKS2 in complex with 2-(4-chlorophenyl)-1,2,3,4- tetrahydroquinazolin-4-one
5NVE	;	1.5	;	Crystal structure of TNKS2 in complex with 2-(4-ethoxyphenyl)-3,4-dihydroquinazolin-4-one
5AL4	;	1.9	;	Crystal structure of TNKS2 in complex with 2-(4-methylpiperazin-1-yl)- 3,4,5,6,7,8-hexahydroquinazolin-4-one
5AKU	;	1.8	;	Crystal structure of TNKS2 in complex with 2-(4-tert-butylphenyl)-1,2, 3,4-tetrahydroquinazolin-4-one
5AL1	;	1.75	;	Crystal structure of TNKS2 in complex with 2-(4-tert-butylphenyl)-1H, 2H,3H,4H-pyrido(2,3-d)pyrimidin-4-one
5OWS	;	1.8	;	Crystal structure of TNKS2 in complex with 2-[4-(4-methyl-2-oxoimidazolidin-4-yl)phenyl]-3,4-dihydroquinazolin-4-one
5NWD	;	1.45	;	Crystal structure of TNKS2 in complex with 2-[4-(diethylamino)phenyl]-3,4-dihydroquinazolin-4-one
5NT4	;	1.9	;	Crystal structure of TNKS2 in complex with 2-[4-(morpholin-4-yl)phenyl]-3,4-dihydroquinazolin-4-one
5NVH	;	1.6	;	Crystal structure of TNKS2 in complex with 2-[4-(piperidin-1-yl)phenyl]-3,4-dihydroquinazolin-4-one
5NUT	;	1.6	;	Crystal structure of TNKS2 in complex with 2-[4-(propan-2-yloxy)phenyl]-3,4-dihydroquinazolin-4-one
5NVF	;	1.55	;	Crystal structure of TNKS2 in complex with 2-[4-(pyridin-2-yl)phenyl]-3,4-dihydroquinazolin-4-one
5NXE	;	1.6	;	Crystal structure of TNKS2 in complex with 2-{4-[(2-hydroxyethyl)(methyl)amino]phenyl}-1,2,3,4-tetrahydroquinazolin-4-one
5NWB	;	1.6	;	Crystal structure of TNKS2 in complex with 2-{4-[(2-hydroxyethyl)(methyl)amino]phenyl}-3,4-dihydroquinazolin-4-one
5NWG	;	1.4	;	Crystal structure of TNKS2 in complex with 7-chloro-2-{4-[(2-hydroxyethyl)(methyl)amino]phenyl}-3,4-dihydroquinazolin-4-one
5NSP	;	2.3	;	Crystal structure of TNKS2 in complex with OD334
6CLW	;	2.74	;	Crystal structure of TnmH
6CLX	;	2.73	;	Crystal structure of TnmH in complex with SAM
8E19	;	2.03	;	Crystal structure of TnmK1 complexed with TNM H
8G5U	;	1.804	;	Crystal structure of TnmK2 complexed with TNM B
5UMQ	;	1.95	;	Crystal structure of TnmS1, an antibiotic binding protein from Streptomyces sp. CB03234
5UMW	;	2.27	;	Crystal structure of TnmS2, an antibiotic binding protein from Streptomyces sp. CB03234
5UMX	;	1.59	;	Crystal structure of TnmS3 in complex with riboflavin
5UMY	;	1.78	;	Crystal structure of TnmS3 in complex with tiancimycin
5W27	;	1.8	;	Crystal structure of TnmS3 in complex with tiancimycin (TNM B)
6BBX	;	2.2	;	Crystal structure of TnmS3 in complex with TNM C
5UMP	;	1.08	;	Crystal structure of TnmS3, an antibiotic binding protein from Streptomyces sp. CB03234
7MBW	;	3.2	;	Crystal structure of TnsC(1-503)A225V
1P6P	;	2.5	;	Crystal Structure of Toad Liver Basic Fatty Acid-Binding Protein
4RNQ	;	2.47	;	Crystal structure of tobacco 5-epi-aristolochene synthase (TEAS) with anilinogeranyl diphosphate (AGPP) and geraniline
3MMG	;	1.7	;	Crystal structure of tobacco vein mottling virus protease
1LC4	;	2.54	;	Crystal Structure of Tobramycin Bound to the Eubacterial 16S rRNA A Site
3BB3	;	2.94	;	Crystal structure of Toc33 from Arabidopsis thaliana in complex with GDP and Mg2+
3BB4	;	2.85	;	Crystal structure of Toc33 from Arabidopsis thaliana in complex with Mg2+ and GMPPNP
3DEF	;	1.96	;	Crystal structure of Toc33 from Arabidopsis thaliana, dimerization deficient mutant R130A
3BB1	;	2.8	;	Crystal structure of Toc34 from Pisum sativum in complex with Mg2+ and GMPPNP
3P2H	;	2.0	;	Crystal structure of TofI in a ternary complex with an inhibitor and MTA
3P2F	;	2.3	;	Crystal structure of TofI in an apo form
7MX5	;	2.42	;	Crystal structure of TolB from Acinetobacter baumannii
4PWZ	;	1.732	;	Crystal structure of TolB protein from Yersinia pestis CO92
2HQS	;	1.5	;	Crystal structure of TolB/Pal complex
4R40	;	2.496	;	Crystal Structure of TolB/Pal complex from Yersinia pestis.
3EDI	;	1.4	;	Crystal structure of tolloid-like protease 1 (TLL-1) protease domain
3EN1	;	3.2	;	Crystal structure of Toluene 2,3-Dioxygenase
3DQY	;	1.2	;	Crystal structure of Toluene 2,3-Dioxygenase Ferredoxin
3EF6	;	1.8	;	Crystal structure of Toluene 2,3-Dioxygenase Reductase
3DHG	;	1.85	;	Crystal Structure of Toluene 4-Monoxygenase Hydroxylase
4FCZ	;	2.604	;	Crystal Structure of Toluene-tolerance protein from Pseudomonas putida (strain KT2440), Northeast Structural Genomics Consortium (NESG) Target PpR99
1WRD	;	1.75	;	Crystal structure of Tom1 GAT domain in complex with ubiquitin
3FP3	;	1.98	;	Crystal structure of Tom71
3FP2	;	1.98	;	Crystal structure of Tom71 complexed with Hsp82 C-terminal fragment
3FP4	;	2.14	;	Crystal structure of Tom71 complexed with Ssa1 C-terminal fragment
3CZ3	;	3.23	;	Crystal structure of Tomato Aspermy Virus 2b in complex with siRNA
6IK7	;	3.1	;	Crystal structure of tomato beta-galactosidase (TBG) 4 in complex with beta-1,3-galactobiose
6IK8	;	2.8	;	Crystal structure of tomato beta-galactosidase (TBG) 4 in complex with beta-1,6-galactobiose
6IK5	;	1.82	;	Crystal structure of tomato beta-galactosidase (TBG) 4 in complex with galactose
6IK6	;	2.791	;	Crystal structure of Tomato beta-galactosidase (TBG) 4 with beta-1,4-galactobiose
3W5F	;	1.65	;	Crystal structure of tomato beta-galactosidase 4
3W5G	;	3.0	;	Crystal structure of tomato beta-galactosidase 4 in complex with galactose
1OYV	;	2.5	;	Crystal structure of tomato inhibitor-II in a ternary complex with subtilisin Carlsberg
3STT	;	2.24	;	Crystal Structure of tomato Methylketone Synthase I Apo form
3STW	;	2.31	;	Crystal Structure of tomato Methylketone Synthase I complexed with 2-tridecanone
3STV	;	2.2	;	Crystal Structure of tomato Methylketone Synthase I complexed with 3-hydroxyoctanoate
3STU	;	1.93	;	Crystal Structure of tomato Methylketone Synthase I complexed with methyl-3-hydroxydodecanoate
3STX	;	2.3	;	Crystal Structure of tomato Methylketone Synthase I H243A variant complexed with beta-ketoheptanoate
3STY	;	1.7	;	Crystal Structure of tomato Methylketone Synthase I T18A mutant
3HGR	;	2.3	;	Crystal structure of tomato OPR1 in complex with pHB
3HGS	;	2.0	;	Crystal structure of tomato OPR3 in complex with pHB
3RY0	;	1.4	;	Crystal structure of TomN, a 4-Oxalocrotonate Tautomerase homologue in Tomaymycin biosynthetic pathway
4MB0	;	1.96	;	Crystal structure of TON1374
4MB2	;	2.19	;	Crystal structure of TON1374 in complex with ATP
3ZPJ	;	2.304	;	Crystal structure of Ton1535 from Thermococcus onnurineus NA1
2GRX	;	3.3	;	Crystal structure of TonB in complex with FhuA, E. coli outer membrane receptor for ferrichrome
4DWZ	;	2.7	;	Crystal Structure of Ton_0340
4FC5	;	2.3	;	Crystal Structure of Ton_0340
5GL2	;	2.03	;	Crystal structure of TON_0340 in complex with Ca
5GL3	;	2.4	;	Crystal structure of TON_0340 in complex with Mg
5GL4	;	2.2	;	Crystal structure of TON_0340 in complex with Mn
5GKX	;	2.01	;	Crystal structure of TON_0340, apo form
3UEB	;	1.98	;	Crystal structure of TON_0450 from Thermococcus onnurineus NA1
1QYS	;	2.5	;	Crystal structure of Top7: A computationally designed protein with a novel fold
1WMN	;	1.8	;	Crystal structure of topaquinone-containing amine oxidase activated by cobalt ion
1WMO	;	1.8	;	Crystal structure of topaquinone-containing amine oxidase activated by nickel ion
6RML	;	2.81	;	Crystal structure of TOPBP1 BRCT0,1,2 in complex with a 53BP1 phosphopeptide
6HM5	;	2.33004	;	Crystal structure of TOPBP1 BRCT0,1,2 in complex with a RAD9 phosphopeptide
6RMM	;	3.53	;	Crystal structure of TOPBP1 BRCT4,5 in complex with a 53BP1 phosphopeptide
3UEN	;	1.9	;	Crystal structure of TopBP1 BRCT4/5 domains
3UEO	;	2.6	;	Crystal structure of TopBP1 BRCT4/5 domains in complex with a phospho-peptide
5U6K	;	2.6	;	Crystal structure of TopBP1 BRCT4/5 in complex with a BLM phosphopeptide
3AL2	;	2.0	;	Crystal Structure of TopBP1 BRCT7/8
3AL3	;	2.15	;	Crystal Structure of TopBP1 BRCT7/8-BACH1 peptide complex
4GFJ	;	2.91	;	Crystal structure of Topo-78, an N-terminal 78kDa fragment of topoisomerase V
5HM5	;	2.4	;	Crystal structure of Topo-97, an N-terminal 97kDa fragment of topoisomerase V
5BOC	;	2.2	;	Crystal structure of topoisomerase ParE inhibitor
2CSD	;	2.9	;	Crystal structure of Topoisomerase V (61 kDa fragment)
2CSB	;	2.3	;	Crystal structure of Topoisomerase V from Methanopyrus kandleri (61 kDa fragment)
7AIW	;	1.9	;	Crystal structure of Torpedo Californica acetylcholinesterase in complex with (E)-10-[(3-Chloro-6,7,10,11-tetrahydro-9-methyl-7,11-methanocycloocta[b]quinolin-12-yl)amino]-N-(4-hydroxy-3-methoxybenzyl)-6-decenamide
6G1V	;	1.82	;	Crystal structure of Torpedo Californica acetylcholinesterase in complex with 12-Amino-3-chloro-6,7,10,11-tetrahydro-5,9-dimethyl-7,11-methanocycloocta[b]quinolin-5-ium
6G1W	;	1.9	;	Crystal structure of Torpedo Californica acetylcholinesterase in complex with 2-{1-[2-(6-Chloro-1,2,3,4-tetrahydroacridin-9-ylamino)ethyl]-1H-1,2,3-triazol-4-yl}-N-[4-(hydroxy)-3-methoxybenzyl]acetamide
7AIX	;	1.86	;	Crystal structure of Torpedo Californica acetylcholinesterase in complex with 2-{1-[4-(12-Amino-3-chloro-6,7,10,11-tetrahydro-7,11-methanocycloocta[b]quinolin-9-yl)butyl]-1H-1,2,3-triazol-4-yl}-N-[4-hydroxy-3-methoxybenzyl]acetamide
7AIV	;	2.55	;	Crystal structure of Torpedo Californica acetylcholinesterase in complex with 4-{[(3-Chloro-6,7,10,11-tetrahydro-9-methyl-7,11-methanocycloocta[b]quinolin-12-yl)amino]methyl}-N-(4-hydroxy-3-methoxybenzyl)benzamide
7AIS	;	1.75	;	Crystal structure of Torpedo Californica acetylcholinesterase in complex with 6-[(3-Chloro-6,7,10,11-tetrahydro-9-methyl-7,11-methanocycloocta[b]quinolin-12-yl)amino]-N-(4-hydroxy-3-methoxybenzyl)hexanamide
7AIT	;	2.1	;	Crystal structure of Torpedo Californica acetylcholinesterase in complex with 7-[(3-Chloro-6,7,10,11-tetrahydro-9-methyl-7,11-methanocycloocta[b]quinolin-12-yl)amino]-N-(4-hydroxy-3-methoxybenzyl)heptanamide
7AIU	;	1.996	;	Crystal structure of Torpedo Californica acetylcholinesterase in complex with 8-[(3-Chloro-6,7,10,11-tetrahydro-9-methyl-7,11-methanocycloocta[b]quinolin-12-yl)amino]-N-(4-hydroxy-3-methoxybenzyl)octanamide
6G1U	;	1.79	;	Crystal structure of Torpedo Californica acetylcholinesterase in complex with 9-Amino-6-chloro-1,2,3,4-tetrahydro-10-methylacridin-10-ium
1ZGB	;	2.3	;	Crystal Structure of Torpedo Californica Acetylcholinesterase in Complex With an (R)-Tacrine(10)-Hupyridone Inhibitor.
1ZGC	;	2.1	;	Crystal Structure of Torpedo Californica Acetylcholinesterase in Complex With an (RS)-Tacrine(10)-Hupyridone Inhibitor.
4H5L	;	2.75	;	Crystal Structure of Toscana Virus Nucleocapsid Protein Hexamer
4FQA	;	2.1	;	Crystal structure of toxic effector Tse1
4FQB	;	2.69	;	crystal structure of toxic effector Tse1 in complex with immune protein Tsi1
3MFG	;	2.37	;	Crystal structure of Toxic Shock Syndrome Toxin 1 (TSST-1) in complex with the human T cell receptor beta chain Vbeta2.1 (EP-8)
4OHJ	;	1.28	;	Crystal structure of toxic shock syndrome toxin-1 (TSST-1) from Staphylococcus aureus
4OF1	;	2.45	;	crystal structure of toxin from staphylococcus aureus Mu50
1PTX	;	1.3	;	CRYSTAL STRUCTURE OF TOXIN II FROM THE SCORPION ANDROCTONUS AUSTRALIS HECTOR REFINED AT 1.3 ANGSTROMS RESOLUTION
6R5M	;	1.9	;	Crystal structure of toxin MT9 from mamba venom
6J7N	;	2.294	;	Crystal structure of toxin TglT (unusual type guanylyltransferase-like toxin, Rv1045) mutant D82A co-expressed with TakA from Mycobacterium tuberculosis
6J7T	;	1.903	;	Crystal structure of toxin TglT (unusual type guanylyltransferase-like toxin, Rv1045) mutant D82A from Mycobacterium tuberculosis
6J7P	;	2.629	;	Crystal structure of toxin TglT (unusual type guanylyltransferase-like toxin, Rv1045) mutant E146Q co-expressed with TakA from Mycobacterium tuberculosis
6J7O	;	1.9	;	Crystal structure of toxin TglT (unusual type guanylyltransferase-like toxin, Rv1045) mutant E146Q from Mycobacterium tuberculosis
6J7R	;	2.299	;	Crystal structure of toxin TglT (unusual type guanylyltransferase-like toxin, Rv1045) mutant S78A co-expressed with TakA from Mycobacterium tuberculosis
6J7Q	;	1.85	;	Crystal structure of toxin TglT (unusual type guanylyltransferase-like toxin, Rv1045) mutant S78A from Mycobacterium tuberculosis
6J7S	;	2.102	;	Crystal structure of toxin TglT (unusual type guanylyltransferase-like toxin, Rv1045) wild type protein from Mycobacterium tuberculosis
5DHL	;	2.67	;	Crystal structure of Toxin, mutant N197W
6IMF	;	2.3	;	Crystal structure of TOXIN/ANTITOXIN complex
3PKV	;	1.34	;	Crystal Structure of Toxoflavin Lyase (TflA)
3PKW	;	1.8	;	Crystal Structure of Toxoflavin Lyase (TflA) bound to Mn(II)
3PKX	;	1.5	;	Crystal Structure of Toxoflavin Lyase (TflA) bound to Mn(II) and Toxoflavin
3OUL	;	1.6	;	Crystal Structure of toxoflavin-degrading enzyme in a substrate-free form
3OUM	;	2.0	;	Crystal Structure of toxoflavin-degrading enzyme in complex with toxoflavin
7NH2	;	1.35	;	Crystal structure of Toxoplasma CPSF4-YTH domain bound to m6A
7NG2	;	1.23	;	Crystal structure of Toxoplasma CPSF4-YTH domain in apo form
6FND	;	2.101	;	Crystal structure of Toxoplasma gondii AKMT
4Z80	;	1.53	;	Crystal structure of Toxoplasma gondii AMA4 DI-DII-EGF1 in complex with a 33 aa TgRON2L1 peptide
3HZT	;	2.0	;	Crystal structure of Toxoplasma gondii CDPK3, TGME49_105860
8BT6	;	2.33	;	Crystal structure of Toxoplasma gondii glideosome-associated connector
8J67	;	1.81	;	Crystal structure of Toxoplasma gondii M2AP
8J64	;	2.0	;	Crystal structure of Toxoplasma gondii MIC2-M2AP complex
2JH1	;	1.9	;	Crystal structure of Toxoplasma gondii micronemal protein 1
3F5E	;	2.0	;	Crystal structure of Toxoplasma gondii micronemal protein 1 bound to 2'F-3'SiaLacNAc1-3
3F53	;	2.0	;	Crystal structure of Toxoplasma gondii micronemal protein 1 bound to 2F-3'SiaLacNAc
2JHD	;	2.3	;	Crystal structure of Toxoplasma gondii micronemal protein 1 bound to 3'-sialyl-N-acetyllactosamine
3F5A	;	2.0	;	Crystal structure of Toxoplasma gondii micronemal protein 1 bound to 3'SiaLacNAc1-3
2JH7	;	2.07	;	Crystal structure of Toxoplasma gondii micronemal protein 1 bound to 6'-sialyl-N-acetyllactosamine
6BXS	;	2.1	;	Crystal structure of Toxoplasma gondii Mitochondrial Association Factor 1 A (MAF1A)
6BXT	;	2.7	;	Crystal structure of Toxoplasma gondii Mitochondrial Association Factor 1 A (MAF1A) in complex with ADPribose
6BXR	;	1.6	;	Crystal structure of Toxoplasma gondii Mitochondrial Association Factor 1 B (MAF1B)
6BXW	;	1.65	;	Crystal structure of Toxoplasma gondii Mitochondrial Association Factor 1 B (MAF1B) in complex with ADPribose
6T6Q	;	2.902	;	Crystal structure of Toxoplasma gondii Morn1 (extended conformation).
6T69	;	2.5	;	Crystal structure of Toxoplasma gondii Morn1(V shape)
4JEP	;	3.1	;	Crystal structure of Toxoplasma gondii nucleoside triphosphate diphosphohydrolase 1 (NTPDase1)
4A57	;	2.0	;	CRYSTAL STRUCTURE OF TOXOPLASMA GONDII NUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 3 (NTPDASE3)
4A59	;	2.2	;	Crystal structure of Toxoplasma gondii nucleoside triphosphate diphosphohydrolase 3 (NTPDase3) in complex with AMP
3BO7	;	2.35	;	Crystal structure of Toxoplasma gondii peptidyl-prolyl cis-trans isomerase, 541.m00136
3NEC	;	1.7	;	Crystal Structure of Toxoplasma gondii Profilin
6AA0	;	3.2	;	Crystal Structure of Toxoplasma gondii Prolyl tRNA Synthetase (TgPRS) in Apo Form
5XIQ	;	2.19	;	Crystal Structure of Toxoplasma gondii Prolyl-tRNA Synthetase (TgPRS) in complex with Halofuginone
5XIG	;	2.41	;	Crystal Structure of Toxoplasma gondii Prolyl-tRNA Synthetase (TgPRS) in complex with Inhibitor 1
5XIH	;	2.2	;	Crystal Structure of Toxoplasma gondii Prolyl-tRNA Synthetase (TgPRS) in complex with inhibitor 5
5XII	;	2.17	;	Crystal Structure of Toxoplasma gondii Prolyl-tRNA Synthetase (TgPRS) in complex with inhibitor 6
5XIJ	;	2.5	;	Crystal Structure of Toxoplasma gondii Prolyl-tRNA Synthetase (TgPRS) in complex with Inhibitor 9
5XIK	;	2.5	;	Crystal Structure of Toxoplasma gondii Prolyl-tRNA Synthetase (TgPRS) in complex with tetrahydro quinazolinone febrifugine
5WA2	;	1.591	;	Crystal structure of Toxoplasma gondii SAG3 (SRS57)
3BYV	;	1.8	;	Crystal structure of Toxoplasma gondii specific rhoptry antigen kinase domain
3ZLE	;	2.35	;	Crystal structure of Toxoplasma gondii sporozoite AMA1
3ZLD	;	3.1	;	Crystal structure of Toxoplasma gondii sporozoite AMA1 in complex with a 36 aa region of sporozoite RON2
5T0L	;	3.13	;	Crystal structure of Toxoplasma gondii TS-DHFR complexed with NADPH, dUMP, PDDF and 5-(4-(3,4-dichlorophenyl)piperazin-1-yl)pyrimidine-2,4-diamine (TRC-15)
6AOH	;	3.5	;	Crystal structure of Toxoplasma gondii TS-DHFR complexed with NADPH, dUMP, PDDF, and 5-(4-(3-(2-methoxypyrimidin-5-yl)phenyl)piperazin-1-yl)pyrimidine-2,4-diamine (TRC-2533)
6AOG	;	3.2	;	Crystal structure of Toxoplasma gondii TS-DHFR complexed with NADPH, dUMP, PDDF, and 5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine (pyrimethamine)
6AOI	;	2.97	;	Crystal structure of Toxoplasma gondii TS-DHFR complexed with NADPH, dUMP, PDDF, and 5-(4-phenylpiperazin-1-yl)-6-propylpyrimidine-2,4-diamine (TRC-2528)
3CE7	;	1.64	;	Crystal structure of toxoplasma specific mitochondrial acyl carrier protein, 59.m03510
3GBG	;	1.9	;	Crystal Structure of ToxT from Vibrio Cholerae O395
5SUX	;	2.0	;	Crystal Structure of ToxT from Vibrio Cholerae O395 bound to (E)-4-(8-methylnaphthalen-1-yl)but-3-enoic acid
5SUW	;	2.3	;	Crystal Structure of ToxT from Vibrio Cholerae O395 bound to 3-(8-Methyl-1,2,3,4-tetrahydronaphthalen-1-yl)propanoic acid
6I1F	;	1.89	;	Crystal structure of TP domain from Chlamydia trachomatis Penicillin-Binding Protein 3 in complex with amoxicillin
6I1H	;	1.78	;	Crystal structure of TP domain from Chlamydia trachomatis Penicillin-Binding Protein 3 in complex with meropenem
6I1G	;	2.13	;	Crystal structure of TP domain from Chlamydia trachomatis Penicillin-Binding Protein 3 in complex with piperacillin
6I1I	;	1.75	;	Crystal structure of TP domain from Escherichia coli penicillin-binding protein 3 in complex with penicillin
7JP2	;	1.38	;	Crystal structure of TP0037 from Treponema pallidum, a D-lactate dehydrogenase
8QAO	;	1.29	;	Crystal structure of TP901-1 CI-NTD89 repressor N-terminal domain
3KT1	;	2.5	;	Crystal structure of Tpa1 from Saccharomyces cerevisiae, a component of the messenger ribonucleoprotein complex
3KT4	;	2.73	;	Crystal structure of Tpa1 from Saccharomyces cerevisiae, a component of the messenger ribonucleoprotein complex
3KT7	;	1.77	;	Crystal structure of Tpa1 from Saccharomyces cerevisiae, a component of the messenger ribonucleoprotein complex
4NHL	;	2.84	;	Crystal structure of Tpa1p from Saccharomyces cerevisiae, termination and polyadenylation protein 1, in complex with N-oxalylglycine (NOG)
4NHM	;	1.9	;	Crystal structure of Tpa1p from Saccharomyces cerevisiae, termination and polyadenylation protein 1, in complex with N-[(1-chloro-4-hydroxyisoquinolin-3-yl)carbonyl]glycine (IOX3/UN9)
4NHK	;	1.9	;	Crystal structure of Tpa1p from Saccharomyces cerevisiae, termination and polyadenylation protein 1, in complex with pyridine-2,4-dicarboxylic acid (2,4-PDCA)
7Q04	;	2.281	;	Crystal structure of TPADO in a substrate-free state
7Q06	;	1.95	;	Crystal structure of TPADO in complex with 2-OH-TPA
7Q05	;	2.08	;	Crystal structure of TPADO in complex with TPA
7XUP	;	2.602	;	Crystal structure of TPe3.0
7XUQ	;	2.5	;	Crystal structure of Tpe3.0 complexed with N-Boc-3-alkenylindole
7NDS	;	2.4	;	Crystal structure of TphC in a closed conformation
7NDR	;	1.97	;	Crystal structure of TphC in an open conformation
7XKX	;	2.57	;	Crystal structure of Tpn2
5I2Y	;	3.0	;	Crystal Structure of TPP1 K170A
5I2X	;	3.0	;	Crystal Structure of TPP1 K170del
5D2U	;	1.8	;	Crystal structure of tPphA Variant - H39A
8FIR	;	1.95	;	Crystal structure of TpPta, a phosphotransacetylase from Treponema pallidum
3Q47	;	1.705	;	Crystal structure of TPR domain of CHIP complexed with pseudophosphorylated Smad1 peptide
3JZB	;	2.007	;	Crystal Structure of TR-alfa bound to the selective thyromimetic TRIAC
4LNW	;	1.9	;	Crystal structure of TR-alpha bound to T3 in a second site
4LNX	;	2.05	;	Crystal structure of TR-alpha bound to T4 in a second site
3JZC	;	2.5	;	Crystal Structure of TR-beta bound to the selective thyromimetic TRIAC
4WHF	;	2.27	;	Crystal Structure of TR3 LBD in complex with 1-(3,4,5-trihydroxyphenyl)decan-1-one
4KZI	;	2.41	;	Crystal Structure of TR3 LBD in complex with DPDO
4WHG	;	2.18	;	Crystal Structure of TR3 LBD in complex with Molecule 3
4RE8	;	2.16	;	Crystal Structure of TR3 LBD in complex with Molecule 5
4REE	;	2.37	;	Crystal Structure of TR3 LBD in complex with Molecule 6
8WUY	;	2.6	;	Crystal Structure of TR3 LBD in complex with para-positioned 3,4,5-trisubstituted benzene derivatives
4KZJ	;	2.12	;	Crystal Structure of TR3 LBD L449W Mutant
4KZM	;	2.3	;	Crystal Structure of TR3 LBD S553A Mutant
4REF	;	2.1	;	Crystal Structure of TR3 LBD_L449W in complex with Molecule 2
4S1Z	;	3.03	;	Crystal structure of TRABID NZF1 in complex with K29 linked di-Ubiquitin
1R8I	;	3.0	;	Crystal structure of TraC
2F2L	;	2.1	;	Crystal structure of tracheal cytotoxin (TCT) bound to the ectodomain complex of peptidoglycan recognition proteins LCa (PGRP-LCa) and LCx (PGRP-LCx)
6AC0	;	1.449	;	Crystal structure of TRADD death domain GlcNAcylated by EPEC effector NleB
5E1T	;	2.8	;	Crystal structure of TRAF1 TRAF domain
3M06	;	2.67	;	Crystal Structure of TRAF2
3M0A	;	2.61	;	Crystal structure of TRAF2:cIAP2 complex
4GHU	;	2.199	;	Crystal structure of TRAF3/Cardif
4K8U	;	2.302	;	Crystal structure of TRAF4 TRAF domain
3HCU	;	2.6	;	Crystal structure of TRAF6 in complex with Ubc13 in the C2 space group
3HCT	;	2.1	;	Crystal structure of TRAF6 in complex with Ubc13 in the P1 space group
8IMS	;	3.3	;	Crystal structure of TRAF7 coiled-coil domain
1D4V	;	2.2	;	Crystal structure of trail-DR5 complex
1DU3	;	2.2	;	Crystal structure of TRAIL-SDR5
8AWZ	;	1.549	;	Crystal structure of Trametes versicolor glutathione transferase Omega 3S in complex with dinitrosyl glutathionyl iron complex (DNGIC)
8AX2	;	1.62	;	Crystal structure of Trametes versicolor glutathione transferase Omega 3S in complex with glutathione and pentachloro-nitrosyl-osmate
8AX1	;	1.65	;	Crystal structure of Trametes versicolor glutathione transferase Omega 3S in complex with hydroxy-tetranitro-nitrosyl-ruthenate
8AX0	;	1.65	;	Crystal structure of Trametes versicolor glutathione transferase Omega 3S in complex with sodium nitroprusside
1JTZ	;	2.6	;	CRYSTAL STRUCTURE OF TRANCE/RANKL CYTOKINE.
7E5M	;	3.2	;	crystal structure of trans assembled human TROP-2
2DXA	;	1.58	;	Crystal structure of trans editing enzyme ProX from E.coli
4GGO	;	2.0	;	Crystal Structure of Trans-2-Enoyl-CoA Reductase from Treponema denticola
6R76	;	2.4	;	Crystal structure of trans-3-Hydroxy-L-proline dehydratase from Thermococcus litoralis - open conformation
6R77	;	2.0	;	Crystal structure of trans-3-Hydroxy-L-proline dehydratase in complex with substrate - closed conformation
3G5T	;	1.119	;	Crystal structure of trans-aconitate 3-methyltransferase from yeast
2PW0	;	1.57	;	crystal structure of trans-aconitate bound to methylaconitate isomerase PrpF from Shewanella oneidensis
2P35	;	1.95	;	Crystal structure of trans-aconitate methyltransferase from Agrobacterium tumefaciens
5O0T	;	2.05	;	CRYSTAL STRUCTURE OF TRANS-MEMBRANE DOMAIN OF Cylindrospermum stagnale NADPH-OXIDASE 5 (NOX5)
7DMB	;	2.1	;	Crystal structure of trans-methyltransferase CalH complex with SAH
3OPZ	;	3.4	;	Crystal structure of trans-sialidase in complex with the Fab fragment of a neutralizing monoclonal IgG antibody
1VPX	;	2.4	;	Crystal structure of Transaldolase (EC 2.2.1.2) (TM0295) from Thermotoga maritima at 2.40 A resolution
3CLM	;	1.14	;	Crystal structure of transaldolase (YP_208650.1) from Neisseria gonorrhoeae FA 1090 at 1.14 A resolution
1WX0	;	2.27	;	Crystal structure of transaldolase from Thermus thermophilus HB8
8IOZ	;	2.33	;	Crystal structure of transaminase
7YPM	;	1.984	;	Crystal structure of transaminase CC1012 complexed with PLP and L-alanine
7YPN	;	2.049	;	Crystal structure of transaminase CC1012 mutant M9 complexed with PLP
1EXJ	;	3.0	;	CRYSTAL STRUCTURE OF TRANSCRIPTION ACTIVATOR BMRR, FROM B. SUBTILIS, BOUND TO 21 BASE PAIR BMR OPERATOR AND TPP
1EXI	;	3.12	;	CRYSTAL STRUCTURE OF TRANSCRIPTION ACTIVATOR BMRR, FROM B. SUBTILIS, BOUND TO 21 BASE PAIR BMR OPERATOR AND TPSB
2QUF	;	2.8	;	Crystal Structure of Transcription Factor AXXA-PF0095 from Pyrococcus furiosus
7FDO	;	1.752	;	Crystal structure of transcription factor CPC in complex with EGL3
1TJL	;	2.0	;	Crystal structure of transcription factor DksA from E. coli
6ABQ	;	2.3	;	Crystal structure of transcription factor from Listeria monocytogenes
6ABT	;	2.8	;	Crystal structure of transcription factor from Listeria monocytogenes
5O9J	;	2.0	;	Crystal structure of transcription factor IIB Mja mini-intein
5O9I	;	2.5	;	Crystal structure of transcription factor IIB Mvu mini-intein
1HZ4	;	1.45	;	CRYSTAL STRUCTURE OF TRANSCRIPTION FACTOR MALT DOMAIN III
7FDM	;	2.5	;	Crystal structure of transcription factor MYB29 in complex with MYC3
2XGX	;	2.85	;	Crystal structure of transcription factor NtcA from Synechococcus elongatus (mercury derivative)
2XHK	;	2.3	;	Crystal structure of transcription factor NtcA from Synechococcus elongatus bound to 2-oxoglutarate
2QLZ	;	2.5	;	Crystal Structure of Transcription Factor PF0095 from Pyrococcus furiosus
5GZB	;	2.704	;	Crystal Structure of Transcription Factor TEAD4 in Complex with M-CAT DNA
8GYZ	;	2.06	;	Crystal structure of transcription factor TGA7 from Arabidopsis
7FDL	;	2.897	;	Crystal structure of transcription factor WER in complex with EGL3
7FDN	;	1.9	;	Crystal structure of transcription factor WER in complex with EGL3
4N9H	;	2.2	;	Crystal structure of Transcription regulation Protein CRP
4N9I	;	2.19	;	Crystal Structure of Transcription regulation protein CRP complexed with cGMP
6N8B	;	2.94	;	Crystal structure of transcription regulator AcaB from uropathogenic E. coli
2O20	;	1.9	;	Crystal structure of transcription regulator CcpA of Lactococcus lactis
1ZYB	;	2.15	;	Crystal structure of transcription regulator from Bacteroides thetaiotaomicron VPI-5482 at 2.15 A resolution
3HUU	;	1.95	;	Crystal structure of transcription regulator like protein from Staphylococcus haemolyticus
4FC8	;	2.5	;	Crystal structure of transcription regulator protein Rtr1 from Kluyveromyces lactis
3DEU	;	2.3	;	Crystal structure of transcription regulatory protein slyA from Salmonella typhimurium in complex with salicylate ligands
4MTN	;	2.579	;	Crystal structure of transcription termination factor NusA from Planctomyces limnophilus DSM 3776
1TYH	;	2.54	;	Crystal Structure of Transcriptional Activator tenA from Bacillus subtilis
4HAM	;	1.905	;	Crystal Structure of Transcriptional Antiterminator from Listeria monocytogenes EGD-e
3JST	;	2.1	;	Crystal structure of transcriptional coactivator/pterin dehydratase from Brucella Melitensis
5DEQ	;	1.95	;	Crystal structure of transcriptional factor AraR from Bacteroides thetaiotaomicron VPI in complex with L-arabinose
2D6Y	;	2.3	;	Crystal Structure of transcriptional factor SCO4008 from Streptomyces coelicolor A3(2)
3T6N	;	2.314	;	Crystal Structure of Transcriptional Regulator
3V6G	;	1.821	;	Crystal Structure of Transcriptional Regulator
3V78	;	2.299	;	Crystal Structure of Transcriptional Regulator
3OIO	;	1.65	;	Crystal structure of transcriptional regulator (AraC-type DNA-binding domain-containing proteins) from Chromobacterium violaceum
3C7J	;	2.1	;	Crystal structure of transcriptional regulator (GntR family member) from Pseudomonas syringae pv. tomato str. DC3000
2ID6	;	1.746	;	Crystal structure of transcriptional regulator (tm1030) at 1.75A resolution
1O5L	;	2.3	;	Crystal structure of Transcriptional regulator (TM1171) from Thermotoga maritima at 2.30 A resolution
1J5Y	;	2.3	;	Crystal structure of transcriptional regulator (TM1602) from Thermotoga maritima at 2.3 A resolution
4O8B	;	2.3	;	Crystal structure of transcriptional regulator BswR
5CHH	;	1.85	;	Crystal structure of transcriptional regulator CdpR from Pseudomonas aeruginosa
1ZK8	;	2.15	;	Crystal structure of transcriptional regulator from Bacillus cereus ATCC 14579
1Z4E	;	2.0	;	Crystal structure of transcriptional regulator from Bacillus halodurans C-125
6VLI	;	2.10002	;	Crystal structure of transcriptional regulator from bacteriophage 186
6VMH	;	2.75	;	Crystal structure of transcriptional regulator from bacteriophage 186
6VPE	;	2.211	;	Crystal structure of transcriptional regulator from bacteriophage 186
3F0C	;	2.96	;	Crystal structure of transcriptional regulator from Cytophaga hutchinsonii ATCC 33406
3OP9	;	1.898	;	Crystal structure of transcriptional regulator from Listeria innocua
2P6T	;	2.9	;	CRYSTAL STRUCTURE OF TRANSCRIPTIONAL REGULATOR NMB0573 and L-LEUCINE COMPLEX FROM NEISSERIA MENINGITIDIS
2P5V	;	1.99	;	Crystal Structure of Transcriptional Regulator NMB0573 from Neisseria Meningitidis
2P6S	;	2.8	;	Crystal Structure of Transcriptional Regulator NMB0573/L-Met Complex from Neisseria Meningitidis
3E97	;	1.86	;	Crystal structure of transcriptional regulator of Crp/Fnr family (YP_604437.1) from DEINOCOCCUS GEOTHERMALIS DSM 11300 at 1.86 A resolution
2RGY	;	2.05	;	Crystal structure of transcriptional regulator of LacI family from Burkhoderia phymatum
3CWR	;	1.5	;	Crystal structure of transcriptional regulator of TetR family (YP_425770.1) from Rhodospirillum rubrum ATCC 11170 at 1.50 A resolution
3DCF	;	2.5	;	Crystal structure of transcriptional regulator of the TetR/AcrR family (YP_290855.1) from THERMOBIFIDA FUSCA YX-ER1 at 2.50 A resolution
1Z77	;	2.0	;	Crystal structure of transcriptional regulator protein from Thermotoga maritima.
8I2K	;	2.303	;	Crystal structure of transcriptional regulator pvrA from Pseudomonas aeruginosa.
2QKO	;	2.35	;	Crystal structure of transcriptional regulator RHA06399 from Rhodococcus sp. RHA1
4NN1	;	2.99	;	Crystal Structure of transcriptional regulator Rv1219c of Mycobacterium tuberculosis
2ID3	;	1.7	;	Crystal structure of transcriptional regulator SCO5951 from Streptomyces coelicolor A3(2)
4I76	;	2.1	;	Crystal structure of transcriptional regulator TM1030 with octanol
3TYR	;	1.699	;	Crystal structure of transcriptional regulator VanUg, Form I
3TYS	;	1.121	;	Crystal structure of transcriptional regulator VanUg, Form II
3HHH	;	2.7	;	Crystal structure of transcriptional regulator, a member of PadR family, from Enterococcus faecalis V583
2GAU	;	1.9	;	Crystal structure of transcriptional regulator, Crp/Fnr family from Porphyromonas gingivalis (APC80792), Structural genomics, MCSG
3L5Z	;	2.9	;	Crystal structure of transcriptional regulator, GntR family from Bacillus cereus
7U5Q	;	3.0	;	Crystal structure of transcriptional regulator, GntR family, from Brucella melitensis
3CJN	;	1.95	;	Crystal structure of transcriptional regulator, MarR family, from Silicibacter pomeroyi
1ZKG	;	2.3	;	Crystal structure of Transcriptional regulator, TETR family (tm1030) from Thermotoga maritima at 2.30 A resolution
1Z0X	;	2.4	;	Crystal structure of transcriptional regulator, tetR Family from Enterococcus faecalis V583
1RZR	;	2.8	;	crystal structure of transcriptional regulator-phosphoprotein-DNA complex
2TGI	;	1.8	;	CRYSTAL STRUCTURE OF TRANSFORMING GROWTH FACTOR-BETA2: AN UNUSUAL FOLD FOR THE SUPERFAMILY
1D4O	;	1.21	;	CRYSTAL STRUCTURE OF TRANSHYDROGENASE DOMAIN III AT 1.2 ANGSTROMS RESOLUTION
1XLT	;	3.1	;	Crystal structure of Transhydrogenase [(domain I)2:domain III] heterotrimer complex
6C8G	;	6.31	;	Crystal structure of Transient Receptor Potential (TRP) channel TRPV4 in the presence of barium
6C8F	;	6.5	;	Crystal structure of Transient Receptor Potential (TRP) channel TRPV4 in the presence of cesium
6C8H	;	6.5	;	Crystal structure of Transient Receptor Potential (TRP) channel TRPV4 in the presence of gadolinium
5WO7	;	3.246	;	Crystal Structure of Transient Receptor Potential (TRP) channel TRPV6*
5WO9	;	3.7	;	Crystal Structure of Transient Receptor Potential (TRP) channel TRPV6* in the presence of Calcium
5WOA	;	3.899	;	Crystal Structure of Transient Receptor Potential (TRP) channel TRPV6* in the presence of Gadolinium
5WO8	;	3.4	;	Crystal Structure of Transient Receptor Potential (TRP) channel TRPV6*-Del1
5WO6	;	3.31	;	Crystal Structure of Transient Receptor Potential (TRP) channel TRPV6cryst
5HJE	;	1.4	;	Crystal Structure of Transketolase complex with sedoheptulose-7-phoaphate from Pichia Stipitis
3M49	;	2.0	;	Crystal Structure of Transketolase Complexed with Thiamine Diphosphate from Bacillus anthracis
5XRY	;	1.3	;	Crystal Structure of Transketolase contains cysteinesufonic acid from Pichia Stipitis
3HYL	;	2.16	;	Crystal Structure of Transketolase from Bacillus anthracis
5ND5	;	1.74	;	Crystal structure of transketolase from Chlamydomonas reinhardtii in complex with TPP and Mg2+
2R5N	;	1.6	;	Crystal structure of transketolase from Escherichia coli in noncovalent complex with acceptor aldose ribose 5-phosphate
8CIP	;	2.1	;	Crystal structure of transketolase from Geobacillus stearothermophilus
5I4I	;	1.06	;	Crystal Structure of Transketolase from Pichia Stipitis
5XTL	;	1.101	;	Crystal Structure of Transketolase in complex with aminopyrimidine and cysteine sulfonic acid adduct from Pichia Stipitis
5XPS	;	1.07	;	Crystal Structure of Transketolase in complex with erythrose-4-phosphate from Pichia Stipitis
5XVT	;	0.85	;	Crystal Structure of Transketolase in complex with hydroxylated TPP from Pichia Stipitis, crystal 2
5XUF	;	0.88	;	Crystal Structure of Transketolase in complex with hydroxylated TPP from Pichia Stipitis, crystal I
5XQA	;	1.14	;	Crystal Structure of Transketolase in complex with ribose-5-phosphate from Pichia Stipitis
3M34	;	1.65	;	Crystal structure of transketolase in complex with thiamin diphosphate and calcium ion
3M6L	;	1.59	;	Crystal structure of transketolase in complex with thiamine diphosphate, ribose-5-phosphate and calcium ion
3M7I	;	1.75	;	Crystal structure of transketolase in complex with thiamine diphosphate, ribose-5-phosphate(pyranose form) and magnesium ion
5XSA	;	0.975	;	Crystal Structure of Transketolase in complex with TPP intermediate III from Pichia Stipitis
5XSB	;	0.918	;	Crystal Structure of Transketolase in complex with TPP intermediate III from Pichia Stipitis
5XSM	;	0.97	;	Crystal Structure of Transketolase in complex with TPP intermediate IV from Pichia Stipitis
5XU9	;	1.166	;	Crystal Structure of Transketolase in complex with TPP intermediate IX and gauche form erythrose-4-phosphate from Pichia Stipitis
5XTV	;	0.931	;	Crystal Structure of Transketolase in complex with TPP intermediate V from Pichia Stipitis
5XTX	;	1.049	;	Crystal Structure of Transketolase in complex with TPP intermediate VII from Pichia Stipitis
5XT0	;	1.15	;	Crystal Structure of Transketolase in complex with TPP intermediate VIII from Pichia Stipitis
5XT4	;	1.06	;	Crystal Structure of Transketolase in complex with TPP intermediate VIII' from Pichia Stipitis
5XS6	;	0.972	;	Crystal Structure of Transketolase in complex with TPP Pichia Stipitis
5XU2	;	0.97	;	Crystal Structure of Transketolase in complex with TPP_III and fructose-6-phosphate from Pichia Stipitis
5XRV	;	1.4	;	Crystal Structure of Transketolase in complex with TPP_V and fructose-6-phosphate from Pichia Stipitis
5XQK	;	1.12	;	Crystal Structure of Transketolase in complex with xylulose-5-phosphate from Pichia Stipitis
5HGX	;	1.09	;	Crystal Structure of Transketolase mutant - H261F from Pichia Stipitis
5I51	;	1.54	;	Crystal Structure of Transketolase mutant-R356L complex with fructose-6-phoaphate from Pichia Stipitis
5I5G	;	1.95	;	Crystal Structure of Transketolase mutant-R525L from Pichia Stipitis
5I5E	;	1.62	;	Crystal Structure of Transketolase mutants-H66/261C complex with xylulose-5-phoaphate from Pichia Stipitis
5HYV	;	1.031	;	Crystal Structure of Transketolase with ThDP from Pichia Stipitis
2YY3	;	2.5	;	Crystal Structure of translation elongation factor EF-1 beta from Pyrococcus horikoshii
1UEB	;	1.65	;	Crystal structure of translation elongation factor P from Thermus thermophilus HB8
4AC9	;	3.03	;	CRYSTAL STRUCTURE OF TRANSLATION ELONGATION FACTOR SELB FROM METHANOCOCCUS MARIPALUDIS IN COMPLEX WITH GDP
4ACB	;	3.34	;	CRYSTAL STRUCTURE OF TRANSLATION ELONGATION FACTOR SELB FROM METHANOCOCCUS MARIPALUDIS IN COMPLEX WITH THE GTP ANALOGUE GPPNHP
4ACA	;	3.15	;	CRYSTAL STRUCTURE OF TRANSLATION ELONGATION FACTOR SELB FROM METHANOCOCCUS MARIPALUDIS, APO FORM
3I4O	;	1.47	;	Crystal Structure of Translation Initiation Factor 1 from Mycobacterium tuberculosis
1IZ6	;	2.0	;	Crystal Structure of Translation Initiation Factor 5A from Pyrococcus Horikoshii
2D74	;	2.8	;	Crystal structure of translation initiation factor aIF2betagamma heterodimer
2DCU	;	3.4	;	Crystal structure of translation initiation factor aIF2betagamma heterodimer with GDP
2IDR	;	1.85	;	Crystal structure of translation initiation factor EIF4E from wheat
4QL5	;	2.025	;	Crystal structure of translation initiation factor IF-1 from Streptococcus pneumoniae TIGR4
1TXJ	;	2.0	;	Crystal structure of translationally controlled tumour-associated protein (TCTP) from Plasmodium knowlesi
4UC2	;	2.4	;	Crystal structure of translocator protein 18kDa (TSPO) from rhodobacter sphaeroides (A139T mutant) in P212121 space group
3EMO	;	3.0	;	Crystal structure of transmembrane Hia 973-1098
6B87	;	2.947	;	Crystal structure of transmembrane protein TMHC2_E
6B85	;	3.889	;	Crystal structure of transmembrane protein TMHC4_R
3MP2	;	2.5	;	Crystal structure of transmissible gastroenteritis virus papain-like protease 1
6P55	;	1.74	;	Crystal structure of transpeptidase domain of PBP2 from Neisseria gonorrhoeae acylated by cefixime
6P54	;	1.83	;	Crystal structure of transpeptidase domain of PBP2 from Neisseria gonorrhoeae acylated by ceftriaxone
6VBC	;	1.55	;	Crystal structure of transpeptidase domain of PBP2 from Neisseria gonorrhoeae cephalosporin-resistant strain H041
6VBD	;	1.8	;	Crystal structure of transpeptidase domain of PBP2 from Neisseria gonorrhoeae cephalosporin-resistant strain H041 acylated by ceftriaxone
8VEP	;	2.002	;	Crystal structure of transpeptidase domain of PBP2 from Neisseria gonorrhoeae cephalosporin-resistant strain H041 acylated by piperacillin
8VEQ	;	2.4	;	Crystal structure of transpeptidase domain of PBP2 from Neisseria gonorrhoeae cephalosporin-resistant strain H041 in complex with azlocillin
8VEN	;	1.8	;	Crystal structure of transpeptidase domain of PBP2 from Neisseria gonorrhoeae cephalosporin-resistant strain H041 in complex with cefoperazone
6P52	;	1.83	;	Crystal structure of transpeptidase domain of PBP2 from Neisseria gonorrhoeae with a bound phosphate at the active site
8RI5	;	1.415	;	Crystal structure of transplatin/B-DNA adduct obtained upon 48 h of soaking
8RI3	;	1.4	;	Crystal structure of transplatin/B-DNA adduct obtained upon 7 days of soaking
5TQC	;	3.0	;	Crystal structure of transport factor karyopherin-beta 2 in complex with the PY-NLS of ribosomal protein L4 (RpL4)
4ZLJ	;	3.257	;	Crystal structure of transporter AcrB
4ZLN	;	3.557	;	Crystal structure of transporter AcrB deletion mutant
4ZLL	;	3.36	;	Crystal structure of transporter AcrB triple mutant
7VPW	;	3.76	;	Crystal structure of Transportin-1 in complex with BAP1 PY-NLS (residues 706-724)
4OL0	;	2.9	;	Crystal structure of transportin-SR2, a karyopherin involved in human disease, in complex with Ran
4FQ3	;	3.0	;	Crystal structure of transportin/FUS-NLS
2EC2	;	2.8	;	Crystal structure of transposase from Sulfolobus tokodaii
6LND	;	2.001	;	Crystal structure of transposition protein TniQ
4WNS	;	1.399	;	Crystal structure of Transthyretin complexed with pterostilbene
1OO2	;	1.56	;	Crystal structure of transthyretin from Sparus aurata
3B56	;	1.55	;	Crystal structure of transthyretin in complex with 3,5-diiodosalicylic acid
6SUG	;	1.21	;	Crystal structure of transthyretin in complex with 3-deoxytolcapone, a tolcapone analogue
8HEJ	;	1.54	;	Crystal structure of Transthyretin in complex with a covalent inhibitor trans-styrylpyrazole
4WO0	;	1.339	;	Crystal structure of transthyretin in complex with apigenin
6R68	;	1.45	;	Crystal structure of transthyretin in complex with CHF4795, a flurbiprofen analogue
4I85	;	1.67	;	Crystal structure of transthyretin in complex with CHF5074 at neutral pH
6R66	;	1.3	;	Crystal structure of transthyretin in complex with CHF5075, a flurbiprofen analogue
6R67	;	1.3	;	Crystal structure of transthyretin in complex with CHF5075, a flurbiprofen analogue
4I89	;	1.69	;	Crystal structure of transthyretin in complex with diflunisal at acidic pH
1Y1D	;	1.7	;	Crystal structure of transthyretin in complex with iododiflunisal
3FCB	;	1.8	;	Crystal structure of transthyretin in complex with iododiflunisal-betaAlaOH
3FC8	;	1.85	;	Crystal structure of transthyretin in complex with iododiflunisal-betaAlaOMe
5AYT	;	1.4	;	Crystal structure of transthyretin in complex with L6
4ABQ	;	1.7	;	CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-1
4ACT	;	1.8	;	CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-17
4AC4	;	1.8	;	CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-18
4ABU	;	1.86	;	CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-2
4ABV	;	1.8	;	CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-3
4ABW	;	1.7	;	Crystal Structure of Transthyretin in Complex With Ligand C-6
4AC2	;	1.81	;	CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-7
1DVY	;	1.9	;	CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH N-(M-TRIFLUOROMETHYLPHENYL) PHENOXAZINE-4,6-DICARBOXYLIC ACID
5OQ0	;	1.94	;	Crystal structure of transthyretin mutant 87-110-117
6R6I	;	1.467	;	Crystal structure of transthyretin mutant A25T in complex with CHF5074, a flurbiprofen analogue
2G3Z	;	1.9	;	Crystal structure of Transthyretin mutant I84A at low pH
2G4E	;	2.17	;	Crystal structure of transthyretin mutant I84A at neutral pH
2G3X	;	1.58	;	Crystal structure of Transthyretin mutant I84S at acidic pH
2NOY	;	1.8	;	Crystal structure of transthyretin mutant I84S at PH 7.5
8I0O	;	1.88	;	Crystal structure of Transthyretin variant A97S in monomeric form
3DK0	;	1.87	;	Crystal structure of transthyretin variant L55P at acidic pH
3DJZ	;	1.82	;	Crystal structure of transthyretin variant L55P at neutral pH
3DJS	;	1.8	;	Crystal structure of transthyretin variant L58H at acidic pH
3DJR	;	2.02	;	CRYSTAL STRUCTURE OF TRANSTHYRETIN VARIANT L58H at neutral pH
3DO4	;	2.4	;	Crystal structure of transthyretin variant T60A at acidic pH
3BT0	;	1.59	;	Crystal structure of transthyretin variant V20S
3DJT	;	2.3	;	Crystal structure of transthyretin variant V30M at acidic pH
3CXF	;	2.3	;	Crystal structure of transthyretin variant Y114H
3DK2	;	2.35	;	Crystal structure of transthyretin variant Y114H at acidic pH
4WNJ	;	1.398	;	Crystal structure of Transthyretin-quercetin complex
5XHG	;	1.76	;	Crystal structure of Trastuzumab Fab fragment bearing Ne-(o-azidobenzyloxycarbonyl)-L-lysine
5XHF	;	3.205	;	Crystal structure of Trastuzumab Fab fragment bearing p-azido-L-phenylalanine
5U91	;	3.104	;	Crystal structure of Tre/loxLTR complex
4TVU	;	2.7	;	Crystal structure of trehalose synthase from Deinococcus radiodurans reveals a closed conformation for catalysis of the intramolecular isomerization
2X6Q	;	2.2	;	Crystal structure of trehalose synthase TreT from P.horikoshi
2X6R	;	2.2	;	Crystal structure of trehalose synthase TreT from P.horikoshi produced by soaking in trehalose
2XA1	;	2.47	;	Crystal structure of trehalose synthase TreT from P.horikoshii (Seleno derivative)
2XA2	;	2.5	;	Crystal structure of trehalose synthase TreT mutant E326A from P. horikoshii in complex with UDPG
2XA9	;	2.5	;	Crystal structure of trehalose synthase TreT mutant E326A from P. horikoshii in complex with UDPG
2XMP	;	2.5	;	Crystal structure of trehalose synthase TreT mutant E326A from P. horishiki in complex with UDP
1U02	;	1.92	;	Crystal structure of trehalose-6-phosphate phosphatase related protein
2PEG	;	1.48	;	Crystal structure of Trematomus bernacchii hemoglobin in a partial hemichrome state
4ODC	;	1.54	;	Crystal structure of Trematomus bernacchii hemoglobin in a partially cyanided state
5GGU	;	2.292	;	Crystal structure of tremelimumab Fab
3RG8	;	1.74	;	Crystal structure of Treponema denticola PurE
3RGG	;	1.82	;	Crystal structure of Treponema denticola PurE bound to AIR
5C5D	;	1.69	;	Crystal structure of Treponema denticola PurE2-S38D
4FBG	;	3.02	;	Crystal structure of Treponema denticola trans-2-enoyl-CoA reductase in complex with NAD
5JIR	;	1.7	;	Crystal structure of Treponema pallidum protein Tp0624
5JK2	;	2.15	;	Crystal structure of Treponema pallidum Tp0751 (Pallilysin)
4XDR	;	1.4	;	Crystal structure of Treponema pallidum TP0796 Flavin trafficking protein, a bifunctional FMN transferase/FAD pyrophosphatase, D284A mutant, ADN bound form
4XDT	;	1.452	;	Crystal structure of Treponema pallidum TP0796 Flavin trafficking protein, a bifunctional FMN transferase/FAD pyrophosphatase, N55Y mutant, FAD bound form
4IFW	;	2.3001	;	Crystal structure of Treponema pallidum TP0796 Flavin trafficking protein, ADP inhibited form
4IFU	;	1.8334	;	Crystal structure of Treponema pallidum TP0796 Flavin trafficking protein, apo form
4IFX	;	1.452	;	Crystal structure of Treponema pallidum TP0796 Flavin trafficking protein, FAD substrate bound form
4IG1	;	1.4318	;	Crystal structure of Treponema pallidum TP0796 Flavin trafficking protein, Mg(II)-AMP product bound form
4IFZ	;	1.9012	;	Crystal structure of Treponema pallidum TP0796 Flavin trafficking protein, Mn(II)-AMP product bound form
4XDU	;	1.35	;	Crystal structure of Treponema pallidum TP0796 Flavin trafficking protein,a bifunctional FMN transferase/FAD pyrophosphatase, N55Y mutant, ADP bound form
2VR5	;	2.8	;	Crystal structure of Trex from Sulfolobus Solfataricus in complex with acarbose intermediate and glucose
5YWT	;	1.7	;	Crystal structure of TREX1 in complex with a duplex DNA with 3' overhang
5YWU	;	3.4	;	Crystal structure of TREX1 in complex with a inosine contained dsDNA
5YWV	;	2.3	;	Crystal structure of TREX1 in complex with a inosine contained ssDNA
5YWS	;	2.0	;	Crystal structure of TREX1 in complex with a Y structured DNA
5XUP	;	2.1	;	Crystal structure of TRF1 and TERB1
3BQO	;	2.0	;	Crystal Structure of TRF1 TRFH domain and TIN2 peptide complex
3BUA	;	2.5	;	Crystal Structure of TRF2 TRFH domain and APOLLO peptide complex
3BU8	;	2.15	;	Crystal Structure of TRF2 TRFH domain and TIN2 peptide complex
7C5D	;	2.151	;	Crystal structure of TRF2 TRFH domain in complex with a MCPH1 peptide
5WQD	;	3.0	;	Crystal structure of TRF2 TRFH in complex with an NBS1 peptide
6VPD	;	2.603	;	Crystal structure of Trgpx in apo form
3ANX	;	2.5	;	Crystal structure of triamine/agmatine aminopropyltransferase (SPEE) from thermus thermophilus, complexed with MTA
4XZS	;	2.12	;	Crystal Structure of TRIAP1-MBP fusion
5HME	;	2.151	;	Crystal structure of Triazine Hydrolase variant (P214T/Y215H)
5HMF	;	1.84	;	Crystal structure of triazine hydrolase variant (P214T/Y215H/E241Q)
5HMD	;	2.1	;	Crystal structure of triazine hydrolase variant (Y215H/E241Q)
3AC4	;	2.7	;	Crystal structure of triazolo pyrimidine derivative bound to the kinase domain of human LCK, (auto-phosphorylated on TYR394)
3AC5	;	2.5	;	Crystal structure of triazolo pyrimidine derivative bound to the kinase domain of human LCK, (auto-phosphorylated on TYR394)
3AD5	;	2.0	;	Crystal structure of Triazolone derivative bound to the kinase domain of human LCK, (auto-phosphorylated on TYR394)
5YJ9	;	2.53	;	Crystal structure of Tribolium castaneum PINK1 kinase domain in complex with AMP-PNP
5BY6	;	1.9	;	Crystal structure of Trichinella spiralis thymidylate synthase complexed with dUMP
4IG7	;	1.996	;	Crystal structure of Trichinella spiralis UCH37 bound to Ubiquitin vinyl methyl ester
4I6N	;	1.701	;	Crystal structure of Trichinella spiralis UCH37 catalytic domain bound to Ubiquitin vinyl methyl ester
5W0A	;	2.898	;	Crystal structure of Trichoderma harzianum endoglucanase I
3C9X	;	1.7	;	Crystal structure of Trichoderma reesei aspartic proteinase
3EMY	;	1.85	;	Crystal structure of Trichoderma reesei aspartic proteinase complexed with pepstatin A
1L5P	;	2.2	;	Crystal Structure of Trichomonas vaginalis Ferredoxin
1Z33	;	2.7	;	Crystal structure of Trichomonas vaginalis purine nucleoside phosphorylase
1Z39	;	2.6	;	Crystal structure of Trichomonas vaginalis purine nucleoside phosphorylase complexed with 2'-deoxyinosine
1Z34	;	2.4	;	Crystal structure of Trichomonas vaginalis purine nucleoside phosphorylase complexed with 2-fluoro-2'-deoxyadenosine
1Z35	;	2.5	;	Crystal structure of Trichomonas vaginalis purine nucleoside phosphorylase complexed with 2-fluoroadenosine
1Z37	;	2.9	;	Crystal structure of Trichomonas vaginalis purine nucleoside phosphorylase complexed with adenosine
1Z36	;	2.6	;	Crystal structure of Trichomonas vaginalis purine nucleoside phosphorylase complexed with formycin A
1Z38	;	2.5	;	Crystal structure of Trichomonas vaginalis purine nucleoside phosphorylase complexed with inosine
4O50	;	1.95	;	Crystal Structure of Trichomonas vaginalis Triosephosphate Isomerase Ile45-Ala mutant (Tvag_497370)
4O4W	;	2.35	;	Crystal Structure of Trichomonas vaginalis Triosephosphate Isomerase Ile45-Gly mutant (Tvag_497370)
4O53	;	2.0	;	Crystal Structure of Trichomonas vaginalis Triosephosphate Isomerase Ile45-Leu mutant (Tvag_497370)
4O54	;	1.9	;	Crystal Structure of Trichomonas vaginalis Triosephosphate Isomerase Ile45-Phe mutant (Tvag_497370)
4O57	;	1.793	;	Crystal Structure of Trichomonas vaginalis Triosephosphate Isomerase Ile45-Tyr mutant (Tvag_497370)
4O52	;	1.95	;	Crystal Structure of Trichomonas vaginalis Triosephosphate Isomerase Ile45-Val mutant (Tvag_497370)
3QST	;	1.75	;	Crystal structure of Trichomonas vaginalis triosephosphate isomerase TVAG_096350 gene (Val-45 variant)
4O4V	;	1.23	;	Crystal Structure of Trichomonas vaginalis Triosephosphate Isomerase Tvag_497370 (Ile-45 variant)
3QSR	;	2.05	;	Crystal structure of Trichomonas vaginalis triosephosphate isomerase TVAG_497370 gene (Ile-45 variant)
4WJE	;	1.285	;	Crystal structure of Trichomonas vaginalis triosephosphate isomerase V45A at 1.3 Angstroms
6YLD	;	1.4	;	Crystal structure of Trichoplax adhaerens trBcl-2L2 bound to trBak BH3
8BP5	;	2.13	;	Crystal structure of Trichoplax Dlg PDZ1 domain
8C1T	;	2.2	;	Crystal structure of Trichoplax Dlg PDZ1 domain in complex with Trichoplax Vangl peptide
8BQ8	;	2.7	;	Crystal structure of Trichoplax Dlg PDZ2 domain in complex with Trichoplax Vangl peptide
8BPM	;	2.8	;	Crystal structure of Trichoplax Dlg PDZ3 domain
8BOJ	;	1.5	;	Crystal structure of Trichoplax Scribble PDZ1 domain
8BUW	;	2.85	;	Crystal structure of Trichoplax Scribble PDZ1 domain in complex with Trichoplax Vangl peptide
8BNB	;	2.11	;	Crystal structure of Trichoplax Scribble PDZ2 domain
8BP4	;	1.15	;	Crystal structure of Trichoplax Scribble PDZ2 domain in complex with Trichoplax Vangl peptide
5A98	;	1.816	;	Crystal structure of Trichoplusia ni CPV15 polyhedra
1Z6O	;	1.91	;	Crystal Structure of Trichoplusia ni secreted ferritin
1GGP	;	2.7	;	CRYSTAL STRUCTURE OF TRICHOSANTHES KIRILOWII LECTIN-1 AND ITS RELATION TO THE TYPE 2 RIBOSOME INACTIVATING PROTEINS
1TCS	;	1.7	;	CRYSTAL STRUCTURE OF TRICHOSANTHIN-NADPH COMPLEX AT 1.7 ANGSTROMS RESOLUTION REVEALS ACTIVE-SITE ARCHITECTURE
2RF3	;	1.75	;	Crystal Structure of Tricyclo-DNA: An Unusual Compensatory Change of Two Adjacent Backbone Torsion Angles
2I36	;	4.1	;	Crystal structure of trigonal crystal form of ground-state rhodopsin
1IHD	;	2.65	;	Crystal Structure of Trigonal Form of D90E Mutant of Escherichia coli Asparaginase II
6FGA	;	2.82	;	Crystal structure of TRIM21 E3 ligase, RING domain in complex with its cognate E2 conjugating enzyme UBE2E1
6S53	;	2.8	;	Crystal structure of TRIM21 RING domain in complex with an isopeptide-linked Ube2N~ubiquitin conjugate
3O37	;	2.0	;	Crystal structure of TRIM24 PHD-Bromo complexed with H3(1-10)K4 peptide
3O34	;	1.9	;	Crystal structure of TRIM24 PHD-Bromo complexed with H3(13-32)K23ac peptide
3O35	;	1.76	;	Crystal structure of TRIM24 PHD-Bromo complexed with H3(23-31)K27ac peptide
3O36	;	1.7	;	Crystal structure of TRIM24 PHD-Bromo complexed with H4(14-19)K16ac peptide
3O33	;	2.0	;	Crystal structure of TRIM24 PHD-Bromo in the free state
4YAB	;	1.9	;	Crystal structure of TRIM24 PHD-bromodomain complexed with 1-methyl-5-(2-methyl-1 3-thiazol-4-yl)-2 3-dihydro-1H-indol-2-one (1)
4YAD	;	1.73	;	Crystal structure of TRIM24 PHD-bromodomain complexed with 2,4-dimethoxy-N-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)benzene-1-sulfonamide (3b)
4YAT	;	2.18	;	Crystal structure of TRIM24 PHD-bromodomain complexed with N-(1,3-dimethyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-yl)-4-methoxybenzene-1-sulfonamide (5b)
4YC9	;	1.82	;	Crystal structure of TRIM24 PHD-bromodomain complexed with N-(6-{3-[4-(dimethylamino)butoxy]-5-propoxyphenoxy}-1,3-dimethyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-yl)-3,4-dimethoxybenzene-1-sulfonamide (8i)
4YAX	;	2.25	;	Crystal structure of TRIM24 PHD-bromodomain complexed with N-[6-(4-methoxyphenoxy)-1,3-dimethyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-yl]benzenesulfonamide (5g)
4YBT	;	1.82	;	Crystal structure of TRIM24 PHD-bromodomain complexed with N-{1,3-dimethyl-2-oxo-6-[3-(oxolan-3-ylmethoxy)phenoxy]-2,3-dihydro-1H-1,3-benzodiazol-5-yl}-1-methyl-1H-imidazole-4-sulfonamide (7l)
4YBS	;	1.83	;	Crystal structure of TRIM24 PHD-bromodomain complexed with N-{1,3-dimethyl-6-[3-(2-methylpropoxy)phenoxy]-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-yl}-1,2-dimethyl-1H-imidazole-4-sulfonamide (7g)
4YBM	;	1.46	;	Crystal structure of TRIM24 PHD-bromodomain complexed with N-{6-[3-(benzyloxy)phenoxy]-1,3-dimethyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-yl}-3,4-dimethoxybenzene-1-sulfonamide (7b)
4ZQL	;	1.79	;	Crystal structure of TRIM24 with 3,4-dimethoxy-N-(6-(4-methoxyphenoxy)-1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)benzenesulfonamide inhibitor
8BD9	;	3.2	;	Crystal structure of TRIM33 alpha PHD-Bromo domain in complex with 10
8BD8	;	3.1	;	Crystal structure of TRIM33 alpha PHD-Bromo domain in complex with 8
8BDY	;	3.05	;	Crystal structure of TRIM33 alpha PHD-Bromo domain in complex with 9
3U5M	;	3.08	;	Crystal structure of TRIM33 PHD-Bromo in the free state
7ZDD	;	1.625	;	Crystal structure of TRIM33 PHD-Bromodomain isoform B in complex with H3K10ac histone peptide.
5MR8	;	1.74	;	Crystal structure of TRIM33 PHD-Bromodomain isoform B in complex with H3K9ac histone peptide
8PD4	;	2.714	;	Crystal structure of TRIM58 PRY-SPRY domain
7JL4	;	1.92	;	Crystal structure of TRIM65 PSpry domain
6UMB	;	1.8	;	Crystal structure of TRIM7 B30.2 domain at 1.8 angstrom resolution
7Y3A	;	1.7	;	Crystal structure of TRIM7 bound to 2C
7Y3B	;	1.76	;	Crystal structure of TRIM7 bound to GN1
7Y3C	;	1.71	;	Crystal structure of TRIM7 bound to RACO-1
7XT2	;	3.0	;	Crystal structure of TRIM72
2O7H	;	1.86	;	Crystal structure of trimeric coiled coil GCN4 leucine zipper
1DRG	;	2.55	;	CRYSTAL STRUCTURE OF TRIMERIC CRE RECOMBINASE-LOX COMPLEX
1F44	;	2.05	;	CRYSTAL STRUCTURE OF TRIMERIC CRE RECOMBINASE-LOX COMPLEX
3NBT	;	2.1	;	Crystal structure of trimeric cytochrome c from horse heart
2FQL	;	3.01	;	Crystal structure of trimeric frataxin from the yeast Saccharomyces cerevisiae
3OER	;	3.2	;	Crystal structure of trimeric frataxin from the yeast saccharomyces cerevisiae, complexed with cobalt
4EC2	;	3.002	;	Crystal structure of trimeric frataxin from the yeast Saccharomyces cerevisiae, complexed with ferrous
3OEQ	;	2.96	;	Crystal structure of trimeric frataxin from the yeast Saccharomyces cerevisiae, with full length n-terminus
4F3J	;	1.337	;	Crystal Structure of Trimeric gC1q Domain of Human C1QTNF5 associated with Late-onset Retinal Macular Degeneration
8IQ5	;	1.38	;	Crystal structure of trimeric K2-2 TSP
8IQ9	;	1.58	;	Crystal structure of trimeric K2-2 TSP in complex with tetrasaccharide and octasaccharide
6NXZ	;	1.75	;	Crystal structure of trimethoprim-resistant type II dihydrofolate reductase in complex with a bisbenzimidazole inhibitor
6NY0	;	1.4	;	Crystal structure of trimethoprim-resistant type II dihydrofolate reductase in complex with a bisbenzimidazole inhibitor
4YYC	;	1.56	;	Crystal structure of trimethylamine methyltransferase from Sinorhizobium meliloti in complex with unknown ligand
7XCL	;	2.5	;	Crystal structure of trimethylamine methyltransferase MttB from Methanosarcina barkeri at 2.5 A resolution
1DKW	;	2.65	;	CRYSTAL STRUCTURE OF TRIOSE-PHOSPHATE ISOMERASE WITH MODIFIED SUBSTRATE BINDING SITE
2H6R	;	2.3	;	Crystal Structure of triosephosphate isomerase (TIM) from Methanocaldococcus jannaschii
7PEK	;	1.74	;	Crystal structure of Triosephosphate Isomerase C216A mutant from Schizosaccharomyces pombe (SpTIM C216A)
7RPN	;	1.37	;	Crystal structure of triosephosphate isomerase from Bacteroides thetaiotaomicron
3KXQ	;	1.6	;	Crystal structure of triosephosphate isomerase from bartonella henselae at 1.6A resolution
4NVT	;	2.1	;	Crystal Structure of Triosephosphate Isomerase from Brucella melitensis
4G1K	;	2.35	;	Crystal structure of triosephosphate isomerase from Burkholderia thailandensis
7R7M	;	2.0	;	Crystal structure of Triosephosphate isomerase from Candidate division Katanobacteria (WWE3) bacterium
7RGC	;	2.09	;	Crystal structure of triosephosphate isomerase from Candidatus Absconditabacteria (Sr1) bacterium
7N8U	;	1.98	;	Crystal structure of Triosephosphate isomerase from Candidatus Prometheoarchaeum syntrophicum
7R9B	;	2.2	;	Crystal structure of Triosephosphate isomerase from Candidatus Roizmanbacteria
4Y8F	;	1.54	;	Crystal structure of Triosephosphate Isomerase from Clostridium perfringens
4Y90	;	2.1	;	Crystal structure of Triosephosphate Isomerase from Deinococcus radiodurans
1M6J	;	1.5	;	CRYSTAL STRUCTURE OF TRIOSEPHOSPHATE ISOMERASE FROM ENTAMOEBA HISTOLYTICA
5UJW	;	2.65	;	Crystal structure of triosephosphate isomerase from Francisella tularensis subsp. tularensis SCHU S4
4Y96	;	1.581	;	Crystal structure of Triosephosphate Isomerase from Gemmata obscuriglobus
7RCQ	;	1.7	;	Crystal structure of triosephosphate isomerase from Ktedonobacter racemifer
3M9Y	;	1.9	;	Crystal structure of Triosephosphate isomerase from methicillin resistant Staphylococcus aureus at 1.9 Angstrom resolution
3UWY	;	2.4	;	Crystal structure of triosephosphate isomerase from Methicillin resistant Staphylococcus Aureus at 2.4 angstrom resolution
3GVG	;	1.55	;	Crystal structure of Triosephosphate isomerase from Mycobacterium tuberculosis
5ZFX	;	1.751	;	Crystal Structure of Triosephosphate isomerase from Opisthorchis viverrini
3TH6	;	2.4	;	Crystal structure of Triosephosphate isomerase from Rhipicephalus (Boophilus) microplus.
6OOI	;	2.14	;	Crystal structure of triosephosphate isomerase from Schistosoma mansoni in complex with 2PG
7PEJ	;	1.79	;	Crystal structure of Triosephosphate Isomerase from Schizosaccharomyces pombe (SpTIM wt)
6W4U	;	1.7	;	Crystal structure of Triosephosphate isomerase from Stenotrophomonas maltophilia K279a
4Y9A	;	2.294	;	Crystal structure of Triosephosphate Isomerase from Streptomyces coelicolor
6OOG	;	2.02	;	Crystal structure of triosephosphate isomerase from Taenia Solium in complex with 2PG
5CSR	;	1.94	;	Crystal structure of triosephosphate isomerase from Thermoplasma acidophilium
5CSS	;	2.17	;	Crystal structure of triosephosphate isomerase from Thermoplasma acidophilum with glycerol 3-phosphate
1CI1	;	2.0	;	CRYSTAL STRUCTURE OF TRIOSEPHOSPHATE ISOMERASE FROM TRYPANOSOMA CRUZI IN HEXANE
4HHP	;	1.5	;	Crystal structure of triosephosphate isomerase from trypanosoma cruzi, mutant e105d
7RMN	;	1.21	;	Crystal structure of triosephosphate isomerase from Verrucomicrobium spinosum
6CG9	;	1.8	;	Crystal structure of Triosephosphate Isomerase from Zea mays (mexican corn)
5ZGA	;	1.793	;	Crystal Structure of Triosephosphate isomerase SAD deletion and N115A mutant from Opisthorchis viverrini
5ZG4	;	1.746	;	Crystal Structure of Triosephosphate isomerase SAD deletion mutant from Opisthorchis viverrini
5ZG5	;	1.597	;	Crystal Structure of Triosephosphate isomerase SADsubAAA mutant from Opisthorchis viverrini
5WS4	;	3.4	;	Crystal structure of tripartite-type ABC transporter MacB from Acinetobacter baumannii
5GKO	;	3.393	;	Crystal structure of tripartite-type ABC transporter, MacB from Acinetobacter baumannii
4WCN	;	1.75	;	Crystal Structure of Tripeptide bound Cell Shape Determinant Csd4 protein from Helicobacter pylori
3LXU	;	3.14	;	Crystal Structure of Tripeptidyl Peptidase 2 (TPP II)
7YOF	;	2.3	;	Crystal Structure of Triple mutant (D67E, A68P, I88L) of O-acetyl-L-serine sulfhydrylase from Haemophilus influenzae at 2.3 A
5D0G	;	1.6	;	Crystal structure of triple mutant (KDA to EGY) of adenylyl cyclase Ma1120 from Mycobacterium avium in complex with GTP and calcium ion
5D0H	;	2.1	;	Crystal Structure of triple mutant (KDA to EGY) of an adenylyl cyclase Ma1120 from Mycobacterium avium in complex with ATP and calcium ion
1D3R	;	1.8	;	CRYSTAL STRUCTURE OF TRIPLEX DNA
8XPC	;	1.55	;	Crystal structure of Tris-bound TsaBgl (DATA I)
8XPD	;	1.7	;	Crystal structure of Tris-bound TsaBgl (DATA II)
8XPE	;	1.95	;	Crystal structure of Tris-bound TsaBgl (DATA III)
6MCD	;	1.5	;	Crystal Structure of tris-thiolate Pb(II) complex with adjacent water in a de novo Three Stranded Coiled Coil Peptide
5GUL	;	1.73	;	Crystal structure of Tris/PPix2/Mg2+ bound form of cyclolavandulyl diphosphate synthase (CLDS) from Streptomyces sp. CL190
5WR7	;	2.76	;	Crystal structure of Trk-A complexed with a selective inhibitor CH7057288
6DKB	;	2.68	;	Crystal structure of Trk-A in complex with the Pan-Trk Kinase Inhibitor, compound 10b.
6J5L	;	2.3	;	Crystal structure of Trk-A in complex with the Pan-Trk Kinase Inhibitor, compound 10e
6DKG	;	2.53	;	Crystal structure of Trk-A in complex with the Pan-Trk Kinase Inhibitor, compound 13b.
6DKI	;	2.11	;	Crystal structure of Trk-A in complex with the Pan-Trk Kinase Inhibitor, compound 19.
6DKW	;	2.91	;	Crystal structure of Trk-A in complex with the Pan-Trk Kinase Inhibitor, compound 3.
7VKM	;	2.55	;	Crystal structure of TrkA (G595R) kinase domain
7VKN	;	2.7	;	Crystal structure of TrkA (G595R) kinase with repotrectinib
3C85	;	1.9	;	Crystal structure of TrkA domain of putative glutathione-regulated potassium-efflux KefB from Vibrio parahaemolyticus
3DOC	;	2.4	;	Crystal Structure of TrkA glyceraldehyde-3-phosphate dehydrogenase from Brucella melitensis
5JFS	;	2.07	;	Crystal structure of TrkA in complex with PF-00593174
5JFV	;	1.59	;	Crystal structure of TrkA in complex with PF-05206283
5JFW	;	1.52	;	Crystal structure of TrkA in complex with PF-05247452
5JFX	;	1.63	;	Crystal structure of TrkA in complex with PF-06273340
5H3Q	;	2.1	;	Crystal Structure of TrkA kinase with ligand
6IQN	;	2.54	;	Crystal structure of TrkA kinase with ligand
7VKO	;	2.9	;	Crystal structure of TrkA kinase with repotrectinib
3FWZ	;	1.79	;	Crystal structure of TrkA-N domain of inner membrane protein ybaL from Escherichia coli
4AT3	;	1.77	;	CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH CPD5N
4AT4	;	2.36	;	CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH EX429
4AT5	;	1.71	;	CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH GW2580
1HCF	;	2.7	;	Crystal structure of TrkB-d5 bound to neurotrophin-4/5
6KZD	;	1.708	;	Crystal structure of TRKc in complex with 3-((6-(4-aminophenyl)imidazo[1,2-a]pyrazin-3-yl)ethynyl)- N-(3-isopropyl-5-((4-methylpiperazin-1-yl)methyl)phenyl)-2- methylbenzamide
6KZC	;	2.0	;	crystal structure of TRKc in complex with 3-(imidazo[1,2-a]pyrazin-3-ylethynyl)-2-methyl-N-(3-((4- methylpiperazin-1-yl)methyl)-5- (trifluoromethyl)phenyl)benzamide
3TLJ	;	2.2	;	Crystal structure of Trm14 from Pyrococcus furiosus in complex with S-adenosyl-L-homocysteine
3TM4	;	1.95	;	Crystal structure of Trm14 from Pyrococcus furiosus in complex with S-adenosylmethionine
3TM5	;	2.27	;	Crystal structure of Trm14 from Pyrococcus furiosus in complex with sinefungin
8BYH	;	2.19	;	Crystal structure of TrmD domain from Calditerrivibrio nitroreducens in complex with S-adenosyl-L-methionine
5ZHK	;	2.3	;	Crystal structure of TrmD from Mycobacterium tuberculosis in complex with active-site inhibitor
5ZHL	;	2.25	;	Crystal structure of TrmD from Mycobacterium tuberculosis in complex with active-site inhibitor
6JOF	;	2.2	;	Crystal structure of TrmD from Mycobacterium tuberculosis in complex with active-site inhibitor
5ZHJ	;	1.75	;	Crystal structure of TrmD from Mycobacterium tuberculosis in complex with S-adenosyl homocysteine (SAH)
5ZHM	;	2.76	;	Crystal structure of TrmD from Pseudomonas aeruginosa in complex with active-site inhibitor
5ZHN	;	2.65	;	Crystal structure of TrmD from Pseudomonas aeruginosa in complex with active-site inhibitor
6AFK	;	2.75	;	Crystal structure of TrmD from Pseudomonas aeruginosa in complex with active-site inhibitor
6JOE	;	2.21	;	Crystal structure of TrmD from Pseudomonas aeruginosa in complex with active-site inhibitor
7KFF	;	1.35	;	Crystal structure of TrmD tRNA (guanine-N1)-methyltransferase from Corynebacterium diphtheriae in complex with SAH
4YPW	;	2.311	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YPX	;	1.89	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YPY	;	1.9	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YPZ	;	1.84	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YQ0	;	1.76	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YQ1	;	2.0	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YQ2	;	2.65	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YQ3	;	2.49	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YQ4	;	1.89	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YQ5	;	1.76	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YQ6	;	1.9	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YQ7	;	1.8	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YQ8	;	1.94	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YQ9	;	1.64	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YQA	;	1.55	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YQB	;	2.1	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YQC	;	1.89	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YQD	;	1.45	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YQG	;	1.858	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YQI	;	1.92	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YQJ	;	1.94	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YQK	;	1.83	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YQL	;	2.401	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YQN	;	2.2	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YQO	;	1.68	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YQP	;	2.601	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YQQ	;	1.78	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YQR	;	1.701	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YQS	;	1.902	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
4YQT	;	1.6	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
5D9F	;	1.91	;	Crystal structure of TrmD, a M1G37 tRNA Methyltransferase with SAM-competitive compounds
6NVR	;	1.562	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in Apo form
6QO2	;	1.68	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with Fragment 1 (1H-Indole-5-carboxamide)
6QOG	;	1.55	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with Fragment 10 (2-Amino-5-bromobenzothiazole)
6QOH	;	1.66	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with Fragment 11 (2-Amino-6-chloropurine)
6QOI	;	1.86	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with Fragment 12 (2-Aminobenzothiazole)
6QOJ	;	2.023	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with Fragment 13 (4-Hydroxyquinazoline)
6QOK	;	1.48	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with Fragment 14 (Methyl 2-aminopyridine-4-carboxylate)
6QOL	;	1.903	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with Fragment 15 (6-quinoxalinamine)
6QOM	;	1.9	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with Fragment 16 (2-Amino-3-nitropyridine)
6QON	;	1.81	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with Fragment 17 (2H-1,3-Benzoxazine-2,4(3H)-dione)
6QOO	;	1.94	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with Fragment 18 (Isoxazole-5-carbothioamide)
6QOP	;	1.912	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with Fragment 19 (5-fluoroquinazolin-4-ol)
6QO3	;	1.65	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with Fragment 2 (5-Amino-3-(2-thienyl) pyrazole)
6QOQ	;	1.67	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with Fragment 20 (6-Aminobenzothiazole)
6QOR	;	1.671	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with Fragment 21 (2-Amino-3-nitrophenol)
6QOS	;	2.052	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with Fragment 22 (Ethyl 1H-pyrazole-4-carboxylate)
6QOT	;	1.62	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with Fragment 23 (3-Amino-5-(4-methoxyphenyl)pyrazole)
6QOU	;	1.56	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with Fragment 24 (Indole-6-boronic acid)
6QOV	;	1.55	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with Fragment 25 (6-Phenyl-3-pyridinyl)methylamine)
6QOW	;	1.53	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with Fragment 26 (6-methoxybenzothiazole-2-carboxylic acid)
6QOX	;	1.74	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with Fragment 27 (Methyl 2-(hydroxymethyl)-6H-thieno[2,3-b]pyrrole-5-carboxylate)
6QO4	;	1.78	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with Fragment 3 (2-(5-Isoxazolyl) phenol)
6QO6	;	1.745	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with Fragment 4 (5-Methoxybenzimidazole)
6QOA	;	1.93	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with Fragment 5 (Isoxazole-5-carboxamide)
6QOC	;	1.84	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with Fragment 6 (2-(1,3-oxazol-5-yl) aniline)
6QOD	;	1.852	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with Fragment 7 (2-Amino-6-fluorobenzothiazole)
6QOE	;	3.06	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with Fragment 8 (3-[(2-thienylthio)methyl]benzoic acid)
6QOF	;	1.76	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with Fragment 9 (Adenine)
6QQQ	;	1.85	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with inhibitor
6QQR	;	1.56	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with inhibitor
6QQS	;	1.76	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with inhibitor
6QQT	;	1.673	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with inhibitor
6QQU	;	1.59	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with inhibitor
6QQV	;	1.712	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with inhibitor
6QQW	;	1.8	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with inhibitor
6QQX	;	2.69	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with inhibitor
6QQY	;	1.49	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with inhibitor
6QQZ	;	1.702	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with inhibitor
6QR0	;	1.59	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with inhibitor
6QR1	;	1.67	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with inhibitor
6QR2	;	1.55	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with inhibitor
6QR3	;	1.614	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with inhibitor
6QR4	;	1.52	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with inhibitor
6QR5	;	1.81	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with inhibitor
6QR6	;	1.71	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with inhibitor
6QR7	;	2.03	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with inhibitor
6QR8	;	2.15	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with inhibitor
6QR9	;	2.42	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with inhibitor
6QRA	;	1.71	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with inhibitor
6QRB	;	1.66	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with inhibitor
6QRC	;	1.73	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with inhibitor
6QRD	;	1.75	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with inhibitor
6QRE	;	1.93	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with inhibitor
6QRF	;	1.86	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with inhibitor
6QRG	;	1.84	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with inhibitor
6NW6	;	1.67	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with S-Adenosyl methionine
6NW7	;	1.481	;	Crystal structure of TrmD, a tRNA-(N1G37) methyltransferase, from Mycobacterium abscessus in complex with S-Adenosyl-L-homocysteine
8B1N	;	2.0	;	Crystal structure of TrmD-Tm1570 from Calditerrivibrio nitroreducens in complex with S-adenosyl-L-methionine
3E5Y	;	2.4	;	Crystal structure of TrmH family RNA methyltransferase from Burkholderia pseudomallei
5GRA	;	3.005	;	Crystal structure of TrmJ from Z. mobilis ZM4
7E3T	;	2.1	;	Crystal structure of TrmL from Mycoplasma capricolum
7E3S	;	2.1	;	Crystal structure of TrmL from Shewanella oneidensis
7E3R	;	1.79	;	Crystal structure of TrmL from Vibrio vulnificus
3TMA	;	2.05	;	Crystal structure of TrmN from Thermus thermophilus
7BTZ	;	2.4	;	Crystal structure of TrmO
7BTU	;	1.91	;	Crystal structure of TrmO from P. areuginosa
7BU1	;	2.49	;	Crystal structure of TrmO from Pseudomonas aeruginosa
5ZW3	;	2.27	;	Crystal Structure of TrmR from B. subtilis
8K1F	;	2.4	;	Crystal Structure of TrmR from Fusobacterium nucleatum
6W14	;	2.0	;	Crystal structure of tRNA (guanine-N(1)-)-methyltransferase from Mycobacterium smegmatis
6W15	;	2.0	;	Crystal structure of tRNA (guanine-N(1)-)-methyltransferase with bound SAH from Mycobacterium smegmatis
3KNU	;	2.25	;	Crystal structure of tRNA (guanine-N1)-methyltransferase from Anaplasma phagocytophilum
2YVL	;	2.2	;	Crystal structure of tRNA (m1A58) methyltransferase TrmI from Aquifex aeolicus
1OY5	;	2.6	;	Crystal structure of tRNA (m1G37) methyltransferase from Aquifex aeolicus
4JAK	;	2.0	;	Crystal structure of tRNA (Um34/Cm34) methyltransferase TrmL from Escherichia coli
4JAL	;	2.0	;	Crystal structure of tRNA (Um34/Cm34) methyltransferase TrmL from Escherichia coli with SAH
7YW3	;	2.5	;	Crystal structure of tRNA 2'-phosphotransferase from Homo sapiens
7YW2	;	2.23	;	Crystal structure of tRNA 2'-phosphotransferase from Mus musculus
7YW4	;	2.18	;	Crystal structure of tRNA 2'-phosphotransferase from Saccharomyces cerevisiae
7CPH	;	2.3	;	Crystal structure of tRNA adenosine deaminase from Bacillus subtilis
1WWR	;	1.8	;	Crystal structure of tRNA adenosine deaminase TadA from Aquifex aeolicus
1Z3A	;	2.03	;	Crystal structure of tRNA adenosine deaminase TadA from Escherichia coli
5ZW4	;	1.7	;	Crystal structure of tRNA bound TrmR
3D3Q	;	2.7	;	Crystal structure of tRNA delta(2)-isopentenylpyrophosphate transferase (SE0981) from Staphylococcus epidermidis. Northeast Structural Genomics Consortium target SeR100
5EHK	;	2.708	;	Crystal structure of tRNA dependent lantibiotic dehydratase MibB from Microbispora sp. 107891
4RVZ	;	2.9	;	Crystal structure of tRNA fluorescent labeling enzyme
2DUL	;	1.9	;	Crystal structure of tRNA G26 methyltransferase Trm1 in apo form from Pyrococcus horikoshii
3IEF	;	2.5	;	Crystal structure of tRNA guanine-n1-methyltransferase from Bartonella henselae using MPCS.
2QGN	;	2.4	;	Crystal structure of tRNA isopentenylpyrophosphate transferase (BH2366) from Bacillus halodurans, Northeast Structural Genomics Consortium target BhR41.
2ZM5	;	2.55	;	Crystal structure of tRNA modification enzyme MiaA in the complex with tRNA(Phe)
2ZXU	;	2.75	;	Crystal structure of tRNA modification enzyme MiaA in the complex with tRNA(Phe) and DMASPP
1VFG	;	2.8	;	Crystal structure of tRNA nucleotidyltransferase complexed with a primer tRNA and an incoming ATP analog
4WC2	;	2.8	;	Crystal structure of tRNA nucleotidyltransferase complexed with a primer tRNA and an incoming ATP analog
4LT8	;	3.14	;	Crystal Structure of tRNA Proline (CGG) Bound to Codon CCC-G on the Ribosome
4LNT	;	2.94	;	Crystal Structure of tRNA Proline (CGG) Bound to Codon CCC-U on the Ribosome
4LSK	;	3.48001	;	Crystal Structure of tRNA Proline (CGG) Bound to Codon CCG-G on the Ribosome
1R3E	;	2.1	;	Crystal Structure of tRNA Pseudouridine Synthase TruB and Its RNA Complex: RNA-protein Recognition Through a Combination of Rigid Docking and Induced Fit
1R3F	;	1.85	;	Crystal Structure of tRNA Pseudouridine Synthase TruB and Its RNA Complex: RNA-protein Recognition Through a Combination of Rigid Docking and Induced Fit
2ZW9	;	2.5	;	Crystal structure of tRNA wybutosine synthesizing enzyme TYW4
2ZWA	;	1.7	;	Crystal structure of tRNA wybutosine synthesizing enzyme TYW4
2ZZK	;	2.706	;	Crystal structure of tRNA wybutosine synthesizing enzyme TYW4
5XOX	;	3.0	;	Crystal structure of tRNA(His) guanylyltranserase from Saccharomyces cerevisiae
1UAJ	;	1.85	;	Crystal structure of tRNA(m1G37)methyltransferase: Insight into tRNA recognition
1UAK	;	2.05	;	Crystal structure of tRNA(m1G37)methyltransferase: Insight into tRNA recognition
1UAL	;	1.8	;	Crystal structure of tRNA(m1G37)methyltransferase: Insight into tRNA recognition
1UAM	;	2.2	;	Crystal structure of tRNA(m1G37)methyltransferase: Insight into tRNA recognition
2ZPA	;	2.35	;	Crystal Structure of tRNA(Met) Cytidine Acetyltransferase
4WD9	;	2.9	;	Crystal structure of tRNA-dependent lantibiotic dehydratase NisB in complex with NisA leader peptide
4WFS	;	2.68	;	Crystal Structure of tRNA-dihydrouridine(20) synthase catalytic domain
4WFT	;	1.7	;	Crystal structure of tRNA-dihydrouridine(20) synthase dsRBD domain
1K4G	;	1.7	;	CRYSTAL STRUCTURE OF TRNA-GUANINE TRANSGLYCOSYLASE (TGT) COMPLEXED WITH 2,6-DIAMINO-8-(1H-IMIDAZOL-2-YLSULFANYLMETHYL)-3H-QUINAZOLINE-4-ONE
1K4H	;	1.8	;	CRYSTAL STRUCTURE OF TRNA-GUANINE TRANSGLYCOSYLASE (TGT) COMPLEXED WITH 2,6-Diamino-8-propylsulfanylmethyl-3H-quinazoline-4-one
1P0B	;	1.7	;	Crystal Structure Of tRNA-Guanine Transglycosylase (TGT) From Zymomonas mobilis Complexed With Archaeosine Precursor, Preq0
2QII	;	1.7	;	Crystal Structure Of tRNA-Guanine Transglycosylase (TGT) From Zymomonas mobilis Complexed With Archaeosine Precursor, Preq0
2BBF	;	1.7	;	Crystal structure of tRNA-guanine transglycosylase (TGT) from Zymomonas mobilis in complex with 6-amino-3,7-dihydro-imidazo[4,5-g]quinazolin-8-one
2CV8	;	2.8	;	Crystal structure of tRNA-intron endonuclease from Sulfolobus tokodaii
3OCQ	;	2.05	;	crystal structure of tRNA-specific Adenosine deaminase from Salmonella enterica
4TUB	;	3.6	;	Crystal structure of tRNA-Thr bound to Codon ACC-C on the Ribosome
3ONP	;	1.9	;	Crystal Structure of tRNA/rRNA Methyltransferase SpoU from Rhodobacter sphaeroides
4KDZ	;	2.32	;	Crystal structure of tRNA/rRNA methyltransferase YibK from Escherichia coli (Target NYSGRC-012599)
1WW1	;	2.6	;	Crystal structure of tRNase Z from Thermotoga maritima
7VNV	;	1.9	;	Crystal Structure of tRNAVal from Sulfolobus Tokodaii
7VNW	;	2.61	;	Crystal Structure of tRNAVal from Sulfolobus Tokodaii(Dephosphorylated)
6OF6	;	3.2	;	Crystal structure of tRNA^ Ala(GGC) bound to cognate 70S A-site
6OJ2	;	3.2	;	Crystal structure of tRNA^ Ala(GGC) bound to the near-cognate 70S A-site
6ORD	;	3.1	;	Crystal structure of tRNA^ Ala(GGC) U32-A38 bound to cognate 70S A site
6OPE	;	3.1	;	Crystal structure of tRNA^ Ala(GGC) U32-A38 bound to near-cognate 70S A site
8FON	;	3.64	;	Crystal structure of tRNA^Lys(SUU) bound to AUA codon in the ribosomal P site
8FOM	;	3.58	;	Crystal structure of tRNA^Lys(SUU) bound to UAA codon in the ribosomal P site
4MO9	;	1.925	;	Crystal Structure of TroA-like Periplasmic Binding Protein FepB from Veillonella parvula
4MX8	;	2.911	;	Crystal Structure of TroA-like Periplasmic Binding Protein Peripla_BP_2 from Xylanimonas cellulosilytica
1IO0	;	1.45	;	CRYSTAL STRUCTURE OF TROPOMODULIN C-TERMINAL HALF
1C1G	;	7.0	;	CRYSTAL STRUCTURE OF TROPOMYOSIN AT 7 ANGSTROMS RESOLUTION IN THE SPERMINE-INDUCED CRYSTAL FORM
3AZD	;	0.98	;	Crystal structure of tropomyosin N-terminal fragment at 0.98A resolution
3BOM	;	1.35	;	Crystal structure of trout hemoglobin at 1.35 Angstrom resolution
1YDG	;	2.0	;	Crystal Structure of Trp repressor binding protein WrbA
1YRH	;	3.11	;	Crystal Structure Of Trp Repressor Binding Protein Wrba in complex with FMN
1TRO	;	1.9	;	CRYSTAL STRUCTURE OF TRP REPRESSOR OPERATOR COMPLEX AT ATOMIC RESOLUTION
3WO1	;	2.3	;	Crystal structure of Trp332Ala mutant YwfE, an L-amino acid ligase, with bound ADP-Mg-Ala
4WUI	;	1.09	;	Crystal structure of TrpF from Jonesia denitrificans
7MQV	;	2.4	;	Crystal structure of truncated (ACT domain removed) prephenate dehydrogenase tyrA from Bacillus anthracis in complex with NAD
7EQR	;	2.75003	;	Crystal structure of Truncated (Delta 1-19) Chitoporin VhChiP from Vibrio harveyi in complex with chitohexaose
4IKU	;	1.3	;	Crystal structure of truncated (delta 1-89) human methionine aminopeptidase Type 1 in complex with 2-((5-chloro-6-methyl-2-(pyridin-2-yl)pyrimidin-4-yl)amino)-3-phenylpropanamide
4IKT	;	1.6	;	Crystal structure of truncated (delta 1-89) human methionine aminopeptidase Type 1 in complex with N1-(5-chloro-6-methyl-2-(pyridin-2-yl)pyrimidin-4-yl)-N2-(5-(trifluoromethyl)pyridin-2-yl)ethane-1,2-diamine
4IKS	;	1.7	;	Crystal structure of truncated (delta 1-89) human methionine aminopeptidase Type 1 in complex with N1-(5-chloro-6-methyl-2-(pyridin-2-yl)pyrimidin-4-yl)-N2-(6-(trifluoromethyl)pyridin-2-yl)ethane-1,2-diamine
2G6P	;	1.9	;	Crystal structure of truncated (delta 1-89) human methionine aminopeptidase Type 1 in complex with Pyridyl pyrimidine derivative
4OIX	;	1.55	;	Crystal structure of truncated Acylphosphatase from S. sulfataricus
4OJ1	;	1.7	;	Crystal structure of truncated Acylphosphatase from S. sulfataricus
3RMJ	;	1.95	;	Crystal structure of truncated alpha-Isopropylmalate Synthase from Neisseria meningitidis
6HVG	;	2.8	;	Crystal Structure of Truncated Alternansucrase from Leuconostoc mesenteroides NRRL B-1355
7ZP2	;	2.292	;	Crystal Structure of truncated aspartate transcarbamoylase from Plasmodium falciparum in complex with BDA-04
7ZID	;	2.55	;	Crystal Structure of truncated aspartate transcarbamoylase from Plasmodium falciparum in complex with BDA-14
7ZST	;	2.5	;	Crystal Structure of truncated aspartate transcarbamoylase from Plasmodium falciparum in complex with FLA-01
7ZCZ	;	2.45	;	Crystal Structure of truncated aspartate transcarbamoylase from Plasmodium falciparum with bound inhibitor 1-(4-chlorophenyl)methanamine
6FBA	;	2.0	;	Crystal Structure of truncated aspartate transcarbamoylase from Plasmodium falciparum with bound inhibitor 2,3-naphthalenediol
7ZGS	;	2.349	;	Crystal Structure of truncated aspartate transcarbamoylase from Plasmodium falciparum with bound inhibitor 2-phenylethan-1-amine
7ZHI	;	2.946	;	Crystal Structure of truncated aspartate transcarbamoylase from Plasmodium falciparum with bound inhibitor indole
7ZEA	;	2.448	;	Crystal Structure of truncated aspartate transcarbamoylase from Plasmodium falciparum with bound inhibitor O-benzylhydroxylamine
6HL7	;	2.5	;	Crystal structure of truncated aspartate transcarbamoylase from Plasmodium falciparum with mutated active site (R109A/K138A) and N-carbamoyl-L-phosphate bound
6WWX	;	2.2	;	Crystal structure of truncated bacteriophage hyaluronan lyase HylP in complex with unsaturated hyaluronan tetra-saccharides
4ILD	;	3.27	;	Crystal structure of truncated Bovine viral diarrhea virus 1 E2 envelope protein
4FVA	;	2.07	;	Crystal structure of truncated Caenorhabditis elegans TDP2
4J3Q	;	2.9	;	Crystal structure of truncated catechol oxidase from Aspergillus oryzae
5EKI	;	1.9	;	Crystal Structure of Truncated CCL21
4YKD	;	1.932	;	Crystal structure of truncated cerebral cavernous malformation 2 C-terminal adaptor domain
4YL6	;	2.1	;	Crystal structure of truncated cerebral cavernous malformation 2 C-terminal adaptor domain in complex with an internal helix of mitogen-activated protein kinase kinase kinase 3
3HDF	;	1.7	;	Crystal structure of truncated endolysin R21 from phage 21
3USZ	;	2.1	;	Crystal structure of truncated exo-1,3/1,4-beta-glucanase (EXOP) from Pseudoalteromonas sp. BB1
3BFQ	;	1.34	;	Crystal structure of truncated FimG (FimGt) in complex with the donor strand peptide of FimF (DSF)
3BFW	;	1.8	;	Crystal structure of truncated FimG (FimGt) in complex with the donor strand peptide of FimF (DSF)
4ZZK	;	2.75	;	Crystal structure of truncated FlgD (monoclinic form) from the human pathogen Helicobacter pylori
5K5Y	;	2.85	;	Crystal structure of truncated FlgD (monoclinic form) from the human pathogen Helicobacter pylori (strain 26695)
4ZZF	;	2.1673	;	Crystal structure of truncated FlgD (tetragonal form) from the human pathogen Helicobacter pylori
3T49	;	1.45	;	Crystal structure of truncated form of Staphylococcal Complement Inhibitor B (SCIN-B) at 1.5 Angstrom
3T47	;	1.301	;	Crystal Structure of truncated form of Staphylococcal Complement Inhibitor D (SCIN-D) at 1.3 Angstrom
3T48	;	1.5	;	Crystal Structure of truncated form of Staphylococcal Complement Inhibitor D (SCIN-D) at 1.5 Angstrom
3AQ5	;	1.78	;	Crystal structure of truncated hemoglobin from Tetrahymena pyriformis, Fe(II)-O2 form
3AQ6	;	1.93	;	Crystal structure of truncated hemoglobin from Tetrahymena pyriformis, Fe(III) form
3AQ8	;	1.83	;	Crystal structure of truncated hemoglobin from Tetrahymena pyriformis, Q46E mutant, Fe(III) form
3AQ9	;	1.74	;	Crystal structure of truncated hemoglobin from Tetrahymena pyriformis, Q50E mutant, Fe(III) form
3AQ7	;	1.77	;	Crystal structure of truncated hemoglobin from Tetrahymena pyriformis, Y25F mutant, Fe(III) form
3FY3	;	1.8	;	Crystal structure of truncated hemolysin A from P. mirabilis
4W8Q	;	1.428	;	Crystal structure of truncated hemolysin A from P. mirabilis at 1.4 Angstroms resolution
4W8T	;	1.539	;	Crystal structure of truncated hemolysin A Q125S from P. mirabilis at 1.5 Angstroms resolution
4W8S	;	1.511	;	Crystal structure of truncated hemolysin A Q125S/Y134S from P. mirabilis at 1.5 Angstroms resolution
1OKI	;	1.4	;	Crystal structure of truncated human beta-B1-crystallin
5MC7	;	1.6	;	Crystal structure of Truncated Human Coatomer Protein Complex, subunit Z1 (CopZ1)
4CNS	;	2.4	;	Crystal structure of truncated human CRMP-4
4B91	;	1.7	;	Crystal structure of truncated human CRMP-5
4B92	;	2.9	;	Crystal structure of truncated human CRMP-5 soaked with Zn
1FT0	;	2.6	;	CRYSTAL STRUCTURE OF TRUNCATED HUMAN RHOGDI K113A MUTANT
1FSO	;	2.0	;	CRYSTAL STRUCTURE OF TRUNCATED HUMAN RHOGDI QUADRUPLE MUTANT
1FST	;	2.7	;	CRYSTAL STRUCTURE OF TRUNCATED HUMAN RHOGDI TRIPLE MUTANT
5XQH	;	2.04	;	Crystal structure of truncated human Rogdi
2D4L	;	1.7	;	Crystal structure of truncated in C-terminal M-PMV dUTPase
4RFU	;	1.2	;	Crystal structure of truncated P-domain from Grouper nervous necrosis virus capsid protein at 1.2A
4MN6	;	2.1	;	Crystal structure of truncated PAS domain from S. aureus YycG
4C44	;	2.65	;	Crystal Structure of Truncated Plant Hemoglobin from Arabidopsis thaliana
6JDS	;	2.5	;	Crystal structure of truncated PRRSV nsp10 (helicase)
5B5U	;	2.61	;	Crystal structure of truncated Pyrococcus furiosus L-asparaginase with peptide
1FT3	;	2.8	;	CRYSTAL STRUCTURE OF TRUNCATED RHOGDI K141A MUTANT
1Y5H	;	1.5	;	Crystal structure of truncated Se-Met Hypoxic Response Protein I (HRPI)
6WXA	;	2.3	;	Crystal structure of truncated Streptococcal bacteriophage hyaluronidase complexed with unsaturated hyaluronan hexa-saccharides
5ILQ	;	2.5	;	Crystal structure of truncated unliganded Aspartate Transcarbamoylase from Plasmodium falciparum
7AY0	;	3.6	;	Crystal structure of truncated USP1-UAF1
7AY2	;	3.2	;	Crystal structure of truncated USP1-UAF1 reacted with ubiquitin-prg
5Y4T	;	1.4	;	Crystal structure of Trx domain of Grx3 from Saccharomyces cerevisiae
6GC1	;	2.7	;	Crystal structure of Trx-like and NHL repeat containing domains of human NHLRC2
7D6L	;	1.947	;	Crystal structure of Trx2 from D. radiodurans R1
3WZS	;	1.7	;	Crystal structure of Trx3 domain of UGGT (detergent-bound form)
3WZT	;	3.4	;	Crystal structure of Trx3 domain of UGGT (detergent-unbound form)
3APS	;	1.9	;	Crystal structure of Trx4 domain of ERdj5
5ZF2	;	1.98	;	Crystal structure of Trxlp from Edwardsiella tarda EIB202
3FB3	;	2.35	;	Crystal Structure of Trypanosoma Brucei Acetyltransferase, Tb11.01.2886
5TVO	;	1.481	;	Crystal structure of Trypanosoma brucei AdoMetDC-delta26 monomer
5TVM	;	2.408	;	Crystal structure of Trypanosoma brucei AdoMetDC/prozyme heterodimer
5TVF	;	2.42	;	Crystal structure of Trypanosoma brucei AdoMetDC/prozyme heterodimer in complex with inhibitor CGP 40215
6BM7	;	2.98	;	Crystal structure of Trypanosoma brucei AdoMetDC/prozyme heterodimer in complex with pyrimidineamine inhibitor UTSAM568
3H9D	;	2.3	;	Crystal Structure of Trypanosoma brucei ATG8
7E3E	;	2.3	;	Crystal structure of Trypanosoma brucei cathepsin B R91C/T223C mutant
7E3G	;	3.86	;	Crystal structure of Trypanosoma brucei cathepsin B R91C/T223C mutant in the living cell
7E3F	;	2.35	;	Crystal structure of Trypanosoma brucei cathepsin B Y217C/S275C mutant
4DLC	;	1.759	;	Crystal Structure of Trypanosoma brucei dUTPase with dUMP, MgF3- transition state analogue, and Mg2+
4DL8	;	1.698	;	Crystal structure of Trypanosoma brucei dUTPase with dUMP, planar [AlF3-OPO3] transition state analogue, Mg2+, and Na+
4DKB	;	1.831	;	Crystal Structure of Trypanosoma brucei dUTPase with dUpNp and Ca2+
4DK4	;	1.9	;	Crystal Structure of Trypanosoma brucei dUTPase with dUpNp, Ca2+ and Na+
3WXI	;	2.9	;	Crystal structure of trypanosoma brucei gambiense glycerol kinase (ligand-free form)
3WXL	;	1.9	;	Crystal structure of trypanosoma brucei gambiense glycerol kinase complex with adp, mg2+, and glycerol
6J9V	;	2.4	;	Crystal structure of Trypanosoma brucei gambiense glycerol kinase complex with ADP.
6J9Q	;	2.7	;	Crystal structure of Trypanosoma brucei gambiense glycerol kinase complex with AMP-PNP.
6JAE	;	2.3	;	Crystal structure of Trypanosoma brucei gambiense glycerol kinase complex with Pi (pyrophosphatase reaction)
6JAF	;	2.9	;	Crystal structure of Trypanosoma brucei gambiense glycerol kinase complex with PPi (pyrophosphatase reaction)
3WXK	;	2.37	;	Crystal structure of trypanosoma brucei gambiense glycerol kinase in complex with glycerol
3WXJ	;	2.7	;	Crystal structure of trypanosoma brucei gambiense glycerol kinase in complex with glycerol 3-phosphate
6J9X	;	2.7	;	Crystal structure of Trypanosoma brucei gambiense glycerol kinase phosphorylated at Thr12(pyrophosphatase reaction)
6AJB	;	2.9	;	Crystal structure of Trypanosoma brucei glycosomal isocitrate dehydrogenase in complex with NADH, alpha-ketoglutarate and ca2+
6AJ6	;	3.2	;	Crystal structure of Trypanosoma brucei glycosomal isocitrate dehydrogenase in complex with NADP+
6AJ8	;	2.4	;	Crystal structure of Trypanosoma brucei glycosomal isocitrate dehydrogenase in complex with NADP+, alpha-ketoglutarate and ca2+
6AJA	;	2.85	;	Crystal structure of Trypanosoma brucei glycosomal isocitrate dehydrogenase in complex with NADPH, alpha-ketoglutarate and ca2+
6APU	;	1.842	;	Crystal structure of Trypanosoma brucei hypoxanthine-guanine phosphoribosyltranferase in complex with (2-{[2-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)ethyl](3-aminopropyl)amino}ethyl)phosphonic acid
6MXG	;	2.392	;	Crystal structure of Trypanosoma brucei hypoxanthine-guanine phosphoribosyltranferase in complex with XMP
6MXC	;	1.993	;	Crystal structure of Trypanosoma brucei hypoxanthine-guanine-xanthine phosphoribosyltranferase in complex with GMP
6MXD	;	2.96	;	Crystal structure of Trypanosoma brucei hypoxanthine-guanine-xanthine phosphoribosyltranferase in complex with IMP
6MXB	;	2.192	;	Crystal structure of Trypanosoma brucei hypoxanthine-guanine-xanthine phosphoribosyltranferase in complex with XMP
5FSU	;	1.95	;	Crystal structure of Trypanosoma brucei macrodomain (crystal form 1)
5FSV	;	1.2	;	Crystal structure of Trypanosoma brucei macrodomain (crystal form 2)
5FSX	;	2.0	;	Crystal structure of Trypanosoma brucei macrodomain in complex with ADP
5FSY	;	1.7	;	Crystal structure of Trypanosoma brucei macrodomain in complex with ADP-ribose
6T4R	;	2.352	;	Crystal structure of Trypanosoma brucei Morn1
6T68	;	2.54	;	Crystal structure of Trypanosoma brucei Morn1
3I3G	;	1.86	;	Crystal Structure of Trypanosoma brucei N-acetyltransferase (Tb11.01.2886) at 1.86A
3BJE	;	1.44	;	Crystal structure of Trypanosoma brucei nucleoside phosphorylase shows uridine phosphorylase activity
1QU4	;	2.9	;	CRYSTAL STRUCTURE OF TRYPANOSOMA BRUCEI ORNITHINE DECARBOXYLASE
1F3T	;	2.0	;	CRYSTAL STRUCTURE OF TRYPANOSOMA BRUCEI ORNITHINE DECARBOXYLASE (ODC) COMPLEXED WITH PUTRESCINE, ODC'S REACTION PRODUCT.
6RT2	;	1.3	;	Crystal structure of Trypanosoma Brucei PEX14 N-terminal domain in complex with small molecules designed to investigate the water envelope
5OML	;	1.5	;	Crystal structure of Trypanosoma Brucei PEX14 N-terminal domain in complex with small molecules to investigate the water envelope
3F9R	;	1.85	;	Crystal Structure of Trypanosoma Brucei phosphomannosemutase, TB.10.700.370
5KLH	;	1.646	;	Crystal Structure of Trypanosoma brucei Procyclic Specific Surface Antigen-2
4M36	;	2.042	;	Crystal structure of Trypanosoma brucei protein arginine methyltransferase 7
4M37	;	1.7	;	Crystal structure of Trypanosoma brucei protein arginine methyltransferase 7 complex with AdoHcy
4M38	;	2.2	;	Crystal structure of Trypanosoma brucei protein arginine methyltransferase 7 complex with AdoHcy and histone H4 peptide
5EKU	;	2.801	;	Crystal Structure of Trypanosoma Brucei Protein Arginine Methyltransferase PRMT7 in complex with S-Adenosyl-L-homocysteine
3M4U	;	2.392	;	Crystal Structure of Trypanosoma brucei Protein Tyrosine Phosphatase TbPTP1
2XTB	;	2.8	;	Crystal Structure of Trypanosoma brucei rhodesiense Adenosine Kinase Complexed with Activator
3OTX	;	1.55	;	Crystal Structure of Trypanosoma brucei rhodesiense Adenosine Kinase Complexed with Inhibitor AP5A
5AB4	;	1.751	;	Crystal structure of Trypanosoma brucei SCP2-thiolase like protein (TbSLP) form-I.
5AB5	;	2.0	;	Crystal structure of Trypanosoma brucei SCP2-thiolase like protein (TbSLP) form-II.
5AB6	;	1.9	;	Crystal structure of Trypanosoma brucei SCP2-thiolase like protein (TbSLP) in complex with acetoacetyl-CoA.
5AB7	;	2.3	;	Crystal structure of Trypanosoma brucei SCP2-thiolase like protein (TbSLP) in complex with malonyl-CoA.
8PF3	;	2.15	;	Crystal structure of Trypanosoma brucei trypanothione reductase in complex with 1-(3,4-dichlorobenzyl)-4-(((5-((4-fluorophenethyl)carbamoyl)furan-2-yl)methyl)(4-fluorophenyl)carbamoyl)-1-(3-phenylpropyl)piperazin-1-ium
8PF5	;	2.42	;	Crystal structure of Trypanosoma brucei trypanothione reductase in complex with 1-(3,4-dichlorobenzyl)-4-(((5-((4-fluorophenethyl)carbamoyl)furan-2-yl)methyl)carbamoyl)-1-(3-phenylpropyl)piperazin-1-ium
8PF4	;	1.84	;	Crystal structure of Trypanosoma brucei trypanothione reductase in complex with 4-(((5-((4-fluorophenethyl)carbamoyl)furan-2-yl)methyl)(4-fluorophenyl)carbamoyl)-1-methyl-1-(3-phenylpropyl)piperazin-1-ium
5CUY	;	2.5	;	Crystal structure of Trypanosoma brucei Vacuolar Soluble Pyrophosphatases in apo form
6Y0D	;	1.62	;	Crystal structure of Trypanosoma cruzi antigen TcSMP11.90
2J1Q	;	1.9	;	Crystal structure of Trypanosoma cruzi arginine kinase
6NP7	;	2.16	;	Crystal structure of Trypanosoma cruzi bromodomain BDF2 (TcCLB.506553.20)
4BMM	;	2.84	;	Crystal structure of Trypanosoma cruzi CYP51 bound to the inhibitor (R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-2',3, 5'-trifluoro-(1,1'-biphenyl)-4-carboxamide
4C27	;	1.95	;	Crystal structure of Trypanosoma cruzi CYP51 bound to the inhibitor (R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-2-fluoro-4-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)benzamide
4BY0	;	3.1	;	Crystal structure of Trypanosoma cruzi CYP51 bound to the inhibitor (R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-3,3'- difluoro-(1,1'-biphenyl)-4-carboxamide
4C0C	;	2.04	;	Crystal structure of Trypanosoma cruzi CYP51 bound to the inhibitor (R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4-(4-(2,4-difluorophenyl)piperazin-1-yl)-2-fluorobenzamide.
4UQH	;	2.43	;	Crystal structure of Trypanosoma cruzi CYP51 bound to the inhibitor (R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4-(4-(3,4-difluorophenyl)piperazin-1-yl)-2-fluorobenzamide.
4C28	;	2.03	;	Crystal structure of Trypanosoma cruzi CYP51 bound to the inhibitor (R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4-(4-(4-chlorophenyl)piperazin-1-yl)-2-fluorobenzamide.
4COH	;	2.08	;	Crystal structure of Trypanosoma cruzi CYP51 bound to the sulfonamide derivative of the 4-aminopyridyl-based inhibitor
6AJC	;	2.4	;	Crystal structure of Trypanosoma cruzi cytosolic isocitrate dehydrogenase in complex with NADP+, isocitrate and ca2+
7MF4	;	1.55	;	Crystal structure of Trypanosoma cruzi cytosolic Malic Enzyme
2H2Q	;	2.4	;	Crystal structure of Trypanosoma cruzi Dihydrofolate Reductase-Thymidylate synthase
5T7O	;	1.8	;	Crystal structure of Trypanosoma cruzi Dihydrofolate Reductase-Thymidylate Synthase in complex with (6S)-5,6,7,8-TETRAHYDROFOLATE
3W1M	;	1.9	;	Crystal structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with 5-bromoorotate
3W1L	;	1.7	;	Crystal structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with 5-chloroorotate
3W1P	;	2.0	;	Crystal structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with 5-ethenyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid
3W1N	;	2.4	;	Crystal structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with 5-iodoorotate
2E68	;	1.38	;	Crystal structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with dihydroorotate
2E6D	;	1.94	;	Crystal structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with fumarate
5E93	;	1.41	;	Crystal Structure of Trypanosoma cruzi Dihydroorotate Dehydrogenase in Complex with Neq0071
5EA9	;	1.71	;	Crystal Structure of Trypanosoma cruzi Dihydroorotate Dehydrogenase in Complex with Neq0130
2E6A	;	1.64	;	Crystal structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with orotate
2E6F	;	1.26	;	Crystal structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with oxonate
2DJL	;	1.38	;	Crystal structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with succinate
4DWB	;	2.1	;	Crystal structure of Trypanosoma cruzi farnesyl diphosphate synthase in complex with [2-(n-pentylamino)ethane-1,1-diyl]bisphosphonic acid and Mg2+
4MYL	;	1.531	;	Crystal structure of Trypanosoma cruzi Formiminoglutamase (oxidized) at pH 4.6
4MYK	;	1.518	;	Crystal structure of Trypanosoma cruzi formiminoglutamase (oxidized) with Mn2+2 at pH 8.5
4MYN	;	1.799	;	Crystal structure of Trypanosoma cruzi formiminoglutamase N114H variant with Mn2+2
4MXR	;	1.849	;	Crystal structure of Trypanosoma cruzi formiminoglutamase with Mn2+2
4MYF	;	1.799	;	Crystal structure of Trypanosoma cruzi formiminoglutamase(oxidized) with Mn2+2 at pH 6.0
5BRD	;	2.4	;	Crystal structure of Trypanosoma cruzi glucokinase in complex with inhibitor BENZ-GlcN
5BRE	;	2.5	;	Crystal structure of Trypanosoma cruzi glucokinase in complex with inhibitor CBZ-GlcN
5BRH	;	1.9	;	Crystal structure of Trypanosoma cruzi glucokinase in complex with inhibitor DBT-GlcN
5BRF	;	2.102	;	Crystal structure of Trypanosoma cruzi glucokinase in complex with inhibitor HPOP-GlcN
7S2H	;	1.8	;	Crystal structure of Trypanosoma cruzi glucokinase in the apo form (open conformation)
1QXS	;	2.75	;	CRYSTAL STRUCTURE OF Trypanosoma cruzi GLYCERALDEHYDE-3- PHOSPHATE DEHYDROGENASE COMPLEXED WITH AN ANALOGUE OF 1,3- BisPHOSPHO-D-GLYCERIC ACID
7Q1C	;	2.3	;	Crystal structure of Trypanosoma cruzi histone deacetylase DAC2 complexed with a hydroxamate inhibitor
7Q1B	;	1.75	;	Crystal structure of Trypanosoma cruzi histone deacetylase DAC2 complexed with Quisinostat
5FSZ	;	2.0	;	Crystal structure of Trypanosoma cruzi macrodomain
4DVH	;	2.23	;	Crystal structure of Trypanosoma cruzi mitochondrial iron superoxide dismutase
7OPT	;	2.02	;	Crystal structure of Trypanosoma cruzi peroxidase
7OQR	;	1.76	;	Crystal structure of Trypanosoma cruzi peroxidase
8B5V	;	1.6	;	Crystal Structure of Trypanosoma Cruzi phosphomannosemutase
3QV9	;	2.1	;	Crystal structure of Trypanosoma cruzi pyruvate kinase(TcPYK)in complex with ponceau S.
4YV0	;	1.95	;	Crystal structure of Trypanosoma cruzi spermidine synthase in complex with (2S)-N-methyl-N-phenyl-2,3-dihydro-1,4-benzodioxine- 2-carboxamid
5B1S	;	1.58	;	Crystal structure of Trypanosoma cruzi spermidine synthase in complex with 2-(2-fluorophenyl)ethanamine
4YV2	;	2.17	;	Crystal structure of Trypanosoma cruzi spermidine synthase in complex with 2-phenyl-1,2-thiazol-3(2H)-one
4YUX	;	1.6	;	Crystal structure of Trypanosoma cruzi spermidine synthase in complex with 2H-1,4-benzothiazin-3-amine
5Y4P	;	2.16	;	Crystal structure of Trypanosoma cruzi spermidine synthase in complex with 5-methoxy-2-(5-methyl-4,5-dihydro-1H-imidazol-2-yl)phenol
4YUZ	;	1.97	;	Crystal structure of Trypanosoma cruzi spermidine synthase in complex with 5-[(4-methylbenzyl)oxy]quinazoline-2,4-diamine
4YUV	;	1.6	;	Crystal structure of Trypanosoma cruzi spermidine synthase in complex with decarboxylated S-adenosylmethionine
4YUY	;	1.58	;	Crystal structure of Trypanosoma cruzi spermidine synthase in complex with isoquinolin-1-amine
5Y4Q	;	2.07	;	Crystal structure of Trypanosoma cruzi spermidine synthase in complex with N-(4-methoxyphenyl)quinolin-4-amine
4YV1	;	1.85	;	Crystal structure of Trypanosoma cruzi spermidine synthase in complex with quinolin-8-yl piperidine-1-carboxylate
4YUW	;	1.97	;	Crystal structure of Trypanosoma cruzi spermidine synthase in complex with trans-4-methylcyclohexylamine
3H79	;	1.5	;	Crystal structure of Trypanosoma cruzi thioredoxin-like hypothetical protein Q4DV70
1GXF	;	2.7	;	CRYSTAL STRUCTURE OF TRYPANOSOMA CRUZI TRYPANOTHIONE REDUCTASE IN COMPLEX WITH THE INHIBITOR QUINACRINE MUSTARD
1BZL	;	2.4	;	CRYSTAL STRUCTURE OF TRYPANOSOMA CRUZI TRYPANOTHIONE REDUCTASE IN COMPLEX WITH TRYPANOTHIONE, AND THE STRUCTURE-BASED DISCOVERY OF NEW NATURAL PRODUCT INHIBITORS
5CUV	;	2.62	;	Crystal structure of Trypanosoma cruzi Vacuolar Soluble Pyrophosphatases in apo form
5CUU	;	2.96	;	Crystal structure of Trypanosoma cruzi Vacuolar Soluble Pyrophosphatases in complex with bisphosphonate inhibitor BPH-1260
2FF2	;	2.2	;	Crystal structure of Trypanosoma vivax nucleoside hydrolase co-crystallized with ImmucillinH
3EPW	;	1.3	;	Crystal structure of Trypanosoma vivax nucleoside hydrolase in complex with the inhibitor (2R,3R,4S)-1-[(4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-2-(hydroxymethyl)pyrrolidin-3,4-diol
3EPX	;	1.85	;	Crystal structure of Trypanosoma vivax nucleoside hydrolase in complex with the inhibitor (2R,3R,4S)-2-(hydroxymethyl)-1-(quinolin-8-ylmethyl)pyrrolidin-3,4-diol
2FF1	;	2.07	;	Crystal structure of Trypanosoma vivax nucleoside hydrolase soaked with ImmucillinH
7SCR	;	2.12068	;	Crystal structure of trypanosome brucei hypoxanthine-guanine-xanthine phosphoribzosyltransferase in complex with (4S,7S)-7-hydroxy-4-((guanin-9-yl)methyl)-2,5-dioxaheptan-1,7-diphosphonate
4DZW	;	3.05	;	Crystal Structure of Trypanosome cruzi farnesyl diphosphate synthase in complex with [2-(cyclohexylamino)ethane-1,1-diyl]bisphosphonic acid and Mg2+
4DWG	;	2.01	;	Crystal structure of Trypanosome cruzi farnesyl diphosphate synthase in complex with [2-(n-heptylamino)ethane-1,1-diyl]bisphosphonic acid and Mg2+
4E1E	;	2.65	;	Crystal structure of Trypanosome cruzi farnesyl diphosphate synthase in complex with [2-(n-hexylamino)ethane-1,1-diyl]bisphosphonic acid and Mg2+
4DXJ	;	2.35	;	Crystal structure of Trypanosome cruzi farnesyl diphosphate synthase in complex with [2-(n-propylamino)ethane-1,1-diyl]bisphosphonic acid and Mg2+
2X50	;	3.3	;	Crystal structure of Trypanothione reductase from Leishmania infantum in complex with NADPH and silver
6OEY	;	2.1	;	Crystal structure of Trypanothione Reductase from Trypanosoma brucei in complex with inhibitor (+)-5-{5-[1-(Pyrrolidin-1-yl)cyclohexyl]-1,3-thiazol-2-yl}-1-{[(2S)-pyrrolidin-2-yl]methyl}-1H-indole
6OEZ	;	2.5	;	Crystal structure of Trypanothione Reductase from Trypanosoma brucei in complex with inhibitor (+)-N-(Cyclobutylmethyl)-3-{5-[1-(pyrrolidin-1-yl)cyclohexyl]-2-(1-{[(2S)-pyrro-lidin-2-yl]methyl}-1H-indol-5-yl)-1,3-thiazol-4-yl}prop-2-yn-1-amine
6OEX	;	2.1	;	Crystal structure of Trypanothione Reductase from Trypanosoma brucei in complex with inhibitor 3-(2-{1-[2-(Piperidin-4-yl)ethyl]-1H-indol-5-yl}-5-[1-(pyrrolidin-1-yl)cyclohexyl]-1,3- thiazol-4-yl)-N-(2,2,2-trifluoroethyl)prop-2-yn-1-amine
4NEV	;	2.5	;	Crystal structure of Trypanothione Reductase from Trypanosoma brucei in complex with inhibitor EP127 (5-{5-[1-(PYRROLIDIN-1-YL)CYCLOHEXYL]-1,3-THIAZOL-2-YL}-1H-INDOLE)
6BTL	;	2.797	;	Crystal structure of Trypanothione Reductase from Trypanosoma brucei in complex with inhibitor RD117 1-[2-(Piperazin-1-yl)ethyl]-5-{5-[1-(pyrrolidin-1-yl)cyclohexyl]-1,3-thiazol-2-yl}-1H-indole
6BU7	;	2.73	;	Crystal structure of Trypanothione Reductase from Trypanosoma brucei in complex with inhibitor RD130 1-[2-(Piperidin-4-yl)ethyl]-5-{5-[1-(pyrrolidin-1-yl)cyclohexyl]-1,3-thiazol-2-yl}-1H-indole
4NEW	;	2.8	;	Crystal structure of Trypanothione Reductase from Trypanosoma cruzi in complex with inhibitor EP127 (5-{5-[1-(PYRROLIDIN-1-YL)CYCLOHEXYL]-1,3-THIAZOL-2-YL}-1H-INDOLE)
4NIY	;	2.84	;	Crystal structure of trypsiligase (K60E/N143H/Y151H/D189K trypsin) complexed to YRH-ecotin (M84Y/M85R/A86H ecotin)
4NIW	;	1.31	;	Crystal structure of trypsiligase (K60E/N143H/Y151H/D189K trypsin) orthorhombic form
4NIX	;	1.3	;	Crystal structure of trypsiligase (K60E/N143H/Y151H/D189K trypsin) orthorhombic form, zinc-bound
4NIV	;	1.0	;	Crystal structure of trypsiligase (K60E/N143H/Y151H/D189K trypsin) trigonal form
4ZIQ	;	2.55	;	Crystal structure of trypsin activated alpha-2-macroglobulin from Escherichia coli.
5KUC	;	2.0	;	Crystal structure of trypsin activated Cry6Aa
7JWX	;	2.38	;	Crystal Structure of Trypsin Bound O-methyl Benzamidine
1JIR	;	2.0	;	Crystal Structure of Trypsin Complex with Amylamine in Cyclohexane
3RXP	;	1.6	;	Crystal structure of Trypsin complexed with (1,5-dimethylpyrazol-3-yl)methanamine
3RXL	;	1.7	;	Crystal structure of Trypsin complexed with (2,5-dimethyl-3-furyl)methanamine
3RXT	;	1.7	;	Crystal structure of Trypsin complexed with (3-methoxyphenyl)methanamin (F04 and F03, cocktail experiment)
3ATI	;	1.71	;	Crystal structure of trypsin complexed with (3-methoxyphenyl)methanamine
3RXD	;	1.7	;	Crystal structure of Trypsin complexed with (3-methoxyphenyl)methanamine
3RXS	;	1.74	;	Crystal structure of Trypsin complexed with (3-methoxyphenyl)methanamine (F04 and A06, cocktail experiment)
3RXO	;	1.6	;	Crystal structure of Trypsin complexed with (3-pyrrol-1-ylphenyl)methanamine
3A80	;	1.75	;	Crystal Structure of Trypsin complexed with (E)-2-(4-carbamimidoylbenzylideneaminooxy)-2-methylpropanoic acid (soaking 40seconds)
3A85	;	1.75	;	Crystal Structure of Trypsin complexed with (E)-2-(4-carbamimidoylbenzylideneaminooxy)acetic acid (soaking 15 seconds)
3A86	;	1.75	;	Crystal Structure of Trypsin complexed with (E)-2-(4-carbamimidoylbenzylideneaminooxy)acetic acid (soaking 30 seconds)
3A7X	;	1.75	;	Crystal Structure of Trypsin complexed with (E)-2-(4-carbamimidoylbenzylideneaminooxy)acetic acid (soaking 45seconds)
3A8C	;	1.85	;	Crystal Structure of Trypsin complexed with (E)-2-(4-carbamimidoylbenzylideneaminooxy)acetic acid (soaking with mixture of [(E)-2-(4-carbamimidoylbenzylideneaminooxy)acetic acid] and [(E)-2-(4-carbamimidoylbenzylideneaminooxy)-2-methylpropanoic acid])
3A8D	;	1.75	;	Crystal Structure of Trypsin complexed with (E)-2-(4-carbamimidoylbenzylideneaminooxy)acetic acid (under aniline-free condition)
3A7Y	;	1.81	;	Crystal Structure of Trypsin complexed with (E)-4-((1-methylpiperidin-3-yloxyimino)methyl)benzimidamide (soaking 2hours)
3A7Z	;	1.8	;	Crystal Structure of Trypsin complexed with (E)-4-((1-methylpiperidin-4-yloxyimino)methyl)benzimidamide (soaking 3hours)
3A88	;	1.75	;	Crystal Structure of Trypsin complexed with (E)-4-((2-nicotinoylhydrazono)methyl)benzimidamide (soaking 30 minutes)
3A89	;	1.8	;	Crystal Structure of Trypsin complexed with (E)-4-((2-nicotinoylhydrazono)methyl)benzimidamide (soaking 4 hours)
3A87	;	1.75	;	Crystal Structure of Trypsin complexed with (E)-4-((2-nicotinoylhydrazono)methyl)benzimidamide (soaking 5 minutes)
3A81	;	1.78	;	Crystal Structure of Trypsin complexed with (E)-4-((2-nicotinoylhydrazono)methyl)benzimidamide (soaking 8 hours)
3A8B	;	1.75	;	Crystal Structure of Trypsin complexed with (E)-4-((4-bromophenylimino)methyl)benzimidamide
3A7W	;	1.75	;	Crystal Structure of Trypsin complexed with (E)-4-((tetrahydro-2H-pyran-2-yloxyimino)methyl)benzimidamide (soaking 4hours)
3RXH	;	1.7	;	Crystal structure of Trypsin complexed with 2-(1H-imidazol-4-yl)ethanamine
3ATM	;	1.72	;	Crystal structure of trypsin complexed with 2-(1H-indol-3-yl)ethanamine
3RXI	;	1.6	;	Crystal structure of Trypsin complexed with 2-(1H-indol-3-yl)ethanamine
3RXC	;	1.7	;	Crystal structure of Trypsin complexed with 2-aminopyridine
3A7V	;	1.75	;	Crystal Structure of Trypsin complexed with 3-formylbenzimidamide
3RXG	;	1.7	;	Crystal structure of Trypsin complexed with 4-aminocyclohexanol
3RXF	;	1.7	;	Crystal structure of Trypsin complexed with 4-aminopyridine
3A7T	;	1.75	;	Crystal Structure of Trypsin complexed with 4-formylbenzimidamide
3A8A	;	1.4	;	Crystal Structure of Trypsin complexed with 4-formylbenzimidamide and aniline
3RXJ	;	1.7	;	Crystal structure of Trypsin complexed with 4-guanidinobenzoic acid
3RXB	;	1.7	;	Crystal structure of Trypsin complexed with 4-guanidinobutanoic acid
3RXE	;	1.7	;	Crystal structure of Trypsin complexed with benzamide
3RXQ	;	1.68	;	Crystal structure of Trypsin complexed with benzamide (F01 and F05, cocktail experiment)
3RXU	;	1.68	;	Crystal structure of Trypsin complexed with benzamide (F05 and A06, cocktail experiment)
3RXV	;	1.7	;	Crystal structure of Trypsin complexed with benzamide (F05 and F03, cocktail experiment)
3ATL	;	1.74	;	Crystal structure of trypsin complexed with benzamidine
2FTL	;	1.62	;	Crystal structure of trypsin complexed with BPTI at 100K
3ATK	;	1.74	;	Crystal structure of trypsin complexed with cycloheptanamine
3RXA	;	1.7	;	Crystal structure of Trypsin complexed with cycloheptanamine
3RXR	;	1.72	;	Crystal structure of Trypsin complexed with cycloheptanamine (F01 and F03, cocktail experiment)
3RXK	;	1.6	;	Crystal structure of Trypsin complexed with methyl 4-amino-1-methyl-pyrrolidine-2-carboxylate
3A82	;	1.75	;	Crystal Structure of Trypsin complexed with pre-synthesized (E)-2-(4-carbamimidoylbenzylideneaminooxy)acetic acid
3A83	;	1.78	;	Crystal Structure of Trypsin complexed with pre-synthesized (E)-4-((2-nicotinoylhydrazono)methyl)benzimidamide
2FTM	;	1.65	;	Crystal structure of trypsin complexed with the BPTI variant (Tyr35->Gly)
3RXM	;	1.7	;	Crystal structure of Trypsin complexed with [2-(2-thienyl)thiazol-4-yl]methanamine
3A84	;	1.75	;	Crystal Structure of Trypsin complexed with(E)-2-(4-carbamimidoylbenzylideneaminooxy)acetic acid (soaking 5 seconds)
1LQE	;	2.2	;	CRYSTAL STRUCTURE OF TRYPSIN IN COMPLEX WITH 79.
7VO7	;	2.25	;	Crystal structure of trypsin in complex with Lima bean trypsin inhibitor at 2.25A resolution.
6KV2	;	2.003	;	Crystal structure of trypsin inhibitor 1 from Senna obtusifolia
1Z7K	;	1.9	;	Crystal Structure of Trypsin- Ovomucoid turkey egg white inhibitor complex
1YF4	;	1.98	;	Crystal Structure of trypsin-vasopressin complex
4GUX	;	1.803	;	Crystal structure of trypsin:MCoTi-II complex
8U5F	;	2.32	;	Crystal Structure of Trypsinized Clostridium perfringens Enterotoxin
2AGW	;	1.45	;	Crystal structure of tryptamine-reduced aromatic amine dehydrogenase (AADH) from Alcaligenes faecalis in complex with tryptamine
2NW7	;	2.7	;	Crystal Structure of Tryptophan 2,3-dioxygenase (TDO) from Xanthomonas campestris in complex with ferric heme. Northeast Structural Genomics Target XcR13
2NW9	;	1.8	;	Crystal Structure of Tryptophan 2,3-dioxygenase (TDO) from Xanthomonas campestris in complex with ferrous heme and 6-fluoro-tryptophan. Northeast Structural Genomics Target XcR13
2NW8	;	1.6	;	Crystal Structure of Tryptophan 2,3-dioxygenase (TDO) from Xanthomonas campestris in complex with ferrous heme and tryptophan. Northeast Structural Genomics Target XcR13.
2NOX	;	2.4	;	Crystal structure of tryptophan 2,3-dioxygenase from Ralstonia metallidurans
2WET	;	2.4	;	Crystal structure of tryptophan 5-halogenase (PyrH) complex with FAD (tryptophan)
2WEU	;	1.7	;	Crystal structure of tryptophan 5-halogenase (PyrH) complex with substrate tryptophan
4Z43	;	2.29	;	Crystal structure of Tryptophan 7-halogenase (PrnA) Mutant E450K
2PYX	;	1.5	;	Crystal structure of tryptophan halogenase (YP_750003.1) from Shewanella frigidimarina NCIMB 400 at 1.50 A resolution
5ZBD	;	1.8	;	Crystal structure of tryptophan oxidase (C395A mutant) from Chromobacterium violaceum
1UJP	;	1.34	;	Crystal Structure of Tryptophan Synthase A-Subunit From Thermus thermophilus HB8
1WXJ	;	1.7	;	Crystal Structure Of Tryptophan Synthase A-Subunit with Indole-3-propanol phosphate From Thermus Thermophilus Hb8
5KIN	;	2.45	;	Crystal structure of tryptophan synthase alpha beta complex from Streptococcus pneumoniae
5K9X	;	2.016	;	Crystal structure of Tryptophan synthase alpha chain from Legionella pneumophila subsp. pneumophila
1RD5	;	2.02	;	Crystal structure of Tryptophan synthase alpha chain homolog BX1: a member of the chemical plant defense system
5KZM	;	2.804	;	Crystal structure of Tryptophan synthase alpha-beta chain complex from Francisella tularensis
1WQ5	;	2.3	;	Crystal structure of tryptophan synthase alpha-subunit from Escherichia coli
1V7Y	;	2.5	;	Crystal structure of tryptophan synthase alpha-subunit from Escherichia coli at room temperature
3VND	;	2.6	;	Crystal structure of tryptophan synthase alpha-subunit from the psychrophile Shewanella frigidimarina K14-2
4HPJ	;	1.45	;	Crystal structure of Tryptophan Synthase at 1.45 A resolution in complex with 2-aminophenol quinonoid in the beta site and the F9 inhibitor in the alpha site
4HPX	;	1.65	;	Crystal structure of Tryptophan Synthase at 1.65 A resolution in complex with alpha aminoacrylate E(A-A) and benzimidazole in the beta site and the F9 inhibitor in the alpha site
1X1Q	;	2.5	;	Crystal structure of tryptophan synthase beta chain from Thermus thermophilus HB8
6V82	;	2.424	;	Crystal structure of tryptophan synthase from Chlamydia trachomatis D/UW-3/CX
5TCJ	;	2.4	;	Crystal structure of tryptophan synthase from M. tuberculosis - aminoacrylate and BRD4592-bound form
6DWE	;	2.691	;	Crystal structure of tryptophan synthase from M. tuberculosis - aminoacrylate- and BRD0059-bound form
6UB9	;	2.783	;	Crystal structure of tryptophan synthase from M. tuberculosis - AMINOACRYLATE- AND BRD6309-BOUND FORM
6USA	;	2.406	;	Crystal structure of tryptophan synthase from M. tuberculosis - aminoacrylate- and GSK1-bound form
6U6C	;	2.402	;	Crystal structure of tryptophan synthase from M. tuberculosis - aminoacrylate- and GSK2-bound form
5TCG	;	2.4	;	Crystal structure of tryptophan synthase from M. tuberculosis - aminoacrylate-bound form
5TCI	;	2.45	;	Crystal structure of tryptophan synthase from M. tuberculosis - BRD4592-bound form
5TCF	;	2.46	;	Crystal structure of tryptophan synthase from M. tuberculosis - ligand-free form
5TCH	;	2.35	;	Crystal structure of tryptophan synthase from M. tuberculosis - ligand-free form, TrpA-G66V mutant
6E9P	;	2.569	;	Crystal structure of tryptophan synthase from M. tuberculosis - open form with BRD0059 bound
6UAP	;	2.745	;	Crystal structure of tryptophan synthase from M. tuberculosis - open form with BRD6309 bound
1KFK	;	2.4	;	Crystal structure of Tryptophan Synthase From Salmonella Typhimurium
4XUG	;	1.65	;	Crystal structure of Tryptophan Synthase from Salmonella typhimurium in complex with 2-({[4-(Trifluoromethoxy)Phenyl]Sulfonyl}Amino)Ethyl Dihydrogen Phosphate (F9F) inhibitor in the alpha site and ammonium ion in the metal coordination site.
5CGQ	;	1.18	;	Crystal structure of Tryptophan Synthase from Salmonella typhimurium in complex with F9 ligand in the alpha-site and the product L-Tryptophan in the beta-site.
4Y6G	;	1.65	;	Crystal structure of Tryptophan Synthase from Salmonella typhimurium in complex with N-(4'-trifluoromethoxybenzoyl)-2-amino-1-ethylphosphate (F6F) inhibitor in the alpha-site and beta-site.
4WX2	;	1.75	;	Crystal structure of Tryptophan Synthase from Salmonella typhimurium in complex with two F6F molecules in the alpha-site and one F6F molecule in the beta-site
4KKX	;	1.77	;	Crystal structure of Tryptophan Synthase from Salmonella typhimurium with 2-aminophenol quinonoid in the beta site and the F6 inhibitor in the alpha site
7MT6	;	1.7	;	Crystal structure of tryptophan synthase in complex with F9, Cs+, benzimidazole, pH7.8 - alpha aminoacrylate form - E(A-A)(BZI)
7MT5	;	1.5	;	Crystal structure of tryptophan synthase in complex with F9, Cs+, pH7.8 - alpha aminoacrylate form - E(A-A)
7MT4	;	1.4	;	Crystal structure of tryptophan Synthase in complex with F9, NH4+, pH7.8 - alpha aminoacrylate form - E(A-A)
5KMY	;	1.908	;	Crystal structure of tryptophan synthase subunit alpha from Legionella pneumophila str. Paris
6UL2	;	1.979	;	Crystal structure of tryptophan-6-halogenase BorH complexed with L-tryptophan
6NCR	;	1.75	;	Crystal Structure of Tryptophan-tRNA ligase from Chlamydia trachomatis with bound L-tryptophan
1YIA	;	3.7	;	Crystal structure of tryptophanyl tRNA synthetase II from Deinococcus radiodurans in complex with 5-Hydroxy tryptophan.
1YID	;	2.4	;	Crystal structure of tryptophanyl tRNA synthetase II from Deinococcus radiodurans in complex with ATP.
1YI8	;	2.1	;	Crystal structure of tryptophanyl trRNA synthetase II from Deinococcus radiodurans in complex with L-Trp
2G36	;	2.5	;	Crystal structure of Tryptophanyl-tRNA synthetase (EC 6.1.1.2) (Tryptophan-tRNA ligase)(TrpRS) (tm0492) from THERMOTOGA MARITIMA at 2.50 A resolution
1MAU	;	2.15	;	Crystal structure of Tryptophanyl-tRNA Synthetase Complexed with ATP and Tryptophanamide in a Pre-Transition state Conformation
1M83	;	2.2	;	Crystal Structure of Tryptophanyl-tRNA Synthetase Complexed with ATP in a Closed, Pre-transition State Conformation
1MAW	;	3.0	;	Crystal Structure of Tryptophanyl-tRNA Synthetase Complexed with ATP in an Open Conformation
1MB2	;	2.7	;	Crystal Structure of Tryptophanyl-tRNA Synthetase Complexed with Tryptophan in an Open Conformation
7EER	;	2.0	;	Crystal structure of Tryptophanyl-tRNA synthetase from Bacillus stearothermophilus in complex with 05E6 and ATP
7CMS	;	2.2	;	Crystal structure of Tryptophanyl-tRNA synthetase from Bacillus stearothermophilus in complex with chuangxinmycin
7CKI	;	2.3	;	Crystal structure of Tryptophanyl-tRNA synthetase from Bacillus stearothermophilus in complex with chuangxinmycin and ATP
3M5W	;	2.32	;	Crystal Structure of Tryptophanyl-tRNA Synthetase from Campylobacter jejuni
3TZL	;	2.154	;	Crystal Structure of Tryptophanyl-tRNA Synthetase from Campylobacter jejuni complexed with ADP and Tryptophane
6MTK	;	2.0	;	Crystal structure of Tryptophanyl-tRNA synthetase from Elizabethkingia anophelis NUHP1
5V0I	;	1.9	;	Crystal Structure of Tryptophanyl-tRNA Synthetase from Escherichia coli Complexed with AMP and Tryptophan
3A04	;	1.97	;	Crystal structure of tryptophanyl-tRNA synthetase from hyperthermophilic archaeon, Aeropyrum pernix K1
3A05	;	2.2	;	Crystal structure of tryptophanyl-tRNA synthetase from hyperthermophilic archaeon, Aeropyrum pernix K1 complex with tryptophan
2YY5	;	2.55	;	Crystal Structure of tryptophanyl-tRNA synthetase from Mycoplasma pneumoniae
2EL7	;	2.5	;	Crystal structure of Tryptophanyl-tRNA synthetase from Thermus thermophilus
3SZ3	;	1.5	;	Crystal structure of Tryptophanyl-tRNA synthetase from Vibrio cholerae with an endogenous tryptophan
3N9I	;	1.95	;	Crystal structure of tryptophanyl-tRNA synthetase from Yersinia pestis CO92
6PFA	;	2.79	;	Crystal structure of TS-DHFR from Cryptosporidium hominis in complex with NADPH, FdUMP and 2-((4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)methyl)benzoic acid.
6PFH	;	2.94	;	Crystal structure of TS-DHFR from Cryptosporidium hominis in complex with NADPH, FdUMP and 2-(2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-4-cyanophenyl)acetic acid.
6PFC	;	2.689	;	Crystal structure of TS-DHFR from Cryptosporidium hominis in complex with NADPH, FdUMP and 2-(2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-4-methoxyphenyl)acetic acid
6PF9	;	2.89	;	Crystal structure of TS-DHFR from Cryptosporidium hominis in complex with NADPH, FdUMP and 2-(2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)phenyl)acetic acid.
6PFG	;	2.706	;	Crystal structure of TS-DHFR from Cryptosporidium hominis in complex with NADPH, FdUMP and 2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-4-carbamoylbenzoic acid.
6PF8	;	2.533	;	Crystal structure of TS-DHFR from Cryptosporidium hominis in complex with NADPH, FdUMP and 2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-4-chlorobenzoic acid
6PFF	;	2.982	;	Crystal structure of TS-DHFR from Cryptosporidium hominis in complex with NADPH, FdUMP and 2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-4-cyanobenzoic acid.
6PFE	;	2.812	;	Crystal structure of TS-DHFR from Cryptosporidium hominis in complex with NADPH, FdUMP and 2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-4-methoxybenzoic acid.
6PF7	;	2.795	;	Crystal structure of TS-DHFR from Cryptosporidium hominis in complex with NADPH, FdUMP and 2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)benzoic acid
6PF6	;	2.502	;	Crystal structure of TS-DHFR from Cryptosporidium hominis in complex with NADPH, FdUMP and 2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)terephthalic acid
6PFD	;	3.324	;	Crystal structure of TS-DHFR from Cryptosporidium hominis in complex with NADPH, FdUMP and 2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)terephthalic acid.
4Q0E	;	2.78	;	Crystal structure of TS-DHFR from Cryptosporidium hominis in complex with NADPH, FdUMP and 2-amino-4-oxo-4,7-dihydro-pyrrolo[2,3-d]pyrimidine-methyl-phenyl-L-glutamic acid.
6PFB	;	3.089	;	Crystal structure of TS-DHFR from Cryptosporidium hominis in complex with NADPH, FdUMP and 3-(2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)phenyl)propanoic acid.
6PFI	;	2.89	;	Crystal structure of TS-DHFR from Cryptosporidium hominis in complex with NADPH, FdUMP and 3-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-4-(carboxymethyl)benzoic acid.
4Q0D	;	3.449	;	Crystal structure of TS-DHFR from Cryptosporidium hominis in complex with NADPH, FdUMP, methotrexate and 2-amino-4-oxo-4,7-dihydro-pyrrolo[2,3-d]pyrimidine-methyl-phenyl-L-glutamic acid.
6OJS	;	3.214	;	Crystal structure of TS-DHFR from Cryptosporidium hominis in complex with NADPH, FdUMP, MTX and 2-amino-4-oxo-4,7-dihydro-pyrrolo[2,3-d]pyrimidine-methyl-phenyl-D-glutamic acid
4KY8	;	3.084	;	Crystal structure of TS-DHFR from Cryptosporidium hominis in complex with NADPH, methotrexate, FdUMP and 4-((2-amino-6-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)thio)-2-chlorophenyl)-L-glutamic acid
6WEP	;	2.79	;	Crystal structure of TS-DHFR from Cryptosporidium hominis with Apo-TS site
5XCX	;	2.04	;	Crystal structure of TS2/16 Fv-clasp fragment
8SY8	;	2.18	;	Crystal structure of TsaC
3FXU	;	1.95	;	Crystal structure of TsaR in complex with its effector p-toluenesulfonate
3FXR	;	2.5	;	Crystal structure of TsaR in complex with sulfate
4KK0	;	2.9	;	Crystal Structure of TSC1 core domain from S. pombe
4KK1	;	3.3	;	Crystal Structure of TSC1 core domain from S. pombe
4N80	;	2.4	;	Crystal structure of Tse3-Tsi3 complex
4N88	;	2.8	;	Crystal structure of Tse3-Tsi3 complex with calcium ion
4N7S	;	2.101	;	Crystal structure of Tse3-Tsi3 complex with Zinc ion
3OBS	;	1.5	;	Crystal structure of Tsg101 UEV domain
6NOI	;	1.8	;	Crystal structure of Tsn15 in apo form
6RK1	;	1.63	;	Crystal structure of TSP1 domain from CCN3
7RDB	;	2.52	;	Crystal structure of Tspan15 large extracellular loop (Tspan15 LEL)
7RD5	;	3.6	;	Crystal structure of Tspan15 large extracellular loop (Tspan15 LEL) in complex with 1C12 Fab
5WWN	;	2.805	;	Crystal structure of Tsr1
7CWW	;	2.0	;	Crystal structure of TsrL
5Y0E	;	2.5	;	Crystal structure of TssK
4V3I	;	1.499	;	Crystal Structure of TssL from Vibrio cholerae.
1W3M	;	1.0	;	Crystal structure of tsushimycin
6Y9L	;	4.1	;	Crystal structure of TSWV glycoprotein N ectodomain (sGn)
6Y9M	;	3.4	;	Crystal structure of TSWV glycoprotein N ectodomain (sGn)
6YA0	;	2.86	;	Crystal structure of TSWV glycoprotein N ectodomain (Trypsin treated)
6YA2	;	2.5	;	Crystal structure of TSWV glycoprotein N ectodomain (Trypsin treated)
2IEL	;	1.6	;	CRYSTAL STRUCTURE OF TT0030 from Thermus Thermophilus
1V9S	;	2.1	;	Crystal structure of TT0130 protein from Thermus thermophilus HB8
1ULS	;	2.4	;	Crystal structure of tt0140 from Thermus thermophilus HB8
1ULU	;	2.0	;	Crystal structure of tt0143 from Thermus thermophilus HB8
2YW9	;	2.5	;	Crystal structure of TT0143 from Thermus thermophilus HB8
1ULT	;	2.55	;	Crystal structure of tt0168 from Thermus thermophilus HB8
1V25	;	2.3	;	Crystal structure of tt0168 from Thermus thermophilus HB8
1V26	;	2.5	;	Crystal structure of tt0168 from Thermus thermophilus HB8
1ULQ	;	3.0	;	Crystal structure of tt0182 from Thermus thermophilus HB8
2ZVB	;	2.0	;	Crystal structure of TT0207 from Thermus thermophilus HB8
2YXZ	;	1.9	;	Crystal structure of tt0281 from Thermus thermophilus HB8
1WLU	;	1.45	;	Crystal structure of TT0310 protein from Thermus thermophilus HB8
1WLV	;	1.9	;	Crystal structure of TT0310 protein from Thermus thermophilus HB8
1WM6	;	2.4	;	Crystal structure of TT0310 protein from Thermus thermophilus HB8
1WN3	;	2.1	;	Crystal structure of TT0310 protein from Thermus thermophilus HB8
2CUK	;	2.0	;	Crystal structure of TT0316 protein from Thermus thermophilus HB8
2D1Y	;	1.65	;	Crystal structure of TT0321 from Thermus thermophilus HB8
1V8H	;	1.2	;	Crystal structure of TT0351 protein from Thermus thermophilus HB8
1YYA	;	1.6	;	Crystal structure of TT0473, putative Triosephosphate Isomerase from Thermus thermophilus HB8
1X1E	;	1.76	;	Crystal Structure of TT0495 protein from Thermus thermophilus HB8
4JP2	;	1.15	;	Crystal Structure of TT0495 protein from Thermus thermophilus HB8
4JP3	;	1.5	;	Crystal Structure of TT0495 protein from Thermus thermophilus HB8
1ULR	;	1.3	;	Crystal structure of tt0497 from Thermus thermophilus HB8
2D1C	;	1.8	;	Crystal Structure Of TT0538 protein from Thermus thermophilus HB8
1IUH	;	2.5	;	Crystal structure of TT0787 of thermus thermophilus HB8
1UFK	;	1.9	;	Crystal structure of TT0836
1WDI	;	2.1	;	Crystal Structure Of TT0907 From Thermus Thermophilus HB8
2DEH	;	2.45	;	Crystal structure of tt0972 protein form Thermus Thermophilus with Cl(-) ions
2DEG	;	1.7	;	Crystal structure of tt0972 protein form Thermus Thermophilus with Mn2(+) ions
2CZ8	;	1.5	;	Crystal Structure of tt0972 protein from Thermus thermophilus
2DEV	;	2.45	;	Crystal structure of tt0972 protein from Thermus Thermophilus with Cs(+) ions
2CWD	;	1.9	;	Crystal Structure of TT1001 protein from Thermus thermophilus HB8
1UFL	;	2.7	;	Crystal Structure of TT1020 from Thermus thermophilus HB8
1V3R	;	1.85	;	Crystal structure of TT1020 from Thermus thermophilus HB8
1V3S	;	1.85	;	Crystal structure of TT1020 from Thermus thermophilus HB8
1V9O	;	2.0	;	Crystal structure of TT1020 from Thermus thermophilus HB8
1VFJ	;	1.7	;	Crystal structure of TT1020 from Thermus thermophilus HB8
1UFR	;	2.6	;	Crystal Structure of TT1027 from Thermus thermophilus HB8
7C3O	;	1.89	;	Crystal structure of TT109 from CANDIDA ALBICANS
1UF9	;	2.8	;	Crystal structure of TT1252 from Thermus thermophilus
2GS9	;	2.6	;	Crystal structure of TT1324 from Thermus thermophilis HB8
1WD5	;	2.0	;	Crystal structure of TT1426 from Thermus thermophilus HB8
1UFA	;	2.2	;	Crystal structure of TT1467 from Thermus thermophilus HB8
1UF3	;	2.1	;	Crystal structure of TT1561 of thermus thermophilus HB8
2CU3	;	1.7	;	Crystal structure of TT1568 from Thermus thermophilus HB8
1V6Z	;	2.0	;	Crystal structure of TT1573 from Thermus thermophilus
1WXW	;	2.55	;	Crystal structure of Tt1595, a putative SAM-dependent methyltransferase from Thermus thermophillus HB8
1WXX	;	1.8	;	Crystal structure of Tt1595, a putative SAM-dependent methyltransferase from Thermus thermophillus HB8
1UFO	;	1.6	;	Crystal Structure of TT1662 from Thermus thermophilus
1UFB	;	1.9	;	Crystal structure of TT1696 from Thermus thermophilus HB8
1WDJ	;	2.0	;	Crystal structure of TT1808 from Thermus thermophilus HB8
2YQY	;	2.0	;	Crystal structure of TT2238, a four-helix bundle protein
3ZJK	;	2.2	;	crystal structure of Ttb-gly F401S mutant
4BCE	;	2.0	;	crystal structure of Ttb-gly N282T mutant
7ZHN	;	1.85	;	Crystal structure of TTBK1 in complex with AMG28
7ZHQ	;	1.8	;	Crystal structure of TTBK1 in complex with compound 10 (7-009)
7ZHO	;	2.08	;	Crystal structure of TTBK1 in complex with compound 3 (7-001)
7ZHP	;	1.8	;	Crystal structure of TTBK1 in complex with compound 9 (7-005)
7Q8W	;	2.02	;	Crystal structure of TTBK1 in complex with VNG1.35 (compound 23)
7Q8V	;	2.13	;	Crystal structure of TTBK1 in complex with VNG2.73 (compound 42)
7Q8Z	;	1.57	;	Crystal structure of TTBK2 in complex with VNG1.33 (compound 27)
7Q90	;	1.6	;	Crystal structure of TTBK2 in complex with VNG1.63 (compound 32)
7Q8Y	;	1.6	;	Crystal structure of TTBK2 in complex with VNG2.73 (compound 42)
2PL2	;	2.5	;	Crystal structure of TTC0263: a thermophilic TPR protein in Thermus thermophilus HB27
3VV5	;	1.9	;	Crystal structure of TTC0807 complexed with (S)-2-aminoethyl-L-cysteine (AEC)
3VVF	;	1.9	;	Crystal structure of TTC0807 complexed with Arginine
3VVE	;	2.0	;	Crystal structure of TTC0807 complexed with Lysine
3VVD	;	2.05	;	Crystal structure of TTC0807 complexed with Ornithine
6KE1	;	3.39	;	Crystal structure of TtCas1
6KDV	;	3.11	;	Crystal structure of TtCas1-DNA complex
7YLL	;	2.60001	;	Crystal structure of TTEDbh
2XRN	;	2.9	;	Crystal structure of TtgV
2XRO	;	3.4	;	Crystal structure of TtgV in complex with its DNA operator
2CSL	;	2.5	;	Crystal structure of TTHA0137 from Thermus Thermophilus HB8
2CVL	;	1.65	;	Crystal structure of TTHA0137 from Thermus Thermophilus HB8
2CW4	;	1.8	;	Crystal structure of TTHA0137 from Thermus Thermophilus HB8
5YTP	;	2.457	;	Crystal Structure of TTHA0139 L34A from Thermus thermophilus HB8
5YTQ	;	2.393	;	Crystal Structure of TTHA0139 L34A with Lanthanum from Thermus thermophilus HB8
3VUQ	;	2.05	;	Crystal structure of TTHA0167, a transcriptional regulator, TetR/AcrR family from Thermus thermophilus HB8
3IEM	;	2.5	;	Crystal Structure of TTHA0252 from Thermus thermophilus HB8 complexed with RNA analog
3IEL	;	2.35	;	Crystal Structure of TTHA0252 from Thermus thermophilus HB8 complexed with UMP
2DKF	;	2.8	;	Crystal Structure of TTHA0252 from Thermus thermophilus HB8, a RNA Degradation Protein of the Metallo-beta-lactamase Superfamily
4X3L	;	1.7	;	Crystal Structure of TTHA0275 from Thermus thermophilus (HB8) in complex with 5'-methylthioadenosine in space group P21212
4X3M	;	1.851	;	Crystal Structure of TTHA0275 from Thermus thermophilus (HB8) in complex with Adenosine in space group P212121
2DSY	;	1.9	;	Crystal structure of TTHA0281 from thermus thermophilus HB8
2ZIE	;	2.5	;	Crystal Structure of TTHA0409, Putatative DNA Modification Methylase from Thermus thermophilus HB8- Selenomethionine derivative
2ZIG	;	2.1	;	Crystal Structure of TTHA0409, Putative DNA Modification Methylase from Thermus thermophilus HB8
2ZIF	;	2.4	;	Crystal Structure of TTHA0409, Putative DNA Modification Methylase from Thermus thermophilus HB8- Complexed with S-Adenosyl-L-Methionine
2Z0Y	;	2.8	;	Crystal structure of TTHA0657-SAM complex
2HTM	;	2.3	;	Crystal structure of TTHA0676 from Thermus thermophilus HB8
2DJW	;	2.4	;	Crystal structure of TTHA0845 from Thermus thermophilus HB8
2D4R	;	2.4	;	Crystal structure of TTHA0849 from Thermus thermophilus HB8
3OPF	;	1.95	;	Crystal structure of TTHA0988 in space group P212121
3OEP	;	1.75	;	Crystal structure of TTHA0988 in space group P43212
3ORE	;	2.9	;	Crystal structure of TTHA0988 in space group P6522
4U00	;	2.1	;	Crystal structure of TTHA1159 in complex with ADP
2CY2	;	2.0	;	Crystal structure of TTHA1209 in complex with acetyl coenzyme A
2D4O	;	1.8	;	Crystal structure of TTHA1254 (I68M mutant) from Thermus thermophilus HB8
2D4P	;	1.7	;	Crystal structure of TTHA1254 (wild type) from Thermus thermophilus HB8
2ZCW	;	1.5	;	Crystal Structure of TTHA1359, a Transcriptional Regulator, CRP/FNR family from Thermus thermophilus HB8
2Z1K	;	2.3	;	Crystal Structure of Ttha1563 from Thermus thermophilus HB8
2YYB	;	2.6	;	Crystal structure of TTHA1606 from Thermus thermophilus HB8
2ZWR	;	2.2	;	Crystal structure of TTHA1623 from thermus thermophilus HB8
2ZZI	;	2.8	;	Crystal structure of TTHA1623 in a di-iron-bound form
2DT5	;	2.16	;	Crystal Structure of TTHA1657 (AT-rich DNA-binding protein) from Thermus thermophilus HB8
2EPG	;	2.1	;	Crystal structure of TTHA1785
2ELC	;	1.55	;	Crystal structure of TTHA1842 from Thermus thermophilus HB8
2HIA	;	1.6	;	Crystal structure of TTHB049 from Thermus thermophilus HB8
2OWD	;	1.65	;	Crystal structure of TTHB049 from Thermus thermophilus HB8
2OWE	;	1.7	;	Crystal structure of TTHB049 from Thermus thermophilus HB8
2P2Y	;	1.95	;	Crystal structure of TTHB049 from Thermus thermophilus HB8
2P2Z	;	1.75	;	Crystal structure of TTHB049 from Thermus thermophilus HB8
2P30	;	1.85	;	Crystal structure of TTHB049 from Thermus thermophilus HB8
2P6M	;	1.9	;	Crystal structure of TTHB049 from Thermus thermophilus HB8
2P6O	;	1.65	;	Crystal structure of TTHB049 from Thermus thermophilus HB8
2P75	;	1.7	;	Crystal structure of TTHB049 from Thermus thermophilus HB8
2P77	;	1.9	;	Crystal structure of TTHB049 from Thermus thermophilus HB8
2P78	;	1.75	;	Crystal structure of TTHB049 from Thermus thermophilus HB8
2P79	;	1.75	;	Crystal structure of TTHB049 from Thermus thermophilus HB8
2P9F	;	1.75	;	Crystal structure of TTHB049 from Thermus thermophilus HB8
2P9Y	;	1.85	;	Crystal structure of TTHB049 from Thermus thermophilus HB8
2P9Z	;	1.7	;	Crystal structure of TTHB049 from Thermus thermophilus HB8
2PA0	;	2.3	;	Crystal structure of TTHB049 from Thermus thermophilus HB8
3B02	;	1.92	;	Crystal structure of TTHB099, a transcriptional regulator CRP family from Thermus thermophilus HB8
2ZCA	;	1.8	;	Crystal Structure of TTHB189, a CRISPR-associated protein, Cse2 family from Thermus thermophilus HB8
7F4S	;	3.09	;	Crystal structure of TthMTA1-PteMTA9 complex
3DBQ	;	2.7	;	Crystal structure of TTK kinase domain
4ZEG	;	2.33	;	Crystal structure of TTK kinase domain in complex with a pyrazolopyrimidine inhibitor
7CLH	;	2.9	;	Crystal structure of TTK kinase domain in complex with compound 19
7CJA	;	2.49	;	Crystal structure of TTK kinase domain in complex with compound 28
7CHT	;	2.4	;	Crystal structure of TTK kinase domain in complex with compound 30
7CIL	;	2.3	;	Crystal structure of TTK kinase domain in complex with compound 7
7CHM	;	2.65	;	Crystal structure of TTK kinase domain in complex with compound 8
7CHN	;	2.4	;	Crystal structure of TTK kinase domain in complex with compound 9
4JT3	;	2.2	;	Crystal Structure of TTK kinase domain with an inhibitor: 400740
4JS8	;	1.94	;	Crystal structure of TTK kinase domain with an inhibitor: 401348
4O6L	;	2.38	;	Crystal Structure of TTK kinase domain with an inhibitor: 401498 (N-[(1R)-1-(2-chlorophenyl)propyl]-3-{4-[(1-methylpiperidin-4-yl)oxy]phenyl}-1H-indazole-5-carboxamide)
1WDT	;	2.2	;	Crystal structure of ttk003000868 from Thermus thermophilus HB8
1WWI	;	1.58	;	Crystal structure of ttk003001566 from Thermus Thermophilus HB8
1WWS	;	1.9	;	Crystal structure of ttk003001566 from Thermus Thermophilus HB8
1WK4	;	2.8	;	Crystal structure of ttk003001606
1WWP	;	2.11	;	Crystal structure of ttk003001694 from Thermus Thermophilus HB8
2ZDJ	;	2.2	;	Crystal Structure of TTMA177, a Hypothetical Protein from Thermus thermophilus phage TMA
7N7V	;	1.99	;	Crystal structure of TtnM, a Fe(II)-alpha-ketoglutarate-dependent hydroxylase from the tautomycetin biosynthesis pathway in Streptomyces griseochromogenes at 2 A.
5ZG8	;	2.4	;	Crystal Structure of TtNRS
4I87	;	1.69	;	Crystal structure of TTR variant I84S in complex with CHF5074 at acidic pH
7Y1I	;	2.79	;	Crystal Structure of TTR-G67R
5CR1	;	1.545	;	Crystal structure of TTR/resveratrol/T4 complex
2Y6Y	;	2.2	;	Crystal structure of TtrD from Archaeoglobus fulgidus
4YJ3	;	3.75	;	Crystal structure of tubulin bound to compound 2
4YJ2	;	2.6	;	Crystal structure of tubulin bound to MI-181
3MXZ	;	1.599	;	Crystal Structure of tubulin folding cofactor A from Arabidopsis thaliana
7E4P	;	2.4	;	Crystal structure of tubulin in complex with Ansamitocin P3
8AHM	;	2.42	;	Crystal structure of tubulin in complex with C(13)/C(13')-Bis-Desmethyl-Disorazole Z
7E4R	;	2.597	;	Crystal structure of tubulin in complex with D-DM1-SMe
6K9V	;	2.543	;	Crystal structure of tubulin in complex with inhibitor D64
7E4Q	;	2.501	;	Crystal structure of tubulin in complex with L-DM1-SMe
7E4Y	;	2.708	;	Crystal structure of tubulin in complex with L-DM4-SMe
7E4Z	;	2.69	;	Crystal structure of tubulin in complex with Maytansinol
7EN3	;	2.643	;	Crystal structure of tubulin in complex with Tubulysin analogue TGL
7VMJ	;	2.9	;	Crystal structure of tubulin with 17a
7VMG	;	2.39	;	Crystal structure of tubulin with 17j
7VMK	;	2.5	;	Crystal structure of tubulin with 3
6LSN	;	2.445	;	Crystal structure of tubulin-inhibitor complex
4I4T	;	1.8	;	Crystal structure of tubulin-RB3-TTL-Zampanolide complex
4I55	;	2.2	;	Crystal structure of tubulin-stathmin-TTL complex
4IHJ	;	2.0	;	Crystal structure of tubulin-stathmin-TTL-ADP complex
4IIJ	;	2.6	;	Crystal structure of tubulin-stathmin-TTL-apo complex
5KX5	;	2.5	;	Crystal structure of tubulin-stathmin-TTL-Compound 11 complex
5Z4P	;	2.5	;	Crystal structure of tubulin-stathmin-TTL-Compound TCA complex
5XAF	;	2.551	;	Crystal structure of tubulin-stathmin-TTL-Compound Z1 complex
5XAG	;	2.56	;	Crystal structure of tubulin-stathmin-TTL-Compound Z2 complex
4I50	;	2.3	;	Crystal structure of tubulin-stathmin-TTL-Epothilone A complex
4ZI7	;	2.51	;	CRYSTAL STRUCTURE OF TUBULIN-STATHMIN-TTL-HTI286 COMPLEX
4ZHQ	;	2.55	;	Crystal structure of Tubulin-Stathmin-TTL-MMAE Complex
5LP6	;	2.9	;	Crystal structure of Tubulin-Stathmin-TTL-Thiocolchicine Complex
4ZOL	;	2.5	;	Crystal Structure of Tubulin-Stathmin-TTL-Tubulysin M Complex
5BMV	;	2.5	;	CRYSTAL STRUCTURE OF TUBULIN-STATHMIN-TTL-Vinblastine COMPLEX
3NTK	;	1.8	;	Crystal structure of Tudor
3NTH	;	2.8	;	Crystal structure of Tudor and Aubergine [R13(me2s)] complex
3NTI	;	2.8	;	Crystal structure of Tudor and Aubergine [R15(me2s)] complex
3Q1J	;	2.35	;	Crystal structure of tudor domain 1 of human PHD finger protein 20
3QII	;	2.3	;	Crystal structure of tudor domain 2 of human PHD finger protein 20
3DLM	;	1.77	;	Crystal structure of Tudor domain of human Histone-lysine N-methyltransferase SETDB1
3S6W	;	1.78	;	Crystal structure of Tudor domain of human TDRD3
4QQ6	;	1.75	;	Crystal Structure of tudor domain of SMN1 in complex with a small organic molecule
3UTN	;	1.9	;	Crystal structure of Tum1 protein from Saccharomyces cerevisiae
1DKO	;	2.38	;	CRYSTAL STRUCTURE OF TUNGSTATE COMPLEX OF ESCHERICHIA COLI PHYTASE AT PH 6.6 WITH TUNGSTATE BOUND AT THE ACTIVE SITE AND WITH HG2+ CATION ACTING AS AN INTERMOLECULAR BRIDGE
2AKC	;	2.3	;	Crystal structure of tungstate complex of the PhoN protein from S. typhimurium
4LHB	;	2.5	;	Crystal structure of tungsten cofactor synthesizing protein MoaB from Pyrococcus furiosus
3K8B	;	2.3	;	Crystal structure of Turkey (Meleagiris gallopova)hemoglobin at 2.3 Angstrom
1LJN	;	1.19	;	Crystal Structure of Turkey Egg Lysozyme Complex with Di-N-acetylchitobiose at 1.19A Resolution
7SGX	;	3.13	;	Crystal Structure of Turtle Cadherin-23 EC1-2
8SFU	;	1.8	;	Crystal structure of TuUGT202A2 (Tetur22g00270) in complex with naringin
8GKN	;	2.7	;	Crystal structure of TuUGT202A2 (Tetur22g00270) in complex with S-naringenin
8SFY	;	2.35	;	Crystal structure of TuUGT202A2 (Tetur22g00270) in complex with UDP-glucose
4O1S	;	2.7008	;	Crystal structure of TvoVMA intein
7ASU	;	2.23	;	Crystal structure of tWHD1 of Rpc5 subunit of human RNA Polymerase III
7ASV	;	1.55	;	Crystal structure of tWHD2 of Rpc5 subunit of human RNA Polymerase III
4HTS	;	4.0	;	Crystal Structure of Twin Arginine Translocase Receptor- TatC
4HTT	;	6.8	;	Crystal Structure of Twin Arginine Translocase Receptor- TatC in DDM
2RJO	;	2.05	;	Crystal structure of Twin-arginine translocation pathway signal protein from Burkholderia phytofirmans
4OJI	;	2.3	;	Crystal Structure of Twister Ribozyme
4QJD	;	3.1	;	Crystal Structure of Twister with the Nucleotide 5'- to the Cleavage Site Disordered at 3.1 A Resolution
3OBW	;	2.6	;	Crystal structure of two archaeal Pelotas reveal inter-domain structural plasticity
1D2P	;	2.5	;	CRYSTAL STRUCTURE OF TWO B REPEAT UNITS (B1B2) OF THE COLLAGEN BINDING PROTEIN (CNA) OF STAPHYLOCOCCUS AUREUS
1QUU	;	2.5	;	CRYSTAL STRUCTURE OF TWO CENTRAL SPECTRIN-LIKE REPEATS FROM ALPHA-ACTININ
3ILH	;	2.59	;	Crystal structure of Two component response regulator from Cytophaga hutchinsonii
8RSA	;	1.8	;	CRYSTAL STRUCTURE OF TWO COVALENT NUCLEOSIDE DERIVATIVES OF RIBONUCLEASE A
9RSA	;	1.8	;	CRYSTAL STRUCTURE OF TWO COVALENT NUCLEOSIDE DERIVATIVES OF RIBONUCLEASE A
1IHX	;	2.8	;	Crystal structure of two D-glyceraldehyde-3-phosphate dehydrogenase complexes: a case of asymmetry
6KOZ	;	2.25	;	Crystal structure of two domain M1 zinc metallopeptidase E323 mutant bound to L-Leucine amino acid
6KP0	;	2.1	;	Crystal structure of two domain M1 zinc metallopeptidase E323A mutant bound to L-arginine
6KP1	;	2.19	;	Crystal structure of two domain M1 zinc metallopeptidase E323A mutant bound to L-methionine amino acid
6KOY	;	2.35	;	Crystal structure of two domain M1 Zinc metallopeptidase E323A mutant bound to L-tryptophan amino acid
4QR9	;	2.0	;	Crystal structure of two HMGB1 Box A domains cooperating to underwind and kink a DNA
2ZG2	;	2.85	;	Crystal Structure of Two N-terminal Domains of Native Siglec-5
2ZG3	;	3.0	;	Crystal Structure of Two N-terminal Domains of Native Siglec-5 in Complex with 3'-Sialyllactose
2ZG1	;	2.7	;	Crystal Structure of Two N-terminal Domains of Siglec-5 in Complex with 6'-Sialyllactose
7DMN	;	2.0	;	Crystal structure of two pericyclases catalyzing [4+2] cycloaddition
7E22	;	2.63	;	Crystal structure of two pericyclases catalyzing [4+2] cycloaddition
2E26	;	2.0	;	Crystal structure of two repeat fragment of reelin
393D	;	2.0	;	CRYSTAL STRUCTURE OF TWO SELF-COMPLEMENTARY CHIMERIC DECAMER D(CCGG)R(C)D(GCCGG) AND D(CCGG)R(CG)D(CCGG)
394D	;	1.9	;	CRYSTAL STRUCTURE OF TWO SELF-COMPLEMENTARY CHIMERIC DECAMERS D(CCGG)R(C)D(GCCGG) AND D(CCGG)R(CG)D(CCGG)
4EGL	;	2.9	;	Crystal structure of two tandem RNA recognition motifs of Human antigen R
3P01	;	2.65	;	Crystal structure of two-component response regulator from Nostoc sp. PCC 7120
3CZ5	;	2.7	;	Crystal structure of two-component response regulator, LuxR family, from Aurantimonas sp. SI85-9A1
8AIP	;	2.35	;	Crystal Structure of Two-domain bacterial laccase from the actinobacterium Streptomyces carpinensis VKM Ac-1300
6THF	;	1.47	;	Crystal structure of two-domain Cu nitrite reductase from Bradyrhizobium sp. ORS 375
5LHL	;	2.0	;	Crystal Structure of Two-Domain Laccase from Streptomyces griseoflavus
6S0O	;	1.8	;	Crystal Structure of Two-Domain Laccase from Streptomyces griseoflavus produced at 0.25 mM copper sulfate in growth medium
4NB7	;	2.55	;	Crystal Structure of Two-Domain Laccase from Streptomyces LIvidans AC1709 in complex with azide after 180 min soaking
4NAJ	;	2.6	;	Crystal Structure of Two-Domain Laccase from Streptomyces Lividans AC1709 in complex with azide after 90 min soaking
6FDJ	;	2.308	;	Crystal Structure of Two-Domain Laccase mutant H165A from Streptomyces griseoflavus with high copper ions occupancy
7PU0	;	2.2	;	Crystal Structure of Two-Domain Laccase mutant H165A/M199G from Streptomyces griseoflavus
7PUH	;	1.3	;	Crystal Structure of Two-Domain Laccase mutant H165A/R240H from Streptomyces griseoflavus
5MKM	;	1.996	;	Crystal Structure of Two-Domain Laccase mutant H165F from Streptomyces griseoflavus
6FC7	;	1.95	;	Crystal Structure of Two-Domain Laccase mutant H165F from Streptomyces griseoflavus with high copper ions occupancy
6RHQ	;	1.98	;	Crystal Structure of Two-Domain Laccase mutant I170A from Streptomyces griseoflavus
6RH9	;	1.85	;	Crystal Structure of Two-Domain Laccase mutant I170F from Streptomyces griseoflavus
7PFR	;	1.75	;	Crystal Structure of Two-Domain Laccase mutant M199A from Streptomyces griseoflavus
8P9U	;	2.0	;	Crystal Structure of Two-Domain Laccase mutant M199A/D268N from Streptomyces griseoflavus
7PES	;	1.75	;	Crystal Structure of Two-Domain Laccase mutant M199G from Streptomyces griseoflavus
7PTM	;	1.85	;	Crystal Structure of Two-Domain Laccase mutant M199G/R240H from Streptomyces griseoflavus
8P9V	;	2.2	;	Crystal Structure of Two-Domain Laccase mutant M199G/R240H/D268N from Streptomyces griseoflavus
6ZIP	;	2.05	;	Crystal Structure of Two-Domain Laccase mutant R240A from Streptomyces griseoflavus
6ZIJ	;	1.6	;	Crystal Structure of Two-Domain Laccase mutant R240H from Streptomyces griseoflavus
7PEN	;	1.6	;	Crystal Structure of Two-Domain Laccase mutant Y230A from Streptomyces griseoflavus
4FW1	;	1.86	;	Crystal structure of two-domain RSV INTEGRASE covalently linked with DNA
5KS8	;	3.01	;	Crystal structure of two-subunit pyruvate carboxylase from Methylobacillus flagellatus
5NPF	;	1.38	;	Crystal structure of txGH116 (beta-glucosidase from Thermoanaerobacterium xylolyticum) in complex with beta Cyclophellitol Cyclosulfate probe ME594
5O0S	;	1.16	;	Crystal structure of txGH116 (beta-glucosidase from Thermoanaerobacterium xylolyticum) in complex with unreacted beta Cyclophellitol Cyclosulfate probe ME711
8I5O	;	2.3	;	Crystal structure of TxGH116 D593A acid/base mutant from Thermoanaerobacterium xylanolyticum
8I5P	;	2.35	;	Crystal structure of TxGH116 D593A acid/base mutant from Thermoanaerobacterium xylanolyticum with cellobiose
8I5Q	;	2.2	;	Crystal structure of TxGH116 D593A acid/base mutant from Thermoanaerobacterium xylanolyticum with laminaribiose
8I5R	;	1.65	;	Crystal structure of TxGH116 D593N acid/base mutant from Thermoanaerobacterium xylanolyticum
8I5S	;	1.45	;	Crystal structure of TxGH116 D593N acid/base mutant from Thermoanaerobacterium xylanolyticum with 2-deoxy-2-fluoroglucoside
8I5T	;	1.5	;	Crystal structure of TxGH116 D593N acid/base mutant from Thermoanaerobacterium xylanolyticum with cellobiose
8I5U	;	1.4	;	Crystal structure of TxGH116 D593N acid/base mutant from Thermoanaerobacterium xylanolyticum with laminaribiose
7DKS	;	1.65	;	Crystal structure of TxGH116 E441A nucleophile mutant from Thermoanaerobacterium xylanolyticum
7DKT	;	1.65	;	Crystal structure of TxGH116 E441A nucleophile mutant from Thermoanaerobacterium xylanolyticum with alpha-glucosyl fluoride
7DKU	;	1.6	;	Crystal structure of TxGH116 E441A nucleophile mutant from Thermoanaerobacterium xylanolyticum with cellobiose
7DKV	;	1.7	;	Crystal structure of TxGH116 E441A nucleophile mutant from Thermoanaerobacterium xylanolyticum with cellotriose
7DKW	;	1.78	;	Crystal structure of TxGH116 E441G nucleophile mutant from Thermoanaerobacterium xylanolyticum with autocondensation products from alpha-fluoroglucoside.
7DKX	;	1.7	;	Crystal structure of TxGH116 E441G nucleophile mutant from Thermoanaerobacterium xylanolyticum with cellobiose
7DKY	;	1.95	;	Crystal structure of TxGH116 E441G nucleophile mutant from Thermoanaerobacterium xylanolyticum with cellotriose
7W2S	;	1.85	;	Crystal structure of TxGH116 E730A mutant from Thermoanaerobacterium xylanolyticum with glucose
7W2T	;	2.15	;	Crystal structure of TxGH116 E730Q mutant from Thermoanaerobacterium xylanolyticum with glucose
8JBO	;	2.0	;	Crystal structure of TxGH116 from Thermoanaerobacterium xylanolyticum with isofagomine
7W2V	;	1.8	;	Crystal structure of TxGH116 R786A mutant from Thermoanaerobacterium xylanolyticum with glucose
7W2X	;	1.8	;	Crystal structure of TxGH116 R786K mutant from Thermoanaerobacterium xylanolyticum
7W2W	;	1.79	;	Crystal structure of TxGH116 R786K mutant from Thermoanaerobacterium xylanolyticum with glucose
4PY1	;	2.16	;	Crystal structure of Tyk2 in complex with compound 15, 6-((2,5-dimethoxyphenyl)thio)-3-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazine
6AAM	;	1.98	;	Crystal structure of TYK2 in complex with peficitinib
7UYR	;	2.15	;	Crystal structure of TYK2 kinase domain in complex with compound 12
7UYS	;	2.15	;	Crystal structure of TYK2 kinase domain in complex with compound 16
7UYT	;	2.14	;	Crystal structure of TYK2 kinase domain in complex with compound 25
7UYU	;	2.05	;	Crystal structure of TYK2 kinase domain in complex with compound 30
6VNY	;	2.3	;	Crystal structure of TYK2 kinase with compound 10
6VNS	;	2.09	;	Crystal structure of TYK2 kinase with compound 13
6VNV	;	2.15	;	Crystal structure of TYK2 kinase with compound 14
6VNX	;	2.18	;	Crystal structure of TYK2 kinase with compound 19
6X8F	;	2.15	;	Crystal structure of TYK2 with Compound 11
6X8G	;	2.21	;	Crystal structure of TYK2 with Compound 22
6OVA	;	2.5	;	Crystal Structure of TYK2 with novel pyrrolidinone inhibitor
6M83	;	1.3685	;	Crystal structure of TylM1 S120A bound to SAH and dTDP-phenol
6M81	;	1.782	;	Crystal structure of TylM1 Y14F bound to SAH and dTDP-phenol
6M82	;	1.3971	;	Crystal structure of TylM1 Y14paF bound to SAH and dTDP-phenol
6MEB	;	1.8	;	Crystal structure of Tylonycteris bat coronavirus HKU4 macrodomain in complex with nicotinamide adenine dinucleotide (NAD+)
3RHT	;	1.83	;	Crystal structure of type 1 glutamine amidotransferase (GATase1)-like protein from Planctomyces limnophilus
4IKR	;	1.78	;	Crystal structure of Type 1 human methionine aminopeptidase in complex with 2-(4-(5-chloro-6-methyl-2-(pyridin-2-yl)pyrimidin-4-yl)piperazin-1-yl)ethanol
2NQ7	;	1.6	;	Crystal structure of type 1 human methionine aminopeptidase in complex with 3-(2,2-Dimethylpropionylamino)pyridine-2-carboxylic acid thiazole-2-ylamide
3U70	;	2.0	;	Crystal structure of type 1 ribosome inactivating protein complexed with adenine in low ionic solvent
4Q9F	;	1.75	;	Crystal structure of type 1 ribosome inactivating protein from Momordica balsamina in complex with guanosine mono phosphate at 1.75 Angstrom resolution
4GUW	;	1.6	;	Crystal structure of type 1 Ribosome inactivating protein from Momordica balsamina with lipopolysaccharide at 1.6 Angstrom resolution
1B12	;	1.95	;	CRYSTAL STRUCTURE OF TYPE 1 SIGNAL PEPTIDASE FROM ESCHERICHIA COLI IN COMPLEX WITH A BETA-LACTAM INHIBITOR
1VBI	;	1.8	;	Crystal structure of type 2 malate/lactate dehydrogenase from thermus thermophilus HB8
5JF1	;	2.0	;	Crystal structure of type 2 PDF from Streptococcus agalactiae in complex with actinonin
5JF6	;	1.7	;	Crystal structure of type 2 PDF from Streptococcus agalactiae in complex with inhibitor 6b (AB47)
5JF2	;	2.0	;	Crystal structure of type 2 PDF from Streptococcus agalactiae in complex with inhibitor AT002
5JF3	;	1.6	;	Crystal structure of type 2 PDF from Streptococcus agalactiae in complex with inhibitor AT018
5JF4	;	2.4	;	Crystal structure of type 2 PDF from Streptococcus agalactiae in complex with inhibitor AT019
5JF5	;	1.8	;	Crystal structure of type 2 PDF from Streptococcus agalactiae in complex with inhibitor AT020
5JF8	;	1.8	;	Crystal structure of type 2 PDF from Streptococcus agalactiae in complex with inhibitor RAS358 (21)
5JF7	;	2.1	;	Crystal structure of type 2 PDF from Streptococcus agalactiae in complex with inhibitor SMP289
5JF0	;	1.6	;	Crystal structure of type 2 PDF from Streptococcus agalactiae in complex with tripeptide Met-Ala-Arg
5JEZ	;	1.7	;	Crystal structure of type 2 PDF from Streptococcus agalactiae in complex with tripeptide Met-Ala-Ser
5JEY	;	2.8	;	Crystal structure of type 2 PDF from Streptococcus agalactiae, crystallized in cacodylate buffer
5JEX	;	2.0	;	Crystal structure of type 2 PDF from Streptococcus agalactiae, crystallized in imidazole buffer
1IO2	;	2.0	;	Crystal structure of type 2 ribonuclease h from hyperthermophilic archaeon, thermococcus kodakaraensis kod1
4F0W	;	1.24	;	Crystal structure of type effector Tse1 C30A mutant from Pseudomonas aeruginousa
4F0V	;	1.6	;	Crystal structure of type effector Tse1 from Pseudomonas aeruginousa
3JS3	;	2.2	;	Crystal structure of type I 3-dehydroquinate dehydratase (aroD) from Clostridium difficile with covalent reaction intermediate
3M7W	;	1.95	;	Crystal Structure of Type I 3-Dehydroquinate Dehydratase (aroD) from Salmonella typhimurium LT2 in Covalent Complex with Dehydroquinate
3OEX	;	1.9	;	Crystal Structure of Type I 3-Dehydroquinate Dehydratase (aroD) from Salmonella typhimurium with close loop conformation.
2BQ4	;	1.68	;	Crystal structure of type I cytochrome c3 from Desulfovibrio africanus
8B2A	;	1.65	;	Crystal structure of type I dehydroquinase from Salmonella typhi inhibited by an epoxide derivative
8B2B	;	1.9	;	Crystal structure of type I dehydroquinase from Salmonella typhi inhibited by an epoxide derivative
8B2C	;	1.55	;	Crystal structure of type I dehydroquinase from Salmonella typhi inhibited by an epoxide derivative
2B3L	;	1.5	;	Crystal structure of type I human methionine aminopeptidase in the apo form
5WRU	;	3.193	;	Crystal structure of type I inorganic pyrophosphatase from P falciparum
5WRT	;	2.348	;	Crystal structure of type I inorganic pyrophosphatase from Toxoplasma gondii.
4TZ7	;	3.31	;	Crystal structure of type I phosphatidylinositol 4-phosphate 5-kinase alpha from Zebrafish
2AR0	;	2.8	;	Crystal structure of Type I restriction enzyme EcoKI M protein (EC 2.1.1.72) (M.EcoKI)
2OKC	;	2.2	;	Crystal structure of Type I restriction enzyme StySJI M protein (NP_813429.1) from Bacteroides thetaiotaomicron VPI-5482 at 2.20 A resolution
3MRW	;	1.7	;	Crystal Structure of type I ribosome inactivating protein from Momordica balsamina at 1.7 A resolution
3MRY	;	2.0	;	Crystal Structure of type I ribosome inactivating protein from Momordica balsamina with 6-aminopurine at 2.0A resolution
3NX9	;	1.7	;	Crystal structure of type I ribosome inactivating protein in complex with maltose at 1.7A resolution
6YES	;	4.1	;	Crystal structure of type I-D CRISPR-Cas nuclease Cas10d
6THH	;	3.48	;	Crystal structure of type I-D CRISPR-Cas nuclease Cas10d in complex with the SIRV3 AcrID1 (gp02) anti-CRISPR protein
1UAY	;	1.4	;	Crystal Structure of Type II 3-Hydroxyacyl-CoA Dehydrogenase from Thermus thermophilus HB8
7E8N	;	2.2	;	Crystal structure of Type II citrate synthase (HyCS) from Hymenobacter sp. PAMC 26554
1GU0	;	2.0	;	CRYSTAL STRUCTURE OF TYPE II DEHYDROQUINASE FROM STREPTOMYCES COELICOLOR
1GU1	;	1.8	;	Crystal structure of type II dehydroquinase from Streptomyces coelicolor complexed with 2,3-anhydro-quinic acid
1D0I	;	1.8	;	CRYSTAL STRUCTURE OF TYPE II DEHYDROQUINASE FROM STREPTOMYCES COELICOLOR COMPLEXED WITH PHOSPHATE IONS
4ZC1	;	2.52	;	Crystal Structure of type II Dehydroquinate dehydratase from Acinetobacter baumannii with a different crystal form at 2.52 A Resolution
1V1J	;	2.2	;	Crystal structure of type II Dehydroquintae Dehydratase from Streptomyces coelicolor in complex with 3-fluoro
4O91	;	2.393	;	Crystal Structure of type II inhibitor NG25 bound to TAK1-TAB1
1X0A	;	2.0	;	Crystal Structure of type II malate/lactate dehydrogenase from thermus thermophilus HB8
4QII	;	1.64	;	Crystal Structure of type II MenB from Mycobacteria tuberculosis
1WTE	;	1.9	;	Crystal structure of type II restrcition endonuclease, EcoO109I complexed with cognate DNA
1WTD	;	2.401	;	Crystal structure of type II restrcition endonuclease, EcoO109I DNA-free form
2QVS	;	2.5	;	Crystal Structure of Type IIa Holoenzyme of cAMP-dependent Protein Kinase
3V1Z	;	2.2	;	Crystal structure of Type IIF restriction endonuclease Bse634I with cognate DNA
3V20	;	2.35	;	Crystal structure of Type IIF restriction endonuclease Bse634I with cognate DNA
3V21	;	2.7	;	Crystal structure of Type IIF restriction endonuclease Bse634I with cognate DNA
4ABT	;	2.22	;	Crystal structure of Type IIF restriction endonuclease NgoMIV with cognate uncleaved DNA
1AME	;	1.65	;	CRYSTAL STRUCTURE OF TYPE III ANTIFREEZE PROTEIN AT 4 C
1GZI	;	1.8	;	CRYSTAL STRUCTURE OF TYPE III ANTIFREEZE PROTEIN FROM OCEAN POUT, AT 1.8 ANGSTROM RESOLUTION
4QMK	;	2.5	;	Crystal structure of type III effector protein ExoU (exoU)
5B8H	;	2.1999	;	Crystal Structure of Type III pantothenate kinase (PanK III) from Burkholderia cenocepacia complexed with pantothenate, imidodiphosphate, and AMP
4O5F	;	1.55	;	Crystal structure of Type III pantothenate kinase from Burkholderia thailandensis in complex with pantothenate and phosphate
4O8K	;	1.7	;	Crystal structure of Type III pantothenate kinase from Burkholderia thailandensis, apo structure
3VS8	;	1.76	;	Crystal structure of type III PKS ArsC
3VS9	;	1.99	;	Crystal structure of type III PKS ArsC mutant
7CB3	;	2.31	;	Crystal structure of type III polyketide synthase from Mycobacterium marinum
7D41	;	2.419	;	Crystal structure of type III polyketide synthase from Mycobacterium marinum - P 21 21 21 Space group
4YJY	;	1.86	;	Crystal structure of Type III polyketide synthase from Oryza sativa
3A12	;	2.3	;	Crystal structure of Type III Rubisco complexed with 2-CABP
3KDN	;	2.09	;	Crystal structure of Type III Rubisco SP4 mutant complexed with 2-CABP
3A13	;	2.34	;	Crystal structure of Type III Rubisco SP4 mutant complexed with 2-CABP and activated with Ca
3KDO	;	2.36	;	Crystal structure of Type III Rubisco SP6 mutant complexed with 2-CABP
6IFN	;	2.9	;	Crystal structure of Type III-A CRISPR Csm complex
6EKR	;	2.88	;	Crystal structure of Type IIP restriction endonuclease Kpn2I
6EK1	;	2.601	;	Crystal structure of Type IIP restriction endonuclease PfoI
6EKO	;	2.284	;	Crystal structure of Type IIP restriction endonuclease PfoI with cognate DNA
3FHU	;	2.1	;	Crystal structure of type IV b pilin from Salmonella typhi
1T60	;	1.5	;	Crystal structure of Type IV collagen NC1 domain from bovine lens capsule
3WX6	;	2.7	;	Crystal structure of Type Six Secretion System protein
3VPI	;	1.5	;	Crystal structure of type VI effector Tse1 from Pseudomonas aeruginosa
3VPJ	;	2.5	;	crystal structure of type VI effector Tse1 from Pseudomonas aeruginosa in complex with immune protein Tsi1
3WA5	;	1.9	;	Crystal Structure of type VI peptidoglycan muramidase effector Tse3 in complex with its cognate immunity protein Tsi3
6V98	;	1.8	;	Crystal structure of Type VI secretion system effector, TseH (VCA0285)
5ZBL	;	2.3	;	Crystal structure of type-I LOG from Corynebacterium glutamicum in complex with AMP
5ZBJ	;	1.89	;	Crystal structure of type-I LOG from Pseudomonas aeruginosa PAO1
5ZBK	;	2.3	;	Crystal structure of type-I LOG from Pseudomonas aeruginosa PAO1 in complex with AMP
3KHK	;	2.55	;	Crystal structure of type-I restriction-modification system methylation subunit (MM_0429) from Methanosarchina mazei.
1YDX	;	2.3	;	Crystal structure of Type-I restriction-modification system S subunit from M. genitalium
6Z1Y	;	2.0	;	Crystal structure of type-I ribosome-inactivating protein trichobakin (TBK)
3KIP	;	2.95	;	Crystal structure of type-II 3-dehydroquinase from C. albicans
5WQ3	;	1.95	;	Crystal structure of type-II LOG from Corynebacterium glutamicum
5ZI9	;	2.5	;	Crystal structure of type-II LOG from Streptomyces coelicolor A3
3KS2	;	3.3	;	Crystal Structure of Type-III Secretion Chaperone IpgC from Shigella flexneri (residues 10-155)
4PXG	;	2.45	;	Crystal Structure of TypeII restriction Enzyme Sau3AI
7XIO	;	2.64	;	Crystal structure of TYR from Ralstonia
2Q05	;	2.57	;	Crystal structure of tyr/ser protein phosphatase from Vaccinia virus WR
5LQ0	;	2.9	;	Crystal structure of Tyr24 phosphorylated Annexin A2 at 2.9 A resolution
5LQ2	;	3.4	;	Crystal structure of Tyr24 phosphorylated Annexin A2 at 3.4 A resolution
1ZL6	;	2.4	;	Crystal structure of Tyr350Ala mutant of Clostridium botulinum neurotoxin E catalytic domain
2EFO	;	2.4	;	Crystal structure of Tyr77 to Ala of ST1022 from Sulfolobus tokodaii 7
2EFP	;	2.2	;	Crystal Structure of Tyr77 to Ala of ST1022-Glutamine Complex from Sulolobus tokodaii 7
6J2U	;	1.3	;	Crystal structure of Tyrosinase caddy protein(MelC1)with Tyrosinase (MelC2)from Streptomyces avermitilis in complex with Zinc ion
3NM8	;	2.0	;	Crystal structure of Tyrosinase from Bacillus megaterium
3NQ0	;	2.2	;	Crystal Structure of Tyrosinase from Bacillus megaterium crystallized in the absence of Zinc
3NTM	;	2.3	;	Crystal Structure of Tyrosinase from Bacillus megaterium crystallized in the absence of zinc, partial occupancy of CuB
4J6T	;	2.43	;	Crystal Structure of Tyrosinase from Bacillus megaterium F197A mutant
3NQ1	;	2.3	;	Crystal Structure of Tyrosinase from Bacillus megaterium in complex with inhibitor kojic acid
4D87	;	3.5	;	Crystal Structure of Tyrosinase from Bacillus megaterium in complex with SDS
4J6U	;	2.5	;	Crystal Structure of Tyrosinase from Bacillus megaterium N205A mutant
4J6V	;	1.9	;	Crystal Structure of Tyrosinase from Bacillus megaterium N205D mutant
3NQ5	;	2.3	;	Crystal Structure of Tyrosinase from Bacillus megaterium R209H mutant
3NPY	;	2.192	;	Crystal Structure of Tyrosinase from Bacillus megaterium soaked in CuSO4
4HD4	;	1.8	;	Crystal Structure of Tyrosinase from Bacillus megaterium V218F mutant
4HD6	;	2.0	;	Crystal Structure of Tyrosinase from Bacillus megaterium V218F mutant soaked in CuSO4
4HD7	;	2.1	;	Crystal Structure of Tyrosinase from Bacillus megaterium V218G mutant soaked in CuSO4
6EI4	;	2.0	;	Crystal Structure of tyrosinase from Bacillus megaterium with B5N inhibitor in the active site
5I3A	;	2.2	;	Crystal Structure of tyrosinase from Bacillus megaterium with configuration A of hydroquinone inhibitor in the active site
5I3B	;	2.2	;	Crystal Structure of tyrosinase from Bacillus megaterium with configuration B of hydroquinone inhibitor in the active site
5I38	;	2.6	;	Crystal Structure of tyrosinase from Bacillus megaterium with inhibitor kojic acid in the active site
6QXD	;	2.317	;	Crystal Structure of tyrosinase from Bacillus megaterium with JKB inhibitor in the active site.
4P6S	;	2.2	;	Crystal Structure of tyrosinase from Bacillus megaterium with L-DOPA in the active site
4P6T	;	2.5	;	Crystal Structure of tyrosinase from Bacillus megaterium with p-tyrosol in the active site
5OAE	;	2.7	;	Crystal Structure of tyrosinase from Bacillus megaterium with SVF inhibitor in the active site
4P6R	;	2.2	;	Crystal Structure of tyrosinase from Bacillus megaterium with tyrosine in the active site
8HPI	;	2.54	;	Crystal structure of Tyrosinase from Priestia megaterium
7CIT	;	1.5	;	Crystal structure of tyrosinase from Streptomyces castaneoglobisporus in complex with the caddie protein obtained by soaking in the solution containing Cu(II) and hydroxylamine for 24 h
6RRQ	;	2.7	;	Crystal structure of tyrosinase PvdP from Pseudomonas aeruginosa bound to copper
6RRP	;	2.4	;	Crystal structure of tyrosinase PvdP from Pseudomonas aeruginosa bound to copper and phenylthiourea
4IX8	;	2.35	;	Crystal structure of Tyrosine aminotransferase from Leishmania infantum
1BW0	;	2.5	;	CRYSTAL STRUCTURE OF TYROSINE AMINOTRANSFERASE FROM TRYPANOSOMA CRUZI
3FSL	;	2.35	;	Crystal structure of tyrosine aminotransferase tripple mutant (P181Q,R183G,A321K) from Escherichia coli at 2.35 A resolution
4QBT	;	2.1	;	Crystal structure of tyrosine bound human tyrosyl tRNA synthetase
5HSI	;	1.732	;	Crystal structure of tyrosine decarboxylase at 1.73 Angstroms resolution
6LIV	;	2.31	;	Crystal structure of Tyrosine decarboxylase in complex with PLP
5TKD	;	1.92	;	CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH 6-[(3,5-DIMETHYLPHE NYL)AMINO]-8- (METHYLAMINO)IMIDAZO[1,2-B]PYRIDAZINE-3-CARBO XAMIDE
4WOV	;	1.8	;	CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH BMS-066 AKA 2-METHOXY-N-({6-[3-METHYL-7-(METHYLAMINO)-3,5,8,10-TETRAAZATRICYCLO[7.3.0.0, 6]DODECA-1(9),2(6),4,7,11-PENTAEN-11-YL]PYRIDIN-2-YL}METHY L)ACETAMIDE
6NZP	;	2.35	;	CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH COMPOUND-11 AKA 6-CYCLOPROPANEAMIDO-4-{[2-METHOXY-3-(1-METHYL-1H-1,2,4-TRI AZOL-3-YL)PHENYL]AMINO}-N-(?H?)METHYLPYRIDAZINE-3-CARBOXAMIDE
7K7Q	;	2.27	;	CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH COMPOUND-12 AKA:6-[(cyclopropanecarbonyl)amino]-4-({3-[6-(dimethylcarbamoyl)pyridazin-3-yl]-2-methoxyphenyl}amino)-N-methylpyridazine-3-carboxamide
7K7O	;	2.82	;	CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH COMPOUND-12 AKA:6-[(cyclopropanecarbonyl)amino]-4-{[2-methoxy-3-(pyrimidin-2-yl)phenyl]amino}-N-methylpyridazine-3-carboxamide
6NSL	;	2.15	;	CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH Compound-6c AKA 6-((1-(4-CYANOPHENY L)-2-OXO-1,2-DIHYDRO-3-PYRIDINYL)AMINO)-N-CYCLOPROPYL-8-(M ETHYLAMINO)IMIDAZO[1,2-B]PYRIDAZINE-3-CARBOXAMIDE
6NZR	;	2.56	;	CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH Compound_12 AKA 4-[(2-methanesulfonylphenyl)amino]-N-(H3)methyl-6-[(pyridin-2- yl)amino]pyridazine-3-carboxamide
6NZQ	;	2.11	;	CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH Compound_29 AKA 6-[(5-FLUORO-4-METH YLPYRIDIN-2-YL)AMINO]-4-({2-METHOXY-3-[(PYRIDIN-2-YLMETHYL )CARBAMOYL]PHENYL}AMINO)-N-METHYLPYRIDINE-3-CARBOXAMIDE
6NZH	;	2.73	;	CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH Compound_40 AKA 6-cyclopropaneamido-4-[(2-methanesulfonylphenyl)amino]-N-methylpyridine-3-carboxamide
6NZE	;	1.96	;	CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH Compound_5 AKA 4-[(2-CARBAMOYLPHEN YL)AMINO]-6-[(5-FLUOROPYRIDIN-2-YL)AMINO]-N-METHYLPYRIDINE -3-CARBOXAMIDE
6NZF	;	2.39	;	CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH Compound_5 AKA 4-[(2-CARBAMOYLPHEN YL)AMINO]-6-[(5-FLUOROPYRIDIN-2-YL)AMINO]-N-METHYLPYRIDINE -3-CARBOXAMIDE
2PVF	;	1.8	;	Crystal Structure of Tyrosine Phosphorylated Activated FGF Receptor 2 (FGFR2) Kinase Domain in Complex with ATP Analog and Substrate Peptide
6D22	;	2.46	;	Crystal structure of Tyrosine-protein kinase receptor
6D1Y	;	1.93	;	Crystal structure of Tyrosine-protein kinase receptor in complex with 2,4-dichloro-N-(3-methyl-1-phenyl-1H-pyrazol-5-yl)benzamide Inhibitor
6D20	;	1.94	;	Crystal structure of Tyrosine-protein kinase receptor in complex with 5-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4(3H)-one and 5-{[2,4-dichloro-5-(pyridin-2-yl)benzene-1-carbonyl]amino}-N-(2-hydroxy-2-methylpropyl)-1-phenyl-1H-pyrazole-3-carboxamide Inhibitors
6D1Z	;	1.87	;	Crystal structure of Tyrosine-protein kinase receptor in complex with 5-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4(3H)-one Inhibitor
4RSS	;	1.83	;	Crystal structure of tyrosine-protein kinase SYK with an inhibitor
6BYQ	;	2.2	;	Crystal structure of Tyrosine-tRNA ligase from Helicobacter pylori G27
4HPW	;	1.998	;	Crystal structure of Tyrosine-tRNA ligase mutant complexed with unnatural amino acid 3-o-methyl-Tyrosine
6BQY	;	2.1	;	Crystal Structure of Tyrosine-tRNA Synthetase from Acinetobacter baumannii
6BQZ	;	2.3	;	Crystal Structure of Tyrosine-tRNA Synthetase from Acinetobacter baumannii with bound L-Tyrosine
2CYB	;	1.8	;	Crystal structure of Tyrosyl-tRNA Synthetase complexed with L-tyrosine from Archaeoglobus fulgidus
2CYC	;	2.2	;	Crystal structure of Tyrosyl-tRNA Synthetase complexed with L-tyrosine from Pyrococcus horikoshii
3N2Y	;	2.49	;	Crystal structure of tyrosyl-tRNA synthetase complexed with p-(2-tetrazolyl)-phenylalanine
2CYA	;	2.2	;	Crystal structure of tyrosyl-tRNA synthetase from Aeropyrum pernix
6OTJ	;	2.85	;	Crystal Structure of Tyrosyl-tRNA synthetase from Neisseria gonorrhoeae with bound L-Tyr
5YJ3	;	2.845	;	Crystal structure of TZAP and telomeric DNA complex
4WZ0	;	1.954	;	Crystal structure of U-box 1 of LubX / LegU2 / Lpp2887 from Legionella pneumophila str. Paris
4WZ2	;	3.408	;	Crystal structure of U-box 2 of LubX / LegU2 / Lpp2887 from Legionella pneumophila str. Paris, Ile175Met mutant
4XI1	;	2.983	;	Crystal structure of U-box 2 of LubX / LegU2 / Lpp2887 from Legionella pneumophila str. Paris, wild-type
3L1X	;	2.6	;	Crystal Structure of U-box Domain of Human E4B Ubiquitin Ligase
6XLW	;	1.5	;	Crystal structure of U2AF65 bound to AdML splice site sequence
4BWQ	;	2.1	;	Crystal structure of U5-15kD in a complex with PQBP1
6SVS	;	2.5	;	Crystal Structure of U:A-U-rich RNA triple helix with 11 consecutive base triples
8ENK	;	2.5	;	Crystal structure of UAP56 in complex with Tho1, the yeast homolog of human SARNP
6JB7	;	2.1	;	Crystal structure of Ub-conjugated Ube2K C92K&K97A mutant (isopeptide linkage), 2.1 A resolution
6JB6	;	2.7	;	Crystal structure of Ub-conjugated Ube2K C92K&K97A mutant (isopeptide linkage), 2.7 A resolution
4NNJ	;	2.4	;	Crystal structure of Uba1 in complex with ubiquitin-AMP and thioesterified ubiquitin
3ONG	;	2.3	;	Crystal structure of UBA2ufd-Ubc9: insights into E1-E2 interactions in Sumo pathways
3ONH	;	1.601	;	Crystal structure of UBA2ufd-Ubc9: insights into E1-E2 interactions in Sumo pathways
6YUB	;	2.195	;	Crystal structure of Uba4 from Chaetomium thermophilum
6YUC	;	3.15	;	Crystal structure of Uba4-Urm1 from Chaetomium thermophilum
6Z6S	;	3.153	;	Crystal structure of Uba4-Urm1 from Chaetomium thermophilum
7NVK	;	2.651	;	Crystal structure of UBA5 fragment fused to the N-terminus of UFC1
5O63	;	1.6	;	Crystal structure of UbaLAI restriction endonuclease B3 domain domain (mutant L24M L53M L95M) with cognate DNA
8GXR	;	1.7	;	crystal structure of UBC domain of UBE2O
4JQU	;	1.81	;	Crystal structure of Ubc7p in complex with the U7BR of Cue1p
5F6V	;	1.492	;	Crystal structure of Ubc9 (K48/K49A/E54A) complexed with Fragment 1 (biphenol from fragment cocktail screen)
5F6W	;	1.699	;	Crystal structure of Ubc9 (K48/K49A/E54A) complexed with Fragment 1 (biphenol)
5F6X	;	1.56	;	Crystal structure of Ubc9 (K48/K49A/E54A) complexed with Fragment 2 (mercaptobenzoxazole from cocktail screen)
5F6Y	;	1.14	;	Crystal structure of Ubc9 (K48/K49A/E54A) complexed with Fragment 2 (mercaptobenzoxazole)
5F6D	;	1.553	;	Crystal structure of Ubc9 (K48A/K49A/E54A) complexed with Fragment 6
5F6U	;	1.552	;	Crystal Structure of Ubc9 (K48A/K49A/E54A) complexed with Fragment 8 (JSS190B146)
5D1K	;	1.78	;	Crystal Structure of UbcH5B in Complex with the RING-U5BR Fragment of AO7
5D1M	;	1.581	;	Crystal Structure of UbcH5B in Complex with the RING-U5BR Fragment of AO7 (P199A)
5D1L	;	1.618	;	Crystal Structure of UbcH5B in Complex with the RING-U5BR Fragment of AO7 (Y165A)
1X23	;	1.85	;	Crystal structure of ubch5c
1WZV	;	2.1	;	Crystal Structure of UbcH8
1WZW	;	2.4	;	Crystal Structure of UbcH8
3H8K	;	1.8	;	Crystal structure of Ube2g2 complxed with the G2BR domain of gp78 at 1.8-A resolution
7LEW	;	1.736	;	Crystal structure of UBE2G2 in complex with the UBE2G2-binding region of AUP1
6IF1	;	2.466	;	Crystal structure of Ube2K and K48-linked di-ubiquitin complex
5DFL	;	2.1	;	Crystal structure of Ube2K~Ubiquitin conjugate
7V8F	;	1.66	;	Crystal structure of UBE2L3 bound to HOIP RING1 domain.
7YW1	;	3.27	;	crystal structure of UBE2O
4KDC	;	2.09	;	Crystal Structure of UBIG
5DPM	;	2.1	;	Crystal structure of UbiG mutant in complex with SAH
4KDR	;	2.003	;	Crystal Structure of UBIG/SAH complex
4II2	;	2.2	;	Crystal structure of Ubiquitin activating enzyme 1 (Uba1) in complex with the Ub E2 Ubc4, ubiquitin, and ATP/Mg
3KW5	;	2.83	;	Crystal structure of ubiquitin carboxy terminal hydrolase L1 bound to ubiquitin vinylmethylester
2ETL	;	2.4	;	Crystal Structure of Ubiquitin Carboxy-terminal Hydrolase L1 (UCH-L1)
1VJV	;	1.74	;	Crystal structure of Ubiquitin carboxyl-terminal hydrolase 6 (yfr010w) from Saccharomyces cerevisiae at 1.74 A resolution
7BBF	;	2.54	;	Crystal structure of ubiquitin charged Ube2N (Ube2N~Ub) in complex with Ube2V2
2H2Y	;	2.8	;	Crystal structure of ubiquitin conjugating enzyme E2 from plasmodium falciparum
3WE5	;	1.7	;	Crystal structure of ubiquitin conjugating enzyme E2 UbcA1 from Agrocybe aegerita
2Q0V	;	2.4	;	Crystal structure of ubiquitin conjugating enzyme E2, putative, from Plasmodium falciparum
2BEP	;	1.8	;	Crystal structure of ubiquitin conjugating enzyme E2-25K
6NYA	;	2.065	;	Crystal Structure of ubiquitin E1 (Uba1) in complex with Ubc3 (Cdc34) and ubiquitin
5IA7	;	2.0	;	Crystal structure of Ubiquitin fold modifier 1 (Ufm1)
4GU2	;	1.35	;	Crystal structure of ubiquitin from Entamoeba histolytica to 1.35 Angstrom
4GSW	;	2.15	;	Crystal structure of ubiquitin from Entamoeba histolytica to 2.15 Angstrom
2ZCB	;	1.6	;	Crystal Structure of ubiquitin P37A/P38A
8OYP	;	2.44	;	Crystal structure of Ubiquitin specific protease 11 (USP11) in complex with a substrate mimetic
3E46	;	1.86	;	Crystal structure of ubiquitin-conjugating enzyme E2-25kDa (Huntington interacting protein 2) M172A mutant
3F92	;	2.23	;	Crystal structure of ubiquitin-conjugating enzyme E2-25kDa (Huntington Interacting Protein 2) M172A mutant crystallized at pH 8.5
5V0R	;	1.55	;	Crystal structure of ubiquitin-conjugating enzyme from Naegleria fowleri with modified Cys99
6MJ9	;	1.85	;	CRYSTAL STRUCTURE OF UBIQUITIN-CONJUGATING ENZYME FROM NAEGLERIA FOWLERI, APO FORM
5XPK	;	2.274	;	Crystal structure of ubiquitin-k6mimic
6P0Q	;	1.72	;	Crystal Structure of Ubiquitin-like Domain of Human WDR12
2ZEQ	;	1.65	;	Crystal structure of ubiquitin-like domain of murine Parkin
6QLH	;	1.57	;	Crystal structure of UbiX in complex with reduced FMN and isopentyl monophosphate
4RHF	;	1.764	;	Crystal structure of UbiX mutant V47S from Colwellia psychrerythraea 34H
4RHE	;	2.003	;	Crystal structure of UbiX, an aromatic acid decarboxylase from the Colwellia psychrerythraea 34H
6M8T	;	1.67	;	Crystal structure of UbiX-like FMN prenyltransferase AF1214 from Archaeoglobus fulgidus, FMN complex
6M8U	;	2.221	;	Crystal structure of UbiX-like FMN prenyltransferase AF1214 from Archaeoglobus fulgidus, prenylated-FMN complex
6M8V	;	2.221	;	Crystal structure of UbiX-like FMN prenyltransferase MJ0101 from Methanocaldococcus jannaschii, FMN complex
8HDA	;	1.93	;	Crystal structure of Ubl1 (residues 18-111) of SARS-CoV-2
8XAB	;	1.49	;	Crystal structure of Ubl1 domain of nonstructural protein 3 of SARS-CoV-2
6P5L	;	3.296	;	Crystal Structure of Ubl123 with an EZH2 peptide
3SHQ	;	1.96	;	Crystal Structure of UBLCP1
7WUK	;	1.63	;	Crystal structure of UBR bof from PRT6
7WUL	;	1.58	;	Crystal structure of UBR bof from PRT6 (RDG pH5.5)
7WUN	;	1.53	;	Crystal structure of UBR bof from PRT6 (RSG)
7WUM	;	1.58	;	Crystal structure of UBR box from PRT6 (RDG pH 8.5)
8J9Q	;	2.18	;	Crystal structure of UBR box of UBR4 apo
8J9R	;	1.65	;	Crystal structure of UBR box of YIFS-UBR4
5VMD	;	2.202	;	Crystal structure of UBR-box from UBR6 in a domain-swapping conformation
3VHS	;	1.9	;	Crystal structure of UBZ of human WRNIP1
4UF5	;	3.7	;	Crystal structure of UCH-L5 in complex with inhibitory fragment of INO80G
3IHR	;	2.95	;	Crystal Structure of Uch37
4WLP	;	3.102	;	Crystal structure of UCH37-NFRKB Inhibited Deubiquitylating Complex
1XD3	;	1.45	;	Crystal structure of UCHL3-UbVME complex
6CKY	;	1.8	;	Crystal structure of UcmS2
5VWM	;	1.8	;	Crystal structure of UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase (LpxC) from Pseudomonas aeruginosa in complex with CHIR-090 inhibitor
3NKL	;	1.9	;	Crystal Structure of UDP-D-Quinovosamine 4-Dehydrogenase from Vibrio fischeri
6O87	;	1.75	;	Crystal Structure of UDP-dependent glucosyltransferases (UGT) from Stevia rebaudiana in complex with UDP
6O88	;	1.99	;	Crystal Structure of UDP-dependent glucosyltransferases (UGT) from Stevia rebaudiana in complex with UDP and rebaudioside A
3HDQ	;	2.36	;	Crystal structure of UDP-galactopyranose mutase (oxidized form) in complex with substrate
3HDY	;	2.4	;	Crystal Structure of UDP-galactopyranose mutase (reduced form) in complex with substrate
3UKA	;	2.64	;	CRYSTAL STRUCTURE OF UDP-galactopyranose mutase from Aspergillus fumigatus
3UKL	;	2.63	;	Crystal structure of UDP-galactopyranose mutase from Aspergillus fumigatus in complex with UDP
3UKH	;	2.3	;	Crystal structure of udp-galactopyranose mutase from Aspergillus fumigatus in complex with UDPGALP (non-reduced)
3UKF	;	2.5	;	CRYSTAL STRUCTURE OF UDP-galactopyranose mutase from Aspergillus fumigatus in complex with UDPgalp (reduced)
4XGK	;	2.652	;	Crystal structure of UDP-galactopyranose mutase from Corynebacterium diphtheriae in complex with 2-[4-(4-chlorophenyl)-7-(2-thienyl)-2-thia-5,6,8,9-tetrazabicyclo[4.3.0]nona-4,7,9-trien-3-yl]acetic
3MJ4	;	2.65	;	Crystal structure of UDP-galactopyranose mutase in complex with phosphonate analog of UDP-galactopyranose
3HE3	;	2.4	;	Crystal Structure of UDP-galactopyranose mutase in complex with UDP
3ICP	;	2.01	;	Crystal Structure of UDP-galactose 4-epimerase
3KO8	;	1.8	;	Crystal Structure of UDP-galactose 4-epimerase
1LRL	;	1.8	;	Crystal Structure of UDP-Galactose 4-Epimerase Mutant Y299C Complexed with UDP-Glucose
4LIS	;	2.8	;	Crystal Structure of UDP-galactose-4-epimerase from Aspergillus nidulans
7XPP	;	2.6	;	Crystal Structure of UDP-Glc/GlcNAc 4-Epimerase with NAD
7XPO	;	1.25	;	Crystal Structure of UDP-Glc/GlcNAc 4-Epimerase with NAD/UDP-Glc
7XPQ	;	2.15	;	Crystal Structure of UDP-Glc/GlcNAc 4-Epimerase with NAD/UDP-GlcNAc
4ZHT	;	2.69	;	Crystal structure of UDP-GlcNAc 2-epimerase
6VLC	;	2.15	;	Crystal structure of UDP-GlcNAc 2-epimerase from Neisseria meningitidis bound to UDP-GlcNAc
5XVS	;	2.383	;	Crystal structure of UDP-GlcNAc 2-epimerase NeuC complexed with UDP
5ZLT	;	2.5	;	Crystal structure of UDP-GlcNAc 2-epimerase NeuC complexed with UDP
2GN8	;	2.1	;	Crystal structure of UDP-GlcNAc inverting 4,6-dehydratase in complex with NADP and UDP
2GNA	;	2.6	;	Crystal structure of UDP-GlcNAc inverting 4,6-dehydratase in complex with NADP and UDP-Gal
2GN9	;	2.8	;	Crystal structure of UDP-GlcNAc inverting 4,6-dehydratase in complex with NADP and UDP-Glc
2GN6	;	2.7	;	Crystal structure of UDP-GlcNAc inverting 4,6-dehydratase in complex with NADP and UDP-GlcNAc
2GN4	;	1.9	;	Crystal structure of UDP-GlcNAc inverting 4,6-dehydratase in complex with NADPH and UDP-GlcNAc
3EHE	;	1.87	;	Crystal structure of UDP-glucose 4 epimerase (galE-1) from Archaeoglobus fulgidus
2C20	;	2.7	;	CRYSTAL STRUCTURE OF UDP-GLUCOSE 4-EPIMERASE
7YSY	;	2.16	;	Crystal Structure of UDP-glucose 4-epimerase (Rv3634c) co-crystallized with UDP-N-acetylgalactosamine from Mycobacterium tuberculosis
7YSM	;	1.87	;	Crystal Structure of UDP-glucose 4-epimerase (Rv3634c) co-crystallized with UDP-N-acetylglucosamine from Mycobacterium tuberculosis
7YS8	;	2.02	;	Crystal Structure of UDP-glucose 4-epimerase (Rv3634c) from Mycobacterium tuberculosis
7YST	;	1.88	;	Crystal Structure of UDP-glucose 4-epimerase (Rv3634c) in complex with both UDP-glucose and UDP-galactose in chain B from Mycobacterium tuberculosis
7YS9	;	1.65	;	Crystal Structure of UDP-glucose 4-epimerase (Rv3634c) in complex with both UDP-Glucose and UDP-Galactose in chainA from Mycobacterium tuberculosis
7YT0	;	1.76	;	Crystal Structure of UDP-glucose 4-epimerase (Rv3634c) in complex with UDP-galactose from Mycobacterium tuberculosis
7YSA	;	1.95	;	Crystal Structure of UDP-glucose 4-epimerase (Rv3634c) in complex with UDP-glucose in chain A and UDP-galactose in chain B from Mycobacterium tuberculosis
4ZRM	;	1.9	;	Crystal Structure of UDP-Glucose 4-Epimerase (TM0509) from Hyperthermophilic Eubacterium Thermotoga maritima
4ZRN	;	2.0	;	Crystal Structure of UDP-Glucose 4-Epimerase (TM0509) with UDP-glucose from Hyperthermophilic Eubacterium Thermotoga Maritima
6K0G	;	1.8	;	Crystal Structure of UDP-glucose 4-epimerase from Bifidobacterium longum in complex with NAD+ and UDP
6K0I	;	1.8	;	Crystal Structure of UDP-glucose 4-epimerase from Bifidobacterium longum in complex with NAD+ and UDP-Glc
6K0H	;	2.0	;	Crystal Structure of UDP-glucose 4-epimerase from Bifidobacterium longum in complex with NAD+ and UDP-GlcNAc
4WOK	;	1.85	;	Crystal structure of UDP-glucose 4-epimerase from Brucella ovis in complex with NAD
3GG2	;	1.7	;	Crystal structure of UDP-glucose 6-dehydrogenase from Porphyromonas gingivalis bound to product UDP-glucuronate
3PJG	;	2.7	;	Crystal structure of UDP-glucose dehydrogenase from Klebsiella pneumoniae complexed with product UDP-glucuronic acid
3GUE	;	1.92	;	Crystal Structure of UDP-glucose phosphorylase from Trypanosoma Brucei, (Tb10.389.0330)
2PA4	;	2.0	;	Crystal structure of UDP-glucose pyrophosphorylase from Corynebacteria glutamicum in complex with magnesium and UDP-glucose
5NZM	;	2.35	;	Crystal structure of UDP-glucose pyrophosphorylase from Leishmania major in complex with murrayamine-I
5NZK	;	2.45	;	Crystal structure of UDP-glucose pyrophosphorylase from Leishmania major in complex with phenylalanine
5NZL	;	2.4	;	Crystal structure of UDP-glucose pyrophosphorylase from Leishmania major in complex with resveratrol
5WEG	;	2.0	;	Crystal Structure of UDP-glucose pyrophosphorylase from Sugarcane
8B31	;	1.75	;	Crystal structure of UDP-glucose pyrophosphorylase from Thermocrispum agreste DSM 44070
8B6D	;	2.1	;	Crystal structure of UDP-glucose pyrophosphorylase from Thermocrispum agreste DSM 44070 in complex with UDP
8B68	;	1.6	;	Crystal structure of UDP-glucose pyrophosphorylase from Thermocrispum agreste DSM 44070 in complex with UDP-glucose
5NZJ	;	1.95	;	Crystal structure of UDP-glucose pyrophosphorylase G45Y mutant from Leishmania major in complex with UDP-glucose
3R2W	;	3.6	;	Crystal Structure of UDP-glucose Pyrophosphorylase of Homo Sapiens
5NZI	;	2.05	;	Crystal structure of UDP-glucose pyrophosphorylase S374F mutant from Leishmania major in complex with UDP-glucose
5NZG	;	1.6	;	Crystal structure of UDP-glucose pyrophosphorylase S374W mutant from Leishmania major in complex with UDP-glucose
5NZH	;	2.9	;	Crystal structure of UDP-glucose pyrophosphorylase V402W mutant from Leishmania major
5J49	;	1.8	;	Crystal structure of UDP-glucose pyrophosporylase / UTP-glucose-1-phosphate uridylyltransferase from Burkholderia xenovorans
7KN1	;	1.45	;	Crystal structure of UDP-glucose-4-epimerase (galE) from Stenotrophomonas maltophila with bound NAD and formylated UDP-arabinopyranose
3WC4	;	1.85	;	Crystal structure of UDP-glucose: anthocyanidin 3-O-glucosyltransferase from Clitoria ternatea
4REM	;	2.55	;	Crystal structure of UDP-glucose: anthocyanidin 3-O-glucosyltransferase in complex with delphinidin
4REL	;	1.754	;	Crystal structure of UDP-glucose: anthocyanidin 3-O-glucosyltransferase in complex with kaempferol
4REN	;	2.704	;	Crystal structure of UDP-glucose: anthocyanidin 3-O-glucosyltransferase in complex with petunidin
4WHM	;	1.851	;	Crystal structure of UDP-glucose: anthocyanidin 3-O-glucosyltransferase in complex with UDP
1IIR	;	1.8	;	Crystal Structure of UDP-glucosyltransferase GtfB
5V2K	;	2.002	;	Crystal structure of UDP-glucosyltransferase, UGT74F2 (T15A), with UDP and 2-bromobenzoic acid
5V2J	;	1.8	;	Crystal structure of UDP-glucosyltransferase, UGT74F2 (T15S), with UDP and 2-bromobenzoic acid
5U6N	;	2.001	;	Crystal structure of UDP-glucosyltransferase, UGT74F2 (T15S), with UDP and salicylic acid
5U6S	;	1.996	;	Crystal structure of UDP-glucosyltransferase, UGT74F2, with UDP and 2-bromobenzoic acid
5U6M	;	2.568	;	Crystal structure of UDP-glucosyltransferase, UGT74F2, with UDP and salicylic acid
6ZLA	;	2.2	;	Crystal Structure of UDP-Glucuronic acid 4-epimerase from Bacillus cereus in complex with NAD
6ZL6	;	1.7	;	Crystal Structure of UDP-Glucuronic acid 4-epimerase from Bacillus cereus in complex with UDP and NAD
6ZLL	;	1.85	;	Crystal Structure of UDP-Glucuronic acid 4-epimerase from Bacillus cereus in complex with UDP-Galacturonic acid and NAD
6ZLD	;	1.8	;	Crystal Structure of UDP-Glucuronic acid 4-epimerase from Bacillus cereus in complex with UDP-Glucuronic acid and NAD
6ZLJ	;	1.7	;	Crystal Structure of UDP-Glucuronic acid 4-epimerase Y149F mutant from Bacillus cereus in complex with UDP-4-DEOXY-4-FLUORO-Glucuronic acid and NAD
5JZX	;	2.2	;	Crystal Structure of UDP-N-acetylenolpyruvoylglucosamine reductase (MurB) from Mycobacterium tuberculosis
7ORZ	;	1.85	;	Crystal structure of UDP-N-acetylenolpyruvoylglucosamine reductase (MurB) from Pseudomonas aeruginosa in complex with FAD and a pyrazole derivative (fragment 18)
7OSQ	;	2.07	;	Crystal structure of UDP-N-acetylenolpyruvoylglucosamine reductase (MurB) from Pseudomonas aeruginosa in complex with FAD and a pyrazole derivative (fragment 18)
7OR2	;	2.35	;	Crystal structure of UDP-N-acetylenolpyruvoylglucosamine reductase (MurB) from Pseudomonas aeruginosa in complex with FAD and a pyrazole derivative (fragment 4)
2GQT	;	1.3	;	Crystal Structure of UDP-N-Acetylenolpyruvylglucosamine Reductase (MurB) from Thermus caldophilus
2GQU	;	1.6	;	Crystal Structure of UDP-N-Acetylenolpyruvylglucosamine Reductase (MurB) from Thermus caldophilus
4MO2	;	2.0	;	Crystal Structure of UDP-N-acetylgalactopyranose mutase from Campylobacter jejuni
6WFM	;	1.95	;	Crystal structure of UDP-N-acetylglucosamine 1-carboxyvinyltransferase (murA) from Stenotrophomonas maltophilia K279a
5BQ2	;	1.7	;	Crystal structure of UDP-N-acetylglucosamine 1-carboxyvinyltransferase (UDP-N-acetylglucosamine enolpyruvyl transferase, EPT) from Pseudomonas aeruginosa
2YVW	;	1.81	;	Crystal structure of UDP-N-acetylglucosamine 1-carboxyvinyltransferase from Aquifex aeolicus VF5
1O6C	;	2.9	;	Crystal structure of UDP-N-acetylglucosamine 2-epimerase
1V4V	;	1.8	;	Crystal Structure Of UDP-N-Acetylglucosamine 2-Epimerase From Thermus Thermophilus HB8
1J2Z	;	2.1	;	Crystal structure of UDP-N-acetylglucosamine acyltransferase
2RL1	;	2.2	;	Crystal structure of UDP-N-acetylglucosamine enolpyruvyl transferase from Haemophilus influenzae in complex with UDP-N-acetylglucosamine
2RL2	;	2.3	;	Crystal structure of UDP-N-acetylglucosamine enolpyruvyl transferase from Haemophilus influenzae in complex with UDP-N-acetylglucosamine and fosfomycin
5JXX	;	3.001	;	Crystal structure of UDP-N-acetylglucosamine O-acyltransferase (LpxA) from Moraxella catarrhalis RH4.
1VM8	;	2.5	;	Crystal structure of UDP-N-acetylglucosamine pyrophosphorylase (Agx2) from Mus musculus at 2.50 A resolution
1VGV	;	2.31	;	Crystal structure of UDP-N-acetylglucosamine_2 epimerase
1J6U	;	2.3	;	Crystal structure of UDP-N-acetylmuramate-alanine ligase MurC (TM0231) from Thermotoga maritima at 2.3 A resolution
8EGM	;	2.2	;	Crystal Structure of UDP-N-acetylmuramate-L-alanine ligase (UDP-N-acetylmuramoyl-L-alanine synthetase, MurC) Pseudomonas aeruginosa in complex with compound AZ13644908
8EGN	;	1.95	;	Crystal Structure of UDP-N-acetylmuramate-L-alanine ligase (UDP-N-acetylmuramoyl-L-alanine synthetase, MurC) Pseudomonas aeruginosa in complex with ligand AZ-13643701
8EWA	;	1.85	;	Crystal Structure of UDP-N-acetylmuramate-L-alanine ligase (UDP-N-acetylmuramoyl-L-alanine synthetase, MurC) Pseudomonas aeruginosa in complex with ligand AZ-13644923
7BVA	;	2.303	;	Crystal structure of UDP-N-acetylmuramic Acid L-alanine ligase (MurC) from Mycobacterium bovis
7BVB	;	3.191	;	Crystal structure of UDP-N-acetylmuramic Acid L-alanine ligase (MurC) from Mycobacterium bovis in complex with UDP-N-acetylglucosamine
1P31	;	1.85	;	Crystal Structure of UDP-N-acetylmuramic acid:L-alanine Ligase (MurC) from Haemophilus influenzae
1P3D	;	1.7	;	Crystal Structure of UDP-N-acetylmuramic acid:L-alanine ligase (MurC) in Complex with UMA and ANP.
7SY9	;	2.75	;	Crystal Structure of UDP-N-acetylmuramoylalanine--D-glutamate ligase (MurD) from Pseudomonas aeruginosa PAO1
7U35	;	1.95	;	Crystal Structure of UDP-N-acetylmuramoylalanine--D-glutamate ligase (MurD) from Pseudomonas aeruginosa PAO1 in complex with ADP
8DP2	;	1.6	;	Crystal Structure of UDP-N-acetylmuramoylalanine--D-glutamate ligase (MurD) from Pseudomonas aeruginosa PAO1 in complex with UMA (Uridine-5'-diphosphate-N-acetylmuramoyl-L-Alanine)
7SIR	;	1.65	;	Crystal Structure of UDP-N-acetylmuramoylalanine-D-glutamate ligase from Acinetobacter baumannii AB5075-UW
7TI7	;	1.5	;	Crystal Structure of UDP-N-acetylmuramoylalanine-D-glutamate ligase from Acinetobacter baumannii AB5075-UW in complex with ADP
6KVL	;	1.998	;	Crystal structure of UDP-RebB-SrUGT76G1
6KVK	;	2.397	;	Crystal structure of UDP-Sm-SrUGT76G1
6KVI	;	2.598	;	Crystal structure of UDP-SrUGT76G1
4HFQ	;	1.39	;	Crystal structure of UDP-X diphosphatase
6KVJ	;	2.499	;	Crystal structure of UDPX-SrUGT76G1
7NW1	;	1.95	;	Crystal structure of UFC1 in complex with UBA5
7NVJ	;	2.2	;	Crystal structure of UFC1 Y110A & F121A
3M63	;	2.4	;	Crystal structure of Ufd2 in complex with the ubiquitin-like (UBL) domain of Dsk2
3M62	;	2.4	;	Crystal structure of Ufd2 in complex with the ubiquitin-like (UBL) domain of Rad23
7W3N	;	1.6	;	Crystal structure of Ufm1 fused to UFBP1 UFIM
5HKH	;	2.55	;	Crystal structure of Ufm1 in complex with UBA5
5EJJ	;	2.8	;	Crystal structure of UfSP from C.elegans
2I5K	;	3.1	;	Crystal structure of Ugp1p
6R1B	;	2.27	;	Crystal structure of UgpB from Mycobacterium tuberculosis in complex with glycerophosphocholine
6L90	;	2.02	;	Crystal structure of ugt transferase enzyme
6L8Z	;	2.1	;	Crystal structure of ugt transferase mutant in complex with UPG
6L8W	;	2.05	;	Crystal structure of ugt transferase mutant2
7VLB	;	3.0	;	Crystal structure of UGT109A1 from Bacillus
7Q3S	;	1.59	;	Crystal structure of UGT706F8 from Zea mays
8CGQ	;	2.04	;	Crystal structure of UGT708A6 with UDP
8HOK	;	2.15	;	crystal structure of UGT71AP2
8HOJ	;	2.9	;	Crystal structure of UGT71AP2 in complex with UDP
8INO	;	2.3	;	Crystal structure of UGT74AN3 in complex UDP and PER
8IN7	;	1.9	;	Crystal structure of UGT74AN3-UDP
8INA	;	1.86	;	Crystal structure of UGT74AN3-UDP
8INV	;	1.85	;	Crystal structure of UGT74AN3-UDP-BUF
8INJ	;	1.76	;	Crystal structure of UGT74AN3-UDP-DIG
8IND	;	1.85	;	Crystal structure of UGT74AN3-UDP-RES
7ZER	;	1.42	;	Crystal structure of UGT85B1 from Sorghum bicolor in complex with UDP
7ZF0	;	1.5	;	Crystal structure of UGT85B1 from Sorghum bicolor in complex with UDP and p-hydroxymandelonitrile
6M2V	;	3.0	;	Crystal structure of UHRF1 SRA complexed with fully-mCHG DNA.
6B9M	;	1.68	;	Crystal structure of UHRF1 TTD domain in complex with the polybasic region
5JUE	;	1.65	;	Crystal Structure of UIC2 Fab
7ATH	;	2.343	;	Crystal structure of UipA
7ATK	;	2.855	;	Crystal structure of UipA in complex with Uranium
2WOM	;	3.2	;	Crystal Structure of UK-453061 bound to HIV-1 Reverse Transcriptase (K103N).
2WON	;	2.8	;	Crystal Structure of UK-453061 bound to HIV-1 Reverse Transcriptase (wild-type).
6NYP	;	2.7	;	Crystal structure of UL144/BTLA complex
6QAS	;	1.75	;	Crystal structure of ULK1 in complexed with PF-03814735
8SV9	;	2.3	;	Crystal structure of ULK1 kinase domain with inhibitor MR-2088
6YID	;	2.7	;	Crystal structure of ULK2 in complex with SBI-0206965
6QAT	;	2.77	;	Crystal structure of ULK2 in complexed with hesperadin
6QAU	;	2.48	;	Crystal structure of ULK2 in complexed with MRT67307
6QAV	;	2.05	;	Crystal structure of ULK2 in complexed with MRT68921
2VA1	;	2.5	;	Crystal structure of UMP kinase from Ureaplasma parvum
7BIX	;	3.12	;	Crystal structure of UMPK from M. tuberculosis in complex with UDP and UTP (C2 form)
7BL7	;	3.33	;	Crystal structure of UMPK from M. tuberculosis in complex with UDP and UTP (P21212 form)
1M7N	;	2.7	;	Crystal Structure of Unactivated APO Insulin-like Growth Factor-1 Receptor Kinase Domain
6ITT	;	2.103	;	Crystal structure of unactivated c-KIT in complex with compound
1EJ7	;	2.45	;	CRYSTAL STRUCTURE OF UNACTIVATED TOBACCO RUBISCO WITH BOUND PHOSPHATE IONS
3WHI	;	2.4	;	Crystal structure of unautoprocessed form of IS1-inserted Pro-subtilisin E
2Z2Z	;	1.87	;	Crystal structure of unautoprocessed form of Tk-subtilisin soaked by 10mM CaCl2
5CIP	;	2.48	;	Crystal Structure of Unbound 4E10
5JOR	;	2.206	;	Crystal structure of unbound anti-glycan antibody Fab14.22 at 2.2 A
6AVN	;	2.5	;	Crystal structure of unbound anti-HIV antibody Fab PGV19 at 2.5 A
1SGZ	;	2.0	;	Crystal Structure of Unbound Beta-Secretase Catalytic Domain.
4S2P	;	1.7	;	Crystal structure of unbound OXA-48
4X1W	;	1.95	;	Crystal structure of unbound RHDVb P domain
2A5A	;	2.08	;	Crystal structure of unbound SARS coronavirus main peptidase in the space group C2
5IFA	;	1.821	;	Crystal structure of unbound VRC01c-HuGL2 Fab from an HIV-1 naive donor at 1.82 A
5O44	;	3.14	;	Crystal structure of unbranched mixed tri-Ubiquitin chain containing K48 and K63 linkages.
6H6A	;	2.0	;	Crystal structure of UNC119 in complex with LCK peptide
7OK6	;	1.949	;	Crystal structure of UNC119B in complex with LCK peptide
4W9R	;	2.703	;	Crystal structure of uncharacterised protein Coch_1243 from Capnocytophaga ochracea DSM 7271
5T2X	;	2.303	;	Crystal structure of Uncharacterised protein lpg1670
5COF	;	1.35	;	Crystal structure of Uncharacterised protein Q1R1X2 from Escherichia coli UTI89
2IEC	;	2.33	;	Crystal Structure of uncharacterized conserved archael protein from Methanopyrus kandleri
1Q9U	;	1.8	;	Crystal structure of uncharacterized conserved protein DUF302 from Bacillus stearothermophilus
2YZS	;	2.0	;	Crystal structure of uncharacterized conserved protein from Aquifex aeolicus
2YWI	;	1.6	;	Crystal structure of uncharacterized conserved protein from Geobacillus kaustophilus
2YYT	;	2.3	;	Crystal structure of uncharacterized conserved protein from Geobacillus kaustophilus
2YYU	;	2.2	;	Crystal structure of uncharacterized conserved protein from Geobacillus kaustophilus
2YWJ	;	1.9	;	Crystal structure of uncharacterized conserved protein from Methanocaldococcus jannaschii
2YZI	;	2.25	;	Crystal structure of uncharacterized conserved protein from Pyrococcus horikoshii
2YZQ	;	1.63	;	Crystal structure of uncharacterized conserved protein from Pyrococcus horikoshii
2YYV	;	1.65	;	Crystal structure of uncharacterized conserved protein from Thermotoga maritima
2YZO	;	1.85	;	Crystal structure of uncharacterized conserved protein from Thermotoga maritima
2ZBU	;	2.1	;	Crystal structure of uncharacterized conserved protein from Thermotoga maritima
2ZBV	;	2.05	;	Crystal structure of uncharacterized conserved protein from Thermotoga maritima
2Z06	;	2.2	;	Crystal structure of uncharacterized conserved protein from Thermus thermophilus
2YWA	;	3.2	;	Crystal structure of uncharacterized conserved protein from Thermus thermophilus HB8
2YZT	;	1.8	;	Crystal structure of uncharacterized conserved protein from Thermus thermophilus HB8
2YZY	;	1.6	;	Crystal structure of uncharacterized conserved protein from Thermus thermophilus HB8
2Z07	;	2.1	;	Crystal structure of uncharacterized conserved protein from Thermus thermophilus HB8
2Z08	;	1.55	;	Crystal structure of uncharacterized conserved protein from Thermus thermophilus HB8
2Z09	;	1.65	;	Crystal structure of uncharacterized conserved protein from Thermus thermophilus HB8
2Z0J	;	1.5	;	Crystal structure of uncharacterized conserved protein from Thermus thermophilus HB8
2Z3V	;	1.65	;	Crystal structure of uncharacterized conserved protein from Thermus thermophilus HB8
4PIB	;	2.0	;	Crystal Structure of Uncharacterized Conserved Protein PixA from Burkholderia thailandensis
3H8U	;	1.8	;	Crystal structure of uncharacterized conserved protein with double-stranded beta-helix domain (YP_001338853.1) from Klebsiella pneumoniae subsp. pneumoniae MGH 78578 at 1.80 A resolution
2R5X	;	2.04	;	Crystal structure of uncharacterized conserved protein YugN from Geobacillus kaustophilus HTA426
4RGP	;	2.299	;	Crystal Structure of Uncharacterized CRISPR/Cas System-associated Protein Csm6 from Streptococcus mutans
4HCF	;	1.703	;	Crystal Structure of Uncharacterized Cupredoxin-like Domain Protein Cupredoxin_1 with Copper Bound from Bacillus anthracis
5TK2	;	1.4	;	Crystal Structure of Uncharacterized Cupredoxin-like domain protein from Bacillus anthracis
5TK4	;	1.46	;	Crystal Structure of Uncharacterized Cupredoxin-like Domain Protein from Bacillus anthracis
3FEZ	;	2.1	;	Crystal structure of uncharacterized ferredoxin fold protein related to antibiotic biosynthesis monooxygenases (YP_014836.1) from LISTERIA MONOCYTOGENES 4b F2365 at 2.10 A resolution
4RCK	;	2.999	;	Crystal Structure of Uncharacterized Membrane Spanning Protein from Vibrio fischeri
3BV6	;	1.8	;	Crystal structure of uncharacterized metallo protein from Vibrio cholerae with beta-lactamase like fold
2OYO	;	1.51	;	Crystal structure of Uncharacterized peroxidase-related protein (YP_604910.1) from Deinococcus geothermalis DSM 11300 at 1.51 A resolution
2PFX	;	1.7	;	Crystal structure of uncharacterized peroxidase-related protein (YP_614459.1) from Silicibacter sp. TM1040 at 1.70 A resolution
2PR7	;	1.44	;	Crystal structure of uncharacterized protein (NP_599989.1) from Corynebacterium glutamicum ATCC 13032 Kitasato at 1.44 A resolution
2Q22	;	2.11	;	Crystal structure of uncharacterized protein (YP_323524.1) from Anabaena variabilis ATCC 29413 at 2.11 A resolution
2Q03	;	1.8	;	Crystal structure of uncharacterized protein (YP_563039.1) from Shewanella denitrificans OS217 at 1.80 A resolution
3RAG	;	1.8	;	Crystal Structure of Uncharacterized protein Aaci_0196 from Alicyclobacillus acidocaldarius subsp. acidocaldarius DSM 446
2QNI	;	1.8	;	Crystal structure of uncharacterized protein Atu0299
2QPV	;	2.35	;	Crystal structure of uncharacterized protein Atu1531
2QV5	;	1.9	;	Crystal structure of uncharacterized protein ATU2773 from Agrobacterium tumefaciens C58
5JBR	;	1.65	;	Crystal structure of uncharacterized protein Bcav_2135 from Beutenbergia cavernae
2QUP	;	2.0	;	Crystal structure of uncharacterized protein BH1478 from Bacillus halodurans
3FYF	;	2.2	;	Crystal structure of uncharacterized protein bvu_3222 from bacteroides vulgatus
3FF4	;	2.1	;	Crystal structure of uncharacterized protein CHU_1412
3BZB	;	2.79	;	Crystal structure of uncharacterized protein CMQ451C from the primitive red alga Cyanidioschyzon merolae
3HLU	;	2.65	;	Crystal Structure of Uncharacterized Protein Conserved in Bacteria DUF2179 from Eubacterium ventriosum
3FLJ	;	2.0	;	Crystal structure of uncharacterized protein conserved in bacteria with a cystatin-like fold (YP_168589.1) from SILICIBACTER POMEROYI DSS-3 at 2.00 A resolution
3FEQ	;	2.63	;	Crystal structure of uncharacterized protein eah89906
6OSX	;	1.45	;	Crystal structure of uncharacterized protein ECL_02694
3DBY	;	2.1	;	Crystal structure of uncharacterized protein from Bacillus cereus G9241 (CSAP Target)
3GW4	;	2.49	;	Crystal structure of uncharacterized protein from Deinococcus radiodurans. Northeast Structural Genomics Consortium Target DrR162B.
3FDI	;	2.2	;	Crystal structure of uncharacterized protein from Eubacterium ventriosum ATCC 27560.
3PES	;	1.3	;	Crystal structure of uncharacterized protein from Pseudomonas phage YuA
4IQN	;	1.75	;	Crystal structure of uncharacterized protein from Salmonella enterica subsp. enterica serovar typhimurium str. 14028s
3F42	;	1.78	;	Crystal structure of uncharacterized protein HP0035 from Helicobacter pylori
3BVC	;	2.75	;	Crystal structure of uncharacterized protein Ism_01780 from Roseovarius nubinhibens ISM
2PW6	;	2.27	;	Crystal structure of uncharacterized protein JW3007 from Escherichia coli K12
4LQB	;	1.72	;	Crystal structure of uncharacterized protein Kfla3161
5L0L	;	1.8	;	Crystal structure of Uncharacterized protein LPG0439
5BQ9	;	2.2785	;	Crystal structure of uncharacterized protein lpg1496 Legionella pneumophila subsp. pneumophila
5SUJ	;	2.356	;	Crystal structure of uncharacterized protein LPG2148 from Legionella pneumophila
5L1A	;	2.4	;	Crystal structure of uncharacterized protein LPG2271 from Legionella pneumophila
3CAX	;	2.43	;	Crystal structure of uncharacterized protein PF0695
1VAJ	;	1.82	;	Crystal Structure of Uncharacterized Protein PH0010 From Pyrococcus horikoshii
3BS4	;	1.6	;	Crystal structure of uncharacterized protein PH0321 from Pyrococcus horikoshii in complex with an unknown peptide
1V30	;	1.4	;	Crystal Structure Of Uncharacterized Protein PH0828 From Pyrococcus horikoshii
1IXL	;	1.94	;	Crystal structure of uncharacterized protein PH1136 from Pyrococcus horikoshii
3K4I	;	1.69	;	CRYSTAL STRUCTURE OF uncharacterized protein PSPTO_3204 from Pseudomonas syringae pv. tomato str. DC3000
5COM	;	1.85	;	Crystal structure of Uncharacterized Protein Q187F5 from Clostridium difficile 630
5CQV	;	1.9	;	Crystal structure of uncharacterized protein Q8DWV2 from Streptococcus agalactiae
3C9P	;	1.96	;	Crystal structure of uncharacterized protein SP1917
1WOZ	;	1.94	;	Crystal structure of uncharacterized protein ST1454 from Sulfolobus tokodaii
1VE0	;	2.0	;	Crystal structure of uncharacterized protein ST2072 from Sulfolobus tokodaii
1WVT	;	2.3	;	Crystal structure of uncharacterized protein ST2180 from Sulfolobus tokodaii
3RMS	;	2.133	;	Crystal structure of uncharacterized protein Svir_20580 from Saccharomonospora viridis
3RMQ	;	1.85	;	Crystal structure of uncharacterized protein Svir_20580 from Saccharomonospora viridis (V71M mutant)
3JYG	;	1.95	;	Crystal structure of uncharacterized protein WS1659 from Wolinella succinogenes
2RJB	;	2.6	;	Crystal structure of uncharacterized protein YdcJ (SF1787) from Shigella flexneri which includes domain DUF1338. Northeast Structural Genomics Consortium target SfR276
3RBY	;	2.301	;	Crystal structure of uncharacterized protein YLR301w from Saccharomycces cerevisiae
3KVP	;	2.404	;	Crystal Structure of Uncharacterized protein ymzC Precursor from Bacillus subtilis, Northeast Structural Genomics Consortium Target SR378A
4MNU	;	1.898	;	Crystal Structure of Uncharacterized SlyA-like Transcription Regulator from Listeria monocytogenes
4ML9	;	1.841	;	Crystal Structure of Uncharacterized TIM Barrel Protein with the Conserved Phosphate Binding Site fromSebaldella termitidis
3IRS	;	1.76	;	CRYSTAL STRUCTURE OF UNCHARACTERIZED TIM-BARREL PROTEIN BB4693 FROM Bordetella bronchiseptica
3K4W	;	1.92	;	CRYSTAL STRUCTURE OF Uncharacterized Tim-Barrel Protein Bb4693 From Bordetella Bronchiseptica
3C9G	;	2.3	;	Crystal structure of uncharacterized UPF0201 protein AF_135
4O47	;	1.9	;	Crystal structure of uncleaved guinea pig L-asparaginase type III
1OVA	;	1.95	;	CRYSTAL STRUCTURE OF UNCLEAVED OVALBUMIN AT 1.95 ANGSTROMS RESOLUTION
8EYJ	;	1.738	;	Crystal Structure of uncleaved SARS-CoV-2 Main Protease C145S mutant in complex with Nirmatrelvir
4IHE	;	1.5	;	Crystal Structure of Uncleaved ThnT T282A
3S3U	;	1.6	;	Crystal Structure of Uncleaved ThnT T282C
4IHD	;	1.65	;	Crystal Structure of Uncleaved ThnT T282C, derivatized at the active site with EtHg
1K92	;	1.6	;	Crystal Structure of Uncomplexed E. coli Argininosuccinate Synthetase
3IXO	;	1.7	;	Crystal Structure of uncomplexed HIV_1 Protease Subtype A
6FF8	;	2.13	;	Crystal structure of uncomplexed Rab32 in the active GTP-bound state at 2.13 Angstrom resolution
1KW2	;	2.15	;	CRYSTAL STRUCTURE OF UNCOMPLEXED VITAMIN D-BINDING PROTEIN
3UFK	;	2.1	;	Crystal structure of UndA complexed with Iron Nitrilotriacetate
3UFH	;	2.23	;	Crystal structure of UndA with Iron Citrate bound
1F75	;	2.2	;	CRYSTAL STRUCTURE OF UNDECAPRENYL DIPHOSPHATE SYNTHASE FROM MICROCOCCUS LUTEUS B-P 26
1X07	;	2.2	;	Crystal structure of undecaprenyl pyrophosphate synthase in complex with Mg and IPP
1X06	;	1.9	;	Crystal structure of undecaprenyl pyrophosphate synthase in complex with Mg, IPP and Fspp
1V7U	;	2.35	;	Crystal structure of Undecaprenyl Pyrophosphate Synthase with farnesyl pyrophosphate
2OYT	;	2.0	;	Crystal Structure of UNG2/DNA(TM)
4Z2A	;	1.89	;	Crystal structure of unglycosylated apo human furin @1.89A
5BPM	;	1.83	;	Crystal structure of unhydrolyzed ATP bound human Hsp70 NBD double mutant E268Q+R272K.
1KLJ	;	2.44	;	Crystal structure of uninhibited factor VIIa
5TUN	;	1.62	;	Crystal structure of uninhibited human Cathepsin K at 1.62 Angstrom resolution
4WY2	;	1.8	;	Crystal structure of universal stress protein E from Proteus mirabilis in complex with UDP-3-O-[(3R)-3-hydroxytetradecanoyl]-N-acetyl-alpha-glucosamine
2PFS	;	2.25	;	Crystal structure of universal stress protein from Nitrosomonas europaea
3TNJ	;	2.0	;	Crystal structure of universal stress protein from Nitrosomonas europaea with AMP bound
5AHW	;	2.15	;	Crystal structure of universal stress protein MSMEG_3811 in complex with cAMP
2OKQ	;	1.8	;	Crystal structure of unknown conserved ybaA protein from Shigella flexneri
4DCI	;	2.82	;	Crystal structure of unknown funciton protein from Synechococcus sp. WH 8102
5HX0	;	1.851	;	Crystal structure of unknown function protein Dfer_1899 fromDyadobacter fermentans DSM 18053
3B48	;	2.21	;	Crystal structure of unknown function protein EF1359
3M6J	;	1.9	;	Crystal structure of unknown function protein from Leptospirillum rubarum
3OMD	;	1.5	;	Crystal structure of unknown function protein from Leptospirillum rubarum
2QZG	;	2.09	;	Crystal structure of unknown function protein MMP1188
7M92	;	2.35	;	Crystal structure of unknown function protein protein B9J08_000055 Candida auris
2QNG	;	1.4	;	Crystal structure of unknown function protein SAV2460
2QWV	;	2.6	;	Crystal structure of unknown function protein VCA1059
2OYZ	;	1.71	;	Crystal structure of unknown function protein VPA0057 from Vibrio parahaemolyticus (targeted domain 2-94)
2QHQ	;	1.76	;	Crystal structure of unknown function protein VPA0580
6UXT	;	1.797	;	Crystal structure of unknown function protein yfdX from Shigella flexneri
6LRF	;	2.05466	;	Crystal structure of unliganded AgrE
1T4K	;	2.5	;	Crystal Structure of Unliganded Aldolase Antibody 93F3 Fab
4KWT	;	1.86	;	Crystal structure of unliganded anabolic ornithine carbamoyltransferase from Vibrio vulnificus at 1.86 A resolution
4M61	;	1.62	;	Crystal structure of unliganded anti-DNA Fab A52
3CGU	;	2.51	;	Crystal Structure of unliganded Argos
3R7D	;	2.196	;	Crystal Structure of Unliganded Aspartate Transcarbamoylase from Bacillus subtilis
8AMJ	;	2.02	;	Crystal structure of unliganded AUGUGGCAU duplex
3KLI	;	2.65	;	Crystal structure of unliganded AZT-resistant HIV-1 Reverse Transcriptase
3IBF	;	2.5	;	Crystal structure of unliganded caspase-7
4QF1	;	2.4	;	Crystal structure of unliganded CH59UA, the inferred unmutated ancestor of the RV144 anti-HIV antibody lineage producing CH59
3ZNJ	;	2.1	;	Crystal structure of unliganded ClcF from R.opacus 1CP in crystal form 1.
3TH7	;	2.1	;	Crystal structure of unliganded Co2+2-HAI (pH 7.0)
6X2O	;	2.551	;	Crystal Structure of unliganded CRM1(E571K)-Ran-RanBP1
6X2M	;	2.351	;	Crystal Structure of unliganded CRM1-Ran-RanBP1
4X1E	;	2.4	;	Crystal structure of unliganded E. coli transcriptional regulator RutR, W167A mutant
1DRA	;	1.9	;	CRYSTAL STRUCTURE OF UNLIGANDED ESCHERICHIA COLI DIHYDROFOLATE REDUCTASE. LIGAND-INDUCED CONFORMATIONAL CHANGES AND COOPERATIVITY IN BINDING
1DRB	;	1.96	;	CRYSTAL STRUCTURE OF UNLIGANDED ESCHERICHIA COLI DIHYDROFOLATE REDUCTASE. LIGAND-INDUCED CONFORMATIONAL CHANGES AND COOPERATIVITY IN BINDING
5DFR	;	2.3	;	CRYSTAL STRUCTURE OF UNLIGANDED ESCHERICHIA COLI DIHYDROFOLATE REDUCTASE. LIGAND-INDUCED CONFORMATIONAL CHANGES AND COOPERATIVITY IN BINDING
7ZNZ	;	1.8	;	Crystal structure of unliganded form of FucOB, a GH95 family alpha-1,2-fucosidase from Akkermansia muciniphila
1EX6	;	2.3	;	CRYSTAL STRUCTURE OF UNLIGANDED FORM OF GUANYLATE KINASE FROM YEAST
1ZNW	;	2.1	;	Crystal Structure Of Unliganded Form Of Mycobacterium tuberculosis Guanylate Kinase
2ANC	;	3.2	;	Crystal Structure Of Unliganded Form Of Oligomeric E.coli Guanylate Kinase
2GTY	;	1.3	;	Crystal structure of unliganded griffithsin
2Y7A	;	2.06	;	Crystal structure of unliganded GTB P156L
3TGT	;	1.9	;	Crystal structure of unliganded HIV-1 clade A/E strain 93TH057 gp120 core
3TGQ	;	3.4	;	Crystal structure of unliganded HIV-1 clade B strain YU2 gp120 core
3TGR	;	2.8	;	Crystal structure of unliganded HIV-1 clade C strain C1086 gp120 core
3TIH	;	4.0	;	Crystal structure of unliganded HIV-1 clade C strain ZM109F.PB4 gp120 core
6UTD	;	2.2	;	CRYSTAL STRUCTURE OF UNLIGANDED HIV-1 LM/HS CLADE A/E CRF01 GP120 CORE
6UTB	;	2.5	;	CRYSTAL STRUCTURE OF UNLIGANDED HIV-1 LM/HT CLADE A/E CRF01 GP120 CORE
1LY2	;	1.8	;	Crystal structure of unliganded human CD21 SCR1-SCR2 (Complement receptor type 2)
2F7M	;	2.3	;	Crystal Structure of Unliganded Human FPPS
4XQR	;	2.15	;	Crystal structure of unliganded human FPPS at 2.15 angstrom resolution
5N9B	;	1.9	;	Crystal Structure of unliganded human IL-17RA
1LLS	;	1.8	;	CRYSTAL STRUCTURE OF UNLIGANDED MALTOSE BINDING PROTEIN WITH XENON
6YJQ	;	1.9	;	Crystal structure of unliganded MGAT5 (alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase V) luminal domain with a Lys329-Ile345 loop truncation
6YJV	;	1.7	;	Crystal structure of unliganded MGAT5 (alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase V) luminal domain with a Lys329-Ile345 loop truncation, in complex with UDP-2-deoxy-2-fluoroglucose and biantennary pentasaccharide M592
6YJR	;	2.198	;	Crystal structure of unliganded MGAT5 (alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase V) luminal domain.
6ZVO	;	1.371	;	Crystal structure of unliganded MLKL executioner domain
1EJD	;	1.55	;	Crystal structure of unliganded mura (type1)
1EJC	;	1.8	;	Crystal structure of unliganded mura (type2)
7QQF	;	2.43	;	Crystal structure of unliganded MYORG
2VUS	;	2.6	;	Crystal structure of unliganded NmrA-AreA zinc finger complex
3JVU	;	3.1	;	Crystal structure of unliganded P. aeruginosa PilT
7OJT	;	3.67	;	Crystal structure of unliganded PatA, a membrane associated acyltransferase from Mycobacterium smegmatis
2QYM	;	1.9	;	crystal structure of unliganded PDE4C2
3LFV	;	2.8	;	crystal structure of unliganded PDE5A GAF domain
5DVF	;	2.5	;	Crystal structure of unliganded periplasmic glucose binding protein (ppGBP) from P. putida CSV86
2CCK	;	2.21	;	CRYSTAL STRUCTURE OF UNLIGANDED S. AUREUS THYMIDYLATE KINASE
3OKM	;	2.4	;	Crystal structure of unliganded S25-39
3VYC	;	2.1	;	Crystal structure of unliganded Saccharomyces cerevisiae CRM1 (Xpo1p)
2ZKG	;	1.77	;	Crystal structure of unliganded SRA domain of mouse Np95
1NLZ	;	3.0	;	Crystal structure of unliganded traffic ATPase of the type IV secretion system of helicobacter pylori
4OJV	;	1.31	;	Crystal structure of unliganded yeast PDE1
4RJT	;	2.7	;	Crystal Structure of Unliganded, Full Length hUGDH at pH 7.0
1IM6	;	1.74	;	CRYSTAL STRUCTURE OF UNLIGATED HPPK(R82A) FROM E.COLI AT 1.74 ANGSTROM RESOLUTION
1KBR	;	1.55	;	CRYSTAL STRUCTURE OF UNLIGATED HPPK(R92A) FROM E.COLI AT 1.55 ANGSTROM RESOLUTION
5YVY	;	3.2	;	Crystal structure of unlinked full length NS3 protein (eD4NS2BNS3) from DENV4 in closed conformation
6Y3B	;	1.59	;	Crystal Structure of Unlinked NS2B-NS3 Protease from Zika Virus in Complex with Inhibitor MI-2110
7ZTM	;	1.45	;	Crystal Structure of Unlinked NS2B-NS3 Protease from Zika Virus in Complex with Inhibitor MI-2128
7ZUM	;	1.75	;	Crystal Structure of Unlinked NS2B-NS3 Protease from Zika Virus in Complex with Inhibitor MI-2130
7ZWK	;	2.0	;	Crystal Structure of Unlinked NS2B-NS3 Protease from Zika Virus in Complex with Inhibitor MI-2162
7PGC	;	1.55	;	Crystal Structure of Unlinked NS2B-NS3 Protease from Zika Virus in Complex with Inhibitor MI-2191
7ZV4	;	1.69	;	Crystal Structure of Unlinked NS2B-NS3 Protease from Zika Virus in Complex with Inhibitor MI-2195
7ZVV	;	1.75	;	Crystal Structure of Unlinked NS2B-NS3 Protease from Zika Virus in Complex with Inhibitor MI-2196
7ZQ1	;	1.52	;	Crystal Structure of Unlinked NS2B-NS3 Protease from Zika Virus in Complex with Inhibitor MI-2205
7ZQF	;	1.68	;	Crystal Structure of Unlinked NS2B-NS3 Protease from Zika Virus in Complex with Inhibitor MI-2206
7PG1	;	1.95	;	Crystal Structure of Unlinked NS2B-NS3 Protease from Zika Virus in Complex with Inhibitor MI-2221
7ZYS	;	1.26	;	Crystal Structure of Unlinked NS2B-NS3 Protease from Zika Virus in Complex with Inhibitor MI-2227
8A15	;	1.23	;	Crystal Structure of Unlinked NS2B-NS3 Protease from Zika Virus in Complex with Inhibitor MI-2230
7O55	;	1.95	;	Crystal Structure of Unlinked NS2B-NS3 Protease from Zika Virus in Complex with Inhibitor MI-2231
7PFY	;	1.38	;	Crystal Structure of Unlinked NS2B-NS3 Protease from Zika Virus in Complex with Inhibitor MI-2241
7PFQ	;	1.45	;	Crystal Structure of Unlinked NS2B-NS3 Protease from Zika Virus in Complex with Inhibitor MI-2247
7OBV	;	1.3	;	Crystal Structure of Unlinked NS2B-NS3 Protease from Zika Virus in Complex with Inhibitor MI-2248
8AQB	;	1.28	;	Crystal Structure of Unlinked NS2B-NS3 Protease from Zika Virus in Complex with Inhibitor MI-2257
8AQK	;	1.2	;	Crystal Structure of Unlinked NS2B-NS3 Protease from Zika Virus in Complex with Inhibitor MI-2258
7ZW5	;	1.38	;	Crystal Structure of Unlinked NS2B-NS3 Protease from Zika Virus in Complex with Inhibitor MI-2259
8AQA	;	1.35	;	Crystal Structure of Unlinked NS2B-NS3 Protease from Zika Virus in Complex with Inhibitor MI-2260
7PFZ	;	1.45	;	Crystal Structure of Unlinked NS2B-NS3 Protease from Zika Virus in Complex with Inhibitor MI-2267
7O2M	;	1.9	;	Crystal Structure of Unlinked NS2B-NS3 Protease from Zika Virus in Complex with Inhibitor MI-2289
7ZPD	;	1.4	;	Crystal Structure of Unlinked NS2B-NS3 Protease from Zika Virus in Complex with Inhibitor MI-2293
7OC2	;	1.5	;	Crystal Structure of Unlinked NS2B-NS3 Protease from Zika Virus in Complex with Inhibitor MI-2295
7ZNO	;	1.7	;	Crystal Structure of Unlinked NS2B_NS3 Protease from Zika Virus in Complex with Boronate Inhibitor MI-2270
7ZMI	;	2.15	;	Crystal Structure of Unlinked NS2B_NS3 Protease from Zika Virus in Complex with Inhibitor MI-2113
7ZLD	;	1.61	;	Crystal Structure of Unlinked NS2B_NS3 Protease from Zika Virus in Complex with Inhibitor MI-2223
7ZLC	;	1.75	;	Crystal Structure of Unlinked NS2B_NS3 Protease from Zika Virus in Complex with Inhibitor MI-2224
8EIF	;	2.1	;	Crystal structure of unmodified Pseudomonas aeruginosa protein PA0709
4P70	;	3.68	;	Crystal Structure of Unmodified tRNA Proline (CGG) Bound to Codon CCG on the Ribosome
5BYU	;	2.4	;	Crystal structure of unnamed thioesterase Ipg2867 from Legionella pneumophila
5DIO	;	2.6	;	Crystal structure of unnamed thioesterase lpg2867 from Legionella pneumophila, the D21A mutant
3N8V	;	3.05	;	Crystal Structure of Unoccupied Cyclooxygenase-1
6AEX	;	2.393	;	Crystal structure of unoccupied murine uPAR
3F6P	;	1.95	;	Crystal Structure of unphosphorelated receiver domain of YycF
2B1J	;	2.4	;	Crystal Structure of Unphosphorylated CheY Bound to the N-Terminus of FliM
1JPA	;	1.91	;	Crystal Structure of unphosphorylated EphB2 receptor tyrosine kinase and juxtamembrane region
6D3L	;	3.1	;	Crystal structure of unphosphorylated human PKR
6D3K	;	2.6	;	Crystal structure of unphosphorylated human PKR kinase domain in complex with ADP
4BKZ	;	2.2	;	Crystal structure of unphosphorylated Maternal Embryonic Leucine zipper Kinase (MELK) in complex with a benzodipyrazole inhibitor
4BL1	;	2.6	;	Crystal structure of unphosphorylated Maternal Embryonic Leucine zipper Kinase (MELK) in complex with AMP-PNP
4BKY	;	1.83	;	Crystal structure of unphosphorylated Maternal Embryonic Leucine zipper Kinase (MELK) in complex with pyrrolopyrazole inhibitor
3A60	;	2.8	;	Crystal structure of unphosphorylated p70S6K1 (Form I)
3A61	;	3.43	;	Crystal structure of unphosphorylated p70S6K1 (Form II)
2PSQ	;	2.4	;	Crystal Structure of Unphosphorylated Unactivated Wild Type FGF Receptor 2 (FGFR2) Kinase Domain
6PB9	;	2.109	;	Crystal structure of unsaturated fatty acid bound ToxT K231A from Vibrio cholerae strain SCE256
6P7R	;	1.8	;	Crystal structure of unsaturated fatty acid bound wild-type ToxT from Vibrio cholerae strain SCE256
2ZZR	;	1.75	;	Crystal structure of unsaturated glucuronyl hydrolase from Streptcoccus agalactiae
3ANJ	;	1.95	;	Crystal structure of unsaturated glucuronyl hydrolase from Streptcoccus agalactiae
3VXD	;	2.0	;	Crystal structure of unsaturated glucuronyl hydrolase mutant D115N from Streptcoccus agalactiae
3WUX	;	1.792	;	Crystal structure of unsaturated glucuronyl hydrolase mutant D115N/K370S from Streptococcus agalactiae
3ANI	;	2.5	;	Crystal structure of unsaturated glucuronyl hydrolase mutant D175N from Streptcoccus agalactiae
3ANK	;	2.02	;	Crystal structure of unsaturated glucuronyl hydrolase mutant D175N from Streptcoccus agalactiae complexed with dGlcA-GalNAc6S
3WIW	;	1.35	;	Crystal structure of unsaturated glucuronyl hydrolase specific for heparin
1VD5	;	1.8	;	Crystal Structure of Unsaturated Glucuronyl Hydrolase, Responsible for the Degradation of Glycosaminoglycan, from Bacillus sp. GL1 at 1.8 A Resolution
2D8L	;	1.7	;	Crystal Structure of Unsaturated Rhamnogalacturonyl Hydrolase in complex with dGlcA-GalNAc
3PFT	;	1.601	;	Crystal Structure of Untagged C54A Mutant Flavin Reductase (DszD) in Complex with FMN From Mycobacterium goodii
7Q2T	;	1.651	;	Crystal structure of untagged rat C2orf32 (also known as CNRIP1) in a domain-swapped conformation
7LK3	;	1.9	;	Crystal structure of untwinned human GABARAPL2
5GSE	;	3.14	;	Crystal structure of unusual nucleosome
6DCL	;	2.497	;	Crystal structure of UP1 bound to pri-miRNA-18a terminal loop
1PO6	;	2.1	;	Crystal Structure of UP1 Complexed With d(TAGG(6MI)TTAGGG): A Human Telomeric Repeat Containing 6-methyl-8-(2-deoxy-beta-ribofuranosyl)isoxanthopteridine (6MI)
1U1K	;	2.0	;	Crystal Structure of UP1 Complexed With d(TTAGGGTT 7DA GGG); A Human Telomeric Repeat Containing 7-deaza-adenine
1U1L	;	2.0	;	Crystal Structure of UP1 Complexed With d(TTAGGGTT PRN GGG); A Human Telomeric Repeat Containing nebularine
1U1N	;	2.1	;	Crystal Structure of UP1 Complexed With d(TTAGGGTTA (PRN)GG); A Human Telomeric Repeat Containing Nebularine
1U1P	;	1.9	;	Crystal Structure of UP1 Complexed With d(TTAGGGTTA 2PR GG); A Human Telomeric Repeat Containing 2-aminopurine
1U1M	;	2.0	;	Crystal Structure of UP1 Complexed With d(TTAGGGTTA 7GU GG); A Human Telomeric Repeat Containing 7-deaza-guanine
1U1Q	;	1.8	;	Crystal Structure of UP1 Complexed With d(TTAGGGTTA(DI)GG); A Human Telomeric Repeat Containing Inosine
1U1R	;	1.8	;	Crystal Structure of UP1 Complexed With d(TTAGGGTTAG(2PR)G); A Human Telomeric Repeat Containing 2-aminopurine
1PGZ	;	2.6	;	Crystal Structure of UP1 Complexed With d(TTAGGGTTAG(6-MI)G); A Human Telomeric Repeat Containing 6-methyl-8-(2-deoxy-beta-ribofuranosyl)isoxanthopteridine (6-MI)
1U1O	;	2.0	;	Crystal Structure of UP1 Complexed With d(TTAGGGTTAG(DI)G); A Human Telomeric Repeat Containing Inosine
6AG9	;	1.63	;	Crystal structure of uPA in complex with 3,5-bis(azanyl)-6-(1-benzofuran-2-yl)-N-carbamimidoyl-pyrazine-2- carboxamide
6AG3	;	2.48	;	Crystal structure of uPA in complex with 3,5-bis(azanyl)-N-carbamimidoyl-6-(2,4-dimethoxypyrimidin-5-yl)pyrazine-2-carboxamide
7VM5	;	1.97	;	Crystal structure of uPA in complex with 4-guanidinobenzoic acid
7VM6	;	1.79	;	Crystal structure of uPA in complex with 6-amidino-2-naphthol
5HGG	;	1.97	;	Crystal structure of uPA in complex with a camelid-derived antibody fragment
7DZD	;	2.0	;	Crystal structure of uPA in complex with cleaved camostat
7VM4	;	2.01	;	Crystal structure of uPA in complex with nafamostat
5XG4	;	3.0	;	Crystal structure of uPA in complex with quercetin
5WXS	;	2.3	;	Crystal structure of uPA in complex with S2444
5WXF	;	1.46	;	Crystal structure of uPA in complex with upain-2-2
5WXO	;	1.64	;	Crystal structure of uPA in complex with upain-2-2-W3A
5WXP	;	1.75	;	Crystal structure of uPA in complex with upain-2-3-W3A
5WXQ	;	1.79	;	Crystal structure of uPA in complex with upain-2-4
5WXR	;	1.75	;	Crystal structure of uPA in complex with upain-2-4-W3A
5WXT	;	2.1	;	Crystal structure of uPA-S195A in complex with S2444
6JYQ	;	1.75	;	Crystal structure of uPA_H99Y in complex with 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(furan-2-yl)pyrazine-2-carboxamide
6JYP	;	2.25	;	Crystal structure of uPA_H99Y in complex with 3-azanyl-5-(azepan-1-yl)-N-[bis(azanyl)methylidene]-6-chloranyl-pyrazine-2-carboxamide
6L04	;	2.21	;	Crystal structure of uPA_H99Y in complex with 31F
6L05	;	2.49	;	Crystal structure of uPA_H99Y in complex with 50F
2NV4	;	2.2	;	Crystal structure of UPF0066 protein AF0241 in complex with S-adenosylmethionine. Northeast Structural Genomics Consortium target GR27
3BHP	;	2.01	;	Crystal structure of UPF0291 protein ynzC from Bacillus subtilis at resolution 2.0 A. Northeast Structural Genomics Consortium target SR384
3DB9	;	2.8	;	Crystal structure of UPF0317 protein Atu3911 from Agrobacterium tumefaciens. NorthEast Strcutural Genomics target AtR186
2PIF	;	2.3	;	Crystal structure of UPF0317 protein PSPTO_5379 from Pseudomonas syringae pv. tomato. NorthEast Structural Genomics target PsR181
2OYR	;	2.0	;	Crystal Structure of UPF0341 Protein (yhiQ) from Shigella flexneri in complex with S-Adenosyl Homocysteine, Northeast Structural Genomics Target SfR275
2PGX	;	2.0	;	Crystal structure of UPF0341 protein yhiQ from E. coli, Northeast Structural Genomics Target ER585
2PKW	;	2.1	;	Crystal structure of UPF0341 protein yhiQ from Salmonella typhimurium, Northeast Structural Genomics Consortium Target StR221
2O6K	;	2.1	;	Crystal structure of UPF0346 from Staphylococcus aureus. Northeast Structural Genomics target ZR218.
2B0O	;	2.06	;	Crystal structure of UPLC1 GAP domain
4Q9O	;	2.2	;	Crystal structure of Upps + inhibitor
4Q9M	;	2.06	;	Crystal structure of UPPs in complex with FPP and an allosteric inhibitor
4YTW	;	1.4	;	Crystal structure of Ups1-Mdm35 complex
4YTX	;	3.2	;	Crystal structure of Ups1-Mdm35 complex with PA
5XLS	;	2.5	;	Crystal structure of UraA in occluded conformation
5GN2	;	1.952	;	Crystal structure of Uracil DNA glycosylase (BdiUNG) from Bradyrhizobium diazoefficiens
5GRK	;	2.804	;	Crystal structure of Uracil DNA glycosylase -Xanthine complex from Bradyrhizobium diazoefficiens
5GNW	;	2.869	;	Crystal structure of Uracil DNA glycosylase-Uracil complex from Bradyrhizobium diazoefficiens.
2JHQ	;	1.5	;	Crystal structure of Uracil DNA-glycosylase from Vibrio cholerae
1O5O	;	2.3	;	Crystal structure of Uracil phosphoribosyltransferase (TM0721) from Thermotoga maritima at 2.30 A resolution
3QE7	;	2.781	;	Crystal Structure of Uracil Transporter--UraA
1VK2	;	1.9	;	Crystal structure of Uracil-DNA glycosylase (TM0511) from Thermotoga maritima at 1.90 A resolution
1OKB	;	1.9	;	crystal structure of Uracil-DNA glycosylase from Atlantic cod (Gadus morhua)
4LYL	;	1.93	;	Crystal structure of uracil-DNA glycosylase from cod (Gadus morhua) in complex with the proteinaceous inhibitor UGI
3A7N	;	1.95	;	Crystal structure of uracil-DNA glycosylase from Mycobacterium tuberculosis
2ZHX	;	3.1	;	Crystal structure of Uracil-DNA Glycosylase from Mycobacterium tuberculosis in complex with a proteinaceous inhibitor
1L9G	;	2.5	;	CRYSTAL STRUCTURE OF URACIL-DNA GLYCOSYLASE FROM T. MARITIMA
1UI0	;	1.5	;	Crystal Structure Of Uracil-DNA Glycosylase From Thermus Thermophilus HB8
1UI1	;	2.8	;	Crystal Structure Of Uracil-DNA Glycosylase From Thermus Thermophilus HB8
2D3Y	;	1.55	;	Crystal structure of uracil-DNA glycosylase from Thermus Thermophilus HB8
2DEM	;	1.95	;	Crystal structure of Uracil-DNA glycosylase in complex with AP:A containing DNA
2DP6	;	1.8	;	Crystal structure of uracil-DNA glycosylase in complex with AP:C containing DNA
2DDG	;	2.1	;	Crystal structure of uracil-DNA glycosylase in complex with AP:G containing DNA
2FUB	;	2.3	;	Crystal structure of urate oxidase at 140 MPa
1J2G	;	2.2	;	Crystal structure of Urate oxidase from Bacillus SP. TB-90 co-crystallized with 8-Azaxanthine
7CUC	;	1.44	;	Crystal Structure of Urate Oxidase from Bacillus sp. TB-90 in the absence from Chloride Anion at 1.44 A resolution
7CUF	;	1.46	;	Crystal Structure of Urate Oxidase from Bacillus sp. TB-90 in the absence from Chloride Anion at 1.44 A resolution
7CUG	;	1.62	;	Crystal Structure of Urate Oxidase from Bacillus sp. TB-90 in the absence from Chloride Anion at 1.62 A resolution
5LL1	;	2.8	;	Crystal structure of urate oxidase from zebrafish
5M98	;	2.8	;	Crystal structure of urate oxidase from zebrafish
3GKO	;	1.6	;	Crystal structure of urate oxydase using surfactant Poloxamer 188 as a New Crystallizing Agent
3SJS	;	1.9	;	Crystal structure of URE3-binding protein from Entamoeba histolytica, (D127A,N129A) mutant, native form
3SIA	;	2.05	;	Crystal structure of URE3-binding protein, (D127A,N129A) mutant, iodide phased
3SIB	;	1.9	;	Crystal structure of URE3-binding protein, wild-type
4Q04	;	1.9	;	Crystal structure of URE3-BP from Entomaeba histolytica without calcium
1UBP	;	1.65	;	CRYSTAL STRUCTURE OF UREASE FROM BACILLUS PASTEURII INHIBITED WITH BETA-MERCAPTOETHANOL AT 1.65 ANGSTROMS RESOLUTION
4Z42	;	3.01	;	Crystal structure of urease from Yersinia enterocolitica
4FUR	;	2.1	;	Crystal Structure of Urease subunit gamma 2 from Brucella melitensis biovar Abortus 2308
3L9Z	;	2.08	;	Crystal Structure of UreE from Helicobacter pylori (apo form)
3NXZ	;	2.7	;	Crystal Structure of UreE from Helicobacter pylori (Cu2+ bound form)
3LA0	;	2.86	;	Crystal Structure of UreE from Helicobacter pylori (metal of unknown identity bound)
3NY0	;	3.09	;	Crystal Structure of UreE from Helicobacter pylori (Ni2+ bound form)
3ISL	;	2.06	;	Crystal structure of ureidoglycine-glyoxylate aminotransferase (pucG) from Bacillus subtilis
4FJS	;	2.13	;	Crystal structure of ureidoglycolate dehydrogenase enzyme in apo form
1XRH	;	2.25	;	Crystal Structure of Ureidoglycolate Dehydrogenase from Escherichia Coli
4H8A	;	1.64	;	Crystal structure of ureidoglycolate dehydrogenase in binary complex with NADH
4FJU	;	1.771	;	Crystal structure of ureidoglycolate dehydrogenase in ternary complex with NADH and glyoxylate
1YQC	;	1.709	;	Crystal Structure of Ureidoglycolate Hydrolase (AllA) from Escherichia coli O157:H7
1XSQ	;	1.6	;	Crystal structure of ureidoglycolate hydrolase from E.coli. Northeast Structural Genomics Consortium target ET81.
1VAX	;	1.99	;	Crystal Structure of Uricase from Arthrobacter globiformis
2YZE	;	1.99	;	Crystal structure of uricase from Arthrobacter globiformis
2YZD	;	2.24	;	Crystal structure of uricase from Arthrobacter globiformis in complex with 8-azaxanthin (inhibitor)
2YZC	;	1.88	;	Crystal structure of uricase from Arthrobacter globiformis in complex with allantoate
2YZB	;	1.9	;	Crystal structure of uricase from Arthrobacter globiformis in complex with uric acid (substrate)
1VAY	;	2.24	;	Crystal Structure of Uricase from Arthrobacter globiformis with inhibitor 8-azaxanthine
7M7K	;	1.89	;	Crystal structure of uridine bound to Geobacillus thermoglucosidasius pyrimidine nucleoside phosphorylase PyNP
3PNS	;	2.002	;	Crystal Structure of Uridine Phosphorylase Complexed with Uracil from Vibrio cholerae O1 biovar El Tor
4TXH	;	1.892	;	Crystal structure of uridine phosphorylase from Schistosoma mansoni in APO form
4TXN	;	2.0	;	Crystal structure of uridine phosphorylase from Schistosoma mansoni in complex with 5-fluorouracil
4TXJ	;	1.662	;	Crystal structure of uridine phosphorylase from Schistosoma mansoni in complex with thymidine
4TXM	;	1.93	;	Crystal structure of uridine phosphorylase from Schistosoma mansoni in complex with thymine
4TXL	;	1.92	;	Crystal structure of uridine phosphorylase from Schistosoma mansoni in complex with uracil
3O6V	;	1.695	;	Crystal structure of Uridine Phosphorylase from Vibrio cholerae O1 biovar El Tor
4MCH	;	1.73	;	Crystal structure of uridine phosphorylase from vibrio fischeri es114 complexed with 6-hydroxy-1-naphthoic acid, NYSGRC Target 029520.
4MCI	;	2.01	;	Crystal structure of uridine phosphorylase from vibrio fischeri es114 complexed with DMSO, NYSGRC Target 029520.
4LNH	;	2.3	;	Crystal structure of uridine phosphorylase from Vibrio fischeri ES114, NYSGRC Target 29520.
2YQC	;	1.9	;	Crystal Structure of uridine-diphospho-N-acetylglucosamine pyrophosphorylase from Candida albicans, in the apo-like form
2YQS	;	2.3	;	Crystal structure of uridine-diphospho-N-acetylglucosamine pyrophosphorylase from Candida albicans, in the product-binding form
2YQJ	;	2.31	;	Crystal Structure of uridine-diphospho-N-acetylglucosamine pyrophosphorylase from Candida albicans, in the reaction-completed form
2YQH	;	2.3	;	Crystal structure of uridine-diphospho-N-acetylglucosamine pyrophosphorylase from Candida albicans, in the substrate-binding form
2A1F	;	2.1	;	Crystal Structure of Uridylate kinase
2IJ9	;	2.9	;	Crystal Structure of Uridylate Kinase from Archaeoglobus Fulgidus
4A7W	;	1.8	;	Crystal structure of uridylate kinase from Helicobacter pylori
4A7X	;	2.49	;	Crystal structure of uridylate kinase from Helicobacter pylori
2J4J	;	2.1	;	Crystal structure of uridylate kinase from Sulfolobus solfataricus in complex with UMP and AMPPCP to 2.1 Angstrom resolution
2J4K	;	2.2	;	Crystal structure of uridylate kinase from Sulfolobus solfataricus in complex with UMP to 2.2 Angstrom resolution
2J4L	;	2.8	;	Crystal structure of uridylate kinase from Sulfolobus solfataricus in complex with UTP to 2.8 Angstrom resolution
2QJL	;	1.44	;	Crystal structure of Urm1
2FKN	;	2.2	;	crystal structure of urocanase from bacillus subtilis
1YWH	;	2.7	;	crystal structure of urokinase plasminogen activator receptor
4OS1	;	2.2	;	Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK601 (bicyclic 1)
4OS2	;	1.79	;	Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK602 (bicyclic 1)
4OS4	;	2.0	;	Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK603 (bicyclic 1)
4OS5	;	2.26	;	Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK603 (bicyclic 2)
4OS6	;	1.75	;	Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK604 (bicyclic 2)
4OS7	;	2.0	;	Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK607 (bicyclic)
4MNW	;	1.49	;	Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK749
4MNX	;	1.85	;	Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK811
4MNY	;	1.7	;	Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK903
3RFT	;	1.9	;	Crystal structure of uronate dehydrogenase from Agrobacterium tumefaciens
3RFV	;	2.1	;	Crystal structure of Uronate dehydrogenase from Agrobacterium tumefaciens complexed with NADH and product
3RFX	;	1.9	;	Crystal structure of uronate dehydrogenase from Agrobacterium tumefaciens, Y136A mutant complexed with NAD
1J5S	;	2.85	;	Crystal structure of uronate isomerase (TM0064) from Thermotoga maritima at 2.85 A resolution
3HK5	;	2.2	;	Crystal structure of uronate isomerase from Bacillus halodurans complexed with zinc and D-Arabinarate
3HK7	;	2.2	;	Crystal structure of uronate isomerase from Bacillus halodurans complexed with zinc and D-Arabinarate, monoclinic crystal form
3HK8	;	2.2	;	Crystal structure of uronate isomerase from Bacillus halodurans complexed with zinc and D-Arabinohydroxamate
3HKA	;	1.9	;	Crystal structure of uronate isomerase from Bacillus halodurans complexed with zinc and D-Fructuronate
3HK9	;	2.1	;	Crystal structure of uronate isomerase from Bacillus halodurans complexed with zinc and D-Glucuronate
1V9A	;	2.0	;	Crystal structure of Uroporphyrin-III C-methyl transferase from Thermus thermophilus complexed with S-adenyl homocysteine
1VE2	;	1.8	;	Crystal structure of uroporphyrin-III-C-methyltransferase from thermus thermophilus
4EXQ	;	1.65	;	CRYSTAL STRUCTURE of UROPORPHYRINOGEN DECARBOXYLASE (UPD) FROM BURKHOLDERIA THAILANDENSIS E264
2EJA	;	1.9	;	Crystal Structure Of Uroporphyrinogen Decarboxylase From Aquifex aeolicus
2INF	;	2.3	;	Crystal Structure of Uroporphyrinogen Decarboxylase from Bacillus subtilis
3CYV	;	2.8	;	Crystal structure of uroporphyrinogen decarboxylase from Shigella flexineri: new insights into its catalytic mechanism
6W2O	;	1.55	;	Crystal structure of uroporphyrinogen III decarboxylate (hemE) from Stenotrophomonas maltophilia
1WCW	;	1.3	;	Crystal Structure of Uroporphyrinogen III Synthase from an Extremely Thermophilic Bacterium Thermus thermophilus HB8 (Wild type, Native, Form-1 crystal)
1WD7	;	1.6	;	Crystal Structure of Uroporphyrinogen III Synthase from an Extremely Thermophilic Bacterium Thermus thermophilus HB8 (Wild type, Native, Form-2 crystal)
3RE1	;	2.5	;	Crystal structure of uroporphyrinogen III synthase from Pseudomonas syringae pv. tomato DC3000
3P9Z	;	2.1	;	Crystal structure of uroporphyrinogen-III synthetase from Helicobacter pylori 26695
7XS4	;	1.846	;	Crystal structure of URT1 in complex with AAAU RNA
8HIC	;	1.6	;	Crystal structure of UrtA from Prochlorococcus marinus str. MIT 9313 in complex with urea and calcium
7S6E	;	1.973	;	Crystal structure of UrtA from Synechococcus CC9311 in complex with urea and calcium
7S6F	;	1.8	;	Crystal structure of UrtA1 from Synechococcus WH8102 in complex with urea and calcium
1IQB	;	1.9	;	Crystal Structure of Urtica dioica Agglutinin Isolectin I
1EHD	;	1.5	;	CRYSTAL STRUCTURE OF URTICA DIOICA AGGLUTININ ISOLECTIN VI
1EHH	;	1.9	;	CRYSTAL STRUCTURE OF URTICA DIOICA AGGLUTININ ISOLECTIN VI COMPLEX WITH TRI-N-ACETYLCHITOTRIOSE
3FIP	;	3.154	;	Crystal structure of Usher PapC translocation pore
6LSU	;	2.7	;	Crystal structure of Uso1-2
5CHT	;	2.8	;	Crystal structure of USP18
5CHV	;	3.005	;	Crystal structure of USP18-ISG15 complex
3V6E	;	2.1	;	Crystal Structure of USP2 and a mutant form of Ubiquitin
3V6C	;	1.7	;	Crystal Structure of USP2 in complex with mutated ubiquitin
5OHP	;	2.8	;	Crystal structure of USP30 (C77A) in complex with Lys6-linked diubiquitin
5OHK	;	2.34	;	Crystal structure of USP30 in covalent complex with ubiquitin propargylamide (high resolution)
5OHN	;	3.6	;	Crystal structure of USP30 in covalent complex with ubiquitin propargylamide (low resolution)
5TXK	;	1.84	;	CRYSTAL STRUCTURE OF USP35 C450S IN COMPLEX WITH UBIQUITIN
8ITP	;	3.0	;	Crystal structure of USP47 catalytic domain complex with ubiquitin
8ITN	;	2.6	;	Crystal structure of USP47apo catalytic domain
5KYE	;	1.97	;	Crystal structure of USP7 catalytic domain [H294E] mutant in complex with ubiquitin
5KYF	;	1.45	;	Crystal structure of USP7 catalytic domain [L299A] mutant in complex with ubiquitin
5KYD	;	1.62	;	Crystal structure of USP7 catalytic domain [V302K] mutant in complex with ubiquitin
5KYC	;	1.426	;	Crystal structure of USP7 catalytic domain [V302K] mutant in complex with ubiquitin (malonate bound)
6F5H	;	2.16	;	Crystal structure of USP7 in complex with a 4-hydroxypiperidine based inhibitor
5N9R	;	2.23	;	Crystal structure of USP7 in complex with a potent, selective and reversible small-molecule inhibitor
5N9T	;	1.73	;	Crystal structure of USP7 in complex with a potent, selective and reversible small-molecule inhibitor
8D4Z	;	2.26	;	Crystal structure of USP7 in complex with allosteric inhibitor FX1-3763
4Z97	;	2.998	;	Crystal structure of USP7 in complex with DNMT1(K1115Q)
7XPY	;	2.35	;	Crystal structure of USP7 in complex with its inhibitor
5NGF	;	2.33	;	Crystal structure of USP7 in complex with the covalent inhibitor, FT827
5NGE	;	2.35	;	Crystal structure of USP7 in complex with the non-covalent inhibitor, FT671
5C6D	;	2.292	;	Crystal structure of USP7 in complex with UHRF1
4WPH	;	2.92	;	Crystal structure of USP7 ubiquitin-like domains in compact conformation
4WPI	;	3.4	;	Crystal structure of USP7 ubiquitin-like domains in extended conformation
5GG4	;	3.11	;	Crystal structure of USP7 with RNF169 peptide
7VIJ	;	2.3	;	Crystal structure of USP7-HUBL domain
4JJQ	;	1.95	;	Crystal structure of usp7-ntd with an e2 enzyme
4KG9	;	1.7	;	Crystal Structure Of USP7-NTD with MCM-BP
5C56	;	2.685	;	Crystal structure of USP7/HAUSP in complex with ICP0
3NTN	;	2.2	;	Crystal Structure of UspA1 head and neck domain from Moraxella catarrhalis
3HMW	;	3.0	;	Crystal structure of ustekinumab FAB
3HMX	;	3.0	;	Crystal structure of ustekinumab FAB/IL-12 complex
3AHW	;	1.03	;	Crystal Structure of Ustilago sphaerogena Ribonuclease U2 complexed with adenosine 2'-monophosphate
3AGN	;	0.96	;	Crystal Structure of Ustilago sphaerogena Ribonuclease U2 Complexed with adenosine 3'-monophosphate
3AGO	;	0.99	;	Crystal Structure of Ustilago sphaerogena Ribonuclease U2 complexed with adenosine 3'-monophosphate
3AHS	;	1.32	;	Crystal Structure of Ustilago sphaerogena Ribonuclease U2B
6A0P	;	2.0	;	Crystal structure of Usutu virus envelope protein in the pre-fusion state
5VCT	;	1.9	;	Crystal structure of UTP-glucose-1-phosphate uridylyltransferase from Burkholderia ambifaria
5VE7	;	2.3	;	Crystal structure of UTP-glucose-1-phosphate uridylyltransferase from Burkholderia ambifaria in complex with UTP
5I1F	;	2.15	;	Crystal structure of UTP-glucose-1-phosphate uridylyltransferase from Burkholderia vietnamiensis in complex with Uridine-5'-diphosphate-glucose
5YDU	;	2.646	;	Crystal structure of Utp30
5N1A	;	2.15	;	Crystal structure of Utp4 from Chaetomium thermophilum
2G80	;	2.28	;	Crystal structure of UTR4 protein (Unknown transcript 4 protein) (yel038w) from Saccharomyces cerevisiae at 2.28 A resolution
6FUK	;	2.0	;	Crystal structure of UTX complexed with 5-carboxy-8-hydroxyquinoline
6FUL	;	1.649	;	Crystal structure of UTX complexed with 5-hydroxy-4-keto-1-methyl-picolinate
6G8F	;	2.043	;	Crystal structure of UTX complexed with GSK-J1
4NBM	;	1.61	;	Crystal structure of UVB photoreceptor UVR8 and light-induced structural changes at 180K
4NAA	;	1.67	;	Crystal structure of UVB photoreceptor UVR8 from Arabidopsis thaliana and UV-induced structural changes at 120K
4DNW	;	1.773	;	Crystal structure of UVB-resistance protein UVR8
3UX8	;	2.1	;	Crystal structure of UvrA
3UWX	;	4.398	;	Crystal structure of UvrA-UvrB complex
3FPN	;	1.8	;	Crystal structure of UvrA-UvrB interaction domains
2VF7	;	2.3	;	Crystal structure of UvrA2 from Deinococcus radiodurans
2VF8	;	3.0	;	Crystal structure of UvrA2 from Deinococcus radiodurans
6O8F	;	2.81	;	Crystal structure of UvrB bound to duplex DNA
6O8E	;	2.61	;	Crystal structure of UvrB bound to duplex DNA with ADP
6O8G	;	2.64	;	Crystal structure of UvrB bound to fully duplex DNA
6O8H	;	2.39	;	Crystal structure of UvrB mutant bound to duplex DNA
2IS2	;	3.0	;	Crystal structure of UvrD-DNA binary complex
2IS6	;	2.2	;	Crystal structure of UvrD-DNA-ADPMgF3 ternary complex
2IS4	;	2.6	;	Crystal structure of UvrD-DNA-ADPNP ternary complex
2IS1	;	2.9	;	Crystal structure of UvrD-DNA-SO4 complex
3SK7	;	1.5	;	Crystal Structure of V. cholerae SeqA
3W3A	;	3.9	;	Crystal structure of V1-ATPase at 3.9 angstrom resolution
1S1W	;	2.7	;	Crystal structure of V106A mutant HIV-1 reverse transcriptase in complex with UC-781
1S1X	;	2.8	;	Crystal structure of V108I mutant HIV-1 reverse transcriptase in complex with nevirapine
7BIG	;	1.8	;	Crystal structure of v13WRAP-T, a 7-bladed designer protein
3HPR	;	2.0	;	Crystal structure of V148G adenylate kinase from E. coli, in complex with Ap5A
4DBZ	;	2.643	;	Crystal Structure of V151L Actinorhodin Polyketide Ketoreductase with NADPH
4BN1	;	2.499	;	Crystal structure of V174M mutant of Aurora-A kinase
1G3O	;	1.65	;	CRYSTAL STRUCTURE OF V19E MUTANT OF FERREDOXIN I
2HJO	;	1.25	;	Crystal structure of V224H design intermediate for GFP metal ion reporter
6I3A	;	1.45	;	Crystal structure of v22Pizza6-AYW, a circularly permuted designer protein
7BIF	;	1.4	;	Crystal structure of v22WRAP-T, a 7-bladed designer protein
6BNN	;	1.55	;	Crystal structure of V278E-glyoxalase I mutant from Zea mays in space group P4(1)2(1)2
6BNX	;	1.8	;	Crystal structure of V278E-glyoxalase I mutant from Zea mays in space group P6(3)
4OJ4	;	2.3	;	Crystal structure of V290M PPARgamma mutant in complex with diclofenac
4PWE	;	1.4	;	Crystal structure of V30M mutant human transthyretin
4PWH	;	1.798	;	Crystal structure of V30M mutant human transthyretin complexed with caffeic acid 1,1-dimethylallyl ester
4PWG	;	1.798	;	Crystal structure of V30M mutant human transthyretin complexed with caffeic acid ethyl ester
4QRF	;	1.8	;	Crystal structure of V30M mutant human transthyretin complexed with caffeic acid phenethyl ester
4PWK	;	1.59	;	Crystal structure of V30M mutant human transthyretin complexed with dihydroguaiaretic acid
4PWF	;	1.6	;	Crystal structure of V30M mutant human transthyretin complexed with ferulic acid phenethyl ester
4N87	;	1.794	;	Crystal structure of V30M mutant human transthyretin complexed with glabridin
4PWJ	;	1.55	;	Crystal structure of V30M mutant human transthyretin complexed with nordihydroguaiaretic acid
4PWI	;	1.494	;	Crystal structure of V30M mutant human transthyretin complexed with rosmarinic acid
6IMX	;	1.602	;	Crystal structure of V30M mutated transthyretin in complex with 18-Crown-6
4Y9G	;	1.89	;	Crystal structure of V30M mutated transthyretin in complex with 3-isomangostin
6IMY	;	1.501	;	Crystal structure of V30M mutated transthyretin in complex with 4'-caroboxybenzo-18-Crown-6
7DT8	;	1.25	;	Crystal structure of V30M mutated transthyretin in complex with 4-chloro-9-oxo-9H-xanthene-2-carboxylic acid
7EJR	;	1.451	;	Crystal structure of V30M mutated transthyretin in complex with 8-chloro-9-oxo-9H-xanthene-3-carboxylic acid
4Y9B	;	1.4	;	Crystal structure of V30M mutated transthyretin in complex with alpha-mangostin
4Y9E	;	1.49	;	Crystal structure of V30M mutated transthyretin in complex with gamma-mangostin
7DT6	;	1.3	;	Crystal structure of V30M mutated transthyretin in complex with purpurin
4Y9C	;	1.49	;	Crystal structure of V30M mutated transthyretin with bromide in complex with alpha-mangostin
4Y9F	;	1.5	;	Crystal structure of V30M mutated transthyretin with bromide in complex with gamma-mangostin
3NG5	;	1.7	;	Crystal Structure of V30M transthyretin complexed with (-)-epigallocatechin gallate (EGCG)
8II4	;	1.499	;	Crystal structure of V30M-TTR in complex with 6-hydroxy BBM
8II3	;	1.399	;	Crystal structure of V30M-TTR in complex with 6-hydroxy BID
8II2	;	1.798	;	Crystal structure of V30M-TTR in complex with BBM
8II1	;	1.907	;	Crystal structure of V30M-TTR in complex with BID
7ERK	;	1.703	;	Crystal structure of V30M-TTR in complex with dasatinib
7ERJ	;	1.892	;	Crystal structure of V30M-TTR in complex with dichlorophen
7W9Q	;	1.599	;	Crystal structure of V30M-TTR in complex with naringenin derivative-14
7W9R	;	1.997	;	Crystal structure of V30M-TTR in complex with naringenin derivative-18
7ERI	;	1.813	;	Crystal structure of V30M-TTR in complex with triclabendazole
3FJB	;	2.0	;	Crystal structure of V31I mutant of Human acidic fibroblast growth factor
6I39	;	1.05	;	Crystal structure of v31Pizza6-AYW, a circularly permuted designer protein
7BID	;	1.8	;	Crystal structure of v31WRAP-T, a 7-bladed designer protein
6XNW	;	1.9	;	Crystal structure of V39A mutant of human CEACAM1
1T9P	;	1.5	;	Crystal Structure of V44A, G45P Cp Rubredoxin
1T9O	;	2.0	;	Crystal Structure of V44G Cp Rubredoxin
1T9Q	;	1.8	;	Crystal Structure of V44L Cp Rubredoxin
1LQX	;	1.8	;	Crystal structure of V45E mutant of cytochrome b5
1LR6	;	1.9	;	Crystal structure of V45Y mutant of cytochrome b5
4RWK	;	2.982	;	Crystal structure of V561M FGFR1 gatekeeper mutation (C488A, C584S, V561M) in complex with N-{3-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R,5S)-3,5-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
4RWI	;	2.292	;	Crystal structure of V561M FGFR1 gatekeeper mutation (C488A, C584S, V561M), apo
3SVA	;	3.02	;	Crystal structure of V57D mutant of human cystatin C
6ROA	;	2.65	;	Crystal structure of V57G mutant of human cystatin C
3S67	;	2.26	;	Crystal structure of V57P mutant of human cystatin C
4GGG	;	1.998	;	Crystal structure of V66A/L68V CzrA in the Zn(II)bound state.
6CDB	;	1.99	;	Crystal Structure of V66L CzrA in the Zn(II)bound state
5U9K	;	2.7	;	Crystal structure of V71F mutant of the FKBP domain of human aryl hydrocarbon receptor-interacting protein-like 1 (AIPL1)
5V35	;	2.5	;	Crystal structure of V71F mutant of the FKBP domain of human aryl hydrocarbon receptor-interacting protein-like 1 (AIPL1) complexed with S-farnesyl-L-cysteine methyl ester
6TD0	;	0.99	;	Crystal structure of vaborbactam bound to KPC-2
6KBN	;	3.2	;	Crystal structure of Vac8 (del 19-33) bound to Atg13
6KBM	;	2.902	;	Crystal structure of Vac8 bound to Atg13
7YCJ	;	2.101	;	Crystal structure of Vac8 bound to Vac17
5XJG	;	2.4	;	Crystal structure of Vac8p bound to Nvj1p
7JKS	;	3.45	;	Crystal structure of vaccine-elicited broadly neutralizing VRC01-class antibody 2411a in complex with HIV-1 gp120 core
7JKT	;	2.75	;	Crystal structure of vaccine-elicited broadly neutralizing VRC01-class antibody 2413a in complex with HIV-1 gp120 core
5TR8	;	2.01	;	Crystal structure of vaccine-elicited pan- influenza H1N1 neutralizing murine antibody 441D6.
6URM	;	2.65	;	Crystal structure of vaccine-elicited receptor-binding site targeting antibody LPAF-a.01 in complex with Hemagglutinin H1 A/California/04/2009
6CB6	;	1.8	;	CRYSTAL STRUCTURE OF VACCINIA VIRUS A6 N-TERMINUS (SPACE GROUP C2)
6CB7	;	1.6	;	CRYSTAL STRUCTURE OF VACCINIA VIRUS A6 N-TERMINUS (SPACE GROUP C2)
5CYW	;	2.0	;	Crystal Structure of Vaccinia Virus C7
7T7H	;	1.78	;	Crystal structure of Vaccinia Virus decapping enzyme D9 in complex with inhibitor CP100356
7SEZ	;	1.70001	;	Crystal structure of Vaccinia Virus decapping enzyme D9 in complex with m7GDP
7SF0	;	1.95	;	Crystal structure of Vaccinia Virus decapping enzyme D9 in complex with trinucleotide substrate
7YTT	;	1.81	;	Crystal structure of vaccinia virus G3/L5 sub-complex (SeMet-labeled, P21 space group)
7YTU	;	1.504	;	Crystal structure of vaccinia virus G3/L5 sub-complex (SeMet-labeled, P31 space group)
1YPY	;	1.51	;	Crystal Structure of Vaccinia Virus L1 protein
2I39	;	2.2	;	Crystal structure of Vaccinia virus N1L protein
3OWG	;	2.86	;	Crystal structure of vaccinia virus Polyadenylate polymerase(vp55)
4M0S	;	2.58	;	Crystal structure of Vaccinia virus protein A46
6I2M	;	2.3	;	Crystal structure of vaccinia virus protein A55 BTB-Back domain in complex with human Cullin-3 N-terminus
2W0S	;	2.918	;	Crystal structure of vaccinia virus thymidylate kinase bound to brivudin-5'-monophosphate
2V54	;	2.4	;	Crystal structure of vaccinia virus thymidylate kinase bound to TDP
4IRB	;	2.3	;	Crystal Structure of Vaccinia Virus Uracil DNA Glycosylase Mutant del171-172D4
3NT7	;	2.4	;	Crystal Structure of Vaccinia Virus Uracil DNA Glycosylase R187V Mutant
2OWQ	;	2.4	;	Crystal structure of vaccinia virus uracil-DNA glycosylase
4QC9	;	2.259	;	Crystal structure of Vaccinia virus uracil-DNA glycosylase mutant 3GD4
4QCA	;	1.9	;	Crystal structure of Vaccinia virus uracil-DNA glycosylase mutant R167AD4
6BEG	;	3.1	;	Crystal structure of VACV D13 F486A mutant
6BEF	;	3.21	;	Crystal structure of VACV D13 in complex with 3-formyl rifamycin SV
8F65	;	2.85	;	Crystal structure of VACV D13 in complex with BBL030900
6BEC	;	2.91	;	Crystal structure of VACV D13 in complex with Rifabutin
6BED	;	2.75	;	Crystal structure of VACV D13 in complex with Rifampicin
6BEB	;	2.55	;	Crystal structure of VACV D13 in complex with Rifamycin SV
6BEH	;	3.0	;	Crystal structure of VACV D13 in complex with Rifapentine
6BEE	;	3.11	;	Crystal structure of VACV D13 in complex with Rifaximin
8F47	;	3.1	;	Crystal structure of VACV D13 in complex with STK69439
6BEI	;	2.81	;	Crystal structure of VACV D13 in its apo (unbound) form
6FAS	;	1.9	;	Crystal structure of VAL1 B3 domain in complex with cognate DNA
1ES1	;	2.1	;	CRYSTAL STRUCTURE OF VAL61HIS MUTANT OF TRYPSIN-SOLUBILIZED FRAGMENT OF CYTOCHROME B5
2OCI	;	1.9	;	Crystal structure of valacyclovir hydrolase complexed with a product analogue
2OCK	;	1.85	;	Crystal structure of valacyclovir hydrolase D123N mutant
2OCL	;	1.9	;	Crystal structure of valacyclovir hydrolase S122A mutant
3G7Q	;	1.8	;	Crystal structure of valine-pyruvate aminotransferase AvtA (NP_462565.1) from Salmonella typhimurium LT2 at 1.80 A resolution
3RUG	;	2.2	;	Crystal structure of Valpha10-Vbeta8.1 NKT TCR in complex with CD1d-alphaglucosylceramide (C20:2)
1WQ8	;	1.9	;	Crystal structure of Vammin, a VEGF-F from a snake venom
3P20	;	2.85	;	Crystal structure of vanadate bound subunit A of the A1AO ATP synthase
5LPC	;	3.1	;	Crystal structure of Vanadium-dependent Haloperoxidase from A. marina
1GHG	;	0.98	;	CRYSTAL STRUCTURE OF VANCOMYCIN AGLYCON
1SHO	;	1.09	;	CRYSTAL STRUCTURE OF VANCOMYCIN AT ATOMIC RESOLUTION
4F78	;	1.95	;	Crystal Structure of Vancomycin Resistance D,D-dipeptidase VanXYg
4MUQ	;	1.364	;	Crystal Structure of Vancomycin Resistance D,D-dipeptidase VanXYg in complex with D-Ala-D-Ala phosphinate analog
4MUR	;	1.65	;	Crystal structure of vancomycin resistance D,D-dipeptidase/D,D-pentapeptidase VanXYc D59S mutant
4MUS	;	1.675	;	Crystal structure of vancomycin resistance D,D-dipeptidase/D,D-pentapeptidase VanXYc D59S mutant in complex with D-Ala-D-Ala phosphinate analog
4MUT	;	2.25	;	Crystal structure of vancomycin resistance D,D-dipeptidase/D,D-pentapeptidase VanXYc D59S mutant in complex with D-Alanine
4OAK	;	2.0	;	Crystal structure of vancomycin resistance D,D-dipeptidase/D,D-pentapeptidase VanXYc D59S mutant in complex with D-Alanine-D-Alanine and copper (II)
5HNM	;	2.3	;	Crystal structure of vancomycin resistance D,D-pentapeptidase VanY E175A mutant from VanB-type resistance cassette in complex with Zn(II)
5M2K	;	1.0	;	Crystal structure of vancomycin-Zn(II) complex
5M2H	;	0.95	;	Crystal structure of vancomycin-Zn(II)-citrate complex
4Q9T	;	3.0	;	Crystal structure of Vanderwaltozyma polyspora Nup133 Beta-propeller domain
4FU0	;	2.35	;	Crystal Structure of VanG D-Ala:D-Ser Ligase from Enterococcus faecalis
6XM9	;	1.651	;	Crystal structure of vanillin bound to Co-LSD4 from Sphingobium sp. strain SYK-6
1R44	;	2.25	;	Crystal Structure of VanX
6F73	;	2.22	;	Crystal structure of VAO-type flavoprotein MtVAO615 at pH 5.0 from Myceliophthora thermophila C1
6F72	;	2.0	;	Crystal structure of VAO-type flavoprotein MtVAO615 at pH 7.5 from Myceliophthora thermophila C1
6F74	;	2.2	;	Crystal structure of VAO-type flavoprotein MtVAO713 from Myceliophthora thermophila C1
2DW0	;	2.15	;	Crystal structure of VAP2 from Crotalus atrox venom (Form 2-1 crystal)
2DW1	;	2.5	;	Crystal structure of VAP2 from Crotalus atrox venom (Form 2-2 crystal)
2DW2	;	2.7	;	Crystal structure of VAP2 from Crotalus atrox venom (Form 2-5 crystal)
6IFC	;	1.99	;	Crystal structure of VapBC from Salmonella typhimurium
4CHG	;	2.1	;	Crystal structure of VapBC15 complex from Mycobacterium tuberculosis
3ZVK	;	2.5	;	Crystal structure of VapBC2 from Rickettsia felis bound to a DNA fragment from their promoter
3CPZ	;	2.8	;	Crystal structure of VAR2CSA DBL3x domain in the presence of dodecasaccharide of CSA
5UEI	;	1.702	;	Crystal Structure of Variable Lymphocyte Receptor (VLR) O13 (Apo)
5UF1	;	2.03	;	Crystal Structure of Variable Lymphocyte Receptor (VLR) O13 in complex with H-trisaccharide
5UF4	;	2.04	;	Crystal Structure of Variable Lymphocyte Receptor (VLR) O13 with LNnT bound
5UFD	;	1.696	;	Crystal Structure of Variable Lymphocyte Receptor (VLR) RBC36 (Apo)
3E6J	;	1.67	;	Crystal Structure of Variable Lymphocyte Receptor (VLR) RBC36 in Complex with H-trisaccharide
5UFF	;	2.137	;	Crystal Structure of Variable Lymphocyte Receptor (VLR) RBC36 with Fucose(alpha-1-2)Lactose bound
5UFB	;	1.844	;	Crystal Structure of Variable Lymphocyte Receptor (VLR) Tn4-22 (Apo)
5UFC	;	1.888	;	Crystal Structure of Variable Lymphocyte Receptor (VLR) Tn4-22 with H-trisaccharide bound
6BXD	;	1.103	;	Crystal structure of Variable Lymphocyte Receptor 2 (VLR2)
6BXE	;	1.651	;	Crystal structure of Variable Lymphocyte Receptor 9 (VLR9)
3M18	;	1.95	;	Crystal structure of variable lymphocyte receptor VLRA.R2.1 in complex with hen egg lysozyme
3M19	;	1.7	;	Crystal structure of variable lymphocyte receptor VLRA.R5.1
1JZA	;	2.2	;	Crystal Structure of Variant 2 Scorpion Toxin from Centruroides sculpturatus Ewing
1JZB	;	2.81	;	Crystal Structure of Variant 2 Scorpion Toxin from Centruroides sculpturatus Ewing
4RPE	;	1.6	;	Crystal Structure of Variant G186E from Pseudomonas Aeruginosa Lipoxygenase 2 at 1.60A (C2)
2RG2	;	1.8	;	Crystal structure of variant R18L of conjugated bile acid hydrolase from Clostridium perfringens
6Z8H	;	1.38	;	Crystal structure of Variant Surface Glycoprotein VSG13
6YGT	;	1.635	;	Crystal structure of variant T52P of the intracellular chorismate mutase from Mycobacterium tuberculosis
5NDY	;	1.949	;	crystal structure of variants
5NEZ	;	2.394	;	crystal structure of variants
5NF1	;	2.697	;	crystal structure of variants
1OSN	;	3.2	;	Crystal structure of Varicella zoster virus thymidine kinase in complex with BVDU-MP and ADP
5AJK	;	2.55	;	Crystal structure of variola virus virulence factor F1L in complex with human Bak BH3 domain
5AJJ	;	1.75	;	Crystal structure of variola virus virulence factor F1L in complex with human Bid BH3 domain
7Z4X	;	2.05	;	Crystal structure of Variovorax paradoxus indole monooxygenase (VpIndA1) in complex with FAD
7Z94	;	1.74	;	Crystal structure of Variovorax paradoxus indole monooxygenase (VpIndA1) in complex with indole
3ALA	;	2.9	;	Crystal structure of vascular adhesion protein-1 in space group C2
2ERP	;	2.95	;	Crystal structure of vascular apoptosis-inducing protein-1(inhibitor-bound form)
2ERO	;	2.5	;	Crystal structure of vascular apoptosis-inducing protein-1(orthorhombic crystal form)
2ERQ	;	2.5	;	Crystal structure of vascular apoptosis-inducing protein-1(tetragonal crystal form)
6D3O	;	3.1	;	Crystal Structure of Vascular Endothelial Growth Factor (VEGF8-109) with HH4, an alpha/beta-Peptide with Irregular Secondary Structure
6V7K	;	2.5	;	Crystal Structure of Vascular Endothelial Growth Factor (VEGF8-109) with one copy of HH4, an alpha/beta-Peptide with Irregular Secondary Structure
2XV7	;	2.9	;	Crystal structure of vascular endothelial growth factor D
2VWE	;	3.4	;	Crystal Structure of Vascular Endothelial Growth Factor-B in Complex with a Neutralizing Antibody Fab Fragment
6QBY	;	2.09	;	Crystal structure of VASH 2 in complex with SVBP
6OCG	;	1.833	;	Crystal structure of VASH1-SVBP complex bound with EpoY
6OCH	;	2.003	;	Crystal structure of VASH1-SVBP complex bound with parthenolide
6J7B	;	1.618	;	Crystal structure of VASH1-SVBP in complex with epoY
6JZE	;	2.51	;	Crystal structure of VASH2-SVBP complex with the magic triangle I3C
1KK6	;	2.5	;	Crystal Structure of Vat(D) (Form I)
1KK5	;	2.7	;	Crystal Structure of Vat(D) (Form II)
1KK4	;	2.7	;	Crystal Structure of Vat(D) in Complex with Acetyl-CoA
1KHR	;	2.8	;	Crystal Structure of Vat(D) in Complex with Virginiamycin and Coenzyme A
1GCQ	;	1.68	;	CRYSTAL STRUCTURE OF VAV AND GRB2 SH3 DOMAINS
1GCP	;	2.1	;	CRYSTAL STRUCTURE OF VAV SH3 DOMAIN
4U5T	;	3.301	;	Crystal Structure of VBP Leucine Zipper with Bound Arylstibonic Acid
7E1B	;	4.587	;	Crystal structure of VbrR-DNA complex
4R5M	;	1.89	;	Crystal structure of Vc-Aspartate beta-semialdehyde-dehydrogenase with NADP and 4-Nitro-2-Phosphono-Benzoic acid
3OT1	;	1.16	;	Crystal structure of VC2308 protein
1ZNO	;	2.0	;	Crystal Structure of VC702 from Vibrio Cholerae, Northeast Structural Genomics Consortium Target: VcP1
3KYG	;	2.1	;	Crystal structure of VCA0042 (L135R) complexed with c-di-GMP
2RDE	;	1.92	;	Crystal structure of VCA0042 complexed with c-di-GMP
1XT5	;	1.15	;	Crystal Structure of VCBP3, domain 1, from Branchiostoma floridae
4PD5	;	2.906	;	Crystal structure of vcCNT-7C8C bound to gemcitabine
4PD6	;	2.08	;	Crystal structure of vcCNT-7C8C bound to uridine
7A5Q	;	1.68	;	Crystal structure of VcSiaP bound to sialic acid
8PZ7	;	2.93	;	crystal structure of VDR complex with D-Bishomo-1a,25-dihydroxyvitamin D3 Analog 57
1KB4	;	2.8	;	Crystal Structure of VDR DNA-binding Domain Bound to a Canonical Direct Repeat with Three Base Pair Spacer (DR3) Response Element
1KB2	;	2.7	;	Crystal Structure of VDR DNA-binding Domain Bound to Mouse Osteopontin (SPP) Response Element
1KB6	;	2.7	;	Crystal Structure of VDR DNA-binding Domain Bound to Rat Osteocalcin (OC) Response Element
3M7R	;	1.8	;	Crystal structure of VDR H305Q mutant
8PZ9	;	2.74	;	Crystal structure of VDR in complex with D-Bishomo-1a,25-dihydroxyvitamin D3 Analog 55
5GIC	;	2.352	;	Crystal structure of VDR in complex with DLAM-2P
5GID	;	2.151	;	Crystal structure of VDR in complex with DLAM-4 (C2 form)
5GIE	;	2.387	;	Crystal structure of VDR in complex with DLAM-4P (P21 form)
2HAM	;	1.9	;	Crystal structure of VDR LBD complexed to 2alpha-propyl-calcitriol
2HAR	;	1.9	;	Crystal structure of VDR LBD in complex with 2 alpha-(3-hydroxy-1-propoxy) calcitriol
2HB7	;	1.8	;	Crystal structure of VDR LBD in complex with 2alpha(3-hydroxy-1-propyl) calcitriol
2HAS	;	1.96	;	Crystal structure of VDR LBD in complex with 2alpha-(1-propoxy) calcitriol
2HB8	;	2.0	;	Crystal structure of VDR LBD in complex with 2alpha-methyl calcitriol
1S19	;	2.1	;	Crystal structure of VDR ligand binding domain complexed to calcipotriol.
5B41	;	1.89	;	Crystal structure of VDR-LBD complexed with 2-methylidene-19-nor-1a,25-dihydroxyvitamin D3
5B5B	;	2.0	;	Crystal structure of VDR-LBD complexed with 2-methylidene-26,27-diphenyl-19-nor-1,25-dihydroxyvitamin D3
3WT7	;	2.4	;	Crystal structure of VDR-LBD complexed with 22R-Butyl-2-methylidene-26,27-dimethyl-19,24-dinor-1 ,25-dihydroxyvitamin D3
3WTQ	;	2.1	;	Crystal structure of VDR-LBD complexed with 22S-butyl-2-methylidene-19-nor-1a,25-dihydroxyvitamin D3
5XPL	;	2.05	;	Crystal structure of VDR-LBD complexed with 22S-butyl-25-hydroxyphenyl-2-methylidene-19,26,27-trinor-25-oxo-1-hydroxyvitamin D3
5XPM	;	2.2	;	Crystal structure of VDR-LBD complexed with 22S-Butyl-25RS-(hydroxyphenyl)-25-methoxy-2-methylidene-19,26,27-trinor-1-hydroxyvitamin D3
5XPO	;	2.28	;	Crystal structure of VDR-LBD complexed with 25-(hydroxyphenyl)-2-methylidene-19,26,27-trinor-25-oxo-1-hydroxyvitamin D3
5XPP	;	2.85	;	Crystal structure of VDR-LBD complexed with 25RS-(Hydroxyphenyl)-2-methylidene-19,26,27-trinor-1,25-dihydroxyvitamin D3
5XPN	;	1.96	;	Crystal structure of VDR-LBD complexed with 25RS-(hydroxyphenyl)-25-methoxy-2-methylidene-19,26,27-trinor-1-hydroxyvitamin D3
5XUQ	;	2.8	;	Crystal structure of VDR-LBD complexed with an antagonist, 2-methylidene-19,26,27-trinor-22-(S)-butyl-1-hydroxy-25-oxo-25-(1H-pyrrol-2-yl)- vitamin D3
3AFR	;	2.0	;	Crystal Structure of VDR-LBD/22S-Butyl-1a,24R-dihydroxyvitamin D3 complex
5AWK	;	2.9	;	Crystal structure of VDR-LBD/partial agonist complex: 22S-ethyl analogue
5AWJ	;	2.2	;	Crystal structure of VDR-LBD/partial agonist complex: 22S-hexyl analogue
1QS1	;	1.5	;	CRYSTAL STRUCTURE OF VEGETATIVE INSECTICIDAL PROTEIN2 (VIP2)
5K64	;	2.44	;	Crystal structure of VEGF binding IgG1-Fc (Fcab 448)
5K65	;	2.5	;	Crystal structure of VEGF binding IgG1-Fc (Fcab CT6)
5O4E	;	2.15	;	Crystal structure of VEGF in complex with heterodimeric Fcab JanusCT6
5T89	;	4.0	;	Crystal structure of VEGF-A in complex with VEGFR-1 domains D1-6
2X1W	;	2.7	;	Crystal Structure of VEGF-C in Complex with Domains 2 and 3 of VEGFR2
2X1X	;	3.1	;	CRYSTAL STRUCTURE OF VEGF-C IN COMPLEX WITH DOMAINS 2 AND 3 OF VEGFR2 IN A TETRAGONAL CRYSTAL FORM
4BSK	;	4.201	;	Crystal structure of VEGF-C in complex with VEGFR-3 domains D1-2
4CL7	;	2.0	;	Crystal structure of VEGFR-1 domain 2 in presence of Cobalt
5ABD	;	1.995	;	CRYSTAL STRUCTURE OF VEGFR-1 DOMAIN 2 IN PRESENCE OF CU
4CKV	;	2.055	;	Crystal structure of VEGFR-1 domain 2 in presence of Zn
5OYJ	;	2.38	;	Crystal structure of VEGFR-2 domains 4-5 in complex with DARPin D4b
4BSJ	;	2.5	;	Crystal structure of VEGFR-3 extracellular domains D4-5
3HNG	;	2.7	;	Crystal structure of VEGFR1 in complex with N-(4-Chlorophenyl)-2-((pyridin-4-ylmethyl)amino)benzamide
4AGC	;	2.0	;	CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH AXITINIB (AG-013736) (N-Methyl-2-(3-((E)-2-pyridin-2-yl- vinyl)-1H-indazol-6-ylsulfanyl)-benzamide)
4ASD	;	2.03	;	Crystal Structure of VEGFR2 (Juxtamembrane and Kinase Domains) in Complex with SORAFENIB (BAY 43-9006)
4AGD	;	2.81	;	CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SUNITINIB (SU11248) (N-2-diethylaminoethyl)-5-((Z)-(5- fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3- carboxamide)
4ASE	;	1.83	;	CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH TIVOZANIB (AV-951)
3KVQ	;	2.7	;	Crystal structure of VEGFR2 extracellular domain D7
1Y6A	;	2.1	;	Crystal structure of VEGFR2 in complex with a 2-anilino-5-aryl-oxazole inhibitor
1Y6B	;	2.1	;	Crystal structure of VEGFR2 in complex with a 2-anilino-5-aryl-oxazole inhibitor
3CJF	;	2.15	;	Crystal structure of VEGFR2 in complex with a 3,4,5-trimethoxy aniline containing pyrimidine
3CJG	;	2.25	;	Crystal structure of VEGFR2 in complex with a 3,4,5-trimethoxy aniline containing pyrimidine
2OH4	;	2.05	;	Crystal structure of Vegfr2 with a benzimidazole-urea inhibitor
8DUF	;	1.46	;	Crystal structure of Venezuelan Equine Encephalitis alphavirus (VEEV) nonstructural protein 2 (nsp2) (K741A/K767A) protease domain
2HWK	;	2.45	;	Crystal Structure of Venezuelan Equine Encephalitis Alphavirus nsP2 Protease Domain
7DLK	;	2.1	;	Crystal Structure of veratryl alcohol bound Dye Decolorizing peroxidase from Bacillus subtilis
4U50	;	3.2	;	Crystal structure of Verrucarin bound to the yeast 80S ribosome
2BOQ	;	1.33	;	Crystal structure of versatile peroxidase
8HS7	;	2.0	;	Crystal structure of Vesicle-associated membrane protein-associated protein SCS2 from yeast
1LG7	;	1.96	;	Crystal structure of Vesicular Stomatitis Virus Matrix Protein
2P4H	;	1.4	;	Crystal Structure of Vestitone Reductase from Alfalfa (Medicago sativa L.)
4YFL	;	3.387	;	Crystal structure of VH1-46 germline-derived CD4-binding site-directed antibody 1B2530 in complex with HIV-1 clade A/E 93TH057 gp120
4RWY	;	2.128	;	Crystal structure of VH1-46 germline-derived CD4-binding site-directed antibody 8ANC131 in complex with HIV-1 clade B YU2 gp120
4RX4	;	3.45	;	Crystal structure of VH1-46 germline-derived CD4-binding site-directed antibody 8ANC134 in complex with HIV-1 clade A Q842.d12 gp120
6DBA	;	1.3	;	Crystal Structure of VHH R303
6DBF	;	1.55	;	Crystal Structure of VHH R303 in complex with InlB-LRR
6DBG	;	1.51	;	Crystal Structure of VHH R303 in complex with InlB-LRR-IR
6DBD	;	1.755	;	Crystal Structure of VHH R326
6DBE	;	1.65	;	Crystal Structure of VHH R330
6QKD	;	1.9	;	CRYSTAL STRUCTURE OF vhh-based FAB-fragment of antibody BCD-085
8EI3	;	3.49	;	Crystal structure of VHL in complex with H313, a Helicon Polypeptide
1L5A	;	2.55	;	Crystal Structure of VibH, an NRPS Condensation Enzyme
8GSM	;	2.88	;	Crystal Structure of VibMO1
6KD0	;	1.8	;	Crystal Structure of Vibralactone Cyclase
7YZZ	;	1.29	;	Crystal structure of Vibrio alkaline phosphatase in 0.5 M NaCl
7Z00	;	2.6	;	Crystal structure of Vibrio alkaline phosphatase in 1.0 M KBr
7QOW	;	1.2	;	Crystal structure of Vibrio alkaline phosphatase in 1.0 M NaCl
7QP8	;	1.7	;	Crystal structure of Vibrio alkaline phosphatase with bound HEPES
4LW9	;	1.9	;	Crystal structure of Vibrio cholera major pseudopilin EpsG
3DP9	;	2.3	;	Crystal structure of Vibrio cholerae 5'-methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) complexed with butylthio-DADMe-Immucillin A
4WKB	;	1.37	;	Crystal structure of Vibrio cholerae 5'-methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) complexed with methylthio-DADMe-Immucillin-A
4X24	;	1.5	;	Crystal structure of Vibrio cholerae 5'-methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) complexed with methylthio-DADMe-Immucillin-A
4OXI	;	2.261	;	Crystal structure of Vibrio cholerae adenylation domain AlmE in complex with glycyl-adenosine-5'-phosphate
4KSS	;	7.58	;	Crystal Structure of Vibrio cholerae ATPase GspsE Hexamer
4XJ4	;	1.596	;	Crystal structure of Vibrio cholerae DncV 3'-deoxy ATP bound form
4XJ5	;	1.552	;	Crystal structure of Vibrio cholerae DncV 3'-deoxy GTP bound form
4XJ1	;	1.77	;	Crystal structure of Vibrio cholerae DncV apo form
4TY0	;	1.8	;	Crystal structure of Vibrio cholerae DncV cyclic AMP-GMP synthase in complex with linear intermediate 5' pppA(3',5')pG
4TXZ	;	2.8	;	Crystal structure of Vibrio cholerae DncV cyclic AMP-GMP synthase in complex with nonhydrolyzable GTP
4TXY	;	3.0001	;	Crystal structure of Vibrio cholerae DncV cyclic AMP-GMP synthase, a prokaryotic cGAS homolog
4XJ3	;	1.65	;	Crystal structure of Vibrio cholerae DncV GTP bound form
7LUI	;	1.74	;	Crystal structure of Vibrio cholerae DsbA in complex with bile salt taurocholate
6IDS	;	2.79	;	Crystal structure of Vibrio cholerae MATE transporter VcmN D35N mutant
6IDR	;	2.502	;	Crystal structure of Vibrio cholerae MATE transporter VcmN in the bent form
6IDP	;	2.205	;	Crystal structure of Vibrio cholerae MATE transporter VcmN in the straight form
6K26	;	1.85	;	Crystal structure of Vibrio cholerae methionine aminopeptidase
6LH7	;	1.473	;	Crystal Structure of Vibrio cholerae Methionine Aminopeptidase with Partially Occupied Metals
7EYM	;	1.38	;	Crystal structure of Vibrio cholerae ppnP
1P9R	;	2.5	;	Crystal Structure of Vibrio cholerae putative NTPase EpsE
1P9W	;	2.7	;	Crystal Structure of Vibrio cholerae putative NTPase EpsE
4KKQ	;	2.16	;	Crystal structure of Vibrio cholerae RbmA (crystal form 1)
4KKP	;	2.5	;	Crystal structure of Vibrio cholerae RbmA (crystal form 2)
4KKR	;	2.0	;	Crystal structure of Vibrio cholerae RbmA (crystal form 3)
7DWN	;	2.32	;	Crystal structure of Vibrio fischeri DarR in complex with DNA reveals the transcriptional activation mechanism of LTTR family members
7DWO	;	2.611	;	Crystal structure of Vibrio fischeri DarR in complex with DNA reveals the transcriptional activation mechanism of LTTR family members
3B9A	;	1.8	;	Crystal structure of Vibrio harveyi chitinase A complexed with hexasaccharide
3B9D	;	1.72	;	Crystal structure of Vibrio harveyi chitinase A complexed with pentasaccharide
2HJE	;	1.7	;	Crystal structure of Vibrio harveyi LuxQ periplasmic domain
3R6M	;	3.1	;	Crystal structure of Vibrio parahaemolyticus YeaZ
1V7V	;	1.8	;	Crystal structure of Vibrio proteolyticus chitobiose phosphorylase
1V7W	;	1.6	;	Crystal structure of Vibrio proteolyticus chitobiose phosphorylase in complex with GlcNAc
1V7X	;	2.0	;	Crystal structure of Vibrio proteolyticus chitobiose phosphorylase in complex with GlcNAc and sulfate
2ISA	;	1.97	;	Crystal Structure of Vibrio salmonicida catalase
3NQX	;	1.7	;	Crystal structure of vibriolysin MCP-02 mature enzyme, a zinc metalloprotease from M4 family
2Z4T	;	2.5	;	Crystal Structure of Vibrionaceae Photobacterium sp. JT-ISH-224 2,6-sialyltransferase in a Ternary Complex with Donor Product CMP and Accepter Substrate Lactose
6L4C	;	3.191	;	Crystal structure of vicilin from Corylus avellana (Hazelnut)
6L4M	;	3.302	;	Crystal structure of vicilin from Solanum lycopersicum (tomato)
6VGV	;	1.65	;	Crystal structure of VidaL intein
6VGW	;	1.51	;	Crystal structure of VidaL intein (selenomethionine variant)
2RJY	;	1.4	;	Crystal structure of villin headpiece, P21 21 21 space group
5N5I	;	2.2	;	Crystal Structure of VIM-1 metallo-beta-lactamase in complex with hydrolysed meropenem
6DD1	;	1.7	;	Crystal structure of VIM-2 complexed with compound 14
6DD0	;	1.5	;	Crystal structure of VIM-2 complexed with compound 8
6TGI	;	1.6	;	Crystal structure of VIM-2 in complex with triazole-based inhibitor OP24
7YHB	;	1.43	;	Crystal structure of VIM-2 MBL in complex with (2-(4-phenyl-1H-1,2,3-triazol-1-yl)benzyl)phosphonic acid
7DUE	;	1.799	;	Crystal structure of VIM-2 MBL in complex with (R)-1-(sec-butyl)-1H-imidazole-2-carboxylic acid
7DYY	;	1.798	;	Crystal structure of VIM-2 MBL in complex with 1-((2-aminobenzo[d]thiazol-6-yl)methyl)-1H-imidazole-2-carboxylic acid
7DUY	;	1.999	;	Crystal structure of VIM-2 MBL in complex with 1-(2-(1H-1,2,3-triazol-1-yl)ethyl)-1H-imidazole-2-carboxylic acid
7DV0	;	1.601	;	Crystal structure of VIM-2 MBL in complex with 1-(4-(trifluoromethyl)benzyl)-1H-imidazole-2-carboxylic acid
7DV1	;	1.966	;	Crystal structure of VIM-2 MBL in complex with 1-(4-hydroxybenzyl)-1H-imidazole-2-carboxylic acid
7DUX	;	1.981	;	Crystal structure of VIM-2 MBL in complex with 1-(but-3-en-1-yl)-1H-imidazole-2-carboxylic acid
7DYZ	;	1.902	;	Crystal structure of VIM-2 MBL in complex with 1-(but-3-en-1-yl)-4-methyl-1H-imidazole-2-carboxylic acid
7DZ0	;	3.227	;	Crystal structure of VIM-2 MBL in complex with 1-(but-3-en-1-yl)-5-methyl-1H-imidazole-2-carboxylic acid
7DZ1	;	2.708	;	Crystal structure of VIM-2 MBL in complex with 1-benzyl-5-methyl-1H-imidazole-2-carboxylic acid
7DUZ	;	1.6	;	Crystal structure of VIM-2 MBL in complex with 1-cyclobutyl-1H-imidazole-2-carboxylic acid
7DUB	;	1.599	;	Crystal structure of VIM-2 MBL in complex with 1-isopropyl-1H-imidazole-2-carboxylic acid
7DU1	;	1.79	;	Crystal structure of VIM-2 MBL in complex with 1-propyl-1H-imidazole-2-carboxylic acid
7YHC	;	2.153	;	Crystal structure of VIM-2 MBL in complex with 3-(4-(3-aminophenyl)-1H-1,2,3-triazol-1-yl)phthalic acid
7YHD	;	1.696	;	Crystal structure of VIM-2 MBL in complex with 3-(4-(4-(2-aminoethoxy)phenyl)-1H-1,2,3-triazol-1-yl)phthalic acid
5YD7	;	1.7	;	Crystal Structure OF VIM-2 Metallo-beta-lactamase
8I52	;	1.58	;	Crystal structure of VIM-2 metallo-beta-lactamase in complex with 10-HHIA
6KXO	;	1.49	;	Crystal Structure Of VIM-2 Metallo-beta-lactamase In Complex With Inhibitor NO9
6KZN	;	1.5	;	Crystal Structure Of VIM-2 Metallo-beta-lactamase In Complex With Inhibitor X2
4PVO	;	1.48	;	Crystal Structure of VIM-2 metallo-beta-lactamase in complex with ML302 and ML302F
4PVT	;	2.0	;	Crystal Structure of VIM-2 metallo-beta-lactamase in complex with ML302F
6O5T	;	2.1	;	Crystal Structure of VIM-2 with Compound 16
7A60	;	1.47	;	Crystal structure of VIM-2 with hydrolyzed faropenem (ring-open form)
7YRP	;	2.0	;	Crystal structure of VIM-28 metallo-beta-lactamase
7DUF	;	2.61	;	Crystal structure of VIM1 PHD finger.
3UF1	;	2.81	;	Crystal Structure of Vimentin (fragment 144-251) from Homo sapiens, Northeast Structural Genomics Consortium Target HR4796B
5WHF	;	2.25	;	Crystal structure of vimentin coil 1B packed in a high-order filamentous form
3SSU	;	2.603	;	Crystal structure of vimentin coil1A/1B fragment
3S4R	;	2.452	;	Crystal structure of vimentin coil1A/1B fragment with a stabilizing mutation
3SWK	;	1.7	;	Crystal structure of vimentin coil1B fragment
3WMR	;	1.95	;	Crystal structure of VinJ
7F2R	;	1.95	;	Crystal structure of VinK-VinL covalent complex formed with a pantetheineamide cross-linking probe
3WV4	;	2.15	;	Crystal structure of VinN
2BGH	;	2.6	;	Crystal structure of Vinorine Synthase
2WBQ	;	1.1	;	Crystal structure of VioC in complex with (2S,3S)-hydroxyarginine
2WBP	;	1.16	;	Crystal structure of VioC in complex with Fe(II), (2S,3S)- hydroxyarginine, and succinate
2WBO	;	1.3	;	Crystal structure of VioC in complex with L-arginine
8H0M	;	1.702	;	Crystal structure of VioD
3C4A	;	2.3	;	Crystal structure of vioD hydroxylase in complex with FAD from Chromobacterium violaceum. Northeast Structural Genomics Consortium Target CvR158
8GQR	;	2.1	;	Crystal structure of VioD with FAD
2ZF3	;	2.0	;	Crystal Structure of VioE
2ZF4	;	2.18	;	Crystal Structure of VioE complexed with phenylpyruvic acid
1QS2	;	2.7	;	CRYSTAL STRUCTURE OF VIP2 WITH NAD
2DUO	;	1.8	;	Crystal structure of VIP36 exoplasmic/lumenal domain, Ca2+-bound form
2DUQ	;	1.8	;	Crystal structure of VIP36 exoplasmic/lumenal domain, Ca2+/Man-bound form
2DUR	;	1.65	;	Crystal structure of VIP36 exoplasmic/lumenal domain, Ca2+/Man2-bound form
2E6V	;	2.5	;	Crystal structure of VIP36 exoplasmic/lumenal domain, Ca2+/Man3GlcNAc-bound form
2DUP	;	2.1	;	Crystal structure of VIP36 exoplasmic/lumenal domain, metal-free form
4AKF	;	2.9	;	Crystal structure of VipD from Legionella pneumophila
5VSL	;	1.972	;	Crystal structure of viperin with bound [4Fe-4S] cluster and S-adenosylhomocysteine (SAH)
5VSM	;	1.7	;	Crystal structure of viperin with bound [4Fe-4S] cluster, 5'-deoxyadenosine, and L-methionine
6WQB	;	1.75	;	Crystal structure of VipF from Legionella hackeliae in complex with acetyl-CoA
6WQC	;	2.34	;	Crystal structure of VipF from Legionella hackeliae in complex with CoA
4ZLT	;	3.0	;	Crystal structure of viral chemokine binding protein R17 in complex with CCL3
1CM9	;	2.1	;	CRYSTAL STRUCTURE OF VIRAL MACROPHAGE INFLAMMATORY PROTEIN-II
2FHT	;	1.7	;	Crystal Structure of Viral Macrophage Inflammatory Protein-II
2FJ2	;	2.3	;	Crystal Structure of Viral Macrophage Inflammatory Protein-II
4HDH	;	2.28	;	Crystal Structure of viral RdRp in complex with ATP
4HDG	;	2.38	;	Crystal Structure of viral RdRp in complex with GTP
6SQG	;	1.9	;	Crystal structure of viral rhodopsin OLPVRII
3VWB	;	2.416	;	Crystal structure of VirB core domain (Se-Met derivative) complexed with the cis-acting site (5-BRU modifications) upstream icsb promoter
3W3C	;	2.431	;	Crystal structure of VirB core domain complexed with the cis-acting site upstream icsb promoter
3W2A	;	2.775	;	Crystal structure of VirB core domain complexed with the cis-acting site upstream icsp promoter
2BHM	;	2.4	;	Crystal structure of VirB8 from Brucella suis
4AKZ	;	2.25	;	CRYSTAL STRUCTURE OF VIRB8 FROM BRUCELLA SUIS
4AKY	;	2.6	;	CRYSTAL STRUCTURE OF VIRB8 FROM BRUCELLA SUIS IN COMPLEX WITH INTERACTION INHIBITOR 2-(butylamino)-8-quinolinol
7PKW	;	1.835	;	Crystal structure of VIRB8-like OrfG central and C-terminal domains of Streptococcus thermophilus ICESt3 (Gram positive conjugative type IV secretion system).
6ZGN	;	1.75	;	Crystal structure of VirB8-like OrfG central domain of Streptococcus thermophilus ICESt3; a putative assembly factor of a gram positive conjugative Type IV secretion system.
1YIT	;	2.8	;	Crystal Structure Of Virginiamycin M and S Bound To The 50S Ribosomal Subunit Of Haloarcula Marismortui
4LUQ	;	1.77	;	Crystal structure of virulence effector Tse3 in complex with neutralizer Tsi3
2OZ6	;	2.8	;	Crystal Structure of Virulence Factor Regulator from Pseudomonas aeruginosa in complex with cAMP
3HNQ	;	2.1	;	Crystal Structure of Virulence protein STM3117 from Salmonella typhimurium. Northeast Structural Genomics Consortium target id StR274
3Q5Z	;	1.9	;	Crystal structure of virulent allele ROP5B pseudokinase domain
3Q60	;	1.72	;	Crystal structure of virulent allele ROP5B pseudokinase domain bound to ATP
2E0Z	;	3.6	;	Crystal structure of virus-like particle from Pyrococcus furiosus
7K6V	;	3.0	;	Crystal Structure of Virus-like Particles of GII.4 Norovirus Houston virus (HOV)
2RG9	;	1.95	;	Crystal structure of viscum album mistletoe lectin I in native state at 1.95 A resolution, comparison of structure active site conformation in ricin and in viscumin
5LX5	;	1.88	;	CRYSTAL STRUCTURE OF VISFATIN IN COMPLEX WITH SAR154782-RP.
5LX3	;	2.1	;	CRYSTAL STRUCTURE OF VISFATIN IN COMPLEX WITH SAR154782.
2G95	;	1.9	;	Crystal Structure of Visfatin/Pre-B Cell Colony Enhancing Factor 1/Nicotinamide Phosphoribosyltransferase
2G96	;	2.9	;	Crystal Structure of Visfatin/Pre-B Cell Colony Enhancing Factor 1/Nicotinamide Phosphoribosyltransferase In Complex with Niconamide Mononucleotide
2G97	;	2.9	;	Crystal Structure of Visfatin/Pre-B Cell Colony Enhancing Factor 1/Nicotinamide Phosphoribosyltransferase In Complex with the Specific Inhibitor FK-866
6MVL	;	1.61	;	Crystal structure of VISTA bound to a pH-selective antibody Fab fragment
3UGX	;	2.649	;	Crystal Structure of Visual Arrestin
3CV9	;	1.7	;	Crystal structure of vitamin D hydroxylase cytochrome P450 105A1 (R73A/R84A mutant) in complex with 1alpha,25-dihydroxyvitamin D3
2ZBY	;	1.6	;	Crystal structure of vitamin D hydroxylase cytochrome P450 105A1 (R84A mutant)
5X7E	;	1.9	;	Crystal structure of vitamin D hydroxylase cytochrome P450 105A1 (R84A mutant) in complex with 1,25-dihydroxyvitamin D2
2ZBZ	;	1.9	;	Crystal structure of vitamin D hydroxylase cytochrome P450 105A1 (R84A mutant) in complex with 1,25-dihydroxyvitamin D3
3CV8	;	2.0	;	Crystal structure of vitamin D hydroxylase cytochrome P450 105A1 (R84F mutant)
2ZBX	;	1.5	;	Crystal structure of vitamin D hydroxylase cytochrome P450 105A1 (wild type) with imidazole bound
2HBH	;	2.65	;	Crystal structure of Vitamin D nuclear receptor ligand binding domain bound to a locked side-chain analog of calcitriol and SRC-1 peptide
1YNW	;	3.0	;	Crystal Structure of Vitamin D Receptor and 9-cis Retinoic Acid Receptor DNA-Binding Domains Bound to a DR3 Response Element
4YNK	;	2.3	;	Crystal structure of vitamin D receptor ligand binding domain complexed with a 19-norvitamin D compound
1VMO	;	2.2	;	CRYSTAL STRUCTURE OF VITELLINE MEMBRANE OUTER LAYER PROTEIN I (VMO-I): A FOLDING MOTIF WITH HOMOLOGOUS GREEK KEY STRUCTURES RELATED BY AN INTERNAL THREE-FOLD SYMMETRY
3VDM	;	1.98	;	Crystal Structure of VldE, the pseudo-glycosyltransferase which catalyzes non-glycosidic C-N coupling in Validamycin A biosynthesis
3VDN	;	2.55	;	Crystal Structure of VldE, the pseudo-glycosyltransferase, in complex with GDP
4F96	;	2.152	;	Crystal Structure of VldE, the pseudo-glycosyltransferase, in complex with GDP
4F9F	;	2.807	;	Crystal Structure of VldE, the pseudo-glycosyltransferase, in complex with GDP and Trehalose
4F97	;	2.108	;	Crystal Structure of VldE, the pseudo-glycosyltransferase, in complex with GDP and validoxylamine A 7'-phosphate
6LFD	;	1.92	;	Crystal structure of VMB-1 at pH5.5(Bis-Tris)
6LF4	;	2.01	;	Crystal structure of VMB-1 bound to hydrolyzed meropenem
4RDY	;	2.0	;	Crystal structure of VmoLac bound to 3-oxo-C10 AHL
4RE0	;	2.35	;	Crystal structure of VmoLac in P622 space group
4RDZ	;	1.8	;	Crystal structure of VmoLac in P64 space group
7SKZ	;	1.86	;	Crystal Structure of VN01H1 Fab in complex with SARS-CoV-2 S fusion peptide
8HGI	;	1.95	;	Crystal structure of VNAR aGFP14 in complex with GFP
2GF4	;	2.07	;	Crystal structure of Vng1086c from Halobacterium salinarium (Halobacterium halobium). Northeast Structural Genomics Target HsR14
6TD1	;	1.2	;	Crystal structure of VNRX-5133 (taniborbactam) bound to KPC-2
7XL0	;	1.7	;	Crystal structure of Vobarilizumab at 1.70 Angstrom
7SIT	;	3.32	;	Crystal structure of Voltage gated potassium ion channel, Kv 1.2 chimera-3m
4G7V	;	2.5	;	Crystal structure of voltage sensing domain of Ci-VSP with fragment antibody (R217E, 2.5 A)
4G7Y	;	2.8	;	Crystal structure of voltage sensing domain of Ci-VSP with fragment antibody (R217E, 2.8 A)
4G80	;	3.58	;	Crystal structure of voltage sensing domain of Ci-VSP with fragment antibody (WT, 3.8 A)
5YUB	;	3.40004	;	Crystal structure of voltage-gated sodium channel NavAb E32Q mutant
6P6X	;	2.75	;	Crystal structure of voltage-gated sodium channel NavAb G94C/Q150C mutant in the activated state
5YUA	;	2.80086	;	Crystal structure of voltage-gated sodium channel NavAb in high-pH condition
5YUC	;	3.40099	;	Crystal structure of voltage-gated sodium channel NavAb N49K mutant
8H9W	;	2.7	;	Crystal structure of voltage-gated sodium channel NavAb N49K mutant in calcium ion condition
8H9O	;	3.3	;	Crystal structure of voltage-gated sodium channel NavAb N49K mutant in sodium ion condition
8HA2	;	3.3	;	Crystal structure of voltage-gated sodium channel NavAb N49K/L176G mutant in calcium ion condition
8HA1	;	3.5	;	Crystal structure of voltage-gated sodium channel NavAb N49K/L176G mutant in sodium ion condition
8H9Y	;	3.4	;	Crystal structure of voltage-gated sodium channel NavAb N49K/L176Q mutant in calcium ion condition
8H9X	;	3.4	;	Crystal structure of voltage-gated sodium channel NavAb N49K/L176Q mutant in sodium ion condition
6P6Y	;	2.89	;	Crystal structure of voltage-gated sodium channel NavAb V100C/Q150C disulfide crosslinked mutant in the activated state
3HXO	;	2.4	;	Crystal Structure of Von Willebrand Factor (VWF) A1 Domain in Complex with DNA Aptamer ARC1172, an Inhibitor of VWF-Platelet Binding
3HXQ	;	2.694	;	Crystal Structure of Von Willebrand Factor (VWF) A1 Domain in Complex with DNA Aptamer ARC1172, an Inhibitor of VWF-Platelet Binding
1UEX	;	2.85	;	Crystal structure of von Willebrand Factor A1 domain complexed with snake venom bitiscetin
3SEO	;	2.305	;	Crystal structure of VopL C terminal domain
4N6Q	;	1.79	;	Crystal structure of VosA velvet domain
4N6R	;	2.2	;	Crystal structure of VosA-VelB-complex
2R7Q	;	2.9	;	Crystal Structure of VP1 apoenzyme of Rotavirus SA11 (C-terminal hexahistidine-tagged)
2R7O	;	3.35	;	Crystal Structure of VP1 apoenzyme of Rotavirus SA11 (N-terminal hexahistidine-tagged)
7SL5	;	2.5	;	Crystal Structure of VP12E7 Fab in complex with SARS-CoV-2 S fusion peptide
2PNL	;	2.21	;	Crystal structure of VP4 protease from infectious pancreatic necrosis virus (IPNV) in space group P1
2PNM	;	2.3	;	Crystal Structure of VP4 protease from infectious pancreatic necrosis virus (IPNV) in space group P6122
6QGI	;	2.46	;	Crystal structure of VP5 from Haloarchaeal pleomorphic virus 2
6QGL	;	2.69	;	Crystal structure of VP5 from Haloarchaeal pleomorphic virus 6
1QHD	;	1.95	;	CRYSTAL STRUCTURE OF VP6, THE MAJOR CAPSID PROTEIN OF GROUP A ROTAVIRUS
2GJ2	;	2.35	;	Crystal Structure of VP9 from White Spot Syndrome Virus
3VB9	;	2.1	;	Crystal structure of VPA0735 from Vibrio parahaemolyticus in monoclinic form, NorthEast Structural Genomics target VpR109
2P3Y	;	1.8	;	Crystal structure of VPA0735 from Vibrio parahaemolyticus. NorthEast Structural Genomics target VpR109
7X4O	;	2.02	;	Crystal structure of Vps17p PX from S. cerevisiae (Space)
5XCK	;	2.2	;	Crystal structure of Vps29 double mutant (D62A/H86A) from Entamoeba histolytica
5XCJ	;	1.859	;	Crystal structure of Vps29 single mutant (D62A) from Entamoeba histolytica
5ANL	;	2.7	;	Crystal structure of VPS34 in complex with (2S)-8-((3R)-3- Methylmorpholin-4-yl)-1-(3-methyl-2-oxo- butyl)-2-(trifluoromethyl)-3, 4-dihydro-2H-pyrimido(1,2-a)pyrimidin-6- one, processed with the CrystalDirect automated mounting and cryo-cooling technology
8RXR	;	2.06	;	Crystal structure of VPS34 in complex with inhibitor SB02024
4OYS	;	2.9	;	CRYSTAL STRUCTURE OF VPS34 IN COMPLEX WITH SAR405.
3MHV	;	3.1	;	Crystal Structure of Vps4 and Vta1
4NIQ	;	2.301	;	Crystal Structure of Vps4 MIT-Vfa1 MIM2
5FVK	;	1.658	;	Crystal structure of Vps4-Vfa1 complex from S.cerevisiae at 1.66 A resolution.
5FVL	;	1.973	;	Crystal structure of Vps4-Vps20 complex from S.cerevisiae
1XWI	;	2.8	;	Crystal Structure of VPS4B
3C9D	;	2.0	;	Crystal structure of Vps75
7VF4	;	3.1	;	Crystal structure of Vps75 from Candida albicans
6U1Q	;	2.87	;	Crystal Structure of VpsO (VC0937) Kinase domain
7V2B	;	3.2	;	Crystal Structure of VpsR display novel dimeric architecture and c-di-GMP binding: mechanistic implications in oligomerization, ATPase activity and DNA binding.
7V2V	;	3.194	;	Crystal Structure of VpsR display novel dimeric architecture and c-di-GMP binding: mechanistic implications in oligomerization, ATPase activity and DNA binding.
7V3W	;	3.205	;	Crystal Structure of VpsR display novel dimeric architecture and c-di-GMP binding: mechanistic implications in oligomerization, ATPase activity and DNA binding.
7V4E	;	4.0	;	Crystal Structure of VpsR display novel dimeric architecture and c-di-GMP binding: mechanistic implications in oligomerization, ATPase activity and DNA binding.
6U1P	;	2.201	;	Crystal structure of VpsU (VC0916) from Vibrio cholerae
5XHX	;	2.1	;	Crystal structure of VqsR LBD domain from Pseudomonas aeruginosa
1WQ9	;	2.0	;	Crystal structure of VR-1, a VEGF-F from a snake venom
5IES	;	2.16	;	Crystal structure of VRC01c-HuGL2 Fab from an HIV-1 naive donor in complex with with a germline-targeting gp120 engineered outer domain eOD-GT8 at 2.16 A
5IF0	;	2.44	;	Crystal structure of VRC01c-HuGL2 Fab from an HIV-1 naive donor in complex with with a germline-targeting gp120 engineered outer domain eOD-GT8 at 2.44 A
5JOF	;	3.208	;	Crystal structure of VRC03 gHVgLV antigen-binding fragment.
6MTO	;	2.634	;	Crystal structure of VRC42.01 Fab in complex with T117-F MPER scaffold
6MTP	;	2.036	;	Crystal structure of VRC42.04 Fab in complex with gp41 peptide
6MTQ	;	2.7	;	Crystal structure of VRC42.N1 Fab in complex with T117-F MPER scaffold
6MTR	;	1.798	;	Crystal structure of VRC43.01 Fab
6MTS	;	2.437	;	Crystal structure of VRC43.03 Fab
6MTT	;	1.7	;	Crystal structure of VRC46.01 Fab in complex with gp41 peptide
4I1K	;	1.6	;	Crystal Structure of VRN1 (Residues 208-341)
3KMA	;	1.6	;	Crystal Structure of vSET under Condition A
3KMJ	;	1.85	;	Crystal structure of vSET under condition B
3KMT	;	1.78	;	Crystal structure of vSET/SAH/H3 ternary complex
4PFE	;	2.603	;	Crystal structure of vsfGFP-0
6Z8G	;	1.56	;	Crystal structure of VSG13 soaked in 0.5 M used to phase VSG13 to solve the structure.
1TD3	;	2.37	;	Crystal structure of VSHP_BPP21 in space group C2
1TD4	;	1.5	;	Crystal structure of VSHP_BPP21 in space group H3 with high resolution.
5I2M	;	2.4	;	CRYSTAL STRUCTURE OF VSV-INDIANA (MUDD-SUMMERS STRAIN) GLYCOPROTEIN UNDER ITS ACIDIC CONFORMATION
5Y9S	;	2.199	;	Crystal structure of VV2_1132, a LysR family transcriptional regulator
6JKZ	;	1.397	;	Crystal structure of VvPlpA from Vibrio vulnificus
6JL0	;	2.073	;	Crystal structure of VvPlpA from Vibrio vulnificus
6JL1	;	2.29	;	Crystal structure of VvPlpA G389D from Vibrio vulnificus
6JL2	;	2.3	;	Crystal structure of VvPlpA G389N from Vibrio vulnificus
3GXB	;	1.9	;	Crystal structure of VWF A2 domain
6H1A	;	1.75	;	Crystal structure of VX surrogate NEMP inhibited recombinant human bile salt activated lipase
4I5O	;	4.4787	;	Crystal Structure of W-W-R ClpX Hexamer
4I34	;	4.1218	;	Crystal Structure of W-W-W ClpX Hexamer
3N7M	;	2.6	;	Crystal structure of W1252A mutant of HCR D/C VPI 5995
3E1Q	;	2.6	;	Crystal structure of W133F variant E. coli Bacterioferritn with iron.
1WA0	;	1.6	;	Crystal Structure Of W138H Mutant Of Alcaligenes Xylosoxidans Nitrite Reductase
1SC6	;	2.09	;	Crystal Structure of W139G D-3-Phosphoglycerate dehydrogenase complexed with NAD+
6QLV	;	2.391	;	Crystal structure of W200H UbiX in complex with a geranyl-FMN N5 adduct
5L2H	;	1.8013	;	Crystal Structure of W26A mutant of anti-EGFR Centyrin P54AR4-83v2
1PZT	;	1.92	;	CRYSTAL STRUCTURE OF W314A-BETA-1,4-GALACTOSYLTRANSFERASE (B4GAL-T1) CATALYTIC DOMAIN WITHOUT SUBSTRATE
6KXN	;	1.5	;	Crystal structure of W50A mutant of Chitiniphilus shinanonensis chitinase ChiL (CsChiL) complexed with N,N'-diacetylchitobiose
4OJB	;	2.0	;	Crystal structure of W741L-AR-LBD
4OK1	;	2.09	;	Crystal structure of W741L-AR-LBD bound with co-regulator peptide
4OKB	;	2.95	;	Crystal structure of W741L-AR-LBD bound with co-regulator peptide
4OKT	;	2.5	;	Crystal structure of W741L-AR-LBD bound with co-regulator peptide
4OKW	;	2.0	;	Crystal structure of W741L-AR-LBD bound with co-regulator peptide
4OKX	;	2.1	;	Crystal structure of W741L-AR-LBD bound with co-regulator peptide
4OLM	;	2.8	;	Crystal structure of W741L-AR-LBD bound with co-regulator peptide
1JF2	;	1.72	;	Crystal Structure of W92F obelin mutant from Obelia longissima at 1.72 Angstrom resolution
3QDA	;	1.57	;	Crystal structure of W95L beta-2 microglobulin
5ZT3	;	1.304	;	Crystal structure of WA352 from Oryza sativa
2IV7	;	1.6	;	Crystal Structure of WaaG, a glycosyltransferase involved in lipopolysaccharide biosynthesis
2IW1	;	1.5	;	Crystal Structure of WaaG, a glycosyltransferase involved in lipopolysaccharide biosynthesis
2DRE	;	2.0	;	Crystal structure of Water-soluble chlorophyll protein from lepidium virginicum at 2.00 angstrom resolution
5K19	;	2.602	;	Crystal structure of WD repeat-containing protein 20
6PBG	;	1.72	;	Crystal structure of WD-repeat domain of human coatomer subunit Alpha (COPA)
6VYC	;	2.1	;	Crystal structure of WD-repeat domain of human WDR91
3ODT	;	1.35	;	Crystal structure of WD40 beta propeller domain of Doa1
4OZU	;	1.65	;	Crystal Structure of WD40 domain from Toxoplasma gondii coronin
3FM0	;	1.7	;	Crystal structure of WD40 protein Ciao1
5H1J	;	2.0	;	Crystal structure of WD40 repeat domains of Gemin5
5H1K	;	1.9	;	Crystal structure of WD40 repeat domains of Gemin5 in complex with 13-nt U4 snRNA fragment
5H1L	;	2.1	;	Crystal structure of WD40 repeat domains of Gemin5 in complex with 7-nt U4 snRNA fragment
5H1M	;	2.492	;	Crystal structure of WD40 repeat domains of Gemin5 in complex with M7G
3I2N	;	1.95	;	Crystal Structure of WD40 repeats protein WDR92
7CFP	;	1.6	;	Crystal structure of WDR5 in complex with a H3Q5ser peptide
7CFQ	;	1.6	;	Crystal structure of WDR5 in complex with H3K4me3Q5ser peptide
4Y7R	;	1.898	;	Crystal structure of WDR5 in complex with MYC MbIIIb peptide
3UVK	;	1.4	;	Crystal structure of WDR5 in complex with the WDR5-interacting motif of MLL2
3UVL	;	2.2	;	Crystal structure of WDR5 in complex with the WDR5-interacting motif of MLL3
3UVM	;	1.57	;	Crystal structure of WDR5 in complex with the WDR5-interacting motif of MLL4
3UVN	;	1.792	;	Crystal structure of WDR5 in complex with the WDR5-interacting motif of SET1A
3UVO	;	2.2	;	Crystal structure of WDR5 in complex with the WDR5-interacting motif of SET1B
6WJQ	;	2.71	;	Crystal structure of WDR5 in complex with the WIN peptide of PDPK1
3MXX	;	2.05	;	Crystal structure of WDR5 mutant (S62A)
3N0D	;	2.3	;	Crystal structure of WDR5 mutant (W330F)
3N0E	;	2.5	;	Crystal structure of WDR5 mutant (W330Y)
4QQE	;	1.8	;	Crystal structure of WDR5, WD repeat domain 5 in complex with compound SGC-DS-MT-0345
6BYN	;	2.69	;	Crystal structure of WDR5-Mb(S4) monobody complex
2H13	;	1.58	;	Crystal structure of WDR5/histone H3 complex
1XE4	;	1.95	;	Crystal Structure of Weissella viridescens FemX (K36M) Mutant
1XF8	;	1.9	;	Crystal Structure of Weissella viridescens FemX (Y254F) Mutant
1NE9	;	1.7	;	Crystal Structure of Weissella viridescens FemX at 1.7 Ang Resolution
1XIX	;	2.0	;	Crystal Structure of Weissella viridescens FemX Form II
3GKR	;	1.6	;	Crystal Structure of Weissella viridescens FemX:UDP-MurNAc-hexapeptide complex
1P4N	;	1.9	;	Crystal Structure of Weissella viridescens FemX:UDP-MurNAc-pentapeptide complex
4II9	;	1.66	;	Crystal structure of Weissella viridescens FemXVv non-ribosomal amino acid transferase in complex with a peptidyl-RNA conjugate
7Z5Y	;	1.71	;	CRYSTAL STRUCTURE OF WEISSELLA VIRIDESCENS FEMXVV NON-RIBOSOMAL AMINO ACID TRANSFERASE IN COMPLEX WITH A PEPTIDYL-XNA CONJUGATE
7Z5Z	;	1.49	;	CRYSTAL STRUCTURE OF WEISSELLA VIRIDESCENS FEMXVV NON-RIBOSOMAL AMINO ACID TRANSFERASE IN COMPLEX WITH A PEPTIDYL-XNA CONJUGATE
7Z6A	;	1.66	;	CRYSTAL STRUCTURE OF WEISSELLA VIRIDESCENS FEMXVV NON-RIBOSOMAL AMINO ACID TRANSFERASE IN COMPLEX WITH A PEPTIDYL-XNA CONJUGATE
7Z6K	;	1.6	;	CRYSTAL STRUCTURE OF WEISSELLA VIRIDESCENS FEMXVV NON-RIBOSOMAL AMINO ACID TRANSFERASE IN COMPLEX WITH A PEPTIDYL-XNA CONJUGATE
6YHR	;	2.2	;	Crystal structure of Werner syndrome helicase
8YLE	;	1.86	;	Crystal structure of Werner syndrome helicase complexed with AMP-PCP
5IDK	;	1.5	;	Crystal structure of West Nile Virus NS2B-NS3 protease in complex with a capped dipeptide boronate inhibitor
7AHY	;	2.532	;	Crystal structure of Western clawed frog MDM2 RING domain homodimer
7AHZ	;	1.82	;	Crystal structure of Western clawed frog MDM2 RING domain homodimer bound to UbcH5B-Ub
2IDV	;	2.3	;	Crystal structure of wheat C113S mutant EIF4E bound TO 7-methyl-GDP
4E1Q	;	1.251	;	Crystal structure of Wheat Cyclophilin A at 1.25 A resolution
4AML	;	1.6	;	CRYSTAL STRUCTURE OF WHEAT GERM AGGLUTININ ISOLECTIN 1 IN COMPLEX WITH GLYCOSYLURETHAN
2X52	;	1.7	;	CRYSTAL STRUCTURE OF WHEAT GERM AGGLUTININ ISOLECTIN 3 IN COMPLEX WITH A SYNTHETIC DIVALENT CARBOHYDRATE LIGAND
5ZVL	;	2.963	;	Crystal Structure of Wheat Glutarredoxin
7XDS	;	2.06	;	Crystal structure of wheat stem rust effector AvrSr35
6Y38	;	1.697	;	Crystal structure of Whirlin PDZ3 in complex with Myosin 15a C-terminal PDZ binding motif peptide
6Y9O	;	1.632	;	Crystal structure of Whirlin PDZ3_C-ter in complex with CASK internal PDZ binding motif peptide
6Y9P	;	3.169	;	Crystal structure of Whirlin PDZ3_C-ter in complex with Harmonin a1 C-terminal PDZ binding motif peptide
6Y9N	;	1.93	;	Crystal structure of Whirlin PDZ3_C-ter in complex with Myosin 15a C-terminal PDZ binding motif peptide
6Y9Q	;	1.315	;	Crystal structure of Whirlin PDZ3_C-ter in complex with Taperin internal PDZ binding motif peptide
7CC8	;	2.3	;	Crystal structure of White Spot Syndrome Virus Thymidylate Synthase - Apo form
7CCA	;	2.75	;	Crystal structure of White Spot Syndrome Virus Thymidylate Synthase - ternary complex with Methotrexate and dUMP
6HJ5	;	2.08	;	Crystal structure of Whitewater Arroyo virus GP1 glycoprotein at pH 5.6
6HJ4	;	2.43	;	Crystal structure of Whitewater Arroyo virus GP1 glycoprotein at pH 7.5
6CEN	;	1.61	;	Crystal Structure of WHSC1L1 in Complex with Inhibitor PEP21
4RXJ	;	2.1	;	crystal structure of WHSC1L1-PWWP2
6ECS	;	2.9	;	Crystal structure of WHV core protein mutant Y132A dimer
4KOO	;	1.88	;	Crystal Structure of WHY1 from Arabidopsis thaliana
4KOP	;	1.75	;	Crystal Structure of WHY2 from Arabidopsis thaliana
4KOQ	;	1.85	;	Crystal Structure of WHY3 from Arabidopsis thaliana
2XSR	;	1.8	;	Crystal structure of wild type Acinetobacter radioresistens catechol 1,2 dioxygenase
5TJ3	;	1.7	;	Crystal structure of wild type alkaline phosphatase PafA to 1.7A resolution
6KXR	;	2.45074	;	Crystal structure of wild type Alp1U from the biosynthesis of kinamycins
2JCO	;	2.57	;	Crystal structure of wild type alpha-1,3 Galactosyltransferase in the absence of ligands
5O87	;	2.2	;	Crystal structure of wild type Aplysia californica AChBP in complex with nicotine
5O8T	;	2.2	;	Crystal structure of wild type Aplysia californica AChBP in complex with strychnine
3Q4C	;	3.2	;	Crystal Structure of Wild Type BRAF kinase domain in complex with organometallic inhibitor CNS292
7DP4	;	1.5	;	Crystal structure of wild type Brugia malayi thymidylate synthase complexed with 2'-deoxyuridine monophosphate and methotrexate
6WY4	;	1.8	;	Crystal Structure of Wild Type Class D beta-lactamase from Clostridium difficile 630
1NZB	;	3.1	;	Crystal structure of wild type Cre recombinase-loxP synapse
5GQL	;	1.78	;	Crystal structure of Wild Type Cypovirus Polyhedra
7XHR	;	1.801	;	Crystal structure of Wild Type Cypovirus Polyhedra produced by cell-free protein synthesis
7XWS	;	1.95	;	Crystal structure of Wild Type Cypovirus Polyhedra produced by cell-free protein synthesis with small volume
4XVA	;	2.66	;	Crystal structure of wild type cytochrome c peroxidase
1HY0	;	2.2	;	CRYSTAL STRUCTURE OF WILD TYPE DUCK DELTA 1 CRYSTALLIN (EYE LENS PROTEIN)
1HY1	;	2.3	;	CRYSTAL STRUCTURE OF WILD TYPE DUCK DELTA 2 CRYSTALLIN (EYE LENS PROTEIN)
4TS9	;	1.77	;	Crystal structure of wild type E. Coli purine nucleoside phosphorylase with 6 FMC molecules
3N1S	;	1.45	;	Crystal structure of wild type ecHint GMP complex
7T4I	;	2.61	;	Crystal Structure of wild type EGFR in complex with TAK-788
6T8I	;	1.4	;	Crystal structure of wild type EndoBT-3987 from Bacteroides thetaiotamicron VPI-5482
2IDZ	;	2.0	;	Crystal structure of wild type Enoyl-ACP(CoA) reductase from Mycobacterium tuberculosis in complex with NADH-INH
2PTS	;	2.0	;	Crystal structure of wild type Escherichia coli adenylosuccinate lyase
4BUQ	;	2.199	;	Crystal structure of wild type FimH lectin domain in complex with heptyl alpha-D-mannopyrannoside
1ZSR	;	2.06	;	Crystal structure of wild type HIV-1 protease (BRU isolate) with a hydroxyethylamine peptidomimetic inhibitor BOC-PHE-PSI[S-CH(OH)CH2NH]-PHE-GLU-PHE-NH2
2PSU	;	1.93	;	Crystal Structure of wild type HIV-1 protease in complex with CARB-AD37
2PSV	;	1.75	;	Crystal Structure of wild type HIV-1 protease in complex with CARB-KB45
4HLA	;	1.95	;	Crystal structure of wild type HIV-1 protease in complex with darunavir
5KAO	;	1.8	;	Crystal structure of wild type HIV-1 protease in complex with GRL-10413
4I8W	;	1.96	;	Crystal structure of wild type HIV-1 protease in complex with non-peptidic inhibitor, GRL007
4I8Z	;	1.75	;	Crystal structure of wild type HIV-1 protease in complex with non-peptidic inhibitor, GRL008
3I6O	;	1.17	;	Crystal structure of wild type HIV-1 protease with macrocyclic inhibitor GRL-0216A
3H5B	;	1.29	;	Crystal structure of wild type HIV-1 protease with novel P1'-ligand GRL-02031
4XEM	;	1.278	;	Crystal Structure of wild type human AlaRS catalytic domain
4F46	;	1.69	;	Crystal structure of wild type human CD38 in complex with NAADP and ADPRP
4QZU	;	1.5	;	Crystal Structure of wild type Human Cellular Retinol Binding Protein II (hCRBPII) bound to retinol at 11 KeV beam energy
4QZT	;	1.9	;	Crystal Structure of wild type Human Cellular Retinol Binding Protein II (hCRBPII) bound to retinol at 7 KeV beam energy
4IMN	;	2.09	;	Crystal structure of wild type human Lipocalin PGDS bound with PEG MME 2000
4IMO	;	1.88	;	Crystal structure of wild type human Lipocalin PGDS in complex with substrate analog U44069
7AYB	;	1.85	;	Crystal Structure of wild type human mitochondrial 2-Enoyl Thioester Reductase (MECR)
7PCK	;	3.2	;	CRYSTAL STRUCTURE OF WILD TYPE HUMAN PROCATHEPSIN K
4P1J	;	2.62	;	Crystal structure of wild type Hypocrea jecorina Cel7a in a hexagonal crystal form
4P1H	;	1.5	;	Crystal structure of wild type Hypocrea jecorina Cel7a in a monoclinic crystal form
6J42	;	2.492	;	Crystal Structure of Wild Type KatB, a manganese catalase from Anabaena
1PJI	;	1.9	;	Crystal structure of wild type Lactococcus lactis FPG complexed to a 1,3 propanediol containing DNA
1PM5	;	1.95	;	Crystal structure of wild type Lactococcus lactis Fpg complexed to a tetrahydrofuran containing DNA
3F74	;	1.7	;	Crystal structure of wild type LFA1 I domain
3F78	;	1.6	;	Crystal structure of wild type LFA1 I domain complexed with isoflurane
3VOE	;	2.6	;	Crystal Structure of wild type MarR (apo form) from E.coli
6JLR	;	2.901	;	Crystal structure of wild type MNK2 in complex with inhibitor
4AHP	;	2.1	;	Crystal Structure of Wild Type N-acetylneuraminic acid lyase from Staphylococcus aureus
3ZOW	;	2.35	;	Crystal Structure of Wild Type Nitrosomonas europaea Cytochrome c552
6Z2Q	;	2.347	;	Crystal structure of wild type OgpA from Akkermansia muciniphila in complex with an O-glycopeptide (GalGalNAc-TS) product
6Z2O	;	1.649	;	Crystal structure of wild type OgpA from Akkermansia muciniphila in P 21 21 21
6Z2D	;	1.899	;	Crystal structure of wild type OgpA from Akkermansia muciniphila in P 41 21 2
8P9E	;	2.25	;	Crystal structure of wild type p63-p73 heterotetramer (tetramerisation domain) in complex with darpin 1810 F11
2Z4U	;	1.1	;	Crystal structure of wild type PD-L4 from Phytolacca dioica leaves
2V5F	;	2.03	;	Crystal structure of wild type peptide-binding domain of human type I collagen prolyl 4-hydroxylase.
5YB0	;	2.94	;	Crystal Structure of Wild Type Phosphoserine aminotransferase (PSAT) from E. histolytica
6A2K	;	2.38	;	Crystal structure of wild type Plasmodium falciparum DHFR-TS complexed with BT1, NADPH, and dUMP
6A2M	;	2.2	;	Crystal structure of wild type Plasmodium falciparum DHFR-TS complexed with BT2, NADPH, and dUMP
6A2O	;	2.35	;	Crystal structure of wild type Plasmodium falciparum DHFR-TS complexed with BT3, NADPH, and dUMP
5AOD	;	2.4	;	Crystal structure of wild type pneumolysin.
4H2A	;	1.62	;	Crystal structure of wild type protective antigen to 1.62 A (pH 7.5)
2QJP	;	2.6	;	Crystal structure of wild type rhodobacter sphaeroides with stigmatellin and antimycin inhibited
3NUG	;	1.788	;	Crystal structure of wild type tetrameric pyridoxal 4-dehydrogenase from Mesorhizobium loti
1I0A	;	2.5	;	CRYSTAL STRUCTURE OF WILD TYPE TURKEY DELTA 1 CRYSTALLIN (EYE LENS PROTEIN)
5XCH	;	2.85	;	Crystal structure of Wild type Vps29 complexed with Zn+2 from Entamoeba histolytica
5XCE	;	1.86	;	Crystal structure of Wild type Vps29 from Entamoeba histolytica
1XAE	;	2.7	;	Crystal structure of wild type yellow fluorescent protein zFP538 from Zoanthus
6DND	;	2.1	;	Crystal structure of wild-type (WT) human Glutamate oxaloacetate transaminase 1 (GOT1)
3HPQ	;	2.0	;	Crystal structure of wild-type adenylate kinase from E. coli, in complex with Ap5A
1QRX	;	1.6	;	CRYSTAL STRUCTURE OF WILD-TYPE ALPHA-LYTIC PROTEASE AT 1.6 A, PH 5.14
8ET4	;	2.95	;	Crystal structure of wild-type arabidopsis thaliana acetohydroxyacid synthase in complex with amidosulfuron
6WJO	;	1.693	;	Crystal structure of wild-type Arginine Repressor from the pathogenic bacterium Corynebacterium pseudotuberculosis bound to tyrosine
5IR4	;	1.48	;	Crystal structure of wild-type bacterial lipoxygenase from Pseudomonas aeruginosa PA-LOX with space group C2221 at 1.48 A resolution
5IR5	;	1.9	;	Crystal structure of wild-type bacterial lipoxygenase from Pseudomonas aeruginosa PA-LOX with space group P21212 at 1.9 A resolution
1FS3	;	1.4	;	CRYSTAL STRUCTURE OF WILD-TYPE BOVINE PANCREATIC RIBONUCLEASE A
1TJR	;	2.3	;	Crystal structure of wild-type BX1 complexed with a sulfate ion
8OW3	;	2.27	;	Crystal structure of wild-type c-MET bound by compound 2
8AN8	;	2.394	;	Crystal structure of wild-type c-MET bound by compound 7.
7YIB	;	2.18	;	Crystal structure of wild-type Cap4 SAVED domain-containing receptor from Enterobacter cloacae
6EID	;	2.39	;	Crystal structure of wild-type Channelrhodopsin 2
3B8S	;	2.0	;	Crystal structure of wild-type chitinase A from Vibrio harveyi
7A1H	;	1.9	;	Crystal structure of wild-type CI2
6SD9	;	2.35	;	Crystal structure of wild-type cMET bound by foretinib
6SDE	;	2.49	;	Crystal structure of wild-type cMET bound by savolitinib
4GEK	;	1.5	;	Crystal Structure of wild-type CmoA from E.coli
3WYP	;	1.3	;	Crystal structure of wild-type core streptavidin in complex with D-biotin/biotin-D-sulfoxide at 1.3 A resolution
1OUQ	;	3.2	;	Crystal structure of wild-type Cre recombinase-loxP synapse
3D7S	;	2.8	;	Crystal structure of Wild-Type E. Coli Asparate Transcarbamoylase at pH 8.5 at 2.80 A Resolution
8E9K	;	1.83	;	Crystal structure of wild-type E. coli aspartate aminotransferase bound to maleate at 278 K
8E9P	;	2.08	;	Crystal structure of wild-type E. coli aspartate aminotransferase in the ligand-free form at 278 K
8E9T	;	2.13	;	Crystal structure of wild-type E. coli aspartate aminotransferase in the ligand-free form at 303 K
3GUH	;	2.79	;	Crystal Structure of Wild-type E.coli GS in complex with ADP and DGM
2QZS	;	2.2	;	Crystal Structure of Wild-type E.coli GS in complex with ADP and Glucose(wtGSb)
2R4T	;	2.258	;	Crystal Structure of Wild-type E.coli GS in Complex with ADP and Glucose(wtGSc)
2R4U	;	2.367	;	Crystal Structure of Wild-type E.coli GS in complex with ADP and Glucose(wtGSd)
7EXF	;	2.17	;	Crystal structure of wild-type from Arabidopsis thaliana complexed with Galactose
6BAT	;	3.4	;	Crystal Structure of Wild-Type GltPh in complex with L-aspartate
3E76	;	3.94	;	Crystal structure of Wild-type GroEL with bound Thallium ions
4XZD	;	1.7	;	Crystal Structure of Wild-type HasA from Yersinia pseudotuberculosis
1UC0	;	1.85	;	Crystal structure of wild-type hen-egg white lysozyme singly labeled with 2',3'-epoxypropyl beta-glycoside of N-acetyllactosamine
3EKY	;	1.8	;	Crystal Structure of wild-type HIV protease in complex with the inhibitor, Atazanavir
3EL1	;	1.7	;	Crystal Structure of wild-type HIV protease in complex with the inhibitor, Atazanavir
3O9G	;	1.65	;	Crystal Structure of wild-type HIV-1 Protease in complex with af53
3SA7	;	1.5	;	Crystal structure of wild-type HIV-1 protease in complex with AF55
3O9E	;	1.5	;	Crystal Structure of wild-type HIV-1 Protease in complex with af60
3O9I	;	1.45	;	Crystal Structure of wild-type HIV-1 Protease in complex with af61
3SA9	;	1.7	;	Crystal structure of Wild-type HIV-1 protease in complex With AF68
3SA5	;	1.65	;	Crystal structure of wild-type HIV-1 protease in complex with AF69
3SA6	;	1.75	;	Crystal structure of wild-type HIV-1 protease in complex with AF71
3SA4	;	1.8	;	Crystal structure of wild-type HIV-1 protease in complex with AF72
3SAA	;	1.95	;	Crystal structure of Wild-type HIV-1 protease in complex With AF77
3SAB	;	1.5	;	Crystal structure of wild-type HIV-1 protease in complex with AF78
3SAC	;	1.5	;	Crystal structure of wild-type HIV-1 protease in complex with AF80
3SA3	;	1.65	;	Crystal structure of wild-type HIV-1 protease in complex with AG23
4DQB	;	1.5	;	Crystal Structure of wild-type HIV-1 Protease in Complex with DRV
3SA8	;	1.5	;	Crystal structure of wild-type HIV-1 protease in complex with KB83
3O99	;	1.95	;	Crystal Structure of wild-type HIV-1 Protease in complex with kd13
3O9A	;	1.9	;	Crystal Structure of wild-type HIV-1 Protease in complex with kd14
3O9D	;	1.85	;	Crystal Structure of wild-type HIV-1 Protease in complex with kd19
3O9C	;	1.85	;	Crystal Structure of wild-type HIV-1 Protease in complex with kd20
3O9B	;	1.5	;	Crystal Structure of wild-type HIV-1 Protease in Complex with kd25
3O9H	;	1.7	;	Crystal Structure of wild-type HIV-1 Protease in complex with kd26
3O9F	;	1.7	;	Crystal Structure of wild-type HIV-1 Protease in complex with kd27
4DJO	;	1.78	;	Crystal Structure of wild-type HIV-1 Protease in Complex with MKP56
4DJP	;	1.4	;	Crystal Structure of wild-type HIV-1 Protease in Complex with MKP73
4DJQ	;	1.4	;	Crystal Structure of wild-type HIV-1 Protease in Complex with MKP86
4DJR	;	1.55	;	Crystal Structure of wild-type HIV-1 Protease in Complex with MKP97
3R4B	;	1.9	;	Crystal Structure of Wild-type HIV-1 Protease in Complex With TMC310911
6BZ2	;	1.67	;	Crystal structure of wild-type HIV-1 protease with a novel HIV-1 inhibitor GRL-14213A of 6-5-5-ring fused crown-like tetrahydropyranofuran as the P2-ligand, a cyclopropylaminobenzothiazole as the P2'-ligand and 3,5-difluorophenylmethyl as the P1-ligand
3ST5	;	1.45	;	Crystal structure of wild-type HIV-1 protease with C3-Substituted Hexahydrocyclopentafuranyl Urethane as P2-Ligand, GRL-0489A
4DFG	;	1.23	;	Crystal Structure of Wild-type HIV-1 Protease with Cyclopentyltetrahydro- furanyl Urethanes as P2-ligand, GRL-0249A
3OK9	;	1.27	;	Crystal structure of wild-type HIV-1 protease with new oxatricyclic designed inhibitor GRL-0519A
4KB9	;	1.29	;	Crystal structure of wild-type HIV-1 protease with novel tricyclic P2-ligands GRL-0739A
3KLF	;	3.15	;	Crystal structure of wild-type HIV-1 Reverse Transcriptase crosslinked to a DSDNA with a bound excision product, AZTPPPPA
3AJO	;	1.52	;	Crystal structure of wild-type human ferritin H chain
5SSZ	;	1.02	;	Crystal Structure of wild-type human formylglycine generating enzyme bound to Cu(I)
3S4M	;	1.3	;	Crystal structure of wild-type human frataxin
7N36	;	2.0	;	Crystal structure of wild-type human gamma(S)-crystallin
3TJB	;	2.38	;	Crystal structure of wild-type human peroxiredoxin IV
5EPC	;	1.85	;	Crystal structure of wild-type human phosphoglucomutase 1
6UIQ	;	2.3	;	Crystal structure of wild-type human phosphoglucomutase 1 in complex with Glucose-6-Phosphate
6CZK	;	2.001	;	Crystal structure of wild-type human pro-cathepsin H
5M4J	;	1.55	;	Crystal Structure of Wild-Type Human Prolidase with GlyPro ligand
5M4L	;	1.49	;	Crystal Structure of Wild-Type Human Prolidase with Mg ions and LeuPro ligand
5M4G	;	1.48	;	Crystal Structure of Wild-Type Human Prolidase with Mn ions
5M4Q	;	1.73	;	Crystal Structure of Wild-Type Human Prolidase with Mn ions and Pro ligand
3W3B	;	1.9	;	Crystal structure of wild-type human transthyretin
4IKI	;	2.0	;	Crystal structure of wild-type human transthyretin in complex with indomethacin
4IIZ	;	2.1	;	Crystal structure of wild-type human transthyretin in complex with lumiracoxib
4IKJ	;	2.1	;	Crystal structure of wild-type human transthyretin in complex with sulindac
4IKK	;	1.9	;	Crystal structure of wild-type human transthyretin in complex with sulindac
4IKL	;	1.9	;	Crystal structure of wild-type human transthyretin in complex with sulindac
6HNN	;	2.7	;	Crystal structure of wild-type IdmH, a putative polyketide cyclase from Streptomyces antibioticus
5UD7	;	2.20002	;	Crystal Structure of Wild-Type Ig-like Domain
2FNS	;	1.85	;	Crystal structure of wild-type inactive (D25N) HIV-1 protease complexed with wild-type HIV-1 NC-p1 substrate.
3OEW	;	2.2	;	Crystal structure of wild-type InhA:NADH complex
1EJX	;	1.6	;	CRYSTAL STRUCTURE OF WILD-TYPE KLEBSIELLA AEROGENES UREASE AT 100K
1EJW	;	1.9	;	CRYSTAL STRUCTURE OF WILD-TYPE KLEBSIELLA AEROGENES UREASE AT 298K
6MBU	;	1.45	;	Crystal structure of wild-type KRAS (1-169) bound to GDP and Mg (Space group P3)
6OB2	;	2.845	;	Crystal structure of wild-type KRAS (GMPPNP-bound) in complex with GAP-related domain (GRD) of neurofibromin (NF1)
6XI7	;	1.95	;	Crystal Structure of wild-type KRAS (GMPPNP-bound) in complex with RAS-binding domain (RBD) and cysteine-rich domain (CRD) of RAF1/CRAF (crystal form I)
6XHB	;	2.5	;	Crystal Structure of wild-type KRAS (GMPPNP-bound) in complex with RAS-binding domain (RBD) and cysteine-rich domain (CRD) of RAF1/CRAF (crystal form II)
6MBT	;	1.45	;	Crystal structure of wild-type KRAS bound to GDP and Mg (Space group C2)
6VJJ	;	1.4	;	Crystal Structure of wild-type KRAS4b (GMPPNP-bound) in complex with RAS-binding domain (RBD) of RAF1/CRAF
6VC8	;	2.5	;	Crystal structure of wild-type KRAS4b(1-169) in complex with GMPPNP and Mg ion
8APZ	;	1.75	;	Crystal structure of wild-type L-N-Carbamoylase from Sinorhizobium meliloti
3AUL	;	2.39	;	Crystal structure of wild-type Lys48-linked diubiquitin in an open conformation
3TPQ	;	3.45	;	Crystal structure of wild-type MAL RPEL domain in complex with five G-actins
5WGZ	;	2.041	;	Crystal Structure of Wild-type MalA', isomalbrancheamide B complex
5WGW	;	2.092	;	Crystal Structure of Wild-type MalA', malbrancheamide B complex
5WGR	;	2.362	;	Crystal Structure of Wild-type MalA', premalbrancheamide complex
5WCZ	;	1.58	;	Crystal Structure of Wild-Type MalL from Bacillus subtilis with TS analogue 1-deoxynojirimycin
8IBO	;	1.83	;	Crystal structure of Wild-Type Mycobacterium tuberculosis ClpC1 N-terminal domain in complex with Lassomycin
3X3U	;	2.09	;	Crystal structure of wild-type of E. coli CutA1
2AQ8	;	1.92	;	Crystal structure of wild-type of Enoyl-ACP(CoA) reductase from Mycobacterium tuberculosis in complex with NADH.
4YL9	;	2.353	;	Crystal Structure of wild-type of hsp14.1 from Sulfolobus solfatataricus P2
3U00	;	1.65	;	Crystal structure of wild-type onconase at 1.65 A resolution
3PHN	;	1.46	;	Crystal structure of wild-type onconase with resolution 1.46 A
5VE3	;	1.793	;	Crystal structure of wild-type persulfide dioxygenase-rhodanese fusion protein from Burkholderia phytofirmans
3QGT	;	2.3	;	Crystal structure of Wild-type PfDHFR-TS COMPLEXED WITH NADPH, dUMP AND PYRIMETHAMINE
2V5Q	;	2.3	;	CRYSTAL STRUCTURE OF WILD-TYPE PLK-1 KINASE DOMAIN IN COMPLEX WITH A SELECTIVE DARPIN
3WI4	;	3.32	;	Crystal structure of wild-type PorB from Neisseria meningitidis serogroup B
8GOT	;	1.989	;	Crystal structure of wild-type protease 3C from Seneca Valley Virus
2BUM	;	1.8	;	Crystal Structure Of Wild-Type Protocatechuate 3,4-Dioxygenase from Acinetobacter Sp. ADP1
2BUR	;	1.8	;	Crystal Structure Of Wild-Type Protocatechuate 3,4-Dioxygenase from Acinetobacter Sp. ADP1 in Complex with 4-hydroxybenzoate
2BUQ	;	1.8	;	Crystal Structure Of Wild-Type Protocatechuate 3,4-Dioxygenase from Acinetobacter Sp. ADP1 in Complex with Catechol
4C4P	;	2.0	;	Crystal Structure of Wild-Type Rab11 Complexed to FIP2
3O79	;	1.6	;	Crystal Structure of Wild-type Rabbit PrP 126-230
3TH5	;	2.3	;	Crystal structure of wild-type RAC1
5TW8	;	1.72	;	Crystal structure of wild-type S. aureus penicillin binding protein 4 (PBP4) in complex with ceftaroline
5TXI	;	1.6	;	Crystal structure of wild-type S. aureus penicillin binding protein 4 (PBP4) in complex with ceftobiprole
5TY7	;	1.894	;	Crystal structure of wild-type S. aureus penicillin binding protein 4 (PBP4) in complex with nafcillin
3ZBG	;	1.85	;	Crystal structure of wild-type SCP2 thiolase from Leishmania mexicana at 1.85 A
4BI9	;	2.45	;	Crystal structure of wild-type SCP2 thiolase from Trypanosoma brucei.
2IHE	;	2.1	;	Crystal structure of wild-type single-stranded DNA binding protein from Thermus aquaticus
4RHJ	;	1.8	;	Crystal structure of wild-type T. brucei arginase-like protein in a reduced form
3N4Y	;	2.4	;	Crystal structure of wild-type T. celer L30e in low ionic strength condition without precipitant
8IG1	;	1.451	;	Crystal structure of wild-type transthyretin in complex with rafoxanide
2WSY	;	3.05	;	CRYSTAL STRUCTURE OF WILD-TYPE TRYPTOPHAN SYNTHASE
1XC4	;	2.8	;	Crystal structure of wild-type tryptophan synthase alpha-subunits from Escherichia coli
1TJP	;	1.5	;	Crystal Structure Of Wild-Type Tryptophan Synthase Complexed With 1-[(2-hydroxylphenyl)amino]3-glycerolphosphate
1A50	;	2.3	;	CRYSTAL STRUCTURE OF WILD-TYPE TRYPTOPHAN SYNTHASE COMPLEXED WITH 5-FLUOROINDOLE PROPANOL PHOSPHATE
1A5S	;	2.3	;	CRYSTAL STRUCTURE OF WILD-TYPE TRYPTOPHAN SYNTHASE COMPLEXED WITH 5-FLUOROINDOLE PROPANOL PHOSPHATE AND L-SER BOUND AS AMINO ACRYLATE TO THE BETA SITE
1QOQ	;	1.8	;	CRYSTAL STRUCTURE OF WILD-TYPE TRYPTOPHAN SYNTHASE COMPLEXED WITH INDOLE GLYCEROL PHOSPHATE
1QOP	;	1.4	;	CRYSTAL STRUCTURE OF WILD-TYPE TRYPTOPHAN SYNTHASE COMPLEXED WITH INDOLE PROPANOL PHOSPHATE
1KFJ	;	1.8	;	CRYSTAL STRUCTURE OF WILD-TYPE TRYPTOPHAN SYNTHASE COMPLEXED WITH L-SERINE
1K3U	;	1.7	;	CRYSTAL STRUCTURE OF WILD-TYPE TRYPTOPHAN SYNTHASE COMPLEXED WITH N-[1H-INDOL-3-YL-ACETYL]ASPARTIC ACID
1K7E	;	2.3	;	CRYSTAL STRUCTURE OF WILD-TYPE TRYPTOPHAN SYNTHASE COMPLEXED WITH N-[1H-INDOL-3-YL-ACETYL]GLYCINE ACID
1K7F	;	1.9	;	CRYSTAL STRUCTURE OF WILD-TYPE TRYPTOPHAN SYNTHASE COMPLEXED WITH N-[1H-INDOL-3-YL-ACETYL]VALINE ACID
4MRQ	;	1.9	;	Crystal Structure of wild-type unphosphorylated PMM/PGM
5Y6U	;	1.5	;	Crystal structure of wild-type YabJ protein from Bacillus subtilis (natto).
4ML2	;	1.5	;	Crystal structure of wild-type YafQ
3BDG	;	1.4	;	Crystal structure of wild-type/T155V mixed dimer of E. coli alkaline phosphatase
2ZGK	;	3.0	;	Crystal structure of wildtype AAL
2HBQ	;	1.8	;	Crystal structure of wildtype human caspase-1 in complex with 3-[2-(2-benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-4-oxo-pentanoic acid (z-VAD-FMK)
2B8U	;	1.8	;	Crystal structure of wildtype human Interleukin-4
2H4P	;	1.7	;	Crystal structure of wildtype MENT in the cleaved conformation
2H4R	;	2.7	;	Crystal structure of wildtype MENT in the native conformation
7MU2	;	1.85	;	Crystal Structure of WIPI2 in complex with W2IR of ATG16L1
7F69	;	1.5	;	Crystal structure of WIPI2b in complex with ATG16L1
7XFR	;	1.76	;	Crystal structure of WIPI2b in complex with the second site of ATG16L1
1U36	;	1.89	;	Crystal structure of WLAC mutant of dimerisation domain of NF-kB p50 transcription factor
4LY3	;	1.9	;	Crystal structure of WlaRD, a sugar 3N-formyl transferase in the presence of dTPD-Qui3N, dTDP-Qui3NFo, and THF
5WDY	;	2.458	;	Crystal structure of WNK1 in complex with 1-cyclohexyl-N-({6-fluoro-1-[2-(3-methoxyphenyl)pyridin-4-yl]-1H-indol-3-yl}methyl)methanamine (compound 6)
5TF9	;	2.5	;	Crystal structure of WNK1 in complex with Mn2+AMPPNP and WNK476
5WE8	;	2.006	;	Crystal structure of WNK1 in complex with N-{(3R)-1-[(4-chlorophenyl)methyl]pyrrolidin-3-yl}-2-(3-methoxyphenyl)-N-methylquinoline-4-carboxamide (compound 8)
5DRB	;	1.65	;	Crystal structure of WNK1 in complex with WNK463
5O2C	;	2.4	;	Crystal structure of WNK3 kinase and CCT1 didomain in a unphosphorylated state
5O2B	;	2.038	;	Crystal structure of WNK3 kinase domain in a diphosphorylated state and in a complex with the inhibitor PP-121
5O26	;	2.379	;	Crystal structure of WNK3 kinase domain in a diphosphorylated state and in complex with AMP-PNP/Mg2+
5O23	;	2.25	;	Crystal structure of WNK3 kinase domain in a monophosphorylated apo state
5O1V	;	1.723	;	Crystal structure of WNK3 kinase domain in a monophosphorylated apo state (A-loop swapped)
5O21	;	2.06	;	Crystal structure of WNK3 kinase domain in a monophosphorylated state with chloride bound in the active site
7FIT	;	2.75	;	Crystal structure of Wolbachia cytoplasmic incompatibility factor CidA from wMel
7ESX	;	1.8	;	Crystal structure of Wolbachia cytoplasmic incompatibility factor CidA from wPip
3F4R	;	1.6	;	Crystal structure of Wolbachia pipientis alpha-DsbA1
3F4T	;	1.85	;	Crystal structure of Wolbachia pipientis alpha-DsbA1 C97A/C146A
3F4S	;	1.55	;	Crystal structure of Wolbachia pipientis alpha-DsbA1 T172V
4DYP	;	2.82	;	Crystal Structure of WSN/A Influenza Nucleoprotein with BMS-831780 Ligand Bound
4DYB	;	2.8	;	Crystal Structure of WSN/A Influenza Nucleoprotein with BMS-883559 Ligand Bound
4DYN	;	2.4	;	Crystal Structure of WSN/A Influenza Nucleoprotein with BMS-885838 Ligand Bound
4DYA	;	2.75	;	Crystal Structure of WSN/A Influenza Nucleoprotein with BMS-885986 Ligand Bound
4DYT	;	3.0	;	Crystal Structure of WSN/A Influenza Nucleoprotein with Three Mutations (E53D, Y289H, Y313V)
5XBN	;	1.761	;	crystal structure of Wss1 from saccharomyces cerevisiae
5XBV	;	1.804	;	Crystal structure of Wss1 mutant from saccharomyces cerevisiae
2ZUG	;	2.72	;	Crystal structure of WSSV ICP11
7YXC	;	2.25	;	Crystal structure of WT AncGR2-LBD bound to dexamethasone and SHP coregulator fragment
7YXD	;	2.3	;	Crystal structure of WT AncGR2-LBD bound to dexamethasone and SHP coregulator fragment
7YXN	;	2.46	;	Crystal structure of WT AncGR2-LBD bound to dexamethasone and SHP coregulator fragment
7YXO	;	2.99	;	Crystal structure of WT AncGR2-LBD bound to dexamethasone and SHP coregulator fragment
7YXP	;	3.36	;	Crystal structure of WT AncGR2-LBD WT bound to dexamethasone and SHP coregulator fragment
5DCG	;	2.01	;	Crystal Structure of WT Apo Human Glutathione Transferase Pi
7BKF	;	1.139	;	Crystal structure of WT BA3943, a CE4 family pseudoenzyme from Bacillus Anthracis
4R4L	;	2.245	;	Crystal structure of wt cGMP dependent protein kinase I alpha (PKGI alpha) leucine zipper
8EIN	;	2.7	;	Crystal structure of WT cyanophycin dipeptide hydrolase CphZ from Acinetobacter baylyi DSM587
5XKX	;	1.5	;	Crystal structure of WT DddY
4G0N	;	2.45	;	Crystal Structure of wt H-Ras-GppNHp bound to the RBD of Raf Kinase
2I4D	;	1.5	;	Crystal structure of WT HIV-1 protease with GS-8373
6VJW	;	2.02	;	Crystal structure of WT hMBD4 complexed with T:G mismatch DNA
4CNT	;	2.65	;	CRYSTAL STRUCTURE OF WT HUMAN CRMP-4
4CNU	;	2.8	;	CRYSTAL STRUCTURE OF WT HUMAN CRMP-4 from lattice translocation
4B90	;	2.2	;	Crystal structure of WT human CRMP-5
5DDL	;	1.98	;	Crystal Structure of WT Human Glutathione Transferase Pi soaked with a metalloid then back-soaked with glutathione
1OWG	;	2.1	;	Crystal structure of WT IHF complexed with an altered H' site (T44A)
8T71	;	1.8	;	Crystal Structure of WT KRAS4a with bound GDP and Mg ion
8T72	;	1.6	;	Crystal structure of WT KRAS4a with bound GMPPNP and Mg ion
4FA4	;	2.14	;	Crystal Structure of WT MauG in Complex with Pre-Methylamine Dehydrogenase Aged 10 Days
4FA1	;	2.18	;	Crystal Structure of WT MauG in Complex with Pre-Methylamine Dehydrogenase Aged 130 Days.
4FA5	;	1.94	;	Crystal Structure of WT MauG in Complex with Pre-Methylamine Dehydrogenase Aged 20 Days
4FA9	;	2.09	;	Crystal Structure of WT MauG in Complex with Pre-Methylamine Dehydrogenase Aged 30 Days
4FAN	;	2.08	;	Crystal Structure of WT MauG in Complex with Pre-Methylamine Dehydrogenase Aged 40 Days
4FAV	;	2.08	;	Crystal Structure of WT MauG in Complex with Pre-Methylamine Dehydrogenase Aged 50 Days
4FB1	;	2.15	;	Crystal Structure of WT MauG in Complex with Pre-Methylamine Dehydrogenase Aged 60 Days
6ZDY	;	1.45	;	Crystal structure of WT murine S100A9 bound to calcium and zinc
6KC8	;	2.9	;	Crystal structure of WT Nme1Cas9 in complex with sgRNA and target DNA (ATATGATT PAM) in post-cleavage state
8ACM	;	2.14	;	Crystal structure of WT p38alpha
8ACO	;	2.65	;	Crystal structure of WT p38alpha
7L4J	;	2.451	;	Crystal structure of WT PPM1H phosphatase
3Q8A	;	3.129	;	Crystal structure of WT Protective Antigen (pH 5.5)
3Q8B	;	2.0	;	Crystal structure of WT Protective Antigen (pH 9.0)
5IPY	;	1.5	;	Crystal structure of WT RnTmm
1EP7	;	2.1	;	CRYSTAL STRUCTURE OF WT THIOREDOXIN H FROM CHLAMYDOMONAS REINHARDTII
5YAC	;	3.3	;	Crystal structure of WT Trm5b from Pyrococcus abyssi
7JW5	;	1.526	;	Crystal structure of WT-CYP199A4 in complex with 4-phenylbenzoic acid
7ERH	;	1.55	;	Crystal structure of WT-TTR in complex with bithionol
3MC4	;	1.95	;	Crystal structure of WW/RSP5/WWP domain: bacterial transferase hexapeptide repeat: serine O-Acetyltransferase from Brucella Melitensis
4ROF	;	2.03	;	Crystal Structure of WW3 domain of ITCH in complex with TXNIP peptide
5DZD	;	1.57	;	Crystal Structure of WW4 domain of ITCH in complex with TXNIP peptide
2W8I	;	3.0	;	Crystal structure of Wza24-345.
2ZSG	;	1.65	;	Crystal structure of X-Pro aminopeptidase from Thermotoga maritima MSB8
4S2R	;	1.949	;	Crystal structure of X-prolyl aminopeptidase from Caenorhabditis elegans: a cytosolic enzyme with a di-nuclear active site
4S2T	;	2.15	;	Crystal structure of X-prolyl aminopeptidase from Caenorhabditis elegans: a cytosolic enzyme with a di-nuclear active site
6N1E	;	1.7	;	Crystal structure of X. citri phosphoglucomutase in complex with 1-methyl-glucose 6-phosphate
6MLW	;	1.9	;	Crystal structure of X. citri phosphoglucomutase in complex with 2-fluoro mannosyl-1-methyl-phosphonic acid
6MLF	;	1.75	;	Crystal structure of X. citri phosphoglucomutase in complex with 6-fluoro glucose 1-phosphate
6MNV	;	1.65	;	Crystal structure of X. citri phosphoglucomutase in complex with CH2FG1P
6MLH	;	1.65	;	Crystal structure of X. citri phosphoglucomutase in complex with GLUCOPYRANOSYL-1-METHYL-PHOSPHONIC ACID
1XOD	;	1.15	;	Crystal structure of X. tropicalis Spred1 EVH-1 domain
5UWS	;	2.401	;	Crystal Structure of X11L2 NES Peptide in complex with CRM1-Ran-RanBP1
7PHZ	;	1.66	;	Crystal structure of X77 bound to the main protease (3CLpro/Mpro) of SARS-CoV-2 in spacegroup P2(1)2(1)2(1).
5CNX	;	2.6	;	Crystal structure of Xaa-Pro aminopeptidase from Escherichia coli K12
4R60	;	1.83	;	Crystal Structure of Xaa-Pro dipeptidase from Xanthomonas campestris
5CIK	;	2.2	;	Crystal Structure of Xaa-Pro dipeptidase from Xanthomonas campestris in citrate condition
5FCF	;	1.85	;	Crystal Structure of Xaa-Pro dipeptidase from Xanthomonas campestris, phosphate and Mn bound
5FCH	;	1.95	;	Crystal Structure of Xaa-Pro dipeptidase from Xanthomonas campestris, phosphate and Zn bound
5GIU	;	1.61	;	Crystal structure of Xaa-Pro peptidase from Deinococcus radiodurans, metal-free active site
7KMM	;	1.899	;	Crystal structure of XAC1771, a novel carbohydrate acetylesterase from Xanthomonas citri
7KMN	;	1.8	;	Crystal structure of XAC1772, a GH35 xyloglucan-active beta-galactosidase from Xanthomonas citri
4W7V	;	1.43	;	Crystal structure of XacCel5A in complex with cellobiose
4W7U	;	1.48	;	Crystal structure of XacCel5A in the native form
1X1H	;	2.3	;	Crystal Structure of Xanthan Lyase (N194A)
1X1I	;	1.8	;	Crystal Structure of Xanthan Lyase (N194A) Complexed with a Product
1X1J	;	2.1	;	Crystal Structure of Xanthan Lyase (N194A) with a Substrate.
2E22	;	2.4	;	Crystal structure of xanthan lyase in complex with mannose
2W3R	;	2.9	;	Crystal Structure of Xanthine Dehydrogenase (desulfo form) from Rhodobacter capsulatus in complex with hypoxanthine
2W3S	;	2.6	;	Crystal Structure of Xanthine Dehydrogenase (desulfo form) from Rhodobacter capsulatus in Complex with Xanthine
2W55	;	3.4	;	Crystal Structure of Xanthine Dehydrogenase (E232Q variant) from Rhodobacter capsulatus in Complex with Hypoxanthine
7DQX	;	3.44	;	Crystal structure of xanthine dehydrogenase family protein
1JRO	;	2.7	;	Crystal Structure of Xanthine Dehydrogenase from Rhodobacter capsulatus
2W54	;	3.3	;	Crystal Structure of Xanthine Dehydrogenase from Rhodobacter capsulatus in Complex with Bound Inhibitor Pterin-6-aldehyde
1JRP	;	3.0	;	Crystal Structure of Xanthine Dehydrogenase inhibited by alloxanthine from Rhodobacter capsulatus
1FO4	;	2.1	;	CRYSTAL STRUCTURE OF XANTHINE DEHYDROGENASE ISOLATED FROM BOVINE MILK
1FIQ	;	2.5	;	CRYSTAL STRUCTURE OF XANTHINE OXIDASE FROM BOVINE MILK
3ETR	;	2.2	;	Crystal structure of xanthine oxidase in complex with lumazine
1Y0B	;	1.8	;	Crystal Structure of Xanthine Phosphoribosyltransferase from Bacillus subtilis.
7ELS	;	3.0	;	Crystal structure of xanthine riboswitch with 8-azaxanthine
7ELR	;	2.66	;	Crystal structure of xanthine riboswitch with xanthine
7ELP	;	2.79	;	Crystal structure of xanthine riboswitch with xanthine, iridium hexammine soak
7ELQ	;	2.6	;	Crystal structure of xanthine riboswitch with xanthine, manganese saok
6KP5	;	1.1	;	crystal structure of Xanthine-guanine phosphoribosyltransferase (XGPRT) from Yersinia pestis in P21212 space group with sulphate ions in the active site
5XTK	;	1.74	;	Crystal structure of Xanthine-guanine phosphoribosyltransferase from Yersinia pestis
3ROW	;	1.8487	;	Crystal Structure of Xanthomonas campestri OleA
5ZJ0	;	1.9	;	Crystal structure of Xanthomonas campestris FlgL (space group C2)
5ZIZ	;	2.2	;	Crystal structure of Xanthomonas campestris FlgL (space group H3)
8FA4	;	1.699	;	Crystal structure of Xanthomonas campestris GanA beta-galactosidase
8FA5	;	1.7	;	Crystal structure of Xanthomonas campestris GH35 beta-galactosidase
8FAA	;	2.5	;	Crystal structure of Xanthomonas campestris GH35 beta-galactosidase
5VXD	;	1.968	;	Crystal structure of Xanthomonas campestris OleA E117A
5VXE	;	1.66	;	Crystal structure of Xanthomonas campestris OleA E117A bound with Cerulenin
5VXH	;	1.84	;	Crystal structure of Xanthomonas campestris OleA E117D
5VXI	;	2.08	;	Crystal structure of Xanthomonas campestris OleA E117D bound with Cerulenin
5VXF	;	1.75	;	Crystal structure of Xanthomonas campestris OleA E117Q
5VXG	;	2.07	;	Crystal structure of Xanthomonas campestris OleA E117Q bound with Cerulenin
6B2R	;	1.77	;	Crystal structure of Xanthomonas campestris OleA H285A
6B2T	;	2.8	;	Crystal structure of Xanthomonas campestris OleA H285D
6B2S	;	2.0	;	Crystal structure of Xanthomonas campestris OleA H285N
6B2U	;	2.04	;	Crystal structure of Xanthomonas campestris OleA H285N with Cerulenin
8ORN	;	2.2	;	Crystal structure of Xanthomonas campestris pv. campestris LolA-LolB complex
7P46	;	1.7	;	Crystal Structure of Xanthomonas campestris Tryptophan 2,3-dioxygenase (TDO)
7DFT	;	1.8	;	Crystal structure of Xanthomonas oryzae ClpP
7DFU	;	1.901	;	Crystal structure of Xanthomonas oryzae ClpP S68Y in complex with ADEP4.
6K62	;	2.55	;	Crystal structure of Xanthomonas PcrK
7EF7	;	1.5	;	Crystal Structure of Xanthosine monophosphate phosphatase complex with XMP
7EF6	;	1.34	;	Crystal Structure of Xanthosine monophosphate phosphatase in the unliganded state
3ODG	;	1.64	;	crystal structure of xanthosine phosphorylase bound with xanthine from Yersinia pseudotuberculosis
6GY8	;	2.5	;	Crystal structure of XaxA from Xenorhabdus nematophila
6GY7	;	3.4	;	Crystal structure of XaxB from Xenorhabdus nematophil
2GU9	;	1.4	;	Crystal structure of XC5357 from Xanthomonas campestris: A putative tetracenomycin polyketide synthesis protein adopting a novel cupin subfamily structure
2FUK	;	1.6	;	Crystal structure of XC6422 from Xanthomonas campestris: a member of a/b serine hydrolase without lid at 1.6 resolution
6K4Q	;	2.7	;	Crystal structure of xCas9 in complex with sgRNA and DNA (CGG PAM)
6K4U	;	3.2	;	Crystal structure of xCas9 in complex with sgRNA and DNA (TGA PAM)
6K4S	;	3.01	;	Crystal structure of xCas9 in complex with sgRNA and DNA (TGC PAM)
6K4P	;	2.9	;	Crystal structure of xCas9 in complex with sgRNA and DNA (TGG PAM)
6AEB	;	3.004	;	Crystal structure of xCas9 in complex with sgRNA and target DNA (AAG PAM)
6AEG	;	2.701	;	Crystal structure of xCas9 in complex with sgRNA and target DNA (GAT PAM)
7VK9	;	2.9	;	Crystal structure of xCas9 P411T
7YQR	;	2.0	;	Crystal Structure of Xcc NAMPT and its complex with NAM
7YQQ	;	2.22	;	Crystal Structure of Xcc NAMPT and its complex with NMN
3S6K	;	2.8018	;	Crystal structure of xcNAGS
3VL8	;	1.9	;	Crystal structure of XEG
3VLB	;	2.7	;	Crystal structure of xeg-edgp
3VL9	;	1.2	;	Crystal structure of xeg-xyloglucan
4W87	;	2.15	;	Crystal structure of XEG5A, a GH5 xyloglucan-specific endo-beta-1,4-glucanase from metagenomic library, in complex with a xyloglucan oligosaccharide
4W89	;	2.4	;	Crystal structure of XEG5A, a GH5 xyloglucan-specific endo-beta-1,4-glucanase from metagenomic library, in complex with cellotriose
4W88	;	1.58	;	Crystal structure of XEG5A, a GH5 xyloglucan-specific endo-beta-1,4-glucanase from ruminal metagenomic library, in complex with a xyloglucan oligosaccharide and TRIS
4W85	;	1.92	;	Crystal structure of XEG5A, a GH5 xyloglucan-specific endo-beta-1,4-glucanase from ruminal metagenomic library, in complex with glucose
4W86	;	2.64	;	Crystal structure of XEG5A, a GH5 xyloglucan-specific endo-beta-1,4-glucanase from ruminal metagenomic library, in complex with glucose and TRIS
4W84	;	1.79	;	Crystal structure of XEG5A, a GH5 xyloglucan-specific endo-beta-1,4-glucanase from ruminal metagenomic library, in the native form
4W8B	;	1.15	;	Crystal structure of XEG5B, a GH5 xyloglucan-specific beta-1,4-glucanase from ruminal metagenomic library, in complex with XXLG
4W8A	;	1.72	;	Crystal structure of XEG5B, a GH5 xyloglucan-specific beta-1,4-glucanase from ruminal metagenomic library, in the native form
5CPN	;	1.8	;	Crystal structure of XenA from Pseudomonas putida in complex with an NADH mimic (mAc)
5CPO	;	1.65	;	Crystal structure of XenA from Pseudomonas putida in complex with an NADH mimic (mBu)
2UYW	;	1.7	;	Crystal structure of Xenavidin
2UZ2	;	1.7	;	Crystal structure of Xenavidin
1VGI	;	1.9	;	Crystal structure of xenon bound rat heme-heme oxygenase-1 complex
5ZC0	;	2.75	;	Crystal structure of Xenopus embryonic epidermal lectin in complex with Samarium ions
7FAD	;	3.204	;	Crystal structure of Xenopus GCP2-N terminal domain and Mzt2
6WCD	;	1.54	;	Crystal Structure of Xenopus laevis APE2 Catalytic Domain
5U6Z	;	2.6	;	Crystal Structure of Xenopus laevis Apex2 C-terminal Znf-GRF Domain
6A2B	;	2.8	;	Crystal Structure of Xenopus laevis MHC I complex
1U20	;	2.1	;	Crystal Structure of Xenopus laevis nudix hydrolase nuclear SnoRNA decapping Protein X29
3EBE	;	2.3	;	Crystal structure of xenopus laevis replication initiation factor MCM10 internal domain
3K6D	;	1.8	;	Crystal structure of Xenopus laevis T-cadherin EC1
6D35	;	3.9	;	Crystal structure of Xenopus Smoothened in complex with cholesterol
6D32	;	3.751	;	Crystal structure of Xenopus Smoothened in complex with cyclopamine
3NR6	;	1.97	;	Crystal structure of xenotropic murine leukemia virus-related virus (XMRV) protease
5HXY	;	2.5	;	Crystal structure of XerA recombinase
5JK0	;	2.1	;	Crystal structure of XerH site-specific recombinase bound to difH substrate: pre-cleavage complex
5JJV	;	2.4	;	Crystal structure of XerH site-specific recombinase bound to palindromic difH substrate: post-cleavage complex
3JXS	;	1.6	;	Crystal structure of XG34, an evolved xyloglucan binding CBM
6K01	;	2.839	;	Crystal structure of xH2A-H2B
4OXC	;	2.9	;	Crystal structure of XIAP BIR1 domain
2POI	;	1.8	;	Crystal structure of XIAP BIR1 domain (I222 form)
2QRA	;	2.5	;	Crystal structure of XIAP BIR1 domain (P21 form)
3EYL	;	3.0	;	Crystal structure of XIAP BIR3 domain in complex with a Smac-mimetic compound
3CLX	;	2.7	;	Crystal structure of XIAP BIR3 domain in complex with a Smac-mimetic compound, Smac005
3CM2	;	2.5	;	Crystal Structure of XIAP BIR3 domain in complex with a Smac-mimetic compound, Smac010
2VSL	;	2.1	;	Crystal Structure of XIAP BIR3 with a Bivalent Smac Mimetic
3HL5	;	1.8	;	Crystal structure of XIAP BIR3 with CS3
4HY0	;	2.84	;	Crystal structure of XIAP BIR3 with T3256336
4J3Y	;	1.45	;	Crystal structure of XIAP-BIR2 domain
4WVS	;	2.09	;	Crystal structure of XIAP-BIR2 domain complexed with (S)-3-(4-methoxyphenyl)-2-((S)-2-((S)-1-((S)-2-((S)-2-(methylamino)propanamido)pent-4-ynoyl)pyrrolidine-2-carboxamido)-3-phenylpropanamido)propanoic acid
4WVT	;	1.96	;	Crystal structure of XIAP-BIR2 domain complexed with ligand bound
4WVU	;	2.02	;	CRYSTAL STRUCTURE OF XIAP-BIR2 DOMAIN COMPLEXED WITH LIGAND BOUND
4J44	;	1.3	;	Crystal structure of XIAP-BIR2 domain with AIAV bound
4J48	;	2.1	;	Crystal structure of XIAP-BIR2 domain with AMRV bound
4J45	;	1.48	;	Crystal structure of XIAP-BIR2 domain with ATAA bound
4J46	;	1.42	;	Crystal structure of XIAP-BIR2 domain with AVPI bound
4J47	;	1.35	;	Crystal structure of XIAP-BIR2 domain with SVPI bound
4KJU	;	1.6	;	Crystal structure of XIAP-Bir2 with a bound benzodiazepinone inhibitor.
4KJV	;	1.7	;	Crystal structure of XIAP-Bir2 with a bound spirocyclic benzoxazepinone inhibitor.
3CM7	;	3.1	;	Crystal Structure of XIAP-BIR3 domain in complex with Smac-mimetic compuond, Smac005
3G76	;	3.0	;	Crystal structure of XIAP-BIR3 in complex with a bivalent compound
6EY2	;	2.7	;	Crystal structure of XIAP-BIR3 in complex with a cIAP1-selective SM
3EMQ	;	2.73	;	Crystal structure of xilanase XynB from Paenibacillus barcelonensis complexed with an inhibitor
5YCF	;	1.938	;	Crystal structure of Xiphophorus maculatus adenylate kinase
2NWV	;	1.85	;	Crystal structure of XisI protein-like (YP_323822.1) from Anabaena Variabilis ATCC 29413 at 1.85 A resolution
5EJ3	;	1.314	;	Crystal structure of XlnB2
1MG7	;	1.55	;	Crystal Structure of xol-1
3E6G	;	2.8	;	Crystal structure of XometC, a cystathionine c-lyase-like protein from Xanthomonas oryzae pv.oryzae
3WYG	;	2.15	;	Crystal structure of Xpo1p-PKI-Gsp1p-GTP complex
5XOJ	;	2.2	;	Crystal structure of Xpo1p-PKI-Nup42p-Gsp1p-GTP complex
3WYF	;	2.22	;	Crystal structure of Xpo1p-Yrb2p-Gsp1p-GTP complex
6JMG	;	2.701	;	Crystal structure of xRbj
3Q4F	;	5.5	;	Crystal structure of xrcc4/xlf-cernunnos complex
2Y35	;	3.2	;	Crystal structure of Xrn1-substrate complex
4EI5	;	3.1	;	Crystal Structure of XV19 TCR in complex with CD1d-sulfatide C24:1
4F0A	;	3.25	;	Crystal structure of XWnt8 in complex with the cysteine-rich domain of Frizzled 8
1YRZ	;	2.0	;	Crystal structure of xylan beta-1,4-xylosidase from Bacillus Halodurans C-125
1TA3	;	1.7	;	Crystal Structure of xylanase (GH10) in complex with inhibitor (XIP)
3NJ3	;	1.88	;	Crystal structure of xylanase 10B from Thermotoga petrophila RKU-1 in complex with xylobiose
2DEP	;	1.8	;	Crystal Structure of xylanase B from Clostridium stercorarium F9
1V6W	;	2.0	;	Crystal Structure Of Xylanase From Streptomyces Olivaceoviridis E-86 Complexed With 2(2)-4-O-methyl-alpha-D-glucuronosyl-xylobiose
1V6U	;	2.1	;	Crystal Structure Of Xylanase From Streptomyces Olivaceoviridis E-86 Complexed With 2(2)-alpha-L-arabinofuranosyl-xylobiose
1V6V	;	2.1	;	Crystal Structure Of Xylanase From Streptomyces Olivaceoviridis E-86 Complexed With 3(2)-alpha-L-arabinofuranosyl-xylotriose
1V6X	;	2.1	;	Crystal Structure Of Xylanase From Streptomyces Olivaceoviridis E-86 Complexed With 3(3)-4-O-methyl-alpha-D-glucuronosyl-xylotriose
1ISZ	;	2.0	;	Crystal structure of xylanase from Streptomyces olivaceoviridis E-86 complexed with galactose
1ISY	;	2.1	;	Crystal structure of xylanase from Streptomyces olivaceoviridis E-86 complexed with glucose
1IT0	;	2.0	;	Crystal structure of xylanase from Streptomyces olivaceoviridis E-86 complexed with lactose
1ISW	;	2.1	;	Crystal structure of xylanase from Streptomyces olivaceoviridis E-86 complexed with xylobiose
1ISV	;	2.1	;	Crystal structure of xylanase from Streptomyces olivaceoviridis E-86 complexed with xylose
1ISX	;	2.1	;	Crystal structure of xylanase from Streptomyces olivaceoviridis E-86 complexed with xylotriose
3AKP	;	1.2	;	Crystal structure of xylanase from Trichoderma longibrachiatum
3AKQ	;	0.97	;	Crystal structure of xylanase from Trichoderma longibrachiatum
3AKR	;	1.1	;	Crystal structure of xylanase from Trichoderma longibrachiatum
3AKS	;	0.97	;	Crystal structure of xylanase from Trichoderma longibrachiatum
3AKT	;	1.0	;	Crystal structure of xylanase from Trichoderma longibrachiatum
8YJJ	;	1.9	;	Crystal structure of xylanase from Trichoderma longibrachiatum
1OM0	;	1.8	;	crystal structure of xylanase inhibitor protein (XIP-I) from wheat
3EMZ	;	2.08	;	Crystal structure of xylanase XynB from Paenibacillus barcinonensis complexed with a conduramine derivative
1ZB8	;	2.4	;	Crystal structure of Xylella fastidiosa organic peroxide resistance protein
1ZB9	;	1.8	;	Crystal structure of Xylella fastidiosa organic peroxide resistance protein
3IXR	;	1.6	;	Crystal Structure of Xylella fastidiosa PrxQ C47S Mutant
7DFK	;	1.4	;	Crystal structure of xylitol-bound glucose isomerase by serial millisecond crystallography
3VXC	;	1.85	;	Crystal Structure of Xylobiose-BxlE complex from Streptomyces thermoviolaceus OPC-520
6BSW	;	2.156	;	Crystal structure of Xyloglucan Xylosyltransferase 1 ternary form
6BSV	;	2.433	;	Crystal structure of Xyloglucan Xylosyltransferase binary form
6BSU	;	1.497	;	Crystal structure of xyloglucan xylosyltransferase I
4HGX	;	2.6	;	Crystal structure of xylose isomerase domain containing protein (stm4435) from salmonella typhimurium lt2 with unknown ligand
3TVA	;	2.148	;	Crystal Structure of Xylose isomerase domain protein from Planctomyces limnophilus
4OVX	;	2.253	;	Crystal structure of Xylose isomerase domain protein from Planctomyces limnophilus DSM 3776
4XKM	;	2.1	;	Crystal structure of Xylose Isomerase from an human intestinal tract microbe Bacteroides thetaiotaomicron
5NH6	;	1.75	;	Crystal structure of xylose isomerase from Piromyces E2 Complexed with one Mg2+ ion and xylitol
5NHD	;	1.8	;	Crystal structure of xylose isomerase from Piromyces E2 in complex with 2 Ni2+ ions and xylose
5NH4	;	1.8	;	Crystal structure of xylose isomerase from Piromyces E2 in complex with one Mg2+ ions and glycerol
5NH8	;	1.86	;	Crystal structure of xylose isomerase from Piromyces E2 in complex with two Ca2+ ions and xylose
5NHE	;	1.86	;	Crystal structure of xylose isomerase from Piromyces E2 in complex with two Cd2+ ions and xylose
5NHC	;	1.93	;	Crystal structure of xylose isomerase from Piromyces E2 in complex with two Co2+ ions and xylulose
5NHB	;	2.4	;	Crystal structure of xylose isomerase from Piromyces E2 in complex with two Fe2+ ions
5NH7	;	1.9	;	Crystal structure of xylose isomerase from Piromyces E2 in complex with two Mg2+ ions and xylose
5NH9	;	2.08	;	Crystal structure of xylose isomerase from Piromyces E2 in complex with two Mn2+ ions and xylose
5YN3	;	2.7	;	Crystal structure of xylose isomerase from Piromyces sp. E2
5NHA	;	1.8	;	Crystal structure of xylose isomerase from Piromyces sp. E2 in complex with two Mn2+ ions and sorbitol
8YUD	;	2.81	;	Crystal structure of Xylose isomerase from Streptomyces avermitilis
1QT1	;	1.85	;	CRYSTAL STRUCTURE OF XYLOSE ISOMERASE FROM STREPTOMYCES DIASTATICUS NO.7 M1033 AT 1.85 A RESOLUTION
4E3V	;	1.503	;	Crystal Structure of XYLOSE ISOMERASE FROM STREPTOMYCES RUBIGINOSUS Cryoprotected in Proline
5ZCM	;	1.7	;	Crystal structure of Xylose reductase from Debaryomyces nepalensis in complex with NADP-DTT adduct
3HZ6	;	1.65	;	Crystal structure of xylulokinase from Chromobacterium violaceum
3KZB	;	2.705	;	Crystal structure of xylulokinase from Chromobacterium violaceum
8BBI	;	2.1	;	Crystal structure of Xyn11 double mutant L271S, K275H from Psedothermotoga thermarum
1F5J	;	1.8	;	CRYSTAL STRUCTURE OF XYNB, A HIGHLY THERMOSTABLE BETA-1,4-XYLANASE FROM DICTYOGLOMUS THERMOPHILUM RT46B.1, AT 1.8 A RESOLUTION
3EMC	;	2.1	;	Crystal structure of XynB, an intracellular xylanase from Paenibacillus barcinonensis
3GTN	;	2.68	;	Crystal Structure of XynC from Bacillus subtilis 168
4RUA	;	3.07	;	Crystal structure of Y-family DNA polymerase Dpo4 bypassing a MeFapy-dG adduct
4RUC	;	2.9	;	Crystal structure of Y-family DNA polymerase Dpo4 extending from a MeFapy-dG:dC pair
6SYN	;	2.63	;	Crystal structure of Y. pestis penicillin-binding protein 3
6TUD	;	3.0	;	Crystal structure of Y. pestis penicillin-binding protein 3
2Z23	;	2.0	;	Crystal structure of Y.pestis oligo peptide binding protein OppA with tri-lysine ligand
3MII	;	2.4	;	Crystal structure of Y0R391Cp/HSP33 from Saccharomyces cerevisiae
1UKT	;	2.2	;	Crystal structure of Y100L mutant cyclodextrin glucanotransferase compexed with an acarbose
7MS8	;	2.5	;	Crystal structure of Y103F mutant of Cg10062 with a covalent intermediate of the hydration of acetylenecarboxylic acid
3WIB	;	1.95	;	Crystal structure of Y109W Mutant Haloalkane Dehalogenase DatA from Agrobacterium tumefaciens C58
3IWV	;	1.68	;	Crystal structure of Y116T mutant of 5-HYDROXYISOURATE HYDROLASE (TRP)
3IWU	;	2.3	;	Crystal structure of Y116T/I16A double mutant of 5-hydroxyisourate hydrolase
3Q1E	;	1.95	;	Crystal structure of Y116T/I16A double mutant of 5-hydroxyisourate hydrolase in complex with T4
4MRX	;	1.718	;	Crystal Structure of Y138F obelin mutant from Obelia longissima at 1.72 Angstrom resolution
5XUN	;	2.0	;	Crystal structure of Y145F mutant of KacT
4AI5	;	2.22	;	Crystal structure of Y16F of 3-methyladenine DNA glycosylase I (TAG) in complex with 3-methyladenine
1JKH	;	2.5	;	CRYSTAL STRUCTURE OF Y181C MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH DMP-266(EFAVIRENZ)
1JLB	;	3.0	;	CRYSTAL STRUCTURE OF Y181C MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH NEVIRAPINE
1JLC	;	3.0	;	CRYSTAL STRUCTURE OF Y181C MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH PETT-2
1JLA	;	2.5	;	CRYSTAL STRUCTURE OF Y181C MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH TNK-651
1JLE	;	2.8	;	CRYSTAL STRUCTURE OF Y188C MUTANT HIV-1 REVERSE TRANSCRIPTASE
2OPS	;	2.3	;	Crystal Structure of Y188C Mutant HIV-1 Reverse Transcriptase in Complex with GW420867X.
1JLF	;	2.6	;	CRYSTAL STRUCTURE OF Y188C MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH NEVIRAPINE
1JLG	;	2.6	;	CRYSTAL STRUCTURE OF Y188C MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH UC-781
6W2I	;	1.45	;	Crystal Structure of Y188G Variant of the Internal UBA Domain of HHR23A
6W2G	;	1.1	;	Crystal Structure of Y188G Variant of the Internal UBA Domain of HHR23A in Monoclinic Unit Cell
3EH8	;	2.7	;	Crystal structure of Y2 I-AniI variant (F13Y/S111Y)/DNA complex with calcium
5FHR	;	1.63	;	Crystal structure of Y200L mutant of Rat Catechol-O-Methyltransferase in complex with AdoMet and 3,5-dinitrocatechol
4DC1	;	2.82	;	Crystal Structure of Y202F Actinorhodin Polyketide Ketoreductase with NADPH
8G0O	;	2.1	;	Crystal structure of Y281F mutant of Hyaluronate lyase B from Cutibacterium acnes
3TLD	;	1.896	;	Crystal Structure of Y29F mutant of Vitreoscilla hemoglobin
3NBJ	;	1.9	;	Crystal Structure of Y305F mutant of the copper amine oxidase from Hansenula polymorpha expressed in yeast
3OEF	;	1.6	;	Crystal structure of Y323F inactive mutant of p38alpha MAP kinase
5I7M	;	1.93	;	Crystal structure of Y345F mutant of human primase p58 iron-sulfur cluster domain
5DQO	;	2.3	;	Crystal structure of Y347F mutant of human primase p58 iron-sulfur cluster domain
5BSI	;	2.0	;	Crystal structure of Y36A mutant of human macrophage migration inhibitory factor
2W7D	;	1.8	;	Crystal structure of Y51FbsSHMT internal aldimine
2W7G	;	1.92	;	Crystal structure of Y51FbsSHMT L-allo-Threonine extrnal aldimine
2W7F	;	1.67	;	Crystal structure of Y51FbsSHMT L-Ser external aldimine
2W7H	;	1.67	;	Crystal structure of Y51FbsSHMT obtained in the presence of Gly and 5- Formyl Tetrahydrofolate
2W7E	;	1.69	;	Crystal structure of Y51FbsSHMT obtained in the presence of Glycine
2VMS	;	2.15	;	Crystal structure of Y60AbsSHMT crystallized in the presence of Glycine
2VMU	;	1.84	;	Crystal structure of Y60AbsSHMT crystallized in the presence of L- allo-Thr
2VMR	;	1.7	;	Crystal structure of Y60AbsSHMT internal aldimine
2VMT	;	1.72	;	Crystal structure of Y60AbsSHMT L-Ser external aldimine
2W7J	;	1.68	;	Crystal structure of Y61AbsSHMT Glycine external aldimine
2W7I	;	2.72	;	Crystal structure of Y61AbsSHMT internal aldimine
2W7L	;	2.41	;	Crystal structure of Y61AbsSHMT L-allo-Threonine external aldimine
2W7K	;	2.42	;	Crystal structure of Y61AbsSHMT L-Serine external aldimine
2W7M	;	1.86	;	Crystal structure of Y61AbsSHMT obtained in the presence of Glycine and 5-Formyl tetrahydrofolate
4Y4S	;	1.75	;	Crystal Structure of Y75A HasA dimer from Yersinia pseudotuberculosis
5EIZ	;	1.96	;	Crystal structure of Y99A mutant of human macrophage migration inhibitory factor
6OYE	;	1.53	;	Crystal structure of Y99F mutant of human macrophage migration inhibitory factor
6OY8	;	1.53	;	Crystal structure of Y99G mutant of human macrophage migration inhibitory factor
5DOL	;	2.7	;	Crystal structure of YabA amino-terminal domain from Bacillus subtilis
5GHU	;	1.63	;	Crystal structure of YadV chaperone at 1.63 Angstrom
3OKX	;	1.8	;	Crystal structure of YaeB-like protein from Rhodopseudomonas palustris
4V95	;	3.2	;	Crystal structure of YAEJ bound to the 70S ribosome
2OT9	;	1.97	;	Crystal structure of YaeQ protein from Pseudomonas syringae
3EFC	;	3.3	;	Crystal Structure of YaeT periplasmic domain
4MMJ	;	1.8	;	crystal structure of YafQ from E.coli strain BL21(DE3)
4MMG	;	1.5	;	crystal structure of YafQ mutant H87Q from E.coli
4ONV	;	2.57	;	Crystal structure of YagE, a KDG aldolase protein in complex with 2-Keto-3-deoxy gluconate
4PTN	;	1.99	;	Crystal Structure of YagE, a KDG aldolase protein in complex with Magnesium cation coordinated L-glyceraldehyde
4OE7	;	1.99	;	Crystal structure of YagE, a KDG aldolase protein, in complex with aldol condensed product of pyruvate and glyoxal
2V8Z	;	2.2	;	Crystal Structure of YagE, a prophage protein belonging to the dihydrodipicolinic acid synthase family from E. coli K12
2V9D	;	2.15	;	Crystal Structure of YagE, a prophage protein belonging to the dihydrodipicolinic acid synthase family from E. coli K12
3N2X	;	2.2	;	Crystal structure of YagE, a prophage protein belonging to the dihydrodipicolinic acid synthase family from E. coli K12 in complex with pyruvate
3NEV	;	2.19	;	Crystal structure of YagE, a prophage protein from E. coli K12 in complex with KDGal
7DE5	;	1.55	;	Crystal structure of yak lactoperoxidase at 1.55 A resolution.
6L2J	;	1.933	;	Crystal structure of yak lactoperoxidase at 1.93 A resolution.
6KY7	;	2.27	;	Crystal structure of yak lactoperoxidase at 2.27 A resolution
7C74	;	2.73	;	Crystal structure of yak lactoperoxidase using data obtained from crystals soaked in CaCl2 at 2.73 A resolution
7C73	;	2.7	;	Crystal structure of yak lactoperoxidase using data obtained from crystals soaked in MgCl2 at 2.70 A resolution
7D52	;	2.2	;	Crystal structure of yak lactoperoxidase with a disordered propionic group of heme moiety at 2.20 A resolution
6L5G	;	2.5	;	Crystal structure of yak lactoperoxidase with disordered heme moiety at 2.50 A resolution
7C75	;	2.7	;	Crystal structure of yak lactoperoxidase with partially coordinated Na ion in the distal heme cavity
1SV4	;	2.15	;	Crystal Structure of Yan-SAM
1SV0	;	2.07	;	Crystal Structure Of Yan-SAM/Mae-SAM Complex
6JK0	;	3.1	;	Crystal Structure of YAP1 and Dendrin complex
6JK1	;	2.0	;	Crystal Structure of YAP1 and Dendrin complex 2
5YTX	;	1.551	;	Crystal structure of YB1 cold-shock domain in complex with UCAACU
5YTV	;	1.7	;	Crystal structure of YB1 cold-shock domain in complex with UCAUCU
5YTT	;	1.6	;	Crystal structure of YB1 cold-shock domain in complex with UCAUGU
5YTS	;	1.77	;	Crystal structure of YB1 cold-shock domain in complex with UCUUCU
1NJK	;	1.9	;	Crystal Structure of YbaW Probable Thioesterase from Escherichia coli
3LYW	;	1.9	;	Crystal structure of YbbR family protein Dhaf_0833 from Desulfitobacterium hafniense DCB-2. Northeast Structural Genomics Consortium target id DhR29B
7CFY	;	2.4051	;	Crystal Structure of YbeA CP74 W48F
7CF7	;	1.6178	;	Crystal Structure of YbeA CP74 W72F
7CEM	;	2.4251	;	Crystal Structure of YbeA CP74 W7F
1RLM	;	1.9	;	Crystal Structure of ybiV from Escherichia coli K12
6VU7	;	2.59	;	Crystal structure of YbjN, a putative transcription regulator from E. coli
4CLC	;	2.8	;	Crystal structure of Ybr137w protein
6KTC	;	2.008	;	Crystal structure of YBX1 CSD with m5C RNA
6KUG	;	1.4	;	Crystal structure of YBX1 CSD with RNA
3V7E	;	2.8	;	Crystal structure of YbxF bound to the SAM-I riboswitch aptamer
2C6H	;	2.35	;	Crystal structure of YC-17-bound cytochrome P450 PikC (CYP107L1)
2CA0	;	2.85	;	Crystal structure of YC-17-bound cytochrome P450 PikC (CYP107L1)
2CD8	;	1.7	;	Crystal structure of YC-17-bound cytochrome P450 PikC (CYP107L1)
7XBN	;	2.0	;	Crystal Structure of YC-17-bound cytochrome P450 PikC with the unnatural amino acid p-Acetyl-L-Phenylalanine incorporated at position 238
3HPE	;	2.1	;	Crystal structure of yceI (HP1286) from Helicobacter pylori
2XBG	;	1.5	;	Crystal Structure of YCF48 from Thermosynechococcus elongatus
3HZE	;	2.0	;	Crystal Structure of Ycf54 protein from Thermosynechococcus elongatus, Northeast Structural Genomics Consortium Target TeR59
1YIX	;	1.9	;	Crystal structure of YCFH, TATD homolog from Escherichia coli K12, at 1.9 A resolution
5Y6F	;	2.3	;	Crystal structure of YcgR in complex with c-di-GMP from Escherichia coli
5Y6H	;	1.774	;	Crystal structure of YcgR-N domain of YcgR from Escherichia coli
5XHU	;	2.1	;	Crystal structure of ycgT from bacillus subtilis
1JX7	;	2.8	;	Crystal structure of ychN protein from E.coli
3OGH	;	1.65	;	Crystal structure of yciE protein from E. coli CFT073, a member of ferritine-like superfamily of diiron-containing four-helix-bundle proteins
3F1K	;	2.6	;	Crystal Structure of yciK from E. coli, an oxidoreductase, complexed with NADP+ at 2.6A resolution
5XB6	;	2.0	;	Crystal structure of YcjY from E. Coli
6U6A	;	2.45	;	Crystal structure of Yck2 from Candida albicans in complex with kinase inhibitor GW461484A
6U69	;	2.61	;	Crystal structure of Yck2 from Candida albicans, apoenzyme
2IEE	;	2.2	;	Crystal Structure of YCKB_BACSU from Bacillus subtilis. Northeast Structural Genomics Consortium target SR574.
1M3S	;	1.95	;	Crystal structure of YckF from Bacillus subtilis
4R2J	;	2.36	;	Crystal structure of YdaA (Universal Stress Protein E) from Salmonella typhimurium
3QD7	;	2.3	;	Crystal structure of YdaL, a stand-alone small MutS-related protein from Escherichia coli
2PIG	;	2.38	;	Crystal structure of ydcK from Salmonella cholerae at 2.38 A resolution. Northeast Structural Genomics target SCR6
2F9C	;	2.8	;	Crystal structure of YDCK from Salmonella cholerae. NESG target SCR6
4ES4	;	2.9	;	Crystal structure of YdiV and FlhD complex
4QYX	;	1.69	;	Crystal structure of YDR533Cp
6QK8	;	2.917	;	Crystal structure of yeast 14-3-3 protein (Bmh1) from Saccharomyces cerevisiae with the Nha1p (yeast Na+/H+ antiporter) 14-3-3 binding motif Ser481
5LVZ	;	1.95	;	Crystal structure of yeast 14-3-3 protein from Lachancea thermotolerans
4LTC	;	2.5	;	Crystal structure of yeast 20S proteasome in complex with enone carmaphycin analogue 6
4HRC	;	2.8	;	Crystal structure of yeast 20S proteasome in complex with epoxyketone carmaphycin analogue 3
3NZJ	;	2.4	;	Crystal structure of yeast 20S proteasome in complex with ligand 2a
3DY4	;	2.8	;	Crystal structure of yeast 20S proteasome in complex with spirolactacystin
3DY3	;	2.81	;	Crystal structure of yeast 20S proteasome in complex with the epimer form of spirolactacystin
4HRD	;	2.8	;	Crystal structure of yeast 20S proteasome in complex with the natural product carmaphycin A
4HNP	;	2.8	;	Crystal structure of yeast 20S proteasome in complex with vinylketone carmaphycin analogue VNK1
4K6N	;	1.9	;	Crystal structure of yeast 4-amino-4-deoxychorismate lyase
1N0H	;	2.8	;	Crystal Structure of Yeast Acetohydroxyacid Synthase in Complex with a Sulfonylurea Herbicide, Chlorimuron Ethyl
1T9B	;	2.2	;	Crystal structure of yeast acetohydroxyacid synthase in complex with a sulfonylurea herbicide, chlorsulfuron
1T9D	;	2.3	;	Crystal Structure Of Yeast Acetohydroxyacid Synthase In Complex With A Sulfonylurea Herbicide, Metsulfuron methyl
1T9C	;	2.34	;	Crystal Structure Of Yeast Acetohydroxyacid Synthase In Complex With A Sulfonylurea Herbicide, Sulfometuron methyl
1T9A	;	2.59	;	Crystal structure of yeast acetohydroxyacid synthase in complex with a sulfonylurea herbicide, tribenuron methyl
5CSK	;	3.1	;	Crystal structure of yeast acetyl-CoA carboxylase, unbiotinylated
1RY2	;	2.3	;	Crystal structure of yeast acetyl-coenzyme A synthetase in complex with AMP
3RLS	;	1.7	;	Crystal structure of yeast AF-9 homolog protein Yaf9
4OE6	;	1.951	;	Crystal Structure of Yeast ALDH4A1
4OE4	;	2.168	;	Crystal Structure of Yeast ALDH4A1 Complexed with NAD+
3MKQ	;	2.5	;	Crystal structure of yeast alpha/betaprime-COP subcomplex of the COPI vesicular coat
6U3W	;	2.394	;	Crystal structure of yeast alpha/epsilon-COP of the COPI vesicular coat
3MKR	;	2.6	;	Crystal structure of yeast alpha/epsilon-COP subcomplex of the COPI vesicular coat
1S4N	;	2.01	;	Crystal structure of yeast alpha1,2-mannosyltransferase Kre2p/Mnt1p
1S4O	;	2.01	;	Crystal structure of yeast alpha1,2-mannosyltransferase Kre2p/Mnt1p: binary complex with GDP/Mn
1S4P	;	2.01	;	Crystal structure of yeast alpha1,2-mannosyltransferase Kre2p/Mnt1p: ternary complex with GDP/Mn and methyl-alpha-mannoside acceptor
4R8F	;	2.5	;	Crystal structure of yeast aminopeptidase 1 (Ape1)
4I5T	;	2.3	;	Crystal structure of yeast Ap4A phosphorylase Apa2
4I5W	;	2.793	;	Crystal structure of yeast Ap4A phosphorylase Apa2 in complex with AMP
4I5V	;	2.696	;	Crystal structure of yeast Ap4A phosphorylase Apa2 in complex with Ap4A
1G6Q	;	2.9	;	CRYSTAL STRUCTURE OF YEAST ARGININE METHYLTRANSFERASE, HMT1
1F7V	;	2.9	;	CRYSTAL STRUCTURE OF YEAST ARGINYL-TRNA SYNTHETASE COMPLEXED WITH THE TRNAARG
1J70	;	2.3	;	CRYSTAL STRUCTURE OF YEAST ATP SULFURYLASE
5M52	;	3.4	;	Crystal structure of yeast Brr2 full-lenght in complex with Prp8 Jab1 domain
4BL0	;	1.95	;	Crystal structure of yeast Bub3-Bub1 bound to phospho-Spc105
4DS7	;	2.15	;	Crystal structure of yeast calmodulin bound to the C-terminal fragment of spindle pole body protein Spc110
6CPU	;	1.8	;	Crystal structure of yeast caPDE2
6CPT	;	1.9	;	crystal structure of yeast caPDE2 in complex with IBMX
6LBR	;	2.5	;	Crystal structure of yeast Cdc13 and ssDNA
6LBT	;	2.6	;	Crystal structure of yeast Cdc13 and Stn1
3MKS	;	2.6	;	Crystal Structure of yeast Cdc4/Skp1 in complex with an allosteric inhibitor SCF-I2
3V46	;	1.549	;	Crystal Structure of Yeast Cdc73 C-Terminal Domain
5ME9	;	2.7	;	Crystal structure of yeast Cdt1 (N terminal and middle domain), form 1.
5MEA	;	2.152	;	Crystal structure of yeast Cdt1 (N terminal and middle domain), form 2.
5MEB	;	1.8	;	Crystal structure of yeast Cdt1 C-terminal domain
5MEC	;	2.13	;	Crystal structure of yeast Cdt1 middle domain (residues 294-433)
1F18	;	1.7	;	Crystal structure of yeast copper-zinc superoxide dismutase mutant GLY85ARG
4OBX	;	2.2	;	Crystal structure of yeast Coq5 in the apo form
4OBW	;	2.4	;	crystal structure of yeast Coq5 in the SAM bound form
3TDD	;	2.7	;	Crystal structure of yeast CP in complex with Belactosin C
3M1I	;	2.0	;	Crystal structure of yeast CRM1 (Xpo1p) in complex with yeast RanBP1 (Yrb1p) and yeast RanGTP (Gsp1pGTP)
1F1G	;	1.35	;	Crystal structure of yeast cuznsod exposed to nitric oxide
1VDN	;	1.6	;	Crystal Structure Of Yeast Cyclophilin A Complexed With ACE-Ala-Ala-Pro-Ala-7-Amino-4-Methylcoumarin
1IST	;	1.9	;	Crystal structure of yeast cyclophilin A, CPR1
2CYP	;	1.7	;	Crystal structure of yeast cytochrome C peroxidase refined at 1.7-angstroms resolution
1OX7	;	1.43	;	Crystal structure of yeast cytosine deaminase apo-enzyme: inorganic zinc bound
8I3N	;	1.73	;	crystal structure of yeast cytosine deaminase mutant yCD-RQ
8I3O	;	2.0	;	crystal structure of yeast cytosine deaminase mutant yCD-RQ-1/8SAH
8I3P	;	1.3	;	crystal structure of yeast cytosine deaminase mutant yCD-RQ-1/8SAH in complex with (R)-4-hydroxy-3,4-dihydropyrimidin-2(1H)-one
4ZDE	;	2.1	;	Crystal structure of yeast D3,D2-enoyl-CoA isomerase F268A mutant
4FVM	;	2.3	;	Crystal structure of yeast DNA polymerase alpha
4FXD	;	3.0	;	Crystal structure of yeast DNA polymerase alpha bound to DNA/RNA
4FYD	;	3.1	;	Crystal structure of yeast DNA polymerase alpha bound to DNA/RNA and dGTP
3ETU	;	2.4	;	Crystal structure of yeast Dsl1p
1JEH	;	2.4	;	CRYSTAL STRUCTURE OF YEAST E3, LIPOAMIDE DEHYDROGENASE
1N0U	;	2.12	;	Crystal structure of yeast elongation factor 2 in complex with sordarin
3AI4	;	1.6	;	Crystal structure of yeast enhanced green fluorescent protein - mouse polymerase iota ubiquitin binding motif fusion protein
3AI5	;	1.4	;	Crystal structure of yeast enhanced green fluorescent protein-ubiquitin fusion protein
4ZDF	;	1.81	;	Crystal structure of yeast enoyl-CoA isomerase helix-10 deletion (ScECI2-H10) mutant
4GZC	;	1.3	;	Crystal structure of yeast Ent2 ENTH domain
4GZD	;	1.75	;	Crystal structure of yeast Ent2 ENTH domain triple mutant N112D,S114E, E118Q
5CMY	;	2.09	;	Crystal structure of yeast Ent5 N-terminal domain-native
5J08	;	1.8	;	Crystal structure of yeast Ent5 N-terminal domain-native P21
5CMW	;	2.2	;	Crystal structure of yeast Ent5 N-terminal domain-soaked in KI
3W4Y	;	2.0	;	Crystal structure of yeast Erv1 core
3TO9	;	2.0	;	Crystal structure of yeast Esa1 E338Q HAT domain bound to coenzyme A with active site lysine acetylated
3TO7	;	1.9	;	Crystal structure of yeast Esa1 HAT domain bound to coenzyme A with active site lysine acetylated
3TO6	;	2.1	;	Crystal structure of yeast Esa1 HAT domain complexed with H4K16CoA bisubstrate inhibitor
1MJA	;	2.26	;	Crystal structure of yeast Esa1 histone acetyltransferase domain complexed with acetyl coenzyme A
1FY7	;	2.0	;	CRYSTAL STRUCTURE OF YEAST ESA1 HISTONE ACETYLTRANSFERASE DOMAIN COMPLEXED WITH COENZYME A
1MJB	;	2.5	;	Crystal structure of yeast Esa1 histone acetyltransferase E338Q mutant complexed with acetyl coenzyme A
1MJ9	;	2.5	;	Crystal structure of yeast Esa1(C304S) mutant complexed with Coenzyme A
2WSI	;	1.9	;	Crystal structure of yeast FAD synthetase (Fad1) in complex with FAD
2UV8	;	3.1	;	Crystal structure of yeast fatty acid synthase with stalled acyl carrier protein at 3.1 angstrom resolution
2PQR	;	1.88	;	Crystal structure of yeast Fis1 complexed with a fragment of yeast Caf4
2PQN	;	2.15	;	Crystal structure of yeast Fis1 complexed with a fragment of yeast Mdv1
3UUX	;	3.9	;	Crystal structure of yeast Fis1 in complex with Mdv1 fragment containing N-terminal extension and coiled coil domains
3KO6	;	2.55	;	Crystal structure of yeast free methionine-R-sulfoxide reductase Ykg9 in complex with the substrate
1YCD	;	1.7	;	Crystal structure of yeast FSH1/YHR049W, a member of the serine hydrolase family
5DCA	;	2.8	;	Crystal structure of yeast full length Brr2 in complex with Prp8 Jab1 domain
5CN2	;	2.25	;	Crystal structure of yeast GGA1_GAE domain-C2221
5CN1	;	2.31	;	Crystal structure of yeast GGA1_GAE domain-P21
4KQM	;	2.77	;	Crystal structure of yeast glycogen synthase E169Q mutant in complex with glucose and UDP
4KQ1	;	2.66	;	Crystal structure of yeast glycogen synthase in complex with uridine-5'-monophosphate
1I21	;	2.4	;	CRYSTAL STRUCTURE OF YEAST GNA1
1I1D	;	1.8	;	CRYSTAL STRUCTURE OF YEAST GNA1 BOUND TO COA AND GLNAC-6P
1EX7	;	1.9	;	CRYSTAL STRUCTURE OF YEAST GUANYLATE KINASE IN COMPLEX WITH GUANOSINE-5'-MONOPHOSPHATE
1F1D	;	2.1	;	Crystal structure of yeast H46C cuznsod mutant
1F1A	;	1.8	;	Crystal structure of yeast H48Q cuznsod fals mutant analog
3B8A	;	2.95	;	Crystal structure of yeast hexokinase PI in complex with glucose
1IG8	;	2.2	;	Crystal Structure of Yeast Hexokinase PII with the correct amino acid sequence
5LSB	;	2.7	;	Crystal structure of yeast Hsh49p in complex with Cus1p binding domain.
5LSL	;	1.65	;	Crystal structure of yeast Hsh49p in complex with Cus1p binding domain.
3QFP	;	2.26	;	Crystal structure of yeast Hsp70 (Bip/Kar2) ATPase domain
3QFU	;	1.8	;	Crystal structure of Yeast Hsp70 (Bip/kar2) complexed with ADP
1CT5	;	2.0	;	CRYSTAL STRUCTURE OF YEAST HYPOTHETICAL PROTEIN YBL036C-SELENOMET CRYSTAL
5COG	;	1.613	;	Crystal structure of Yeast IRC4
3UC9	;	1.8	;	Crystal Structure of Yeast Irc6p - A Novel Type of Conserved Clathrin Accessory Protein
1EE4	;	2.1	;	CRYSTAL STRUCTURE OF YEAST KARYOPHERIN (IMPORTIN) ALPHA IN A COMPLEX WITH A C-MYC NLS PEPTIDE
1UN0	;	2.6	;	Crystal Structure of Yeast Karyopherin (Importin) alpha in complex with a Nup2p N-terminal fragment
1V59	;	2.2	;	Crystal structure of yeast lipoamide dehydrogenase complexed with NAD+
4PVC	;	2.0	;	Crystal structure of yeast methylglyoxal/ isovaleraldehyde reductase Gre2
4PVD	;	2.4	;	Crystal structure of yeast methylglyoxal/isovaleraldehyde reductase Gre2 complexed with NADPH
2HLD	;	2.8	;	Crystal structure of yeast mitochondrial F1-ATPase
3QUW	;	1.75	;	Crystal structure of yeast Mmf1
3L4N	;	1.5	;	Crystal structure of yeast monothiol glutaredoxin Grx6
5J3R	;	2.46	;	Crystal structure of yeast monothiol glutaredoxin Grx6 in complex with a glutathione-coordinated [2Fe-2S] cluster
4Y49	;	3.95	;	Crystal structure of yeast N-terminal acetyltransferase (ppGpp) NatE in complex with a bisubstrate
4XNH	;	2.1	;	Crystal structure of yeast N-terminal acetyltransferase NatE (IP6) in complex with a bisubstrate
4XPD	;	2.81	;	Crystal structure of yeast N-terminal acetyltransferase NatE (ppGpp) in complex with a bisubstrate
3AFO	;	2.0	;	Crystal Structure of Yeast NADH Kinase complexed with NADH
6O3W	;	2.1	;	Crystal structure of yeast Nrd1 CID in complex with Sen1 NIM1
6O3X	;	1.994	;	Crystal structure of yeast Nrd1 CID in complex with Sen1 NIM2
6O3Y	;	2.799	;	Crystal structure of yeast Nrd1 CID in complex with Sen1 NIM3
7PL7	;	2.6	;	Crystal structure of yeast Otu2 OTU domain
7TL2	;	1.529	;	Crystal Structure of Yeast p58C Multi-Tyrosine Mutant 5YF412
7TL3	;	2.066	;	Crystal Structure of Yeast p58C Multi-Tyrosine Mutant 5YF431
7TL4	;	1.805	;	Crystal Structure of Yeast p58C Multi-Tyrosine Mutant 6YF
2OQ2	;	2.1	;	Crystal structure of yeast PAPS reductase with PAP, a product complex
5ZUT	;	2.82	;	Crystal Structure of Yeast PCNA in Complex with N24 Peptide
6TNA	;	2.7	;	CRYSTAL STRUCTURE OF YEAST PHENYLALANINE T-RNA. I.CRYSTALLOGRAPHIC REFINEMENT
1EVV	;	2.0	;	CRYSTAL STRUCTURE OF YEAST PHENYLALANINE TRANSFER RNA AT 2.0 A RESOLUTION
4OJX	;	1.31	;	crystal structure of yeast phosphodiesterase-1 in complex with GMP
3ELS	;	1.8	;	Crystal Structure of Yeast Pml1p, Residues 51-204
4MM2	;	1.6	;	Crystal structure of yeast primase catalytic subunit
4YHR	;	2.9502	;	Crystal Structure of Yeast Proliferating Cell Nuclear Antigen
3VLD	;	2.05	;	Crystal structure of yeast proteasome interacting protein
3VLE	;	2.41	;	Crystal structure of yeast proteasome interacting protein
3VLF	;	3.8	;	Crystal structure of yeast proteasome interacting protein
2B5E	;	2.4	;	Crystal Structure of Yeast Protein Disulfide Isomerase
3BOA	;	3.7	;	Crystal structure of yeast protein disulfide isomerase.
3E9P	;	2.1	;	Crystal Structure of Yeast Prp8, Residues 1827-2092
3E9O	;	2.0	;	Crystal Structure of Yeast Prp8, Residues 1836-2092
4DZS	;	3.14	;	Crystal structure of yeast Puf4p RNA binding domain in complex with HO-4BE mutant RNA
3O06	;	2.35	;	Crystal Structure of yeast pyridoxal 5-phosphate synthase Snz1
3O07	;	1.8	;	Crystal structure of yeast pyridoxal 5-phosphate synthase Snz1 complexed with substrate G3P
3O05	;	2.2	;	Crystal Structure of Yeast Pyridoxal 5-Phosphate Synthase Snz1 Complxed with Substrate PLP
4K25	;	2.88	;	Crystal Structure of yeast Qri7 homodimer
3CPI	;	2.3	;	Crystal structure of yeast Rab-GDI
1K83	;	2.8	;	Crystal Structure of Yeast RNA Polymerase II Complexed with the Inhibitor Alpha Amanitin
4X6A	;	3.96	;	Crystal structure of yeast RNA polymerase II encountering oxidative Cyclopurine DNA lesions
2ALE	;	1.8	;	Crystal structure of yeast RNA splicing factor Snu13p
5T16	;	2.783	;	Crystal structure of yeast RNase III (Rnt1p) complexed with a non-hydrolyzable RNA substrate analog
4OOG	;	2.5	;	Crystal structure of yeast RNase III (Rnt1p) complexed with the product of dsRNA processing
3VL1	;	1.6	;	Crystal structure of yeast Rpn14
3ACP	;	2.0	;	Crystal Structure of Yeast Rpn14, a Chaperone of the 19S Regulatory Particle of the Proteasome
6J0V	;	2.314	;	Crystal Structure of Yeast Rtt107
6J0X	;	2.31	;	Crystal Structure of Yeast Rtt107 and Mms22
6J0W	;	2.4	;	Crystal Structure of Yeast Rtt107 and Nse6
6J0Y	;	1.8	;	Crystal Structure of Yeast Rtt107 and Slx4
4TU3	;	3.187	;	Crystal structure of yeast Sac1/Vps74 complex
2B7K	;	1.8	;	Crystal Structure of Yeast Sco1
2B7J	;	2.3	;	Crystal Structure of Yeast Sco1 with Copper Bound
2PM6	;	2.45	;	Crystal Structure of yeast Sec13/31 edge element of the COPII vesicular coat, native version
2PM7	;	2.35	;	Crystal structure of yeast Sec13/31 edge element of the COPII vesicular coat, selenomethionine version
2PM9	;	3.3	;	Crystal structure of yeast Sec13/31 vertex element of the COPII vesicular coat
3B7Q	;	2.03	;	Crystal Structure of Yeast Sec14 Homolog Sfh1 in Complex with Phosphatidylcholine
3B7Z	;	2.03	;	Crystal Structure of Yeast Sec14 Homolog Sfh1 in Complex with Phosphatidylcholine or Phosphatidylinositol
3B74	;	1.9	;	Crystal Structure of Yeast Sec14 Homolog Sfh1 in Complex with Phosphatidylethanolamine
3B7N	;	1.86	;	Crystal Structure of Yeast Sec14 Homolog Sfh1 in Complex with Phosphatidylinositol
6ZZZ	;	2.54	;	Crystal structure of yeast Sec62 cytoplasmic domain
1Z9Z	;	1.95	;	Crystal structure of yeast sla1 SH3 domain 3
1N9S	;	3.5	;	Crystal structure of yeast SmF in spacegroup P43212
3BIP	;	1.94	;	Crystal structure of yeast Spt16 N-terminal Domain
3BIQ	;	1.73	;	Crystal structure of yeast Spt16 N-terminal Domain
3BIT	;	1.9	;	Crystal structure of yeast Spt16 N-terminal Domain
6LBS	;	2.6	;	Crystal structure of yeast Stn1
6LBU	;	2.0	;	Crystal structure of yeast Stn1 and Ten1
1Y14	;	2.3	;	Crystal structure of yeast subcomplex of Rpb4 and Rpb7
4M6B	;	1.78	;	Crystal structure of yeast Swr1-Z domain in complex with H2A.Z-H2B dimer
1FIO	;	2.1	;	CRYSTAL STRUCTURE OF YEAST T-SNARE PROTEIN SSO1
2J49	;	2.3	;	Crystal structure of yeast TAF5 N-terminal domain
1TBP	;	2.6	;	CRYSTAL STRUCTURE OF YEAST TATA-BINDING PROTEIN AND MODEL FOR INTERACTION WITH DNA
3OIP	;	2.504	;	Crystal structure of Yeast telomere protein Cdc13 OB1
3OIQ	;	2.4	;	Crystal structure of yeast telomere protein Cdc13 OB1 and the catalytic subunit of DNA polymerase alpha Pol1
3RMH	;	1.902	;	Crystal Structure of yeast telomere protein Cdc13 OB4
4Y4L	;	2.0	;	Crystal structure of yeast Thi4-C205S
1IG0	;	1.8	;	Crystal Structure of yeast Thiamin Pyrophosphokinase
3F3R	;	1.8	;	Crystal structure of yeast Thioredoxin1-glutathione mixed disulfide complex
3TMK	;	2.0	;	CRYSTAL STRUCTURE OF YEAST THYMIDYLATE KINASE COMPLEXED WITH THE BISUBSTRATE INHIBITOR TP5A AT 2.0 A RESOLUTION: IMPLICATIONS FOR CATALYSIS AND AZT ACTIVATION
2FXT	;	3.2	;	Crystal Structure of Yeast Tim44
5IW7	;	3.6	;	Crystal structure of yeast Tsr1, a pre-40S ribosome synthesis factor
7C06	;	3.02	;	Crystal structure of yeast U2AF1 complex bound to 3' splice site RNA, 5'-UAGGU.
7C07	;	3.2	;	Crystal structure of yeast U2AF1 complex bound to 5'-AAGGU RNA.
1ZX2	;	2.1	;	Crystal Structure of Yeast UBP3-associated Protein BRE5
2PKO	;	1.8	;	Crystal structure of yeast Urm1 at 1.8 A resolution
5BW9	;	7.0	;	Crystal Structure of Yeast V1-ATPase in the Autoinhibited Form
5D80	;	6.202	;	Crystal Structure of Yeast V1-ATPase in the Autoinhibited Form
2ZIH	;	2.8	;	Crystal Structure of Yeast Vps74
2ZII	;	3.05	;	Crystal Structure of Yeast Vps74-N-term Truncation Variant
3ONJ	;	1.92	;	Crystal structure of yeast Vti1p_Habc domain
2C5Q	;	1.7	;	Crystal structure of yeast YER010Cp
1NJR	;	1.9	;	Crystal structure of yeast ymx7, an ADP-ribose-1''-monophosphatase
1TY8	;	2.1	;	Crystal structure of yeast ymx7, an ADP-ribose-1''-monophosphatase, complexed with ADP
1TXZ	;	2.05	;	Crystal structure of yeast ymx7, an ADP-ribose-1''-monophosphatase, complexed with ADP-ribose
1NKQ	;	2.2	;	Crystal structure of yeast ynq8, a fumarylacetoacetate hydrolase family protein
1JZT	;	1.94	;	Crystal structure of yeast ynu0, YNL200c
1C02	;	1.8	;	CRYSTAL STRUCTURE OF YEAST YPD1P
1W2W	;	1.75	;	Crystal structure of yeast Ypr118w, a methylthioribose-1-phosphate isomerase related to regulatory eIF2B subunits
6LS6	;	2.2	;	Crystal Structure of YEATS domain of AF9 in complex with H3K9bz peptide
6LSD	;	2.05	;	Crystal Structure of YEATS domain of human YEATS2 in complex with H3K27bz peptide
5XNV	;	2.696	;	Crystal structure of YEATS2 YEATS bound to H3K27ac peptide
5IQL	;	2.1	;	Crystal structure of YEATS2 YEATS bound to H3K27cr peptide
7EIE	;	1.67	;	Crystal structure of YEATS2 YEATS domain
2FRX	;	2.9	;	Crystal structure of YebU, a m5C RNA methyltransferase from E.coli
1IM8	;	2.2	;	Crystal structure of YecO from Haemophilus influenzae (HI0319), a methyltransferase with a bound S-adenosylhomocysteine
6KBU	;	2.1	;	Crystal structure of yedK
6KBS	;	1.601	;	Crystal structure of yedK in complex with ssDNA
6KBX	;	1.221	;	Crystal structure of yedK in complex with ssDNA containing abasic site
6KBZ	;	1.653	;	Crystal structure of yedK with ssDNA containing a tetrahydrofuran abasic site
6KCQ	;	1.701	;	Crystal structure of yedK with ssDNA containing an abasic site
6KIJ	;	1.58	;	Crystal structure of yedK with ssDNA containing an abasic site
1XVI	;	2.26	;	Crystal Structure of YedP, phosphatase-like domain protein from Escherichia coli K12
2H28	;	2.1	;	Crystal structure of YeeU from E. coli. Northeast Structural Genomics target ER304
2A6Q	;	2.05	;	Crystal structure of YefM-YoeB complex
2JGR	;	2.65	;	Crystal structure of YegS in complex with ADP
3EVA	;	1.5	;	Crystal structure of yellow fever virus methyltransferase complexed with S-adenosyl-L-homocysteine
3EVB	;	1.85	;	Crystal structure of yellow fever virus methyltransferase complexed with S-adenosyl-L-homocysteine
6URV	;	2.9	;	Crystal structure of Yellow Fever Virus NS2B-NS3 protease domain
1YKS	;	1.8	;	Crystal structure of yellow fever virus NS3 helicase
6QSN	;	3.004	;	Crystal structure of Yellow fever virus polymerase NS5A
2OGR	;	1.8	;	Crystal Structure of Yellow Fluorescent Protein from Zoanthus sp. at 1.8 A Resolution
1XA9	;	2.5	;	Crystal structure of yellow fluorescent protein zFP538 K66M green mutant
4RYV	;	1.38	;	Crystal structure of yellow lupin LLPR-10.1A protein in complex with trans-zeatin
5MXB	;	1.51	;	Crystal structure of yellow lupin LLPR-10.2B protein in complex with melatonin
5MXW	;	1.57	;	Crystal structure of yellow lupin LLPR-10.2B protein in complex with melatonin and trans-zeatin.
4Y31	;	1.32	;	Crystal structure of yellow lupine LlPR-10.1A protein in ligand-free form
5C9Y	;	1.5	;	Crystal structure of yellow lupine LlPR-10.1A protein partially saturated with trans-zeatin
3F2E	;	1.668	;	Crystal structure of Yellowstone SIRV coat protein C-terminus
4IZK	;	2.3	;	Crystal structure of yellowtail ascites virus VP4 protease active site mutant (K674A) reveals both an acyl-enzyme complex and an empty active site
4IZJ	;	2.5	;	Crystal structure of yellowtail ascites virus VP4 protease with a wild-type active site reveals acyl-enzyme complexes and product complexes.
1JD1	;	1.7	;	Crystal Structure of YEO7_yeast
3BCY	;	1.7	;	Crystal structure of YER067W
2PSB	;	2.1	;	Crystal structure of YerB protein from Bacillus subtilis. NorthEast Structural Genomics target SR586
5A0F	;	2.0	;	Crystal structure of Yersinia Afp18-modified RhoA
2FN0	;	1.85	;	Crystal structure of Yersinia enterocolitica salicylate synthase (Irp9)
8SZD	;	1.25	;	Crystal structure of Yersinia pestis dihydrofolate reductase at 1.25-A resolution
8SZE	;	2.5	;	Crystal structure of Yersinia pestis dihydrofolate reductase in complex with Trimethoprim
4FCE	;	1.955	;	Crystal structure of Yersinia pestis GlmU in complex with alpha-D-glucosamine 1-phosphate (GP1)
2QX0	;	1.8	;	Crystal Structure of Yersinia pestis HPPK (Ternary Complex)
2GFF	;	1.75	;	Crystal Structure of Yersinia pestis LsrG
6MNU	;	2.172	;	Crystal structure of Yersinia pestis UDP-glucose pyrophosphorylase
2Y2F	;	1.78	;	Crystal structure of Yersinia pestis YopH in complex with an aminooxy- containing platform compound for inhibitor design
1YPT	;	2.5	;	CRYSTAL STRUCTURE OF YERSINIA PROTEIN TYROSINE PHOSPHATASE AT 2.5 ANGSTROMS AND THE COMPLEX WITH TUNGSTATE
2I42	;	2.2	;	Crystal structure of Yersinia protein tyrosine phosphatase complexed with vanadate, a transition state analogue
1PM4	;	1.755	;	Crystal structure of Yersinia pseudotuberculosis-derived mitogen (YPM)
4PGW	;	3.6	;	Crystal structure of YetJ from Bacillus Subtilis at pH 6 by Pt-SAD
4PGS	;	2.5	;	Crystal structure of YetJ from Bacillus Subtilis at pH 6 by soaking
4PGU	;	3.401	;	Crystal structure of YetJ from Bacillus Subtilis at pH 7 by soaking
4PGR	;	1.95	;	Crystal structure of YetJ from Bacillus Subtilis at pH 8
4PGV	;	2.61	;	Crystal structure of YetJ from Bacillus Subtilis at pH 8 by back soaking
6NQ7	;	2.5	;	Crystal structure of YetJ from Bacillus Subtilis crystallized in lipidic cubic phase
6NQ8	;	3.1	;	Crystal structure of YetJ mutant from Bacillus Subtilis - D171E
6NQ9	;	3.1	;	Crystal structure of YetJ mutant from Bacillus Subtilis - D195E
2VWS	;	1.39	;	Crystal structure of YfaU, a metal ion dependent class II aldolase from Escherichia coli K12
2VWT	;	1.93	;	Crystal structure of YfaU, a metal ion dependent class II aldolase from Escherichia coli K12 - Mg-pyruvate product complex
1Q7E	;	1.6	;	Crystal Structure of YfdW protein from E. coli
2GA8	;	1.775	;	Crystal structure of YFH7 from Saccharomyces cerevisiae: a putative P-loop containing kinase with a circular permutation.
2GAA	;	1.95	;	Crystal structure of YFH7 from Saccharomyces cerevisiae: a putative P-loop containing kinase with a circular permutation.
4V8I	;	2.7	;	Crystal structure of YfiA bound to the 70S ribosome.
6IKJ	;	1.76	;	Crystal structure of YfiB(F48S)
6IKK	;	2.19	;	Crystal structure of YfiB(L43P) in complex with YfiR
6IKI	;	2.204	;	Crystal structure of YfiB(W55L)
7F3V	;	1.47	;	Crystal structure of YfiH with C107A mutation in complex with endogenous UDP-MurNAc
7W1G	;	1.86	;	Crystal structure of YfiH with C107A mutation in complex with UDP-MurNAc-L-Serine
1RKT	;	1.95	;	Crystal structure of yfiR, a putative transcriptional regulator from Bacillus subtilis
4ETM	;	1.6	;	Crystal structure of YfkJ from Bacillus subtilis
3D0W	;	2.0	;	Crystal structure of YflH protein from Bacillus subtilis. Northeast Structural Genomics Consortium target SR326
2EUC	;	2.5	;	Crystal structure of YfmB from Bacillus subtilis. NESG TARGET SR324
6IW1	;	3.1	;	Crystal structure of YFV-17D sE in postfusion state
6IW4	;	2.801	;	Crystal structure of YFV-17D sE in prefusion state
6IW5	;	2.5	;	Crystal structure of YFV-China sE in prefusion state
6VOP	;	2.65	;	Crystal structure of YgbL, a putative aldolase/epimerase/decarboxylase from Escherichia coli
6VOQ	;	2.49	;	Crystal structure of YgbL, a putative aldolase/epimerase/decarboxylase from Klebsiella pneumoniae
1X6I	;	1.2	;	Crystal structure of ygfY from Escherichia coli
1X6J	;	2.0	;	Crystal structure of ygfY from Escherichia coli
6KZW	;	2.08	;	Crystal structure of YggS family pyridoxal phosphate-dependent enzyme PipY from Fusobacterium nucleatum
7F8E	;	2.08	;	Crystal structure of YggS from Fusobacterium nucleatum
7YGF	;	2.08	;	Crystal structure of YggS from Fusobacterium nucleatum
3N6Q	;	1.8	;	Crystal structure of YghZ from E. coli
1R6Y	;	2.2	;	Crystal structure of YgiN from Escherichia coli
1TUV	;	1.7	;	Crystal structure of YgiN in complex with menadione
4UOY	;	2.305	;	Crystal structure of YgjG in complex with Pyridoxal-5'-phosphate
4UOX	;	2.085	;	Crystal structure of YgjG in complex with Pyridoxal-5'-phosphate and putrescine
8H58	;	2.639	;	Crystal structure of YhaJ effector binding domain
8H5A	;	2.803	;	Crystal structure of YhaJ effector binding domain (ligand-bound)
1OI4	;	2.03	;	Crystal Structure of yhbO from Escherichia coli
2OZZ	;	2.298	;	Crystal structure of YhfZ from Shigella flexneri
1TQ5	;	1.76	;	Crystal Structure of YhhW from Escherichia coli
1YM5	;	2.05	;	Crystal structure of YHI9, the yeast member of the phenazine biosynthesis PhzF enzyme superfamily.
3GYG	;	2.45	;	Crystal structure of yhjK (haloacid dehalogenase-like hydrolase protein) from Bacillus subtilis
2OD7	;	2.0	;	Crystal Structure of yHst2 bound to the intermediate analogue ADP-HPD, and and aceylated H4 peptide
2OD2	;	2.0	;	Crystal Structure of yHst2 I117F mutant bound to carba-NAD+ and an acetylated H4 peptide
3WO6	;	2.403	;	Crystal structure of YidC from Bacillus halodurans (form I)
3WO7	;	3.201	;	Crystal structure of YidC from Bacillus halodurans (form II)
3WVF	;	3.2	;	Crystal structure of YidC from Escherichia coli
5Y83	;	3.842	;	Crystal structure of YidC from Thermotoga maritima
5YHI	;	2.85	;	Crystal structure of YiiM from Escherichia coli
5YHH	;	2.0	;	Crystal structure of YiiM from Geobacillus stearothermophilus
6KQW	;	2.18	;	Crystal structure of Yijc from B. subtilis
6KQX	;	2.44	;	Crystal structure of Yijc from B. subtilis in complex with UDP
6UHX	;	2.75	;	Crystal structure of YIR035C short chain dehydrogenases/reductase from Saccharomyces cerevisiae
8SUU	;	2.26	;	Crystal structure of YisK from Bacillus subtilis in apo form
8SKY	;	2.4	;	Crystal structure of YisK from Bacillus subtilis in complex with oxalate
8SUT	;	1.93	;	Crystal structure of YisK from Bacillus subtilis in complex with reaction product 4-Hydroxy-2-oxoglutaric acid
2YV5	;	1.9	;	Crystal structure of Yjeq from Aquifex aeolicus
1U0L	;	2.8	;	Crystal structure of YjeQ from Thermotoga maritima
1ZZM	;	1.8	;	Crystal structure of YJJV, TATD Homolog from Escherichia coli k12, at 1.8 A resolution
6CC1	;	2.54	;	Crystal structure of ykoY-alx riboswitch chimera bound to cadmium
6CC3	;	2.698	;	Crystal structure of ykoY-mntP riboswitch chimera bound to cadmium
2QIK	;	1.35	;	Crystal structure of YkqA from Bacillus subtilis. Northeast Structural Genomics Target SR631
4EEE	;	2.71	;	Crystal Structure of YLDV 14L IL-18 Binding Protein in Complex with Human IL-18
4EKX	;	1.75	;	Crystal Structure of YLDV 14L IL-18 Binding Protein in Complex with Human IL-18
1U41	;	2.202	;	Crystal structure of YLGV mutant of dimerisation domain of NF-kB p50 transcription factor
1UQW	;	2.72	;	Crystal structure of yliB protein from escherichia coi
6T0Y	;	1.2	;	Crystal structure of YlmD from Geobacillus stearothermophilus
6T1B	;	1.2	;	Crystal structure of YlmD from Geobacillus stearothermophilus in complex with inosine
3HSB	;	2.2	;	Crystal structure of YmaH (Hfq) from Bacillus subtilis in complex with an RNA aptamer
3AHU	;	2.2	;	Crystal structure of YmaH (Hfq) from Bacillus subtilis in complex with an RNA aptamer.
4R2L	;	1.8	;	Crystal structure of YnaF (Universal Stress Protein F) from Salmonella typhimurium
3IPO	;	2.4	;	Crystal structure of YnjE
4OFL	;	2.7	;	Crystal structure of YntA from Yersinia pestis in complex with Ni(L-His)2
4OFO	;	3.0	;	Crystal structure of YntA from Yersinia pestis, unliganded form
2A6S	;	1.77	;	Crystal structure of YoeB under isopropanol condition
2A6R	;	2.05	;	Crystal structure of YoeB under PEG condition
7VM0	;	1.9	;	Crystal structure of YojK from B.subtilis in complex with UDP
8H5D	;	2.5	;	Crystal structure of YojK mutant in complex with UDP
2NYG	;	2.6	;	Crystal structure of YokD protein from Bacillus subtilis
2YDU	;	1.79	;	Crystal structure of YopH in complex with 3-(1,1-dioxido-3- oxoisothiazolidin-5-yl)benzaldeyde
3BM8	;	2.7	;	crystal structure of YopH mutant D356A complexed with irreversible inhibitor PVSN
3U96	;	1.8	;	Crystal Structure of YopHQ357F(Catalytic Domain, Residues 163-468) in complex with pNCS
1G9U	;	2.35	;	CRYSTAL STRUCTURE OF YOPM-LEUCINE RICH EFFECTOR PROTEIN FROM YERSINIA PESTIS
8BJ6	;	2.6	;	Crystal structure of YopR
8BJV	;	2.2	;	Crystal structure of YopR
8BPZ	;	2.2	;	Crystal structure of YopR
6U8T	;	2.39	;	Crystal structure of YopT domain of Pasteurella Multocida PfhB2-toxin
3KB2	;	2.2	;	Crystal Structure of YorR protein in complex with phosphorylated GDP from Bacillus subtilis, Northeast Structural Genomics Consortium Target SR256
1C03	;	2.3	;	CRYSTAL STRUCTURE OF YPD1P (TRICLINIC FORM)
4N5C	;	3.25	;	Crystal structure of Ypp1
3CPJ	;	2.35	;	Crystal structure of Ypt31 in complex with yeast Rab-GDI
5UB8	;	2.35	;	Crystal structure of YPT31, a Rab family GTPase from Candida albicans, in complex with GDP and Zn(II)
3RWO	;	1.7	;	Crystal structure of YPT32 in complex with GDP
3RWM	;	2.0	;	Crystal Structure of Ypt32 in Complex with GppNHp
4PHF	;	1.95	;	Crystal structure of Ypt7 covalently modified with GDP
4PHH	;	2.35	;	Crystal structure of Ypt7 covalently modified with GNP
4PHG	;	1.9	;	Crystal structure of Ypt7 covalently modified with GTP
3H2Y	;	1.8	;	Crystal structure of YqeH GTPase from Bacillus anthracis with dGDP bound
8WMY	;	1.91	;	Crystal structure of YqeK in complex with MG and ADP.
2GO8	;	2.3	;	Crystal structure of YQJZ_BACSU FROM Bacillus subtilis. Northeast structural genomics TARGET SR435
8T9P	;	2.04	;	Crystal Structure of YR, a heterohexamer of the 4-oxalocrotonate tautomerase (4-OT) family
5NFL	;	1.903	;	Crystal structure of YrbA from Sinorhizobium meliloti in complex with cobalt.
5NFM	;	0.8	;	Crystal structure of YrbA from Sinorhizobium meliloti in complex with copper.
5NFK	;	0.98	;	Crystal structure of YrbA from Sinorhizobium meliloti in complex with nickel.
2R8E	;	1.4	;	Crystal structure of YrbI from Escherichia coli in complex with Mg
3I6B	;	2.49	;	Crystal structure of YrbI lacking the last 8 residues, in complex with Kdo and inorganic phosphate
2R8X	;	2.6	;	Crystal structure of YrbI phosphatase from Escherichia coli
2R8Y	;	1.85	;	Crystal structure of YrbI phosphatase from Escherichia coli in a complex with Ca
2R8Z	;	2.1	;	Crystal structure of YrbI phosphatase from Escherichia coli in complex with a phosphate and a calcium ion
2Q7F	;	2.49	;	Crystal structure of YrrB: a TPR protein with an unusual peptide-binding site
3UEP	;	2.25	;	Crystal structure of YscQ-C from Yersinia pseudotuberculosis
1SVW	;	2.8	;	Crystal Structure of YsxC complexed with GMPPNP
2Q83	;	2.5	;	Crystal structure of ytaA (2635576) from Bacillus subtilis at 2.50 A resolution
4U8T	;	2.7	;	Crystal structure of YTH domain of Zygosaccharomyces rouxii MRB1 protein in complex with N6-Methyladenosine RNA
6ZD9	;	1.51	;	Crystal structure of YTHDC1 apo purified using GST tag
8Q2X	;	1.6	;	Crystal structure of YTHDC1 in complex with Compound 10 (ZA_294)
8Q2Y	;	1.71	;	Crystal structure of YTHDC1 in complex with Compound 11 (ZA_572)
8Q31	;	1.32	;	Crystal structure of YTHDC1 in complex with Compound 12 (ZA_341)
8Q32	;	1.43	;	Crystal structure of YTHDC1 in complex with Compound 13 (ZA_364)
8Q33	;	1.43	;	Crystal structure of YTHDC1 in complex with Compound 15 (ZA_343)
8Q35	;	1.31	;	Crystal structure of YTHDC1 in complex with Compound 16 (ZA_354)
8Q37	;	1.28	;	Crystal structure of YTHDC1 in complex with Compound 18 (ZA_312)
8Q38	;	1.42	;	Crystal structure of YTHDC1 in complex with Compound 19 (ZA_347)
8Q39	;	1.42	;	Crystal structure of YTHDC1 in complex with Compound 21 (ZA_515)
8Q3A	;	1.43	;	Crystal structure of YTHDC1 in complex with Compound 22 (ZA_393)
8Q3G	;	1.42	;	Crystal structure of YTHDC1 in complex with Compound 23 (ZA_385)
8Q4M	;	1.43	;	Crystal structure of YTHDC1 in complex with Compound 25 (ZA_349)
8Q4N	;	1.42	;	Crystal structure of YTHDC1 in complex with Compound 26 (ZA_513)
8Q4P	;	1.43	;	Crystal structure of YTHDC1 in complex with Compound 27 (ZA_309)
8Q4Q	;	1.4	;	Crystal structure of YTHDC1 in complex with Compound 29 (ZA_337)
8Q2Q	;	1.3	;	Crystal structure of YTHDC1 in complex with Compound 2b (YL_32)
8Q2R	;	1.6	;	Crystal structure of YTHDC1 in complex with Compound 3 (ZA_431)
8Q4R	;	1.43	;	Crystal structure of YTHDC1 in complex with Compound 30 (ZA_326)
8Q4T	;	1.51	;	Crystal structure of YTHDC1 in complex with Compound 31 (ZA_400)
8Q4U	;	1.37	;	Crystal structure of YTHDC1 in complex with Compound 36 (ZA_540b)
8Q4V	;	1.36	;	Crystal structure of YTHDC1 in complex with Compound 37 (ZA_356)
8Q2S	;	1.41	;	Crystal structure of YTHDC1 in complex with Compound 4 (ZA_232)
8Q4W	;	1.61	;	Crystal structure of YTHDC1 in complex with Compound 40 (CS_3a)
8Q2T	;	1.41	;	Crystal structure of YTHDC1 in complex with Compound 5 (ZA_236)
8Q2U	;	1.36	;	Crystal structure of YTHDC1 in complex with Compound 6 (ZA_308)
8Q2V	;	1.71	;	Crystal structure of YTHDC1 in complex with Compound 7 (ZA_560)
8Q2W	;	1.41	;	Crystal structure of YTHDC1 in complex with Compound 8 (CS_01)
6ZD3	;	1.25	;	Crystal structure of YTHDC1 M438A mutant
6ZDA	;	1.3	;	Crystal structure of YTHDC1 M438A mutant complex with m6A
6ZD4	;	1.4	;	Crystal structure of YTHDC1 S378A mutant
6ZD5	;	2.3	;	Crystal structure of YTHDC1 S378A mutant complex with m6A
6ZD8	;	1.5	;	Crystal structure of YTHDC1 T379V mutant
6ZD7	;	1.75	;	Crystal structure of YTHDC1 T379V mutant complex with m6A
6YM2	;	1.7	;	Crystal structure of YTHDC1 with compound ADO_AC_25
6YL8	;	1.5	;	Crystal structure of YTHDC1 with compound DHU_DC1_011
6YNI	;	1.36	;	Crystal structure of YTHDC1 with compound DHU_DC1_036
6YKE	;	1.52	;	Crystal structure of YTHDC1 with compound DHU_DC1_038
6YNJ	;	1.5	;	Crystal structure of YTHDC1 with compound DHU_DC1_046
6YNK	;	1.3	;	Crystal structure of YTHDC1 with compound DHU_DC1_068
6YNL	;	1.5	;	Crystal structure of YTHDC1 with compound DHU_DC1_078
6YL9	;	1.5	;	Crystal structure of YTHDC1 with compound DHU_DC1_085
6YKI	;	1.3	;	Crystal structure of YTHDC1 with compound DHU_DC1_092
6YNM	;	1.5	;	Crystal structure of YTHDC1 with compound DHU_DC1_096
6YKJ	;	1.6	;	Crystal structure of YTHDC1 with compound DHU_DC1_125
6YNN	;	1.2	;	Crystal structure of YTHDC1 with compound DHU_DC1_135
6YNO	;	1.4	;	Crystal structure of YTHDC1 with compound DHU_DC1_139
6ZCM	;	1.24	;	Crystal structure of YTHDC1 with compound DHU_DC1_180
7PJ7	;	1.41	;	Crystal structure of YTHDC1 with compound DHU_DC1_222
7PJ8	;	1.4	;	Crystal structure of YTHDC1 with compound DHU_DC1_225
7PJP	;	1.61	;	Crystal structure of YTHDC1 with compound DHU_DC1_226
7PJ9	;	1.72	;	Crystal structure of YTHDC1 with compound DHU_DC1_232
6YKZ	;	1.2	;	Crystal structure of YTHDC1 with compound DHU_DC1_234
7PJA	;	1.85	;	Crystal structure of YTHDC1 with compound PSI_DC1_002
7PJB	;	1.9	;	Crystal structure of YTHDC1 with compound PSI_DC1_004
7PJQ	;	1.2	;	Crystal structure of YTHDC1 with compound T96
6YNP	;	1.1	;	Crystal structure of YTHDC1 with compound T96C1
6YL0	;	1.2	;	Crystal structure of YTHDC1 with compound T_96
6YOQ	;	1.3	;	Crystal structure of YTHDC1 with compound VVR_DC1_002
7P87	;	1.3	;	Crystal structure of YTHDC1 with compound YLI_DC1_001
6YM8	;	1.5	;	Crystal structure of YTHDC1 with compound YLI_DC1_002
7P88	;	1.5	;	Crystal structure of YTHDC1 with compound YLI_DC1_002
7P8A	;	1.7	;	Crystal structure of YTHDC1 with compound YLI_DC1_003
7P8B	;	1.2	;	Crystal structure of YTHDC1 with compound YLI_DC1_006
7P8F	;	1.5	;	Crystal structure of YTHDC1 with compound YLI_DC1_008
6SYZ	;	2.28	;	Crystal structure of YTHDC1 with fragment 1 (DHU_DC1_141)
6SZT	;	1.5	;	Crystal structure of YTHDC1 with fragment 10 (DHU_DC1_076)
6SZX	;	1.17	;	Crystal structure of YTHDC1 with fragment 11 (DHU_DC1_128)
6SZY	;	1.79	;	Crystal structure of YTHDC1 with fragment 12 (DHU_DC1_150)
6T01	;	1.5	;	Crystal structure of YTHDC1 with fragment 13 (DHU_DC1_153)
6T0O	;	1.71	;	Crystal structure of YTHDC1 with fragment 14 (ACA_DC1_004)
6T02	;	1.1	;	Crystal structure of YTHDC1 with fragment 15 (DHU_DC1_169)
6T03	;	1.5	;	Crystal structure of YTHDC1 with fragment 16 (DHU_DC1_017)
6T04	;	1.5	;	Crystal structure of YTHDC1 with fragment 17 (DHU_DC1_042)
6T05	;	1.5	;	Crystal structure of YTHDC1 with fragment 18 (DHU_DC1_048)
6T06	;	2.4	;	Crystal structure of YTHDC1 with fragment 19 (DHU_DC1_045)
6SZ1	;	1.75	;	Crystal structure of YTHDC1 with fragment 2 (DHU_DC1_140)
6T07	;	1.5	;	Crystal structure of YTHDC1 with fragment 20 (DHU_DC1_134)
6T08	;	1.41	;	Crystal structure of YTHDC1 with fragment 21 (DHU_DC1_131)
6T0X	;	1.36	;	Crystal structure of YTHDC1 with fragment 22 (ACA_DC1_001)
6T0Z	;	1.43	;	Crystal structure of YTHDC1 with fragment 23 (ACA_DC1_005)
6T09	;	1.75	;	Crystal structure of YTHDC1 with fragment 24 (PSI_DC1_003)
6T0A	;	2.02	;	Crystal structure of YTHDC1 with fragment 25 (PSI_DC1_005)
6T0C	;	2.03	;	Crystal structure of YTHDC1 with fragment 26 (DHU_DC1_198)
6T0D	;	1.43	;	Crystal structure of YTHDC1 with fragment 27 (DHU_DC1_256)
6T10	;	1.48	;	Crystal structure of YTHDC1 with fragment 28 (DHU_DC1_176)
6T11	;	1.49	;	Crystal structure of YTHDC1 with fragment 29 (DHU_DC1_218)
6SZ2	;	1.52	;	Crystal structure of YTHDC1 with fragment 3 (DHU_DC1_149)
6T12	;	1.46	;	Crystal structure of YTHDC1 with fragment 30 (DHU_DC1_220)
6SZ3	;	1.28	;	Crystal structure of YTHDC1 with fragment 4 (DHU_DC1_158)
6SZ7	;	2.31	;	Crystal structure of YTHDC1 with fragment 5 (DHU_DC1_066)
6SZ8	;	1.47	;	Crystal structure of YTHDC1 with fragment 6 (DHU_DC1_034)
6SZL	;	1.45	;	Crystal structure of YTHDC1 with fragment 7 (DHU_DC1_021)
6SZN	;	1.47	;	Crystal structure of YTHDC1 with fragment 8 (DHU_DC1_006)
6SZR	;	1.64	;	Crystal structure of YTHDC1 with fragment 9 (DHU_DC1_107)
6ZCN	;	1.6	;	Crystal structure of YTHDC1 with m6A
4RCI	;	1.97	;	Crystal structure of YTHDF1 YTH domain
8BS4	;	2.1	;	Crystal structure of YTHDF1 YTH domain dimer
4RCJ	;	1.6	;	Crystal structure of YTHDF1 YTH domain in complex with 5mer m6A RNA
7PCU	;	2.65	;	Crystal structure of YTHDF1 YTH domain in complex with ebselen
7QKN	;	2.15	;	Crystal structure of YTHDF1 YTH domain in complex with the ebsulfur derivative compound 7
7QL7	;	2.3	;	Crystal structure of YTHDF1 YTH domain in complex with the ebsulfur derivative compound 9
7A1V	;	2.2	;	Crystal structure of YTHDF2 in complex with m1A
7BIK	;	2.1	;	Crystal structure of YTHDF2 in complex with m6Am
7YWB	;	1.92	;	Crystal structure of YTHDF2 in complex with N6-Methyladenine
7Z7B	;	1.8	;	Crystal structure of YTHDF2 with compound YLI_DC1_003
7Z7F	;	1.95	;	Crystal structure of YTHDF2 with compound YLI_DC1_005
7Z54	;	1.82	;	Crystal structure of YTHDF2 with compound YLI_DC1_006
7Z5M	;	1.7	;	Crystal structure of YTHDF2 with compound YLI_DC1_008
7R5L	;	1.7	;	Crystal structure of YTHDF2 with compound YLI_DC1_015
7Z8X	;	1.96	;	Crystal structure of YTHDF2 with compound YLI_DC1_017
7Z8W	;	1.9	;	Crystal structure of YTHDF2 with compound YLI_DC1_018
7R5F	;	2.0	;	Crystal structure of YTHDF2 with compound YLI_DF_012
7Z93	;	1.97	;	Crystal structure of YTHDF2 with compound YLI_DF_022
7Z92	;	1.91	;	Crystal structure of YTHDF2 with compound YLI_DF_024
7YX6	;	1.8	;	Crystal structure of YTHDF2 with compound YLI_DF_027
7Z4U	;	1.83	;	Crystal structure of YTHDF2 with compound YLI_DF_028
7R5W	;	1.75	;	Crystal structure of YTHDF2 with compound YLI_DF_029
7ZG4	;	2.01	;	Crystal structure of YTHDF2 with compound YLI_DF_042
7YXE	;	1.85	;	Crystal structure of YTHDF2 with compound ZA_143
7Z8P	;	1.97	;	Crystal structure of YTHDF2 with compound ZA_166
7Z26	;	1.9	;	Crystal structure of YTHDF2 YTH domain in complex with m6A RNA
8BS6	;	1.2	;	Crystal structure of YTHDF3 disulfide mutant (closed conformation)
6ZOT	;	2.7	;	Crystal structure of YTHDF3 YTH domain in complex with m6A RNA
8BS5	;	2.49	;	Crystal structure of YTHDF3 YTH domain open conformation
4DVR	;	2.5	;	Crystal structure of YU2 gp120 core in complex with Fab 48d and NBD-557
5LU9	;	2.27	;	Crystal structure of YVAD-cmk bound human legumain (AEP) in complex with compound 11
5LU8	;	1.95	;	CRYSTAL STRUCTURE OF YVAD-CMK BOUND HUMAN LEGUMAIN (AEP) IN COMPLEX WITH COMPOUND 11B
2F07	;	2.3	;	Crystal Structure of YvdT from Bacillus subtilis
3D3F	;	2.4	;	Crystal Structure of Yvgn and cofactor NADPH from Bacillus subtilis
5M43	;	1.646	;	Crystal structure of Yvh1 phosphatase domain from Chaetomium thermophilum
4U0V	;	2.051	;	Crystal structure of YvoA from Bacillus subtilis in complex with glucosamine-6-phosphate
4U0W	;	2.001	;	Crystal structure of YvoA from Bacillus subtilis in complex with N-acetylglucosamine-6-phosphate
3U49	;	1.75	;	Crystal structure of YwfH, NADPH dependent reductase involved in Bacilysin biosynthesis
3U4C	;	2.03	;	Crystal structure of YwfH, NADPH dependent reductase involved in Bacilysin biosynthesis
3U4D	;	2.7	;	Crystal structure of YwfH, NADPH dependent reductase involved in Bacilysin biosynthesis
2OP8	;	2.5	;	Crystal Structure of YwhB- Homologue of 4-Oxalocrotonate Tautomerase
1R0U	;	1.75	;	Crystal structure of ywiB protein from Bacillus subtilis
4ETI	;	1.8	;	Crystal Structure of YwlE from Bacillus subtilis
4ETN	;	1.1	;	Crystal structure of YwlE mutant from Bacillus subtilis
1Y3T	;	2.4	;	Crystal structure of YxaG, a dioxygenase from Bacillus subtilis
2ZXJ	;	1.87	;	Crystal structure of YycF DNA-binding domain from Staphylococcus aureus
6EBB	;	2.022	;	Crystal Structure of YycF homologue, crystals grown in Tris buffer
2ZWM	;	2.04	;	Crystal structure of YycF receiver domain from Bacillus subtilis
2FGT	;	2.3	;	Crystal Structure of YycH from Bacillus subtilis
5HXN	;	2.05	;	Crystal Structure of Z,Z-Farnesyl Diphosphate Synthase (D71M and E75A mutants) from the Wild Tomato Solanum habrochaites
5HXQ	;	1.95	;	Crystal Structure of Z,Z-Farnesyl Diphosphate Synthase (D71M, E75A and H103Y Mutants) Complexed with DMSPP
5HXP	;	1.95	;	Crystal Structure of Z,Z-Farnesyl Diphosphate Synthase (D71M, E75A and H103Y Mutants) Complexed with IPP
5HXT	;	2.15	;	Crystal Structure of Z,Z-Farnesyl Diphosphate Synthase (D71M, E75A and H103Y Mutants) Complexed with IPP and DMSPP
5HXO	;	2.05	;	Crystal Structure of Z,Z-Farnesyl Diphosphate Synthase with D71M, E75A and H103Y Mutants
7ATG	;	0.6	;	Crystal structure of Z-DNA in complex with putrescinium and potassium cations at ultrahigh-resolution
6AQT	;	1.05	;	Crystal Structure of Z-DNA with 6-fold Twinning_Z3A
6AQV	;	1.3	;	Crystal Structure of Z-DNA with 6-fold Twinning_Z3B
6AQW	;	1.3	;	Crystal Structure of Z-DNA with 6-fold Twinning_Z4A
6AQX	;	1.55	;	Crystal Structure of Z-DNA with 6-fold Twinning_Z4B
6BST	;	1.45	;	CRYSTAL STRUCTURE OF Z-DNA WITH UNTYPICALLY COORDINATED CA2+ ION
3PVG	;	1.5	;	Crystal structure of Z. mays CK2 alpha subunit in complex with the inhibitor 4,5,6,7-tetrabromo-1-carboxymethylbenzimidazole (K68)
1J91	;	2.22	;	Crystal structure of Z. mays CK2 kinase alpha subunit in complex with the ATP-competitive inhibitor 4,5,6,7-tetrabromobenzotriazole
3KXH	;	1.7	;	Crystal structure of Z. mays CK2 kinase alpha subunit in complex with the inhibitor (2-dymethylammino-4,5,6,7-tetrabromobenzoimidazol-1yl-acetic acid (K66)
3KXG	;	1.7	;	Crystal structure of Z. mays CK2 kinase alpha subunit in complex with the inhibitor 3,4,5,6,7-pentabromo-1H-indazole (K64)
3KXM	;	1.75	;	Crystal structure of Z. mays CK2 kinase alpha subunit in complex with the inhibitor K74
3KXN	;	2.0	;	Crystal structure of Z. mays CK2 kinase alpha subunit in complex with the inhibitor tetraiodobenzimidazole (K88)
4RLK	;	1.24	;	Crystal structure of Z. mays CK2alpha in complex with the ATP-competitive inhibitor 4-[(E)-(fluoren-9-ylidenehydrazinylidene)-methyl] benzoate
6UTA	;	3.1	;	Crystal structure of Z004 iGL Fab in complex with ZIKV EDIII
6UTE	;	2.9	;	Crystal structure of Z032 Fab in complex with WNV EDIII
6LXK	;	3.608	;	Crystal structure of Z2B3 D102R Fab in complex with influenza virus neuraminidase from A/Serbia/NS-601/2014 (H1N1)
6LXI	;	2.5	;	Crystal structure of Z2B3 Fab in complex with influenza virus neuraminidase from A/Brevig Mission/1/1918 (H1N1)
2D40	;	2.41	;	Crystal Structure of Z3393 from Escherichia coli O157:H7
6FP5	;	2.0	;	Crystal structure of ZAD-domain of CG2712 protein from D.melanogaster
7PO9	;	1.9	;	Crystal structure of ZAD-domain of M1BP protein from D.melanogaster
7POK	;	1.8	;	Crystal structure of ZAD-domain of Pita protein from D.melanogaster
7POH	;	2.85	;	Crystal structure of ZAD-domain of Serendipity-d protein from D.melanogaster
7PPP	;	2.9	;	Crystal structure of ZAD-domain of ZNF_276 protein from rabbit.
3L25	;	2.0	;	Crystal structure of Zaire Ebola VP35 interferon inhibitory domain bound to 8 bp dsRNA
3L26	;	2.4	;	Crystal structure of Zaire Ebola VP35 interferon inhibitory domain bound to 8 bp dsRNA
3L29	;	1.7	;	Crystal Structure of Zaire Ebola VP35 interferon inhibitory domain K319A/R322A mutant
3L28	;	2.4	;	Crystal structure of Zaire Ebola VP35 interferon inhibitory domain K339A mutant
3L27	;	1.95	;	Crystal structure of Zaire Ebola VP35 interferon inhibitory domain R312A mutant
5BPV	;	1.952	;	Crystal Structure of Zaire ebolavirus VP35 RNA binding domain mutant I278A
6JUT	;	2.1	;	Crystal structure of ZAK in complex with compound 6k
6JUU	;	1.903	;	Crystal structure of ZAK in complex with compound 6r
5X5O	;	1.868	;	Crystal structure of ZAK in complex with compound D2829
7YAW	;	2.1	;	Crystal structure of ZAK in complex with compound YH-180
7YAZ	;	2.54	;	Crystal structure of ZAK in complex with compound YH-186
4KMF	;	1.7	;	Crystal structure of Zalpha domain from Carassius auratus PKZ in complex with Z-DNA
3F21	;	2.2	;	Crystal structure of Zalpha in complex with d(CACGTG)
3F23	;	2.7	;	Crystal structure of Zalpha in complex with d(CGGCCG)
3F22	;	2.5	;	Crystal structure of Zalpha in complex with d(CGTACG)
7QRJ	;	1.38	;	Crystal structure of Zamilon vitis protein Zav_19
4IAG	;	1.9	;	Crystal structure of ZbmA, the zorbamycin binding protein from Streptomyces flavoviridis
6E93	;	1.747	;	Crystal Structure of ZBTB38 C-terminal Zinc Fingers 6-9 in complex with methylated DNA
6E94	;	1.594	;	Crystal Structure of ZBTB38 C-terminal Zinc Fingers 6-9 K1055R in complex with methylated DNA
8H9H	;	2.2	;	Crystal structure of ZBTB7A in complex with GACCC-containing sequence
7EYI	;	2.401	;	Crystal structure of ZBTB7A in complex with gamma-globin -200 sequence element with C-194A mutation
7NDK	;	2.34	;	Crystal structure of ZC3H12C PIN catalytic mutant
7NDH	;	1.94	;	Crystal structure of ZC3H12C PIN domain
7NDI	;	2.875	;	Crystal structure of ZC3H12C PIN domain with Mg2+ Ion
7NDJ	;	1.649	;	Crystal structure of ZC3H12C PIN-CCCH Zn Finger domain with RNA heptamer
6AVY	;	2.24	;	Crystal structure of Zea mays acyl-protein thioesterase 2
7TN5	;	2.9	;	Crystal structure of Zea mays Inositol-tetrakisphosphate Kinase 1 (ITPK1)
7TN7	;	2.25	;	Crystal structure of Zea mays Inositol-tetrakisphosphate Kinase 1 mutant (ZmITPK1 residues 18-218-Gly-Ser-Gly-Ser-Gly-248-328)
7TN3	;	2.9	;	Crystal structure of Zea mays Inositol-tetrakisphosphate Kinase 1 mutant (ZmITPK1-F189A/H192A)
7TN6	;	2.85	;	Crystal structure of Zea mays Inositol-tetrakisphosphate Kinase 1 mutant (ZmITPK1-H192A)
7TN8	;	2.6	;	Crystal structure of Zea mays Inositol-tetrakisphosphate Kinase 1 mutant (ZmITPK1-H192A) in complex with InsP6
3VO1	;	2.0	;	Crystal structure of Zea mays leaf ferredoxin-NADP+ reductase II
3VO2	;	1.39	;	Crystal structure of Zea mays leaf ferredoxin-NADP+ reductase III
4FT2	;	3.2	;	crystal structure of Zea mays ZMET2 in complex H3(1-15)K9me2 peptide and SAH
4FT4	;	2.7	;	crystal structure of Zea mays ZMET2 in complex H3(1-32)K9me2 peptide and SAH
4ORD	;	1.8	;	Crystal Structure of Zebra Fish Thioesterase Superfamily Member 2
6A6J	;	2.255	;	Crystal structure of Zebra fish Y-box protein1 (YB-1) Cold-shock domain in complex with 6mer m5C RNA
4NPL	;	1.651	;	Crystal structure of Zebrafish ALKBH5 in complex with alpha-ketoglutarate
4NPM	;	1.803	;	Crystal structure of Zebrafish ALKBH5 in complex with succinic acid
2O3C	;	2.3	;	Crystal structure of zebrafish Ape
5GPQ	;	2.1	;	Crystal Structure of zebrafish ASC CARD Domain
5GPP	;	2.0	;	Crystal structure of zebrafish ASC PYD domain
4OUS	;	1.05	;	Crystal structure of zebrafish Caprin-2 C1q domain
5Y3C	;	1.96	;	Crystal structure of zebrafish Ccd1 DIX domain
3ELZ	;	2.2	;	Crystal structure of Zebrafish Ileal Bile Acid-Bindin Protein complexed with cholic acid (crystal form A).
3EM0	;	2.2	;	Crystal structure of Zebrafish Ileal Bile Acid-Bindin Protein complexed with cholic acid (crystal form B).
4LUR	;	1.9	;	Crystal Structure of Zebrafish Interphotoreceptor Retinoid-Binding Protein (IRBP) Module 1
2QO4	;	1.5	;	Crystal structure of zebrafish liver bile acid-binding protein complexed with cholic acid
5XSZ	;	3.2	;	Crystal structure of zebrafish lysophosphatidic acid receptor LPA6
7AH2	;	2.872	;	Crystal structure of Zebrafish MDM2 RING domain homodimer
4KZG	;	2.9	;	Crystal structure of zebrafish MO25
5OTN	;	0.99	;	Crystal structure of zebrafish MTH1 in complex with O6-methyl-dGMP
5HZX	;	1.9	;	Crystal structure of zebrafish MTH1 in complex with TH588
7D87	;	2.11	;	Crystal Structure of zebrafish PHF14-PZP in complex with H3(1-25)
6CN3	;	3.351	;	Crystal structure of zebrafish Phosphatidylinositol-4-phosphate 5- kinase alpha isoform D236A
6CN2	;	3.102	;	Crystal structure of zebrafish Phosphatidylinositol-4-phosphate 5- kinase alpha isoform D236N with bound ATP/Ca2+
6CMW	;	3.15	;	Crystal structure of zebrafish Phosphatidylinositol-4-phosphate 5- kinase alpha isoform with bound ATP/Ca2+
4DTE	;	1.96	;	Crystal structure of zebrafish plasminogen activator inhibitor-1 (PAI-1)
3B98	;	2.08	;	Crystal structure of zebrafish prostacyclin synthase (cytochrome P450 8A1)
3B99	;	2.5	;	Crystal structure of zebrafish prostacyclin synthase (cytochrome P450 8A1) in complex with substrate analog U51605
5FUB	;	1.997	;	Crystal Structure of zebrafish Protein Arginine Methyltransferase 2 catalytic domain with SAH
5G02	;	2.451	;	Crystal Structure of zebrafish Protein Arginine Methyltransferase 2 with SFG
5IU9	;	3.59	;	Crystal Structure of Zebrafish Protocadherin-19 EC1-4
5CO1	;	2.51	;	Crystal Structure of Zebrafish Protocadherin-19 EC3-4
6PGW	;	3.0	;	Crystal structure of zebrafish Protocadherin-19 EC3-6
5H11	;	2.732	;	Crystal structure of Zebrafish Sec10
4PBP	;	1.648	;	crystal structure of zebrafish short-chain pentraxin protein
4PBO	;	1.701	;	Crystal structure of zebrafish short-chain pentraxin protein without calcium ions
4UUB	;	2.9	;	Crystal structure of zebrafish Sirtuin 5 in complex with 2R-butyl- succinylated CPS1-peptide
6FLG	;	2.5	;	Crystal structure of zebrafish Sirtuin 5 in complex with 3(S)-(naphthylthio)succinyl-CPS1 peptide
4UU8	;	2.9	;	Crystal structure of zebrafish Sirtuin 5 in complex with 3,3-dimethyl- succinylated CPS1-peptide
6FKY	;	2.98	;	Crystal structure of zebrafish Sirtuin 5 in complex with 3-(benzylthio)succinyl-CPS1 peptide
6FKZ	;	3.3	;	Crystal structure of zebrafish Sirtuin 5 in complex with 3-(phenylthio)succinyl-CPS1 peptide
4UU7	;	3.0	;	Crystal structure of zebrafish Sirtuin 5 in complex with 3-methyl- succinylated CPS1-peptide
4UTX	;	3.1	;	Crystal structure of zebrafish Sirtuin 5 in complex with 3-nitro- propionylated CPS1-peptide
4UTV	;	2.4	;	Crystal structure of zebrafish Sirtuin 5 in complex with 3-phenyl- succinylated CPS1-peptide
4UUA	;	2.8	;	Crystal structure of zebrafish Sirtuin 5 in complex with 3S-Z-amino- succinylated CPS1-peptide
4UTZ	;	3.3	;	Crystal structure of zebrafish Sirtuin 5 in complex with adipoylated CPS1-peptide
4UTR	;	2.9	;	Crystal structure of zebrafish Sirtuin 5 in complex with glutarylated CPS1-peptide
4UTN	;	3.0	;	Crystal structure of zebrafish Sirtuin 5 in complex with succinylated CPS1-peptide
5XDZ	;	1.7	;	Crystal structure of zebrafish SNX25 PX domain
7EXP	;	2.297	;	Crystal structure of zebrafish TRAP1 with AMPPNP and MitoQ
6MD5	;	1.7	;	Crystal structure of zebrafish Vps26A
7D86	;	1.84	;	Crystal Structure of zebrafishPHF14-PZP
7UVF	;	2.6	;	Crystal structure of ZED8 Fab complex with CD8 alpha
7XYT	;	1.5	;	Crystal structure of ZER1 bound to AFLH degron
7EP3	;	1.513	;	Crystal structure of ZER1 bound to GAGN degron
7EP4	;	2.07	;	Crystal structure of ZER1 bound to GFLH degron
7EP5	;	2.02	;	Crystal structure of ZER1 bound to GKLH degron
7XYS	;	1.7	;	Crystal structure of ZER1 bound to SFLH degron
7XYU	;	2.7	;	Crystal structure of ZER1 bound to TFLH degron
3TFZ	;	2.39	;	Crystal structure of Zhui aromatase/cyclase from Streptomcyes sp. R1128
3NAR	;	2.6	;	Crystal structure of ZHX1 HD4 (zinc-fingers and homeoboxes protein 1, homeodomain 4)
3NAU	;	2.7	;	Crystal structure of ZHX2 HD2 (zinc-fingers and homeoboxes protein 2, homeodomain 2)
7YW8	;	2.5	;	Crystal structure of zika E protein
6KK5	;	2.03	;	Crystal structure of Zika NS2B-NS3 protease with compound 15
6KK6	;	1.74	;	Crystal structure of Zika NS2B-NS3 protease with compound 16
6L50	;	1.95	;	Crystal structure of Zika NS2B-NS3 protease with compound 16
6JPW	;	1.951	;	Crystal structure of Zika NS2B-NS3 protease with compound 1C
6KK2	;	2.02	;	Crystal structure of Zika NS2B-NS3 protease with compound 2
6KK3	;	2.05	;	Crystal structure of Zika NS2B-NS3 protease with compound 4
7DOC	;	1.904	;	Crystal structure of Zika NS2B-NS3 protease with compound 5
6L4Z	;	1.9	;	Crystal structure of Zika NS2B-NS3 protease with compound 6
6KPQ	;	2.62	;	Crystal structure of Zika NS2B-NS3 protease with compound 8
6KK4	;	1.74	;	Crystal structure of Zika NS2B-NS3 protease with compound 9
7VLG	;	1.771	;	Crystal structure of Zika NS2B-NS3 protease with compound MI2201
7VLH	;	2.621	;	Crystal structure of Zika NS2B-NS3 protease with compound MI2219
7VLI	;	2.385	;	Crystal structure of Zika NS2B-NS3 protease with compound MI2220
5ZMS	;	1.8	;	Crystal structure of Zika NS3 protease in complex with 4-guanidinomethyl-phenylacetyl-Lys-Lys-Arg-H
5ZOB	;	2.0	;	Crystal structure of Zika NS3 protease with 4-guanidinomethyl-phenylacetyl-Arg-Arg-Arg-4-amidinobenzylamide
5ZMQ	;	1.987	;	Crystal structure of Zika NS3 protease with phenylacetyl-Lys-Lys-Arg-COOH inhibitor
7YW7	;	2.6	;	Crystal structure of zika virus E protein
7A3U	;	3.0	;	Crystal structure of Zika virus envelope glycoprotein in complex with the divalent F(ab')2 fragment of the broadly neutralizing human antibody EDE1 C10
7A3N	;	2.1	;	Crystal structure of Zika virus envelope glycoprotein in complex with the Fab fragment of the broadly neutralizing human antibody EDE1 C10
5JHM	;	2.0	;	Crystal structure of Zika virus Envelope protein
5JHL	;	3.0	;	Crystal structure of zika virus envelope protein in complex with a flavivirus broadly-protective antibody
5T1V	;	3.1	;	Crystal structure of Zika virus NS2B-NS3 protease in apo-form.
5LC0	;	2.7	;	Crystal structure of Zika virus NS2B-NS3 protease in complex with a boronate inhibitor
5JMT	;	1.796	;	Crystal structure of Zika virus NS3 helicase
5YOF	;	1.51	;	Crystal structure of zika virus NS3 protease in complex with a dipeptide inhibitor
5YOD	;	1.9	;	Crystal structure of zika virus NS3 protease in complex with a small molecule inhibitor
5M5B	;	2.01	;	Crystal structure of Zika virus NS5 methyltransferase
5WZ1	;	2.507	;	Crystal structure of Zika virus NS5 methyltransferase bound to S-adenosyl-L-methionine
5WZ2	;	2.6	;	Crystal structure of Zika virus NS5 methyltransferase bound to SAM and RNA analogue (m7GpppA)
5TFR	;	3.05	;	Crystal structure of Zika Virus NS5 protein
5U04	;	1.9	;	Crystal structure of Zika virus NS5 RNA-dependent RNA polymerase
5WZ3	;	1.804	;	Crystal structure of Zika virus NS5 RNA-dependent RNA polymerase(RdRP)
7U4A	;	3.15	;	Crystal Structure of Zika virus xrRNA1 mutant
5WXB	;	1.762	;	crystal structure of ZIKV MTase in complex with SAH
5K8U	;	1.601	;	Crystal structure of ZIKV NS3 helicase in complex with ADP and Mn2+
5K8I	;	1.694	;	Crystal structure of ZIKV NS3 helicase in complex with ATP and Mn2+
5K8L	;	1.751	;	Crystal structure of ZIKV NS3 helicase in complex with GTP-gammar S
5K8T	;	1.848	;	Crystal structure of ZIKV NS3 helicase in complex with GTP-gammar S and an magnesium ion
5GOZ	;	2.049	;	Crystal structure of ZIKV NS5 Methyltransferase in complex with GTP and SAH
5GP1	;	2.444	;	Crystal structure of ZIKV NS5 Methyltransferase in complex with GTP and SAH
6UX2	;	3.01	;	Crystal structure of ZIKV RdRp in complex with STAT2
6PLK	;	2.3	;	Crystal structure of ZIKV-116 Fab in complex with ZIKV envelope DIII
5XM5	;	1.493	;	Crystal structure of Zinc binding protein ZinT at 1.49 Angstrom from E. coli
6LM2	;	2.13008	;	Crystal structure of Zinc binding protein ZinT from E. coli
5YXC	;	1.763	;	Crystal structure of Zinc binding protein ZinT in complex with citrate from E. coli
7DK1	;	1.902	;	Crystal structure of Zinc bound SARS-CoV-2 main protease
7T91	;	2.05	;	Crystal structure of Zinc finger motif 1 and 2 of GLI1 DNA binding region
6S4J	;	1.5	;	Crystal structure of zinc free A14E, B25H, B29K(N(eps)-[2-(2-[2-(2-[2-(Octadecandioyl-gamma-Glu)amino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl]), desB27, desB30 human insulin
6S4I	;	1.511	;	Crystal structure of zinc free A14E, B25H, B29K(N(eps)-[2-(2-[2-(2-[2-(Octadecandioyl-gamma-Glu)amino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl]), desB30 human insulin
3ASE	;	1.75	;	Crystal Structure of Zinc myoglobin soaked with Ru3O cluster
1P26	;	2.92	;	Crystal structure of zinc(II)-d(GGCGCC)2
1ZJL	;	2.0	;	Crystal structure of zinc-bound engineered maltose binding protein
6TYJ	;	1.6	;	Crystal structure of zinc-bound Hemerythrin HHE cation binding domain-containing protein (soak): Rv2633c homolog from Mycobacterium kansasii
4NUO	;	1.75	;	Crystal structure of zinc-bound Na-ASP-2
3MZ8	;	2.7	;	Crystal Structure of Zinc-Bound Natrin From Naja atra
2EPF	;	2.3	;	Crystal Structure of Zinc-Bound Pseudecin From Pseudechis Porphyriacus
3IC1	;	2.3	;	Crystal structure of zinc-bound succinyl-diaminopimelate desuccinylase from Haemophilus influenzae
4PPZ	;	2.0	;	Crystal structure of zinc-bound succinyl-diaminopimelate desuccinylase from Neisseria meningitidis MC58
4DT3	;	1.8	;	Crystal structure of zinc-charged lysozyme
1FBX	;	2.8	;	CRYSTAL STRUCTURE OF ZINC-CONTAINING E.COLI GTP CYCLOHYDROLASE I
3BDH	;	1.85	;	Crystal structure of zinc-deficient wild-type E. coli alkaline phosphatase
3LMC	;	1.997	;	Crystal Structure of zinc-dependent peptidase from Methanocorpusculum labreanum (strain Z), Northeast Structural Genomics Consortium Target MuR16
1Y2G	;	1.9	;	Crystal STructure of ZipA in complex with an inhibitor
1S1S	;	2.1	;	Crystal Structure of ZipA in complex with indoloquinolizin 10b
1S1J	;	2.18	;	Crystal Structure of ZipA in complex with indoloquinolizin inhibitor 1
1Y2F	;	2.0	;	Crystal Structure of ZipA with an inhibitor
2CBN	;	2.9	;	Crystal structure of ZipD from Escherichia coli
5Y6C	;	2.398	;	Crystal structure of ZmASCH S128A mutant protein from Zymomonas mobilis
5Y6B	;	2.0	;	Crystal structure of ZmASCH Y47F mutant protein from Zymomonas mobilis
6LF6	;	2.044	;	Crystal structure of ZmCGTa in complex with UDP
6YAP	;	1.9	;	Crystal structure of ZmCKO4a in complex with inhibitor 1-(3-Chloro-5-trifluoromethoxy-phenyl)-3-[2-(2-hydroxy-ethyl)-phenyl]-urea
6YAO	;	2.0	;	Crystal structure of ZmCKO4a in complex with inhibitor 1-[2-(2-Hydroxy-ethyl)-phenyl]-3-(3-trifluoromethoxy-phenyl)-urea
7UBU	;	2.39	;	Crystal structure of ZMET2 in complex with hemimethylated CAG DNA and a histone H3Kc9me2 peptide
7X7L	;	1.887	;	Crystal structure of ZmHPPD-Y13161 complex
7Y01	;	2.8	;	Crystal structure of ZmMCM10 in complex with 16nt ssDNA at 2.8. Angstrom resolution
6IS9	;	1.86	;	Crystal Structure of ZmMOC1
6IS8	;	1.68	;	Crystal structure of ZmMoc1 D115N mutant in complex with Holliday junction
6JRG	;	2.005	;	Crystal structure of ZmMoc1 H253A mutant in complex with Holliday junction
6JRF	;	2.047	;	Crystal structure of ZmMoc1-Holliday junction Complex in the presence of Calcium
5SYT	;	2.0	;	Crystal Structure of ZMPSTE24
6BH8	;	3.85	;	Crystal structure of ZMPSTE24 in complex with phosphoramidon
5Y1Z	;	2.676	;	Crystal structure of ZMYND8 PHD-BROMO-PWWP tandem in complex with Drebrin ADF-H domain
5C0Q	;	2.499	;	Crystal structure of Zn bound CbsA from Thermotoga neapolitana
7W8I	;	1.943	;	Crystal structure of Zn bound human Focal Adhesion Targeting (FAT) domain of the Focal Adhesion Kinase
7W9U	;	2.163	;	Crystal Structure of Zn bound human Focal Adhesion Targeting (FAT) domain of the Focal Adhesion Kinase
7JJ9	;	1.58	;	Crystal structure of Zn(II)-bound AdcA from Streptococcus pneumoniae
4IXN	;	2.05	;	Crystal Structure of Zn(II)-bound E37A,C66A,C67A triple mutant YjiA GTPase
4IXM	;	2.57	;	Crystal structure of Zn(II)-bound YjiA GTPase from E. coli
7JJB	;	1.1	;	Crystal structure of Zn(II)-bound ZinT-like domain of Streptococcus pneumoniae AdcA
1K0F	;	2.5	;	Crystal structure of Zn(II)-free T. pallidum TroA
5U2O	;	1.46	;	Crystal structure of Zn-binding triple mutant of GH family 9 endoglucanase J30
5C22	;	2.302	;	Crystal structure of Zn-bound HlyD from E. coli
5CMQ	;	1.935	;	Crystal Structure of Zn-bound Human H-Ferritin variant 122H-delta C-star
5UP9	;	2.45	;	Crystal Structure of Zn-bound Human Heavy-Chain ferritin variant 122H-delta C-star with para-xylenedihydroxamate
2G54	;	2.25	;	Crystal structure of Zn-bound human insulin-degrading enzyme in complex with insulin B chain
2Z45	;	2.15	;	Crystal Structure of Zn-bound ORF134
7DNR	;	1.7	;	Crystal Structure of Zn-bound SIS Domain of Glucosamine-6-P Synthase from E. coli
5G6T	;	2.15	;	Crystal structure of Zn-containing NagZ H174A mutant from Pseudomonas aeruginosa
3BE7	;	2.3	;	Crystal structure of Zn-dependent arginine carboxypeptidase
3DUG	;	2.62	;	Crystal structure of zn-dependent arginine carboxypeptidase complexed with zinc
5NL4	;	1.32	;	Crystal structure of Zn1.3-E16V human ubiquitin (hUb) mutant adduct, from a solution 35 mM zinc acetate/1.3 mM E16V hUb
5NL5	;	1.96	;	Crystal structure of Zn1.7-E16V human ubiquitin (hUb) mutant adduct, from a solution 70 mM zinc acetate/1.3 mM E16V hUb
1EWC	;	1.95	;	CRYSTAL STRUCTURE OF ZN2+ LOADED STAPHYLOCOCCAL ENTEROTOXIN H
1I4H	;	2.9	;	Crystal structure of Zn2+ soaked Staphylococcal enterotoxin A mutant H187A
2ZN8	;	2.7	;	Crystal structure of Zn2+-bound form of ALG-2
3AAK	;	2.7	;	Crystal structure of Zn2+-bound form of des3-20ALG-2F122A
2ZRT	;	3.3	;	Crystal structure of Zn2+-bound form of des3-23ALG-2
2ZNE	;	2.2	;	Crystal structure of Zn2+-bound form of des3-23ALG-2 complexed with Alix ABS peptide
7Z6M	;	2.51	;	Crystal structure of Zn2+-transporter BbZIP in a cadmium bound state
7Z6N	;	2.57	;	Crystal structure of Zn2+-transporter BbZIP in a metal-stripped state
5NLI	;	1.53	;	Crystal structure of Zn2-E16V human ubiquitin (hUb) mutant adduct, from a solution 35 mM zinc acetate/10% v/v TFE/1.3 mM E16V hUb
4K7S	;	1.76	;	Crystal structure of Zn2-hUb (human ubiquitin) adduct from a solution 35 mM zinc acetate/1.3 mM hUb
4K7U	;	1.76	;	Crystal structure of Zn2.3-hUb (human ubiquitin) adduct from a solution 70 mM zinc acetate/1.3 mM hUb
5NLF	;	1.5	;	Crystal structure of Zn2.7-E16V human ubiquitin (hUb) mutant adduct, from a solution 100 mM zinc acetate/1.3 mM E16V hUb
5NLJ	;	1.53	;	Crystal structure of Zn3-E16V human ubiquitin (hUb) mutant adduct, from a solution 70 mM zinc acetate/20% v/v TFE/1.3 mM E16V hUb
4K7W	;	1.76	;	Crystal structure of Zn3-hUb(human ubiquitin) adduct from a solution 100 mM zinc acetate/1.3 mM hUb
5NMC	;	1.7	;	Crystal structure of Zn3-hUb(human ubiquitin) adduct from a solution 70 mM zinc acetate/20% v/v TFE/1.3 mM hUb
3LNN	;	2.796	;	Crystal structure of ZneB from Cupriavidus metallidurans
3UK3	;	2.1	;	Crystal structure of ZNF217 bound to DNA
4IS1	;	2.1	;	Crystal structure of ZNF217 bound to DNA
4F2J	;	2.64	;	Crystal structure of ZNF217 bound to DNA, P6522 crystal form
7YSF	;	2.4	;	Crystal structure of ZNF524 ZF1-4 in complex with telomeric DNA
3CK6	;	1.9	;	Crystal structure of ZntB cytoplasmic domain from Vibrio parahaemolyticus RIMD 2210633
1PQ4	;	1.9	;	Crystal structure of ZnuA
7RCJ	;	3.15	;	Crystal structure of ZnuA from Citrobacter koseri
2OSV	;	1.75	;	Crystal Structure of ZnuA from E. coli
2H3M	;	2.9	;	Crystal Structure of ZO-1 PDZ1
2H2C	;	2.0	;	Crystal Structure of ZO-1 PDZ1 Bound to a Phage-Derived Ligand (WRRTTWV)
2H2B	;	1.6	;	Crystal Structure of ZO-1 PDZ1 Bound to a Phage-Derived Ligand (WRRTTYL)
3SHU	;	2.75	;	Crystal structure of ZO-1 PDZ3
3SHW	;	2.9	;	Crystal structure of ZO-1 PDZ3-SH3-Guk supramodule complex with Connexin-45 peptide
6LOF	;	2.6	;	Crystal structure of ZsYellow soaked by Cu2+
8JBW	;	2.65	;	Crystal structure of ZtHPPD-(+)-Usnic acid complex
3F59	;	2.0	;	Crystal structure of ZU5-ANK, the spectrin binding region of human erythroid ankyrin
3UD1	;	2.0	;	Crystal structure of ZU5A-ZU5B domains of human erythrocyte ankyrin
4GEL	;	1.756	;	Crystal structure of Zucchini
4GEM	;	2.206	;	Crystal structure of Zucchini (K171A)
4GEN	;	2.2	;	Crystal structure of Zucchini (monomer)
4GGJ	;	1.75	;	Crystal structure of Zucchini from mouse (mZuc / PLD6 / MitoPLD)
4GGK	;	2.1	;	Crystal structure of Zucchini from mouse (mZuc / PLD6 / MitoPLD) bound to tungstate
4RUO	;	2.805	;	Crystal structure of zVDR L337H mutant-gemini complex
4RUP	;	2.75	;	Crystal structure of zVDR L337H mutant-Gemini72 complex
4RUJ	;	2.352	;	Crystal structure of zVDR L337H mutant-VD complex
3IF8	;	2.55	;	Crystal Structure of ZWILCH, a member of the RZZ kinetochore complex
7XYW	;	2.5	;	Crystal structure of ZYG11B bound to AFLH degron
7XYX	;	2.87	;	Crystal structure of ZYG11B bound to CFLH degron
7EP1	;	1.852	;	Crystal structure of ZYG11B bound to GFLH degron
7EP2	;	2.38	;	Crystal structure of ZYG11B bound to GGFN degron
7EP0	;	2.16	;	Crystal structure of ZYG11B bound to GSTE degron
7XV7	;	2.6	;	Crystal structure of ZYG11B bound to ORF10 peptide
7XYV	;	2.52	;	Crystal structure of ZYG11B bound to SFLH degron
3NOM	;	2.4	;	Crystal Structure of Zymomonas mobilis Glutaminyl Cyclase (monoclinic form)
3NOL	;	1.7	;	Crystal structure of Zymomonas mobilis Glutaminyl Cyclase (trigonal form)
4ZP1	;	2.205	;	Crystal structure of Zymomonas mobilis pyruvate decarboxylase variant Glu473Ala
1P0E	;	2.4	;	CRYSTAL STRUCTURE OF ZYMOMONAS MOBILIS tRNA-GUANINE TRANSGLYCOSYLASE (TGT) COCRYSTALLISED WITH PREQ1 AT PH 5.5
1P0D	;	1.9	;	CRYSTAL STRUCTURE OF ZYMOMONAS MOBILIS tRNA-GUANINE TRANSGLYCOSYLASE (TGT) CRYSTALLISED AT PH 5.5
3LXF	;	2.3	;	Crystal Structure of [2Fe-2S] Ferredoxin Arx from Novosphingobium aromaticivorans
1FRR	;	1.8	;	CRYSTAL STRUCTURE OF [2FE-2S] FERREDOXIN I FROM EQUISETUM ARVENSE AT 1.8 ANGSTROMS RESOLUTION
7YRA	;	1.79	;	Crystal structure of [2Fe-2S]-TtPetA
1Z5T	;	1.6	;	Crystal Structure of [d(CGCGAA(Z3dU)(Z3dU)CGCG)]2, Z3dU:5-(3-aminopropyl)-2'-deoxyuridine, in presence of thallium I.
6TTL	;	2.9	;	crystal structure of [FeFe]-hydrogenase CbA5H (partial) from Clostridium beijerinckii in Hinact state
6NAC	;	1.55	;	Crystal structure of [FeFe]-hydrogenase I (CpI) solved with single pulse free electron laser data
6N6P	;	1.95	;	Crystal structure of [FeFe]-hydrogenase in the presence of 7 mM Sodium dithionite
6HAV	;	1.06	;	Crystal structure of [Fe]-hydrogenase (Hmd) from Methanococcus aeolicus in complex with FeGP and methenyl-tetrahydromethanopterin (close form A) at 1.06 A resolution
6HAE	;	1.85	;	Crystal structure of [Fe]-hydrogenase (Hmd) from Methanococcus aeolicus in complex with FeGP cofactor and methenyl-tetrahydromethanopterin (close form B)
6HAC	;	2.3	;	Crystal structure of [Fe]-hydrogenase (Hmd) holoenzyme from Methanococcus aeolicus (open form)
7RMS	;	1.1	;	Crystal structure of [I11G]cycloviolacin O2
7RMR	;	1.04	;	Crystal structure of [I11L]cycloviolacin O2
2QO3	;	2.59	;	Crystal Structure of [KS3][AT3] didomain from module 3 of 6-deoxyerthronolide B synthase
6C9U	;	2.09	;	Crystal structure of [KS3][AT3] didomain from module 3 of 6-deoxyerthronolide B synthase in complex with antibody fragment (Fab)
3HAW	;	1.3	;	Crystal structure of [L-Ala51/51']HIV-1 protease with reduced isostere MVT-101 inhibitor
3MYR	;	2.1	;	Crystal structure of [NiFe] hydrogenase from Allochromatium vinosum in its Ni-A state
3VX3	;	2.1	;	Crystal structure of [NiFe] hydrogenase maturation protein HypB from Thermococcus kodakarensis KOD1
2Z1D	;	2.07	;	Crystal structure of [NiFe] hydrogenase maturation protein, HypD from Thermococcus kodakaraensis
2I60	;	2.4	;	Crystal structure of [Phe23]M47, a scorpion-toxin mimic of CD4, in complex with HIV-1 YU2 GP120 envelope glycoprotein and anti-HIV-1 antibody 17B
3K7R	;	2.28	;	Crystal structure of [TM][CuAtx1]3
4MPQ	;	1.75	;	Crystal structure of1-pyrroline-4-hydroxy-2-carboxylate deaminase from Brucella melitensis ATCC 23457
4HA2	;	2.9	;	Crystal structure ofa phenyl alanine 91 mutant of WCI
7BXW	;	1.77629	;	Crystal structure ofF RTT109 FROM Candida albicans
3MXO	;	1.7	;	Crystal structure oh human phosphoglycerate mutase family member 5 (PGAM5)
7KSB	;	1.95	;	Crystal structure on Act c 10.0101
7ODC	;	1.6	;	CRYSTAL STRUCTURE ORNITHINE DECARBOXYLASE FROM MOUSE, TRUNCATED 37 RESIDUES FROM THE C-TERMINUS, TO 1.6 ANGSTROM RESOLUTION
6B22	;	1.93	;	Crystal structure OXA-24 beta-lactamase complexed with WCK 4234 by co-crystallization
2EPI	;	1.7	;	Crystal Structure pf hypothetical protein MJ1052 from Methanocaldococcus jannascii (Form 2)
2D0I	;	1.95	;	Crystal Structure PH0520 protein from Pyrococcus horikoshii OT3
6CWA	;	1.77	;	CRYSTAL STRUCTURE PHGDH IN COMPLEX WITH NADH AND 3-PHOSPHOGLYCERATE AT 1.77 A RESOLUTION
1FE1	;	3.8	;	CRYSTAL STRUCTURE PHOTOSYSTEM II
3WOG	;	2.0	;	Crystal structure plant lectin in complex with ligand
3TKM	;	1.953	;	Crystal structure PPAR delta binding GW0742
3HBN	;	1.85	;	Crystal structure PseG-UDP complex from Campylobacter jejuni
4YFD	;	3.253	;	Crystal structure PTP delta Ig1-Fn2 in complex with IL-1RAcP
3D9C	;	2.3	;	Crystal Structure PTP1B complex with aryl Seleninic acid
3EAX	;	1.9	;	Crystal structure PTP1B complex with small molecule compound LZP-6
3EB1	;	2.4	;	Crystal structure PTP1B complex with small molecule inhibitor LZP-25
3E2R	;	1.85	;	Crystal Structure PutA86-630 Mutant Y540S Complexed with L-tetrahydro-2-furoic acid
5JQC	;	2.149	;	Crystal structure putative autolysin from Listeria monocytogenes
6SW6	;	2.85	;	Crystal structure R264H mutant of the human S-adenosylmethionine synthetase 1
4B6I	;	1.95	;	Crystal structure Rap2b (SMA2266) from Serratia marcescens
3E2S	;	2.0	;	Crystal Structure Reduced PutA86-630 Mutant Y540S Complexed with L-proline
3E2Q	;	1.75	;	Crystal Structure Reduced PutA86-630 Mutant Y540S Complexed with trans-4-hydroxy-L-proline
4QT3	;	1.4	;	Crystal structure resolution of Plasmodium falciparum FK506 binding domain (FKBP35) in complex with Rapamycin at 1.4A resolution
6XTL	;	1.8	;	Crystal structure reveals non-coordinative binding of O2 to the copper center of the formylglycine-generating enzyme - FGE:Ag:S complex
6XTN	;	1.4	;	Crystal structure reveals non-coordinative binding of O2 to the copper center of the formylglycine-generating enzyme - FGE:Ag:S:NO complex
6XTM	;	1.25	;	Crystal structure reveals non-coordinative binding of O2 to the copper center of the formylglycine-generating enzyme - FGE:Ag:S:O2 complex
6XTO	;	1.4	;	Crystal structure reveals non-coordinative binding of O2 to the copper center of the formylglycine-generating enzyme - FGE:Cu:S:NO complex
6XTP	;	1.8	;	Crystal structure reveals non-coordinative binding of O2 to the copper center of the formylglycine-generating enzyme - FGE:Cu:S:O2-1a complex
6XTQ	;	1.4	;	Crystal structure reveals non-coordinative binding of O2 to the copper center of the formylglycine-generating enzyme - FGE:Cu:S:O2-1b complex
6XTR	;	1.2	;	Crystal structure reveals non-coordinative binding of O2 to the copper center of the formylglycine-generating enzyme - FGE:Cu:S:O2-1c complex
6XTS	;	1.2	;	Crystal structure reveals non-coordinative binding of O2 to the copper center of the formylglycine-generating enzyme - FGE:Cu:S:O2-1d complex
4BJ6	;	3.26	;	Crystal structure Rif2 in complex with the C-terminal domain of Rap1 (Rap1-RCT)
3E9F	;	1.8	;	Crystal structure short-form (residue1-113) of Eaf3 chromo domain
1COB	;	2.0	;	CRYSTAL STRUCTURE SOLUTION AND REFINEMENT OF THE SEMISYNTHETIC COBALT SUBSTITUTED BOVINE ERYTHROCYTE ENZYME SUPEROXIDE DISMUTASE AT 2.0 ANGSTROMS RESOLUTION
1OYJ	;	1.95	;	Crystal structure solution of Rice GST1 (OsGSTU1) in complex with glutathione.
3MXW	;	1.83	;	Crystal structure Sonic hedgehog bound to the 5E1 fab fragment
4ANN	;	1.05	;	Crystal Structure Staphylococcus aureus ESSB cytoplasmic fragment
3BXV	;	2.7	;	Crystal structure studies on sulfur oxygenase reductase from Acidianus tengchongensis
5F9P	;	2.078	;	Crystal structure study of anthrone oxidase-like protein
4FCH	;	1.3	;	Crystal Structure SusE from Bacteroides thetaiotaomicron with maltoheptaose
1T6H	;	2.01	;	Crystal Structure T4 Lysozyme incorporating an unnatural amino acid p-iodo-L-phenylalanine at position 153
1EWQ	;	2.2	;	CRYSTAL STRUCTURE TAQ MUTS COMPLEXED WITH A HETERODUPLEX DNA AT 2.2 A RESOLUTION
5DS4	;	3.2	;	Crystal structure the Escherichia coli Cas1-Cas2 complex bound to protospacer DNA
5DS5	;	2.951	;	Crystal structure the Escherichia coli Cas1-Cas2 complex bound to protospacer DNA and Mg
5DS6	;	3.352	;	Crystal structure the Escherichia coli Cas1-Cas2 complex bound to protospacer DNA with splayed ends
3EO9	;	1.8	;	Crystal structure the Fab fragment of Efalizumab
3EOA	;	2.8	;	Crystal structure the Fab fragment of Efalizumab in complex with LFA-1 I domain, Form I
3EOB	;	3.6	;	Crystal structure the Fab fragment of Efalizumab in complex with LFA-1 I domain, Form II
3C09	;	3.2	;	Crystal structure the Fab fragment of matuzumab (Fab72000) in complex with domain III of the extracellular region of EGFR
3C08	;	2.15	;	Crystal structure the Fab fragment of matuzumab/EMD72000 (Fab72000)
3NFS	;	2.6	;	Crystal structure the Fab fragment of therapeutic antibody daclizumab
3K3V	;	1.8	;	Crystal structure the GYF domain of S. Cerevisiae SMY2
2FPR	;	1.7	;	Crystal structure the N-terminal domain of E. coli HisB. Apo Mg model.
6EVO	;	1.55	;	Crystal structure the peptide-substrate-binding domain of human type II collagen prolyl 4-hydroxylase complexed with Pro-Pro-Gly-Pro-Arg-Gly-Pro-Pro-Gly.
6EVP	;	1.68	;	Crystal structure the peptide-substrate-binding domain of human type II collagen prolyl 4-hydroxylase complexed with Pro-Pro-Gly-Pro-Glu-Gly-Pro-Pro-Gly.
6M6V	;	3.08	;	Crystal structure the toxin-antitoxin MntA-HepT
6M6U	;	2.349	;	Crystal structure the toxin-antitoxin MntA-HpeT mutant-D39ED41E
6M6W	;	2.611	;	Crystal structure the toxin-antitoxin MntA-HpeT mutant-Y104A
1MYT	;	1.74	;	CRYSTAL STRUCTURE TO 1.74 ANGSTROMS RESOLUTION OF METMYOGLOBIN FROM YELLOWFIN TUNA (THUNNUS ALBACARES): AN EXAMPLE OF A MYOGLOBIN LACKING THE D HELIX
1MAM	;	2.45	;	CRYSTAL STRUCTURE TO 2.45 A RESOLUTION OF A MONOCLONAL FAB SPECIFIC FOR THE BRUCELLA A CELL WALL POLYSACCHARIDE ANTIGEN
4LXY	;	1.64	;	Crystal structure WlaRD, a sugar 3N-formyl transferase in the presence of dTDP and 10-N-Formyl-THF
4LXQ	;	1.4	;	Crystal structure WlaRD, a sugar 3N-formyl transferase in the presence of dTdp and 5-N-Formyl-THF
4LXX	;	1.45	;	Crystal structure WlaRD, a sugar 3N-formyl transferase in the presence of dTDP-Fuc3NFo and 5-N-Formyl-THF
4LY0	;	1.6	;	Crystal structure WlaRD, a sugar 3N-formyl transferase in the presence of dTDP-Glc and 10-N-Formyl-THF
4LXT	;	1.4	;	Crystal structure WlaRD, a sugar 3N-formyl transferase in the presence of dTdp-Qui3N and 5-N-Formyl-THF
3OIS	;	1.65	;	Crystal Structure Xylellain, a cysteine protease from Xylella fastidiosa
3BLU	;	2.0	;	crystal structure YopH complexed with inhibitor PVS
1XAS	;	2.6	;	CRYSTAL STRUCTURE, AT 2.6 ANGSTROMS RESOLUTION, OF THE STREPTOMYCES LIVIDANS XYLANASE A, A MEMBER OF THE F FAMILY OF BETA-1,4-D-GLYCANSES
1MYK	;	2.4	;	CRYSTAL STRUCTURE, FOLDING, AND OPERATOR BINDING OF THE HYPERSTABLE ARC REPRESSOR MUTANT PL8
5DOM	;	1.69	;	Crystal structure, maturation and flocculating properties of a 2S albumin from Moringa oleifera seeds
4AUE	;	2.7	;	Crystal structure, recombinant expression and mutagenesis studies of the bifunctional catalase-phenol oxidase from Scytalidium thermophilum
4AUL	;	1.5	;	Crystal structure, recombinant expression and mutagenesis studies of the bifunctional catalase-phenol oxidase from Scytalidium thermophilum
4AUM	;	1.4	;	Crystal structure, recombinant expression and mutagenesis studies of the bifunctional catalase-phenol oxidase from Scytalidium thermophilum
4AUN	;	1.92	;	Crystal structure, recombinant expression and mutagenesis studies of the bifunctional catalase-phenol oxidase from Scytalidium thermophilum
1FRG	;	2.8	;	CRYSTAL STRUCTURE, SEQUENCE, AND EPITOPE MAPPING OF A PEPTIDE COMPLEX OF AN ANTI-INFLUENZA HA PEPTIDE ANTIBODY FAB 26(SLASH)9: FINE-TUNING ANTIBODY SPECIFICITY
1XK7	;	1.6	;	Crystal Structure- C2 form- of Escherichia coli Crotonobetainyl-CoA: carnitine CoA transferase (CaiB)
1XK6	;	1.85	;	Crystal Structure- P1 form- of Escherichia coli Crotonobetainyl-CoA: carnitine CoA Transferase (CaiB)
5HA9	;	4.01	;	Crystal structure-based design and disovery of a novel PARP1 antiagonist (BL-PA10) that induces apoptosis and inhibits metastasis in triple negative breast cancer
5CNR	;	2.59	;	Crystal structure-guided design of self-assembling RNA nano triangles
6Z6C	;	1.4	;	Crystal structurel of FleA lectin in complex with a monovalent inhibitor
3OO6	;	2.15	;	Crystal structures and biochemical characterization of the bacterial solute receptor AcbH reveal an unprecedented exclusive substrate preference for b-D-galactopyranose
3OO7	;	2.1	;	Crystal structures and biochemical characterization of the bacterial solute receptor AcbH reveal an unprecedented exclusive substrate preference for b-D-galactopyranose
3OO8	;	1.6	;	Crystal structures and biochemical characterization of the bacterial solute receptor AcbH reveal an unprecedented exclusive substrate preference for b-D-galactopyranose
3OO9	;	1.76	;	Crystal structures and biochemical characterization of the bacterial solute receptor AcbH reveal an unprecedented exclusive substrate preference for b-D-galactopyranose
3OOA	;	2.04	;	Crystal structures and biochemical characterization of the bacterial solute receptor AcbH reveal an unprecedented exclusive substrate preference for b-D-galactopyranose
3A9U	;	2.4	;	Crystal structures and enzymatic mechanisms of a Populus tomentosa 4-coumarate--CoA ligase
3A9V	;	2.5	;	Crystal structures and enzymatic mechanisms of a Populus tomentosa 4-coumarate--CoA ligase
3NI2	;	1.9	;	Crystal structures and enzymatic mechanisms of a Populus tomentosa 4-coumarate:CoA ligase
2YQU	;	1.7	;	Crystal structures and evolutionary relationship of two different lipoamide dehydrogenase(E3s) from Thermus thermophilus
3NAH	;	2.75	;	Crystal structures and functional analysis of murine norovirus RNA-dependent RNA polymerase
3NAI	;	2.56	;	Crystal structures and functional analysis of murine norovirus RNA-dependent RNA polymerase
3QID	;	2.5	;	Crystal structures and functional analysis of murine norovirus RNA-dependent RNA polymerase
5F5D	;	2.5	;	Crystal structures and Inhibition kinetics reveal a two-state catalytic mechanism with drug design implications for rhomboid proteolysis
2BSR	;	2.3	;	Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-B2705
2BSS	;	2.0	;	Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-B2705
2BST	;	2.1	;	Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-B2705
3MFM	;	2.38	;	Crystal Structures and Mutational Analyses of Acyl-CoA Carboxylase Subunit of Streptomyces coelicolor
7K05	;	1.85	;	Crystal structures and ribonuclease activity of the Flavivirus host factor ERI3 that is involved in viral RNA synthesis define the ERI subfamily of structure-specific 3-prime - 5-prime exoribonucleases
7K06	;	1.95	;	Crystal structures and ribonuclease activity of the Flavivirus host factor ERI3 that is involved in viral RNA synthesis define the ERI subfamily of structure-specific 3-prime - 5-prime exoribonucleases
7K07	;	2.15	;	Crystal structures and ribonuclease activity of the Flavivirus host factor ERI3 that is involved in viral RNA synthesis define the ERI subfamily of structure-specific 3-prime - 5-prime exoribonucleases
7LPY	;	1.85	;	Crystal structures and ribonuclease activity of the Flavivirus host factor ERI3 that is involved in viral RNA synthesis define the ERI subfamily of structure-specific 3-prime - 5-prime exoribonucleases
7LPZ	;	1.55	;	Crystal structures and ribonuclease activity of the Flavivirus host factor ERI3 that is involved in viral RNA synthesis define the ERI subfamily of structure-specific 3-prime - 5-prime exoribonucleases
7LQ0	;	1.6	;	Crystal structures and ribonuclease activity of the Flavivirus host factor ERI3 that is involved in viral RNA synthesis define the ERI subfamily of structure-specific 3-prime - 5-prime exoribonucleases
3BW2	;	2.1	;	Crystal structures and site-directed mutagenesis study of nitroalkane oxidase from Streptomyces ansochromogenes
3BW3	;	2.2	;	Crystal structures and site-directed mutagenesis study of nitroalkane oxidase from Streptomyces ansochromogenes
3BW4	;	2.2	;	Crystal structures and site-directed mutagenesis study of nitroalkane oxidase from Streptomyces ansochromogenes
2ZD0	;	2.5	;	Crystal structures and thermostability of mutant TRAP3 A5 (ENGINEERED TRAP)
2ZCZ	;	1.8	;	Crystal structures and thermostability of mutant TRAP3 A7 (ENGINEERED TRAP)
1Q21	;	2.2	;	CRYSTAL STRUCTURES AT 2.2 ANGSTROMS RESOLUTION OF THE CATALYTIC DOMAINS OF NORMAL RAS PROTEIN AND AN ONCOGENIC MUTANT COMPLEXED WITH GSP
2Q21	;	2.2	;	CRYSTAL STRUCTURES AT 2.2 ANGSTROMS RESOLUTION OF THE CATALYTIC DOMAINS OF NORMAL RAS PROTEIN AND AN ONCOGENIC MUTANT COMPLEXED WITH GSP
1SES	;	2.5	;	CRYSTAL STRUCTURES AT 2.5 ANGSTROMS RESOLUTION OF SERYL-TRNA SYNTHETASE COMPLEXED WITH TWO DIFFERENT ANALOGUES OF SERYL-ADENYLATE
1SET	;	2.55	;	CRYSTAL STRUCTURES AT 2.5 ANGSTROMS RESOLUTION OF SERYL-TRNA SYNTHETASE COMPLEXED WITH TWO DIFFERENT ANALOGUES OF SERYL-ADENYLATE
1PHO	;	3.0	;	CRYSTAL STRUCTURES EXPLAIN FUNCTIONAL PROPERTIES OF TWO E. COLI PORINS
2XRQ	;	2.4	;	Crystal structures exploring the origins of the broader specificity of escherichia coli heat-labile enterotoxin compared to cholera toxin
2XRS	;	1.81	;	Crystal structures exploring the origins of the broader specificity of escherichia coli heat-labile enterotoxin compared to cholera toxin
5DD0	;	2.488	;	Crystal structures in an anti-HIV antibody lineage from immunization of Rhesus macaques
5DD1	;	1.597	;	Crystal structures in an anti-HIV antibody lineage from immunization of Rhesus macaques
5DD3	;	1.797	;	Crystal structures in an anti-HIV antibody lineage from immunization of Rhesus macaques
5DD5	;	1.9	;	Crystal structures in an anti-HIV antibody lineage from immunization of Rhesus macaques
5DD6	;	1.699	;	Crystal structures in an anti-HIV antibody lineage from immunization of Rhesus macaques
3BZ7	;	2.0	;	Crystal Structures of (S)-(-)-Blebbistatin Analogs bound to Dictyostelium discoideum myosin II
3BZ8	;	2.2	;	Crystal Structures of (S)-(-)-Blebbistatin Analogs bound to Dictyostelium discoideum myosin II
3BZ9	;	2.1	;	Crystal Structures of (S)-(-)-Blebbistatin Analogs bound to Dictyostelium discoideum myosin II
7DLD	;	1.75	;	Crystal structures of (S)-carbonyl reductases from Candida parapsilosis in different oligomerization states
2AHR	;	2.15	;	Crystal Structures of 1-Pyrroline-5-Carboxylate Reductase from Human Pathogen Streptococcus pyogenes
8G93	;	1.91	;	Crystal structures of 17-beta-hydroxysteroid dehydrogenase 13
8G9V	;	2.645	;	Crystal structures of 17-beta-hydroxysteroid dehydrogenase 13
7EUS	;	2.3	;	Crystal structures of 2-oxoglutarate dependent dioxygenase (CTB9) from Cercospora sp. JNU001
7EUT	;	2.497	;	Crystal structures of 2-oxoglutarate dependent dioxygenase (CTB9) in complex with N-oxalylglycine
7EUU	;	2.202	;	Crystal structures of 2-oxoglutarate dependent dioxygenase (CTB9) in complex with N-oxalylglycine and pre-cercosporin
5AVM	;	2.2	;	Crystal structures of 5-aminoimidazole ribonucleotide (AIR) synthetase, PurM, from Thermus thermophilus
2V7B	;	1.84	;	Crystal structures of a benzoate CoA ligase from Burkholderia xenovorans LB400
1UX5	;	2.5	;	Crystal Structures of a Formin Homology-2 domain reveal a flexibly tethered dimer architecture
1UX4	;	3.3	;	Crystal structures of a Formin Homology-2 domain reveal a tethered-dimer architecture
3KFE	;	3.5	;	Crystal structures of a group II chaperonin from Methanococcus maripaludis
3KFK	;	6.003	;	Crystal structures of a group II chaperonin from Methanococcus maripaludis
2AOA	;	1.99	;	Crystal structures of a high-affinity macrocyclic peptide mimetic in complex with the Grb2 SH2 domain
2AOB	;	1.8	;	Crystal structures of a high-affinity macrocyclic peptide mimetic in complex with the Grb2 SH2 domain
1RPI	;	1.86	;	Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity
1RQ9	;	2.6	;	Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity
1RV7	;	2.7	;	Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity
1S3Q	;	2.1	;	Crystal structures of a novel open pore ferritin from the hyperthermophilic Archaeon Archaeoglobus fulgidus
1SQ3	;	2.7	;	Crystal structures of a novel open pore ferritin from the hyperthermophilic Archaeon Archaeoglobus fulgidus.
1C2Y	;	3.3	;	CRYSTAL STRUCTURES OF A PENTAMERIC FUNGAL AND AN ICOSAHEDRAL PLANT LUMAZINE SYNTHASE REVEALS THE STRUCTURAL BASIS FOR DIFFERENCES IN ASSEMBLY
1C41	;	3.1	;	CRYSTAL STRUCTURES OF A PENTAMERIC FUNGAL AND AN ICOSAHEDRAL PLANT LUMAZINE SYNTHASE REVEALS THE STRUCTURAL BASIS FOR DIFFERENCES IN ASSEMBLY
2HZE	;	1.8	;	Crystal structures of a poxviral glutaredoxin in the oxidized and reduced states show redox-correlated structural changes
2HZF	;	1.8	;	Crystal structures of a poxviral glutaredoxin in the oxidized and reduced states show redox-correlated structural changes
3QFE	;	2.35	;	Crystal structures of a putative dihydrodipicolinate synthase family protein from Coccidioides immitis
1GTA	;	2.4	;	CRYSTAL STRUCTURES OF A SCHISTOSOMAL DRUG AND VACCINE TARGET: GLUTATHIONE S-TRANSFERASE FROM SCHISTOSOMA JAPONICA AND ITS COMPLEX WITH THE LEADING ANTISCHISTOSOMAL DRUG PRAZIQUANTEL
1GTB	;	2.6	;	CRYSTAL STRUCTURES OF A SCHISTOSOMAL DRUG AND VACCINE TARGET: GLUTATHIONE S-TRANSFERASE FROM SCHISTOSOMA JAPONICA AND ITS COMPLEX WITH THE LEADING ANTISCHISTOSOMAL DRUG PRAZIQUANTEL
6GG9	;	2.04	;	Crystal structures of a short blue light photoreceptor protein PpSB1-LOV mutant (dark state) - R61H/R66I
2HZL	;	1.4	;	Crystal structures of a sodium-alpha-keto acid binding subunit from a TRAP transporter in its closed forms
2HZK	;	1.7	;	Crystal structures of a sodium-alpha-keto acid binding subunit from a TRAP transporter in its open form
3GKZ	;	1.9	;	Crystal structures of a therapeutic single chain antibody in complex methamphetamine
7ACN	;	2.0	;	CRYSTAL STRUCTURES OF ACONITASE WITH ISOCITRATE AND NITROISOCITRATE BOUND
8ACN	;	2.0	;	CRYSTAL STRUCTURES OF ACONITASE WITH ISOCITRATE AND NITROISOCITRATE BOUND
1QB8	;	2.0	;	CRYSTAL STRUCTURES OF ADENINE PHOSPHORIBOSYLTRANSFERASE FROM LEISHMANIA DONOVANI
1QCC	;	1.98	;	CRYSTAL STRUCTURES OF ADENINE PHOSPHORIBOSYLTRANSFERASE FROM LEISHMANIA DONOVANI
1QCD	;	2.48	;	CRYSTAL STRUCTURES OF ADENINE PHOSPHORIBOSYLTRANSFERASE FROM LEISHMANIA DONOVANI
1QB7	;	1.5	;	CRYSTAL STRUCTURES OF ADENINE PHOSPHORIBOSYLTRANSFERASE FROM LEISHMANIA DONOVANI.
1V79	;	2.5	;	Crystal structures of adenosine deaminase complexed with potent inhibitors
1V7A	;	2.5	;	Crystal structures of adenosine deaminase complexed with potent inhibitors
4JLD	;	1.552	;	Crystal Structures of adenylate kinase with 2 ADP's
4JLB	;	1.528	;	Crystal Structures of Adenylate kinase with 2ADP's
7C7F	;	1.7	;	Crystal structures of AKR1C3 binary complex with NADP+
7C7G	;	1.86	;	Crystal structures of AKR1C3 ternary complex with NADP+ and the chromene derivative 2j
7C7H	;	1.86	;	Crystal structures of AKR1C3 ternary complex with NADP+ and the chromene derivative 2l
5K52	;	2.4	;	Crystal structures of aldehyde deformylating oxygenase from Limnothrix sp. KNUA012
5K53	;	1.8	;	Crystal structures of aldehyde deformylating oxygenase from Oscillatoria sp. KNUA011
1P11	;	1.93	;	CRYSTAL STRUCTURES OF ALPHA-LYTIC PROTEASE COMPLEXES WITH IRREVERSIBLY BOUND PHOSPHONATE ESTERS
1P12	;	1.9	;	CRYSTAL STRUCTURES OF ALPHA-LYTIC PROTEASE COMPLEXES WITH IRREVERSIBLY BOUND PHOSPHONATE ESTERS
7VW5	;	2.3	;	Crystal structures of alphavirus nonstructural protein 4 (nsP4) reveal an intrinsically dynamic RNA-dependent RNA polymerase fold
3B3L	;	2.9	;	Crystal structures of alternatively-spliced isoforms of human ketohexokinase
2A46	;	1.65	;	Crystal structures of amFP486, a cyan fluorescent protein from Anemonia majano, and variants
247D	;	2.8	;	CRYSTAL STRUCTURES OF AN A-FORM DUPLEX WITH SINGLE-ADENOSINE BULGES AND A CONFORMATIONAL BASIS FOR SITE SPECIFIC RNA SELF-CLEAVAGE
248D	;	1.83	;	CRYSTAL STRUCTURES OF AN A-FORM DUPLEX WITH SINGLE-ADENOSINE BULGES AND A CONFORMATIONAL BASIS FOR SITE SPECIFIC RNA SELF-CLEAVAGE
3UXW	;	2.27	;	Crystal Structures of an A-T-hook/DNA complex
2A9O	;	1.65	;	Crystal structures of an activated YycF homologue, the essential response regulator from S.pneumoniae in complex with BeF3 and the effect of pH on BeF3 binding, possible phosphate in the active site
1IGF	;	2.8	;	CRYSTAL STRUCTURES OF AN ANTIBODY TO A PEPTIDE AND ITS COMPLEX WITH PEPTIDE ANTIGEN AT 2.8 ANGSTROMS
2IGF	;	2.8	;	CRYSTAL STRUCTURES OF AN ANTIBODY TO A PEPTIDE AND ITS COMPLEX WITH PEPTIDE ANTIGEN AT 2.8 ANGSTROMS
1R8B	;	2.0	;	Crystal Structures of an Archaeal Class I CCA-Adding Enzyme and Its Nucleotide
1R8C	;	1.9	;	Crystal Structures of an Archaeal Class I CCA-Adding Enzyme and Its Nucleotide
1R89	;	1.8	;	Crystal Structures of an Archaeal Class I CCA-Adding Enzyme and Its Nucleotide Complexes
1R8A	;	2.1	;	Crystal Structures of an Archaeal Class I CCA-Adding Enzyme and Its Nucleotide Complexes
6DLA	;	2.004	;	Crystal structures of an influenza A hemagglutinin antibody Fab CH65:7969d2
2PMK	;	1.6	;	Crystal structures of an isolated ABC-ATPase in complex with TNP-ADP
7DEV	;	3.1	;	Crystal Structures of Anthocyanin 5,3'-aromatic acyltransferase from Gentiana triflora
7DEX	;	2.5	;	Crystal Structures of Anthocyanin 5,3'-aromatic acyltransferase H174A mutant with caffeoyl-CoA
4IFJ	;	1.8	;	Crystal Structures of apo Keap1, Keap1-peptide, and Keap1-compound complexes
4IFL	;	1.8	;	Crystal Structures of apo Keap1, Keap1-peptide, and Keap1-compound complexes
4IFN	;	2.4	;	Crystal Structures of apo Keap1, Keap1-peptide, and Keap1-compound complexes
7JRR	;	2.16	;	Crystal structures of artificially designed homomeric RNA nanoarchitectures
7JRS	;	3.21	;	Crystal structures of artificially designed homomeric RNA nanoarchitectures
7JRT	;	3.07	;	Crystal structures of artificially designed homomeric RNA nanoarchitectures
4BF2	;	2.11	;	Crystal Structures of Ask1-inhibitor Complexes
4BHN	;	2.3	;	Crystal Structures of Ask1-inhibitor Complexes
4BIB	;	2.43	;	Crystal Structures of Ask1-inhibitor Complexes
4BIC	;	2.62	;	Crystal Structures of Ask1-inhibitor Complexes
4BID	;	2.8	;	Crystal Structures of Ask1-inhibitor Complexes
4BIE	;	2.36	;	Crystal Structures of Ask1-inhibitor Complexes
7AT1	;	2.8	;	CRYSTAL STRUCTURES OF ASPARTATE CARBAMOYLTRANSFERASE LIGATED WITH PHOSPHONOACETAMIDE, MALONATE, AND CTP OR ATP AT 2.8-ANGSTROMS RESOLUTION AND NEUTRAL P*H
8AT1	;	2.8	;	CRYSTAL STRUCTURES OF ASPARTATE CARBAMOYLTRANSFERASE LIGATED WITH PHOSPHONOACETAMIDE, MALONATE, AND CTP OR ATP AT 2.8-ANGSTROMS RESOLUTION AND NEUTRAL P*H
3AMS	;	2.08	;	Crystal Structures of Bacillus subtilis Alkaline Phytase in Complex with Ca2+, Cd2+, Co2+, Ni2+, Mg2+ and myo-Inositol Hexasulfate
3AMR	;	1.25	;	Crystal Structures of Bacillus subtilis Alkaline Phytase in Complex with Ca2+, Co2+, Ni2+, Mg2+ and myo-Inositol Hexasulfate
1DKR	;	2.3	;	CRYSTAL STRUCTURES OF BACILLUS SUBTILIS PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE: MOLECULAR BASIS OF ALLOSTERIC INHIBITION AND ACTIVATION.
1DKU	;	2.2	;	CRYSTAL STRUCTURES OF BACILLUS SUBTILIS PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE: MOLECULAR BASIS OF ALLOSTERIC INHIBITION AND ACTIVATION.
4GZY	;	3.5054	;	Crystal structures of bacterial RNA Polymerase paused elongation complexes
4GZZ	;	4.2927	;	Crystal structures of bacterial RNA Polymerase paused elongation complexes
5CF3	;	2.031	;	Crystal structures of Bbp from Staphylococcus aureus
5CFA	;	1.45	;	Crystal structures of Bbp from Staphylococcus aureus with peptide ligand
6XFI	;	2.0	;	Crystal Structures of beta-1,4-N-Acetylglucosaminyltransferase 2 (POMGNT2): Structural Basis for Inherited Muscular Dystrophies
3UYY	;	2.5	;	Crystal Structures of Branched-Chain Aminotransferase from Deinococcus radiodurans Complexes with alpha-Ketoisocaproate and L-Glutamate Suggest Its Radio-Resistance for Catalysis
3UZB	;	3.0	;	Crystal Structures of Branched-Chain Aminotransferase from Deinococcus radiodurans Complexes with alpha-Ketoisocaproate and L-Glutamate Suggest Its Radio-Resistance for Catalysis
3UZO	;	2.0	;	Crystal Structures of Branched-Chain Aminotransferase from Deinococcus radiodurans Complexes with alpha-Ketoisocaproate and L-Glutamate Suggest Its Radio-Resistance for Catalysis
6JIF	;	1.7	;	Crystal Structures of Branched-Chain Aminotransferase from Pseudomonas sp. UW4
4KU5	;	2.17	;	Crystal Structures of C143S Xanthomonas campestris OleA with Bound Lauric Acid and Lauroyl-CoA
2REA	;	2.5	;	Crystal structures of C2ALPHA-PI3 kinase PX-domain domain indicate conformational change associated with ligand binding.
2RED	;	2.1	;	Crystal structures of C2ALPHA-PI3 kinase PX-domain domain indicate conformational change associated with ligand binding.
1M8S	;	1.9	;	Crystal Structures of Cadmium-binding Acidic Phospholipase A2 from the Venom of Agkistrodon halys pallas at 1.9 Resolution (crystal grown at pH 5.9)
1M8R	;	1.9	;	Crystal Structures of Cadmium-binding Acidic Phospholipase A2 from the Venom of Agkistrodon halys pallas at 1.9 Resolution (crystal grown at pH 7.4)
2CDR	;	1.7	;	Crystal structures of caspase-3 in complex with aza-peptide epoxide inhibitors.
2CNK	;	1.75	;	Crystal structures of caspase-3 in complex with aza-peptide epoxide inhibitors.
2CNL	;	1.67	;	Crystal structures of caspase-3 in complex with aza-peptide epoxide inhibitors.
2CNN	;	1.7	;	Crystal structures of caspase-3 in complex with aza-peptide epoxide inhibitors.
2CNO	;	1.95	;	Crystal structures of caspase-3 in complex with aza-peptide epoxide inhibitors.
2C1E	;	1.77	;	Crystal structures of caspase-3 in complex with aza-peptide Michael acceptor inhibitors.
2C2K	;	1.87	;	Crystal structures of caspase-3 in complex with aza-peptide Michael acceptor inhibitors.
2C2M	;	1.94	;	Crystal structures of caspase-3 in complex with aza-peptide Michael acceptor inhibitors.
2C2O	;	2.45	;	Crystal structures of caspase-3 in complex with aza-peptide Michael acceptor inhibitors.
3DEH	;	2.5	;	Crystal Structures of Caspase-3 with Bound Isoquinoline-1,3,4-trione Derivative Inhibitors
3DEI	;	2.8	;	Crystal Structures of Caspase-3 with Bound Isoquinoline-1,3,4-trione Derivative Inhibitors
3DEJ	;	2.6	;	Crystal Structures of Caspase-3 with Bound Isoquinoline-1,3,4-trione Derivative Inhibitors
3DEK	;	2.4	;	Crystal Structures of Caspase-3 with Bound Isoquinoline-1,3,4-trione Derivative Inhibitors
3AFB	;	1.76	;	Crystal structures of catalytic site mutants of active domain 2 of chitinase from Pyrococcus furiosus
3A4W	;	1.8	;	Crystal structures of catalytic site mutants of active domain 2 of thermostable chitinase from Pyrococcus furiosus complexed with chito-oligosaccharides
3A4X	;	1.76	;	Crystal structures of catalytic site mutants of active domain 2 of thermostable chitinase from Pyrococcus furiosus complexed with chito-oligosaccharides
1NPZ	;	2.0	;	Crystal structures of Cathepsin S inhibitor complexes
1NQC	;	1.8	;	Crystal structures of Cathepsin S inhibitor complexes
4WOQ	;	2.2	;	Crystal Structures of CdNal from Clostridium difficile in complex with ketobutyric
4WOZ	;	1.96	;	Crystal Structures of CdNal from Clostridium difficile in complex with mannosamine
4DBF	;	1.9	;	Crystal structures of Cg1458
1YII	;	1.42	;	Crystal Structures of Chicken Annexin V in Complex with Ca2+
1YJ0	;	2.95	;	Crystal Structures of Chicken Annexin V in Complex with Zn2+
4QY5	;	1.501	;	Crystal structures of chimeric beta-lactamase cTEM-19m showing different conformations
4QY6	;	1.15	;	Crystal structures of chimeric beta-lactamase cTEM-19m showing different conformations
1B4P	;	1.7	;	CRYSTAL STRUCTURES OF CLASS MU CHIMERIC GST ISOENZYMES M1-2 AND M2-1
2CN2	;	2.1	;	Crystal Structures of Clostridium thermocellum Xyloglucanase
2CN3	;	1.95	;	Crystal Structures of Clostridium thermocellum Xyloglucanase
3QPS	;	2.351	;	Crystal structures of CmeR-bile acid complexes from Campylobacter jejuni
3QQA	;	2.2	;	Crystal structures of CmeR-bile acid complexes from Campylobacter jejuni
2D3H	;	1.22	;	Crystal structures of collagen model peptides (Pro-Pro-Gly)4-Hyp-Hyp-Gly-(Pro-Pro-Gly)4
2D3F	;	1.26	;	Crystal structures of collagen model peptides (Pro-Pro-Gly)4-Pro-Hyp-Gly-(Pro-Pro-Gly)4
1V7H	;	1.25	;	Crystal Structures of Collagen Model Peptides with Pro-Hyp-Gly Sequence at 1.26 A
1V6Q	;	1.25	;	Crystal Structures of Collagen Model Peptides with Pro-Hyp-Gly Sequence at 1.3 A
1V4F	;	1.26	;	Crystal structures of collagen model peptides with pro-hyp-gly sequence at 1.3A
1ZM1	;	2.3	;	Crystal structures of complex F. succinogenes 1,3-1,4-beta-D-glucanase and beta-1,3-1,4-cellotriose
3LZZ	;	2.5	;	Crystal structures of Cupin superfamily BbDUF985 from Branchiostoma belcheri tsingtauense in apo and GDP-bound forms
3LOI	;	2.1	;	Crystal structures of Cupin superfamily BbDUF985 from Branchiostoma belcheri tsingtauense in the apo and GDP-bound forms
4K34	;	2.69	;	Crystal structures of CusC review conformational changes accompanying folding and transmembrane channel formation
4K7K	;	2.53	;	Crystal structures of CusC review conformational changes accompanying folding and transmembrane channel formation
4K7R	;	2.094	;	Crystal structures of CusC review conformational changes accompanying folding and transmembrane channel formation
5NS4	;	2.4	;	Crystal structures of Cy3 cyanine fluorophores stacked onto the end of double-stranded RNA
5NS3	;	2.4	;	Crystal structures of Cy5 cyanine fluorophores stacked onto the end of double-stranded RNA
1ARU	;	1.6	;	CRYSTAL STRUCTURES OF CYANIDE-AND TRIIODIDE-BOUND FORMS OF ARTHROMYCES RAMOSUS PEROXIDASE AT DIFFERENT PH VALUES. PERTURBATIONS OF ACTIVE SITE RESIDUES AND THEIR IMPLICATION IN ENZYME CATALYSIS
1ARV	;	1.6	;	CRYSTAL STRUCTURES OF CYANIDE-AND TRIIODIDE-BOUND FORMS OF ARTHROMYCES RAMOSUS PEROXIDASE AT DIFFERENT PH VALUES. PERTURBATIONS OF ACTIVE SITE RESIDUES AND THEIR IMPLICATION IN ENZYME CATALYSIS
1ARW	;	1.6	;	CRYSTAL STRUCTURES OF CYANIDE-AND TRIIODIDE-BOUND FORMS OF ARTHROMYCES RAMOSUS PEROXIDASE AT DIFFERENT PH VALUES. PERTURBATIONS OF ACTIVE SITE RESIDUES AND THEIR IMPLICATION IN ENZYME CATALYSIS
1ARX	;	1.9	;	CRYSTAL STRUCTURES OF CYANIDE-AND TRIIODIDE-BOUND FORMS OF ARTHROMYCES RAMOSUS PEROXIDASE AT DIFFERENT PH VALUES. PERTURBATIONS OF ACTIVE SITE RESIDUES AND THEIR IMPLICATION IN ENZYME CATALYSIS
1ARY	;	1.9	;	CRYSTAL STRUCTURES OF CYANIDE-AND TRIIODIDE-BOUND FORMS OF ARTHROMYCES RAMOSUS PEROXIDASE AT DIFFERENT PH VALUES. PERTURBATIONS OF ACTIVE SITE RESIDUES AND THEIR IMPLICATION IN ENZYME CATALYSIS
6BUM	;	1.51	;	Crystal structures of cyanuric acid hydrolase from Moorella thermoacetica
6BUN	;	1.78	;	Crystal structures of cyanuric acid hydrolase from Moorella thermoacetica
6BUO	;	1.85	;	Crystal structures of cyanuric acid hydrolase from Moorella thermoacetica
6DHJ	;	3.2	;	Crystal structures of cyanuric acid hydrolase from Moorella thermoacetica
6CWJ	;	2.253	;	Crystal structures of cyanuric acid hydrolase from Moorella thermoacetica complexed with 1,3-Acetone Dicarboxylic Acid
6BUQ	;	1.88	;	Crystal structures of cyanuric acid hydrolase from Moorella thermoacetica complexed with barbituric acid
6BUR	;	2.18	;	Crystal structures of cyanuric acid hydrolase from Moorella thermoacetica complexed with barbituric acid
6BUP	;	1.88	;	Crystal structures of cyanuric acid hydrolase from Moorella thermoacetica complexed with cyanuric acid
2RMA	;	2.1	;	Crystal structures of cyclophilin A complexed with cyclosporin A and N-methyl-4-[(E)-2-butenyl]-4,4-dimethylthreonine cyclosporin A
2RMB	;	2.1	;	Crystal structures of cyclophilin A complexed with cyclosporin A and N-methyl-4-[(E)-2-butenyl]-4,4-dimethylthreonine cyclosporin A
4DXY	;	2.0	;	Crystal structures of CYP101D2 Y96A mutant
6C2H	;	1.49	;	Crystal Structures of Cystathionine beta-Synthase from Saccharomyces cerevisiae: the Structure of the Catalytic Core
6C2Z	;	1.37	;	Crystal Structures of Cystathionine beta-Synthase from Saccharomyces cerevisiae: the Structure of the PLP-Aminoacrylate Intermediate
6C2Q	;	2.17	;	Crystal Structures of Cystathionine beta-Synthase from Saccharomyces cerevisiae: the Structure of the PLP-L-Serine Intermediate
6C4P	;	2.3	;	Crystal Structures of Cystathionine beta-Synthase from Saccharomyces cerevisiae: the Structure of the PMP Complex
4CPP	;	2.11	;	CRYSTAL STRUCTURES OF CYTOCHROME P450-CAM COMPLEXED WITH CAMPHANE, THIOCAMPHOR, AND ADAMANTANE: FACTORS CONTROLLING P450 SUBSTRATE HYDROXYLATION
6CPP	;	1.9	;	CRYSTAL STRUCTURES OF CYTOCHROME P450-CAM COMPLEXED WITH CAMPHANE, THIOCAMPHOR, AND ADAMANTANE: FACTORS CONTROLLING P450 SUBSTRATE HYDROXYLATION
8CPP	;	2.1	;	CRYSTAL STRUCTURES OF CYTOCHROME P450-CAM COMPLEXED WITH CAMPHANE, THIOCAMPHOR, AND ADAMANTANE: FACTORS CONTROLLING P450 SUBSTRATE HYDROXYLATION
1EHE	;	1.7	;	CRYSTAL STRUCTURES OF CYTOCHROME P450NOR AND ITS MUTANTS (SER286 VAL, THR) IN THE FERRIC RESTING STATE AT CRYOGENIC TEMPERATURE: A COMPARATIVE ANALYSIS WITH MONOOXYGENASE CYTOCHROME P450S
1EHF	;	1.7	;	CRYSTAL STRUCTURES OF CYTOCHROME P450NOR AND ITS MUTANTS (SER286 VAL, THR) IN THE FERRIC RESTING STATE AT CRYOGENIC TEMPERATURE: A COMPARATIVE ANALYSIS WITH MONOOXYGENASE CYTOCHROME P450S
1EHG	;	1.7	;	CRYSTAL STRUCTURES OF CYTOCHROME P450NOR AND ITS MUTANTS (SER286 VAL, THR) IN THE FERRIC RESTING STATE AT CRYOGENIC TEMPERATURE: A COMPARATIVE ANALYSIS WITH MONOOXYGENASE CYTOCHROME P450S
319D	;	2.2	;	CRYSTAL STRUCTURES OF D(CCGGG(BR)5CCCGG)-ORTHOGONAL FORM
318D	;	2.0	;	CRYSTAL STRUCTURES OF D(CCGGGCC(BR)5CGG)-HEXAGONAL FORM
320D	;	2.15	;	CRYSTAL STRUCTURES OF D(CCGGGCCCGG)-ORTHOGONAL FORM
321D	;	2.15	;	CRYSTAL STRUCTURES OF D(CCGGGCCCGG)-ORTHOGONAL FORM
322D	;	2.5	;	CRYSTAL STRUCTURES OF D(CCGGGCCM5CGG)-HEXAGONAL FORM
323D	;	2.15	;	CRYSTAL STRUCTURES OF D(CCGGGCCM5CGG)-ORTHOGONAL FORM
324D	;	2.15	;	CRYSTAL STRUCTURES OF D(CCGGGCCM5CGG)-ORTHOGONAL FORM
325D	;	2.5	;	CRYSTAL STRUCTURES OF D(CM5CGGGCCM5CGG)-HEXAGONAL FORM
326D	;	2.15	;	CRYSTAL STRUCTURES OF D(CM5CGGGCCM5CGG)-ORTHOGONAL FORM
1R3Z	;	1.7	;	Crystal structures of d(Gm5CGm5CGCGC) and d(GCGCGm5CGm5C): Effects of methylation on alternating DNA octamers
1R41	;	1.9	;	Crystal structures of d(Gm5CGm5CGCGC) and d(GCGCGm5CGm5C): Effects of methylation on alternating DNA octamers
327D	;	1.94	;	CRYSTAL STRUCTURES OF D(GM5CGM5CGCGCGC)
7DZ2	;	1.55	;	Crystal structures of D-allulose 3-epimerase from Sinorhizobium fredii
7DZ6	;	2.1	;	Crystal structures of D-allulose 3-epimerase with D-allulose from Sinorhizobium fredii
7DZ3	;	1.88	;	Crystal structures of D-allulose 3-epimerase with D-fructose from Sinorhizobium fredii
7DZ5	;	1.7	;	Crystal structures of D-allulose 3-epimerase with D-sorbose from Sinorhizobium fredii
7DZ4	;	1.84	;	Crystal structures of D-allulose 3-epimerase with D-tagatose from Sinorhizobium fredii
3VNI	;	1.98	;	Crystal structures of D-Psicose 3-epimerase from Clostridium cellulolyticum H10 and its complex with ketohexose sugars
3VNK	;	2.02	;	Crystal structures of D-Psicose 3-epimerase with D-fructose from Clostridium cellulolyticum H10
3VNJ	;	2.08	;	Crystal structures of D-Psicose 3-epimerase with D-psicose from Clostridium cellulolyticum H10
3VNM	;	2.12	;	Crystal structures of D-Psicose 3-epimerase with D-sorbose from Clostridium cellulolyticum H10
3VNL	;	2.15	;	Crystal structures of D-Psicose 3-epimerase with D-tagatose from Clostridium cellulolyticum H10
4PLQ	;	2.1	;	Crystal Structures of Designed Armadillo Repeat Proteins: Implications of Construct Design and Crystallization Conditions on Overall Structure.
4PLR	;	2.1	;	Crystal Structures of Designed Armadillo Repeat Proteins: Implications of Construct Design and Crystallization Conditions on Overall Structure.
4PLS	;	2.35	;	Crystal Structures of Designed Armadillo Repeat Proteins: Implications of Construct Design and Crystallization Conditions on Overall Structure.
4GZG	;	1.49	;	Crystal structures of DHPA-CO complex
8A4Q	;	1.75	;	crystal structures of diastereomer (R,S,S)-13b (13b-H) in complex with the SARS-CoV-2 Mpro.
8A4T	;	2.5	;	crystal structures of diastereomer (S,S,S)-13b (13b-K) in complex with the SARS-CoV-2 Mpro
6A1O	;	2.49	;	Crystal structures of disordered Z-type helices
6A1Q	;	2.501	;	Crystal structures of disordered Z-type helices
4B5X	;	1.8	;	Crystal structures of divalent metal dependent pyruvate aldolase (HpaI), mutant D42A
4B5W	;	1.792	;	Crystal structures of divalent metal dependent pyruvate aldolase R70A mutant, HpaI, in complex with pyruvate
4B5V	;	2.041	;	Crystal structures of divalent metal dependent pyruvate aldolase, HpaI, in complex with 4-hydroxyl-2-ketoheptane-1,7-dioate
4B5T	;	1.923	;	Crystal structures of divalent metal dependent pyruvate aldolase, HpaI, in complex with ketobutyrate
4B5S	;	1.68	;	Crystal structures of divalent metal dependent pyruvate aldolase, HpaI, in complex with pyruvate
4B5U	;	1.913	;	Crystal structures of divalent metal dependent pyruvate aldolase, HpaI, in complex with pyruvate and succinic semialdehyde
4B29	;	1.72	;	Crystal structures of DMSP lyases RdDddP and RnDddQII
4JZY	;	2.34	;	Crystal structures of Drosophila Cryptochrome
2FQD	;	2.4	;	Crystal Structures of E. coli Laccase CueO under different copper binding situations
2FQE	;	1.92	;	Crystal Structures of E. coli Laccase CueO under different copper binding situations
2FQF	;	2.0	;	Crystal Structures of E. coli Laccase CueO under different copper binding situations
2FQG	;	2.3	;	Crystal Structures of E. coli Laccase CueO under different copper binding situations
1U99	;	2.6	;	Crystal Structures of E. coli RecA in a Compressed Helical Filament Form 4
5YYM	;	2.2	;	Crystal structures of E.coli arginyl-trna synthetase (argrs) in complex with substrate Arg
5B63	;	3.0	;	Crystal structures of E.coli arginyl-tRNA synthetase (ArgRS) in complex with substrate tRNA(Arg)
5YYN	;	3.0	;	Crystal structures of E.coli arginyl-trna synthetase (argrs) in complex with substrate TRNA(Arg)
1YN3	;	1.35	;	Crystal Structures of EAP Domains from Staphylococcus aureus Reveal an Unexpected Homology to Bacterial Superantigens
1YN4	;	1.8	;	Crystal Structures of EAP Domains from Staphylococcus aureus Reveal an Unexpected Homology to Bacterial Superantigens
1YN5	;	2.2	;	Crystal Structures of EAP Domains from Staphylococcus aureus Reveal an Unexpected Homology to Bacterial Superantigens
4R3P	;	2.905	;	Crystal structures of EGFR in complex with Mig6
4R3R	;	3.25	;	Crystal structures of EGFR in complex with Mig6
5ZH0	;	1.08	;	Crystal Structures of Endo-beta-1,4-xylanase II
5ZF3	;	1.2	;	Crystal Structures of Endo-beta-1,4-xylanase II Complexed with Xylotriose
6JUG	;	1.19	;	Crystal Structures of Endo-beta-1,4-xylanase II Complexed with Xylotriose
6JWB	;	1.15	;	Crystal Structures of Endo-beta-1,4-xylanase II Complexed with Xylotriose
6JXL	;	1.3	;	Crystal Structures of Endo-beta-1,4-xylanase II Complexed with Xylotriose
6JZP	;	1.12	;	Crystal Structures of Endo-beta-1,4-xylanase II Complexed with Xylotriose
6K9W	;	1.1	;	Crystal Structures of Endo-beta-1,4-xylanase II Complexed with Xylotriose
2BZZ	;	0.98	;	Crystal Structures of Eosinophil-derived Neurotoxin in Complex with the Inhibitors 5'-ATP, Ap3A, Ap4A and Ap5A
2C01	;	1.24	;	Crystal Structures of Eosinophil-derived Neurotoxin in Complex with the Inhibitors 5'-ATP, Ap3A, Ap4A and Ap5A
2C02	;	2.0	;	Crystal Structures of Eosinophil-derived Neurotoxin in Complex with the Inhibitors 5'-ATP, Ap3A, Ap4A and Ap5A
2C05	;	1.86	;	Crystal Structures of Eosinophil-derived Neurotoxin in Complex with the Inhibitors 5'-ATP, Ap3A, Ap4A and Ap5A
3DFR	;	1.7	;	CRYSTAL STRUCTURES OF ESCHERICHIA COLI AND LACTOBACILLUS CASEI DIHYDROFOLATE REDUCTASE REFINED AT 1.7 ANGSTROMS RESOLUTION. I. GENERAL FEATURES AND BINDING OF METHOTREXATE
4DFR	;	1.7	;	CRYSTAL STRUCTURES OF ESCHERICHIA COLI AND LACTOBACILLUS CASEI DIHYDROFOLATE REDUCTASE REFINED AT 1.7 ANGSTROMS RESOLUTION. I. GENERAL FEATURES AND BINDING OF METHOTREXATE
1ASL	;	2.6	;	CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS
1ASM	;	2.35	;	CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS
1ASN	;	2.5	;	CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS
3QN6	;	1.79	;	Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine
3QPG	;	1.79	;	Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine
6DFR	;	2.4	;	CRYSTAL STRUCTURES OF ESCHERICHIA COLI DIHYDROFOLATE REDUCTASE. THE NADP+ HOLOENZYME AND THE FOLATE(DOT)NADP+ TERNARY COMPLEX. SUBSTRATE BINDING AND A MODEL FOR THE TRANSITION STATE
7DFR	;	2.5	;	CRYSTAL STRUCTURES OF ESCHERICHIA COLI DIHYDROFOLATE REDUCTASE. THE NADP+ HOLOENZYME AND THE FOLATE(DOT)NADP+ TERNARY COMPLEX. SUBSTRATE BINDING AND A MODEL FOR THE TRANSITION STATE
1BU6	;	2.37	;	CRYSTAL STRUCTURES OF ESCHERICHIA COLI GLYCEROL KINASE AND THE MUTANT A65T IN AN INACTIVE TETRAMER: CONFORMATIONAL CHANGES AND IMPLICATIONS FOR ALLOSTERIC REGULATION
1GLF	;	2.62	;	CRYSTAL STRUCTURES OF ESCHERICHIA COLI GLYCEROL KINASE AND THE MUTANT A65T IN AN INACTIVE TETRAMER: CONFORMATIONAL CHANGES AND IMPLICATIONS FOR ALLOSTERIC REGULATION
3ZGL	;	1.68	;	Crystal structures of Escherichia coli IspH in complex with AMBPP a potent inhibitor of the methylerythritol phosphate pathway
3ZGN	;	1.95	;	Crystal structures of Escherichia coli IspH in complex with TMBPP a potent inhibitor of the methylerythritol phosphate pathway
5GSO	;	2.6	;	Crystal Structures of EV71 3C Protease in complex with NK-1.8k
4J1N	;	2.45	;	Crystal structures of FabI from F. tularensis in complex with novel inhibitors based on the benzimidazole scaffold
7WUA	;	1.999	;	Crystal structures of FadD32 from Corynebacterium diphtheriae
3S5H	;	1.603	;	Crystal structures of falcilysin, a M16 metalloprotease from the malaria parasite Plasmodium falciparum
3S5I	;	1.743	;	Crystal structures of falcilysin, a M16 metalloprotease from the malaria parasite Plasmodium falciparum
3S5K	;	3.2	;	Crystal structures of falcilysin, a M16 metalloprotease from the malaria parasite Plasmodium falciparum
3S5M	;	1.55	;	Crystal structures of falcilysin, a M16 metalloprotease from the malaria parasite Plasmodium falciparum
1F7D	;	1.4	;	CRYSTAL STRUCTURES OF FELINE IMMUNODEFICIENCY VIRUS DUTP PYROPHOSPHATASE AND ITS NUCLEOTIDE COMPLEXES IN THREE CRYSTAL FORMS
1F7K	;	2.2	;	CRYSTAL STRUCTURES OF FELINE IMMUNODEFICIENCY VIRUS DUTP PYROPHOSPHATASE AND ITS NUCLEOTIDE COMPLEXES IN THREE CRYSTAL FORMS.
1F7N	;	2.2	;	CRYSTAL STRUCTURES OF FELINE IMMUNODEFICIENCY VIRUS DUTP PYROPHOSPHATASE AND ITS NUCLEOTIDE COMPLEXES IN THREE CRYSTAL FORMS.
1F7O	;	2.2	;	CRYSTAL STRUCTURES OF FELINE IMMUNODEFICIENCY VIRUS DUTP PYROPHOSPHATASE AND ITS NUCLEOTIDE COMPLEXES IN THREE CRYSTAL FORMS.
1F7P	;	2.3	;	CRYSTAL STRUCTURES OF FELINE IMMUNODEFICIENCY VIRUS DUTP PYROPHOSPHATASE AND ITS NUCLEOTIDE COMPLEXES IN THREE CRYSTAL FORMS.
1F7Q	;	2.26	;	CRYSTAL STRUCTURES OF FELINE IMMUNODEFICIENCY VIRUS DUTP PYROPHOSPHATASE AND ITS NUCLEOTIDE COMPLEXES IN THREE CRYSTAL FORMS.
1F7R	;	2.5	;	CRYSTAL STRUCTURES OF FELINE IMMUNODEFICIENCY VIRUS DUTP PYROPHOSPHATASE AND ITS NUCLEOTIDE COMPLEXES IN THREE CRYSTAL FORMS.
1CL6	;	1.7	;	CRYSTAL STRUCTURES OF FERRIC-NO COMPLEXES OF FUNGAL NITRIC OXIDE REDUCTASE AND ITS SER286 MUTANTS AT CRYOGENIC TEMPERATURE
1CMJ	;	1.7	;	CRYSTAL STRUCTURES OF FERRIC-NO COMPLEXES OF FUNGAL NITRIC OXIDE REDUCTASE AND THEIR SER286 MUTANTS AT CRYOGENIC TEMPERATURE
1CMN	;	1.7	;	CRYSTAL STRUCTURES OF FERRIC-NO COMPLEXES OF FUNGAL NITRIC OXIDE REDUCTASE AND THEIR SER286 MUTANTS AT CRYOGENIC TEMPERATURE
4ZTT	;	1.83	;	Crystal structures of ferritin mutants reveal diferric-peroxo intermediates
5C6F	;	2.0	;	Crystal structures of ferritin mutants reveal side-on binding to diiron and end-on cleavage of oxygen
1TWN	;	2.2	;	Crystal structures of ferrous and ferrous-NO forms of verdoheme in a complex with human heme oxygenase-1: catalytic implications for heme cleavage
1TWR	;	2.1	;	Crystal structures of ferrous and ferrous-NO forms of verdoheme in a complex with human heme oxygenase-1: catalytic implications for heme cleavage
6VGC	;	2.37	;	Crystal Structures of FLAP bound to DG-031
6VGI	;	2.61	;	Crystal Structures of FLAP bound to MK-866
5XFV	;	1.79	;	Crystal structures of FMN-bound form of dihydroorotate dehydrogenase from Trypanosoma brucei
5XFW	;	1.6	;	Crystal structures of FMN-free form of dihydroorotate dehydrogenase from Trypanosoma brucei
3BI2	;	2.3	;	Crystal structures of fms1 in complex with its inhibitors
3BI4	;	2.2	;	Crystal structures of fms1 in complex with its inhibitors
3BI5	;	2.5	;	Crystal structures of fms1 in complex with its inhibitors
6TPV	;	1.8	;	Crystal structures of FNIII domain one and two of the human leucocyte common antigen-related protein, LAR
6TPW	;	2.9	;	Crystal structures of FNIII domain one through four of the human leucocyte common antigen-related protein ( LAR)
6TPT	;	3.2	;	Crystal structures of FNIII domain three and four of the human leucocyte common antigen-related protein, LAR
6TPU	;	1.55	;	Crystal structures of FNIII domain three and four of the human leucocyte common antigen-related protein, LAR
5XT2	;	2.652	;	Crystal structures of full-length FixJ from B. japonicum crystallized in space group P212121
3UYW	;	1.903	;	Crystal structures of globular head of 2009 pandemic H1N1 hemagglutinin
3UYX	;	1.8	;	Crystal structures of globular head of 2009 pandemic H1N1 hemagglutinin
4LZ5	;	1.5	;	Crystal structures of GLuR2 ligand-binding-domain in complex with glutamate and positive allosteric modulators
4LZ7	;	2.1	;	Crystal structures of GLuR2 ligand-binding-domain in complex with glutamate and positive allosteric modulators
4LZ8	;	1.85	;	Crystal structures of GLuR2 ligand-binding-domain in complex with glutamate and positive allosteric modulators
1OR0	;	2.0	;	Crystal Structures of Glutaryl 7-Aminocephalosporanic Acid Acylase: Insight into Autoproteolytic Activation
3S8R	;	2.5	;	Crystal Structures of Glutaryl 7-Aminocephalosporanic Acid Acylase: Insight into Autoproteolytic Activation
2ADV	;	2.244	;	Crystal Structures Of Glutaryl 7-Aminocephalosporanic Acid Acylase: mutational study of activation mechanism
3V1Y	;	1.86	;	Crystal structures of glyceraldehyde-3-phosphate dehydrogenase complexes with NAD
1HVQ	;	2.2	;	CRYSTAL STRUCTURES OF HEVAMINE, A PLANT DEFENCE PROTEIN WITH CHITINASE AND LYSOZYME ACTIVITY, AND ITS COMPLEX WITH AN INHIBITOR
2P5E	;	1.89	;	Crystal Structures of High Affinity Human T-Cell Receptors Bound to pMHC Reveal Native Diagonal Binding Geometry
2P5W	;	2.2	;	Crystal structures of high affinity human T-cell receptors bound to pMHC reveal native diagonal binding geometry
2PYE	;	2.3	;	Crystal Structures of High Affinity Human T-Cell Receptors Bound to pMHC RevealNative Diagonal Binding Geometry TCR Clone C5C1 Complexed with MHC
2PYF	;	2.2	;	Crystal Structures of High Affinity Human T-Cell Receptors Bound to pMHC RevealNative Diagonal Binding Geometry Unbound TCR Clone 5-1
3BXR	;	1.6	;	Crystal Structures Of Highly Constrained Substrate And Hydrolysis Products Bound To HIV-1 Protease. Implications For Catalytic Mechanism
3BXS	;	1.6	;	Crystal Structures Of Highly Constrained Substrate And Hydrolysis Products Bound To HIV-1 Protease. Implications For Catalytic Mechanism
1SDT	;	1.3	;	Crystal structures of HIV protease V82A and L90M mutants reveal changes in indinavir binding site.
1SDU	;	1.25	;	Crystal structures of HIV protease V82A and L90M mutants reveal changes in indinavir binding site.
1SDV	;	1.4	;	Crystal structures of HIV protease V82A and L90M mutants reveal changes in indinavir binding site.
2VG5	;	2.8	;	Crystal structures of HIV-1 reverse transcriptase complexes with thiocarbamate non-nucleoside inhibitors
2VG6	;	3.01	;	Crystal structures of HIV-1 reverse transcriptase complexes with thiocarbamate non-nucleoside inhibitors
2VG7	;	2.82	;	Crystal structures of HIV-1 reverse transcriptase complexes with thiocarbamate non-nucleoside inhibitors
1IDA	;	1.7	;	CRYSTAL STRUCTURES OF HIV-2 PROTEASE IN COMPLEX WITH INHIBITORS CONTAINING THE HYDROXYETHYLAMINE DIPEPTIDE ISOSTERE
1IDB	;	2.2	;	Crystal structures of HIV-2 protease in complex with inhibitors containing the hydroxyethylamine dipeptide isostere
1XR8	;	2.3	;	Crystal Structures of HLA-B*1501 in Complex with Peptides from Human UbcH6 and Epstein-Barr Virus EBNA-3
1XR9	;	1.788	;	Crystal Structures of HLA-B*1501 in Complex with Peptides from Human UbcH6 and Epstein-Barr Virus EBNA-3
2WIW	;	1.8	;	Crystal structures of Holliday junction resolvases from Archaeoglobus fulgidus bound to DNA substrate
2WIZ	;	3.3	;	Crystal structures of Holliday junction resolvases from Archaeoglobus fulgidus bound to DNA substrate
2WJ0	;	3.1	;	Crystal structures of Holliday junction resolvases from Archaeoglobus fulgidus bound to DNA substrate
3L9E	;	2.05	;	Crystal structures of holo and Cu-deficient Cu/ZnSOD from the silkworm Bombyx mori and the implications in Amyotrophic lateral sclerosis
3L9Y	;	1.8	;	Crystal structures of holo and Cu-deficient Cu/ZnSOD from the silkworm Bombyx mori and the implications in Amyotrophic lateral sclerosis
5NAY	;	1.8	;	Crystal structures of homooligomers of collagen type IV. alpha1NC1
5NB2	;	2.5	;	Crystal structures of homooligomers of collagen type IV. alpha2NC1
5NB0	;	2.7	;	Crystal structures of homooligomers of collagen type IV. alpha3NC1
5NB1	;	2.82	;	Crystal structures of homooligomers of collagen type IV. alpha4NC1
5NAZ	;	1.85	;	Crystal structures of homooligomers of collagen type IV. alpha5NC1
5NAX	;	2.82	;	Crystal structures of homooligomers of the non-collagenous domains of collagen type IV. alpha121NC1
3FZH	;	2.0	;	Crystal Structures of Hsc70/Bag1 in Complex with Small Molecule Inhibitors
3FZK	;	2.1	;	Crystal Structures of Hsc70/Bag1 in Complex with Small Molecule Inhibitors
3FZL	;	2.2	;	Crystal Structures of Hsc70/Bag1 in Complex with Small Molecule Inhibitors
3FZM	;	2.3	;	Crystal Structures of Hsc70/Bag1 in Complex with Small Molecule Inhibitors
8G84	;	2.467	;	Crystal structures of HSD17B13 complexes
6WET	;	2.6	;	Crystal structures of human E-NPP 1: apo
6WFJ	;	2.5	;	Crystal structures of human E-NPP 1: apo
6WEU	;	2.65	;	Crystal structures of human E-NPP 1: bound to adenosine-5'-thio-monophosphate
6WEW	;	2.73	;	Crystal structures of human E-NPP 1: bound to N-{4-[(7-methoxyquinolin-4-yl)oxy]phenyl}sulfuric diamide
6WEV	;	2.9	;	Crystal structures of human E-NPP 1: bound to N-{[1-(6,7-dimethoxy-5,8-dihydroquinazolin-4-yl)piperidin-4-yl]methyl}sulfuric diamide
1EAV	;	2.6	;	Crystal Structures of Human Gephyrin and Plant Cnx1 G domains - Comparative Analysis and Functional Implications
1YC1	;	1.7	;	Crystal Structures of human HSP90alpha complexed with dihydroxyphenylpyrazoles
4O0S	;	2.5	;	Crystal structures of human kinase Aurora A
4O0U	;	2.6	;	Crystal structures of human kinase Aurora A
4O0W	;	2.6	;	Crystal structures of human kinase Aurora A
4AN2	;	2.5	;	Crystal structures of human MEK1 with carboxamide-based allosteric inhibitor XL518 (GDC-0973), or related analogs.
4AN3	;	2.1	;	Crystal structures of human MEK1 with carboxamide-based allosteric inhibitor XL518 (GDC-0973), or related analogs.
4AN9	;	2.8	;	Crystal structures of human MEK1 with carboxamide-based allosteric inhibitor XL518 (GDC-0973), or related analogs.
4ANB	;	2.2	;	Crystal structures of human MEK1 with carboxamide-based allosteric inhibitor XL518 (GDC-0973), or related analogs.
5WS3	;	2.3	;	Crystal structures of human orexin 2 receptor bound to the selective antagonist EMPA determined by serial femtosecond crystallography at SACLA
4L3J	;	2.1	;	Crystal structures of human p70S6K1 kinase domain
4L3L	;	2.1	;	Crystal structures of human p70S6K1 kinase domain (Zinc anomalous)
4L42	;	2.8	;	Crystal structures of human p70S6K1-PIF
4L43	;	3.0	;	Crystal structures of human p70S6K1-T389A (form I)
4L44	;	2.9	;	Crystal structures of human p70S6K1-T389A (form II)
4L45	;	2.9	;	Crystal structures of human p70S6K1-T389E
4L46	;	3.01	;	Crystal structures of human p70S6K1-WT
5B6N	;	2.895	;	Crystal structures of human peroxiredoxin 6 in sulfinic acid state
6SNO	;	2.7	;	Crystal structures of human PGM1 isoform 2
6SNP	;	2.75	;	Crystal structures of human PGM1 isoform 2
6SNQ	;	2.7	;	Crystal structures of human PGM1 isoform 2
1ND5	;	2.9	;	Crystal Structures of Human Prostatic Acid Phosphatase in Complex with a Phosphate Ion and alpha-Benzylaminobenzylphosphonic Acid Update the Mechanistic Picture and Offer New Insights into Inhibitor Design
1ND6	;	2.4	;	Crystal Structures of Human Prostatic Acid Phosphatase in Complex with a Phosphate Ion and alpha-Benzylaminobenzylphosphonic Acid Update the Mechanistic Picture and Offer New Insights into Inhibitor Design
2BTZ	;	2.2	;	crystal structures of human pyruvate dehydrogenase kinase 2 containing physiological and synthetic ligands
2BU2	;	2.4	;	crystal structures of human pyruvate dehydrogenase kinase 2 containing physiological and synthetic ligands
2BU5	;	2.35	;	crystal structures of human pyruvate dehydrogenase kinase 2 containing physiological and synthetic ligands
2BU6	;	2.4	;	crystal structures of human pyruvate dehydrogenase kinase 2 containing physiological and synthetic ligands
2BU7	;	2.4	;	crystal structures of human pyruvate dehydrogenase kinase 2 containing physiological and synthetic ligands
2BU8	;	2.5	;	crystal structures of human pyruvate dehydrogenase kinase 2 containing physiological and synthetic ligands
7RT9	;	1.9	;	Crystal structures of human PYY and NPY
7RTA	;	2.6	;	Crystal structures of human PYY and NPY
5XNQ	;	2.802	;	Crystal structures of human SALM5
5XNP	;	3.729	;	Crystal structures of human SALM5 in complex with human PTPdelta
5F70	;	1.8	;	Crystal structures of human TIM members
2QUK	;	2.8	;	Crystal structures of human tryptophanyl-tRNA synthetase in complex with ATP(putative)
2QUH	;	2.4	;	Crystal structures of human tryptophanyl-tRNA synthetase in complex with Trp
2QUJ	;	2.42	;	Crystal structures of human tryptophanyl-tRNA synthetase in complex with TrpAMP
2QUI	;	2.4	;	Crystal structures of human tryptophanyl-tRNA synthetase in complex with Tryptophanamide and ATP
6ADG	;	3.0	;	Crystal Structures of IDH1 R132H in complex with AG-881
6ADI	;	1.969	;	Crystal Structures of IDH2 R140Q in complex with AG-881
2PXY	;	2.23	;	Crystal structures of immune receptor complexes
3L0P	;	3.0	;	Crystal structures of Iron containing Adenylate kinase from Desulfovibrio gigas
3EYG	;	1.9	;	Crystal structures of JAK1 and JAK2 inhibitor complexes
3EYH	;	2.0	;	Crystal structures of JAK1 and JAK2 inhibitor complexes
3FUP	;	2.4	;	Crystal structures of JAK1 and JAK2 inhibitor complexes
3H7S	;	2.3	;	Crystal structures of K63-linked di- and tri-ubiquitin reveal a highly extended chain architecture
1G7U	;	2.8	;	CRYSTAL STRUCTURES OF KDO8P SYNTHASE IN ITS BINARY COMPLEX WITH SUBSTRATE PHOSPHOENOL PYRUVATE
1G7V	;	2.4	;	CRYSTAL STRUCTURES OF KDO8P SYNTHASE IN ITS BINARY COMPLEXES WITH THE MECHANISM-BASED INHIBITOR
1WVW	;	2.4	;	Crystal structures of kinase domain of DAP kinase in complex with small molecular inhibitors
1WVX	;	2.6	;	Crystal structures of kinase domain of DAP kinase in complex with small molecular inhibitors
1WVY	;	2.8	;	Crystal structures of kinase domain of DAP kinase in complex with small molecular inhibitors
1F9T	;	1.5	;	CRYSTAL STRUCTURES OF KINESIN MUTANTS REVEAL A SIGNALLING PATHWAY FOR ACTIVATION OF THE MOTOR ATPASE
3IGY	;	2.003	;	Crystal structures of Leishmania mexicana phosphoglycerate mutase at high cobalt concentrations
3IGZ	;	1.9	;	Crystal structures of Leishmania mexicana phosphoglycerate mutase at low cobalt concentration
3HQO	;	3.4	;	Crystal structures of Leishmania mexicana pyruvate kinase (LmPYK) in complex with ATP and Oxalate
4XPW	;	1.17	;	Crystal structures of Leu114F mutant
4LI1	;	2.658	;	Crystal Structures of Lgr4 and its complex with R-spondin1
4LI2	;	3.19	;	Crystal Structures of Lgr4 and its complex with R-spondin1
4EAY	;	2.35	;	Crystal structures of mannonate dehydratase from Escherichia coli strain K12 complexed with D-mannonate
7WDN	;	1.8	;	Crystal structures of MeBglD2 in complex with various saccharides
7WDO	;	2.21	;	Crystal structures of MeBglD2 in complex with various saccharides
7WDP	;	2.39	;	Crystal structures of MeBglD2 in complex with various saccharides
7WDR	;	2.0	;	Crystal structures of MeBglD2 in complex with various saccharides
7WDS	;	1.68	;	Crystal structures of MeBglD2 in complex with various saccharides
7WDV	;	1.812	;	Crystal structures of MeBglD2 in complex with various saccharides
3MDD	;	2.4	;	CRYSTAL STRUCTURES OF MEDIUM CHAIN ACYL-COA DEHYDROGENASE FROM PIG LIVER MITOCHONDRIA WITH AND WITHOUT SUBSTRATE
3MDE	;	2.4	;	CRYSTAL STRUCTURES OF MEDIUM CHAIN ACYL-COA DEHYDROGENASE FROM PIG LIVER MITOCHONDRIA WITH AND WITHOUT SUBSTRATE
3WB9	;	1.93	;	Crystal Structures of meso-diaminopimelate dehydrogenase from Symbiobacterium thermophilum
3WBB	;	1.93	;	Crystal Structures of meso-diaminopimelate dehydrogenase from Symbiobacterium thermophilum
1PHD	;	1.6	;	CRYSTAL STRUCTURES OF METYRAPONE-AND PHENYLIMIDAZOLE-INHIBITED COMPLEXES OF CYTOCHROME P450-CAM
1PHE	;	1.6	;	CRYSTAL STRUCTURES OF METYRAPONE-AND PHENYLIMIDAZOLE-INHIBITED COMPLEXES OF CYTOCHROME P450-CAM
1PHF	;	1.6	;	CRYSTAL STRUCTURES OF METYRAPONE-AND PHENYLIMIDAZOLE-INHIBITED COMPLEXES OF CYTOCHROME P450-CAM
1PHG	;	1.6	;	CRYSTAL STRUCTURES OF METYRAPONE-AND PHENYLIMIDAZOLE-INHIBITED COMPLEXES OF CYTOCHROME P450-CAM
5LDT	;	2.88	;	Crystal Structures of MOMP from Campylobacter jejuni
5LDV	;	2.1	;	Crystal Structures of MOMP from Campylobacter jejuni
4YK5	;	1.42	;	Crystal Structures of mPGES-1 Inhibitor Complexes
4YL0	;	1.52	;	Crystal Structures of mPGES-1 Inhibitor Complexes
4YL1	;	1.41	;	Crystal Structures of mPGES-1 Inhibitor Complexes
4YL3	;	1.41	;	Crystal Structures of mPGES-1 Inhibitor Complexes
4EI2	;	3.108	;	Crystal Structures of MthK RCK gating ring bound to Barium
3OQ7	;	1.71	;	Crystal Structures of Multidrug-Resistant Clinical Isolate 769 HIV-1 Protease Variants
3OQA	;	2.25	;	Crystal Structures of Multidrug-Resistant Clinical Isolate 769 HIV-1 Protease Variants
3OQD	;	1.71	;	Crystal Structures of Multidrug-Resistant Clinical Isolate 769 HIV-1 Protease Variants
3PJ6	;	2.25	;	Crystal Structures of Multidrug-Resistant Clinical Isolate 769 HIV-1 Protease Variants
3R0Y	;	1.65	;	Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors
3R0W	;	1.7	;	Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors.
1WBX	;	1.9	;	CRYSTAL STRUCTURES OF MURINE MHC CLASS I H-2 Db AND Kb MOLECULES IN COMPLEX WITH CTL EPITOPES FROM INFLUENZA A VIRUS: IMPLICATIONS FOR TCR REPERTOIRE SELECTION AND IMMUNODOMINANCE
1WBY	;	2.3	;	CRYSTAL STRUCTURES OF MURINE MHC CLASS I H-2 Db AND Kb MOLECULES IN COMPLEX WITH CTL EPITOPES FROM INFLUENZA A VIRUS: IMPLICATIONS FOR TCR REPERTOIRE SELECTION AND IMMUNODOMINANCE
1WBZ	;	2.0	;	CRYSTAL STRUCTURES OF MURINE MHC CLASS I H-2 Db AND Kb MOLECULES IN COMPLEX WITH CTL EPITOPES FROM INFLUENZA A VIRUS: IMPLICATIONS FOR TCR REPERTOIRE SELECTION AND IMMUNODOMINANCE
3UQS	;	2.0	;	Crystal structures of murine norovirus RNA-dependent RNA polymerase
3UR0	;	2.45	;	Crystal structures of murine norovirus RNA-dependent RNA polymerase in complex with Suramin
2TRS	;	2.04	;	CRYSTAL STRUCTURES OF MUTANT (BETAK87T) TRYPTOPHAN SYNTHASE ALPHA2 BETA2 COMPLEX WITH LIGANDS BOUND TO THE ACTIVE SITES OF THE ALPHA AND BETA SUBUNITS REVEAL LIGAND-INDUCED CONFORMATIONAL CHANGES
2TSY	;	2.5	;	CRYSTAL STRUCTURES OF MUTANT (BETAK87T) TRYPTOPHAN SYNTHASE ALPHA2 BETA2 COMPLEX WITH LIGANDS BOUND TO THE ACTIVE SITES OF THE ALPHA AND BETA SUBUNITS REVEAL LIGAND-INDUCED CONFORMATIONAL CHANGES
2TYS	;	1.9	;	CRYSTAL STRUCTURES OF MUTANT (BETAK87T) TRYPTOPHAN SYNTHASE ALPHA2 BETA2 COMPLEX WITH LIGANDS BOUND TO THE ACTIVE SITES OF THE ALPHA AND BETA SUBUNITS REVEAL LIGAND-INDUCED CONFORMATIONAL CHANGES
1FQE	;	1.8	;	CRYSTAL STRUCTURES OF MUTANT (K206A) THAT ABOLISH THE DILYSINE INTERACTION IN THE N-LOBE OF HUMAN TRANSFERRIN
1FQF	;	2.1	;	CRYSTAL STRUCTURES OF MUTANT (K296A) THAT ABOLISH THE DILYSINE INTERACTION IN THE N-LOBE OF HUMAN TRANSFERRIN
2UVR	;	2.9	;	Crystal structures of mutant Dpo4 DNA polymerases with 8-oxoG containing DNA template-primer constructs
2UVU	;	2.7	;	Crystal structures of mutant Dpo4 DNA polymerases with 8-oxoG containing DNA template-primer constructs
2UVV	;	2.2	;	Crystal structures of mutant Dpo4 DNA polymerases with 8-oxoG containing DNA template-primer constructs
2UVW	;	2.09	;	Crystal structures of mutant Dpo4 DNA polymerases with 8-oxoG containing DNA template-primer constructs
2WES	;	2.5	;	Crystal structures of mutant E46Q of tryptophan 5-halogenase (PyrH)
4HK8	;	1.151	;	Crystal Structures of Mutant Endo- -1,4-xylanase II Complexed with substrate (1.15 A) and Products (1.6 A)
4HKO	;	1.5	;	Crystal Structures of Mutant Endo-beta-1,4-xylanase II (E177Q) in the apo form
5ZH9	;	1.15	;	Crystal Structures of Mutant Endo-beta-1,4-xylanase II (Y88F)
5ZII	;	1.3	;	Crystal Structures of Mutant Endo-beta-1,4-xylanase II (Y88F)Complexed with Xylotriose
4HK9	;	1.55	;	Crystal Structures of Mutant Endo-beta-1,4-xylanase II Complexed with substrate (1.15 A) and Products (1.6 A)
4HKL	;	1.1	;	Crystal Structures of Mutant Endo-beta-1,4-xylanase II Complexed with substrate (1.15 A) and Products (1.6 A)
4HKW	;	1.65	;	Crystal Structures of Mutant Endo-beta-1,4-xylanase II Complexed with Substrate and Products
5ZKZ	;	1.3	;	Crystal Structures of Mutant Endo-beta-1,4-xylanase II(Y77F) Complexed with Xylotriose
5ZIW	;	1.3	;	Crystal Structures of Mutant Endo-beta-1,4-xylanase(Y77F)
1DMM	;	1.9	;	CRYSTAL STRUCTURES OF MUTANT ENZYMES Y57F OF KETOSTEROID ISOMERASE FROM PSEUDOMONAS PUTIDA BIOTYPE B
1PXA	;	2.3	;	CRYSTAL STRUCTURES OF MUTANT PSEUDOMONAS AERUGINOSA P-HYDROXYBENZOATE HYDROXYLASE: THE TYR201PHE, TYR385PHE, AND ASN300ASP VARIANTS
1PXB	;	2.3	;	CRYSTAL STRUCTURES OF MUTANT PSEUDOMONAS AERUGINOSA P-HYDROXYBENZOATE HYDROXYLASE: THE TYR201PHE, TYR385PHE, AND ASN300ASP VARIANTS
1PXC	;	2.1	;	CRYSTAL STRUCTURES OF MUTANT PSEUDOMONAS AERUGINOSA P-HYDROXYBENZOATE HYDROXYLASE: THE TYR201PHE, TYR385PHE, AND ASN300ASP VARIANTS
1F9U	;	1.7	;	CRYSTAL STRUCTURES OF MUTANTS REVEAL A SIGNALLING PATHWAY FOR ACTIVATION OF THE KINESIN MOTOR ATPASE
1F9V	;	1.3	;	CRYSTAL STRUCTURES OF MUTANTS REVEAL A SIGNALLING PATHWAY FOR ACTIVATION OF THE KINESIN MOTOR ATPASE
1F9W	;	2.5	;	CRYSTAL STRUCTURES OF MUTANTS REVEAL A SIGNALLING PATHWAY FOR ACTIVATION OF THE KINESIN MOTOR ATPASE
4RHT	;	2.7633	;	Crystal structures of Mycobacterium tuberculosis 6-oxopurine phosphoribosyltransferase which is a potential target for drug development against this disease
4RHU	;	2.573	;	Crystal structures of Mycobacterium tuberculosis 6-oxopurine phosphoribosyltransferase which is a potential target for drug development against this disease
4RHY	;	2.3196	;	Crystal structures of Mycobacterium tuberculosis 6-oxopurine phosphoribosyltransferase which is a potential target for drug development against this disease
2VOR	;	2.3	;	Crystal Structures of Mycobacterium tuberculosis Folylpolyglutamate Synthase Complexed with ADP and AMPPCP
3DHY	;	2.0	;	Crystal Structures of Mycobacterium tuberculosis S-Adenosyl-L-Homocysteine Hydrolase in Ternary Complex with Substrate and Inhibitors
4G5X	;	1.29	;	Crystal structures of N-acyl homoserine lactonase AidH
4G9E	;	1.088	;	Crystal structures of N-acyl homoserine lactonase AidH complexed with N-butanoyl homoserine
4G9G	;	1.35	;	Crystal structures of N-acyl homoserine lactonase AidH E219G mutant
4G8C	;	1.11	;	Crystal structures of N-acyl homoserine lactonase AidH E219G mutant complexed with N-hexanoyl homoserine
4G8D	;	1.35	;	Crystal structures of N-acyl homoserine lactonase AidH S102G mutant
4G8B	;	1.302	;	Crystal structures of N-acyl homoserine lactonase AidH S102G mutant complexed with N-hexanoyl homoserine lactone
7DDF	;	4.62	;	Crystal structures of Na+,K+-ATPase in complex with beryllium fluoride
7DDL	;	3.2	;	Crystal structures of Na+,K+-ATPase in complex with bufalin
7DDI	;	3.72	;	Crystal structures of Na+,K+-ATPase in complex with digitoxin
7DDH	;	3.46	;	Crystal structures of Na+,K+-ATPase in complex with digoxin
7WYS	;	3.71	;	Crystal structures of Na+,K+-ATPase in complex with istaroxime
7WYT	;	2.9	;	Crystal structures of Na+,K+-ATPase in complex with ouabain
7DDK	;	3.5	;	Crystal structures of Na+,K+-ATPase in complex with rostafuroxin
4LTD	;	2.186	;	Crystal structures of NADH:FMN oxidoreductase (EMOB) - apo form
4LTM	;	2.497	;	Crystal structures of NADH:FMN oxidoreductase (EMOB) - FMN complex
4LTN	;	1.996	;	Crystal structures of NADH:FMN oxidoreductase (EMOB) - FMN, NADH complex
1LYA	;	2.5	;	CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN
1LYB	;	2.5	;	CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN
3D12	;	3.005	;	Crystal Structures of Nipah Virus G Attachment Glycoprotein in Complex with its Receptor Ephrin-B3
1GMN	;	2.3	;	CRYSTAL STRUCTURES OF NK1-HEPARIN COMPLEXES REVEAL THE BASIS FOR NK1 ACTIVITY AND ENABLE ENGINEERING OF POTENT AGONISTS OF THE MET RECEPTOR
1GMO	;	3.0	;	CRYSTAL STRUCTURES OF NK1-HEPARIN COMPLEXES REVEAL THE BASIS FOR NK1 ACTIVITY AND ENABLE ENGINEERING OF POTENT AGONISTS OF THE MET RECEPTOR
4N1J	;	2.6	;	Crystal structures of NLRP14 pyrin domain reveal a conformational switch mechanism, regulating its molecular interactions
4N1K	;	3.0	;	Crystal structures of NLRP14 pyrin domain reveal a conformational switch mechanism, regulating its molecular interactions
4N1L	;	1.986	;	Crystal structures of NLRP14 pyrin domain reveal a conformational switch mechanism, regulating its molecular interactions
3VUT	;	3.5	;	Crystal structures of non-phosphorylated MAP2K4
5TSN	;	2.1	;	Crystal structures of Norwalk virus polymerase bound to an RNA primer-template duplex
3AV9	;	1.7	;	Crystal structures of novel allosteric peptide inhibitors of HIV integrase in the LEDGF binding site
3AVA	;	1.7	;	Crystal structures of novel allosteric peptide inhibitors of HIV integrase in the LEDGF binding site
3AVB	;	1.85	;	Crystal structures of novel allosteric peptide inhibitors of HIV integrase in the LEDGF binding site
3AVC	;	1.77	;	Crystal structures of novel allosteric peptide inhibitors of HIV integrase in the LEDGF binding site
3AVF	;	1.7	;	Crystal structures of novel allosteric peptide inhibitors of HIV integrase in the LEDGF binding site
3AVG	;	1.7	;	Crystal structures of novel allosteric peptide inhibitors of HIV integrase in the LEDGF binding site
3AVH	;	1.88	;	Crystal structures of novel allosteric peptide inhibitors of HIV integrase in the LEDGF binding site
3AVI	;	1.7	;	Crystal structures of novel allosteric peptide inhibitors of HIV integrase in the LEDGF binding site
3AVJ	;	1.7	;	Crystal structures of novel allosteric peptide inhibitors of HIV integrase in the LEDGF binding site
3AVK	;	1.75	;	Crystal structures of novel allosteric peptide inhibitors of HIV integrase in the LEDGF binding site
3AVL	;	1.88	;	Crystal structures of novel allosteric peptide inhibitors of HIV integrase in the LEDGF binding site
3AVM	;	1.88	;	Crystal structures of novel allosteric peptide inhibitors of HIV integrase in the LEDGF binding site
3AVN	;	2.1	;	Crystal structures of novel allosteric peptide inhibitors of HIV integrase in the LEDGF binding site
1XD5	;	2.0	;	Crystal structures of novel monomeric monocot mannose-binding lectins from Gastrodia elata
1XD6	;	2.0	;	Crystal structures of novel monomeric monocot mannose-binding lectins from Gastrodia elata
1PT3	;	2.5	;	Crystal structures of nuclease-ColE7 complexed with octamer DNA
7CB4	;	2.04	;	Crystal structures of of BlAsnase
290D	;	2.5	;	CRYSTAL STRUCTURES OF OLIGODEOXYRIBONUCLEOTIDES CONTAINING 6'-ALPHA-METHYL AND 6'-ALPHA-HYDROXY CARBOCYCLIC THYMIDINES
291D	;	2.14	;	CRYSTAL STRUCTURES OF OLIGODEOXYRIBONUCLEOTIDES CONTAINING 6'-ALPHA-METHYL AND 6'-ALPHA-HYDROXY CARBOCYCLIC THYMIDINES
1DR4	;	2.4	;	CRYSTAL STRUCTURES OF ORGANOMERCURIAL-ACTIVATED CHICKEN LIVER DIHYDROFOLATE REDUCTASE COMPLEXES
1DR5	;	2.4	;	CRYSTAL STRUCTURES OF ORGANOMERCURIAL-ACTIVATED CHICKEN LIVER DIHYDROFOLATE REDUCTASE COMPLEXES
1DR6	;	2.4	;	CRYSTAL STRUCTURES OF ORGANOMERCURIAL-ACTIVATED CHICKEN LIVER DIHYDROFOLATE REDUCTASE COMPLEXES
1DR7	;	2.4	;	CRYSTAL STRUCTURES OF ORGANOMERCURIAL-ACTIVATED CHICKEN LIVER DIHYDROFOLATE REDUCTASE COMPLEXES
1FDA	;	2.1	;	CRYSTAL STRUCTURES OF OXIDIZED AND REDUCED AZOTOBACTER VINELANDII FERREDOXIN AT PH 8 AND PH 6
1FDB	;	2.2	;	CRYSTAL STRUCTURES OF OXIDIZED AND REDUCED AZOTOBACTER VINELANDII FERREDOXIN AT PH 8 AND PH 6
5FD1	;	1.9	;	CRYSTAL STRUCTURES OF OXIDIZED AND REDUCED AZOTOBACTER VINELANDII FERREDOXIN AT PH 8 AND PH 6
2OBR	;	2.2	;	Crystal Structures of P Domain of Norovirus VA387
2OBS	;	2.0	;	Crystal Structures of P Domain of Norovirus VA387 in Complex with Blood Group Trisaccharides type A
2OBT	;	2.0	;	Crystal Structures of P Domain of Norovirus VA387 in Complex with Blood Group Trisaccharides type B
3L13	;	3.0	;	Crystal Structures of Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors
1GK9	;	1.3	;	Crystal structures of penicillin acylase enzyme-substrate complexes: Structural insights into the catalytic mechanism
1GKF	;	1.41	;	Crystal structures of penicillin acylase enzyme-substrate complexes: Structural insights into the catalytic mechanism
1GM7	;	1.45	;	Crystal structures of penicillin acylase enzyme-substrate complexes: Structural insights into the catalytic mechanism
1GM8	;	2.0	;	Crystal structures of penicillin acylase enzyme-substrate complexes: Structural insights into the catalytic mechanism
1GM9	;	1.8	;	Crystal structures of penicillin acylase enzyme-substrate complexes: Structural insights into the catalytic mechanism
3A3J	;	2.15	;	Crystal structures of penicillin binding protein 5 from Haemophilus influenzae
1AYA	;	2.05	;	CRYSTAL STRUCTURES OF PEPTIDE COMPLEXES OF THE AMINO-TERMINAL SH2 DOMAIN OF THE SYP TYROSINE PHOSPHATASE
1AYB	;	3.0	;	CRYSTAL STRUCTURES OF PEPTIDE COMPLEXES OF THE AMINO-TERMINAL SH2 DOMAIN OF THE SYP TYROSINE PHOSPHATASE
1AYC	;	2.3	;	CRYSTAL STRUCTURES OF PEPTIDE COMPLEXES OF THE AMINO-TERMINAL SH2 DOMAIN OF THE SYP TYROSINE PHOSPHATASE
1AYD	;	2.2	;	CRYSTAL STRUCTURES OF PEPTIDE COMPLEXES OF THE AMINO-TERMINAL SH2 DOMAIN OF THE SYP TYROSINE PHOSPHATASE
1Q1Y	;	1.9	;	Crystal Structures of Peptide Deformylase from Staphylococcus aureus Complexed with Actinonin
3TCN	;	2.3	;	Crystal structures of Peptidyl-tRNA hydrolase from Mycobacterium tuberculosis - Form 2 grown in presence of Pentaglycine
3TD2	;	2.5	;	Crystal structures of Peptidyl-tRNA hydrolase from Mycobacterium tuberculosis - Form 5
6JON	;	2.34	;	Crystal structures of phage NrS-1 N300-dNTPs-Mg2+ complex provide molecular mechanisms for substrate specificity
6JOP	;	2.353	;	Crystal structures of phage NrS-1 N300-dNTPs-Mg2+ complex provide molecular mechanisms for substrate specificity
6JOQ	;	2.4	;	Crystal structures of phage NrS-1 N300-dNTPs-Mg2+ complex provide molecular mechanisms for substrate specificity
2I0U	;	2.2	;	Crystal structures of phospholipases A2 from Vipera nikolskii venom revealing Triton X-100 bound in hydrophobic channel
1AT1	;	2.8	;	CRYSTAL STRUCTURES OF PHOSPHONOACETAMIDE LIGATED T AND PHOSPHONOACETAMIDE AND MALONATE LIGATED R STATES OF ASPARTATE CARBAMOYLTRANSFERASE AT 2.8-ANGSTROMS RESOLUTION AND NEUTRAL P*H
2AT1	;	2.8	;	CRYSTAL STRUCTURES OF PHOSPHONOACETAMIDE LIGATED T AND PHOSPHONOACETAMIDE AND MALONATE LIGATED R STATES OF ASPARTATE CARBAMOYLTRANSFERASE AT 2.8-ANGSTROMS RESOLUTION AND NEUTRAL PH
3AT1	;	2.8	;	CRYSTAL STRUCTURES OF PHOSPHONOACETAMIDE LIGATED T AND PHOSPHONOACETAMIDE AND MALONATE LIGATED R STATES OF ASPARTATE CARBAMOYLTRANSFERASE AT 2.8-ANGSTROMS RESOLUTION AND NEUTRAL PH
7XSV	;	2.66	;	Crystal Structures of PIM1 in Complex with Macrocyclic Compound H3
1QYC	;	2.2	;	Crystal structures of pinoresinol-lariciresinol and phenylcoumaran benzylic ether reductases, and their relationship to isoflavone reductases
1QYD	;	2.5	;	Crystal structures of pinoresinol-lariciresinol and phenylcoumaran benzylic ether reductases, and their relationship to isoflavone reductases
1TG5	;	1.9	;	Crystal structures of plant 4-hydroxyphenylpyruvate dioxygenases complexed with DAS645
5EMG	;	1.06	;	Crystal structures of PNA p(GCTGCTGC)2 duplex containing T-T mismatches
3TTN	;	2.0	;	Crystal structures of polyamine receptors SpuD and SpuE from Pseudomonas aeruginosa
5J0E	;	2.81	;	Crystal structures of Pribnow box consensus promoter sequence (P32)
5F26	;	3.0	;	Crystal structures of Pribnow box consensus promoter sequence (P63)
1S1P	;	1.2	;	Crystal structures of prostaglandin D2 11-ketoreductase (AKR1C3) in complex with the non-steroidal anti-inflammatory drugs flufenamic acid and indomethacin
1S1R	;	2.0	;	Crystal structures of prostaglandin D2 11-ketoreductase (AKR1C3) in complex with the non-steroidal anti-inflammatory drugs flufenamic acid and indomethacin
1S2A	;	1.7	;	Crystal structures of prostaglandin D2 11-ketoreductase in complex with the non-steroidal anti-inflammatory drugs flufenamic acid and indomethacin
1S2C	;	1.8	;	Crystal structures of prostaglandin D2 11-ketoreductase in complex with the non-steroidal anti-inflammatory drugs flufenamic acid and indomethacin
4DY7	;	2.8	;	Crystal structures of protease nexin-1 in complex with S195A thrombin
1XH4	;	2.45	;	Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants
1XH5	;	2.05	;	Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants
1XH6	;	1.9	;	Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants
1XH7	;	2.47	;	Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants
1XH8	;	1.6	;	Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants
1XH9	;	1.64	;	Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants
1XHA	;	2.46	;	Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants
1YWV	;	2.0	;	Crystal Structures of Proto-Oncogene Kinase Pim1: a Target of Aberrant Somatic Hypermutations in Diffuse Large Cell Lymphoma
3JYL	;	2.4	;	Crystal structures of Pseudomonas syringae pv. Tomato DC3000 quinone oxidoreductase
3JYN	;	2.01	;	Crystal structures of Pseudomonas syringae pv. Tomato DC3000 quinone oxidoreductase complexed with NADPH
4JV5	;	3.162	;	Crystal structures of pseudouridinilated stop codons with ASLs
4JYA	;	3.098	;	Crystal structures of pseudouridinilated stop codons with ASLs
2ZN7	;	2.1	;	CRYSTAL STRUCTURES OF PTP1B-Inhibitor Complexes
5OR2	;	2.5	;	Crystal structures of PYR1/HAB1 in complex with synthetic analogues of Abscisic Acid
5OR6	;	2.4	;	Crystal structures of PYR1/HAB1 in complex with synthetic analogues of Abscisic Acid
4E2T	;	1.75	;	Crystal Structures of RadA intein from Pyrococcus horikoshii
4E2U	;	1.582	;	Crystal Structures of RadAmin intein from Pyrococcus horikoshii
1U8Y	;	1.55	;	CRystal structures of Ral-GppNHp and Ral-GDP reveal two novel binding sites that are also present in Ras and Rap
1U8Z	;	1.5	;	Crystal structures of Ral-GppNHp and Ral-GDP reveal two novel binding sites that are also present in Ras and Rap
1U90	;	2.0	;	Crystal structures of Ral-GppNHp and Ral-GDP reveal two novel binding sites that are also present in Ras and Rap
1RPT	;	3.0	;	CRYSTAL STRUCTURES OF RAT ACID PHOSPHATASE COMPLEXED WITH THE TRANSITIONS STATE ANALOGS VANADATE AND MOLYBDATE: IMPLICATIONS FOR THE REACTION MECHANISM
1BRB	;	2.1	;	CRYSTAL STRUCTURES OF RAT ANIONIC TRYPSIN COMPLEXED WITH THE PROTEIN INHIBITORS APPI AND BPTI
2ZVJ	;	2.3	;	Crystal structures of rat Catechol-O-Methyltransferase complexed with coumarine-based inhibitor
3A7D	;	2.4	;	Crystal Structures of rat Catechol-O-Methyltransferase complexed with new bi-substrate type inhibitor
3VT3	;	1.7	;	Crystal structures of rat VDR-LBD with R270L mutation
3VT4	;	1.9	;	Crystal structures of rat VDR-LBD with R270L mutation
3VT5	;	2.11	;	Crystal structures of rat VDR-LBD with R270L mutation
3VT7	;	1.65	;	Crystal structures of rat VDR-LBD with W282R mutation
3VT8	;	2.1	;	Crystal structures of rat VDR-LBD with W282R mutation
3VT9	;	2.35	;	Crystal structures of rat VDR-LBD with W282R mutation
1CGE	;	1.9	;	CRYSTAL STRUCTURES OF RECOMBINANT 19-KDA HUMAN FIBROBLAST COLLAGENASE COMPLEXED TO ITSELF
1CGF	;	2.1	;	CRYSTAL STRUCTURES OF RECOMBINANT 19-KDA HUMAN FIBROBLAST COLLAGENASE COMPLEXED TO ITSELF
1IPK	;	2.7	;	CRYSTAL STRUCTURES OF RECOMBINANT AND NATIVE SOYBEAN BETA-CONGLYCININ BETA HOMOTRIMERS
1IPJ	;	2.7	;	CRYSTAL STRUCTURES OF RECOMBINANT AND NATIVE SOYBEAN BETA-CONGLYCININ BETA HOMOTRIMERS COMPLEXES WITH N-ACETYL-D-GLUCOSAMINE
1DHF	;	2.3	;	CRYSTAL STRUCTURES OF RECOMBINANT HUMAN DIHYDROFOLATE REDUCTASE COMPLEXED WITH FOLATE AND 5-DEAZOFOLATE
2DHF	;	2.3	;	CRYSTAL STRUCTURES OF RECOMBINANT HUMAN DIHYDROFOLATE REDUCTASE COMPLEXED WITH FOLATE AND 5-DEAZOFOLATE
1CPJ	;	2.2	;	CRYSTAL STRUCTURES OF RECOMBINANT RAT CATHEPSIN B AND A CATHEPSIN B-INHIBITOR COMPLEX: IMPLICATIONS FOR STRUCTURE-BASED INHIBITOR DESIGN
1CTE	;	2.1	;	CRYSTAL STRUCTURES OF RECOMBINANT RAT CATHEPSIN B AND A CATHEPSIN B-INHIBITOR COMPLEX: IMPLICATIONS FOR STRUCTURE-BASED INHIBITOR DESIGN
1THE	;	1.9	;	CRYSTAL STRUCTURES OF RECOMBINANT RAT CATHEPSIN B AND A CATHEPSIN B-INHIBITOR COMPLEX: IMPLICATIONS FOR STRUCTURE-BASED INHIBITOR DESIGN
1FUS	;	1.3	;	CRYSTAL STRUCTURES OF RIBONUCLEASE F1 OF FUSARIUM MONILIFORME IN ITS FREE FORM AND IN COMPLEX WITH 2'GMP
1FUT	;	2.0	;	CRYSTAL STRUCTURES OF RIBONUCLEASE F1 OF FUSARIUM MONILIFORME IN ITS FREE FORM AND IN COMPLEX WITH 2'GMP
1RDA	;	2.15	;	CRYSTAL STRUCTURES OF RIBONUCLEASE HI ACTIVE SITE MUTANTS FROM ESCHERICHIA COLI
1RDB	;	1.9	;	CRYSTAL STRUCTURES OF RIBONUCLEASE HI ACTIVE SITE MUTANTS FROM ESCHERICHIA COLI
1RDC	;	2.3	;	CRYSTAL STRUCTURES OF RIBONUCLEASE HI ACTIVE SITE MUTANTS FROM ESCHERICHIA COLI
1RMS	;	1.9	;	CRYSTAL STRUCTURES OF RIBONUCLEASE MS COMPLEXED WITH 3'-GUANYLIC ACID A GP*C ANALOGUE, 2'-DEOXY-2'-FLUOROGUANYLYL-3',5'-CYTIDINE
5HP8	;	2.3	;	Crystal structures of RidA in complex with pyruvate
5HP7	;	2.0	;	Crystal structures of RidA in the apo form
4U34	;	1.35	;	Crystal Structures of RNA Duplexes Containing 2-thio-Uridine
4U35	;	1.55	;	Crystal Structures of RNA Duplexes Containing 2-thio-Uridine
4ADL	;	2.2	;	Crystal structures of Rv1098c in complex with malate
2P6E	;	2.9	;	Crystal structures of Saccharomyces cerevisiae N-myristoyltransferase with bound myristoyl-CoA
2P6F	;	3.1	;	Crystal structures of Saccharomyces cerevisiae N-myristoyltransferase with bound myristoyl-CoA and inhibitors
2P6G	;	3.0	;	Crystal structures of Saccharomyces cerevisiae N-myristoyltransferase with bound myristoyl-CoA and inhibitors
1EQ4	;	1.8	;	CRYSTAL STRUCTURES OF SALT BRIDGE MUTANTS OF HUMAN LYSOZYME
1EQ5	;	1.8	;	CRYSTAL STRUCTURES OF SALT BRIDGE MUTANTS OF HUMAN LYSOZYME
1EQE	;	1.8	;	CRYSTAL STRUCTURES OF SALT BRIDGE MUTANTS OF HUMAN LYSOZYME
2A5K	;	2.3	;	Crystal structures of SARS coronavirus main peptidase inhibited by an aza-peptide epoxide in space group P212121
2A5I	;	1.88	;	Crystal structures of SARS coronavirus main peptidase inhibited by an aza-peptide epoxide in the space group C2
8IHO	;	2.55	;	Crystal structures of SARS-CoV-2 papain-like protease in complex with covalent inhibitors
3S6G	;	2.6681	;	Crystal structures of Seleno-substituted mutant mmNAGS in space group P212121
1QPP	;	2.6	;	CRYSTAL STRUCTURES OF SELF CAPPING PAPD CHAPERONE HOMODIMERS
1QPX	;	2.4	;	CRYSTAL STRUCTURES OF SELF-CAPPING PAPD CHAPERONE HOMODIMERS
1GY1	;	1.65	;	Crystal structures of Ser86Asp and Met148Leu Rusticyanin
1BYA	;	2.2	;	CRYSTAL STRUCTURES OF SOYBEAN BETA-AMYLASE REACTED WITH BETA-MALTOSE AND MALTAL: ACTIVE SITE COMPONENTS AND THEIR APPARENT ROLE IN CATALYSIS
1BYB	;	1.9	;	CRYSTAL STRUCTURES OF SOYBEAN BETA-AMYLASE REACTED WITH BETA-MALTOSE AND MALTAL: ACTIVE SITE COMPONENTS AND THEIR APPARENT ROLE IN CATALYSIS
1BYC	;	2.2	;	CRYSTAL STRUCTURES OF SOYBEAN BETA-AMYLASE REACTED WITH BETA-MALTOSE AND MALTAL: ACTIVE SITE COMPONENTS AND THEIR APPARENT ROLE IN CATALYSIS
1BYD	;	2.2	;	CRYSTAL STRUCTURES OF SOYBEAN BETA-AMYLASE REACTED WITH BETA-MALTOSE AND MALTAL: ACTIVE SITE COMPONENTS AND THEIR APPARENT ROLE IN CATALYSIS
5Y5T	;	1.8	;	Crystal structures of spleen tyrosine kinase in complex with a novel inhibitor
5Y5U	;	2.14	;	Crystal structures of spleen tyrosine kinase in complex with a novel inhibitor
6AQJ	;	1.373	;	Crystal structures of Staphylococcus aureus ketol-acid reductoisomerase in complex with two transition state analogs that have biocidal activity.
1Z28	;	2.3	;	Crystal Structures of SULT1A2 and SULT1A1*3: Implications in the bioactivation of N-hydroxy-2-acetylamino fluorine (OH-AAF)
1Z29	;	2.4	;	Crystal Structures of SULT1A2 and SULT1A1*3: Implications in the bioactivation of N-hydroxy-2-acetylamino fluorine (OH-AAF)
2AXH	;	2.7	;	Crystal structures of T cell receptor beta chains related to rheumatoid arthritis
2AXJ	;	2.65	;	Crystal structures of T cell receptor beta chains related to rheumatoid arthritis
1THN	;	2.5	;	Crystal Structures of the ADP and ATP bound forms of the Bacillus Anti-sigma factor SpoIIAB in complex with the Anti-anti-sigma SpoIIAA: inhibitory complex with ADP, crystal form I
1TH8	;	2.4	;	Crystal Structures of the ADP and ATP bound forms of the Bacillus Anti-sigma factor SpoIIAB in complex with the Anti-anti-sigma SpoIIAA: inhibitory complex with ADP, crystal form II
1TID	;	2.5	;	Crystal Structures of the ADP and ATP bound forms of the Bacillus Anti-sigma factor SpoIIAB in complex with the Anti-anti-sigma SpoIIAA: Poised for phosphorylation complex with ATP, crystal form I
1TIL	;	2.7	;	Crystal Structures of the ADP and ATP bound forms of the Bacillus Anti-sigma factor SpoIIAB in complex with the Anti-anti-sigma SpoIIAA:Poised for phosphorylation complex with ATP, crystal form II
6KUX	;	2.7	;	Crystal structures of the alpha2A adrenergic receptor in complex with an antagonist RSC.
2LHM	;	1.8	;	CRYSTAL STRUCTURES OF THE APO-AND HOLOMUTANT HUMAN LYSOZYMES WITH AN INTRODUCED CA2+ BINDING SITE
3LHM	;	1.8	;	CRYSTAL STRUCTURES OF THE APO-AND HOLOMUTANT HUMAN LYSOZYMES WITH AN INTRODUCED CA2+ BINDING SITE
2CF6	;	2.6	;	Crystal Structures of the Arabidopsis Cinnamyl Alcohol Dehydrogenases AtCAD5
2CF5	;	2.0	;	Crystal Structures of the Arabidopsis Cinnamyl Alcohol Dehydrogenases, AtCAD5
2I6I	;	2.15	;	crystal structures of the archaeal sulfolobus PTP-fold phosphatase
2PVU	;	1.79	;	Crystal structures of the arginine-, lysine-, histidine-binding protein ArtJ from the thermophilic bacterium Geobacillus stearothermophilus
2Q2A	;	1.79	;	Crystal structures of the arginine-, lysine-, histidine-binding protein ArtJ from the thermophilic bacterium Geobacillus stearothermophilus
2Q2C	;	2.35	;	Crystal structures of the arginine-, lysine-, histidine-binding protein ArtJ from the thermophilic bacterium Geobacillus stearothermophilus
217D	;	1.7	;	CRYSTAL STRUCTURES OF THE B-FORM DNA-RNA CHIMER (5'-D(*IP*)-R(*CP*)-D(*IP*)-R(*CP*)-D(*IP*CP*IP*C)-3') COMPLEXED WITH DISTAMYCIN
216D	;	1.73	;	CRYSTAL STRUCTURES OF THE B-FORM DNA-RNA CHIMER (5'-D(*IP*)-R(*CP*)-D(*IP*CP*IP*CP*IP*C)-3') COMPLEXED WITH DISTAMYCIN
1HZ6	;	1.7	;	CRYSTAL STRUCTURES OF THE B1 DOMAIN OF PROTEIN L FROM PEPTOSTREPTOCOCCUS MAGNUS WITH A TYROSINE TO TRYPTOPHAN SUBSTITUTION
1HZ5	;	1.8	;	CRYSTAL STRUCTURES OF THE B1 DOMAIN OF PROTEIN L FROM PEPTOSTREPTOCOCCUS MAGNUS, WITH A TYROSINE TO TRYPTOPHAN SUBSTITUTION
4P20	;	2.7	;	Crystal structures of the bacterial ribosomal decoding site complexed with amikacin
1ENA	;	2.15	;	CRYSTAL STRUCTURES OF THE BINARY CA2+ AND PDTP COMPLEXES AND THE TERNARY COMPLEX OF THE ASP 21->GLU MUTANT OF STAPHYLOCOCCAL NUCLEASE. IMPLICATIONS FOR CATALYSIS AND LIGAND BINDING
1ENC	;	1.95	;	CRYSTAL STRUCTURES OF THE BINARY CA2+ AND PDTP COMPLEXES AND THE TERNARY COMPLEX OF THE ASP 21->GLU MUTANT OF STAPHYLOCOCCAL NUCLEASE. IMPLICATIONS FOR CATALYSIS AND LIGAND BINDING
2ENB	;	2.05	;	CRYSTAL STRUCTURES OF THE BINARY CA2+ AND PDTP COMPLEXES AND THE TERNARY COMPLEX OF THE ASP 21->GLU MUTANT OF STAPHYLOCOCCAL NUCLEASE. IMPLICATIONS FOR CATALYSIS AND LIGAND BINDING
7SOL	;	2.25001	;	Crystal Structures of the bispecific ubiquitin/FAT10 activating enzyme, Uba6
5KHN	;	3.445	;	Crystal structures of the Burkholderia multivorans hopanoid transporter HpnN
5KHS	;	3.758	;	Crystal structures of the Burkholderia multivorans hopanoid transporter HpnN
1RO9	;	2.13	;	CRYSTAL STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHODIESTERASE 4B2B COMPLEXED WITH 8-Br-AMP
1ROR	;	2.0	;	CRYSTAL STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHODIESTERASE 4B2B COMPLEXED WITH AMP
3P73	;	1.32	;	Crystal Structures of the Chicken YF1*7.1 molecule
3P77	;	1.6	;	Crystal Structures of the Chicken YF1*7.1 molecule
1C8C	;	1.45	;	CRYSTAL STRUCTURES OF THE CHROMOSOMAL PROTEINS SSO7D/SAC7D BOUND TO DNA CONTAINING T-G MISMATCHED BASE PAIRS
4FH3	;	2.0	;	Crystal structures of the Cid1 poly (U) polymerase reveal the mechanism for UTP selectivity
4FHP	;	2.5	;	Crystal structures of the Cid1 poly (U) polymerase reveal the mechanism for UTP selectivity - CaUTP bound
4FHX	;	2.7	;	Crystal structures of the Cid1 poly (U) polymerase reveal the mechanism for UTP selectivity - H336N mutant bound to MgATP
4FHY	;	2.7	;	Crystal structures of the Cid1 poly (U) polymerase reveal the mechanism for UTP selectivity - Mg 3'-dATP bound
4FHV	;	2.1	;	Crystal structures of the Cid1 poly (U) polymerase reveal the mechanism for UTP selectivity - MgCTP bound
4FHW	;	2.5	;	Crystal structures of the Cid1 poly (U) polymerase reveal the mechanism for UTP selectivity - MgGTP bound
4FH5	;	2.3	;	Crystal structures of the Cid1 poly (U) polymerase reveal the mechanism for UTP selectivity - MgUTP bound
1INC	;	1.94	;	CRYSTAL STRUCTURES OF THE COMPLEX OF PORCINE PANCREATIC ELASTASE WITH TWO VALINE-DERIVED BENZOXAZINONE INHIBITORS
1AV4	;	2.2	;	CRYSTAL STRUCTURES OF THE COPPER-CONTAINING AMINE OXIDASE FROM ARTHROBACTER GLOBIFORMIS IN THE HOLO-AND APO-FORMS: IMPLICATIONS FOR THE BIOGENESIS OF TOPA QUINONE
1AVK	;	2.2	;	CRYSTAL STRUCTURES OF THE COPPER-CONTAINING AMINE OXIDASE FROM ARTHROBACTER GLOBIFORMIS IN THE HOLO-AND APO-FORMS: IMPLICATIONS FOR THE BIOGENESIS OF TOPA QUINONE
1AVL	;	2.8	;	CRYSTAL STRUCTURES OF THE COPPER-CONTAINING AMINE OXIDASE FROM ARTHROBACTER GLOBIFORMIS IN THE HOLO-AND APO-FORMS: IMPLICATIONS FOR THE BIOGENESIS OF TOPA QUINONE
3T53	;	3.37	;	Crystal structures of the extrusion state of the CusBA adaptor-transporter complex
1OZR	;	1.74	;	Crystal Structures of the Ferric, Ferrous and Ferrous-NO Forms of the Asp140Ala Mutant of Human Heme Oxygenase-1: Catalytic Implications
1OZW	;	1.55	;	Crystal Structures of the Ferric, Ferrous and Ferrous-NO Forms of the Asp140Ala Mutant of Human Heme Oxygenase-1: Catalytic Implications
1OYK	;	2.59	;	Crystal Structures of the Ferric, Ferrous, and Ferrous-NO Forms of the Asp140Ala Mutant of Human Heme Oxygenase-1: Catalytic Implications
1OYL	;	1.59	;	Crystal Structures of the Ferric, Ferrous, and Ferrous-NO Forms of the Asp140Ala Mutant of Human Heme Oxygenase-1: Catalytic Implications
1OZL	;	1.58	;	Crystal Structures of the Ferric, Ferrous, and Ferrous-NO Forms of the Asp140Ala Mutant of Human Heme Oxygenase-1: Catalytic Implications
1OZE	;	2.19	;	Crystal Structures of the Ferric, Ferrous, and Ferrous-NO Forms of the Asp140Ala Mutant of Human Heme Oxygenase-1:Catalytic Implications
4JN3	;	1.69	;	Crystal structures of the first condensation domain of the CDA synthetase
4JN5	;	2.44	;	Crystal structures of the first condensation domain of the CDA synthetase
1XJZ	;	1.88	;	Crystal Structures of the G139A, G139A-NO and G143H Mutants of Human Heme Oxygenase-1
1XK0	;	2.18	;	Crystal Structures of the G139A, G139A-NO and G143H Mutants of Human Heme Oxygenase-1
1XK1	;	2.08	;	Crystal Structures of the G139A, G139A-NO and G143H Mutants of Human Heme Oxygenase-1
3GIY	;	1.6	;	Crystal Structures of the G81A Mutant of the Active Chimera of (S)-Mandelate Dehydrogenase and its Complex with Two of its Substrates
3JYR	;	1.75	;	Crystal structures of the GacH receptor of Streptomyces glaucescens GLA.O in the unliganded form and in complex with acarbose and an acarbose homolog. Comparison with acarbose-loaded maltose binding protein of Salmonella typhimurium.
3JZJ	;	1.4	;	Crystal structures of the GacH receptor of Streptomyces glaucescens GLA.O in the unliganded form and in complex with acarbose and an acarbose homolog. Comparison with acarbose-loaded maltose binding protein of Salmonella typhimurium.
3K00	;	1.55	;	Crystal structures of the GacH receptor of Streptomyces glaucescens GLA.O in the unliganded form and in complex with acarbose and an acarbose homolog. Comparison with acarbose-loaded maltose binding protein of Salmonella typhimurium.
3K01	;	1.35	;	Crystal structures of the GacH receptor of Streptomyces glaucescens GLA.O in the unliganded form and in complex with acarbose and an acarbose homolog. Comparison with acarbose-loaded maltose binding protein of Salmonella typhimurium.
3K02	;	1.55	;	Crystal structures of the GacH receptor of Streptomyces glaucescens GLA.O in the unliganded form and in complex with acarbose and an acarbose homolog. Comparison with acarbose-loaded maltose binding protein of Salmonella typhimurium.
6IEH	;	2.892	;	Crystal structures of the hMTR4-NRDE2 complex
1G4A	;	3.0	;	CRYSTAL STRUCTURES OF THE HSLVU PEPTIDASE-ATPASE COMPLEX REVEAL AN ATP-DEPENDENT PROTEOLYSIS MECHANISM
1G4B	;	7.0	;	CRYSTAL STRUCTURES OF THE HSLVU PEPTIDASE-ATPASE COMPLEX REVEAL AN ATP-DEPENDENT PROTEOLYSIS MECHANISM
4RSY	;	1.93	;	Crystal structures of the Human leukotriene A4 Hydrolase complex with a potential inhibitor H7
1WD0	;	1.9	;	Crystal structures of the hyperthermophilic chromosomal protein Sac7d in complex with DNA decamers
1WD1	;	2.2	;	Crystal structures of the hyperthermophilic chromosomal protein Sac7d in complex with DNA decamers
2HQT	;	1.9	;	Crystal structures of the interacting domains from yeast glutamyl-tRNA synthetase and tRNA aminoacylation and nuclear export cofactor Arc1p reveal a novel function for an old fold
2HRA	;	1.9	;	Crystal structures of the interacting domains from yeast glutamyl-tRNA synthetase and tRNA aminoacylation and nuclear export cofactor Arc1p reveal a novel function for an old fold
3E87	;	2.3	;	Crystal structures of the kinase domain of AKT2 in complex with ATP-competitive inhibitors
3E88	;	2.5	;	Crystal structures of the kinase domain of AKT2 in complex with ATP-competitive inhibitors
3E8D	;	2.7	;	Crystal structures of the kinase domain of AKT2 in complex with ATP-competitive inhibitors
3E8C	;	2.2	;	Crystal structures of the kinase domain of PKA in complex with ATP-competitive inhibitors
3E8E	;	2.0	;	Crystal structures of the kinase domain of PKA in complex with ATP-competitive inhibitors
1KFD	;	3.9	;	CRYSTAL STRUCTURES OF THE KLENOW FRAGMENT OF DNA POLYMERASE I COMPLEXED WITH DEOXYNUCLEOSIDE TRIPHOSPHATE AND PYROPHOSPHATE
3SQ9	;	3.1	;	Crystal Structures of the Ligand Binding Domain of a Pentameric Alpha7 Nicotinic Receptor Chimera
3SQ6	;	2.8	;	Crystal Structures of the Ligand Binding Domain of a Pentameric Alpha7 Nicotinic Receptor Chimera with its Agonist Epibatidine
1UIV	;	1.95	;	Crystal structures of the liganded and unliganded nickel binding protein NikA from Escherichia coli (Nickel liganded form)
1UIU	;	1.85	;	Crystal structures of the liganded and unliganded nickel binding protein NikA from Escherichia coli (Nickel unliganded form)
4L4Y	;	1.9	;	Crystal structures of the LsrR proteins complexed with phospho-AI-2 and its two different analogs reveal distinct mechanisms for ligand recognition
4L4Z	;	2.3	;	Crystal structures of the LsrR proteins complexed with phospho-AI-2 and its two different analogs reveal distinct mechanisms for ligand recognition
4L50	;	2.1	;	Crystal structures of the LsrR proteins complexed with phospho-AI-2 and its two different analogs reveal distinct mechanisms for ligand recognition
4L51	;	1.9	;	Crystal structures of the LsrR proteins complexed with phospho-AI-2 and its two different analogs reveal distinct mechanisms for ligand recognition
4L5I	;	3.21	;	Crystal structures of the LsrR proteins complexed with phospho-AI-2 and its two different analogs reveal distinct mechanisms for ligand recognition
4L5J	;	2.6	;	Crystal structures of the LsrR proteins complexed with phospho-AI-2 and its two different analogs reveal distinct mechanisms for ligand recognition
2PSD	;	1.4	;	Crystal Structures of the Luciferase and Green Fluorescent Protein from Renilla Reniformis
2PSE	;	2.5	;	Crystal Structures of the Luciferase and Green Fluorescent Protein from Renilla Reniformis
2PSF	;	1.4	;	Crystal Structures of the Luciferase and Green Fluorescent Protein from Renilla Reniformis
2PSH	;	1.79	;	Crystal Structures of the Luciferase and Green Fluorescent Protein from Renilla Reniformis
2PSJ	;	1.8	;	Crystal Structures of the Luciferase and Green Fluorescent Protein from Renilla Reniformis
2RH7	;	1.5	;	Crystal Structures of the Luciferase and Green Fluorescent Protein from Renilla Reniformis
3N42	;	3.0	;	Crystal structures of the mature envelope glycoprotein complex (furin cleavage) of Chikungunya virus.
3N43	;	2.58	;	Crystal structures of the mature envelope glycoprotein complex (trypsin cleavage) of Chikungunya virus.
2CHS	;	1.9	;	CRYSTAL STRUCTURES OF THE MONOFUNCTIONAL CHORISMATE MUTASE FROM BACILLUS SUBTILIS AND ITS COMPLEX WITH A TRANSITION STATE ANALOG
2CHT	;	2.2	;	CRYSTAL STRUCTURES OF THE MONOFUNCTIONAL CHORISMATE MUTASE FROM BACILLUS SUBTILIS AND ITS COMPLEX WITH A TRANSITION STATE ANALOG
2AEM	;	2.8	;	Crystal Structures of the MthK RCK Domain
2AEF	;	1.7	;	Crystal Structures of the MthK RCK Domain in Ca2+ bound form
2AEJ	;	2.1	;	Crystal Structures of the MthK RCK Domain in no Ca2+ bound form
6H6D	;	2.4	;	Crystal structures of the murine class I major histocompatibility complex H-2Db in complex with adenovirus-derived peptide Ad10
3QUK	;	2.41	;	Crystal structures of the murine class I major histocompatibility complex H-2Db in complex with LCMV-derived gp33 altered peptide ligand (Y4A)
3QUL	;	2.0	;	Crystal structures of the murine class I major histocompatibility complex H-2Db in complex with LCMV-derived gp33 altered peptide ligand (Y4S)
1S7U	;	2.2	;	Crystal structures of the murine class I major histocompatibility complex H-2Db in complex with LCMV-derived gp33 index peptide and three of its escape variants
1S7V	;	2.2	;	Crystal structures of the murine class I major histocompatibility complex H-2Db in complex with LCMV-derived gp33 index peptide and three of its escape variants
1S7W	;	2.4	;	Crystal structures of the murine class I major histocompatibility complex H-2Db in complex with LCMV-derived gp33 index peptide and three of its escape variants
1S7X	;	2.41	;	Crystal structures of the murine class I major histocompatibility complex H-2Db in complex with LCMV-derived gp33 index peptide and three of its escape variants
6MP1	;	2.211	;	Crystal structures of the murine class I major histocompatibility complex H-2Db in complex with the mutant TRP1-K8 peptide
6MP0	;	2.0	;	Crystal structures of the murine class I major histocompatibility complex H-2Db in complex with the TRP1-M9 peptide
6H6H	;	2.4	;	Crystal structures of the murine class I major histocompatibility complex H-2Dbm13 in complex with adenovirus-derived peptide Ad10
1S7Q	;	1.99	;	Crystal structures of the murine class I major histocompatibility complex H-2Kb in complex with LCMV-derived gp33 index peptide and three of its escape variants
1S7R	;	2.95	;	Crystal structures of the murine class I major histocompatibility complex H-2Kb in complex with LCMV-derived gp33 index peptide and three of its escape variants
1S7S	;	1.99	;	Crystal structures of the murine class I major histocompatibility complex H-2Kb in complex with LCMV-derived gp33 index peptide and three of its escape variants
1S7T	;	2.3	;	Crystal structures of the murine class I major histocompatibility complex H-2Kb in complex with LCMV-derived gp33 index peptide and three of its escape variants
1CMK	;	2.9	;	CRYSTAL STRUCTURES OF THE MYRISTYLATED CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE REVEAL OPEN AND CLOSED CONFORMATIONS
6AIC	;	1.8	;	Crystal structures of the N-terminal domain of Staphylococcus aureus DEAD-box Cold shock RNA helicase CshA in complex with AMP
1D0E	;	3.0	;	CRYSTAL STRUCTURES OF THE N-TERMINAL FRAGMENT FROM MOLONEY MURINE LEUKEMIA VIRUS REVERSE TRANSCRIPTASE COMPLEXED WITH NUCLEIC ACID: FUNCTIONAL IMPLICATIONS FOR TEMPLATE-PRIMER BINDING TO THE FINGERS DOMAIN
1QAI	;	2.3	;	CRYSTAL STRUCTURES OF THE N-TERMINAL FRAGMENT FROM MOLONEY MURINE LEUKEMIA VIRUS REVERSE TRANSCRIPTASE COMPLEXED WITH NUCLEIC ACID: FUNCTIONAL IMPLICATIONS FOR TEMPLATE-PRIMER BINDING TO THE FINGERS DOMAIN
1QAJ	;	2.3	;	CRYSTAL STRUCTURES OF THE N-TERMINAL FRAGMENT FROM MOLONEY MURINE LEUKEMIA VIRUS REVERSE TRANSCRIPTASE COMPLEXED WITH NUCLEIC ACID: FUNCTIONAL IMPLICATIONS FOR TEMPLATE-PRIMER BINDING TO THE FINGERS DOMAIN
2WIA	;	2.45	;	Crystal Structures of the N-terminal Intracellular Domain of FeoB from Klebsiella Pneumoniae in Apo Form
2WIB	;	2.56	;	Crystal Structures of the N-terminal Intracellular Domain of FeoB from Klebsiella Pneumoniae in GDP binding state
2WIC	;	2.05	;	Crystal Structures of the N-terminal Intracellular Domain of FeoB from Klebsiella Pneumoniae in GMPPNP binding state
6AIB	;	1.5	;	Crystal structures of the N-terminal RecA-like domain 1 of Staphylococcus aureus DEAD-box Cold shock RNA helicase CshA
3D11	;	2.306	;	Crystal Structures of the Nipah G Attachment Glycoprotein
1P3T	;	2.1	;	Crystal Structures of the NO-and CO-Bound Heme Oxygenase From Neisseria Meningitidis: Implications for Oxygen Activation
1P3U	;	1.75	;	Crystal Structures of the NO-and CO-Bound Heme Oxygenase From Neisseria Meningitidis: Implications for Oxygen Activation
1P3V	;	2.25	;	Crystal Structures of the NO-and CO-Bound Heme Oxygenase From Neisseria Meningitidis: Implications for Oxygen Activation
1MZ8	;	2.0	;	CRYSTAL STRUCTURES OF THE NUCLEASE DOMAIN OF COLE7/IM7 IN COMPLEX WITH A PHOSPHATE ION AND A ZINC ION
1U54	;	2.8	;	Crystal Structures of the Phosphorylated and Unphosphorylated Kinase Domains of the CDC42-associated Tyrosine Kinase ACK1 bound to AMP-PCP
2C81	;	1.7	;	Crystal structures of the PLP- and PMP-bound forms of BtrR, a dual functional aminotransferase involved in butirosin biosynthesis.
3T51	;	3.9	;	Crystal structures of the pre-extrusion and extrusion states of the CusBA adaptor-transporter complex
1IYZ	;	2.8	;	Crystal Structures of the Quinone Oxidoreductase from Thermus thermophilus HB8 and Its Complex with NADPH
1IZ0	;	2.3	;	Crystal Structures of the Quinone Oxidoreductase from Thermus thermophilus HB8 and Its Complex with NADPH
6QF7	;	4.0	;	Crystal structures of the recombinant beta-Factor XIIa protease with bound Thr-Arg and Pro-Arg substrate mimetics
1MHX	;	1.8	;	Crystal Structures of the redesigned protein G variant NuG1
3V1O	;	1.876	;	Crystal structures of the reverse transcriptase-associated ribonuclease H domain of xenotropic murine leukemia-virus related virus
3V1Q	;	2.0	;	Crystal structures of the reverse transcriptase-associated ribonuclease H domain of xenotropic murine leukemia-virus related virus
3V1R	;	2.8	;	Crystal structures of the reverse transcriptase-associated ribonuclease H domain of XMRV with inhibitor beta-thujaplicinol
3B5J	;	2.0	;	Crystal Structures of the S504A Mutant of an Isolated ABC-ATPase in Complex with TNP-ADP
2V6N	;	1.98	;	Crystal structures of the SARS-coronavirus main proteinase inactivated by benzotriazole compounds
5GVT	;	2.61	;	Crystal structures of the serine protease domain of murine plasma kallikrein
6A8O	;	2.77	;	Crystal structures of the serine protease domain of murine plasma kallikrein with peptide inhibitor mupain-1-16
6G8T	;	2.67	;	Crystal Structures of the Single PDZ Domains from GRASP65 and their Interaction with the Golgin GM130
6G8W	;	2.12	;	Crystal Structures of the Single PDZ Domains from GRASP65 and their Interaction with the Golgin GM130
6G8Y	;	1.4	;	Crystal Structures of the Single PDZ Domains from GRASP65 and their Interaction with the Golgin GM130
1I94	;	3.2	;	CRYSTAL STRUCTURES OF THE SMALL RIBOSOMAL SUBUNIT WITH TETRACYCLINE, EDEINE AND IF3
3E5E	;	2.9	;	Crystal Structures of the SMK box (SAM-III) Riboswitch with SAH
3E5F	;	2.7	;	Crystal Structures of the SMK box (SAM-III) Riboswitch with Se-SAM
3U7K	;	1.9	;	Crystal structures of the Staphylococcus aureus peptide deformylase in complex with two classes of new inhibitors
3U7L	;	2.01	;	Crystal structures of the Staphylococcus aureus peptide deformylase in complex with two classes of new inhibitors
3U7M	;	2.15	;	Crystal structures of the Staphylococcus aureus peptide deformylase in complex with two classes of new inhibitors
3U7N	;	2.3	;	Crystal structures of the Staphylococcus aureus peptide deformylase in complex with two classes of new inhibitors
2HFN	;	1.8	;	Crystal Structures of the Synechocystis Photoreceptor Slr1694 Reveal Distinct Structural States Related to Signaling
2HFO	;	2.1	;	Crystal Structures of the Synechocystis Photoreceptor Slr1694 Reveal Distinct Structural States Related to Signaling
5H36	;	3.409	;	Crystal structures of the TRIC trimeric intracellular cation channel orthologue from Rhodobacter sphaeroides
5H35	;	2.642	;	Crystal structures of the TRIC trimeric intracellular cation channel orthologue from Sulfolobus solfataricus
1Z1W	;	2.7	;	Crystal structures of the tricorn interacting facor F3 from Thermoplasma acidophilum, a zinc aminopeptidase in three different conformations
1Z5H	;	2.3	;	Crystal structures of the Tricorn interacting Factor F3 from Thermoplasma acidophilum
5Z1Q	;	2.3	;	Crystal structures of the trimeric N-terminal domain of Ciliate Euplotes octocarinatus Centrin
2AAG	;	1.85	;	Crystal Structures of the Wild-type, Mutant-P1A and Inactivated Malonate Semialdehyde Decarboxylase: A Structural Basis for the Decarboxylase and Hydratase Activities
2AAJ	;	2.74	;	Crystal Structures of the Wild-type, Mutant-P1A and Inactivated Malonate Semialdehyde Decarboxylase: A Structural Basis for the Decarboxylase and Hydratase Activities
2AAL	;	1.65	;	Crystal Structures of the Wild-type, Mutant-P1A and Inactivated Malonate Semialdehyde Decarboxylase: A Structural Basis for the Decarboxylase and Hydratase Activities
3AMG	;	2.4	;	Crystal structures of Thermotoga maritima Cel5A in complex with Cellobiose substrate, mutant form
3AOF	;	1.288	;	Crystal structures of Thermotoga maritima Cel5A in complex with Mannotriose substrate
3AMC	;	1.4	;	Crystal structures of Thermotoga maritima Cel5A, apo form and dimer/au
3AMD	;	2.0	;	Crystal structures of Thermotoga maritima Cel5A, apo form and tetramer/au
4POM	;	1.85	;	Crystal structures of thioredoxin with mesna at 1.85A resolution
4POK	;	2.52	;	Crystal structures of thioredoxin with mesna at 2.5A resolution
4POL	;	2.8	;	Crystal structures of thioredoxin with mesna at 2.8A resolution
1A4W	;	1.8	;	CRYSTAL STRUCTURES OF THROMBIN WITH THIAZOLE-CONTAINING INHIBITORS: PROBES OF THE S1' BINDING SITE
2B1G	;	2.1	;	Crystal structures of transition state analogue inhibitors of inosine monophosphate cyclohydrolase
2B1I	;	2.02	;	crystal structures of transition state analogue inhibitors of inosine monophosphate cyclohydrolase
2IU0	;	2.53	;	crystal structures of transition state analogue inhibitors of inosine monophosphate cyclohydrolase
2IU3	;	2.9	;	Crystal structures of transition state analogue inhibitors of inosine monophosphate cyclohydrolase
4WF7	;	2.21	;	Crystal structures of trehalose synthase from Deinococcus radiodurans reveal that a closed conformation is involved in the intramolecular isomerization catalysis
1MAP	;	2.4	;	CRYSTAL STRUCTURES OF TRUE ENZYMATIC REACTION INTERMEDIATES: ASPARTATE AND GLUTAMATE KETIMINES IN ASPARTATE AMINOTRANSFERASE
1MAQ	;	2.3	;	CRYSTAL STRUCTURES OF TRUE ENZYMATIC REACTION INTERMEDIATES: ASPARTATE AND GLUTAMATE KETIMINES IN ASPARTATE AMINOTRANSFERASE
2GIA	;	1.89	;	Crystal structures of trypanosoma bruciei MRP1/MRP2
2GID	;	3.35	;	Crystal structures of trypanosoma bruciei MRP1/MRP2
1THI	;	3.2	;	CRYSTAL STRUCTURES OF TWO INTENSELY SWEET PROTEINS
3MON	;	2.8	;	CRYSTAL STRUCTURES OF TWO INTENSELY SWEET PROTEINS
1KSX	;	3.2	;	Crystal Structures of Two Intermediates in the Assembly of the Papillomavirus Replication Initiation Complex
1KSY	;	3.05	;	Crystal Structures of Two Intermediates in the Assembly of the Papillomavirus Replication Initiation Complex
396D	;	1.8	;	CRYSTAL STRUCTURES OF TWO ISOMOPHOUS A-DNA DECAMERS D(GTACGCGTAC) AND D(GGCCGCGGCC)
395D	;	1.9	;	CRYSTAL STRUCTURES OF TWO ISOMORPHOUS A-DNA DECAMERS D(GTACGCGTAC) AND D(GGCCGCGGCC)
1NCB	;	2.5	;	CRYSTAL STRUCTURES OF TWO MUTANT NEURAMINIDASE-ANTIBODY COMPLEXES WITH AMINO ACID SUBSTITUTIONS IN THE INTERFACE
1NCC	;	2.5	;	CRYSTAL STRUCTURES OF TWO MUTANT NEURAMINIDASE-ANTIBODY COMPLEXES WITH AMINO ACID SUBSTITUTIONS IN THE INTERFACE
7DMO	;	2.0	;	Crystal structures of two pericyclases catalyzing [4+2] cycloadditions
4O1J	;	2.695	;	Crystal structures of two tetrameric beta-carbonic anhydrases from the filamentous ascomycete Sordaria macrospora.
4O1K	;	1.83	;	Crystal structures of two tetrameric beta-carbonic anhydrases from the filamentous ascomycete Sordaria macrospora.
1PZV	;	2.52	;	Crystal structures of two UBC (E2) enzymes of the ubiquitin-conjugating system in Caenorhabditis elegans
1Q34	;	2.9	;	Crystal structures of two UBC (E2) enzymes of the ubiquitin-conjugating system in Caenorhabditis elegans
1UIW	;	1.5	;	Crystal Structures of Unliganded and Half-Liganded Human Hemoglobin Derivatives Cross-Linked between Lys 82beta1 and Lys 82beta2
5YVU	;	2.491	;	Crystal structures of unlinked full length NS3 from Dengue virus provide insights into dynamics of protease domain
5GPI	;	1.578	;	Crystal Structures of Unlinked NS2B-NS3 Protease from Zika Virus and Its Complex with a Reverse Peptide Inhibitor
3KGP	;	2.35	;	Crystal Structures of Urokinase-type Plasminogen Activator in Complex with 4-(Aminomethyl) Benzoic Acid and 4-(Aminomethyl-phenyl)-methanol
3KHV	;	2.35	;	Crystal Structures of Urokinase-type Plasminogen Activator in Complex with 4-(Aminomethyl) Benzoic Acid and 4-(Aminomethyl-phenyl)-methanol
3OTM	;	1.5	;	Crystal structures of wild-type gamma-carbonic anhydrase from Methanosarcina thermophila
1PBB	;	2.5	;	CRYSTAL STRUCTURES OF WILD-TYPE P-HYDROXYBENZOATE HYDROXYLASE COMPLEXED WITH 4-AMINOBENZOATE, 2,4-DIHYDROXYBENZOATE AND 2-HYDROXY-4-AMINOBENZOATE AND OF THE TRY222ALA MUTANT, COMPLEXED WITH 2-HYDROXY-4-AMINOBENZOATE. EVIDENCE FOR A PROTON CHANNEL AND A NEW BINDING MODE OF THE FLAVIN RING
1PBC	;	2.8	;	CRYSTAL STRUCTURES OF WILD-TYPE P-HYDROXYBENZOATE HYDROXYLASE COMPLEXED WITH 4-AMINOBENZOATE, 2,4-DIHYDROXYBENZOATE AND 2-HYDROXY-4-AMINOBENZOATE AND OF THE TRY222ALA MUTANT, COMPLEXED WITH 2-HYDROXY-4-AMINOBENZOATE. EVIDENCE FOR A PROTON CHANNEL AND A NEW BINDING MODE OF THE FLAVIN RING
1PBD	;	2.3	;	CRYSTAL STRUCTURES OF WILD-TYPE P-HYDROXYBENZOATE HYDROXYLASE COMPLEXED WITH 4-AMINOBENZOATE, 2,4-DIHYDROXYBENZOATE AND 2-HYDROXY-4-AMINOBENZOATE AND OF THE TRY222ALA MUTANT, COMPLEXED WITH 2-HYDROXY-4-AMINOBENZOATE. EVIDENCE FOR A PROTON CHANNEL AND A NEW BINDING MODE OF THE FLAVIN RING
1PBF	;	2.7	;	CRYSTAL STRUCTURES OF WILD-TYPE P-HYDROXYBENZOATE HYDROXYLASE COMPLEXED WITH 4-AMINOBENZOATE, 2,4-DIHYDROXYBENZOATE AND 2-HYDROXY-4-AMINOBENZOATE AND OF THE TRY222ALA MUTANT, COMPLEXED WITH 2-HYDROXY-4-AMINOBENZOATE. EVIDENCE FOR A PROTON CHANNEL AND A NEW BINDING MODE OF THE FLAVIN RING
1YHA	;	2.5	;	CRYSTAL STRUCTURES OF Y41H AND Y41F MUTANTS OF GENE V PROTEIN FROM FF PHAGE SUGGEST POSSIBLE PROTEIN-PROTEIN INTERACTIONS IN GVP-SSDNA COMPLEX
1YHB	;	2.2	;	CRYSTAL STRUCTURES OF Y41H AND Y41F MUTANTS OF GENE V PROTEIN FROM FF PHAGE SUGGEST POSSIBLE PROTEIN-PROTEIN INTERACTIONS IN GVP-SSDNA COMPLEX
2FN1	;	2.1	;	Crystal structures of Yersinia enterocolitica salicylate synthase (Irp9) in complex with the reaction products salicylate and pyruvate
3BLT	;	2.2	;	Crystal structures of YopH complexed with PVSN and PVS, inhibitors of YopH which co-valent bind to Cys of active site
3TIO	;	1.41	;	Crystal structures of yrdA from Escherichia coli, a homologous protein of gamma-class carbonic anhydrase, show possible allosteric conformations
3TIS	;	2.3	;	Crystal structures of yrdA from Escherichia coli, a homologous protein of gamma-class carbonic anhydrases, show possible allosteric conformations
3QY6	;	1.8	;	Crystal structures of YwqE from Bacillus subtilis and CpsB from Streptococcus pneumoniae, unique metal-dependent tyrosine phosphatases
3QY7	;	1.62	;	Crystal structures of YwqE from Bacillus subtilis and CpsB from Streptococcus pneumoniae, unique metal-dependent tyrosine phosphatases
3QY8	;	2.0	;	Crystal structures of YwqE from Bacillus subtilis and CpsB from Streptococcus pneumoniae, unique metal-dependent tyrosine phosphatases
2XB4	;	1.8	;	Crystal structures of zinc containing Adenylate kinase from Desulfovibrio gigas
3L0S	;	2.0	;	Crystal structures of Zinc, Cobalt and Iron containing Adenylate kinase from Gram-negative bacteria Desulfovibrio gigas
2EBF	;	1.9	;	Crystal structures reveal a thiol-protease like catalytic triad in the C-terminal region of Pasteurella multocida toxin
2EBH	;	2.4	;	Crystal structures reveal a thiol-protease like catalytic triad in the C-terminal region of Pasteurella multocida toxin
2EC5	;	2.6	;	Crystal structures reveal a thiol-protease like catalytic triad in the C-terminal region of Pasteurella multocida toxin
5J3W	;	2.55	;	Crystal structures reveal signaling states of a short blue light photoreceptor protein PpSB1-LOV (dark state)
5J4E	;	2.67	;	Crystal structures reveal signaling states of a short blue light photoreceptor protein PpSB1-LOV (Photoexcited state)
4F1Z	;	2.3	;	Crystal structures reveal the multi-ligand binding mechanism of the Staphylococcus aureus ClfB
4F20	;	2.502	;	Crystal structures reveal the multi-ligand binding mechanism of the Staphylococcus aureus ClfB
4F24	;	2.509	;	Crystal structures reveal the multi-ligand binding mechanism of the Staphylococcus aureus ClfB
4F27	;	1.917	;	Crystal structures reveal the multi-ligand binding mechanism of the Staphylococcus aureus ClfB
4YZS	;	3.14	;	Crystal structures reveal transient PERK luminal domain tetramerization in ER stress signaling
4YZY	;	3.2	;	Crystal structures reveal transient PERK luminal domain tetramerization in ER stress signaling
1IAA	;	1.9	;	CRYSTAL STRUCTURES, SPECTROSCOPIC FEATURES, AND CATALYTIC PROPERTIES OF COBALT(II), COPPER(II), NICKEL(II), AND MERCURY(II) DERIVATIVES OF THE ZINC ENDOPEPTIDASE ASTACIN. A CORRELATION OF STRUCTURE AND PROTEOLYTIC ACTIVITY
1IAB	;	1.79	;	CRYSTAL STRUCTURES, SPECTROSCOPIC FEATURES, AND CATALYTIC PROPERTIES OF COBALT(II), COPPER(II), NICKEL(II), AND MERCURY(II) DERIVATIVES OF THE ZINC ENDOPEPTIDASE ASTACIN. A CORRELATION OF STRUCTURE AND PROTEOLYTIC ACTIVITY
1IAE	;	1.83	;	CRYSTAL STRUCTURES, SPECTROSCOPIC FEATURES, AND CATALYTIC PROPERTIES OF COBALT(II), COPPER(II), NICKEL(II), AND MERCURY(II) DERIVATIVES OF THE ZINC ENDOPEPTIDASE ASTACIN. A CORRELATION OF STRUCTURE AND PROTEOLYTIC ACTIVITY
3VQJ	;	1.2	;	Crystal Structutre of Thiobacillus thioparus THI115 Carbonyl Sulfide Hydrolase
3VRK	;	1.33	;	Crystal Structutre of Thiobacillus thioparus THI115 Carbonyl Sulfide Hydrolase / Thiocyanate complex
6L5Z	;	3.05	;	Crystal strucutre of AF9 YEATS domain in complex with a cyclopeptide inhibitor
7XEX	;	3.0	;	Crystal strucutre of apoCasDinG
7XF1	;	3.2	;	Crystal strucutre of apoCasDinG in complex with ssDNA
7XF0	;	3.1	;	Crystal strucutre of CasDinG in complex with ATP
8FX9	;	1.36	;	Crystal strucutre of Mycobacterium tuberculosis Mycothiol-S-transferase enzyme
7XAE	;	3.44	;	Crystal strucutre of PD-L1 and 3ONJA protein
7XAD	;	3.0	;	Crystal strucutre of PD-L1 and DBL2_02 designed protein binder
7XYQ	;	2.85	;	Crystal strucutre of PD-L1 and the computationally designed DBL1_03 protein binder
3UE1	;	2.73	;	Crystal strucuture of Acinetobacter baumanni PBP1A in complex with MC-1
3QMF	;	2.6	;	Crystal strucuture of an inositol monophosphatase family protein (SAS2203) from Staphylococcus aureus MSSA476
8GTH	;	3.1	;	Crystal strucuture of cyt c551 from anoxygenic phototrophic bacterium Roseiflexus castenholzii
3VVX	;	2.05	;	Crystal Strucuture of RamR (Transcriptional Regurator of TetR Family) from Salmonella Typhimurium
3VW2	;	2.34	;	Crystal Strucuture of The Berberine-bound Form of RamR (Transcriptional Regurator of TetR Family) from Salmonella Typhimurium
3VW1	;	2.21	;	Crystal Strucuture of the Crystal Violet-Bound Form of RamR (Transcriptional Regurator of TetR Family) from Salmonella Typhimurium
3VVY	;	1.63	;	Crystal Strucuture of The Ethidium-Bound Form of RamR (Transcriptional Regurator of TetR Family) from Salmonella Typhimurium
3VVZ	;	2.51	;	Crystal Strucuture of The Rhodamine 6G-Bound Form of RamR (Transcriptional Regurator of TetR Family) from Salmonella Typhimurium
2H5J	;	2.0	;	Crystal strusture of caspase-3 with inhibitor Ac-DMQD-Cho
2H65	;	2.3	;	Crystal strusture of caspase-3 with inhibitor Ac-VDVAD-Cho
1LQO	;	2.0	;	Crystal Strutcure of the Fosfomycin Resistance Protein A (FosA) Containing Bound Thallium Cations
6YAQ	;	1.95	;	Crystal sttructure of ZmCKO8 in complex with inhibitor 1-(3-Chloro-5-trifluoromethoxy-phenyl)-3-[2-(2-hydroxy-ethyl)-phenyl]-urea
3GCY	;	1.8	;	Crystal studies of d(CACGCG).d(CGCGTG) grown in presence of calcium chloride
3GDA	;	1.88	;	Crystal study of d(CACGCG).d(CGCGTG) grwon in presence of stannous chloride
4QGW	;	1.77	;	Crystal sturcture of the R132K:R111L:L121D mutant of Cellular Retinoic Acid Binding ProteinII complexed with a synthetic ligand (Merocyanine) at 1.77 angstrom resolution
1I7H	;	1.7	;	CRYSTAL STURCUTURE OF FDX
6IYV	;	1.5	;	Crystal sturucture of L,D-transpeptidase LdtMt2 from Mycobacterium tuberculosis in complex with ertapenem adduct
6IYW	;	1.6	;	Crystal sturucture of L,D-transpeptidase LdtMt2 from Mycobacterium tuberculosis in complex with Imipenem adduct
4O6J	;	2.3	;	Crystal sturucture of T. acidophilum IdeR
1WJX	;	1.7	;	Crystal sturucture of TT0801 from Thermus thermophilus
1MY2	;	1.8	;	crystal titration experiment (AMPA complex control)
1MXW	;	1.9	;	crystal titration experiments (AMPA co-crystals soaked in 1 mM BrW)
1MXZ	;	1.9	;	crystal titration experiments (AMPA co-crystals soaked in 1 uM BrW)
1MXV	;	1.95	;	crystal titration experiments (AMPA co-crystals soaked in 10 mM BrW)
1MY1	;	1.9	;	crystal titration experiments (AMPA co-crystals soaked in 10 nM BrW)
1MXY	;	1.95	;	crystal titration experiments (AMPA co-crystals soaked in 10 uM BrW)
1MY0	;	1.9	;	crystal titration experiments (AMPA co-crystals soaked in 100 nM BrW)
1MXX	;	2.0	;	crystal titration experiments (AMPA co-crystals soaked in 100 uM BrW)
8AR9	;	2.36	;	Crystal to structure pipeline for ambient temperature, in situ crystallography at beamline VMXi
1XEQ	;	2.1	;	Crystal tructure of RNA binding domain of influenza B virus non-structural protein
7JJV	;	1.21	;	Crystal waters on the nine polyproline type II helical bundle springtail antifreeze protein from Granisotoma rainieri match the ice lattice
2B92	;	3.2	;	Crystal-structure of the N-terminal Large GTPase Domain of human Guanylate Binding protein 1 (hGBP1) in complex with GDP/AlF3
2D4H	;	2.9	;	Crystal-structure of the N-terminal large GTPase Domain of human Guanylate Binding protein 1 (hGBP1) in complex with GMP
2B8W	;	2.22	;	Crystal-structure of the N-terminal Large GTPase Domain of human Guanylate Binding protein 1 (hGBP1) in complex with GMP/AlF4
2BC9	;	2.8	;	Crystal-structure of the N-terminal large GTPase Domain of human Guanylate Binding protein 1 (hGBP1) in complex with non-hydrolysable GTP analogue GppNHp
5CO2	;	1.7	;	Crystalization of human zinc insulin at pH 5.5
1GD9	;	1.8	;	CRYSTALL STRUCTURE OF PYROCOCCUS PROTEIN-A1
1D9D	;	2.18	;	CRYSTALL STRUCTURE OF THE COMPLEX OF DNA POLYMERASE I KLENOW FRAGMENT WITH SHORT DNA FRAGMENT CARRYING 2'-0-AMINOPROPYL-RNA MODIFICATIONS 5'-D(TCG)-AP(AUC)-3'
6L98	;	1.77	;	Crystalline cast nephropathy-causing Bence-Jones protein AK: An entire immunoglobulin lambda light chain dimer
1M9P	;	2.1	;	Crystalline Human Carbonmonoxy Hemoglobin C Exhibits The R2 Quaternary State at Neutral pH In The Presence of Polyethylene Glycol: The 2.1 Angstrom Resolution Crystal Structure
1NEJ	;	2.1	;	Crystalline Human Carbonmonoxy Hemoglobin S (Liganded Sickle Cell Hemoglobin) Exhibits The R2 Quaternary State At Neutral pH In The Presence Of Polyethylene Glycol: The 2.1 Angstrom Resolution Crystal Structure
1TAR	;	2.2	;	CRYSTALLINE MITOCHONDRIAL ASPARTATE AMINOTRANSFERASE EXISTS IN ONLY TWO CONFORMATIONS
1TAS	;	2.8	;	CRYSTALLINE MITOCHONDRIAL ASPARTATE AMINOTRANSFERASE EXISTS IN ONLY TWO CONFORMATIONS
1TAT	;	3.0	;	CRYSTALLINE MITOCHONDRIAL ASPARTATE AMINOTRANSFERASE EXISTS IN ONLY TWO CONFORMATIONS
6JQF	;	1.9	;	Crystallization analysis of a beta-N-acetylhexosaminidase (Am2136) from Akkermansia muciniphila
4FDM	;	1.6	;	Crystallization and 3D structure elucidation of thermostable L2 lipase from thermophilic locally isolated Bacillus sp. L2.
3QY4	;	1.65	;	Crystallization and in situ data collection of Lysozyme using the Crystal Former
5EZ6	;	1.8	;	Crystallization and preliminary X-ray crystallographic analysis of a small GTPase RhoA
1WBC	;	2.95	;	CRYSTALLIZATION AND PRELIMINARY X-RAY STUDIES OF PSOPHOCARPIN B1, A CHYMOTRYPSIN INHIBITOR FROM WINGED BEAN SEEDS
7QNM	;	2.73	;	Crystallization and structural analyses of ZgHAD, a L-2-haloacid dehalogenase from the marine Flavobacterium Zobellia galactanivorans
4LSW	;	1.64	;	Crystallization and Structural Analysis of 2-Hydroxyacid Dehydrogenase from Ketogulonicigenium vulgare Y25
3DMI	;	1.5	;	Crystallization and Structural Analysis of Cytochrome c6 from the Diatom Phaeodactylum tricornutum at 1.5 A resolution
1PNE	;	2.0	;	CRYSTALLIZATION AND STRUCTURE DETERMINATION OF BOVINE PROFILIN AT 2.0 ANGSTROMS RESOLUTION
5Z0Y	;	2.5	;	Crystallization and structure determination of cytoplasm serine hydroxymethyltransferase (SHMT) from Pichia pastoris
1JW1	;	4.0	;	Crystallization and structure determination of goat lactoferrin at 4.0 resolution: A new form of packing in lactoferrins with a high solvent content in crystals
2OXO	;	2.0	;	Crystallization and structure determination of the core-binding domain of bacteriophage lambda integrase
1FXA	;	2.5	;	CRYSTALLIZATION AND STRUCTURE DETERMINATION TO 2.5-ANGSTROMS RESOLUTION OF THE OXIDIZED [2FE-2S] FERREDOXIN ISOLATED FROM ANABAENA 7120
5EKF	;	2.0	;	Crystallization and X-ray Diffraction Data Collection of Importin-alpha from Mus musculus Complexed with a XPG NLS Peptide, fragment 1
5EKG	;	2.8	;	Crystallization and X-ray Diffraction Data Collection of Importin-alpha from Mus musculus Complexed with a XPG NLS Peptide, fragment 2
1CXA	;	2.2	;	CRYSTALLIZATION AND X-RAY STRUCTURE DETERMINATION OF CYTOCHROME C2 FROM RHODOBACTER SPHAEROIDES IN THREE CRYSTAL FORMS
1CXC	;	1.6	;	CRYSTALLIZATION AND X-RAY STRUCTURE DETERMINATION OF CYTOCHROME C2 FROM RHODOBACTER SPHAEROIDES IN THREE CRYSTAL FORMS
2CXB	;	1.95	;	CRYSTALLIZATION AND X-RAY STRUCTURE DETERMINATION OF CYTOCHROME C2 FROM RHODOBACTER SPHAEROIDES IN THREE CRYSTAL FORMS
2YOR	;	2.19	;	Crystallization of a 45 kDa peroxygenase- peroxidase from the mushroom Agrocybe aegerita and structure determination by SAD utilizing only the haem iron
2YP1	;	2.31	;	Crystallization of a 45 kDa peroxygenase- peroxidase from the mushroom Agrocybe aegerita and structure determination by SAD utilizing only the haem iron
5FUJ	;	1.83	;	Crystallization of a dimeric heme peroxygenase from the fungus Marasmius rotula
5FUK	;	1.55	;	Crystallization of a dimeric heme peroxygenase from the fungus Marasmius rotula
7DLH	;	1.789	;	Crystallization of Cationic Peroxidase from Proso Millet and Identification of Its Phosphatase Active Sites
7SMV	;	1.93	;	Crystallization of feline coronavirus Mpro with GC376 reveals mechanism of inhibition
7SNA	;	2.05	;	Crystallization of feline coronavirus Mpro with GC376 reveals mechanism of inhibition
2J1D	;	2.25	;	Crystallization of hDaam1 C-terminal Fragment
1DEH	;	2.2	;	CRYSTALLIZATION OF HUMAN BETA1 ALCOHOL DEHYDROGENASE (15 MG/ML) IN 50 MM SODIUM PHOSPHATE (PH 7.5), 2.0 MM NAD+ AND 1 MM 4-IODOPYRAZOLE AT 25 OC, 13% (W/V) PEG 8000
1HTB	;	2.4	;	CRYSTALLIZATION OF HUMAN BETA3 ALCOHOL DEHYDROGENASE (10 MG/ML) IN 100 MM SODIUM PHOSPHATE (PH 7.5), 7.5 MM NAD+ AND 1 MM 4-IODOPYRAZOLE AT 25 C
6BL6	;	2.8	;	Crystallization of lipid A transporter MsbA from Salmonella typhimurium
8GN6	;	2.1	;	Crystallization of Sialidase from Porphyromonas gingivalis
3DIQ	;	2.7	;	Crystallization of the Thermotoga maritima lysine riboswitch bound to homoarginine
3DJ0	;	2.5	;	Crystallization of the Thermotoga maritima lysine riboswitch bound to L-4-oxalysine
3DIZ	;	2.85	;	Crystallization of the Thermotoga maritima lysine riboswitch bound to lysine in the Absence of Mg2+
3DIM	;	2.9	;	Crystallization of the Thermotoga maritima lysine riboswitch bound to lysine, Cs+ Soak
3DIO	;	2.4	;	Crystallization of the Thermotoga maritima lysine riboswitch bound to lysine, IRIDIUM HEXAMINE SOAK
3DIX	;	2.9	;	Crystallization of the Thermotoga maritima lysine riboswitch bound to lysine, K+ anomalous data
3DIY	;	2.71	;	Crystallization of the Thermotoga maritima lysine riboswitch bound to lysine, Mn2+ soak
3DJ2	;	2.5	;	Crystallization of the Thermotoga maritima lysine riboswitch bound to lysine, Tl+ Soak
3DIR	;	2.9	;	Crystallization of the Thermotoga maritima lysine riboswitch bound to N6-1-iminoethyl-L-Lysine
3DIS	;	3.1	;	Crystallization of the Thermotoga maritima lysine riboswitch in free form
2HBN	;	1.55	;	Crystallization of the Tl+-form of the Oxytricha nova G-quadruplex
1MDC	;	1.75	;	CRYSTALLIZATION, STRUCTURE DETERMINATION AND LEAST-SQUARES REFINEMENT TO 1.75 ANGSTROMS RESOLUTION OF THE FATTY-ACID-BINDING PROTEIN ISOLATED FROM MANDUCA SEXTA L
5EOS	;	4.7	;	Crystallizing Strained DNA: Self-Assembly of 3D Crystals Containing a Torsionally-Stressed Component
2UYG	;	2.2	;	Crystallogaphic structure of the typeII 3-Dehydroquinase from Thermus Thermophilus
3FVL	;	1.85	;	Crystallogic studies on the Complex of Carboxypeptidase A with inhibitors using alpha-hydroxy ketone as zinc-binding group
3GWH	;	1.95	;	Crystallographic Ab Initio protein solution far below atomic resolution
1RDH	;	2.8	;	CRYSTALLOGRAPHIC ANALYSES OF AN ACTIVE HIV-1 RIBONUCLEASE H DOMAIN SHOW STRUCTURAL FEATURES THAT DISTINGUISH IT FROM THE INACTIVE FORM
1HIX	;	2.0	;	CRYSTALLOGRAPHIC ANALYSES OF FAMILY 11 ENDO-BETA-1,4-XYLANASE XYL1 FROM STREPTOMYCES SP. S38
1NHP	;	2.0	;	CRYSTALLOGRAPHIC ANALYSES OF NADH PEROXIDASE CYS42ALA AND CYS42SER MUTANTS: ACTIVE SITE STRUCTURE, MECHANISTIC IMPLICATIONS, AND AN UNUSUAL ENVIRONMENT OF ARG303
1NHQ	;	2.0	;	CRYSTALLOGRAPHIC ANALYSES OF NADH PEROXIDASE CYS42ALA AND CYS42SER MUTANTS: ACTIVE SITE STRUCTURE, MECHANISTIC IMPLICATIONS, AND AN UNUSUAL ENVIRONMENT OF ARG303
1PSS	;	3.0	;	CRYSTALLOGRAPHIC ANALYSES OF SITE-DIRECTED MUTANTS OF THE PHOTOSYNTHETIC REACTION CENTER FROM RHODOBACTER SPHAEROIDES
1PST	;	3.0	;	CRYSTALLOGRAPHIC ANALYSES OF SITE-DIRECTED MUTANTS OF THE PHOTOSYNTHETIC REACTION CENTER FROM RHODOBACTER SPHAEROIDES
1DWB	;	3.16	;	CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS
1DWC	;	3.0	;	CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS
1DWD	;	3.0	;	CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS
1DWE	;	3.0	;	Crystallographic analysis at 3.0-Angstroms resolution of the binding to human thrombin of four active site-directed inhibitors
2OMA	;	2.15	;	Crystallographic analysis of a chemically modified triosephosphate isomerase from Trypanosoma cruzi with dithiobenzylamine (DTBA)
5HVP	;	2.0	;	CRYSTALLOGRAPHIC ANALYSIS OF A COMPLEX BETWEEN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE AND ACETYL-PEPSTATIN AT 2.0-ANGSTROMS RESOLUTION
1APT	;	1.8	;	CRYSTALLOGRAPHIC ANALYSIS OF A PEPSTATIN ANALOGUE BINDING TO THE ASPARTYL PROTEINASE PENICILLOPEPSIN AT 1.8 ANGSTROMS RESOLUTION
1APU	;	1.8	;	Crystallographic analysis of a pepstatin analogue binding to the aspartyl proteinase penicillopepsin at 1.8 angstroms resolution
4KI2	;	3.3	;	Crystallographic analysis of an RNA-polymerase sigma-subunit fragment complexed with -10 promoter element ssDNA
3IIQ	;	2.0	;	Crystallographic analysis of bacterial signal peptidase in ternary complex with Arylomycin A2 and a beta-sultam inhibitor
2V3P	;	2.9	;	Crystallographic analysis of beta-axial ligand substitutions in cobalamin bound to transcobalamin
158D	;	1.9	;	CRYSTALLOGRAPHIC ANALYSIS OF C-C-A-A-G-C-T-T-G-G AND ITS IMPLICATIONS FOR BENDING IN B-DNA
2WUV	;	2.24	;	Crystallographic analysis of counter-ion effects on subtilisin enzymatic action in acetonitrile
2WUW	;	2.23	;	Crystallographic analysis of counter-ion effects on subtilisin enzymatic action in acetonitrile (native data)
3G5F	;	1.4	;	Crystallographic analysis of cytochrome P450 cyp121
3G5H	;	1.4	;	Crystallographic analysis of cytochrome P450 cyp121
1A8K	;	2.0	;	CRYSTALLOGRAPHIC ANALYSIS OF HUMAN IMMUNODEFICIENCY VIRUS 1 PROTEASE WITH AN ANALOG OF THE CONSERVED CA-P2 SUBSTRATE: INTERACTIONS WITH FREQUENTLY OCCURRING GLUTAMIC ACID RESIDUE AT P2' POSITION OF SUBSTRATES
2WQQ	;	2.25	;	Crystallographic analysis of monomeric CstII
6K3H	;	2.179	;	Crystallographic Analysis of Nucleoside Diphosphate Kinase (NDK) from Aspergillus Flavus
1OXY	;	2.4	;	CRYSTALLOGRAPHIC ANALYSIS OF OXYGENATED AND DEOXYGENATED STATES OF ARTHROPOD HEMOCYANIN SHOWS UNUSUAL DIFFERENCES
1BRG	;	2.2	;	CRYSTALLOGRAPHIC ANALYSIS OF PHE->LEU SUBSTITUTION IN THE HYDROPHOBIC CORE OF BARNASE
1VPE	;	2.0	;	CRYSTALLOGRAPHIC ANALYSIS OF PHOSPHOGLYCERATE KINASE FROM THE HYPERTHERMOPHILIC BACTERIUM THERMOTOGA MARITIMA
4G0A	;	2.0995	;	Crystallographic Analysis of Rotavirus NSP2-RNA Complex Reveals Specific Recognition of 5'-GG Sequence for RTPase activity
4G0J	;	3.398	;	Crystallographic Analysis of Rotavirus NSP2-RNA Complex Reveals Specific Recognition of 5'-GG Sequence for RTPase activity
2DHC	;	2.3	;	CRYSTALLOGRAPHIC ANALYSIS OF THE CATALYTIC MECHANISM OF HALOALKANE DEHALOGENASE
2DHD	;	2.13	;	CRYSTALLOGRAPHIC ANALYSIS OF THE CATALYTIC MECHANISM OF HALOALKANE DEHALOGENASE
2DHE	;	2.13	;	CRYSTALLOGRAPHIC ANALYSIS OF THE CATALYTIC MECHANISM OF HALOALKANE DEHALOGENASE
2YPI	;	2.5	;	CRYSTALLOGRAPHIC ANALYSIS OF THE COMPLEX BETWEEN TRIOSEPHOSPHATE ISOMERASE AND 2-PHOSPHOGLYCOLATE AT 2.5-ANGSTROMS RESOLUTION. IMPLICATIONS FOR CATALYSIS
1SUX	;	2.0	;	CRYSTALLOGRAPHIC ANALYSIS OF THE COMPLEX BETWEEN TRIOSEPHOSPHATE ISOMERASE FROM TRYPANOSOMA CRUZI AND 3-(2-benzothiazolylthio)-1-propanesulfonic acid
3MND	;	2.2	;	Crystallographic analysis of the cystosolic cu/zn Superoxide dismutase from taenia solium
1GLG	;	2.0	;	CRYSTALLOGRAPHIC ANALYSIS OF THE EPIMERIC AND ANOMERIC SPECIFICITY OF THE PERIPLASMIC TRANSPORT(SLASH)CHEMOTACTIC PROTEIN RECEPTOR FOR D-GLUCOSE AND D-GALACTOSE
1J78	;	2.31	;	Crystallographic analysis of the human vitamin D binding protein
5EST	;	2.09	;	Crystallographic analysis of the inhibition of porcine pancreatic elastase by a peptidyl boronic acid: structure of a reaction intermediate
4G51	;	2.5	;	Crystallographic analysis of the interaction of nitric oxide with hemoglobin from Trematomus bernacchii in the T quaternary structure (fully ligated state).
1RQ3	;	1.91	;	Crystallographic Analysis of the Interaction of Nitric Oxide with Quaternary-T Human Deoxyhemoglobin, Deoxyhemoglobin
1RQ4	;	2.11	;	Crystallographic Analysis of the Interaction of Nitric Oxide with Quaternary-T Human Hemoglobin, HEMOGLOBIN EXPOSED TO NO UNDER AEROBIC CONDITIONS
1RQA	;	2.11	;	Crystallographic Analysis of the Interaction of Nitric Oxide with Quaternary-T Human Hemoglobin. Beta W73E hemoglobin exposed to NO under anaerobic conditions
1RPS	;	2.11	;	Crystallographic Analysis of the Interaction of Nitric Oxide with Quaternary-T Human Hemoglobin. Hemoglobin exposed to NO under anerobic conditions
1GLU	;	2.9	;	CRYSTALLOGRAPHIC ANALYSIS OF THE INTERACTION OF THE GLUCOCORTICOID RECEPTOR WITH DNA
1R4O	;	2.5	;	Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA
1R4R	;	3.0	;	Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA
2WLC	;	1.95	;	Crystallographic analysis of the polysialic acid O-acetyltransferase OatWY
2WLD	;	2.2	;	Crystallographic analysis of the polysialic acid O-acetyltransferase OatWY
2WLE	;	2.19	;	Crystallographic analysis of the polysialic acid O-acetyltransferase OatWY
2WLF	;	2.35	;	Crystallographic analysis of the polysialic acid O-acetyltransferase OatWY
2WLG	;	1.9	;	Crystallographic analysis of the polysialic acid O-acetyltransferase OatWY
1BIC	;	1.9	;	CRYSTALLOGRAPHIC ANALYSIS OF THR-200-> HIS HUMAN CARBONIC ANHYDRASE II AND ITS COMPLEX WITH THE SUBSTRATE, HCO3-
1APV	;	1.8	;	CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION STATE MIMICS BOUND TO PENICILLOPEPSIN: DIFLUOROSTATINE-AND DIFLUOROSTATONE-CONTAINING PEPTIDES
1APW	;	1.8	;	CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION STATE MIMICS BOUND TO PENICILLOPEPSIN: DIFLUOROSTATINE-AND DIFLUOROSTATONE-CONTAINING PEPTIDES
1PPK	;	1.8	;	CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION STATE MIMICS BOUND TO PENICILLOPEPSIN: PHOSPHOROUS-CONTAINING PEPTIDE ANALOGUES
1PPL	;	1.7	;	CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION-STATE MIMICS BOUND TO PENICILLOPEPSIN: PHOSPHORUS-CONTAINING PEPTIDE ANALOGUES
1PPM	;	1.7	;	CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION-STATE MIMICS BOUND TO PENICILLOPEPSIN: PHOSPHORUS-CONTAINING PEPTIDE ANALOGUES
2FD2	;	1.9	;	CRYSTALLOGRAPHIC ANALYSIS OF TWO SITE-DIRECTED MUTANTS OF AZOTOBACTER VINELANDII FERREDOXIN
2V3N	;	2.73	;	Crystallographic analysis of upper axial ligand substitutions in cobalamin bound to transcobalamin
2R7C	;	2.7	;	Crystallographic and biochemical analysis of rotavirus NSP2 with nucleotides reveals an NDP kinase like activity
1TN2	;	3.0	;	CRYSTALLOGRAPHIC AND BIOCHEMICAL INVESTIGATION OF THE LEAD(II)-CATALYZED HYDROLYSIS OF YEAST PHENYLALANINE T-RNA
1TN1	;	3.0	;	CRYSTALLOGRAPHIC AND BIOCHEMICAL INVESTIGATION OF THE LEAD(II)-CATALYZED HYDROLYSIS OF YEAST PHENYLALANINE TRNA
4GRO	;	2.0	;	Crystallographic and biological characterization of N- and C- terminus mutants of human MIF
4GRP	;	1.27	;	Crystallographic and biological characterization of N- and C- terminus mutants of human MIF
4GRU	;	1.92	;	crystallographic and biological characterization of N- and C- terminus mutants of human MIF
1DPB	;	2.5	;	CRYSTALLOGRAPHIC AND ENZYMATIC INVESTIGATIONS ON THE ROLE OF SER558, HIS610 AND ASN614 IN THE CATALYTIC MECHANISM OF AZOTOBACTER VINELANDII DIHYDROLIPOAMIDE ACETYLTRANSFERASE (E2P)
1DPC	;	2.6	;	CRYSTALLOGRAPHIC AND ENZYMATIC INVESTIGATIONS ON THE ROLE OF SER558, HIS610 AND ASN614 IN THE CATALYTIC MECHANISM OF AZOTOBACTER VINELANDII DIHYDROLIPOAMIDE ACETYLTRANSFERASE (E2P)
1DPD	;	2.7	;	CRYSTALLOGRAPHIC AND ENZYMATIC INVESTIGATIONS ON THE ROLE OF SER558, HIS610 AND ASN614 IN THE CATALYTIC MECHANISM OF AZOTOBACTER VINELANDII DIHYDROLIPOAMIDE ACETYLTRANSFERASE (E2P)
4EUG	;	1.4	;	Crystallographic and Enzymatic Studies of an Active Site Variant H187Q of Escherichia Coli Uracil DNA Glycosylase: Crystal Structures of Mutant H187Q and its Uracil Complex
5EUG	;	1.6	;	CRYSTALLOGRAPHIC AND ENZYMATIC STUDIES OF AN ACTIVE SITE VARIANT H187Q OF ESCHERICHIA COLI URACIL DNA GLYCOSYLASE: CRYSTAL STRUCTURES OF MUTANT H187Q AND ITS URACIL COMPLEX
1EDB	;	2.01	;	CRYSTALLOGRAPHIC AND FLUORESCENCE STUDIES OF THE INTERACTION OF HALOALKANE DEHALOGENASE WITH HALIDE IONS: STUDIES WITH HALIDE COMPOUNDS REVEAL A HALIDE BINDING SITE IN THE ACTIVE SITE
1EDD	;	2.19	;	CRYSTALLOGRAPHIC AND FLUORESCENCE STUDIES OF THE INTERACTION OF HALOALKANE DEHALOGENASE WITH HALIDE IONS: STUDIES WITH HALIDE COMPOUNDS REVEAL A HALIDE BINDING SITE IN THE ACTIVE SITE
2EDA	;	2.19	;	CRYSTALLOGRAPHIC AND FLUORESCENCE STUDIES OF THE INTERACTION OF HALOALKANE DEHALOGENASE WITH HALIDE IONS: STUDIES WITH HALIDE COMPOUNDS REVEAL A HALIDE BINDING SITE IN THE ACTIVE SITE
2EDC	;	2.3	;	CRYSTALLOGRAPHIC AND FLUORESCENCE STUDIES OF THE INTERACTION OF HALOALKANE DEHALOGENASE WITH HALIDE IONS: STUDIES WITH HALIDE COMPOUNDS REVEAL A HALIDE BINDING SITE IN THE ACTIVE SITE
2IB7	;	2.05	;	Crystallographic and kinetic studies of human mitochondrial acetoacetyl-CoA thiolase (T2): the importance of potassium and chloride for its structure and function
2IB8	;	1.85	;	Crystallographic and kinetic studies of human mitochondrial acetoacetyl-CoA thiolase (T2): the importance of potassium and chloride for its structure and function
2IB9	;	2.05	;	Crystallographic and kinetic studies of human mitochondrial acetoacetyl-CoA thiolase (T2): the importance of potassium and chloride for its structure and function
2IBU	;	1.9	;	Crystallographic and kinetic studies of human mitochondrial acetoacetyl-CoA thiolase (T2): the importance of potassium and chloride for its structure and function
2IBW	;	1.9	;	Crystallographic and kinetic studies of human mitochondrial acetoacetyl-CoA thiolase (T2): the importance of potassium and chloride for its structure and function
2IBY	;	1.85	;	Crystallographic and kinetic studies of human mitochondrial acetoacetyl-CoA thiolase (T2): the importance of potassium and chloride for its structure and function
2V8W	;	2.3	;	Crystallographic and mass spectrometric characterisation of eIF4E with N7-cap derivatives
2V8X	;	2.3	;	Crystallographic and mass spectrometric characterisation of eIF4E with N7-cap derivatives
2V8Y	;	2.1	;	Crystallographic and mass spectrometric characterisation of eIF4E with N7-cap derivatives
4TIM	;	2.4	;	CRYSTALLOGRAPHIC AND MOLECULAR MODELING STUDIES ON TRYPANOSOMAL TRIOSEPHOSPHATE ISOMERASE: A CRITICAL ASSESSMENT OF THE PREDICTED AND OBSERVED STRUCTURES OF THE COMPLEX WITH 2-PHOSPHOGLYCERATE
3M23	;	1.4	;	Crystallographic and Single Crystal Spectral Analysis of the Peroxidase Ferryl Intermediate
3M25	;	1.4	;	Crystallographic and Single Crystal Spectral Analysis of the Peroxidase Ferryl Intermediate
3M26	;	1.4	;	Crystallographic and Single Crystal Spectral Analysis of the Peroxidase Ferryl Intermediate
3M27	;	1.4	;	Crystallographic and Single Crystal Spectral Analysis of the Peroxidase Ferryl Intermediate
3M28	;	1.4	;	Crystallographic and Single Crystal Spectral Analysis of the Peroxidase Ferryl Intermediate
3M29	;	1.4	;	Crystallographic and Single Crystal Spectral Analysis of the Peroxidase Ferryl Intermediate
3M2A	;	1.4	;	Crystallographic and Single Crystal Spectral Analysis of the Peroxidase Ferryl Intermediate
3M2B	;	1.4	;	Crystallographic and Single Crystal Spectral Analysis of the Peroxidase Ferryl Intermediate
3M2C	;	1.4	;	Crystallographic and Single Crystal Spectral Analysis of the Peroxidase Ferryl Intermediate
3M2D	;	1.4	;	Crystallographic and Single Crystal Spectral Analysis of the Peroxidase Ferryl Intermediate
3M2E	;	1.4	;	Crystallographic and Single Crystal Spectral Analysis of the Peroxidase Ferryl Intermediate
3M2F	;	1.4	;	Crystallographic and Single Crystal Spectral Analysis of the Peroxidase Ferryl Intermediate
3M2G	;	1.4	;	Crystallographic and Single Crystal Spectral Analysis of the Peroxidase Ferryl Intermediate
3M2H	;	1.4	;	Crystallographic and Single Crystal Spectral Analysis of the Peroxidase Ferryl Intermediate
3M2I	;	1.4	;	Crystallographic and Single Crystal Spectral Analysis of the Peroxidase Ferryl Intermediate
1UZ9	;	1.6	;	Crystallographic and solution studies of N-lithocholyl insulin: a new generation of prolonged-acting insulins.
3TCO	;	1.9	;	Crystallographic and spectroscopic characterization of Sulfolobus solfataricus TrxA1 provide insights into the determinants of thioredoxin fold stability
1ZLQ	;	1.8	;	Crystallographic and spectroscopic evidence for high affinity binding of Fe EDTA (H2O)- to the periplasmic nickel transporter NikA
1SRE	;	1.78	;	CRYSTALLOGRAPHIC AND THERMODYNAMIC COMPARISON OF NATURAL AND SYNTHETIC LIGANDS BOUND TO STREPTAVIDIN
1GPY	;	2.4	;	CRYSTALLOGRAPHIC BINDING STUDIES ON THE ALLOSTERIC INHIBITOR GLUCOSE-6-PHOSPHATE TO T STATE GLYCOGEN PHOSPHORYLASE B
2X16	;	2.13	;	Crystallographic binding studies with an engineered monomeric variant of triosephosphate isomerase
2X1R	;	1.98	;	Crystallographic binding studies with an engineered monomeric variant of triosephosphate isomerase
2X1S	;	1.93	;	Crystallographic binding studies with an engineered monomeric variant of triosephosphate isomerase
2X1T	;	1.83	;	Crystallographic binding studies with an engineered monomeric variant of triosephosphate isomerase
2X1U	;	1.84	;	Crystallographic binding studies with an engineered monomeric variant of triosephosphate isomerase
2X2G	;	1.9	;	CRYSTALLOGRAPHIC BINDING STUDIES WITH AN ENGINEERED MONOMERIC VARIANT OF TRIOSEPHOSPHATE ISOMERASE
1K08	;	2.26	;	Crystallographic Binding Study of 10 mM N-benzoyl-N'-beta-D-glucopyranosyl urea to glycogen phosphorylase b
1K06	;	1.8	;	Crystallographic Binding Study of 100 mM N-benzoyl-N'-beta-D-glucopyranosyl urea to glycogen phosphorylase b
4ZK6	;	1.895	;	Crystallographic Capture of Quinolinate Synthase (NadA) from Pyrococcus horikoshii in its Substrates and Product-Bound States
6NSU	;	2.15	;	Crystallographic Capture of Quinolinate Synthase (NadA) from Pyrococcus horikoshii in its Substrates and Product-Bound States
1TRZ	;	1.6	;	CRYSTALLOGRAPHIC EVIDENCE FOR DUAL COORDINATION AROUND ZINC IN THE T3R3 HUMAN INSULIN HEXAMER
1RRX	;	2.1	;	Crystallographic Evidence for Isomeric Chromophores in 3-Fluorotyrosyl-Green Fluorescent Protein
1OMP	;	1.8	;	CRYSTALLOGRAPHIC EVIDENCE OF A LARGE LIGAND-INDUCED HINGE-TWIST MOTION BETWEEN THE TWO DOMAINS OF THE MALTODEXTRIN-BINDING PROTEIN INVOLVED IN ACTIVE TRANSPORT AND CHEMOTAXIS
5AGC	;	4.0	;	Crystallographic forms of the Vps75 tetramer
1TJX	;	1.04	;	Crystallographic Identification of Ca2+ Coordination Sites in Synaptotagmin I C2B Domain
1TJM	;	1.18	;	Crystallographic Identification of Sr2+ Coordination Site in Synaptotagmin I C2B Domain
2YZ3	;	2.3	;	Crystallographic Investigation of Inhibition Mode of the VIM-2 Metallo-beta-lactamase from Pseudomonas aeruginosa with Mercaptocarboxylate Inhibitor
2PED	;	2.95	;	Crystallographic model of 9-cis-rhodopsin
2G87	;	2.6	;	Crystallographic model of bathorhodopsin
2HPY	;	2.8	;	Crystallographic model of lumirhodopsin
6DHZ	;	2.8	;	Crystallographic octamer of a metal-free RIDC1 variant bearing two disulfide bonded cysteines
1FC1	;	2.9	;	CRYSTALLOGRAPHIC REFINEMENT AND ATOMIC MODELS OF A HUMAN FC FRAGMENT AND ITS COMPLEX WITH FRAGMENT B OF PROTEIN A FROM STAPHYLOCOCCUS AUREUS AT 2.9-AND 2.8-ANGSTROMS RESOLUTION
1FC2	;	2.8	;	Crystallographic Refinement and Atomic Models of a Human FC Fragment and its Complex with Fragment B of Protein A from Staphylococcus Aureus at 2.9-and 2.8-Angstroms Resolution
1CTS	;	2.7	;	CRYSTALLOGRAPHIC REFINEMENT AND ATOMIC MODELS OF TWO DIFFERENT FORMS OF CITRATE SYNTHASE AT 2.7 AND 1.7 ANGSTROMS RESOLUTION
2CTS	;	2.0	;	CRYSTALLOGRAPHIC REFINEMENT AND ATOMIC MODELS OF TWO DIFFERENT FORMS OF CITRATE SYNTHASE AT 2.7 AND 1.7 ANGSTROMS RESOLUTION
3CTS	;	1.7	;	CRYSTALLOGRAPHIC REFINEMENT AND ATOMIC MODELS OF TWO DIFFERENT FORMS OF CITRATE SYNTHASE AT 2.7 AND 1.7 ANGSTROMS RESOLUTION
2CWG	;	2.0	;	CRYSTALLOGRAPHIC REFINEMENT AND STRUCTURE ANALYSIS OF THE COMPLEX OF WHEAT GERM AGGLUTININ WITH A BIVALENT SIALOGLYCOPEPTIDE FROM GLYCOPHORIN A
3DNI	;	2.0	;	CRYSTALLOGRAPHIC REFINEMENT AND STRUCTURE OF DNASE I AT 2 ANGSTROMS RESOLUTION
5RUB	;	1.7	;	CRYSTALLOGRAPHIC REFINEMENT AND STRUCTURE OF RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE FROM RHODOSPIRILLUM RUBRUM AT 1.7 ANGSTROMS RESOLUTION
1PRC	;	2.3	;	CRYSTALLOGRAPHIC REFINEMENT AT 2.3 ANGSTROMS RESOLUTION AND REFINED MODEL OF THE PHOTOSYNTHETIC REACTION CENTER FROM RHODOPSEUDOMONAS VIRIDIS
1TEC	;	2.2	;	CRYSTALLOGRAPHIC REFINEMENT BY INCORPORATION OF MOLECULAR DYNAMICS. THE THERMOSTABLE SERINE PROTEASE THERMITASE COMPLEXED WITH EGLIN-C
4BP2	;	1.6	;	CRYSTALLOGRAPHIC REFINEMENT OF BOVINE PRO-PHOSPHOLIPASE A2 AT 1.6 ANGSTROMS RESOLUTION
1RBP	;	2.0	;	CRYSTALLOGRAPHIC REFINEMENT OF HUMAN SERUM RETINOL BINDING PROTEIN AT 2 ANGSTROMS RESOLUTION
2I1B	;	2.0	;	CRYSTALLOGRAPHIC REFINEMENT OF INTERLEUKIN-1 BETA AT 2.0 ANGSTROMS RESOLUTION
1OVO	;	1.9	;	CRYSTALLOGRAPHIC REFINEMENT OF JAPANESE QUAIL OVOMUCOID, A KAZAL-TYPE INHIBITOR, AND MODEL BUILDING STUDIES OF COMPLEXES WITH SERINE PROTEASES
1LGA	;	2.03	;	CRYSTALLOGRAPHIC REFINEMENT OF LIGNIN PEROXIDASE AT 2 ANGSTROMS
2AAI	;	2.5	;	Crystallographic refinement of ricin to 2.5 Angstroms
4RXN	;	1.2	;	CRYSTALLOGRAPHIC REFINEMENT OF RUBREDOXIN AT 1.2 ANGSTROMS RESOLUTION
2ACT	;	1.7	;	CRYSTALLOGRAPHIC REFINEMENT OF THE STRUCTURE OF ACTINIDIN AT 1.7 ANGSTROMS RESOLUTION BY FAST FOURIER LEAST-SQUARES METHODS
1FDL	;	2.5	;	CRYSTALLOGRAPHIC REFINEMENT OF THE THREE-DIMENSIONAL STRUCTURE OF THE FAB D1.3-LYSOZYME COMPLEX AT 2.5-ANGSTROMS RESOLUTION
1SK8	;	1.65	;	Crystallographic snapshots of Aspergillus fumigatus phytase revealing its enzymatic dynamics
1SK9	;	1.64	;	Crystallographic snapshots of Aspergillus fumigatus phytase revealing its enzymatic dynamics
1SKA	;	1.69	;	Crystallographic snapshots of Aspergillus fumigatus phytase revealing its enzymatic dynamics
1SKB	;	1.58	;	Crystallographic snapshots of Aspergillus fumigatus phytase revealing its enzymatic dynamics
3EPH	;	2.95	;	Crystallographic snapshots of eukaryotic dimethylallyltransferase acting on tRNA: Insight into tRNA recognition and reaction mechanism
3EPJ	;	3.1	;	Crystallographic snapshots of eukaryotic dimethylallyltransferase acting on tRNA: Insight into tRNA recognition and reaction mechanism
3EPK	;	3.2	;	Crystallographic snapshots of eukaryotic dimethylallyltransferase acting on tRNA: Insight into tRNA recognition and reaction mechanism
3EPL	;	3.6	;	Crystallographic snapshots of eukaryotic dimethylallyltransferase acting on tRNA: Insight into tRNA recognition and reaction mechanism
7UX4	;	2.23	;	Crystallographic snapshots of ternary complexes of thermophilic secondary alcohol dehydrogenase from Thermoanaerobacter pseudoethanolicus reveal the dynamics of ligand exchange and the proton relay network.
6MK3	;	1.478	;	Crystallographic solvent mapping analysis of DMSO bound to APE1
6MKK	;	1.442	;	Crystallographic solvent mapping analysis of DMSO/Mg bound to APE1
6MKM	;	1.673	;	Crystallographic solvent mapping analysis of DMSO/Tris bound to APE1
6MKO	;	2.09	;	Crystallographic solvent mapping analysis of glycerol bound to APE1
1TLP	;	2.3	;	CRYSTALLOGRAPHIC STRUCTURAL ANALYSIS OF PHOSPHORAMIDATES AS INHIBITORS AND TRANSITION-STATE ANALOGS OF THERMOLYSIN
2TMN	;	1.6	;	CRYSTALLOGRAPHIC STRUCTURAL ANALYSIS OF PHOSPHORAMIDATES AS INHIBITORS AND TRANSITION-STATE ANALOGS OF THERMOLYSIN
5A7E	;	1.5	;	Crystallographic Structural Determination of a Trigonal Laccase from Coriolopsis Gallica (CgL) to 1.5 A resolution
3SIM	;	2.1	;	Crystallographic structure analysis of family 18 Chitinase from Crocus vernus
1PGI	;	3.5	;	CRYSTALLOGRAPHIC STRUCTURE ANALYSIS OF GLUCOSE 6-PHOSPHATE ISOMERASE AT 3.5 ANGSTROMS RESOLUTION
4GY7	;	1.492	;	Crystallographic structure analysis of urease from Jack bean (Canavalia ensiformis) at 1.49 A Resolution
6OTY	;	2.598	;	Crystallographic Structure of (HbII-HbIII)-O2 from Lucina pectinata at pH 4.0
6OTW	;	2.447	;	Crystallographic Structure of (HbII-HbIII)-O2 from Lucina pectinata at pH 5.0
6OTX	;	2.539	;	Crystallographic Structure of (HbII-HbIII)-O2 from Lucina pectinata at pH 7.0
4AIZ	;	1.75	;	Crystallographic structure of 3mJL2 from the germinal line lambda 3
5BWI	;	1.6	;	Crystallographic structure of a bacterial heparanase
1NDR	;	3.0	;	CRYSTALLOGRAPHIC STRUCTURE OF A BLUE COPPER NITRITE REDUCTASE FROM ALCALIGENES XYLOSOXIDANS
5BKN	;	3.0	;	Crystallographic structure of a cubic crystal form of STMV (84.5 degree rotation) grown from chloride
7M50	;	2.31	;	Crystallographic structure of a cubic crystal form of STMV grown from ammonium sulfate
7M54	;	3.8	;	Crystallographic structure of a cubic crystal form of STMV grown from bromide
7M3T	;	3.2	;	Crystallographic structure of a cubic crystal of STMV (80.7 degree rotation about 111) grown from chloride
5BKQ	;	3.19	;	Crystallographic structure of a cubic form of STMV grown from nitrate
4WKJ	;	2.8	;	Crystallographic Structure of a Dodecameric RNA-DNA Hybrid
1UZA	;	1.5	;	Crystallographic structure of a feruloyl esterase from Aspergillus niger
1BLS	;	2.3	;	CRYSTALLOGRAPHIC STRUCTURE OF A PHOSPHONATE DERIVATIVE OF THE ENTEROBACTER CLOACAE P99 CEPHALOSPORINASE: MECHANISTIC INTERPRETATION OF A BETA-LACTAMASE TRANSITION STATE ANALOG
1ORD	;	3.0	;	CRYSTALLOGRAPHIC STRUCTURE OF A PLP-DEPENDENT ORNITHINE DECARBOXYLASE FROM LACTOBACILLUS 30A TO 3.1 ANGSTROMS RESOLUTION
7M57	;	4.0	;	Crystallographic structure of a primitive orthorhombic crystal form of STMV
1T0T	;	1.75	;	Crystallographic structure of a putative chlorite dismutase
1HTO	;	2.4	;	CRYSTALLOGRAPHIC STRUCTURE OF A RELAXED GLUTAMINE SYNTHETASE FROM MYCOBACTERIUM TUBERCULOSIS
2FSE	;	3.1	;	Crystallographic structure of a rheumatoid arthritis MHC susceptibility allele, HLA-DR1 (DRB1*0101), complexed with the immunodominant determinant of human type II collagen
8QIJ	;	2.073	;	Crystallographic Structure of a Salicylate Synthase from M. abscessus (Mab-SaS)
1NDS	;	2.8	;	CRYSTALLOGRAPHIC STRUCTURE OF A SUBSTRATE BOUND BLUE COPPER NITRITE REDUCTASE FROM ALCALIGENES XYLOSOXIDANS
4AIX	;	1.8	;	Crystallographic structure of an amyloidogenic variant, 3rC34Y, of the germinal line lambda 3
4AJ0	;	1.7	;	Crystallographic structure of an amyloidogenic variant, 3rCW, of the germinal line lambda 3
1RNA	;	2.25	;	CRYSTALLOGRAPHIC STRUCTURE OF AN RNA HELIX: [U(U-A)6A]2
1U9C	;	1.35	;	Crystallographic structure of APC35852
5CAZ	;	1.8	;	Crystallographic structure of apo human rotavirus K8 VP8*
5CA6	;	1.9	;	Crystallographic structure of apo porcine rotavirus TFR-41 VP8*
2C2B	;	2.6	;	Crystallographic structure of Arabidopsis thaliana Threonine synthase complexed with pyridoxal phosphate and S-adenosylmethionine
3SOI	;	1.729	;	Crystallographic structure of Bacillus licheniformis beta-lactamase W210F/W229F/W251F at 1.73 angstrom resolution
4HNJ	;	2.9	;	Crystallographic structure of BCL-xL domain-swapped dimer in complex with PUMA BH3 peptide at 2.9A resolution
1URX	;	1.7	;	Crystallographic structure of beta-agarase A in complex with oligoagarose
2WME	;	2.1	;	Crystallographic structure of betaine aldehyde dehydrogenase from Pseudomonas aeruginosa
3ZQA	;	2.45	;	CRYSTALLOGRAPHIC STRUCTURE OF BETAINE ALDEHYDE DEHYDROGENASE MUTANT C286A FROM PSEUDOMONAS AERUGINOSA IN COMPLEX WITH NADPH
2XDR	;	2.301	;	CRYSTALLOGRAPHIC STRUCTURE OF BETAINE ALDEHYDE DEHYDROGENASE MUTANT E252A FROM PSEUDOMONAS AERUGINOSA
6FIE	;	1.51	;	Crystallographic structure of calcium loaded Calbindin-D28K.
7WNP	;	1.72	;	Crystallographic structure of copper amine oxidase from Arthrobacter glibiformis at pD 7.4 determined by both X-ray and neutron diffraction data at 1.72 angstrom resolution.
7WNP	;	1.72	;	Crystallographic structure of copper amine oxidase from Arthrobacter glibiformis at pD 7.4 determined by both X-ray and neutron diffraction data at 1.72 angstrom resolution.
7WNO	;	1.72	;	Crystallographic structure of copper amine oxidase from Arthrobacter glibiformis at pD 7.4 determined by only neutron diffraction data.
1DAA	;	1.94	;	CRYSTALLOGRAPHIC STRUCTURE OF D-AMINO ACID AMINOTRANSFERASE COMPLEXED WITH PYRIDOXAL-5'-PHOSPHATE
4DAA	;	2.4	;	CRYSTALLOGRAPHIC STRUCTURE OF D-AMINO ACID AMINOTRANSFERASE IN PYRIDOXAL-5'-PHOSPHATE (PLP) FORM
2DAA	;	2.1	;	CRYSTALLOGRAPHIC STRUCTURE OF D-AMINO ACID AMINOTRANSFERASE INACTIVATED BY D-CYCLOSERINE
3DAA	;	1.9	;	CRYSTALLOGRAPHIC STRUCTURE OF D-AMINO ACID AMINOTRANSFERASE INACTIVATED BY PYRIDOXYL-D-ALANINE
7UOI	;	1.6	;	Crystallographic structure of DapE from Enterococcus faecium
2H5Z	;	1.92	;	Crystallographic structure of digestive lysozyme 1 from Musca domestica bound to chitotetraose at 1.92 A resolution
1DOT	;	2.35	;	CRYSTALLOGRAPHIC STRUCTURE OF DUCK OVOTRANSFERRIN AT 2.3 ANGSTROMS RESOLUTION
3UQI	;	1.302	;	Crystallographic structure of FKBP12 from Aedes aegypti
5G52	;	3.802	;	Crystallographic structure of full particle of Deformed Wing Virus
5UR0	;	1.94	;	Crystallographic structure of glyceraldehyde-3-phosphate dehydrogenase from Naegleria gruberi
7JH0	;	2.51	;	Crystallographic structure of glyceraldehyde-3-phosphate dehydrogenase from Schistosoma mansoni
2Y6Z	;	2.6	;	Crystallographic structure of GM23 an example of Catalytic migration from TIM to thiamin phosphate synthase.
2Y70	;	2.3	;	CRYSTALLOGRAPHIC STRUCTURE OF GM23, MUTANT G89D, AN EXAMPLE OF CATALYTIC MIGRATION FROM TIM TO THIAMIN PHOSPHATE SYNTHASE.
3PI4	;	3.17	;	Crystallographic Structure of HbII-oxy from Lucina pectinata at pH 4.0
3PI3	;	1.95	;	Crystallographic Structure of HbII-oxy from Lucina pectinata at pH 5.0
3PI2	;	1.85	;	Crystallographic Structure of HbII-oxy from Lucina pectinata at pH 8.0
3PI1	;	2.002	;	Crystallographic Structure of HbII-oxy from Lucina pectinata at pH 9.0
4L5N	;	2.16	;	Crystallographic Structure of HHV-1 Uracil-DNA Glycosylase complexed with the Bacillus phage PZA inhibitor protein p56
2GJX	;	2.8	;	Crystallographic structure of human beta-Hexosaminidase A
1EKF	;	1.95	;	CRYSTALLOGRAPHIC STRUCTURE OF HUMAN BRANCHED CHAIN AMINO ACID AMINOTRANSFERASE (MITOCHONDRIAL) COMPLEXED WITH PYRIDOXAL-5'-PHOSPHATE AT 1.95 ANGSTROMS (ORTHORHOMBIC FORM)
2JG9	;	1.9	;	Crystallographic structure of human C1q globular heads (P1)
2JG8	;	2.05	;	Crystallographic structure of human C1q globular heads complexed to phosphatidyl-serine
2HNT	;	2.5	;	CRYSTALLOGRAPHIC STRUCTURE OF HUMAN GAMMA-THROMBIN
5CB7	;	1.35	;	Crystallographic structure of human rotavirus K8 VP8* in complex with A-type HBGA
2F0R	;	2.26	;	Crystallographic structure of human Tsg101 UEV domain
7NLC	;	1.398	;	Crystallographic structure of human Tsg101 UEV domain in complex with a HEV ORF3 peptide
7KEM	;	1.77	;	Crystallographic structure of L,D-transpeptidase 2 from Mycobacterium tuberculosis
2VDT	;	3.2	;	Crystallographic structure of Levansucrase from Bacillus subtilis mutant S164A
1PYZ	;	1.25	;	CRYSTALLOGRAPHIC STRUCTURE OF MIMOCHROME IV
5G31	;	2.0	;	Crystallographic structure of mutant C73S of thioredoxin from Litopenaeus vannamei
5G30	;	1.65	;	Crystallographic structure of mutant D60S of thioredoxin from Litopenaeus vannamei
5G2Z	;	1.88	;	Crystallographic structure of mutant W31A of thioredoxin from Litopenaeus vannamei
1NGK	;	2.11	;	Crystallographic Structure of Mycobacterium tuberculosis Hemoglobin O
7SD5	;	1.53	;	Crystallographic structure of neutralizing antibody 10-40 in complex with SARS-CoV-2 spike receptor binding domain
7L5B	;	3.18	;	Crystallographic structure of neutralizing antibody 2-15 in complex with SARS-CoV-2 spike receptor-binding Domain (RBD).
7L2C	;	3.65	;	Crystallographic structure of neutralizing antibody 2-51 in complex with SARS-CoV-2 spike N-terminal domain (NTD)
7FCQ	;	1.89	;	Crystallographic structure of neutralizing antibody P14-44 in complex with SARS-CoV-2 spike receptor-binding Domain (RBD)
4UOH	;	2.007	;	Crystallographic structure of nucleoside diphosphate kinase from Litopenaeus vannamei complexed with ADP
4UOF	;	2.102	;	Crystallographic structure of nucleoside diphosphate kinase from Litopenaeus vannamei complexed with dADP
4UOG	;	2.3	;	Crystallographic structure of nucleoside diphosphate kinase from Litopenaeus vannamei complexed with dCDP
6XUU	;	1.57	;	Crystallographic structure of oligosaccharide dehydrogenase from Pycnoporus cinnabarinus, glucose-bound form
6XUV	;	1.75	;	Crystallographic structure of oligosaccharide dehydrogenase from Pycnoporus cinnabarinus, laminaribiose-bound form
6XUT	;	1.6	;	Crystallographic structure of oligosaccharide dehydrogenase from Pycnoporus cinnabarinus, ligand-free form
7KV0	;	2.501	;	Crystallographic structure of Paenibacillus xylanivorans GH11
3TCY	;	1.55	;	Crystallographic structure of phenylalanine hydroxylase from Chromobacterium violaceum (cPAH) bound to phenylalanine in a site distal to the active site
3TK2	;	1.35	;	Crystallographic structure of phenylalanine hydroxylase from Chromobacterium violaceum cocrystallized with phenylalanine in a site distal to the active site
4ETL	;	1.49	;	Crystallographic structure of phenylalanine hydroxylase from Chromobacterium violaceum F258A mutation
4ESM	;	1.35	;	Crystallographic structure of phenylalanine hydroxylase from Chromobacterium violaceum Y155A mutation
2PIL	;	2.6	;	Crystallographic Structure of Phosphorylated Pilin from Neisseria: Phosphoserine Sites Modify Type IV Pilus Surface Chemistry
5F8B	;	2.54	;	Crystallographic Structure of PsoE with Co
5FHI	;	2.41	;	Crystallographic structure of PsoE without Co
1YIO	;	2.2	;	Crystallographic structure of response regulator StyR from Pseudomonas fluorescens
2PV2	;	1.3	;	Crystallographic Structure of SurA first peptidyl-prolyl isomerase domain complexed with peptide NFTLKFWDIFRK
2PV1	;	1.3	;	Crystallographic Structure of SurA first peptidyl-prolyl isomerase domain complexed with peptide WEYIPNV
2PV3	;	3.39	;	Crystallographic Structure of SurA fragment lacking the second peptidyl-prolyl isomerase domain complexed with peptide NFTLKFWDIFRK
1M5Y	;	3.0	;	Crystallographic Structure of SurA, a Molecular Chaperone that Facilitates Outer Membrane Porin Folding
6OV6	;	1.82	;	CRYSTALLOGRAPHIC STRUCTURE OF THE C24 PROTEIN FROM THE ANTARCTIC MICROORGANISM BIZIONIA ARGENTINENSIS
6HPO	;	1.67	;	Crystallographic structure of the catalytic domain of Human Phenylalanine Hydroxylase (hPAH CD) in complex with iron at 1.6 Angstrom
6VIN	;	3.04	;	Crystallographic structure of the circularly permuted human Taspase1 protein
2V64	;	2.9	;	Crystallographic structure of the conformational dimer of the Spindle Assembly Checkpoint protein Mad2.
5BKL	;	2.94	;	Crystallographic structure of the cubic crystal form of STMV (77.9 degree rotation) grown from NaCl
6EAW	;	1.289	;	Crystallographic structure of the cyclic heptapeptide derived from the BTCI inhibitor bound to beta-trypsin in space group P 21 21 21
6EAV	;	1.391	;	Crystallographic structure of the cyclic heptapeptide derived from the BTCI inhibitor bound to beta-trypsin in space group P 4(1) 2(1) 2
6EAX	;	1.189	;	Crystallographic structure of the cyclic hexapeptide derived from the BTCI inhibitor bound to beta-trypsin in space group P 21 21 21
6EAT	;	1.149	;	Crystallographic structure of the cyclic nonapeptide derived from the BTCI inhibitor bound to beta-trypsin in space group P 21 21 21.
6E5M	;	1.612	;	Crystallographic structure of the cyclic nonapeptide derived from the BTCI inhibitor bound to beta-trypsin in space group P 32 2 1
5XNX	;	3.7	;	Crystallographic structure of the enzymatically active N-terminal domain of the Rel protein from Mycobacterium tuberculosis
43C9	;	2.2	;	CRYSTALLOGRAPHIC STRUCTURE OF THE ESTEROLYTIC AND AMIDOLYTIC 43C9 ANTIBODY
43CA	;	2.3	;	CRYSTALLOGRAPHIC STRUCTURE OF THE ESTEROLYTIC AND AMIDOLYTIC 43C9 ANTIBODY WITH BOUND P-NITROPHENOL
5AN1	;	2.0	;	Crystallographic structure of the Glutathione S-Transferase from Litopenaeus vannamei complexed with Glutathione
4CDH	;	2.3	;	Crystallographic structure of the Human Igg1 alpha 2-6 sialilated Fc-Fragment
4UWW	;	1.44	;	Crystallographic Structure of the Intramineral Protein Struthicalcin from Struthio camelus Eggshell
1IJD	;	3.0	;	Crystallographic Structure of the LH3 Complex from Rhodopseudomonas acidophila strain 7050
4PXJ	;	2.06	;	Crystallographic structure of the LZII fragment (anti-parallel orientation) from JIP3
2QT7	;	1.3	;	Crystallographic structure of the mature ectodomain of the human receptor-type protein-tyrosine phosphatase IA-2 at 1.30 Angstroms
4HTI	;	1.954	;	Crystallographic structure of the membrane-proximal ectodomain of the human receptor-type protein-tyrosine phosphatase phogrin
4HTJ	;	2.011	;	Crystallographic structure of the membrane-proximal ectodomain of the human receptor-type protein-tyrosine phosphatase phogrin at pH 4.6
2H5Y	;	1.7	;	Crystallographic structure of the Molybdate-Binding Protein of Xanthomonas citri at 1.7 Ang resolution bound to molybdate
7M2T	;	2.71	;	Crystallographic Structure of the Monoclinic Form of Satellite Tobacco Mosaic Virus
4CAJ	;	2.191	;	Crystallographic structure of the mouse SIGN-R1 CRD domain in complex with sialic acid
1G8O	;	2.3	;	CRYSTALLOGRAPHIC STRUCTURE OF THE NATIVE BOVINE ALPHA-1,3-GALACTOSYLTRANSFERASE CATALYTIC DOMAIN
3ZHG	;	1.87	;	Crystallographic structure of the native mouse SIGN-R1 CRD domain
1NIP	;	2.9	;	CRYSTALLOGRAPHIC STRUCTURE OF THE NITROGENASE IRON PROTEIN FROM AZOTOBACTER VINELANDII
1W0H	;	1.59	;	Crystallographic structure of the nuclease domain of 3'hExo, a DEDDh family member, bound to rAMP
6EAU	;	1.18	;	Crystallographic structure of the octapeptide derived from the BTCI inhibitor bound to beta-trypsin in space group P 21 21 21.
4A1S	;	2.1	;	Crystallographic structure of the Pins:Insc complex
3MZI	;	2.304	;	Crystallographic structure of the pseudo-Signaling State of the BLUF Photoreceptor PixD (slr1694) Y8F mutant
7M3R	;	2.1	;	Crystallographic Structure of the Rhombohedral Crystal Form of STMV Grown from Bromide
7M2V	;	1.8	;	Crystallographic Structure of the Rhombohedral Crystal Form of STMV Grown from Chloride
1YC6	;	2.9	;	Crystallographic Structure of the T=1 Particle of Brome Mosaic Virus
5G5E	;	1.8	;	Crystallographic structure of the Tau class glutathione S-transferase MiGSTU from mango Mangifera indica L.
5G5F	;	2.3	;	Crystallographic structure of the Tau class glutathione S-transferase MiGSTU in complex with reduced glutathione.
5KEJ	;	2.35	;	Crystallographic structure of the Tau class glutathione S-transferase MiGSTU in complex with S-hexyl-glutathione
3ZZX	;	1.88	;	Crystallographic structure of thioredoxin from Litopenaeus vannamei
4AJ7	;	2.035	;	Crystallographic structure of thioredoxin from Litopenaeus vannamei (oxidized form).
4AJ8	;	1.54	;	Crystallographic structure of thioredoxin from Litopenaeus vannamei (partially reduced).
4AJ6	;	2.0	;	Crystallographic structure of thioredoxin from Litopenaeus vannamei (reduced form).
4V2L	;	1.65	;	Crystallographic structure of thioredoxin from Litopenaeus vannamei: Radiation damage effect at 3.4 MGy, focused in disulfide bonds.
4V2M	;	1.841	;	Crystallographic structure of thioredoxin from Litopenaeus vannamei: Radiation damage effect at 34 MGy, focused in disulfide bonds.
4V2N	;	2.15	;	Crystallographic structure of thioredoxin from Litopenaeus vannamei: Radiation damage effect at 85 MGy, focused in disulfide bonds
4FXU	;	1.9	;	Crystallographic structure of trimeric riboflavin synthase from Brucella abortus
4GQN	;	1.85	;	Crystallographic structure of trimeric Riboflavin Synthase from Brucella abortus in complex with 5-Nitro-6-(D-Ribitylamino)-2,4(1H,3H) Pyrimidinedione
4E0F	;	2.85	;	Crystallographic structure of trimeric Riboflavin Synthase from Brucella abortus in complex with riboflavin
4G6I	;	1.78	;	Crystallographic structure of trimeric riboflavin synthase from Brucella abortus in complex with roseoflavin
7FCP	;	2.4	;	Crystallographic structure of two neutralizing antibodies in complex with SARS-CoV-2 spike receptor-binding Domain (RBD)
7FH0	;	3.2	;	Crystallographic structure of two neutralizing nanobodies in complex with SARS-CoV-2 spike receptor-binding Domain (RBD)
3DDL	;	1.9	;	Crystallographic Structure of Xanthorhodopsin, a Light-Driven Ion Pump with Dual Chromophore
5YUM	;	2.432	;	Crystallographic structures of IlvN.Val/Ile complexes:Conformational selectivity for feedback inhibition of AHASs
1RBC	;	2.0	;	CRYSTALLOGRAPHIC STRUCTURES OF RIBONUCLEASE S VARIANTS WITH NONPOLAR SUBSTITUTION AT POSITION 13: PACKING AND CAVITIES
1RBD	;	1.7	;	CRYSTALLOGRAPHIC STRUCTURES OF RIBONUCLEASE S VARIANTS WITH NONPOLAR SUBSTITUTION AT POSITION 13: PACKING AND CAVITIES
1RBE	;	1.75	;	CRYSTALLOGRAPHIC STRUCTURES OF RIBONUCLEASE S VARIANTS WITH NONPOLAR SUBSTITUTION AT POSITION 13: PACKING AND CAVITIES
1RBF	;	1.8	;	CRYSTALLOGRAPHIC STRUCTURES OF RIBONUCLEASE S VARIANTS WITH NONPOLAR SUBSTITUTION AT POSITION 13: PACKING AND CAVITIES
1RBG	;	1.8	;	CRYSTALLOGRAPHIC STRUCTURES OF RIBONUCLEASE S VARIANTS WITH NONPOLAR SUBSTITUTION AT POSITION 13: PACKING AND CAVITIES
1RBH	;	1.7	;	CRYSTALLOGRAPHIC STRUCTURES OF RIBONUCLEASE S VARIANTS WITH NONPOLAR SUBSTITUTION AT POSITION 13: PACKING AND CAVITIES
1RBI	;	1.8	;	CRYSTALLOGRAPHIC STRUCTURES OF RIBONUCLEASE S VARIANTS WITH NONPOLAR SUBSTITUTION AT POSITION 13: PACKING AND CAVITIES
1NRN	;	3.1	;	CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
1NRO	;	3.1	;	CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
1NRP	;	3.0	;	CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
1NRQ	;	3.5	;	CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
1NRR	;	2.4	;	Crystallographic structures of Thrombin complexed with Thrombin receptor peptides: Existence of expected and novel binding modes
1NRS	;	2.4	;	CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
2EQL	;	2.5	;	CRYSTALLOGRAPHIC STUDIES OF A CALCIUM BINDING LYSOZYME FROM EQUINE MILK AT 2.5 ANGSTROMS RESOLUTION
1HQ7	;	2.1	;	CRYSTALLOGRAPHIC STUDIES OF A DODECAMER B-DNA D-(GCAAACGTTTGC)2
1I44	;	2.4	;	CRYSTALLOGRAPHIC STUDIES OF AN ACTIVATION LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
2CA2	;	1.9	;	CRYSTALLOGRAPHIC STUDIES OF INHIBITOR BINDING SITES IN HUMAN CARBONIC ANHYDRASE II. A PENTACOORDINATED BINDING OF THE SCN-ION TO THE ZINC AT HIGH P*H
3CA2	;	2.0	;	CRYSTALLOGRAPHIC STUDIES OF INHIBITOR BINDING SITES IN HUMAN CARBONIC ANHYDRASE II. A PENTACOORDINATED BINDING OF THE SCN-ION TO THE ZINC AT HIGH P*H
1ADB	;	2.4	;	CRYSTALLOGRAPHIC STUDIES OF ISOSTERIC NAD ANALOGUES BOUND TO ALCOHOL DEHYDROGENASE: SPECIFICITY AND SUBSTRATE BINDING IN TWO TERNARY COMPLEXES
1ADC	;	2.7	;	CRYSTALLOGRAPHIC STUDIES OF ISOSTERIC NAD ANALOGUES BOUND TO ALCOHOL DEHYDROGENASE: SPECIFICITY AND SUBSTRATE BINDING IN TWO TERNARY COMPLEXES
1P34	;	2.7	;	Crystallographic Studies of Nucleosome Core Particles containing Histone 'Sin' Mutants
1P3A	;	3.0	;	Crystallographic Studies of Nucleosome Core Particles containing Histone 'Sin' Mutants
1P3B	;	3.0	;	Crystallographic Studies of Nucleosome Core Particles containing Histone 'Sin' Mutants
1P3F	;	2.9	;	Crystallographic Studies of Nucleosome Core Particles containing Histone 'Sin' Mutants
1P3G	;	2.7	;	Crystallographic Studies of Nucleosome Core Particles containing Histone 'Sin' Mutants
1P3I	;	2.3	;	Crystallographic Studies of Nucleosome Core Particles containing Histone 'Sin' Mutants
1P3K	;	2.9	;	Crystallographic Studies of Nucleosome Core Particles containing Histone 'Sin' Mutants
1P3L	;	2.4	;	Crystallographic Studies of Nucleosome Core Particles containing Histone 'Sin' Mutants
1P3M	;	2.9	;	Crystallographic Studies of Nucleosome Core Particles containing Histone 'Sin' Mutants
1P3O	;	2.75	;	Crystallographic Studies of Nucleosome Core Particles containing Histone 'Sin' Mutants
1P3P	;	2.7	;	Crystallographic Studies of Nucleosome Core Particles containing Histone 'Sin' Mutants
1CAN	;	1.9	;	CRYSTALLOGRAPHIC STUDIES OF THE BINDING OF PROTONATED AND UNPROTONATED INHIBITORS TO CARBONIC ANHYDRASE USING HYDROGEN SULPHIDE AND NITRATE ANIONS
1CAO	;	1.9	;	CRYSTALLOGRAPHIC STUDIES OF THE BINDING OF PROTONATED AND UNPROTONATED INHIBITORS TO CARBONIC ANHYDRASE USING HYDROGEN SULPHIDE AND NITRATE ANIONS
1FBC	;	2.6	;	CRYSTALLOGRAPHIC STUDIES OF THE CATALYTIC MECHANISM OF THE NEUTRAL FORM OF FRUCTOSE-1,6-BISPHOSPHATASE
1FBD	;	2.9	;	CRYSTALLOGRAPHIC STUDIES OF THE CATALYTIC MECHANISM OF THE NEUTRAL FORM OF FRUCTOSE-1,6-BISPHOSPHATASE
1FBE	;	3.0	;	CRYSTALLOGRAPHIC STUDIES OF THE CATALYTIC MECHANISM OF THE NEUTRAL FORM OF FRUCTOSE-1,6-BISPHOSPHATASE
1FBF	;	2.7	;	CRYSTALLOGRAPHIC STUDIES OF THE CATALYTIC MECHANISM OF THE NEUTRAL FORM OF FRUCTOSE-1,6-BISPHOSPHATASE
1FBG	;	3.0	;	CRYSTALLOGRAPHIC STUDIES OF THE CATALYTIC MECHANISM OF THE NEUTRAL FORM OF FRUCTOSE-1,6-BISPHOSPHATASE
1FBH	;	2.5	;	CRYSTALLOGRAPHIC STUDIES OF THE CATALYTIC MECHANISM OF THE NEUTRAL FORM OF FRUCTOSE-1,6-BISPHOSPHATASE
1ADF	;	2.9	;	CRYSTALLOGRAPHIC STUDIES OF TWO ALCOHOL DEHYDROGENASE-BOUND ANALOGS OF THIAZOLE-4-CARBOXAMIDE ADENINE DINUCLEOTIDE (TAD), THE ACTIVE ANABOLITE OF THE ANTITUMOR AGENT TIAZOFURIN
1ADG	;	2.7	;	CRYSTALLOGRAPHIC STUDIES OF TWO ALCOHOL DEHYDROGENASE-BOUND ANALOGS OF THIAZOLE-4-CARBOXAMIDE ADENINE DINUCLEOTIDE (TAD), THE ACTIVE ANABOLITE OF THE ANTITUMOR AGENT TIAZOFURIN
1CRB	;	2.1	;	CRYSTALLOGRAPHIC STUDIES ON A FAMILY OF CELLULAR LIPOPHILIC TRANSPORT PROTEINS. REFINEMENT OF P2 MYELIN PROTEIN AND THE STRUCTURE DETERMINATION AND REFINEMENT OF CELLULAR RETINOL-BINDING PROTEIN IN COMPLEX WITH ALL-TRANS-RETINOL
1PMP	;	2.7	;	CRYSTALLOGRAPHIC STUDIES ON A FAMILY OF CELLULAR LIPOPHILIC TRANSPORT PROTEINS. REFINEMENT OF P2 MYELIN PROTEIN AND THE STRUCTURE DETERMINATION AND REFINEMENT OF CELLULAR RETINOL-BINDING PROTEIN IN COMPLEX WITH ALL-TRANS-RETINOL
1WUY	;	2.26	;	Crystallographic studies on acyl ureas, a new class of inhibitors of glycogen phosphorylase. Broad specificity of the allosteric site
1WV0	;	2.26	;	Crystallographic studies on acyl ureas, a new class of inhibitors of glycogen phosphorylase. Broad specificity of the allosteric site
1WV1	;	2.26	;	Crystallographic studies on acyl ureas, a new class of inhibitors of glycogenphosphorylase. Broad specificity of the allosteric site
1FEL	;	1.8	;	CRYSTALLOGRAPHIC STUDIES ON COMPLEXES BETWEEN RETINOIDS AND PLASMA RETINOL-BINDING PROTEIN
1FEM	;	1.9	;	CRYSTALLOGRAPHIC STUDIES ON COMPLEXES BETWEEN RETINOIDS AND PLASMA RETINOL-BINDING PROTEIN
1FEN	;	1.9	;	CRYSTALLOGRAPHIC STUDIES ON COMPLEXES BETWEEN RETINOIDS AND PLASMA RETINOL-BINDING PROTEIN
2FFR	;	2.03	;	Crystallographic studies on N-azido-beta-D-glucopyranosylamine, an inhibitor of glycogen phosphorylase: comparison with N-acetyl-beta-D-glucopyranosylamine
1PLJ	;	2.8	;	CRYSTALLOGRAPHIC STUDIES ON P21H-RAS USING SYNCHROTRON LAUE METHOD: IMPROVEMENT OF CRYSTAL QUALITY AND MONITORING OF THE GTPASE REACTION AT DIFFERENT TIME POINTS
1PLK	;	2.8	;	CRYSTALLOGRAPHIC STUDIES ON P21H-RAS USING SYNCHROTRON LAUE METHOD: IMPROVEMENT OF CRYSTAL QUALITY AND MONITORING OF THE GTPASE REACTION AT DIFFERENT TIME POINTS
1PLL	;	2.8	;	CRYSTALLOGRAPHIC STUDIES ON P21H-RAS USING SYNCHROTRON LAUE METHOD: IMPROVEMENT OF CRYSTAL QUALITY AND MONITORING OF THE GTPASE REACTION AT DIFFERENT TIME POINTS
1BIL	;	2.4	;	CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS
1BIM	;	2.8	;	CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS
1WW2	;	1.9	;	Crystallographic studies on two bioisosteric analogues, N-acetyl-beta-D-glucopyranosylamine and N-trifluoroacetyl-beta-D-glucopyranosylamine, potent inhibitors of muscle glycogen phosphorylase
1WW3	;	1.8	;	Crystallographic studies on two bioisosteric analogues, N-acetyl-beta-D-glucopyranosylamine and N-trifluoroacetyl-beta-D-glucopyranosylamine, potent inhibitors of muscle glycogen phosphorylase
1NWO	;	1.92	;	CRYSTALLOGRAPHIC STUDY OF AZURIN FROM PSEUDOMONAS PUTIDA
1NWP	;	1.6	;	CRYSTALLOGRAPHIC STUDY OF AZURIN FROM PSEUDOMONAS PUTIDA
1PGN	;	2.3	;	CRYSTALLOGRAPHIC STUDY OF COENZYME, COENZYME ANALOGUE AND SUBSTRATE BINDING IN 6-PHOSPHOGLUCONATE DEHYDROGENASE: IMPLICATIONS FOR NADP SPECIFICITY AND THE ENZYME MECHANISM
1PGO	;	2.5	;	CRYSTALLOGRAPHIC STUDY OF COENZYME, COENZYME ANALOGUE AND SUBSTRATE BINDING IN 6-PHOSPHOGLUCONATE DEHYDROGENASE: IMPLICATIONS FOR NADP SPECIFICITY AND THE ENZYME MECHANISM
1PGP	;	2.5	;	CRYSTALLOGRAPHIC STUDY OF COENZYME, COENZYME ANALOGUE AND SUBSTRATE BINDING IN 6-PHOSPHOGLUCONATE DEHYDROGENASE: IMPLICATIONS FOR NADP SPECIFICITY AND THE ENZYME MECHANISM
1PGQ	;	3.17	;	CRYSTALLOGRAPHIC STUDY OF COENZYME, COENZYME ANALOGUE AND SUBSTRATE BINDING IN 6-PHOSPHOGLUCONATE DEHYDROGENASE: IMPLICATIONS FOR NADP SPECIFICITY AND THE ENZYME MECHANISM
1LRA	;	1.9	;	CRYSTALLOGRAPHIC STUDY OF GLU 58 ALA RNASE T1(ASTERISK)2'-GUANOSINE MONOPHOSPHATE AT 1.9 ANGSTROMS RESOLUTION
4L1A	;	1.9	;	Crystallographic study of multi-drug resistant HIV-1 protease Lopinavir complex: mechanism of drug recognition and resistance
4ANK	;	1.7	;	Crystallographic study of novel transthyretin ligands exhibiting negative-cooperativity between two T4 binding sites.
1BD1	;	1.6	;	CRYSTALLOGRAPHIC STUDY OF ONE TURN OF G/C-RICH B-DNA
2EST	;	2.5	;	Crystallographic study of the binding of a trifluoroacetyl dipeptide anilide inhibitor with elastase
4KXI	;	2.0	;	Crystallographic study of the complex of Ni(II) Schiff base complex and HEW Lysozyme
1KBI	;	2.3	;	Crystallographic Study of the Recombinant Flavin-binding Domain of Baker's Yeast Flavocytochrome b2: Comparison with the Intact Wild-type Enzyme
1KBJ	;	2.5	;	Crystallographic Study of the Recombinant Flavin-binding Domain of Baker's Yeast Flavocytochrome b2: comparison with the Intact Wild-type Enzyme
1LZ2	;	2.8	;	CRYSTALLOGRAPHIC STUDY OF TURKEY EGG-WHITE LYSOZYME AND ITS COMPLEX WITH A DISACCHARIDE
6R27	;	3.4	;	Crystallographic superstructure of the photosensory core module (PAS-GAF-PHY) of the bacterial phytochrome Agp1 (AtBphP1) locked in a Pr-like state
3N85	;	3.2	;	Crystallographic trimer of HER2 extracellular regions in complex with tryptophan-rich antibody fragment
6WYU	;	1.76	;	Crystallographic trimer of metal-free TriCyt2
7JRQ	;	1.75	;	Crystallographically Characterized De Novo Designed Mn-Diphenylporphyrin Binding Protein
1TG6	;	2.1	;	Crystallography and mutagenesis point to an essential role for the N-terminus of human mitochondrial ClpP
6OL2	;	2.1	;	Crystallography of novel WNK1 and WNK3 inhibitors discovered from high-throughput-screening
6DHY	;	2.22	;	Crystallogrpahic tetramer of Zn-bound RIDC1 variant bearing two disulfide bonded cysteines
1NWN	;	2.8	;	Crystals of CO-HbI in which the structure was converted to its unligated state, and then converted back to its original CO-ligated state.
4N6S	;	2.4	;	Crystals of cross-linked stabilized and functional Phycobilisomes: only phycocyanin rods contribute to diffraction.
1ENS	;	2.8	;	CRYSTALS OF DEMETALLIZED CONCANAVALIN A SOAKED WITH COBALT HAVING A COBALT ION BOUND IN THE S1 SITE
1CES	;	2.7	;	CRYSTALS OF DEMETALLIZED CONCANAVALIN A SOAKED WITH ZINC HAVE A ZINC ION BOUND IN THE S1 SITE
2DVF	;	2.74	;	Crystals of peanut lectin grown in the presence of GAL-ALPHA-1,3-GAL-BETA-1,4-GAL
1JYM	;	2.8	;	Crystals of Peptide Deformylase from Plasmodium falciparum with Ten Subunits per Asymmetric Unit Reveal Critical Characteristics of the Active Site for Drug Design
1RQC	;	2.8	;	Crystals of peptide deformylase from Plasmodium falciparum with ten subunits per asymmetric unit reveal critical characteristics of the active site for drug design
3N5M	;	2.05	;	Crystals structure of a Bacillus anthracis aminotransferase
5K3G	;	2.859	;	Crystals structure of Acyl-CoA oxidase-1 in Caenorhabditis elegans, Apo form-I
5K3H	;	2.48	;	Crystals structure of Acyl-CoA oxidase-1 in Caenorhabditis elegans, Apo form-II
5K3J	;	2.68	;	Crystals structure of Acyl-CoA oxidase-2 in Caenorhabditis elegans bound with FAD, ascaroside-CoA, and ATP
3PYX	;	1.6	;	Crystals Structure of Aspartate beta-Semialdehyde Dehydrogenase complex with NADP and 2-aminoterephthalate
3PZB	;	2.0	;	Crystals Structure of Aspartate beta-Semialdehyde Dehydrogenase complex with NADP and D-2,3-Diaminopropionate
3Q1L	;	2.3	;	Crystals Structure of Aspartate beta-Semialdehyde Dehydrogenase from Streptococcus pneumoniae with cysteamine bound covalently to Cys 128
3Q11	;	1.8	;	Crystals Structure of Aspartate beta-Semialdehyde Dehydrogenase from Streptococcus pneumoniae with NADP and aspartyl beta-difluorophosphonate
3PZR	;	1.75	;	Crystals structure of aspartate beta-Semialdehyde dehydrogenase from Vibrio Cholerae with NADP and product of S-carbamoyl-L-cysteine
3Q0E	;	1.8	;	Crystals Structure of Aspartate beta-Semialdehyde Dehydrogenase from Vibrio Cholerae with product of S-allyl-L-cysteine sulfoxide
6B8U	;	2.68	;	Crystals Structure of B-Raf kinase domain in complex with an Imidazopyridinyl benzamide inhibitor
5YF7	;	2.27	;	Crystals structure of Classical swine fever virus NS5B (residues 1-672)
6AE7	;	3.8	;	Crystals structure of Classical swine fever virus NS5B (residues 1-672, E472A mutant)
6AE5	;	2.754	;	Crystals structure of Classical swine fever virus NS5B (residues 1-672, Y471A mutant, form 1)
6AE6	;	3.856	;	Crystals structure of Classical swine fever virus NS5B (residues 1-672, Y471A mutant, form 2)
5YF8	;	3.396	;	Crystals structure of Classical swine fever virus NS5B (residues 1-672, Y471A-E472A mutant)
5YF6	;	2.1	;	Crystals structure of Classical swine fever virus NS5B (residues 1-682)
5YF5	;	2.49	;	Crystals structure of Classical swine fever virus NS5B (residues 1-694)
6AE4	;	2.95	;	Crystals structure of Classical swine fever virus NS5B (residues 1-694, Y471A mutant)
7EKJ	;	3.06	;	Crystals structure of classical swine fever virus NS5B (residues 91-694)
4IWV	;	2.1	;	Crystals structure of Human Glucokinase in complex with small molecule activator
3RVG	;	2.498	;	Crystals structure of Jak2 with a 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitor
3G1P	;	1.4	;	Crystals structure of PhnP from E.coli K-12
2YX7	;	2.05	;	Crystals structure of T132A mutant of St1022 from sulfolobus tokodaii 7
7KZ7	;	1.8	;	Crystals Structure of the Mutated Protease Domain of Botulinum Neurotoxin X (X4130B1).
6WTT	;	2.15	;	Crystals Structure of the SARS-CoV-2 (COVID-19) main protease with inhibitor GC-376
3VON	;	3.15	;	Crystalstructure of the ubiquitin protease
2YXY	;	2.2	;	Crystarl structure of Hypothetical conserved protein, GK0453
6JXG	;	1.9	;	Crystasl Structure of Beta-glucosidase D2-BGL from Chaetomella Raphigera
7XPV	;	2.4	;	crysteal structure of MtdL-S228A-His soaked with GDP-Fucf and Mn
2ZMK	;	2.5	;	Crystl structure of Basic Winged bean lectin in complex with Gal-alpha-1,4-Gal-Beta-Ethylene
3TON	;	2.953	;	Crystral Structure of the C-terminal Subunit of Human Maltase-Glucoamylase
3TOP	;	2.881	;	Crystral Structure of the C-terminal Subunit of Human Maltase-Glucoamylase in Complex with Acarbose
2QLY	;	2.0	;	Crystral Structure of the N-terminal Subunit of Human Maltase-Glucoamylase
2QMJ	;	1.9	;	Crystral Structure of the N-terminal Subunit of Human Maltase-Glucoamylase in Complex with Acarbose
2RFO	;	2.6	;	Crystral Structure of the nucleoporin Nic96
7JOD	;	1.33	;	Crytsal structure of BbKI complexed with Human Kallikrein 4
4YVD	;	1.7	;	Crytsal structure of human Pleiotropic Regulator 1 (PRL1)
1PO9	;	2.0	;	Crytsal structure of isoaspartyl dipeptidase
4LCN	;	1.8	;	Crytsal structure of NE0047 in complex with 2'-DEOXY-GUANOSINE
4LCP	;	2.0	;	Crytsal structure of NE0047 in complex with 2,6-diaminopurine
6JUV	;	3.043	;	Crytsal structure of ScpB derived from Pyrococcus yayanosii
5JIG	;	1.0	;	Crytsal structure of Wss1 from S. pombe
6CWW	;	1.851	;	Cs H-NOX mutant with unnatural amino acid 4-cyano-L-phenylalanine at site 5
2HG5	;	2.75	;	Cs+ complex of a K channel with an amide to ester substitution in the selectivity filter
3HNT	;	1.8	;	CS-35 Fab complex with a linear, terminal oligoarabinofuranosyl tetrasaccharide from lipoarabinomannan
3HNS	;	2.0	;	CS-35 Fab Complex with Oligoarabinofuranosyl Hexasaccharide
3HNV	;	2.0	;	CS-35 Fab Complex with Oligoarabinofuranosyl Tetrasaccharide (branch part of Hexasaccharide)
6D10	;		;	CS-rosetta determined structures of the C-terminal domain of AlgF from P. aeruginosa
6CZT	;		;	CS-rosetta determined structures of the N-terminal domain of AlgF from P. aeruginosa
6P6B	;		;	CS-Rosetta Model of PEA-15 Death Effector Domain
6P6C	;		;	CS-Rosetta Model of PEA-15 Death Effector Domain in the Complex with ERK2
7SQY	;	3.4	;	CSDaV GFP mutant
7SQZ	;	3.1	;	CSDaV wild-type
1C0N	;	2.8	;	CSDB PROTEIN, NIFS HOMOLOGUE
6WXJ	;	2.62	;	CSF1R signaling is a regulator of pathogenesis in progressive MS
6H9H	;	1.75	;	Csf5, CRISPR-Cas type IV Cas6 crRNA endonuclease
6H9I	;	2.29	;	Csf5, CRISPR-Cas type IV Cas6 crRNA endonuclease
6L7A	;	3.38	;	CsgFG complex in Curli biogenesis system
6L7C	;	3.34	;	CsgFG complex with substrate CsgAN6 peptide in Curli biogenesis system
5IVL	;	2.3	;	CshA Helicase
3BRF	;	2.47	;	CSL (Lag-1) bound to DNA with Lin-12 RAM peptide, C2221
3BRD	;	2.21	;	CSL (Lag-1) bound to DNA with Lin-12 RAM peptide, P212121
3BRG	;	2.2	;	CSL (RBP-Jk) bound to DNA
3IAG	;	2.0	;	CSL (RBP-Jk) bound to HES-1 nonconsensus site
4J2X	;	2.85	;	CSL (RBP-Jk) with corepressor KyoT2 bound to DNA
6WQU	;	2.41	;	CSL (RBPJ) bound to Notch3 RAM and DNA
5EG6	;	2.094	;	CSL-RITA complex bound to DNA
2K37	;		;	CsmA
2G13	;	1.61	;	CsoS1A with sulfate ion
6FF1	;	1.3	;	CsoZ metallochaperone
6CJ8	;		;	CSP1
6COW	;		;	CSP1
6OC4	;		;	CSP1-cyc(Dab6E10)
6OLD	;		;	CSP1-cyc(Dap6E10)
6OBW	;		;	CSP1-cyc(K6D10)
6OC2	;		;	CSP1-cyc(Orn6D10)
6COO	;		;	CSP1-E1A
6V1N	;		;	CSP1-E1A-cyc(Dap6E10)
6COS	;		;	CSP1-f11
6COR	;		;	CSP1-F11A
6COQ	;		;	CSP1-K6A
6COP	;		;	CSP1-R3A
6COT	;		;	CSP2-d10
6COU	;		;	CSP2-E1Ad10
6COV	;		;	CSP2-l14
7NWW	;	3.05	;	CspA-27 cotranslational folding intermediate 1
7OIF	;	3.0	;	CspA-27 cotranslational folding intermediate 2
7OIG	;	3.2	;	CspA-27 cotranslational folding intermediate 3
7OT5	;	2.9	;	CspA-70 cotranslational folding intermediate 1
7OII	;	3.0	;	CspA-70 cotranslational folding intermediate 2
7ZJJ	;	2.1	;	CspZ (BbCRASP-2) from Borrelia burgdorferi strain B379
7ZJK	;	2.45	;	CspZ (BbCRASP-2) from Borrelia burgdorferi strain B408
2MFH	;		;	Csr/Rsm protein-RNA recognition - A molecular affinity ruler: RsmZ(36-44)/RsmE(dimer) 2:1 complex
2MFC	;		;	Csr/Rsm protein-RNA recognition - A molecular affinity ruler: RsmZ(SL1)/RsmE(dimer) 2:1 complex
2MFE	;		;	Csr/Rsm protein-RNA recognition - A molecular affinity ruler: RsmZ(SL2)/RsmE(dimer) 2:1 complex
2MFF	;		;	Csr/Rsm protein-RNA recognition - A molecular affinity ruler: RsmZ(SL3)/RsmE(dimer) 2:1 complex
2MFG	;		;	Csr/Rsm protein-RNA recognition - A molecular affinity ruler: RsmZ(SL4)/RsmE(dimer) 2:1 complex
6VJG	;	1.8	;	Csx3-I222 Crystal Form at 1.8 Angstrom Resolution
6TY2	;	1.98	;	CT PART CRYSTAL STRUCTURE OF THE RYMV-ENCODED VIRAL RNA SILENCING SUPPRESSOR P1
7WVE	;	3.11	;	CT-mut (D523K,D524K,E527K) TLR3-poly(I:C) complex
2EYY	;		;	CT10-Regulated Kinase isoform I
2EYZ	;		;	CT10-Regulated Kinase isoform II
5F16	;	1.2	;	CTA-modified hen egg-white lysozyme
1HL3	;	3.1	;	CtBP/BARS in ternary complex with NAD(H) and PIDLSKK peptide
2HU2	;	2.85	;	CTBP/BARS in ternary complex with NAD(H) and RRTGAPPAL peptide
1HKU	;	2.3	;	CtBP/BARS: a dual-function protein involved in transcription corepression and Golgi membrane fission
7KWM	;	2.3	;	CtBP1 (28-375) L182F/V185T - AMP
4U6Q	;	2.3	;	CtBP1 bound to inhibitor 2-(hydroxyimino)-3-phenylpropanoic acid
4LCE	;	2.38	;	CtBP1 in complex with substrate MTOB
4U6S	;	2.1	;	CtBP1 in complex with substrate phenylpyruvate
3GA0	;	3.4	;	CtBP1/BARS Gly172->Glu mutant structure: impairing NAD(H) binding and dimerization
4LCJ	;	2.86	;	CtBP2 in complex with substrate MTOB
1ZFG	;	1.75	;	CTC Duplex B-DNA
2XQO	;	1.4	;	CtCel124: a cellulase from Clostridium thermocellum
5T0U	;	3.199	;	CTCF ZnF2-7 and DNA complex structure
3LFY	;	2.6	;	CTD of Tarocystatin in complex with papain
2GHQ	;	2.05	;	CTD-specific phosphatase Scp1 in complex with peptide C-terminal domain of RNA polymerase II
2GHT	;	1.8	;	CTD-specific phosphatase Scp1 in complex with peptide from C-terminal domain of RNA polymerase II
8BA1	;		;	CTD12-CTD12 heterodimer from CPSF73 and CPSF100
8Q9O	;	3.1	;	CTE tau intermediate amyloid (LIA-17)
8QJJ	;	3.35	;	CTE type II (tau intermediate amyloid)
8OT6	;	2.0	;	CTE typeI tau filament from Guam ALS/PDC
8OTG	;	2.1	;	CTE typeI tau filament from Kii ALS/PDC
8OTC	;	3.2	;	CTE typeII tau filament from Guam ALS/PDC
8OTI	;	2.7	;	CTE typeIII tau filament
8OT9	;	3.4	;	CTE typeIII tau filament from Guam ALS/PDC
7L7Q	;	3.7	;	Ctf3c with Ulp2-KIM
4AOU	;	2.5	;	CtIDH bound to NADP. The complex structures of Isocitrate dehydrogenase from Clostridium thermocellum and Desulfotalea psychrophila, support a new active site locking mechanism
5GGV	;	1.998	;	CTLA-4 in complex with tremelimumab Fab
1AH1	;		;	CTLA-4, NMR, 20 STRUCTURES
8G8N	;	3.0	;	CTLA4 Fab with peptide
7SWG	;		;	cTnC-TnI chimera complexed with A1
7SWI	;		;	cTnC-TnI chimera complexed with A2
7SXC	;		;	cTnC-TnI chimera complexed with calcium
1COZ	;	2.0	;	CTP:GLYCEROL-3-PHOSPHATE CYTIDYLYLTRANSFERASE FROM BACILLUS SUBTILIS
8HP2	;	3.05	;	CtPDC
8HP4	;	2.52	;	CtPDC complex
5TQR	;	2.571	;	ctPRC2 in an autoinhibited conformation bound to S-adenosylmethionine
6FH4	;	2.49	;	CtsR C-terminal domain with bound phospho-arginine
6D7H	;	1.801	;	CTX-M-14 Apoenzyme
6D7I	;	2.001	;	CTX-M-14 Apoenzyme D233N Point Mutant
6OOJ	;	1.4	;	CTX-M-14 Beta Lactamase with Compound 14
6OOF	;	1.236	;	CTX-M-14 Beta Lactamase with Compound 20
6OOK	;	1.4	;	CTX-M-14 Beta Lactamase with Compound 3
8ELA	;	1.5	;	CTX-M-14 beta-lactamase mutant - N132A w MES
8ELB	;	1.5	;	CTX-M-14 beta-lactamase mutant- N132A
4UA6	;	0.79	;	CTX-M-14 Class A Beta-Lactamase Apo Crystal Structure at 0.79 Angstrom Resolution
4UA9	;	0.84	;	CTX-M-14 Class A Beta-Lactamase in Complex with a Boronic Acid Acylation Transition State Analog at Sub-Angstrom Resolution
4UA7	;	0.89	;	CTX-M-14 Class A Beta-Lactamase in Complex with a Non-Covalent Inhibitor at Sub-Angstrom Resolution
4UAA	;	0.86	;	CTX-M-14 Class A Beta-Lactamase in Complex with a Non-Covalent Inhibitor at Sub-Angstrom Resolution
6MZ1	;	1.0	;	CTX-M-14 Class A Beta-Lactamase in Complex with Avibactam at pH 5.3
6MZ2	;	0.83	;	CTX-M-14 Class A Beta-Lactamase in Complex with Avibactam at pH 7.9
5U53	;	1.4	;	CTX-M-14 E166A with acylated ceftazidime molecule
6CYK	;	1.7	;	CTX-M-14 N106S mutant
6CYN	;	1.6	;	CTX-M-14 N106S/D240G mutant
5TWD	;	1.7	;	CTX-M-14 P167S apoenzyme
5VTH	;	2.2	;	CTX-M-14 P167S:E166A mutant
5TW6	;	1.7	;	CTX-M-14 P167S:E166A mutant with acylated ceftazidime molecule
5TWE	;	1.5	;	CTX-M-14 P167S:S70G mutant enzyme crystallized with ceftazidime
6BT6	;	1.05	;	CTX-M-14 S237A Beta-Lactamase in Complex with a Non-Covalent Tetrazole Inhibitor
7UON	;	1.35	;	CTX-M-14 Y105W mutant
4S2I	;	1.6	;	CTX-M-15 in complex with Avibactam
5FAO	;	3.01	;	CTX-M-15 in complex with FPI-1465
5FA7	;	1.67	;	CTX-M-15 in complex with FPI-1523
5FAP	;	2.7	;	CTX-M-15 in complex with FPI-1602
7S5S	;	1.4	;	CTX-M-15 WT in complex with BLIP WT
6BN3	;	1.278	;	CTX-M-151 class A extended-spectrum beta-lactamase apo crystal structure at 1.3 Angstrom resolution
6BPF	;	1.318	;	CTX-M-151 class A extended-spectrum beta-lactamase crystal structure in complex with avibactam at 1.32 Angstrom resolution
6OOH	;	1.499	;	CTX-M-27 Beta Lactamase with Compound 14
6OOE	;	1.26	;	CTX-M-27 Beta Lactamase with Compound 20
6BU3	;	1.15	;	CTX-M-27 Beta-Lactamase in Complex with a Non-Covalent Tetrazole Inhibitor
5ZB7	;	1.63	;	CTX-M-64 apoenzyme
6J25	;	1.2	;	CTX-M-64 beta-lactamase mutant-S130T
6J2K	;	1.44	;	CTX-M-64 beta-lactamase S130T clavulanic acid complex
6J2B	;	1.44	;	CTX-M-64 beta-lactamase S130T sulbactam complex
6ITY	;	2.14	;	CTX-M-64 sulbactam complex
5KMU	;	1.8	;	CTX-M-9 beta lactamase mutant - T165W
2P74	;	0.88	;	CTX-M-9 class A beta-lactamase apo crystal structure at 0.88 Angstrom resolution
3G2Y	;	1.31	;	CTX-M-9 class A beta-lactamase complexed with compound 1 (GF4)
4DDY	;	1.36	;	CTX-M-9 class A beta-lactamase complexed with compound 10
4DDS	;	1.36	;	CTX-M-9 class A beta-lactamase complexed with compound 11
3G34	;	1.31	;	CTX-M-9 class A beta-lactamase complexed with compound 11 (1CE)
4DE2	;	1.4	;	CTX-M-9 class A beta-lactamase complexed with compound 12
3G35	;	1.41	;	CTX-M-9 class A beta-lactamase complexed with compound 12 (F13)
4DE0	;	1.12	;	CTX-M-9 class A beta-lactamase complexed with compound 16
4DE1	;	1.26	;	CTX-M-9 class A beta-lactamase complexed with compound 18
3G2Z	;	1.5	;	CTX-M-9 class A beta-lactamase complexed with compound 2 (GZ2)
3G30	;	1.8	;	CTX-M-9 class A beta-lactamase complexed with compound 3 (G30)
4DE3	;	1.44	;	CTX-M-9 class A beta-lactamase complexed with compound 4
3G31	;	1.7	;	CTX-M-9 class A beta-lactamase complexed with compound 4 (GF1)
3G32	;	1.31	;	CTX-M-9 class A beta-lactamase complexed with compound 6 (3G3)
4LEN	;	1.5	;	CTX-M-9 in complex with the broad spectrum inhibitor 3-(2- carboxyvinyl)benzo(b)thiophene-2-boronic acid
3HLW	;	1.5	;	CTX-M-9 S70G in complex with cefotaxime
3Q1F	;	1.5	;	CTX-M-9 S70G in complex with hydrolyzed piperacillin
3Q07	;	1.5	;	CTX-M-9 S70G in complex with piperacillin
8R7M	;	1.0	;	CTX-M14 in complex with boric acid and 1,2-diol boric ester
5KMT	;	1.7	;	CTX-M9 mutant L48A
3VGD	;	2.4	;	Ctystal structure of glycosyltrehalose trehalohydrolase (D252E)
2XXF	;	1.5	;	Cu metallated H254F mutant of nitrite reductase
6ZU6	;	1.15	;	Cu nitrite reductase from Achromobacter cycloclastes: MSOX series at 170K, dose point 1
6ZUB	;	1.08	;	Cu nitrite reductase from Achromobacter cycloclastes: MSOX series at 170K, dose point 2
6ZUD	;	1.1	;	Cu nitrite reductase from Achromobacter cycloclastes: MSOX series at 170K, dose point 3
6ZUA	;	1.14	;	Cu nitrite reductase from Achromobacter cycloclastes: MSOX series at 170K, dose point 4
6ZUT	;	1.15	;	Cu nitrite reductase MSOX series at 170K, dose point 5
5OF5	;	1.08	;	Cu nitrite reductase serial data at varying temperatures
5OF6	;	1.08	;	Cu nitrite reductase serial data at varying temperatures 190K 0.48MGy
5OF7	;	1.27	;	Cu nitrite reductase serial data at varying temperatures 190K 0.48MGy
5OF8	;	1.34	;	Cu nitrite reductase serial data at varying temperatures 190K 0.48MGy
5OFD	;	1.77	;	Cu nitrite reductase serial data at varying temperatures 190K 0.48MGy
5OFE	;	1.84	;	Cu nitrite reductase serial data at varying temperatures 190K 0.48MGy
5OFC	;	1.68	;	Cu nitrite reductase serial data at varying temperatures 190K 21.65MGy
5OFF	;	1.41	;	Cu nitrite reductase serial data at varying temperatures RT 0.03MGy
5OFG	;	1.49	;	Cu nitrite reductase serial data at varying temperatures RT 0.06MGy
5OG2	;	1.64	;	Cu nitrite reductase serial data at varying temperatures RT 0.09MGy
5OFH	;	1.58	;	Cu nitrite reductase serial data at varying temperatures RT 0.15MGy
5OG3	;	1.7	;	Cu nitrite reductase serial data at varying temperatures RT 0.15MGy
5OG4	;	1.76	;	Cu nitrite reductase serial data at varying temperatures RT 0.18MGy
5OG5	;	1.82	;	Cu nitrite reductase serial data at varying temperatures RT 0.21MGy
5OG6	;	1.85	;	Cu nitrite reductase serial data at varying temperatures RT 0.24MGy
5OGF	;	1.88	;	Cu nitrite reductase serial data at varying temperatures RT 0.27MGy
5OGG	;	1.91	;	Cu nitrite reductase serial data at varying temperatures RT 0.30MGy
6TWE	;		;	Cu(I) NMR solution structure of the chitin-active lytic polysaccharide monooxygenase BlLPMO10A
2KM0	;		;	Cu(I)-bound CopK
6WKT	;	3.4	;	Cu(I)-bound Copper Storage Protein BsCsp3
5FJE	;	1.9	;	CU(I)-CSP1 (COPPER STORAGE PROTEIN 1) FROM METHYLOSINUS TRICHOSPORIUM OB3B
5ARN	;	2.3	;	Cu(I)-CSP3 (COPPER STORAGE PROTEIN 3) FROM METHYLOSINUS
5NQM	;	1.59	;	CU(I)-CSP3 (COPPER STORAGE PROTEIN 3) FROM METHYLOSINUS
5NQN	;	1.62	;	CU(I)-CSP3 (COPPER STORAGE PROTEIN 3) FROM METHYLOSINUS
5NQO	;	1.15	;	CU(I)-CSP3 (COPPER STORAGE PROTEIN 3) FROM METHYLOSINUS
2C9P	;	2.25	;	Cu(I)Cu(II)-CopC at pH 4.5
2C9Q	;	1.6	;	Cu(I)Cu(II)-CopC at pH 7.5
6KOD	;	3.0	;	Cu(II) complex of HOCl-induced flavoprotein disulfide reductase RclA C43S mutant from Escherichia coli
6KYY	;	2.8	;	Cu(II) complex of HOCl-induced flavoprotein disulfide reductase RclA from Escherichia coli
6KZY	;	2.30057	;	Cu(II) loaded Tegillarca granosa ferritin
6L58	;	3.90271	;	Cu(II) loaded Tegillarca granosa M-ferritin soaked with Fe(II)
3JTB	;	1.8	;	Cu(II) N47S/F114N variant of Pseudomonas Aeruginosa Azurin
3JT2	;	2.1	;	Cu(II) N47S/M121L variant of Pseudomonas Aeruginosa azurin
6DYD	;	1.724	;	Cu(II)-bound structure of the engineered cyt cb562 variant, CH3
6DYF	;	1.1	;	Cu(II)-bound structure of the engineered cyt cb562 variant, CH3Y
6HY8	;	1.22	;	Cu(II)-substituted Wells-Dawson binding to Hen Egg-White Lysozyme (HEWL)
6LV9	;	1.2	;	Cu- Carbonic Anhydrase II pH 7.8 0 atm CO2
6LVA	;	1.2	;	Cu- Carbonic Anhydrase II pH 7.8 20 atm CO2
7LSJ	;	1.26	;	Cu-bound crystal structure of the engineered cyt cb562 variant, DiCyt2 - H63A, crystallized in the presence of Cu(II)
7LSL	;	1.64	;	Cu-bound crystal structure of the engineered cyt cb562 variant, DiCyt2 - H63A, crystallized in the presence of Ni(II)
7LV4	;	1.99	;	Cu-bound crystal structure of the engineered cyt cb562 variant, DiCyt2 - H97A, crystallized in the presence of Cu(II)
7LV1	;	1.91	;	Cu-bound crystal structure of the engineered cyt cb562 variant, DiCyt2, crystallized in the presence of Cu(II)
6P16	;	1.913	;	Cu-bound PCuAC domain from PmoF1
6P1E	;	1.605	;	Cu-bound PmoF1 PCuAC domain (dimer)
6X8X	;	2.505	;	Cu-bound structure of an engineered metal-dependent protein trimer, TriCyt1
6WZ3	;	1.8	;	Cu-bound structure of the engineered protein trimer, TriCyt3
6PDV	;	1.23	;	Cu-Carbonic Anhydrase II, A Nitrite Reductase
1ZV2	;	1.74	;	Cu-containing nitrite reductase
2A3T	;	1.85	;	Cu-containing nitrite reductase
6HBE	;	1.63	;	Cu-containing nitrite reductase (NirK) from Thermus scotoductus SA-01
2DWT	;	1.9	;	Cu-containing nitrite reductase at pH 6.0 with bound nitrite
2DWS	;	1.85	;	Cu-containing nitrite reductase at pH 8.4 with bound nitrite
3SES	;	1.9	;	Cu-mediated Dimer of Maltose-binding Protein A216H/K220H by Synthetic Symmetrization
3SB8	;	2.65	;	Cu-mediated Dimer of T4 Lysozyme D61H/K65H by Synthetic Symmetrization
3SB6	;	2.7	;	Cu-mediated Dimer of T4 Lysozyme D61H/K65H/R76H/R80H by Synthetic Symmetrization
3SB9	;	2.45	;	Cu-mediated Dimer of T4 Lysozyme R76H/R80H by Synthetic Symmetrization
3SB7	;	2.7	;	Cu-mediated Trimer of T4 Lysozyme D61H/K65H/R76H/R80H by Synthetic Symmetrization
1AQS	;		;	CU-METALLOTHIONEIN FROM SACCHAROMYCES CEREVISIAE, NMR, 10 STRUCTURES
1AQR	;		;	CU-METALLOTHIONEIN FROM SACCHAROMYCES CEREVISIAE, NMR, MINIMIZED AVERAGE STRUCTURE
6RUK	;	1.2	;	Cu-substituted alpha-Keggin bound to Proteinase K solved by MR
3PU7	;	1.8	;	Cu-Zn Tomato Chloroplast Superoxide Dismutase
2AQQ	;	1.65	;	CU/ZN superoxid dismutate from neisseria meningitidis K91E mutant
2APS	;	1.9	;	CU/ZN SUPEROXIDE DISMUTASE FROM ACTINOBACILLUS PLEUROPNEUMONIAE
4L05	;	1.098	;	Cu/Zn superoxide dismutase from Brucella abortus
2AQN	;	1.4	;	CU/ZN superoxide dismutase from neisseria meningitidis
2AQP	;	1.3	;	CU/ZN superoxide dismutase from neisseria meningitidis E73A mutant
2AQS	;	1.7	;	CU/ZN superoxide dismutase from neisseria meningitidis K91E, K94E double mutant
2AQR	;	1.75	;	CU/ZN superoxide dismutase from neisseria meningitidis K91Q mutant
2AQT	;	1.8	;	CU/ZN superoxide dismutase from neisseria meningitidis K91Q, K94Q double mutant
7WWT	;	1.6	;	Cu/Zn-superoxide dismutase from dog (Canis familiaris)
3E12	;	1.7	;	Cu2+ substituted Aquifex aeolicus KDO8PS in complex with KDO8P
3E0I	;	1.703	;	Cu2+ substituted Aquifex aeolicus KDO8PS in complex with PEP
3IUD	;	2.44	;	Cu2+-bound form of Pseudomonas stutzeri L-rhamnose isomerase
3DEM	;	2.3	;	CUB1-EGF-CUB2 domain of HUMAN MASP-1/3
5CKQ	;	3.704	;	CUB1-EGF-CUB2 domains of rat MASP-1
6F1D	;	1.95	;	CUB2 domain of C1r
4MBB	;	1.849	;	Cubic crystal form of PIR1 dual specificity phosphatase core
5FYA	;	2.141	;	Cubic crystal of the native PlpD
1IER	;	2.26	;	CUBIC CRYSTAL STRUCTURE OF NATIVE HORSE SPLEEN FERRITIN
1DAT	;	2.05	;	CUBIC CRYSTAL STRUCTURE RECOMBINANT HORSE L APOFERRITIN
7QGF	;	1.203	;	Cubic Insulin SAD phasing at 14.2 keV
6LS3	;	2.815	;	cubic-shaped crystal of TmFtn mutant-T4FY stimulated by Mg
2CBP	;	1.8	;	CUCUMBER BASIC PROTEIN, A BLUE COPPER PROTEIN
6MRL	;	3.2	;	Cucumber Leaf Spot Virus
1F15	;	3.2	;	CUCUMBER MOSAIC VIRUS (STRAIN FNY)
1JER	;	1.6	;	CUCUMBER STELLACYANIN, CU2+, PH 7.0
5N10	;	1.6	;	Cucurbit[8]uril and 14-3-3 based binary bivalent supramolecular-protein assembly platform
1MN3	;	2.3	;	Cue domain of yeast Vps9p
3OD3	;	1.1	;	CueO at 1.1 A resolution including residues in previously disordered region
3PAU	;	2.0	;	CueO in the resting oxidized state
6IM7	;	1.97	;	CueO-12.1 multicopper oxidase
6IM8	;	1.801	;	CueO-PM2 multicopper oxidase
6XH7	;	3.9	;	CueR-TAC without RNA
6XH8	;	4.1	;	CueR-transcription activation complex with RNA transcript
5W1U	;	2.5	;	Culex quinquefasciatus carboxylesterase B2
6V4C	;	1.97	;	Culex quinquefasciatus D7 long form 1- CxD7L1 in complex with ADP
2MYL	;		;	Cullin3 - BTB interface: a novel target for stapled peptides
2MYM	;		;	Cullin3 - BTB interface: a novel target for stapled peptides
8KHP	;	3.67	;	CULLIN3-KLHL22-RBX1 E3 ligase
1WQL	;	2.2	;	Cumene dioxygenase (cumA1A2) from Pseudomonas fluorescens IP01
1L42	;	1.8	;	CUMULATIVE SITE-DIRECTED CHARGE-CHANGE REPLACEMENTS IN BACTERIOPHAGE T4 LYSOZYME SUGGEST THAT LONG-RANGE ELECTROSTATIC INTERACTIONS CONTRIBUTE LITTLE TO PROTEIN STABILITY
1L43	;	1.8	;	CUMULATIVE SITE-DIRECTED CHARGE-CHANGE REPLACEMENTS IN BACTERIOPHAGE T4 LYSOZYME SUGGEST THAT LONG-RANGE ELECTROSTATIC INTERACTIONS CONTRIBUTE LITTLE TO PROTEIN STABILITY
1L44	;	1.7	;	CUMULATIVE SITE-DIRECTED CHARGE-CHANGE REPLACEMENTS IN BACTERIOPHAGE T4 LYSOZYME SUGGEST THAT LONG-RANGE ELECTROSTATIC INTERACTIONS CONTRIBUTE LITTLE TO PROTEIN STABILITY
1L45	;	1.7	;	CUMULATIVE SITE-DIRECTED CHARGE-CHANGE REPLACEMENTS IN BACTERIOPHAGE T4 LYSOZYME SUGGEST THAT LONG-RANGE ELECTROSTATIC INTERACTIONS CONTRIBUTE LITTLE TO PROTEIN STABILITY
1L46	;	1.7	;	CUMULATIVE SITE-DIRECTED CHARGE-CHANGE REPLACEMENTS IN BACTERIOPHAGE T4 LYSOZYME SUGGEST THAT LONG-RANGE ELECTROSTATIC INTERACTIONS CONTRIBUTE LITTLE TO PROTEIN STABILITY
1L47	;	1.7	;	CUMULATIVE SITE-DIRECTED CHARGE-CHANGE REPLACEMENTS IN BACTERIOPHAGE T4 LYSOZYME SUGGEST THAT LONG-RANGE ELECTROSTATIC INTERACTIONS CONTRIBUTE LITTLE TO PROTEIN STABILITY
2K38	;		;	Cupiennin 1A, NMR, minimized average structure
3RNS	;	2.07	;	Cupin 2 conserved barrel domain protein from Leptotrichia buccalis
5OVU	;	2.1	;	Cupriavidus metallidurans BPH
3OV2	;	2.32	;	Curcumin synthase 1 from Curcuma longa
5DP2	;	0.96	;	CurF ER cyclopropanase from curacin A biosynthetic pathway
2NA4	;		;	Curli secretion specificity factor CsgE W48A/F79A mutant
2A2B	;		;	Curvacin A
6B79	;	1.8	;	Curved pair of sheets formed from SOD1 residues 28-38 with familial mutation G37R.
6MNT	;		;	CUS-3 coat protein I-domain
3EF3	;	1.5	;	cut-1a; NCN-Pt-Pincer-Cutinase Hybrid
3ESA	;	2.0	;	cut-1b; NCN-Pt-Pincer-Cutinase Hybrid
3ESB	;	2.3	;	cut-1c; NCN-Pt-Pincer-Cutinase Hybrid
3ESC	;	1.2	;	cut-2a; NCN-Pt-Pincer-Cutinase Hybrid
3ESD	;	1.22	;	cut-2b; NCN-Pt-Pincer-Cutinase Hybrid
6YWO	;	1.9	;	CutA in complex with A3 RNA
6YWN	;	1.45	;	CutA in complex with CMPCPP
8CWO	;	2.84	;	Cutibacterium acnes 30S ribosomal subunit with Sarecycline bound, body domain only in the local refined map
8CVO	;	2.95	;	Cutibacterium acnes 30S ribosomal subunit with Sarecycline bound, head domain only in the local refined map
8CVM	;	2.66	;	Cutibacterium acnes 50S ribosomal subunit with P-site tRNA and Sarecycline bound in the local refined map
8CRX	;	2.78	;	Cutibacterium acnes 70S ribosome with mRNA, P-site tRNA and Sarecycline bound
2CUT	;	1.9	;	CUTINASE, A LIPOLYTIC ENZYME WITH A PREFORMED OXYANION HOLE
1CUU	;	1.69	;	CUTINASE, A199C MUTANT
1CUV	;	2.01	;	CUTINASE, A85F MUTANT
1CUW	;	2.7	;	CUTINASE, G82A, A85F, V184I, A185L, L189F MUTANT
1CUX	;	1.75	;	CUTINASE, L114Y MUTANT
1CUY	;	1.69	;	CUTINASE, L189F MUTANT
1CUZ	;	2.1	;	CUTINASE, L81G, L182G MUTANT
1CUA	;	1.8	;	CUTINASE, N172K MUTANT
1CUB	;	1.75	;	CUTINASE, N172K, R196D MUTANT, MONOCLINIC CRYSTAL FORM
1CUD	;	2.7	;	CUTINASE, N172K, R196D MUTANT, MONOCLINIC CRYSTAL FORM WITH THREE MOLECULES PER ASYMMETRIC UNIT
1CUC	;	1.75	;	CUTINASE, N172K, R196D MUTANT, ORTHORHOMBIC CRYSTAL FORM
1CUE	;	2.1	;	CUTINASE, Q121L MUTANT
1CUF	;	1.75	;	CUTINASE, R156L MUTANT
1CUG	;	1.75	;	CUTINASE, R17E, N172K MUTANT
1CUH	;	1.75	;	CUTINASE, R196E MUTANT
1CUI	;	2.5	;	CUTINASE, S120A MUTANT
1CUJ	;	1.6	;	CUTINASE, S120C MUTANT
7MMX	;	1.9	;	CutN from Type I Cut MCP
6XPH	;	1.8	;	CutR dimer with domain swap
6XPI	;	2.6	;	CutR flat hexamer, form 1
6XPJ	;	1.5	;	CutR flat hexamer, form 2
6XPK	;	2.8	;	CutR Screw, form 1 with 41.9 angstrom pitch
6XPL	;	3.3	;	CutR Screw, form 2 with 33.8 angstrom pitch
6S85	;	4.2	;	Cutting state of the E. coli Mre11-Rad50 (SbcCD) head complex bound to ADP and dsDNA.
5NLT	;	1.9	;	CvAA9A
7QUW	;	1.65	;	CVB3-3Cpro in complex with inhibitor MG-78
7WL3	;	2.95	;	CVB5 expended empty particle
7XB2	;	2.81	;	CVB5-intermediate altered particle containing VP1/VP2/VP3 and RNA genome
8VIB	;	4.6	;	CW Flagellar Switch Complex - FliF, FliG, FliM, and FliN forming single subunit of the C-ring from Salmonella
8VKQ	;	4.6	;	CW Flagellar Switch Complex - FliF, FliG, FliM, and FliN forming the C-ring from Salmonella
8VID	;	5.9	;	CW Flagellar Switch Complex with extra density - FliF, FliG, FliM, and FliN forming single subunit of the C-ring from Salmonella
8VKR	;	5.9	;	CW Flagellar Switch Complex with extra density - FliF, FliG, FliM, and FliN forming the C-ring from Salmonella
4QQ4	;	1.75	;	CW-type zinc finger of MORC3 in complex with the amino terminus of histone H3
4O62	;	1.78	;	CW-type zinc finger of ZCWPW2 in complex with the amino terminus of histone H3
4Z0O	;	1.57	;	CW-type zinc finger of ZCWPW2 with F78D mutation
6LXS	;	1.58	;	CWA protein-SdrC
6YVH	;	3.19	;	CWC22-CWC27-EIF4A3 Complex
5NJL	;	1.9	;	Cwp2 from Clostridium difficile
5J72	;	1.7	;	Cwp6 from Clostridium difficile
5J6Q	;	2.1	;	Cwp8 from Clostridium difficile
8EVI	;	2.64	;	CX3CR1 nucleosome and PU.1 complex containing disulfide bond mutations
8EVH	;	2.85	;	CX3CR1 nucleosome and wild type PU.1 complex
8EVJ	;	4.1	;	CX3CR1 nucleosome bound PU.1 and C/EBPa
3GV3	;	1.6	;	CXCL12 (SDF) in trigonal space group
1ILP	;		;	CXCR-1 N-TERMINAL PEPTIDE BOUND TO INTERLEUKIN-8
1ILQ	;		;	CXCR-1 N-TERMINAL PEPTIDE BOUND TO INTERLEUKIN-8 (MINIMIZED MEAN)
1LV9	;		;	CXCR3 Binding Chemokine IP-10/CXCL10
8K2X	;	3.2	;	CXCR3-DNGi complex activated by CXCL10
8HNK	;	3.01	;	CXCR3-DNGi complex activated by CXCL11
8HNL	;	2.98	;	CXCR3-DNGi complex activated by PS372424
8HNM	;	2.94	;	CXCR3-DNGi complex activated by VUF11222
6ASB	;	2.85	;	CXXC and PHD-type zinc finger regions of FBXL19 in complex with DNA
5T3I	;	1.6	;	cyan fluorescence protein soaked with selenourea for 5 min
4Y42	;	2.09	;	Cyanase (CynS) from Serratia proteamaculans
6B6M	;	1.91	;	Cyanase from Serratia proteamaculans
2G3H	;	1.4	;	Cyanide Binding and Heme Cavity Conformational Transitions in Drosophila melanogaster Hexa-coordinate Hemoglobin
3BA2	;	1.8	;	Cyanide bound Chlorin substituted Myoglobin
2W3H	;	1.8	;	Cyanide bound structure of the first GAF domain of Mycobacterium tuberculosis DosS
1O76	;	1.8	;	CYANIDE COMPLEX OF P450CAM FROM PSEUDOMONAS PUTIDA
8P4I	;	3.83	;	Cyanide dihydratase from Bacillus pumilus C1
9ER3	;	2.8	;	Cyanide dihydratase from Bacillus pumilus C1 E155R variant with altered helical twist.
8C5I	;	3.15	;	Cyanide dihydratase from Bacillus pumilus C1 variant - Q86R,H305K,H308K,H323K
3I04	;	2.15	;	Cyanide-bound structure of bifunctional carbon monoxide dehydrogenase/acetyl-CoA synthase from Moorella thermoacetica, cyanide-bound C-cluster
8AJ6	;	1.5	;	cyanide-bound [FeFe]-hydrogenase I from Clostridium pasteurianum (CpI)
8AP2	;	1.39	;	cyanide-bound [FeFe]-hydrogenase I from Clostridium pasteurianum (CpI) at 1.39 Angstrom
6FGZ	;	7.002	;	Cyanidioschyzon merolae Dnm1 (CmDnm1)
6FOS	;	4.0	;	Cyanidioschyzon merolae photosystem I
6GFO	;	2.1	;	cyanobacterial GAPDH with full-length CP12
6GG7	;	1.32	;	cyanobacterial GAPDH with full-length CP12
6GHL	;	2.378	;	cyanobacterial GAPDH with full-length CP12
6GHR	;	2.249	;	cyanobacterial GAPDH with full-length CP12
6GFR	;	1.919	;	cyanobacterial GAPDH with NAD
6GFQ	;	1.4	;	cyanobacterial GAPDH with NAD and CP12 bound
6GFP	;	1.54	;	cyanobacterial GAPDH with NADP bound
6LU1	;	3.2	;	Cyanobacterial PSI Monomer from T. elongatus by Single Particle CRYO-EM at 3.2 A Resolution
8URW	;	2.79	;	Cyanobacterial RNA polymerase elongation complex with NusG and CTP
8SYI	;	2.94	;	Cyanobacterial RNAP-EC
3C27	;	2.182	;	Cyanofluorophenylacetamides as Orally Efficacious Thrombin Inhibitors
1O1I	;	2.3	;	Cyanomet hemoglobin (A-GLY-C:V1M,L29F,H58Q; B,D:V1M,L106W)
1ABY	;	2.6	;	CYANOMET RHB1.1 (RECOMBINANT HEMOGLOBIN)
2JHO	;	1.4	;	Cyanomet Sperm Whale Myoglobin at 1.4A resolution
8KEA	;	3.44	;	Cyanophage A-1(L) baseplate-initiators
7F38	;	3.35	;	Cyanophage A-1(L) capsid asymmetric unit
8TS6	;	3.44	;	Cyanophage A-1(L) portal
8KEE	;	3.26	;	Cyanophage A-1(L) sheath-tube
8KEC	;	3.9	;	Cyanophage A-1(L) tail fiber
7EEL	;	3.26	;	Cyanophage Pam1 capsid asymmetric unit
7EEP	;	3.75	;	Cyanophage Pam1 portal-adaptor complex
7EEQ	;	3.96	;	Cyanophage Pam1 tail machine
7EEA	;	2.671	;	Cyanophage Pam1 tailspike receptor-binding domain
7YFZ	;	3.19	;	Cyanophage Pam3 baseplate proteins
8HDT	;	3.17	;	Cyanophage Pam3 capsid asymmetric unit
7YFW	;	3.96	;	Cyanophage Pam3 fiber
7YPX	;	3.12	;	Cyanophage Pam3 fiber
8HDR	;	3.66	;	Cyanophage Pam3 neck
8HDS	;	3.57	;	Cyanophage Pam3 portal-adaptor
8HDW	;	3.0	;	Cyanophage Pam3 Sheath-tube
6ZPA	;	0.860003	;	Cyanophage S-2L HD phosphohydrolase (DatZ) bound to dA and one catalytic Zn2+ ion
6ZPB	;	1.72097	;	Cyanophage S-2L HD phosphohydrolase (DatZ) bound to dA and two catalytic Co2+ ions
6ZPC	;	1.26836	;	Cyanophage S-2L HD phosphohydrolase (DatZ) bound to dATP
7ODY	;	1.43	;	Cyanophage S-2L MazG-like pyrophosphohydrolase bound to dGDP and three catalytic Mn2+ ions per active site
6ZP9	;	1.50002	;	Cyanophage S-2L Primase-Polymerase (PrimPol), AEP domain (PP-N190)
7ODX	;	1.69617	;	Cyanophage S-2L Succinoaminodeoxyadenylate synthetase (PurZ) bound to dGMP and dATP as an energy donor
7TXV	;	2.7	;	Cyanophycin synthetase 1 from Synechocystis sp. UTEX2470 E82Q with ATP and 16x(Asp-Arg)
7LGJ	;	2.6	;	Cyanophycin synthetase 1 from Synechocystis sp. UTEX2470 with ADPCP and 8x(Asp-Arg)-NH2
7TXU	;	2.6	;	Cyanophycin synthetase 1 from Synechocystis sp. UTEX2470 with ATP and 16x(Asp-Arg)
7LGQ	;	2.7	;	Cyanophycin synthetase 1 from Synechocystis sp. UTEX2470 with ATP and 8x(Asp-Arg)-Asn
7LGN	;	3.1	;	Cyanophycin synthetase 1 from T. morbirosei
7LGM	;	4.4	;	Cyanophycin synthetase from A. baylyi DSM587 with ATP
5MED	;	1.8	;	Cyanothece lipoxygenase 2 (CspLOX2)
5MEF	;	2.357	;	Cyanothece lipoxygenase 2 (CspLOX2) variant - L304F
5MEE	;	2.5	;	Cyanothece lipoxygenase 2 (CspLOX2) variant - L304V
1J4V	;		;	CYANOVIRIN-N
3EZM	;	1.5	;	CYANOVIRIN-N
1LOM	;	1.72	;	CYANOVIRIN-N DOUBLE MUTANT P51S S52P
6X7H	;	1.25	;	Cyanovirin-N Mutation I34Y with Dimannose bound
4BVT	;	3.1	;	Cyanuric acid hydrolase: evolutionary innovation by structural concatenation
4BVQ	;	1.9	;	Cyanuric acid hydrolase: evolutionary innovation by structural concatenation.
4BVR	;	2.58	;	Cyanuric acid hydrolase: evolutionary innovation by structural concatenation.
4BVS	;	2.6	;	Cyanuric acid hydrolase: evolutionary innovation by structural concatenation.
8OF7	;	1.66	;	Cyc15 Diels Alderase
3PQV	;	2.609	;	Cyclase homolog
1THF	;	1.45	;	CYCLASE SUBUNIT OF IMIDAZOLEGLYCEROLPHOSPHATE SYNTHASE FROM THERMOTOGA MARITIMA
8F9X	;	2.32	;	Cyclase-PTE
4XAF	;	1.66	;	Cycles of destabilization and repair underlie evolutionary transitions in enzymes
4XAY	;	1.84	;	Cycles of destabilization and repair underlie evolutionary transitions in enzymes
4XAZ	;	1.55	;	Cycles of destabilization and repair underlie evolutionary transitions in enzymes
4XAG	;	1.6	;	Cycles of destabilization and repair underlie the evolution of new enzyme function
8ORK	;	1.64	;	cyclic 2,3-diphosphoglycerate synthetase from the hyperthermophilic archaeon Methanothermus fervidus
8ORU	;	2.23	;	cyclic 2,3-diphosphoglycerate synthetase from the hyperthermophilic archaeon Methanothermus fervidus bound to 2,3-diphosphoglycerate and ADP.
6A0J	;	1.6	;	Cyclic alpha-maltosyl-(1-->6)-maltose hydrolase from Arthrobacter globiformis, complex with Cyclic alpha-maltosyl-(1-->6)-maltose
6A0L	;	2.1	;	Cyclic alpha-maltosyl-(1-->6)-maltose hydrolase from Arthrobacter globiformis, complex with maltose
6A0K	;	1.94	;	Cyclic alpha-maltosyl-(1-->6)-maltose hydrolase from Arthrobacter globiformis, complex with panose
5ZXG	;	2.4	;	Cyclic alpha-maltosyl-(1-->6)-maltose hydrolase from Arthrobacter globiformis, ligand-free form
4F9E	;	2.75	;	Cyclic di-GMP Sensing via the Innate Immune Signaling Protein STING
7WG5	;	3.89	;	Cyclic electron transport supercomplex NDH-PSI from Arabidopsis
6NFG	;	2.76	;	CYCLIC GMP-AMP SYNTHASE in complex with compound 16 inhibitor: 7-hydroxy-N-methyl-5-phenylpyrazolo[1,5-a]pyrimidine-3-carboxamide
6NFO	;	2.93	;	CYCLIC GMP-AMP SYNTHASE in complex with compound 20 inhibitor: 7-hydroxy-N-[(2S)-1-hydroxypropan-2-yl]-5-phenylpyrazolo[1,5-a]pyrimidine-3-carboxamide
1KP5	;	2.6	;	Cyclic Green Fluorescent Protein
3WNF	;	1.45	;	Cyclic hexapeptide CKIDNC in complex with HIV-1 integrase
4Y1C	;	2.3	;	Cyclic hexapeptide cyc[NdPopPKID] in complex with HIV-1 integrase core domain
4Y1D	;	1.93	;	Cyclic hexapeptide cyc[NdPopPKID] in complex with HIV-1 integrase core domain
3WNE	;	1.7	;	Cyclic hexapeptide PKIDNG in complex with HIV-1 integrase
3WNG	;	1.75	;	Cyclic hexapeptide PKIDNp in complex with HIV-1 integrase
3WNH	;	1.5	;	Cyclic hexapeptide PKZDNv in complex with HIV-1 integrase
3ALB	;	1.85	;	Cyclic Lys48-linked tetraubiquitin
7CAP	;	1.33	;	Cyclic Lys48-linked triubiquitin
2J15	;		;	Cyclic MrIA: An exceptionally stable and potent cyclic conotoxin with a novel topological fold that targets the norepinephrine transporter.
3DN7	;	1.8	;	Cyclic nucleotide binding regulatory protein from Cytophaga hutchinsonii.
4F8A	;	2.2	;	Cyclic nucleotide binding-homology domain from mouse EAG1 potassium channel
2P7R	;		;	Cyclic pentapeptide which inhibits Hantavirus
8Q1N	;	1.843	;	Cyclic peptide binder of the WBM-site of WDR5
1BZH	;	2.1	;	Cyclic peptide inhibitor of human PTP1B
7EZW	;	2.35	;	Cyclic Peptide that Interacts with the eIF4E Capped-mRNA Binding Site
1RGR	;		;	Cyclic Peptides Targeting PDZ Domains of PSD-95: Structural Basis for Enhanced Affinity and Enzymatic Stability
3HET	;	2.1	;	Cyclic residues in alpha/beta-peptide helix bundles: GCN4-pLI side chain sequence on an (alpha-alpha-beta) backbone with a cyclic beta-residue at position 10
3HEU	;	2.0	;	Cyclic residues in alpha/beta-peptide helix bundles: GCN4-pLI side chain sequence on an (alpha-alpha-beta) backbone with a cyclic beta-residue at position 13
3HEV	;	2.0	;	Cyclic residues in alpha/beta-peptide helix bundles: GCN4-pLI side chain sequence on an (alpha-alpha-beta) backbone with a cyclic beta-residue at position 19
3HEW	;	2.0	;	Cyclic residues in alpha/beta-peptide helix bundles: GCN4-pLI side chain sequence on an (alpha-alpha-beta) backbone with a cyclic beta-residue at position 22
3HEY	;	2.0	;	Cyclic residues in alpha/beta-peptide helix bundles: GCN4-pLI side chain sequence on an (alpha-alpha-beta) backbone with cyclic beta-residues at positions 1, 4, 10, 19 and 28
3HEX	;	2.8	;	Cyclic residues in alpha/beta-peptide helix bundles: GCN4-pLI side chain sequence on an (alpha-alpha-beta) backbone with cyclic beta-residues at positions 1, 4, 19 and 28
4CQ0	;	1.45	;	Cyclic secondary sulfonamides: unusually good inhibitors of cancer- related carbonic anhydrase enzymes
7D4O	;	1.87	;	cyclic trinucleotide synthase CdnD in complex with ATP and ADP
1OKW	;	2.5	;	Cyclin A binding groove inhibitor Ac-Arg-Arg-Leu-Asn-(m-Cl-Phe)-NH2
1URC	;	2.6	;	Cyclin A binding groove inhibitor Ace-Arg-Lys-Leu-Phe-Gly
1OL2	;	2.6	;	Cyclin A binding groove inhibitor H-Arg-Arg-Leu-Asn-(p-F-Phe)-NH2
1OKV	;	2.4	;	Cyclin A binding groove inhibitor H-Arg-Arg-Leu-Ile-Phe-NH2
1OL1	;	2.9	;	Cyclin A binding groove inhibitor H-Cit-Cit-Leu-Ile-(p-F-Phe)-NH2
1FIN	;	2.3	;	CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
2PK2	;	2.67	;	Cyclin box structure of the P-TEFb subunit Cyclin T1 derived from a fusion complex with EIAV Tat
2FVD	;	1.85	;	Cyclin Dependent Kinase 2 (CDK2) with diaminopyrimidine inhibitor
1KXU	;	2.6	;	CYCLIN H, A POSITIVE REGULATORY SUBUNIT OF CDK ACTIVATING KINASE
1KE7	;	2.0	;	CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3-OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONE
1KE9	;	2.0	;	CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE
1KE8	;	2.0	;	CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2-YL)BENZENESULFONAMIDE
1KE6	;	2.0	;	CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO-8H-[1,3]THIAZOLO[5,4-E]INDOL-8-YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
8ERD	;	1.33	;	Cyclin-free CDK2 in complex with Cpd17
8ERN	;	1.64	;	Cyclin-free CDK2 in complex with Cpd21
1YJF	;	1.35	;	Cyclized post-translational product for S65A Y66S (GFPhal) green fluorescent protein variant
1YJ2	;	1.5	;	Cyclized, non-dehydrated post-translational product for S65A Y66S H148G GFP variant
2QT2	;	1.31	;	Cyclized-Dehydrated Intermediate of GFP Variant Q183E in Chromophore Maturation
1FMQ	;	2.0	;	Cyclo-butyl-bis-furamidine complexed with dCGCGAATTCGCG
6MW2	;	0.77	;	cyclo-Mle-Phe-Mle-D-Phe. D-Phe analogue of pseudoxylallemycin A.
6MW1	;	0.77	;	cyclo-Mle-Phe-Mle-Phe. Pseudoxylallemycin A.
2LL5	;		;	Cyclo-TC1 Trp-cage
5F7S	;	2.3	;	Cycloalternan-degrading enzyme from Trueperella pyogenes
5I0F	;	1.85	;	Cycloalternan-degrading enzyme from Trueperella pyogenes in complex with covalent intermediate
5I0G	;	2.15	;	Cycloalternan-degrading enzyme from Trueperella pyogenes in complex with cycloalternan
5I0E	;	2.3	;	Cycloalternan-degrading enzyme from Trueperella pyogenes in complex with isomaltose
5I0D	;	1.77	;	Cycloalternan-forming enzyme from Listeria monocytogenes in complex with cycloalternan
5HPO	;	1.8	;	Cycloalternan-forming enzyme from Listeria monocytogenes in complex with maltopentaose
5HXM	;	1.9	;	Cycloalternan-forming enzyme from Listeria monocytogenes in complex with panose
5F7U	;	1.7	;	Cycloalternan-forming enzyme from Listeria monocytogenes in complex with pentasaccharide substrate
5GZI	;	2.17	;	Cyclodeaminase_PA
5GZJ	;	1.87	;	Cyclodeaminase_PA
5GZL	;	2.0	;	Cyclodeaminase_PA
5GZM	;	1.8	;	Cyclodeaminase_PA
1PAM	;	1.8	;	CYCLODEXTRIN GLUCANOTRANSFERASE
1CYG	;	2.5	;	CYCLODEXTRIN GLUCANOTRANSFERASE (E.C.2.4.1.19) (CGTASE)
3BMV	;	1.6	;	Cyclodextrin glycosyl transferase from Thermoanerobacterium thermosulfurigenes EM1 mutant S77P
3BMW	;	1.6	;	Cyclodextrin glycosyl transferase from Thermoanerobacterium thermosulfurigenes EM1 mutant S77P complexed with a maltoheptaose inhibitor
2CXG	;	2.5	;	CYCLODEXTRIN GLYCOSYLTRANSFERASE COMPLEXED TO THE INHIBITOR ACARBOSE
6AIJ	;	2.096	;	Cyclodextrin glycosyltransferase from Paenibacillus macerans mutant N603D
1TCM	;	2.2	;	CYCLODEXTRIN GLYCOSYLTRANSFERASE W616A MUTANT FROM BACILLUS CIRCULANS STRAIN 251
7P98	;	2.0	;	Cyclohex-1-ene-1-carboxyl-CoA dehydrogenase in a substrate-free state
8AGN	;	1.957	;	Cyclohexane epoxide low pH soak of epoxide hydrolase from metagenomic source ch65
8AGS	;	1.61	;	Cyclohexane epoxide soak of epoxide hydrolase from metagenomic source ch65 resulting in halogenated compound in the active site
8AM3	;	1.86	;	Cyclohexanone dehydrogenase (CDH) from Alicycliphilus denitrificans K601 - wildtype
8AM8	;	1.85	;	Cyclohexanone dehydrogenase (CDH) from Alicycliphilus denitrificans K601 complexed with dehydrogenated substrate - W113A mutant
8AM6	;	1.33	;	Cyclohexanone dehydrogenase (CDH) from Alicycliphilus denitrificans K601 complexed with dehydrogenated substrate cyclohex-2-en-1-one - inactive mutant (Y195F)
5M0Z	;	1.6	;	Cyclohexanone Monooxygenase from T. municipale: reduced enzyme bound to NADP+
3UCL	;	2.36	;	Cyclohexanone-bound crystal structure of cyclohexanone monooxygenase in the Rotated conformation
7N8B	;	3.05	;	Cycloheximide bound vacant 80S structure isolated from cbf5-D95A
4I58	;	3.0	;	Cyclohexylamine Oxidase from Brevibacterium oxydans IH-35A
4I59	;	2.93	;	Cyclohexylamine Oxidase from Brevibacterium oxydans IH-35A complexed with cyclohexanone
1EA9	;	3.2	;	Cyclomaltodextrinase
1H3G	;	2.1	;	Cyclomaltodextrinase from Flavobacterium sp. No. 92: from DNA sequence to protein structure
4AS0	;	2.3	;	Cyclometalated Phthalimides as Protein Kinase Inhibitors
3PGH	;	2.5	;	CYCLOOXYGENASE-2 (PROSTAGLANDIN SYNTHASE-2) COMPLEXED WITH A NON-SELECTIVE INHIBITOR, FLURBIPROFEN
4COX	;	2.9	;	CYCLOOXYGENASE-2 (PROSTAGLANDIN SYNTHASE-2) COMPLEXED WITH A NON-SELECTIVE INHIBITOR, INDOMETHACIN
1CX2	;	3.0	;	CYCLOOXYGENASE-2 (PROSTAGLANDIN SYNTHASE-2) COMPLEXED WITH A SELECTIVE INHIBITOR, SC-558
6COX	;	2.8	;	CYCLOOXYGENASE-2 (PROSTAGLANDIN SYNTHASE-2) COMPLEXED WITH A SELECTIVE INHIBITOR, SC-558 IN I222 SPACE GROUP
7KZL	;	1.3	;	Cyclopentane peptide nucleic acid in complex with DNA
1E8K	;	1.9	;	Cyclophilin 3 Complexed With Dipeptide Ala-Pro
2IGW	;	1.78	;	CYCLOPHILIN 3 complexed with DIPEPTIDE GLY-PRO
2IGV	;	1.67	;	CYCLOPHILIN 3 Complexed with DIPEPTIDE SER-PRO
1E3B	;	1.85	;	CYCLOPHILIN 3 FROM C.ELEGANS COMPLEXED WITH AUP(ET)3
6FK1	;	1.299	;	Cyclophilin A
2MS4	;		;	Cyclophilin a complexed with a fragment of crk-ii
1FGL	;	1.8	;	Cyclophilin A complexed with a fragment of HIV-1 GAG protein
2CYH	;	1.64	;	CYCLOPHILIN A COMPLEXED WITH DIPEPTIDE ALA-PRO
5CYH	;	2.1	;	CYCLOPHILIN A COMPLEXED WITH DIPEPTIDE GLY-PRO
4CYH	;	2.1	;	CYCLOPHILIN A COMPLEXED WITH DIPEPTIDE HIS-PRO
3CYH	;	1.9	;	CYCLOPHILIN A COMPLEXED WITH DIPEPTIDE SER-PRO
1LOP	;	1.8	;	CYCLOPHILIN A COMPLEXED WITH SUCCINYL-ALA-PRO-ALA-P-NITROANILIDE
6GJI	;	1.6	;	Cyclophilin A complexed with the tri-vector ligand 8.
6GJL	;	1.16	;	Cyclophilin A complexed with tri-vector ligand 10.
6GJN	;	1.7	;	Cyclophilin A complexed with tri-vector ligand 15.
6GJJ	;	1.38	;	Cyclophilin A complexed with tri-vector ligand 2.
6GJM	;	1.354	;	Cyclophilin A complexed with tri-vector ligand 4.
6GJY	;	1.29	;	Cyclophilin A complexed with tri-vector ligand 5.
6GJP	;	1.94	;	Cyclophilin A complexed with tri-vector ligand 7.
6GJR	;	1.69	;	Cyclophilin A complexed with tri-vector ligand 9.
6GS6	;	1.16	;	Cyclophilin A single mutant D66A in complex with an inhibitor.
5FJB	;	9.0	;	Cyclophilin A Stabilize HIV-1 Capsid through a Novel Non- canonical Binding Site
1CYN	;	1.85	;	CYCLOPHILIN B COMPLEXED WITH [D-(CHOLINYLESTER)SER8]-CYCLOSPORIN
1A58	;	1.95	;	CYCLOPHILIN FROM BRUGIA MALAYI
2HQJ	;	2.0	;	Cyclophilin from Leishmania major
1XQ7	;	2.07	;	Cyclophilin from Trypanosoma cruzi bound to cyclosporin A
1H0P	;	1.75	;	Cyclophilin_5 from C. elegans
7QOS	;	1.6	;	Cyclopropane fatty acid synthase from Aquifex aeolicous with bound ligands
6BQC	;	2.073	;	Cyclopropane fatty acid synthase from E. coli
2GJ0	;		;	Cycloviolacin O14
6Z34	;	2.27	;	CymD monoaromatic hydrocarbon channel
4MYE	;	1.65	;	Cymosema roseum seed lectin structure complexed with X-man
8IJM	;	3.13	;	Cyo-EM structure of K794A non-gastric proton pump in Na+ bound E1AMPPCP state
8IJL	;	2.62	;	Cyo-EM structure of wildtype non-gastric proton pump in the presence of Na+, AlF and ADP
1PYC	;		;	CYP1 (HAP1) DNA-BINDING DOMAIN (RESIDUES 60-100), NMR, 15 STRUCTURES
6WGW	;	1.73	;	CYP101D1 D259E Hydroxycamphor bound
8DMG	;	4.4	;	CYP102A1 in Closed Conformation
8DME	;	6.5	;	CYP102A1 in Open Conformation
7Q9E	;	1.7	;	CYP106A1
4YT3	;	1.8	;	CYP106A2
5IKI	;	2.4	;	CYP106A2 WITH SUBSTRATE ABIETIC ACID
6RQ3	;	1.5	;	CYP121 in complex with 2,6-dimethyl dicyclotyrosine
6RQ1	;	1.49	;	CYP121 in complex with 2-methyl dicyclotyrosine
6RQ5	;	1.55	;	CYP121 in complex with 3,5-dimethyl dicyclotyrosine
6RQE	;	1.37	;	CYP121 in complex with 3-acetylene dicyclotyrosine
6RQB	;	1.459	;	CYP121 in complex with 3-bromo dicyclotyrosine
6RQD	;	1.499	;	CYP121 in complex with 3-chloro dicyclotyrosine
6RQ6	;	1.42	;	CYP121 in complex with 3-fluoro dicyclotyrosine
6RQ8	;	1.41	;	CYP121 in complex with 3-iodo dicyclotyrosine
6RQ0	;	1.6	;	CYP121 in complex with 3-methyl dicyclotyrosine
6RQ9	;	1.4	;	CYP121 in complex with O-methyl dicyclotyrosine
3NC6	;	3.1	;	CYP134A1 1-phenylimidazole bound structure
3NC7	;	3.3	;	CYP134A1 2-phenylimidazole bound structure
3NC3	;	2.66	;	CYP134A1 structure with a closed substrate binding loop
3NC5	;	2.9	;	CYP134A1 structure with an open substrate binding loop
8B2P	;	1.95	;	CYP153A71 from Acinetobacter dieselolei bound to octanoic acid
5H1Z	;	3.1	;	CYP153D17 from Sphingomonas sp. PAMC 26605
6A7I	;	2.19	;	CYP154C4 from Streptomyces sp. W2061
2NNH	;	2.6	;	CYP2C8dH complexed with 2 molecules of 9-cis retinoic acid
2NNJ	;	2.28	;	CYP2C8dH complexed with felodipine
2NNI	;	2.8	;	CYP2C8dH complexed with montelukast
2VN0	;	2.7	;	CYP2C8DH COMPLEXED WITH TROGLITAZONE
6UNL	;	2.55	;	CYP3A4 bound to an inhibitor
6UNM	;	2.83	;	CYP3A4 bound to an inhibitor
7UF9	;	2.45	;	CYP3A4 bound to an inhibitor
7UFA	;	2.5	;	CYP3A4 bound to an inhibitor
7UFB	;	2.25	;	CYP3A4 bound to an inhibitor
8EKT	;	2.29	;	CYP51 from Acanthamoeba castellanii in complex with the tetrazole-based IND inhibitor VT-1161(VT1)
2W0B	;	1.56	;	CYP51 OF M. TUBERCULOSIS BOUND TO AN INHIBITOR 3-{[(4-METHYLPHENYL)SULFONYL]AMINO}PROPYL PYRIDIN-4-YLCARBAMATE
2W09	;	1.57	;	CYP51 OF M. TUBERCULOSIS BOUND TO AN INHIBITOR CIS-4-METHYL-N-[(1S)-3-(METHYLSULFANYL)-1-(PYRIDIN-4-YLCARBAMOYL)PROPYL]CYCLOHEXANECARBOXAMIDE
2W0A	;	1.6	;	CYP51 of M. tuberculosis bound to an inhibitor N-[(1S)-2-METHYL-1-(PYRIDIN-4-YLCARBAMOYL)PROPYL]CYCLOHEXANECARBOXAMIDE
4BJK	;	2.67	;	CYP51 of Trypanosoma brucei bound to (S)-N-(3-(1H-indol-3-yl)-1-oxo-1- (pyridin-4-ylamino)propan-2-yl)-3,3'-difluoro-(1,1'-biphenyl)-4- carboxamide
5YLW	;	1.7	;	CYP76AH1 from Salvia miltiorrhiza
5YM3	;	2.601	;	CYP76AH1-4pi from salvia miltiorrhiza
7CB9	;	1.9	;	CYP76AH1/miltiradiene from Salvia miltiorrhiza
1AWR	;	1.58	;	CYPA COMPLEXED WITH HAGPIA
1AWQ	;	1.58	;	CYPA COMPLEXED WITH HAGPIA (PSEUDO-SYMMETRIC MONOMER)
1AWV	;	2.34	;	CYPA COMPLEXED WITH HVGPIA
1AWU	;	2.34	;	CYPA COMPLEXED WITH HVGPIA (PSEUDO-SYMMETRIC MONOMER)
5WC7	;	1.43	;	CypA Mutant - I97V S99T C115S
6BTA	;	1.5	;	CypA Mutant - S99T C115S
7WZG	;	2.0	;	Cypemycin N-terminal methyltransferase CypM
1JA1	;	1.8	;	CYPOR-Triple Mutant
1J9Z	;	2.7	;	CYPOR-W677G
1JA0	;	2.6	;	CYPOR-W677X
5URH	;	2.5	;	CYPOR/D632A with NADP+
7YRN	;	2.99	;	Cyro-EM structure of HCMV glycoprotein B in complex with 1B03 Fab
5BKG	;	3.8	;	Cyro-EM structure of human Glycine Receptor alpha2-beta heteromer, glycine bound, (semi)open state
5BKF	;	3.6	;	Cyro-EM structure of human Glycine Receptor alpha2-beta heteromer, Glycine bound, desensitized state
7KUY	;	3.6	;	Cyro-EM structure of human Glycine Receptor alpha2-beta heteromer, strychnine bound state
7L31	;	3.8	;	Cyro-EM structure of human Glycine Receptor alpha2-beta heteromer, strychnine bound state, 3.8 Angstrom
8JD9	;	2.87	;	Cyro-EM structure of the Na+/H+ antipoter SOS1 from Arabidopsis thaliana,class1
8JDA	;	3.67	;	Cyro-EM structure of the Na+/H+ antipoter SOS1 from Arabidopsis thaliana,class2
5V7U	;	1.64	;	Cyrstal structure of anti-Tau antibody CBTAU-22.1 Fab
5V7R	;	2.3	;	Cyrstal structure of anti-Tau antibody CBTAU-7.1 Fab
2Q1K	;	2.7	;	Cyrstal Structure of AscE from Aeromonas hydrophilla
2AJU	;	1.5	;	Cyrstal structure of cocaine catalytic antibody 7A1 Fab'
7AJL	;	2.37	;	Cyrstal structure of CYRI-B/Fam49B
1SOG	;	1.85	;	Cyrstal Structure of Cytochrome c Peroxidase Mutant: CcPK2M2
1STQ	;	1.82	;	Cyrstal Structure of Cytochrome c Peroxidase Mutant: CcPK2M3
3Q29	;	2.3	;	Cyrstal structure of human alpha-synuclein (1-19) fused to maltose binding protein (MBP)
3Q26	;	1.54	;	Cyrstal structure of human alpha-synuclein (10-42) fused to maltose binding protein (MBP)
3Q27	;	1.302	;	Cyrstal structure of human alpha-synuclein (32-57) fused to maltose binding protein (MBP)
3Q28	;	1.6	;	Cyrstal structure of human alpha-synuclein (58-79) fused to maltose binding protein (MBP)
1ZKF	;	2.55	;	Cyrstal Structure of Human Cyclophilin-A in Complex with suc-AGPF-pNA
1Y6Q	;	2.2	;	Cyrstal structure of MTA/AdoHcy nucleosidase complexed with MT-DADMe-ImmA
4ORE	;	2.2	;	Cyrstal structure of O-acetylserine sulfhydrylase ternary complex from Haemophilus influenzae at 2.2 A
7DZV	;	1.6	;	Cyrstal structure of PETase E186A mutant from Rhizobacter gummiphilus
7DZT	;	2.35	;	Cyrstal structure of PETase from Rhizobacter gummiphilus
7DZU	;	2.4	;	Cyrstal structure of PETase K169A mutant from Rhizobacter gummiphilus
4J51	;	2.3	;	Cyrstal structure of protein tyrosine phosphatase Lyp catalytic domain complex with small molecular inhibitor L75N04
8JCA	;	1.65	;	Cyrstal structure of SKIP RUN domain in complex with GTP-bound Arl8b(Q75L)
4RTT	;	1.87	;	Cyrstal structure of SLIT-ROBO Rho GTPase-activating protein 2 fragment
4RUG	;	1.73	;	Cyrstal structure of SLIT-ROBO Rho GTPase-activating protein 2 fragment
3CYE	;	1.65	;	Cyrstal structure of the native 1918 H1N1 neuraminidase from a crystal with lattice-translocation defects
3C1M	;	2.3	;	Cyrstal Structure of threonine-sensitive aspartokinase from Methanococcus jannaschii with MgAMP-PNP and L-aspartate
7BA8	;	1.2	;	Cys-42-tethered stabilizer 10 of 14-3-3(sigma)/ERa PPI
7BA9	;	1.48	;	Cys-42-tethered stabilizer 11 of 14-3-3(sigma)/ERa PPI
7BAA	;	1.1	;	Cys-42-tethered stabilizer 12 of 14-3-3(sigma)/ERa PPI
7BAB	;	1.3	;	Cys-42-tethered stabilizer 13 of 14-3-3(sigma)/ERa PPI
7BA3	;	1.4	;	Cys-42-tethered stabilizer 6 of 14-3-3(sigma)/ERa PPI
7BA5	;	1.45	;	Cys-42-tethered stabilizer 7 of 14-3-3(sigma)/ERa PPI
7BA6	;	1.4	;	Cys-42-tethered stabilizer 8 of 14-3-3(sigma)/ERa PPI
7BA7	;	1.45	;	Cys-42-tethered stabilizer 9 of 14-3-3(sigma)/ERa PPI
7B9M	;	1.7	;	Cys-45-tethered stabilizer 3 of 14-3-3(sigma)/ERa PPI
7B9R	;	1.15	;	Cys-45-tethered stabilizer 4 of 14-3-3(sigma)/ERa PPI
7B9T	;	1.15	;	Cys-45-tethered stabilizer 5 of 14-3-3(sigma)/ERa PPI
5LWZ	;	2.1	;	Cys-Gly dipeptidase GliJ (space group C2)
5LX0	;	2.4	;	Cys-Gly dipeptidase GliJ (space group P3221)
5NRT	;	2.2	;	Cys-Gly dipeptidase GliJ in complex with Ca2+
5NS2	;	2.2	;	Cys-Gly dipeptidase GliJ in complex with Co2+
5NS5	;	2.2	;	Cys-Gly dipeptidase GliJ in complex with Cu2+ and Zn2+
5NRX	;	2.35	;	Cys-Gly dipeptidase GliJ in complex with Fe2+
5NRY	;	1.85	;	Cys-Gly dipeptidase GliJ in complex with Fe3+
5NRZ	;	2.05	;	Cys-Gly dipeptidase GliJ in complex with Mn2+
5NS1	;	2.4	;	Cys-Gly dipeptidase GliJ in complex with Ni2+
5NRU	;	2.15	;	Cys-Gly dipeptidase GliJ in complex with Zn2+
5LX1	;	2.7	;	Cys-Gly dipeptidase GliJ mutant D304A
5LX4	;	1.9	;	Cys-Gly dipeptidase GliJ mutant D38H
5LX7	;	1.95	;	Cys-Gly dipeptidase GliJ mutant D38N
4IEV	;	1.6	;	Cys-only bound Cysteine Dioxygenase at pH 8.0 in the presence of Cys
4IEW	;	1.45	;	Cys-only bound Cysteine Dioxygenase at pH 9.0 in the presence of Cys
4IER	;	1.45	;	Cys-persulfenate bound Cysteine Dioxygenase at pH 5.5 in the presence of Cys
4IES	;	1.4	;	Cys-persulfenate bound Cysteine Dioxygenase at pH 6.2 in the presence of Cys
4IET	;	1.4	;	Cys-persulfenate bound Cysteine Dioxygenase at pH 6.8 in the presence of Cys
4IEU	;	1.25	;	Cys-persulfenate bound Cysteine Dioxygenase at pH 7.0 in the presence of Cys
4IEY	;	1.63	;	Cys-persulfenate bound Cysteine Dioxygenase at pH 7.0 in the presence of Cys, home-source structure
1G3S	;	2.4	;	CYS102SER DTXR
1G3T	;	2.35	;	CYS102SER DTXR
4IEC	;	2.0	;	Cys105 covalent modification by 2-hydroxyethyl disulfide in Mycobacterium tuberculosis methionine aminopeptidase Type 1c
7X68	;	1.8	;	CYS179 and CYS504 of CRMP2 were covalently binded by a Sesquiterpene lactone
2YNV	;	2.05	;	Cys221 oxidized, Mono zinc GIM-1 - GIM-1-Ox. Crystal structures of Pseudomonas aeruginosa GIM-1: active site plasticity in metallo-beta- lactamases
2ZVT	;	1.9	;	Cys285Ser mutant PPARgamma ligand-binding domain complexed with 15-deoxy-delta12,14-prostaglandin J2
1O04	;	1.42	;	Cys302Ser mutant of human mitochondrial aldehyde dehydrogenase complexed with NAD+ and Mg2+
1NZW	;	2.65	;	Cys302Ser mutant of human mitochondrial aldehyde dehydrogenase complexed with NADH and Mg2+
1YAX	;	2.4	;	Cystal structure Analysis of S.typhimurium PhoQ sensor domain with Calcium
5GXU	;	2.3	;	Cystal structure of Arabidopsis ATR2
2OG7	;	1.66	;	Cystal structure of asparagine oxygenase in complex with Fe(II), 2S,3S-3-hydroxyasparagine and succinate
5JW6	;	2.39	;	Cystal structure of aspartate semialdehyde dehydrogenase from Aspergillus fumigatus
5CEF	;	2.6	;	Cystal structure of aspartate semialdehyde dehydrogenase from Cryptococcus neoformans
7XYR	;	2.0	;	Cystal Structure of Beta-glucuronidase from Bacteroides thetaiotaomicron
4N4A	;	2.35	;	Cystal structure of Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1
4IM9	;	2.46	;	Cystal structure of DnaG primase C-terminal domain from Vibrio cholerae
3BVB	;	1.3	;	Cystal structure of HIV-1 Active Site Mutant D25N and inhibitor Darunavir
3BVA	;	1.05	;	Cystal structure of HIV-1 Active Site Mutant D25N and p2-NC analog inhibitor
7CNC	;	1.6	;	cystal structure of human ERH in complex with DGCR8
4KI5	;	2.47	;	Cystal structure of human factor VIII C2 domain in a ternary complex with murine inhbitory antibodies 3E6 and G99
5HU4	;	2.3	;	Cystal structure of listeria monocytogenes sortase A
4GUM	;	2.33	;	Cystal structure of locked-trimer of human MIF
6PWH	;	1.749	;	Cystal structure of Myotoxin II from Bothrops moojeni co-crystallized with Varespladib (LY315920)
3JTT	;	2.8	;	Cystal structure of Rhesus macaque MHC class I:Mamu-A*02
3V7C	;	2.7	;	Cystal structure of SaBPL in complex with inhibitor
4RTA	;	2.123	;	Cystal structure of the Dpy30 for MLL/SET1 COMPASS H3K4 trimethylation
3KO1	;	3.7	;	Cystal structure of thermosome from Acidianus tengchongensis strain S5
7O3I	;	1.5	;	Cystal structure of Zymogen Granule Protein 16 (ZG16)
7O4P	;	1.08	;	Cystal structure of Zymogen Granule Protein 16 (ZG16)
7O88	;	1.2	;	Cystal structure of Zymogen Granule Protein 16 (ZG16)
1CL1	;	1.83	;	CYSTATHIONINE BETA-LYASE (CBL) FROM ESCHERICHIA COLI
1CL2	;	2.2	;	CYSTATHIONINE BETA-LYASE (CBL) FROM ESCHERICHIA COLI IN COMPLEX WITH AMINOETHOXYVINYLGLYCINE
2GQN	;	1.8	;	Cystathionine Beta-Lyase (CBL) from Escherichia Coli in complex with N-Hydrazinocarbonylmethyl-2-Nitro-Benzamide
2FQ6	;	1.78	;	Cystathionine beta-lyase (cbl) from escherichia coli in complex with n-hydrazinocarbonylmethyl-2-trifluoromethyl-benzamide
6XWL	;	3.201	;	Cystathionine beta-synthase from Toxoplasma gondii
7XOY	;	4.25	;	Cystathionine beta-synthase of Mycobacterium tuberculosis in the presence of S-adenosylmethionine and serine.
7XOH	;	3.6	;	Cystathionine beta-synthase of Mycobacterium tuberculosis in the presence of S-adenosylmethionine.
8BIZ	;	1.891	;	Cystathionine gamma-lyase from Toxoplasma gondii in complex with cysteine
8BIU	;	1.899	;	Cystathionine gamma-lyase in complex with cystathionine
8BIV	;	2.22	;	Cystathionine gamma-lyase N360S mutant from Toxoplasma gondii
8BIX	;	1.59	;	Cystathionine gamma-lyase N360S mutant from Toxoplasma gondii in complex with cystathionine
8BIW	;	1.981	;	Cystathionine gamma-lyase N360S mutant in complex with DL-propargylglycine
1CS1	;	1.5	;	CYSTATHIONINE GAMMA-SYNTHASE (CGS) FROM ESCHERICHIA COLI
1QGN	;	2.9	;	CYSTATHIONINE GAMMA-SYNTHASE FROM NICOTIANA TABACUM
1I41	;	3.2	;	CYSTATHIONINE GAMMA-SYNTHASE IN COMPLEX WITH THE INHIBITOR APPA
1I48	;	3.25	;	CYSTATHIONINE GAMMA-SYNTHASE IN COMPLEX WITH THE INHIBITOR CTCPO
1I43	;	3.1	;	CYSTATHIONINE GAMMA-SYNTHASE IN COMPLEX WITH THE INHIBITOR PPCA
1M54	;	2.9	;	CYSTATHIONINE-BETA SYNTHASE: REDUCED VICINAL THIOLS
7U7H	;	2.9	;	Cysteate acyl-ACP transferase from Alistipes finegoldii
2N8C	;		;	Cystein knot with 2fp integrin avb6 cancer recognition site
7D5Y	;	2.2	;	Cystein protease domain from MARTX toxin
4JTO	;	2.0	;	Cysteine bound Cysteine Dioxygenase at pH 8.0 in the presence of Cys and dithionite
4Z82	;	1.7	;	Cysteine bound rat cysteine dioxygenase C164S variant at pH 8.1
2MQ2	;		;	Cysteine Deleted Protegrin-1 (CDP-1): Anti-bacterial Activity, Outer-Membrane Disruption and Selectivity
2MQ4	;		;	Cysteine Deleted Protegrin-1 (CDP-1): Anti-bacterial Activity, Outer-Membrane Disruption and Selectivity
2MQ5	;		;	Cysteine Deleted Protegrin-1 (CDP-1): Anti-bacterial Activity, Outer-Membrane Disruption and Selectivity
4XF4	;	1.3485	;	Cysteine dioxygenase at pH 8.0 in complex with homocysteine
4JTN	;	1.593	;	Cysteine Dioxygenase at pH 8.0 in the presence of dithionite
4XFG	;	1.401	;	cysteine dioxygenase variant - C93A at pH 6.2 with cysteine
4XF9	;	1.3	;	cysteine dioxygenase variant - C93A at pH 8.0 in complex with homocysteine
4XFB	;	1.35	;	cysteine dioxygenase variant - C93A at pH 8.0 unliganded
4XF0	;	1.3994	;	cysteine dioxygenase variant - C93A at pH 8.0 with cysteine
6U4L	;	1.911	;	cysteine dioxygenase variant - C93E
4XFC	;	1.351	;	cysteine dioxygenase variant - Y157F at pH 6.2 unliganded
4XFH	;	1.35	;	cysteine dioxygenase variant - Y157F at pH 6.2 with cysteine
4XFF	;	1.25	;	cysteine dioxygenase variant - Y157F at pH 6.2 with dithionite
4XFI	;	1.4	;	cysteine dioxygenase variant - Y157F at pH 6.2 with homocysteine
4XFA	;	1.65	;	cysteine dioxygenase variant - Y157F at pH 8.0 in complex with homocysteine
4XF1	;	1.55	;	cysteine dioxygenase variant - Y157F at pH 8.0 with cysteine
4XF3	;	1.55	;	cysteine dioxygenase variant - Y157F at pH 8.0 with cysteine and dithionite
4XEZ	;	1.2469	;	cysteine dioxygenase variant - Y157F at pH 8.0 with dithionite
2N8B	;		;	Cysteine knot with integrin avb6 cancer recognition site
5JX7	;	2.3	;	Cysteine mutant (C224A) structure of As (III) S-adenosyl methyltransferase
5WT6	;	3.3	;	Cysteine persulfide intermediate of NifS from Helicobacter pylori
2P82	;	2.1	;	Cysteine protease ATG4A
1IRC	;	2.17	;	CYSTEINE RICH INTESTINAL PROTEIN
1IML	;		;	CYSTEINE RICH INTESTINAL PROTEIN, NMR, 48 STRUCTURES
6PU1	;	2.28	;	Cysteine stabilized hexameric HIV-1 CA in complex with SEC24C peptide
8B9M	;	1.75	;	Cysteine Synthase from Leishmania Infantum
8B9Y	;	1.8	;	Cysteine Synthase from Trypanosoma cruzi with PLP and OAS
8B9W	;	2.75	;	Cysteine Synthase from Trypanosoma theileri with PLP bound
8QHP	;	2.8	;	Cysteine tRNA ligase homodimer
1R0W	;	2.2	;	Cystic fibrosis transmembrane conductance regulator (CFTR) nucleotide-binding domain one (NBD1) apo
1R0Y	;	2.55	;	Cystic fibrosis transmembrane conductance regulator (CFTR) nucleotide-binding domain one (NBD1) with ADP
1R0X	;	2.2	;	Cystic fibrosis transmembrane conductance regulator (CFTR) nucleotide-binding domain one (NBD1) with ATP
1R10	;	3.0	;	Cystic fibrosis transmembrane conductance regulator (CFTR) nucleotide-binding domain one (NBD1) with ATP, I4122 space group
1CKW	;		;	CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR: SOLUTION STRUCTURES OF PEPTIDES BASED ON THE PHE508 REGION, THE MOST COMMON SITE OF DISEASE-CAUSING DELTA-F508 MUTATION
1CKX	;		;	Cystic fibrosis transmembrane conductance regulator: Solution structures of peptides based on the Phe508 region, the most common site of disease-causing Delta-F508 mutation
1CKY	;		;	CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR: SOLUTION STRUCTURES OF PEPTIDES BASED ON THE PHE508 REGION, THE MOST COMMON SITE OF DISEASE-CAUSING DELTA-F508 MUTATION
1CKZ	;		;	CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR: SOLUTION STRUCTURES OF PEPTIDES BASED ON THE PHE508 REGION, THE MOST COMMON SITE OF DISEASE-CAUSING DELTA-F508 MUTATION
3TX3	;	2.3	;	CysZ, a putative sulfate permease
6AMG	;	1.45	;	cyt P460 of Nitrosomonas sp. AL212
3GJA	;	2.2	;	CytC3
3GJB	;	2.2	;	CytC3 with Fe(II) and alpha-ketoglutarate
2G84	;	1.4	;	Cytidine and deoxycytidylate deaminase zinc-binding region from Nitrosomonas europaea.
7VTF	;	2.20203	;	cytidine bound structure of Pseudouridine kinase (PUKI) from Escherichia coli strain B
7JTU	;	3.0	;	Cytidine deaminase T6S toxin from Pseudomonas syringae
1KDP	;	2.3	;	CYTIDINE MONOPHOSPHATE KINASE FROM E. COLI IN COMPLEX WITH 2'-DEOXY-CYTIDINE MONOPHOSPHATE
1KDO	;	1.9	;	CYTIDINE MONOPHOSPHATE KINASE FROM E. COLI IN COMPLEX WITH CYTIDINE MONOPHOSPHATE
1KDT	;	1.95	;	CYTIDINE MONOPHOSPHATE KINASE FROM E.COLI IN COMPLEX WITH 2',3'-DIDEOXY-CYTIDINE MONOPHOSPHATE
1KDR	;	2.25	;	CYTIDINE MONOPHOSPHATE KINASE FROM E.COLI IN COMPLEX WITH ARA-CYTIDINE MONOPHOSPHATE
2CMK	;	2.0	;	CYTIDINE MONOPHOSPHATE KINASE IN COMPLEX WITH CYTIDINE-DI-PHOSPHATE
1W97	;	2.7	;	cyto-EpsL: the cytoplasmic domain of EpsL, an inner membrane component of the type II secretion system of Vibrio cholerae
1YF5	;	2.75	;	Cyto-Epsl: The Cytoplasmic Domain Of Epsl, An Inner Membrane Component Of The Type II Secretion System Of Vibrio Cholerae
5A5I	;	2.0	;	Cytochrome 2C9 P450 inhibitor complex
5A5J	;	2.9	;	Cytochrome 2C9 P450 inhibitor complex
4B8N	;	1.95	;	Cytochrome b5 of Ostreococcus tauri virus 2
3U8P	;	2.75	;	Cytochrome b562 integral fusion with EGFP
4H0L	;	3.25	;	Cytochrome b6f Complex Crystal Structure from Mastigocladus laminosus with n-Side Inhibitor NQNO
4PV1	;	3.0	;	Cytochrome B6F structure from M. laminosus with the quinone analog inhibitor stigmatellin
4D6U	;	4.09	;	Cytochrome bc1 bound to the 4(1H)-pyridone GSK932121
4D6T	;	3.57	;	Cytochrome bc1 bound to the 4(1H)-pyridone GW844520
5NMI	;	3.5	;	Cytochrome bc1 bound to the inhibitor MJM170
1BE3	;	3.0	;	CYTOCHROME BC1 COMPLEX FROM BOVINE
1BGY	;	3.0	;	CYTOCHROME BC1 COMPLEX FROM BOVINE
1BCC	;	3.16	;	CYTOCHROME BC1 COMPLEX FROM CHICKEN
3H1H	;	3.16	;	Cytochrome bc1 complex from chicken
3L71	;	2.84	;	Cytochrome BC1 complex from chicken with azoxystrobin bound
4U3F	;	3.2312	;	Cytochrome bc1 complex from chicken with designed inhibitor bound
3L74	;	2.76	;	Cytochrome BC1 complex from chicken with famoxadone bound
3L75	;	2.79	;	Cytochrome BC1 complex from chicken with fenamidone bound
3TGU	;	2.7	;	Cytochrome bc1 complex from chicken with pfvs-designed moa inhibitor bound
3L73	;	3.04	;	Cytochrome BC1 complex from chicken with triazolone inhibitor
3L70	;	2.75	;	Cytochrome BC1 complex from chicken with trifloxystrobin bound
8SMR	;	2.7	;	cytochrome bc1-cbb3 supercomplex from Pseudomonas aeruginosa
8SNH	;	2.7	;	cytochrome bc1-cbb3 supercomplex from Pseudomonas aeruginosa
7QHO	;	3.1	;	Cytochrome bcc-aa3 supercomplex (respiratory supercomplex III2/IV2) from Corynebacterium glutamicum (as isolated)
7QHM	;	2.8	;	Cytochrome bcc-aa3 supercomplex (respiratory supercomplex III2/IV2) from Corynebacterium glutamicum (stigmatellin and azide bound)
7OSE	;	3.0	;	cytochrome bd-II type oxidase with bound aurachin D
1OCD	;		;	CYTOCHROME C (OXIDIZED) FROM EQUUS CABALLUS, NMR, MINIMIZED AVERAGE STRUCTURE
2FRC	;		;	CYTOCHROME C (REDUCED) FROM EQUUS CABALLUS, NMR, MINIMIZED AVERAGE STRUCTURE
1I54	;	1.5	;	CYTOCHROME C (TUNA) 2FE:1ZN MIXED-METAL PORPHYRINS
1I55	;	2.0	;	CYTOCHROME C (TUNA) WITH 2ZN:1FE MIXED-METAL PORPHYRINS
5T8W	;	1.6	;	Cytochrome c - calixarene free
1CRC	;	2.08	;	CYTOCHROME C AT LOW IONIC STRENGTH
6RSL	;	1.988	;	Cytochrome c co-crystallized with 10 eq. sulfonato-calix[8]arene and 25 eq. spermine (dry-coating method) - structure III
6RSK	;	2.31	;	Cytochrome c co-crystallized with 20 eq. sulfonato-calix[8]arene and 15 eq. spermine - structure II
6RSJ	;	2.27	;	Cytochrome c co-crystallized with 20 eq. sulfonato-calix[8]arene and soaked with 25 eq. spermine - structure I
6RSI	;	2.48	;	cytochrome c co-crystallized with 25 eq. sulfonato-calix[8]arene - structure 0
1W2L	;	1.3	;	Cytochrome c domain of caa3 oxygen oxidoreductase
2L4D	;		;	cytochrome c domain of pp3183 protein from Pseudomonas putida
3CP5	;	1.24	;	Cytochrome c from rhodothermus marinus
6ZMQ	;	2.67	;	Cytochrome c Heme Lyase CcmF
5LYC	;	1.8	;	Cytochrome c in complex with phosphonato-calix[6]arene
6Y0J	;	2.7	;	Cytochrome c in complex with phosphonato-calix[6]arene and sulfonato-calix[8]arene
6GD6	;	1.2	;	Cytochrome c in complex with Sulfonato-calix[8]arene, H3 form with ammonium sulfate
6GD7	;	1.55	;	Cytochrome c in complex with Sulfonato-calix[8]arene, H3 form with PEG
6GD8	;	2.5	;	Cytochrome c in complex with Sulfonato-calix[8]arene, P31 form
6GD9	;	2.65	;	Cytochrome c in complex with Sulfonato-calix[8]arene, P43212 form
6GDA	;	2.8	;	Cytochrome c in complex with Sulfonato-calix[8]arene, P43212 form soaked with Spermine
1IRW	;	2.0	;	CYTOCHROME C ISOZYME 1, REDUCED, MUTANT WITH ASN 52 REPLACED BY ALA AND CYS 102 REPLACED BY THR
1IRV	;	1.9	;	CYTOCHROME C ISOZYME 1, REDUCED, MUTANT WITH ILE 75 REPLACED BY MET AND CYS 102 REPLACED BY THR
7O38	;	3.0	;	cytochrome C kustc0562 from Kuenenia stuttgartiensis
8CE1	;	3.47	;	Cytochrome c maturation complex CcmABCD
8CEA	;	3.94	;	Cytochrome c maturation complex CcmABCD, E154Q
8CE5	;	3.62	;	Cytochrome c maturation complex CcmABCD, E154Q, ATP-bound
8CE8	;	3.81	;	Cytochrome c maturation complex CcmABCDE
1QDB	;	1.9	;	CYTOCHROME C NITRITE REDUCTASE
1OAH	;	2.3	;	Cytochrome c Nitrite Reductase from Desulfovibrio desulfuricans ATCC 27774: The relevance of the two calcium sites in the structure of the catalytic subunit (NrfA).
1FS7	;	1.6	;	CYTOCHROME C NITRITE REDUCTASE FROM WOLINELLA SUCCINOGENES
2E81	;	2.0	;	Cytochrome c Nitrite Reductase from Wolinella succinogenes with bound intermediate hydroxylamine
2E80	;	1.6	;	Cytochrome c Nitrite Reductase from Wolinella succinogenes with bound substrate nitrite
1FS9	;	2.0	;	CYTOCHROME C NITRITE REDUCTASE FROM WOLINELLA SUCCINOGENES-AZIDE COMPLEX
1FS8	;	1.6	;	CYTOCHROME C NITRITE REDUCTASE FROM WOLINELLA SUCCINOGENES-SULFATE COMPLEX
1CZJ	;	2.16	;	CYTOCHROME C OF CLASS III (AMBLER) 26 KD
7MQZ	;	2.39	;	Cytochrome c oxidase assembly factor 7
6PW1	;	2.1	;	Cytochrome c Oxidase delta 16
6PW0	;	2.5	;	Cytochrome C oxidase delta 6 mutant
5WEH	;	3.45	;	Cytochrome c oxidase from Rhodobacter sphaeroides in the reduced state
6YMY	;	3.41	;	Cytochrome c oxidase from Saccharomyces cerevisiae
8C8Q	;	3.36	;	Cytochrome c oxidase from Schizosaccharomyces pombe
7AU3	;	2.56	;	Cytochrome c oxidase structure in F-state
7AU6	;	2.4	;	Cytochrome c oxidase structure in O-state
7ATE	;	2.4	;	Cytochrome c oxidase structure in P-state
7ATN	;	2.66	;	Cytochrome c oxidase structure in R-state
2EUO	;	1.45	;	Cytochrome c peroxidase (CCP) in complex with 1-methyl-1-lambda-5-pyridin-3-yl-amine
2EUU	;	1.45	;	Cytochrome c peroxidase (CCP) in complex with 1H-imidazol-2-ylmethanol
2EUN	;	1.7	;	Cytochrome c peroxidase (CCP) in complex with 2,4-diaminopyrimidine
2AQD	;	1.35	;	cytochrome c peroxidase (CCP) in complex with 2,5-diaminopyridine
2EUT	;	1.12	;	Cytochrome c peroxidase (CCP) in complex with 2-amino-4-picoline
2EUP	;	1.4	;	Cytochrome c peroxidase (CCP) in complex with 2-amino-5-picoline
2EUR	;	1.39	;	Cytochrome c peroxidase (CCP) in complex with 4-pyridylcarbinol
2EUS	;	1.55	;	Cytochrome c peroxidase (CCP) in complex with benzylamine
2Y5A	;	1.25	;	Cytochrome c peroxidase (CCP) W191G bound to 3-aminopyridine
3O5C	;	1.8	;	Cytochrome c Peroxidase BccP of Shewanella oneidensis
3HQ6	;	2.0	;	Cytochrome c peroxidase from G. sulfurreducens, wild type
1DSG	;	2.56	;	CYTOCHROME C PEROXIDASE H175G MUTANT, IMIDAZOLE COMPLEX AT PH 5, ROOM TEMPERATURE.
1DSO	;	2.03	;	CYTOCHROME C PEROXIDASE H175G MUTANT, IMIDAZOLE COMPLEX AT PH 6, ROOM TEMPERATURE.
1DSP	;	2.03	;	CYTOCHROME C PEROXIDASE H175G MUTANT, IMIDAZOLE COMPLEX AT PH 7, ROOM TEMPERATURE.
1DS4	;	2.02	;	CYTOCHROME C PEROXIDASE H175G MUTANT, IMIDAZOLE COMPLEX, PH 6, 100K
1DSE	;	2.0	;	CYTOCHROME C PEROXIDASE H175G MUTANT, IMIDAZOLE COMPLEX, WITH PHOSPHATE BOUND, PH 6, 100K
2RBV	;	1.39	;	Cytochrome C Peroxidase in complex with (1-methyl-1h-pyrrol-2-yl)-methylamine
2ANZ	;	1.75	;	cytochrome c peroxidase in complex with 2,6-diaminopyridine
2AS2	;	1.45	;	cytochrome c peroxidase in complex with 2-iminopiperidine
2AS4	;	1.3	;	cytochrome c peroxidase in complex with 3-fluorocatechol
2RBU	;	1.8	;	Cytochrome C Peroxidase in complex with cyclopentane-carboximidamide
2AS6	;	1.45	;	cytochrome c peroxidase in complex with cyclopentylamine
2AS3	;	1.4	;	cytochrome c peroxidase in complex with phenol
4A71	;	1.61	;	cytochrome c peroxidase in complex with phenol
2AS1	;	1.55	;	cytochrome c peroxidase in complex with thiopheneamidine
4A78	;	2.01	;	cytochrome c peroxidase M119W in complex with guiacol
4A7M	;	1.71	;	cytochrome c peroxidase S81W mutant
1RYC	;	1.8	;	CYTOCHROME C PEROXIDASE W191G FROM SACCHAROMYCES CEREVISIAE
2RBZ	;	1.8	;	Cytochrome C Peroxidase W191G in complex 3-methoxypyridine
2RBW	;	1.5	;	Cytochrome C Peroxidase W191G in complex with 1,2-dimethyl-1h-pyridin-5-amine
2RC2	;	1.5	;	Cytochrome C Peroxidase W191G in complex with 1-methyl-2-vinyl-pyridinium
2RC1	;	2.49	;	Cytochrome C Peroxidase W191G in complex with 2,4,5-trimethyl-3-oxazoline
2RC0	;	1.5	;	Cytochrome C Peroxidase W191G in complex with 2-imino-4-methylpiperdine
2RBX	;	1.5	;	Cytochrome C Peroxidase W191G in complex with pyrimidine-2,4,6-triamine.
4A6Z	;	1.61	;	Cytochrome c peroxidase with bound guaiacol
2X08	;	2.01	;	cytochrome c peroxidase: ascorbate bound to the engineered ascorbate binding site
2X07	;	1.86	;	cytochrome c peroxidase: engineered ascorbate binding site
2EUQ	;	1.3	;	Cytochrome c peroxydase (CCP) in complex with 3-thienylmethylamine
6HIH	;	1.6	;	Cytochrome c prime beta from Methylococcus capsulatus (Bath)
7ZVZ	;	1.68	;	Cytochrome c prime beta from Methylococcus capsulatus (Bath): Chemically Reduced Ferrous Form
6ZSK	;	1.6	;	Cytochrome c prime beta from Methylococcus capsulatus (Bath): CO complex
7ZPS	;	1.56	;	Cytochrome c prime beta from Methylococcus capsulatus (Bath): NO complex
2YL0	;	0.95	;	CYTOCHROME C PRIME FROM ALCALIGENES XYLOSOXIDANS: AS ISOLATED L16A VARIANT AT 0.95 A RESOLUTION
2YL7	;	0.9	;	CYTOCHROME C PRIME FROM ALCALIGENES XYLOSOXIDANS: AS ISOLATED L16G VARIANT AT 0.9 A RESOLUTION - RESTRAINT REFINEMENT
3ZTM	;	0.9	;	Cytochrome c prime from alcaligenes xylosoxidans: as isolated L16G variant at 0.9 A resolution: unrestraint refinement
2YLG	;	1.05	;	CYTOCHROME C PRIME FROM ALCALIGENES XYLOSOXIDANS: ASCORBATE AND CARBON MONOOXIDE BOUND L16A VARIANT AT 1.05 A RESOLUTION
2YL1	;	1.03	;	CYTOCHROME C PRIME FROM ALCALIGENES XYLOSOXIDANS: CARBON MONOOXIDE BOUND L16A VARIANT AT 1.03 A RESOLUTION - Restraint refinement
3ZQY	;	1.03	;	CYTOCHROME C PRIME FROM ALCALIGENES XYLOSOXIDANS: CARBON MONOOXIDE BOUND L16A VARIANT AT 1.03 A RESOLUTION- NON-RESTRAINT REFINEMENT
2YL3	;	1.04	;	CYTOCHROME C PRIME FROM ALCALIGENES XYLOSOXIDANS: CARBON MONOOXIDE BOUND L16G VARIANT AT 1.04 A RESOLUTION - RESTRAINT REFINED
3ZTZ	;	1.05	;	Cytochrome c prime from alcaligenes xylosoxidans: carbon monooxide bound L16G variant at 1.05 A resolution: unrestraint refinement
2XL6	;	1.07	;	Cytochrome c prime from Alcaligenes xylosoxidans: Ferrous R124A variant with bound NO
2XM4	;	1.1	;	Cytochrome c prime from Alcaligenes xylosoxidans: Ferrous R124E variant
2XLO	;	1.24	;	Cytochrome c prime from Alcaligenes xylosoxidans: Ferrous R124E variant with bound NO
2XLV	;	1.24	;	Cytochrome c prime from Alcaligenes xylosoxidans: Ferrous R124F variant with bound NO
2XM0	;	1.25	;	Cytochrome c prime from Alcaligenes xylosoxidans: Ferrous R124K variant
2XLE	;	1.12	;	Cytochrome c prime from Alcaligenes xylosoxidans: Ferrous R124K variant with bound NO
2XLD	;	1.4	;	Cytochrome c prime from Alcaligenes xylosoxidans: Ferrous R124Q variant
2XLW	;	1.17	;	Cytochrome c prime from Alcaligenes xylosoxidans: Ferrous R124Q variant with bound NO
2XLM	;	1.19	;	Cytochrome c prime from Alcaligenes xylosoxidans: Ferrous recombinant native with bound NO
4ULV	;	1.29	;	Cytochrome c prime from Shewanella frigidimarina
1CGN	;	2.15	;	CYTOCHROME C'
1CGO	;	1.8	;	CYTOCHROME C'
1RCP	;	2.0	;	CYTOCHROME C'
1E83	;	2.05	;	Cytochrome c' from Alcaligenes xylosoxidans - oxidized structure
1E84	;	1.9	;	Cytochrome c' from Alcaligenes xylosoxidans - reduced structure
1E86	;	1.95	;	Cytochrome c' from Alcaligenes xylosoxidans - reduced structure with CO bound to distal side of heme
1E85	;	1.35	;	Cytochrome c' from Alcaligenes xylosoxidans - reduced structure with NO bound to proximal side of heme
1GQA	;	1.8	;	Cytochrome c' from Rhodobacter Spheriodes
1CPQ	;	1.72	;	CYTOCHROME C' FROM RHODOPSEUDOMONAS CAPSULATA
1A7V	;	2.3	;	CYTOCHROME C' FROM RHODOPSEUDOMONAS PALUSTRIS
5GUX	;	3.3	;	Cytochrome c-dependent nitric oxide reductase (cNOR) from Pseudomonas aeruginosa in complex with xenon
7VFJ	;	3.98	;	Cytochrome c-type biogenesis protein CcmABCD
7F02	;	3.24	;	Cytochrome c-type biogenesis protein CcmABCD from E. coli
7F03	;	3.29	;	Cytochrome c-type biogenesis protein CcmABCD from E. coli in complex with ANP
7F04	;	2.86	;	Cytochrome c-type biogenesis protein CcmABCD from E. coli in complex with Heme and ATP.
7VFP	;	4.03	;	Cytochrome c-type biogenesis protein CcmABCD from E. coli in complex with heme and single ATP
1C2N	;		;	CYTOCHROME C2, NMR, 20 STRUCTURES
1W7O	;	1.81	;	cytochrome c3 from Desulfomicrobium baculatus
3CYR	;	1.6	;	CYTOCHROME C3 FROM DESULFOVIBRIO DESULFURICANS ATCC 27774P
1I77	;	1.95	;	CYTOCHROME C3 FROM DESULFOVIBRIO DESULFURICANS ESSEX 6
2CTH	;	1.67	;	CYTOCHROME C3 FROM DESULFOVIBRIO VULGARIS HILDENBOROUGH
1WAD	;	1.8	;	CYTOCHROME C3 WITH 4 HEME GROUPS AND ONE CALCIUM ION
1NEW	;		;	Cytochrome C551.5, NMR
1FOC	;	3.0	;	Cytochrome C557: improperly folded thermus thermophilus C552
1CYI	;	1.9	;	CYTOCHROME C6
1CYJ	;	1.9	;	CYTOCHROME C6
1KIB	;	3.5	;	cytochrome c6 from Arthrospira maxima: an assembly of 24 subunits in the form of an oblate shell
6TSY	;	2.25	;	Cytochrome c6 from Thermosynechococcus elongatus in a monoclinic space group
1OS6	;	1.45	;	Cytochrome c7 (PpcA) from Geobacter sulfurreducens
1HH5	;	1.9	;	cytochrome c7 from Desulfuromonas acetoxidans
1AOQ	;	1.8	;	CYTOCHROME CD1 NITRITE REDUCTASE WITH SUBSTRATE AND PRODUCT BOUND
1DY7	;	1.6	;	Cytochrome cd1 Nitrite Reductase, CO complex
1HJ3	;	1.6	;	Cytochrome cd1 Nitrite Reductase, dioxygen complex
1QKS	;	1.28	;	CYTOCHROME CD1 NITRITE REDUCTASE, OXIDISED FORM
1HCM	;	2.5	;	Cytochrome cd1 Nitrite Reductase, oxidised from from tetragonal crystals
1E2R	;	1.59	;	CYTOCHROME CD1 NITRITE REDUCTASE, REDUCED AND CYANIDE BOUND
1AOF	;	2.0	;	CYTOCHROME CD1 NITRITE REDUCTASE, REDUCED FORM
1H9X	;	2.1	;	Cytochrome cd1 Nitrite Reductase, reduced form
1H9Y	;	2.4	;	Cytochrome cd1 Nitrite Reductase, reduced form complexed to CN
1HJ5	;	1.46	;	Cytochrome cd1 Nitrite Reductase, reoxidised enzyme
1HJ4	;	1.6	;	Cytochrome cd1 Nitrite Reductase, x-ray reduced dioxygen complex
1GQ1	;	1.4	;	CYTOCHROME CD1 NITRITE REDUCTASE, Y25S mutant, OXIDISED FORM
1QN2	;	2.01	;	cytochrome cH from Methylobacterium extorquens
2C8S	;	1.6	;	CYTOCHROME CL FROM METHYLOBACTERIUM EXTORQUENS
1D7D	;	1.9	;	CYTOCHROME DOMAIN OF CELLOBIOSE DEHYDROGENASE, HP3 FRAGMENT, PH 7.5
1PL3	;	1.9	;	Cytochrome Domain Of Cellobiose Dehydrogenase, M65H mutant
1D7C	;	1.9	;	CYTOCHROME DOMAIN OF CELLOBIOSE DEHYDROGENASE, PH 4.6
1D7B	;	1.9	;	CYTOCHROME DOMAIN OF CELLOBIOSE DEHYDROGENASE, PH 7.5
4QI3	;	1.4	;	Cytochrome domain of Myriococcum thermophilum cellobiose dehydrogenase, MtCYT
1CFM	;	2.0	;	CYTOCHROME F FROM CHLAMYDOMONAS REINHARDTII
1CI3	;	1.9	;	CYTOCHROME F FROM THE B6F COMPLEX OF PHORMIDIUM LAMINOSUM
5UCW	;	1.7	;	Cytochrome P411 P-4 A82L A78V F263L amination catalyst
4H23	;	3.3	;	Cytochrome P411BM3-CIS cyclopropanation catalyst
5W0C	;	2.001	;	Cytochrome P450 (CYP) 2C9 TCA007 Inhibitor Complex
8SPD	;	2.9	;	Cytochrome P450 (CYP) 3A4 crystallized with clotrimazole
8SG5	;	2.8	;	Cytochrome P450 (CYP) 3A5 crystallized with clotrimazole
7DLS	;	2.06	;	Cytochrome P450 (CYP105D18) complex with papaverine
7DI3	;	1.69	;	Cytochrome P450 (CYP105D18) W.T.
1OXA	;	2.1	;	CYTOCHROME P450 (DONOR:O2 OXIDOREDUCTASE)
6L39	;	2.97	;	Cytochrome P450 107G1 (RapN)
6L3A	;	3.0	;	Cytochrome P450 107G1 (RapN) with everolimus
1E9X	;	2.1	;	Cytochrome P450 14 alpha-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with 4-phenylimidazole
1EA1	;	2.21	;	Cytochrome P450 14 alpha-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with fluconazole
1H5Z	;	2.05	;	CYTOCHROME P450 14 ALPHA-STEROL DEMETHYLASE (CYP51) FROM MYCOBACTERIUM TUBERCULOSIS IN FERRIC LOW-SPIN STATE
7TEF	;	1.98	;	Cytochrome P450 14 alpha-sterol demethylase CYP51 from Mycobacterium marinum
3UAS	;	2.939	;	Cytochrome P450 2B4 covalently bound to the mechanism-based inactivator 9-ethynylphenanthrene
3TK3	;	2.8001	;	Cytochrome P450 2B4 mutant L437A in complex with 4-(4-chlorophenyl)imidazole
3KOH	;	2.9	;	Cytochrome P450 2E1 with omega-imidazolyl octanoic acid
4D75	;	2.25	;	Cytochrome P450 3A4 bound to an inhibitor
4D78	;	2.8	;	Cytochrome P450 3A4 bound to an inhibitor
4D7D	;	2.76	;	Cytochrome P450 3A4 bound to an inhibitor
4D6Z	;	1.93	;	Cytochrome P450 3A4 bound to imidazole and an inhibitor
8GK3	;	2.6	;	Cytochrome P450 3A7 in complex with Dehydroepiandrosterone sulfate
2UWH	;	2.8	;	Cytochrome P450 BM3 mutant in complex with palmitic acid
5E9Z	;	2.23	;	Cytochrome P450 BM3 mutant M11
4DUF	;	1.8	;	cytochrome P450 BM3h-2G9 MRI sensor bound to serotonin
4DUC	;	1.92	;	cytochrome P450 BM3h-2G9 MRI sensor, no ligand
4DUE	;	1.7	;	cytochrome P450 BM3h-2G9C6 MRI sensor bound to serotonin
4DUD	;	1.85	;	cytochrome P450 BM3h-2G9C6 MRI sensor, no ligand
4DTZ	;	1.55	;	cytochrome P450 BM3h-8C8 MRI sensor bound to dopamine
4DTW	;	1.8	;	cytochrome P450 BM3h-8C8 MRI sensor bound to serotonin
4DTY	;	1.45	;	cytochrome P450 BM3h-8C8 MRI sensor, no ligand
4DUB	;	1.7	;	cytochrome P450 BM3h-9D7 MRI sensor bound to dopamine
4DUA	;	2.0	;	cytochrome P450 BM3h-9D7 MRI sensor, no ligand
4DU2	;	1.9	;	cytochrome P450 BM3h-B7 MRI sensor bound to dopamine
1IZO	;	2.1	;	Cytochrome P450 BS beta Complexed with Fatty Acid
5GWE	;	2.0	;	cytochrome P450 CREJ
5XJN	;	1.7	;	cytochrome P450 CREJ in complex with (4-ethylphenyl) dihydrogen phosphate
8C9I	;	2.05	;	Cytochrome P450 CYP141A1 (Rv3121) from Mycobacterium tuberculosis
8CKN	;	1.54	;	Cytochrome P450 CYP143A1 (Rv1785c) from Mycobacterium tuberculosis
7QAN	;	2.01	;	Cytochrome P450 Enzyme AbyV
7X53	;	3.35	;	cytochrome P450 monooxygenase
8Q5J	;	1.48	;	Cytochrome P450 monooxygenase from Streptomyces scabiei (SscaCYP)
6M4P	;	2.3	;	Cytochrome P450 monooxygenase StvP2 substrate-bound structure
6M4Q	;	1.35	;	Cytochrome P450 monooxygenase StvP2 substrate-free structure
4ZFB	;	2.84	;	Cytochrome P450 pentamutant from BM3 bound to Palmitic Acid
4ZF8	;	2.766	;	Cytochrome P450 pentamutant from BM3 with bound Metyrapone
4ZF6	;	2.773	;	Cytochrome P450 pentamutant from BM3 with bound PEG
6FYJ	;	1.3	;	Cytochrome P450 peroxygenase CYP152K6 in complex with Myristic Acid
6T1U	;	1.5	;	Cytochrome P450 reductase from Candida tropicalis
6T1T	;	2.08	;	Cytochrome P450 reductase in complex with NADPH from Candida tropicalis
8HG9	;	2.79	;	Cytochrome P450 steroid hydroxylase (BaCYP106A6) from Bacillus species
6F0B	;	2.8	;	Cytochrome P450 TxtC employs substrate conformational switching for sequential aliphatic and aromatic thaxtomin hydroxylation
6F0C	;	1.7	;	Cytochrome P450 TxtC employs substrate conformational switching for sequential aliphatic and aromatic thaxtomin hydroxylation
5GNL	;	1.95	;	Cytochrome P450 Vdh (CYP107BR1) F106V mutant
5GNM	;	2.7	;	Cytochrome P450 Vdh (CYP107BR1) L348M mutant
4ZFA	;	2.765	;	Cytochrome P450 wild type from BM3 with bound PEG
2WIY	;	1.49	;	Cytochrome P450 XplA heme domain P21212
6HQW	;	2.9	;	Cytochrome P450-153 from Novosphingobium aromaticivorans
6HQG	;	2.9	;	Cytochrome P450-153 from Phenylobacterium zucineum
6HQD	;	1.8	;	Cytochrome P450-153 from Pseudomonas sp. 19-rlim
1NOO	;	2.2	;	CYTOCHROME P450-CAM COMPLEXED WITH 5-EXO-HYDROXYCAMPHOR
4H24	;	2.5	;	Cytochrome P450BM3-CIS cyclopropanation catalyst
2ZQX	;	2.37	;	Cytochrome P450BSbeta cocrystallized with heptanoic acid
2H7Q	;	1.5	;	Cytochrome P450cam complexed with imidazole
1AKD	;	1.8	;	CYTOCHROME P450CAM FROM PSEUDOMONAS PUTIDA, COMPLEXED WITH 1S-CAMPHOR
1K2O	;	1.65	;	Cytochrome P450Cam with Bound BIS(2,2'-BIPYRIDINE)-(5-METHYL-2-2'-BIPYRIDINE)-C2-ADAMANTANE RUTHENIUM (II)
6NBL	;	2.15	;	Cytochrome P450cam-putidaredoxin complex bound to camphor and cyanide
1EGY	;	2.35	;	CYTOCHROME P450ERYF WITH 9-AMINOPHENANTHRENE BOUND
5YHJ	;	2.3	;	Cytochrome P450EX alpha (CYP152N1) wild-type with myristic acid
3VM4	;	1.94	;	Cytochrome P450SP alpha (CYP152B1) in complex with (R)-ibuprophen
3VOO	;	2.34	;	Cytochrome P450SP alpha (CYP152B1) mutant A245E
3VTJ	;	2.56	;	Cytochrome P450SP alpha (CYP152B1) mutant A245H
3AWP	;	1.8	;	Cytochrome P450SP alpha (CYP152B1) mutant F288G
3AWQ	;	1.9	;	Cytochrome P450SP alpha (CYP152B1) mutant L78F
3VNO	;	2.17	;	Cytochrome P450SP alpha (CYP152B1) mutant R241E
3AWM	;	1.65	;	Cytochrome P450SP alpha (CYP152B1) wild-type with palmitic acid
8EUH	;	2.0	;	cytochrome P450terp (cyp108A1) bound to alpha-terpineol
8EUK	;	1.98	;	cytochrome P450terp (cyp108A1) bound to ethylene glycol
8EUL	;	2.24	;	cytochrome P450terp (cyp108A1) mutant F188A bound to alpha-terpineol
6HIU	;	1.36	;	Cytochrome P460 from Methylococcus capsulatus (Bath)
2JE2	;	1.8	;	Cytochrome P460 from Nitrosomonas europaea - probable nonphysiological oxidized form
2JE3	;	1.8	;	Cytochrome P460 from Nitrosomonas europaea - probable physiological form
6P73	;	1.65	;	Cytochrome-C-nitrite reductase
2WIV	;	1.9	;	Cytochrome-P450 XplA heme domain P21
1URY	;	2.4	;	cytoglobin cavities
1BC9	;		;	CYTOHESIN-1/B2-1 SEC7 DOMAIN, NMR, MINIMIZED AVERAGE STRUCTURE
2B5I	;	2.3	;	cytokine receptor complex
4NN5	;	1.898	;	Cytokine receptor complex - Crystal form 1A
4NN6	;	2.545	;	Cytokine receptor complex - Crystal form 1B
4NN7	;	3.775	;	Cytokine receptor complex - Crystal form 2
6RPY	;	1.97	;	Cytokine receptor-like factor 3 C-terminus residues 174-442: Hg-SAD derivative
6RPX	;	1.61	;	Cytokine receptor-like factor 3 C-terminus residues 174-442: native
6RPZ	;	1.74	;	Cytokine receptor-like factor 3 C-terminus residues 174-442: native collected with 1.7A wavelength
1INR	;	2.0	;	CYTOKINE SYNTHESIS
6EE9	;		;	Cytokine-like Peptide Stress-response Peptide-1 from Manduca Sexta
5W54	;		;	Cytokine-like Stress Response Peptide-2 in Manduca Sexta
5UWC	;	2.4	;	Cytokine-receptor complex
4KC3	;	3.2702	;	Cytokine/receptor binary complex
1BQU	;	2.0	;	CYTOKYNE-BINDING REGION OF GP130
4UXV	;	3.961	;	Cytoplasmic domain of bacterial cell division protein EzrA
4UY3	;	2.6	;	Cytoplasmic domain of bacterial cell division protein ezra
3AUW	;	3.56	;	Cytoplasmic domain of inward rectifier potassium channel Kir3.2 in complex with cadmium
6CV9	;	3.8	;	Cytoplasmic domain of mTRPC6
2JA3	;	3.05	;	Cytoplasmic Domain of the Human Chloride Transporter ClC-5 in complex with ADP
2J9L	;	2.3	;	Cytoplasmic Domain of the Human Chloride Transporter ClC-5 in complex with ATP
4NH0	;	2.9	;	Cytoplasmic domain of the Thermomonospora curvata Type VII Secretion ATPase EccC
6D7L	;	4.0	;	Cytoplasmic domain of TRPC3
6Y4R	;	2.594	;	Cytoplasmic domain of TssL from Acinetobacter baumannii
1IAS	;	2.9	;	CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
7NMB	;		;	cytoplasmic domain of Vibrio cholerae ToxR
2KJ1	;		;	cytoplasmic domain structure of BM2 proton channel from influenza B virus
2GIX	;	2.02	;	Cytoplasmic Domain Structure of Kir2.1 containing Andersen's Mutation R218Q and Rescue Mutation T309K
8GPS	;	1.39	;	Cytoplasmic domain structure of the MgtE Mg2+ channel from Chryseobacterium hispalense
8GPV	;	1.82	;	Cytoplasmic domain structure of the MgtE Mg2+ channel from Clostridiales bacterium
7UZV	;	2.5	;	Cytoplasmic domains of Band 3-I (local refinement from consensus reconstruction of ankyrin complexes)
7Z8K	;	4.37	;	Cytoplasmic dynein (A1) bound to BICDR1
7Z8J	;	3.93	;	Cytoplasmic dynein (A2) bound to BICDR1
7Z8L	;	4.9	;	Cytoplasmic dynein light intermediate chain (B1) bound to the motor domain (A2).
8PQZ	;	5.5	;	Cytoplasmic dynein-1 A1/A2 motor domains bound to LIS1
8PR2	;	3.8	;	Cytoplasmic dynein-1 heavy chain bound to JIP3-LZI
8PR3	;	3.9	;	Cytoplasmic dynein-1 heavy chain bound to JIP3-RH1
7Z8G	;	3.52	;	Cytoplasmic dynein-1 motor domain
7Z8H	;	3.41	;	Cytoplasmic dynein-1 motor domain AAA1, AAA2, and AAA3 subunits
8PQW	;	4.2	;	Cytoplasmic dynein-1 motor domain bound to dynactin-p150glued and LIS1
8PQY	;	3.8	;	Cytoplasmic dynein-1 motor domain bound to LIS1
8PQV	;	4.0	;	Cytoplasmic dynein-1 motor domain in post-powerstroke state
8PR0	;	9.4	;	Cytoplasmic dynein-A heavy chain bound to dynactin-p150glued and IC-LC tower
8PR1	;	8.2	;	Cytoplasmic dynein-B heavy chain bound to IC-LC tower
3SOZ	;	2.6	;	Cytoplasmic Protein STM1381 from Salmonella typhimurium LT2
2GK3	;	2.25	;	Cytoplasmic Protein STM3548 from Salmonella typhimurium
7SC5	;	3.88	;	Cytoplasmic tail deleted HIV Env trimer in nanodisc
7SD3	;	3.67	;	Cytoplasmic tail deleted HIV-1 Env bound with three 4E10 Fabs
4W68	;	2.0	;	Cytoplasmically Produced Homodimeric Single Domain Antibody (sdAb) C22A/C99V variant against Staphylococcal enterotoxin B (SEB)
1U47	;	2.0	;	cytosine-8-Oxoguanine base pair at the polymerase active site
1NK6	;	2.1	;	CYTOSINE-CYTOSINE MISMATCH AT THE POLYMERASE ACTIVE SITE
7MHT	;	2.87	;	CYTOSINE-SPECIFIC METHYLTRANSFERASE HHAI/DNA COMPLEX
8MHT	;	2.76	;	CYTOSINE-SPECIFIC METHYLTRANSFERASE HHAI/DNA COMPLEX
9MHT	;	2.39	;	CYTOSINE-SPECIFIC METHYLTRANSFERASE HHAI/DNA COMPLEX
1NJZ	;	2.0	;	CYTOSINE-THYMINE MISMATCH AT THE POLYMERASE ACTIVE SITE
4KX5	;	1.9	;	Cytosolic 5'-nucleotidase III complexed with cytidine 5'-monophosphate
8DJR	;	1.46	;	Cytosolic ascorbate peroxidase from Sorghum bicolor
8DJU	;	1.5	;	Cytosolic ascorbate peroxidase from Sorghum bicolor - bicyclic dehydroascorbic acid complex
8DJX	;	1.34	;	Cytosolic ascorbate peroxidase from Sorghum bicolor - Compound II
8DJT	;	1.16	;	Cytosolic ascorbate peroxidase from Sorghum bicolor - four ascorbates complex
8DJW	;	1.8	;	Cytosolic ascorbate peroxidase from Sorghum bicolor - hydroperoxo complex
8DJS	;	1.19	;	Cytosolic ascorbate peroxidase from Sorghum bicolor - one ascorbate complex
8FF6	;	2.49	;	Cytosolic ascorbate peroxidase mutant from Panicum virgatum
8FF7	;	2.194	;	Cytosolic ascorbate peroxidase mutant from Panicum virgatum- ascorbate complex
7NPT	;	3.27	;	Cytosolic bridge of an intact ESX-5 inner membrane complex
6EI0	;	1.34	;	Cytosolic copper storage protein Csp from Streptomyces lividans: apo form
6EK9	;	1.5	;	Cytosolic copper storage protein Csp from Streptomyces lividans: Cu loaded form
5HFG	;	1.823	;	Cytosolic disulfide reductase DsbM from Pseudomonas aeruginosa
5HFI	;	1.801	;	Cytosolic disulfide reductase DsbM from Pseudomonas aeruginosa with GSH
1NZN	;	2.0	;	Cytosolic domain of the human mitchondrial fission protein Fis1 adopts a TPR fold
2HES	;	1.7	;	Cytosolic Iron-sulphur Assembly Protein- 1
5NUF	;	1.8	;	Cytosolic Malate Dehydrogenase 1
5NUE	;	1.35	;	Cytosolic Malate Dehydrogenase 1 (peroxide-treated)
5NQ4	;		;	Cytotoxin-1 in DPC-micelle
1A5P	;	1.6	;	C[40,95]A VARIANT OF BOVINE PANCREATIC RIBONUCLEASE A
3DT5	;	1.94	;	C_terminal domain of protein of unknown function AF_0924 from Archaeoglobus fulgidus.
2P64	;	2.5	;	D domain of b-TrCP
2MN0	;		;	D loop of tRNA(Met)
7T6Y	;	2.3	;	d((CGA)5TGA) parallel-stranded homo-duplex
4M94	;	2.14	;	d(ATCCGTTATAACGGAT) complexed with Moloney Murine Leukemia virus reverse transcriptase catalytic fragment
4M95	;	1.72	;	d(ATCCGTTATAACGGAT)complexed with Moloney Murine Leukemia virus reverse transcriptase catalytic fragment
2R2R	;	2.1	;	d(ATTAGTTATAACTAAT) complexed with MMLV RT catalytic fragment
2R2T	;	2.0	;	d(ATTTAGTTAACTAAAT) complexed with MMLV RT catalytic fragment
8Q5Q	;		;	d(ATTTC)3 dimeric structure
7ZQM	;	1.41	;	d(CGCGCG)2 Z-DNA AT 3000 BARS (300 MPa)
7ZQN	;	1.41	;	d(CGCGCG)2 Z-DNA AT 5400 BARS (540 MPa)
7ZQO	;	1.8	;	d(CGCGCG)2 Z-DNA AT 7150 BARS (715 MPa)
7ZQL	;	2.55	;	d(CGCGTTAACGCG)2 B-DODECAMER AT 3100 BARS (310 MPa)
2GB9	;	1.7	;	d(CGTACG)2 crosslinked bis-acridine complex
1ZTW	;	1.8	;	d(CTTAATTCGAATTAAG) complexed with Moloney Murine Leukemia Virus Reverse Transcriptase catalytic fragment
2FJW	;	1.95	;	d(CTTGAATGCATTCAAG) in complex with MMLV RT catalytic fragment
7SB8	;	1.317	;	d(GA(CGA)5) parallel-stranded homo-duplex
3T86	;	1.9	;	d(GCATGCT) + calcium
1R2O	;	2.38	;	d(GCATGCT) + Ni2+
432D	;	1.89	;	D(GGCCAATTGG) COMPLEXED WITH DAPI
2PL8	;	1.65	;	D(GTATACC) under hydrostatic pressure of 1.04 GPa
2PLB	;	1.6	;	D(GTATACC) under hydrostatic pressure of 1.39 GPa
4R8J	;	1.21	;	d(TCGGCGCCGA) with lambda-[Ru(TAP)2(dppz)]2+ soaked in D2O
2PKV	;	1.6	;	D-(GGTATACC) ambient pressure
2PL4	;	1.65	;	D-(GGTATACC) under 0.55 GPa hydrostatic pressure
2PLO	;	1.4	;	D-(GTATACC) low temperature (100K)
5MH5	;	1.4	;	D-2-hydroxyacid dehydrogenases (D2-HDH) from Haloferax mediterranei in complex with 2-keto-hexanoic acid and NADP+ (1.4 A resolution)
5MH6	;	1.35	;	D-2-hydroxyacid dehydrogenases (D2-HDH) from Haloferax mediterranei in complex with 2-ketohexanoic acid and NAD+ (1.35 A resolution)
5MHA	;	1.57	;	D-2-hydroxyacid dehydrogenases (D2-HDH) from Haloferax mediterranei in complex with a mixture of 2-ketohexanoic acid and 2-hydroxyhexanoic acid, and NADPH (1.57 A resolution)
3V4Z	;	2.69	;	D-alanine--D-alanine ligase from Yersinia pestis
1EHI	;	2.38	;	D-ALANINE:D-LACTATE LIGASE (LMDDL2) OF VANCOMYCIN-RESISTANT LEUCONOSTOC MESENTEROIDES
8I31	;	2.28	;	D-alanyl carrier protein
8I32	;	2.1	;	D-alanyl carrier protein mutant-S36A
6O93	;	2.178	;	D-alanyl transferase DltD from Enterococcus faecalis
6PFX	;	1.5	;	D-alanyl transferase DltD from Enterococcus faecium
1E4E	;	2.5	;	D-alanyl-D-lacate ligase
1C0P	;	1.2	;	D-AMINO ACIC OXIDASE IN COMPLEX WITH D-ALANINE AND A PARTIALLY OCCUPIED BIATOMIC SPECIES
1AN9	;	2.5	;	D-AMINO ACID OXIDASE COMPLEX WITH O-AMINOBENZOATE
1KIF	;	2.6	;	D-AMINO ACID OXIDASE FROM PIG KIDNEY
1C0L	;	1.73	;	D-AMINO ACID OXIDASE: STRUCTURE OF SUBSTRATE COMPLEXES AT VERY HIGH RESOLUTION REVEAL THE CHEMICAL REACTTION MECHANISM OF FLAVIN DEHYDROGENATION
4NBI	;	1.86	;	D-aminoacyl-tRNA deacylase (DTD) from Plasmodium falciparum in complex with D-tyrosyl-3'-aminoadenosine at 1.86 Angstrom resolution
4NBJ	;	2.2	;	D-aminoacyl-tRNA deacylase (DTD) from Plasmodium falciparum in complex with D-tyrosyl-3'-aminoadenosine at 2.20 Angstrom resolution
5J61	;	2.1	;	D-aminoacyl-tRNA deacylase (DTD) from Plasmodium falciparum in complex with glycyl-3'-aminoadenosine at 2.10 Angstrom resolution
8E92	;	3.96	;	D-cycloserine and glutamate bound Human GluN1a-GluN2C NMDA receptor in intact conformation
8E98	;	3.75	;	D-cycloserine and glutamate bound Human GluN1a-GluN2C NMDA receptor in nanodisc - intact conformation
8E93	;	3.71	;	D-cycloserine and glutamate bound Human GluN1a-GluN2C NMDA receptor in splayed conformation
5I0R	;	1.35	;	D-cysteine bound C93A mutant of Cysteine Dioxygenase at pH 8
4D96	;	2.09	;	D-Cysteine desulfhydrase from Salmonella typhimurium complexed with 1-amino-1-carboxycyclopropane (ACC)
4D9F	;	2.61	;	D-Cysteine desulfhydrase from Salmonella typhimurium complexed with D-cycloserine (DCS)
4D9E	;	2.47	;	D-Cysteine desulfhydrase from Salmonella typhimurium complexed with L-cycloserine (LCS)
1DPT	;	1.54	;	D-DOPACHROME TAUTOMERASE
3KER	;	2.78	;	D-Dopachrome tautomerase (D-DT)/ macrophage migration inhibitory factor 2 (MIF2) complexed with inhibitor 4-IPP
3KAN	;	1.13	;	D-dopachrome tautomerase (D-DT)/macrophage migration inhibitory factor 2 (MIF2) complexed with inhibitor 4-IPP
3OET	;	2.36	;	D-Erythronate-4-Phosphate Dehydrogenase complexed with NAD
5IHE	;	2.5	;	D-family DNA polymerase - DP1 subunit (3'-5' proof-reading exonuclease)
6HMF	;	2.6	;	D-family DNA polymerase - DP1 subunit (3'-5' proof-reading exonuclease) H451 proof-reading deficient variant
5IJL	;	2.19	;	D-family DNA polymerase - DP2 subunit (catalytic subunit)
3ROJ	;	2.3	;	D-fructose 1,6-bisphosphatase class 2/sedoheptulose 1,7-bisphosphatase of Synechocystis sp. PCC 6803
3RPL	;	2.4	;	D-fructose 1,6-bisphosphatase class 2/sedoheptulose 1,7-bisphosphatase of Synechocystis sp. PCC 6803 in complex with FRUCTOSE-1,6-BISPHOSPHATE
6CKG	;	2.0	;	D-glycerate 3-kinase from Cryptococcus neoformans var. grubii serotype A (H99 / ATCC 208821 / CBS 10515 / FGSC 9487)
1GKP	;	1.295	;	D-Hydantoinase (Dihydropyrimidinase) from Thermus sp. in space group C2221
1GKQ	;	2.6	;	D-Hydantoinase (Dihydropyrimidinase) from Thermus sp. in space group P212121
2DLD	;	2.7	;	D-LACTATE DEHYDROGENASE COMPLEXED WITH NADH AND OXAMATE
7NZP	;	1.345	;	D-lyxose isomerase from the hyperthermophilic archaeon Thermofilum sp complexed with D-fructose
7NZQ	;	1.57	;	D-lyxose isomerase from the hyperthermophilic archaeon Thermofilum sp complexed with D-mannose
7NZO	;	1.67	;	D-lyxose isomerasefrom the hyperthermophilic archaeon Thermofilum sp
3MGN	;	1.4	;	D-Peptide inhibitor PIE71 in complex with IQN17
8OIK	;	1.62	;	D-PHAT domain (NTD) of human SAMD4A
1NZQ	;	2.18	;	D-Phe-Pro-Arg-Type Thrombin Inhibitor
7LSP	;		;	D-Phenylseptin - The second residue of PHE of the peptide is a D-amino acid
7LL8	;	2.31	;	D-Protein RFX-V1 Bound to the VEGFR1 Domain 2 Site on VEGF-A
7LL9	;	2.9	;	D-Protein RFX-V2 Bound to the VEGFR1 Domain 3 Site on VEGF-A
1URP	;	2.3	;	D-RIBOSE-BINDING PROTEIN FROM ESCHERICHIA COLI
1RPX	;	2.3	;	D-RIBULOSE-5-PHOSPHATE 3-EPIMERASE FROM SOLANUM TUBEROSUM CHLOROPLASTS
3LBM	;	1.48	;	D-sialic acid aldolase
3LBC	;	1.85	;	D-sialic acid aldolase complexed with L-arabinose
3WQG	;	1.55	;	D-threo-3-hydroxyaspartate dehydratase C353A mutant in the metal-free form
3WQC	;	1.5	;	D-threo-3-hydroxyaspartate dehydratase from Delftia sp. HT23
3WQE	;	1.6	;	D-threo-3-hydroxyaspartate dehydratase from Delftia sp. HT23 complexed with D-allothreonine
3WQD	;	1.5	;	D-threo-3-hydroxyaspartate dehydratase from Delftia sp. HT23 complexed with D-erythro-3-hydroxyaspartate
3WQF	;	2.3	;	D-threo-3-hydroxyaspartate dehydratase from Delftia sp. HT23 in the metal-free form
4PB3	;	1.7	;	D-threo-3-hydroxyaspartate dehydratase H351A mutant
4PB4	;	1.8	;	D-threo-3-hydroxyaspartate dehydratase H351A mutant complexed with 2-amino maleic acid
4PB5	;	1.9	;	D-threo-3-hydroxyaspartate dehydratase H351A mutant complexed with L-erythro-3-hydroxyaspartate
1JKE	;	1.55	;	D-Tyr tRNATyr deacylase from Escherichia coli
3KO5	;	2.09	;	D-Tyr-tRNA(Tyr) deacylase from Plasmodium falciparum in complex with ADP
3LMV	;	2.833	;	D-Tyr-tRNA(Tyr) Deacylase from plasmodium falciparum in complex with hepes
3KO3	;	2.8	;	D-tyrosyl-tRNA(Tyr) deacylase from Plasmodium falciparum incomplex with ADP, obtained through soaking native enzyme crystal with the ATP
3CWH	;	2.2	;	D-xylose Isomerase in complex with linear product, per-deuterated xylulose
7QUP	;	3.8	;	D. melanogaster 13-protofilament microtubule
7QUC	;	3.2	;	D. melanogaster alpha/beta tubulin heterodimer in the GDP form
7QUD	;	3.47	;	D. melanogaster alpha/beta tubulin heterodimer in the GTP form
6RAW	;	3.7	;	D. melanogaster CMG-DNA, State 1A
6RAX	;	3.99	;	D. melanogaster CMG-DNA, State 1B
6RAY	;	4.28	;	D. melanogaster CMG-DNA, State 2A
6RAZ	;	4.46	;	D. melanogaster CMG-DNA, State 2B
6S8R	;	2.41	;	D. melanogaster RNA helicase Me31B in complex with GIGYF
2RHF	;	1.1	;	D. radiodurans RecQ HRDC domain 3
8DEJ	;	2.86	;	D. vulgaris type I-C Cascade bound to dsDNA target
6TPL	;	1.8	;	D0-D1 domain of Intimin
6TQD	;	1.48	;	D00-D0 domain of Intimin
7R7U	;	4.3	;	D1 and D2 domain structure of the p97(R155H)-p47 complex
7NGP	;	15.0	;	D1-state of wild type human mitochondrial LONP1 protease
1KIY	;	2.4	;	D100E trichodiene synthase
1KIZ	;	2.6	;	D100E trichodiene synthase complexed with pyrophosphate
1YYT	;	2.9	;	D100E Trichodiene Synthase: Complex With Mg, Pyrophosphate, and (4R)-7-azabisabolene
1YYU	;	2.95	;	D100E Trichodiene Synthase: Complex With Mg, Pyrophosphate, and (4S)-7-azabisabolene
6P7C	;	2.76	;	D104A/S128A S. typhimurium siroheme synthase
6ULU	;	2.76	;	D104A/S128A S. typhimurium siroheme synthase
6P7D	;	2.4	;	D104N S. typhimurium siroheme synthase
1JL1	;	1.3	;	D10A E. coli ribonuclease HI
6I03	;	1.02	;	D10N variant of beta-phosphoglucomutase from Lactococcus lactis complexed with tetrafluoroaluminate and beta-G6P to 1.02 A
5OJZ	;	1.3	;	D10N variant of beta-phosphoglucomutase from Lactococcus lactis inhibited by a beryllium triflouride phosphoenzyme analogue to 1.3A resolution.
5OK1	;	1.86	;	D10N variant of beta-phosphoglucomutase from Lactococcus lactis trapped with native beta-glucose 1,6-bisphosphate intermediate to 1.9A resolution.
5L3L	;		;	D11 bound IGF-II
5L3N	;		;	D11 bound [N29, S39_PQ]-IGF-II
5L3M	;		;	D11 bound [S39_PQ]-IGF-II
3ZDN	;	2.55	;	D11-C mutant of monoamine oxidase from Aspergillus niger
3NJK	;	1.5	;	D116A mutant of SO1698 protein, an aspartic peptidase from Shewanella oneidensis, at pH5.5
3NJL	;	1.75	;	D116A mutant of SO1698 protein, an aspartic peptidase from Shewanella oneidensis, at pH7.5
1WNV	;	1.85	;	D136A mutant of Heme Oxygenase from Corynebacterium diphtheriae (HmuO)
1WNX	;	1.85	;	D136E mutant of Heme Oxygenase from Corynebacterium diphtheriae (HmuO)
1WNW	;	1.7	;	D136N mutant of Heme Oxygenase from Corynebacterium diphtheriae (HmuO)
1B0T	;	2.1	;	D15K/K84D MUTANT OF AZOTOBACTER VINELANDII FDI
6HDG	;	1.15	;	D170N variant of beta-phosphoglucomutase from Lactococcus lactis complexed with beta-G1P in a closed conformer to 1.2 A.
6HDF	;	1.4	;	D170N variant of beta-phosphoglucomutase from Lactococcus lactis in an open conformer to 1.4 A.
3C1U	;	1.33	;	D192N mutant of Rhamnogalacturonan acetylesterase
1QQM	;	1.9	;	D199S MUTANT OF BOVINE 70 KILODALTON HEAT SHOCK PROTEIN
1D3L	;	3.25	;	D1D2-ICAM-1 FULLY GLYCOSYLATED, VARIATION OF D1-D2 INTERDOMAIN ANGLE IN DIFFERENT CRYSTAL STRUCTURES.
3S8W	;	2.6	;	D2 domain of human IFNAR2
1D2N	;	1.75	;	D2 DOMAIN OF N-ETHYLMALEIMIDE-SENSITIVE FUSION PROTEIN
1NSF	;	1.9	;	D2 HEXAMERIZATION DOMAIN OF N-ETHYLMALEIMIDE SENSITIVE FACTOR (NSF)
4OZG	;	3.0	;	D2 protein complex
2ZD2	;	1.8	;	D202K mutant of P. denitrificans Atp12p
1QQN	;	1.9	;	D206S MUTANT OF BOVINE 70 KILODALTON HEAT SHOCK PROTEIN
1QTZ	;	2.0	;	D20C MUTANT OF T4 LYSOZYME
1QT5	;	1.8	;	D20E MUTANT STRUCTURE OF T4 LYSOZYME
2YHK	;	1.91	;	D214A mutant of tyrosine phenol-lyase from Citrobacter freundii
1BJG	;	2.3	;	D221(169)N MUTANT DOES NOT PROMOTE OPENING OF THE COFACTOR IMIDAZOLIDINE RING
1DNA	;	2.2	;	D221(169)N MUTANT DOES NOT PROMOTE OPENING OF THE COFACTOR IMIDAZOLIDINE RING
1C9Z	;	2.4	;	D232-CGTACG
1KY5	;	2.8	;	D244E mutant S-Adenosylhomocysteine hydrolase refined with noncrystallographic restraints
1XLM	;	2.4	;	D254E, D256E MUTANT OF D-XYLOSE ISOMERASE COMPLEXED WITH AL3 AND XYLITOL
6PR3	;	1.96	;	D262A/S128A S. typhimurium siroheme synthase
6PR4	;	2.24	;	D262N/S128A S. typhimurium siroheme synthase
2OUI	;	1.77	;	D275P mutant of alcohol dehydrogenase from protozoa Entamoeba histolytica
6MR8	;	1.897	;	D276G DNA polymerase beta substrate complex with templating adenine and incoming Fapy-dGTP analog
6DIC	;	1.992	;	D276G DNA polymerase beta substrate complex with templating cytosine and incoming Fapy-dGTP analog
5FO0	;	2.51	;	D298E mutant of FAD synthetase from Corynebacterium ammoniagenes
8IMK	;	2.48	;	D3-D4, D1-D2, D'3-D'4, D'1-D'2 cylinder in cyanobacterial phycobilisome from Anthocerotibacter panamensis (Cluster C)
5WKF	;	2.95	;	D30 TCR in complex with HLA-A*11:01-GTS1
5WKH	;	3.2	;	D30 TCR in complex with HLA-A*11:01-GTS3
3WNO	;	1.9	;	D308A mutant of Bacillus circulans T-3040 cycloisomaltooligosaccharide glucanotransferase complexed with cycloisomaltooctaose
3WNM	;	2.25	;	D308A mutant of Bacillus circulans T-3040 cycloisomaltooligosaccharide glucanotransferase complexed with isomaltoheptaose
3WNL	;	2.6	;	D308A mutant of Bacillus circulans T-3040 cycloisomaltooligosaccharide glucanotransferase complexed with isomaltohexaose
3WNN	;	2.25	;	D308A mutant of Bacillus circulans T-3040 cycloisomaltooligosaccharide glucanotransferase complexed with isomaltooctaose
3WNP	;	2.8	;	D308A, F268V, D469Y, A513V, and Y515S quintuple mutant of Bacillus circulans T-3040 cycloisomaltooligosaccharide glucanotransferase complexed with isomaltoundecaose
7DT9	;	1.89	;	D30N HIV Protease in complex with Saquinavir
6C8Y	;	1.942	;	D30N HIV-1 protease in complex with a phenylboronic acid (P2') analog of darunavir
8ESY	;	1.35	;	D30N mutant HIV protease in complex with benzoxaborolone analog of darunavir
4Q5M	;	1.795	;	D30N tethered HIV-1 protease dimer/saquinavir complex
3EWU	;	1.6	;	D312N mutant of human orotidyl-5'-monophosphate decarboxylase in complex with 6-acetyl-UMP, covalent adduct
3EX6	;	1.3	;	D312N mutant of human orotidyl-5'-monophosphate decarboxylase in complex with 6-azido-UMP, covalent adduct
3EWW	;	1.1	;	D312N mutant of human orotidyl-5'-monophosphate decarboxylase in complex with 6-cyano-UMP, covalent adduct
7BA2	;	3.0	;	D319A mutant of the PilB minor pilin from Streptococcus sanguinis
5IMH	;	2.471	;	D31P mutant of C69-family cysteine dipeptidase from Lactobacillus farciminis
7DVB	;	2.05	;	D335N variant of Bt4394 in complex with 6SO3-NAG-oxazoline intermediate
3DFN	;	1.86	;	D33N mutant fructose-1,6-bisphosphate aldolase from rabbit muscle
3DFQ	;	1.82	;	D33S mutant fructose-1,6-bisphosphate aldolase from rabbit muscle
1N11	;	2.7	;	D34 REGION OF HUMAN ANKYRIN-R AND LINKER
6D8G	;	3.0	;	D341A D367A calcium binding mutant of Bacteroides uniformis beta-glucuronidase 2
3PVI	;	1.59	;	D34G MUTANT OF PVUII ENDONUCLEASE COMPLEXED WITH COGNATE DNA SHOWS THAT ASP34 IS DIRECTLY INVOLVED IN DNA RECOGNITION AND INDIRECTLY INVOLVED IN CATALYSIS
3NJH	;	1.94	;	D37A mutant of SO1698 protein, an aspartic peptidase from Shewanella oneidensis.
8HAY	;	2.74	;	d4-bound btDPP4
1OC5	;	1.7	;	D405N mutant of the CELLOBIOHYDROLASE CEL6A FROM HUMICOLA INSOLENS in complex with methyl-cellobiosyl-4-deoxy-4-thio-beta-D-cellobioside
1OC7	;	1.11	;	D405N mutant of the CELLOBIOHYDROLASE CEL6A FROM HUMICOLA INSOLENS in complex with methyl-tetrathio-alpha-d-cellopentoside at 1.1 angstrom resolution
4MML	;	1.801	;	D40A Hfq from Pseudomonas aeruginosa
3FBM	;	3.1	;	D431N Mutant VP2 Protein of Infectious Bursal Disease Virus; Derived T=1 Particles
6AH7	;	2.38	;	D45W/H226G mutant of marine bacterial prolidase
8HWA	;	3.7	;	D5 ATP-ADP-Apo-ssDNA IS1
8HWB	;	3.9	;	D5 ATP-ADP-Apo-ssDNA IS2
8HWG	;	3.0	;	D5 ATPrS-ADP-ssDNA form
3OJP	;	1.81	;	D52N Mutant of Hen Egg White Lysozyme (HEWL)
3NA4	;	1.9	;	D53P beta-2 microglobulin mutant
1DSN	;	2.05	;	D60S N-TERMINAL LOBE HUMAN LACTOFERRIN
1BA2	;	2.1	;	D67R MUTANT OF D-RIBOSE-BINDING PROTEIN FROM ESCHERICHIA COLI
6MTF	;	1.92	;	D7 protein from Phlebotomus duboscqi, native
3CAU	;	4.2	;	D7 symmetrized structure of unliganded GroEL at 4.2 Angstrom resolution by cryoEM
3GTX	;	1.62	;	D71G/E101G mutant in organophosphorus hydrolase from Deinococcus radiodurans
3GTH	;	1.98	;	D71G/E101G/M234I mutant in organophosphorus hydrolase from Deinococcus radiodurans
3GTI	;	2.42	;	D71G/E101G/M234L mutant in organophosphorus hydrolase from Deinococcus radiodurans
3GTF	;	1.98	;	D71G/E101G/V235L mutant in organophosphorus hydrolase from Deinococcus radiodurans
2BVU	;	2.5	;	D83R mutant of Asaris suum major sperm protein (MSP)
5X8D	;	2.26	;	D90L mutant of thermus thermophilus HB8 thymidylate kinase
1GY5	;	2.3	;	D92N,D94N double point mutant of human Nuclear Transport Factor 2 (NTF2)
1AKU	;	1.9	;	D95A HYDROQUINONE FLAVODOXIN MUTANT FROM D. VULGARIS
1AKQ	;	1.9	;	D95A OXIDIZED FLAVODOXIN MUTANT FROM D. VULGARIS
1AKV	;	2.0	;	D95A SEMIQUINONE FLAVODOXIN MUTANT FROM D. VULGARIS
1C7E	;	2.25	;	D95E HYDROQUINONE FLAVODOXIN MUTANT FROM D. VULGARIS
1C7F	;	2.0	;	D95E OXIDIZED FLAVODOXIN MUTANT FROM D. VULGARIS
3UB3	;	2.75	;	D96N variant of TIR domain of Mal/TIRAP
3LGK	;	1.892	;	D99N Epi-isozizaene synthase
2BCM	;	1.48	;	DaaE adhesin
8AFU	;	1.99	;	DaArgC - N-acetyl-gamma-glutamyl-phosphate Reductase of Denitrovibrio acetiphilus
8AFV	;	2.19	;	DaArgC3 - Engineered Formyl Phosphate Reductase with 3 substitutions (S178V, G182V, L233I)
6T2J	;	1.7	;	dAb3
6SC6	;	2.25	;	dAb3/HOIP-RBR apo structure
6SC9	;	2.47	;	dAb3/HOIP-RBR-HOIPIN-8
6SC5	;	2.1	;	dAb3/HOIP-RBR-Ligand2
6SC7	;	2.56	;	dAb3/HOIP-RBR-Ligand3
6SC8	;	2.106	;	dAb3/HOIP-RBR-Ligand4
4YHN	;	2.31	;	Dabigatran Reversal Agent
8E0T	;	1.94	;	DAHP (3-deoxy-D-arabinoheptulosonate-7-phosphate) Synthase complexed with DAHP Oxime in unbound:(bound)2:other conformations
8E0S	;	1.65	;	DAHP (3-deoxy-D-arabinoheptulosonate-7-phosphate) Synthase complexed with DAHP Oxime in unbound:(bound)2:unbound conformations
8E0Y	;	2.01	;	DAHP (3-deoxy-D-arabinoheptulosonate-7-phosphate) Synthase complexed with DAHP oxime, Pr(III), and Pi in unbound:(bound)2:other Conformations
8E0V	;	2.3	;	DAHP (3-deoxy-D-arabinoheptulosonate-7-phosphate) Synthase complexed with Mn(II), PEP, and Pi in unbound:(bound)2:other Conformations
8E0X	;	1.97	;	DAHP (3-deoxy-D-arabinoheptulosonate-7-phosphate) Synthase complexed with Mn(II), PEP, and Pi in unbound:(bound)2:other Conformations
8E0U	;	2.42	;	DAHP (3-deoxy-D-arabinoheptulosonate-7-phosphate) Synthase complexed with Sulfate in unbound:(bound)2:other conformations
5CKS	;	2.1181	;	DAHP (3-deoxy-D-arabinoheptulosonate-7-phosphate) Synthase in complex with DAHP Oxime.
8E0Z	;	2.4	;	DAHP (3-deoxy-D-arabinoheptulosonate-7-phosphate) Synthase unbound:(bound)2:unbound Conformations
7RUD	;	2.8	;	DAHP synthase complex with trifluoropyruvate oxime
7RUE	;	2.5	;	DAHP synthase complexed with trifluoropyruvate semicarbazone
5HUC	;	2.45	;	DAHP synthase from Corynebacterium glutamicum
5HUE	;	2.65	;	DAHP synthase from Corynebacterium glutamicum in complex with tryptophan
5CKV	;	2.787	;	DAHP synthase from Mycobacterium tuberculosis, fully inhibited by tyrosine, phenylalanine, and tryptophan
6FHP	;	1.703	;	DAIP in complex with a C-terminal fragment of thermolysin
2NMV	;	2.95	;	Damage detection by the UvrABC pathway: Crystal structure of UvrB bound to fluorescein-adducted DNA
6ZAS	;	1.3	;	Damage-free as-isolated copper nitrite reductase from Bradyrhizobium sp. ORS 375 (two-domain) determined by serial femtosecond rotation crystallography
6ZAU	;	1.3	;	Damage-free nitrite-bound copper nitrite reductase from Bradyrhizobium sp. ORS 375 (two-domain) determined by serial femtosecond rotation crystallography
6ZAW	;	1.3	;	Damage-free NO-bound copper nitrite reductase from Bradyrhizobium sp. ORS 375 (two-domain) determined by serial femtosecond rotation crystallography
7SA4	;	2.55	;	Damaged 70S ribosome with PrfH bound
4E54	;	2.85	;	Damaged DNA induced UV-damaged DNA-binding protein (UV-DDB) dimerization and its roles in chromatinized DNA repair
4E5Z	;	3.22	;	Damaged DNA induced UV-damaged DNA-binding protein (UV-DDB) dimerization and its roles in chromatinized DNA repair
8EFQ	;	3.3	;	DAMGO-bound mu-opioid receptor-Gi complex
6V4I	;		;	DanD
6EWL	;	1.4	;	Danio rerio CEP120 first C2 domain (C2A)
5UGV	;	2.25	;	DapB from Mycobacterium tuberculosis
7LGP	;	1.91	;	DapE enzyme from Shigella flexneri
1XT7	;		;	Daptomycin NMR Structure
6YJ7	;	1.64	;	DarB fom B. subtilis in complex with AMP
6YJA	;	1.7	;	DarB fom B. subtilis in complex with c-di-AMP
6YJ9	;	1.5	;	DarB in complex with 3'3'cGAMP
6YJ8	;	1.84	;	DarB-APO
6S7Y	;	2.3	;	dARC1 capsid domain dimer, hexagonal form at 2.3 Angstrom
6S7X	;	1.7	;	dARC1 capsid domain dimer, orthorhombic form at 1.7 Angstrom
7VIW	;	1.74	;	Dark adapted MmCPDII during oxidized to semiquinone TR-SFX studies
6P58	;	1.499	;	Dark and Steady State-Illuminated Crystal Structure of Cyanobacteriochrome Receptor PixJ at 150K
2XDQ	;	2.4	;	Dark Operative Protochlorophyllide Oxidoreductase (ChlN-ChlB)2 Complex
8C31	;	1.8	;	Dark state 1.8 Angstrom crystal structure of cobalamin binding domain belonging to a light-dependent transcription regulator TtCarH obtained under aerobic condition
8C73	;	1.7	;	Dark state 1.8 Angstrom crystal structure of cobalamin binding domain belonging to a light-dependent transcription regulator TtCarH obtained under aerobic condition form ll
8C35	;	2.1	;	Dark state 2.1 Angstrom crystal structure of H132A variant of cobalamin binding domain belonging to a light-dependent transcription regulator TtCarH
8C32	;	2.2	;	Dark state 2.2 Angstrom crystal structure of cobalamin binding domain belonging to a light-dependent transcription regulator TtCarH obtained under anaerobic condition
7ZBC	;	1.8	;	Dark state crystal structure of bovine rhodopsin in Lipidic Cubic Phase (SACLA)
7ZBE	;	1.8	;	Dark state crystal structure of bovine rhodopsin in Lipidic Cubic Phase (SwissFEL)
8C3I	;	2.1	;	Dark state of PAS-GAF fragment from Deinococcus radiodurans phytochrome
7CRJ	;	1.65	;	Dark State Structure of Chloride ion pumping rhodopsin (ClR) with NTQ motif
7ZCM	;	2.85	;	Dark state structure of Sensory Rhodopsin II in complex with HtrII solved by room temperature serial synchrotron crystallography
7PNC	;	2.2	;	Dark state structure of Sensory Rhodopsin II solved by serial millisecond crystallography
2IYG	;	2.3	;	Dark state structure of the BLUF domain of the rhodobacterial protein AppA
7AV4	;	1.936	;	Dark state structure of the C432S mutant of Fatty Acid Photodecarboxylase (FAP)
2POX	;	1.946	;	Dark state structure of the reversibly switchable fluorescent protein Dronpa
6PTX	;	1.65	;	Dark, 100K, PCM Myxobacterial Phytochrome, P2, Wild Type,
7YC7	;	1.95	;	Dark, fully reduced structure of the MmCPDII-DNA complex as produced at SwissFEL
6PU2	;	2.2	;	Dark, Mutant H275T , 100K, PCM Myxobacterial Phytochrome, P2
6PTQ	;	2.1	;	Dark, Room Temperature, PCM Myxobacterial Phytochrome, P2, Wild Type
6GUX	;	1.3	;	Dark-adapted structure of Archaerhodopsin-3 at 100K
6S63	;	1.85	;	Dark-adapted structure of Archaerhodopsin-3 obtained from LCP crystals using a thin-film sandwich at room temperature
6UYK	;	2.6	;	Dark-operative protochlorophyllide oxidoreductase in the nucleotide-free form.
4HH0	;	2.6	;	Dark-state structure of AppA C20S without the Cys-rich region from Rb. sphaeroides
4HH1	;	3.501	;	Dark-state structure of AppA wild-type without the Cys-rich region from Rb. sphaeroides
4J88	;	2.08	;	Dark-state structure of sfGFP containing the unnatural amino acid p-azido-phenylalanine at residue 66
7RHD	;	1.9	;	darkmRuby M94T/F96Y mutant at pH 7.5
7DNE	;	1.9	;	DARPin 5m3_D12 in complex with V3-IY (MN) crown mimetic
7DNG	;	1.42	;	DARPin 63_B7 in complex with linear V3-crown (MN) peptide
7DNF	;	1.78	;	DARPin 63_B7 in complex with V3-IY (MN) crown mimetic
4DUI	;	1.16	;	DARPIN D1 binding to tubulin beta chain (not in complex)
6SA6	;	1.6	;	DARPin-Armadillo fusion A5
6SA7	;	3.3	;	DARPin-Armadillo fusion C8long83
5AQ7	;	2.1	;	DARPin-based Crystallization Chaperones exploit Molecular Geometry as a Screening Dimension in Protein Crystallography
5AQ8	;	1.62	;	DARPin-based Crystallization Chaperones exploit Molecular Geometry as a Screening Dimension in Protein Crystallography
5AQ9	;	1.86	;	DARPin-based Crystallization Chaperones exploit Molecular Geometry as a Screening Dimension in Protein Crystallography
5AQA	;	2.6	;	DARPin-based Crystallization Chaperones exploit Molecular Geometry as a Screening Dimension in Protein Crystallography
5AQB	;	1.37	;	DARPin-based Crystallization Chaperones exploit Molecular Geometry as a Screening Dimension in Protein Crystallography
5FIN	;	2.34	;	DARPins as a new tool for experimental phasing in protein crystallography
5FIO	;	2.1	;	DARPins as a new tool for experimental phasing in protein crystallography
7BHE	;	2.297	;	DARPin_D5/Her3 domain 4 complex, monoclinic crystals
7BHF	;	1.997	;	DARPin_D5/Her3 domain 4 complex, orthorhombic crystals
3SO9	;	2.87	;	Darunavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant
7KTY	;	2.0	;	Data clustering and dynamics of chymotrypsinogen average structure
7KU2	;	2.185	;	Data clustering and dynamics of chymotrypsinogen clulster 140 (structure)
7KTZ	;	2.0	;	Data clustering and dynamics of chymotrypsinogen cluster 131 (purple) structure
7KU0	;	2.02	;	Data clustering and dynamics of chymotrypsinogen cluster 138 (yellow) structure
7KU1	;	2.39	;	Data clustering and dynamics of chymotrypsinogen cluster 139 (green) structure
7KU3	;	2.0	;	Data clustering and dynamics of chymotrypsinogen cluster 141 (cyan) structure
7WNR	;		;	Data-driven HADDOCK model of mycobacterial nMazE6-operator DNA complex
2KAE	;		;	data-driven model of MED1:DNA complex
1OWM	;	2.3	;	DATA1:DNA photolyase / received X-rays dose 1.2 exp15 photons/mm2
1OWN	;	2.3	;	DATA3:DNA photolyase / received X-rays dose 4.8 exp15 photons/mm2
1OWO	;	2.3	;	DATA4:photoreduced DNA photolyase / received X-rays dose 1.2 exp15 photons/mm2
1OWP	;	2.3	;	DATA6:photoreduced DNA pholyase / received X-rays dose 4.8 exp15 photons/mm2
2KZS	;		;	DAXX helical bundle (DHB) domain
2KZU	;		;	DAXX helical bundle (DHB) domain / Rassf1C complex
1LUL	;	3.3	;	DB58, A LEGUME LECTIN FROM DOLICHOS BIFLORUS
4HYK	;	2.802	;	Dbh Ternary Complex (substrates partially disordered)
1DBH	;	2.3	;	DBL AND PLECKSTRIN HOMOLOGY DOMAINS FROM HSOS1
1BY1	;		;	DBL homology domain from beta-PIX
5K78	;	2.64	;	Dbr1 in complex with 16-mer branched RNA
8DZK	;	2.1	;	Dbr1 in complex with 5-mer cleavage product
5K77	;	2.17	;	Dbr1 in complex with 7-mer branched RNA
4PEG	;	2.0	;	Dbr1 in complex with guanosine-5'-monophosphate
4PEF	;	1.96	;	Dbr1 in complex with sulfate
4PEI	;	1.95	;	Dbr1 in complex with synthetic branched RNA analog
4PEH	;	2.1	;	Dbr1 in complex with synthetic linear RNA
1KZG	;	2.6	;	DbsCdc42(Y889F)
1VP9	;	1.95	;	DC26 MUTANT OF VACCINIA VIRUS PROTEIN VP39 IN COMPLEX WITH S-ADENOSYLHOMOCYSTEINE
1P39	;	2.0	;	DC26 MUTANT OF VACCINIA VIRUS PROTEIN VP39 IN COMPLEX WITH S-ADENOSYLHOMOCYSTEINE AND M7G(5')PPPG
1V39	;	1.8	;	DC26 MUTANT OF VACCINIA VIRUS PROTEIN VP39 IN COMPLEX WITH S-ADENOSYLHOMOCYSTEINE AND M7G(5')PPPG
2VP3	;	1.95	;	DC26 MUTANT OF VACCINIA VIRUS PROTEIN VP39 IN COMPLEX WITH S-ADENOSYLHOMOCYSTEINE AND M7G(5')PPPG
1B5E	;	1.6	;	DCMP HYDROXYMETHYLASE FROM T4
1B5D	;	2.2	;	DCMP Hydroxymethylase from T4 (Intact)
1B49	;	2.3	;	DCMP HYDROXYMETHYLASE FROM T4 (PHOSPHATE-BOUND)
6B5Q	;	2.16	;	DCN1 bound to 38
6XOM	;	2.1	;	DCN1 bound to 8
6XOL	;	2.39	;	DCN1 bound to DI-1548
6XOO	;	2.06	;	DCN1 bound to DI-1859
5UFI	;	2.58	;	DCN1 bound to DI-591
6XOP	;	2.07	;	DCN1 bound to inhibitor 10
6XON	;	2.8	;	DCN1 bound to inhibitor 9
6XOQ	;	2.07	;	DCN1 covalently bound to inhibitor 4
4GAO	;	3.28	;	DCNL complex with N-terminally acetylated NEDD8 E2 peptide
4GBA	;	2.4	;	DCNL complex with N-terminally acetylated NEDD8 E2 peptide
1DCO	;	2.3	;	DCOH, A BIFUNCTIONAL PROTEIN-BINDING TRANSCRIPTIONAL COACTIVATOR
1DCP	;	2.3	;	DCOH, A BIFUNCTIONAL PROTEIN-BINDING TRANSCRIPTIONAL COACTIVATOR, COMPLEXED WITH BIOPTERIN
1USM	;	1.2	;	DCOH, A BIFUNCTIONAL PROTEIN-BINDING TRANSCRIPTIONAL COACTIVATOR, PRO9LEU MUTANT
1USO	;	1.3	;	DCOH, A BIFUNCTIONAL PROTEIN-BINDING TRANSCRIPTIONAL COACTIVATOR, PRO9LEU MUTANT
4QDE	;	2.9	;	Dcps in complex with covalent inhibitor
4QEB	;	3.21	;	Dcps in complex with covalent inhibitor targeting Tyrosine
4QDV	;	2.8	;	Dcps in complex with covalent ligand
4ZMU	;	2.502	;	Dcsbis, a diguanylate cyclase from Pseudomonas aeruginosa
1XS1	;	1.8	;	dCTP deaminase from Escherichia coli in complex with dUTP
1XS4	;	2.53	;	dCTP deaminase from Escherichia coli- E138A mutant enzyme in complex with dCTP
1XS6	;	2.0	;	dCTP deaminase from Escherichia coli. E138A mutant enzyme in complex with dUTP
4XJC	;	2.35	;	dCTP deaminase-dUTPase from Bacillus halodurans
2HXB	;	2.55	;	dCTP deaminase-dUTPase from Methanocaldococcus jannaschii
2N97	;		;	DD homodimer
1H70	;	1.8	;	DDAH FROM PSEUDOMONAS AERUGINOSA. C249S MUTANT COMPLEXED WITH CITRULLINE
2JAI	;	2.3	;	DDAH1 complexed with citrulline
2JAJ	;	2.0	;	DDAH1 complexed with L-257
7ANI	;	1.3	;	DdahB, GDP-mannoheptose C3,5 epimerase from Campylobacter jejuni
7ANJ	;	2.35	;	DdahB, GDP-mannoheptose C3,5 epimerase from Campylobacter jejuni complexed to GDP-mannose
7D4J	;	2.09	;	ddATP complex of cyclic trinucleotide synthase CdnD
1QSY	;	2.3	;	DDATP-Trapped closed ternary complex of the large fragment of DNA Polymerase I from thermus aquaticus
2HVI	;	1.98	;	ddCTP:G pair in the polymerase active site (0 position)
2HVH	;	2.492	;	ddCTP:O6MeG pair in the polymerase active site (0 position)
2N62	;		;	ddFLN5+110
1QSS	;	2.3	;	DDGTP-TRAPPED CLOSED TERNARY COMPLEX OF THE LARGE FRAGMENT OF DNA POLYMERASE I FROM THERMUS AQUATICUS
7ANH	;	2.08	;	DdhaC
8EVX	;	1.55	;	DdlA from Pseudomonas aeruginosa PAO1 in complex with ADP and phosphorylated D-cycloserine
8EVW	;	1.22	;	DdlA from Pseudomonas aeruginosa PAO1 in complex with ATP and D-ala-D-ala
8EVZ	;	2.45	;	DdlB from Pseudomonas aeruginosa PAO1 in complex with ADP and phosphorylated D-cycloserine
8EVY	;	2.35	;	DdlB from Pseudomonas aeruginosa PAO1 in complex with ATP and D-ala-D-ala
6BSD	;	2.606	;	DDR1 bound to Dasatinib
6BRJ	;	2.231	;	DDR1 bound to VX-680
6Y23	;	2.58	;	DDR1 kinase autoinhibited by its juxtamembrane region
6FIQ	;	1.79	;	DDR1, 1-(1H-indazole-5-carbonyl)-5'-methoxy-1'-[2-oxo-2-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethyl]spiro[piperidine-4,3'-pyrrolo[3,2-b]pyridine]-2'-one, 1.790A, P212121, Rfree=23.8%
6FIO	;	1.99	;	DDR1, 2-[1'-(1H-indazole-5-carbonyl)-4-methyl-2-oxospiro[indole-3,4'-piperidine]-1-yl]-N-(2,2,2-trifluoroethyl)acetamide, 1.990A, P6522, Rfree=27.7%
5SAW	;	1.601	;	DDR1, 2-[3-(2-pyridin-3-ylethynyl)phenyl]-N-[3-(trifluoromethyl)phenyl]acetamide, 1.601A, P212121, Rfree=22.6%
5SAX	;	1.902	;	DDR1, 2-[3-(2-pyridin-3-ylethynyl)phenyl]-N-[3-(trifluoromethyl)phenyl]acetamide, 1.902A, second P212121 form, Rfree=25.4%, second form
6FEX	;	1.291	;	DDR1, 2-[4-bromo-2-oxo-1'-(1H-pyrazolo[4,3-b]pyridine-5-carbonyl)spiro[indole-3,4'-piperidine]-1-yl]-N-(2,2,2-trifluoroethyl)acetamide, 1.291A, P212121, Rfree=17.4%
6FEW	;	1.44	;	DDR1, 2-[8-(1H-indazole-5-carbonyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]-N-methylacetamide, 1.440A, P1211, Rfree=24.1%
6FIL	;	1.73	;	DDR1, 2-[8-(1H-indazole-5-carbonyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]-N-methylacetamide, 1.730A, P212121, Rfree=24.5%
5SB2	;	1.6	;	DDR1, 3-chloro-N-[(1R,2S)-2-phenylcyclopropyl]-5-(1H-pyrrolo[2,3-b]pyridin-5-yloxymethyl)benzamide, 1.600A, P212121, Rfree=23.2%
5SAZ	;	1.8	;	DDR1, 3-chloro-N-[4-chloro-3-(1H-pyrrolo[2,3-b]pyridin-5-ylcarbamoyl)phenyl]-4-(2-hydroxyethylamino)benzamide, 1.802A, P212121, Rfree=22.2%
6FIN	;	1.67	;	DDR1, 3-[(3-cyclopropyl-1,2,4-oxadiazol-5-yl)methyl]-8-(1H-indazole-5-carbonyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one, 1.670A, P1211, Rfree=22.8%
5SAU	;	1.8	;	DDR1, 3-[2-(6-aminopyridin-3-yl)ethynyl]-N-[3-(trifluoromethyl)phenyl]benzamide, 1.800A, P212121, Rfree=23.1%
5SB1	;	1.53	;	DDR1, 4-chloro-N-[(3S,4R)-4-phenylpyrrolidin-3-yl]-3-(1H-pyrrolo[2,3-b]pyridin-5-yloxymethyl)benzamide, 1.530A, P212121, Rfree=21.4%
5SAV	;	1.76	;	DDR1, N-[2-[3-(2-aminopyrimidin-5-yl)oxyphenyl]ethyl]-3-(trifluoromethoxy)benzamide, 1.760A, P212121, Rfree=23.5%
5SAY	;	2.19	;	DDR1, N-[2-[3-(2-aminopyrimidin-5-yl)oxyphenyl]ethyl]-3-(trifluoromethoxy)benzamide, 2.190A, P1211, Rfree=27.7%
5SB0	;	1.97	;	DDR1, N-[[2-(2-pyridin-3-yloxyethyl)cyclohexyl]methyl]-3-(trifluoromethoxy)benzamide, 1.970A, P212121, Rfree=25.6%
1QTM	;	2.3	;	DDTTP-TRAPPED CLOSED TERNARY COMPLEX OF THE LARGE FRAGMENT OF DNA POLYMERASE I FROM THERMUS AQUATICUS
2HHW	;	1.88	;	ddTTP:O6-methyl-guanine pair in the polymerase active site, in the closed conformation
3LY5	;	2.8	;	DDX18 dead-domain
2JGN	;	1.91	;	DDX3 helicase domain
7LIU	;	3.001	;	DDX3X bound to ATP analog and remodeled RNA:DNA hybrid
4CT5	;	3.0	;	DDX6
4X8I	;	2.5	;	de novo crystal structure of the Pyrococcus Furiosus TET3 aminopeptidase
5F72	;	1.85	;	De novo design and crystallographic validation of antibodies targeting a pre-selected epitope
7VQV	;	1.53	;	de novo design based on 1r26
7VU4	;	1.7	;	de novo design based on 1r26
8HDU	;	2.71	;	De novo design cavitated protein without predefined topology
8HDV	;	2.65	;	De novo design cavitated protein without predefined topology
8JPA	;	2.3	;	De novo design cavitated protein without predefined topology
6D0T	;	1.63	;	De novo design of a fluorescence-activating beta barrel - BB1
6DMP	;		;	De Novo Design of a Protein Heterodimer with Specificity Mediated by Hydrogen Bond Networks
5WOC	;		;	De Novo Design of Covalently Constrained Meso-size Protein Scaffolds with Unique Tertiary Structures
5WOD	;		;	De Novo Design of Covalently Constrained Meso-size Protein Scaffolds with Unique Tertiary Structures
8GJG	;	1.95	;	De novo design of high-affinity protein binders to bioactive helical peptides
8GJI	;	1.81	;	De novo design of high-affinity protein binders to bioactive helical peptides
8T5E	;	3.0	;	De novo design of high-affinity protein binders to bioactive helical peptides
8T5F	;	1.99	;	De novo design of high-affinity protein binders to bioactive helical peptides
6MPW	;	2.5	;	De Novo Design of membrane protein--mini-eVgL membrane protein, C2221 form-1
6MQ2	;	2.5	;	De Novo Design of membrane protein--mini-eVgL membrane protein, C2221 form-2
8GL3	;	2.3	;	De novo design of monomeric helical bundles for pH-controlled membrane lysis
5V2G	;		;	De Novo Design of Novel Covalent Constrained Meso-size Peptide Scaffolds with Unique Tertiary Structures
5V2O	;	1.2	;	De Novo Design of Novel Covalent Constrained Meso-size Peptide Scaffolds with Unique Tertiary Structures
5WLL	;	1.9	;	De Novo Design of Polynuclear Transition Metal Clusters in Helix Bundles-4DH1
5WLM	;	1.95	;	De Novo Design of Polynuclear Transition Metal Clusters in Helix Bundles-4DH2
5WLJ	;	1.6	;	De Novo Design of Polynuclear Transition Metal Clusters in Helix Bundles-4EH1
5WLK	;	1.8	;	De Novo Design of Polynuclear Transition Metal Clusters in Helix Bundles-4EH2
5IZS	;	2.36	;	De novo design of protein homo-oligomers with modular hydrogen bond network-mediated specificity
5J0H	;	1.64	;	De novo design of protein homo-oligomers with modular hydrogen bond network-mediated specificity
5J0I	;	2.202	;	De novo design of protein homo-oligomers with modular hydrogen bond network-mediated specificity
5J0J	;	2.256	;	De novo design of protein homo-oligomers with modular hydrogen bond network-mediated specificity
5J0K	;	1.54	;	De novo design of protein homo-oligomers with modular hydrogen bond network-mediated specificity
5J0L	;	2.63	;	De novo design of protein homo-oligomers with modular hydrogen bond network-mediated specificity
5J10	;	2.02	;	De novo design of protein homo-oligomers with modular hydrogen bond network-mediated specificity
5J2L	;	1.96	;	De novo design of protein homo-oligomers with modular hydrogen bond network-mediated specificity
5J73	;	2.56	;	De novo design of protein homo-oligomers with modular hydrogen bond network-mediated specificity
6X9Z	;	2.05	;	De novo design of transmembrane beta-barrels
7DKO	;	2.6	;	De novo design protein AM2M
7FBB	;	2.307	;	De novo design protein D12 with MBP tag
7FBC	;	1.85	;	De novo design protein D22 with MBP tag
7FBD	;	2.85	;	De novo design protein D53 with MBP tag
7DKK	;	2.1	;	De novo design protein XM2H
7A8S	;	1.58	;	de novo designed ba8-barrel sTIM11 with an alpha-helical extension
7VQL	;	1.75	;	de novo designed based on 1r26
7UNH	;	2.4	;	De novo designed chlorophyll dimer protein in apo state, SP2
7UNJ	;	2.0	;	De novo designed chlorophyll dimer protein with Zn pheophorbide a methyl ester matching geometry of purple bacterial special pair, SP1-ZnPPaM
7UNI	;	2.5	;	De novo designed chlorophyll dimer protein with Zn pheophorbide a methyl ester, SP2-ZnPPaM
8OYV	;	2.79	;	De novo designed Claudin fold CLF_4
7Q1Q	;	1.0	;	De novo designed homo-dimeric antiparallel helices Homomer-S
6N9H	;	1.039	;	De novo designed homo-trimeric amantadine-binding protein
6NAF	;	2.5	;	De novo designed homo-trimeric amantadine-binding protein
6NAF	;	1.923	;	De novo designed homo-trimeric amantadine-binding protein
8FLX	;	4.5	;	De novo designed homotrimer; the fusion product of BGL17 and DHR59
8EK4	;	2.35	;	De novo designed ice-binding proteins from twist-constrained helices
6VFJ	;	5.35	;	De novo designed icosahedral nanoparticle I53_dn5
6W90	;	1.5	;	De novo designed NTF2 fold protein NT-9
6VFI	;	4.54	;	De novo designed octahedral nanoparticle O43_dn18
1PBZ	;		;	DE NOVO DESIGNED PEPTIDE-METALLOPORPHYRIN COMPLEX, SOLUTION STRUCTURE
7VTY	;	2.5	;	de novo designed protein
8JU8	;	1.85	;	de novo designed protein
6YWC	;	2.85	;	De novo designed protein 4E1H_95 in complex with 101F antibody
6YWD	;	3.2	;	De novo designed protein 4H_01 in complex with Mota antibody
7VQW	;	2.45	;	de novo designed protein based on 1r26
6NUK	;	1.92	;	De novo designed protein Ferredog-Diesel
6MRR	;	1.18	;	De novo designed protein Foldit1
6MSP	;		;	De novo Designed Protein Foldit3
6WI5	;	1.83	;	De novo designed protein Foldit4
7DGU	;	1.75	;	De novo designed protein H4A1R
7DGW	;	1.35	;	De novo designed protein H4A2S
7DGY	;	1.8	;	De novo designed protein H4C2R
1LQ7	;		;	De Novo Designed Protein Model of Radical Enzymes
6MRS	;	1.541	;	De novo designed protein Peak6
6W9Y	;	2.55	;	De novo designed receptor transmembrane domains enhance CAR-T cytotoxicity and attenuate cytokine release
6W9Z	;	2.7	;	De novo designed receptor transmembrane domains enhance CAR-T cytotoxicity and attenuate cytokine release
6WA0	;	3.484	;	De novo designed receptor transmembrane domains enhance CAR-T cytotoxicity and attenuate cytokine release
8OYW	;	1.5	;	De novo designed rhomboid protease-like fold RPF_9
6VGB	;		;	De novo designed Rossmann fold protein ROS2_36830
6VG7	;		;	De novo designed Rossmann fold protein ROS2_49223
6VGA	;		;	De novo designed Rossmann fold protein ROS2_835
8OYX	;	2.11	;	De novo designed soluble GPCR-like fold GLF_18
8OYY	;	1.85	;	De novo designed soluble GPCR-like fold GLF_32
6VFH	;	3.86	;	De novo designed tetrahedral nanoparticle T33_dn10
6VFK	;	4.25	;	De novo designed tetrahedral nanoparticle T33_dn10 displaying 4 copies of BG505-SOSIP trimer on the surface
6VL6	;	4.6	;	De novo designed tetrahedral nanoparticle T33_dn2 presenting BG505 SOSIP trimers
8OYS	;	1.34	;	De novo designed TIM barrel fold TBF_24
7RMY	;	3.17	;	De Novo designed tunable protein pockets, D_3-337
7JH6	;	3.5	;	De novo designed two-domain di-Zn(II) and porphyrin-binding protein
2XYY	;	3.8	;	De Novo model of Bacteriophage P22 procapsid coat protein
2XYZ	;	4.0	;	De Novo model of Bacteriophage P22 virion coat protein
4GN0	;	1.75	;	De novo phasing of a Hamp-complex using an improved Arcimboldo method
8D9P	;	1.9	;	De Novo Photosynthetic Reaction Center Protein Equipped with Heme B and Mn(II) cations
5VJT	;	1.45	;	De Novo Photosynthetic Reaction Center Protein Equipped with Heme B and Zn(II) cations
5VJS	;	2.0	;	De Novo Photosynthetic Reaction Center Protein Equipped with Heme B, a synthetic Zn porphyrin, and Zn(II) cations
8D9O	;	1.78	;	De Novo Photosynthetic Reaction Center Protein in Apo-State
5VJU	;	2.08	;	De Novo Photosynthetic Reaction Center Protein Variant Equipped with His-Tyr H-bond, Heme B, and Cd(II) ions
6VTW	;	2.6	;	De novo protein design enables the precise induction of RSV-neutralizing antibodies
8AH9	;	1.747	;	De novo retro-aldolase RAbetaB-16.1
8BL3	;	2.8	;	De novo single-chain immunoglobulin dimer scIg12
8BL6	;	2.8	;	De novo single-chain immunoglobulin dimer scIg12+EF3a
5FOZ	;	2.4	;	De novo structure of the binary mosquito larvicide BinAB at pH 10
5FOY	;	2.25	;	De novo structure of the binary mosquito larvicide BinAB at pH 7
7SKP	;	2.5	;	De novo synthetic protein DIG14 (tetragonal space group)
7SKO	;	2.05	;	De novo synthetic protein DIG8-CC (orthogonal space group)
7SKN	;	2.3	;	De novo synthetic protein DIG8-CC (tetragonal space group)
5U9U	;	1.69	;	De Novo Three-stranded Coiled Coil Peptide Containing a Tris-thiolate Site Engineered by D-Cysteine Ligands
6WXO	;	1.41	;	De novo TIM barrel-ferredoxin fold fusion homodimer with 2-histidine 2-glutamate centre TFD-HE
6WXP	;	2.5	;	De novo TIM barrel-ferredoxin fold fusion homodimer with 4-glutamate centre TFD-EE
8WAT	;	2.82	;	De novo transcribing complex 10 (TC10), the early elongation complex with Pol II positioned 10nt downstream of TSS
8WAU	;	2.78	;	De novo transcribing complex 11 (TC11), the early elongation complex with Pol II positioned 11nt downstream of TSS
8WAV	;	2.72	;	De novo transcribing complex 12 (TC12), the early elongation complex with Pol II positioned 12nt downstream of TSS
8WAW	;	3.02	;	De novo transcribing complex 13 (TC13), the early elongation complex with Pol II positioned 13nt downstream of TSS
8WAX	;	2.75	;	De novo transcribing complex 14 (TC14), the early elongation complex with Pol II positioned 14nt downstream of TSS
8WAY	;	2.85	;	De novo transcribing complex 15 (TC15), the early elongation complex with Pol II positioned 15nt downstream of TSS
8WAZ	;	2.76	;	De novo transcribing complex 16 (TC16), the early elongation complex with Pol II positioned 16nt downstream of TSS
8WB0	;	2.94	;	De novo transcribing complex 17 (TC17), the early elongation complex with Pol II positioned 17nt downstream of TSS
7FB8	;		;	De Novo-Designed and Disulfide-Bridged Peptide Heterodimer - hd1
7FBA	;		;	De Novo-Designed and Disulfide-Bridged Peptide Heterodimer - hd2
6Z35	;		;	De-novo Maquette 2 protein with buried ion-pair
2AGA	;		;	De-ubiquitinating function of ataxin-3: insights from the solution structure of the Josephin domain
1W2N	;	2.7	;	Deacetoxycephalosporin C synthase (with a N-terminal his-tag) in complex with Fe(II) and ampicillin
1W2O	;	3.0	;	Deacetoxycephalosporin C synthase (with a N-terminal his-tag) in complex with Fe(II) and deacetoxycephalosporin C
1W2A	;	2.51	;	Deacetoxycephalosporin C synthase (with his-tag) complexed with Fe(II) and ethylene glycol
1UNB	;	1.5	;	Deacetoxycephalosporin C synthase complexed with 2-oxoglutarate and ampicillin
1UOB	;	1.7	;	Deacetoxycephalosporin C synthase complexed with 2-oxoglutarate and penicillin G
2JB8	;	1.53	;	Deacetoxycephalosporin C synthase complexed with 5-hydroxy-4-keto valeric acid
1UOG	;	1.7	;	Deacetoxycephalosporin C synthase complexed with deacetoxycephalosporin C
1RXF	;	1.5	;	DEACETOXYCEPHALOSPORIN C SYNTHASE COMPLEXED WITH FE(II)
1RXG	;	1.5	;	DEACETOXYCEPHALOSPORIN C SYNTHASE COMPLEXED WITH FE(II) AND 2-OXOGLUTARATE
1UOF	;	1.6	;	Deacetoxycephalosporin C synthase complexed with Penicillin G
1UO9	;	1.5	;	Deacetoxycephalosporin C synthase complexed with succinate
1DCS	;	1.3	;	DEACETOXYCEPHALOSPORIN C SYNTHASE FROM S. CLAVULIGERUS
6O2R	;	3.3	;	Deacetylated Microtubules
6O2S	;	4.0	;	Deacetylated Microtubules
4ACP	;	2.49	;	Deactivation of human IgG1 Fc by endoglycosidase treatment
6ZKS	;	3.1	;	Deactive complex I, open1
6ZKT	;	2.8	;	Deactive complex I, open2
6ZKU	;	3.0	;	Deactive complex I, open3
6ZKV	;	2.9	;	Deactive complex I, open4
7W31	;	3.1	;	Deactive state CI from DQ-NADH dataset, Subclass 1
7W32	;	2.9	;	Deactive state CI from DQ-NADH dataset, Subclass 2
7W35	;	3.0	;	Deactive state CI from DQ-NADH dataset, Subclass 3
7W4J	;	3.2	;	Deactive state CI from Q1-NADH dataset, Subclass 1
7W4K	;	3.2	;	Deactive state CI from Q1-NADH dataset, Subclass 2
7W4L	;	3.1	;	Deactive state CI from Q1-NADH dataset, Subclass 3
7W4M	;	3.3	;	Deactive state CI from Q1-NADH dataset, Subclass 4
7W4N	;	3.0	;	Deactive state CI from Q1-NADH dataset, Subclass 5
7W4Q	;	3.3	;	Deactive state CI from Q1-NADH dataset, Subclass 6
7W00	;	3.5	;	Deactive state CI from Q10 dataset, Subclass 1
7W0H	;	3.4	;	Deactive state CI from Q10 dataset, Subclass 2
7W1O	;	3.5	;	Deactive state CI from Q10-NADH dataset, Subclass 1
7W1P	;	3.1	;	Deactive state CI from Q10-NADH dataset, Subclass 2
7W2K	;	2.9	;	Deactive state CI from Rotenone-NADH dataset, Subclass 1
7W2L	;	3.0	;	Deactive state CI from Rotenone-NADH dataset, Subclass 2
7V2K	;	2.7	;	Deactive state complex I from DQ-NADH dataset
7V30	;	2.7	;	Deactive state complex I from Q1-NADH dataset
7V2D	;	3.3	;	Deactive state complex I from Q10 dataset
7V2F	;	3.1	;	Deactive state complex I from Q10-NADH dataset
7V32	;	3.2	;	Deactive state complex I from rotenone dataset
7V3M	;	2.9	;	Deactive state complex I from rotenone-NADH dataset
7PLI	;	2.5	;	DEAD-box helicase DbpA bound to single stranded RNA and ADP/BeF3
7PMQ	;	3.22	;	DEAD-box helicase DbpA in the active conformation bound to a hairpin loop RNA and ADP/BeF3
7PMM	;	3.0	;	DEAD-box helicase DbpA in the active conformation bound to a ss/dsRNA junction and ADP/BeF3
4TYN	;	2.959	;	DEAD-box helicase Mss116 bound to ssDNA and ADP-BeF
4TYW	;	2.197	;	DEAD-box helicase Mss116 bound to ssRNA and ADP-BeF
4TYY	;	2.74	;	DEAD-box helicase Mss116 bound to ssRNA and CDP-BeF
4TZ0	;	2.35	;	DEAD-box helicase Mss116 bound to ssRNA and GDP-BeF
4TZ6	;	3.209	;	DEAD-box helicase Mss116 bound to ssRNA and UDP-BeF
5GI4	;	2.244	;	DEAD-box RNA helicase
5GJU	;	1.6	;	DEAD-box RNA helicase
4PXA	;	3.2	;	DEAD-box RNA helicase DDX3X Cancer-associated mutant D354V
4PX9	;	2.31	;	DEAD-box RNA helicase DDX3X Domain 1 with N-terminal ATP-binding Loop
2IGU	;		;	Deamidated analogue of ImI Conotoxin
1DY5	;	0.87	;	Deamidated derivative of bovine pancreatic ribonuclease
7B7Z	;	1.7	;	DeAMPylation complex of monomeric FICD and AMPylated BiP (state 1)
7B80	;	1.87	;	DeAMPylation complex of monomeric FICD and AMPylated BiP (state 2)
2XZS	;	2.0	;	Death associated protein kinase 1 residues 1-312
1P4F	;	1.9	;	DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH BOUND INHIBITOR FRAGMENT
1E3Y	;		;	Death domain from human FADD/MORT1
1E41	;		;	Death domain from human FADD/MORT1
1FAD	;		;	DEATH DOMAIN OF FAS-ASSOCIATED DEATH DOMAIN PROTEIN, RESIDUES 89-183
1NGR	;		;	DEATH DOMAIN OF P75 LOW AFFINITY NEUROTROPHIN RECEPTOR, RESIDUES 334-418, NMR, 20 STRUCTURES
6FHA	;	2.3	;	Death-associated Protein Kinase 1 (DAPK1) catalytic and auto-regulatory domains with S289A and S308A mutations
6FHB	;	1.75	;	Death-associated Protein Kinase 1 (DAPK1) catalytic and auto-regulatory domains with S289A and S308E mutations
6QMO	;	1.87	;	Death-associated Protein Kinase 1 (DAPK1) catalytic and auto-regulatory domains with S289E and S308A mutations
6QN4	;	2.5	;	Death-associated Protein Kinase 1 (DAPK1) catalytic and auto-regulatory domains with S289E and S308E mutations
2VHA	;	1.0	;	DEBP
4HQH	;	1.8	;	Decamer Fluoro Carbocyclic LNA (R-F-cLNA) crystal structure
1A9B	;	3.2	;	DECAMER-LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO HLA-B3501 DUE TO NONSTANDARD POSITIONING OF THE C-TERMINUS
1A9E	;	2.5	;	DECAMER-LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO HLA-B3501 DUE TO NONSTANDARD POSITIONING OF THE C-TERMINUS
2A3X	;	3.0	;	Decameric crystal structure of human serum amyloid P-component bound to Bis-1,2-{[(Z)-2carboxy- 2-methyl-1,3-dioxane]- 5-yloxycarbonyl}-piperazine
1LGN	;	2.8	;	DECAMERIC DAMP COMPLEX OF HUMAN SERUM AMYLOID P COMPONENT
4K2J	;	2.05	;	Decameric ring structure of KSHV (HHV-8) latency-associated nuclear antigen (LANA) DNA binding domain
2A3W	;	2.2	;	Decameric structure of human serum amyloid P-component bound to Bis-1,2-{[(Z)-2-carboxy-2-methyl-1,3-dioxane]-5-yloxycarbamoyl}-ethane
2HEX	;	2.1	;	DECAMERS OBSERVED IN THE CRYSTALS OF BOVINE PANCREATIC TRYPSIN INHIBITOR
1HH3	;	1.0	;	Decaplanin first P21-Form
1HHA	;	1.9	;	Decaplanin first P6122-Form
1HHF	;	1.47	;	Decaplanin second P6122-Form
1C5B	;	2.1	;	DECARBOXYLASE CATALYTIC ANTIBODY 21D8 UNLIGANDED FORM
1C5C	;	1.61	;	DECARBOXYLASE CATALYTIC ANTIBODY 21D8-HAPTEN COMPLEX
1OK1	;	2.6	;	Decay accelerating factor (cd55) : the structure of an intact human complement regulator.
1OJV	;	2.3	;	Decay accelerating factor (CD55): the structure of an intact human complement regulator.
1OJW	;	2.3	;	Decay accelerating factor (CD55): the structure of an intact human complement regulator.
1OJY	;	2.6	;	Decay accelerating factor (cd55): the structure of an intact human complement regulator.
1OK2	;	2.5	;	Decay accelerating factor (CD55): the structure of an intact human complement regulator.
1OK3	;	2.2	;	Decay accelerating factor (cd55): the structure of an intact human complement regulator.
1OK9	;	3.0	;	Decay accelerating factor (CD55): The structure of an intact human complement regulator.
4ON9	;	2.71	;	DECH box helicase domain
4KP4	;	3.0	;	Deciphering cis-trans directionality and visualizing autophosphorylation in histidine kinases.
1IC2	;	2.0	;	DECIPHERING THE DESIGN OF THE TROPOMYOSIN MOLECULE
5BNL	;	2.0	;	Deciphering the Mechanism of Carbonic Anhydrase Inhibition with Coumarins and Thiocoumarins
6ZRE	;	2.8	;	Deciphering the role of the channel constrictions in the opening mechanism of MexAB-OprM efflux pump from Pseudomonas aeruginosa
7AKZ	;	3.2	;	Deciphering the role of the channel constrictions in the opening mechanism of MexAB-OprM efflux pump from Pseudomonas aeruginosa
6V4B	;	1.75	;	DeCLIC N-terminal Domain 34-202
1MVR	;	12.8	;	Decoding Center & Peptidyl transferase center from the X-ray structure of the Thermus thermophilus 70S ribosome, aligned to the low resolution Cryo-EM map of E.coli 70S Ribosome
2VP7	;	1.65	;	Decoding of methylated histone H3 tail by the Pygo-BCL9 Wnt signaling complex
2VPB	;	1.59	;	Decoding of methylated histone H3 tail by the Pygo-BCL9 Wnt signaling complex
2VPD	;	2.77	;	Decoding of methylated histone H3 tail by the Pygo-BCL9 Wnt signaling complex
2VPE	;	1.7	;	Decoding of methylated histone H3 tail by the Pygo-BCL9 Wnt signaling complex
2VPG	;	1.6	;	Decoding of methylated histone H3 tail by the Pygo-BCL9 Wnt signaling complex
5YAN	;	1.77	;	Deconstructing the Salt-Bridge Network of a Computationally Designed Collagen Heterotrimer
2CL8	;	2.8	;	Dectin-1 in complex with beta-glucan
4CR2	;	7.7	;	Deep classification of a large cryo-EM dataset defines the conformational landscape of the 26S proteasome
4CR3	;	9.3	;	Deep classification of a large cryo-EM dataset defines the conformational landscape of the 26S proteasome
4CR4	;	8.8	;	Deep classification of a large cryo-EM dataset defines the conformational landscape of the 26S proteasome
8VEC	;	2.0	;	Deep Mutational Scanning of SARS-CoV-2 PLpro
8XHO	;	2.5	;	Deep sea bacterial PET plastic hydrolase MtCut with mutation S178C
8JX6	;	2.1	;	Deep-Sea Helicase 9 (DSH9)
4H2L	;	1.779	;	Deer mouse hemoglobin in hydrated format
5KER	;	2.202	;	Deer mouse recombinant hemoglobin from high altitude species
4UF1	;	2.3	;	Deerpox virus DPV022 in complex with Bak BH3
4UF2	;	3.0	;	Deerpox virus DPV022 in complex with Bax BH3
4UF3	;	2.7	;	Deerpox virus DPV022 in complex with Bim BH3
1B8W	;		;	DEFENSIN-LIKE PEPTIDE 1
334D	;	1.8	;	DEFINING GC-SPECIFICITY IN THE MINOR GROOVE: SIDE-BY-SIDE BINDING OF THE DI-IMIDAZOLE LEXITROPSIN TO C-A-T-G-G-C-C-A-T-G
6ID4	;	2.4	;	Defining the structural basis for human alloantibody binding to human leukocyte antigen allele HLA-A*11:01
1VJM	;	2.3	;	Deformation of helix C in the low-temperature L-intermediate of bacteriorhodopsin
5JYK	;	2.297	;	Deg9 crystal under 289K
5ILA	;	3.001	;	Deg9 protease domain
1JTO	;	2.5	;	Degenerate interfaces in antigen-antibody complexes
1JTP	;	1.9	;	Degenerate interfaces in antigen-antibody complexes
1JTT	;	2.1	;	Degenerate interfaces in antigen-antibody complexes
6JW3	;	3.1	;	Degenerate RVD RG forms a distinct loop conformation
6JW4	;	3.09	;	Degenerate RVD RG forms a distinct loop conformation
1HHZ	;	0.99	;	Deglucobalhimycin in complex with cell wall pentapeptide
1HHY	;	0.89	;	Deglucobalhimycin in complex with D-Ala-D-Ala
5O0K	;	2.3	;	Deglycosylated Nogo Receptor with native disulfide structure
5O0Q	;	2.5	;	Deglycosylated Nogo Receptor with native disulfide structure
5O0R	;	2.5	;	Deglycosylated Nogo Receptor with native disulfide structure
5O0L	;	2.511	;	Deglycosylated Nogo Receptor with native disulfide structure 2
5O0M	;	1.9	;	Deglycosylated Nogo Receptor with native disulfide structure 3
5O0N	;	2.5	;	Deglycosylated Nogo Receptor with native disulfide structure 4
5O0O	;	2.2	;	Deglycosylated Nogo Receptor with native disulfide structure 5
5O0P	;	2.0	;	Deglycosylated Nogo Receptor with native disulfide structure 6
4A8D	;	28.0	;	DegP dodecamer with bound OMP
2XT0	;	1.9	;	Dehalogenase DPpA from Plesiocystis pacifica SIR-I
6A41	;	1.97	;	Dehalogenation enzyme
5V5R	;	1.2	;	Dehaloperoxidase A I9L mutant
1EWA	;	2.5	;	Dehaloperoxidase and 4-iodophenol
6I7F	;	1.85	;	Dehaloperoxidase B from Amphitrite ornata - complex with 2,4-dichlorophenol
6I6G	;	1.85	;	Dehaloperoxidase B from Amphitrite ornata - complex with 5-bromoindole
5K1L	;	1.08	;	Dehaloperoxidase B from Amphitrite ornata: benzimidazole complex
5LLZ	;	1.14	;	Dehaloperoxidase B from Amphitrite ornata: benzotriazole complex
5LKV	;	1.08	;	Dehaloperoxidase B from Amphitrite ornata: imidazole complex
5LK9	;	1.12	;	Dehaloperoxidase B from Amphitrite ornata: indazole complex
8DOI	;	1.93	;	Dehaloperoxidase B in complex with 2,2'-Biphenol
8DOJ	;	1.3	;	Dehaloperoxidase B in complex with 3,3'-Biphenol
6CKE	;	1.37	;	Dehaloperoxidase B in complex with 4-Br-guaiacol
6CRE	;	1.58	;	Dehaloperoxidase B in complex with 5-Br-ortho-guaiacol
6CO5	;	1.686	;	Dehaloperoxidase B in complex with 6-Br-ortho-guaiacol
8DOG	;	1.48	;	Dehaloperoxidase B in complex with Bisphenol E
8DOH	;	1.75	;	Dehaloperoxidase B in complex with Bisphenol F
6CH6	;	1.7	;	Dehaloperoxidase B in complex with substrate 2,4-dimethoxyphenol
6ONX	;	1.7	;	Dehaloperoxidase B in complex with substrate 4-Br-cresol
6ONK	;	1.5	;	Dehaloperoxidase B in complex with substrate 4-Cl-cresol
6ONR	;	1.35	;	Dehaloperoxidase B in complex with substrate 4-methyl-cresol
6CH5	;	1.65	;	Dehaloperoxidase B in complex with substrate 4-Nitroguaiacol
6OO1	;	1.602	;	Dehaloperoxidase B in complex with substrate o-cresol
6OO6	;	2.1	;	Dehaloperoxidase B in complex with substrate p-cresol
5CHR	;	1.98	;	Dehaloperoxidase B in complex with substrate p-nitrocatechol
5CHQ	;	1.87	;	Dehaloperoxidase B in complex with substrate p-nitrophenol
6OO8	;	1.8	;	Dehaloperoxidase B in complex with substrate pentachlorophenol
6ONZ	;	1.8	;	Dehaloperoxidase B in complex with substtrate 4-nitro-cresol
5V5Q	;	1.961	;	Dehaloperoxidase B L9I mutant
5VLX	;	1.8	;	Dehaloperoxidase B mutant F21W
5VTS	;	1.571	;	Dehaloperoxidase B Y28F mutant
5VTT	;	1.903	;	Dehaloperoxidase B Y38F mutant
4JAC	;	1.934	;	Dehaloperoxidase-Hemoglobin T56S
6ONG	;	1.42	;	Dehaloperoxidate B in complex with substrate 4-F-cresol
8FZQ	;	4.3	;	Dehosphorylated, ATP-bound human cystic fibrosis transmembrane conductance regulator (CFTR)
5BP2	;	1.75	;	Dehydratase domain (DH) of a mycocerosic acid synthase-like (MAS-like) PKS, crystal form 1
5BP3	;	1.45	;	Dehydratase domain (DH) of a mycocerosic acid synthase-like (MAS-like) PKS, crystal form 2
3KG6	;	2.7	;	Dehydratase domain from CurF module of Curacin polyketide synthase
3KG7	;	2.77	;	Dehydratase domain from CurH module of Curacin polyketide synthase
3KG8	;	2.45	;	Dehydratase domain from CurJ module of Curacin polyketide synthase
3KG9	;	1.7	;	Dehydratase domain from CurK module of Curacin polyketide synthase
7ZMF	;	2.21	;	Dehydratase domain of module 3 from Brevibacillus Brevis orphan BGC11
4OOC	;	2.7	;	Dehydratase domain of the polyketide PpsC from Mycobacterium tuberculosis
6M7Y	;	2.794	;	Dehydratase, NisB, bound to a non-eliminable substrate analog
1OS3	;	1.95	;	Dehydrated T6 human insulin at 100 K
1OS4	;	2.25	;	Dehydrated T6 human insulin at 295 K
4LTG	;	1.18	;	Dehydration/Rehydration of a Nucleic Acid system containing a Polypyridyl Ruthenium Complex at 74% relative humidity (2/7)
4LTI	;	1.41	;	Dehydration/Rehydration of a Nucleic Acid system containing a Polypyridyl Ruthenium Complex at 74% relative humidity (4/7)
4LTK	;	1.45	;	Dehydration/Rehydration of a Nucleic Acid system containing a Polypyridyl Ruthenium Complex at 74% relative humidity (6/7)
4LTH	;	1.6	;	Dehydration/Rehydration of a Nucleic Acid system containing a Polypyridyl Ruthenium Complex at 97% relative humidity (3/7)
4LTJ	;	1.8	;	Dehydration/Rehydration of a Nucleic Acid system containing a Polypyridyl Ruthenium Complex at 97% relative humidity (5/7)
4LTL	;	2.07	;	Dehydration/Rehydration of a Nucleic Acid system containing a Polypyridyl Ruthenium Complex at 97% relative humidity (7/7)
4LTF	;	1.5	;	Dehydration/Rehydration of a Nucleic Acid system containing a Polypyridyl Ruthenium Complex at 97% relative humidity(1/7)
6NDT	;	1.424	;	Dehydroalanine intermediate of the FlgE D2 domain
5D9W	;	1.6897	;	Dehydroascorbate reductase (OsDHAR) complexed with ASA
5N9U	;		;	Dehydroascorbate reductase 3A from Populus trichocarpa complexed with GSH.
5D9X	;	1.68	;	Dehydroascorbate reductase complexed with GSH
4QI5	;	2.4	;	Dehydrogenase domain of Myriococcum thermophilum cellobiose dehydrogenase with bound cellobionolactam, MtDH
4QI4	;	2.7	;	Dehydrogenase domain of Myriococcum thermophilum cellobiose dehydrogenase, MtDH
7E5Z	;	3.6	;	Dehydrogenase holoenzyme
5SWV	;	2.65	;	Dehydroquinate dehydratase and shikimate dehydrogenase from S. pombe AroM
5SWU	;	2.1	;	Dehydroquinate dehydratase from A. fumigatus AroM
8CKA	;	2.52	;	Deinococcus radidurans HPI S-layer
4Q0H	;	1.157	;	Deinococcus radiodurans BphP PAS-GAF
4Q0I	;	1.744	;	Deinococcus radiodurans BphP PAS-GAF D207A mutant
7Z9D	;	1.88	;	Deinococcus radiodurans BphP PAS-GAF H260A mutant
7Z9E	;	1.48	;	Deinococcus radiodurans BphP PAS-GAF H260A/Y263F mutant
6FTD	;	1.4	;	Deinococcus radiodurans BphP PAS-GAF H290T mutant
5NFX	;	1.34	;	Deinococcus radiodurans BphP PAS-GAF Y263F mutant
5NWN	;	3.6	;	Deinococcus radiodurans BphP PAS-GAF-PHY Y263F mutant, dark
5NM3	;	3.3	;	Deinococcus radiodurans BphP PAS-GAF-PHY Y263F mutant, pre-illuminated
4Q0J	;	2.747	;	Deinococcus radiodurans BphP photosensory module
4TRT	;	2.0	;	Deinococcus radiodurans DNA polymerase III subunit beta
2XQC	;	1.9	;	DEINOCOCCUS RADIODURANS ISDRA2 TRANSPOSASE COMPLEXED WITH LEFT END RECOGNITION AND CLEAVAGE SITE AND ZN
2XM3	;	2.3	;	Deinococcus radiodurans ISDra2 Transposase Left end DNA complex
2XMA	;	2.3	;	DEINOCOCCUS RADIODURANS ISDRA2 TRANSPOSASE RIGHT END DNA COMPLEX
2XO6	;	1.9	;	DEINOCOCCUS RADIODURANS ISDRA2 TRANSPOSASE Y132F MUTANT COMPLEXED WITH LEFT END RECOGNITION AND CLEAVAGE SITE
1XP8	;	2.5	;	Deinococcus radiodurans RecA in complex with ATP-gamma-S
8B0Q	;	1.8	;	Deinococcus radiodurans UvrC C-terminal half
5JEU	;	0.97	;	del-[Ru(phen)2(dppz)]2+ bound to d(TCGGCGCCGA) with Ba2+
5JEV	;	0.99	;	del-[Ru(phen)2(dppz]2+ bound to d(TCGGCGCCGA) with Cobalt hexammine
2UYA	;	2.0	;	DEL162-163 mutant of Bacillus subtilis Oxalate Decarboxylase OxdC
2Z2B	;	1.85	;	Deletion 107-116 mutant of dihydroorotase from E. coli
1NVJ	;	2.15	;	Deletion Mutant (Delta 141) of Molybdopterin Synthase
4CGT	;	2.6	;	DELETION MUTANT DELTA(145-150), F151D OF CYCLODEXTRIN GLYCOSYLTRANSFERASE
1OOZ	;	2.1	;	Deletion mutant of SUCCINYL-COA:3-KETOACID COA TRANSFERASE FROM PIG HEART
1OPE	;	2.5	;	Deletion mutant of SUCCINYL-COA:3-KETOACID COA TRANSFERASE FROM PIG HEART
1B21	;	2.0	;	DELETION OF A BURIED SALT BRIDGE IN BARNASE
1B2Z	;	2.03	;	DELETION OF A BURIED SALT BRIDGE IN BARNASE
1B20	;	1.7	;	DELETION OF A BURIED SALT-BRIDGE IN BARNASE
5K94	;	2.1	;	Deletion-Insertion Chimera of MBP with the Preprotein Cross-Linking Domain of the SecA ATPase
2K7V	;		;	Deletions in a surface loop divert the folding of a protein domain into a metastable dimeric form
6JYT	;	2.8	;	Delicate structural coordination of the Severe Acute Respiratory Syndrome coronavirus Nsp13 upon ATP hydrolysis
7TOV	;	3.16	;	Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 1-RBD-up conformation; consensus state D2
7TP7	;	3.48	;	Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 1-RBD-up conformation; Subclassification D11 state
7TP8	;	3.4	;	Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 1-RBD-up conformation; Subclassification D12 state
7TP9	;	3.48	;	Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 1-RBD-up conformation; Subclassification D13 state
7TPA	;	3.6	;	Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 1-RBD-up conformation; Subclassification D14 state
7TPC	;	3.91	;	Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 1-RBD-up conformation; Subclassification D15 state
7TPE	;	4.0	;	Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 1-RBD-up conformation; Subclassification D16 state
7TPF	;	3.4	;	Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 1-RBD-up conformation; Subclassification D17 state
7TPH	;	3.58	;	Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 2-RBD-up conformation - D3
7TOU	;	3.24	;	Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 3-RBD-down conformation; consensus state D1
7TP2	;	3.72	;	Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 3-RBD-down conformation; Subclassification D10 state
7TOX	;	3.62	;	Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 3-RBD-down conformation; Subclassification D5 state
7TOY	;	3.53	;	Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 3-RBD-down conformation; Subclassification D6 state
7TOZ	;	4.07	;	Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 3-RBD-down conformation; Subclassification D7 state
7TP0	;	3.57	;	Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 3-RBD-down conformation; Subclassification D8 state
7TP1	;	3.81	;	Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 3-RBD-down conformation; Subclassification D9 state
7TPL	;	3.87	;	Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the M1 conformation, D4
3EIN	;	1.126	;	Delta class GST
7ZJL	;	2.6	;	Delta SARS-CoV-2 spike protein in complex with REGN10987 Fab homologue.
7WG9	;	3.5	;	Delta Spike Trimer(1 RBD Up)
7WG8	;	3.9	;	Delta Spike Trimer(3 RBD Down)
7VHH	;	3.8	;	Delta variant of SARS-CoV-2 Spike protein
1U81	;		;	Delta-17 Human ADP Ribosylation Factor 1 Complexed with GDP
2GDJ	;	2.5	;	Delta-62 RADA recombinase in complex with AMP-PNP and magnesium
1VTX	;		;	DELTA-ATRACOTOXIN-HV1 (VERSUTOXIN) FROM HADRONYCHE VERSUTA, NMR, 20 STRUCTURES
1CBY	;	2.6	;	DELTA-ENDOTOXIN
7PTY	;	4.63	;	Delta-latroinsectotoxin dimer
6GFK	;	2.3	;	delta-N METTL16 MTase domain
1E5I	;	2.1	;	DELTA-R306 DEACETOXYCEPHALOSPORIN C SYNTHASE COMPLEXED WITH IRON AND 2-OXOGLUTARATE.
1E5H	;	1.96	;	DELTA-R307A DEACETOXYCEPHALOSPORIN C SYNTHASE COMPLEXED WITH SUCCINATE AND CARBON DIOXIDE
8CII	;	2.7	;	Delta-RBD complex with BA.2-07 fab, SARS1-34 fab and C1 nanobody
1DTC	;		;	DELTA-TOXIN AND ANALOGUES AS PEPTIDE MODELS FOR PROTEIN ION CHANNELS
2DTB	;		;	DELTA-TOXIN AND ANALOGUES AS PEPTIDE MODELS FOR PROTEIN ION CHANNELS
1FD6	;		;	DELTA0: A COMPUTATIONALLY DESIGNED CORE VARIANT OF THE B1 DOMAIN OF STREPTOCOCCAL PROTEIN G
1FCL	;		;	DELTA1.5: A COMPUTATIONALLY DESIGNED CORE VARIANT OF THE B1 DOMAIN OF STREPTOCOCCAL PROTEIN G
6SKJ	;	2.8	;	DeltaC2 C-terminal truncation of HsNMT1 in complex with MyrCoA and GNCFSKPR substrates
6SK8	;	1.87	;	DeltaC3 C-terminal truncation of HsNMT1 in complex with MyrCoA and GDCFSKPR substrates
7EMK	;	2.3	;	Dendrorhynchus zhejiangensis ferritin
4CCT	;	4.5	;	Dengue 1 cryo-EM reconstruction
5EC8	;	1.714	;	DENGUE 3 NS5 METHYLTRANSFERASE BOUND TO S-ADENOSYL METHIONINE AND COMPOUND BF175
4CTK	;	1.53	;	DENGUE 3 NS5 METHYLTRANSFERASE BOUND TO S-ADENOSYL METHIONINE AND FRAGMENT 2A4
4CTJ	;	1.47	;	DENGUE 3 NS5 METHYLTRANSFERASE BOUND TO S-ADENOSYL METHIONINE AND FRAGMENT 3A9
5EIF	;	1.5	;	DENGUE 3 NS5 METHYLTRANSFERASE BOUND TO S-ADENOSYL METHIONINE AND FRAGMENT NB2C3
5EIW	;	1.611	;	DENGUE 3 NS5 METHYLTRANSFERASE BOUND TO S-ADENOSYL METHIONINE AND FRAGMENT NB3C2
5E9Q	;	1.79	;	DENGUE 3 NS5 METHYLTRANSFERASE BOUND TO S-ADENOSYL METHIONINE AND MOLECULE BF174
5EHI	;	1.303	;	DENGUE 3 NS5 METHYLTRANSFERASE BOUND TO S-ADENOSYL METHIONINE AND MOLECULE BF287
5EHG	;	2.02	;	DENGUE 3 NS5 METHYLTRANSFERASE BOUND TO S-ADENOSYL METHIONINE AND MOLECULE BF341
5EKX	;	1.76	;	DENGUE 3 NS5 METHYLTRANSFERASE BOUND TO S-ADENOSYLMETHIONINE AND FRAGMENT NB2E11
3P97	;	1.7	;	Dengue 3 NS5 Methyltransferase bound to the substrate S-Adenosyl methionine
5JJS	;	1.65	;	Dengue 3 NS5 protein with compound 27
5JJR	;	1.99	;	Dengue 3 NS5 protein with compound 29
1L9K	;	2.4	;	dengue methyltransferase
3P8Z	;	1.7	;	Dengue Methyltransferase bound to a SAM-based inhibitor
4R8S	;	1.48	;	Dengue serotype 3 methyltransferase bound to Sinefungin
4HHJ	;	1.79	;	Dengue serotype 3 RNA-dependent RNA polymerase
5HMX	;	2.4	;	Dengue serotype 3 RNA-dependent RNA polymerase bound to compound 10
5HMY	;	2.1	;	Dengue serotype 3 RNA-dependent RNA polymerase bound to compound 15
5HMZ	;	1.99	;	Dengue serotype 3 RNA-dependent RNA polymerase bound to compound 23
5I3P	;	2.45	;	DENGUE SEROTYPE 3 RNA-DEPENDENT RNA POLYMERASE BOUND TO COMPOUND 27
5I3Q	;	1.88	;	DENGUE SEROTYPE 3 RNA-DEPENDENT RNA POLYMERASE BOUND TO COMPOUND 29
5HN0	;	2.05	;	Dengue serotype 3 RNA-dependent RNA polymerase bound to compound 4
5HMW	;	2.15	;	Dengue serotype 3 RNA-dependent RNA polymerase bound to compound 5
5F41	;	2.0	;	DENGUE SEROTYPE 3 RNA-DEPENDENT RNA POLYMERASE BOUND TO FD-83-KI26
5F3T	;	2.05	;	Dengue serotype 3 RNA-dependent RNA polymerase bound to JF-31-MG46
3VWS	;	2.1	;	Dengue serotype 3 RNA-dependent RNA polymerase bound to NITD-107
6XD0	;	2.012	;	Dengue serotype 3 RNA-dependent RNA polymerase bound to NITD-434
6XD1	;	1.954	;	Dengue serotype 3 RNA-dependent RNA polymerase bound to NITD-640
5F3Z	;	2.0	;	Dengue serotype 3 RNA-dependent RNA polymerase bound to PC-79-SH52
4O6B	;	3.0005	;	Dengue Type2 Virus Non-structural protein 1 (NS1) Form 1 crystal
5XC7	;	2.1	;	Dengue Virus 4 NS3 Helicase D290A mutant
2JLS	;	2.23	;	Dengue virus 4 NS3 helicase in complex with ADP
2JLR	;	2.0	;	Dengue virus 4 NS3 helicase in complex with AMPPNP
2JLU	;	2.04	;	Dengue virus 4 NS3 helicase in complex with ssRNA
2JLZ	;	2.2	;	Dengue virus 4 NS3 helicase in complex with ssRNA and ADP
2JLY	;	2.4	;	Dengue virus 4 NS3 helicase in complex with ssRNA and ADP-Phosphate
2JLX	;	2.2	;	Dengue virus 4 NS3 helicase in complex with ssRNA and ADP-Vanadate
2JLV	;	1.9	;	Dengue virus 4 NS3 helicase in complex with ssRNA and AMPPNP
5XC6	;	2.9	;	Dengue Virus 4 NS3 Helicase in complex with SSRNA SLA12
2JLW	;	2.6	;	Dengue virus 4 NS3 helicase in complex with ssRNA2
2JLQ	;	1.67	;	Dengue virus 4 NS3 helicase structure, apo enzyme.
4V0R	;	2.4	;	DENGUE VIRUS FULL LENGTH NS5 COMPLEXED WITH GTP AND SAH
4V0Q	;	2.3	;	Dengue Virus Full Length NS5 Complexed with SAH
5DTO	;	2.603	;	Dengue virus full length NS5 complexed with viral Cap 0-RNA and SAH
5ZQK	;	2.3	;	Dengue Virus Non Structural Protein 5
4OIG	;	2.69	;	Dengue Virus Non-structural Protein NS1
4M9F	;	2.7	;	Dengue virus NS2B-NS3 protease A125C variant at pH 8.5
2FOM	;	1.5	;	Dengue Virus NS2B/NS3 Protease
2J7U	;	1.85	;	Dengue virus NS5 RNA dependent RNA polymerase domain
2J7W	;	2.6	;	Dengue virus NS5 RNA dependent RNA polymerase domain complexed with 3' dGTP
3U1I	;	2.3	;	Dengue virus protease covalently bound to a peptide
4C11	;	2.6	;	Dengue virus RNA dependent RNA polymerase with residues from the NS5 linker region
2BHR	;	2.8	;	Dengue virus RNA helicase
2BMF	;	2.41	;	Dengue virus RNA helicase at 2.4A
7LYF	;	3.4	;	Dengue virus RNA promoter stem-loop A fused with tRNA-scaffold
4R8R	;	1.46	;	Dengue virus serotype 3 methyltransferase without a bound S-adenosyl methionine
6H80	;	2.3	;	Dengue-RdRp3-inhibitor complex co-crystallisation
6H9R	;	2.4	;	Dengue-RdRp3-inhibitor complex soaking
6VG5	;	1.5	;	DengueV-2 Capsid ST148 inhibitor Complex
6VSO	;	3.001	;	DengueV-2 Capsid Structure
2H5F	;	1.9	;	Denmotoxin: A the three-finger toxin from colubrid snake Boiga dendrophila with bird-specific activity
3KYV	;	1.1	;	Denovo X-ray crystal structure determination of H-labeled perdeuterated rubredoxin at 100K
7P12	;	1.69	;	DeNovoTIM13-SB, a de novo designed TIM barrel with a salt-bridge cluster
7OSV	;	1.66	;	DeNovoTIM6-SB, a de novo designed TIM barrel with a salt-bridge cluster (crystal form 1)
7OT8	;	2.22	;	DeNovoTIM6-SB, a de novo designed TIM barrel with a salt-bridge cluster (crystal form 2)
7K7H	;	3.0	;	Density-fitted Model Structure of Antibody Variable Domains of TyTx1 in Complex with PltB pentamer of Typhoid Toxin
6VX4	;	3.12	;	Density-fitted Model Structure of Antibody Variable Domains of TyTx11 in Complex with Typhoid Toxin
7K7I	;	3.13	;	Density-fitted Model Structure of Antibody Variable Domains of TyTx4 in Complex with PltB pentamer of Typhoid Toxin
6WEQ	;	3.2	;	DENV1 NS1 in complex with neutralizing 2B7 Fab fragment
7K4L	;		;	DENV1 SLA bottom stem RNA (DenvBS)
7UMC	;		;	DENV1 SLA RNA (DenvSLATL)
7UMD	;		;	DENV1 SLA three-way junction RNA (DenvSLAsh)
7UME	;		;	DENV1 SLA top stemloop RNA (DenvTSL)
6WER	;	3.96	;	DENV2 NS1 in complex with neutralizing 2B7 Fab fragment
7K93	;	2.89	;	DENV2 NS1 in complex with neutralizing 2B7 single chain Fab variable region (scFv)
7V3J	;	4.9	;	DENV2:F(ab')2-local
7V3F	;	3.1	;	DENV2_NGC_Fab_C10 28degree (1Fab:3E)
7V3G	;	3.3	;	DENV2_NGC_Fab_C10 28degrees (2Fab:3E)
7V3H	;	3.6	;	DENV2_NGC_Fab_C10 28degrees (3Fab:3E)
7V3I	;	4.4	;	DENV2_NGC_Fab_C10 4degrees (3Fab:3E)
8BCR	;	1.9	;	DENV3 Methyltransferase in complexed with AT-9010 and SAH
4R9N	;	1.869	;	DeoR family transcriptional regulator from Listeria monocytogenes.
1GBU	;	1.8	;	DEOXY (BETA-(C93A,C112G)) HUMAN HEMOGLOBIN
1CG5	;	1.6	;	DEOXY FORM HEMOGLOBIN FROM DASYATIS AKAJEI
1GCV	;	2.0	;	DEOXY FORM HEMOGLOBIN FROM MUSTELUS GRISEUS
5UT8	;	1.78	;	Deoxy form of sperm whale myoglobin H64A
5UTC	;	1.8	;	Deoxy form of sperm whale myoglobin V68A/I107Y
1LFL	;	2.7	;	DEOXY HEMOGLOBIN (90% RELATIVE HUMIDITY)
1O1O	;	1.8	;	Deoxy hemoglobin (A,C:V1M,V62L; B,D:V1M,V67L)
1O1K	;	2.0	;	Deoxy hemoglobin (A,C:V1M; B,D:V1M,V67W)
1O1J	;	1.9	;	Deoxy hemoglobin (A-GLY-C:V1M,L29F,H58Q; B,D:V1M,L106W)
1O1L	;	1.8	;	Deoxy hemoglobin (A-GLY-C:V1M,L29W,H58Q; B,D:V1M)
1O1P	;	1.8	;	Deoxy hemoglobin (A-GLY-C:V1M; B,D:V1M,C93A,N108K)
1O1M	;	1.85	;	Deoxy hemoglobin (A-GLYGLYGLY-C:V1M,L29F,H58Q B,D:V1M,V67W)
1O1N	;	1.8	;	Deoxy hemoglobin (A-GLYGLYGLY-C:V1M,L29W; B,D:V1M)
1A3N	;	1.8	;	DEOXY HUMAN HEMOGLOBIN
1C7B	;	1.803	;	DEOXY RHB1.0 (RECOMBINANT HEMOGLOBIN)
1ABW	;	2.0	;	DEOXY RHB1.1 (RECOMBINANT HEMOGLOBIN)
1C7C	;	1.8	;	DEOXY RHB1.1 (RECOMBINANT HEMOGLOBIN)
1C7D	;	1.8	;	DEOXY RHB1.2 (RECOMBINANT HEMOGLOBIN)
2AWC	;	2.2	;	deoxy-DcrH-Hr
1IBE	;	1.8	;	DEOXY-HAEMOGLOBIN TRAPPED IN THE HIGH-AFFINITY (R) STATE
1A6N	;	1.15	;	DEOXY-MYOGLOBIN, ATOMIC RESOLUTION
1I2L	;	2.3	;	DEOXYCHORISMATE LYASE FROM ESCHERICHIA COLI WITH INHIBITOR
4L7Y	;	1.8	;	Deoxygenated Hb in complex with the allosteric effectors, IRL2500 and 2,3-DPG
1QI8	;	1.8	;	DEOXYGENATED STRUCTURE OF A DISTAL POCKET HEMOGLOBIN MUTANT
2W72	;	1.07	;	DEOXYGENATED STRUCTURE OF A DISTAL SITE HEMOGLOBIN MUTANT PLUS XE
4XDS	;	3.354	;	Deoxyguanosinetriphosphate Triphosphohydrolase from Escherichia coli with Nickel
4X9E	;	3.1	;	DEOXYGUANOSINETRIPHOSPHATE TRIPHOSPHOHYDROLASE from Escherichia coli with two DNA effector molecules
6FM0	;	1.7	;	Deoxyguanylosuccinate synthase (DgsS) and ATP structure at 1.7 Angstrom resolution
6TNH	;	2.21	;	Deoxyguanylosuccinate synthase (DgsS) quaternary structure with AMPPcP, dGMP, Asp, Magnesium at 2.21 Angstrom resolution
6FKO	;	2.1	;	Deoxyguanylosuccinate synthase (DgsS) quaternary structure with ATP, dGMP, hadacidin at 2.1 Angstrom resolution
6FM1	;	2.35	;	Deoxyguanylosuccinate synthase (DgsS) quaternary structure with ATPanddGMP at 2.3 Angstrom resolution
6FLF	;	1.33	;	Deoxyguanylosuccinate synthase (DgsS) structure at 1.33 Angstrom resolution.
6FM3	;	1.95	;	Deoxyguanylosuccinate synthase (DgsS) structure with ADP at 1.9 Angstrom resolution
6RM2	;	2.5	;	Deoxyguanylosuccinate synthase (DgsS) structure with ATP, IMP, Magnesium
5KDQ	;	2.15	;	Deoxyhemoglobin in Complex with an Aryloxyalkanoic acid
4ROL	;	1.7	;	Deoxyhemoglobin in complex with imidazolylacryloyl derivatives
4ROM	;	1.9	;	Deoxyhemoglobin in complex with imidazolylacryloyl derivatives
3WCP	;	1.94	;	Deoxyhemoglobin SH-drug complex
1GLI	;	2.5	;	DEOXYHEMOGLOBIN T38W (ALPHA CHAINS), V1G (ALPHA AND BETA CHAINS)
1RLZ	;	2.15	;	Deoxyhypusine synthase holoenzyme in its high ionic strength, low pH crystal form
1ROZ	;	2.21	;	Deoxyhypusine synthase holoenzyme in its low ionic strength, high pH crystal form
1RQD	;	3.0	;	deoxyhypusine synthase holoenzyme in its low ionic strength, high pH crystal form with the inhibitor GC7 bound in the active site
1DEK	;	2.0	;	DEOXYNUCLEOSIDE MONOPHOSPHATE KINASE COMPLEXED WITH DEOXY-GMP
1DEL	;	2.2	;	DEOXYNUCLEOSIDE MONOPHOSPHATE KINASE COMPLEXED WITH DEOXY-GMP AND AMP
8CI9	;	1.41	;	Deoxypodophyllotoxin Synthase in complex with Tris
6L25	;	1.85	;	Deoxyribonuclease from Staphylococcus aureus
6YBH	;	2.4	;	Deoxyribonucleoside Kinase
2A4A	;	1.84	;	Deoxyribose-phosphate aldolase from P. yoelii
1DUD	;	2.3	;	DEOXYURIDINE 5'-TRIPHOSPHATE NUCLEOTIDE HYDROLASE (D-UTPASE) COMPLEXED WITH THE SUBSTRATE ANALOGUE DEOXYURIDINE 5'-DIPHOSPHATE (D-UDP)
1DUP	;	1.9	;	DEOXYURIDINE 5'-TRIPHOSPHATE NUCLEOTIDO HYDROLASE (D-UTPASE)
7KWL	;		;	Deoxyuridine in DNA Structure: Solution Structure of [d(CGUGAATTCGCG)]2
7BFS	;		;	deoxyxylose nucleic acid hairpin
7BFX	;		;	deoxyxylose nucleic acid hairpin
4ZO4	;	2.57	;	Dephospho-CoA kinase from Campylobacter jejuni.
1JJV	;	2.0	;	DEPHOSPHO-COA KINASE IN COMPLEX WITH ATP
8EJ1	;	6.9	;	Dephosphorylated human delta F508 cystic fibrosis transmembrane conductance regulator (CFTR)
5UAR	;	3.73	;	Dephosphorylated, ATP-free cystic fibrosis transmembrane conductance regulator (CFTR) from zebrafish
5UAK	;	3.87	;	Dephosphorylated, ATP-free human cystic fibrosis transmembrane conductance regulator (CFTR)
2I61	;	1.2	;	Depressant anti-insect neurotoxin, LqhIT2 from Leiurus quinquestriatus hebraeus
4FPD	;	2.65	;	Deprotonation of D96 in bacteriorhodopsin opens the proton uptake pathway
7PED	;	1.93	;	DEPTOR DEP domain tandem (DEPt)
1AHM	;		;	DER F 2, THE MAJOR MITE ALLERGEN FROM DERMATOPHAGOIDES FARINAE, NMR, 10 STRUCTURES
1AHK	;		;	DER F 2, THE MAJOR MITE ALLERGEN FROM DERMATOPHAGOIDES FARINAE, NMR, MINIMIZED AVERAGE STRUCTURE
2PM1	;	1.6	;	Derivative of human alpha-defensin 1 (HNP1)
5TX4	;	1.876	;	Derivative of mouse TGF-beta2, with a deletion of residues 52-71 and K25R, R26K, L51R, A74K, C77S, L89V, I92V, K94R T95K, I98V single amino acid substitutions, bound to human TGF-beta type II receptor ectodomain residues 15-130
3OJO	;	2.5	;	Derivative structure of the UDP-N-acetyl-mannosamine dehydrogenase Cap5O from S. aureus
1JK4	;	2.3	;	DES 1-6 BOVINE NEUROPHYSIN II COMPLEX WITH VASOPRESSIN
7JP3	;	1.95	;	Des-B29,B30-insulin
2LJ5	;		;	Description of the Structural fluctuations of proteins from structure-based calculations of Residual dipolar couplings
7QHH	;	3.6	;	Desensitized state of GluA1/2 AMPA receptor in complex with TARP-gamma 8 (TMD-LBD)
5VOE	;	2.0	;	DesGla-XaS195A Bound to Aptamer 11F7t
5VOF	;	2.25	;	DesGla-XaS195A Bound to Aptamer 11F7t and Rivaroxaban
1DEI	;	1.6	;	DESHEPTAPEPTIDE (B24-B30) INSULIN
3FEI	;	2.4	;	Design and biological evaluation of novel, balanced dual PPARa/g agonists
3FEJ	;	2.01	;	Design and biological evaluation of novel, balanced dual PPARa/g agonists
6KH0	;	2.0	;	Design and crystal structure of protein MOFs with ferritin nanocages as linkers and nickel clusters as nodes
6KH1	;	2.4	;	Design and crystal structure of protein MOFs with ferritin nanocages as linkers and nickel clusters as nodes
6KH3	;	2.3	;	Design and crystal structure of protein MOFs with ferritin nanocages as linkers and nickel clusters as nodes
6KH4	;	2.302	;	Design and crystal structure of protein MOFs with ferritin nanocages as linkers and nickel clusters as nodes
6KH5	;	2.294	;	Design and crystal structure of protein MOFs with ferritin nanocages as linkers and nickel clusters as nodes
2BVX	;	3.2	;	Design and Discovery of Novel, Potent Thrombin Inhibitors with a Solubilizing Cationic P1-P2-Linker
2BXT	;	1.83	;	Design and Discovery of Novel, Potent Thrombin Inhibitors with a Solubilizing Cationic P1-P2-Linker
2BXU	;	2.8	;	Design and Discovery of Novel, Potent Thrombin Inhibitors with a Solubilizing Cationic P1-P2-Linker
3O9L	;	2.4	;	Design and optimisation of new piperidines as renin inhibitors
5K7K	;	2.3	;	Design and Optimization of Biaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7: Discovery of Clinical Candidate PF-05089771
3OAD	;	2.17	;	Design and optimization of new piperidines as renin inhibitors
3OAG	;	2.3	;	Design and optimization of new piperidines as renin inhibitors
3G6Z	;	2.0	;	Design and Preparation of Potent, Non-Peptidic, Bioavailable Renin Inhibitors
3G70	;	2.0	;	Design and Preparation of Potent, Non-Peptidic, Bioavailable Renin Inhibitors
3G72	;	1.9	;	Design and Preparation of Potent, Non-Peptidic, Bioavailable Renin Inhibitors
3QTF	;	1.5703	;	Design and SAR of macrocyclic Hsp90 inhibitors with increased metabolic stability and potent cell-proliferation activity
1L77	;	2.05	;	DESIGN AND STRUCTURAL ANALYSIS OF ALTERNATIVE HYDROPHOBIC CORE PACKING ARRANGEMENTS IN BACTERIOPHAGE T4 LYSOZYME
1L79	;	1.9	;	DESIGN AND STRUCTURAL ANALYSIS OF ALTERNATIVE HYDROPHOBIC CORE PACKING ARRANGEMENTS IN BACTERIOPHAGE T4 LYSOZYME
1L80	;	1.8	;	DESIGN AND STRUCTURAL ANALYSIS OF ALTERNATIVE HYDROPHOBIC CORE PACKING ARRANGEMENTS IN BACTERIOPHAGE T4 LYSOZYME
1L81	;	2.0	;	DESIGN AND STRUCTURAL ANALYSIS OF ALTERNATIVE HYDROPHOBIC CORE PACKING ARRANGEMENTS IN BACTERIOPHAGE T4 LYSOZYME
1L82	;	2.1	;	DESIGN AND STRUCTURAL ANALYSIS OF ALTERNATIVE HYDROPHOBIC CORE PACKING ARRANGEMENTS IN BACTERIOPHAGE T4 LYSOZYME
2L78	;	2.0	;	DESIGN AND STRUCTURAL ANALYSIS OF ALTERNATIVE HYDROPHOBIC CORE PACKING ARRANGEMENTS IN BACTERIOPHAGE T4 LYSOZYME
4KIJ	;	2.8	;	Design and structural analysis of aromatic inhibitors of type II dehydroquinase dehydratase from Mycobacterium tuberculosis - compound 35c [3,4-dihydroxy-5-(3-nitrophenoxy)benzoic acid]
4KI7	;	2.8	;	Design and structural analysis of aromatic inhibitors of type II dehydroquinase from Mycobacterium tuberculosis - compound 41c [3-hydroxy-5-(3-nitrophenoxy)benzoic acid]
4KIU	;	2.4	;	Design and structural analysis of aromatic inhibitors of type II dehydroquinate dehydratase from Mycobacterium tuberculosis - compound 49d [5-[(3-nitrobenzyl)oxy]benzene-1,3-dicarboxylic acid]
4KIW	;	2.57	;	Design and structural analysis of aromatic inhibitors of type II dehydroquinate dehydratase from Mycobacterium tuberculosis - compound 49e [5-[(3-nitrobenzyl)amino]benzene-1,3-dicarboxylic acid]
4FA6	;	2.7	;	Design and Synthesis of a Novel Pyrrolidinyl Pyrido Pyrimidinone Derivative as a Potent Inhibitor of PI3Ka and mTOR
4FAD	;	2.7	;	Design and Synthesis of a Novel Pyrrolidinyl Pyrido Pyrimidinone Derivative as a Potent Inhibitor of PI3Ka and mTOR
3PTG	;	2.43	;	Design and Synthesis of a Novel, Orally Efficacious Tri-substituted Thiophene Based JNK Inhibitor
5TQ4	;	2.3	;	Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin
5TQ5	;	2.3	;	Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin
5TQ6	;	2.06	;	Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin
5TQ7	;	2.1	;	Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin
5TQ8	;	1.59	;	Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin
5TQ3	;	2.69	;	Design and Synthesis of a pan-JAK kinase inhibitor clinical candidate (PF-06263276) suitable for the treatment of inflammatory diseases of the lungs and skin
4B00	;	1.83	;	Design and Synthesis of BACE1 Inhibitors with In Vivo Brain Reduction of beta-Amyloid Peptides (COMPOUND (R)-41)
4AZY	;	1.79	;	Design and Synthesis of BACE1 Inhibitors with In Vivo Brain Reduction of beta-Amyloid Peptides (COMPOUND 10)
3RTP	;	2.4	;	Design and synthesis of brain penetrant selective JNK inhibitors with improved pharmacokinetic properties for the prevention of neurodegeneration
1BIW	;	2.5	;	DESIGN AND SYNTHESIS OF CONFORMATIONALLY-CONSTRAINED MMP INHIBITORS
3OXI	;	2.2	;	Design and Synthesis of Disubstituted Thiophene and Thiazole Based Inhibitors of JNK for the Treatment of Neurodegenerative Diseases
4WHZ	;	1.79	;	Design and Synthesis of Highly Potent and Isoform Selective JNK3 Inhibitors: SAR Studies on Aminopyrazole Derivatives
3QI1	;	2.3	;	Design and synthesis of hydroxyethylamine (hea) BACE-1 inhibitors: prime side chromane-containing inhibitors
9LDB	;	2.2	;	DESIGN AND SYNTHESIS OF NEW ENZYMES BASED ON THE LACTATE DEHYDROGENASE FRAMEWORK
9LDT	;	2.0	;	DESIGN AND SYNTHESIS OF NEW ENZYMES BASED ON THE LACTATE DEHYDROGENASE FRAMEWORK
2Q6B	;	2.0	;	Design and synthesis of novel, conformationally restricted HMG-COA reductase inhibitors
2Q6C	;	2.0	;	Design and synthesis of novel, conformationally restricted HMG-COA reductase inhibitors
3ZPS	;	1.55	;	Design and Synthesis of P1-P3 Macrocyclic Tertiary Alcohol Comprising HIV-1 Protease Inhibitors
3ZPT	;	1.54	;	Design and Synthesis of P1-P3 Macrocyclic Tertiary Alcohol Comprising HIV-1 Protease Inhibitors
3ZPU	;	1.8	;	Design and Synthesis of P1-P3 Macrocyclic Tertiary Alcohol Comprising HIV-1 Protease Inhibitors
3IVH	;	1.8	;	Design and Synthesis of Potent BACE-1 Inhibitors with Cellular Activity: Structure-Activity Relationship of P1 Substituents
3IVI	;	2.2	;	Design and Synthesis of Potent BACE-1 Inhibitors with Cellular Activity: Structure-Activity Relationship of P1 Substituents
4EWO	;	1.8	;	Design and synthesis of potent hydroxyethylamine (hea) bace-1 inhibitors
4EXG	;	1.8	;	Design and synthesis of potent hydroxyethylamine (hea) bace-1 inhibitors
2Q1L	;	2.05	;	Design and Synthesis of Pyrrole-based, Hepatoselective HMG-CoA Reductase Inhibitors
4I0D	;	1.91	;	Design and Synthesis of Thiophene Dihydroisoquinolins as Novel BACE-1 Inhibitors
4I0E	;	1.7	;	Design and Synthesis of Thiophene Dihydroisoquinolins as Novel BACE-1 Inhibitors
4I0F	;	1.8	;	Design and Synthesis of Thiophene Dihydroisoquinolins as Novel BACE-1 Inhibitors
4I0G	;	1.78	;	Design and Synthesis of Thiophene Dihydroisoquinolins as Novel BACE-1 Inhibitors
4I12	;	1.78	;	Design and synthesis of thiophene dihydroisoquinolins as novel BACE-1 inhibitors
4I1C	;	2.0	;	Design and synthesis of thiophene dihydroisoquinolins as novel BACE-1 inhibitors
3RFJ	;	1.78	;	Design of a binding scaffold based on variable lymphocyte receptors of jawless vertebrates by module engineering
3RFS	;	1.7	;	Design of a binding scaffold based on variable lymphocyte receptors of jawless vertebrates by module engineering
2N07	;		;	Design of a Highly Stable Disulfide-Deleted Mutant of Analgesic Cyclic alpha-Conotoxin Vc1.1
5VAV	;		;	Design of a novel cyclic peptide that alleviates symptoms in a murine model of inflammatory bowel disease
6B17	;	1.25	;	Design of a short thermally stable alpha-helix embedded in a macrocycle
6ANF	;		;	Design of a short thermo-stable alpha-helix embedded in a macrocycle
8I4O	;	3.1	;	Design of a split green fluorescent protein for sensing and tracking an beta-amyloid
2I9M	;		;	Design of a-helix based on conformationally restricted libraries
8FG6	;	2.3	;	Design of amyloidogenic peptide traps
2JZQ	;		;	Design of an Active Ultra-Stable Single-Chain Insulin Analog 20 Structures
3FQ9	;	1.35	;	Design of an insulin analog with enhanced receptor-binding selectivity. Rationale, structure, and therapeutic implications
2I9O	;		;	Design of bivalent miniprotein consisting of two independent elements, a b-hairpin peptide and a-helix peptide, tethered by eight glycines
2I9N	;		;	Design of bivalent miniprotein consisting of two independent elements, a b-hairpin peptide and a-helix peptide, tethered by four glycines
2EIO	;	2.6	;	Design of Disulfide-linked Thioredoxin Dimers and Multimers Through Analysis of Crystal Contacts
2EIQ	;	1.9	;	Design of Disulfide-linked Thioredoxin Dimers and Multimers Through Analysis of Crystal Contacts
2EIR	;	2.5	;	Design of Disulfide-linked Thioredoxin Dimers and Multimers Through Analysis of Crystal Contacts
8E55	;	3.85	;	Design of Diverse Asymmetric Pockets in de novo Homo-oligomeric Proteins
1GG8	;	2.31	;	DESIGN OF INHIBITORS OF GLYCOGEN PHOSPHORYLASE: A STUDY OF ALPHA-AND BETA-C-GLUCOSIDES AND 1-THIO-BETA-D-GLUCOSE COMPOUNDS
4B1F	;	2.05	;	Design of Inhibitors of Helicobacter pylori Glutamate Racemase as Selective Antibacterial Agents: Incorporation of Imidazoles onto a Core Pyrazolopyrimidinedione Scaffold to Improve Bioavailabilty
1VL3	;		;	DESIGN OF NEW MIMOCHROMES WITH UNIQUE TOPOLOGY
1MHW	;	1.9	;	Design of non-covalent inhibitors of human cathepsin L. From the 96-residue proregion to optimized tripeptides
6U3I	;	2.9	;	Design of organo-peptides as bipartite PCSK9 antagonists
1EOJ	;	2.1	;	Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures
1EOL	;	2.1	;	Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures
4FGA	;	2.3	;	Design of peptide inhibitors of group II phospholipase A2: Crystal structure of the complex of phospholipsae A2 with a designed tripeptide, Ala- Tyr- Lys at 2.3 A resolution
4GFY	;	2.7	;	Design of peptide inhibitors of phospholipase A2: crystal Structure of phospholipase A2 complexed with a designed tetrapeptide Val - Ilu- Ala - Lys at 2.7 A resolution
1TG4	;	1.7	;	Design of specific inhibitors of groupII phospholipase A2(PLA2): Crystal structure of the complex formed between russells viper PLA2 and designed peptide Phe-Leu-Ala-Tyr-Lys at 1.7A resolution
1SQZ	;	1.2	;	Design of specific inhibitors of Phopholipase A2: Crystal structure of the complex formed between Group II Phopholipase A2 and a designed peptide Dehydro-Ile-Ala-Arg-Ser at 1.2A resolution
1JQ8	;	2.0	;	Design of specific inhibitors of phospholipase A2: Crystal structure of a complex formed between phospholipase A2 from Daboia russelli pulchella and a designed pentapeptide Leu-Ala-Ile-Tyr-Ser at 2.0 resolution
2DO2	;	2.6	;	Design of specific inhibitors of phospholipase A2: Crystal structure of the complex formed between a group II Cys 49 phospholipase A2 and a designed pentapeptide Ala-Leu-Ala-Ser-Lys at 2.6A resolution
1T37	;	2.6	;	Design of specific inhibitors of phospholipase A2: Crystal structure of the complex formed between group I phospholipase A2 and a designed pentapeptide Leu-Ala-Ile-Tyr-Ser at 2.6A resolution
2RD4	;	2.97	;	Design of specific inhibitors of Phospholipase A2: Crystal structure of the complex of phospholipase A2 with pentapeptide Leu-Val-Phe-Phe-Ala at 2.9 A resolution
2FNX	;	2.7	;	Design of Specific Peptide Inhibitors of Phospholipase A2 (PLA2): Crystal Structure of the Complex of PLA2 with a Highly Potent Peptide Val-Ile-Ala-Lys at 2.7A Resolution
2GNS	;	2.3	;	Design of specific peptide inhibitors of phospholipase A2: Crystal structure of the complex formed between a group II phospholipase A2 and a designed pentapeptide Ala- Leu- Val- Tyr- Lys at 2.3 A resolution
1NA0	;	1.6	;	Design of Stable alpha-Helical Arrays from an Idealized TPR Motif
1NA3	;	1.55	;	Design of Stable alpha-Helical Arrays from an Idealized TPR Motif
1NO9	;	1.9	;	Design of weakly basic thrombin inhibitors incorporating novel P1 binding functions: molecular and X-ray crystallographic studies.
9HVP	;	2.8	;	Design, activity and 2.8 Angstroms crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease
3OGT	;	1.75	;	Design, Chemical synthesis, Functional characterization and Crystal structure of the sidechain analogue of 1,25-dihydroxyvitamin D3.
2LTN	;	1.7	;	DESIGN, EXPRESSION, AND CRYSTALLIZATION OF RECOMBINANT LECTIN FROM THE GARDEN PEA (PISUM SATIVUM)
7VUN	;	2.701	;	Design, modification, evaluation and cocrystal studies of novel phthalimides regulating PD-1/PD-L1 interaction
3UXE	;	1.5	;	Design, Synthesis and Biological Evaluation of Potent Quinoline and Pyrroloquinoline Ammosamide Analogues as Inhibitors for Quinone Reductase 2
3UXH	;	1.53	;	Design, Synthesis and Biological Evaluation of Potetent Quinoline and Pyrroloquinoline Ammosamide Analogues as Inhibitors of Quinone Reductase 2
5IIS	;	2.1	;	Design, synthesis and structure activity relationship of potent pan-PIM kinase inhibitors derived from the pyridyl-amide scaffold
1E26	;	2.0	;	Design, Synthesis and X-ray Crystal Structure of a Potent Dual Inhibitor of Thymidylate Synthase and Dihydrofolate Reductase as an Antitumor Agent.
4CBT	;	3.03	;	Design, synthesis, and biological evaluation of potent and selective Class IIa HDAC inhibitors as a potential therapy for Huntington's disease
4CBY	;	2.72	;	Design, synthesis, and biological evaluation of potent and selective Class IIa HDAC inhibitors as a potential therapy for Huntington's disease
3R21	;	2.9	;	Design, synthesis, and biological evaluation of pyrazolopyridine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (Part I)
3R22	;	2.9	;	Design, synthesis, and biological evaluation of pyrazolopyridine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (Part I)
2GYI	;	1.6	;	DESIGN, SYNTHESIS, AND CHARACTERIZATION OF A POTENT XYLOSE ISOMERASE INHIBITOR, D-THREONOHYDROXAMIC ACID, AND HIGH-RESOLUTION X-RAY CRYSTALLOGRAPHIC STRUCTURE OF THE ENZYME-INHIBITOR COMPLEX
5UUU	;	2.7	;	Design, Synthesis, and Evaluation of the First Selective and Potent G-protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure
5UVC	;	2.65	;	Design, Synthesis, and Evaluation of the First Selective and Potent G-protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure
1FKG	;	2.0	;	DESIGN, SYNTHESIS, AND KINETIC EVALUATION OF HIGH-AFFINITY FKBP LIGANDS, AND THE X-RAY CRYSTAL STRUCTURES OF THEIR COMPLEXES WITH FKBP12
1FKH	;	1.95	;	DESIGN, SYNTHESIS, AND KINETIC EVALUATION OF HIGH-AFFINITY FKBP LIGANDS, AND THE X-RAY CRYSTAL STRUCTURES OF THEIR COMPLEXES WITH FKBP12
1FKI	;	2.2	;	DESIGN, SYNTHESIS, AND KINETIC EVALUATION OF HIGH-AFFINITY FKBP LIGANDS, AND THE X-RAY CRYSTAL STRUCTURES OF THEIR COMPLEXES WITH FKBP12
6V8C	;	1.9	;	Design, Synthesis, and Mechanism of Fluorine-substituted Cyclohexene Analogues of GAMA-Aminobutyric Acid (GABA) as Selective Ornithine Aminotransferase Inactivators
6V8D	;	2.25	;	Design, Synthesis, and Mechanism of Fluorine-substituted Cyclohexene Analogues of GAMA-Aminobutyric Acid (GABA) as Selective Ornithine Aminotransferase Inactivators
1QF4	;	2.2	;	DESIGN, SYNTHESIS, AND X-RAY CRYSTAL STRUCTURE OF AN ENZYME BOUND BISUBSTRATE HYBRID INHIBITOR OF ADENYLOSUCCINATE SYNTHETASE
1QF5	;	2.0	;	DESIGN, SYNTHESIS, AND X-RAY CRYSTAL STRUCTURE OF AN ENZYME BOUND BISUBSTRATE HYBRID INHIBITOR OF ADENYLOSUCCINATE SYNTHETASE
3GHC	;	1.3	;	Design, Synthesis, and X-ray Crystal Structure of Classical and Nonclassical 2-amino-4-oxo-5-substituted-6-thieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors and as potential antitumor agenst
6D1L	;	1.4	;	Design, synthesis, and X-ray of selenides bearing benzenesulfonamide moiety with neuropathic pain modulating effects
6D1M	;	1.21	;	Design, synthesis, and X-ray of selenides bearing benzenesulfonamide moiety with neuropathic pain modulating effects
3NU0	;	1.35	;	Design, Synthesis, Biological Evaluation and X-ray Crystal Structure of Novel Classical 6,5,6-TricyclicBenzo[4,5]thieno[2,3-d]pyrimidines as Dual Thymidylate Synthase and Dihydrofolate Reductase Inhibitors
3NTZ	;	1.35	;	Design, Synthesis, Biological Evaluation and X-ray Crystal Structures of Novel Classical 6,5,6-tricyclicbenzo[4,5]thieno[2,3-d]pyrimidines as Dual Thymidylate Synthase and Dihydrofolate Reductase Inhibitors
8ENJ	;	2.81	;	Design, synthesis, biological evaluation, and X-ray crystallography of diarylpyrazole derivatives possessing terminal arylsulfonamide moieties as anti-proliferative agents targeting c-Jun N-terminal kinase (JNK)
3TKC	;	1.75	;	Design, Synthesis, Evaluation and Structure of Vitamin D Analogues with Furan Side Chains
5URC	;	1.85	;	Design, Synthesis, Functional and Biological Evaluation of Ether and Ester Derivatives of the Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease
6CEH	;	1.43	;	Design, Synthesis, X-ray and Biological Activities of Selenides Bearing the Benzenesulfonamide Moiety as New Class of Agents for Prevention of Diabetic Cerebrovascular Pathology
5OP1	;	2.284	;	Designed Ankyrin Repeat Protein (DARPin) A4 in complex with Lysozyme
3NOC	;	2.7	;	Designed ankyrin repeat protein (DARPin) binders to AcrB: Plasticity of the Interface
3NOG	;	3.34	;	Designed ankyrin repeat protein (DARPin) Binders to AcrB: Plasticity of the Interface
5OOV	;	1.365	;	Designed Ankyrin Repeat Protein (DARPin) ETVD-1 in complex with Lysozyme
5OP3	;	1.359	;	Designed Ankyrin Repeat Protein (DARPin) NDNH-1 selected by directed evolution against Lysozyme
5OOY	;	1.72	;	Designed Ankyrin Repeat Protein (DARPin) VHAH-1 in complex with Lysozyme
5OOU	;	2.104	;	Designed Ankyrin Repeat Protein (DARPin) YTRL-1 selected by directed evolution against Lysozyme
5OOS	;	2.26	;	Designed Ankyrin Repeat Protein (DARPin) YTRL-2 selected by directed evolution against Lysozyme
5MFL	;	2.5	;	Designed armadillo repeat protein (KR)5_GS10_YIIIM6AII
4DB6	;	1.8	;	Designed Armadillo repeat protein (YIIIM3AII)
4DB9	;	2.4	;	Designed Armadillo repeat protein (YIIIM3AIII)
4DBA	;	2.4	;	Designed Armadillo repeat protein (YIIM3AII)
2RU5	;		;	Designed Armadillo Repeat Protein Fragment (MAII)
6S9O	;	3.17	;	Designed Armadillo Repeat protein internal Lock1 fused to target peptide KRKRKLKFKR
6S9P	;	2.8	;	Designed Armadillo Repeat protein internal Lock2 fused to target peptide KRKAKITWKR
6S9L	;	2.1	;	Designed Armadillo Repeat protein Lock1 bound to (KR)4KLSF target
6S9M	;	2.0	;	Designed Armadillo Repeat protein Lock2 fused to target peptide KRKRKAKITW
6S9N	;	2.1	;	Designed Armadillo Repeat protein Lock2 fused to target peptide KRKRKAKLSF
7QNP	;	1.586	;	Designed Armadillo repeat protein N(A4)M4C(AII) co-crystallized with hen egg white lysozyme
5MFM	;	2.3	;	Designed armadillo repeat protein peptide fusion YIIIM6AII_GS11_(KR)5
2RU4	;		;	Designed Armadillo Repeat Protein Self-ASsembled Complex (YIIM2-MAII)
4V3Q	;	1.8	;	Designed armadillo repeat protein with 4 internal repeats, 2nd generation C-cap and 3rd generation N-cap.
4V3O	;	2.0	;	Designed armadillo repeat protein with 5 internal repeats, 2nd generation C-cap and 3rd generation N-cap.
4V3R	;	1.95	;	Designed armadillo repeat protein with 5 internal repeats, 2nd generation C-cap and 3rd generation N-cap.
5MFB	;	2.3	;	Designed armadillo repeat protein YIII(Dq)4CqI
5MFK	;	2.3	;	Designed armadillo repeat protein YIII(Dq.V1)4CPAF in complex with peptide (KR)4
5MFI	;	1.45	;	Designed armadillo repeat protein YIII(Dq.V2)4CqI in complex with peptide (KR)4
5MFJ	;	1.53	;	Designed armadillo repeat protein YIII(Dq.V2)4CqI in complex with peptide (KR)5
5MFD	;	2.3	;	Designed armadillo repeat protein YIIIM''6AII in complex with pD_(KR)5
5MFO	;	1.3	;	Designed armadillo repeat protein YIIIM3AIII
5MFN	;	2.8	;	Designed armadillo repeat protein YIIIM5AII
5MFC	;	2.4	;	Designed armadillo repeat protein YIIIM5AII in complex with (KR)4-GFP
5MFE	;	1.95	;	Designed armadillo repeat protein YIIIM5AII in complex with (RR)4 peptide
5AEI	;	1.83	;	Designed Armadillo repeat protein YIIIM5AII in complex with peptide (KR)5
5MFG	;	1.901	;	Designed armadillo repeat protein YIIIM5AII in complex with peptide (RR)4
5MFF	;	1.9	;	Designed armadillo repeat protein YIIIM5AII in complex with peptide (RR)5
5MFH	;	2.0	;	Designed armadillo repeat protein YIIIM5AII in complex with peptide (RR)5
4DB8	;	2.5	;	Designed Armadillo-repeat Protein
5K67	;	1.7	;	Designed Artificial Cupredoxins
5K68	;	1.4	;	Designed Artificial Cupredoxins
5L3Y	;	1.7	;	Designed Artificial Cupredoxins
5WBC	;	1.72	;	Designed Artificial Cupredoxins - WT
7F1H	;	1.14	;	Designed enzyme RA61 M48K/I72D mutant: form I
7F1I	;	1.4	;	Designed enzyme RA61 M48K/I72D mutant: form II
7F1J	;	1.6	;	Designed enzyme RA61 M48K/I72D mutant: form III
7F1K	;	1.05	;	Designed enzyme RA61 M48K/I72D mutant: form IV
7F1L	;	1.7	;	Designed enzyme RA61 M48K/I72D mutant: form V
7UD6	;	2.59	;	Designed Enzyme SH3-588 (Catechol O-methyltransferase catalytic domain and Src homology 3 binding domain fusion)
2MJ9	;		;	Designed Exendin-4 analogues
7XX4	;	2.43	;	designed glycosyltransferase
1Y4C	;	1.9	;	Designed Helical Protein fusion MBP
1UTS	;		;	Designed HIV-1 TAR Binding Ligand
2LR2	;		;	Designed IgG and lanthanide binding probe for solution NMR, MRI and luminescence microscopy
5KUX	;	1.8	;	Designed influenza hemagglutinin binding protein HSB.2
8ETQ	;	2.42	;	Designed pentafoil knot protein folded into a trefoil knot
7UDY	;	2.4	;	Designed pentameric channel QLLL
7UDV	;	2.4	;	Designed pentameric proton channel LLQL
7UDZ	;	2.48	;	Designed pentameric proton channel LQLL
7UDX	;	2.99	;	Designed pentameric proton channel QLQL
7UDW	;	3.0	;	Designed pentameric proton channel QQLL
1BYZ	;	0.9	;	DESIGNED PEPTIDE ALPHA-1, P1 FORM
3AL1	;	0.75	;	DESIGNED PEPTIDE ALPHA-1, RACEMIC P1BAR FORM
5YKQ	;		;	Designed peptide CAY1 from Odorrana andersonii skin secretion
8GN5	;	4.02	;	Designed pH-responsive P22 VLP
4HX9	;	2.68	;	Designed Phosphodeoxyribosyltransferase
1VJQ	;	2.098	;	Designed protein based on backbone conformation of procarboxypeptidase-A (1AYE) with sidechains chosen for maximal predicted stability.
6DLC	;	3.261	;	Designed protein DHD1:234_A, Designed protein DHD1:234_B
5YXI	;		;	Designed protein dRafX6
3UXA	;	2.5	;	Designed protein KE59 R1 7/10H
3UXD	;	1.8	;	Designed protein KE59 R1 7/10H with dichlorobenzotriazole (DBT)
3UY7	;	1.45	;	Designed protein KE59 R1 7/10H with G130S mutation
3UZ5	;	1.9	;	Designed protein KE59 R13 3/11H
3UZJ	;	1.69	;	Designed protein KE59 R13 3/11H with benzotriazole
3UY8	;	2.41	;	Designed protein KE59 R5_11/5F
3UYC	;	2.2	;	Designed protein KE59 R8_2/7A
6NE1	;	3.011	;	Designed repeat protein in complex with Fz4
6NE2	;	1.299	;	Designed repeat protein in complex with Fz7
6NDZ	;	2.264	;	Designed repeat protein in complex with Fz8
6NE4	;	1.648	;	Designed repeat protein specifically in complex with Fz7CRD
7RA9	;	2.2	;	Designed StabIL-2 seq1
7RAA	;	2.69	;	Designed StabIL-2 seq15
7L85	;	2.9	;	Designed tetrahedral nanoparticle T33-31 presenting BG505 SOSIP trimers
3KD7	;	2.85	;	Designed TPR module (CTPR390) in complex with its peptide-ligand (Hsp90 peptide)
5FZQ	;	2.148	;	Designed TPR Protein M4N
5FZR	;	2.045	;	Designed TPR Protein M4N delta C (CF I)
5FZS	;	1.652	;	Designed TPR Protein M4N delta C (CF II)
7SQ3	;	2.453	;	Designed trefoil knot protein, variant 1
7SQ4	;	1.493	;	Designed trefoil knot protein, variant 2
7SQ5	;	2.205	;	Designed trefoil knot protein, variant 3
1COI	;	2.1	;	DESIGNED TRIMERIC COILED COIL-VALD
5JQZ	;	3.83	;	Designed two-ring homotetramer at 3.8A resolution
6Y07	;		;	Designing a Granulopoietic Protein by Topological Rescaffolding 1: Sohair
5W6W	;	3.06	;	Designing Higher Resolution Self-Assembled 3D DNA Crystals via Strand Terminus Modifications
5TPR	;	1.7	;	Desmethyl-4-deoxygadusol synthase from Anabaena variabilis (Ava_3858) with NAD+ and Zn2+ bound
1DDL	;	2.7	;	DESMODIUM YELLOW MOTTLE TYMOVIRUS
2CEU	;	1.8	;	Despentapeptide insulin in acetic acid (pH 2)
1AK7	;		;	DESTRIN, NMR, 20 STRUCTURES
1AK6	;		;	DESTRIN, NMR, MINIMIZED AVERAGE STRUCTURE
1DFX	;	1.9	;	DESULFOFERRODOXIN FROM DESULFOVIBRIO DESULFURICANS, ATCC 27774
1DCD	;	2.0	;	DESULFOREDOXIN COMPLEXED WITH CD2+
3F6R	;	2.0	;	Desulfovibrio desulfuricans (ATCC 29577) oxidized flavodoxin
3F6S	;	2.502	;	Desulfovibrio desulfuricans (ATCC 29577) oxidized flavodoxin alternate conformers
3F90	;	2.5	;	Desulfovibrio desulfuricans (ATCC 29577) semiquinone flavodoxin
8BJ7	;	1.04	;	Desulfovibrio desulfuricans FeFe Hydrogenase C178A mutant in Hinact-like state
8BJ8	;	1.01	;	Desulfovibrio desulfuricans FeFe Hydrogenase C178A mutant in Htrans-like state
1MJI	;	2.5	;	DETAILED ANALYSIS OF RNA-PROTEIN INTERACTIONS WITHIN THE BACTERIAL RIBOSOMAL PROTEIN L5/5S RRNA COMPLEX
3KSA	;	3.3	;	Detailed structural insight into the DNA cleavage complex of type IIA topoisomerases (cleaved form)
3KSB	;	3.5	;	Detailed structural insight into the DNA cleavage complex of type IIA topoisomerases (re-sealed form)
3K9F	;	2.9	;	Detailed structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases
1UKJ	;	1.8	;	Detailed structure of L-Methionine-Lyase from Pseudomonas putida
1DK1	;	2.8	;	DETAILED VIEW OF A KEY ELEMENT OF THE RIBOSOME ASSEMBLY: CRYSTAL STRUCTURE OF THE S15-RRNA COMPLEX
4IFV	;	2.05	;	Detecting Allosteric Sites of HIV-1 Reverse Transcriptase by X-Ray Crystallographic Fragment Screening
2XRE	;	2.45	;	Detection of cobalt in previously unassigned human SENP1 structure
2ALU	;	2.09	;	Detection of new binding site in the C-terminal lobe of lactoferrin:Crystal structure of the complex formed between bovine lactoferrin and a tetrasaccharide at 2.1A resolution
7UWP	;	1.95	;	Detergent-bound CYP51 from Acanthamoeba castellanii
1CER	;	2.5	;	DETERMINANTS OF ENZYME THERMOSTABILITY OBSERVED IN THE MOLECULAR STRUCTURE OF THERMUS AQUATICUS D-GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE AT 2.5 ANGSTROMS RESOLUTION
4LKV	;	3.5109	;	Determinants of lipid substrate and membrane binding for the tetraacyldisaccharide-1-phosphate 4 -kinase LpxK
1BMD	;	1.9	;	DETERMINANTS OF PROTEIN THERMOSTABILITY OBSERVED IN THE 1.9 ANGSTROMS CRYSTAL STRUCTURE OF MALATE DEHYDROGENASE FROM THE THERMOPHILIC BACTERIUM THERMUS FLAVUS
7KCI	;	1.95	;	DETERMINANTS OF REPRESSOR/OPERATOR RECOGNITION FROM THE STRUCTURE OF THE TRP OPERATOR BINDING SITE
2SOD	;	2.0	;	DETERMINATION AND ANALYSIS OF THE 2 ANGSTROM STRUCTURE OF COPPER, ZINC SUPEROXIDE DISMUTASE
1SAR	;	1.8	;	DETERMINATION AND RESTRAINED LEAST-SQUARES REFINEMENT OF THE CRYSTAL STRUCTURES OF RIBONUCLEASE SA AND ITS COMPLEX WITH 3'-GUANYLIC ACID AT 1.8 ANGSTROMS RESOLUTION
2SAR	;	1.8	;	DETERMINATION AND RESTRAINED LEAST-SQUARES REFINEMENT OF THE CRYSTAL STRUCTURES OF RIBONUCLEASE SA AND ITS COMPLEX WITH 3'-GUANYLIC ACID AT 1.8 ANGSTROMS RESOLUTION
344D	;	1.46	;	DETERMINATION BY MAD-DM OF THE STRUCTURE OF THE DNA DUPLEX D(ACGTACG(5-BRU))2 AT 1.46A AND 100K
1NCV	;		;	DETERMINATION CC-CHEMOKINE MCP-3, NMR, 7 STRUCTURES
1PIT	;		;	DETERMINATION OF A HIGH-QUALITY NUCLEAR MAGNETIC RESONANCE SOLUTION STRUCTURE OF THE BOVINE PANCREATIC TRYPSIN INHIBITOR AND COMPARISON WITH THREE CRYSTAL STRUCTURES
2K0P	;		;	Determination of a Protein Structure in the Solid State from NMR Chemical Shifts
1DYA	;	1.9	;	DETERMINATION OF ALPHA-HELIX PROPENSITY WITHIN THE CONTEXT OF A FOLDED PROTEIN: SITES 44 AND 131 IN BACTERIOPHAGE T4 LYSOZYME
1DYB	;	1.75	;	DETERMINATION OF ALPHA-HELIX PROPENSITY WITHIN THE CONTEXT OF A FOLDED PROTEIN: SITES 44 AND 131 IN BACTERIOPHAGE T4 LYSOZYME
1DYC	;	2.1	;	DETERMINATION OF ALPHA-HELIX PROPENSITY WITHIN THE CONTEXT OF A FOLDED PROTEIN: SITES 44 AND 131 IN BACTERIOPHAGE T4 LYSOZYME
1DYD	;	2.1	;	DETERMINATION OF ALPHA-HELIX PROPENSITY WITHIN THE CONTEXT OF A FOLDED PROTEIN: SITES 44 AND 131 IN BACTERIOPHAGE T4 LYSOZYME
1DYE	;	1.8	;	DETERMINATION OF ALPHA-HELIX PROPENSITY WITHIN THE CONTEXT OF A FOLDED PROTEIN: SITES 44 AND 131 IN BACTERIOPHAGE T4 LYSOZYME
1DYF	;	1.9	;	DETERMINATION OF ALPHA-HELIX PROPENSITY WITHIN THE CONTEXT OF A FOLDED PROTEIN: SITES 44 AND 131 IN BACTERIOPHAGE T4 LYSOZYME
1DYG	;	2.1	;	DETERMINATION OF ALPHA-HELIX PROPENSITY WITHIN THE CONTEXT OF A FOLDED PROTEIN: SITES 44 AND 131 IN BACTERIOPHAGE T4 LYSOZYME
1Q7O	;		;	Determination of f-MLF-OH Peptide Structure with solid-state magic-angle spinning NMR Spectroscopy
1BUB	;		;	DETERMINATION OF INTERNUCLEAR ANGLES OF DNA USING PARAMAGNETIC ASSISTED MAGNETIC ALIGNMENT
1ATY	;		;	DETERMINATION OF LOCAL PROTEIN STRUCTURE BY SPIN LABEL DIFFERENCE 2D NMR: THE REGION NEIGHBORING ASP61 OF SUBUNIT C OF THE F1FO ATP SYNTHASE
4BR3	;	2.2	;	Determination of potential scaffolds for human choline kinase alpha 1 by chemical deconvolution studies
2NVH	;	1.53	;	Determination of Solvent Content in Cavities in Interleukin-1 Using Experimentally-Phased Electron Density
2AIT	;		;	DETERMINATION OF THE COMPLETE THREE-DIMENSIONAL STRUCTURE OF THE ALPHA-AMYLASE INHIBITOR TENDAMISTAT IN AQUEOUS SOLUTION BY NUCLEAR MAGNETIC RESONANCE AND DISTANCE GEOMETRY
1CTI	;		;	DETERMINATION OF THE COMPLETE THREE-DIMENSIONAL STRUCTURE OF THE TRYPSIN INHIBITOR FROM SQUASH SEEDS IN AQUEOUS SOLUTION BY NUCLEAR MAGNETIC RESONANCE AND A COMBINATION OF DISTANCE GEOMETRY AND DYNAMICAL SIMULATED ANNEALING
2CTI	;		;	DETERMINATION OF THE COMPLETE THREE-DIMENSIONAL STRUCTURE OF THE TRYPSIN INHIBITOR FROM SQUASH SEEDS IN AQUEOUS SOLUTION BY NUCLEAR MAGNETIC RESONANCE AND A COMBINATION OF DISTANCE GEOMETRY AND DYNAMICAL SIMULATED ANNEALING
3PL1	;	2.2	;	Determination of the crystal structure of the pyrazinamidase from M.tuberculosis : a structure-function analysis for prediction resistance to pyrazinamide.
4R7G	;	2.9	;	Determination of the formylglycinamide ribonucleotide amidotransferase ammonia pathway by combining 3D-RISM theory with experiment
1AHD	;		;	DETERMINATION OF THE NMR SOLUTION STRUCTURE OF AN ANTENNAPEDIA HOMEODOMAIN-DNA COMPLEX
3CYS	;		;	DETERMINATION OF THE NMR SOLUTION STRUCTURE OF THE CYCLOPHILIN A-CYCLOSPORIN A COMPLEX
2CCX	;		;	DETERMINATION OF THE NUCLEAR MAGNETIC RESONANCE SOLUTION STRUCTURE OF CARDIOTOXIN CTX IIB FROM NAJA MOSSAMBICA MOSSAMBICA
1PRA	;		;	DETERMINATION OF THE NUCLEAR MAGNETIC RESONANCE SOLUTION STRUCTURE OF THE DNA-BINDING DOMAIN (RESIDUES 1 TO 69) OF THE 434 REPRESSOR AND COMPARISON WITH THE X-RAY CRYSTAL STRUCTURE
1ADR	;		;	DETERMINATION OF THE NUCLEAR MAGNETIC RESONANCE STRUCTURE OF THE DNA-BINDING DOMAIN OF THE P22 C2 REPRESSOR (1-76) IN SOLUTION AND COMPARISON WITH THE DNA-BINDING DOMAIN OF THE 434 REPRESSOR
1CTA	;		;	DETERMINATION OF THE SOLUTION STRUCTURE OF A SYNTHETIC TWO-SITE CALCIUM-BINDING HOMODIMERIC PROTEIN DOMAIN BY NMR SPECTROSCOPY
1CTD	;		;	DETERMINATION OF THE SOLUTION STRUCTURE OF A SYNTHETIC TWO-SITE CALCIUM-BINDING HOMODIMERIC PROTEIN DOMAIN BY NMR SPECTROSCOPY
1CLB	;		;	Determination of the solution structure of apo calbindin D9K by nmr spectroscopy
1GNA	;		;	DETERMINATION OF THE SOLUTION STRUCTURE OF THE PEPTIDE HORMONE GUANYLIN: OBSERVATION OF A NOVEL FORM OF TOPOLOGICAL STEREOISOMERISM
1GNB	;		;	DETERMINATION OF THE SOLUTION STRUCTURE OF THE PEPTIDE HORMONE GUANYLIN: OBSERVATION OF A NOVEL FORM OF TOPOLOGICAL STEREOISOMERISM
2IGG	;		;	DETERMINATION OF THE SOLUTION STRUCTURES OF DOMAINS II AND III OF PROTEIN G FROM STREPTOCOCCUS BY 1H NMR
2IGH	;		;	DETERMINATION OF THE SOLUTION STRUCTURES OF DOMAINS II AND III OF PROTEIN G FROM STREPTOCOCCUS BY 1H NMR
8BBQ	;	1.43	;	Determination of the structure of active tyrosinase from bacterium Verrucomicrobium spinosum
8BBR	;	1.64	;	Determination of the structure of active tyrosinase from bacterium Verrucomicrobium spinosum
1PPO	;	1.8	;	DETERMINATION OF THE STRUCTURE OF PAPAYA PROTEASE OMEGA
1RES	;		;	DETERMINATION OF THE STRUCTURE OF THE DNA BINDING DOMAIN OF GAMMA DELTA RESOLVASE IN SOLUTION
1RET	;		;	DETERMINATION OF THE STRUCTURE OF THE DNA BINDING DOMAIN OF GAMMA DELTA RESOLVASE IN SOLUTION
1BK8	;		;	DETERMINATION OF THE THREE-DIMENSIONAL SOLUTION STRUCTURE OF AESCULUS HIPPOCASTANUM ANTIMICROBIAL PROTEIN 1 (AH-AMP1) BY 1H NMR, 25 STRUCTURES
1AYJ	;		;	DETERMINATION OF THE THREE-DIMENSIONAL SOLUTION STRUCTURE OF RAPHANUS SATIVUS ANTIFUNGAL PROTEIN 1 (RS-AFP1) BY 1H NMR, 20 STRUCTURES
1BDS	;		;	DETERMINATION OF THE THREE-DIMENSIONAL SOLUTION STRUCTURE OF THE ANTIHYPERTENSIVE AND ANTIVIRAL PROTEIN BDS-I FROM THE SEA ANEMONE ANEMONIA SULCATA. A STUDY USING NUCLEAR MAGNETIC RESONANCE AND HYBRID DISTANCE GEOMETRY-DYNAMICAL SIMULATED ANNEALING
2BDS	;		;	DETERMINATION OF THE THREE-DIMENSIONAL SOLUTION STRUCTURE OF THE ANTIHYPERTENSIVE AND ANTIVIRAL PROTEIN BDS-I FROM THE SEA ANEMONE ANEMONIA SULCATA. A STUDY USING NUCLEAR MAGNETIC RESONANCE AND HYBRID DISTANCE GEOMETRY-DYNAMICAL SIMULATED ANNEALING
2L7S	;		;	Determination of the three-dimensional structure of adrenomedullin, a first step towards the analysis of its interactions with receptors and small molecules
1MTX	;		;	DETERMINATION OF THE THREE-DIMENSIONAL STRUCTURE OF MARGATOXIN BY 1H, 13C, 15N TRIPLE-RESONANCE NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
1SCY	;		;	DETERMINATION OF THE THREE-DIMENSIONAL STRUCTURE OF SCYLLATOXIN BY 1H NUCLEAR MAGNETIC RESONANCE
1HOM	;		;	DETERMINATION OF THE THREE-DIMENSIONAL STRUCTURE OF THE ANTENNAPEDIA HOMEODOMAIN FROM DROSOPHILA IN SOLUTION BY 1H NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
1CBH	;		;	DETERMINATION OF THE THREE-DIMENSIONAL STRUCTURE OF THE C-TERMINAL DOMAIN OF CELLOBIOHYDROLASE I FROM TRICHODERMA REESEI. A STUDY USING NUCLEAR MAGNETIC RESONANCE AND HYBRID DISTANCE GEOMETRY-DYNAMICAL SIMULATED ANNEALING
2CBH	;		;	DETERMINATION OF THE THREE-DIMENSIONAL STRUCTURE OF THE C-TERMINAL DOMAIN OF CELLOBIOHYDROLASE I FROM TRICHODERMA REESEI. A STUDY USING NUCLEAR MAGNETIC RESONANCE AND HYBRID DISTANCE GEOMETRY-DYNAMICAL SIMULATED ANNEALING
2OEH	;		;	Determination of the Three-dimensional Structure of the Mrf2-DNA Complex Using Paramagnetic Spin Labeling
1CAU	;	2.3	;	DETERMINATION OF THREE CRYSTAL STRUCTURES OF CANAVALIN BY MOLECULAR REPLACEMENT
1CAW	;	2.6	;	DETERMINATION OF THREE CRYSTAL STRUCTURES OF CANAVALIN BY MOLECULAR REPLACEMENT
1CAX	;	2.6	;	DETERMINATION OF THREE CRYSTAL STRUCTURES OF CANAVALIN BY MOLECULAR REPLACEMENT
4B0Y	;	3.5	;	Determination of X-ray Structure of human SOUL by Molecular Replacement
4XS7	;	2.4	;	Determining the Molecular Basis for Starter Unit Selection During Daunorubicin Biosynthesis
4XS9	;	2.002	;	Determining the Molecular Basis for Starter Unit Selection During Daunorubicin Biosynthesis
4XSA	;	2.204	;	Determining the Molecular Basis for Starter Unit Selection During Daunorubicin Biosynthesis
4XSB	;	2.203	;	Determining the Molecular Basis for Starter Unit Selection During Daunorubicin Biosynthesis
5TT4	;	2.5	;	Determining the Molecular Basis For Starter Unit Selection During Daunorubicin Biosynthesis
5A6M	;	1.17	;	Determining the specificities of the catalytic site from the very high resolution structure of the thermostable glucuronoxylan endo-Beta-1, 4-xylanase, CtXyn30A, from Clostridium thermocellum with a xylotetraose bound
1DAE	;	1.7	;	DETHIOBIOTIN SYNTHETASE COMPLEXED WITH 3-(1-AMINOETHYL) NONANEDIOIC ACID
1DAH	;	1.64	;	DETHIOBIOTIN SYNTHETASE COMPLEXED WITH 7,8-DIAMINO-NONANOIC ACID, 5'-ADENOSYL-METHYLENE-TRIPHOSPHATE, AND MANGANESE
1DAI	;	1.64	;	DETHIOBIOTIN SYNTHETASE COMPLEXED WITH 7-(CARBOXYAMINO)-8-AMINO-NONANOIC ACID
1DAG	;	1.64	;	DETHIOBIOTIN SYNTHETASE COMPLEXED WITH 7-(CARBOXYAMINO)-8-AMINO-NONANOIC ACID AND 5'-ADENOSYL-METHYLENE-TRIPHOSPHATE
1DAF	;	1.7	;	DETHIOBIOTIN SYNTHETASE COMPLEXED WITH 7-(CARBOXYAMINO)-8-AMINO-NONANOIC ACID, ADP, AND CALCIUM
1DAD	;	1.6	;	DETHIOBIOTIN SYNTHETASE COMPLEXED WITH ADP
1BS1	;	1.8	;	DETHIOBIOTIN SYNTHETASE COMPLEXED WITH DETHIOBIOTIN, ADP , INORGANIC PHOSPHATE AND MAGNESIUM
1DAM	;	1.8	;	DETHIOBIOTIN SYNTHETASE COMPLEXED WITH DETHIOBIOTIN, ADP, INORGANIC PHOSPHATE AND MAGNESIUM
1DAK	;	1.6	;	DETHIOBIOTIN SYNTHETASE FROM ESCHERICHIA COLI, COMPLEX REACTION INTERMEDIATE ADP AND MIXED ANHYDRIDE
1A82	;	1.8	;	DETHIOBIOTIN SYNTHETASE FROM ESCHERICHIA COLI, COMPLEX WITH SUBSTRATES ATP AND DIAMINOPELARGONIC ACID
1UCH	;	1.8	;	DEUBIQUITINATING ENZYME UCH-L3 (HUMAN) AT 1.8 ANGSTROM RESOLUTION
1ZIQ	;	1.72	;	Deuterated gammaE crystallin in D2O solvent
1ZIR	;	1.36	;	Deuterated gammaE crystallin in H2O solvent
1EB6	;	1.0	;	Deuterolysin from Aspergillus oryzae
6FYZ	;	2.15	;	Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor
4LMQ	;	2.773	;	Development and Preclinical Characterization of a Humanized Antibody Targeting CXCL12
3CB9	;	1.31	;	Development of a family of redox-sensitive green fluorescent protein indicators for use in relatively oxidizing subcellular environments
3CBE	;	1.488	;	Development of a family of redox-sensitive green fluorescent protein indicators for use in relatively oxidizing subcellular environments
3CD1	;	1.312	;	Development of a family of redox-sensitive green fluorescent protein indicators for use in relatively oxidizing subcellular environments
3CD9	;	1.502	;	Development of a family of redox-sensitive green fluorescent protein indicators for use in relatively oxidizing subcellular environments
5C0N	;	3.0	;	Development of a monoclonal antibody targeting secreted aP2 to treat diabetes and fatty liver disease
4ZAE	;	1.86	;	Development of a novel class of potent and selective FIXa inhibitors
5EGM	;	1.841	;	Development of a novel tricyclic class of potent and selective FIXa inhibitors
4AJM	;	2.4	;	Development of a plate-based optical biosensor methodology to identify PDE10 fragment inhibitors
5D8J	;	3.0	;	Development of a therapeutic monoclonal antibody targeting secreted aP2 to treat type 2 diabetes.
6GOU	;	2.9	;	Development of Alkyl Glycerone Phosphate Synthase Inhibitors: Complex with Inhibitor 2I
7T3F	;	1.28	;	Development of BRD4 inhibitors as arsenicals antidotes
3D62	;	2.7	;	Development of Broad-Spectrum Halomethyl Ketone Inhibitors Against Coronavirus Main Protease 3CLpro
4X6H	;	1.0	;	Development of N-(Functionalized benzoyl)-homocycloleucyl-glycinonitriles as Potent Cathepsin K Inhibitors.
4X6I	;	1.87	;	Development of N-(Functionalized benzoyl)-homocycloleucyl-glycinonitriles as Potent Cathepsin K Inhibitors.
4X6J	;	1.59	;	Development of N-(Functionalized benzoyl)-homocycloleucyl-glycinonitriles as Potent Cathepsin K Inhibitors.
6K5O	;	1.8	;	Development of Novel Lithocholic Acid Derivatives as Vitamin D Receptor Agonists
4FHH	;	2.33	;	Development of synthetically accessible non-secosteroidal hybrid molecules combining vitamin D receptor agonism and histone deacetylase inhibition
4FHI	;	2.4	;	Development of synthetically accessible non-secosteroidal hybrid molecules combining vitamin D receptor agonism and histone deacetylase inhibition
1OGM	;	1.8	;	Dex49A from Penicillium minioluteum
1OGO	;	1.65	;	Dex49A from Penicillium minioluteum complex with isomaltose
6NZS	;	1.4	;	Dextranase AoDex KQ11
8PUR	;	1.85	;	DexyHemoglobin structure from serial synchrotron crystallography with fixed target
7YE0	;	2.75	;	DF-SFX MmCPDII-DNA complex: steady state oxidized complex
7U49	;	1.72	;	DFC-CTX-M-15
3MFN	;	2.02	;	Dfer_2879 protein of unknown function from Dyadobacter fermentans
7BVS	;	2.85	;	DfgA-DfgB complex apo
7EXB	;	2.4	;	DfgA-DfgB complex apo 2.4 angstrom
2RCE	;	2.35	;	DFP modified DegS delta PDZ
3LH3	;	2.35	;	DFP modified DegS delta PDZ
1CI9	;	1.8	;	DFP-INHIBITED ESTERASE ESTB FROM BURKHOLDERIA GLADIOLI
3O4P	;	0.85	;	DFPase at 0.85 Angstrom resolution (H atoms included)
7REG	;	1.77	;	DfrA1 complexed with NADPH and 4'-chloro-3'-(4-(2,4-diamino-6-ethylpyrimidin-5-yl)but-3-yn-2-yl)-[1,1'-biphenyl]-4-carboxamide (UCP1228)
7RGJ	;	1.44	;	DfrA1 complexed with NADPH and 5-(3-(7-(4-(aminomethyl)phenyl)benzo[d][1,3]dioxol-5-yl)but-1-yn-1-yl)-6-ethylpyrimidine-2,4-diamine (UCP1223)
7RGO	;	1.92	;	DfrA5 complexed with NADPH and 4'-chloro-3'-(4-(2,4-diamino-6-ethylpyrimidin-5-yl)but-3-yn-2-yl)-[1,1'-biphenyl]-4-carboxamide (UCP1228)
7RGK	;	2.19	;	DfrA5 complexed with NADPH and 5-(3-(7-(4-(aminomethyl)phenyl)benzo[d][1,3]dioxol-5-yl)but-1-yn-1-yl)-6-ethylpyrimidine-2,4-diamine (UCP1223)
8AH3	;	1.4	;	DG04279 glycoside hydrolase family 172
6PX7	;		;	Dg12a in Weaponisation 'on the fly': Convergent recruitment of knottin and defensin scaffolds as neurotoxins in the venom of assassin fly Dolopus genitalis (Diptera: Asilidae)
6PX8	;		;	Dg3b in Weaponisation 'on the fly': Convergent recruitment of knottin and defensin scaffolds as neurotoxins in the venom of assassin fly Dolopus genitalis (Diptera: Asilidae)
5D6I	;	3.091	;	DgkA - CIM
7DVM	;		;	DgkA structure in E.coli lipid bilayer
7BVR	;	2.6	;	DgpB-DgpC complex apo
7EXZ	;	2.5	;	DgpB-DgpC complex apo 2.5 angstrom
7M0O	;	1.62	;	DGT-28 EPSPS
6E6E	;	2.15	;	DGY-06-116, a novel and selective covalent inhibitor of SRC kinase
6VTU	;	2.61	;	DH717.1 Fab monomer in complex with man9 glycan
8H4L	;	3.07	;	DHA-bound FFAR4 in complex with Gq
8H4I	;	3.06	;	DHA-bound FFAR4 in complex with Gs
4YMZ	;	1.87	;	DHAP bound Leptospira Interrogans Triosephosphate Isomerase (LiTIM)
6DLM	;	1.753	;	DHD127
6DKM	;	2.38	;	DHD131
6DMA	;	3.363	;	DHD15_closed
6DM9	;	2.25	;	DHD15_extended
6E9Z	;	3.4	;	DHF119 filament
6E9Y	;	4.3	;	DHF38 filament
6E9R	;	5.9	;	DHF46 filament
6E9T	;	5.4	;	DHF58 filament
6E9V	;	6.9	;	DHF79 filament
6E9X	;	7.8	;	DHF91 filament
1ZDR	;	2.0	;	DHFR from Bacillus Stearothermophilus
2RK2	;	1.9	;	DHFR R-67 complexed with NADP
2RK1	;	1.26	;	DHFR R67 Complexed with NADP and dihydrofolate
7FQ7	;	1.1	;	DHFR:NADP+:FOL complex (crystal 1, pass 1, 295 K)
7FQ8	;	1.21	;	DHFR:NADP+:FOL complex (crystal 1, pass 2, 310 K)
7FQ9	;	1.11	;	DHFR:NADP+:FOL complex (crystal 1, pass 3, 295 K)
7FQA	;	1.08	;	DHFR:NADP+:FOL complex (crystal 1, pass 4, 280 K)
7FQB	;	1.14	;	DHFR:NADP+:FOL complex (crystal 1, pass 5, 295 K)
7FQC	;	1.18	;	DHFR:NADP+:FOL complex (crystal 2, pass 1, 295 K)
7FQD	;	1.17	;	DHFR:NADP+:FOL complex (crystal 2, pass 2, 280 K)
7FQE	;	1.18	;	DHFR:NADP+:FOL complex (crystal 2, pass 3, 295 K)
7FQF	;	1.23	;	DHFR:NADP+:FOL complex (crystal 2, pass 4, 310 K)
7FQG	;	1.19	;	DHFR:NADP+:FOL complex (crystal 2, pass 5, 295 K)
5SSS	;	1.14	;	DHFR:NADP+:FOL complex at 270 K (crystal 1)
5SST	;	1.07	;	DHFR:NADP+:FOL complex at 270 K (crystal 2)
5SSU	;	1.12	;	DHFR:NADP+:FOL complex at 270 K (crystal 3)
5SSV	;	1.08	;	DHFR:NADP+:FOL complex at 270 K (crystal 4)
5SSW	;	1.06	;	DHFR:NADP+:FOL complex at 270 K (multi-crystal)
7FPL	;	1.17	;	DHFR:NADP+:FOL complex at 280 K (crystal 1)
7FPM	;	1.04	;	DHFR:NADP+:FOL complex at 280 K (crystal 2)
7FPN	;	1.04	;	DHFR:NADP+:FOL complex at 280 K (crystal 3)
7FPO	;	1.06	;	DHFR:NADP+:FOL complex at 280 K (crystal 4)
7FPP	;	1.03	;	DHFR:NADP+:FOL complex at 280 K (crystal 5)
7FPQ	;	1.03	;	DHFR:NADP+:FOL complex at 280 K (multi-crystal)
7FPR	;	1.07	;	DHFR:NADP+:FOL complex at 290 K (crystal 1)
7FPS	;	1.26	;	DHFR:NADP+:FOL complex at 290 K (crystal 2)
7FPT	;	1.07	;	DHFR:NADP+:FOL complex at 290 K (crystal 3)
7FPU	;	1.05	;	DHFR:NADP+:FOL complex at 290 K (crystal 4)
7FPV	;	1.04	;	DHFR:NADP+:FOL complex at 290 K (crystal 5)
7FPW	;	1.04	;	DHFR:NADP+:FOL complex at 290 K (multi-crystal)
7FPX	;	1.06	;	DHFR:NADP+:FOL complex at 300 K (crystal 1)
7FPY	;	1.12	;	DHFR:NADP+:FOL complex at 300 K (crystal 2)
7FPZ	;	1.32	;	DHFR:NADP+:FOL complex at 300 K (crystal 3)
7FQ0	;	1.15	;	DHFR:NADP+:FOL complex at 300 K (crystal 4)
7FQ1	;	1.18	;	DHFR:NADP+:FOL complex at 300 K (crystal 5)
7FQ2	;	1.07	;	DHFR:NADP+:FOL complex at 300 K (multi-crystal)
7FQ3	;	1.3	;	DHFR:NADP+:FOL complex at 310 K (crystal 1)
7FQ4	;	1.33	;	DHFR:NADP+:FOL complex at 310 K (crystal 2)
7FQ5	;	1.35	;	DHFR:NADP+:FOL complex at 310 K (crystal 3)
7FQ6	;	1.29	;	DHFR:NADP+:FOL complex at 310 K (multi-crystal)
1U68	;	2.4	;	DHNA 7,8 DIHYDRONEOPTERIN COMPLEX
1RSI	;	2.2	;	DHNA complex with 2-Amino-5-bromo-3-hydroxy-6-phenylpyrimidine
1RRI	;	2.0	;	DHNA complex with 3-(5-amino-7-hydroxy-[1,2,3] triazolo [4,5-d]pyrimidin-2-yl)-benzoic acid
1RSD	;	2.5	;	DHNA complex with 3-(5-Amino-7-hydroxy-[1,2,3]triazolo[4,5-d]pyrimidin-2-yl)-N-[2-(2-hydroxymethyl-phenylsulfanyl)-benzyl]-benzamide
1RS2	;	2.31	;	DHNA complex with 8-Amino-1,3-dimethyl-3,7-dihydropurine-2,6-dione
1RRY	;	2.7	;	DHNA complexed with 2-amino-4-hydroxy-5-carboxyethylpyrimidine
1RRW	;	2.21	;	DHNA complexed with 9-methylguanine
1RS4	;	2.7	;	DHNA, 7,8-Dihydroneopterin Aldolase complexed with 3-(5-Amino-7-hydroxy-[1,2,3]triazolo[4,5-d]pyrimidin-2-yl)-N-(3,5-dichlorobenzyl)-benzamide
5KSW	;	2.47	;	DHODB-I74D mutant
8DHF	;	1.78	;	DHODH IN COMPLEX WITH LIGAND 11
7K2U	;	1.73	;	DHODH IN COMPLEX WITH LIGAND 13
8DHG	;	1.85	;	DHODH IN COMPLEX WITH LIGAND 19
8DHH	;	2.02	;	DHODH IN COMPLEX WITH LIGAND 29
7LZO	;	1.93	;	DHP B in complex with 2,4-Dibromophenol substrate
7LZK	;	1.49	;	DHP B in complex with 2,4-Dichlorophenol substrate
7LZN	;	1.95	;	DHP B in complex with 2,4-Dichlorophenol substrate
7M0F	;	1.48	;	DHP B in complex with 4-bromophenol ligand
7M0H	;	1.91	;	DHP B in complex with 4-chlorophenol ligand
5UKY	;	2.02	;	DHp domain of PhoR of M. tuberculosis - native data
5UKV	;	1.9	;	DHp domain of PhoR of M. tuberculosis - SeMet
5B1N	;	1.33	;	DHp domain structure of EnvZ from Escherichia coli
5B1O	;	2.3	;	DHp domain structure of EnvZ P248A mutant
4JYQ	;	1.8	;	DHP-CO crystal structure
6MHA	;	1.497	;	dHP1 Chromodomain Y24W variant bound to histone H3 peptide containing trimethyllysine
3OU2	;	1.5	;	DhpI-SAH complex structure
3OU6	;	2.3	;	DhpI-SAM complex
3OU7	;	2.3	;	DhpI-SAM-HEP complex
7MQJ	;	2.23	;	Dhr1 Helicase Core
5VHE	;	3.793	;	DHX36 in complex with the c-Myc G-quadruplex
5VHA	;	2.227	;	DHX36 with an N-terminal truncation
5VHD	;	2.55	;	DHX36 with an N-terminal truncation bound to ADP-AlF4
5VHC	;	2.49	;	DHX36 with an N-terminal truncation bound to ADP-BeF3
1RZ6	;	2.2	;	Di-haem Cytochrome c Peroxidase, Form IN
1RZ5	;	2.4	;	Di-haem Cytochrome c Peroxidase, Form OUT
1NML	;	2.2	;	Di-haemic Cytochrome c Peroxidase from Pseudomonas nautica 617, form IN (pH 4.0)
2LHX	;		;	Di-O-GalNAc glycosylated Mucin sequence based on MUC2 Mucin glycoprotein tandem repeat
2LHY	;		;	Di-O-GalNAc glycosylated Mucin sequence based on MUC2 Mucin glycoprotein tandem repeat
2LHZ	;		;	Di-O-GalNAc glycosylated Mucin sequence based on MUC2 Mucin glycoprotein tandem repeat
7NDY	;	1.44	;	Di-phosphorylated Barrier-to-Autointegration Factor (BAF) in complex with LEM domain of Emerin
6QKA	;	2.1	;	Di-tert-butyl Polysulfide inhibited sulfur oxygenase reductase
5N58	;	1.957	;	di-Zinc VIM-5 metallo-beta-lactamase in complex with (1-chloro-4-hydroxyisoquinoline-3-carbonyl)-D-tryptophan (Compound 1)
8OLN	;	3.3	;	DI1 Abeta fibril from tg-SwDI mouse
8OLG	;	4.2	;	DI2 Abeta fibril from tg-SwDI mouse
8OLQ	;	4.0	;	DI3 Abeta fibril from tg-SwDI mouse
2GYP	;	1.4	;	Diabetes mellitus due to a frustrated Schellman motif in HNF-1a
1XW7	;	2.3	;	Diabetes-Associated Mutations in Human Insulin: Crystal Structure and Photo-Cross-Linking Studies of A-Chain Variant Insulin Wakayama
5FCS	;	2.01	;	Diabody
4Y5V	;	2.604	;	Diabody 305 complex with EpoR
4Y5X	;	3.15	;	Diabody 305 complex with EpoR
4Y5Y	;	2.85	;	Diabody 330 complex with EpoR
6VUG	;	3.0	;	Diabody bound to a Reverse Transcriptase Aptamer Complex
5DWK	;	2.601	;	Diacylglycerol Kinase solved by multi crystal multi orientation native SAD
7L8N	;	1.94	;	Diadenylate cyclase with AMP from Streptococcus mutans
1DKA	;	2.6	;	DIALKYLGLYCINE DECARBOXYLASE STRUCTURE: BIFUNCTIONAL ACTIVE SITE AND ALKALI METAL BINDING SITES
2DKB	;	2.1	;	DIALKYLGLYCINE DECARBOXYLASE STRUCTURE: BIFUNCTIONAL ACTIVE SITE AND ALKALI METAL BINDING SITES
6QKM	;	2.102	;	Diallyl trisulfide inhibited sulfur oxygenase reductase
4NGW	;	1.37	;	Dialyzed HEW lysozyme batch crystallized in 0.5 M YbCl3 and collected at 100 K
4NGY	;	1.35	;	Dialyzed HEW lysozyme batch crystallized in 0.75 M YbCl3 and collected at 100 K
4NGJ	;	1.1	;	Dialyzed HEW lysozyme batch crystallized in 1.0 M RbCl and collected at 100 K
4NG8	;	1.09	;	Dialyzed HEW lysozyme batch crystallized in 1.9 M CsCl and collected at 100 K.
3UBP	;	2.0	;	DIAMIDOPHOSPHATE INHIBITED BACILLUS PASTEURII UREASE
6SLK	;	2.2	;	Diaminobutyrate acetyltransferase EctA from Paenibacillus lautus
6SK1	;	1.5	;	Diaminobutyrate acetyltransferase EctA from Paenibacillus lautus in complex with coenzyme A
6SJY	;	2.2	;	Diaminobutyrate acetyltransferase EctA from Paenibacillus lautus in complex with its product ADABA
6SL8	;	1.53	;	Diaminobutyrate acetyltransferase EctA from Paenibacillus lautus in complex with its substrate L-2,4-diaminobutyric acid (DAB)
6SLL	;	1.2	;	Diaminobutyrate acetyltransferase EctA from Paenibacillus lautus in complex with its substrate L-2,4-diaminobutyric acid (DAB) and coenzyme A
1BWZ	;	2.72	;	DIAMINOPIMELATE EPIMERASE FROM HEMOPHILUS INFLUENZAE
2HMV	;	2.2	;	Diamond-shaped octameric ring structure of an RCK domain with ADP bound
2HMU	;	2.25	;	Diamond-shaped octameric ring structure of an RCK domain with ATP bound
2HMT	;	2.2	;	Diamond-shaped octameric ring structure of an RCK domain with NADH bound
4J91	;	2.93	;	Diamond-shaped octameric structure of KtrA with ADP bound
1Y59	;	1.2	;	Dianhydrosugar-based benzamidine, factor Xa specific inhibitor in complex with bovine trypsin mutant
1Y5A	;	1.4	;	Dianhydrosugar-based benzamidine, factor Xa specific inhibitor in complex with bovine trypsin mutant
1Y5B	;	1.65	;	Dianhydrosugar-based benzamidine, factor Xa specific inhibitor in complex with bovine trypsin mutant
1Y5U	;	1.6	;	Dianhydrosugar-based benzamidine, factor Xa specific inhibitor in complex with bovine trypsin mutant
7FFC	;	2.61	;	Diarylpentanoid-producing polyketide synthase (A210E mutant)
7FFI	;	2.4	;	Diarylpentanoid-producing polyketide synthase (F340W mutant)
7FFG	;	2.3	;	Diarylpentanoid-producing polyketide synthase (N199F mutant)
7FFH	;	2.2	;	Diarylpentanoid-producing polyketide synthase (N199L mutant)
7FFA	;	1.98	;	Diarylpentanoid-producing polyketide synthase from Aquilaria sinensis
4IA1	;	2.44	;	Diastereotopic and Deuterium Effects in Gemini
4IA2	;	2.95	;	Diastereotopic and Deuterium Effects in Gemini
4IA3	;	2.7	;	Diastereotopic and Deuterium Effects in Gemini
4IA7	;	2.7	;	Diastereotopic and Deuterium Effects in Gemini
5VFD	;	1.93	;	Diazabicyclooctenone ETX2514 bound to Class D beta lactamase OXA-24 from A. baumannii
7NKU	;	3.4	;	diazaborine bound Drg1(AFG2)
8IFD	;	2.59	;	Dibekacin-added human 80S ribosome
8IFB	;	2.43	;	Dibekacin-bound E.coli 70S ribosome in the PURE system
5MTX	;	1.8	;	Dibenzooxepinone inhibitor 12b in complex with p38 MAPK
5MTY	;	2.31	;	Dibenzosuberone inhibitor 8e in complex with p38 MAPK
4NXL	;	2.3	;	Dibenzothiophene monooxygenase (DszC) from Rhodococcus erythropolis
2KOU	;		;	DICER LIKE protein
7W0C	;	3.93	;	Dicer2-Loqs-PD-dsRNA complex at early-translocation state
7W0B	;	3.33	;	Dicer2-LoqsPD complex at apo status
7W0D	;	4.18	;	Dicer2-LoqsPD-dsRNA complex at mid-translocation state
3SOK	;	2.3	;	Dichelobacter nodosus pilin FimA
2DAU	;		;	DICKERSON-DREW DNA DODECAMER, NMR, MINIMIZED AVERAGE STRUCTURE
6PAE	;	1.6	;	Dickeya chrysanthemi complex with L-Asp at pH 5.6
4PJK	;	2.15	;	Dicty myosin II R238E.E459R mutant (with ADP.Pi) in the Pi release state
4ZZQ	;	2.1	;	Dictyostelium discoideum cellobiohydrolase Cel7A apo structure
5F9K	;	2.179	;	Dictyostelium discoideum dUTPase at 2.2 Angstrom
7ODZ	;	1.6	;	Dictyostelium discoideum dye decolorizing peroxidase DyPA in complex with an activated form of oxygen and veratryl alcohol
7O9L	;	1.85	;	Dictyostelium discoideum dye decolorizing peroxidase DyPA in complex with cyanide.
7WN9	;	2.3	;	Dictyostelium discoideum Lactate dehydrogenase (DicLDHA)
8GRV	;	2.9	;	Dictyostelium discoideum Lactate dehydrogenase (DicLDHA)with NAD
1W9K	;	2.05	;	Dictyostelium discoideum Myosin II motor domain S456E with bound MgADP-BeFx
1D0X	;	2.0	;	DICTYOSTELIUM MYOSIN S1DC (MOTOR DOMAIN FRAGMENT) COMPLEXED WITH M-NITROPHENYL AMINOETHYLDIPHOSPHATE BERYLLIUM TRIFLUORIDE.
1D1C	;	2.3	;	DICTYOSTELIUM MYOSIN S1DC (MOTOR DOMAIN FRAGMENT) COMPLEXED WITH N-METHYL-O-NITROPHENYL AMINOETHYLDIPHOSPHATE BERYLLIUM TRIFLUORIDE.
1D1A	;	2.0	;	DICTYOSTELIUM MYOSIN S1DC (MOTOR DOMAIN FRAGMENT) COMPLEXED WITH O,P-DINITROPHENYL AMINOETHYLDIPHOSPHATE BERYLLIUM TRIFLUORIDE.
1D1B	;	2.0	;	DICTYOSTELIUM MYOSIN S1DC (MOTOR DOMAIN FRAGMENT) COMPLEXED WITH O,P-DINITROPHENYL AMINOPROPYLDIPHOSPHATE BERYLLIUM TRIFLUORIDE.
1D0Y	;	2.0	;	DICTYOSTELIUM MYOSIN S1DC (MOTOR DOMAIN FRAGMENT) COMPLEXED WITH O-NITROPHENYL AMINOETHYLDIPHOSPHATE BERYLLIUM FLUORIDE.
1D0Z	;	2.0	;	DICTYOSTELIUM MYOSIN S1DC (MOTOR DOMAIN FRAGMENT) COMPLEXED WITH P-NITROPHENYL AMINOETHYLDIPHOSPHATE BERYLLIUM TRIFLUORIDE.
4ZZP	;	2.7	;	Dictyostelium purpureum cellobiohydrolase Cel7A apo structure
3GYE	;	2.0	;	Didydroorotate dehydrogenase from Leishmania major
6E6Y	;	1.6	;	Dieckmann cyclase, NcmC
6E6T	;	1.6	;	Dieckmann cyclase, NcmC, bound to cerulenin
1A4J	;	2.1	;	DIELS ALDER CATALYTIC ANTIBODY GERMLINE PRECURSOR
1A4K	;	2.4	;	DIELS ALDER CATALYTIC ANTIBODY WITH TRANSITION STATE ANALOGUE
7Z6P	;	1.56	;	Diels-Alderase AbyU mutant - Y76F
1DIN	;	1.8	;	DIENELACTONE HYDROLASE AT 2.8 ANGSTROMS
1DCI	;	1.5	;	DIENOYL-COA ISOMERASE
4L7H	;	1.85	;	Diethylaminosulfur Trifluoride-Mediated Intramolecular Cyclization of 2-hydroxy-benzylureas to Fused Bicyclic Aminooxazoline Compounds and Evaluation of Their Biochemical Activity Against Beta-Secretase-1 (BACE-1)
4L7J	;	1.651	;	Diethylaminosulfur Trifluoride-Mediated Intramolecular Cyclization of 2-hydroxy-benzylureas to Fused Bicyclic Aminooxazoline Compounds and Evaluation of Their Biochemical Activity Against Beta-Secretase-1 (BACE-1)
4L7G	;	1.38	;	Diethylaminosulfur Trifluoride-Mediated Intramolecular Cyclization of 2-hydroxy-benzylureas to Fused Bicyclic Aminooxazoline Compounds and Evaluation of Their Biochemical Activity Against Beta-Secretase-1 (BACE1)
4GXN	;	2.2	;	Diethylphosphonate Inhibited Structure of the Proteus mirabilis Lipase
1XLW	;	2.1	;	Diethylphosphorylated Butyrylcholinesterase (Nonaged) Obtained By Reaction With Echothiophate
7O8D	;	1.12	;	diFe-sulerythrin oxidised by H2O2
7O8A	;	1.21	;	diFe-sulerythrin reduced with Na-dithionite
3QYT	;	2.8	;	Diferric bound human serum transferrin
1N04	;	2.8	;	Diferric chicken serum transferrin at 2.8 A resolution.
3I5J	;	1.9	;	Diferric Resting State Toluene 4-Monooxygenase HD complex
5O8B	;	1.7	;	Difference-refined excited-state structure of rsEGFP2 1ps following 400nm-laser irradiation of the off-state.
7R36	;	2.2	;	Difference-refined structure of fatty acid photodecarboxylase 2 microsecond following 400-nm laser irradiation of the dark-state determined by SFX
7R33	;	2.0	;	Difference-refined structure of fatty acid photodecarboxylase 20 ps following 400-nm laser irradiation of the dark-state determined by SFX
7R35	;	2.0	;	Difference-refined structure of fatty acid photodecarboxylase 300 ns following 400-nm laser irradiation of the dark-state determined by SFX
7R34	;	2.0	;	Difference-refined structure of fatty acid photodecarboxylase 900 ps following 400-nm laser irradiation of the dark-state determined by SFX
6T3A	;	1.85	;	Difference-refined structure of rsEGFP2 10 ns following 400-nm laser irradiation of the off-state determined by SFX
1N9U	;		;	Differences and Similarities in Solution Structures of Angiotensin I & II: Implication for Structure-Function Relationship
1N9V	;		;	Differences and Similarities in Solution Structures of Angiotensin I & II: Implication for Structure-Function Relationship.
7Z2R	;	2.574	;	Differences between the GluD1 and GluD2 receptors revealed by GluD1 X-ray crystallography, binding studies and molecular dynamics
1HUG	;	2.0	;	Differences in anionic inhibition of Human Carbonic Anhydrase I revealed from the structures of iodide and gold cyanide inhibitor complexes
1HUH	;	2.2	;	DIFFERENCES IN ANIONIC INHIBITION OF HUMAN CARBONIC ANHYDRASE I REVEALED FROM THE STRUCTURES OF IODIDE AND GOLD CYANIDE INHIBITOR COMPLEXES
2JOW	;		;	Differences in the electrostatic surfaces of the type III secretion needle proteins
2SPT	;	2.5	;	DIFFERENCES IN THE METAL ION STRUCTURE BETWEEN SR-AND CA-PROTHROMBIN FRAGMENT 1
4JEQ	;	2.303	;	Different Contribution of Conserved Amino Acids to the Global Properties of Homologous Enzymes
1HSB	;	1.9	;	DIFFERENT LENGTH PEPTIDES BIND TO HLA-AW68 SIMILARLY AT THEIR ENDS BUT BULGE OUT IN THE MIDDLE
4J89	;	2.1	;	Different photochemical events of a genetically encoded aryl azide define and modulate GFP fluorescence
3ERY	;	1.95	;	Different thermodynamic binding mechanisms and peptide fine specificities associated with a panel of structurally similar high-affinity T cell receptors
4RE2	;	2.0	;	Different transition state conformations for the hydrolysis of beta-mannosides and beta-glucosides in the rice Os7BGlu26 family GH1 beta-mannosidase/beta-glucosidase
4RE3	;	2.55	;	Different transition state conformations for the hydrolysis of beta-mannosides and beta-glucosides in the rice Os7BGlu26 family GH1 beta-mannosidase/beta-glucosidase
4RE4	;	2.29	;	Different transition state conformations for the hydrolysis of beta-mannosides and beta-glucosides in the rice Os7BGlu26 family GH1 beta-mannosidase/beta-glucosidase
2C5N	;	2.1	;	Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design
2C5O	;	2.1	;	Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design
2C5V	;	2.9	;	Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design
2C5X	;	2.9	;	Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design
2C5Y	;	2.25	;	DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
4AZ5	;	1.73	;	Differential inhibition of the tandem GH20 catalytic modules in the pneumococcal exo-beta-D-N-acetylglucosaminidase, StrH
4AZ6	;	1.36	;	Differential inhibition of the tandem GH20 catalytic modules in the pneumococcal exo-beta-D-N-acetylglucosaminidase, StrH
4AZ7	;	1.7	;	Differential inhibition of the tandem GH20 catalytic modules in the pneumococcal exo-beta-D-N-acetylglucosaminidase, StrH
4AZB	;	2.1	;	Differential inhibition of the tandem GH20 catalytic modules in the pneumococcal exo-beta-D-N-acetylglucosaminidase, StrH
4AZC	;	2.09	;	Differential inhibition of the tandem GH20 catalytic modules in the pneumococcal exo-beta-D-N-acetylglucosaminidase, StrH
4AZG	;	2.4	;	Differential inhibition of the tandem GH20 catalytic modules in the pneumococcal exo-beta-D-N-acetylglucosaminidase, StrH
4AZH	;	2.22	;	Differential inhibition of the tandem GH20 catalytic modules in the pneumococcal exo-beta-D-N-acetylglucosaminidase, StrH
4AZI	;	1.98	;	Differential inhibition of the tandem GH20 catalytic modules in the pneumococcal exo-beta-D-N-acetylglucosaminidase, StrH
2VA0	;	2.602	;	Differential regulation of the xylan degrading apparatus of Cellvibrio japonicus by a novel two component system
1BPM	;	2.9	;	DIFFERENTIATION AND IDENTIFICATION OF THE TWO CATALYTIC METAL BINDING SITES IN BOVINE LENS LEUCINE AMINOPEPTIDASE BY X-RAY CRYSTALLOGRAPHY
1BPN	;	2.9	;	DIFFERENTIATION AND IDENTIFICATION OF THE TWO CATALYTIC METAL BINDING SITES IN BOVINE LENS LEUCINE AMINOPEPTIDASE BY X-RAY CRYSTALLOGRAPHY
6SHG	;	3.35051	;	Diffraction data for RoAb13 crystal co-crystallised with PIYDIN and its RoAb13 structure
4TW9	;	2.4	;	Difluoro-dioxolo-benzoimidazol-benzamides as potent inhibitors of CK1delta and epsilon with nanomolar inhibitory activity on cancer cell proliferation
6QJ7	;	1.69	;	Difluorophenyl diacylhydrazides: Potent inhibitors of Serum- and Glucocorticoid-inducible Kinase 1 (SGK1)
7V1W	;	1.86	;	Difructose dianhydride I synthase/hydrolase (alphaFFase1) from Bifidobacterium dentium in complex with beta-D-arabinofuranose
7V1X	;	1.76	;	Difructose dianhydride I synthase/hydrolase (alphaFFase1) from Bifidobacterium dentium in complex with beta-D-fructofuranose
7V1V	;	1.96	;	Difructose dianhydride I synthase/hydrolase (alphaFFase1) from Bifidobacterium dentium, ligand-free form
6ZXC	;	2.8	;	Diguanylate cyclase DgcR (I-site mutant) in activated state
6ZXB	;	2.2	;	Diguanylate cyclase DgcR (I-site mutant) in native state
6ZXM	;	3.3	;	Diguanylate cyclase DgcR in complex with c-di-GMP
3TVK	;	1.8	;	Diguanylate cyclase domain of DgcZ
6N1P	;	6.35	;	Dihedral oligomeric complex of GyrA N-terminal fragment with DNA, solved by cryoEM in C2 symmetry
6N1Q	;	5.16	;	Dihedral oligomeric complex of GyrA N-terminal fragment, solved by cryoEM in D2 symmetry
2FW5	;	2.0	;	Diheme cytochrome c from Rhodobacter sphaeroides
7ZS0	;	1.75	;	Diheme cytochrome c Kustd1711 from Kuenenia stuttgartiensis
7ZS1	;	1.7	;	Diheme cytochrome c Kustd1711 from Kuenenia stuttgartiensis, M292C mutant
7ZS2	;	1.12	;	Diheme cytochrome c Kustd1711 from Kuenenia stuttgartiensis, M292H mutant
3OA8	;	1.77	;	Diheme SoxAX
3OCD	;	2.25	;	Diheme SoxAX - C236M mutant
6MM9	;	5.97	;	Diheteromeric NMDA receptor GluN1/GluN2A in the '1-Knuckle' conformation, in complex with glycine and glutamate, in the presence of 1 micromolar zinc chloride, and at pH 6.1
6MMK	;	6.08	;	Diheteromeric NMDA receptor GluN1/GluN2A in the '1-Knuckle' conformation, in complex with glycine and glutamate, in the presence of 1 micromolar zinc chloride, and at pH 7.4
6MML	;	7.14	;	Diheteromeric NMDA receptor GluN1/GluN2A in the '2-Knuckle-Asymmetric' conformation, in complex with glycine and glutamate, in the presence of 1 micromolar zinc chloride, and at pH 7.4
6MMP	;	6.88	;	Diheteromeric NMDA receptor GluN1/GluN2A in the '2-Knuckle-Symmetric' conformation, in complex with glycine and glutamate, in the presence of 0.1 millimolar EDTA, and at pH 8.0
6MMN	;	7.51	;	Diheteromeric NMDA receptor GluN1/GluN2A in the '2-Knuckle-Symmetric' conformation, in complex with glycine and glutamate, in the presence of 1 micromolar zinc chloride, and at pH 8.0
6MMG	;	6.23	;	Diheteromeric NMDA receptor GluN1/GluN2A in the '2-Knuckle-Symmetric' conformation, in complex with glycine and glutamate, in the presence of 1 millimolar EDTA, and at pH 7.4
6MMR	;	5.13	;	Diheteromeric NMDA receptor GluN1/GluN2A in the '2-Knuckle-Symmetric' conformation, in complex with glycine and glutamate, in the presence of 1 millimolar zinc chloride, 3 millimolar EDTA, and at pH 7.4
6MMA	;	6.31	;	Diheteromeric NMDA receptor GluN1/GluN2A in the 'Extended' conformation, in complex with glycine and glutamate, in the presence of 1 micromolar zinc chloride, and at pH 6.1
6MMM	;	6.84	;	Diheteromeric NMDA receptor GluN1/GluN2A in the 'Extended-1' conformation, in complex with glycine and glutamate, in the presence of 1 micromolar zinc chloride, and at pH 7.4
6MMH	;	8.21	;	Diheteromeric NMDA receptor GluN1/GluN2A in the 'Extended-2' conformation, in complex with glycine and glutamate, in the presence of 1 millimolar zinc chloride, and at pH 7.4
6MMI	;	8.93	;	Diheteromeric NMDA receptor GluN1/GluN2A in the 'Splayed-Open' conformation, in complex with glycine and glutamate, in the presence of 1 millimolar zinc chloride, and at pH 7.4
6MMB	;	12.7	;	Diheteromeric NMDA receptor GluN1/GluN2A in the 'Super-Splayed' conformation, in complex with glycine and glutamate, in the presence of 1 micromolar zinc chloride, and at pH 6.1
6MMJ	;	16.5	;	Diheteromeric NMDA receptor GluN1/GluN2A in the 'Super-Splayed' conformation, in complex with glycine and glutamate, in the presence of 1 millimolar zinc chloride, and at pH 7.4
6RTD	;	2.36	;	Dihydro-heme d1 dehydrogenase NirN in complex with DHE
6RTE	;	1.94	;	Dihydro-heme d1 dehydrogenase NirN in complex with DHE
1C3V	;	2.39	;	DIHYDRODIPICOLINATE REDUCTASE FROM MYCOBACTERIUM TUBERCULOSIS COMPLEXED WITH NADPH AND PDC
5Z2D	;	1.8	;	Dihydrodipicolinate reductase from Paenisporosarcina sp. TG-14
5KT0	;	2.83	;	Dihydrodipicolinate reductase from the industrial and evolutionarily important cyanobacteria Anabaena variabilis.
1DHP	;	2.3	;	DIHYDRODIPICOLINATE SYNTHASE
7KXG	;	2.28	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni with pyruvate bound in the active site and L-histidine bound at the allosteric site
7KWP	;	2.26	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni with pyruvate bound in the active site and L-lysine bound at the allosteric site in C2221 space group
7KXH	;	1.94	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni with pyruvate bound in the active site and R,R-bislysine bound at the allosteric site in C2221 space group
7L4B	;	2.42	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni with pyruvate bound in the active site in P1211 space group
7KN2	;	2.53	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, E88A mutant with pyruvate bound in the active site
7KN9	;	2.07	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, E88A mutant with pyruvate bound in the active site and L-lysine bound at the allosteric site
7KNZ	;	2.28	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, E88A mutant with pyruvate bound in the active site and R,R-bislysine at the allosteric site
7KO1	;	2.5	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, E88D mutant with pyruvate bound in the active site
7KO3	;	2.22	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, E88D mutant with pyruvate bound in the active site and L-lysine bound at the allosteric site
7KOC	;	2.06	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, E88Q mutant with pyruvate bound in the active site
7KPC	;	1.76	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, E88Q mutant with pyruvate bound in the active site and L-lysine bound at the allosteric site
7KPE	;	2.06	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, E88Q mutant with pyruvate bound in the active site and R,R-bislysine at the allosteric site
7KR8	;	2.12	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, H56A mutant with pyruvate bound in the active site
7KR7	;	2.22	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, H56A mutant with pyruvate bound in the active site and L-lysine at the allosteric site
7KTO	;	2.13	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, H56A mutant with pyruvate bound in the active site and R,R-bislysine bound at the allosteric site
7KU6	;	2.81	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, H56N mutant with pyruvate bound in the active site
7KUZ	;	2.25	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, H56N mutant with pyruvate bound in the active site and L-lysine bound at the allosteric site
7KWF	;	2.82	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, H56N mutant with pyruvate bound in the active site and R,R-bislysine bound at the allosteric site
7KG5	;	1.95	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, H56W mutant with pyruvate bound in the active site
7KG9	;	2.06	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, H56W mutant with pyruvate bound in the active site and L-lysine bound at the allosteric site
7KH4	;	1.75	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, H56W mutant with pyruvate bound in the active site and R,R-bislysine bound at the allosteric site
7KLQ	;	2.5	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, H59A mutant with pyruvate bound in the active site
7KLS	;	2.59	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, H59A mutant with pyruvate bound in the active site and L-lysine bound at the allosteric site
7KM0	;	2.6	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, H59A mutant with pyruvate bound in the active site and R,R-bislysine bound at the allosteric site
7KEL	;	2.1	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, H59K mutant with pyruvate bound in the active site
7KG2	;	1.89	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, H59K mutant with pyruvate bound in the active site and L-histidine bound at the allosteric site
7LBD	;	1.99	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, H59K mutant with pyruvate bound in the active site in C2221 space group
7KLT	;	1.97	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, H59N mutant with pyruvate bound in the active site
7KLY	;	1.67	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, H59N mutant with pyruvate bound in the active site and L-lysine bound at the allosteric site
7KM1	;	1.84	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, H59N mutant with pyruvate bound in the active site and R,R-bislysine bound at the allosteric site
6TZU	;	1.8	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, N84A mutant with pyruvate bound in the active site
7KK1	;	1.77	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, N84A mutant with pyruvate bound in the active site and L-lysine bound at the allosteric site
7KKD	;	1.6	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, N84A mutant with pyruvate bound in the active site and R,R-bislysine bound at the allosteric site
6U01	;	1.87	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, N84D mutant with pyruvate bound in the active site
7KKG	;	1.64	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, N84D mutant with pyruvate bound in the active site and L-lysine bound at the allosteric site
7KKT	;	1.71	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, N84D mutant with pyruvate bound in the active site and R,R-bislysine bound at the allosteric site
7LCF	;	2.69	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, with pyruvate bound in the active site and L-lysine bound at the allosteric site in C121 space group
7KX1	;	2.04	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, Y110F mutant with pyruvate bound in the active in C2221 space group
7KZ2	;	1.9	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, Y110F mutant with pyruvate bound in the active site and L-lysine bound at the allosteric site in C2221 space group
7M06	;	2.7	;	Dihydrodipicolinate synthase (DHDPS) from C.jejuni, Y110F mutant with R,R-bislysine bound at the allosteric site at 2.7 Angstrom
2A6N	;	1.94	;	Dihydrodipicolinate synthase (E. coli)- mutant R138A
2A6L	;	2.05	;	Dihydrodipicolinate synthase (E. coli)- mutant R138H
3I7R	;	2.1	;	Dihydrodipicolinate synthase - K161R
7LVL	;	2.01	;	Dihydrodipicolinate synthase bound with allosteric inhibitor (S)-lysine from Candidatus Liberibacter solanacearum
2ATS	;	1.9	;	Dihydrodipicolinate synthase co-crystallised with (S)-lysine
4LY8	;	1.7	;	dihydrodipicolinate synthase from C. jejuni with pyruvate bound to the active site
4M19	;	2.0	;	dihydrodipicolinate synthase from C. jejuni with pyruvate bound to the active site and Lysine bound to allosteric site
7KWN	;	2.24	;	Dihydrodipicolinate synthase from C. jejuni with pyruvate bound to the active site in C2221 space group
4R53	;	2.0	;	dihydrodipicolinate synthase from C. jejuni with vacant active site and vacant allosteric site
4MLR	;	2.2	;	dihydrodipicolinate synthase from C. jejuni, Y110F mutation with pyruvate and Lysine
4MLJ	;	2.3	;	dihydrodipicolinate synthase from C. jejuni, Y110F mutation with pyruvate bound to the active site
3G0S	;	1.85	;	Dihydrodipicolinate synthase from Salmonella typhimurium LT2
4ICN	;	2.5	;	Dihydrodipicolinate synthase from shewanella benthica
4HNN	;	2.4	;	Dihydrodipicolinate Synthase from the common grapevine with pyruvate and lysine
5KTL	;	1.92	;	Dihydrodipicolinate synthase from the industrial and evolutionarily important cyanobacteria Anabaena variabilis.
3I7Q	;	2.0	;	Dihydrodipicolinate synthase mutant - K161A
3I7S	;	2.3	;	Dihydrodipicolinate synthase mutant - K161A - with the substrate pyruvate bound in the active site.
7JZ7	;	1.74	;	Dihydrodipicolinate synthase mutant S48F
7JZ8	;	1.82	;	Dihydrodipicolinate synthase mutant S48F with lysine in the allosteric site
7JZG	;	1.82	;	Dihydrodipicolinate synthase mutant S48F with lysine in the allosteric site and pyruvate in the catalytic site
7JZF	;	1.82	;	Dihydrodipicolinate synthase mutant S48F with pyruvate in the catalytic site
7JZE	;	2.0	;	Dihydrodipicolinate synthase mutant S48W
7JZD	;	1.91	;	Dihydrodipicolinate synthase mutation S48W with Lysine in the allosteric site
4I7U	;	1.55	;	Dihydrodipicolinate Synthase of Agrobacterium tumefaciens
7JZA	;	1.82	;	Dihydrodipicolinate synthase S48F mutant with lysine in the allosteric site, and pyruvate and succinic semi-aldehyde in the catalytic site
7JZ9	;	1.82	;	Dihydrodipicolinate synthase S48F with pyruvate and succinic semi-aldehyde
7JZC	;	2.07	;	Dihydrodipicolinate synthase S48W mutant with lysine in the allosteric site, and pyruvate in the catalytic site
7JZB	;	1.93	;	Dihydrodipicolinate synthase S48W with lysine in the allosteric site, and pyruvate and succinic semi-aldehyde
7LOY	;	2.4	;	Dihydrodipicolinate synthase with pyruvate from Candidatus Liberibacter solanacearum
8GEK	;	1.93	;	Dihydrodipicolinate synthase with pyruvate from Candidatus Liberibacter solanacearum
1VDR	;	2.55	;	DIHYDROFOLATE REDUCTASE
6DRS	;	1.997	;	Dihydrofolate Reductase (DHFR) of Aspergillus flavus in complex with a small molecule inhibitor
6DTC	;	2.0	;	Dihydrofolate Reductase (DHFR) of Aspergillus flavus in complex with a small molecule inhibitor
1DIS	;		;	DIHYDROFOLATE REDUCTASE (E.C.1.5.1.3) COMPLEX WITH BRODIMOPRIM-4,6-DICARBOXYLATE
1DIU	;		;	DIHYDROFOLATE REDUCTASE (E.C.1.5.1.3) COMPLEX WITH BRODIMOPRIM-4,6-DICARBOXYLATE
1RX5	;	2.3	;	DIHYDROFOLATE REDUCTASE (E.C.1.5.1.3) COMPLEXED WITH 5,10-DIDEAZATETRAHYDROFOLATE
1RX4	;	2.2	;	DIHYDROFOLATE REDUCTASE (E.C.1.5.1.3) COMPLEXED WITH 5,10-DIDEAZATETRAHYDROFOLATE AND 2'-MONOPHOSPHOADENOSINE 5'-DIPHOSPHORIBOSE
1RX6	;	2.0	;	DIHYDROFOLATE REDUCTASE (E.C.1.5.1.3) COMPLEXED WITH 5,10-DIDEAZATETRAHYDROFOLATE AND NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE (REDUCED FORM)
1RX3	;	2.2	;	DIHYDROFOLATE REDUCTASE (E.C.1.5.1.3) COMPLEXED WITH METHOTREXATE AND NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE (REDUCED FORM)
1RX9	;	1.9	;	DIHYDROFOLATE REDUCTASE (E.C.1.5.1.3) COMPLEXED WITH NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE (OXIDIZED FORM)
1RX1	;	2.0	;	DIHYDROFOLATE REDUCTASE (E.C.1.5.1.3) COMPLEXED WITH NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE (REDUCED FORM)
1RX2	;	1.8	;	DIHYDROFOLATE REDUCTASE (E.C.1.5.1.3) COMPLEXED WITH WITH FOLATE AND NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE (OXIDIZED FORM)
1RC4	;	1.9	;	DIHYDROFOLATE REDUCTASE COMPLEXED WITH 5,10-DIDEAZATETRAHYDROFOLATE AND NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE (OXIDIZED FORM)
1RD7	;	2.6	;	DIHYDROFOLATE REDUCTASE COMPLEXED WITH FOLATE
1RE7	;	2.6	;	DIHYDROFOLATE REDUCTASE COMPLEXED WITH FOLATE
8UCX	;	1.57	;	Dihydrofolate Reductase Complexed with Folate
1RX8	;	2.8	;	DIHYDROFOLATE REDUCTASE COMPLEXED WITH FOLATE AND 2'-MONOPHOSPHOADENOSINE 5'-DIPHOSPHORIBOSE
1RA8	;	1.8	;	DIHYDROFOLATE REDUCTASE COMPLEXED WITH FOLATE AND 2-MONOPHOSPHOADENOSINE 5'-DIPHOSPHORIBOSE
1RA2	;	1.6	;	DIHYDROFOLATE REDUCTASE COMPLEXED WITH FOLATE AND NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE (OXIDIZED FORM)
1RB2	;	2.1	;	DIHYDROFOLATE REDUCTASE COMPLEXED WITH FOLATE AND NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE (OXIDIZED FORM)
1RG7	;	2.0	;	DIHYDROFOLATE REDUCTASE COMPLEXED WITH METHOTREXATE
1DRE	;	2.6	;	DIHYDROFOLATE REDUCTASE COMPLEXED WITH METHOTREXATE AND NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE (OXIDIZED FORM)
1RA3	;	1.8	;	DIHYDROFOLATE REDUCTASE COMPLEXED WITH METHOTREXATE AND NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE (OXIDIZED FORM)
1RB3	;	2.3	;	DIHYDROFOLATE REDUCTASE COMPLEXED WITH METHOTREXATE AND NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE (OXIDIZED FORM)
1RH3	;	2.4	;	DIHYDROFOLATE REDUCTASE COMPLEXED WITH METHOTREXATE AND NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE (REDUCED FORM)
1AO8	;		;	DIHYDROFOLATE REDUCTASE COMPLEXED WITH METHOTREXATE, NMR, 21 STRUCTURES
1RA9	;	1.55	;	DIHYDROFOLATE REDUCTASE COMPLEXED WITH NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE (OXIDIZED FORM)
1RA1	;	1.9	;	DIHYDROFOLATE REDUCTASE COMPLEXED WITH NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE (REDUCED FORM)
4M7U	;	2.1014	;	Dihydrofolate reductase from Enterococcus faecalis complexed with NADP(H)
4M7V	;	2.3	;	Dihydrofolate reductase from Enterococcus faecalis complexed with NADP(H)and RAB-propyl
2CIG	;	1.9	;	Dihydrofolate reductase from Mycobacterium tuberculosis inhibited by the acyclic 4R isomer of INH-NADP a derivative of the prodrug isoniazid.
1CZ3	;	2.1	;	DIHYDROFOLATE REDUCTASE FROM THERMOTOGA MARITIMA
1D1G	;	2.1	;	DIHYDROFOLATE REDUCTASE FROM THERMOTOGA MARITIMA
1DG8	;	2.0	;	DIHYDROFOLATE REDUCTASE OF MYCOBACTERIUM TUBERCULOSIS COMPLEXED WITH NADPH
1DG7	;	1.8	;	DIHYDROFOLATE REDUCTASE OF MYCOBACTERIUM TUBERCULOSIS COMPLEXED WITH NADPH AND 4-BROMO WR99210
1DF7	;	1.7	;	DIHYDROFOLATE REDUCTASE OF MYCOBACTERIUM TUBERCULOSIS COMPLEXED WITH NADPH AND METHOTREXATE
1DG5	;	2.0	;	DIHYDROFOLATE REDUCTASE OF MYCOBACTERIUM TUBERCULOSIS COMPLEXED WITH NADPH AND TRIMETHOPRIM
7XH2	;	2.8	;	Dihydrofolate Reductase-like Protein SacH in safracin biosynthesis
7XH4	;	2.2	;	Dihydrofolate Reductase-like Protein SacH in safracin biosynthesis complex with safracin A
5U8U	;	1.35	;	Dihydrolipoamide dehydrogenase (LpdG) from Pseudomonas aeruginosa
5U8V	;	1.45	;	Dihydrolipoamide dehydrogenase (LpdG) from Pseudomonas aeruginosa bound to NAD+
5U8W	;	1.79	;	Dihydrolipoamide dehydrogenase (LpdG) from Pseudomonas aeruginosa bound to NADH
1EBD	;	2.6	;	DIHYDROLIPOAMIDE DEHYDROGENASE COMPLEXED WITH THE BINDING DOMAIN OF THE DIHYDROLIPOAMIDE ACETYLASE
1DXL	;	3.15	;	Dihydrolipoamide dehydrogenase of glycine decarboxylase from Pisum Sativum
4JDR	;	2.5	;	Dihydrolipoamide dehydrogenase of pyruvate dehydrogenase from escherichia coli
4JQ9	;	2.17	;	Dihydrolipoyl dehydrogenase of Escherichia coli pyruvate dehydrogenase complex
1B5S	;	4.4	;	DIHYDROLIPOYL TRANSACETYLASE (E.C.2.3.1.12) CATALYTIC DOMAIN (RESIDUES 184-425) FROM BACILLUS STEAROTHERMOPHILUS
6ZLM	;	4.3	;	Dihydrolipoyllysine-residue acetyltransferase component of fungal pyruvate dehydrogenase complex with protein X bound
7SU7	;	2.09	;	Dihydroneopterin aldolase (DHNA) from Yersinia pestis co-crystallized with product
6OJO	;	1.886	;	Dihydroneopterin aldolase (DHNA) from Yersinia pestis co-crystallized with pterine
7SU8	;	2.65	;	DIHYDRONEOPTERIN ALDOLASE (DHNA) FROM YERSINIA PESTIS with alkylated Cys50 CO-CRYSTALLIZED with 7,8-dihydroneopterin
7SU6	;	2.15	;	DIHYDRONEOPTERIN ALDOLASE (DHNA) Lys98Ala FROM YERSINIA PESTIS CO-CRYSTALLIZED with 7,8-dihydroneopterin
7SU4	;	1.78	;	Dihydroneopterin aldolase (DHNA) Tyr53Phe from Yersinia pestis co-crystallized with 7,8-dihydroneopterin
3R2E	;	2.15	;	Dihydroneopterin aldolase/dihydroneopterin triphosphate 2'-epimerase from Yersinia pestis.
6GDE	;	2.45	;	DIHYDROOROTASE FROM AQUIFEX AEOLICUS STANDARD (P,T)
6GDD	;	2.6	;	DIHYDROOROTASE FROM AQUIFEX AEOLICUS UNDER 1200 BAR OF HYDROSTATIC PRESSURE
6GDF	;	2.5	;	DIHYDROOROTASE FROM AQUIFEX AEOLICUS UNDER 600 BAR OF HYDROSTATIC PRESSURE
3MPG	;	2.6	;	Dihydroorotase from Bacillus anthracis
4YIW	;	2.45	;	DIHYDROOROTASE FROM BACILLUS ANTHRACIS WITH SUBSTRATE BOUND
1XGE	;	1.9	;	Dihydroorotase from Escherichia coli: Loop Movement and Cooperativity between subunits
7UOF	;	1.9	;	Dihydroorotase from M. jannaschii
2B4G	;	1.95	;	dihydroorotate dehydrogenase
3U2O	;	2.18	;	Dihydroorotate Dehydrogenase (DHODH) crystal structure in complex with small molecule inhibitor
1DOR	;	2.0	;	DIHYDROOROTATE DEHYDROGENASE A FROM LACTOCOCCUS LACTIS
2DOR	;	2.0	;	DIHYDROOROTATE DEHYDROGENASE A FROM LACTOCOCCUS LACTIS COMPLEXED WITH OROTATE
4WZH	;	2.12	;	Dihydroorotate dehydrogenase from Leishmania Viannia braziliensis
8B1V	;	1.882	;	Dihydroprecondylocarpine acetate synthase 2 from Tabernanthe iboga
8B26	;	2.42	;	Dihydroprecondylocarpine acetate synthase 2 from Tabernanthe iboga
8B25	;	2.24	;	Dihydroprecondylocarpine acetate synthase 2 from Tabernanthe iboga - stemmadenine acetate bound structure
8B27	;	2.45	;	Dihydroprecondylocarpine acetate synthase from Catharanthus roseus
2VEF	;	1.8	;	Dihydropteroate synthase from Streptococcus pneumoniae
2VEG	;	2.4	;	Dihydropteroate synthase from Streptococcus pneumoniae: complex with 6-hydroxymethyl-7,8-dihydropterin monophosphate
6OFW	;	1.96	;	Dihydropteroate synthase from Xanthomonas albilineans in complex with 7,8-dihydropteroate
3TYC	;	2.303	;	Dihydropteroate Synthase in complex with DHP+
3TYE	;	2.3	;	Dihydropteroate Synthase in complex with DHP-STZ
3TYB	;	2.6	;	Dihydropteroate Synthase in complex with pHBA and DHP+
3TYD	;	2.5	;	Dihydropteroate Synthase in complex with PPi and DHP+
3TYA	;	2.611	;	Dihydropteroate Synthase in complex with product
1AD1	;	2.2	;	DIHYDROPTEROATE SYNTHETASE (APO FORM) FROM STAPHYLOCOCCUS AUREUS
1AD4	;	2.4	;	DIHYDROPTEROATE SYNTHETASE COMPLEXED WITH OH-CH2-PTERIN-PYROPHOSPHATE FROM STAPHYLOCOCCUS AUREUS
1TWS	;	2.0	;	Dihydropteroate Synthetase From Bacillus anthracis
1TX2	;	1.83	;	Dihydropteroate Synthetase, With Bound Inhibitor MANIC, From Bacillus anthracis
1TX0	;	2.15	;	Dihydropteroate Synthetase, With Bound Product Analogue Pteroic Acid, From Bacillus anthracis
1TWZ	;	2.75	;	Dihydropteroate Synthetase, With Bound Substrate Analogue PtP, From Bacillus anthracis
1TWW	;	2.5	;	Dihydropteroate Synthetase, With Bound Substrate Analogue PtPP, From Bacillus anthracis
7M32	;	1.82	;	Dihydropyrimidine Dehydrogenase (DPD) C671A Mutant Soaked with Uracil and NADPH Anaerobically
8F5W	;	1.97	;	Dihydropyrimidine Dehydrogenase (DPD) C671S Mutant Soaked with Dihydrothymine and NADPH Quasi-Anaerobically
8F61	;	2.14	;	Dihydropyrimidine Dehydrogenase (DPD) C671S Mutant Soaked with Dihydrothymine Quasi-Anaerobically
7M31	;	1.69	;	Dihydropyrimidine Dehydrogenase (DPD) C671S Mutant Soaked with Thymine and NADPH Anaerobically
8F6N	;	2.12	;	Dihydropyrimidine Dehydrogenase (DPD) C671S Mutant Soaked with Thymine Quasi-Anaerobically
1H7W	;	1.9	;	Dihydropyrimidine dehydrogenase (DPD) from pig
1GTE	;	1.65	;	DIHYDROPYRIMIDINE DEHYDROGENASE (DPD) FROM PIG, BINARY COMPLEX WITH 5-IODOURACIL
1H7X	;	2.01	;	Dihydropyrimidine dehydrogenase (DPD) from pig, ternary complex of a mutant enzyme (C671A), NADPH and 5-fluorouracil
1GTH	;	2.25	;	DIHYDROPYRIMIDINE DEHYDROGENASE (DPD) FROM PIG, TERNARY COMPLEX WITH NADPH AND 5-IODOURACIL
1GT8	;	3.3	;	DIHYDROPYRIMIDINE DEHYDROGENASE (DPD) FROM PIG, TERNARY COMPLEX WITH NADPH AND URACIL-4-ACETIC ACID
2IU5	;	1.6	;	Dihydroxyacetone kinase operon activator DhaS
2IU4	;	1.96	;	Dihydroxyacetone kinase operon co-activator Dha-DhaQ
3MHG	;	1.92	;	Dihydroxyacetone phosphate carbanion intermediate in tagatose-1,6-bisphosphate aldolase from Streptococcus pyogenes
2QUT	;	1.88	;	Dihydroxyacetone phosphate enamine intermediate in fructose-1,6-bisphosphate aldolase from rabbit muscle
3DFO	;	1.94	;	Dihydroxyacetone phosphate Schiff base and enamine intermediates in D33N mutant fructose-1,6-bisphosphate aldolase from rabbit muscle
3DFS	;	2.03	;	Dihydroxyacetone phosphate Schiff base intermediate in D33S mutant fructose-1,6-bisphosphate aldolase from rabbit muscle
2QUU	;	1.98	;	Dihydroxyacetone phosphate Schiff base intermediate in mutant fructose-1,6-bisphosphate aldolase from rabbit muscle
8IMU	;	1.93	;	Dihydroxyacid dehydratase (DHAD) mutant-V497F
3EKO	;	1.55	;	Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone
3EKR	;	2.0	;	Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone
3HLH	;	1.8	;	Diisopropyl fluorophosphatase (DFPase), active site mutants
3HLI	;	1.4	;	diisopropyl fluorophosphatase (DFPase), active site mutants
3LI3	;	1.66	;	Diisopropyl fluorophosphatase (DFPase), D121E mutant
3LI5	;	1.36	;	Diisopropyl fluorophosphatase (DFPase), E21Q,N120D,N175D,D229N mutant
3LI4	;	1.35	;	Diisopropyl fluorophosphatase (DFPase), N120D,N175D,D229N mutant
6Y5I	;	5.5	;	Dilated form 1 of X-31 Influenza Haemagglutinin at pH 5 (State II)
6Y5J	;	5.6	;	Dilated form 2 of X-31 Influenza Haemagglutinin at pH 5 (State III)
7WWO	;	2.17	;	Dimer form of hypothetical protein TTHA1873 from Thermus thermophilus
5XLL	;	2.201	;	Dimer form of M. tuberculosis PknI sensor domain
1FYR	;	2.4	;	DIMER FORMATION THROUGH DOMAIN SWAPPING IN THE CRYSTAL STRUCTURE OF THE GRB2-SH2 AC-PYVNV COMPLEX
1JU1	;		;	Dimer Initiation Sequence of HIV-1Lai Genomic RNA: NMR Solution Structure of the Extended Duplex
4OSD	;	1.96	;	Dimer of a C-terminal fragment of phage T4 gp5 beta-helix
8F4N	;	2.95	;	Dimer of aminoglycoside efflux pump AcrD
8F56	;	2.98	;	Dimer of aminoglycoside efflux pump AcrD treated with gentamicin
1FLM	;	1.3	;	DIMER OF FMN-BINDING PROTEIN FROM DESULFOVIBRIO VULGARIS (MIYAZAKI F)
5TEO	;	2.046	;	Dimer of HIV-1 Gag CTD-SP1 fragment
6VFF	;	2.8	;	Dimer of Human Adenosine Deaminase Acting on dsRNA (ADAR2) mutant E488Q bound to dsRNA sequence derived from human GLI1 gene
4M6F	;	4.99	;	Dimer of the G-Segment Invertase bound to a DNA substrate
6EHO	;	3.5	;	Dimer of the Sortilin Vps10p domain at low pH
5B21	;	2.24	;	Dimer structure of murine Nectin-1 D1
5B22	;	2.58	;	Dimer structure of murine Nectin-3 D1D2
7VT0	;	3.4	;	Dimer structure of SORLA
5NMT	;	2.3	;	Dimer structure of Sortilin ectodomain crystal form 1, 2.3A
5NNI	;	3.21	;	Dimer structure of Sortilin ectodomain crystal form 2, 3.2 Angstrom
5NNJ	;	4.0	;	Dimer structure of Sortilin ectodomain crystal form 3, 4.0 Angstrom
2XJ9	;	2.8	;	Dimer Structure of the bacterial cell division regulator MipZ
6FV7	;	3.7	;	Dimer structure of the MATE family multidrug resistance transporter Aq_128 from Aquifex aeolicus in the outward-facing state
6FV8	;	3.0	;	Dimer structure of the MATE family multidrug resistance transporter Aq_128 from Aquifex aeolicus in the outward-facing state
6NZN	;		;	Dimer-of-dimer amyloid fibril structure of glucagon
7MFF	;	3.89	;	Dimeric (BRAF)2:(14-3-3)2 complex bound to SB590885 Inhibitor
2ZYA	;	1.6	;	Dimeric 6-phosphogluconate dehydrogenase complexed with 6-phosphogluconate
3FWN	;	1.5	;	Dimeric 6-phosphogluconate dehydrogenase complexed with 6-phosphogluconate and 2'-monophosphoadenosine-5'-diphosphate
2ZYD	;	1.5	;	Dimeric 6-phosphogluconate dehydrogenase complexed with glucose
4AEA	;	1.94	;	Dimeric alpha-cobratoxin X-ray structure: Localization of intermolecular disulfides and possible mode of binding to nicotinic acetylcholine receptors
3S84	;	2.4	;	Dimeric apoA-IV
3X15	;	1.6	;	Dimeric Aquifex aeolicus cytochrome c555
2XR1	;	2.59	;	DIMERIC ARCHAEAL CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR WITH N-TERMINAL KH DOMAINS (KH-CPSF) FROM METHANOSARCINA MAZEI
6HUN	;	1.802	;	Dimeric Archeal Rubisco from Hyperthermus butylicus
4W7Y	;	2.5	;	Dimeric BAP29 vDED with disulfide bonds in crystal contacts
1XCD	;	2.31	;	Dimeric bovine tissue-extracted decorin, crystal form 1
1XEC	;	2.3	;	Dimeric bovine tissue-extracted decorin, crystal form 2
8EZ9	;	5.67	;	Dimeric complex of DNA-PKcs
4X9Z	;	1.5	;	Dimeric conotoxin alphaD-GeXXA
3CZ2	;	2.5	;	Dimeric crystal structure of a pheromone binding protein from Apis mellifera at pH 7.0
3CYZ	;	1.8	;	Dimeric crystal structure of a pheromone binding protein from Apis mellifera in complex with 9-keto-2(E)-decenoic acid at pH 7.0
3CZ0	;	1.7	;	Dimeric crystal structure of a pheromone binding protein from Apis mellifera in complex with the n-butyl benzene sulfonamide at pH 7.0
3CZ1	;	1.5	;	Dimeric crystal structure of a pheromone binding protein from Apis mellifera in complex with the n-butyl benzene sulfonamide at pH 7.0
3D78	;	1.6	;	Dimeric crystal structure of a pheromone binding protein mutant D35N, from apis mellifera, at pH 7.0
5UA0	;	2.3	;	Dimeric crystal structure of HTPA reductase from arabidopsis thaliana
5ZB3	;	3.506	;	Dimeric crystal structure of ORF57 from KSHV
1DS5	;	3.16	;	DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
5YBA	;	2.062	;	Dimeric Cyclophilin from T.vaginalis in complex with Myb1 peptide
6MOJ	;	2.431	;	Dimeric DARPin A_angle_R5 complex with EpoR
6MOK	;	5.101	;	Dimeric DARPin A_distance_R7 complex with EpoR
6MOI	;	2.065	;	Dimeric DARPin C_angle_R5 complex with EpoR
6MOG	;	1.21	;	Dimeric DARPin C_R3
6MOH	;	3.2	;	Dimeric DARPin C_R3 complex with EpoR
2POQ	;	2.59	;	Dimeric Dihydrodiol Dehydrogenase complexed with inhibitor, Isoascorbic acid
1JVC	;		;	Dimeric DNA Quadruplex Containing Major Groove-Aligned A.T.A.T and G.C.G.C Tetrads Stabilized by Inter-Subunit Watson-Crick A:T and G:C Pairs
6OTR	;	3.12	;	Dimeric E.coli YoeB bound to Thermus thermophilus 70S post-cleavage (AAU)
6OXI	;	3.495	;	Dimeric E.coli YoeB bound to Thermus thermophilus 70S post-cleavage (UAA)
6OXA	;	3.25	;	Dimeric E.coli YoeB bound to Thermus thermophilus 70S pre-cleavage (AAU)
7COH	;	1.3	;	Dimeric Form of Bovine Heart Cytochrome c Oxidase in the Fully Oxidized State
3NVA	;	2.504	;	Dimeric form of CTP synthase from Sulfolobus solfataricus
8FVJ	;	3.54	;	Dimeric form of HIV-1 Vif in complex with human CBF-beta, ELOB, ELOC, and CUL5
8SL4	;	7.0	;	Dimeric form of human adenylyl cyclase 5
4QKH	;	1.8	;	Dimeric form of human LLT1, a ligand for NKR-P1
4QKI	;	1.8	;	Dimeric form of human LLT1, a ligand for NKR-P1
7OYG	;	5.5	;	Dimeric form of SARS-CoV-2 RNA-dependent RNA polymerase
1ITV	;	1.95	;	Dimeric form of the haemopexin domain of MMP9
6WA1	;		;	Dimeric form of the trans-stabilized Hemolysin II C-terminal domain
7XFV	;		;	Dimeric G-quadruplex DNA Formed in the Proximal Promoter of VEGFR-2
7XH3	;		;	Dimeric G-quadruplex DNA Formed in the Proximal Promoter of VEGFR-2
3WUI	;	1.8	;	Dimeric horse cytochrome c formed by refolding from molten globule state
3WC8	;	1.8	;	Dimeric horse cytochrome c obtained by refolding with desalting method
3VM9	;	1.05	;	Dimeric horse myoglobin
4EDF	;	2.08	;	Dimeric hUGDH, K94E
2KYO	;		;	Dimeric human ckit-2 proto-oncogene promoter quadruplex DNA NMR, 10 structures
8FZK	;	2.1	;	Dimeric human importin alpha subunit
6IZE	;	2.29	;	Dimeric human TCTP
3VYM	;	2.0	;	Dimeric Hydrogenobacter thermophilus cytochrome c552
4ZID	;	1.8	;	Dimeric Hydrogenobacter thermophilus cytochrome c552 obtained from Escherichia coli
7ZYX	;		;	Dimeric i-motif from 2'Farabinocytidine-modified TC5
7JG1	;	3.3	;	Dimeric Immunoglobin A (dIgA)
3T11	;	2.22	;	Dimeric inhibitor of HIV-1 protease.
6LTF	;	1.61	;	Dimeric isocitrate dehydrogenase from Xanthomonas campestris pv. campestris 8004
6M3S	;	2.3	;	Dimeric isocitrate dehydrogenase from Xanthomonas campestris pv. campestris 8004
1Y8D	;		;	Dimeric parallel-stranded tetraplex with 3+1 5' G-tetrad interface, single-residue chain reversal loops and GAG triad in the context of A(GGGG) pentad
7O01	;	17.1	;	Dimeric Photosystem I of a temperature sensitive mutant Chlamydomonas reinhardtii
2LXV	;		;	Dimeric pil-e g-quadruplex dna from neisseria gonorrhoeae, NMR 11 structures
4V07	;	2.1	;	Dimeric pseudorabies virus protease pUL26N at 2.1 A resolution
7ZQ9	;	2.74	;	Dimeric PSI of Chlamydomonas reinhardtii at 2.74 A resolution (symmetry expanded)
7ZQD	;	2.97	;	Dimeric PSI of Chlamydomonas reinhardtii at 2.97 A resolution
1P7N	;	2.6	;	Dimeric Rous Sarcoma virus Capsid protein structure with an upstream 25-amino acid residue extension of C-terminal of Gag p10 protein
4FMM	;	2.34	;	Dimeric Sec14 family homolog 3 from Saccharomyces cerevisiae presents some novel features of structure that lead to a surprising ""dimer-monomer"" state change induced by substrate binding
6K7C	;	1.15	;	Dimeric Shewanella violacea cytochrome c5
1EU6	;		;	DIMERIC SOLUTION STRUCTURE OF THE CYCLIC OCTAMER CD(CATTCATT)
1N96	;		;	DIMERIC SOLUTION STRUCTURE OF THE CYCLIC OCTAMER CD(CGCTCATT)
1EU2	;		;	DIMERIC SOLUTION STRUCTURE OF THE CYCLIC OCTAMER CD(TGCTCGCT)
2HK4	;		;	Dimeric solution structure of the cyclic octamer d(CCGTCCGT)
2K97	;		;	Dimeric solution structure of the cyclic octamer d(pCGCTCCGT)
2K8Z	;		;	Dimeric solution structure of the DNA loop d(TCGTTGCT)
2K90	;		;	Dimeric solution structure of the DNA loop d(TGCTTCGT)
3I32	;	2.8	;	Dimeric structure of a Hera helicase fragment including the C-terminal RecA domain, the dimerization domain, and the RNA binding domain
3TIF	;	1.7995	;	Dimeric structure of a post-hydrolysis state of the ATP-binding cassette MJ0796 bound to ADP and Pi
7Y7U	;	1.89	;	Dimeric structure of a Quorum-Quenching metallo-hydrolase, LrsL
6P2J	;	3.0	;	Dimeric structure of ACAT1
4JUP	;	3.2	;	Dimeric structure of CARMA1 CARD
2WK4	;	2.98	;	Dimeric structure of D347G D348G mutant of the sapporovirus RNA dependent RNA polymerase
2Y4P	;	2.65	;	Dimeric structure of DAPK-1 catalytic domain
3ZXT	;	2.65	;	Dimeric structure of DAPK-1 catalytic domain in complex with AMPPCP- Mg
1IZ3	;	2.8	;	Dimeric structure of FIH (Factor inhibiting HIF)
7XBL	;	2.0	;	Dimeric structure of human galectin-7 in complex with three glycerol
7XAC	;	1.8	;	Dimeric structure of human galectin-7 in complex with two glycerol
6OJE	;	1.95	;	Dimeric structure of LRRK2 GTPase domain
6OJF	;	1.6	;	Dimeric structure of LRRK2 GTPase domain
6KLH	;	3.7	;	Dimeric structure of Machupo virus polymerase bound to vRNA promoter
1L2T	;	1.9	;	Dimeric Structure of MJ0796, a Bacterial ABC Transporter Cassette
3FN3	;	2.7	;	Dimeric Structure of PD-L1
1X9V	;		;	Dimeric structure of the C-terminal domain of Vpr
7AHF	;	2.15	;	Dimeric structure of the catalytic domain of the human ubiquitin-conjugating enzyme UBE2S L114E varaiant
1F5W	;	1.7	;	DIMERIC STRUCTURE OF THE COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR D1 DOMAIN
1EAJ	;	1.35	;	DIMERIC STRUCTURE OF THE COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR D1 DOMAIN AT 1.35 ANGSTROM RESOLUTION
2MRZ	;		;	Dimeric structure of the Human A-box
3L2J	;	3.24	;	Dimeric structure of the ligand-free extracellular domain of the human parathyroid hormone receptor (PTH1R)
4GS3	;	1.09	;	Dimeric structure of the N-terminal domain of PriB protein from Thermoanaerobacter tencongensis solved ab initio
1KIX	;	2.7	;	Dimeric Structure of the O. nova Telomere End Binding Protein Alpha Subunit with Bound ssDNA
2LOH	;		;	Dimeric structure of transmembrane domain of amyloid precursor protein in micellar environment
4UPI	;	1.25	;	Dimeric sulfatase SpAS1 from Silicibacter pomeroyi
4UPL	;	1.805	;	Dimeric sulfatase SpAS2 from Silicibacter pomeroyi
8KGE	;	3.8	;	Dimeric tail tube protein gpVs of bacteriophage lambda
8R1G	;	3.99	;	Dimeric ternary structure of E6AP-E6-p53
1AFO	;		;	DIMERIC TRANSMEMBRANE DOMAIN OF HUMAN GLYCOPHORIN A, NMR, 20 STRUCTURES
1H6O	;	2.9	;	Dimerisation domain from human TRF1
1H6P	;	2.2	;	Dimeristion domain from human TRF2
2F42	;	2.5	;	dimerization and U-box domains of Zebrafish C-terminal of HSP70 interacting protein
5J97	;	2.55	;	Dimerization domain of cytoplasmic activation/proliferation-associated protein-2 (caprin-2)
1TFE	;	1.7	;	DIMERIZATION DOMAIN OF EF-TS FROM T. THERMOPHILUS
1G2Z	;	1.15	;	DIMERIZATION DOMAIN OF HNF-1ALPHA WITH A LEU 13 SELENOMETHIONINE SUBSTITUTION
2VPV	;	2.7	;	Dimerization Domain of Mif2p
6FXA	;	1.5	;	Dimerization domain of TP901-1 CI repressor
3RYL	;	3.1	;	Dimerization domain of Vibrio parahemolyticus VopL
6S9S	;	2.2	;	Dimerization domain of Xenopus laevis LDB1 in complex with darpin 10
6S9T	;	2.05	;	Dimerization domain of Xenopus laevis LDB1 in complex with darpin 3
5IRT	;		;	Dimerization interface of the noncrystalline HIV-1 capsid protein lattice from solid state NMR spectroscopy of tubular assemblies
2J3E	;	3.2	;	Dimerization is important for the GTPase activity of chloroplast translocon components atToc33 and psToc159
1EI1	;	2.3	;	DIMERIZATION OF E. COLI DNA GYRASE B PROVIDES A STRUCTURAL MECHANISM FOR ACTIVATING THE ATPASE CATALYTIC CENTER
5CQR	;	3.015	;	Dimerization of Elp1 is essential for Elongator complex assembly
5CQS	;	2.7	;	Dimerization of Elp1 is essential for Elongator complex assembly
1QFH	;	2.2	;	DIMERIZATION OF GELATION FACTOR FROM DICTYOSTELIUM DISCOIDEUM: CRYSTAL STRUCTURE OF ROD DOMAINS 5 AND 6
3GGQ	;	2.0	;	Dimerization of Hepatitis E Virus Capsid Protein E2s Domain is Essential for Virus-Host Interaction
1V05	;	1.43	;	Dimerization of human Filamin C: crystal structure of the domain 24
7BQF	;	1.70038	;	Dimerization of SAV1 WW tandem
1DP4	;	2.0	;	DIMERIZED HORMONE BINDING DOMAIN OF THE ATRIAL NATRIURETIC PEPTIDE RECEPTOR
5UNE	;	2.9001	;	Dimerized Structure Gives Further Insight Into the Function of the Novel RNA Gene: HAR1
6QJC	;	1.7	;	Dimethyl disulfide inhibited sulfur oxygenase reductase
5O1S	;	1.9	;	Dimethyl fumarate is an allosteric covalent inhibitor of the p90 ribosomal S6 kinases
1MNY	;		;	Dimethyl propionate ester heme-containing cytochrome b5
7P2H	;	2.15	;	Dimethylated fusion protein of RSL and mussel adhesion peptide (Mefp) in complex with cucurbit[7]uril, H3 sheet assembly
7P2I	;	1.489	;	Dimethylated fusion protein of RSL and nucleoporin peptide (Nup) in complex with cucurbit[7]uril, F432 cage assembly
7P2J	;	1.98	;	Dimethylated fusion protein of RSL and trimeric coiled coil (4dzn) in complex with cucurbit[7]uril, H3 sheet assembly
6S99	;	2.649	;	Dimethylated fusion protein of RSL and trimeric coiled coil in complex with cucurbit[7]uril
8CF7	;	1.14	;	Dimethylated RSL-R5 in complex with cucurbit[7]uril, C121 sheet assembly
8CF6	;	1.34	;	Dimethylated RSL-R5 in complex with cucurbit[7]uril, F432 cage assembly
7W8J	;	2.5	;	Dimethylformamidase, 2x(A2B2)
7O91	;	1.1	;	diMn-sulerythrin
7O93	;	1.17	;	diMn-sulerythrin
7O99	;	1.24	;	diMn-sulerythrin
7O9E	;	1.25	;	diNi-sulerythrin
7O9C	;	1.6	;	diNi-sulerythrin treated by hydrogen perxoide
8UX7	;	2.2	;	Dioclea megacarpa lectin (DmegA) complexed with X-Man
5YSH	;	1.9	;	Diol dehydratase - alpha/T172A mutant complexed with AdoCbl, aerobically-prepared crystal
7XRK	;	2.3	;	Diol dehydratase complexed with AdoMeCbl
7XRL	;	1.75	;	Diol dehydratase complexed with AdoMeCbl and 1,2-propanediol
5YRV	;	1.55	;	Diol dehydratase, AdoCbl/1,2-propanediol, anaerobically-prepared crystal
5YRT	;	1.7	;	Diol dehydratase, AdoCbl/substrate-free, anaerobically-prepared crystal
1DIO	;	2.2	;	DIOL DEHYDRATASE-CYANOCOBALAMIN COMPLEX FROM KLEBSIELLA OXYTOCA
1Y66	;	1.65	;	Dioxane contributes to the altered conformation and oligomerization state of a designed engrailed homeodomain variant
7OLR	;	2.1	;	Dioxygenase AsqJ in complex with 2 and alpha-ketoglutarate
7OLT	;	1.5	;	Dioxygenase AsqJ in complex with 2 and Tris
7OLK	;	1.7	;	Dioxygenase AsqJ in complex with 2b and Tris
7OLP	;	1.55	;	Dioxygenase AsqJ mutant (V72I) in complex with 2 and alpha-ketoglutarate
7OLQ	;	2.05	;	Dioxygenase AsqJ mutant (V72I) in complex with 2 and Tris
7OLO	;	2.0	;	Dioxygenase AsqJ mutant (V72I) in complex with 2b and glycerol
7OLL	;	1.9	;	Dioxygenase AsqJ mutant (V72I) in complex with 2b and Tris
7OLM	;	1.75	;	Dioxygenase AsqJ mutant (V72I) in complex with 2b-O-O and Tris
3V7B	;	1.743	;	Dip2269 protein from corynebacterium diphtheriae
2QJR	;	2.2	;	dipepdyl peptidase IV in complex with inhibitor PZF
2HOW	;	2.4	;	Dipeptidase (PH0974) from Pyrococcus horikoshii OT3
7ZC2	;	2.72	;	Dipeptide and tripeptide Permease C (DtpC)
1DPP	;	3.2	;	DIPEPTIDE BINDING PROTEIN COMPLEX WITH GLYCYL-L-LEUCINE
6RNG	;	2.15	;	Dipeptide Gly-Pro binds to a glycolytic enzyme fructose bisphosphate aldolase
6RS1	;	1.9	;	Dipeptide Gly-Pro binds to a glycolytic enzyme fructose bisphosphate aldolase
2WHZ	;	1.75	;	Dipeptide Inhibitors of Thermolysin
2WI0	;	1.95	;	Dipeptide Inhibitors of Thermolysin
1MS6	;	1.9	;	Dipeptide Nitrile Inhibitor Bound to Cathepsin S.
1DPE	;	2.0	;	DIPEPTIDE-BINDING PROTEIN
1JQP	;	2.4	;	dipeptidyl peptidase I (cathepsin C), a tetrameric cysteine protease of the papain family
6WOH	;	1.7	;	Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with 1,5-di-methylenebisphosphonate inositol tetrakisphosphate (1,5-PCP-IP4)
6WO9	;	2.0	;	Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with 1-diphosphoinositol pentakisphosphate (1-IP7) and Mg
6WOI	;	1.5	;	Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with 1-Diphosphoinositol pentakisphosphate, Mg, and Fluoride ion, presoaked with 1,5-IP8, Mg and Fluoride for 30 seconds
6WOA	;	1.5	;	Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with 2-Diphosphoinositol pentakisphosphate (2-IP7), Mg, and Fluoride ion
7TN4	;	1.85	;	Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with 3-diphosphoinositol 1,2,4,5-tetrakisphosphate (3-PP-IP4), Mg and Fluoride ion
6WOB	;	1.45	;	Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with 4-diphosphoinositol pentakisphosphate (4-IP7), Mg, and Fluoride ion
8G9C	;	1.4	;	Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with 5- difluoromethylenebisphosphonate inositol pentakisphosphate (5-PCF2P-IP5), an analogue of 5-InsP7
8G9D	;	1.6	;	Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with 5- phosphonodifluoroacetamide inositol pentakisphosphate (5-PCF2Am-InsP5), an analogue of 5-InsP7
6WO8	;	1.7	;	Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with 5-diphosphoinositol 1,3,4,6-tetrakisphosphate (5-PP-IP4), Mg, and Fluoride ion
6WO7	;	1.4	;	Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with 5-Diphosphoinositol pentakisphosphate (5-IP7), Mg, and Fluoride ion
6WOC	;	1.35	;	Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with 5-diphosphoinositol pentakisphosphate and Mg, presoaked with 5-IP7, Mg and Fluoride, soaking 1min in the absence of Fluoride.
6WOG	;	1.5	;	Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with 5-methylenebisphosphonate inositol pentakisphosphate (5-PCP-IP5)
6WOE	;	1.4	;	Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with inositol hexakisphosphate and Mg, presoaked with 5-IP7, Mg and Fluoride, soaking 10min in the absence of Fluoride.
6WOF	;	1.6	;	Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with inositol hexakisphosphate and Mg, presoaked with 5-IP7, Mg and Fluoride, soaking 20min in the absence of Fluoride.
6WOD	;	1.35	;	Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with inositol hexakisphosphate and Mg, presoaked with 5-IP7, Mg and Fluoride, soaking 2min in the absence of Fluoride.
8TF9	;	1.55	;	Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with myo-5-IP7, produced upon myo-IP6 phosphorylation by TvI
8TFA	;	1.4	;	Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with myo-5-PP-IP4, produced upon myo-(2OH)-IP5 phosphorylation by TvIPK
8T98	;	1.3	;	Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with Scyllo-3-PP-(1,2,4,5)IP4, Mg, and Fluoride ion
8T99	;	1.5	;	Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with Scyllo-L-1,4-[PP]2-(2,3)IP2, Mg, and Fluoride ion
4Z7C	;	2.2	;	Diphosphomevalonate decarboxylase from the Sulfolobus solfataricus, space group h32
4Z7Y	;	2.7	;	diphosphomevalonate decarboxylase from the Sulfolobus solfataricus, space group P21
2TDX	;	2.4	;	DIPHTHERIA TOX REPRESSOR (C102D MUTANT) COMPLEXED WITH NICKEL
1F5T	;	3.0	;	DIPHTHERIA TOX REPRESSOR (C102D MUTANT) COMPLEXED WITH NICKEL AND DTXR CONSENSUS BINDING SEQUENCE
1DDN	;	3.0	;	DIPHTHERIA TOX REPRESSOR (C102D MUTANT)/TOX DNA OPERATOR COMPLEX
1TOX	;	2.3	;	DIPHTHERIA TOXIN DIMER COMPLEXED WITH NAD
5Z2E	;	1.8	;	Dipicolinate bound Dihydrodipicolinate reductase from Paenisporosarcina sp. TG-14
7BKX	;	2.35	;	Diploptera punctata inspired lipocalin-like Milk protein expressed in Saccharomyces cerevisiae
2JSV	;		;	Dipole tensor-based refinement for atomic-resolution structure determination of a nanocrystalline protein by solid-state NMR spectroscopy
7DMC	;	2.34	;	Dipyridamole binds to the N-terminal domain of human Hsp90A
2FB4	;	1.9	;	DIR PRIMAERSTRUKTUR DES KRISTALLISIERBAREN MONOKLONALEN IMMUNOGLOBULINS IGG1 KOL. II. AMINOSAEURESEQUENZ DER L-KETTE, LAMBDA-TYP, SUBGRUPPE I (GERMAN)
2IG2	;	3.0	;	DIR PRIMAERSTRUKTUR DES KRISTALLISIERBAREN MONOKLONALEN IMMUNOGLOBULINS IGG1 KOL. II. AMINOSAEURESEQUENZ DER L-KETTE, LAMBDA-TYP, SUBGRUPPE I (GERMAN)
6D74	;		;	Direct Activation of the Executioner Domain of MLKL by a Select Repertoire of Inositol Phosphates
1C57	;	2.4	;	DIRECT DETERMINATION OF THE POSITIONS OF DEUTERIUM ATOMS OF BOUND WATER IN CONCANAVALIN A BY NEUTRON LAUE CRYSTALLOGRAPHY
1CCM	;		;	DIRECT NOE REFINEMENT OF CRAMBIN FROM 2D NMR DATA USING A SLOW-COOLING ANNEALING PROTOCOL
1CCN	;		;	DIRECT NOE REFINEMENT OF CRAMBIN FROM 2D NMR DATA USING A SLOW-COOLING ANNEALING PROTOCOL
1KGK	;	1.0	;	Direct Observation of a Cytosine Analog that Forms Five Hydrogen Bonds to Guanosine; Guanyl G-Clamp
5G18	;	1.1	;	Direct Observation of Active-site Protonation States in a Class A beta lactamase with a monobactam substrate
1YPA	;	2.0	;	DIRECT OBSERVATION OF BETTER HYDRATION AT THE N-TERMINUS OF AN ALPHA-HELIX WITH GLYCINE RATHER THAN ALANINE AS N-CAP
1YPB	;	2.0	;	DIRECT OBSERVATION OF BETTER HYDRATION AT THE N-TERMINUS OF AN ALPHA-HELIX WITH GLYCINE RATHER THAN ALANINE AS N-CAP
1YPC	;	1.7	;	DIRECT OBSERVATION OF BETTER HYDRATION AT THE N-TERMINUS OF AN ALPHA-HELIX WITH GLYCINE RATHER THAN ALANINE AS N-CAP
5X2R	;	2.7	;	Direct Observation of Conformational Population Shifts in Hemoglobin: Crystal Structure of Half-Liganded Hemoglobin after Adding 10 mM phosphate pH 6.9.
5X2S	;	2.39	;	Direct Observation of Conformational Population Shifts in Hemoglobin: Crystal Structure of Half-Liganded Hemoglobin after Adding 4 mM bezafibrate pH 6.5.
5X2T	;	2.64	;	Direct Observation of Conformational Population Shifts in Hemoglobin: Crystal Structure of Half-Liganded Hemoglobin after Adding 4 mM bezafibrate pH 7.2.
5X2U	;	2.53	;	Direct Observation of Conformational Population Shifts in Hemoglobin: Crystal Structure of Half-Liganded Hemoglobin after Adding 80 mM phosphate pH 6.7.
1J3Z	;	1.6	;	Direct observation of photolysis-induced tertiary structural changes in human haemoglobin; Crystal structure of alpha(Fe-CO)-beta(Ni) hemoglobin (laser unphotolysed)
1J41	;	1.45	;	Direct observation of photolysis-induced tertiary structural changes in human haemoglobin; Crystal structure of alpha(Ni)-beta(Fe) hemoglobin (laser photolysed)
1J40	;	1.45	;	Direct observation of photolysis-induced tertiary structural changes in human haemoglobin; Crystal structure of alpha(Ni)-beta(Fe-CO) hemoglobin (laser unphotolysed)
1J3Y	;	1.55	;	Direct observation of photolysis-induced tertiary structural changes in human hemoglobin; Crystal structure of alpha(Fe)-beta(Ni) hemoglobin (laser photolysed)
223D	;	1.7	;	DIRECT OBSERVATION OF TWO BASE-PAIRING MODES OF A CYTOSINE-THYMINE ANALOGUE WITH GUANINE IN A DNA Z-FORM DUPLEX: SIGNIFICANCE FOR BASE ANALOGUE MUTAGENESIS
4WHW	;	1.345	;	Direct photocapture of bromodomains using tropolone chemical probes
1ESA	;	1.65	;	DIRECT STRUCTURE OBSERVATION OF AN ACYL-ENZYME INTERMEDIATE IN THE HYDROLYSIS OF AN ESTER SUBSTRATE BY ELASTASE
1ESB	;	2.3	;	DIRECT STRUCTURE OBSERVATION OF AN ACYL-ENZYME INTERMEDIATE IN THE HYDROLYSIS OF AN ESTER SUBSTRATE BY ELASTASE
4CRY	;	1.61	;	Direct visualisation of strain-induced protein post-translational modification
4CS0	;	2.1	;	Direct visualisation of strain-induced protein post-translational modification
4CRZ	;	1.7	;	Direct visualisation of strain-induced protein prost-translational modification
5OXU	;	1.47	;	Direct-evolutioned unspecific peroxygenase from Agrocybe aegerita
6EKX	;	1.13	;	Direct-evolutioned unspecific peroxygenase from Agrocybe aegerita, in complex with 1-naphthol (I)
6EKY	;	1.23	;	Direct-evolutioned unspecific peroxygenase from Agrocybe aegerita, in complex with 1-naphthol (II)
5OXT	;	1.42	;	DIRECT-EVOLUTIONED UNSPECIFIC PEROXYGENASE FROM AGROCYBE AEGERITA, IN COMPLEX WITH ACETATE
5OY2	;	1.36	;	Direct-evolutioned unspecific peroxygenase from Agrocybe aegerita, in complex with DMP
5OY1	;	1.43	;	Direct-evolutioned unspecific peroxygenase from Agrocybe aegerita, in complex with DMSO
6EKW	;	1.43	;	Direct-evolutioned unspecific peroxygenase from Agrocybe aegerita, in complex with naphthalene
6EKZ	;	1.08	;	Direct-evolutioned unspecific peroxygenase from Agrocybe aegerita, in complex with propranolol
6EL0	;	1.65	;	Direct-evolutioned unspecific peroxygenase from Agrocybe aegerita, in complex with styrene
6EL4	;	1.53	;	Direct-evolutioned unspecific peroxygenase from Agrocybe aegerita, in complex with veratryl alcohol
3IJ7	;	2.0	;	Directed 'in situ' Elongation as a Strategy to Characterize the Covalent Glycosyl-Enzyme Catalytic Intermediate of Human Pancreatic a-Amylase
3IJ8	;	1.43	;	Directed 'in situ' Elongation as a Strategy to Characterize the Covalent Glycosyl-Enzyme Catalytic Intermediate of Human Pancreatic a-Amylase
3IJ9	;	1.85	;	Directed 'in situ' Elongation as a Strategy to Characterize the Covalent Glycosyl-Enzyme Catalytic Intermediate of Human Pancreatic a-Amylase
4JXI	;	2.29	;	Directed evolution and rational design of a de novo designed esterase toward improved catalysis. Northeast Structural Genomics Consortium (NESG) Target OR184
4P62	;	1.89	;	Directed evolution of a B3 metallo-beta-lactamase AIM-1
6U18	;	2.0	;	Directed evolution of a biosensor selective for the macrolide antibiotic clarithromycin
3CBD	;	2.65	;	Directed Evolution of cytochrome P450 BM3, to octane monoxygenase 139-3
2F54	;	2.7	;	Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity
2F53	;	2.1	;	Directed Evolution of Human T-cell Receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without apparent cross-reactivity
5KQT	;	1.99	;	Directed Evolution of Transaminases By Ancestral Reconstruction. Using Old Proteins for New Chemistries
5KQU	;	2.62	;	Directed Evolution of Transaminases By Ancestral Reconstruction. Using Old Proteins for New Chemistries
5KQW	;	2.23	;	Directed Evolution of Transaminases By Ancestral Reconstruction. Using Old Proteins for New Chemistries
5KR3	;	1.95	;	Directed Evolution of Transaminases By Ancestral Reconstruction. Using Old Proteins for New Chemistries
5KR4	;	2.0	;	Directed Evolution of Transaminases By Ancestral Reconstruction. Using Old Proteins for New Chemistries
5KR5	;	2.1	;	Directed Evolution of Transaminases By Ancestral Reconstruction. Using Old Proteins for New Chemistries
5KR6	;	1.99	;	Directed Evolution of Transaminases By Ancestral Reconstruction. Using Old Proteins for New Chemistries
4Z08	;	1.8	;	Directed evolutionary changes in Kemp Eliminase KE07 - Crystal 1 KE07 design
5D32	;	2.1	;	Directed evolutionary changes in Kemp Eliminase KE07 - Crystal 11 round 6
5D33	;	1.59	;	Directed evolutionary changes in Kemp Eliminase KE07 - Crystal 12 round 7
5D37	;	2.04	;	Directed evolutionary changes in Kemp Eliminase KE07 - Crystal 16 round 7
5D38	;	1.427	;	Directed evolutionary changes in Kemp Eliminase KE07 - Crystal 17 round 7-2
6C7H	;	2.43	;	Directed evolutionary changes in Kemp Eliminase KE07 - Crystal 18 Design Trp50Ala mutant
6C7M	;	1.45	;	Directed evolutionary changes in Kemp Eliminase KE07 - Crystal 19 round 5
6C7T	;	1.83	;	Directed evolutionary changes in Kemp Eliminase KE07 - Crystal 20 round 5
6DKV	;	1.89	;	Directed evolutionary changes in Kemp Eliminase KE07 - Crystal 21 round 5
6C7V	;	1.64	;	Directed evolutionary changes in Kemp Eliminase KE07 - Crystal 22 round 5
6C8B	;	1.61	;	Directed evolutionary changes in Kemp Eliminase KE07 - Crystal 23 round 6
6CAI	;	1.82	;	Directed evolutionary changes in Kemp Eliminase KE07 - Crystal 24 round 7
6DC1	;	2.68	;	Directed evolutionary changes in Kemp Eliminase KE07 - Crystal 25 round 7
6CT3	;	1.9	;	Directed evolutionary changes in Kemp Eliminase KE07 - Crystal 27 round 7-2
6DNJ	;	1.65	;	Directed evolutionary changes in Kemp Eliminase KE07 - Crystal 28 round 5
5D2T	;	1.87	;	Directed evolutionary changes in Kemp Eliminase KE07 - Crystal 3 Wild Type
5D2V	;	2.02	;	Directed evolutionary changes in Kemp Eliminase KE07 - Crystal 4 Wild Type
5D2W	;	1.66	;	Directed evolutionary changes in Kemp Eliminase KE07 - Crystal 5 Wild Type
5D2X	;	1.76	;	Directed evolutionary changes in Kemp Eliminase KE07 - Crystal 6 Round5
5D2Y	;	1.984	;	Directed evolutionary changes in Kemp Eliminase KE07 - Crystal 7 Round 5
5D30	;	1.69	;	Directed evolutionary changes in Kemp Eliminase KE07 - Crystal 9 Round 5
5JQJ	;	1.67	;	Directed evolutionary changes in MBL super family - NDM-1 Round 10 crystal-1
5K4M	;	1.98	;	Directed evolutionary changes in MBL super family - NDM-1 Round 10 crystal-3
6BM9	;	2.19	;	Directed evolutionary changes in MBL super family - VIM-2 Round 10
2ORF	;	1.85	;	Directing Macromolecular Conformation Through Halogen Bonds
2ORG	;	2.0	;	Directing Macromolecular Conformation Through Halogen Bonds
2ORH	;	1.9	;	Directing Macromolecular Conformation Through Halogen Bonds
3ERZ	;	3.056	;	Directing Noble Metal Ion Chemistry within a Designed Ferritin Protein. Mercury Ions on the Three-Fold Channel
3ES3	;	2.795	;	Directing Noble Metal Ion Chemistry within a Designed Ferritin Protein. The Complex with Gold ions. Ferritin H8-H9x Mutant
8OQC	;	1.5	;	Dirhodium tetraacetate/ribonuclease A adduct in the P3221 space group (1 h soaking)
8OQD	;	1.54	;	Dirhodium tetraacetate/ribonuclease A adduct in the P3221 space group (1 h soaking)
8OQE	;	1.5	;	Dirhodium tetraacetate/ribonuclease A adduct in the P3221 space group (6 h soaking)
5Y4M	;	1.31	;	Discoidin domain of human CASPR2
2XMY	;	1.9	;	Discovery and Characterisation of 2-Anilino-4-(thiazol-5-yl) pyrimidine Transcriptional CDK Inhibitors as Anticancer Agents
2XNB	;	1.85	;	Discovery and Characterisation of 2-Anilino-4-(thiazol-5-yl) pyrimidine Transcriptional CDK Inhibitors as Anticancer Agents
6I8S	;	2.9	;	Discovery and characterisation of an antibody that selectively modulates the inhibitory activity of plasminogen activator inhibitor-1
3PYY	;	1.85	;	Discovery and Characterization of a Cell-Permeable, Small-molecule c-Abl Kinase Activator that Binds to the Myristoyl Binding Site
7YPD	;	1.27	;	Discovery and characterization of a new carbonyl reductase from Rhodotorula toluroides reducing fluoroketones, and X-ray analysis of the variant by rational engineering
5FIP	;	1.88	;	Discovery and characterization of a novel thermostable and highly halotolerant GH5 cellulase from an Icelandic hot spring isolate
6FAO	;	1.88	;	Discovery and characterization of a thermostable GH6 endoglucanase from a compost metagenome
5AIH	;	1.42	;	Discovery and characterization of thermophilic limonene-1,2-epoxide hydrolases from hot spring metagenomic libraries. CH55-sample-Native
5AII	;	1.47	;	Discovery and characterization of thermophilic limonene-1,2-epoxide hydrolases from hot spring metagenomic libraries. CH55-sample-PEG complex
5AIG	;	1.16	;	Discovery and characterization of thermophilic limonene-1,2-epoxide hydrolases from hot spring metagenomic libraries. Tomsk-sample- Valpromide complex
5AIF	;	1.26	;	Discovery and characterization of thermophilic limonene-1,2-epoxide hydrolases from hot spring metagenomic libraries. Tomsk-sample-Native
3LDX	;	2.246	;	Discovery and Clinical Evaluation of RWJ-671818, a Thrombin Inhibitor with an Oxyguanidine P1 Motif
8STG	;	3.79	;	Discovery and clinical validation of RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
8JBA	;	2.6	;	Discovery and Crystallography Study of Novel Oxadiazole Analogs as Small Molecule PD-1/PD-L1 inhibitors
7QH1	;	2.74	;	Discovery and development of a novel inhaled antivirulence therapy for the treatment of Pseudomonas aeruginosa infections in patients with chronic respiratory disease
2JNR	;		;	Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide
4F08	;	2.82	;	Discovery and Optimization of C-2 Methyl Imidazo-pyrrolopyridines as Potent and Orally Bioavailable JAK1 Inhibitors with Selectivity over JAK2
4F09	;	2.4	;	Discovery and Optimization of C-2 Methyl Imidazo-pyrrolopyridines as Potent and Orally Bioavailable JAK1 Inhibitors with Selectivity over JAK2
4AJW	;	2.8	;	Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3KBeta Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers
4BFR	;	2.8	;	Discovery and Optimization of Pyrimidone Indoline Amide PI3Kbeta Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers
6U5M	;	1.8	;	Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protein-protein interaction
6U5Y	;	1.532	;	Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protein-protein interaction
6U6W	;	1.2	;	Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protein-protein interaction
6U80	;	1.55	;	Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protein-protein interaction
6U8B	;	1.261	;	Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protein-protein interaction
6U8L	;	1.57	;	Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protein-protein interaction
6U8O	;	1.6	;	Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protein-protein interaction
5IS5	;	2.85	;	Discovery and Pharmacological Characterization of Novel Quinazoline-based PI3K delta-selective Inhibitors
7SQM	;	1.78	;	Discovery and Preclinical Pharmacology of INE963, A Potent and Fast-Acting Blood-Stage Antimalarial with a High Barrier to Resistance and Potential for Single-Dose Cure in Uncomplicated Malaria
3EMG	;	2.6	;	Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK)
5XE5	;	2.17	;	Discovery and structural analysis of a phloretin hydrolase from the opportunistic pathogen Mycobacterium abscessus
5XEY	;	1.82	;	Discovery and structural analysis of a phloretin hydrolase from the opportunistic pathogen Mycobacterium abscessus
3P2N	;	1.95	;	Discovery and structural characterization of a new glycoside hydrolase family abundant in coastal waters that was annotated as 'hypothetical protein'
5K5E	;	2.8	;	Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening
6UCS	;	1.85	;	Discovery and Structure-Based optimization of potent and selective WDR5 inhibitors containing a dihydroisoquinolinone bicyclic core
6JKE	;	1.5	;	Discovery and the crystal structure of NS5 in complex with the N-terminal bromodomain of BRD2.
4UWF	;	2.99	;	Discovery of (2S)-8-((3R)-3-Methylmorpholin-4-yl)-1-(3-methyl-2-oxo- butyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido(1,2-a)pyrimidin-6- one: a Novel Potent and Selective Inhibitor of Vps34 for the Treatment of Solid Tumors
4UWG	;	2.7	;	Discovery of (2S)-8-((3R)-3-Methylmorpholin-4-yl)-1-(3-methyl-2-oxo- butyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido(1,2-a)pyrimidin-6- one: a Novel Potent and Selective Inhibitor of Vps34 for the Treatment of Solid Tumors
4UWH	;	1.93	;	Discovery of (2S)-8-((3R)-3-Methylmorpholin-4-yl)-1-(3-methyl-2-oxo- butyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido(1,2-a)pyrimidin-6- one: a Novel Potent and Selective Inhibitor of Vps34 for the Treatment of Solid Tumors
4UWK	;	2.83	;	Discovery of (2S)-8-((3R)-3-Methylmorpholin-4-yl)-1-(3-methyl-2-oxo- butyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido(1,2-a)pyrimidin-6- one: a Novel Potent and Selective Inhibitor of Vps34 for the Treatment of Solid Tumors
4UWL	;	2.8	;	Discovery of (2S)-8-((3R)-3-Methylmorpholin-4-yl)-1-(3-methyl-2-oxo- butyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido(1,2-a)pyrimidin-6- one: a Novel Potent and Selective Inhibitor of Vps34 for the Treatment of Solid Tumors
8UV0	;	1.55	;	Discovery of (4-Pyrazolyl)-2-Aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependent Kinase 2
3L16	;	2.9	;	Discovery of (thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer
3L17	;	3.0	;	Discovery of (thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer
5KE0	;	1.68	;	Discovery of 1-1H-Pyrazolo 4,3-c pyridine-6-yl urea Inhibitors of Extracellular Signal Regulated Kinase ERK for the Treatment of Cancers
4RCH	;	2.3	;	Discovery of 2-Pyridyl Ureas as Glucokinase Activators
2GU8	;	2.2	;	Discovery of 2-Pyrimidyl-5-Amidothiophenes as Novel and Potent Inhibitors for AKT: Synthesis and SAR Studies
6CPW	;	1.85	;	Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology
5DGZ	;	2.502	;	Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitors
3JXW	;	2.8	;	Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as Potent, Highly Selective and Orally Bioavailable Pim Kinases Inhibitors
3JY0	;	2.4	;	Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as Potent, Highly Selective and Orally Bioavailable Pim Kinases Inhibitors
3JYA	;	2.1	;	Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as Potent, Highly Selective and Orally Bioavailable Pim Kinases Inhibitors
4O6E	;	1.95	;	Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine Inhibitors of Erk2
4N00	;	1.8	;	Discovery of 7-THP chromans: BACE1 inhibitors that reduce A-beta in the CNS
3K5K	;	1.7	;	Discovery of a 2,4-Diamino-7-aminoalkoxy-quinazoline as a Potent Inhibitor of Histone Lysine Methyltransferase, G9a
5GXO	;	2.3	;	Discovery of a compound that activates SIRT3 to deacetylate Manganese Superoxide Dismutase
6LLC	;	2.501	;	Discovery of A Dual Inhibitor of NQO1 and GSTP1 for Treating Malignant Glioblastoma
6LLX	;	1.581	;	Discovery of A Dual Inhibitor of NQO1 and GSTP1 for Treating Malignant Glioblastoma
5VQJ	;	1.761	;	Discovery of a first GH11 exo-1,4-beta-xylanase from a diverse microbial sugar cane bagasse composting community
5V8O	;	3.1	;	Discovery of a high affinity inhibitor of cGAS
6NAO	;	3.23	;	Discovery of a high affinity inhibitor of cGAS
6D8E	;	2.537	;	Discovery of a Highly Potent and Broadly Effective EGFR and HER2 Exon 20 Insertion Mutant Inhibitor
7U8H	;	1.702	;	Discovery of a KRAS G12V Inhibitor in vivo Tool Compound starting from an HSQC-NMR based Fragment Hit
3R92	;	1.5801	;	Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model.
5WHR	;	2.28	;	Discovery of a novel and selective IDO-1 inhibitor PF-06840003 and its characterization as a potential clinical candidate.
5LN2	;	1.58	;	Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument
2X8D	;	1.9	;	Discovery of a Novel Class of triazolones as Checkpoint Kinase Inhibitors - Hit to Lead Exploration
2X8E	;	2.5	;	Discovery of a Novel Class of triazolones as Checkpoint Kinase Inhibitors - Hit to Lead Exploration
2X8I	;	1.92	;	Discovery of a Novel Class of triazolones as Checkpoint Kinase Inhibitors - Hit to Lead Exploration
2FLB	;	1.95	;	Discovery of a Novel Hydroxy Pyrazole Based Factor IXa Inhibitor
5G3M	;	1.85	;	Discovery of a novel secreted phospholipase A2 (sPLA2) inhibitor.
5G3N	;	1.8	;	Discovery of a novel secreted phospholipase A2 (sPLA2) inhibitor.
4KM3	;	3.2	;	Discovery of a novel structural motif in methionine aminopeptidase from Streptococci with possible post-translational modification
6P5M	;	2.65	;	Discovery of a Novel, Highly Potent, and Selective Thieno[3,2-d]pyrimidinone-Based Cdc7 inhibitor with a Quinuclidine Moiety (TAK-931) as an Orally Active Investigational Anti-Tumor Agent
6P5P	;	3.3	;	Discovery of a Novel, Highly Potent, and Selective Thieno[3,2-d]pyrimidinone-Based Cdc7 inhibitor with a Quinuclidine Moiety (TAK-931) as an Orally Active Investigational Anti-Tumor Agent
3RWP	;	1.92	;	Discovery of a Novel, Potent and Selective Inhibitor of 3-Phosphoinositide Dependent Kinase (PDK1)
3RWQ	;	2.55	;	Discovery of a Novel, Potent and Selective Inhibitor of 3-Phosphoinositide Dependent Kinase (PDK1)
3ZIM	;	2.85	;	Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kalpha
4QVX	;	2.1	;	Discovery of a Potent and Selective BCL-XL Inhibitor That Demonstrates Thrombocytopenia and Inhibits Tumor Growth in Vivo
5BQH	;	1.601	;	Discovery of a Potent and Selective mPGES-1 Inhibitor for the Treatment of Pain
5BQI	;	1.88	;	Discovery of a Potent and Selective mPGES-1 Inhibitor for the Treatment of Pain
5U9D	;	1.33	;	Discovery of a potent BTK inhibitor with a novel binding mode using parallel selections with a DNA-encoded chemical library
5T9U	;	2.301	;	Discovery of a Potent Cyclophilin Inhibitor (Compound 3) based on Structural Simplification of Sanglifehrin A
5T9W	;	2.0	;	Discovery of a Potent Cyclophilin Inhibitor (Compound 5) based on Structural Simplification of Sanglifehrin A
5T9Z	;	1.4	;	Discovery of a Potent Cyclophilin Inhibitor (Compound 6) based on Structural Simplification of Sanglifehrin A
5TA2	;	1.48	;	Discovery of a Potent Cyclophilin Inhibitor (Compound 7) based on Structural Simplification of Sanglifehrin A
5TA4	;	1.5	;	Discovery of a Potent Cyclophilin Inhibitor (Compound 8) based on Structural Simplification of Sanglifehrin A
4BBX	;	2.5	;	Discovery of a potent, selective and orally active PDE10A inhibitor for the treatment of schizophrenia
3V5Q	;	2.2001	;	Discovery of a selective TRK Inhibitor with efficacy in rodent cancer tumor models
4AGW	;	2.6	;	Discovery of a small molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases
3RKZ	;	1.5693	;	Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor capable of significantly decreasing tumor volume in a mouse xenograft model.
5J6D	;	1.9	;	Discovery of acyl guanidine tryptophan hydroxylase-1 inhibitors
6N9P	;	2.23	;	Discovery of affinity-based probes for Btk occupancy assay
3H0B	;	2.7	;	Discovery of aminoheterocycles as a novel beta-secretase inhibitor class
4B6E	;	2.46	;	Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function
4B6F	;	2.89	;	Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function
4B71	;	2.5	;	Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function
4B73	;	2.5	;	Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function
4B74	;	2.18	;	Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function
4B75	;	2.53	;	Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function
4B76	;	2.14	;	Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function
7RN5	;	2.28	;	Discovery of an Anion-Dependent Farnesyltransferase Inhibitor from a Phenotypic Screen
7RNI	;	1.978	;	Discovery of an Anion-Dependent Farnesyltransferase Inhibitor from a Phenotypic Screen
4MZ4	;	1.63	;	Discovery of an Irreversible HCV NS5B Polymerase Inhibitor
7NQQ	;	1.943	;	Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2
7NQW	;	1.775	;	Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2
7NR3	;	1.897	;	Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2
7NR5	;	1.766	;	Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2
7NR8	;	1.627	;	Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2
7NR9	;	1.906	;	Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2
3BM9	;	1.6	;	Discovery of Benzisoxazoles as Potent Inhibitors of Chaperone Hsp90
3BMY	;	1.6	;	Discovery of Benzisoxazoles as Potent Inhibitors of Chaperone Hsp90
4X2I	;	1.2	;	Discovery of benzotriazolo diazepines as orally-active inhibitors of BET bromodomains: Crystal structure of BRD4 with CPI-13
7D5L	;	2.15	;	Discovery of BMS-986144, a Third Generation, Pan Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
3KSQ	;	2.1	;	Discovery of C-Imidazole Azaheptapyridine FPT Inhibitors
5O83	;	2.9	;	Discovery of CDZ173 (leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors
2XP3	;	2.0	;	DISCOVERY OF CELL-ACTIVE PHENYL-IMIDAZOLE PIN1 INHIBITORS BY STRUCTURE-GUIDED FRAGMENT EVOLUTION
2XP4	;	1.8	;	DISCOVERY OF CELL-ACTIVE PHENYL-IMIDAZOLE PIN1 INHIBITORS BY STRUCTURE-GUIDED FRAGMENT EVOLUTION
2XP5	;	1.9	;	DISCOVERY OF CELL-ACTIVE PHENYL-IMIDAZOLE PIN1 INHIBITORS BY STRUCTURE-GUIDED FRAGMENT EVOLUTION
2XP6	;	1.9	;	DISCOVERY OF CELL-ACTIVE PHENYL-IMIDAZOLE PIN1 INHIBITORS BY STRUCTURE-GUIDED FRAGMENT EVOLUTION
2XP7	;	2.0	;	DISCOVERY OF CELL-ACTIVE PHENYL-IMIDAZOLE PIN1 INHIBITORS BY STRUCTURE-GUIDED FRAGMENT EVOLUTION
2XP8	;	2.1	;	DISCOVERY OF CELL-ACTIVE PHENYL-IMIDAZOLE PIN1 INHIBITORS BY STRUCTURE-GUIDED FRAGMENT EVOLUTION
2XP9	;	1.9	;	DISCOVERY OF CELL-ACTIVE PHENYL-IMIDAZOLE PIN1 INHIBITORS BY STRUCTURE-GUIDED FRAGMENT EVOLUTION
2XPA	;	1.9	;	DISCOVERY OF CELL-ACTIVE PHENYL-IMIDAZOLE PIN1 INHIBITORS BY STRUCTURE-GUIDED FRAGMENT EVOLUTION
2XPB	;	2.0	;	DISCOVERY OF CELL-ACTIVE PHENYL-IMIDAZOLE PIN1 INHIBITORS BY STRUCTURE-GUIDED FRAGMENT EVOLUTION
3ODK	;	2.3	;	Discovery of cell-active phenyl-imidazole Pin1 inhibitors by structure-guided fragment evolution
2YDI	;	1.6	;	Discovery of Checkpoint Kinase Inhibitor AZD7762 by Structure Based Design and Optimization of Thiophene Carboxamide Ureas
2YDJ	;	1.85	;	Discovery of Checkpoint Kinase Inhibitor AZD7762 by Structure Based Design and Optimization of Thiophene Carboxamide Ureas
2YDK	;	1.9	;	Discovery of Checkpoint Kinase Inhibitor AZD7762 by Structure Based Design and Optimization of Thiophene Carboxamide Ureas
5VP0	;	2.2	;	Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4-(trifluoromethoxy)phenyl]-2-methoxyethyl}-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders
5VP1	;	1.86	;	Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4-(trifluoromethoxy)phenyl]-2-methoxyethyl}-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders
4X1I	;	3.11	;	Discovery of cytotoxic Dolastatin 10 analogs with N-terminal modifications
4X1K	;	3.5	;	Discovery of cytotoxic Dolastatin 10 analogs with N-terminal modifications
4X1Y	;	3.19	;	Discovery of cytotoxic Dolastatin 10 analogs with N-terminal modifications
4X20	;	3.5	;	Discovery of cytotoxic Dolastatin 10 analogs with N-terminal modifications
4ZYC	;	1.95	;	Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode: Hdm2 (MDM2) complexed with cpd5
3OW3	;	1.9	;	Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors
3OW4	;	2.6	;	Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors
4NCG	;	2.58	;	Discovery of Doravirine, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses
7FGT	;		;	Discovery of DS15060524; Gene targeting chimera (GeneTAC) for the treatment of Friedreich's Ataxia (FRDA)
4C66	;	1.87	;	Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains
4C67	;	1.55	;	Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains
6UJH	;	1.493	;	Discovery of fragment-inspired heterocyclic benzenesulfonamides as inhibitors of the WDR5-MYC interaction
6UJJ	;	1.731	;	Discovery of fragment-inspired heterocyclic benzenesulfonamides as inhibitors of the WDR5-MYC interaction
6UJL	;	1.599	;	Discovery of fragment-inspired heterocyclic benzenesulfonamides as inhibitors of the WDR5-MYC interaction
6UIF	;	1.603	;	Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC interaction
6UIK	;	1.6	;	Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC interaction
6UJ4	;	1.53	;	Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC interaction
6UOZ	;	1.532	;	Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC interaction
7DV6	;	2.39	;	Discovery of Functionally Selective Transforming Growth Factor beta Type II Receptor (TGF-beta RII) Inhibitors as Anti-Fibrosis Agents
3TL5	;	2.788	;	Discovery of GDC-0980: a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor for the Treatment of Cancer
4CZS	;	1.73	;	Discovery of Glycomimetic Ligands via Genetically-encoded Library of Phage displaying Mannose-peptides
6X5J	;	2.513	;	Discovery of Hydroxy Pyrimidine Factor IXa Inhibitors
6X5L	;	2.246	;	Discovery of Hydroxy Pyrimidine Factor IXa Inhibitors
6X5P	;	1.997	;	Discovery of Hydroxy Pyrimidine Factor IXa Inhibitors
5IU2	;	2.7	;	Discovery of imidazoquinolines as a novel class of potent, selective and in vivo efficacious COT kinase inhibitors
5FI4	;	2.5	;	Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse xenograft model
8ATB	;	2.35	;	Discovery of IRAK4 Inhibitor 16
8ATL	;	2.464	;	Discovery of IRAK4 Inhibitor 23
8ATN	;	2.171	;	Discovery of IRAK4 Inhibitor 38
8BR6	;	2.167	;	Discovery of IRAK4 Inhibitor 40
8BR5	;	2.7	;	Discovery of IRAK4 Inhibitor 41
8BR7	;	2.119	;	Discovery of IRAK4 Inhibitors BAY1834845 and BAY1830839
7QPF	;	1.7	;	Discovery of Lu AF11167, a Phosphodiesterase 10A inhibitor clinical candidate
7QPM	;	2.4	;	Discovery of Lu AF11167, a Phosphodiesterase 10A inhibitor clinical candidate
7QPQ	;	2.2	;	Discovery of Lu AF11167, a Phosphodiesterase 10A inhibitor clinical candidate
7QPV	;	2.3	;	Discovery of Lu AF11167, a Phosphodiesterase 10A inhibitor clinical candidate
7QQ4	;	2.45	;	Discovery of Lu AF11167, a Phosphodiesterase 10A inhibitor clinical candidate
6U06	;	1.96	;	Discovery of Lysine-Targeted eIF4E Inhibitors through Covalent Docking
6U09	;	1.79	;	Discovery of Lysine-Targeted eIF4E Inhibitors through Covalent Docking
6ZJZ	;	2.489	;	Discovery of M5049: a novel selective TLR7/8 inhibitor for treatment of autoimmunity
8DI4	;	2.016	;	Discovery of MK-8189, a highly potent and selective PDE10A inhibitor for the treatment of schizophrenia
6DCG	;	1.45	;	Discovery of MK-8353: An Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology
5U6I	;	1.69	;	Discovery of MLi-2, an Orally Available and Selective LRRK2 Inhibitor that Reduces Brain Kinase Activity
5J87	;	1.59	;	Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a Highly Selective Irreversible BTK Kinase Inhibitor
4MDS	;	1.598	;	Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: identification of ML300 and non-covalent nanomolar inhibitors with an induced-fit binding
3S85	;	2.8	;	Discovery of New HIV Protease Inhibitors with Potential for Convenient Dosing and Reduced Side Effects: A-790742 and A-792611.
5LAY	;	2.71	;	Discovery of New Natural-product-inspired Spiro-oxindole Compounds as Orally Active Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2) IN COMPLEX WITH COMPOUND 6g
5G3J	;	2.4	;	Discovery of New Selective Glucocorticoid Receptor Agonist Leads
5WEX	;	1.26	;	Discovery of new selenoureido analogs of 4-(4-fluorophenylureido) benzenesulfonamides as carbonic anhydrase inhibitors
2X5O	;	1.46	;	Discovery of Novel 5-Benzylidenerhodanine- and 5-Benzylidene- thiazolidine-2,4-dione Inhibitors of MurD Ligase
5HKM	;	2.1	;	DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
5HNG	;	3.01	;	DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
5HO7	;	3.0	;	DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
5HO8	;	2.7	;	DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
3V01	;	2.705	;	Discovery of Novel Allosteric MEK Inhibitors Possessing Classical and Non-classical Bidentate Ser212 Interactions.
3V04	;	2.7	;	Discovery of Novel Allosteric MEK Inhibitors Possessing Classical and Non-classical Bidentate Ser212 Interactions.
5TNO	;	1.54	;	Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors
5TNT	;	1.4	;	Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors
3PDF	;	1.85	;	Discovery of Novel Cyanamide-Based Inhibitors of Cathepsin C
2F9B	;	2.54	;	Discovery of Novel Heterocyclic Factor VIIa Inhibitors
3HQW	;	1.7	;	Discovery of novel inhibitors of PDE10A
3HQY	;	2.0	;	Discovery of novel inhibitors of PDE10A
3HQZ	;	1.7	;	Discovery of novel inhibitors of PDE10A
3HR1	;	1.53	;	Discovery of novel inhibitors of PDE10A
4XIP	;	1.7	;	Discovery of novel oxazepine and diazepine carboxamides as two new classes of heat shock protein 90 inhibitors
4XIQ	;	1.84	;	Discovery of novel oxazepine and diazepine carboxamides as two new classes of heat shock protein 90 inhibitors
4XIR	;	1.7	;	Discovery of novel oxazepine and diazepine carboxamides as two new classes of heat shock protein 90 inhibitors
4XIT	;	1.86	;	Discovery of novel oxazepine and diazepine carboxamides as two new classes of heat shock protein 90 inhibitors
8K5N	;	2.2	;	Discovery of Novel PD-L1 Inhibitors That Induce Dimerization and Degradation of PD-L1 Based on Fragment Coupling Strategy
6L3X	;	2.3054	;	Discovery of novel peptidomimetic boronate ClpP inhibitors with noncanonical enzyme mechanism as potent virulence blockers in vitro and in vivo
6L40	;	2.209	;	Discovery of novel peptidomimetic boronate ClpP inhibitors with noncanonical enzyme mechanism as potent virulence blockers in vitro and in vivo
7DY7	;	2.42	;	Discovery of Novel Small-molecule Inhibitors of PD-1/PD-L1 Axis that Promotes PD-L1 Internalization and Degradation
3ARA	;	1.7	;	Discovery of Novel Uracil Derivatives as Potent Human dUTPase Inhibitors
4QYY	;	1.65	;	Discovery of Novel, Dual Mechanism ERK Inhibitors by Affinity Selection Screening of an Inactive Kinase State
5I4V	;	2.61	;	Discovery of novel, orally efficacious Liver X Receptor (LXR) beta agonists
4ZYI	;	1.67	;	Discovery of NVP-CGM097 - a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical trials in p53wt tumors: Hdm2 (MDM2) complexed with cpd2
4ZYF	;	1.8	;	Discovery of NVP-CGM097 - a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical trials in p53wt tumors: Hdm2 (MDM2) complexed with NVP-CGM097
4B6L	;	1.9	;	Discovery of Oral Polo-Like Kinase (PLK) Inhibitors with Enhanced Selectivity Profile using Residue Targeted Drug Design
3UI7	;	2.28	;	Discovery of orally active pyrazoloquinoline as a potent PDE10 inhibitor for the management of schizophrenia
5LWP	;	2.4	;	Discovery of phenoxyindazoles and phenylthioindazoles as RORg inverse agonists
6D9X	;	1.83	;	Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Using Fragment-Based Methods and Structure-Based Design
6DAI	;	1.63	;	Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Using Fragment-Based Methods and Structure-Based Design
6DAK	;	1.6	;	Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Using Fragment-Based Methods and Structure-Based Design
6DAR	;	1.88	;	Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Using Fragment-Based Methods and Structure-Based Design
6DAS	;	1.8	;	Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Using Fragment-Based Methods and Structure-Based Design
6E1Y	;	1.219	;	Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Using Fragment-Based Methods and Structure-Based Design
4LTS	;	1.692	;	Discovery of Potent and Efficacious Cyanoguanidine-containing Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors
4LWW	;	1.641	;	Discovery of Potent and Efficacious Cyanoguanidine-containing Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors
4JNM	;	2.2	;	Discovery of Potent and Efficacious Urea-containing Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors with Reduced CYP2C9 Inhibition Properties
3V6R	;	2.6	;	Discovery of potent and selective covalent inhibitors of JNK
3V6S	;	2.97	;	Discovery of potent and selective covalent inhibitors of JNK
6K1S	;	2.6	;	Discovery of Potent and Selective Covalent Protein Arginine Methyltransferase (PRMT5) Inhibitors
4HW2	;	2.8	;	Discovery of potent Mcl-1 inhibitors using fragment-based methods and structure-based design
4HW3	;	2.4	;	Discovery of potent Mcl-1 inhibitors using fragment-based methods and structure-based design
4HW4	;	1.53	;	Discovery of potent Mcl-1 inhibitors using fragment-based methods and structure-based design
6NE5	;	1.85	;	Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors that Demonstrate in vivo Activity in Mouse Xenograft Models of Human Cancer
5IEZ	;	2.6	;	Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) inhibitors using Structure-Based Design
5IF4	;	2.392	;	Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) inhibitors using Structure-Based Design
7UAS	;	1.808	;	Discovery of Potent Orally Bioavailable WD Repeat Domain 5 (WDR5) Inhibitors Using a Pharmacophore-Based Optimization
1BQO	;	2.3	;	DISCOVERY OF POTENT, ACHIRAL MATRIX METALLOPROTEINASE INHIBITORS
2H96	;	3.0	;	Discovery of Potent, Highly Selective, and Orally Bioavailable Pyridine Carboxamide C-jun NH2-terminal Kinase Inhibitors
2HVX	;	2.6	;	Discovery of Potent, Orally Active, Nonpeptide Inhibitors of Human Mast Cell Chymase by Using Structure-Based Drug Design
6K9U	;	2.35	;	Discovery of Pyrazolo[1,5-a]pyrimidine Derivative as a Highly Selective PDE10A Inhibitor
4MBI	;	2.3	;	Discovery of Pyrazolo[1,5a]pyrimidine-based Pim1 Inhibitors
4MBL	;	2.6	;	Discovery of Pyrazolo[1,5a]pyrimidine-based Pim1 Inhibitors
4UVH	;	1.89	;	Discovery of pyrimidine isoxazoles InhA in complex with compound 10
4UVG	;	1.92	;	Discovery of pyrimidine isoxazoles InhA in complex with compound 15
4UVI	;	1.73	;	Discovery of pyrimidine isoxazoles InhA in complex with compound 23
4UVD	;	1.82	;	Discovery of pyrimidine isoxazoles InhA in complex with compound 6
4UVE	;	1.99	;	Discovery of pyrimidine isoxazoles InhA in complex with compound 9
3UFL	;	1.9	;	Discovery of Pyrrolidine-based b-Secretase Inhibitors: Lead Advancement through Conformational Design for Maintenance of Ligand Binding Efficiency
7WO1	;	2.15	;	Discovery of SARS-CoV-2 3CLpro peptidomimetic inhibitors through H41-specific protein-ligand interactions
6VRV	;	1.74	;	Discovery of SARxxxx92, a pan-PIM kinase inhibitor, efficacious in a KG1 tumor model
4HEJ	;	2.0	;	Discovery of Selective and Potent Inhibitors of Gram-positive Bacterial Thymidylate Kinase (TMK): Compund 16
4HDC	;	2.05	;	Discovery of Selective and Potent Inhibitors of Gram-positive Bacterial Thymidylate Kinase (TMK: Compound 41)
7X6T	;	1.44	;	Discovery of Selective BRD4 BD1 Inhibitor Based on [1,2,4] triazolo [4,3-b] pyridazine Scaffold
7M40	;	1.88	;	Discovery of small molecule antagonists of human Retinoblastoma Binding Protein 4 (RBBP4)
5OCG	;	1.48	;	Discovery of small molecules binding to KRAS via high affinity antibody fragment competition method.
5OCO	;	1.66	;	Discovery of small molecules binding to KRAS via high affinity antibody fragment competition method.
5OCT	;	2.07	;	Discovery of small molecules binding to KRAS via high affinity antibody fragment competition method.
4EPT	;	2.0	;	Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-mediated Activation
4EPV	;	1.35	;	Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-mediated Activation
4EPW	;	1.7	;	Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-mediated Activation
4EPX	;	1.76	;	Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-mediated Activation
4EPY	;	1.801	;	Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-mediated Activation
4EPR	;	2.0	;	Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation.
7LJE	;	2.607	;	Discovery of Spirohydantoins as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases
5KOQ	;	2.7	;	Discovery of TAK-272: A Novel, Potent and Orally Active Renin In-hibitor
5KOS	;	2.41	;	Discovery of TAK-272: A Novel, Potent and Orally Active Renin In-hibitor
5KOT	;	2.1	;	Discovery of TAK-272: A Novel, Potent and Orally Active Renin In-hibitor
5TR6	;	1.93	;	Discovery of TAK-659, an Orally Available Investigational Inhibitor of Spleen Tyrosine Kinase (SYK)
5TT7	;	1.77	;	Discovery of TAK-659, an Orally Available Investigational Inhibitor of Spleen Tyrosine Kinase (SYK)
3KL6	;	1.45	;	Discovery of Tetrahydropyrimidin-2(1H)-one derivative TAK-442: A potent, selective and orally active factor Xa inhibitor
8RIJ	;	1.96	;	Discovery of the first orally bioavailable ADAMTS7 inhibitor BAY-9835
2OBQ	;	2.5	;	Discovery of the HCV NS3/4A Protease Inhibitor SCH503034. Key Steps in Structure-Based Optimization
3ML8	;	2.7	;	Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04691502 through Structure Based Drug Design
3ML9	;	2.55	;	Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04691502 through Structure Based Drug Design
8CAR	;	2.68	;	Discovery of the lanthipeptide Curvocidin and structural insights into its trifunctional synthetase CuvL
8CAV	;	2.87	;	Discovery of the lanthipeptide Curvocidin and structural insights into its trifunctional synthetase CuvL
6IVX	;	2.35	;	Discovery of the Second Generation ROR gamma Inhibitors Composed of an Azole Scaffold.
4J6I	;	2.9	;	Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase beta isoform
4YTC	;	2.16	;	Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the Treatment of Autoimmune Disease
4YTI	;	2.52	;	Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the Treatment of Autoimmune Disease
4YTF	;	1.78	;	Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the Treatment of Autoimmune Diseases
4YTH	;	2.04	;	Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the Treatment of Autoimmune Diseases
3FLI	;	2.0	;	Discovery of XL335, a Highly Potent, Selective and Orally-Active Agonist of the Farnesoid X Receptor (FXR)
5NES	;	1.606	;	Discovery, crystal structures and atomic force microscopy study of thioether ligated D,L-cyclic antimicrobial peptides against multidrug resistant Pseudomonas aeruginosa
5NEY	;	1.55	;	Discovery, crystal structures and atomic force microscopy study of thioether ligated D,L-cyclic antimicrobial peptides against multidrug resistant Pseudomonas aeruginosa
5NF0	;	1.271	;	Discovery, crystal structures and atomic force microscopy study of thioether ligated D,L-cyclic antimicrobial peptides against multidrug resistant Pseudomonas aeruginosa
2AB9	;		;	Discovery, structural determination and processing of the precursor protein that produces the cyclic trypsin inhibitor SFTI-1
5FLF	;	2.58	;	DISEASE LINKED MUTATION IN FGFR
3BIR	;	1.8	;	DISECTING HISTIDINE INTERACTIONS IN RIBONUCLEASE T1 BY ASN AND GLN SUBSTITUTIONS
5BIR	;	2.0	;	DISECTING HISTIDINE INTERACTIONS IN RIBONUCLEASE T1 USING ASN AND GLN MUTATIONS
3FY5	;	2.4	;	Dishevelled PDZ domain homodimer
464D	;	1.23	;	DISORDER AND TWIN REFINEMENT OF RNA HEPTAMER DOUBLE HELIX
466D	;	1.16	;	DISORDER AND TWIN REFINEMENT OF RNA HEPTAMER DOUBLE HELIX
6E1Z	;	1.1	;	Displacement of WDR5 from chromatin by a pharmacological WIN site inhibitor with picomolar affinity
6E22	;	1.6	;	Displacement of WDR5 from chromatin by a pharmacological WIN site inhibitor with picomolar affinity
6E23	;	1.66	;	Displacement of WDR5 from chromatin by a pharmacological WIN site inhibitor with picomolar affinity
5JR8	;	2.65	;	Disposal of Iron by a Mutant form of Siderocalin NGAL
5CSY	;	2.05	;	Disproportionating enzyme 1 from Arabidopsis - acarbose soak
5CSU	;	2.53	;	Disproportionating enzyme 1 from Arabidopsis - acarviostatin soak
5CPQ	;	2.13	;	Disproportionating enzyme 1 from Arabidopsis - apo form
5CPT	;	2.3	;	Disproportionating enzyme 1 from Arabidopsis - beta cyclodextrin soak
5CQ1	;	2.3	;	Disproportionating enzyme 1 from Arabidopsis - cycloamylose soak
5CPS	;	1.8	;	Disproportionating enzyme 1 from Arabidopsis - maltotriose soak
6B1I	;	2.3	;	Disrupted hydrogen bond network impairs ATPase activity in an Hsc70 cysteine mutant
6B1M	;	1.9	;	Disrupted hydrogen bond network impairs ATPase activity in an Hsc70 cysteine mutant
6B1N	;	1.8	;	Disrupted hydrogen bond network impairs ATPase activity in an Hsc70 cysteine mutant
3K74	;	1.95	;	Disruption of protein dynamics by an allosteric effector antibody
1O5A	;	1.68	;	Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala190 Protease (Ala190 uPA)
1O5B	;	1.85	;	Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala190 Protease (Ala190 uPA)
1O5C	;	1.63	;	Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala190 Protease (Ala190 uPA)
1O5D	;	2.05	;	Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala190 Protease (Ala190 uPA)
1O5E	;	1.75	;	Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala190 Protease (Ala190 uPA)
1O5F	;	1.78	;	Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala190 Protease (Ala190 uPA)
1O5G	;	1.75	;	Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala190 Protease (Ala190 uPA)
1HV0	;	1.6	;	DISSECTING ELECTROSTATIC INTERACTIONS AND THE PH-DEPENDENT ACTIVITY OF A FAMILY 11 GLYCOSIDASE
1HV1	;	1.8	;	DISSECTING ELECTROSTATIC INTERACTIONS AND THE PH-DEPENDENT ACTIVITY OF A FAMILY 11 GLYCOSIDASE
3J28	;	12.9	;	Dissecting the in vivo assembly of the 30S ribosomal subunit reveals the role of RimM
3J29	;	14.0	;	Dissecting the in vivo assembly of the 30S ribosomal subunit reveals the role of RimM
3J2A	;	13.1	;	Dissecting the in vivo assembly of the 30S ribosomal subunit reveals the role of RimM
3J2B	;	13.6	;	Dissecting the in vivo assembly of the 30S ribosomal subunit reveals the role of RimM
3J2C	;	13.2	;	Dissecting the in vivo assembly of the 30S ribosomal subunit reveals the role of RimM
3J2D	;	18.7	;	Dissecting the in vivo assembly of the 30S ribosomal subunit reveals the role of RimM
3J2E	;	15.3	;	Dissecting the in vivo assembly of the 30S ribosomal subunit reveals the role of RimM
3J2F	;	17.6	;	Dissecting the in vivo assembly of the 30S ribosomal subunit reveals the role of RimM
3J2G	;	16.5	;	Dissecting the in vivo assembly of the 30S ribosomal subunit reveals the role of RimM
3J2H	;	18.8	;	Dissecting the in vivo assembly of the 30S ribosomal subunit reveals the role of RimM
2AB4	;	2.4	;	Dissecting the Roles of a Strictly Conserved Tyrosine in Substrate Recognition and Catalysis by Pseudouridine 55 Synthase
5HD7	;	1.69	;	Dissecting Therapeutic Resistance to ERK Inhibition Rat Mutant SCH772984 in complex with (3R)-1-(2-oxo-2-{4-[4-(pyrimidin-2-yl)phenyl]piperazin-1-yl}ethyl)-N-[3-(pyridin-4-yl)-2H-indazol-5-yl]pyrrolidine-3-carboxamide
5HD4	;	1.45	;	Dissecting Therapeutic Resistance to ERK Inhibition Rat Wild Type SCH772984 in complex with (3R)-1-(2-oxo-2-{4-[4-(pyrimidin-2-yl)phenyl]piperazin-1-yl}ethyl)-N-[3-(pyridin-4-yl)-2H-indazol-5-yl]pyrrolidine-3-carboxamide
1LYE	;	1.8	;	DISSECTION OF HELIX CAPPING IN T4 LYSOZYME BY STRUCTURAL AND THERMODYNAMIC ANALYSIS OF SIX AMINO ACID SUBSTITUTIONS AT THR 59
1LYF	;	1.8	;	DISSECTION OF HELIX CAPPING IN T4 LYSOZYME BY STRUCTURAL AND THERMODYNAMIC ANALYSIS OF SIX AMINO ACID SUBSTITUTIONS AT THR 59
1LYG	;	1.8	;	DISSECTION OF HELIX CAPPING IN T4 LYSOZYME BY STRUCTURAL AND THERMODYNAMIC ANALYSIS OF SIX AMINO ACID SUBSTITUTIONS AT THR 59
1LYH	;	1.7	;	DISSECTION OF HELIX CAPPING IN T4 LYSOZYME BY STRUCTURAL AND THERMODYNAMIC ANALYSIS OF SIX AMINO ACID SUBSTITUTIONS AT THR 59
1LYI	;	2.0	;	DISSECTION OF HELIX CAPPING IN T4 LYSOZYME BY STRUCTURAL AND THERMODYNAMIC ANALYSIS OF SIX AMINO ACID SUBSTITUTIONS AT THR 59
1LYJ	;	1.8	;	DISSECTION OF HELIX CAPPING IN T4 LYSOZYME BY STRUCTURAL AND THERMODYNAMIC ANALYSIS OF SIX AMINO ACID SUBSTITUTIONS AT THR 59
2BO4	;	1.95	;	Dissection of mannosylglycerate synthase: an archetypal mannosyltransferase
2BO6	;	2.45	;	DISSECTION OF MANNOSYLGLYCERATE SYNTHASE: AN ARCHETYPAL MANNOSYLTRANSFERASE
2BO7	;	2.95	;	DISSECTION OF MANNOSYLGLYCERATE SYNTHASE: AN ARCHETYPAL MANNOSYLTRANSFERASE
2BO8	;	2.8	;	DISSECTION OF MANNOSYLGLYCERATE SYNTHASE: AN ARCHETYPAL MANNOSYLTRANSFERASE
1LZA	;	1.6	;	DISSECTION OF PROTEIN-CARBOHYDRATE INTERACTIONS IN MUTANT HEN EGG-WHITE LYSOZYME COMPLEXES AND THEIR HYDROLYTIC ACTIVITY
1LZB	;	1.5	;	DISSECTION OF PROTEIN-CARBOHYDRATE INTERACTIONS IN MUTANT HEN EGG-WHITE LYSOZYME COMPLEXES AND THEIR HYDROLYTIC ACTIVITY
1LZC	;	1.8	;	DISSECTION OF PROTEIN-CARBOHYDRATE INTERACTIONS IN MUTANT HEN EGG-WHITE LYSOZYME COMPLEXES AND THEIR HYDROLYTIC ACTIVITY
1LZD	;	1.8	;	DISSECTION OF PROTEIN-CARBOHYDRATE INTERACTIONS IN MUTANT HEN EGG-WHITE LYSOZYME COMPLEXES AND THEIR HYDROLYTIC ACTIVITY
1LZE	;	1.8	;	DISSECTION OF PROTEIN-CARBOHYDRATE INTERACTIONS IN MUTANT HEN EGG-WHITE LYSOZYME COMPLEXES AND THEIR HYDROLYTIC ACTIVITY
1LZG	;	1.8	;	DISSECTION OF PROTEIN-CARBOHYDRATE INTERACTIONS IN MUTANT HEN EGG-WHITE LYSOZYME COMPLEXES AND THEIR HYDROLYTIC ACTIVITY
1TAY	;	1.7	;	DISSECTION OF THE FUNCTIONAL ROLE OF STRUCTURAL ELEMENTS OF TYROSINE-63 IN THE CATALYTIC ACTION OF HUMAN LYSOZYME
1TBY	;	1.77	;	DISSECTION OF THE FUNCTIONAL ROLE OF STRUCTURAL ELEMENTS OF TYROSINE-63 IN THE CATALYTIC ACTION OF HUMAN LYSOZYME
1TCY	;	1.7	;	DISSECTION OF THE FUNCTIONAL ROLE OF STRUCTURAL ELEMENTS OF TYROSINE-63 IN THE CATALYTIC ACTION OF HUMAN LYSOZYME
1TDY	;	1.7	;	DISSECTION OF THE FUNCTIONAL ROLE OF STRUCTURAL ELEMENTS OF TYROSINE-63 IN THE CATALYTIC ACTION OF HUMAN LYSOZYME
2NAP	;	1.9	;	DISSIMILATORY NITRATE REDUCTASE (NAP) FROM DESULFOVIBRIO DESULFURICANS
3MM7	;	1.9	;	Dissimilatory sulfite reductase carbon monoxide complex
3MM6	;	1.9	;	Dissimilatory sulfite reductase cyanide complex
3MMB	;	2.3	;	Dissimilatory sulfite reductase in complex with the endproduct sulfide
3MM5	;	1.8	;	Dissimilatory sulfite reductase in complex with the substrate sulfite
3MM8	;	2.28	;	Dissimilatory sulfite reductase nitrate complex
3MM9	;	2.1	;	Dissimilatory sulfite reductase nitrite complex
3MMA	;	2.3	;	Dissimilatory sulfite reductase phosphate complex
7R10	;	4.0	;	Dissociated S1 domain of Alpha Variant SARS-CoV-2 Spike bound to ACE2
7R0Z	;	3.5	;	Dissociated S1 domain of Alpha Variant SARS-CoV-2 Spike bound to ACE2 (Non-Uniform Refinement)
7R11	;	3.5	;	Dissociated S1 domain of Beta Variant SARS-CoV-2 Spike bound to ACE2 (Non-Uniform Refinement)
7R12	;	3.3	;	Dissociated S1 domain of Mink Variant SARS-CoV-2 Spike bound to ACE2 (Non-Uniform Refinement)
7A91	;	3.6	;	Dissociated S1 domain of SARS-CoV-2 Spike bound to ACE2 (Non-Uniform Refinement)
7A92	;	4.2	;	Dissociated S1 domain of SARS-CoV-2 Spike bound to ACE2 (Unmasked Refinement)
5OI2	;	2.2	;	Dissociation of biochemical and antiretroviral activities of Integrase-LEDGF Allosteric Inhibitors revealed by resistance of A125 polymorphic HIV-1
5OI3	;	2.3	;	Dissociation of biochemical and antiretroviral activities of Integrase-LEDGF Allosteric Inhibitors revealed by resistance of A125 polymorphic HIV-1
5OI5	;	2.4	;	Dissociation of biochemical and antiretroviral activities of Integrase-LEDGF Allosteric Inhibitors revealed by resistance of A125 polymorphic HIV-1
5OI8	;	2.35	;	Dissociation of biochemical and antiretroviral activities of Integrase-LEDGF Allosteric Inhibitors revealed by resistance of A125 polymorphic HIV-1
5OIA	;	2.2	;	Dissociation of biochemical and antiretroviral activities of Integrase-LEDGF Allosteric Inhibitors revealed by resistance of A125 polymorphic HIV-1
2QFE	;	1.45	;	Distal C2-Like Domain of Human Calpain-7
4ATJ	;	2.5	;	DISTAL HEME POCKET MUTANT (H42E) OF RECOMBINANT HORSERADISH PEROXIDASE IN COMPLEX WITH BENZHYDROXAMIC ACID
1KZM	;	2.0	;	Distal Heme Pocket Mutant (R38S/H42E) of Recombinant Horseradish Peroxidase C (HRP C).
1YCA	;	2.9	;	DISTAL POCKET POLARITY IN LIGAND BINDING TO MYOGLOBIN: DEOXY AND CARBONMONOXY FORMS OF A THREONINE68 (E11) MUTANT INVESTIGATED BY X-RAY CRYSTALLOGRAPHY AND INFRARED SPECTROSCOPY
1YCB	;	2.1	;	DISTAL POCKET POLARITY IN LIGAND BINDING TO MYOGLOBIN: DEOXY AND CARBONMONOXY FORMS OF A THREONINE68 (E11) MUTANT INVESTIGATED BY X-RAY CRYSTALLOGRAPHY AND INFRARED SPECTROSCOPY
1MYJ	;	1.9	;	DISTAL POLARITY IN LIGAND BINDING TO MYOGLOBIN: STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF A THREONINE68(E11) MUTANT
4JRC	;	2.673	;	Distal Stem I region from G. kaustophilus glyQS T box RNA
2W8D	;	2.35	;	Distinct and essential morphogenic functions for wall- and lipo- teichoic acids in Bacillus subtilis
6XR8	;	2.9	;	Distinct conformational states of SARS-CoV-2 spike protein
6XRA	;	3.0	;	Distinct conformational states of SARS-CoV-2 spike protein
2GJD	;	1.75	;	Distinct functional domains of Ubc9 dictate cell survival and resistance to genotoxic stress
6M2C	;	2.702	;	Distinct mechanism of MUL1-RING domain simultaneously recruiting E2 enzyme and the substrate p53-TAD domain
1MMM	;	2.2	;	DISTINCT METAL ENVIRONMENT IN IRON-SUBSTITUTED MANGANESE SUPEROXIDE DISMUTASE PROVIDES A STRUCTURAL BASIS OF METAL SPECIFICITY
3EL3	;	3.3	;	Distinct Monooxygenase and Farnesene Synthase Active Sites in Cytochrome P450 170A1
3FX8	;	2.44	;	Distinct recognition of three-way DNA junctions by a thioester variant of a metallo-supramolecular cylinder ('helicate')
3I1D	;	2.5	;	Distinct recognition of three-way DNA junctions by the two enantiomers of a metallo-supramolecular cylinder ('helicate')
4NNU	;	2.81	;	Distinct structural features of TFAM drive mitochondrial DNA packaging versus transcriptional activation
4NOD	;	2.897	;	Distinct structural features of TFAM drive mitochondrial DNA packaging versus transcriptional activation
2LZ6	;		;	Distinct ubiquitin binding modes exhibited by sh3 domains: molecular determinants and functional implications
2MCN	;		;	Distinct ubiquitin binding modes exhibited by SH3 domains: molecular determinants and functional implications
5AGZ	;	1.2	;	Disubstituted bis-THF moieties as new P2 ligands in non-peptidal HIV- 1 Protease Inhibitors (II)
5AH6	;	1.5	;	Disubstituted bis-THF moieties as new P2 ligands in non-peptidal HIV- 1 Protease Inhibitors (II)
5AH7	;	1.55	;	Disubstituted bis-THF moieties as new P2 ligands in non-peptidal HIV- 1 Protease Inhibitors (II)
5AH8	;	1.26	;	Disubstituted bis-THF moieties as new P2 ligands in non-peptidal HIV- 1 Protease Inhibitors (II)
5AH9	;	1.44	;	Disubstituted bis-THF moieties as new P2 ligands in non-peptidal HIV- 1 Protease Inhibitors (II)
5AHA	;	1.35	;	Disubstituted bis-THF moieties as new P2 ligands in non-peptidal HIV- 1 Protease Inhibitors (II)
5AHB	;	1.5	;	Disubstituted bis-THF moieties as new P2 ligands in non-peptidal HIV- 1 Protease Inhibitors (II)
5AHC	;	1.5	;	Disubstituted bis-THF moieties as new P2 ligands in non-peptidal HIV- 1 Protease Inhibitors (II)
5L6N	;	1.627	;	Disulfated madanin-thrombin complex
6FX4	;	2.5	;	Disulfide between E3 HECT ligase Smurf2 and Ubiquitin G76C
6FYH	;	2.906	;	Disulfide between ubiquitin G76C and the E3 HECT ligase Huwe1
4EDI	;	1.998	;	Disulfide bonded EutL from Clostridium perfringens
3OJW	;	2.2	;	Disulfide crosslinked cytochrome P450 reductase inactive
3OJX	;	2.5	;	Disulfide crosslinked cytochrome P450 reductase inactive
1MJV	;	2.1	;	DISULFIDE DEFICIENT MUTANT OF VASCULAR ENDOTHELIAL GROWTH FACTOR A (C51A and C60A)
1MKG	;	2.5	;	DISULFIDE DEFICIENT MUTANT OF VASCULAR ENDOTHELIAL GROWTH FACTOR A (C57A and C102A)
1MKK	;	1.32	;	Disulfide deficient mutant of vascular endothelial growth factor A (C61A and C104A)
1LK0	;	1.6	;	Disulfide intermediate of C89L Arsenate reductase from pI258
4ML1	;	1.978	;	Disulfide isomerase (DsbP) from multidrug resistance IncA/C transferable plasmid in oxidized state (P212121 space group)
4ML6	;	2.3	;	Disulfide isomerase from multidrug resistance IncA/C conjugative plasmid in reduced state
4MLY	;	2.207	;	Disulfide isomerase from multidrug resistance IncA/C related integrative and conjugative elements in oxidized state (P21 space group)
4XRO	;	2.01	;	Disulfide stabilized HIV-1 CA hexamer 4mut (S41A, Q67H, V165I, L172I)
4XRQ	;	1.95	;	Disulfide stabilized HIV-1 CA hexamer 4mut (S41A, Q67H, V165I, L172I) in complex with PF-3450074
7RMJ	;	2.27	;	Disulfide stabilized HIV-1 CA hexamer in complex with capsid inhibitor (S)-N-(1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide
7SNN	;	2.37	;	Disulfide stabilized HIV-1 CA hexamer in complex with capsid inhibitor N-(1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(difluoromethyl)-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl)acetamide
7SNL	;	2.39	;	Disulfide stabilized HIV-1 CA hexamer in complex with capsid inhibitor N-(1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide
4QNB	;	1.996	;	Disulfide stabilized HIV-1 CA hexamer in complex with PHENYL-L-PHENYLALANINAMIDE inhibitor
7KJP	;	3.86	;	Disulfide Stabilized Norovirus GI.1 VLP Shell Region
4M5T	;	2.0	;	Disulfide trapped human alphaB crystallin core domain in complex with C-terminal peptide
5XBD	;		;	Disulfide-constrained Wound Healing Peptide Derived from Pereskia bleo
1AR2	;	2.8	;	DISULFIDE-FREE IMMUNOGLOBULIN FRAGMENT
6AI5	;	1.81	;	Disulfide-free, Zn-directed tetramer of the engineered cyt cb562 variant, C96T/A104AB3
2OJ1	;	2.3	;	Disulfide-linked dimer of azurin N42C/M64E double mutant
6ZD0	;	4.6	;	Disulfide-locked early prepore intermedilysin-CD59
7TV5	;		;	Disulfide-rich venom peptide lasiocepsin: P20A mutant
8TY6	;	3.3	;	Disulfide-stabilized HIV-1 CA hexamer in complex with PQBP1 Nt
1ZDC	;		;	DISULFIDE-STABILIZED MINI PROTEIN A DOMAIN, Z34C, NMR, 24 STRUCTURES
1ZDD	;		;	DISULFIDE-STABILIZED MINI PROTEIN A DOMAIN, Z34C, NMR, MINIMIZED MEAN STRUCTURE
2N65	;		;	Disulphide linked homodimer of designed antimicrobial peptide VG16KRKP
3SBB	;	1.434	;	Disulphide-mediated Tetramer of T4 Lysozyme R76C/R80C by Synthetic Symmetrization
1B0Q	;		;	DITHIOL ALPHA MELANOTROPIN PEPTIDE CYCLIZED VIA RHENIUM METAL COORDINATION
7C10	;	2.806	;	Dithiol cGrx1
7ZXZ	;	1.45	;	dithiol-ligand bound to streptavidin
4U2L	;	1.337	;	Dithionite reduced cholesterol in complex with sulfite
2DMR	;	2.8	;	DITHIONITE REDUCED DMSO REDUCTASE FROM RHODOBACTER CAPSULATUS
1PIM	;	2.0	;	DITHIONITE REDUCED E. COLI RIBONUCLEOTIDE REDUCTASE R2 SUBUNIT, D84E MUTANT
4X9N	;	2.499	;	Dithionite reduced L-alpha-Glycerophosphate Oxidase from Mycoplasma pneumoniae with FAD bound
6N4L	;	1.13	;	Dithionite-reduced ADP-bound form of the nitrogenase Fe-protein from A. vinelandii
6N4K	;	1.756	;	Dithionite-reduced nucleotide-free form of the nitrogenase Fe-protein from A. vinelandii
1NZA	;	1.7	;	Divalent cation tolerance protein (Cut A1) from thermus thermophilus HB8
1XK8	;	2.7	;	Divalent cation tolerant protein CUTA from Homo sapiens O60888
1F21	;	1.4	;	DIVALENT METAL COFACTOR BINDING IN THE KINETIC FOLDING TRAJECTORY OF E. COLI RIBONUCLEASE HI
1UT5	;	2.75	;	Divalent metal ions (manganese) bound to T5 5'-exonuclease
1UT8	;	2.75	;	Divalent metal ions (zinc) bound to T5 5'-exonuclease
3R4C	;	1.82	;	Divergence of Structure and Function Among Phosphatases of the Haloalkanoate (HAD) Enzyme Superfamily: Analysis of BT1666 from Bacteroides thetaiotaomicron
1UET	;	2.0	;	Divergent evolutions of trinucleotide polymerization revealed by an archaeal CCA-adding enzyme structure
1UEU	;	2.0	;	Divergent evolutions of trinucleotide polymerization revealed by an archaeal CCA-adding enzyme structure
1UEV	;	2.7	;	Divergent evolutions of trinucleotide polymerization revealed by an archaeal CCA-adding enzyme structure
4IS8	;	2.78	;	Divergent sequence tunes ligand sensitivity in phospholipid-regulated hormone receptors
3AZR	;	1.71	;	Diverse Substrates Recognition Mechanism Revealed by Thermotoga maritima Cel5A Structures in Complex with Cellobiose
3AZT	;	1.8	;	Diverse Substrates Recognition Mechanism Revealed by Thermotoga maritima Cel5A Structures in Complex with Cellotetraose
3AZS	;	1.69	;	Diverse Substrates Recognition Mechanism Revealed by Thermotoga maritima Cel5A Structures in Complex with Mannotriose
3IGL	;	1.8	;	Diversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs (p53-DNA complex 1)
3IGK	;	1.7	;	Diversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs (p53-DNA complex 2)
3KZ8	;	1.91	;	Diversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs (p53-DNA complex 3)
4UET	;		;	Diversity in the structures and ligand binding sites among the fatty acid and retinol binding proteins of nematodes revealed by Na-FAR-1 from Necator americanus
6MRA	;	1.7	;	Diversity in the type II Natural Killer T cell receptor repertoire and antigen specificity leads to differing CD1d docking strategies
6MSS	;	3.0	;	Diversity in the type II Natural Killer T cell receptor repertoire and antigen specificity leads to differing CD1d docking strategies
4HXD	;	2.85	;	Diversity of ubiquitin and ISG15 specificity amongst nairoviruses viral ovarian tumor domain proteases
151D	;	1.4	;	DIVERSITY OF WATER RING SIZE AT DNA INTERFACES: HYDRATION AND DYNAMICS OF DNA-ANTHRACYCLINE COMPLEXES
152D	;	1.4	;	DIVERSITY OF WATER RING SIZE AT DNA INTERFACES: HYDRATION AND DYNAMICS OF DNA-ANTHRACYCLINE COMPLEXES
2WUJ	;	1.4	;	DivIVA N-terminal domain
2WUK	;	1.9	;	DivIVA N-terminal domain, F17A mutant
4WIP	;	2.691	;	DIX domain of human Dvl2
5J6U	;		;	DIY G-Quadruplexes: Solution Structure of d(GGGGTTTGGGGTTTTGGGGAAGGGG) in sodium
5J05	;		;	DIY G-Quadruplexes: Solution structure of d(GGGTTTGGGTTTTGGGAGGG) in sodium
5J4W	;		;	DIY G-Quadruplexes: Solution structure of d(GGTTTGGTTTTGGTTGG) in sodium
5J4P	;		;	DIY G-Quadruplexes: Solution structure of d(GGTTTGGTTTTGGTTTGG) in sodium
2R1U	;	1.5	;	DJ-1 activation by catechol quinone modification
6AF5	;	1.65	;	DJ-1 after backsoaking
6AFB	;	1.6	;	DJ-1 C106S incubated with isatin
6AF7	;	1.3	;	DJ-1 C106S unbound
4BTE	;	1.38	;	DJ-1 Cu(I) complex
6AFH	;	1.65	;	DJ-1 with compound 10
6AFI	;	1.65	;	DJ-1 with compound 11
6AFJ	;	1.48	;	DJ-1 with compound 13
6AFL	;	1.6	;	DJ-1 with compound 15
6AFC	;	1.45	;	DJ-1 with compound 4
6AFD	;	1.48	;	DJ-1 with compound 6
6AFE	;	1.5	;	DJ-1 with compound 7
6AFF	;	1.6	;	DJ-1 with compound 8
6AFG	;	1.5	;	DJ-1 with compound 9
6AFA	;	1.65	;	DJ-1 with isatin (low concentration)
6AF9	;	1.39	;	DJ-1 with isatin bound (high concentration)
5VO1	;	2.45	;	DLK in complex with compound 10 (5-(1-isopropyl-5-(3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl)-1H-pyrazol-3-yl)-3-(trifluoromethyl)pyridin-2-amine)
5CEQ	;	1.911	;	DLK in complex with inhibitor 2-((1-cyclopentyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-pyrazol-3-yl)amino)isonicotinonitrile
5CEO	;	2.28	;	DLK in complex with inhibitor 2-((6-(3,3-difluoropyrrolidin-1-yl)-4-(1-(oxetan-3-yl)piperidin-4-yl)pyridin-2-yl)amino)isonicotinonitrile
5VO2	;	2.96	;	DLK in complex with inhibitor 5-(1-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-pyrazol-3-yl)-3-(trifluoromethyl)pyridin-2-amine (compound 7)
5CEP	;	1.99	;	DLK in complex with inhibitor N-(1-isopropyl-5-(piperidin-4-yl)-1H-pyrazol-3-yl)-4-(trifluoromethyl)pyridin-2-amine
6XF8	;	6.5	;	DLP 5 fold
1JI5	;	2.5	;	Dlp-1 from bacillus anthracis
1JIG	;	1.46	;	Dlp-2 from Bacillus anthracis
5NBJ	;	1.266	;	DLS Tetragonal - ReHEWL
8HF1	;	3.7	;	DmDcr-2/R2D2/LoqsPD with 19bp-dsRNA in Trimer state
8HF0	;	3.72	;	DmDcr-2/R2D2/LoqsPD with 50bp-dsRNA in Dimer state
7W0E	;	4.03	;	dmDicer2-LoqsPD-dsRNA Active-dicing status
7W0A	;	3.12	;	dmDicer2-LoqsPD-dsRNA Dimer status
7W0F	;	4.55	;	dmDicer2-LoqsPD-dsRNA Post-dicing status
6IY8	;	3.42	;	DmpR-phenol complex of Pseudomonas putida
1H5N	;	2.0	;	DMSO REDUCTASE MODIFIED BY THE PRESENCE OF DMS AND AIR
2EYA	;		;	DMSO refined solution structure of crambin in acetone/water
2EYC	;		;	DMSO refined solution structure of crambin in dpc micelles
7CM9	;	2.249	;	DMSP lyase DddX
3TFH	;	2.1	;	DMSP-dependent demethylase from P. ubique - apo
3TFJ	;	1.6	;	DMSP-dependent demethylase from P. ubique - with cofactor THF
3TFI	;	1.6	;	DMSP-dependent demethylase from P. ubique - with substrate DMSP
5Y72	;	1.65	;	DMSPP Bound AmbP3
7W8W	;	1.8	;	DMSPP- and 5-Me-Trp-bound 6-dimethylallyl tryptophan synthase, IptA
7W8X	;	1.45	;	DMSPP- and 6-Me-Trp-bound dimethylallyl tryptophan synthase, IptA
7W8Y	;	1.39	;	DMSPP- and Naplha-Me-Trp-bound 6-dimethylallyl tryptophan synthase, IptA
7W8V	;	1.61	;	DMSPP- and Trp-bound 6-dimethylallyl tryptophan synthase, IptA
1ZHU	;		;	DNA (5'-D(*CP*AP*AP*TP*GP*CP*AP*AP*TP*G)-3'), NMR, 10 STRUCTURES
127D	;	2.0	;	DNA (5'-D(*CP*GP*CP*GP*AP*AP*TP*TP*CP*GP*CP*G)-3') COMPLEXED WITH HOECHST 33258
129D	;	2.25	;	DNA (5'-D(*CP*GP*CP*GP*AP*AP*TP*TP*CP*GP*CP*G)-3') COMPLEXED WITH HOECHST 33342
1RME	;		;	DNA (5'-D(MCYP*CP*TP*CP*C)-3') tetramer, NMR, 1 structure
1DCT	;	2.8	;	DNA (CYTOSINE-5) METHYLASE FROM HAEIII COVALENTLY BOUND TO DNA
2LAR	;		;	DNA / RNA Hybrid containing a central stereo specific Rp borano phosphate linkage
2LB4	;		;	DNA / RNA Hybrid containing a central stereo specific Sp borano phosphate linkage
5TGP	;	1.6	;	DNA 8mer containing two 2SeT modifications
2BQ3	;	2.0	;	DNA Adduct Bypass Polymerization by Sulfolobus solfataricus Dpo4. Analysis and Crystal Structures of Multiple Base-Pair Substitution and Frameshift Products with the Adduct 1,N2-Ethenoguanine
2BQR	;	2.37	;	DNA Adduct Bypass Polymerization by Sulfolobus solfataricus Dpo4. Analysis and Crystal Structures of Multiple Base-Pair Substitution and Frameshift Products with the Adduct 1,N2-Ethenoguanine
2BQU	;	2.5	;	DNA Adduct Bypass Polymerization by Sulfolobus solfataricus Dpo4. Analysis and Crystal Structures of Multiple Base-Pair Substitution and Frameshift Products with the Adduct 1,N2-Ethenoguanine
2BR0	;	2.17	;	DNA Adduct Bypass Polymerization by Sulfolobus solfataricus Dpo4. Analysis and Crystal Structures of Multiple Base-Pair Substitution and Frameshift Products with the Adduct 1,N2-Ethenoguanine
229D	;		;	DNA ANALOG OF YEAST TRANSFER RNA PHE ANTICODON DOMAIN WITH MODIFIED BASES 5-METHYL CYTOSINE AND 1-METHYL GUANINE
1ILC	;	2.2	;	DNA Bending by an Adenine-Thymine Tract and Its Role in Gene Regulation.
3MX4	;	2.5	;	DNA binding and cleavage by the GIY-YIG endonuclease R.Eco29KI inactive variant E142Q
3NIC	;	2.8	;	DNA binding and cleavage by the GIY-YIG endonuclease R.Eco29kI inactive variant Y49F
1U3E	;	2.92	;	DNA binding and cleavage by the HNH homing endonuclease I-HmuI
4HCA	;	2.8	;	DNA binding by GATA transcription factor-complex 1
4HC9	;	1.6	;	DNA binding by GATA transcription factor-complex 3
5JU7	;	2.05	;	DNA BINDING DOMAIN OF E.COLI CADC
3MLO	;	3.01	;	DNA binding domain of Early B-cell Factor 1 (Ebf1) bound to DNA (Crystal form I)
3MLN	;	2.4	;	DNA binding domain of Early B-cell Factor 1 (Ebf1) bound to DNA (crystal form II)
7D9K	;	2.9	;	DNA binding domain of human DNA Ligase IV - Wild type
7D9Y	;	2.76	;	DNA binding domain of human DNA Ligase IV mutant - A3V
8BBM	;	1.95	;	DNA binding domain of J-DNA Binding Protein 1 (JBP1)
6QEC	;	1.9	;	DNA binding domain of LUX ARRYTHMO in complex with DNA
3SQI	;	2.8245	;	DNA binding domain of Ndc10
7PC1	;	1.9	;	DNA binding domain of partition protein StbA of plasmid R388
3SSC	;	2.1	;	DNA binding domain of restriction endonuclease bound to DNA
3SSD	;	2.2	;	DNA binding domain of restriction endonuclease bound to DNA
3SSE	;	2.7	;	DNA binding domain of restriction endonuclease bound to DNA
6GCE	;	1.6	;	DNA binding domain of restriction endonuclease McrBC in complex with 5-formylcytosine DNA
6GCD	;	1.8	;	DNA binding domain of restriction endonuclease McrBC in complex with 5-hydroxymethylcytosine DNA
6GCF	;	1.55	;	DNA binding domain of restriction endonuclease McrBC in complex with N4-methylcytosine DNA
4ZC3	;	1.4	;	DNA binding domain of small terminase SF6 phage
1KAF	;	1.6	;	DNA Binding Domain Of The Phage T4 Transcription Factor MotA (AA105-211)
3G8U	;	1.9	;	DNA binding domain:GilZ 16bp complex-5
4KPY	;	2.406	;	DNA binding protein and DNA complex structure
6GDR	;	2.33	;	DNA binding with a minimal scaffold: Structure-function analysis of Lig E DNA ligases
6LTY	;	3.28	;	DNA bound antitoxin HigA3
2K1N	;		;	DNA bound structure of the N-terminal domain of AbrB
7WWV	;	3.2	;	DNA bound-ICP1 Csy complex
7XP3	;	3.25	;	DNA complex form of ORESARA1(ANAC092) NAC Domain
1LQ1	;	2.3	;	DNA Complexed Structure of the Key Transcription Factor Initiating Development in Sporulation Bacteria
2M3P	;		;	DNA containing a cluster of 8-oxo-guanine and abasic site lesion: alpha anomer
2M43	;		;	DNA containing a cluster of 8-oxo-guanine and abasic site lesion: alpha anomer (AP6, 8OG 14)
2M3Y	;		;	DNA containing a cluster of 8-oxo-guanine and abasic site lesion: beta anomer
2M44	;		;	DNA containing a cluster of 8-oxo-guanine and abasic site lesion: beta anomer (6AP, 8OG14)
2M40	;		;	DNA containing a cluster of 8-oxo-guanine and THF lesion
6QJO	;	1.8	;	DNA containing both right- and left-handed parallel-stranded G-quadruplexes
7EAY	;	2.5	;	DNA containing Cu(II)-mediated 4-N-carboxymethylcytosine base pairs
8S9N	;	1.89	;	DNA cytosine-N4 methyltransferase (residues 61-324) from the Bdelloid rotifer Adineta vaga - C2 crystal form
8S9O	;	1.94	;	DNA cytosine-N4 methyltransferase (residues 61-324) from the Bdelloid rotifer Adineta vaga - P1 crystal form
8S9M	;	1.49	;	DNA cytosine-N4 methyltransferase (residues 79-324) from the Bdelloid rotifer Adineta vaga
1QKG	;		;	DNA DECAMER DUPLEX CONTAINING T-T DEWAR PHOTOPRODUCT
1CFL	;		;	DNA DECAMER DUPLEX CONTAINING T5-T6 PHOTOADDUCT
1QL5	;		;	DNA DECAMER DUPLEX CONTAINING T5-T6 PHOTOADDUCT
1CW9	;	1.55	;	DNA DECAMER WITH AN ENGINEERED CROSSLINK IN THE MINOR GROOVE
154D	;	2.5	;	DNA DISTORTION IN BIS-INTERCALATED COMPLEXES
1D44	;	2.0	;	DNA DODECAMER C-G-C-G-A-A-T-T-C-G-C-G/HOECHST 33258 COMPLEX: 0 DEGREES C, PIPERAZINE DOWN
1D43	;	2.0	;	DNA DODECAMER C-G-C-G-A-A-T-T-C-G-C-G/HOECHST 33258 COMPLEX: 0 DEGREES C, PIPERAZINE UP
1D46	;	2.0	;	DNA DODECAMER C-G-C-G-A-A-T-T-C-G-C-G/HOECHST 33258 COMPLEX:-100 DEGREES C, PIPERAZINE DOWN
1D45	;	1.9	;	DNA DODECAMER C-G-C-G-A-A-T-T-C-G-C-G/HOECHST 33258 COMPLEX:-25 DEGREES C, PIPERAZINE DOWN
4GLH	;	1.662	;	DNA dodecamer containing 5-hydroxymethyl cytosine
4GLC	;	1.831	;	DNA dodecamer containing 5-hydroxymethyl-cytosine
4HLI	;	1.99	;	DNA dodecamer containing 5-hydroxymethyl-cytosine
4GLG	;	1.72	;	DNA dodecamer containing 5-methyl cytosine
4NZV	;	1.901	;	DNA Double-Strand Break Repair Pathway Choice Is Directed by Distinct MRE11 Nuclease Activities
4O24	;	2.3	;	DNA Double-Strand Break Repair Pathway Choice Is Directed by Distinct MRE11 Nuclease Activities
4O43	;	2.4	;	DNA Double-Strand Break Repair Pathway Choice Is Directed by Distinct MRE11 Nuclease Activities
4O4K	;	2.1	;	DNA Double-Strand Break Repair Pathway Choice Is Directed by Distinct MRE11 Nuclease Activities
4O5G	;	2.301	;	DNA Double-Strand Break Repair Pathway Choice Is Directed by Distinct MRE11 Nuclease Activities
1WAN	;		;	DNA DTA TRIPLEX, NMR, 7 STRUCTURES
7YGO	;	2.403	;	DNA duplex containing 5OHU-Hg(II)-T base pairs
7YGP	;	1.997	;	DNA duplex containing 5OHU-T base pairs
1AXP	;		;	DNA DUPLEX CONTAINING A PURINE-RICH STRAND, NMR, 6 STRUCTURES
5HQF	;		;	DNA duplex containing a ribonolactone lesion
5HQQ	;		;	DNA duplex containing a ribonolactone lesion
7EDV	;	2.01	;	DNA duplex containing C-G-Au-C base triple
2LZV	;		;	DNA duplex containing mispair-aligned O4U-heptylene-O4U interstrand cross-link
2LZW	;		;	DNA duplex containing mispair-aligned O6G-heptylene-O6G interstrand cross-link
7EDW	;	2.0	;	DNA duplex containing T-T base pairs in complex with Au(III)
4RHD	;	1.7	;	DNA Duplex with Novel ZP Base Pair
7B72	;		;	DNA duplex with phosphoryl guanidine moiety, Rp-diastereomer
104D	;		;	DNA DUPLEXES FLANKED BY HYBRID DUPLEXES: THE SOLUTION STRUCTURE OF CHIMERIC JUNCTIONS IN
8V6I	;	14.06	;	DNA elongation complex (configuration 1) of Xenopus laevis DNA polymerase alpha-primase
8V6J	;	11.11	;	DNA elongation complex (configuration 2) of Xenopus laevis DNA polymerase alpha-primase
1JB7	;	1.86	;	DNA G-Quartets in a 1.86 A Resolution Structure of an Oxytricha nova Telomeric Protein-DNA Complex
8DVY	;	2.36	;	DNA glycosylase MutY variant N146S in complex with DNA containing d(8-oxo-G) paired with an enzyme-generated abasic site product (AP) and crystalized with calcium acetate
8DW7	;	1.96	;	DNA glycosylase MutY variant N146S in complex with DNA containing the transition state analog 1N paired with d(8-oxo-G)
4KTN	;	1.69	;	Dna gyrase atp binding domain of enterococcus faecalis in complex with a small molecule inhibitor ((3S)-1-[2-(PYRIDO[2,3-B]PYRAZIN-7-YLSULFANYL)-9H-PYRIMIDO[4,5-B]INDOL-4-YL]PYRROLIDIN-3-AMINE)
4KSG	;	1.75	;	Dna gyrase atp binding domain of enterococcus faecalis in complex with a small molecule inhibitor (4-[(1S,5R,6R)-6-AMINO-1-METHYL-3-AZABICYCLO[3.2.0]HEPT-3-YL]-6-FLUORO-N-METHYL-2-[(2-METHYLPYRIMIDIN-5-YL)OXY]-9H-PYRIMIDO[4,5-B]INDOL-8-AMINE)
4KSH	;	1.7	;	Dna gyrase atp binding domain of enterococcus faecalis in complex with a small molecule inhibitor (7-({4-[(3R)-3-AMINOPYRROLIDIN-1-YL]-5-CHLORO-6-ETHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-2-YL}SULFANYL)-1,5-NAPHTHYRIDIN-1(4H)-OL)
7MVS	;	2.60137	;	DNA gyrase complexed with uncleaved DNA and Compound 7 to 2.6A resolution
6IUE	;	1.901	;	DNA helical wire containing Hg(II)
122D	;	1.7	;	DNA HELIX STRUCTURE AND REFINEMENT ALGORITHM: COMPARISON OF MODELS FOR D(CCAGGCM==5==CTGG) DERIVED FROM NUCLSQ, TNT, AND X-PLOR
123D	;	1.7	;	DNA HELIX STRUCTURE AND REFINEMENT ALGORITHM: COMPARISON OF MODELS FOR D(CCAGGCM==5==CTGG) DERIVED FROM NUCLSQ, TNT, AND X-PLOR
4GQD	;	1.94	;	DNA Holliday junction stabilized by chlorine halogen bond.
4GSG	;	2.0	;	DNA Holliday junction stabilized by chlorine halogen bond. Cl1J construct of related reference.
4GSI	;	2.38	;	DNA Holliday junction stabilized by fluorine halogen bond. F2J construct of related reference.
4GS2	;	1.9	;	DNA Holliday junction stabilized by iodine halogen bond. I1J construct in related reference.
4GRE	;	1.7	;	DNA holliday junction stabilized by iodine halogen bond. I2J Construct of related reference
8V6G	;	11.16	;	DNA initiation complex (configuration 1) of Xenopus laevis DNA polymerase alpha-primase
8V6H	;	11.11	;	DNA initiation complex (configuration 2) of Xenopus laevis DNA polymerase alpha-primase
8G9L	;	3.3	;	DNA initiation subcomplex of Xenopus laevis DNA polymerase alpha-primase
4GLW	;	2.0	;	DNA ligase A in complex with inhibitor
4GLX	;	1.9	;	DNA ligase A in complex with inhibitor
4EQ5	;	2.85	;	DNA ligase from the archaeon Thermococcus sibiricus
3RR5	;	3.018	;	DNA ligase from the archaeon Thermococcus sp. 1519
8OYR	;	2.21	;	DNA Major Groove Binding by lambda-[Ru(phen)2(phi)]2+
2PV0	;	3.3	;	DNA methyltransferase 3 like protein (DNMT3L)
6K0W	;	2.65	;	DNA methyltransferase in complex with sinefungin
8QHM	;	3.0	;	DNA mimic Foldamer with sticky ends
6J37	;		;	DNA minidumbbell structure of two CTTG repeats
459D	;	2.3	;	DNA MINOR-GROOVE RECOGNITION OF A TRIS-BENZIMIDAZOLE DRUG
458D	;	2.3	;	DNA MINOR-GROOVE RECOGNITION OF A TRIS-BENZIMIDAZOLE DRUG BY A NON-SELF-COMPLEMENTARY AT-RICH SEQUENCE
1AZO	;	1.7	;	DNA MISMATCH REPAIR PROTEIN MUTH FROM E. COLI
2AZO	;	2.3	;	DNA MISMATCH REPAIR PROTEIN MUTH FROM E. COLI
6RMN	;	2.2	;	DNA mismatch repair proteins MLH1 and MLH3
6SHX	;	2.4	;	DNA mismatch repair proteins MLH1 and MLH3
6SNS	;	2.6	;	DNA mismatch repair proteins MLH1 and MLH3
6SNV	;	2.5	;	DNA mismatch repair proteins MLH1 and MLH3
7KUL	;	1.64	;	DNA modification at 3' end of RNA primer complex with guanosine dinucleotide ligand G(5')ppp(5')G
4OC8	;	2.884	;	DNA modification-dependent restriction endonuclease AspBHI
6PBD	;	2.343	;	DNA N6-Adenine Methyltransferase CcrM In Complex with Double-Stranded DNA Oligonucleotide Containing Its Recognition Sequence GAATC
4H5A	;	1.42	;	DNA octamer D (GTseGTACAC) partially crosslinked with platinum
4FP6	;	1.28	;	DNA octamer d(gtggccac) with 2'-se modification
4I1G	;	1.25	;	dna octamer d(GTseGTACAC) partially crosslinked with two platinums
2DZ7	;	1.6	;	DNA Octaplex Formation with an I-Motif of A-Quartets: The Revised Crystal Structure of d(GCGAAAGC)
2RRR	;		;	DNA oligomer containing ethylene cross-linked cyclic 2'-deoxyuridylate dimer
2RRQ	;		;	DNA oligomer containing propylene cross-linked cyclic 2'-deoxyuridylate dimer
7ARE	;	7.4	;	DNA origami pointer object v2
7BHO	;	36.44	;	DNA origami signpost designed model
1KTQ	;	2.5	;	DNA POLYMERASE
5LEW	;	2.8	;	DNA polymerase
1NOY	;	2.2	;	DNA POLYMERASE (E.C.2.7.7.7)/DNA COMPLEX
9ICY	;	3.0	;	DNA POLYMERASE BETA (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA (NON GAPPED DNA ONLY)
9ICN	;	3.0	;	DNA POLYMERASE BETA (E.C.2.7.7.7)/DNA COMPLEX + 2',3'-DIDEOXYCYTIDINE-5'-TRIPHOSPHATE, SOAKED IN THE PRESENCE OF DDCTP AND MGCL2
9ICS	;	2.9	;	DNA POLYMERASE BETA (E.C.2.7.7.7)/DNA COMPLEX + 2',3'-DIDEOXYCYTIDINE-5'-TRIPHOSPHATE, SOAKED IN THE PRESENCE OF DDCTP AND MNCL2
9ICA	;	3.0	;	DNA POLYMERASE BETA (E.C.2.7.7.7)/DNA COMPLEX + 2'-DEOXYADENOSINE-5'-O-(1-THIOTRIPHOSPHATE), SOAKED IN THE PRESENCE OF DATP(ALPHA)S AND MNCL2
9ICB	;	3.2	;	DNA POLYMERASE BETA (E.C.2.7.7.7)/DNA COMPLEX + 2'-DEOXYADENOSINE-5'-TRIPHOSPHATE, SOAKED IN THE PRESENCE OF DATP AND COCL2
9ICC	;	3.1	;	DNA POLYMERASE BETA (E.C.2.7.7.7)/DNA COMPLEX + 2'-DEOXYADENOSINE-5'-TRIPHOSPHATE, SOAKED IN THE PRESENCE OF DATP AND CRCL3
9ICF	;	3.0	;	DNA POLYMERASE BETA (E.C.2.7.7.7)/DNA COMPLEX + 2'-DEOXYADENOSINE-5'-TRIPHOSPHATE, SOAKED IN THE PRESENCE OF DATP AND ZNCL2
9ICV	;	2.7	;	DNA POLYMERASE BETA (E.C.2.7.7.7)/DNA COMPLEX + 2'-DEOXYADENOSINE-5'-TRIPHOSPHATE, SOAKED IN THE PRESENCE OF DATP AND ZNCL2
9ICR	;	3.0	;	DNA POLYMERASE BETA (E.C.2.7.7.7)/DNA COMPLEX + 2'-DEOXYCYTIDINE-5'-TRIPHOSPHATE, SOAKED IN THE PRESENCE OF DCTP AND MNCL2
9ICT	;	3.0	;	DNA POLYMERASE BETA (E.C.2.7.7.7)/DNA COMPLEX + 2'-DEOXYGUANOSINE-5'-TRIPHOSPHATE, SOAKED IN THE PRESENCE OF DGTP AND MNCL2
8ICJ	;	3.2	;	DNA POLYMERASE BETA (E.C.2.7.7.7)/DNA COMPLEX + THYMIDINE-5'-TRIPHOSPHATE, SOAKED IN THE PRESENCE OF DTTP AND MGCL2
8ICY	;	3.1	;	DNA POLYMERASE BETA (E.C.2.7.7.7)/DNA COMPLEX + THYMIDINE-5'-TRIPHOSPHATE, SOAKED IN THE PRESENCE OF DTTP AND MNCL2
9ICK	;	2.7	;	DNA POLYMERASE BETA (E.C.2.7.7.7)/DNA COMPLEX, SOAKED IN THE PRESENCE OF ARTIFICIAL MOTHER LIQUOR
7ICE	;	2.8	;	DNA POLYMERASE BETA (E.C.2.7.7.7)/DNA COMPLEX, SOAKED IN THE PRESENCE OF CACL2
7ICG	;	3.0	;	DNA POLYMERASE BETA (E.C.2.7.7.7)/DNA COMPLEX, SOAKED IN THE PRESENCE OF CDCL2
7ICH	;	2.9	;	DNA POLYMERASE BETA (E.C.2.7.7.7)/DNA COMPLEX, SOAKED IN THE PRESENCE OF COCL2
9ICO	;	2.9	;	DNA POLYMERASE BETA (E.C.2.7.7.7)/DNA COMPLEX, SOAKED IN THE PRESENCE OF DTTP AND MGCL2
7ICK	;	2.9	;	DNA POLYMERASE BETA (E.C.2.7.7.7)/DNA COMPLEX, SOAKED IN THE PRESENCE OF MGCL2
1ZQR	;	3.7	;	DNA POLYMERASE BETA (E.C.2.7.7.7)/DNA COMPLEX, SOAKED IN THE PRESENCE OF NICL2
7ICN	;	2.8	;	DNA POLYMERASE BETA (E.C.2.7.7.7)/DNA COMPLEX, SOAKED IN THE PRESENCE OF NICL2
9ICL	;	2.8	;	DNA POLYMERASE BETA (E.C.2.7.7.7)/DNA COMPLEX, SOAKED IN THE PRESENCE OF PYROPHOSPHATE AND MNCL2
7ICO	;	3.3	;	DNA POLYMERASE BETA (E.C.2.7.7.7)/DNA COMPLEX, SOAKED IN THE PRESENCE OF ZNCL2
7ICQ	;	2.9	;	DNA POLYMERASE BETA (E.C.2.7.7.7)/DNA COMPLEX, SOAKED IN THE PRESENCE OF ZNCL2
7ICR	;	3.0	;	DNA POLYMERASE BETA (E.C.2.7.7.7)/DNA COMPLEX, SOAKED IN THE PRESENCE OF ZNCL2
7ICS	;	2.8	;	DNA POLYMERASE BETA (E.C.2.7.7.7)/DNA COMPLEX, SOAKED IN THE PRESENCE OF ZNCL2
7ICT	;	2.8	;	DNA POLYMERASE BETA (E.C.2.7.7.7)/DNA COMPLEX, SOAKED IN THE PRESENCE OF ZNCL2 AND MGCL2
9ICJ	;	3.1	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA
8ICC	;	2.8	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA (NO 5'-PHOSPHATE)
1ZQG	;	3.1	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF A SODIUM-FREE ARTIFICIAL MOTHER LIQUOR AT PH 6.5
1ZQH	;	3.1	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF A SODIUM-FREE ARTIFICIAL MOTHER LIQUOR AT PH 7.5
8ICB	;	3.1	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF ARTIFICIAL MOTHER LIQUOR
8ICN	;	2.8	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF ATP (1 MILLIMOLAR) AND MNCL2 (5 MILLIMOLAR)
8ICO	;	2.7	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF AZT-TP (1 MILLIMOLAR) AND MNCL2 (5 MILLIMOLAR)
1ZQN	;	3.0	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF BACL2 (15 MILLIMOLAR) AND NACL (15 MILLIMOLAR)
1ZQB	;	3.2	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF BACL2 (150 MILLIMOLAR)
1ZQC	;	3.2	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF CACL2 (15 MILLIMOLAR)
1ZQJ	;	3.3	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF CACL2 (15 MILLIMOLAR) AND MGCL2 (15 MILLIMOLAR)
1ZQO	;	3.2	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF CACL2 (15 MILLIMOLAR) AND NACL (15 MILLIMOLAR)
1ZQD	;	3.5	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF CACL2 (150 MILLIMOLAR)
1ZQE	;	3.7	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF CRCL3 (SATURATED SOLUTION)
1ZQF	;	2.9	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF CSCL (150 MILLIMOLAR)
1ZQT	;	3.4	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF DATP (0.01 MILLIMOLAR) AND ZNCL2 (0.02 MILLIMOLAR)
8ICA	;	3.0	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF DATP (1 MILLIMOLAR) AND CACL2 (5 MILLIMOLAR)
8ICE	;	3.2	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF DATP (1 MILLIMOLAR) AND CDCL2 (1 MILLIMOLAR)
9ICE	;	3.3	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF DATP (1 MILLIMOLAR) AND CUCL2 (0.1 MILLIMOLAR)
8ICG	;	3.3	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF DATP (1 MILLIMOLAR) AND MGCL2 (5 MILLIMOLAR)
8ICP	;	2.9	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF DATP (1 MILLIMOLAR) AND MNCL2 (5 MILLIMOLAR)
8ICR	;	2.9	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF DATP (1 MILLIMOLAR) AND MNCL2 (5 MILLIMOLAR)
8ICL	;	3.1	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF DATP (1 MILLIMOLAR) AND NICL2 (5 MILLIMOLAR)
8ICK	;	2.7	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF DATP (1 MILLIMOLAR), MGCL2 (5 MILLIMOLAR), AND MNCL2 (5 MILLIMOLAR)
8ICM	;	2.9	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF DATP (1 MILLIMOLAR), MNCL2 (5 MILLIMOLAR), AND AMMONIUM SULFATE (75 MILLIMOLAR)
8ICF	;	2.9	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF DATP (10 MILLIMOLAR) AND MGCL2 (50 MILLIMOLAR)
8ICH	;	3.3	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF DCTP (1 MILLIMOLAR) AND MGCL2 (5 MILLIMOLAR)
8ICS	;	2.9	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF DCTP (1 MILLIMOLAR) AND MNCL2 (5 MILLIMOLAR)
8ICT	;	3.1	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF DCTP (1 MILLIMOLAR) AND MNCL2 (5 MILLIMOLAR)
9ICG	;	3.0	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF DCTP (1 MILLIMOLAR) AND ZNCL2 (1 MILLIMOLAR)
8ICU	;	3.0	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF DDATP (1 MILLIMOLAR) AND MNCL2 (5 MILLIMOLAR)
8ICI	;	2.8	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF DGTP (1 MILLIMOLAR) AND MGCL2 (5 MILLIMOLAR)
8ICV	;	3.2	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF DGTP (1 MILLIMOLAR) AND MNCL2 (5 MILLIMOLAR)
9ICH	;	2.9	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF DGTP (1 MILLIMOLAR) AND ZNCL2 (1 MILLIMOLAR)
8ICW	;	3.3	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF DTTP (1 MILLIMOLAR) AND MNCL2 (5 MILLIMOLAR)
8ICX	;	3.0	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF DTTP (1 MILLIMOLAR) AND MNCL2 (5 MILLIMOLAR)
9ICI	;	3.1	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF DTTP (1 MILLIMOLAR) AND ZNCL2 (1 MILLIMOLAR)
1ZQI	;	2.7	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF KCL (150 MILLIMOLAR)
1ZQA	;	3.2	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF KCL (150 MILLIMOLAR) AT PH 7.5
1ZQK	;	3.2	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF KCL (75 MILLIMOLAR) AND MGCL2 (75 MILLIMOLAR)
1ZQP	;	2.8	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF KCL (75 MILLIMOLAR) AND NACL (75 MILLIMOLAR)
1ZQM	;	3.2	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF MNCL2 (15 MILLIMOLAR)
1ZQL	;	3.3	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF MNCL2 (15 MILLIMOLAR) AND MGCL2 (15 MILLIMOLAR)
1ZQQ	;	3.3	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF MNCL2 (15 MILLIMOLAR) AND NACL (15 MILLIMOLAR)
8ICQ	;	3.0	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF OF DATP (0.1 MILLIMOLAR) AND MNCL2 (0.5 MILLIMOLAR)
8ICZ	;	3.1	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF OF DATP (1 MILLIMOLAR), MNCL2 (5 MILLIMOLAR), AND LITHIUM SULFATE (75 MILLIMOLAR)
1ZQS	;	3.3	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SEVEN BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF TLCL (0.5 MILLIMOLAR)
9ICX	;	2.6	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SIX BASE PAIRS OF DNA (NON GAPPED DNA ONLY)
9ICW	;	2.6	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SIX BASE PAIRS OF DNA; NATIVE STRUCTURE
7ICU	;	3.3	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SIX BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF CDCL2 (0.1 MILLIMOLAR)
7ICF	;	3.1	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SIX BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF CDCL2 (0.1 MILLIMOLAR) (FOUR-DAY SOAK)
7ICI	;	2.8	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SIX BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF CRCL3 (0.1 MILLIMOLAR)
7ICJ	;	3.5	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SIX BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF CUCL2 (0.1 MILLIMOLAR)
9ICQ	;	2.9	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SIX BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF DATP (1 MILLIMOLAR) AND MNCL2 (5 MILLIMOLAR)
9ICU	;	2.9	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SIX BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF DTTP (1 MILLIMOLAR) AND MNCL2 (5 MILLIMOLAR)
7ICL	;	3.1	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SIX BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF MNCL2 (0.1 MILLIMOLAR)
7ICV	;	2.8	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SIX BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF MNCL2 (0.1 MILLIMOLAR) AND IN THE ABSENCE OF NACL
7ICM	;	3.0	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SIX BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF MNCL2 (1.0 MILLIMOLAR)
9ICP	;	3.1	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SIX BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF PYROPHOSPHATE (1 MILLIMOLAR) AND MGCL2 (5 MILLIMOLAR)
7ICP	;	3.0	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SIX BASE PAIRS OF DNA; SOAKED IN THE PRESENCE OF ZNCL2 (0.01 MILLIMOLAR)
9ICM	;	2.9	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7) COMPLEXED WITH SIX BASE PAIRS OF DOUBLE STRANDED DNA (NO 5'-PHOSPHATE)
1ZQU	;	2.6	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7), 31-KD DOMAIN; SOAKED IN THE PRESENCE OF ARTIFICIAL MOTHER LIQUOR
1ZQV	;	2.7	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7), 31-KD DOMAIN; SOAKED IN THE PRESENCE OF CACL2 (150 MILLIMOLAR)
1ZQW	;	2.3	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7), 31-KD DOMAIN; SOAKED IN THE PRESENCE OF CSCL (150 MILLIMOLAR)
1ZQX	;	2.5	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7), 31-KD DOMAIN; SOAKED IN THE PRESENCE OF KCL (150 MILLIMOLAR)
1ZQY	;	2.3	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7), 31-KD DOMAIN; SOAKED IN THE PRESENCE OF MGCL2 (50 MILLIMOLAR)
1NOM	;	3.0	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7), 31-KD DOMAIN; SOAKED IN THE PRESENCE OF MNCL2 (5 MILLIMOLAR)
1ZQZ	;	2.7	;	DNA POLYMERASE BETA (POL B) (E.C.2.7.7.7), 31-KD DOMAIN; SOAKED IN THE PRESENCE OF MNCL2 (50 MILLIMOLAR)
5V1G	;	1.798	;	DNA polymerase beta binary complex with 8-oxoG at the primer terminus
5V1H	;	1.946	;	DNA polymerase beta binary complex with 8-oxoG:A at the primer terminus
5BOM	;	2.0002	;	DNA polymerase beta binary complex with a templating 5ClC
4UB3	;	2.06	;	DNA polymerase beta closed product complex with a templating cytosine and 8-oxodGMP, 60 s
5UGP	;	1.955	;	DNA polymerase beta complex with a 1nt gap and dCMPPNP
5U8G	;	2.166	;	DNA Polymerase Beta crystallized in PEG 400
4M9G	;	2.01	;	DNA Polymerase Beta E295K Binary Complex
4M9N	;	2.275	;	DNA Polymerase Beta E295K Soaked with dATP
4M9L	;	2.091	;	DNA Polymerase Beta E295K Soaked with dCTP
4M9H	;	2.394	;	DNA Polymerase Beta E295K Soaked with dTTP
4M9J	;	2.038	;	DNA Polymerase Beta E295K Soaked with dUMPNPP
4PPX	;	2.08	;	DNA Polymerase Beta E295K with Spiroiminodihydantoin in Templating Position
5U8H	;	2.155	;	DNA Polymerase Beta G231D crystallized in PEG 400
6BTE	;	2.2	;	DNA Polymerase Beta I260Q Binary Complex
6BTF	;	1.75	;	DNA Polymerase Beta I260Q Ternary Complex
5UGN	;	1.997	;	DNA polymerase beta imidodiphosphate reactant complex
4KLO	;	1.845	;	DNA polymerase beta matched nick complex with Mg2+ and PPi, 30 min
4KLM	;	1.747	;	DNA polymerase beta matched product complex with Mg2+, 11 h
4KLG	;	1.701	;	DNA polymerase beta matched product complex with Mg2+, 40 s
4KLL	;	1.841	;	DNA polymerase beta matched product complex with Mg2+, 45 min
4KLJ	;	1.799	;	DNA polymerase beta matched product complex with Mg2+, 5 min
4KLI	;	1.597	;	DNA polymerase beta matched product complex with Mg2+, 90 s
4KLH	;	1.876	;	DNA polymerase beta matched product complex with Mn2+, 40 s
4KLE	;	1.97	;	DNA polymerase beta matched reactant complex with Mg2+, 10 s
4KLF	;	1.85	;	DNA polymerase beta matched reactant complex with Mg2+, 20 s
4KLD	;	1.916	;	DNA polymerase beta matched substrate complex with Ca2+, 0 s
4KLU	;	1.97	;	DNA polymerase beta mismatched product complex with Mn2+, 15 h
4KLT	;	1.979	;	DNA polymerase beta mismatched product complex with Mn2+, 30 min
4KLS	;	1.978	;	DNA polymerase beta mismatched reactant complex with Mn2+, 10 min
4LVS	;	2.002	;	DNA polymerase beta mismatched substrate complex with Mn2+, 2.5 min
3RH5	;	2.096	;	DNA Polymerase Beta Mutant (Y271) with a dideoxy-terminated primer with an incoming deoxynucleotide (dCTP)
3RH6	;	2.048	;	DNA Polymerase Beta Mutant (Y271) with a dideoxy-terminated primer with an incoming ribonucleotide (rCTP)
3OGU	;	1.845	;	DNA Polymerase beta mutant 5P20 complexed with 6bp of DNA
5UGO	;	1.897	;	DNA polymerase beta nick complex with imidodiphosphate
5V1J	;	2.616	;	DNA polymerase beta open product complex with 8-oxoG:C and inserted dCTP
5V1O	;	1.801	;	DNA polymerase beta product complex with 8-oxoG:A and inserted dCTP
4UB1	;	2.341	;	DNA polymerase beta product complex with a templating adenine and 8-oxodGMP, 90 s
4UAY	;	1.984	;	DNA polymerase beta product complex with a templating adenine and inserted 8-oxodGMP, 40 s
4UB2	;	2.51	;	DNA polymerase beta product complex with a templating cytosine and 8-oxodGMP, 120 s
5U9H	;	1.85	;	DNA polymerase beta product complex with inserted Sp-isomer of dCTP-alpha-S
5V1R	;	2.077	;	DNA polymerase beta reactant complex with 8-oxoG:C at the primer terminus and incoming dCTP
4UAZ	;	1.88	;	DNA polymerase beta reactant complex with a templating adenine and incoming 8-oxodGTP, 20 s
4UBB	;	1.9	;	DNA polymerase beta reactant complex with a templating cytosine and incoming 8-oxodGTP, 40 s
5U8I	;	2.45	;	DNA Polymerase Beta S229L crystallized in PEG 400
5V1F	;	2.181	;	DNA polymerase beta substrate complex with 8-oxoG at the primer terminus and incoming dCTP
5V1N	;	2.005	;	DNA polymerase beta substrate complex with 8-oxoG:A at the primer terminus and incoming dCTP
5VEZ	;	2.039	;	DNA polymerase beta substrate complex with 8-oxoG:A at the primer terminus and incoming dCTP analog
5V1P	;	1.991	;	DNA polymerase beta substrate complex with 8-oxoG:C at the primer terminus and incoming dCTP analog
4UAW	;	1.9	;	DNA polymerase beta substrate complex with a templating adenine and incoming 8-oxodGTP, 0 s
4UBC	;	2.0	;	DNA polymerase beta substrate complex with a templating cytosine and incoming 8-oxodGTP, 0 s
4UB4	;	1.954	;	DNA polymerase beta substrate complex with a templating cytosine and incoming dGTP, 0 s
4UB5	;	2.15	;	DNA polymerase beta substrate complex with a templating cytosine, incoming 8-oxodGTP, and Mn2+, 5 s
5WNY	;	2.1	;	DNA polymerase beta substrate complex with incoming 5-FdUTP
5WNZ	;	2.2	;	DNA polymerase beta substrate complex with incoming 5-FodCTP
5WO0	;	1.6	;	DNA polymerase beta substrate complex with incoming 5-FodUTP
5WNX	;	2.55	;	DNA polymerase beta substrate complex with incoming 6-TdGTP
6MR7	;	2.144	;	DNA polymerase beta substrate complex with templating adenine and incoming Fapy-dGTP analog
6DIA	;	1.969	;	DNA polymerase beta substrate complex with templating cytosine and incoming Fapy-dGTP analog
5BPC	;	2.0	;	DNA polymerase beta ternary complex with a templating 5ClC and incoming dATP analog
5BOL	;	1.981	;	DNA polymerase beta ternary complex with a templating 5ClC and incoming dGTP analog
5V1I	;	2.035	;	DNA polymerase beta ternary product complex with 8-oxoG:C and inserted dCTP
2I9G	;	2.1	;	DNA Polymerase Beta with a Benzo[c]phenanthrene diol epoxide adducted guanine base
3RH4	;	1.918	;	DNA Polymerase Beta with a dideoxy-terminated primer with an incoming ribonucleotide (rCTP)
3LK9	;	2.5	;	DNA polymerase beta with a gapped DNA substrate and dTMP(CF2)P(CF2)P
2FMS	;	2.0	;	DNA Polymerase beta with a gapped DNA substrate and dUMPNPP with magnesium in the catalytic site
3C2K	;	2.4	;	DNA POLYMERASE BETA with a gapped DNA substrate and DUMPNPP with Manganese in the active site
3GDX	;	2.2	;	Dna polymerase beta with a gapped DND substrate and dTMP(CF2)PP
2FMP	;	1.65	;	DNA Polymerase beta with a terminated gapped DNA substrate and ddCTP with sodium in the catalytic site
4NY8	;	2.246	;	DNA polymerase beta with O6mG in the template base opposite to incoming non-hydrolyzable CTP with manganese in the active site
4NXZ	;	2.557	;	DNA polymerase beta with O6mG in the template base opposite to incoming non-hydrolyzable TTP with manganese in the active site
1BPX	;	2.4	;	DNA POLYMERASE BETA/DNA COMPLEX
3O59	;	2.2	;	DNA polymerase D large subunit DP2(1-300) from Pyrococcus horikoshii
3MFI	;	1.76	;	DNA Polymerase Eta in Complex With a cis-syn Thymidine Dimer
2WTF	;	2.5	;	DNA polymerase eta in complex with the cis-diammineplatinum (II) 1,3- GTG intrastrand cross-link
3MFH	;	2.0	;	DNA Polymerase Eta in Complex With Undamaged DNA
1WAF	;	3.2	;	DNA POLYMERASE FROM BACTERIOPHAGE RB69
1WAJ	;	2.8	;	DNA POLYMERASE FROM BACTERIOPHAGE RB69
7PU7	;	2.9	;	DNA polymerase from M. tuberculosis
1QHT	;	2.1	;	DNA POLYMERASE FROM THERMOCOCCUS SP. 9ON-7 ARCHAEON
1KFS	;	2.1	;	DNA POLYMERASE I KLENOW FRAGMENT (E.C.2.7.7.7) MUTANT/DNA COMPLEX
1KLN	;	3.2	;	DNA POLYMERASE I KLENOW FRAGMENT (E.C.2.7.7.7) MUTANT/DNA COMPLEX
1KRP	;	2.2	;	DNA polymerase I Klenow fragment (E.C.2.7.7.7) mutant/DNA complex
1KSP	;	2.3	;	DNA polymerase I Klenow fragment (E.C.2.7.7.7) mutant/DNA complex
4F2R	;	1.63	;	DNA Polymerase I Large Fragment complex 3
4F2S	;	1.651	;	DNA Polymerase I Large Fragment complex 4
4F3O	;	1.57	;	DNA Polymerase I Large Fragment Complex 5
4F4K	;	1.6	;	DNA Polymerase I Large Fragment Complex 6
6UR4	;	2.25	;	DNA polymerase I Large Fragment from Bacillus stearothermophilus with DNA template and 3'-amino primer
6UR2	;	2.27	;	DNA polymerase I Large Fragment from Bacillus stearothermophilus with DNA template and primer containing an N3'-> P5' linkage
6US5	;	2.25	;	DNA polymerase I Large Fragment from Bacillus stearothermophilus with DNA template, 3'-amino primer, dGpNHpp analog, and Mn2+
6UR9	;	2.1	;	DNA polymerase I Large Fragment from Bacillus stearothermophilus with DNA template, dideoxy primer, 3'-amino-ddGTP (nGTP), and Ca2+
3BDP	;	1.9	;	DNA POLYMERASE I/DNA COMPLEX
5YUR	;	2.035	;	DNA polymerase IV - DNA ternary complex 1
6IG1	;	1.97	;	DNA polymerase IV - DNA ternary complex 10
5YUZ	;	1.83	;	DNA polymerase IV - DNA ternary complex 11
5YV0	;	2.09	;	DNA polymerase IV - DNA ternary complex 12
5YV1	;	2.09	;	DNA polymerase IV - DNA ternary complex 13
5YV2	;	1.9	;	DNA polymerase IV - DNA ternary complex 14
5YUS	;	1.94	;	DNA polymerase IV - DNA ternary complex 2
5YUT	;	2.15	;	DNA polymerase IV - DNA ternary complex 3
5YUU	;	1.892	;	DNA polymerase IV - DNA ternary complex 4
5YUV	;	2.06	;	DNA polymerase IV - DNA ternary complex 5
5YUW	;	2.124	;	DNA polymerase IV - DNA ternary complex 6
5YV3	;	2.03	;	DNA polymerase IV - DNA ternary complex 7
5YUX	;	2.04	;	DNA polymerase IV - DNA ternary complex 8
5YUY	;	1.74	;	DNA polymerase IV - DNA ternary complex 9
5ZLV	;	2.35	;	DNA polymerase IV - DNA ternary complex with 50mM MgCl2
5YYD	;	2.05	;	DNA polymerase IV - ternary complex 15
5YYE	;	2.325	;	DNA polymerase IV - ternary complex 16
5T14	;	3.0	;	DNA polymerase kappa extending beyond a bulky major benzo[a]pyrene adduct
7UN7	;	2.04	;	DNA Polymerase lambda in complex with a 1nt microhomology substrate
2BCR	;	1.75	;	DNA polymerase lambda in complex with a DNA duplex containing an unpaired Damp
2BCU	;	2.2	;	DNA polymerase lambda in complex with a DNA duplex containing an unpaired Damp and a T:T mismatch
2BCS	;	2.2	;	DNA polymerase lambda in complex with a DNA duplex containing an unpaired Dcmp
2BCQ	;	1.65	;	DNA polymerase lambda in complex with a DNA duplex containing an unpaired Dtmp
3MDA	;	2.031	;	DNA polymerase lambda in complex with araC
3MDC	;	1.999	;	DNA polymerase lambda in complex with dFdCTP
2PFP	;	2.1	;	DNA Polymerase lambda in complex with DNA and dCTP
2PFO	;	2.0	;	DNA Polymerase lambda in complex with DNA and dUPNPP
2BCV	;	2.0	;	DNA polymerase lambda in complex with Dttp and a DNA duplex containing an unpaired Dtmp
7M4D	;	1.817	;	DNA Polymerase Lambda, dCTP:At Ca2+ Ground State Ternary Complex
7M4F	;	1.947	;	DNA Polymerase Lambda, dCTP:At Mg2+ Product State Ternary Complex, 300 min
7M4G	;	1.88	;	DNA Polymerase Lambda, dCTP:At Mg2+ Product State Ternary Complex, 960 min
7M4E	;	1.903	;	DNA Polymerase Lambda, dCTP:At Mg2+ Reaction State Ternary Complex, 120 min
7M4I	;	2.005	;	DNA Polymerase Lambda, dCTP:At Mn2+ Product State Ternary Complex, 420 min
7M4J	;	2.377	;	DNA Polymerase Lambda, dCTP:At Mn2+ Product State Ternary Complex, 960 min
7M4H	;	1.923	;	DNA Polymerase Lambda, dCTP:At Mn2+ Reaction State Ternary Complex, 225 min
7M43	;	1.978	;	DNA Polymerase Lambda, TTP:At Ca2+ Ground State Ternary Complex
7M46	;	1.92	;	DNA Polymerase Lambda, TTP:At Mg2+ Product State Ternary Complex, 5 min
7M47	;	1.648	;	DNA Polymerase Lambda, TTP:At Mg2+ Product State Ternary Complex, 60 min
7M48	;	1.93	;	DNA Polymerase Lambda, TTP:At Mg2+ Product State Ternary Complex, 960 min
7M45	;	1.889	;	DNA Polymerase Lambda, TTP:At Mg2+ Reaction State Ternary Complex, 120 sec
7M44	;	1.901	;	DNA Polymerase Lambda, TTP:At Mg2+ Reaction State Ternary Complex, 90 sec
7M4A	;	1.868	;	DNA Polymerase Lambda, TTP:At Mn2+ Product State Ternary Complex, 20 min
7M4B	;	1.66	;	DNA Polymerase Lambda, TTP:At Mn2+ Product State Ternary Complex, 60 min
7M4C	;	1.95	;	DNA Polymerase Lambda, TTP:At Mn2+ Product State Ternary Complex, 960 min
7M49	;	1.6	;	DNA Polymerase Lambda, TTP:At Mn2+ Reaction State Ternary Complex, 5 min
7M4K	;	1.719	;	DNA Polymerase Lambda, TTPaS:At Ca2+ Ground State Ternary Complex
7M4L	;	1.701	;	DNA Polymerase Lambda, TTPaS:At Mn2+ Product State Ternary Complex, 60 min
7KTK	;	1.419	;	DNA Polymerase Mu (K438D), 8-oxodGTP:Ct Ground State Ternary Complex, 50 mM Mg2+ (90min)
7KTJ	;	1.452	;	DNA Polymerase Mu (K438D), 8-oxodGTP:Ct Pre-Catalytic Ground State Ternary Complex, 20 mM Ca2+ (120min)
7KTL	;	1.421	;	DNA Polymerase Mu (K438D), 8-oxodGTP:Ct Product State Ternary Complex, 50 mM Mn2+ (90min)
7KTM	;	1.528	;	DNA Polymerase Mu (K438D), 8-oxodGTP:Ct Reaction State Ternary Complex, 50 mM Mn2+ (30min)
5TXX	;	1.948	;	DNA Polymerase Mu Pre-Catalytic Ground State Ternary Complex, Ca2+
5TYF	;	1.971	;	DNA Polymerase Mu Product Complex, 10 mM Mg2+ (270 min)
5TYE	;	2.047	;	DNA Polymerase Mu Product Complex, 10 mM Mg2+ (60 min)
5TYG	;	1.726	;	DNA Polymerase Mu Product Complex, 10 mM Mg2+ (960 min)
5TYX	;	1.948	;	DNA Polymerase Mu Product Complex, Mn2+ (15 min)
5TYY	;	1.931	;	DNA Polymerase Mu Product Complex, Mn2+ (60 min)
5TYZ	;	1.977	;	DNA Polymerase Mu Product Complex, Mn2+ (960 min)
5TYD	;	1.899	;	DNA Polymerase Mu Reactant Complex, 10 mM Mg2+ (45 min)
5TXZ	;	1.651	;	DNA Polymerase Mu Reactant Complex, 100mM Mg2+ (15 min)
5TYC	;	2.101	;	DNA Polymerase Mu Reactant Complex, 10mM Mg2+ (15 min)
5TYB	;	1.848	;	DNA Polymerase Mu Reactant Complex, 10mM Mg2+ (7.5 min)
5TYW	;	1.88	;	DNA Polymerase Mu Reactant Complex, Mn2+ (10 min)
5TYU	;	2.048	;	DNA Polymerase Mu Reactant Complex, Mn2+ (4 min)
5TYV	;	1.93	;	DNA Polymerase Mu Reactant Complex, Mn2+ (7.5 min)
6VF7	;	1.871	;	DNA Polymerase Mu, 8-oxodGTP:At Ground State Ternary Complex, 50 mM Mn2+ (15 min)
7KT3	;	1.879	;	DNA Polymerase Mu, 8-oxodGTP:At Pre-Catalytic Ground State Ternary Complex, 20 mM Ca2+ (120min)
7KTN	;	1.33	;	DNA Polymerase Mu, 8-oxodGTP:At Product State Ternary Complex, 10 mM Mg2+ (2160min)
7KT5	;	1.46	;	DNA Polymerase Mu, 8-oxodGTP:At Product State Ternary Complex, 10 mM Mn2+ (120min)
7KT6	;	1.87	;	DNA Polymerase Mu, 8-oxodGTP:At Product State Ternary Complex, 10 mM Mn2+ (960min)
7KT8	;	1.701	;	DNA Polymerase Mu, 8-oxodGTP:At Product State Ternary Complex, 50 mM Mg2+ (180min)
7KT9	;	1.482	;	DNA Polymerase Mu, 8-oxodGTP:At Product State Ternary Complex, 50 mM Mg2+ (960min)
7KT4	;	1.922	;	DNA Polymerase Mu, 8-oxodGTP:At Reaction State Ternary Complex, 10 mM Mn2+ (30min)
7KT7	;	1.76	;	DNA Polymerase Mu, 8-oxodGTP:At Reaction State Ternary Complex, 50 mM Mg2+ (60min)
7KTA	;	1.844	;	DNA Polymerase Mu, 8-oxodGTP:Ct Pre-Catalytic Ground State Ternary Complex, 20 mM Ca2+ (120min)
7KTH	;	1.476	;	DNA Polymerase Mu, 8-oxodGTP:Ct Product State Ternary Complex, 10 mM Mg2+ (2160min)
7KTC	;	1.653	;	DNA Polymerase Mu, 8-oxodGTP:Ct Product State Ternary Complex, 10 mM Mn2+ (120min)
7KTD	;	1.551	;	DNA Polymerase Mu, 8-oxodGTP:Ct Product State Ternary Complex, 10 mM Mn2+ (960min)
7KTI	;	1.57	;	DNA Polymerase Mu, 8-oxodGTP:Ct Product State Ternary Complex, 20 uM Mn2+ (120min)
7KTF	;	1.489	;	DNA Polymerase Mu, 8-oxodGTP:Ct Product State Ternary Complex, 50 mM Mg2+ (180min)
7KTG	;	1.445	;	DNA Polymerase Mu, 8-oxodGTP:Ct Product State Ternary Complex, 50 mM Mg2+ (960min)
7KTB	;	1.576	;	DNA Polymerase Mu, 8-oxodGTP:Ct Reaction State Ternary Complex, 10 mM Mn2+ (40min)
7KTE	;	1.479	;	DNA Polymerase Mu, 8-oxodGTP:Ct Reaction State Ternary Complex, 50 mM Mg2+ (90min)
6VF3	;	1.521	;	DNA Polymerase Mu, 8-oxorGTP:At Ground State Ternary Complex, 50 mM Mn2+ (15 min)
6VEZ	;	1.875	;	DNA Polymerase Mu, 8-oxorGTP:At Pre-Catalytic Ternary Complex, 20 mM Ca2+ (60 min)
6VF1	;	1.68	;	DNA Polymerase Mu, 8-oxorGTP:At Product State Ternary Complex, 50 mM Mg2+ (120 min)
6VF2	;	1.6	;	DNA Polymerase Mu, 8-oxorGTP:At Product State Ternary Complex, 50 mM Mg2+ (960 min)
6VF5	;	1.6	;	DNA Polymerase Mu, 8-oxorGTP:At Product State Ternary Complex, 50 mM Mn2+ (120 min)
6VF6	;	1.69	;	DNA Polymerase Mu, 8-oxorGTP:At Product State Ternary Complex, 50 mM Mn2+ (960 min)
6VF0	;	1.58	;	DNA Polymerase Mu, 8-oxorGTP:At Reaction State Ternary Complex, 50 mM Mg2+ (30 min)
6VF4	;	1.75	;	DNA Polymerase Mu, 8-oxorGTP:At Reaction State Ternary Complex, 50 mM Mn2+ (30 min)
6VFA	;	1.76	;	DNA Polymerase Mu, 8-oxorGTP:Ct Ground State Ternary Complex, 50 mM Mn2+ (15 min)
6VF8	;	1.7	;	DNA Polymerase Mu, 8-oxorGTP:Ct Pre-Catalytic Ternary Complex, 20 mM Ca2+ (120 min)
6VFC	;	1.59	;	DNA Polymerase Mu, 8-oxorGTP:Ct Product State Ternary Complex, 50 mM Mn2+ (2160 min)
6VFB	;	1.55	;	DNA Polymerase Mu, 8-oxorGTP:Ct Reaction State Ternary Complex, 50 mM Mn2+ (960 min)
6VF9	;	1.56	;	DNA Polymerase Mu, 8-oxorGTP:Ct Ternary Complex, 50 mM Mg2+ (2160 min)
7KT0	;	1.36	;	DNA Polymerase Mu, dGTP:At Ground State Ternary Complex, 50 mM Mg2+ (60min)
7KSZ	;	1.417	;	DNA Polymerase Mu, dGTP:At Pre-Catalytic Ground State Ternary Complex, 10 mM Ca2+ (960min)
7KT2	;	1.499	;	DNA Polymerase Mu, dGTP:At Product State Ternary Complex, 50 mM Mn2+ (225min)
7KT1	;	1.665	;	DNA Polymerase Mu, dGTP:At Reaction State Ternary Complex, 50 mM Mn2+ (180min)
7KSS	;	1.503	;	DNA Polymerase Mu, dGTP:Ct Pre-Catalytic Ground State Ternary Complex, 10 mM Ca2+ (20min)
7KSX	;	1.57	;	DNA Polymerase Mu, dGTP:Ct Product State Ternary Complex, 10 mM Mg2+ (30min)
7KSY	;	1.577	;	DNA Polymerase Mu, dGTP:Ct Product State Ternary Complex, 10 mM Mg2+ (960min)
7KSU	;	1.65	;	DNA Polymerase Mu, dGTP:Ct Product State Ternary Complex, 10 mM Mn2+ (4min)
7KSV	;	1.64	;	DNA Polymerase Mu, dGTP:Ct Product State Ternary Complex, 10 mM Mn2+ (960min)
7KSW	;	1.49	;	DNA Polymerase Mu, dGTP:Ct Reaction State Ternary Complex, 10 mM Mg2+ (10min)
7KST	;	1.599	;	DNA Polymerase Mu, dGTP:Ct Reaction State Ternary Complex, 10 mM Mn2+ (2min)
3F2C	;	2.5	;	DNA Polymerase PolC from Geobacillus kaustophilus complex with DNA, dGTP and Mn
3F2B	;	2.39	;	DNA Polymerase PolC from Geobacillus kaustophilus complex with DNA, dGTP, Mg and Zn
3F2D	;	2.51	;	DNA Polymerase PolC from Geobacillus kaustophilus complex with DNA, dGTP, Mn and Zn
6FVL	;	1.975	;	DNA polymerase sliding clamp from Escherichia coli with bound P7 peptide
7AZE	;	1.82	;	DNA polymerase sliding clamp from Escherichia coli with peptide 18 bound
7AZD	;	2.19	;	DNA polymerase sliding clamp from Escherichia coli with peptide 20 bound
7AZC	;	1.77	;	DNA polymerase sliding clamp from Escherichia coli with peptide 22 bound
7AZK	;	2.05	;	DNA polymerase sliding clamp from Escherichia coli with peptide 35 bound
7AZ6	;	1.93	;	DNA polymerase sliding clamp from Escherichia coli with peptide 36 bound
7AZ7	;	1.65	;	DNA polymerase sliding clamp from Escherichia coli with peptide 37 bound
7AZL	;	2.42	;	DNA polymerase sliding clamp from Escherichia coli with peptide 38 bound
7AZG	;	2.92	;	DNA polymerase sliding clamp from Escherichia coli with peptide 4 bound
7AZ8	;	1.61	;	DNA polymerase sliding clamp from Escherichia coli with peptide 43 bound
7AZ5	;	1.87	;	DNA polymerase sliding clamp from Escherichia coli with peptide 47 bound
7AZF	;	1.93	;	DNA polymerase sliding clamp from Escherichia coli with peptide 8 bound
6FVN	;	3.142	;	DNA polymerase sliding clamp from Mycobacterium tuberculosis with bound P7 peptide
3AU2	;	1.4	;	DNA polymerase X from Thermus thermophilus HB8 complexed with Ca-dGTP
3AUO	;	2.7	;	DNA polymerase X from Thermus thermophilus HB8 ternary complex with 1-nt gapped DNA and ddGTP
3AU6	;	3.3	;	DNA polymerase X from Thermus thermophilus HB8 ternary complex with primer/template DNA and ddGTP
3SPZ	;	2.43	;	DNA Polymerase(L415A/L561A/S565G/Y567A) Ternary Complex with dUpCpp Opposite dA (Ca2+)
3SQ0	;	2.0	;	DNA Polymerase(L561A/S565G/Y567A) Ternary Complex with dUpNpp Opposite dA (Mn2+)
4Q45	;	2.176	;	DNA Polymerase- damaged DNA complex
1JRE	;	2.65	;	DNA PROTECTION AND BINDING BY E. COLI DPS PROTEIN
1JTS	;	2.6	;	DNA PROTECTION AND BINDING BY E. COLI DPS PROTEIN
1L8H	;	3.2	;	DNA PROTECTION AND BINDING BY E. COLI DPS PROTEIN
1L8I	;	3.0	;	Dna Protection and Binding by E. Coli DPS Protein
7EAQ	;	2.39	;	DNA quadruplex composed of i-motif and Z-DNA
1A6H	;		;	DNA QUADRUPLEX CONTAINING GCGC TETRAD, NMR, 4 STRUCTURES
1AFF	;		;	DNA QUADRUPLEX CONTAINING GGGG TETRADS AND (T.A).A TRIADS, NMR, 8 STRUCTURES
1PAR	;	2.6	;	DNA RECOGNITION BY BETA-SHEETS IN THE ARC REPRESSOR-OPERATOR CRYSTAL STRUCTURE
1D66	;	2.7	;	DNA RECOGNITION BY GAL4: STRUCTURE OF A PROTEIN/DNA COMPLEX
1HCP	;		;	DNA RECOGNITION BY THE OESTROGEN RECEPTOR: FROM SOLUTION TO THE CRYSTAL
4RZL	;	2.1	;	DNA recognition domain of the cytosine modification-dependent restriction endonuclease LpnPI
1LJM	;	2.5	;	DNA recognition is mediated by conformational transition and by DNA bending
2VA8	;	2.3	;	DNA Repair Helicase Hel308
8FAK	;	3.22	;	DNA replication fork binding triggers structural changes in the PriA DNA helicase that regulate the PriA-PriB replication restart pathway in E. coli
5GHR	;	2.509	;	DNA replication protein
5GHS	;	2.591	;	DNA replication protein
5GHT	;	2.795	;	DNA replication protein
5X06	;	3.237	;	DNA replication regulation protein
4YS5	;	1.65	;	DNA sequence containing 2'-Se-dC modification
2LIB	;		;	DNA sequence context conceals alpha anomeric lesion
3KUY	;	2.9	;	DNA Stretching in the Nucleosome Facilitates Alkylation by an Intercalating Antitumor Agent
4KBD	;		;	DNA STRUCTURE OF A MUTATED KB SITE
6BWY	;	2.9	;	DNA substrate selection by APOBEC3G
3G6V	;	2.2	;	DNA synthesis across an abasic lesion by human DNA polymerase-iota
5H6K	;	1.8	;	DNA targeting ADP-ribosyltransferase Pierisin-1
5H6M	;	1.9	;	DNA targeting ADP-ribosyltransferase Pierisin-1
5H6J	;	1.9	;	DNA targeting ADP-ribosyltransferase Pierisin-1 in complex with beta-NAD+
5H6L	;	2.1	;	DNA targeting ADP-ribosyltransferase Pierisin-1 in complex with beta-NAD+
5H6N	;	1.8	;	DNA targeting ADP-ribosyltransferase Pierisin-1, autoinhibitory form
6Z01	;	1.9	;	DNA Topoisomerase
6Z03	;	2.2	;	DNA Topoisomerase
1BWG	;		;	DNA TRIPLEX WITH 5' AND 3' JUNCTIONS, NMR, 10 STRUCTURES
1FZS	;		;	DNA WITH PYRENE PAIRED AT ABASIC SITE
1FZL	;		;	DNA WITH PYRENE PAIRED AT ABASIC SITES
2NBJ	;		;	DNA-archeal MC1 protein complex structure by NMR
8CMP	;	1.06	;	DNA-binding bacterial histone protein HBB from Bdellovibrio bacteriovorus
2BBY	;		;	DNA-BINDING DOMAIN FROM HUMAN RAP30, NMR, 30 STRUCTURES
1BBY	;		;	DNA-BINDING DOMAIN FROM HUMAN RAP30, NMR, MINIMIZED AVERAGE
2XB0	;	2.0	;	DNA-binding domain from Saccharomyces cerevisiae chromatin- remodelling protein Chd1
7PC6	;	1.92	;	DNA-binding domain of a p53 homolog from the hydrothermal vent annelid Alvinella pompejana
7OYK	;	2.101	;	DNA-binding domain of CggR in complex with the DNA operator
7BHY	;	2.3	;	DNA-binding domain of DeoR in complex with the DNA operator
1DHM	;		;	DNA-BINDING DOMAIN OF E2 FROM HUMAN PAPILLOMAVIRUS-31, NMR, MINIMIZED AVERAGE STRUCTURE
1FLI	;		;	DNA-BINDING DOMAIN OF FLI-1
7S03	;	2.37	;	DNA-binding domain of human SETMAR in complex with Hsmar1 terminal inverted repeat (TIR) DNA
1BA5	;		;	DNA-BINDING DOMAIN OF HUMAN TELOMERIC PROTEIN, HTRF1, NMR, 18 STRUCTURES
1BM8	;	1.71	;	DNA-BINDING DOMAIN OF MBP1
1IGN	;	2.25	;	DNA-BINDING DOMAIN OF RAP1 IN COMPLEX WITH TELOMERIC DNA SITE
2M9H	;		;	DNA-binding domain of T. brucei telomeric protein tbTRF
1CIT	;	2.7	;	DNA-BINDING MECHANISM OF THE MONOMERIC ORPHAN NUCLEAR RECEPTOR NGFI-B
1CLD	;		;	DNA-binding protein
3RHI	;	2.48	;	DNA-binding protein HU from Bacillus anthracis
1HUU	;	2.0	;	DNA-BINDING PROTEIN HU FROM BACILLUS STEAROTHERMOPHILUS
1DBQ	;	2.2	;	DNA-BINDING REGULATORY PROTEIN
3LHQ	;	1.56	;	DNA-binding transcriptional repressor AcrR from Salmonella typhimurium.
3ZQL	;	2.99	;	DNA-bound form of TetR-like repressor SimR
6GVQ	;		;	DNA-bound pRN1 helix bundle domain with ATP and magnesium in the interaction buffer
7KWK	;	1.37	;	DNA-DB1879 complex: The DNA sequence 5'-CGCGAATTCGCG-3' presents a binding site for the heterocyclic small molecule (DB1879).
7KU4	;	1.6	;	DNA-DB818 complex: The DNA sequence 5'-CGCGAATTCGCG-3' presents a binding site for the heterocyclic small molecule (DB818).
1DA0	;	1.5	;	DNA-DRUG INTERACTIONS: THE CRYSTAL STRUCTURE OF D(CGATCG) COMPLEXED WITH DAUNOMYCIN
1VTI	;	1.7	;	DNA-DRUG INTERACTIONS: THE CRYSTAL STRUCTURES OF D(TGATCA) COMPLEXED WITH DAUNOMYCIN
1VTH	;	1.6	;	DNA-DRUG INTERACTIONS: THE CRYSTAL STRUCTURES OF D(TGTACA) COMPLEXED WITH DAUNOMYCIN
224D	;	1.4	;	DNA-DRUG REFINEMENT: A COMPARISON OF THE PROGRAMS NUCLSQ, PROLSQ, SHELXL93 AND X-PLOR, USING THE LOW TEMPERATURE D(TGATCA)-NOGALAMYCIN STRUCTURE
245D	;	1.4	;	DNA-DRUG REFINEMENT: A COMPARISON OF THE PROGRAMS NUCLSQ, PROLSQ, SHELXL93 AND X-PLOR, USING THE LOW TEMPERATURE D(TGATCA)-NOGALAMYCIN STRUCTURE
8EWV	;	3.4	;	DNA-encoded library (DEL)-enabled discovery of proximity inducing small molecules
8OM5	;	3.52	;	DNA-free open form of MutSbeta
8DUO	;	5.7	;	DNA-free T4 Bacteriophage gp41 hexamer
6WBO	;	2.65	;	DNA-Ligase from Thermococcus gammatolerans
1D17	;	2.0	;	DNA-NOGALAMYCIN INTERACTIONS
182D	;	1.8	;	DNA-NOGALAMYCIN INTERACTIONS: THE CRYSTAL STRUCTURE OF D(TGATCA) COMPLEXED WITH NOGALAMYCIN
7SGL	;	3.0	;	DNA-PK complex of DNA end processing
7Z87	;	2.91	;	DNA-PK in the active state
7Z88	;	3.33	;	DNA-PK in the intermediate state
8BH3	;	4.55	;	DNA-PK Ku80 mediated dimer bound to PAXX
8BHY	;	5.33	;	DNA-PK Ku80 mediated dimer bound to PAXX and XLF
8BHV	;	4.51	;	DNA-PK XLF mediated dimer bound to PAXX
7OTP	;	3.4	;	DNA-PKcs in complex with ATPgammaS-Mg
7OTW	;	2.99	;	DNA-PKcs in complex with AZD7648
7OTY	;	2.96	;	DNA-PKcs in complex with M3814
7OTV	;	3.24	;	DNA-PKcs in complex with wortmannin
8CIY	;	1.54	;	DNA-polymerase sliding clamp (DnaN) from Escherichia coli in complex with Cyclohexyl-Griselimycin.
8CIX	;	1.76	;	DNA-polymerase sliding clamp (DnaN) from Escherichia coli in complex with Griselimycin.
8CIZ	;	2.27	;	DNA-polymerase sliding clamp (DnaN) from Escherichia coli in complex with Mycoplanecin A.
6NUA	;	1.64	;	DNA-protein crosslink between E. coli YedK and ssDNA containing an abasic site
6FFR	;		;	DNA-RNA Hybrid Quadruplex with Flipped Tetrad
8OMO	;	3.43	;	DNA-unbound MutSbeta-ATP complex (bent clamp form)
8OMQ	;	3.11	;	DNA-unbound MutSbeta-ATP complex (straight clamp form)
1OO7	;		;	DNA.RNA HYBRID DUPLEX CONTAINING A 5-PROPYNE DNA STRAND AND PURINE-RICH RNA STRAND, NMR, 4 STRUCTURES
6RR9	;	3.432	;	DNA/RNA binding protein
7Q3Z	;	1.85	;	DNA/RNA binding protein
219D	;		;	DNA/RNA HYBRID DUPLEX (5'-D(*GP*CP*TP*AP*TP*AP*APS*TP*GP*G)-3')(DOT) (5'-R(*CP*CP*AP*UP*UP*AP*UP*AP*GP*C)-3') WITH A PHOSPHOROTHIOATE MOIETY
1DRR	;		;	DNA/RNA HYBRID DUPLEX CONTAINING A PURINE-RICH DNA STRAND, NMR, 10 STRUCTURES
1RRD	;		;	DNA/RNA HYBRID DUPLEX CONTAINING A PURINE-RICH RNA STRAND, NMR, 10 STRUCTURES
2E0G	;		;	DnaA N-terminal domain
1Z8S	;		;	DnaB binding domain of DnaG (P16) from Bacillus stearothermophilus (residues 452-597)
6CBR	;	1.5	;	DnaG Primase C-terminal domain complex with SSB C-terminal peptide
6CBS	;	1.85	;	DnaG Primase C-terminal domain complex with SSB C-terminal peptide
6CBT	;	2.1	;	DnaG Primase C-terminal domain complex with SSB C-terminal peptide
1IUR	;		;	DnaJ domain of human KIAA0730 protein
6Z5N	;		;	DnaJB1 JD-GF
2DNJ	;	2.0	;	DNASE I-INDUCED DNA CONFORMATION. 2 ANGSTROMS STRUCTURE OF A DNASE I-OCTAMER COMPLEX
2RU8	;		;	DnaT C-terminal domain
7X9D	;	3.08	;	DNMT3B in complex with harmine
2PVC	;	3.69	;	DNMT3L recognizes unmethylated histone H3 lysine 4
7F59	;	4.2	;	DNQX-bound GluK2-1xNeto2 complex
7F56	;	4.1	;	DNQX-bound GluK2-1xNeto2 complex, with asymmetric LBD
7F5A	;	6.4	;	DNQX-bound GluK2-2xNeto2 complex
7OY1	;	2.39	;	DnrK mutant RTCR
1UTB	;	2.59	;	DntR from Burkholderia sp. strain DNT
1UTH	;	2.2	;	DntR from Burkholderia sp. strain DNT in complex with Thiocyanate
2Y7R	;	2.99	;	DntR Inducer Binding Domain
2Y7W	;	2.89	;	DntR Inducer Binding Domain
2Y84	;	2.8	;	DntR Inducer Binding Domain
2Y7K	;	1.95	;	DntR Inducer Binding Domain in Complex with Salicylate. Monoclinic crystal form
2Y7P	;	1.85	;	DntR Inducer Binding Domain in Complex with Salicylate. Trigonal crystal form
2NMB	;		;	DNUMB PTB DOMAIN COMPLEXED WITH A PHOSPHOTYROSINE PEPTIDE, NMR, ENSEMBLE OF STRUCTURES.
1PVX	;	1.59	;	DO-1,4-BETA-XYLANASE, ROOM TEMPERATURE, PH 4.5
7AVC	;	1.2	;	DoBi scaffold based on PIH1D1 N-terminal domain
8I5V	;	1.726	;	DOCK10 mutant L1903Y complexed with Rac1
6AJL	;	3.23	;	DOCK7 mutant I1836Y complexed with Cdc42
2N1A	;		;	Docked structure between SUMO1 and ZZ-domain from CBP
2H9R	;		;	Docking and dimerization domain (D/D) of the regulatory subunit of the Type II-alpha cAMP-dependent protein kinase A associated with a Peptide derived from an A-kinase anchoring protein (AKAP)
2DRN	;		;	Docking and dimerization domain (D/D) of the Type II-alpha regulatory subunity of protein kinase A (PKA) in complex with a peptide from an A-kinase anchoring protein
2GPH	;	1.9	;	Docking motif interactions in the MAP kinase ERK2
2FVO	;	12.8	;	Docking of the modified RF1 X-ray structure into the Low Resolution Cryo-EM map of E.coli 70S Ribosome bound with RF1
1MI6	;	12.8	;	Docking of the modified RF2 X-ray structure into the Low Resolution Cryo-EM map of RF2 E.coli 70S Ribosome
2O0F	;	15.5	;	Docking of the modified RF3 X-ray structure into cryo-EM map of E.coli 70S ribosome bound with RF3
4U3C	;	3.98	;	Docking Site of Maltohexaose in the Mtb GlgE
2WQT	;	2.8	;	Dodecahedral assembly of MhpD
4AQQ	;	4.75	;	Dodecahedron formed of penton base protein from adenovirus Ad3
4AR2	;	3.8	;	Dodecahedron formed of penton base protein from adenovirus Ad3
6I4O	;		;	Dodecamer DNA containing the synthetic base pair P-Z
6I4N	;		;	Dodecamer DNA containing the synthetic base pair P-Z in complex with a pyrrole-imidazole polyamide
4P4X	;	1.898	;	Dodecamer formed by a macrocyclic peptide derived from beta-2-microglobulin (63-69) - (ORN)YLL(PHI)YTE(ORN)KVA(MLE)AVK
4P4W	;	1.498	;	Dodecamer formed by a macrocyclic peptide derived from beta-2-microglobulin (63-69) - (ORN)YLL(PHI)YTE(ORN)KVA(MVA)AVK
4QC7	;	1.9	;	Dodecamer structure of 5-formylcytosine containing DNA
2ZY2	;	3.3	;	dodecameric L-aspartate beta-decarboxylase
2ZY3	;	2.5	;	dodecameric L-aspartate beta-decarboxylase
2ZY4	;	2.0	;	dodecameric L-aspartate beta-decarboxylase
5ZS6	;	2.81191	;	Dodecameric structure of a small Heat Shock Protein from Mycobacterium marinum M: Form-2
4JLY	;	2.882	;	Dodecameric structure of spermidine N-acetyltransferase from Vibrio cholerae
4YGO	;	2.5	;	Dodecameric structure of spermidine N-acetyltransferase from Vibrio cholerae in intermediate state
4JJX	;	2.83	;	Dodecameric structure of spermidine N-acetyltransferase SpeG from Vibrio cholerae O1 biovar eltor
7KM2	;	2.19	;	Dodecameric Structure of the Chlamydia trachomatis Flavin Prenyltransferase UbiX Ortholog CT220 with FMN
7KM3	;	2.26	;	Dodecameric Structure of the Chlamydia trachomatis Flavin Prenyltransferase UbiX Ortholog CT220 with FMN and DMAP
6RI3	;	2.4	;	Dodecin from Streptomyces davaonensis
2W0D	;	2.0	;	Does a Fast Nuclear Magnetic Resonance Spectroscopy- and X-Ray Crystallography Hybrid Approach Provide Reliable Structural Information of Ligand-Protein Complexes? A Case Study of Metalloproteinases.
2BTM	;	2.4	;	DOES THE HIS12-LYS13 PAIR PLAY A ROLE IN THE ADAPTATION OF THERMOPHILIC TIMS TO HIGH TEMPERATURES?
7DH5	;	3.16	;	Dog beta3 adrenergic receptor bound to mirabegron in complex with a miniGs heterotrimer
8SZR	;	2.97	;	Dog DHX9 bound to ADP
1RP1	;	2.1	;	DOG PANCREATIC LIPASE RELATED PROTEIN 1
1LU2	;	2.8	;	DOLICHOS BIFLORUS SEED LECTIN IN COMPLEX WITH THE BLOOD GROUP A TRISACCHARIDE
5MM1	;	2.6	;	Dolichyl phosphate mannose synthase in complex with GDP and dolichyl phosphate mannose
5MLZ	;	2.0	;	Dolichyl phosphate mannose synthase in complex with GDP and Mg2+
5MM0	;	2.3	;	Dolichyl phosphate mannose synthase in complex with GDP-mannose and Mn2+ (donor complex)
2MFI	;		;	Domain 1 of E. coli ribosomal protein S1
7RAW	;	2.1	;	Domain 1 of Starch adherence system protein 20 (Sas20) from Ruminococcus bromii
7RFT	;	1.53	;	Domain 1 of Starch adherence system protein 20 (Sas20) from Ruminococcus bromii with maltotriose
2MFL	;		;	Domain 2 of E. coli ribosomal protein S1
8AQ9	;		;	Domain 2 of zinc-loaded Caenorhabditis elegans MTL-1
8C27	;	2.63	;	Domain 3 of Group B Streptococcus pilus protein as scaffold for the display of foreign epitopes
1EGJ	;	2.8	;	DOMAIN 4 OF THE BETA COMMON CHAIN IN COMPLEX WITH AN ANTIBODY
5JR0	;		;	Domain 4 Segment 6 of voltage-gated sodium channel Nav1.4
1AD6	;	2.3	;	DOMAIN A OF HUMAN RETINOBLASTOMA TUMOR SUPPRESSOR
2JVN	;		;	Domain C of human PARP-1
6RCC	;	1.43	;	Domain C P140 Mycoplasma genitalium
5I2T	;	2.543	;	Domain characterization of the WD protein Pwp2 and their relevance in ribosome biogenesis
1AMA	;	2.3	;	DOMAIN CLOSURE IN MITOCHONDRIAL ASPARTATE AMINOTRANSFERASE
1H4U	;	2.2	;	Domain G2 of mouse nidogen-1
6FN8	;	1.55	;	Domain II of the HUMAN COPPER CHAPERONE FOR SUPEROXIDE DISMUTASE at 1.55 A resolution
6FOL	;	2.55	;	Domain II of the human copper chaperone in complex with human Cu,Zn superoxide dismutase
7SGT	;		;	Domain III (EDIII) of the POWV E glycoprotein
1AER	;	2.3	;	DOMAIN III OF PSEUDOMONAS AERUGINOSA EXOTOXIN COMPLEXED WITH BETA-TAD
1DMA	;	2.5	;	DOMAIN III OF PSEUDOMONAS AERUGINOSA EXOTOXIN COMPLEXED WITH NICOTINAMIDE AND AMP
2LQ8	;		;	Domain interaction in Thermotoga maritima NusG
2I7A	;	1.8	;	Domain IV of Human Calpain 13
1MNF	;	3.0	;	Domain motions in GroEL upon binding of an oligopeptide
4PHR	;	1.34	;	Domain of unknown function 1792 (DUF1792) with manganese
3JAB	;	11.0	;	Domain organization and conformational plasticity of the G protein effector, PDE6
3JBQ	;	11.0	;	Domain Organization and Conformational Plasticity of the G Protein Effector, PDE6
3FFZ	;	2.65	;	Domain organization in Clostridium butulinum neurotoxin type E is unique: Its implication in faster translocation
2HF2	;	1.9	;	Domain shifting confirms monomeric structure of Escherichia sugar phosphatase SUPH
5O2Z	;	1.7	;	Domain swap dimer of the G167R variant of gelsolin second domain
5QU5	;	1.11	;	Domain Swap in the first SH3 domain of human Nck1
5FEA	;	2.6	;	Domain Swapped Bromodomain from Leishmania donovani
5XFU	;	2.611	;	Domain swapped dimer crystal structure of loop1 deletion mutant in Single-chain Monellin
5YCU	;	2.32	;	Domain swapped dimer of engineered hairpin loop1 mutant in Single-chain Monellin
6L4N	;	2.431	;	Domain swapped dimer of Monellin loop1 mutant with QVPAG motif
6TGK	;	1.3	;	Domain swapped E6AP C-lobe dimer
3MQ6	;	2.0	;	Domain swapped SgrAI with DNA and calcium bound
1HT9	;	1.76	;	DOMAIN SWAPPING EF-HANDS
4HDD	;	1.35	;	Domain swapping in the cytoplasmic domain of the Escherichia coli rhomboid protease
3DIE	;	1.85	;	Domain swapping of Staphylococcus Aureus thioredoxin W28A mutant
1HZU	;	2.7	;	DOMAIN SWING UPON HIS TO ALA MUTATION IN NITRITE REDUCTASE OF PSEUDOMONAS AERUGINOSA
1HZV	;	2.83	;	DOMAIN SWING UPON HIS TO ALA MUTATION IN NITRITE REDUCTASE OF PSEUDOMONAS AERUGINOSA
3QOP	;	1.96	;	Domain-domain flexibility leads to allostery within the camp receptor protein (CRP)
3RDI	;	2.95	;	Domain-domain flexibility leads to allostery within the camp receptor protein (CRP)
3ROU	;	2.1	;	Domain-domain flexibility leads to allostery within the camp receptor protein (CRP)
3RPQ	;	2.61	;	Domain-domain flexibility leads to allostery within the camp receptor protein (CRP)
3RYP	;	1.6	;	Domain-domain flexibility leads to allostery within the camp receptor protein (CRP)
3RYR	;	2.7	;	Domain-domain flexibility leads to allostery within the camp receptor protein (CRP)
8HNJ	;	2.03	;	Domain-stabilized glutamine-binding protein
6L1V	;	2.25	;	Domain-swapped Alcaligenes xylosoxidans azurin dimer
1L5B	;	2.0	;	DOMAIN-SWAPPED CYANOVIRIN-N DIMER
5AWI	;	1.85	;	Domain-swapped cytochrome cb562 dimer
1H8X	;	2.0	;	Domain-swapped Dimer of a Human Pancreatic Ribonuclease Variant
6Q2C	;	1.8	;	Domain-swapped dimer of Acanthamoeba castellanii CYP51
5SUZ	;	1.84	;	Domain-swapped dimer of human Dishevelled2 DEP domain: C-centered monoclinic crystal form crystallised from monomeric fraction
5SUY	;	1.88	;	Domain-swapped dimer of human Dishevelled2 DEP domain: monoclinic crystal form crystallised from dimeric fraction
5LNP	;	1.99	;	Domain-swapped dimer of human Dishevelled2 DEP domain: monoclinic crystal form crystallised from monomeric fraction
3X39	;	1.5	;	Domain-swapped dimer of Pseudomonas aeruginosa cytochrome c551
2NLU	;		;	Domain-Swapped Dimer of the PWWP Module of Human Hepatoma-derived Growth Factor
5JUI	;	2.1	;	domain-swapped dimer of the the KRT10-binding region (BR) of PsrP
6LAY	;	3.001	;	Domain-swapped dimer structure of a Single-chain Monellin loop1-delta4-QVVAG mutant
1DZ3	;	1.65	;	DOMAIN-SWAPPING IN THE SPORULATION RESPONSE REGULATOR SPO0A
1PN6	;	10.8	;	Domain-wise fitting of the crystal structure of T.thermophilus EF-G into the low resolution map of the release complex.Puromycin.EFG.GDPNP of E.coli 70S ribosome.
1A7L	;	2.9	;	DOMINANT B-CELL EPITOPE FROM THE PRES2 REGION OF HEPATITIS B VIRUS IN THE FORM OF AN INSERTED PEPTIDE SEGMENT IN MALTODEXTRIN-BINDING PROTEIN
2N18	;		;	Dominant form of the low-affinity complex of yeast cytochrome c and cytochrome c peroxidase
1PQN	;		;	dominant negative human hDim1 (hDim1 1-128)
8GC2	;	4.1	;	Domoate-bound GluK2 kainate receptor in partially-open conformation 1
8GC4	;	3.93	;	Domoate-bound GluK2 kainate receptor in partially-open conformation 3
8GC5	;	3.93	;	Domoate-bound GluK2 kainate receptors in non-active conformation
8GC3	;	3.8	;	Domote-bound GluK2 kainate receptors in partially-open conformation 2
1ECG	;	2.3	;	DON INACTIVATED ESCHERICHIA COLI GLUTAMINE PHOSPHORIBOSYLPYROPHOSPHATE (PRPP) AMIDOTRANSFERASE
3GEA	;	1.699	;	Donor strand complemented FaeG monomer of F4 variant ad
4WE2	;	1.5	;	Donor strand complemented FaeG of F4ab fimbriae
3GGH	;	1.639	;	Donor strand complemented FaeG of F4ad fimbriae
3HLR	;	2.3	;	Donor strand complemented FaeG of F4ad fimbriae
2R1T	;	1.7	;	dopamine quinone conjugation to DJ-1
8IRR	;	3.2	;	Dopamine Receptor D1R-Gs-Rotigotine complex
8IRS	;	3.0	;	Dopamine Receptor D2R-Gi-Rotigotine complex
7CMV	;	2.7	;	Dopamine Receptor D3R-Gi-PD128907 complex
7CMU	;	3.0	;	Dopamine Receptor D3R-Gi-Pramipexole complex
8IRT	;	2.7	;	Dopamine Receptor D3R-Gi-Rotigotine complex
8IRU	;	3.2	;	Dopamine Receptor D4R-Gi-Rotigotine complex
8IRV	;	3.1	;	Dopamine Receptor D5R-Gs-Rotigotine complex
8Y0W	;	3.4	;	dormant ribosome with eIF5A, eEF2 and SERBP1
8Y0X	;	3.3	;	Dormant ribosome with SERBP1
8Y0U	;	3.59	;	dormant ribosome with STM1
1BVO	;	2.7	;	DORSAL HOMOLOGUE GAMBIF1 BOUND TO DNA
4YNR	;	1.92	;	DosS GAFA Domain Reduced CO Bound Crystal Structure
4YOF	;	1.9	;	DosS GAFA Domain Reduced Nitric Oxide Bound Crystal Structure
6O96	;	3.5	;	Dot1L bound to the H2BK120 Ubiquitinated nucleosome
3QOX	;	2.3	;	DOT1L structure in complex with SAH
3QOW	;	2.1	;	DOT1L Structure in complex with SAM
5FR1	;	2.75	;	Double acetylated RhoGDI-alpha in complex with RhoA-GDP
5WBF	;	2.19	;	Double CACHE (dCACHE) sensing domain of TlpC chemoreceptor from Helicobacter pylori
1OF8	;	1.5	;	double complex of the tyrosine sensitive DAHP Synthase from S. cerevisiae with Co2+, PEP and the E4P analogoue G3P
6ENO	;	1.635	;	Double cubane cluster oxidoreductase
7EY3	;	2.04	;	Double cysteine mutations in T1 lipase
7VHL	;	3.9	;	Double deletion S-2P trimer(1 Up)
7VHM	;	3.2	;	Double deletion S-2P trimer(3 down)
2J4M	;		;	Double dockerin from Piromyces equi Cel45A
2J4N	;		;	Double dockerin from Piromyces equi Cel45A
5YCW	;	2.285	;	Double domain swapped dimer of engineered hairpin loop1 and loop3 mutant in Single-chain Monellin
1CGC	;	2.2	;	DOUBLE HELIX CONFORMATION GROOVE DIMENSIONS AND LIGAND BINDING POTENTIAL OF A G/C-STRETCH IN B-DNA
2D57	;	3.2	;	Double layered 2D crystal structure of AQUAPORIN-4 (AQP4M23) at 3.2 a resolution by electron crystallography
8HMW	;		;	Double methyl modification on guanosine promotes unusual structural distortion and conformational transition in Z-DNA
3UM6	;	2.65	;	Double mutant (A16V+S108T) Plasmodium falciparum DHFR-TS (T9/94) complexed with cycloguanil, NADPH and dUMP
3UM5	;	2.4	;	Double mutant (A16V+S108T) Plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS-T9/94) complexed with pyrimethamine, NADPH, and dUMP
1J3J	;	2.3	;	Double mutant (C59R+S108N) Plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) complexed with pyrimethamine, NADPH, and dUMP
8C87	;	2.45	;	Double mutant A(L172)C/L(L246)C structure of Photosynthetic Reaction Center From Cereibacter sphaeroides strain RV
8C5X	;	2.6	;	Double mutant A(L37)C/S(L99)C structure of Photosynthetic Reaction Center From Cereibacter sphaeroides strain RV
8C6K	;	2.86	;	Double mutant A(L53)C/I(L64)C structure of Photosynthetic Reaction Center From Cereibacter sphaeroides strain RV
8C88	;	2.75	;	Double mutant G(M19)C/T(L214)C structure of Photosynthetic Reaction Center From Cereibacter sphaeroides strain RV
4ZGJ	;	2.0	;	Double Mutant H80A/H81A of Fe-Type Nitrile Hydratase from Comamonas testosteroni Ni1
4ZGE	;	2.8	;	Double Mutant H80W/H81W of Fe-Type Nitrile Hydratase from Comamonas testosteroni Ni1
8C3F	;	2.6	;	Double mutant I(L177)H/F(M197)H structure of Photosynthetic Reaction Center From Cereibacter sphaeroides strain RV
2BXJ	;	2.4	;	Double Mutant of the Ribosomal Protein S6
1PYY	;	2.42	;	Double mutant PBP2x T338A/M339F from Streptococcus pneumoniae strain R6 at 2.4 A resolution
7F3Z	;	2.6	;	Double mutant Plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS-K1, C59R+S108N) complexed with Trimethoprim (TOP), NADPH and dUMP
8C7C	;	2.6	;	Double mutant V(M84)C/A(L278)C structure of Photosynthetic Reaction Center From Cereibacter sphaeroides strain RV
2UYE	;	2.2	;	Double mutant Y110S,F111V DntR from Burkholderia sp. strain DNT in complex with thiocyanate
6M2O	;	1.57	;	Double mutant(H333A/I334A) crystal structure of benzoate coenzyme A ligase
7DH4	;	2.41	;	Double mutant- V493I-V507M coiled coil domain of Trypanosoma brucei coronin
7N84	;	11.6	;	Double nuclear outer ring from the isolated yeast NPC
8TIE	;	8.1	;	Double nuclear outer ring of Nup84-complexes from the yeast NPC
3JD6	;	4.1	;	Double octamer structure of retinoschisin, a cell-cell adhesion protein of the retina
2D3G	;	1.7	;	Double sided ubiquitin binding of Hrs-UIM
3EIK	;	1.9	;	double stranded DNA binding protein
1STU	;		;	DOUBLE STRANDED RNA BINDING DOMAIN
2GFA	;	2.1	;	double tudor domain complex structure
2GF7	;	2.2	;	Double tudor domain structure
2WQW	;	2.24	;	DOUBLE-DISULFIDE CROSS-LINKED CRYSTAL DIMER of the Listeria monocytogenes InlB internalin domain
4WW4	;	2.94	;	Double-heterohexameric rings of full-length Rvb1(ADP)/Rvb2(ADP)
5FM7	;	2.901	;	Double-heterohexameric rings of full-length Rvb1(ADP)Rvb2(ADP)
5FM6	;	2.997	;	Double-heterohexameric rings of full-length Rvb1(ADP)Rvb2(apo)
4WVY	;	3.64	;	Double-heterohexameric rings of full-length Rvb1(ATP)/Rvb2(apo)
8BZU	;		;	Double-ion dependent DNA quadruplex structure formed by C.elegans telomeric sequence
8BU8	;	6.56	;	Double-motif Single-stranded Paranemic Crossover RNA Triangle (2PXT)
8OOU	;	2.9	;	Double-ring nucleocapsid of the Respiratory Syncytial Virus
6U08	;	2.491	;	Double-stranded DNA-specific cytidine deaminase type VI secretion system effector and cognate immunity complex from Burkholderia cenocepacia
4ES1	;	1.1	;	Double-stranded Endonuclease Activity in B. halodurans Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated Cas2 Protein
4ES2	;	1.299	;	Double-stranded Endonuclease Activity in B. halodurans Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated Cas2 Protein
4ES3	;	1.704	;	Double-stranded Endonuclease Activity in B. halodurans Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated Cas2 Protein
1UIL	;		;	Double-stranded RNA-binding motif of Hypothetical protein BAB28848
2NSK	;	1.5	;	Doubled Modified Selenium DNA
6VH7	;	3.8	;	Doublet Tau Fibril from Corticobasal Degeneration Human Brain Tissue
3BQD	;	2.5	;	Doubling the Size of the Glucocorticoid Receptor Ligand Binding Pocket by Deacylcortivazol
6BGL	;	3.4	;	Doubly PafE-capped 20S core particle in Mycobacterium tuberculosis
7XUH	;	2.76	;	Down-regulated in adenoma in complex with TQR1122
7TLA	;	3.13	;	Down-state locked rS2d SARS-CoV-2 spike ectodomain in the RBD-down conformation, State 1
7TLB	;	3.06	;	Down-state locked rS2d SARS-CoV-2 spike ectodomain in the RBD-down conformation, State 2
7TLC	;	2.83	;	Down-state locked, S2 stabilized rS2d-HexaPro SARS-CoV-2 spike ectodomain in the RBD-down conformation, State 1
7TLD	;	2.89	;	Down-state locked, S2 stabilized rS2d-HexaPro SARS-CoV-2 spike ectodomain in the RBD-down conformation, State 2
1KZZ	;	3.5	;	DOWNSTREAM REGULATOR TANK BINDS TO THE CD40 RECOGNITION SITE ON TRAF3
1L0A	;	2.9	;	DOWNSTREAM REGULATOR TANK BINDS TO THE CD40 RECOGNITION SITE ON TRAF3
7B8R	;	2.1	;	Doxycycline bound structure of bacterial efflux pump.
3X0R	;	1.15	;	DP ribose pyrophosphatase from Thermus thermophilus HB8 in E'-state at reaction time of 30 min
7DG9	;	1.602	;	DPBB domain of VCP-like ATPase from Aeropyrum pernix
7DG7	;	1.604	;	DPBB domain of VCP-like ATPase from Methanopyrus kandleri
7DBO	;	1.9	;	DPBB domain of VCP-like ATPase from Thermoplasma acidophilum
2I1D	;		;	DPC micelle-bound NMR structures of Tritrp1
2I1E	;		;	DPC micelle-bound NMR structures of Tritrp2
2I1F	;		;	DPC micelle-bound NMR structures of Tritrp3
2I1G	;		;	DPC micelle-bound NMR structures of Tritrp5
2I1H	;		;	DPC micelle-bound NMR structures of Tritrp7
2I1I	;		;	DPC micelle-bound NMR structures of Tritrp8
5I3L	;	1.85	;	DPF3b in complex with H3K14ac peptide
8UAO	;	3.6	;	DpHF18 filament
8UBG	;	3.5	;	DpHF19 filament
8UB3	;	3.3	;	DpHF7 filament
4AOV	;	1.93	;	DpIDH-NADP. The complex structures of Isocitrate dehydrogenase from Clostridium thermocellum and Desulfotalea psychrophila, support a new active site locking mechanism
7LZJ	;	2.7	;	DpK2 bacteriophage tail spike depolymerase
2DPM	;	1.8	;	DPNM DNA ADENINE METHYLTRANSFERASE FROM STREPTOCCOCUS PNEUMONIAE COMPLEXED WITH S-ADENOSYLMETHIONINE
1S9F	;	2.0	;	DPO with AT matched
3RB3	;	2.8	;	Dpo4 extension ternary complex with 3'-terminal primer A base opposite the 1-methylguanine (m1g) lesion
3RB6	;	2.7	;	Dpo4 extension ternary complex with 3'-terminal primer A base opposite the 3-methylcytosine (m3c) lesion
3RAQ	;	2.25	;	Dpo4 extension ternary complex with 3'-terminal primer C base opposite the 1-methylguanine (MG1) lesion
3RBD	;	2.502	;	Dpo4 extension ternary complex with 3'-terminal primer C base opposite the 3-methylcytosine (m3c) lesion
3RB0	;	3.225	;	Dpo4 extension ternary complex with 3'-terminal primer G base opposite the 1-methylguanine (M1G) lesion
3RB4	;	2.805	;	Dpo4 extension ternary complex with 3'-terminal primer G base opposite the 3-methylcytosine (m3c) lesion
3RAX	;	1.891	;	Dpo4 extension ternary complex with 3'-terminal primer T base opposite the 1-methylguanine (M1G) lesion
3RBE	;	2.8	;	Dpo4 extension ternary complex with 3'-terminal primer t base opposite the 3-methylcytosine (m3c) lesion
3KHH	;	2.7	;	Dpo4 extension ternary complex with a C base opposite the 2-aminofluorene-guanine [AF]G lesion
3GII	;	2.6	;	Dpo4 extension ternary complex with disordered A opposite an oxoG in anti conformation
3KHG	;	2.96	;	Dpo4 extension ternary complex with misinserted A opposite the 2-aminofluorene-guanine [AF]G lesion
3GIM	;	2.7	;	Dpo4 extension ternary complex with oxoG(anti)-G(syn) pair
3GIL	;	2.71	;	Dpo4 extension ternary complex with oxoG(anti)-T(anti) pair
3GIJ	;	2.4	;	Dpo4 extension ternary complex with oxoG(syn)-A(anti) and oxoG(anti)-A(syn) pairs
3GIK	;	2.9	;	Dpo4 extension ternary complex with the oxoG(anti)-C(anti) pair
4FBU	;	2.6	;	Dpo4 polymerase pre-insertion binary complex with the N-(deoxyguanosin-8-yl)-1-aminopyrene lesion
3KHL	;	2.1	;	Dpo4 post-extension ternary complex with misinserted A opposite the 2-aminofluorene-guanine [AF]G lesion
3KHR	;	2.01	;	Dpo4 post-extension ternary complex with the correct C opposite the 2-aminofluorene-guanine [AF]G lesion
4FBT	;	2.0	;	Dpo4 post-insertion complex with the N-(deoxyguanosin-8-yl)-1-aminopyrene lesion
1S97	;	2.4	;	DPO4 with GT mismatch
3PR5	;	2.4	;	Dpo4 Y12A mutant incorporating ADP opposite template dT
3PR4	;	2.65	;	Dpo4 Y12A mutant incorporating dADP opposite template dT
6RN6	;	2.4	;	DPP1 in complex with inhibitor
6RN7	;	1.66	;	DPP1 in complex with inhibitor
6RN9	;	1.9	;	DPP1 in complex with inhibitor
6RNE	;	1.65	;	DPP1 in complex with inhibitor
6RNI	;	1.54	;	DPP1 in complex with inhibitor
4N8E	;	2.3	;	DPP4 complexed with compound 12a
4N8D	;	1.65	;	DPP4 complexed with syn-7aa
6EOS	;	3.1	;	DPP8 - Apo, space group 19
6EOO	;	2.5	;	DPP8 - Apo, space group 20
6EOT	;	3.5	;	DPP8 - SLRFLYEG, space group 19
6EOP	;	2.4	;	DPP8 - SLRFLYEG, space group 20
6QZW	;	3.2	;	DPP8 bound to a dipeptide (MP) from the N-terminus of BRCA2
7SVO	;	2.58	;	DPP8 IN COMPLEX WITH LIGAND ICeD-1
7SVM	;	2.69	;	DPP8 IN COMPLEX WITH LIGAND ICeD-2
6EOR	;	2.9	;	DPP9 - 1G244
6EOQ	;	3.0	;	DPP9 - Apo
6QZV	;	3.0	;	DPP9 bound to a dipeptide (MP) from the N-terminus of BRCA2
7SVN	;	2.78	;	DPP9 IN COMPLEX WITH LIGAND ICeD-1
7SVL	;	2.46	;	DPP9 IN COMPLEX WITH LIGAND ICeD-2
2C2F	;	1.61	;	Dps from Deinococcus radiodurans
2C2U	;	1.1	;	Dps from Deinococcus radiodurans
5HJH	;	1.88	;	Dps4 from Nostoc punctiforme in complex with Fe ions
5I4J	;	2.394	;	Dps4 from Nostoc punctiforme in complex with Zn ions
4CY9	;	1.78	;	DpsA14 from Streptomyces coelicolor
4CYA	;	1.86	;	DpsA15 from Streptomyces coelicolor
4CYB	;	1.78	;	DpsC from Streptomyces coelicolor
5UQD	;	1.798	;	DPY-21 in complex with Fe(II) and alpha-Ketoglutarate
6U3M	;	1.9	;	DQ2-P.fluor-alpha1a
7KEI	;	1.75	;	DQA1*01:02/DQB1*06:02 in complex with a hemagglutinin peptide from the H1N1 pandemic flu virus.
7N19	;	2.38	;	DR3 in complex with Aspergillus nidulans NAD-dependent histone deacetylase hst4 peptide
1UT1	;	1.7	;	DraE adhesin from Escherichia Coli
2JKL	;	1.9	;	DraE Adhesin in complex with Bromamphenicol
2JKJ	;	2.3	;	DraE Adhesin in complex with Chloramphenicol Succinate
2W5P	;	1.9	;	DraE Adhesin in complex with Chloramphenicol Succinate (monoclinic form)
2JKN	;	1.9	;	DraE Adhesin in complex with Chloramphenicol Succinate (trigonal form)
2QZV	;	9.0	;	Draft Crystal Structure of the Vault Shell at 9 Angstroms Resolution
6N8U	;	1.96	;	DRAFT model of Schistosoma japonicum Glutathione S-transferase expression tag
3ST2	;	1.9	;	Dreiklang - equilibrium state
3ST3	;	1.702	;	Dreiklang - off state
3ST4	;	2.0	;	Dreiklang - on state
7V6E	;	3.0	;	DREP3
7CJY	;	2.2	;	Drimenol synthase from Persicaria hydropiper
7XQZ	;	2.0	;	Drimenyl diphosphate synthase D303A from Streptomyces showdoensis in complex with 2-fluorofarnesyl diphosphate (2F-FPP) and Mg2+
7XRA	;	1.95	;	Drimenyl diphosphate synthase D303A from Streptomyces showdoensis in complex with farnesyl diphosphate (FPP) and Mg2+
7XRU	;	2.5	;	Drimenyl diphosphate synthase D303E from Streptomyces showdoensis in complex with 2-fluorofarnesyl diphosphate (2F-FPP) and Mg2+
7XR7	;	1.63	;	Drimenyl diphosphate synthase D303E from Streptomyces showdoensis in complex with farnesyl diphosphate (FPP) and Mg2+
7XQ4	;	1.58	;	Drimenyl diphosphate synthase from Streptomyces showdoensis (apo)
7S9V	;	3.3	;	DrmAB:ADP
2KHX	;		;	Drosha double-stranded RNA binding motif
2NA2	;		;	DROSHA QUAD MUTANT DOUBLE-STRANDED RNA BINDING COMPETENT
6LXE	;	4.2	;	DROSHA-DGCR8 complex
4CA7	;	1.82	;	Drosophila Angiotensin converting enzyme (AnCE) in complex with a phosphinic tripeptide FI
4CA8	;	1.99	;	Drosophila Angiotensin converting enzyme (AnCE) in complex with a phosphinic tripeptide FII
5ONB	;	3.0	;	Drosophila Bag-of-marbles CBM peptide bound to human CAF40
5ONA	;	2.7	;	Drosophila Bag-of-marbles CBM peptide bound to human CAF40-CNOT1
5HU3	;	1.885	;	Drosophila CaMKII-D136N in complex with a phosphorylated fragment of the Eag potassium channel and Mg2+/ADP
5FG8	;	1.955	;	Drosophila CaMKII-wt in complex with a fragment of the Eag potassium channel and Mg2+/ADP
5H9B	;	2.25	;	Drosophila CaMKII-wt in complex with a fragment of the Eag potassium channel and Mg2+/AMPPN
6BUA	;	7.1	;	Drosophila Dicer-2 apo homology model (helicase, Platform-PAZ, RNaseIII domains)
6BU9	;	6.8	;	Drosophila Dicer-2 bound to blunt dsRNA
6TIS	;	2.3	;	DROSOPHILA GDP-TUBULIN
6TIZ	;	2.197	;	DROSOPHILA GDP-TUBULIN Y222F MUTANT
6TIY	;	2.293	;	DROSOPHILA GMPCPP-TUBULIN
6TIU	;	3.571	;	DROSOPHILA GTP-TUBULIN Y222F MUTANT
3P7J	;	2.3	;	Drosophila HP1a chromo shadow domain
2WB2	;	2.95	;	Drosophila Melanogaster (6-4) Photolyase Bound To double stranded Dna containing a T(6-4)C Photolesion
3CVU	;	2.0	;	Drosophila melanogaster (6-4) photolyase bound to ds DNA with a T-T (6-4) photolesion
3CVV	;	2.1	;	Drosophila melanogaster (6-4) photolyase bound to ds DNA with a T-T (6-4) photolesion and F0 cofactor
3CVY	;	2.7	;	Drosophila melanogaster (6-4) photolyase bound to repaired ds DNA
3CVW	;	3.2	;	Drosophila melanogaster (6-4) photolyase H365N mutant bound to ds DNA with a T-T (6-4) photolesion and cofactor F0
3CVX	;	3.2	;	Drosophila melanogaster (6-4) photolyase H369M mutant bound to ds DNA with a T-T (6-4) photolesion
7PX0	;	2.2	;	Drosophila melanogaster Aldehyde Oxidase 1
7MFW	;	2.104	;	Drosophila melanogaster Canoe PDZ domain in complex with Echinoid C-terminal region
6XWT	;	3.47	;	drosophila melanogaster CENP-A/H4 bound to N-terminal CAL1 fragment
6O2K	;	1.81	;	Drosophila melanogaster CENP-C cupin domain
8B9Z	;	3.28	;	Drosophila melanogaster complex I in the Active state (Dm1)
8BA0	;	3.68	;	Drosophila melanogaster complex I in the Twisted state (Dm2)
5F68	;	1.23	;	Drosophila Melanogaster Cycle W398A PAS-B with Bound Ethylene Glycol
5F69	;	1.374	;	Drosophila Melanogaster Cycle W398A PAS-B with Bound Glycerol
5F6A	;	1.93	;	Drosophila Melanogaster Cycle W398A PAS-B with Empty Pocket
2VPP	;	2.2	;	Drosophila melanogaster deoxyribonucleoside kinase successfully activates gemcitabine in transduced cancer cell lines
1LPV	;		;	DROSOPHILA MELANOGASTER DOUBLESEX (DSX), NMR, 18 STRUCTURES
2BK9	;	1.2	;	Drosophila Melanogaster globin
8EXW	;	2.5	;	Drosophila melanogaster indirect flight muscle myosin II (subfragment-1)
8CLS	;	4.0	;	Drosophila melanogaster insulin receptor ectodomain in complex with DILP5
7YXJ	;	2.45	;	Drosophila melanogaster JMJD7 (dmJMJD7) in complex with Mn and 2,4-PDCA
7YXG	;	1.641	;	Drosophila melanogaster JMJD7 (dmJMJD7) in complex with Mn and 2OG
7YXK	;	2.43	;	Drosophila melanogaster JMJD7 (dmJMJD7) in complex with Mn and N-oxalyl-D-alanine (NODA)
7YXL	;	2.2	;	Drosophila melanogaster JMJD7 (dmJMJD7) in complex with Mn and N-oxalyl-D-phenylalanine (NOFD)
7YXI	;	2.1	;	Drosophila melanogaster JMJD7 (dmJMJD7) in complex with Mn and N-oxalylglycine (NOG)
7YXH	;	2.3	;	Drosophila melanogaster JMJD7 (dmJMJD7) in complex with Mn and succinate
7CFB	;	2.1	;	Drosophila melanogaster Krimper eTud1 apo structure
7CFC	;	2.4	;	Drosophila melanogaster Krimper eTud1-Ago3 complex
7CFD	;	2.704	;	Drosophila melanogaster Krimper eTud2-AubR15me2 complex
7KYD	;	2.5	;	Drosophila melanogaster long-chain fatty-acyl-CoA synthetase CG6178
4Y5J	;	2.303	;	Drosophila melanogaster Mini spindles TOG3
6XU8	;	3.0	;	Drosophila melanogaster Ovary 80S ribosome
4RKE	;	2.0006	;	Drosophila melanogaster Rab2 bound to GMPPNP
4RKF	;	1.5	;	Drosophila melanogaster Rab3 bound to GMPPNP
8C7G	;	3.2	;	Drosophila melanogaster Rab7 GEF complex Mon1-Ccz1-Bulli
7UW8	;	2.5	;	Drosophila melanogaster setdb1-tuor domain
7UVE	;	2.3	;	Drosophila melanogaster setdb1-tuor domain with peptide H3K9me2K14ac
6XU6	;	3.5	;	Drosophila melanogaster Testis 80S ribosome
6XU7	;	4.9	;	Drosophila melanogaster Testis polysome ribosome
7B6H	;	5.4	;	Drosophila melanogaster TRAPP C11 subunits region 1 to 718
7B6E	;	4.5	;	Drosophila melanogaster TRAPP C8 subunits region 355 to 661
7B6D	;	4.27	;	Drosophila melanogaster TRAPPCore (C1, C2, C2L, C3a/b, C4, C5, C6 subunits)
7B6R	;	5.8	;	Drosophila melanogaster TRAPPIII partial complex: core plus C8 and C11 attached region
8AK3	;	1.9	;	Drosophila melanogaster UNC89 Protein Kinase 1 in complex with ADP
8AK2	;	1.75	;	Drosophila melanogaster UNC89 Protein Kinase Domain 1 (apo)
3M9Q	;	1.29	;	Drosophila MSL3 chromodomain
4WXJ	;	2.002	;	Drosophila muscle GluRIIB complex with glutamate
5FU7	;	3.1	;	drosophila nanos NBR peptide bound to the NOT module of the human CCR4-NOT complex
3DCO	;	11.0	;	Drosophila NOD (3DC4) and Bovine Tubulin (1JFF) Docked into the 11-Angstrom Cryo-EM Map of Nucleotide-Free NOD Complexed to the Microtubule
6HOM	;	2.1	;	Drosophila NOT4 CBM peptide bound to human CAF40
6HON	;	2.2	;	Drosophila NOT4 CBM peptide bound to human CAF40
2PYO	;	2.43	;	Drosophila nucleosome core
2NQB	;	2.3	;	Drosophila Nucleosome Structure
2GTE	;	1.4	;	Drosophila OBP LUSH bound to attractant pheromone 11-cis-vaccenyl acetate
2QDI	;	2.0	;	Drosophila OBP LUSH D118A mutation
6S9F	;	1.969	;	Drosophila OTK, extracellular domains 3-5
6P5A	;	3.6	;	Drosophila P element transposase strand transfer complex
6PE2	;	4.0	;	Drosophila P element transposase strand transfer complex
7F5T	;	4.1	;	Drosophila P5CS filament with glutamate
7F5U	;	4.1	;	Drosophila P5CS filament with glutamate and ATPgammaS
7F5V	;	3.6	;	Drosophila P5CS filament with glutamate, ATP, and NADPH
1SXR	;	1.56	;	Drosophila Peptidoglycan Recognition Protein (PGRP)-SA
7NSY	;	1.4	;	Drosophila PGRP-LB C160S mutant
7NSX	;	1.9	;	Drosophila PGRP-LB wild-type
7NSZ	;	1.3	;	Drosophila PGRP-LB Y78F mutant
7NT0	;	1.8	;	Drosophila PGRP-LB Y78F mutant in complex with tracheal cytotoxin (TCT)
6FKM	;	2.96	;	Drosophila Plexin A in complex with Semaphorin 1b
6FKN	;	4.801	;	Drosophila Plexin A in complex with Semaphorin 1b
1R18	;	2.2	;	Drosophila protein isoaspartyl methyltransferase with S-adenosyl-L-homocysteine
3H3D	;	2.3	;	Drosophila Pumilio RNA binding domain (Puf domain)
2VRA	;	3.2	;	Drosophila Robo IG1-2 (monoclinic form)
2VR9	;	3.2	;	Drosophila Robo IG1-2 (tetragonal form)
6QP9	;	3.6	;	Drosophila Semaphorin 1a, extracellular domains 1-2
6FKK	;	2.78	;	Drosophila Semaphorin 1b, extracellular domains 1-2
6QP7	;	1.96	;	Drosophila Semaphorin 2a
6QP8	;	2.33	;	Drosophila Semaphorin 2b
8OIJ	;	2.0	;	Drosophila Smaug-Smoothened complex
4TUX	;	3.08	;	drosophila stem-loop binding protein complexed with histone mRNA stem-loop
4TUW	;	2.902	;	drosophila stem-loop binding protein complexed with histone mRNA stem-loop, phospho mimic of TPNK and C-terminal region
4TV0	;	2.601	;	Drosophila stem-loop binding protein complexed with histone mRNA stem-loop, Selenomethionine derivative
1TAF	;	2.0	;	DROSOPHILA TBP ASSOCIATED FACTORS DTAFII42/DTAFII62 HETEROTETRAMER
1XW9	;	2.3	;	Drosophila thioredoxin, oxidized, P21
1XWC	;	2.3	;	Drosophila thioredoxin, reduced, P6522
6Y6E	;	2.02	;	drosophila Unr CSD456
7VNA	;	2.597	;	drosophlia AHR PAS-B domain
7VNH	;	2.402	;	drosophlia AHR PAS-B domain bound by the antagonist alpha-naphthoflavone
1XWA	;	2.2	;	Drospohila thioredoxin, oxidized, P41212
1XWB	;	2.2	;	Drospohila thioredoxin, oxidized, P42212
1CTR	;	2.45	;	DRUG BINDING BY CALMODULIN: CRYSTAL STRUCTURE OF A CALMODULIN-TRIFLUOPERAZINE COMPLEX
8CLH	;	2.5	;	Drug cocktail (Colchicine, Epothilone A, Peloruside, Ansamitocin P3, Vinblastine) bound to tubulin (T2R-TTL) complex
2J8S	;	2.54	;	Drug Export Pathway of Multidrug Exporter AcrB Revealed by DARPin Inhibitors
3LOK	;	2.48	;	Drug resistant cSrc kinase domain in complex with covalent inhibitor PD168393
3F3W	;	2.6	;	Drug resistant cSrc kinase domain in complex with inhibitor RL45 (Type II)
7MAR	;	1.7	;	Drug Resistant HIV-1 Protease (L10F, M46I, I47V, I50V, F53L, L63P, I72V, G73S, V82I, I85V) in Complex with DRV
7MAS	;	1.5	;	Drug Resistant HIV-1 Protease (L10F, M46I, I50V, F53L, L63P, G73S) in Complex with DRV
7MAQ	;	1.93	;	Drug Resistant HIV-1 Protease (L10F, V32I, L33F, K45I, A71V, V82I, I84V) in Complex with DRV
7MAP	;	1.951	;	Drug Resistant HIV-1 Protease (L10I, V32I, L33F, K45I, M46I, I50V, A71V, V82I, I84V) in Complex with DRV
166D	;	2.2	;	DRUG-DNA MINOR GROOVE RECOGNITION: CRYSTAL STRUCTURE OF GAMMA-OXAPENTAMIDINE COMPLEXED WITH D(CGCGAATTCGCG)2
7RIT	;	5.2	;	Drug-free A. baumannii MsbA
1D32	;	1.7	;	DRUG-INDUCED DNA REPAIR: X-RAY STRUCTURE OF A DNA-DITERCALINIUM COMPLEX
1AZM	;	2.0	;	DRUG-PROTEIN INTERACTIONS: STRUCTURE OF SULFONAMIDE DRUG COMPLEXED WITH HUMAN CARBONIC ANHYDRASE I
1BZM	;	2.0	;	DRUG-PROTEIN INTERACTIONS: STRUCTURE OF SULFONAMIDE DRUG COMPLEXED WITH HUMAN CARBONIC ANHYDRASE I
1CZM	;	2.0	;	DRUG-PROTEIN INTERACTIONS: STRUCTURE OF SULFONAMIDE DRUG COMPLEXED WITH HUMAN CARBONIC ANHYDRASE I
3FGD	;	1.33	;	Drugscore FP: Thermoylsin in complex with fragment.
1AC1	;	2.0	;	DSBA MUTANT H32L
1ACV	;	1.9	;	DSBA MUTANT H32S
1BQ7	;	2.8	;	DSBA MUTANT P151A, ROLE OF THE CIS-PROLINE IN THE ACTIVE SITE OF DSBA
3DKS	;	1.9	;	DsbA substrate complex
2L0M	;		;	DsbB2 peptide structure in 100% TFE
2L0L	;		;	DsbB2 peptide structure in 70% TFE
2L0O	;		;	DsbB3 peptide structure in 100% TFE
2L0N	;		;	DsbB3 peptide structure in 70% TFE
1JZO	;	1.92	;	DsbC C101S
1G0T	;	2.6	;	DSBC MUTANT C101S
1JZD	;	2.3	;	DsbC-DsbDalpha complex
2JU5	;		;	DsbH Oxidoreductase
8T1K	;	3.14	;	DSBU crosslinked nNOS-CaM oxygenase homodimer
5ZCR	;	2.4	;	DSM5389 glycosyltrehalose synthase
1A1F	;	2.1	;	DSNR (ZIF268 VARIANT) ZINC FINGER-DNA COMPLEX (GACC SITE)
1A1G	;	1.9	;	DSNR (ZIF268 VARIANT) ZINC FINGER-DNA COMPLEX (GCGT SITE)
4X8W	;	2.647	;	dsRBD3 of Loquacious
5MUU	;	4.0	;	dsRNA bacteriophage phi6 nucleocapsid
6SX2	;	1.9	;	dsRNA recognition by R38AK41A mutant of H7N1 NS1 RNA Binding Domain
8HIP	;	2.77	;	dsRNA transporter
8HKE	;	3.71	;	dsRNA transporter
4NIN	;	1.402	;	DSVISLS segment 101-107 from Human Superoxide Dismutase
2JZ1	;		;	DSX_long
2JZ0	;		;	DSX_short
7WDW	;	2.39	;	DsyB in complex with SAH and MTHB
7WDQ	;	2.35	;	DsyB in complex with SAM
3KO9	;	2.75	;	DTD from Plasmodium falciparum in complex with D-Arginine
3KOB	;	2.99	;	DTD from Plasmodium falciparum in complex with D-Glutamic acid
3KOC	;	2.91	;	DTD from Plasmodium falciparum in complex with D-Histidine
3KO7	;	2.21	;	DTD from Plasmodium falciparum in complex with D-Lysine
3KOD	;	3.0	;	DTD from Plasmodium falciparum in complex with D-Serine
4LXU	;	1.4	;	dTdp-Fuc3N and 5-N-Formyl-THF
1BXK	;	1.9	;	DTDP-GLUCOSE 4,6-DEHYDRATASE FROM E. COLI
1H7L	;	1.98	;	dTDP-MAGNESIUM COMPLEX OF SPSA FROM BACILLUS SUBTILIS
1H7Q	;	2.0	;	dTDP-MANGANESE COMPLEX OF SPSA FROM BACILLUS SUBTILIS
7PVI	;	1.434	;	dTDP-sugar epimerase
7PWB	;	1.87	;	dTDP-sugar epimerase from Coxiella burnetii in complex with dTDP
5XAI	;	2.0	;	dTMP bound Crystal structure of thymidylate kinase (aq_969) from Aquifex Aeolicus VF5
8B18	;	2.3	;	DtpB-Nb132-AF
8B19	;	2.45	;	DtpB-Nb132-AFA
8B1A	;	2.15	;	DtpB-Nb132-AI
8B1B	;	2.8	;	DtpB-Nb132-AL
8B1C	;	2.56	;	DtpB-Nb132-ALA
8B1D	;	2.3	;	DtpB-Nb132-APF
8B1E	;	2.47	;	DtpB-Nb132-AQ
8B1F	;	2.35	;	DtpB-Nb132-AV
8B1G	;	2.5	;	DtpB-Nb132-AW
8B17	;	2.5	;	DtpB-Nb132-AWA
8B1H	;	2.6	;	DtpB-Nb132-KV
8B1I	;	2.55	;	DtpB-Nb132-MS
8B1K	;	2.8	;	DtpB-Nb132-NV
8B1J	;	2.67	;	DtpB-Nb132-SL
7B24	;	2.05	;	DtxR-like iron-dependent regulator IdeR (P39G variant) complexed with cobalt and its consensus DNA-binding sequence
7B25	;	2.34	;	DtxR-like iron-dependent regulator IdeR (Q43A variant) complexed with cobalt and its consensus DNA-binding sequence
7B1V	;	2.04	;	DtxR-like iron-dependent regulator IdeR complexed with cobalt
7B1Y	;	2.12	;	DtxR-like iron-dependent regulator IdeR complexed with cobalt and its consensus DNA-binding sequence
7B23	;	2.15	;	DtxR-like iron-dependent regulator IdeR complexed with cobalt and the SACE_2689 promoter DNA-binding sequence
7B20	;	2.18	;	DtxR-like iron-dependent regulator IdeR complexed with iron and its consensus DNA-binding sequence
4TQ8	;	1.52	;	Dual binding mode for 3-(9H-fluoren-9-ylideneaminooxy)propanoic acid binding to Human transthyretin (TTR)
2BXV	;	2.15	;	Dual binding mode of a novel series of DHODH inhibitors
2FPT	;	2.4	;	Dual Binding Mode of a Novel Series of DHODH inhibitors
2FPV	;	1.8	;	Dual binding mode of a novel series of DHODH inhibitors
2FPY	;	2.0	;	Dual binding mode of a novel series of DHODH inhibitors
1SZM	;	2.5	;	DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
2EWA	;	2.1	;	Dual binding mode of pyridinylimidazole to MAP kinase p38
2FQI	;	1.95	;	dual binding modes of a novel series of DHODH inhibitors
6T3J	;	3.05	;	Dual Epitope Targeting by Anti-DR5 Antibodies
4LH4	;	1.8	;	Dual inhibition of HIV-1 replication by Integrase-LEDGF allosteric inhibitors is predominant at post-integration stage during virus production rather than at integration
4LH5	;	2.19	;	Dual inhibition of HIV-1 replication by Integrase-LEDGF allosteric inhibitors is predominant at post-integration stage during virus production rather than at integration
6B2P	;	3.01	;	Dual Inhibition of the Essential Protein Kinases A and B in Mycobacterium tuberculosis
6B2Q	;	2.88	;	Dual Inhibition of the Essential Protein Kinases A and B in Mycobacterium tuberculosis
2A4O	;	1.55	;	Dual modes of modification of Hepatitis A virus 3C protease by a serine derived beta-lactone: selective crytstallization and high resolution structure of the His102 adduct
2CXV	;	1.4	;	Dual Modes of Modification of Hepatitis A Virus 3C Protease by a Serine-Derived betaLactone: Selective Crystallization and High-resolution Structure of the His-102 Adduct
8EV1	;	1.83	;	Dual Modulators
8EV2	;	2.01	;	Dual Modulators
3BE1	;	2.9	;	Dual specific bH1 Fab in complex with the extracellular domain of HER2/ErbB-2
3BDY	;	2.6	;	Dual specific bH1 Fab in complex with VEGF
6QHO	;	2.7	;	Dual specificity mitogen-activated protein kinase kinase 7 in complex with pyrazolopyrimidine 1a
7NCY	;	2.0	;	Dual specificity phosphatase from Sulfolobales Beppu filamentous virus 3
4ZFF	;	2.75	;	Dual-acting Fab 5A12 in complex with VEGF
1PYN	;	2.2	;	DUAL-SITE POTENT, SELECTIVE PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR USING A LINKED FRAGMENT STRATEGY AND A MALONATE HEAD ON THE FIRST SITE
4ZFG	;	2.27	;	Dual-specificity Fab 5A12 in complex with Angiopoietin 2
2Y1O	;	1.49	;	Dual-target Inhibitor of MurD and MurE Ligases: Design, Synthesis and Binding Mode Studies
1QMU	;	2.7	;	Duck carboxypeptidase D domain II
1H8L	;	2.6	;	Duck Carboxypeptidase D Domain II in complex with GEMSA
6YGH	;	3.7	;	Duck hepatitis B virus capsid
6YGI	;	3.0	;	Duck hepatitis B virus capsid Mutant R124E_delta78-122
6YXR	;	3.4	;	Dunaliella Minimal Photosystem I
6QPH	;	3.4	;	Dunaliella minimal PSI complex
6SL5	;	2.84	;	Dunaliella Photosystem I Supercomplex
6WGL	;	2.82	;	Dupilumab fab with Crystal Kappa design complexed with human IL-4 receptor
2O80	;		;	Duplex DNA containing an abasic site with an opposite dC (alpha anomer) in 5'-G_AC-3' (10 structure ensemble and averaged structure)
2O82	;		;	Duplex DNA containing an abasic site with an opposite dC (beta anomer) in 5'-G_AC-3' (10 structure ensemble and averaged structure)
2O7W	;		;	Duplex DNA containing an abasic site with an opposite G (alpha anomer) in 5'-G_AC-3' (10 structure ensemble and averaged structure)
2O7X	;		;	Duplex DNA containing an abasic site with an opposite G (beta anomer) in 5'-G_AC-3' (10 structure ensemble and averaged structure)
2O7Y	;		;	Duplex DNA containing an abasic site with an opposite T (alpha anomer) in 5'-G_AC-3' (10 structure ensemble and averaged structure)
2O7Z	;		;	Duplex DNA containing an abasic site with an opposite T (beta anomer) in 5'-G_AC-3' (10 structure ensemble and averaged structure)
3RZG	;	1.62	;	Duplex Interrogation by a Direct DNA Repair Protein in the Search of Damage
3RZH	;	2.25	;	Duplex Interrogation by a Direct DNA Repair Protein in the Search of Damage
3RZJ	;	2.5	;	Duplex Interrogation by a Direct DNA Repair Protein in the Search of Damage
3RZK	;	2.78	;	Duplex Interrogation by a Direct DNA Repair Protein in the Search of Damage
3RZL	;	2.6	;	Duplex Interrogation by a Direct DNA Repair Protein in the Search of Damage
3RZM	;	3.06	;	Duplex Interrogation by a Direct DNA Repair Protein in the Search of Damage
1AG3	;		;	DUPLEX OLIGODEOXYNUCLEOTIDE CONTAINING PROPANODEOXYGUANOSINE OPPOSITE A TWO-BASE DELETION, NMR, MINIMIZED AVERAGE STRUCTURE
7QTN	;	1.2	;	Duplex RNA containing Xanthosine-Cytosine base pairs
7QUA	;	1.0	;	Duplex RNA containing Xanthosine-Cytosine base pairs
410D	;	1.6	;	DUPLEX [5'-D(GCGTA+TACGC)]2 WITH INCORPORATED 2'-O-ETHOXYMETHYLENE RIBONUCLEOSIDE
411D	;	1.93	;	DUPLEX [5'-D(GCGTA+TACGC)]2 WITH INCORPORATED 2'-O-METHOXYETHYL RIBONUCLEOSIDE
412D	;	1.65	;	DUPLEX [5'-D(GCGTA+TACGC)]2 WITH INCORPORATED 2'-O-METHYL-[TRI(OXYETHYL)] RIBONUCLEOSIDE
8DUT	;	7.4	;	Duplex-G-quadruplex-duplex (DGD) class_1
1P56	;	1.8	;	Duplication-extension of Helix A of T4 lysozyme
7PWJ	;	1.944	;	dUTPase from human in complex with Stl
7PWX	;	2.75	;	dUTPase from M. tuberculosis in complex with Stl
4GV8	;	2.1	;	DUTPase from phage phi11 of S.aureus: visualization of the species-specific insert
8HRV	;	2.0	;	dutpase of helicobacter pylori 26695
7WG1	;	2.19	;	DVAA-KlAte1
7WG4	;	1.51	;	DVAA-KlAte1
7BZX	;	4.0	;	DXPS
6I8Q	;	1.74	;	Dye type peroxidase Aa from Streptomyces lividans: 117.6 kGy structure
6I8J	;	1.9	;	Dye type peroxidase Aa from Streptomyces lividans: 131.2 kGy structure
6I91	;	1.78	;	Dye type peroxidase Aa from Streptomyces lividans: 156.8 kGy structure
6Q31	;	1.78	;	Dye type peroxidase Aa from Streptomyces lividans: 156.8 kGy structure
6I8K	;	1.98	;	Dye type peroxidase Aa from Streptomyces lividans: 164 kGy structure
6Q34	;	1.82	;	Dye type peroxidase Aa from Streptomyces lividans: 196 kGy structure
6Q3D	;	1.93	;	Dye type peroxidase Aa from Streptomyces lividans: 235.2 kGy structure
6Q3E	;	2.03	;	Dye type peroxidase Aa from Streptomyces lividans: 274.4 kGy structure
6I7Z	;	1.78	;	Dye type peroxidase Aa from Streptomyces lividans: 32.8 kGy structure
6IBN	;	2.18	;	Dye type peroxidase Aa from Streptomyces lividans: 32.8 kGy structure
6I8O	;	1.7	;	Dye type peroxidase Aa from Streptomyces lividans: 39.2kGy structure
6I8E	;	1.78	;	Dye type peroxidase Aa from Streptomyces lividans: 65.6 kGy structure
6I8P	;	1.73	;	Dye type peroxidase Aa from Streptomyces lividans: 78.4 kGy structure
6I8I	;	1.83	;	Dye type peroxidase Aa from Streptomyces lividans: 98.4 kGy structure
6I7C	;	1.88	;	Dye type peroxidase Aa from Streptomyces lividans: imidazole complex
6TB8	;	1.8	;	Dye Type Peroxidase Aa from Streptomyces lividans: spectroscopically-validated ferric state
3AFV	;	1.4	;	Dye-decolorizing peroxidase (DyP) at 1.4 A resolution
3VXJ	;	1.39	;	Dye-decolorizing peroxidase (DyP) complex with 2,6-dimethoxyphenol
3VXI	;	1.5	;	Dye-decolorizing peroxidase (DyP) complex with ascorbic acid
3MM1	;	1.42	;	Dye-decolorizing peroxidase (DyP) D171N
3MM3	;	1.4	;	Dye-decolorizing peroxidase (DyP) D171N in complex with cyanide
3MM2	;	1.45	;	Dye-decolorizing peroxidase (DyP) in complex with cyanide
5DE0	;	2.24	;	Dye-decolorizing protein from V. cholerae
6YR4	;	1.85	;	Dye-type peroxidase DtpB in the ferryl state: Spectroscopically Validated composite structure
8PR4	;	3.5	;	Dynactin pointed end bound to JIP3
2N1T	;		;	Dynamic binding mode of a synaptotagmin-1-SNARE complex in solution
7B3K	;		;	Dynamic complex between all-D-enantiomeric peptide D3 with L723P mutant of amyloid precursor protein (APP) 672-726 fragment (amyloid beta 1-55)
7B3J	;		;	Dynamic complex between all-D-enantiomeric peptide D3 with wild-type amyloid precursor protein 672-726 fragment (amyloid beta 1-55)
3OFS	;	2.2	;	Dynamic conformations of the CD38-mediated NAD cyclization captured using multi-copy crystallography
3K6M	;	1.5	;	Dynamic domains of Succinyl-CoA:3-ketoacid-coenzyme A transferase from pig heart.
2KU1	;		;	Dynamic Regulation of Archaeal Proteasome Gate Opening as Studied by TROSY-NMR
2KU2	;		;	Dynamic Regulation of Archaeal Proteasome Gate Opening as Studied by TROSY-NMR
3KFY	;	2.08	;	Dynamic switching and partial occupancies of a small molecule inhibitor complex of DHFR
5FNC	;	2.2	;	Dynamic Undocking and the Quasi-Bound State as tools for Drug Design
5FND	;	2.0	;	Dynamic Undocking and the Quasi-Bound State as tools for Drug Design
5FNF	;	2.1	;	Dynamic Undocking and the Quasi-Bound State as tools for Drug Design
1MFS	;		;	DYNAMICAL BEHAVIOR OF THE HIV-1 NUCLEOCAPSID PROTEIN; NMR, 30 STRUCTURES
2KJJ	;		;	Dynamics of insulin probed by 1H-NMR amide proton exchange anomalous flexibility of the receptor-binding surface
7W9A	;	2.12	;	Dynamics of lipid displacement inside the hydrophobic cavity of a non-specific lipid transfer protein from Solanum melongena
2DYN	;	2.3	;	DYNAMIN (PLECKSTRIN HOMOLOGY DOMAIN) (DYNPH)
2X2F	;	2.0	;	Dynamin 1 GTPase dimer, short axis form
3ZYC	;	2.2	;	DYNAMIN 1 GTPASE GED FUSION DIMER COMPLEXED WITH GMPPCP
5D3Q	;	1.7	;	Dynamin 1 GTPase-BSE fusion dimer complexed with GDP
2X2E	;	2.0	;	Dynamin GTPase dimer, long axis form
1YGT	;	1.7	;	Dynein Light Chain TcTex-1
6F1Y	;	3.4	;	Dynein light intermediate chain region of the dynein tail/dynactin/BICDR1 complex
4AI6	;	3.4	;	Dynein Motor Domain - ADP complex
4AKH	;	3.6	;	Dynein Motor Domain - AMPPNP complex
4AKG	;	3.3	;	Dynein Motor Domain - ATP complex
4AKI	;	3.7	;	Dynein Motor Domain - LuAc derivative
4D07	;	1.85	;	DYNLL2 dynein light chain binds to an extended, unstructured linear motif of myosin 5a tail
6V04	;	1.5	;	DynU16 crystal structure, a putative protein in the dynemicin biosynthetic locus
8CK9	;	1.6	;	DyP-type peroxidase from Thermobifida halotolerans
5AG0	;	1.75	;	DyP-type peroxidase of Auricularia auricula-judae (AauDyPI) crystallized at pH 6.5
5AG1	;	1.85	;	DyP-type peroxidase of Auricularia auricula-judae (AauDyPI) with meso- nitrated heme
4G2C	;	2.25	;	DyP2 from Amycolatopsis sp. ATCC 39116
3QNR	;	2.25	;	DyPB from Rhodococcus jostii RHA1, crystal form 1
3QNS	;	1.4	;	DyPB from Rhodococcus jostii RHA1, crystal form 2
4HOV	;	2.2	;	DypB N246A in complex with manganese
6UWY	;	2.95	;	DYRK1A bound to a harmine derivative
7ZH8	;	2.3	;	DYRK1a in Complex with a Bromo-Triazolo-Pyridine
5A4Q	;	2.37	;	DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
5A4L	;	2.73	;	DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
6EIJ	;	2.42	;	DYRK1A in complex with HG-8-60-1
5A3X	;	2.26	;	DYRK1A in complex with hydroxy benzothiazole fragment
6EIS	;	2.36	;	DYRK1A in complex with JWC-055
6EIV	;	2.68	;	DYRK1A in complex with JWD-065
5A4E	;	2.68	;	DYRK1A in complex with methoxy benzothiazole fragment
5A4T	;	2.15	;	DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
5A54	;	2.63	;	DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
6EIQ	;	2.3	;	DYRK1A in complex with XMD14-124
6EIR	;	2.4	;	DYRK1A in complex with XMD15-27-2
6EJ4	;	2.88	;	DYRK1A in complex with XMD7-112
6EIF	;	2.22	;	DYRK1A in complex with XMD7-117
6EIL	;	2.465	;	DYRK1A in complex with XMD8-49
6EIP	;	2.56	;	DYRK1A in complex with XMD8-62e
6UIP	;	3.7	;	DYRK1A Kinase Domain in Complex with a 6-azaindole Derivative, GNF2133.
6YF8	;	3.198	;	DYRK1A with PST001
8BAO	;	2.06	;	Dysgonamonadaceae bacterium CRISPR ancillary nuclease 2
5LOV	;	2.4	;	DZ-2384 tubulin complex
6SAR	;	2.18	;	E coli BepA/YfgC
4XKU	;	1.78	;	E coli BFR variant Y114F
4XKT	;	1.82	;	E coli BFR variant Y149F
2GMS	;	1.8	;	E coli GDP-4-keto-6-deoxy-D-mannose-3-dehydratase with bound hydrated PLP
5KNV	;	2.861	;	E coli hypoxanthine guanine phosphoribosyltransferase in complexed with 9-[(N-Phosphonoethyl-N-phosphonobutyl)-2-aminoethyl]-hypoxanthine
5KNS	;	2.792	;	E coli hypoxanthine guanine phosphoribosyltransferase in complexed with 9-[(N-phosphonoethyl-N-phosphonoethoxyethyl)-2-aminoethyl]hypoxanthine
5LRY	;	1.4	;	E coli [NiFe] Hydrogenase Hyd-1 mutant E28D
8FVB	;	2.03	;	E coli. CTP synthase in complex with CTP
8FVE	;	2.4	;	E coli. CTP synthase in complex with CTP (potassium malonate + 100 mM MgCl2)
8SBR	;	2.59	;	E coli. CTP synthase in complex with CTP (sodium malonate + 20 mM MgCl2)
8FV6	;	2.25	;	E coli. CTP synthase in complex with dF-dCTP
8FVD	;	2.38	;	E coli. CTP synthase in complex with dF-dCTP (potassium malonate + 100 mM MgCl2)
8FVC	;	2.281	;	E coli. CTP synthase in complex with dF-dCTP (potassium malonate + 5 mM MgCl2)
8FV8	;	2.05	;	E coli. CTP synthase in complex with dF-dCTP + ADP
8FV7	;	2.08	;	E coli. CTP synthase in complex with dF-dCTP + ATP
8FVA	;	2.4	;	E coli. CTP synthase in complex with F-araCTP
8FV9	;	1.991	;	E coli. CTP synthase in complex with F-dCTP
3DU2	;	3.1	;	E(L212)A mutant structure of photosynthetic reaction center from Rhodobacter sphaeroides
3DU3	;	2.8	;	E(L212)A, D(L213)A, A(M249)Y triple mutant structure of photosynthetic reaction center
3DUQ	;	2.7	;	E(L212)A, D(L213)A, N(M5)D triple mutant structure of photosynthetic reaction center from Rhodobacter sphaeroides
3DTS	;	3.1	;	E(L212)A, D(L213)A, R(M233)L triple mutant structure of photosynthetic reaction center from Rhodobacter sphaeroides
1K6N	;	3.1	;	E(L212)A,D(L213)A Double Mutant Structure of Photosynthetic Reaction Center from Rhodobacter Sphaeroides
3DSY	;	3.0	;	E(L212)Q mutant structure of photosynthetic reaction center from Rhodobacter sphaeroides
3DTR	;	3.1	;	E(L212)Q, L(L227)F double mutant structure of photosynthetic reaction center from Rhodobacter sphaeroides
3DTA	;	3.2	;	E(L212)Q, N(M44)D double mutant structure of photosynthetic reaction center from Rhodobacter sphaeroides
1Q1P	;	3.2	;	E-Cadherin activation
1EDH	;	2.0	;	E-CADHERIN DOMAINS 1 AND 2 IN COMPLEX WITH CALCIUM
1MOW	;	2.4	;	E-DreI
1NOQ	;		;	e-motif structure
4C16	;	1.93	;	E-selectin lectin, EGF-like and two SCR domains complexed with glycomimetic antagonist
6EYI	;	2.04	;	E-selectin lectin, EGF-like and two SCR domains complexed with glycomimetic ligand BW69669
6EYJ	;	2.2	;	E-selectin lectin, EGF-like and two SCR domains complexed with glycomimetic ligand NV354
6EYK	;	2.21	;	E-selectin lectin, EGF-like and two SCR domains complexed with glycomimetic ligand NV355
4CSY	;	2.41	;	E-selectin lectin, EGF-like and two SCR domains complexed with Sialyl Lewis X
4E7F	;	2.15	;	E. cloacae C115D MurA in complex with UDP
4E7E	;	2.3	;	E. cloacae C115D MurA in complex with UDP-glucose
3V4T	;	2.5	;	E. cloacae C115D MURA liganded with UNAG
4E7G	;	1.6	;	E. cloacae C115D/R120A MurA in the unliganded state
3LTH	;	1.75	;	E. cloacae MurA dead-end complex with UNAG and fosfomycin
3SWI	;	2.8	;	E. Cloacae MurA in complex with Enolpyruvyl-UDP-N-acetylgalactosamine and covalent adduct of PEP with CYS115
3SWQ	;	1.83	;	E. Cloacae MurA in complex with Enolpyruvyl-UNAG
4E7D	;	2.5	;	E. cloacae MurA in complex with UDP
4E7B	;	2.0	;	E. cloacae MurA in complex with UDP-glucose
3SU9	;	2.2	;	E. Cloacae MURA in complex with UDP-N-acetylmuramic acid and covalent adduct of PEP with Cys115
3UPK	;	2.0	;	E. cloacae MURA in complex with UNAG
4E7C	;	2.1	;	E. cloacae MurA in complex with UTP
3SWA	;	1.9	;	E. Cloacae MurA R120A complex with UNAG and covalent adduct of PEP with CYS115
4V41	;	2.5	;	E. COLI (LAC Z) BETA-GALACTOSIDASE (NCS CONSTRAINED MONOMER-MONOCLINIC)
1HN1	;	3.0	;	E. COLI (LAC Z) BETA-GALACTOSIDASE (ORTHORHOMBIC)
3IAP	;	2.0	;	E. coli (lacZ) beta-galactosidase (E416Q)
3IAQ	;	2.7	;	E. coli (lacz) beta-galactosidase (E416V)
1JZ8	;	1.5	;	E. COLI (lacZ) BETA-GALACTOSIDASE (E537Q) IN COMPLEX WITH ALLOLACTOSE
1JYN	;	1.8	;	E. COLI (lacZ) BETA-GALACTOSIDASE (E537Q) IN COMPLEX WITH LACTOSE
1JYV	;	1.75	;	E. COLI (lacZ) BETA-GALACTOSIDASE (E537Q) IN COMPLEX WITH ONPG
1JYW	;	1.55	;	E. COLI (lacZ) BETA-GALACTOSIDASE (E537Q) IN COMPLEX WITH PNPG
1PX3	;	1.6	;	E. COLI (LACZ) BETA-GALACTOSIDASE (G794A)
1PX4	;	1.6	;	E. COLI (LACZ) BETA-GALACTOSIDASE (G794A) WITH IPTG BOUND
4DUV	;	2.1	;	E. coli (lacZ) beta-galactosidase (G974A) 2-deoxy-galactosyl-enzyme and bis-Tris complex
4DUW	;	2.2	;	E. coli (lacZ) beta-galactosidase (G974A) in complex with allolactose
3DYM	;	2.05	;	E. coli (lacZ) beta-galactosidase (H418E)
3DYP	;	1.75	;	E. coli (lacZ) beta-galactosidase (H418N)
3DYO	;	1.8	;	E. coli (lacZ) beta-galactosidase (H418N) in complex with IPTG
3I3E	;	2.1	;	E. COLI (lacZ) BETA-GALACTOSIDASE (M542A)
3I3D	;	2.2	;	E. COLI (lacZ) BETA-GALACTOSIDASE (M542A) IN COMPLEX WITH IPTG
3VD3	;	2.8	;	E. coli (lacZ) beta-galactosidase (N460D)
3VD4	;	2.0	;	E. coli (lacZ) beta-galactosidase (N460D) in complex with IPTG
3VD5	;	2.7	;	E. coli (lacZ) beta-galactosidase (N460S)
3VD7	;	2.87	;	E. coli (lacZ) beta-galactosidase (N460S) in complex with galactotetrazole
3VD9	;	2.05	;	E. coli (lacZ) beta-galactosidase (N460S) in complex with IPTG
4DUX	;	2.3	;	E. coli (lacZ) beta-galactosidase (N460S) in complex with L-ribose
3VDA	;	2.5	;	E. coli (lacZ) beta-galactosidase (N460T)
3CZJ	;	2.05	;	E. COLI (lacZ) BETA-GALACTOSIDASE (N460T) IN COMPLEX WITH D-GALCTOPYRANOSYL-1-ONE
3VDB	;	2.05	;	E. coli (lacZ) beta-galactosidase (N460T) in complex with galactonolactone
3VDC	;	2.55	;	E. coli (lacZ) beta-galactosidase (N460T) in complex with IPTG
1F4A	;	2.8	;	E. COLI (LACZ) BETA-GALACTOSIDASE (NCS CONSTRAINED MONOMER-ORTHORHOMBIC)
1F4H	;	2.8	;	E. COLI (LACZ) BETA-GALACTOSIDASE (ORTHORHOMBIC)
3MUY	;	2.5	;	E. coli (lacZ) beta-galactosidase (R599A)
3MV0	;	2.2	;	E. COLI (lacZ) BETA-GALACTOSIDASE (R599A) IN COMPLEX WITH D-GALCTOPYRANOSYL-1-ONE
3SEP	;	2.05	;	E. coli (lacZ) beta-galactosidase (S796A)
3T09	;	1.75	;	E. coli (LacZ) beta-galactosidase (S796A) galactonolactone complex
3T08	;	2.0	;	E. coli (LacZ) beta-galactosidase (S796A) IPTG complex
3T2O	;	1.85	;	E. coli (lacZ) beta-galactosidase (S796D)
3T2Q	;	2.4	;	E. coli (lacZ) beta-galactosidase (S796D) in complex with galactonolactone
3T2P	;	2.6	;	E. coli (lacZ) beta-galactosidase (S796D) in complex with IPTG
3T0A	;	1.9	;	E. coli (LacZ) beta-galactosidase (S796T)
3T0B	;	2.4	;	E. coli (LacZ) beta-galactosidase (S796T) IPTG complex
4V44	;	2.7	;	E. COLI (lacZ) BETA-GALACTOSIDASE IN COMPLEX WITH 2-F-LACTOSE
1JZ5	;	1.8	;	E. COLI (lacZ) BETA-GALACTOSIDASE IN COMPLEX WITH D-GALCTOPYRANOSYL-1-ON
1JZ6	;	2.1	;	E. COLI (lacZ) BETA-GALACTOSIDASE IN COMPLEX WITH GALACTO-TETRAZOLE
1JZ7	;	1.5	;	E. COLI (lacZ) BETA-GALACTOSIDASE IN COMPLEX WITH GALACTOSE
1JYX	;	1.75	;	E. COLI (lacZ) BETA-GALACTOSIDASE IN COMPLEX WITH IPTG
1JZ3	;	1.75	;	E. COLI (lacZ) BETA-GALACTOSIDASE-TRAPPED 2-DEOXY-GALACTOSYL ENZYME INTERMEDIATE
1JZ4	;	2.1	;	E. COLI (lacZ) BETA-GALACTOSIDASE-TRAPPED 2-DEOXY-GALACTOSYL-ENZYME INTERMEDIATE (Low Bis-Tris)
4V45	;	2.6	;	E. COLI (lacZ) BETA-GALACTOSIDASE-TRAPPED 2-F-GALACTOSYL-ENZYME INTERMEDIATE
1JZ2	;	2.1	;	E. COLI (lacZ) BETA-GALACTOSIDASE-TRAPPED 2-F-GALACTOSYL-ENZYME INTERMEDIATE (ORTHORHOMBIC)
2JGD	;	2.6	;	E. COLI 2-oxoglutarate dehydrogenase (E1o)
4WWL	;	2.23	;	E. coli 5'-nucleotidase mutant I521C labeled with MTSL (intermediate form)
6XZ7	;	2.1	;	E. coli 50S ribosomal subunit in complex with dirithromycin, fMet-Phe-tRNA(Phe) and deacylated tRNA(iMet).
8E44	;	2.53	;	E. coli 50S ribosome bound to antibiotic analog SLC09
8E45	;	2.3	;	E. coli 50S ribosome bound to antibiotic analog SLC17
8E46	;	2.32	;	E. coli 50S ribosome bound to antibiotic analog SLC21
8E47	;	2.32	;	E. coli 50S ribosome bound to antibiotic analog SLC26
8E48	;	2.27	;	E. coli 50S ribosome bound to antibiotic analog SLC30
8E49	;	2.05	;	E. coli 50S ribosome bound to antibiotic analog SLC31
6PCH	;	2.9	;	E. coli 50S ribosome bound to compound 21
6PCS	;	2.8	;	E. coli 50S ribosome bound to compound 40e
6PCR	;	2.5	;	E. coli 50S ribosome bound to compound 40o
6PC8	;	2.9	;	E. coli 50S ribosome bound to compound 40q
6PCT	;	2.8	;	E. coli 50S ribosome bound to compound 41q
6PC7	;	2.5	;	E. coli 50S ribosome bound to compound 46
6PC6	;	2.5	;	E. coli 50S ribosome bound to compound 47
8E35	;	2.27	;	E. coli 50S ribosome bound to compound SAB002
8E30	;	1.91	;	E. coli 50S ribosome bound to compound streptogramin A analog 3142
8E36	;	2.38	;	E. coli 50S ribosome bound to compound streptogramin A analog 3146
8E43	;	2.09	;	E. coli 50S ribosome bound to compound streptogramin A analog 3336
8E33	;	2.23	;	E. coli 50S ribosome bound to compound streptogramin analog SAB001
8E32	;	2.35	;	E. coli 50S ribosome bound to compound streptogramin analogs SA1 and SB1
6PC5	;	2.7	;	E. coli 50S ribosome bound to compounds 46 and VS1
6WYV	;	2.75	;	E. coli 50S ribosome bound to compounds 47 and VS1
8E3L	;	2.35	;	E. coli 50S ribosome bound to D-linker solithromycin conjugate
8E3M	;	2.25	;	E. coli 50S ribosome bound to L-linker solithromycin conjugate
8E3O	;	1.99	;	E. coli 50S ribosome bound to solithromycin and VM1
8E42	;	2.29	;	E. coli 50S ribosome bound to tiamulin and azithromycin
8E41	;	2.13	;	E. coli 50S ribosome bound to tiamulin and VS1
6PCQ	;	2.6	;	E. coli 50S ribosome bound to VM2
7ODE	;	2.84	;	E. coli 50S ribosome LiCl core particle
5ZZM	;	8.1	;	E. coli 50S subunit bound HflX protein in presence of ATP (AMP-PNP) and GTP (GMP-PNP) analogs.
6U48	;	2.87	;	E. coli 50S with phazolicin (PHZ) bound in exit tunnel
5ETP	;	1.05	;	E. coli 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase complexed with AMPCPP and inhibitor at 1.05 angstrom resolution
5ETO	;	1.07	;	E. coli 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase complexed with AMPCPP and inhibitor at 1.07 angstrom resolution
5ETK	;	1.09	;	E. coli 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase complexed with AMPCPP and inhibitor at 1.09 angstrom resolution
5ETN	;	1.4	;	E. coli 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase complexed with AMPCPP and inhibitor at 1.40 angstrom resolution
5ETM	;	1.46	;	E. coli 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase complexed with AMPCPP and inhibitor at 1.46 angstrom resolution
5ETL	;	1.82	;	E. coli 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase complexed with AMPCPP and inhibitor at 1.82 angstrom resolution
7B5K	;	2.9	;	E. coli 70S containing suppressor tRNA in the A-site stabilized by a Negamycin analogue and P-site tRNA-nascent chain.
6HRM	;	2.96	;	E. coli 70S d2d8 stapled ribosome
8AYE	;	1.96	;	E. coli 70S ribosome bound to thermorubin and fMet-tRNA
8HTZ	;	2.4	;	E. coli 70S ribosome complexed with H. marismortui tRNA_Ile2 bearing agm2C34 in classical state
8HU1	;	2.69	;	E. coli 70S ribosome complexed with tRNA_Ile2 bearing L34 and ct6A37 in classical state
8HSP	;	2.32	;	E. coli 70S ribosome complexed with tRNA_Ile2 bearing L34 and t6A37 in classical state
6XZA	;	2.66	;	E. coli 70S ribosome in complex with dirithromycin, and deacylated tRNA(iMet) (focused classification).
6XZB	;	2.54	;	E. coli 70S ribosome in complex with dirithromycin, fMet-Phe-tRNA(Phe) and deacylated tRNA(iMet) (focused classification).
8EIU	;	2.24	;	E. coli 70S ribosome with A-loop mutations U2554C and U2555C
8FTO	;	1.85	;	E. coli 70S ribosome with an improved MS2 tag inserted in H98
7TOS	;	2.9	;	E. coli 70S ribosomes bound with the ALS/FTD-associated dipeptide repeat protein PR20
4V7A	;	9.0	;	E. coli 70S-fMetVal-tRNAVal post-translocation complex (post4)
4V75	;	12.0	;	E. coli 70S-fMetVal-tRNAVal-tRNAfMet complex in classic post-translocation state (post1)
4V6Y	;	12.0	;	E. coli 70S-fMetVal-tRNAVal-tRNAfMet complex in classic pre-translocation state (pre1a)
4V6Z	;	12.0	;	E. coli 70S-fMetVal-tRNAVal-tRNAfMet complex in classic pre-translocation state (pre1b)
4V72	;	13.0	;	E. coli 70S-fMetVal-tRNAVal-tRNAfMet complex in hybrid pre-translocation state (pre4)
4V73	;	15.0	;	E. coli 70S-fMetVal-tRNAVal-tRNAfMet complex in hybrid pre-translocation state (pre5a)
4V76	;	17.0	;	E. coli 70S-fMetVal-tRNAVal-tRNAfMet complex in intermediate post-translocation state (post2a)
4V77	;	17.0	;	E. coli 70S-fMetVal-tRNAVal-tRNAfMet complex in intermediate post-translocation state (post2b)
4V78	;	20.0	;	E. coli 70S-fMetVal-tRNAVal-tRNAfMet complex in intermediate post-translocation state (post3a)
4V79	;	15.0	;	E. coli 70S-fMetVal-tRNAVal-tRNAfMet complex in intermediate post-translocation state (post3b)
4V71	;	20.0	;	E. coli 70S-fMetVal-tRNAVal-tRNAfMet complex in intermediate pre-translocation state (pre2)
4V70	;	17.0	;	E. coli 70S-fMetVal-tRNAVal-tRNAfMet complex in intermediate pre-translocation state (pre3)
6ZTL	;	3.5	;	E. coli 70S-RNAP expressome complex in collided state bound to NusG
6ZTM	;	3.3	;	E. coli 70S-RNAP expressome complex in collided state without NusG
6ZTJ	;	3.4	;	E. coli 70S-RNAP expressome complex in NusG-coupled state (38 nt intervening mRNA)
6ZTN	;	3.9	;	E. coli 70S-RNAP expressome complex in NusG-coupled state (42 nt intervening mRNA)
6ZTO	;	3.0	;	E. coli 70S-RNAP expressome complex in uncoupled state 1
6ZU1	;	3.0	;	E. coli 70S-RNAP expressome complex in uncoupled state 2
6ZTP	;	3.0	;	E. coli 70S-RNAP expressome complex in uncoupled state 6
8CRG	;	1.49	;	E. coli adenylate kinase in complex with two ADP molecules as a result of enzymatic AP4A hydrolysis
6TNM	;	2.95	;	E. coli aerobic trifunctional enzyme subunit-alpha
7LBA	;	2.2	;	E. coli Agmatinase
5TPQ	;	2.45	;	E. coli alkaline phosphatase D101A, D153A, R166S, E322A, K328A mutant
5C66	;	2.03	;	E. Coli Alkaline Phosphatase in complex with tungstate
1KH7	;	2.4	;	E. COLI ALKALINE PHOSPHATASE MUTANT (D153GD330N)
1KH9	;	2.5	;	E. COLI ALKALINE PHOSPHATASE MUTANT (D153GD330N) COMPLEX WITH PHOSPHATE
1KHK	;	2.5	;	E. COLI ALKALINE PHOSPHATASE MUTANT (D153HD330N)
1KHL	;	2.5	;	E. COLI ALKALINE PHOSPHATASE MUTANT (D153HD330N) COMPLEX WITH PHOSPHATE
1KHJ	;	2.3	;	E. COLI ALKALINE PHOSPHATASE MUTANT (D153HD330N) MIMIC OF THE TRANSITION STATES WITH ALUMINIUM FLUORIDE
1KHN	;	2.6	;	E. COLI ALKALINE PHOSPHATASE MUTANT (D153HD330N) ZINC FORM
1KH4	;	2.4	;	E. COLI ALKALINE PHOSPHATASE MUTANT (D330N) IN COMPLEX WITH PHOSPHATE
1KH5	;	2.0	;	E. COLI ALKALINE PHOSPHATASE MUTANT (D330N) MIMIC OF THE TRANSITION STATES WITH ALUMINIUM FLUORIDE
1ELX	;	2.6	;	E. COLI ALKALINE PHOSPHATASE MUTANT (S102A)
1ELY	;	2.8	;	E. COLI ALKALINE PHOSPHATASE MUTANT (S102C)
1ELZ	;	2.8	;	E. COLI ALKALINE PHOSPHATASE MUTANT (S102G)
3CMR	;	2.05	;	E. coli alkaline phosphatase mutant R166S in complex with phosphate
4KM4	;	2.8	;	E. coli alkaline phosphatase mutant S102G/R166S in complex with inorganic phosphate
3TG0	;	1.2	;	E. coli alkaline phosphatase with bound inorganic phosphate
1GYT	;	2.5	;	E. coli Aminopeptidase A (PepA)
6G8B	;	2.374	;	E. coli Aminopeptidase N solved by Native SAD from a dataset collected in 60 second with JUNGFRAU detector
2BHA	;	2.4	;	E. coli Aminopeptidase P in complex with substrate
6YSV	;	2.7	;	E. coli anaerobic trifunctional enzyme subunit-alpha
6YSW	;	2.82	;	E. coli anaerobic trifunctional enzyme subunit-alpha in complex with coenzyme A
8QBT	;	2.2	;	E. coli ApdP-stalled ribosomal complex
8FTN	;	2.8	;	E. coli ArnA dehydrogenase domain mutant - N492A
4FYW	;	2.1	;	E. coli Aspartate Transcarbamoylase complexed with CTP
4FYY	;	1.9395	;	E. coli Aspartate Transcarbamoylase Complexed with CTP, UTP, and Mg2+
4FYX	;	2.0889	;	E. coli Aspartate Transcarbamoylase complexed with dCTP, UTP, and Mg2+
2IPO	;	2.6	;	E. coli Aspartate Transcarbamoylase complexed with N-phosphonacetyl-L-asparagine
1SKU	;	2.6	;	E. coli Aspartate Transcarbamylase 240's Loop Mutant (K244N)
6KJ9	;	2.5	;	E. coli ATCase catalytic subunit mutant - G128/130A
6KJ7	;	2.839	;	E. coli ATCase catalytic subunit mutant - G166P
6KJA	;	3.064	;	E. coli ATCase holoenzyme mutant - G128/130A (catalytic chain)
6KJ8	;	3.011	;	E. coli ATCase holoenzyme mutant - G166P (catalytic chain)
6OQR	;	3.1	;	E. coli ATP Synthase ADP State 1a
6VWK	;	3.3	;	E. coli ATP Synthase ADP Sub-state 3a Fo Focussed
8DBP	;	3.6	;	E. coli ATP synthase imaged in 10mM MgATP State1 ""half-up
8DBQ	;	4.0	;	E. coli ATP synthase imaged in 10mM MgATP State1 ""half-up"" Fo classified
8DBT	;	3.1	;	E. coli ATP synthase imaged in 10mM MgATP State2 ""down
8DBU	;	3.4	;	E. coli ATP synthase imaged in 10mM MgATP State2 ""down"" Fo classified
8DBR	;	3.2	;	E. coli ATP synthase imaged in 10mM MgATP State2 ""half-up
8DBS	;	3.5	;	E. coli ATP synthase imaged in 10mM MgATP State2 ""half-up"" Fo classified
8DBV	;	3.7	;	E. coli ATP synthase imaged in 10mM MgATP State3 ""down
8DBW	;	4.1	;	E. coli ATP synthase imaged in 10mM MgATP State3 ""down"" Fo classified
6OQS	;	3.3	;	E. coli ATP synthase State 1b
6OQT	;	3.1	;	E. coli ATP synthase State 1c
6OQU	;	3.2	;	E. coli ATP synthase State 1d
6PQV	;	3.3	;	E. coli ATP Synthase State 1e
6WNQ	;	3.4	;	E. coli ATP Synthase State 2a
6OQV	;	3.3	;	E. coli ATP Synthase State 2b
6OQW	;	3.1	;	E. coli ATP synthase State 3a
6WNR	;	3.3	;	E. coli ATP synthase State 3b
2HTN	;	2.5	;	E. coli bacterioferritin in its as-isolated form
8BVQ	;	3.3	;	E. coli BAM complex (BamABCDE) bound to darobactin B
7R1W	;	3.6	;	E. coli BAM complex (BamABCDE) bound to dynobactin A
5LJO	;	4.9	;	E. coli BAM complex (BamABCDE) by cryoEM
8BWC	;	3.5	;	E. coli BAM complex (BamABCDE) wild-type
3F1V	;	1.77	;	E. coli Beta Sliding Clamp, 148-153 Ala Mutant
1DP0	;	1.7	;	E. COLI BETA-GALACTOSIDASE AT 1.7 ANGSTROM
1MKA	;	2.0	;	E. COLI BETA-HYDROXYDECANOYL THIOL ESTER DEHYDRASE MODIFIED BY ITS CLASSIC MECHANISM-BASED INACTIVATOR, 3-DECYNOYL-N-ACETYL CYSTEAMINE
2BUI	;	2.4	;	E. COLI BETA-KETOACYL (ACYL CARRIER PROTEIN) SYNTHASE I IN COMPLEX WITH OCTANOIC ACID, 120K
2BUH	;	1.9	;	E. COLI BETA-KETOACYL (ACYL CARRIER PROTEIN) SYNTHASE I, 120 K
1H4F	;	2.0	;	E. COLI BETA-KETOACYL [ACYL CARRIER PROTEIN] SYNTHASE I K328R
6X7R	;	1.35	;	E. coli beta-ketoacyl-[acyl carrier protein] synthase III (FabH) in complex with oxa(dethia)-coenzyme A
8D1U	;	1.302	;	E. coli beta-ketoacyl-[acyl carrier protein] synthase III (FabH) with an acetylated cysteine and in complex with oxa(dethia)-Coenzyme A
4XKS	;	1.57	;	E. coli BFR variant Y45F
2IOB	;	2.2	;	E. coli Bifunctional glutathionylspermidine synthetase/amidase Apo protein
2IO9	;	2.2	;	E. coli Bifunctional glutathionylspermidine synthetase/amidase Incomplex with Mg2+ ,GSH and ADP
2IO8	;	2.1	;	E. coli Bifunctional glutathionylspermidine synthetase/amidase Incomplex with Mg2+ and ADP
2IOA	;	2.8	;	E. coli Bifunctional glutathionylspermidine synthetase/amidase Incomplex with Mg2+ and ADP and phosphinate inhibitor
2IO7	;	2.7	;	E. coli Bifunctional glutathionylspermidine synthetase/amidase Incomplex with Mg2+ and AMPPNP
7Z18	;	1.98	;	E. coli C-P lyase bound to a PhnK ABC dimer and ATP
7Z17	;	2.57	;	E. coli C-P lyase bound to a PhnK ABC dimer in an open conformation
7Z15	;	1.93	;	E. coli C-P lyase bound to a PhnK/PhnL dual ABC dimer and ADP + Pi
7Z19	;	2.57	;	E. coli C-P lyase bound to a single PhnK ABC domain
7Z16	;	2.09	;	E. coli C-P lyase bound to PhnK/PhnL dual ABC dimer with AMPPNP and PhnK E171Q mutation
8BAR	;	1.63	;	E. coli C7 DarT1 in complex with ADP-ribosylated ssDNA and nicotinamide
8BAS	;	1.92	;	E. coli C7 DarT1 in complex with carba-NAD and DNA
8BAQ	;	2.0	;	E. coli C7 DarT1 in complex with NAD+
4FT8	;	1.966	;	E. coli Catabolite Activator Protein with Cobalt and Sulfate Ligands
5VHU	;	1.8	;	E. coli CFT073 c3406
5UQI	;	1.62	;	E. coli CFT073 c3406 in complex with A5P
5VHT	;	2.0	;	E. coli chorismate mutase with orthogonal interface containing p-benzoyl phenylalanine
8GJ3	;	2.8	;	E. coli clamp loader on primed template DNA
8GIY	;	3.7	;	E. coli clamp loader with closed clamp
8GJ2	;	2.6	;	E. coli clamp loader with closed clamp on primed template DNA
8GIZ	;	2.7	;	E. coli clamp loader with open clamp
8GJ0	;	2.9	;	E. coli clamp loader with open clamp on primed template DNA (form 1)
8GJ1	;	3.0	;	E. coli clamp loader with open clamp on primed template DNA (form 2)
3O2H	;	1.7	;	E. coli ClpS in complex with a Leu N-end rule peptide
3O2B	;	2.05	;	E. coli ClpS in complex with a Phe N-end rule peptide
2W0Q	;	2.48	;	E. coli copper amine oxidase in complex with Xenon
6S1K	;	8.38	;	E. coli Core Signaling Unit, carrying QQQQ receptor mutation
8ENQ	;	3.6	;	E. coli CsgA fibril (218-pixel box size)
2Y2T	;	2.3	;	E. coli CsgC in reduced form
5U6R	;	5.7	;	E. coli CTP synthase CC mutant filament (product-bound)
2XSK	;	1.7	;	E. coli curli protein CsgC - SeCys
6O10	;	2.0	;	E. coli cysteine desulfurase SufS
6O11	;	1.84	;	E. coli cysteine desulfurase SufS C364A with a Cys-aldimine intermediate
6MRI	;	2.62	;	E. coli cysteine desulfurase SufS E250A with a cysteine persulfide intermediate
6MRH	;	2.02	;	E. coli cysteine desulfurase SufS E96A with a cysteine persulfide intermediate
6O12	;	2.05	;	E. coli cysteine desulfurase SufS H123A
6O13	;	2.203	;	E. coli cysteine desulfurase SufS H123A with a Cys-ketimine intermediate
6MR6	;	2.019	;	E. coli cysteine desulfurase SufS H55A with a cysteine persulfide intermediate
7RUJ	;	2.5	;	E. coli cysteine desulfurase SufS N99A
7RW3	;	2.3	;	E. coli cysteine desulfurase SufS N99D
7RRN	;	2.3	;	E. coli cysteine desulfurase SufS R56A
6MRE	;	2.5	;	E. coli cysteine desulfurase SufS R92A with a cysteine persulfide intermediate
6MR2	;	2.404	;	E. coli cysteine desulfurase SufS with a cysteine persulfide intermediate
6UY5	;	1.501	;	E. coli cysteine desulfurase SufS with a spontaneously rotated beta-hairpin
1B23	;	2.6	;	E. coli cysteinyl-tRNA and T. aquaticus elongation factor EF-TU:GTP ternary complex
7N9Z	;	2.19	;	E. coli cytochrome bo3 in MSP nanodisc
8F6C	;	3.46	;	E. coli cytochrome bo3 ubiquinol oxidase dimer
8F68	;	3.15	;	E. coli cytochrome bo3 ubiquinol oxidase monomer
6E9N	;	2.915	;	E. coli D-galactonate:proton symporter in the inward open form
6E9O	;	3.501	;	E. coli D-galactonate:proton symporter mutant E133Q in the outward substrate-bound form
7LVC	;	1.7	;	E. coli DHFR by Native Mn,P,S-SAD at Room Temperature
6MTH	;	1.35	;	E. coli DHFR complex modeled with three ligand states
6MT8	;	1.35	;	E. coli DHFR complex modeled with two ligand states
6MR9	;	1.35	;	E. coli DHFR complex with a reaction intermediate
6CQA	;	2.2	;	E. coli DHFR complex with inhibitor AMPQD
8DAI	;	1.14	;	E. coli DHFR complex with NADP+ and 10-methylfolate
8G50	;	1.7	;	E. coli DHFR complex with NADP+ and folate: EF-X excited state model by Laue diffraction (electric field along b axis; 8-fold extrapolation of structure factor differences)
8G4Z	;	1.7	;	E. coli DHFR complex with NADP+ and folate: EF-X off model by Laue diffraction (no electric field)
6CW7	;	1.03	;	E. coli DHFR product complex with (6S)-5,6,7,8-TETRAHYDROFOLATE
6CXK	;	1.108	;	E. coli DHFR substrate complex with Dihydrofolate
6CYV	;	1.3	;	E. coli DHFR ternary complex with NADP and dihydrofolate
3DU0	;	2.0	;	E. coli dihydrodipicolinate synthase with first substrate, pyruvate, bound in active site
7MQP	;	2.1	;	E. coli dihydrofolate reductase complexed with 4'-chloro-3'-(4-(2,4-diamino-6-ethylpyrimidin-5-yl)but-3-yn-2-yl)-[1,1'-biphenyl]-4-carboxamide (UCP1228)
7REB	;	1.91	;	E. coli dihydrofolate reductase complexed with 5-(3-(7-(4-(aminomethyl)phenyl)benzo[d][1,3]dioxol-5-yl)but-1-yn-1-yl)-6-ethylpyrimidine-2,4-diamine (UCP1223)
7T6H	;	2.42	;	E. coli dihydroorotate dehydrogenase
7T5Y	;	2.62	;	E. coli dihydroorotate dehydrogenase bound to the inhibitor HMNQ
7T5K	;	2.25	;	E. coli dihydroorotate dehydrogenase bound to the inhibitor HQNO
7T6C	;	2.53	;	E. coli dihydroorotate dehydrogenase bound to the ubiquinone surrogate DCIP
5U0V	;	1.7	;	E. coli dihydropteroate synthase complexed with 6-methylamino-5-nitrosoisocytosine
5U0W	;	1.968	;	E. coli dihydropteroate synthase complexed with 9-methylguanine
5U0Z	;	2.29	;	E. coli dihydropteroate synthase complexed with an 8-mercaptoguanine derivative
5V79	;	2.25	;	E. coli dihydropteroate synthase complexed with an 8-mercaptoguanine derivative: 2-((2-amino-9-methyl-6-oxo-6,9-dihydro-1H-purin-8-yl)thio)-N-phenylacetamide
5V7A	;	2.35	;	E. coli dihydropteroate synthase complexed with an 8-mercaptoguanine derivative: 2-((2-amino-9-methyl-6-oxo-6,9-dihydro-1H-purin-8-yl)thio)acetic acid
5U13	;	1.951	;	E. coli dihydropteroate synthase complexed with an 8-mercaptoguanine derivative: 2-amino-8-{[2-(4-methoxyphenyl)-2-oxoethyl]sulfanyl}-1,7-dihydro-6H-purin-6-one
5U12	;	1.839	;	E. coli dihydropteroate synthase complexed with an 8-mercaptoguanine derivative: 2-azanyl-8-[(2-fluorophenyl)methylsulfanyl]-1,9-dihydropurin-6-one
5U11	;	1.994	;	E. coli dihydropteroate synthase complexed with an 8-mercaptoguanine derivative: 2-[(2-amino-6-oxo-6,9-dihydro-1H-purin-8-yl)sulfanyl]-N-methylacetamide
5U14	;	1.953	;	E. coli dihydropteroate synthase complexed with an 8-mercaptoguanine derivative: 4-{2-[(2-amino-6-oxo-6,9-dihydro-1H-purin-8-yl)sulfanyl]ethyl}benzene-1-sulfonamide
5U0Y	;	1.88	;	E. coli dihydropteroate synthase complexed with an 8-mercaptoguanine derivative: [(2-amino-6-oxo-6,9-dihydro-1H-purin-8-yl)sulfanyl]acetic acid
5U10	;	2.04	;	E. coli dihydropteroate synthase complexed with pteroic acid
4YCO	;	2.1	;	E. coli dihydrouridine synthase C (DusC) in complex with tRNAPhe
4YCP	;	2.55	;	E. coli dihydrouridine synthase C (DusC) in complex with tRNATrp
6RKU	;	4.0	;	E. coli DNA Gyrase - DNA binding and cleavage domain in State 1
6RKS	;	4.0	;	E. coli DNA Gyrase - DNA binding and cleavage domain in State 1 without TOPRIM insertion
6RKV	;	4.6	;	E. coli DNA Gyrase - DNA binding and cleavage domain in State 2
5MMP	;	2.05	;	E. coli DNA Gyrase B 24 kDa ATPase domain in complex with 1-ethyl-3-[5-pyridin-4-yl-8-(pyridin-3-ylamino)-isoquinolin-3-yl]-urea
5MMN	;	1.9	;	E. coli DNA Gyrase B 24 kDa ATPase domain in complex with 1-ethyl-3-[8-methyl-5-(2-methyl-pyridin-4-yl)-isoquinolin-3-yl]-urea
5MMO	;	1.81	;	E. coli DNA Gyrase B 24 kDa ATPase domain in complex with [3-(3-ethyl-ureido)-5-(pyridin-4-yl)-isoquinolin-8-yl-methyl]-carbamic acid prop-2-ynyl ester
8QDX	;	3.0	;	E. coli DNA gyrase bound to a DNA crossover
8QQS	;	2.9	;	E. coli DNA gyrase bound to a linear part of a DNA minicircle
1BDX	;	6.0	;	E. COLI DNA HELICASE RUVA WITH BOUND DNA HOLLIDAY JUNCTION, ALPHA CARBONS AND PHOSPHATE ATOMS ONLY
1MMI	;	1.848	;	E. COLI DNA POLYMERASE BETA SUBUNIT
8SY7	;	2.65	;	E. coli DNA-directed RNA polymerase transcription elongation complex bound the unnatural dB-STP base pair in the active site
8SY6	;	3.28	;	E. coli DNA-directed RNA polymerase transcription elongation complex bound the unnatural dB-UTP base pair in the active site
8SY5	;	2.7	;	E. coli DNA-directed RNA polymerase transcription elongation complex bound the unnatural dS-BTP base pair in the active site
8TXO	;	3.1	;	E. coli DNA-directed RNA polymerase transcription elongation complex bound to the unnatural dZ-PTP base pair in the active site
7T21	;	5.4	;	E. coli DnaB bound to ssDNA and ADP-AlF4
7T20	;	4.7	;	E. coli DnaB bound to ssDNA and AMPPNP
7T22	;	4.2	;	E. coli DnaB bound to three DnaG C-terminal domains, ssDNA, ADP and AlF4
7T23	;	4.2	;	E. coli DnaB bound to two DnaG C-terminal domains, ssDNA, ADP and AlF4
6QEL	;	3.9	;	E. coli DnaBC apo complex
6QEM	;	3.4	;	E. coli DnaBC complex bound to ssDNA
8SXX	;	3.6	;	E. coli dodecamer SIR2
5JFZ	;	2.4	;	E. coli EcFicT in complex with EcFicA mutant E28G
5JFF	;	2.0	;	E. coli EcFicT mutant G55R in complex with EcFicA
8FR3	;	2.23	;	E. coli EF-Tu in complex with KKL-55
2BVN	;	2.3	;	E. coli EF-Tu:GDPNP in complex with the antibiotic enacyloxin IIa
1OB2	;	3.35	;	E. coli elongation factor EF-Tu complexed with the antibiotic kirromycin, a GTP analog, and Phe-tRNA
1I30	;	2.4	;	E. Coli Enoyl Reductase +NAD+SB385826
1I2Z	;	2.8	;	E. COLI ENOYL REDUCTASE IN COMPLEX WITH NAD AND BRL-12654
1MFP	;	2.33	;	E. coli Enoyl Reductase in complex with NAD and SB611113
1D8A	;	2.2	;	E. COLI ENOYL REDUCTASE/NAD+/TRICLOSAN COMPLEX
3FJX	;	1.75	;	E. coli EPSP synthase (T97I) liganded with S3P
3FJZ	;	1.7	;	E. coli EPSP synthase (T97I) liganded with S3P and glyphosate
3FK0	;	1.7	;	E. coli EPSP synthase (TIPS mutation) liganded with S3P
3FK1	;	1.7	;	E. coli EPSP synthase (TIPS mutation) liganded with S3P and glyphosate
2QFQ	;	1.5	;	E. coli EPSP synthase Pro101Leu liganded with S3P
2PQ9	;	1.6	;	E. coli EPSPS liganded with (R)-difluoromethyl tetrahedral reaction intermediate analog
8TXR	;	3.8	;	E. coli ExoVII(H238A)
5MY1	;	7.6	;	E. coli expressome
1ZPL	;	1.7	;	E. coli F17a-G lectin domain complex with GlcNAc(beta1-O)Me
2BSC	;	1.4	;	E. coli F17a-G lectin domain complex with N-acetylglucosamine, high- resolution structure
2BSB	;	2.4	;	E. coli F17e-G lectin domain complex with N-acetylglucosamine
5LNE	;	2.2	;	E. coli F9 pilus adhesin FmlH bound to the Thomsen-Friedenreich (TF) antigen
5BNM	;	1.7	;	E. coli FabH with Small Molecule Inhibitor 1
5BNR	;	1.89	;	E. coli Fabh with small molecule inhibitor 2
5BNS	;	2.2	;	E. coli Fabh with small molecule inhibitor 2
3PF1	;	2.7	;	E. coli FadL Asp348Ala mutant
1QFG	;	2.5	;	E. COLI FERRIC HYDROXAMATE RECEPTOR (FHUA)
1QFF	;	2.7	;	E. COLI FERRIC HYDROXAMATE UPTAKE RECEPTOR (FHUA) IN COMPLEX WITH BOUND FERRICHROME-IRON
1AHN	;	2.6	;	E. COLI FLAVODOXIN AT 2.6 ANGSTROMS RESOLUTION
5O28	;	1.89	;	E. coli FolD apo
5O22	;	2.1	;	E. coli FolD in complex with carolacton
2QVR	;	2.18	;	E. coli Fructose-1,6-bisphosphatase: Citrate, Fru-2,6-P2, and Mg2+ bound
7Q6D	;	2.8	;	E. coli FtsA 1-405 ATP 3 Ni
2J5P	;		;	E. coli FtsK gamma domain
2IUS	;	2.7	;	E. coli FtsK motor domain
6OS7	;	1.36	;	E. coli fumarase mutant - R126A
6P3C	;	1.459	;	E. coli fumarase mutant - T187A
2OI5	;	2.25	;	E. coli GlmU- Complex with UDP-GlcNAc and Acetyl-CoA
2OI6	;	2.2	;	E. coli GlmU- Complex with UDP-GlcNAc, CoA and GlcN-1-PO4
2OI7	;	2.54	;	E. coli GlmU- Complex with UDP-GlcNAc, desulpho-CoA and GlcNAc-1-PO4
1ECQ	;	2.0	;	E. COLI GLUCARATE DEHYDRATASE BOUND TO 4-DEOXYGLUCARATE
1EC8	;	1.9	;	E. COLI GLUCARATE DEHYDRATASE BOUND TO PRODUCT 2,3-DIHYDROXY-5-OXO-HEXANEDIOATE
1EC9	;	2.0	;	E. COLI GLUCARATE DEHYDRATASE BOUND TO XYLAROHYDROXAMATE
1EC7	;	1.9	;	E. COLI GLUCARATE DEHYDRATASE NATIVE ENZYME
2VF4	;	2.95	;	E. coli glucosamine-6-P synthase
2J6H	;	2.35	;	E. coli glucosamine-6-P synthase in complex with glucose-6P and 5-oxo- L-norleucine
3A30	;	2.2	;	E. coli Gsp amidase C59 acetate modification
3A2Y	;	1.95	;	E. coli Gsp amidase C59A complexed with Gsp
3A2Z	;	1.5	;	E. coli Gsp amidase Cys59 sulfenic acid
6OHB	;	2.3	;	E. coli Guanine Deaminase
6OHC	;	2.3	;	E. coli Guanine Deaminase
4PRV	;	2.0	;	E. coli GyrB 43-kDa N-terminal fragment in complex with ADP
4PRX	;	1.8	;	E. coli GyrB 43-kDa N-terminal fragment in complex with ADP+Pi
4PU9	;	2.4	;	E. coli GyrB 43-kDa N-terminal fragment in complex with ADP-BeF3
7DQS	;	1.85	;	E. coli GyrB ATPase domain in complex with 2-chlorophenol
7DQH	;	1.91	;	E. coli GyrB ATPase domain in complex with 2-hydroxybenzamide
7DQJ	;	1.92	;	E. coli GyrB ATPase domain in complex with 3,4-Dihydroxyacetophenone
7DQL	;	1.93	;	E. coli GyrB ATPase domain in complex with 4-chlorobenzene-1,2-diol
7DQW	;	1.88	;	E. coli GyrB ATPase domain in complex with 4-chlorophenol
7DOR	;	1.89	;	E. coli GyrB ATPase domain in complex with 4-nitropheno
7DQI	;	1.91	;	E. coli GyrB ATPase domain in complex with Esculetin
7DQF	;	1.8	;	E. coli GyrB ATPase domain in complex with methyl 2,4-dihydroxybenzoate
7DPR	;	1.75	;	E. coli GyrB ATPase domain in complex with methyl 3,4-dihydroxybenzoate
7DQU	;	1.88	;	E. coli GyrB ATPase domain in complex with methyl 4-hydroxybenzoate
7DPS	;	2.26	;	E. coli GyrB ATPase domain in complex with Methyl 4-hydroxycinnamate
7DQM	;	1.78	;	E. coli GyrB ATPase domain in complex with Naringenin
2H1F	;	2.4	;	E. coli heptosyltransferase WaaC with ADP
2H1H	;	2.4	;	E. coli heptosyltransferase WaaC with ADP-2-deoxy-2-fluoro heptose
2GT1	;	1.9	;	E. coli heptosyltransferase WaaC.
1D8L	;	2.5	;	E. COLI HOLLIDAY JUNCTION BINDING PROTEIN RUVA NH2 REGION LACKING DOMAIN III
5KNR	;	2.864	;	E. coli HPRT in complexed with 9-[(N-phosphonoethyl-N-phosphonoethoxyethyl)-2-aminoethyl]-guanine
5JRD	;	1.2	;	E. coli Hydrogenase-1 variant P508A
6EHQ	;	2.2	;	E. coli Hydrogenase-2 (as isolated form).
6EN9	;	1.5	;	E. coli Hydrogenase-2 (hydrogen reduced form)
6EHS	;	1.5	;	E. coli Hydrogenase-2 chemically reduced structure
3BUL	;	2.3	;	E. coli I690C/G743C MetH C-terminal fragment (649-1227)
3CW5	;	3.1	;	E. coli Initiator tRNA
3CW6	;	3.3	;	E. coli Initiator tRNA
4CHU	;	2.489	;	E. coli IscR-DNA complex
1YQN	;	3.11	;	E. coli ispF double mutant
3ULK	;	2.3	;	E. coli Ketol-acid reductoisomerase in complex with NADPH and Mg2+
6PA3	;	1.65	;	E. coli L-asparaginase II double mutant (T89V,K162T) in complex with L-Asn at pH 7.0
6PA4	;	1.85	;	E. coli L-asparaginase II double mutant (T89V,K162T) in complex with L-Asp at pH 7.0
6PAC	;	1.6	;	E. coli L-asparaginase II in complex with L-Asp at pH 5.6
6PAB	;	1.73	;	E. coli L-asparaginase II in complex with L-Asp at pH 7.0
6PA2	;	1.9	;	E. coli L-asparaginase II mutant (K162M) in complex with L-Asp at pH 5.6
6PA9	;	1.88	;	E. coli L-asparaginase II mutant (T12V) in complex with L-Asn at pH 7.0
6PAA	;	1.85	;	E. coli L-asparaginase II mutant (T12V) in complex with L-Asp at pH 5.5
8ECD	;	1.62	;	E. coli L-asparaginase II mutant (V27T) in complex with L-Asp
8ECE	;	1.86	;	E. coli L-asparaginase II mutant (V27T) in complex with L-Glu
1KNP	;	2.6	;	E. coli L-aspartate oxidase: mutant R386L in complex with succinate
4D7Z	;	1.9	;	E. coli L-aspartate-alpha-decarboxylase mutant N72Q to a resolution of 1.9 Angstroms
5BR4	;	0.91	;	E. coli lactaldehyde reductase (FucO) M185C mutant
6B88	;	2.407	;	E. coli LepB in complex with GNE0775 ((4S,7S,10S)-10-((S)-4-amino-2-(2-(4-(tert-butyl)phenyl)-4-methylpyrimidine-5-carboxamido)-N-methylbutanamido)-16,26-bis(2-aminoethoxy)-N-(2-iminoethyl)-7-methyl-6,9-dioxo-5,8-diaza-1,2(1,3)-dibenzenacyclodecaphane-4-carboxamide)
2MHK	;		;	E. coli LpoA N-terminal domain
6B8B	;	1.95	;	E. coli LptB in complex with ADP and a novobiocin derivative
6B89	;	2.0	;	E. coli LptB in complex with ADP and novobiocin
5WLY	;	2.0	;	E. coli LpxH- 8 mutations
2PJJ	;	2.46	;	E. coli lytic transglycosylase MltA-D308A in apo-1 form
2PIC	;	2.25	;	E. coli lytic transglycosylase MltA-D308A in apo-2 form
5KKA	;	1.75	;	E. coli malate dehydrogenase with the inhibitor 6DHNAD
1OCX	;	2.15	;	E. coli maltose-O-acetyltransferase
5CKF	;	2.8	;	E. coli MazF E24A form I
5CKH	;	2.449	;	E. coli MazF E24A form IIb
5CKD	;	1.698	;	E. coli MazF E24A form III
5CK9	;	1.898	;	E. coli MazF form I
5CKB	;	2.799	;	E. coli MazF form II
5CO7	;	3.489	;	E. coli MazF form III
5CR2	;	2.9	;	E. coli MazF in complex with single strand DNA substrate analog
5CQX	;	1.63	;	E. coli MazF mutant E24A in complex with MazE residues 68-82 form I
5CQY	;	2.481	;	E. coli MazF mutant E24A in complex with MazE residues 68-82 form II
4P9F	;	2.099	;	E. coli McbR/YncC
1K7Y	;	3.0	;	E. coli MetH C-terminal fragment (649-1227)
6IZ7	;	11.8	;	E. coli methionine aminopeptidase crystal structure fitted into the cryo-EM density map of E. coli 70S ribosome in complex with methionine aminopeptidase
2P9A	;	1.6	;	E. coli methionine aminopeptidase dimetalated with inhibitor YE6
4PNC	;	1.54	;	E. COLI METHIONINE AMINOPEPTIDASE IN COMPLEX WITH INHIBITOR 7-METHOXY-2-METHYLEN-3,4-DIHYDRONAPHTHALEN-1(2H)-ONE
2GU4	;	1.8	;	E. coli methionine aminopeptidase in complex with NleP, 1: 0.5, di-metalated
2GU5	;	1.6	;	E. coli methionine aminopeptidase in complex with NleP, 1: 1, di-metalated
2GU6	;	1.7	;	E. coli methionine aminopeptidase in complex with NleP, 1: 2, di-metalated
1YVM	;	1.6	;	E. coli Methionine Aminopeptidase in complex with thiabendazole
2Q94	;	1.63	;	E. coli methionine aminopeptidase Mn-form with inhibitor A04
2Q95	;	1.7	;	E. coli methionine aminopeptidase Mn-form with inhibitor A05
2Q96	;	1.6	;	E. coli methionine aminopeptidase Mn-form with inhibitor A18
2Q93	;	1.6	;	E. coli methionine aminopeptidase Mn-form with inhibitor B21
2Q92	;	1.9	;	E. coli methionine aminopeptidase Mn-form with inhibitor B23
2P99	;	1.8	;	E. coli methionine aminopeptidase monometalated with inhibitor YE6
2P98	;	1.7	;	E. coli methionine aminopeptidase monometalated with inhibitor YE7
2GU7	;	2.0	;	E. coli methionine aminopeptidase unliganded, 1:0.5
3D27	;	2.2	;	E. coli methionine aminopeptidase with Fe inhibitor W29
1C21	;	1.8	;	E. COLI METHIONINE AMINOPEPTIDASE: METHIONINE COMPLEX
1C24	;	1.7	;	E. COLI METHIONINE AMINOPEPTIDASE: METHIONINE PHOSPHINATE COMPLEX
1C23	;	2.0	;	E. COLI METHIONINE AMINOPEPTIDASE: METHIONINE PHOSPHONATE COMPLEX
1C22	;	1.75	;	E. COLI METHIONINE AMINOPEPTIDASE: TRIFLUOROMETHIONINE COMPLEX
1C27	;	1.95	;	E. COLI METHIONINE AMINOPEPTIDASE:NORLEUCINE PHOSPHONATE COMPLEX
1ZP3	;	1.85	;	E. coli Methylenetetrahydrofolate Reductase (oxidized)
6GRI	;	2.7	;	E. coli Microcin synthetase McbBCD complex
6GOS	;	2.1	;	E. coli Microcin synthetase McbBCD complex with pro-MccB17 bound
6GRG	;	2.35	;	E. coli Microcin synthetase McbBCD complex with pro-MccB17, ADP and phosphate bound
6GRH	;	1.85	;	E. coli Microcin synthetase McbBCD complex with truncated pro-MccB17 bound
5NJC	;	1.35	;	E. coli Microcin-processing metalloprotease TldD/E (TldD E263A mutant) with hexapeptide bound
5NJF	;	1.42	;	E. coli Microcin-processing metalloprotease TldD/E (TldD H262A mutant) with pentapeptide bound
5NJB	;	1.5	;	E. coli Microcin-processing metalloprotease TldD/E with actinonin bound
5NJA	;	1.4	;	E. coli Microcin-processing metalloprotease TldD/E with angiotensin analogue bound
5NJ9	;	1.25	;	E. coli Microcin-processing metalloprotease TldD/E with DRVY angiotensin fragment bound
5NJ5	;	1.9	;	E. coli Microcin-processing metalloprotease TldD/E with phosphate bound
7MEW	;	3.9	;	E. coli MsbA in complex with G247
6BPP	;	2.92	;	E. coli MsbA in complex with LPS and inhibitor G092
7SEL	;	2.978	;	E. coli MsbA in complex with LPS and inhibitor G7090 (compound 3)
6BPL	;	2.908	;	E. coli MsbA in complex with LPS and inhibitor G907
3SWD	;	2.5	;	E. coli MurA in complex with UDP-N-acetylmuramic acid and covalent adduct of PEP with Cys115
6UU8	;	4.4	;	E. coli mutant sigma-S transcription initiation complex with a 7-nt RNA (""Fresh"" mutant crystal soaked with GTP, UTP, and CTP for 30 minutes)
6UU9	;	5.4	;	E. coli mutant sigma-S transcription initiation complex with an 8-nt RNA (""Fresh"" mutant crystal soaked with GTP, UTP, CTP, and ddATP for 30 minutes)
7AWT	;	2.73	;	E. coli NADH quinone oxidoreductase hydrophilic arm
7Q0O	;	0.96	;	E. coli NfsA
7Z0W	;	2.06	;	E. coli NfsA bound to NADP+
7NNX	;	1.7	;	E. coli NfsA with 1,4-benzoquinone
7NIY	;	1.03	;	E. coli NfsA with FMN
8AJX	;	1.25	;	E. coli NfsA with Fumarate
7NMP	;	1.25	;	E. coli NfsA with hydroquinone
7NB9	;	1.09	;	E. coli NfsA with nitrofurantoin
8C5P	;	1.69	;	E. coli NfsB mutant N71S T41L with acetate
8CCV	;	2.2	;	E. coli NfsB mutant T41LN71S with nicotinate
8OG3	;	2.09	;	E. coli NfsB triple mutant T41L/N71S/F124T bound to citrate
8C5F	;	1.6	;	E. coli NfsB-T41Q/N71S/F124T mutant bound to acetate
8C5E	;	1.65	;	E. coli NfsB-T41Q/N71S/F124T mutant bound to nicotinic acid
8CJ0	;	1.99	;	E. coli NfsB-T41Q/N71S/F124T/M127V mutant bound to nicotinate
1KMJ	;	2.0	;	E. coli NifS/CsdB protein at 2.0A with the cysteine persulfide intermediate (residue CSS).
1KMK	;	2.2	;	E. coli NifS/CsdB protein at 2.20A with the cysteine perselenide intermediate (residue CSZ).
3OD2	;	2.6	;	E. coli NikR soaked with excess nickel ions
3L1T	;	2.3	;	E. coli NrfA sulfite ocmplex
3ZBE	;		;	E. coli O157 ParE2-associated antitoxin 2 (PaaA2)
2J7L	;	2.6	;	E. coli P Pilus chaperone PapD in complex with a pilus biogenesis inhibitor, pilicide 2c
2XG4	;	2.4	;	E. coli P pilus chaperone-subunit complex PapD-PapH bound to pilus biogenesis inhibitor, pilicide 2c
2XG5	;	2.0	;	E. coli P pilus chaperone-subunit complex PapD-PapH bound to pilus biogenesis inhibitor, pilicide 5d
5HL9	;	2.7	;	E. coli PBP1b in complex with acyl-ampicillin and moenomycin
5HLB	;	2.42	;	E. coli PBP1b in complex with acyl-aztreonam and moenomycin
5HLD	;	2.31	;	E. coli PBP1b in complex with acyl-CENTA and moenomycin
5HLA	;	2.36	;	E. coli PBP1b in complex with acyl-cephalexin and moenomycin
5FGZ	;	2.85	;	E. coli PBP1b in complex with FPI-1465
6IY7	;	10.5	;	E. coli peptide deformylase crystal structure fitted into the cryo-EM density map of E. coli 70S ribosome in complex with peptide deformylase
7N3J	;	2.0	;	E. coli peptidyl-prolyl cis-trans isomerase, mutant Phe27CF3-Tyr/Phe98CF3-Tyr
7RFD	;	1.35	;	E. coli peptidyl-prolyl cis-trans isomerase, mutant Phe4Ala Phe27CF3-Phe/Phe98CF3-Phe
1K2V	;	1.97	;	E. COLI PERIPLASMIC PROTEIN FHUD COMPLEXED WITH DESFERAL
6BY1	;	3.94	;	E. coli pH03H9 complex
2PXZ	;	2.23	;	E. coli phosphoenolpyruvate carboxykinase (PEPCK) complexed with ATP, Mg2+, Mn2+, carbon dioxide and oxaloacetate
6AT4	;	1.332	;	E. coli phosphoenolpyruvate carboxykinase bound to thiosulfate
6AT2	;	1.444	;	E. coli phosphoenolpyruvate carboxykinase G209N mutant bound to thiosulfate
6ASM	;	1.55	;	E. coli phosphoenolpyruvate carboxykinase G209S K212C mutant bound to thiosulfate
6ASI	;	1.789	;	E. coli phosphoenolpyruvate carboxykinase G209S mutant bound to methanesulfonate
6ASN	;	1.549	;	E. coli phosphoenolpyruvate carboxykinase K212I F216V mutant bound to methanesulfonate
6V2L	;	1.7	;	E. coli Phosphoenolpyruvate carboxykinase S250A
6AT3	;	1.455	;	E. coli phosphoenolpyruvate carboxykinase Y207F mutant bound to thiosulfate and oxaloacetate
8Q72	;	4.17	;	E. coli plasmid-borne JetABCD(E248A) core in a cleavage-competent state
7OE0	;	2.69	;	E. coli pre-30S delta rbfA ribosomal subunit class F
6DCR	;	1.978	;	E. coli PriA helicase winged helix domain deletion protein
1TXY	;	2.0	;	E. coli PriB
6ASV	;	2.21	;	E. coli PRPP Synthetase
2NSL	;	2.0	;	E. coli PurE H45N mutant complexed with CAIR
2NSJ	;	2.31	;	E. coli PurE H45Q mutant complexed with CAIR
2NSH	;	1.8	;	E. coli PurE H45Q mutant complexed with nitro-AIR
1L8A	;	1.85	;	E. COLI PYRUVATE DEHYDROGENASE
2IEA	;	1.85	;	E. coli pyruvate dehydrogenase
3LPL	;	2.1	;	E. coli pyruvate dehydrogenase complex E1 component E571A mutant
3LQ4	;	1.98	;	E. coli pyruvate dehydrogenase complex E1 E235A mutant with high TDP concentration
3LQ2	;	1.96	;	E. coli pyruvate dehydrogenase complex E1 E235A mutant with low TDP concentration
2G67	;	2.32	;	E. Coli Pyruvate Dehydrogenase E1 Component (Apoenzyme)
2QTC	;	1.77	;	E. coli Pyruvate dehydrogenase E1 component E401K mutant with phosphonolactylthiamin diphosphate
2QTA	;	1.85	;	E. coli Pyruvate dehydrogenase E1 component E401K mutant with thiamin diphosphate
2G28	;	1.85	;	E. Coli Pyruvate Dehydrogenase H407A variant Phosphonolactylthiamin Diphosphate Complex
1RP7	;	2.09	;	E. COLI PYRUVATE DEHYDROGENASE INHIBITOR COMPLEX
2G25	;	2.1	;	E. Coli Pyruvate Dehydrogenase Phosphonolactylthiamin Diphosphate Complex
8EDQ	;	2.88	;	E. coli pyruvate kinase (PykF) I264F
8EDR	;	2.64	;	E. coli pyruvate kinase (PykF) P70Q
8EDT	;	2.09	;	E. coli Pyruvate kinase (PykF) T462I
5VPN	;	4.2232	;	E. coli Quinol fumarate reductase FrdA E245Q mutation
2B76	;	3.3	;	E. coli Quinol fumarate reductase FrdA E49Q mutation
3CIR	;	3.65	;	E. coli Quinol fumarate reductase FrdA T234A mutation
1KF6	;	2.7	;	E. coli Quinol-Fumarate Reductase with Bound Inhibitor HQNO
1XMV	;	1.9	;	E. coli RecA in complex with MgADP
1XMS	;	2.1	;	E. coli RecA in complex with MnAMP-PNP
3Q8D	;	2.3	;	E. coli RecO complex with SSB C-terminus
1WUD	;	2.2	;	E. coli RecQ HRDC domain
6BOK	;	3.55	;	E. coli release factor 1 (containing deletion 302-304) bound to the 70S ribosome
5J4D	;	3.1	;	E. coli release factor 1 bound to the 70S ribosome in response to a pseudouridylated stop codon
1UAA	;	3.0	;	E. COLI REP HELICASE/DNA COMPLEX
1RKD	;	1.84	;	E. COLI RIBOKINASE COMPLEXED WITH RIBOSE AND ADP
1RK2	;	2.25	;	E. COLI RIBOKINASE COMPLEXED WITH RIBOSE AND ADP, SOLVED IN SPACE GROUP P212121
1RKS	;	2.4	;	E. COLI RIBOKINASE IN COMPLEX WITH D-RIBOSE
1KVA	;	1.8	;	E. COLI RIBONUCLEASE HI D134A MUTANT
1KVB	;	1.9	;	E. COLI RIBONUCLEASE HI D134H MUTANT
1KVC	;	1.9	;	E. COLI RIBONUCLEASE HI D134N MUTANT
7VSE	;	2.08	;	E. coli Ribonuclease HI in complex one Zn2+ (His124 N-epsilon binding)
7VSC	;	1.83	;	E. coli Ribonuclease HI in complex with one Mg2+ (1)
7VSD	;	1.7	;	E. coli Ribonuclease HI in complex with one Mg2+ (2)
7VSB	;	1.84	;	E. coli Ribonuclease HI in complex with one Zn2+ (His124 N-delta binding)
7VSA	;	1.76	;	E. coli Ribonuclease HI in complex with two Mg2+
3N4M	;	2.987	;	E. coli RNA polymerase alpha subunit C-terminal domain in complex with CAP and DNA
5CIZ	;	5.0098	;	E. coli RNA polymerase alpha subunit CTD in complex with CAP and DNA: A(5)-tract binding site for alpha CTD
5TBZ	;	7.0	;	E. Coli RNA Polymerase complexed with NusG
8PBL	;	2.87	;	E. coli RNA polymerase elongation complex stalled at thymine dimer lesion
6WMU	;	3.18	;	E. coli RNAPs70-SspA-gadA DNA complex
2PQY	;	2.3	;	E. coli RNase 1 (in vitro refolded with DsbA only)
2PQX	;	1.42	;	E. coli RNase 1 (in vivo folded)
7SP3	;	1.6	;	E. coli RppH bound to Ap4A
4S2V	;	1.7	;	E. coli RppH structure, KI soak
7LNN	;	2.5	;	E. coli S-adenosyl methionine transferase co-crystallized with guanosine-5'-imidotriphosphate
1JKJ	;	2.35	;	E. coli SCS
6UU2	;	4.404	;	E. coli sigma-S transcription initiation complex with 3-nt RNA (""Old"" crystal soaked with GTP and ATP for 30 minutes)
6UU4	;	4.305	;	E. coli sigma-S transcription initiation complex with a 3-nt RNA (""old"" crystal soaked with GTP and dinucleotide GpA for 30 minutes)
6UUC	;	4.096	;	E. coli sigma-S transcription initiation complex with a 3-nt RNA and a mismatching ATP (""Fresh"" crystal soaked with ATP for 2 hours)
6UU0	;	3.9	;	E. coli sigma-S transcription initiation complex with a 3-nt RNA and a mismatching GTP (""Fresh"" crystal soaked with GTP for 1 hour)
6UTW	;	3.854	;	E. coli sigma-S transcription initiation complex with a 4-nt RNA (""Fresh"" crystal)
6UU1	;	4.097	;	E. coli sigma-S transcription initiation complex with a 4-nt RNA and a CTP (""Fresh"" crystal soaked with CTP, GTP, and ddTTP for 30 minutes)
6UU3	;	4.002	;	E. coli sigma-S transcription initiation complex with a 4-nt RNA and a CTP (""Old"" crystal soaked with GTP, ATP, CTP, and ddTTP for 30 minutes)
6UU6	;	4.201	;	E. coli sigma-S transcription initiation complex with a 4-nt RNA and a UTP (""Old"" crystal soaked with UTP, ddCTP, and dinucleotide ApG for 30 minutes)
6UTZ	;	3.803	;	E. coli sigma-S transcription initiation complex with a 6-nt RNA (""Fresh"" crystal soaked with CTP and UTP for 30 minutes)
6UTV	;	3.45	;	E. coli sigma-S transcription initiation complex with a 6-nt RNA (""Fresh"" crystal soaked with CTP, UTP, GTP, and ddATP for 150 seconds)
6UU5	;	5.403	;	E. coli sigma-S transcription initiation complex with a 6-nt RNA (""Old"" crystal soaked with GTP, UTP, CTP, and dinucleotide GpA for 30 minutes)
6UU7	;	4.4	;	E. coli sigma-S transcription initiation complex with a 6-nt RNA and an NTP (""Old"" crystal soaked with UTP, CTP, ddGTP, and dinucleotide ApG for 30 minutes)
6UUA	;	4.002	;	E. coli sigma-S transcription initiation complex with a mismatching CTP (""Fresh"" crystal soaked with CTP for 2 hours)
6UTY	;	4.15	;	E. coli sigma-S transcription initiation complex with a mismatching CTP (""Old"" crystal soaked with CTP for 30 minutes)
6UUB	;	3.955	;	E. coli sigma-S transcription initiation complex with a mismatching UTP (""Fresh"" crystal soaked with UTP for 2 hours)
6UTX	;	4.05	;	E. coli sigma-S transcription initiation complex with an empty bubble (""Old"" crystal)
8SUW	;	3.15	;	E. coli SIR2-HerA complex (dodecamer SIR2 bound 4 protomers of HerA)
8SUB	;	2.89	;	E. coli SIR2-HerA complex (dodecamer SIR2 pentamer HerA)
8SU9	;	2.83	;	E. coli SIR2-HerA complex (hexamer HerA bound with dodecamer Sir2)
8UAF	;	3.18	;	E. coli Sir2_HerA complex (12:6) bound with NAD+
8UAE	;	3.25	;	E. coli Sir2_HerA complex (12:6) with ATPgamaS
4PNV	;	1.86	;	E. coli sliding clamp apo-crystal in P21 space group with larger cell dimensions
4PNU	;	1.9	;	E. coli sliding clamp in complex with (R)-6-bromo-9-(2-((R)-1-carboxy-2-phenylethylamino)-2-oxoethyl)-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid
4PNW	;	2.0	;	E. coli sliding clamp in complex with (R)-6-bromo-9-(2-((S)-1-carboxy-2-phenylethylamino)-2-oxoethyl)-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid
4OVH	;	2.25	;	E. coli sliding clamp in complex with (R)-6-bromo-9-(2-(carboxymethylamino)-2-oxoethyl)-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid
4N9A	;	1.9	;	E. coli sliding clamp in complex with (R)-6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxylic acid
4OVF	;	2.05	;	E. coli sliding clamp in complex with (R)-6-chloro-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid
4OVG	;	1.9	;	E. coli sliding clamp in complex with (R)-9-(2-amino-2-oxoethyl)-6-chloro-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid
4MJP	;	1.855	;	E. coli sliding clamp in complex with (R)-Vedaprofen
4K3K	;	1.85	;	E. Coli sliding clamp in complex with (S)-2-(4-methylpentanamido)-3-phenylpropanoic acid
4MJR	;	1.62	;	E. coli sliding clamp in complex with (S)-Carprofen
4N94	;	1.73	;	E. coli sliding clamp in complex with 3,4-difluorobenzamide
4N98	;	1.7	;	E. coli sliding clamp in complex with 4'-fluorobiphenyl-4-carboxylic acid
4N95	;	1.8	;	E. coli sliding clamp in complex with 5-chloroindoline-2,3-dione
4N97	;	1.97	;	E. coli sliding clamp in complex with 5-nitroindole
4N99	;	2.3	;	E. coli sliding clamp in complex with 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-7-carboxylic acid
4N96	;	1.7	;	E. coli sliding clamp in complex with 6-nitroindazole
4K3L	;	1.5	;	E. coli sliding clamp in complex with AcLF dipeptide
4K3O	;	2.0	;	E. coli sliding clamp in complex with AcQADLF
4K3P	;	2.15	;	E. coli sliding clamp in complex with AcQLALF
4K3Q	;	1.85	;	E. coli sliding clamp in complex with AcQLDAF
4K3R	;	1.86	;	E. coli sliding clamp in complex with AcQLDLA
4MJQ	;	1.73	;	E. coli sliding clamp in complex with Bromfenac
4K3S	;	1.75	;	E. coli sliding clamp in P1 crystal space group
2WDV	;	3.2	;	E. coli succinate:quinone oxidoreductase (SQR) with an empty quinone- binding pocket
2WDQ	;	2.4	;	E. coli succinate:quinone oxidoreductase (SQR) with carboxin bound
2WDR	;	3.2	;	E. coli succinate:quinone oxidoreductase (SQR) with pentachlorophenol bound
6FH8	;	1.64	;	E. coli surface display of streptavidin for directed evolution of an allylic deallocase
6LFB	;	1.99	;	E. coli Thioesterase I mutant DG
6LFC	;	2.7	;	E. coli Thioesterase I mutant DG
1U8U	;	2.08	;	E. coli Thioesterase I/Protease I/Lysophospholiase L1 in complexed with octanoic acid
1J00	;	2.0	;	E. coli Thioesterase I/Protease I/Lysophospholipase L1 in complexed with diethyl phosphono moiety
4HUA	;	1.1	;	E. coli thioredoxin variant with (4R)-FluoroPro76 as single proline residue
4HU9	;	1.55	;	E. coli thioredoxin variant with (4S)-FluoroPro76 as single proline residue
4HU7	;	1.4	;	E. coli thioredoxin variant with Pro76 as single proline residue
1TJS	;	2.2	;	E. COLI THYMIDYLATE SYNTHASE
2FTQ	;	1.81	;	E. coli thymidylate synthase at 1.8 A resolution
1JUT	;	2.7	;	E. coli Thymidylate Synthase Bound to dUMP and LY338529, A Pyrrolo(2,3-d)pyrimidine-based Antifolate
3BGX	;	1.93	;	E. coli Thymidylate Synthase C146S mutant complexed with dTMP and MTF
3B9H	;	2.49	;	E. coli thymidylate synthase complexed with 5-NITRO-2'-DEOXY URIDINE
1AOB	;	2.1	;	E. COLI THYMIDYLATE SYNTHASE COMPLEXED WITH DDURD
1BID	;	2.2	;	E. COLI THYMIDYLATE SYNTHASE COMPLEXED WITH DUMP
1BDU	;	2.1	;	E. COLI THYMIDYLATE SYNTHASE COMPLEXED WITH DURD
1JTU	;	2.2	;	E. coli Thymidylate Synthase in a Complex with dUMP and LY338913, A Polyglutamylated Pyrrolo(2,3-d)pyrimidine-based Antifolate
1SYN	;	2.0	;	E. COLI THYMIDYLATE SYNTHASE IN COMPLEX WITH BW1843U89 AND 2'-DEOXYURIDINE 5'-MONOPHOSPHATE (DUMP)
1AN5	;	2.6	;	E. COLI THYMIDYLATE SYNTHASE IN COMPLEX WITH CB3717
1DDU	;	2.1	;	E. COLI THYMIDYLATE SYNTHASE IN COMPLEX WITH CB3717 AND 2',5'-DIDEOXYURIDINE (DDURD)
1TDU	;	2.1	;	E. COLI THYMIDYLATE SYNTHASE IN COMPLEX WITH CB3717 AND 2'-DEOXYURIDINE (DURD)
1AXW	;	1.7	;	E. COLI THYMIDYLATE SYNTHASE IN COMPLEX WITH METHOTREXATE (MTX) AND 2'-DEOXYURIDINE 5'-MONOPHOSPHATE (DUMP)
1TRG	;	1.9	;	E. COLI THYMIDYLATE SYNTHASE IN SYMMETRIC COMPLEX WITH CB3717 AND 2'-DEOXYURIDINE 5'-MONOPHOSPHATE (DUMP)
1KCE	;	2.0	;	E. COLI THYMIDYLATE SYNTHASE MUTANT E58Q IN COMPLEX WITH CB3717 AND 2'-DEOXYURIDINE 5'-MONOPHOSPHATE (DUMP)
1ZPR	;	2.5	;	E. COLI THYMIDYLATE SYNTHASE MUTANT E58Q IN COMPLEX WITH CB3717 AND 2'-DEOXYURIDINE 5'-MONOPHOSPHATE (DUMP)
6CDZ	;	2.4	;	E. coli thymidylate synthase mutant I264Am
1BQ2	;	2.2	;	E. COLI THYMIDYLATE SYNTHASE MUTANT N177A
1BQ1	;	2.5	;	E. COLI THYMIDYLATE SYNTHASE MUTANT N177A IN COMPLEX WITH CB3717 AND 2'-DEOXYURIDINE 5'-MONOPHOSPHATE (DUMP)
3BFI	;	2.2	;	E. Coli Thymidylate Synthase Y209M mutant complexed with 5-nitro-dUMP
4GEV	;	1.3	;	E. coli thymidylate synthase Y209W variant in complex with substrate and a cofactor analog
2FTN	;	1.6	;	E. coli thymidylate synthase Y94F mutant
4YLO	;	6.0	;	E. coli Transcription Initiation Complex - 16-bp spacer and 4-nt RNA
4YLP	;	5.5	;	E. coli Transcription Initiation Complex - 16-bp spacer and 5-nt RNA
4YLN	;	5.5	;	E. coli Transcription Initiation Complex - 17-bp spacer and 4-nt RNA
4XK4	;	2.27	;	E. coli transcriptional regulator RUTR with dihydrouracil
3SSX	;	1.5801	;	E. coli trp aporeporessor L75F mutant
3SSW	;	1.6693	;	E. coli trp aporepressor
2OZ9	;	1.65	;	E. coli TRP holorepressor, orthorhombic crystal form
1ZT9	;	2.0	;	E. coli trp repressor, tetragonal crystal form
8I1Z	;	1.8	;	E. coli tryptophanyl-tRNA synthetase bound with a chemical fragment
8I27	;	1.95	;	E. coli tryptophanyl-tRNA synthetase bound with a chemical fragment at the dimerization interface
8I2A	;	2.35	;	E. coli tryptophanyl-tRNA synthetase bound with a chemical fragment at the dimerization interface
8I2C	;	2.07	;	E. coli tryptophanyl-tRNA synthetase bound with a chemical fragment at the dimerization interface
8I2J	;	2.65	;	E. coli tryptophanyl-tRNA synthetase bound with a chemical fragment at the dimerization interface
8I2L	;	1.95	;	E. coli tryptophanyl-tRNA synthetase bound with a chemical fragment at the dimerization interface
1JTQ	;	2.5	;	E. coli TS Complex with dUMP and the Pyrrolo(2,3-d)pyrimidine-based Antifolate LY341770
3BHR	;	1.9	;	E. coli TS complexed with 5-NO2dUMP and tetrahydrofolate at 1.9 A resolution (space group 152)
2A9W	;	1.65	;	E. coli TS complexed with dUMP and inhibitor GA9
7JX1	;	1.82	;	E. coli TSase complex with a bi-substrate reaction intermediate analog
7JXF	;	1.5	;	E. coli TSase complex with a bi-substrate reaction intermediate diastereomer analog
2E99	;	2.0	;	E. coli undecaprenyl pyrophosphate synthase in complex with BPH-608
2E9A	;	2.1	;	E. coli undecaprenyl pyrophosphate synthase in complex with BPH-628
2E98	;	1.9	;	E. coli undecaprenyl pyrophosphate synthase in complex with BPH-629
2E9C	;	2.05	;	E. coli undecaprenyl pyrophosphate synthase in complex with BPH-675
2E9D	;	2.5	;	E. coli undecaprenyl pyrophosphate synthase in complex with BPH-676
1UEH	;	1.73	;	E. coli undecaprenyl pyrophosphate synthase in complex with Triton X-100, magnesium and sulfate
1RXS	;	2.8	;	E. coli uridine phosphorylase: 2'-deoxyuridine phosphate complex
1RXC	;	2.35	;	E. COLI uridine phosphorylase: 5-fluorouracil ribose-1-phosphate complex
1RXU	;	3.1	;	E. coli uridine phosphorylase: thymidine phosphate complex
1RXY	;	1.7	;	E. coli uridine phosphorylase: type-B native
8BFN	;	3.52	;	E. coli Wadjet JetABC dimer of dimers
8AS8	;	3.0	;	E. coli Wadjet JetABC monomer
4WQ4	;	2.33	;	E. coli YgjD(E12A)-YeaZ heterodimer in complex with ATP
8GEO	;	2.89	;	E. eligens beta-glucuronidase bound to 3-OH-desloratidine-glucuronide
8GEQ	;	2.75	;	E. eligens beta-glucuronidase bound to ceritinib-glucuronide
8GER	;	2.4	;	E. eligens beta-glucuronidase bound to norquetiapine-glucuronide
8GEN	;	2.94	;	E. eligens beta-glucuronidase bound to UNC10201652-glucuronide
5XVO	;	3.1	;	E. fae Cas1-Cas2/prespacer/target ternary complex revealing DNA sampling and half-integration states
5XVP	;	3.0	;	E. fae Cas1-Cas2/prespacer/target ternary complex revealing the fully integrated states
7P7Q	;	2.4	;	E. faecalis 70S ribosome bound by PoxtA-EQ2, high-resolution combined volume
7P7U	;	3.1	;	E. faecalis 70S ribosome with P-tRNA, state IV
7TB0	;	1.65	;	E. faecium MurAA in complex with fosfomycin and UNAG
8D84	;	2.65	;	E. faecium MurAA in complex with UDP-N-acetylmuramic acid (UNAM) and a covalent adduct of PEP with Cys119
5XVN	;	3.25	;	E. far Cas1-Cas2/prespacer binary complex
3E1F	;	3.0	;	E.Coli (lacZ) beta-galactosidase (H418E) in complex with galactose
3I3B	;	2.2	;	E.coli (lacz) Beta-Galactosidase (M542A) in Complex with D-Galactopyranosyl-1-on
3MV1	;	2.2	;	E.Coli (lacZ) beta-galactosidase (R599A) in complex with Guanidinium
3MUZ	;	1.9	;	E.Coli (lacZ) beta-galactosidase (R599A) in complex with IPTG
3T0D	;	1.93	;	E.coli (lacZ) beta-galactosidase (S796T) in complex with galactonolactone
5NQI	;	0.851	;	E.coli 16S rRNA Sarcin-Ricin Loop containing a 5-hydroxymethylcytosine modification
4Y27	;	0.998	;	E.coli 23S Sarcin-Ricil Loop, modified with a 2-Me on G2661 and a methylphosphonate on A2662
4V5H	;	5.8	;	E.Coli 70s Ribosome Stalled During Translation Of Tnac Leader Peptide.
5VWQ	;	1.8	;	E.coli Aspartate aminotransferase-(1R,3S,4S)-3-amino-4-fluorocyclopentane-1-carboxylic acid (FCP)
5VWR	;	1.72	;	E.coli Aspartate aminotransferase-(1R,3S,4S)-3-amino-4-fluorocyclopentane-1-carboxylic acid (FCP)-alpha-ketoglutarate
7BTK	;	2.7	;	E.coli beta-galactosidase (E537Q) in complex with fluorescent probe KSA01
7BRS	;	2.67	;	E.coli beta-galactosidase (E537Q) in complex with fluorescent probe KSA02
6KUZ	;	2.83	;	E.coli beta-galactosidase (E537Q) in complex with fluorescent probe KSL01
1E58	;	1.25	;	E.coli cofactor-dependent phosphoglycerate mutase
1E59	;	1.3	;	E.coli cofactor-dependent phosphoglycerate mutase complexed with vanadate
4AZ4	;	1.8	;	E.coli deformylase with Co(II) and hydrosulfide
7OI0	;	2.76	;	E.coli delta rbfA pre-30S ribosomal subunit class D
3CW0	;	2.4	;	E.coli DmsD
7TTV	;	1.99	;	E.coli DsbA in complex with 4-phenyl-2-(3-phenylpropyl)thiazole-5-carboxylic acid
6PVY	;	1.74	;	E.coli DsbA in complex with benzofuran compound 26 ([6-(3-methoxyphenoxy)-1-benzofuran-3-yl]acetic acid)
6PVZ	;	1.99	;	E.coli DsbA in complex with benzofuran compound 28 ((6-benzyl-1-benzofuran-3-yl)acetic acid)
8DN0	;	1.57	;	E.coli DsbA in complex with N-(2-fluorophenyl)-5-methylisoxazole-3-carboxamide
6WVF	;	2.9	;	E.coli DsbB C104S with ubiquinone
2QFU	;	1.6	;	E.coli EPSP synthase Pro101Leu liganded with S3P and glyphosate
2QFS	;	1.55	;	E.coli EPSP synthase Pro101Ser liganded with S3P
2QFT	;	1.55	;	E.coli EPSP synthase Pro101Ser liganded with S3P and glyphosate
1W7K	;	2.1	;	E.coli FolC in complex with ADP, without folate substrate
1W78	;	1.82	;	E.coli FolC in complex with DHPP and ADP
1DB3	;	2.3	;	E.COLI GDP-MANNOSE 4,6-DEHYDRATASE
4AA7	;	2.0	;	E.coli GlmU in complex with an antibacterial inhibitor
5F5J	;	2.4	;	E.coli GlpG Y205F mutant complexed with aldehyde inhibitor in DMPC/CHAPSO bicelle
5F5K	;	2.4	;	E.Coli GlpG Y205F mutant complexed with aldehyde inhibitor in DMPC/CHAPSO bicelle
4AMV	;	2.05	;	E.COLI GLUCOSAMINE-6P SYNTHASE IN COMPLEX WITH FRUCTOSE-6P
8JZJ	;	1.99	;	E.coli Glyceraldehyde-3-phosphate dehydrogenase structure under cryoprotect condition of ammonium sulfate
7Z9M	;	3.3	;	E.coli gyrase holocomplex with 217 bp DNA and Albi-1 (site AA)
7Z9K	;	3.25	;	E.coli gyrase holocomplex with 217 bp DNA and Albi-1 (site TG)
7Z9G	;	3.25	;	E.coli gyrase holocomplex with 217 bp DNA and Albi-2
7Z9C	;	3.06	;	E.coli gyrase holocomplex with 217 bp DNA and albicidin
7P2X	;	1.6	;	E.coli GyrB24 with inhibitor KOB20 (EBL2583)
7P2M	;	1.16	;	E.coli GyrB24 with inhibitor LMD43 (EBL2560)
7P2W	;	1.65	;	E.coli GyrB24 with inhibitor LMD92 (EBL2682)
7P2N	;	1.16	;	E.coli GyrB24 with inhibitor LSJ38 (EBL2684)
1QOY	;	2.0	;	E.coli Hemolysin E (HlyE, ClyA, SheA)
4QVD	;	1.972	;	E.coli Hfq in complex with RNA Ads
4QVC	;	1.99	;	E.coli Hfq in complex with RNA Aus
1PVF	;	1.78	;	E.coli IPP isomerase in complex with diphosphate
1S98	;	2.3	;	E.coli IscA crystal structure to 2.3 A
2BYY	;	2.2	;	E.coli KAS I H298E Mutation
6P9P	;	2.0	;	E.coli LpxA in complex with Compound 1
6P9Q	;	1.7	;	E.coli LpxA in complex with UDP-3-O-(R-3-hydroxymyristoyl)-GlcNAc and Compound 2
6P9R	;	1.75	;	E.coli LpxA in complex with UDP-3-O-(R-3-hydroxymyristoyl)-GlcNAc and Compound 6
6P9S	;	1.7	;	E.coli LpxA in complex with UDP-3-O-(R-3-hydroxymyristoyl)-GlcNAc and Compound 7
6P9T	;	1.75	;	E.coli LpxA in complex with UDP-3-O-(R-3-hydroxymyristoyl)-GlcNAc and Compound 8
6P83	;	1.7	;	E.coli LpxD in complex with compound 1o
6P84	;	1.7	;	E.coli LpxD in complex with compound 2o
6P85	;	1.9	;	E.coli LpxD in complex with compound 3
6P86	;	1.8	;	E.coli LpxD in complex with compound 4.1
6P87	;	1.9	;	E.coli LpxD in complex with compound 5
6P88	;	1.7	;	E.coli LpxD in complex with compound 6
6P89	;	1.4	;	E.coli LpxD in complex with compound 7
6P8A	;	1.8	;	E.coli LpxD in complex with compound 8.1
6P8B	;	2.0	;	E.coli LpxD in complex with peptide FITC-RJPXD33
6KA1	;	1.543	;	E.coli Malate dehydrogenase
5CKE	;	2.311	;	E.coli MazF E24A form IIa
2MAT	;	1.9	;	E.COLI METHIONINE AMINOPEPTIDASE AT 1.9 ANGSTROM RESOLUTION
4MAT	;	2.0	;	E.COLI METHIONINE AMINOPEPTIDASE HIS79ALA MUTANT
3MAT	;	2.0	;	E.COLI METHIONINE AMINOPEPTIDASE TRANSITION-STATE INHIBITOR COMPLEX
1NG9	;	2.6	;	E.coli MutS R697A: an ATPase-asymmetry mutant
1WXF	;	2.3	;	E.coli NAD Synthetase
1WXE	;	1.9	;	E.coli NAD Synthetase, AMP
1WXI	;	1.7	;	E.coli NAD Synthetase, AMP.PP
1WXG	;	1.9	;	E.coli NAD Synthetase, DND
1WXH	;	1.9	;	E.coli NAD Synthetase, NAD
2J4U	;	2.99	;	E.coli OmpC - camel Lactoferrin complex
8OFE	;	1.4	;	E.coli Peptide Deformylase with bound inhibitor
7XMU	;	2.3	;	E.coli phosphoribosylpyrophosphate (PRPP) synthetase type A filament bound with ADP, Pi and R5P
7XMV	;	2.6	;	E.coli phosphoribosylpyrophosphate (PRPP) synthetase type A(AMP/ADP) filament bound with ADP, AMP and R5P
7XN3	;	2.9	;	E.coli phosphoribosylpyrophosphate (PRPP) synthetase type B filament bound with Pi
2AI8	;	1.7	;	E.coli Polypeptide Deformylase complexed with SB-485343
1EQN	;	2.9	;	E.COLI PRIMASE CATALYTIC CORE
4NTN	;	1.99	;	E.coli QueD, SeMet protein, 2A resolution
2PKX	;	2.54	;	E.coli response regulator PhoP receiver domain
6DNC	;	3.7	;	E.coli RF1 bound to E.coli 70S ribosome in response to UAU sense A-site codon
7M8E	;	3.4	;	E.coli RNAP-RapA elongation complex
2Z70	;	1.7	;	E.coli RNase 1 in complex with d(CGCGATCGCG)
7UO0	;	3.4	;	E.coli RNaseP Holoenzyme with Mg2+
7UO1	;	3.2	;	E.coli RNaseP Holoenzyme with Mg2+
7UO2	;	3.1	;	E.coli RNaseP Holoenzyme with Mg2+
7UO5	;	3.1	;	E.coli RNaseP Holoenzyme with Mg2+
1C7Y	;	3.1	;	E.COLI RUVA-HOLLIDAY JUNCTION COMPLEX
6FI7	;		;	E.coli Sigma factor S (RpoS) Region 4
4K3M	;	1.85	;	E.coli sliding clamp in complex with AcALDLF peptide
1IVN	;	1.9	;	E.coli Thioesterase I/Protease I/Lysophospholiase L1
3BHL	;	1.4	;	E.coli thymidylate synthase complexes with 5-NO2dUMP and tetrahydrofolate at 1.4 A resolution
6RJC	;	1.05	;	E.coli transketolase apoenzyme
8WA7	;	1.63	;	E.coli transketolase soaked with donor ketose D-fructose
6YE6	;	1.56	;	E.coli's Putrescine receptor PotF complexed with Agmatine
6YE7	;	1.6	;	E.coli's Putrescine receptor PotF complexed with Cadaverine
6YE0	;	1.63	;	E.coli's Putrescine receptor PotF complexed with Putrescine
6YE8	;	1.5	;	E.coli's Putrescine receptor PotF complexed with Spermidine
6YEC	;	2.09	;	E.coli's Putrescine receptor PotF complexed with Spermine
6YEB	;	1.97	;	E.coli's Putrescine receptor PotF in its closed apo state
6YED	;	2.18	;	E.coli's Putrescine receptor PotF in its open apo state
7OYY	;	1.36	;	E.coli's putrescine receptor variant PotF/D (4JDF) with mutation S247D in complex with spermidine
7OYV	;	1.9	;	E.coli's putrescine receptor variant PotF/D (4JDF) with mutations E39D F88A S247D in complex with spermidine
7OYT	;	1.6	;	E.coli's putrescine receptor variant PotF/D (4JDF) with mutations E39D F88L in complex with spermidine
7OYW	;	1.28	;	E.coli's putrescine receptor variant PotF/D (4JDF) with mutations E39D F88L S247D in complex with spermidine
7OYU	;	1.95	;	E.coli's putrescine receptor variant PotF/D (4JDF) with mutations E39D Y87S F88Y in complex with spermidine
7OYX	;	1.37	;	E.coli's putrescine receptor variant PotF/D (4JDF) with mutations E39D Y87S F88Y S247D in complex with spermidine
7OYS	;	1.57	;	E.coli's putrescine receptor variant PotF/D (4JDF) with mutations E39D Y87S in complex with spermidine
7OYZ	;	1.49	;	E.coli's putrescine receptor variant PotF/D in complex with spermidine
4I42	;	1.848	;	E.coli. 1,4-dihydroxy-2-naphthoyl coenzyme A synthase (ecMenB) in complex with 1-hydroxy-2-naphthoyl-CoA
3BCX	;	2.4	;	E1 Dehydrase
3BB8	;	2.35	;	E1 Dehydrase H220K Mutant
6H77	;	2.1	;	E1 enzyme for ubiquitin like protein activation in complex with UBL
6H78	;	2.7	;	E1 enzyme for ubiquitin like protein activation.
4H1W	;	3.1	;	E1 structure of the (SR) Ca2+-ATPase in complex with Sarcolipin
5CBE	;	2.4	;	E10 in complex with CXCL13
1QUG	;	1.9	;	E108V MUTANT OF T4 LYSOZYME
2QQC	;	2.0	;	E109Q mutant of Pyruvoyl-dependent Arginine Decarboxylase from Methanococcus jannashii
7R6Y	;	2.25	;	E117K mutant pyruvate kinase from rabbit muscle
5VQN	;	2.002	;	E119D mutant of 2009 H1N1 PA Endonuclease in complex with RO-7
1QT6	;	1.9	;	E11H Mutant of T4 Lysozyme
1QT7	;	1.8	;	E11N Mutant of T4 Lysozyme
3A6J	;	2.0	;	E122Q mutant creatininase complexed with creatine
3A6L	;	2.0	;	E122Q mutant creatininase, Zn-Zn type
7NE4	;	2.717	;	E125A mutant of oligopeptidase B from S. proteomaculans with modified hinge region
4RRL	;	1.965	;	E129A mutant of N-terminal editing domain of threonyl-tRNA synthetase from Aeropyrum pernix with L-Ser3AA
4RRM	;	1.55	;	E129A mutant of N-terminal editing domain of threonyl-tRNA synthetase from Aeropyrum pernix with L-Thr3AA
3VGU	;	2.3	;	E134A mutant nucleoside diphosphate kinase derived from Halomonas sp. 593
3VGV	;	2.5	;	E134A mutant nucleoside diphosphate kinase derived from Halomonas sp. 593
3AMQ	;	1.8	;	E134C-Cellobiose co-crystal of cellulase 12A from thermotoga maritima
3AMN	;	1.47	;	E134C-Cellobiose complex of cellulase 12A from thermotoga maritima
3AMP	;	1.78	;	E134C-Cellotetraose complex of cellulase 12A from thermotoga maritima
2V9X	;	2.2	;	E138D variant of Escherichia coli dCTP deaminase in complex with dUTP
3AWH	;	1.6	;	E13K mutant of FMN-binding protein from Desulfovibrio vulgaris (Miyazaki F)
3A6R	;	1.2	;	E13Q mutant of FMN-binding protein from Desulfovibrio vulgaris (Miyazaki F)
3AMF	;	1.6	;	E13R mutant of FMN-binding protein from Desulfovibrio vulgaris (Miyazaki F)
3A6Q	;	1.4	;	E13T mutant of FMN-binding protein from Desulfovibrio vulgaris (Miyazaki F)
8SG4	;	3.11	;	E1435Q Ycf1 mutant in dephosphorylated state
7M68	;	4.04	;	E1435Q Ycf1 mutant in inward-facing narrow conformation
7M69	;	3.42	;	E1435Q Ycf1 mutant in inward-facing wide conformation
2UY9	;	3.1	;	E162A mutant of Bacillus subtilis Oxalate Decarboxylase OxdC
5KSC	;	2.1	;	E166A/R274N/R276N Toho-1 Beta-lactamase aztreonam acyl-enzyme intermediate
3ESY	;	2.39	;	E16KE61K Flavodoxin from Anabaena
3ESX	;	2.31	;	E16KE61KD126KD150K Flavodoxin from Anabaena
1QQO	;	1.9	;	E175S MUTANT OF BOVINE 70 KILODALTON HEAT SHOCK PROTEIN
7TGP	;	1.4	;	E176T/Y188G variant of the internal UBA Domain of HHR23A
5DAA	;	2.9	;	E177K MUTANT OF D-AMINO ACID AMINOTRANSFERASE COMPLEXED WITH PYRIDOXAMINE-5'-PHOSPHATE
1G2W	;	2.0	;	E177S MUTANT OF THE PYRIDOXAL-5'-PHOSPHATE ENZYME D-AMINO ACID AMINOTRANSFERASE
4X88	;	3.5	;	E178D Selectivity filter mutant of NavMS voltage-gated pore
3K3T	;	1.75	;	E185A mutant of peptidoglycan hydrolase from Sphingomonas sp. A1
4JEY	;	1.55	;	E198A mutant of N-acetylornithine aminotransferase from Salmonella typhimurium
3PRN	;	1.9	;	E1M, A104W MUTANT OF RH. BLASTICA PORIN
1BH3	;	2.19	;	E1M, A116K MUTANT OF RH. BLASTICA PORIN
7PRN	;	2.25	;	E1M, D97A, E99A MUTANT OF RH. BLASTICA PORIN
6PRN	;	2.04	;	E1M, K50A, R52A MUTANT OF RH. BLASTICA PORIN
8PRN	;	2.3	;	E1M, K50A, R52A, D97A, E99A MUTANT OF RH. BLASTICA PORIN
5PRN	;	2.0	;	E1M, Y96W, S119W MUTANT OF RH. BLASTICA PORIN
2LQ7	;		;	E2 binding surface on Uba3 beta-grasp domain undergoes a conformational transition
6ZLO	;	2.9	;	E2 core of the fungal Pyruvate dehydrogenase complex with asymmetric interior PX30 component
1JJH	;	2.5	;	E2 DNA-binding Domain from Bovine Papillomavirus Type 1
1DBD	;		;	E2 DNA-BINDING DOMAIN FROM PAPILLOMAVIRUS BPV-1
7W7W	;	3.2	;	E2 Pi of SERCA2b
7OJX	;	2.4	;	E2 UBE2K covalently linked to donor Ub, acceptor di-Ub, and RING E3 primed for K48-linked Ub chain synthesis
2E2C	;	2.0	;	E2-C, AN UBIQUITIN CONJUGATING ENZYME REQUIRED FOR THE DESTRUCTION OF MITOTIC CYCLINS
2K4D	;		;	E2-c-Cbl recognition is necessary but not sufficient for ubiquitination activity
3FN1	;	2.5	;	E2-RING expansion of the NEDD8 cascade confers specificity to cullin modification.
5JNE	;	2.85	;	E2-SUMO-Siz1 E3-SUMO-PCNA complex
5LJP	;	1.1	;	E20K/I59A/E72K/I92A/D126K/A142V FLAVODOXIN FROM ANABAENA
6SXR	;	1.64	;	E221Q mutant of GH54 a-l-arabinofuranosidase soaked with 4-nitrophenyl a-l-arabinofuranoside
2GDU	;	2.1	;	E232Q mutant of sucrose phosphorylase from BIFIDOBACTERIUM ADOLESCENTIS in complex with sucrose
2JJH	;	2.7	;	E243 mutant of M. tuberculosis Rv3290C
1E5N	;	3.2	;	E246C mutant of P fluorescens subsp. cellulosa xylanase A in complex with xylopentaose
4N8K	;	2.0	;	E249A mutant, RipA structure
4N8L	;	2.817	;	E249D mutant, RipA structure
3ZUG	;	2.05	;	E268D mutant of FAD synthetase from Corynebacterium ammoniagenes
6A8T	;	2.1	;	E269A mutant of highly active EfBSH
2PBO	;	1.85	;	E27Q mutant of EXO-B-(1,3)-Glucanase from Candida Albicans at 1.85 A
1PI3	;	1.2	;	E28Q mutant Benzoylformate Decarboxylase From Pseudomonas Putida
2PC8	;	1.8	;	E292Q mutant of EXO-B-(1,3)-Glucanase from Candida Albicans in complex with two separately bound glucopyranoside units at 1.8 A
3JVZ	;	3.3	;	E2~Ubiquitin-HECT
3JW0	;	3.1	;	E2~Ubiquitin-HECT
5CH3	;	1.71	;	E3 alpha-esterase-7 carboxylesterase
5CH5	;	1.53	;	E3 alpha-esterase-7 carboxylesterase
7OVX	;	1.7	;	E3 RING ligase binding domain
7OW2	;	2.17	;	E3 RING ligase binding domain with peptide
4WHV	;	8.3	;	E3 ubiquitin-protein ligase RNF8 in complex with Ubiquitin-conjugating enzyme E2 N and Polyubiquitin-B
7CMK	;	3.4	;	E30 E-particle in complex with 6C5
7C80	;	3.7	;	E30 F-particle in complex with 4B10
7C81	;	3.1	;	E30 F-particle in complex with 6C5
7C9W	;	3.6	;	E30 F-particle in complex with CD55
7C9V	;	3.3	;	E30 F-particle in complex with FcRn
5FO1	;	2.45	;	E301A mutant of FAD synthetase from Corynebacterium ammoniagenes
1KQ7	;	2.6	;	E315Q Mutant Form of Fumarase C from E.coli
8ANX	;	1.2	;	E329A Mutant Thermogutta terrifontis endoglucanase catalytic domain with C-linker from glycoside hydrolase family 5 (TtEnd5A-CDC-E329A)
4KLA	;	2.6	;	E343D variant of human ferrochelatase
4KLC	;	2.4	;	E343D/F110A Double mutant of human ferrochelatase
4KLR	;	2.18	;	E343Q variant of human ferrochelatase
3OK0	;	1.82	;	E35A Mutant of Hen Egg White Lysozyme (HEWL)
8FY1	;	2.56	;	E3:PROTAC:target ternary complex structure (VCB/753b/BCL-2)
8FY0	;	2.94	;	E3:PROTAC:target ternary complex structure (VCB/753b/BCL-xL)
8FY2	;	2.98	;	E3:PROTAC:target ternary complex structure (VCB/WH244/BCL-2)
4J8Y	;	1.7	;	E3_5 DARPin D77S mutant
4J7W	;	1.6	;	E3_5 DARPin L86A mutant
7WX0	;	1.4	;	E40K variant of Cu/Zn-superoxide dismutase from dog (Canis familiaris)
7WX1	;	1.65	;	E40K/M117L variant of Cu/Zn-superoxide dismutase from dog (Canis familiaris)
7XYL	;	2.099	;	E426Q-glycine-glycylthricin complex
1BYP	;	1.75	;	E43K,D44K DOUBLE MUTANT PLASTOCYANIN FROM SILENE
6B2J	;	2.21	;	E45A mutant of HIV-1 capsid protein (other crystal form)
6B2I	;	2.5	;	E45A mutant of the HIV-1 capsid protein
6B2K	;	2.0	;	E45A/R132T mutant of HIV-1 capsid protein
5IWE	;	1.71	;	E45Q mutant of phenazine biosynthesis protein PhzF in complex with (5R,6R)-6-azaniumyl-5-ethoxycyclohexa-1,3-diene-1-carboxylate
1OTA	;	1.1	;	E46Q MUTANT OF PHOTOACTIVE YELLOW PROTEIN, P63 AT 295K
1OTE	;	1.4	;	E46Q MUTANT OF PHOTOACTIVE YELLOW PROTEIN, P65 AT 110K
1OTI	;	1.4	;	E46Q MUTANT OF PHOTOACTIVE YELLOW PROTEIN, P65 AT 295K
5KDP	;	1.9	;	E491A mutant of choline TMA-lyase
5FAV	;	1.6	;	E491Q mutant of choline TMA-lyase
6AJQ	;	1.342	;	E52Q mutant form of Uracil DNA glycosylase X from Mycobacterium smegmatis.
6K1L	;	2.46	;	E53A mutant of a putative cystathionine gamma-lyase
1RIJ	;		;	E6-bind Trp-cage (E6apn1)
1RIK	;		;	E6-binding zinc finger (E6apc1)
1RIM	;		;	E6-binding zinc finger (E6apc2)
4N8H	;	2.4	;	E61V mutant, RipA structure
2Y3H	;	1.892	;	E63Q mutant of Cupriavidus metallidurans CH34 CnrXs
2VXN	;	0.82	;	E65Q-TIM complexed with phosphoglycolohydroxamate at 0.82 A resolution
3U78	;	2.689	;	E67-2 selectively inhibits KIAA1718, a human histone H3 lysine 9 Jumonji demethylase
3ZXC	;	1.4	;	E69 deletion mutant single insulin-like growth factor binding domain protein (SIBD-1) from Cupiennius salei
5JDP	;		;	E73V mutant of the human voltage-dependent anion channel
1RV4	;	2.95	;	E75L MUTANT OF RABBIT CYTOSOLIC SERINE HYDROXYMETHYLTRANSFERASE
1RV3	;	2.4	;	E75L MUTANT OF RABBIT CYTOSOLIC SERINE HYDROXYMETHYLTRANSFERASE, COMPLEX WITH GLYCINE
1RVU	;	2.5	;	E75Q MUTANT OF RABBIT CYTOSOLIC SERINE HYDROXYMETHYLTRANSFERASE
1RVY	;	2.9	;	E75Q MUTANT OF RABBIT CYTOSOLIC SERINE HYDROXYMETHYLTRANSFERASE, COMPLEX WITH GLYCINE
1OH3	;	1.5	;	E78R mutant of a carbohydrate binding module family 29
3O31	;	1.7	;	E81Q mutant of MtNAS in complex with a reaction intermediate
6QMV	;	1.87	;	E87D sulfur oxygenase reductase
4ZRQ	;	2.6	;	E88 deletion mutant of CD320 in complex with TC2
2YGA	;	2.37	;	E88G-N92L Mutant of N-Term HSP90 complexed with Geldanamycin
2YGE	;	1.956	;	E88G-N92L Mutant of N-Term HSP90 complexed with Geldanamycin
2AR3	;	2.2	;	E90A mutant structure of PlyL
4YO5	;	3.35	;	EAEC T6SS TssA-Cterminus
8IHM	;	3.58	;	Eaf3 CHD domain bound to the nucleosome
8EP1	;	5.4	;	Eag Kv channel with voltage sensor in the down conformation
8EP0	;	4.9	;	Eag Kv channel with voltage sensor in the intermediate conformation
8EOW	;	3.9	;	Eag Kv channel with voltage sensor in the up conformation
6XRF	;	2.56	;	EagT6 Tse6 NT complex
3S83	;	1.34	;	EAL domain of phosphodiesterase PdeA
3U2E	;	2.32	;	EAL domain of phosphodiesterase PdeA in complex with 5'-pGpG and Mg++
4HJF	;	1.75	;	EAL domain of phosphodiesterase PdeA in complex with c-di-GMP and Ca++
3MLP	;	2.8	;	Early B-cell Factor 1 (Ebf1) bound to DNA
3MUJ	;	1.92	;	Early B-cell factor 3 (EBF3) IPT/TIG and dimerization helices
8Q62	;	3.72	;	Early closed conformation of the g-tubulin ring complex
6Y7C	;	3.8	;	Early cytoplasmic yeast pre-40S particle (purified with Tsr1 as bait)
1ADU	;	3.0	;	EARLY E2A DNA-BINDING PROTEIN
1ADV	;	3.2	;	EARLY E2A DNA-BINDING PROTEIN
1T18	;	1.6	;	Early intermediate IE1 from time-resolved crystallography of the E46Q mutant of PYP
1T19	;	1.6	;	Early intermediate IE2 from time-resolved crystallography of the E46Q mutant of PYP
6TPS	;	3.54	;	early intermediate RNA Polymerase I Pre-initiation complex - eiPIC
7ZKQ	;	3.15	;	Early Pp module assembly intermediate of complex I
8BEK	;	2.86	;	Early transcription elongation state of influenza A/H7N9 backtracked polymerase with singly incoporated T1106 at the U +1 position
7R0E	;	2.51	;	Early transcription elongation state of influenza A/H7N9 polymerase backtracked due to double incoproation of nucleotide analogue T1106 and with singly incoporated T1106 at the +1 position
8BF5	;	2.96	;	Early transcription elongation state of influenza A/H7N9 polymerase stalled with incoming GTP analogue
7R1F	;	2.58	;	Early transcription elongation state of influenza B polymerase backtracked due to double incoproation of nucleotide analogue T1106
8BE0	;	2.34	;	Early transcription elongation state of influenza B/Mem polymerase backtracked due to double incoproation of nucleotide analogue T1106 and with singly incoporated T1106 at the C +1 position
8BDR	;	2.7	;	Early transcription elongation state of influenza B/Mem polymerase backtracked due to double incoproation of nucleotide analogue T1106 and with singly incoporated T1106 at the U +1 position
5WXK	;	1.801	;	EarP bound with domain I of EF-P
5XVR	;	1.63	;	EarP bound with dTDP-rhamnose (co-crystal)
5WXI	;	2.0	;	EarP bound with dTDP-rhamnose (soaked)
8UFA	;	2.86	;	Eastern equine encephalitis virus (PE-6) VLP (asymmetric unit)
8UFB	;	3.89	;	Eastern equine encephalitis virus (PE-6) VLP in complex with full-length VLDLR (asymmetric unit)
8UFC	;	3.09	;	Eastern equine encephalitis virus (PE-6) VLP in complex with VLDLR LA(1-2) (asymmetric unit)
7YNL	;	2.6	;	EB-bound alpha-synuclein fibrils
7OLG	;		;	EB1 bound to MACF peptide
3TQ7	;	2.3	;	EB1c/EB3c heterodimer in complex with the CAP-Gly domain of P150glued
1B3T	;	2.2	;	EBNA-1 NUCLEAR PROTEIN/DNA COMPLEX
7U1T	;	3.3	;	EBNA1 DNA binding domain (401-641) binds to half Dyad Symmetry element
8DLF	;	3.23	;	EBNA1 DNA binding domain (DBD) (458-617)+2 repeats of family repeat (FR) region
7K7R	;	2.5	;	EBNA1 peptide AA386-405 with Fab MS39p2w174
6C54	;	5.8	;	Ebola nucleoprotein nucleocapsid-like assembly and the asymmetric unit
6OZ9	;	3.462	;	Ebola virus glycoprotein in complex with EBOV-520 Fab
7KEX	;	4.25	;	Ebola virus GP (mucin deleted, Makona strain) bound to antibody Fab EBOV-293
7KF9	;	4.4	;	Ebola virus GP (mucin deleted, Makona strain) bound to antibody Fab EBOV-296 and EBOV-515
7KFH	;	3.8	;	Ebola virus GP (mucin deleted, Makona strain) bound to antibody Fab EBOV-437
7KFB	;	3.9	;	Ebola virus GP (mucin deleted, Makona strain) bound to antibody Fab EBOV-442
6DZL	;	4.14	;	Ebola virus Makona variant GP (mucin-deleted) in complex with pan-ebolavirus human antibody ADI-15878 Fab
1H2C	;	1.6	;	Ebola virus matrix protein VP40 N-terminal domain in complex with RNA (High-resolution VP40[55-194] variant).
1H2D	;	2.6	;	Ebola virus matrix protein VP40 N-terminal domain in complex with RNA (Low-resolution VP40[31-212] variant).
6NUT	;	3.1	;	Ebola virus nucleoprotein - RNA complex
4ZTA	;	2.4	;	Ebola virus nucleoprotein bound to VP35 chaperoning peptide I212121
4ZTI	;	2.4	;	Ebola virus nucleoprotein bound to VP35 chaperoning peptide P212121
4ZTG	;	2.8	;	Ebola virus nucleoprotein bound to VP35 chaperoning peptide P22121
5Z9W	;	3.6	;	Ebola virus nucleoprotein-RNA complex
4U2X	;	3.153	;	Ebola virus VP24 in complex with Karyopherin alpha 5 C-terminus
4M0Q	;	1.921	;	Ebola virus VP24 structure
5T3T	;	2.2	;	Ebola virus VP30 CTD bound to nucleoprotein
4IBB	;	1.752	;	Ebola virus VP35 bound to small molecule
4IBC	;	1.745	;	Ebola virus VP35 bound to small molecule
4IBD	;	1.84	;	Ebola virus VP35 bound to small molecule
4IBE	;	1.95	;	Ebola virus VP35 bound to small molecule
4IBF	;	2.291	;	Ebola virus VP35 bound to small molecule
4IBG	;	1.413	;	Ebola virus VP35 bound to small molecule
4IBI	;	1.473	;	Ebola virus VP35 bound to small molecule
4IBJ	;	1.54	;	Ebola virus VP35 bound to small molecule
4IBK	;	1.85	;	Ebola virus VP35 bound to small molecule
7K5D	;	1.78	;	Ebola virus VP40 octameric ring generated by a DNA oligonucleotide
7K5L	;	1.38	;	Ebola virus VP40 octameric ring generated by an RNA oligonucleotide
4R0R	;	2.15	;	Ebolavirus GP Prehairpin Intermediate Mimic
7M8L	;	3.9	;	EBOV GP bound to rEBOV-442 and rEBOV-515 Fabs
5KEL	;	4.3	;	EBOV GP in complex with variable Fab domains of IgGs c2G4 and c13C6
5KEN	;	4.3	;	EBOV GP in complex with variable Fab domains of IgGs c4G7 and c13C6
6PCI	;	4.12	;	EBOV GPdMuc (Makona) in complex with rEBOV-520 and rEBOV-548 Fabs
6UYE	;	3.96	;	EBOV GPdMuc Makona bound to rEBOV-548 Fab
5KEM	;	5.5	;	EBOV sGP in complex with variable Fab domains of IgGs c13C6 and BDBV91
1HWN	;	2.8	;	EBULIN COMPLEXED WITH GALACTOSE, TRIGONAL CRYSTAL FORM
1HWO	;	2.9	;	EBULIN COMPLEXED WITH LACTOSE, TRIGONAL CRYSTAL FORM
1HWP	;	3.1	;	EBULIN COMPLEXED WITH PTEROIC ACID, TRIGONAL CRYSTAL FORM
1HWM	;	2.8	;	EBULIN,ORTHORHOMBIC CRYSTAL FORM MODEL
2WE2	;	1.5	;	EBV dUTPase double mutant Gly78Asp-Asp131Ser with dUMP
2WE3	;	2.0	;	EBV dUTPase inactive mutant deleted of motif V
2WE1	;	1.8	;	EBV dUTPase mutant Asp131Asn with bound dUMP
2WE0	;	2.01	;	EBV dUTPase mutant Cys4Ser
7T7I	;	3.97	;	EBV nuclear egress complex
6LQN	;	1.60002	;	EBV tegument protein BBRF2
6LQO	;	3.09113	;	EBV tegument protein BBRF2/BSRF1 complex
2N4C	;		;	EC-NMR Structure of Agrobacterium tumefaciens Atu1203 Determined by Combining Evolutionary Couplings (EC) and Sparse NMR Data. Northeast Structural Genomics Consortium target AtT10
2N4D	;		;	EC-NMR Structure of Agrobacterium tumefaciens Atu1203 Determined by Combining Evolutionary Couplings (EC) and Sparse NMR Data. Northeast Structural Genomics Consortium target AtT10
2N4F	;		;	EC-NMR Structure of Arabidopsis thaliana At2g32350 Determined by Combining Evolutionary Couplings (EC) and Sparse NMR Data. Northeast Structural Genomics Consortium target AR3433A
2N49	;		;	EC-NMR Structure of Erwinia carotovora ECA1580 N-terminal Domain Determined by Combining Evolutionary Couplings (EC) and Sparse NMR Data. Northeast Structural Genomics Consortium target EwR156A
2N45	;		;	EC-NMR Structure of Escherichia coli Maltose-binding protein Determined by Combining Evolutionary Couplings (EC) and Sparse NMR Data with a second set of RDC data simulated for an alternative alignment tensor. Northeast Structural Genomics Consortium target ER690
2N44	;		;	EC-NMR Structure of Escherichia coli Maltose-binding protein Determined by Combining Evolutionary Couplings (EC) and Sparse NMR Data. Northeast Structural Genomics Consortium target ER690
2N48	;		;	EC-NMR Structure of Escherichia coli YiaD Determined by Combining Evolutionary Couplings (EC) and Sparse NMR Data. Northeast Structural Genomics Consortium target ER553
2N42	;		;	EC-NMR Structure of Human H-RasT35S mutant protein Determined by Combining Evolutionary Couplings (EC) and Sparse NMR Data
2N46	;		;	EC-NMR Structure of Human H-RasT35S mutant protein Determined by Combining Evolutionary Couplings (EC) and Sparse NMR Data
2N4A	;		;	EC-NMR Structure of Ralstonia metallidurans Rmet_5065 Determined by Combining Evolutionary Couplings (EC) and Sparse NMR Data. Northeast Structural Genomics Consortium target CrR115
2N4B	;		;	EC-NMR Structure of Ralstonia metallidurans Rmet_5065 Determined by Combining Evolutionary Couplings (EC) and Sparse NMR Data. Northeast Structural Genomics Consortium target CrR115
2N47	;		;	EC-NMR Structure of Synechocystis sp. PCC 6803 Slr1183 Determined by Combining Evolutionary Couplings (EC) and Sparse NMR Data. Northeast Structural Genomics Consortium target SgR145
6NXC	;	1.74	;	ECAI(T162A) MUTANT IN COMPLEX WITH CITRATE AT PH 4
6NXB	;	1.75	;	ECAII IN COMPLEX WITH CITRATE AT PH 7
6NXA	;	1.93	;	ECAII(D90T,K162T) MUTANT AT PH 7
6NX6	;	2.15	;	ECAII(D90T,K162T) MUTANT IN COMPLEX WITH CITRATE AT PH 5
6NX7	;	2.15	;	ECAII(D90T,K162T) MUTANT IN COMPLEX WITH CITRATE AT PH 5.6
6NX8	;	1.85	;	ECAII(D90T,K162T) MUTANT IN COMPLEX WITH CITRATE AT PH 6.2
6NX9	;	1.97	;	ECAII(D90T,K162T) MUTANT IN COMPLEX WITH CITRATE AT PH 7
6PA8	;	1.9	;	ECAII(T89V,K162T) MUTANT IN COMPLEX WITH L-ASN AT PH 7.0
6PA6	;	2.12	;	ECAII(T89V,K162T) MUTANT IN COMPLEX WITH L-ASN AT PH 8.3 in space group C2
6PA5	;	2.0	;	ECAII(T89V,K162T) MUTANT IN COMPLEX WITH L-ASN AT PH 8.3 IN SPACE GROUP P2(1)
7B7J	;	1.66	;	EccD5 ubiqutin like domain from Mycobacterium xenopi
8I9O	;	2.9	;	ecCTPS filament bound with CTP, NADH, DON
4X5F	;	1.7	;	ecDHFR complexed with folate and NADP+ at 0.1 MPa
4X5G	;	1.9	;	ecDHFR complexed with folate and NADP+ at 270 MPa
4X5H	;	1.9	;	ecDHFR complexed with folate and NADP+ at 500 MPa
4X5I	;	1.8	;	ecDHFR complexed with folate and NADP+ at 660 MPa
4X5J	;	1.85	;	ecDHFR complexed with folate and NADP+ at 750 MPa
4Z0M	;	1.97	;	EchA5 Mycobacterium tuberculosis
5W1J	;	2.7	;	Echinococcus granulosus thioredoxin glutathione reductas (egTGR)
5W1L	;	2.88	;	Echinococcus granulosus thioredoxin glutathione reductas (egTGR) with Gold
1XVN	;	1.5	;	echinomycin (ACGTACGT)2 complex
1XVR	;	1.4	;	echinomycin (CGTACG)2 complex
1PFE	;	1.1	;	Echinomycin-(gcgtacgc)2 complex
2ECH	;		;	ECHISTATIN-THE REFINED STRUCTURE OF A DISINTEGRIN IN SOLUTION BY 1H NMR
7XXG	;	3.37	;	Echo 18 at pH5.5
7XXJ	;	3.33	;	Echo 18 incubated with FcRn at pH5.5
1EV1	;	3.55	;	ECHOVIRUS 1
6RJF	;	3.5	;	Echovirus 1 intact particle
1H8T	;	2.9	;	Echovirus 11
6HBH	;	3.36	;	Echovirus 18 A-particle
6HBJ	;	3.16	;	Echovirus 18 empty particle
6HBG	;	3.16	;	Echovirus 18 native particle
6HBK	;	3.8	;	Echovirus 18 Open particle without one pentamer
6HBL	;	3.7	;	Echovirus 18 Open particle without three pentamers
6HHT	;	4.05	;	Echovirus 18 Open particle without two pentamers
7C9X	;	3.4	;	Echovirus 3 F-particle
7C9T	;	2.9	;	Echovirus 30 A-particle
7C9U	;	3.4	;	Echovirus 30 E-particle
7C9S	;	2.9	;	Echovirus 30 F-particle
8GSC	;	3.4	;	Echovirus3 A-particle in complex with 6D10 Fab
8GSE	;	3.7	;	Echovirus3 capsid protein in complex with 6D10 Fab (upright)
7EAI	;	3.8	;	Echovirus3 empty compacted particle
7EAH	;	3.1	;	Echovirus3 empty expanded particle
7EAJ	;	4.1	;	Echovirus3 empty expanded particle in complex with 5G3 fab
8GSF	;	3.6	;	Echovirus3 empty particle in complex with 6D10 Fab (sideling)
7EAK	;	3.9	;	Echovirus3 full particle in complex with 5G3 fab
8GSD	;	3.1	;	Echovirus3 full particle in complex with 6D10 Fab
6YF6	;	2.0	;	EclA C-terminal domain; sugar-binding protein
6YGQ	;	1.9	;	EclA N-terminal domain; PllA-like lectin
5EJ5	;	2.3	;	EcMenD-ThDP-Mn2+ complex soaked with 2-ketoglutarate for 1.5 h
5EJ4	;	1.773	;	EcMenD-ThDP-Mn2+ complex soaked with 2-ketoglutarate for 15 min
5EJ9	;	1.72	;	EcMenD-ThDP-Mn2+ complex soaked with 2-ketoglutarate for 2 min and isochorismate for 13 min
5EJA	;	1.6	;	EcMenD-ThDP-Mn2+ complex soaked with 2-ketoglutarate for 2 min and soaked with isochorismate for 7 min
5EJ7	;	1.56	;	EcMenD-ThDP-Mn2+ complex soaked with 2-ketoglutarate for 21 s
5EJ6	;	2.243	;	EcMenD-ThDP-Mn2+ complex soaked with 2-ketoglutarate for 2min then soaked with isochorismate for 2 min
5EJ8	;	1.34	;	EcMenD-ThDP-Mn2+ complex structure soaked with 2-ketoglutarate for 2 min
7UW5	;	3.84	;	EcMscK G924S mutant in a closed conformation
7UX1	;	3.48	;	EcMscK in an Open Conformation
2EWN	;	2.8	;	Ecoli Biotin Repressor with co-repressor analog
5I5H	;	1.65	;	Ecoli global domain 245-586
6YD9	;	1.6	;	Ecoli GyrB24 with inhibitor 16a
7BTR	;	4.54	;	EcoR124I-ArdA in the Restriction-Alleviation State
7BTO	;	3.97	;	EcoR124I-ArdA in the Translocation State
7BTQ	;	4.54	;	EcoR124I-DNA in the Restriction-Alleviation State
7BTP	;	4.01	;	EcoR124I-Ocr in Restriction-Alleviation State
7BST	;	4.37	;	EcoR124I-Ocr in the Intermediate State
1EON	;	1.6	;	ECORV BOUND TO 3'-S-PHOSPHOROTHIOLATE DNA AND CA2+
1EOO	;	2.16	;	ECORV BOUND TO COGNATE DNA
1EOP	;	2.6	;	ECORV BOUND TO COGNATE DNA
1SX8	;	2.15	;	EcoRV bound to cognate DNA and Mn2+
1EO4	;	1.9	;	ECORV BOUND TO MN2+ AND COGNATE DNA CONTAINING A 3'S SUBSTITION AT THE CLEAVAGE SITE
1BGB	;	2.0	;	ECORV ENDONUCLEASE COMPLEX WITH 5'-CGGGATATCCC DNA
1AZ3	;	2.4	;	ECORV ENDONUCLEASE, UNLIGANDED, FORM B
1AZ4	;	2.4	;	ECORV ENDONUCLEASE, UNLIGANDED, FORM B, T93A MUTANT
1AZ0	;	2.0	;	ECORV ENDONUCLEASE/DNA COMPLEX
2GE5	;	2.4	;	EcoRV Restriction Endonuclease C-terminal deletion mutant/GATATC/Ca2+
2B0D	;	2.0	;	EcoRV Restriction Endonuclease/GAATTC/Ca2+
2B0E	;	1.9	;	EcoRV Restriction Endonuclease/GAAUTC/Ca2+
1BSS	;	2.15	;	ECORV-T93A/DNA/CA2+
7E8R	;	1.9	;	EcoT38I restriction endonuclease
7EDB	;	2.39	;	EcoT38I restriction endonuclease complexed with DNA
1EZU	;	2.4	;	ECOTIN Y69F, D70P BOUND TO D102N TRYPSIN
3UE5	;	2.76	;	ECP-cleaved Actin in complex with Spir domain D
4Z9D	;	1.8	;	EcPltA
4Z9C	;	2.35	;	EcPltAB Oxidized
1ECI	;		;	ECTATOMIN (WATER SOLUTION, NMR 20 STRUCTURES)
5FUU	;	4.19	;	Ectodomain of cleaved wild type JR-FL EnvdCT trimer in complex with PGT151 Fab
6DCQ	;	3.1	;	Ectodomain of full length, wild type HIV-1 glycoprotein clone PC64M18C043 in complex with PGT151 Fab
8DFP	;	3.17	;	Ectodomain of full-length KIT(DupA502,Y503)-SCF dimers
8DFQ	;	3.96	;	Ectodomain of full-length KIT(T417I,delta418-419)-SCF dimers
8DFM	;	3.45	;	Ectodomain of full-length wild-type KIT-SCF dimers
1FCG	;	2.0	;	ECTODOMAIN OF HUMAN FC GAMMA RECEPTOR, FCGRIIA
6Y5H	;	3.0	;	Ectodomain of X-31 Haemagglutinin at pH 5 (State I)
6Y5G	;	3.0	;	Ectodomain of X-31 Haemagglutinin at pH 8
7X77	;	2.2	;	Ectodomain structure of per os infectivity factor 5
1GKS	;		;	ECTOTHIORHODOSPIRA HALOPHILA CYTOCHROME C551 (REDUCED), NMR, 37 STRUCTURES
7WVF	;	3.91	;	ectoTLR3-mAb12-poly(I:C) complex
7WV5	;	3.1	;	ectoTLR3-poly(I:C)
7WV4	;	3.35	;	ectoTLR3-poly(I:C) cluster
6T5K	;	1.33	;	ECV-1 from Echinicola vietnamensis. Environmental metallo-beta-lactamases exhibit high enzymatic activity under zinc deprivation
3UTC	;	1.9	;	Ec_IspH in complex with (E)-4-hydroxybut-3-enyl diphosphate
3UV6	;	1.7	;	Ec_IspH in complex with 4-hydroxybutyl diphosphate (1301)
3UWM	;	1.8	;	Ec_IspH in complex with 4-oxobutyl diphosphate (1302)
3UTD	;	1.7	;	Ec_IspH in complex with 4-oxopentyl diphosphate
3UV3	;	1.6	;	Ec_IspH in complex with but-2-ynyl diphosphate (1086)
3UV7	;	1.6	;	Ec_IspH in complex with buta-2,3-dienyl diphosphate (1300)
6RXA	;	1.44	;	EDDS lyase variant D290M/Y320M with bound formate
6RX8	;	1.92	;	EDDS lyase variant D290M/Y320M with bound fumarate
6ZVH	;	2.9	;	EDF1-ribosome complex
8FAM	;	1.95	;	Edited Octopus bimaculoides Synaptotagmin 1 C2A (I248V) at room temperature
4RRF	;	1.7	;	Editing domain of threonyl-tRNA synthetase from Methanococcus jannaschii with L-Ser3AA
4RRG	;	1.93	;	Editing domain of threonyl-tRNA synthetase from Methanococcus jannaschii with L-Thr3AA
6SSO	;	1.211	;	EDN mutant L45H
7XEY	;	2.29	;	EDS1-PAD4 complexed with pRib-ADP
5DQP	;	2.146	;	EDTA monooxygenase (EmoA) from Chelativorans sp. BNC1
2CE7	;	2.44	;	EDTA treated
2WO0	;	2.6	;	EDTA treated E. coli copper amine oxidase
2WOF	;	2.25	;	EDTA treated E. coli copper amine oxidase
2GNT	;	2.02	;	EDTA treated P. angolensis lectin (PAL) remetallized with calcium (1 hour treatment)
3SW3	;	2.35	;	EDTA-free crystal structure of the mutant C221D of carbapenemase CphA from Aeromonas hydrophila
2GNB	;	2.27	;	EDTA-treated (2 weeks) P. angolensis lectin
3WSH	;	2.8	;	EDTA-treated, oxidized HcgD from Methanocaldococcus jannaschii
3WSI	;	2.3	;	EDTA-treated, reduced HcgD from Methanocaldococcus jannaschii
1JOC	;	2.2	;	EEA1 homodimer of C-terminal FYVE domain bound to inositol 1,3-diphosphate
6YVI	;	2.26	;	EED in complex with a cyano-benzofuran
6SFC	;	2.0	;	EED in complex with a methyl-thiazole
6SFB	;	1.52	;	EED in complex with a triazolopyrimidine
6YVJ	;	1.84	;	EED in complex with a triazolopyrimidine
5GSA	;	2.49	;	EED in complex with an allosteric PRC2 inhibitor
5H14	;	1.9	;	EED in complex with an allosteric PRC2 inhibitor EED666
7P3C	;	1.61	;	EED in complex with compound 4
7P3G	;	2.39	;	EED in complex with compound 4
7P3J	;	1.93	;	EED in complex with compound 4
5H25	;	2.88	;	EED in complex with PRC2 allosteric inhibitor compound 11
7QK4	;	1.602	;	EED in complex with PRC2 allosteric inhibitor compound 22 (MAK683)
7QJG	;	1.8	;	EED in complex with PRC2 allosteric inhibitor compound 6
7QJU	;	1.8	;	EED in complex with PRC2 allosteric inhibitor compound 7
5H24	;	2.5	;	EED in complex with PRC2 allosteric inhibitor compound 8
5H19	;	1.9	;	EED in complex with PRC2 allosteric inhibitor EED162
5H17	;	2.3	;	EED in complex with PRC2 allosteric inhibitor EED210
5H13	;	1.9	;	EED in complex with PRC2 allosteric inhibitor EED396
5H15	;	2.27	;	EED in complex with PRC2 allosteric inhibitor EED709
3JZH	;	2.05	;	EED-H3K79me3
3JPX	;	2.05	;	EED: A Novel Histone Trimethyllysine Binder Within The EED-EZH2 Polycomb Complex
6ODF	;	5.8	;	EEEV glycoproteins bound with heparan sulfate
8EOD	;		;	EEVD:Sis1-81 (J domain) bound conformation
2PMY	;	2.3	;	EF-hand domain of human RASEF
6TS3	;	1.28	;	EF-hands 3 and 4 of alpha-actinin in complex with CaMKII regulatory segment
1H8B	;		;	EF-hands 3,4 from alpha-actinin / Z-repeat 7 from titin
4G5G	;	2.3	;	ef-tu (Escherichia coli) complexed with nvp-ldu796
3U6B	;	2.12	;	Ef-tu (escherichia coli) in complex with nvp-ldi028
3U6K	;	2.45	;	Ef-tu (escherichia coli) in complex with nvp-ldk733
3U2Q	;	2.7	;	EF-Tu (Escherichia coli) in complex with NVP-LFF571
5JBQ	;	2.006	;	EF-TU (ESCHERICHIA COLI) IN COMPLEX WITH THIOMURACIN ANALOG
2C77	;	1.6	;	EF-Tu complexed with a GTP analog and the antibiotic GE2270 A
2C78	;	1.4	;	EF-Tu complexed with a GTP analog and the antibiotic pulvomycin
1AIP	;	3.0	;	EF-TU EF-TS COMPLEX FROM THERMUS THERMOPHILUS
1QZD	;	10.0	;	EF-Tu.kirromycin coordinates fitted into the cryo-EM map of EF-Tu ternary complex (GDP.Kirromycin) bound 70S ribosome
1D26	;	2.12	;	EFFECT OF A SINGLE 3'-METHYLENE PHOSPHONATE LINKAGE ON THE CONFORMATION OF AN A-DNA OCTAMER DOUBLE HELIX
1XQK	;	1.95	;	Effect of a Y265F Mutant on the Transamination Based Cycloserine Inactivation of Alanine Racemase
1XQL	;	1.8	;	Effect of a Y265F Mutant on the Transamination Based Cycloserine Inactivation of Alanine Racemase
1YKX	;	1.9	;	Effect of alcohols on protein hydration
1YKY	;	1.9	;	Effect of alcohols on protein hydration
1YKZ	;	1.8	;	Effect of alcohols on protein hydration
1YL0	;	1.9	;	Effect of alcohols on protein hydration
1YL1	;	1.9	;	Effect of alcohols on protein hydration
1Z55	;	1.9	;	Effect of alcohols on protein hydration
6CCP	;	2.2	;	EFFECT OF ARGININE-48 REPLACEMENT ON THE REACTION BETWEEN CYTOCHROME C PEROXIDASE AND HYDROGEN PEROXIDE
7CCP	;	2.2	;	EFFECT OF ARGININE-48 REPLACEMENT ON THE REACTION BETWEEN CYTOCHROME C PEROXIDASE AND HYDROGEN PEROXIDE
3A34	;	1.65	;	Effect of Ariginine on lysozyme
3EMS	;	1.651	;	Effect of Ariginine on lysozyme
329D	;	2.7	;	EFFECT OF CYTOSINE METHYLATION ON DNA-DNA RECOGNITION AT CPG STEPS
1YX9	;	3.0	;	Effect of Dimethyl Sulphoxide on the crystal structure of Porcine Pepsin
240D	;	2.0	;	EFFECT OF END BASE STEPS ON DNA FORM: CRYSTAL STRUCTURE OF THE A-DNA DECAMER D(CCGGGCCCGG)
3CYW	;	1.4	;	Effect of Flap Mutations on Structure of HIV-1 Protease and Inhibition by Saquinavir and Darunavir
5ZU2	;	2.441	;	Effect of mutation (R554A) on FAD modification in Aspergillus oryzae RIB40formate oxidase
5ZU3	;	2.4	;	Effect of mutation (R554K) on FAD modification in Aspergillus oryzae RIB40formate oxidase
1P4Y	;	1.7	;	Effect of Sequence on the Conformational Geometry of DNA Holliday Junctions
1P4Z	;	2.0	;	Effect of Sequence on the Conformational Geometry of DNA Holliday Junctions
1P54	;	1.9	;	Effect of Sequence on the Conformational Geometry of DNA Holliday Junctions
1T9N	;	2.0	;	Effect of Shuttle Location and pH Environment on H+ Transfer in Human Carbonic Anhydrase II
1TB0	;	2.0	;	Effect of Shuttle Location and pH Environment on H+ Transfer in Human Carbonic Anhydrase II
1TBT	;	2.0	;	Effect of Shuttle Location and pH Environment on H+ Transfer in Human Carbonic Anhydrase II
1TE3	;	2.0	;	Effect of Shuttle Location and pH Environment on H+ Transfer in Human Carbonic Anhydrase II
1TEQ	;	2.0	;	Effect of Shuttle Location and pH Environment on H+ Transfer in Human Carbonic Anhydrase II
1TEU	;	2.0	;	Effect of Shuttle Location and pH Environment on H+ Transfer in Human Carbonic Anhydrase II
1TG3	;	1.8	;	Effect of Shuttle Location and pH Environment on H+ Transfer in Human Carbonic Anhydrase II
1TG9	;	1.9	;	Effect of Shuttle Location and pH Environment on H+ Transfer in Human Carbonic Anhydrase II
1TH9	;	1.63	;	Effect of Shuttle Location and pH Environment on H+ Transfer in Human Carbonic Anhydrase II
1THK	;	1.8	;	Effect of Shuttle Location and pH Environment on H+ Transfer in Human Carbonic Anhydrase II
3V2J	;	1.699	;	Effect of Sucrose and Glycerol as Cryoprotectans, on the Inhibition of Human Carbonic Anhydrase II
3V2M	;	1.471	;	Effect of Sucrose and Glycerol as Cryoprotectans, on the Inhibition of Human Carbonic Anhydrase II
3M3U	;	2.35	;	Effect of temperature on tryptophan fluorescence in lysozyme crystals
1BEK	;	2.2	;	EFFECT OF UNNATURAL HEME SUBSTITUTION ON KINETICS OF ELECTRON TRANSFER IN CYTOCHROME C PEROXIDASE
1BEP	;	2.2	;	EFFECT OF UNNATURAL HEME SUBSTITUTION ON KINETICS OF ELECTRON TRANSFER IN CYTOCHROME C PEROXIDASE
1BJ9	;	2.2	;	EFFECT OF UNNATURAL HEME SUBSTITUTION ON KINETICS OF ELECTRON TRANSFER IN CYTOCHROME C PEROXIDASE
2F97	;	2.2	;	Effector Binding Domain of BenM (crystals generated from high pH conditions)
7YHJ	;	3.237	;	Effector binding domain of LysR-Type transcription factor LrhA from E. coli
3ONM	;	2.4	;	Effector binding Domain of LysR-Type transcription factor RovM from Y. pseudotuberculosis
5TED	;	1.889	;	Effector binding domain of QuiR in complex with shikimate
3N6T	;	1.85	;	Effector binding domain of TsaR
3N6U	;	1.87	;	Effector binding domain of TsaR in complex with its inducer p-toluenesulfonate
3O9T	;	2.2	;	Effector domain from influenza A/PR/8/34 NS1
3OA9	;	2.9	;	Effector domain of influenza A/Duck/Albany/76 NS1
3O9S	;	2.48	;	Effector domain of influenza A/PR/8/34 NS1
3O9U	;	3.2	;	Effector domain of influenza A/PR/8/34 NS1
3O9Q	;	2.5	;	Effector domain of NS1 from A/PR/8/34 containing a W187A mutation
3O9R	;	2.0	;	Effector domain of NS1 from influenza A/PR/8/34 containing a W187A mutation
3RVC	;	1.8	;	Effector domain of NS1 from influenza A/PR/8/34 containing a W187A mutation
6H56	;	3.2	;	Effector domain of Pseudomonas aeruginosa VgrG2b
1DNF	;	1.5	;	EFFECTS OF 5-FLUOROURACIL/GUANINE WOBBLE BASE PAIRS IN Z-DNA. MOLECULAR AND CRYSTAL STRUCTURE OF D(CGCGFG)
2CYM	;	2.0	;	EFFECTS OF AMINO ACID SUBSTITUTION ON THREE-DIMENSIONAL STRUCTURE: AN X-RAY ANALYSIS OF CYTOCHROME C3 FROM DESULFOVIBRIO VULGARIS HILDENBOROUGH AT 2 ANGSTROMS RESOLUTION
1BX3	;	2.3	;	EFFECTS OF COMMONLY USED CRYOPROTECTANTS ON GLYCOGEN PHOSPHORYLASE ACTIVITY AND STRUCTURE
1S02	;	1.9	;	EFFECTS OF ENGINEERED SALT BRIDGES ON THE STABILITY OF SUBTILISIN BPN'
1BKU	;		;	EFFECTS OF GLYCOSYLATION ON THE STRUCTURE AND DYNAMICS OF EEL CALCITONIN, NMR, 10 STRUCTURES
3CJZ	;	1.8	;	Effects of N2,N2-dimethylguanosine on RNA structure and stability: crystal structure of an RNA duplex with tandem m22G:A pairs
1FB9	;		;	EFFECTS OF S-SULFONATION ON THE SOLUTION STRUCTURE OF SALMON CALCITONIN
1RAT	;	1.5	;	EFFECTS OF TEMPERATURE ON PROTEIN STRUCTURE AND DYNAMICS: X-RAY CRYSTALLOGRAPHIC STUDIES OF THE PROTEIN RIBONUCLEASE-A AT NINE DIFFERENT TEMPERATURES FROM 98 TO 320 K
2RAT	;	1.5	;	EFFECTS OF TEMPERATURE ON PROTEIN STRUCTURE AND DYNAMICS: X-RAY CRYSTALLOGRAPHIC STUDIES OF THE PROTEIN RIBONUCLEASE-A AT NINE DIFFERENT TEMPERATURES FROM 98 TO 320 K
3RAT	;	1.5	;	EFFECTS OF TEMPERATURE ON PROTEIN STRUCTURE AND DYNAMICS: X-RAY CRYSTALLOGRAPHIC STUDIES OF THE PROTEIN RIBONUCLEASE-A AT NINE DIFFERENT TEMPERATURES FROM 98 TO 320 K
4RAT	;	1.5	;	EFFECTS OF TEMPERATURE ON PROTEIN STRUCTURE AND DYNAMICS: X-RAY CRYSTALLOGRAPHIC STUDIES OF THE PROTEIN RIBONUCLEASE-A AT NINE DIFFERENT TEMPERATURES FROM 98 TO 320 K
5RAT	;	1.5	;	Effects of temperature on protein structure and dynamics: X-ray crystallographic studies of the protein ribonuclease-A at nine different temperatures from 98 TO 320 K
6RAT	;	1.5	;	EFFECTS OF TEMPERATURE ON PROTEIN STRUCTURE AND DYNAMICS: X-RAY CRYSTALLOGRAPHIC STUDIES OF THE PROTEIN RIBONUCLEASE-A AT NINE DIFFERENT TEMPERATURES FROM 98 TO 320 K
7RAT	;	1.5	;	EFFECTS OF TEMPERATURE ON PROTEIN STRUCTURE AND DYNAMICS: X-RAY CRYSTALLOGRAPHIC STUDIES OF THE PROTEIN RIBONUCLEASE-A AT NINE DIFFERENT TEMPERATURES FROM 98 TO 320 K
8RAT	;	1.5	;	EFFECTS OF TEMPERATURE ON PROTEIN STRUCTURE AND DYNAMICS: X-RAY CRYSTALLOGRAPHIC STUDIES OF THE PROTEIN RIBONUCLEASE-A AT NINE DIFFERENT TEMPERATURES FROM 98 TO 320 K
9RAT	;	1.5	;	EFFECTS OF TEMPERATURE ON PROTEIN STRUCTURE AND DYNAMICS: X-RAY CRYSTALLOGRAPHIC STUDIES OF THE PROTEIN RIBONUCLEASE-A AT NINE DIFFERENT TEMPERATURES FROM 98 TO 320 K
6C93	;	2.674	;	Effects of the E310A Mutation of Cytochrome P450 4B1 (CYP4B1) on n-Octane binding and Heme Ruffling
6LKS	;	3.24	;	Effects of zinc ion on oligomerization and pH stability of influenza virus hemagglutinin
2L6S	;		;	Efficacy of an HIV-1 entry inhibitor targeting the GP41 fusion peptide
2L6T	;		;	Efficacy of an HIV-1 entry inhibitor targeting the GP41 fusion peptide
2C22	;	2.56	;	Efficient and High Fidelity Incorporation of dCTP Opposite 7,8- Dihydro-8-oxodeoxyguanosine by Sulfolobus solfataricus DNA Polymerase Dpo4
2C28	;	2.27	;	Efficient and High Fidelity Incorporation of dCTP Opposite 7,8- Dihydro-8-oxodeoxyguanosine by Sulfolobus solfataricus DNA Polymerase Dpo4
2C2D	;	2.57	;	Efficient and High Fidelity Incorporation of dCTP Opposite 7,8- Dihydro-8-oxodeoxyguanosine by Sulfolobus solfataricus DNA Polymerase Dpo4
2C2E	;	2.61	;	Efficient and High Fidelity Incorporation of dCTP Opposite 7,8- Dihydro-8-oxodeoxyguanosine by Sulfolobus solfataricus DNA Polymerase Dpo4
2C2R	;	2.55	;	Efficient and High Fidelity Incorporation of dCTP Opposite 7,8- Dihydro-8-oxodeoxyguanosine by Sulfolobus solfataricus DNA Polymerase Dpo4
5JQ1	;	1.83	;	Efficient targeting of the asialoglycoprotein receptor by polyvalent display of a compact galactosamine mimic
5JPV	;	1.9	;	Efficient targeting of the asialoglycoprotein receptor by polyvalent display of a compact galactoseamine mimic
2PIS	;	2.8	;	Efforts toward Expansion of the Genetic Alphabet: Structure and Replication of Unnatural Base Pairs
5XNG	;		;	EFK17A structure in Microgel MAA60
5XRX	;		;	EFK17DA structure in Microgel MAA60
3ZCW	;	1.691	;	Eg5 - New allosteric binding site
4AS7	;	2.4	;	Eg5 complex 1
5ZO9	;	2.7	;	Eg5 motor domain in complex with STLC-type inhibitor PVEI0021 (C2 type)
5ZO8	;	2.2	;	Eg5 motor domain in complex with STLC-type inhibitor PVEI0021 (P21 type)
4ZHI	;	2.3	;	Eg5 motor domain mutant E162S
4ZCA	;	2.3	;	Eg5 motor domain mutant Y231F
4BXN	;	2.793	;	Eg5(WT) complex
4A1Z	;	2.8	;	Eg5-1
4A28	;	2.55	;	Eg5-2
4B7B	;	2.5	;	Eg5-3
6G6Y	;	1.8	;	Eg5-inhibitor complex
6G6Z	;	2.8	;	Eg5-inhibitor complex
6HKX	;	2.8	;	Eg5-inhibitor complex
6HKY	;	2.75	;	Eg5-inhibitor complex
2KV4	;		;	EGF
2BOU	;	1.9	;	EGF Domains 1,2,5 of human EMR2, a 7-TM immune system molecule, in complex with barium.
2BO2	;	2.6	;	EGF Domains 1,2,5 of human EMR2, a 7-TM immune system molecule, in complex with calcium.
2BOX	;	2.5	;	EGF Domains 1,2,5 of human EMR2, a 7-TM immune system molecule, in complex with strontium.
6YLQ	;	1.65	;	EGFP in neutral pH, Directionality of Optical Properties of Fluorescent Proteins
5N9O	;	1.53	;	EGFP(enhanced green fluorescent protein) mutant - L232H
6YLP	;	1.55	;	EGFP_in_Acidic_env Directionality of Optical Properties of Fluorescent Proteins
5HG9	;	2.15	;	EGFR (L858R, T790M, V948R) in complex with 1-[(3R,4R)-3-[({2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-(trifluoromethyl)pyrrolidin-1-yl]prop-2-en-1-one
5HG7	;	1.85	;	EGFR (L858R, T790M, V948R) in complex with 1-{(3R,4R)-3-[5-Chloro-2-(1-methyl-1H-pyrazol-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxymethyl]-4-methoxy-pyrrolidin-1-yl}propenone (PF-06459988)
5HG8	;	1.42	;	EGFR (L858R, T790M, V948R) in complex with N-[3-({2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)phenyl]prop-2-enamide
5HG5	;	1.52	;	EGFR (L858R, T790M, V948R) in complex with N-{3-[(2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy]phenyl}prop-2-enamide
7LTX	;	2.3	;	EGFR (T790M/V948R) in complex with quinazolinone allosteric inhibitor
7LG8	;	2.93	;	EGFR (T79M/V948R) in complex with naquotinib and an allosteric inhibitor
4LRM	;	3.526	;	EGFR D770_N771insNPG in complex with PD168393
6P8Q	;	1.9	;	EGFR in complex with a dihydrodibenzodiazepinone allosteric inhibitor.
7U9A	;	2.6	;	EGFR in complex with a macrocyclic inhibitor
7K1I	;	3.202	;	EGFR kinase (L858R/V948R) in complex with allosteric inhibitor JBJ-09-063
5EDP	;	2.9	;	EGFR kinase (T790M/L858R) apo
4RJ7	;	2.55	;	EGFR kinase (T790M/L858R) with inhibitor compound 1
5EDQ	;	2.8	;	EGFR kinase (T790M/L858R) with inhibitor compound 15: ~{N}-(7-chloranyl-1~{H}-indazol-3-yl)-7,7-dimethyl-2-(1~{H}-pyrazol-4-yl)-5~{H}-furo[3,4-d]pyrimidin-4-amine
5EDR	;	2.6	;	EGFR kinase (T790M/L858R) with inhibitor compound 27: ~{N}-(1~{H}-indazol-3-yl)-7,7-dimethyl-2-(2-methylpyrazol-3-yl)-5~{H}-furo[3,4-d]pyrimidin-4-amine
4RJ6	;	2.7	;	EGFR kinase (T790M/L858R) with inhibitor compound 4
4RJ5	;	3.1	;	EGFR kinase (T790M/L858R) with inhibitor compound 5
4RJ4	;	2.78	;	EGFR kinase (T790M/L858R) with inhibitor compound 6
4RJ8	;	2.5	;	EGFR kinase (T790M/L858R) with inhibitor compound 8
7JXQ	;	1.83	;	EGFR kinase (T790M/V948R) in complex with allosteric inhibitor JBJ-09-063
7JXL	;	2.4	;	EGFR kinase (T790M/V948R) in complex with AZ5104
7JXM	;	2.192	;	EGFR kinase (T790M/V948R) in complex with osimertinib and EAI045
7JXP	;	2.16	;	EGFR kinase (T790M/V948R) in complex with osimertinib and JBJ-04-125-02
7JXW	;	2.5	;	EGFR kinase (T790M/V948R) in complex with osimertinib and JBJ-09-063
7JXI	;	3.0	;	EGFR kinase (T790M/V948R) in complex with PF-06747775
7JXK	;	3.1	;	EGFR kinase (T790M/V948R) in complex with PF-06747775 and JBJ-04-125-02
8A2B	;	1.69	;	EGFR kinase domain (L858R/V948R) in complex with 2-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-1-yl)-2-[6-[2-[4-[[4-(hydroxymethyl)-1-piperidyl]methyl]phenyl]ethynyl]-1-oxo-4-(trifluoromethyl)isoindolin-2-yl]-N-thiazol-2-yl-acetamide
8A2D	;	1.11	;	EGFR kinase domain (L858R/V948R) in complex with 2-[4-(difluoromethyl)-6-[2-[4-[[4-(hydroxymethyl)-1-piperidyl]methyl]phenyl]ethynyl]-7-methyl-indazol-2-yl]-2-spiro[6,7-dihydropyrrolo[1,2-c]imidazole-5,1'-cyclopropane]-1-yl-N-thiazol-2-yl-acetamide
1XKK	;	2.4	;	EGFR kinase domain complexed with a quinazoline inhibitor- GW572016
3LZB	;	2.7	;	EGFR kinase domain complexed with an imidazo[2,1-b]thiazole inhibitor
3W33	;	1.7	;	EGFR kinase domain complexed with compound 19b
3W32	;	1.8	;	EGFR kinase domain complexed with compound 20a
3POZ	;	1.5	;	EGFR Kinase domain complexed with tak-285
8A27	;	1.07	;	EGFR kinase domain in complex with 2-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-1-yl)-2-[6-[2-[4-[[4-(hydroxymethyl)-1-piperidyl]methyl]phenyl]ethynyl]-1-oxo-4-(trifluoromethyl)isoindolin-2-yl]-N-thiazol-2-yl-acetamide
8A2A	;	1.43	;	EGFR kinase domain in complex with 2-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-1-yl)-2-[6-[2-[4-[[4-(hydroxymethyl)-1-piperidyl]methyl]phenyl]ethynyl]-1-oxo-4-(trifluoromethyl)isoindolin-2-yl]-N-thiazol-2-yl-acetamide (form 2)
5FEQ	;	3.4	;	EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE
5FED	;	2.651	;	EGFR kinase domain in complex with a covalent aminobenzimidazole inhibitor.
5D41	;	2.31	;	EGFR kinase domain in complex with mutant selective allosteric inhibitor
5HCZ	;	2.62	;	EGFR kinase domain mutant ""TMLR"" with 3-azetidinyl azaindazole compound 21
5HCY	;	2.46	;	EGFR kinase domain mutant ""TMLR"" with 3-carboxamide azaindole compound 13
5HIC	;	2.6	;	EGFR kinase domain mutant ""TMLR"" with a imidazopyridinyl-aminopyrimidine inhibitor
5HIB	;	2.85	;	EGFR kinase domain mutant ""TMLR"" with a pyrazolopyrimidine inhibitor
5HCX	;	2.6	;	EGFR kinase domain mutant ""TMLR"" with azabenzimidazole compound 7
5C8K	;	3.0	;	EGFR kinase domain mutant ""TMLR"" with compound 1
5C8M	;	2.9	;	EGFR kinase domain mutant ""TMLR"" with compound 17
5C8N	;	2.401	;	EGFR kinase domain mutant ""TMLR"" with compound 23
5CAL	;	2.7	;	EGFR kinase domain mutant ""TMLR"" with compound 24
5CAN	;	2.8	;	EGFR kinase domain mutant ""TMLR"" with compound 27
8HY7	;	2.91	;	EGFR kinase domain mutant ""TMLR"" with compound 28f
5CAO	;	2.6	;	EGFR kinase domain mutant ""TMLR"" with compound 29
5CAP	;	2.4	;	EGFR kinase domain mutant ""TMLR"" with compound 30
5CAQ	;	2.5	;	EGFR kinase domain mutant ""TMLR"" with compound 33
5CAS	;	2.1	;	EGFR kinase domain mutant ""TMLR"" with compound 41a
5CAU	;	2.25	;	EGFR kinase domain mutant ""TMLR"" with compound 41b
5EM7	;	2.81	;	EGFR kinase domain mutant ""TMLR"" with pyridone compound 13: 4-[(2-methoxyphenyl)amino]-~{N}-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxidanylidene-1~{H}-pyridine-3-carboxamide
5EM6	;	2.78	;	EGFR kinase domain mutant ""TMLR"" with pyridone compound 19: 4-[(2-azanylpyrimidin-4-yl)amino]-~{N}-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxidanylidene-1~{H}-pyridine-3-carboxamide
5EM5	;	2.65	;	EGFR kinase domain mutant ""TMLR"" with pyridone compound 2: 4-[2-(4-chlorophenyl)ethylamino]-~{N}-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxidanylidene-1~{H}-pyridine-3-carboxamide
5Y25	;	3.102	;	EGFR kinase domain mutant (T790M/L858R) with covalent ligand NS-062
5FEE	;	2.7	;	EGFR kinase domain T790M mutant in complex with a covalent aminobenzimidazole inhibitor.
3W2P	;	2.05	;	EGFR Kinase domain T790M/L858R mutant with compound 2
3W2R	;	2.05	;	EGFR Kinase domain T790M/L858R mutant with compound 4
3W2Q	;	2.2	;	EGFR kinase domain T790M/L858R mutant with HKI-272
3W2O	;	2.35	;	EGFR Kinase domain T790M/L858R Mutant with TAK-285
5CAV	;	2.73	;	EGFR kinase domain with compound 41a
3W2S	;	1.9	;	EGFR kinase domain with compound4
5EM8	;	2.8	;	EGFR kinase domain with pyridone compound 13: 4-[(2-methoxyphenyl)amino]-~{N}-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxidanylidene-1~{H}-pyridine-3-carboxamide
7U99	;	2.5	;	EGFR kinase in complex with a macrocyclic inhibitor
8F1Z	;	2.4	;	EGFR kinase in complex with Bayer #33
8F1X	;	2.3	;	EGFR kinase in complex with mobocertinib (TAK-788)
8F1Y	;	2.75	;	EGFR kinase in complex with poziotinib
8TJL	;	2.7	;	EGFR kinase in complex with pyrazolopyrimidine covalent inhibitor
8F1H	;	2.8	;	EGFR kinase in complex with TAS6417 (CLN-081)
4LQM	;	2.5	;	EGFR L858R in complex with PD168393
5CZI	;	2.6	;	EGFR L858R MUTANT IN COMPLEX WITH A SHC PEPTIDE SUBSTRATE
5CZH	;	2.8	;	EGFR L858R MUTANT IN COMPLEX WITH AN OPTIMAL PEPTIDE SUBSTRATE
4LL0	;	4.0	;	EGFR L858R/T790M in complex with PD168393
7K1H	;	2.602	;	EGFR L858R/V948R in complex with osimertinib and allosteric inhibitor JBJ-09-063
6JRX	;	2.201	;	EGFR T790M/C797S in complex with compound 6i
2M20	;		;	EGFR transmembrane - juxtamembrane (TM-JM) segment in bicelles: MD guided NMR refined structure.
6DUK	;	2.2	;	EGFR with an allosteric inhibitor
8WD4	;	2.55	;	EGFR(L858R/T790/C797S) in complex with compound 5j
7U98	;	3.42	;	EGFR(T790M/V948R) in complex with a macrocyclic inhibitor
6XL4	;	2.06	;	EGFR(T790M/V948R) in complex with AZD9291 and DDC4002
8FV3	;	2.1	;	EGFR(T790M/V948R) in complex with compound 1 (LN4503)
8FV4	;	2.2	;	EGFR(T790M/V948R) in complex with compound 2 (LN5993)
7UKW	;	2.6	;	EGFR(T790M/V948R) in complex with Lazertinib (YH25448)
6V6K	;	2.2	;	EGFR(T790M/V948R) in complex with LN2057
6V5N	;	2.4	;	EGFR(T790M/V948R) in complex with LN2084
6V6O	;	2.1	;	EGFR(T790M/V948R) in complex with LN2380
6V5P	;	2.3	;	EGFR(T790M/V948R) in complex with LN2725
6V66	;	1.79	;	EGFR(T790M/V948R) in complex with LN2899
6WXN	;	1.76	;	EGFR(T790M/V948R) in complex with LN3844
8EME	;	3.32	;	EGFR(T790M/V948R) in complex with ZNL-0056
8GB4	;	2.59	;	EGFR(T790M/V948R) kinase in complex with benzimidazole allosteric inhibitor
8F1W	;	3.2	;	EGFR(T790M/V948R) kinase in complex with poziotinib
4LI5	;	2.64	;	EGFR-K IN COMPLEX WITH N-[3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-4-methoxy-phenyl] Prop-2-enamide
6S9B	;	3.25	;	EGFR-KINASE IN COMPLEX WITH COMPOUND 1
6S9C	;	2.73	;	EGFR-KINASE IN COMPLEX WITH COMPOUND 5
6S9D	;	2.67	;	EGFR-KINASE IN COMPLEX WITH COMPOUND 6
5J9Z	;	2.5	;	EGFR-T790M in complex with pyrazolopyrimidine inhibitor 1a
5J9Y	;	2.8	;	EGFR-T790M in complex with pyrazolopyrimidine inhibitor 1b
4X9J	;	1.412	;	EGR-1 with Doubly Methylated DNA
4R2D	;	2.088	;	Egr1/Zif268 zinc fingers in complex with formylated DNA
4R2C	;	1.89	;	Egr1/Zif268 zinc fingers in complex with hydroxymethylated DNA
4R2A	;	1.591	;	Egr1/Zif268 zinc fingers in complex with methylated DNA
6QKJ	;	2.2	;	EgtB from Chloracidobacterium thermophilum, a type II sulfoxide synthase in complex with N,N,N-trimethyl-histidine
1DUC	;	2.05	;	EIAV DUTPASE DUDP/STRONTIUM COMPLEX
1DUN	;	1.9	;	EIAV DUTPASE NATIVE
2FMB	;	1.8	;	EIAV PROTEASE COMPLEXED WITH AN INHIBITOR LP-130
1FMB	;	1.8	;	EIAV PROTEASE COMPLEXED WITH THE INHIBITOR HBY-793
6K71	;	4.3	;	eIF2 - eIF2B complex
6K72	;	4.6	;	eIF2(aP) - eIF2B complex
6JLY	;	3.5	;	eIF2a - eIF2B complex
7D46	;	4.0	;	eIF2B apo
7D45	;	3.8	;	eIF2B-eIF2(aP), aP1 complex
7D44	;	4.0	;	eIF2B-eIF2(aP), aP2 complex
7D43	;	4.3	;	eIF2B-eIF2(aP), aPg complex
7F64	;	2.42	;	eIF2B-SFSV NSs
7VLK	;	2.27	;	eIF2B-SFSV NSs C2-imposed
7F66	;	2.76	;	eIF2B-SFSV NSs-1-eIF2
7F67	;	3.59	;	eIF2B-SFSV NSs-2-eIF2
6I7T	;	4.61	;	eIF2B:eIF2 complex
6I3M	;	3.93	;	eIF2B:eIF2 complex, phosphorylated on eIF2 alpha serine 52.
1S0U	;	2.4	;	eIF2gamma apo
5K1H	;	4.9	;	eIF3b relocated to the intersubunit face to interact with eIF1 and below the eIF2 ternary-complex. from the structure of a partial yeast 48S preinitiation complex in closed conformation.
5BXV	;	2.1	;	eIF4E complex
7D6Y	;	1.668	;	eIF4E in Complex with a Disulphide-Free Autonomous VH Domain
7XTP	;	1.828	;	eIF4E in Complex with a Disulphide-Free Autonomous VH Domain
1EJH	;	2.2	;	EIF4E/EIF4G PEPTIDE/7-METHYL-GDP
7OW7	;	2.4	;	EIF6-bound large subunit of the human ribosome
2LBO	;		;	Eimeria tenella microneme protein 3 MAR_B domain
8IN3	;	1.15	;	Eisenia hydrolysis-enhancing protein from Aplysia kurodai
8IN4	;	1.4	;	Eisenia hydrolysis-enhancing protein from Aplysia kurodai
8IN6	;	1.9	;	Eisenia hydrolysis-enhancing protein from Aplysia kurodai complex with tannic acid
3JBS	;	2.9	;	eL6 protein from yeast 60S ribosomal subunit
1O2G	;	1.58	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O2H	;	1.77	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O2I	;	1.5	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O2J	;	1.65	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O2K	;	1.63	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O2L	;	1.68	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O2M	;	1.69	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O2N	;	1.5	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O2O	;	1.63	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O2P	;	1.47	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O2Q	;	1.5	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O2R	;	1.45	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O2S	;	1.65	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O2T	;	1.62	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O2U	;	1.41	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O2V	;	1.5	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O2W	;	1.38	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O2X	;	1.46	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O2Y	;	1.45	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O2Z	;	1.65	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O30	;	1.55	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O31	;	1.66	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O32	;	1.78	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O33	;	1.46	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O34	;	1.5	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O35	;	1.41	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O36	;	1.7	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O37	;	1.45	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O38	;	1.38	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O39	;	1.59	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O3A	;	2.0	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O3B	;	1.75	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O3C	;	1.64	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O3D	;	1.33	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O3E	;	1.64	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O3F	;	1.55	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O3G	;	1.55	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O3H	;	1.53	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O3I	;	1.51	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O3J	;	1.4	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O3K	;	1.43	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O3L	;	1.4	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O3M	;	1.55	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O3N	;	1.55	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O3O	;	1.55	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
1O3P	;	1.81	;	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
6Q8S	;	1.8	;	Elastase (PPE) under 2 kbar of argon
2BLQ	;	1.33	;	Elastase After A High Dose X-Ray ""Burn""
2BLO	;	1.33	;	Elastase before a high dose x-ray ""burn""
1U4G	;	1.4	;	Elastase of Pseudomonas aeruginosa with an inhibitor
7KOE	;	2.9	;	Electron bifurcating flavoprotein Fix/EtfABCX
7Q4V	;	4.7	;	Electron bifurcating hydrogenase - HydABC from A. woodii
5VU2	;	6.8	;	Electron cryo-microscopy of ""immature"" Chikungunya VLP
3JBM	;	3.9	;	Electron cryo-microscopy of a virus-like particle of orange-spotted grouper nervous necrosis virus
5AEF	;	5.0	;	Electron cryo-microscopy of an Abeta(1-42)amyloid fibril
3J9B	;	4.3	;	Electron cryo-microscopy of an RNA polymerase
4UQ8	;	4.95	;	Electron cryo-microscopy of bovine Complex I
6NK7	;	4.99	;	Electron Cryo-Microscopy of Chikungunya in Complex with Mouse Mxra8 Receptor
3J2W	;	5.0	;	Electron cryo-microscopy of Chikungunya virus
5ANY	;	16.9	;	Electron cryo-microscopy of chikungunya virus in complex with neutralizing antibody Fab CHK265
6NK5	;	4.16	;	Electron Cryo-Microscopy Of Chikungunya VLP
6NK6	;	4.06	;	Electron Cryo-Microscopy Of Chikungunya VLP in complex with mouse Mxra8 receptor
3J2Y	;	14.9	;	Electron Cryo-microscopy of Chikungunya VLP in complex with neutralizing antibody Fab 9.8B
3J30	;	16.0	;	Electron Cryo-microscopy of Chikungunya VLP in complex with neutralizing antibody Fab CHK152
3J2Z	;	16.9	;	Electron Cryo-microscopy of Chikungunya VLP in complex with neutralizing antibody Fab m10
3J2X	;	15.6	;	Electron Cryo-microscopy of Chikungunya VLP in complex with neutralizing antibody Fab m242
5A33	;	3.04	;	Electron cryo-microscopy of Cowpea Mosaic Virus (CPMV) empty virus like particle (eVLP)
5A32	;	3.44	;	Electron cryo-microscopy of Cowpea Mosaic Virus containing RNA-1 (CPMVb)
3J82	;	7.7	;	Electron cryo-microscopy of DNGR-1 in complex with F-actin
4CI0	;	3.36	;	Electron cryo-microscopy of F420-reducing NiFe hydrogenase Frh
5FN1	;	3.9	;	Electron cryo-microscopy of filamentous flexible virus PepMV (Pepino Mosaic Virus)
3J7E	;	13.6	;	Electron cryo-microscopy of human papillomavirus 16 and H16.V5 Fab fragments
3J7G	;	13.6	;	Electron cryo-microscopy of human papillomavirus 16 and H16.V5 Fab fragments
3J6R	;	9.1	;	Electron cryo-microscopy of Human Papillomavirus Type 16 capsid
4UPB	;	11.0	;	Electron cryo-microscopy of the complex formed between the hexameric ATPase RavA and the decameric inducible decarboxylase LdcI
6O85	;	3.03	;	Electron cryo-microscopy of the eukaryotic translation initiation factor 2B bound to eukaryotic translation initiation factor 2 from Homo sapiens
6O9Z	;	3.03	;	Electron cryo-microscopy of the eukaryotic translation initiation factor 2B bound to eukaryotic translation initiation factor 2 from Homo sapiens
6O81	;	3.21	;	Electron cryo-microscopy of the eukaryotic translation initiation factor 2B bound to translation initiation factor 2 from Homo sapiens
6CAJ	;	2.8	;	Electron cryo-microscopy of the eukaryotic translation initiation factor 2B from Homo sapiens
7L7G	;	3.0	;	Electron cryo-microscopy of the eukaryotic translation initiation factor 2B from Homo sapiens (updated model of PDB ID: 6CAJ)
3JC1	;	4.0	;	Electron cryo-microscopy of the IST1-CHMP1B ESCRT-III copolymer
4UOM	;	17.0	;	Electron Cryo-microscopy of Venezuelan Equine Encephalitis Virus TC- 83 in complex with neutralizing antibody Fab F5
4UOK	;	18.0	;	Electron Cryo-microscopy of Venezuelan Equine Encephalitis Virus TC-83 in complex with neutralizing antibody Fab 3B4C-4
3J8G	;	5.0	;	Electron cryo-microscopy structure of EngA bound with the 50S ribosomal subunit
5XWY	;	3.2	;	Electron cryo-microscopy structure of LbuCas13a-crRNA binary complex
4UF8	;	10.9	;	Electron cryo-microscopy structure of PB1-p62 filaments
4UF9	;	10.3	;	Electron cryo-microscopy structure of PB1-p62 type T filaments
6G1K	;	3.6	;	Electron cryo-microscopy structure of the canonical TRPC4 ion channel
6U5V	;	2.8	;	Electron cryomicroscopy Structure of C. albicans FAS in the Apo state
6U5W	;	3.3	;	Electron cryomicroscopy structure of C. albicans FAS in the KS-stalled state
6U5T	;	2.9	;	Electron cryomicroscopy Structure of S. cerevisiae FAS in the Apo state
6U5U	;	2.8	;	Electron cryomicroscopy Structure of S. cerevisiae FAS in the KS-stalled state
7DI8	;	3.2	;	Electron crystallographic structure of Catalase using a direct electron detector at 300 kV
3DWW	;	3.5	;	Electron crystallographic structure of human microsomal prostaglandin E synthase 1
2B6O	;	1.9	;	Electron crystallographic structure of lens Aquaporin-0 (AQP0) (lens MIP) at 1.9A resolution, in a closed pore state
3M9I	;	2.5	;	Electron crystallographic structure of lens Aquaporin-0 (AQP0) (lens MIP) in E. coli polar lipids
7VI4	;	0.95	;	Electron crystallographic structure of TIA-1 prion-like domain, A381T mutant
7VI5	;	1.761	;	Electron crystallographic structure of TIA-1 prion-like domain, wild type sequence
3ZEE	;	6.1	;	Electron cyro-microscopy helical reconstruction of Par-3 N terminal domain
2SGA	;	1.5	;	ELECTRON DENSITY CALCULATIONS AS AN EXTENSION OF PROTEIN STRUCTURE REFINEMENT. STREPTOMYCES GRISEUS PROTEASE AT 1.5 ANGSTROMS RESOLUTION
4UQ6	;	12.8	;	Electron density map of GluA2em in complex with LY451646 and glutamate
4UQK	;	16.4	;	Electron density map of GluA2em in complex with quisqualate and LY451646
4UQQ	;	7.6	;	Electron density map of GluK2 desensitized state in complex with 2S,4R-4-methylglutamate
3J4P	;	4.8	;	Electron Microscopy Analysis of a Disaccharide Analog complex Reveals Receptor Interactions of Adeno-Associated Virus
3CRE	;	17.0	;	Electron Microscopy model of the Saf Pilus- Type A
3CRF	;	17.0	;	Electron Microscopy model of the Saf Pilus- Type B
1U74	;	2.4	;	Electron Transfer Complex between cytochrome C and cytochrome C peroxidase
1U75	;	2.55	;	Electron Transfer Complex between Horse Heart Cytochrome c and Zinc-Porphyrin Substituted Cytochrome c Peroxidase
5IY5	;	2.0	;	Electron transfer complex of cytochrome c and cytochrome c oxidase at 2.0 angstrom resolution
3O1Y	;	1.75	;	Electron transfer complexes: Experimental mapping of the redox-dependent cytochrome c electrostatic surface
3O20	;	1.9	;	Electron transfer complexes:experimental mapping of the Redox-dependent Cytochrome C electrostatic surface
1EFP	;	2.6	;	ELECTRON TRANSFER FLAVOPROTEIN (ETF) FROM PARACOCCUS DENITRIFICANS
4KPU	;	1.6	;	Electron transferring flavoprotein of Acidaminococcus fermentans: Towards a mechanism of flavin-based electron bifurcation
4L1F	;	1.79	;	Electron transferring flavoprotein of Acidaminococcus fermentans: Towards a mechanism of flavin-based electron bifurcation
4L2I	;	1.45	;	Electron transferring flavoprotein of Acidaminococcus fermentans: Towards a mechanism of flavin-based electron bifurcation
3YPI	;	2.8	;	ELECTROPHILIC CATALYSIS IN TRIOSEPHOSPHASE ISOMERASE: THE ROLE OF HISTIDINE-95
8AO6	;	1.811	;	electrophilic inhibitor (7) of ERK2
5VIE	;	2.6	;	Electrophilic probes for deciphering substrate recognition by O-GlcNAc transferase
5VIF	;	2.25	;	Electrophilic probes for deciphering substrate recognition by O-GlcNAc transferase
1C2B	;	4.5	;	ELECTROPHORUS ELECTRICUS ACETYLCHOLINESTERASE
1C2O	;	4.2	;	ELECTROPHORUS ELECTRICUS ACETYLCHOLINESTERASE
4P68	;	2.26	;	Electrostatics of Active Site Microenvironments for E. coli DHFR
4P66	;	1.84	;	Electrostatics of Active Site Microenvironments of E. coli DHFR
7DDU	;	1.9	;	Elephant seal myoglobin esMb
8D65	;	3.47	;	ELIC apo in 2:1:1 POPC:POPE:POPG nanodisc
8D63	;	3.14	;	ELIC apo in POPC nanodisc
4Z90	;	3.0	;	ELIC bound with the anesthetic isoflurane in the resting state
4Z91	;	3.3915	;	ELIC cocrystallized with isofluorane in a desensitized state
8D66	;	3.14	;	ELIC with cysteamine in 2:1:1 POPC:POPE:POPG nanodisc
8D64	;	3.14	;	ELIC with cysteamine in POPC nanodisc
8F33	;	3.28	;	ELIC with Propylamine in saposin nanodiscs with 2:1:1 POPC:POPE:POPG
8F32	;	3.71	;	ELIC with Propylamine in SMA nanodiscs with 2:1:1 POPC:POPE:POPG
8F34	;	3.12	;	ELIC with Propylamine in spMSP1D1 nanodiscs with 2:1:1 POPC:POPE:POPG
8TWZ	;	3.17	;	ELIC with Propylamine in spNW15 nanodiscs with 2:1:1 POPC:POPE:POPG
4YEU	;	4.6	;	ELIC-GLIC chimera in the resting conformation
6V03	;	3.3	;	ELIC-propylammonium complex in POPC-only nanodiscs
8D67	;	3.3	;	ELIC3 with cysteamine in 2:1:1 POPC:POPE:POPG nanodisc
8VUW	;	3.19	;	ELIC5 with cysteamine in 2:1:1 POPC:POPE:POPG nanodisc in open conformation
8TWV	;	3.4	;	ELIC5 with Propylamine in spNW15 nanodiscs with 2:1:1 POPC:POPE:POPG
1ZW7	;		;	Elimination of the C-cap in Ubiquitin Structure, Dynamics and Thermodynamic Consequences
1XYW	;		;	elk prion protein
1DUX	;	2.1	;	ELK-1/DNA STRUCTURE REVEALS HOW RESIDUES DISTAL FROM DNA-BINDING SURFACE AFFECT DNA-RECOGNITION
7R21	;	3.1	;	elongated Cascade complex from type I-A CRISPR-Cas system
7R2K	;	3.3	;	elongated Cascade complex from type I-A CRISPR-Cas system
6FON	;	3.05	;	Elongated conformer of the human copper chaperone for SOD1 complexed with human SOD1
6DS9	;	1.34	;	Elongated version of a de novo designed three helix bundle structure (GRa3D)
7N1P	;	2.33	;	Elongating 70S ribosome complex in a classical pre-translocation (PRE-C) conformation
7N2C	;	2.72	;	Elongating 70S ribosome complex in a fusidic acid-stalled intermediate state of translocation bound to EF-G(GDP) (INT2)
7N2U	;	2.53	;	Elongating 70S ribosome complex in a hybrid-H1 pre-translocation (PRE-H1) conformation
7N30	;	2.66	;	Elongating 70S ribosome complex in a hybrid-H2* pre-translocation (PRE-H2*) conformation
7N31	;	2.69	;	Elongating 70S ribosome complex in a post-translocation (POST) conformation
7N2V	;	2.54	;	Elongating 70S ribosome complex in a spectinomycin-stalled intermediate state of translocation bound to EF-G in an active, GTP conformation (INT1)
8BGH	;	2.88	;	Elongating E. coli 70S ribosome containing acylated tRNA(iMet) in the P-site and AAA mRNA codon in the A-site after uncompleted di-peptide formation
8BGE	;	2.11	;	Elongating E. coli 70S ribosome containing acylated tRNA(iMet) in the P-site and AAm6A mRNA codon in the A-site after uncompleted di-peptide formation
8BHL	;	2.21	;	Elongating E. coli 70S ribosome containing acylated tRNA(iMet) in the P-site and Am6AA mRNA codon in the A-site after uncompleted di-peptide formation
8BHP	;	2.37	;	Elongating E. coli 70S ribosome containing acylated tRNA(iMet) in the P-site and m6AAA mRNA codon in the A-site after uncompleted di-peptide formation
8BF7	;	2.33	;	Elongating E. coli 70S ribosome containing deacylated tRNA(iMet) in the P-site and AAA mRNA codon with cognate dipeptidyl-tRNA(Lys) in the A-site
8BH4	;	2.62	;	Elongating E. coli 70S ribosome containing deacylated tRNA(iMet) in the P-site and AAm6A mRNA codon with cognate dipeptidyl-tRNA(Lys) in the A-site
8BHJ	;	2.81	;	Elongating E. coli 70S ribosome containing deacylated tRNA(iMet) in the P-site and Am6AA mRNA codon with cognate dipeptidyl-tRNA(Lys) in the A-site
8BHN	;	2.85	;	Elongating E. coli 70S ribosome containing deacylated tRNA(iMet) in the P-site and m6AAA mRNA codon with cognate dipeptidyl-tRNA(Lys) in the A-site
4BY7	;	3.15	;	elongating RNA Polymerase II-Bye1 TLD complex
4BY1	;	3.6	;	elongating RNA Polymerase II-Bye1 TLD complex soaked with AMPCPP
2R93	;	4.0	;	Elongation complex of RNA polymerase II with a hepatitis delta virus-derived RNA stem loop
2R92	;	3.8	;	Elongation complex of RNA polymerase II with artificial RdRP scaffold
4V6F	;	3.1	;	Elongation complex of the 70S ribosome with three tRNAs and mRNA.
2IW3	;	2.4	;	Elongation Factor 3 in complex with ADP
1EFU	;	2.5	;	ELONGATION FACTOR COMPLEX EF-TU/EF-TS FROM ESCHERICHIA COLI
4FN5	;	2.9	;	ELONGATION FACTOR G 1 (PSEUDOMONAS AERUGINOSA) IN COMPLEX WITH Argyrin B
1DAR	;	2.4	;	ELONGATION FACTOR G IN COMPLEX WITH GDP
1ELO	;	2.8	;	ELONGATION FACTOR G WITHOUT NUCLEOTIDE
5OT7	;	3.8	;	Elongation factor G-ribosome complex captures in the absence of inhibitors.
6S8Z	;	2.2	;	Elongation Factor P from Corynebacterium glutamicum
1ENW	;		;	ELONGATION FACTOR TFIIS DOMAIN II
1HA3	;	2.0	;	ELONGATION FACTOR TU IN COMPLEX WITH aurodox
4PC7	;	3.6003	;	Elongation factor Tu:Ts complex in a near GTP conformation.
4PC2	;	2.1999	;	Elongation factor Tu:Ts complex with a bound GDP
4PC1	;	1.95	;	Elongation Factor Tu:Ts complex with a bound phosphate
4PC6	;	2.2	;	Elongation factor Tu:Ts complex with bound GDPNP
4PC3	;	1.8313	;	Elongation factor Tu:Ts complex with partially bound GDP
6QK7	;	3.3	;	Elongator catalytic subcomplex Elp123 lobe
1FA4	;		;	ELUCIDATION OF THE PARAMAGNETIC RELAXATION OF HETERONUCLEI AND PROTONS IN CU(II) PLASTOCYANIN FROM ANABAENA VARIABILIS
1KAL	;		;	ELUCIDATION OF THE PRIMARY AND THREE-DIMENSIONAL STRUCTURE OF THE UTEROTONIC POLYPEPTIDE KALATA B1
1CHV	;		;	ELUCIDATION OF THE SOLUTION STRUCTURE OF CARDIOTOXIN ANALOGUE V FROM THE TAIWAN COBRA (NAJA NAJA ATRA) VENOM
4PXI	;	3.2	;	Elucidation of the Structural and Functional Mechanism of Action of the TetR Family Protein, CprB from S. coelicolor A3(2)
4KE4	;	2.012	;	Elucidation of the structure and reaction mechanism of Sorghum bicolor hydroxycinnamoyltransferase and its structural relationship to other CoA-dependent transferases and synthases
2Y2W	;	2.5	;	Elucidation of the substrate specificity and protein structure of AbfB, a family 51 alpha-L-arabinofuranosidase from Bifidobacterium longum.
4QEC	;	1.9	;	ElxO with NADP Bound
4QED	;	1.85	;	ElxO Y152F with NADPH Bound
5MG3	;	14.0	;	EM fitted model of bacterial holo-translocon
6QD7	;	3.1	;	EM structure of a EBOV-GP bound to 3T0331 neutralizing antibody
6QD8	;	3.3	;	EM structure of a EBOV-GP bound to 4M0368 neutralizing antibody
6MYX	;	6.0	;	EM structure of Bacillus subtilis ribonucleotide reductase inhibited double-helical filament of NrdE alpha subunit with dATP
6MW3	;	4.65	;	EM structure of Bacillus subtilis ribonucleotide reductase inhibited filament composed of NrdE alpha subunit and NrdF beta subunit with dATP
6WKW	;	3.6	;	EM structure of CtBP2 with a minimal dehydrogenase domain of CtBP2
7YQC	;	2.82	;	EM structure of human PA28gamma
7YQD	;	3.4	;	EM structure of human PA28gamma (wild-type)
6U2J	;	2.37	;	EM structure of MPEG-1 (L425K, alpha conformation) soluble pre-pore complex
6U2K	;	2.93	;	EM structure of MPEG-1 (L425K, alpha conformation) soluble pre-pore complex
6U2L	;	2.83	;	EM structure of MPEG-1 (L425K, beta conformation) soluble pre-pore complex
6U2W	;	3.63	;	EM structure of MPEG-1(L425K) pre-pore complex bound to liposome
6U23	;	3.49	;	EM structure of MPEG-1(w.t.) soluble pre-pore
5AKA	;	5.7	;	EM structure of ribosome-SRP-FtsY complex in closed state
7NDC	;	4.1	;	EM structure of SARS-CoV-2 Spike glycoprotein (all RBD down) in complex with COVOX-159
7NDA	;	3.3	;	EM structure of SARS-CoV-2 Spike glycoprotein (all RBD down) in complex with COVOX-253H55L Fab
7NDD	;	4.2	;	EM structure of SARS-CoV-2 Spike glycoprotein (one RBD up) in complex with COVOX-159
7ND9	;	2.8	;	EM structure of SARS-CoV-2 Spike glycoprotein (one RBD up) in complex with COVOX-253H55L Fab
7ND5	;	3.4	;	EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-150 Fab
7NDB	;	4.6	;	EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-253H165L Fab
7ND7	;	3.6	;	EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-316 Fab
7ND8	;	3.5	;	EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-384 Fab
7ND3	;	3.7	;	EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-40 Fab
7ND6	;	7.3	;	EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-40 Fab
7ND4	;	3.6	;	EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-88 Fab
6N4C	;	17.0	;	EM structure of the DNA wrapping in bacterial open transcription initiation complex
3J04	;	20.0	;	EM structure of the heavy meromyosin subfragment of Chick smooth muscle Myosin with regulatory light chain in phosphorylated state
5H0S	;	3.3	;	EM Structure of VP1A and VP1B
7YR5	;	3.63	;	Embigin facilitates monocarboxylate transporter 1 localization to plasma membrane and transition to a decoupling state
2BRS	;	2.2	;	EMBP Heparin complex
2JOX	;		;	Embryonic Neural Inducing Factor Churchill is not a DNA-Binding Zinc Finger Protein: Solution Structure Reveals a Solvent-Exposed beta-Sheet and Zinc Binuclear Cluster
7PBE	;	3.0	;	Emergence of immune escape at dominant SARS-CoV-2 killer T-cell epitope
4BF7	;	2.001	;	Emericilla nidulans endo-beta-1,4-galactanase
6ZYG	;		;	Emfourin (M4in) from Serratia proteamaculans, M4 family peptidase inhibitor
5FAI	;	1.8	;	EMG1 N1-Specific Pseudouridine Methyltransferase
8RBS	;	18.0	;	Emiliania huxleyi virus 201 (EhV-201) asymmetrical unit of capsid proteins predicted by AlphaFold2 fitted into the cryo-EM density of EhV-201 virion composite map.
8RBT	;	12.0	;	Emiliania huxleyi virus 201 (EhV-201) capsid proteins predicted by AlphaFold2 fitted into a cryo-EM density map of the EhV-201 virion capsid.
7PXH	;	2.59	;	Emodepside-bound Drosophila Slo channel
1KVF	;		;	EMP-18 Erythropoietin Receptor Agonist Peptide
8CAZ	;	2.11	;	empty 30S head
6V12	;	3.08	;	Empty AAV8 particles
6V1T	;	3.39	;	Empty AAVrh.39 particle
8G5V	;	3.0	;	Empty capsid of Hepatitis B virus
7QWX	;	2.9	;	Empty capsid of Saccharomyces cerevisiae virus L-BCLa
3J2J	;	9.54	;	Empty coxsackievirus A9 capsid
8GHS	;	4.0	;	Empty HBV Cp183 capsid with importin-beta, subparticle reconstruction at 2-fold location
3KJE	;	2.3	;	Empty state of CooC1
3B62	;	4.4	;	EmrE multidrug transporter in complex with P4P, P21 crystal form
3B5D	;	3.8	;	EmrE multidrug transporter in complex with TPP, C2 crystal form
3B61	;	4.5	;	EmrE multidrug transporter, apo crystal form
7JK8	;		;	EmrE S64V mutant bound to tetra(4-fluorophenyl)phosphonium at pH 5.8
7SFQ	;		;	EmrE S64V Mutant Bound to tetra(4-fluorophenyl)phosphonium at pH 8.0
7LXE	;	1.88	;	ENAH EVH1 domain bound to peptide from ABI1
7LXF	;	1.65	;	ENAH EVH1 domain bound to peptide from protein PCARE
5NC7	;	2.7	;	ENAH EVH1 in complex with Ac-WPPPPTEDEL-NH2
5N9P	;	1.8	;	ENAH EVH1 in complex with Ac-[2-Cl-F]-PP-[ProM-1]-NH2
5N9C	;	1.16	;	ENAH EVH1 in complex with Ac-[2-Cl-F]-PP-[ProM-1]-OH
5ND0	;	1.45	;	ENAH EVH1 in complex with Ac-[2-Cl-F]-PP-[ProM-1]-TEDEL-NH2
5NBX	;	1.65	;	ENAH EVH1 in complex with Ac-[2-Cl-F]-PP-[ProM-9]-OH
5N91	;	1.49	;	ENAH EVH1 in complex with Ac-[2-Cl-F]-PPPP-OH
6XVT	;	1.4	;	ENAH EVH1 in complex with Ac-[2-Cl-F]-PPPPTEDDL-NH2
6XXR	;	1.48	;	ENAH EVH1 in complex with Ac-[2-Cl-F]-PPPPTEDEA-NH2
5NC2	;	1.58	;	ENAH EVH1 in complex with Ac-[2-Cl-F]-PPPPTEDEL-NH2
5NAJ	;	1.46	;	ENAH EVH1 in complex with Ac-[2-Cl-F]-[ProM-1]-[ProM-1]-OH
5NCP	;	1.65	;	ENAH EVH1 in complex with Ac-[2-Cl-F]-[ProM-2]-[ProM-12]-OH
5NDU	;	1.42	;	ENAH EVH1 in complex with Ac-[2-Cl-F]-[ProM-2]-[ProM-12]-OMe
5NEG	;	1.29	;	ENAH EVH1 in complex with Ac-[2-Cl-F]-[ProM-2]-[ProM-13]-OEt
6RCF	;	1.1	;	ENAH EVH1 in complex with Ac-[2-Cl-F]-[ProM-2]-[ProM-15]-OH
6RCJ	;	1.35	;	ENAH EVH1 in complex with Ac-[2-Cl-F]-[ProM-2]-[ProM-15]-OMe
7A5M	;	0.78	;	ENAH EVH1 in complex with Ac-[2-Cl-F]-[ProM-2]-[ProM-17]-OMe
7AKI	;	1.36	;	ENAH EVH1 in complex with Ac-[2-Cl-F]-[ProM-2]-[ProM-1]-NH2
6RD2	;	1.0	;	ENAH EVH1 in complex with Ac-[2-Cl-F]-[ProM-2]-[ProM-1]-TEDEL-NH2
5NBF	;	1.15	;	ENAH EVH1 in complex with Ac-[2-Cl-F]-[ProM-2]-[ProM-3]-OH
5NCF	;	1.4	;	ENAH EVH1 in complex with Ac-[2-Cl-F]-[ProM-2]-[ProM-4]-OH
5NCG	;	1.02	;	ENAH EVH1 in complex with Ac-[2-Cl-F]-[ProM-2]-[ProM-9]-OH
4MY6	;	1.7	;	EnaH-EVH1 in complex with peptidomimetic low-molecular weight inhibitor Ac-[2-Cl-F]-[ProM-2]-[ProM-1]-OH
2C1O	;	2.75	;	ENAIIHis Fab fragment in the free form
1EXA	;	1.59	;	ENANTIOMER DISCRIMINATION ILLUSTRATED BY CRYSTAL STRUCTURES OF THE HUMAN RETINOIC ACID RECEPTOR HRARGAMMA LIGAND BINDING DOMAIN: THE COMPLEX WITH THE ACTIVE R-ENANTIOMER BMS270394.
1EXX	;	1.67	;	ENANTIOMER DISCRIMINATION ILLUSTRATED BY CRYSTAL STRUCTURES OF THE HUMAN RETINOIC ACID RECEPTOR HRARGAMMA LIGAND BINDING DOMAIN: THE COMPLEX WITH THE INACTIVE S-ENANTIOMER BMS270395.
5UR9	;	2.198	;	Enantiomer-Specific Binding of the Potent Antinociceptive Agent SBFI-26 to Anandamide transporters FABP5
5URA	;	1.85002	;	Enantiomer-Specific Binding of the Potent Antinociceptive Agent SBFI-26 to Anandamide transporters FABP7
3QLB	;	3.26	;	Enantiopyochelin outer membrane TonB-dependent transporter from Pseudomonas fluorescens bound to the ferri-enantiopyochelin
6NJ8	;	3.85	;	Encapsulin iron storage compartment from Quasibacillus thermotolerans
1Z3C	;	2.2	;	Encephalitozooan cuniculi mRNA Cap (Guanine-N7) Methyltransferasein complexed with AzoAdoMet
2HV9	;	2.6	;	Encephalitozoon cuniculi mRNA Cap (Guanine-N7) Methyltransferase in complex with sinefungin
7O9W	;	3.5	;	Encequidar-bound human P-glycoprotein in complex with UIC2-Fab
7V06	;		;	Encoded Conformational Dynamics of the HIV Splice Site A3 Regulatory Locus: Implications for differential binding of hnRNP Splicing Auxiliary Factors
4COD	;	2.4	;	Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA
2CL2	;	1.35	;	Endo-1,3(4)-beta-glucanase from Phanerochaete chrysosporium, solved using native sulfur SAD, exhibiting intact heptasaccharide glycosylation
3ATG	;	1.66	;	endo-1,3-beta-glucanase from Cellulosimicrobium cellulans
8YA6	;	1.92	;	endo-1,3-fucanase Fun168A
8YA7	;	1.99	;	endo-1,3-fucanase Fun168A,complex with fucotetraose
1NLR	;	1.75	;	ENDO-1,4-BETA-GLUCANASE CELB2, CELLULASE, NATIVE STRUCTURE
1BK1	;	2.0	;	ENDO-1,4-BETA-XYLANASE C
1XYF	;	1.9	;	ENDO-1,4-BETA-XYLANASE FROM STREPTOMYCES OLIVACEOVIRIDIS
1REF	;	1.8	;	ENDO-1,4-BETA-XYLANASE II COMPLEX WITH 2,3-EPOXYPROPYL-BETA-D-XYLOSIDE
1REE	;	1.6	;	ENDO-1,4-BETA-XYLANASE II COMPLEX WITH 3,4-EPOXYBUTYL-BETA-D-XYLOSIDE
1RED	;	1.6	;	ENDO-1,4-BETA-XYLANASE II COMPLEX WITH 4,5-EPOXYPENTYL-BETA-D-XYLOSIDE
1YNA	;	1.55	;	ENDO-1,4-BETA-XYLANASE, ROOM TEMPERATURE, PH 4.0
8IC1	;	1.8	;	endo-alpha-D-arabinanase EndoMA1 D51N mutant from Microbacterium arabinogalactanolyticum in complex with arabinooligosaccharides
8HHV	;	1.6	;	endo-alpha-D-arabinanase EndoMA1 from Microbacterium arabinogalactanolyticum
3ECQ	;	2.9	;	Endo-alpha-N-acetylgalactosaminidase from Streptococcus pneumoniae: SeMet structure
5GZH	;	1.8	;	Endo-beta-1,2-glucanase from Chitinophaga pinensis - ligand free form
5GZK	;	1.7	;	Endo-beta-1,2-glucanase from Chitinophaga pinensis - sophorotriose and glucose complex
1C8Y	;	2.0	;	Endo-Beta-N-Acetylglucosaminidase H, D130A Mutant
1C8X	;	2.0	;	Endo-Beta-N-Acetylglucosaminidase H, D130E Mutant
1C3F	;	2.1	;	Endo-Beta-N-Acetylglucosaminidase H, D130N Mutant
1C93	;	2.1	;	Endo-Beta-N-Acetylglucosaminidase H, D130N/E132Q Double Mutant
1C92	;	2.1	;	Endo-Beta-N-Acetylglucosaminidase H, E132A Mutant
1C91	;	2.1	;	Endo-Beta-N-Acetylglucosaminidase H, E132D
1C90	;	2.1	;	Endo-Beta-N-Acetylglucosaminidase H, E132Q Mutant
8AN0	;	2.41	;	Endo-D-arabinofuranase AraH2 from Mycobacterium tuberculosis
6DLH	;	2.2	;	Endo-fucoidan hydrolase MfFcnA4 from glycoside hydrolase family 107
6DMS	;	2.85	;	Endo-fucoidan hydrolase MfFcnA4_H294Q from glycoside hydrolase family 107
6DNS	;	2.24	;	Endo-fucoidan hydrolase MfFcnA9 from glycoside hydrolase family 107
6M8N	;	1.55	;	Endo-fucoidan hydrolase P5AFcnA from glycoside hydrolase family 107
4XZW	;	1.5	;	Endo-glucanase chimera C10
4XZB	;	1.62	;	endo-glucanase GsCelA P1
2OSW	;	1.6	;	Endo-glycoceramidase II from Rhodococcus sp.
2OYL	;	1.8	;	Endo-glycoceramidase II from Rhodococcus sp.: cellobiose-like imidazole complex
2OYK	;	1.5	;	Endo-glycoceramidase II from Rhodococcus sp.: cellobiose-like isofagomine complex
2OYM	;	1.86	;	Endo-glycoceramidase II from Rhodococcus sp.: five-membered iminocyclitol complex
2OSX	;	1.1	;	Endo-glycoceramidase II from Rhodococcus sp.: Ganglioside GM3 Complex
2OSY	;	2.1	;	Endo-glycoceramidase II from Rhodococcus sp.: Lactosyl-Enzyme Intermediate
6R3U	;	1.9	;	Endo-levanase BT1760 mutant E221A from Bacteroides thetaiotaomicron complexed with levantetraose
7B7A	;	1.3	;	ENDO-POLYGALACTURONASE FROM ARABIDOPSIS THALIANA
1CZF	;	1.68	;	ENDO-POLYGALACTURONASE II FROM ASPERGILLUS NIGER
1TF4	;	1.9	;	ENDO/EXOCELLULASE FROM THERMOMONOSPORA
1JS4	;	2.0	;	ENDO/EXOCELLULASE:CELLOBIOSE FROM THERMOMONOSPORA
4TF4	;	2.0	;	ENDO/EXOCELLULASE:CELLOPENTAOSE FROM THERMOMONOSPORA
3TF4	;	2.2	;	ENDO/EXOCELLULASE:CELLOTRIOSE FROM THERMOMONOSPORA
5AO5	;	2.48	;	Endo180 D1-4, monoclinic form
5AO6	;	3.36	;	Endo180 D1-4, trigonal form
1VRX	;	2.4	;	Endocellulase e1 from acidothermus cellulolyticus mutant y245g
6R70	;	3.5	;	Endogeneous native human 20S proteasome
7UOM	;	3.8	;	Endogenous dihydrolipoamide acetyltransferase (E2) core of pyruvate dehydrogenase complex from bovine kidney
7UOL	;	3.5	;	Endogenous dihydrolipoamide succinyltransferase (E2) core of 2-oxoglutarate dehydrogenase complex from bovine kidney
8UC0	;	2.42	;	Endogenous ligand bound FLVCR1
6SA9	;	1.8	;	Endogenous Retrovirus HML2 Capsid NTD
8IRM	;	2.6	;	Endogenous substrate adenine bound state of Arabidopsis AZG1 at pH 5.5
3UTZ	;	2.18	;	Endogenous-like inhibitory antibodies targeting activated metalloproteinase motifs show therapeutic potential
6KDD	;	1.92	;	endoglucanase
1CEM	;	1.65	;	ENDOGLUCANASE A (CELA) CATALYTIC CORE, RESIDUES 33-395
1IS9	;	1.03	;	Endoglucanase A from Clostridium thermocellum at atomic resolution
1H0B	;	1.8	;	Endoglucanase cel12A from Rhodothermus marinus
1W3K	;	1.2	;	ENDOGLUCANASE CEL5A FROM BACILLUS AGARADHAERENS IN COMPLEX WITH CELLOBIO DERIVED-TETRAHYDROOXAZINE
1W3L	;	1.04	;	ENDOGLUCANASE CEL5A FROM BACILLUS AGARADHAERENS IN COMPLEX WITH CELLOTRI DERIVED-TETRAHYDROOXAZINE
1HF6	;	1.15	;	ENDOGLUCANASE CEL5A FROM BACILLUS AGARADHAERENS IN THE ORTHORHOMBIC CRYSTAL FORM IN COMPLEX WITH CELLOTRIOSE
1QI2	;	1.75	;	ENDOGLUCANASE CEL5A FROM BACILLUS AGARADHAERENS IN THE TETRAGONAL CRYSTAL FORM IN COMPLEX WITH 2',4'-DINITROPHENYL 2-DEOXY-2-FLUORO-B-D-CELLOTRIOSIDE
1QI0	;	2.1	;	ENDOGLUCANASE CEL5A FROM BACILLUS AGARADHAERENS IN THE TETRAGONAL CRYSTAL FORM IN COMPLEX WITH CELLOBIOSE
1E5J	;	1.85	;	ENDOGLUCANASE CEL5A FROM BACILLUS AGARADHAERENS IN THE TETRAGONAL CRYSTAL FORM IN COMPLEX WITH METHYL-4II-S-ALPHA-CELLOBIOSYL-4II-THIO-BETA-CELLOBIOSIDE
1A3H	;	1.57	;	ENDOGLUCANASE CEL5A FROM BACILLUS AGARADHERANS AT 1.6A RESOLUTION
1H2J	;	1.15	;	ENDOGLUCANASE CEL5A IN COMPLEX WITH UNHYDROLYSED AND COVALENTLY LINKED 2,4-DINITROPHENYL-2-DEOXY-2-FLUORO-CELLOBIOSIDE AT 1.15 A RESOLUTION
1TVP	;	1.6	;	Endoglucanase cel5G from Pseudoalteromonas haloplanktis in complex with cellobiose
1DYS	;	1.6	;	Endoglucanase CEL6B from Humicola insolens
1HD5	;	1.66	;	Endoglucanase from Humicola insolens AT 1.7A resolution
2OVW	;	2.3	;	ENDOGLUCANASE I COMPLEXED WITH CELLOBIOSE
4OVW	;	2.3	;	ENDOGLUCANASE I COMPLEXED WITH EPOXYBUTYL CELLOBIOSE
1OVW	;	2.7	;	ENDOGLUCANASE I COMPLEXED WITH NON-HYDROLYSABLE SUBSTRATE ANALOGUE
1EG1	;	3.6	;	ENDOGLUCANASE I FROM TRICHODERMA REESEI
3OVW	;	2.3	;	ENDOGLUCANASE I NATIVE STRUCTURE
2ENG	;	1.5	;	ENDOGLUCANASE V
8A49	;	3.45	;	Endoglycosidase S in complex with IgG1 Fc
3HMC	;	1.44	;	Endolysin from Bacillus anthracis
7Q47	;	1.6	;	Endolysin from bacteriophage Enc34, catalytic domain
7M5I	;	1.71	;	Endolysin from Escherichia coli O157:H7 phage FAHEc1
7RUM	;	2.99	;	Endolysin from Escherichia coli O157:H7 phage FTEbC1, LysT84
6ILU	;	1.601	;	Endolysin LysPBC5 CBD
6SRT	;	1.21	;	Endolysine N-acetylmuramoyl-L-alanine amidase LysCS from Clostridium intestinale URNW
1VYB	;	1.8	;	Endonuclease domain of human LINE1 ORF2p
1WDU	;	2.4	;	Endonuclease domain of TRAS1, a telomere-specific non-LTR retrotransposon
5FDD	;	2.506	;	Endonuclease inhibitor 1 bound to influenza strain H1N1 polymerase acidic subunit N-terminal region at pH 7.0
5I13	;	2.151	;	Endonuclease inhibitor 2 bound to influenza strain H1N1 polymerase acidic subunit N-terminal region at pH 7.0
5FDG	;	2.1	;	Endonuclease inhibitor 3 bound to influenza strain H1N1 polymerase acidic subunit N-terminal region at pH 7.0
4ZHZ	;	2.5	;	Endonuclease inhibitor bound to influenza strain H1N1 polymerase acidic subunit N-terminal region with expelling one of the metal ions in the active site
4ZI0	;	1.802	;	Endonuclease inhibitor bound to influenza strain H1N1 polymerase acidic subunit N-terminal region without a chelation to the metal ions in the active site
5OMT	;	1.35	;	Endonuclease NucB
7YZO	;	3.4	;	Endonuclease state of the E. coli Mre11-Rad50 (SbcCD) head complex bound to ADP and dsDNA
7Z03	;	3.7	;	Endonuclease state of the E. coli Mre11-Rad50 (SbcCD) head complex bound to ADP and extended dsDNA
1E7D	;	2.8	;	Endonuclease VII (ENDOVII) Ffrom Phage T4
1EN7	;	2.4	;	ENDONUCLEASE VII (ENDOVII) FROM PHAGE T4
1E7L	;	1.32	;	Endonuclease VII (EndoVII) N62D mutant from phage T4
3TEB	;	2.99	;	endonuclease/exonuclease/phosphatase family protein from Leptotrichia buccalis C-1013-b
6UP6	;	9.0	;	Endophilin B1 helical scaffold
6UPN	;	10.0	;	Endophilin B1 helical scaffold
7NSK	;	3.1	;	Endoplasmic reticulum aminopeptidase 2 complexed with a hydroxamic ligand
7NUP	;	3.1	;	Endoplasmic reticulum aminopeptidase 2 complexed with a mixed hydroxamic and sulfonyl ligand
2M66	;		;	Endoplasmic reticulum protein 29 (ERp29) C-terminal domain: 3D Protein Fold Determination from Backbone Amide Pseudocontact Shifts Generated by Lanthanide Tags at Multiple Sites
6O6I	;		;	Endoplasmic reticulum protein 29 (ERp29) C-terminal domain: Structure Determination from Backbone Amide Pseudocontact Shifts Generated by Double-histidine Cobalt Tags
1SEN	;	1.199	;	Endoplasmic reticulum protein Rp19 O95881
1HG8	;	1.73	;	Endopolygalacturonase from the phytopathogenic fungus Fusarium moniliforme
1K5C	;	0.96	;	Endopolygalacturonase I from Stereum purpureum at 0.96 A resolution
1KCC	;	1.0	;	Endopolygalacturonase I from Stereum purpureum complexed with a galacturonate at 1.00 A resolution.
1KCD	;	1.15	;	Endopolygalacturonase I from Stereum purpureum complexed with two galacturonate at 1.15 A resolution.
5XE2	;	2.01	;	Endoribonuclease from Mycobacterial species
5XE3	;	2.3	;	Endoribonuclease in complex with its cognate antitoxin from Mycobacterial species
1V0E	;	1.9	;	Endosialidase of Bacteriophage K1F
1V0F	;	2.55	;	Endosialidase of Bacteriophage K1F in complex with oligomeric alpha-2,8-sialic acid
1KOE	;	1.5	;	ENDOSTATIN
1EPO	;	2.0	;	ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH CP-81,282 (MOR PHE NLE CHF NME)
1EPP	;	1.9	;	ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH PD-130,693 (MAS PHE LYS+MTF STA MBA)
1EPQ	;	1.9	;	ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH PD-133,450 (SOT PHE GLY+SCC GCL)
1EPR	;	2.3	;	ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH PD-135,040
7QLU	;	1.41	;	Endothiapepsin apo at 100K
7QLY	;	1.79	;	Endothiapepsin apo at 298K
1GVT	;	0.98	;	Endothiapepsin complex with CP-80,794
1GVU	;	0.94	;	Endothiapepsin complex with H189
1E5O	;	2.05	;	Endothiapepsin complex with inhibitor DB2
1GVW	;	1.0	;	Endothiapepsin complex with PD-130,328
1E80	;	2.05	;	Endothiapepsin complex with renin inhibitor MERCK-KGAA-EMD56133
1E82	;	2.05	;	Endothiapepsin complex with renin inhibitor MERCK-KGAA-EMD59601
1E81	;	2.05	;	Endothiapepsin complex with renin inhibitor MERCK-KGAA-EMD61395
1GVX	;	1.0	;	Endothiapepsin complexed with H256
4LP9	;	1.35	;	Endothiapepsin complexed with Phe-reduced-Tyr peptide.
7QLW	;	1.41	;	Endothiapepsin in 10% DMSO at 100 K
7QM0	;	1.79	;	Endothiapepsin in 10% DMSO at 298 K
7QLX	;	1.39	;	Endothiapepsin in 20% DMSO at 100 K
7QM1	;	1.79	;	Endothiapepsin in 20% DMSO at 298 K
7QLV	;	1.41	;	Endothiapepsin in 5% DMSO at 100 K
7QLZ	;	1.79	;	Endothiapepsin in 5% DMSO at 298 K
6RSV	;	1.1	;	Endothiapepsin in complex with 017
4LBT	;	1.251	;	Endothiapepsin in complex with 100mM acylhydrazone inhibitor
4KUP	;	1.311	;	Endothiapepsin in complex with 20mM acylhydrazone inhibitor
4LHH	;	1.73	;	Endothiapepsin in complex with 2mM acylhydrazone inhibitor
5LWR	;	1.249	;	Endothiapepsin in complex with a derivative of fragment 177
3PB5	;	1.9	;	Endothiapepsin in complex with a fragment
3PBD	;	1.7	;	Endothiapepsin in complex with a fragment
3PBZ	;	1.48	;	Endothiapepsin in complex with a fragment
3PCW	;	1.25	;	Endothiapepsin in complex with a fragment
3PGI	;	1.9	;	Endothiapepsin in complex with a fragment
3PI0	;	1.64	;	Endothiapepsin in complex with a fragment
3PLD	;	1.4	;	Endothiapepsin in complex with a fragment
3PLL	;	1.73	;	Endothiapepsin in complex with a fragment
3PM4	;	1.68	;	Endothiapepsin in complex with a fragment
3PMU	;	1.43	;	Endothiapepsin in complex with a fragment
3PMY	;	1.38	;	Endothiapepsin in complex with a fragment
2JJI	;	1.57	;	Endothiapepsin in complex with a gem-diol inhibitor.
2JJJ	;	1.0	;	Endothiapepsin in complex with a gem-diol inhibitor.
3T7P	;	1.35	;	Endothiapepsin in complex with a hydrazide derivative
5LWT	;	1.069	;	Endothiapepsin in complex with a methoxylated derivative of fragment 177
3Q6Y	;	1.351	;	Endothiapepsin in complex with a pyrrolidine based inhibitor
3T6I	;	1.32	;	Endothiapepsin in complex with an azepin derivative
3PSY	;	1.43	;	Endothiapepsin in complex with an inhibitor based on the Gewald reaction
3T7Q	;	1.3	;	Endothiapepsin in complex with an inhibitor based on the Gewald reaction
3T7X	;	1.27	;	Endothiapepsin in complex with an inhibitor based on the Gewald reaction
3PCZ	;	1.5	;	Endothiapepsin in complex with benzamidine
5HCT	;	1.36	;	Endothiapepsin in complex with biacylhydrazone
5IS4	;	1.368	;	Endothiapepsin in complex with chiral brominated primary amine fragment
5ISJ	;	1.651	;	Endothiapepsin in complex with chiral chlorinated primary amine fragment
6RON	;	1.15	;	Endothiapepsin in complex with compound 046
5SAR	;	0.98	;	Endothiapepsin in complex with compound FU290-1
5SAS	;	1.17	;	Endothiapepsin in complex with compound FU290-2
5SAK	;	1.1	;	Endothiapepsin in complex with compound FU5-1
5SAL	;	1.0	;	Endothiapepsin in complex with compound FU5-2
5SAM	;	1.2	;	Endothiapepsin in complex with compound FU5-3
5SAN	;	0.94	;	Endothiapepsin in complex with compound FU5-4
5SAO	;	1.0	;	Endothiapepsin in complex with compound FU58-1
5SAP	;	1.04	;	Endothiapepsin in complex with compound FU58-2
5SAQ	;	1.02	;	Endothiapepsin in complex with compound FU58-3
5SAT	;	1.4	;	Endothiapepsin in complex with compound FU66-1
7QM9	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping down structure 1)
7QMI	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping down structure 10)
7QMJ	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping down structure 11)
7QMK	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping down structure 12)
7QML	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping down structure 13)
7QMM	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping down structure 14)
7QMN	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping down structure 15)
7QMO	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping down structure 16)
7QMP	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping down structure 17)
7QMQ	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping down structure 18)
7QMA	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping down structure 2)
7QMB	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping down structure 3)
7QMC	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping down structure 4)
7QMD	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping down structure 5)
7QME	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping down structure 6)
7QMF	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping down structure 7)
7QMG	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping down structure 8)
7QMH	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping down structure 9)
7QMR	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping up structure 1)
7QN0	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping up structure 10)
7QN1	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping up structure 11)
7QN2	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping up structure 12)
7QN3	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping up structure 13)
7QN4	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping up structure 14)
7QMS	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping up structure 2)
7QMT	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping up structure 3)
7QMU	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping up structure 4)
7QMV	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping up structure 5)
7QMW	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping up structure 6)
7QMX	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping up structure 7)
7QMY	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping up structure 8)
7QMZ	;	1.79	;	Endothiapepsin in complex with compound TL00150 at room-temperature (temperature ramping up structure 9)
7QM5	;	1.79	;	Endothiapepsin in complex with compound TL00150 in 10% DMSO at 298 K
7QM6	;	1.81	;	Endothiapepsin in complex with compound TL00150 in 15% DMSO at 298 K
7QM7	;	1.79	;	Endothiapepsin in complex with compound TL00150 in 20% DMSO at 298 K
7QM8	;	1.79	;	Endothiapepsin in complex with compound TL00150 in 40% DMSO at 298 K
7QM3	;	1.79	;	Endothiapepsin in complex with compound TL00150 in 5% DMSO at 298 K
7QM4	;	1.79	;	Endothiapepsin in complex with compound TL00150 in 8% DMSO at 298 K
5ISK	;	1.14	;	Endothiapepsin in complex with fluorinated primary amine fragment
4Y37	;	1.69	;	Endothiapepsin in complex with fragement 305
4Y3M	;	1.55	;	Endothiapepsin in complex with fragment 103
4Y3Q	;	1.17	;	Endothiapepsin in complex with fragment 109
4Y41	;	1.403	;	Endothiapepsin in complex with fragment 112
4Y4T	;	1.301	;	Endothiapepsin in complex with fragment 114
4Y4W	;	1.451	;	Endothiapepsin in complex with fragment 125
4Y4E	;	1.3	;	Endothiapepsin in complex with fragment 131
4Y4U	;	1.754	;	Endothiapepsin in complex with fragment 14
5J25	;	1.24	;	Endothiapepsin in complex with fragment 158
4Y47	;	1.19	;	Endothiapepsin in complex with fragment 162
4Y44	;	1.24	;	Endothiapepsin in complex with fragment 164
4Y3P	;	1.55	;	Endothiapepsin in complex with fragment 17
4Y3X	;	1.25	;	Endothiapepsin in complex with fragment 171
5LWS	;	1.03	;	Endothiapepsin in complex with fragment 177 and a derivative thereof
4Y3A	;	1.17	;	Endothiapepsin in complex with fragment 181
4Y3H	;	1.23	;	Endothiapepsin in complex with fragment 189
5DR0	;	1.4	;	Endothiapepsin in complex with fragment 203
4Y3L	;	1.16	;	Endothiapepsin in complex with fragment 205
4Y5A	;	1.45	;	Endothiapepsin in complex with fragment 206
4Y3T	;	1.42	;	Endothiapepsin in complex with fragment 207
5DQ5	;	1.47	;	Endothiapepsin in complex with fragment 209
4YCK	;	1.07	;	Endothiapepsin in complex with fragment 211
4YCT	;	1.13	;	Endothiapepsin in complex with fragment 216
4YCY	;	1.699	;	Endothiapepsin in complex with fragment 218
4YD3	;	1.248	;	Endothiapepsin in complex with fragment 224
4YD4	;	1.27	;	Endothiapepsin in complex with fragment 227
5DR4	;	1.5	;	Endothiapepsin in complex with fragment 231
4YD5	;	1.209	;	Endothiapepsin in complex with fragment 236
4YD6	;	1.298	;	Endothiapepsin in complex with fragment 240
4YD7	;	1.419	;	Endothiapepsin in complex with fragment 255
4Y58	;	1.17	;	Endothiapepsin in complex with fragment 260
4Y5B	;	1.24	;	Endothiapepsin in complex with fragment 261
4Y3S	;	1.1	;	Endothiapepsin in complex with fragment 266
4Y5C	;	1.19	;	Endothiapepsin in complex with fragment 267
4Y5E	;	1.116	;	Endothiapepsin in complex with fragment 268
4Y5G	;	1.47	;	Endothiapepsin in complex with fragment 272
4Y3N	;	1.34	;	Endothiapepsin in complex with fragment 273
4Y5K	;	1.439	;	Endothiapepsin in complex with fragment 274
5DR1	;	1.45	;	Endothiapepsin in complex with fragment 278
4Y3G	;	1.13	;	Endothiapepsin in complex with fragment 285
4Y4A	;	1.278	;	Endothiapepsin in complex with fragment 286
4Y35	;	1.457	;	Endothiapepsin in complex with fragment 290
4Y45	;	1.06	;	Endothiapepsin in complex with fragment 291
4Y3R	;	1.13	;	Endothiapepsin in complex with fragment 306
5DPZ	;	1.328	;	Endothiapepsin in complex with fragment 31
5DR7	;	1.234	;	Endothiapepsin in complex with fragment 311
4Y3D	;	1.482	;	Endothiapepsin in complex with fragment 321
4Y4B	;	1.108	;	Endothiapepsin in complex with fragment 323
4Y5M	;	1.28	;	Endothiapepsin in complex with fragment 328
5DR8	;	1.47	;	Endothiapepsin in complex with fragment 330
5DR3	;	1.24	;	Endothiapepsin in complex with fragment 333
4Y5N	;	1.29	;	Endothiapepsin in complex with fragment 337
4Y5P	;	1.229	;	Endothiapepsin in complex with fragment 338
5DQ1	;	1.489	;	Endothiapepsin in complex with fragment 34
4Y3W	;	1.58	;	Endothiapepsin in complex with fragment 35
4Y36	;	1.59	;	Endothiapepsin in complex with fragment 4
4Y3Z	;	1.12	;	Endothiapepsin in complex with fragment 41
4Y43	;	1.48	;	Endothiapepsin in complex with fragment 42
5DQ2	;	1.514	;	Endothiapepsin in complex with fragment 48
4Y3E	;	1.25	;	Endothiapepsin in complex with fragment 5
4Y4X	;	1.67	;	Endothiapepsin in complex with fragment 51
4Y51	;	1.603	;	Endothiapepsin in complex with fragment 52
4Y53	;	1.62	;	Endothiapepsin in complex with fragment 54
4Y54	;	1.61	;	Endothiapepsin in complex with fragment 56
4Y56	;	1.63	;	Endothiapepsin in complex with fragment 58
4Y57	;	1.49	;	Endothiapepsin in complex with fragment 63
5DQ4	;	1.15	;	Endothiapepsin in complex with fragment 66
4Y4Z	;	1.48	;	Endothiapepsin in complex with fragment 73
4Y39	;	1.2	;	Endothiapepsin in complex with fragment 75
4Y3F	;	1.4	;	Endothiapepsin in complex with fragment 78
4Y50	;	1.32	;	Endothiapepsin in complex with fragment 81
4Y38	;	1.1	;	Endothiapepsin in complex with fragment B29
4Y3J	;	1.31	;	Endothiapepsin in complex with fragment B30
4ZE6	;	1.17	;	Endothiapepsin in complex with fragment B39
4Y3Y	;	1.346	;	Endothiapepsin in complex with fragment B42
4Y48	;	1.249	;	Endothiapepsin in complex with fragment B50
4Y4D	;	1.269	;	Endothiapepsin in complex with fragment B51
4Y4G	;	1.439	;	Endothiapepsin in complex with fragment B53
4ZEA	;	1.2	;	Endothiapepsin in complex with fragment B91
4Y4J	;	1.03	;	Endothiapepsin in complex with fragment B97
3WZ6	;	1.404	;	Endothiapepsin in complex with Gewald reaction-derived inhibitor (5)
3WZ7	;	1.9	;	Endothiapepsin in complex with Gewald reaction-derived inhibitor (6)
3WZ8	;	1.45	;	Endothiapepsin in complex with Gewald reaction-derived inhibitor (8)
5HCO	;	1.17	;	Endothiapepsin in complex with hydrazide
5OG7	;	1.823	;	Endothiapepsin in complex with hydrazide fragment
6SCV	;	1.7	;	Endothiapepsin in complex with ligand 69
7QLT	;	1.39	;	Endothiapepsin in complex with ligand TL00150 in 10% DMSO at 100K
3PRS	;	1.38	;	Endothiapepsin in complex with ritonavir
3PWW	;	1.22	;	Endothiapepsin in complex with saquinavir
4LAP	;	1.12	;	Endothiapepsin in complex with thiophen-based inhibitor SAP114
4L6B	;	1.37	;	Endothiapepsin in complex with thiophen-based inhibitor SAP128
4Y5L	;	0.99	;	Endothiapepsin in its apo form
1OD1	;	1.37	;	Endothiapepsin PD135,040 complex
7BKV	;	1.24	;	Endothiapepsin structure obtained at 100K with fragment AC39729 bound
7BKW	;	1.43	;	Endothiapepsin structure obtained at 100K with fragment BTB09871 bound
7BKU	;	1.4	;	Endothiapepsin structure obtained at 100K with fragment JFD03909 bound
7BKZ	;	1.9	;	Endothiapepsin structure obtained at 298K after a soaking with fragment AC39729 from a dataset collected with JUNGFRAU detector
7NKW	;	2.27	;	Endothiapepsin structure obtained at 298K after a soaking with fragment JFD03909 from a dataset collected with JUNGFRAU detector
7BKR	;	2.1	;	Endothiapepsin structure obtained at 298K and 40 mM DMSO from a dataset collected with JUNGFRAU detector
7BKY	;	1.9	;	Endothiapepsin structure obtained at 298K with fragment BTB09871 bound from a dataset collected with JUNGFRAU detector
5OJE	;	1.579	;	Endothiapepsin with Ligand VSK-B24
3URI	;	2.1	;	Endothiapepsin-DB5 complex.
3URL	;	2.0	;	Endothiapepsin-DB6 complex.
4JME	;	1.7	;	Enduracididine biosynthesis enzyme MppR complexed with 2-keto-enduracididine
4JMC	;	1.72	;	Enduracididine biosynthesis enzyme MppR complexed with pyruvate
4JMD	;	1.67	;	Enduracididine biosynthesis enzyme MppR complexed with the condensation product of pyruvate and imidazole 4-carboxaldehyde
4JM3	;	1.85	;	Enduracididine Biosynthesis Enzyme MppR with HEPES Buffer Bound
5OCS	;	1.7	;	Ene-reductase (ER/OYE) from Ralstonia (Cupriavidus) metallidurans
1NKO	;	1.45	;	Energetic and structural basis of sialylated oligosaccharide recognition by the natural killer cell inhibitory receptor p75/AIRM1 or Siglec-7
7KOT	;	1.74	;	Energetic and structural effects of the Tanford transition on the ligand recognition of bovine Beta-lactoglobulin
7KP5	;	2.4	;	Energetic and structural effects of the Tanford transition on the ligand recognition of bovine Beta-lactoglobulin
7UMH	;	2.6	;	Energetic robustness to large scale structural dynamics in a photosynthetic supercomplex
1QHE	;	2.0	;	ENERGETICS OF A HYDROGEN BOND (CHARGED AND NEUTRAL) AND OF A CATION-PI INTERACTION IN APOFLAVODOXIN
3J6E	;	4.7	;	Energy minimized average structure of Microtubules stabilized by GmpCpp
6QEV	;	2.7	;	EngBF DARPin Fusion 4b B6
6SH9	;	2.4	;	EngBF DARPin Fusion 4b D12
6QFK	;	2.0	;	EngBF DARPin Fusion 4b G10
6QEP	;	2.6	;	EngBF DARPin Fusion 4b H14
6QFO	;	2.3	;	EngBF DARPin Fusion 9b 3G124
3ZZS	;	1.49	;	Engineered 12-subunit Bacillus stearothermophilus trp RNA-binding attenuation protein (TRAP)
3ZZQ	;	1.75	;	Engineered 12-subunit Bacillus subtilis trp RNA-binding attenuation protein (TRAP)
5L86	;	1.9	;	engineered ascorbate peroxidise
1AXK	;	2.1	;	ENGINEERED BACILLUS BIFUNCTIONAL ENZYME GLUXYN-1
1BXM	;	2.15	;	ENGINEERED BETA-CRYPTOGEIN COMPLEXED WITH ERGOSTEROL
6XVE	;	2.15	;	Engineered beta-lactoglobulin: variant F105L
6RWQ	;	2.05	;	Engineered beta-lactoglobulin: variant F105L in complex with myristic acid
5NUM	;	2.3	;	Engineered beta-lactoglobulin: variant F105L-L39A in complex with chlorpromazine (LG-LA-CLP)
5NUN	;	1.95	;	Engineered beta-lactoglobulin: variant F105L-L39A-M107F in complex with chlorpromazine (LG-LAF-CLP)
6QPD	;	2.0	;	Engineered beta-lactoglobulin: variant I56F
5NUJ	;	2.6	;	Engineered beta-lactoglobulin: variant I56F-L39A in complex with chlorpromazine (LG-FA-CLP)
5NUK	;	1.7	;	Engineered beta-lactoglobulin: variant I56F-L39A-M107F in complex with chlorpromazine (LG-FAF-CLP)
6QI7	;	2.5	;	Engineered beta-lactoglobulin: variant L39Y in complex with endogenous ligand
6QPE	;	2.2	;	Engineered beta-lactoglobulin: variant L58F
6RWP	;	2.1	;	Engineered beta-lactoglobulin: variant L58F in complex with myristic acid
6RYT	;	2.1	;	Engineered beta-lactoglobulin: variant M107L
6RWR	;	2.1	;	Engineered beta-lactoglobulin: variant M107L in complex with myristic acid
6WK3	;	2.45	;	Engineered carbene transferase RmaNOD Q52V, putative nitric oxide dioxygenase from Rhodothermus marinus
4ZWZ	;	1.62	;	Engineered Carbonic Anhydrase IX mimic in complex with a glucosyl sulfamate inhibitor
4ZX1	;	1.501	;	Engineered Carbonic Anhydrase IX mimic in complex with a glucosyl sulfamate inhibitor
4ZWX	;	1.696	;	Engineered Carbonic Anhydrase IX mimic in complex with glucosyl sulfamate inhibitor
2I3R	;	1.85	;	Engineered catalytic domain of protein tyrosine phosphatase HPTPbeta
2HC1	;	1.3	;	Engineered catalytic domain of protein tyrosine phosphatase HPTPbeta.
5DPN	;	1.606	;	Engineered CBM X-2 L110F in complex with branched carbohydrate XXXG.
5DPN	;	1.6	;	Engineered CBM X-2 L110F in complex with branched carbohydrate XXXG.
5ZL9	;	2.6	;	Engineered chitinase, SmChiAB-FYSFV
6Y7T	;	2.5	;	Engineered conjugation of lysine-specific molecular tweezers with ExoS derived peptidic inhibitor enhance affinity towards target protein 14-3-3 through ditopic binding
6CUN	;	1.29	;	Engineered Cytochrome c from Rhodothermus marinus (Rma TDE) bound to carbene intermediate (1-ethoxy-1-oxopropan-2-ylidene)
6CUK	;	1.47	;	Engineered Cytochrome c from Rhodothermus marinus, Rma TDE
4J8T	;	2.05	;	Engineered Digoxigenin binder DIG10.2
4J9A	;	3.2	;	Engineered Digoxigenin binder DIG10.3
5BVB	;	2.06	;	Engineered Digoxigenin binder DIG5.1a
7M2W	;	3.0	;	Engineered disulfide cross-linked closed conformation of the Yeast gamma-TuRC(SS)
4POY	;	1.5	;	Engineered Dual Specific VHH antibody
4PPT	;	1.5	;	Engineered Dual Specific VHH Antibody in Complex with a Nickel (II) Ion
4PIP	;	1.8	;	Engineered EgtD variant EgtD-M252V,E282A in complex with tryptophan and SAH
8RVJ	;	3.1	;	Engineered Encapsulin P3P4
2I9K	;	2.65	;	Engineered Extrahelical Base Destabilization Enhances Sequence Discrimination of DNA Methyltransferase M.HhaI
6OEL	;	3.1	;	Engineered Fab bound to IL-4 receptor
4X0K	;	2.04	;	Engineered Fab fragment specific for EYMPME (EE) peptide
6C4U	;	2.6	;	Engineered FHA with Myc-pTBD peptide
6K1M	;	2.32	;	Engineered form of a putative cystathionine gamma-lyase
6Y4J	;	1.38	;	Engineered Fructosyl Peptide Oxidase
8BLZ	;	1.7	;	Engineered Fructosyl Peptide Oxidase - D02 mutant
8BLX	;	1.71	;	Engineered Fructosyl Peptide Oxidase - X02A mutant
8BJY	;	1.475	;	Engineered Fructosyl Peptide Oxidase - X02B mutant
8BMU	;	1.6	;	Engineered Fructosyl Peptide Oxidase - X04 mutant
8EYZ	;	2.99	;	Engineered glutamine binding protein bound to GLN and a cobaloxime ligand
8PN7	;	2.03	;	Engineered glycolyl-CoA carboxylase (G20R variant) with bound CoA
8PN8	;	2.31	;	Engineered glycolyl-CoA carboxylase (L100N variant) with bound CoA
6YBQ	;	1.96	;	Engineered glycolyl-CoA carboxylase (quintuple mutant) with bound CoA
6GVS	;	2.579	;	Engineered glycolyl-CoA reductase comprising 8 mutations with bound NADP+
5YCT	;	1.851	;	Engineered hairpin loop3 mutant monomer in Single-chain Monellin
7EOY	;	3.6	;	Engineered Hepatitis B virus core antigen T=3
7EP6	;	3.86	;	Engineered Hepatitis B virus core antigen T=4
7FDJ	;	4.4	;	Engineered Hepatitis B virus core antigen with short linker T=4
3SSK	;	1.361	;	Engineered high-affinity halide-binding protein derived from YFP: bromide complex
3SSH	;	1.277	;	Engineered high-affinity halide-binding protein derived from YFP: chloride complex
3SS0	;	1.492	;	Engineered high-affinity halide-binding protein derived from YFP: fluoride complex
3SRY	;	1.159	;	Engineered high-affinity halide-binding protein derived from YFP: halide-free
3SSL	;	1.449	;	Engineered high-affinity halide-binding protein derived from YFP: iodide complex
1N3W	;	2.6	;	Engineered High-Affinity Maltose-Binding Protein
1NL5	;	2.1	;	Engineered High-affinity Maltose-Binding Protein
6HSV	;	2.45	;	Engineered higher-order assembly of Cholera Toxin B subunits via the addition of C-terminal parallel coiled-coiled domains
6CUV	;	2.26	;	Engineered Holo TrpB from Pyrococcus furiosus, PfTrpB7E6
6CUT	;	1.77	;	Engineered Holo TrpB from Pyrococcus furiosus, PfTrpB7E6 with (2S,3S)-isopropylserine bound as the external aldimine
8EGY	;	2.05	;	Engineered holo tyrosine synthase (TmTyrS1) derived from T. maritima TrpB
5EIG	;	2.7	;	Engineered human cystathionine gamma lyase (E59T, E339V) to deplet cysteine
8FCY	;	3.4	;	Engineered human dynein motor domain in microtubule-bound state
8FD6	;	2.9	;	Engineered human dynein motor domain in the microtubule-unbound state in the buffer containing ATP-Vi
8FDT	;	3.2	;	Engineered human dynein motor domain in the microtubule-unbound state with LIS1 complex in the buffer containing ATP-Vi
8FDU	;	3.3	;	Engineered human dynein motor domain in the microtubule-unbound state with LIS1 complex in the buffer containing ATP-Vi (local refined on AAA3-AAA5 and LIS1)
6Q3K	;	1.5	;	Engineered Human HLA_A2 MHC Class I molecule in complex with NV9 peptide
6Q3S	;	2.5	;	Engineered Human HLA_A2 MHC Class I molecule in complex with TCR and SV9 peptide
5V43	;	2.32	;	Engineered human IgG Fc domain aglyco801
5V4E	;	3.216	;	Engineered human IgG Fc domain glyco801 (Fc801)
1LK3	;	1.91	;	ENGINEERED HUMAN INTERLEUKIN-10 MONOMER COMPLEXED TO 9D7 FAB FRAGMENT
4IAW	;	2.4	;	Engineered human lipocalin 2 (C26) in complex with Y-DTPA
4IAX	;	1.9	;	Engineered human lipocalin 2 (CL31) in complex with Y-DTPA
3BX7	;	2.1	;	Engineered Human Lipocalin 2 (LCN2) in Complex with the Extracellular Domain of Human CTLA-4
3BX8	;	2.0	;	Engineered Human Lipocalin 2 (LCN2), apo-form
3DSZ	;	2.0	;	Engineered human lipocalin 2 in complex with Y-DTPA
3DTQ	;	2.5	;	Engineered human lipocalin 2 with specificity for Y-DTPA, apo-form
7ZMZ	;	3.2	;	Engineered Interleukin 2 bound to CD25 receptor
5E4E	;	3.0	;	Engineered Interleukin-13 bound to receptor
6Z2C	;	1.8	;	Engineered lipocalin C3A5 in complex with a transition state analog
1KXO	;	1.8	;	ENGINEERED LIPOCALIN DIGA16 : APO-FORM
1LKE	;	1.9	;	ENGINEERED LIPOCALIN DIGA16 IN COMPLEX WITH DIGOXIGENIN
1N0S	;	2.0	;	ENGINEERED LIPOCALIN FLUA IN COMPLEX WITH FLUORESCEIN
3SVE	;	1.492	;	Engineered low-affinity halide-binding protein derived from YFP: bromide complex
3SST	;	1.403	;	Engineered low-affinity halide-binding protein derived from YFP: chloride complex
3SSV	;	1.861	;	Engineered low-affinity halide-binding protein derived from YFP: fluoride complex
3SSP	;	1.628	;	Engineered low-affinity halide-binding protein derived from YFP: halide-free
3SSY	;	1.769	;	Engineered low-affinity halide-binding protein derived from YFP: iodide complex
4UM1	;	2.83	;	Engineered Ls-AChBP with alpha4-alpha4 binding pocket in complex with NS3573
4UM3	;	2.703	;	Engineered Ls-AChBP with alpha4-alpha4 binding pocket in complex with NS3920
3SVD	;	1.78	;	Engineered medium-affinity halide-binding protein derived from YFP: bromide complex
3SVC	;	1.31	;	Engineered medium-affinity halide-binding protein derived from YFP: chloride complex
3SVB	;	1.3	;	Engineered medium-affinity halide-binding protein derived from YFP: fluoride complex
3ST0	;	1.19	;	Engineered medium-affinity halide-binding protein derived from YFP: halide-free
3SV5	;	1.53	;	Engineered medium-affinity halide-binding protein derived from YFP: iodide complex
8C3E	;	2.1	;	Engineered mini-protein LCB2 (blocking ligand of SARS-Cov-2 spike protein)
8CMV	;	1.28	;	Engineered PETase enzyme from LCC - C09 mutant
7P85	;	1.47	;	Engineered phosphotriesterase BdPTE 10-2-C3(C59V/C227V) in complex with ethyl-4-methylbenzylphosphonate
7MKV	;	2.25	;	Engineered PLP-dependent decarboxylative aldolase from Aspergillus flavus, UstD2.0, bound as the internal aldimine
7ZFM	;	1.711	;	Engineered Protein Targeting the Zika Viral Envelope Fusion Loop
2HC2	;	1.4	;	Engineered protein tyrosine phosphatase beta catalytic domain
3C72	;	2.3	;	Engineered RabGGTase in complex with a peptidomimetic inhibitor
3HXF	;	1.9	;	Engineered RabGGTase in complex with a peptidomimetic inhibitor (compound 32)
3HXE	;	1.95	;	Engineered RabGGTase in complex with a peptidomimetic inhibitor (compound 37)
3HXB	;	2.25	;	Engineered RabGGTase in complex with a peptidomimetic inhibitor (compound 6)
3HXC	;	1.95	;	Engineered RabGGTase in complex with a peptidomimetic inhibitor (compound 8)
3HXD	;	1.95	;	Engineered RabGGTase in complex with a peptidomimetic inhibitor (compound 9)
4GTT	;	2.05	;	Engineered RabGGTase in complex with BMS analogue 12
4GTV	;	1.95	;	Engineered RabGGTase in complex with BMS analogue 13
4GTS	;	2.45	;	Engineered RabGGTase in complex with BMS analogue 16
8EK5	;	2.11	;	Engineered scFv 10LH bound to PHOX2B/HLA-A24:02
6P79	;	1.583	;	Engineered single chain antibody C9+C14 ScFv
6M8F	;	1.1	;	Engineered sperm whale myoglobin-based carbene transferase
7SLI	;	2.0	;	Engineered sperm whale myoglobin-based carbene transferase MbBTIC-C2
7SLH	;	1.15	;	Engineered sperm whale myoglobin-based carbene transferase MbBTIC-C3
6QW4	;	2.1	;	Engineered streptavidin variant (ACGR) in complex with the Strep-tag II peptide
6QBB	;	1.52	;	Engineered streptavidin variant (ENAGY) in complex with the Strep-tag II peptide
6SOS	;	2.2	;	Engineered streptavidin variant (ENAGY) in complex with the Twin-Strep-tag peptide
6QSY	;	1.7	;	Engineered streptavidin variant (H--WY) in complex with the Strep-tag II peptide
6SOK	;	1.96	;	Engineered streptavidin variant (VTAR) in complex with the Twin-Strep-tag peptide
6TIP	;	2.1	;	Engineered streptavidin variant (YNAFM) in complex with the Strep-tag II peptide
3Q7J	;	2.91	;	Engineered Thermoplasma Acidophilum F3 factor mimics human aminopeptidase N (APN) as a target for anticancer drug development
4P08	;	2.341	;	Engineered thermostable dimeric cocaine esterase
6CUZ	;	1.75	;	Engineered TrpB from Pyrococcus furiosus, PfTrpB7E6 with (2S,3R)-ethylserine bound as the amino-acrylate
6AM7	;	1.47	;	Engineered tryptophan synthase b-subunit from Pyrococcus furiosus, PfTrpB2B9
6AM8	;	1.83	;	Engineered tryptophan synthase b-subunit from Pyrococcus furiosus, PfTrpB2B9 with Trp bound as E(Aex2)
5VM5	;	1.67	;	Engineered tryptophan synthase b-subunit from Pyrococcus furiosus, PfTrpB2B9, with Ser bound
6AM9	;	2.09	;	Engineered tryptophan synthase b-subunit from Pyrococcus furiosus, PfTrpB2B9, with Ser-bound in a predominantly closed state.
7ROF	;	2.39	;	Engineered tryptophan synthase b-subunit from Pyrococcus furiosus, PfTrpB2B9-H275E with L-Trp non-covalently bound
7RNP	;	2.25	;	Engineered tryptophan synthase b-subunit from Pyrococcus furiosus, PfTrpB2B9_H275E with 4-Cl-Trp non-covalently bound
6AMC	;	1.93	;	Engineered tryptophan synthase b-subunit from Pyrococcus furiosus, PfTrpB4D11
6AMH	;	1.63	;	Engineered tryptophan synthase b-subunit from Pyrococcus furiosus, PfTrpB4D11 with Ser bound as E(Aex1)
6AMI	;	1.97	;	Engineered tryptophan synthase b-subunit from Pyrococcus furiosus, PfTrpB4D11 with Trp non-covalently bound
6VZR	;	2.6	;	Engineered TTLL6 bound to the initiation analog
6VZQ	;	3.08	;	Engineered TTLL6 mutant bound to alpha-elongation analog
6VZS	;	2.66	;	Engineered TTLL6 mutant bound to gamma-elongation analog
8EGZ	;	1.9	;	Engineered tyrosine synthase (TmTyrS1) derived from T. maritima TrpB with Ser bound as the amino-acrylate intermediate
8EH1	;	2.0	;	Engineered tyrosine synthase (TmTyrS1) derived from T. maritima TrpB with Ser bound as the amino-acrylate intermediate and complexed with 4-hydroxyquinoline
8EH0	;	1.7	;	Engineered tyrosine synthase (TmTyrS1) derived from T. maritima TrpB with Ser bound as the amino-acrylate intermediate and complexed with quinoline N-oxide
4OUD	;	2.65	;	Engineered tyrosyl-tRNA synthetase with the nonstandard amino acid L-4,4-biphenylalanine
5T2N	;	2.079	;	Engineered variant of I-OnuI meganuclease targeting the Anopheles AGAP007280 gene; harbors 38 point mutations relative to wild-type I-OnuI
5T2O	;	2.801	;	Engineered variant of I-OnuI meganuclease targeting the Anopheles AGAP011377 gene; harbors 53 point mutations relative to wild-type I-OnuI
5THG	;	3.106	;	Engineered variant of I-OnuI meganuclease targeting the HIV CCR5 gene; harbors 43 point mutations relative to wild-type I-OnuI
5T8D	;	2.15	;	Engineered variant of I-OnuI meganuclease targeting the HIV integrase gene; harbors 47 point mutations relative to wild-type I-OnuI
5T2H	;	2.517	;	Engineered variant of I-OnuI meganuclease targeting the Human TCRa gene; harbors 43 point mutations relative to wild-type I-OnuI
6UWK	;	2.533	;	Engineered variant of I-OnuI meganuclease with improved stability and fully altered specificity targeting human chromosome 11 trans integration site
6UVW	;	2.551	;	Engineered variant of I-OnuI meganuclease with improved thermostability
6UWG	;	2.22	;	Engineered variant of I-OnuI meganuclease with improved thermostability and E178D mutation at catalytic site
6UW0	;	2.72	;	Engineered variant of I-OnuI meganuclease with improved thermostability and fully altered specificity targeting cholera toxin A subunit
4AW4	;	1.93	;	Engineered variant of Listeria monocytogenes InlB internalin domain with an additional leucine rich repeat inserted
3KX9	;	2.101	;	Engineering a closed form of the Archaeoglobus fulgidus ferritin by site directed mutagenesis
1A7B	;	3.1	;	ENGINEERING A MISFOLDED FORM OF CD2
1A64	;	2.0	;	ENGINEERING A MISFOLDED FORM OF RAT CD2
1SYC	;	1.8	;	ENGINEERING ALTERNATIVE BETA-TURN TYPES IN STAPHYLOCOCCAL NUCLEASE
1SYD	;	1.7	;	ENGINEERING ALTERNATIVE BETA-TURN TYPES IN STAPHYLOCOCCAL NUCLEASE
1SYE	;	1.8	;	ENGINEERING ALTERNATIVE BETA-TURN TYPES IN STAPHYLOCOCCAL NUCLEASE
1SYF	;	1.8	;	ENGINEERING ALTERNATIVE BETA-TURN TYPES IN STAPHYLOCOCCAL NUCLEASE
1SYG	;	1.9	;	ENGINEERING ALTERNATIVE BETA-TURN TYPES IN STAPHYLOCOCCAL NUCLEASE
3E2N	;	1.3	;	Engineering ascorbate peroxidase activity into cytochrome c peroxidase
1KRJ	;	2.0	;	Engineering Calcium-binding site into Cytochrome c Peroxidase (CcP)
8EP8	;	2.45	;	Engineering Crystals with Tunable Symmetries from 14- or 16-Base-Long DNA Strands
8EPB	;	2.61	;	Engineering Crystals with Tunable Symmetries from 14- or 16-Base-Long DNA Strands
8EPD	;	2.42	;	Engineering Crystals with Tunable Symmetries from 14- or 16-Base-Long DNA Strands
8EPE	;	2.45	;	Engineering Crystals with Tunable Symmetries from 14- or 16-Base-Long DNA Strands
8EPF	;	2.61	;	Engineering Crystals with Tunable Symmetries from 14- or 16-Base-Long DNA Strands
8EPG	;	2.15	;	Engineering Crystals with Tunable Symmetries from 14- or 16-Base-Long DNA Strands
8EPI	;	2.55	;	Engineering Crystals with Tunable Symmetries from 14- or 16-Base-Long DNA Strands
8F40	;	2.45	;	Engineering Crystals with Tunable Symmetries from 14- or 16-Base-Long DNA Strands
8F42	;	2.55	;	Engineering Crystals with Tunable Symmetries from 14- or 16-Base-Long DNA Strands
7D8B	;	2.46	;	Engineering Disulphide-Free Autonomous Antibody VH Domains to modulate intracellular pathways
3Q3F	;	2.169	;	Engineering Domain-Swapped Binding Interfaces by Mutually Exclusive Folding: Insertion of Ubiquitin into position 103 of Barnase
3CMS	;	2.0	;	ENGINEERING ENZYME SUB-SITE SPECIFICITY: PREPARATION, KINETIC CHARACTERIZATION AND X-RAY ANALYSIS AT 2.0-ANGSTROMS RESOLUTION OF VAL111PHE SITE-MUTATED CALF CHYMOSIN
1GJ6	;	1.5	;	ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
1GJ7	;	1.5	;	ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
1GJ8	;	1.64	;	ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
1GJ9	;	1.8	;	ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
1GJA	;	1.56	;	ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
1GJB	;	1.9	;	ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
1GJC	;	1.73	;	ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
1GJD	;	1.75	;	ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
1A6P	;	2.08	;	ENGINEERING OF A MISFOLDED FORM OF CD2
3T1G	;	2.35	;	Engineering of organophosphate hydrolase by computational design and directed evolution
5LO2	;		;	Engineering protein stability with atomic precision in a monomeric miniprotein
5LO3	;		;	Engineering protein stability with atomic precision in a monomeric miniprotein
5LO4	;		;	Engineering protein stability with atomic precision in a monomeric miniprotein
3ZXJ	;	1.85	;	Engineering the active site of a GH43 glycoside hydrolase generates a biotechnologically significant enzyme that displays both endo- xylanase and exo-arabinofuranosidase activity
3ZXK	;	1.44	;	Engineering the active site of a GH43 glycoside hydrolase generates a biotechnologically significant enzyme that displays both endo- xylanase and exo-arabinofuranosidase activity
3ZXL	;	1.871	;	Engineering the active site of a GH43 glycoside hydrolase generates a biotechnologically significant enzyme that displays both endo- xylanase and exo-arabinofuranosidase activity
2XH7	;	1.8	;	Engineering the enolase active site pocket: Crystal structure of the D321A mutant of yeast enolase 1
2XH4	;	1.7	;	Engineering the enolase active site pocket: Crystal structure of the S39A D321A mutant of yeast enolase 1
2XH2	;	1.8	;	Engineering the enolase active site pocket: Crystal structure of the S39N D321A mutant of yeast enolase 1
2XGZ	;	1.8	;	Engineering the enolase active site pocket: Crystal structure of the S39N D321R mutant of yeast enolase 1
2XH0	;	1.7	;	Engineering the enolase active site pocket: Crystal structure of the S39N Q167K D321R mutant of yeast enolase 1
4CA2	;	2.1	;	ENGINEERING THE HYDROPHOBIC POCKET OF CARBONIC ANHYDRASE II
6CA2	;	2.5	;	ENGINEERING THE HYDROPHOBIC POCKET OF CARBONIC ANHYDRASE II
7CA2	;	2.4	;	ENGINEERING THE HYDROPHOBIC POCKET OF CARBONIC ANHYDRASE II
8CA2	;	2.4	;	ENGINEERING THE HYDROPHOBIC POCKET OF CARBONIC ANHYDRASE II
9CA2	;	2.8	;	ENGINEERING THE HYDROPHOBIC POCKET OF CARBONIC ANHYDRASE II
2I5X	;	1.7	;	Engineering the PTPbeta catalytic domain with improved crystallization properties
5D8I	;	2.05	;	Engineering the Species-Specificity of an Inhibitory Antibody Targeting a Modulator of Tumor Stroma
1YQA	;		;	Engineering the structural stability and functional properties of the GI domain into the intrinsically unfolded GII domain of the yeast linker histone Hho1p
5M7Q	;	1.8	;	Engineering the Thermostability of Nanobodies - NbD2
1HVA	;	2.3	;	ENGINEERING THE ZINC BINDING SITE OF HUMAN CARBONIC ANHYDRASE II: STRUCTURE OF THE HIS-94-> CYS APOENZYME IN A NEW CRYSTALLINE FORM
3HDD	;	2.2	;	ENGRAILED HOMEODOMAIN DNA COMPLEX
2P81	;		;	Engrailed homeodomain helix-turn-helix motif
1DU0	;	2.0	;	ENGRAILED HOMEODOMAIN Q50A VARIANT DNA COMPLEX
2HDD	;	1.9	;	ENGRAILED HOMEODOMAIN Q50K VARIANT DNA COMPLEX
3P2P	;	2.1	;	ENHANCED ACTIVITY AND ALTERED SPECIFICITY OF PHOSPHOLIPASE A2 BY DELETION OF A SURFACE LOOP
1S6Z	;	1.5	;	Enhanced Green Fluorescent Protein Containing the Y66L Substitution
2FO4	;	2.7	;	Enhanced MHC class I binding and immune responses through anchor modification of the non-canonical tumor associated MUC1-8 peptide
1L19	;	1.7	;	ENHANCED PROTEIN THERMOSTABILITY FROM DESIGNED MUTATIONS THAT INTERACT WITH ALPHA-HELIX DIPOLES
1L20	;	1.85	;	ENHANCED PROTEIN THERMOSTABILITY FROM DESIGNED MUTATIONS THAT INTERACT WITH ALPHA-HELIX DIPOLES
1L23	;	1.7	;	ENHANCED PROTEIN THERMOSTABILITY FROM SITE-DIRECTED MUTATIONS THAT DECREASE THE ENTROPY OF UNFOLDING
1L24	;	1.7	;	ENHANCED PROTEIN THERMOSTABILITY FROM SITE-DIRECTED MUTATIONS THAT DECREASE THE ENTROPY OF UNFOLDING
5DY6	;	2.66	;	Enhanced superfolder GFP with DBCO at 148
1CNM	;	2.2	;	ENHANCEMENT OF CATALYTIC EFFICIENCY OF PROTEINASE K THROUGH EXPOSURE TO ANHYDROUS ORGANIC SOLVENT AT 70 DEGREES CELSIUS
1EGQ	;	1.55	;	ENHANCEMENT OF ENZYME ACTIVITY THROUGH THREE-PHASE PARTITIONING: CRYSTAL STRUCTURE OF A MODIFIED SERINE PROTEINASE AT 1.5 A RESOLUTION
189L	;	2.5	;	ENHANCEMENT OF PROTEIN STABILITY BY THE COMBINATION OF POINT MUTATIONS IN T4 LYSOZYME IS ADDITIVE
4FHB	;	2.8	;	Enhancing DHFR catalysis by binding of an allosteric regulator nanobody (Nb179)
1RWE	;	1.8	;	Enhancing the activity of insulin at receptor edge: crystal structure and photo-cross-linking of A8 analogues
2K91	;		;	Enhancing the activity of insulin by stereospecific unfolding
2K9R	;		;	Enhancing the activity of insulin by stereospecific unfolding
2W68	;	2.5	;	ENHANCING THE RECEPTOR AFFINITY OF THE SIALIC ACID-BINDING DOMAIN OF VIBRIO CHOLERAE SIALIDASE THROUGH MULTIVALENCY
3KQ6	;	1.9	;	Enhancing the Therapeutic Properties of a Protein by a Designed Zinc-Binding Site, Structural principles of a novel long-acting insulin analog
5J9S	;	2.702	;	ENL YEATS in complex with histone H3 acetylation at K27
1E9I	;	2.48	;	Enolase from E.coli
5OHG	;	1.997	;	enolase in complex with RNase E
1NAW	;	2.0	;	ENOLPYRUVYL TRANSFERASE
2NSD	;	1.9	;	Enoyl acyl carrier protein reductase InhA in complex with N-(4-methylbenzoyl)-4-benzylpiperidine
1H0K	;	2.11	;	Enoyl thioester reductase 2
1GU7	;	1.7	;	Enoyl thioester reductase from Candida tropicalis
1GUF	;	2.25	;	Enoyl thioester reductase from Candida tropicalis
4BKO	;	1.9	;	Enoyl-ACP reducatase FabV from Burkholderia pseudomallei (apo)
4BKU	;	1.841	;	Enoyl-ACP reductase FabI from Burkholderia pseudomallei with cofactor NADH and inhibitor PT155
3LT4	;	2.25	;	Enoyl-ACP Reductase from Plasmodium falciparum (PfENR) in complex with triclosan variant PB4
3LSY	;	2.85	;	Enoyl-ACP Reductase from Plasmodium falciparum (PfENR) in complex with triclosan variant T0
3LT0	;	1.96	;	Enoyl-ACP Reductase from Plasmodium falciparum (PfENR) in complex with triclosan variant T1
3LT1	;	2.2	;	Enoyl-ACP Reductase from Plasmodium falciparum (PfENR) in complex with triclosan variant T2
3LT2	;	2.5	;	Enoyl-ACP Reductase from Plasmodium falciparum (PfENR) in complex with triclosan variant T3
4BKQ	;	2.3	;	Enoyl-ACP reductase from Yersinia pestis (wildtype)with cofactor NADH
4BKR	;	1.798	;	Enoyl-ACP reductase from Yersinia pestis (wildtype, removed Histag) with cofactor NADH
4W82	;	1.7	;	Enoyl-acyl carrier protein-reductase domain from human fatty acid synthase
4W9N	;	1.84	;	Enoyl-acyl carrier protein-reductase domain from human fatty acid synthase complexed with triclosan
6OWE	;	1.72	;	Enoyl-CoA carboxylases/reductases in complex with ethylmalonyl CoA
6LVP	;	2.69	;	Enoyl-CoA hydratase (HyECH) from Hymenobacter sp. PAMC 26628
2DUB	;	2.4	;	ENOYL-COA HYDRATASE COMPLEXED WITH OCTANOYL-COA
6IJK	;	2.0	;	Enoyl-CoA hydratase/isomerase family protein from Cupriavidus necator H16
6LVO	;	2.36	;	Enoyl-CoA isomerase (BoECI) from Bosea sp. PAMC 26642
8C00	;	2.9	;	Enp1TAP-S21_A population of yeast small ribosomal subunit precursors depleted of rpS21/eS21
8C01	;	2.7	;	Enp1TAP_A population of yeast small ribosomal subunit precursors
4PTH	;	0.85	;	Ensemble model for Escherichia coli dihydrofolate reductase at 100K
4PTJ	;	1.05	;	Ensemble model for Escherichia coli dihydrofolate reductase at 277K
1MPE	;		;	Ensemble of 20 structures of the tetrameric mutant of the B1 domain of streptococcal protein G
1Q10	;		;	Ensemble of 40 Structures of the Dimeric Mutant of the B1 Domain of Streptococcal Protein G
1OV2	;		;	Ensemble of the solution structures of domain one of receptor associated protein
2JXM	;		;	Ensemble of twenty structures of the Prochlorothrix hollandica plastocyanin- cytochrome f complex
4QA9	;	1.56	;	Ensemble refinement of an epoxide hydrolase from Streptomyces carzinostaticus subsp. neocarzinostaticus.
4XQ2	;	2.1	;	Ensemble refinement of cystathione gamma lyase (CalE6) D7G from Micromonospora echinospora
4Q29	;	1.349	;	Ensemble Refinement of plu4264 protein from Photorhabdus luminescens
4M83	;	1.698	;	Ensemble refinement of protein crystal structure (2IYF) of macrolide glycosyltransferases OleD complexed with UDP and Erythromycin A
4M7P	;	1.77	;	Ensemble refinement of protein crystal structure of macrolide glycosyltransferases OleD
2Q52	;	1.38	;	Ensemble refinement of the crystal structure of a glycolipid transfer-like protein from Galdieria sulphuraria
2Q4O	;	1.95	;	Ensemble refinement of the crystal structure of a lysine decarboxylase-like protein from Arabidopsis thaliana gene At2g37210
2Q4D	;	2.152	;	Ensemble refinement of the crystal structure of a lysine decarboxylase-like protein from Arabidopsis thaliana gene At5g11950
2Q4U	;	2.1	;	Ensemble refinement of the crystal structure of an EF-hand protein from Danio rerio Dr.36843
2Q4H	;	1.834	;	Ensemble refinement of the crystal structure of GALT-like protein from Arabidopsis thaliana At5g18200
2Q4L	;	2.3	;	Ensemble refinement of the crystal structure of GALT-like protein from Arabidopsis thaliana At5g18200
2Q4N	;	1.32	;	Ensemble refinement of the crystal structure of protein from Arabidopsis thaliana At1g79260
2Q4M	;	1.7	;	Ensemble refinement of the crystal structure of protein from Arabidopsis thaliana At5g01750
2Q4P	;	2.32	;	Ensemble refinement of the crystal structure of protein from Mus musculus Mm.29898
2Q4F	;	2.0	;	Ensemble refinement of the crystal structure of putative histidine-containing phosphotransfer protein from rice, Ak104879
5EJU	;	1.65	;	Ensemble refinement of the Crystal Structure of the Reversibly photoswitching chromoprotein Dathail, Ground State
2Q53	;	2.01	;	Ensemble refinement of the crystal structure of uncharacterized protein loc79017 from Homo sapiens
4TYV	;	1.75	;	Ensemble refinement of the E502A variant of sacteLam55A from Streptomyces sp. SirexAA-E in complex with glucose
4TZ5	;	1.75	;	Ensemble refinement of the E502A variant of sacteLam55A from Streptomyces sp. SirexAA-E in complex with laminarihexaose
4TZ3	;	1.9	;	Ensemble refinement of the E502A variant of sacteLam55A from Streptomyces sp. SirexAA-E in complex with laminaritetraose
4TZ1	;	1.5	;	Ensemble refinement of the E502A variant of sacteLam55A from Streptomyces sp. SirexAA-E in complex with laminaritriose
2Q3O	;	2.0	;	Ensemble refinement of the protein crystal structure of 12-oxo-phytodienoate reductase isoform 3
2Q4T	;	2.35	;	Ensemble refinement of the protein crystal structure of a cytosolic 5'-nucleotidase III from Mus musculus Mm.158936
2Q50	;	2.45	;	Ensemble refinement of the protein crystal structure of a glyoxylate/hydroxypyruvate reductase from Homo sapiens
2Q47	;	3.3	;	Ensemble refinement of the protein crystal structure of a putative phosphoprotein phosphatase from Arabidopsis thaliana gene At1g05000
2Q4I	;	1.71	;	Ensemble refinement of the protein crystal structure of allene oxide cyclase from Arabidopsis thaliana At3g25770
2Q3M	;	1.9	;	Ensemble refinement of the protein crystal structure of an Arabidopsis thaliana putative steroid sulphotransferase
2Q51	;	2.8	;	Ensemble refinement of the protein crystal structure of an aspartoacylase from Homo sapiens
2Q4Z	;	1.8	;	Ensemble refinement of the protein crystal structure of an aspartoacylase from Rattus norvegicus
2Q4C	;	2.508	;	Ensemble refinement of the protein crystal structure of annexin from Arabidopsis thaliana gene At1g35720
2Q3Q	;	2.1	;	Ensemble refinement of the protein crystal structure of At1g24000 from Arabidopsis thaliana
2Q3R	;	2.0	;	Ensemble refinement of the protein crystal structure of At1g76680 from Arabidopsis thaliana
2Q4Y	;	2.06	;	Ensemble refinement of the protein crystal structure of At1g77540-coenzyme A complex
2Q3P	;	1.9	;	Ensemble refinement of the protein crystal structure of At3g17210 from Arabidopsis thaliana
2Q4S	;	1.75	;	Ensemble refinement of the protein crystal structure of cysteine dioxygenase type I from Mus musculus Mm.241056
2Q4W	;	1.7	;	Ensemble refinement of the protein crystal structure of cytokinin oxidase/dehydrogenase (CKX) from Arabidopsis thaliana At5g21482
2Q44	;	1.15	;	Ensemble refinement of the protein crystal structure of gene product from Arabidopsis thaliana At1g77540
2Q40	;	1.7	;	Ensemble refinement of the protein crystal structure of gene product from Arabidopsis thaliana At2g17340
2Q49	;	2.19	;	Ensemble refinement of the protein crystal structure of gene product from Arabidopsis thaliana At2g19940
2Q3V	;	1.8	;	Ensemble refinement of the protein crystal structure of gene product from Arabidopsis thaliana At2g34160
2Q4J	;	1.863	;	Ensemble refinement of the protein crystal structure of gene product from Arabidopsis thaliana At3g03250, a putative UDP-glucose pyrophosphorylase
2Q4X	;	2.1	;	Ensemble refinement of the protein crystal structure of gene product from Arabidopsis thaliana At3g16990
2Q4A	;	2.39	;	Ensemble refinement of the protein crystal structure of gene product from Arabidopsis thaliana At3g21360
2Q3T	;	1.6	;	Ensemble refinement of the protein crystal structure of gene product from Arabidopsis thaliana At3g22680
2Q4E	;	2.49	;	Ensemble refinement of the protein crystal structure of gene product from Arabidopsis thaliana At4g09670
2Q46	;	1.8	;	Ensemble refinement of the protein crystal structure of gene product from Arabidopsis thaliana At5g02240
2Q3S	;	2.1	;	Ensemble refinement of the protein crystal structure of gene product from Arabidopsis thaliana At5g06450
2Q3U	;	1.53	;	Ensemble refinement of the protein crystal structure of gene product from Arabidopsis thaliana At5g08170, agmatine iminohydrolase
2Q48	;	1.8	;	Ensemble refinement of the protein crystal structure of gene product from Arabidopsis thaliana At5g48480
2Q4K	;	2.5	;	Ensemble refinement of the protein crystal structure of gene product from Homo sapiens Hs.433573
2Q4Q	;	2.59	;	Ensemble refinement of the protein crystal structure of gene product from Homo sapiens Hs.95870
2Q42	;	1.742	;	Ensemble refinement of the protein crystal structure of glyoxalase II from Arabidopsis thaliana gene At2g31350
2RGZ	;	2.61	;	Ensemble refinement of the protein crystal structure of human heme oxygenase-2 C127A (HO-2) with bound heme
2Q4R	;	2.09	;	Ensemble refinement of the protein crystal structure of human phosphomannomutase 2 (PMM2)
2Q4G	;	1.954	;	Ensemble refinement of the protein crystal structure of human ribonuclease inhibitor complexed with ribonuclease I
2Q43	;	2.0	;	Ensemble refinement of the protein crystal structure of IAA-aminoacid hydrolase from Arabidopsis thaliana gene At5g56660
2Q45	;	2.1	;	Ensemble refinement of the protein crystal structure of putative tropinone reductase from Arabidopsis thaliana gene At1g07440
2Q4B	;	2.096	;	Ensemble refinement of the protein crystal structure of selenomethionyl gene product from Arabidopsis thaliana At5g02240 in space group P21212
2Q41	;	2.7	;	Ensemble refinement of the protein crystal structure of spermidine synthase from Arabidopsis thaliana gene At1g23820
2Q3W	;	1.48	;	Ensemble refinement of the protein crystal structure of the cys84ala cys85ala double mutant of the [2Fe-2S] ferredoxin subunit of toluene-4-monooxygenase from Pseudomonas mendocina KR1
2Q4V	;	1.842	;	Ensemble refinement of the protein crystal structure of thialysine n-acetyltransferase (SSAT2) from Homo sapiens
7MHL	;	1.55	;	Ensemble refinement structure of SARS-CoV-2 main protease (Mpro) at 100 K
7MHM	;	1.5302	;	Ensemble refinement structure of SARS-CoV-2 main protease (Mpro) at 240 K
7MHN	;	2.1908	;	Ensemble refinement structure of SARS-CoV-2 main protease (Mpro) at 277 K
7MHO	;	1.88	;	Ensemble refinement structure of SARS-CoV-2 main protease (Mpro) at 298 K
7MHP	;	2.0005	;	Ensemble refinement structure of SARS-CoV-2 main protease (Mpro) at 298 K at high humidity
7MHQ	;	1.9601	;	Ensemble refinement structure of SARS-CoV-2 main protease (Mpro) at 310 K
2N5T	;		;	Ensemble solution structure of the phosphoenolpyruvate-Enzyme I complex from the bacterial phosphotransferase system
2N2K	;		;	Ensemble structure of the closed state of Lys63-linked diubiquitin in the absence of a ligand
1JOQ	;		;	Ensemble structures for Staphylococcal nuclease-H124L in ternary complex with Ca2+ and thymidine-3',5'-bisphosphate
1JOR	;		;	Ensemble structures for unligated Staphylococcal nuclease-H124L
2K7A	;		;	Ensemble Structures of the binary complex between the SH3 and SH2 domain of interleukin-2 tyrosine kinase.
8R8J	;	1.4	;	Ensemble-refined carboxymyoglobin photolysis power titration, 101 mJ/cm2
8R8G	;	1.4	;	Ensemble-refined carboxymyoglobin photolysis power titration, 18 mJ/cm2
8R8H	;	1.4	;	Ensemble-refined carboxymyoglobin photolysis power titration, 31 mJ/cm2
8R8I	;	1.4	;	Ensemble-refined carboxymyoglobin photolysis power titration, 56 mJ/cm2
8R8F	;	1.4	;	Ensemble-refined carboxymyoglobin photolysis power titration, 6 mJ/cm2
5BP8	;	1.8	;	ent-Copalyl diphosphate synthase from Streptomyces platensis
3M4Q	;	3.0	;	Entamoeba histolytica asparaginyl-tRNA synthetase (AsnRS)
3M4P	;	2.83	;	Entamoeba histolytica asparaginyl-tRNA synthetase (AsnRS) in complex with asparaginyl-adenylate
8IW2	;	1.75	;	Entamoeba histolytica Pyruvate kinase
4CW9	;	1.84	;	Entamoeba histolytica thiredoxin C34S mutant
4YO3	;	3.37	;	Enteroaggregative Escherichia Coli TssA N-terminal fragment
1Q2Q	;	1.4	;	Enterobacter cloacae GC1 class C beta-lactamase complexed with penem WAY185229
1RGZ	;	1.37	;	Enterobacter cloacae GC1 Class C beta-Lactamase Complexed with Transition-State Analog of Cefotaxime
3NX2	;	2.01	;	Enterobacter sp. Px6-4 Ferulic Acid Decarboxylase in complex with substrate analogues
4KU0	;	1.15	;	Enterobacteria phage T4 gp5.4 PAAR repeat protein in complex with T4 gp5 beta-helix fragment
2GZR	;	2.3	;	Enterobactin and Salmochelin Hydrolase IroE
2GZS	;	1.4	;	Enterobactin Hydolase IroE Complex with DFP
2M5Z	;		;	Enterocin 7A
2M60	;		;	Enterocin 7B
6Z9L	;	3.063	;	Enterococcal PrgA
6ORI	;	1.4	;	Enterococcal surface protein, partial N-terminal region
1R59	;	2.5	;	Enterococcus casseliflavus glycerol kinase
1XUP	;	2.75	;	ENTEROCOCCUS CASSELIFLAVUS GLYCEROL KINASE COMPLEXED WITH GLYCEROL
3D7E	;	2.03	;	Enterococcus casseliflavus glycerol kinase mutant HIS232ALA complexed with glycerol
7OCY	;	4.25	;	Enterococcus faecalis EfrCD in complex with a nanobody
5NV5	;	2.4	;	Enterococcus faecalis FIC protein
6ERB	;	2.2	;	Enterococcus faecalis FIC protein (H111A) in complex with sulfate.
5NWF	;	2.6	;	Enterococcus faecalis FIC protein (H111A).
6EP2	;	2.15	;	Enterococcus faecalis FIC protein in complex with ADP and calcium ion.
6EP5	;	1.928	;	Enterococcus faecalis FIC protein in complex with ADP.
6EP0	;	2.35	;	Enterococcus faecalis FIC protein in complex with AMP and calcium ion.
6ER8	;	2.292	;	Enterococcus faecalis FIC protein in complex with phosphate.
7F7Q	;	1.42	;	Enterococcus faecalis GH31 alpha-N-acetylgalactosaminidase D455A in complex with p-nitrophenyl alpha-N-acetylgalactosaminide
7F7R	;	1.63	;	Enterococcus faecalis GH31 alpha-N-acetylgalactosaminidase D455N in complex with Tn antigen
6BSQ	;	1.8	;	Enterococcus faecalis Penicillin Binding Protein 4 (PBP4)
5J7W	;	2.5	;	Enterococcus faecalis thymidylate synthase complex with methotrexate
6TUG	;	2.42	;	Enterococcus italicus Csm6 bound to cyclic hexa-2'-fluoro-hexa-dAMP
2LNH	;		;	Enterohaemorrhagic E. coli (EHEC) exploits a tryptophan switch to hijack host F-actin assembly
2M7A	;		;	Enteropathogenic Escherichia coli 0111:H- str. 11128 ORF EC0111_1119 similar to bacteriophage lambda ea8.5
6ZOV	;	2.19	;	ENTEROPEPTIDASE IN COMPLEX WITH COMPOUND 6
7DA6	;	2.2	;	Enterovirus 71 2A Protease mutant- C110A in complex with peptide inhibitor
5F8G	;	2.78	;	Enterovirus 71 Polymerase Elongation Complex (C1S1 Form)
5F8H	;	2.45	;	Enterovirus 71 Polymerase Elongation Complex (C1S1/2 Form)
5F8I	;	2.503	;	Enterovirus 71 Polymerase Elongation Complex (C1S2/3 Form)
5F8J	;	2.675	;	Enterovirus 71 Polymerase Elongation Complex (C1S4 Form)
5F8L	;	2.812	;	Enterovirus 71 Polymerase Elongation Complex (C3S1 Form)
5F8M	;	2.83	;	Enterovirus 71 Polymerase Elongation Complex (C3S4/5 Form)
5F8N	;	2.484	;	Enterovirus 71 Polymerase Elongation Complex (C3S6 Form)
6WDS	;	2.9	;	Enterovirus D68 in complex with human monoclonal antibody EV68-159
6WDT	;	3.1	;	Enterovirus D68 in complex with human monoclonal antibody EV68-228
5JA1	;	3.0	;	EntF, a Terminal Nonribosomal Peptide Synthetase Module Bound to the MbtH-Like Protein YbdZ
5JA2	;	3.0	;	EntF, a Terminal Nonribosomal Peptide Synthetase Module Bound to the non-Native MbtH-Like Protein PA2412
1LZ4	;	1.8	;	ENTHALPIC DESTABILIZATION OF A MUTANT HUMAN LYSOZYME LACKING A DISULFIDE BRIDGE BETWEEN CYSTEINE-77 AND CYSTEINE-95
5LNK	;	3.9	;	Entire ovine respiratory complex I
1NHT	;	2.5	;	ENTRAPMENT OF 6-THIOPHOSPHORYL-IMP IN THE ACTIVE SITE OF CRYSTALLINE ADENYLOSUCCINATE SYNTHETASE FROM ESCHERICHIA COLI DATA COLLECTED AT 100K
1KSZ	;	2.8	;	ENTRAPMENT OF 6-THIOPHOSPHORYL-IMP IN THE ACTIVE SITE OF CRYSTALLINE ADENYLOSUCCINATE SYNTHETASE FROM ESCHERICHIA COLI, DATA COLLECTED AT 298K
1GEQ	;	2.0	;	Entropic stabilization of the tryptophan synthase A-subunit from a hyperthermophile, pyrococcus furiosus: X-ray analysis and calorimetry
6TPI	;	2.1	;	EnvC bound to the FtsX periplasmic domain
1SVB	;	1.9	;	ENVELOPE GLYCOPROTEIN FROM TICK-BORNE ENCEPHALITIS VIRUS
5CAY	;	3.0	;	Envelope glycoprotein gp120 core from HIV type 2 bound to the first two domains of human soluble CD4 receptor
7A4A	;	3.76	;	Envelope glycprotein of endogenous retrovirus Y032 (Atlas virus) from the human hookworm Ancylostoma ceylanicum
7DDA	;	2.51	;	Envelope protein VP37 a crystal structure from White Spot Syndrome Virus
7RWL	;	3.14	;	Envelope-associated Adeno-associated virus serotype 2
2VUJ	;	1.8	;	Environmentally isolated GH11 xylanase
4DHX	;	2.1	;	ENY2:GANP complex
2P6Z	;	1.93	;	Enzymatic and Structural Characterisation of Amphinase, a Novel Cytotoxic Ribonuclease from Rana pipiens Oocytes
2P7S	;	1.8	;	Enzymatic and Structural Characterisation of Amphinase, a Novel Cytotoxic Ribonuclease from Rana pipiens Oocytes
1W8M	;	1.65	;	Enzymatic and Structural Characterisation of Non Peptide Ligand Cyclophilin Complexes
1W8L	;	1.8	;	Enzymatic and structural characterization of non peptide ligand cyclophilin complexes
1W8V	;	1.7	;	Enzymatic and structural characterization of non peptide ligand cyclophilin complexes
5YFE	;	1.39	;	Enzymatic and structural characterization of the poly (ethylene terephthalate) hydrolase PETase from I. sakaiensis
2MH1	;		;	Enzymatic cyclisation of kalata B1 using sortase A
1CHM	;	1.9	;	ENZYMATIC MECHANISM OF CREATINE AMIDINOHYDROLASE AS DEDUCED FROM CRYSTAL STRUCTURES
8FUN	;	2.24	;	Enzymatically Active, Mn/Fe Metallated Form of AibH1H2
8QMK	;	1.3	;	Enzymatically-produced complex-B bound TmHydE structure
1SCA	;	2.0	;	ENZYME CRYSTAL STRUCTURE IN A NEAT ORGANIC SOLVENT
1SCB	;	2.3	;	ENZYME CRYSTAL STRUCTURE IN A NEAT ORGANIC SOLVENT
3DNK	;	2.84	;	Enzyme deglycosylated Human IgG1 Fc fragment
1E2A	;	2.3	;	ENZYME IIA FROM THE LACTOSE SPECIFIC PTS FROM LACTOCOCCUS LACTIS
7AHR	;	2.21	;	Enzyme of biosynthetic pathway
7AN5	;	1.91	;	Enzyme of biosynthetic pathway
7AN6	;	1.91	;	Enzyme of biosynthetic pathway
7AN7	;	1.81	;	Enzyme of biosynthetic pathway
7AN8	;	2.01	;	Enzyme of biosynthetic pathway
7AN9	;	2.11	;	Enzyme of biosynthetic pathway
7YWC	;	1.917	;	Enzyme of biosynthetic pathway
1IXO	;	2.3	;	Enzyme-analogue substrate complex of Pyridoxine 5'-Phosphate Synthase
1P5D	;	1.6	;	Enzyme-ligand complex of P. aeruginosa PMM/PGM
1P5G	;	1.61	;	Enzyme-ligand complex of P. aeruginosa PMM/PGM
1PCJ	;	2.0	;	Enzyme-ligand complex of P. aeruginosa PMM/PGM
1PCM	;	1.9	;	Enzyme-ligand complex of P. aeruginosa PMM/PGM
1IXP	;	2.3	;	Enzyme-phosphate Complex of Pyridoxine 5'-Phosphate synthase
1IXQ	;	2.3	;	Enzyme-Phosphate2 Complex of Pyridoxine 5'-Phosphate synthase
1QH9	;	2.5	;	ENZYME-PRODUCT COMPLEX OF L-2-HALOACID DEHALOGENASE
5FLI	;	2.15	;	enzyme-substrate complex of Ni-quercetinase
1IXN	;	2.3	;	Enzyme-Substrate Complex of Pyridoxine 5'-Phosphate Synthase
5JXY	;	1.71	;	Enzyme-substrate complex of TDG catalytic domain bound to a G/U analog
3MS8	;	1.7	;	Enzyme-Substrate interactions of IXT6, the intracellular xylanase of G. stearothermophilus.
3MSD	;	1.58	;	Enzyme-Substrate interactions of IXT6, the intracellular xylanase of G. stearothermophilus.
3MSG	;	1.5	;	Enzyme-Substrate interactions of IXT6, the intracellular xylanase of G. stearothermophilus.
3MUA	;	1.5	;	Enzyme-Substrate interactions of IXT6, the intracellular xylanase of G. stearothermophilus.
3MUI	;	1.8	;	Enzyme-Substrate interactions of IXT6, the intracellular xylanase of G. stearothermophilus.
1HCB	;	1.6	;	ENZYME-SUBSTRATE INTERACTIONS: STRUCTURE OF HUMAN CARBONIC ANHYDRASE I COMPLEXED WITH BICARBONATE
5FLJ	;	1.818	;	enzyme-substrate-dioxygen complex of Ni-quercetinase
1ZUX	;	1.85	;	EosFP Fluorescent Protein- Green Form
1HI4	;	1.8	;	Eosinophil-derived Neurotoxin (EDN) - Adenosien-3'-5'-Diphosphate Complex
1HI3	;	1.8	;	Eosinophil-derived Neurotoxin (EDN) - Adenosine 2'-5'-Diphosphate Complex
1HI5	;	1.8	;	Eosinophil-derived Neurotoxin (EDN) - Adenosine-5'-Diphosphate Complex
1HI2	;	1.6	;	Eosinophil-derived Neurotoxin (EDN) - Sulphate Complex
7DAE	;	2.394	;	EPB in complex with tubulin
5RZQ	;	1.88	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z100642432
5RYR	;	1.87	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z104584152
5RZ3	;	1.74	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z1259341037
5RZ8	;	1.66	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z1263714198
5RZK	;	1.84	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z1266823232
5RZG	;	1.7	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z133729708
5RYO	;	1.58	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z136583524
5RYV	;	1.69	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z1373430305
5RZL	;	1.71	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z1492796719
5RZ0	;	1.74	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z1497321453
5RYU	;	1.63	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z1545196403
5RYN	;	1.88	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z1545312521
5RZZ	;	1.76	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z1551999220
5RYS	;	1.75	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z1593306637
5RZS	;	1.69	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z1703168683
5RZN	;	1.83	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z1745658474
5RYP	;	1.63	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z1929757385
5RZD	;	1.81	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z198194394
5RZY	;	1.75	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z219104216
5RYX	;	1.63	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z2234920345
5RZW	;	1.62	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z2574937229
5RZB	;	1.59	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z271004858
5RZ1	;	1.62	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z27682767
5RZE	;	1.69	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z2856434786
5S00	;	1.77	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z2856434793
5RZX	;	1.74	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z2856434814
5RZM	;	1.71	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z2856434815
5RYW	;	1.66	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z2856434829
5RZ5	;	1.63	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z2856434851
5RYZ	;	1.61	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z2856434868
5RZH	;	1.88	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z2856434890
5RZ4	;	1.61	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z2856434909
5RZO	;	1.97	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z2856434925
5RZJ	;	1.68	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z2856434938
5RZ6	;	1.64	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z2856434944
5RZC	;	1.75	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z300245038
5RYM	;	1.64	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z31217395
5RZV	;	1.75	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z31504642
5RZU	;	1.66	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z32400357
5RZP	;	1.7	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z33546965
5RZI	;	2.09	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z48852953
5RZR	;	1.78	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z53825177
5RYT	;	1.72	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z54226006
5RZF	;	1.76	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z57040482
5RYY	;	1.69	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z57257264
5RYQ	;	1.64	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z57258487
5RZ7	;	1.76	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z57472297
5RZ2	;	1.77	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z68277692
5RZA	;	1.89	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z729352906
5RZT	;	1.79	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z763030030
5RZ9	;	1.79	;	EPB41L3 PanDDA analysis group deposition -- Crystal Structure of the FERM domain of human EPB41L3 in complex with Z943693514
7DAD	;	2.85	;	EPD in complex with tubulin
2K9Y	;		;	EphA2 dimeric structure in the lipidic bicelle at pH 5.0
6NK0	;	1.53	;	EphA2 LBD in complex with bA-WLA-Yam peptide
6NK2	;	2.2	;	EphA2 LBD in complex with bA-WLA-YRPK bio peptide
6NK1	;	1.55	;	EphA2 LBD in complex with bA-WLA-YRPKbio peptide
6NKP	;	2.033	;	EphA2 LBD in complex with bA-WLA-YSKbio peptide
6NJZ	;	1.9	;	EphA2 LBD in complex with YSA-GSGSK-bio peptide
2KSO	;		;	EphA2:SHIP2 SAM:SAM complex
4M4R	;	3.13	;	Epha4 ectodomain complex with ephrin a5
1SHW	;	2.2	;	EphB2 / EphrinA5 Complex Structure
2QBX	;	2.3	;	EphB2/SNEW Antagonistic Peptide Complex
5L6O	;	1.88	;	EphB3 kinase domain covalently bound to an irreversible inhibitor (compound 3)
5L6P	;	2.26	;	EphB3 kinase domain covalently bound to an irreversible inhibitor (compound 6)
2VWU	;	2.0	;	ephB4 kinase domain inhibitor complex
2VWV	;	1.9	;	ephB4 kinase domain inhibitor complex
2VWW	;	1.9	;	ephB4 kinase domain inhibitor complex
2VWX	;	1.65	;	ephB4 kinase domain inhibitor complex
2VWY	;	1.65	;	ephB4 kinase domain inhibitor complex
2VWZ	;	1.65	;	ephB4 kinase domain inhibitor complex
2VX0	;	2.1	;	ephB4 kinase domain inhibitor complex
2VX1	;	1.65	;	ephB4 kinase domain inhibitor complex
2X9F	;	1.75	;	ephB4 kinase domain inhibitor complex
2XVD	;	1.7	;	ephB4 kinase domain inhibitor complex
2YN8	;	2.11	;	ephB4 kinase domain inhibitor complex
4BB4	;	1.65	;	ephB4 kinase domain inhibitor complex
7K7J	;	3.004	;	EphB6 receptor ectodomain
8JWS	;	2.0	;	ePHD domain of PHD Finger Protein 7 (PHF7)
1SHX	;	2.1	;	Ephrin A5 ligand structure
2F01	;	0.85	;	Epi-biotin complex with core streptavidin
2GH7	;	1.0	;	Epi-biotin complex with core streptavidin
3KBK	;	1.9	;	Epi-isozizaene synthase complexed with Hg
3KB9	;	1.598	;	Epi-isozizaene synthase: Complex with Mg, inorganic pyrophosphate and benzyl triethyl ammonium cation
1G5Q	;	2.57	;	EPID H67N COMPLEXED WITH SUBSTRATE PEPTIDE DSYTC
1FGD	;		;	EPIDERMAL GROWTH FACTOR (EGF) SUBDOMAIN OF HUMAN THROMBOMODULIN (NMR, 11 STRUCTURES)
1FGE	;		;	EPIDERMAL GROWTH FACTOR (EGF) SUBDOMAIN OF HUMAN THROMBOMODULIN (NMR, 14 STRUCTURES)
1M17	;	2.6	;	Epidermal Growth Factor Receptor tyrosine kinase domain with 4-anilinoquinazoline inhibitor erlotinib
2K2T	;		;	Epidermal growth Factor-like domain 2 from Toxoplasma gondii Microneme protein 6
1EDM	;	1.5	;	EPIDERMAL GROWTH FACTOR-LIKE DOMAIN FROM HUMAN FACTOR IX
6SIF	;	1.69	;	Epidermicin antimicrobial protein from Staphylococcus epidermidis
6SIG	;	1.58	;	Epidermicin antimicrobial protein from Staphylococcus epidermidis
3QJG	;	2.04	;	Epidermin biosynthesis protein EpiD from Staphylococcus aureus
1AGJ	;	1.7	;	EPIDERMOLYTIC TOXIN A FROM STAPHYLOCOCCUS AUREUS
1BTW	;	1.7	;	Episelection: novel KI ~nanomolar inhibitors of serine proteases selected by binding or chemistry on an enzyme surface
1BTX	;	1.7	;	Episelection: Novel Ki ~Nanomolar Inhibitors of Serine Proteases Selected by Binding or Chemistry on an Enzyme Surface
1BTZ	;	2.0	;	Episelection: novel KI ~nanomolar inhibitors of serine proteases selected by binding or chemistry on an enzyme surface
3RFN	;	1.8	;	Epitope backbone grafting by computational design for improved presentation of linear epitopes on scaffold proteins
3RHU	;	2.8	;	Epitope backbone grafting by computational design for improved presentation of linear epitopes on scaffold proteins
3RI0	;	2.25	;	Epitope backbone grafting by computational design for improved presentation of linear epitopes on scaffold proteins
3RIJ	;	2.3	;	Epitope backbone grafting by computational design for improved presentation of linear epitopes on scaffold proteins
3PP3	;	2.508	;	Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for the type I / type II distinction of anti- CD20 antibodies
3PP4	;	1.6	;	Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for the type I / type II distinction of anti- CD20 antibodies
7T72	;	3.177	;	Epitope-based selection of SARS-CoV-2 neutralizing antibodies from convalescent patients
7YUE	;	2.35	;	Epitope-directed anti-SARS CoV 2 scFv engineered against the key spike protein region.
1KVG	;		;	EPO-3 beta Hairpin Peptide
8CLG	;	2.8	;	Epothilone A and Colchicine bound to tubulin (T2R-TTL) complex
1Q5D	;	1.93	;	Epothilone B-bound Cytochrome P450epoK
7AC0	;	2.177	;	Epoxide hydrolase CorEH without ligand
6UNW	;	2.21	;	Epoxide hydrolase from an endophytic Streptomyces
8HGU	;	1.94	;	Epoxide hydrolase from Bosea sp. PAMC 26642
8HM5	;	2.43	;	Epoxide hydrolase from Caballeronia sordidicola PAMC 26510
1R1B	;		;	EPRS SECOND REPEATED ELEMENT, NMR, MINIMIZED AVERAGE STRUCTURE
1I0C	;	2.0	;	EPS8 SH3 CLOSED MONOMER
1I07	;	1.8	;	EPS8 SH3 DOMAIN INTERTWINED DIMER
7TZK	;	1.43	;	EPS8 SH3 Domain with NleH1 PxxDY Motif
2E5Y	;	1.92	;	Epsilon subunit and ATP complex of F1F0-ATP synthase from the Thermophilic Bacillus PS3
1AQT	;	2.3	;	EPSILON SUBUNIT OF F1F0-ATP SYNTHASE FROM ESCHERICHIA COLI
4RG4	;	2.51	;	Epsilon-caprolactone-bound crystal structure of cyclohexanone monooxygenase in the Loose conformation
4RG3	;	1.94	;	Epsilon-caprolactone-bound crystal structure of cyclohexanone monooxygenase in the Tight conformation
1H0A	;	1.7	;	Epsin ENTH bound to Ins(1,4,5)P3
1Q36	;	1.6	;	EPSP synthase (Asp313Ala) liganded with tetrahedral reaction intermediate
5BS5	;	2.49	;	EPSP synthase from Acinetobacter baumannii
2AA9	;	1.5	;	EPSP synthase liganded with shikimate
2AAY	;	1.55	;	EPSP synthase liganded with shikimate and glyphosate
1X8T	;	1.9	;	EPSPS liganded with the (R)-phosphonate analog of the tetrahedral reaction intermediate
1X8R	;	1.5	;	EPSPS liganded with the (S)-phosphonate analog of the tetrahedral reaction intermediate
2BSY	;	1.5	;	Epstein Barr Virus dUTPase
2BT1	;	2.7	;	Epstein Barr Virus dUTPase in complex with a,b-imino dUTP
2H6O	;	3.5	;	Epstein Barr Virus Major Envelope Glycoprotein
1VHI	;	2.5	;	EPSTEIN BARR VIRUS NUCLEAR ANTIGEN-1 DNA-BINDING DOMAIN, RESIDUES 470-607
2W45	;	3.0	;	Epstein-Barr virus alkaline nuclease
2W4B	;	3.5	;	Epstein-Barr virus alkaline nuclease D203S mutant
7P9W	;	2.0001	;	Epstein-Barr virus encoded apoptosis regulator BHRF1 in complex with Puma BH3
7P33	;	2.78543	;	Epstein-Barr virus encoded Bcl-2 homolog BHRF-1 in complex with Bid BH3 peptide
1O6E	;	2.3	;	Epstein-Barr virus protease
7WLP	;	2.29	;	Epstein-Barr virus protein BKRF4 restricts nucleosome assembly to suppress host antiviral responses
2J8X	;	2.3	;	Epstein-Barr virus uracil-DNA glycosylase in complex with Ugi from PBS-2
5SZX	;	2.251	;	Epstein-Barr virus Zta DNA binding domain homodimer in complex with methylated DNA
7BR7	;	4.3	;	Epstein-Barr virus, C1 portal-proximal penton vertex, CATC binding
7BQT	;	4.8	;	Epstein-Barr virus, C12 portal dodecamer
7BR8	;	3.8	;	Epstein-Barr virus, C5 penton vertex, CATC absent.
7BQX	;	4.2	;	Epstein-Barr virus, C5 portal vertex
7BSI	;	4.1	;	Epstein-Barr virus, one asymmetric unit structure of the icosahedral tegumented capsid
7JSX	;	2.06	;	EPYC1(106-135) peptide-bound Rubisco
7JFO	;	2.13	;	EPYC1(49-72)-bound Rubisco
7JQA	;	1.53	;	EQADH-NADH-4-BROMOBENZYL ALCOHOL, P21
7K35	;	1.2	;	EQADH-NADH-4-METHYLBENZYL ALCOHOL, p21
6XT2	;	1.55	;	EQADH-NADH-HEPTAFLUOROBUTANOL, P21
3G6G	;	2.31	;	Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations
6ZLK	;	1.5	;	Equilibrium Structure of UDP-Glucuronic acid 4-epimerase from Bacillus cereus in complex with UDP-Glucuronic acid/UDP-Galacturonic acid and NAD
2V93	;		;	EQUILLIBRIUM MIXTURE OF OPEN AND PARTIALLY-CLOSED SPECIES IN THE APO STATE OF MALTODEXTRIN-BINDING PROTEIN BY PARAMAGNETIC RELAXATION ENHANCEMENT NMR
1IAZ	;	1.9	;	EQUINATOXIN II
4IUM	;	1.45	;	Equine arteritis virus papain-like protease 2 (PLP2) covalently bound to ubiquitin
2WFF	;	4.0	;	Equine Rhinitis A Virus
2WS9	;	3.0	;	Equine Rhinitis A Virus at Low pH
2XBO	;	4.0	;	Equine Rhinitis A Virus in Complex with its Sialic Acid Receptor
3MDJ	;	2.95	;	ER Aminopeptidase, ERAP1, Bound to the Zinc Aminopeptidase Inhibitor, Bestatin
7NEL	;	1.45	;	ER-PRS*(+) (Y537S) in complex with estradiol and SRC-2 coactivator peptide
7NFB	;	1.33	;	ER-PRS*(+) (Y537S) in complex with genistein and SRC-2 coactivator peptide
7NDO	;	1.6	;	ER-PRS*(-) (L536S, L372R) in complex with raloxifene
1QKD	;	1.49	;	ERABUTOXIN
1QKE	;	1.5	;	ERABUTOXIN
7MWC	;	3.0	;	ERAP1 binds peptide C-terminus of a LPF sequence (AAAAFKARKF)
7MWB	;	3.2	;	ERAP1 binds peptide C-terminus of a SPF sequence (FKARKF)
6MGQ	;	2.92	;	ERAP1 in the open conformation bound to 10mer phosphinic inhibitor DG014
6EA4	;	2.45	;	ERAP2 bound to Aryl Sulfonamide Uncompetitive Inhibitor
8CF8	;	2.2	;	Eravacycline bound to the 30S head
6SQ0	;	1.77	;	ERa_L536S (L536S/C381S/C471S,C530S) in complex with a bridged tetracyclic indole (compound 8)
6SUO	;	1.74	;	ERa_L536S (L536S/C381S/C471S,C530S) in complex with a tricyclic indole (compound 6)
2JWA	;		;	ErbB2 transmembrane segment dimer spatial structure
2R4B	;	2.4	;	ErbB4 kinase domain complexed with a thienopyrimidine inhibitor
1N7T	;		;	ERBIN PDZ domain bound to a phage-derived peptide
8QFL	;	1.75	;	Ergothioneine dioxygenase from Thermocatellispora tengchongensis in complex with iron
8QFM	;	1.9	;	Ergothioneine dioxygenase from Thermocatellispora tengchongensis in complex with manganese
8QFN	;	1.75	;	Ergothioneine dioxygenase from Thermocatellispora tengchongensis in complex with manganese and in presence of catalase aerobic
8QFP	;	2.2	;	Ergothioneine dioxygenase from Thermocatellispora tengchongensis in complex with manganese and in presence of catalase anaerobic
8QFQ	;	2.1	;	Ergothioneine dioxygenase, variant H147A, from Thermocatellispora tengchongensis in complex with manganese
8QFO	;	2.05	;	Ergothioneine dioxygenase, variant Y149F, from Thermocatellispora tengchongensis in complex with manganese
6FNR	;	1.83	;	Ergothioneine-biosynthetic methyltransferase EgtD in complex with chlorohistidine
6FNS	;	1.85	;	Ergothioneine-biosynthetic methyltransferase EgtD in complex with morpholinohistidine
6FNQ	;	1.75	;	Ergothioneine-biosynthetic methyltransferase EgtD in complex with N,N,N-trimethylhistidine (hercynine)
4PIN	;	1.9	;	Ergothioneine-biosynthetic methyltransferase EgtD in complex with N,N-dimethylhistidine
4PIO	;	1.506	;	Ergothioneine-biosynthetic methyltransferase EgtD in complex with N,N-dimethylhistidine and SAH
6FNT	;	1.9	;	Ergothioneine-biosynthetic methyltransferase EgtD in complex with pyrrolidinohistidine
4PIM	;	1.75	;	Ergothioneine-biosynthetic methyltransferase EgtD, apo form
4ZFK	;	1.82	;	Ergothioneine-biosynthetic Ntn hydrolase EgtC with glutamine
4ZFJ	;	1.75	;	Ergothioneine-biosynthetic Ntn hydrolase EgtC, apo form
4ZFL	;	1.7	;	Ergothioneine-biosynthetic Ntn hydrolase variant EgtC_C2A with natural substrate
4X8E	;	1.6	;	Ergothioneine-biosynthetic sulfoxide synthase EgtB in complex with N,N,N-trimethyl-histidine
4X8D	;	1.98	;	Ergothioneine-biosynthetic sulfoxide synthase EgtB in complex with N,N-dimethyl-histidine and gamma-glutamyl-cysteine
4X8B	;	1.7	;	Ergothioneine-biosynthetic sulfoxide synthase EgtB, apo form
4F5D	;	3.0	;	ERIS/STING in complex with ligand
4S34	;	2.5	;	ERK2 (I84A) in complex with AMP-PNP
5BUI	;	2.12	;	ERK2 complexed with 2-pyridiyl tetrahydroazaindazole
5BUJ	;	1.85	;	ERK2 complexed with a N-H tetrahydroazaindazole
5BUE	;	2.4	;	ERK2 complexed with N-benzylpyridone tetrahydroazaindazole
4S30	;	2.0	;	ERK2 intrinsically active mutant (I84A)
4S2Z	;	1.48	;	ERK2 Intrinsically active mutant R65S
6RFP	;	1.74	;	ERK2 MAP kinase with mutations at Helix-G
6RFO	;	1.7	;	ERK2 MAP kinase with the activation loop of p38alpha
6Q7K	;	1.84	;	ERK2 mini-fragment binding
6Q7S	;	1.73	;	ERK2 mini-fragment binding
6Q7T	;	1.6	;	ERK2 mini-fragment binding
6QA1	;	1.58	;	ERK2 mini-fragment binding
6QA3	;	1.57	;	ERK2 mini-fragment binding
6QA4	;	1.6	;	ERK2 mini-fragment binding
6QAG	;	2.07	;	ERK2 mini-fragment binding
6QAH	;	1.58	;	ERK2 mini-fragment binding
6QAL	;	1.57	;	ERK2 mini-fragment binding
6QAQ	;	1.58	;	ERK2 mini-fragment binding
6QAW	;	1.84	;	ERK2 mini-fragment binding
4S33	;	1.48	;	ERK2 R65S mutant complexed with AMP-PNP
6GJB	;	1.82	;	Erk2 signalling protein
6GJD	;	1.58	;	Erk2 signalling protein
5O7I	;	2.38	;	ERK5 in complex with a pyrrole inhibitor
7PUS	;	2.59	;	ERK5 in complex with Pyrrole Carboxamide scaffold
5BYY	;	2.79	;	ERK5 IN COMPLEX WITH SMALL MOLECULE
5BYZ	;	1.65	;	ERK5 in complex with small molecule
6V5D	;		;	EROS3 RDC and NOE Derived Ubiquitin Ensemble
4BF3	;	2.37	;	ErpC, a member of the complement regulator acquiring family of surface proteins from Borrelia burgdorfei, possesses an architecture previously unseen in this protein family.
5JZE	;	2.47	;	Erve virus viral OTU domain protease in complex with mouse ISG15
5FR7	;	1.95	;	Erwinia amylovora AmyR amylovoran repressor, a member of the YbjN protein family
5F52	;	1.63	;	Erwinia chrysanthemi L-asparaginase + Aspartic acid
5HW0	;	1.702	;	Erwinia chrysanthemi L-asparaginase + Glutamic acid
5I48	;	1.5	;	Erwinia chrysanthemi L-asparaginase A31I + E63Q mutation + Aspartic acid
5I4B	;	1.6	;	Erwinia chrysanthemi L-asparaginase E63Q +S254N mutation + L-Aspartic acid
5I3Z	;	2.05	;	Erwinia chrysanthemi L-asparaginase E63Q mutation + Aspartic acid
1AXY	;	1.95	;	ERYTHRINA CORALLODENDRON LECTIN
1AXZ	;	1.95	;	ERYTHRINA CORALLODENDRON LECTIN IN COMPLEX WITH D-GALACTOSE
1AX1	;	1.95	;	ERYTHRINA CORALLODENDRON LECTIN IN COMPLEX WITH LACTOSE
1AX2	;	1.95	;	ERYTHRINA CORALLODENDRON LECTIN IN COMPLEX WITH N-ACETYLLACTOSAMINE
1AX0	;	1.9	;	ERYTHRINA CORALLODENDRON LECTIN IN COMPLEX WITH N-ACTYLGALACTOSAMINE
3N3H	;	2.0	;	Erythrina corallodendron lectin mutant (Y106G) in complex with citrate
3N36	;	2.3	;	Erythrina corallodendron lectin mutant (Y106G) in complex with Galactose
3N35	;	2.0	;	Erythrina corallodendron lectin mutant (Y106G) with N-Acetylgalactosamine
1UZZ	;	2.13	;	Erythrina cristagalli bound to N-linked oligosaccharide and lactose
1V00	;	1.7	;	Erythrina cristagalli lectin
1UZY	;	2.0	;	Erythrina crystagalli lectin
4R3A	;	2.92	;	Erythrobacter litoralis EL346 blue-light activated histidine kinase
7UZE	;	2.4	;	Erythrocyte ankyrin-1 complex class 2 local refinement of AQP1 (C4 symmetry applied)
6ZOC	;	2.89	;	Erythromycin binding to the access pocket of AcrB-G616P L protomer and 3-formylrifamycin SV binding to the access pocket of AcrB-G616P T protomer
8FFS	;	2.96	;	Erythromycin bound Klebsiella pneumoniae AcrB multidrug efflux pump
6XCQ	;	2.0	;	Erythromycin esterase EreC, mutant H289N in its closed conformation
6XCS	;	2.4	;	Erythromycin esterase mutant EreC H289N in its open conformation
6S0Z	;	2.3	;	Erythromycin Resistant Staphylococcus aureus 50S ribosome (delta R88 A89 uL22) in complex with erythromycin.
6S12	;	3.2	;	Erythromycin Resistant Staphylococcus aureus 50S ribosome (delta R88 A89 uL22).
6S0X	;	2.425	;	Erythromycin Resistant Staphylococcus aureus 70S ribosome (delta R88 A89 uL22) in complex with erythromycin.
6S13	;	3.58	;	Erythromycin Resistant Staphylococcus aureus 70S ribosome (delta R88 A89 uL22).
7Q4K	;	3.0	;	Erythromycin-stalled Escherichia coli 70S ribosome with streptococcal MsrDL nascent chain
1CN4	;	2.8	;	ERYTHROPOIETIN COMPLEXED WITH EXTRACELLULAR DOMAINS OF ERYTHROPOIETIN RECEPTOR
3OPR	;	1.65	;	ESBL R164H mutant of SHV-1 beta-lactamase complexed to SA2-13
3OPL	;	1.8	;	ESBL R164H mutant SHV-1 beta-lactamase
3OPH	;	1.34	;	ESBL R164S mutant of SHV-1 beta-lactamase
3OPP	;	1.8	;	ESBL R164S mutant of SHV-1 beta-lactamase complexed with SA2-13
6E9E	;	3.4	;	EsCas13d-crRNA binary complex
6E9F	;	3.3	;	EsCas13d-crRNA-target RNA ternary complex
2AAC	;	1.6	;	ESCHERCHIA COLI GENE REGULATORY PROTEIN ARAC COMPLEXED WITH D-FUCOSE
5VT0	;	3.78	;	Escherichia coli 6S RNA derivative in complex with Escherichia coli RNA polymerase sigma70-holoenzyme
8EKC	;	2.7	;	Escherichia coli 70S ribosome bound to thermorubin, deacylated P-site tRNAfMet and aminoacylated A-site Phe-tRNA
6TQM	;	3.8	;	Escherichia coli AdhE structure in its compact conformation
6TQH	;	3.4	;	Escherichia coli AdhE structure in its extended conformation
6R8U	;	3.0	;	Escherichia coli AGPase in complex with AMP.
6SI8	;	3.4	;	Escherichia coli AGPase in complex with AMP.
6SHQ	;	3.2	;	Escherichia coli AGPase in complex with AMP. Symmetry C2
6R8B	;	3.1	;	Escherichia coli AGPase in complex with FBP.
6SHJ	;	3.2	;	Escherichia coli AGPase in complex with FBP. Symmetry applied C2
6SHN	;	3.3	;	Escherichia coli AGPase in complex with FBP. Symmetry C1
5MNI	;	3.09	;	Escherichia coli AGPase mutant R130A apo form
4RTD	;	3.65	;	Escherichia coli alpha-2-macroglobulin activated by porcine elastase
8BNR	;	10.3	;	Escherichia coli anaerobic fatty acid beta oxidation trifunctional enzyme (anEcTFE) octameric complex
8BNU	;	3.55	;	Escherichia coli anaerobic fatty acid beta oxidation trifunctional enzyme (anEcTFE) tetrameric complex
8BRJ	;	4.08	;	Escherichia coli anaerobic fatty acid beta oxidation trifunctional enzyme (anEcTFE) trimeric complex
3OT7	;	1.901	;	Escherichia coli apo-manganese superoxide dismutase
3E2C	;	1.8	;	Escherichia coli Bacterioferritin Mutant E128R/E135R
6P8K	;	1.7	;	Escherichia coli Bacterioferritin Substituted with Zinc Protoporphyrin IX
6P8L	;	2.1	;	Escherichia coli Bacterioferritin Substituted with Zinc Protoporphyrin IX (Zn Absorption Edge X-ray Data)
1MKB	;	2.0	;	ESCHERICHIA COLI BETA-HYDROXYDECANOYL THIOL ESTER DEHYDRASE AT PH 5 AND 21 DEGREES C
6Z9H	;	1.72	;	Escherichia coli D-2-deoxyribose-5-phosphate aldolase - C47V/G204A/S239D mutant
6Z9J	;	1.5	;	Escherichia coli D-2-deoxyribose-5-phosphate aldolase - N21K mutant
6Z9I	;	1.86	;	Escherichia coli D-2-deoxyribose-5-phosphate aldolase - N21K mutant complex with reaction products
8UW0	;	0.93	;	Escherichia coli DHFR bound to NADP+ and folate, 17.2 MGy dose
1DRV	;	2.2	;	ESCHERICHIA COLI DHPR/ACNADH COMPLEX
1DRU	;	2.2	;	ESCHERICHIA COLI DHPR/NADH COMPLEX
1DRW	;	2.2	;	ESCHERICHIA COLI DHPR/NHDH COMPLEX
1ARZ	;	2.6	;	ESCHERICHIA COLI DIHYDRODIPICOLINATE REDUCTASE IN COMPLEX WITH NADH AND 2,6 PYRIDINE DICARBOXYLATE
1F76	;	2.5	;	ESCHERICHIA COLI DIHYDROOROTATE DEHYDROGENASE
5L3J	;	2.83	;	ESCHERICHIA COLI DNA GYRASE B IN COMPLEX WITH BENZOTHIAZOLE-BASED INHIBITOR
6GCM	;	2.45	;	Escherichia coli DPS
8OUC	;	1.37	;	Escherichia coli DPS
4CTI	;	2.847	;	Escherichia coli EnvZ histidine kinase catalytic part fused to Archaeoglobus fulgidus Af1503 HAMP domain
1D8S	;	4.4	;	ESCHERICHIA COLI F1 ATPASE
1ZK5	;	1.4	;	Escherichia coli F17fG lectin domain complex with N-acetylglucosamine
1QKC	;	3.1	;	ESCHERICHIA COLI FERRIC HYDROXAMATE UPTAKE RECEPTOR (FHUA) IN COMPLEX DELTA TWO-ALBOMYCIN
7O9G	;	2.8	;	Escherichia coli Ffh in complex with ppGpp
7O9I	;	2.49	;	Escherichia coli Ffh in complex with pppGpp
4V0B	;	2.55	;	Escherichia coli FtsH hexameric N-domain
7O9H	;	2.4	;	Escherichia coli FtsY in complex with pppGpp
8GZY	;	2.6	;	Escherichia coli FtsZ complexed with monobody (P21)
8GZX	;	1.84	;	Escherichia coli FtsZ complexed with monobody (P212121)
1GMX	;	1.1	;	Escherichia coli GlpE sulfurtransferase
1GN0	;	1.8	;	Escherichia coli GlpE sulfurtransferase soaked with KCN
1ECF	;	2.0	;	ESCHERICHIA COLI GLUTAMINE PHOSPHORIBOSYLPYROPHOSPHATE (PRPP) AMIDOTRANSFERASE
1ECJ	;	2.5	;	ESCHERICHIA COLI GLUTAMINE PHOSPHORIBOSYLPYROPHOSPHATE (PRPP) AMIDOTRANSFERASE COMPLEXED WITH 2 AMP PER TETRAMER
1ECB	;	2.7	;	ESCHERICHIA COLI GLUTAMINE PHOSPHORIBOSYLPYROPHOSPHATE (PRPP) AMIDOTRANSFERASE COMPLEXED WITH 2 GMP, 1 MG PER SUBUNIT
1ECC	;	2.4	;	ESCHERICHIA COLI GLUTAMINE PHOSPHORIBOSYLPYROPHOSPHATE (PRPP) AMIDOTRANSFERASE COMPLEXED WITH MN-CPRPP AND 5-OXO-NORLEUCINE
1BWF	;	3.0	;	ESCHERICHIA COLI GLYCEROL KINASE MUTANT WITH BOUND ATP ANALOG SHOWING SUBSTANTIAL DOMAIN MOTION
1GLJ	;	3.0	;	ESCHERICHIA COLI GLYCEROL KINASE MUTANT WITH BOUND ATP ANALOG SHOWING SUBSTANTIAL DOMAIN MOTION
1GLL	;	3.0	;	ESCHERICHIA COLI GLYCEROL KINASE MUTANT WITH BOUND ATP ANALOG SHOWING SUBSTANTIAL DOMAIN MOTION
1GPM	;	2.2	;	ESCHERICHIA COLI GMP SYNTHETASE COMPLEXED WITH AMP AND PYROPHOSPHATE
6AYI	;	2.09	;	Escherichia coli GusR
1TII	;	2.25	;	ESCHERICHIA COLI HEAT LABILE ENTEROTOXIN TYPE IIB
1QB5	;	1.9	;	ESCHERICHIA COLI HEAT LABILE ENTEROTOXIN TYPE IIB B-PENTAMER
1QCB	;	2.2	;	ESCHERICHIA COLI HEAT LABILE ENTEROTOXIN TYPE IIB B-PENTAMER
8GW2	;	2.71	;	Escherichia Coli Heat Labile Enterotoxin Type IIB B-Pentamer Circular Permutant CP13-14
8H2R	;	2.9	;	Escherichia Coli Heat Labile Enterotoxin Type IIB B-Pentamer Circular Permutant CP52-53
5G3L	;	1.72	;	ESCHERICHIA COLI HEAT LABILE ENTEROTOXIN TYPE IIB B-PENTAMER COMPLEXED WITH SIALYLATED SUGAR
5UK7	;	3.0	;	Escherichia coli Hfq bound to dsDNA
4PNO	;	0.97	;	Escherichia coli Hfq-RNA complex at 0.97 A Resolution
2XZR	;	2.8	;	Escherichia coli Immunoglobulin-binding protein EibD 391-438 FUSED TO GCN4 ADAPTORS
3W7U	;	1.99	;	Escherichia coli K12 YgjK complexed with galactose
3W7S	;	1.9	;	Escherichia coli K12 YgjK complexed with glucose
3W7T	;	1.5	;	Escherichia coli K12 YgjK complexed with mannose
1YRL	;	2.6	;	Escherichia coli ketol-acid reductoisomerase
1YON	;	1.95	;	Escherichia coli ketopantoate reductase in complex with 2-monophosphoadenosine-5'-diphosphate
6MGC	;	1.35	;	Escherichia coli KpsC, N-terminal domain
5TT5	;	1.552	;	Escherichia coli LigA (K115M) in complex with NAD+
8BRW	;	1.73	;	Escherichia coli methionyl-tRNA synthetase mutant L13C,I297C
8BRX	;	1.54	;	Escherichia coli methionyl-tRNA synthetase mutant L13C,I297C complexed with beta-3-methionine
8BRU	;	1.55	;	Escherichia coli methionyl-tRNA synthetase mutant L13M,I297C
8BRV	;	1.53	;	Escherichia coli methionyl-tRNA synthetase mutant L13M,I297C complexed with beta3-methionine.
1B5T	;	2.5	;	ESCHERICHIA COLI METHYLENETETRAHYDROFOLATE REDUCTASE
1ZRQ	;	2.2	;	Escherichia coli Methylenetetrahydrofolate Reductase (reduced) complexed with NADH, pH 6.0
1ZPT	;	1.95	;	Escherichia coli Methylenetetrahydrofolate Reductase (reduced) complexed with NADH, pH 7.25
2F00	;	2.5	;	Escherichia coli MurC
2HUR	;	1.62	;	Escherichia coli nucleoside diphosphate kinase
8IOX	;	2.95	;	Escherichia coli OpgD mutant-D388N
8IP1	;	2.06	;	Escherichia coli OpgD mutant-D388N with beta-1,2-glucan
8IP2	;	1.81	;	Escherichia coli OpgG mutant-D361N with beta-1,2-glucan
8PKL	;	3.09	;	Escherichia coli paused disome complex (leading 70S non-rotated closed PRE state)
8RCL	;	3.49	;	Escherichia coli paused disome complex (Non-rotated disome interface class 1)
8RCM	;	3.59	;	Escherichia coli paused disome complex (Non-rotated disome interface class 2)
8R3V	;	3.28	;	Escherichia coli paused disome complex (non-rotated disome interface)
8PEG	;	3.3	;	Escherichia coli paused disome complex (queueing 70S non-rotated closed PRE state)
8RCS	;	4.46	;	Escherichia coli paused disome complex (Rotated disome interface class 1)
8RCT	;	5.32	;	Escherichia coli paused disome complex (Rotated disome interface class 2)
5G5G	;	1.7	;	Escherichia coli Periplasmic Aldehyde Oxidase
5G5H	;	2.3	;	Escherichia coli Periplasmic Aldehyde Oxidase R440H mutant
8FXT	;	1.53	;	Escherichia coli periplasmic Glucose-Binding Protein glucose complex: Acrylodan conjugate attached at W183C
7Z2T	;	1.41	;	Escherichia coli periplasmic phytase AppA D304A mutant, complex with myo-inositol hexakissulfate
7Z32	;	1.85	;	Escherichia coli periplasmic phytase AppA D304A mutant, phosphohistidine intermediate
7Z2W	;	1.42	;	Escherichia coli periplasmic phytase AppA D304A,T305E mutant, complex with myo-inositol hexakissulfate
7Z3V	;	2.6	;	Escherichia coli periplasmic phytase AppA D304E mutant, complex with myo-inositol hexakissulfate
7Z2Y	;	1.86	;	Escherichia coli periplasmic phytase AppA T305E mutant, complex with myo-inositol hexakissulfate
7Z2S	;	1.72	;	Escherichia coli periplasmic phytase AppA, complex with myo-inositol hexakissulfate
7Z1J	;	1.85	;	Escherichia coli periplasmic phytase AppA, complex with phosphate
3VUS	;	1.65	;	Escherichia coli PgaB N-terminal domain
2PNH	;	2.25	;	Escherichia coli PriB E39A variant
1PR5	;	2.5	;	Escherichia coli Purine Nucleoside Phosphorylase Complexed with 7-deazaadenosine and Phosphate/Sulfate
1PR4	;	2.4	;	Escherichia coli Purine Nucleoside Phosphorylase Complexed with 9-beta-D-ribofuranosyl-6-methylthiopurine and Phosphate/Sulfate
1PR6	;	2.1	;	Escherichia coli Purine Nucleoside Phosphorylase Complexed with 9-beta-D-xylofuranosyladenine and Phosphate/Sulfate
1PR2	;	2.3	;	Escherichia coli Purine Nucleoside Phosphorylase Complexed with 9-beta-D-[2-deoxyribofuranosyl]-6-methylpurine and Phosphate/Sulfate
1PR1	;	2.3	;	Escherichia coli Purine Nucleoside Phosphorylase Complexed with Formycin B and Phosphate/Sulfate
1PR0	;	2.2	;	Escherichia coli Purine Nucleoside Phosphorylase Complexed with Inosine and Phosphate/Sulfate
1YQQ	;	2.6	;	Escherichia coli purine nucleoside phosphorylase II, the product of the xapA gene
1YQU	;	3.1	;	Escherichia coli purine nucleoside phosphorylase II, the product of the xapA gene
1YR3	;	3.2	;	Escherichia coli purine nucleoside phosphorylase II, the product of the xapA gene
1QHM	;	2.8	;	ESCHERICHIA COLI PYRUVATE FORMATE LYASE LARGE DOMAIN
8EDS	;	2.1	;	Escherichia coli pyruvate kinase (PykF) P70Q
8EU4	;	2.1	;	Escherichia coli pyruvate kinase A301S
8EQ3	;	2.01	;	Escherichia coli pyruvate kinase A301T
8EQ1	;	2.32	;	Escherichia coli pyruvate kinase D127N
8EQ0	;	2.62	;	Escherichia coli pyruvate kinase G381A
6AWF	;	3.35	;	Escherichia coli quinol:fumarate reductase crystallized without dicarboxylate
6Y2R	;	3.89	;	Escherichia coli R255A RnlA endoribonuclease (single alanine mutant of RnlA)
6Y2S	;	3.79	;	Escherichia coli R318A RnlA endoribonuclease (single alanine mutant of RnlA)
3REC	;		;	ESCHERICHIA COLI RECA PROTEIN-BOUND DNA, NMR, 1 STRUCTURE
2ARC	;	1.5	;	ESCHERICHIA COLI REGULATORY PROTEIN ARAC COMPLEXED WITH L-ARABINOSE
1ECR	;	2.7	;	ESCHERICHIA COLI REPLICATION TERMINATOR PROTEIN (TUS) COMPLEXED WITH DNA
4XR1	;	2.4	;	Escherichia Coli Replication Terminator Protein (Tus) Complexed With DNA- AG/AT mismatch.
4XR0	;	2.8	;	Escherichia Coli Replication Terminator Protein (Tus) Complexed With DNA- G/T mismatch.
4XR3	;	2.7	;	Escherichia Coli Replication Terminator Protein (Tus) Complexed With DNA- GC(6) swapped.
2EWJ	;	2.7	;	Escherichia Coli Replication Terminator Protein (Tus) Complexed With DNA- Locked form
2I06	;	2.2	;	Escherichia Coli Replication Terminator Protein (Tus) Complexed With DNA- Locked form
2I05	;	2.6	;	Escherichia Coli Replication Terminator Protein (Tus) Complexed With TerA DNA
4XR2	;	2.35	;	Escherichia Coli Replication Terminator Protein (Tus) H114A mutant Complexed With DNA- TerA lock.
8E70	;	4.1	;	Escherichia coli Rho-dependent transcription pre-termination complex containing 18 nt long RNA spacer, dC75 rut mimic RNA, Mg-ADP-BeF3, and NusG; Rho hexamer part
8E6Z	;	4.1	;	Escherichia coli Rho-dependent transcription pre-termination complex containing 18 nt long RNA spacer, dC75 rut mimic RNA, Mg-ADP-BeF3, and NusG; TEC part
8E6W	;	4.27	;	Escherichia coli Rho-dependent transcription pre-termination complex containing 18 nt long RNA spacer, lambda-tR1 rut RNA, Mg-ADP-BeF3, and NusG; Rho part
8E6X	;	4.27	;	Escherichia coli Rho-dependent transcription pre-termination complex containing 18 nt long RNA spacer, lambda-tR1 rut RNA, Mg-ADP-BeF3, and NusG; TEC part
8E3H	;	6.5	;	Escherichia coli Rho-dependent transcription pre-termination complex containing 18 nt long RNA spacer, Mg-ADP-BeF3, and NusG; Rho hexamer part
8E3F	;	6.5	;	Escherichia coli Rho-dependent transcription pre-termination complex containing 18 nt long RNA spacer, Mg-ADP-BeF3, and NusG; TEC part
8E5L	;	4.2	;	Escherichia coli Rho-dependent transcription pre-termination complex containing 21 nt long RNA spacer, Mg-ADP-BeF3, and NusG; Rho hexamer part
8E5K	;	4.2	;	Escherichia coli Rho-dependent transcription pre-termination complex containing 21 nt long RNA spacer, Mg-ADP-BeF3, and NusG; TEC part
8E5P	;	4.4	;	Escherichia coli Rho-dependent transcription pre-termination complex containing 24 nt long RNA spacer, Mg-ADP-BeF3, and NusG; Rho hexamer part
8E5O	;	4.4	;	Escherichia coli Rho-dependent transcription pre-termination complex containing 24 nt long RNA spacer, Mg-ADP-BeF3, and NusG; TEC part
7MKQ	;	4.8	;	Escherichia coli RNA polymerase and RapA binary complex
7MKN	;	3.3	;	Escherichia coli RNA polymerase and RapA elongation complex
5UAH	;	4.1	;	Escherichia coli RNA polymerase and Rifampin complex, RpoB D516V mutant
5UAL	;	3.887	;	Escherichia coli RNA polymerase and Rifampin complex, RpoB S531L mutant
5UAC	;	3.8	;	Escherichia coli RNA polymerase and Rifampin complex, wild-type
7KHC	;	4.14	;	Escherichia coli RNA polymerase and rrnBP1 promoter closed complex
7KHI	;	3.62	;	Escherichia coli RNA polymerase and rrnBP1 promoter complex with DksA/ppGpp
7KHB	;	3.53	;	Escherichia coli RNA polymerase and rrnBP1 promoter open complex
7KHE	;	3.58	;	Escherichia coli RNA polymerase and rrnBP1 promoter pre-open complex with DksA/ppGpp
6VJS	;	4.02	;	Escherichia coli RNA polymerase and ureidothiophene-2-carboxylic acid complex
6PSQ	;	3.4	;	Escherichia coli RNA polymerase closed complex (TRPc) with TraR and rpsT P2 promoter
7MKP	;	3.41	;	Escherichia coli RNA polymerase core enzyme
7MKO	;	3.15	;	Escherichia coli RNA polymerase elongation complex
4YFX	;	3.844	;	Escherichia coli RNA polymerase in complex with Myxopyronin B
4YFN	;	3.817	;	Escherichia coli RNA polymerase in complex with squaramide compound 14 (N-[3,4-dioxo-2-(4-{[4-(trifluoromethyl)benzyl]amino}piperidin-1-yl)cyclobut-1-en-1-yl]-3,5-dimethyl-1,2-oxazole-4-sulfonamide)
4YFK	;	3.571	;	Escherichia coli RNA polymerase in complex with squaramide compound 8.
5UAG	;	3.399	;	Escherichia coli RNA polymerase mutant - RpoB D516V
6PSV	;	3.5	;	Escherichia coli RNA polymerase promoter unwinding intermediate (TpreRPo) with TraR and rpsT P2 promoter
6PSR	;	3.4	;	Escherichia coli RNA polymerase promoter unwinding intermediate (TRPi1) with TraR and rpsT P2 promoter
6PSS	;	3.5	;	Escherichia coli RNA polymerase promoter unwinding intermediate (TRPi1.5a) with TraR and mutant rpsT P2 promoter
6PST	;	3.0	;	Escherichia coli RNA polymerase promoter unwinding intermediate (TRPi1.5b) with TraR and mutant rpsT P2 promoter
6PSU	;	3.9	;	Escherichia coli RNA polymerase promoter unwinding intermediate (TRPi2) with TraR and rpsT P2 promoter
6PSW	;	3.7	;	Escherichia coli RNA polymerase promoter unwinding intermediate (TRPo) with TraR and rpsT P2 promoter
5UAQ	;	3.6	;	Escherichia coli RNA polymerase RpoB H526Y mutant
5UAJ	;	3.915	;	Escherichia coli RNA polymerase RpoB S531L mutant
6N62	;	3.803	;	Escherichia coli RNA polymerase sigma70-holoenzyme bound to upstream fork promoter DNA
6N61	;	3.253	;	Escherichia coli RNA polymerase sigma70-holoenzyme bound to upstream fork promoter DNA and Capistruin
6N60	;	3.68	;	Escherichia coli RNA polymerase sigma70-holoenzyme bound to upstream fork promoter DNA and Microcin J25 (MccJ25)
2ID0	;	2.35	;	Escherichia coli RNase II
6Y2Q	;	2.99	;	Escherichia coli RnlA endoribonuclease
6Y2P	;	2.64	;	Escherichia coli RnlA-RnlB Toxin-Antitoxin System.
7TH0	;	1.9	;	Escherichia coli RpnA-S
6CUX	;	4.104	;	Escherichia coli RpoB S531L mutant RNA polymerase holoenzyme in complex with Kanglemycin A
1CUK	;	1.9	;	ESCHERICHIA COLI RUVA PROTEIN AT PH 4.9 AND ROOM TEMPERATURE
2FSF	;	2.0	;	Escherichia coli SecA, the preprotein translocase dimeric ATPase
7N4E	;	3.8	;	Escherichia coli sigma 70-dependent paused transcription elongation complex
6FQD	;	2.10001	;	Escherichia Coli Signal Recognition Particle Receptor FtsY NGdN1
3HVV	;	1.75	;	Escherichia coli Thiol peroxidase (Tpx) peroxidatic cysteine to serine mutant (C61S)
3HVX	;	2.12	;	Escherichia coli Thiol peroxidase (Tpx) resolving cysteine to serine mutant (C95S) with an intermolecular disulfide bond
3HVS	;	1.8	;	Escherichia coli Thiol peroxidase (Tpx) wild type disulfide form
3I43	;	2.8	;	Escherichia coli Thiol peroxidase (Tpx) wild type disulfide form
3CWN	;	1.4	;	Escherichia coli transaldolase b mutant f178y
6XIJ	;	8.0	;	Escherichia coli transcription-translation complex A (TTC-A) containing an 24 nt long mRNA spacer, NusG, and fMet-tRNAs at E-site and P-site
6VYS	;	3.7	;	Escherichia coli transcription-translation complex A1 (TTC-A1) containing a 21 nt long mRNA spacer, NusG, and fMet-tRNAs at E-site and P-site
6VYQ	;	3.7	;	Escherichia coli transcription-translation complex A1 (TTC-A1) containing an 15 nt long mRNA spacer, NusG, and fMet-tRNAs at E-site and P-site
6VYR	;	3.8	;	Escherichia coli transcription-translation complex A1 (TTC-A1) containing an 18 nt long mRNA spacer, NusG, and fMet-tRNAs at E-site and P-site
6VZJ	;	4.1	;	Escherichia coli transcription-translation complex A1 (TTC-A1) containing mRNA with a 15 nt long spacer, fMet-tRNAs at E-site and P-site, and lacking transcription factor NusG
6VYT	;	14.0	;	Escherichia coli transcription-translation complex A2 (TTC-A2) containing a 15 nt long mRNA spacer, NusG, and fMet-tRNAs at P-site and E-site
6XII	;	7.0	;	Escherichia coli transcription-translation complex B (TTC-B) containing an 24 nt long mRNA spacer, NusG, and fMet-tRNAs at E-site and P-site
6XDR	;	4.7	;	Escherichia coli transcription-translation complex B (TTC-B) containing an 27 nt long mRNA spacer, NusG, and fMet-tRNAs at E-site and P-site
6XGF	;	5.0	;	Escherichia coli transcription-translation complex B (TTC-B) containing an 30 nt long mRNA spacer, NusG, and fMet-tRNAs at E-site and P-site
6VZ7	;	7.0	;	Escherichia coli transcription-translation complex C1 (TTC-C1) containing a 27 nt long mRNA spacer, NusG, and fMet-tRNAs at P-site and E-site
6VYU	;	7.0	;	Escherichia coli transcription-translation complex C2 (TTC-C2) containing a 27 nt long mRNA spacer
6VYW	;	7.0	;	Escherichia coli transcription-translation complex C3 (TTC-C3) containing mRNA with a 27 nt long spacer, NusG, and fMet-tRNAs at E-site and P-site
6VYX	;	9.9	;	Escherichia coli transcription-translation complex C4 (TTC-C4) containing mRNA with a 21 nt long spacer, transcription factor NusG, and fMet-tRNAs at P-site and E-site
6VYY	;	9.9	;	Escherichia coli transcription-translation complex C5 (TTC-C5) containing mRNA with a 21 nt long spacer, NusG, and fMet-tRNAs at E-site and P-site
6VYZ	;	9.9	;	Escherichia coli transcription-translation complex C6 (TTC-C6) containing mRNA with a 21 nt long spacer, NusA, and fMet-tRNAs at E-site and P-site
6VZ2	;	10.0	;	Escherichia coli transcription-translation complex D1 (TTC-D1) containing mRNA with a 27 nt long spacer, NusG, and fMet-tRNAs at E-site and P-site
6VZ3	;	8.9	;	Escherichia coli transcription-translation complex D2 (TTC-D2) containing mRNA with a 27 nt long spacer
6VZ5	;	8.9	;	Escherichia coli transcription-translation complex D3 (TTC-D3) containing mRNA with a 21 nt long spacer, NusG, and fMet-tRNAs at E-site and P-site
6TJ9	;	0.95	;	Escherichia coli transketolase in complex with cofactor analog 2'-methoxythiamine and substrate xylulose 5-phosphate
6TJ8	;	0.921	;	Escherichia coli transketolase in complex with cofactor analog 2'-methoxythiamine diphosphate
6P24	;	2.12	;	Escherichia coli tRNA synthetase
6P26	;	3.16	;	Escherichia coli tRNA synthetase in complex with compound 1
6OZ5	;	2.5	;	Escherichia coli tRNA synthetase in complex with compound 3
4W4H	;	2.89	;	Escherichia coli tryptophanase in holo form
7R5Q	;	1.9	;	Escherichia coli type II Asparaginase N24S mutant in complex with GLU
7R57	;	1.4	;	Escherichia coli type II Asparaginase N24S mutant in its apo form
7P9C	;	1.6	;	Escherichia coli type II L-asparaginase
1WQ3	;	2.0	;	Escherichia coli tyrosyl-tRNA synthetase mutant complexed with 3-iodo-L-tyrosine
1WQ4	;	2.0	;	Escherichia coli tyrosyl-tRNA synthetase mutant complexed with L-tyrosine
1VBN	;	2.7	;	Escherichia coli tyrosyl-tRNA synthetase mutant complexed with Tyr-AMS
1LQJ	;	3.35	;	ESCHERICHIA COLI URACIL-DNA GLYCOSYLASE
1EUI	;	3.2	;	ESCHERICHIA COLI URACIL-DNA GLYCOSYLASE COMPLEX WITH URACIL-DNA GLYCOSYLASE INHIBITOR PROTEIN
1LQG	;	2.9	;	ESCHERICHIA COLI URACIL-DNA GLYCOSYLASE COMPLEX WITH URACIL-DNA GLYCOSYLASE INHIBITOR PROTEIN
1LQM	;	3.2	;	ESCHERICHIA COLI URACIL-DNA GLYCOSYLASE COMPLEX WITH URACIL-DNA GLYCOSYLASE INHIBITOR PROTEIN
2UUG	;	2.6	;	ESCHERICHIA COLI URACIL-DNA GLYCOSYLASE:INHIBITOR COMPLEX WITH H187D MUTANT UDG AND WILD-TYPE UGI
1UUG	;	2.4	;	ESCHERICHIA COLI URACIL-DNA GLYCOSYLASE:INHIBITOR COMPLEX WITH WILD-TYPE UDG AND WILD-TYPE UGI
2G8X	;	1.83	;	Escherichia coli Y209W apoprotein
1WNB	;	2.2	;	Escherichia coli YdcW gene product is a medium-chain aldehyde dehydrogenase (complexed with nadh and betaine aldehyde)
1WND	;	2.1	;	Escherichia coli YdcW gene product is a medium-chain aldehyde dehydrogenase as determined by kinetics and crystal structure
7BHA	;	2.19	;	Escherichia coli YtfE
7BE8	;	2.02	;	Escherichia coli YtfE (Mn)
7BHC	;	1.87	;	Escherichia coli YtfE E125L
7BHB	;	2.36	;	Escherichia coli YtfE E159L
7OYI	;	1.86	;	Escherichia coli YtfE_E159L(MN)
1ICM	;	1.5	;	ESCHERICHIA COLI-DERIVED RAT INTESTINAL FATTY ACID BINDING PROTEIN WITH BOUND MYRISTATE AT 1.5 A RESOLUTION AND I-FABPARG106-->GLN WITH BOUND OLEATE AT 1.74 A RESOLUTION
1ICN	;	1.74	;	ESCHERICHIA COLI-DERIVED RAT INTESTINAL FATTY ACID BINDING PROTEIN WITH BOUND MYRISTATE AT 1.5 A RESOLUTION AND I-FABPARG106-->GLN WITH BOUND OLEATE AT 1.74 A RESOLUTION
5XGU	;	1.846	;	Escherichia coli. RNase R
2CAZ	;	3.6	;	ESCRT-I core
5XDJ	;		;	Esculentin-1a(1-21)NH2
4WJY	;	2.15	;	Esherichia coli nitrite reductase NrfA H264N
8Q7Y	;	2.6	;	ESIBD structure of beta-galactosidase
1PIK	;		;	ESPERAMICIN A1-DNA COMPLEX, NMR, 4 STRUCTURES
4FMA	;	2.15	;	EspG structure
4FMC	;	2.8	;	EspG-Rab1 complex
4FMD	;	3.05	;	EspG-Rab1 complex structure at 3.05 A
4FME	;	4.1	;	EspG-Rab1-Arf6 complex
7VKI	;	1.65	;	ESRP1 qRRM2 in complex with 12mer-RNA
7WRN	;	1.85	;	ESRP1 RNaseH-qRRM1 tandem domain
4LYA	;	2.45	;	EssC (ATPases 2 and 3) from Geobacillus thermodenitrificans (SeMet)
2WTM	;	1.6	;	Est1E from Butyrivibrio proteoclasticus
6Q44	;		;	Est3 telomerase subunit in the yeast Hansenula polymorpha
5EGN	;	2.636	;	Est816 as an N-Acyl homoserine lactone degrading enzyme
2W79	;	1.85	;	Establishing wild-type levels of catalytic activity on natural and artificial (ba)8-barrel protein scaffolds
7ATL	;	2.478	;	EstCE1, a hydrolase with promiscuous acyltransferase activity
5H3H	;	1.9	;	Esterase (EaEST) from Exiguobacterium antarcticum
7C2C	;	1.55	;	Esterase AlinE4 mutant, D162A
7C84	;	1.552	;	Esterase AlinE4 mutant, D162A
7C2D	;	1.75	;	Esterase AlinE4 mutant-S13A
7C85	;	1.75	;	Esterase AlinE4 mutant-S13A
7C29	;	2.18	;	Esterase CrmE10 mutant-D178A
4C1B	;	2.501	;	Esterase domain of the ZfL2-1 ORF1 protein from the zebrafish ZfL2-1 retrotransposon
6Y9K	;	2.298	;	Esterase EST8 with transacylase activity
1CI8	;	2.0	;	ESTERASE ESTB FROM BURKHOLDERIA GLADIOLI: AN ESTERASE WITH (BETA)-LACTAMASE FOLD.
4C87	;	2.65	;	Esterase LpEst1 from Lactobacillus plantarum WCFS1
4C88	;	2.65	;	Esterase LpEst1 from Lactobacillus plantarum: native structure
5THM	;	2.15	;	Esterase-6 from Drosophila melanogaster
8HEA	;	1.74	;	Esterase2 (EaEst2) from Exiguobacterium antarcticum
6FCJ	;	2.49	;	Estimation of Protein-Ligand Unbinding Kinetics Using Non-Equilibrium Targeted Molecular Dynamics Simulations
6EI5	;	2.2	;	Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation
6EL5	;	1.67	;	Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation
6ELN	;	1.6	;	Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation
6ELO	;	1.8	;	Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation
6ELP	;	1.85	;	Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation
6EY8	;	2.16	;	Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation
6EY9	;	2.0	;	Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation
6EYA	;	2.1	;	Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation
6EYB	;	1.9	;	Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation
6F1N	;	2.09	;	Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation
8IK1	;	2.35	;	EstL5 in complex of PMSF
1X8V	;	1.55	;	Estriol-bound and ligand-free structures of sterol 14alpha-demethylase (CYP51)
3OS8	;	2.031	;	Estrogen Receptor
3OS9	;	2.303	;	Estrogen Receptor
3OSA	;	2.296	;	Estrogen Receptor
5GTR	;	2.804	;	estrogen receptor alpha in complex with a stabilized peptide antagonist 6
7QVJ	;	1.68	;	ESTROGEN RECEPTOR ALPHA IN COMPLEX WITH COMPOUND 29
2BJ4	;	2.0	;	ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH A PHAGE-DISPLAY DERIVED PEPTIDE ANTAGONIST
2JF9	;	2.1	;	ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH A TAMOXIFEN-SPECIFIC PEPTIDE ANTAGONIST
2JFA	;	2.55	;	ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH AN AFFINITY-SELECTED COREPRESSOR PEPTIDE
7YMK	;	2.25	;	Estrogen Receptor Alpha Ligand Binding Domain C381S C417S Y537S Mutant in Complex with an Covalent Selective Estrogen Receptor Degrader 29c and GRIP Peptide
5W9C	;	1.802	;	Estrogen Receptor Alpha Ligand Binding Domain C381S, C417S, C530S in Complex with 4-hydroxytamoxifen
5W9D	;	1.6464	;	Estrogen Receptor Alpha Ligand Binding Domain C381S, C417S, C530S Mutant in Complex with Endoxifen
8DUB	;	1.84	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with ((1'-(4-((1-ethylpyrrolidin-3-yl)methyl)phenyl)-6'-hydroxy-1',4'-dihydro-2'<i>H</i>-spiro[cyclopropane-1,3'-isoquinolin]-2'-yl)(phenyl)methanone
8DVB	;	2.19	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with (1'-(4-((1-butylpyrrolidin-3-yl)methoxy)phenyl)-6'-hydroxy-1',4'-dihydro-2'<i>H</i>-spiro[cyclopropane-1,3'-isoquinolin]-2'-yl)(phenyl)methanone
8DU6	;	2.1	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with (1'-(4-((1-ethylazetidin-3-yl)oxy)phenyl)-6'-hydroxy-1',4'-dihydro-2'<i>H</i>-spiro[cyclopropane-1,3'-isoquinolin]-2'-yl)(phenyl)methanone
8DUC	;	1.7	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with (1'-(4-(2-(1-ethylpyrrolidin-3-yl)ethoxy)phenyl)-6'-hydroxy-1',4'-dihydro-2'<i>H</i>-spiro[cyclopropane-1,3'-isoquinolin]-2'-yl)(phenyl)methanone
8DUI	;	2.04	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with (1'-(4-(2-(dimethylamino)ethoxy)phenyl)-6'-hydroxy-1',4'-dihydro-2'<i>H</i>-spiro[cyclopropane-1,3'-isoquinolin]-2'-yl)(phenyl)methanone
8DUS	;	1.9	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with (1'-(4-(2-(ethylamino)ethoxy)phenyl)-6'-hydroxy-1',4'-dihydro-2'<i>H</i>-spiro[cyclopropane-1,3'-isoquinolin]-2'-yl)(phenyl)methanone
5T97	;	3.0	;	ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH (2E)-3-(4-{(1R)-6-hydroxy-1-methyl-2-[4-(propan-2 -yl)phenyl]-1,2,3,4- tetrahydroisoquinolin-1-yl}phenyl)prop-2-enoic acid
5T92	;	2.22	;	ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH (2E)-3-{4-[(1R)-2-(4-fluorophenyl)-6-hydroxy-1-methy l-1,2,3,4- tetrahydroisoquinolin-1-yl]phenyl}prop-2-enoic acid
8DV5	;	1.85	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with (6'-hydroxy-1'-(4-((1-pentylpyrrolidin-3-yl)methoxy)phenyl)-1',4'-dihydro-2'<i>H</i>-spiro[cyclopropane-1,3'-isoquinolin]-2'-yl)(phenyl)methanone
8DV8	;	1.7	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with (6'-hydroxy-1'-(4-((2-(1-propylpyrrolidin-3-yl)ethyl)thio)phenyl)-1',4'-dihydro-2'<i>H</i>-spiro[cyclopropane-1,3'-isoquinolin]-2'-yl)(phenyl)methanone
8DUH	;	1.9	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with (6'-hydroxy-1'-(4-(2-((<i>R</i>)-2-methylpyrrolidin-1-yl)ethoxy)phenyl)-1',4'-dihydro-2'<i>H</i>-spiro[cyclopropane-1,3'-isoquinolin]-2'-yl)(phenyl)methanone
8DUG	;	2.2	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with (6'-hydroxy-1'-(4-(2-((<i>S</i>)-3-methylpyrrolidin-1-yl)ethoxy)phenyl)-1',4'-dihydro-2'<i>H</i>-spiro[cyclopropane-1,3'-isoquinolin]-2'-yl)(phenyl)methanone
8DUD	;	1.81	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with (6'-hydroxy-1'-(4-(2-(1-propylpyrrolidin-3-yl)ethoxy)phenyl)-1',4'-dihydro-2'<i>H</i>-spiro[cyclopropane-1,3'-isoquinolin]-2'-yl)(phenyl)methanone
8DV7	;	1.59	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with (6'-hydroxy-1'-(4-(2-(1-propylpyrrolidin-3-yl)ethyl)phenyl)-1',4'-dihydro-2'<i>H</i>-spiro[cyclopropane-1,3'-isoquinolin]-2'-yl)(phenyl)methanone
8DUK	;	1.7	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with (6'-hydroxy-1'-(4-(2-(methylamino)ethoxy)phenyl)-1',4'-dihydro-2'<i>H</i>-spiro[cyclopropane-1,3'-isoquinolin]-2'-yl)(phenyl)methanone
8DU8	;	1.47	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with (6-hydroxy-1-(4-((1-propylazetidin-3-yl)oxy)phenyl)-3,4-dihydroisoquinolin-2(1H)-yl)(phenyl)methanone
8DU9	;	2.5	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with (6-hydroxy-1-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-3,4-dihydroisoquinolin-2(1H)-yl)(phenyl)methanone
7R62	;	1.5	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with a Desmethyl ICI164,384 Derivative
7UJM	;	1.8	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with a Methylated Lasofoxifene Derivative That Increases Receptor Resonance Time in the Nucleus of Breast Cancer Cells
7UJF	;	1.7	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with a Methylated Lasofoxifene Derivative with Selective Estrogen Receptor Degrader Properties
7N9O	;	2.0	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with Aliphatic SERD S-C10(15)
4XI3	;	2.491	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with Bazedoxifene
5WGQ	;	2.3	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with Estradiol and SRC2-BCP1
5WGD	;	1.8	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with Estradiol and SRC2-LP1
6VJD	;	1.8	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with Lasofoxifene
6B0F	;	2.86	;	ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH LSZ102
5UFX	;	1.5503	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with OP1074
5UFW	;	1.583	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with OP1154
6C42	;	1.997	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with OP1156
7TE7	;	1.85	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with RAD1901
7KBS	;	1.834	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with Raloxifene
7UJO	;	1.449	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with RU39411
6VPF	;	1.6	;	Estrogen Receptor Alpha Ligand Binding Domain in Complex with the Selective Estrogen Receptor Modulator Clomiphene
7T2X	;	2.6	;	Estrogen Receptor Alpha Ligand Binding Domain Y537S in Complex with 2-chloro-4-((4-hydroxybenzyl)amino)-5-phenylthieno[2,3-d]pyrimidin-6-ol and GRIP Peptide
7SFO	;	1.9	;	Estrogen Receptor Alpha Ligand Binding Domain Y537S in Complex with 3-(((2-chloro-5-phenylthieno[2,3-d]pyrimidin-4-yl)amino)methyl)phenol and GRIP Peptide
7RKE	;	1.55	;	Estrogen Receptor Alpha Ligand Binding Domain Y537S in Complex with 4-(((2-chloro-5-phenylthieno[2,3-d]pyrimidin-4-yl)amino)methyl)phenol and GRIP Peptide
6V87	;	2.4	;	Estrogen Receptor Alpha Ligand Binding Domain Y537S in Complex with 4-Hydroxytamoxifen
7UJ8	;	2.385	;	Estrogen Receptor Alpha Ligand Binding Domain Y537S in Complex with 4-Hydroxytamoxifen
6V8T	;	2.1	;	Estrogen Receptor Alpha Ligand Binding Domain Y537S in Complex with LSZ102
7JHD	;	2.402	;	Estrogen Receptor Alpha Ligand Binding Domain Y537S in Complex with TTC-352 and GRIP Peptide
7RNM	;	1.9	;	Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutant in Complex with 2-(2-Chloro-5-phenylthieno[2,3-d]pyrimidin-4-yl)isoindolin-5-ol and GRIP Peptide
6D0F	;	2.5	;	Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutant in Complex with 3OHTPE and GRIP Peptide
7UJY	;	1.7	;	Estrogen receptor alpha ligand binding domain Y537S mutant in complex with a methylated lasofoxifene derivative that enhances estrogen receptor alpha nuclear resonance time
7UJW	;	2.6	;	Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutant in Complex with a Methylated Lasofoxifene Derivative that Possesses Selective Estrogen Receptor Degrader Activities
7Y8G	;	2.14	;	Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutant in Complex with an Inhibitor 30a and GRIP Peptide
7Y8F	;	2.22	;	Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutant in Complex with an Inhibitor 30o and GRIP Peptide
6CBZ	;	1.65	;	Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutant in Complex with Estradiol and GRIP Peptide
5T1Z	;	2.102	;	Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutant in Complex with Ethoxytriphenylethylene and GRIP Peptide
6VGH	;	2.1	;	Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutant In Complex with Lasofoxifene
7UJ7	;	1.68	;	Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutant in Complex with RU39411
6PIT	;	2.25	;	Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutant in Complex with SRC2 Stapled Peptide 41A and Estradiol
5DXB	;	2.08	;	Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutant in Complex with Stapled Peptide SRC2-P1 and Estradiol
5DX3	;	2.0903	;	Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutant in Complex with Stapled Peptide SRC2-P3 and Estradiol
5DXE	;	1.5	;	Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutant in Complex with Stapled Peptide SRC2-P4 and Estradiol
5DXG	;	1.86	;	Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutant in Complex with Stapled Peptide SRC2-P5
5HYR	;	2.271	;	Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutant in Complex with Stapled Peptide SRC2-SP2 and Estradiol
6CZN	;	2.5	;	Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutant in Complex with Z2OHTPE and a glucocorticoid receptor-interacting protein 1 NR box II peptide
2R6W	;	2.0	;	Estrogen receptor alpha ligand-binding domain complexed to a SERM
1A52	;	2.8	;	ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN COMPLEXED TO ESTRADIOL
2Q70	;	1.95	;	Estrogen receptor alpha ligand-binding domain complxed to a benzopyran ligand
2QE4	;	2.4	;	Estrogen receptor alpha ligand-binding domain in complex with a benzopyran agonist
2R6Y	;	2.0	;	Estrogen receptor alpha ligand-binding domain in complex with a SERM
6CHZ	;	1.68	;	Estrogen Receptor Alpha Y537S bound to antagonist H3B-9224.
6CHW	;	1.89	;	Estrogen Receptor Alpha Y537S covalently bound to antagonist H3B-5942.
2JJ3	;	2.28	;	Estrogen receptor beta ligand binding domain in complex with a Benzopyran agonist
2QTU	;	2.53	;	Estrogen receptor beta ligand-binding domain complexed to a benzopyran ligand
2Z4B	;	2.34	;	Estrogen receptor beta ligand-binding domain complexed to a benzopyran ligand
1NDE	;	3.0	;	Estrogen Receptor beta with Selective Triazine Modulator
4J24	;	2.1	;	Estrogen Receptor in complex with proline-flanked LXXLL peptides
4J26	;	2.3	;	Estrogen Receptor in complex with proline-flanked LXXLL peptides
6SBO	;	1.48	;	Estrogen receptor mutant L536S
1LO1	;		;	ESTROGEN RELATED RECEPTOR 2 DNA BINDING DOMAIN IN COMPLEX WITH DNA
3K6P	;	1.996	;	Estrogen Related Receptor alpha in Complex with an Ether Based Ligand
2P7Z	;	2.5	;	Estrogen Related Receptor Gamma in complex with 4-hydroxy-tamoxifen
2GP7	;	2.45	;	Estrogen Related Receptor-gamma ligand binding domain
2GPU	;	1.7	;	Estrogen Related Receptor-gamma ligand binding domain complexed with 4-hydroxy-tamoxifen
2GPV	;	2.85	;	Estrogen Related Receptor-gamma ligand binding domain complexed with 4-hydroxy-tamoxifen and a SMRT peptide
2GPP	;	2.6	;	Estrogen Related Receptor-gamma ligand binding domain complexed with a RIP140 peptide and synthetic ligand GSK4716
2GPO	;	1.95	;	Estrogen Related Receptor-gamma ligand binding domain complexed with a synthetic peptide from RIP140
1AQU	;	1.6	;	ESTROGEN SULFOTRANSFERASE WITH BOUND INACTIVE COFACTOR PAP AND 17-BETA ESTRADIOL
1BO6	;	2.1	;	ESTROGEN SULFOTRANSFERASE WITH INACTIVE COFACTOR PAP AND VANADATE
1AQY	;	1.75	;	ESTROGEN SULFOTRANSFERASE WITH PAP
6LIT	;	2.0	;	Estrogen-related receptor beta(ERR2) in complex with BPA
6LN4	;	2.61	;	Estrogen-related receptor beta(ERR2) in complex with PGC1a-2a
1IOL	;	2.3	;	ESTROGENIC 17-BETA HYDROXYSTEROID DEHYDROGENASE COMPLEXED 17-BETA-ESTRADIOL
3DHE	;	2.3	;	ESTROGENIC 17-BETA HYDROXYSTEROID DEHYDROGENASE COMPLEXED DEHYDROEPIANDROSTERONE
1DHT	;	2.24	;	ESTROGENIC 17-BETA HYDROXYSTEROID DEHYDROGENASE COMPLEXED DIHYDROTESTOSTERONE
4LWS	;	2.0	;	EsxA : EsxB (SeMet) hetero-dimer from Thermomonospora curvata
8XGR	;	3.2	;	ETB-eGt complex bound to endothelin-1
8IY5	;	2.8	;	ETB-Gi complex bound to endothelin-1
8IY6	;	3.13	;	ETB-Gi complex bound to Endotheline-1, focused on receptor
6XIU	;	3.0	;	ETEC Rns bound to a potential inhibitor, decanoic acid
2ALC	;		;	ETHANOL REGULON TRANSCRIPTIONAL ACTIVATOR DNA-BINDING DOMAIN FROM ASPERGILLUS NIDULANS
3ALC	;		;	ETHANOL REGULON TRANSCRIPTIONAL ACTIVATOR DNA-BINDING DOMAIN FROM ASPERGILLUS NIDULANS
7XRM	;	2.13	;	Ethanolamine ammonia-lyase complexed with AdoMeCbl
7XRN	;	2.07	;	Ethanolamine ammonia-lyase complexed with AdoMeCbl in the presence of substrate
5YSR	;	2.05	;	Ethanolamine ammonia-lyase, AdoCbl/2-amino-1-propanol
5YSN	;	2.001	;	Ethanolamine ammonia-lyase, AdoCbl/substrate-free
3I71	;	2.1	;	Ethanolamine Utilization Microcompartment Shell Subunit, EutK C-terminal domain
3I82	;	2.31	;	Ethanolamine Utilization Microcompartment Shell Subunit, EutL Closed Form
3I87	;	2.3	;	Ethanolamine Utilization Microcompartment Shell Subunit, EutL Open Form
3I6P	;	2.1	;	Ethanolamine Utilization Microcompartment Shell Subunit, EutM
3I96	;	1.65	;	Ethanolamine Utilization Microcompartment Shell Subunit, EutS
3IA0	;	2.5	;	Ethanolamine Utilization Microcompartment Shell Subunit, EutS-G39V mutant
2Z9H	;	2.71	;	Ethanolamine utilization protein, EutN
8UBX	;	2.5	;	Ethanolamine-bound FLVCR1
5AE3	;	2.18	;	Ether Lipid-Generating Enzyme AGPS in complex with antimycin A
5ADZ	;	2.2	;	Ether Lipid-Generating Enzyme AGPS in complex with inhibitor 1a
5AE2	;	2.0	;	Ether Lipid-Generating Enzyme AGPS in complex with inhibitor 1e
5AE1	;	2.1	;	Ether Lipid-Generating Enzyme AGPS in complex with inhibitor ZINC69435460
4O7U	;	2.4	;	Etherocomplex of Enteroccocus faecalis thymidylate synthase with 5-hydroxymethilene-6-hydrofolic acid and the phtalimidic inhibitor SS7
3SDG	;	1.87	;	Ethionamide Boosters Part 2: Combining Bioisosteric Replacement and Structure-Based Drug Design to Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors.
3SFI	;	2.31	;	Ethionamide Boosters Part 2: Combining Bioisosteric Replacement and Structure-Based Drug Design to Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors.
5NIM	;	1.5	;	EthR complex
5NIO	;	1.4	;	EthR complex
5NIZ	;	1.95	;	EthR complex
5NJ0	;	2.1	;	EthR complex
3G1O	;	1.85	;	EthR from Mycobacterium tuberculosis in complex with compound BDM14500
3G1L	;	1.7	;	EthR from Mycobacterium tuberculosis in complex with compound BDM14744
3O8G	;	1.9	;	EthR from Mycobacterium tuberculosis in complex with compound BDM14801
3O8H	;	1.9	;	EthR from Mycobacterium tuberculosis in complex with compound BDM14950
3Q0V	;	1.95	;	ETHR From mycobacterium tuberculosis in complex with compound bdm31369
3Q0U	;	1.7	;	EthR from Mycobacterium tuberculosis in complex with compound BDM31379
3G1M	;	1.7	;	EthR from Mycobacterium tuberculosis in complex with compound BDM31381
3Q0W	;	1.6	;	ETHR From mycobacterium tuberculosis in complex with compound BDM33066
3Q3S	;	2.0	;	EthR from Mycobacterium tuberculosis in complex with compound BDM5683
6R1P	;	1.8	;	EthR ligand complex
6R1S	;	1.8	;	EthR ligand complex
6HRW	;	2.45	;	EthR2 in complex with compound 1 (BDM14272)
6HRX	;	1.87	;	EthR2 in complex with compound 2 (BDM72201)
6HRY	;	1.84	;	EthR2 in complex with compound 3 (BDM72719)
6HS2	;	1.87	;	EthR2 in complex with compound 31 (BDM76150)
6HRZ	;	1.57	;	EthR2 in complex with compound 4 (BDM72170)
6HS0	;	1.45	;	EthR2 in complex with compound 5 (BDM71847)
6HS1	;	1.69	;	EthR2 in complex with compound 9 (BDM76060)
5N7O	;	2.3	;	EthR2 in complex with SMARt-420 compound
2IVF	;	1.88	;	Ethylbenzene dehydrogenase from Aromatoleum aromaticum
6VP5	;	1.97	;	Ethylene forming enzyme (EFE) D191E variant in complex with Fe(II), L-arginine, and 2OG
6VP4	;	1.83	;	Ethylene forming enzyme (EFE) in complex with Fe(II), L-arginine, and 2OG
8UC2	;	1.6	;	Ethylene forming enzyme (EFE) R171A variant in complex with nickel and Benzoic acid
5V2U	;	2.058	;	Ethylene forming enzyme apo form
5LSQ	;	1.55	;	Ethylene Forming Enzyme from Pseudomonas syringae pv. phaseolicola - I222 crystal form
5MOF	;	1.45	;	Ethylene Forming Enzyme from Pseudomonas syringae pv. phaseolicola - I222 crystal form in complex with manganese and 2-oxoglutarate
5LUN	;	1.08	;	Ethylene Forming Enzyme from Pseudomonas syringae pv. phaseolicola - P1 ultra-high resolution crystal form in complex with iron, N-oxalylglycine and arginine
5V2X	;	1.847	;	Ethylene forming enzyme in complex with manganese and 2-oxoglutarate
5V31	;	2.45	;	Ethylene forming enzyme in complex with manganese and L-arginine
5V32	;	1.486	;	Ethylene forming enzyme in complex with manganese and malic acid
5V2T	;	1.227	;	Ethylene forming enzyme in complex with manganese and tartrate
5V2Z	;	1.23	;	Ethylene forming enzyme in complex with manganese, 2-oxoadipic acid and L-arginine
5VKB	;	1.139	;	Ethylene forming enzyme in complex with manganese, 2-oxoglutarate and argininamide
6CBA	;	1.13	;	Ethylene forming enzyme in complex with manganese, 2-oxoglutarate and canavanine
5V2Y	;	1.428	;	Ethylene forming enzyme in complex with manganese, 2-oxoglutarate and L-arginine
5VKA	;	1.169	;	Ethylene forming enzyme in complex with manganese, 2-oxoglutarate and N-omega-hydroxy-L-arginine
5V34	;	1.48	;	Ethylene forming enzyme in complex with manganese, malic acid and L-arginine
5V2V	;	3.04	;	Ethylene forming enzyme in complex with nickel
6CF3	;	1.12	;	Ethylene forming enzyme Y306A variant in complex with manganese and 2-oxoglutarate
3FC4	;	1.79	;	Ethylene glycol inhibited form of Aldehyde oxidoreductase from Desulfovibrio gigas
4APY	;	2.0	;	Ethylene glycol-bound form of P450 CYP125A3 from Mycobacterium smegmatis
1XLV	;	2.247	;	Ethylphosphorylated Butyrylcholinesterase (Aged) Obtained By Reaction With Echothiophate
1GVJ	;	1.53	;	ETS-1 DNA BINDING AND AUTOINHIBITORY DOMAINS
2JV3	;		;	Ets-1 PNT domain (29-138) NMR structure ensemble
1K79	;	2.4	;	Ets-1(331-440)+GGAA duplex
1K7A	;	2.8	;	Ets-1(331-440)+GGAG duplex
3MFK	;	3.0	;	Ets1 complex with stromelysin-1 promoter DNA
3RI4	;	3.0	;	Ets1 cooperative binding to widely separated sites on promoter DNA
6DA1	;	2.00013	;	ETS1 in complex with synthetic SRR mimic
6DAT	;	2.35003	;	ETS1 in complex with synthetic SRR mimic
3J5S	;	7.5	;	EttA binds to ribosome exit site and regulates translation by restricting ribosome and tRNA dynamics
8E66	;	2.35	;	ETV6 H396Y variant bound to DNA containing the sequence GGAA
8E67	;	2.3	;	ETV6 H396Y variant bound to DNA containing the sequence GGAT
2HPI	;	3.0	;	Eubacterial and Eukaryotic Replicative DNA Polymerases are not Homologous: X-ray Structure of DNA Polymerase III
2HPM	;	3.7	;	Eubacterial and Eukaryotic Replicative DNA Polymerases are not Homologous: X-ray Structure of DNA Polymerase III
6BJW	;	3.0	;	Eubacterium eligens Beta-glucuronidase
6D4O	;	2.9	;	Eubacterium eligens beta-glucuronidase bound to an amoxapine-glucuronide conjugate
6BJQ	;	2.7	;	Eubacterium eligens beta-glucuronidase bound to glucuronic acid
6BO6	;	2.801	;	Eubacterium eligens beta-glucuronidase bound to UNC4917 glucuronic acid conjugate
7JJN	;	2.25	;	Eubacterium rectale Amy13B (EUR_01860)
7BUX	;	2.2	;	Eucommia ulmoides FPS1
7BUW	;	3.3	;	Eucommia ulmoides TPT3 mutant -C94Y/A95F
7BUU	;	3.0	;	Eucommia ulmoides TPT3, crystal form 1
7BUV	;	3.3	;	Eucommia ulmoides TPT3, crystal form 2
8BAP	;	2.3	;	Eugenol Oxidase (EUGO) from Rhodococcus jostii RHA1, eightfold mutant active on propanol syringol
8BAM	;	1.65	;	Eugenol Oxidase (EUGO) from Rhodococcus jostii RHA1, tenfold mutant active on propanol syringol
7YWU	;	2.8	;	Eugenol oxidase from rhodococcus jostii: mutant S81H, A423M, H434Y, S394V, I445D, S518P
7YWV	;	2.4	;	Eugenol oxidase from rhodococcus jostii: mutant S81H, D151E, A423M, H434Y, S394V, Q425S, I445D, S518P
3B7B	;	2.99	;	EuHMT1 (Glp) Ankyrin Repeat Domain (Structure 1)
3B95	;	2.99	;	EuHMT1 (Glp) Ankyrin Repeat Domain (Structure 2)
3UMV	;	1.705	;	Eukaryotic Class II CPD photolyase structure reveals a basis for improved UV-tolerance in plants
1FYO	;		;	EUKARYOTIC DECODING REGION A-SITE RNA
1FYP	;		;	EUKARYOTIC DECODING REGION A-SITE RNA-PAROMOMYCIN COMPLEX
4U0Z	;	2.95	;	Eukaryotic Fic Domain containing protein with bound APCPP
6EZO	;	4.1	;	Eukaryotic initiation factor EIF2B in complex with ISRIB
6GRD	;	2.66	;	eukaryotic junction-resolving enzyme GEN-1 binding with Cesium
6GRB	;	2.4	;	eukaryotic junction-resolving enzyme GEN-1 binding with Potassium
6GRC	;	2.452	;	eukaryotic junction-resolving enzyme GEN-1 binding with Sodium
6WQ1	;	2.295	;	Eukaryotic LanCL2 protein
5GOX	;	2.405	;	Eukaryotic Rad50 Functions as A Rod-shaped Dimer
3K4X	;	2.98	;	Eukaryotic Sliding Clamp PCNA Bound to DNA
8TQO	;	3.1	;	Eukaryotic translation initiation factor 2B tetramer
8TQZ	;	2.9	;	Eukaryotic translation initiation factor 2B with a mutation (L516A) in the delta subunit
1EIF	;	1.9	;	EUKARYOTIC TRANSLATION INITIATION FACTOR 5A FROM METHANOCOCCUS JANNASCHII
2EIF	;	1.8	;	Eukaryotic translation initiation factor 5A from Methanococcus jannaschii
2LT8	;		;	Eurocin solution structure
6FKW	;	1.4	;	Europium-containing methanol dehydrogenase
4UA8	;	1.54	;	EUR_01830 (maltotriose-binding protein) complexed with maltotriose
4UAC	;	1.6	;	EUR_01830 with acarbose
4E4R	;	1.44	;	EutD phosphotransacetylase from Staphylococcus aureus
4FDZ	;	1.802	;	EutL from Clostridium perfringens, Crystallized Under Reducing Conditions
6UH6	;	2.98	;	EV-A71 strain 11316 complexed with MADAL compound 22
6UH7	;	2.87	;	EV-A71 strain 11316 complexed with MADAL compound 30
6DIZ	;	3.59	;	EV-A71 strain 11316 complexed with tryptophan dendrimer MADAL_0385
7QUB	;	2.07	;	EV-A71-3Cpro in complex with inhibitor MG78
7ECY	;	3.6	;	EV-D68 in complex with 2H12 Fab (State 3)
7EBZ	;	3.09	;	EV-D68 in complex with 2H12 Fab (state S1)
7EBR	;	3.6	;	EV-D68 in complex with 2H12 Fab (state S2)
7EC5	;	2.89	;	EV-D68 in complex with 8F12 Fab
7L8H	;	1.95	;	EV68 3C protease (3Cpro) in Complex with Rupintrivir
7WFX	;	1.95	;	EVAA-KlAte1
7WG2	;	1.76	;	EVAA-KlAte1
4DD2	;	1.55	;	EVAL processed HEWL, carboplatin aqueous glycerol
4DD3	;	1.7	;	EVAL processed HEWL, carboplatin aqueous paratone
4DD7	;	1.6	;	EVAL processed HEWL, carboplatin DMSO glycerol
4DD9	;	1.6	;	EVAL processed HEWL, carboplatin DMSO paratone
4DD0	;	1.7	;	EVAL processed HEWL, cisplatin aqueous glycerol
4DD1	;	1.7	;	EVAL processed HEWL, cisplatin aqueous paratone
4DDC	;	1.8	;	EVAL processed HEWL, cisplatin DMSO NAG silicone oil
4DDB	;	3.0	;	EVAL processed HEWL, cisplatin DMSO paratone pH 6.5
4DDA	;	2.48	;	EVAL processed HEWL, NAG
4DRO	;	1.1	;	EVALUATION OF SYNTHETIC FK506 ANALOGS AS LIGANDS FOR FKBP51 AND FKBP52: COMPLEX OF FKBP51 WITH (1R)-3-(3,4-dimethoxyphenyl)-1-phenylpropyl (2S)-1-{[(1R,2S)-2-ethyl-1-hydroxycyclohexyl](oxo)acetyl}piperidine-2-carboxylate
4DRK	;	1.5	;	EVALUATION OF SYNTHETIC FK506 ANALOGS AS LIGANDS FOR FKBP51 AND FKBP52: COMPLEX OF FKBP51 WITH {3-[(1R)-3-(3,4-dimethoxyphenyl)-1-({[(2S)-1-(3,3-dimethyl-2-oxopentanoyl)piperidin-2-yl]carbonyl}oxy)propyl]phenoxy}acetic acid
4DRM	;	1.48	;	EVALUATION OF SYNTHETIC FK506 ANALOGS AS LIGANDS FOR FKBP51 AND FKBP52: COMPLEX OF FKBP51 WITH {3-[(1R)-3-(3,4-dimethoxyphenyl)-1-({[(2S)-1-{[(1S,2R)-2-ethyl-1-hydroxycyclohexyl](oxo)acetyl}piperidin-2-yl]carbonyl}oxy)propyl]phenoxy}acetic acid
4DRN	;	1.069	;	EVALUATION OF SYNTHETIC FK506 ANALOGS AS LIGANDS FOR FKBP51 AND FKBP52: COMPLEX OF FKBP51 WITH {3-[(1R)-3-(3,4-dimethoxyphenyl)-1-({[(2S)-1-{[(1S,2R)-2-ethyl-1-hydroxycyclohexyl](oxo)acetyl}piperidin-2-yl]carbonyl}oxy)propyl]phenoxy}acetic acid
4DRP	;	1.8	;	Evaluation of Synthetic FK506 Analogs as Ligands for the FK506-Binding Proteins 51 and 52: Complex of FKBP51 with 2-(3-((R)-3-(3,4-dimethoxyphenyl)-1-((S)-1-(2-((1R,2S)-2-ethyl-1-hydroxy-cyclohexyl)-2-oxoacetyl)piperidine-2-carbonyloxy)propyl)phenoxy)acetic acid from cocrystallization
3F8V	;	1.08	;	Evaulaution at Atomic Resolution of the Role of Strain in Destabilizing the Temperature Sensitive T4 Lysozyme Mutant Arg96-->His
3F9L	;	1.19	;	Evaulaution at Atomic Resolution of the Role of Strain in Destabilizing the Temperature Sensitive T4 Lysozyme Mutant Arg96-->His
3FA0	;	1.09	;	Evaulaution at Atomic Resolution of the Role of Strain in Destabilizing the Temperature Sensitive T4 Lysozyme Mutant Arg96-->His
3FAD	;	1.2	;	Evaulaution at Atomic Resolution of the Role of Strain in Destabilizing the Temperature Sensitive T4 Lysozyme Mutant Arg96-->His
1JGG	;	2.0	;	Even-skipped Homeodomain Complexed to AT-rich DNA
8CAM	;	1.86	;	Evernimicin bound to the 50S subunit
1QC6	;	2.6	;	EVH1 domain from ENA/VASP-like protein in complex with ACTA peptide
1EVH	;	1.8	;	EVH1 DOMAIN FROM MURINE ENABLED IN COMPLEX WITH ACTA PEPTIDE
1I7A	;	2.24	;	EVH1 DOMAIN FROM MURINE HOMER 2B/VESL 2
4EPK	;	2.6009	;	Evidence for a Dual Role of an Active Site Histidine in alpha-Amino-beta-Carboxymuconate-epsilon-Semialdehyde Decarboxylase
4ERA	;	2.398	;	Evidence for a Dual Role of an Active Site Histidine in alpha-Amino-beta-Carboxymuconate-epsilon-Semialdehyde Decarboxylase
4ERG	;	2.789	;	Evidence for a Dual Role of an Active Site Histidine in alpha-Amino-beta-Carboxymuconate-epsilon-Semialdehyde Decarboxylase
4ERI	;	2.0006	;	Evidence for a Dual Role of an Active Site Histidine in alpha-Amino-beta-Carboxymuconate-epsilon-Semialdehyde Decarboxylase
2Y6P	;	2.1	;	Evidence for a Two-Metal-Ion-Mechanism in the Kdo- Cytidylyltransferase KdsB
1WPD	;		;	Evidence for domain-specific recognition of SK and Kv channels by MTX and HsTx1 scorpion toxins
3R33	;	2.09	;	Evidence for dynamic motion in proteins as a mechanism for ligand dissociation
1T93	;	1.62	;	Evidence for Multiple Substrate Recognition and Molecular Mechanism of C-C reaction by Cytochrome P450 CYP158A2 from Streptomyces Coelicolor A3(2)
1PLG	;	2.8	;	EVIDENCE FOR THE EXTENDED HELICAL NATURE OF POLYSACCHARIDE EPITOPES. THE 2.8 ANGSTROMS RESOLUTION STRUCTURE AND THERMODYNAMICS OF LIGAND BINDING OF AN ANTIGEN BINDING FRAGMENT SPECIFIC FOR ALPHA-(2->8)-POLYSIALIC ACID
1CLA	;	2.34	;	EVIDENCE FOR TRANSITION-STATE STABILIZATION BY SERINE-148 IN THE CATALYTIC MECHANISM OF CHLORAMPHENICOL ACETYLTRANSFERASE
1BZ5	;	2.58	;	EVIDENCE OF A COMMON DECAMER IN THREE CRYSTAL STRUCTURES OF BPTI, CRYSTALLIZE FROM THIOCYANATE, CHLORIDE OR SULFATE
1B0C	;	2.8	;	EVIDENCE OF A COMMON DECAMER IN THREE CRYSTAL STRUCTURES OF BPTI, CRYSTALLIZED FROM THIOCYANATE, CHLORIDE OR SULFATE
4S3M	;	2.6	;	Evidence of kinetic cooperativity in dimeric Ketopantoate Reductase from Staphylococcus aureus
4YCA	;	1.81	;	Evidence of Kinetic Cooperativity in dimeric Ketopantoate Reductase from Staphylococcus aureus
2MTW	;		;	Evidence supporting the hypothesis that specifically modifying a malaria peptide to fit into HLA-DR 1*03 molecules induces antibody production and protection
4C90	;	2.65	;	Evidence that GH115 alpha-glucuronidase activity is dependent on conformational flexibility
4C91	;	2.14	;	Evidence that GH115 alpha-glucuronidase activity is dependent on conformational flexibility
1R5V	;	2.5	;	Evidence that structural rearrangements and/or flexibility during TCR binding can contribute to T-cell activation
1R5W	;	2.9	;	Evidence that structural rearrangements and/or flexibility during TCR binding can contribute to T-cell activation
1ML3	;	2.5	;	Evidences for a flip-flop catalytic mechanism of Trypanosoma cruzi glyceraldehyde-3-phosphate dehydrogenase, from its crystal structure in complex with reacted irreversible inhibitor 2-(2-phosphono-ethyl)-acrylic acid 4-nitro-phenyl ester
7UI5	;		;	Evolution avoids a pathological stabilizing interaction in the immune protein S100A9
6NW4	;	3.0	;	Evolution of a computationally designed Kemp eliminase
2P4I	;	2.5	;	Evolution of a highly Selective and Potent 2-(Pyridin-2-yl)-1,3,5-triazine Tie-2 Kinase Inhibitor
7LQ3	;	2.55	;	Evolution of a sigma-(c-di-GMP)-antisigma switch
2FL9	;	17.0	;	Evolution of bacteriophage tails: Structure of T4 gene product 10
3C2T	;	3.0	;	Evolution of chlorella virus dUTPase
3C3I	;	3.0	;	Evolution of chlorella virus dUTPase
3CA9	;	3.0	;	Evolution of chlorella virus dUTPase
2FM7	;	2.8	;	Evolution of Enzymatic Activity in the Tautomerase Superfamily: Mechanistic and Structural Consequences of the L8R Mutation in 4-Oxalocrotonate Tautomerase
1HDF	;	2.35	;	Evolution of the eye lens beta-gamma-crystallin domain fold
2X82	;	2.6	;	Evolutionary basis of HIV restriction by the antiretroviral TRIMCyp
2X83	;	1.7	;	Evolutionary basis of HIV restriction by the antiretroviral TRIMCyp
6RM3	;	3.4	;	Evolutionary compaction and adaptation visualized by the structure of the dormant microsporidian ribosome
2LKB	;		;	Evolutionary diversification of Mesobuthus alpha-scorpion toxins affecting sodium channels
5KNN	;	2.68	;	Evolutionary gain of alanine mischarging to non-cognate tRNAs with a G4:U69 base pair
4MB8	;	2.4009	;	Evolutionary history and metabolic insights of ancient mammalian uricases
3IIO	;	2.25	;	Evolutionary optimization of computationally designed enzymes: Kemp eliminases of the KE07 series
3IIP	;	2.3	;	Evolutionary optimization of computationally designed enzymes: Kemp eliminases of the KE07 series
3IIV	;	1.8	;	Evolutionary optimization of computationally designed enzymes: Kemp eliminases of the KE07 series
7PNA	;	1.9	;	Evolved unspecific peroxygenase with A77L mutation in complex with 12-methoxylauric acid
7PN5	;	1.82	;	Evolved unspecific peroxygenase with A77L mutation in complex with hexane
7PN9	;	1.85	;	Evolved unspecific peroxygenase with A77L mutation in complex with lauric acid
7PN6	;	1.5	;	Evolved unspecific peroxygenase with A77L mutation in complex with myristic acid
7PN4	;	2.05	;	Evolved unspecific peroxygenase with A77L mutation in complex with naphthalene
7PN7	;	1.65	;	Evolved unspecific peroxygenase with A77L mutation in complex with palmitoleic acid
7PN8	;	1.5	;	Evolved unspecific peroxygenase with A77L mutation in complex with tetradecane
3QI8	;	3.2	;	Evolved variant of cytochrome P450 (BM3, CYP102A1)
8HFB	;	2.24	;	Evolved variant of quercetin 2,4-dioxygenase from Bacillus subtilis
6PWD	;	2.47	;	Ewingella americana HopBF1 kinase
6PWG	;	1.89	;	Ewingella americana HopBF1 kinase bound to AMP-PNP
7SJQ	;	2.0	;	Ex silico engineering of cystine-dense peptides yielding a potent bispecific T-cell engager
8P8R	;	1.42	;	Ex vivo Ym1 crystal structure
8P8T	;	1.71	;	Ex vivo Ym2 crystal structure
7S1M	;	2.41	;	Ex4-D-Ala bound to the glucagon-like peptide-1 receptor/g protein complex (conformer 1)
7S3I	;	2.51	;	Ex4-D-Ala bound to the glucagon-like peptide-1 receptor/g protein complex (conformer 2)
6TYI	;	3.3	;	ExbB-ExbD complex in MSP1E3D1 nanodisc
5J1O	;		;	Excited state (Bound-like) sampled during RDC restrained Replica-averaged Metadynamics (RAM) simulations of the HIV-1 TAR complexed with cyclic peptide mimetic of Tat
1ILX	;	3.8	;	Excited State Dynamics in Photosystem II Revised. New Insights from the X-ray Structure.
6GDZ	;		;	exendin-4 based dual GLP-1/glucagon receptor agonist
6GE2	;		;	exendin-4 based dual GLP-1/glucagon receptor agonist
5NIQ	;		;	exendin-4 variant with dual GLP-1 / glucagon receptor activity
7LLL	;	3.7	;	Exendin-4-bound Glucagon-Like Peptide-1 (GLP-1) Receptor in complex with Gs protein
1EXF	;	2.1	;	EXFOLIATIVE TOXIN A
3TU1	;	1.603	;	Exhaustive Fluorine Scanning towards Potent p53-MDM2 Antagonist
8IC8	;	2.42	;	Exo-alpha-D-arabinofuranosidase from Microbacterium arabinogalactanolyticum
1EQP	;	1.9	;	EXO-B-(1,3)-GLUCANASE FROM CANDIDA ALBICANS
1CZ1	;	1.85	;	EXO-B-(1,3)-GLUCANASE FROM CANDIDA ALBICANS AT 1.85 A RESOLUTION
1EQC	;	1.85	;	EXO-B-(1,3)-GLUCANASE FROM CANDIDA ALBICANS IN COMPLEX WITH CASTANOSPERMINE AT 1.85 A
2PB1	;	1.9	;	Exo-B-(1,3)-Glucanase from Candida Albicans in complex with unhydrolysed and covalently linked 2,4-dinitrophenyl-2-deoxy-2-fluoro-B-D-glucopyranoside at 1.9 A
6ZB8	;	1.35	;	Exo-beta-1,3-glucanase from moose rumen microbiome, active site mutant E167Q/E295Q
6ZB9	;	2.5	;	Exo-beta-1,3-glucanase from moose rumen microbiome, wild type
7BOB	;	2.2	;	Exo-beta-1,4-mannosidase Op5Man5 from Opitutaceae bacterium strain TAV5
8IC6	;	1.75	;	exo-beta-D-arabinanase ExoMA2 from Microbacterium arabinogalactanolyticum in complex with Tris
8IC7	;	1.35	;	exo-beta-D-arabinofuranosidase ExoMA2 from Microbacterium arabinogalactanolyticum in complex with beta-D-arabinofuranose
6JOW	;	1.75	;	Exo-beta-D-glucosaminidase from Pyrococcus furiosus
1UUQ	;	1.5	;	Exo-mannosidase from Cellvibrio mixtus
7ODJ	;	1.3	;	Exo-mannosidase from Cellvibrio mixtus bound to N-alkyl mannocyclophellitol aziridine
6GN0	;	3.24	;	Exoenzyme S from Pseudomonas aeruginosa in complex with human 14-3-3 protein beta, tetrameric crystal form
6GN8	;	2.34	;	Exoenzyme S from Pseudomonas aeruginosa in complex with human 14-3-3 protein beta, trimeric crystal form
6GNK	;	2.55	;	Exoenzyme S from Pseudomonas aeruginosa in complex with human 14-3-3 protein beta, trimeric crystal form bound to Carba-NAD
6GNJ	;	3.24	;	Exoenzyme S from Pseudomonas aeruginosa in complex with human 14-3-3 protein beta, trimeric crystal form in complex with STO1101
6GNN	;	3.79	;	Exoenzyme T from Pseudomonas aeruginosa in complex with human 14-3-3 protein beta, tetrameric crystal form bound to STO1101
3C94	;	2.7	;	ExoI/SSB-Ct complex
7R6N	;	4.1	;	Exon-free state of the Tetrahymena group I intron, symmetry-expanded monomer from a synthetic trimeric construct
3Q7B	;	2.0	;	Exonuclease domain of Lassa virus nucleoprotein
3Q7C	;	1.5	;	Exonuclease domain of Lassa virus nucleoprotein bound to manganese
5FIS	;	1.6	;	Exonuclease domain-containing 1 (Exd1) in the Gd bound conformation
5FIQ	;	2.4	;	Exonuclease domain-containing 1 (Exd1) in the native conformation
3C95	;	1.7	;	Exonuclease I (apo)
1AKO	;	1.7	;	EXONUCLEASE III FROM ESCHERICHIA COLI
5J8N	;	1.44	;	Exonuclease III homologue Mm3148 from Methanosarcina mazei
4FZY	;	2.5	;	Exonuclease X in complex with 12bp blunt-ended dsDNA
4FZX	;	2.3	;	Exonuclease X in complex with 3' overhanging duplex DNA
4FZZ	;	2.8	;	Exonuclease X in complex with 5' overhanging duplex DNA
8OG1	;	1.58	;	Exostosin-like 3 apo enzyme
8OG4	;	2.1	;	Exostosin-like 3 UDP complex
8BR0	;	2.218	;	ExoY Nucleotidyl Cyclase domain from Vibrio nigripulchritudo MARTX toxin (residue Q3455 to L3863) in complex with 3'deoxyCTP and two manganese cations bound to Latrunculin-B-ADP-Mn-actin
8BJJ	;	1.699	;	ExoY Nucleotidyl Cyclase domain from Vibrio nigripulchritudo MARTX toxin, bound to ATP-Mg-actin, human profilin 1 and a sulfate ion
8BO1	;	2.501	;	ExoY Nucleotidyl Cyclase domain from Vibrio nigripulchritudo MARTX toxin, bound to Latrunculin-B-ATP-Mg-actin, and 3'-DEOXYADENOSINE-5'-TRIPHOSPHATE and 2 Mg ions
8BR1	;	2.044	;	ExoY Nucleotidyl Cyclase domain from Vibrio nigripulchritudo MARTX toxin, bound to Latrunculin-B-ATP-Mg-actin, and 3'-DEOXYADENOSINE-5'-TRIPHOSPHATE and 2 Mg ions
6RPL	;	3.85	;	Expanded bat circovirus with DNA VLP
8AW6	;	3.5	;	Expanded Coxsackievirus A9 after 0.01% faf-BSA treatment
8AXX	;	3.3	;	Expanded Coxsackievirus A9 after treatment with endosomal ionic buffer
5KWL	;	4.8	;	expanded poliovirus in complex with VHH 10E
5KTZ	;	4.3	;	expanded poliovirus in complex with VHH 12B
5KU0	;	5.3	;	expanded poliovirus in complex with VHH 17B
5KU2	;	5.3	;	expanded poliovirus in complex with VHH 7A
3UVF	;	3.0	;	Expanding LAGALIDADG endonuclease scaffold diversity by rapidly surveying evolutionary sequence space
5F2B	;	1.7	;	Expanding Nature's Catalytic Repertoire -Directed Evolution of an Artificial Metalloenzyme for In Vivo Metathesis
5IRA	;	1.5	;	Expanding Nature's Catalytic Repertoire -Directed Evolution of an Artificial Metalloenzyme for In Vivo Metathesis
6V94	;	1.8	;	Expanding the Chemical Landscape of SOS1 Activators Using Fragment Based Methods
6V9F	;	1.849	;	Expanding the Chemical Landscape of SOS1 Activators Using Fragment Based Methods
6V9J	;	1.76	;	Expanding the Chemical Landscape of SOS1 Activators Using Fragment Based Methods
6V9L	;	1.698	;	Expanding the Chemical Landscape of SOS1 Activators Using Fragment Based Methods
6V9M	;	1.648	;	Expanding the Chemical Landscape of SOS1 Activators Using Fragment Based Methods
6V9N	;	1.648	;	Expanding the Chemical Landscape of SOS1 Activators Using Fragment Based Methods
6V9O	;	1.799	;	Expanding the Chemical Landscape of SOS1 Activators Using Fragment Based Methods
1OXD	;	1.15	;	Expansion of the Genetic Code Enables Design of a Novel ""Gold"" Class of Green Fluorescent Proteins
1OXE	;	1.15	;	Expansion of the Genetic Code Enables Design of a Novel ""Gold"" Class of Green Fluorescent Proteins
1OXF	;	1.69	;	Expansion of the Genetic Code Enables Design of a Novel ""Gold"" Class of Green Fluorescent Proteins
1ODZ	;	1.4	;	Expansion of the glycosynthase repertoire to produce defined manno-oligosaccharides
5M9W	;	1.21	;	Experimental MAD phased structure of thermolysin in complex with inhibitor JC65.
1XDV	;	4.1	;	Experimentally Phased Structure of Human the Son of Sevenless protein at 4.1 Ang.
5JAH	;	2.06	;	Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>) Discovered Through X-Ray Fragment Screening
5JAL	;	2.06	;	Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>) Discovered Through X-Ray Fragment Screening
5JAN	;	2.12	;	Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>) Discovered Through X-Ray Fragment Screening
5JAO	;	2.06	;	Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>) Discovered Through X-Ray Fragment Screening
5JAP	;	2.46	;	Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>) Discovered Through X-Ray Fragment Screening
5JAR	;	2.11	;	Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>) Discovered Through X-Ray Fragment Screening
5JAS	;	2.06	;	Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>) Discovered Through X-Ray Fragment Screening
5JAT	;	2.04	;	Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>) Discovered Through X-Ray Fragment Screening
5JAU	;	1.95	;	Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>) Discovered Through X-Ray Fragment Screening
3VBQ	;	1.85	;	Exploitation of hydrogen bonding constraints and flat hydrophobic energy landscapes in Pim-1 kinase needle screening and inhibitor design
3VBT	;	2.23	;	Exploitation of hydrogen bonding constraints and flat hydrophobic energy landscapes in Pim-1 kinase needle screening and inhibitor design
3VBV	;	2.08	;	Exploitation of hydrogen bonding constraints and flat hydrophobic energy landscapes in Pim-1 kinase needle screening and inhibitor design
3VBW	;	2.48	;	Exploitation of hydrogen bonding constraints and flat hydrophobic energy landscapes in Pim-1 kinase needle screening and inhibitor design
3VBX	;	2.03	;	Exploitation of hydrogen bonding constraints and flat hydrophobic energy landscapes in Pim-1 kinase needle screening and inhibitor design
3VBY	;	2.27	;	Exploitation of hydrogen bonding constraints and flat hydrophobic energy landscapes in Pim-1 kinase needle screening and inhibitor design
3VC4	;	2.23	;	Exploitation of hydrogen bonding constraints and flat hydrophobic energy landscapes in Pim-1 kinase needle screening and inhibitor design
8G9S	;	3.4	;	Exploiting Activation and Inactivation Mechanisms in Type I-C CRISPR-Cas3 for Genome Editing Applications
8G9T	;	3.6	;	Exploiting Activation and Inactivation Mechanisms in Type I-C CRISPR-Cas3 for Genome Editing Applications
8G9U	;	3.0	;	Exploiting Activation and Inactivation Mechanisms in Type I-C CRISPR-Cas3 for Genome Editing Applications
8GAF	;	3.64	;	Exploiting Activation and Inactivation Mechanisms in Type I-C CRISPR-Cas3 for Genome Editing Applications
8GAM	;	3.46	;	Exploiting Activation and Inactivation Mechanisms in Type I-C CRISPR-Cas3 for Genome Editing Applications
8GAN	;	3.26	;	Exploiting Activation and Inactivation Mechanisms in Type I-C CRISPR-Cas3 for Genome Editing Applications
5T31	;	2.85	;	Exploiting an Asp-Glu switch in Glycogen Synthase Kinase 3 to design paralog selective inhibitors for use in acute myeloid leukemia
4DRQ	;	1.0	;	Exploration of Pipecolate Sulfonamides as Binders of the FK506-Binding Proteins 51 and 52: Complex of FKBP51 with 2-(3-((R)-1-((S)-1-(3,5-dichlorophenylsulfonyl)piperidine-2-carbonyloxy)-3-(3,4-dimethoxy -phenyl)propyl)phenoxy)acetic acid
3HEZ	;	2.0	;	Exploring backbone pattern in alpha/beta-peptide helix bundles: The GCN4-pLI side chain sequence on different (alpha-alpha-alpha-beta) backbones
6ATL	;	1.8	;	Exploring Cystine Dense Peptide Space to Open a Unique Molecular Toolbox
6ATM	;	2.09	;	Exploring Cystine Dense Peptide Space to Open a Unique Molecular Toolbox
6ATN	;	1.76	;	Exploring Cystine Dense Peptide Space to Open a Unique Molecular Toolbox
6ATS	;	1.9	;	Exploring Cystine Dense Peptide Space to Open a Unique Molecular Toolbox
6ATU	;	2.4	;	Exploring Cystine Dense Peptide Space to Open a Unique Molecular Toolbox
6ATW	;	1.53	;	Exploring Cystine Dense Peptide Space to Open a Unique Molecular Toolbox
6ATY	;	1.8	;	Exploring Cystine Dense Peptide Space to Open a Unique Molecular Toolbox
6AU7	;	1.9	;	Exploring Cystine Dense Peptide Space to Open a Unique Molecular Toolbox
6AUP	;	1.95	;	Exploring Cystine Dense Peptide Space to Open a Unique Molecular Toolbox
6AV8	;	1.89	;	Exploring Cystine Dense Peptide Space to Open a Unique Molecular Toolbox
6AVA	;	2.2	;	Exploring Cystine Dense Peptide Space to Open a Unique Molecular Toolbox
6AVC	;	1.88	;	Exploring Cystine Dense Peptide Space to Open a Unique Molecular Toolbox
6AVD	;	1.8	;	Exploring Cystine Dense Peptide Space to Open a Unique Molecular Toolbox
7SOH	;	1.81	;	Exploring Cystine Dense Peptide Space to Open a Unique Molecular Toolbox
3BC3	;	2.2	;	Exploring inhibitor binding at the S subsites of cathepsin L
5I4X	;	1.607	;	Exploring onset of lysozyme denaturation by urea - soak period 2 hours
5I54	;	1.608	;	Exploring onset of lysozyme denaturation by urea - soak period 4 hours
5I53	;	1.608	;	Exploring onset of lysozyme denaturation by urea - soak period 7 hours
5I4Y	;	1.607	;	Exploring onset of lysozyme denaturation by urea: soak period 10 hours.
4LIN	;	2.7	;	Exploring the atomic structure and conformational flexibility of a 320 angstrom long engineered viral fiber using X-ray crystallography
1WVJ	;	1.75	;	Exploring the GluR2 ligand-binding core in complex with the bicyclic AMPA analogue (S)-4-AHCP
8B5D	;	2.0	;	Exploring the ligand binding and conformational dynamics of receptor domain 1 of the ABC transporter GlnPQ
8B5E	;	1.6	;	Exploring the ligand binding and conformational dynamics of receptor domain 1 of the ABC transporter GlnPQ
5I4W	;	1.6	;	Exploring the onset of lysozyme denaturation by urea
2ZDA	;	1.73	;	Exploring Thrombin S1 pocket
2ZDV	;	1.72	;	Exploring Thrombin S1 pocket
2ZF0	;	2.2	;	Exploring Thrombin S1 Pocket
2ZFF	;	1.47	;	Exploring Thrombin S1-pocket
2ZFQ	;	1.8	;	Exploring thrombin S3 pocket
2ZFR	;	1.85	;	Exploring thrombin S3 pocket
2ZG0	;	1.75	;	Exploring thrombin S3 pocket
2ZHE	;	2.1	;	Exploring thrombin S3 pocket
2ZHF	;	1.98	;	Exploring thrombin S3 pocket
2ZHW	;	2.02	;	Exploring thrombin S3 pocket
2ZDK	;	1.67	;	Exploring Trypsin S3 Pocket
2ZDL	;	1.8	;	Exploring trypsin S3 pocket
2ZDM	;	1.93	;	Exploring trypsin S3 pocket
2ZDN	;	1.98	;	Exploring trypsin S3 pocket
2ZFS	;	1.51	;	Exploring trypsin S3 pocket
2ZFT	;	1.76	;	Exploring trypsin S3 pocket
2ZHD	;	1.94	;	Exploring trypsin S3 pocket
2ZQ1	;	1.68	;	Exploring trypsin S3 pocket
2ZQ2	;	1.4	;	Exploring trypsin S3 pocket
6RWY	;	5.11	;	Export apparatus core and inner rod of the Shigella type 3 secretion system
3QVD	;	2.0	;	Exposure of rubrerythrin from Pyrococcus furiosus to peroxide, fifteen second time point.
2LA1	;		;	Expression in Pichia pastoris and backbone dynamics of dendroaspin, a three finger toxin
6S9Z	;	0.95	;	Expression tag modified N-terminus of human Carbonic Anhydrase II covalently linked to fragment
5WUG	;	2.216	;	Expression, characterization and crystal structure of a novel beta-glucosidase from Paenibacillus barengoltzii
5WVP	;	2.294	;	Expression, characterization and crystal structure of a novel beta-glucosidase from Paenibacillus barengoltzii
1TDR	;	2.5	;	EXPRESSION, CHARACTERIZATION, AND CRYSTALLOGRAPHIC ANALYSIS OF TELLUROMETHIONYL DIHYDROFOLATE REDUCTASE
2ANY	;	1.4	;	Expression, Crystallization and the Three-dimensional Structure of the Catalytic Domain of Human Plasma Kallikrein: Implications for Structure-Based Design of Protease Inhibitors
2ANW	;	1.85	;	Expression, crystallization and three-dimensional structure of the catalytic domain of human plasma kallikrein: Implications for structure-based design of protease inhibitors
4JB4	;	2.39	;	Expression, Purification, Characterization, and Solution NMR Study of Highly Deuterated Yeast Cytochrome c Peroxidase with Enhanced Solubility
3HGF	;	4.0	;	Expression, purification, spectroscopical and crystallographical studies of segments of the nucleotide binding domain of the reticulocyte binding protein Py235 of Plasmodium yoelii
7S5U	;	4.41	;	Extended bipolar assembly domain of kinesin-5 minifilament
5O2X	;	0.95	;	Extended catalytic domain of H. jecorina LPMO9A a.k.a EG4
5O2W	;	2.0	;	Extended catalytic domain of Hypocrea jecorina LPMO 9A.
7S67	;	3.8	;	Extended conformation of daytime state KaiC
7S66	;	2.8	;	Extended conformation of nighttime state KaiC
8CPY	;	3.9	;	Extended cowpea chlorotic mottle virus
6BUS	;	1.9	;	Extended E2 DNA-binding domain of the Bovine Papillomavirus-1
7QGQ	;		;	Extended H/L (SLPH/SLPL) complex from C. difficile (CD630 strain) fit into R20291 S-layer negative stain map
6K2C	;	2.703	;	Extended Hect domain of UBE3C E3 Ligase
6ZYA	;	3.5	;	Extended human uromodulin filament core at 3.5 A resolution
4C0H	;	2.7	;	Extended interface between Pcf11p and Clp1p and structural basis for ATP loss in Gly135Arg point mutant
6Y5K	;	4.2	;	Extended Intermediate form of X-31 Influenza Haemagglutinin at pH 5 (State IV)
6RQR	;	2.2	;	Extended NHERF1 PDZ2 domain in complex with the PDZ-binding motif of CFTR
8OEJ	;	8.0	;	Extended RPA-DNA nucleoprotein filament
6URT	;	3.27	;	Extended Sensor Paddles with Bound Lipids Revealed in Mechanosensitive Channel YnaI
1PD7	;		;	Extended SID of Mad1 bound to the PAH2 domain of mSin3B
2KEM	;		;	Extended structure of citidine deaminase domain of APOBEC3G
6S8S	;	2.21	;	Extended structure of the human DDX6 C-terminal domain in complex with an EDC3 FDF peptide
2CJX	;	1.7	;	Extended substrate recognition in caspase-3 revealed by high resolution X-ray structure analysis
2CJY	;	1.67	;	Extended substrate recognition in caspase-3 revealed by high resolution X-ray structure analysis
2DKO	;	1.06	;	Extended substrate recognition in caspase-3 revealed by high resolution X-ray structure analysis
2WAC	;	2.1	;	Extended Tudor domain of Drosophila Melanogaster Tudor-SN (p100)
4NPJ	;	2.101	;	Extended-Synaptotagmin 2, C2A- and C2B-domains
4NPK	;	2.552	;	Extended-Synaptotagmin 2, C2A- and C2B-domains, calcium bound
4P42	;	2.44	;	Extended-Synaptotagmin 2, SMP - C2A - C2B Domains
1NMQ	;	2.4	;	Extendend Tethering: In Situ Assembly of Inhibitors
2O2W	;		;	Extending powder diffraction to proteins: structure solution of the second SH3 domain from ponsin
2MZU	;		;	Extending the eNOE data set of large proteins by evaluation of NOEs with unresolved diagonals
1ROQ	;		;	Extending the Family of UNCG-like Tetraloop Motifs: NMR Structure of a CACG Tetraloop from Coxsackievirus B3
5FUO	;	3.6	;	Extending the half-life of a Fab fragment through generation of a humanised anti-Human Serum Albumin (HSA) Fv domain: an investigation into the correlation between affinity and serum half-life
5FUZ	;	2.68	;	Extending the half-life of a Fab fragment through generation of a humanised anti-Human Serum Albumin (HSA) Fv domain: an investigation into the correlation between affinity and serum half-life
1U48	;	2.1	;	Extension of a cytosine-8-oxoguanine base pair
1U4B	;	1.6	;	Extension of an adenine-8oxoguanine mismatch
241D	;	1.85	;	EXTENSION OF THE FOUR-STRANDED INTERCALATED CYTOSINE MOTIF BY ADENINE.ADENINE BASE PAIRING IN THE CRYSTAL STRUCTURE OF D(CCCAAT)
5FHJ	;	1.68	;	Extensive amphimorphism in DNA: Three stable conformations for the decadeoxynucleotide d(GCATGCATGC)
5FHL	;	1.791	;	Extensive amphimorphism in DNA: Three stable conformations for the decadeoxynucleotide d(GCATGCATGC)
4C3U	;	2.29	;	Extensive counter-ion interactions with subtilisin in aqueous medium, Cs derivative
4C3V	;	2.26	;	Extensive counter-ion interactions with subtilisin in aqueous medium, no Cs soak
5B61	;	3.115	;	Extra-superfolder GFP
6TJ2	;	1.32	;	Extracellular alpha/beta-hydrolase from Paenibacillus species shares structural and functional homology to Tobacco Salicylic Acid Binding Protein 2
8CTG	;	3.8	;	Extracellular architecture of an engineered canonical Wnt signaling ternary complex
8W7P	;	1.8	;	Extracellular domain of a sensor histidine kinase
2ICC	;	1.2	;	Extracellular Domain of CRIg
5OTT	;	1.92	;	Extracellular domain of GLP-1 receptor in complex with exendin-4 variant Gly2Hcs/Thr5Hcs
5OTV	;	2.0	;	Extracellular domain of GLP-1 receptor in complex with GLP-1 variant Ala8Cyc/Thr11Hcs
5OTX	;	2.0	;	Extracellular domain of GLP-1 receptor in complex with GLP-1 variant Ala8Cys/Thr11Cys
5OTW	;	2.1	;	Extracellular domain of GLP-1 receptor in complex with GLP-1 variant Ala8Hcs/Thr11Cys
5OTU	;	1.8	;	Extracellular domain of GLP-1 receptor in complex with GLP-1 variant Ala8Hcs/Thr11Hcs
5MJ0	;	3.2	;	Extracellular domain of human CD83 - cubic crystal form
5MJ1	;	1.8	;	Extracellular domain of human CD83 - rhombohedral crystal form
5MJ2	;	1.98	;	Extracellular domain of human CD83 - rhombohedral crystal form after UV-RIP (S-SAD data)
5MIX	;	1.701	;	Extracellular domain of human CD83 - trigonal crystal form
1P57	;	1.75	;	Extracellular domain of human hepsin
1TFH	;	2.4	;	EXTRACELLULAR DOMAIN OF HUMAN TISSUE FACTOR
1RWI	;	1.8	;	Extracellular domain of Mycobacterium tuberculosis PknD
1RWL	;	1.9	;	Extracellular domain of Mycobacterium tuberculosis PknD
1EXT	;	1.85	;	EXTRACELLULAR DOMAIN OF THE 55KDA TUMOR NECROSIS FACTOR RECEPTOR. CRYSTALLIZED AT PH3.7 IN P 21 21 21.
1N7D	;	3.7	;	Extracellular domain of the LDL receptor
4XJJ	;	1.4	;	Extracellular domain of type II Transforming Growth Factor Beta receptor in complex with 2-(2-Hydroxyethyl)NDSB-201
4P7U	;	1.502	;	Extracellular domain of type II Transforming Growth Factor Beta receptor in complex with NDSB-201
4QQV	;	3.45	;	Extracellular domains of mouse IL-3 beta receptor
2XGR	;	1.7	;	extracellular endonuclease
6O06	;	3.6	;	Extracellular factors prime enterovirus particles for uncoating
5ERE	;	2.0	;	Extracellular ligand binding receptor from Desulfohalobium retbaense DSM5692
4K90	;	1.8	;	Extracellular metalloproteinase from Aspergillus
2XH3	;	2.49	;	extracellular nuclease
4NZL	;	1.85	;	Extracellular proteins of Staphylococcus aureus inhibit the neutrophil serine proteases
1BOY	;	2.2	;	EXTRACELLULAR REGION OF HUMAN TISSUE FACTOR
5KVM	;	2.449	;	Extracellular region of mouse GPR56/ADGRG1 in complex with FN3 monobody
1OLL	;	1.93	;	Extracellular region of the human receptor NKp46
4OVJ	;	1.65	;	Extracellular solute-binding protein family 1 from Alicyclobacillus acidocaldarius subsp. acidocaldarius DSM 446
5A2E	;	3.15	;	Extracellular SRCR domains of human CD6
4PUD	;	2.01	;	Extracellulr Xylanase from Geobacillus stearothermophilus: E159Q mutant, with xylopentaose in active site
4PUE	;	2.2	;	Extracellulr Xylanase from Geobacillus stearothermophilus: E159Q mutant, with xylotetraose in active site
1M6P	;	1.8	;	EXTRACYTOPLASMIC DOMAIN OF BOVINE CATION-DEPENDENT MANNOSE 6-PHOSPHATE RECEPTOR
1XI6	;	2.8	;	Extragenic suppressor from Pyrococcus furiosus Pfu-1862794-001
6GAU	;	3.3	;	Extremely 'open' clamp structure of DNA gyrase: role of the Corynebacteriales GyrB specific insert
6GAV	;	2.6	;	Extremely 'open' clamp structure of DNA gyrase: role of the Corynebacteriales GyrB specific insert
4BNR	;	2.0	;	Extremely stable complex of crayfish trypsin with bovine trypsin inhibitor
6RPV	;		;	Extremely stable monomeric variant of human cystatin C with single amino acid substitution
2JLD	;	2.35	;	Extremely Tight Binding of Ruthenium Complex to Glycogen Synthase Kinase 3
6ZQO	;	2.2	;	EYFP mutant - F165G
1P4D	;	2.6	;	F factor TraI Relaxase Domain
2A0I	;	2.72	;	F Factor TraI Relaxase Domain bound to F oriT Single-stranded DNA
7P0Q	;	1.73	;	F(M197)H mutant structure of Photosynthetic Reaction Center From Rhodobacter Sphaeroides strain RV by fixed-target serial synchrotron crystallography (100K, 26keV)
7P17	;	2.22	;	F(M197)H mutant structure of Photosynthetic Reaction Center From Rhodobacter Sphaeroides strain RV by fixed-target serial synchrotron crystallography (room temperature, 12keV)
7P2C	;	2.04	;	F(M197)H mutant structure of Photosynthetic Reaction Center From Rhodobacter Sphaeroides strain RV by fixed-target serial synchrotron crystallography (room temperature, 26keV)
7OD5	;	2.1	;	F(M197)H mutant structure of Photosynthetic Reaction Center From Rhodobacter Sphaeroides strain RV LSP crystallization
8C4E	;	2.6	;	F-actin decorated by SipA426-685
8C4C	;	2.7	;	F-actin decorated by SipA497-669
6KLN	;	3.4	;	F-actin of cardiac thin filament in high-calcium state
6KLL	;	3.0	;	F-actin of cardiac thin filament in low-calcium state
7BT7	;	3.8	;	F-actin-ADP complex structure
6M5G	;	3.6	;	F-actin-Utrophin complex
4DYL	;	2.18	;	F-BAR domain of human FES tyrosine kinase
6BRT	;	2.393	;	F-box protein CTH with hydrolase
6BRP	;	2.39	;	F-box protein form 2
8GRE	;	2.3	;	F-box protein in complex with skp1(FL) and substrate
6NM5	;	6.2	;	F-pilus/MS2 Maturation protein complex
1SZL	;		;	F-spondin TSR domain 1
1VEX	;		;	F-spondin TSR domain 4
6WLM	;	7.4	;	F. nucleatum glycine riboswitch with glycine models, 7.4 Angstrom resolution
6WMR	;	3.46	;	F. tularensis RNAPs70-(MglA-SspA)-iglA DNA complex
6WMT	;	4.43	;	F. tularensis RNAPs70-(MglA-SspA)-ppGpp-PigR-iglA DNA complex
6WMP	;	2.98	;	F. tularensis RNAPs70-iglA DNA complex
7XKO	;	3.4	;	F1 domain of epsilon C-terminal domain deleted FoF1 from Bacillus PS3,state1,nucleotide depeleted
7XKP	;	3.0	;	F1 domain of epsilon C-terminal domain deleted FoF1 from Bacillus PS3,state1,unisite condition
8HH7	;	2.5	;	F1 domain of FoF1-ATPase from Bacillus PS3, 81 degrees, lowATP
8HH9	;	3.6	;	F1 domain of FoF1-ATPase from Bacillus PS3, 90 degrees, low ATP
8HH4	;	3.1	;	F1 domain of FoF1-ATPase from Bacillus PS3,101 degrees, highATP
8HH5	;	2.9	;	F1 domain of FoF1-ATPase from Bacillus PS3,120 degrees,highATP
8HHA	;	3.4	;	F1 domain of FoF1-ATPase from Bacillus PS3,120 degrees,lowATP
8HH3	;	4.3	;	F1 domain of FoF1-ATPase from Bacillus PS3,90 degrees,highATP
8HHC	;	3.3	;	F1 domain of FoF1-ATPase from Bacillus PS3,post-hyd',lowATP
8HH2	;	3.0	;	F1 domain of FoF1-ATPase from Bacillus PS3,post-hyd,highATP
8HH8	;	2.8	;	F1 domain of FoF1-ATPase from Bacillus PS3,post-hyd,lowATP
8HH6	;	2.9	;	F1 domain of FoF1-ATPase from Bacillus PS3,step waiting,highATP
8HHB	;	3.5	;	F1 domain of FoF1-ATPase from Bacillus PS3,step waiting,lowATP
7XKQ	;	3.3	;	F1 domain of FoF1-ATPase with the down form of epsilon subunit from Bacillus PS3
7XKR	;	2.6	;	F1 domain of FoF1-ATPase with the up form of epsilon subunit from Bacillus PS3
8HUG	;	2.15	;	F1 in complex with CRM1-Ran-RanBP1
6Q45	;	3.6	;	F1-ATPase from Fusobacterium nucleatum
6FOC	;	4.0	;	F1-ATPase from Mycobacterium smegmatis
4ASU	;	2.6	;	F1-ATPase in which all three catalytic sites contain bound nucleotide, with magnesium ion released in the Empty site
7YRY	;	3.0	;	F1-ATPase of Acinetobacter baumannii
1TPG	;		;	F1-G MODULE PAIR RESIDUES 1-91 (C83S) OF TISSUE-TYPE PLASMINOGEN ACTIVATOR (T-PA) (NMR, 298K, PH2.95, REPRESENTATIVE STRUCTURE)
1NT5	;		;	F1-Gramicidin A in Sodium Dodecyl Sulfate Micelles (NMR)
1NT6	;		;	F1-Gramicidin C In Sodium Dodecyl Sulfate Micelles (NMR)
7MRV	;	1.57	;	F100A mutant structure of MIF2 (D-DT)
6EH7	;	1.89	;	F11 Human T-Cell Receptor specific for influenza virus haaemagglutinin epitope PKYVKQNTLKLAT carried by Human Leukocyte Antigen HLA-DR0101
6EH6	;	1.78	;	F11 T-Cell Receptor Recognising PKYVKQNTLKLAT Peptide Presented by HLA-DR*0101
6FR9	;	1.62	;	F11 T-Cell Receptor Recognising PKYVKQNTLKLAT Peptide Presented by HLA-DR*0101
6FRA	;	1.73	;	F11 T-Cell Receptor Recognising PKYVKQNTLKLAT Peptide Presented by HLA-DR*0101
6FRB	;	1.75	;	F11 T-Cell Receptor Recognising PKYVKQNTLKLAT Peptide Presented by HLA-DR*0101
6FRC	;	1.59	;	F11 T-Cell Receptor Recognising PKYVKQNTLKLAT Peptide Presented by HLA-DR*0101
6FUM	;	1.76	;	F11 T-Cell Receptor Recognising PKYVKQNTLKLAT Peptide Presented by HLA-DR*0101
6FUN	;	1.58	;	F11 T-Cell Receptor Recognising PKYVKQNTLKLAT Peptide Presented by HLA-DR*0101
6FUO	;	1.7	;	F11 T-Cell Receptor Recognising PKYVKQNTLKLAT Peptide Presented by HLA-DR*0101
6FUP	;	1.72	;	F11 T-Cell Receptor Recognising PKYVKQNTLKLAT Peptide Presented by HLA-DR*0101
6FUQ	;	1.6	;	F11 T-Cell Receptor Recognising PKYVKQNTLKLAT Peptide Presented by HLA-DR*0101
6FUR	;	1.73	;	F11 T-Cell Receptor Recognising PKYVKQNTLKLAT Peptide Presented by HLA-DR*0101
2QD2	;	2.2	;	F110A variant of human ferrochelatase with protoheme bound
1F11	;	3.0	;	F124 FAB FRAGMENT FROM A MONOCLONAL ANTI-PRES2 ANTIBODY
3O6A	;	2.0	;	F144Y/F258Y Double Mutant of Exo-beta-1,3-glucanase from Candida albicans at 2 A
1O9Z	;	1.75	;	F17-aG lectin domain from Escherichia coli (ligand free)
1O9V	;	1.75	;	F17-aG lectin domain from Escherichia coli in complex with a selenium carbohydrate derivative
1O9W	;	1.65	;	F17-aG lectin domain from Escherichia coli in complex with N-acetyl-glucosamine
3MPN	;	2.25	;	F177R1 mutant of LeuT
3F6J	;	1.75	;	F17a-G lectin domain with bound GlcNAc(beta1-3)Gal
3F64	;	1.95	;	F17a-G lectin domain with bound GlcNAc(beta1-O)paranitrophenyl ligand
3FFO	;	2.1	;	F17b-G lectin domain with bound GlcNAc(beta1-2)man
4K0O	;	2.15	;	F17b-G lectin domain with bound GlcNAc(beta1-3)Gal
6FSL	;	2.5	;	F194W mutant of the dye-decolorizing peroxidase (DYP) from Pleurotus ostreatus
6FSK	;	1.56	;	F194Y mutant of the Dye-decolorizing peroxidase (DYP) from Pleurotus ostreatus
3LG5	;	1.641	;	F198A Epi-isozizaene synthase: Complex with Mg, inorganic pyrophosphate and benzyl triethyl ammonium cation
8SU4	;	1.43	;	F198S epi-Isozizaene Synthase: complex with 3 Mg2+, inorganic pyrophosphate, and benzyl triethyl ammonium cation
8SU5	;	1.48	;	F198T epi-Isozizaene Synthase: complex with 3 Mg2+, inorganic pyrophosphate, and benzyl triethyl ammonium cation
7P2Y	;	3.1	;	F1Fo-ATP synthase from Acinetobacter baumannii (state 1)
7P3N	;	4.6	;	F1Fo-ATP synthase from Acinetobacter baumannii (state 2)
7P3W	;	4.3	;	F1Fo-ATP synthase from Acinetobacter baumannii (state 3)
5FNZ	;	2.52	;	F206W mutant of FAD synthetase from Corynebacterium ammoniagenes
3AGC	;	2.0	;	F218V mutant of the substrate-bound red chlorophyll catabolite reductase from Arabidopsis thaliana
3AGB	;	2.2	;	F218V mutant of the substrate-free form of red chlorophyll catabolite reductase from Arabidopsis thaliana
1P8I	;	1.86	;	F219L BACTERIORHODOPSIN MUTANT
3N9K	;	1.7	;	F229A/E292S Double Mutant of Exo-beta-1,3-glucanase from Candida albicans in Complex with Laminaritriose at 1.7 A
7ZKV	;	2.066	;	F231A variant of the CODH/ACS complex of C. hydrogenoformans
3LNM	;	2.9	;	F233W mutant of the Kv2.1 paddle-Kv1.2 chimera channel
4Q74	;	2.19	;	F241A Fc
2PF0	;	1.9	;	F258I mutant of EXO-B-(1,3)-GLUCANASE FROM CANDIDA ALBICANS at 1.9 A
7SMJ	;	1.58	;	F2N structure, protein design with deep learning
7XXP	;	2.052	;	F316A-glycine-streptothricin F complex
5KJE	;	1.26	;	F322L horse liver alcohol dehydrogenase complexed with NAD+ and pentafluorobenzyl alcohol
7ZS4	;	1.75	;	F32V Cytochrome c prime beta from Methylococcus capsulatus (Bath)
7ZSV	;	1.74	;	F32V Cytochrome c prime beta from Methylococcus capsulatus (Bath) Chemically Reduced Ferrous Form
7ZSX	;	1.77	;	F32V Cytochrome c prime beta from Methylococcus capsulatus (Bath): CO Complex
7ZSW	;	1.94	;	F32V Cytochrome c prime beta from Methylococcus capsulatus (Bath): NO Complex
4F4D	;	1.8	;	F337R variant of human ferrochelatase
4FWY	;	1.8	;	F33Y CuB myoglobin (F33Y L29H F43H sperm whale myoglobin) with copper bound
1P0V	;	2.05	;	F393A mutant heme domain of flavocytochrome P450 BM3
1P0W	;	2.0	;	F393W mutant heme domain of flavocytochrome P450 BM3
1P0X	;	2.0	;	F393Y mutant heme domain of flavocytochrome P450 BM3
6LZU	;	1.9	;	F411A mutant of chitin-specific solute binding protein from Vibrio harveyi co-crystalized with chitobiose.
4XOQ	;	2.05	;	F420 complex of coenzyme F420:L-glutamate ligase (FbiB) from Mycobacterium tuberculosis (C-terminal domain)
7ULE	;	1.7	;	F420-1/GDP complex of F420-gamma glutamyl ligase (CofE) from Archaeoglobus fulgidus
8G8P	;	1.83	;	F420-2/GTP(GDP) complex of F420-gamma glutamyl ligase (CofE) from Archaeoglobus fulgidus
5LXE	;	1.47	;	F420-dependent glucose-6-phosphate dehydrogenase from Rhodococcus jostii RHA1
1RHC	;	1.8	;	F420-dependent secondary alcohol dehydrogenase in complex with an F420-acetone adduct
5N2I	;	1.8	;	F420:NADPH oxidoreductase from Thermobifida fusca with NADP+ bound
6LZV	;	2.2	;	F437A mutant of chitin-specific solute binding protein from Vibrio harveyi co-crystalized with chitobiose.
2YCP	;	2.0	;	F448H mutant of tyrosine phenol-lyase from Citrobacter freundii in complex with quinonoid intermediate formed with 3-fluoro-L-tyrosine
4Z44	;	2.204	;	F454K Mutant of Tryptophan 7-halogenase PrnA
1IZR	;	1.5	;	F46A mutant of bovine pancreatic ribonuclease A
1IZP	;	1.5	;	F46L mutant of bovine pancreatic ribonuclease A
1IZQ	;	1.8	;	F46V mutant of bovine pancreatic ribonuclease A
8CJC	;	2.22	;	F515A variant of the CODH/ACS complex of C. hydrogenoformans
3QXD	;	2.302	;	F54C HLA-DR1 bound with CLIP peptide
6MSF	;	2.8	;	F6 APTAMER MS2 COAT PROTEIN COMPLEX
6VVN	;	1.39	;	F6 fused 4-OT wild type asymmetric trimer
4N8J	;	2.01	;	F60M mutant, RipA structure
7ZRW	;	1.96	;	F61V Cytochrome c prime beta from Methylococcus capsulatus (Bath)
7ZRX	;	2.04	;	F61V Cytochrome c prime beta from Methylococcus capsulatus (Bath) Chemically Reduced Ferrous State
7ZTI	;	2.09	;	F61V Cytochrome c prime beta from Methylococcus capsulatus (Bath): CO Complex
7ZQZ	;	1.68	;	F61V Cytochrome c prime beta from Methylococcus capsulatus (Bath): NO complex
4FDK	;	2.1	;	F78L Tt H-NOX
8HLZ	;	3.5	;	F8-A22-E4 complex of MPXV in hexameric form
8HM0	;	3.1	;	F8-A22-E4 complex of MPXV in trimeric form
3M6E	;	2.65	;	F80A mutant of the Urea Transporter from Desulfovibrio Vulgaris
2VLQ	;	1.6	;	F86A mutant of E9 DNase domain in complex with Im9
6ARO	;	1.2	;	F9 pilus adhesin FmlH lectin domain from E. coli UTI89 co-crystallized with 8-hydroxyquinoline beta-galactoside
6ARN	;	1.25	;	F9 pilus adhesin FmlH lectin domain from E. coli UTI89 co-crystallized with o-methoxyphenyl beta-galactoside (OMPG)
6AOY	;	1.8	;	F9 pilus adhesin FmlH lectin domain from E. coli UTI89 co-crystallized with o-nitrophenyl beta-galactoside (ONPG)
6ARM	;	1.5	;	F9 pilus adhesin FmlH lectin domain from E. coli UTI89 co-crystallized with o-nitrophenyl beta-galactoside (ONPG)
6AS8	;	2.101	;	F9 pilus adhesin FmlH lectin domain from E. coli UTI89 co-crystallized with ortho-biphenyl-2'-carboxyl N-acetyl-beta-galactosaminoside
6AOX	;	2.1	;	F9 pilus adhesin FmlH lectin domain from E. coli UTI89 co-crystallized with TF antigen
6MAQ	;	1.31	;	F9 Pilus Adhesin FmlH Lectin Domain from E. coli UTI89 in Complex with Galactoside 2'-{[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-nitro-[1,1'-biphenyl]-3-carboxylic acid
6MAP	;	1.08	;	F9 Pilus Adhesin FmlH Lectin Domain from E. coli UTI89 in Complex with Galactoside 5-nitro-2'-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-[1,1'-biphenyl]-3-carboxylic acid
6MAW	;	1.75	;	F9 Pilus Adhesin FmlH Lectin Domain from E. coli UTI89 in Complex with Galactoside N-[(2S,3R,4R,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-{[S-methyl-6-(trifluoromethyl)-[1,1'-biphenyl]-3'-yl]oxy}oxan-3-yl]acetamide
2CO5	;	2.2	;	F93 FROM STIV, a winged-helix DNA-binding protein
8E7U	;	1.19	;	F93A Horse Liver Alcohol Dehydrogenase in Complex with NADH and N-Cyclohexylformamide
8ECT	;	1.6	;	F93AL57A Horse Liver Alcohol Dehydrogenase in Complex with NADH and N-Cyclohexylformamide
8ECS	;	1.2	;	F93G Horse Liver Alcohol Dehydrogenase in Complex with NADH and N-Cyclohexylformamide
8ECU	;	1.3	;	F93S Horse Liver Alcohol Dehydrogenase in Complex with NADH and N-Cyclohexylformamide
8EE3	;	1.55	;	F93Y Horse Liver Alcohol Dehydrogenase in Complex with NADH and N-Cyclohexylformamide
6AXN	;	1.9	;	F95C Epi-isozizaene synthase
4LZ3	;	2.095	;	F95H Epi-isozizaene synthase: Complex with Mg, inorganic pyrophosphate and benzyl triethyl ammonium cation
4LTZ	;	2.448	;	F95M Epi-isozizaene synthase: Complex with Mg, inorganic pyrophosphate and benzyl triethyl ammonium cation
6AX9	;	2.403	;	F95N Epi-isozizaene synthase
6OFV	;	1.91	;	F95Q Epi-isozizaene synthase
8SU3	;	1.29	;	F95S epi-Isozizaene Synthase: complex with 3 Mg2+, inorganic pyrophosphate, and benzyl triethyl ammonium cation
8V3K	;	1.47	;	F95S-F198S epi-Isozizaene Synthase: complex with 3 Mg2+, inorganic pyrophosphate, and benzyl triethyl ammonium cation
6AXM	;	1.8	;	F95Y Epi-isozizaene synthase
4Z0S	;	2.39	;	F96A Mutant of Plasmodium Falciparum Triosephosphate Isomerase
8SU1	;	1.37	;	F96H epi-Isozizaene Synthase: complex with 3 Mg2+ and pamidronate
8SU2	;	1.33	;	F96H epi-Isozizaene Synthase: complex with 3 Mg2+ and risedronate
7KJG	;	1.3	;	F96M epi-isozizaene synthase: complex with 3 Mg2+ and BTAC
7KJD	;	1.5	;	F96M epi-isozizaene synthase: complex with 3 Mg2+ and risedronate
6AXO	;	2.1	;	F96S Epi-isozizaene synthase
7KJE	;	1.6	;	F96S epi-isozizaene synthase: complex with 3 Mg2+ and neridronate
4YWI	;	1.85	;	F96S/L167V Double mutant of Plasmodium Falciparum Triosephosphate Isomerase
4Z0J	;	2.07	;	F96S/S73A Double mutant of Plasmodium Falciparum Triosephosphate Isomerase
4YXG	;	1.9	;	F96Y Mutant of Plasmodium Falciparum Triosephosphate Isomerase
6HU4	;	2.64	;	F97L Hepatitis B core protein capsid
2AV0	;	1.5	;	F97L with CO bound
2AV3	;	1.7	;	F97L- no ligand
2AUR	;	2.3	;	F97V (no ligand bound)
2KQU	;		;	F98N apoflavodoxin from Anabaena PCC 7119
3M09	;	2.009	;	F98Y TMP-resistant Dihydrofolate Reductase from Staphylococcus aureus with inhibitor RAB1
6MRG	;	2.77	;	FAAH bound to non covalent inhibitor
1S5I	;	2.7	;	Fab (LNKB-2) of monoclonal antibody to Human Interleukin-2, crystal structure
1F8T	;	2.2	;	FAB (LNKB-2) OF MONOCLONAL ANTIBODY, CRYSTAL STRUCTURE
6M87	;	2.609	;	Fab 10A6 in complex with MPTS
8FAX	;	2.1	;	Fab 1249A8-MERS Stem Helix Complex
7LFA	;	1.857	;	Fab 3B6 bound to ApoL1 NTD
5MVZ	;	2.15	;	Fab 4AB007 bound to Interleukin-1-beta
7LF7	;	2.026	;	Fab 6D12 bound to ApoL1 NTD
7LF8	;	2.15	;	Fab 6D12 bound to ApoL2 NTD
7OX3	;	1.7	;	Fab 6D3: hIL-9 complex
7OX2	;	3.34	;	Fab 6E2: hIL-9 complex
7LFD	;	2.157	;	Fab 7D6 bound to ApoL1 BH3 like peptide
7LFB	;	1.913	;	Fab 7D6 bound to ApoL1 NTD
7OX1	;	2.49	;	Fab 7D6: hIL-9 complex
1EMT	;	2.25	;	FAB ANTIBODY FRAGMENT OF AN C60 ANTIFULLERENE ANTIBODY
6WIO	;	2.17	;	Fab antigen complex
6WIR	;	2.96	;	Fab antigen complex
8CWK	;	2.368	;	Fab arm of antibodies 4G1-C2 and 10G4 bound to CoV-2 receptor binding domain (RBD)
8CWI	;	1.873	;	Fab arm of antibody 10G4 bound to CoV-2 receptor binding domain (RBD)
8DXT	;	2.25	;	Fab arm of antibody GAR12 bound to the receptor binding domain of SARS-CoV-2.
8CWJ	;	2.449	;	Fab arms of antibodies 4C12-B12 and CR3022 bound to pangolin receptor binding domain (pRBD)
8DXU	;	2.728	;	Fab arms of antibodies GAR03 and 10G4 bound to the receptor binding domain of SARS-CoV-2 in a 1:1:1 complex.
4R7N	;	3.45	;	Fab C2E3
6H06	;	2.63	;	FAB CBTAU-22.1 IN COMPLEX WITH TAU PEPTIDE V1088-5
7JWP	;	3.0	;	Fab CJ11 in complex IL-18 peptide liberated by Caspase cleavage
7JWQ	;	2.001	;	Fab CJ11 in complex IL-1beta peptide liberated by Caspase cleavage
5OB5	;	1.65	;	fAb complex with GroBeta. AbVance: increasing our knowledge of antibody structural space to enable faster and better decision-making in antibody drug discovery.
4OCX	;	2.39	;	Fab complex with methotrexate
1RVF	;	4.0	;	FAB COMPLEXED WITH INTACT HUMAN RHINOVIRUS
6H0E	;	1.95	;	FAB dmCBTAU-22.1 IN COMPLEX WITH TAU PEPTIDE V1088-23
1QBL	;	2.26	;	FAB E8 (FABE8A) X-RAY STRUCTURE AT 2.26 ANGSTROM RESOLUTION
1QBM	;	2.37	;	FAB E8B ANTIBODY, X-RAY STRUCTURE AT 2.37 ANGSTROMS RESOLUTION
2OK0	;	1.89	;	Fab ED10-DNA complex
4OCY	;	2.79	;	Fab for methotrexate (unbound apo)
1YUH	;	3.0	;	FAB FRAGMENT
1A3R	;	2.1	;	FAB FRAGMENT (ANTIBODY 8F5) COMPLEXED WITH PEPTIDE FROM HUMAN RHINOVIRUS (SEROTYPE 2) VIRAL CAPSID PROTEIN VP2 (RESIDUES 156-170)
1QKZ	;	1.95	;	Fab fragment (MN14C11.6) in complex with a peptide antigen derived from Neisseria meningitidis P1.7 serosubtype antigen and domain II from Streptococcal protein G
7S4G	;	2.2	;	Fab fragment bound to the Cter peptide of Ly6G6D
6PLH	;	1.6	;	FAB fragment complexed with C-mannosylated tryptophan peptide
3X3G	;	2.51	;	Fab fragment from anti TRAIL-R2 Human Agonist Antibody KMTR2
1BZ7	;	2.5	;	FAB FRAGMENT FROM MURINE ASCITES
2JB5	;	2.8	;	Fab fragment in complex with small molecule hapten, crystal form-1
2JB6	;	2.85	;	Fab fragment in complex with small molecule hapten, crystal form-2
4ONG	;	2.2	;	Fab fragment of 3D6 in complex with amyloid beta 1-40
4ONF	;	2.0	;	Fab fragment of 3D6 in complex with amyloid beta 1-7
4YR6	;	2.38	;	Fab fragment of 5G6 in complex with epitope peptide
1A5F	;	2.8	;	FAB FRAGMENT OF A MONOCLONAL ANTI-E-SELECTIN ANTIBODY
6HX4	;	2.95	;	Fab fragment of a native monomer-selective antibody in complex with alpha-1-antitrypsin
1NLD	;	2.9	;	FAB FRAGMENT OF A NEUTRALIZING ANTIBODY DIRECTED AGAINST AN EPITOPE OF GP41 FROM HIV-1
6GXX	;	1.85	;	Fab fragment of an antibody selective for alpha-1-antitrypsin in the native conformation
6I1O	;	1.93	;	Fab fragment of an antibody selective for wild-type alpha-1-antitrypsin
6I3Z	;	3.1	;	Fab fragment of an antibody selective for wild-type alpha-1-antitrypsin in complex with its antigen
6QU9	;	1.9	;	Fab fragment of an antibody that inhibits polymerisation of alpha-1-antitrypsin
6NEX	;	2.15	;	Fab fragment of anti-cocaine antibody h2E2
6NFN	;	2.63	;	Fab fragment of anti-cocaine antibody h2E2 bound to benzoylecgonine
6WK4	;	2.1	;	Fab Fragment of Anti-human LAG3 antibody (13E2)
6WKM	;	2.1	;	Fab Fragment of Anti-human LAG3 antibody (22D2)
6WJU	;	3.1	;	Fab Fragment of Anti-human LAG3 antibody (4A10)
6WKL	;	1.89	;	Fab Fragment of Anti-human LAG3 antibody (BAP050)
6H3H	;	1.92	;	Fab fragment of antibody against fullerene C60
4AMK	;	2.05	;	Fab fragment of antiporphrin antibody 13g10
4AT6	;	2.549	;	Fab fragment of antiporphyrin antibody 14H7
5AZE	;	2.2	;	Fab fragment of calcium-dependent antigen binding antibody, 6RL#9
1Y18	;	2.8	;	Fab fragment of catalytic elimination antibody 34E4 E(H50)D mutant in complex with hapten
5CGY	;	2.07	;	Fab fragment of Chikungunya virus neutralizing human monoclonal antibody 4J21
4POZ	;	1.75	;	Fab fragment of Der p 1 specific antibody 10B9
1AD0	;	2.5	;	FAB FRAGMENT OF ENGINEERED HUMAN MONOCLONAL ANTIBODY A5B7
4KTD	;	2.0	;	Fab fragment of HIV vaccine-elicited CD4bs-directed antibody, GE136, from non-human primate
4KTE	;	1.8	;	Fab fragment of HIV vaccine-elicited CD4bs-directed antibody, GE148, from non-human primate
4Q2Z	;	1.93	;	Fab fragment of HIV vaccine-elicited CD4bs-directed antibody, GE356, from a non-human primate
8V7O	;	3.57	;	Fab fragment of human mAb #58 in complex with computationally optimized broadly reactive H1 influenza hemagglutinin X6
2HWZ	;	1.8	;	Fab fragment of Humanized anti-viral antibody MEDI-493 (Synagis TM)
1A6T	;	2.7	;	FAB FRAGMENT OF MAB1-IA MONOCLONAL ANTIBODY TO HUMAN RHINOVIRUS 14 NIM-IA SITE
1F90	;	2.6	;	FAB FRAGMENT OF MONOCLONAL ANTIBODY (LNKB-2) AGAINST HUMAN INTERLEUKIN-2 IN COMPLEX WITH ANTIGENIC PEPTIDE
4WCY	;	2.0	;	Fab fragment of mouse AZ130 monoclonal antibody
1EJO	;	2.3	;	FAB FRAGMENT OF NEUTRALISING MONOCLONAL ANTIBODY 4C4 COMPLEXED WITH G-H LOOP FROM FMDV.
2BMK	;	2.3	;	Fab fragment of PLP-dependent catalytic antibody 15A9 in complex with phosphopyridoxyl-D-alanine
1WC7	;	2.33	;	FAB FRAGMENT OF PLP-DEPENDENT CATALYTIC ANTIBODY 15A9 IN COMPLEX WITH PHOSPHOPYRIDOXYL-L-ALANINE
6ELE	;	1.78	;	FAB Fragment. AbVance: Increasing our knowledge of antibody structural space to enable faster and better decision making in antibody drug discovery
6ELJ	;	1.9	;	FAB Fragment. AbVance: Increasing our knowledge of antibody structural space to enable faster and better decision making in antibody drug discovery
6ELL	;	1.9	;	FAB Fragment. AbVance: Increasing our knowledge of antibody structural space to enable faster and better decision making in antibody drug discovery
6EMJ	;	2.3	;	FAB Fragment. AbVance: Increasing our knowledge of antibody structural space to enable faster and better decision making in antibody drug discovery
5CHN	;	2.047	;	Fab fragments of chikungunya virus neutralizing human monoclonal antibody 5M16
8TFP	;	1.78	;	Fab from C10-S66K antibody in complex with carfentanil
8TFQ	;	1.8	;	Fab from C10-S66K antibody in complex with fentanyl
8T0O	;	2.3	;	Fab from mAb RB2AT_87
1R24	;	3.1	;	FAB FROM MURINE IGG3 KAPPA
7B0B	;	2.98	;	Fab HbnC3t1p1_C6 bound to SARS-CoV-2 RBD
4R7D	;	2.753	;	Fab Hu 15C1
7YZJ	;	2.6	;	FAB IN COMPLEX WITH ANTIGENIC PEPTIDE OF INTERLEUKIN-2
1SEQ	;	1.78	;	Fab MNAC13
7JVD	;	2.3	;	Fab of 5.6 monoclonal mouse IgG1 co-crystallized with the trisaccharide form of serotype 3 pneumococcal capsular polysaccharide
6CT7	;	1.903	;	Fab of anti-a-synuclein antibody BIIB054 in complex with acetylated a-synuclein peptide (1-10)
6TXZ	;	3.06	;	FAB PART OF M6903 IN COMPLEX WITH HUMAN TIM3
6WG8	;	1.36	;	Fab portion of dupilumab with Crystal Kappa design
6WGK	;	1.62	;	Fab portion of dupilumab with Crystal Kappa design and intrachain disulfide
6WGJ	;	1.9	;	Fab portion of dupilumab with Crystal Kappa design and no interchain disulfide
8AWL	;	1.62	;	Fab RVFV-268
8G2O	;	1.7	;	Fab structure - Anti-ApoE-7C11 antibody
4F57	;	1.7	;	Fab structure of a neutralizing antibody L1 from an early subtype A HIV-1 infected patient
4F58	;	2.488	;	Fab structure of a neutralizing antibody L3 from an early subtype A HIV-1 infected patient
4OAW	;	2.8	;	Fab structure of anti-HIV gp120 V2 mAb 2158
5UBY	;	2.6	;	Fab structure of anti-HIV-1 gp120 mAb 1A8
4D9L	;	2.485	;	Fab structure of anti-HIV-1 gp120 V2 mAb 697
4EBQ	;	1.6	;	Fab structure of anti-Vaccinia virus D8L antigen mouse IgG2a LA5
4Z95	;	1.79	;	Fab structure of antibody S1-15 in complex with ssDNA DNA, 5'-5(dT)-p-3'
4Z8F	;	1.75	;	Fab structure of antibody S1-15 in complex with ssDNA DNA, 5'-p5(dT)p-3'
6W73	;	2.8	;	Fab Structure of CD4 Binding Site (CD4bs) Huamn Monoclonal Antibody HmAb64
5UBZ	;	2.75	;	Fab structure of HIV gp120 specific mAb 1E12
4ODV	;	2.15	;	Fab Structure of lipid A-specific antibody A6 in complex with lipid A carbohydrate backbone
4ODT	;	1.95	;	Fab Structure of lipid A-specific antibody S1-15 in complex with lipid A carbohydrate backbone
4ZTP	;	1.63	;	Fab structure of rabbit monoclonal antibody R53 targeting an epitope in HIV-1 gp120 C4 region
3V0V	;	2.13	;	Fab WN1 222-5 unliganded
7E6P	;	2.5	;	Fab-amyloid beta fragment complex
8H8Q	;	2.5	;	Fab-amyloid beta fragment complex at neutral pH
3U0T	;	2.5	;	Fab-antibody complex
2C1P	;	2.0	;	Fab-fragment of enantioselective antibody complexed with finrozole
5OBF	;	1.92	;	fAb. AbVance: increasing our knowledge of antibody structural space to enable faster and better decision-making in antibody drug discovery.
6DC9	;	2.999	;	Fab/epitope complex of human chimeric monoclonal antibody h4E6 targeting a phosphorylated tau epitope.
6DCA	;	2.599	;	Fab/epitope complex of mouse monoclonal antibody 6B2 targeting a non-phosphorylated tau epitope.
6DC8	;	1.799	;	Fab/epitope complex of mouse monoclonal antibody 8B2 targeting a non-phosphorylated tau epitope.
6BB4	;	2.099	;	Fab/epitope complex of mouse monoclonal antibody C5.2 targeting a phospho-tau epitope.
4ZTO	;	2.3	;	Fab/epitope complex structure of rabbit monoclonal antibody R53 targeting an epitope in HIV-1 gp120 C4 region
7WPV	;	2.46	;	Fab14 - a SARS-CoV2 RBD neutralising antibody
7RXL	;	1.823	;	Fab1488 in complex with the C-terminal alpha-TSR domain of P. falciparum
7RXP	;	1.761	;	Fab1512 in complex with the C-terminal alpha-TSR domain of P. falciparum
7RXI	;	2.15	;	Fab234 in complex with the C-terminal alpha-TSR domain of P. falciparum
7RXJ	;	2.345	;	Fab236 in complex with the C-terminal alpha-TSR domain of P. falciparum
7S0X	;	2.8	;	Fab352 in complex with the C-terminal alphaTSR domain of P. falciparum
6UC5	;	1.75	;	Fab397 in complex with NPNA peptide
5DYO	;	2.36	;	Fab43.1 complex with flourescein
6S44	;	3.19	;	Faba bean necrotic stunt virus (FBNSV)
7DZE	;	1.55	;	Fabp ground state captured by XFELs
7DZK	;	1.54	;	Fabp protein after hv
7DZJ	;	1.63	;	Fabp protein before hv
5HZ6	;	1.14	;	FABP4 in complex with 6-Chloro-2-isopropyl-4-(3-isopropyl-phenyl)-quinoline-3-carboxylic acid
5HZ8	;	1.12	;	FABP4_3 in complex with 6,8-Dichloro-4-phenyl-2-piperidin-1-yl-quinoline-3-carboxylic acid
5HZ5	;	1.4	;	FABP5 in complex with 6-Chloro-4-phenyl-2-piperidin-1-yl-3-(1H-tetrazol-5-yl)-quinoline
8IVF	;	2.6	;	FABP7 complexed with 25-HC
8IVL	;	2.7	;	FABP7 complexed with Cholesterol
1D35	;	1.3	;	FACILE FORMATION OF A CROSSLINKED ADDUCT BETWEEN DNA AND THE DAUNORUBICIN DERIVATIVE MAR70 MEDIATED BY FORMALDEHYDE: MOLECULAR STRUCTURE OF THE MAR70-D(CGTNACG) COVALENT ADDUC
1D36	;	1.5	;	FACILE FORMATION OF A CROSSLINKED ADDUCT BETWEEN DNA AND THE DAUNORUBICIN DERIVATIVE MAR70 MEDIATED BY FORMALDEHYDE: MOLECULAR STRUCTURE OF THE MAR70-D(CGTNACG) COVALENT ADDUC
1DLE	;	2.1	;	FACTOR B SERINE PROTEASE DOMAIN
1DFP	;	2.4	;	FACTOR D INHIBITED BY DIISOPROPYL FLUOROPHOSPHATE
7KE1	;	1.5	;	Factor H enhancing human antibody fragment (Fab) to meningococcal Factor H binding protein
7KET	;	2.0	;	Factor H enhancing human antibody fragment (Fab) to meningococcal Factor H binding protein
7LCV	;	1.7	;	Factor H enhancing human antibody fragment (Fab) to meningococcal Factor H binding protein
5OP6	;	2.45	;	Factor Inhibiting HIF (FIH) in complex with zinc and GSK128863
5OP8	;	2.3	;	Factor Inhibiting HIF (FIH) in complex with zinc and Molidustat
5OPC	;	2.3	;	Factor Inhibiting HIF (FIH) in complex with zinc and Vadadustat
6HL5	;	1.98	;	Factor Inhibiting HIF (FIH) in complex with zinc, NOG and ASPP1(932-954)
6HKP	;	1.9	;	Factor Inhibiting HIF (FIH) in complex with zinc, NOG and ASPP2 (970-992)
6HL6	;	1.97	;	Factor Inhibiting HIF (FIH) in complex with zinc, NOG and iASPP(670-693)
6HC8	;	1.9	;	Factor Inhibiting HIF (FIH) in complex with zinc, NOG and TRPA1 (313-339)
6HA6	;	1.98	;	Factor Inhibiting HIF (FIH) in complex with zinc, NOG and TRPV3 (220-246)
6H9J	;	1.83	;	Factor Inhibiting HIF (FIH) in complex with zinc, NOG and TRPV3 (229-255)
2XUM	;	2.2	;	FACTOR INHIBITING HIF (FIH) Q239H MUTANT IN COMPLEX WITH ZN(II), NOG AND ASP-SUBSTRATE PEPTIDE (20-MER)
5JWK	;	2.3	;	Factor Inhibiting HIF D201E in Complex with Fe, and Alpha-Ketoglutarate
5JWL	;	2.4	;	Factor Inhibiting HIF D201E in Complex with Zn, and Alpha-Ketoglutarate
4Z2W	;	2.5	;	Factor Inhibiting HIF in Complex with Fe, and Alpha-Ketoglutarate
1H2N	;	2.84	;	Factor Inhibiting HIF-1 alpha
2ILM	;	2.3	;	Factor Inhibiting HIF-1 Alpha D201A Mutant in Complex with FE(II), Alpha-Ketoglutarate and HIF-1 Alpha 35mer
3D8C	;	2.1	;	Factor inhibiting HIF-1 alpha D201G mutant in complex with ZN(II), alpha-ketoglutarate and HIF-1 alpha 19mer
8IHZ	;	2.22	;	FACTOR INHIBITING HIF-1 ALPHA in complex with (5-(1-(3-(4-chlorophenyl)propyl)-1H-1,2,3-triazol-4-yl)-3-hydroxypicolinoyl)glycine
8II0	;	2.04	;	FACTOR INHIBITING HIF-1 ALPHA in complex with (5-(3-(3-chlorophenyl)isoxazol-5-yl)-3-hydroxypicolinoyl)glycine
3KCY	;	2.59	;	Factor inhibiting HIF-1 alpha in complex with 8-hydroxyquinoline
4BIO	;	2.45	;	FACTOR INHIBITING HIF-1 ALPHA IN COMPLEX WITH 8-HYDROXYQUINOLINE-5- CARBOXYLIC ACID
3KCX	;	2.6	;	Factor inhibiting HIF-1 alpha in complex with Clioquinol
6RUJ	;	2.42	;	Factor inhibiting HIF-1 alpha in complex with consensus ankyrin repeat domain-(d)3-hydroxy-Leu peptide
4NR1	;	2.68	;	Factor inhibiting HIF-1 alpha in complex with consensus ankyrin repeat domain-(d)allyl-GLY peptide
4JAA	;	2.39	;	Factor inhibiting HIF-1 alpha in complex with consensus ankyrin repeat domain-(d)LEU peptide
4B7E	;	2.5	;	FACTOR INHIBITING HIF-1 ALPHA IN COMPLEX WITH CONSENSUS ANKYRIN REPEAT DOMAIN-LEU PEPTIDE (20-MER)
4B7K	;	2.39	;	FACTOR INHIBITING HIF-1 ALPHA IN COMPLEX WITH CONSENSUS ANKYRIN REPEAT DOMAIN-SER PEPTIDE (20-MER)
4AI8	;	2.4	;	FACTOR INHIBITING HIF-1 ALPHA IN COMPLEX WITH DAMINOZIDE
1H2K	;	2.15	;	Factor Inhibiting HIF-1 alpha in complex with HIF-1 alpha fragment peptide
1H2L	;	2.25	;	Factor Inhibiting HIF-1 alpha in complex with HIF-1 alpha fragment peptide
1H2M	;	2.5	;	Factor Inhibiting HIF-1 alpha in complex with HIF-1 alpha fragment peptide
1YCI	;	2.7	;	Factor inhibiting HIF-1 alpha in complex with N-(carboxycarbonyl)-D-phenylalanine
3P3N	;	2.4	;	Factor inhibiting HIF-1 Alpha in complex with Notch 1 fragment mouse notch (1930-1949) peptide
3P3P	;	2.6	;	Factor inhibiting HIF-1 Alpha in complex with Notch 1 fragment mouse notch (1997-2016) peptide
2YC0	;	2.15	;	FACTOR INHIBITING HIF-1 ALPHA IN COMPLEX WITH R-2-HYDROXYGLUTARATE
2YDE	;	2.28	;	FACTOR INHIBITING HIF-1 ALPHA IN COMPLEX WITH S-2-HYDROXYGLUTARATE
2Y0I	;	2.28	;	FACTOR INHIBITING HIF-1 ALPHA IN COMPLEX WITH TANKYRASE-2 (TNKS2) FRAGMENT PEPTIDE (21-MER)
7A1K	;	1.99	;	FACTOR INHIBITING HIF-1 ALPHA IN COMPLEX WITH ZN(II) AND 3-((9,9-dimethyl-9H-fluoren-2-yl)methyl)-2-oxoglutarate
7A1J	;	1.9	;	FACTOR INHIBITING HIF-1 ALPHA IN COMPLEX WITH ZN(II) AND 3-(3-phenylpropyl)-2-oxoglutarate
7A1L	;	2.29	;	FACTOR INHIBITING HIF-1 ALPHA IN COMPLEX WITH ZN(II) AND 3-methyl-2-oxoglutarate
7A1M	;	2.18	;	FACTOR INHIBITING HIF-1 ALPHA IN COMPLEX WITH ZN(II) AND 3-propyl-2-oxoglutarate
7A1Q	;	1.75	;	FACTOR INHIBITING HIF-1 ALPHA IN COMPLEX WITH ZN(II), 3-(carboxycarbonyl)cyclopentane-1-carboxylic acid, AND CONSENSUS ANKYRIN REPEAT DOMAIN (20-MER)
7A1N	;	2.01	;	FACTOR INHIBITING HIF-1 ALPHA IN COMPLEX WITH ZN(II), 3-methyl-2-oxoglutarate, AND CONSENSUS ANKYRIN REPEAT DOMAIN (20-MER)
7A1S	;	2.01	;	FACTOR INHIBITING HIF-1 ALPHA IN COMPLEX WITH ZN(II), 3-methyl-2-oxoglutarate, AND TANKYRASE-2 (TNKS2) FRAGMENT PEPTIDE (21-MER)
7A1O	;	2.21	;	FACTOR INHIBITING HIF-1 ALPHA IN COMPLEX WITH ZN(II), 4-ethyl-2-oxoglutarate, AND CONSENSUS ANKYRIN REPEAT DOMAIN (20-MER)
7A1P	;	1.76	;	FACTOR INHIBITING HIF-1 ALPHA IN COMPLEX WITH ZN(II), 4-propyl-2-oxoglutarate, AND CONSENSUS ANKYRIN REPEAT DOMAIN (20-MER)
2WA3	;	2.5	;	FACTOR INHIBITING HIF-1 ALPHA WITH 2-(3-hydroxyphenyl)-2-oxoacetic acid
2CGO	;	2.3	;	FACTOR INHIBITING HIF-1 ALPHA with fumarate
2WA4	;	2.5	;	FACTOR INHIBITING HIF-1 ALPHA WITH N,3-dihydroxybenzamide
2W0X	;	2.12	;	FACTOR INHIBITING HIF-1 ALPHA WITH PYRIDINE 2,4 DICARBOXYLIC ACID
2CGN	;	2.4	;	FACTOR INHIBITING HIF-1 ALPHA with succinate
2WPI	;	1.99	;	factor IXa superactive double mutant
2WPM	;	2.0	;	factor IXa superactive mutant, EGR-CMK inhibited
2WPH	;	1.5	;	factor IXa superactive triple mutant
2WPL	;	1.82	;	factor IXa superactive triple mutant, EDTA-soaked
2WPK	;	2.21	;	factor IXa superactive triple mutant, ethylene glycol-soaked
2WPJ	;	1.6	;	factor IXa superactive triple mutant, NaCl-soaked
8CN9	;	3.4	;	Factor VII binding Fab of the bispecific antibody HMB-001 in complex with Factor VII
5TQF	;	1.85	;	Factor VIIa in complex with the inhibitor (11R)-11-[(1-aminoisoquinolin-6-yl)amino]-16-(cyclopropylsulfonyl)-13-methyl-2,13-diazatricyclo[13.3.1.1~6,10~]icosa-1(19),6(20),7,9,15,17-hexaene-3,12-dione
4NG9	;	2.2	;	Factor viia in complex with the inhibitor (2R)-2-[(1-aminoisoquinolin-6-yl)amino]-2-[3-ethoxy-4-(propan-2-yloxy)phenyl]-n-(3-sulfamoylbenzyl)ethanamide
4NGA	;	2.15	;	Factor viia in complex with the inhibitor (2R)-2-[(1-aminoisoquinolin-6-yl)amino]-2-[3-ethoxy-4-(propan-2-yloxy)phenyl]-N-[2-(propan-2-ylsulfonyl)benzyl]ethanamide
4ZXY	;	2.06	;	FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (2R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione
5L30	;	1.73	;	Factor VIIa in complex with the inhibitor (2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,15,17-trimethyl-7-[1-(1H-tetrazol-5-yl)cyclopropyl]-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione
5I46	;	2.06	;	Factor VIIA in complex with the inhibitor (2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-8-fluoro-7-hydroxy-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione
5TQE	;	1.9	;	Factor VIIa in complex with the inhibitor (5R)-5-[(1-aminoisoquinolin-6-yl)amino]-19-(cyclopropylsulfonyl)-3-methyl-13-oxa-3,15-diazatricyclo[14.3.1.1~6,10~]henicosa-1(20),6(21),7,9,16,18-hexaene-4,14-dione
5TQG	;	1.9	;	Factor VIIa in complex with the inhibitor (5R,11R)-11-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-16-(cyclopropylsulfonyl)-7-(2,2-difluoroethoxy)-5,13-dimethyl-2,13-diazatricyclo[13.3.1.1~6,10~]icosa-1(19),6(20),7,9,15,17-hexaene-3,12-dione
4X8V	;	2.5	;	FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (methyl {3-[(2R)-1-{(2R)-2-(3,4-dimethoxyphenyl)-2-[(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)amino]acetyl}pyrrolidin-2-yl]-4-(propan-2-ylsulfonyl)phenyl}carbamate)
5L2Z	;	1.79	;	Factor VIIa in complex with the inhibitor 1-[(2R,15R)-2-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-4,15,17-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaen-7-yl]cyclohexane-1-carboxylic acid
5L2Y	;	1.82	;	Factor VIIa in complex with the inhibitor 1-[(2R,15R)-2-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-4,15,20-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6,8,10(21),16,19-hexaen-7-yl] cyclobutane-1-carboxylic acid
4YT7	;	2.3	;	Factor VIIa in complex with the inhibitor 2-(2-{(R)-[(4-carbamimidoylphenyl)amino][5-ethoxy-2-fluoro-3-(propan-2-yloxy)phenyl]methyl}-1H-imidazol-4-yl)benzamide
4NA9	;	2.24	;	Factor VIIa in complex with the inhibitor 3'-amino-5'-[(2s,4r)-6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydroquinolin-2-yl]biphenyl-2-carboxylic acid
5U6J	;	2.3	;	Factor VIIa in complex with the inhibitor 3-{[(2R)-17-ethyl-4-methyl-3,12-dioxo-7-[(propan-2-yl)sulfonyl]-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaen-2-yl]amino}benzamide
4X8S	;	2.1	;	FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 4-BROMO-2-METHOXYPHENOL
4YT6	;	2.07	;	Factor VIIa in complex with the inhibitor 4-{[(R)-[5-ethoxy-2-fluoro-3-(propan-2-yloxy)phenyl](4-phenyl-1H-imidazol-2-yl)methyl]amino}benzenecarboximidamide
4X8U	;	2.1	;	FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 5-CHLORO-1H-INDOLE-2-CARBOXYLIC ACID
4X8T	;	2.2	;	FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 7-chloro-3,4-dihydroisoquinolin-1(2H)-one
4ZXX	;	2.6	;	FACTOR VIIA IN COMPLEX WITH THE INHIBITOR N-{3-[(2R)-1-{(2R)-2-[(1-aminoisoquinolin-6-yl)amino]-2-phenylacetyl}pyrrolidin-2-yl]-4-(propan-2-ylsulfonyl)phenyl}acetamide
2B7D	;	2.24	;	Factor VIIa Inhibitors: Chemical Optimization, Preclinical Pharmacokinetics, Pharmacodynamics, and Efficacy in a Baboon Thrombosis Model
7KBT	;	4.15	;	Factor VIII in complex with the anti-C2 domain antibody, G99
3HNB	;	1.15	;	Factor VIII Trp2313-His2315 segment is involved in membrane binding as shown by crystal structure of complex between factor VIII C2 domain and an inhibitor
3HNY	;	1.07	;	Factor VIII Trp2313-His2315 segment is involved in membrane binding as shown by crystal structure of complex between factor VIII C2 domain and an inhibitor
3HOB	;	2.07	;	Factor VIII Trp2313-His2315 segment is involved in membrane binding as shown by crystal structure of complex between factor VIII C2 domain and an inhibitor
2BOK	;	1.64	;	Factor Xa - cation
2JKH	;	1.25	;	Factor Xa - cation inhibitor complex
2Y5F	;	1.29	;	FACTOR XA - CATION INHIBITOR COMPLEX
2Y5G	;	1.29	;	FACTOR XA - CATION INHIBITOR COMPLEX
2Y5H	;	1.33	;	FACTOR XA - CATION INHIBITOR COMPLEX
4ZH8	;	1.8	;	Factor Xa complex with GTC000006
4Y6D	;	1.55	;	Factor Xa complex with GTC000101
4ZHA	;	1.86	;	Factor Xa complex with GTC000102
4Y71	;	1.8	;	Factor Xa complex with GTC000398
4Y76	;	2.0	;	Factor Xa complex with GTC000401
4Y79	;	2.1	;	Factor Xa complex with GTC000406
4Y7A	;	1.99	;	Factor Xa complex with GTC000422
4Y7B	;	1.79	;	Factor Xa complex with GTC000441
1XKA	;	2.3	;	FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A,(2S)-(3'-AMIDINO-3-BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID
1XKB	;	2.4	;	FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A,(2S)-(3'-AMIDINO-3-BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID
3LIW	;	2.22	;	Factor XA in complex with (R)-2-(1-ADAMANTYLCARBAMOYLAMINO)-3-(3-CARBAMIDOYL-PHENYL)-N-PHENETHYL-PROPIONIC ACID AMIDE
3IIT	;	1.8	;	Factor XA in complex with a cis-1,2-diaminocyclohexane derivative
3Q3K	;	2.0	;	Factor Xa in complex with a phenylenediamine derivative
4A7I	;	2.4	;	Factor Xa in complex with a potent 2-amino-ethane sulfonamide inhibitor
2XBV	;	1.66	;	Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor
2XBW	;	1.72	;	Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor
2XBX	;	1.85	;	Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor
2XBY	;	2.02	;	Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor
2XC0	;	2.05	;	Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor
2XC4	;	1.67	;	Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor
2XC5	;	1.7	;	Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor
2W26	;	2.08	;	Factor Xa in complex with BAY59-7939
3TK5	;	2.2	;	Factor Xa in complex with D102-4380
3TK6	;	1.8	;	factor Xa in complex with D46-5241
4BTT	;	2.59	;	factor Xa in complex with the dual thrombin-FXa inhibitor 31.
4BTU	;	2.37	;	Factor Xa in complex with the dual thrombin-FXa inhibitor 57.
4BTI	;	2.3	;	factor Xa in complex with the dual thrombin-FXa inhibitor 58.
2EI6	;	2.3	;	FACTOR XA IN COMPLEX WITH THE INHIBITOR (-)-cis-N1-[(5-Chloroindol-2-yl)carbonyl]-N2-[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]-1,2-cyclohexanediamine
2EI8	;	2.1	;	FACTOR XA IN COMPLEX WITH THE INHIBITOR (1S,2R,4S)-N1-[(5-chloroindol-2-yl)carbonyl]-4-(N,N-dimethylcarbamoyl)-N2-[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]-1,2-cyclohexanediamine
3FFG	;	1.54	;	Factor XA in complex with the inhibitor (R)-6-(2'-((3- HYDROXYPYRROLIDIN-1-YL)METHYL)BIPHENYL-4-YL)-1-(3-(5-OXO-4,5-DIHYDRO-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN- 7(4H)-ONE
1Z6E	;	1.8	;	Factor XA in complex with the inhibitor 1-(3'-amino-1,2-benzisoxazol-5'-yl)-n-(4-(2'-((dimethylamino)methyl)-1h-imidazol-1-yl)-2-fluorophenyl)-3-(trifluoromethyl)-1h-pyrazole-5-carboxamide (razaxaban; DPC906; BMS-561389)
3KQD	;	2.75	;	Factor xa in complex with the inhibitor 1-(3-(5-oxo-4,5- dihydro-1h-1,2,4-triazol-3-yl)phenyl)-6-(2'-(pyrrolidin-1- ylmethyl)biphenyl-4-yl)-3-(trifluoromethyl)-5,6-dihydro- 1h-pyrazolo[3,4-c]pyridin-7(4h)-one
2FZZ	;	2.2	;	Factor Xa in complex with the inhibitor 1-(3-amino-1,2-benzisoxazol-5-yl)-6-(2'-(((3r)-3-hydroxy-1-pyrrolidinyl)methyl)-4-biphenylyl)-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7h-pyrazolo[3,4-c]pyridin-7-one
3CS7	;	2.2	;	FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(4-methoxyphenyl)-6-(4-(1-(pyrrolidin-1-ylmethyl)cyclopropyl)phenyl)-3-(trifluoromethyl)-5,6-dihydro-1H-pyrazolo[3,4-c]pyridin-7(4H)-one
3M37	;	1.9	;	Factor XA in complex with the inhibitor 1-[2-(aminomethyl)phenyl]-N-(3-fluoro-2'-sulfamoylbiphenyl-4-yl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC602)
3M36	;	2.15	;	Factor XA in complex with the inhibitor 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)biphenyl-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423)
1V3X	;	2.2	;	Factor Xa in complex with the inhibitor 1-[6-methyl-4,5,6,7-tetrahydrothiazolo(5,4-c)pyridin-2-yl] carbonyl-2-carbamoyl-4-(6-chloronaphth-2-ylsulphonyl)piperazine
2D1J	;	2.2	;	Factor Xa in complex with the inhibitor 2-[[4-[(5-chloroindol-2-yl)sulfonyl]piperazin-1-yl] carbonyl]thieno[3,2-b]pyridine n-oxide
2G00	;	2.1	;	Factor Xa in complex with the inhibitor 3-(6-(2'-((dimethylamino)methyl)-4-biphenylyl)-7-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-1-yl)benzamide
2P94	;	1.8	;	Factor xa in complex with the inhibitor 3-chloro-N-((1R,2S)-2-(4-(2-oxopyridin-1(2H)-yl)benzamido)cyclohexyl)-1H-indole-6-carboxamide
3KQE	;	2.35	;	Factor xa in complex with the inhibitor 3-methyl-1-(3-(5- oxo-4,5-dihydro-1h-1,2,4-triazol-3-yl)phenyl)-6-(2'- (pyrrolidin-1-ylmethyl)biphenyl-4-yl)-5,6-dihydro-1h- pyrazolo[3,4-c]pyridin-7(4h)-one
1WU1	;	2.3	;	Factor Xa in complex with the inhibitor 4-[(5-chloroindol-2-yl)sulfonyl]-2-(2-methylpropyl)-1-[[5-(pyridin-4-yl) pyrimidin-2-yl]carbonyl]piperazine
2P95	;	2.2	;	Factor xa in complex with the inhibitor 5-chloro-N-((1R,2S)-2-(4-(2-oxopyridin-1(2H)-YL)benzamido) cyclopentyl)thiophene-2-carboxamide
2P93	;	1.9	;	Factor xa in complex with the inhibitor 5-chloro-N-(2-(4-(2-oxopyridin-1(2H)-yl)benzamido)ethyl)thiophene-2-carboxamide
3KQC	;	2.2	;	Factor xa in complex with the inhibitor 6-(2'- (methylsulfonyl)biphenyl-4-yl)-1-(3-(5-oxo-4,5-dihydro-1h- 1,2,4-triazol-3-yl)phenyl)-3-(trifluoromethyl)-5,6- dihydro-1h-pyrazolo[3,4-c]pyridin-7(4h)-one
2P16	;	2.3	;	Factor Xa in Complex with the Inhibitor APIXABAN (BMS-562247) AKA 1-(4-METHOXYPHENYL)-7-OXO-6-(4-(2-OXO-1-PIPERIDINYL)PHENYL)-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3, 4-C]PYRIDINE-3-CARBOXAMIDE
3CEN	;	1.6	;	Factor XA in complex with the inhibitor N-(2-(((5-chloro-2-pyridinyl) amino)sulfonyl)phenyl)-4-(2-oxo-1(2H)-pyridinyl)benzamide
3KQB	;	2.25	;	Factor xa in complex with the inhibitor n-(3-fluoro-2'- (methylsulfonyl)biphenyl-4-yl)-1-(3-(5-oxo-4,5-dihydro-1h- 1,2,4-triazol-3-yl)phenyl)-3-(trifluoromethyl)-1h- pyrazole-5-carboxamide
2EI7	;	2.3	;	FACTOR XA IN COMPLEX WITH THE INHIBITOR trans-N1-[(5-Chloroindol-2-yl)carbonyl]-N2-[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]-1,2-cyclohexanediamine
2PR3	;	1.5	;	Factor XA inhibitor
1G2L	;	1.9	;	FACTOR XA INHIBITOR COMPLEX
1G2M	;	3.02	;	FACTOR XA INHIBITOR COMPLEX
2UWP	;	1.75	;	Factor Xa inhibitor complex
1MTS	;	1.9	;	FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
1MTU	;	1.9	;	FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
1MTV	;	1.9	;	FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
1MTW	;	1.9	;	FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
1QL7	;	2.1	;	FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
1QL8	;	3.0	;	FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
1V2K	;	2.0	;	Factor XA specific Inhibitor in complex with bovine trypsin variant X(triple.Glu)bT.D2
1J17	;	2.0	;	FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH RAT TRYPSIN MUTANT X99/175/190RT
1QL9	;	2.3	;	FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH RAT TRYPSIN MUTANT X99RT
7QOT	;	3.24	;	Factor XI and Plasma Kallikrein apple domain structures reveals different kininogen bound complexes
7QOX	;	2.32	;	Factor XI and Plasma Kallikrein apple domain structures reveals different kininogen bound complexes
1ZLR	;	2.5	;	Factor XI catalytic domain complexed with 2-guanidino-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl nicotinate
1ZPZ	;	2.5	;	Factor XI catalytic domain complexed with N-((R)-1-(4-bromophenyl)ethyl)urea-Asn-Val-Arg-alpha-ketothiazole
1ZRK	;	2.3	;	Factor XI complexed with 3-hydroxypropyl 3-(7-amidinonaphthalene-1-carboxamido)benzenesulfonate
1ZSL	;	2.05	;	Factor XI complexed with a pyrimidinone inhibitor
5EXN	;	1.49	;	FACTOR XIA (C500S [C122S]) IN COMPLEX WITH THE INHIBITOR methyl ~{N}-[4-[2-[(1~{S})-1-[[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]amino]-2-phenyl-ethyl]pyridin-4-yl]phenyl]carbamate
4X6P	;	1.93	;	FACTOR XIA (PICHIA PASTORIS; C500S [C122S]) IN COMPLEX WITH THE INHIBITOR (2E)-N-{(1S)-1-[4-(3-amino-1H-indazol-6-yl)-1H-imidazol-2-yl]-2-phenylethyl}-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enamide
7MBO	;	0.924	;	FACTOR XIA (PICHIA PASTORIS; C500S [C122S]) IN COMPLEX WITH THE INHIBITOR Milvexian (BMS-986177), IUPAC NAME:(6R,10S)-10-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6- oxopyrimidin-1(6H)-yl}-1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-15,11- (metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6H)-one
3SOR	;	1.8	;	Factor XIa in complex with a clorophenyl-tetrazole inhibitor
6VLV	;	1.72	;	Factor XIa in complex with compound 11
7V0Z	;	1.8	;	Factor XIa in Complex with Compound 2a
7V10	;	1.798	;	Factor XIa in Complex with Compound 2d
7V11	;	1.472	;	Factor XIa in Complex with Compound 2e
7V12	;	1.631	;	Factor XIa in Complex with Compound 2f
7V13	;	1.589	;	Factor XIa in Complex with Compound 2g
7V14	;	1.697	;	Factor XIa in Complex with Compound 2h
7V15	;	1.679	;	Factor XIa in Complex with Compound 2i
7V16	;	1.505	;	Factor XIa in Complex with Compound 2j
7V17	;	1.522	;	Factor XIa in Complex with Compound 2k
7V18	;	1.732	;	Factor XIa in Complex with Compound 3f
6VLU	;	1.6	;	Factor XIa in complex with compound 7
5TKS	;	1.55	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR ((15S)-18-CHLORO- 15-(((2E)-3-(5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL)-2- PROPENOYL)AMINO)-17,19-DIAZATRICYCLO[14.2.1.0~2,7~]NONADECA-1(18),2,4,6,16(19)-PENTAEN-5-YL)CARBAMATE
4Y8Z	;	2.2	;	Factor XIa in complex with the inhibitor (2E)-N-[(1S)-1-[5-chloro-4-(4-hydroxy-2-oxo-1,2-dihydroquinolin-6-yl)-1H-imidazol-2-yl]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enamide
4TY7	;	2.09	;	Factor XIa in complex with the inhibitor (2S)-6-amino-N-{(1S)-1-[4-(3-amino-2H-indazol-6-yl)-5-chloro-1H-imidazol-2-yl]-2-phenylethyl}-2-ethylhexanamide
4X6M	;	2.4	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR 1-{(1S)-1-[4-(3-amino-1H-indazol-6-yl)-5-chloro-1H-imidazol-2-yl]-2-phenylethyl}-3-[2-(aminomethyl)-5-chlorobenzyl]urea
4X6N	;	2.1	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR 1-{(1S)-1-[4-(3-amino-1H-indazol-6-yl)-5-chloro-1H-imidazol-2-yl]-2-phenylethyl}-3-[5-chloro-2-(1H-tetrazol-1-yl)benzyl]urea
4NA7	;	2.8	;	Factor XIA in complex with the inhibitor 3'-[(2S,4R)-6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydroquinolin-2-yl]-4-carbamoyl-5'-[(3-methylbutanoyl)amino]biphenyl-2-carboxylic acid
5EXL	;	2.3	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-(aminomethyl)-~{N}-[(1~{S})-1-[4-(3-oxidanyl-1~{H}-indazol-5-yl)pyridin-2-yl]-2-phenyl-ethyl]cyclohexane-1-carboxamide
5E2O	;	2.08	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[(N-{(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}-L-phenylalanyl)amino]benzoic acid
5QCL	;	2.11	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[[(1~{S})-2-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-3,4-dihydro-1~{H}-isoquinolin-1-yl]carbonylamino]benzoic acid
5QCN	;	2.3	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[[(1~{S})-2-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-5-[(3~{S})-3-ethoxycarbonylpiperidin-1-yl]carbonyl-3,4-dihydro-1~{H}-isoquinolin-1-yl]carbonylamino]benzoic acid
5QCK	;	2.64	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[[(2~{S},3~{R})-1-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-3-phenyl-pyrrolidin-2-yl]carbonylamino]benzoic acid
4TY6	;	1.85	;	Factor XIa in complex with the inhibitor 4-{2-[(1S)-1-({[trans-4-(aminomethyl)cyclohexyl]carbonyl}amino)-2-phenylethyl]-1H-imidazol-4-yl}benzamide
4NA8	;	2.3	;	Factor XIa in complex with the inhibitor 5-aminocarbonyl-2-[3-[(2s,4r)-6-carbamimidoyl-4-methyl-4-phenyl-2,3-dihydro-1h-quinolin-2-yl]phenyl]benzoic acid
5QTX	;	2.07	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR ethyl (2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-14-[(methoxycarbonyl)amino]-1,2,3,4,5,6,7,9-octahydro-11,8-(azeno)-1,9-benzodiazacyclotridecine-2-carboxylate
5QTY	;	1.89	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR ethyl (2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-15-[(methoxycarbonyl)amino]-2,3,4,5,6,7-hexahydro-1H-12,8-(metheno)-1,9-benzodiazacyclotetradecine-2-carboxylate
6W50	;	1.95	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL ((10R,14S)- 14-(4-(3-CHLORO-2,6-DIFLUOROPHENYL)-6-OXO-3,6-DIHYDRO- 1(2H)-PYRIDINYL)-10-METHYL-9-OXO-8,16- DIAZATRICYCLO[13.3.1.0~2,7~]NONADECA-1(19),2,4,6,15,17- HEXAEN-5-YL)CARBAMATE
5TKT	;	2.12	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL ((12E,15S)-15-(((2E)-3-(5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL)-2-PROPENOYL)AMINO)-9-OXO-8,17,19-TRIAZATRICYCLO[14.2.1.0~2,7~]NONADECA-1(18),2,4,6,12,16(19)-HEXAEN-5-YL)CARBAMATE
5TKU	;	2.12	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL ((15S)-15-(((2E)-3-(5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL)-2-PROPENOYL)AMINO)-9-OXO-8,17,19-TRIAZATRICYCLO[14.2.1.0~2,7~]NONADECA-1(18),2,4,6,16(19)-PENTAEN-5-YL)CARBAMATE
5QTW	;	2.12	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl (2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-14-[(methoxycarbonyl)amino]-2,3,4,5,6,7-hexahydro-1H-8,11-epimino-1,9-benzodiazacyclotridecine-2-carboxylate
4Y8X	;	1.9	;	Factor XIa in complex with the inhibitor methyl (4-{4-chloro-2-[(1S)-1-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-2-phenylethyl]-1H-imidazol-5-yl}phenyl)carbamate
4Y8Y	;	2.6	;	Factor XIa in complex with the inhibitor methyl (4-{4-chloro-2-[(1S)-1-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-3-(morpholin-4-yl)-3-oxopropyl]-1H-imidazol-5-yl}phenyl)carbamate
4X6O	;	2.1	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl (4-{4-chloro-2-[(1S)-1-({3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]propanoyl}amino)-2-phenylethyl]-1H-imidazol-5-yl}phenyl)carbamate
6C0S	;	2.35	;	Factor XIA in complex with the inhibitor methyl (4-{6-[(1S)-2-[(3R)-1-acetylpiperidin-3-yl]-1-({(2E)-3-[5-chloro-2- (1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)ethyl]-3-chloropyridazin-4-yl}phenyl) carbamate
5WB6	;	2.35	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(11S)-11-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-6-fluoro-2-oxo-1,3,4,10,11,13-hexahydro-2H-5,9:15,12-di(azeno)-1,13-benzodiazacycloheptadecin-18-yl]carbamate
5QTV	;	2.2	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-2-(trifluoromethyl)-2,3,4,5,6,7-hexahydro-1H-8,11-epimino-1,9-benzodiazacyclotridecin-14-yl]carbamate
5Q0G	;	2.6	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(3R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-3-ethyl-2-oxo-1,2,3,4,5,6,7,9-octahydro-11,8-(azeno)-1,9-benzodiazacyclotridecin-14-yl]carbamate
5QTU	;	2.53	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(3R,7S)-7-{[1-(3-chloro-2-fluorophenyl)-5-methyl-1H-imidazole-4-carbonyl]amino}-3-methyl-2-oxo-2,3,4,5,6,7-hexahydro-1H-12,8-(metheno)-1,9-benzodiazacyclotetradecin-15-yl]carbamate
5QTT	;	2.23	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(3R,7S)-7-{[5-amino-1-(3-chloro-2-fluorophenyl)-1H-pyrazole-4-carbonyl]amino}-3-methyl-2-oxo-2,3,4,5,6,7-hexahydro-1H-12,8-(metheno)-1,9-benzodiazacyclotetradecin-15-yl]carbamate
5Q0H	;	2.5	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(4R,5E,8S)-11-chloro-8-[(2,6-difluoro-4-methylbenzene-1-carbonyl)amino]-4-methyl-2-oxo-1,3,4,7,8,10-hexahydro-2H-12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate
5Q0F	;	2.12	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(4R,5E,8S)-8-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-4-methyl-2-oxo-1,3,4,7,8,10-hexahydro-2H-12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate
5Q0E	;	2.12	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(4S,8S)-8-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-4-methyl-2-oxo-1,3,4,5,6,7,8,10-octahydro-2H-12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate
5QQP	;	2.08	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(5E,8S)-8-[(4S)-4-(3-chlorophenyl)-2-oxopiperidin-1-yl]-2-oxo-1,3,4,7,8,10-hexahydro-2H-12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate
5QQO	;	2.0	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(5E,8S)-8-[(6R)-6-(3-chlorophenyl)-2-oxo-1,3-oxazinan-3-yl]-2-oxo-1,3,4,7,8,10-hexahydro-2H-12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate
5Q0D	;	2.12	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-2-oxo-1,2,3,4,5,6,7,9-octahydro-11,8-(azeno)-1,9-benzodiazacyclotridecin-14-yl]carbamate
5EXM	;	2.09	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl ~{N}-[4-[2-[(1~{S})-1-[[4-(aminomethyl)cyclohexyl]carbonylamino]-2-phenyl-ethyl]pyridin-4-yl]phenyl]carbamate
5QCM	;	2.2	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl ~{N}-[4-[[(1~{S})-2-[(~{E})-3-[3-chloranyl-2-fluoranyl-6-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-3,4-dihydro-1~{H}-isoquinolin-1-yl]carbonylamino]phenyl]carbamate
5E2P	;	2.11	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR N-[(1S)-1-benzyl-2-[2-[5-chloro-2-(tetrazol-1-yl)phenyl]ethylamino]-2-oxo-ethyl]-4-hydroxy-2-oxo-1H-quinoline-6-carboxamide
4WXI	;	2.6	;	FACTOR XIA IN COMPLEX WITH THE INHIBITOR trans-N-{(1S)-1-[4-(3-amino-2H-indazol-6-yl)pyridin-2-yl]-2-phenylethyl}-4-(aminomethyl)cyclohexanecarboxamide
7PRJ	;	1.2	;	Factor XII Fibronectin type II (FXII FnII) domain
7PRK	;	1.64	;	Factor XII Fibronectin type II (FXII FnII) domain
8K73	;	2.02	;	Factor-inhibiting hypoxia-inducible factor in complex with Zn(II) and 2-(3-hydroxy-2-((1-(phenylsulfonyl)pyrrolidine-3-carbonyl)imino)-2,3-dihydrothiazol-4-yl)acetic acid
8K71	;	2.23	;	Factor-inhibiting hypoxia-inducible factor in complex with Zn(II) and 2-(3-hydroxy-2-((2-((naphthalen-2-ylmethyl)sulfonyl)acetyl)imino)-2,3-dihydrothiazol-4-yl)acetic acid
8K72	;	2.45	;	Factor-inhibiting hypoxia-inducible factor in complex with Zn(II) and 2-(3-hydroxy-2-((3-(phenylsulfonamido)propanoyl)imino)-2,3-dihydrothiazol-4-yl)acetic acid
1W7X	;	1.8	;	Factor7 - 413 complex
1W8B	;	3.0	;	Factor7 - 413 complex
258D	;	1.58	;	FACTORS AFFECTING SEQUENCE SELECTIVITY ON NOGALAMYCIN INTERCALATION: THE CRYSTAL STRUCTURE OF D(TGTACA)-NOGALAMYCIN
1TVC	;		;	FAD and NADH binding domain of methane monooxygenase reductase from Methylococcus capsulatus (Bath)
3PND	;	2.75	;	FAD binding by ApbE protein from Salmonella enterica: a new class of FAD binding proteins
5ZW2	;	1.803	;	FAD complex of PigA
7LO1	;	2.09	;	FAD-dependent monooxygenase AfoD from A. nidulans
8AQ8	;	1.95	;	FAD-dependent monooxygenase from Stenotrophomonas maltophilia
6NES	;	1.75	;	FAD-dependent monooxygenase TropB from T. stipitatus
6NEU	;	2.3	;	FAD-dependent monooxygenase TropB from T. stipitatus R206Q variant
6NET	;	2.25	;	FAD-dependent monooxygenase TropB from T. stipitatus substrate complex
6NEV	;	2.303	;	FAD-dependent monooxygenase TropB from T. stipitatus Y239F Variant
6ZE2	;	1.31	;	FAD-dependent oxidoreductase from Chaetomium thermophilum
6ZE3	;	2.22	;	FAD-dependent oxidoreductase from Chaetomium thermophilum in complex with fragment (4-methoxycarbonylphenyl)methylazanium
6ZE5	;	1.82	;	FAD-dependent oxidoreductase from Chaetomium thermophilum in complex with fragment 2-(1H-indol-3-yl)-N-[(1-methyl-1H-pyrrol-2-yl)methyl]ethanamine
6ZE6	;	1.26	;	FAD-dependent oxidoreductase from Chaetomium thermophilum in complex with fragment 4-nitrocatechol
6ZE4	;	1.6	;	FAD-dependent oxidoreductase from Chaetomium thermophilum in complex with fragment 4-oxo-N-[(1S)-1-(pyridin-3-yl)ethyl]-4-(thiophen-2-yl)butanamide
7VZS	;	1.8	;	FAD-dpendent Glucose Dehydrogenase complexed with an inhibitor at pH7.56
7VZP	;	1.2	;	FAD-dpendent Glucose Dehydrogenase from Aspergillus oryzae
8BGR	;	1.8	;	FAD-independent Methylene-Tetrahydrofolate Reductase from Mycobacterium hassiacum
4LDK	;	2.04	;	FAD-linked sulfhydryl oxidase ALR mutation
5ZW7	;	1.3	;	FAD-PigA complex at 1.3 A
1A1Z	;		;	FADD DEATH EFFECTOR DOMAIN, F25G MUTANT, NMR MINIMIZED AVERAGE STRUCTURE
1A1W	;		;	FADD DEATH EFFECTOR DOMAIN, F25Y MUTANT, NMR MINIMIZED AVERAGE STRUCTURE
1E2X	;	2.0	;	FadR, fatty acid responsive transcription factor from E. coli
1H9T	;	3.25	;	FADR, FATTY ACID RESPONSIVE TRANSCRIPTION FACTOR FROM E. COLI IN COMPLEX WITH FADB OPERATOR
1H9G	;	2.1	;	FadR, FATTY ACID RESPONSIVE TRANSCRIPTION FACTOR FROM E. COLI, in complex with myristoyl-CoA
4P96	;	2.2	;	FadR, Fatty Acid Responsive Transcription Factor from Vibrio cholerae
4P9U	;	3.208	;	FadR, Fatty Acid Responsive Transcription Factor from Vibrio cholerae, in Complex with DNA
4PDK	;	2.8	;	FadR, Fatty Acid Responsive Transcription Factor from Vibrio cholerae, in Complex with oleoyl-CoA
1HW2	;	3.25	;	FADR-DNA COMPLEX: TRANSCRIPTIONAL CONTROL OF FATTY ACID METABOLISM IN ECHERICHIA COLI
8P4X	;	2.57	;	FAD_ox bound dark state structure of PdLCry
6ED2	;	2.3	;	Faecalibacterium prausnitzii beta-glucuronidase
6U7I	;	2.7	;	Faecalibacterium prausnitzii Beta-glucuronidase
3GFU	;	1.991	;	FaeE-FaeG chaperone-major pilin complex of F4 ac 5/95 fimbriae
3GEW	;	2.0	;	FaeE-FaeG chaperone-major pilin complex of F4 ad fimbriae
2J6G	;	1.55	;	FaeG from F4ac ETEC strain 5_95, produced in tobacco plant chloroplast
2J6R	;	1.9	;	FaeG from F4ac ETEC strain GIS26, produced in tobacco plant chloroplast
7PI4	;	2.24	;	FAK Protac GSK215 in complex with FAK and pVHL:ElonginC:ElonginB
6TY3	;	6.32	;	FAK structure from single particle analysis of 2D crystals
6TY4	;	5.96	;	FAK structure with AMP-PNP from single particle analysis of 2D crystals
6DJY	;	3.9	;	Fako virus
4WSF	;	1.501	;	Falafel EVH1 domain bound to CENP-C FIM
7VPE	;	1.62	;	Falcilysin in complex with A1
7DI7	;	1.82	;	Falcilysin in complex with chloroquine
7DIA	;	1.55	;	Falcilysin in complex with mefloquine
7DIJ	;	1.9	;	Falcilysin in complex with MK-4815
8HO4	;	1.96	;	Falcilysin in complex with MMV000848
8HO5	;	2.003	;	Falcilysin in complex with MMV665806
8EQB	;	6.5	;	FAM46C/BCCIPalpha/Nanobody complex
1AZV	;	1.9	;	FAMILIAL ALS MUTANT G37R CUZNSOD (HUMAN)
4B3K	;	2.6	;	Family 1 6-phospho-beta-D glycosidase from Streptococcus pyogenes
4B3L	;	2.51	;	Family 1 6-phospho-beta-D glycosidase from Streptococcus pyogenes
1OD0	;	2.11	;	Family 1 b-glucosidase from Thermotoga maritima
1OIF	;	2.12	;	Family 1 b-glucosidase from Thermotoga maritima
1OIM	;	2.15	;	Family 1 b-glucosidase from Thermotoga maritima
1OIN	;	2.15	;	Family 1 b-glucosidase from Thermotoga maritima
1UZ1	;	2.0	;	Family 1 b-glucosidase from Thermotoga maritima in complex with isofagomine lactam
1W3J	;	2.0	;	Family 1 b-glucosidase from Thermotoga maritima in complex with tetrahydrooxazine
2MWK	;		;	Family 1 Carbohydrate-Binding Module from Trichoderma reesei Cel7A with O-mannose residues at Thr1, Ser3, and Ser14
1GXM	;	1.32	;	Family 10 polysaccharide lyase from Cellvibrio cellulosa
1GXN	;	1.5	;	Family 10 polysaccharide lyase from Cellvibrio cellulosa
2CNC	;	2.4	;	Family 10 xylanase
6R31	;	2.6	;	Family 11 Carbohydrate-Binding Module from Clostridium thermocellum in complex with beta-1,3-1,4-mixed-linked tetrasaccharide
6R3M	;	1.45	;	Family 11 Carbohydrate-Binding Module from Clostridium thermocellum in complex with beta-1,3-1,4-mixed-linked tetrasaccharide
1V0A	;	1.98	;	Family 11 Carbohydrate-Binding Module of cellulosomal cellulase Lic26A-Cel5E of Clostridium thermocellum
1IGO	;	2.2	;	Family 11 xylanase
2JEN	;	1.4	;	Family 12 xyloglucanase from Bacillus licheniformis in complex with ligand
7TAA	;	1.98	;	FAMILY 13 ALPHA AMYLASE IN COMPLEX WITH ACARBOSE
2ZEW	;	1.4	;	Family 16 Cabohydrate Binding Domain Module 1
2ZEX	;	1.2	;	Family 16 carbohydrate binding module
2ZEY	;	2.2	;	Family 16 carbohydrate binding module
2ZEZ	;	1.9	;	Family 16 Carbohydrate Binding Module-2
5A29	;	1.9	;	Family 2 Pectate Lyase from Vibrio vulnificus
2C24	;	2.27	;	FAMILY 30 CARBOHYDRATE-BINDING MODULE OF CELLULOSOMAL CELLULASE CEL9D- CEL44B OF CLOSTRIDIUM THERMOCELLUM
2WZ8	;	1.5	;	Family 35 carbohydrate binding module from Clostridium thermocellum
2JG0	;	1.5	;	Family 37 trehalase from Escherichia coli in complex with 1- thiatrehazolin
2JJB	;	1.9	;	Family 37 trehalase from Escherichia coli in complex with casuarine-6- O-alpha-glucopyranose
2JF4	;	2.2	;	Family 37 trehalase from Escherichia coli in complex with validoxylamine
4B96	;	1.911	;	Family 3b carbohydrate-binding module from the biomass sensoring system of Clostridium clariflavum
2CC0	;	1.6	;	Family 4 carbohydrate esterase from Streptomyces lividans in complex with acetate
4ZBX	;	1.7	;	Family 4 uracil-DNA glycosylase from Sulfolobus tokodaii (free form, X-ray wavelength=0.9000)
4ZBZ	;	1.9	;	Family 4 uracil-DNA glycosylase from Sulfolobus tokodaii (free form, X-ray wavelength=1.5418)
4ZBY	;	1.7	;	Family 4 uracil-DNA glycosylase from Sulfolobus tokodaii (uracil complex form)
2V38	;	1.5	;	Family 5 endoglucanase Cel5A from Bacillus agaradhaerens in complex with cellobio-derived noeuromycin
2JEQ	;	1.94	;	Family 5 xyloglucanase from Paenibacillus pabuli in complex with ligand
2VNG	;	1.4	;	Family 51 carbohydrate binding module from a family 98 glycoside hydrolase produced by Clostridium perfringens in complex with blood group A-trisaccharide ligand.
2VNO	;	1.45	;	Family 51 carbohydrate binding module from a family 98 glycoside hydrolase produced by Clostridium perfringens in complex with blood group B-trisaccharide ligand.
2VNR	;	1.55	;	Family 51 carbohydrate binding module from a family 98 glycoside hydrolase produced by Clostridium perfringens.
2V5C	;	2.1	;	Family 84 glycoside hydrolase from Clostridium perfringens, 2.1 Angstrom structure
2VCC	;	2.0	;	Family 89 Glycoside Hydrolase from Clostridium perfringens
2VC9	;	2.36	;	Family 89 Glycoside Hydrolase from Clostridium perfringens in complex with 2-acetamido-1,2-dideoxynojirmycin
2VCA	;	2.05	;	Family 89 glycoside hydrolase from Clostridium perfringens in complex with beta-N-acetyl-D-glucosamine
2VCB	;	2.2	;	Family 89 Glycoside Hydrolase from Clostridium perfringens in complex with PUGNAc
1I8U	;	1.9	;	FAMILY 9 CARBOHYDRATE-BINDING MODULE FROM THERMOTOGA MARITIMA XYLANASE 10A
1I82	;	1.9	;	FAMILY 9 CARBOHYDRATE-BINDING MODULE FROM THERMOTOGA MARITIMA XYLANASE 10A WITH CELLOBIOSE
1I8A	;	1.9	;	FAMILY 9 CARBOHYDRATE-BINDING MODULE FROM THERMOTOGA MARITIMA XYLANASE 10A WITH GLUCOSE
6Y9T	;	2.78	;	Family GH13_31 enzyme
1RH9	;	1.5	;	Family GH5 endo-beta-mannanase from Lycopersicon esculentum (tomato)
1KX7	;		;	Family of 30 conformers of a mono-heme ferrocytochrome c from Shewanella putrefaciens solved by NMR
1N65	;		;	FAMILY OF NMR SOLUTION STRUCTURES OF CA CE CALBINDIN D9K IN DENATURATING CONDITIONS
1KQV	;		;	Family of NMR Solution Structures of Ca Ln Calbindin D9K
4RIC	;	2.8	;	FAN1 Nuclease bound to 5' hydroxyl (dT-dT) single flap DNA
4RIA	;	3.0	;	FAN1 Nuclease bound to 5' phosphorylated nicked DNA
4RI8	;	2.9	;	FAN1 Nuclease bound to 5' phosphorylated p(dG)/3'(dT-dT-dT-dT) double flap DNA
4RIB	;	3.25	;	FAN1 Nuclease bound to 5' phosphorylated p(dT) single flap DNA
4RI9	;	2.9	;	FAN1 Nuclease bound to 5' phosphorylated p(dT)/3'(dT-dT-dT-dT-dT-dT-dT-dT) double flap DNA
7KUO	;	2.281	;	FANA modification at 3' end of RNA primer complex with guanosine dinucleotide ligand G(5')ppp(5')G
6VAD	;	3.3	;	Fanconi Anemia ID complex
7ZW0	;	2.4	;	FAP-80S Complex - Rotated state
6XHH	;	1.5	;	Far-red absorbing dark state of JSC1_58120g3 with bound 18-1, 18-2 dihydrobiliverdin IXa (DHBV), the native chromophore precursor
6XHG	;	2.3	;	Far-red absorbing dark state of JSC1_58120g3 with bound biliverdin IXa (BV)
8HW1	;	3.13	;	Far-red light-harvesting complex of Antarctic alga Prasiola crispa
8THV	;		;	FARFAR-NMR ensemble of HIV-1 TAR with apical loop capturing ground and excited conformational states
8HD3	;	2.29	;	Farnesoid X Receptor Agonists_FXR fused with a HD3 peptide
1X81	;	3.5	;	Farnesyl transferase structure of Jansen compound
5FR2	;	3.35	;	Farnesylated RhoA-GDP in complex with RhoGDI-alpha, lysine acetylated at K178
1N9A	;	3.2	;	Farnesyltransferase complex with tetrahydropyridine inhibitors
1DDF	;		;	FAS DEATH DOMAIN, NMR, MINIMIZED AVERAGE STRUCTURE
2LTC	;		;	Fas1-4, R555W
5WT7	;		;	FAS1-IV domain of Human Periostin
1KU6	;	2.5	;	Fasciculin 2-Mouse Acetylcholinesterase Complex
1MAH	;	3.2	;	FASCICULIN2-MOUSE ACETYLCHOLINESTERASE COMPLEX
7ZAU	;	2.2	;	Fascin-1 in complex with Nb 3E11
5FWZ	;	2.3	;	Fasciola hepatica calcium binding protein FhCaBP2: Structure of the dynein light chain-like domain. P41212 mercury derivative.
5FX0	;	2.3	;	Fasciola hepatica calcium binding protein FhCaBP2: Structure of the dynein light chain-like domain. P6422 native.
2FHE	;	2.3	;	FASCIOLA HEPATICA GLUTATHIONE S-TRANSFERASE ISOFORM 1 IN COMPLEX WITH GLUTATHIONE
2WB9	;	1.59	;	Fasciola hepatica sigma class GST
2WDU	;	1.62	;	Fasciola hepatica sigma class GST
8FWD	;	3.67	;	Fast and versatile sequence- independent protein docking for nanomaterials design using RPXDock
1SFQ	;	1.91	;	Fast form of thrombin mutant R(77a)A bound to PPACK
7AV6	;	1.5	;	FAST in a domain-swapped dimer form
2VAE	;	1.64	;	Fast maturing red fluorescent protein, DsRed.T4
6SKY	;	2.8	;	FAT and kinase domain of CtTel1
2L6H	;		;	Fat domain of focal adhesion kinase tethered to LD4 motif of paxillin via GGS linker
2L6G	;		;	FAT-LD2 Double labeled construct with free LD4 peptide
4N03	;	1.15	;	Fatty acid ABC transporter substrate-binding protein from Thermomonospora curvata
6KVR	;	2.2	;	Fatty acid amide hydrolase
4XCP	;	2.14	;	Fatty Acid and Retinol binding protein Na-FAR-1 from Necator americanus
1WDK	;	2.5	;	fatty acid beta-oxidation multienzyme complex from Pseudomonas fragi, form I (native2)
1WDM	;	3.8	;	fatty acid beta-oxidation multienzyme complex from Pseudomonas fragi, form I (native3)
1WDL	;	3.5	;	fatty acid beta-oxidation multienzyme complex from Pseudomonas fragi, form II (native4)
2D3T	;	3.4	;	Fatty Acid beta-oxidation multienzyme complex from Pseudomonas Fragi, Form V
2DT8	;	1.48	;	Fatty Acid Binding of a DegV family Protein from Thermus thermophilus
3PL5	;	2.04	;	Fatty acid binding protein
2FLJ	;		;	Fatty acid binding protein from locust flight muscle in complex with oleate
5DIC	;	1.185	;	Fatty acid binding protein OBP56a from the oral disk of the blowfly Phormia regina
6TA1	;	3.1	;	Fatty acid synthase of S. cerevisiae
5GGE	;	1.861	;	Fatty Acid-Binding Protein in Brain Tissue of Drosophila melanogaster
5U0M	;	3.075	;	Fatty aldehyde dehydrogenase from Marinobacter aquaeolei VT8 and cofactor complex
5J7O	;	2.37	;	Faustovirus major capsid protein
5J7U	;	2.44	;	Faustovirus major capsid protein
5J7V	;	15.5	;	Faustovirus major capsid protein
2B7Y	;	3.0	;	Fava Bean Lectin-Glucose Complex
2MWB	;		;	FBP28 WW2 mutant W457F
1E0L	;		;	FBP28WW domain from Mus musculus
2RM0	;		;	FBP28WW2 domain in complex with a PPPLIPPPP peptide
2RLY	;		;	FBP28WW2 domain in complex with PTPPPLPP peptide
2JUP	;		;	FBP28WW2 domain in complex with the PPLIPPPP peptide
6WNX	;	2.5	;	FBXW11-SKP1 in complex with a pSer33/pSer37 Beta-Catenin peptide
5WAV	;	2.6	;	Fc AbVance: Increasing our knowledge of antibody structural space to enable faster and better decision-making in antibody drug discovery.
5NSG	;	2.22	;	Fc DEDE homodimer variant
5NSC	;	2.3	;	Fc DEKK heterodimer variant
5DVL	;	1.9	;	Fc Design 20.8.37 A chain homodimer Y349S/T366M/K370Y/K409V
5DVM	;	2.95	;	Fc Design 20.8.37 B chain homodimer E357D/S364R/Y407A
5DVK	;	2.6	;	Fc Design 7.7 B chain homodimer T366V/K409I
4ZNC	;	2.28	;	Fc fragment of human IgG in complex with the C domain of staphylococcal protein A mutant - Q9W
5VGP	;	2.116	;	Fc fragment of human IgG1 antibody, from NIST mAb
1DN2	;	2.7	;	FC FRAGMENT OF HUMAN IGG1 IN COMPLEX WITH AN ENGINEERED 13 RESIDUE PEPTIDE DCAWHLGELVWCT-NH2
3D6G	;	2.3	;	Fc fragment of IgG1 (Herceptin) with protein-A mimetic peptide dendrimer ligand.
1L6X	;	1.65	;	FC FRAGMENT OF RITUXIMAB BOUND TO A MINIMIZED VERSION OF THE B-DOMAIN FROM PROTEIN A CALLED Z34C
5DJ0	;	2.28	;	Fc Heterodimer Design 11.2 Y349S/K370Y + E357D/S364Q
5DJX	;	2.25	;	Fc Heterodimer Design 2.9 L368M/K370E + E357A/S364G
5DJY	;	2.15	;	Fc Heterodimer Design 20.8 Y349S/T366V/K370Y/K409V + E357D/S364Q/Y407A
5DK0	;	2.3	;	Fc Heterodimer Design 20.8.34 Y349S/T366M/K370Y/K409V + E356G/E357D/S364Q/Y407A
5DJD	;	2.3	;	Fc Heterodimer Design 5.1 T366V + Y407F
5DJ6	;	2.0	;	Fc Heterodimer Design 6.1 F405W/Y407A + T366M
5DJ2	;	2.56	;	Fc Heterodimer Design 7.4 Y407A + T366V/K409V
5DJ8	;	2.4	;	Fc Heterodimer Design 7.7 D399M/Y407A + T366V/K409I
5DJZ	;	1.9	;	Fc Heterodimer Design 7.8 D399M/Y407A + T366V/K409V
5DJC	;	2.1	;	Fc Heterodimer Design 8.1 L368V/Y407A + T366V/K409F
5DJA	;	2.9	;	Fc Heterodimer Design 9.1 Y407M + T366I
5DK2	;	2.6	;	Fc Heterodimer E356K/D399K + K392D/K409D
6FGO	;	2.5	;	Fc in complex with engineered calcium binding domain Z
5DVN	;	2.5	;	Fc K392D/K409D homodimer
5DVO	;	2.5	;	Fc K392D/K409D homodimer
5DI8	;	1.9	;	Fc Knob-Hole Heterodimer T366W + T366S/L368A/Y407V
5Y56	;	2.653	;	Fc mutant (K392D/K409D/D399K)
2RGS	;	2.13	;	FC-fragment of monoclonal antibody IGG2B from Mus musculus
8BZF	;	1.53	;	FC-J acetonide stabilizer of 14-3-3 and ERalpha
5WAW	;	2.25	;	FcAbVance: Increasing our knowledge of antibody structural space to enable faster and better decision-making in antibody drug discovery
8QCI	;	2.2	;	FCGBP D10 Assembly Segment
5JP2	;	2.4	;	Fcho1 Mu homology domain (Danio Rerio) with bound Eps15 peptide
7OHI	;	1.41	;	FCHO1-peptide-AP2 alpha ear complex
2V0O	;	2.3	;	FCHO2 F-BAR domain
8BPF	;	3.5	;	FcMR binding at subunit Fcu1 of IgM pentamer
8BPG	;	3.1	;	FcMR binding at subunit Fcu3 of IgM pentamer
8J0D	;	3.19	;	FCP heterodimer, Lhca2, and Lhcf5 together as the M1 side binds to the PSII core in the diatom Thalassiosira pseudonana
1FDM	;		;	FD MAJOR COAT PROTEIN IN SDS MICELLES, NMR, 20 STRUCTURES
8UGC	;	4.0	;	FD15: Flat repeat helix-turn-helix-turn protein
4E9L	;	1.9	;	FdeC, a Novel Broadly Conserved Escherichia coli Adhesin Eliciting Protection against Urinary Tract Infections
5KTC	;	1.8	;	FdhC with bound products: Coenzyme A and 3-[(R)-3-hydroxybutanoylamino]-3,6-dideoxy-d-galactose
5KTD	;	1.9	;	FdhC with bound products: Coenzyme A and dTDP-3-amino-3,6-dideoxy-d-glucose
4XPI	;	1.97	;	Fe protein independent substrate reduction by nitrogenase variants altered in intramolecular electron transfer
7O1T	;	1.5	;	Fe(CO)2CNCl species bound [HydE from T. Maritima
6L56	;	1.85301	;	Fe(II) loaded Tegillarca granosa ferritin
6DY4	;	1.9	;	Fe(II)-bound structure of the engineered cyt cb562 variant, CH2E
6DYE	;	2.25	;	Fe(II)-bound structure of the engineered cyt cb562 variant, CH3
6DYG	;	1.49	;	Fe(II)-bound structure of the engineered cyt cb562 variant, CH3Y
3SCG	;	3.0	;	Fe(II)-HppE with R-HPP
3SCF	;	2.85	;	Fe(II)-HppE with S-HPP and NO
5ZM2	;	2.5	;	Fe(II)/(alpha)ketoglutarate-dependent dioxygenase AndA
5ZM3	;	2.25	;	Fe(II)/(alpha)ketoglutarate-dependent dioxygenase AndA with preandiloid B
5ZM4	;	1.95	;	Fe(II)/(alpha)ketoglutarate-dependent dioxygenase AndA with preandiloid C
5DAP	;	1.7	;	Fe(II)/(alpha)ketoglutarate-dependent dioxygenase AsqJ
5DAQ	;	1.7	;	Fe(II)/(alpha)ketoglutarate-dependent dioxygenase AsqJ in complex with 4-Methoxycyclopeptin
5DAV	;	1.8	;	Fe(II)/(alpha)ketoglutarate-dependent dioxygenase AsqJ in complex with 4-Methoxydehydrocyclopeptin
5DAW	;	1.6	;	Fe(II)/(alpha)ketoglutarate-dependent dioxygenase AsqJ in complex with cyclopeptin
5DAX	;	1.7	;	Fe(II)/(alpha)ketoglutarate-dependent dioxygenase AsqJ in complex with demethylated cyclopeptin
5OA4	;	1.55	;	Fe(II)/(alpha)ketoglutarate-dependent dioxygenase AsqJ_V72I mutant in complex with 4-methoxycyclopeptin (1)
5OA7	;	1.65	;	Fe(II)/(alpha)ketoglutarate-dependent dioxygenase AsqJ_V72I mutant in complex with cyclopeptin (1b)
5OA8	;	1.75	;	Fe(II)/(alpha)ketoglutarate-dependent dioxygenase AsqJ_V72I mutant in complex with demethylated cyclopeptin (1d)
6EOZ	;	1.55	;	Fe(II)/(alpha)ketoglutarate-dependent dioxygenase AsqJ_V72K mutant in complex with cyclopeptin (1b)
5YBL	;	2.108	;	Fe(II)/(alpha)ketoglutarate-dependent dioxygenase AusE
5YBM	;	2.115	;	Fe(II)/(alpha)ketoglutarate-dependent dioxygenase PrhA
5YBN	;	2.104	;	Fe(II)/(alpha)ketoglutarate-dependent dioxygenase PrhA in complex with (alpha)ketoglutarate
5YBO	;	2.204	;	Fe(II)/(alpha)ketoglutarate-dependent dioxygenase PrhA in complex with preaustinoid A1
5YBS	;	2.3	;	Fe(II)/(alpha)ketoglutarate-dependent dioxygenase PrhA-V150L/A232S in complex with berkeleyone A
5YBP	;	2.312	;	Fe(II)/(alpha)ketoglutarate-dependent dioxygenase PrhA-V150L/A232S in complex with preaustinoid A1
5YBQ	;	2.25	;	Fe(II)/(alpha)ketoglutarate-dependent dioxygenase PrhA-V150L/A232S in complex with preaustinoid A2
5YBR	;	2.261	;	Fe(II)/(alpha)ketoglutarate-dependent dioxygenase PrhA-V150L/A232S in complex with preaustinoid A3
5YBT	;	2.35	;	Fe(II)/(alpha)ketoglutarate-dependent dioxygenase PrhA-V150L/A232S/M241V in complex with berkeleyone A
7EYR	;	2.12	;	Fe(II)/(alpha)ketoglutarate-dependent dioxygenase SptF apo
7EYT	;	2.1	;	Fe(II)/(alpha)ketoglutarate-dependent dioxygenase SptF with andilesin C and NOG
7EYW	;	2.1	;	Fe(II)/(alpha)ketoglutarate-dependent dioxygenase SptF with terretonin C
7EYU	;	2.05	;	Fe(II)/(alpha)ketoglutarate-dependent dioxygenase SptF-N65T mutant with andiconin D
7VBR	;	2.1	;	Fe(II)/(alpha)ketoglutarate-dependent dioxygenase TlxI
8A82	;	2.05	;	Fe(II)/aKG-dependent halogenase OocPQ
8FUO	;	2.43	;	Fe-bound AibH1H2
6WZ0	;	1.7	;	Fe-bound structure of an engineered metal-dependent protein trimer, TriCyt2
4XET	;	1.3	;	Fe-Cl bound Y157F CDO at pH ~7.0 in the presence of azide
2VP1	;	2.7	;	Fe-FutA2 from Synechocystis PCC6803
1FEH	;	1.8	;	FE-ONLY HYDROGENASE FROM CLOSTRIDIUM PASTEURIANUM
6G2G	;	2.57	;	Fe-S assembly Cfd1
7KUG	;	1.55	;	Fe-S cluster-bound transcription activator WhiB7 in complex with the SigmaAr4-RNAP Beta flap tip chimera
2C6R	;	2.1	;	FE-SOAKED CRYSTAL STRUCTURE OF THE DPS92 FROM DEINOCOCCUS RADIODURANS
1COJ	;	1.9	;	FE-SOD FROM AQUIFEX PYROPHILUS, A HYPERTHERMOPHILIC BACTERIUM
1VZ4	;	2.5	;	Fe-Succinate Complex of AtsK
2CZ7	;	1.8	;	Fe-type NHase photo-activated for 75min at 105K
2VC0	;	2.5	;	Feast or famine regulatory protein (Rv3291c)from M. tuberculosis complexed with L-Leucine
2VC1	;	2.75	;	Feast or famine regulatory protein (Rv3291c)from M. tuberculosis complexed with L-Methionine
2VBW	;	2.2	;	Feast or famine regulatory protein (Rv3291c)from M. tuberculosis complexed with L-Phenylalanine
2VBX	;	2.75	;	Feast or famine regulatory protein (Rv3291c)from M. tuberculosis complexed with L-Phenylalanine
2VBZ	;	2.8	;	Feast or famine regulatory protein (Rv3291c)from M. tuberculosis complexed with L-Tryptophan
2VBY	;	2.8	;	Feast or famine regulatory protein (Rv3291c)from M. tuberculosis complexed with L-Tyrosine
2CSE	;	7.0	;	Features of Reovirus Outer-Capsid Protein mu1 Revealed by Electron and Image Reconstruction of the virion at 7.0-A Resolution
7CTC	;	2.0	;	FECH - inhibitor complex 1
7CT7	;	2.0	;	FECH - inhibitor complex 2
8XV9	;	3.8	;	Fedratinib-bound human SLC19A3
2LGS	;	2.8	;	FEEDBACK INHIBITION OF FULLY UNADENYLYLATED GLUTAMINE SYNTHETASE FROM SALMONELLA TYPHIMURIUM BY GLYCINE, ALANINE, AND SERINE
6SG2	;	1.65	;	FeFe Hydrogenase from Desulfovibrio desulfuricans in Hinact state
1W7R	;	1.4	;	Feglymycin P64 crystal form
1W7Q	;	1.1	;	Feglymycin P65 crystal form
6GEM	;	3.462	;	FeII-Dependent Halogenase Wi-WelO15
6GSH	;	3.0	;	Feline Calicivirus Strain F9
6GSI	;	3.75	;	Feline Calicivirus Strain F9 bound to a soluble ectodomain fragment of feline junctional adhesion molecule A - leading to assembly of a portal structure at a unique three-fold axis.
4PB6	;	8.0	;	Feline calicivirus VP1 T=1 virus-like particle
6WTJ	;	1.9	;	Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication
6WTK	;	2.0	;	Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication
6WTM	;	1.85	;	Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication
1C8E	;	3.0	;	FELINE PANLEUKOPENIA VIRUS EMPTY CAPSID STRUCTURE
1C8F	;	3.0	;	FELINE PANLEUKOPENIA VIRUS EMPTY CAPSID STRUCTURE
1C8G	;	3.0	;	FELINE PANLEUKOPENIA VIRUS EMPTY CAPSID STRUCTURE
3G7X	;	1.55	;	Female-specific histamine-binding protein 2, D24R mutant
3GAQ	;	2.25	;	Female-specific Histamine-Binding Protein, D24R Mutant
1L5H	;	2.3	;	FeMo-cofactor Deficient Nitrogenase MoFe Protein
5HDC	;	1.6	;	Femtosecond Structural Dynamics Drives the Trans/Cis Isomerization in Photoactive Yellow Protein: 100 fs to 400 fs Structure
5HD5	;	1.6	;	Femtosecond Structural Dynamics Drives the Trans/Cis Isomerization in Photoactive Yellow Protein: 200 ns time delay photo-activated (light) structure
5HDS	;	1.6	;	Femtosecond Structural Dynamics Drives the Trans/Cis Isomerization in Photoactive Yellow Protein: 3 ps Structure
5HDD	;	1.6	;	Femtosecond Structural Dynamics Drives the Trans/Cis Isomerization in Photoactive Yellow Protein: 800 fs to 1200 fs Structure
5HD3	;	1.6	;	Femtosecond Structural Dynamics Drives the Trans/Cis Isomerization in Photoactive Yellow Protein: Dark structure of photoactive yellow protein
6XYG	;	1.5	;	Femtosecond structure of bovine trypsin at room temperature
6TK2	;	2.5	;	Femtosecond to millisecond structural changes in a light-driven sodium pump: 1ms structure of KR2 with extrapolated, light and dark datasets
6TK4	;	2.25	;	Femtosecond to millisecond structural changes in a light-driven sodium pump: 1ns+16ns structure of KR2 with extrapolated, light and dark datasets
6TK1	;	2.5	;	Femtosecond to millisecond structural changes in a light-driven sodium pump: 20ms structure of KR2 with extrapolated, light and dark datasets
6TK3	;	2.25	;	Femtosecond to millisecond structural changes in a light-driven sodium pump: 30us+150us structure of KR2 with extrapolated, light and dark datasets
6TK5	;	2.25	;	Femtosecond to millisecond structural changes in a light-driven sodium pump: 800fs+2ps structure of KR2 with extrapolated, light and dark datasets
6TK7	;	1.6	;	Femtosecond to millisecond structural changes in a light-driven sodium pump: Dark structure in acidic conditions
6TK6	;	1.6	;	Femtosecond to millisecond structural changes in a light-driven sodium pump: Dark structure in neutral conditions with attached light datasets at 800fs, 2ps, 100ps, 1ns, 16ns, 1us, 30us, 150us, 1ms and 20ms
3PCQ	;	8.984	;	Femtosecond X-ray protein Nanocrystallography
1B43	;	2.0	;	FEN-1 FROM P. FURIOSUS
8JLQ	;	2.84	;	Fenoldopam-bound hTAAR1-Gs protein complex
8EF5	;	3.3	;	Fentanyl-bound mu-opioid receptor-Gi complex
7WQU	;	4.202	;	FeoC from Klebsiella pneumoniae
4XJ2	;	1.8	;	FerA - NADH:FMN oxidoreductase from Paracoccus denitrificans in complex with FMN
3U7R	;	1.4	;	FerB - flavoenzyme NAD(P)H:(acceptor) oxidoreductase (FerB) from Paracoccus denitrificans
2HE7	;	2.0	;	FERM domain of EPB41L3 (DAL-1)
2AL6	;	2.35	;	FERM domain of Focal Adhesion Kinase
5BOK	;	2.4	;	Ferredoxin component of 3-nitrotoluene dioxygenase from Diaphorobacter sp. strain DS2
2Z8Q	;	1.7	;	ferredoxin from Pyrococcus furiosus, D14C variant
6KV0	;	1.4	;	Ferredoxin I from C. reinhardtii, high X-ray dose
6KUM	;	1.4	;	Ferredoxin I from C. reinhardtii, low X-ray dose
6JO2	;	1.55	;	Ferredoxin I from Thermosynechococcus elongatus
5H57	;	2.5	;	Ferredoxin III from maize root
1QOA	;	1.7	;	FERREDOXIN MUTATION C49S
1QOB	;	1.8	;	FERREDOXIN MUTATION D62K
1QOF	;	1.8	;	FERREDOXIN MUTATION Q70K
1QOG	;	1.8	;	FERREDOXIN MUTATION S47A
5VJ7	;	2.55	;	Ferredoxin NADP Oxidoreductase (Xfn)
4C43	;	1.7	;	FERREDOXIN NADP REDUCTASE MUTANT WITH GLU 103 REPLACED BY TYR, TYR 104 REPLACED BY PHE, SER 109 REPLACED BY PHE AND GLY 110 REPLACED BY PRO (E103Y-Y104F-S109F-G110P)
3GCE	;	2.0	;	Ferredoxin of carbazole 1,9a-dioxygenase from Nocardioides aromaticivorans IC177
1F3P	;	2.4	;	FERREDOXIN REDUCTASE (BPHA4)-NADH COMPLEX
1A8P	;	2.0	;	FERREDOXIN REDUCTASE FROM AZOTOBACTER VINELANDII
7C3A	;	2.6	;	Ferredoxin reductase in carbazole 1,9a-dioxygenase
7C3B	;	2.4	;	Ferredoxin reductase in carbazole 1,9a-dioxygenase (FAD apo form)
1E9M	;	2.07	;	Ferredoxin VI from Rhodobacter Capsulatus
1AWD	;	1.4	;	FERREDOXIN [2FE-2S] OXIDIZED FORM FROM CHLORELLA FUSCA
5C2U	;	1.55	;	Ferredoxin-like domain of nucleoporin Nup54 bound to a nanobody
2B5O	;	2.499	;	ferredoxin-NADP reductase
3CRZ	;	1.9	;	Ferredoxin-NADP Reductase
3ZC3	;	2.3	;	FERREDOXIN-NADP REDUCTASE (MUTATION S80A) COMPLEXED WITH NADP BY COCRYSTALLIZATION
1W34	;	1.73	;	FERREDOXIN-NADP REDUCTASE (MUTATION: Y 303 S)
2BSA	;	1.92	;	Ferredoxin-Nadp Reductase (Mutation: Y 303 S) complexed with NADP
1W87	;	3.0	;	FERREDOXIN-NADP REDUCTASE (MUTATION: Y 303 W) COMPLEXED WITH NADP BY COCRYSTALLIZATION
2VZL	;	1.93	;	FERREDOXIN-NADP REDUCTASE (MUTATIONS: T155G, A160T, L263P AND Y303S) COMPLEXED WITH NAD BY COCRYSTALLIZATION
3ZBT	;	1.92	;	Ferredoxin-NADP Reductase Mutant with SER 59 Replaced by ALA (S59A)
3ZBU	;	1.89	;	Ferredoxin-NADP Reductase Mutant with SER 80 Replaced by ALA (S80A)
2X3U	;	1.93	;	Ferredoxin-NADP reductase mutant with Tyr 303 replaced by Phe (Y303F)
4BPR	;	2.0	;	FERREDOXIN-NADP REDUCTASE MUTANT WITH TYR 79 REPLACED BY PHE (Y79F)
4K1X	;	1.7	;	Ferredoxin-NADP(H) Reductase mutant with Ala 266 replaced by Tyr (A266Y) and residues 267-272 deleted.
1B2R	;	1.8	;	FERREDOXIN-NADP+ REDUCTASE (MUTATION: E 301 A)
1W35	;	1.9	;	FERREDOXIN-NADP+ REDUCTASE (MUTATION: Y 303 W)
1GJR	;	2.1	;	Ferredoxin-NADP+ Reductase complexed with NADP+ by COCRYSTALLIZATION
5H59	;	1.65	;	Ferredoxin-NADP+ reductase from maize root
2OK8	;	2.4	;	Ferredoxin-NADP+ reductase from Plasmodium falciparum
2OK7	;	2.7	;	Ferredoxin-NADP+ reductase from Plasmodium falciparum with 2'P-AMP
2BMW	;	1.5	;	Ferredoxin: NADP+ Reductase Mutant With Thr 155 Replaced By Gly, Ala 160 Replaced By Thr, Leu 263 Replaced By Pro, Arg 264 Replaced By Pro and Gly 265 Replaced by Pro (T155G-A160T-L263P-R264P-G265P)
2VYQ	;	1.9	;	FERREDOXIN:NADP REDUCTASE MUTANT WITH THR 155 REPLACED BY GLY, ALA 160 REPLACED BY THR, LEU 263 REPLACED BY PRO AND TYR 303 REPLACED BY SER (T155G-A160T-L263P-Y303S)
1FRQ	;	1.95	;	FERREDOXIN:NADP+ OXIDOREDUCTASE (FERREDOXIN REDUCTASE) MUTANT E312A
1BX0	;	1.9	;	Ferredoxin:nadp+ oxidoreductase (ferredoxin reductase) mutant e312l
1BX1	;	1.9	;	FERREDOXIN:NADP+ OXIDOREDUCTASE (FERREDOXIN REDUCTASE) MUTANT E312Q
1BJK	;	2.3	;	FERREDOXIN:NADP+ REDUCTASE MUTANT WITH ARG 264 REPLACED BY GLU (R264E)
1OGJ	;	1.64	;	FERREDOXIN:NADP+ REDUCTASE MUTANT WITH LEU 263 REPLACED BY PRO (L263P)
1QH0	;	1.93	;	FERREDOXIN:NADP+ REDUCTASE MUTANT WITH LEU 76 MUTATED BY ASP AND LEU 78 MUTATED BY ASP
1QGZ	;	2.3	;	FERREDOXIN:NADP+ REDUCTASE MUTANT WITH LEU 78 REPLACED BY ASP (L78D)
1E62	;	2.3	;	Ferredoxin:NADP+ reductase mutant with Lys 75 replaced by Arg (K75R)
1E64	;	2.3	;	FERREDOXIN:NADP+ REDUCTASE MUTANT WITH LYS 75 REPLACED BY GLN (K75Q)
1QGY	;	1.7	;	Ferredoxin:NADP+ reductase mutant with Lys 75 replaced by Glu (K75E)
1E63	;	2.3	;	Ferredoxin:NADP+ Reductase Mutant with LYS 75 Replaced by SER (K75S)
1BQE	;	2.45	;	FERREDOXIN:NADP+ REDUCTASE MUTANT WITH THR 155 REPLACED BY GLY (T155G)
1OGI	;	1.64	;	FERREDOXIN:NADP+ REDUCTASE MUTANT WITH THR 155 REPLACED BY GLY AND ALA 160 REPLACED BY THR (T155G-A160T)
1H42	;	2.15	;	FERREDOXIN:NADP+ REDUCTASE MUTANT WITH THR 155 REPLACED BY GLY, ALA 160 REPLACED BY THR AND LEU 263 REPLACED BY PRO (T155G-A160T-L263P)
1H85	;	2.3	;	FERREDOXIN:NADP+ REDUCTASE MUTANT WITH VAL 136 REPLACED BY LEU (V136L)
1Y4T	;	1.8	;	Ferric binding protein from Campylobacter jejuni
4ELO	;	1.914	;	Ferric binding protein in apo form 1
4ELP	;	2.07	;	Ferric binding protein in apo form 2
4ELQ	;	1.893	;	Ferric binding protein with carbonate
4ELR	;	2.502	;	Ferric binding protein with iron and carbonate
3FWF	;	1.83	;	Ferric camphor bound cytochrome P450cam containing a Selenocysteine as the 5th heme ligand, monoclinic crystal form
3FWJ	;	1.9	;	Ferric camphor bound Cytochrome P450cam containing a selenocysteine as the 5th heme ligand, orthorombic crystal form
3FWI	;	2.4	;	Ferric camphor bound Cytochrome P450cam containing a selenocysteine as the 5th heme ligand, tetragonal crystal form
3FWG	;	1.55	;	Ferric camphor bound Cytochrome P450cam, Arg365Leu, Glu366Gln, monoclinic crystal form
6GZW	;	1.41	;	Ferric DtpA from Streptomyces lividans
1FEP	;	2.4	;	FERRIC ENTEROBACTIN RECEPTOR
3LR7	;	1.6	;	Ferric horse heart myoglobin, nitrite adduct
3HC9	;	2.0	;	Ferric Horse Heart Myoglobin; H64V mutant
3HEP	;	1.95	;	Ferric Horse Heart Myoglobin; H64V Mutant, Nitrite Modified
3HEN	;	1.9	;	Ferric Horse Heart Myoglobin; H64V/V67R Mutant
3HEO	;	2.0	;	Ferric Horse Heart Myoglobin; H64V/V67R mutant, Nitrite Modified
1W4W	;	1.55	;	Ferric horseradish peroxidase C1A in complex with formate
1QJQ	;	2.95	;	FERRIC HYDROXAMATE RECEPTOR FROM ESCHERICHIA COLI (FHUA)
2FCP	;	2.5	;	FERRIC HYDROXAMATE UPTAKE RECEPTOR (FHUA) FROM E.COLI
1FCP	;	2.7	;	FERRIC HYDROXAMATE UPTAKE RECEPTOR (FHUA) FROM E.COLI IN COMPLEX WITH BOUND FERRICHROME-IRON
1MOH	;	1.9	;	FERRIC MONOMERIC HEMOGLOBIN I (HB I)
6H5Z	;	1.8	;	Ferric murine neuroglobin F106A mutant
6H6I	;	1.6	;	Ferric murine neuroglobin Gly-loop mutant
6RA6	;	2.3	;	Ferric murine neuroglobin Gly-loop44-47/F106A mutant
1DZ4	;	1.6	;	ferric p450cam from pseudomonas putida
3P5Q	;	2.0	;	Ferric R-state human aquomethemoglobin
1FSL	;	2.3	;	FERRIC SOYBEAN LEGHEMOGLOBIN COMPLEXED WITH NICOTINATE
1MZB	;	1.8	;	Ferric uptake regulator
1MRP	;	1.6	;	FERRIC-BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE
8C4L	;	1.86	;	Ferric-siderophore reduction in Shewanella biscestrii: Structural and functional characterization of SbiSIP reveals unforeseen specificity
4B8Y	;	1.9	;	Ferrichrome-bound FhuD2
1AXQ	;	2.1	;	FERRICYANIDE OXIDIZED FDI
1Z4A	;	2.3	;	Ferritin from T. maritima
6IPO	;	2.998	;	Ferritin mutant C90A/C102A/C130A/D144C
8IQX	;	2.5	;	ferritin mutant-P156H
7XRG	;	1.9	;	ferritin nanocage assembly with nickel ion
6JOB	;	2.93	;	Ferritin variant with ""GMG"" motif
5U1A	;	2.0	;	Ferritin with Gc MtrE loop 1 inserted at His34
5U1B	;	2.81	;	Ferritin with Gc MtrE loop2 inserted at the N-terminus
1AK1	;	1.9	;	FERROCHELATASE FROM BACILLUS SUBTILIS
2J19	;	1.75	;	Ferrous Chloroperoxidase (high dose data set)
1Z8P	;	1.85	;	Ferrous dioxygen complex of the A245S cytochrome P450eryF
1Z8Q	;	2.0	;	Ferrous dioxygen complex of the A245T cytochrome P450eryF
1Z8O	;	1.7	;	Ferrous dioxygen complex of the wild-type cytochrome P450eryF
1W4Y	;	1.6	;	Ferrous horseradish peroxidase C1A in complex with carbon monoxide
5JP7	;	1.26	;	Ferrous Leu 16 Val mutant of cytochrome c prime from Alcaligenes xylosoxidans
2NX0	;	0.95	;	Ferrous nitrosyl blackfin tuna myoglobin
1DZ6	;	1.9	;	ferrous p450cam from pseudomonas putida
2WTN	;	2.1	;	Ferulic Acid bound to Est1E from Butyrivibrio proteoclasticus
4S13	;	2.348	;	Ferulic Acid Decarboxylase (FDC1)
4UU3	;	1.15	;	Ferulic acid decarboxylase from Enterobacter sp.
4UU2	;	1.49	;	Ferulic acid decarboxylase from Enterobacter sp., single mutant
5YAL	;	1.5	;	Ferulic acid esterase from Streptomyces cinnamoneus at 1.5 A resolution
5YAE	;	2.4	;	Ferulic acid esterase from Streptomyces cinnamoneus at 2.4 A resolution
7Z2V	;	1.45	;	Ferulic acid esterase variant S114A from Lactobacillus buchneri
1GKK	;	1.6	;	Feruloyl esterase domain of XynY from clostridium thermocellum
4BAG	;	1.9	;	Feruloyl Esterase Domain of XYNY from Clostridium thermocellum after exposure to 266nm UV laser
4H35	;	1.9	;	Feruloyl Esterase Domain of XYNY from Clostridium thermocellum before exposure to 266nm UV laser
1UWC	;	1.08	;	Feruloyl esterase from Aspergillus niger
7XRH	;	2.3	;	Feruloyl esterase from Lactobacillus acidophilus
7XRI	;	2.19	;	Feruloyl esterase mutant -S106A
7XWV	;	1.81	;	Feruloyl-CoA hydratase/lyase complexed with Vanillin and Coenzyme A
7XWC	;	1.986	;	Feruloyl-CoA hydratase/lyase from Sphingomonas paucimobilis SYK-6
1JT1	;	1.78	;	FEZ-1 metallo-beta-lactamase from Legionella gormanii modelled with D-captopril
5W90	;	1.78	;	FEZ-1 metallo-beta-lactamase from Legionella gormanii modelled with unknown ligand
1L9Y	;	2.01	;	FEZ-1-Y228A, A Mutant of the Metallo-beta-lactamase from Legionella gormanii
2LKS	;		;	Ff11-60
6WAC	;	2.9	;	FF248-249AA PCNA mutant defective in BIR
3B4Y	;	1.95	;	FGD1 (Rv0407) from Mycobacterium tuberculosis
2K4A	;		;	FGF-1-C2A binary complex structure: a key component in the fibroblast growthfactor non-classical pathway
2KI4	;		;	FGF1-S100A13 complex structure: key component in non-classical path way of FGF1
3C4F	;	2.07	;	FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3-methoxybenzyl)-7-azaindole
5ZV2	;	2.86	;	FGFR-1 in complex with ligand lenvatinib
4UWY	;	2.305	;	FGFR1 Apo structure
6NVL	;	2.7	;	FGFR1 complex with N-(2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-3-methylphenyl)acrylamide
4V05	;	2.57	;	FGFR1 in complex with AZD4547.
5A46	;	2.63	;	FGFR1 in complex with dovitinib
4V01	;	2.33	;	FGFR1 in complex with ponatinib (co-crystallisation).
4V04	;	2.12	;	FGFR1 in complex with ponatinib.
6C19	;	2.12	;	FGFR1 kinase complex with inhibitor SN36985
6C18	;	2.3	;	FGFR1 kinase complex with inhibitor SN37115
6C1C	;	2.15	;	FGFR1 kinase complex with inhibitor SN37116
6C1B	;	2.0	;	FGFR1 kinase complex with inhibitor SN37118
7OZF	;	1.82	;	FGFR1 kinase domain (residues 458-765) with mutations C488A, C584S in complex with 19.
7OZD	;	1.82	;	FGFR1 kinase domain (residues 458-765) with mutations C488A, C584S in complex with 34.
7OZB	;	1.71	;	FGFR1 kinase domain (residues 458-765) with mutations C488A, C584S in complex with 38.
5UQ0	;	2.3	;	FGFR1 kinase domain complex with fragment 2,2-dimethyl-2,3-dihydrobenzofuran-7-carboxamide
5UR1	;	2.2	;	FGFR1 kinase domain complex with SN37333 in reversible binding mode
6C1O	;	2.29	;	FGFR1 kinase domain complexed with FIIN-1
8XLO	;	2.36	;	FGFR1 kinase domain with a dual-warhead covalent inhibitor CXF-007
8JMZ	;	1.988	;	FGFR1 kinase domain with sulfatinib
5A4C	;	2.09	;	FGFR1 ligand complex
5AM7	;	1.957	;	FGFR1 mutant with an inhibitor
8H75	;	3.75	;	FGFR2 in complex with YJ001
1OEC	;	2.4	;	FGFr2 kinase domain
7OZY	;	2.28	;	FGFR2 kinase domain (residues 461-763) in complex with 38.
8U1F	;	3.33	;	FGFR2 Kinase Domain Bound to Irreversible Inhibitor Cmpd 10
8SWE	;	2.24	;	FGFR2 Kinase Domain Bound to Reversible Inhibitor Cmpd 3
8E1X	;	2.68	;	FGFR2 kinase domain in complex with a Pyrazolo[1,5-a]pyrimidine analog (Compound 29)
3GRW	;	2.1	;	FGFR3 in complex with a Fab
2LZL	;		;	FGFR3tm
7DTZ	;	2.01	;	FGFR4 complex with a covalent inhibitor
6NVK	;	2.3	;	FGFR4 complex with BLU-554, N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide
6NVJ	;	2.3	;	FGFR4 complex with N-(2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-3-fluorophenyl)acrylamide
6NVH	;	1.9	;	FGFR4 complex with N-(2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-3-methylphenyl)acrylamide
6NVG	;	1.99	;	FGFR4 complex with N-(3,5-dichloro-2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)phenyl)acrylamide
6NVI	;	2.117	;	FGFR4 complex with N-(3-chloro-2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-5-fluorophenyl)acrylamide
6J6Y	;	2.15	;	FGFR4 D2 - Fab complex
4UXQ	;	1.85	;	FGFR4 in complex with Ponatinib
8XLQ	;	1.95	;	FGFR4 kinase domain with a dual-warhead covalent inhibitor CXF-007
7JT9	;	1.93	;	Fgr SH3 domain crystal structure
7N8R	;	1.2	;	FGTGFG segment from the Nucleoporin p54, residues 63-68
7SCG	;	3.0	;	FH210 bound Mu Opioid Receptor-Gi Protein Complex
1GXC	;	2.7	;	FHA domain from human Chk2 kinase in complex with a synthetic phosphopeptide
2JPE	;		;	FHA domain of NIPP1
7SA6	;	2.9	;	fHbp mutant 2416 bound to Fab JAR5
1FIT	;	1.85	;	FHIT (FRAGILE HISTIDINE TRIAD PROTEIN)
2FIT	;	1.9	;	FHIT (FRAGILE HISTIDINE TRIAD PROTEIN)
3FIT	;	2.4	;	FHIT (FRAGILE HISTIDINE TRIAD PROTEIN) IN COMPLEX WITH ADENOSINE/SULFATE AMP ANALOG
4FIT	;	2.5	;	FHIT-APO
5FIT	;	2.3	;	FHIT-SUBSTRATE ANALOG
6FIT	;	2.6	;	FHIT-TRANSITION STATE ANALOG
1BY3	;	2.74	;	FHUA FROM E. COLI
4CU4	;	2.3	;	FhuA from E. coli in complex with the lasso peptide microcin J25 (MccJ25)
1BY5	;	2.6	;	FHUA FROM E. COLI, WITH ITS LIGAND FERRICHROME
1FI1	;	2.9	;	FhuA in complex with lipopolysaccharide and rifamycin CGP4832
1K7S	;	2.6	;	FhuD complexed with albomycin-delta 2
8JOU	;	4.1	;	Fiber I and fiber-tail-adaptor of phage GP4
7QVI	;	3.0	;	Fiber-forming RubisCO derived from ancestral sequence reconstruction and rational engineering
8JMW	;	2.9	;	Fibril form of serine peptidase Vpr
5VSG	;	1.1	;	Fibrils of the super helical repeat peptide, SHR-FF, grown at elevated temperature
1N73	;	2.9	;	Fibrin D-Dimer, Lamprey complexed with the PEPTIDE LIGAND: GLY-HIS-ARG-PRO-AMIDE
4KTY	;	1.98	;	Fibrin-stabilizing factor with a bound ligand
2FFD	;	2.89	;	Fibrinogen Fragment D with ""A"" knob peptide mimic GPRVVE
6Y41	;	1.79	;	Fibrinogen-like globe domain of human ANGPTL2
6Y43	;	1.6	;	Fibrinogen-like globe domain of human ANGPTL6
6QNV	;	1.4	;	Fibrinogen-like globe domain of Human Tenascin-C
1AA0	;	2.2	;	FIBRITIN DELETION MUTANT E (BACTERIOPHAGE T4)
1AVY	;	1.85	;	FIBRITIN DELETION MUTANT M (BACTERIOPHAGE T4)
5EW8	;	1.63	;	FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
4UWC	;	1.96	;	Fibroblast growth factor receptor 1 kinase in complex with JK-P3
4UWB	;	2.31	;	Fibroblast growth factor receptor 1 kinase in complex with JK-P5
5NUD	;	2.5	;	FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE DOMAIN (449-753) IN COMPLEX WITH IRREVERSIBLE LIGAND CGA159527
5NWZ	;	2.37	;	FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE DOMAIN (449-753) IN COMPLEX WITH IRREVERSIBLE LIGAND CGA159527
3M7P	;	2.5	;	Fibronectin fragment
5EU0	;	1.6	;	FIC domain of Bep1 from Bartonella rochalimae in complex with BiaA
5CGL	;	2.35	;	Fic protein from Neisseria meningitidis (NmFic) mutant E102R in dimeric form
5CKL	;	0.99	;	Fic protein from Neisseria meningitidis (NmFic) mutant E156R in dimeric form
5CMT	;	0.99	;	Fic protein from Neisseria meningitidis (NmFic) mutant E156R Y183F in dimeric form
3S6A	;	2.2	;	Fic protein from NEISSERIA MENINGITIDIS in complex with AMPPNP
3SE5	;	1.7	;	Fic protein from NEISSERIA MENINGITIDIS mutant delta8 in complex with AMPPNP
3ZLM	;	2.0	;	Fic protein from Neisseria meningitidis mutant E186G in complex with AMPPNP
3SN9	;	3.03	;	Fic protein from NEISSERIA MENINGITIDIS mutant S182A/E186A in complex with AMPPNP
3ZEC	;	2.2	;	Fic protein from SHEWANELLA ONEIDENSIS (E73G mutant) in complex with AMPPNP
3ZCN	;	1.7	;	Fic protein from SHEWANELLA ONEIDENSIS in complex with ATP
5JJ7	;	3.749	;	Fic-1 (aa134 - 508 E274G) from C. elegans
5JJ6	;	2.907	;	Fic-1 (aa134 - 508) from C. elegans
4YYQ	;	1.594	;	Ficin A
4YYR	;	1.349	;	Ficin B crystal form I
4YYS	;	1.35	;	Ficin B crystal form II
4YYU	;	1.177	;	Ficin C crystal form I
4YYW	;	1.446	;	Ficin D2
4YYV	;	1.902	;	Ficin isoform C crystal form II
1EF3	;	2.8	;	FIDARESTAT BOUND TO HUMAN ALDOSE REDUCTASE
1AZZ	;	2.3	;	FIDDLER CRAB COLLAGENASE COMPLEXED TO ECOTIN
2AGO	;	2.85	;	Fidelity of Dpo4: effect of metal ions, nucleotide selection and pyrophosphorolysis
2AGP	;	2.9	;	Fidelity of Dpo4: effect of metal ions, nucleotide selection and pyrophosphorolysis
2AGQ	;	2.1	;	Fidelity of Dpo4: effect of metal ions, nucleotide selection and pyrophosphorolysis
1JN3	;	2.35	;	FIDELITY PROPERTIES AND STRUCTURE OF M282L MUTATOR MUTANT OF DNA POLYMERASE: SUBTLE STRUCTURAL CHANGES INFLUENCE THE MECHANISM OF NUCLEOTIDE DISCRIMINATION
4LYU	;	1.75	;	Fifteen minutes iron loaded frog M ferritin
4MN9	;	1.15	;	Fifteen minutes iron loaded frog M ferritin mutant H54Q
4OYN	;	1.43	;	Fifteen minutes iron loaded human H ferritin
6IAF	;	1.35	;	Fifteen minutes iron loaded Rana Catesbeiana H' ferritin variant H54N
1ADX	;		;	FIFTH EGF-LIKE DOMAIN OF THROMBOMODULIN (TMEGF5), NMR, 14 STRUCTURES
2ADX	;		;	FIFTH EGF-LIKE DOMAIN OF THROMBOMODULIN (TMEGF5), NMR, MINIMIZED AVERAGE STRUCTURE
8IMB	;	2.9	;	Filament interface structure of GAC with phosphate
6G2I	;	5.9	;	Filament of acetyl-CoA carboxylase and BRCT domains of BRCA1 (ACC-BRCT) at 5.9 A resolution
6G2H	;	4.6	;	Filament of acetyl-CoA carboxylase and BRCT domains of BRCA1 (ACC-BRCT) core at 4.6 A resolution
4HYY	;	2.603	;	Filament of octameric rings of DMC1 recombinase from Homo sapiens
8IMA	;	2.9	;	Filament structure of GAC with phosphate
7LRG	;	6.1	;	Filamentous actin decorated with human cardiac myosin binding protein C C2 domain
8CCN	;	3.5	;	Filamentous actin II from Plasmodium falciparum
5HBD	;	1.65	;	Filamentous Assembly of Green Fluorescent Protein Supported by a C-terminal fusion of 18-residues, viewed in space group C2
5HW9	;	3.0	;	Filamentous Assembly of Green Fluorescent Protein Supported by a C-terminal fusion of 18-residues, viewed in space group P21
5HGE	;	1.863	;	Filamentous Assembly of Green Fluorescent Protein Supported by a C-terminal fusion of 18-residues, viewed in space group P212121
6AS9	;	1.75	;	Filamentous Assembly of Green Fluorescent Protein Supported by a C-terminal fusion of 18-residues, viewed in space group P212121 form 2
1HGV	;	2.4	;	Filamentous Bacteriophage PH75
1HGZ	;	2.4	;	Filamentous Bacteriophage PH75
1HH0	;	2.4	;	Filamentous Bacteriophage PH75
3J1R	;	7.5	;	Filaments from Ignicoccus hospitalis Show Diversity of Packing in Proteins Containing N-terminal Type IV Pilin Helices
2WFN	;	3.2	;	Filamin A actin binding domain
2K7P	;		;	Filamin A Ig-like domains 16-17
2K7Q	;		;	Filamin A Ig-like domains 18-19
7SC4	;	1.85	;	filamin complex-1
7SFT	;		;	Filamin complex-2
3V69	;	2.2	;	Filia-N crystal structure
6KMF	;	3.6	;	FimA type V pilus from P.gingivalis
5NKT	;	1.5	;	FimA wt from E. coli
5LP9	;	0.886266	;	FimA wt from S. flexneri
1KIU	;	3.0	;	FimH adhesin Q133N mutant-FimC chaperone complex with methyl-alpha-D-mannose
1TR7	;	2.1	;	FimH adhesin receptor binding domain from uropathogenic E. coli
1KLF	;	2.79	;	FIMH ADHESIN-FIMC CHAPERONE COMPLEX WITH D-MANNOSE
7BHD	;	1.4	;	FimH in complex with alpha1,6 core-fucosylated oligomannose-3, crystallized in the trigonal space group
8BXY	;	1.45	;	FimH in complex with alpha1,6 core-fucosylated oligomannose-3, crystallized in the trigonal space group
4ATT	;	1.251	;	FimH lectin domain co-crystal with a alpha-D-mannoside O-linked to a propynyl para methoxy phenyl
4AV4	;	1.9	;	FimH lectin domain co-crystal with a alpha-D-mannoside O-linked to a propynyl pyridine
4AUJ	;	1.527	;	FimH lectin domain co-crystal with a alpha-D-mannoside O-linked to para hydroxypropargyl phenyl
8BVD	;	2.995	;	FimH lectin domain in complex with mannose C-linked to quinoline
7QUO	;	3.0	;	FimH lectin domain in complex with oligomannose-6
8BY3	;	3.186	;	FimH lectin domain in complex with oligomannose-6
8G4U	;	2.9	;	Final ketosynthase+acyltransferase of the erythromycin modular polyketide synthase
4EKH	;	1.75	;	Final Thaumatin Structure for Radiation Damage Experiment at 100 K
4EKT	;	1.75	;	Final Thaumatin Structure for Radiation Damage Experiment at 180 K
4EL3	;	1.95	;	Final Thaumatin Structure for Radiation Damage Experiment at 240 K
4EKA	;	1.55	;	Final Thaumatin Structure for Radiation Damage Experiment at 25 K
4ELA	;	2.0	;	Final Thaumatin Structure for Radiation Damage Experiment at 300 K
4EPB	;	1.75	;	Final Urease Structure for Radiation Damage Experiment at 100 K
4EPE	;	2.05	;	Final Urease Structure for Radiation Damage Experiment at 300 K
1PBP	;	1.9	;	FINE TUNING OF THE SPECIFICITY OF THE PERIPLASMIC PHOSPHATE TRANSPORT RECEPTOR: SITE-DIRECTED MUTAGENESIS, LIGAND BINDING, AND CRYSTALLOGRAPHIC STUDIES
3PSL	;	1.7	;	Fine-tuning the stimulation of MLL1 methyltransferase activity by a histone H3 based peptide mimetic
3GED	;	1.698	;	Fingerprint and Structural Analysis of a Apo SCOR enzyme from Clostridium thermocellum
3GEG	;	2.102	;	Fingerprint and Structural Analysis of a SCOR enzyme with its bound cofactor from Clostridium thermocellum
1LCI	;	2.0	;	FIREFLY LUCIFERASE
3IEP	;	2.1	;	Firefly luciferase apo structure (P41 form)
3IER	;	2.05	;	Firefly luciferase apo structure (P41 form) with PEG 400 bound
1BA3	;	2.2	;	FIREFLY LUCIFERASE IN COMPLEX WITH BROMOFORM
3IES	;	2.0	;	Firefly luciferase inhibitor complex
8U66	;	2.21	;	Firmicutes Rubisco
2V9Q	;	2.5	;	First and second Ig domains from human Robo1
2V9R	;	2.0	;	First and second Ig domains from human Robo1 (Form 2)
6OXB	;	1.86	;	First bromo-adjacent homology (BAH) domain of human Polybromo-1 (PBRM1)
5N16	;	1.76	;	First Bromodomain (BD1) from Candida albicans Bdf1 bound to a dibenzothiazepinone (compound 1)
5N17	;	1.6	;	First Bromodomain (BD1) from Candida albicans Bdf1 bound to a dibenzothiazepinone (compound 3)
5N15	;	2.37	;	First Bromodomain (BD1) from Candida albicans Bdf1 in the unbound form
5TCM	;	2.2	;	First Bromodomain from Leishmania donovani LdBPK.091320 complexed with BI-2536
5D24	;	1.65	;	First bromodomain of BRD4 bound to inhibitor XD26
5D25	;	1.7	;	First bromodomain of BRD4 bound to inhibitor XD27
5D26	;	1.82	;	First bromodomain of BRD4 bound to inhibitor XD28
5D3H	;	1.7	;	First bromodomain of BRD4 bound to inhibitor XD29
5D3J	;	1.7	;	First bromodomain of BRD4 bound to inhibitor XD33
5D3L	;	1.5	;	First bromodomain of BRD4 bound to inhibitor XD35
5D3N	;	2.15	;	First bromodomain of BRD4 bound to inhibitor XD40
5D3P	;	1.95	;	First bromodomain of BRD4 bound to inhibitor XD41
5D3R	;	2.2	;	First bromodomain of BRD4 bound to inhibitor XD42
5D3S	;	1.75	;	First bromodomain of BRD4 bound to inhibitor XD44
5D3T	;	1.93	;	First bromodomain of BRD4 bound to inhibitor XD47
7UGF	;	1.45	;	First bromodomain of BRD4 liganded with BMS-536924
8FVK	;	1.53	;	First bromodomain of BRD4 liganded with CCS-1477
7UTY	;	1.55	;	First bromodomain of BRD4 liganded with compound 2c
7UUU	;	1.52	;	First bromodomain of BRDT liganded with compound 2c
2FWS	;		;	First Ca2+ binding domain of the Na,Ca-exchanger (NCX1)
7UVG	;	1.77	;	First cohesin of Sca5 from Ruminococcus bromii
5DU9	;	1.6	;	First condensation domain of the calcium-dependent antibiotic synthetase in complex with substrate analogue 2a
5DUA	;	1.9	;	First condensation domain of the calcium-dependent antibiotic synthetase in complex with substrate analogue 3a
4PPO	;	1.73	;	First Crystal Structure for an Oxaliplatin-Protein Complex
1Q6V	;	1.86	;	First crystal structure of a C49 monomer PLA2 from the venom of Daboia russelli pulchella at 1.8 A resolution
2QZ6	;	2.26	;	First crystal structure of a psychrophile class C beta-lactamase
3P59	;	2.1793	;	First Crystal Structure of a RNA Nanosquare
4CE5	;	1.63	;	First crystal structure of an (R)-selective omega-transaminase from Aspergillus terreus
3RWK	;	2.1	;	First crystal structure of an endo-inulinase, from Aspergillus ficuum: structural analysis and comparison with other GH32 enzymes.
3SC7	;	1.5	;	First crystal structure of an endo-inulinase, from Aspergillus ficuum: structural analysis and comparison with other GH32 enzymes.
5I82	;	2.35	;	First Crystal Structure of E.coli Based Recombinant Diphtheria Toxin Mutant CRM197
6R3R	;	1.65	;	First crystal structure of endo-levanase BT1760 from Bacteroides thetaiotaomicron
6S6R	;	1.58001	;	First crystal structure of parasitic PEX14 in complex with a fragment molecule 1H-indole-7-carboxylic acid
6FO5	;	0.95	;	FIRST DOMAIN OF HUMAN BROMODOMAIN BRD4 IN COMPLEX WITH INHIBITOR #17
5EIS	;	1.6	;	FIRST DOMAIN OF HUMAN BROMODOMAIN BRD4 IN COMPLEX WITH INHIBITOR 3-(4-Chlorobenzyl)-7-ethyl-3,7-dihydropurine-2,6-dione
5EGU	;	2.21	;	FIRST DOMAIN OF HUMAN BROMODOMAIN BRD4 IN COMPLEX WITH INHIBITOR 3-Butyl-8-(6-butyl-5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylsulfanylmethyl)-7-ethyl-3,7-dihydropurine-2,6-dione
5DLZ	;	1.7	;	FIRST DOMAIN OF HUMAN BROMODOMAIN BRD4 IN COMPLEX WITH INHIBITOR 4-[(1-methyl-2-oxo-1,2-dihydroquinolin-4-yl)oxy]-N-({1-[(3-methylphe methyl]piperidin-4-yl}methyl)butanamide
5EI4	;	1.05	;	First domain of human bromodomain BRD4 in complex with inhibitor 8-(5-Amino-1H-[1,2,4]triazol-3-ylsulfanylmethyl)-3-(4-chlorobenzyl)-7-ethyl-3,7-dihydropurine-2,6-dione
6FNX	;	1.19	;	FIRST DOMAIN OF HUMAN BROMODOMAIN BRD4 IN COMPLEX WITH INHIBITOR F1
5DLX	;	1.9	;	FIRST DOMAIN OF HUMAN BROMODOMAIN BRD4 IN COMPLEX WITH INHIBITOR N-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-1-{3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-6-yl}piperidine-4-carboxamide
2B7E	;		;	First FF domain of Prp40 Yeast Protein
6GZ8	;	1.0	;	First GerMN domain of the sporulation protein GerM from Bacillus subtilis
3NJW	;	0.86	;	First High Resolution Crystal Structure of a Lasso Peptide
1V40	;	1.9	;	First Inhibitor Complex Structure of Human Hematopoietic Prostaglandin D Synthase
7EDO	;	2.7	;	First insight into marsupial MHC I peptide presentation: immune features of lower mammals paralleled with bats
8PPO	;	2.0	;	First Intermediate Amyloid (FIA) - Tau
3F7Q	;	1.75	;	First pair of Fibronectin type III domains and part of the connecting segment of the integrin beta4
3F7R	;	2.036	;	First pair of Fibronectin type III domains and part of the connecting segment of the integrin beta4
2KQB	;		;	First PBZ domain of human APLF protein
2KQD	;		;	First PBZ domain of human APLF protein in complex with ribofuranosyladenosine
1G9O	;	1.5	;	FIRST PDZ DOMAIN OF THE HUMAN NA+/H+ EXCHANGER REGULATORY FACTOR
1FU2	;		;	FIRST PROTEIN STRUCTURE DETERMINED FROM X-RAY POWDER DIFFRACTION DATA
1FUB	;		;	FIRST PROTEIN STRUCTURE DETERMINED FROM X-RAY POWDER DIFFRACTION DATA
7NZC	;	1.111	;	First SH3 domain of POSH (Plenty of SH3 Domains protein)
7RCC	;	2.45	;	First stage engineered variant of I-OnuI after initial reassembly
1SLP	;		;	FIRST STEM LOOP OF THE SL1 RNA FROM CAENORHABDITIS ELEGANS, NMR, 16 STRUCTURES
1SLO	;		;	FIRST STEM LOOP OF THE SL1 RNA FROM CAENORHABDITIS ELEGANS, NMR, MINIMIZED AVERAGE STRUCTURE
1KPM	;	1.8	;	First Structural Evidence of a Specific Inhibition of Phospholipase A2 by Vitamin E and its Implications in Inflammation: Crystal Structure of the Complex Formed between Phospholipase A2 and Vitamin E at 1.8 A Resolution.
3ERH	;	2.4	;	First structural evidence of substrate specificity in mammalian peroxidases: Crystal structures of substrate complexes with lactoperoxidases from two different species
3ERI	;	2.5	;	First structural evidence of substrate specificity in mammalian peroxidases: Crystal structures of substrate complexes with lactoperoxidases from two different species
1FV0	;	1.7	;	FIRST STRUCTURAL EVIDENCE OF THE INHIBITION OF PHOSPHOLIPASE A2 BY ARISTOLOCHIC ACID: CRYSTAL STRUCTURE OF A COMPLEX FORMED BETWEEN PHOSPHOLIPASE A2 AND ARISTOLOCHIC ACID
4O8A	;	2.0	;	First structure of a proline utilization A proline dehydrogenase domain
1IAG	;	2.0	;	FIRST STRUCTURE OF A SNAKE VENOM METALLOPROTEINASE: A PROTOTYPE FOR MATRIX METALLOPROTEINASES(SLASH)COLLAGENASES
4CGV	;	2.54	;	First TPR of Spaghetti (RPAP3) bound to HSP90 peptide SRMEEVD
2X2U	;	2.0	;	First two Cadherin-like domains from Human RET
6H7X	;	2.892	;	First X-ray structure of full-length human RuvB-Like 2.
4RBY	;	1.19	;	First X-ray structure of RNA containing guanosine phosphorodithioate
7ND1	;		;	First-in-class small molecule inhibitors of Polycomb Repressive Complex 1 (PRC1) RING domain
3V4J	;	2.04	;	First-In-Class Small Molecule Inhibitors of the Single-strand DNA Cytosine Deaminase APOBEC3G
3V4K	;	1.38	;	First-In-Class Small Molecule Inhibitors of the Single-strand DNA Cytosine Deaminase APOBEC3G
6GST	;	2.2	;	FIRST-SPHERE AND SECOND-SPHERE ELECTROSTATIC EFFECTS IN THE ACTIVE SITE OF A CLASS MU GLUTATHIONE TRANSFERASE
6GSU	;	1.85	;	FIRST-SPHERE AND SECOND-SPHERE ELECTROSTATIC EFFECTS IN THE ACTIVE SITE OF A CLASS MU GLUTATHIONE TRANSFERASE
6GSV	;	1.75	;	FIRST-SPHERE AND SECOND-SPHERE ELECTROSTATIC EFFECTS IN THE ACTIVE SITE OF A CLASS MU GLUTATHIONE TRANSFERASE
6GSW	;	1.85	;	FIRST-SPHERE AND SECOND-SPHERE ELECTROSTATIC EFFECTS IN THE ACTIVE SITE OF A CLASS MU GLUTATHIONE TRANSFERASE
6GSX	;	1.91	;	FIRST-SPHERE AND SECOND-SPHERE ELECTROSTATIC EFFECTS IN THE ACTIVE SITE OF A CLASS MU GLUTATHIONE TRANSFERASE
6GSY	;	2.2	;	FIRST-SPHERE AND SECOND-SPHERE ELECTROSTATIC EFFECTS IN THE ACTIVE SITE OF A CLASS MU GLUTATHIONE TRANSFERASE
7YA9	;	1.7	;	Fis1 (Mitochondrial fission 1 protein)
2I2Q	;	1.72	;	Fission Yeast cofilin
2R6P	;	24.0	;	Fit of E protein and Fab 1A1D-2 into 24 angstrom resolution cryoEM map of Fab complexed with dengue 2 virus.
2BGY	;	9.0	;	Fit of the x-ray structure of the baterial flagellar hook fragment flge31 into an EM map from the hook of Caulobacter crescentus.
5ZUF	;	6.8	;	Fit R10 Fab coordinates into the cryo-EM of EV71 in complex with A9
5ZUD	;	4.9	;	Fit R10 Fab coordinates into the cryo-EM of EV71 in complex with D6
2BSQ	;	3.0	;	FitAB bound to DNA
3J0J	;	9.7	;	Fitted atomic models of Thermus thermophilus V-ATPase subunits into cryo-EM map
2C7D	;	8.7	;	Fitted coordinates for GroEL-ADP7-GroES Cryo-EM complex (EMD-1181)
2C7C	;	7.7	;	FITTED COORDINATES FOR GROEL-ATP7-GROES CRYO-EM COMPLEX (EMD-1180)
4V93	;	8.1	;	Fitted coordinates for Lumbricus terrestris hemoglobin cryo-EM complex (EMD-2627)
8D87	;	27.2	;	Fitted crystal structure of the homotrimer of fusion glycoprotein E1 from SFV into subtomogram averaged CHIKV E1 glycoprotein density
2YBB	;	19.0	;	Fitted model for bovine mitochondrial supercomplex I1III2IV1 by single particle cryo-EM (EMD-1876)
6UT7	;	4.26	;	Fitted model for the tetradecameric assembly of Thermococcus gammatolerans McrB AAA+ hexamers with bound McrC
4A82	;	9.0	;	Fitted model of staphylococcus aureus sav1866 model ABC transporter in the human cystic fibrosis transmembrane conductance regulator volume map EMD-1966.
2P8Y	;	11.7	;	Fitted structure of ADPR-eEF2 in the 80S:ADPR-eEF2:GDP:sordarin cryo-EM reconstruction
2P8X	;	9.7	;	Fitted structure of ADPR-eEF2 in the 80S:ADPR-eEF2:GDPNP cryo-EM reconstruction
2P8Z	;	8.9	;	Fitted structure of ADPR-eEF2 in the 80S:ADPR-eEF2:GDPNP:sordarin cryo-EM reconstruction
2P8W	;	11.3	;	Fitted structure of eEF2 in the 80S:eEF2:GDPNP cryo-EM reconstruction
5KHE	;	35.0	;	Fitted structure of rubella virus capsid protein
5KHF	;	35.0	;	Fitted structure of rubella virus capsid protein
2QZD	;	14.0	;	Fitted structure of SCR4 of DAF into cryoEM density
1EG0	;	11.5	;	FITTING OF COMPONENTS WITH KNOWN STRUCTURE INTO AN 11.5 A CRYO-EM MAP OF THE E.COLI 70S RIBOSOME
1LS2	;	16.8	;	Fitting of EF-Tu and tRNA in the Low Resolution Cryo-EM Map of an EF-Tu Ternary Complex (GDP and Kirromycin) Bound to E. coli 70S Ribosome
3J93	;	8.8	;	Fitting of Fab into the cryoEM density map of EV71 procapsid in complex with Fab22A12
1PDF	;	12.0	;	Fitting of gp11 crystal structure into 3D cryo-EM reconstruction of bacteriophage T4 baseplate-tail tube complex
3FOI	;	16.0	;	Fitting of gp18M crystal structure into 3D cryo-EM reconstruction of bacteriophage T4 contracted tail
3FOH	;	15.0	;	Fitting of gp18M crystal structure into 3D cryo-EM reconstruction of bacteriophage T4 extended tail
1PDJ	;	12.0	;	Fitting of gp27 into cryoEM reconstruction of bacteriophage T4 baseplate
1PDL	;	12.0	;	Fitting of gp5 in the cryoEM reconstruction of the bacteriophage T4 baseplate
1PDM	;	12.0	;	Fitting of gp8 structure into the cryoEM reconstruction of the bacteriophage T4 baseplate
1TJA	;	16.0	;	Fitting of gp8, gp9, and gp11 into the cryo-EM reconstruction of the bacteriophage T4 contracted tail
1PDP	;	12.0	;	Fitting of gp9 structure into the bacteriophage T4 baseplate cryoEM reconstruction
2AGN	;	15.0	;	Fitting of hepatitis C virus internal ribosome entry site domains into the 15 A Cryo-EM map of a HCV IRES-80S ribosome (H. sapiens) complex
2WFS	;	12.0	;	Fitting of influenza virus NP structure into the 9-fold symmetryzed cryoEM reconstruction of an active RNP particle.
1JQS	;	18.0	;	Fitting of L11 protein and elongation factor G (domain G' and V) in the cryo-em map of E. coli 70S ribosome bound with EF-G and GMPPCP, a nonhydrolysable GTP analog
1JQM	;	18.0	;	Fitting of L11 protein and elongation factor G (EF-G) in the cryo-em map of e. coli 70S ribosome bound with EF-G, GDP and fusidic acid
1JQT	;	18.0	;	Fitting of L11 protein in the low resolution cryo-EM map of E.coli 70S ribosome
4BX4	;	8.7	;	Fitting of the bacteriophage Phi8 P1 capsid protein into cryo-EM density
3J0H	;	18.0	;	Fitting of the bacteriophage phiKZ gp29PR structure into the cryo-EM density map of the phiKZ extended tail sheath
1PDI	;	12.0	;	Fitting of the C-terminal part of the short tail fibers into the cryo-EM reconstruction of T4 baseplate
3DNY	;	12.6	;	Fitting of the eEF2 crystal structure into the cryo-EM density map of the eEF2.80S.AlF4-.GDP complex
2FL8	;	12.0	;	Fitting of the gp10 trimer structure into the cryoEM map of the bacteriophage T4 baseplate in the hexagonal conformation.
3H3W	;	12.0	;	Fitting of the gp6 crystal structure into 3D cryo-EM reconstruction of bacteriophage T4 dome-shaped baseplate
3H3Y	;	16.0	;	Fitting of the gp6 crystal structure into 3D cryo-EM reconstruction of bacteriophage T4 star-shaped baseplate
1ZKU	;	15.0	;	Fitting of the gp9 structure in the EM density of bacteriophage T4 extended tail
2XQL	;	19.5	;	Fitting of the H2A-H2B histones in the electron microscopy map of the complex Nucleoplasmin:H2A-H2B histones (1:5).
3J0I	;	19.0	;	Fitting of the phiKZ gp29PR structure into the cryo-EM density map of the phiKZ polysheath
3ZBI	;	8.5	;	Fitting result in the O-layer of the subnanometer structure of the bacterial pKM101 type IV secretion system core complex digested with elastase
3ZBJ	;	8.5	;	Fitting results in the I-layer of the subnanometer structure of the bacterial pKM101 type IV secretion system core complex digested with elastase
1MJ1	;	13.0	;	FITTING THE TERNARY COMPLEX OF EF-Tu/tRNA/GTP AND RIBOSOMAL PROTEINS INTO A 13 A CRYO-EM MAP OF THE COLI 70S RIBOSOME
1DUT	;	1.9	;	FIV DUTP PYROPHOSPHATASE
4FIV	;	1.8	;	FIV PROTEASE COMPLEXED WITH AN INHIBITOR LP-130
1GVV	;	1.05	;	Five Atomic Resolution Structures of Endothiapepsin Inhibitor Complexes; implications for the Aspartic Proteinase Mechanism
4LYX	;	1.23	;	five minutes iron loaded frog M ferritin
4ZJK	;	1.56	;	FIVE MINUTES IRON LOADED HUMAN H FERRITIN
5J93	;	1.1	;	Five minutes iron loaded Rana Catesbeiana H' ferritin variant E57A/E136A/D140A
2RDK	;	1.35	;	Five site mutated Cyanovirin-N with Mannose dimer bound
1QHP	;	1.7	;	FIVE-DOMAIN ALPHA-AMYLASE FROM BACILLUS STEAROTHERMOPHILUS, MALTOSE COMPLEX
1QHO	;	1.7	;	FIVE-DOMAIN ALPHA-AMYLASE FROM BACILLUS STEAROTHERMOPHILUS, MALTOSE/ACARBOSE COMPLEX
2GLI	;	2.6	;	FIVE-FINGER GLI/DNA COMPLEX
1AJL	;		;	FIVE-NUCLEOTIDE BULGE LOOP FROM TETRAHYMENA THERMOPHILA GROUP I INTRON
1AJT	;		;	FIVE-NUCLEOTIDE BULGE LOOP FROM TETRAHYMENA THERMOPHILA GROUP I INTRON, NMR, 1 STRUCTURE
7ASX	;	1.8	;	Fixed-target serial femtosecond crystallography using in cellulo grown Neurospora crassa HEX-1 microcrystals. (Chip 1)
7ASI	;	1.704	;	Fixed-target serial femtosecond crystallography using in cellulo grown Neurospora crassa HEX-1 microcrystals. (Chips 1+2)
5J5U	;	2.3	;	Fjoh_4561 chitin-binding protein
1FKD	;	1.72	;	FK-506 BINDING PROTEIN: THREE-DIMENSIONAL STRUCTURE OF THE COMPLEX WITH THE ANTAGONIST L-685,818
2FKE	;	1.72	;	FK-506-BINDING PROTEIN: THREE-DIMENSIONAL STRUCTURE OF THE COMPLEX WITH THE ANTAGONIST L-685,818
3O5L	;	1.3	;	Fk1 domain mutant A19T of FKBP51, crystal form I
3O5M	;	1.6	;	Fk1 domain mutant A19T of FKBP51, crystal form II
3O5O	;	1.15	;	Fk1 domain mutant A19T of FKBP51, crystal form III
3O5P	;	1.0	;	Fk1 domain mutant A19T of FKBP51, crystal form IV
3O5Q	;	0.96	;	Fk1 domain mutant A19T of FKBP51, crystal form IV, in presence of DMSO
3O5G	;	2.0	;	Fk1 domain of FKBP51, crystal form I
3O5I	;	1.8	;	Fk1 domain of FKBP51, crystal form II
3O5J	;	1.7	;	Fk1 domain of FKBP51, crystal form III
3O5E	;	1.6	;	Fk1 domain of FKBP51, crystal form VI
3O5F	;	1.65	;	Fk1 domain of FKBP51, crystal form VII
3O5K	;	2.7	;	Fk1 domain of FKBP51, crystal form VIII
1QPL	;	2.9	;	FK506 BINDING PROTEIN (12 KDA, HUMAN) COMPLEX WITH L-707,587
1QPF	;	2.5	;	FK506 BINDING PROTEIN (12 KDA, HUMAN) COMPLEX WITH L-709,858
1J4R	;	1.8	;	FK506 BINDING PROTEIN COMPLEXED WITH FKB-001
1BKF	;	1.6	;	FK506 BINDING PROTEIN FKBP MUTANT R42K/H87V COMPLEX WITH IMMUNOSUPPRESSANT FK506
1EYM	;	2.0	;	FK506 BINDING PROTEIN MUTANT, HOMODIMERIC COMPLEX
2PBC	;	1.8	;	FK506-binding protein 2
2DG4	;	1.7	;	FK506-binding protein mutant WF59 complexed with Rapamycin
2DG9	;	1.7	;	FK506-binding protein mutant WL59 complexed with Rapamycin
1R2J	;	2.1	;	FkbI for Biosynthesis of Methoxymalonyl Extender Unit of Fk520 Polyketide Immunosuppresant
1D7J	;	1.85	;	FKBP COMPLEXED WITH 4-HYDROXY-2-BUTANONE
1D7H	;	1.9	;	FKBP COMPLEXED WITH DMSO
1D7I	;	1.9	;	FKBP COMPLEXED WITH METHYL METHYLSULFINYLMETHYL SULFIDE (DSS)
1BL4	;	1.9	;	FKBP MUTANT F36V COMPLEXED WITH REMODELED SYNTHETIC LIGAND
1AUE	;	2.33	;	FKBP-RAPAMYCIN BINDING DOMAIN (FRB) OF THE FKBP-RAPAMYCIN ASSOCIATED PROTEIN
8PDF	;	1.2	;	FKBP12 in complex with PROTAC 6a2
6YF3	;	1.0	;	FKBP12 in complex with the BMP potentiator compound 10 at 1.00A resolution
6YF2	;	1.03	;	FKBP12 in complex with the BMP potentiator compound 6 at 1.03A resolution
6YF1	;	1.12	;	FKBP12 in complex with the BMP potentiator compound 8 at 1.12A resolution
6YF0	;	1.55	;	FKBP12 in complex with the BMP potentiator compound 9 at 1.55 A resolution
7U8D	;	1.39	;	FKBP12 mutant V55G bound to Rapa*-3Z
1A7X	;	2.0	;	FKBP12-FK1012 COMPLEX
8ER6	;	2.81	;	FKBP12-FRB in Complex with Compound 11
8ER7	;	3.07	;	FKBP12-FRB in Complex with Compound 12
4NNR	;	1.98	;	FKBP13-FK506 Complex
8ETI	;	3.7	;	Fkbp39 associated 60S nascent ribosome State 1
8ETJ	;	3.2	;	Fkbp39 associated 60S nascent ribosome State 2
8ETG	;	3.4	;	Fkbp39 associated 60S nascent ribosome State 3
8ETC	;	3.1	;	Fkbp39 associated nascent 60S ribosome State 4
8PJA	;	1.6	;	FKBP51FK1 F67E/K58 (i, i+9) in complex with SAFit1
8PJ8	;	1.5	;	FKBP51FK1 F67E/K60Orn (i, i+7) in complex with SAFit1
5XMM	;	2.9	;	FLA-E*01801-167W/S
3CS1	;	2.0	;	Flagellar Calcium-binding Protein (FCaBP) from T. cruzi
1ORJ	;	2.25	;	FLAGELLAR EXPORT CHAPERONE
1ORY	;	2.45	;	FLAGELLAR EXPORT CHAPERONE IN COMPLEX WITH ITS COGNATE BINDING PARTNER
8JMV	;	2.9	;	Flagellar fibrils from Bacillus amyloliquefaciens
6NQW	;	1.9	;	Flagellar protein FcpA from Leptospira biflexa - hexagonal form
6NQY	;	2.5	;	Flagellar protein FcpA from Leptospira biflexa / ab-centered monoclinic form
6NQX	;	2.95	;	Flagellar protein FcpA from Leptospira biflexa / primitive monoclinic form
6NQZ	;	2.58	;	Flagellar protein FcpB from Leptospira interrogans
5YUD	;	4.28	;	Flagellin derivative in complex with the NLR protein NAIP5
4YDS	;	2.3	;	FlaH from Sulfolobus acidocaldarius with ATP and Mg-Ion
5K97	;	2.102	;	Flap endonuclease 1 (FEN1) D233N with cleaved product fragment and Sm3+
5UM9	;	2.805	;	Flap endonuclease 1 (FEN1) D86N with 5'-flap substrate DNA and Sm3+
5KSE	;	2.105	;	Flap endonuclease 1 (FEN1) R100A with 5'-flap substrate DNA and Sm3+
1A76	;	2.0	;	FLAP ENDONUCLEASE-1 FROM METHANOCOCCUS JANNASCHII
1A77	;	2.0	;	FLAP ENDONUCLEASE-1 FROM METHANOCOCCUS JANNASCHII
8FEV	;	2.21	;	Flavanone 4-Reductase from Sorghum bicolor-NADP(H) and dihydroquercetin complex
8FEU	;	2.12	;	Flavanone 4-Reductase from Sorghum bicolor-NADP(H) and naringenin complex
8FET	;	2.202	;	Flavanone 4-Reductase from Sorghum bicolor-NADP(H) complex
8FEW	;	2.02	;	Flavanone 4-Reductase from Sorghum bicolor-naringenin complex
6I20	;	1.37	;	Flavin Analogue Sheds Light on Light-Oxygen-Voltage Domain Mechanism
6I21	;	1.5	;	Flavin Analogue Sheds Light on Light-Oxygen-Voltage Domain Mechanism
6I22	;	1.66	;	Flavin Analogue Sheds Light on Light-Oxygen-Voltage Domain Mechanism
6I23	;	2.0	;	Flavin Analogue Sheds Light on Light-Oxygen-Voltage Domain Mechanism
6I24	;	1.43	;	Flavin Analogue Sheds Light on Light-Oxygen-Voltage Domain Mechanism
6I25	;	1.97	;	Flavin Analogue Sheds Light on Light-Oxygen-Voltage Domain Mechanism
8CQS	;	1.7	;	Flavin mononucleotide-dependent nitroreductase B.thetaiotaomicron (BT_0217)
8CQT	;	2.2	;	Flavin mononucleotide-dependent nitroreductase B.thetaiotaomicron (BT_1316)
8CQU	;	1.8	;	Flavin mononucleotide-dependent nitroreductase B.thetaiotaomicron (BT_1680)
8CQV	;	1.7	;	Flavin mononucleotide-dependent nitroreductase B.thetaiotaomicron (BT_3392)
4C5O	;	2.6	;	Flavin monooxygenase from Stenotrophomonas maltophilia. Q193R H194T mutant
1RZ0	;	2.2	;	Flavin reductase PheA2 in native state
6NXI	;	1.61	;	Flavin Transferase ApbE from Vibrio cholerae
6NXJ	;	1.92	;	Flavin Transferase ApbE from Vibrio cholerae, H257G mutant
5Z8T	;	2.33	;	Flavin-containing monooxygenase
4A9W	;	2.72	;	Flavin-containing monooxygenase from Stenotrophomonas maltophilia
5IOR	;	1.95	;	Flavin-dependent thymidylate synthase in complex with FAD and 2'-deoxyuridine-5'-monosulfate
5IOQ	;	1.93	;	Flavin-dependent thymidylate synthase in complex with FAD and deoxyuridine
5IOT	;	2.0	;	Flavin-dependent thymidylate synthase R174A variant in complex with FAD and dUMP
5IOS	;	1.9	;	Flavin-dependent thymidylate synthase R90A variant in complex with FAD and deoxyuridine monophosphate
5JFE	;	2.03	;	Flavin-dependent thymidylate synthase with H2-dUMP
6H43	;	2.2	;	Flavin-dependent Tryptophan 6-halogenase Thal
8AD8	;	2.95	;	Flavin-dependent tryptophan 6-halogenase Thal in complex with a D-Trp-Ser dipeptide
8AD7	;	2.33	;	Flavin-dependent tryptophan 6-halogenase Thal in complex with D-Trp
6SLS	;	2.32	;	Flavin-dependent tryptophan 6-halogenase Thal in complex with FAD
6H44	;	2.55	;	Flavin-dependent Tryptophan 6-halogenase Thal in complex with tryptophan
6SLT	;	2.7	;	Flavin-dependent tryptophan 6-halogenase Thal in complex with tryptophan and FAD
7AQU	;	1.63	;	Flavin-dependent tryptophan halogenase Thal: N-terminally His-tagged form of quintuple mutant (NHis-Thal-RebH5)
7AQV	;	1.84	;	Flavin-dependent tryptophan halogenase Thal: N-terminally His-tagged form of quintuple mutant (NHis-Thal-RebH5)
6KET	;	1.6	;	Flavin-utilizing Monooxygenase (OX) Domain of Hybrid Polyketide/Non-Ribosomal Peptide Synthetase
3G4C	;	2.05	;	Flavine dependant thymidylate syntahse S88C mutant
5NJU	;	2.1	;	Flavivirus NS5 domain
5NJV	;	2.0	;	Flavivirus NS5 domain
4DIK	;	1.75	;	Flavo Di-iron protein H90A mutant from Thermotoga maritima
5V8S	;	1.41	;	Flavo di-iron protein H90D mutant from Thermotoga maritima
4DIL	;	2.0	;	Flavo Di-iron protein H90N mutant from Thermotoga maritima
8A06	;	4.0	;	Flavobacterium infecting lipid-containing phage FLiP penton protein
6DQW	;	2.6	;	Flavobacterium johnsoniae class Id ribonucleotide reductase alpha subuint
6JR6	;	2.0	;	Flavobacterium johnsoniae GH31 dextranase, FjDex31A
6JR7	;	1.75	;	Flavobacterium johnsoniae GH31 dextranase, FjDex31A, complexed with glucose
6JR8	;	1.8	;	Flavobacterium johnsoniae GH31 dextranase, FjDex31A, mutant D412A complexed with isomaltotriose
1QCW	;	2.75	;	Flavocytochrome B2, ARG289LYS mutant
1QJD	;	1.8	;	Flavocytochrome C3 from Shewanella frigidimarina
1E39	;	1.8	;	Flavocytochrome C3 from Shewanella frigidimarina histidine 365 mutated to alanine
1Y0P	;	1.5	;	Flavocytochrome c3 with mesaconate bound
5LLD	;	2.651	;	Flavodiiron core of Escherichia coli flavorubredoxin in the reduced form.
1OFV	;	1.7	;	FLAVODOXIN FROM ANACYSTIS NIDULANS: REFINEMENT OF TWO FORMS OF THE OXIDIZED PROTEIN
3KAQ	;	2.25	;	Flavodoxin from D. desulfuricans (semireduced form)
3KAP	;	2.05	;	Flavodoxin from Desulfovibrio desulfuricans ATCC 27774 (oxidized form)
1FUE	;	2.4	;	FLAVODOXIN FROM HELICOBACTER PYLORI
2W5U	;	2.62	;	Flavodoxin from Helicobacter pylori in complex with the C3 inhibitor
1WSB	;	1.8	;	Flavodoxin mutant- S64C
1FDR	;	1.7	;	FLAVODOXIN REDUCTASE FROM E. COLI
1AG9	;	1.8	;	FLAVODOXINS THAT ARE REQUIRED FOR ENZYME ACTIVATION: THE STRUCTURE OF OXIDIZED FLAVODOXIN FROM ESCHERICHIA COLI AT 1.8 ANGSTROMS RESOLUTION.
7D38	;	2.649	;	flavone reductase
7D3A	;	2.552	;	flavone reductase
7D3B	;	2.25	;	flavone reductase
6G87	;	2.92	;	Flavonoid-responsive Regulator FrrA
6G8H	;	2.6	;	Flavonoid-responsive Regulator FrrA in complex with (R,S)-Naringenin
6G8G	;	2.6	;	Flavonoid-responsive Regulator FrrA in complex with Genistein
1C8K	;	1.76	;	FLAVOPIRIDOL INHIBITS GLYCOGEN PHOSPHORYLASE BY BINDING AT THE INHIBITOR SITE
1E1Y	;	2.23	;	Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site
1GFZ	;	2.3	;	FLAVOPIRIDOL INHIBITS GLYCOGEN PHOSPHORYLASE BY BINDING AT THE INHIBITOR SITE
1FVP	;	2.7	;	FLAVOPROTEIN 390
2D5M	;	1.05	;	Flavoredoxin of Desulfovibrio vulgaris (Miyazaki F)
6ZEP	;	1.61	;	Flavourzyme Leucine Aminopeptidase A proenzyme
4WXM	;	2.3	;	FleQ REC domain from Pseudomonas aeruginosa PAO1
2E2D	;	2.0	;	Flexibility and variability of TIMP binding: X-ray structure of the complex between collagenase-3/MMP-13 and TIMP-2
1WRP	;	2.2	;	FLEXIBILITY OF THE DNA-BINDING DOMAINS OF TRP REPRESSOR
3WRP	;	1.8	;	FLEXIBILITY OF THE DNA-BINDING DOMAINS OF TRP REPRESSOR
2MEZ	;		;	Flexible anchoring of archaeal MBF1 on ribosomes suggests role as recruitment factor
6IZB	;	1.899	;	Flexible loop truncated human TCTP
6NDV	;	1.502	;	FlgE D2 domain K336A mutant
5WRH	;	7.4	;	FlgG structure based on the CryoEM map of the bacterial flagellar polyrod
8FTX	;		;	FlgN-FliJ fusion complex
4YXB	;	2.56	;	FliM(SPOA)::FliN fusion protein
1M3V	;		;	FLIN4: Fusion of the LIM binding domain of Ldb1 and the N-terminal LIM domain of LMO4
5OAC	;	4.0	;	FLiP major capsid protein
8FTW	;		;	FliT-FliJ fusion complex
6G4A	;		;	FLN5 (full length)
4AHY	;	1.7	;	Flo5A cocrystallized with 3 mM GdAc3
4AHW	;	1.5	;	Flo5A showing a heptanuclear gadolinium cluster on its surface
4AI1	;	1.8	;	Flo5A showing a heptanuclear gadolinium cluster on its surface after 19 min of soaking
4AI2	;	1.79	;	Flo5A showing a heptanuclear gadolinium cluster on its surface after 41 min of soaking
4AHZ	;	1.9	;	Flo5A showing a heptanuclear gadolinium cluster on its surface after 60 min of soaking
4AI3	;	1.9	;	Flo5A showing a heptanuclear gadolinium cluster on its surface after 60 min of soaking
4AI0	;	1.8	;	Flo5A showing a heptanuclear gadolinium cluster on its surface after 9 min of soaking
4AHX	;	1.6	;	Flo5A showing a trinuclear gadolinium cluster on its surface
2AZ0	;	2.6	;	Flock House virus B2-dsRNA Complex (P212121)
2AZ2	;	2.6	;	Flock House virus B2-dsRNA Complex (P4122)
1WKP	;	2.6	;	Flowering locus t (ft) from arabidopsis thaliana
1FLO	;	2.65	;	FLP Recombinase-Holliday Junction Complex I
1P4E	;	2.7	;	Flpe W330F mutant-DNA Holliday Junction Complex
1M6X	;	2.8	;	Flpe-Holliday Junction Complex
7D39	;	2.198	;	FLR-apo
4V2D	;	2.5	;	FLRT2 LRR domain
4V2E	;	2.5	;	FLRT3 LRR domain
5CMN	;	3.605	;	FLRT3 LRR domain in complex with LPHN3 Olfactomedin domain
4NBE	;	2.1	;	Fluorene-bound oxygenase with Phe275 replaced by Trp and ferredoxin complex of carbazole 1,9a-dioxygenase (form2)
5T3K	;	2.142	;	Fluorescence detection of RNA-ligand binding and crystal structure determination of ribosomal decoding site RNA using a heavy atom containing fluorescent ribonucleoside
2A53	;	1.45	;	fluorescent protein asFP595, A143S, off-state
2A54	;	1.45	;	fluorescent protein asFP595, A143S, on-state, 1min irradiation
2A56	;	1.9	;	fluorescent protein asFP595, A143S, on-state, 5min irradiation
2A52	;	1.7	;	fluorescent protein asFP595, S158V, on-state
2A50	;	1.3	;	fluorescent protein asFP595, wt, off-state
5BQL	;	2.39	;	Fluorescent protein cyOFP
2BTJ	;	2.0	;	Fluorescent Protein EosFP - red form
6AA7	;	1.8	;	Fluorescent protein from Acropora digitifera
2WIS	;	2.35	;	Fluorescent protein KillerRed in the bleached state
2WIQ	;	2.0	;	Fluorescent protein KillerRed in the native state
2WHS	;	2.1	;	Fluorescent Protein mKeima at pH 3.8
2WHT	;	1.9	;	Fluorescent Protein mKeima at pH 5.6
2WHU	;	2.65	;	Fluorescent Protein mKeima at pH 8.0
7KKA	;	2.5	;	Fluoride channel Fluc-Ec2 mutant S81A with bromide
7KK9	;	3.1	;	Fluoride channel Fluc-Ec2 mutant S81A/T82A with bromide
7KKB	;	2.9	;	Fluoride channel Fluc-Ec2 mutant S81C with bromide
7KK8	;	2.7	;	Fluoride channel Fluc-Ec2 mutant S81T with bromide
7KKR	;	3.11	;	Fluoride channel Fluc-Ec2 wild-type with bromide
2AKM	;	1.92	;	Fluoride Inhibition of Enolase: Crystal Structure of the Inhibitory Complex
2AKZ	;	1.36	;	Fluoride Inhibition of Enolase: Crystal Structure of the Inhibitory Complex
1NEL	;	2.6	;	FLUORIDE INHIBITION OF YEAST ENOLASE: CRYSTAL STRUCTURE OF THE ENOLASE-MG2+-F--PI COMPLEX AT 2.6-ANGSTROMS RESOLUTION
1E6A	;	1.9	;	Fluoride-inhibited substrate complex of Saccharomyces cerevisiae inorganic pyrophosphatase
5LMZ	;	2.55	;	Fluorinase from Streptomyces sp. MA37
4CQJ	;	2.44	;	Fluorinase substrate flexibility enables last step aqueous and ambient 18F fluorination of a RGD peptide for positron emission tomography
6ZAM	;	1.55	;	Fluorine labeled IPNS S55C in complex with Fe and ACV under anaerobic conditions.
5HSU	;	1.46	;	Fluorine substituted 5-methyl-6-(2',4'-difluoromethoxyphenythio)thieno[2,3-d]pyrimidine-2,4-diamine
5HSR	;	1.21	;	Fluorine substituted 5-methyl-6-(3',4'-difluoromethoxyphenythio)thieno[2,3-d]pyrimidine-2,4-diamine
5HQZ	;	1.46	;	Fluorine substituted 5-methyl-6-(4'-trifluoromethoxyphenythio)thieno[2,3-d]pyrimidine-2,4-diamine
3NJ4	;	2.5	;	Fluoro-neplanocin A in Human S-Adenosylhomocysteine Hydrolase
7A43	;	1.75	;	Fluoroacetate Dehalogenase measured by serial femtosecond crystallography
7A42	;	1.75	;	Fluoroacetate Dehalogenase measured by serial synchrotron crystallography
6MUH	;	1.8	;	Fluoroacetate dehalogenase, room temperature structure solved by serial 1 degree oscillation crystallography
6MUY	;	1.8	;	Fluoroacetate dehalogenase, room temperature structure solved by serial 3 degree oscillation crystallography
6MZZ	;	1.8	;	Fluoroacetate dehalogenase, room temperature structure, using first 1 degree of total 3 degree oscillation
6N00	;	1.9	;	Fluoroacetate dehalogenase, room temperature structure, using last 1 degree of total 3 degree oscillation and 144 kGy dose
3RYX	;	1.6	;	Fluoroalkyl and Alkyl Chains Have Similar Hydrophobicities in Binding to the Hydrophobic Wall of Carbonic Anhydrase
3RYY	;	1.16	;	Fluoroalkyl and Alkyl Chains Have Similar Hydrophobicities in Binding to the Hydrophobic Wall of Carbonic Anhydrase
3RYZ	;	1.37	;	Fluoroalkyl and Alkyl Chains Have Similar Hydrophobicities in Binding to the Hydrophobic Wall of Carbonic Anhydrase
3RZ0	;	1.798	;	Fluoroalkyl and Alkyl Chains Have Similar Hydrophobicities in Binding to the Hydrophobic Wall of Carbonic Anhydrase
3RZ1	;	1.51	;	Fluoroalkyl and Alkyl Chains Have Similar Hydrophobicities in Binding to the Hydrophobic Wall of Carbonic Anhydrase
3RZ5	;	1.65	;	Fluoroalkyl and Alkyl Chains Have Similar Hydrophobicities in Binding to the Hydrophobic Wall of Carbonic Anhydrase
3RZ7	;	1.8	;	Fluoroalkyl and Alkyl Chains Have Similar Hydrophobicities in Binding to the Hydrophobic Wall of Carbonic Anhydrase
3RZ8	;	1.7	;	Fluoroalkyl and Alkyl Chains Have Similar Hydrophobicities in Binding to the Hydrophobic Wall of Carbonic Anhydrase
5J75	;	2.0	;	Fluorogen Activating Protein AM2.2 in complex with ML342
5J74	;	2.7	;	Fluorogen activating protein AM2.2 in complex with TO1-2p
6UBO	;	1.58	;	Fluorogen Activating Protein Dib1
3T0W	;	1.501	;	Fluorogen activating protein M8VL in complex with dimethylindole red
3T0X	;	1.96	;	Fluorogen Activating Protein M8VLA4(S55P) in complex with dimethylindole red
3RT6	;	2.836	;	Fluorowillardiine bound to the ligand binding domain of GluA3
6H0C	;	1.592	;	Flv1 flavodiiron core from Synechocystis sp. PCC6803
8D7F	;	2.62	;	FlvF from Aspergillus flavus in complex with Bis-Tris
7URV	;	3.05	;	FMC63 scFv in complex with soluble CD19
8HBG	;	3.6	;	FMDV (A/TUR/14/98) in complex with M678F
8HBI	;	2.9	;	FMDV (A/TUR/14/98) in complex with M688F
6S2L	;	2.3	;	FMDV 3D polymerase crystallized in presence of (F)uridylylated VPg peptide
8C1N	;	1.7	;	FMDV 3D polymerase in complex with 3B1 protein solved in P212121 space group
8C2P	;	1.85	;	FMDV 3D polymerase in complex with 3B3
5OYI	;	8.2	;	FMDV A10 dissociated pentamer
7DST	;	3.1	;	FMDV capsid in complex with M170 Nab
1QMY	;	1.9	;	FMDV LEADER PROTEASE (LBSHORT-C51A-C133S)
6FFA	;	1.5	;	FMDV Leader protease bound to substrate ISG15
8USM	;	1.63	;	FmlH Lectin Domain UTI89 - AM4085
4XOO	;	2.1	;	FMN complex of coenzyme F420:L-glutamate ligase (FbiB) from Mycobacterium tuberculosis (C-terminal domain)
7KGZ	;	2.4	;	FMN-binding beta-glucuronidase from Roseburia hominis
1AXJ	;		;	FMN-BINDING PROTEIN FROM DESULFOVIBRIO VULGARIS (MIYAZAKI F), NMR, 20 STRUCTURES
7EG5	;	1.96	;	FMN-bound form of YviC from Lactococcus lactis subsp. lactis Il1403
5J62	;	2.15	;	FMN-dependent Nitroreductase (CDR20291_0684) from Clostridium difficile R20291
5J6C	;	2.096	;	FMN-dependent Nitroreductase (CDR20291_0767) from Clostridium difficile R20291
7F2U	;	1.984	;	FmnB complexed with ADP
7ESC	;	2.201	;	FmnB complexed with AMP
7ESB	;	1.7	;	FmnB complexed with ATP
3EOJ	;	1.3	;	Fmo protein from Prosthecochloris Aestuarii 2K AT 1.3A Resolution
4BCL	;	1.9	;	FMO protein from Prosthecochloris aestuarii 2K at Room Temperature
8ON7	;	2.5	;	FMRFa-bound Malacoceros FaNaC1 in lipid nanodiscs
8ONA	;	3.0	;	FMRFa-bound Malacoceros FaNaC1 in lipid nanodiscs in presence of diminazene
4QVZ	;	3.195	;	FMRP N-terminal domain
4QW2	;	2.989	;	FMRP N-terminal domain (R138Q)
7ZAL	;	2.732	;	FNIP family proteins from Cafeteria roenbergensis virus (CroV): leucine-rich repeats with novel structural features
6J9L	;	1.78	;	FnoBH+AcrIIC2
3MHP	;	1.7	;	FNR-recruitment to the thylakoid
4FC4	;	2.4	;	FNT family ion channel
6ZA9	;	3.76	;	Fo domain of Ovine ATP synthase
2AEH	;	2.53	;	Focal adhesion kinase 1
4D4R	;	1.55	;	Focal Adhesion Kinase catalytic domain
4D4S	;	2.0	;	Focal Adhesion Kinase catalytic domain
4D4V	;	2.1	;	Focal Adhesion Kinase catalytic domain
4D4Y	;	1.8	;	Focal Adhesion Kinase catalytic domain
4D55	;	2.3	;	Focal Adhesion Kinase catalytic domain
4D5H	;	1.75	;	Focal Adhesion Kinase catalytic domain
4D5K	;	1.75	;	Focal Adhesion Kinase catalytic domain
4GU9	;	2.4	;	Focal adhesion kinase catalytic domain in complex with (2-Fluoro-phenyl)-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine
4KAO	;	2.39	;	FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-(4-pyridin-3- yl-phenyl)-urea
4K9Y	;	2.0	;	FOCAL ADHESION KINASE Catalytic domain in complex with 1-[4-(6-Amino-purin-9-yl)-phenyl]-3-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-urea
4KAB	;	2.71	;	FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-Methyl-1,4-dihydro-pyrazolo[4,5-c]pyrazole
6YVY	;	1.918	;	FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 4-{[4-{[(1R,2R)-2-(dimethylamino)cyclopentyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}-N-methylbenzenesulfonamide
6YVS	;	1.81	;	FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 5-{4-[(Pyridin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one
6YOJ	;	1.361	;	FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-1H-quinolin-2-one
4BRX	;	2.05	;	Focal Adhesion Kinase catalytic domain in complex with a diarylamino- 1,3,5-triazine inhibitor
4C7T	;	2.05	;	Focal Adhesion Kinase catalytic domain in complex with a diarylamino- 1,3,5-triazine inhibitor
2JKK	;	2.0	;	Focal Adhesion Kinase catalytic domain in complex with bis-anilino pyrimidine inhibitor
2JKM	;	2.31	;	Focal Adhesion Kinase catalytic domain in complex with bis-anilino pyrimidine inhibitor
2JKO	;	1.65	;	Focal Adhesion Kinase catalytic domain in complex with bis-anilino pyrimidine inhibitor
2JKQ	;	2.6	;	Focal Adhesion Kinase catalytic domain in complex with bis-anilino pyrimidine inhibitor
4D58	;	1.95	;	Focal Adhesion Kinase catalytic domain in complex with bis-anilino pyrimidine inhibitor
6GCR	;	2.3	;	Focal Adhesion Kinase catalytic domain in complex with irreversible inhibitor
6GCW	;	2.0	;	Focal Adhesion Kinase catalytic domain in complex with irreversible inhibitor
6GCX	;	1.553	;	Focal Adhesion Kinase catalytic domain in complex with irreversible inhibitor
6YR9	;	1.925	;	FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-Methyl-N-(2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide
6YQ1	;	1.784	;	FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-Methyl-N-(3-{[2-(2-oxo-1,2,3,4-tetrahydro-quinolin-6-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide
6YT6	;	1.537	;	FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-Methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide
6YXV	;	2.298	;	FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-Methyl-N-{3-[(2-phenylamino-5-trifluoromethyl-pyrimidin-4-ylamino)-methyl]-pyridin-2-yl}-methanesulfonamide
4GU6	;	1.95	;	FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-Cyano-2-phenyl-1H-pyrrolo[2,3-b]pyridin-4-ylamino)- methyl]-pyridin-2-yl}-N-methyl-methanesulfonamide
3PXK	;	1.79	;	FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH Pyrrolo[2,3-d]thiazole
6OG3	;	4.1	;	Focus classification structure of the hyperactive ClpB mutant K476C, bound to casein, NTD-trimer
6OG2	;	4.1	;	Focus classification structure of the hyperactive ClpB mutant K476C, bound to casein, post-state
6OG1	;	3.3	;	Focus classification structure of the hyperactive ClpB mutant K476C, bound to casein, pre-state
8BV5	;	3.54	;	Focus refinement of soluble domain of Adenylyl cyclase 8 bound to stimulatory G protein, Forskolin, ATPalphaS, and Ca2+/Calmodulin in lipid nanodisc conditions
7PDD	;	4.2	;	Focus refinement of soluble domain of Adenylyl cyclase 9 in complex with DARPin C4 and MANT-GTP
7PDF	;	3.8	;	focus refinement of soluble domain of adenylyl cyclase 9 in complex with Gs protein alpha subunit and MANT-GTP
8DTB	;	3.14	;	Focus/local refined map in C1 of signal subtracted RyR1 particles in complex with ImperaCalcin
8DRP	;	2.84	;	Focus/local refined map in C4 of signal subtracted RyR1 particles
8C1B	;	3.8	;	Focused map for structure of IgE bound to the ectodomain of FceRIa
8ES4	;	3.3	;	Focused reconstruction of HRP29 tail
8JPF	;	3.02	;	Focused refiment structure of NTSR1 in NTSR1-GRK2-Galpha(q) complexes
6YJ5	;	3.5	;	Focused refinement cryo-EM structure of the yeast mitochondrial complex I sub-stoichiometric sulfur transferase subunit
7VIA	;	3.88	;	Focused refinement of asymmetric unit of bacteriophage lambda procapsid at 3.88 Angstrom
8JPE	;	2.91	;	Focused refinement structure of Galpha(q) in NTSR1-GRK2-Galpha(q) complexes
8JPD	;	2.81	;	Focused refinement structure of GRK2 in NTSR1-GRK2-Galpha(q) complexes
6Q16	;	4.1	;	Focussed refinement of InvGN0N1:PrgHK:SpaPQR:PrgIJ from Salmonella SPI-1 injectisome NC-base
6PEM	;	3.5	;	Focussed refinement of InvGN0N1:SpaPQR:PrgHK from Salmonella SPI-1 injectisome NC-base
6PEP	;	3.8	;	Focussed refinement of InvGN0N1:SpaPQR:PrgIJ from the Salmonella SPI-1 injectisome needle complex
8HH1	;	2.9	;	FoF1-ATPase from Bacillus PS3, 81 degrees, highATP
5D3M	;	3.303	;	Folate ECF transporter: AMPPNP bound state
5JSZ	;	3.004	;	Folate ECF transporter: apo state
1CO1	;		;	FOLD OF THE CBFA
5O2A	;	1.9	;	FolD Q98H
8QNJ	;		;	Folded alpha helical de novo proteins from Apilactobacillus kunkeei
8QNT	;		;	Folded alpha helical de novo proteins from Apilactobacillus kunkeei
8QNV	;		;	Folded alpha helical de novo proteins from Apilactobacillus kunkeei
7OGT	;	5.5	;	Folded elbow of cohesin
1NSO	;		;	Folded monomer of protease from Mason-Pfizer monkey virus
6BY7	;	7.5	;	Folding DNA into a lipid-conjugated nano-barrel for controlled reconstitution of membrane proteins
5M6S	;	4.8	;	folding intermediate of spectrin R16
2L2P	;		;	Folding Intermediate of the Fyn SH3 A39V/N53P/V55L from NMR Relaxation Dispersion Experiments
6ZH5	;	2.7	;	Folding of an iron binding peptide in response to sedimentation is resolved using ferritin as a nano-reactor
6ZLG	;	3.0	;	Folding of an iron binding peptide in response to sedimentation is resolved using ferritin as a nano-reactor
6ZLQ	;	3.3	;	Folding of an iron binding peptide in response to sedimentation is resolved using ferritin as a nano-reactor
2J5A	;	2.3	;	Folding of S6 structures with divergent amino-acid composition: pathway flexibility within partly overlapping foldons
2KAZ	;		;	Folding topology of a bimolecular DNA quadruplex containing a stable mini-hairpin motif within the connecting loop
2WW7	;	1.06	;	foldon containing beta-turn mimic
2WW6	;	0.98	;	foldon containing D-amino acids in turn positions
4NCU	;	1.11	;	Foldon domain wild type
4NCW	;	1.3	;	foldon domain wild type C-conjugate
4NCV	;	1.2	;	Foldon domain wild type N-conjugate
8I2H	;	6.0	;	Follicle stimulating hormone receptor
3GJN	;	2.48	;	Following evolutionary paths to high affinity and selectivity protein-protein interactions using Colicin7 and Immunity proteins
3GKL	;	2.2	;	Following evolutionary paths to high affinity and selectivity protein-protein interactions using Colicin7 and Immunity proteins
1N15	;	2.9	;	FOLLOWING THE C HEME REDUCTION IN NITRITE REDUCTASE FROM PSEUDOMONAS AERUGINOSA
1N50	;	2.9	;	FOLLOWING THE C HEME REDUCTION IN NITRITE REDUCTASE FROM PSEUDOMONAS AERUGINOSA
1N90	;	2.9	;	FOLLOWING THE C HEME REDUCTION IN NITRITE REDUCTASE FROM PSEUDOMONAS AERUGINOSA
1FGS	;	2.4	;	FOLYLPOLYGLUTAMATE SYNTHETASE FROM LACTOBACILLUS CASEI
7D3R	;	3.49	;	FOOT AND MOUTH DISEASE VIRUS A/WH/CHA/09-BOUND THE SINGLE CHAIN FRAGME ANTIBODY R50
7D3K	;	3.9	;	FOOT AND MOUTH DISEASE VIRUS O/TIBET/99-BOUND THE SINGLE CHAIN FRAGMEN ANTIBODY B77
7EO0	;	3.75	;	FOOT AND MOUTH DISEASE VIRUS O/TIBET/99-BOUND THE SINGLE CHAIN FRAGMEN ANTIBODY C4
7D3L	;	3.68	;	FOOT AND MOUTH DISEASE VIRUS O/TIBET/99-BOUND THE SINGLE CHAIN FRAGMEN ANTIBODY F145
7D3M	;	3.94	;	FOOT AND MOUTH DISEASE VIRUS O/TIBET/99-BOUND THE SINGLE CHAIN FRAGMEN ANTIBODY R50
1WNE	;	3.0	;	Foot and Mouth Disease Virus RNA-dependent RNA polymerase in complex with a template-primer RNA
2F8E	;	2.9	;	Foot and Mouth Disease Virus RNA-dependent RNA polymerase in complex with uridylylated VPg protein
2D7S	;	3.0	;	Foot and Mouth Disease Virus RNA-dependent RNA polymerase in complex with VPg protein
5GAM	;	3.7	;	Foot region of the yeast spliceosomal U4/U6.U5 tri-snRNP
1ZBE	;	3.0	;	Foot-and Mouth Disease Virus Serotype A1061
2E9R	;	2.81	;	Foot-and-mouth disease virus RNA-dependent RNA polymerase in complex with a template-primer RNA and with ribavirin
2E9Z	;	3.0	;	Foot-and-mouth disease virus RNA-polymerase in complex with a template- primer RNA, ATP and UTP
2E9T	;	2.6	;	Foot-and-mouth disease virus RNA-polymerase RNA dependent in complex with a template-primer RNA and 5F-UTP
1ZBA	;	2.0	;	Foot-and-Mouth Disease virus serotype A1061 complexed with oligosaccharide receptor.
1QQP	;	1.9	;	FOOT-AND-MOUTH DISEASE VIRUS/ OLIGOSACCHARIDE RECEPTOR COMPLEX.
1U09	;	1.91	;	Footand Mouth Disease Virus RNA-dependent RNA polymerase
3V19	;	2.0	;	Forestalling insulin fibrillation by insertion of a chiral clamp mechanism-based application of protein engineering to global health
3V1G	;	2.2	;	Forestalling insulin fibrillation by insertion of a chiral clamp mechanism-based application of protein engineering to global health
2ZVC	;	2.0	;	Form 2 structure (C2221) of TT0207 from Thermus thermophilus HB8
1D33	;	1.5	;	Formaldehyde cross-links daunorubicin and DNA efficiently: HPLC and X-RAY diffraction studies
2D34	;	1.4	;	FORMALDEHYDE CROSS-LINKS DAUNORUBICIN AND DNA EFFICIENTLY: HPLC AND X-RAY DIFFRACTION STUDIES
1B25	;	1.85	;	FORMALDEHYDE FERREDOXIN OXIDOREDUCTASE FROM PYROCOCCUS FURIOSUS
1B4N	;	2.4	;	FORMALDEHYDE FERREDOXIN OXIDOREDUCTASE FROM PYROCOCCUS FURIOSUS, COMPLEXED WITH GLUTARATE
8PVM	;	1.38	;	formaldehyde-inhibited [FeFe]-hydrogenase CpI from Clostridium pasteurianum, variant C299D
8QM3	;	1.53	;	formaldehyde-inhibited [FeFe]-hydrogenase I from Clostridium pasteurianum (CpI)
5LCY	;	2.19	;	Formaldehyde-Responsive Regulator FrmR E64H variant from Salmonella enterica serovar Typhimurium
2PP8	;	1.5	;	Formate bound to oxidized wild type AfNiR
3Q7K	;	2.8	;	Formate Channel FocA from Salmonella typhimurium
2W3U	;	1.96	;	formate complex of the Ni-Form of E.coli deformylase
7XQW	;	2.83	;	Formate dehydrogenase (FDH) from Methylobacterium extorquens AM1 (MeFDH1)
7BKC	;	3.0	;	Formate dehydrogenase - heterodisulfide reductase - formylmethanofuran dehydrogenase complex from Methanospirillum hungatei (dimeric, composite structure)
7BKD	;	3.0	;	Formate dehydrogenase - heterodisulfide reductase - formylmethanofuran dehydrogenase complex from Methanospirillum hungatei (heterodislfide reductase core and mobile arm in conformational state 1, composite structure)
7BKE	;	2.8	;	Formate dehydrogenase - heterodisulfide reductase - formylmethanofuran dehydrogenase complex from Methanospirillum hungatei (heterodisulfide reductase core and mobile arm in conformational state 2, composite structure)
7BKB	;	3.5	;	Formate dehydrogenase - heterodisulfide reductase - formylmethanofuran dehydrogenase complex from Methanospirillum hungatei (hexameric, composite structure)
6VW8	;	2.3	;	Formate Dehydrogenase FdsABG subcomplex FdsBG from C. necator
6VW7	;	2.0	;	Formate Dehydrogenase FdsABG subcomplex FdsBG from C. necator - NADH bound
7YA4	;	1.8	;	Formate dehydrogenase from Novosphingobium sp. AP12 with NAD and Azide
7YA3	;	3.0	;	Formate dehydrogenase from Novosphingobium sp. AP12 with NADP and Azide
7QZ1	;	2.1	;	Formate dehydrogenase from Starkeya novella
8J3P	;	2.3	;	Formate dehydrogenase mutant from from Candida dubliniensis M4 complexed with NADP+
1KQF	;	1.6	;	FORMATE DEHYDROGENASE N FROM E. COLI
1KQG	;	2.8	;	FORMATE DEHYDROGENASE N FROM E. COLI
8J3O	;	2.65	;	Formate dehydrogenase wild-type enzyme from Candida dubliniensis complexed with NADH
7C11	;	2.815	;	Formate--tetrahydrofolate ligase from Methylobacterium extorquens CM4 strain
7XZN	;	2.04	;	Formate-tetrahydrofolate ligase from Peptostreptococcus anaerobius
7XZO	;	2.31	;	Formate-tetrahydrofolate ligase in complex with ATP
7XZP	;	2.56	;	Formate-tetrahydrofolate ligase in complex with berberine
385D	;	1.6	;	FORMATION OF A NEW COMPOUND IN THE CRYSTAL STRUCTURE OF CYANOMORPHOLINODOXORUBICIN COMPLEXED WITH D(CGATCG)
1I6Q	;	2.7	;	Formation of a protein intermediate and its trapping by the simultaneous crystallization process: Crystal structure of an iron-saturated intermediate in the FE3+ binding pathway of camel lactoferrin at 2.7 resolution
1H6N	;	2.11	;	Formation of a tyrosyl radical intermediate in Proteus mirabilis catalase by directed mutagenesis and consequences for nucleotide reactivity
1H7K	;	2.4	;	Formation of a tyrosyl radical intermediate in Proteus mirabilis catalase by directed mutagenesis and consequences for nucleotide reactivity
2ARG	;		;	FORMATION OF AN AMINO ACID BINDING POCKET THROUGH ADAPTIVE ZIPPERING-UP OF A LARGE DNA HAIRPIN LOOP, NMR, 9 STRUCTURES
3J47	;	7.4	;	Formation of an intricate helical bundle dictates the assembly of the 26S proteasome lid
1CP4	;	1.9	;	FORMATION, CRYSTAL STRUCTURE, AND REARRANGEMENT OF A CYTOCHROME P450-CAM IRON-PHENYL COMPLEX
8HZB	;	3.2	;	Formed alpha-synuclein fibrils after incubation with heparin for 1 hour (Hep-remod-1)
8HZC	;	3.2	;	Formed alpha-synuclein fibrils after incubation with heparin for 1 hour (Hep-remod-2)
8HZS	;	3.3	;	Formed alpha-synuclein fibrils after incubation with heparin for 3 days (Hep-remod-3)
8VG3	;		;	Formerly degenerate seventh zinc finger domain from transcription factor ZNF711 rehabilitated by experimental NMR structure
3UJN	;	2.98	;	Formyl Glycinamide Ribonucleotide Amidotransferase from Salmonella Typhimurium : Role of the ATP complexation and glutaminase domain in catalytic coupling
3UGJ	;	1.78	;	Formyl Glycinamide ribonucletide amidotransferase from Salmonella Typhimurum: Role of the ATP complexation and glutaminase domain in catalytic coupling
1T3Z	;	2.3	;	Formyl-CoA Tranferase mutant Asp169 to Ser
1P5R	;	2.5	;	Formyl-CoA Transferase in complex with Coenzyme A
1T4C	;	2.61	;	Formyl-CoA Transferase in complex with Oxalyl-CoA
1VGQ	;	2.13	;	Formyl-CoA transferase mutant Asp169 to Ala
1VGR	;	2.1	;	Formyl-CoA transferase mutant Asp169 to Glu
2VJN	;	2.0	;	Formyl-CoA transferase mutant variant G260A
2VJO	;	2.2	;	Formyl-CoA transferase mutant variant Q17A with aspartyl-CoA thioester intermediates and oxalate
2VJP	;	1.95	;	Formyl-CoA transferase mutant variant W48F
2VJQ	;	1.8	;	Formyl-CoA transferase mutant variant W48Q
2VJL	;	2.0	;	Formyl-CoA transferase with aspartyl-CoA thioester intermediate derived from formyl-CoA
2VJK	;	1.97	;	Formyl-CoA transferase with aspartyl-CoA thioester intermediate derived from oxalyl-CoA
2VJM	;	1.89	;	Formyl-CoA transferase with aspartyl-formyl anhydide intermediate
3UBM	;	1.992	;	Formyl-CoA:oxalate CoA-transferase from Acetobacter aceti
6JFO	;	1.6	;	Formyl-Met-Ala-Ser bound crystal structure of class II peptide deformylase from methicillin resistant Staphylococcus aureus
4NT8	;	2.2	;	Formyl-methionine-alanine complex structure of peptide deformylase from Xanthomoonas oryzae pv. oryzae
3UMM	;	3.2	;	Formylglycinamide ribonucleotide amidotransferase from Salmonella typhimurium: Role of the ATP complexation and glutaminase domain in catalytic coupling
6MUJ	;	2.249	;	Formylglycine generating enzyme bound to copper
2AFT	;	1.66	;	Formylglycine generating enzyme C336S mutant
2AIJ	;	1.55	;	Formylglycine generating enzyme C336S mutant covalently bound to substrate peptide CTPSR
2AIK	;	1.73	;	Formylglycine generating enzyme C336S mutant covalently bound to substrate peptide LCTPSRA
2AFY	;	1.49	;	Formylglycine generating enzyme C341S mutant
2Q17	;	2.1	;	Formylglycine Generating Enzyme from Streptomyces coelicolor
5NXL	;	1.66	;	Formylglycine generating enzyme from T. curvata in complex with Ag(I)
5NYY	;	1.28	;	Formylglycine generating enzyme from T. curvata in complex with Cd(II)
1M5H	;	2.0	;	Formylmethanofuran:tetrahydromethanopterin formyltransferase from Archaeoglobus fulgidus
1FTR	;	1.7	;	FORMYLMETHANOFURAN:TETRAHYDROMETHANOPTERIN FORMYLTRANSFERASE FROM METHANOPYRUS KANDLERI
1M5S	;	1.85	;	Formylmethanofuran:tetrahydromethanopterin fromyltransferase from Methanosarcina barkeri
8AOZ	;	1.9	;	ForT Mutant L24A
8AP0	;	1.6	;	ForT Mutant T138V
6YQQ	;	2.5	;	ForT-PRPP complex
1TN4	;	1.95	;	FOUR CALCIUM TNC
2TN4	;	2.0	;	FOUR CALCIUM TNC
7ZUR	;	1.6	;	Four carbons pendant pyridine derivative of the natural alkaloid Berberine as Human Telomeric G-quadruplex Binder
1QU7	;	2.6	;	FOUR HELICAL-BUNDLE STRUCTURE OF THE CYTOPLASMIC DOMAIN OF A SERINE CHEMOTAXIS RECEPTOR
1HAQ	;		;	FOUR MODELS OF HUMAN FACTOR H DETERMINED BY SOLUTION SCATTERING CURVE-FITTING AND HOMOLOGY MODELLING
8ASI	;	2.9	;	Four subunit cytochrome b-c1 complex from Rhodobacter sphaeroides in native nanodiscs - consensus refinement in the b-b conformation
8ASJ	;	3.75	;	Four subunit cytochrome b-c1 complex from Rhodobacter sphaeroides in native nanodiscs - focussed refinement in the b-c conformation
2JST	;		;	Four-Alpha-Helix Bundle with Designed Anesthetic Binding Pockets II: Halothane Effects on Structure and Dynamics
6TYH	;	1.60002	;	Four-Disulfide Insulin Analog A22/B22
6G7M	;	1.71	;	Four-site variant (Y222C, C197S, C432S, C433S) of E. coli hydrogenase-2
1ZF2	;	1.95	;	Four-stranded DNA Holliday Junction (CCC)
1FBR	;		;	FOURTH AND FIFTH FIBRONECTIN TYPE I MODULE PAIR
1ZAQ	;		;	FOURTH EGF-LIKE DOMAIN OF THROMBOMODULIN, NMR, 12 STRUCTURES
1AW0	;		;	FOURTH METAL-BINDING DOMAIN OF THE MENKES COPPER-TRANSPORTING ATPASE, NMR, 20 STRUCTURES
2AW0	;		;	FOURTH METAL-BINDING DOMAIN OF THE MENKES COPPER-TRANSPORTING ATPASE, NMR, 20 STRUCTURES
7NZD	;	1.45	;	Fourth SH3 domain of POSH (Plenty of SH3 Domains protein)
7RCF	;	2.233	;	Fourth stage reengineered variant of I-OnuI with stability enhancing substitutions
2GDL	;		;	Fowlicidin-2: NMR structure of antimicrobial peptide
5ZA2	;	1.503	;	Fox-4 beta-lactamase complexed with avibactam
5MAB	;	2.436	;	FoxE P3121 crystal structure of Rhodopseudomonas ferrooxidans SW2 putative iron oxidase
5MVO	;	2.668	;	FoxE P43212 crystal structure of Rhodopseudomonas ferrooxidans SW2 putative iron oxidase
8BZM	;	2.69	;	FOXK1-ELF1-heterodimer bound to DNA
4WK8	;	3.4006	;	FOXP3 forms a domain-swapped dimer to bridge DNA
8SRP	;	3.7	;	FoxP3 forms Ladder-like multimer to bridge TTTG repeats
8SRO	;	3.3	;	FoxP3 tetramer on TTTG repeats
8D47	;	2.0	;	fp.006 Fab in complex with SARS-CoV-2 Fusion Peptide
1JBV	;	1.95	;	FPGS-AMPPCP complex
1JBW	;	1.85	;	FPGS-AMPPCP-folate complex
8S9J	;	2.25	;	FphA, Staphylococcus aureus fluorophosphonate-binding serine hydrolases A, apo form
8G48	;	1.95	;	FphE, Staphylococcus aureus fluorophosphonate-binding serine hydrolases E, dimeric apo form
8G49	;	1.6	;	FphE, Staphylococcus aureus fluorophosphonate-binding serine hydrolases E, Oxadiazolone compound 3 bound
8T88	;	1.54	;	FphE, Staphylococcus aureus fluorophosphonate-binding serine hydrolases E, Oxadiazolone JJ004 bound
8T87	;	1.62	;	FphE, Staphylococcus aureus fluorophosphonate-binding serine hydrolases E, unbound dimer crystal form 1
6VH9	;	1.71	;	FphF, Staphylococcus aureus fluorophosphonate-binding serine hydrolases F, apo form
6VHD	;	1.98	;	FphF, Staphylococcus aureus fluorophosphonate-binding serine hydrolases F, KT129 bound
6VHE	;	1.94	;	FphF, Staphylococcus aureus fluorophosphonate-binding serine hydrolases F, KT130 bound
6WCX	;	2.89	;	FphF, Staphylococcus aureus fluorophosphonate-binding serine hydrolases F, substrate bound
8FTP	;	1.37	;	FphH, Staphylococcus aureus fluorophosphonate-binding serine hydrolases H, apo form
8G0N	;	1.14	;	FphI, Staphylococcus aureus fluorophosphonate-binding serine hydrolases I, apo form
4BF8	;		;	Fpr4 PPI domain
2C7G	;	1.8	;	FprA from Mycobacterium tuberculosis: His57Gln mutant
1FRB	;	1.7	;	FR-1 PROTEIN/NADPH/ZOPOLRESTAT COMPLEX
7KRI	;	1.58	;	FR6-bound SARS-CoV-2 Nsp9 RNA-replicase
5GWF	;	1.55	;	FraC with GlcNAc(6S) bound
8PIF	;	1.782	;	Fragment 12 in complex with KLHDC2
5MB3	;	1.049	;	Fragment 333 at a concentration of 50mM in complex with Endothiapepsin
6S40	;	1.9	;	Fragment AZ-001 binding at the p53pT387/14-3-3 sigma interface and additional sites
6RWI	;	1.65	;	Fragment AZ-002 binding at the p53pT387/14-3-3 sigma interface
6RL3	;	1.3	;	Fragment AZ-003 binding at the p53pT387/14-3-3 sigma interface
6RHC	;	1.2	;	Fragment AZ-003 binding at the TAZpS89/14-3-3 sigma interface
6S9Q	;	1.69	;	Fragment AZ-004 binding at a primary and secondary site in a p53pT387/14-3-3 complex
6SLW	;	2.0	;	Fragment AZ-004 binding at the TAZpS89/14-3-3 sigma interface
6RX2	;	1.82	;	Fragment AZ-005 binding at the p53pT387/14-3-3 sigma interface
6R5L	;	1.884	;	Fragment AZ-006 binding at the p53pT387/14-3-3 sigma interface
6RJQ	;	1.885	;	Fragment AZ-006 binding at the TAZpS89/14-3-3 sigma interface
6RWH	;	1.68	;	Fragment AZ-007 binding at a primary and secondary binding site of the the p53pT387/14-3-3 sigma complex
6RWS	;	1.53	;	Fragment AZ-009 binding at the p53pT387/14-3-3 sigma interface
6RWU	;	1.46	;	Fragment AZ-010 binding at the p53pT387/14-3-3 sigma interface
6SLX	;	1.80005	;	Fragment AZ-010 binding at the TAZpS89/14-3-3 sigma interface
6SIP	;	1.60045	;	Fragment AZ-011 binding at the p53pT387/14-3-3 sigma interface
6SIQ	;	1.60121	;	Fragment AZ-012 binding at the p53pT387/14-3-3 sigma interface
6SLV	;	1.9	;	Fragment AZ-013 binding at the p53pT387/14-3-3 sigma interface
6RK8	;	1.602	;	Fragment AZ-014 binding at the p53pT387/14-3-3 sigma interface
6RJZ	;	1.58	;	Fragment AZ-015 binding at the p53pT387/14-3-3 sigma interface
6RM5	;	1.884	;	Fragment AZ-016 binding at the p53pT387/14-3-3 sigma interface
6SIO	;	1.60418	;	Fragment AZ-017 binding at the p53pT387/14-3-3 sigma interface
6S39	;	1.88	;	Fragment AZ-018 binding at the p53pT387/14-3-3 sigma interface
6RJL	;	1.28	;	Fragment AZ-018 binding at the TAZpS89/14-3-3 sigma interface
6S3C	;	2.0	;	Fragment AZ-019 binding at the p53pT387/14-3-3 sigma interface
6RP6	;	1.885	;	Fragment AZ-019 binding at the TAZpS89/14-3-3 sigma interface
6SIN	;	1.64	;	Fragment AZ-020 binding at the p53pT387/14-3-3 sigma interface
6RKK	;	1.88	;	Fragment AZ-021 binding at the p53pT387/14-3-3 sigma interface
6RKM	;	1.88	;	Fragment AZ-022 binding at the p53pT387/14-3-3 sigma interface
6RKI	;	1.88	;	Fragment AZ-023 binding at the p53pT387/14-3-3 sigma interface
6RL6	;	1.6	;	Fragment AZ-024 binding at the p53pT387/14-3-3 sigma interface
6RL4	;	1.6	;	Fragment AZ-025 binding at the p53pT387/14-3-3 sigma interface
6RM7	;	1.6	;	Fragment AZ-026 binding at the p53pT387/14-3-3 sigma interface
2MD2	;		;	Fragment based approach and binding behavior of LFampinB with Lipopolysaccharide: biophysical aspects
2MD4	;		;	Fragment based approach and binding behavior of LFampinB with Lipopolysaccharide: biophysical aspects
2MD1	;		;	Fragment based approach and binding behavior of LFampinB with Lipopolysaccharide:biophysical aspects
2MD3	;		;	Fragment based approach and binding behavior of LFampinB with Lipopolysaccharide:biophysical aspects
3MSK	;	2.0	;	Fragment Based Discovery and Optimisation of BACE-1 Inhibitors
3MSL	;	2.4	;	Fragment Based Discovery and Optimisation of BACE-1 Inhibitors
3S2O	;	2.6	;	Fragment based discovery and optimisation of bace-1 inhibitors
3ZW3	;	2.8	;	Fragment based discovery of a novel and selective PI3 Kinase inhibitor
3E62	;	1.922	;	Fragment based discovery of JAK-2 inhibitors
3E63	;	1.9	;	Fragment based discovery of JAK-2 inhibitors
3E64	;	1.8	;	Fragment based discovery of JAK-2 inhibitors
1WBU	;	1.9	;	Fragment based lead discovery using crystallography
1WBN	;	2.4	;	fragment based p38 inhibitors
1WBO	;	2.16	;	fragment based p38 inhibitors
6Y8M	;	1.9	;	Fragment bikinin bound to Interleukin 1 beta
4UCO	;	2.5	;	Fragment bound to H.influenza NAD dependent DNA ligase
4UCR	;	2.15	;	Fragment bound to H.influenza NAD dependent DNA ligase
4UCS	;	1.9	;	Fragment bound to H.influenza NAD dependent DNA ligase
4UCT	;	2.1	;	Fragment bound to H.influenza NAD dependent DNA ligase
4UCU	;	2.1	;	Fragment bound to H.influenza NAD dependent DNA ligase
4UCV	;	2.6	;	Fragment bound to H.influenza NAD dependent DNA ligase
3ZVV	;	2.5	;	Fragment Bound to PI3Kinase gamma
6H6Q	;	2.63	;	Fragment Derived XIAP inhibitor
6H6R	;	2.03	;	Fragment Derived XIAP inhibitor
1N8E	;	4.5	;	Fragment Double-D from Human Fibrin
2Y56	;	3.59	;	Fragment growing induces conformational changes in acetylcholine- binding protein: A structural and thermodynamic analysis - (Compound 3)
2Y57	;	3.3	;	Fragment growing induces conformational changes in acetylcholine- binding protein: A structural and thermodynamic analysis - (Compound 4)
2Y58	;	3.25	;	Fragment growing induces conformational changes in acetylcholine- binding protein: A structural and thermodynamic analysis - (Compound 6)
2Y54	;	3.65	;	Fragment growing induces conformational changes in acetylcholine- binding protein: A structural and thermodynamic analysis - (Fragment 1)
6SPL	;	1.38	;	Fragment KCL615 in complex with MAP kinase p38-alpha
6SP9	;	1.22	;	Fragment KCL802 in complex with MAP kinase p38-alpha
6Y81	;	1.54	;	Fragment KCL_1088 in complex with MAP kinase p38-alpha
6Y7W	;	1.39	;	Fragment KCL_1337 in complex with MAP kinase p38-alpha
6Y85	;	1.58	;	Fragment KCL_1410 in complex with MAP kinase p38-alpha
6Y7X	;	1.45	;	Fragment KCL_771 in complex with MAP kinase p38-alpha
6Y82	;	1.44	;	Fragment KCL_804 in complex with MAP kinase p38-alpha
6Y7Z	;	1.35	;	Fragment KCL_914 in complex with MAP kinase p38-alpha
6Y80	;	1.24	;	Fragment KCL_916 in complex with MAP kinase p38-alpha
6Y8I	;	1.46	;	Fragment KCL_I013 in complex with IL-1-beta
6YCW	;	1.34	;	Fragment KCL_K767 in complex with MAP kinase p38-alpha
6YCU	;	1.35	;	Fragment KCL_K777 in complex with MAP kinase p38-alpha
6SOT	;	1.54	;	Fragment N11290a in complex with MAP kinase p38-alpha
6SO2	;	1.6	;	Fragment N13460a in complex with MAP kinase p38-alpha
6SOU	;	1.5	;	Fragment N13565a in complex with MAP kinase p38-alpha
6SO1	;	1.66	;	Fragment N13569a in complex with MAP kinase p38-alpha
6SOI	;	1.55	;	Fragment N13788a in complex with MAP kinase p38-alpha
6SOD	;	1.87	;	Fragment N14056a in complex with MAP kinase p38-alpha
5UNA	;	2.55	;	Fragment of 7SK snRNA methylphosphate capping enzyme
6EDF	;	1.4	;	Fragment of a tyrosine-protein kinase
1G5G	;	3.3	;	FRAGMENT OF FUSION PROTEIN FROM NEWCASTLE DISEASE VIRUS
6CCT	;	2.4	;	Fragment of GID4 in complex with a short peptide
6MFA	;	1.754	;	Fragment of human fibronectin containing the 4th-7th type III domains
1FNF	;	2.0	;	FRAGMENT OF HUMAN FIBRONECTIN ENCOMPASSING TYPE-III REPEATS 7 THROUGH 10
6NLY	;	2.307	;	Fragment of human mitochondrial Alanyl-tRNA Synthetase C-Ala domain
4E1H	;	1.4	;	Fragment of human prion protein
4E1I	;	2.03	;	Fragment of human prion protein
5JEQ	;	1.9	;	Fragment of nitrate/nitrite sensor histidine kinase NarQ (R50K) in symmetric apo state
6YUE	;	2.4	;	Fragment of nitrate/nitrite sensor histidine kinase NarQ (R50S variant)
5JEF	;	2.42	;	Fragment of nitrate/nitrite sensor histidine kinase NarQ (WT) in asymmetric holo state
5IJI	;	1.94	;	Fragment of nitrate/nitrite sensor histidine kinase NarQ (WT) in symmetric holo state
7SAF	;	2.45	;	Fragment of streptococcal M87 protein fused to GCN4 adaptor
7SAY	;	2.1	;	Fragment of streptococcal M87 protein fused to GCN4 adaptor in complex with human cathelicidin
6H8F	;	1.78	;	Fragment of the C-terminal domain of the TssA component of the type VI secretion system from Burkholderia cenocepacia
3B8P	;	3.1	;	Fragment of WzzB, Polysaccharide Co-polymerase from Salmonella Typhimurium
6SO4	;	1.51	;	Fragment RZ132 in complex with MAP kinase p38-alpha
8C6P	;	1.1	;	Fragment screening hit I bound to endothiapepsin
8C6Q	;	1.25	;	Fragment screening hit II bound to endothiapepsin
8C6S	;	1.1	;	Fragment screening hit III bound to endothiapepsin
8C6T	;	1.15	;	Fragment screening hit IV bound to endothiapepsin
3M2Z	;	1.7	;	Fragment tethered to Carbonic Anhydrase II H64C mutant
3M5T	;	1.95	;	Fragment tethered to Carbonic Anhydrase II H64C mutant
6S97	;	1.953	;	Fragment transplantation onto a hyperstable ancestor of haloalkane dehalogenases and Renilla luciferase (Anc-FT)
3AO1	;	1.9	;	Fragment-based approach to the design of ligands targeting a novel site in HIV-1 integrase
3AO2	;	1.8	;	Fragment-based approach to the design of ligands targeting a novel site on HIV-1 integrase
3AO3	;	1.9	;	Fragment-based approach to the design of ligands targeting a novel site on HIV-1 integrase
3AO4	;	1.95	;	Fragment-based approach to the design of ligands targeting a novel site on HIV-1 integrase
3AO5	;	1.8	;	Fragment-based approach to the design of ligands targeting a novel site on HIV-1 integrase
3OVN	;	1.95	;	Fragment-based approach to the design of ligands targeting a novel site on HIV-1 integrase
4N9B	;	2.859	;	Fragment-based Design of 3-Aminopyridine-derived Amides as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT)
4N9C	;	1.751	;	Fragment-based Design of 3-Aminopyridine-derived Amides as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT)
4N9D	;	1.701	;	Fragment-based Design of 3-Aminopyridine-derived Amides as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT)
4N9E	;	1.72	;	Fragment-based Design of 3-Aminopyridine-derived Amides as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT)
3OMO	;	2.21	;	Fragment-Based Design of novel Estrogen Receptor Ligands
3OMP	;	2.05	;	Fragment-Based Design of novel Estrogen Receptor Ligands
3OMQ	;	1.97	;	Fragment-Based Design of novel Estrogen Receptor Ligands
4CC5	;	1.88	;	Fragment-Based Discovery of 6 Azaindazoles As Inhibitors of Bacterial DNA Ligase
4CC6	;	2.01	;	Fragment-Based Discovery of 6 Azaindazoles As Inhibitors of Bacterial DNA Ligase
5L3A	;	1.98	;	Fragment-based discovery of 6-arylindazole JAK inhibitors
6G8X	;	1.76	;	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6G91	;	1.8	;	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6G92	;	1.99	;	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6G93	;	1.67	;	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6G97	;	1.9	;	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6G9A	;	1.91	;	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6G9D	;	1.8	;	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6G9H	;	1.73	;	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6G9J	;	1.98	;	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6G9K	;	1.94	;	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6G9M	;	1.86	;	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6G9N	;	1.76	;	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6GDM	;	1.91	;	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6GDQ	;	1.86	;	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6GE0	;	1.82	;	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
7N5O	;	1.25	;	Fragment-Based Discovery of a Novel Bruton's Tyrosine Kinase Inhibitor
7N5R	;	1.55	;	Fragment-Based Discovery of a Novel Bruton's Tyrosine Kinase Inhibitor
7N5X	;	1.6	;	Fragment-Based Discovery of a Novel Bruton's Tyrosine Kinase Inhibitor
4LUO	;	1.54	;	Fragment-Based Discovery of a Potent Inhibitor of Replication Protein A Protein-Protein Interactions
4LUV	;	1.4	;	Fragment-Based Discovery of a Potent Inhibitor of Replication Protein A Protein-Protein Interactions
4LUZ	;	1.9	;	Fragment-Based Discovery of a Potent Inhibitor of Replication Protein A Protein-Protein Interactions
4LW1	;	1.631	;	Fragment-Based Discovery of a Potent Inhibitor of Replication Protein A Protein-Protein Interactions
4LWC	;	1.61	;	Fragment-Based Discovery of a Potent Inhibitor of Replication Protein A Protein-Protein Interactions
4O0A	;	1.2	;	Fragment-Based Discovery of a Potent Inhibitor of Replication Protein A Protein-Protein Interactions
4Z3V	;	1.6	;	Fragment-Based Discovery of a Small Molecule Reversible Inhibitor of Bruton's Tyrosine Kinase
6NCN	;	1.82	;	Fragment-based Discovery of an apoE4 Stabilizer
6NCO	;	1.707	;	Fragment-based Discovery of an apoE4 Stabilizer
4K8A	;	2.91	;	Fragment-based discovery of Focal Adhesion Kinase Inhibitors
2VIN	;	1.9	;	Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator
2VIO	;	1.8	;	Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator
2VIP	;	1.72	;	Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator
2VIQ	;	2.0	;	Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator
2VIV	;	1.72	;	Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator
2VIW	;	2.05	;	Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator
5BVK	;	2.29	;	Fragment-based discovery of potent and selective DDR1/2 inhibitors
5BVN	;	2.21	;	Fragment-based discovery of potent and selective DDR1/2 inhibitors
5BVO	;	1.98	;	Fragment-based discovery of potent and selective DDR1/2 inhibitors
5BVW	;	1.94	;	Fragment-based discovery of potent and selective DDR1/2 inhibitors
4IJH	;	1.498	;	Fragment-based Discovery of Protein-Protein Interaction Inhibitors of Replication Protein A
4IJL	;	1.7	;	Fragment-based Discovery of Protein-Protein Interaction Inhibitors of Replication Protein A
6TPD	;	1.99	;	Fragment-based discovery of pyrazolopyridones as JAK1 inhibitors with excellent subtype selectivity
6TPE	;	2.87	;	Fragment-based discovery of pyrazolopyridones as JAK1 inhibitors with excellent subtype selectivity
6TPF	;	2.31	;	Fragment-based discovery of pyrazolopyridones as JAK1 inhibitors with excellent subtype selectivity
2W1H	;	2.15	;	Fragment-Based Discovery of the Pyrazol-4-yl urea (AT9283), a Multi- targeted Kinase Inhibitor with Potent Aurora Kinase Activity
7N5Y	;	1.85	;	Fragment-Based Drug Design of a Novel, Covalent Bruton's Tyrosine Kinase Inhibitor
5YAV	;	1.989	;	Fragment-based Drug Discovery of inhibitors to block PDEdelta-RAS protein-protein interaction
5YAW	;	2.027	;	Fragment-based Drug Discovery of inhibitors to block PDEdelta-RAS protein-protein interaction
5C3H	;	2.65	;	Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 1
5C7D	;	2.25	;	Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 17
5C7C	;	2.32	;	Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 18
5C0L	;	2.6	;	Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 2
5C84	;	2.36	;	Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 20
5C83	;	2.33	;	Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 21
5C0K	;	2.2	;	Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 3
5C3K	;	2.02	;	Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 4
5C7B	;	2.68	;	Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 5
5C7A	;	2.36	;	Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 7
4LV9	;	1.807	;	Fragment-based Identification of Amides Derived From trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT)
4LVA	;	1.55	;	Fragment-based Identification of Amides Derived From trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT)
4LVB	;	1.836	;	Fragment-based Identification of Amides Derived From trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT)
4LVD	;	1.75	;	Fragment-based Identification of Amides Derived From trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT)
4LVF	;	1.5	;	Fragment-based Identification of Amides Derived From trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT)
4LVG	;	1.702	;	Fragment-based Identification of Amides Derived From trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT)
5LYY	;	2.17	;	Fragment-based inhibitors of Lipoprotein associated Phospholipase A2
5LZ2	;	2.1	;	Fragment-based inhibitors of Lipoprotein associated Phospholipase A2
5LZ4	;	2.07	;	Fragment-based inhibitors of Lipoprotein associated Phospholipase A2
5LZ5	;	2.05	;	Fragment-based inhibitors of Lipoprotein associated Phospholipase A2
5LZ7	;	2.1	;	Fragment-based inhibitors of Lipoprotein associated Phospholipase A2
5LZ8	;	2.11	;	Fragment-based inhibitors of Lipoprotein associated Phospholipase A2
5LZ9	;	2.06	;	Fragment-based inhibitors of Lipoprotein associated Phospholipase A2
7DXL	;	3.146	;	Fragment-based Lead Discovery of Indazole-based Compounds as AXL Kinase Inhibitors
4BDA	;	2.6	;	Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)
4BDB	;	2.5	;	Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)
4BDC	;	3.0	;	Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)
4BDD	;	2.67	;	Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)
4BDE	;	2.55	;	Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)
4BDF	;	2.7	;	Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)
4BDG	;	2.84	;	Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)
4BDH	;	2.7	;	Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)
4BDI	;	2.32	;	Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)
4BDJ	;	3.01	;	Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)
4BDK	;	3.3	;	Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)
5AQF	;	1.88	;	Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQG	;	2.24	;	Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQH	;	2.0	;	Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQI	;	1.98	;	Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQJ	;	1.96	;	Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQK	;	2.09	;	Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQL	;	1.69	;	Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQM	;	1.63	;	Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQN	;	2.45	;	Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQO	;	2.12	;	Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQP	;	2.08	;	Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQQ	;	2.72	;	Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQR	;	1.91	;	Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQS	;	2.0	;	Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQT	;	1.9	;	Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQU	;	1.92	;	Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQV	;	1.75	;	Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQW	;	1.53	;	Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQX	;	2.12	;	Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQY	;	1.56	;	Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
4TYL	;	1.85	;	Fragment-Based Screening of the Bromodomain of ATAD2
4TZ2	;	1.7	;	Fragment-Based Screening of the Bromodomain of ATAD2
8BWX	;	1.6	;	Fragment-linked stabilizer for 14-3-3 and ERa (1075298)
8BYF	;	1.65	;	fragment-linked stabilizer for ERa - 14-3-3 interaction (1047455)
8BYG	;	1.7	;	fragment-linked stabilizer for ERa - 14-3-3 interaction (1047648)
8BXI	;	1.2	;	fragment-linked stabilizer for ERa - 14-3-3 interaction (1074361)
8BYO	;	1.2	;	fragment-linked stabilizer for ERa - 14-3-3 interaction (1074361)
8BX3	;	1.2	;	fragment-linked stabilizer for ERa - 14-3-3 interaction (1074372)
8BWJ	;	1.6	;	fragment-linked stabilizer for ERa - 14-3-3 interaction (1074386)
8BX0	;	1.6	;	fragment-linked stabilizer for ERa - 14-3-3 interaction (1074388)
8BX4	;	1.6	;	fragment-linked stabilizer for ERa - 14-3-3 interaction (1074392)
8BWZ	;	1.6	;	fragment-linked stabilizer for ERa - 14-3-3 interaction (1074393)
8BYY	;	1.6	;	fragment-linked stabilizer for ERa - 14-3-3 interaction (1074395)
8BXM	;	1.6	;	fragment-linked stabilizer for ERa - 14-3-3 interaction (1074397)
8BYB	;	1.6	;	fragment-linked stabilizer for ERa - 14-3-3 interaction (1074398)
8BXN	;	1.6	;	fragment-linked stabilizer for ERa - 14-3-3 interaction (1074399)
8BXO	;	1.6	;	fragment-linked stabilizer for ERa - 14-3-3 interaction (1075287)
8BY9	;	1.6	;	fragment-linked stabilizer for ERa - 14-3-3 interaction (1075292)
8BXS	;	1.6	;	Fragment-linked stabilizer for ERa - 14-3-3 interaction (1075293)
8BXQ	;	1.6	;	fragment-linked stabilizer for ERa - 14-3-3 interaction (1075296)
8C0K	;	1.4	;	fragment-linked stabilizer for ERa - 14-3-3 interaction (1075302)
8BYE	;	1.6	;	fragment-linked stabilizer for ERa - 14-3-3 interaction (1075313)
8BYC	;	1.6	;	fragment-linked stabilizer for ERa - 14-3-3 interaction (1075316)
8BYZ	;	1.4	;	fragment-linked stabilizer for ERa - 14-3-3 interaction (AZ210)
8BYD	;	1.6	;	fragment-linked stabilizer for ERa - 14-3-3 interactions (1075288)
4AB8	;	1.6	;	Fragments bound to bovine trypsin for the SAMPL challenge
4AB9	;	1.2	;	Fragments bound to bovine trypsin for the SAMPL challenge
4ABA	;	1.25	;	Fragments bound to bovine trypsin for the SAMPL challenge
4ABB	;	1.25	;	Fragments bound to bovine trypsin for the SAMPL challenge
4ABD	;	1.25	;	Fragments bound to bovine trypsin for the SAMPL challenge
4ABE	;	1.3	;	Fragments bound to bovine trypsin for the SAMPL challenge
4ABF	;	1.3	;	Fragments bound to bovine trypsin for the SAMPL challenge
4ABG	;	1.52	;	Fragments bound to bovine trypsin for the SAMPL challenge
4ABH	;	1.25	;	Fragments bound to bovine trypsin for the SAMPL challenge
3VQ4	;	1.9	;	Fragments bound to HIV-1 integrase
5DVA	;	2.50004	;	Fragments bound to the OXA-48 beta-lactamase: Compound 1
5DTK	;	1.6	;	Fragments bound to the OXA-48 beta-lactamase: Compound 17
5DTS	;	1.94016	;	Fragments bound to the OXA-48 beta-lactamase: Compound 2
5DTT	;	2.10001	;	Fragments bound to the OXA-48 beta-lactamase: Compound 3
6SOV	;	1.31	;	Fragments KCL_615 and KCL_802 in complex with MAP kinase p38-alpha
6Y7Y	;	1.51	;	Fragments KCL_771 and KCL_802 in complex with MAP kinase p38-alpha
3SOJ	;	1.0	;	Francisella tularensis pilin PilE
4HS5	;	1.45	;	Frataxin from Psychromonas ingrahamii as a model to study stability modulation within CyaY protein family
6B58	;	2.611	;	FrdA-SdhE assembly intermediate
7PAU	;	8.3	;	free 50S in complex with ribosome recycling factor in untreated Mycoplasma pneumoniae cells
7PAT	;	9.2	;	free 50S in untreated Mycoplasma pneumoniae cells
2X25	;	1.2	;	Free acetyl-CypA orthorhombic form
2X2A	;	1.4	;	Free acetyl-CypA trigonal form
1HKL	;	2.68	;	FREE AND LIGANDED FORM OF AN ESTEROLYTIC CATALYTIC ANTIBODY
1EOV	;	2.3	;	FREE ASPARTYL-TRNA SYNTHETASE (ASPRS) (E.C. 6.1.1.12) FROM YEAST
2LKC	;		;	Free B.st IF2-G2
1OAQ	;	1.5	;	Free conformation Ab1 of the IgE SPE-7
1OCW	;	2.0	;	Free conformation Ab2 of the IgE SPE-7
5OCZ	;		;	Free DNA_hairpin polyamides studies
7ZEV	;		;	Free form of extended Cyp33-RRM
4Q1O	;	1.75	;	Free form of TvNiR, high dose data set
4Q0T	;	1.7	;	Free form of TvNiR, low dose data set
4Q17	;	1.75	;	Free form of TvNiR, middle dose data set
4MYV	;	1.801	;	Free HSV-2 gD structure
1Z7G	;	1.9	;	Free human HGPRT
4EZ4	;	2.99	;	free KDM6B structure
5M3M	;	4.0	;	Free monomeric RNA polymerase I at 4.0A resolution
3DMV	;	1.65	;	Free of ligand binding in the hydrophobic cavity of T4 lysozyme L99A mutant
1BHH	;	1.9	;	FREE P56LCK SH2 DOMAIN
5X0G	;	1.9	;	Free serine kinase (E30A mutant) in complex with ADP
5X0F	;	1.76	;	Free serine kinase (E30A mutant) in complex with AMP
5X0E	;	2.0	;	Free serine kinase (E30A mutant) in complex with phosphoserine and AMP
5X0K	;	1.65	;	Free serine kinase (E30Q mutant) in complex with AMP
5X0J	;	1.43	;	Free serine kinase (E30Q mutant) in complex with phosphoserine and AMP
5X0B	;	1.75	;	Free serine kinase in complex with AMP
5FLH	;	1.802	;	Free state of Ni-quercetinase
3QXU	;	1.8	;	Free Structure of an Anti-Methotrexate CDR1-3 Graft VHH Antibody
3QXW	;	1.85	;	Free structure of an anti-methotrexate CDR1-4 Graft VHH Antibody
5XO4	;		;	Free Thanatin at 298K
8IL1	;		;	Free Thanatin IM14
8IL2	;		;	Free Thanatin PM15
5XO5	;		;	Free Thanatin Y10A M21A
2Z5J	;	3.4	;	Free Transportin 1
8X40	;		;	Free VF16 in aqueous solution
3IQN	;	2.7	;	Free-state structural transitions of the SAM-I riboswitch
4BB5	;	2.2	;	Free-Wilson and Structural Approaches to Co-optimising Human and Rodent Isoform Potency for 11b-Hydroxysteroid Dehydrogenase Type 1 11b-HSD1 Inhibitors
4BB6	;	2.55	;	Free-Wilson and Structural Approaches to Co-optimising Human and Rodent Isoform Potency for 11b-Hydroxysteroid Dehydrogenase Type 1 11b-HSD1 Inhibitors
5O4M	;	2.1	;	Fresh crystals of HcgC from Methanococcus maripaludis cocrystallized with SAH and pyridinol
7FH6	;	1.55	;	Friedel-Crafts alkylation enzyme CylK
7FH8	;	1.32	;	Friedel-Crafts alkylation enzyme CylK mutant H391A
7FH7	;	1.42	;	Friedel-Crafts alkylation enzyme CylK mutant Y37F
1AOL	;	2.0	;	FRIEND MURINE LEUKEMIA VIRUS RECEPTOR-BINDING DOMAIN
7VCO	;	1.6	;	Frischella perrara beta-fructofuranosidase
7VCP	;	2.0	;	Frischella perrara beta-fructofuranosidase in complex with fructose
7X8T	;	2.51	;	Frizzled 10 CRD in complex with hB9L9.3 Fab
7X8P	;	2.24	;	Frizzled 2 CRD in complex with pF7_A5 Fab
7X8Q	;	2.65	;	Frizzled-10 CRD in complex with F10_A9 Fab
5UN6	;	3.2	;	Frizzled-8 complex with designed surrogate Wnt agonist, A1 dataset
5UN5	;	2.994	;	Frizzled-8 complex with designed surrogate Wnt agonist, crystal form 1
6TFM	;	2.343	;	Frizzled8 CRD
8X0T	;	2.5	;	Frizzled8 CRD in complex with pF8_AC3 Fab
8GLR	;	1.83	;	FrlB - Deglycase for 6-phosphofructose lysine
6LXX	;	2.4	;	Frog EPDR1 with an Ir atom
4MY7	;	1.48	;	frog M ferritin iron-loaded under anaerobic environment
4MKU	;	1.3	;	Frog M ferritin mutant H54Q
3KA4	;	1.4	;	Frog M-ferritin with cobalt
4LPN	;	1.66	;	Frog M-ferritin with cobalt, D127E mutant
3KA3	;	1.4	;	Frog M-ferritin with magnesium
4LPM	;	1.65	;	Frog M-ferritin with magnesium, D127E mutant
3SHX	;	1.35	;	Frog M-ferritin with magnesium, L134P mutant
3SE1	;	1.65	;	Frog M-ferritin with magnesium, R72D mutant
3SH6	;	1.4	;	Frog M-ferritin, D122R mutant, with magnesium
3KA6	;	1.4	;	Frog M-ferritin, EED mutant, with cobalt
3KA9	;	1.45	;	Frog M-ferritin, EEH mutant, with cobalt
3KA8	;	1.35	;	Frog M-ferritin, EQH mutant, with cobalt
4K5C	;	1.7	;	From DARPins to LoopDARPins: Novel LoopDARPin Design Allows the Selection of Low Picomolar Binders in a Single Round of Ribosome Display
5NJ4	;	2.4	;	From macrocrystals to microcrystals: a strategy for membrane protein serial crystallography
5O4C	;	2.8	;	From macrocrystals to microcrystals: a strategy for membrane protein serial crystallography
5O64	;	3.3	;	From macrocrystals to microcrystals: a strategy for membrane protein serial crystallography
3U48	;	2.2	;	From soil to structure: a novel dimeric family 3-beta-glucosidase isolated from compost using metagenomic analysis
3U4A	;	2.196	;	From soil to structure: a novel dimeric family 3-beta-glucosidase isolated from compost using metagenomic analysis
2QHA	;	1.45	;	From Structure to Function: Insights into the Catalytic Substrate Specificity and Thermostability Displayed by Bacillus subtilis mannanase BCman
6Z8I	;	2.62	;	Fructo-oligosaccharide transporter BT 1762-63
6Z9A	;	3.1	;	Fructo-oligosaccharide transporter BT 1762-63
6ZAZ	;	2.69	;	Fructo-oligosaccharide transporter BT 1762-63
1QO5	;	2.5	;	Fructose 1,6-bisphosphate Aldolase from Human Liver Tissue
1FDJ	;	2.1	;	FRUCTOSE 1,6-BISPHOSPHATE ALDOLASE FROM RABBIT LIVER
1ADO	;	1.9	;	FRUCTOSE 1,6-BISPHOSPHATE ALDOLASE FROM RABBIT MUSCLE
1EWD	;	2.464	;	FRUCTOSE 1,6-BISPHOSPHATE ALDOLASE FROM RABBIT MUSCLE
1EWE	;	2.6	;	Fructose 1,6-Bisphosphate Aldolase from Rabbit Muscle
1EX5	;	2.2	;	FRUCTOSE 1,6-BISPHOSPHATE ALDOLASE FROM RABBIT MUSCLE
3B8D	;	2.0	;	Fructose 1,6-bisphosphate aldolase from rabbit muscle
2X7X	;	2.64	;	Fructose binding periplasmic domain of hybrid two component system BT1754
1UXD	;		;	Fructose repressor DNA-binding domain, NMR, 34 structures
1UXC	;		;	FRUCTOSE REPRESSOR DNA-BINDING DOMAIN, NMR, MINIMIZED STRUCTURE
1FPI	;	2.3	;	FRUCTOSE-1,6-BISPHOSPHATASE (D-FRUCTOSE-1,6-BISPHOSPHATE 1-PHOSPHOHYDROLASE) COMPLEXED WITH AMP, 2,5-ANHYDRO-D-GLUCITOL-1,6-BISPHOSPHATE AND POTASSIUM IONS (100 MM)
1FPL	;	2.3	;	FRUCTOSE-1,6-BISPHOSPHATASE (D-FRUCTOSE-1,6-BISPHOSPHATE 1-PHOSPHOHYDROLASE) COMPLEXED WITH AMP, 2,5-ANHYDRO-D-GLUCITOL-1,6-BISPHOSPHATE AND THALLIUM IONS (10 MM)
1FPJ	;	2.2	;	FRUCTOSE-1,6-BISPHOSPHATASE (D-FRUCTOSE-1,6-BISPHOSPHATE 1-PHOSPHOHYDROLASE) COMPLEXED WITH AMP, 2,5-ANHYDRO-D-GLUCITOL-1,6-BISPHOSPHATE, THALLIUM (10 MM) AND LITHIUM IONS (10 MM)
1FPK	;	3.0	;	FRUCTOSE-1,6-BISPHOSPHATASE (D-FRUCTOSE-1,6-BISPHOSPHATE 1-PHOSPHOHYDROLASE) COMPLEXED WITH THALLIUM IONS (10 MM)
1FJ6	;	2.5	;	FRUCTOSE-1,6-BISPHOSPHATASE (MUTANT Y57W) PRODUCT/ZN COMPLEX (R-STATE)
1FJ9	;	2.5	;	FRUCTOSE-1,6-BISPHOSPHATASE (MUTANT Y57W) PRODUCTS/ZN/AMP COMPLEX (T-STATE)
1EYJ	;	2.28	;	FRUCTOSE-1,6-BISPHOSPHATASE COMPLEX WITH AMP, MAGNESIUM, FRUCTOSE-6-PHOSPHATE AND PHOSPHATE (T-STATE)
1NV7	;	2.15	;	Fructose-1,6-Bisphosphatase Complex With AMP, Magnesium, Fructose-6-Phosphate, Phosphate and Thallium (20 mM)
1EYK	;	2.23	;	FRUCTOSE-1,6-BISPHOSPHATASE COMPLEX WITH AMP, ZINC, FRUCTOSE-6-PHOSPHATE AND PHOSPHATE (T-STATE)
1NUZ	;	1.9	;	Fructose-1,6-Bisphosphatase Complex with Magnesium, Fructose-6-Phosphate and Phosphate
1EYI	;	2.32	;	FRUCTOSE-1,6-BISPHOSPHATASE COMPLEX WITH MAGNESIUM, FRUCTOSE-6-PHOSPHATE AND PHOSPHATE (R-STATE)
1NUW	;	1.3	;	Fructose-1,6-Bisphosphatase Complex with Magnesium, Fructose-6-Phosphate and Phosphate at pH 9.6
1NUY	;	1.3	;	Fructose-1,6-Bisphosphatase Complex with Magnesium, Fructose-6-Phosphate, and Phosphate
1NV0	;	1.8	;	Fructose-1,6-Bisphosphatase Complex with Magnesium, Fructose-6-Phosphate, Phosphate and 1 mM Thallium
1NUX	;	1.6	;	Fructose-1,6-Bisphosphatase Complex with Magnesium, Fructose-6-Phosphate, Phosphate and inhibitory concentrations of Potassium (200mM)
1NV3	;	2.0	;	Fructose-1,6-Bisphosphatase Complex with Magnesium, Fructose-6-Phosphate, Phosphate and Thallium (100 mM)
1NV2	;	2.1	;	Fructose-1,6-Bisphosphatase Complex with Magnesium, Fructose-6-Phosphate, Phosphate and Thallium (20 mM)
1NV1	;	1.9	;	Fructose-1,6-Bisphosphatase Complex with Magnesium, Fructose-6-Phosphate, Phosphate and Thallium (5 mM)
1NV4	;	1.9	;	Fructose-1,6-Bisphosphatase Complex with Magnesium, Fructose-6-Phosphate, Phosphate, EDTA and Thallium (1 mM)
1NV6	;	2.15	;	Fructose-1,6-Bisphosphatase Complex With Magnesium, Fructose-6-Phosphate, Phosphate, EDTA and Thallium (20 mM)
1NV5	;	1.9	;	Fructose-1,6-Bisphosphatase Complex with Magnesium, Fructose-6-Phosphate, Phosphate, EDTA and Thallium (5 mM)
1Q9D	;	2.35	;	Fructose-1,6-bisphosphatase Complexed with a New Allosteric Site Inhibitor (I-State)
1CNQ	;	2.27	;	FRUCTOSE-1,6-BISPHOSPHATASE COMPLEXED WITH FRUCTOSE-6-PHOSPHATE AND ZINC IONS
2JJK	;	2.0	;	FRUCTOSE-1,6-BISPHOSPHATASE(D-FRUCTOSE-1,6-BISPHOSPHATE -1- PHOSPHOHYDROLASE) (E.C.3.1.3.11) COMPLEXED WITH A DUAL BINDING AMP SITE INHIBITOR
2VT5	;	2.2	;	FRUCTOSE-1,6-BISPHOSPHATASE(D-FRUCTOSE-1,6-BISPHOSPHATE -1- PHOSPHOHYDROLASE) (E.C.3.1.3.11) COMPLEXED WITH A DUAL BINDING AMP SITE INHIBITOR
1FTA	;	2.3	;	FRUCTOSE-1,6-BISPHOSPHATASE(D-FRUCTOSE-1,6-BISPHOSPHATE, 1-PHOSPHOHYDROLASE) (E.C.3.1.3.11) COMPLEXED WITH THE ALLOSTERIC INHIBITOR AMP
2WBB	;	2.22	;	FRUCTOSE-1,6-BISPHOSPHATASE(D-FRUCTOSE-1,6-BISPHOSPHATE-1- PHOSPHOHYDROLASE) (E.C.3.1.3.11) COMPLEXED WITH AN AMP SITE INHIBITOR
2WBD	;	2.4	;	FRUCTOSE-1,6-BISPHOSPHATASE(D-FRUCTOSE-1,6-BISPHOSPHATE-1- PHOSPHOHYDROLASE) (E.C.3.1.3.11) COMPLEXED WITH AN AMP SITE INHIBITOR
1J4E	;	2.65	;	FRUCTOSE-1,6-BISPHOSPHATE ALDOLASE COVALENTLY BOUND TO THE SUBSTRATE DIHYDROXYACETONE PHOSPHATE
2QAP	;	1.59	;	Fructose-1,6-bisphosphate aldolase from Leishmania mexicana
2QDH	;	1.9	;	Fructose-1,6-bisphosphate aldolase from Leishmania mexicana in complex with mannitol-1,6-bisphosphate, a competitive inhibitor
1A5C	;	3.0	;	FRUCTOSE-1,6-BISPHOSPHATE ALDOLASE FROM PLASMODIUM FALCIPARUM
1ZAH	;	1.8	;	Fructose-1,6-bisphosphate aldolase from rabbit muscle
2OT0	;	2.05	;	Fructose-1,6-bisphosphate aldolase from rabbit muscle in complex with a C-terminal peptide of Wiskott-Aldrich syndrome protein
1ZAJ	;	1.89	;	Fructose-1,6-bisphosphate aldolase from rabbit muscle in complex with mannitol-1,6-bisphosphate, a competitive inhibitor
2OT1	;	2.05	;	Fructose-1,6-bisphosphate aldolase from rabbit muscle in complex with naphthol AS-E phosphate, a competitive inhibitor
1ZAL	;	1.89	;	Fructose-1,6-bisphosphate aldolase from rabbit muscle in complex with partially disordered tagatose-1,6-bisphosphate, a weak competitive inhibitor
5TLW	;	2.29	;	Fructose-1,6-bisphosphate aldolase from rabbit muscle in complex with the inhibitor 1-phosphate-benzene 4-bisphosphonate
5TLH	;	2.204	;	Fructose-1,6-bisphosphate aldolase from rabbit muscle in complex with the inhibitor 2-naphthol 6-bisphosphonate
5TLE	;	1.576	;	Fructose-1,6-bisphosphate aldolase from rabbit muscle in complex with the inhibitor 2-phosphate-naphthalene 6-bisphosphonate
5TLZ	;	1.97	;	Fructose-1,6-bisphosphate aldolase from rabbit muscle in complex with the inhibitor naphthalene 2,6-bisphosphate
5F4X	;	1.84	;	Fructose-1,6-bisphosphate aldolase K229M mutant from rabbit muscle
3T2C	;	1.3	;	Fructose-1,6-bisphosphate aldolase/phosphatase from Thermoproteus neutrophilus, DHAP-bound form
3T2E	;	1.66	;	Fructose-1,6-bisphosphate aldolase/phosphatase from Thermoproteus neutrophilus, F6P-bound form
3T2D	;	1.36	;	Fructose-1,6-bisphosphate aldolase/phosphatase from Thermoproteus neutrophilus, FBP-bound form
3T2B	;	1.52	;	Fructose-1,6-bisphosphate aldolase/phosphatase from Thermoproteus neutrophilus, ligand free
3T2F	;	1.9	;	Fructose-1,6-bisphosphate aldolase/phosphatase from Thermoproteus neutrophilus, soaked with EDTA and DHAP
3T2G	;	3.0	;	Fructose-1,6-bisphosphate aldolase/phosphatase from Thermoproteus neutrophilus, Y229F variant with DHAP
2QDG	;	2.2	;	Fructose-1,6-bisphosphate Schiff base intermediate in FBP aldolase from Leishmania mexicana
1ZAI	;	1.76	;	Fructose-1,6-bisphosphate Schiff base intermediate in FBP aldolase from rabbit muscle
1L6W	;	1.93	;	Fructose-6-phosphate aldolase
7QXF	;	2.62	;	Fructose-6-phosphate aldolase (FSA) mutant R134V, S166G, with covalently bound active site ligand
4S1F	;	2.242	;	Fructose-6-phosphate aldolase A from E.coli soaked in acetylacetone
4RXG	;	2.154	;	Fructose-6-phosphate aldolase Q59E from E.coli
4RZ4	;	1.75	;	Fructose-6-phosphate aldolase Q59E Y131F from E.coli
4RXF	;	2.4	;	Fructose-6-phosphate aldolase Y131F from E.coli
4MOZ	;	2.15	;	Fructose-bisphosphate aldolase from Slackia heliotrinireducens DSM 20476
7EFS	;	2.5	;	Fructose-bisphosphate aldolase in Artemisia sieversiana pollen
5TQZ	;	1.6	;	Frutapin complexed with alpha-D-glucose
5M6O	;	1.7	;	Frutapin complexed with alpha-D-mannose
5KRP	;	1.58	;	Frutapin, a lectin from Artocarpus incisa: Cloning, Expressing and Structural Analysis.
4FBY	;	6.56	;	fs X-ray diffraction of Photosystem II
8I2G	;	2.8	;	FSHR-Follicle stimulating hormone-compound 716340-Gs complex
4GTM	;	2.2	;	FTase in complex with BMS analogue 11
4GTQ	;	2.6	;	FTase in complex with BMS analogue 12
4GTR	;	2.2	;	FTase in complex with BMS analogue 13
4GTO	;	2.15	;	FTase in complex with BMS analogue 14
4GTP	;	2.75	;	FTase in complex with BMS analogue 16
7MGT	;	1.54	;	Ftp from Treponema pallidum bound to an ADP-like inhibitor
7R5E	;	2.2	;	FtrA-P19 from Rubrivivax gelatinosus in complex with copper and magnesium (X1)
7R5G	;	2.2	;	FtrA-P19 from Rubrivivax gelatinosus in complex with copper and magnesium (X2)
7R3S	;	1.79	;	FtrA/P19 of Rubrivivax gelatinosus in complex with Ni
1E4F	;	1.9	;	FtsA (apo form) from Thermotoga maritima
1E4G	;	2.6	;	FtsA (ATP-bound form) from Thermotoga maritima
6Z4W	;	1.36	;	FtsE structure from Streptococcus pneumoniae in complex with ADP (space group P 1)
6Z63	;	1.57	;	FtsE structure from Streptococus pneumoniae in complex with ADP at 1.57 A resolution (spacegroup P 21)
6Z67	;	2.4	;	FtsE structure of Streptococcus pneumoniae in complex with AMPPNP at 2.4 A resolution
1EIZ	;	1.7	;	FTSJ RNA METHYLTRANSFERASE COMPLEXED WITH S-ADENOSYLMETHIONINE
1EJ0	;	1.5	;	FTSJ RNA METHYLTRANSFERASE COMPLEXED WITH S-ADENOSYLMETHIONINE, MERCURY DERIVATIVE
6T8B	;	3.65	;	FtsK motor domain with dsDNA, translocating state
6DLX	;	1.848	;	FtsY-NG domain bound to fragment 3.
6N5I	;	1.498	;	FtsY-NG high-resolution
6N5J	;	1.37	;	FtsY-NG high-resolution
6N6N	;	1.877	;	FtsY-NG high-resolution
6NC1	;	1.598	;	FtsY-NG high-resolution
6NC4	;	1.6	;	FtsY-NG high-resolution
6N9B	;	1.219	;	FtsY-NG ultra high-resolution
2VAM	;	2.5	;	FtsZ B. subtilis
1W59	;	2.7	;	FtsZ dimer, empty (M. jannaschii)
1W5B	;	2.2	;	FtsZ dimer, GTP soak (M. jannaschii)
1W5A	;	2.4	;	FtsZ dimer, MgGTP soak (M. jannaschii)
2VAP	;	1.7	;	FtsZ GDP M. jannaschii
1W58	;	2.5	;	FtsZ GMPCPP soak I213 (M. jannaschii)
2VAW	;	2.9	;	FtsZ Pseudomonas aeruginosa GDP
1W5E	;	3.0	;	FtsZ W319Y mutant, P1 (M. jannaschii)
1W5F	;	2.0	;	FtsZ, T7 mutated, domain swapped (T. maritima)
6SI9	;	1.9	;	FtsZ-refold
6D3I	;	3.196	;	ftv7 dioxygenase with 2,4-D bound
7YUD	;	2.98	;	FTY720p-bound human SPNS2
6D1O	;	2.7	;	FT_5 dioxygenase apoenzyme
6D3J	;	3.0	;	FT_T dioxygenase holoenzyme
6D3H	;	2.03	;	FT_T dioxygenase with bound dichlorprop
6D3M	;	2.03	;	FT_T dioxygenase with bound quizalofop
1K12	;	1.9	;	Fucose Binding lectin
6ZFC	;	1.65	;	Fucose-binding lectin from Burkholderia ambifaria (BamBL) in complex with a fucosyl derivative
6X7J	;	0.97	;	fucose-bound structure of Marinomonas primoryensis PA14 carbohydrate-binding domain
6GY9	;	1.83	;	Fucose-functionalized precision glycomacromolecules targeting human norovirus capsid protein
1IUB	;	2.31	;	Fucose-specific lectin from Aleuria aurantia (Hg-derivative form)
1IUC	;	2.24	;	Fucose-specific lectin from Aleuria aurantia with three ligands
8ANR	;	1.62	;	Fucosylated alternate chirality linear peptide FHP30 bound to the fucose binding lectin LecB PA-IIL from Pseudomonas aeruginosa at 1.6 Angstrom resolution.
6Y0W	;	2.06	;	Fucosylated antimicrobial linear peptide cFucRH46D in complex with the fucose binding lectin LecB from Pseudomonas aeruginosa at 2.1 Angstrom resolution
6Y0X	;	2.425	;	Fucosylated antimicrobial peptide SB6 in complex with the lectin LecRSL from Ralstonia solanacearum at 2.4 Angstrom resolution
6Y0U	;	1.489	;	Fucosylated Bicyclic peptide bp71 bound to the fucose binding lectin LecB PA-IIL from Pseudomonas aeruginosa at 1.5 Angstrom resolution
6Y0V	;	1.98	;	Fucosylated bicyclic peptide bp71 bound to the fucose binding lectin LecB PA-IIL from Pseudomonas aeruginosa at 1.7 Angstrom resolution
7NEW	;	2.02	;	Fucosylated heterochiral linear peptide Fdln69 bound to the fucose binding lectin LecB PA-IIL from Pseudomonas aeruginosa at 2.0 Angstrom resolution
7NEF	;	1.51	;	Fucosylated linear peptide Fln65 bound to the fucose binding lectin LecB PA-IIL from Pseudomonas aeruginosa at 1.5 Angstrom resolution
8AOO	;	1.18	;	Fucosylated mixed-chirality linear peptide FHP31 bound to the fucose binding lectin LecB PA-IIL from Pseudomonas aeruginosa at 1.2 Angstrom resolution.
8AN9	;	1.273	;	Fucosylated mixed-chirality linear peptide FHP5 bound to the fucose binding lectin LecB PA-IIL from Pseudomonas aeruginosa at 1.3 Angstrom resolution.
8ANO	;	1.29	;	Fucosylated mixed-chirality linear peptide FHP8 bound to the fucose binding lectin LecB PA-IIL from Pseudomonas aeruginosa at 1.3 Angstrom resolution.
2LYG	;		;	Fuc_TBA
7NFT	;	3.14	;	Fujian capbinding domain in complex with Nb8208
7NFQ	;	1.68	;	Fujian capmidlink domain in complex with Nb8193
7NFR	;	1.88	;	Fujian capmidlink domain in complex with Nb8194
8A9U	;	3.1	;	Full AAV3B-VP1KO virion
7QWZ	;	3.7	;	Full capsid of Saccharomyces cerevisiae virus L-BCLa
8OOI	;	2.61	;	Full composite cryo-EM map of p97/VCP in ADP.Pi state
7CGV	;	2.38	;	Full consensus L-threonine 3-dehydrogenase, FcTDH-IIYM (NAD+ bound form)
6V55	;	2.38	;	Full extracellular region of zebrafish Gpr126/Adgrg6
7MI9	;	3.89	;	Full integration complex of Cas1/Cas2 from Cas4-containing system
7M6N	;	2.61	;	Full length alpha1 Glycine receptor in presence of 0.1mM Glycine
7M6O	;	2.84	;	Full length alpha1 Glycine receptor in presence of 0.1mM Glycine and 32uM Tetrahydrocannabinol
7M6P	;	3.28	;	Full length alpha1 Glycine receptor in presence of 1mM Glycine
7M6Q	;	2.91	;	Full length alpha1 Glycine receptor in presence of 1mM Glycine and 32uM Tetrahydrocannabinol State 1
7M6R	;	3.57	;	Full length alpha1 Glycine receptor in presence of 1mM Glycine and 32uM Tetrahydrocannabinol State 2
7M6S	;	3.61	;	Full length alpha1 Glycine receptor in presence of 1mM Glycine and 32uM Tetrahydrocannabinol State 3
7M6M	;	3.09	;	Full length alpha1 Glycine receptor in presence of 32uM Tetrahydrocannabinol
2WTR	;	2.9	;	Full length Arrestin2
6LJ3	;	2.0	;	full length ASFV dUTPase in complex with alpha,beta-iminodUTP and magnesium ion
3LJ5	;	7.497	;	Full Length Bacteriophage P22 Portal Protein
8HDF	;	2.24	;	Full length crystal structure of mycobacterium tuberculosis FadD23 in complex with ANP and PLM
6G4G	;	2.8	;	Full length ectodomain of ectonucleotide phosphodiesterase/pyrophosphatase-3 (NPP3) including the SMB domains but with a partially disordered active site structure
6QKZ	;	6.3	;	Full length GluA1/2-gamma8 complex
4U1Y	;	3.8999	;	Full length GluA2-FW-(R,R)-2b complex
4U1W	;	3.25	;	Full length GluA2-kainate-(R,R)-2b complex crystal form A
4U1X	;	3.301	;	Full length GluA2-kainate-(R,R)-2b complex crystal form B
6UBS	;	3.33	;	Full length Glycine receptor reconstituted in lipid nanodisc in Apo/Resting conformation
6UBT	;	3.55	;	Full length Glycine receptor reconstituted in lipid nanodisc in Gly-bound desensitized conformation
6VM0	;	3.14	;	Full length Glycine receptor reconstituted in lipid nanodisc in Gly/IVM-conformation (State-1)
6VM2	;	3.34	;	Full length Glycine receptor reconstituted in lipid nanodisc in Gly/IVM-conformation (State-2)
6VM3	;	3.07	;	Full length Glycine receptor reconstituted in lipid nanodisc in Gly/IVM-conformation (State-3)
6UD3	;	3.5	;	Full length Glycine receptor reconstituted in lipid nanodisc in Gly/PTX-bound open/blocked conformation
6OLP	;	4.2	;	Full length HIV-1 Env AMC011 in complex with PGT151 Fab
7DF8	;	3.03	;	full length hNPC1L1-Apo
6C4K	;	2.65	;	Full length hUGDH with A104L substitution in the absence of ligand
7XF5	;	3.9	;	Full length human CLC-2 channel in apo state
5NVU	;	15.0	;	Full length human cytoplasmic dynein-1 in the phi-particle conformation
6O1G	;	2.2	;	Full length human plasma kallikrein with inhibitor
8GCD	;	2.97	;	Full length Integrin AlphaIIbBeta3 in inactive state
2JQF	;		;	Full Length Leader Protease of Foot and Mouth Disease Virus C51A Mutant
6PH4	;	3.25	;	Full length LOV-PAS-HK construct from the LOV-HK sensory protein from Brucella abortus (light-adapted, construct 15-489)
6SX5	;	2.2	;	Full length Mutant Open-form Sodium Channel NavMs
6YZ2	;	2.2	;	Full length Open-form Sodium Channel NavMs F208L
6YZ0	;	2.3	;	Full length Open-form Sodium Channel NavMs F208L in complex with Cannabidiol (CBD)
5HVD	;	2.6	;	Full length Open-form Sodium Channel NavMs I218C
6QZZ	;	1.85	;	full length OphA V404E in complex with SAH
6QZY	;	1.61	;	full length OphA V406P in complex with SAH
3EJC	;	1.85	;	Full length Receptor Binding Protein from Lactococcal phage TP901-1
7MSW	;	3.76	;	Full length SARS-CoV-2 Nsp2
4ZR0	;	3.8	;	Full length scs7p (only hydroxylase domain visible)
3PC2	;	1.8	;	Full length structure of cystathionine beta-synthase from Drosophila
3PC3	;	1.55	;	Full length structure of cystathionine beta-synthase from Drosophila in complex with aminoacrylate
3PC4	;	1.7	;	Full length structure of cystathionine beta-synthase from Drosophila in complex with serine
8BJD	;	2.4	;	Full length structure of LpMIP with bound inhibitor JK095
2Y1V	;	2.39	;	Full length structure of RrgB Pilus protein from Streptococcus pneumoniae
8BJC	;	1.71	;	Full length structure of the apo-state LpMIP.
8BK4	;	1.34	;	Full length structure of the apo-state LpMIP.
2PY4	;	1.49	;	Full length structure of the Mycobacterium tuberculosis dUTPase complexed with magnesium and alpha,beta-imido-dUTP.
4CGQ	;	2.0	;	Full length Tah1 bound to HSP90 peptide SRMEEVD
4CGU	;	2.11	;	Full length Tah1 bound to yeast PIH1 and HSP90 peptide SRMEEVD
5HVX	;	2.45	;	Full length Wild-Type Open-form Sodium Channel NavMs
1LUG	;	0.95	;	Full Matrix Error Analysis of Carbonic Anhydrase
1LUQ	;	0.96	;	Full Matrix Error Analysis of Streptavidin
8AGD	;	3.5	;	Full SDBC and SOD assembly
1FSD	;		;	FULL SEQUENCE DESIGN 1 (FSD-1) OF BETA BETA ALPHA MOTIF, NMR, 41 STRUCTURES
1FSV	;		;	FULL SEQUENCE DESIGN 1 (FSD-1) OF BETA BETA ALPHA MOTIF, NMR, MINIMIZED AVERAGE STRUCTURE
6XV2	;		;	Full structure of RYMV P1 protein, derived from crystallographic and NMR data.
3J7L	;	3.8	;	Full virus map of brome mosaic virus
6DG7	;	3.32	;	Full-length 5-HT3A receptor in a serotonin-bound conformation- State 1
6DG8	;	3.89	;	Full-length 5-HT3A receptor in a serotonin-bound conformation- State 2
4U2Q	;	3.5247	;	Full-length AMPA subtype ionotropic glutamate receptor GluA2 in complex with partial agonist kainate
4U2P	;	3.2386	;	Full-length AMPA subtype ionotropic glutamate receptor GluA2 in the apo state
8E40	;	3.57	;	Full-length APOBEC3G in complex with HIV-1 Vif, CBF-beta, and fork RNA
1R8Q	;	1.86	;	FULL-LENGTH ARF1-GDP-MG IN COMPLEX WITH BREFELDIN A AND A SEC7 DOMAIN
6RBG	;	3.0	;	full-length bacterial polysaccharide co-polymerase
8BHW	;	3.2	;	Full-length bacterial polysaccharide co-polymerase WzzE from E. coli. C4 symmetry
8P3O	;	2.9	;	Full-length bacterial polysaccharide co-polymerase WzzE mutant R267A from E. coli. C4 symmetry
8P3P	;	2.5	;	Full-length bacterial polysaccharide co-polymerase WzzE mutant R267E from E. coli. C4 symmetry
3WPU	;	1.6	;	Full-length beta-fructofuranosidase from Microbacterium saccharophilum K-1
4FXQ	;	1.9599	;	Full-length Certhrax toxin from Bacillus cereus in complex with Inhibitor P6
2Q5T	;	2.1	;	Full-length Cholix toxin from Vibrio Cholerae
3Q9O	;	1.793	;	Full-length Cholix toxin from Vibrio cholerae in complex with NAD
7PFP	;	6.1	;	Full-length cryo-EM structure of the native human uromodulin (UMOD)/Tamm-Horsfall protein (THP) filament
8HD4	;	2.68	;	Full-length crystal structure of mycobacterium tuberculosis FadD23 in complex with AMPC16
7UDI	;	2.24	;	Full-length dimer of DNA-Damage Response Protein C from Deinococcus radiodurans
8U0G	;	4.28	;	Full-length dimer of DNA-Damage Response Protein C from Deinococcus radiodurans - Crystal form xMJ7124
8DWS	;	3.73	;	Full-length E47K SPOP
3ZD4	;	2.2	;	Full-Length Hammerhead Ribozyme with G12A substitution at the general base position
2OEU	;	2.0	;	Full-length hammerhead ribozyme with Mn(II) bound
4A92	;	2.73	;	Full-length HCV NS3-4A protease-helicase in complex with a macrocyclic protease inhibitor.
6XLC	;	3.66	;	Full-length Hsc82 bound to AMPPNP
6XLD	;	3.66	;	Full-length Hsc82 in complex with Aha1 CTD in the presence of AMPPNP
6XLF	;	3.15	;	Full-length Hsc82 in complex with Aha1 in the presence of AMP-PNP
6XLE	;	2.74	;	Full-length Hsc82 in complex with two Aha1 CTD in the presence of AMP-PNP
6XLG	;	2.71	;	Full-length Hsc82 in complex with two Aha1 CTD in the presence of ATPgammaS
4IGG	;	3.66	;	Full-length human alpha-catenin crystal structure
3SOA	;	3.5501	;	Full-length human CaMKII
8USO	;	2.3	;	Full-length human CaMKII delta holoenzyme
6WTH	;	3.06	;	Full-length human ENaC ECD
7KCL	;	3.14	;	Full-length human mitochondrial Hsp90 (TRAP1) in complex with SdhB in the presence of AMP-PNP
7KCM	;	3.43	;	Full-length human mitochondrial Hsp90 (TRAP1) in complex with SdhB in the presence of AMP-PNP
7KLV	;	3.1	;	Full-length human mitochondrial Hsp90 (TRAP1) SpyCatcher/SpyTag-SdhB heterodimer in the presence of AMP-PNP
6XG6	;	3.2	;	Full-length human mitochondrial Hsp90 (TRAP1) with ADP-BeF3
7KCK	;	3.26	;	Full-length human mitochondrial Hsp90 (TRAP1) with AMP-PNP
4FIE	;	3.11	;	Full-length human PAK4
6N1K	;	3.057	;	Full-length human phenylalanine hydroxylase (PAH) in the resting state
6DJR	;	5.8	;	Full-length human TRPC3 in GDN
7SL7	;	3.1	;	Full-length insulin receptor bound with both site 1 binding deficient mutant insulin (A-V3E) and site 2 binding deficient mutant insulin (A-L13R)
7SL1	;	3.4	;	Full-length insulin receptor bound with site 1 binding deficient mutant insulin (A-V3E)
7SL2	;	3.6	;	Full-length insulin receptor bound with site 2 binding deficient mutant insulin (A-L13R) -- asymmetric conformation
7SL3	;	3.4	;	Full-length insulin receptor bound with site 2 binding deficient mutant insulin (A-L13R) -- symmetric conformation
7SL4	;	5.0	;	Full-length insulin receptor bound with site 2 binding deficient mutant insulin (B-L17R) -- asymmetric conformation
7SL6	;	3.7	;	Full-length insulin receptor bound with site 2 binding deficient mutant insulin (B-L17R) -- symmetric conformation
7STI	;	4.9	;	Full-length insulin receptor bound with unsaturated insulin WT (1 insulin bound) asymmetric conformation
7STH	;	3.5	;	Full-length insulin receptor bound with unsaturated insulin WT (2 insulin bound) symmetric conformation
7STJ	;	4.4	;	Full-length insulin receptor bound with unsaturated insulin WT (2 insulins bound) asymmetric conformation (Conformation 1)
7STK	;	4.0	;	Full-length insulin receptor bound with unsaturated insulin WT (2 insulins bound) asymmetric conformation (Conformation 2)
6XTU	;	2.52	;	FULL-LENGTH LTTR LYSG FROM CORYNEBACTERIUM GLUTAMICUM
6XTV	;	3.3	;	FULL-LENGTH LTTR LYSG FROM CORYNEBACTERIUM GLUTAMICUM WITH BOUND EFFECTOR ARG
6VDE	;	2.713	;	Full-length M. smegmatis Pol1
2M67	;		;	Full-length mercury transporter protein MerF in lipid bilayer membranes
8SSC	;	2.75	;	Full-Length Methionine synthase from Thermus thermophilus HB8
8FSZ	;	3.79	;	Full-length mouse 5-HT3A receptor in complex with ALB148471, open-like
8FRW	;	2.92	;	Full-length mouse 5-HT3A receptor in complex with ALB148471, pre-activated
8FSB	;	2.75	;	Full-length mouse 5-HT3A receptor in complex with serotonin, open-like
8FRZ	;	2.75	;	Full-length mouse 5-HT3A receptor in complex with serotonin, pre-activated
8FSP	;	3.79	;	Full-length mouse 5-HT3A receptor in complex with SMP100, open-like
8FRX	;	2.7	;	Full-length mouse 5-HT3A receptor in complex with SMP100, pre-activated
6OLY	;	3.112	;	Full-length MthK channel at 3.1 angstrom resolution
5GS6	;	2.852	;	Full-length NS1 structure of Zika virus from 2015 Brazil strain
4X6G	;	2.0	;	Full-length OxyR C199D from pseudomonas aeruginosa
8TUA	;	4.1	;	Full-length P-Rex1 in complex with inositol 1,3,4,5-tetrakisphosphate (IP4)
1OQW	;	2.0	;	Full-Length PAK Pilin from Pseudomonas aeruginosa
2PI2	;	2.0	;	Full-length Replication protein A subunits RPA14 and RPA32
6OR5	;	4.0	;	Full-length S. pombe Mdn1 in the presence of AMPPNP (ring region)
6OR6	;	5.3	;	Full-length S. pombe Mdn1 in the presence of AMPPNP (tail region)
6ORB	;	7.7	;	Full-length S. pombe Mdn1 in the presence of ATP and Rbin-1
7MDE	;	2.7	;	Full-length S95A ClbP
7MDF	;	2.3	;	Full-length S95A ClbP bound to N-acyl-D-asparagine analog
7CM5	;	2.6	;	Full-length Sarm1 in a self-inhibited state
2MWG	;		;	Full-Length Solution Structure Of YtvA, a LOV-Photoreceptor Protein and Regulator of Bacterial Stress Response
5YDW	;	3.3	;	Full-length structure of HypT from Salmonella typhimuriuma (hypochlorite-specific LysR-type transcriptional regulator)
7A2G	;	4.1	;	Full-length structure of the substrate-free tyrosine hydroxylase (apo-TH).
3SZP	;	2.202	;	Full-length structure of the Vibrio cholerae virulence activator, AphB, a member of the LTTR protein family
2XC1	;	1.65	;	Full-length Tailspike Protein Mutant Y108W of Bacteriophage P22
7N9Y	;	4.8	;	Full-length TcdB and CSPG4 (401-560) complex
7JM3	;	3.4	;	Full-length three-dimensional structure of the influenza A virus M1 protein and its organization into a matrix layer
8DWV	;	3.6	;	Full-length wild type SPOP
7MDC	;	2.7	;	Full-length wildtype ClbP inhibited by hexanoyl-D-asparagine boronic acid
2NAM	;		;	Full-length WT SOD1 in DPC MICELLE
1JSF	;	1.15	;	FULL-MATRIX LEAST-SQUARES REFINEMENT OF HUMAN LYSOZYME
1JSE	;	1.12	;	FULL-MATRIX LEAST-SQUARES REFINEMENT OF TURKEY LYSOZYME
2P6J	;		;	Full-sequence computational design and solution structure of a thermostable protein variant
5OBT	;	1.5	;	Fully activated A. thaliana legumain isoform gamma in complex with Ac-YVAD-CMK
2DCP	;		;	Fully automated NMR structure determination of the ENTH-VHS domain AT3G16270 from Arabidopsis thaliana
2DCQ	;		;	Fully automated NMR structure determination of the rhodanese homology domain At4g01050(175-295) from Arabidopsis thaliana
2DCR	;		;	Fully automated solution structure determination of the Fes SH2 domain
5K7X	;	2.803	;	Fully ligated Adenylosuccinate Synthetase from Pyrococcus horikoshii OT3 with GTP, IMP and Hadacidin
2GCQ	;	2.0	;	Fully ligated E.Coli Adenylosuccinate Synthetase with GTP, 2'-deoxy-IMP and Hadacidin
3PZA	;	1.85	;	Fully Reduced (All-ferrous) Pyrococcus rubrerythrin after a 10 second exposure to peroxide.
1YV1	;	1.5	;	Fully reduced state of nigerythrin (all ferrous)
1JJ2	;	2.4	;	Fully Refined Crystal Structure of the Haloarcula marismortui Large Ribosomal Subunit at 2.4 Angstrom Resolution
6ZXL	;	4.2	;	Fully-loaded anthrax lethal toxin in its heptameric pre-pore state and PA7LF(2+1A) arrangement
6ZXK	;	3.8	;	Fully-loaded anthrax lethal toxin in its heptameric pre-pore state and PA7LF(2+1B) arrangement
6ZXJ	;	3.5	;	Fully-loaded anthrax lethal toxin in its heptameric pre-pore state, in which the third lethal factor is masked out (PA7LF3-masked)
1FUO	;	1.98	;	FUMARASE C WITH BOUND CITRATE
1FUR	;	1.95	;	FUMARASE MUTANT H188N WITH BOUND SUBSTRATE L-MALATE AT PUTATIVE ACTIVATOR SITE
1FUQ	;	2.0	;	FUMARASE WITH BOUND 3-TRIMETHYLSILYLSUCCINIC ACID
1FUP	;	2.3	;	FUMARASE WITH BOUND PYROMELLITIC ACID
8SBS	;	1.91	;	Fumarate C - R126A in (3-(N-morpholino)propanesulfonic acid) at pH 7.5
5F92	;	1.859	;	Fumarate hydratase of Mycobacterium tuberculosis in complex with formate
5F91	;	1.998	;	Fumarate hydratase of Mycobacterium tuberculosis in complex with formate and allosteric modulator (N-(5-(azepan-1-ylsulfonyl)-2-methoxyphenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetamide)
6S88	;	1.59	;	Fumarate hydratase of Mycobacterium tuberculosis in complex with formate and allosteric modulator N-(2-Methoxy-5-((1,2,4,5-tetrahydro-3H-benzo[d]azepin-3-yl)sulfonyl)phenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetamide
6S7K	;	1.55	;	Fumarate hydratase of Mycobacterium tuberculosis in complex with formate and allosteric modulator N-(2-Methoxy-5-(N-methylsulfamoyl)phenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetamide
6S7S	;	1.7	;	Fumarate hydratase of Mycobacterium tuberculosis in complex with formate and allosteric modulator N-(2-Methoxy-5-(N-phenylsulfamoyl)phenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetamide
6S7Z	;	1.85	;	Fumarate hydratase of Mycobacterium tuberculosis in complex with formate and allosteric modulator N-(5-((3,4-Dihydroisoquinolin-2(1H)-yl)sulfonyl)-2-methoxyphenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetamide
6S7U	;	1.48	;	Fumarate hydratase of Mycobacterium tuberculosis in complex with formate and allosteric modulator N-(5-(Azepan-1-ylsulfonyl)-2-methoxyphenyl)-2-(1H-indol-3-yl)acetamide
6S7W	;	1.44	;	Fumarate hydratase of Mycobacterium tuberculosis in complex with formate and allosteric modulator N-(5-(Azepan-1-ylsulfonyl)-2-methoxyphenyl)-2-(quinolin-4-yl)acetamide
6S43	;	1.42	;	Fumarate hydratase of Mycobacterium tuberculosis in complex with formate and allosteric modulator N-(5-(Azocan-1-ylsulfonyl)-2-methoxyphenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetamide
5ZYN	;	1.75	;	Fumarate reductase
6IYM	;	2.1	;	Fumarylacetoacetate hydrolase (EaFAH) from psychrophilic Exiguobacterium antarcticum
2IZ5	;	2.29	;	FUNCTION AND STRUCTURE OF THE MOLYBDENUM COFACTOR CARRIER PROTEIN MCP FROM CHLAMYDOMONAS REINHARDTII
7XL7	;	1.85	;	Function And Structure Research of Salmonella typhimurium Unknown Functional Protein MicN
2ZUM	;	1.95	;	Functional Analysis of Hyperthermophilic Endocellulase from the Archaeon Pyrococcus horikoshii
2ZUN	;	2.0	;	Functional Analysis of Hyperthermophilic Endocellulase from the Archaeon Pyrococcus horikoshii
3AXX	;	1.9	;	Functional analysis of hyperthermophilic endocellulase from the Archaeon Pyrococcus horikoshii
2XOG	;	1.72	;	Functional and Structural Analyses of N-Acylsulfonamide-Linked Dinucleoside Inhibitors of Ribonuclease A
2XOI	;	1.72	;	Functional and Structural Analyses of N-Acylsulfonamide-Linked Dinucleoside Inhibitors of Ribonuclease A
2J89	;	1.7	;	Functional and structural aspects of poplar cytosolic and plastidial type A methionine sulfoxide reductases
2EJ4	;		;	Functional and structural basis of nuclear localization signal in ZIC3 zinc finger domain: a role of conserved tryptophan residue in the zinc finger domain
5Z9S	;	2.3	;	Functional and Structural Characterization of a beta-Glucosidase Involved in Saponin Metabolism from Intestinal Bacteria
3CBG	;	2.0	;	Functional and Structural Characterization of a Cationdependent O-Methyltransferase from the Cyanobacterium Synechocystis Sp. Strain PCC 6803
5UM2	;	1.14	;	Functional and structural characterization of a Sulfate-binding protein (Sbp) from Xanthomonas citri
7YQB	;	1.704	;	Functional and Structural Characterization of Norovirus GII.6 in Recognizing Histo-blood Group Antigens
7YQG	;	1.698	;	Functional and Structural Characterization of Norovirus GII.6 in Recognizing Histo-blood Group Antigens
4COK	;	1.69	;	Functional and Structural Characterization of Pyruvate decarboxylase from Gluconoacetobacter diazotrophicus
5GJ6	;	2.388	;	Functional and structural characterization of P[19] rotavirus VP8* interaction with histo-blood group antigens
5YMT	;	2.199	;	Functional and structural characterization of P[19] rotavirus VP8* interaction with histo-blood group antigens
5YMU	;	1.8	;	Functional and structural characterization of P[19] rotavirus VP8* interaction with histo-blood group antigens
7PCA	;	1.05	;	Functional and structural characterization of redox sensitive superfolder green fluorescent protein and variants
7PCZ	;	1.35	;	Functional and structural characterization of redox sensitive superfolder green fluorescent protein and variants
7PD0	;	2.0	;	Functional and structural characterization of redox sensitive superfolder green fluorescent protein and variants
2AS9	;	1.7	;	Functional and structural characterization of Spl proteases from staphylococcus aureus
6KJH	;	1.68	;	Functional and structural insights into the unusual oxyanion hole-like geometry in macrolactin acyltransferase selective for dicarboxylic acyl donors
6KJJ	;	2.492	;	Functional and structural insights into the unusual oxyanion hole-like geometry in macrolactin acyltransferase selective for dicarboxylic acyl donors
6KJP	;	2.06	;	Functional and structural insights into the unusual oxyanion hole-like geometry in macrolactin acyltransferase selective for dicarboxylic acyl donors
6KJQ	;	2.35	;	Functional and structural insights into the unusual oxyanion hole-like geometry in macrolactin acyltransferase selective for dicarboxylic acyl donors
6KJR	;	2.361	;	Functional and structural insights into the unusual oxyanion hole-like geometry in macrolactin acyltransferase selective for dicarboxylic acyl donors
6KJT	;	2.113	;	Functional and structural insights into the unusual oxyanion hole-like geometry in macrolactin acyltransferase selective for dicarboxylic acyl donors
3ZH0	;	2.0	;	Functional and structural role of the N-terminal extension in Methanosarcina acetivorans protoglobin
4J1V	;	1.95	;	Functional and structural studies of MOBKL1B, a Salvador/Warts/Hippo tumor suppressor pathway, in HCV replication
2RGK	;	2.5	;	Functional annotation of Escherichia coli yihS-encoded protein
2ZBL	;	1.6	;	Functional annotation of Salmonella enterica yihS-encoded protein
2R17	;	2.8	;	Functional architecture of the retromer cargo-recognition complex
5M99	;	1.96	;	Functional Characterization and Crystal Structure of Thermostable Amylase from Thermotoga petrophila, reveals High Thermostability and an Archaic form of Dimerization
2HO1	;	2.0	;	Functional Characterization of Pseudomonas Aeruginosa pilF
4P97	;	1.86	;	Functional conservation despite structural divergence in ligand-responsive RNA switches
4PHY	;	3.1	;	Functional conservation despite structural divergence in ligand-responsive RNA switches
8GM4	;	2.12	;	Functional construct of the Eukaryotic elongation factor 2 kinase bound to an ATP-competitive inhibitor
8GM5	;	2.12	;	Functional construct of the Eukaryotic elongation factor 2 kinase bound to Calmodulin, ADP and to the A-484954 inhibitor and showing two conformations for the 498-520 loop
3BZ5	;	2.7	;	Functional domain of InlJ from Listeria monocytogenes includes a cysteine ladder
2ANP	;	1.9	;	Functional Glutamate 151 to Histidine mutant of the aminopeptidase from Aeromonas Proteolytica.
4EP7	;	2.2805	;	Functional implications from the Cid1 poly(U) polymerase crystal structure
4I1B	;	2.0	;	FUNCTIONAL IMPLICATIONS OF INTERLEUKIN-1BETA BASED ON THE THREE-DIMENSIONAL STRUCTURE
6PV6	;	4.5	;	Functional Pathways of Biomolecules Retrieved from Single-particle Snapshots
7JMG	;	4.5	;	Functional Pathways of Biomolecules Retrieved from Single-particle Snapshots - Frame 22 - State 2 (S2)
7JMI	;	4.5	;	Functional Pathways of Biomolecules Retrieved from Single-particle Snapshots - Frame 29 - State 3 (S3)
7JMH	;	4.5	;	Functional Pathways of Biomolecules Retrieved from Single-particle Snapshots - Frame 35 - State 4 (S4)
7JMJ	;	4.5	;	Functional Pathways of Biomolecules Retrieved from Single-particle Snapshots - Frame 37 - State 5 (S5)
7JMF	;	4.5	;	Functional Pathways of Biomolecules Retrieved from Single-particle Snapshots - Frame 42 - State 6 (S6)
2C70	;	2.06	;	Functional Role of the Aromatic Cage in Human Monoamine Oxidase B: Structures and Catalytic Properties of Tyr435 Mutant Proteins
2C72	;	2.0	;	Functional Role of the Aromatic Cage in Human Monoamine Oxidase B: Structures and Catalytic Properties of Tyr435 Mutant Proteins
2C73	;	2.2	;	Functional Role of the Aromatic Cage in Human Monoamine Oxidase B: Structures and Catalytic Properties of Tyr435 Mutant Proteins
2C75	;	1.7	;	Functional Role of the Aromatic Cage in Human Monoamine Oxidase B: Structures and Catalytic Properties of Tyr435 Mutant Proteins
2C76	;	1.7	;	Functional Role of the Aromatic Cage in Human Monoamine Oxidase B: Structures and Catalytic Properties of Tyr435 Mutant Proteins
3HSU	;	1.69	;	Functional roles of the 6-s-cysteinyl, 8 alpha-N1-histidyl FAD in Glucooligosaccharide Oxidase from Acremonium strictum
8IX7	;	1.7	;	Functional significance of serine 13 in the active site of rice Phi-class glutathione S-transferase F3.
3U8B	;	2.299	;	Functionally selective inhibition of Group IIA phospholipase A2 reveals a role for vimentin in regulating arachidonic acid metabolism
3U8D	;	1.805	;	Functionally selective inhibition of Group IIA phospholipase A2 reveals a role for vimentin in regulating arachidonic acid metabolism
3U8H	;	2.3	;	Functionally selective inhibition of Group IIA phospholipase A2 reveals a role for vimentin in regulating arachidonic acid metabolism
3U8I	;	1.1	;	Functionally selective inhibition of Group IIA phospholipase A2 reveals a role for vimentin in regulating arachidonic acid metabolism
3VN3	;	0.95	;	Fungal antifreeze protein exerts hyperactivity by constructing an inequable beta-helix
7WDM	;	2.123	;	Fungal immunomodulatory protein FIP-gmi
7WDL	;	1.903	;	Fungal immunomodulatory protein FIP-nha
8GO6	;	2.813	;	Fungal immunomodulatory protein FIP-nha N39A
8GO7	;	2.303	;	Fungal immunomodulatory protein FIP-nha N5+39A
8GO5	;	2.809	;	Fungal immunomodulatory protein FIP-nha WT
2R0H	;	1.9	;	Fungal lectin CGL3 in complex with chitotriose (chitotetraose)
8GJ5	;	2.3	;	fungal pcna and peptidomimetic
4M8B	;	2.61	;	Fungal Protein
6T2H	;	1.41	;	Furano[2,3-d]prymidine amides as Notum inhibitors
6T2K	;	1.38	;	Furano[2,3-d]prymidine amides as Notum inhibitors
7R1A	;	3.9	;	Furin Cleaved Alpha Variant SARS-CoV-2 Spike in complex with 3 ACE2
6ZGI	;	2.9	;	Furin Cleaved Spike Protein of SARS-CoV-2 in Closed Conformation
6ZGH	;	6.8	;	Furin Cleaved Spike Protein of SARS-CoV-2 in Intermediate Conformation
6ZGG	;	3.8	;	Furin Cleaved Spike Protein of SARS-CoV-2 with One RBD Erect
7VHJ	;	4.2	;	Furin Site deletion of SARS-CoV-2 spike
3PSB	;	3.4	;	Furo[2,3-c]pyridine-based Indanone Oximes as Potent and Selective B-Raf Inhibitors
4TNA	;	2.5	;	FURTHER REFINEMENT OF THE STRUCTURE OF YEAST T-RNA-PHE
4BL4	;	4.06	;	Further structural insights into the binding of complement factor H by complement regulator acquiring surface protein 1, CspA (BbCRASP-1), of Borrelia burgdorferi.
3EY4	;	3.0	;	Further studies with the 2-amino-1,3-thiazol-4(5H)-one class of 11-hydroxysteroid dehydrogenase type 1 (11-HSD1) inhibitors: Reducing pregnane X receptor (PXR) activity and exploring activity in a monkey pharmacodynamic model
7QFY	;	1.62	;	Fusarium oxysporum M36 protease without the propeptide
1FN8	;	0.81	;	FUSARIUM OXYSPORUM TRYPSIN AT ATOMIC RESOLUTION
1FY4	;	0.81	;	FUSARIUM OXYSPORUM TRYPSIN AT ATOMIC RESOLUTION
1FY5	;	0.81	;	Fusarium oxysporum trypsin at atomic resolution
1GDN	;	0.81	;	FUSARIUM OXYSPORUM TRYPSIN AT ATOMIC RESOLUTION
1GDQ	;	0.93	;	FUSARIUM OXYSPORUM TRYPSIN AT ATOMIC RESOLUTION
1GDU	;	1.07	;	FUSARIUM OXYSPORUM TRYPSIN AT ATOMIC RESOLUTION
1XZK	;	2.01	;	FUSARIUM SOLANI CUTINASE COMPLEX WITH DI(ISOPROPYL)PHOSPHATE
1XZL	;	1.69	;	FUSARIUM SOLANI CUTINASE COMPLEX WITH N-HEXYLPHOSPHONATE ETHYL ESTER
1XZM	;	1.75	;	FUSARIUM SOLANI CUTINASE COMPLEX WITH N-UNDECYL O-METHYL CHLORO PHOSPHONATE ESTER
1CUS	;	1.25	;	FUSARIUM SOLANI CUTINASE IS A LIPOLYTIC ENZYME WITH A CATALYTIC SERINE ACCESSIBLE TO SOLVENT
1XZA	;	1.8	;	FUSARIUM SOLANI CUTINASE MUTANT WITH SER 129 REPLACED BY CYS
1XZB	;	1.75	;	FUSARIUM SOLANI CUTINASE MUTANT WITH SER 129 REPLACED BY CYS COMPLEX WITH MERCURY ACETATE
1XZC	;	1.75	;	FUSARIUM SOLANI CUTINASE MUTANT WITH SER 129 REPLACED BY CYS COMPLEX WITH PARA-SULFUROUSPHENYL MERCURY
1XZD	;	2.7	;	FUSARIUM SOLANI CUTINASE MUTANT WITH SER 213 REPLACED BY CYS
1XZE	;	1.75	;	FUSARIUM SOLANI CUTINASE MUTANT WITH SER 92 REPLACED BY CYS
1XZI	;	1.69	;	FUSARIUM SOLANI CUTINASE MUTANT WITH THR 119 REPLACED BY HIS
1XZF	;	1.69	;	FUSARIUM SOLANI CUTINASE MUTANT WITH THR 144 REPLACED BY CYS
1XZJ	;	1.69	;	FUSARIUM SOLANI CUTINASE MUTANT WITH THR 38 REPLACED BY PHE
1XZG	;	1.69	;	FUSARIUM SOLANI CUTINASE MUTANT WITH THR 45 REPLACED BY ALA
1XZH	;	1.69	;	FUSARIUM SOLANI CUTINASE MUTANT WITH THR 80 REPLACED BY PRO
6KC0	;	2.295	;	fused To-MtbCsm1 with 2ATP
6KBD	;	3.0	;	fused To-MtbCsm1 with 2dATP
6WZS	;	3.23	;	Fusibacterium ulcerans ZTP riboswitch bound to m-1-pyridinyl AICA
6WZR	;	3.2	;	Fusibacterium ulcerans ZTP riboswitch bound to p-1-pyridinyl AICA
6ZOD	;	2.85	;	Fusidic acid binding to the allosteric deep transmembrane domain binding pocket, TM7/TM8 groove, and TM1/TM2 groove of the fully induced AcrB T protomer
6ZO5	;	2.5	;	Fusidic acid binding to the TM1/TM2 groove of AcrB-G619P_G621P
6ZOF	;	3.3	;	Fusidic acid binding to the TM7/TM8 groove of AcrB-F380A T protomer
5JMN	;	2.5	;	Fusidic acid bound AcrB
6Q4O	;	2.8	;	Fusidic acid bound AcrB_I27A
6Q4P	;	2.8	;	Fusidic acid bound AcrB_N298A
6Q4N	;	2.8	;	Fusidic acid bound AcrB_V340A
7B8S	;	2.3	;	Fusidic acid bound structure of bacterial efflux pump.
4ADN	;	1.65	;	Fusidic acid resistance protein FusB
4ADO	;	2.3	;	Fusidic acid resistance protein FusB
2KNY	;		;	Fusion construct of CR17 from LRP-1 and ApoE residues 130-149
7R3E	;	3.46	;	Fusion construct of PqsE and RhlR in complex with the synthetic antagonist mBTL
5VAW	;	1.69	;	Fusion of Maltose-binding Protein and PilA from Acinetobacter baumannii AB5075
5IHJ	;	2.2	;	Fusion of Maltose-binding Protein and PilA from Acinetobacter baumannii BIDMC57
5CFV	;	1.8	;	Fusion of Maltose-binding Protein and PilA from Acinetobacter nosocomialis M2
7BG0	;	2.89	;	Fusion of MBP and the backbone of the long-acting amylin analog AM833.
1TOL	;	1.85	;	FUSION OF N-TERMINAL DOMAIN OF THE MINOR COAT PROTEIN FROM GENE III IN PHAGE M13, AND C-TERMINAL DOMAIN OF E. COLI PROTEIN-TOLA
4XEV	;	2.0073	;	Fusion of Pyk2-FAT domain with Leupaxin LD1 motif, complexed with Leupaxin LD4 peptide
7MY8	;		;	Fusion Peptide of SARS-CoV-2 Spike Rearranges into a Wedge Inserted in Bilayered Micelles
6J7I	;	3.3	;	Fusion protein of heme oxygenase-1 and NADPH cytochrome P450 reductase (15aa)
6J7A	;	3.269	;	Fusion protein of heme oxygenase-1 and NADPH cytochrome P450 reductase (17aa)
6J79	;	3.331	;	Fusion protein of heme oxygenase-1 and NADPH-cytochrome P450 reductase (13aa)
5COC	;	2.6691	;	Fusion protein of human calmodulin and B4 domain of protein A from staphylococcal aureus
5CBO	;	2.802	;	Fusion protein of mbp3-16 and B4 domain of protein A from staphylococcal aureus
5CBN	;	2.3	;	Fusion protein of mbp3-16 and B4 domain of protein A from staphylococcal aureus with chemical cross-linker EY-CBS
6F37	;	2.2	;	Fusion protein of RSL and trimeric coiled coil
5EWX	;	2.6	;	Fusion protein of T4 lysozyme and B4 domain of protein A from staphylococcal aureus with chemical cross-linker EY-CBS
6DBS	;	2.602	;	Fusion surface structure, function, and dynamics of gamete fusogen HAP2
2N35	;		;	Fusion to a Highly Stable Consensus Albumin Binding Domain Allows for Tunable Pharmacokinetics
5BTP	;	2.816	;	Fusobacterium ulcerans ZTP riboswitch bound to ZMP
2PT1	;	2.0	;	FutA1 Synechocystis PCC 6803
1A7P	;	2.01	;	FV FRAGMENT OF MOUSE MONOCLONAL ANTIBODY D1.3 (BALB/C, IGG1, K) ENGINEERED MUTANT PRO95L->SER ON VARIANT CHAIN L GLU81->ASP AND CHAIN H LEU312->VAL
1A7Q	;	2.0	;	FV FRAGMENT OF MOUSE MONOCLONAL ANTIBODY D1.3 (BALB/C, IGG1, K) HIGH AFFINITY EXPRESSED VARIANT CONTAINING SER26L->GLY, ILE29L->THR, GLU81L->ASP, THR97L->SER, PRO240H->LEU, ASP258H->ALA, LYS281H->GLU, ASN283H->ASP AND LEU312H->VAL
1A7O	;	2.0	;	FV FRAGMENT OF MOUSE MONOCLONAL ANTIBODY D1.3 (BALB/C, IGG1, K) R96L DELETION MUTANT ON VARIANT FOR CHAIN L GLU81->ASP AND CHAIN H LEU312->VAL
1A7R	;	2.01	;	FV FRAGMENT OF MOUSE MONOCLONAL ANTIBODY D1.3 (BALB/C, IGG1, K) VARIANT CHAIN L GLU81->ASP
1A7N	;	2.01	;	FV FRAGMENT OF MOUSE MONOCLONAL ANTIBODY D1.3 (BALB/C, IGG1, K) VARIANT FOR CHAIN L GLU81->ASP AND CHAIN H LEU312->VAL
1OAR	;	2.23	;	Fv IgE SPE-7 in complex with Alizarin Red
4RZC	;	2.723	;	Fv M6P-1 in complex with mannose-6-phosphate
1KIR	;	2.0	;	FV MUTANT Y(A 50)S (VL DOMAIN) OF MOUSE MONOCLONAL ANTIBODY D1.3 COMPLEXED WITH HEN EGG WHITE LYSOZYME
1KIQ	;	1.85	;	FV MUTANT Y(B 101)F (VH DOMAIN) OF MOUSE MONOCLONAL ANTIBODY D1.3 COMPLEXED WITH HEN EGG WHITE LYSOZYME
1KIP	;	2.1	;	FV MUTANT Y(B 32)A (VH DOMAIN) OF MOUSE MONOCLONAL ANTIBODY D1.3 COMPLEXED WITH HEN EGG WHITE LYSOZYME
1OAX	;	2.67	;	Fv Structure of the IgE SPE-7 in complex with acenaphthenequinone
1OAU	;	1.8	;	Fv Structure of the IgE SPE-7 in complex with DNP-Ser (immunising hapten)
2J8L	;		;	FXI Apple 4 domain loop-out conformation
6AOD	;	1.8	;	FXIa antibody complex
7FBP	;	1.99	;	FXIIa-cMCoFx1 complex
5MHL	;	2.4	;	FXIIIa in complex with the inhibitor Mi0621
5MHM	;	2.12	;	FXIIIa in complex with the inhibitor ZED1630
5MHN	;	2.48	;	FXIIIa in complex with the inhibitor ZED2360
5MHO	;	2.92	;	FXIIIa in complex with the inhibitor ZED2369
3P89	;	2.3	;	FXR bound to a quinolinecarboxylic acid
3P88	;	2.95	;	FXR bound to isoquinolinecarboxylic acid
5YXJ	;	2.62	;	FXR ligand binding domain
4QE8	;	2.62	;	FXR with DM175 and NCoA-2 peptide
3HC6	;	3.2	;	FXR with SRC1 and GSK088
3RVF	;	3.1	;	FXR with SRC1 and GSK2034
3RUU	;	2.502	;	FXR with SRC1 and GSK237
3RUT	;	3.0	;	FXR with SRC1 and GSK359
3DCU	;	2.95	;	FXR with SRC1 and GSK8062
3HC5	;	2.6	;	FXR with SRC1 and GSK826
3DCT	;	2.5	;	FXR with SRC1 and GW4064
6A5W	;	2.88	;	FXR-LBD with HNC143 and SRC1
6A5X	;	2.6	;	FXR-LBD with HNC180 and SRC1
8DDG	;	0.9	;	FYF peptide forms a standard beta-sheet
4E0L	;	1.7	;	FYLLYYT segment from human Beta 2 Microglobulin (62-68) displayed on 54-membered macrocycle scaffold
2MRK	;		;	Fyn SH2 domain in complex with the natural inhibitory phosphotyrosine peptide
6IPZ	;	1.576	;	Fyn SH3 domain R96W mutant, crystallized with 18-crown-6
1WFK	;		;	FYVE domain of FYVE domain containing 19 protein from Mus musculus
8JHC	;	3.3	;	FZD3 in inactive state
8JHI	;	3.2	;	FZD3-Gs complex
8JHB	;	3.3	;	FZD6 Gs complex
8JH7	;	3.2	;	FZD6 in inactive state
7EVW	;	3.22	;	Fzd7 -Gs complex
5NR1	;	2.004	;	FzlA from C. crescentus
1GP2	;	2.3	;	G PROTEIN HETEROTRIMER GI_ALPHA_1 BETA_1 GAMMA_2 WITH GDP BOUND
1GG2	;	2.4	;	G PROTEIN HETEROTRIMER MUTANT GI_ALPHA_1(G203A) BETA_1 GAMMA_2 WITH GDP BOUND
1A13	;		;	G PROTEIN-BOUND CONFORMATION OF MASTOPARAN-X, NMR, 14 STRUCTURES
1YM7	;	4.5	;	G Protein-Coupled Receptor Kinase 2 (GRK2)
4PNK	;	2.56	;	G protein-coupled receptor kinase 2 in complex with GSK180736A
7TD9	;	1.61	;	G-059 bound to the SMARCA4 (BRG1) Bromodomain
1OQX	;	2.6	;	G-2 glycovariant of human IgG Fc bound to minimized version of Protein A called Z34C
7TAB	;	1.16	;	G-925 bound to the SMARCA4 (BRG1) Bromodomain
6K3Y	;		;	G-quadruplex complex with cyclic dinucleotide 3'-3' cGAMP
6K3X	;		;	G-quadruplex complex with linear dinucleotide d(AG)
5LIG	;		;	G-Quadruplex formed at the 5'-end of NHEIII_1 Element in human c-MYC promoter bound to triangulenium based fluorescence probe DAOTA-M2
5MTA	;		;	G-quadruplex formed within promoters of Plasmodium falciparum B var genes
5MTG	;		;	G-quadruplex formed within promoters of Plasmodium falciparum B var genes - form I
5O4D	;		;	G-quadruplex of Human papillomavirus type 52
6JCD	;		;	G-quadruplex peripheral knot
2JWQ	;		;	G-quadruplex recognition by quinacridines: a SAR, NMR and Biological study
2LBY	;		;	G-quadruplex structure formed at the 5'-end of NHEIII_1 element in human c-MYC promoter
2F8U	;		;	G-quadruplex structure formed in human Bcl-2 promoter, hybrid form
7SXP	;	2.9	;	G-quadruplex structure formed in the NRAS mRNA with a G8U substitution
2N3M	;		;	G-quadruplex structure of an anti-proliferative DNA sequence
5OPH	;		;	G-quadruplex structure of DNA oligonucleotide containing GGGGCC repeats linked to ALS and FTD
7OQT	;		;	G-quadruplex structure of the C. elegans telomeric repeat: A two tetrads basket type conformation stabilised by a Hoogsteen C-T base-pair
8PSI	;		;	G-quadruplex with a 1-nt V-shaped loop from a G-rich sequence with five G-runs
6ZRM	;		;	G-quadruplex with a G-A bulge
7ATZ	;		;	G-quadruplex with V-shaped loop from the first repeat of KCNN4 minisatellite
2N60	;		;	G-quadruplexes with (4n-1) guanines in the G-tetrad core: formation of a G-triad water complex and implication for small-molecule binding
1Y27	;	2.4	;	G-riboswitch-guanine complex
2M53	;		;	G-rich VEGF aptamer with LNA modifications
2MKM	;		;	G-triplex structure and formation propensity
2MKO	;		;	G-triplex structure and formation propensity
7UVK	;	3.28	;	G. haemolysans IgA1 protease
1D91	;	2.1	;	G.T BASE PAIRS IN A DNA HELIX. THE CRYSTAL STRUCTURE OF D(G-G-G-G-T-C-C-C)
4G6D	;	1.9971	;	G1 ORF67 / Staphyloccus aureus sigmaA domain 4 complex
4G8X	;	3.001	;	G1 ORF67 / Staphyloccus aureus sigmaA domain 4 complex
4G94	;	1.9971	;	G1 ORF67 / Staphyloccus aureus sigmaA domain 4 complex
1IP5	;	1.8	;	G105A HUMAN LYSOZYME
3QPL	;	3.2	;	G106W mutant of EthR from Mycobacterium tuberculosis
7U2F	;	2.2	;	G116F Pseudomonas aeruginosa azurin
2XMD	;	2.3	;	G117H mutant of human butyrylcholinesterase in complex with echothiophate
2XMC	;	2.4	;	G117H mutant of human butyrylcholinesterase in complex with fluoride anion
2XMB	;	2.1	;	G117H mutant of human butyrylcholinesterase in complex with sulfate
2XMG	;	2.7	;	G117H mutant of human butyrylcholinesterase in complex with VX
1IP6	;	1.8	;	G127A HUMAN LYSOZYME
1IP7	;	1.9	;	G129A HUMAN LYSOZYME
1A4R	;	2.5	;	G12V MUTANT OF HUMAN PLACENTAL CDC42 GTPASE IN THE GDP FORM
5BV8	;	1.59	;	G1324S mutation in von Willebrand Factor A1 domain
1NG8	;		;	G15-Gramicidin A in Sodium Dodecyl Sulfate Micelles (NMR)
7LD6	;	1.3	;	G150A Pseudomonas fluorescens isocyanide hydratase (G150A-1) at 274K, Phenix-refined
7LD7	;	1.25	;	G150A Pseudomonas fluorescens isocyanide hydratase (G150A-2) at 274K, Phenix-refined
7LDB	;	1.35	;	G150A Pseudomonas fluorescens isocyanide hydratase (G150A-3) at 274K, Phenix-refined
7LDM	;	1.15	;	G150T Pseudomonas fluorescens isocyanide hydratase (G150T-1) at 274K, Phenix-refined
7LDI	;	1.2	;	G150T Pseudomonas fluorescens isocyanide hydratase (G150T-2) at 274K, Phenix-refined
7LDO	;	1.1	;	G150T Pseudomonas fluorescens isocyanide hydratase (G150T-3) at 274K, Phenix-refined
1GN6	;	2.9	;	G152A mutant of Mycobacterium tuberculosis iron-superoxide dismutase.
5CT8	;	1.29	;	G158E/K44E/R57E/Y49E Bacillus subtilis lipase A with 0% [BMIM][Cl]
5CTA	;	1.24	;	G158E/K44E/R57E/Y49E Bacillus subtilis lipase A with 10% [BMIM][Cl]
5CUR	;	1.302	;	G158E/K44E/R57E/Y49E Bacillus subtilis lipase A with 20% [BMIM][Cl]
5CT9	;	1.4	;	G158E/K44E/R57E/Y49E Bacillus subtilis lipase A with 5% [BMIM][Cl]
5KJ1	;	1.2	;	G173A horse liver alcohol dehydrogenase complexed with NAD+ and pentafluorobenzyl alcohol
3OV3	;	2.5	;	G211F mutant of curcumin synthase 1 from Curcuma longa
4IHM	;	1.29	;	G215S, A251G, T257A, D260G, T262D mutant of carboxypeptidase T from Thermoactinomyces vulgaris
4IK2	;	1.4	;	G215S, A251G, T257A, D260G, T262D mutant of carboxypeptidase T from Thermoactinomyces vulgaris with N-BOC-L-Leu
4IAV	;	1.35	;	G215S, A251G, T257A, D260G, T262D mutant of carboxypeptidase T from Thermoactinomyces vulgaris with N-Sulfamoyl-L-phenylalanine
4RNU	;	2.677	;	G303 Circular Permutation of Old Yellow Enzyme
4RNV	;	2.473	;	G303 Circular Permutation of Old Yellow Enzyme with the Inhibitor p-Hydroxybenzaldehyde
5MIU	;	3.5	;	G307E variant of Murine Apoptosis Inducing Factor (oxidized state)
5MIV	;	3.1	;	G307E variant of murine Apoptosis Inducing Factor in complex with NAD+
1ZXH	;		;	G311 mutant protein
7SWN	;	4.3	;	G32A4 Fab in complex with SARS-CoV-2 Spike 6P (RBD local reconstruction)
7SWP	;	3.8	;	G32Q4 Fab in complex with SARS-CoV-2 Spike 6P (RBD local reconstruction)
1IP1	;	1.8	;	G37A HUMAN LYSOZYME
4CYR	;	1.72	;	G4 mutant of PAS, arylsulfatase from Pseudomonas Aeruginosa
4CXU	;	2.03	;	G4 mutant of PAS, arylsulfatase from Pseudomonas Aeruginosa, in complex with 3-Br-Phenolphenylphosphonate
4CXS	;	2.3	;	G4 mutant of PAS, arylsulfatase from Pseudomonas aeruginosa, in complex with Phenylphosphonic acid
8FYH	;	3.4	;	G4 RNA-mediated PRC2 dimer
2AVJ	;	2.39	;	G4(Br)UTTG4 dimeric quadruplex
1IP2	;	1.8	;	G48A HUMAN LYSOZYME
1A9M	;	2.3	;	G48H MUTANT OF HIV-1 PROTEASE IN COMPLEX WITH A PEPTIDIC INHIBITOR U-89360E
2AVH	;	1.5	;	G4T3G4 dimeric quadruplex structure
1RDF	;	2.8	;	G50P mutant of phosphonoacetaldehyde hydrolase in complex with substrate analogue vinyl sulfonate
2GC5	;	1.85	;	G51S mutant of L. casei FPGS
2GCB	;	2.3	;	G51S/S52T double mutant of L. casei FPGS
3FC5	;	2.59	;	G586S mutant nNOSoxy
8HQ5	;	2.25	;	G6 in complex with CRM1-Ran-RanBP1
4CYS	;	1.88	;	G6 mutant of PAS, arylsulfatase from Pseudomonas Aeruginosa, in complex with Phenylphosphonic acid
1AKR	;	1.58	;	G61A OXIDIZED FLAVODOXIN MUTANT
1AKW	;	1.75	;	G61L OXIDIZED FLAVODOXIN MUTANT
1AKT	;	1.8	;	G61N OXIDIZED FLAVODOXIN MUTANT
1AZL	;	1.8	;	G61V FLAVODOXIN MUTANT FROM DESULFOVIBRIO VULGARIS
3KMS	;	2.2	;	G62S mutant of foot-and-mouth disease virus RNA-polymerase in complex with a template- primer RNA trigonal structure
3KMQ	;	2.11	;	G62S mutant of foot-and-mouth disease virus RNA-polymerase in complex with a template- primer RNA, tetragonal structure
1IP3	;	1.8	;	G68A HUMAN LYSOZYME
5SUK	;	2.88	;	G6P bound activated state of yeast glycogen synthase 2
5AJ9	;	2.0	;	G7 mutant of PAS, arylsulfatase from Pseudomonas Aeruginosa
1IP4	;	1.8	;	G72A HUMAN LYSOZYME
6ZPP	;	1.5	;	g7941: a virulence factor from Drechmaria coniospora
4CXK	;	1.86	;	G9 mutant of PAS, arylsulfatase from Pseudomonas Aeruginosa
7T8F	;	1.4	;	G93A mutant of human SOD1 bound with Ebselen in P21 space group
7T8H	;	1.5	;	G93A mutant of human SOD1 bound with MR6-26-2 in P21 space group
7T8G	;	1.35	;	G93A mutant of human SOD1 bound with MR6-8-2 in P21 space group
7T8E	;	1.4	;	G93A mutant of human SOD1 in P21 space group
2WZ6	;	1.55	;	G93A SOD1 mutant complexed with Quinazoline.
6CK4	;	3.097	;	G96A mutant of the PRPP riboswitch from T. mathranii bound to ppGpp
3FPD	;	2.4	;	G9a-like protein lysine methyltransferase inhibition by BIX-01294
1MUG	;	1.8	;	G:T/U MISMATCH-SPECIFIC DNA GLYCOSYLASE FROM E.COLI
7BL0	;		;	GA attached to an i-motif clip at 3'-end
7BI0	;		;	GA repetition with i-motif clip at 5'-end
2MH8	;		;	GA-79-MBP cs-rosetta structures
1CFW	;	1.9	;	GA-SUBSTITUTED DESULFOREDOXIN
7PV2	;	3.2	;	GA1 bacteriophage portal protein
2LHC	;		;	Ga98 solution structure
1ZIF	;		;	GAAA RNA TETRALOOP, NMR, 10 STRUCTURES
2I7E	;		;	GAAA tetralooop receptor complex with associated cobalt hexammine.
2I7Z	;		;	GAAA tetraloop receptor complex with associated manganese ions.
6J2V	;	1.9	;	GABA aminotransferase from Corynebacterium glutamicum
1GNU	;	1.75	;	GABA(A) receptor associated protein GABARAP
8BHG	;	2.39	;	GABA-A receptor a5 heteromer - a5V2 - Bretazenil
8BGI	;	2.56	;	GABA-A receptor a5 homomer - a5V1 - Flumazenil
8BEJ	;	3.24	;	GABA-A receptor a5 homomer - a5V3 - APO
8BHA	;	2.67	;	GABA-A receptor a5 homomer - a5V3 - Basmisanil - HR
8BHK	;	3.3	;	GABA-A receptor a5 homomer - a5V3 - Diazepam
8BHM	;	2.95	;	GABA-A receptor a5 homomer - a5V3 - DMCM
8BHO	;	2.93	;	GABA-A receptor a5 homomer - a5V3 - L655708
8BHB	;	2.54	;	GABA-A receptor a5 homomer - a5V3 - RO154513
8BHS	;	3.24	;	GABA-A receptor a5 homomer - a5V3 - RO4938581
8BHI	;	2.67	;	GABA-A receptor a5 homomer - a5V3 - RO5211223
8BHR	;	3.38	;	GABA-A receptor a5 homomer - a5V3 - RO7015738
8BHQ	;	3.3	;	GABA-A receptor a5 homomer - a5V3 - RO7172670
7PC0	;	3.0	;	GABA-A receptor bound by a-Cobratoxin
4Y0I	;	1.662	;	GABA-aminotransferase inactivated by conformationally-restricted inactivator
4ATQ	;	2.75	;	GABA-transaminase A1R958 in complex with external aldimine PLP-GABA adduct
3FQA	;	2.35	;	Gabaculien complex of gabaculine resistant GSAM version
3FQ7	;	2.15	;	Gabaculine complex of GSAM
8AFI	;	2.66	;	GABARAP in complex with LIR motif of HsATG3
5LXH	;	1.58	;	GABARAP-L1 ATG4B LIR Complex
5LXI	;	1.44	;	GABARAP-L1 ATG4B LIR Complex
3WIM	;	2.6	;	GABARAP-LIR peptide complex
2L8J	;		;	GABARAPL-1 NBR1-LIR complex structure
2JUO	;		;	GABPa OST domain
1ZF7	;	1.05	;	GAC Duplex B-DNA
7Z8N	;	2.64	;	GacS histidine kinase from Pseudomonas aeruginosa
4TWS	;	1.45	;	Gadolinium Derivative of Tetragonal Hen Egg-White Lysozyme at 1.45 A Resolution
1H87	;	1.72	;	Gadolinium derivative of tetragonal Hen Egg-White Lysozyme at 1.7 A resolution
6RQ7	;	2.69	;	Gadolinium MRI contrast compound binding in human plasma glycoprotein afamin - resurrection of highly anisotropic data
5N35	;	2.24	;	Gadolinium phased PBP2 (SSO6202) at 2.2 Ang
5GJH	;	1.2	;	Gads SH2 domain/CD28-derived peptide complex
1OIO	;	1.7	;	GafD (F17c-type) Fimbrial adhesin from Escherichia coli
7NDU	;	2.9	;	Gag:02 TCR in complex with HLA-E featuring a non-natural amino acid
7NDQ	;	2.551	;	Gag:02 TCR in complex with HLA-E.
1ZIG	;		;	GAGA RNA TETRALOOP, NMR, 10 STRUCTURES
8J82	;	1.69	;	GaHNL-12gen (artificial S-hydroxynitrile lyase generated by GAOptimizer)
8WY4	;	2.81	;	GajA tetramer with ATP
8J4T	;	3.6	;	GajA-GajB complex
1AW6	;		;	GAL4 (CD), NMR, 24 STRUCTURES
1A6R	;	2.05	;	GAL6 (YEAST BLEOMYCIN HYDROLASE) MUTANT C73A
3GCB	;	1.87	;	GAL6 (YEAST BLEOMYCIN HYDROLASE) MUTANT C73A/DELTAK454
1GCB	;	2.2	;	GAL6, YEAST BLEOMYCIN HYDROLASE DNA-BINDING PROTEASE (THIOL)
6EON	;	1.75	;	Galactanase BT0290
4UEK	;	1.9	;	Galactitol-1-phosphate 5-dehydrogenase from E. coli with Tris within the active site.
2EID	;	2.2	;	Galactose Oxidase W290G mutant
2JKX	;	1.84	;	Galactose oxidase. MatGO. Copper free, expressed in Pichia Pastoris.
2BZD	;	2.0	;	Galactose recognition by the carbohydrate-binding module of a bacterial sialidase.
6BFM	;	1.488	;	Galactose-binding Lectin from Mytilus californianus, Isoform1
6XAC	;	1.22	;	Galactose-bound structure of Marinomonas primoryensis PA14 carbohydrate-binding domain
3UK9	;	3.11	;	Galactose-specific lectin from Dolichos lablab
3UJQ	;	2.06	;	Galactose-specific lectin from Dolichos lablab in complex with galactose
3UL2	;	2.5	;	Galactose-specific lectin from Dolichos lablab in P6522 space group
3UJO	;	2.0	;	Galactose-specific seed lectin from Dolichos lablab in complex with adenine and galactose
2YFN	;	1.45	;	galactosidase domain of alpha-galactosidase-sucrose kinase, AgaSK
2YFO	;	1.35	;	GALACTOSIDASE DOMAIN OF ALPHA-GALACTOSIDASE-SUCROSE KINASE, AGASK, in complex with galactose
1KRR	;	2.5	;	Galactoside Acetyltransferase in Complex with Acetyl-Coenzyme A
1KRV	;	2.8	;	Galactoside Acetyltransferase in Complex with CoA and PNP-beta-Gal
1KQA	;	3.2	;	GALACTOSIDE ACETYLTRANSFERASE IN COMPLEX WITH COENZYME A
1KRU	;	2.8	;	Galactoside Acetyltransferase in Complex with IPTG and Coenzyme A
8ATE	;	1.92	;	Galacturonic acid oxidase from Citrus sinensis
5OLP	;	2.0	;	Galacturonidase
7WQ3	;	2.7	;	Galanin-bound galanin receptor 1 in complex with Gi
7WQ4	;	2.6	;	Galanin-bound galanin receptor 2 in complex with Gq
2PH9	;	2.88	;	Galanthamine bound to an ACh-binding Protein
3WMW	;	2.25	;	GalE-like L-Threonine dehydrogenase from Cupriavidus necator (apo form)
3WMX	;	2.5	;	GalE-like L-Threonine dehydrogenase from Cupriavidus necator (holo form)
2WSU	;	1.9	;	Galectin domain of porcine adenovirus type 4 NADC-1 isolate fibre
2WT1	;	1.9	;	Galectin domain of porcine adenovirus type 4 NADC-1 isolate fibre complexed with lacto-N-neo-tetraose
2WSV	;	2.0	;	Galectin domain of porcine adenovirus type 4 NADC-1 isolate fibre complexed with lactose
2WT0	;	1.91	;	Galectin domain of porcine adenovirus type 4 NADC-1 isolate fibre complexed with N-acetyl-lactosamine
2WT2	;	2.5	;	Galectin domain of porcine adenovirus type 4 NADC-1 isolate fibre complexed with tri(N-acetyl-lactosamine)
2KM2	;		;	Galectin-1 dimer
7NML	;	1.43	;	Galectin-1 in complex with 4-Amino-6-chloro-1,3-benzenedisulfonamide
4Q27	;	1.2	;	Galectin-1 in Complex with a Click-Activated N-Acetyllactosamine
4Q2F	;	1.4	;	Galectin-1 in Complex with Ligand AN020
4Q1R	;	1.47	;	Galectin-1 in Complex with Ligand AN027
5MWX	;	1.29	;	Galectin-1 in Complex with Ligand JB60
5MWT	;	1.711	;	Galectin-1 in Complex with Ligand JB97
8B0Z	;	1.23	;	Galectin-1 in Complex with Ligand JM171
8B0W	;	1.53	;	Galectin-1 in Complex with Ligand MG49
4Q1P	;	1.46	;	Galectin-1 in Complex with Ligand NB169
7LTA	;	1.53	;	Galectin-1 in complex with Trehalose
6QRN	;	1.4	;	Galectin-10 complexed with ribose
5YT4	;	2.0	;	Galectin-10 variant H53A soaked in glycerol for 5 minutes
5XRG	;	1.55	;	Galectin-10/Charcot-Leyden crystal protein crystal structure
5XRH	;	1.55	;	Galectin-10/Charcot-Leyden crystal protein crystal structure
5XRK	;	1.7	;	Galectin-10/Charcot-Leyden crystal protein variant C57A crystal structure
5XRJ	;	1.9	;	Galectin-10/Charcot-Leyden crystal protein variant H53A crystal structure
5XRN	;	1.6	;	Galectin-10/Charcot-Leyden crystal protein variant K73A crystal structure
5XRL	;	2.004	;	Galectin-10/Charcot-Leyden crystal protein variant N65A crystal structure
5XRO	;	1.6	;	Galectin-10/Charcot-Leyden crystal protein variant Q74A crystal structure
5XRP	;	2.001	;	Galectin-10/Charcot-Leyden crystal protein variant Q75A
5XRM	;	1.998	;	Galectin-10/Charcot-Leyden crystal protein variant W72A crystal structure
5XRI	;	1.68	;	Galectin-10/Charcot-Leyden crystal protein-C29A crystal structure
6KJW	;	1.36	;	Galectin-13 variant C136S
6KJY	;	1.5	;	Galectin-13 variant C136S/C138S
6KJX	;	1.53	;	Galectin-13 variant C138S
5XG7	;	1.55	;	Galectin-13/Placental Protein 13 crystal structure
5XG8	;	1.55	;	Galectin-13/Placental Protein 13 variant R53H crystal structure
5Y03	;	2.12	;	Galectin-13/Placental Protein 13 variant R53H crystal structure
6FK2	;	1.01	;	Galectin-3 carbohydrate recognition domain in complex with lactitol
4JC1	;	1.5	;	Galectin-3 carbohydrate recognition domain in complex with thiodigalactoside
8PPN	;	1.8	;	Galectin-3 carbohydrate recognition domain in complex with thiodigalactoside at 1.8 resolution
4JCK	;	1.15	;	Galectin-3 carbohydrate recognition domain in complex with thioditaloside
6KXA	;	1.23	;	Galectin-3 CRD binds to GalA dimer
6KXB	;	1.5	;	Galectin-3 CRD binds to GalA trimer
8OJM	;	1.8	;	Galectin-3 in complex with 2,6-anhydro-3-deoxy-3-S-(beta-D-galactopyranosyl)-3-thio-D-glycero-D-galacto-heptonamide
8OJK	;	1.8	;	Galectin-3 in complex with 2,6-anhydro-3-deoxy-3-S-(beta-D-galactopyranosyl)-3-thio-D-glycero-L-altro-heptonamide
8OJO	;	1.8	;	Galectin-3 in complex with 2,6-Anhydro-5-S-(beta-D-galactopyranosyl)-5-thio-D-altritol
8OJI	;	1.75	;	Galectin-3 in complex with Methyl 2,6-anhydro-3-deoxy-3-S-(b-D-galactopyranosyl)-3-thio-D-glycero-L-altro-heptonate
6QGF	;	1.34	;	Galectin-3C in complex with a pair of enantiomeric ligands: R enantiomer
6QGE	;	1.16	;	Galectin-3C in complex with a pair of enantiomeric ligands: S enantiomer
8PBF	;	1.14	;	Galectin-3C in complex with a triazolesulfane derivative
8PF9	;	1.09	;	Galectin-3C in complex with a triazolesulfane derivative
8PFF	;	1.08	;	Galectin-3C in complex with a triazolesulfone derivative
4BLI	;	1.08	;	Galectin-3c in complex with Bisamido-thiogalactoside derivate 1
4BLJ	;	1.2	;	Galectin-3c in complex with Bisamido-thiogalactoside derivate 2
4BM8	;	0.96	;	Galectin-3c in complex with Bisamido-thiogalactoside derivate 3
5IUQ	;	1.121	;	Galectin-3c in complex with Bisamido-thiogalactoside derivative 4
5ODY	;	1.149	;	Galectin-3C in complex with dithiogalactoside derivative
6QLN	;	1.0	;	Galectin-3C in complex with fluoroaryl triazole monothiogalactoside derivative 2
6QLQ	;	1.079	;	Galectin-3C in complex with fluoroaryltriazole monothiogalactoside derivative 4
6QLR	;	0.97	;	Galectin-3C in complex with fluoroaryltriazole monothiogalactoside derivative 5
6QLS	;	1.047	;	Galectin-3C in complex with fluoroaryltriazole monothiogalactoside derivative 6
6QLT	;	1.15	;	Galectin-3C in complex with fluoroaryltriazole monothiogalactoside derivative-7
6QLU	;	1.1	;	Galectin-3C in complex with fluoroaryltriazole monothiogalactoside derivative-8
6RZG	;	1.015	;	Galectin-3C in complex with meta-fluoroaryltriazole galactopyranosyl 1-thio-D-glucopyranoside derivative
6RZF	;	1.016	;	Galectin-3C in complex with ortho-fluoroaryltriazole galactopyranosyl 1-thio-D-glucopyranoside derivative
6RZH	;	0.947	;	Galectin-3C in complex with para-fluoroaryltriazole galactopyranosyl 1-thio-D-glucopyranoside derivative
6QLO	;	1.18	;	Galectin-3C in complex with substituted fluoroaryltriazole monothiogalactoside derivative 1
6I74	;	0.959	;	Galectin-3C in complex with substituted polyfluoroaryl monothiogalactoside derivative 1
6I75	;	1.171	;	Galectin-3C in complex with substituted polyfluoroaryl monothiogalactoside derivative 2
6QLP	;	1.081	;	Galectin-3C in complex with substituted polyfluoroaryl monothiogalactoside derivative 3
6I78	;	1.15	;	Galectin-3C in complex with substituted polyfluoroaryl monothiogalactoside derivative 5
6I76	;	1.2	;	Galectin-3C in complex with substituted polyfluoroaryl monothiogalactoside derivative-3
6I77	;	1.219	;	Galectin-3C in complex with substituted polyfluoroaryl monothiogalactoside derivative-4
5OAX	;	1.2	;	Galectin-3c in complex with thiogalactoside derivate
6RZI	;	1.095	;	Galectin-3C in complex with trifluoroaryltriazole monothiogalactoside derivative:1(Hydrogen)
6RZJ	;	1.097	;	Galectin-3C in complex with trifluoroaryltriazole monothiogalactoside derivative:2(Fluorine)
6RZK	;	1.046	;	Galectin-3C in complex with trifluoroaryltriazole monothiogalactoside derivative:3(Chlorine)
6RZL	;	1.045	;	Galectin-3C in complex with trifluoroaryltriazole monothiogalactoside derivative:4(Bromine)
6RZM	;	1.345	;	Galectin-3C in complex with trifluoroaryltriazole monothiogalactoside derivative:5(Iodine)
5T7T	;	1.96	;	Galectin-8 N terminal domain in complex with LNT
5VWG	;	2.1	;	Galectin-8 N terminal domain in complex with Methyl 3-O-[1-carboxyethyl]-beta-D-galactopyranoside
8CM8	;	1.22	;	Galectin-8 N-terminal carbohydrate recognition domain in complex with 4-(bromophenyl)phthalazinone D-galactal ligand
7P1M	;	1.52	;	Galectin-8 N-terminal carbohydrate recognition domain in complex with benzimidazole D-galactal ligand
7AEN	;	1.6	;	Galectin-8 N-terminal carbohydrate recognition domain in complex with methyl 3-O-((7-carboxy)quinolin-2-yl)-methoxy)-beta-D-galactopyranoside
7P11	;	2.1	;	Galectin-8 N-terminal carbohydrate recognition domain in complex with quinoline D-galactal ligand
5GZD	;	1.19	;	Galectin-8 N-terminal domain carbohydrate recognition domain
5GZE	;	1.32	;	Galectin-8 N-terminal domain carbohydrate recognition domain
5GZF	;	2.002	;	Galectin-8 N-terminal domain carbohydrate recognition domain
5GZG	;	1.997	;	Galectin-8 N-terminal domain carbohydrate recognition domain
6Z6Y	;	1.34	;	Galectin-8 N-terminal domain in complex with a sulfatide mimicking a sphingolipid
3VKO	;	2.08	;	Galectin-8 N-terminal domain in complex with sialyllactosamine
3VKN	;	1.98	;	Galectin-8 N-terminal domain in free form
6W4Z	;	1.59	;	Galectin-8N terminal domain in complex with Methyl 3-O-[3-O-benzyloxy]-malonyl-beta-D-galactopyranoside
5IT6	;	1.547	;	Galectin-related protein: an integral member of the network of chicken galectins
8E3T	;	2.2	;	Gallium-reconstituted nitrogenase MoFeP mutant S188A from Azotobacter vinelandii after IDS oxidation
1R0F	;	1.6	;	Gallium-substituted rubredoxin
4X38	;	2.12	;	Gallus interleukin-1 beta mutant - E118A
4X3A	;	1.75	;	gallus interleukin-1 beta mutant - R140A
4X39	;	1.61	;	Gallus interleukin-1 beta mutant - T117A
4X37	;	1.63	;	Gallus interleukin-1 mutant - E118K
4D0Z	;	2.2	;	GalNAc-T2 crystal soaked with UDP-5SGalNAc, mEA2 and manganese (Higher resolution dataset)
4D11	;	2.85	;	GalNAc-T2 crystal soaked with UDP-5SGalNAc, mEA2 peptide and manganese (Lower resolution dataset)
4D0T	;	2.45	;	GalNAc-T2 crystal soaked with UDP-GalNAc, EA2 peptide and manganese
6NQT	;	3.05	;	GalNac-T2 soaked with UDP-sugar
6MHF	;	2.0	;	Galphai3 co-crystallized with GIV/Girdin
6MHE	;	2.2	;	Galphai3 co-crystallized with KB752
4BCX	;	2.0	;	gamma 2 adaptin EAR domain crystal structure
2YMT	;	1.802	;	gamma 2 adaptin EAR domain crystal structure with phage peptide GEEWGPWV
3ZHF	;	1.7	;	gamma 2 adaptin EAR domain crystal structure with preS1 site1 peptide NPDWDFN
1DSL	;	1.55	;	GAMMA B CRYSTALLIN C-TERMINAL DOMAIN
1GAM	;	2.6	;	GAMMA B CRYSTALLIN TRUNCATED C-TERMINAL DOMAIN
1HL7	;	1.73	;	Gamma lactamase from an Aureobacterium species in complex with 3a,4,7,7a-tetrahydro-benzo [1,3] dioxol-2-one
2WKN	;	2.08	;	gamma lactamase from Delftia acidovorans
1A7H	;	2.56	;	GAMMA S CRYSTALLIN C-TERMINAL DOMAIN
4M0L	;	2.6	;	Gamma subunit of the translation initiation factor 2 from Sulfolobus solfataricus complexed with GDP
4RJL	;	1.6401	;	Gamma subunit of the translation initiation factor 2 from Sulfolobus solfataricus complexed with GDPCP
6I5M	;	2.4	;	Gamma subunit of the translation initiation factor 2 from Sulfolobus solfataricus in complex with GDP and formate ion
4M4S	;	2.251	;	Gamma subunit of the translation initiation factor 2 from Sulfolobus solfataricus in complex with GDP and formate ion mimic aIF2gamma*GDP*Pi complex (a formate ion substitutes for Pi)
4M53	;	2.0	;	Gamma subunit of the translation initiation factor 2 from Sulfolobus solfataricus in complex with GDPCP
4M2L	;	2.149	;	Gamma subunit of the translation initiation factor 2 from Sulfolobus solfataricus in nucleotide-free form
7NJE	;	3.0	;	gamma(S)-crystallin 9-site deamidation mutant grown inside HARE serial crystallography chip
1GYU	;	1.81	;	Gamma-adaptin appendage domain from clathrin adaptor AP1
1GYW	;	2.4	;	Gamma-adaptin appendage domain from clathrin adaptor AP1 A753D mutant
1GYV	;	1.71	;	Gamma-adaptin appendage domain from clathrin adaptor AP1, L762E mutant
4Y0D	;	2.19	;	Gamma-aminobutyric acid aminotransferase inactivated by (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115)
4Y0H	;	1.63	;	Gamma-aminobutyric acid aminotransferase inactivated by (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115)
8D9V	;	9.4	;	gamma-Arf1 homodimeric interface within AP-1, Arf1, Nef lattice on narrow membrane tubes
8D4D	;	9.6	;	gamma-Arf1 mediated dimeric assembly of AP-1, Arf1, Nef complex within lattice on MHC-I lipopeptide incorporated narrow membrane tubes
8D4G	;	11.6	;	gamma-Arf1 mediated dimeric assembly of AP-1, Arf1, Nef complex within lattice on MHC-I lipopeptide incorporated wide(r) membrane tubes
6SC4	;	2.6	;	Gamma-Carbonic Anhydrase from the Haloarchaeon Halobacterium sp.
4VGC	;	2.1	;	GAMMA-CHYMOTRYPSIN D-NAPHTHYL-1-ACETAMIDO BORONIC ACID INHIBITOR COMPLEX
2VGC	;	1.8	;	GAMMA-CHYMOTRYPSIN D-PARA-CHLORO-1-ACETAMIDO BORONIC ACID INHIBITOR COMPLEX
8GCH	;	1.6	;	GAMMA-CHYMOTRYPSIN IS A COMPLEX OF ALPHA-CHYMOTRYPSIN WITH ITS OWN AUTOLYSIS PRODUCTS
3VGC	;	1.67	;	GAMMA-CHYMOTRYPSIN L-NAPHTHYL-1-ACETAMIDO BORONIC ACID ACID INHIBITOR COMPLEX
1VGC	;	1.9	;	GAMMA-CHYMOTRYPSIN L-PARA-CHLORO-1-ACETAMIDO BORONIC ACID INHIBITOR COMPLEX
1ELP	;	1.95	;	GAMMA-D CRYSTALLIN STRUCTURE AT 1.95 A RESOLUTION
2RBH	;	2.1	;	Gamma-glutamyl cyclotransferase
3CRY	;	1.7	;	Gamma-glutamyl cyclotransferase
5ZJG	;	1.702	;	Gamma-glutamyltranspeptidase from Pseudomonas nitroreducens complexed with Gly-Gly
7D9E	;	1.5	;	Gamma-glutamyltranspeptidase from Pseudomonas nitroreducens complexed with L-DON
7D9W	;	1.9	;	Gamma-glutamyltranspeptidase from Pseudomonas nitroreducens complexed with L-DON
6FD8	;	2.1	;	Gamma-s crystallin dimer
5DSZ	;	2.5	;	Gamma-subunit of the translation initiation factor 2 from S. solfataricus
3I1F	;	2.5	;	Gamma-subunit of the translation initiation factor 2 from S. solfataricus in complex with Gpp(CH2)p
6ZPD	;	2.24	;	gamma-tocopherol transfer protein
1A5D	;	2.3	;	GAMMAE CRYSTALLIN FROM RAT LENS
1A45	;	2.3	;	GAMMAF CRYSTALLIN FROM BOVINE LENS
1HA4	;	2.4	;	GammaS crystallin C terminal domain from Homo Sapiens
2P57	;	1.8	;	GAP domain of ZNF289, an ID1-regulated zinc finger protein
7PGQ	;	3.5	;	GAP-SecPH region of human neurofibromin isoform 2 in closed conformation.
3TGH	;	1.7	;	GAP50 the anchor in the inner membrane complex of Plasmodium
1IHY	;	3.0	;	GAPDH complexed with ADP-ribose
6IEP	;	2.6	;	GAPDH of Streptococcus agalactiae
6YND	;	1.525	;	GAPDH purified from the supernatant of HEK293F cells: crystal form 1 of 4.
6YNE	;	1.853	;	GAPDH purified from the supernatant of HEK293F cells: crystal form 2 of 4.
6YNF	;	2.394	;	GAPDH purified from the supernatant of HEK293F cells: crystal form 3 of 4.
6YNH	;	2.621	;	GAPDH purified from the supernatant of HEK293F cells: crystal form 4 of 4
6GVE	;	3.9	;	GAPDH-CP12-PRK complex
2ID2	;	2.5	;	GAPN T244S mutant X-ray structure at 2.5 A
4AIW	;	1.5	;	GAPR-1 with bound inositol hexakisphosphate
4J2C	;	1.801	;	GARP-SNARE Interaction
7JFY	;	2.10056	;	GAS41 YEATS domain in complex with 5
6VFE	;	3.9	;	Gasdermin D pore
5TIB	;	2.6	;	Gasdermin-B C-terminal domain containing the polymorphism residues Arg299:Ser306 fused to maltose binding protein
5TJ4	;	3.5	;	Gasdermin-B C-terminal domain containing the polymorphism residues Gly299:Pro306 fused to maltose binding protein
5TJ2	;	2.8	;	Gasdermin-B C-terminal domain containing the polymorphism residues Gly299:Ser306 fused to maltose binding protein
1NWM	;	2.4	;	GAT domain of human GGA1
4AQ9	;	6.2	;	Gating movement in acetylcholine receptor analysed by time- resolved electron cryo-microscopy (open class)
4AQ5	;	6.2	;	Gating movement in acetylcholine receptor analysed by time-resolved electron cryo-microscopy (closed class)
7T3C	;	4.0	;	GATOR1-RAG-RAGULATOR - Dual Complex
7T3B	;	3.9	;	GATOR1-RAG-RAGULATOR - GAP Complex
7T3A	;	4.0	;	GATOR1-RAG-RAGULATOR - Inhibitory Complex
8U2C	;	2.5	;	Gaussian mixture model based single particle refinement - ABC transporter (inhibitor-bound ABCG2 from EMPIAR-10374)
8U28	;	3.1	;	Gaussian mixture model based single particle refinement - SARS (SARS-CoV-2 Spike Proteins on intact virions from EMPIAR-10492)
8U26	;	2.5	;	Gaussian Mixture Models based single particle refinement - GPCR (Substance P bound to active human neurokinin 1 receptor in complex with miniGs399 from EMPIAR-10786)
6PQA	;	1.46	;	GAVVGG segment 119-124 from human prion
7QTS	;		;	GB1 in mammalian cells, 10 uM
7QTR	;		;	GB1 in mammalian cells, 50 uM
5Z4B	;		;	GB1 structure determination in living eukaryotic cells by in-cell NMR spectroscopy
1P7E	;		;	GB3 solution structure obtained by refinement of X-ray structure with dipolar couplings
1P7F	;		;	GB3 solution structure obtained by refinement of X-ray structure with dipolar couplings
2OED	;		;	GB3 solution structure obtained by refinement of X-ray structure with dipolar couplings
2LHD	;		;	GB98 solution structure
2LHG	;		;	GB98-T25I solution structure
2LHE	;		;	Gb98-T25I,L20A
3SY3	;	2.14	;	GBAA_1210 protein, a putative adenylate cyclase, from Bacillus anthracis
3TJ7	;	2.1	;	GBAA_1210 protein, a putative adenylate cyclase, from Bacillus anthracis in complex with AMP
2ON8	;	1.35	;	Gbeta1 stabilization by in vitro evolution and computational design
2ONQ	;	1.7	;	Gbeta1 stabilization by in vitro evolution and computational design
8Q4L	;	5.12	;	GBP1 bound by 14-3-3sigma
8FX4	;	3.9	;	GC-C-Hsp90-Cdc37 regulatory complex
1ONH	;	1.38	;	GC1 beta-lactamase with a penem inhibitor
1ZFE	;	2.5	;	GCA Duplex B-DNA
1ZIH	;		;	GCAA RNA TETRALOOP, NMR, 10 STRUCTURES
1QYK	;	1.4	;	GCATGCT + Barium
1QZL	;	2.85	;	GCATGCT + Cobalt
1QYL	;	1.0	;	GCATGCT + Vanadium
1MF5	;	1.1	;	GCATGCT Quadruplex
7ZIE	;	2.9	;	Gcf1p, multimerizes and bridges the mitochondrial DNA from Candida albicans by a specific mechanism.
8FU6	;	2.9	;	GCGR-Gs complex in the presence of RAMP2
6WPW	;	3.1	;	GCGR-Gs signaling complex bound to a designed glucagon derivative
7QQ6	;	2.8	;	GCN2 (EIF2ALPHA KINASE 4, E2AK4) IN COMPLEX WITH COMPOUND 1 (dovitinib)
7QWK	;	2.3	;	GCN2 (EIF2ALPHA KINASE 4, E2AK4) IN COMPLEX WITH COMPOUND 2
2DGC	;	2.2	;	GCN4 BASIC DOMAIN, LEUCINE ZIPPER COMPLEXED WITH ATF/CREB SITE DNA
1GCL	;	2.1	;	GCN4 LEUCINE ZIPPER CORE MUTANT P-LI
1GCM	;	1.8	;	GCN4 LEUCINE ZIPPER CORE MUTANT P-LI
4DMD	;	2.0	;	GCN4 leucine zipper domain in a dimeric oligomerization state
4DME	;	2.2	;	GCN4 leucine zipper domain in a trimeric oligomerization state
2WPY	;	1.75	;	GCN4 leucine zipper mutant with one VxxNxxx motif coordinating chloride
2WQ1	;	1.08	;	GCN4 leucine zipper mutant with three IxxNTxx motifs coordinating bromide
2WQ0	;	1.12	;	GCN4 leucine zipper mutant with three IxxNTxx motifs coordinating chloride
2WQ3	;	1.22	;	GCN4 leucine zipper mutant with three IxxNTxx motifs coordinating chloride and nitrate
2WQ2	;	1.36	;	GCN4 leucine zipper mutant with three IxxNTxx motifs coordinating iodide
2WPZ	;	1.25	;	GCN4 leucine zipper mutant with two VxxNxxx motifs coordinating chloride
3M48	;	1.451	;	GCN4 Leucine Zipper Peptide Mutant
2AHP	;	2.0	;	GCN4 leucine zipper, mutation of Lys15 to epsilon-azido-Lys
6O2E	;	1.896	;	GCN4 with asparagine at position 18
6O2F	;	1.8	;	GCN4 with NPEG4 at position 18
1SWI	;	2.6	;	GCN4-LEUCINE ZIPPER CORE MUTANT AS N16A COMPLEXED WITH BENZENE
3K7Z	;	1.9	;	GCN4-Leucine zipper core mutant as N16A trigonal automatic solution
1ZII	;	1.8	;	GCN4-LEUCINE ZIPPER CORE MUTANT ASN16ABA IN THE DIMERIC STATE
1ZIJ	;	2.0	;	GCN4-LEUCINE ZIPPER CORE MUTANT ASN16ABA IN THE TRIMERIC STATE
1ZIL	;	2.25	;	GCN4-LEUCINE ZIPPER CORE MUTANT ASN16GLN IN THE DIMERIC STATE
1ZIM	;	2.0	;	GCN4-LEUCINE ZIPPER CORE MUTANT ASN16GLN IN THE TRIMERIC STATE
1ZIK	;	1.8	;	GCN4-LEUCINE ZIPPER CORE MUTANT ASN16LYS IN THE DIMERIC STATE
4NJ1	;	2.0	;	GCN4-p1 double Val9, 23 to Ile mutant
6XNL	;	2.2	;	GCN4-p1 Peptide Trimer with iodo-phenylalanine residue at position 16 (IPF-F16)
6XNE	;	1.96	;	GCN4-p1 Peptide Trimer with p-methylphenylalanine residue at position 16 (me-F16)
6XNF	;	2.0	;	GCN4-p1 Peptide Trimer with Tetrafluoroiodophenylalanine residue at position 16 (TFI-F16)
6XNM	;	2.25	;	GCN4-p1 Peptide Trimer with tyrosine residue at position 16
4NIZ	;	2.0	;	GCN4-p1 single Val9 to aminobutyric acid mutant
4NJ0	;	1.9	;	GCN4-p1 single Val9 to Ile mutant
4NJ2	;	2.2	;	GCN4-p1 triple Val9, 23,30 to Ile mutant
4TL1	;	1.8	;	GCN4-p1 with mutation to 1-Aminocyclohexanecarboxylic acid at residue 10
1IJ1	;	1.86	;	GCN4-pVLT Coiled-coil Trimer with Threonine at the d(12) Position
1IJ3	;	1.8	;	GCN4-pVSL Coiled-coil trimer with Serine at the a(16) position
1IJ2	;	1.7	;	GCN4-pVTL Coiled-coil Trimer with Threonine at the a(16) position
5IIV	;		;	GCN4p pH 1.5
4HJD	;	1.7	;	GCN4pLI derivative with alpha/beta/acyclic-gamma amino acid substitution pattern
4HJB	;	1.25	;	GCN4pLI derivative with alpha/beta/cyclic-gamma amino acid substitution pattern
4IUS	;	1.3	;	GCN5-related N-acetyltransferase from Kribbella flavida.
8OSP	;	1.95	;	GCN5-related N-Acetyltransferase from Lactobacillus curiae
5KRB	;	2.101	;	GCNF DNA Binding Domain - Oct4 DR0 Complex
1ZF5	;	0.99	;	GCT duplex B-DNA
7MSA	;	2.24	;	GDC-9545 in complex with estrogen receptor alpha
1E6U	;	1.45	;	GDP 4-keto-6-deoxy-D-mannose epimerase reductase
1E7S	;	1.5	;	GDP 4-keto-6-deoxy-D-mannose epimerase reductase K140R
1E7Q	;	1.6	;	GDP 4-keto-6-deoxy-D-mannose epimerase reductase S107A
1E7R	;	1.6	;	GDP 4-keto-6-deoxy-D-mannose epimerase reductase Y136E
1AS3	;	2.4	;	GDP BOUND G42V GIA1
6JFK	;	1.997	;	GDP bound Mitofusin2 (MFN2)
2C03	;	1.24	;	GDP COMPLEX OF SRP GTPASE FFH NG DOMAIN
1AS2	;	2.8	;	GDP+PI BOUND G42V GIA1
8JGD	;	1.60037	;	GDP-bound KRAS G12C in complex with YK-8S
7EW9	;	2.13	;	GDP-bound KRAS G12D in complex with TH-Z816
7EWA	;	2.25	;	GDP-bound KRAS G12D in complex with TH-Z827
7EWB	;	1.99	;	GDP-bound KRAS G12D in complex with TH-Z835
8JHL	;	2.10004	;	GDP-bound KRAS G12D in complex with YK-8S
6MS9	;	1.49	;	GDP-bound KRAS P34R mutant
1Z0F	;	2.15	;	GDP-Bound Rab14 GTPase
1Z0I	;	2.33	;	GDP-Bound Rab21 GTPase
1Z22	;	2.06	;	GDP-Bound Rab23 GTPase crystallized in C222(1) space group
1Z2A	;	1.9	;	GDP-Bound Rab23 GTPase crystallized in P2(1)2(1)2(1) space group
1Z0A	;	2.12	;	GDP-Bound Rab2A GTPase
1Z0D	;	2.2	;	GDP-Bound Rab5c GTPase
1VG1	;	1.9	;	GDP-Bound Rab7
4P4T	;	2.3	;	GDP-bound stalkless-MxA
8R9R	;	2.42	;	GDP-bound state of S. putrefaciens FlhF
3CNO	;	2.3	;	GDP-bound structue of TM YlqF
1KY3	;	1.35	;	GDP-BOUND YPT7P AT 1.35 A RESOLUTION
4KWE	;	2.91	;	GDP-bound, double-stranded, curved FtsZ protofilament structure
1GFS	;	2.2	;	GDP-FUCOSE SYNTHETASE FROM E. COLI
1FXS	;	2.3	;	GDP-FUCOSE SYNTHETASE FROM ESCHERICHIA COLI COMPLEX WITH NADP
1BSV	;	2.2	;	GDP-FUCOSE SYNTHETASE FROM ESCHERICHIA COLI COMPLEX WITH NADPH
2I8U	;	1.4	;	GDP-mannose mannosyl hydrolase-calcium-GDP product complex
2I8T	;	1.3	;	GDP-mannose mannosyl hydrolase-calcium-GDP-mannose complex
2C5E	;	1.7	;	gdp-mannose-3', 5' -epimerase (arabidopsis thaliana), k217a, with gdp-alpha-d-mannose bound in the active site.
2C59	;	2.0	;	gdp-mannose-3', 5' -epimerase (arabidopsis thaliana), with gdp-alpha-d-mannose and gdp-beta-l-galactose bound in the active site.
2C54	;	1.5	;	gdp-mannose-3', 5' -epimerase (arabidopsis thaliana),k178r, with gdp-beta-l-gulose and gdp-4-keto-beta-l-gulose bound in active site.
2C5A	;	1.4	;	GDP-mannose-3', 5' -epimerase (Arabidopsis thaliana),Y174F, with GDP-beta-L-galactose bound in the active site
5XXV	;	6.46	;	GDP-microtubule complexed with KIF5C in AMPPNP state
5XXW	;	6.0	;	GDP-microtubule complexed with KIF5C in ATP state
5XXT	;	5.35	;	GDP-microtubule complexed with nucleotide-free KIF5C
3DR7	;	1.7	;	GDP-perosamine synthase from Caulobacter crescentus with bound GDP-3-deoxyperosamine
3DR4	;	1.6	;	GDP-perosamine synthase K186A mutant from Caulobacter crescentus with bound sugar ligand
3RYI	;	2.4	;	GDP-Tubulin: rb3 stathmin-like domain complex
2CNW	;	2.39	;	GDPALF4 complex of the SRP GTPases Ffh and FtsY
7E0V	;	1.65	;	GDPD from Pyrococcus furiosus DSM 3638
7E2B	;	1.85	;	GDPD mutant complex from Pyrococcus furiosus DSM 3638
7E2A	;	2.08	;	GDPD mutant from Pyrococcus furiosus DSM 3638
7UT4	;	3.9	;	Gea2 closed/closed conformation (composite structure)
7URR	;	4.7	;	Gea2 closed/open conformation (composite structure)
7UTH	;	3.9	;	Gea2 open/open conformation (composite structure)
7URO	;	4.2	;	Gea2-Arf1 activation intermediate complex (composite structure)
7JWE	;	2.55	;	Gedatolisib bound to the PI3Kg catalytic subunit p110 gamma
3TW8	;	2.1	;	GEF domain of DENND 1B in complex with Rab GTPase Rab35
6H7E	;	2.3	;	GEF regulatory domain
8A3N	;	2.0	;	Geissoschizine synthase from Catharanthus roseus - binary complex with NADP+
1CK7	;	2.8	;	GELATINASE A (FULL-LENGTH)
1YET	;	1.9	;	GELDANAMYCIN BOUND TO THE HSP90 GELDANAMYCIN-BINDING DOMAIN
1NPH	;	3.0	;	Gelsolin Domains 4-6 in Active, Actin Free Conformation Identifies Sites of Regulatory Calcium Ions
1H1V	;	2.99	;	gelsolin G4-G6/actin complex
2X1O	;	1.34	;	Gelsolin Nanobody
2X1P	;	1.1	;	Gelsolin Nanobody
2X1Q	;	1.06	;	Gelsolin Nanobody
4S10	;	2.614	;	Gelsolin nanobody shielding mutant plasma gelsolin from furin proteolysis
4S11	;	1.998	;	Gelsolin nanobody shielding mutant plasma gelsolin from furin proteolysis
5THA	;	1.8	;	Gemin5 WD40 repeats in complex with a guanosyl moiety
1VJI	;	2.003	;	Gene Product of At1g76680 from Arabidopsis thaliana
1Q4R	;	1.9	;	Gene Product of At3g17210 from Arabidopsis Thaliana
1GVP	;	1.6	;	GENE V PROTEIN (SINGLE-STRANDED DNA BINDING PROTEIN)
1VQB	;	1.8	;	GENE V PROTEIN (SINGLE-STRANDED DNA BINDING PROTEIN)
1VQG	;	1.82	;	GENE V PROTEIN MUTANT WITH ILE 47 REPLACED BY LEU 47 (I47L)
1VQH	;	1.8	;	GENE V PROTEIN MUTANT WITH ILE 47 REPLACED BY MET 47 (I47M)
1VQI	;	1.8	;	GENE V PROTEIN MUTANT WITH ILE 47 REPLACED BY VAL 47 (I47V)
1VQA	;	1.8	;	GENE V PROTEIN MUTANT WITH VAL 35 REPLACED BY ALA 35 AND ILE 47 REPLACED BY LEU 47 (V35A, I47L)
1VQJ	;	1.8	;	GENE V PROTEIN MUTANT WITH VAL 35 REPLACED BY ILE 35 (V35I)
1VQD	;	1.82	;	GENE V PROTEIN MUTANT WITH VAL 35 REPLACED BY ILE 35 AND ILE 47 REPLACED BY LEU 47 (V35I, I47L)
1VQE	;	1.8	;	GENE V PROTEIN MUTANT WITH VAL 35 REPLACED BY ILE 35 AND ILE 47 REPLACED BY MET 47 (V35I, I47M)
1VQC	;	1.8	;	GENE V PROTEIN MUTANT WITH VAL 35 REPLACED BY ILE 35 AND ILE 47 REPLACED BY PHE 47 (V35I, I47F)
1VQF	;	1.8	;	GENE V PROTEIN MUTANT WITH VAL 35 REPLACED BY ILE 35 AND ILE 47 REPLACED BY VAL 47 (V35I, I47V)
7BHG	;	2.09	;	Gene-engineered variant of FusionRed with Trp based chromophore - 2.1A
2NNT	;		;	General structural motifs of amyloid protofilaments
2HEO	;	1.7	;	General Structure-Based Approach to the Design of Protein Ligands: Application to the Design of Kv1.2 Potassium Channel Blockers.
7ML3	;	7.6	;	General transcription factor TFIIH (weak binding)
220L	;	1.85	;	GENERATING LIGAND BINDING SITES IN T4 LYSOZYME USING DEFICIENCY-CREATING SUBSTITUTIONS
222L	;	1.9	;	GENERATING LIGAND BINDING SITES IN T4 LYSOZYME USING DEFICIENCY-CREATING SUBSTITUTIONS
223L	;	1.9	;	GENERATING LIGAND BINDING SITES IN T4 LYSOZYME USING DEFICIENCY-CREATING SUBSTITUTIONS
225L	;	1.9	;	GENERATING LIGAND BINDING SITES IN T4 LYSOZYME USING DEFICIENCY-CREATING SUBSTITUTIONS
226L	;	1.8	;	GENERATING LIGAND BINDING SITES IN T4 LYSOZYME USING DEFICIENCY-CREATING SUBSTITUTIONS
227L	;	2.0	;	GENERATING LIGAND BINDING SITES IN T4 LYSOZYME USING DEFICIENCY-CREATING SUBSTITUTIONS
228L	;	1.9	;	GENERATING LIGAND BINDING SITES IN T4 LYSOZYME USING DEFICIENCY-CREATING SUBSTITUTIONS
229L	;	1.8	;	GENERATING LIGAND BINDING SITES IN T4 LYSOZYME USING DEFICIENCY-CREATING SUBSTITUTIONS
252L	;	2.1	;	GENERATING LIGAND BINDING SITES IN T4 LYSOZYME USING DEFICIENCY-CREATING SUBSTITUTIONS
4K7P	;	2.95	;	Generation and Characterization of a Unique Reagent that Recognizes a Panel of Recombinant Human Monoclonal Antibody Therapeutics in the Presence of Endogenous Human IgG
5ZPW	;	2.199	;	Generation of a long-acting fusion inhibitor against HIV-1
3O4L	;	2.54	;	Genetic and structural basis for selection of a ubiquitous T cell receptor deployed in Epstein-Barr virus
7UEL	;	1.9	;	Genetic and structural basis for the human anti-alpha-galactosyl antibody response
7UEN	;	1.55	;	Genetic and structural basis of the human anti-alpha-galactosyl antibody response
4BJU	;	2.35	;	Genetic and structural validation of Aspergillus fumigatus N- acetylphosphoglucosamine mutase as an antifungal target
6GMI	;	1.6	;	Genetic Engineering of an Artificial Metalloenzyme for Transfer Hydrogenation of a Self-Immolative Substrate in E. coli's Periplasm.
3FCA	;	2.149	;	Genetic Incorporation of a Metal-ion Chelating Amino Acid into proteins as biophysical probe
8OSI	;	2.42	;	Genetically encoded green ratiometric calcium indicator FNCaMP in calcium-bound state
7YV3	;	2.0	;	genetically encoded pH sensor Lime at pH10
7YV5	;	2.85	;	genetically encoded pH sensor Lime at pH6
4ZIN	;	1.67	;	Genetically encoded Phenyl Azide Photochemistry Drive Positive and Negative Functional Modulation of a Red Fluorescent Protein
4ZAO	;	1.8	;	Genetically engineered Carbonic anhydrase IX
4M2V	;	1.718	;	Genetically engineered Carbonic Anhydrase IX in complex with Brinzolamide
4M2W	;	1.658	;	Genetically engineered Carbonic Anhydrase IX in complex with Dorzolamide
3JA5	;	12.0	;	Genome and RdRp structure within the capsid of no-transcribing cypovirus
6V10	;	3.77	;	genome-containing AAV8 particles
6V1G	;	2.98	;	Genome-containing AAVrh.10
6V1Z	;	3.58	;	genome-containing AAVrh.39 particles
7UEM	;	2.314	;	Genomic and structural basis for the human anti-alpha-galactosyl antibody response
8SYP	;	2.6	;	Genomic CX3CR1 nucleosome
8F4R	;	3.06	;	Gentamicin bound aminoglycoside efflux pump AcrD
8CGU	;	1.89	;	Gentamicin bound to the 30S body
1BYJ	;		;	GENTAMICIN C1A A-SITE COMPLEX
2W8Z	;	2.3	;	Geobacillus stearothermophilus 6-phosphogluconate dehydrogenase with bound 6- phosphogluconate
2W90	;	2.2	;	Geobacillus stearothermophilus 6-phosphogluconate dehydrogenase with bound 6- phosphogluconate
5T2K	;	1.8	;	Geobacillus stearothermophilus HemQ with Manganese-Coproporphyrin III
3ZBH	;	1.94	;	Geobacillus thermodenitrificans EsxA crystal form I
4C1O	;	1.7	;	Geobacillus thermoglucosidasius GH family 52 xylosidase
4C1P	;	2.634	;	Geobacillus thermoglucosidasius GH family 52 xylosidase
7CHU	;	2.008	;	Geobacillus virus E2 - ORF18
8BAT	;	2.3	;	Geobacter lovleyi NADAR
8G9J	;	2.5	;	Geometrically programmable nanomaterial construction using regularized protein building blocks
8G9K	;	2.48	;	Geometrically programmable nanomaterial construction using regularized protein building blocks
8GA6	;	2.5	;	Geometrically programmable nanomaterial construction using regularized protein building blocks
8GA7	;	2.93	;	Geometrically programmable nanomaterial construction using regularized protein building blocks
1PPC	;	1.8	;	GEOMETRY OF BINDING OF THE BENZAMIDINE-AND ARGININE-BASED INHIBITORS N-ALPHA-(2-NAPHTHYL-SULPHONYL-GLYCYL)-DL-P-AMIDINOPHENYLALANYL-PIPERIDINE (NAPAP) AND (2R,4R)-4-METHYL-1-[N-ALPHA-(3-METHYL-1,2,3,4-TETRAHYDRO-8-QUINOLINESULPHONYL)-L-ARGINYL]-2-PIPERIDINE CARBOXYLIC ACID (MQPA) TO HUMAN ALPHA-THROMBIN: X-RAY CRYSTALLOGRAPHIC DETERMINATION OF THE NAPAP-TRYPSIN COMPLEX AND MODELING OF NAPAP-THROMBIN AND MQPA-THROMBIN
1PPH	;	1.9	;	GEOMETRY OF BINDING OF THE NALPHA-TOSYLATED PIPERIDIDES OF M-AMIDINO-, P-AMIDINO-AND P-GUANIDINO PHENYLALANINE TO THROMBIN AND TRYPSIN: X-RAY CRYSTAL STRUCTURES OF THEIR TRYPSIN COMPLEXES AND MODELING OF THEIR THROMBIN COMPLEXES
1UMP	;	2.13	;	GEOMETRY OF TRITERPENE CONVERSION TO PENTACARBOCYCLIC HOPENE
5DZ2	;	2.111	;	Geosmin synthase from Streptomyces coelicolor N-terminal domain complexed with three Mg2+ ions and alendronic acid
4ZZV	;	1.37	;	Geotrichum candidum Cel7A apo structure at 1.4A
5AMP	;	2.12	;	Geotrichum candidum Cel7A apo structure at 2.1A
4ZZW	;	1.5	;	Geotrichum candidum Cel7A structure complex with cellobiose at 1.5A
4ZZU	;	1.44	;	Geotrichum candidum Cel7A structure complex with thio-linked cellotetraose at 1.4A
4ZZT	;	1.56	;	Geotrichum candidum Cel7A structure complex with thio-linked cellotriose at 1.56A
4TK3	;	2.7	;	Geph E in complex with a GABA receptor alpha3 derived double mutant peptide in spacegroup P21212
4TK1	;	2.7	;	Geph E in complex with a GABA receptor alpha3 subunit derived peptide in space group P21212
4TK2	;	4.1	;	Geph E in complex with a GABA receptor alpha3 subunit derived peptide in space group P61
4TK4	;	3.601	;	GephE in complex with a GABA receptor alpha3 subunit derived double mutant peptide in space group P61
5ERR	;	1.65	;	GephE in complex with Mg(2+) - ADP
5ERS	;	1.7	;	GephE in complex with Mg(2+) - AMP
5ERT	;	2.0	;	GephE in complex with Mn(2+) - ADP
4U91	;	2.0	;	GephE in complex with Para-Phenyl crosslinked Glycine receptor beta subunit derived dimeric peptide
4U90	;	2.0	;	GephE in complex with PEG crosslinked GABA receptor alpha3 subunit derived dimeric peptide
5ERQ	;	1.55	;	Gephyrin E domain at 1.55 angstrom resolution
7FBH	;	2.1	;	geranyl pyrophosphate C6-methyltransferase BezA
7FBO	;	2.56	;	geranyl pyrophosphate C6-methyltransferase BezA binding with S-adenosylhomocysteine
2J1O	;	2.0	;	Geranylgeranyl diphosphate synthase from Sinapis alba
2J1P	;	1.8	;	Geranylgeranyl diphosphate synthase from Sinapis alba in complex with GGPP
2DH4	;	1.98	;	Geranylgeranyl pyrophosphate synthase
5JFQ	;	2.51	;	Geranylgeranyl Pyrophosphate Synthetase from archaeon Geoglobus acetivorans
3ATQ	;	1.85	;	Geranylgeranyl Reductase (GGR) from Sulfolobus acidocaldarius
3ATR	;	1.8	;	Geranylgeranyl Reductase (GGR) from Sulfolobus acidocaldarius co-crystallized with its ligand
3V7I	;	2.9	;	Germicidin synthase (Gcs) from Streptomyces coelicolor, a type III polyketide synthase
1N7M	;	1.8	;	Germline 7G12 with N-methylmesoporphyrin
3F12	;	2.95	;	Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus
6MZJ	;	4.8	;	Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer, 2 Fabs bound, sharpened map
6MYY	;	3.8	;	Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer, 3 Fabs bound, sharpened map
3HG1	;	3.0	;	Germline-governed recognition of a cancer epitope by an immunodominant human T cell receptor
2QPN	;	1.1	;	GES-1 beta-lactamase
3NI9	;	2.0	;	GES-2 carbapenemase apo form
3NIA	;	1.65	;	GES-2 carbapenemase tazobactam complex
4QU3	;	1.402	;	GES-2 ertapenem acyl-enzyme complex
8V9G	;	1.62	;	GES-5-meropenem complex
8V9H	;	1.5	;	GES-5-NA-1-157 complex
7SQ0	;	3.7	;	Get3 bound to ADP and the transmembrane domain of the tail-anchored protein Bos1
7SPY	;	2.23	;	Get3 bound to ATP from G. intestinalis in the closed form
3IO3	;	1.8	;	GEt3 with ADP from D. Hansenii in Closed form
6QZU	;	2.0	;	Getah virus macro domain
6R0R	;	1.45	;	Getah virus macro domain in complex with ADPr covalently bond to Cys34
6R0P	;	1.6	;	Getah virus macro domain in complex with ADPr in double open conformation
6R0T	;	1.85	;	Getah virus macro domain in complex with ADPr in open conformation
6R0F	;	2.05	;	Getah virus macro domain in complex with ADPr, pose 1
6R0G	;	1.7	;	Getah virus macro domain in complex with ADPr, pose 2
6BZM	;	0.9	;	GFGNFGTS from low-complexity/FG repeat domain of Nup98, residues 116-123
2KMK	;		;	Gfi-1 Zinc Fingers 3-5 complexed with DNA
4XGY	;	1.494	;	GFP based antibody (fluorobody)
5HZO	;	2.49	;	GFP mutant S205G
7V0V	;		;	GFP Nanobody NMR Structure
5MSE	;	1.66	;	GFP nuclear transport receptor mimic 3B8
2AWM	;	1.7	;	GFP R96A chromophore maturation recovery mutant R96A Q183R
2AWK	;	1.15	;	GFP R96M mature chromophore
2AWJ	;	1.6	;	GFP R96M pre-cyclized intermediate in chromophore formation
7CD7	;	1.704	;	GFP-40/GFPuv complex, Form I
7CD8	;	2.0	;	GFP-40/GFPuv complex, Form II
5MA6	;	2.3	;	GFP-binding DARPin 3G124nc
5MA8	;	2.35	;	GFP-binding DARPin 3G124nc
5MAD	;	1.53	;	GFP-binding DARPin 3G61
5MA5	;	1.85	;	GFP-binding DARPin fusion gc_K11
5MA4	;	1.4	;	GFP-binding DARPin fusion gc_K7
5MA3	;	1.7	;	GFP-binding DARPin fusion gc_R11
5MA9	;	1.57	;	GFP-binding DARPin fusion gc_R11
5MAK	;	2.5	;	GFP-binding DARPin fusion gc_R7
6FWW	;	1.131	;	GFP/KKK. A redesigned GFP with improved solubility
2QLE	;	1.59	;	GFP/S205V mutant
6HUT	;	1.29	;	GFP8 - a stabilized variant of cycle-3 GFP
6WMW	;	2.91	;	GFRAL receptor bound with two antibody Fabs (3P10, 25M22)
1ZFA	;	1.56	;	GGA Duplex A-DNA
6QEU	;		;	Gga-AvBD11 (Avian beta-defensin 11 from Gallus gallus)
1JUQ	;	2.2	;	GGA3 VHS domain complexed with C-terminal peptide from cation-dependent Mannose 6-phosphate receptor
1JPL	;	2.4	;	GGA3 VHS domain complexed with C-terminal peptide from cation-independent mannose 6-phosphate receptor
1ZFB	;	1.65	;	GGC Duplex B-DNA
4ZMM	;	2.503	;	GGDEF domain of Dcsbis complexed with c-di-GMP
1ZF9	;	1.38	;	GGG Duplex A-DNA
4IZQ	;	2.04	;	GGGCATGCCC in the A-DNA Form
4JEJ	;	1.52	;	GGGPS from Flavobacterium johnsoniae
4MM1	;	2.8004	;	GGGPS from Methanothermobacter thermautotrophicus
1ZF8	;	1.48	;	GGT Duplex A-DNA
3PPD	;	1.5	;	GGVLVN segment from Human Prostatic Acid Phosphatase Residues 260-265, involved in Semen-Derived Enhancer of Viral Infection
7K3Y	;	1.1	;	GGYAGAS segment 52-58 from Keratin-8
7EZO	;	2.80006	;	GH10 domain of bifunctional endoxylanase and arabinofuranosidase of Bi0569
6Q8M	;	1.42	;	GH10 endo-xylanase
6Q8N	;	1.76	;	GH10 endo-xylanase in complex with xylobiose epoxide inhibitor
7PXQ	;	2.3	;	GH115 alpha-1,2-glucuronidase D303A
7PUG	;	2.66	;	GH115 alpha-1,2-glucuronidase in complex with xylopentaose
6G1G	;	1.04	;	GH124 cellulase from Ruminiclostridium thermocellum in complex with Mn and cellotriose
6G1I	;	0.99	;	GH124 cellulase from Ruminiclostridium thermocellum in complex with Mn and fructosylated cellopentaose
7EXW	;	2.2	;	GH127 beta-L-arabinofuranosidase HypBA1 covalently complexed with alpha-L-arabinofuranosylamide
7BZL	;	2.3	;	GH127 beta-L-arabinofuranosidase HypBA1 covalently complexed with beta-L-arabinofuranose-configured cyclophellitol
7DIF	;	1.75	;	GH127 beta-L-arabinofuranosidase HypBA1 covalently complexed with beta-L-arabinofuranose-configured cyclophellitol at 1.75-angstrom resolution
7EXV	;	2.6	;	GH127 beta-L-arabinofuranosidase HypBA1 covalently complexed with beta-L-arabinofuranoylamide
7EXU	;	2.3	;	GH127 beta-L-arabinofuranosidase HypBA1 E322Q mutant complexed with p-nitrophenyl beta-L-arabinofuranoside
6YQH	;	1.41	;	GH146 beta-L-arabinofuranosidase bound to covalent inhibitor
8QF8	;	2.4	;	GH146 beta-L-arabinofuranosidase from Bacteroides thetaioatomicron in complex with beta-l-arabinofurano cyclophellitol aziridine
8XBD	;	2.4	;	GH18 family chitinase from cold seep metagenome
7VQM	;	2.4	;	GH2 beta-galacturonate AqGalA in complex with galacturonide
5A6J	;	1.94	;	GH20C, Beta-hexosaminidase from Streptococcus pneumoniae
5A6K	;	2.1	;	GH20C, Beta-hexosaminidase from Streptococcus pneumoniae in complex with Gal-NGT
5A69	;	2.2	;	GH20C, Beta-hexosaminidase from Streptococcus pneumoniae in complex with Gal-PUGNAc
5AC4	;	2.08	;	GH20C, Beta-hexosaminidase from Streptococcus pneumoniae in complex with GalNAc
5AC5	;	1.84	;	GH20C, Beta-hexosaminidase from Streptococcus pneumoniae in complex with GlcNAc
5A6A	;	2.69	;	GH20C, Beta-hexosaminidase from Streptococcus pneumoniae in complex with NGT
5A6B	;	1.77	;	GH20C, Beta-hexosaminidase from Streptococcus pneumoniae in complex with PUGNAc
8B2S	;	1.94	;	GH24 family muramidase from Trichophaea saccata with an SH3-like cell wall binding domain
6Q7I	;	1.48	;	GH3 exo-beta-xylosidase (XlnD)
6Q7J	;	2.14	;	GH3 exo-beta-xylosidase (XlnD) in complex with xylobiose aziridine activity based probe
6AVH	;	3.011	;	GH3.15 acyl acid amido synthetase
6M76	;	1.4	;	GH31 alpha-N-acetylgalactosaminidase from Enterococcus faecalis
6M77	;	1.9	;	GH31 alpha-N-acetylgalactosaminidase from Enterococcus faecalis in complex with N-acetylgalactosamine
5XB7	;	2.0	;	GH42 alpha-L-arabinopyranosidase from Bifidobacterium animalis subsp. lactis Bl-04
7ERL	;	1.8933	;	GH43 domain of bifunctional endoxylanase and arabinofuranosidase of Bi0569
6B7K	;	2.55	;	GH43 Endo-Arabinanase from Bacillus licheniformis
5OYC	;	1.6	;	GH5 endo-xyloglucanase from Cellvibrio japonicus
5OYD	;	2.1	;	GH5 endo-xyloglucanase from Cellvibrio japonicus
5OYE	;	1.9	;	GH5 endo-xyloglucanase from Cellvibrio japonicus
3AYR	;	2.0	;	GH5 endoglucanase EglA from a ruminal fungus
3AYS	;	2.2	;	GH5 endoglucanase from a ruminal fungus in complex with cellotriose
6XSO	;	1.5	;	GH5-4 broad specificity endoglucanase from an uncultured bacterium
6XRK	;	1.419	;	GH5-4 broad specificity endoglucanase from an uncultured bovine rumen ciliate
6WQY	;	1.05	;	GH5-4 broad specificity endoglucanase from Bacteroides salanitronis
6Q1I	;	1.35	;	GH5-4 broad specificity endoglucanase from Clostrdium longisporum
6PZ7	;	1.25	;	GH5-4 broad specificity endoglucanase from Clostridium acetobutylicum
6UI3	;	1.3	;	GH5-4 broad specificity endoglucanase from Clostridum cellulovorans
6MQ4	;	1.4	;	GH5-4 broad specificity endoglucanase from Hungateiclostridium cellulolyticum
6WQP	;	1.6	;	GH5-4 broad specificity endoglucanase from Ruminococcus champanellensis
6WQV	;	1.45	;	GH5-4 broad specificity endoglucanase from Ruminococcus champanellensis with bound cellotriose
6XSU	;	1.41	;	GH5-4 broad specificity endoglucanase from Ruminococcus flavefaciens
6SXV	;	1.402	;	GH51 a-l-arabinofuranosidase soaked with aziridine inhibitor
6SXU	;	1.398	;	GH51 a-l-arabinofuranosidase soaked with cyclic sulfate inhibitor
6SXT	;	1.466	;	GH54 a-l-arabinofuranosidase soaked with aziridine inhibitor
6SXS	;	1.859	;	GH54 a-l-arabinofuranosidase soaked with cyclic sulfate inhibitor
5JX5	;	1.8	;	GH6 Orpinomyces sp. Y102 enzyme
6IDW	;	2.78	;	GH6 Orpinomyces sp. Y102 enzyme
8H97	;	2.194	;	GH86 agarase Aga86A_Wa
4UF7	;	1.7	;	Ghanaian henipavirus (Gh-M74a) attachment glycoprotein in complex with human ephrinB2
4XI5	;	3.9	;	gHgL of varicella-zoster virus in complex with human neutralizing antibodies
4XHJ	;	3.156	;	gHgL of Varicella-zoster virus in complex with human neutralizing antibodies.
6QUJ	;	1.68	;	GHK tagged GFP variant
6QUI	;	1.94	;	GHK tagged GFP variant at 17Kev
6QUH	;	1.5	;	GHK tagged GFP variant crystal form II at 1.34A wavelength
6QUG	;	2.7	;	GHK tagged MBP-Nup98(1-29)
2LLZ	;		;	GhoS (YjdK) monomer
7F9Y	;	2.9	;	ghrelin-bound ghrelin receptor in complex with Gq
7F9Z	;	3.2	;	GHRP-6-bound ghrelin receptor in complex with Gq
8KFX	;	2.96	;	Gi bound CCR8 complex with nonpeptide agonist LMD-009
8KFY	;	3.06	;	Gi bound CCR8 complex with nonpeptide agonist ZK 756326
8KFZ	;	3.3	;	Gi bound CCR8 in ligand free state
8F7S	;	3.0	;	Gi bound delta-opioid receptor in complex with deltorphin
8F7W	;	3.19	;	Gi bound kappa-opioid receptor in complex with dynorphin
8F7Q	;	3.22	;	Gi bound mu-opioid receptor in complex with beta-endorphin
8F7R	;	3.28	;	Gi bound mu-opioid receptor in complex with endomorphin
8F7X	;	3.28	;	Gi bound nociceptin receptor in complex with nociceptin peptide
8HSC	;	3.22	;	Gi bound Orphan GPR20 complex with Fab046 in ligand-free state
8HS3	;	3.14	;	Gi bound orphan GPR20 in ligand-free state
1BOF	;	2.2	;	GI-ALPHA-1 BOUND TO GDP AND MAGNESIUM
3FFB	;	2.57	;	Gi-alpha-1 mutant in GDP bound form
1CIP	;	1.5	;	GI-ALPHA-1 SUBUNIT OF GUANINE NUCLEOTIDE-BINDING PROTEIN COMPLEXED WITH A GTP ANALOGUE
6H6Z	;	2.085	;	GI.1 human norovirus protruding domain in complex with Nano-62
6H70	;	1.83	;	GI.1 human norovirus protruding domain in complex with Nano-62 and 2-fucosyllactose (2FL)
6H6Y	;	1.58	;	GI.1 human norovirus protruding domain in complex with Nano-7
6H71	;	2.313	;	GI.1 human norovirus protruding domain in complex with Nano-94
6H72	;	2.3	;	GI.1 human norovirus protruding domain in complex with Nano-94 and 2-fucosyllactose (2FL)
7DC6	;	2.68	;	Giant panda MHC class I complexes
3O85	;	1.806	;	Giardia lamblia 15.5kD RNA binding protein
3IAL	;	2.2	;	Giardia lamblia Prolyl-tRNA synthetase in complex with prolyl-adenylate
8BSI	;	3.4	;	Giardia ribosome chimeric hybrid-like GDP+Pi bound state (B1)
8BR8	;	3.35	;	Giardia ribosome in POST-T state (A1)
8BRM	;	3.33	;	Giardia ribosome in POST-T state, no E-site tRNA (A6)
8BSJ	;	6.49	;	Giardia Ribosome in PRE-T Classical State (C)
8BTD	;	4.9	;	Giardia Ribosome in PRE-T Hybrid State (D1)
8BTR	;	3.25	;	Giardia Ribosome in PRE-T Hybrid State (D2)
7WUG	;	3.3	;	GID subcomplex: Gid12 bound Substrate Receptor Scaffolding module
6CDG	;	1.6	;	GID4 fragment in complex with a peptide
6CD9	;	1.55	;	GID4 in complex with a peptide
6CDC	;	1.75	;	GID4 in complex with a tetrapeptide
7U3E	;	1.852	;	GID4 in complex with compound 1
7U3I	;	1.991	;	GID4 in complex with compound 16
7U3F	;	2.3	;	GID4 in complex with compound 4
7U3G	;	2.244	;	GID4 in complex with compound 67
7U3H	;	1.798	;	GID4 in complex with compound 7
7U3J	;	1.642	;	GID4 in complex with compound 88
7U3K	;	2.198	;	GID4 in complex with compound 89
7U3L	;	2.295	;	GID4 in complex with compound 91
6WZX	;	1.75	;	GID4 in complex with IGLWKS peptide
6WZZ	;	1.6	;	GID4 in complex with VGLWKS peptide
6GVZ	;	1.54	;	GII.1 human norovirus protruding domain in complex with glycochenodeoxycholate (GCDCA)
6GW0	;	1.4	;	GII.1 human norovirus protruding domain in complex with taurochenodeoxycholate (TCDCA)
6GW1	;	1.9	;	GII.10 human norovirus protruding domain in complex with glycochenodeoxycholate (GCDCA)
6GW2	;	2.05	;	GII.10 human norovirus protruding domain in complex with taurochenodeoxycholate (TCDCA)
5O04	;	2.3	;	GII.10 Vietnam 026 norovirus protruding domain in complex with Nanobody Nano-26 and Nano-85
5O05	;	2.0	;	GII.10 Vietnam 026 norovirus protruding domain in complex with Nanobody Nano-42
5OMM	;	1.7	;	GII.10 Vietnam 026 protruding domain in complex with Nanobody Nano-14
5OMN	;	2.682	;	GII.10 Vietnam 026 protruding domain in complex with Nanobody Nano-27
5O03	;	2.194	;	GII.10 Vietnam 026 protruding domain in complex with Nanobody Nano-32
6JYN	;	1.599	;	GII.13/21 noroviruses recognize glycans with a terminal beta-galactose via an unconventional glycan binding site
6JYO	;	1.502	;	GII.13/21 noroviruses recognize glycans with a terminal beta-galactose via an unconventional glycan binding site
6JYR	;	1.501	;	GII.13/21 noroviruses recognize glycans with a terminal beta-galactose via an unconventional glycan binding site
6JYS	;	1.697	;	GII.13/21 noroviruses recognize glycans with a terminal beta-galactose via an unconventional glycan binding site
5O02	;	1.72	;	GII.17 Kawasaki323 protruding domain in complex with Nanobody Nano-4
6GW4	;	2.295	;	GII.19 human norovirus protruding domain in complex with glycochenodeoxycholate (GCDCA)
2YNW	;	1.7	;	GIM-1-2Mol native. Crystal structures of Pseudomonas aeruginosa GIM- 1: active site plasticity in metallo-beta-lactamases
2YNT	;	1.598	;	GIM-1-3Mol native. Crystal structures of Pseudomonas aeruginosa GIM- 1: active site plasticity in metallo-beta-lactamases
2ML7	;		;	Ginsentides: Characterization, Structure and Application of a New Class of Highly Stable Cystine Knot Peptides in Ginseng
2L4T	;		;	GIP/Glutaminase L peptide complex
2OTL	;	2.7	;	Girodazole bound to the large subunit of Haloarcula marismortui
7F5X	;	3.5	;	GK domain of Drosophila P5CS filament with glutamate
7WX4	;	3.4	;	GK domain of Drosophila P5CS filament with glutamate and ATPgammaS
7WX3	;	3.1	;	GK domain of Drosophila P5CS filament with glutamate, ATP, and NADPH
5CH9	;	1.9	;	Gkap mutant B12
4OP2	;	2.24	;	GKRP bound to AMG-0471 and Sorbitol-6-Phosphate
4OP1	;	2.39	;	GKRP bound to AMG0556 and Sorbitol-6-Phosphate
1T2X	;	2.3	;	Glactose oxidase C383S mutant identified by directed evolution
2W39	;	1.1	;	Glc(beta-1-3)Glc disaccharide in -1 and -2 sites of Laminarinase 16A from Phanerochaete chrysosporium
6DTE	;	1.929	;	GlcNAc-inspired cyclophellitol bound to NagZ
2WB5	;	2.31	;	GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing cellular hyper-O-GlcNAcylation
1UPS	;	1.82	;	GlcNAc[alpha]1-4Gal releasing endo-[beta]-galactosidase from Clostridium perfringens
5LGW	;	1.95	;	GlgE isoform 1 from Streptomyces coelicolor D394A mutant co-crystallised with maltodextrin
4CN1	;	2.55	;	GlgE isoform 1 from Streptomyces coelicolor D394A mutant with maltose- 1-phosphate bound
5CVS	;	2.3	;	GlgE isoform 1 from Streptomyces coelicolor E423A mutant soaked in maltoheptaose
5LGV	;	2.5	;	GlgE isoform 1 from Streptomyces coelicolor E423A mutant soaked in maltooctaose
4CN4	;	2.4	;	GlgE isoform 1 from Streptomyces coelicolor E423A mutant with 2-deoxy- 2-fluoro-beta-maltosyl modification
4CN6	;	2.29	;	GlgE isoform 1 from Streptomyces coelicolor E423A mutant with maltose bound
3ZT6	;	2.19	;	GlgE isoform 1 from Streptomyces coelicolor with alpha-cyclodextrin and maltose bound
3ZST	;	2.3	;	GlgE isoform 1 from Streptomyces coelicolor with alpha-cyclodextrin bound
3ZT7	;	2.5	;	GlgE isoform 1 from Streptomyces coelicolor with beta-cyclodextrin and maltose bound
3ZT5	;	2.09	;	GlgE isoform 1 from Streptomyces coelicolor with maltose bound
7W2A	;	1.6	;	gliadinase Bga1903
1AGQ	;	1.9	;	GLIAL CELL-DERIVED NEUROTROPHIC FACTOR FROM RAT
4LML	;	3.8	;	GLIC double mutant I9'A T25'A
4LMJ	;	3.44	;	GLIC Liganded-closed-channel Conformation, Mutant T25'A
4LMK	;	3.22	;	GLIC Liganded-closed-channel Conformation, Mutant Y27'A
6F11	;	2.95	;	GLIC mutant D86A
6F0Z	;	2.5	;	GLIC mutant D88N
6F10	;	2.85	;	GLIC mutant D88N
6F12	;	3.2	;	GLIC mutant E181A
6F0I	;	3.0	;	GLIC mutant E26A
6F0J	;	3.15	;	GLIC mutant E26A
6F0U	;	2.35	;	GLIC mutant E35A
6F0M	;	2.65	;	GLIC mutant E35Q
6F13	;	2.7	;	GLIC mutant E75A
6F0N	;	3.2	;	GLIC mutant E82A
6F0R	;	2.5	;	GLIC mutant E82Q
6F0V	;	2.85	;	GLIC mutant E82Q
6F15	;	2.85	;	GLIC mutant H127Q
6F16	;	2.6	;	GLIC mutant H277Q
6ZGK	;	3.6	;	GLIC pentameric ligand-gated ion channel, pH 3
6ZGJ	;	3.4	;	GLIC pentameric ligand-gated ion channel, pH 5
6ZGD	;	4.1	;	GLIC pentameric ligand-gated ion channel, pH 7
5OSA	;	2.75	;	GLIC-GABAAR alpha1 chimera crystallized at pH4.6
5OSC	;	3.1	;	GLIC-GABAAR alpha1 chimera crystallized in complex with pregnenolone sulfate at pH 4.5
5OSB	;	3.8	;	GLIC-GABAAR alpha1 chimera crystallized in complex with THDOC at pH4.5
5IUX	;	2.6	;	GLIC-V135C bimane labelled X-ray structure
5J5T	;	2.85	;	GLK co-crystal structure with aminopyrrolopyrimidine inhibitor
4E1K	;	2.0	;	GlmU in complex with a Quinazoline Compound
3TWD	;	1.9	;	glmuC1 in complex with an antibacterial inhibitor
3SGQ	;	1.8	;	GLN 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 10.7
2SGQ	;	1.8	;	GLN 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 6.5
1Q5T	;	1.9	;	Gln48 PLA2 separated from Vipoxin from the venom of Vipera ammodytes meridionalis.
6H20	;	1.4	;	GlnH bound to Asn, Mycobacterium tuberculosis
6H1U	;	1.68	;	GlnH bound to Asp, Mycobacterium tuberculosis
6H2T	;	1.67	;	GlnH bound to Glu, Mycobacterium tuberculosis
1GNK	;	2.0	;	GLNK, A SIGNAL PROTEIN FROM E. COLI
2GNK	;	2.0	;	GLNK, A SIGNAL PROTEIN FROM E. COLI
7P52	;	1.20002	;	GlnK1 from Methanocaldococcus jannaschii with Mg-ATP and 2-oxoglutarate at a resolution of 1.2 A
7P4V	;	1.94	;	GlnK1 from Methanothermococcus thermolithotrophicus with dADP at a resolution of 1.94 A
3NCP	;	2.35	;	GlnK2 from Archaeoglobus fulgidus
3NCQ	;	1.24	;	GlnK2 from Archaeoglobus fulgidus, ATP complex
3NCR	;	1.44	;	GlnK2 from Archaeoglubus fulgidus, ADP complex
4OZJ	;	1.45	;	GlnK2 from Haloferax mediterranei complexed with ADP
4OZL	;	1.4942	;	GlnK2 from Haloferax mediterranei complexed with AMP
4OZN	;	2.6	;	GlnK2 from Haloferax mediterranei complexed with ATP
7P50	;	1.16	;	GlnK2 from Methanothermococcus thermolithotrophicus in complex with Mg-ATP and 2-oxoglutarate at a resolution of 1.16 A
7P4Y	;	2.3	;	GlnK2 from Methanothermococcus thermolithotrophicus in the apo state at a resolution of 2.3 A
1EZO	;		;	GLOBAL FOLD OF MALTODEXTRIN BINDING PROTEIN COMPLEXED WITH BETA-CYCLODEXTRIN
1EZP	;		;	GLOBAL FOLD OF MALTODEXTRIN BINDING PROTEIN COMPLEXED WITH BETA-CYCLODEXTRIN USING PEPTIDE ORIENTATIONS FROM DIPOLAR COUPLINGS
2M3K	;		;	Global fold of the type IV pilin ComP from Neisseria meningitidis
8DUJ	;	3.7	;	Global map in C1 of RyR1 particles in complex with ImperaCalcin
8OPJ	;	2.99	;	Global refinement of cubic assembly from truncated PVY coat protein with K176C mutation
5YWJ	;	2.102	;	Global regulatory element SarX
6K8E	;	2.002	;	Global regulatory element SarX
1O8T	;		;	Global Structure and Dynamics of Human Apolipoprotein CII in Complex with Micelles: Evidence for increased mobility of the helix involved in the activation of lipoprotein lipase
2W31	;	1.5	;	globin domain of Geobacter sulfurreducens globin-coupled sensor
5OHE	;	1.85	;	Globin sensor domain of AfGcHK (FeIII form) in complex with cyanide
5OHF	;	1.8	;	Globin sensor domain of AfGcHK (FeIII form) in complex with cyanide, partially reduced
6OTD	;	1.8	;	Globin sensor domain of AfGcHK in monomeric form, with imidazole
4BJA	;	1.65	;	Globin-like protein Glb-12 from C.elegans
6HAT	;	1.856	;	Globular domain of herpesvirus saimiri ORF57
5HCA	;	2.15	;	Globular Domain of the Entamoeba histolytica calreticulin in complex with glucose
5HCB	;	2.9	;	Globular Domain of the Entamoeba histolytica calreticulin in complex with glucose
8XVF	;	2.76	;	Globular domain of Trichinella spiralis calreticulin
5HBA	;	2.05	;	Globular Domain of Zebrafish Complement 1qA protein
7P66	;	3.0	;	Globular glial tauopathy type 1 tau filament
7P67	;	3.1	;	Globular glial tauopathy type 2 tau filament
7P68	;	2.9	;	Globular glial tauopathy type 3 tau filament
6Z6V	;	2.19	;	Globular head of C1q in complex with the nanobody C1qNb75
1PK6	;	1.85	;	Globular Head of the Complement System Protein C1q
2W3C	;	2.22	;	Globular head region of the human general vesicular transport factor p115
6F7A	;	6.0	;	Gloeobacter Ligand-gated Ion Channel (GLIC) closed state crystallized in an ultra-swollen lipidic mesophase
3DCN	;	1.9	;	Glomerella cingulata apo cutinase
3DD5	;	2.6	;	Glomerella cingulata E600-cutinase complex
3DEA	;	2.3	;	Glomerella cingulata PETFP-cutinase complex
3SW9	;	3.05	;	GLP (G9a-like protein) SET domain in complex with Dnmt3aK44me0 peptide
3SWC	;	2.332	;	GLP (G9a-like protein) SET domain in complex with Dnmt3aK44me2 peptide
6MBP	;	1.947	;	GLP Methyltransferase with Inhibitor EML741- P3121 Crystal Form
6MBO	;	1.591	;	GLP Methyltransferase with Inhibitor EML741-P212121 Crystal Form
6X18	;	2.1	;	GLP-1 peptide hormone bound to Glucagon-Like peptide-1 (GLP-1) Receptor
7S15	;	3.8	;	GLP-1 receptor bound with Pfizer small molecule agonist
7C2E	;	4.2	;	GLP-1R-Gs complex structure with a small molecule full agonist
7VFR	;	1.56	;	GltA N83K mutant from Bifidobacterium infantis JCM 1222 complexed with lacto-N-tetraose
6UWL	;	3.62	;	GltPh in complex with L-aspartate and sodium ions in intermediate outward-facing state
6UWF	;	3.08	;	GltPh in complex with L-aspartate and sodium ions in outward-facing state
7RCP	;	2.2	;	GltPh mutant (S279E/D405N) in complex with aspartate and sodium ions
6V8G	;	3.38	;	GltPh mutant - Y204L A345V V366A
2SGE	;	1.8	;	GLU 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 10.7
1SGE	;	1.8	;	GLU 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 6.5
2BS3	;	2.19	;	GLU C180 -> GLN VARIANT QUINOL:FUMARATE REDUCTASE FROM WOLINELLA SUCCINOGENES
2BS4	;	2.76	;	GLU C180 -> ILE VARIANT QUINOL:FUMARATE REDUCTASE FROMWOLINELLA SUCCINOGENES
6T6V	;	4.5	;	Glu-494-Ala inactive monomer of a quinol dependent Nitric Oxide Reductase (qNOR) from Alcaligenes xylosoxidans
1FWZ	;	2.3	;	GLU20ALA DTXR
1ZP4	;	1.85	;	Glu28Gln mutant of E. coli Methylenetetrahydrofolate Reductase (oxidized) complex with Methyltetrahydrofolate
3S1D	;	1.75	;	Glu381Ser mutant of maize cytokinin oxidase/dehydrogenase complexed with N6-isopentenyladenosine
2BWY	;	2.4	;	Glu383Ala Escherichia coli Aminopeptidase P
2V3Z	;	1.56	;	Glu383Ala Escherichia coli aminopeptidase P in complex with substrate
6QKC	;	4.4	;	GluA1/2 In complex with auxiliary subunit gamma-8
5WEK	;	4.6	;	GluA2 bound to antagonist ZK and GSG1L in digitonin, state 1
5WEL	;	4.4	;	GluA2 bound to antagonist ZK and GSG1L in digitonin, state 2
5WEM	;	6.1	;	GluA2 bound to GSG1L in digitonin, state 1
5WEN	;	6.8	;	GluA2 bound to GSG1L in digitonin, state 2
8FPS	;	2.38	;	GluA2 flip Q isoform N619K mutant of AMPA receptor in complex with gain-of-function TARP gamma-2, with 10mM CaCl2, 150mM NaCl, 1mM MgCl2, 330uM CTZ, and 100mM glutamate (Open-CaNaMg/N619K)
8FP9	;	2.44	;	GluA2 flip Q isoform of AMPA receptor in complex with gain-of-function TARP gamma-2, with 10mM CaCl2, 150mM NaCl, 1mM MgCl2, 330uM CTZ, and 100mM glutamate (Open-CaNaMg)
8FPG	;	2.32	;	GluA2 flip Q isoform of AMPA receptor in complex with gain-of-function TARP gamma-2, with 10mM CaCl2, 150mM NaCl, 1mM MgCl2, 330uM CTZ, and 100uM CNQX (Closed-CaNaMg)
8FQF	;	2.29	;	GluA2 flip Q isoform of AMPA receptor in complex with gain-of-function TARP gamma-2, with 150mM NaCl, 330uM CTZ, and 100mM glutamate (Open-Na260)
8FP4	;	2.4	;	GluA2 flip Q isoform of AMPA receptor in complex with gain-of-function TARP gamma-2, with 500mM NaCl, 330uM CTZ, and 100mM glutamate (Open-Na610)
8FQB	;	2.36	;	GluA2 flip Q isoform of AMPA receptor in complex with gain-of-function TARP gamma2, with 10mM CaCl2, 140mM NMDG, 330uM CTZ, and 100mM L-glutamate (Open-Ca10)
8FQ5	;	2.34	;	GluA2 flip Q isoform of AMPA receptor in complex with gain-of-function TARP gamma2, with 140mM NMDG, 330uM CTZ, and 100mM L-glutamate (Open-Na110)
8FQ1	;	5.59	;	GluA2 flip Q isoform of AMPA receptor in complex with gain-of-function TARP gamma2, with 150mM CaCl2, 330uM CTZ, and 100mM L-glutamate (Open-Ca150)
6PEQ	;	2.97	;	GluA2 in complex with its auxiliary subunit CNIH3 - map LBD-TMD-C3 - with antagonist ZK200775 -without NTD
6UD8	;	3.2	;	GluA2 in complex with its auxiliary subunit CNIH3 - with antagonist ZK200775
6UCB	;	3.28	;	GluA2 in complex with its auxiliary subunit CNIH3 - with antagonist ZK200775, LBD, TMD, CNIH3, and lipids
6UD4	;	3.3	;	GluA2 in complex with its auxiliary subunit CNIH3 in AS map II - (LBD-TMD-C3(AS) II)- with antagonist ZK200775, without NTD
6FQG	;	2.34139	;	GluA2(flop) G724C ligand binding core dimer bound to L-Glutamate (Form A) at 2.34 Angstrom resolution
6FQI	;	2.91001	;	GluA2(flop) G724C ligand binding core dimer bound to L-Glutamate (Form B) at 2.91 Angstrom resolution
6FQJ	;	2.50002	;	GluA2(flop) G724C ligand binding core dimer bound to ZK200775 at 2.50 Angstrom resolution
6FQH	;	1.7594	;	GluA2(flop) S729C ligand binding core dimer bound to NBQX at 1.76 Angstrom resolution
6FQK	;	1.9801	;	GluA2(flop) S729C ligand binding core dimer bound to ZK200775 at 1.98 Angstrom resolution
5VHW	;	7.8	;	GluA2-0xGSG1L bound to ZK
5VHX	;	8.3	;	GluA2-1xGSG1L bound to ZK
5VHZ	;	8.4	;	GluA2-2xGSG1L bound to L-Quisqualate
5VHY	;	4.6	;	GluA2-2xGSG1L bound to ZK
4L17	;	2.8	;	GluA2-L483Y-A665C ligand-binding domain in complex with the antagonist DNQX
4U22	;	1.4409	;	GluA2flip sLBD complexed with FW and (R,R)-2b crystal form D
4U21	;	1.3908	;	GluA2flip sLBD complexed with FW and (R,R)-2b crystal form E
4U23	;	1.6734	;	GluA2flip sLBD complexed with FW and (R,R)-2b crystal form F
4U1O	;	1.8501	;	GluA2flip sLBD complexed with kainate and (R,R)-2b crystal form C
4U1Z	;	1.9401	;	GluA2flip sLBD complexed with kainate and (R,R)-2b crystal form D
7XM8	;	3.9	;	Glucagon amyloid fibril
6CAM	;	1.75	;	Glucan Binding Protein C of Streptococcus mutans Mediates both Sucrose-Independent and Sucrose-Dependent Adherence
1JDF	;	2.0	;	Glucarate Dehydratase from E.coli N341D mutant
1JCT	;	2.75	;	Glucarate Dehydratase, N341L mutant Orthorhombic Form
2FBA	;	1.1	;	Glucoamylase from Saccharomycopsis fibuligera at atomic resolution
1ACZ	;		;	GLUCOAMYLASE, GRANULAR STARCH-BINDING DOMAIN COMPLEX WITH CYCLODEXTRIN, NMR, 5 STRUCTURES
1AC0	;		;	GLUCOAMYLASE, GRANULAR STARCH-BINDING DOMAIN COMPLEX WITH CYCLODEXTRIN, NMR, MINIMIZED AVERAGE STRUCTURE
1KUL	;		;	GLUCOAMYLASE, GRANULAR STARCH-BINDING DOMAIN, NMR, 5 STRUCTURES
1KUM	;		;	GLUCOAMYLASE, GRANULAR STARCH-BINDING DOMAIN, NMR, MINIMIZED AVERAGE STRUCTURE
1GAH	;	2.0	;	GLUCOAMYLASE-471 COMPLEXED WITH ACARBOSE
1GAI	;	1.7	;	GLUCOAMYLASE-471 COMPLEXED WITH D-GLUCO-DIHYDROACARBOSE
6Q1N	;	2.526	;	Glucocerebrosidase in complex with pharmacological chaperone IMX8
6Q1P	;	2.796	;	Glucocerebrosidase in complex with pharmacological chaperone norIMX8
6BSE	;	2.35	;	Glucocorticoid receptor bound to high cooperativity monomer sequence
5E6C	;	2.2	;	Glucocorticoid receptor DNA binding domain - CCL2 NF-kB response element complex
5E6D	;	2.4	;	Glucocorticoid receptor DNA binding domain - ICAM1 NF-kB response element complex
5VA7	;	2.153	;	Glucocorticoid Receptor DNA Binding Domain - IL11 AP-1 recognition element Complex
5E69	;	1.85	;	Glucocorticoid receptor DNA binding domain - IL8 NF-kB response element complex
5E6A	;	2.197	;	Glucocorticoid receptor DNA binding domain - PLAU NF-kB response element complex
5E6B	;	2.25	;	Glucocorticoid receptor DNA binding domain - RELB NF-kB response element complex
5VA0	;	2.295	;	Glucocorticoid Receptor DNA Binding Domain in complex with AP-1 response element from VCAM-1 Promoter
6X6E	;	2.0	;	Glucocorticoid Receptor DNA binding domain in complex with methylated precursor for a modern recognition element (methylated pre-GBS)
6X6D	;	2.48	;	Glucocorticoid Receptor DNA binding domain in complex with unmodified precursor for a modern recognition element (pre-GBS)
5NFT	;	2.3	;	Glucocorticoid Receptor in complex with AZD5423
6EL9	;	2.19	;	Glucocorticoid Receptor in complex with AZD9567
5NFP	;	2.1	;	Glucocorticoid Receptor in complex with budesonide
6DXK	;	3.05	;	Glucocorticoid Receptor in complex with Compound 11
6EL7	;	2.18	;	Glucocorticoid Receptor in complex with compound 31
6EL6	;	2.4	;	Glucocorticoid Receptor in complex with compound 4
3E7C	;	2.15	;	Glucocorticoid Receptor LBD bound to GSK866
1LAT	;	1.9	;	GLUCOCORTICOID RECEPTOR MUTANT/DNA COMPLEX
3K22	;	2.1	;	Glucocorticoid Receptor with Bound alaninamide 10 with TIF2 peptide
3K23	;	3.0	;	Glucocorticoid Receptor with Bound D-prolinamide 11
3BD8	;	2.1	;	Glucogen Phosphorylase complex with 1(-D-glucopyranosyl) cytosine
3BCU	;	2.03	;	Glucogen Phosphorylase complex with thymidine
3S41	;	2.18	;	Glucokinase in complex with activator and glucose
3VEV	;	1.8	;	Glucokinase in complex with an activator and glucose
3VF6	;	1.86	;	Glucokinase in complex with glucose and activator
3VEY	;	2.25	;	glucokinase in complex with glucose and ATPgS
6O08	;	1.798	;	Gluconobacter Ene-Reductase (GluER)
8FW1	;	1.5	;	Gluconobacter Ene-Reductase (GluER) mutant - PagER
6MYW	;	1.157	;	Gluconobacter Ene-Reductase (GluER) mutant - T36A
4CTM	;	1.95	;	Glucopyranosylidene-spiro-iminothiazolidinone, a New Bicyclic Ring System: Synthesis, Derivatization, and Evaluation as Glycogen Phosphorylase Inhibitors by Enzyme Kinetic and Crystallographic Methods
4CTN	;	2.1	;	Glucopyranosylidene-spiro-iminothiazolidinone, a New Bicyclic Ring System: Synthesis, Derivatization, and Evaluation as Glycogen Phosphorylase Inhibitors by Enzyme Kinetic and Crystallographic Methods
4CTO	;	1.9	;	Glucopyranosylidene-spiro-iminothiazolidinone, a New Bicyclic Ring System: Synthesis, Derivatization, and Evaluation as Glycogen Phosphorylase Inhibitors by Enzyme Kinetic and Crystallographic Methods
7LQM	;	2.3	;	Glucosamie-6-phosphate Deaminase from Pasturella multocida
1HOT	;	2.4	;	GLUCOSAMINE 6-PHOSPHATE DEAMINASE COMPLEXED WITH THE ALLOSTERIC ACTIVATOR N-ACETYL-GLUCOSAMINE-6-PHOSPHATE
1FQO	;	2.2	;	GLUCOSAMINE 6-PHOSPHATE DEAMINASE COMPLEXED WITH THE SUBSTRATE OF THE REVERSE REACTION FRUCTOSE 6-PHOSPHATE (OPEN FORM)
1JXA	;	3.1	;	GLUCOSAMINE 6-PHOSPHATE SYNTHASE WITH GLUCOSE 6-PHOSPHATE
6HWJ	;	1.979	;	Glucosamine kinase (crystal form A)
6HWK	;	2.688	;	Glucosamine kinase (crystal form B)
6HWL	;	2.148	;	Glucosamine kinase in complex with glucosamine, ADP and inorganic phosphate
2WU1	;	2.2	;	Glucosamine-6-Phosphate Deaminase Complexed with the Allosteric Activator N-Acetyl-Glucoamine-6-Phosphate both in the Active and Allosteric sites.
1FRZ	;	2.2	;	GLUCOSAMINE-6-PHOSPHATE DEAMINASE FROM E.COLI, R CONFORMER. COMPLEXED WITH THE ALLOSTERIC ACTIVATOR N-ACETYL-GLUCOSAMINE-6-PHOSPHATE AT 2.2 A RESOLUTION
1CD5	;	2.3	;	GLUCOSAMINE-6-PHOSPHATE DEAMINASE FROM E.COLI, T CONFORMER
1FSF	;	1.9	;	GLUCOSAMINE-6-PHOSPHATE DEAMINASE FROM E.COLI, T CONFORMER, AT 1.9A RESOLUTION
1FS6	;	2.2	;	GLUCOSAMINE-6-PHOSPHATE DEAMINASE FROM E.COLI, T CONFORMER, AT 2.2A RESOLUTION
7LQN	;	3.0	;	Glucosamine-6-phosphate Deaminase from H. influenzae
2VF5	;	2.9	;	Glucosamine-6-phosphate synthase in complex with glucosamine-6- phosphate
1DPG	;	2.0	;	GLUCOSE 6-PHOSPHATE DEHYDROGENASE FROM LEUCONOSTOC MESENTEROIDES
2N9H	;		;	Glucose as a nuclease mimic in DNA
2N9F	;		;	Glucose as non natural nucleobase
7CGZ	;	1.94	;	glucose dehydrogenase
1OAD	;	1.5	;	Glucose isomerase from Streptomyces rubiginosus in P21212 crystal form
7BJZ	;	2.13	;	GLUCOSE ISOMERASE S171W in H32
4W4Q	;	2.0	;	Glucose isomerase structure determined by serial femtosecond crystallography at SACLA
1CF3	;	1.9	;	GLUCOSE OXIDASE FROM APERGILLUS NIGER
1GPE	;	1.8	;	GLUCOSE OXIDASE FROM PENICILLIUM AMAGASAKIENSE
5NIT	;	1.87	;	Glucose oxidase mutant A2
5NIW	;	1.8	;	Glucose oxydase mutant A2
1IBA	;		;	GLUCOSE PERMEASE (DOMAIN IIB), NMR, 11 STRUCTURES
2GPR	;	2.5	;	GLUCOSE PERMEASE IIA FROM MYCOPLASMA CAPRICOLUM
6D23	;	2.85	;	GLUCOSE-6-P DEHYDROGENASE (APO FORM) FROM TRYPANOSOMA CRUZI
8FUY	;	2.45	;	Glucose-6-phosphate 1-dehydrogenase (G6PDH) from Crithidia fasciculata (citrate bound)
8U2W	;	2.35	;	Glucose-6-phosphate 1-dehydrogenase (G6PDH) from Crithidia fasciculata (NADP bound)
7SEI	;	3.65	;	Glucose-6-phosphate 1-dehydrogenase (K403Q)
7SEH	;	2.9	;	Glucose-6-phosphate 1-dehydrogenase (K403QdLtL)
3NB0	;	2.406	;	Glucose-6-Phosphate activated form of Yeast Glycogen Synthase
7E6H	;	2.7	;	glucose-6-phosphate dehydrogenase from Kluyveromyces lactis
7E6I	;	2.39	;	Glucose-6-phosphate dehydrogenase in complex with its substrate glucose-6-phosphate
3Q7I	;	1.54	;	Glucose-6-phosphate isomerase from Francisella tularensis complexed with 6-phosphogluconic acid.
3M5P	;	1.65	;	Glucose-6-phosphate isomerase from Francisella tularensis complexed with fructose-6-phosphate.
3Q88	;	1.7	;	Glucose-6-phosphate isomerase from Francisella tularensis complexed with ribose 1,5-bisphosphate.
3LJK	;	1.48	;	Glucose-6-phosphate isomerase from Francisella tularensis.
1OFG	;	2.7	;	GLUCOSE-FRUCTOSE OXIDOREDUCTASE
2QW1	;	1.7	;	Glucose/galactose binding protein bound to 3-O-methyl D-glucose
4KQ2	;	2.95	;	Glucose1,2cyclic phosphate bound activated state of Yeast Glycogen Synthase
1BGG	;	2.3	;	GLUCOSIDASE A FROM BACILLUS POLYMYXA COMPLEXED WITH GLUCONATE
7XGX	;	2.39	;	Glucosyltransferase
3PIC	;	1.9	;	Glucuronoyl Esterase catalytic domain (Cip2_GE) from Hypocrea jecorina
6GRW	;	1.5	;	Glucuronoyl Esterase from Opitutus terrae (Au derivative)
6GU8	;	2.01808	;	Glucuronoyl Esterase from Solibacter usitatus
6GRY	;	2.00034	;	Glucuronoyl Esterase from Solibacter usitatus.
8VCN	;	1.47	;	GluER mutant - W66F F269Y Q293T F68Y T36E P263L
7YSV	;	8.01	;	GluK1-1a extracellular domain captured in SYM2081 bound desensitized state
7YSJ	;	5.2	;	GluK1-1a in nanodisc captured in SYM2081 bound desensitized state
8GPR	;	8.2	;	GluK1-1a receptor captured in the desensitized state
7KS0	;	5.3	;	GluK2/K5 with 6-Cyano-7-nitroquinoxaline-2,3-dione (CNQX)
7KS3	;	5.8	;	GluK2/K5 with L-Glu
5KUF	;	3.8	;	GluK2EM with 2S,4R-4-methylglutamate
5KUH	;	11.6	;	GluK2EM with LY466195
7VM2	;	5.9	;	GluK3 D759G mutant receptor complex with UBP310 and spermine
6KZM	;	9.6	;	GluK3 receptor complex with kainate
6L6F	;	10.6	;	GluK3 receptor complex with UBP301
6JFZ	;	7.6	;	GluK3 receptor complex with UBP310
6JFY	;	7.4	;	GluK3 receptor trapped in Desensitized state
6CNA	;	4.6	;	GluN1-GluN2B NMDA receptors with exon 5
5FXG	;	6.8	;	GLUN1B-GLUN2B NMDA RECEPTOR IN ACTIVE CONFORMATION
6WHT	;	4.39	;	GluN1b-GluN2B NMDA receptor in active conformation at 4.4 angstrom resolution
6WI1	;	3.62	;	GluN1b-GluN2B NMDA receptor in active conformation stabilized by inter-GluN1b-GluN2B subunit cross-linking
6WHY	;	4.03	;	GluN1b-GluN2B NMDA receptor in complex with GluN1 antagonist L689,560, class 1
6WI0	;	4.27	;	GluN1b-GluN2B NMDA receptor in complex with GluN1 antagonist L689,560, class 2
6WHW	;	4.09	;	GluN1b-GluN2B NMDA receptor in complex with GluN2B antagonist SDZ 220-040, class 1
6WHX	;	4.09	;	GluN1b-GluN2B NMDA receptor in complex with GluN2B antagonist SDZ 220-040, class 2
6WHU	;	3.93	;	GluN1b-GluN2B NMDA receptor in complex with SDZ 220-040 and L689,560, class 1
6WHV	;	4.05	;	GluN1b-GluN2B NMDA receptor in complex with SDZ 220-040 and L689,560, class 2
6WHS	;	4.0	;	GluN1b-GluN2B NMDA receptor in non-active 1 conformation at 3.95 angstrom resolution
6WHR	;	3.99	;	GluN1b-GluN2B NMDA receptor in non-active 2 conformation at 4 angstrom resolution
5FXH	;	5.0	;	GluN1b-GluN2B NMDA receptor in non-active-1 conformation
5FXI	;	6.4	;	GluN1b-GluN2B NMDA receptor structure in non-active-2 conformation
5FXJ	;	6.25	;	GluN1b-GluN2B NMDA receptor structure-Class X
5FXK	;	6.4	;	GluN1b-GluN2B NMDA receptor structure-Class Y
4JWX	;	1.5	;	GluN2A ligand-binding core in complex with propyl-NHP5G
4JWY	;	2.0	;	GluN2D ligand-binding core in complex with propyl-NHP5G
1IIT	;	1.9	;	GLUR0 LIGAND BINDING CORE COMPLEX WITH L-SERINE
1IIW	;	1.9	;	GLUR0 LIGAND BINDING CORE: CLOSED-CLEFT LIGAND-FREE STRUCTURE
1P1N	;	1.6	;	GluR2 Ligand Binding Core (S1S2J) Mutant L650T in Complex with Kainate
3GF7	;	2.4	;	Glutaconyl-coA decarboxylase A subunit from Clostridium symbiosum apoprotein
3GLM	;	2.5	;	Glutaconyl-coA decarboxylase A subunit from Clostridium symbiosum co-crystallized with crotonyl-coA
3GF3	;	1.75	;	Glutaconyl-coA decarboxylase A subunit from Clostridium symbiosum co-crystallized with glutaconyl-coA
3GMA	;	2.6	;	Glutaconyl-coA decarboxylase A subunit from Clostridium symbiosum co-crystallized with glutaryl-CoA
2J5T	;	2.9	;	Glutamate 5-kinase from Escherichia coli complexed with glutamate
2J5V	;	2.5	;	GLUTAMATE 5-KINASE FROM ESCHERICHIA COLI COMPLEXED WITH GLUTAMYL-5-PHOSPHATE AND PYROGLUTAMIC ACID
3T93	;	1.907	;	Glutamate bound to a double cysteine mutant (A452C/S652C) of the ligand binding domain of GluA2
3T9X	;	1.823	;	Glutamate bound to a double cysteine mutant (V484C/E657C) of the ligand binding domain of GluA2
4F3B	;	1.818	;	Glutamate bound to the D655A mutant of the ligand binding domain of GluA3
1AUP	;	2.5	;	GLUTAMATE DEHYDROGENASE
1B26	;	3.0	;	GLUTAMATE DEHYDROGENASE
1BGV	;	1.9	;	GLUTAMATE DEHYDROGENASE
1HRD	;	1.96	;	GLUTAMATE DEHYDROGENASE
7UZM	;	3.24	;	Glutamate dehydrogenase 1 from human liver
3ETG	;	2.5	;	Glutamate dehydrogenase complexed with GW5074
5GUD	;	1.68	;	Glutamate dehydrogenase from Corynebacterium glutamicum (alpha-iminoglutarate/NADP+ complex)
4FCC	;	2.0	;	Glutamate dehydrogenase from E. coli
1BVU	;	2.5	;	GLUTAMATE DEHYDROGENASE FROM THERMOCOCCUS LITORALIS
1EUZ	;	2.25	;	GLUTAMATE DEHYDROGENASE FROM THERMOCOCCUS PROFUNDUS IN THE UNLIGATED STATE
3JD0	;	3.47	;	Glutamate dehydrogenase in complex with GTP
3JD4	;	3.4	;	Glutamate dehydrogenase in complex with NADH and GTP, closed conformation
3JD3	;	3.6	;	Glutamate dehydrogenase in complex with NADH and GTP, open conformation
3JD1	;	3.3	;	Glutamate dehydrogenase in complex with NADH, closed conformation
3JD2	;	3.3	;	Glutamate dehydrogenase in complex with NADH, open conformation
1B1A	;		;	GLUTAMATE MUTASE (B12-BINDING SUBUNIT), NMR, MINIMIZED AVERAGE STRUCTURE
1BE1	;		;	GLUTAMATE MUTASE (B12-BINDING SUBUNIT), NMR, MINIMIZED AVERAGE STRUCTURE
1CB7	;	2.0	;	GLUTAMATE MUTASE FROM CLOSTRIDIUM COCHLEARIUM RECONSTITUTED WITH METHYL-COBALAMIN
1I9C	;	1.9	;	GLUTAMATE MUTASE FROM CLOSTRIDIUM COCHLEARIUM: COMPLEX WITH ADENOSYLCOBALAMIN AND SUBSTRATE
2VVT	;	1.65	;	Glutamate Racemase (MurI) from E. faecalis in complex with a 9-Benzyl Purine inhibitor
5IJW	;	1.76	;	Glutamate Racemase (MurI) from Mycobacterium smegmatis with bound D-glutamate, 1.8 Angstrom resolution, X-ray diffraction
1B73	;	2.3	;	GLUTAMATE RACEMASE FROM AQUIFEX PYROPHILUS
1B74	;	2.3	;	GLUTAMATE RACEMASE FROM AQUIFEX PYROPHILUS
5HJ7	;	2.3	;	Glutamate Racemase Mycobacterium tuberculosis (MurI) with bound D-glutamate, 2.3 Angstrom resolution, X-ray diffraction
1OFE	;	2.45	;	Glutamate Synthase from Synechocystis sp in complex with 2-Oxoglutarate and L-DON at 2.45 Angstrom resolution
1OFD	;	2.0	;	Glutamate Synthase from Synechocystis sp in complex with 2-Oxoglutarate at 2.0 Angstrom resolution
7MFM	;	2.42	;	Glutamate synthase, glutamate dehydrogenase counter-enzyme complex
7MFT	;	3.9	;	Glutamate synthase, glutamate dehydrogenase counter-enzyme complex (GudB6-GltA6-GltB6)
6ZGB	;	3.2	;	glutamate transporter homologue Glttk in complex with a photo cage compound
5JTY	;	2.72	;	Glutamate- and DCKA-bound GluN1/GluN2A agonist binding domains with MPX-007
5I57	;	1.7	;	Glutamate- and glycine-bound GluN1/GluN2A agonist binding domains
5I59	;	2.25	;	Glutamate- and glycine-bound GluN1/GluN2A agonist binding domains with MPX 007
5I58	;	2.52	;	GLUTAMATE- AND GLYCINE-BOUND GLUN1/GLUN2A AGONIST BINDING DOMAINS WITH MPX-004
2CFB	;	2.85	;	Glutamate-1-semialdehyde 2,1-Aminomutase from Thermosynechococcus elongatus
1XFF	;	1.8	;	Glutaminase domain of glucosamine 6-phosphate synthase complexed with glutamate
1XFG	;	1.85	;	Glutaminase domain of glucosamine 6-phosphate synthase complexed with l-glu hydroxamate
2ABW	;	1.62	;	Glutaminase subunit of the plasmodial PLP synthase (Vitamin B6 biosynthesis)
4PGA	;	1.7	;	GLUTAMINASE-ASPARAGINASE FROM PSEUDOMONAS 7A
1GGG	;	2.3	;	GLUTAMINE BINDING PROTEIN OPEN LIGAND-FREE STRUCTURE
1AO0	;	2.8	;	GLUTAMINE PHOSPHORIBOSYLPYROPHOSPHATE (PRPP) AMIDOTRANSFERASE FROM B. SUBTILIS COMPLEXED WITH ADP AND GMP
7CPR	;	2.12	;	glutamine synthetase from Drosophila
8OON	;	2.43	;	Glutamine synthetase from Methanothermococcus thermolithotrophicus at a resolution of 2.43 A
8OOQ	;	2.91	;	Glutamine synthetase from Methanothermococcus thermolithotrophicus in complex with 2-oxoglutarate and Mg at 2.91 A resolution
8OOO	;	2.149	;	Glutamine synthetase from Methanothermococcus thermolithotrophicus in complex with 2-oxoglutarate and MgATP at 2.15 A resolution
8OOL	;	1.65	;	Glutamine synthetase from Methanothermococcus thermolithotrophicus with TbXo4 at a resolution of 1.65 A
8OOW	;	2.64	;	Glutamine synthetase from Methermicoccus shengliensis at a resolution of 2.64 A
8OOX	;	3.09	;	Glutamine synthetase from Methermicoccus shengliensis at a resolution of 3.09 A
8OOZ	;	2.7	;	Glutamine synthetase from Methermicoccus shengliensis in complex with MgATP at 2.7 A resolution
8FBP	;	2.8	;	Glutamine synthetase from Pseudomonas aeruginosa, filament double-unit in compressed conformation
7U6O	;	3.2	;	Glutamine Synthetase Type III from Ostreococcus tauri
1WDN	;	1.94	;	GLUTAMINE-BINDING PROTEIN
1ZJW	;	2.5	;	Glutaminyl-tRNA synthetase complexed to glutamine and 2'deoxy A76 glutamine tRNA
1EUY	;	2.6	;	GLUTAMINYL-TRNA SYNTHETASE COMPLEXED WITH A TRNA MUTANT AND AN ACTIVE SITE INHIBITOR
1QTQ	;	2.25	;	GLUTAMINYL-TRNA SYNTHETASE COMPLEXED WITH TRNA AND AN AMINO ACID ANALOG
2RD2	;	2.6	;	Glutaminyl-tRNA synthetase mutant C229R with bound analog 5'-O-[N-(L-GLUTAMINYL)-SULFAMOYL]ADENOSINE
2RE8	;	2.6	;	Glutaminyl-tRNA synthetase mutant C229R with bound analog 5'-O-[N-(L-GLUTAMYL)-SULFAMOYL]ADENOSINE
1QRT	;	2.7	;	GLUTAMINYL-TRNA SYNTHETASE MUTANT D235G COMPLEXED WITH GLUTAMINE TRANSFER RNA
1QRS	;	2.6	;	GLUTAMINYL-TRNA SYNTHETASE MUTANT D235N COMPLEXED WITH GLUTAMINE TRANSFER RNA
1QRU	;	3.0	;	GLUTAMINYL-TRNA SYNTHETASE MUTANT I129T COMPLEXED WITH GLUTAMINE TRANSFER RNA
1P3C	;	1.5	;	Glutamyl endopeptidase from Bacillus intermedius
1GPJ	;	1.95	;	Glutamyl-tRNA Reductase from Methanopyrus kandleri
1G59	;	2.4	;	GLUTAMYL-TRNA SYNTHETASE COMPLEXED WITH TRNA(GLU).
8I9I	;	3.3	;	Glutamyl-tRNA synthetase from Escherichia Coli bound to Glutamate and Zinc
7WAI	;	2.105	;	Glutamyl-tRNA synthetase from Plasmodium falciparum (PfERS)
7WAJ	;	2.254	;	Glutamyl-tRNA synthetase from Plasmodium falciparum (PfERS) complexed with ATP and Co
7WAK	;	2.782	;	Glutamyl-tRNA synthetase from Plasmodium falciparum (PfERS) in complex with ADP
7WAL	;	2.29	;	Glutamyl-tRNA synthetase from Plasmodium falciparum (PfERS) in complex with Co
7WAO	;	2.582	;	Glutamyl-tRNA synthetase from Plasmodium falciparum (PfERS) in complex with Mn
2CUZ	;	1.98	;	Glutamyl-tRNA synthetase from Thermus thermophilus in complex with L-glutamate
2CV2	;	2.69	;	Glutamyl-tRNA synthetase from Thermus thermophilus in complex with tRNA(Glu) and an enzyme inhibitor, Glu-AMS
2CV0	;	2.4	;	Glutamyl-tRNA synthetase from Thermus thermophilus in complex with tRNA(Glu) and L-glutamate
2CV1	;	2.41	;	Glutamyl-tRNA synthetase from Thermus thermophilus in complex with tRNA(Glu), ATP, and an analog of L-glutamate: a quaternary complex
6EC7	;	2.15	;	Glutamylation domain, TbtB, from thiomuracin biosynthesis
6EC8	;	2.148	;	Glutamylation domain, TbtB, from thiomuracin biosynthesis bound to 5'-phosphodesmethylglutamycin
2X3T	;	2.749	;	Glutaraldehyde-crosslinked wheat germ agglutinin isolectin 1 crystal soaked with a synthetic glycopeptide
6CRQ	;	4.2	;	Glutaraldehyde-treated BG505 SOSIP.664 Env in complex with PGV04 Fab
3D4M	;	2.05	;	Glutaredoxin 2 oxidized structure
1FOV	;		;	GLUTAREDOXIN 3 FROM ESCHERICHIA COLI IN THE FULLY OXIDIZED FORM
2JAC	;	2.02	;	Glutaredoxin Grx1p C30S mutant from yeast
1QFN	;		;	GLUTAREDOXIN-1-RIBONUCLEOTIDE REDUCTASE B1 MIXED DISULFIDE BOND
2AE3	;	2.4	;	Glutaryl 7-Aminocephalosporanic Acid Acylase: mutational study of activation mechanism
2AE4	;	2.3	;	Glutaryl 7-Aminocephalosporanic Acid Acylase: mutational study of activation mechanism
2AE5	;	2.24	;	Glutaryl 7-Aminocephalosporanic Acid Acylase: mutational study of activation mechanism
2R9Z	;	2.1	;	Glutathione amide reductase from Chromatium gracile
2RM5	;		;	Glutathione peroxidase-type tryparedoxin peroxidase, oxidized form
3DWV	;	1.41	;	Glutathione peroxidase-type tryparedoxin peroxidase, oxidized form
2RM6	;		;	Glutathione peroxidase-type tryparedoxin peroxidase, reduced form
6DU7	;	2.56	;	Glutathione reductase from Streptococcus pneumoniae
1R5A	;	2.5	;	Glutathione S-transferase
1V2A	;	2.15	;	Glutathione S-transferase 1-6 from Anopheles dirus species B
7XBA	;	2.83	;	Glutathione S-transferase bound with a covalent inhibitor
5J41	;	1.19035	;	Glutathione S-transferase bound with hydrolyzed Piperlongumine
11GS	;	2.3	;	Glutathione s-transferase complexed with ethacrynic acid-glutathione conjugate (form ii)
12GS	;	2.1	;	GLUTATHIONE S-TRANSFERASE COMPLEXED WITH S-NONYL-GLUTATHIONE
13GS	;	1.9	;	GLUTATHIONE S-TRANSFERASE COMPLEXED WITH SULFASALAZINE
4PNF	;	2.11	;	Glutathione S-Transferase from Drosophila melanogaster - isozyme E6
4PNG	;	1.53	;	Glutathione S-transferase from Drosophila melanogaster - isozyme E7
2GSQ	;	2.2	;	GLUTATHIONE S-TRANSFERASE FROM SQUID DIGESTIVE GLAND COMPLEXED WITH S-(3-IODOBENZYL)GLUTATHIONE
1B8X	;	2.7	;	GLUTATHIONE S-TRANSFERASE FUSED WITH THE NUCLEAR MATRIX TARGETING SIGNAL OF THE TRANSCRIPTION FACTOR AML-1
1BYE	;	2.8	;	GLUTATHIONE S-TRANSFERASE I FROM MAIS IN COMPLEX WITH ATRAZINE GLUTATHIONE CONJUGATE
1AQW	;	1.8	;	GLUTATHIONE S-TRANSFERASE IN COMPLEX WITH GLUTATHIONE
1BX9	;	2.6	;	GLUTATHIONE S-TRANSFERASE IN COMPLEX WITH HERBICIDE
1AQX	;	2.0	;	GLUTATHIONE S-TRANSFERASE IN COMPLEX WITH MEISENHEIMER COMPLEX
1AQV	;	1.94	;	GLUTATHIONE S-TRANSFERASE IN COMPLEX WITH P-BROMOBENZYLGLUTATHIONE
6MHB	;	2.75	;	Glutathione S-Transferase Omega 1 bound to covalent inhibitor 18
6MHC	;	2.0	;	Glutathione S-Transferase Omega 1 bound to covalent inhibitor 37
6MHD	;	2.16	;	Glutathione S-Transferase Omega 1 bound to covalent inhibitor 44
4YQM	;	2.38	;	Glutathione S-transferase Omega 1 bound to covalent inhibitor C1-27
4YQU	;	1.94	;	Glutathione S-transferase Omega 1 bound to covalent inhibitor C1-31
4YQV	;	2.06	;	Glutathione S-transferase Omega 1 bound to covalent inhibitor C4-10
17GS	;	1.9	;	GLUTATHIONE S-TRANSFERASE P1-1
19GS	;	1.9	;	Glutathione s-transferase p1-1
14GS	;	2.8	;	GLUTATHIONE S-TRANSFERASE P1-1 APO FORM 1
16GS	;	1.9	;	GLUTATHIONE S-TRANSFERASE P1-1 APO FORM 3
18GS	;	1.9	;	GLUTATHIONE S-TRANSFERASE P1-1 COMPLEXED WITH 1-(S-GLUTATHIONYL)-2,4-DINITROBENZENE
20GS	;	2.45	;	GLUTATHIONE S-TRANSFERASE P1-1 COMPLEXED WITH CIBACRON BLUE
5O84	;	1.88	;	Glutathione S-transferase Tau 23 (partially oxidized)
3AY8	;	2.1	;	Glutathione S-transferase unclassified 2 from Bombyx mori
1BAY	;	2.0	;	GLUTATHIONE S-TRANSFERASE YFYF CYS 47-CARBOXYMETHYLATED CLASS PI, FREE ENZYME
1GSY	;	2.44	;	GLUTATHIONE S-TRANSFERASE YFYF, CLASS PI, COMPLEXED WITH GLUTATHIONE
1FHE	;	3.0	;	GLUTATHIONE TRANSFERASE (FH47) FROM FASCIOLA HEPATICA
1LJR	;	3.2	;	GLUTATHIONE TRANSFERASE (HGST T2-2) FROM HUMAN
3LJR	;	3.3	;	GLUTATHIONE TRANSFERASE (THETA CLASS) FROM HUMAN IN COMPLEX WITH THE GLUTATHIONE CONJUGATE OF 1-MENAPHTHYL SULFATE
1GSE	;	2.0	;	GLUTATHIONE TRANSFERASE A1-1 COMPLEXED WITH AN ETHACRYNIC ACID GLUTATHIONE CONJUGATE (MUTANT R15K)
1GSF	;	2.7	;	GLUTATHIONE TRANSFERASE A1-1 COMPLEXED WITH ETHACRYNIC ACID
1GSD	;	2.5	;	GLUTATHIONE TRANSFERASE A1-1 IN UNLIGANDED FORM
2VCT	;	2.1	;	Glutathione transferase A2-2 in complex with delta-4-andostrene-3-17- dione
2WJU	;	2.3	;	Glutathione transferase A2-2 in complex with glutathione
2VCV	;	1.8	;	Glutathione transferase A3-3 in complex with glutathione and delta-4- androstene-3-17-dione
2LJR	;	3.2	;	GLUTATHIONE TRANSFERASE APO-FORM FROM HUMAN
4YH2	;	1.72	;	Glutathione Transferase E6 from Drosophila melanogaster
2VO4	;	1.75	;	Glutathione transferase from Glycine max
1EEM	;	2.0	;	GLUTATHIONE TRANSFERASE FROM HOMO SAPIENS
1PMT	;	2.5	;	GLUTATHIONE TRANSFERASE FROM PROTEUS MIRABILIS
2PMT	;	2.7	;	GLUTATHIONE TRANSFERASE FROM PROTEUS MIRABILIS
1KBN	;	2.0	;	Glutathione transferase mutant
1MTC	;	2.2	;	GLUTATHIONE TRANSFERASE MUTANT Y115F
1EOH	;	2.5	;	GLUTATHIONE TRANSFERASE P1-1
8C5D	;	1.28	;	Glutathione transferase P1-1 from Mus musculus
5G5A	;	1.95	;	Glutathione transferase U25 from Arabidopsis thaliana in complex with glutathione disulfide
1FW1	;	1.9	;	Glutathione transferase zeta/maleylacetoacetate isomerase
1TW9	;	1.71	;	Glutathione Transferase-2, apo form, from the nematode Heligmosomoides polygyrus
5LOL	;	2.3	;	Glutathione-bound Dehydroascorbate Reductase 2 of Arabidopsis thaliana
3LVW	;	2.5	;	Glutathione-inhibited ScGCL
2X64	;	2.3	;	GLUTATHIONE-S-TRANSFERASE FROM XYLELLA FASTIDIOSA
7NC3	;	1.65	;	Glutathione-S-transferase GliG (space group P212121)
7NC2	;	1.7	;	Glutathione-S-transferase GliG (space group P3221)
7NC6	;	2.1	;	Glutathione-S-transferase GliG in complex with cyclo[L-Phe-L-Ser]-bis-glutathione-adduct
7NC5	;	1.95	;	Glutathione-S-transferase GliG in complex with reduced glutathione
7NCM	;	1.7	;	Glutathione-S-transferase GliG mutant E82A
7NCL	;	2.0	;	Glutathione-S-transferase GliG mutant E82Q
7NCB	;	1.85	;	Glutathione-S-transferase GliG mutant H26A
7NC9	;	2.55	;	Glutathione-S-transferase GliG mutant H26N
7NCP	;	2.05	;	Glutathione-S-transferase GliG mutant K127A
7NCT	;	2.65	;	Glutathione-S-transferase GliG mutant K127G
7NCU	;	1.5	;	Glutathione-S-transferase GliG mutant K127G in complex with oxidized glutathione
7NCO	;	1.7	;	Glutathione-S-transferase GliG mutant K127R
7NCE	;	2.0	;	Glutathione-S-transferase GliG mutant N27A
7NCD	;	2.05	;	Glutathione-S-transferase GliG mutant N27D
7NC8	;	2.2	;	Glutathione-S-transferase GliG mutant S24A
7NCN	;	1.9	;	Glutathione-S-transferase GliG mutant S83A
7NC1	;	2.6	;	Glutathione-S-transferase GliG with partially disordered active site
4FQU	;	3.0	;	Glutathionyl-Hydroquinone Reductase PcpF of Sphingobium chlorophenolicum
4G0I	;	2.05	;	Glutathionyl-Hydroquinone Reductase, YqjG of Escherichia coli
4G0K	;	2.557	;	Glutathionyl-hydroquinone reductase, YqjG, of E.coli complexed with GS-menadione
4G0L	;	2.62	;	Glutathionyl-hydroquinone Reductase, YqjG, of E.coli complexed with GSH
5GJJ	;		;	Glutathionylated hHsp70 SBD
3O98	;	2.8	;	Glutathionylspermidine synthetase/amidase C59A complex with ADP and Gsp
4CYD	;	1.82	;	GlxR bound to cAMP
1SGQ	;	1.9	;	GLY 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B
4K1T	;	1.6	;	Gly-Ser-SplB protease from Staphylococcus aureus at 1.60 A resolution
4K1S	;	1.96	;	Gly-Ser-SplB protease from Staphylococcus aureus at 1.96 A resolution
2W29	;	4.1	;	Gly102Thr mutant of Rv3291c
1JPK	;	2.2	;	Gly156Asp mutant of Human UroD, human uroporphyrinogen III decarboxylase
6Q3U	;	1.64	;	Gly52Ala mutant of arginine-bound ArgBP from T. maritima
5V6J	;	1.18	;	Glycan binding protein Y3 from mushroom Coprinus comatus possesses anti-leukemic activity
5V6I	;	1.7	;	Glycan binding protein Y3 from mushroom Coprinus comatus possesses anti-leukemic activity - Pt derivative
2WQ8	;	2.19	;	Glycan labelling using engineered variants of galactose oxidase obtained by directed evolution
5SZS	;	3.4	;	Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy
6BFU	;	3.5	;	Glycan shield and fusion activation of a deltacoronavirus spike glycoprotein fine-tuned for enteric infections
8F7T	;	4.1	;	Glycan-Base ConC Env Trimer
1CI5	;		;	GLYCAN-FREE MUTANT ADHESION DOMAIN OF HUMAN CD58 (LFA-3)
5HY8	;	2.3	;	Glycation restrains allosteric transition in hemoglobin: The molecular basis of oxidative stress under hyperglycemic conditions in diabetes
1HBG	;	1.5	;	GLYCERA DIBRANCHIATA HEMOGLOBIN. STRUCTURE AND REFINEMENT AT 1.5 ANGSTROMS RESOLUTION
2HBG	;	1.5	;	GLYCERA DIBRANCHIATA HEMOGLOBIN. STRUCTURE AND REFINEMENT AT 1.5 ANGSTROMS RESOLUTION
1B7G	;	2.05	;	GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASE
7BEX	;	2.054	;	Glyceraldehyde 3-phosphate dehydrogenase from Campylobacter jejeuni - ADP complex
7BEW	;	2.25	;	Glyceraldehyde 3-phosphate dehydrogenase from Campylobacter jejeuni - NAD(P) complex
6M61	;	1.8245	;	Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) with inhibitor heptelidic acid
6IOJ	;	2.29	;	Glyceraldehyde-3-phosphate dehydrogenase A (apo-form)
1DBV	;	2.5	;	GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE MUTANT WITH ASP 32 REPLACED BY GLY, LEU 187 REPLACED BY ALA, AND PRO 188 REPLACED BY SER COMPLEXED WITH NAD+
2DBV	;	2.2	;	GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE MUTANT WITH ASP 32 REPLACED BY GLY, LEU 187 REPLACED BY ALA, AND PRO 188 REPLACED BY SER COMPLEXED WITH NADP+
1NPT	;	2.18	;	Glyceraldehyde-3-Phosphate Dehydrogenase Mutant With Cys 149 replaced by Ala complexed with NAD+
1NQA	;	2.2	;	Glyceraldehyde-3-Phosphate Dehydrogenase Mutant With Cys 149 Replaced By Ala Complexed With Nad+ and D-Glyceraldehyde-3-Phosphate
1NQ5	;	2.11	;	Glyceraldehyde-3-Phosphate Dehydrogenase Mutant With Cys 149 Replaced By Ser Complexed With Nad+
1NQO	;	2.01	;	Glyceraldehyde-3-Phosphate Dehydrogenase Mutant With Cys 149 Replaced By Ser Complexed With Nad+ and D-Glyceraldehyde-3-Phosphate
3DBV	;	2.45	;	GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE MUTANT WITH LEU 33 REPLACED BY THR, THR 34 REPLACED BY GLY, ASP 36 REPLACED BY GLY, LEU 187 REPLACED BY ALA, AND PRO 188 REPLACED BY SER COMPLEXED WITH NAD+
4DBV	;	2.5	;	GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE MUTANT WITH LEU 33 REPLACED BY THR, THR 34 REPLACED BY GLY, ASP 36 REPLACED BY GLY, LEU 187 REPLACED BY ALA, AND PRO 188 REPLACED BY SER COMPLEXED WITH NADP+
1TO6	;	2.5	;	Glycerate kinase from Neisseria meningitidis (serogroup A)
1R9D	;	1.8	;	Glycerol bound form of the B12-independent glycerol dehydratase from Clostridium butyricum
5IKZ	;	2.8	;	Glycerol bound structure of Obc1, a bifunctional enzyme for quorum sensing-dependent oxalogenesis
1NBW	;	2.4	;	Glycerol dehydratase reactivase
1IWP	;	2.1	;	Glycerol Dehydratase-cyanocobalamin Complex of Klebsiella pneumoniae
3FAH	;	1.72	;	Glycerol inhibited form of Aldehyde oxidoreductase from Desulfovibrio gigas
6K76	;	3.05	;	Glycerol kinase form Thermococcus kodakarensis, complex structure with substrate.
6K78	;	2.301	;	Glycerol kinase form Thermococcus kodakarensis, complex structure with substrate.
6K79	;	2.19	;	Glycerol kinase form Thermococcus kodakarensis, complex structure with substrate.
3H45	;	2.65	;	Glycerol Kinase H232E with Ethylene Glycol
3H46	;	1.75	;	Glycerol Kinase H232E with Glycerol
3H3O	;	2.3	;	Glycerol Kinase H232R with Ethylene Glycol
3H3N	;	1.73	;	Glycerol Kinase H232R with Glycerol
4JIC	;	1.6	;	Glycerol Trinitrate Reductase NerA from Agrobacterium radiobacter
1N1D	;	2.0	;	Glycerol-3-phosphate cytidylyltransferase complexed with CDP-glycerol
4OI5	;	1.3	;	Glycerol-free structure of thermolysin in complex with ubtln58
2DXL	;	3.0	;	Glycerophosphodiesterase from Enterobacter aerogenes
2DXN	;	2.92	;	Glycerophosphodiesterase from Enterobacter aerogenes
1GSO	;	1.6	;	GLYCINAMIDE RIBONUCLEOTIDE SYNTHETASE (GAR-SYN) FROM E. COLI.
1PQF	;	2.0	;	Glycine 24 to Serine mutation of aspartate decarboxylase
7SAA	;	2.97	;	Glycine and glutamate bound GluN1a-GluN2B NMDA receptors in non-active 1 conformation at 2.97 Angstrom resolution
8E96	;	3.38	;	Glycine and glutamate bound Human GluN1a-GluN2D NMDA receptor
3ATN	;	1.17	;	Glycine ethyl ester shielding on the aromatic surfaces of lysozyme: Implication for suppression of protein aggregation
3ATO	;	1.17	;	Glycine ethyl ester shielding on the aromatic surfaces of lysozyme: Implication for suppression of protein aggregation
4TOP	;	2.351	;	Glycine max glutathione transferase
6J48	;	1.201	;	Glycine mutation on single layer beta-sheet of OspAsm1
3L2E	;	2.6	;	Glycocyamine kinase, alpha-beta heterodimer from marine worm Namalycastis sp.
3L2D	;	2.4	;	Glycocyamine kinase, beta-beta homodimer from marine worm Namalycastis sp.
4V7N	;	2.3	;	Glycocyamine kinase, beta-beta homodimer from marine worm Namalycastis sp., with transition state analog Mg(II)-ADP-NO3-glycocyamine.
1Z6P	;	2.4	;	Glycogen phosphorylase AMP site inhibitor complex
2QRP	;	1.86	;	Glycogen Phosphorylase b in complex with (1R)-3'-(2-naphthyl)-spiro[1,5-anhydro-D-glucitol-1,5'-isoxazoline]
2QRG	;	1.85	;	Glycogen Phosphorylase b in complex with (1R)-3'-(4-methoxyphenyl)-spiro[1,5-anhydro-D-glucitol-1,5'-isoxazoline]
2QRQ	;	1.8	;	Glycogen Phosphorylase b in complex with (1R)-3'-(4-methylphenyl)-spiro[1,5-anhydro-D-glucitol-1,5'-isoxazoline]
2QRM	;	1.9	;	Glycogen Phosphorylase b in complex with (1R)-3'-(4-nitrophenyl)-spiro[1,5-anhydro-D-glucitol-1,5'-isoxazoline]
2QRH	;	1.83	;	Glycogen Phosphorylase b in complex with (1R)-3'-phenylspiro[1,5-anhydro-D-glucitol-1,5'-isoxazoline]
6QA8	;	2.35	;	Glycogen Phosphorylase b in complex with 28
6QA7	;	2.36	;	Glycogen Phosphorylase b in complex with 29
5O54	;	2.45	;	Glycogen Phosphorylase b in complex with 29a
5O56	;	2.45	;	Glycogen Phosphorylase b in complex with 29b
6R0H	;	2.5	;	Glycogen Phosphorylase b in complex with 3
3SYM	;	2.4	;	Glycogen Phosphorylase b in complex with 3 -C-(hydroxymethyl)-beta-D-glucopyranonucleoside of 5-fluorouracil
6QA6	;	2.4	;	Glycogen Phosphorylase b in complex with 30
5O50	;	1.9	;	Glycogen Phosphorylase b in complex with 33a
5O52	;	1.9	;	Glycogen Phosphorylase b in complex with 33b
6R0I	;	2.4	;	Glycogen Phosphorylase b in complex with 4
2QN1	;	2.401	;	Glycogen Phosphorylase b in complex with asiatic acid
3BCR	;	2.14	;	Glycogen Phosphorylase b in complex with AZT
3SYR	;	2.4	;	Glycogen phosphorylase b in complex with beta-D-glucopyranonucleoside 5-fluorouracil
3T3G	;	2.4	;	Glycogen Phosphorylase b in complex with GlcBrU
3T3I	;	2.65	;	Glycogen Phosphorylase b in complex with GlcCF3U
3T3E	;	2.15	;	Glycogen phosphorylase b in complex with GlcClU
3T3H	;	2.6	;	Glycogen Phosphorylase b in complex with GlcIU
3T3D	;	2.5	;	Glycogen phosphorylase b in complex with GlcU
1UZU	;	2.3	;	Glycogen Phosphorylase b in complex with indirubin-5'-sulphonate
2QN2	;	2.698	;	Glycogen Phosphorylase b in complex with Maslinic Acid
2QN7	;	1.83	;	Glycogen Phosphorylase b in complex with N-4-hydroxybenzoyl-N'-4-beta-D-glucopyranosyl urea
2QN8	;	1.9	;	Glycogen Phosphorylase b in complex with N-4-nitrobenzoyl-N'-beta-D-glucopyranosyl urea
2QLN	;	2.15	;	Glycogen Phosphorylase b in complex with N-4-phenylbenzoyl-N'-beta-D-glucopyranosyl urea
2QNB	;	1.8	;	Glycogen Phosphorylase b in complex with N-benzoyl-N'-beta-D-glucopyranosyl urea
6YVE	;	2.1	;	Glycogen phosphorylase b in complex with pelargonidin 3-O-beta-D-glucoside
3EBO	;	1.9	;	Glycogen Phosphorylase b/Chrysin complex
3EBP	;	2.0	;	Glycogen Phosphorylase b/flavopiridol complex
1GPB	;	1.9	;	GLYCOGEN PHOSPHORYLASE B: DESCRIPTION OF THE PROTEIN STRUCTURE
3BDA	;	2.0	;	Glycogen Phosphorylase complex with 1(-D-glucopyranosyl) cyanuric acid
3BD7	;	1.9	;	Glycogen Phosphorylase complex with 1(-D-glucopyranosyl) thymine
3BCS	;	2.0	;	Glycogen Phosphorylase complex with 1(-D-glucopyranosyl) uracil
3BD6	;	2.0	;	Glycogen Phosphorylase complex with 1(-D-ribofuranosyl) cyanuric acid
3NP7	;	2.05	;	Glycogen phosphorylase complexed with 2,5-dihydroxy-3-(beta-D-glucopyranosyl)-chlorobenzene and 2,5-dihydroxy-4-(beta-D-glucopyranosyl)-chlorobenzene
3NPA	;	1.969	;	Glycogen phosphorylase complexed with 2,5-dihydroxy-4-(beta-D-glucopyranosyl)-bromo-benzene
3MS7	;	1.95	;	Glycogen phosphorylase complexed with 2-chlorobenzaldehyde-4-(2,3,4,6-tetra-O-acetyl-beta-D-glucopyranosyl) thiosemicarbazone
3MSC	;	1.951	;	Glycogen phosphorylase complexed with 2-nitrobenzaldehyde-4-(beta-D-glucopyranosyl)-thiosemicarbazone
3NP9	;	1.999	;	Glycogen phosphorylase complexed with 3-(beta-D-glucopyranosyl)-2-hydroxy-5-methoxy-chlorobenzene
3MTA	;	2.23	;	Glycogen phosphorylase complexed with 3-bromobenzaldehyde-4-(beta-D-glucopyranosyl)-thiosemicarbazone
3MTB	;	1.95	;	Glycogen phosphorylase complexed with 3-chlorobenzaldehyde-4-(beta-D-glucopyranosyl)-thiosemicarbazone
3MRV	;	1.94	;	Glycogen phosphorylase complexed with 3-hydroxybenzaldehyde-4-(beta-D-glucopyranosyl) thiosemicarbazone
3MT7	;	2.0	;	Glycogen phosphorylase complexed with 4-bromobenzaldehyde-4-(beta-D-glucopyranosyl)-thiosemicarbazone
3MT8	;	2.0	;	Glycogen phosphorylase complexed with 4-chlorobenzaldehyde-4-(beta-D-glucopyranosyl)-thiosemicarbazone
3MQF	;	1.951	;	Glycogen phosphorylase complexed with 4-fluorobenzaldehyde-4-(beta-D-glucopyranosyl)-thiosemicarbazone
3MTD	;	2.096	;	Glycogen phosphorylase complexed with 4-hydroxybenzaldehyde-4-(beta-D-glucopyranosyl)-thiosemicarbazone
3MRX	;	1.95	;	Glycogen phosphorylase complexed with 4-methoxybenzaldehyde-4-(2,3,4,6-tetra-O-acetyl-beta-D-glucopyranosyl)-thiosemicarbazone
3MS2	;	2.1	;	Glycogen phosphorylase complexed with 4-methylbenzaldehyde-4-(beta-D-glucopyranosyl) thiosemicarbazone
3MT9	;	2.05	;	Glycogen phosphorylase complexed with 4-nitrobenzaldehyde-4-(beta-D-glucopyranosyl)-thiosemicarbazone
3MRT	;	1.98	;	Glycogen phosphorylase complexed with 4-pyridinecarboxaldehyde-4-(beta-D-glucopyranosyl) thiosemicarbazone
3MS4	;	2.07	;	Glycogen phosphorylase complexed with 4-trifluoromethylbenzaldehyde-4-(beta-D-glucopyranosyl)-thiosemicarbazone
5MCB	;	1.95	;	Glycogen phosphorylase in complex with chlorogenic acid.
5OX0	;	1.9	;	Glycogen Phosphorylase in complex with CK898
5OX4	;	1.8	;	Glycogen Phosphorylase in complex with CK900
4YUA	;	2.0	;	Glycogen phosphorylase in complex with ellagic acid
2QLM	;	2.1	;	Glycogen phosphorylase in complex with FN67
4Z5X	;	2.1	;	Glycogen phosphorylase in complex with gallic acid
5OX1	;	1.85	;	Glycogen Phosphorylase in complex with JLH270
5OWZ	;	1.85	;	Glycogen Phosphorylase in complex with KS172
5OWY	;	1.9	;	Glycogen Phosphorylase in complex with KS252
2QN9	;	2.0	;	Glycogen Phosphorylase in complex with N-4-aminobenzoyl-N'-beta-D-glucopyranosyl urea
2QN3	;	1.96	;	Glycogen Phosphorylase in complex with N-4-chlorobenzoyl-N-beta-D-glucopyranosyl urea
5OX3	;	1.9	;	Glycogen Phosphorylase in complex with SzB102v
2ATI	;	1.9	;	Glycogen Phosphorylase Inhibitors
3E3O	;	2.6	;	Glycogen phosphorylase R state-IMP complex
1Z6Q	;	2.03	;	Glycogen phosphorylase with inhibitor in the AMP site
3O3C	;	3.512	;	Glycogen synthase basal state UDP complex
5VNC	;	2.98	;	Glycogen synthase in complex with UDP and glucosamine
1UV5	;	2.8	;	GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 6-BROMOINDIRUBIN-3'-OXIME
1O9U	;	2.4	;	GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE
3ZDI	;	2.645	;	Glycogen Synthase Kinase 3 Beta complexed with Axin Peptide and Inhibitor 7d
4B7T	;	2.772	;	Glycogen Synthase Kinase 3 Beta complexed with Axin Peptide and Leucettine L4
5KPK	;	2.4	;	Glycogen Synthase Kinase 3 beta Complexed with BRD0209
5KPL	;	2.6	;	Glycogen Synthase Kinase 3 beta Complexed with BRD0705
5KPM	;	2.69	;	Glycogen Synthase Kinase 3 beta Complexed with BRD3731
1H8F	;	2.8	;	Glycogen Synthase Kinase 3 beta.
3F88	;	2.6	;	glycogen synthase Kinase 3beta inhibitor complex
3E3P	;	2.0	;	Glycogen synthase kinase from Leishmania major
6H0U	;	2.3	;	Glycogen synthase kinase-3 beta (GSK3) complex with a covalent [1,2,4]triazolo[1,5-a][1,3,5]triazine inhibitor
1GNG	;	2.6	;	Glycogen synthase kinase-3 beta (GSK3) complex with FRATtide peptide
6TCU	;	2.14	;	Glycogen synthase kinase-3 beta (GSK3b) in complex with ligand 1
1R0E	;	2.25	;	Glycogen synthase kinase-3 beta in complex with 3-indolyl-4-arylmaleimide inhibitor
2OW3	;	2.8	;	Glycogen synthase kinase-3 beta in complex with bis-(indole)maleimide pyridinophane inhibitor
2F15	;	2.0	;	Glycogen-Binding Domain Of The Amp-Activated Protein Kinase beta2 Subunit
4HSI	;	3.101	;	Glycoprotein B from Herpes simplex virus type 1, A504P/R505G/Q507G/N511G mutant, low-pH
4L1R	;	3.0255	;	Glycoprotein B from Herpes Simplex Virus type 1, A549T Rate-of-Entry mutant, low-pH
3NWF	;	3.0	;	Glycoprotein B from Herpes simplex virus type 1, low-pH
3NWA	;	2.2629	;	Glycoprotein B from Herpes simplex virus type 1, W174R mutant, low-pH
3NW8	;	2.75915	;	Glycoprotein B from Herpes simplex virus type 1, Y179S mutant, high-pH
3NWD	;	2.8803	;	Glycoprotein B from Herpes simplex virus type 1, Y179S mutant, low-pH
3REZ	;	2.35	;	glycoprotein GPIb variant
5Z3C	;	1.6	;	Glycosidase E178A
5Z3E	;	1.1	;	Glycosidase E335A
5Z3F	;	1.1	;	Glycosidase E335A in complex with glucose
5Z3D	;	1.25	;	Glycosidase F290Y
7C27	;	1.91	;	Glycosidase F290Y at pH4.5
7C24	;	1.71	;	Glycosidase F290Y at pH8.0
5Z3A	;	1.401	;	Glycosidase Wild Type
7C26	;	1.803	;	Glycosidase Wild Type at pH4.5
7C25	;	1.505	;	Glycosidase Wild Type at pH8.0
5Z3B	;	1.25	;	Glycosidase Y48F
5GSL	;	2.6	;	Glycoside hydrolase A
5GSM	;	1.27	;	Glycoside hydrolase B with product
5MVH	;	1.8	;	Glycoside Hydrolase BACCELL_00856
5MUM	;	1.8	;	Glycoside Hydrolase BACINT_00347
5MUK	;	1.49	;	Glycoside Hydrolase BT3686
5MUL	;	1.39	;	Glycoside Hydrolase BT3686 bound to Glucuronic Acid
5MQM	;	2.11	;	Glycoside hydrolase BT_0986
5MQN	;	1.9	;	Glycoside hydrolase BT_0986
5MWK	;	2.0	;	Glycoside hydrolase BT_0986
5MT2	;	1.41	;	Glycoside hydrolase BT_0996
5MUI	;	1.77	;	Glycoside hydrolase BT_0996
5MQP	;	2.0	;	Glycoside hydrolase BT_1002
5MQO	;	2.5	;	Glycoside hydrolase BT_1003
5MSY	;	2.3	;	Glycoside hydrolase BT_1012
5MSX	;	2.1	;	Glycoside hydrolase BT_3662
6T2B	;	2.13	;	Glycoside hydrolase family 109 from Akkermansia muciniphila in complex with GalNAc and NAD+.
6K9D	;	1.505	;	glycoside hydrolase family 12 (GH12) englucanase
2VN4	;	1.85	;	Glycoside Hydrolase Family 15 Glucoamylase from Hypocrea jecorina
2VN7	;	1.9	;	Glycoside Hydrolase Family 15 Glucoamylase from Hypocrea jecorina
7KR6	;	1.56	;	Glycoside hydrolase family 16 endo-glucanase from Bacteroides ovatus in complex with G4G3G-2F-DNP
6VHO	;	2.148	;	Glycoside hydrolase family 16 endo-glucanase from Bacteroides ovatus in complex with G4G4G3G-NHCOCH2Br
4LYR	;	2.5	;	Glycoside Hydrolase Family 5 Mannosidase from Rhizomucor miehei, E301A mutant
8JHH	;	2.4	;	Glycoside hydrolase family 55 endo-beta-1,3-glucanase from Microdochium nivale
4C1S	;	2.1	;	Glycoside hydrolase family 76 (mannosidase) Bt3792 from Bacteroides thetaiotaomicron VPI-5482
2X1I	;	2.36	;	glycoside hydrolase family 77 4-alpha-glucanotransferase from thermus brockianus
6FOP	;	1.4	;	Glycoside hydrolase family 81 from Clostridium thermocellum (CtLam81A), Mutant E515A
5E97	;	1.63	;	Glycoside Hydrolase ligand structure 1
5NGW	;	2.4	;	Glycoside hydrolase-like protein
7Q1L	;	3.0	;	Glycosilated Human Serum Apo-tranferrin
1A7K	;	2.8	;	GLYCOSOMAL GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE IN A MONOCLINIC CRYSTAL FORM
4Q88	;	1.73	;	Glycosyl hydrolase family 88 from Bacteroides vulgatus
4ZN2	;	2.0	;	Glycosyl hydrolase from Pseudomonas aeruginosa
8DWF	;	2.6	;	Glycosylase MutY variant E43S in complex with DNA containing d(8-oxo-G) paired with substrate adenine
8DW4	;	2.49	;	Glycosylase MutY variant N146S in complex with DNA containing d(8-oxo-G) paired with an abasic site product (AP) generated by the enzyme in crystals by removal of calcium
8DW0	;	1.68	;	Glycosylase MutY variant N146S in complex with DNA containing d(8-oxo-G) paired with an enzyme-generated abasic site (AP) product and crystallized with sodium acetate
8DVP	;	1.54	;	Glycosylase MutY variant N146S in complex with DNA containing d(8-oxo-G) paired with substrate purine
1AYY	;	2.32	;	GLYCOSYLASPARAGINASE
6TBR	;	1.7	;	Glycosylated AA13 Lytic polysaccharide monooxygenase from Aspergillus oryzae in P1 space group
6OMN	;	2.68	;	Glycosylated BMP2 homodimer
1BYV	;		;	GLYCOSYLATED EEL CALCITONIN
1BZB	;		;	GLYCOSYLATED EEL CALCITONIN
6EAQ	;	2.22	;	Glycosylated FCGR3B / CD16b in complex with afucosylated IgG1 Fc
4QKJ	;	2.75	;	Glycosylated form of human LLT1, a ligand for NKR-P1, in this structure forming hexamers
6YSC	;	2.05	;	GLYCOSYLATED KNOB-HOLE/DUMMY FC FRAGMENT
5HYE	;	1.89	;	Glycosylated Knob-Knob Fc fragment (P212121)
5HYF	;	1.8	;	Glycosylated Knob-Knob Fc fragment (P6122)
6YT7	;	1.55	;	GLYCOSYLATED KNOB/DUMMY-HOLE FC FRAGMENT
6YTB	;	1.65	;	GLYCOSYLATED KNOB/DUMMY-HOLE/DUMMY FC FRAGMENT
8AV5	;	1.62	;	Glycosylated PaDa-I mutant of Unspecific Peroxygenase from Agrocybe aegerita
3FUQ	;	2.1	;	Glycosylated SV2 and Gangliosides as Dual Receptors for Botulinum Neurotoxin Serotype F
6SOZ	;	3.42	;	Glycosylated Trypanosoma brucei transferrin receptor in complex with human transferrin
5HYI	;	2.9	;	Glycosylated, disulfide-linked Hole-Hole Fc fragment
5HY9	;	2.7	;	Glycosylated, disulfide-linked Knob-into-Hole Fc fragment
6OYC	;	2.351	;	Glycosylation Associate Protein (Gap123) complex from Streptococcus agalactiae
7OIH	;	2.603	;	Glycosylation in the crystal structure of neutrophil myeloperoxidase
7W0Z	;	2.1	;	Glycosyltranferase UGT74AN2
1BPL	;	2.2	;	GLYCOSYLTRANSFERASE
7W11	;	2.45	;	glycosyltransferase
7W1B	;	2.15	;	Glycosyltransferase
7W1H	;	2.15	;	glycosyltransferase
1LZ0	;	1.8	;	Glycosyltransferase A
1LZI	;	1.35	;	Glycosyltransferase A + UDP + H antigen acceptor
1R7V	;	2.09	;	Glycosyltransferase A in complex with 3-amino-acceptor analog inhibitor
1R7Y	;	1.75	;	Glycosyltransferase A in complex with 3-amino-acceptor analog inhibitor and uridine diphosphate
1R81	;	1.75	;	Glycosyltransferase A in complex with 3-amino-acceptor analog inhibitor and uridine diphosphate-N-acetyl-galactose
1R7T	;	2.09	;	Glycosyltransferase A in complex with 3-deoxy-acceptor analog inhibitor
1LZ7	;	1.65	;	Glycosyltransferase B
1LZJ	;	1.32	;	Glycosyltransferase B + UDP + H antigen acceptor
1R7X	;	1.97	;	Glycosyltransferase B in complex with 3-amino-acceptor analog inhibitor
1R80	;	1.65	;	Glycosyltransferase B in complex with 3-amino-acceptor analog inhibitor and uridine diphosphate
1R82	;	1.55	;	Glycosyltransferase B in complex with 3-amino-acceptor analog inhibitor, and uridine diphosphate-galactose
1R7U	;	1.61	;	Glycosyltransferase B in complex with 3-deoxy-acceptor analog inhibitor
4W6Q	;	2.7	;	Glycosyltransferase C from Streptococcus agalactiae
7ES1	;	1.66	;	glycosyltransferase in complex with UDP and ST
7ERX	;	1.92	;	Glycosyltransferase in complex with UDP and STB
5N7Z	;	1.81	;	glycosyltransferase in LPS biosynthesis
5N80	;	1.92	;	glycosyltransferase LPS biosynthesis in complex with UDP
8WRJ	;	1.85	;	glycosyltransferase UGT74AN3
8WRK	;	2.03	;	glycosyltransferase UGT74AN3
4XYW	;	2.2	;	Glycosyltransferases WbnH
7Y3P	;	2.34	;	Glycos_trans_3N domain-containing protein-YbiB
1GEC	;	2.1	;	GLYCYL ENDOPEPTIDASE-COMPLEX WITH BENZYLOXYCARBONYL-LEUCINE-VALINE-GLYCINE-METHYLENE COVALENTLY BOUND TO CYSTEINE 25
1B76	;	3.4	;	GLYCYL-TRNA SYNTHETASE FROM THERMUS THERMOPHILUS COMPLEXED WITH ATP
1GGM	;	3.4	;	GLYCYL-TRNA SYNTHETASE FROM THERMUS THERMOPHILUS COMPLEXED WITH GLYCYL-ADENYLATE
4KR2	;	3.292	;	Glycyl-tRNA synthetase in complex with tRNA-Gly
4KR3	;	3.235	;	Glycyl-tRNA synthetase mutant E71G in complex with tRNA-Gly
2LBJ	;		;	Glycyl-tRNA(GCC) anticodon stem-loop from Bacillus subtilis
2LBK	;		;	Glycyl-tRNA(UCC)1B anticodon stem-loop from Staphylococcus epidermidis
1MI4	;	1.7	;	Glyphosate insensitive G96A mutant EPSP synthase liganded with shikimate-3-phosphate
2JDD	;	1.6	;	Glyphosate N-acetyltransferase bound to acetyl COA and 3-phosphoglycerate
2JDC	;	1.6	;	Glyphosate N-acetyltransferase bound to oxidized COA and sulfate
2K8X	;		;	GlyTM1b(1-19)zip: A Chimeric Peptide Model of the N-Terminus of a Rat Short Alpha-Tropomyosin with the N-Terminus Encoded by Exon 1b in Complex with TM9d(252-284), a Peptide Model Containing the C Terminus of Alpha-Tropomyosin Encoded by Exon 9d
1IHQ	;		;	GLYTM1BZIP: A CHIMERIC PEPTIDE MODEL OF THE N-TERMINUS OF A RAT SHORT ALPHA TROPOMYOSIN WITH THE N-TERMINUS ENCODED BY EXON 1B
4L6T	;	1.859	;	GM1 bound form of the ECX AB5 holotoxin
1PU5	;	1.9	;	GM2-activator Protein crystal structure
1PUB	;	2.51	;	GM2-activator Protein crystal structure
7CQN	;	1.962	;	GmaS in complex with AMPPCP
7CQQ	;	2.295	;	GmaS in complex with AMPPNP and MetSox
7CQW	;	2.297	;	GmaS/ADP complex-Conformation 1
7CQX	;	2.301	;	GmaS/ADP complex-Conformation 2
7CQU	;	2.06	;	GmaS/ADP/MetSox-P complex
5LTZ	;	1.67	;	GmhA_mutant Q175E
4H1V	;	2.3	;	GMP-PNP bound dynamin-1-like protein GTPase-GED fusion
7DMZ	;	4.3	;	GMPCPP microtubule complex
8IXA	;	4.2	;	GMPCPP-Alpha1A/Beta2A-microtubule decorated with kinesin non-seam region
8IXB	;	4.2	;	GMPCPP-Alpha1A/Beta2A-microtubule decorated with kinesin seam region
8IXD	;	4.4	;	GMPCPP-Alpha1C/Beta2A-microtubule decorated with kinesin non-seam region
8IXE	;	4.4	;	GMPCPP-Alpha1C/Beta2A-microtubule decorated with kinesin seam region
8IXF	;	4.4	;	GMPCPP-Alpha4A/Beta2A-microtubule decorated with kinesin non-seam region
8IXG	;	4.4	;	GMPCPP-Alpha4A/Beta2A-microtubule decorated with kinesin seam region
5XXX	;	6.43	;	GMPCPP-microtubule complexed with nucleotide-free KIF5C
3RYH	;	2.8	;	GMPCPP-Tubulin: RB3 Stathmin-like domain complex
2C04	;	1.15	;	GMPPCP complex of SRP GTPase Ffh NG Domain at ultra-high resolution
4P4S	;	3.3	;	GMPPCP-bound stalkless-MxA
1JPJ	;	2.3	;	GMPPNP Complex of SRP GTPase NG Domain
1JPN	;	1.9	;	GMPPNP Complex of SRP GTPase NG Domain
2J7P	;	1.97	;	GMPPNP-stabilized NG domain complex of the SRP GTPases Ffh and FtsY
2OMM	;	2.0	;	GNNQQNY peptide corresponding to residues 7-13 of yeast prion sup35
7EI5	;	2.9	;	GNRA tetraloop receptor motif composed of RNA and DNA
7EI6	;	2.9	;	GNRA tetraloop receptor motif composed of RNA and DNA
4R1H	;	1.76	;	GntR family transcriptional regulator from Listeria monocytogenes
2EVY	;		;	GNYA tetranucleotide loops found in poliovirus oriL by in vivo SELEX (un)expectedly form a YNMG-like structure
6WPQ	;	1.1	;	GNYNVF from hnRNPA2-low complexity domain segment, residues 286-291, D290V variant
4Y0S	;	1.9	;	Goat beta-lactoglobulin complex with pramocaine (GLG-PRM)
7LWC	;	3.0	;	Goat beta-lactoglobulin mutant Q59A
8DES	;	2.6	;	Gokushovirus EC6098
4Y2I	;	2.0	;	Gold ion bound to GolB
8FJK	;	3.3	;	Golden Shiner Reovirus Core Polar Vertex
8FJL	;	3.27	;	Golden Shiner Reovirus Core Tropical Vertex
1HTY	;	1.4	;	GOLGI ALPHA-MANNOSIDASE II
6RPC	;	1.69	;	GOLGI ALPHA-MANNOSIDASE II
6RRH	;	2.07	;	GOLGI ALPHA-MANNOSIDASE II
3CZS	;	1.3	;	Golgi alpha-mannosidase II (D204A nucleophile mutant)
3CZN	;	1.4	;	Golgi alpha-mannosidase II (D204A nucleophile mutant) in complex with GnMan5Gn
2OW6	;	1.19	;	Golgi alpha-mannosidase II complex with (1r,5s,6s,7r,8s)-1-thioniabicyclo[4.3.0]nonan-5,7,8-triol chloride
2OW7	;	1.77	;	Golgi alpha-mannosidase II complex with (1R,6S,7R,8S)-1-thioniabicyclo[4.3.0]nonan-7,8-diol chloride
2F18	;	1.3	;	GOLGI ALPHA-MANNOSIDASE II complex with (2R,3R,4S)-2-({[(1R)-2-hydroxy-1-phenylethyl]amino}methyl)pyrrolidine-3,4-diol
2F1A	;	1.45	;	GOLGI ALPHA-MANNOSIDASE II COMPLEX WITH (2R,3R,4S)-2-({[(1S)-2-hydroxy-1-phenylethyl]amino}methyl)pyrrolidine-3,4-diol
2F1B	;	1.45	;	GOLGI ALPHA-MANNOSIDASE II COMPLEX WITH (2R,3R,4S,5R)-2-({[(1R)-2-hydroxy-1-phenylethyl]amino}methyl)-5-methylpyrrolidine-3,4-diol
1R34	;	1.95	;	Golgi alpha-mannosidase II complex with 5-thio-D-mannopyranosylamidinium salt
1R33	;	1.8	;	Golgi alpha-mannosidase II complex with 5-thio-D-mannopyranosylamine
2F7Q	;	1.85	;	Golgi alpha-mannosidase II complex with aminocyclopentitetrol
2FYV	;	1.9	;	Golgi alpha-mannosidase II complex with an amino-salacinol carboxylate analog
2F7R	;	1.35	;	Golgi alpha-mannosidase II complex with benzyl-aminocyclopentitetrol
2F7P	;	1.28	;	Golgi alpha-mannosidase II complex with benzyl-mannostatin A
6RQZ	;	1.53	;	GOLGI ALPHA-MANNOSIDASE II complex with Manno-epi-cyclophellitol aziridine
2F7O	;	1.43	;	Golgi alpha-mannosidase II complex with mannostatin A
2ALW	;	1.86	;	Golgi alpha-mannosidase II complex with Noeuromycin
1QWN	;	1.2	;	GOLGI ALPHA-MANNOSIDASE II Covalent Intermediate Complex with 5-fluoro-gulosyl-fluoride
3BUQ	;	2.01	;	Golgi alpha-mannosidase II D204A catalytic nucleophile mutant with bound mannose.
3BUP	;	2.03	;	Golgi alpha-mannosidase II D341N acid-base catalyst mutant with bound mannose
1QX1	;	1.3	;	Golgi alpha-mannosidase II D341N mutant complex with 2-F-mannosyl-F
1QWU	;	2.03	;	Golgi alpha-mannosidase II D341N mutant complex with 5-F-guloside
6RRW	;	2.15	;	GOLGI ALPHA-MANNOSIDASE II in complex with (2R,3R,4R,5S)-1-(5-{[4-(3,4-Dihydro-2H-1,5-benzodioxepin-7-yl)benzyl]oxy}pentyl)-2-(hydroxymethyl)-3,4,5-piperidinetriol
6RRY	;	1.86	;	GOLGI ALPHA-MANNOSIDASE II in complex with (2S,3R)-2-(Hydroxymethyl)-1,2,3,6-tetrahydro-3-pyridinol
6RRX	;	1.84	;	GOLGI ALPHA-MANNOSIDASE II in complex with (2S,3R)-2-(Hydroxymethyl)-3-piperidinol
6RS0	;	1.8	;	GOLGI ALPHA-MANNOSIDASE II in complex with (2S,3S,4R,5R)-1-(2-(Benzyloxy)ethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
6RRU	;	1.9	;	GOLGI ALPHA-MANNOSIDASE II in complex with (5R,6R,7S,8S)-5,6,7,8-tetrahydro-5-(hydroxymethyl)-3-(3-phenylpropyl)imidazo[1,2-a]pyridine-6,7,8-triol
6RRJ	;	1.95	;	GOLGI ALPHA-MANNOSIDASE II in complex with 5-(Adamantan-1yl-methoxy)-pentyl 2,5-dideoxy-2,5-imino-D-talo-hexonamide
3EJQ	;	1.45	;	Golgi alpha-Mannosidase II in complex with 5-substitued swainsonine analog: (5R)-5-[2'-oxo-2'-(4-methylphenyl)ethyl]-swainsonine
3EJR	;	1.27	;	Golgi alpha-Mannosidase II in complex with 5-substitued swainsonine analog: (5R)-5-[2'-oxo-2'-(4-tert-butylphenyl)ethyl]-swainsonine
3EJP	;	1.32	;	Golgi alpha-Mannosidase II in complex with 5-substituted swainsonine analog: (5R)-5-[2'-oxo-2'-(phenyl)ethyl]-swainsonine
3EJS	;	1.35	;	Golgi alpha-Mannosidase II in complex with 5-substituted swainsonine analog: (5S)-5-[2'-(4-tert-butylphenyl)ethyl]-swainsonine
3EJT	;	1.35	;	Golgi alpha-Mannosidase II in complex with 5-substituted swainsonine analog:(5R)-5-[2'-(4-tert-butylphenyl)ethyl]-swainsonine
3EJU	;	1.32	;	Golgi alpha-Mannosidase II in complex with 5-substituted swainsonine analog:(5S)-5-[2'-oxo-2'-(4-tert-butylphenyl)ethyl]-swainsonine
1TQT	;	1.9	;	Golgi alpha-Mannosidase II In Complex With A Diastereomer of Salacinol
1TQW	;	1.2	;	Golgi alpha-Mannosidase II In Complex With A Diastereomer of Seleno-Salacinol
1HXK	;	1.5	;	GOLGI ALPHA-MANNOSIDASE II IN COMPLEX WITH DEOXYMANNOJIRIMICIN
1PS3	;	1.8	;	Golgi alpha-mannosidase II in complex with kifunensine
3DX0	;	1.7	;	Golgi alpha-Mannosidase II in complex with Mannostatin A at pH 5.75
3DX4	;	1.38	;	Golgi alpha-Mannosidase II in complex with Mannostatin analog (1R,2R,3R,4S,5R)-4-amino-5-methoxycyclopentane-1,2,3-triol
3DX3	;	1.42	;	Golgi alpha-Mannosidase II in complex with Mannostatin analog (1R,2R,3S,4R,5R)-5-aminocyclopentane-1,2,3,4-tetraol
3DX1	;	1.21	;	Golgi alpha-Mannosidase II in complex with Mannostatin analog (1S,2S,3R,4R)-4-aminocyclopentane-1,2,3-triol
6RRN	;	1.59	;	GOLGI ALPHA-MANNOSIDASE II in complex with pentyl 2,5-dideoxy-2,5-imino-D-talo-hexonamide
1TQS	;	1.3	;	Golgi alpha-Mannosidase II In Complex With Salacinol
1TQV	;	2.03	;	Golgi alpha-Mannosidase II In Complex With Seleno-Salacinol (Blintol)
1HWW	;	1.87	;	GOLGI ALPHA-MANNOSIDASE II IN COMPLEX WITH SWAINSONINE
1TQU	;	2.03	;	Golgi alpha-Mannosidase II In Complex With The Salacinol Analog Ghavamiol
3BUB	;	1.38	;	Golgi alpha-mannosidase II with an empty active site
3DDG	;	1.74	;	GOLGI MANNOSIDASE II complex with (3R,4R,5R)-3,4-Dihydroxy-5-({[(1R)-2-hydroxy-1 phenylethyl]amino}methyl) methylpyrrolidin-2-one
3DDF	;	1.2	;	GOLGI MANNOSIDASE II complex with (3R,4R,5R)-3,4-Dihydroxy-5-({[(1R)-2-hydroxy-1 phenylethyl]amino}methyl) pyrrolidin-2-one
3D52	;	1.6	;	GOLGI MANNOSIDASE II complex with an N-aryl carbamate derivative of gluco-hydroxyiminolactam
3D51	;	1.43	;	GOLGI MANNOSIDASE II complex with gluco-hydroxyiminolactam
3D4Z	;	1.39	;	GOLGI MANNOSIDASE II complex with gluco-imidazole
3D4Y	;	1.52	;	GOLGI MANNOSIDASE II complex with mannoimidazole
3DX2	;	1.4	;	Golgi mannosidase II complex with MANNOSTATIN B
3D50	;	1.79	;	GOLGI MANNOSIDASE II complex with N-octyl-6-epi-valienamine
3CV5	;	1.6	;	GOLGI MANNOSIDASE II D204A catalytic nucleophile mutant complex with 3alpha,6alpha-mannopentaose
3BVX	;	1.1	;	GOLGI MANNOSIDASE II D204A catalytic nucleophile mutant complex with Methyl (2-deoxy-2-acetamido-beta-D-glucopyranosyl)-(1->2)-(alpha-D-mannopyranosyl)- (1->3)-[(alpha-D-mannopyranosyl)-(1->6)-(alpha-D-mannopyranosyl)-(1->6)]-beta-D-mannopyranoside
3BVW	;	1.2	;	GOLGI MANNOSIDASE II D204A catalytic nucleophile mutant complex with Methyl (2-deoxy-2-acetamido-beta-D-glucopyranosyl)-(1->2)-ALPHA-D-mannopyranosyl- (1->3)-[ALPHA-D-mannopyranosyl-(1->6)-6-thio-alpha-D-mannopyranosyl- (1->6)]-BETA-D-mannopyranoside
3BVT	;	1.3	;	GOLGI MANNOSIDASE II D204A catalytic nucleophile mutant complex with Methyl (alpha-D-mannopyranosyl)-(1->3)-S-alpha-D-mannopyranoside
3BVV	;	1.3	;	Golgi mannosidase II D204A catalytic nucleophile mutant complex with METHYL ALPHA-D-MANNOPYRANOSYL-(1->3)-[6-THIO-ALPHA-D-MANNOPYRANOSYL-(1->6)]-BETA-D-MANNOPYRANOSIDE
3BVU	;	1.12	;	GOLGI MANNOSIDASE II D204A catalytic nucleophile mutant complex with Methyl(alpha-D-mannopyranosyl)-(1->3)-S-[(alpha-D-mannopyranosyl)-(1->6)]-alpha-D-mannopyranoside
3BUI	;	1.25	;	Golgi mannosidase II D204A catalytic nucleophile mutant complex with Tris
3BUD	;	1.85	;	Golgi mannosidase II D204A catalytic nucleophile mutant with an empty active site
4D5M	;	0.85	;	Gonadotropin-releasing hormone agonist
8ECK	;	2.6	;	Gordonia phage Cozz
8EB4	;	2.6	;	Gordonia phage Ziko
7LNK	;	2.76	;	Gorilla Bocavirus 1 Capsid
7SQV	;	2.3	;	Goslar chimallin C1 localized reconstruction
7SQU	;	2.6	;	Goslar chimallin C4 tetramer localized reconstruction
7SQT	;	4.0	;	Goslar chimallin cubic (O, 24mer) assembly
5NSJ	;	2.249	;	GP1 receptor-binding domain from Whitewater Arroyo mammarenavirus
2KCA	;		;	GP16
1G31	;	2.3	;	GP31 CO-CHAPERONIN FROM BACTERIOPHAGE T4
6FTK	;		;	Gp36-MPER
6YSE	;		;	Gp4 from the Pseudomonas phage LUZ24
3P7K	;	2.3	;	GP41 peptide
5HFL	;	2.294	;	Gp41-targeting HIV-1 fusion inhibitors with helical Ile-Asp-Leu tail
5HFM	;	2.298	;	Gp41-targeting HIV-1 fusion inhibitors with hook-like Ile-Asp-Leu tail
1E0K	;	3.3	;	gp4d helicase from phage T7
1E0J	;	3.0	;	gp4d helicase from phage T7 ADPNP complex
5LGM	;		;	Gp5.7 mutant L42A
4Y9V	;	0.9	;	Gp54 tailspike of Acinetobacter baumannii bacteriophage AP22 in complex with A. baumannii capsular saccharide
7Z4W	;	2.7	;	gp6/gp15/gp16 connector complex of bacteriophage SPP1
2LVP	;		;	gp78CUE domain bound to the distal ubiquitin of K48-linked diubiquitin
2LVQ	;		;	gp78CUE domain bound to the proximal ubiquitin of K48-linked diubiquitin
7BOU	;	3.6	;	GP8 of Mature Bacteriophage T7
8H2M	;	3.08	;	gp96 RNA polymerase from P23-45 phage (crystal 1)
8H2N	;	4.41	;	gp96 RNA polymerase from P23-45 phage (crystal 2)
7T62	;	21.0	;	GPC2 HEP CT3 complex
7ZA1	;	4.1	;	GPC3-Unc5D octamer structure and role in cell migration
7ZA2	;	4.6	;	GPC3-Unc5D octamer structure and role in cell migration
7ZA3	;	4.0	;	GPC3-Unc5D octamer structure and role in cell migration
7ZAV	;	2.9	;	GPC3-Unc5D octamer structure and role in cell migration
7ZAW	;	2.58	;	GPC3-Unc5D octamer structure and role in cell migration
6U1N	;	4.0	;	GPCR-Beta arrestin structure in lipid bilayer
1TX9	;	3.31	;	gpd prior to capsid assembly
6MBF	;	1.543	;	GphF Dehydratase 1
6MBG	;	1.852	;	GphF Dehydratase P1711L variant for improved crystallization
6MBH	;	1.7	;	GphF DH1 P1711L, L1744P variant: An isomerase-inactive variant of GphF DH1
6MFC	;	2.589	;	GphF GNAT-like decarboxylase
6MFD	;	2.794	;	GphF GNAT-like decarboxylase in complex with isobutyryl-CoA
7ZHF	;	1.8	;	GPN-loop GTPase from Sulfolobus acidocaldarius closed state (GppNHp)
7ZHK	;	2.4	;	GPN-loop GTPase from Sulfolobus acidocaldarius open state (GDP)
5HCI	;	2.3	;	GPN-loop GTPase Npa3 in complex with GDP
5HCN	;	2.2	;	GPN-loop GTPase Npa3 in complex with GMPPCP
1NAY	;	2.6	;	GPP-Foldon:X-ray structure
1YZK	;	2.0	;	GppNHp bound Rab11 GTPase
1YZT	;	2.05	;	GppNHp-Bound Rab21 GTPase at 2.05 A Resolution
1YZU	;	2.5	;	GppNHp-Bound Rab21 GTPase at 2.50 A Resolution
1Z08	;	1.8	;	GppNHp-Bound Rab21 Q53G mutant GTPase
1YVD	;	1.93	;	GppNHp-Bound Rab22 GTPase
1Z06	;	1.81	;	GppNHp-Bound Rab33 GTPase
3RAB	;	2.0	;	GPPNHP-BOUND RAB3A AT 2.0 A RESOLUTION
1YU9	;	2.07	;	GppNHp-Bound Rab4A
1Z07	;	1.81	;	GppNHp-Bound Rab5c G55Q mutant GTPase
1YZQ	;	1.78	;	GppNHp-Bound Rab6 GTPase
1VG8	;	1.7	;	GPPNHP-Bound Rab7
1YZL	;	1.85	;	GppNHp-Bound Rab9 GTPase
1YZN	;	2.06	;	GppNHp-Bound Ypt1p GTPase
1EK0	;	1.48	;	GPPNHP-BOUND YPT51 AT 1.48 A RESOLUTION
1KY2	;	1.6	;	GPPNHP-BOUND YPT7P AT 1.6 A RESOLUTION
8SX5	;	1.95	;	GpppA dinucleotide binding to RNA CU template
8SWO	;	1.64	;	GpppA dinucleotide ligand binding to RNA UC template
7WXG	;	4.2	;	GPR domain closed form of Drosophila P5CS filament with glutamate, ATP, and NADPH
7WXF	;	3.6	;	GPR domain of Drosophila P5CS filament with glutamate
7WXI	;	4.2	;	GPR domain of Drosophila P5CS filament with glutamate and ATPgammaS
7WXH	;	4.3	;	GPR domain open form of Drosophila P5CS filament with glutamate, ATP, and NADPH
7WZ7	;	2.83	;	GPR110/G12 complex
7WY0	;	2.83	;	GPR110/G13 complex
7X2V	;	3.09	;	GPR110/Gi complex
7WXU	;	2.85	;	GPR110/Gq complex
7WXW	;	2.84	;	GPR110/Gs complex
7EQ1	;	3.3	;	GPR114-Gs-scFv16 complex
7XZ6	;	2.8	;	GPR119-Gs-APD668 complex
7XZ5	;	3.1	;	GPR119-Gs-LPC complex
8SMV	;	2.74	;	GPR161 Gs heterotrimer
8HJ2	;	3.8	;	GPR21 wt with G15 complex
8HJ0	;	3.12	;	GPR21(m5) and G15 complex
8HJ1	;	3.27	;	GPR21(wt) and Gs complex
8U8F	;	3.49	;	GPR3 Orphan G-coupled Protein Receptor in complex with Dominant Negative Gs.
8WW2	;	2.79	;	GPR3/Gs complex
5TZY	;	3.22	;	GPR40 in complex with AgoPAM AP8 and partial agonist MK-8666
5TZR	;	2.2	;	GPR40 in complex with partial agonist MK-8666
8HMP	;	2.77	;	GPR52 with Gs and c17
7SF8	;	2.7	;	GPR56 (ADGRG1) 7TM domain bound to tethered agonist in complex with G protein heterotrimer
4UG1	;	1.6	;	GpsB N-terminal domain
8J9N	;	3.5	;	Gq bound FZD1 in ligand-free state
7ALZ	;	1.67	;	GqqA- a novel type of quorum quenching acylases
7AM0	;	2.5	;	GqqA- a novel type of quorum quenching acylases
7LUZ	;	1.101	;	GQTVTK segment from the Nucleoprotein of SARS-CoV-2, residues 243-248
4HN5	;	1.902	;	GR DNA Binding Domain - TSLP nGRE Complex
4HN6	;	2.549	;	GR DNA Binding Domain R460D/D462R - TSLP nGRE Complex
3G9I	;	1.85	;	GR DNA Binding domain: Pal complex-35
3FYL	;	1.63	;	GR DNA binding domain:CGT complex
3G6Q	;	2.26	;	GR DNA binding domain:FKBP5 binding site complex-9
3G6P	;	1.985	;	GR DNA binding domain:FKBP5 complex, 18bp
3G6R	;	2.3	;	GR DNA binding domain:FKBP5 complex-52, 18bp
3G8X	;	2.05	;	GR DNA binding domain:GilZ 16bp complex-65
3G99	;	1.81	;	GR DNA binding domain:Pal complex-9
3G9J	;	2.32	;	GR DNA binding domain:Pal, 18bp complex-36
3G9P	;	1.652	;	GR DNA binding domain:Sgk 16bp complex-7
3G6U	;	1.9	;	GR DNA-binding domain:FKBP5 16bp complex-49
3G97	;	2.08	;	GR DNA-binding domain:GilZ 16bp complex-9
3G9M	;	1.61	;	GR DNA-binding domain:Sgk 16bp complex-44
3G9O	;	1.65	;	GR DNA-binding domain:Sgk 16bp complex-9
3G6T	;	1.9	;	GR gamma DNA-binding domain:FKBP5 16bp complex-34
4UDD	;	1.8	;	GR in complex with desisobutyrylciclesonide
4UDC	;	2.5	;	GR in complex with dexamethasone
8DZR	;	2.61	;	GR89,696 bound Kappa Opioid Receptor in complex with gustducin
8DZS	;	2.65	;	GR89,696 bound Kappa Opioid Receptor in complex with Gz
3MWM	;	2.4	;	Graded expression of zinc-responsive genes through two regulatory zinc-binding sites in Zur
6J49	;	1.6	;	Grafting VLADV sequence into OspAsm1
1NRM	;		;	Gramicidin A in Dodecyl Phosphocholine Micelles (NMR)
1NRU	;		;	Gramicidin A in Dodecyl Phosphocholine Micelles in the Presence of Excess Na+ (NMR)
1MAG	;		;	GRAMICIDIN A IN HYDRATED DMPC BILAYERS, SOLID STATE NMR
1JNO	;		;	Gramicidin A in Sodium Dodecyl Sulfate Micelles (NMR)
1AV2	;	1.4	;	Gramicidin A/CsCl complex, active as a dimer
1MIC	;		;	GRAMICIDIN A: LEFT-HANDED PARALLEL DOUBLE HELICAL FORM IN METHANOL IN THE PRESENCE OF CACL2, NMR, 20 STRUCTURES
1JO3	;		;	Gramicidin B in Sodium Dodecyl Sulfate Micelles (NMR)
1JO4	;		;	Gramicidin C in Sodium Dodecyl Sulfate Micelles (NMR)
1C4D	;	2.0	;	GRAMICIDIN CSCL COMPLEX
2IZQ	;	0.8	;	Gramicidin D complex with KI
3L8L	;	1.25	;	Gramicidin D complex with sodium iodide
1BDW	;	1.7	;	GRAMICIDIN D FROM BACILLUS BREVIS (ACTIVE FORM)
1ALZ	;	0.86	;	GRAMICIDIN D FROM BACILLUS BREVIS (ETHANOL SOLVATE)
1W5U	;	1.14	;	GRAMICIDIN D FROM BACILLUS BREVIS (ETHANOL SOLVATE)
1ALX	;	1.2	;	GRAMICIDIN D FROM BACILLUS BREVIS (METHANOL SOLVATE)
1AL4	;	1.13	;	GRAMICIDIN D FROM BACILLUS BREVIS (N-PROPANOL SOLVATE)
1GMK	;	2.5	;	GRAMICIDIN/KSCN COMPLEX
8D8N	;	3.6	;	gRAMP non-match PFS target RNA
8D9I	;	3.62	;	gRAMP non-matching PFS-with Mg
8D9E	;	3.76	;	gRAMP-match PFS target
8D9F	;	2.71	;	gRAMP-TPR-CHAT (Craspase)
8D9H	;	3.6	;	gRAMP-TPR-CHAT match PFS target RNA(Craspase)
8D9G	;	2.57	;	gRAMP-TPR-CHAT Non match PFS target RNA(Craspase)
6GNF	;	2.2	;	Granule Bound Starch Synthase from Cyanobacterium sp. CLg1 bound to acarbose and ADP
6GNG	;	2.95	;	Granule Bound Starch Synthase I from Cyanophora paradoxa bound to acarbose and ADP
4GYR	;	2.8	;	Granulibacter bethesdensis allophanate hydrolase apo
4GYS	;	2.201	;	Granulibacter bethesdensis allophanate hydrolase co-crystallized with malonate
4XYG	;	1.7	;	GRANULICELLA M. FORMATE DEHYDROGENASE (FDH)
4XYE	;	1.8	;	GRANULICELLA M. FORMATE DEHYDROGENASE (FDH) IN COMPLEX WITH NAD(+)
4XYB	;	1.38	;	GRANULICELLA M. FORMATE DEHYDROGENASE (FDH) IN COMPLEX WITH NADP(+) AND NaN3
6S2O	;	1.6	;	Granulovirus occlusion bodies by serial electron diffraction
1L9L	;	0.92	;	GRANULYSIN FROM HUMAN CYTOLYTIC T LYMPHOCYTES
4V5W	;	3.7	;	Grapevine Fanleaf virus
7X45	;	2.26	;	Grass carp interferon gamma related
7CJN	;	2.66	;	grass carp interleukin-2
7D9M	;	2.66	;	grass carp interleukin-2
1FAW	;	3.09	;	GRAYLAG GOOSE HEMOGLOBIN (OXY FORM)
1GRI	;	3.1	;	GRB2
4P9Z	;	1.8	;	Grb2 SH2 complexed with a pTyr-Ac6c-Asn tripeptide
4P9V	;	1.64	;	Grb2 SH2 complexed with a pTyr-Ac6cN-Asn tripeptide
6ICH	;	2.0	;	Grb2 SH2 domain in domain swapped dimer form
6ICG	;	1.15	;	Grb2 SH2 domain in phosphopeptide free form
7MPH	;	2.0	;	GRB2 SH2 Domain with Compound 7
3WA4	;	1.35	;	Grb2 SH2 domain/CD28-derived peptide complex
2VVK	;	1.6	;	Grb2 SH3C (1)
2VWF	;	1.58	;	Grb2 SH3C (2)
2W0Z	;	1.7	;	Grb2 SH3C (3)
1BM2	;	2.1	;	GRB2-SH2 DOMAIN IN COMPLEX WITH CYCLO-[N-ALPHA-ACETYL-L-THI ALYSYL-O-PHOSPHOTYROSYL-VALYL-ASPARAGYL-VALYL-PROLYL] (PKF273-791)
1BMB	;	1.8	;	GRB2-SH2 DOMAIN IN COMPLEX WITH KPFY*VNVEF (PKF270-974)
4X6S	;	2.55	;	Grb7 SH2 domain with phosphotyrosine mimetic inhibitor peptide
5TYI	;	2.15	;	Grb7 SH2 with bicyclic peptide containing pY mimetic
5EEL	;	2.47	;	Grb7 SH2 with bicyclic peptide inhibitor
5D0J	;	2.6	;	Grb7 SH2 with inhibitor peptide
3PQZ	;	2.413	;	Grb7 SH2 with peptide
5EEQ	;	1.6	;	Grb7 SH2 with the G7-B1 bicyclic peptide inhibitor
7MP3	;	2.55	;	Grb7-SH2 domain in complex with bicyclic peptide B8
5U1Q	;	2.1	;	Grb7-SH2 with bicyclic peptide inhibitor
5U06	;	2.1	;	Grb7-SH2 with bicyclic peptide inhibitor containing a pY mimetic
1GRJ	;	2.2	;	GREA TRANSCRIPT CLEAVAGE FACTOR FROM ESCHERICHIA COLI
3ZGB	;	2.71	;	Greater efficiency of photosynthetic carbon fixation due to single amino acid substitution
3ZGE	;	2.49	;	Greater efficiency of photosynthetic carbon fixation due to single amino acid substitution
8G4E	;	2.98	;	Green Fluorescence Protein imaged on a cryo-EM imaging scaffold
1EMG	;	2.0	;	GREEN FLUORESCENT PROTEIN (65-67 REPLACED BY CRO, S65T SUBSTITUTION, Q80R)
1EMB	;	2.13	;	GREEN FLUORESCENT PROTEIN (GFP) FROM AEQUOREA VICTORIA, GLN 80 REPLACED WITH ARG
3K1K	;	2.15	;	Green fluorescent protein bound to enhancer nanobody
3G9A	;	1.614	;	Green fluorescent protein bound to minimizer nanobody
4P1Q	;	1.5	;	GREEN FLUORESCENT PROTEIN E222H VARIANT
7LG4	;	1.81	;	Green fluorescent protein from Aequorea macrodactyla - amacGFP
1EMA	;	1.9	;	GREEN FLUORESCENT PROTEIN FROM AEQUOREA VICTORIA
1EMC	;	2.3	;	GREEN FLUORESCENT PROTEIN FROM AEQUOREA VICTORIA, MUTANT
1EME	;	2.5	;	GREEN FLUORESCENT PROTEIN FROM AEQUOREA VICTORIA, MUTANT
1EMF	;	2.4	;	GREEN FLUORESCENT PROTEIN FROM AEQUOREA VICTORIA, MUTANT
1EMK	;	2.1	;	GREEN FLUORESCENT PROTEIN FROM AEQUOREA VICTORIA, MUTANT
1EML	;	2.3	;	GREEN FLUORESCENT PROTEIN FROM AEQUOREA VICTORIA, MUTANT
1EMM	;	2.3	;	GREEN FLUORESCENT PROTEIN FROM AEQUOREA VICTORIA, MUTANT
2EMD	;	2.0	;	GREEN FLUORESCENT PROTEIN FROM AEQUOREA VICTORIA, MUTANT
2EMN	;	2.3	;	GREEN FLUORESCENT PROTEIN FROM AEQUOREA VICTORIA, MUTANT
2EMO	;	2.6	;	GREEN FLUORESCENT PROTEIN FROM AEQUOREA VICTORIA, MUTANT
2HPW	;	1.55	;	Green fluorescent protein from Clytia gregaria
7DIG	;	2.6	;	Green fluorescent protein from Dendronephthya sp. SSAL-2002
2H9W	;	1.82	;	Green fluorescent protein ground states: the influence of a second protonation site near the chromophore
5WTS	;	3.004	;	Green fluorescent protein linked MTide-02 inhibitor in complex with mdm2
1B9C	;	2.4	;	Green Fluorescent Protein Mutant F99S, M153T and V163A
1C4F	;	2.25	;	GREEN FLUORESCENT PROTEIN S65T AT PH 4.6
6IR7	;	1.277	;	Green fluorescent protein variant GFPuv with the modification to 6-hydroxynorleucine at the C-terminus
6IR6	;	1.642	;	Green fluorescent protein variant GFPuv with the native lysine residue at the C-terminus
2QRF	;	1.5	;	Green Fluorescent Protein: Cyclized-only Intermediate of Chromophore Maturation in the Q183E variant
6BHO	;		;	Green Light-Absorbing State of NpR6012g4, a Red/Green Cyanobacteriochrome
2M7V	;		;	Green Light-Absorbing State of TePixJ, an Active Cyanobacteriochrome Domain
2G2R	;	2.75	;	Green-fluorescent antibody 11G10 in complex with its hapten (nitro-stilbene derivative)
3VIC	;	2.2	;	Green-fluorescent variant of the non-fluorescent chromoprotein Rtms5
3VK1	;	2.2	;	Green-fluorescent variant of the non-fluorescent chromoprotein Rtms5
7P2F	;	2.5	;	Green-type copper-nitrite reductase from Sinorhizobium meliloti 2011
5DRG	;	1.14	;	Green/cyan WasCFP at pH 10.0
5DQM	;	1.3	;	Green/cyan WasCFP at pH 2.0
5DQB	;	1.25	;	Green/cyan WasCFP at pH 8.0
5DRF	;	1.14	;	Green/cyan WasCFP-pH5.5 at pH 5.5
5NCH	;	1.819	;	GriE apo form
5NCI	;	1.755	;	GriE in complex with cobalt, alpha-ketoglutarate and l-leucine
5NCJ	;	1.529	;	GriE in complex with manganese, succinate and (2S,4R)-5-hydroxyleucine
7RIB	;	2.1	;	Griffithsin mutant Y28F/Y68F/Y110F
7RKG	;	2.2	;	Griffithsin mutant Y28W
7RID	;	2.3	;	Griffithsin variant Y28A
7RIA	;	1.8	;	Griffithsin variant Y28A/Y68A/Y110A
7RIC	;	1.95	;	Griffithsin variant Y28W/Y68W/Y110W
7RKI	;	2.09	;	Griffithsin-S10Y/S42Y/S88Y
5NLZ	;	1.149	;	GRIFIN (Crystallisation pH: 4.2)
6E1L	;		;	GRN3Ala
1LA1	;	2.06	;	Gro-EL Fragment (Apical Domain) Comprising Residues 188-379
1SS8	;	2.7	;	GroEL
1KID	;	1.7	;	GROEL (HSP60 CLASS) FRAGMENT (APICAL DOMAIN) COMPRISING RESIDUES 191-376, MUTANT WITH ALA 262 REPLACED WITH LEU AND ILE 267 REPLACED WITH MET
1JON	;	2.5	;	GROEL (HSP60 CLASS) FRAGMENT COMPRISING RESIDUES 191-345
2YNJ	;	8.4	;	GroEL at sub-nanometer resolution by Constrained Single Particle Tomography
6KFV	;	3.22	;	GroEL from Xanthomonas oryzae pv. oryzae
5W0S	;	3.5	;	GroEL using cryoEM
8S32	;	2.45	;	GroEL with bound GroTAC peptide
2CGT	;	8.2	;	GROEL-ADP-gp31 COMPLEX
1PF9	;	2.993	;	GroEL-GroES-ADP
1SX4	;	3.0	;	GroEL-GroES-ADP7
1SX3	;	2.0	;	GroEL14-(ATPgammaS)14
8BKZ	;	2.3	;	GroEL:GroES-ATP complex under continuous turnover conditions
6EPF	;	11.8	;	Ground state 26S proteasome (GS1)
6EPC	;	12.3	;	Ground state 26S proteasome (GS2)
5QT3	;	1.95	;	Ground state model of human erythroid-specific 5'-aminolevulinate synthase, ALAS2 - SGC Diamond Xchem fragment screening
4MD2	;	1.73	;	Ground state of bacteriorhodopsin from Halobacterium salinarum
2JAF	;	1.7	;	Ground state of halorhodopsin T203V
5J0M	;		;	Ground state sampled during RDC restrained Replica-averaged Metadynamics (RAM) simulations of the HIV-1 TAR complexed with cyclic peptide mimetic of Tat
6S6C	;	1.07	;	Ground state structure of Archaerhodopsin-3 at 100K
6GUZ	;	1.9	;	Ground state structure of Archaerhodopsin-3 obtained from LCP crystals using a thin-film sandwich at room temperature
2JDI	;	1.9	;	Ground state structure of F1-ATPase from bovine heart mitochondria (Bovine F1-ATPase crystallised in the absence of azide)
5QKB	;	1.58	;	Ground-state model of NUDT5 and corresponding apo datasets for PanDDA analysis
8DG4	;	3.12	;	Group A streptococcus Enolase K252A, K255A, K434A, K435A mutant
4WPG	;	1.1	;	Group A Streptococcus GacA is an essential dTDP-4-dehydrorhamnose reductase (RmlD)
4G1H	;	1.8	;	Group B Streptococcus Pilus Island 1 Sortase C2
5QNI	;	1.967	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_1)
5QNJ	;	1.863	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_10)
5QNK	;	1.898	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_11)
5QNL	;	1.752	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_12)
5QNM	;	1.863	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_13)
5QNN	;	1.787	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_14)
5QNO	;	1.953	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_15)
5QNP	;	1.67	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_16)
5QNQ	;	1.669	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_17)
5QNR	;	1.752	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_18)
5QNS	;	1.785	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_19)
5QNT	;	1.747	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_2)
5QNU	;	1.862	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_20)
5QNV	;	1.75	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_21)
5QNW	;	1.883	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_22)
5QNX	;	1.677	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_23)
5QNY	;	1.595	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_24)
5QNZ	;	1.792	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_25)
5QO0	;	1.832	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_26)
5QO1	;	1.843	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_28)
5QO2	;	1.637	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_3)
5QO3	;	1.728	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_31)
5QO4	;	1.78	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_32)
5QO5	;	1.769	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_34)
5QO6	;	1.794	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_36)
5QO7	;	1.968	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_37)
5QO8	;	1.728	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_38)
5QO9	;	1.59	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_4)
5QOA	;	1.979	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_40)
5QOB	;	1.698	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_5)
5QOC	;	1.67	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_50)
5QOD	;	1.908	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_6)
5QOE	;	1.67	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_7)
5QOF	;	1.637	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_8)
5QOG	;	1.787	;	Group deposition of apo datasets for PANDDA analysis - Crystal Structure of apo EcDsbA after initial refinement (apo_dataset_9)
5QKD	;	2.113	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure A10_1)
5QKE	;	2.117	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure A11_1)
5QKF	;	2.141	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure A12_1)
5QKC	;	2.146	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure A1_1)
5QKH	;	2.654	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure A2_1)
5QKI	;	2.304	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure A2_2)
5QKG	;	1.897	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure A2_3)
5QKJ	;	2.129	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure A3_1)
5QKL	;	2.697	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure A4_1)
5QKK	;	2.075	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure A4_2)
5QKM	;	2.487	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure A5_1)
5QKN	;	1.896	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure A5_2)
5QKO	;	2.004	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure A6_1)
5QKQ	;	2.423	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure A7_1)
5QKR	;	2.502	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure A7_2)
5QKP	;	1.881	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure A7_3)
5QKS	;	2.118	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure A8_1)
5QKT	;	1.896	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure A9_1)
5QKX	;	2.005	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure B10_1)
5QKW	;	1.969	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure B10_2)
5QKY	;	2.416	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure B12_1)
5QKZ	;	2.381	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure B12_2)
5QKU	;	2.306	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure B1_1)
5QKV	;	2.14	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure B1_2)
5QL0	;	2.045	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure B2_1)
5QL1	;	2.137	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure B3_1)
5QL2	;	2.111	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure B4_1)
5QL3	;	1.962	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure B5_1)
5QL4	;	2.006	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure B6_1)
5QL5	;	2.138	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure B6_2)
5QL6	;	2.081	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure B7_1)
5QL7	;	2.15	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure B8_1)
5QL8	;	2.302	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure B9_1)
5QL9	;	2.151	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure B9_2)
5QLB	;	1.959	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure C10_1)
5QLC	;	2.214	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure C11_1)
5QLD	;	2.125	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure C12_1)
5QLA	;	1.864	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure C1_1)
5QLE	;	1.954	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure C2_1)
5QLG	;	2.48	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure C3_1)
5QLF	;	2.003	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure C3_2)
5QLH	;	1.887	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure C4_1)
5QLI	;	2.043	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure C5_1)
5QLJ	;	1.959	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure C6_1)
5QLK	;	1.993	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure C7_1)
5QLL	;	1.96	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure C8_1)
5QLM	;	2.07	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure C9_1)
5QLN	;	2.409	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure COMU_1)
5QLR	;	1.972	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure D10_1)
5QLS	;	2.007	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure D11_1)
5QLT	;	2.402	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure D12_1)
5QLP	;	2.521	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure D1_1)
5QLQ	;	1.866	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure D1_2)
5QLO	;	2.366	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure D1_3)
5QLV	;	2.341	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure D2_1)
5QLU	;	2.197	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure D2_2)
5QLW	;	1.959	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure D3_1)
5QLX	;	1.896	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure D4_1)
5QLY	;	2.175	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure D5_1)
5QLZ	;	1.996	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure D6_1)
5QM0	;	1.917	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure D7_1)
5QM1	;	1.959	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure D8_1)
5QM2	;	1.919	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure D9_1)
5QM4	;	2.007	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure E10_1)
5QM5	;	2.008	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure E11_1)
5QM6	;	2.298	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure E12_1)
5QM3	;	1.982	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure E1_1)
5QM7	;	2.037	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure E2_1)
5QM8	;	1.959	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure E3_1)
5QM9	;	1.962	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure E4_1)
5QMA	;	2.136	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure E5_1)
5QMB	;	1.897	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure E7_1)
5QMC	;	1.887	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure E8_1)
5QMD	;	1.972	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure E9_1)
5QME	;	1.83	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure EDC_1)
5QMG	;	2.109	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure F10_1)
5QMH	;	2.079	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure F11_1)
5QMJ	;	2.304	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure F12_1)
5QMI	;	1.671	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure F12_2)
5QMF	;	2.005	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure F1_1)
5QMK	;	1.836	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure F2_1)
5QML	;	2.195	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure F3_1)
5QMM	;	1.961	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure F4_1)
5QMN	;	1.976	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure F5_1)
5QMO	;	2.052	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure F6_1)
5QMP	;	2.005	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure F7_1)
5QMQ	;	1.897	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure F8_1)
5QMR	;	2.004	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure F9_1)
5QMT	;	2.043	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure G10_1)
5QMU	;	2.043	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure G11_1)
5QMV	;	1.907	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure G12_1)
5QMS	;	2.047	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure G1_1)
5QMW	;	1.959	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure G2_1)
5QMX	;	1.918	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure G3_1)
5QMY	;	2.217	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure G4_1)
5QMZ	;	2.084	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure G5_1)
5QN2	;	2.3	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure G6_1)
5QN0	;	2.007	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure G6_2)
5QN1	;	2.199	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure G6_3)
5QN3	;	2.137	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure G7_1)
5QN4	;	2.373	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure G8_1)
5QN5	;	1.891	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure G8_2)
5QN6	;	1.897	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure G9_1)
5QN7	;	2.136	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure H1_1)
5QN8	;	1.868	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure H2_1)
5QN9	;	1.938	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure H3_1)
5QNA	;	2.139	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure H4_1)
5QNB	;	1.907	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure H5_1)
5QNC	;	2.14	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure H6_1)
5QNE	;	2.394	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure H7_1)
5QND	;	1.899	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure H7_2)
5QNF	;	1.96	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure H9_1)
5QNG	;	1.897	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure HATU_1)
5QNH	;	2.211	;	Group deposition of library data - Crystal Structure of EcDsbA after initial refinement with no ligand modelled (structure Phaux_1)
7GG3	;	1.42	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with AAR-RCN-748c104b-1 (Mpro-x12080)
7GLP	;	1.917	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ADA-UCB-6c2cb422-1 (Mpro-P2005)
7GDD	;	1.34	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ADA-UCB-6c2cb422-1 (Mpro-x10959)
7GE7	;	1.51	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ADA-UCB-6c2cb422-3 (Mpro-x11354)
7GD7	;	1.509	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ADA-UNI-f8e79267-2 (Mpro-x10889)
7GBU	;	1.559	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ADA-UNI-f8e79267-5 (Mpro-x10421)
7GET	;	1.919	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-0c2c77e1-1 (Mpro-x11507)
7GNU	;	1.48	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-133e7cd9-2 (Mpro-P3074)
7GLW	;	1.587	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-1cbc2fae-1 (Mpro-P2036)
7GN7	;	2.349	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-1cbc2fae-2 (Mpro-P2381)
7GNA	;	2.093	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-4483ae88-4 (Mpro-P2415)
7GG6	;	1.599	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-477dc5b7-2 (Mpro-x12171)
7GMJ	;	1.84	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-477dc5b7-4 (Mpro-P2197)
7GK9	;	2.02	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-477dc5b7-5 (Mpro-P0811)
7GLU	;	1.627	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-6479a3a9-2 (Mpro-P2028)
7GHQ	;	1.72	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-64a710fa-1 (Mpro-P0016)
7GGK	;	1.73	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-64a710fa-1 (Mpro-x12661)
7GEZ	;	1.34	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-6747fa38-1 (Mpro-x11541)
7GGE	;	1.63	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-6d04362c-1 (Mpro-x12419)
7GGF	;	1.831	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-6d04362c-2 (Mpro-x12423)
7GLC	;	1.954	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-6f6ae286-3 (Mpro-P1858)
7GM4	;	1.751	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-6f6ae286-5 (Mpro-P2080)
7GIN	;	1.858	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-869ac754-1 (Mpro-P0114)
7GG5	;	1.509	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-87c86d55-1 (Mpro-x12143)
7GHW	;	1.58	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-8b8a49e1-4 (Mpro-P0026)
7GGO	;	1.687	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-8b8a49e1-4 (Mpro-x12682)
7GBS	;	1.54	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-95b75b4d-1 (Mpro-x10417)
7GBK	;	1.5	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-95b75b4d-2 (Mpro-x10359)
7GCC	;	1.61	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-95b75b4d-4 (Mpro-x10566)
7GF1	;	1.881	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-95b75b4d-5 (Mpro-x11543)
7GGY	;	2.17	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-966f8da6-2 (Mpro-x12717)
7GKC	;	1.94	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-9c80c481-1 (Mpro-P0845)
7GM7	;	1.844	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-a577c8a2-1 (Mpro-P2099)
7GFJ	;	1.59	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-c0c213c9-1 (Mpro-x11757)
7GDO	;	1.756	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-c0c213c9-14 (Mpro-x11164)
7GJ9	;	2.09	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-c3a96089-4 (Mpro-P0186)
7GD4	;	1.749	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-c59291d4-2 (Mpro-x10871)
7GD3	;	1.751	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-c59291d4-3 (Mpro-x10870)
7GCZ	;	1.512	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-c59291d4-4 (Mpro-x10820)
7GCY	;	1.618	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-c59291d4-5 (Mpro-x10812)
7GG8	;	1.58	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-cd485364-2 (Mpro-x12202)
7GH0	;	1.69	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-ce760d3f-4 (Mpro-x12723)
7GHR	;	1.655	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-ce760d3f-8 (Mpro-P0017)
7GGL	;	2.218	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-ce760d3f-8 (Mpro-x12674)
7GD5	;	1.809	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-d2866bdf-1 (Mpro-x10876)
7GKM	;	1.95	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-e0fe77e5-13 (Mpro-P0950)
7GNK	;	1.72	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-ecbed2ba-12 (Mpro-P2730)
7GEV	;	1.542	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-f13221e1-4 (Mpro-x11513)
7GJP	;	1.967	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-POS-fe871b40-11 (Mpro-P0626)
7GJL	;	2.17	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-UNI-3735e77e-1 (Mpro-P0600)
7GIM	;	2.03	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-UNI-3735e77e-2 (Mpro-P0111)
7GKH	;	1.99	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-UNI-8d415491-1 (Mpro-P0884)
7GKD	;	2.243	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-UNI-8d415491-3 (Mpro-P0850)
7GKF	;	1.85	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-UNI-8d415491-6 (Mpro-P0872)
7GJG	;	1.99	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ALP-UNI-8e43a71e-8 (Mpro-P0238)
7GG9	;	1.54	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ANT-DIA-62e4526e-1 (Mpro-x12204)
7GBA	;	1.699	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ANT-OPE-d972fbad-1 (Mpro-x10296)
7GCS	;	1.618	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BAR-COM-0f94fc3d-18 (Mpro-x10733)
7GD0	;	1.649	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BAR-COM-0f94fc3d-23 (Mpro-x10834)
7GCU	;	1.541	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BAR-COM-0f94fc3d-25 (Mpro-x10787)
7GD2	;	1.65	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BAR-COM-0f94fc3d-3 (Mpro-x10862)
7GD6	;	1.551	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BAR-COM-0f94fc3d-38 (Mpro-x10888)
7GCN	;	1.62	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BAR-COM-0f94fc3d-41 (Mpro-x10679)
7GCK	;	1.4	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BAR-COM-0f94fc3d-48 (Mpro-x10638)
7GD1	;	1.52	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BAR-COM-0f94fc3d-58 (Mpro-x10856)
7GCL	;	1.829	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BAR-COM-0f94fc3d-59 (Mpro-x10645)
7GHF	;	1.66	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BAR-COM-4e090d3a-47 (Mpro-x3305)
7GHD	;	1.97	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BAR-COM-4e090d3a-57 (Mpro-x3298)
7GJC	;	1.932	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BEN-BAS-c2bc0d80-6 (Mpro-P0207)
7GK0	;	1.96	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BEN-BAS-c2bc0d80-7 (Mpro-P0765)
7GAY	;	1.3	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BEN-DND-031a96cc-8 (Mpro-x10022)
7GH9	;	1.57	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BEN-DND-362d364a-10 (Mpro-x2971)
7GHP	;	1.54	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BEN-DND-4f474d93-1 (Mpro-P0012)
7GGJ	;	1.801	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BEN-DND-4f474d93-1 (Mpro-x12659)
7GCO	;	1.59	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BEN-DND-7e92b6ca-1 (Mpro-x10700)
7GE8	;	1.799	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BEN-DND-7e92b6ca-16 (Mpro-x11366)
7GBT	;	1.25	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BEN-DND-7e92b6ca-2 (Mpro-x10419)
7GBR	;	1.49	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BEN-DND-7e92b6ca-4 (Mpro-x10403)
7GEF	;	1.18	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BEN-DND-93268d01-11 (Mpro-x11428)
7GC2	;	1.731	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BEN-DND-93268d01-13 (Mpro-x10484)
7GEE	;	1.29	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BEN-DND-93268d01-5 (Mpro-x11427)
7GCE	;	1.39	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BEN-DND-93268d01-7 (Mpro-x10598)
7GEB	;	1.391	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BEN-DND-93268d01-8 (Mpro-x11417)
7GHY	;	1.62	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BEN-DND-c852c98b-10 (Mpro-P0031)
7GGT	;	1.82	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BEN-DND-c852c98b-10 (Mpro-x12698)
7GIQ	;	1.916	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BEN-DND-c852c98b-5 (Mpro-P0124)
7GJH	;	1.92	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BEN-DND-f2e727cd-5 (Mpro-P0240)
7GIY	;	2.04	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BRU-CON-c4e3408a-1 (Mpro-P0145)
7GCT	;	1.857	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BRU-LEF-c49414a7-1 (Mpro-x10756)
7GI5	;	2.0	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BRU-THA-92256091-17 (Mpro-P0053)
7GDW	;	1.667	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with BRU-THA-a358fbdd-2 (Mpro-x11233)
7GG7	;	1.51	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with CHO-MSK-00c5269a-2 (Mpro-x12177)
7GFG	;	1.8	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with CHO-MSK-6e55470f-5 (Mpro-x11723)
7GBB	;	1.737	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with DAN-LON-a5fc619e-3 (Mpro-x10306)
7GHA	;	1.72	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with DAN-LON-a5fc619e-8 (Mpro-x3077)
7GHI	;	1.65	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with DAN-PUR-6788a628-2 (Mpro-x3333)
7GH8	;	1.52	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with DAR-DIA-23aa0b97-13 (Mpro-x2964)
7GDG	;	1.811	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with DAR-DIA-23aa0b97-14 (Mpro-x10996)
7GB4	;	1.865	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with DAR-DIA-23aa0b97-6 (Mpro-x10178)
7GHK	;	1.52	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with DAR-DIA-eace69ff-36 (Mpro-x3351)
7GHG	;	1.45	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with DAV-CRI-3edb475e-4 (Mpro-x3324)
7GB3	;	1.379	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with DAV-CRI-3edb475e-6 (Mpro-x10172)
7GAZ	;	1.753	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with DUN-NEW-f8ce3686-14 (Mpro-x10049)
7GD9	;	1.621	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with DUN-NEW-f8ce3686-23 (Mpro-x10899)
7GC5	;	1.57	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with DUN-NEW-f8ce3686-24 (Mpro-x10506)
7GDE	;	1.501	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-0da5ad92-12 (Mpro-x10976)
7GEM	;	1.32	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-0da5ad92-15 (Mpro-x11485)
7GDJ	;	1.769	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-0da5ad92-16 (Mpro-x11013)
7GC4	;	1.736	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-0da5ad92-18 (Mpro-x10494)
7GB5	;	1.261	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-0da5ad92-2 (Mpro-x10201)
7GDK	;	1.735	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-0da5ad92-21 (Mpro-x11025)
7GF3	;	1.628	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-0da5ad92-5 (Mpro-x11557)
7GF5	;	1.37	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-0da5ad92-7 (Mpro-x11562)
7GHX	;	1.49	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-0e5afe9d-1 (Mpro-P0030)
7GGS	;	1.49	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-0e5afe9d-1 (Mpro-x12696)
7GI1	;	1.625	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-0e5afe9d-3 (Mpro-P0038)
7GGU	;	2.29	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-0e5afe9d-3 (Mpro-x12699)
7GL5	;	1.678	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-10fcb19e-1 (Mpro-P1661)
7GJ4	;	2.128	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-5d232de5-1 (Mpro-P0160)
7GIZ	;	1.97	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-5d232de5-4 (Mpro-P0148)
7GJ5	;	2.13	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-5d232de5-5 (Mpro-P0171)
7GK5	;	1.97	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-5d232de5-7 (Mpro-P0793)
7GKA	;	2.06	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-5d232de5-8 (Mpro-P0816)
7GJ2	;	1.87	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-70ae9412-1 (Mpro-P0154)
7GJ0	;	1.81	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-70ae9412-2 (Mpro-P0151)
7GIR	;	2.18	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-971238d3-1 (Mpro-P0125)
7GI2	;	1.61	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-971238d3-5 (Mpro-P0039)
7GGX	;	1.85	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-971238d3-5 (Mpro-x12716)
7GNI	;	1.644	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-b1ef7fe3-1 (Mpro-P2660)
7GJT	;	2.12	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-ba1ac7b9-11 (Mpro-P0642)
7GK2	;	2.01	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-ba1ac7b9-13 (Mpro-P0772)
7GKJ	;	1.76	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-ba1ac7b9-19 (Mpro-P0904)
7GK7	;	2.18	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-ba1ac7b9-21 (Mpro-P0805)
7GNB	;	1.671	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDG-MED-ee636701-1 (Mpro-P2468)
7GH4	;	2.27	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-00c1612e-1 (Mpro-x12777)
7GLB	;	1.95	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-015fb6b4-2 (Mpro-P1835)
7GEH	;	1.23	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-06d94977-2 (Mpro-x11432)
7GDN	;	1.351	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-0e996074-1 (Mpro-x11159)
7GN9	;	2.155	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-12c4873b-2 (Mpro-P2402)
7GMO	;	1.855	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-12c4873b-5 (Mpro-P2206)
7GL3	;	1.751	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-1981ceba-2 (Mpro-P1624)
7GL4	;	1.868	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-1981ceba-3 (Mpro-P1638)
7GL2	;	1.808	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-1981ceba-4 (Mpro-P1623)
7GKG	;	2.03	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-2f867453-1 (Mpro-P0878)
7GJN	;	2.06	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-37aac4bd-4 (Mpro-P0602)
7GGZ	;	1.46	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-3c65e9ce-2 (Mpro-x12719)
7GH3	;	1.901	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-3c65e9ce-4 (Mpro-x12740)
7GN4	;	1.72	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-43f8f7d6-4 (Mpro-P2291)
7GN0	;	1.806	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-43f8f7d6-6 (Mpro-P2256)
7GDI	;	1.8	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-49816e9b-1 (Mpro-x11011)
7GBH	;	1.581	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-49816e9b-2 (Mpro-x10334)
7GLL	;	1.905	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-4fff0a85-1 (Mpro-P1988)
7GLJ	;	1.814	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-4fff0a85-3 (Mpro-P1983)
7GEU	;	1.4	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-50fe53e8-1 (Mpro-x11508)
7GEO	;	1.499	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-50fe53e8-3 (Mpro-x11493)
7GKN	;	1.92	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-611d11e7-4 (Mpro-P0978)
7GE2	;	1.67	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-6af13d92-1 (Mpro-x11313)
7GE0	;	1.701	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-6af13d92-2 (Mpro-x11276)
7GE1	;	1.936	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-6af13d92-3 (Mpro-x11294)
7GL7	;	1.851	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-6bf93aa8-1 (Mpro-P1783)
7GNG	;	1.769	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-705e09b8-1 (Mpro-P2607)
7GLK	;	1.744	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-76744c27-4 (Mpro-P1986)
7GM8	;	1.73	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-7889e8da-3 (Mpro-P2101)
7GM6	;	1.87	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-7889e8da-5 (Mpro-P2090)
7GMV	;	1.899	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-8bb691af-4 (Mpro-P2222)
7GN1	;	1.903	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-8bb691af-6 (Mpro-P2263)
7GNC	;	1.683	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-8bb691af-8 (Mpro-P2487)
7GJF	;	1.96	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-8c98ee63-2 (Mpro-P0224)
7GI0	;	1.58	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-92e193ae-1 (Mpro-P0034)
7GGQ	;	1.811	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-92e193ae-1 (Mpro-x12692)
7GN5	;	1.863	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-968bafd9-1 (Mpro-P2295)
7GNJ	;	1.45	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-976a33d5-1 (Mpro-P2724)
7GK1	;	1.937	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-9e38fd34-1 (Mpro-P0766)
7GEG	;	1.729	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-a364e151-1 (Mpro-x11431)
7GMS	;	1.897	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-be9e6f63-3 (Mpro-P2215)
7GMZ	;	1.617	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-c3ea9889-6 (Mpro-P2243)
7GJI	;	1.59	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-d08626de-3 (Mpro-P0243)
7GJM	;	1.92	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-e4b030d8-11 (Mpro-P0601)
7GGA	;	1.49	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-e4b030d8-13 (Mpro-x12207)
7GN2	;	1.735	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-e69ed63d-1 (Mpro-P2273)
7GMY	;	1.838	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with EDJ-MED-e69ed63d-13 (Mpro-P2242)
7GE5	;	1.641	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ERI-UCB-5b47150d-6 (Mpro-x11339)
7GFC	;	2.23	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ERI-UCB-a0b0dbcb-4 (Mpro-x11616)
7GFZ	;	1.43	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ERI-UCB-a0b0dbcb-8 (Mpro-x12025)
7GG1	;	1.481	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ERI-UCB-a0b0dbcb-9 (Mpro-x12064)
7GHM	;	1.69	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ERI-UCB-ce40166b-17 (Mpro-P0008)
7GGN	;	1.928	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ERI-UCB-d6de1f3c-1 (Mpro-x12679)
7GHS	;	1.659	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ERI-UCB-d6de1f3c-2 (Mpro-P0018)
7GGG	;	1.74	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ERI-UCB-d6de1f3c-2 (Mpro-x12582)
7GHC	;	1.48	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with GAB-REV-70cc3ca5-13 (Mpro-x3108)
7GHL	;	1.41	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with GAB-REV-70cc3ca5-18 (Mpro-x3366)
7GAX	;	1.71	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with GAB-REV-70cc3ca5-4 (Mpro-x10019)
7GHB	;	1.56	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with GAB-REV-70cc3ca5-8 (Mpro-x3080)
7GD8	;	1.64	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JAG-UCB-119787ef-1 (Mpro-x10898)
7GG4	;	1.572	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JAG-UCB-52b62a6f-11 (Mpro-x12136)
7GE6	;	1.62	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JAG-UCB-a3ef7265-18 (Mpro-x11346)
7GBE	;	1.224	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JAG-UCB-a3ef7265-20 (Mpro-x10324)
7GDF	;	1.959	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JAG-UCB-a3ef7265-23 (Mpro-x10995)
7GBI	;	1.291	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JAG-UCB-a3ef7265-3 (Mpro-x10338)
7GEL	;	1.49	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JAG-UCB-cedd89ab-1 (Mpro-x11475)
7GED	;	1.479	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JAG-UCB-cedd89ab-2 (Mpro-x11426)
7GC3	;	1.56	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JAG-UCB-cedd89ab-4 (Mpro-x10488)
7GLO	;	1.927	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JAN-GHE-5a013bed-2 (Mpro-P2001)
7GBX	;	1.91	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JAN-GHE-5a013bed-2 (Mpro-x10466)
7GCF	;	1.419	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JAN-GHE-5a013bed-4 (Mpro-x10604)
7GBG	;	1.461	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JAN-GHE-83b26c96-1 (Mpro-x10329)
7GBP	;	1.7	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JAN-GHE-83b26c96-10 (Mpro-x10395)
7GB9	;	1.4	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JAN-GHE-83b26c96-11 (Mpro-x10248)
7GE9	;	1.49	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JAN-GHE-83b26c96-12 (Mpro-x11368)
7GCB	;	1.608	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JAN-GHE-83b26c96-13 (Mpro-x10565)
7GB8	;	1.957	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JAN-GHE-83b26c96-14 (Mpro-x10247)
7GDL	;	1.864	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JAN-GHE-83b26c96-15 (Mpro-x11041)
7GC8	;	1.801	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JAN-GHE-83b26c96-18 (Mpro-x10535)
7GEA	;	1.831	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JAN-GHE-83b26c96-2 (Mpro-x11372)
7GBO	;	1.619	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JAN-GHE-83b26c96-20 (Mpro-x10392)
7GCG	;	1.887	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JAN-GHE-83b26c96-21 (Mpro-x10606)
7GBV	;	1.67	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JAN-GHE-83b26c96-22 (Mpro-x10422)
7GBQ	;	1.72	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JAN-GHE-83b26c96-23 (Mpro-x10396)
7GBM	;	1.8	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JAN-GHE-83b26c96-3 (Mpro-x10377)
7GBW	;	1.559	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JAN-GHE-83b26c96-8 (Mpro-x10423)
7GBF	;	1.769	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JAN-GHE-83b26c96-9 (Mpro-x10327)
7GKK	;	1.8	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JIN-POS-6dc588a4-6 (Mpro-P0906)
7GB6	;	1.84	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JOR-UNI-2fc98d0b-12 (Mpro-x10236)
7GB7	;	1.55	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with JOR-UNI-2fc98d0b-6 (Mpro-x10237)
7GJW	;	2.456	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with KAD-UNI-80f122c8-2 (Mpro-P0743)
7GDC	;	1.72	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with LON-WEI-0a73fcb8-7 (Mpro-x10942)
7GJZ	;	1.65	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with LON-WEI-9739a092-6 (Mpro-P0764)
7GJJ	;	1.75	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with LON-WEI-9739a092-9 (Mpro-P0394)
7GDH	;	1.891	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with LOR-NEU-c8f11034-6 (Mpro-x11001)
7GDQ	;	1.721	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with LOR-NOR-30067bb9-15 (Mpro-x11204)
7GDS	;	1.46	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with LOR-NOR-30067bb9-18 (Mpro-x11212)
7GDR	;	1.661	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with LOR-NOR-30067bb9-2 (Mpro-x11208)
7GDY	;	1.611	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with LOR-NOR-30067bb9-6 (Mpro-x11258)
7GDX	;	1.839	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with LOR-NOR-30067bb9-7 (Mpro-x11254)
7GFY	;	1.55	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with LOR-NOR-c954e7ad-4 (Mpro-x12010)
7GDT	;	1.509	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAK-UNK-0d6072ac-20 (Mpro-x11223)
7GFT	;	1.639	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAR-UCB-f313ec4d-2 (Mpro-x11813)
7GFS	;	1.679	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAR-UCB-f313ec4d-6 (Mpro-x11812)
7GFK	;	1.5	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-044491d2-1 (Mpro-x11764)
7GGC	;	1.936	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-044491d2-3 (Mpro-x12321)
7GGB	;	1.381	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-044491d2-7 (Mpro-x12300)
7GI3	;	2.1	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-090737b9-1 (Mpro-P0041)
7GH2	;	1.62	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-090737b9-1 (Mpro-x12735)
7GGI	;	1.65	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-14ad9fe9-1 (Mpro-x12640)
7GFX	;	1.55	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-199e2e7c-1 (Mpro-x12000)
7GM9	;	1.826	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-1bed62cf-3 (Mpro-P2113)
7GEN	;	1.529	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-1e5f28a7-1 (Mpro-x11488)
7GIK	;	2.09	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-1f3f1a6f-1 (Mpro-P0098)
7GH1	;	1.52	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-2bb0cf2b-1 (Mpro-x12731)
7GGW	;	1.92	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-2bb0cf2b-2 (Mpro-x12715)
7GFV	;	1.73	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-2db6411e-2 (Mpro-x11852)
7GM1	;	1.939	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-2e8b2191-10 (Mpro-P2072)
7GLX	;	1.494	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-2e8b2191-11 (Mpro-P2039)
7GM2	;	1.891	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-2e8b2191-12 (Mpro-P2074)
7GFA	;	1.971	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-3b92565d-1 (Mpro-x11609)
7GJD	;	1.79	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-3b97339c-2 (Mpro-P0208)
7GJX	;	2.06	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-3ccb8ef6-1 (Mpro-P0744)
7GKS	;	1.809	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-4223bc15-11 (Mpro-P1062)
7GLT	;	1.863	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-4223bc15-12 (Mpro-P2017)
7GKQ	;	2.07	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-4223bc15-18 (Mpro-P1010)
7GKR	;	2.02	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-4223bc15-2 (Mpro-P1015)
7GKV	;	1.876	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-4223bc15-23 (Mpro-P1090)
7GKX	;	1.866	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-4223bc15-28 (Mpro-P1202)
7GKP	;	1.794	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-4223bc15-3 (Mpro-P1007)
7GKO	;	2.05	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-4223bc15-30 (Mpro-P0996)
7GKU	;	1.866	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-4223bc15-40 (Mpro-P1079)
7GNS	;	1.617	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-50a80394-1 (Mpro-P3050)
7GNT	;	1.561	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-50a80394-2 (Mpro-P3054)
7GBZ	;	1.529	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-590ac91e-11 (Mpro-x10474)
7GF4	;	1.561	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-590ac91e-17 (Mpro-x11560)
7GCA	;	1.771	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-590ac91e-18 (Mpro-x10559)
7GCJ	;	1.34	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-590ac91e-19 (Mpro-x10626)
7GC0	;	1.579	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-590ac91e-21 (Mpro-x10476)
7GC9	;	1.771	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-590ac91e-22 (Mpro-x10555)
7GCD	;	1.811	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-590ac91e-23 (Mpro-x10575)
7GCX	;	1.75	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-590ac91e-24 (Mpro-x10801)
7GC1	;	1.59	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-590ac91e-25 (Mpro-x10478)
7GCI	;	1.541	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-590ac91e-27 (Mpro-x10610)
7GBJ	;	1.549	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-590ac91e-32 (Mpro-x10355)
7GC7	;	1.65	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-590ac91e-39 (Mpro-x10525)
7GBY	;	1.608	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-590ac91e-5 (Mpro-x10473)
7GLE	;	1.984	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-5cd9ea36-13 (Mpro-P1889)
7GLZ	;	1.678	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-5cd9ea36-14 (Mpro-P2067)
7GLD	;	1.78	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-5cd9ea36-15 (Mpro-P1879)
7GLN	;	1.836	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-5cd9ea36-16 (Mpro-P1991)
7GMC	;	1.819	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-5cd9ea36-17 (Mpro-P2147)
7GLG	;	1.673	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-5cd9ea36-18 (Mpro-P1980)
7GM5	;	1.709	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-5cd9ea36-2 (Mpro-P2089)
7GLM	;	1.906	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-5cd9ea36-21 (Mpro-P1990)
7GLF	;	1.67	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-5cd9ea36-22 (Mpro-P1978)
7GLY	;	1.805	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-5cd9ea36-23 (Mpro-P2057)
7GFF	;	1.745	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-5d20d11c-1 (Mpro-x11708)
7GIJ	;	1.9	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-5d65ec79-1 (Mpro-P0097)
7GJB	;	2.03	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-5d65ec79-2 (Mpro-P0188)
7GFE	;	1.65	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-6344a35d-1 (Mpro-x11642)
7GI7	;	1.74	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-6c284e65-1 (Mpro-P0057)
7GMA	;	1.865	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-7174c657-5 (Mpro-P2141)
7GMD	;	1.937	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-7174c657-6 (Mpro-P2176)
7GJQ	;	1.97	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-78e1d523-1 (Mpro-P0627)
7GL1	;	1.709	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-8293a91a-8 (Mpro-P1507)
7GNH	;	1.785	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-853c0ffa-9 (Mpro-P2649)
7GL6	;	1.721	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-8695a11f-1 (Mpro-P1701)
7GLA	;	1.684	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-86c60949-2 (Mpro-P1812)
7GG2	;	1.721	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-8a69d52e-7 (Mpro-x12073)
7GMQ	;	1.859	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-90fd5f68-13 (Mpro-P2210)
7GMN	;	2.195	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-90fd5f68-14 (Mpro-P2205)
7GMT	;	1.738	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-90fd5f68-19 (Mpro-P2218)
7GMI	;	2.01	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-90fd5f68-2 (Mpro-P2185)
7GMM	;	1.842	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-90fd5f68-20 (Mpro-P2204)
7GMX	;	2.03	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-90fd5f68-21 (Mpro-P2229)
7GMU	;	1.737	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-90fd5f68-22 (Mpro-P2219)
7GML	;	1.912	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-90fd5f68-28 (Mpro-P2203)
7GMB	;	2.207	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-90fd5f68-31 (Mpro-P2144)
7GMH	;	1.848	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-90fd5f68-37 (Mpro-P2183)
7GME	;	1.846	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-90fd5f68-38 (Mpro-P2177)
7GMP	;	2.083	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-90fd5f68-7 (Mpro-P2207)
7GH6	;	1.57	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-916-2 (Mpro-x2910)
7GHE	;	2.168	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-916a2c5a-4 (Mpro-x3303)
7GJV	;	2.09	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-932d1078-3 (Mpro-P0661)
7GDB	;	1.701	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-968e8d9c-1 (Mpro-x10906)
7GKB	;	1.96	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-96f51285-5 (Mpro-P0831)
7GJO	;	2.2	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-a13804f0-3 (Mpro-P0607)
7GL0	;	1.821	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-a13804f0-4 (Mpro-P1477)
7GLV	;	1.716	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-a54ce14d-2 (Mpro-P2031)
7GLI	;	1.839	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-af1eef35-2 (Mpro-P1982)
7GKZ	;	1.808	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-afb6844f-1 (Mpro-P1474)
7GHV	;	1.63	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-afd4d4fd-2 (Mpro-P0025)
7GGM	;	1.839	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-afd4d4fd-2 (Mpro-x12677)
7GFB	;	1.609	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-b3e365b9-1 (Mpro-x11612)
7GFQ	;	1.551	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-b3e365b9-3 (Mpro-x11809)
7GGD	;	1.48	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-b5746674-38 (Mpro-x12350)
7GF0	;	1.579	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-bb423b95-1 (Mpro-x11542)
7GEW	;	1.461	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-bb423b95-2 (Mpro-x11530)
7GES	;	1.47	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-bb423b95-7 (Mpro-x11501)
7GFU	;	1.6	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-bbbbc21a-3 (Mpro-x11831)
7GLS	;	1.731	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-bfb445d4-2 (Mpro-P2011)
7GFL	;	1.771	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-bfb445d4-2 (Mpro-x11789)
7GM0	;	1.76	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-bfd29aac-1 (Mpro-P2070)
7GB0	;	1.423	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-c0143b99-1 (Mpro-x10082)
7GM3	;	2.02	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-c20a539d-4 (Mpro-P2075)
7GN8	;	1.903	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-c7726e07-5 (Mpro-P2385)
7GGR	;	1.87	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-c7771779-1 (Mpro-x12695)
7GDZ	;	1.839	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-c9973a83-1 (Mpro-x11271)
7GL8	;	1.637	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-dc2604c4-1 (Mpro-P1788)
7GK8	;	2.2	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-dd3ad2b5-2 (Mpro-P0808)
7GKE	;	1.97	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-dd3ad2b5-3 (Mpro-P0851)
7GIV	;	2.198	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-de59a476-2 (Mpro-P0135)
7GJA	;	2.097	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-de59a476-4 (Mpro-P0187)
7GMW	;	1.826	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-e119ab4f-1 (Mpro-P2224)
7GMG	;	1.81	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-e119ab4f-2 (Mpro-P2182)
7GMF	;	1.805	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-e119ab4f-3 (Mpro-P2178)
7GN6	;	2.44	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-e119ab4f-5 (Mpro-P2358)
7GAW	;	1.812	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-e194df51-1 (SARS2_MproA-x0862)
7GNR	;	1.819	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-e48723dc-2 (Mpro-P3038)
7GJE	;	2.03	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-e69ad64a-2 (Mpro-P0213)
7GKW	;	1.911	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-e6dd326d-6 (Mpro-P1200)
7GKT	;	1.839	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-e6dd326d-8 (Mpro-P1073)
7GJR	;	2.25	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-e9e99895-11 (Mpro-P0630)
7GJY	;	2.177	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-e9e99895-13 (Mpro-P0747)
7GJS	;	2.0	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-e9e99895-2 (Mpro-P0640)
7GJU	;	1.94	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-e9e99895-6 (Mpro-P0655)
7GHN	;	1.73	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-f2460aef-1 (Mpro-P0009)
7GF6	;	1.45	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-f42f3716-6 (Mpro-x11564)
7GAV	;	1.77	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-f7918075-2 (SARS2_MproA-x0854)
7GER	;	1.711	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-f7918075-5 (Mpro-x11499)
7GFH	;	1.46	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-f7918075-8 (Mpro-x11742)
7GIW	;	2.45	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-f9802937-7 (Mpro-P0141)
7GFW	;	1.569	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-fa06b69f-6 (Mpro-x11894)
7GK6	;	1.98	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-fb82b63d-1 (Mpro-P0800)
7GK3	;	2.19	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-fb82b63d-3 (Mpro-P0776)
7GIO	;	2.035	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-fce787c2-3 (Mpro-P0121)
7GJ6	;	2.03	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-fce787c2-4 (Mpro-P0178)
7GIT	;	2.06	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-fce787c2-5 (Mpro-P0129)
7GJ8	;	2.003	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MAT-POS-fce787c2-6 (Mpro-P0185)
7GB2	;	1.5	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MED-COV-4280ac29-25 (Mpro-x10155)
7GLR	;	1.788	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MIC-UNK-08cd9c58-1 (Mpro-P2010)
7GF2	;	1.38	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MIC-UNK-08cd9c58-1 (Mpro-x11548)
7GI8	;	1.8	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MIC-UNK-45817b9b-1 (Mpro-P0060)
7GEX	;	1.989	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MIC-UNK-66895286-1 (Mpro-x11532)
7GEY	;	1.341	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MIC-UNK-66895286-3 (Mpro-x11540)
7GHZ	;	1.666	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MIC-UNK-91acba05-6 (Mpro-P0033)
7GGV	;	1.97	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MIC-UNK-91acba05-6 (Mpro-x12710)
7GNF	;	1.69	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MIK-ENA-5d9157e9-5 (Mpro-P2606)
7GNE	;	1.739	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MIK-ENA-5d9157e9-6 (Mpro-P2605)
7GND	;	1.655	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with MIK-UNK-78dbf1b8-1 (Mpro-P2601)
7GCW	;	1.58	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with NAU-LAT-445f63e5-6 (Mpro-x10800)
7GCP	;	1.56	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with NAU-LAT-64f4b287-5 (Mpro-x10710)
7GDP	;	1.821	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with NAU-LAT-8502cac5-2 (Mpro-x11186)
7GDV	;	1.907	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with NAU-LAT-8502cac5-6 (Mpro-x11231)
7GCM	;	1.571	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with NIR-THE-c331be7a-2 (Mpro-x10678)
7GC6	;	1.69	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with NIR-THE-c331be7a-6 (Mpro-x10513)
7GNL	;	1.681	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with NIR-WEI-dcc3321b-1 (Mpro-P2757)
7GNM	;	1.75	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with NIR-WEI-dcc3321b-2 (Mpro-P2761)
7GNN	;	1.81	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with NIR-WEI-dcc3321b-3 (Mpro-P2775)
7GNO	;	1.661	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with NIR-WEI-dcc3321b-4 (Mpro-P2838)
7GNP	;	1.55	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with NIR-WEI-dcc3321b-5 (Mpro-P2889)
7GNQ	;	1.531	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with NIR-WEI-dcc3321b-6 (Mpro-P2916)
7GDU	;	1.63	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with PET-SGC-a8a902d9-1 (Mpro-x11225)
7GFM	;	1.7	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with PET-UNK-1901c25b-1 (Mpro-x11790)
7GJ3	;	1.924	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with PET-UNK-29afea89-2 (Mpro-P0157)
7GFR	;	1.46	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with PET-UNK-3c72d439-1 (Mpro-x11810)
7GFN	;	1.641	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with PET-UNK-7374c256-2 (Mpro-x11797)
7GN3	;	2.012	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with PET-UNK-7fb4f80a-1 (Mpro-P2284)
7GMR	;	1.837	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with PET-UNK-7fb4f80a-2 (Mpro-P2214)
7GLQ	;	2.063	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with PET-UNK-8df914d1-2 (Mpro-P2007)
7GEI	;	1.69	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with PET-UNK-8df914d1-2 (Mpro-x11454)
7GEK	;	1.41	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with PET-UNK-8df914d1-4 (Mpro-x11473)
7GLH	;	1.906	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with PET-UNK-b38839dc-1 (Mpro-P1981)
7GK4	;	2.23	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with PET-UNK-bb7ffe78-1 (Mpro-P0777)
7GEJ	;	1.742	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with PET-UNK-c9c1e0d8-2 (Mpro-x11458)
7GHT	;	1.79	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with PET-UNK-c9c1e0d8-3 (Mpro-P0019)
7GGH	;	1.675	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with PET-UNK-c9c1e0d8-3 (Mpro-x12587)
7GHO	;	1.861	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with PET-UNK-c9c1e0d8-4 (Mpro-P0010)
7GMK	;	1.845	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with PET-UNK-d899bab6-1 (Mpro-P2201)
7GG0	;	1.512	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with PET-UNK-e44ffd04-1 (Mpro-x12026)
7GBL	;	2.16	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with RAL-MED-2de63afb-1 (Mpro-x10371)
7GBN	;	1.944	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with RAL-MED-2de63afb-14 (Mpro-x10387)
7GBD	;	1.78	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with RAL-MED-2de63afb-2 (Mpro-x10322)
7GIU	;	2.0	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with RAL-THA-05e671eb-10 (Mpro-P0130)
7GID	;	1.9	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with RAL-THA-2d450e86-1 (Mpro-P0066)
7GIB	;	1.68	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with RAL-THA-2d450e86-10 (Mpro-P0064)
7GIG	;	1.94	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with RAL-THA-2d450e86-12 (Mpro-P0074)
7GIC	;	1.92	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with RAL-THA-2d450e86-13 (Mpro-P0065)
7GIH	;	1.63	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with RAL-THA-2d450e86-16 (Mpro-P0075)
7GIE	;	2.17	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with RAL-THA-2d450e86-17 (Mpro-P0068)
7GI9	;	1.91	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with RAL-THA-2d450e86-26 (Mpro-P0061)
7GIS	;	1.838	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with RAL-THA-2d450e86-30 (Mpro-P0126)
7GIA	;	2.04	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with RAL-THA-2d450e86-33 (Mpro-P0063)
7GIL	;	2.07	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with RAL-THA-2d450e86-6 (Mpro-P0108)
7GIF	;	1.68	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with RAL-THA-2d450e86-7 (Mpro-P0069)
7GI6	;	1.694	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with RAL-THA-4aa06b95-1 (Mpro-P0056)
7GJK	;	2.1	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with RAL-THA-4aa06b95-7 (Mpro-P0578)
7GFP	;	1.769	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with RAL-THA-6b94ceba-5 (Mpro-x11801)
7GII	;	2.12	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with RAL-THA-8416115c-13 (Mpro-P0091)
7GIP	;	2.05	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with RAL-THA-8416115c-5 (Mpro-P0122)
7GFO	;	1.5	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with ROB-IMP-e811baff-1 (Mpro-x11798)
7GKY	;	1.969	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with RUB-POS-1325a9ea-14 (Mpro-P1470)
7GKI	;	2.0	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with RUB-POS-1325a9ea-4 (Mpro-P0887)
7GKL	;	1.93	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with SAM-UNK-2684b532-12 (Mpro-P0925)
7GHJ	;	1.526	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with SIM-SYN-f15aaa3a-1 (Mpro-x3348)
7GB1	;	1.289	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with STE-KUL-2e0d2e88-2 (Mpro-x10150)
7GF8	;	1.43	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with TAT-ENA-80bfd3e5-37 (Mpro-x11587)
7GF9	;	1.97	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with TAT-ENA-80bfd3e5-4 (Mpro-x11590)
7GF7	;	1.941	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with TAT-ENA-80bfd3e5-7 (Mpro-x11579)
7GHH	;	1.56	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with TOB-UNK-c2aba166-1 (Mpro-x3325)
7GBC	;	1.655	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with TRY-UNI-2eddb1ff-1 (Mpro-x10314)
7GCQ	;	1.693	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with TRY-UNI-2eddb1ff-2 (Mpro-x10723)
7GDA	;	1.709	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with TRY-UNI-2eddb1ff-3 (Mpro-x10900)
7GI4	;	1.72	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with TRY-UNI-2eddb1ff-7 (Mpro-P0045)
7GCV	;	1.964	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with TRY-UNI-2eddb1ff-7 (Mpro-x10789)
7GFD	;	1.851	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with TRY-UNI-2eddb1ff-8 (Mpro-x11641)
7GH5	;	1.66	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with TRY-UNI-714-12 (Mpro-x2908)
7GH7	;	1.67	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with TRY-UNI-714-22 (Mpro-x2912)
7GDM	;	1.52	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with TRY-UNI-714a760b-16 (Mpro-x11044)
7GE4	;	1.302	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with TRY-UNI-714a760b-19 (Mpro-x11318)
7GE3	;	1.27	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with TRY-UNI-714a760b-3 (Mpro-x11317)
7GEC	;	1.25	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with VLA-UCB-00f2c2b3-7 (Mpro-x11424)
7GEQ	;	2.057	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with VLA-UCB-1dbca3b4-15 (Mpro-x11498)
7GHU	;	1.638	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with VLA-UCB-29506327-1 (Mpro-P0022)
7GGP	;	1.902	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with VLA-UCB-29506327-1 (Mpro-x12686)
7GL9	;	1.944	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with VLA-UCB-50c39ae8-2 (Mpro-P1800)
7GJ7	;	1.88	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with VLA-UCB-50c39ae8-7 (Mpro-P0179)
7GJ1	;	1.95	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with VLA-UNK-82501c2c-1 (Mpro-P0153)
7GIX	;	2.07	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with VLA-UNK-cf7facf1-1 (Mpro-P0143)
7GCR	;	1.67	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with WAR-XCH-72a8c209-5 (Mpro-x10728)
7GFI	;	1.6	;	Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Crystal Structure of SARS-CoV-2 main protease in complex with WIL-MOD-03b86a88-6 (Mpro-x11743)
2EX5	;	2.2	;	Group I Intron-encoded Homing Endonuclease I-CeuI Complexed With DNA
1AF5	;	3.0	;	GROUP I MOBILE INTRON ENDONUCLEASE
1BP7	;	3.0	;	GROUP I MOBILE INTRON ENDONUCLEASE I-CREI COMPLEXED WITH HOMING SITE DNA
6D8M	;	3.7	;	Group I self-splicing intron P4-P6 domain mutant A125U/G126U
6D8O	;	2.80112	;	Group I self-splicing intron P4-P6 domain mutant A230U
6D8N	;	3.95427	;	Group I self-splicing intron P4-P6 domain mutant G134A/U185AA
6BJX	;	3.14	;	Group I self-splicing intron P4-P6 domain mutant U131A (with isopropanol soaking)
6D8L	;	3.14022	;	Group I self-splicing intron P4-P6 domain mutant U131A (without isopropanol soaking)
2XYK	;	2.1	;	Group II 2-on-2 Hemoglobin from the Plant Pathogen Agrobacterium tumefaciens
5VZ3	;	1.97	;	Growth Factor Crystal Structure at 1.97 Angstrom Resolution
1CJ1	;	3.0	;	GROWTH FACTOR RECEPTOR BINDING PROTEIN SH2 DOMAIN (HUMAN) COMPLEXED WITH A PHOSPHOTYROSYL DERIVATIVE
1ZFP	;	1.8	;	GROWTH FACTOR RECEPTOR BINDING PROTEIN SH2 DOMAIN COMPLEXED WITH A PHOSPHOTYROSYL PENTAPEPTIDE
1QG1	;		;	GROWTH FACTOR RECEPTOR BINDING PROTEIN SH2 DOMAIN COMPLEXED WITH AN SHC-DERIVED PEPTIDE
8DGO	;	2.3	;	Growth Factor Receptor-Bound Protein 2 (Grb2) bound to phosphorylated PEAK3 (pY24) peptide
1IO6	;		;	GROWTH FACTOR RECEPTOR-BOUND PROTEIN 2 (GRB2) C-TERMINAL SH3 DOMAIN COMPLEXED WITH A LIGAND PEPTIDE (NMR, MINIMIZED MEAN STRUCTURE)
2GH0	;	1.92	;	Growth factor/receptor complex
1BQF	;		;	GROWTH-BLOCKING PEPTIDE (GBP) FROM PSEUDALETIA SEPARATA
1FGZ	;	2.05	;	GRP1 PH DOMAIN (UNLIGANDED)
1FGY	;	1.5	;	GRP1 PH DOMAIN WITH INS(1,3,4,5)P4
2GFD	;	2.3	;	GRP94 in complex with the novel HSP90 Inhibitor Radamide
2FYP	;	1.95	;	GRP94 in complex with the novel HSP90 Inhibitor Radester amine
6CYI	;	1.75658	;	Grp94 N-domain bound to NEOCA
2EXL	;	2.35	;	GRP94 N-terminal Domain bound to geldanamycin
2ESA	;	1.9	;	GRP94 n-terminal domain bound to geldanamycin: effects of mutants 168-169 KS-AA
4I7A	;	3.2	;	GrpN pentameric microcompartment shell protein from Rhodospirillum rubrum
4M8X	;	2.05	;	GS-8374, a Novel Phosphonate-Containing Inhibitor of HIV-1 Protease, Effectively Inhibits HIV PR Mutants with Amino Acid Insertions
4M8Y	;	2.22	;	GS-8374, a Novel Phosphonate-Containing Inhibitor of HIV-1 Protease, Effectively Inhibits HIV PR Mutants with Amino Acid Insertions
1AZT	;	2.3	;	GS-ALPHA COMPLEXED WITH GTP-GAMMA-S
2PBJ	;	2.8	;	GSH-heme bound microsomal prostaglandin E synthase
7K9Y	;	3.2	;	GsI-IIC RT Template-Switching Complex (twinned)
1Q3W	;	2.3	;	GSK-3 Beta complexed with Alsterpaullone
1PYX	;	2.4	;	GSK-3 Beta complexed with AMP-PNP
1Q41	;	2.1	;	GSK-3 Beta complexed with Indirubin-3'-monoxime
1Q4L	;	2.77	;	GSK-3 Beta complexed with Inhibitor I-5
1Q3D	;	2.2	;	GSK-3 Beta complexed with Staurosporine
4IQ6	;	3.12	;	Gsk-3beta with inhibitor 6-chloro-N-cyclohexyl-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2-amine
8J1B	;	3.72	;	GSK101 and Ruthenium Red bound state of mTRPV4
8J1F	;	3.62	;	GSK101 bound state of mTRPV4
7B6F	;	2.05	;	GSK3-beta in complex with compound (S)-5c
5LD8	;	2.13	;	GSK3011724A cocrystallised with Mycobacterium tuberculosis H37Rv KasA
4ACC	;	2.21	;	GSK3b in complex with inhibitor
4ACD	;	2.6	;	GSK3b in complex with inhibitor
4ACG	;	2.6	;	GSK3b in complex with inhibitor
4ACH	;	2.6	;	GSK3b in complex with inhibitor
5OY4	;	3.2	;	GSK3beta complex with N-(6-(3,4-dihydroxyphenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)acetamide
3GB2	;	2.4	;	GSK3beta inhibitor complex
3QC5	;	1.4	;	GspB
3QC6	;	1.9	;	GspB
6EFA	;	1.6	;	GspB Siglec + Unique domains
6EF7	;	1.03	;	GspB Siglec domain
6EF9	;	1.3	;	GspB Siglec domain
6EFB	;	1.9	;	GspB Siglec domain
7LV2	;	1.301	;	GSQASS segment from the Nucleoprotein of SARS-CoV-2, residues 179-184
7ZA5	;	1.87	;	GSTF sh101 mutant
7ZA4	;	2.05	;	GSTF sh155 mutant
6TK8	;	2.78	;	GSTF1 F122T variant from Alopecurus myosuroides
6TJS	;	1.53	;	GSTF1 from Alopecurus myosuroides
6TNL	;	1.95	;	GSTF1 from Alopecurus myosuroides
7OBO	;	2.3	;	GSTF1 from Alopecurus myosuroides
6TO3	;	2.798	;	GSTF1 from Alopecurus myosuroides - covalently modified
8E8P	;	2.281	;	GSTZ1A
4GX5	;	3.7	;	GsuK Channel
4GX2	;	3.2	;	GsuK channel bound to NAD
1VTT	;	1.0	;	GT Wobble Base-Pairing in Z-DNA at 1.0 Angstrom Atomic Resolution: The Crystal Structure of d(CGCGTG)
5CMF	;	1.95	;	GTA mutant with mercury - E303A
5CMH	;	1.61	;	GTA mutant with mercury - E303D
5CMJ	;	1.73	;	GTA mutant with mercury - E303Q
5CMG	;	1.83	;	GTA mutant with mercury- E303C
5CMI	;	1.85	;	GTA mutant without mercury - E303D
2PGV	;	1.79	;	GTB C209A
2PGY	;	2.39	;	GTB C209A, no Hg
5CQL	;	1.69	;	GTB mutant with mercury - E303A
5CQM	;	1.65	;	GTB mutant with mercury - E303C
5CQO	;	1.69	;	GTB mutant with mercury - E303D
5CQP	;	1.83	;	GTB mutant with mercury - E303Q
5CQN	;	1.61	;	GTB mutant without mercury - E303C
8QUA	;	2.0	;	GTP binding protein YsxC from Staphylococcus aureus
7ULD	;	1.3	;	GTP complex of F420-gamma glutamyl ligase (CofE) from Archaeoglobus fulgidus
1GTP	;	3.0	;	GTP CYCLOHYDROLASE I
1A9C	;	2.9	;	GTP CYCLOHYDROLASE I (C110S MUTANT) IN COMPLEX WITH GTP
1A8R	;	2.1	;	GTP CYCLOHYDROLASE I (H112S MUTANT) IN COMPLEX WITH GTP
2QV6	;	2.0	;	GTP cyclohydrolase III from M. jannaschii (MJ0145) complexed with GTP and metal ions
8G6C	;	2.82	;	GTP Cyclohydrolase-IB with manganese
8G8V	;	2.03	;	GTP Cyclohydrolase-IB with sodium
3CNN	;	2.3	;	GTP-bound structure of TM YlqF
5ZUE	;	2.7	;	GTP-bound, double-stranded, curved FtsZ protofilament structure
1AS0	;	2.0	;	GTP-GAMMA-S BOUND G42V GIA1
6XRU	;	1.4	;	GTP-specific succinyl-CoA synthetase complexed with desulfo-coenzyme A, magnesium ions and succinates
7JMK	;	2.5	;	GTP-specific succinyl-CoA synthetase complexed with Mg-GDP in space group P32
7JFP	;	2.55	;	GTP-specific succinyl-CoA synthetase complexed with Mg-GDP, phosphohistidine loop pointing towards nucleotide binding site
7JJ0	;	2.25	;	GTP-specific succinyl-CoA synthetase complexed with Mg-GMPPCP
7JKR	;	2.64	;	GTP-specific succinyl-CoA synthetase complexed with Mg-GMPPNP, phosphohistidine loop pointing towards nucleotide binding site
4DRX	;	2.22	;	GTP-Tubulin in complex with a DARPIN
3RYF	;	2.52	;	GTP-Tubulin: RB3 Stathmin-like domain complex
4YQF	;	2.73	;	GTPase domain of Human Septin 9
4KV9	;	1.93	;	GTPase domain of Septin 10 from Schistosoma mansoni in complex with GDP
4KVA	;	2.14	;	GTPase domain of Septin 10 from Schistosoma mansoni in complex with GTP
5CYP	;	2.893	;	GTPase domain of Septin 9 in complex with GTP-gamma-S
7OGE	;	2.1	;	GTPase HRAS mutant D33K under 200 MPa pressure
7OGF	;	1.8	;	GTPase HRAS mutant D33K under 900 MPa pressure
7OGD	;	1.95	;	GTPase HRAS mutant D33K under ambient pressure
7OGA	;	1.9	;	GTPase HRAS under 200 MPa pressure
7OGB	;	1.85	;	GTPase HRAS under 500 MPa pressure
7OGC	;	1.7	;	GTPase HRAS under 650 MPa pressure
7OG9	;	1.75	;	GTPase HRAS under ambient pressure
7QSC	;	1.91	;	GTPase IN COMPLEX WITH GDP.MGF3-
2BMJ	;	2.1	;	GTPase like domain of Centaurin Gamma 1 (Human)
2IWR	;	1.5	;	Gtpase Like Domain Of Centaurin Gamma 1 (Human)
1TAD	;	1.7	;	GTPASE MECHANISM OF GPROTEINS FROM THE 1.7-ANGSTROM CRYSTAL STRUCTURE OF TRANSDUCIN ALPHA-GDP-ALF4-
1RGP	;	2.0	;	GTPASE-ACTIVATION DOMAIN FROM RHOGAP
7YSR	;	4.3	;	GTPgammaS MT decorated with kinesin
7YSQ	;	6.8	;	GTPgammaS Tube decorated with kinesin
1MSY	;	1.41	;	GUAA tetraloop mutant of Sarcin/Ricin domain from E. Coli 23 S rRNA
5VJ9	;	1.57	;	Guanidine-II riboswitch P2 hairpin dimer from Pseudomonas aeruginosa
5VJB	;	2.1	;	Guanidine-II riboswitch P2 hairpin dimer with 5-bromoU substitution from Pseudomonas aeruginosa
2JUK	;		;	guanidino neomycin B recognition of an HIV-1 RNA helix
1P1B	;	2.8	;	Guanidinoacetate methyltransferase
1XCL	;	2.0	;	Guanidinoacetate methyltransferase containing S-adenosylhomocysteine and guanidine
1XCJ	;	2.0	;	Guanidinoacetate methyltransferase containing S-adenosylhomocysteine and guanidinoacetate
1P1C	;	2.5	;	Guanidinoacetate Methyltransferase with Gd ion
2AH4	;	1.13	;	guanidinobenzoyl-trypsin acyl-enzyme at 1.13 A resolution
1D5T	;	1.04	;	GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR, ALPHA-ISOFORM
1GND	;	1.81	;	GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR, ALPHA-ISOFORM
1KI1	;	2.3	;	Guanine Nucleotide Exchange Region of Intersectin in Complex with Cdc42
2EET	;	1.95	;	Guanine Riboswitch A21G, U75C mutant bound to hypoxanthine
3GOG	;	2.1	;	Guanine riboswitch A21G,U75C mutant bound to 6-chloroguanine
2EES	;	1.75	;	Guanine riboswitch A21U, U75A mutant bound to hypoxanthine
3GER	;	1.7	;	Guanine riboswitch bound to 6-chloroguanine
6UC8	;	1.898	;	Guanine riboswitch bound to 8-aminoguanine
6UC9	;	1.941	;	Guanine riboswitch bound to O6-cyclohexylmethyl guanine
2B57	;	2.15	;	Guanine Riboswitch C74U mutant bound to 2,6-diaminopurine
3GOT	;	1.95	;	Guanine riboswitch C74U mutant bound to 2-fluoroadenine.
2EEU	;	1.95	;	Guanine riboswitch U22A, A52U mutant bound to hypoxanthine
2EEV	;	1.95	;	Guanine riboswitch U22C, A52G mutant bound to hypoxanthine
2EEW	;	2.25	;	Guanine Riboswitch U47C mutant bound to hypoxanthine
1NK7	;	1.9	;	GUANINE-ADENINE MISMATCH AT THE POLYMERASE ACTIVE SITE
1NK4	;	1.6	;	GUANINE-GUANINE MISMATCH AT THE POLYMERASE ACTIVE SITE
6SYK	;		;	Guanine-rich oligonucleotide with 5'- and 3'-GC ends form G-quadruplex with A(GGGG)A hexad, GCGC- and G-quartets and two symmetric GG and AA base pair
6SX6	;		;	Guanine-rich oligonucleotide with 5'-GC end form G-quadruplex with A(GGGG)A hexad, GCGC- and G-quartets and two symmetric GG and AA base pairs
5ZJ4	;	1.49739	;	Guanine-specific ADP-ribosyltransferase
5ZJ5	;	1.56811	;	Guanine-specific ADP-ribosyltransferase with NADH and GDP
1NJW	;	1.9	;	GUANINE-THYMINE MISMATCH AT THE POLYMERASE ACTIVE SITE
150D	;	2.25	;	GUANINE.1,N6-ETHENOADENINE BASE-PAIRS IN THE CRYSTAL STRUCTURE OF D(CGCGAATT(EDA)GCG)
7MO6	;	2.3	;	Guanosine Monophosphate Synthase from Aspergillus fumigatus Af293
2VDW	;	2.7	;	Guanosine N7 methyl-transferase sub-complex (D1-D12) of the vaccinia virus mRNA capping enzyme
3UAT	;	2.7	;	Guanylate Kinase Domains of the MAGUK Family Scaffold Proteins as Specific Phospho-Protein Binding Modules
1Z8F	;	2.5	;	Guanylate Kinase Double Mutant A58C, T157C from Mycobacterium tuberculosis (Rv1389)
3WV9	;	2.75	;	Guanylylpyridinol (GP)- and ATP-bound HcgE from Methanothermobacter marburgensis
3WVC	;	2.0	;	Guanylylpyridinol (GP)-bound HcgF from Methanocaldococcus jannaschii
8HZZ	;	2.2	;	GuApiGT (UGT79B74)
8GHP	;	3.52	;	GUCY2C-ECD bound to anti-GUCY2C-scFv antibody
8GHO	;	1.6	;	GUCY2C-peptide bound to anti-GUCY2C-scFv antibody
3LZ6	;	1.84	;	Guinea Pig 11beta hydroxysteroid dehydrogenase with PF-877423
6PKU	;	1.949	;	Guinea pig N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase (NAGPA) catalytic domain (C51S C221S) in complex with N-acetyl-alpha-D-glucosamine (alpha-GlcNAc) and mannose 6-phosphate (M6P)
6PKY	;	3.0	;	Guinea pig N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase (NAGPA) catalytic domain auto-inhibited by pro-peptide
6DY2	;	2.706	;	Guinea pig N-acylethanolamine-hydrolyzing acid amidase (NAAA) covalently bound to beta-lactam inhibitor ARN726
4KSL	;	2.83	;	Gumby/Fam105B in complex with linear di-ubiquitin
4KSK	;	2.4	;	Gumby/Fam105B in complex with ubiquitin
1C4E	;		;	GURMARIN FROM GYMNEMA SYLVESTRE
1GUR	;		;	GURMARIN, A SWEET TASTE-SUPPRESSING POLYPEPTIDE, NMR, 10 STRUCTURES
6UST	;	2.6	;	Gut microbial sulfatase from Hungatella hathewayi
3ZIN	;	2.0	;	Gu_alpha_helicase
4NIP	;	1.9	;	GVIGIAQ segment 147-153 from Human Superoxide Dismutase
4NIO	;	1.3	;	GVTGIAQ segment 147-153 from Human Superoxide Dismutase with I149T mutation associated with a familial form of amyotrophic lateral sclerosis
8H4K	;	3.1	;	GW9508-bound FFAR4 in complex with Gq
5C2G	;	2.597	;	GWS1B RubisCO: Form II RubisCO derived from uncultivated Gallionellacea species (CABP-bound).
5C2C	;	2.09	;	GWS1B RubisCO: Form II RubisCO derived from uncultivated Gallionellacea species (unliganded form)
3JTS	;	2.801	;	GY9-Mamu-A*02-hb2m
1GYF	;		;	GYF DOMAIN FROM HUMAN CD2BP2 PROTEIN
3NHC	;	1.57	;	GYMLGS segment 127-132 from human prion with M129
6BXX	;	1.1	;	GYNGFG from low-complexity domain of hnRNPA1, residues 243-248
6UM9	;		;	Gypsy Moth Pheromone-binding protein 1 (LdisPBP1) NMR Structure at pH 4.5
1AM2	;	2.2	;	GYRA INTEIN FROM MYCOBACTERIUM XENOPI
4ZVI	;	2.2	;	GYRASE B IN COMPLEX WITH 4,5-DIBROMOPYRROLAMIDE-BASED INHIBITOR
3NHD	;	1.92	;	GYVLGS segment 127-132 from human prion with V129
6AP5	;		;	H, 13C, and 15N Chemical Shift Assignments and structure of Thioredoxin from Mycobacterium thermoresistibile ATCC 19527 and NCTC 10409
3CC5	;	1.91	;	H-2Db complex with human gp100
3CCH	;	2.6	;	H-2Db complex with murine gp100
2GHG	;	3.5	;	h-CHK1 complexed with A431994
8GEW	;	0.973	;	H-FABP crystal soaked in a bromo palmitic acid solution
2J64	;	2.2	;	H-ficolin
2J60	;	1.8	;	H-ficolin complexed to D-fucose
2J5Z	;	1.73	;	H-ficolin complexed to galactose
2GA2	;	1.95	;	h-MetAP2 complexed with A193400
1YW7	;	1.85	;	h-MetAP2 complexed with A444148
1YW8	;	2.65	;	h-MetAP2 complexed with A751277
2EA2	;	2.5	;	h-MetAP2 complexed with A773812
2EA4	;	2.35	;	h-MetAP2 complexed with A797859
1YW9	;	1.64	;	h-MetAP2 complexed with A849519
1HNR	;		;	H-NS (DNA-BINDING DOMAIN)
1HNS	;		;	H-NS (DNA-BINDING DOMAIN)
1NI8	;		;	H-NS dimerization motif
7JR6	;	1.88	;	H-PDGS complexed with a 2-phenylimidazo[1,2-a]pyridine-6-carboxamide inhibitors
7JR8	;	1.13	;	H-PDGS complexed with a 2-phenylimidazo[1,2-a]pyridine-6-carboxamide inhibitors
6W8H	;	1.97	;	H-PGDS complexed with inhibitor 1Y
1P2S	;	2.45	;	H-Ras 166 in 50% 2,2,2 triflouroethanol
1P2V	;	2.3	;	H-RAS 166 in 60 % 1,6 hexanediol
1P2T	;	2.0	;	H-Ras 166 in Aqueous mother liqour, RT
5WDO	;	1.65	;	H-Ras bound to GMP-PNP at 277K
1CLU	;	1.7	;	H-RAS COMPLEXED WITH DIAMINOBENZOPHENONE-BETA,GAMMA-IMIDO-GTP
1RVD	;	1.9	;	H-RAS COMPLEXED WITH DIAMINOBENZOPHENONE-BETA,GAMMA-IMIDO-GTP
3RRY	;	1.6	;	H-Ras crosslinked control, soaked in aqueous solution: one of 10 in MSCS set
1P2U	;	2.0	;	H-Ras in 50% isopropanol
3RRZ	;	1.6	;	H-Ras in 70% glycerol: one of 10 in MSCS set
5WDQ	;	1.25	;	H-Ras mutant L120A bound to GMP-PNP at 100K
5WDP	;	1.35	;	H-Ras mutant L120A bound to GMP-PNP at 277K
1JAH	;	1.8	;	H-RAS P21 PROTEIN MUTANT G12P, COMPLEXED WITH GUANOSINE-5'-[BETA,GAMMA-METHYLENE] TRIPHOSPHATE AND MAGNESIUM
1JAI	;	1.8	;	H-RAS P21 PROTEIN MUTANT G12P, COMPLEXED WITH GUANOSINE-5'-[BETA,GAMMA-METHYLENE] TRIPHOSPHATE AND MANGANESE
4DLR	;	1.319	;	H-Ras PEG 400/Ca(OAc)2, ordered off
3V4F	;	1.391	;	H-Ras PEG 400/CaCl2, ordered off
7DPH	;	1.54	;	H-Ras Q61H in complex with GppNHp (state 1) after structural transition by humidity control
7DPJ	;	1.976	;	H-Ras Q61L in complex with GppNHp (state 1) after structural transition by humidity control
4DLU	;	1.6	;	H-Ras Set 1 Ca(OAc)2, on
4DLS	;	1.819	;	H-Ras Set 1 CaCl2 'Mixed'
4DLX	;	1.731	;	H-Ras Set 1 CaCl2/DTE, ordered off
4DLT	;	1.699	;	H-Ras Set 2 Ca(OAc)2, on
4DLZ	;	1.662	;	H-Ras Set 2 Ca(OAc)2/DTE, ordered off
4DLW	;	1.72	;	H-Ras Set 2 Ca(OAc)2/DTT, on
4DLV	;	1.572	;	H-Ras Set 2 CaCl2/DTT, ordered off
3RSO	;	1.6	;	H-Ras soaked in 20% S,R,S-bisfuranol: 1 of 10 in MSCS set
3RS2	;	1.836	;	H-Ras soaked in 50% 2,2,2-trifluoroethanol: one of 10 in MSCS set
3RS7	;	1.7	;	H-Ras soaked in 50% isopropanol: 1 of 10 in MSCS set
3RS5	;	1.68	;	H-Ras soaked in 55% dimethylformamide: 1 of 10 in MSCS set
3RS4	;	1.7	;	H-Ras soaked in 60% 1,6-hexanediol: 1 of 10 in MSCS set
3RSL	;	1.7	;	H-Ras soaked in 90% R,S,R-bisfuranol: one of 10 in MSCS set
3RS0	;	1.4	;	H-Ras soaked in neat cyclopentanol: one of 10 in MSCS set
3RS3	;	1.52	;	H-Ras soaked in neat hexane: 1 of 10 in MSCS set
3L8Z	;	1.44	;	H-Ras wildtype new crystal form
5B30	;	1.6	;	H-Ras WT in complex with GppNHp (state 1) after structural transition by humidity control
5B2Z	;	1.56	;	H-Ras WT in complex with GppNHp (state 2*) before structural transition by humidity control
4XVQ	;	1.887	;	H-Ras Y137E
4XVR	;	2.031	;	H-Ras Y137F
3OIV	;	1.837	;	H-RasG12V with allosteric switch in the ""off"" state
3OIW	;	1.3	;	H-RasG12V with allosteric switch in the ""on"" state
3OIU	;	1.32	;	H-RasQ61L with allosteric switch in the ""on"" state
6Q5Z	;		;	H-Vc7.2, H-superfamily conotoxin
2VXA	;	2.6	;	H. halophila dodecin in complex with riboflavin
4WAJ	;	2.7	;	H. influenzae beta-carbonic anhydase variant P48S/A49P
4WAK	;	2.49	;	H. influenzae beta-carbonic anhydrase variant W39V/G41A
4WAM	;	2.2	;	H. influenzae beta-carbonic anhydrase variant W39V/G41A/P48S/A49P
3E1V	;	2.8	;	H. influenzae beta-carbonic anhydrase, variant D44N
3E1W	;	2.6	;	H. influenzae beta-carbonic anhydrase, variant D44N in 100 mM sodium bicarbonate
3E3G	;	2.3	;	H. influenzae beta-carbonic anhydrase, variant G41A
3E3I	;	2.0	;	H. influenzae beta-carbonic anhydrase, variant G41A with 100 mM bicarbonate
3E2X	;	2.55	;	H. influenzae beta-carbonic anhydrase, variant V47A
3E31	;	2.95	;	H. influenzae beta-carbonic anhydrase, variant V47A
3E3F	;	2.3	;	H. influenzae beta-carbonic anhydrase, variant V47A with 100 mM bicarbonate
3E24	;	2.301	;	H. influenzae beta-carbonic anhydrase, variant W39F
3E28	;	2.5	;	H. influenzae beta-carbonic anhydrase, variant Y181F
3E2A	;	2.301	;	H. influenzae beta-carbonic anhydrase, variant Y181F with 100 mM bicarbonate
3E2W	;	2.296	;	H. influenzae beta-carbonic anhydrase, variant Y181F with 1M bicarbonate
7SMK	;	1.98	;	H. neapolitanus carboxysomal rubisco/CsoSCA-peptide (1-50)complex
7SNV	;	2.07	;	H. neapolitanus carboxysomal rubisco/CsoSCA-peptide (1-50)complex
2C4V	;	2.5	;	H. pylori type II DHQase in complex with citrate
1L3Q	;		;	H. rufescens abalone shell Lustrin A consensus repeat, FPGKNVNCTSGE, pH 7.4, 1-H NMR structure
2VX9	;	1.65	;	H. salinarum dodecin E45A mutant
7QGE	;	2.27	;	H. SAPIENS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 5,6,7,8-TETRABROMOBENZOTRIAZOLE (TBBt) AT PH 8.5
7QGC	;	2.55	;	H. SAPIENS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 5,6-DIBROMOBENZOTRIAZOLE AT PH 5.5
7QGB	;	2.58	;	H. SAPIENS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 5,6-DIBROMOBENZOTRIAZOLE AT PH 6.5
7QGD	;	2.3	;	H. SAPIENS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 5,6-DIBROMOBENZOTRIAZOLE AT PH 8.5
7PLO	;	2.8	;	H. sapiens replisome-CUL2/LRR1 complex
4MCB	;	1.94	;	H.influenzae TrmD in complex with N-(4-{[(1H-IMIDAZOL-2-YLMETHYL)AMINO]METHYL}BENZYL)-4-OXO-3,4-DIHYDROTHIENO[2,3-D]PYRIMIDINE-5-CARBOXAMIDE
5G4Q	;	2.3	;	H.pylori Beta clamp in complex with 5-chloroisatin
5G48	;	2.28	;	H.pylori Beta clamp in complex with Diflunisal
2C57	;	3.1	;	H.pylori type II dehydroquinase in complex with FA1
2X98	;	1.7	;	H.SALINARUM ALKALINE PHOSPHATASE
6K8G	;	2.0	;	H/D exchanged Hen egg-white lysozyme
6K8G	;	2.0	;	H/D exchanged Hen egg-white lysozyme
7FG8	;	2.0	;	H/D exchanged Hen egg-white lysozyme denatured in acidic conditions and refolded in solution
7FG8	;	2.0	;	H/D exchanged Hen egg-white lysozyme denatured in acidic conditions and refolded in solution
7FGU	;	2.3	;	H/D exchanged Hen egg-white lysozyme denatured in basic conditions and refolded in solution
7FGU	;	2.0	;	H/D exchanged Hen egg-white lysozyme denatured in basic conditions and refolded in solution
7FGV	;	2.0	;	H/D exchanged Hen egg-white lysozyme denatured in heat condition and refolded in solution
7FGV	;	2.0	;	H/D exchanged Hen egg-white lysozyme denatured in heat condition and refolded in solution
4Y0J	;	2.0	;	H/D exchanged human carbonic anhydrase II pH 6 room temperature neutron crystal structure.
7ACY	;	2.55	;	H/L (SLPH/SLPL) complex from C. difficile (CD630 strain)
7ACX	;	2.65	;	H/L (SLPH/SLPL) complex from C. difficile (R7404 strain)
8TPA	;	3.0	;	H1 hemagglutinin (NC99) in complex with medial-junction-targeting Fab 2-2-1G06
8TP5	;	2.9	;	H1 hemagglutinin (NC99) in complex with RBS-targeting Fab 1-1-1E04
8TP3	;	3.6	;	H1 hemagglutinin (NC99) in complex with RBS-targeting Fab 1-1-1F05
7UMM	;	3.36	;	H1 Solomon Islands 2006 hemagglutinin in complex with Ab109
7UMN	;	3.6	;	H1 Solomon Islands 2006 hemagglutinin in complex with Ab36
8AAG	;	10.0	;	H1-bound palindromic nucleosome, state 1
7KBF	;	4.42	;	H1.8 bound nucleosome isolated from metaphase chromosome in Xenopus egg extract (oligo fraction)
7E9D	;	1.89	;	H102A mutant of IRG1 from bacillus
8IIF	;	1.65	;	H109A mutant of uracil DNA glycosylase X
8IIH	;	2.13	;	H109C mutant of uracil DNA glycosylase X
8IIJ	;	1.83	;	H109G mutant of uracil DNA glycosylase X
8IIM	;	1.6	;	H109K mutant of uracil DNA glycosylase X
8IIO	;	1.67	;	H109Q mutant of uracil DNA glycosylase X
6AJS	;	1.632	;	H109S mutant form of Uracil DNA glycosylase X.
6YZ5	;	1.8	;	H11-D4 complex with SARS-CoV-2 RBD
6YZ7	;	3.3	;	H11-D4, SARS-CoV-2 RBD, CR3022 ternary complex
6Z2M	;	2.71	;	H11-D4, SARS-CoV-2 RBD, CR3022 ternary complex
6ZHD	;	3.7	;	H11-H4 bound to Spike
6ZBP	;	1.85	;	H11-H4 complex with SARS-CoV-2
1C9X	;	1.8	;	H119A VARIANT OF RIBONUCLEASE A
1H9N	;	1.85	;	H119N CARBONIC ANHYDRASE II
1H9Q	;	2.2	;	H119Q CARBONIC ANHYDRASE II
1C9V	;	1.7	;	H12A VARIANT OF RIBONUCLEASE A
1TS3	;	2.0	;	H135A MUTANT OF TOXIC SHOCK SYNDROME TOXIN-1 FROM S. AUREUS
1TBJ	;	2.8	;	H141A mutant of rat liver arginase I
1TA1	;	2.5	;	H141C mutant of rat liver arginase I
1TBH	;	2.7	;	H141D mutant of rat liver arginase I
1TBL	;	3.1	;	H141N mutant of rat liver arginase I
3AHH	;	2.1	;	H142A mutant of Phosphoketolase from Bifidobacterium Breve complexed with acetyl thiamine diphosphate
1GN4	;	2.5	;	H145E mutant of Mycobacterium tuberculosis iron-superoxide dismutase.
1GN3	;	4.0	;	H145Q mutant of Mycobacterium tuberculosis iron-superoxide dismutase.
5BXZ	;	2.6	;	H17 Bat Influenza NS1 RNA Binding Domain
5BY1	;	1.751	;	H18 Bat Influenza NS1 RNA Binding Domain
3P74	;	1.2	;	H181N mutant of pentaerythritol tetranitrate reductase containing a C-terminal His8-tag
3P82	;	2.2	;	H184N mutant of pentaerythritol tetranitrate reductase containing bound acetate ion
3LGV	;	2.734	;	H198P mutant of the DegS-deltaPDZ protease
3LGW	;	2.5	;	H198P/T167V double mutant of DegS-deltaPDZ protease
6YEM	;	2.5	;	H1N1 2009 PA Endonuclease in complex with Quambalarine B
4B7J	;	2.417	;	H1N1 2009 Pandemic Influenza Virus: Resistance of the I223R Neuraminidase Mutant Explained by Kinetic and Structural Analysis
4B7M	;	2.5	;	H1N1 2009 Pandemic Influenza Virus: Resistance of the I223R Neuraminidase Mutant Explained by Kinetic and Structural Analysis
4B7N	;	2.84	;	H1N1 2009 Pandemic Influenza Virus: Resistance of the I223R Neuraminidase Mutant Explained by Kinetic and Structural Analysis
4B7Q	;	2.728	;	H1N1 2009 Pandemic Influenza Virus: Resistance of the I223R Neuraminidase Mutant Explained by Kinetic and Structural Analysis
4B7R	;	1.9	;	H1N1 2009 Pandemic Influenza Virus: Resistance of the I223R Neuraminidase Mutant Explained by Kinetic and Structural Analysis
8TP9	;	3.1	;	H2 hemagglutinin (A/Singapore/1/1957) in complex with medial-junction-targeting Fab 2-2-1G06
8TP2	;	3.1	;	H2 hemagglutinin (A/Singapore/1/1957) in complex with RBS-targeting 1-1-1F05
8TP4	;	3.3	;	H2 hemagglutinin (A/Singapore/1/1957) in complex with RBS-targeting Fab 1-1-1E04
8TP6	;	3.1	;	H2 hemagglutinin (A/Singapore/1/1957) in complex with RBS-targeting Fab 4-1-1E02
8TP7	;	2.8	;	H2 hemagglutinin (A/Singapore/1/1957) in complex with Sa-targeting Fab 4-1-1G03
6L9K	;	1.8	;	H2-Ld a1a2 complexed with A5 peptide
6L9N	;	2.6	;	H2-Ld complexed with A5 peptide
6L9M	;	2.6	;	H2-Ld complexed with AH1 peptide
3UQY	;	1.47	;	H2-reduced structure of E. coli hydrogenase-1
8BM3	;	3.5	;	H207A mutant of E. coli PgpB, a PAP2 type phosphatidyl glycerol phosphate and C55-PP phosphatase, in complex with farnesyl pyrophosphate
7L78	;	2.4	;	H235C variant of Yeast Ferrochelatase
3AQI	;	1.7	;	H240A variant of human ferrochelatase
1HSE	;	2.2	;	H253M N TERMINAL LOBE OF HUMAN LACTOFERRIN
3VXQ	;	2.0	;	H27-14 TCR specific for HLA-A24-Nef134-10
3X1F	;	1.35	;	H294M mutant of copper-containing nitrite reductase from Geobacillus thermodenitrificans
3X1G	;	1.3	;	H294M mutant of copper-containing nitrite reductase from Geobacillus thermodenitrificans showing two coordination geometries at the T2Cu site
8G6Q	;	3.41	;	H2AK119ub-modified nucleosome ubiquitin position 1
8G6S	;	3.47	;	H2AK119ub-modified nucleosome ubiquitin position 2
8G6G	;	2.93	;	H2BK120ub+H3K79me2-modified nucleosome ubiquitin position 5
8G6H	;	3.06	;	H2BK120ub+H3K79me2-modified nucleosome ubiquitin position 6
6L49	;	18.9	;	H3-CA-H3 tri-nucleosome with the 22 base-pair linker DNA
6L4A	;	12.3	;	H3-H3-H3 tri-nucleosome with the 22 base-pair linker DNA
6QZM	;	1.6	;	H30 MnSOD-3 Mutant I
6S0D	;	1.52	;	H30 MnSOD-3 Mutant II
6QZN	;	1.64	;	H30 MnSOD-3 Mutant III
2WVM	;	2.977	;	H309A mutant of Mannosyl-3-phosphoglycerate synthase from Thermus thermophilus HB27 in complex with GDP-alpha-D-Mannose and Mg(II)
3AHI	;	2.1	;	H320A mutant of Phosphoketolase from Bifidobacterium Breve complexed with acetyl thiamine diphosphate
8BDU	;	2.471	;	H33 variant of DoBi scaffold based on PIH1D1 N-terminal domain
8PEO	;	2.69	;	H3K36me2 nucleosome-LEDGF/p75 PWWP domain complex
8PEP	;	3.33	;	H3K36me2 nucleosome-LEDGF/p75 PWWP domain complex - pose 2
8PC5	;	3.02	;	H3K36me3 nucleosome-LEDGF/p75 PWWP domain complex
8PC6	;	3.04	;	H3K36me3 nucleosome-LEDGF/p75 PWWP domain complex - pose 2
8UIQ	;	2.17	;	H47Q NicC with 2-mercaptopyridine ligand
8UIV	;	1.511	;	H47Q NicC with bound FAD
1B4T	;	1.8	;	H48C YEAST CU(II)/ZN SUPEROXIDE DISMUTASE ROOM TEMPERATURE (298K) STRUCTURE
4CQW	;	2.3	;	H5 (tyTy) Del133/Ile155Thr Mutant Haemagglutinin in Complex with Avian Receptor Analogue 3'SLN
4CQY	;	2.05	;	H5 (tyTy) Del133/Ile155Thr Mutant Haemagglutinin in Complex with Avian Receptor Analogue LSTa
4CQX	;	2.3	;	H5 (tyTy) Del133/Ile155Thr Mutant Haemagglutinin in Complex with Human Receptor Analogue 6'SLN
4BH1	;	2.15	;	H5 (tyTy) Influenza Virus Haemagglutinin in Complex with Avian Receptor Analogue 3'-SLN
4BH0	;	2.36	;	H5 (tyTy) Influenza Virus Haemagglutinin in Complex with Human Receptor Analogue 6'-SLN
4CQS	;	2.55	;	H5 (VN1194) Asn186Lys Mutant Haemagglutinin in Complex with Avian Receptor Analogue 3'SLN
5AJM	;	2.45	;	H5 (VN1194) Asn186Lys Mutant Haemagglutinin in Complex with Avian Receptor Analogue 3'SLN
4CQU	;	2.48	;	H5 (VN1194) Asn186Lys Mutant Haemagglutinin in Complex with Human Receptor Analogue 6'SLN
4BGY	;	2.68	;	H5 (VN1194) Influenza Virus Haemagglutinin in Complex with Avian Receptor Analogue 3'-SLN
4BGX	;	2.48	;	H5 (VN1194) Influenza Virus Haemagglutinin in Complex with Human Receptor Analogue 6'-SLN
4CQQ	;	2.55	;	H5 (VN1194) Ser227Asn/Gln196Arg Mutant Haemagglutinin in Complex with Avian Receptor Analogue 3'SLN
4CQR	;	2.45	;	H5 (VN1194) Ser227Asn/Gln196Arg Mutant Haemagglutinin in Complex with Human Receptor Analogue 6'SLN
3ZNK	;	2.71	;	H5 Haemagglutinin in Complex with 6-O-Sulfo-2,3-Sialyllactosamine (Sulfated 3'SLN)
3ZNL	;	2.5	;	H5 Haemagglutinin in Complex with 6-O-Sulfo-Sialyl-Lewis X (Sulfated Lewis X)
3ZNM	;	2.4	;	H5 Haemagglutinin in Complex with Sialyl-Lewis X
4GSD	;	2.251	;	H5.3 Fab Structure
3AHJ	;	2.1	;	H553A mutant of Phosphoketolase from Bifidobacterium Breve
3BK9	;	2.15	;	H55A mutant of tryptophan 2,3-dioxygenase from Xanthomonas campestris
3E08	;	1.9	;	H55S mutant Xanthomonas campestris tryptophan 2,3-dioxygenase
3M4G	;	2.05	;	H57A HFQ from Pseudomonas Aeruginosa
3INZ	;	1.7	;	H57T Hfq from Pseudomonas aeruginosa
1P2E	;	2.2	;	H61A mutant of flavocytochrome c3
1P2H	;	2.1	;	H61M mutant of flavocytochrome c3
3AHG	;	1.9	;	H64A mutant of Phosphoketolase from Bifidobacterium Breve complexed with a tricyclic ring form of thiamine diphosphate
5ILM	;	1.7	;	H64A sperm whale myoglobin with a Fe-chlorophenyl moiety
5ILE	;	1.77	;	H64A sperm whale myoglobin with a Fe-tolyl moiety
8F9I	;	1.8	;	H64A swMb-EtNO adduct
8F9N	;	1.8	;	H64A swMb-iPrNO adduct
8F9H	;	1.75	;	H64A swMb-MeNO adduct
8F9J	;	1.75	;	H64A swMb-PrNO adduct
8FB0	;	1.76	;	H64Q Myoglobin in complex with acetamide
5ILR	;	1.87	;	H64Q sperm whale myoglobin with a Fe-chlorophenyl moiety
5ILP	;	1.88	;	H64Q sperm whale myoglobin with a Fe-tolyl moiety
1BJE	;	1.8	;	H64T VARIANT OF MYOGLOBIN (HORSE HEART) RECOMBINANT WILD-TYPE COMPLEXED WITH AZIDE
6MLM	;	3.5	;	H7 HA0 in complex with Fv from H7.5 IgG
1TI8	;	3.0	;	H7 Haemagglutinin
2X1J	;	1.9	;	H71A mutant of the antibiotic resistance protein NimA from Deinococcus radiodurans
2X1K	;	1.55	;	H71S mutant of the antibiotic resistance protein NimA from Deinococcus radiodurans
4BSI	;	2.62	;	H7N3 Avian Influenza Virus Haemagglutinin in Complex with Avian Receptor Analogue 3'-SLN
4BSH	;	2.25	;	H7N3 Avian Influenza Virus Haemagglutinin in Complex with Human Receptor Analogue 6'-SLN
1AUW	;	2.5	;	H91N DELTA 2 CRYSTALLIN FROM DUCK
7ZXL	;	1.2	;	H93A Mutant of Recombinant CODH-II
2H4N	;	1.9	;	H94N CARBONIC ANHYDRASE II COMPLEXED WITH ACETAZOLAMIDE
1H4N	;	2.0	;	H94N CARBONIC ANHYDRASE II COMPLEXED WITH TRIS
7ZXC	;	1.696	;	H96D Mutant of Recombinant CODH-II
1S89	;	2.22	;	H98N Mutant of Methylglyoxal Synthase from E. coli complexed with Phosphoglycolic Acid
1S8A	;	2.2	;	H98Q Mutant of Methylglyoxal Synthase from E. coli complexed with Phosphoglycolic Acid
2O6M	;	2.3	;	H98Q mutant of the homing endonuclease I-PPOI complexed with DNA
3AJ6	;	1.48	;	HA1 (HA33) mutant F179I of botulinum type C progenitor toxin complexed with N-acetylgalactosamine, bound at site II
3AJ5	;	1.8	;	HA1 (HA33) subcomponent of botulinum type C progenitor toxin complexed with N-acetylgalactosamine, bound at site II
3AH4	;	1.78	;	HA1 subcomponent of botulinum type C progenitor toxin complexed with galactose
3AH2	;	1.7	;	HA1 subcomponent of botulinum type C progenitor toxin complexed with N-acetylgalactosamine
3AH1	;	2.2	;	HA1 subcomponent of botulinum type C progenitor toxin complexed with N-acetylneuramic acid
6EH8	;	2.51	;	HA1.7 Human T-Cell Receptor specific for Influenza virus epitope PKYVKQNTLKLAT presented by Human Leukocyte Antigen HLA-DR0101
6EH9	;	2.49	;	HA1.7 Human T-Cell Receptor specific for Influenza virus epitope PKYVKQNTLKLAT presented by Human Leukocyte Antigen HLA-DR0101
6FR6	;	2.98	;	HA1.7 Human T-Cell Receptor specific for Influenza virus epitope PKYVKQNTLKLAT presented by Human Leukocyte Antigen HLA-DR0101
6FR7	;	2.31	;	HA1.7 Human T-Cell Receptor specific for Influenza virus epitope PKYVKQNTLKLAT presented by Human Leukocyte Antigen HLA-DR0101
6FR8	;	2.38	;	HA1.7 Human T-Cell Receptor specific for Influenza virus epitope PKYVKQNTLKLAT presented by Human Leukocyte Antigen HLA-DR0101
6FR5	;	1.37	;	HA1.7 TCR Study of CDR Loop Flexibility
4GKZ	;	2.39	;	HA1.7, a MHC class II restricted TCR specific for haemagglutinin
4LO1	;	2.254	;	HA17-HA33-Gal
4LO2	;	2.254	;	HA17-HA33-Lac
4LO3	;	2.249	;	HA17-HA33-LacNac
2ZS6	;	2.6	;	HA3 subcomponent of botulinum type C progenitor toxin
2ZOE	;	2.6	;	HA3 subcomponent of Clostridium botulinum type C progenitor toxin, complex with N-acetylneuramic acid
4LO8	;	2.4	;	HA70(D3)-HA17
4LO7	;	3.73	;	HA70(D3)-HA17-HA33
4LO5	;	2.7	;	HA70-alpha2,3-SiaLC
4LO6	;	2.3	;	HA70-alpha2,6-SiaLC
8Q0N	;	4.2	;	HACE1 in complex with RAC1 Q61L
1YMQ	;	1.9	;	HAD Superfamily Phosphotransferase Substrate Diversification: Structure and Function Analysis of the HAD Subclass IIB Sugar Phosphatase BT4131
7AGG	;	3.3	;	HAd7 knob in complex with 2 EC2-EC3 modules of DSG-2
7AGF	;	3.1	;	HAd7 knob in complex with 3 EC2-EC3 modules of DSG-2
2LBU	;		;	HADDOCK calculated model of Congo red bound to the HET-s amyloid
2MUS	;		;	HADDOCK calculated model of LIN5001 bound to the HET-s amyloid
2K7F	;		;	HADDOCK calculated model of the complex between the BRCT region of RFC p140 and dsDNA
2L65	;		;	HADDOCK calculated model of the complex of the resistance protein CalC and Calicheamicin-Gamma
2MTZ	;		;	Haddock model of Bacillus subtilis L,D-transpeptidase in complex with a peptidoglycan hexamuropeptide
2N0S	;		;	HADDOCK model of ferredoxin and [FeFe] hydrogenase complex
2L6Y	;		;	haddock model of GATA1NF:Lmo2LIM2-Ldb1LID
2L6Z	;		;	haddock model of GATA1NF:Lmo2LIM2-Ldb1LID with FOG
5Y95	;		;	Haddock model of mSIN3B PAH1 domain
2MF8	;		;	HADDOCK model of MyT1 F4F5 - DNA complex
6TT8	;		;	Haddock model of NDM-1/morin complex
6TTC	;		;	Haddock model of NDM-1/myricetin complex
6TTA	;		;	Haddock model of NDM-1/quercetin complex
2FYL	;		;	Haddock model of the complex between double module of LRP, CR56, and first domain of receptor associated protein, RAP-d1.
2LJY	;		;	Haddock model structure of the N-terminal domain dimer of HPV16 E6
2HV1	;		;	HADDOCK structure of ARNT PAS-B Homodimer
2M1C	;		;	HADDOCK structure of GtYybT PAS Homodimer
2A24	;		;	HADDOCK Structure of HIF-2a/ARNT PAS-B Heterodimer
2LL4	;		;	HADDOCK structure of TgMIC4-A5/lacto-N-biose complex, based on NOE-derived distance restraints
6CW4	;		;	HADDOCK structure of the Rous sarcoma virus matrix protein (M-domain) in complex with inositol 1,3,5-trisphosphate
6CV8	;		;	HADDOCK structure of the Rous sarcoma virus matrix protein (M-domain) in complex with inositol 1,4,5-trisphosphate
6CUS	;		;	HADDOCK structure of the Rous sarcoma virus matrix protein (M-domain) in complex with myo-inositol hexakisphosphate
2KGX	;		;	HADDOCK structure of the talin F3 domain in complex with talin 1655-1822
2K3S	;		;	HADDOCK-derived structure of the CH-domain of the smoothelin-like 1 complexed with the C-domain of apocalmodulin
6NZX	;	1.9	;	Hadesarchaea YNP_N21 cytochrome b5 domain protein (KUO41884.1)
6YBA	;	4.0	;	HAdV-F41 Capsid
6MNJ	;	2.2	;	Hadza microbial sialidase Hz136
4BH4	;	1.9	;	Haemagglutinin from a Transmissible Mutant H5 Influenza Virus in Complex with Avian Receptor Analogue 3'-SLN
4BH3	;	2.0	;	Haemagglutinin from a Transmissible Mutant H5 Influenza Virus in Complex with Human Receptor Analogue 6'-SLN
2YPG	;	2.85	;	Haemagglutinin of 1968 Human H3N2 Virus in Complex with Human Receptor Analogue LSTc
2YP2	;	1.9	;	Haemagglutinin of 2004 Human H3N2 Virus
2YP5	;	1.79	;	Haemagglutinin of 2004 Human H3N2 Virus in Complex with Avian Receptor Analogue 3SLN
2YP3	;	1.88	;	Haemagglutinin of 2004 Human H3N2 Virus in Complex with Human Receptor Analogue 6SLN
2YP4	;	1.85	;	Haemagglutinin of 2004 Human H3N2 Virus in Complex with Human Receptor Analogue LSTc
2YP7	;	1.85	;	Haemagglutinin of 2005 Human H3N2 Virus
2YP9	;	1.79	;	Haemagglutinin of 2005 Human H3N2 Virus in Complex with Avian Receptor Analogue 3SLN
2YP8	;	1.8	;	Haemagglutinin of 2005 Human H3N2 Virus in Complex with Human Receptor Analogue 6SLN
4D00	;	2.5	;	Haemagglutinin of H10N8 Influenza Virus Isolated from Humans in Complex with Human Receptor Analogue 6'SLN
1PBX	;	2.5	;	HAEMOGLOBIN OF THE ANTARCTIC FISH PAGOTHENIA BERNACCHII: AMINO ACID SEQUENCE, OXYGEN EQUILIBRIA AND CRYSTAL STRUCTURE OF ITS CARBONMONOXY DERIVATIVE
4KRI	;	1.72	;	Haemonchus contortus Phospholethanolamine N-methyltransferase 2 in complex with phosphomonomethylethanolamine and S-adenosylhomocysteine
6ROW	;	4.5	;	Haemonchus galactose containing glycoprotein complex
2A8C	;	2.3	;	Haemophilus influenzae beta-carbonic anhydrase
2A8D	;	2.2	;	Haemophilus influenzae beta-carbonic anhydrase complexed with bicarbonate
3OD7	;	1.801	;	Haemophilus influenzae ferric binding protein A -Iron Loaded
3ODB	;	1.62	;	Haemophilus influenzae ferric binding protein A -Iron Loaded -open Conformation
1D9V	;	1.75	;	HAEMOPHILUS INFLUENZAE FERRIC-BINDING PROTEIN APO FORM
5VAT	;	2.6	;	Haemophilus influenzae LpoA: Monoclinic form (Mon2) with 2 molecules per a.u.
3SWE	;	2.2	;	Haemophilus influenzae MurA in complex with UDP-N-acetylmuramic acid and covalent adduct of PEP with Cys117
8GLO	;	1.937	;	Haemophilus parainfluenzae Holo HphA
4ARS	;	1.9	;	Hafnia Alvei phytase apo form
4ARO	;	1.59	;	Hafnia Alvei phytase in complex with myo-inositol hexakis sulphate
4ARU	;	1.45	;	Hafnia Alvei phytase in complex with tartrate
1IT3	;	2.1	;	Hagfish CO ligand hemoglobin
1IT2	;	1.6	;	Hagfish deoxy hemoglobin
8BM4	;		;	Hairpin adopted by modified oligonucleotide A32_mod found in the promoter of AUTS2 gene.
8BM6	;		;	Hairpin adopted by oligonucleotide A36 found in the promoter of AUTS2 gene
8BM7	;		;	Hairpin adopted by oligonucleotide A38 found in the promoter of AUTS2 gene.
5ZE2	;	3.3	;	Hairpin Complex, RAG1/2-hairpin 12RSS/23RSS complex in 5mM Mn2+ for 2 min at 4'C
5ZE1	;	3.0	;	Hairpin Forming Complex, RAG1/2-Nicked 12RSS/23RSS complex in 2mM Mn2+ for 10 min at 4'C
5ZDZ	;	2.8	;	Hairpin Forming Complex, RAG1/2-Nicked 12RSS/23RSS complex in Ca2+
5ZE0	;	2.75	;	Hairpin Forming Complex, RAG1/2-Nicked(with Dideoxy) 12RSS/23RSS complex in Mg2+
2HGF	;		;	HAIRPIN LOOP CONTAINING DOMAIN OF HEPATOCYTE GROWTH FACTOR, NMR, MINIMIZED AVERAGE STRUCTURE
1BJH	;		;	HAIRPIN LOOPS CONSISTING OF SINGLE ADENINE RESIDUES CLOSED BY SHEARED A(DOT)A AND G(DOT)G PAIRS FORMED BY THE DNA TRIPLETS AAA AND GAG: SOLUTION STRUCTURE OF THE D(GTACAAAGTAC) HAIRPIN, NMR, 16 STRUCTURES
7RQ5	;		;	Hairpin near 3'-Splice Site of Influenza A Segment 7 Bound to 5-nt Oligonucleotide
1JBF	;		;	Hairpin Peptide that Inhibits IgE Activity by Binding to the High Affinity IgE Receptor
4DKZ	;	1.8	;	Hairpin structure of a DNA dodecamer containing North-methanocarba-2'-deoxythymidine
1ATV	;		;	HAIRPIN WITH AGAA TETRALOOP, NMR, 4 STRUCTURES
1ATW	;		;	HAIRPIN WITH AGAU TETRALOOP, NMR, 3 STRUCTURES
7YZP	;	4.0	;	Hairpin-bound state of the E. coli Mre11-Rad50 (SbcCD) head complex bound to ADP and a DNA hairpin
1HVW	;		;	HAIRPINLESS MUTANT OF OMEGA-ATRACOTOXIN-HV1A
5C0I	;	1.53	;	HAL-A02 carrying RQFGPDFPTI
7U6I	;	2.05	;	HalB with glycine and succinate
7U6J	;	1.9	;	HalB with lysine and succinate
7U6H	;	2.0	;	HalD with ornithine and alpha-ketoglutarate
7MIB	;	5.8	;	Half integration complex of Cas4/Cas1/Cas2 with Cas4 still on the Non-PAM side
1T3P	;	1.6	;	Half-sandwich arene ruthenium(II)-enzyme complex
7PKY	;	7.9	;	Half-vault structure
7JY4	;	2.42	;	hALK in complex with ((1S,2S)-1-(2,4-difluorophenyl)-2-(2-(3-methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenoxy)cyclopropyl)methanamine
7JYR	;	2.32	;	hALK in complex with 1-[(1R,2R)-1-(2,4-difluorophenyl)-2-[2-(5-methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)phenoxy]cyclopropyl]methanamine
7JYS	;	2.22	;	hALK in complex with 3-(3-chlorophenyl)-5-methyl-1H-pyrazole
7JYT	;	2.0	;	hALK in complex with 3-(3-methyl-1H-pyrazol-5-yl)pyridine
6EDL	;	2.799	;	hALK in complex with compound 1 (S)-N-(1-(2,4-difluorophenyl)ethyl)-3-(3-methyl-1H-pyrazol-5-yl)imidazo[1,2-b]pyridazin-6-amine
6E0R	;	2.303	;	hALK in complex with compound 7 N-((1S)-1-(5-fluoropyridin-2-yl)ethyl)-1-(5-methyl-1H-pyrazol-3-yl)-3-(oxetan-3-ylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-6-amine
6EBW	;	2.455	;	hALK in complex with compound 9 (6-(((1S)-1-(5-Fluoropyridin-2-yl)ethyl)amino)-1-(3-methyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)(morpholin-4-yl)methanone
4AXN	;	1.68	;	Hallmarks of processive and non-processive glycoside hydrolases revealed from computational and crystallographic studies of the Serratia marcescens chitinases
8D04	;	2.11	;	Hallucinated C2 protein assembly HALC2_062
8D05	;	2.51	;	Hallucinated C2 protein assembly HALC2_065
8D03	;	1.75	;	Hallucinated C2 protein assembly HALC2_068
8D06	;	3.4	;	Hallucinated C3 protein assembly HALC3_104
8D07	;	2.09	;	Hallucinated C3 protein assembly HALC3_109
8D08	;	3.3	;	Hallucinated C4 protein assembly HALC4_135
8D09	;	1.9	;	Hallucinated C4 protein assembly HALC4_136
4BRZ	;	1.67	;	Haloalkane dehalogenase
1BE0	;	1.96	;	HALOALKANE DEHALOGENASE AT PH 5.0 CONTAINING ACETIC ACID
1B6G	;	1.15	;	HALOALKANE DEHALOGENASE AT PH 5.0 CONTAINING CHLORIDE
4WCV	;	1.69	;	Haloalkane dehalogenase DhaA mutant from Rhodococcus rhodochrous (T148L+G171Q+A172V+C176G)
4MJ3	;	1.7	;	Haloalkane dehalogenase DmrA from Mycobacterium rhodesiae JS60
5MXP	;	1.45	;	Haloalkane dehalogenase DmxA from Marinobacter sp. ELB17 possessing a unique catalytic residue
3QNM	;	1.7	;	Haloalkane Dehalogenase Family Member from Bacteroides thetaiotaomicron of Unknown Function
1BN6	;	1.5	;	HALOALKANE DEHALOGENASE FROM A RHODOCOCCUS SPECIES
1BN7	;	1.5	;	HALOALKANE DEHALOGENASE FROM A RHODOCOCCUS SPECIES
1HDE	;	2.7	;	HALOALKANE DEHALOGENASE MUTANT WITH PHE 172 REPLACED WITH TRP
1BEE	;	2.6	;	HALOALKANE DEHALOGENASE MUTANT WITH TRP 175 REPLACED BY TYR
1BEZ	;	2.1	;	HALOALKANE DEHALOGENASE MUTANT WITH TRP 175 REPLACED BY TYR AT PH 5
1CIJ	;	2.3	;	HALOALKANE DEHALOGENASE SOAKED WITH HIGH CONCENTRATION OF BROMIDE
4C6H	;	1.61	;	Haloalkane dehalogenase with 1-hexanol
3U1T	;	2.2	;	Haloalkane Dehalogenase, DmmA, of marine microbial origin
2VWQ	;	2.1	;	Haloferax mediterranei glucose dehydrogenase in complex with NADP and Zn.
2VWG	;	2.0	;	Haloferax mediterranei glucose dehydrogenase in complex with NADP, Zn and gluconolactone.
2VWH	;	2.03	;	Haloferax mediterranei glucose dehydrogenase in complex with NADP, Zn and glucose.
2VWP	;	2.01	;	Haloferax mediterranei glucose dehydrogenase in complex with NADPH and Zn.
5TAO	;	2.1	;	Haloferax volcanii Malate Synthase Lead(II) complex
3OYX	;	2.51	;	Haloferax volcanii Malate Synthase Magnesium/Glyoxylate Complex
3PUG	;	2.7	;	Haloferax volcanii Malate Synthase Native at 3mM Glyoxylate
3OYZ	;	1.95	;	Haloferax volcanii Malate Synthase Pyruvate/Acetyl-CoA Ternary Complex
3NNJ	;	2.601	;	Halogenase domain from CurA module (apo Hal)
3NNL	;	2.883	;	Halogenase domain from CurA module (crystal form III)
3NNM	;	2.69	;	Halogenase domain from CurA module (crystal form IV)
3NNF	;	2.201	;	Halogenase domain from CurA module with Fe, chloride, and alpha-ketoglutarate
8AGP	;	1.49	;	Halogenated product of limonene epoxide turnover by epoxide hydrolase from metagenomic source ch65
4IXW	;	2.47	;	Halohydrin dehalogenase (HheC) bound to ethyl (2S)-oxiran-2-ylacetate
4Z9F	;	1.75	;	Halohydrin hydrogen-halide-lyase, HheA
4ZD6	;	1.6	;	Halohydrin hydrogen-halide-lyase, HheB
4ZU3	;	2.2	;	Halohydrin hydrogen-halide-lyases, HheB
6LUQ	;	3.1	;	Haloperidol bound D2 dopamine receptor structure inspired discovery of subtype selective ligands
8Q90	;	2.0	;	Halophilic Lrp transcription factor
5AHY	;	2.15	;	Halorhodopsin from Halobacterium salinarum in a new rhombohedral crystal form
1E12	;	1.8	;	Halorhodopsin, a light-driven chloride pump
7OND	;	1.45	;	HaloTag Engineering for Enhanced Fluorogenicity and Kinetics with a Styrylpyridine Dye
7OO4	;	2.1	;	HaloTag Engineering for Enhanced Fluorogenicity and Kinetics with a Styrylpyridine Dye
7ZBA	;	1.23	;	HaloTag with Me-TRaQ-G ligand
7ZBD	;	1.68	;	HaloTag with TRaQ-G ligand
7ZBB	;	1.95	;	HaloTag with TRaQ-G-ctrl ligand
2KUH	;		;	Halothane binds to druggable sites in calcium-calmodulin: Solution structure of halothane-CaM C-terminal domain
2KUG	;		;	Halothane binds to druggable sites in calcium-calmodulin: Solution Structure of halothane-CaM N-terminal domain
4PTW	;	2.0	;	Halothermothrix orenii beta-glucosidase A, 2-deoxy-2-fluoro-glucose complex
4PTX	;	1.8	;	Halothermothrix orenii beta-glucosidase A, glucose complex
4PTV	;	1.85	;	Halothermothrix orenii beta-glucosidase A, thiocellobiose complex
6QPA	;	2.1	;	Halothiobacillus neapolitanus sulfur oxygenase reductase
2QUW	;	2.2	;	Hammerhead Ribozyme G12A mutant after cleavage
2QUS	;	2.4	;	Hammerhead Ribozyme G12A mutant pre-cleavage
1Q29	;	3.0	;	Hammerhead Ribozyme with 5'-5' G-G linkage: Conformational change experiment
2RDL	;	2.5	;	Hamster Chymase 2
1D2D	;		;	Hamster EprS second repeated element. NMR, 5 structures
6E14	;	4.0	;	Handover mechanism of the growing pilus by the bacterial outer membrane usher FimD
6E15	;	5.1	;	Handover mechanism of the growing pilus by the bacterial outer membrane usher FimD
3SXX	;	1.27	;	Hansenula polymorpha copper amine oxidase-1 in complex with Co(II)
3T0U	;	1.9	;	Hansenula polymorpha copper amine oxidase-1 in complex with Cu(I)
3SX1	;	1.73	;	Hansenula polymorpha copper amine oxidase-1 in its apo form
7NRH	;	19.0	;	Hantaan virus glycoprotein (Gn) in complex with Fab fragment HTN-Gn1.
7O9S	;	2.7	;	Hantaan virus Gn in complex with Fab nnHTN-Gn2
5IZE	;	1.7	;	Hantaan virus L protein cap-snatching endonuclease
8C4T	;	3.23	;	Hantaan virus polymerase bound to its 5' viral RNA
8QHD	;	3.6	;	Hantaan virus polymerase in hexameric state
8C4V	;	3.14	;	Hantaan virus polymerase in replication elongation state
8C4U	;	3.36	;	Hantaan virus polymerase in replication pre-initiation state
7S0K	;	2.3	;	HAP2 from Cyanidioschyzon merolae
5Y7C	;	2.003	;	Hapalindole A and DMSPP Bound AmbP3
5Y84	;	2.0	;	Hapalindole U and DMSPP Bound AmbP3
6M3B	;	2.2	;	hAPC-c25k23 Fab complex
6M3C	;	3.7	;	hAPC-h1573 Fab complex
6Y39	;	2.3	;	HapE-P88L mutant CCAAT-binding complex from Aspergillus nidulans with cycA DNA
7XY0	;	2.43	;	HapR Double mutant Y76F, F171C
7XXS	;	2.25	;	HapR mutant I141V
7XXO	;	2.487	;	HapR Native in CHES buffer pH 9.5
7XYI	;	2.47	;	HapR Quadruple mutant Y76F, L97I, I141V, F171C
7XXT	;	2.501	;	HapR Quadruple mutant, bound to IMTVC-212
7XXN	;	2.45	;	HapR Quadruple mutant, bound to Qstatin
7XY5	;	2.37	;	HapR_Double Mutant with CHES buffer
7Y4J	;	2.69	;	HapR_Triple mutant Y76F, L97I, F171C
6L6I	;	3.24	;	hASIC1a co-crystallized with Mamb-1
6L6N	;	2.86	;	hASIC1a co-crystallized with Nafamostat
6L6P	;	3.08	;	hASIC2a co-crystallized with Mamb-1
1YGH	;	1.9	;	HAT DOMAIN OF GCN5 FROM SACCHAROMYCES CEREVISIAE
6JQ6	;	2.626	;	Hatchet Ribozyme Structure soaking with Ir(NH3)6+
5A97	;	2.7	;	Hazara virus nucleocapsid protain
8C3Y	;	3.8	;	HB3VAR03 apo headstructure (PfEMP1 A)
8C44	;	3.2	;	HB3VAR03 apo headstructure (PfEMP1 A) complexed with EPCR
2NP2	;	3.02	;	Hbb-DNA complex
7PZI	;	2.9	;	HBc-F97L (premature secretion phenotype) in complex with Triton X-100
7PZ9	;	2.8	;	HBc-F97L premature secretion phenotype
7PZL	;	2.8	;	HBc-F97L premature secretion phenotype
7PZM	;	2.9	;	HBc-P5T in complex with X-100
7PZK	;	3.1	;	HBc-WT in complex with Triton X-100
8D1I	;	1.82	;	hBest1 1uM Ca2+ (Ca2+-bound) closed state
8D1J	;	2.05	;	hBest1 5mM Ca2+ (Ca2+-bound) closed state
8D1L	;	2.12	;	hBest1 Ca2+-bound partially open aperture state
8D1K	;	2.28	;	hBest1 Ca2+-bound partially open neck state
8D1M	;	3.11	;	hBest1 Ca2+-unbound closed state
8D1O	;	2.44	;	hBest1_345 Ca2+-bound open state
8D1E	;	1.78	;	hBest2 1uM Ca2+ (Ca2+-bound) closed state
8D1F	;	1.82	;	hBest2 5mM Ca2+ (Ca2+-bound) closed state
8D1G	;	2.07	;	hBest2 Ca2+-bound open state
8D1H	;	1.94	;	hBest2 Ca2+-unbound closed state
3UGY	;	2.1	;	HBI (F80Y) CO bound
3UHN	;	2.0	;	HBI (F80Y) deoxy
2AUQ	;	1.8	;	HbI (F97V) CO bound
3UHI	;	2.5	;	HBI (K96R) CO bound
3UHK	;	2.0	;	HBI (K96R) without ligand bound
3UGZ	;	1.65	;	HBI (L36A) CO bound
3UHQ	;	1.95	;	HBI (L36A) deoxy
3UH5	;	2.1	;	HBI (L36F) CO bound
3UHR	;	1.9	;	HBI (L36F) deoxy
3UHG	;	1.8	;	HBI (L36M) CO bound
3UHS	;	2.1	;	HBI (L36M) deoxy
3UH3	;	1.8	;	HBI (L36V) CO bound
3UHT	;	2.0	;	HBI (L36V) deoxy
3UHH	;	1.5	;	HBI (M37A) CO bound
3UHU	;	2.1	;	HBI (M37A) deoxy
3UHE	;	2.6	;	HBI (M37V,L73I) CO bound
3UHV	;	1.75	;	HBI (M37V,L73I) deoxy
3UHD	;	1.6	;	HBI (N100A) CO bound
3UHX	;	1.7	;	HBI (N100A) deoxy
3UHC	;	1.6	;	HBI (N79A) CO bound
3UHW	;	2.05	;	HBI (N79A) deoxy
3UHB	;	1.6	;	HBI (R104K) CO bound
3UHY	;	2.2	;	HBI (R104K) deoxy
3UH6	;	2.25	;	HBI (T72A) CO bound
3UHZ	;	2.0	;	HBI (T72A) deoxy
3UH7	;	1.8	;	HBI (T72G) CO bound
3UI0	;	1.8	;	HBI (T72G) deoxy
6MAJ	;	2.139	;	HBO1 is required for the maintenance of leukaemia stem cells
6MAK	;	2.13	;	HBO1 is required for the maintenance of leukaemia stem cells
5Y1A	;	1.8	;	HBP35 of Porphyromonas gingivalis
7S76	;	2.5	;	HBV CAPSID Y132A WITH COMPOUND 10b AT 2.5A RESOLUTION
6W0K	;	4.6	;	HBV D78S mutant capsid
7ABL	;	3.2	;	HBV pgRNA T=4 NCP icosahedral symmetry
6UI6	;	3.53	;	HBV T=3 149C3A
6UI7	;	3.65	;	HBV T=4 149C3A
6VZP	;	3.6	;	HBV wild type capsid
6DMX	;	2.8	;	HBZ56 in complex with KIX and c-Myb
6DNQ	;	2.35	;	HBZ77 in complex with KIX and c-Myb
1NB4	;	2.0	;	HC-J4 RNA polymerase apo-form
1NB7	;	2.9	;	HC-J4 RNA polymerase complexed with short RNA template strand
1NB6	;	2.6	;	HC-J4 RNA polymerase complexed with UTP
6WLO	;	11.0	;	hc16 ligase models, 11.0 Angstrom resolution
6WLN	;	10.0	;	hc16 ligase product models, 10.0 Angstrom resolution
3UYN	;	2.6	;	HCA 3
3UYQ	;	1.7	;	HCA 3
4DZ7	;	1.491	;	hCA II in complex with novel sulfonamide inhibitors Set D
4DZ9	;	1.491	;	hCA II in complex with novel sulfonamide inhibitors Set D
3R17	;	1.7	;	hCarbonic anhydrase II bound to N-(2-fluoro.4-sulfamoylphenyl)-2-(thiophen-2-yl) acetamide
8IFU	;	2.37	;	HcCCR in NaCl
6EDC	;	2.712	;	hcGAS-16bp dsDNA complex
3WB1	;	2.4	;	HcgB from Methanocaldococcus jannaschii
3WB0	;	1.91	;	HcgB from Methanocaldococcus jannaschii in complex with light-decomposed FeGP cofactor of [Fe]-hydrogenase
3WB2	;	2.44	;	HcgB from Methanocaldococcus jannaschii in complex with the guanylyl-pyridinol product in a model reaction of [Fe]-hydrogenase cofactor biosynthesis
5D5Q	;	2.5	;	HcgB from Methanocaldococcus jannaschii with the pyridinol derived from FeGP cofactor of [Fe]-hydrogenase
5D5P	;	1.7	;	HcgB from Methanococcus maripaludis
5D5O	;	2.7	;	HcgC from Methanocaldococcus jannaschii
5O4J	;	1.7	;	HcgC from Methanococcus maripaludis cocrystallized with SAH and pyridinol
5O4H	;	1.75	;	HcgC from Methanococcus maripaludis cocrystallized with SAM and pyridinol
5D4V	;	1.6	;	HcgC with SAH and a guanylylpyridinol (GP) derivative
3WV7	;	1.6	;	HcgE from Methanothermobacter marburgensis
3WVB	;	1.7	;	HcgF from Methanocaldococcus jannaschii
2HK5	;	2.0	;	Hck Kinase in Complex with Lck targetted Inhibitor PG-1009247
8QXX	;	1.9	;	HCMV DNA polymerase processivity factor UL44 phosphorylated NLS 410-433 bound to mouse importin alpha 2
8QXW	;	2.0	;	HCMV DNA polymerase processivity factor UL44 unphosphorylated NLS 410-433 bound to mouse importin alpha 2
5IXA	;	2.684	;	HCMV DNA polymerase processivity subunit UL44 at neutral pH and low salt
5IWD	;	2.56	;	HCMV DNA polymerase subunit UL44 complex with a small molecule
8TEA	;	3.4	;	HCMV Pentamer in complex with CS2pt1p2_A10L Fab and CS3pt1p4_C1L Fab
7KDD	;	3.5	;	HCMV postfusion gB in complex with SM5-1 Fab
7KDP	;	3.6	;	HCMV prefusion gB in complex with fusion inhibitor WAY-174865
1JQ7	;	3.0	;	HCMV protease dimer-interface mutant, S225Y complexed to Inhibitor BILC 408
2WPO	;	2.7	;	HCMV protease inhibitor complex
8TCO	;	2.8	;	HCMV Trimer in complex with CS2it1p2_F7K Fab and CS4tt1p1_E3K Fab
8FU4	;	1.6	;	HCMV US11 peptide binding to HLA-A*02:01
5KHK	;	2.07	;	HCN2 CNBD in complex with 2-aminopurine riboside-3', 5'-cyclic monophosphate (2-NH2-cPuMP)
5KHG	;	2.241	;	HCN2 CNBD in complex with cytidine-3', 5'-cyclic monophosphate (cCMP)
5KHH	;	1.77	;	HCN2 CNBD in complex with inosine-3', 5'-cyclic monophosphate (cIMP)
5KHI	;	2.1	;	HCN2 CNBD in complex with purine riboside-3', 5'-cyclic monophosphate (cPuMP)
5KHJ	;	2.01	;	HCN2 CNBD in complex with uridine-3', 5'-cyclic monophosphate (cUMP)
3BPZ	;	1.65	;	HCN2-I 443-460 E502K in the presence of cAMP
3FFQ	;	2.4	;	HCN2I 443-640 apo-state
1Q43	;	2.0	;	HCN2I 443-640 in the presence of cAMP, selenomethionine derivative
1Q5O	;	2.3	;	HCN2J 443-645 in the presence of cAMP, selenomethionine derivative
1Q3E	;	1.9	;	HCN2J 443-645 in the presence of cGMP
4KL1	;	2.7	;	HCN4 CNBD in complex with cGMP
3EWQ	;	2.1	;	HCov-229E Nsp3 ADRP domain
6U7E	;	3.0	;	HCoV-229E RBD Class III in complex with human APN
6U7F	;	2.75	;	HCoV-229E RBD Class IV in complex with human APN
6U7G	;	2.35	;	HCoV-229E RBD Class V in complex with human APN
4W64	;	1.55	;	Hcp1 protein from Acinetobacter baumannii AB0057
2A4R	;	2.4	;	HCV NS3 Protease Domain with a Ketoamide Inhibitor Covalently bound.
3KN2	;	2.3	;	HCV NS3 Protease Domain with ketoamide inhibitor
2F9U	;	2.6	;	HCV NS3 protease domain with NS4a peptide and a ketoamide inhibitor with a P2 norborane
2F9V	;	2.6	;	HCV NS3 protease domain with NS4a peptide and a ketoamide inhibitor with P1 and P2 cyclopropylalannines
3KNX	;	2.65	;	HCV NS3 protease domain with P1-P3 macrocyclic ketoamide inhibitor
1A1R	;	2.5	;	HCV NS3 PROTEASE DOMAIN:NS4A PEPTIDE COMPLEX
2A4Q	;	2.45	;	HCV NS3 protease with NS4a peptide and a covalently bound macrocyclic ketoamide compound.
2FM2	;	2.7	;	HCV NS3-4A protease domain complexed with a ketoamide inhibitor, SCH446211
2GVF	;	2.5	;	HCV NS3-4A protease domain complexed with a macrocyclic ketoamide inhibitor, SCH419021
3LOX	;	2.65	;	HCV NS3-4a protease domain with a ketoamide inhibitor derivative of Boceprevir bound
3LON	;	2.2	;	HCV NS3-4a protease domain with ketoamide inhibitor narlaprevir
3OYP	;	2.76	;	HCV NS3/4A in complex with ligand 3
6VDN	;	2.15	;	HCV NS3/4A protease A156T mutant
6VDL	;	1.95	;	HCV NS3/4A protease A156T mutant in complex with glecaprevir
6VDO	;	2.11	;	HCV NS3/4A protease A156T, D168E double mutant
6VDM	;	1.9	;	HCV NS3/4A protease A156T, D168E double mutant in complex with glecaprevir
6P6M	;	2.201	;	HCV NS3/4A protease domain of genotype 1a C159 in complex with glecaprevir
6P6O	;	2.002	;	HCV NS3/4A protease domain of genotype 1a D168E in complex with glecaprevir
6P6L	;	1.728	;	HCV NS3/4A protease domain of genotype 1a in complex with glecaprevir
6P6R	;	1.749	;	HCV NS3/4A protease domain of genotype 1a3a chimera in complex with glecaprevir
6P6Q	;	3.5	;	HCV NS3/4A protease domain of genotype 1a3a chimera in complex with grazoprevir
6P6S	;	2.0	;	HCV NS3/4A protease domain of genotype 3a in complex with glecaprevir
6P6T	;	2.3	;	HCV NS3/4A protease domain of genotype 4a in complex with glecaprevir
6P6Z	;	2.294	;	HCV NS3/4A protease domain of genotype 4a with an extended linker in complex with glecaprevir
6P6V	;	2.0	;	HCV NS3/4A protease domain of genotype 5a in complex with glecaprevir
4U01	;	2.8	;	HCV NS3/4A serine protease in complex with 6570
3KEE	;	2.4	;	HCV NS3/NS4A complexed with Non-covalent macrocyclic compound TMC435
6MVO	;	1.95	;	HCV NS5B 1A Y316 bound to Compound 49
6MVK	;	2.3	;	HCV NS5B 1b N316 bound to Compound 18
6MVP	;	2.0	;	HCV NS5B 1b N316 bound to Compound 18
6MVQ	;	2.14	;	HCV NS5B 1b N316 bound to Compound 31
2HWH	;	2.3	;	HCV NS5B allosteric inhibitor complex
2HWI	;	2.0	;	HCV NS5B allosteric inhibitor complex
3HKW	;	1.55	;	HCV NS5B genotype 1a in complex with 1,5 benzodiazepine inhibitor 6
4KHR	;	2.45	;	HCV NS5B GT1A C316Y with GSK5852
4KHM	;	1.7	;	HCV NS5B GT1A with GSK5852
4KAI	;	2.3	;	HCV NS5B GT1B N316 with GSK5852A
4KB7	;	1.85	;	HCV NS5B GT1B N316Y with CMPD 32
4KBI	;	2.06	;	HCV NS5B GT1B N316Y with CMPD 4
4KE5	;	2.11	;	HCV NS5B GT1B N316Y with GSK5852
4EAW	;	2.0	;	HCV NS5B in complex with IDX375
5CZB	;	1.96	;	HCV NS5B IN COMPLEX WITH LIGAND IDX17119-5
4DRU	;	2.1	;	HCV NS5B in complex with macrocyclic INDOLE INHIBITOR
3HHK	;	1.7	;	HCV NS5b polymerase complex with a substituted benzothiadizine
2YOJ	;	1.76	;	HCV NS5B polymerase complexed with pyridonylindole compound
3HKY	;	1.9	;	HCV NS5B polymerase genotype 1b in complex with 1,5 benzodiazepine 6
3GOL	;	2.85	;	HCV NS5b polymerase in complex with 1,5 benzodiazepine inhibitor (R)-11d
3GNV	;	2.75	;	HCV NS5B polymerase in complex with 1,5 benzodiazepine inhibitor 1b
3GNW	;	2.39	;	HCV NS5B polymerase in complex with 1,5 benzodiazepine inhibitor 4c
4EO6	;	1.791	;	HCV NS5B polymerase inhibitors: Tri-substituted acylhydrazines as tertiary amide bioisosteres
4EO8	;	1.798	;	HCV NS5B polymerase inhibitors: Tri-substituted acylhydrazines as tertiary amide bioisosteres
4OOW	;	2.57	;	HCV NS5B polymerase with a fragment of quercetagetin
5W2E	;	2.8	;	HCV NS5B RNA-dependent RNA polymerase in complex with non-nucleoside inhibitor MK-8876
3PHE	;	2.2	;	HCV NS5B with a bound quinolone inhibitor
3CSO	;	2.71	;	HCV Polymerase in complex with a 1,5 Benzodiazepine inhibitor
2XI2	;	1.8	;	HCV-H77 NS5B Apo Polymerase
2XI3	;	1.7	;	HCV-H77 NS5B Polymerase Complexed With GTP
2XHU	;	2.287	;	HCV-J4 NS5B Polymerase Orthorhombic Crystal Form
2XHV	;	1.9	;	HCV-J4 NS5B Polymerase Point Mutant Orthorhombic Crystal Form
2XHW	;	2.66	;	HCV-J4 NS5B Polymerase Trigonal Crystal Form
2XWH	;	1.8	;	HCV-J6 NS5B polymerase structure at 1.8 Angstrom
4ADP	;	1.902	;	HCV-J6 NS5B POLYMERASE V405I MUTANT
4AEP	;	1.8	;	HCV-JFH1 NS5B POLYMERASE STRUCTURE AT 1.8 ANGSTROM
2XXD	;	1.881	;	HCV-JFH1 NS5B polymerase structure at 1.9 angstrom
4AEX	;	2.41	;	HCV-JFH1 NS5B POLYMERASE STRUCTURE AT 2.4 ANGSTROM in a primitive orthorhombic space group
2XYM	;	1.774	;	HCV-JFH1 NS5B T385A mutant
5YOX	;	2.61	;	HD domain-containing protein YGK1(YGL101W)
6Z6H	;	8.55	;	HDAC-DC
6Z6F	;	3.11	;	HDAC-PC
6Z6P	;	4.43	;	HDAC-PC-Nuc
6Z6O	;	3.8	;	HDAC-TC
5ICN	;	3.3	;	HDAC1:MTA1 in complex with inositol-6-phosphate and a novel peptide inhibitor based on histone H4
7ZZS	;	1.88	;	HDAC2 complexed with an inhibitory ligand
7ZZO	;	2.0	;	HDAC2 in complex with an inhibitor
7ZZR	;	2.168	;	HDAC2 in complex with inhibitory ligand
5IWG	;	1.66	;	HDAC2 WITH LIGAND BRD4884
5IX0	;	1.72	;	HDAC2 WITH LIGAND BRD7232
8CJ7	;	1.51	;	HDAC6 selective degraded (difluoromethyl)-1,3,4-oxadiazole substrate inhibitor
7ZYU	;	2.43	;	HDAC6 ZnF domain inhibitor - DARPin (Designed Ankyrin repeat protein) F10
3ZNR	;	2.4	;	HDAC7 bound with inhibitor TMP269
3ZNS	;	2.45	;	HDAC7 bound with TFMO inhibitor tmp942
5FCW	;	1.979	;	HDAC8 Complexed with a Hydroxamic Acid
1P84	;	2.5	;	HDBT inhibited Yeast Cytochrome bc1 Complex
5K57	;		;	HDD domain from human Ddi2
1BG8	;	2.2	;	HDEA FROM ESCHERICHIA COLI
3N0H	;	1.92	;	hDHFR double mutant Q35S/N64F Trimethoprim Binary Complex
4G95	;	1.35	;	hDHFR-OAG binary complex
8CN1	;	2.09	;	hDLG1-PDZ1 in complex with a TAX1 peptide from HTLV-1
8CN3	;	2.71	;	hDLG1-PDZ2 in complex with a TAX1 peptide from HTLV-1
6Q9H	;	2.0	;	HDM2 (17-111, WILD TYPE) COMPLEXED WITH COMPOUND 11 AT 2.0A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes
6Q96	;	1.8	;	HDM2 (17-111, WILD TYPE) COMPLEXED WITH COMPOUND 12 AT 1.8A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes
5OC8	;	1.56	;	HDM2 (17-111, WILD TYPE) COMPLEXED WITH NVP-HDM201 AT 1.56A
6Q9O	;	1.21	;	HDM2 (17-111, WILDTYPE) COMPLEXED WITH COMPOUND 10 AT 1.21A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes
6Q9L	;	1.13	;	HDM2 (17-111, WILDTYPE) COMPLEXED WITH COMPOUND 9 AT 1.13A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes
5HMH	;	1.79	;	HDM2 in complex with a 3,3-Disubstituted Piperidine
5HMI	;	1.74	;	HDM2 in complex with a 3,3-Disubstituted Piperidine
5HMK	;	2.17	;	HDM2 in complex with a 3,3-Disubstituted Piperidine
2AXI	;	1.4	;	HDM2 in complex with a beta-hairpin
7NA1	;	2.3	;	HDM2 in complex with compound 2
7NA2	;	1.86	;	HDM2 in complex with compound 56
7NA3	;	2.21	;	HDM2 in complex with compound 62
7NA4	;	1.84	;	HDM2 in complex with compound 63
6Q9U	;	2.4	;	HDMX (14-111; C17S) COMPLEXED WITH COMPOUND 12 AT 2.4A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes
6Q9Q	;	2.1	;	HDMX (14-111; C17S) COMPLEXED WITH COMPOUND 13 AT 2.1A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes
6Q9S	;	2.4	;	HDMX (14-111; C17S) COMPLEXED WITH COMPOUND 14 AT 2.4A: Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes
6Q9Y	;	1.2	;	HDMX (14-111; C17S) COMPLEXED WITH COMPOUND 16 AT 1.20A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes
4Q0W	;	2.1	;	he catalytic core of Rad2 in complex with DNA substrate (complex II)
6X3E	;	3.42	;	hEAAT3-Asymmetric-1o2i
6X3F	;	3.03	;	hEAAT3-IFS-Apo
6X2L	;	2.85	;	hEAAT3-IFS-Na
6X2Z	;	3.03	;	hEAAT3-OFS-Asp
6BL5	;	1.69	;	Head decoration protein from the hyperthermophilic phage P74-26
2WST	;	3.2	;	Head domain of porcine adenovirus type 4 NADC-1 isolate fibre
6SG9	;	3.1	;	Head domain of the mt-SSU assemblosome from Trypanosoma brucei
8HME	;	4.2	;	head module state 1 of Tetrahymena IFT-A
8HMF	;	4.6	;	head module state 2 of Tetrahymena IFT-A
7S0Q	;	3.7	;	Head region of a complex of IGF-I with the ectodomain of a hybrid insulin receptor / type 1 insulin-like growth factor receptor
7U6D	;	5.03	;	Head region of insulin receptor ectodomain (A-isoform) bound to the non-insulin agonist IM459
7U6E	;	3.0	;	Head region of insulin receptor ectodomain (A-isoform) bound to the non-insulin agonist IM462
6VWI	;	3.7	;	Head region of the closed conformation of the human type 1 insulin-like growth factor receptor ectodomain in complex with human insulin-like growth factor II.
6VWG	;	3.21	;	Head region of the open conformation of the human type 1 insulin-like growth factor receptor ectodomain in complex with human insulin-like growth factor II.
5GAO	;	4.2	;	Head region of the yeast spliceosomal U4/U6.U5 tri-snRNP
6YVD	;	7.6	;	Head segment of the S.cerevisiae condensin holocomplex in presence of ATP
6XP5	;	4.2	;	Head-Middle module of Mediator
1QMS	;		;	Head-to-Tail Dimer of Calicheamicin gamma-1-I Oligosaccharide Bound to DNA Duplex, NMR, 9 Structures
8OPH	;	2.93	;	Head-to-tail double ring assembly from truncated PVY coat protein
2VKY	;	2.05	;	Headbinding Domain of Phage P22 Tailspike C-Terminally Fused to Isoleucine Zipper pIIGCN4 (Chimera I)
5J7E	;	1.9	;	hEAG PAS domain
1DM9	;	2.0	;	HEAT SHOCK PROTEIN 15 KD
3W1Z	;	2.401	;	Heat shock protein 16.0 from Schizosaccharomyces pombe
4WV5	;	2.04	;	HEAT SHOCK PROTEIN 70 SUBSTRATE BINDING DOMAIN
4WV7	;	2.42	;	HEAT SHOCK PROTEIN 70 SUBSTRATE BINDING DOMAIN WITH COVALENTLY LINKED NOVOLACTONE
4YKQ	;	1.91	;	Heat Shock Protein 90 Bound to CS301
4YKR	;	1.61	;	Heat Shock Protein 90 Bound to CS302
4YKT	;	1.85	;	Heat Shock Protein 90 Bound to CS307
4YKU	;	1.7	;	Heat Shock Protein 90 Bound to CS311
4YKW	;	1.85	;	Heat Shock Protein 90 Bound to CS312
4YKX	;	1.8	;	Heat Shock Protein 90 Bound to CS318
4YKY	;	1.78	;	Heat Shock Protein 90 Bound to CS319
4YKZ	;	1.85	;	Heat Shock Protein 90 Bound to CS320
3HSF	;		;	HEAT SHOCK TRANSCRIPTION FACTOR (HSF)
1FBU	;	2.0	;	HEAT SHOCK TRANSCRIPTION FACTOR DNA BINDING DOMAIN
1FBS	;	2.0	;	HEAT SHOCK TRANSCRIPTION FACTOR DNA BINDING DOMAIN CONTAINING THE P237A MUTATION
1FBQ	;	2.0	;	HEAT SHOCK TRANSCRIPTION FACTOR DNA BINDING DOMAIN CONTAINING THE P237K MUTATION
3HTS	;	1.75	;	HEAT SHOCK TRANSCRIPTION FACTOR/DNA COMPLEX
1LTI	;	2.13	;	HEAT-LABILE ENTEROTOXIN (LT-I) COMPLEX WITH T-ANTIGEN
1EEF	;	1.8	;	HEAT-LABILE ENTEROTOXIN B-PENTAMER COMPLEXED WITH BOUND LIGAND PEPG
1DJR	;	1.3	;	HEAT-LABILE ENTEROTOXIN B-PENTAMER COMPLEXED WITH M-CARBOXYPHENYL-ALPHA-D-GALACTOSE
1LT6	;	2.2	;	HEAT-LABILE ENTEROTOXIN B-PENTAMER COMPLEXED WITH METANITROPHENYLGALACTOSIDE
1PZI	;	1.99	;	Heat-Labile Enterotoxin B-Pentamer Complexed With Nitrophenyl Galactoside 2a
1EFI	;	1.6	;	HEAT-LABILE ENTEROTOXIN B-PENTAMER COMPLEXED WITH PARA-AMINOPHENYL-ALPHA-D-GALACTOPYRANOSIDE
1LT5	;	1.7	;	HEAT-LABILE ENTEROTOXIN B-PENTAMER COMPLEXED WITH THIODIGALACTOSIDE
1FD7	;	1.8	;	HEAT-LABILE ENTEROTOXIN B-PENTAMER WITH BOUND LIGAND BMSC001
1JQY	;	2.14	;	HEAT-LABILE ENTEROTOXIN B-PENTAMER WITH LIGAND BMSC-0010
1LT3	;	2.0	;	HEAT-LABILE ENTEROTOXIN DOUBLE MUTANT N40C/G166C
4FP5	;	1.4	;	Heat-labile enterotoxin ILT-IIbB5 S74A mutant
4FO2	;	1.5	;	Heat-labile enterotoxin LT-IIb-B5(T13I) mutant
1LT4	;	2.0	;	HEAT-LABILE ENTEROTOXIN MUTANT S63K
1BA0	;	1.9	;	HEAT-SHOCK COGNATE 70KD PROTEIN 44KD ATPASE N-TERMINAL 1NGE 3
1BA1	;	1.7	;	HEAT-SHOCK COGNATE 70KD PROTEIN 44KD ATPASE N-TERMINAL MUTANT WITH CYS 17 REPLACED BY LYS
2GKI	;	2.88	;	Heavy and light chain variable single domains of an anti-DNA binding antibody hydrolyze both double- and single-stranded DNAs without sequence specificity
7KE3	;	2.2	;	Heavy chain ferritin with C-terminal EBNA1 epitope
7KE5	;	2.8	;	Heavy chain ferritin with N-terminal EBNA1 epitope
3JAX	;	23.0	;	Heavy meromyosin from Schistosoma mansoni muscle thick filament by negative stain EM
5A6P	;	2.1	;	Heavy metal associated domain of NLR-type immune receptor Pikp1 from rice (Oryza sativa)
6JX5	;	2.402	;	Hect domain of AREL1
3SJU	;	2.4	;	Hedamycin Polyketide Ketoreductase bound to NADPH
6TYY	;	1.36	;	Hedgehog autoprocessing mutant D46H
7K65	;	3.4	;	Hedgehog receptor Patched (PTCH1) in complex with conformation selective nanobody TI23
4MC0	;	2.7	;	Hedycaryol apo
4MC8	;	1.9	;	Hedycaryol synthase in complex with HEPES
4MC3	;	1.5	;	Hedycaryol synthase in complex with Nerolidol
5E62	;	2.203	;	HEF-mut with Tr323 complex
7WHF	;	2.1	;	Heimdallarchaeota gelsolin (2DGel) bound to rabbit actin
6YRR	;		;	Heimdallarchaeota profilin
7M18	;	3.38	;	HeLa-tubulin in complex with cryptophycin 1
7LXB	;	3.26	;	HeLa-tubulin in complex with cryptophycin 52
1XCE	;		;	Helica Structure of DNA by Design: The T(GGGG)T Hexad Alignment
8D13	;	2.43	;	Helical ADP-F-actin
8D14	;	2.51	;	Helical ADP-Pi-F-actin
7AOY	;	13.0	;	Helical arrangement of Bunyamwera virus nucleocapsid protein within a native ribonucleoprotein
5LOY	;	2.5	;	Helical Assembly of a Designed Anbu Protein
5LOX	;	2.9	;	Helical Assembly of the Anbu Complex from Pseudomonas aeruginosa
6N2P	;	4.0	;	Helical assembly of the CARD9 CARD
3L4H	;	1.8	;	Helical box domain and second WW domain of the human E3 ubiquitin-protein ligase HECW1
8QX5	;	1.9	;	Helical Carotenoid Protein 4 (HCP4) from Anabaena with bound Canthaxanthin
3HD7	;	3.4	;	HELICAL EXTENSION OF THE NEURONAL SNARE COMPLEX INTO THE MEMBRANE, spacegroup C 1 2 1
3IPD	;	4.8	;	Helical extension of the neuronal SNARE complex into the membrane, spacegroup I 21 21 21
5JZC	;	4.2	;	helical filament
7JK9	;	3.1	;	Helical filaments of plant light-dependent protochlorophyllide oxidoreductase (LPOR) bound to NADPH, Pchlide, and membrane
6RSQ	;	2.37	;	Helical folded domain of mouse CAP1
2L2R	;		;	Helical hairpin structure of a novel antimicrobial peptide EcAMP1 from seeds of barnyard grass (Echinochloa crus-galli)
2KNS	;		;	Helical Hairpin Structure of Pardaxin in Lipopolysaccharide Micelles: Studied by NMR Spectroscopy
2K98	;		;	Helical hairpin structure of potent antimicrobial peptide MSI-594 in the presence of Lipopolysaccharide micelle
1DLB	;	2.0	;	HELICAL INTERACTIONS IN THE HIV-1 GP41 CORE REVEALS STRUCTURAL BASIS FOR THE INHIBITORY ACTIVITY OF GP41 PEPTIDES
3J4S	;	6.8	;	Helical Model of TubZ-Bt four-stranded filament
3J4T	;	10.8	;	Helical model of TubZ-Bt two-stranded filament
6I3N	;	3.1	;	Helical MyD88 death domain filament
4CKG	;	15.0	;	Helical reconstruction of ACAP1(BAR-PH domain) decorated membrane tubules by cryo-electron microscopy
4CKH	;	17.0	;	Helical reconstruction of ACAP1(BAR-PH domain) decorated membrane tubules by cryo-electron microscopy
6GK2	;	4.9	;	Helical reconstruction of BCL10 CARD and MALT1 DEATH DOMAIN complex
7C2S	;	10.4	;	Helical reconstruction of Dengue virus serotype 3 complexed with Fab C10
6Z5L	;	3.8	;	Helical reconstruction of influenza A virus M1 in complex with nucleic acid.
8EFH	;	3.3	;	Helical reconstruction of the human cardiac actin-tropomyosin-myosin complex in complex with ADP-Mg2+
8EFI	;	3.4	;	Helical reconstruction of the human cardiac actin-tropomyosin-myosin complex in the rigor form
8ENC	;	3.6	;	Helical reconstruction of the human cardiac actin-tropomyosin-myosin loop 4 7G mutant complex
8Q6T	;	18.0	;	Helical reconstruction of the relaxed thick filament from FIB milled left ventricular mouse myofibrils
6OFE	;	3.61	;	Helical reconstruction of Type III Secretion System Needle filament mutant-PrgI S49A
7C2T	;	9.4	;	Helical reconstruction of Zika virus complexed with Fab C10
3U0R	;	2.5	;	Helical repeat structure of apoptosis inhibitor 5 reveals protein-protein interaction modules
3V6A	;	2.6	;	Helical repeat structure of apoptosis inhibitor 5 reveals protein-protein interaction modules
6I2N	;	3.3	;	Helical RNA-bound Hantaan virus nucleocapsid
8DDY	;	2.89	;	Helical rods of far-red light-absorbing allophycocyanin in Synechococcus sp.
8BI4	;	4.3	;	Helical shell of CCMV capsid protein on DNA origami 6HB-2k
8BTP	;	2.75	;	Helical structure of BcThsA in complex with 1''-3'gc(etheno)ADPR
8BTO	;	2.96	;	Helical structure of BcThsA in complex with 1''-3'gcADPR
5H3D	;	14.0	;	Helical structure of membrane tubules decorated by ACAP1 (BARPH doamin) protein by cryo-electron microscopy and MD simulation
1BDE	;		;	HELICAL STRUCTURE OF POLYPEPTIDES FROM THE C-TERMINAL HALF OF HIV-1 VPR, NMR, 20 STRUCTURES
7ABK	;	3.6	;	Helical structure of PspA
7P3R	;	3.65	;	Helical structure of the toxin MakA from Vibrio cholera
3HCL	;	2.59	;	Helical superstructures in a DNA oligonucleotide crystal
5Z51	;	1.583	;	Helicase binding domain of primase from Mycobacterium tuberculosis
6TUN	;	2.07	;	Helicase domain complex
3OIY	;	2.35	;	Helicase domain of reverse gyrase from Thermotoga maritima
3P4X	;	2.41	;	Helicase domain of reverse gyrase from Thermotoga maritima
3P4Y	;	3.2	;	Helicase domain of reverse gyrase from Thermotoga maritima - P2 form
2PJR	;	2.9	;	HELICASE PRODUCT COMPLEX
5MZN	;	1.787	;	Helicase Sen1
3PJR	;	3.3	;	HELICASE SUBSTRATE COMPLEX
1OUV	;	2.0	;	Helicobacter cysteine rich protein C (HcpC)
7S9Z	;	4.14	;	Helicobacter Hepaticus CcsBA Closed Conformation
7S9Y	;	3.56	;	Helicobacter Hepaticus CcsBA Open Conformation
7ZQT	;	2.7	;	Helicobacter pylori adhesin BabA bound to neutralising human antibody.
6GBG	;	2.8	;	Helicobacter pylori adhesin HopQ type I bound to the N-terminal domain of human CEACAM1
6GBH	;	2.59	;	Helicobacter pylori adhesin HopQ type II bound to the N-terminal domain of human CEACAM1
6BGE	;	2.9	;	HELICOBACTER PYLORI ATPASE, HP0525, IN COMPLEX WITH 1G2 COMPOUND
3IEC	;	2.2	;	Helicobacter pylori CagA Inhibits PAR1/MARK Family Kinases by Mimicking Host Substrates
2A9E	;	1.76	;	Helicobacter pylori catalase compound I
1KLX	;	1.95	;	Helicobacter pylori cysteine rich protein B (hcpB)
2DYU	;	1.75	;	Helicobacter pylori formamidase AmiF contains a fine-tuned cysteine-glutamate-lysine catalytic triad
2DYV	;	2.0	;	Helicobacter pylori formamidase AmiF contains a fine-tuned cysteine-glutamate-lysine catalytic triad
2E2K	;	2.5	;	Helicobacter pylori formamidase AmiF contains a fine-tuned cysteine-glutamate-lysine catalytic triad
2E2L	;	2.29	;	Helicobacter pylori formamidase AmiF contains a fine-tuned cysteine-glutamate-lysine catalytic triad
3NM4	;	1.7	;	Helicobacter pylori MTAN
3NM6	;	1.602	;	Helicobacter pylori MTAN complexed with adenine and tris
3NM5	;	1.8	;	Helicobacter pylori MTAN complexed with Formycin A
4OJT	;	1.5	;	Helicobacter pylori MTAN complexed with S-ribosylhomocysteine and adenine
2FN6	;	2.483	;	Helicobacter pylori PseC, aminotransferase involved in the biosynthesis of pseudoaminic acid
7PCR	;	2.75	;	Helicobacter pylori RNase J
6F93	;	2.8	;	Helicobacter pylori serine hydroxymethyl transferase in apo form
2Q0L	;	1.45	;	Helicobacter pylori thioredoxin reductase reduced by sodium dithionite in complex with NADP+
6QSU	;	2.4	;	Helicobacter pylori urease with BME bound in the active site
6ZJA	;	2.0	;	Helicobacter pylori urease with inhibitor bound in the active site
6NYF	;	3.2	;	Helicobacter pylori Vacuolating Cytotoxin A Oligomeric Assembly 1 (OA-1)
6NYG	;	3.9	;	Helicobacter pylori Vacuolating Cytotoxin A Oligomeric Assembly 2a (OA-2a)
6NYJ	;	3.2	;	Helicobacter pylori Vacuolating Cytotoxin A Oligomeric Assembly 2b (OA-2b)
6NYL	;	3.7	;	Helicobacter pylori Vacuolating Cytotoxin A Oligomeric Assembly 2c (OA-2c)
6NYM	;	3.6	;	Helicobacter pylori Vacuolating Cytotoxin A Oligomeric Assembly 2d (OA-2d)
6NYN	;	3.5	;	Helicobacter pylori Vacuolating Cytotoxin A Oligomeric Assembly 2e (OA-2e)
7KL6	;	1.97	;	Helicobacter pylori Xanthine-Guanine-Hypoxanthine Phosphoribosyltransferase
7KL7	;	1.47	;	Helicobacter pylori Xanthine-Guanine-Hypoxanthine Phosphoribosyltransferase
7VW9	;	2.05	;	Helicoverpa armigera pheromone-binding protein PBP1 at pH 5.5
7VW8	;	1.3	;	Helicoverpa armigera pheromone-binding protein PBP1 at pH 7.5
7VWA	;	2.1	;	Helicoverpa armigera pheromone-binding protein PBP1 with Z-9-hexadecenal
7LCC	;	3.66	;	Helitron transposase bound to LTS
1WTT	;		;	HELIX 45 (16S RRNA) FROM B. STEAROTHERMOPHILUS, NMR, 11 STRUCTURES
1WTS	;		;	HELIX 45 (16S RRNA) FROM B. STEAROTHERMOPHILUS, NMR, MINIMIZED AVERAGE STRUCTURE
1FDF	;		;	HELIX 7 BOVINE RHODOPSIN
2OXJ	;	2.0	;	Helix Bundle Quaternary Structure from alpha/beta-Peptide Foldamers: GCN4-p1 with beta-residues at b and f heptad positions.
2OXK	;	2.0	;	Helix Bundle Quaternary Structure from alpha/beta-Peptide Foldamers: GCN4-pLI with beta-residues at b and f heptad positions.
1NUB	;	2.8	;	HELIX C DELETION MUTANT OF BM-40 FS-EC DOMAIN PAIR
1CE9	;	1.8	;	HELIX CAPPING IN THE GCN4 LEUCINE ZIPPER
1ANA	;	2.0	;	HELIX GEOMETRY AND HYDRATION IN AN A-DNA TETRAMER. IC-C-G-G
3DNB	;	1.3	;	HELIX GEOMETRY, HYDRATION, AND G.A MISMATCH IN A B-DNA DECAMER
1VRZ	;	1.05	;	Helix turn helix motif
1EM7	;	2.0	;	HELIX VARIANT OF THE B1 DOMAIN FROM STREPTOCOCCAL PROTEIN G
6MGM	;	1.791	;	Helix-Loop-helix motif of mouse DNA-binding protein inhibitor ID-1
6U2U	;	1.5	;	Helix-Loop-helix motif of mouse DNA-binding protein inhibitor ID-1
1PCG	;	2.7	;	Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor-coactivator interactions
7DKJ	;	3.7	;	Hemagglutinin Influenza A virus (A/Okuda/1957(H2N2) bound with a neutralizing antibody
1HA0	;	2.8	;	HEMAGGLUTININ PRECURSOR HA0
5E5W	;	2.4	;	Hemagglutinin-esterase-fusion mutant structure of influenza D virus
5E64	;	2.4	;	Hemagglutinin-esterase-fusion protein structure of influenza D virus
7JL6	;	2.1	;	Heme binding to SrrB PAS domain plays a role in redox regulation of S. aureus SrrAB two-component system
6TV2	;	1.561	;	Heme d1 biosynthesis associated Protein NirF
6TV9	;	1.893	;	Heme d1 biosynthesis associated Protein NirF in complex with dihydro-heme d1
7P6L	;	2.33	;	Heme domain of CYP505A30, a fungal hydroxylase from Myceliophthora thermophila, bound to dodecanoic acid
7W7D	;	3.4	;	Heme exporter HrtBA in complex with heme
7W78	;	2.884	;	Heme exporter HrtBA in complex with Mg-AMPPNP
7W79	;	3.1	;	Heme exporter HrtBA in complex with Mn-AMPPNP
7W7B	;	3.0	;	Heme exporter HrtBA in complex with protoporphyrin IX containing manganese(III), high resolution data
7W7A	;	3.204	;	Heme exporter in complex with Mn-containing protoporphyrin IX, Mn-anomalous data
7W7C	;	2.8	;	Heme exporter in the unliganded form
3ATJ	;	2.2	;	HEME LIGAND MUTANT OF RECOMBINANT HORSERADISH PEROXIDASE IN COMPLEX WITH BENZHYDROXAMIC ACID
2FC1	;	2.0	;	Heme NO Complex in NOS
6EHA	;	2.0	;	Heme oxygenase 1 in complex with inhibitor
7DVV	;	2.49	;	Heme sensor protein PefR from Streptococcus agalactiae bound to operator DNA (28-mer)
1B2V	;	1.9	;	HEME-BINDING PROTEIN A
8WB2	;	1.9	;	Heme-bound Arabidopsis thaliana temperature-induced lipocalin
8G64	;	1.6	;	Heme-bound flavodoxin FldH from Fusobacterium nucleatum
6G5A	;	1.483	;	Heme-carbene complex in myoglobin H64V/V68A containing an N-methylhistidine as the proximal ligand, 1.48 angstrom resolution
6G5B	;	1.6	;	Heme-carbene complex in myoglobin H64V/V68A containing an N-methylhistidine as the proximal ligand, 1.6 angstrom resolution
8QZF	;	1.8	;	Heme-domain BM3 mutant T268E
8QZE	;	1.87	;	Heme-domain BM3 variant 21B3_F87V-A328F
8DEN	;	1.69	;	Heme-Free Cytochrome Variant ApoCyt
1UVY	;	2.4	;	HEME-LIGAND TUNNELING IN GROUP I TRUNCATED HEMOGLOBINS
1UVX	;	2.45	;	Heme-ligand tunneling on group I truncated hemoglobins
2FBZ	;	2.1	;	Heme-No complex in a bacterial Nitric Oxide Synthase
1BVB	;	2.6	;	HEME-PACKING MOTIFS REVEALED BY THE CRYSTAL STRUCTURE OF CYTOCHROME C554 FROM NITROSOMONAS EUROPAEA
3DWJ	;	2.75	;	Heme-proximal W188H mutant of inducible nitric oxide synthase
3AGT	;	1.4	;	Hemerythrin-like domain of DcrH (met)
3AGU	;	1.805	;	Hemerythrin-like domain of DcrH (semimet-R)
3WAQ	;	1.8	;	Hemerythrin-like domain of DcrH I119E mutant (met)
3WHN	;	1.9	;	Hemerythrin-like domain of DcrH I119H mutant (met)
1JRS	;	1.8	;	HEMIACETAL COMPLEX BETWEEN LEUPEPTIN AND TRYPSIN
1JRT	;	1.7	;	HEMIACETAL COMPLEX BETWEEN LEUPEPTIN AND TRYPSIN
7XQI	;	3.7	;	Hemichannel-focused structure of C-terminal truncated connexin43/Cx43/GJA1 gap junction intercellular channel in POPE nanodiscs (FIN conformation)
7XQG	;	3.8	;	Hemichannel-focused structure of C-terminal truncated connexin43/Cx43/GJA1 gap junction intercellular channel in POPE nanodiscs (GCN conformation)
7XQH	;	3.8	;	Hemichannel-focused structure of C-terminal truncated connexin43/Cx43/GJA1 gap junction intercellular channel in POPE nanodiscs (GCN-TM1i conformation)
7XQJ	;	4.0	;	Hemichannel-focused structure of C-terminal truncated connexin43/Cx43/GJA1 gap junction intercellular channel in POPE nanodiscs (PLN conformation)
1Z5X	;	3.07	;	hemipteran ecdysone receptor ligand-binding domain complexed with ponasterone A
1NV9	;	2.356	;	HemK, apo structure
1DE4	;	2.8	;	HEMOCHROMATOSIS PROTEIN HFE COMPLEXED WITH TRANSFERRIN RECEPTOR
8TNV	;	1.5	;	Hemocyanin Functional Unit CCHB-g of Concholepas concholepas
1BZ1	;	1.59	;	HEMOGLOBIN (ALPHA + MET) VARIANT
1BZZ	;	1.59	;	HEMOGLOBIN (ALPHA V1M) MUTANT
2VYW	;	1.8	;	Hemoglobin (Hb2) from trematode Fasciola hepatica
1A0U	;	2.14	;	HEMOGLOBIN (VAL BETA1 MET) MUTANT
1A0Z	;	2.0	;	HEMOGLOBIN (VAL BETA1 MET) MUTANT
1A01	;	1.8	;	HEMOGLOBIN (VAL BETA1 MET, TRP BETA37 ALA) MUTANT
1A00	;	2.0	;	HEMOGLOBIN (VAL BETA1 MET, TRP BETA37 TYR) MUTANT
1BZ0	;	1.5	;	HEMOGLOBIN A (HUMAN, DEOXY, HIGH SALT)
1X9F	;	2.6	;	Hemoglobin Dodecamer from Lumbricus Erythrocruorin
2B7H	;	2.2	;	Hemoglobin from Cerdocyon thous, a canidae from Brazil, at 2.2 Angstroms resolution
1EBT	;	1.9	;	HEMOGLOBIN I FROM THE CLAM LUCINA PECTINATA BOUND WITH CYANIDE
1B0B	;	1.43	;	HEMOGLOBIN I FROM THE CLAM LUCINA PECTINATA, CYANIDE COMPLEX AT 100 KELVIN
3AK5	;	2.2	;	Hemoglobin protease (Hbp) passenger missing domain-2
6R2O	;	2.46	;	Hemoglobin structure from serial crystallography with a 3D-printed nozzle.
1BAB	;	1.5	;	HEMOGLOBIN THIONVILLE: AN ALPHA-CHAIN VARIANT WITH A SUBSTITUTION OF A GLUTAMATE FOR VALINE AT NA-1 AND HAVING AN ACETYLATED METHIONINE NH2 TERMINUS
1W3G	;	2.68	;	Hemolytic lectin from the mushroom Laetiporus sulphureus complexed with two N-acetyllactosamine molecules.
3C7X	;	1.7	;	Hemopexin-like domain of matrix metalloproteinase 14
4DTG	;	1.8	;	Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model
7VGO	;	1.2	;	Hen egg lysozyme
6P4D	;	1.05	;	Hen egg lysozyme (HEL) containing three point mutations (HEL3x): R21Q, R73E, and D101R
5FEK	;	1.8	;	Hen egg lysozyme at room temperature solved from 3600 diffraction images acquired by ultrasonic acoustic levitation method and processed by CrystFEL
5FEL	;	1.8	;	Hen egg lysozyme at room temperature solved from dataset acquired by oscillation method
5FDJ	;	1.8	;	Hen egg lysozyme at room temperature solved from datasets acquired by ultrasonic acoustic levitation method and processed by CrystFEL
7VGP	;	1.91	;	Hen egg lysozyme refolded after denaturation at acidic pH
8YA1	;	1.57	;	HEN EGG WHITE LYSOZYME
7NKF	;	1.7	;	Hen egg white lysozyme (HEWL) Grown inside (Not centrifuged) HARE serial crystallography chip.
7NJF	;	1.7	;	Hen egg white lysozyme (HEWL) grown inside HARE serial crystallography chip
8B3L	;	1.71	;	Hen Egg White Lysozyme 2s in situ crystallization
8B3T	;	1.78	;	Hen Egg White Lysozyme 4s in situ crystallization
8B3U	;	1.71	;	Hen Egg White Lysozyme 6s in situ crystallization
8B3V	;	1.74	;	Hen Egg White Lysozyme 8s in situ crystallization
5KXK	;	1.198	;	Hen Egg White Lysozyme at 100K, Data set 1
5KXL	;	1.198	;	Hen Egg White Lysozyme at 100K, Data set 2
5KXM	;	1.198	;	Hen Egg White Lysozyme at 100K, Data set 3
5KXN	;	1.198	;	Hen Egg White Lysozyme at 100K, Data set 4
5KXO	;	1.2	;	Hen Egg White Lysozyme at 278K, Data set 1
5KY1	;	1.2	;	Hen Egg White Lysozyme at 278K, Data set 10
5KXP	;	1.2	;	Hen Egg White Lysozyme at 278K, Data set 2
5KXR	;	1.2	;	Hen Egg White Lysozyme at 278K, Data set 3
5KXS	;	1.2	;	Hen Egg White Lysozyme at 278K, Data set 4
5KXT	;	1.2	;	Hen Egg White Lysozyme at 278K, Data set 5
5KXW	;	1.2	;	Hen Egg White Lysozyme at 278K, Data set 6
5KXX	;	1.2	;	Hen Egg White Lysozyme at 278K, Data set 7
5KXY	;	1.2	;	Hen Egg White Lysozyme at 278K, Data set 8
5KXZ	;	1.2	;	Hen Egg White Lysozyme at 278K, Data set 9
7L84	;	1.7	;	Hen Egg White Lysozyme by Native S-SAD at Room Temperature
5LVG	;	2.0	;	Hen Egg White Lysozyme co-crystallized with cis-Ru(DMSO)4Cl2
5LVH	;	1.55	;	Hen Egg White Lysozyme co-crystallized with trans-Ru(DMSO)4Cl2
5LVJ	;	1.6	;	Hen Egg White Lysozyme co-crystallized with [H2Ind][trans-RuCl4(DMSO)(HInd)]
5LVI	;	1.7	;	Hen Egg White Lysozyme co-crystallized with [HIsq][trans-RuCl4(DMSO)(Isq)]
6CIW	;	1.42	;	Hen Egg White Lysozyme Cocrystallized with 1,3-Di(2-pyridyl)propane
8RT3	;	1.09	;	Hen Egg White Lysozyme Crystallized with Bioassembler in Space Microgravity Conditions
8RT2	;	0.8	;	Hen Egg White Lysozyme Crystallized with Bioassembler on Earth
3KAM	;	1.59	;	Hen Egg White Lysozyme Derivatized with rhenium(I) diaquatricarbonyl cation
2WAR	;	1.8	;	Hen Egg White Lysozyme E35Q chitopentaose complex
5APC	;	1.7	;	Hen Egg White Lysozyme illuminated with 0.4THz radiation
6TVL	;	1.395	;	Hen Egg White Lysozyme in complex with a ""half sandwich""-type Ru(II) coordination compound
7KH5	;	1.295	;	Hen Egg White Lysozyme in complex with tetrabromoterephthalic acid
1FLQ	;	1.801	;	HEN EGG WHITE LYSOZYME MUTANT WITH ALANINE SUBSTITUTED FOR GLYCINE
1FLU	;	1.785	;	HEN EGG WHITE LYSOZYME MUTANT WITH ALANINE SUBSTITUTED FOR GLYCINE
1FLW	;	1.812	;	HEN EGG WHITE LYSOZYME MUTANT WITH ALANINE SUBSTITUTED FOR GLYCINE
1FLY	;	1.833	;	HEN EGG WHITE LYSOZYME MUTANT WITH ALANINE SUBSTITUTED FOR GLYCINE
1FN5	;	1.78	;	HEN EGG WHITE LYSOZYME MUTANT WITH ALANINE SUBSTITUTED FOR GLYCINE
5GWB	;	2.001	;	Hen Egg White Lysozyme native crystals soaked for 2 hours in precipitant solution containing 1 M guanidine hydrochloride and 25% glycerol, before data collection
1LKS	;	1.1	;	HEN EGG WHITE LYSOZYME NITRATE
5APD	;	1.7	;	Hen Egg White Lysozyme not illuminated with 0.4THz radiation
5APF	;	1.7	;	Hen Egg White Lysozyme reference dataset even frames
5APE	;	1.7	;	Hen Egg White Lysozyme reference dataset odd frames
8RNV	;	1.08	;	Hen Egg White Lysozyme soaked with cis-Ru(DMSO)4Cl2
8RNW	;	1.12	;	Hen Egg White Lysozyme soaked with trans-Ru(DMSO)4Cl2
8RNY	;	1.02	;	Hen Egg White Lysozyme soaked with with [H2Ind][trans-RuCl4(DMSO)(HInd)]
8RNX	;	1.25	;	Hen Egg White Lysozyme soaked with [HIsq][trans-RuCl4(DMSO)(Isq)]
1AT6	;	1.8	;	HEN EGG WHITE LYSOZYME WITH A ISOASPARTATE RESIDUE
1AT5	;	1.8	;	HEN EGG WHITE LYSOZYME WITH A SUCCINIMIDE RESIDUE
5B5J	;	1.26	;	Hen egg white lysozyme with boron tracedrug UTX-97
1A2Y	;	1.5	;	HEN EGG WHITE LYSOZYME, D18A MUTANT, IN COMPLEX WITH MOUSE MONOCLONAL ANTIBODY D1.3
5MYY	;	1.1	;	Hen Egg-White Lysozyme (HEWL) cocrystallized in the presence of Cadmium sulphate
8BQQ	;	1.57	;	Hen Egg-White Lysozyme (HEWL) complexed with amine-functionalised Anderson-Evans polyoxometalate
8BQR	;	2.32	;	Hen Egg-White Lysozyme (HEWL) complexed with biotin-functionalised Anderson-Evans polyoxometalate
5FHW	;	1.52	;	Hen Egg-White Lysozyme (HEWL) complexed with Hf(IV)-substituted Wells Dawson-type polyoxometalate
8BQP	;	1.24	;	Hen Egg-White Lysozyme (HEWL) complexed with methyl-functionalised Anderson-Evans polyoxometalate
8BQT	;	1.47	;	Hen Egg-White Lysozyme (HEWL) complexed with two methyl-functionalised Anderson-Evans polyoxometalates
4XYY	;	1.38	;	Hen Egg-White Lysozyme (HEWL) complexed with Zr(IV)-substituted Keggin-type polyoxometalate
6APM	;	2.05	;	Hen egg-white lysozyme (WT), solved with serial millisecond crystallography using synchrotron radiation
6S2N	;	1.8	;	Hen egg-white lysozyme by serial electron diffraction
6BRE	;	1.86	;	Hen Egg-White Lysozyme cocrystallized with Cadmium sulphate using CuKalpha source.
3RZ4	;	1.8	;	Hen egg-white lysozyme in HEPES buffer at pH 7.5
5B59	;	2.0	;	Hen egg-white lysozyme modified with a keto-ABNO.
4N5R	;	2.1	;	Hen egg-white lysozyme phased using free-electron laser data
5YIN	;	1.66	;	Hen egg-white lysozyme precipitant-free orthorhombic form
5OER	;	1.9	;	Hen egg-white lysozyme refined against 5000 9 keV diffraction patterns
5T3F	;	1.45	;	hen egg-white lysozyme soaked with selenourea for 10 min
8JQV	;	1.83	;	Hen egg-white lysozyme solved from 1D fixed target delivery system
4ET8	;	1.9	;	Hen egg-white lysozyme solved from 40 fs free-electron laser pulse data
4ET9	;	1.9	;	Hen egg-white lysozyme solved from 5 fs free-electron laser pulse data
4RLM	;	1.9	;	Hen egg-white lysozyme solved from serial crystallography at a synchrotron source, data processed with CrystFEL
4RLN	;	2.17	;	Hen egg-white lysozyme solved from serial crystallography at a synchrotron source, data processed with nXDS
4BS7	;	1.701	;	Hen egg-white lysozyme structure determined at room temperature by in- situ diffraction and SAD phasing in ChipX
3ZEK	;	1.43	;	Hen egg-white lysozyme structure determined at room temperature by in- situ diffraction in ChipX
6H0L	;	1.9	;	Hen egg-white lysozyme structure determined with data from the EuXFEL, 9.22 keV photon energy
6H0K	;	2.2	;	Hen egg-white lysozyme structure determined with data from the EuXFEL, the first MHz free electron laser, 7.47 keV photon energy
4RW1	;	1.9	;	Hen egg-white lysozyme structure from a spent-beam experiment at LCLS: original beam
4RW2	;	2.3	;	Hen egg-white lysozyme structure from a spent-beam experiment at LCLS: refocused beam
4BAP	;	1.207	;	Hen egg-white lysozyme structure in complex with the europium tris- hydroxyethylcholinetriazoledipicolinate complex at 1.21 A resolution.
4BAF	;	1.507	;	Hen egg-white lysozyme structure in complex with the europium tris- hydroxyethyltriazoledipicolinate complex at 1.51 A resolution.
4BAD	;	1.35	;	Hen egg-white lysozyme structure in complex with the europium tris- hydroxymethyltriazoledipicolinate complex at 1.35 A resolution.
7RYD	;	1.18	;	Hen egg-white lysozyme with ionic liquid butylammonium nitrate 1 mol%
7RZ1	;	2.046	;	Hen egg-white lysozyme with ionic liquid ethanolammonium formate 14.4 mol%
7RZ2	;	1.07	;	Hen egg-white lysozyme with ionic liquid ethanolammonium formate 4 mol%
7RZ0	;	1.38	;	Hen egg-white lysozyme with ionic liquid ethanolammonium formate 6.7 mol%
7RYK	;	1.76	;	Hen egg-white lysozyme with ionic liquid ethanolammonium nitrate 1 mol%
7JMU	;	1.2	;	Hen egg-white lysozyme with ionic liquid ethylammonium nitrate
7RXY	;	1.6	;	Hen egg-white lysozyme with ionic liquid ethylammonium nitrate 5 mol%
1UCO	;	2.0	;	HEN EGG-WHITE LYSOZYME, LOW HUMIDITY FORM
2B5Z	;	1.6	;	Hen lysozyme chemically glycosylated
8DZ7	;	1.34	;	Hen lysozyme in orthorhombic space group at ambient temperature - diffuse scattering dataset
8DYZ	;	1.272	;	Hen lysozyme in tetragonal space group at ambient temperature - diffuse scattering dataset
6O2H	;	1.212	;	Hen lysozyme in triclinic space group at ambient temperature - diffuse scattering dataset
4I8S	;	2.0	;	Hen Lysozyme protein crystallization via standard hanging drop vapor diffusion
5JO7	;	2.15	;	Henbane premnaspirodiene synthase (HPS), also known as Henbane vetispiradiene synthase (HVS) from Hyoscyamus muticus
2X9M	;	2.9	;	Hendra virus attachment glycoprotein
2VSK	;	3.3	;	Hendra virus attachment glycoprotein in complex with human cell surface receptor ephrinB2
7SYY	;	2.74	;	Hendra virus G protein head domain in complex with cross-neutralizing murine antibody hAH1.3
7SYZ	;	2.86	;	Hendra virus G protein head domain in complex with cross-neutralizing murine antibody hAH1.3
4HEO	;	1.65	;	Hendra virus Phosphoprotein C terminal domain
6BW1	;	2.2	;	Hendra virus W protein C-terminus in complex with Importin alpha 1
6BW9	;	1.6	;	Hendra virus W protein C-terminus in complex with Importin alpha 3 crystal form 1
6BWA	;	2.2	;	Hendra virus W protein C-terminus in complex with Importin alpha 3 crystal form 2
6BWB	;	2.3	;	Hendra virus W protein C-terminus in complex with Importin alpha 3 crystal form 3
6W0L	;	2.3	;	Henipavirus W protein interacts with 14-3-3 to modulate host gene expression
1KMX	;		;	Heparin-binding Domain from Vascular Endothelial Growth Factor
1VGH	;		;	HEPARIN-BINDING DOMAIN FROM VASCULAR ENDOTHELIAL GROWTH FACTOR, NMR, 20 STRUCTURES
2VGH	;		;	HEPARIN-BINDING DOMAIN FROM VASCULAR ENDOTHELIAL GROWTH FACTOR, NMR, MINIMIZED AVERAGE STRUCTURE
7V4A	;	3.2	;	Heparin-induced alpha-synuclein fibrils polymorph 1
7V4B	;	3.1	;	Heparin-induced alpha-synuclein fibrils polymorph 3
7V4C	;	3.3	;	Heparin-induced alpha-synuclein fibrils polymorph 4
1AXM	;	3.0	;	HEPARIN-LINKED BIOLOGICALLY-ACTIVE DIMER OF FIBROBLAST GROWTH FACTOR
2AXM	;	3.0	;	HEPARIN-LINKED BIOLOGICALLY-ACTIVE DIMER OF FIBROBLAST GROWTH FACTOR
7V4D	;	3.5	;	Heparin-remodelled alpha-synuclein fibrils
5JMF	;	1.854	;	Heparinase III-BT4657 gene product
5JMD	;	2.4	;	Heparinase III-BT4657 gene product, Methylated Lysines
3E7J	;	2.1	;	HeparinaseII H202A/Y257A double mutant complexed with a heparan sulfate tetrasaccharide substrate
1HAV	;	2.0	;	HEPATITIS A VIRUS 3C PROTEINASE
2QIJ	;	8.9	;	Hepatitis B Capsid Protein with an N-terminal extension modelled into 8.9 A data.
8GBU	;	2.5	;	Hepatitis B capsid Y132A mutant with compound AB-506
7OD6	;	3.0	;	Hepatitis B core protein + GSLLGRMKGA
7OD7	;	2.8	;	Hepatitis B core protein + SLLGRM
7OCO	;	3.2	;	Hepatitis B core protein -low secretion phenotype L60V
7OCW	;	3.2	;	Hepatitis B core protein -low secretion phenotype P5T
7OEV	;	3.1	;	Hepatitis B core protein mutant F97L with bound GSLLGRMKGA
7OEW	;	2.9	;	Hepatitis B core protein mutant F97L with bound MHRSLLGRMKGA
7OD8	;	3.0	;	Hepatitis B core Protein mutant L60V + GSLLGRMKGA
7OEN	;	3.2	;	Hepatitis B core protein mutant P5T with bound GSLLGRMKGA
7OD4	;	2.8	;	Hepatitis B core protein.
6CWT	;	3.151	;	Hepatitis B core-antigen in complex with Fab e21
6CWD	;	3.33	;	Hepatitis B core-antigen in complex with scFv e13
6CVK	;	2.38	;	Hepatitis B e-antigen in complex with scFv e13
8G8Y	;	3.8	;	Hepatitis B virus capsid bound to importin alpha1
8G6V	;	3.4	;	Hepatitis B virus capsid bound to importin alpha1/beta heterodimer
8BER	;	4.0	;	Hepatitis B virus core antigen (HBc) with the insertion of four external domains of the influenza A M2 protein (HBc/4M2e) with T=3 topology
8BDZ	;	3.13	;	Hepatitis B virus core antigen (HBc) with the insertion of four external domains of the influenza A M2 protein (HBc/4M2e) with T=4 topology
5GMZ	;	1.7	;	Hepatitis B virus core protein Y132A mutant in complex with 4-methyl heteroaryldihydropyrimidine
5WRE	;	1.946	;	Hepatitis B virus core protein Y132A mutant in complex with heteroaryldihydropyrimidine (HAP_R01)
8I71	;	1.6	;	Hepatitis B virus core protein Y132A mutant in complex with Linvencorvir (RG7907), a Hepatitis B Virus (HBV) Core Protein Allosteric Modulator (CpAM)
5T2P	;	1.693	;	Hepatitis B virus core protein Y132A mutant in complex with sulfamoylbenzamide (SBA_R01)
8KHU	;	2.0	;	Hepatitis B virus core protein Y132A mutant in complex with THPP derivatives 48
5WTW	;	2.623	;	Hepatitis B virus core protein Y132A mutant in P 41 21 2 Space Group
6TIK	;	3.4	;	Hepatitis B virus core shell--virus-like particle with NadA epitope
2A4G	;	2.5	;	Hepatitis C Protease NS3-4A serine protease with Ketoamide Inhibitor SCH225724 Bound
1A1V	;	2.2	;	HEPATITIS C VIRUS NS3 HELICASE DOMAIN COMPLEXED WITH SINGLE STRANDED SDNA
1A1Q	;	2.4	;	HEPATITIS C VIRUS NS3 PROTEINASE
2AX1	;	2.1	;	Hepatitis C Virus NS5b RNA Polymerase in complex with a covalent inhibitor (5ee)
2AWZ	;	2.15	;	Hepatitis C Virus NS5b RNA Polymerase in complex with a covalent inhibitor (5h)
2AX0	;	2.0	;	Hepatitis C Virus NS5b RNA Polymerase in complex with a covalent inhibitor (5x)
1C2P	;	1.9	;	HEPATITIS C VIRUS NS5B RNA-DEPENDENT RNA POLYMERASE
1YVF	;	2.5	;	Hepatitis C virus NS5B RNA-dependent RNA polymerase complex with inhibitor PHA-00729145
1Z4U	;	2.8	;	hepatitis C virus NS5B RNA-dependent RNA polymerase complex with inhibitor PHA-00799585
1YUY	;	1.9	;	HEPATITIS C VIRUS NS5B RNA-DEPENDENT RNA POLYMERASE GENOTYPE 2a
1YV2	;	2.5	;	Hepatitis C virus NS5B RNA-dependent RNA Polymerase genotype 2a
3FQK	;	2.2	;	Hepatitis C virus polymerase NS5B (BK 1-570) with HCV-796 inhibitor
3G86	;	2.2	;	Hepatitis C virus polymerase NS5B (BK 1-570) with thiazine inhibitor
3MF5	;	2.0	;	Hepatitis C virus polymerase NS5B (BK) with amide bioisostere thumb site inhibitor
4IH5	;	1.9	;	Hepatitis C Virus polymerase NS5B (BK) with fragment-based compounds
4IH6	;	2.2	;	Hepatitis C Virus polymerase NS5B (BK) with fragment-based compounds
4IH7	;	2.3	;	Hepatitis C Virus polymerase NS5B (BK) with fragment-based compounds
3FQL	;	1.8	;	Hepatitis C virus polymerase NS5B (CON1 1-570) with HCV-796 inhibitor
4MIB	;	2.3	;	Hepatitis C Virus polymerase NS5B genotype 1b (BK) in complex with Compound 48 (N-({(3S)-1-[6-tert-butyl-5-methoxy-8-(2-oxo-1,2-dihydropyridin-3-yl)quinolin-3-yl]pyrrolidin-3-yl}methyl)methanesulfonamide)
4MK9	;	2.05	;	Hepatitis C Virus polymerase NS5B genotype 1b (BK) in complex with inhibitor 12 (N-{2-[3-tert-butyl-2-methoxy-5-(2-oxo-1,2-dihydropyridin-3-yl)phenyl]-1,3-benzoxazol-5-yl}methanesulfonamide)
4MKA	;	2.05	;	Hepatitis C Virus polymerase NS5B genotype 1b (BK) in complex with inhibitor 13 (N-{2-[3-tert-butyl-2-methoxy-5-(2-oxo-1,2-dihydropyridin-3-yl)phenyl]-1,3-benzoxazol-5-yl}methanesulfonamide)
4MKB	;	1.9	;	Hepatitis C Virus polymerase NS5B genotype 1b (BK) in complex with inhibitor 14 (N-(4-{(E)-2-[3-tert-butyl-2-methoxy-5-(3-oxo-2,3-dihydropyridazin-4-yl)phenyl]ethenyl}phenyl)methanesulfonamide)
4MK7	;	2.8	;	Hepatitis C Virus polymerase NS5B genotype 1b (BK) in complex with inhibitor 2 (3-(3-tert-butyl-4-methoxyphenyl)pyridin-2(1H)-one)
4MK8	;	2.09	;	Hepatitis C Virus polymerase NS5B genotype 1b (BK) in complex with inhibitor 4 (N-(4-{2-[3-tert-butyl-2-methoxy-5-(2-oxo-1,2-dihydropyridin-3-yl)phenyl]ethyl}phenyl)methanesulfonamide)
4MIA	;	2.8	;	Hepatitis C Virus polymerase NS5B genotype 1b (BK) in complex with RG7109 (N-{4-[6-tert-butyl-5-methoxy-8-(6-methoxy-2-oxo-2,5-dihydropyridin-3-yl)quinolin-3-yl]phenyl}methanesulfonamide)
6W4G	;	1.95	;	Hepatitis C virus polymerase NS5B with RO inhibitor for SAR studies
3H5S	;	2.0	;	Hepatitis C virus polymerase NS5B with saccharin inhibitor
3H5U	;	1.95	;	Hepatitis C virus polymerase NS5B with saccharin inhibitor 1
3H59	;	2.1	;	Hepatitis C virus polymerase NS5B with thiazine inhibitor 2
1YVX	;	2.0	;	Hepatitis C Virus RNA Polymerase Genotype 2a In Complex With Non- Nucleoside Analogue Inhibitor
1YVZ	;	2.2	;	Hepatitis C Virus RNA Polymerase Genotype 2a In Complex With Non- Nucleoside Analogue Inhibitor
1GX5	;	1.7	;	Hepatitis C Virus RNA Polymerase in Complex with GTP and Manganese
1NHU	;	2.0	;	Hepatitis C virus RNA polymerase in complex with non-nucleoside analogue inhibitor
1NHV	;	2.9	;	Hepatitis C virus RNA polymerase in complex with non-nucleoside analogue inhibitor
1GX6	;	1.85	;	Hepatitis C Virus RNA polymerase in complex with UTP and manganese
2GIR	;	1.9	;	Hepatitis C virus RNA-dependent RNA polymerase NS5B with NNI-1 inhibitor
2GIQ	;	1.65	;	Hepatitis C virus RNA-dependent RNA polymerase NS5B with NNI-2 inhibitor
2OIH	;	2.4	;	Hepatitis Delta Virus gemonic ribozyme precursor with C75U mutation and bound to monovalent cation Tl+
1SJ3	;	2.2	;	Hepatitis Delta Virus Gemonic Ribozyme Precursor, with Mg2+ Bound
2OJ3	;	2.9	;	Hepatitis Delta Virus ribozyme precursor structure, with C75U mutation, bound to Tl+ and cobalt hexammine (Co(NH3)63+)
3RKC	;	1.79	;	Hepatitis E Virus Capsid Protein E2s Domain (genotype IV)
3RKD	;	1.9	;	Hepatitis E Virus E2s domain (Genotype I) in complex with a neutralizing antibody
4PLK	;	4.0	;	Hepatitis E Virus E2s domain (Genotype I) in complex with a neutralizing antibody 8G12
4PLJ	;	2.3	;	Hepatitis E Virus E2s domain (Genotype IV) in complex with a neutralizing antibody 8G12
2ZTN	;	3.56	;	Hepatitis E virus ORF2 (Genotype 3)
4HS8	;	2.6	;	Hepatitus C envelope glycoprotein E2 fragment 412-423 with humanized and affinity-matured antibody hu5B3.v3
4HS6	;	1.53	;	Hepatitus C envelope glycoprotein E2 fragment 412-423 with humanized and affinity-matured antibody MRCT10.v362
4AVX	;	1.68	;	Hepatocyte Growth Factor-Regulated Tyrosine Kinase Substrate (Hgs-Hrs) bound to an IP2 compound at 1.68 A Resolution
1IC8	;	2.6	;	HEPATOCYTE NUCLEAR FACTOR 1A BOUND TO DNA : MODY3 GENE PRODUCT
2H8R	;	3.2	;	Hepatocyte Nuclear Factor 1b bound to DNA: MODY5 Gene Product
1LV2	;	2.7	;	Hepatocyte Nuclear Factor 4 is a Transcription Factor that Constitutively Binds Fatty Acids
3BGL	;	2.225	;	Hepatoselectivity of Statins: Design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors
3H0T	;	1.89	;	Hepcidin-Fab complex
4B0F	;	2.8	;	Heptameric core complex structure of C4b-binding (C4BP) protein from human
1JBM	;	1.85	;	Heptameric crystal structure of Mth649, an Sm-like archaeal protein from Methanobacterium thermautotrophicum
3J83	;	30.0	;	Heptameric EspB Rosetta model guided by EM density
7T8C	;	4.5	;	Heptameric Human Twinkle Helicase Clinical Variant W315L
5LU7	;	1.92	;	Heptose isomerase GmhA mutant - D61A
5LU6	;	1.67	;	Heptose isomerase mutant - H64Q
2GP0	;	2.05	;	HePTP Catalytic Domain (residues 44-339), S225D mutant
4ICZ	;	1.9	;	HER2 1221/1222 phosphorylation regulated by PTPN9
3MZW	;	2.9	;	HER2 extracelluar region with affinity matured 3-helix affibody ZHER2:342
7PCD	;	1.77	;	HER2 IN COMPLEX WITH A COVALENT INHIBITOR
5O4G	;	3.0	;	HER2 in complex with Fab MF3958
7JXH	;	3.27	;	HER2 in complex with JBJ-08-178-01
3RCD	;	3.21	;	HER2 Kinase Domain Complexed with TAK-285
6ZQK	;	2.2	;	HER2-binding scFv-Fab fusion 841
4P59	;	3.4	;	HER3 extracellular domain in complex with Fab fragment of MOR09825
5O4O	;	3.4	;	HER3 in complex with Fab MF3178
5O7P	;	4.5	;	HER3 in complex with Fab MF3178
6OP9	;	2.501	;	HER3 pseudokinase domain bound to bosutinib
3I31	;	1.8	;	Hera helicase RNA binding domain is an RRM fold
5MAO	;	1.35	;	HERA HELICASE RNA BINDING DOMAIN with TNCS in P212121
2GXQ	;	1.2	;	HERA N-terminal domain in complex with AMP, crystal form 1
2GXS	;	1.66	;	HERA N-terminal domain in complex with AMP, crystal form 2
2GXU	;	1.67	;	HERA N-terminal domain in complex with orthophosphate, crystal form 1
7KBP	;	2.3	;	Herceptin Diabody with R83T, E85C Mutations
1HAE	;		;	HEREGULIN-ALPHA EPIDERMAL GROWTH FACTOR-LIKE DOMAIN, NMR, 20 STRUCTURES
1HAF	;		;	HEREGULIN-ALPHA EPIDERMAL GROWTH FACTOR-LIKE DOMAIN, NMR, MINIMIZED AVERAGE STRUCTURE
8IOB	;	3.9	;	Herg1a-herg1b closed state 1
8IO5	;	3.8	;	Herg1a-herg1b closed state 2
8IO4	;	3.5	;	Herg1a-herg1b open state
4D1Q	;	3.4	;	Hermes transposase bound to its terminal inverted repeat
6DX0	;	2.9	;	Hermes transposase deletion dimer complex with (A/T) DNA
6DWW	;	2.851	;	Hermes transposase deletion dimer complex with (A/T) DNA and Mn2+
6DWZ	;	3.2	;	Hermes transposase deletion dimer complex with (C/G) DNA
6DWY	;	3.2	;	Hermes transposase deletion dimer complex with (C/G) DNA and Ca2+
2KI5	;	1.9	;	HERPES SIMPLEX TYPE-1 THYMIDINE KINASE IN COMPLEX WITH THE DRUG ACICLOVIR AT 1.9A RESOLUTION
3SKU	;	4.0	;	Herpes simplex virus glycoprotein D bound to the human receptor nectin-1
6ODM	;	4.3	;	Herpes simplex virus type 1 (HSV-1) portal vertex-adjacent capsid/CATC, asymmetric unit
6OD7	;	5.6	;	Herpes simplex virus type 1 (HSV-1) pUL6 portal protein, dodecameric complex
8BQ1	;	2.32	;	Herpes simplex virus type 1 protease
1AT3	;	2.5	;	HERPES SIMPLEX VIRUS TYPE II PROTEASE
1QHI	;	1.9	;	HERPES SIMPLEX VIRUS TYPE-I THYMIDINE KINASE COMPLEXED WITH A NOVEL NON-SUBSTRATE INHIBITOR, 9-(4-HYDROXYBUTYL)-N2-PHENYLGUANINE
8C9M	;	3.2	;	HERV-K Gag immature lattice
6Z0L	;	2.33	;	Het-N2 - De novo designed three-helix heterodimer with Cysteine at the N2 position of the alpha-helix
7BEY	;	1.5	;	Het-N2-SO3- - De novo designed three-helix heterodimer with Cysteine S-sulfate at the N2 position of the alpha-helix
6Z0M	;	1.45	;	Het-Ncap - De novo designed three-helix heterodimer with Cysteine at the Ncap position of the alpha-helix
5VTE	;	2.023	;	Hetero antiparallel coiled coil hexamer formed by de novo peptides
1PK1	;	1.8	;	Hetero SAM domain structure of Ph and Scm.
5XX6	;	1.31	;	Hetero-micro-seeding: Crystal structure of BPTI-[5,55]C14GA38I variant using micro-seeds from -C14GA38G variant
5XX7	;	1.38	;	Hetero-micro-seeding: Crystal structure of BPTI-[5,55]C14GA38I variant using micro-seeds from -C14GA38I variant
5XX8	;	1.3	;	Hetero-micro-seeding: Crystal structure of BPTI-[555]C14GA38I variant using micro-seeds from -C14GA38L variant
7DN1	;	1.74	;	Hetero-oligomers of SCR-SCR2 crystal structure with NADPH
1RSO	;		;	Hetero-tetrameric L27 (Lin-2, Lin-7) domain complexes as organization platforms of supra-molecular assemblies
3TNU	;	3.005	;	Heterocomplex of coil 2B domains of human intermediate filament proteins, keratin 5 (KRT5) and keratin 14 (KRT14)
4V1T	;	2.14	;	Heterocyclase in complex with substrate and Cofactor
4V1U	;	2.86	;	Heterocyclase in complex with substrate and Cofactor
4V1V	;	3.01	;	Heterocyclase in complex with substrate and Cofactor
1G05	;	2.45	;	HETEROCYCLE-BASED MMP INHIBITOR WITH P2'SUBSTITUENTS
1U9H	;	2.17	;	Heterocyclic Peptide Backbone Modification in GCN4-pLI Based Coiled Coils: Replacement of E(22)L(23)
1U9F	;	2.2	;	Heterocyclic Peptide Backbone Modification in GCN4-pLI Based Coiled Coils: Replacement of K(15)L(16)
1U9G	;	2.2	;	Heterocyclic Peptide Backbone Modification in GCN4-pLI Based Coiled Coils: Replacement of K(8)L(9)
2AG3	;	2.0	;	Heterocyclic Peptide Backbone Modification in Gcn4-pLI Based Coiled Coils: Substitution of the K(15)-L(16) amide with a triazole
1JK9	;	2.9	;	Heterodimer between H48F-ySOD1 and yCCS
2L9B	;		;	Heterodimer between Rna14p monkeytail domain and Rna15p hinge domain of the yeast CF IA complex
5XED	;	1.55	;	Heterodimer constructed from M61A PA cyt c551-HT cyt c552 and HT cyt c552-PA cyt c551 chimeric proteins
5XEC	;	1.1	;	Heterodimer constructed from PA cyt c551-HT cyt c552 and HT cyt c552-PA cyt c551 chimeric proteins
5XN6	;	3.598	;	Heterodimer crystal structure of geranylgeranyl diphosphate synthases 1 with GGPPS Recruiting Protein(OsGRP) from Oryza sativa
8ALO	;	3.002	;	Heterodimer formation of sensory domains of Vibrio cholerae regulators ToxR and ToxS
7RHZ	;	4.48	;	Heterodimer of Cre recombinase mutants D33A/A36V/R192A and R72E/L115D/R119D in complex with loxP DNA.
4WV6	;	1.75	;	Heterodimer of Importin alpha 1 with nuclear localization signal of TAF8
1OEY	;	2.0	;	Heterodimer of p40phox and p67phox PB1 domains from human NADPH oxidase
4WV4	;	1.909	;	Heterodimer of TAF8/TAF10
8G18	;	2.85	;	Heterodimer of the GluN1b-GluN2B NMDA receptor amino-terminal domains bound to allosteric inhibitor 93-108
6E7W	;	2.67	;	Heterodimer of the GluN1b-GluN2B NMDA receptor amino-terminal domains bound to allosteric inhibitor 93-115
6E7U	;	2.27	;	Heterodimer of the GluN1b-GluN2B NMDA receptor amino-terminal domains bound to allosteric inhibitor 93-31
6E7R	;	2.1	;	Heterodimer of the GluN1b-GluN2B NMDA receptor amino-terminal domains bound to allosteric inhibitor 93-4
6E7S	;	2.72	;	Heterodimer of the GluN1b-GluN2B NMDA receptor amino-terminal domains bound to allosteric inhibitor 93-5
6E7T	;	2.31	;	Heterodimer of the GluN1b-GluN2B NMDA receptor amino-terminal domains bound to allosteric inhibitor 93-6
6E7V	;	2.6	;	Heterodimer of the GluN1b-GluN2B NMDA receptor amino-terminal domains bound to allosteric inhibitor 93-88
6E7X	;	2.58	;	Heterodimer of the GluN1b-GluN2B NMDA receptor amino-terminal domains bound to allosteric inhibitor 93-97
7VBQ	;	1.95	;	Heterodimer structure of Fe(II)/(alpha)ketoglutarate-dependent dioxygenase TlxIJ
6RAI	;	2.9	;	Heterodimeric ABC exporter TmrAB in ATP-bound outward-facing occluded conformation
6RAH	;	2.8	;	Heterodimeric ABC exporter TmrAB in ATP-bound outward-facing open conformation
6RAF	;	3.8	;	Heterodimeric ABC exporter TmrAB in inward-facing narrow conformation under turnover conditions
6RAN	;	4.2	;	Heterodimeric ABC exporter TmrAB in inward-facing wide conformation
6RAG	;	4.2	;	Heterodimeric ABC exporter TmrAB in inward-facing wide conformation under turnover conditions
6RAK	;	3.3	;	Heterodimeric ABC exporter TmrAB in vanadate trapped outward-facing occluded conformation
6RAJ	;	3.5	;	Heterodimeric ABC exporter TmrAB in vanadate trapped outward-facing open conformation
6RAL	;	3.5	;	Heterodimeric ABC exporter TmrAB under turnover conditions in asymmetric unlocked return conformation
6RAM	;	3.8	;	Heterodimeric ABC exporter TmrAB under turnover conditions in asymmetric unlocked return conformation with wider opened intracellular gate
8FPF	;	3.27	;	Heterodimeric ABC transporter BmrCD in the inward-facing conformation bound to ATP: BmrCD_IF-ATP
8T3K	;	3.33	;	Heterodimeric ABC transporter BmrCD in the inward-facing conformation bound to ATP: BmrCD_IF-ATP2
8SZC	;	3.06	;	Heterodimeric ABC transporter BmrCD in the inward-facing conformation bound to substrate and ATP: BmrCD_IF-1HT/ATP
8FMV	;	3.34	;	Heterodimeric ABC transporter BmrCD in the inward-facing conformation bound to substrate and ATP: BmrCD_IF-2HT/ATP
8T1P	;	2.96	;	Heterodimeric ABC transporter BmrCD in the occluded conformation bound to ADPVi: BmrCD_OC-ADPVi
8FHK	;	2.9	;	Heterodimeric ABC transporter BmrCD in the occluded conformation bound to ATP: BmrCD_OC-ATP
2KS1	;		;	Heterodimeric association of Transmembrane domains of ErbB1 and ErbB2 receptors Enabling Kinase Activation
4PAS	;	1.62	;	Heterodimeric coiled-coil structure of human GABA(B) receptor
8OK9	;	2.5	;	Heterodimeric complex of Archaeoglobus fulgidus Argonaute protein Af1318 (AfAgo) with DNA and AfAgo-N protein containing N-L1-L2 domains
7S7Q	;	2.85	;	Heterodimeric complex of Pf12 and Pf41 of Plasmodium falciparum
4XRS	;	3.5	;	Heterodimeric complex of transcription factors MEIS1 and DLX3 on specific DNA
4BSV	;	1.75	;	Heterodimeric Fc Antibody Azymetric Variant 1
4BSW	;	2.15	;	Heterodimeric Fc Antibody Azymetric Variant 2
7TTZ	;	2.35	;	Heterodimeric IgA Fc in complex with Staphylococcus aureus protein SSL7
7OVO	;	2.1	;	Heterodimeric murine tRNA-guanine transglycosylase in complex with queuine
7OWZ	;	2.6	;	Heterodimeric murine tRNA-guanine transglycosylase in complex with queuine and in the presence of Anderson-Evans type (TEW) and Strandberg type polyoxometalate (POM)
7OVS	;	2.6	;	Heterodimeric murine tRNA-guanine transglycosylase in the presence of Anderson-Evans type (TEW) and Strandberg type polyoxometalate (POM)
3WYO	;	2.0	;	Heterodimeric myoglobin formed by domain swapping
5TTH	;	3.2	;	Heterodimeric SpyCatcher/SpyTag-fused zebrafish TRAP1 in ATP/ADP-hybrid state
4NIF	;	2.15	;	Heterodimeric structure of ERK2 and RSK1
1ZT2	;	3.33	;	Heterodimeric structure of the core primase.
7B2I	;	1.65	;	Heterodimeric tRNA-Guanine Transglycosylase from mouse
7OV9	;	1.9	;	Heterodimeric tRNA-Guanine Transglycosylase from mouse, apo-structure
6DTK	;	2.0	;	Heterodimers of FALS mutant SOD enzyme
5ODC	;	2.3	;	Heterodisulfide reductase / [NiFe]-hydrogenase complex from Methanothermococcus thermolithotrophicus at 2.3 A resolution
5ODI	;	2.4	;	Heterodisulfide reductase / [NiFe]-hydrogenase complex from Methanothermococcus thermolithotrophicus cocrystallized with CoM-SH
5ODQ	;	2.15	;	Heterodisulfide reductase / [NiFe]-hydrogenase complex from Methanothermococcus thermolithotrophicus soaked with bromoethanesulfonate.
5ODR	;	2.2	;	Heterodisulfide reductase / [NiFe]-hydrogenase complex from Methanothermococcus thermolithotrophicus soaked with heterodisulfide for 2 minutes.
5ODH	;	2.2	;	Heterodisulfide reductase / [NiFe]-hydrogenase complex from Methanothermococcus thermolithotrophicus soaked with heterodisulfide for 3.5 minutes
1K1H	;		;	HETERODUPLEX OF CHIRALLY PURE METHYLPHOSPHONATE/DNA DUPLEX
1K1R	;		;	HETERODUPLEX OF CHIRALLY PURE R-METHYLPHOSPHONATE/DNA DUPLEX
4WC8	;	1.908	;	Heterogeneous dodecamer formed from macrocycles containing a sequence from beta-2-microglobulin(63-69).
1TXP	;		;	Heterogeneous Nuclear Ribonucleoprotein (hnRNP) C Oligomerization Domain Tetramer
1HD0	;		;	HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN D0 (HNRNP D0 RBD1), NMR
1HD1	;		;	HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN D0 (HNRNP D0 RBD1), NMR
7ZUG	;	1.075	;	Heterogeneous nuclear ribonucleoprotein H1, qRRM2 domain
5US3	;		;	Heterogeneous-backbone Foldamer Mimic of the Sp1-3 Zinc Finger
6E5H	;		;	Heterogeneous-Backbone Mimics of a Designed Disulfide-Rich Protein: Aib turn
6E5K	;		;	Heterogeneous-Backbone Mimics of a Designed Disulfide-Rich Protein: Aib turn, Aib helix, N-methyl hairpin
6E5J	;		;	Heterogeneous-Backbone Mimics of a Designed Disulfide-Rich Protein: Aib turn, beta3 helix, N-methyl hairpin
6E5I	;		;	Heterogeneous-Backbone Mimics of a Designed Disulfide-Rich Protein: Orn turn
7RAP	;		;	Heterogeneous-backbone proteomimetic analogue of the disulfide-rich venom peptide lasiocepsin
7TV7	;		;	Heterogeneous-backbone proteomimetic analogue of the disulfide-rich venom peptide lasiocepsin: beta-3-Lys modified loop
7TV8	;		;	Heterogeneous-backbone proteomimetic analogue of the disulfide-rich venom peptide lasiocepsin: D-Ala modified loop
7TV6	;		;	Heterogeneous-backbone proteomimetic analogue of the disulfide-rich venom peptide lasiocepsin: native loop
8FUL	;	2.29	;	Heterologous AibH1H2 purified from Lysogeny broth
8ARC	;	2.1	;	Heterologous Complex of Aeromonas hydrophila Type III secretion substrate AscX with Photorhabdus luminescens subsp. laumondii LscY
8ARA	;	2.3	;	Heterologous Complex of Aeromonas hydrophila Type III secretion substrate AscX with Yersinia enterocolitica chaperone YscY
8ARB	;	2.63	;	Heterologous Complex of shortened Aeromonas hydrophila Type III secretion substrate AscX with Yersinia enterocolitica chaperone YscY
6LID	;	2.7	;	Heteromeric amino acid transporter b0,+AT-rBAT complex
6LI9	;	2.3	;	Heteromeric amino acid transporter b0,+AT-rBAT complex bound with Arginine
8HLA	;	2.81	;	Heteromeric ring comprised of peroxiredoxin from Thermococcus kodakaraensis (TkPrx) F42C/C46S/C205S/C211S mutant modified with 2-(bromoacetyl)naphthalene (Naph@TkPrx*F42C) and TkPrx C46S/F76C/C205S/C211S mutant modified with 2-(bromoacetyl)naphthalene (Naph@TkPrx*F76C) (Naph@(MIX|3:3))
6HYG	;	2.31	;	Heteromeric tandem IgG4/IgG1 Fc
5L1C	;		;	Heteronuclear Solution Structure of Chlorotoxin
1XOF	;	1.95	;	Heterooligomeric Beta Beta Alpha Miniprotein
3HE5	;	1.75	;	Heterospecific coiled-coil pair SYNZIP2:SYNZIP1
3HE4	;	2.46	;	Heterospecific coiled-coil pair SYNZIP5:SYNZIP6
2GAG	;	1.85	;	Heteroteterameric sarcosine: structure of a diflavin metaloenzyme at 1.85 a resolution
7YCS	;	1.79	;	Heterotetramer of Antitoxin PrpA together with Toxin PrpT from Pseudoalteromonas rubra
7YCU	;	1.79	;	Heterotetramer of Antitoxin PrpA together with Toxin PrpT from Pseudoalteromonas rubra
8B69	;	3.07	;	Heterotetramer of K-Ras4B(G12V) and Rgl2(RBD)
2YFW	;	2.6	;	Heterotetramer structure of Kluyveromyces lactis Cse4,H4
4NUV	;	2.6	;	Heterotetramer structure of Region II from Plasmodium vivax Duffy Binding Protein (PvDBP) bound to the ectodomain of the Duffy Antigen Receptor for Chemokines (DARC)
7EIV	;	2.68	;	heterotetrameric glycyl-tRNA synthetase from Escherichia coli
6GZC	;	2.0	;	heterotetrameric katanin p60:p80 complex
3AD7	;	2.2	;	Heterotetrameric Sarcosine Oxidase from Corynebacterium sp. U-96 in complex with methylthio acetate
3AD8	;	2.2	;	Heterotetrameric Sarcosine Oxidase from Corynebacterium sp. U-96 in complex with pyrrole 2-carboxylate
3ADA	;	2.2	;	Heterotetrameric Sarcosine Oxidase from Corynebacterium sp. U-96 in complex with sulfite
3AD9	;	2.3	;	Heterotetrameric Sarcosine Oxidase from Corynebacterium sp. U-96 sarcosine-reduced form
2GAH	;	2.0	;	Heterotetrameric sarcosine: structure of a diflavin metaloenzyme at 1.85 a resolution
6YUP	;	2.9	;	Heterotetrameric structure of the rBAT-b(0,+)AT1 complex
4NUU	;	1.95	;	Heterotrimer structure of Region II from Plasmodium vivax Duffy Binding Protein (PvDBP) bound to the ectodomain of the Duffy Antigen Receptor for Chemokines (DARC)
1GOT	;	2.0	;	HETEROTRIMERIC COMPLEX OF A GT-ALPHA/GI-ALPHA CHIMERA AND THE GT-BETA-GAMMA SUBUNITS
1A0R	;	2.8	;	HETEROTRIMERIC COMPLEX OF PHOSDUCIN/TRANSDUCIN BETA-GAMMA
5KDO	;	1.9	;	Heterotrimeric complex of the 4 alanine insertion variant of the Gi alpha1 subunit and the Gbeta1-Ggamma1
6CRK	;	2.0	;	Heterotrimeric G-protein in complex with an antibody fragment
2KW3	;		;	Heterotrimeric interaction between RFX5 and RFXAP
2HII	;	2.79	;	heterotrimeric PCNA sliding clamp
2HIK	;	3.3	;	heterotrimeric PCNA sliding clamp
8E0O	;	2.1	;	Heterotrimeric variant of tcTRP9, hetBGL03-15-18
5H83	;	2.25	;	HETEROYOHIMBINE SYNTHASE HYS FROM CATHARANTHUS ROSEUS - APO FORM
5FI5	;	2.25	;	HETEROYOHIMBINE SYNTHASE THAS1 FROM CATHARANTHUS ROSEUS - APO FORM
5FI3	;	1.05	;	HETEROYOHIMBINE SYNTHASE THAS1 FROM CATHARANTHUS ROSEUS - COMPLEX WITH NADP+
5H82	;	2.05	;	HETEROYOHIMBINE SYNTHASE THAS2 FROM CATHARANTHUS ROSEUS - APO FORM
5H81	;	2.1	;	HETEROYOHIMBINE SYNTHASE THAS2 FROM CATHARANTHUS ROSEUS - COMPLEX WITH NADP+
4WP4	;	1.43	;	Hev b 6.02 (hevein) extracted from surgical gloves
7BV0	;	1.801	;	HEV-C E2s
1LLO	;	1.85	;	HEVAMINE A (A PLANT ENDOCHITINASE/LYSOZYME) COMPLEXED WITH ALLOSAMIDIN
2HVM	;	1.8	;	HEVAMINE A AT 1.8 ANGSTROM RESOLUTION
1KR1	;	2.0	;	Hevamine Mutant D125A/E127A in Complex with Tetra-NAG
1KQY	;	1.92	;	Hevamine Mutant D125A/E127A/Y183F in Complex with Penta-NAG
1KQZ	;	1.92	;	Hevamine Mutant D125A/E127A/Y183F in Complex with Tetra-NAG
1KR0	;	1.92	;	Hevamine Mutant D125A/Y183F in Complex with Tetra-NAG
2LB7	;		;	Hevein-type Antifungal Peptide with a Unique 10-Cysteine Motif
1HEV	;		;	HEVEIN: THE NMR ASSIGNMENT AND AN ASSESSMENT OF SOLUTION-STATE FOLDING FOR THE AGGLUTININ-TOXIN MOTIF
4IAS	;	2.6	;	HEW Lysozyme by langmuir- blodgett modified vapour diffusion
4IAT	;	2.0	;	HEW Lysozyme by langmuir- blodgett modified vapour diffusion
7A70	;	1.8	;	HEW lysozyme in complex with Ti(OH)4
6Q8R	;	1.7	;	HEW Lysozyme under 2 kbar of argon
1LPI	;	2.0	;	HEW LYSOZYME: TRP...NA CATION-PI INTERACTION
2BLY	;	1.4	;	HEWL after a high dose x-ray ""burn""
2VB1	;	0.65	;	HEWL at 0.65 angstrom resolution
2BLX	;	1.4	;	HEWL before a high dose x-ray ""burn""
4LT1	;	2.3	;	HEWL co-crystallised with Carboplatin in non-NaCl conditions: crystal 1 processed using the XDS software package
3TXD	;	1.53	;	HEWL co-crystallization with carboplatin in aqueous media with glycerol as the cryoprotectant
3TXE	;	1.7	;	HEWL co-crystallization with carboplatin in aqueous media with paratone as the cryoprotectant
3TXH	;	1.69	;	HEWL co-crystallization with carboplatin in DMSO media with glycerol as the cryoprotectant
3TXI	;	1.6	;	HEWL co-crystallization with carboplatin in DMSO media with paratone as the cryoprotectant
3TXB	;	1.59	;	HEWL co-crystallization with cisplatin in aqueous media with glycerol as the cryoprotectant
3TXF	;	1.69	;	HEWL co-crystallization with cisplatin in DMSO media with glycerol as the cryoprotectant
3TXG	;	1.7	;	HEWL co-crystallization with cisplatin in DMSO media with paratone as the cryoprotectant
3TXK	;	3.0	;	HEWL co-crystallization with cisplatin in DMSO media with paratone as the cryoprotectant at pH 6.5
3TXJ	;	2.48	;	HEWL co-crystallization with NAG with silicone oil as the cryoprotectant
4LT0	;	2.1	;	HEWL co-crystallized with Carboplatin in non-NaCl conditions: crystal 1 processed using the EVAL software package
4LT2	;	2.0	;	HEWL co-crystallized with Carboplatin in non-NaCl conditions: crystal 2 processed using the EVAL software package
4LT3	;	2.0	;	HEWL co-crystallized with Carboplatin in non-NaCl conditions: crystal 2 processed using the XDS software package
6A4Q	;	1.75	;	HEWL crystals soaked in 2.5M GuHCl for 110 minutes
6A4O	;	1.75	;	HEWL crystals soaked in 2.5M GuHCl for 20 minutes
6A4P	;	1.76	;	HEWL crystals soaked in 2.5M GuHCl for 40 minutes
6A4N	;	1.75	;	HEWL crystals soaked in 2.5M GuHCl for 8 minutes
7BMR	;	1.78	;	HEWL in cesium chloride (0.25 M CsCl in protein buffer and 1.71 M CsCl in cryo protectant)
7BMP	;	1.9	;	HEWL in cesium chloride (0.25 M CsCl in protein buffer and cryo protectant).
7BMO	;	1.9	;	HEWL in cesium chloride (0.25 M CsCl in protein buffer)
7BMS	;	1.75	;	HEWL in cesium chloride (1.5 M CsCl in crystallization condition and cryo protectant)
7BMQ	;	1.79	;	HEWL in cesium chloride (1.71 M CsCl in cryo protectant)
7BMT	;	1.47	;	HEWL in sodium chloride
6QWW	;	1.35	;	HEWL lysozyme, crystallized from CuCl2 solution
6QWZ	;	1.35	;	HEWL lysozyme, crystallized from KCl solution
6QX0	;	1.35	;	HEWL lysozyme, crystallized from LiCl solution
6QWY	;	1.35	;	HEWL lysozyme, crystallized from NaCl solution
6QWX	;	1.35	;	HEWL lysozyme, crystallized from NiCl2 solution
8C5K	;	2.16	;	HEX-1 (in cellulo, in situ) crystallized and diffracted in High Five cells. Growth and SX data collection at 296 K on CrystalDirect plates
7NJH	;	2.5	;	HEX1 (in cellulo) grown inside HARE serial crystallography chip
7NJI	;	2.3	;	HEX1 (in cellulo) loaded on HARE serial crystallography chip
2WX5	;	2.63	;	Hexa-coordination of a bacteriochlorophyll cofactor in the Rhodobacter sphaeroides reaction centre
6LR1	;	2.5	;	Hexachlorobenzene Monooxygenase (HcbA1) from Nocardioides sp. strain PD653
7CZA	;	3.21	;	Hexachlorobenzene monooxygenase (HcbA1) from Nocardioides sp. strain PD653 complexed with FMN
1GWS	;	2.4	;	hexadecaheme high molecular weight cytochrome Hmc from Desulfovibrio vulgaris Hildenborough
7URZ	;	3.45	;	Hexadecameric hub domain of CaMKII beta
3DMZ	;	2.0	;	Hexafluorobenzene binding in the hydrophobic cavity of T4 lysozyme L99A mutant
3QLA	;	1.6	;	Hexagonal complex structure of ATRX ADD bound to H3K9me3 peptide
2UV1	;	2.6	;	Hexagonal crystal form of GamS from bacteriophage lambda.
3ZTQ	;	2.1	;	Hexagonal crystal form P61 of the Aquifex aeolicus nucleoside diphosphate kinase
3C17	;	1.95	;	Hexagonal Crystal Structure of Precursor E. coli Isoaspartyl Peptidase/l-Asparaginase (ECAIII) with Active-site T179A mutation
3D1D	;	2.6	;	Hexagonal crystal structure of Tas3 C-terminal alpha motif
4R0N	;	2.0	;	Hexagonal form of phosphopantetheine adenylyltransferase from Mycobacterium tuberculosis
3ZTS	;	2.3	;	Hexagonal form P6122 of the Aquifex aeolicus nucleoside diphosphate kinase (FINAL STAGE OF RADIATION DAMAGE)
3ZTR	;	2.3	;	Hexagonal form P6122 of the Aquifex aeolicus nucleoside diphosphate kinase (FIRST STAGE OF RADIATION DAMAGE)
3BQB	;	2.7	;	Hexagonal kristal form of 2-keto-3-deoxyarabinonate dehydratase
3DL2	;	2.1	;	Hexagonal structure of the LDH domain of Human Ubiquitin-conjugating Enzyme E2-like Isoform A
6D5O	;	2.00005	;	Hexagonal thermolysin (295 K) in the presence of 50% DMF
6D5N	;	2.00004	;	Hexagonal thermolysin (295) in the presence of 50% xylose
6D5P	;	3.00011	;	Hexagonal thermolysin cryocooled to 100 K with 20% xylose as cryoprotectant
6D5Q	;	2.00016	;	Hexagonal thermolysin cryocooled to 100 K with 30% xylose as cryoprotectant
6D5U	;	2.0001	;	Hexagonal thermolysin cryocooled to 100 K with 50% methanol as cryoprotectant
6D5S	;	2.00004	;	Hexagonal thermolysin cryocooled to 100 K with 50% MPD as cryoprotectant
6D5T	;	2.00004	;	Hexagonal thermolysin cryocooled to 100 K with 50% MPD as cryoprotectant
6D5R	;	2.00002	;	Hexagonal thermolysin cryocooled to 100 K with 50% xylose as cryoprotectant
4X0S	;	2.032	;	Hexamer formed by a macrocycle containing a sequence from beta-2-microglobulin (63-69).
4P4V	;	1.97	;	Hexamer formed by a macrocyclic peptide derived from beta-2-microglobulin (63-69) - (ORN)YLL(PHI)YTE(ORN)KVA(MAA)AVK
4P4Y	;	1.509	;	Hexamer formed by a macrocyclic peptide derived from beta-2-microglobulin (63-69) - (ORN)YLL(PHI)YTE(ORN)KVT(MAA)TVK
7SNQ	;	2.81	;	Hexamer HIV-1 CA in complex with CPSF6 peptide and IP6 ligand
4U0B	;	2.8	;	Hexamer HIV-1 CA in complex with CPSF6 peptide, P212121 crystal form
6VWS	;	6.08	;	Hexamer of Helical HIV capsid by RASTR method
6ECO	;	4.2	;	Hexamer-2-Foldon HIV-1 capsid platform
3CR8	;	2.95	;	Hexameric APS kinase from Thiobacillus denitrificans
6PIH	;	6.6	;	Hexameric ArnA cryo-EM structure
7O41	;	7.6	;	Hexameric composite model of the Inner Membrane Complex (IMC) with the Arches from the fully-assembled R388 type IV secretion system determined by cryo-EM.
4IDX	;	3.21	;	hexameric crystal structure of Schmallenberg virus nucleoprotein
4LF1	;	2.38	;	Hexameric Form II RuBisCO from Rhodopseudomonas palustris, activated and complexed with 2-CABP
4LF2	;	2.38	;	Hexameric Form II RuBisCO from Rhodopseudomonas palustris, activated and complexed with sulfate and magnesium
7T13	;	3.15	;	Hexameric HIV-1 (M-group) CA Q50Y mutant
7QDF	;	2.304	;	Hexameric HIV-1 (M-group) CA R120 mutant
8D3B	;	3.3	;	Hexameric HIV-1 (M-group) Q50Y/R120 mutant
7T12	;	3.0	;	Hexameric HIV-1 (O-group) CA
5JPA	;	1.7	;	Hexameric HIV-1 CA H12Y mutant
4U0F	;	2.22	;	Hexameric HIV-1 CA in Complex with BI-2
4U0A	;	2.05	;	Hexameric HIV-1 CA in complex with CPSF6 peptide, P6 crystal form
5HGM	;	2.04	;	Hexameric HIV-1 CA in complex with dATP
8QUI	;	1.69	;	Hexameric HIV-1 CA in complex with DDD00024969
8QUH	;	1.55	;	Hexameric HIV-1 CA in complex with DDD00057456
8QUB	;	1.63	;	Hexameric HIV-1 CA in complex with DDD00074110
8QUX	;	2.3	;	Hexameric HIV-1 CA in complex with DDD00100333
8QUK	;	1.38	;	Hexameric HIV-1 CA in complex with DDD00100439
8QUJ	;	1.63	;	Hexameric HIV-1 CA in complex with DDD00100452
8QUL	;	1.67	;	Hexameric HIV-1 CA in complex with DDD00100555
8QUW	;	2.02	;	Hexameric HIV-1 CA in complex with DDD01044153
8QUY	;	1.88	;	Hexameric HIV-1 CA in complex with DDD01728501
8QV4	;	2.7	;	Hexameric HIV-1 CA in complex with DDD01728503
8QV1	;	2.2	;	Hexameric HIV-1 CA in complex with DDD01728505
8QV9	;	1.76	;	Hexameric HIV-1 CA in complex with DDD01829021
8QVA	;	2.0	;	Hexameric HIV-1 CA in complex with DDD01829894
5HGP	;	1.95	;	Hexameric HIV-1 CA in complex with hexacarboxybenzene
4U0D	;	3.0	;	Hexameric HIV-1 CA in complex with Nup153 peptide, P212121 crystal form
4U0C	;	1.77	;	Hexameric HIV-1 CA in complex with Nup153 peptide, P6 crystal form
4U0E	;	2.043	;	Hexameric HIV-1 CA in complex with PF3450074
5HGO	;	2.0	;	Hexameric HIV-1 CA R18G mutant
5HGN	;	1.9	;	Hexameric HIV-1 CA, apo form
5HGL	;	3.1	;	Hexameric HIV-1 CA, open conformation
8BTB	;	14.0	;	Hexameric human IgG3 Fc complex
1OLO	;	2.55	;	Hexameric Replicative DNA Helicase RepA from Plasmid RSF1010 - Cubic Crystal Structure
8IGW	;	4.2	;	Hexameric Ring Complex of Engineered V1-ATPase bound to 4 ADPs: A3(De)3_(ADP)3cat,1non-cat, Hexameric Ring Complex of Engineered V1-ATPase bound to 5 ADPs: A3(De)3_(ADP)3cat,2non-cat
8IGV	;	3.15	;	Hexameric Ring Complex of Engineered V1-ATPase bound to 5 ADPs: A3(De)3_(ADP-Pi)1cat(ADP)2cat,2non-cat
7COQ	;	3.44	;	Hexameric Ring Complex of Engineered V1-ATPase bound to AMP-PNP: A3(De)3_(ANP)1cat
8IGU	;	2.77	;	Hexameric Ring Complex of Engineered V1-ATPase: A3(De)3_empty
4DC9	;	2.6	;	Hexameric ring of Methanococcus voltae RadA
4J4R	;	1.9	;	Hexameric SFTSVN
7T15	;	2.05	;	Hexameric SIVcpz CA
7T14	;	2.25	;	Hexameric SIVmac CA
5E7S	;	3.03	;	Hexameric structure of a LonA protease domain in active state
5ZL1	;	3.2	;	Hexameric structure of copper-containing nitrite reductase of an anammox organism KSU-1
6L8D	;	2.91	;	Hexameric structure of the ATPase subunit of magnesium chelatase
2NZM	;	1.8	;	Hexasaccharide I bound to Bacillus subtilis pectate lyase
1BDG	;	2.6	;	HEXOKINASE FROM SCHISTOSOMA MANSONI COMPLEXED WITH GLUCOSE
6RSW	;	1.95	;	HFD domain of mouse CAP1 bound to the pointed end of G-actin
1A6Z	;	2.6	;	HFE (HUMAN) HEMOCHROMATOSIS PROTEIN
8P91	;	1.4	;	Hfq from Chromobacterium haemolyticum; a P6 space group monomer
6XYJ	;	2.772	;	Hfq from E.coli with inserted long loop L4 sequence
4J6Y	;	2.1405	;	Hfq from Pseudomonas aeruginosa crystallized in GTP presence
6BDG	;	1.964	;	HFQ monomer in spacegroup p6 at 1.93 angstrom resolution
1U1T	;	1.9	;	Hfq protein from Pseudomonas aeruginosa. High-salt crystals
1U1S	;	1.6	;	Hfq protein from Pseudomonas aeruginosa. Low-salt crystals
8BVJ	;	4.5	;	Hfq-Crc-estA translation repression complex
3HCN	;	1.6	;	Hg and protoporphyrin bound Human Ferrochelatase
1QML	;	3.0	;	Hg complex of yeast 5-aminolaevulinic acid dehydratase
2YAW	;	2.499	;	HG INHIBITED SULFUR OXYGENASE REDUCTASE
1DHG	;	2.5	;	HG-SUBSTITUTED DESULFOREDOXIN
6NUG	;		;	hGRNA4-28_3s
2MW2	;		;	Hha-H-NS46 charge zipper complex
2C7R	;	1.9	;	HhaI DNA methyltransferase (T250G mutant) complex with oligonucleotide containing 2-aminopurine as a target base (GPGC:GMGC) and SAH
2C7O	;	1.9	;	HhaI DNA methyltransferase complex with 13mer oligonucleotide containing 2-aminopurine adjacent to the target base (PCGC:GMGC) and SAH
2C7P	;	1.7	;	HhaI DNA methyltransferase complex with oligonucleotide containing 2- aminopurine opposite to the target base (GCGC:GMPC) and SAH
2C7Q	;	1.85	;	HhaI DNA methyltransferase complex with oligonucleotide containing 2- aminopurine outside the recognition sequence (paired with G) and SAH
2UYC	;	2.0	;	HhaI DNA methyltransferase R163N mutant complex with 13mer GCGC-GMGC oligonucleotide and SAH
2UZ4	;	2.1	;	HhaI DNA methyltransferase R165N mutant complex with 13mer GCGC-GMGC oligonucleotide and SAH
2UYH	;	2.63	;	HhaI DNA methyltransferase S87Q-Q237S mutant complex with 13mer GCGC- GMGC oligonucleotide and SAH
6UKF	;	1.0	;	HhaI endonuclease in Complex with DNA at 1 Angstrom Resolution
6UKG	;	1.16	;	HhaI endonuclease in Complex With DNA in space group P21 (pH 4.2)
6UKI	;	2.7	;	HhaI endonuclease in Complex with DNA in space group P212121 (pH 6.0)
6UKH	;	2.82	;	HhaI endonuclease in Complex with DNA in space group P41212 (pH 6.0)
6UKE	;	1.62	;	HhaI endonuclease in Complex with Iodine-Labelled DNA
1SKM	;	2.2	;	HhaI methyltransferase in complex with DNA containing an abasic south carbocyclic sugar at its target site
5UDH	;	3.24	;	HHARI/ARIH1-UBCH7~Ubiquitin
6UJO	;	2.25	;	HHAT L75F Neoantigen Peptide KQWLVWLFL Presented by HLA-A206
6UJQ	;	2.55	;	HHAT Wild Type Peptide KQWLVWLLL Presented by HLA-A206
5I8K	;	1.771	;	HHH1 Fab fragment
7PGM	;	2.7	;	HHIP-C in complex with heparin
7PGL	;	2.63	;	HHIP-N, the N-terminal domain of the Hedgehog-Interacting Protein (HHIP), apo-form
7PGK	;	2.75	;	HHIP-N, the N-terminal domain of the Hedgehog-Interacting Protein (HHIP), in complex with glycosaminoglycan mimic SOS
7PGN	;	2.4	;	HHP-C in complex with glycosaminoglycan mimic SOS
1QZE	;		;	HHR23a protein structure based on residual dipolar coupling data
2APN	;		;	hi1723 solution structure
2GR8	;	2.0	;	Hia 1022-1098
2GR7	;	2.3	;	Hia 992-1098
5ND9	;	3.7	;	Hibernating ribosome from Staphylococcus aureus (Rotated state)
5ND8	;	3.7	;	Hibernating ribosome from Staphylococcus aureus (Unrotated state)
3PDM	;	3.5	;	Hibiscus Latent Singapore virus
7TXC	;	3.04	;	HIC2 zinc finger domain in complex with the DNA binding motif-2 of the BCL11A enhancer
4P78	;	2.12	;	HicA3 and HicB3 toxin-antitoxin complex
6YOZ	;	1.88	;	HiCel7B labelled with b-1,4-glucosyl cyclophellitol
6YP1	;	1.2	;	HiCel7B unliganded
6XH5	;	3.32	;	Hierarchical design of multi-scale protein complexes by combinatorial assembly of oligomeric helical bundle and repeat protein building blocks
6XI6	;	2.69	;	Hierarchical design of multi-scale protein complexes by combinatorial assembly of oligomeric helical bundle and repeat protein building blocks
5L9V	;	1.829	;	HIF prolyl hydroxylase 2 (PHD2-R281C/P317C) cross-linked to HIF-1alpha NODD-L397C/D412C and N-oxalylglycine (NOG) (complex-1)
5LAS	;	2.1	;	HIF prolyl hydroxylase 2 (PHD2-R281C/P317C/R396T) cross-linked to HIF-1alpha NODD-L397C/D412C and N-oxalylglycine (NOG) (complex-3)
5LA9	;	2.813	;	HIF prolyl hydroxylase 2 (PHD2-R281C/V314C) cross-linked to HIF-1alpha NODD-L397C/D412C and N-oxalylglycine (NOG) (complex-2)
4UWD	;	1.721	;	HIF prolyl hydroxylase 2 (PHD2/ EGLN1) D315E VARIANT in complex with Mn(II) and N-[(1-chloro-4-hydroxyisoquinolin-3-yl)carbonyl]glycine (IOX3/UN9)
5L9B	;	1.95	;	HIF PROLYL HYDROXYLASE 2 (PHD2/ EGLN1) IN COMPLEX WITH 2-OXOGLUTARATE (2OG) AND HIF-1ALPHA CODD (556-574)
6YW1	;	1.46	;	HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with 2OG and RaPID-derived silent allosteric cyclic peptide 3C (14-mer)
6ST3	;	2.426	;	HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with 4-hydroxy-N-(4-phenoxybenzyl)-2-(1H-pyrazol-1-yl)pyrimidine-5-carboxamide
6QGV	;	1.4	;	HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with a Spiro[4.5]decanone inhibitor (JPHM-2-167)
6YVX	;	1.8	;	HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with bicyclic BB-287
6YW2	;	2.14	;	HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with bicyclic FG2216 and RaPID-derived cyclic peptide 3C (14-mer)
6YVZ	;	1.91	;	HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with bicyclic JLS-367
5OX5	;	2.251	;	HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with CCT6, a GSK1278863-related compound
4BQY	;	1.53	;	HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with Fe(II) and N-[(1-chloro-4-hydroxyisoquinolin-3-yl)carbonyl]alanine
6YVT	;	2.847	;	HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with MD-253
4BQW	;	1.79	;	HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with Mn(II) and 2-(4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamido)acetic acid
4BQX	;	1.79	;	HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with Mn(II) and N-[(1-chloro-4-hydroxyisoquinolin-3-yl)carbonyl]glycine (IOX3/UN9)
6YVW	;	1.97	;	HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with monocyclic BB-328
6YW3	;	2.279	;	HIF PROLYL HYDROXYLASE 2 (PHD2/ EGLN1) in complex with N-Oxalyl Glycine (NOG), HIF-1ALPHA CODD (556-574) and a RaPID-derived cyclic peptide 3C (14-mer)
5L9R	;	1.81	;	HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with N-oxalylglycine (NOG)
6YW4	;	1.528	;	HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with N-oxalylglycine (NOG) and a RaPID-derived silent allosteric cyclic peptide 3C (14-mer)
5OX6	;	1.99	;	HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with Vadadustat
5LBE	;	1.749	;	HIF prolyl hydroxylase 2 (PHD2/EGLN1) G294E variant in complex with Mn(II) and N-[(1-chloro-4-hydroxyisoquinolin-3-yl)carbonyl]glycine (IOX3/FG2216)
5LBC	;	1.816	;	HIF prolyl hydroxylase 2 (PHD2/EGLN1) I280V/R281L/I292V variant in complex with Mn(II) and N-[(1-chloro-4-hydroxyisoquinolin-3-yl)carbonyl]glycine (IOX3/FG2216)
6ZBO	;	1.79	;	HIF Prolyl Hydroxylase 2 (PHD2/EGLN1) in Complex with 1-(6-morpholinopyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-ol (Molidustat)
7Q5X	;	1.21	;	HIF PROLYL HYDROXYLASE 2 (PHD2/EGLN1) IN COMPLEX WITH 2-OXOGLUTARATE (2OG) AND HIF-2 ALPHA CODD (523-542)
5A3U	;	3.3	;	HIF prolyl hydroxylase 2 (PHD2/EGLN1) in complex with 6-(5-oxo-4-(1H- 1,2,3-triazol-1-yl)-2,5-dihydro-1H-pyrazol-1-yl)nicotinic acid
7Q5V	;	1.17	;	HIF PROLYL HYDROXYLASE 2 (PHD2/EGLN1) IN COMPLEX WITH N-OXALYLGLYCINE (NOG) AND HIF-2 ALPHA CODD (523-542)
6ZBN	;	2.01	;	HIF Prolyl Hydroxylase 2 (PHD2/EGLN1) in complex with tert-butyl 6-(5-hydroxy-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-1-yl)nicotinate (IOX4)
5LBF	;	1.8995	;	HIF prolyl hydroxylase 2 (PHD2/EGLN1) K293K/G294E variant in complex with Mn(II) and N-[(1-chloro-4-hydroxyisoquinolin-3-yl)carbonyl]glycine (IOX3/FG2216)
5LAT	;	1.9	;	HIF prolyl hydroxylase 2 (PHD2/EGLN1) P317R variant in complex with Mn(II) and N-[(1-chloro-4-hydroxyisoquinolin-3-yl)carbonyl]glycine (IOX3/UN9)
5LB6	;	1.7	;	HIF prolyl hydroxylase 2 (PHD2/EGLN1) R371H variant in complex with Mn(II) and N-[(1-chloro-4-hydroxyisoquinolin-3-yl)carbonyl]glycine (IOX3/UN9)
5LBB	;	1.7	;	HIF prolyl hydroxylase 2 (PHD2/EGLN1) R396T variant in complex with Mn(II) and N-[(1-chloro-4-hydroxyisoquinolin-3-yl)carbonyl]glycine (IOX3/UN9)
2MO5	;		;	hIFABP-oleate complex
2MJI	;		;	HIFABP_Ketorolac_complex
6JQ4	;	2.0	;	HIGA Escherichia coli-K12
4JFH	;	2.4	;	High Affinity alpha24-beta17 T Cell Receptor for A2 HLA-Melanoma peptide complex
3J1T	;	9.7	;	High affinity dynein microtubule binding domain - tubulin complex
1UZV	;	1.0	;	High affinity fucose binding of Pseudomonas aeruginosa lectin II: 1.0 A crystal structure of the complex
1RPQ	;	3.0	;	High Affinity IgE Receptor (alpha chain) Complexed with Tight-Binding E131 'zeta' Peptide from Phage Display
3UTU	;	1.55	;	High affinity inhibitor of human thrombin
8G0I	;	2.2	;	High Affinity nanobodies against GFP
3VTG	;	1.34	;	High choriolytic enzyme 1 (HCE-1), a hatching enzyme zinc-protease from Oryzias latipes (Medaka fish)
6WVM	;	3.3	;	High curvature lateral interaction within a 13-protofilament, Taxol stabilized microtubule
2LS7	;		;	High Definition Solution Structure of PED/PEA-15 Death Effector Domain
5LH3	;	1.64	;	High dose Thaumatin - 0-40 ms.
5LMH	;	1.96	;	High dose Thaumatin - 160-200 ms.
5LH6	;	2.16	;	High dose Thaumatin - 360-400 ms.
5LH5	;	1.69	;	High dose Thaumatin - 40-80 ms.
5LH7	;	2.28	;	High dose Thaumatin - 760-800 ms.
4FON	;	1.05	;	High Energy Remote SAD structure solution of Proteinase K from the 37.8 keV Tellurium K edge
1W6Z	;	1.65	;	High Energy Tetragonal Lysozyme X-ray Structure
2KK5	;		;	High Fidelity Base Pairing at the 3'-Terminus
6DRC	;	3.92	;	High IP3 Ca2+ human type 3 1,4,5-inositol trisphosphate receptor
1TIO	;	1.93	;	HIGH PACKING DENSITY FORM OF BOVINE BETA-TRYPSIN IN CYCLOHEXANE
3H8F	;	2.2	;	High pH native structure of leucine aminopeptidase from Pseudomonas putida
4GEY	;	2.7	;	High pH structure of Pseudomonas putida OprB
2P4M	;	1.8	;	High pH structure of Rtms5 H146S variant
3BQC	;	1.5	;	High pH-value crystal structure of emodin in complex with the catalytic subunit of protein kinase CK2
1NEH	;		;	HIGH POTENTIAL IRON-SULFUR PROTEIN
3HW7	;	2.0	;	High pressure (0.57 GPa) crystal structure of bovine copper, zinc superoxide dismutase at 2.0 angstroms
2OQN	;	1.9	;	High Pressure Cryocooling of Capillary Sample Cryoprotection and Diffraction Phasing at Long Wavelengths
2OQU	;	1.8	;	High Pressure Cryocooling of Capillary Sample Cryoprotection and Diffraction Phasing at Long Wavelengths
5O6N	;	1.35	;	High pressure flash cooled concanavalin A
5O6Q	;	1.45	;	High pressure flash cooled hen egg white lysozyme
4WLD	;	1.54	;	High pressure protein crystallography of hen egg white lysozyme at 0.1 MPa
4WLT	;	1.6	;	High pressure protein crystallography of hen egg white lysozyme at 190 MPa
4WLX	;	1.6	;	High pressure protein crystallography of hen egg white lysozyme at 280 MPa
4WLY	;	1.62	;	High pressure protein crystallography of hen egg white lysozyme at 380 MPa
4WM1	;	1.6	;	High pressure protein crystallography of hen egg white lysozyme at 500 MPa
4WM2	;	1.6	;	High pressure protein crystallography of hen egg white lysozyme at 600 MPa
4WM3	;	1.55	;	High pressure protein crystallography of hen egg white lysozyme at 710 MPa
4WM4	;	1.6	;	High pressure protein crystallography of hen egg white lysozyme at 800 MPa
4WM5	;	1.6	;	High pressure protein crystallography of hen egg white lysozyme at 890 MPa
4WM6	;	1.85	;	High pressure protein crystallography of hen egg white lysozyme at 950 MPa
4XEN	;	1.55	;	High pressure protein crystallography of hen egg white lysozyme in complex with Tetra-N-acetylchitotetraose at 920 MPa
2OE4	;	2.1	;	High Pressure Psuedo Wild Type T4 Lysozyme
6QRH	;	2.152	;	High pressure structure of bovine insulin (100 MPa)
6QRK	;	2.102	;	High pressure structure of bovine insulin (200 MPa)
6QQG	;	2.149	;	High pressure structure of bovine insulin (60 MPa)
3I7X	;	2.6	;	High pressure structure of I106A RNase A variant (0.35 GPa)
3I7Y	;	2.4	;	High pressure structure of I106A variant of RNase A (0.48 GPa)
3I7W	;	2.35	;	High pressure structure of wild-type RNase A (0.67 GPa)
3EOX	;	2.61	;	High quality structure of cleaved PAI-1-stab
4L57	;	1.08	;	High resolutin structure of human cytosolic 5'(3')-deoxyribonucleotidase
4AZS	;	2.15	;	High resolution (2.2 A) crystal structure of WbdD.
2LEU	;		;	HIGH RESOLUTION 1H NMR STUDY OF LEUCOCIN A IN 90% AQUEOUS TRIFLUOROETHANOL (TFE) (0.1% TFA), 18 STRUCTURES
3LEU	;		;	HIGH RESOLUTION 1H NMR STUDY OF LEUCOCIN A IN DODECYLPHOSPHOCHOLINE MICELLES, 19 STRUCTURES (1:40 RATIO OF LEUCOCIN A:DPC) (0.1% TFA)
2WTG	;	1.5	;	High resolution 3D structure of C.elegans globin-like protein GLB-1
440D	;	1.1	;	HIGH RESOLUTION A-DNA CRYSTAL STRYCTURES OF D(AGGGGCCCCT): AN A-DNA MODEL OF POLY(DG).POLY(DC)
441D	;	1.5	;	HIGH RESOLUTION A-DNA CRYSTAL STRYCTURES OF D(AGGGGCCCCT): AN A-DNA MODEL OF POLY(DG).POLY(DC)
2YOB	;	1.9	;	High resolution AGXT_M structure
6PEA	;	1.36	;	High Resolution Apo Carbonic Anhydrase II
6SL9	;	1.27	;	High resolution apo structure of isomerase PaaG
6LQH	;	2.94	;	High resolution architecture of curli complex
5NB3	;	1.38	;	High resolution C-phycoerythrin from marine cyanobacterium Phormidium sp. A09DM at pH 7.5
7XNX	;	2.7	;	High resolution cry-EM structure of the human 80S ribosome from SNORD127+/+ Kasumi-1 cells
7XNY	;	2.5	;	High resolution cry-EM structure of the human 80S ribosome from SNORD127+/- Kasumi-1 cells
7KZF	;	3.1	;	High resolution cryo EM analysis of HPV16 identifies minor structural protein L2 and describes capsid flexibility
5KEP	;	4.3	;	High resolution cryo-EM maps of Human Papillomavirus 16 reveal L2 location and heparin-induced conformational changes
5KEQ	;	4.3	;	High resolution cryo-EM maps of Human papillomavirus 16 reveal L2 location and heparin-induced conformational changes
6PJ6	;	2.2	;	High resolution cryo-EM structure of E.coli 50S
6YL3	;	1.98	;	High resolution cryo-EM structure of urease from the pathogen Yersinia enterocolitica
6X9O	;	2.6	;	High resolution cryoEM structure of huntingtin in complex with HAP40
1ME4	;	1.2	;	High Resolution Crystal Structure Analysis Of Cruzain non-covalently Bound To A Hydroxymethyl Ketone Inhibitor (I)
1ME3	;	1.2	;	High Resolution Crystal Structure Analysis Of Cruzain non-covalently Bound To A Hydroxymethyl Ketone Inhibitor (II)
6X44	;	2.19734	;	High Resolution Crystal Structure Analysis of SERA5 proenzyme from plasmodium falciparum
6X42	;	1.2	;	High Resolution Crystal Structure Analysis of SERA5E from plasmodium falciparum
3D5Y	;	1.22	;	High resolution crystal structure of 1,5-alpha-arabinanase catalytic mutant (AbnBE201A)
3CU9	;	1.06	;	High resolution crystal structure of 1,5-alpha-L-arabinanase from Geobacillus Stearothermophilus
3F0D	;	1.2	;	High resolution crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphatase synthase from Burkholderia pseudomallei
5VEJ	;	1.301	;	High resolution crystal structure of a fluoride-inhibited organo-phosphate-degrading metallohydrolase
2Z79	;	1.3	;	High resolution crystal structure of a glycoside hydrolase family 11 xylanase of Bacillus subtilis
3BQX	;	1.4	;	High resolution crystal structure of a glyoxalase-related enzyme from Fulvimarina pelagi
4TSV	;	1.8	;	HIGH RESOLUTION CRYSTAL STRUCTURE OF A HUMAN TNF-ALPHA MUTANT
5TSW	;	2.5	;	HIGH RESOLUTION CRYSTAL STRUCTURE OF A HUMAN TNF-ALPHA MUTANT
6THT	;	1.14	;	High resolution crystal structure of a Leaf-branch compost cutinase quintuple variant
1B4K	;	1.67	;	High resolution crystal structure of a MG2-dependent 5-aminolevulinic acid dehydratase
6EQE	;	0.92	;	High resolution crystal structure of a polyethylene terephthalate degrading hydrolase from Ideonella sakaiensis
1GT9	;	1.38	;	High resolution crystal structure of a thermostable serine-carboxyl type proteinase, kumamolisin (kscp)
1TUX	;	1.8	;	HIGH RESOLUTION CRYSTAL STRUCTURE OF A THERMOSTABLE XYLANASE FROM THERMOASCUS AURANTIACUS
5TOQ	;	1.2	;	High resolution crystal structure of AAT
1PW9	;	1.6	;	High resolution crystal structure of an active recombinant fragment of human lung surfactant protein D
1PWB	;	1.4	;	High resolution crystal structure of an active recombinant fragment of human lung surfactant protein D with maltose
6KRB	;	2.375	;	High resolution crystal structure of an Acylphosphatase protein cage
1XDN	;	1.2	;	High resolution crystal structure of an editosome enzyme from trypanosoma brucei: RNA editing ligase 1
1I71	;	1.45	;	HIGH RESOLUTION CRYSTAL STRUCTURE OF APOLIPOPROTEIN(A) KRINGLE IV TYPE 7: INSIGHTS INTO LIGAND BINDING
3C9A	;	1.6	;	High Resolution Crystal Structure of Argos bound to the EGF domain of Spitz
3S9X	;	1.35	;	High resolution crystal structure of ASCH domain from Lactobacillus crispatus JV V101
3BH4	;	1.4	;	High resolution crystal structure of Bacillus amyloliquefaciens alpha-amylase
5XLU	;	1.45	;	High Resolution Crystal Structure of Bacillus Licheniformis Gamma Glutamyl Transpeptidase with Acivicin
4BPH	;	1.8	;	High resolution crystal structure of Bacillus subtilis DltC
4BPF	;	1.01	;	High resolution crystal structure of Bacillus subtilis DltC S36A
4ATE	;	1.1	;	High resolution crystal structure of beta-porphyranase A from Zobellia galactanivorans
4AO1	;	1.58	;	High resolution crystal structure of bovine pancreatic ribonuclease crystallized using ionic liquid
7NQ6	;	1.5	;	High resolution crystal structure of C-terminal domain (residues 715-866) of Nucleoporin-98
4IQB	;	1.13	;	High Resolution Crystal Structure of C.elegans Thymidylate Synthase
3AXJ	;	2.1	;	High resolution crystal structure of C3PO
1TLO	;	1.9	;	High resolution crystal structure of calpain I protease core in complex with E64
1TL9	;	1.8	;	High resolution crystal structure of calpain I protease core in complex with leupeptin
4W5Z	;	1.32	;	High resolution crystal structure of catalytic domain of Chitinase 60 from psychrophilic bacteria Moritella marina.
2J1E	;	2.4	;	High Resolution Crystal Structure of CBM32 from a N-acetyl-beta- hexosaminidase in complex with lacNAc
6ZXT	;	1.4	;	High resolution crystal structure of chloroplastic ribose-5-phosphate isomerase from Chlamydomonas reinhardtii
1R6B	;	2.25	;	High resolution crystal structure of ClpA
3WA2	;	1.08	;	High resolution crystal structure of copper amine oxidase from arthrobacter globiformis
6L8S	;	1.58	;	High resolution crystal structure of crustacean hemocyanin.
3HD3	;	1.75	;	High resolution crystal structure of cruzain bound to the vinyl sulfone inhibitor SMDC-256047
3LA1	;	1.29	;	High resolution crystal structure of CyPet mutant A167I
3VTT	;	1.7	;	High Resolution crystal structure of Dengue 3 Envelope protein domain III (ED3)
1G9V	;	1.85	;	HIGH RESOLUTION CRYSTAL STRUCTURE OF DEOXY HEMOGLOBIN COMPLEXED WITH A POTENT ALLOSTERIC EFFECTOR
8B3X	;	1.531	;	High resolution crystal structure of dimeric SUDV VP40
4HNO	;	0.9194	;	High resolution crystal structure of DNA Apurinic/apyrimidinic (AP) endonuclease IV Nfo from Thermatoga maritima
2V33	;	1.55	;	High resolution crystal structure of domain III of E1 fusion glycoprotein of Semliki Forest Virus
1EP0	;	1.5	;	HIGH RESOLUTION CRYSTAL STRUCTURE OF DTDP-6-DEOXY-D-XYLO-4-HEXULOSE 3,5-EPIMERASE FROM METHANOBACTERIUM THERMOAUTOTROPHICUM
8AII	;	1.82	;	High Resolution Crystal Structure of Enterococcus faecium Nicotinate Nucleotide Adenylyltransferase Complexed with Adenine
2NQH	;	1.1	;	High Resolution crystal structure of Escherichia coli endonuclease IV (Endo IV) E261Q mutant
2NQ9	;	1.45	;	High resolution crystal structure of Escherichia coli endonuclease IV (Endo IV) Y72A mutant bound to damaged DNA
1XEN	;	1.85	;	High Resolution Crystal Structure of Escherichia coli Iron- Peptide Deformylase Bound To Formate
1XEM	;	1.76	;	High Resolution Crystal Structure of Escherichia coli Zinc- Peptide Deformylase bound to formate
7R5I	;	1.08	;	High resolution Crystal structure of ExsFA, a Bacillus cereus spore exosporium protein
4ZKA	;	1.8	;	High Resolution Crystal Structure of Fox1 RRM
3VWI	;	1.7	;	High resolution crystal structure of FraC in the monomeric form
6CQP	;	1.446	;	High resolution crystal structure of FtsY-NG domain of E. coli
6CS8	;	1.749	;	High resolution crystal structure of FtsY-NG domain of E. coli
6CVD	;	1.78	;	High resolution crystal structure of FtsY-NG domain of E. coli bound to fragment 1
5DVI	;	1.25	;	High resolution crystal Structure of glucose complexed periplasmic glucose binding protein (ppGBP) from P. putida CSV86
4HHL	;	1.73	;	High resolution crystal structure of Glucose Isomerase from Streptomyces sp. SK
7XZG	;	1.879	;	High resolution crystal Structure of Glyceraldehyde-3-Phosphate Dehydrogenase from Candida albicans complexed with NAD+
7DY4	;	1.3	;	High resolution crystal structure of hemoglobin M Boston.
7DY3	;	1.4	;	High resolution crystal structure of hemoglobin M Iwate.
3O1C	;	1.08	;	High resolution crystal structure of histidine triad nucleotide-binding protein 1 (Hint1) C38A mutant from rabbit complexed with Adenosine
3O1X	;	1.08	;	High resolution crystal structure of histidine triad nucleotide-binding protein 1 (Hint1) C84A mutant from rabbit complexed with adenosine
3O1Z	;	1.3	;	High resolution crystal structure of histidine triad nucleotide-binding protein 1 (Hint1) double cysteine mutant from rabbit
3BVN	;	2.55	;	High resolution crystal structure of HLA-B*1402 in complex with the latent membrane protein 2 peptide (LMP2) of Epstein-Barr virus
2RH1	;	2.4	;	High resolution crystal structure of human B2-adrenergic G protein-coupled receptor.
5YXK	;	1.9	;	High resolution crystal structure of Human B7-2 IgV domain in P21 space group
1HKM	;	2.55	;	High resolution crystal structure of human chitinase in complex with demethylallosamidin
6SZP	;	1.76	;	High resolution crystal structure of human DDAH-1 in complex with N-(4-Aminobutyl)-N'-(2-Methoxyethyl)guanidine
4IGH	;	1.3	;	High resolution crystal structure of human dihydroorotate dehydrogenase bound with 4-quinoline carboxylic acid analog
4OQV	;	1.23	;	High resolution crystal structure of human dihydroorotate dehydrogenase bound with DSM338 (N-[3,5-difluoro-4-(trifluoromethyl)phenyl]-5-methyl-2-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine)
6JBU	;	1.849	;	High resolution crystal structure of human FLRT3 LRR domain in complex with mouse CIRL3 Olfactomedin like domain
4WLH	;	1.28	;	High resolution crystal structure of human kynurenine aminotransferase-I bound to PLP cofactor
4WLJ	;	1.54	;	High resolution crystal structure of human kynurenine aminotransferase-I in complex with aminooxyacetate
7XTX	;	1.28	;	High resolution crystal structure of human macrophage migration inhibitory factor in complex with methotrexate
7O63	;	1.16	;	High resolution crystal structure of human mitochondrial ferritin (hMTF)
7VO6	;	1.71	;	High resolution crystal structure of human PSMD10 (Gankyrin)
1WMS	;	1.25	;	High resolution crystal structure of human Rab9 GTPase: a novel antiviral drug target
4YDM	;	1.25	;	High resolution crystal structure of human transthyretin bound to ligand and conjugates of 3-(5-(3,5-dichloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)phenyl fluorosulfate
4YDN	;	1.35	;	High resolution crystal structure of human transthyretin bound to ligand and conjugates of 4-(5-(3,5-dichloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)phenyl fluorosulfate
6E7E	;	1.12	;	High resolution crystal structure of IncA soluble domain
1PEW	;	1.6	;	High Resolution Crystal Structure of Jto2, a mutant of the non-amyloidogenic Lamba6 Light Chain, Jto
1OGX	;	2.0	;	High Resolution Crystal Structure Of Ketosteroid Isomerase Mutant D40N(D38N, Ti Numbering) from Pseudomonas putida Complexed With Equilenin At 2.0 A Resolution.
6THS	;	1.1	;	High resolution crystal structure of Leaf-branch cutinase S165A variant
2CB8	;	1.4	;	High resolution crystal structure of liganded human L-ACBP
7FDS	;	1.258	;	High resolution crystal structure of LpqH from Mycobacterium tuberculosis
5E68	;	1.58	;	High resolution crystal structure of LuxS - Quorum sensor molecular complex from Salmonella typhi at 1.58 Angstroms
7CM8	;	1.9	;	High resolution crystal structure of M92A mutant of O-acetyl-L-serine sulfhydrylase from Haemophilus influenzae
1GCY	;	1.6	;	HIGH RESOLUTION CRYSTAL STRUCTURE OF MALTOTETRAOSE-FORMING EXO-AMYLASE
1YYD	;	1.45	;	High Resolution Crystal Structure of Manganese Peroxidase
3FHR	;	1.9	;	High resolution crystal structure of mitogen-activated protein kinase-activated protein kinase 3 (MK3)-inhibitor complex
3FXW	;	2.0	;	High resolution crystal structure of mitogen-activated protein kinase-activated protein kinase 3/inhibitor 2 complex
6WBJ	;	1.651	;	High resolution crystal structure of mRECK(CC4) in fusion with engineered MBP
1MD6	;	1.6	;	High resolution crystal structure of murine IL-1F5 reveals unique loop conformation for specificity
1T1G	;	1.18	;	High Resolution Crystal Structure of Mutant E23A of Kumamolisin, a sedolisin type proteinase (previously called Kumamolysin or KSCP)
1T1I	;	1.28	;	High Resolution Crystal Structure of Mutant W129A of Kumamolisin, a Sedolisin Type Proteinase (previously called Kumamolysin or KSCP)
6SPT	;	1.2	;	High resolution crystal structure of N-terminal domain of PEX14 from Trypanosoma brucei in complex with the fist compound with sub-micromolar trypanocidal activity
3BZQ	;	1.4	;	High resolution crystal structure of Nitrogen Regulatory Protein (Rv2919c) of Mycobacterium tuberculosis
3HB3	;	2.25	;	High resolution crystal structure of Paracoccus denitrificans cytochrome c oxidase
6FJ3	;	2.5	;	High resolution crystal structure of parathyroid hormone 1 receptor in complex with a peptide agonist.
1XF6	;	1.1	;	High resolution crystal structure of phycoerythrin 545 from the marine cryptophyte rhodomonas CS24
1XG0	;	0.97	;	High resolution crystal structure of phycoerythrin 545 from the marine cryptophyte rhodomonas CS24
1GS3	;	2.1	;	High resolution crystal structure of PI delta-5-3-Ketosteroid Isomerase mutants Y30F/Y55F/Y115F/D38N (Y32F/Y57F/Y119F/D40N, PI numbering)complexed with equilenin at 2.1 A resolution
3P9V	;	1.78	;	High Resolution Crystal Structure of protein Maqu_3174 from Marinobacter aquaeolei, Northeast Structural Genomics Consortium Target MqR197
6K8M	;	1.45	;	High resolution crystal structure of proteinase K with thiourea
2V6U	;	1.6	;	High resolution crystal structure of pterin-4a-carbinolamine dehydratase from Toxoplasma gondii
7KP2	;	1.03	;	High Resolution Crystal Structure of Putative Pterin Binding Protein (PruR) from Vibrio cholerae O1 biovar El Tor str. N16961 in Complex with Neopterin
7KOM	;	0.99	;	High Resolution Crystal Structure of Putative Pterin Binding Protein PruR (VV2_1280) from Vibrio vulnificus CMCP6
4IUZ	;	1.6	;	High resolution crystal structure of racemic ester insulin
3SGZ	;	1.35	;	High resolution crystal structure of rat long chain hydroxy acid oxidase in complex with the inhibitor 4-carboxy-5-[(4-chiorophenyl)sulfanyl]-1, 2, 3-thiadiazole.
4U5Q	;	1.811	;	High resolution crystal structure of reductase (R) domain of nonribosomal peptide synthetase from Mycobacterium tuberculosis
4Z2O	;	1.17	;	High resolution crystal structure of short hoefavidin-hoef-peptide complex
7VDN	;	0.93	;	High resolution crystal structure of Sperm Whale Myoglobin in the carbonmonoxy form
6GID	;	1.9	;	High resolution crystal structure of substrate-free human neprilysin
2F2Q	;	1.45	;	High resolution crystal structure of T4 lysozyme mutant L20R63/A liganded to guanidinium ion
4DYQ	;	1.502	;	High resolution crystal structure of terminase small subunit gp1 of the bacterial virus sf6
160D	;	1.65	;	HIGH RESOLUTION CRYSTAL STRUCTURE OF THE A-DNA DECAMER D(CCCGGCCGGG): NOVEL INTERMOLECULAR BASE-PAIRED G*(G.C) TRIPLETS
2VPA	;	1.2	;	High resolution crystal structure of the antibiotic resistance protein NimA from Deinococcus radiodurans
1QG5	;	2.0	;	HIGH RESOLUTION CRYSTAL STRUCTURE OF THE BOVINE BETA-LACTOGLOBULIN (ISOFORM A)
1B8E	;	1.95	;	HIGH RESOLUTION CRYSTAL STRUCTURE OF THE BOVINE BETA-LACTOGLOBULIN (ISOFORMS A AND B) IN ORTHOROMBIC SPACE GROUP
5OAV	;	0.95	;	High resolution crystal structure of the c-Src-SH3 domain mutant E93V in complex with the high affinity synthetic peptide APP12: monoclinic crystal
2FWG	;	1.1	;	high resolution crystal structure of the C-terminal domain of the electron transfer catalyst DsbD (photoreduced form)
2FWF	;	1.3	;	high resolution crystal structure of the C-terminal domain of the electron transfer catalyst DsbD (reduced form)
3B8Z	;	1.4	;	High Resolution Crystal Structure of the Catalytic Domain of ADAMTS-5 (Aggrecanase-2)
1MJJ	;	2.1	;	HIGH RESOLUTION CRYSTAL STRUCTURE OF THE COMPLEX OF THE FAB FRAGMENT OF ESTEROLYTIC ANTIBODY MS6-12 AND A TRANSITION-STATE ANALOG
2DQT	;	1.8	;	High resolution crystal structure of the complex of the hydrolytic antibody Fab 6D9 and a transition-state analog
1ZGO	;	1.4	;	High Resolution Crystal Structure of the Discosoma Red Fluorescent Protein (DsRed)
7KPO	;	1.28	;	High Resolution Crystal Structure of the DNA-binding Domain from the Sensor Histidine Kinase ChiS from Vibrio cholerae
3CA7	;	1.5	;	High Resolution Crystal Structure of the EGF domain of Spitz
2RDZ	;	1.74	;	High Resolution Crystal Structure of the Escherichia coli Cytochrome c Nitrite Reductase.
1MJ8	;	1.75	;	High Resolution Crystal Structure Of The Fab Fragment of The Esterolytic Antibody MS6-126
1DLF	;	1.45	;	HIGH RESOLUTION CRYSTAL STRUCTURE OF THE FV FRAGMENT FROM AN ANTI-DANSYL SWITCH VARIANT ANTIBODY IGG2A(S) CRYSTALLIZED AT PH 5.25
2DLF	;	1.55	;	HIGH RESOLUTION CRYSTAL STRUCTURE OF THE FV FRAGMENT FROM AN ANTI-DANSYL SWITCH VARIANT ANTIBODY IGG2A(S) CRYSTALLIZED AT PH 6.75
6CHX	;	1.4	;	High Resolution Crystal Structure of the Hemagglutinin H1 Head Domain of Influenza A virus Solomon Islands
3MVC	;	1.401	;	High resolution crystal structure of the heme domain of GLB-6 from C. elegans
4CSR	;	1.5	;	High resolution crystal structure of the histone fold dimer (NF-YB)-(NF-YC)
2CKK	;	1.45	;	High resolution crystal structure of the human kin17 C-terminal domain containing a kow motif
1H1W	;	2.0	;	High resolution crystal structure of the human PDK1 catalytic domain
1T1E	;	1.18	;	High Resolution Crystal Structure of the Intact Pro-Kumamolisin, a Sedolisin Type Proteinase (previously called Kumamolysin or KSCP)
5MX9	;	1.12	;	High resolution crystal structure of the MCR-2 catalytic domain
1KPV	;	1.71	;	High resolution crystal structure of the MHC class I complex H-2Kb/SEV9
1KPU	;	1.5	;	High resolution crystal structure of the MHC class I complex H-2Kb/VSV8
4AY0	;	1.52	;	High resolution crystal structure of the monomeric subunit-free Caf1M chaperone
4MZD	;	1.1	;	High resolution crystal structure of the nisin leader peptidase NisP from Lactococcus lactis
4E2B	;	1.269	;	High resolution crystal structure of the old yellow enzyme from Trypanosoma cruzi
3E86	;	1.6	;	High resolution Crystal Structure of the open NaK channel pore
1UNQ	;	0.98	;	High resolution crystal structure of the Pleckstrin Homology Domain Of Protein Kinase B/Akt Bound To Ins(1,3,4,5)-Tetrakisphophate
1MHN	;	1.8	;	High resolution crystal structure of the SMN Tudor domain
2FJ9	;	1.6	;	High resolution crystal structure of the unliganded human ACBP
4OEO	;	1.9	;	High resolution crystal structure of the unliganded ZO-1 PDZ1 domain
3CM3	;	1.32	;	High Resolution Crystal Structure of the Vaccinia Virus Dual-Specificity Phosphatase VH1
1J0O	;	1.15	;	High Resolution Crystal Structure of the wild type Tetraheme Cytochrome c3 from Desulfovibrio vulgaris Miyazaki F
1I24	;	1.2	;	HIGH RESOLUTION CRYSTAL STRUCTURE OF THE WILD-TYPE PROTEIN SQD1, WITH NAD AND UDP-GLUCOSE
4I6R	;	1.38	;	High Resolution Crystal Structure of the Wild-Type Restriction-Modification Controller Protein C.Esp1396I (Triclinic form)
3L84	;	1.36	;	High resolution crystal structure of transketolase from Campylobacter jejuni subsp. jejuni NCTC 11168
4UC1	;	1.8	;	High resolution crystal structure of translocator protein 18kDa (TSPO) from Rhodobacter sphaeroides (A139T Mutant) in C2 space group
3LBW	;	1.65	;	High resolution crystal structure of transmembrane domain of M2
3BKD	;	2.05	;	High resolution Crystal structure of Transmembrane domain of M2 protein
4O0C	;	1.5	;	High resolution crystal structure of uncleaved human L-asparaginase protein
2UVO	;	1.4	;	High Resolution Crystal Structure of Wheat Germ Agglutinin in Complex with N-Acetyl-D-Glucosamine
3D9A	;	1.2	;	High Resolution Crystal Structure Structure of HyHel10 Fab Complexed to Hen Egg Lysozyme
1HGA	;	2.1	;	HIGH RESOLUTION CRYSTAL STRUCTURES AND COMPARISONS OF T STATE DEOXYHAEMOGLOBIN AND TWO LIGANDED T-STATE HAEMOGLOBINS: T(ALPHA-OXY)HAEMOGLOBIN AND T(MET)HAEMOGLOBIN
1HGB	;	2.1	;	HIGH RESOLUTION CRYSTAL STRUCTURES AND COMPARISONS OF T STATE DEOXYHAEMOGLOBIN AND TWO LIGANDED T-STATE HAEMOGLOBINS: T(ALPHA-OXY)HAEMOGLOBIN AND T(MET)HAEMOGLOBIN
1HGC	;	2.1	;	HIGH RESOLUTION CRYSTAL STRUCTURES AND COMPARISONS OF T STATE DEOXYHAEMOGLOBIN AND TWO LIGANDED T-STATE HAEMOGLOBINS: T(ALPHA-OXY)HAEMOGLOBIN AND T(MET)HAEMOGLOBIN
2MGA	;	2.2	;	HIGH RESOLUTION CRYSTAL STRUCTURES OF FIVE DISTAL HISTIDINE MUTANTS OF SPERM WHALE MYOGLOBIN
2MGB	;	2.0	;	HIGH RESOLUTION CRYSTAL STRUCTURES OF FIVE DISTAL HISTIDINE MUTANTS OF SPERM WHALE MYOGLOBIN
2MGC	;	1.9	;	HIGH RESOLUTION CRYSTAL STRUCTURES OF FIVE DISTAL HISTIDINE MUTANTS OF SPERM WHALE MYOGLOBIN
2MGD	;	1.8	;	HIGH RESOLUTION CRYSTAL STRUCTURES OF FIVE DISTAL HISTIDINE MUTANTS OF SPERM WHALE MYOGLOBIN
2MGE	;	1.7	;	HIGH RESOLUTION CRYSTAL STRUCTURES OF FIVE DISTAL HISTIDINE MUTANTS OF SPERM WHALE MYOGLOBIN
2MGF	;	1.8	;	HIGH RESOLUTION CRYSTAL STRUCTURES OF FIVE DISTAL HISTIDINE MUTANTS OF SPERM WHALE MYOGLOBIN
2MGG	;	1.8	;	HIGH RESOLUTION CRYSTAL STRUCTURES OF FIVE DISTAL HISTIDINE MUTANTS OF SPERM WHALE MYOGLOBIN
2MGH	;	2.0	;	HIGH RESOLUTION CRYSTAL STRUCTURES OF FIVE DISTAL HISTIDINE MUTANTS OF SPERM WHALE MYOGLOBIN
2MGI	;	2.0	;	HIGH RESOLUTION CRYSTAL STRUCTURES OF FIVE DISTAL HISTIDINE MUTANTS OF SPERM WHALE MYOGLOBIN
2MGJ	;	2.0	;	HIGH RESOLUTION CRYSTAL STRUCTURES OF FIVE DISTAL HISTIDINE MUTANTS OF SPERM WHALE MYOGLOBIN
2MGK	;	2.0	;	HIGH RESOLUTION CRYSTAL STRUCTURES OF FIVE DISTAL HISTIDINE MUTANTS OF SPERM WHALE MYOGLOBIN
2MGL	;	2.0	;	HIGH RESOLUTION CRYSTAL STRUCTURES OF FIVE DISTAL HISTIDINE MUTANTS OF SPERM WHALE MYOGLOBIN
2MGM	;	1.9	;	HIGH RESOLUTION CRYSTAL STRUCTURES OF FIVE DISTAL HISTIDINE MUTANTS OF SPERM WHALE MYOGLOBIN
1HRN	;	1.8	;	HIGH RESOLUTION CRYSTAL STRUCTURES OF RECOMBINANT HUMAN RENIN IN COMPLEX WITH POLYHYDROXYMONOAMIDE INHIBITORS
3O90	;	1.94	;	High resolution crystal structures of Streptococcus pneumoniae nicotinamidase with trapped intermediates provide insights into catalytic mechanism and inhibition by aldehydes
3O91	;	1.63	;	High resolution crystal structures of Streptococcus pneumoniae nicotinamidase with trapped intermediates provide insights into catalytic mechanism and inhibition by aldehydes
3O92	;	1.9	;	High resolution crystal structures of Streptococcus pneumoniae nicotinamidase with trapped intermediates provide insights into catalytic mechanism and inhibition by aldehydes
3O93	;	1.84	;	High resolution crystal structures of Streptococcus pneumoniae nicotinamidase with trapped intermediates provide insights into catalytic mechanism and inhibition by aldehydes
3O94	;	1.6	;	High resolution crystal structures of Streptococcus pneumoniae nicotinamidase with trapped intermediates provide insights into catalytic mechanism and inhibition by aldehydes
1NR2	;	2.18	;	High resolution crystal structures of thymus and activation-regulated chemokine
1NR4	;	1.72	;	High resolution crystal structures of thymus and activation-regulated chemokine
2OKB	;	2.15	;	High Resolution Crystal Structures of Vaccinia Virus dUTPase
2OKD	;	2.4	;	High Resolution Crystal Structures of Vaccinia Virus dUTPase
2OKE	;	2.5	;	High Resolution Crystal Structures of Vaccinia Virus dUTPase
2OL0	;	2.1	;	High Resolution Crystal Structures of Vaccinia Virus dUTPase
2OL1	;	1.8	;	High Resolution Crystal Structures of Vaccinia Virus dUTPase
3SDH	;	1.4	;	HIGH RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF A COOPERATIVE DIMERIC HEMOGLOBIN
4SDH	;	1.6	;	HIGH RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF A COOPERATIVE DIMERIC HEMOGLOBIN
2W5F	;	1.9	;	High resolution crystallographic structure of the Clostridium thermocellum N-terminal endo-1,4-beta-D-xylanase 10B (Xyn10B) CBM22-1- GH10 modules complexed with xylohexaose
2WYS	;	2.75	;	High resolution crystallographic structure of the Clostridium thermocellum N-terminal endo-1,4-beta-D-xylanase 10B (Xyn10B) CBM22-1- GH10 modules complexed with xylohexaose
2WZE	;	2.5	;	High resolution crystallographic structure of the Clostridium thermocellum N-terminal endo-1,4-beta-D-xylanase 10B (Xyn10B) CBM22-1- GH10 modules complexed with xylohexaose
2CTV	;	1.95	;	HIGH RESOLUTION CRYSTALLOGRAPHIC STUDIES OF NATIVE CONCANAVALIN A USING RAPID LAUE DATA COLLECTION METHODS AND THE INTRODUCTION OF A MONOCHROMATIC LARGE-ANGLE OSCILLATION TECHNIQUE (LOT)
1XEO	;	1.3	;	High Resolution Crystals Structure of Cobalt- Peptide Deformylase Bound To Formate
2RB8	;	1.45	;	High resolution design of a protein loop
2RBL	;	2.1	;	High resolution design of a protein loop
2RH2	;	0.96	;	High Resolution DHFR R-67
6Q5U	;	2.75	;	High resolution electron cryo-microscopy structure of the bacteriophage PR772
2FVY	;	0.92	;	High Resolution Glucose Bound Crystal Structure of GGBP
3J08	;	10.0	;	High resolution helical reconstruction of the bacterial p-type ATPase copper transporter CopA
3J09	;	10.0	;	High resolution helical reconstruction of the bacterial p-type ATPase copper transporter CopA
3EC0	;	1.18	;	High Resolution HIV-2 Protease Structure in Complex with Antiviral Inhibitor GRL-06579A
3ECG	;	1.18	;	High Resolution HIV-2 Protease Structure in Complex with Antiviral Inhibitor GRL-98065
3EBZ	;	1.2	;	High Resolution HIV-2 Protease Structure in Complex with Clinical Drug Darunavir
4Z51	;	1.86	;	High Resolution Human Septin 3 GTPase domain
4Z54	;	1.83	;	High Resolution Human Septin3 GTPase domain with alpha-zero helix in complex with GDP
4IHN	;	1.16	;	High Resolution Insulin by Langmuir-Blodgett Modified Hanging Drop Vapour Diffusion
1L7M	;	1.48	;	HIGH RESOLUTION LIGANDED STRUCTURE OF PHOSPHOSERINE PHOSPHATASE (PI COMPLEX)
7RVB	;	2.04	;	High resolution map of molecular chaperone Artemin
4F3N	;	1.75	;	High resolution native crystal structure of an uncharacterized ACR, COG1565 superfamily protein from Burkholderia thailandensis, solved by iodide ion SAD
5WJR	;	1.7	;	High resolution native hexamer DNA and RNA hybrid in complex with RNase H catalytic domain D132N mutant
5FLE	;	1.23	;	High resolution NI,FE-CODH-320 mV with CN state
2KMJ	;		;	High resolution NMR solution structure of a complex of HIV-2 TAR RNA and a synthetic tripeptide in a 1:2 stoichiometry
7LDF	;		;	High resolution NMR solution structure of a de novo designed minimal thioredoxin fold protein
2LYE	;		;	High resolution NMR solution structure of a symmetrical theta-defensin, BTD-2
2LHP	;		;	High resolution NMR solution structure of helix H1 of the chimpanzee HAR1 RNA
2LUB	;		;	High resolution NMR solution structure of helix H1 of the human HAR1 RNA
1PS2	;		;	HIGH RESOLUTION NMR SOLUTION STRUCTURE OF HUMAN PS2, 19 STRUCTURES
2LYF	;		;	High resolution NMR solution structure of the theta-defensin RTD-1
1U01	;		;	High resolution NMR structure of 5-d(GCGT*GCG)-3/5-d(CGCACGC)-3 (T*represents a cyclohexenyl nucleotide)
1NAJ	;		;	High resolution NMR Structure Of DNA Dodecamer Determined In Aqueous Dilute Liquid Crystalline Phase
2L6R	;		;	High resolution NMR structure of gpW (W protein of bacteriophage lambda) at acidic pH
4BA8	;		;	High resolution NMR structure of the C mu3 domain from IgM
8DRH	;		;	HIGH RESOLUTION NMR STRUCTURE OF THE D(GCGTCAGG)R(CCUGACGC) HYBRID, MINIMIZED AVERAGE STRUCTURE
8PSH	;		;	HIGH RESOLUTION NMR STRUCTURE OF THE STEREOREGULAR (ALL-RP)-PHOSPHOROTHIOATE-DNA/RNA HYBRID D (G*PS*C*PS*G*PS*T*PS*C*PS*A*PS*G*PS*G)R(CCUGACGC), MINIMIZED AVERAGE STRUCTURE
2LZI	;		;	High resolution NMR structure of the theta-defensin HTD-2 (retrocyclin 2)
1XF7	;		;	High Resolution NMR Structure of the Wilms' Tumor Suppressor Protein (WT1) Finger 3
3LDC	;	1.45	;	High resolution open MthK pore structure crystallized in 100 mM K+
3LDE	;	2.208	;	High resolution open MthK pore structure crystallized in 100 mM K+ and further soaked in 100 mM Na+.
3LDD	;	1.45	;	High resolution open MthK pore structure crystallized in 100 mM K+ and further soaked in 99 mM Na+/1 mM K+.
1FHG	;	2.0	;	HIGH RESOLUTION REFINEMENT OF TELOKIN
1D78	;	1.4	;	HIGH RESOLUTION REFINEMENT OF THE HEXAGONAL A-DNA OCTAMER D(GTGTACAC) AT 1.4 ANGSTROMS RESOLUTION
1D79	;	1.45	;	HIGH RESOLUTION REFINEMENT OF THE HEXAGONAL A-DNA OCTAMER D(GTGTACAC) AT 1.4 ANGSTROMS RESOLUTION
7KUK	;	1.67	;	High resolution RNA primer complex with guanosine dinucleotide ligand G(5')ppp(5')G
1YFQ	;	1.1	;	High resolution S. cerevisiae Bub3 mitotic checkpoint protein
5AOZ	;	1.14	;	High resolution SeMet structure of the third cohesin from Ruminococcus flavefaciens scaffoldin protein, ScaB
5CYO	;	2.0354	;	High resolution Septin 9 GTPase domain in complex with GDP
2XMN	;	2.85	;	High resolution snapshots of defined TolC open states present an iris- like movement of periplasmic entrance helices
2UVS	;		;	High Resolution Solid-state NMR structure of Kaliotoxin
1MDJ	;		;	HIGH RESOLUTION SOLUTION NMR STRUCTURE OF MIXED DISULFIDE INTERMEDIATE BETWEEN HUMAN THIOREDOXIN (C35A, C62A, C69A, C73A) MUTANT AND A 13 RESIDUE PEPTIDE COMPRISING ITS TARGET SITE IN HUMAN NFKB (RESIDUES 56-68 OF THE P50 SUBUNIT OF NFKB)
1MDK	;		;	HIGH RESOLUTION SOLUTION NMR STRUCTURE OF MIXED DISULFIDE INTERMEDIATE BETWEEN HUMAN THIOREDOXIN (C35A, C62A, C69A, C73A) MUTANT AND A 13 RESIDUE PEPTIDE COMPRISING ITS TARGET SITE IN HUMAN NFKB (RESIDUES 56-68 OF THE P50 SUBUNIT OF NFKB)
1CQG	;		;	HIGH RESOLUTION SOLUTION NMR STRUCTURE OF MIXED DISULFIDE INTERMEDIATE BETWEEN HUMAN THIOREDOXIN (C35A, C62A, C69A, C73A) MUTANT AND A 13 RESIDUE PEPTIDE COMPRISING ITS TARGET SITE IN HUMAN REF-1 (RESIDUES 59-71 OF THE P50 SUBUNIT OF NFKB), NMR, 31 STRUCTURES
1CQH	;		;	HIGH RESOLUTION SOLUTION NMR STRUCTURE OF MIXED DISULFIDE INTERMEDIATE BETWEEN HUMAN THIOREDOXIN (C35A, C62A, C69A, C73A) MUTANT AND A 13 RESIDUE PEPTIDE COMPRISING ITS TARGET SITE IN HUMAN REF-1 (RESIDUES 59-71 OF THE P50 SUBUNIT OF NFKB), NMR, MINIMIZED AVERAGE STRUCTURE
1MDI	;		;	HIGH RESOLUTION SOLUTION NMR STRUCTURE OF MIXED DISULFIDE INTERMEDIATE BETWEEN MUTANT HUMAN THIOREDOXIN AND A 13 RESIDUE PEPTIDE COMPRISING ITS TARGET SITE IN HUMAN NFKB
1SAE	;		;	HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI-DIMENSIONAL NMR (SAC STRUCTURES)
1SAK	;		;	HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI-DIMENSIONAL NMR (SAC STRUCTURES)
3SAK	;		;	HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI-DIMENSIONAL NMR (SAC STRUCTURES)
1SAF	;		;	HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI-DIMENSIONAL NMR (SAD STRUCTURES)
1SAL	;		;	HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI-DIMENSIONAL NMR (SAD STRUCTURES)
5FZV	;		;	High resolution solution NMR structure of the spider venom peptide U3- scytotoxin-Sth1a
5FZW	;		;	High resolution solution NMR structure of the spider venom peptide U3- scytotoxin-Sth1h
5FZX	;		;	High resolution solution NMR structure of the spider venom peptide U5- scytotoxin-Sth1a
2K0T	;		;	High Resolution Solution NMR Structures of Oxaliplatin-DNA Adduct
2K0U	;		;	High Resolution Solution NMR Structures of Oxaliplatin-DNA Adduct
2K0V	;		;	High Resolution Solution NMR Structures of Undamaged DNA Dodecamer Duplex
2CNP	;		;	HIGH RESOLUTION SOLUTION STRUCTURE OF APO RABBIT CALCYCLIN, NMR, 22 STRUCTURES
1E9T	;		;	High resolution solution structure of human intestinal trefoil factor
1NB1	;		;	High resolution solution structure of kalata B1
1CKR	;		;	HIGH RESOLUTION SOLUTION STRUCTURE OF THE HEAT SHOCK COGNATE-70 KD SUBSTRATE BINDING DOMAIN OBTAINED BY MULTIDIMENSIONAL NMR TECHNIQUES
7HSC	;		;	HIGH RESOLUTION SOLUTION STRUCTURE OF THE HEAT SHOCK COGNATE-70 KD SUBSTRATE BINDING DOMAIN OBTAINED BY MULTIDIMENSIONAL NMR TECHNIQUES
1FMY	;		;	HIGH RESOLUTION SOLUTION STRUCTURE OF THE PROTEIN PART OF CU7 METALLOTHIONEIN
1RXR	;		;	HIGH RESOLUTION SOLUTION STRUCTURE OF THE RETINOID X RECEPTOR DNA BINDING DOMAIN, NMR, 20 STRUCTURE
3NHE	;	1.26	;	High Resolution Structure (1.26A) of USP2a in Complex with Ubiquitin
1E93	;	2.0	;	High resolution structure and biochemical properties of a recombinant catalase depleted in iron
2V03	;	1.33	;	High resolution structure and catalysis of an O-acetylserine sulfhydrylase
2M1I	;		;	High resolution structure and dynamics of CsPinA parvulin at physiological temperature
1SB2	;	1.9	;	High resolution Structure determination of rhodocetin
4B9F	;	1.19	;	High resolution structure for family 3a carbohydrate binding module from the cipA scaffolding of clostridium thermocellum
5UOU	;	1.5	;	High resolution structure of 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase from Klebsiella pneumoniae subsp. pneumoniae MGH 78578
5HD6	;	1.35	;	High resolution structure of 3-hydroxydecanoyl-(acyl carrier protein) dehydratase from Yersinia pestis at 1.35 A
4JJ2	;	1.28	;	High resolution structure of a C-terminal fragment of the T4 phage gp5 beta-helix
2AHN	;	1.3	;	High resolution structure of a cherry allergen Pru av 2
3HSY	;	1.75	;	High resolution structure of a dimeric GluR2 N-terminal domain (NTD)
7W7R	;	3.46	;	High resolution structure of a fish aquaporin reveals a novel extracellular fold.
7W7S	;	1.9	;	High resolution structure of a fish aquaporin reveals a novel extracellular fold.
1GTO	;	1.82	;	HIGH RESOLUTION STRUCTURE OF A HYPERSTABLE HELICAL BUNDLE PROTEIN MUTANT
4R8I	;	2.05	;	High Resolution Structure of a Mirror-Image RNA Oligonucleotide Aptamer in Complex with the Chemokine CCL2
4V1L	;	1.75	;	High resolution structure of a novel carbohydrate binding module from glycoside hydrolase family 9 (Cel9A) from Ruminococcus flavefaciens FD-1
4JP6	;	1.0	;	High resolution structure of a papaya barwin-like protein
4JP7	;	1.05	;	High resolution structure of a papaya barwin-like protein (crystal form 2)
1T28	;		;	High resolution structure of a picornaviral internal cis-acting replication element
4AFF	;	1.05	;	High resolution structure of a PII mutant (I86N) protein in complex with ATP, MG and FLC
1SFI	;	1.65	;	High resolution structure of a potent, cyclic protease inhibitor from sunflower seeds
2R8S	;	1.95	;	High resolution structure of a specific synthetic FAB bound to P4-P6 RNA ribozyme domain
3CVM	;	2.02	;	High resolution structure of a stable Plasminogen activator inhibitor type-1 in its protease cleaved form
1N7S	;	1.45	;	High Resolution Structure of a Truncated Neuronal SNARE Complex
1DZD	;		;	High resolution structure of acidic fibroblast growth factor (27-154), 24 NMR structures
1DZC	;		;	High resolution structure of acidic fibroblast growth factor. Mutant FGF-4-ALA-(24-154), 24 NMR structures
5KZH	;	1.61	;	High Resolution Structure of Acinetobacter baumannii beta-lactamase OXA-51
5L2F	;	1.77	;	High Resolution Structure of Acinetobacter baumannii beta-lactamase OXA-51 I129L/K83D bound to doripenem
7OUB	;	1.82	;	High resolution structure of Alpha-1-acid glycoprotein bound to potent anti-tumour compound UCN-01
3NGP	;	1.084	;	High resolution structure of alpha-spectrin SH3 domain mutant with a redesigned core
5HWE	;	1.71	;	high resolution structure of barbiturase
5HY1	;	2.01	;	high resolution structure of barbiturase
2FJ8	;	1.19	;	High resolution structure of barley Bowman-Birk inhibitor
1YNO	;	1.22	;	High Resolution Structure of Benzoylformate Decarboxylase from Pseudomonas Putida Complexed with Thiamine Thiazolone Diphosphate
6IQX	;	1.432	;	High resolution structure of bilirubin oxidase from Myrothecium verrucaria - M467Q mutant, aerobically prepared
6IQY	;	1.6	;	High resolution structure of bilirubin oxidase from Myrothecium verrucaria - M467Q mutant, anaerobically prepared
6IQZ	;	1.46	;	High resolution structure of bilirubin oxidase from Myrothecium verrucaria - wild type
7PPA	;	1.48	;	High resolution structure of bone morphogenetic protein receptor type II (BMPRII) extracellular domain in complex with BMP10
1YPH	;	1.34	;	High resolution structure of bovine alpha-chymotrypsin
7C4I	;	1.37	;	High resolution structure of BRPF1 Bromo Domain from Biortus
3L0F	;	1.35	;	High resolution structure of C-Phycocyanin from Thermosynechococcus elongatus
5DEV	;	1.71	;	High resolution structure of CCG DNA repeats at 1.71 angstrom resolution
8ONX	;	1.3	;	High resolution structure of Chaetomium thermophilum MAP2
4HNR	;	1.9	;	High resolution structure of Chemotaxis response regulator CheY4 of Vibrio cholerae
3TO5	;	1.65	;	High resolution structure of CheY3 from Vibrio cholerae
1R6C	;	2.15	;	High resolution structure of ClpN
2XMX	;	1.67	;	High resolution structure of Colicin M
5YBZ	;	1.711	;	High resolution structure of complement C1q-like protein 3 C1q domain
6CAF	;	1.3	;	High Resolution Structure of Concanavalin B from Jack Bean (Canavalia ensiformis), A Chitinase-like Protein
7OY2	;	2.06	;	High resolution structure of cytochrome bd-II oxidase from E. coli
4IK5	;	2.5	;	High resolution structure of Delta-REST-GCaMP3
4GSX	;	1.903	;	High resolution structure of dengue virus serotype 1 sE containing stem
3ULD	;	1.6	;	High resolution structure of DNA/RNA hybrid in complex with RNase H catalytic domain D132N mutant
2LTQ	;		;	High resolution structure of DsbB C41S by joint calculation with solid-state NMR and X-ray data
6IW3	;	1.64	;	High resolution structure of Dvl2-DIX Y27W/C80S mutant
2HPH	;	1.33	;	High resolution structure of E. coli glucose/galactose binding protein bound with glucose
4DY4	;	1.2	;	High resolution structure of E.coli WrbA with FMN
1PO7	;	1.2	;	HIGH RESOLUTION STRUCTURE OF E28A MUTANT BENZOYLFORMATE DECARBOXYLASE FROM PSEUDOMONAS PUTIDA
1Q6Z	;	1.0	;	HIGH RESOLUTION STRUCTURE OF E28A MUTANT BENZOYLFORMATE DECARBOXYLASE FROM PSEUDOMONAS PUTIDA COMPLEXED WITH THIAMIN THIAZOLONE DIPHOSPHATE
4QEQ	;	1.381	;	High resolution structure of egg white lysozyme
8SPS	;	3.0	;	High resolution structure of ESRRB nucleosome bound OCT4 at site a and site b
4BV0	;	3.1	;	High Resolution Structure of Evolved Agonist-bound Neurotensin Receptor 1 Mutant without Lysozyme Fusion
6LHS	;	3.35	;	High resolution structure of FANCA C-terminal domain (CTD)
6LHU	;	3.46	;	High resolution structure of FANCA C-terminal domain (CTD)
1LQK	;	1.35	;	High Resolution Structure of Fosfomycin Resistance Protein A (FosA)
4AK4	;	1.65	;	High resolution structure of Galactose Binding lectin from Champedak (CGB)
4IK4	;	2.01	;	High resolution structure of GCaMP3 at pH 5.0
4IK3	;	2.007	;	High resolution structure of GCaMP3 at pH 8.5
4IK8	;	1.55	;	High resolution structure of GCaMP3 dimer form 1 at pH 7.5
4IK9	;	1.8	;	High resolution structure of GCaMP3 dimer form 2 at pH 7.5
4IK1	;	2.0	;	High resolution structure of GCaMPJ at pH 8.5
2BMD	;	1.8	;	high resolution structure of GDP-bound human Rab4a
6Y0H	;	1.0	;	High resolution structure of GH11 xylanase from Nectria haematococca
3O21	;	2.201	;	High resolution structure of GluA3 N-terminal domain (NTD)
2BME	;	1.57	;	high resolution structure of GppNHp-bound human Rab4a
5WQQ	;	0.8	;	High resolution structure of high-potential iron-sulfur protein in the oxidized state
5WQR	;	0.8	;	High resolution structure of high-potential iron-sulfur protein in the reduced state
2A1E	;	1.3	;	High resolution structure of HIV-1 PR with TS-126
1HG7	;	1.15	;	High resolution structure of HPLC-12 type III antifreeze protein from Ocean Pout Macrozoarces americanus
3KV2	;	1.55	;	HIGH RESOLUTION STRUCTURE OF HUMAN ARGINASE I IN COMPLEX WITH THE STRONG INHIBITOR N(omega)-hydroxy-nor-L-arginine (nor-NOHA)
3KS3	;	0.9	;	High resolution structure of Human Carbonic Anhydrase II at 0.9 A
2J8B	;	1.15	;	High resolution structure of human CD59
2UWR	;	1.34	;	High resolution structure of human CD59
2UX2	;	1.8	;	High resolution structure of human CD59
3ZXF	;	1.38	;	High resolution structure of Human Galectin-7
4EW1	;	1.522	;	High resolution structure of human glycinamide ribonucleotide transformylase in apo form.
3TW2	;	1.38	;	High resolution structure of human histidine triad nucleotide-binding protein 1 (hHINT1)/AMP complex in a monoclinic space group
2QXI	;	1.0	;	High resolution structure of Human Kallikrein 7 in Complex with Suc-Ala-Ala-Pro-Phe-chloromethylketone
7QPP	;	1.52	;	High resolution structure of human VDR ligand binding domain in complex with calcitriol
5I39	;	1.2	;	High resolution structure of L-amino acid deaminase from Proteus vulgaris with the deletion of the specific insertion sequence
2RFV	;	1.355	;	High resolution structure of L-methionine gamma-lyase from Citrobacter freundii
7W5D	;	1.141	;	High resolution structure of lectin-ike Ox-LDL Receptor 1
7XMP	;	1.27	;	High resolution structure of lectin-like Ox-LDL receptor 1 in space group P 32 2 1
4K8M	;	0.87	;	High resolution structure of M.tb NRDH
4ZYB	;	1.5	;	High resolution structure of M23 peptidase LytM with substrate analogue
3ZS3	;	1.8	;	High resolution structure of Mal d 2, the thaumatin like food allergen from apple
4AKD	;	2.1	;	High resolution structure of Mannose Binding lectin from Champedak (CMB)
6H40	;	1.053	;	High resolution structure of MeT1 from Mycobacterium hassiacum in complex with 3-methoxy-1,2-propanediol.
1XBI	;	1.45	;	High resolution structure of Methanocaldococcus jannaschii L7AE
4D8B	;	1.058	;	High resolution structure of monomeric S. progenies SpeB reveals role of glycine-rich active site loop
4GAC	;	1.64	;	High resolution structure of mouse aldehyde reductase (AKR1a4) in its apo-form
5T5X	;	1.84	;	High resolution structure of mouse Cryptochrome 1
6KIR	;	1.55	;	High resolution structure of mouse CXorf40A
2XIU	;	1.5	;	High resolution structure of MTSL-tagged CylR2.
5WOP	;	1.52	;	High Resolution Structure of Mutant CA09-PB2cap
2BJI	;	1.24	;	High Resolution Structure of myo-Inositol Monophosphatase, The Target of Lithium Therapy
6LUH	;	1.5	;	High resolution structure of N(omega)-hydroxy-L-arginine hydrolase
3NT1	;	1.73	;	High resolution structure of naproxen:COX-2 complex.
2XI8	;	1.21	;	High resolution structure of native CylR2
4LQH	;	1.16	;	High resolution structure of native frog M ferritin
5OKB	;	1.331	;	High resolution structure of native Gan1D, a putative 6-phospho-beta-galactosidase from Geobacillus stearothermophilus
6FPO	;	1.05	;	High resolution structure of native Hydrogenase (Hyd-1)
2OL2	;	2.0	;	High Resolution Structure of Native PCI in Space Group P21
4D1T	;	1.25	;	High resolution structure of native tVIM-7 from Pseudomonas aeruginosa
8Q3E	;	2.174	;	High Resolution Structure of Nucleosome Core with Bound Foamy Virus GAG Peptide
1P4C	;	1.35	;	High Resolution Structure of Oxidized Active Mutant of (S)-Mandelate Dehydrogenase
3A71	;	1.14	;	High resolution structure of Penicillium chrysogenum alpha-L-arabinanase
3A72	;	1.04	;	High resolution structure of Penicillium chrysogenum alpha-L-arabinanase complexed with arabinobiose
6AIR	;	0.85	;	High resolution structure of perdeuterated high-potential iron-sulfur protein
2QMV	;		;	High Resolution Structure of Peroxisone Proliferation-Activated Receptor gamma and Characterisation of its Interaction with the Co-activator Transcriptional Intermediary Factor 2
2Q5B	;	1.45	;	High resolution structure of Plastocyanin from Phormidium laminosum
3VWC	;	1.5	;	High resolution structure of proteinase inhibitor from Coprinopsis cinerea
2VEB	;	1.3	;	High resolution structure of protoglobin from Methanosarcina acetivorans C2A
3EER	;	1.45	;	High resolution structure of putative organic hydroperoxide resistance protein from Vibrio cholerae O1 biovar eltor str. N16961
7O0J	;	1.4	;	High resolution structure of recombinant chichen liver Bile Acid Binding Protein (cL-BABP)
1LP8	;	1.65	;	HIGH RESOLUTION STRUCTURE OF RECOMBINANT DIANTHIN ANTIVIRAL PROTEIN-POTENT ANTI-HIV AGENT
1LPD	;	1.7	;	HIGH RESOLUTION STRUCTURE OF RECOMBINANT DIANTHIN ANTIVIRAL PROTEIN-POTENT ANTI-HIV AGENT (COMPLEX WITH ADENINE)
1LPC	;	1.7	;	HIGH RESOLUTION STRUCTURE OF RECOMBINANT DIANTHIN ANTIVIRAL PROTEIN-POTENT ANTI-HIV AGENT (COMPLEX WITH CYCLIC AMP)
6AIQ	;	0.85	;	High resolution structure of recombinant high-potential iron-sulfur protein
2LYN	;	2.07	;	HIGH RESOLUTION STRUCTURE OF RED ABALONE LYSIN DIMER
1P5B	;	1.35	;	High Resolution Structure of Reduced Active Mutant of (S)-Mandelate Dehydrogenase
6Z3C	;	1.74	;	High resolution structure of RgNanOx
1MXR	;	1.42	;	High resolution structure of Ribonucleotide reductase R2 from E. coli in its oxidised (Met) form
2FN3	;	1.0	;	High resolution structure of s26a mutant of benzoylformate decarboxylase from pseudomonas putida complexed with thiamine thiazolone diphosphate
4CNN	;	1.0	;	High resolution structure of Salmonella typhi type I dehydroquinase
6ELW	;	1.3	;	High resolution structure of selenocysteine containing human GPX4
1O7S	;	1.75	;	High resolution structure of Siglec-7
1O7V	;	1.9	;	High resolution structure of Siglec-7
2JG2	;	1.3	;	HIGH RESOLUTION STRUCTURE OF SPT WITH PLP INTERNAL ALDIMINE
2E7Y	;	1.97	;	High resolution structure of T. maritima tRNase Z
2X9N	;	1.15	;	High resolution structure of TbPTR1 in complex with cyromazine
2X9G	;	1.1	;	High resolution structure of TbPTR1 in complex with Pemetrexed
2X9V	;	1.3	;	High resolution structure of TbPTR1 with trimetrexate
6SHK	;	1.992	;	High resolution structure of the antimicrobial peptide Dermcidin from human
2WFB	;	2.0	;	High resolution structure of the apo form of the orange protein (ORP) from Desulfovibrio gigas
3ZCC	;	1.25	;	High resolution structure of the asymmetric R333G Hamp-Dhp mutant
3NKE	;	1.4	;	High resolution structure of the C-terminal domain CRISP-associated protein Cas1 from Escherichia coli str. K-12
4BA6	;	1.42	;	High Resolution structure of the C-terminal family 65 Carbohydrate Binding Module (CBM65B) of endoglucanase Cel5A from Eubacterium cellulosolvens
1JGM	;	1.3	;	High Resolution Structure of the Cadmium-containing Phosphotriesterase from Pseudomonas diminuta
4FK9	;	1.06	;	High Resolution Structure of the Catalytic Domain of Mannanase SActE_2347 from Streptomyces sp. SirexAA-E
5BY5	;	1.2	;	High resolution structure of the ectoine synthase from the cold-adapted marine bacterium Sphingopyxis alaskensis
4V2X	;	1.64	;	High resolution structure of the full length tri-modular endo-beta-1, 4-glucanase B (Cel5B) from Bacillus halodurans
3PWF	;	1.64	;	High resolution structure of the fully reduced form of rubrerythrin from P. furiosus
5OQ3	;	1.35	;	High resolution structure of the functional region of Cwp19 from Clostridium difficile
4GPA	;	2.25	;	High resolution structure of the GluA4 N-terminal domain (NTD)
2B8A	;		;	High Resolution Structure of the HDGF PWWP Domain
1XO0	;	2.0	;	High resolution structure of the holliday junction intermediate in cre-loxp site-specific recombination
1WKU	;	1.6	;	High resolution structure of the human alpha-actinin isoform 3
5B8C	;	2.146	;	High resolution structure of the human PD-1 in complex with pembrolizumab Fv
8BHX	;	1.25	;	High resolution structure of the iron Superoxide Dismutase from Thermobifida fusca
7P20	;	1.4	;	High resolution structure of the Juniperus ashei allergen - Jun a 3
2P9H	;	2.0	;	High resolution structure of the Lactose Repressor bound to IPTG
2QF5	;	2.23	;	High resolution structure of the major periplasmic domain from the cell shape-determining filament MreC (monoclinic form)
2QF4	;	1.2	;	High resolution structure of the major periplasmic domain from the cell shape-determining filament MreC (orthorhombic form)
4FKA	;	1.08	;	High resolution structure of the manganese derivative of insulin
1I0B	;	1.3	;	HIGH RESOLUTION STRUCTURE OF THE MANGANESE-CONTAINING PHOSPHOTRIESTERASE FROM PSEUDOMONAS DIMINUTA
7M6A	;	3.36	;	High resolution structure of the membrane embedded skeletal muscle ryanodine receptor
7M6L	;	3.98	;	High resolution structure of the membrane embedded skeletal muscle ryanodine receptor
4U9I	;	1.06	;	High Resolution Structure Of The Ni-R State Of [Nife]Hydrogenase From Desulufovibrio Vulgaris Miyazaki F
4C6A	;	1.25	;	High Resolution Structure of the Nucleoside diphosphate kinase
1QJP	;	1.65	;	HIGH RESOLUTION STRUCTURE OF THE OUTER MEMBRANE PROTEIN A (OMPA) TRANSMEMBRANE DOMAIN
1WUK	;	1.1	;	High resolution Structure Of The Oxidized State Of [Nife]Hydrogenase From Desulufovibrio Vulgaris Miyazaki F
5G51	;	1.45	;	High resolution structure of the part of VP3 protein of Deformed Wing Virus forming P-domain
5OVZ	;	1.75	;	High resolution structure of the PBP NocT in complex with nopaline
2VPO	;	1.8	;	High resolution structure of the periplasmic binding protein TeaA from TeaABC TRAP transporter of Halomonas elongata in complex with hydroxyectoine
1H10	;	1.4	;	HIGH RESOLUTION STRUCTURE OF THE PLECKSTRIN HOMOLOGY DOMAIN OF PROTEIN KINASE B/AKT BOUND TO INS(1,3,4,5)-TETRAKISPHOPHATE
1EYU	;	1.78	;	HIGH RESOLUTION STRUCTURE OF THE PVUII ENDONCULEASE/COGNATE DNA COMPLEX AT PH 4.6
2LIS	;	1.35	;	HIGH RESOLUTION STRUCTURE OF THE RED ABALONE LYSIN MONOMER
1WUL	;	1.5	;	High Resolution Structure Of The Reduced State Of [Nife]Hydrogenase From Desulufovibrio Vulgaris Miyazaki F
2KRN	;		;	High resolution structure of the second SH3 domain of CD2AP
8C41	;	2.393	;	High resolution structure of the Streptococcus pneumoniae topoisomerase IV-DNA complex with the novel fluoroquinolone Delafloxacin
2XJ3	;	1.23	;	High resolution structure of the T55C mutant of CylR2.
5A6L	;	1.8	;	High resolution structure of the thermostable glucuronoxylan endo-Beta-1, 4-xylanase, CtXyn30A, from Clostridium thermocellum with two xylobiose units bound
4UYQ	;	1.81	;	High resolution structure of the third cohesin ScaC in complex with the ScaB dockerin with a mutation in the C-terminal helix (IN to SI) from Acetivibrio cellulolyticus displaying a type I interaction.
4UYP	;	1.49	;	High resolution structure of the third cohesin ScaC in complex with the ScaB dockerin with a mutation in the N-terminal helix (IN to SI) from Acetivibrio cellulolyticus displaying a type I interaction.
1HZY	;	1.3	;	HIGH RESOLUTION STRUCTURE OF THE ZINC-CONTAINING PHOSPHOTRIESTERASE FROM PSEUDOMONAS DIMINUTA
1I0D	;	1.3	;	HIGH RESOLUTION STRUCTURE OF THE ZINC/CADMIUM-CONTAINING PHOSPHOTRIESTERASE FROM PSEUDOMONAS DIMINUTA
4BUO	;	2.75	;	High Resolution Structure of Thermostable Agonist-bound Neurotensin Receptor 1 Mutant without Lysozyme Fusion
2WYU	;	1.5	;	High resolution structure of Thermus thermophilus enoyl-acyl carrier protein reductase apo-form
2WYW	;	1.9	;	High resolution structure of Thermus thermophilus enoyl-acyl carrier protein reductase NAD and triclosan-form
2WYV	;	1.86	;	High resolution structure of Thermus thermophilus enoyl-acyl carrier protein reductase NAD-form
5VT3	;	1.98	;	High resolution structure of thioredoxin-disulfide reductase from Vibrio vulnificus CMCP6 in complex with NADP and FAD
4FZL	;	1.46	;	High resolution structure of truncated bacteriocin syringacin M from Pseudomonas syringae pv. tomato DC3000
2XOL	;	1.35	;	High resolution structure of TtrD from Archaeoglobus fulgidus
6ZFL	;	1.6	;	High resolution structure of VEGF-A 12:107 crystallized in tetragonal form
4H60	;	1.66	;	High resolution structure of Vibrio cholerae chemotaxis protein CheY4 crystallized in low pH (4.0) condition
4MAS	;	1.22	;	High Resolution Structure of Wild Type Human Transthyretin in Complex with 3,3',5,5'-tetrachloro-[1,1'-biphenyl]-4,4'diol
2JIC	;	1.5	;	High resolution structure of xylanase-II from one micron beam experiment
6L8G	;	1.0	;	High resolution structure of YoeB in complex with YefM C-terminus(46N-83V) from Staphylococcus aureus.
1MFB	;	2.1	;	HIGH RESOLUTION STRUCTURES OF ANTIBODY FAB FRAGMENT COMPLEXED WITH CELL-SURFACE OLIGOSACCHARIDE OF PATHOGENIC SALMONELLA
1MFC	;	2.1	;	HIGH RESOLUTION STRUCTURES OF ANTIBODY FAB FRAGMENT COMPLEXED WITH CELL-SURFACE OLIGOSACCHARIDE OF PATHOGENIC SALMONELLA
1RTH	;	2.2	;	HIGH RESOLUTION STRUCTURES OF HIV-1 RT FROM FOUR RT-INHIBITOR COMPLEXES
1RTI	;	3.0	;	HIGH RESOLUTION STRUCTURES OF HIV-1 RT FROM FOUR RT-INHIBITOR COMPLEXES
1VRT	;	2.2	;	HIGH RESOLUTION STRUCTURES OF HIV-1 RT FROM FOUR RT-INHIBITOR COMPLEXES
1VRU	;	2.4	;	HIGH RESOLUTION STRUCTURES OF HIV-1 RT FROM FOUR RT-INHIBITOR COMPLEXES
2NAC	;	1.8	;	HIGH RESOLUTION STRUCTURES OF HOLO AND APO FORMATE DEHYDROGENASE
2NAD	;	2.05	;	HIGH RESOLUTION STRUCTURES OF HOLO AND APO FORMATE DEHYDROGENASE
4D8E	;	1.497	;	High resolution structures of monomeric S. pyogenes SpeB reveals role of glycine-rich active site loop
4D8I	;	1.377	;	High resolution structures of monomeric S. pyogenes SpeB reveals role of glycine-rich active site loop
4STD	;	2.15	;	HIGH RESOLUTION STRUCTURES OF SCYTALONE DEHYDRATASE-INHIBITOR COMPLEXES CRYSTALLIZED AT PHYSIOLOGICAL PH
2G82	;	1.65	;	High Resolution Structures of Thermus aquaticus Glyceraldehyde-3-Phosphate Dehydrogenase: Role of 220's Loop Motion in Catalysis
1YMB	;	1.9	;	HIGH RESOLUTION STUDY OF THE THREE-DIMENSIONAL STRUCTURE OF HORSE HEART METMYOGLOBIN
4YSE	;	1.2	;	High resolution synchrotron structure of copper nitrite reductase from Alcaligenes faecalis
8V04	;	1.58	;	High resolution TMPRSS2 structure following acylation by nafamostat
6WX3	;	1.2	;	High resolution Tryptophan Synthase crystal structure from Salmonella typhimurium in complex with F9 inhibitor in the alpha-site, Cesium ion at the metal coordination site and internal aldimine form.
3AGI	;	1.2	;	High resolution X-ray analysis of Arg-lysozyme complex in the presence of 500 mM Arg
8AAZ	;	1.27	;	High resolution X-ray analysis of ATP lysozyme complex in the presence of 80 mM ATP
5CE4	;	0.98	;	High Resolution X-Ray and Neutron diffraction structure of H-FABP
5EN9	;	1.5	;	High resolution x-ray crystal structure of isotope-labeled ester-insulin
4LFQ	;	1.059	;	High resolution x-ray crystal structure of L-ShK toxin
5UDP	;	1.348	;	High resolution x-ray crystal structure of synthetic insulin lispro
2YVB	;	1.62	;	High resolution X-ray crystal structure of Tetragonal Hen egg white lysozyme
1QKO	;	2.1	;	HIGH RESOLUTION X-RAY STRUCTURE OF AN EARLY INTERMEDIATE IN THE BACTERIORHODOPSIN PHOTOCYCLE
1QKP	;	2.1	;	HIGH RESOLUTION X-RAY STRUCTURE OF AN EARLY INTERMEDIATE IN THE BACTERIORHODOPSIN PHOTOCYCLE
7PTZ	;	1.093	;	High resolution X-ray structure of E. coli expressed Lentinus similis LPMO.
1KJL	;	1.4	;	High Resolution X-Ray Structure of Human Galectin-3 in complex with LacNAc
2FGQ	;	1.45	;	High resolution X-ray structure of Omp32 in complex with malate
4LFS	;	0.97	;	High resolution x-ray structure of racemic ShK toxin
5AB8	;	1.53	;	High resolution X-ray structure of the N-terminal truncated form (residues 1-11) of Mycobacterium tuberculosis HbN
7PU1	;	1.06	;	High resolution X-ray structure of Thermoascus aurantiacus LPMO
4N9V	;	1.1	;	High resolution x-ray structure of urate oxidase in complex with 8-azaxanthine
4N9S	;	1.06	;	High resolution X-RAY STRUCTURE OF URATE OXIDASE IN COMPLEX WITH 8-HYDROXYXANTHINE
2HBC	;	2.1	;	HIGH RESOLUTION X-RAY STRUCTURES OF MYOGLOBIN-AND HEMOGLOBIN-ALKYL ISOCYANIDE COMPLEXES
2HBD	;	2.2	;	HIGH RESOLUTION X-RAY STRUCTURES OF MYOGLOBIN-AND HEMOGLOBIN-ALKYL ISOCYANIDE COMPLEXES
2HBE	;	2.0	;	HIGH RESOLUTION X-RAY STRUCTURES OF MYOGLOBIN-AND HEMOGLOBIN-ALKYL ISOCYANIDE COMPLEXES
2HBF	;	2.2	;	HIGH RESOLUTION X-RAY STRUCTURES OF MYOGLOBIN-AND HEMOGLOBIN-ALKYL ISOCYANIDE COMPLEXES
2MYA	;	1.8	;	HIGH RESOLUTION X-RAY STRUCTURES OF MYOGLOBIN-AND HEMOGLOBIN-ALKYL ISOCYANIDE COMPLEXES
2MYB	;	1.9	;	HIGH RESOLUTION X-RAY STRUCTURES OF MYOGLOBIN-AND HEMOGLOBIN-ALKYL ISOCYANIDE COMPLEXES
2MYC	;	1.8	;	HIGH RESOLUTION X-RAY STRUCTURES OF MYOGLOBIN-AND HEMOGLOBIN-ALKYL ISOCYANIDE COMPLEXES
2MYD	;	1.8	;	HIGH RESOLUTION X-RAY STRUCTURES OF MYOGLOBIN-AND HEMOGLOBIN-ALKYL ISOCYANIDE COMPLEXES
2MYE	;	1.68	;	HIGH RESOLUTION X-RAY STRUCTURES OF MYOGLOBIN-AND HEMOGLOBIN-ALKYL ISOCYANIDE COMPLEXES
1MYG	;	1.75	;	HIGH RESOLUTION X-RAY STRUCTURES OF PIG METMYOGLOBIN AND TWO CD3 MUTANTS MB(LYS45-> ARG) AND MB(LYS45-> SER)
1MYH	;	1.9	;	HIGH RESOLUTION X-RAY STRUCTURES OF PIG METMYOGLOBIN AND TWO CD3 MUTANTS MB(LYS45-> ARG) AND MB(LYS45-> SER)
1MYI	;	2.0	;	HIGH RESOLUTION X-RAY STRUCTURES OF PIG METMYOGLOBIN AND TWO CD3 MUTANTS MB(LYS45-> ARG) AND MB(LYS45-> SER)
2FGR	;	1.5	;	High resolution Xray structure of Omp32
5FNP	;	1.8	;	High resolution Zn containing Iron sulfur cluster repair protein YtfE
6DIN	;	1.8	;	High resolutionstructure of apo dTDP-4-dehydrorhamnose 3,5-epimerase
1HKK	;	1.85	;	High resoultion crystal structure of human chitinase in complex with allosamidin
5OWH	;	2.3	;	High salt structure of human protein kinase CK2alpha in complex with 3-aminopropyl-4,5,6,7-tetrabromobenzimidazol
4EK7	;	2.3	;	High speed X-ray analysis of plant enzymes at room temperature
2CI0	;	1.53	;	High throughput screening and x-ray crystallography assisted evaluation of small molecule scaffolds for CYP51 inhibitors
2CIB	;	1.5	;	High throughput screening and x-ray crystallography assisted evaluation of small molecule scaffolds for CYP51 inhibitors
4TPY	;	1.3	;	High throughput screening using acoustic droplet ejection to combine protein crystals and chemical libraries on crystallization plates at high density
4KO4	;	2.0	;	High X-ray dose structure of anaerobically purified Dm. baculatum [NiFeSe]-hydrogenase after crystallization under air
4KO1	;	1.55	;	High X-ray dose structure of H2-activated anaerobically purified Dm. baculatum [NiFeSe]-hydrogenase after crystallization under air
5VXZ	;	2.3	;	High-affinity AXL decoy receptor
6UMT	;	1.986	;	High-affinity human PD-1 PD-L2 complex
4CWM	;	2.09	;	High-glycosylation crystal structure of the bifunctional endonuclease (AtBFN2) from Arabidopsis thaliana
3HIP	;	2.8	;	HIGH-POTENTIAL IRON-SULFUR PROTEIN FROM CHROMATIUM PURPURATUM
5Z6F	;	1.801	;	High-pressure Crystal Structure Analysis of DHFR(0.1 MPa)
5Z6J	;	1.803	;	High-pressure Crystal Structure Analysis of M20 loop closed DHFR at 220 MPa
5Z6K	;	1.802	;	High-pressure Crystal Structure Analysis of M20 loop closed DHFR at 400 MPa
5Z6L	;	1.9	;	High-pressure Crystal Structure Analysis of M20 loop closed DHFR at 650 MPa
5Z6M	;	2.202	;	High-pressure Crystal Structure Analysis of M20 loop closed DHFR at 800 MPa
2OE9	;	2.01	;	High-pressure structure of pseudo-WT T4 Lysozyme
2OEA	;	2.01	;	High-pressure structure of pseudo-WT T4 Lysozyme
2OE7	;	2.1	;	High-Pressure T4 Lysozyme
4M5Q	;	1.534	;	High-resolution apo influenza 2009 H1N1 endonuclease structure
4V8M	;	5.57	;	High-resolution cryo-electron microscopy structure of the Trypanosoma brucei ribosome
6GV4	;	2.8	;	High-resolution Cryo-EM of Fab-labeled human parechovirus 3
5SYF	;	3.5	;	High-resolution cryo-EM reconstruction of Taxol-stabilized microtubule
7ZHG	;	2.25	;	High-resolution cryo-EM structure of Pyrococcus abyssi 30S ribosomal subunit bound to mRNA and initiator tRNA anticodon stem-loop
6QZP	;	2.9	;	High-resolution cryo-EM structure of the human 80S ribosome
2OM3	;	4.4	;	High-resolution cryo-EM structure of Tobacco Mosaic Virus
6C1D	;	3.2	;	High-Resolution Cryo-EM Structures of Actin-bound Myosin States Reveal the Mechanism of Myosin Force Sensing
6C1G	;	3.8	;	High-Resolution Cryo-EM Structures of Actin-bound Myosin States Reveal the Mechanism of Myosin Force Sensing
6C1H	;	3.9	;	High-Resolution Cryo-EM Structures of Actin-bound Myosin States Reveal the Mechanism of Myosin Force Sensing
4G03	;	2.216	;	High-resolution Crystal Structural Variance Analysis between Recombinant and Wild-type Human Serum Albumin
4G04	;	2.301	;	High-resolution Crystal Structural Variance Analysis between Recombinant and Wild-type Human Serum Albumin
4QRN	;	1.07	;	HIGH-RESOLUTION CRYSTAL STRUCTURE of 5-CARBOXYVANILLATE DECARBOXYLASE (TARGET EFI-505250) FROM NOVOSPHINGOBIUM AROMATICIVORANS DSM 12444 COMPLEXED WITH MANGANESE AND 4-HYDROXY-3-METHOXY-5-NITROBENZOIC ACID
363D	;	2.0	;	High-resolution crystal structure of a fully modified N3'-> P5' phosphoramidate DNA dodecamer duplex
7LHK	;	1.95	;	High-Resolution Crystal Structure of a Lipin/Pah Phosphatidic Acid Phosphatase
1KUF	;	1.35	;	High-resolution Crystal Structure of a Snake Venom Metalloproteinase from Taiwan Habu
2RCI	;	1.8	;	High-resolution crystal structure of activated Cyt2Ba monomer from Bacillus thuringiensis subsp. israelensis
6QHJ	;	1.25	;	High-resolution crystal structure of calcium- and sodium-bound mouse Olfactomedin-1 beta-propeller domain
6DTD	;	1.65	;	High-resolution crystal structure of Cas13b from Prevotella buccae
1ZBZ	;	1.29	;	High-Resolution Crystal Structure of Compound I intermediate of Cytochrome c Peroxidase (CcP)
4Q4W	;	1.4	;	High-resolution crystal structure of Coxsackievirus A24v
7R8T	;	1.366	;	High-resolution crystal structure of CYP199A4 bound to 4-ethylbenzoic acid
2CPP	;	1.63	;	HIGH-RESOLUTION CRYSTAL STRUCTURE OF CYTOCHROME P450-CAM
6RQX	;	1.68	;	High-resolution crystal structure of ERAP1 in complex with 10mer phosphinic peptide
6RYF	;	1.72	;	High-resolution crystal structure of ERAP1 in complex with 15mer phosphinic peptide
7Z28	;	1.55	;	High-resolution crystal structure of ERAP1 with bound bestatin analogue inhibitor
6Q4R	;	1.6	;	High-resolution crystal structure of ERAP1 with bound phosphinic transition-state analogue inhibitor
1GZ9	;	1.7	;	High-Resolution Crystal Structure of Erythrina cristagalli Lectin in Complex with 2'-alpha-L-Fucosyllactose
1GZC	;	1.58	;	High-Resolution crystal structure of Erythrina cristagalli lectin in complex with lactose
4W4O	;	1.8	;	High-resolution crystal structure of Fc bound to its human receptor Fc-gamma-RI
6CDX	;	1.0	;	High-resolution crystal structure of fluoropropylated cystine knot, binding to alpha-5 beta-6 integrin
4HS1	;	0.87	;	High-resolution crystal structure of Glutaredoxin like protein NrdH from Mycobacterium tuberculosis.
7MSE	;	1.27	;	High-resolution crystal structure of hMIF2 with tartrate at the active site
7LL4	;	1.31	;	High-resolution crystal structure of human JAK2 kinase domain (JH1) bound to PN5-114.
7LL5	;	1.5	;	High-resolution crystal structure of human JAK2 kinase domain (JH1) bound to PN5-150.
7RN6	;	1.5	;	High-resolution crystal structure of human JAK2 kinase domain (JH1) bound to type-II inhibitor BBT594
7REE	;	1.38	;	High-resolution crystal structure of human JAK2 kinase domain (JH1) bound to YM2-059
7MDL	;	2.32	;	High-resolution crystal structure of human SepSecS-tRNASec complex
8AQL	;	1.23	;	High-resolution crystal structure of human SHMT2
4H5Y	;	2.1	;	High-resolution crystal structure of Legionella pneumophila LidA (60-594)
1ZBY	;	1.2	;	High-Resolution Crystal Structure of Native (Resting) Cytochrome c Peroxidase (CcP)
4KGD	;	1.06	;	High-resolution crystal structure of pyruvate oxidase from L. plantarum in complex with phosphate
3A1G	;	1.7	;	High-Resolution Crystal Structure of RNA polymerase PB1-PB2 subunits from Influenza A Virus
7DA0	;	1.25	;	High-resolution crystal structure of the chicken MHF complex
4PWQ	;	1.4	;	HIGH-RESOLUTION CRYSTAL STRUCTURE OF THE E1-DOMAIN of THE AMYLOID PRECURSOR PROTEIN
5GXG	;	1.7	;	High-resolution crystal structure of the electron transfer complex of cytochrome p450cam with putidaredoxin
1QTW	;	1.02	;	HIGH-RESOLUTION CRYSTAL STRUCTURE OF THE ESCHERICHIA COLI DNA REPAIR ENZYME ENDONUCLEASE IV
5U09	;	2.6	;	High-resolution crystal structure of the human CB1 cannabinoid receptor
4PZ3	;	1.083	;	High-resolution crystal structure of the human CD44 hyaluronan binding domain complex with undefined peptides
4PZ4	;	1.6	;	High-resolution crystal structure of the human CD44 hyaluronan binding domain in new space group
8G9Z	;	2.07	;	High-resolution crystal structure of the human selenomethionine-derived SepSecS-tRNASec complex
5HZ7	;	1.43	;	High-resolution crystal structure of the minor DNA-binding pilin ComP from Neisseria meningitidis in fusion with MBP
7YOA	;	1.67	;	High-resolution crystal structure of the mouse alpha-defensin cryptdin 14
8AMY	;	1.67	;	High-resolution crystal structure of the Mu8.1 conotoxin from Conus Mucronatus
2W12	;	1.46	;	High-resolution crystal structure of the P-I snake venom metalloproteinase BaP1 in complex with a peptidomimetic: insights into inhibitor binding
2W13	;	1.14	;	High-resolution crystal structure of the P-I snake venom metalloproteinase BaP1 in complex with a peptidomimetic: insights into inhibitor binding
2W14	;	1.08	;	High-resolution crystal structure of the P-I snake venom metalloproteinase BaP1 in complex with a peptidomimetic: insights into inhibitor binding
2W15	;	1.05	;	High-resolution crystal structure of the P-I snake venom metalloproteinase BaP1 in complex with a peptidomimetic: insights into inhibitor binding
1Y7Y	;	1.69	;	High-resolution crystal structure of the restriction-modification controller protein C.AhdI from Aeromonas hydrophila
5LBN	;	1.42	;	High-resolution crystal structure of the UBC core domain of UBE2E1/UbcH6
4WDC	;	1.29	;	High-resolution crystal structure of water-soluble FraC (mutation F16P)
3VSY	;	1.5	;	High-resolution crystal structure of wild-type KSI in the apo form at neutral pH
1ZX6	;	1.6	;	High-resolution crystal structure of yeast Pin3 SH3 domain
4R15	;	0.97	;	High-resolution crystal structure of Z-DNA in complex with Cr3+ cations
4KT6	;	1.71	;	High-resolution crystal structure Streptococcus pyogenes beta-NAD+ glycohydrolase in complex with its endogenous inhibitor IFS reveals a water-rich interface
1MOB	;	2.2	;	HIGH-RESOLUTION CRYSTAL STRUCTURES OF DISTAL HISTIDINE MUTANTS OF SPERM WHALE MYOGLOBIN
1MOC	;	2.0	;	HIGH-RESOLUTION CRYSTAL STRUCTURES OF DISTAL HISTIDINE MUTANTS OF SPERM WHALE MYOGLOBIN
1MOD	;	2.0	;	HIGH-RESOLUTION CRYSTAL STRUCTURES OF DISTAL HISTIDINE MUTANTS OF SPERM WHALE MYOGLOBIN
2YHW	;	1.64	;	High-resolution crystal structures of N-Acetylmannosamine kinase: Insights about substrate specificity, activity and inhibitor modelling.
7JRI	;	2.4	;	High-resolution Crystal Structures of Transient Intermediates in the Phytochrome Photocycle, 33 ms structure
2A2A	;	1.47	;	High-resolution crystallographic analysis of the autoinhibited conformation of a human death-associated protein kinase
6OFF	;	3.2	;	High-resolution filamentous structures of in vitro polymerized PrgI needle
3ZP8	;	1.55	;	HIGH-RESOLUTION FULL-LENGTH HAMMERHEAD RIBOZYME
4M5R	;	1.4	;	High-resolution influenza 2009 H1N1 endonuclease bound to 4-(1H-IMIDAZOL-1-YL)PHENOL
5F66	;	1.15	;	High-resolution isotropic multiconformer synchrotron model of CypA at 273 K
7U0Z	;	4.2	;	High-resolution map of tau filament from progressive supranuclear palsy (PSP) case 1
4YUO	;	1.2	;	High-resolution multiconformer synchrotron model of CypA at 273 K
6L46	;	1.5	;	High-resolution neutron and X-ray joint refined structure of copper-containing nitrite reductase from Geobacillus thermodenitrificans
6L46	;	1.3	;	High-resolution neutron and X-ray joint refined structure of copper-containing nitrite reductase from Geobacillus thermodenitrificans
7VOS	;	1.2	;	High-resolution neutron and X-ray joint refined structure of high-potential iron-sulfur protein in the oxidized state
7VOS	;	0.66	;	High-resolution neutron and X-ray joint refined structure of high-potential iron-sulfur protein in the oxidized state
5D4H	;	1.3	;	High-resolution nitrite complex of a copper nitrite reductase determined by synchrotron radiation crystallography
2M5S	;		;	High-resolution NMR structure and cryo-EM imaging support multiple functional roles for the accessory I-domain of phage P22 coat protein
1RHX	;		;	HIGH-RESOLUTION NMR STRUCTURE OF A PUTATIVE SULFUR TRANSFERASE (TM0979) FROM THERMOTOGA MARITIMA
2MUH	;		;	High-resolution NMR structure of the protegrin-2 docked to DPC Micelles
1P98	;		;	High-resolution NMR structure of the Ubl-domain of HHR23A
4UZW	;		;	High-resolution NMR structures of the domains of Saccharomyces cerevisiae Tho1
4UZX	;		;	High-resolution NMR structures of the domains of Saccharomyces cerevisiae Tho1
3NEF	;	2.4	;	High-resolution pyrabactin-bound PYL1 structure
1YCC	;	1.23	;	HIGH-RESOLUTION REFINEMENT OF YEAST ISO-1-CYTOCHROME C AND COMPARISONS WITH OTHER EUKARYOTIC CYTOCHROMES C
2KRJ	;		;	High-Resolution Solid-State NMR Structure of a 17.6 kDa Protein
2MS7	;		;	High-resolution solid-state NMR structure of the helical signal transduction filament MAVS CARD
1NC8	;		;	HIGH-RESOLUTION SOLUTION NMR STRUCTURE OF THE MINIMAL ACTIVE DOMAIN OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE-2 NUCLEOCAPSID PROTEIN, 15 STRUCTURES
2LR9	;		;	High-resolution solution NMR structure of the rho-conotoxin TIA.
1AQ5	;		;	HIGH-RESOLUTION SOLUTION NMR STRUCTURE OF THE TRIMERIC COILED-COIL DOMAIN OF CHICKEN CARTILAGE MATRIX PROTEIN, 20 STRUCTURES
1MNL	;		;	HIGH-RESOLUTION SOLUTION STRUCTURE OF A SWEET PROTEIN SINGLE-CHAIN MONELLIN (SCM) DETERMINED BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY AND DYNAMICAL SIMULATED ANNEALING CALCULATIONS, 21 STRUCTURES
2BCA	;		;	HIGH-RESOLUTION SOLUTION STRUCTURE OF CALCIUM-LOADED CALBINDIN D9K
2BCB	;		;	HIGH-RESOLUTION SOLUTION STRUCTURE OF CALCIUM-LOADED CALBINDIN D9K
1NBJ	;		;	High-resolution solution structure of cycloviolacin O1
1EZT	;		;	HIGH-RESOLUTION SOLUTION STRUCTURE OF FREE RGS4 BY NMR
1EZY	;		;	HIGH-RESOLUTION SOLUTION STRUCTURE OF FREE RGS4 BY NMR
2GE4	;		;	High-resolution solution structure of outer membrane protein A transmembrane domain
9PCY	;		;	HIGH-RESOLUTION SOLUTION STRUCTURE OF REDUCED FRENCH BEAN PLASTOCYANIN AND COMPARISON WITH THE CRYSTAL STRUCTURE OF POPLAR PLASTOCYANIN
1PLA	;		;	HIGH-RESOLUTION SOLUTION STRUCTURE OF REDUCED PARSLEY PLASTOCYANIN
1PLB	;		;	HIGH-RESOLUTION SOLUTION STRUCTURE OF REDUCED PARSLEY PLASTOCYANIN
2KNI	;		;	High-resolution solution structure of the ASIC1a blocker PcTX1
1BBO	;		;	HIGH-RESOLUTION SOLUTION STRUCTURE OF THE DOUBLE CYS2*HIS2 ZINC FINGER FROM THE HUMAN ENHANCER BINDING PROTEIN MBP-1
1Z2Q	;		;	High-resolution solution structure of the LM5-1 FYVE domain from Leishmania major
2GW9	;		;	High-resolution solution structure of the mouse defensin Cryptdin4
1OLG	;		;	HIGH-RESOLUTION SOLUTION STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI-DIMENSIONAL NMR
1OLH	;		;	HIGH-RESOLUTION SOLUTION STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI-DIMENSIONAL NMR
2LL1	;		;	High-resolution solution structure of the orally active insecticidal spider venom peptide U1-TRTX-Sp1a
2GWP	;		;	High-resolution solution structure of the salt-bridge defficient mouse defensin (E15D)-Cryptdin4
2Y9F	;	1.47	;	High-resolution Structural Insights on the Sugar-recognition and Fusion Tag Properties of a Versatile b-Trefoil Lectin Domain
2Y9G	;	1.67	;	High-resolution Structural Insights on the Sugar-recognition and Fusion Tag Properties of a Versatile b-Trefoil Lectin Domain
6BSP	;	4.7	;	High-Resolution Structure Analysis of Antibody V5 and U4 Conformational Epitope on Human Papillomavirus 16
6BT3	;	4.7	;	High-Resolution Structure Analysis of Antibody V5 Conformational Epitope on Human Papillomavirus 16
1KUW	;		;	High-Resolution Structure and Localization of Amylin Nucleation Site in Detergent Micelles
2GZU	;		;	High-resolution structure determination of the CylR2 homodimer using intermonomer distances from paramagnetic relaxation enhancement and NMR dipolar couplings
208D	;	2.05	;	HIGH-RESOLUTION STRUCTURE OF A DNA HELIX FORMING (C.G)*G BASE TRIPLETS
4YPV	;	1.85	;	High-resolution structure of a metagenome-derived esterase Est8
1D27	;	2.0	;	HIGH-RESOLUTION STRUCTURE OF A MUTAGENIC LESION IN DNA
4UQL	;	1.22	;	High-resolution structure of a Ni-A Ni-Sox mixture of the D. fructosovorans NiFe-hydrogenase L122A mutant
2GQV	;	1.1	;	High-resolution structure of a plasmid-encoded dihydrofolate reductase: pentagonal network of water molecules in the D2-symmetric active site
6GFE	;	1.8	;	High-resolution Structure of a therapeutic full-length anti-NPRA Antibody with exceptional Conformational Diversity
4D40	;	1.669	;	High-Resolution Structure of a Type IV Pilin from Shewanella oneidensis
2ZNF	;		;	HIGH-RESOLUTION STRUCTURE OF AN HIV ZINC FINGERLIKE DOMAIN VIA A NEW NMR-BASED DISTANCE GEOMETRY APPROACH
4KL8	;	1.52	;	High-resolution structure of anaerobically purified Dm. baculatum [NiFeSe]-hydrogenase after crystallization under air
1IH7	;	2.21	;	High-Resolution Structure of Apo RB69 DNA Polymerase
4FH4	;	1.09	;	high-resolution structure of apo wt SHV-1 beta-lactamase
1ATA	;		;	HIGH-RESOLUTION STRUCTURE OF ASCARIS TRYPSIN INHIBITOR IN SOLUTION: DIRECT EVIDENCE FOR A PH INDUCED CONFORMATIONAL TRANSITION IN THE REACTIVE SITE
1ATB	;		;	HIGH-RESOLUTION STRUCTURE OF ASCARIS TRYPSIN INHIBITOR IN SOLUTION: DIRECT EVIDENCE FOR A PH INDUCED CONFORMATIONAL TRANSITION IN THE REACTIVE SITE
1ATD	;		;	HIGH-RESOLUTION STRUCTURE OF ASCARIS TRYPSIN INHIBITOR IN SOLUTION: DIRECT EVIDENCE FOR A PH INDUCED CONFORMATIONAL TRANSITION IN THE REACTIVE SITE
1ATE	;		;	HIGH-RESOLUTION STRUCTURE OF ASCARIS TRYPSIN INHIBITOR IN SOLUTION: DIRECT EVIDENCE FOR A PH INDUCED CONFORMATIONAL TRANSITION IN THE REACTIVE SITE
3J8Y	;	5.0	;	High-resolution structure of ATP analog-bound kinesin on microtubules
3CFC	;	1.7	;	High-resolution structure of blue fluorescent antibody EP2-19G2
3CFB	;	1.6	;	High-resolution structure of blue fluorescent antibody EP2-19G2 in complex with stilbene hapten at 100K
4NPD	;	0.9	;	High-resolution structure of C domain of staphylococcal protein A at cryogenic temperature
4NPE	;	1.42	;	High-resolution structure of C domain of staphylococcal protein A at room temperature
4JZ5	;	1.1	;	High-resolution structure of catalytic domain of endolysin ply40 from bacteriophage P40 of Listeria monocytogenes
5HUB	;	1.06	;	High-resolution structure of chorismate mutase from Corynebacterium glutamicum
6CN8	;	1.4	;	High-resolution structure of ClpC1-NTD binding to Rufomycin-I
3A5F	;	1.19	;	High-resolution structure of DHDPS from Clostridium botulinum in complex with pyruvate
4KN9	;	1.4	;	High-resolution structure of H2-activated anaerobically purified Dm. baculatum [NiFeSe]-hydrogenase after crystallization under air
4X9D	;	1.5	;	High-resolution structure of Hfq from Methanococcus jannaschii in complex with UMP
5LXX	;	1.25	;	High-resolution structure of human collapsin response mediator protein 2
6KIS	;	1.54	;	High-resolution structure of mouse CXorf40A (soaked with Methylmercury chloride)
3PIU	;	1.35	;	High-resolution structure of native Malus domestica ACC synthase
7POG	;	2.83	;	High-resolution structure of native toxin A from Clostridioides difficile
3J8X	;	5.0	;	High-resolution structure of no-nucleotide kinesin on microtubules
3ERX	;	1.25	;	High-resolution structure of Paracoccus pantotrophus pseudoazurin
4URH	;	1.44	;	High-resolution structure of partially oxidized D. fructosovorans NiFe-hydrogenase
7N8O	;	1.93	;	High-resolution structure of photosystem II from the mesophilic cyanobacterium, Synechocystis sp. PCC 6803
7RCV	;	2.01	;	High-resolution structure of photosystem II from the mesophilic cyanobacterium, Synechocystis sp. PCC 6803
3ZOJ	;	0.88	;	High-resolution structure of Pichia Pastoris aquaporin Aqy1 at 0.88 A
3NS2	;	1.634	;	High-resolution structure of pyrabactin-bound PYL2
4FEG	;	1.09	;	High-resolution structure of pyruvate oxidase in complex with reaction intermediate 2-hydroxyethyl-thiamin diphosphate carbanion-enamine, crystal A
4FEE	;	1.13	;	High-resolution structure of pyruvate oxidase in complex with reaction intermediate 2-hydroxyethyl-thiamin diphosphate carbanion-enamine, crystal B
4WEE	;	0.891	;	High-resolution structure of Synaptotagmin 1 C2A
5KB6	;	1.2	;	High-resolution structure of the adenosine kinase from Mus musculus in complex with adenosine
7QE7	;	2.9	;	High-resolution structure of the Anaphase-promoting complex/cyclosome (APC/C) bound to co-activator Cdh1
1LYV	;	1.363	;	High-resolution structure of the catalytically inactive yersinia tyrosine phosphatase C403A mutant in complex with phosphate.
8GY5	;	1.98	;	High-resolution structure of the cemiplimab Fab in complex with PD-1
4WWD	;	1.3	;	High-resolution structure of the Co-bound form of the Y135F mutant of C. metallidurans CnrXs
2W73	;	1.45	;	High-resolution structure of the complex between calmodulin and a peptide from calcineurin A
1P9D	;		;	High-resolution structure of the complex of HHR23A ubiquitin-like domain and the C-terminal ubiquitin-interacting motif of proteasome subunit S5a
4UQP	;	1.42	;	High-resolution structure of the D. fructosovorans NiFe-hydrogenase L122A mutant after exposure to air
2Q9T	;	1.43	;	High-resolution structure of the DING protein from Pseudomonas fluorescens
4YBB	;	2.1	;	High-resolution structure of the Escherichia coli ribosome
5IT8	;	3.12	;	High-resolution structure of the Escherichia coli ribosome
3HUP	;	1.371	;	High-resolution structure of the extracellular domain of human CD69
4D77	;	1.481	;	High-resolution structure of the extracellular olfactomedin domain from gliomedin
2KJ3	;		;	High-resolution structure of the HET-s(218-289) prion in its amyloid form obtained by solid-state NMR
7AGV	;	1.85	;	High-resolution structure of the K+/H+ antiporter subunit KhtT in complex with c-di-AMP
4MIW	;	1.72	;	High-resolution structure of the N-terminal endonuclease domain of the Lassa virus L polymerase
4WWB	;	1.11	;	High-resolution structure of the Ni-bound form of the Y135F mutant of C. metallidurans CnrXs
7SZY	;	2.4	;	High-resolution structure of the nuclease domain from the main replication protein NS1 of Human Parvovirus B19
2VPN	;	1.55	;	High-resolution structure of the periplasmic ectoine-binding protein from TeaABC TRAP-transporter of Halomonas elongata
2WIE	;	2.13	;	High-resolution structure of the rotor ring from a proton dependent ATP synthase
6WEY	;	0.95	;	High-resolution structure of the SARS-CoV-2 NSP3 Macro X domain
1L34	;	1.9	;	HIGH-RESOLUTION STRUCTURE OF THE TEMPERATURE-SENSITIVE MUTANT OF PHAGE LYSOZYME, ARG 96 (RIGHT ARROW) HIS
3PP5	;	1.5	;	High-resolution structure of the trimeric Scar/WAVE complex precursor Brk1
4IOT	;	1.85	;	High-resolution Structure of Triosephosphate isomerase from E. coli
4WWF	;	1.1	;	High-resolution structure of two Ni-bound forms of the M123C mutant of C. metallidurans CnrXs
4NPF	;	1.49	;	High-resolution structure of two tandem B domains of staphylococcal protein A connected by the conserved linker
4TPN	;	1.18	;	High-resolution structure of TxtE in the absence of substrate
4TPO	;	1.225	;	High-resolution structure of TxtE with bound tryptophan substrate
8BF1	;	1.36	;	High-resolution structure of unliganded PPAR gamma in complex with the peptide PGC-1 alpha
7EOW	;	1.6	;	High-resolution structure of vWF A1 domain in complex with caplacizumab, the first nanobody-based medicine
6NNR	;	1.05	;	high-resolution structure of wild-type E. coli thymidylate synthase
4W7W	;	1.05	;	High-resolution structure of XacCel5A in complex with cellopentaose
1ZUY	;	1.39	;	High-resolution structure of yeast Myo5 SH3 domain
1AKY	;	1.63	;	HIGH-RESOLUTION STRUCTURES OF ADENYLATE KINASE FROM YEAST LIGATED WITH INHIBITOR AP5A, SHOWING THE PATHWAY OF PHOSPHORYL TRANSFER
2AKY	;	1.96	;	HIGH-RESOLUTION STRUCTURES OF ADENYLATE KINASE FROM YEAST LIGATED WITH INHIBITOR AP5A, SHOWING THE PATHWAY OF PHOSPHORYL TRANSFER
1SCR	;	2.0	;	HIGH-RESOLUTION STRUCTURES OF SINGLE-METAL-SUBSTITUTED CONCANAVALIN A: THE CO,CA-PROTEIN AT 1.6 ANGSTROMS AND THE NI,CA-PROTEIN AT 2.0 ANGSTROMS
1SCS	;	1.6	;	HIGH-RESOLUTION STRUCTURES OF SINGLE-METAL-SUBSTITUTED CONCANAVALIN A: THE CO,CA-PROTEIN AT 1.6 ANGSTROMS AND THE NI,CA-PROTEIN AT 2.0 ANGSTROMS
1XNB	;	1.49	;	HIGH-RESOLUTION STRUCTURES OF XYLANASES FROM B. CIRCULANS AND T. HARZIANUM IDENTIFY A NEW FOLDING PATTERN AND IMPLICATIONS FOR THE ATOMIC BASIS OF THE CATALYSIS
1XND	;	2.0	;	HIGH-RESOLUTION STRUCTURES OF XYLANASES FROM B. CIRCULANS AND T. HARZIANUM IDENTIFY A NEW FOLDING PATTERN AND IMPLICATIONS FOR THE ATOMIC BASIS OF THE CATALYSIS
2GLK	;	0.94	;	High-resolution study of D-Xylose isomerase, 0.94A resolution.
3ZNF	;		;	HIGH-RESOLUTION THREE-DIMENSIONAL STRUCTURE OF A SINGLE ZINC FINGER FROM A HUMAN ENHANCER BINDING PROTEIN IN SOLUTION
4ZNF	;		;	HIGH-RESOLUTION THREE-DIMENSIONAL STRUCTURE OF A SINGLE ZINC FINGER FROM A HUMAN ENHANCER BINDING PROTEIN IN SOLUTION
1HRC	;	1.9	;	HIGH-RESOLUTION THREE-DIMENSIONAL STRUCTURE OF HORSE HEART CYTOCHROME C
6K9I	;	1.8	;	High-resolution three-dimensional structure of horse heart cytochrome C at room temperature
6I1B	;		;	HIGH-RESOLUTION THREE-DIMENSIONAL STRUCTURE OF INTERLEUKIN-1 BETA IN SOLUTION BY THREE-AND FOUR-DIMENSIONAL NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
7I1B	;		;	HIGH-RESOLUTION THREE-DIMENSIONAL STRUCTURE OF INTERLEUKIN-1 BETA IN SOLUTION BY THREE-AND FOUR-DIMENSIONAL NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
3TRX	;		;	HIGH-RESOLUTION THREE-DIMENSIONAL STRUCTURE OF REDUCED RECOMBINANT HUMAN THIOREDOXIN IN SOLUTION
4TRX	;		;	HIGH-RESOLUTION THREE-DIMENSIONAL STRUCTURE OF REDUCED RECOMBINANT HUMAN THIOREDOXIN IN SOLUTION
2AAS	;		;	HIGH-RESOLUTION THREE-DIMENSIONAL STRUCTURE OF RIBONUCLEASE A IN SOLUTION BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
4ER4	;	2.1	;	HIGH-RESOLUTION X-RAY ANALYSES OF RENIN INHIBITOR-ASPARTIC PROTEINASE COMPLEXES
7XHK	;	2.3	;	High-resolution X-ray cocrystal structure of USP7 in complex with LX04-46
7XHH	;	2.1	;	High-resolution X-ray cocrystal structure of USP7 in complex with X4
3WDN	;	0.86	;	High-resolution X-ray crystal structure of bovine H-protein using a high-pressure cryocooling method
5ER2	;	1.8	;	High-resolution X-ray diffraction study of the complex between endothiapepsin and an oligopeptide inhibitor. the analysis of the inhibitor binding and description of the rigid body shift in the enzyme
5XPF	;	1.04	;	High-resolution X-ray structure of the T26H mutant of T4 lysozyme
4F6A	;	2.009	;	High-resolution x-ray Structure of the tetramutant of BH1408 protein from Bacillus halodurans, Northeast Structural Genomics Consortium (NESG) Target BhR182
1TFD	;	2.3	;	HIGH-RESOLUTION X-RAY STUDIES ON RABBIT SERUM TRANSFERRIN: PRELIMINARY STRUCTURE ANALYSIS OF THE N-TERMINAL HALF-MOLECULE AT 2.3 ANGSTROMS RESOLUTION
1DXT	;	1.7	;	HIGH-RESOLUTION X-RAY STUDY OF DEOXY RECOMBINANT HUMAN HEMOGLOBINS SYNTHESIZED FROM BETA-GLOBINS HAVING MUTATED AMINO TERMINI
1DXU	;	1.7	;	HIGH-RESOLUTION X-RAY STUDY OF DEOXY RECOMBINANT HUMAN HEMOGLOBINS SYNTHESIZED FROM BETA-GLOBINS HAVING MUTATED AMINO TERMINI
1DXV	;	1.7	;	HIGH-RESOLUTION X-RAY STUDY OF DEOXY RECOMBINANT HUMAN HEMOGLOBINS SYNTHESIZED FROM BETA-GLOBINS HAVING MUTATED AMINO TERMINI
1HBA	;	2.1	;	HIGH-RESOLUTION X-RAY STUDY OF DEOXYHEMOGLOBIN ROTHSCHILD 37BETA TRP-> ARG: A MUTATION THAT CREATES AN INTERSUBUNIT CHLORIDE-BINDING SITE
1HBB	;	1.9	;	HIGH-RESOLUTION X-RAY STUDY OF DEOXYHEMOGLOBIN ROTHSCHILD 37BETA TRP-> ARG: A MUTATION THAT CREATES AN INTERSUBUNIT CHLORIDE-BINDING SITE
4CH8	;	1.75	;	High-salt crystal structure of a thrombin-GpIbalpha peptide complex
5OMY	;	1.95	;	HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
6HBN	;	1.59	;	HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA/CSKN2A1 GENE PRODUCT) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR THN27
4UB7	;	2.1	;	High-salt structure of protein kinase CK2 catalytic subunit with 4'-carboxy-6,8-bromo-flavonol (FLC26) showing an extreme distortion of the ATP-binding loop combined with a pi-halogen bond
5MS6	;	1.9	;	High-salt structure of RavZ LIR2-fused human LC3B
5MQW	;	2.4	;	High-speed fixed-target serial virus crystallography
7KUW	;	2.43	;	High-throughput design and refinement of stable proteins using sequence-only models
6MH8	;	4.2	;	High-viscosity injector-based Pink Beam Serial Crystallography of Micro-crystals at a Synchrotron Radiation Source
6MH6	;	1.8	;	High-viscosity injector-based Pink Beam Serial Crystallography of Micro-crystals at a Synchrotron Radiation Source.
1TQ3	;	1.89	;	Higher resolution crystal structure of the third PDZ domain of post synaptic PSD-95 protein
6YXP	;	1.6	;	Higher resolution structure of the N-terminal module of the human SWI/SNF-subunit BAF155/SMARCC1
3UR7	;	1.4	;	Higher-density crystal structure of potato endo-1,3-beta-glucanase
7UT1	;	3.8	;	Higher-order assembly of multiple MMTV strand transfer complex intasomes
6FHE	;	1.93	;	Highly active enzymes by automated modular backbone assembly and sequence design
6FHF	;	1.85	;	Highly active enzymes by automated modular backbone assembly and sequence design
7D9X	;	1.74	;	Highly active mutant W525D of Gamma-glutamyltranspeptidase from Pseudomonas nitroreducens
4EFX	;	1.98	;	Highly biologically active insulin with additional disulfide bond
6STH	;	1.726	;	Highly cationic RSL-R8 in complex with sulfonato-calix[8]arene
5WXE	;		;	Highly disulfide-constrained antifeedant jasmintides from Jasminum sambac flowers
1IJ9	;	3.0	;	Highly Hydrated Human VCAM-1 Fragment
6XWY	;	1.75	;	Highly pH-resistant long stokes-shift, red fluorescent protein mCRISPRed
4PP7	;	3.4	;	Highly Potent and Selective 3-N-methylquinazoline-4(3H)-one Based Inhibitors of B-RafV600E Kinase
6D3X	;	1.8	;	Highly Potent and Selective Plasmin Inhibitors Based on the Sunflower Trypsin Inhibitor-1 Scaffold Attenuate Fibrinolysis in Plasma
6D3Y	;	1.32	;	Highly Potent and Selective Plasmin Inhibitors Based on the Sunflower Trypsin Inhibitor-1 Scaffold Attenuate Fibrinolysis in Plasma
6D40	;	1.43	;	Highly Potent and Selective Plasmin Inhibitors Based on the Sunflower Trypsin Inhibitor-1 Scaffold Attenuate Fibrinolysis in Plasma
2WD3	;	1.8	;	Highly Potent First Examples of Dual Aromatase-Steroid Sulfatase Inhibitors based on a Biphenyl Template
7PHS	;	2.77	;	highly potent IL6 antagonistic antibody selected from a camelid immune phage display repertoire
3SN7	;	1.82	;	Highly Potent, Selective, and Orally Active Phosphodiestarase 10A Inhibitors
3SNI	;	1.9	;	Highly Potent, Selective, and Orally Active Phosphodiestarase 10A Inhibitors
3SNL	;	2.4	;	Highly Potent, Selective, and Orally Active Phosphodiestarase 10A Inhibitors
3OY1	;	1.7	;	Highly Selective c-Jun N-Terminal Kinase (JNK) 2 and 3 Inhibitors with In Vitro CNS-like Pharmacokinetic Properties
5WWK	;	3.199	;	Highly stable green fluorescent protein
6SU8	;	2.48	;	Highly thermostable endoglucanase Cel7B
6HLK	;	2.42	;	Hijacking the Hijackers: Escherichia coli Pathogenicity Islands Redirect Helper Phage Packaging for Their Own Benefit.
6HN7	;	3.0	;	Hijacking the Hijackers: Escherichia coli Pathogenicity Islands Redirect Helper Phage Packaging for Their Own Benefit.
7OX5	;	3.09	;	hIL-9:hIL-9Ra complex
4KPZ	;	2.09	;	Hin GlmU bound to a small molecule fragment
4KNX	;	1.9	;	Hin GlmU Bound to WG176
4KNR	;	2.1	;	Hin GlmU bound to WG188
4KQL	;	2.31	;	Hin GlmU bound to WG578
4KPX	;	2.21	;	Hin GlmU bound to WG766
1HCR	;	2.3	;	HIN RECOMBINASE BOUND TO DNA: THE ORIGIN OF SPECIFICITY IN MAJOR AND MINOR GROOVE INTERACTIONS
1TW8	;	2.8	;	HincII bound to Ca2+ and cognate DNA GTCGAC
1XHV	;	2.5	;	HincII bound to cleaved cognate DNA GTCGAC and Mn2+
1XHU	;	2.95	;	HincII bound to cleaved, cognate DNA containing GTCGAC
1KC6	;	2.6	;	HincII Bound to Cognate DNA
1TX3	;	2.5	;	HINCII BOUND TO COGNATE DNA
2GIE	;	2.6	;	HincII bound to cognate DNA GTTAAC
1GUB	;	3.1	;	Hinge-bending motion of D-allose binding protein from Escherichia coli: three open conformations
1GUD	;	1.71	;	Hinge-bending motion of D-allose binding protein from Escherichia coli: three open conformations
3NX0	;	2.04	;	Hinge-loop mutation can be used to control 3D domain swapping and amyloidogenesis of human cystatin C
4MCD	;	1.55	;	hinTrmD in complex with 5-PHENYLTHIENO[2,3-D]PYRIMIDIN-4(3H)-ONE
4MCC	;	1.95	;	HinTrmD in complex with N-[4-(AMINOMETHYL)BENZYL]-4-OXO-3,4-DIHYDROTHIENO[2,3-D]PYRIMIDINE-5-CARBOXAMIDE
1R0D	;	1.9	;	HIP1R THATCH DOMAIN CORE
4Z5H	;	2.1	;	HipB(S29A)-O2 20mer complex
4YG4	;	3.5	;	HipB-O1-O1* complex
4YG1	;	3.25	;	HipB-O1-O2 complex/P21212 crystal form
4Z58	;	2.5	;	HipB-O3 20mer complex
4Z5C	;	2.5	;	HipB-O3 21mer complex
4Z59	;	2.3	;	HipB-O4 20mer complex
4Z5D	;	2.15	;	HipB-O4 21mer complex
6P5S	;	2.194	;	HIPK2 kinase domain bound to CX-4945
8A9M	;	2.2	;	Hippeastrum hybrid agglutinin, HHA, complex with beta-mannose
5GDS	;	2.1	;	HIRUNORMS ARE TRUE HIRUDIN MIMETICS. THE CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN:HIRUNORM V COMPLEX
1BX7	;	1.2	;	HIRUSTASIN FROM HIRUDO MEDICINALIS AT 1.2 ANGSTROMS
1BX8	;	1.4	;	HIRUSTASIN FROM HIRUDO MEDICINALIS AT 1.4 ANGSTROMS
4GWJ	;	1.6	;	His 62 mutant of the lectin binding domain of Lectinolysin complexed with Lewis b
4GWI	;	1.6	;	His 62 mutant of the lectin binding domain of lectinolysin complexed with Lewis y
4RNT	;	2.2	;	HIS 92 ALA MUTATION IN RIBONUCLEASE T1 INDUCES SEGMENTAL FLEXIBILITY. AN X-RAY STUDY
7CPC	;	2.801	;	His-Mediated Reversible Self-assembly of Ferritin Nanocage with Ni binding
7CPI	;	2.602	;	His-Mediated Reversible Self-assembly of Ferritin Nanocage with Zn binding
6IPY	;	1.343	;	His-tagged Fyn SH3 domain R96I mutant
5XDH	;	1.32	;	His/DOPA ligated cytochrome c from an anammox organism KSU-1
1CM3	;	1.6	;	HIS15ASP HPR FROM E. COLI
2BWS	;	1.75	;	His243Ala Escherichia coli Aminopeptidase P
2V3X	;	1.7	;	His243Ala Escherichia coli aminopeptidase P in complex with substrate
3MJM	;	1.87	;	His257Ala mutant of dihydroorotase from E. coli
2BWW	;	2.61	;	His350Ala Escherichia coli Aminopeptidase P
2BWX	;	1.7	;	His354Ala Escherichia coli Aminopeptidase P
2BWV	;	1.7	;	His361Ala Escherichia coli Aminopeptidase P
2V3Y	;	1.6	;	His361Ala Escherichia coli aminopeptidase P in complex with product
1G8Z	;	2.0	;	HIS57ALA MUTANT OF CHOLERA TOXIN B-PENATMER
4K36	;	1.619	;	His6 tagged anSMEcpe with bound AdoMet
1MGN	;	1.9	;	HIS64(E7)-> TYR APOMYOGLOBIN AS A REAGENT FOR MEASURING RATES OF HEMIN DISSOCIATION
1RN4	;	1.8	;	HIS92ALA MUTATION IN RIBONUCLEASE T1 INDUCES SEGMENTAL FLEXIBILITY. AN X-RAY STUDY
7QC3	;	1.65	;	HisF from T. maritima
1H5Y	;	2.0	;	HisF protein from Pyrobaculum aerophilum
7QC7	;	1.6	;	HisF-C9A-D11E-V33A_L50H_I52H mutant (apo) from T. maritima
7QC9	;	1.8	;	HisF-C9A-D11E-V33A_L50H_I52H mutant in complex with Ni(II) from T. maritima
7QC8	;	1.8	;	HisF-C9A-D11E-V33A_L50H_I52H mutant in complex with Zn(II) from T. maritima
7QC6	;	2.1	;	HisF_C9A_L50H_I52H mutant (apo) from T. maritima
1QFT	;	1.25	;	HISTAMINE BINDING PROTEIN FROM FEMALE BROWN EAR RHIPICEPHALUS APPENDICULATUS
1QFV	;	1.36	;	HISTAMINE BINDING PROTEIN FROM FEMALE BROWN EAR RHIPICEPHALUS APPENDICULATUS
3K30	;	2.7	;	Histamine dehydrogenase from Nocardiodes simplex
2AOW	;	2.97	;	Histamine Methyltransferase (Natural Variant I105) Complexed with the Acetylcholinesterase Inhibitor and Altzheimer's Disease Drug Tacrine
2AOX	;	3.12	;	Histamine Methyltransferase (Primary Variant T105) Complexed with the Acetylcholinesterase Inhibitor and Altzheimer's Disease Drug Tacrine
2AOV	;	2.48	;	Histamine Methyltransferase Complexed with the Antifolate Drug Metoprine
2AOT	;	1.9	;	Histamine Methyltransferase Complexed with the Antihistamine Drug Diphenhydramine
2AOU	;	2.3	;	Histamine Methyltransferase Complexed with the Antimalarial Drug Amodiaquine
8JXT	;	3.07	;	Histamine-bound H4R/Gi complex
3QIM	;	2.1	;	Histidine 416 of the periplamsic binding protein NikA is essential for nickel uptake in Escherichia coli
5CCP	;	2.2	;	HISTIDINE 52 IS A CRITICAL RESIDUE FOR RAPID FORMATION OF CYTOCHROME C PEROXIDASE COMPOUND I
1B8F	;	2.1	;	Histidine ammonia-lyase (HAL) from Pseudomonas putida
1GKM	;	1.0	;	HISTIDINE AMMONIA-LYASE (HAL) FROM PSEUDOMONAS PUTIDA INHIBITED WITH L-CYSTEINE
1GK3	;	2.25	;	Histidine Ammonia-Lyase (HAL) Mutant D145A from Pseudomonas putida
1EB4	;	2.0	;	Histidine Ammonia-Lyase (HAL) Mutant F329A from Pseudomonas putida
1GK2	;	1.9	;	Histidine Ammonia-Lyase (HAL) Mutant F329G from Pseudomonas putida
1GKJ	;	1.7	;	Histidine Ammonia-Lyase (HAL) Mutant Y280F from Pseudomonas putida
4R39	;	2.603	;	Histidine kinase domain from Erythrobacter litoralis EL346 blue-light activated histidine kinase
5EPV	;	2.51	;	Histidine kinase domain from the LOV-HK blue-light receptor from Brucella abortus
8JWD	;	1.33	;	Histidine kinase QseE sensor domain of Escherichia coli O157:H7
5C93	;	2.518	;	Histidine kinase with ATP
5ZL6	;	2.1	;	Histidine Racemase from Leuconostoc mesenteroides subsp. sake NBRC 102480
5RHN	;	2.31	;	HISTIDINE TRIAD NUCLEOTIDE-BINDING PROTEIN (HINT) FROM RABBIT COMPLEXED WITH 8-BR-AMP
4RHN	;	1.9	;	HISTIDINE TRIAD NUCLEOTIDE-BINDING PROTEIN (HINT) FROM RABBIT COMPLEXED WITH ADENOSINE
3RHN	;	2.1	;	HISTIDINE TRIAD NUCLEOTIDE-BINDING PROTEIN (HINT) FROM RABBIT COMPLEXED WITH GMP
6RHN	;	2.15	;	HISTIDINE TRIAD NUCLEOTIDE-BINDING PROTEIN (HINT) FROM RABBIT WITHOUT NUCLEOTIDE
7MQW	;	1.55	;	Histidine triad protein
4XWJ	;	2.095	;	Histidine-containing phosphocarrier protein (HPr) and antisigma factor Rsd complex
2HPR	;	2.0	;	HISTIDINE-CONTAINING PHOSPHOCARRIER PROTEIN HPR MUTANT WITH MET 51 REPLACED BY VAL AND SER 83 REPLACED BY CYS (M51V, S83C)
1A0B	;	2.06	;	HISTIDINE-CONTAINING PHOSPHOTRANSFER DOMAIN OF ARCB FROM ESCHERICHIA COLI
2A0B	;	1.57	;	HISTIDINE-CONTAINING PHOSPHOTRANSFER DOMAIN OF ARCB FROM ESCHERICHIA COLI
1OPD	;	1.5	;	HISTIDINE-CONTAINING PROTEIN (HPR), MUTANT WITH SER 46 REPLACED BY ASP (S46D)
2YZ5	;	2.1	;	Histidinol Phosphate Phosphatase complexed with Phosphate
2YXO	;	1.6	;	Histidinol Phosphate Phosphatase complexed with Sulfate
5ZON	;	1.94	;	Histidinol phosphate phosphatase from Mycobacterium tuberculosis
2Z4G	;	1.8	;	Histidinol Phosphate Phosphatase from Thermus thermophilus HB8
5T3J	;	2.55	;	Histidinol Phosphate Phosphatase(HPP) soaked with selenourea for 10 min
1H1C	;	2.85	;	Histidinol-phosphate aminotransferase (HisC) from Thermotoga maritima
1UU0	;	2.85	;	Histidinol-phosphate aminotransferase (HisC) from Thermotoga maritima (Apo-form)
1UU2	;	2.8	;	Histidinol-phosphate aminotransferase (HisC) from Thermotoga maritima (apo-form)
3CQ4	;	2.2	;	Histidinol-phosphate aminotransferase from Corynebacterium glutamicum
3CQ6	;	2.1	;	Histidinol-phosphate aminotransferase from Corynebacterium glutamicum holo-form (PLP covalently bound )
3CQ5	;	1.8	;	Histidinol-phosphate aminotransferase from Corynebacterium glutamicum in complex with PMP
1HTT	;	2.6	;	HISTIDYL-TRNA SYNTHETASE
3HRI	;	2.85	;	Histidyl-tRNA synthetase (apo) from Trypanosoma brucei
1KMN	;	2.8	;	HISTIDYL-TRNA SYNTHETASE COMPLEXED WITH HISTIDINOL AND ATP
1KMM	;	2.6	;	HISTIDYL-TRNA SYNTHETASE COMPLEXED WITH HISTIDYL-ADENYLATE
1H4V	;	2.4	;	HISTIDYL-TRNA SYNTHETASE from Thermus Thermophilus (ligand free)
3LC0	;	1.8	;	Histidyl-tRNA synthetase from Trypanosoma cruzi (Histidine complex)
3HRK	;	3.05	;	Histidyl-tRNA synthetase from Trypanosoma cruzi (Histidyl-adenylate complex)
1ADJ	;	2.7	;	HISTIDYL-TRNA SYNTHETASE IN COMPLEX WITH HISTIDINE
1ADY	;	2.8	;	HISTIDYL-TRNA SYNTHETASE IN COMPLEX WITH HISTIDYL-ADENYLATE
1FNE	;	1.9	;	HISTOCOMPATIBILITY ANTIGEN
1FNG	;	1.9	;	HISTOCOMPATIBILITY ANTIGEN
1IEA	;	2.3	;	HISTOCOMPATIBILITY ANTIGEN
1IEB	;	2.7	;	HISTOCOMPATIBILITY ANTIGEN
1HDM	;	2.5	;	HISTOCOMPATIBILITY ANTIGEN HLA-DM
1F3J	;	3.1	;	HISTOCOMPATIBILITY ANTIGEN I-AG7
1IAK	;	1.9	;	HISTOCOMPATIBILITY ANTIGEN I-AK
1BOB	;	2.3	;	HISTONE ACETYLTRANSFERASE HAT1 FROM SACCHAROMYCES CEREVISIAE IN COMPLEX WITH ACETYL COENZYME A
1QSO	;	2.9	;	Histone Acetyltransferase HPA2 from Saccharomyces Cerevisiae
1QSM	;	2.4	;	Histone Acetyltransferase HPA2 from Saccharomyces Cerevisiae in Complex with Acetyl Coenzyme A
8GQ4	;	1.77	;	Histone acetyltransferase Rtt109 mutant-N195A
1BFM	;		;	HISTONE B FROM METHANOTHERMUS FERVIDUS
5BT1	;	2.62	;	histone chaperone Hif1 playing with histone H2A-H2B dimer
6WHN	;	1.54	;	Histone deacetylases complex with peptide macrocycles
6WHO	;	2.2	;	Histone deacetylases complex with peptide macrocycles
6WHQ	;	2.35	;	Histone deacetylases complex with peptide macrocycles
6WHZ	;	2.9	;	Histone deacetylases complex with peptide macrocycles
6WI3	;	2.35	;	Histone deacetylases complex with peptide macrocycles
4QWN	;	2.1	;	Histone demethylase KDM2A-H3K36ME1-alpha-KG complex structure
4CZZ	;	3.0	;	Histone demethylase LSD1(KDM1A)-CoREST3 Complex
6R0N	;	2.1	;	Histone fold domain of AtNF-YB2/NF-YC3 in I2
6R0M	;	2.3	;	Histone fold domain of AtNF-YB2/NF-YC3 in P212121
6R0L	;	2.7	;	Histone fold domain of OsGhd8/NF-YC7 in I2
2BYK	;	2.4	;	Histone fold heterodimer of the Chromatin Accessibility Complex
2BYM	;	2.8	;	Histone fold heterodimer of the Chromatin Accessibility Complex
8FVX	;	1.8	;	Histone from Bdellovibrio bacteriovorus
8FW7	;	2.0	;	Histone from Bdellovibrio bacteriovorus bound to dsDNA
4IGP	;	3.003	;	Histone H3 Lysine 4 Demethylating Rice JMJ703 apo enzyme
4IGQ	;	2.35	;	Histone H3 Lysine 4 Demethylating Rice JMJ703 in complex with methylated H3K4 substrate
4IGO	;	2.4	;	Histone H3 Lysine 4 Demethylating rice Rice JMJ703 in complex with alpha-KG
2H68	;	1.79	;	Histone H3 recognition and presentation by the WDR5 module of the MLL1 complex
2H6K	;	1.89	;	Histone H3 recognition and presentation by the WDR5 module of the MLL1 complex
2H6N	;	1.5	;	Histone H3 recognition and presentation by the WDR5 module of the MLL1 complex
2H6Q	;	1.87	;	Histone H3 recognition and presentation by the WDR5 module of the MLL1 complex
7AT8	;	4.4	;	Histone H3 recognition by nucleosome-bound PRC2 subunit EZH2.
7DYG	;	2.0	;	Histone lysine demethylase 4D (KDM4D) in complex with the inhibitor 2-(1H-pyrazol-3-yl)isonicotinic acid
3U4S	;	2.15	;	Histone Lysine demethylase JMJD2A in complex with T11C peptide substrate crosslinked to N-oxalyl-D-cysteine
6ACL	;	1.92	;	histone lysine desuccinylase Sirt5 in complex with succinyl peptide H2AK95
6ACO	;	1.71	;	histone lysine desuccinylase Sirt5 in complex with succinyl peptide H2BK120
6ACE	;	1.98	;	histone lysine desuccinylase Sirt5 in complex with succinyl peptide H3K122
6ACP	;	2.3	;	histone lysine desuccinylase Sirt5 in complex with succinyl peptide H4K91
7YRD	;	3.2	;	histone methyltransferase
7YRG	;	4.2	;	histone methyltransferase
2HIO	;	3.1	;	HISTONE OCTAMER (CHICKEN), CHROMOSOMAL PROTEIN
1HIO	;	3.1	;	HISTONE OCTAMER (CHICKEN), CHROMOSOMAL PROTEIN, ALPHA CARBONS ONLY
1HUE	;		;	HISTONE-LIKE PROTEIN
7LMT	;	2.27	;	Histone-lysine N-methyltransferase NSD2-PWWP1 with compound MRT10241866a
7MDN	;	2.42	;	Histone-lysine N-methyltransferase NSD2-PWWP1 with compound MRT10241866a
6XCG	;	1.64	;	Histone-lysine N-methyltransferase NSD2-PWWP1 with compound UNC6934
7R79	;	1.6	;	Histoplasma capsulatum H88 Calcium Binding Protein 1 (Cbp1)
5UVM	;	2.3	;	HIT family hydrolase from Clostridium thermocellum Cth-393
4ZGL	;	2.95	;	Hit Like Protein
1A8O	;	1.7	;	HIV CAPSID C-TERMINAL DOMAIN
4IPY	;	1.64	;	HIV capsid C-terminal domain
1AUM	;	3.0	;	HIV CAPSID C-TERMINAL DOMAIN (CAC146)
2M8L	;		;	HIV capsid dimer structure
6R6Q	;	2.73	;	HIV capsid hexamer with IP5 ligand
6R8C	;	1.92	;	HIV capsid hexamer with IP5 ligand
6ES8	;	1.9	;	HIV capsid hexamer with IP6 ligand
6H09	;	2.0	;	HIV capsid hexamer with IP6 ligand
6P65	;	3.94	;	HIV Env 16055 NFL TD 2CC+ in complex with antibody 1C2 fragment antigen binding
6P62	;	3.57	;	HIV Env BG505 NFL TD+ in complex with antibody E70 fragment antigen binding
6DID	;	4.71	;	HIV Env BG505 SOSIP with polyclonal Fabs from immunized rabbit #3417 post-boost#1
3VTP	;	1.9	;	HIV fusion inhibitor MT-C34
1MEQ	;		;	HIV gp120 C5
5T3S	;	4.5	;	HIV gp140 trimer MD39-10MUTA in complex with Fabs PGT124 and 35022
1AIK	;	2.0	;	HIV GP41 CORE STRUCTURE
3G7A	;	2.8	;	HIV gp41 six-helix bundle composed of a chimeric alpha+alpha/beta-peptide analogue of the CHR domain in complex with an NHR domain alpha-peptide
3F50	;	2.8	;	HIV gp41 six-helix bundle composed of an alpha/beta-peptide analogue of the CHR domain in complex with an NHR domain alpha-peptide
3F4Y	;	2.0	;	HIV gp41 six-helix bundle containing a mutant CHR alpha-peptide sequence
6ERM	;	2.0	;	HIV Hexamer with ligand
6ERN	;	2.36	;	HIV Hexamer with ligand
3LPT	;	2.0	;	HIV integrase
3LPU	;	1.95	;	HIV integrase
5OYM	;	2.05	;	HIV Integrase Binding Domain of Lens Epithelium-Derived Growth Factor
5HRS	;	1.86	;	HIV Integrase Catalytic Domain containing F185K + A124N + T125A mutations complexed with GSK0002
5HRR	;	1.88	;	HIV Integrase Catalytic Domain containing F185K + A124N + T125S mutations complexed with GSK0002
5HRP	;	1.81	;	HIV Integrase Catalytic Domain containing F185K + A124T mutations complexed with GSK0002
5HRN	;	1.75	;	HIV Integrase Catalytic Domain containing F185K mutation complexed with GSK0002
6VKA	;	1.863	;	HIV Integrase Core domain (IN) in complex with dimer-spanning ligand
6VLH	;	2.036	;	HIV Integrase Core domain (IN) in complex with dimer-spanning ligand
7L1P	;	1.85	;	HIV Integrase Core domain (IN) in complex with dimer-spanning ligand
6VQS	;	2.38	;	HIV Integrase Core domain (IN) in complex with [5-(3-fluorophenyl)-1-benzofuran-3-yl]acetic acid
1HYZ	;	2.3	;	HIV INTEGRASE CORE DOMAIN COMPLEXED WITH A DERIVATIVE OF TETRAPHENYL ARSONIUM.
1HYV	;	1.7	;	HIV INTEGRASE CORE DOMAIN COMPLEXED WITH TETRAPHENYL ARSONIUM
7RQ0	;	1.95	;	HIV Integrase CORE domain in complex with 2-{2-[2-(3-{[4-(2-{[(3-{2-[3-(carboxymethyl)-5-methyl-1-benzofuran-2-yl]ethynyl}phenyl)methyl]amino}ethyl)piperazin-1-yl]methyl}phenyl)ethynyl]-5-methyl-1-benzofuran-3-yl}acetic acid
6VX2	;	2.4	;	HIV Integrase core domain in complex with inhibitor (5-methyl-1-benzofuran-3-yl)acetic acid
6W0U	;	2.19	;	HIV Integrase core domain in complex with inhibitor 2-(2-ethynyl-5-methyl-1-benzofuran-3-yl)acetic acid
6WC8	;	1.88	;	HIV Integrase core domain in complex with inhibitor 2-(5-(3-fluorophenyl)-2-(2-(thiophen-2-yl)ethynyl)-1- benzofuran-3-yl)ethanoic acid
7L23	;	2.26	;	HIV Integrase core domain in complex with inhibitor 2-(5-(3-fluorophenyl)-2-(2-(thiophen-2-yl)ethynyl)-1- benzofuran-3-yl)ethanoic acid
7L2Y	;	1.982	;	HIV Integrase core domain in complex with inhibitor 2-(5-(3-fluorophenyl)-2-(2-(thiophen-2-yl)ethynyl)-1- benzofuran-3-yl)ethanoic acid
6W42	;	2.26	;	HIV Integrase core domain in complex with inhibitor 2-(5-methyl-2-(2-(thiophen-2-yl)ethynyl)-1-benzofuran-3-yl)acetic acid
7SIA	;	1.85	;	HIV Integrase core domain in complex with inhibitor 2-[2-(2-{3-[(4-{2-[(3-{2-[3-(carboxymethyl)-5-methyl-1-benzofuran-2-yl]ethynyl}phenyl)formamido]ethyl}piperazin-1-yl)methyl]phenyl}ethynyl)-5-methyl-1-benzofuran-3-yl]acetic acid
6WE7	;	2.28	;	HIV Integrase core domain in complex with inhibitor 3-methyl-2-{5-methyl-2-[2-(thiophen-2-yl)ethynyl]-1- benzofuran-3-yl}butanoic acid
6UM8	;	2.33	;	HIV Integrase in complex with Compound-14
7T9H	;	2.53	;	HIV Integrase in complex with Compound-15
7T9O	;	1.95	;	HIV Integrase in complex with Compound-25
4NYF	;	1.9	;	HIV integrase in complex with inhibitor
3RL2	;	2.386	;	HIV Nef derived peptide Nef73 complexed to HLA-A*0301
3CMO	;	2.3	;	HIV neutralizing monoclonal antibody YZ18
3CLE	;	2.5	;	HIV neutralizing monoclonal antibody YZ23
3CLF	;	2.0	;	HIV neutralizing monoclonal antibody YZ23
3GGU	;	1.8	;	HIV PR drug resistant patient's variant in complex with darunavir
3U7S	;	2.05	;	HIV PR drug resistant patient's variant in complex with darunavir
4EJD	;	1.103	;	HIV Protease (PR) dimer in closed form with pepstatin in active site and fragment 1F1 in the outside/top of flap
4EJK	;	1.794	;	HIV Protease (PR) dimer in closed form with pepstatin in active site and fragment 1F1-N in the outside/top of flap
4TVG	;	2.18	;	HIV Protease (PR) dimer in closed form with pepstatin in active site and fragment AK-2097 in the outside/top of flap
4TVH	;	2.195	;	HIV Protease (PR) dimer in closed form with TL-3 in active site and fragment AK-2097 in the outside/top of flap
4E43	;	1.54	;	HIV protease (PR) dimer with acetate in exo site and peptide in active site
3KFR	;	1.3	;	HIV Protease (PR) dimer with inhibitor TL-3 bound and fragment 1F1 in the outside/top of flap
3KFS	;	1.8	;	HIV Protease (PR) dimer with inhibitor TL-3 bound and fragment 2F4 in the outside/top of flap
5VJ3	;	2.0	;	HIV Protease (PR) in open form with Mg2+ in active site and HIVE-9 in eye site
5W5W	;	3.0	;	HIV Protease (PR) in open form with Mg2+ in active site and HIVE-9 in eye site
3KFN	;	1.77	;	HIV Protease (PR) with inhibitor TL-3 and fragment hit 4D9 by soaking
3KFP	;	1.77	;	HIV Protease (PR) with inhibitor TL-3 bound, and DMSOs in exo site
5VEA	;	2.0	;	HIV Protease (PR) with TL-3 in active site and 4-methylbenzene-1,2-diamine in exosite
5VCK	;	1.8	;	HIV Protease (PR) with TL-3 in the active site and (Z)-N-(thiazol-2-yl)-N'-tosylcarbamimidate in the exosite
3M9F	;	1.8	;	HIV protease complexed with compound 10b
4MC9	;	1.19	;	HIV protease in complex with AA74
8ESX	;	1.35	;	HIV protease in complex with benzoxaborolone analog of darunavir
4MC6	;	1.31	;	HIV protease in complex with SA499
4MC2	;	1.56	;	HIV protease in complex with SA525P
4MC1	;	1.39	;	HIV protease in complex with SA526P
3GGA	;	2.5	;	HIV Protease inhibitors with pseudo-symmetric cores
1T3R	;	1.2	;	HIV protease wild-type in complex with TMC114 inhibitor
3KF0	;	1.8	;	HIV Protease with fragment 4D9 bound
1ZP8	;	2.02	;	HIV Protease with inhibitor AB-2
1YT9	;	3.0	;	HIV Protease with oximinoarylsulfonamide bound
1ZPA	;	2.02	;	HIV Protease with Scripps AB-3 Inhibitor
3GGV	;	3.09	;	HIV Protease, pseudo-symmetric inhibitors
3GGX	;	2.7	;	HIV Protease, pseudo-symmetric inhibitors
5VZ6	;	2.6	;	HIV Reverse Transcriptase complexed with (E)-3-(pyrimidin-2-yl)-N-(5-(5,6,7,8-tetrahydronaphthalen-2-yl)-1H-pyrazol-3-yl)acrylamide
2RF2	;	2.4	;	HIV reverse transcriptase in complex with inhibitor 7e (NNRTI)
3DRP	;	2.6	;	HIV reverse transcriptase in complex with inhibitor R8e
3DRS	;	3.15	;	HIV reverse transcriptase K103N mutant in complex with inhibitor R8D
7SLR	;	2.179	;	HIV Reverse Transcriptase with compound Pyr01
7SLS	;	2.078	;	HIV Reverse Transcriptase with compound Pyr02
3DRR	;	2.89	;	HIV reverse transcriptase Y181C mutant in complex with inhibitor R8e
3RL1	;	2.0	;	HIV RT derived peptide complexed to HLA-A*0301
1TCX	;	2.3	;	HIV TRIPLE MUTANT PROTEASE COMPLEXED WITH INHIBITOR SB203386
1BDR	;	2.8	;	HIV-1 (2: 31, 33-37) PROTEASE COMPLEXED WITH INHIBITOR SB203386
1BDL	;	2.8	;	HIV-1 (2:31-37) PROTEASE COMPLEXED WITH INHIBITOR SB203386
1BDQ	;	2.5	;	HIV-1 (2:31-37, 47, 82) PROTEASE COMPLEXED WITH INHIBITOR SB203386
3LEV	;	2.5	;	HIV-1 antibody 2F5 in complex with epitope scaffold ES2
6U59	;	3.86	;	HIV-1 B41 SOSIP.664 in complex with rabbit antibody 13B
6UDJ	;	2.5	;	HIV-1 bNAb 1-18 in complex with BG505 SOSIP.664 and 10-1074
6UDK	;	3.9	;	HIV-1 bNAb 1-55 in complex with modified BG505 SOSIP-based immunogen RC1 and 10-1074
6ECN	;	3.4	;	HIV-1 CA 1/2-hexamer-EE
6BHS	;	1.984	;	HIV-1 CA hexamer in complex with IP6, hexagonal crystal form
6BHT	;	2.689	;	HIV-1 CA hexamer in complex with IP6, orthorhombic crystal form
5TSX	;	1.899	;	HIV-1 CA hexamer with NUP153 peptide - P1 crystal form
5TSV	;	2.502	;	HIV-1 CA hexamer with NUP153 peptide - R3 crystal form
8G6M	;	3.1	;	HIV-1 CA lattice bound to IP6, pH 7.4
8G6K	;	3.6	;	HIV-1 CA lattice bound to IP6; from capsid-like particles
5HGK	;	1.763	;	HIV-1 CA N-terminal domain, open conformation
2BUO	;	1.7	;	HIV-1 capsid C-terminal domain in complex with an inhibitor of particle assembly
3DTJ	;	4.0	;	HIV-1 capsid C-terminal domain mutant (E187A)
3DS1	;	1.6	;	HIV-1 capsid C-terminal domain mutant (E187A) in complex with an inhibitor of particle assembly (CAI)
3DPH	;	2.01	;	HIV-1 capsid C-terminal domain mutant (L211S)
3DS4	;	1.12	;	HIV-1 capsid C-terminal domain mutant (L211S) in complex with an inhibitor of particle assembly (CAI)
3DS5	;	2.4	;	HIV-1 capsid C-terminal domain mutant (N183A)
3DS0	;	1.6	;	HIV-1 capsid C-terminal domain mutant (N183A) in complex with an inhibitor of particle assembly (CAI)
3DS2	;	1.2	;	HIV-1 capsid C-terminal domain mutant (Y169A)
3DS3	;	2.7	;	HIV-1 capsid C-terminal domain mutant (Y169A) in complex with an inhibitor of particle assembly (CAI)
4COC	;	1.59	;	HIV-1 capsid C-terminal domain mutant (Y169L)
4COP	;	1.85	;	HIV-1 capsid C-terminal domain mutant (Y169S)
6OMT	;	2.052	;	HIV-1 capsid hexamer R18D mutant
8G6N	;	3.5	;	HIV-1 capsid lattice bound to dNTPs
8G6O	;	3.1	;	HIV-1 capsid lattice bound to IP6 and Lenacapavir
8G6L	;	3.3	;	HIV-1 capsid lattice bound to IP6, pH 6.2
2M8N	;		;	HIV-1 capsid monomer structure
1AFV	;	3.7	;	HIV-1 CAPSID PROTEIN (P24) COMPLEX WITH FAB25.3
1BAJ	;	2.6	;	HIV-1 CAPSID PROTEIN C-TERMINAL FRAGMENT PLUS GAG P2 DOMAIN
1BMX	;		;	HIV-1 CAPSID PROTEIN MAJOR HOMOLOGY REGION PEPTIDE ANALOG, NMR, 8 STRUCTURES
2N1Q	;		;	HIV-1 Core Packaging Signal
3WFV	;	1.8	;	HIV-1 CRF07 gp41
2FD0	;	1.8	;	HIV-1 DIS kissing-loop in complex with lividomycin
2FCX	;	2.0	;	HIV-1 DIS kissing-loop in complex with neamine
2FCY	;	2.2	;	HIV-1 DIS kissing-loop in complex with Neomycin
2FCZ	;	2.01	;	HIV-1 DIS kissing-loop in complex with ribostamycin
1Y3O	;	2.7	;	HIV-1 DIS RNA subtype F- Mn soaked
1ZCI	;	1.65	;	HIV-1 DIS RNA subtype F- monoclinic form
1Y3S	;	2.25	;	HIV-1 DIS RNA subtype F- MPD form
1YXP	;	2.4	;	HIV-1 DIS RNA subtype F- Zn soaked
1Y6S	;	2.9	;	HIV-1 DIS(Mal) duplex Ba-soaked
1Y6T	;	2.6	;	HIV-1 Dis(Mal) Duplex Co Hexamine-Soaked
1WVD	;	2.93	;	HIV-1 Dis(Mal) Duplex CoCl2-Soaked
1Y90	;	3.08	;	HIV-1 Dis(Mal) Duplex Mn-Soaked
1Y95	;	2.8	;	HIV-1 Dis(Mal) Duplex Pb-Soaked
1Y73	;	2.9	;	HIV-1 Dis(Mal) Duplex Pt-Soaked
1O3Z	;	2.65	;	HIV-1 DIS(MAL) DUPLEX RU HEXAMINE-SOAKED
1NLC	;	1.85	;	HIV-1 DIS(Mal) duplex Zn-soaked
7PC2	;	2.8	;	HIV-1 Env (BG505 SOSIP.664) in complex with the IgA bNAb 7-269 and the antibody 3BNC117.
5WDU	;	7.0	;	HIV-1 Env BG505 SOSIP.664 H72C-H564C trimer in complex with bNAbs PGT122 Fab, 35O22 Fab and NIH45-46 scFv
8GJE	;	3.4	;	HIV-1 Env subtype C CZA97.12 SOSIP.664 in complex with 3BNC117 Fab
8GPJ	;	3.5	;	HIV-1 Env X16 UFO in complex with 8ANC195 Fab
8GPI	;	3.0	;	HIV-1 Env X18 UFO in complex with 8ANC195 Fab
8GPG	;	4.1	;	HIV-1 Env X18 UFO in complex with F6 Fab
7T74	;	3.35	;	HIV-1 Envelope ApexGT2 in complex with PCT64.35S Fab and RM20A3 Fab
7T75	;	2.7	;	HIV-1 Envelope ApexGT2 in complex with RM20A3 Fab
7T73	;	4.0	;	HIV-1 Envelope ApexGT2.2MUT in complex with PCT64.LMCA Fab
7T76	;	4.43	;	HIV-1 Envelope ApexGT3 in complex with PG9.iGL Fab
7T77	;	4.75	;	HIV-1 Envelope ApexGT3.N130 in complex with PG9 Fab
6X9R	;	3.1	;	HIV-1 Envelope Glycoprotein BG505 SOSIP.664 expressed in HEK293F cells in complex with RM20A3 Fab
6X9T	;	3.2	;	HIV-1 Envelope Glycoprotein BG505 SOSIP.664 expressed in HEK293S cells in complex with RM20A3 Fab
6X9S	;	3.1	;	HIV-1 Envelope Glycoprotein BG505 SOSIP.664 expressed in stable CHO cells in complex with RM20A3 Fab
6X9V	;	3.5	;	HIV-1 Envelope Glycoprotein BG505 SOSIP.664, expressed in HEK293S cells and deglycosylated by endoglycosidase H, in complex with RM20A3 Fab
6X9U	;	3.2	;	HIV-1 Envelope Glycoprotein BG505 SOSIP.664, expressed in HEK293S cells and partially deglycosylated by endoglycosidase H, in complex with RM20A3 Fab
6MAR	;	4.5	;	HIV-1 Envelope Glycoprotein Clone BG505 delCT N332T in complex with broadly neutralizing antibody Fab PGT151
7ASH	;	4.2	;	HIV-1 Gag immature lattice. GagdeltaMASP1T8I
7ASL	;	4.5	;	HIV-1 Gag immature lattice. GagSP1T8I
5F4P	;	2.6	;	HIV-1 gp120 complex with BNM-III-170
8FLY	;	2.04	;	HIV-1 gp120 complex with BNM-III-170
5F4U	;	3.1	;	HIV-1 gp120 complex with BNM-IV-197
5F4R	;	2.8	;	HIV-1 gp120 complex with BNW-IV-147
7TJP	;	2.77	;	HIV-1 gp120 complex with CJF-II-195
7TJO	;	3.07	;	HIV-1 gp120 complex with CJF-II-197-S
7RSZ	;	2.79	;	HIV-1 gp120 complex with CJF-II-204
7RSY	;	2.7	;	HIV-1 gp120 complex with CJF-III-049-R
7RSX	;	2.75	;	HIV-1 gp120 complex with CJF-III-049-S
8FLZ	;	2.0	;	HIV-1 gp120 complex with CJF-III-049-S
8FM7	;	2.34	;	HIV-1 gp120 complex with CJF-III-192
8FM0	;	2.08	;	HIV-1 gp120 complex with CJF-III-214
8FM3	;	2.11	;	HIV-1 gp120 complex with CJF-III-288
8FM2	;	2.4	;	HIV-1 gp120 complex with CJF-III-289
8FM8	;	2.47	;	HIV-1 gp120 complex with CJF-IV-046
8FM4	;	2.18	;	HIV-1 gp120 complex with CJF-IV-047
8FM5	;	1.88	;	HIV-1 gp120 complex with DY-III-065
5F4L	;	2.7	;	HIV-1 gp120 complex with JP-III-048
1GC1	;	2.5	;	HIV-1 GP120 CORE COMPLEXED WITH CD4 AND A NEUTRALIZING HUMAN ANTIBODY
2NY1	;	1.99	;	HIV-1 gp120 Envelope Glycoprotein (I109C, T257S, S334A, S375W, Q428C) Complexed with CD4 and Antibody 17b
2NY3	;	2.0	;	HIV-1 gp120 Envelope Glycoprotein (K231C, T257S, E267C, S334A, S375W) Complexed with CD4 and Antibody 17b
2NY4	;	2.0	;	HIV-1 gp120 Envelope Glycoprotein (K231C, T257S, E268C, S334A, S375W) Complexed with CD4 and Antibody 17b
2NY6	;	2.8	;	HIV-1 gp120 Envelope Glycoprotein (M95W, W96C, I109C, T123C, T257S, V275C,S334A, S375W, Q428C, G431C) Complexed with CD4 and Antibody 17b
2NY5	;	2.5	;	HIV-1 gp120 Envelope Glycoprotein (M95W, W96C, I109C, T257S, V275C, S334A, S375W, Q428C, A433M) Complexed with CD4 and Antibody 17b
2NY0	;	2.2	;	HIV-1 gp120 Envelope Glycoprotein (M95W, W96C, T257S, V275C, S334A, S375W, A433M) Complexed with CD4 and Antibody 17b
2NY2	;	2.0	;	HIV-1 gp120 Envelope Glycoprotein (T123C, T257S, S334A, S375W, G431C) Complexed with CD4 and Antibody 17b
2NXZ	;	2.04	;	HIV-1 gp120 Envelope Glycoprotein (T257S, S334A, S375W) Complexed with CD4 and Antibody 17b
2NY7	;	2.3	;	HIV-1 gp120 Envelope Glycoprotein Complexed with the Broadly Neutralizing CD4-Binding-Site Antibody b12
2NXY	;	2.0	;	HIV-1 gp120 Envelope Glycoprotein(S334A) Complexed with CD4 and Antibody 17b
2ME1	;		;	HIV-1 gp41 clade B double alanine mutant Membrane Proximal External Region peptide in DPC micelle
2ME2	;		;	HIV-1 gp41 clade C Membrane Proximal External Region peptide in DPC micelle
2ME3	;		;	HIV-1 gp41 clade C Membrane Proximal External Region peptide in DPC micelle
2ME4	;		;	HIV-1 gp41 clade C Membrane Proximal External Region peptide in DPC micelle
8F3A	;	1.2	;	HIV-1 gp41 coiled-coil pocket IQN17
8F3B	;	2.0	;	HIV-1 gp41 coiled-coil pocket IQN22
1I5X	;	1.8	;	HIV-1 GP41 CORE
1I5Y	;	2.1	;	HIV-1 GP41 CORE
2PV6	;		;	HIV-1 gp41 Membrane Proximal Ectodomain Region peptide in DPC micelle
5KA6	;	1.85	;	HIV-1 gp41 variant Q552R and L555M resistance mutations
5KA5	;	1.8	;	HIV-1 gp41 variant V549E resistance mutation
1G9M	;	2.2	;	HIV-1 HXBC2 GP120 ENVELOPE GLYCOPROTEIN COMPLEXED WITH CD4 AND INDUCED NEUTRALIZING ANTIBODY 17B
1RZJ	;	2.2	;	HIV-1 HXBC2 GP120 ENVELOPE GLYCOPROTEIN COMPLEXED WITH CD4 AND INDUCED NEUTRALIZING ANTIBODY 17B
6BHR	;	2.908	;	HIV-1 immature CTD-SP1 hexamer in complex with IP6
3VQ6	;	1.8	;	HIV-1 IN core domain in complex with (1-methyl-5-phenyl-1H-pyrazol-4-yl)methanol
3VQ8	;	1.6	;	HIV-1 IN core domain in complex with (3R)-3,4-dihydro-2H-chromen-3-ylmethanol
3VQC	;	2.3	;	HIV-1 IN core domain in complex with (5-METHYL-3-PHENYL-1,2-OXAZOL-4-YL)METHANOL
3VQA	;	1.9	;	HIV-1 IN core domain in complex with 1-benzothiophen-6-amine 1,1-dioxide
3VQP	;	2.1	;	HIV-1 IN core domain in complex with 2,3-dihydro-1,4-benzodioxin-5-ylmethanol
3VQ7	;	1.63	;	HIV-1 IN core domain in complex with 4-(1H-pyrrol-1-yl)aniline
3VQD	;	2.0	;	HIV-1 IN core domain in complex with 5-methyl-3-phenyl-1,2-oxazole-4-carboxylic acid
3VQ9	;	1.9	;	HIV-1 IN core domain in complex with 6-fluoro-1,3-benzothiazol-2-amine
3VQB	;	2.1	;	HIV-1 IN core domain in complex with 6-fluoro-4H-1,3-benzodioxine-8-carboxylic acid
3VQ5	;	1.7	;	HIV-1 IN core domain in complex with N-METHYL-1-(4-METHYL-2-PHENYL-1,3-THIAZOL-5-YL)METHANAMINE
3VQE	;	1.7	;	HIV-1 IN core domain in complex with [1-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]methanol
2XYE	;	2.0	;	HIV-1 Inhibitors with a Tertiary-Alcohol-containing Transition-State Mimic and various P2 and P1 prime Substituents
2XYF	;	1.8	;	HIV-1 Inhibitors with a Tertiary-Alcohol-containing Transition-State Mimic and various P2 and P1 prime Substituents
1EX4	;	2.8	;	HIV-1 INTEGRASE CATALYTIC CORE AND C-TERMINAL DOMAIN
8S9Q	;	2.26	;	HIV-1 Integrase Catalytic Core Domain (CCD) F185H Mutant Complexed with STP03-0404
5KRT	;	1.651	;	HIV-1 Integrase Catalytic Core Domain (CCD) in Complex with a Fragment-Derived Allosteric Inhibitor
4GVM	;	2.16	;	HIV-1 Integrase Catalytic Core Domain A128T Mutant Complexed with Allosteric Inhibitor
4JLH	;	2.09	;	HIV-1 Integrase Catalytic Core Domain A128T Mutant Complexed with Allosteric Inhibitor
8CBR	;	1.8	;	HIV-1 Integrase Catalytic Core Domain and C-Terminal Domain in Complex with Allosteric Integrase Inhibitor BDM-2
8A1P	;	1.8	;	HIV-1 Integrase Catalytic Core Domain and C-Terminal Domain in Complex with Allosteric Integrase Inhibitor BI-D
8BUV	;	2.04	;	HIV-1 Integrase Catalytic Core Domain and C-Terminal Domain in Complex with Allosteric Integrase Inhibitor LEDGIN 3
8CBS	;	1.7	;	HIV-1 Integrase Catalytic Core Domain and C-Terminal Domain in Complex with Allosteric Integrase Inhibitor MUT871
8CBT	;	2.14	;	HIV-1 Integrase Catalytic Core Domain and C-Terminal Domain in Complex with Allosteric Integrase Inhibitor MUT872
8CBU	;	2.44	;	HIV-1 Integrase Catalytic Core Domain and C-Terminal Domain in Complex with Allosteric Integrase Inhibitor MUT884
8CBV	;	1.82	;	HIV-1 Integrase Catalytic Core Domain and C-Terminal Domain in Complex with Allosteric Integrase Inhibitor MUT916
8A1Q	;	2.06	;	HIV-1 Integrase Catalytic Core Domain and C-Terminal Domain in Complex with Allosteric Integrase Inhibitor STP0404 (Pirmitegravir)
4GW6	;	2.65	;	HIV-1 Integrase Catalytic Core Domain Complexed with Allosteric Inhibitor
4ID1	;	1.87	;	HIV-1 Integrase Catalytic Core Domain Complexed with Allosteric Inhibitor
6EB1	;	2.2	;	HIV-1 Integrase Catalytic Core Domain Complexed with Allosteric Inhibitor (2S)-tert-butoxy[3-(3,4-dihydro-2H-1-benzopyran-6-yl)-1-phenylisoquinolin-4-yl]acetic acid
4O0J	;	2.05	;	HIV-1 Integrase Catalytic Core Domain Complexed with Allosteric Inhibitor (2S)-tert-butoxy[4-(4-chlorophenyl)-6-(3,4-dimethylphenyl)-2,5-dimethylpyridin-3-yl]ethanoic acid
4O55	;	2.24	;	HIV-1 Integrase Catalytic Core Domain Complexed with Allosteric Inhibitor (2S)-tert-butoxy[6-(5-chloro-1H-benzimidazol-2-yl)-2,5-dimethyl-4-phenylpyridin-3-yl]ethanoic acid
4O5B	;	2.37	;	HIV-1 Integrase Catalytic Core Domain Complexed with Allosteric Inhibitor (2S)-tert-butoxy[6-(5-chloro-1H-benzimidazol-2-yl)-2,5-dimethyl-4-phenylpyridin-3-yl]ethanoic acid
6EB2	;	2.493	;	HIV-1 Integrase Catalytic Core Domain Complexed with Allosteric Inhibitor (2S)-[1-(1-benzyl-1H-pyrazol-4-yl)-3-(3,4-dihydro-2H-1-benzopyran-6-yl)isoquinolin-4-yl](tert-butoxy)acetic acid
6NUJ	;	2.10003	;	HIV-1 Integrase Catalytic Core Domain Complexed with Allosteric Inhibitor BI-224436
7KE0	;	2.19	;	HIV-1 Integrase catalytic core domain complexed with allosteric inhibitor STP03-0404
8D3S	;	1.84	;	HIV-1 Integrase Catalytic Core Domain F185H Mutant Complexed with BKC-110
5KRS	;	1.7	;	HIV-1 Integrase Catalytic Core Domain in Complex with an Allosteric Inhibitor, 3-(1H-pyrrol-1-yl)-2-thiophenecarboxylic acid
7UE1	;	3.0	;	HIV-1 Integrase Catalytic Core Domain Mutant (KGD) in Complex with Inhibitor GRL-142
4TSX	;	1.94	;	HIV-1 Integrase Catalytic Core Domain Mutant Complexed with Allosteric Inhibitor
4DMN	;	2.45	;	HIV-1 Integrase Catalytical Core Domain
1BIS	;	1.95	;	HIV-1 INTEGRASE CORE DOMAIN
1BIZ	;	1.95	;	HIV-1 INTEGRASE CORE DOMAIN
1BIU	;	2.5	;	HIV-1 INTEGRASE CORE DOMAIN COMPLEXED WITH MG++
3VQQ	;	2.0	;	HIV-1 integrase core domain in complex with 2,1,3-benzothiadiazol-4-amine
3MED	;	2.5	;	HIV-1 K103N Reverse Transcriptase in Complex with TMC125
3MEG	;	2.8	;	HIV-1 K103N Reverse Transcriptase in Complex with TMC278
6UK0	;	2.75695	;	HIV-1 M184V reverse transcriptase-DNA complex
6UIR	;	2.639	;	HIV-1 M184V reverse transcriptase-DNA complex with (-)-FTC-TP
6UIS	;	2.74834	;	HIV-1 M184V reverse transcriptase-DNA complex with dCTP
8CKV	;	2.89	;	HIV-1 mature capsid hexamer from CA-IP6 CLPs
8CL1	;	3.35	;	HIV-1 mature capsid hexamer from CA-IP6 CLPs, bound to CPSF6 peptide.
8CKY	;	2.6	;	HIV-1 mature capsid hexamer from CA-IP6 CLPs, bound to Nup153 peptide
8CL3	;	3.14	;	HIV-1 mature capsid hexamer from CA-IP6 CLPs, bound to Sec24C peptide.
8CKX	;	2.97	;	HIV-1 mature capsid hexamer next to pentamer (type I) from CA-IP6 CLPs
8CL0	;	3.12	;	HIV-1 mature capsid hexamer next to pentamer (type I) from CA-IP6 CLPs bound to Nup153 peptide.
8CKW	;	3.12	;	HIV-1 mature capsid pentamer from CA-IP6 CLPs
8CL2	;	3.45	;	HIV-1 mature capsid pentamer from CA-IP6 CLPs bound to CPSF6 peptide
8CKZ	;	3.07	;	HIV-1 mature capsid pentamer from CA-IP6 CLPs bound to Nup153 peptide
8CL4	;	3.14	;	HIV-1 mature capsid pentamer from CA-IP6 CLPs bound to Sec24C peptide
1MES	;	1.9	;	HIV-1 MUTANT (I84V) PROTEASE COMPLEXED WITH DMP323
1MER	;	1.9	;	HIV-1 MUTANT (I84V) PROTEASE COMPLEXED WITH DMP450
1MET	;	1.9	;	HIV-1 MUTANT (V82F) PROTEASE COMPLEXED WITH DMP323
1MEU	;	1.9	;	HIV-1 MUTANT (V82F, I84V) PROTEASE COMPLEXED WITH DMP323
1UPH	;		;	HIV-1 Myristoylated Matrix
2NEF	;		;	HIV-1 NEF (REGULATORY FACTOR), NMR, 40 STRUCTURES
1QA4	;		;	HIV-1 NEF ANCHOR DOMAIN, NMR, 2 STRUCTURES
4EMZ	;	2.9	;	HIV-1 Nef in complex with MHC-I cytoplasmic domain and Mu1 adaptin subunit of AP1 adaptor (second domain)
4EN2	;	2.58	;	HIV-1 Nef in complex with MHC-I cytoplasmic domain and Mu1 adaptin subunit of AP1 adaptor (second domain)
6URI	;	3.0	;	HIV-1 Nef in complex with the CD4 cytoplasmic domain and the AP2 clathrin adaptor complex
3RBB	;	2.35	;	HIV-1 NEF protein in complex with engineered HCK SH3 domain
3REA	;	2.0	;	HIV-1 Nef protein in complex with engineered Hck-SH3 domain
3REB	;	3.45	;	HIV-1 Nef protein in complex with engineered Hck-SH3 domain
1EFN	;	2.5	;	HIV-1 NEF PROTEIN IN COMPLEX WITH R96I MUTANT FYN SH3 DOMAIN
4ORZ	;	2.0	;	HIV-1 Nef protein in complex with single domain antibody sdAb19 and an engineered Hck SH3 domain
1AVV	;	3.0	;	HIV-1 NEF PROTEIN, UNLIGANDED CORE DOMAIN
3Q1S	;	2.15	;	HIV-1 neutralizing antibody Z13e1 in complex with epitope display protein
1NXR	;		;	HIV-1 POLYPURINE HYBRID, R(GAGGACUG):D(CAGTCCTC), NMR, 18 STRUCTURES
2PYM	;	1.9	;	HIV-1 PR mutant in complex with nelfinavir
2PYN	;	1.85	;	HIV-1 PR mutant in complex with nelfinavir
2Q63	;	2.2	;	HIV-1 PR mutant in complex with nelfinavir
2Q64	;	2.5	;	HIV-1 PR mutant in complex with nelfinavir
2QAK	;	2.2	;	HIV-1 PR mutant in complex with nelfinavir
2RKF	;	1.8	;	HIV-1 PR resistant mutant + LPV
2RKG	;	1.8	;	HIV-1 PR resistant mutant + LPV
6BRA	;	1.111	;	HIV-1 protease (D25N, inactive) in complex with phage display optimized substrate SGIFLETS
1BV9	;	2.0	;	HIV-1 PROTEASE (I84V) COMPLEXED WITH XV638 OF DUPONT PHARMACEUTICALS
7MA2	;	1.869	;	HIV-1 Protease (I84V) in Complex with a Darunavir Derivative
7MA1	;	1.848	;	HIV-1 Protease (I84V) in Complex with GRL-98065
7MAB	;	1.879	;	HIV-1 Protease (I84V) in Complex with GS-8374
7M9G	;	1.87	;	HIV-1 Protease (I84V) in Complex with LR2-18
7M9H	;	1.891	;	HIV-1 Protease (I84V) in Complex with LR2-20
7M9I	;	1.817	;	HIV-1 Protease (I84V) in Complex with LR2-26
7MA0	;	1.92	;	HIV-1 Protease (I84V) in Complex with LR2-91
7M9O	;	1.895	;	HIV-1 Protease (I84V) in Complex with LR3-48
7M9P	;	1.819	;	HIV-1 Protease (I84V) in Complex with LR3-55
7M9N	;	1.82	;	HIV-1 Protease (I84V) in Complex with LR3-68
7M9V	;	1.891	;	HIV-1 Protease (I84V) in Complex with NR01-141
7M9W	;	1.901	;	HIV-1 Protease (I84V) in Complex with NR02-73
7M9X	;	1.831	;	HIV-1 Protease (I84V) in Complex with NR02-79
7MAC	;	1.7	;	HIV-1 Protease (I84V) in Complex with PD4 (LR4-23)
7MAD	;	1.7	;	HIV-1 Protease (I84V) in Complex with PD5 (LR4-22)
7MAE	;	1.735	;	HIV-1 Protease (I84V) in Complex with PU1 (LR3-46)
7MAO	;	1.861	;	HIV-1 Protease (I84V) in Complex with PU10 (LR4-07)
7MAF	;	1.902	;	HIV-1 Protease (I84V) in Complex with PU2 (LR2-79)
7MAG	;	1.92	;	HIV-1 Protease (I84V) in Complex with PU3 (LR3-69)
7MAH	;	1.881	;	HIV-1 Protease (I84V) in Complex with PU4 (LR2-78)
7MAI	;	1.79	;	HIV-1 Protease (I84V) in Complex with PU5 (LR4-47)
7MAJ	;	1.871	;	HIV-1 Protease (I84V) in Complex with PU6 (LR3-66)
7MAK	;	1.972	;	HIV-1 Protease (I84V) in Complex with PU7 (LR3-67)
7MAL	;	1.898	;	HIV-1 Protease (I84V) in Complex with PU8 (LR4-06)
7MAN	;	1.892	;	HIV-1 Protease (I84V) in Complex with PU9 (LR2-80)
7M9Z	;	1.828	;	HIV-1 Protease (I84V) in Complex with TMC-126
7MAA	;	1.933	;	HIV-1 Protease (I84V) in Complex with UMass10
7MA3	;	1.969	;	HIV-1 Protease (I84V) in Complex with UMass2
7MA4	;	1.989	;	HIV-1 Protease (I84V) in Complex with UMass3
7MA5	;	1.977	;	HIV-1 Protease (I84V) in Complex with UMass4
7MA6	;	1.995	;	HIV-1 Protease (I84V) in Complex with UMass5
7MA7	;	1.919	;	HIV-1 Protease (I84V) in Complex with UMass7
7MA8	;	1.901	;	HIV-1 Protease (I84V) in Complex with UMass8
7MA9	;	1.9	;	HIV-1 Protease (I84V) in Complex with UMass9
4GB2	;	1.788	;	HIV-1 protease (mutant Q7K L33I L63I) in complex with a bicyclic pyrrolidine inhibitor
3QIH	;	1.39	;	HIV-1 protease (mutant Q7K L33I L63I) in complex with a novel inhibitor
3QN8	;	1.382	;	HIV-1 protease (mutant Q7K L33I L63I) in complex with a novel inhibitor
3QP0	;	1.45	;	HIV-1 protease (mutant Q7K L33I L63I) in complex with a novel inhibitor
3QBF	;	1.45	;	HIV-1 protease (mutant Q7K L33I L63I) in complex with a three-armed pyrrolidine-based inhibitor
3QPJ	;	1.61	;	HIV-1 protease (mutant Q7K L33I L63I) in complex with a three-armed pyrrolidine-based inhibitor
3QRM	;	1.731	;	HIV-1 protease (mutant Q7K L33I L63I) in complex with a three-armed pyrrolidine-based inhibitor
3QRO	;	1.616	;	HIV-1 protease (mutant Q7K L33I L63I) in complex with a three-armed pyrrolidine-based inhibitor
3QRS	;	1.59	;	HIV-1 protease (mutant Q7K L33I L63I) in complex with a three-armed pyrrolidine-based inhibitor
1BWB	;	1.8	;	HIV-1 PROTEASE (V82F/I84V) DOUBLE MUTANT COMPLEXED WITH SD146 OF DUPONT PHARMACEUTICALS
1BWA	;	1.9	;	HIV-1 PROTEASE (V82F/I84V) DOUBLE MUTANT COMPLEXED WITH XV638 OF DUPONT PHARMACEUTICALS
1GNO	;	2.3	;	HIV-1 PROTEASE (WILD TYPE) COMPLEXED WITH U89360E (INHIBITOR)
3TOF	;	1.45	;	HIV-1 Protease - Epoxydic Inhibitor Complex (pH 6 - Orthorombic Crystal form P212121)
3TOG	;	1.24	;	HIV-1 Protease - Epoxydic Inhibitor Complex (pH 9 - Monoclinic Crystal form P21)
3TOH	;	1.116	;	HIV-1 Protease - Epoxydic Inhibitor Complex (pH 9 - Orthorombic Crystal form P212121)
1UPJ	;	2.22	;	HIV-1 PROTEASE COMPLEX WITH U095438 [3-[1-(4-BROMOPHENYL) ISOBUTYL]-4-HYDROXYCOUMARIN
2UPJ	;	3.0	;	HIV-1 PROTEASE COMPLEX WITH U100313 ([3-[[3-[CYCLOPROPYL [4-HYDROXY-2OXO-6-[1-(PHENYLMETHYL)PROPYL]-2H-PYRAN-3-YL] METHYL]PHENYL]AMINO]-3-OXO-PROPYL]CARBAMIC ACID TERT-BUTYL ESTER)
1MTR	;	1.75	;	HIV-1 PROTEASE COMPLEXED WITH A CYCLIC PHE-ILE-VAL PEPTIDOMIMETIC INHIBITOR
1D4K	;	1.85	;	HIV-1 PROTEASE COMPLEXED WITH A MACROCYCLIC PEPTIDOMIMETIC INHIBITOR
1D4L	;	1.75	;	HIV-1 PROTEASE COMPLEXED WITH A MACROCYCLIC PEPTIDOMIMETIC INHIBITOR
1A30	;	2.0	;	HIV-1 PROTEASE COMPLEXED WITH A TRIPEPTIDE INHIBITOR
1ODY	;	2.0	;	HIV-1 PROTEASE COMPLEXED WITH AN INHIBITOR LP-130
4FL8	;	1.2	;	HIV-1 protease complexed with gem-diol-amine tetrahedral intermediate
3B7V	;	1.46	;	HIV-1 protease complexed with gem-diol-amine tetrahedral intermediate NLLTQI
5UFZ	;	1.649	;	HIV-1 Protease complexed with Inhibitor: (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(1S,2S)-1-(1-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}cyclopropyl)-1-hydroxy-3-phenylpropan-2-yl]carbamate
1B6J	;	1.85	;	HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 1
1Z1R	;	1.85	;	HIV-1 protease complexed with Macrocyclic peptidomimetic inhibitor 2
1Z1H	;	1.85	;	HIV-1 protease complexed with macrocyclic peptidomimetic inhibitor 3
1B6L	;	1.75	;	HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 4
1B6K	;	1.85	;	HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 5
1B6M	;	1.85	;	HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 6
1B6P	;	2.0	;	HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 7
1VIJ	;	2.4	;	HIV-1 PROTEASE COMPLEXED WITH THE INHIBITOR HOE/BAY 793 HEXAGONAL FORM
1VIK	;	2.4	;	HIV-1 PROTEASE COMPLEXED WITH THE INHIBITOR HOE/BAY 793 ORTHORHOMBIC FORM
1HPX	;	2.0	;	HIV-1 PROTEASE COMPLEXED WITH THE INHIBITOR KNI-272
7DPQ	;	1.65	;	HIV-1 Protease D30N mutant
7DOZ	;	1.91	;	HIV-1 Protease D30N mutant in complex with Nelfinavir
1HXW	;	1.8	;	HIV-1 PROTEASE DIMER COMPLEXED WITH A-84538
1PRO	;	1.8	;	HIV-1 PROTEASE DIMER COMPLEXED WITH A-98881
2I4X	;	1.55	;	HIV-1 Protease I84V, L90M with GS-8374
2I4V	;	1.5	;	HIV-1 protease I84V, L90M with TMC126
2PWC	;	1.78	;	HIV-1 protease in complex with a amino decorated pyrrolidine-based inhibitor
3BGC	;	1.8	;	HIV-1 protease in complex with a benzyl decorated oligoamine
2PWR	;	1.5	;	HIV-1 protease in complex with a carbamoyl decorated pyrrolidine-based inhibitor
2QNQ	;	2.3	;	HIV-1 Protease in complex with a chloro decorated pyrrolidine-based inhibitor
1DIF	;	1.7	;	HIV-1 PROTEASE IN COMPLEX WITH A DIFLUOROKETONE CONTAINING INHIBITOR A79285
2ZGA	;	1.65	;	HIV-1 protease in complex with a dimethylallyl decorated pyrrolidine based inhibitor (hexagonal space group)
3CKT	;	1.65	;	HIV-1 protease in complex with a dimethylallyl decorated pyrrolidine based inhibitor (orthorombic space group)
2QNP	;	1.41	;	HIV-1 Protease in complex with a iodo decorated pyrrolidine-based inhibitor
3BGB	;	1.9	;	HIV-1 protease in complex with a isobutyl decorated oligoamine
2QNN	;	1.48	;	HIV-1 protease in complex with a multiple decorated pyrrolidine-based inhibitor
2PQZ	;	1.55	;	HIV-1 Protease in complex with a pyrrolidine-based inhibitor
3BHE	;	1.75	;	HIV-1 protease in complex with a three armed pyrrolidine derivative
1XL5	;	1.73	;	HIV-1 Protease in complex with amidhyroxysulfone
1M0B	;	2.45	;	HIV-1 protease in complex with an ethyleneamine inhibitor
3PSU	;	2.07	;	HIV-1 protease in complex with an isobutyl decorated oligoamine (symmetric binding mode)
1WBK	;	2.0	;	HIV-1 protease in complex with asymmetric inhibitor, BEA568
1W5V	;	1.8	;	HIV-1 protease in complex with fluoro substituted diol-based C2- symmetric inhibitor
1W5W	;	1.8	;	HIV-1 protease in complex with fluoro substituted diol-based C2- symmetric inhibitor
1W5X	;	1.9	;	HIV-1 protease in complex with fluoro substituted diol-based C2- symmetric inhibitor
1W5Y	;	1.9	;	HIV-1 protease in complex with fluoro substituted diol-based C2- symmetric inhibitor
2BQV	;	2.1	;	HIV-1 protease in complex with inhibitor AHA455
1XL2	;	1.5	;	HIV-1 Protease in complex with pyrrolidinmethanamine
1A8G	;	2.5	;	HIV-1 PROTEASE IN COMPLEX WITH SDZ283-910
1WBM	;	2.0	;	HIV-1 protease in complex with symmetric inhibitor, BEA450
1AJV	;	2.0	;	HIV-1 PROTEASE IN COMPLEX WITH THE CYCLIC SULFAMIDE INHIBITOR AHA006
1AJX	;	2.0	;	HIV-1 PROTEASE IN COMPLEX WITH THE CYCLIC UREA INHIBITOR AHA001
1EBW	;	1.81	;	HIV-1 protease in complex with the inhibitor BEA322
1EBY	;	2.294	;	HIV-1 protease in complex with the inhibitor BEA369
1EBZ	;	2.01	;	HIV-1 protease in complex with the inhibitor BEA388
1EC0	;	1.79	;	HIV-1 protease in complex with the inhibitor bea403
1EC1	;	2.1	;	HIV-1 protease in complex with the inhibitor BEA409
1D4I	;	1.81	;	HIV-1 protease in complex with the inhibitor BEA425
1EC2	;	2.0	;	HIV-1 protease in complex with the inhibitor BEA428
1D4H	;	1.81	;	HIV-1 Protease in complex with the inhibitor BEA435
1EC3	;	1.8	;	HIV-1 protease in complex with the inhibitor MSA367
1D4J	;	1.81	;	HIV-1 protease in complex with the inhibitor MSL370
2WKZ	;	1.7	;	HIV-1 Protease Inhibitors Containing a Tertiary Alcohol in the Transition-State Mimic with Improved Cell-Based Antiviral Activity
2WL0	;	1.9	;	HIV-1 Protease Inhibitors Containing a Tertiary Alcohol in the Transition-State Mimic with Improved Cell-Based Antiviral Activity
1QBR	;	1.8	;	HIV-1 PROTEASE INHIBITORS WIIH LOW NANOMOLAR POTENCY
1QBS	;	1.8	;	HIV-1 PROTEASE INHIBITORS WIIH LOW NANOMOLAR POTENCY
1QBT	;	2.1	;	HIV-1 PROTEASE INHIBITORS WIIH LOW NANOMOLAR POTENCY
1QBU	;	1.8	;	HIV-1 PROTEASE INHIBITORS WIIH LOW NANOMOLAR POTENCY
6PRF	;	1.21	;	HIV-1 Protease multiple drug resistant clinical isolate mutant PR20 with GRL-14213A
6P9B	;	1.75	;	HIV-1 Protease multiple drug resistant mutant PRS5B with Amprenavir
6P9A	;	1.66	;	HIV-1 Protease multiple mutant PRS5B with Darunavir
2F80	;	1.45	;	HIV-1 Protease mutant D30N complexed with inhibitor TMC114
2QCI	;	1.2	;	HIV-1 Protease mutant D30N with potent Antiviral inhibitor GRL-98065
3JVY	;	1.6	;	HIV-1 Protease Mutant G86A with DARUNAVIR
3JVW	;	1.8	;	HIV-1 Protease Mutant G86A with symmetric inhibitor DMP323
3JW2	;	1.8	;	HIV-1 Protease Mutant G86S with DARUNAVIR
4FLG	;	1.31	;	HIV-1 protease mutant I47V complexed with reaction intermediate
2F8G	;	1.22	;	HIV-1 protease mutant I50V complexed with inhibitor TMC114
2QD6	;	1.28	;	HIV-1 Protease Mutant I50V with potent Antiviral inhibitor GRL-98065
3B80	;	1.5	;	HIV-1 protease mutant I54V complexed with gem-diol-amine intermediate NLLTQI
2QD8	;	1.35	;	HIV-1 Protease Mutant I84V with potent Antiviral inhibitor GRL-98065
3PWR	;	1.45	;	HIV-1 Protease Mutant L76V complexed with Saquinavir
3PWM	;	1.46	;	HIV-1 Protease Mutant L76V with Darunavir
2F81	;	1.25	;	HIV-1 Protease mutant L90M complexed with inhibitor TMC114
4FM6	;	1.4	;	HIV-1 protease mutant V32I complexed with reaction intermediate
2QD7	;	1.11	;	HIV-1 Protease Mutant V82A with potent Antiviral inhibitor GRL-98065
1GNN	;	2.3	;	HIV-1 PROTEASE MUTANT WITH VAL 82 REPLACED BY ASN (V82N) COMPLEXED WITH U89360E (INHIBITOR)
1GNM	;	2.3	;	HIV-1 PROTEASE MUTANT WITH VAL 82 REPLACED BY ASP (V82D) COMPLEXED WITH U89360E (INHIBITOR)
2AZ9	;	2.5	;	HIV-1 Protease NL4-3 1X mutant
2AZB	;	2.03	;	HIV-1 Protease NL4-3 3X mutant in complex with inhibitor, TL-3
2AZC	;	2.01	;	HIV-1 Protease NL4-3 6X mutant
6OPY	;	2.13	;	HIV-1 Protease NL4-3 I13V, G16E, V32I, L33F, K45I, M46I, A71V, L76V, V82F, I84V Mutant in complex with darunavir
6OPW	;	2.1	;	HIV-1 Protease NL4-3 I13V, G16E, V32I, L33F, K45I, M46I, A71V, V82F, I84V Mutant in complex with darunavir
6OPZ	;	2.201	;	HIV-1 Protease NL4-3 I13V, G16E, V32I, L33F, K45I, M46I, I54L, A71V, L76V, V82F, I84V Mutant in complex with darunavir
6OPX	;	2.03	;	HIV-1 Protease NL4-3 I13V, G16E, V32I, L33F, K45I, M46I, L76V, V82F, I84V Mutant in complex with darunavir
6OPV	;	1.91	;	HIV-1 Protease NL4-3 I13V, G16E, V32I, L33F, K45I, M46I, V82F, I84V Mutant in complex with darunavir
2AZ8	;	2.0	;	HIV-1 Protease NL4-3 in complex with inhibitor, TL-3
6OPU	;	1.94	;	HIV-1 Protease NL4-3 K45I, M46I, V82F, I84V Mutant in complex with darunavir
6OOT	;	1.822	;	HIV-1 Protease NL4-3 L89V, L90M Mutant in complex with darunavir
6OOS	;	1.9	;	HIV-1 Protease NL4-3 L90M Mutant in complex with darunavir
6OPT	;	1.96	;	HIV-1 Protease NL4-3 V82F, I84V Mutant in complex with darunavir
6OPS	;	2.08	;	HIV-1 Protease NL4-3 WT in complex with darunavir
6PJB	;	1.984	;	HIV-1 Protease NL4-3 WT in Complex with Lopinavir
6OXW	;	1.982	;	HIV-1 Protease NL4-3 WT in Complex with LR-100
6OXS	;	1.989	;	HIV-1 Protease NL4-3 WT in Complex with LR-76
6OXR	;	2.035	;	HIV-1 Protease NL4-3 WT in Complex with LR-82
6OXT	;	1.861	;	HIV-1 Protease NL4-3 WT in Complex with LR-84
6OXV	;	1.991	;	HIV-1 Protease NL4-3 WT in Complex with LR-85
6OXU	;	1.861	;	HIV-1 Protease NL4-3 WT in Complex with LR-99
6OXX	;	1.962	;	HIV-1 Protease NL4-3 WT in Complex with LR2-18
6OXY	;	1.96	;	HIV-1 Protease NL4-3 WT in Complex with LR2-19
6OXZ	;	1.961	;	HIV-1 Protease NL4-3 WT in Complex with LR2-20
6OY0	;	2.0	;	HIV-1 Protease NL4-3 WT in Complex with LR2-21
6OY2	;	1.99	;	HIV-1 Protease NL4-3 WT in Complex with LR2-25
6OY1	;	2.0	;	HIV-1 Protease NL4-3 WT in Complex with LR2-26
6PJD	;	1.892	;	HIV-1 Protease NL4-3 WT in Complex with LR2-32
6PJM	;	1.93	;	HIV-1 Protease NL4-3 WT in Complex with LR2-35
6PJN	;	1.98	;	HIV-1 Protease NL4-3 WT in Complex with LR2-41
6PJO	;	1.95	;	HIV-1 Protease NL4-3 WT in Complex with LR2-42
6PJE	;	1.922	;	HIV-1 Protease NL4-3 WT in Complex with LR2-43
6PJF	;	1.94	;	HIV-1 Protease NL4-3 WT in Complex with LR2-44
6OXO	;	2.003	;	HIV-1 Protease NL4-3 WT in Complex with LR2-91
6PJH	;	1.85	;	HIV-1 Protease NL4-3 WT in Complex with LR3-28
6PJK	;	2.002	;	HIV-1 Protease NL4-3 WT in Complex with LR3-29
6PJI	;	1.9	;	HIV-1 Protease NL4-3 WT in Complex with LR3-43
6PJL	;	1.993	;	HIV-1 Protease NL4-3 WT in Complex with LR3-95
6PJG	;	1.8	;	HIV-1 Protease NL4-3 WT in Complex with LR3-97
6PJC	;	1.965	;	HIV-1 Protease NL4-3 WT in Complex with LR4-41
6OXP	;	1.97	;	HIV-1 Protease NL4-3 WT in Complex with UMass3
6OXQ	;	1.89	;	HIV-1 Protease NL4-3 WT in Complex with UMass8
3NDT	;	1.72	;	HIV-1 Protease Saquinavir:Ritonavir 1:1 complex structure
3NDW	;	1.14	;	HIV-1 Protease Saquinavir:Ritonavir 1:15 complex structure
3NDU	;	1.25	;	HIV-1 Protease Saquinavir:Ritonavir 1:5 complex structure
3NDX	;	1.03	;	HIV-1 Protease Saquinavir:Ritonavir 1:50 complex structure
2WHH	;	1.69	;	HIV-1 protease tethered dimer Q-product complex along with nucleophilic water molecule
1D4Y	;	1.97	;	HIV-1 PROTEASE TRIPLE MUTANT/TIPRANAVIR COMPLEX
1HPO	;	2.5	;	HIV-1 PROTEASE TRIPLE MUTANT/U103265 COMPLEX
3S43	;	1.26	;	HIV-1 protease triple mutants V32I, I47V, V82I with antiviral drug amprenavir
3S54	;	1.42	;	HIV-1 protease triple mutants V32I, I47V, V82I with antiviral drug darunavir in space group P21212
3S53	;	1.5	;	HIV-1 protease triple mutants V32I, I47V, V82I with antiviral drug darunavir in space group P212121
3S56	;	1.88	;	HIV-1 protease triple mutants V32I, I47V, V82I with antiviral drug saquinavir
6OTG	;	1.5	;	HIV-1 protease triple mutants V32I, I47V, V82I with GRL-011-11A (a methylamine bis-Tetrahydrofuran P2-Ligand, sulfonamide isostere derivate)
1D4S	;	2.5	;	HIV-1 PROTEASE V82F/I84V DOUBLE MUTANT/TIPRANAVIR COMPLEX
1G2K	;	1.95	;	HIV-1 PROTEASE WITH CYCLIC SULFAMIDE INHIBITOR, AHA047
6DJ5	;	1.75	;	HIV-1 protease with mutation L76V in complex with GRL-0519 (tris-tetrahydrofuran as P2 ligand)
6DJ7	;	1.31	;	HIV-1 protease with mutation L76V in complex with GRL-5010 (gem-difluoro-bis-tetrahydrofuran as P2 ligand)
6DJ2	;	1.36	;	HIV-1 protease with single mutation L76V in complex with Lopinavir
6DIL	;	1.482	;	HIV-1 protease with single mutation L76V in complex with tipranavir
2I4U	;	1.5	;	HIV-1 protease with TMC-126
7LE0	;	1.952	;	HIV-1 Protease WT (NL4-3) in Complex with a Darunavir Derivative
7LDZ	;	1.861	;	HIV-1 Protease WT (NL4-3) in Complex with GRL-98065
7LE7	;	1.978	;	HIV-1 Protease WT (NL4-3) in Complex with GS-8374
7M9K	;	1.838	;	HIV-1 Protease WT (NL4-3) in Complex with LR3-48
7M9M	;	1.881	;	HIV-1 Protease WT (NL4-3) in Complex with LR3-55
7M9J	;	1.859	;	HIV-1 Protease WT (NL4-3) in Complex with LR3-68
7M9L	;	1.752	;	HIV-1 Protease WT (NL4-3) in Complex with LR4-15
7M9Q	;	1.952	;	HIV-1 Protease WT (NL4-3) in Complex with LR4-33
7M9R	;	1.891	;	HIV-1 Protease WT (NL4-3) in Complex with LR4-44
7M9S	;	1.961	;	HIV-1 Protease WT (NL4-3) in Complex with NR01-141
7M9T	;	1.95	;	HIV-1 Protease WT (NL4-3) in Complex with NR02-73
7M9U	;	1.911	;	HIV-1 Protease WT (NL4-3) in Complex with NR02-79
7LE8	;	1.644	;	HIV-1 Protease WT (NL4-3) in Complex with PD4 (LR4-23)
7LE9	;	1.797	;	HIV-1 Protease WT (NL4-3) in Complex with PD5 (LR4-22)
7LEA	;	2.0	;	HIV-1 Protease WT (NL4-3) in Complex with PU1 (LR3-46)
7LEI	;	1.943	;	HIV-1 Protease WT (NL4-3) in Complex with PU10 (LR4-07)
7LEB	;	1.89	;	HIV-1 Protease WT (NL4-3) in Complex with PU2 (LR2-79)
7LEC	;	1.94	;	HIV-1 Protease WT (NL4-3) in Complex with PU3 (LR3-69)
7LED	;	1.996	;	HIV-1 Protease WT (NL4-3) in Complex with PU4 (LR2-78)
7LEE	;	1.795	;	HIV-1 Protease WT (NL4-3) in Complex with PU5 (LR4-47)
7LEF	;	1.93	;	HIV-1 Protease WT (NL4-3) in Complex with PU7 (LR3-67)
7LEG	;	1.96	;	HIV-1 Protease WT (NL4-3) in Complex with PU8 (LR4-06)
7LEH	;	2.0	;	HIV-1 Protease WT (NL4-3) in Complex with PU9 (LR2-80)
7LDY	;	1.984	;	HIV-1 Protease WT (NL4-3) in Complex with TMC-126
7LE6	;	1.962	;	HIV-1 Protease WT (NL4-3) in Complex with UMass10
7LE1	;	2.001	;	HIV-1 Protease WT (NL4-3) in Complex with UMass2
7LE2	;	1.971	;	HIV-1 Protease WT (NL4-3) in Complex with UMass4
7LE3	;	1.87	;	HIV-1 Protease WT (NL4-3) in Complex with UMass5
7LE4	;	1.993	;	HIV-1 Protease WT (NL4-3) in Complex with UMass7
7LE5	;	1.863	;	HIV-1 Protease WT (NL4-3) in Complex with UMass9
2I4W	;	1.55	;	HIV-1 protease WT with GS-8374
5T84	;	1.65	;	HIV-1 protease, unbound subtype B L63P construct
1BVG	;		;	HIV-1 PROTEASE-DMP323 COMPLEX IN SOLUTION, NMR MINIMIZED AVERAGE STRUCTURE
1BVE	;		;	HIV-1 PROTEASE-DMP323 COMPLEX IN SOLUTION, NMR, 28 STRUCTURES
2BPV	;	1.9	;	HIV-1 protease-inhibitor complex
2BPW	;	2.8	;	HIV-1 protease-inhibitor complex
2BPX	;	2.8	;	HIV-1 protease-inhibitor complex
2BPY	;	1.9	;	HIV-1 protease-inhibitor complex
2BPZ	;	2.5	;	HIV-1 protease-inhibitor complex
7UPJ	;	2.0	;	HIV-1 PROTEASE/U101935 COMPLEX
1HXB	;	2.3	;	HIV-1 proteinase complexed with RO 31-8959
1ODX	;	2.0	;	HIV-1 Proteinase mutant A71T, V82A
2M1A	;		;	HIV-1 Rev ARM peptide (residues T34-R50)
6BSY	;	2.25	;	HIV-1 Rev assembly domain (residues 1-69)
7U0F	;	3.53	;	HIV-1 Rev in complex with tubulin
5DHV	;	2.3	;	HIV-1 Rev NTD dimers with variable crossing angles
5DHX	;	2.9	;	HIV-1 Rev NTD dimers with variable crossing angles
5DHY	;	3.1	;	HIV-1 Rev NTD dimers with variable crossing angles
5DHZ	;	4.3	;	HIV-1 Rev NTD dimers with variable crossing angles
1RPV	;		;	HIV-1 REV PROTEIN (RESIDUES 34-50)
1REV	;	2.6	;	HIV-1 REVERSE TRANSCRIPTASE
7AID	;	3.15	;	HIV-1 REVERSE TRANSCRIPTASE COMPLEX WITH DNA AND D-ASPARTATE TENOFOVIR
7AHX	;	2.73	;	HIV-1 REVERSE TRANSCRIPTASE COMPLEX WITH DNA AND D-ASPARTATE TENOFOVIR WITH BOUND MANGANESE
7OTA	;	3.0	;	HIV-1 REVERSE TRANSCRIPTASE COMPLEX WITH DNA AND INHIBITOR RMC-230
7OTK	;	2.95	;	HIV-1 REVERSE TRANSCRIPTASE COMPLEX WITH DNA AND INHIBITOR RMC-233
7OTN	;	3.4	;	HIV-1 REVERSE TRANSCRIPTASE COMPLEX WITH DNA AND INHIBITOR RMC-247
7OTX	;	3.45	;	HIV-1 REVERSE TRANSCRIPTASE COMPLEX WITH DNA AND INHIBITOR RMC-257
7OTZ	;	3.1	;	HIV-1 REVERSE TRANSCRIPTASE COMPLEX WITH DNA AND INHIBITOR RMC-259
7OUT	;	3.2	;	HIV-1 REVERSE TRANSCRIPTASE COMPLEX WITH DNA AND INHIBITOR RMC-264
7OT6	;	3.2	;	HIV-1 REVERSE TRANSCRIPTASE COMPLEX WITH DNA AND inhibitor RMC-282
7AIG	;	2.95	;	HIV-1 REVERSE TRANSCRIPTASE COMPLEX WITH DNA AND L-GLUTAMATE TENOFOVIR
7AIF	;	2.75	;	HIV-1 REVERSE TRANSCRIPTASE COMPLEX WITH DNA AND L-GLUTAMATE TENOFOVIR WITH BOUND MANGANESE
7AIJ	;	2.95	;	HIV-1 REVERSE TRANSCRIPTASE COMPLEX WITH DNA AND L-METHIONINE TENOFOVIR
7AII	;	2.62	;	HIV-1 REVERSE TRANSCRIPTASE COMPLEX WITH DNA AND L-METHIONINE TENOFOVIR WITH BOUND MANGANESE
5CYQ	;	2.147	;	HIV-1 reverse transcriptase complexed with 4-bromopyrazole
5CYM	;	2.1	;	HIV-1 reverse transcriptase complexed with 4-iodopyrazole
1KLM	;	2.65	;	HIV-1 REVERSE TRANSCRIPTASE COMPLEXED WITH BHAP U-90152
1TV6	;	2.8	;	HIV-1 Reverse Transcriptase Complexed with CP-94,707
1RT5	;	2.9	;	HIV-1 REVERSE TRANSCRIPTASE COMPLEXED WITH UC10
1RT6	;	2.8	;	HIV-1 REVERSE TRANSCRIPTASE COMPLEXED WITH UC38
1RT4	;	2.9	;	HIV-1 REVERSE TRANSCRIPTASE COMPLEXED WITH UC781
1RT7	;	3.0	;	HIV-1 REVERSE TRANSCRIPTASE COMPLEXED WITH UC84
1N5Y	;	3.1	;	HIV-1 Reverse Transcriptase Crosslinked to Post-Translocation AZTMP-Terminated DNA (Complex P)
1N6Q	;	3.0	;	HIV-1 Reverse Transcriptase Crosslinked to pre-translocation AZTMP-terminated DNA (complex N)
1T05	;	3.0	;	HIV-1 reverse transcriptase crosslinked to template-primer with tenofovir-diphosphate bound as the incoming nucleotide substrate
1T03	;	3.1	;	HIV-1 reverse transcriptase crosslinked to tenofovir terminated template-primer (complex P)
8FCC	;	2.57	;	HIV-1 Reverse Transcriptase in complex with 5-membered bicyclic core NNRTI
8FCD	;	2.57	;	HIV-1 Reverse Transcriptase in complex with 6-membered bicyclic core NNRTI
8FCE	;	2.77	;	HIV-1 Reverse Transcriptase in complex with 7-membered bicyclic core NNRTI
5K14	;	2.402	;	HIV-1 Reverse Transcriptase in complex with a 2,6-difluorophenyl DAPY analog
4I7F	;	2.5	;	HIV-1 Reverse Transcriptase in complex with a phosphonate analog of nevirapine
3KJV	;	3.1	;	HIV-1 reverse transcriptase in complex with DNA
5J2M	;	2.432	;	HIV-1 reverse transcriptase in complex with DNA and EFdA-triphosphate, a translocation-defective RT inhibitor
5J2Q	;	2.789	;	HIV-1 reverse transcriptase in complex with DNA that has incorporated a mismatched EFdA-MP at the N-(pre-translocation) site
5J2P	;	2.53	;	HIV-1 reverse transcriptase in complex with DNA that has incorporated EFdA-MP at the P-(post-translocation) site and a second EFdA-MP at the N-(pre-translocation) site
5J2N	;	2.896	;	HIV-1 reverse transcriptase in complex with DNA that has incorporated EFdA-MP at the P-(post-translocation) site and dTMP at the N-(pre-translocation) site
2YNH	;	2.9	;	HIV-1 Reverse Transcriptase in complex with inhibitor GSK500
2YNG	;	2.12	;	HIV-1 Reverse Transcriptase in complex with inhibitor GSK560
2YNI	;	2.49	;	HIV-1 Reverse Transcriptase in complex with inhibitor GSK952
3QLH	;	2.7	;	HIV-1 Reverse Transcriptase in Complex with Manicol at the RNase H Active Site and TMC278 (Rilpivirine) at the NNRTI Binding Pocket
1IKY	;	3.0	;	HIV-1 Reverse Transcriptase in Complex with the Inhibitor MSC194
1EET	;	2.73	;	HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH THE INHIBITOR MSC204
3MEC	;	2.3	;	HIV-1 Reverse Transcriptase in Complex with TMC125
3MEE	;	2.4	;	HIV-1 Reverse Transcriptase in Complex with TMC278
3K2P	;	2.04	;	HIV-1 Reverse Transcriptase Isolated RnaseH Domain with the Inhibitor beta-thujaplicinol Bound at the Active Site
7DBN	;	2.67	;	HIV-1 reverse transcriptase mutant Q151M/Y115F/F116Y/M184V/F160M:DNA:dCTP ternary complex
7DBM	;	2.43	;	HIV-1 reverse transcriptase mutant Q151M/Y115F/F116Y/M184V:DNA:dGTP ternary complex
5XN0	;	2.596	;	HIV-1 reverse transcriptase Q151M:DNA binary complex
5XN2	;	2.381	;	HIV-1 reverse transcriptase Q151M:DNA:dGTP ternary complex
5XN1	;	2.446	;	HIV-1 reverse transcriptase Q151M:DNA:entecavir-triphosphate ternary complex
5DZM	;	2.05	;	HIV-1 Reverse Transcriptase RH domain
5T82	;		;	HIV-1 reverse transcriptase thumb subdomain
3NBP	;	2.95	;	HIV-1 reverse transcriptase with aminopyrimidine inhibitor 2
4KFB	;	1.854	;	HIV-1 reverse transcriptase with bound fragment at NNRTI adjacent site
4IDK	;	2.1	;	HIV-1 reverse transcriptase with bound fragment at the 428 site
4IG0	;	2.5	;	HIV-1 reverse transcriptase with bound fragment at the 507 site
4ICL	;	1.8	;	HIV-1 reverse transcriptase with bound fragment at the incoming dNTP binding site
4IFY	;	2.1	;	HIV-1 reverse transcriptase with bound fragment at the Knuckles site
4ID5	;	1.95	;	HIV-1 reverse transcriptase with bound fragment at the RNase H primer grip site
4IG3	;	1.95	;	HIV-1 reverse transcriptase with bound fragment near Knuckles site
3LP0	;	2.79	;	HIV-1 reverse transcriptase with inhibitor
3LP1	;	2.23	;	HIV-1 reverse transcriptase with inhibitor
3LP2	;	2.8	;	HIV-1 reverse transcriptase with inhibitor
6IK9	;	2.435	;	HIV-1 reverse transcriptase with Q151M/G112S/D113A/Y115F/F116Y/F160L/I159L:DNA:dGTP ternary complex
6IKA	;	2.598	;	HIV-1 reverse transcriptase with Q151M/G112S/D113A/Y115F/F116Y/F160L/I159L:DNA:entecavir-triphosphate ternary complex
6KDO	;	2.573	;	HIV-1 reverse transcriptase with Q151M/Y115F/F116Y/M184V/F160M:DNA:lamivudine 5'-triphosphate ternary complex
6KDK	;	2.56	;	HIV-1 reverse transcriptase with Q151M/Y115F/F116Y:DNA:dCTP ternary complex
6KDN	;	2.303	;	HIV-1 reverse transcriptase with Q151M/Y115F/F116Y:DNA:dGTP ternary complex
6KDM	;	2.32	;	HIV-1 reverse transcriptase with Q151M/Y115F/F116Y:DNA:entecavir 5'-triphosphate ternary complex
6KDJ	;	2.51	;	HIV-1 reverse transcriptase with Q151M/Y115F/F116Y:DNA:lamivudine 5'-triphosphate ternary complex
3IG1	;	2.8	;	HIV-1 Reverse Transcriptase with the Inhibitor beta-Thujaplicinol Bound at the RNase H Active Site
6DTW	;	2.742	;	HIV-1 Reverse Transcriptase Y181C Mutant in complex with JLJ 578
2YNF	;	2.36	;	HIV-1 Reverse Transcriptase Y188L mutant in complex with inhibitor GSK560
3KK2	;	2.9	;	HIV-1 reverse transcriptase-DNA complex with dATP bound in the nucleotide binding site
3KK3	;	2.9	;	HIV-1 reverse transcriptase-DNA complex with GS-9148 terminated primer
3KK1	;	2.7	;	HIV-1 reverse transcriptase-DNA complex with nuceotide inhibitor GS-9148-diphosphate bound in nucleotide site
2HMI	;	2.8	;	HIV-1 REVERSE TRANSCRIPTASE/FRAGMENT OF FAB 28/DNA COMPLEX
8DXJ	;	1.8	;	HIV-1 reverse transcriptase/rilpivirine with bound fragment 1-N-methyl-4-(trifluoromethyl)benzene-1,2-diamine at the NNRTI adjacent site
8DXE	;	1.85	;	HIV-1 reverse transcriptase/rilpivirine with bound fragment 2-amino-6-fluorobenzonitrile at the NNRTI adjacent site
8DX8	;	1.85	;	HIV-1 reverse transcriptase/rilpivirine with bound fragment 2-chloro-6-fluorophenethylamine at the 415 site
8DX3	;	2.06	;	HIV-1 reverse transcriptase/rilpivirine with bound fragment 3-bromobenzylamine in the thumb subdomain
8DX2	;	2.0	;	HIV-1 reverse transcriptase/rilpivirine with bound fragment 4-amino-3-bromopyridine at multiple sites
8DXM	;	1.99	;	HIV-1 reverse transcriptase/rilpivirine with bound fragment 4-bromophenol at the Knuckles site
8DXK	;	2.0	;	HIV-1 reverse transcriptase/rilpivirine with bound fragment 4-bromopyrazole at multiple sites
8DXL	;	2.25	;	HIV-1 reverse transcriptase/rilpivirine with bound fragment 4-iodopyrazole at multiple sites
8DXG	;	2.1	;	HIV-1 reverse transcriptase/rilpivirine with bound fragment 5-(trifluoromethyl)pyridin-2-ol at W24 site
8DXB	;	2.1	;	HIV-1 reverse transcriptase/rilpivirine with bound fragment 5-fluoroindole-2-carboxylic acid at the NNRTI Adjacent site
8DXH	;	1.8	;	HIV-1 reverse transcriptase/rilpivirine with bound fragment 5-fluoroquinazolin-4-ol at W266 site
8DXI	;	1.95	;	HIV-1 reverse transcriptase/rilpivirine with bound fragment [1-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]methanol at multiple sites
1BVJ	;		;	HIV-1 RNA A-RICH HAIRPIN LOOP
3M8Q	;	2.7	;	HIV-1 RT with AMINOPYRIMIDINE NNRTI
3M8P	;	2.67	;	HIV-1 RT with NNRTI TMC-125
3DYA	;	2.3	;	HIV-1 RT with non-nucleoside inhibitor annulated Pyrazole 1
3DI6	;	2.65	;	HIV-1 RT with pyridazinone non-nucleoside inhibitor
3FFI	;	2.6	;	HIV-1 RT with pyridone non-nucleoside inhibitor
1TVR	;	3.0	;	HIV-1 RT/9-CL TIBO
1BQM	;	3.1	;	HIV-1 RT/HBY 097
7D7S	;	3.32	;	HIV-1 SF2 Nef in complex with the Fyn SH3 R96I mutant
1Y99	;	2.4	;	HIV-1 subtype A DIS RNA duplex
1XPF	;	2.3	;	HIV-1 subtype A genomic RNA Dimerization Initiation Site
2OIJ	;	2.31	;	HIV-1 subtype B DIS RNA extended duplex AuCl3 soaked
1XPE	;	1.94	;	HIV-1 subtype B genomic RNA Dimerization Initiation Site
2QEK	;	1.8	;	HIV-1 subtype F DIS RNA extended duplex form
1XP7	;	2.5	;	HIV-1 subtype F genomic RNA Dimerization Initiation Site
6CYT	;	3.5	;	HIV-1 TAR loop in complex with Tat:AFF4:P-TEFb
1QD3	;		;	HIV-1 TAR RNA/NEOMYCIN B COMPLEX
1TAC	;		;	HIV-1 TAT CYS-, NMR, 10 STRUCTURES
5SVZ	;	2.0	;	HIV-1 Tat NLS in complex with importin alpha
2BGN	;	3.15	;	HIV-1 Tat protein derived N-terminal nonapeptide Trp2-Tat(1-9) bound to the active site of Dipeptidyl peptidase IV (CD26)
1TBC	;		;	HIV-1 TAT, NMR, 10 STRUCTURES
1AI1	;	2.8	;	HIV-1 V3 LOOP MIMIC
2MA9	;		;	HIV-1 Vif SOCS-box and Elongin BC solution structure
3QAA	;	1.4	;	HIV-1 wild type protease with a substituted bis-Tetrahydrofuran inhibitor, GRL-044-10A
5JFU	;	1.7	;	HIV-1 wild Type protease with GRL-007-14A (a Adamantane P1-Ligand with bis-THF in P2 and benzylamine in P1')
6U7O	;	1.33	;	HIV-1 wild type protease with GRL-00819A, with phenyl-boronic-acid as P2'-ligand and with a 6-5-5-ring fused crown-like tetrahydropyranofuran as the P2-ligand
5BRY	;	1.34	;	HIV-1 wild Type protease with GRL-011-11A (a methylamine bis-Tetrahydrofuran P2-Ligand, sulfonamide isostere derivate)
7TO6	;	1.21	;	HIV-1 wild type protease with GRL-01717A, with C-4 substituted cyclohexane-fused bis-tetrahydrofuran (Chf-THF) derivatives as P2-ligand [diastereomer 2]
6VOE	;	1.3	;	HIV-1 wild type protease with GRL-019-17A, a tricyclic cyclohexane fused tetrahydrofuranofuran (CHf-THF) derivative as the P2 ligand and a aminobenzothiazole(Abt)-based P2'-ligand
8FUI	;	1.25	;	HIV-1 wild type protease with GRL-02519A, with N-(2,5-dimethylphenyl)-4-(pyridin-3-yl)pyrimidin-2-amine as P2-P3 group
6VCE	;	1.18	;	HIV-1 wild type protease with GRL-026-18A, a crown-like tetrahydropyranotetrahydrofuran with a bridged methylene group as a P2 ligand
6DV0	;	1.2	;	HIV-1 wild type protease with GRL-02815A, a thiochroman heterocycle with (S)-Boc-amine functionality as the P2 ligand
5JG1	;	1.16	;	HIV-1 wild Type protease with GRL-031-14A (a Adamantane P1-Ligand with tetrahydropyrano-tetrahydrofuran in P2 and isobutylamine in P1')
6U7P	;	1.13	;	HIV-1 wild type protease with GRL-03119A, with phenyl-boronic-acid as P2'-ligand and with a hexahydro-4H-furo-pyran as the P2-ligand
6CDL	;	1.25	;	HIV-1 wild type protease with GRL-03214A, 6-5-5-ring fused umbrella-like tetrahydropyranofuran as the P2-ligand, a cyclopropylaminobenzothiazole as the P2'-ligand and 3,5-difluorophenylmethyl as the P1-ligand
6CDJ	;	1.13	;	HIV-1 wild type protease with GRL-03314A, 6-5-5-ring fused umbrella-like tetrahydropyranofuran as the P2-ligand, a cyclopropylaminobenzothiazole as the P2'-ligand and 3,5-difluorophenylmethyl as the P1-ligand
6E9A	;	1.22	;	HIV-1 WILD TYPE PROTEASE WITH GRL-034-17A, (3aS, 5R, 6aR)-2-OXOHEXAHYD CYCLOPENTA[D]-5-OXAZOLYL URETHANE WITH A BICYCLIC OXAZOLIDINONE SCAFF AS THE P2 LIGAND
8FUJ	;	1.12	;	HIV-1 wild type protease with GRL-03419A, with N-(2,5-dimethylphenyl)-4-(pyridin-3-yl)pyrimidin-2-amine as P2-P3 group and 3,5-difluorophenylmethyl as the P1 group
6E7J	;	1.3	;	HIV-1 wild type protease with GRL-042-17A, 3-phenylhexahydro-2h-cyclopenta[d]oxazol-2-one with a bicyclic oxazolidinone scaffold as the P2 ligand
6DV4	;	1.14	;	HIV-1 wild type protease with GRL-04315A, a tetrahydronaphthalene carboxamide with (R)-Boc-amine and (S)-hydroxyl functionalities as the P2 ligand
5BS4	;	1.29	;	HIV-1 wild Type protease with GRL-047-11A (a methylamine bis-Tetrahydrofuran P2-Ligand, 4-amino sulfonamide derivative)
4U8W	;	1.3	;	HIV-1 wild Type protease with GRL-050-10A (a Gem-difluoro-bis-Tetrahydrofuran as P2-Ligand)
5UPZ	;	1.27	;	HIV-1 wild Type protease with GRL-0518A , an isophthalamide-derived P2-P3 ligand with the para-hydoxymethyl sulfonamide isostere as the P2' group
6VOD	;	1.25	;	HIV-1 wild type protease with GRL-052-16A, a tricyclic cyclohexane fused tetrahydrofuranofuran (CHf-THF) derivative as the P2 ligand
7TO5	;	1.13	;	HIV-1 wild type protease with GRL-05816A, with C-4 substituted cyclohexane-fused bis-tetrahydrofuran (Chf-THF) derivatives as P2-ligand [diastereomer 1]
4ZIP	;	1.11	;	HIV-1 wild Type protease with GRL-0648A (a isophthalamide-derived P2-Ligand)
4ZLS	;	1.53	;	HIV-1 wild Type protease with GRL-096-13A (a Boc-derivative P2-Ligand, 3,-5-dimethylbiphenyl P1-Ligand)
5JFP	;	1.49	;	HIV-1 wild Type protease with GRL-097-13A (a Adamantane P1-Ligand with bis-THF in P2 and isobutylamine in P1')
5ULT	;	1.53	;	HIV-1 wild Type protease with GRL-100-13A (a Crown-like Oxotricyclic Core as the P2-Ligand with the sulfonamide isostere as the P2' group)
8F0F	;	1.29	;	HIV-1 wild type protease with GRL-110-19A, a chloroacetamide derivative based on Darunavir as P2' group
5UOV	;	1.33	;	HIV-1 wild Type protease with GRL-1118A , an isophthalamide-derived P2-P3 ligand with the sulfonamide isostere as the P2' group
6UJZ	;	2.55643	;	HIV-1 wild-type reverse transcriptase-DNA complex with (+)-FTC-TP
6UJY	;	2.59456	;	HIV-1 wild-type reverse transcriptase-DNA complex with (-)-3TC-TP
6UJX	;	2.70451	;	HIV-1 wild-type reverse transcriptase-DNA complex with (-)-FTC-TP
6UIT	;	2.80607	;	HIV-1 wild-type reverse transcriptase-DNA complex with dCTP
1G9N	;	2.9	;	HIV-1 YU2 GP120 ENVELOPE GLYCOPROTEIN COMPLEXED WITH CD4 AND INDUCED NEUTRALIZING ANTIBODY 17B
1RZK	;	2.9	;	HIV-1 YU2 GP120 ENVELOPE GLYCOPROTEIN COMPLEXED WITH CD4 AND INDUCED NEUTRALIZING ANTIBODY 17B
1K9W	;	3.1	;	HIV-1(MAL) RNA Dimerization Initiation Site
8FZC	;	5.5	;	HIV-2 Gag Capsid from Immature Virus-like Particles
5UPJ	;	2.3	;	HIV-2 PROTEASE/U99283 COMPLEX
6UPJ	;	2.34	;	HIV-2 PROTEASE/U99294 COMPLEX
1AJU	;		;	HIV-2 TAR-ARGININAMIDE COMPLEX, NMR, 20 STRUCTURES
1AKX	;		;	HIV-2 TRANS ACTIVATING REGION RNA COMPLEX WITH ARGININAMIDE, NMR, MINIMIZED AVERAGE STRUCTURE
8F22	;	2.5	;	HIV-CA Disulfide linked Hexamer bound to 11l capsid inhibitor.
8TOV	;	2.7	;	HIV-CA Disulfide linked Hexamer bound to Quinazolin-4-one Scaffold inhibitor
8TQP	;	2.9	;	HIV-CA Disulfide linked Hexamer bound to Quinazolin-4-one Scaffold inhibitor
3VIE	;	1.8	;	HIV-gp41 fusion inhibitor Sifuvirtide
3E01	;	2.95	;	HIV-RT with non-nucleoside inhibitor annulated pyrazole 2
5KGX	;	2.67	;	HIV1 catalytic core domain in complex with an inhibitor (2~{S})-2-[3-(3,4-dihydro-2~{H}-chromen-6-yl)-1-methyl-indol-2-yl]-2-[(2-methylpropan-2-yl)oxy]ethanoic acid
5KGW	;	2.34	;	HIV1 catalytic core domain in complex with inhibitor: (2~{S})-2-[3-(3,4-dihydro-2~{H}-chromen-6-yl)-1-methyl-indol-2-yl]-2-[(2-methylpropan-2-yl)oxy]ethanoic acid
5BU8	;	2.202	;	HK620 Tail Needle crystallized at pH 7.5 and derivatized with Xenon
5BU5	;	1.952	;	HK620 Tail Needle crystallized at pH 9 (crystal form I)
5BVZ	;	2.5	;	HK620 Tail Needle crystallized at pH 9 (Crystal form II)
3DDX	;		;	HK97 bacteriophage capsid Expansion Intermediate-II model
8CEZ	;	2.97	;	HK97 Portal Protein In situ (prohead II)
3QPR	;	5.2	;	HK97 Prohead I encapsidating inactive virally encoded protease
8CFA	;	3.06	;	HK97 Prohead II as part of a DNA packaging complex
8POP	;	3.0	;	HK97 small terminase in complex with DNA
3J1A	;	16.0	;	HK97-like fold fitted into 3D reconstruction of bacteriophage CW02
6T8P	;	2.02	;	HKATII IN COMPLEX WITH LIGAND (2R)-N-benzyl-1-[6-methyl-5-(oxan-4-yl)-7-oxo-6H,7H-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide
6T8Q	;	2.51	;	HKATII IN COMPLEX WITH LIGAND (2R)-N-benzyl-1-[6-methyl-5-(oxan-4-yl)-7-oxo-6H,7H-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide
8OMK	;	2.48	;	hKHK-C in complex with ADP & fructose 1-phosphate
4YOJ	;	1.9	;	HKU4 3CLpro bound to non-covalent inhibitor 2A
4YO9	;	2.3	;	HKU4 3CLpro unbound structure
4YOG	;	2.0	;	HKU4-3CLpro bound to non-covalent inhibitor 3B
2HLC	;	1.7	;	HL COLLAGENASE STRUCTURE AT 1.7A RESOLUTION
5NMK	;	1.66	;	HLA A02 presenting SLFNTIAVL
5NMH	;	1.55	;	HLA A02 presenting SLYNTIATL
8TUB	;	2.4	;	HLA B7:02 with HPNGYKSLSTL
8TUH	;	2.20011	;	HLA B7:02 with RPIIRPATL
1M05	;	1.9	;	HLA B8 in complex with an Epstein Barr Virus determinant
5EU3	;	1.97	;	HLA Class I antigen
5EU4	;	2.12	;	HLA Class I antigen
5EU5	;	1.54	;	HLA Class I antigen
5EU6	;	2.02	;	HLA Class I antigen
5C09	;	2.475	;	HLA class I histocompatibility antigen
6EQA	;	3.16	;	HLA class I histocompatibility antigen
6EQB	;	2.81	;	HLA class I histocompatibility antigen
4U1H	;	1.59	;	HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escape through identical epitopes
4U1I	;	1.92	;	HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escape through identical epitopes
4U1J	;	1.38	;	HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escape through identical epitopes
4U1K	;	2.09	;	HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escape through identical epitopes
4U1L	;	2.06	;	HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escape through identical epitopes
4U1M	;	1.18	;	HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escape through identical epitopes
4U1N	;	1.77	;	HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escape through identical epitopes
4U1S	;	1.76	;	HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escape through identical epitopes
6HBY	;	1.95	;	HLA class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope
7N6D	;	2.3	;	HLA peptide complex
5HGA	;	2.199	;	HLA*A2402 complex with HIV nef138 Y2F-8mer mutant epitope
5HGH	;	2.392	;	HLA*A2402 complexed with HIV nef138 10mer epitope
5HGB	;	2.4	;	HLA*A2402 complexed with HIV nef138 8mer epitope
5HGD	;	2.07	;	HLA*A2402 complexed with HIV nef138 Y2F mutant 10mer epitope
6MPP	;		;	HLA-A*01:01 complex with NRAS Q61K peptide by NMR
6APN	;	2.22	;	HLA-A*0201 single chain trimer with HPV.16 E7 peptide LLMGTLGIV
6E1I	;	1.99	;	HLA-A*0201 single chain trimer with murine H2K alpha 3 domain and HPV.16 E7 peptide YMLDLQPET
7MJ6	;	1.95	;	HLA-A*02:01 bound to Neuroblastoma Derived IGFBPL1 peptide
7MJ7	;	1.6	;	HLA-A*02:01 bound to Neuroblastoma Derived IGFBPL1 peptide
7MJ8	;	1.79	;	HLA-A*02:01 bound to Neuroblastoma Derived IGFBPL1 peptide
7MJ9	;	1.75	;	HLA-A*02:01 bound to Neuroblastoma Derived mutant IGFBPL1 peptide
2HN7	;	1.6	;	HLA-A*1101 in complex with HBV peptide homologue
7MJA	;	1.69	;	HLA-A*24:02 bound to Neuroblastoma derived PHOX2B peptide
5C0D	;	1.68	;	HLA-A02 carrying AQWGPDPAAA
5N1Y	;	1.39	;	HLA-A02 carrying MVWGPDPLYV
5C0J	;	1.64	;	HLA-A02 carrying RQFGPDWIVA
5C0F	;	1.463	;	HLA-A02 carrying RQWGPDPAAV
5C0E	;	1.491	;	HLA-A02 carrying YLGGPDFPTI
5C0G	;	1.37	;	HLA-A02 carrying YLGGPDFPTI
6NCA	;	3.3	;	HLA-A2 (A*02:01) bound to a peptide from the Epstein-Barr virus BRLF1 protein
3V5H	;	1.63	;	HLA-A2.1 KVAEIVHFL
3V5D	;	2.0	;	HLA-A2.1 KVAELVHFL
3WL9	;	1.66	;	HLA-A24 in complex with HIV-1 Nef126-10(8I10F)
3WLB	;	2.0	;	HLA-A24 in complex with HIV-1 Nef126-10(8T10F)
3VXO	;	2.61	;	HLA-A24 in complex with HIV-1 Nef134-10(2F)
3VXP	;	2.5	;	HLA-A24 in complex with HIV-1 Nef134-10(6L)
3VXN	;	1.95	;	HLA-A24 in complex with HIV-1 Nef134-10(wt)
4WU7	;	2.297	;	HLA-A24 in complex with HIV-1 Nef134-8(2F)
4WU5	;	2.4	;	HLA-A24 in complex with HIV-1 Nef134-8(wt)
8ISN	;	2.48	;	HLA-A24 in complex with modified 9mer WT1 peptide
7LGT	;	1.97	;	HLA-B*07:02 in complex with 229E-derived coronavirus nucleocapsid peptide N75-83
7LGD	;	2.88	;	HLA-B*07:02 in complex with SARS-CoV-2 nucleocapsid peptide N105-113
6UZP	;	2.08	;	HLA-B*15:01 complexed with a synthetic peptide
6UZQ	;	2.395	;	HLA-B*15:01 complexed with a synthetic peptide
6UZS	;	1.9	;	HLA-B*15:01 complexed with a synthetic peptide
6VB3	;	2.0	;	HLA-B*15:01 complexed with a synthetic peptide
6UZM	;	1.798	;	HLA-B*15:02 complexed with a synthetic peptide
6UZN	;	2.22	;	HLA-B*15:02 complexed with a synthetic peptide
6UZO	;	2.349	;	HLA-B*15:02 complexed with a synthetic peptide
6VB0	;	1.9	;	HLA-B*15:02 complexed with a synthetic peptide
6VB1	;	1.75	;	HLA-B*15:02 complexed with a synthetic peptide
6VB2	;	1.41	;	HLA-B*15:02 complexed with a synthetic peptide
6VB4	;	2.334	;	HLA-B*15:02 complexed with a synthetic peptide
6VB5	;	2.15	;	HLA-B*15:02 complexed with a synthetic peptide
6VB6	;	2.15	;	HLA-B*15:02 complexed with a synthetic peptide
6VB7	;	2.1	;	HLA-B*15:02 complexed with a synthetic peptide
6VIU	;	2.334	;	HLA-B*15:02 complexed with a synthetic peptide
4XXC	;	1.426	;	HLA-B*1801 in complex with a self-peptide, DELEIKAY
4JQV	;	1.5	;	HLA-B*18:01 in complex with Epstein-Barr virus BZLF1-derived peptide (residues 173-180)
1JGE	;	2.1	;	HLA-B*2705 bound to nona-peptide m9
1JGD	;	1.9	;	HLA-B*2709 bound to deca-peptide s10R
1K5N	;	1.09	;	HLA-B*2709 BOUND TO NONA-PEPTIDE M9
7T0L	;	3.0	;	HLA-B*27:05 in complex with the pan-HLA-Ia monoclonal antibody W6/32
6VPZ	;	2.1	;	HLA-B*27:05 presenting an HIV-1 11mer peptide
6VQE	;	1.77	;	HLA-B*27:05 presenting an HIV-1 13mer peptide
6VQ2	;	2.25	;	HLA-B*27:05 presenting an HIV-1 14mer peptide
6VQZ	;	2.25	;	HLA-B*27:05 presenting an HIV-1 6mer peptide
6VQY	;	2.57	;	HLA-B*27:05 presenting an HIV-1 7mer peptide
6VQD	;	1.88	;	HLA-B*27:05 presenting an HIV-1 8mer peptide
1SYV	;	1.7	;	HLA-B*4405 complexed to the dominant self ligand EEFGRAYGF
4JQX	;	1.9	;	HLA-B*44:03 in complex with Epstein-Barr virus BZLF1-derived peptide (residues 169-180)
3UPR	;	1.999	;	HLA-B*57:01 complexed to pep-V and Abacavir
6D2R	;	1.83	;	HLA-B*57:01 presenting GSFDYSGVHLW
6D2T	;	1.9	;	HLA-B*57:01 presenting LALLTGVRW
6D2B	;	2.04	;	HLA-B*57:01 presenting LSDSTARDVTW
5VUD	;	2.0	;	HLA-B*57:01 presenting LSSPVTKSW
5VUE	;	1.8	;	HLA-B*57:01 presenting LTVQVARVW
5VUF	;	1.9	;	HLA-B*57:01 presenting LTVQVARVY
5T6W	;	1.9	;	HLA-B*57:01 presenting SSTRGISQLW
6V2O	;	1.27	;	HLA-B*57:01 presenting the peptide ASLNLPAVSW
6D29	;	1.88	;	HLA-B*57:01 presenting TSMSFVPRPW
5T6Y	;	1.76	;	HLA-B*57:01 presenting TSTFEDVKILAF
5T6X	;	1.686	;	HLA-B*57:01 presenting TSTTSVASSW
3VRJ	;	1.9	;	HLA-B*57:01-LTTKLTNTNI in complex with abacavir
3VRI	;	1.6	;	HLA-B*57:01-RVAQLENVYI in complex with abacavir
5VVP	;	2.0	;	HLA-B*57:03 presenting LSSPVTKSW
5VWD	;	1.8	;	HLA-B*57:03 presenting LTVQVARVW
6V2P	;	1.3	;	HLA-B*57:03 presenting the peptide ASLNLPAVSW
6V2Q	;	1.6	;	HLA-B*57:03 presenting the peptide LSSPVTKSF
5VWH	;	1.648	;	HLA-B*58:01 presenting LSSPVTKSW
5VWJ	;	2.0	;	HLA-B*58:01 presenting LTVQVARVW
5VWF	;	1.8	;	HLA-B*58:03 presenting LTVQVARVY
5W69	;	2.8	;	HLA-C*06:02 presenting ARFNDLRFV
5W6A	;	1.74	;	HLA-C*06:02 presenting ARTELYRSL
5W67	;	2.3	;	HLA-C*06:02 presenting VRSRR(ABA)LRL
4NT6	;	1.84	;	HLA-C*0801 Crystal Structure
4I0P	;	3.2	;	HLA-DO in complex with HLA-DM
6MFG	;	2.0	;	HLA-DQ2-glia-alpha1
6MFF	;	2.6	;	HLA-DQ2-glia-omega1
8W83	;	2.818	;	HLA-DQ2.5-alpha1 gliadin peptide in complex with DQN0344AE02
8W84	;	2.105	;	HLA-DQ2.5-alpha2 gliadin peptide in complex with DQN0344AE02
8W86	;	2.236	;	HLA-DQ2.5-B/C hordein peptide in complex with DQN0385AE02
8W85	;	2.769	;	HLA-DQ2.5-gamma2 gliadin peptide in complex with DQN0385AE01
1IIE	;		;	HLA-DR ANTIGENS ASSOCIATED INVARIANT CHAIN
1AQD	;	2.45	;	HLA-DR1 (DRA, DRB1 0101) HUMAN CLASS II HISTOCOMPATIBILITY PROTEIN (EXTRACELLULAR DOMAIN) COMPLEXED WITH ENDOGENOUS PEPTIDE
3QXA	;	2.712	;	HLA-DR1 bound with CLIP peptide
1SJH	;	2.25	;	HLA-DR1 complexed with a 13 residue HIV capsid peptide
1SJE	;	2.45	;	HLA-DR1 complexed with a 16 residue HIV capsid peptide bound in a hairpin conformation
1T5W	;	2.4	;	HLA-DR1 in complex with a synthetic peptide (AAYSDQATPLLLSPR)
1T5X	;	2.5	;	HLA-DR1 in complex with a synthetic peptide (AAYSDQATPLLLSPR) and the superantigen SEC3-3B2
4X5X	;	3.199	;	HLA-DR1 mutant bN82A with covalently linked CLIP106-120(M107W)
4X5W	;	1.34	;	HLA-DR1 with CLIP102-120(M107W)
4AH2	;	2.36	;	HLA-DR1 with covalently linked CLIP106-120 in canonical orientation
4AEN	;	2.2	;	HLA-DR1 with covalently linked CLIP106-120 in reversed orientation
6QZA	;	3.09	;	HLA-DR1 with GMF Influenza PB1 Peptide
6QZD	;	2.66	;	HLA-DR1 with SGP Influenza Matrix Peptide
6QZC	;	1.64	;	HLA-DR1 with the QAR Peptide
6BIJ	;	2.1	;	HLA-DRB1 in complex with citrullinated fibrinogen peptide
6BIL	;	2.4	;	HLA-DRB1 in complex with citrullinated fibrinogen peptide
6BIZ	;	2.1	;	HLA-DRB1 in complex with citrullinated Histone 2B peptide
6BIV	;	2.9	;	HLA-DRB1 in complex with citrullinated LL37 peptide
6BIX	;	2.2	;	HLA-DRB1 in complex with citrullinated LL37 peptide
6BIR	;	2.3	;	HLA-DRB1 in complex with citrullinated Vimentin peptide
6BIY	;	2.05005	;	HLA-DRB1 in complex with Histone 2B peptide
6BIN	;	2.50001	;	HLA-DRB1 in complex with Type II collagen peptide
6ATZ	;	2.7	;	HLA-DRB1*1402 in complex with citrullinated fibrinogen peptide
6ATI	;	1.98	;	HLA-DRB1*1402 in complex with Vimentin-64Cit59-71
6ATF	;	1.9	;	HLA-DRB1*1402 in complex with Vimentin59-71
8TBP	;	3.12621	;	HLA-DRB1*15:01 in complex with smith antigen
7P4B	;	1.72	;	HLA-E*01:03 in complex with IL9
7P49	;	2.05	;	HLA-E*01:03 in complex with Mtb14
6GH1	;	2.1	;	HLA-E*01:03 in complex with Mtb44
6GL1	;	2.623	;	HLA-E*01:03 in complex with the HIV epitope, RL9HIV
6GH4	;	2.16	;	HLA-E*01:03 in complex with the Mtb44 peptide variant: Mtb44*P2-Gln.
6GGM	;	2.734	;	HLA-E*01:03 in complex with the Mtb44 peptide variant: Mtb44*P2-Phe.
6GHN	;	2.542	;	HLA-E*01:03 in complex with the Mtb44 peptide variant: Mtb44*P9-Phe.
6PX6	;	3.0	;	HLA-TCR complex
6PY2	;	2.82543	;	HLA-TCR complex
3V5K	;	2.31	;	HLA2.1 KVAELVWFL
5L0M	;	2.197	;	hLRH-1 DNA Binding Domain - 12bp Oct4 promoter complex
4K2E	;	1.8	;	HlyU from Vibrio cholerae N16961
7QZV	;		;	Hm-AMP2
7QZW	;		;	Hm-AMP8
6OVC	;		;	hMcl1 inhibitor complex
4YT2	;	1.65	;	Hmd II from Methanocaldococcus jannaschii
6HUY	;	2.25	;	HmdII from Desulfurobacterium thermolithotrophum reconstitued with Fe-guanylylpyridinol (FeGP) cofactor and co-crystallized with methenyl-tetrahydrofolate form A
6HUZ	;	1.85	;	HmdII from Desulfurobacterium thermolithotrophum reconstituted with Fe-guanylylpyridinol (FeGP) cofactor and co-crystallized with methenyl-tetrahydrofolate form B
6HUX	;	2.5	;	HmdII from Methanocaldococcus jannaschii reconstitued with Fe-guanylylpyridinol (FeGP) cofactor and co-crystallized with methenyl-tetrahydromethanopterin at 2.5 A resolution
4YT5	;	1.9	;	HmdII from Methanocaldococcus jannaschii with bound methylene-tetrahydromethanopterin
1CG7	;		;	HMG PROTEIN NHP6A FROM SACCHAROMYCES CEREVISIAE
6HR7	;	2.4	;	HMG-CoA reductase from Methanothermococcus thermolithotrophicus apo form at 2.4 A resolution
6HR8	;	2.9	;	HMG-CoA reductase from Methanothermococcus thermolithotrophicus in complex with NADPH at 2.9 A resolution
1R7I	;	2.21	;	HMG-CoA Reductase from P. mevalonii, native structure at 2.2 angstroms resolution.
4I56	;	1.5	;	HMG-CoA reductase from pseudomonas mevalonii complexed with dithio-HMG-coa
1R31	;	2.1	;	HMG-CoA reductase from Pseudomonas mevalonii complexed with HMG-CoA
4I4B	;	1.7	;	HMG-CoA Reductase from Pseudomonas mevalonii complexed with NAD and intermediate hemiacetal form of HMG-CoA
2FA3	;	2.52	;	HMG-CoA synthase from Brassica juncea in complex with acetyl-CoA and acetyl-cys117.
2F9A	;	2.51	;	HMG-CoA synthase from Brassica juncea in complex with F-244
2FA0	;	2.49	;	HMG-CoA synthase from Brassica juncea in complex with HMG-CoA and covalently bound to HMG-CoA
2F82	;	2.1	;	HMG-CoA synthase from Brassica juncea in the apo-form
2HDB	;	2.2	;	HMG-CoA synthase from Enterococcus faecalis. Mutation alanine 110 to glycine
1E7J	;		;	HMG-D complexed to a bulge DNA
2LY4	;		;	HMGB1-facilitated p53 DNA binding occurs via HMG-box/p53 transactivation domain interaction and is regulated by the acidic tail
8DJM	;	3.23	;	HMGCR-UBIAD1 Complex State 1
8DJK	;	3.33	;	HMGCR-UBIAD1 Complex State 2
3NM9	;	2.85	;	HMGD(M13A)-DNA complex
5KSZ	;	2.5	;	hMiro EF hand and cGTPase domains in the GMPPCP-bound state
5KTY	;	2.522	;	hMiro EF hand and cGTPase domains, GDP and Ca2+ bound state
5KSP	;	2.162	;	hMiro1 C-domain GDP Complex C2221 Crystal Form
5KSY	;	2.482	;	hMiro1 C-domain GDP Complex P41212 Crystal Form
5KSO	;	2.25	;	hMiro1 C-domain GDP-Pi Complex P3121 Crystal Form
5KU1	;	2.501	;	hMiro1 EF hand and cGTPase domains in the GDP-bound state
5KUT	;	1.693	;	hMiro2 C-terminal GTPase domain, GDP-bound
5I8O	;	1.8	;	HMM5 Fab in complex with disaccharide
6FTH	;	1.46851	;	HMO binding ABC-transporter associated Solute Binding Protein, Blon_2347 From Bifidobacterium longum infantis ATCC 15697
4FVC	;	1.75	;	HmoB structure with heme
6OC7	;	1.296	;	HMP42 Fab in complex with Protein G
8EAY	;	3.33	;	HMPV F complex with 4I3 Fab
8EBP	;	3.38	;	HMPV F dimer bound to RSV-199 Fab
8E2U	;	3.48	;	HMPV F monomer bound to RSV-199 Fab
8TW3	;	2.9	;	hMPV fusion protein complexed with single domain antibodies sdHMPV16 and sdHMPV12
2KAR	;		;	HNE-dG adduct mismatched with dA in acidic solution
2KAS	;		;	HNE-dG adduct mismatched with dA in basic solution
1G2Y	;	1.0	;	HNF-1ALPHA DIMERIZATION DOMAIN, WITH SELENOMETHIONINE SUBSTITUED AT LEU 12
1M7W	;	2.8	;	HNF4a ligand binding domain with bound fatty acid
6CHT	;	3.174	;	HNF4alpha in complex with the corepressor EBP1 fragment
7MPZ	;	2.04	;	HNH Nuclease Domain from G. stearothermophilus Cas9
8F43	;	1.37	;	HNH Nuclease Domain from G. stearothermophilus Cas9, K597A mutant
6O56	;	1.9	;	HNH Nuclease from S. pyogenes Cas9
3C6X	;	1.05	;	HNL from Hevea brasiliensis to atomic resolution
3C6Y	;	1.25	;	HNL from Hevea brasiliensis to atomic resolution
3C6Z	;	1.05	;	HNL from Hevea brasiliensis to atomic resolution
3C70	;	1.05	;	HNL from Hevea brasiliensis to atomic resolution
1HA1	;	1.75	;	HNRNP A1 (RBD1,2) FROM HOMO SAPIENS
5V16	;		;	HnRNP A1 Alters the Conformation of a Conserved Enterovirus IRES Domain to Stimulate Viral Translation
5V17	;		;	HnRNP A1 Alters the Conformation of a Conserved Enterovirus IRES Domain to Stimulate Viral Translation
6J60	;	0.96	;	hnRNP A1 reversible amyloid core GFGGNDNFG (residues 209-217)
5MPL	;		;	hnRNP A1 RRM2 in complex with 5'-UCAGUU-3' RNA
5ZGL	;	0.95	;	hnRNP A1 segment GGGYGGS (residues 234-240)
5TBX	;	1.767	;	hnRNP A18 RNA Recognition Motif
7WM3	;	1.62	;	hnRNP A2/B1 RRMs in complex with single-stranded DNA
8HNI	;	2.644	;	hnRNP A2/B1 RRMs in complex with telomeric DNA
5ZGD	;	1.401	;	hnRNPA1 reversible amyloid core GFGGNDNFG (residues 209-217) determined by X-ray
8DU2	;	3.3	;	HnRNPA2 D290V LCD PM1
8DUW	;	3.2	;	HnRNPA2 D290V LCD PM2
8EC7	;	3.9	;	HnRNPA2 D290V LCD PM3
6WQK	;	3.1	;	hnRNPA2 Low complexity domain (LCD) determined by cryoEM
7CRE	;	3.0	;	hnRNPK KH3 domain in complex with a ssDNA fragment from the SIRLOIN element
7CRU	;	2.8	;	hnRNPK NLS in complex with Importin alpha 1 (KPNA2)
4XBA	;	1.5	;	Hnt3
4YKL	;	2.25	;	Hnt3 in complex with DNA and guanosine
6KGY	;	2.9	;	HOCl-induced flavoprotein disulfide reductase RclA from Escherichia coli
8JTV	;	3.77	;	hOCT1 in complex with metformin in inward occluded conformation
8JTT	;	3.87	;	hOCT1 in complex with metformin in outward occluded conformation
8JTS	;	4.14	;	hOCT1 in complex with metformin in outward open conformation
8JTX	;	3.28	;	hOCT1 in complex with nb5660 in inward facing fully open conformation
8JTW	;	3.23	;	hOCT1 in complex with nb5660 in inward facing partially open 1 conformation
8JTY	;	3.26	;	hOCT1 in complex with nb5660 in inward facing partially open 2 conformation
8JU0	;	2.98	;	hOCT1 in complex with spironolactone in inward facing occluded conformation
8JTZ	;	3.27	;	hOCT1 in complex with spironolactone in outward facing partially occluded conformation
6RTQ	;	2.0	;	Hoefavidin P61C mutant generates a stabilized octamer
4AGA	;	1.5	;	Hofmeister effects of ionic liquids in protein crystallization: direct and water-mediated interactions
1LWY	;	2.01	;	hOgg1 Borohydride-Trapped Intermediate without 8-oxoguanine
8EAZ	;	3.08	;	HOIL-1/E2-Ub/Ub transthiolation complex
6GZY	;	2.15	;	HOIP-fragment5 complex
6KC5	;	1.543	;	HOIP-HOIPIN1 complex
6KC6	;	2.123	;	HOIP-HOIPIN8 complex
5YIL	;	3.0	;	Hoisting-loop in bacterial multidrug exporter AcrB is a highly flexible hinge that enables the large motion of the subdomains
1HJP	;	2.5	;	HOLLIDAY JUNCTION BINDING PROTEIN RUVA FROM E. COLI
1OB8	;	1.8	;	Holliday Junction Resolving Enzyme
1OB9	;	2.0	;	Holliday Junction Resolving Enzyme
1L4J	;	1.85	;	Holliday Junction TCGGTACCGA with Na and Ca Binding Sites.
6GDH	;	2.85	;	Holliday Junctions formed from Telomeric DNA
6GDN	;	3.0	;	Holliday Junctions formed from Telomeric DNA
6GDS	;	2.95	;	Holliday Junctions formed from Telomeric DNA
1JKF	;	2.4	;	Holo 1L-myo-inositol-1-phosphate Synthase
5H9H	;	2.5	;	holo acyl carrier protein (holo-ACP) from Helicobacter pylori
2BGS	;	1.64	;	HOLO ALDOSE REDUCTASE FROM BARLEY
2EUH	;	2.6	;	HOLO FORM OF A NADP DEPENDENT ALDEHYDE DEHYDROGENASE COMPLEX WITH NADP+
2N8Y	;		;	Holo form of Calmodulin-Like Domain of Human Non-Muscle alpha-actinin 1
3TEN	;	2.6	;	Holo form of carbon disulfide hydrolase
1IU7	;	1.8	;	HOLO FORM OF COPPER-CONTAINING AMINE OXIDASE FROM ARTHROBACTER GLOBIFORMIS
7WIR	;	1.5	;	Holo form of N381A mutant of copper amine oxidase from Arthrobacter globiformis
6JWF	;	1.3	;	Holo form of Pyranose Dehydrogenase PQQ domain from Coprinopsis cinerea
7RED	;	1.53	;	Holo Hemophilin from A. baumannii
6AZU	;	2.822	;	Holo IDO1 crystal structure
7EZ2	;	3.05	;	Holo L-16 ScaI Tetrahymena ribozyme
7WH9	;	2.803	;	holo structure of emodin 1-OH O-methyltransferase complex with emodin and S-Adenosyl-L-homocysteine
7RNQ	;	2.102	;	Holo structure of engineered TrpB, 2B9-H275E, from Pyrococcus furiosus in the extended-open conformation
4XDZ	;	1.15	;	Holo structure of ketol-acid reductoisomerase from Ignisphaera aggregans
2JL4	;	2.3	;	Holo structure of Maleyl Pyruvate Isomerase, a bacterial glutathione- s-transferase in Zeta class
2MR8	;		;	holo structure of the Peptidyl Carrier Protein Domain 7 of the teicoplanin producing Non-ribosomal peptide synthetase
5DVZ	;	1.69	;	Holo TrpB from Pyrococcus furiosus
2EZ1	;	1.9	;	Holo tyrosine phenol-lyase from Citrobacter freundii at pH 8.0
6Q1D	;	1.79	;	Holo YfeA reconstituted by zinc soaking
1F7T	;	1.8	;	HOLO-(ACYL CARRIER PROTEIN) SYNTHASE AT 1.8A
1F7L	;	1.5	;	HOLO-(ACYL CARRIER PROTEIN) SYNTHASE IN COMPLEX WITH COENZYME A AT 1.5A
1F80	;	2.3	;	HOLO-(ACYL CARRIER PROTEIN) SYNTHASE IN COMPLEX WITH HOLO-(ACYL CARRIER PROTEIN)
6HQI	;	1.85	;	holo-form of polyphenol oxidase from Solanum lycopersicum
7CDL	;	1.85	;	holo-methanol dehydrogenase (MDH) with Cys131-Cys132 reduced from Methylococcus capsulatus (Bath)
2Y3Y	;	2.39	;	Holo-Ni(II) HpNikR is a symmetric tetramer containing four canonic square-planar Ni(II) ions at physiological pH
6W4X	;	3.6	;	Holocomplex of E. coli class Ia ribonucleotide reductase with GDP and TTP
2VBI	;	2.75	;	Holostructure of pyruvate decarboxylase from Acetobacter pasteurianus
2MOK	;		;	holo_FldA
2M6S	;		;	Holo_YqcA
1QRY	;		;	Homeobox protein VND (ventral nervous system defective protein)
5LUX	;	3.23	;	Homeobox transcription factor CDX1 bound to methylated DNA
5LTY	;	2.66	;	Homeobox transcription factor CDX2 bound to methylated DNA
2LFB	;		;	HOMEODOMAIN FROM RAT LIVER LFB1/HNF1 TRANSCRIPTION FACTOR, NMR, 20 STRUCTURES
1FJL	;	2.0	;	HOMEODOMAIN FROM THE DROSOPHILA PAIRED PROTEIN BOUND TO A DNA OLIGONUCLEOTIDE
1DDW	;	1.7	;	HOMER EVH1 DOMAIN UNLIGANDED
3R3P	;	2.2	;	Homing Endonuclease I-Bth0305I Catalytic Domain
1G9Y	;	2.05	;	HOMING ENDONUCLEASE I-CREI / DNA SUBSTRATE COMPLEX WITH CALCIUM
1IPP	;	2.2	;	HOMING ENDONUCLEASE/DNA COMPLEX
5KKQ	;	1.744	;	Homo sapiens CCCTC-binding factor (CTCF) ZnF3-7 and DNA complex structure
5K5H	;	3.108	;	Homo sapiens CCCTC-binding factor (CTCF) ZnF4-7 and DNA complex structure
5K5J	;	2.287	;	Homo sapiens CCCTC-binding factor (CTCF) ZnF5-8 and DNA complex structure in space group P41212
5K5I	;	2.19	;	Homo sapiens CCCTC-binding factor (CTCF) ZnF5-8 and DNA complex structure in space group P65
5K5L	;	3.125	;	Homo sapiens CCCTC-binding factor (CTCF) ZnF6-8 and H19 sequence DNA complex structure
6DE4	;	2.411	;	Homo sapiens dihydrofolate reductase complexed with beta-NADPH and 3'-[(2R)-4-(2,4-diamino-6-ethylphenyl)but-3-yn-2-yl]-5'-methoxy-[1,1'-biphenyl]-4-carboxylic acid
4Z49	;	1.7	;	Homo Sapiens Fatty Acid Synthetase, Thioesterase Domain at 1.7 Angstroms Resolution
6VCU	;	1.69	;	Homo sapiens FKBP12 protein bound with APX879 in P32 space group
8CR2	;	4.2	;	Homo sapiens Get1/Get2 heterotetramer (a3' deletion variant) in complex with a Get3 dimer
8CR1	;	3.2	;	Homo sapiens Get1/Get2 heterotetramer in complex with a Get3 dimer
8CQZ	;	2.8	;	Homo sapiens Get3 in complex with the Get1 cytoplasmic domain
7X1O	;	2.04	;	Homo sapiens Prolyl-tRNA Synthetase (HsPRS) in Complex with double inhibitors HF and L95
7X09	;	1.7	;	Homo sapiens Prolyl-tRNA Synthetase (HsPRS) in Complex with inhibitors L95 and Halofuginone
7F98	;	1.999	;	Homo sapiens Prolyl-tRNA Synthetase (HsPRS) in Complex with L-proline and compound L95
7F9B	;	1.995	;	Homo sapiens Prolyl-tRNA Synthetase (HsPRS) in Complex with L-proline and compound L95
7F99	;	1.979	;	Homo sapiens Prolyl-tRNA Synthetase (HsPRS) in Complex with L-proline and compound L96
7F9C	;	2.196	;	Homo sapiens Prolyl-tRNA Synthetase (HsPRS) in Complex with L-proline and compound L96
7F9D	;	2.497	;	Homo sapiens Prolyl-tRNA Synthetase (HsPRS) in Complex with L-proline and compound L96
7F9A	;	1.999	;	Homo sapiens Prolyl-tRNA Synthetase (HsPRS) in Complex with L-proline and compound L97
6WN7	;	1.25	;	Homo sapiens S100A5
6SO5	;	4.2	;	Homo sapiens WRB/CAML heterotetramer in complex with a TRC40 dimer
8GBC	;		;	Homo sapiens Zalpha mutant - N173S
8GBD	;		;	Homo sapiens Zalpha mutant - P193A
1GHC	;		;	HOMO-AND HETERONUCLEAR TWO-DIMENSIONAL NMR STUDIES OF THE GLOBULAR DOMAIN OF HISTONE H1: FULL ASSIGNMENT, TERTIARY STRUCTURE, AND COMPARISON WITH THE GLOBULAR DOMAIN OF HISTONE H5
5XN5	;	2.002	;	Homo-dimer crystal structure of geranylgeranyl diphosphate synthases 1 from Oryza sativa
5B3I	;	1.89	;	Homo-dimeric structure of cytochrome c' from Thermophilic Hydrogenophilus thermoluteolus
1OKK	;	2.05	;	HOMO-HETERODIMERIC COMPLEX OF THE SRP GTPASES
8GI1	;	3.65	;	Homo-octamer of PbuCsx28 protein
3IVS	;	2.24	;	Homocitrate Synthase Lys4
3IVT	;	2.67	;	Homocitrate Synthase Lys4 bound to 2-OG
3IVU	;	2.72	;	Homocitrate Synthase Lys4 bound to 2-OG
3MI3	;	2.38	;	Homocitrate Synthase Lys4 bound to Lysine
8ENO	;	2.71	;	Homocitrate-deficient nitrogenase MoFe-protein from A. vinelandii nifV knockout in complex with NafT
8ENN	;	2.58	;	Homocitrate-deficient nitrogenase MoFe-protein from Azotobacter vinelandii nifV knockout
7LXG	;	2.2	;	Homocitrullinated beta-lactamase OXA-48
4PIY	;	1.6	;	Homocysteine bound Cysteine Dioxygenase C93A variant at pH 6.2
4PIZ	;	1.4	;	Homocysteine-bound Cysteine Dioxygenase at pH 6.2
2BZY	;	2.5	;	Homodimer of CrkL-SH3C domain
4XRM	;	1.6	;	homodimer of TALE type homeobox transcription factor MEIS1 complexes with specific DNA
5V8K	;	2.2	;	Homodimeric reaction center of H. modesticaldum
4TYU	;	2.13	;	Homodimeric Single Domain Antibody (sdAb) against Staphylococcal enterotoxin B (SEB)
4U7S	;	2.07	;	Homodimeric Single Domain Antibody (sdAb) against Staphylococcal enterotoxin B (SEB) Crystallized for 5 months
4U05	;	2.5	;	Homodimeric Single Domain Antibody (sdAb) against Staphylococcal enterotoxin B (SEB) S74A Variant
7ZVJ	;	2.61	;	Homodimeric structure of LARGE1
6YUZ	;	2.8	;	Homodimeric structure of the rBAT complex
2M0B	;		;	Homodimeric transmembrane domain of the human receptor tyrosine kinase ErbB1 (EGFR, HER1) in micelles
5MYA	;	2.9	;	Homodimerization of Tie2 Fibronectin-like domains 1-3 in space group C2
5MYB	;	2.6	;	Homodimerization of Tie2 Fibronectin-like domains 2 and 3 in space group P21
5AA6	;	2.26	;	Homohexameric Structure of the second Vanadate-Dependent Bromoperoxidase (AnII) from Ascophyllum nodosum
1PBK	;	2.5	;	HOMOLOGOUS DOMAIN OF HUMAN FKBP25
4V61	;	9.4	;	Homology model for the Spinach chloroplast 30S subunit fitted to 9.4A cryo-EM map of the 70S chlororibosome.
8SYF	;	19.0	;	Homology model of Acto-HMM complex in ADP-state. Chicken smooth muscle HMM and chicken pectoralis actin
3IYS	;	11.3	;	Homology model of avian polyomavirus asymmetric unit
4BIQ	;	6.09	;	Homology model of coxsackievirus A7 (CAV7) empty capsid proteins.
4BIP	;	8.23	;	Homology model of coxsackievirus A7 (CAV7) full capsid proteins.
3J0G	;	4.8	;	Homology model of E3 protein of Venezuelan Equine Encephalitis Virus TC-83 strain fitted with a cryo-EM map
3J0A	;	26.0	;	Homology model of human Toll-like receptor 5 fitted into an electron microscopy single particle reconstruction
7QIO	;	9.0	;	Homology model of myosin neck domain in skeletal sarcomere
7P3X	;	9.1	;	Homology model of the full-length AP-3 complex in a compact open conformation
7P3Z	;	10.5	;	Homology model of the full-length AP-3 complex in a stretched open conformation
7P3Y	;	10.1	;	Homology model of the full-length AP-3 complex in an intermediate open conformation
7NEP	;	10.2	;	Homology model of the in situ actomyosin complex from the A-band of mouse psoas muscle sarcomere in the rigor state
1TRJ	;	11.7	;	Homology Model of Yeast RACK1 Protein fitted into 11.7A cryo-EM map of Yeast 80S Ribosome
1DGV	;		;	HOMOLOGY-BASED MODEL OF APO CIB (CALCIUM-AND INTEGRIN-BINDING PROTEIN)
1DGU	;		;	HOMOLOGY-BASED MODEL OF CALCIUM-SATURATED CIB (CALCIUM-AND INTEGRIN-BINDING PROTEIN)
8P3T	;	3.39	;	Homomeric GluA1 in tandem with TARP gamma-3, desensitized conformation 1
8P3U	;	3.77	;	Homomeric GluA1 in tandem with TARP gamma-3, desensitized conformation 2
8P3V	;	3.53	;	Homomeric GluA1 in tandem with TARP gamma-3, desensitized conformation 3
8P3W	;	3.53	;	Homomeric GluA1 in tandem with TARP gamma-3, desensitized conformation 4
8P3X	;	3.36	;	Homomeric GluA2 flip R/G-edited Q/R-edited F231A mutant in tandem with TARP gamma-2, desensitized conformation 1
8P3Z	;	3.46	;	Homomeric GluA2 flip R/G-edited Q/R-edited F231A mutant in tandem with TARP gamma-2, desensitized conformation 2
8P3Y	;	3.55	;	Homomeric GluA2 flip R/G-edited Q/R-edited F231A mutant in tandem with TARP gamma-2, desensitized conformation 3
8PIV	;	3.46	;	Homomeric GluA2 flip R/G-unedited Q/R-edited F231A mutant in tandem with TARP gamma-2, desensitized conformation 1
8P3S	;	2.95	;	Homomeric GluA2 flip R/G-unedited Q/R-edited F231A mutant in tandem with TARP gamma-2, desensitized conformation 2
8P3Q	;	2.95	;	Homomeric GluA2 flip R/G-unedited Q/R-edited F231A mutant in tandem with TARP gamma-2, desensitized conformation 3
1K5K	;		;	Homonuclear 1H Nuclear Magnetic Resonance Assignment and Structural Characterization of HIV-1 Tat Mal Protein
1JFW	;		;	HOMONUCLEAR AND HETERONUCLEAR 1H-13C NUCLEAR MAGNETIC RESONANCE ASSIGNMENT AND STRUCTURAL CHARACTERIZATION OF A HIV-1 TAT PROTEIN
8EBO	;	1.98	;	Homopurine parallel G-quadruplex from human chromosome 7 stabilized by K+ ions
1EBU	;	2.6	;	HOMOSERINE DEHYDROGENASE COMPLEX WITH NAD ANALOGUE AND L-HOMOSERINE
1EBF	;	2.3	;	HOMOSERINE DEHYDROGENASE FROM S. CEREVISIAE COMPLEX WITH NAD+
3JSA	;	1.95	;	Homoserine dehydrogenase from Thermoplasma volcanium complexed with NAD
2EJW	;	1.7	;	Homoserine Dehydrogenase from Thermus thermophilus HB8
5XDF	;	2.0	;	Homoserine dehydrogenase from Thermus thermophilus HB8 complexed with HSE
6A0S	;	2.0	;	Homoserine dehydrogenase from Thermus thermophilus HB8 complexed with HSE and NADPH
6A0R	;	1.83	;	Homoserine dehydrogenase from Thermus thermophilus HB8 unliganded form
1TVE	;	3.0	;	Homoserine Dehydrogenase in complex with 4-(4-hydroxy-3-isopropylphenylthio)-2-isopropylphenol
1Q7G	;	2.6	;	Homoserine Dehydrogenase in complex with suicide inhibitor complex NAD-5-hydroxy-4-Oxonorvaline
6A0U	;	1.93	;	Homoserine dehydrogenase K195A mutant from Thermus thermophilus HB8 complexed with HSE and NADP+
6A0T	;	1.87	;	Homoserine dehydrogenase K99A mutant from Thermus thermophilus HB8 complexed with HSE and NADP+
5W8P	;	1.69	;	Homoserine transacetylase MetX from Mycobacterium abscessus
5W8O	;	1.47	;	Homoserine transacetylase MetX from Mycobacterium hassiacum
6PUX	;	1.9	;	Homoserine transacetylase MetX from Mycobacterium tuberculosis
7MN3	;		;	Homotarsinin monomer - Htr-M
8GOH	;	1.1	;	Homotetramic Antiparallel Coiled-Coil of 23-residues LacI C-terminal tetramerization helix
8E0L	;	2.1	;	Homotrimeric variant of tcTRP9, BGL06
8E12	;	3.0	;	Homotrimeric variant of tcTRP9, BGL14
8E0M	;	4.0	;	Homotrimeric variant of tcTRP9, BGL15
8E0N	;	3.0	;	Homotrimeric variant of tcTRP9, BGL18
6VLP	;	1.681	;	Hop phytocystatin in space group C2221
6VLQ	;	1.799	;	Hop phytocystatin in space group P22121
7ZU0	;	4.4	;	HOPS tethering complex from yeast
7V4S	;	1.2	;	Horcolin complex with methyl-alpha-mannose
1PRX	;	2.0	;	HORF6 A NOVEL HUMAN PEROXIDASE ENZYME
1A28	;	1.8	;	HORMONE-BOUND HUMAN PROGESTERONE RECEPTOR LIGAND-BINDING DOMAIN
4DWV	;	1.14	;	Horse alcohol dehydrogenase complexed with NAD+ and 2,3,4,5,6-pentafluorobenzyl alcohol
6SUV	;	2.502	;	Horse cytochrome c complexed by octa-anionic calixarene
2O58	;	1.65	;	Horse heart met manganese myoglobin
4TWU	;	1.08	;	Horse heart myoglobin mutant (D44K/D60K/E85K) with Zn-deuteroporphyrin IX
4TWV	;	1.06	;	Horse heart myoglobin mutant (K45E/K63E/K96E) with Zn-deuteroporphyrin IX
5Z7E	;	1.8	;	Horse Heart Myoglobin Mutant - H93M
5Z7F	;	1.9	;	Horse Heart Myoglobin Mutant -V68A/I107Y-Sulfide Derivative
2FRI	;	1.6	;	Horse Heart Myoglobin, Nitrite Adduct, Co-crystallized
2FRF	;	1.2	;	Horse Heart Myoglobin, Nitrite Adduct, Crystal Soak
3RJN	;	1.9	;	Horse heart myoglobin: D44K/D60K mutant with zinc (II) -deuteroporphyrin dimethyl ester
5LG2	;	2.22	;	Horse L type ferritin iron loaded for 60 minutes
5VN1	;	1.25	;	horse liver alcohol dehydrogenae complexed with NADH (R,S)-N-1-methylhexylformamide
3OQ6	;	1.2	;	Horse liver alcohol dehydrogenase A317C mutant complexed with NAD+ and 2,3,4,5,6-pentafluorobenzyl alcohol
1QLJ	;	2.8	;	HORSE LIVER ALCOHOL DEHYDROGENASE APO ENZYME DOUBLE MUTANT OF GLY 293 ALA AND PRO 295 THR
1YE3	;	1.59	;	HORSE LIVER ALCOHOL DEHYDROGENASE APOENZYME
1QLH	;	2.07	;	HORSE LIVER ALCOHOL DEHYDROGENASE COMPLEXED TO NAD DOUBLE MUTANT OF GLY 293 ALA AND PRO 295 THR
1BTO	;	2.0	;	HORSE LIVER ALCOHOL DEHYDROGENASE COMPLEXED TO NADH AND (1S,3R)3-BUTYLTHIOLANE 1-OXIDE
3BTO	;	1.66	;	HORSE LIVER ALCOHOL DEHYDROGENASE COMPLEXED TO NADH AND (1S,3S)3-BUTYLTHIOLANE 1-OXIDE
1LDY	;	2.5	;	HORSE LIVER ALCOHOL DEHYDROGENASE COMPLEXED TO NADH AND CYCLOHEXYL FORMAMIDE (CXF)
1LDE	;	2.5	;	HORSE LIVER ALCOHOL DEHYDROGENASE COMPLEXED TO NADH AND N-FORMYL PIPERDINE
5VJ5	;	1.9	;	Horse Liver Alcohol Dehydrogenase Complexed with 1,10-Phenanthroline
5VJG	;	1.9	;	horse liver alcohol dehydrogenase complexed with 2,2'bipyridine
5VKR	;	1.8	;	Horse liver alcohol dehydrogenase complexed with adenosine-5-diphosphoribose
4DXH	;	1.12	;	Horse liver alcohol dehydrogenase complexed with NAD+ and 2,2,2-trifluoroethanol
7UDD	;	1.1	;	Horse liver alcohol dehydrogenase complexed with NAD+ and 2,2,2-trifluoroethanol at 150 K
1MG0	;	1.8	;	Horse Liver Alcohol Dehydrogenase Complexed With NAD+ and 2,3-Difluorobenzyl Alcohol
1N92	;	1.47	;	Horse Liver Alcohol Dehydrogenase Complexed with NAD+ and 4-Iodopyrazole
5VL0	;	1.2	;	horse liver alcohol dehydrogenase complexed with NADH and N-benzyformamide
1P1R	;	1.57	;	Horse liver alcohol dehydrogenase complexed with NADH and R-N-1-methylhexylformamide
6NBB	;	2.9	;	Horse liver alcohol dehydrogenase determined using single-particle cryo-EM at 200 keV
7UHW	;	1.3	;	Horse liver alcohol dehydrogenase G173A, complexed with NAD+ and 2,3,4,5,6-pentafluorobenzyl alcohol at 120 K
7UHX	;	1.3	;	Horse liver alcohol dehydrogenase G173A, complexed with NAD+ and 2,3,4,5,6-pentafluorobenzyl alcohol at 150 K
7UHV	;	1.3	;	Horse liver alcohol dehydrogenase G173A, complexed with NAD+ and 2,3,4,5,6-pentafluorobenzyl alcohol at 50 K
1QV7	;	1.8	;	HORSE LIVER ALCOHOL DEHYDROGENASE HIS51GLN/LYS228ARG MUTANT COMPLEXED WITH NAD+ AND 2,3-DIFLUOROBENZYL ALCOHOL
1QV6	;	1.8	;	HORSE LIVER ALCOHOL DEHYDROGENASE HIS51GLN/LYS228ARG MUTANT COMPLEXED WITH NAD+ AND 2,4-DIFLUOROBENZYL ALCOHOL
7RM6	;	1.43	;	Horse liver alcohol dehydrogenase in complex with NADH and N-cylcohexyl formamide
1MGO	;	1.2	;	Horse Liver Alcohol Dehydrogenase Phe93Ala Mutant
1JU9	;	2.0	;	HORSE LIVER ALCOHOL DEHYDROGENASE VAL292SER MUTANT
1N8K	;	1.13	;	Horse Liver Alcohol Dehydrogenase Val292Thr Mutant Complexed to NAD+ and Pyrazole
7UEI	;	1.2	;	Horse liver alcohol dehydrogenase with NAD and pentafluorobenzyl alcohol at 100 K, 1.2 A, crystal 16
7UEJ	;	1.2	;	horse liver alcohol dehydrogenase with NAD and pentafluorobenzyl alcohol at 150 K
7UDR	;	1.2	;	Horse liver alcohol dehydrogenase with NAD and pentafluorobenzyl alcohol at 25 K
7UEC	;	1.2	;	Horse liver alcohol dehydrogenase with NAD and pentafluorobenzyl alcohol at 50 K
7UEE	;	1.2	;	Horse liver alcohol dehydrogenase with NAD and pentafluorobenzyl alcohol at 75 K
7UEF	;	1.2	;	Horse liver alcohol dehydrogenase with NAD and pentafluorobenzyl alcohol at 85 K
7UDE	;	1.1	;	Horse liver alcohol dehydrogenase with NAD and trifluoroethanol at 125 K
7UA6	;	1.1	;	Horse liver alcohol dehydrogenase with NAD and trifluoroethanol at 25K
7UC9	;	1.1	;	Horse liver alcohol dehydrogenase with NAD and trifluoroethanol at 45 K
7UCA	;	1.1	;	Horse liver alcohol dehydrogenase with NAD and trifluoroethanol at 65 K
7UCU	;	1.1	;	Horse liver alcohol dehydrogenase with NAD and trifluoroethanol at 85K
4XD2	;	1.1	;	Horse liver alcohol dehydrogenase-NADH complex
8G2L	;	1.42	;	Horse liver alcohol dehydrogense His-51 Gln form complexed with NAD+ and 2,2,2-trifluoroethanol
8G4V	;	1.2	;	Horse liver alcohol dehydrogense His-51-Gln form complexed with NAD+ and 2,3,4,5,6-pentafluorobenzyl alcohol
8G2S	;	1.45	;	Horse liver alcohol dehydrogense His-51-Gln form complexed with NAD+ and capric acid
8G2X	;	1.47	;	Horse liver alcohol dehydrogense His-51-Gln form complexed with NAD+ and pyrazole
8G41	;	1.5	;	Horse liver alcohol dehydrogense His-51-Gln form complexed with NADH
8G39	;	1.42	;	Horse liver alcohol dehydrogense His-51-Gln form complexed with NADH and N-cyclohexylformamide
6CXX	;	1.26	;	Horse liver E267H alcohol dehydrogenase complex with 3'-dephosphocoenzyme A
6CY3	;	2.3	;	Horse liver E267N alcohol dehydrogenase complex with 3'-dephosphocoenzyme A
6OWM	;	1.1	;	Horse liver F93W alcohol dehydrogenase complexed with NAD and pentafluorobenzyl alcohol
6OWP	;	1.14	;	Horse liver F93W alcohol dehydrogenase complexed with NAD and trifluoroethanol
6O91	;	1.1	;	Horse liver L57F alcohol dehydrogenase complexed with NAD and pentafluorobenzyl alcohol
6OA7	;	1.1	;	Horse liver L57F alcohol dehydrogenase E complexed with NAD and trifluoroethanol
5KCP	;	1.1	;	horse liver S48T alcohol dehydrogenase complexed with NAD and pentafluorobenzyl alcohol
5KCZ	;	1.14	;	horse liver S48T alcohol dehydrogenase complexed with NAD and trifluoroethanol
2ZLT	;	1.9	;	Horse methemoglobin high salt, pH 7.0
2ZLX	;	2.8	;	Horse methemoglobin high salt, pH 7.0 (66% relative humidity)
2ZLW	;	2.9	;	Horse methemoglobin high salt, pH 7.0 (75% relative humidity)
2ZLV	;	2.0	;	Horse methemoglobin high salt, pH 7.0 (79% relative humidity)
2ZLU	;	2.0	;	Horse methemoglobin high salt, pH 7.0 (88% relative humidity)
1Y8H	;	3.1	;	HORSE METHEMOGLOBIN LOW SALT, PH 7.0
1Y8K	;	2.3	;	Horse methemoglobin low salt, PH 7.0 (88% relative humidity)
1Y8I	;	2.6	;	Horse methemoglobin low salt, PH 7.0 (98% relative humidity)
1HPL	;	2.3	;	HORSE PANCREATIC LIPASE. THE CRYSTAL STRUCTURE AT 2.3 ANGSTROMS RESOLUTION
2KU4	;		;	Horse prion protein
2YLJ	;	1.69	;	Horse Radish Peroxidase, mutant S167Y
5DQF	;	2.15	;	Horse Serum Albumin (ESA) in complex with Cetirizine
4DE6	;	2.18	;	Horse spleen apo-ferritin complex with arachidonic acid
3RAV	;	1.9	;	Horse spleen apo-ferritin with bound Pentobarbital
3RD0	;	2.0	;	Horse spleen apo-ferritin with bound thiopental
2W0O	;	1.5	;	Horse spleen apoferritin
3F32	;	1.7	;	Horse spleen apoferritin
6PXM	;	2.1	;	Horse spleen apoferritin light chain
6RA8	;	2.0	;	Horse spleen apoferritin under 2 kBar of argon
5D5R	;	1.6	;	Horse-heart myoglobin - deoxy state
8DWM	;	2.99	;	Host-guest complex of bleomycin A2 fully bound to CTTAGTTATAACTAAG
1X1K	;	1.1	;	Host-guest peptide (Pro-Pro-Gly)4-(Pro-alloHyp-Gly)-(Pro-Pro-Gly)4
8DW8	;	2.58	;	Host-guest structure of BLMA2 partially bound to 5'-ATTAGTTATAACTAAT-3'
1ZNV	;	2.0	;	How a His-metal finger endonuclease ColE7 binds and cleaves DNA with a transition metal ion cofactor
1BMT	;	3.0	;	HOW A PROTEIN BINDS B12: A 3.O ANGSTROM X-RAY STRUCTURE OF THE B12-BINDING DOMAINS OF METHIONINE SYNTHASE
102L	;	1.74	;	HOW AMINO-ACID INSERTIONS ARE ALLOWED IN AN ALPHA-HELIX OF T4 LYSOZYME
103L	;	1.9	;	HOW AMINO-ACID INSERTIONS ARE ALLOWED IN AN ALPHA-HELIX OF T4 LYSOZYME
104L	;	2.8	;	HOW AMINO-ACID INSERTIONS ARE ALLOWED IN AN ALPHA-HELIX OF T4 LYSOZYME
201L	;	2.0	;	HOW AMINO-ACID INSERTIONS ARE ALLOWED IN AN ALPHA-HELIX OF T4 LYSOZYME
205L	;	2.1	;	HOW AMINO-ACID INSERTIONS ARE ALLOWED IN AN ALPHA-HELIX OF T4 LYSOZYME
1CCF	;		;	How an Epidermal Growth Factor (EGF)-Like Domain Binds Calcium-High Resolution NMR Structure of the Calcium Form of the NH2-Terminal EGF-Like Domain in Coagulation Factor X
2NS7	;	2.4	;	How an in vitro selected peptide mimics the antibiotic tetracycline to induce TET repressor
2NS8	;	2.55	;	How an in vitro selected peptide mimics the antibiotic tetracycline to induce TET repressor
1TFW	;	2.2	;	How CCA is added to the 3' end of immature tRNA without the use of an oligonucleotide template
1TFY	;	3.2	;	How CCA is added to the 3' end of immature tRNA without the use of an oligonucleotide template
1F7A	;	2.0	;	HOW DOES A SYMMETRIC DIMER RECOGNIZE AN ASYMMETRIC SUBSTRATE? A SUBSTRATE COMPLEX OF HIV-1 PROTEASE.
2OLQ	;	1.94	;	How Does an Enzyme Recognize CO2?
2BV9	;	1.5	;	HOW FAMILY 26 GLYCOSIDE HYDROLASES ORCHESTRATE CATALYSIS ON DIFFERENT POLYSACCHARIDES. STRUCTURE AND ACTIVITY OF A CLOSTRIDIUM THERMOCELLUM LICHENASE, CtLIC26A
2BVD	;	1.6	;	HOW FAMILY 26 GLYCOSIDE HYDROLASES ORCHESTRATE CATALYSIS ON DIFFERENT POLYSACCHARIDES. STRUCTURE AND ACTIVITY OF A CLOSTRIDIUM THERMOCELLUM LICHENASE, CtLIC26A
5KDI	;	1.45	;	How FAPP2 Selects Simple Glycosphingolipids Using the GLTP-fold
1CCI	;	2.4	;	HOW FLEXIBLE ARE PROTEINS? TRAPPING OF A FLEXIBLE LOOP
4BII	;	1.95	;	How nature bridges the gap: Crystallographic elucidation of pyridomycin binding to InhA
1HPM	;	1.7	;	HOW POTASSIUM AFFECTS THE ACTIVITY OF THE MOLECULAR CHAPERONE HSC70. II. POTASSIUM BINDS SPECIFICALLY IN THE ATPASE ACTIVE SITE
3CVH	;	2.9	;	How TCR-like antibody recognizes MHC-bound peptide
3CVI	;	1.8	;	How TCR-like antibody recognizes MHC-bound peptide
1IND	;	2.2	;	HOW THE ANTI-(METAL CHELATE) ANTIBODY CHA255 IS SPECIFIC FOR THE METAL ION OF ITS ANTIGEN: X-RAY STRUCTURES FOR TWO FAB'(SLASH)HAPTEN COMPLEXES WITH DIFFERENT METALS IN THE CHELATE
1INE	;	2.8	;	HOW THE ANTI-(METAL CHELATE) ANTIBODY CHA255 IS SPECIFIC FOR THE METAL ION OF ITS ANTIGEN: X-RAY STRUCTURES FOR TWO FAB'(SLASH)HAPTEN COMPLEXES WITH DIFFERENT METALS IN THE CHELATE
3OUY	;	2.69	;	How the CCA-adding Enzyme Selects Adenine Over Cytosine at Position 76 of tRNA
3OV7	;	3.0	;	How the CCA-Adding Enzyme Selects Adenine over Cytosine in Position 76 of tRNA
3OVA	;	1.98	;	How the CCA-adding Enzyme Selects Adenine over Cytosine in Position 76 of tRNA
3OVB	;	1.95	;	How the CCA-adding Enzyme Selects Adenine over Cytosine in Position 76 of tRNA
3OVS	;	2.8	;	How the CCA-adding Enzyme Selects Adenine over Cytosine in Position 76 of tRNA
2JZW	;		;	How the HIV-1 nucleocapsid protein binds and destabilises the (-)primer binding site during reverse transcription
3D36	;	2.03	;	How to Switch Off a Histidine Kinase: Crystal Structure of Geobacillus stearothermophilus KinB with the Inhibitor Sda
6CGT	;	2.6	;	HOXA COMPLEX OF CYCLODEXTRIN GLYCOSYLTRANSFERASE MUTANT
8BYX	;	3.0	;	HOXB13-homodimer bound to DNA
5EG0	;	3.101	;	HOXB13-MEIS1 heterodimer bound to DNA
5EGO	;	2.54	;	HOXB13-MEIS1 heterodimer bound to methylated DNA
1P0J	;		;	HP (2-20) Substitution ASP To TRP Modification In SDS-D25 Micelles
1P0L	;		;	HP (2-20) Substitution GLN To TRP Modification In SDS-D25 MICELLES
1P0O	;		;	HP (2-20) substitution of Trp for Gln and Asp at position 17 and 19 MODIFICATION IN SDS-D25 MICELLES
1P5L	;		;	HP (2-20) Substitution PHE5 to SER modification in sds-d25 micelles
1P5K	;		;	HP (2-20) Substitution SER to LEU11 modification in sds-d25 micelles
1S4Z	;		;	HP1 chromo shadow domain in complex with PXVXL motif of CAF-1
4CZ4	;		;	HP24stab derived from the villin headpiece subdomain
4CZ3	;		;	HP24wt derived from the villin headpiece subdomain
8SMK	;	3.5	;	hPAD4 bound to Activating Fab hA362
8SML	;	3.3	;	hPAD4 bound to inhibitory Fab hI365
5N1B	;	2.9	;	hPAD4 crystal complex with AFM-14a
5N0Y	;	2.23	;	hPAD4 crystal complex with AFM-30a
5N0Z	;	2.52	;	hPAD4 crystal complex with AFM-41a
5N0M	;	2.18	;	hPAD4 crystal complex with BB-F-amidine
6HIG	;	2.2	;	hPD-1/NBO1a Fab complex
3ITU	;	1.58	;	hPDE2A catalytic domain complexed with IBMX
6TX3	;	2.96	;	HPF1 bound to catalytic fragment of PARP2
6TX1	;	2.091	;	HPF1 from Nematostella vectensis
6N4E	;	1.65	;	hPGDS complexed with a quinoline-3-carboxamide
6W58	;	2.395	;	hPGDS complexed with an aza-quinoline
8XYA	;	2.7	;	hPhK alpha-beta-gamma-delta subcomplex in inactive state
8XY7	;	2.9	;	hPhK alpha-gamma subcomplex in active state
8XYB	;	3.1	;	hPhK gamma-delta subcomplex in inactive state
7M0K	;	2.01	;	HPK1 IN COMPLEX WITH COMPOUND 1
7M0L	;	2.43	;	HPK1 IN COMPLEX WITH COMPOUND 1
7M0M	;	1.93	;	HPK1 IN COMPLEX WITH COMPOUND 1
7L24	;	2.68	;	HPK1 IN COMPLEX WITH COMPOUND 11
7L25	;	1.85	;	HPK1 IN COMPLEX WITH COMPOUND 18
7L26	;	2.3	;	HPK1 IN COMPLEX WITH COMPOUND 38
1H7U	;	2.7	;	hPMS2-ATPgS
2DPW	;	2.9	;	Hpothetical Transferase Structure from Thermus thermophilus
2VST	;	2.35	;	hPPARgamma Ligand binding domain in complex with 13-(S)-HODE
2VV1	;	2.2	;	hPPARgamma Ligand binding domain in complex with 4-HDHA
2VV3	;	2.85	;	hPPARgamma Ligand binding domain in complex with 4-oxoDHA
2VV2	;	2.75	;	hPPARgamma Ligand binding domain in complex with 5-HEPA
3X1H	;	2.3	;	hPPARgamma Ligand binding domain in complex with 5-oxo-tricosahexaenoic acid
3X1I	;	2.4	;	hPPARgamma Ligand binding domain in complex with 6-oxo-tetracosahexaenoic acid
2VV4	;	2.35	;	hPPARgamma Ligand binding domain in complex with 6-oxoOTE
2VSR	;	2.05	;	hPPARgamma Ligand binding domain in complex with 9-(S)-HODE
2VV0	;	2.55	;	hPPARgamma Ligand binding domain in complex with DHA
1KNX	;	2.5	;	HPr kinase/phosphatase from Mycoplasma pneumoniae
2IV5	;		;	hPrP-173-195 solution structure
2IV6	;		;	hPrP-173-195-D178N solution structure
2IV4	;		;	hPrP180-195 structure
3LRU	;	1.85	;	hPRP8 Non-Native Subdomain
1FYY	;		;	HPRT GENE MUTATION HOTSPOT WITH A BPDE2(10R) ADDUCT
1E2M	;	2.2	;	HPT + HMTT
1E2N	;	2.2	;	HPT + HMTT
1R8P	;		;	HPV-16 E2C solution structure
1R6N	;	2.4	;	HPV11 E2 TAD complex crystal structure
1R6K	;	2.5	;	HPV11 E2 TAD crystal structure
8GCR	;	3.38	;	HPV16 E6-E6AP-p53 complex
7EOA	;	1.24	;	HR-PETase from Bacterium HR29
1URF	;		;	HR1b domain from PRK1
8BWG	;	1.32	;	HRas (1-166) Y64 phosphorylation
7JII	;	1.532	;	HRAS A59E GDP
7JIH	;	1.989	;	HRAS A59E GppNHp
7JIF	;	1.757	;	HRAS A59T GppNHp
7JIG	;	2.322	;	HRAS A59T GppNHp crystal 2
6MQT	;	1.498	;	HRAS G12S in complex with GDP
7TAM	;	1.87	;	HRas G12V in complex with GDP
6DZH	;	1.95	;	HRAS G13D bound to GDP (H13GDP)
6E6C	;	1.9	;	HRAS G13D bound to GppNHp (H13GNP)
6E6P	;	1.93	;	HRAS G13D bound to GppNHp (Ha,b,c13GNP)
8ELS	;	2.267	;	HRAS R97A Crystal Form 1 R-state
8ELW	;	1.699	;	HRAS R97A Crystal Form 1 T-State
8ELK	;	1.8	;	HRAS R97F Crystal Form 1
8ELR	;	2.05	;	HRAS R97F Crystal Form 2
8ELU	;	1.93	;	HRAS R97G Crystal form 1
8ELT	;	1.66	;	HRAS R97G Crystal Form 2
8ELX	;	1.975	;	HRAS R97I Crystal Form 1
8ELV	;	2.153	;	HRAS R97I Crystal Form 2
8FG4	;	1.85	;	HRAS R97L Crystal Form 1
8FG3	;	1.49	;	HRAS R97L Crystal Form 2
8ELZ	;	1.961	;	HRAS R97M Crystal Form 1
8ELY	;	1.75	;	HRAS R97M Crystal Form 2
8EM0	;	2.109	;	HRAS R97V Crystal Form 1
8CNJ	;	1.35	;	HRas(1-166) in complex with GDP and BeF3-
6CXN	;		;	HRFLRH peptide NMR structure
6CXP	;		;	HRFLRH peptide NMR structure in the presence of Cd(II)
6CXQ	;		;	HRFLRH peptide NMR structure in the presence of CO2
6CXR	;		;	HRFLRH peptide NMR structure in the presence of Zn(II)
6IAA	;	3.6	;	hRobo2 ectodomain
6I9S	;	2.48	;	hRobo2 Extracellular Domains 2-3
1QKL	;		;	hRPABC14.4, essential subunit of human RNA polymerases I, II and III
6UYI	;		;	hRpn13:hRpn2:K48-diubiquitin
6UYJ	;		;	hRpn13:hRpn2:K48-diubiquitin
5NOH	;	1.8	;	HRSV M2-1 core domain
2L9J	;		;	hRSV M2-1 core domain structure
5NKX	;	2.00009	;	HRSV M2-1 core domain, P3221 crystal form
4C3E	;	2.4	;	HRSV M2-1 mutant S58D S61D, P21 crystal
4C3B	;	2.95	;	HRSV M2-1, P21 crystal form
4C3D	;	2.52	;	HRSV M2-1, P422 crystal form
6KZ0	;	2.4	;	HRV14 3C in complex with single chain antibody GGVV
6KYZ	;	1.845	;	HRV14 3C in complex with single chain antibody YDF
7BG7	;	2.4	;	HRV14 in complex with its receptor ICAM-1
7BG6	;	2.6	;	HRV14 native particle solved by cryoEM
1HRV	;	3.0	;	HRV14/SDZ 35-682 COMPLEX
1VRH	;	3.0	;	HRV14/SDZ 880-061 COMPLEX
3FC6	;	2.063	;	hRXRalpha & mLXRalpha with an indole Pharmacophore, SB786875
6MBM	;		;	HS02 - Intragenic antimicrobial peptides derived from the protein unconventional myosin 1h
6VLA	;		;	Hs05 - Intragenic antimicrobial peptide
4K2C	;	3.23	;	HSA Ligand Free
6EFC	;	1.4	;	Hsa Siglec + Unique domains (unliganded)
6X3Q	;	2.15	;	Hsa Siglec and Unique domains in complex with 3'sialyl-N-acetyllactosamine trisaccharide
6X3K	;	2.5	;	Hsa Siglec and Unique domains in complex with 6S-sialy-Lewisx
7KMJ	;	1.33	;	Hsa Siglec and Unique domains in complex with Sialyl Lewis C
6EFD	;	1.85	;	Hsa Siglec and Unique domains in complex with the sialyl T antigen trisaccharide
7Y2D	;	2.0	;	HSA-Cu agent complex
4IW1	;	2.56	;	HSA-fructose complex
4IW2	;	2.41	;	HSA-glucose complex
7WZ9	;	2.83	;	HSA-In agent complex
5GIY	;	2.543	;	HSA-Palmitic acid-[RuCl5(ind)]2-
8ISM	;	2.76	;	HSA-Pt compound complex
5JZS	;	2.27	;	HsaD bound to 3,5-dichloro-4-hydroxybenzoic acid
6ZFX	;	2.88	;	hSARM1 GraFix-ed
7ANW	;	2.68	;	hSARM1 NAD+ complex
1FPO	;	1.8	;	HSC20 (HSCB), A J-TYPE CO-CHAPERONE FROM E. COLI
4H5T	;	1.9	;	HSC70 NBD with ADP and Mg
4H5W	;	1.94	;	HSC70 NBD with betaine
4H5V	;	1.75	;	HSC70 NBD with Mg
4H5R	;	1.64	;	HSC70 NBD with Na, Cl and glycerol
4H5N	;	1.86	;	HSC70 NBD with PO4, Na, Cl
1U00	;	1.95	;	HscA substrate binding domain complexed with the IscU recognition peptide ELPPVKIHC
6QUS	;	3.7	;	HsCKK (human CAMSAP1) decorated 13pf taxol-GDP microtubule
6QVJ	;	3.8	;	HsCKK (human CAMSAP1) decorated 14pf taxol-GDP microtubule
8G89	;	2.222	;	HSD17B13 in complex with cofactor and inhibitor
6KWW	;	3.0	;	HslU from Staphylococcus aureus
5JI2	;	3.307	;	HslU L199Q in HslUV complex
5TXV	;	7.086	;	HslU P21 cell with 4 hexamers
1IM2	;	2.8	;	HslU, Haemophilus Influenzae, Selenomethionine Variant
1KYI	;	3.1	;	HslUV (H. influenzae)-NLVS Vinyl Sulfone Inhibitor Complex
5JI3	;	3.0	;	HslUV complex
1E94	;	2.8	;	HslV-HslU from E.coli
4UBF	;	3.0	;	HsMCAK motor domain complex
4U6W	;	1.83	;	HsMetAP (F220M) in complex with 1-amino-2-propylpentyl]phosphonic acid
4U76	;	1.87	;	HsMetAP (F309M) holo form
4U70	;	1.6	;	HsMetAP (F309M) in complex with (1-amino-2-cyclohexylethyl)phosphonic acid
4U75	;	1.94	;	HsMetAP (F309M) in complex with Methionine
4U69	;	1.6	;	HsMetAP complex with (1-amino-2-methylpentyl)phosphonic acid
4U1B	;	1.89	;	HsMetAP in complex with (1-amino-2-propylpentyl)phosphonic acid
4U6E	;	1.9	;	HsMetAP in complex with (amino(phenyl)methyl)phosphonic acid
4U6J	;	1.56	;	HsMetAP in complex with methionine
4U6C	;	1.91	;	HsMetAP in complex with [(1R)-1-amino-3-cyclopentylpropyl]phosphonic acid
4U73	;	1.8	;	HsMetAP(F309M) IN COMPLEX WITH (amino(phenyl)methyl)phosphonic acid
4U71	;	1.8	;	HsMetAP(F309M) IN COMPLEX WITH 1- amino(cyclohexyl)methy)phosphonic acid
4U6Z	;	1.8	;	HsMetAP(F309M) in complex with 1-amino-2-propylpentyl)phosphonic acid
7OWU	;	2.08	;	HsNMT1 in complex with both CoA and Myr-ANCFSKPR peptide
7OWP	;	1.81	;	HsNMT1 in complex with both MyrCoA and ACE-G-(L-ORN)SFSKPR
6SK2	;	1.90001	;	HsNMT1 in complex with both MyrCoA and Acetylated-GKSFSKPR peptide reveals N-terminal Lysine Myristoylation
6SJZ	;	1.995	;	HsNMT1 in complex with both MyrCoA and Acetylated-GNCFSKPR substrates
6QRM	;	2.3	;	HsNMT1 in complex with both MyrCoA and GNCFSKRRAA substrates
7OWM	;	1.5	;	HsNMT1 in complex with both MyrCoA and HCPA substrate peptide GKQNSKLR
7OWO	;	1.7	;	HsNMT1 in complex with both MyrCoA and N-acetylated KSFSKPR peptide
7OWN	;	2.1	;	HsNMT1 in complex with both MyrCoA and peptide AKSFSKPR
7OWR	;	2.39	;	HsNMT1 in complex with both MyrCoA and peptide GGKSFSKPR
7OWQ	;	3.0	;	HsNMT1 in complex with both MyrCoA and peptide N-Methylated-GNCFSKPR
5O9T	;	2.15	;	HsNMT1 in complex with CoA and acetylated-NCFSKPK peptide
5O9U	;	1.85	;	HsNMT1 in complex with CoA and Myristoylated-GCSVSKKK octapeptide
5O9V	;	2.201	;	HsNMT1 in complex with CoA and Myristoylated-GGCFSKPK octapeptide
5O9S	;	2.7	;	HsNMT1 in complex with CoA and Myristoylated-GKSNSKLK octapeptide
6LSZ	;	1.992	;	HSP 90 in complex with Ganetespib
6N8T	;	7.7	;	Hsp104DWB closed conformation
6N8Z	;	9.3	;	HSP104DWB extended conformation
6N8V	;	9.3	;	Hsp104DWB open conformation
4FEI	;	2.4	;	Hsp17.7 from Deinococcus radiodurans
6L6M	;	3.28	;	HSP18.5 from E. histolytica
5NMS	;	10.0	;	Hsp21 dodecamer, structural model based on cryo-EM and homology modelling
7BZY	;	3.7	;	Hsp21-DXPS
1HW7	;	2.2	;	HSP33, HEAT SHOCK PROTEIN WITH REDOX-REGULATED CHAPERONE ACTIVITY
6D6X	;		;	HSP40 co-chaperone Sis1 J-domain
1XAO	;	2.07	;	Hsp40-Ydj1 dimerization domain
5AQZ	;	1.65	;	HSP72 with adenosine-derived inhibitor
5AR0	;	1.9	;	HSP72 with adenosine-derived inhibitor
5MKS	;	1.99	;	HSP72-NBD bound to compound TCI 8 - Tyr15 in down-conformation
5MKR	;	1.87	;	HSP72-NBD bound to compound TCI 8 - Tyr15 in up-conformation
2JJC	;	1.95	;	Hsp90 alpha ATPase domain with bound small molecule fragment
7UR3	;	1.6	;	Hsp90 alpha inhibitor
7D25	;	1.65	;	Hsp90 alpha N-terminal domain in complex with a 14 compund
7D24	;	1.55	;	Hsp90 alpha N-terminal domain in complex with a 4B compund
7D22	;	1.6	;	Hsp90 alpha N-terminal domain in complex with a 6B compund
7D1V	;	1.332	;	Hsp90 alpha N-terminal domain in complex with a 6C compund
7D26	;	1.75	;	Hsp90 alpha N-terminal domain in complex with a 8 compund
3VHA	;	1.39	;	Hsp90 alpha N-terminal domain in complex with a macrocyclic inhibitor
3VHC	;	1.41	;	Hsp90 alpha N-terminal domain in complex with a macrocyclic inhibitor
3VHD	;	1.52	;	Hsp90 alpha N-terminal domain in complex with a macrocyclic inhibitor, CH5164840
3WHA	;	1.3	;	Hsp90 alpha N-terminal domain in complex with a tricyclic inhibitor
3B24	;	1.7	;	Hsp90 alpha N-terminal domain in complex with an aminotriazine fragment molecule
5H22	;	1.499	;	Hsp90 alpha N-terminal domain in complex with an inhibitor
4EEH	;	1.6	;	Hsp90 Alpha N-terminal Domain in Complex with an Inhibitor 3-(4-Hydroxy-phenyl)-1H-indazol-6-ol
4EFT	;	2.12	;	Hsp90 Alpha N-terminal Domain in Complex with an Inhibitor 3-Cyclohexyl-2-(6-hydroxy-1H-indazol-3-yl)-propionitrile
4EFU	;	2.0	;	Hsp90 Alpha N-terminal Domain in Complex with an Inhibitor 6-Hydroxy-3-(3-methyl-benzyl)-1H-indazole-5-carboxylic acid benzyl-methyl-amide
3B25	;	1.75	;	Hsp90 alpha N-terminal domain in complex with an inhibitor CH4675194
3B28	;	1.35	;	Hsp90 alpha N-terminal domain in complex with an inhibitor CH5015765
3B26	;	2.1	;	Hsp90 alpha N-terminal domain in complex with an inhibitor Ro1127850
3B27	;	1.5	;	Hsp90 alpha N-terminal domain in complex with an inhibitor Ro4919127
2W0G	;	1.88	;	HSP90 CO-CHAPERONE CDC37
6HFM	;	1.55	;	Hsp90 co-chaperone Cns1 C-domain from Saccharomyces cerevisiae
6HFT	;	2.8	;	Hsp90 co-chaperone Cns1 from Saccharomyces cerevisiae (delta69)
2XD6	;	2.2	;	Hsp90 complexed with a resorcylic acid macrolactone.
2QFO	;	1.68	;	HSP90 complexed with A143571 and A516383
2QF6	;	3.1	;	HSP90 complexed with A56322
2QG2	;	1.8	;	HSP90 complexed with A917985
2QG0	;	1.85	;	HSP90 complexed with A943037
2AKP	;	1.94	;	Hsp90 Delta24-N210 mutant
6HHR	;	2.0	;	Hsp90 in complex with 5-(2,4-Dihydroxy-phenyl)-4-(2-fluoro-phenyl)-2,4-dihydro-[1,2,4]triazole-3-thione
5J27	;	1.7	;	HSP90 in complex with 5-[4-(2-Fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-2,4-dihydroxy-N-methyl-N-propyl-benzenesulfonamide
5J20	;	1.76	;	HSP90 in complex with 5-[4-(2-Fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-N-furan-2-ylmethyl-2,4-dihydroxy-N-methyl-benzamide
6LR9	;	2.196	;	HSP90 in complex with Debio0932
6LT8	;	1.593	;	HSP90 in complex with KW-2478
5J9X	;	1.8	;	HSP90 in complex with N-Butyl-5-[4-(2-fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-2,4-dihydroxy-N-methyl-benzamide
6LTI	;	1.588	;	HSP90 in complex with NVP-AUY922
6LTK	;	2.141	;	HSP90 in complex with SNX-2112
5OD7	;	2.0	;	Hsp90 inhibitor desolvation as a rationale to steer on-rates and impact residence time
2YE2	;	1.9	;	HSP90 inhibitors and drugs from fragment and virtual screening
2YE3	;	1.95	;	HSP90 inhibitors and drugs from fragment and virtual screening
2YE4	;	2.3	;	HSP90 inhibitors and drugs from fragment and virtual screening
2YE5	;	1.73	;	HSP90 inhibitors and drugs from fragment and virtual screening
2YE6	;	2.56	;	HSP90 inhibitors and drugs from fragment and virtual screening
2YE7	;	2.2	;	HSP90 inhibitors and drugs from fragment and virtual screening
2YE8	;	2.3	;	HSP90 inhibitors and drugs from fragment and virtual screening
2YE9	;	2.2	;	HSP90 inhibitors and drugs from fragment and virtual screening
2YEA	;	1.73	;	HSP90 inhibitors and drugs from fragment and virtual screening
2YEB	;	2.4	;	HSP90 inhibitors and drugs from fragment and virtual screening
2YEC	;	2.1	;	HSP90 inhibitors and drugs from fragment and virtual screening
2YED	;	2.1	;	HSP90 inhibitors and drugs from fragment and virtual screening
2YEE	;	2.3	;	HSP90 inhibitors and drugs from fragment and virtual screening
2YEF	;	1.55	;	HSP90 inhibitors and drugs from fragment and virtual screening
2YEG	;	2.5	;	HSP90 inhibitors and drugs from fragment and virtual screening
2YEH	;	2.1	;	HSP90 inhibitors and drugs from fragment and virtual screening
2YEI	;	2.2	;	HSP90 inhibitors and drugs from fragment and virtual screening
2YEJ	;	2.2	;	HSP90 inhibitors and drugs from fragment and virtual screening
3T10	;	1.24	;	HSP90 N-terminal domain bound to ACP
1BYQ	;	1.5	;	HSP90 N-TERMINAL DOMAIN BOUND TO ADP-MG
3T2S	;	1.501	;	HSP90 N-terminal domain bound to AGS
3T1K	;	1.5	;	HSP90 N-terminal domain bound to ANP
3T0Z	;	2.192	;	Hsp90 N-terminal domain bound to ATP
4CE1	;	2.01	;	Hsp90 N-terminal domain bound to macrolactam analogues of radicicol.
4CE2	;	2.38	;	Hsp90 N-terminal domain bound to macrolactam analogues of radicicol.
4CE3	;	2.31	;	Hsp90 N-terminal domain bound to macrolactam analogues of radicicol.
3K98	;	2.4	;	HSP90 N-terminal domain in complex with (1R)-2-(5-chloro-2,4-dihydroxybenzoyl)-N-ethylisoindoline-1-carboxamide
3HEK	;	1.95	;	HSP90 N-terminal domain in complex with 1-{4-[(2R)-1-(5-chloro-2,4-dihydroxybenzoyl)pyrrolidin-2-yl]benzyl}-3,3-difluoropyrrolidinium
3K99	;	2.1	;	HSP90 N-terminal domain in complex with 4-(1,3-dihydro-2H-isoindol-2-ylcarbonyl)benzene-1,3-diol
3K97	;	1.95	;	HSP90 N-terminal domain in complex with 4-chloro-6-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol
3INW	;	1.95	;	HSP90 N-TERMINAL DOMAIN with pochoxime A
3INX	;	1.75	;	HSP90 N-TERMINAL DOMAIN with pochoxime B
8GAE	;	3.3	;	Hsp90 provides platform for CRaf dephosphorylation by PP5
8GFT	;	3.8	;	Hsp90 provides platform for CRaf dephosphorylation by PP5
5LNY	;	1.88	;	HSP90 WITH indazole derivative
5LNZ	;	1.54	;	HSP90 WITH indazole derivative
5LO0	;	2.3	;	HSP90 WITH indazole derivative
5LO1	;	2.7	;	HSP90 WITH indazole derivative
5LO6	;	2.4	;	HSP90 WITH indazole derivative
5LO5	;	1.44	;	HSP90 WITH indole derivative
7Y04	;	3.5	;	Hsp90-AhR-p23 complex
8H77	;	3.2	;	Hsp90-AhR-p23-XAP2 complex
4EGH	;	1.6	;	Hsp90-alpha ATPase domain in complex with (4-Hydroxyphenyl)morpholin-4-yl methanone
4EGI	;	1.79	;	Hsp90-alpha ATPase domain in complex with 2-Amino-4-ethylthio-6-methyl-1,3,5-triazine
6N8X	;	1.49484	;	Hsp90-alpha bound to PU-11-trans
6CYH	;	1.49	;	Hsp90-alpha N-domain bound to NEACA
6B99	;	1.60238	;	Hsp90-alpha N-domain bound to NECA
6CYG	;	1.50392	;	Hsp90-alpha N-domain bound to NEOCA
6B9A	;	1.65381	;	Hsp90-alpha N-domain bound to NPCA
6OLX	;	1.43761	;	Hsp90-alpha S52A bound to PU-11-trans
6N8Y	;	1.55391	;	Hsp90-beta bound to PU-11-trans
3QDD	;	1.79	;	HSP90A N-terminal domain in complex with BIIB021
7LSZ	;	1.7	;	Hsp90a N-terminal inhibitor
7LT0	;	1.697	;	Hsp90a N-terminal inhibitor
6U9B	;	1.75	;	Hsp90a NTD covalently bound to sulfonyl fluoride 5 at K58
6U99	;	1.6	;	Hsp90a NTD covalently bound to sulfonyl fluoride probe 1 at K58
6U9A	;	1.65	;	Hsp90a NTD K58R bound reversibly to sulfonyl fluoride 5
6U98	;	1.5	;	Hsp90a NTD K58R bound reversibly to sulfonyl fluoride 6
7ULJ	;	1.82	;	Hsp90b N-terminal domain in complex with 42C
3NMQ	;	2.2	;	Hsp90b N-terminal domain in complex with EC44, a pyrrolo-pyrimidine methoxypyridine inhibitor
5UC4	;	2.05	;	Hsp90b N-terminal domain with inhibitors
5UCH	;	2.654	;	Hsp90b N-terminal domain with inhibitors
5UCI	;	2.7	;	Hsp90b N-terminal domain with inhibitors
5UCJ	;	1.693	;	Hsp90b N-terminal domain with inhibitors
6EWN	;	2.29	;	HspA from Thermosynechococcus vulcanus in the presence of 2M urea with initial stages of denaturation
3Q9P	;	2.0	;	HspB1 fragment
3Q9Q	;	2.2	;	HspB1 fragment second crystal form
6BP9	;		;	HSPB5 alpha-crystallin domain mutant R120G-ACD
8IWP	;	3.59	;	hSPCA1 in the CaE1 state
8IWR	;	3.52	;	hSPCA1 in the CaE1-ATP state
8IWW	;	3.71	;	hSPCA1 in the CaE1P-ADP state
8IWS	;	3.42	;	hSPCA1 in the CaE2P state
8IWU	;	3.31	;	hSPCA1 in the E2~P state
8IWT	;	3.25	;	hSPCA1 in the early E2P state
7PMW	;	4.1	;	HsPepT1 bound to Ala-Phe in the outward facing occluded conformation
7PMX	;	3.5	;	HsPepT1 bound to Ala-Phe in the outward facing open conformation
7PMY	;	3.8	;	HsPepT2 bound to Ala-Phe in the inward facing partially occluded conformation
2RPE	;		;	hsRad51-bound ssDNA
3FPO	;	1.5	;	HSSNNF segment from Islet Amyloid Polypeptide (IAPP or Amylin)
2QQF	;	2.0	;	Hst2 bound to ADP-HPD and Acetylated histone H4
2QQG	;	2.05	;	Hst2 bound to ADP-HPD, acetyllated histone H4 and nicotinamide
7OB3	;	2.3	;	hSTING in complex with 3',3'-c-di-araAMP
6Y99	;	2.984	;	hSTING mutant R232K in complex with 2',3'-cGAMP
1JAS	;		;	HsUbc2b
8OJC	;	2.08	;	HSV-1 DNA polymerase active site in alternative exonuclease state
8OJD	;	2.46	;	HSV-1 DNA polymerase beta-hairpin loop
8OJA	;	1.87	;	HSV-1 DNA polymerase-processivity factor complex in exonuclease state
8OJB	;	1.9	;	HSV-1 DNA polymerase-processivity factor complex in exonuclease state active site
8OJ7	;	2.46	;	HSV-1 DNA polymerase-processivity factor complex in halted elongation state
8OJ6	;	2.41	;	HSV-1 DNA polymerase-processivity factor complex in pre-translocation state
4ZXS	;	2.772	;	HSV-1 nuclear egress complex
8G6D	;	3.92	;	HSV-1 Nuclear Egress Complex (SUP; UL31-R229L)
7LUF	;	3.5	;	HSV1 polymerase ternary complex with dsDNA and PNU-183792
1BH8	;	3.0	;	HTAFII18/HTAFII28 HETERODIMER CRYSTAL STRUCTURE
1BH9	;	2.6	;	HTAFII18/HTAFII28 HETERODIMER CRYSTAL STRUCTURE WITH BOUND PCMBS
2OYY	;	2.5	;	HTHP: a hexameric tyrosine-coordinated heme protein
8ERH	;	1.47	;	HTLV-1 capsid protein C-terminal domain
8ERI	;	2.25	;	HTLV-1 capsid protein full-length
8ERG	;	2.1	;	HTLV-1 capsid protein N-terminal domain hexagonal crystal form
8ERF	;	1.47	;	HTLV-1 capsid protein N-terminal domain orthorhombic crystal form
8ERE	;	0.87	;	HTLV-1 capsid protein N-terminal domain triclinic crystal form
1MG1	;	2.5	;	HTLV-1 GP21 ECTODOMAIN/MALTOSE-BINDING PROTEIN CHIMERA
3WSJ	;	2.404	;	HTLV-1 protease in complex with the HIV-1 protease inhibitor Indinavir
6WHA	;	3.36	;	HTR2A bound to 25-CN-NBOH in complex with a mini-Galpha-q protein, beta/gamma subunits and an active-state stabilizing single-chain variable fragment (scFv16) obtained by cryo-electron microscopy (cryoEM)
3MH4	;	3.1	;	HtrA proteases are activated by a conserved mechanism that can be triggered by distinct molecular cues
3MH5	;	3.0	;	HtrA proteases are activated by a conserved mechanism that can be triggered by distinct molecular cues
3MH6	;	3.6	;	HtrA proteases are activated by a conserved mechanism that can be triggered by distinct molecular cues
3MH7	;	2.961	;	HtrA proteases are activated by a conserved mechanism that can be triggered by distinct molecular cues
7CO5	;	2.345	;	HtrA-type protease AlgW with decapeptide
7CO2	;	2.1	;	HtrA-type protease AlgW with tripeptide
7CO7	;	2.6	;	HtrA-type protease AlgWS227A with decapeptide
7CO3	;	1.9	;	HtrA-type protease AlgWS227A with tripeptide
2JOA	;		;	HtrA1 bound to an optimized peptide: NMR assignment of PDZ domain and ligand resonances
3TJN	;	3.0	;	HtrA1 catalytic domain, apo form
3TJO	;	2.301	;	HtrA1 catalytic domain, mutationally inactivated
6Z0E	;	2.6	;	HtrA1 inactive protease domain S328A with CARASIL mutation R274Q
6Z0X	;	3.1	;	HtrA1 inactive protease domain S328A with CARASIL mutations D174R R274Q
6Z0Y	;	2.2	;	HtrA1 inactive protease domain S328A with CARASIL mutations D174R R274Q
7SJN	;	3.4	;	HtrA1:Fab15H6.v4 complex
7SJO	;	3.3	;	HtrA1S328A:Fab15H6.v4 complex
5M3O	;	1.7	;	HTRA2 A141S mutant structure
5TO1	;	1.69	;	HtrA2 exposed (L266R, F303A) mutant
5TNY	;	1.7	;	HTRA2 G399S mutant
5WYN	;	2.05	;	HtrA2 Pathogenic Mutant
5FHT	;	1.95	;	HtrA2 protease mutant V226K
5TNZ	;	1.75	;	HtrA2 S142D mutant
5TO0	;	1.9	;	HTRA2 S276C mutant
5M3N	;	1.649	;	HTRA2 wild-type structure
7U8U	;	3.065	;	hTRAP1 with inhibitors
7U8V	;	1.448	;	hTRAP1 with inhibitors
7U8W	;	1.706	;	hTRAP1 with inhibitors
7U8X	;	1.6	;	hTRAP1 with inhibitors
1W0T	;	2.0	;	hTRF1 DNA-binding domain in complex with telomeric DNA.
1W0U	;	1.8	;	hTRF2 DNA-binding domain in complex with telomeric DNA.
6NRA	;	7.7	;	hTRiC-hPFD Class1 (No PFD)
6NRB	;	8.7	;	hTRiC-hPFD Class2
6NRC	;	8.3	;	hTRiC-hPFD Class3
6NRD	;	8.2	;	hTRiC-hPFD Class4
6NR9	;	8.5	;	hTRiC-hPFD Class5
6NR8	;	7.8	;	hTRiC-hPFD Class6
8VLX	;	2.6	;	HTT in complex with HAP40 and a small molecule.
8W15	;	2.72	;	HTT in complex with HAP40 in the apo state.
6GHT	;	1.12	;	HtxB D206A protein variant from Pseudomonas stutzeri in complex with hypophosphite to 1.12 A resolution
6GHQ	;	1.53	;	HtxB D206N protein variant from Pseudomonas stutzeri in a partially open conformation to 1.53 A resolution
6EMN	;	1.25	;	HtxB from Pseudomonas stutzeri in complex with phosphite to 1.25 A resolution
5EKA	;	1.69	;	HU DNA-binding protein from Thermus thermophilus
1B8Z	;	1.6	;	HU FROM THERMOTOGA MARITIMA
1RIY	;	1.8	;	HU mutant V42I from Thermotoga maritima
4YF0	;	2.79	;	HU38-19bp
4YFH	;	3.49	;	HU38-20bp
6J71	;	2.918	;	HuA21-scFv in complex with the extracellular domain(ECD) of HER2
6O8Q	;	3.216	;	HUaa 19bp SYM DNA pH 4.5
6O6K	;	3.601	;	HUaa 19bp SYM DNA pH 5.5
4YEX	;	3.2	;	HUaa-19bp
4YEY	;	3.354	;	HUaa-20bp
4YEW	;	2.683	;	HUab-19bp
4YFT	;	2.914	;	HUab-20bp
6OAJ	;	4.092	;	HUaE34K 19bp SYM DNA
8EG6	;	1.82	;	huCaspase-6 in complex with inhibitor 2a
8EG5	;	2.14	;	huCaspase-6 in complex with inhibitor 3a
2YN2	;	2.05	;	Huf protein - paralogue of the tau55 histidine phosphatase domain
5TJH	;	2.05	;	hUGDH A136M Substitution
6KJU	;	1.75	;	Huge conformation shift of Vibrio cholerae VqmA dimer in the absence of target DNA provides insight into DNA-binding mechanisms of LuxR-type receptors
5WR0	;	2.85	;	Huisgen cycloaddition for PPARg-LBD labeling by soaking method
7LTM	;	2.49	;	Hum8 capsid
2RN5	;		;	Humal Insulin Mutant B31Lys-B32Arg
6NQ5	;	1.85	;	human (alpha met/beta hemichrome) hemoglobin with S-nitrosation at beta-Cys93
2IRW	;	3.1	;	Human 11-beta-Hydroxysteroid Dehydrogenase (HSD1) with NADP and Adamantane Ether Inhibitor
2ILT	;	2.3	;	Human 11-beta-Hydroxysteroid Dehydrogenase (HSD1) with NADP and Adamantane Sulfone Inhibitor
4HFR	;	2.73	;	Human 11beta-Hydroxysteroid Dehydrogenase Type 1 in complex with an orally bioavailable acidic inhibitor AZD4017.
4P38	;	2.8	;	Human 11beta-Hydroxysteroid Dehydrogenase Type 1 in complex with AZD8329
7DXK	;	4.1	;	Human 128QHuntingtin-HAP40 complex structure
4IHL	;	2.2	;	Human 14-3-3 isoform zeta in complex with a diphoyphorylated C-RAF peptide and Cotylenin A
5LU1	;	2.4	;	Human 14-3-3 sigma CLU3 mutant complexed with short HSPB6 phosphopeptide
5LU2	;	2.5	;	Human 14-3-3 sigma complexed with long HSPB6 phosphopeptide
6T80	;	2.99	;	Human 14-3-3 sigma fused to the AANAT peptide including phosphoserine-205
6T5F	;	2.63	;	Human 14-3-3 sigma fused to the StARD1 peptide including phosphoserine-195
6T5H	;	2.04	;	Human 14-3-3 sigma fused to the StARD1 peptide including phosphoserine-57
7NFW	;	1.19	;	Human 14-3-3 sigma in complex with human Estrogen Receptor alpha peptide
7NIZ	;	1.48	;	Human 14-3-3 sigma in complex with human Estrogen Receptor alpha peptide and ligands Fusicoccin-A and WR-1065
8P0D	;	1.31	;	Human 14-3-3 sigma in complex with human MDM2 peptide
6TLF	;	2.9	;	human 14-3-3 sigma isoform in complex with IMP
6TM7	;	3.0	;	Human 14-3-3 sigma isoform in complex with PLP
7Q16	;	2.356	;	Human 14-3-3 zeta fused to the BAD peptide including phosphoserine-74
8FD8	;	3.3	;	human 15-PGDH with NADH bound
1A27	;	1.9	;	HUMAN 17-BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE 1 C-TERMINAL DELETION MUTANT COMPLEXED WITH ESTRADIOL AND NADP+
1FDS	;	1.7	;	HUMAN 17-BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE 1 COMPLEXED WITH 17-BETA-ESTRADIOL
1FDT	;	2.2	;	HUMAN 17-BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE 1 COMPLEXED WITH ESTRADIOL AND NADP+
1FDU	;	2.7	;	HUMAN 17-BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE 1 MUTANT H221L COMPLEXED WITH ESTRADIOL AND NADP+
1FDV	;	3.1	;	HUMAN 17-BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE 1 MUTANT H221L COMPLEXED WITH NAD+
1FDW	;	2.7	;	HUMAN 17-BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE 1 MUTANT H221Q COMPLEXED WITH ESTRADIOL
5HS6	;	2.02	;	Human 17beta-hydroxysteroid dehydrogenase type 14 in complex with Estrone
6Y5Q	;	7.1	;	human 17S U2 snRNP
7Q3L	;	2.21	;	Human 17S U2 snRNP 5' domain
6Y53	;	7.1	;	human 17S U2 snRNP low resolution part
5NQK	;	3.25	;	human 199.16 TCR in complex with Melan-A/MART-1 (26-35) peptide and HLA-A2
5NHT	;	3.2	;	human 199.54-16 TCR in complex with Melan-A/MART-1 (26-35) peptide and HLA-A2
8CVT	;	3.0	;	Human 19S-20S proteasome, state SD2
3DO3	;	2.5	;	Human 1gG1 Fc fragment, 2.5 Angstrom structure
6RGQ	;	2.6	;	Human 20S Proteasome
7PG9	;	3.7	;	human 20S proteasome
8QYL	;	2.67	;	Human 20S proteasome assembly intermediate structure 2
8QYM	;	2.73	;	Human 20S proteasome assembly intermediate structure 3
8QZ9	;	2.95	;	Human 20S proteasome assembly intermediate structure 4
8QYN	;	2.88	;	Human 20S proteasome assembly intermediate structure 5
8QYJ	;	2.73	;	Human 20S proteasome assembly structure 1
6XMJ	;	3.0	;	Human 20S proteasome bound to an engineered 11S (PA26) activator
5LF3	;	2.1	;	Human 20S proteasome complex with Bortezomib at 2.1 Angstrom
5LF4	;	1.99	;	Human 20S proteasome complex with Delanzomib at 2.0 Angstrom
5LF1	;	2.0	;	Human 20S proteasome complex with Dihydroeponemycin at 2.0 Angstrom
5LF0	;	2.41	;	Human 20S proteasome complex with Epoxomicin at 2.4 Angstrom
5LF7	;	2.0	;	Human 20S proteasome complex with Ixazomib at 2.0 Angstrom
5LEY	;	1.9	;	Human 20S proteasome complex with Oprozomib at 1.9 Angstrom
5LEZ	;	2.19	;	Human 20S proteasome complex with Oprozomib in Mg-Acetate at 2.2 Angstrom
5LF6	;	2.07	;	Human 20S proteasome complex with Z-LLY-ketoaldehyde at 2.1 Angstrom
7NAN	;	2.8	;	Human 20S proteasome core particle
8BZL	;	2.14	;	Human 20S Proteasome in complex with peptide activator peptide BLM42
8CVR	;	2.7	;	Human 20S proteasome with MG-132
6REY	;	3.0	;	Human 20S-PA200 Proteasome Complex
5M32	;	3.8	;	Human 26S proteasome in complex with Oprozomib
2WEF	;	1.8	;	Human 3'(2'), 5'-bisphosphate nucleotidase 1 (BPNT1) in complex with AMP, PO4 and Magnesium
3OLH	;	2.5	;	Human 3-mercaptopyruvate sulfurtransferase
1BNK	;	2.7	;	HUMAN 3-METHYLADENINE DNA GLYCOSYLASE COMPLEXED TO DNA
3BD9	;	2.3	;	human 3-O-sulfotransferase isoform 5 with bound PAP
1J96	;	1.25	;	Human 3alpha-HSD type 3 in Ternary Complex with NADP and Testosterone
5OA3	;	4.2	;	Human 40S-eIF2D-re-initiation complex
7DXJ	;	3.6	;	Human 46QHuntingtin-HAP40 complex structure
8A6L	;	3.18	;	Human 4F2hc-LAT2 heterodimeric amino acid transporter in complex with anticalin D11vs
1YQK	;	2.5	;	Human 8-oxoguanine glycosylase crosslinked with guanine containing DNA
6W0M	;	2.37	;	Human 8-oxoguanine glycosylase crosslinked with oxoG lesion containing DNA
6W13	;	2.38	;	Human 8-oxoguanine glycosylase interrogating fully intrahelical oxoG lesion DNA
6W0R	;	2.35	;	Human 8-oxoguanine glycosylase interrogating fully intrahelical undamaged DNA
5V3P	;	2.5	;	Human A20 OTU domain (I325N) with acetamidylated C103
5V3B	;	3.0	;	Human A20 OTU domain (WT) with acetamidylated C103
7BP8	;	3.9	;	Human AAA+ ATPase VCP mutant - T76A, ADP-bound form
7BPA	;	3.3	;	Human AAA+ ATPase VCP mutant - T76A, AMP-PNP-bound form, Conformation I
7BP9	;	3.6	;	Human AAA+ ATPase VCP mutant - T76E, ADP-bound form
7BPB	;	4.3	;	Human AAA+ ATPase VCP mutant - T76E, AMP-PNP bound form, Conformation I
8F5B	;	3.95	;	Human ABCA4 structure in complex with AMP-PNP
7M1Q	;	2.92	;	Human ABCA4 structure in complex with N-ret-PE
7M1P	;	3.6	;	Human ABCA4 structure in the unbound state
6NLO	;	2.85022	;	Human ABCC6 NBD1 H812A in Apo state
6BZS	;	2.2999	;	Human ABCC6 NBD1 in Apo state
6BZR	;	2.79999	;	Human ABCC6 NBD2 in ADP-bound state
6P7F	;	2.85004	;	Human ABCC6 NBD2 R1459D mutant in Apo state
2HYY	;	2.4	;	Human Abl kinase domain in complex with imatinib (STI571, Glivec)
3CS9	;	2.21	;	Human ABL kinase in complex with nilotinib
2XYN	;	2.81	;	HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
6BJI	;	1.54	;	Human ABO(H) blood group glycosyltransferase GTA D302C mutant
6BJJ	;	1.45	;	Human ABO(H) blood group glycosyltransferase GTB D302A mutant
6BJK	;	2.12	;	Human ABO(H) blood group glycosyltransferase GTB D302C mutant
6BJL	;	1.69	;	Human ABO(H) blood group glycosyltransferase GTB D302L mutant
6BJM	;	1.45	;	Human ABO(H) blood group glycosyltransferase GTB R188K mutant
3FF6	;	3.19	;	Human ACC2 CT domain with CP-640186
1B41	;	2.76	;	HUMAN ACETYLCHOLINESTERASE COMPLEXED WITH FASCICULIN-II, GLYCOSYLATED PROTEIN
4BDT	;	3.104	;	Human acetylcholinesterase in complex with huprine W and fasciculin 2
8AEV	;	2.89	;	Human acetylcholinesterase in complex with N,N,N-trimethyl-2-oxo-2-(2-(pyridin-2-ylmethylene)hydrazineyl)ethan-1-aminium
6NEA	;	2.419	;	Human Acetylcholinesterase in complex with reactivator, HLo7
8AEN	;	3.01	;	Human acetylcholinesterase in complex with zinc and N,N,N-trimethyl-2-oxo-2-(2-(pyridin-2-ylmethylene)hydrazineyl)ethan-1-aminium
5U7Z	;	2.5	;	Human acid ceramidase (ASAH1, aCDase) self-activated
1OGS	;	2.0	;	human acid-beta-glucosidase
1RG8	;	1.1	;	Human Acidic Fibroblast Growth Factor (haFGF-1) at 1.10 angstrom resolution (140 amino acid form)
1P63	;	1.6	;	Human Acidic Fibroblast Growth Factor. 140 Amino Acid Form with Amino Terminal His Tag and Leu111 Replaced with Ile (L111I)
1JT3	;	1.95	;	Human Acidic Fibroblast Growth Factor. 141 Amino Acid Form with Amino Histidine Tag AND LEU 73 REPLACED BY VAL (L73V)
1JY0	;	1.7	;	Human acidic fibroblast growth factor. 141 amino acid form with amino terminal His tag and Cys 117 replaced with Val (C117V).
1JTC	;	1.7	;	Human Acidic Fibroblast Growth Factor. 141 Amino Acid Form with Amino Terminal His Tag AND LEU 44 REPLACED BY PHE (L44F)
1JT7	;	1.7	;	Human Acidic Fibroblast Growth Factor. 141 Amino Acid Form with Amino Terminal His Tag AND LEU 44 REPLACED BY PHE AND LEU 73 REPLACED BY VAL AND VAL 109 REPLACED BY LEU (L44F/L73V/V109L)
1M16	;	1.7	;	Human Acidic Fibroblast Growth Factor. 141 Amino Acid Form with Amino Terminal His Tag and Leu 44 Replaced with Phe (L44F), Leu 73 Replaced with Val (L73V), Val 109 Replaced with Leu (V109L) and Cys 117 Replaced with Val (C117V).
1JT5	;	1.85	;	Human Acidic Fibroblast Growth Factor. 141 Amino Acid Form with Amino Terminal His Tag AND LEU 73 REPLACED BY VAL AND VAL 109 REPLACED BY LEU (L73V/V109L)
1JT4	;	1.78	;	Human Acidic Fibroblast Growth Factor. 141 Amino Acid Form with Amino Terminal His Tag AND VAL 109 REPLACED BY LEU (V109L)
1K5V	;	2.1	;	Human acidic fibroblast growth factor. 141 amino acid form with amino terminal His tag with Asn106 replaced by Gly (N106G).
1K5U	;	2.0	;	Human acidic fibroblast growth factor. 141 amino acid form with amino terminal His tag with His93 replaced by Gly (H93G).
1JQZ	;	1.65	;	Human Acidic Fibroblast Growth Factor. 141 Amino Acid Form with Amino Terminal His Tag.
4QGN	;	3.05	;	Human acireductone dioxygenase with iron ion and L-methionine in active center
4FO0	;	2.6	;	Human actin-related protein Arp8 in its ATP-bound state
1AUT	;	2.8	;	Human activated protein C
4GAH	;	2.3	;	Human acyl-CoA thioesterases 4 in complex with undecan-2-one-CoA inhibitor
3B7K	;	2.7	;	Human Acyl-coenzyme A thioesterase 12
4MOC	;	2.5	;	Human Acyl-coenzyme A Thioesterase 12
3K2I	;	2.4	;	Human Acyl-coenzyme A thioesterase 4
5W78	;	2.271	;	Human acyloxyacyl hydrolase (AOAH), proteolytically processed
5W7C	;	2.23	;	Human acyloxyacyl hydrolase (AOAH), proteolytically processed, S263A mutant, with LPS
2K7K	;		;	Human Acylphosphatase (AcPh) common type
2K7J	;		;	Human Acylphosphatase(AcPh) surface charge-optimized
6D06	;	2.55	;	Human ADAR2d E488Y mutant complexed with dsRNA containing an abasic site opposite the edited base
1ORE	;	2.1	;	Human Adenine Phosphoribosyltransferase
1ZN8	;	1.76	;	Human Adenine Phosphoribosyltransferase Complexed with AMP, in Space Group P1 at 1.76 A Resolution
1ZN7	;	1.83	;	Human Adenine Phosphoribosyltransferase Complexed with PRPP, ADE and R5P
1ZN9	;	2.05	;	Human Adenine Phosphoribosyltransferase in Apo and AMP Complexed Forms
5HP3	;	3.091	;	Human Adenosine Deaminase Acting on dsRNA (ADAR2) bound to dsRNA sequence derived from S. cerevisiae BDF2 gene with AC mismatch at reaction site
5HP2	;	2.983	;	Human Adenosine Deaminase Acting on dsRNA (ADAR2) bound to dsRNA sequence derived from S. cerevisiae BDF2 gene with AU basepair at reaction site
5ED2	;	2.95	;	Human Adenosine Deaminase Acting on dsRNA (ADAR2) mutant E488Q bound to dsRNA sequence derived from human GLI1 gene
5ED1	;	2.77	;	Human Adenosine Deaminase Acting on dsRNA (ADAR2) mutant E488Q bound to dsRNA sequence derived from S. cerevisiae BDF2 gene
8E4X	;	2.8	;	Human Adenosine Deaminase Acting on dsRNA (ADAR2-R2D) bound to dsRNA containing a G:3-deaza dA pair adjacent to the target site
8E0F	;	2.7	;	Human Adenosine Deaminase Acting on dsRNA (ADAR2-RD) bound to dsRNA containing a G-G pair adjacent to the target site
2I6A	;	2.2	;	Human Adenosine Kinase in Complex With 5'-Deoxy-5-Iodotubercidin
2I6B	;	2.3	;	Human Adenosine Kinase in Complex with An Acetylinic Inhibitor
4O1L	;	2.5	;	Human Adenosine Kinase in complex with inhibitor
2C6S	;	3.6	;	human adenovirus penton base 2 12 chimera
1QHV	;	1.51	;	HUMAN ADENOVIRUS SEROTYPE 2 FIBRE HEAD
2BZU	;	1.5	;	Human Adenovirus Serotype 41 Fiber Head
6ZC5	;	2.5	;	Human Adenovirus serotype D10 FiberKnob protein
8QK3	;	3.2	;	Human Adenovirus type 11 fiber knob in complex with its cell receptors, Desmoglein-2 and CD46
8QJX	;	3.3	;	Human Adenovirus type 11 fiber knob in complex with two copies of its cell receptor, Desmoglein-2
8QJY	;	3.5	;	Human Adenovirus type 11 fiber knob in complex with two copies of its cell receptor, Desmoglein-2
2O39	;	2.85	;	Human Adenovirus type 11 knob in complex with domains SCR1 and SCR2 of CD46 (membrane cofactor protein, MCP)
3L89	;	3.5	;	Human Adenovirus type 21 knob in complex with domains SCR1 and SCR2 of CD46 (membrane cofactor protein, MCP)
8OFP	;	3.1	;	Human adenovirus type 24 fiber-knob protein
8OFQ	;	1.6	;	Human adenovirus type 25 fiber-knob protein
8OFR	;	2.51	;	Human adenovirus type 25 fiber-knob protein complexed with sialic acid
6QNT	;	3.5	;	Human Adenovirus type 3 fiber knob in complex with one copy of Desmoglein-2
6QNU	;	3.8	;	Human Adenovirus type 3 fiber knob in complex with two copies of Desmoglein-2
8OFS	;	2.56	;	Human adenovirus type 30 fiber-knob protein complexed with sialic acid
8OFT	;	2.0	;	Human adenovirus type 32 fiber-knob protein
8OFU	;	1.61	;	Human adenovirus type 53 fiber-knob protein
8OFV	;	1.77	;	Human adenovirus type 53 fiber-knob protein complexed with sialic acid
8COI	;	3.17	;	Human adenovirus-derived synthetic ADDobody binder
7DE3	;	2.197	;	Human adenylate kinase 1 (hAK1) mutant-R128W
2VD6	;	2.0	;	Human adenylosuccinate lyase in complex with its substrate N6-(1,2- Dicarboxyethyl)-AMP, and its products AMP and fumarate.
2V40	;	1.9	;	Human Adenylosuccinate synthetase isozyme 2 in complex with GDP
8SL3	;	7.0	;	Human adenylyl Cyclase 5 in complex with Gbg
8B55	;	1.36	;	Human ADGRG4 PTX-like domain
3P6G	;	1.2	;	Human adipocyte lipid-binding protein FABP4 in complex with (R)-ibuprofen
3P6F	;	1.2	;	Human adipocyte lipid-binding protein FABP4 in complex with (S)-3-phenyl butyric acid
3P6H	;	1.15	;	Human adipocyte lipid-binding protein FABP4 in complex with (S)-ibuprofen
3P6D	;	1.06	;	Human adipocyte lipid-binding protein FABP4 in complex with 3-(4-methoxy-3-methylphenyl) propionic acid
3P6E	;	1.08	;	Human adipocyte lipid-binding protein FABP4 in complex with 3-(4-methoxyphenyl) propionic acid
3P6C	;	1.25	;	Human adipocyte lipid-binding protein FABP4 in complex with citric acid
6AYL	;	1.86	;	Human adipocyte lipid-binding protein FABP4 in complex with fluorescein
3RZY	;	1.08	;	Human adipocyte lipid-binding protein FABP4, Apo form at 1.08 Ang resolution.
3EP6	;	1.7	;	Human AdoMetDC D174N mutant complexed with S-Adenosylmethionine methyl ester and no putrescine bound
3EP3	;	1.84	;	Human AdoMetDC D174N mutant with no putrescine bound
3EPA	;	2.1	;	Human AdoMetDC E178Q mutant complexed with putrescine
3EP8	;	1.97	;	Human AdoMetDC E178Q mutant complexed with S-Adenosylmethionine methyl ester and no putrescine bound
3EP5	;	1.99	;	Human AdoMetDC E178Q mutant with no putrescine bound
3EPB	;	1.75	;	Human AdoMetDC E256Q mutant complexed with putrescine
3EP7	;	2.0	;	Human AdoMetDC E256Q mutant complexed with S-Adenosylmethionine methyl ester and no putrescine bound
3EP4	;	1.89	;	Human AdoMetDC E256Q mutant with no putrescine bound
3DZ3	;	2.62	;	Human AdoMetDC F223A mutant with covalently bound S-Adenosylmethionine methyl ester
3H0V	;	2.24	;	Human AdoMetDC with 5'-Deoxy-5'-(dimethylsulfonio) adenosine
3H0W	;	1.81	;	Human AdoMetDC with 5'-Deoxy-5'-[(N-dimethyl)amino]-8-methyl-adenosine
3DZ4	;	1.84	;	Human AdoMetDC with 5'-[(2-carboxamidoethyl)methylamino]-5'-deoxy-8-methyladenosine
3DZ2	;	1.86	;	Human AdoMetDC with 5'-[(3-aminopropyl)methylamino]-5'deoxy-8-methyladenosine
3DZ6	;	1.83	;	Human AdoMetDC with 5'-[(4-aminooxybutyl)methylamino]-5'deoxy-8-ethyladenosine
3DZ7	;	1.91	;	Human AdoMetDC with 5'-[(carboxamidomethyl)methylamino]-5'-deoxy-8-methyladenosine
3DZ5	;	2.43	;	Human AdoMetDC with covalently bound 5'-[(2-aminooxyethyl)methylamino]-5'-deoxy-8-methyladenosine
3EP9	;	2.35	;	Human AdoMetDC with no putrescine bound
1HUR	;	2.0	;	HUMAN ADP-RIBOSYLATION FACTOR 1 COMPLEXED WITH GDP, FULL LENGTH NON-MYRISTOYLATED
2FOZ	;	1.6	;	human ADP-ribosylhydrolase 3
2FP0	;	2.05	;	human ADP-ribosylhydrolase 3
7AKR	;	1.95	;	Human ADP-ribosylserine hydrolase ARH3 mutant E41A in complex with ADP-ribose dimer
7AKS	;	1.86	;	Human ADP-ribosylserine hydrolase ARH3 mutant E41A in complex with H2B-S7-mar peptide
8HE8	;	3.05	;	Human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitor
4F0E	;	2.4	;	Human ADP-RIBOSYLTRANSFERASE 7 (ARTD7/PARP15), CATALYTIC DOMAIN IN COMPLEX WITH STO1102
8GVH	;	3.32	;	Human AE2 in acidic KNO3
5OKL	;	2.09	;	Human afamin monoclinic crystal form
6FAK	;	1.9	;	Human afamin orthorhombic crystal form by controlled hydration
8D71	;	2.5	;	Human Ago2 bound to miR122(21nt)
8D6J	;	2.5	;	Human Ago2 bound to miR122(21nt) with PIWI loop swapped to AtAgo10 sequence
4GAB	;	1.5971	;	Human AKR1B10 mutant V301L complexed with NADP+ and fidarestat
4GA8	;	1.942	;	Human AKR1B10 mutant V301L complexed with NADP+ and sorbinil
3IHJ	;	2.3	;	Human alanine aminotransferase 2 in complex with PLP
3R9A	;	2.35	;	Human alanine-glyoxylate aminotransferase in complex with the TPR domain of human PEX5P
6RV1	;	3.0	;	human Alanine:Glyoxylate Aminotransferase major allele (AGT-Ma)
6RV0	;	2.7	;	human Alanine:Glyoxylate Aminotransferase major allele (AGT-Ma); with PMP in the active site
5AC2	;	1.85	;	human aldehyde dehydrogenase 1A1 with duocarmycin analog
5FHZ	;	2.9	;	Human aldehyde dehydrogenase 1A3 complexed with NAD(+) and retinoic acid
4UHW	;	2.6	;	Human aldehyde oxidase
4UHX	;	2.7	;	Human aldehyde oxidase in complex with phthalazine and thioridazine
7ORC	;	2.7	;	Human Aldehyde Oxidase in complex with Raloxifene
6Q6Q	;	3.10004	;	Human aldehyde oxidase SNP G1269R
7OPN	;	2.6	;	Human Aldehyde Oxidase SNP R1231H in complex with Raloxifene
5EPG	;	3.39	;	Human aldehyde oxidase SNP S1271L
4WB9	;	2.07	;	Human ALDH1A1 complexed with NADH
7UM9	;	1.8	;	Human ALDH1A1 with bound compound CM38
6XML	;	1.88	;	Human aldolase A I98C
6XMO	;	2.6	;	Human aldolase A I98F
6XMM	;	2.11	;	Human aldolase A I98S
6XMH	;	1.95	;	Human aldolase A wild type
3Q67	;	1.55	;	Human Aldose Reductase C298S mutant in Complex with NADP+ in Space Group P212121
4QX4	;	1.259	;	Human Aldose Reductase complexed with a ligand with a new scaffold at 1.26 A
4YS1	;	1.07	;	Human Aldose Reductase complexed with a ligand with an IDD structure (2) at 1.07 A.
4PUU	;	1.14	;	Human Aldose Reductase complexed with a ligand with an IDD structure (2-(2-carbamoyl-5-fluoro-phenoxy)acetic acid) at 1.14 A
4QR6	;	1.05	;	Human Aldose Reductase complexed with a ligand with an IDD structure (2-[2-(1,3-benzothiazol-2-ylmethylcarbamoyl)-5-fluoro-phenoxy]acetic acid) at 1.05 A
4PUW	;	1.12	;	Human Aldose Reductase complexed with a ligand with an IDD structure (2-[5-fluoro-2-(prop-2-ynylcarbamoyl)phenoxy]acetic acid) at 1.12 A
4Q7B	;	1.19	;	Human Aldose Reductase complexed with a ligand with an IDD structure ([2-(benzylcarbamoyl)-5-fluorophenoxy]acetic acid) at 1.19 A
4QBX	;	0.98	;	Human Aldose Reductase complexed with a ligand with an IDD structure ({5-fluoro-2-[(3-nitrobenzyl)carbamoyl]phenoxy}acetic acid) at 0.98 A
4RPQ	;	1.2	;	Human Aldose Reductase complexed with a ligand with an IDD structure at 1.20 A (1)
2FZB	;	1.5	;	Human Aldose Reductase complexed with four tolrestat molecules at 1.5 A resolution.
2IKI	;	1.47	;	Human aldose reductase complexed with halogenated IDD-type inhibitor
3G5E	;	1.8	;	Human aldose reductase complexed with IDD 740 inhibitor
1EL3	;	1.7	;	HUMAN ALDOSE REDUCTASE COMPLEXED WITH IDD384 INHIBITOR
2DUZ	;	1.6	;	Human Aldose Reductase complexed with inhibitor zopolrestat after 3 days soaking (3days_soaked_2)
2FZ9	;	1.6	;	Human Aldose Reductase complexed with inhibitor zopolrestat after six days soaking.
2HV5	;	1.59	;	Human Aldose Reductase complexed with inhibitor zopolrestat after three days soaking (3days_soaked_3)
2FZ8	;	1.48	;	Human Aldose reductase complexed with inhibitor zopolrestat at 1.48 A(1 day soaking).
2IKJ	;	1.55	;	Human aldose reductase complexed with nitro-substituted IDD-type inhibitor
2IKH	;	1.55	;	Human aldose reductase complexed with nitrofuryl-oxadiazol inhibitor at 1.55 A
2NVD	;	1.55	;	Human Aldose Reductase complexed with novel naphtho[1,2-d]isothiazole acetic acid derivative (2)
2NVC	;	1.65	;	Human Aldose Reductase complexed with novel naphtho[1,2-d]isothiazole acetic acid derivative (3)
1Z89	;	1.43	;	Human Aldose Reductase complexed with novel Sulfonyl-pyridazinone Inhibitor
1Z8A	;	0.95	;	Human Aldose Reductase complexed with novel Sulfonyl-pyridazinone Inhibitor
4YU1	;	1.02	;	Human Aldose Reductase complexed with Schl12134 (3-[5-(3-nitrophenyl)-2-thienyl]propanoic acid) at 1.02 A
4PRT	;	0.96	;	Human Aldose Reductase complexed with Schl12221 ({2-[5-(3-NITROPHENYL)FURAN-2-YL]PHENYL}ACETIC ACID) at 0.96 A
4NKC	;	1.12	;	Human Aldose Reductase complexed with Schl7764 at 1.12 A
4PR4	;	1.06	;	Human Aldose Reductase complexed with Schl7802 at 1.06 A
4PRR	;	1.01	;	Human Aldose Reductase complexed with Schl7815 ((3-[3-(5-NITROFURAN-2-YL)PHENYL]PROPANOIC ACID)at 1.01 A
2FZD	;	1.08	;	Human aldose reductase complexed with tolrestat at 1.08 A resolution.
2DV0	;	1.62	;	Human Aldose Reductase complexed with zopolrestat after 6 days soaking(6days_soaked_2)
2PDY	;	1.65	;	Human aldose reductase double mutant S302R-C303D complexed with fidarestat.
2PDX	;	1.65	;	Human aldose reductase double mutant S302R-C303D complexed with zopolrestat.
8AE9	;	0.95	;	Human Aldose Reductase in Complex with a Hydroxyphenyl-Thiophen-Acid Inhibitor (Schl32357)
8BJL	;	0.97	;	Human Aldose Reductase in Complex with a Ligand with a Fluoro-Indol-Acetic-Acid Structure (Schl44172)
3T42	;	1.28	;	Human aldose reductase in complex with a nitrile-containing IDD inhibitor
6TUC	;	1.06	;	Human Aldose Reductase in complex with ALR25
6TUF	;	1.15	;	Human Aldose Reductase in complex with ALR43
2J8T	;	0.82	;	Human aldose reductase in complex with NADP and citrate at 0.82 angstrom
1US0	;	0.66	;	Human Aldose Reductase in complex with NADP+ and the inhibitor IDD594 at 0.66 Angstrom
2I16	;	0.81	;	Human aldose reductase in complex with NADP+ and the inhibitor IDD594 at temperature of 15K
2I17	;	0.81	;	Human aldose reductase in complex with NADP+ and the inhibitor IDD594 at temperature of 60K
3GHR	;	1.0	;	Human aldose reductase in complex with NADP+ and the inhibitor IDD594. Investigation of global effects of radiation damage on protein structure. First stage of radiation damage
3GHU	;	1.2	;	Human aldose reductase in complex with NADP+ and the inhibitor IDD594. Investigation of global effects of radiation damage on protein structure. Forth stage of radiation damage.
3GHS	;	1.0	;	Human aldose reductase in complex with NADP+ and the inhibitor IDD594. Investigation of global effects of radiation damage on protein structure. Second stage of radiation damage.
3GHT	;	1.1	;	Human aldose reductase in complex with NADP+ and the inhibitor IDD594. Investigation of global effects of radiation damage on protein structure. Third stage of radiation damage.
1Z3N	;	1.04	;	Human aldose reductase in complex with NADP+ and the inhibitor lidorestat at 1.04 angstrom
5HA7	;	1.65	;	Human Aldose Reductase in Complex with NADP+ and WY14643 in Space Group P212121
3Q65	;	2.09	;	Human Aldose Reductase in Complex with NADP+ in Space Group P212121
6SYW	;	0.93	;	human Aldose Reductase in complex with SAR25
8B66	;	0.95	;	Human Aldose Reductase Mutant A299G in Complex with a Ligand with an IDD Structure (3-({[2-(carboxymethoxy)-4-fluorobenzoyl]amino}methyl)benzoic acid)
8AUU	;	0.95	;	Human Aldose Reductase Mutant A299G in Complex with a Ligand with an IDD Structure ({5-fluoro-2-[(3-nitrobenzyl)carbamoyl]phenoxy}acetic acid)
8B3N	;	1.03	;	Human Aldose Reductase Mutant A299G/L300G in Complex with a Ligand with an IDD Structure (3-({[2-(carboxymethoxy)-4-fluorobenzoyl]amino}methyl)benzoic acid)
8B3R	;	0.96	;	Human Aldose Reductase Mutant A299G/L300G in Complex with a Ligand with an IDD Structure ({5-fluoro-2-[(3-nitrobenzyl)carbamoyl]phenoxy}acetic acid)
2PDW	;	1.55	;	Human aldose reductase mutant C303D complexed with fidarestat.
2PDU	;	1.55	;	Human aldose reductase mutant C303D complexed with IDD393.
2PDQ	;	1.73	;	Human aldose reductase mutant C303D complexed with uracil-type inhibitor.
2PDC	;	1.65	;	Human aldose reductase mutant F121P complexed with IDD393.
2PDB	;	1.6	;	Human aldose reductase mutant F121P complexed with zopolrestat.
6Y1P	;	0.94	;	Human Aldose Reductase Mutant L300/301A in Complex with a Ligand with an IDD Structure (3-({[2-(carboxymethoxy)-4-fluorobenzoyl]amino}methyl)benzoic acid)
6XUM	;	0.97	;	Human Aldose Reductase Mutant L300/301A in Complex with a Ligand with an IDD Structure ({5-fluoro-2-[(3-nitrobenzyl)carbamoyl]phenoxy}acetic acid)
2PDJ	;	1.57	;	Human aldose reductase mutant L300A complexed with IDD393.
2PDI	;	1.55	;	Human aldose reductase mutant L300A complexed with zopolrestat at 1.55 A.
6TXP	;	0.95	;	Human Aldose Reductase Mutant L300A in Complex with a Ligand with an IDD Structure (3-({[2-(carboxymethoxy)-4-fluorobenzoyl]amino}methyl)benzoic acid)
6T3P	;	0.97	;	Human Aldose Reductase Mutant L300A in Complex with a Ligand with an IDD Structure ({5-fluoro-2-[(3-nitrobenzyl)carbamoyl]phenoxy}acetic acid)
8CNP	;	0.94	;	Human Aldose Reductase Mutant L300G in Complex with a Ligand with an IDD Structure (3-({[2-(carboxymethoxy)-4-fluorobenzoyl]amino}methyl)benzoic acid)
8CNF	;	0.95	;	Human Aldose Reductase Mutant L300G in Complex with a Ligand with an IDD Structure ({5-fluoro-2-[(3-nitrobenzyl)carbamoyl]phenoxy}acetic acid)
2PDH	;	1.45	;	Human aldose reductase mutant L300P complexed with uracil-type inhibitor at 1.45 A.
2PDF	;	1.56	;	Human aldose reductase mutant L300P complexed with zopolrestat.
6T7Q	;	1.01	;	Human Aldose Reductase Mutant L301A in Complex with a Ligand with an IDD Structure (3-({[2-(carboxymethoxy)-4-fluorobenzoyl]amino}methyl)benzoic acid)
6TD8	;	0.97	;	Human Aldose Reductase Mutant L301A in Complex with a Ligand with an IDD Structure ({5-fluoro-2-[(3-nitrobenzyl)carbamoyl]phenoxy}acetic acid)
2PDK	;	1.55	;	Human aldose reductase mutant L301M complexed with sorbinil.
2PDL	;	1.47	;	Human aldose reductase mutant L301M complexed with tolrestat.
2PDP	;	1.65	;	Human aldose reductase mutant S302R complexed with IDD 393.
2PDN	;	1.7	;	Human aldose reductase mutant S302R complexed with uracil-type inhibitor.
2PDM	;	1.75	;	Human aldose reductase mutant S302R complexed with zopolrestat.
3LQL	;	1.13	;	Human Aldose Reductase mutant T113A complexed with IDD 594
3LQG	;	1.35	;	Human aldose reductase mutant T113A complexed with IDD388
3MB9	;	1.65	;	Human Aldose Reductase mutant T113A complexed with Zopolrestat
3LBO	;	1.1	;	Human aldose reductase mutant T113C complexed with IDD594
3LEP	;	0.99	;	Human Aldose Reductase mutant T113C in complex with IDD388
3LZ3	;	1.03	;	Human aldose reductase mutant T113S complexed with IDD388
3LD5	;	1.27	;	Human aldose reductase mutant T113S complexed with IDD594
3LEN	;	1.21	;	Human Aldose Reductase mutant T113S complexed with Zopolrestat
3M4H	;	0.94	;	Human Aldose Reductase mutant T113V complexed with IDD388
3M64	;	1.3	;	Human aldose reductase mutant T113V complexed with IDD393
3LZ5	;	0.95	;	Human aldose reductase mutant T113V complexed with IDD594
3MC5	;	1.14	;	Human Aldose Reductase mutant T113V in complex with IDD393 crystallized in spacegroup P1
3M0I	;	1.07	;	Human Aldose Reductase mutant T113V in complex with Zopolrestat
2PD9	;	1.55	;	Human aldose reductase mutant V47I complexed with fidarestat.
2PD5	;	1.6	;	Human aldose reductase mutant V47I complexed with zopolrestat
2R24	;	2.194	;	Human Aldose Reductase structure
2R24	;	1.752	;	Human Aldose Reductase structure
2PDG	;	1.42	;	Human aldose reductase with uracil-type inhibitor at 1.42A.
2HVO	;	1.65	;	Human Aldose Reductase-zopolrestat complex obtained by cocrystallisation (10days_cocryst)
2HVN	;	1.58	;	Human Aldose Reductase-zopolrestat complex obtained by cocrystallisation after one day (1day_cocryst)
5UDY	;	2.6	;	Human alkaline sphingomyelinase (alk-SMase, ENPP7, NPP7)
5TCD	;	2.4	;	Human alkaline sphingomyelinase (ENPP7) in complex with phosphocholine
7VJV	;	1.75	;	Human AlkB homolog ALKBH6 in complex with alpha-katoglutarate and Mn
7VJS	;	1.792	;	Human AlkB homolog ALKBH6 in complex with Tris and Ni
7EKP	;	2.85	;	human alpha 7 nicotinic acetylcholine receptor bound to EVP-6124
7EKT	;	3.02	;	human alpha 7 nicotinic acetylcholine receptor bound to EVP-6124 and PNU-120596
7EKI	;	3.18	;	human alpha 7 nicotinic acetylcholine receptor in apo-form
1HSO	;	2.5	;	HUMAN ALPHA ALCOHOL DEHYDROGENASE (ADH1A)
1ZTG	;	3.0	;	human alpha polyC binding protein KH1
5NHU	;	1.45	;	HUMAN ALPHA THROMBIN COMPLEXED WITH ANOPHELES GAMBIAE cE5 ANTICOAGULANT
1NY2	;	2.3	;	Human alpha thrombin inhibited by RPPGF and hirugen
6X5H	;	2.25	;	Human Alpha-1,6-fucosyltransferase (FUT8) bound to GDP
6X5R	;	2.4	;	Human Alpha-1,6-fucosyltransferase (FUT8) bound to GDP and A2-Asn
6X5S	;	3.3	;	Human Alpha-1,6-fucosyltransferase (FUT8) bound to GDP and A3'-Asn
6X5T	;	2.47	;	Human Alpha-1,6-fucosyltransferase (FUT8) bound to GDP and A3-Asn
6X5U	;	3.2	;	Human Alpha-1,6-fucosyltransferase (FUT8) bound to GDP and NM5M2-Asn
2PM4	;	1.95	;	Human alpha-defensin 1 (multiple Arg->Lys mutant)
2PM5	;	2.4	;	Human alpha-defensin 1 derivative (HNP1)
3HG2	;	2.3	;	Human alpha-galactosidase catalytic mechanism 1. Empty active site
3HG3	;	1.9	;	Human alpha-galactosidase catalytic mechanism 2. Substrate bound
3HG4	;	2.3	;	Human alpha-galactosidase catalytic mechanism 3. Covalent intermediate
3HG5	;	2.3	;	Human alpha-galactosidase catalytic mechanism 4. Product bound
3S48	;	3.05	;	Human Alpha-Haemoglobin Complexed with the First NEAT Domain of IsdH from Staphylococcus aureus
3W81	;	2.3	;	Human alpha-l-iduronidase
3W82	;	2.76	;	Human alpha-L-iduronidase in complex with iduronic acid
1B9O	;	1.15	;	HUMAN ALPHA-LACTALBUMIN, LOW TEMPERATURE FORM
2FUE	;	1.75	;	Human alpha-Phosphomannomutase 1 with D-mannose 1-phosphate and Mg2+ cofactor bound
2FUC	;	2.1	;	Human alpha-Phosphomannomutase 1 with Mg2+ cofactor bound
1HBT	;	2.0	;	Human alpha-thrombin complexed with a peptidyl pyridinium methyl ketone containing bivalent inhibitor
1LHF	;	2.4	;	HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BORO-HOMOLYS-OH
1LHE	;	2.25	;	HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BORO-N-BUTYL-AMIDINO-GLYCINE-OH
1LHC	;	1.95	;	HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BOROARG-OH
1LHD	;	2.35	;	HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BOROLYS-OH
1LHG	;	2.25	;	HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BOROORNITHINE-OH
3TU7	;	2.49	;	Human alpha-thrombin complexed with N-(methylsulfonyl)-D-phenylalanyl-N-((1-carbamimidoyl-4-piperidinyl)methyl)-l-prolinamide (BMS-189664)
1BMN	;	2.8	;	HUMAN ALPHA-THROMBIN COMPLEXED WITH [S-(R*,R*)]-1-(AMINOIMINOMETHYL)-N-[[1-[N-[(2-NAPHTHALENYLSULFONYL)-L-SERYL]-PYRROLIDINYL]METHYL]-3-PIPERIDENECARBOXAMIDE (BMS-189090)
1BMM	;	2.6	;	HUMAN ALPHA-THROMBIN COMPLEXED WITH [S-(R*,R*)]-4-[(AMINOIMINOMETHYL)AMINO]-N-[[1-[3-HYDROXY-2-[(2-NAPHTHALENYLSULFONYL)AMINO]-1-OXOPROPYL]-2-PYRROLIDINYL] METHYL]BUTANAMIDE (BMS-186282)
1QUR	;	2.0	;	HUMAN ALPHA-THROMBIN IN COMPLEX WITH BIVALENT, BENZAMIDINE-BASED SYNTHETIC INHIBITOR
1AFE	;	2.0	;	HUMAN ALPHA-THROMBIN INHIBITION BY CBZ-PRO-AZALYS-ONP
1AE8	;	2.0	;	HUMAN ALPHA-THROMBIN INHIBITION BY EOC-D-PHE-PRO-AZALYS-ONP
1AIX	;	2.1	;	HUMAN ALPHA-THROMBIN TERNARY COMPLEX WITH EXOSITE INHIBITOR HIRUGEN AND ACTIVE SITE INHIBITOR PHCH2OCO-D-DPA-PRO-BOROVAL
1AI8	;	1.85	;	HUMAN ALPHA-THROMBIN TERNARY COMPLEX WITH THE EXOSITE INHIBITOR HIRUGEN AND ACTIVE SITE INHIBITOR PHCH2OCO-D-DPA-PRO-BOROMPG
7SR9	;	2.1	;	Human alpha-thrombin with 180- and 220- loops replaced with homologous loops from protein C
3VXE	;	1.25	;	Human alpha-thrombin-Bivalirudin complex at PD5.0
6AVR	;	35.0	;	Human alpha-V beta-3 Integrin (intermediate conformation) in complex with the therapeutic antibody LM609
6AVU	;	35.0	;	Human alpha-V beta-3 Integrin (open conformation) in complex with the therapeutic antibody LM609
8D0O	;	2.1	;	Human alpha1,3-fucosyltransferase FUT9, heavy atom derivative
1LTO	;	2.2	;	Human alpha1-tryptase
2P9R	;	2.3	;	Human alpha2-macroglogulin is composed of multiple domains, as predicted by homology with complement component C3
8D3W	;	3.5	;	Human alpha3 Na+/K+-ATPase in its AMPPCP-bound cytoplasmic side-open state
8D3V	;	3.4	;	Human alpha3 Na+/K+-ATPase in its cytoplasmic side-open state
8D3Y	;	3.9	;	Human alpha3 Na+/K+-ATPase in its exoplasmic side-open state
8D3X	;	4.1	;	Human alpha3 Na+/K+-ATPase in its K+-occluded state
8D3U	;	3.7	;	Human alpha3 Na+/K+-ATPase in its Na+-occluded state
6PV8	;	3.87	;	Human alpha3beta4 nicotinic acetylcholine receptor in complex with AT-1001
6PV7	;	3.34	;	Human alpha3beta4 nicotinic acetylcholine receptor in complex with nicotine
8C9X	;	2.3	;	human alpha7 nicotinic receptor in complex with the C4 nanobody
8CAU	;	3.4	;	human alpha7 nicotinic receptor in complex with the C4 nanobody and nicotine
8CI2	;	4.4	;	human alpha7 nicotinic receptor in complex with the C4 nanobody under sub-saturating conditions
8CE4	;	2.7	;	Human alpha7 nicotinic receptor in complex with the E3 nanobody
8CI1	;	2.8	;	Human alpha7 nicotinic receptor in complex with the E3 nanobody and nicotine
2WJ7	;	2.631	;	human alphaB crystallin
3L1G	;	3.32	;	Human AlphaB crystallin
2Y1Z	;	2.5	;	Human alphaB Crystallin ACD R120G
2Y1Y	;	2.0	;	Human alphaB crystallin ACD(residues 71-157)
4M5S	;	1.37	;	Human alphaB crystallin core domain in complex with C-terminal peptide
2Y22	;	3.7	;	Human AlphaB-crystallin Domain (residues 67-157)
5AOX	;	2.04	;	Human Alu RNA retrotransposition complex in the ribosome-stalling conformation
2V9Y	;	2.1	;	Human aminoimidazole ribonucleotide synthetase
4FYQ	;	1.9	;	Human aminopeptidase N (CD13)
4FYT	;	1.85	;	Human aminopeptidase N (CD13) in complex with amastatin
4FYS	;	2.01	;	Human aminopeptidase N (CD13) in complex with angiotensin IV
4FYR	;	1.91	;	Human aminopeptidase N (CD13) in complex with bestatin
3AQV	;	2.08	;	Human AMP-activated protein kinase alpha 2 subunit kinase domain (T172D) complexed with compound C
7TYF	;	2.2	;	Human Amylin1 Receptor in complex with Gs and rat amylin peptide
7TYW	;	3.0	;	Human Amylin1 Receptor in complex with Gs and salmon calcitonin peptide
7TYH	;	3.3	;	Human Amylin2 Receptor in complex with Gs and human calcitonin peptide
7TYX	;	2.55	;	Human Amylin2 Receptor in complex with Gs and rat amylin peptide
7TYY	;	3.0	;	Human Amylin2 Receptor in complex with Gs and salmon calcitonin peptide
8F0K	;	1.9	;	Human Amylin3 Receptor in complex with Gs and Pramlintide analogue peptide San385
8F2A	;	2.2	;	Human Amylin3 Receptor in complex with Gs and Pramlintide analogue peptide San385 (Cluster 5 conformation)
7TZF	;	2.4	;	Human Amylin3 Receptor in complex with Gs and rat amylin peptide
2YHD	;	2.2	;	Human androgen receptor in complex with AF2 small molecule inhibitor
1E3G	;	2.4	;	Human Androgen Receptor Ligand Binding in complex with the ligand metribolone (R1881)
5M9R	;	1.44	;	Human angiogenin ALS variant F100I
5M9T	;	2.2	;	Human angiogenin ALS variant H114R
5M9C	;	2.05	;	Human angiogenin ALS variant K40R
5M9P	;	1.8	;	Human angiogenin ALS variant T80S
5M9S	;	1.85	;	Human angiogenin ALS variant V103I
5EPZ	;	1.85	;	Human Angiogenin in complex with sulphate anions at a basic solution
5EQO	;	2.4	;	Human Angiogenin in complex with sulphate anions at an acidic solution
7PNP	;	1.8	;	Human Angiogenin mutant-S28A
7PNR	;	1.6	;	Human Angiogenin mutant-S28AT36AS37A
5M9A	;	1.95	;	Human angiogenin PD variant H13R
5M9G	;	2.28	;	Human angiogenin PD variant K54R
5M9J	;	1.9	;	Human angiogenin PD variant K60E
5M9M	;	1.65	;	Human angiogenin PD variant Q77P
5M9Q	;	1.35	;	Human angiogenin PD variant R95Q
5M9V	;	1.7	;	Human angiogenin PD/ALS variant R121C
7PNJ	;	3.1	;	Human Angiogenin quardruple mutant-S28AT36AS37AS87A
6U0A	;	2.11	;	Human Angiopoietin-Like 4 C-Terminal Domain (cANGPTL4) with Glycerol
6U73	;	2.38	;	Human Angiopoietin-Like 4 C-Terminal Domain (cANGPTL4) with Myristic Acid
6U1U	;	1.75	;	Human Angiopoietin-Like 4 C-Terminal Domain (cANGPTL4) with Palmitic Acid
4BZS	;	2.1	;	Human angiotenisn converting enzyme N-domain in complex with K-26
2XYD	;	2.15	;	human Angiotenisn converting enzyme N-domain in complex with Phosphinic tripeptide
4CA5	;	1.85	;	Human Angiotensin converting enzyme in complex with a phosphinic tripeptide FI
2XY9	;	1.97	;	Human Angiotensin converting enzyme in complex with phosphinic tripeptide
4CA6	;	1.91	;	Human Angiotensin converting enzyme N-domain in complex with a phosphinic tripeptide FI
8QFX	;	1.6	;	Human Angiotensin-1 converting enzyme N-domain in complex with the lactotripeptide IPP
8QHL	;	1.9	;	Human Angiotensin-1 converting enzyme N-domain in complex with the lactotripeptide VPP
4APH	;	1.99	;	Human angiotensin-converting enzyme in complex with angiotensin-II
4APJ	;	2.6	;	Human angiotensin-converting enzyme in complex with BPPb
7Z9F	;	1.7	;	Human anionic trypsin after autoproteolysis at Arg122
7DTO	;	2.8	;	Human Annexin A2 with C132-C261 intramolecular disulfide bond
2HYW	;	2.1	;	Human Annexin A2 with Calcium bound
2HYV	;	1.42	;	Human Annexin A2 with heparin hexasaccharide bound
2HYU	;	1.86	;	Human Annexin A2 with heparin tetrasaccharide bound
2XO2	;	2.8	;	Human Annexin V with incorporated Methionine analogue Azidohomoalanine
2XO3	;	2.3	;	Human Annexin V with incorporated Methionine analogue Homopropargylglycine
1SAV	;	2.5	;	HUMAN ANNEXIN V WITH PROLINE SUBSTITUTION BY THIOPROLINE
6A4K	;	3.15	;	Human antibody 32D6 Fab in complex with H1N1 influenza A virus HA1
6JP7	;	1.909	;	Human antibody 32D6 Fab in complex with PEG
4YK4	;	2.8	;	Human antibody 641 I-9 in complex with influenza hemagglutinin H1 Solomon Islands/03/2006
5IBL	;	3.39	;	Human antibody 6639 in complex with influenza hemagglutinin H1 X-181
5W6G	;	2.79	;	Human antibody 6649 in complex with influenza hemagglutinin H1 Solomon Islands
6XPQ	;	4.2	;	Human antibody D1 H1-17/H3-14 in complex with the influenza hemagglutinin head domain of A/Texas/50/2012(H3N2)
6XPR	;	4.092	;	Human antibody D2 H1-1/H3-1 H3 in complex with the influenza hemagglutinin head domain of A/Texas/50/2012(H3N2)
5UR8	;	1.755	;	Human antibody fragment (Fab) to meningococcal Factor H binding protein
6Q18	;	2.55	;	Human antibody H1244 in complex with the influenza hemagglutinin head domain of A/Beijing/262/95(H1N1)
6Q1G	;	1.75	;	Human antibody H1244 of the human antibody lineage 652
6E56	;	2.0	;	Human antibody H2214 in complex with influenza hemagglutinin A/Aichi/2/1968 (X-31) (H3N2)
6Q0O	;	3.0	;	human antibody H2227 lineage 652 in complex with influenza hemagglutinin head domain of A/Solomon Islands/3/2006(H1N1)
4YJZ	;	2.72	;	Human antibody H2526 in complex with influenza hemagglutinin H1 Solomon Islands/03/2006
5UG0	;	3.4	;	Human antibody H2897 in complex with influenza hemagglutinin H1 Solomon Islands/03/2006
7TRH	;	3.0	;	Human antibody K03.28 in complex with the influenza hemagglutinin head domain of A/California/07/2009(H1N1)(X-181)
6XPX	;	2.598	;	Human antibody S1V2-51 in complex with the influenza hemagglutinin head domain of A/Aichi/2/1968 (X-31)(H3N2)
6XPY	;	3.603	;	Human antibody S1V2-58 in complex with the influenza hemagglutinin head domain of A/Texas/50/2012(H3N2)
6XPZ	;	3.45	;	Human antibody S1V2-83 in complex with the influenza hemagglutinin head domain of A/Moscow/10/1999(H3N2)
6E4X	;	2.25	;	Human antibody S5V2-29 in complex with influenza hemagglutinin A/Texas/50/2012 (H3N2)
7TRI	;	3.6	;	Human antibody S8V1-172 in complex with the influenza hemagglutinin head domain of A/Sydney/05/1997(H3N2)
6XQ0	;	2.3	;	Human antibody S8V2-18 in complex with the influenza hemagglutinin head domain of A/California/7/2009(NYMC-X181)(H1N1)
6XQ2	;	3.002	;	Human antibody S8V2-37 in complex with the influenza hemagglutinin head domain of A/Texas/50/2012(H3N2)
6XQ4	;	3.347	;	Human antibody S8V2-47 in complex with the influenza hemagglutinin head domain of A/Beijing/262/1995(H1N1)
6P94	;	2.09	;	Human APE1 C65A AP-endonuclease product complex
5DFJ	;	1.85	;	Human APE1 E96Q/D210N mismatch substrate complex
1DE9	;	3.0	;	HUMAN APE1 ENDONUCLEASE WITH BOUND ABASIC DNA AND MN2+ ION
7TC2	;	1.43	;	Human APE1 in complex with 5-nitroindole-2-carboxylic acid
7TC3	;	1.252	;	Human APE1 in the apo form
6P93	;	2.1	;	Human APE1 K98A AP-endonuclease product complex
5DFH	;	1.949	;	Human APE1 mismatch product complex
5DFI	;	1.63	;	Human APE1 phosphorothioate substrate complex
5DG0	;	1.8	;	Human APE1 phosphorothioate substrate complex with Mn2+
5DFF	;	1.57	;	Human APE1 product complex
6BOQ	;	1.96	;	Human APE1 substrate complex with an A/A mismatch adjacent the THF
6BOS	;	2.304	;	Human APE1 substrate complex with an A/C mismatch adjacent the THF
6BOV	;	1.975	;	Human APE1 substrate complex with an A/G mismatch adjacent the THF
6BOT	;	2.3	;	Human APE1 substrate complex with an C/C mismatch adjacent the THF
6BOR	;	1.84	;	Human APE1 substrate complex with an G/G mismatch adjacent the THF
6BOU	;	2.538	;	Human APE1 substrate complex with an T/C mismatch adjacent the THF
6BOW	;	1.59	;	Human APE1 substrate complex with an T/T mismatch adjacent the THF
7MCR	;	1.9	;	Human Apex/Ref1 homodimer formed under oxidative condition
7MEV	;	1.6	;	Human Apex/Ref1 monomer with C138A mutation
4PYI	;	1.35	;	human apo COMT
6M52	;	2.6	;	Human apo ferritin frozen on TEM grid with amorphous carbon supporting film
6M54	;	2.4	;	Human apo ferritin frozen on TEM grid with Amorphous nickel titanium alloy supporting film
7Z5G	;	2.113	;	human apo MATCAP
6UMV	;	1.424	;	Human apo PD-1 double mutant
6UMU	;	1.183	;	Human apo PD-1 triple mutant
8BDC	;	2.65	;	Human apo TRPM8 in a closed state (composite map)
4PYJ	;	1.9	;	human apo-COMT, single domain swap
6FFK	;	1.94	;	Human apo-SOD1 bound to PtCl2(1R,2R-1,4-DACH
6AYG	;	4.65	;	Human Apo-TRPML3 channel at pH 4.8
6AYE	;	4.06	;	Human apo-TRPML3 channel at pH 7.4
8FVI	;	3.24	;	Human APOBEC3H bound to HIV-1 Vif in complex with CBF-beta, ELOB, ELOC, and CUL5
8CPS	;	1.82	;	Human apoferritin
8CPV	;	1.76	;	Human apoferritin
8CPW	;	1.79	;	Human apoferritin after 405 nm + 488 nm laser exposure in presence of rsEGFP2
8CPM	;	1.81	;	Human apoferritin after 405 nm laser exposure
8CPT	;	1.79	;	Human apoferritin after 488 nm laser exposure
8CPX	;	1.76	;	Human apoferritin after 488 nm laser exposure in presence of rsEGFP2
8CPU	;	1.76	;	Human apoferritin after 561 nm laser exposure
1IOJ	;		;	HUMAN APOLIPOPROTEIN C-I, NMR, 18 STRUCTURES
8AX9	;	1.549	;	Human Apolipoprotein E4 (ApoE4) N-terminal domain (space group P212121)
8AX8	;	1.551	;	Human Apolipoprotein E4 (ApoE4) N-terminal domain (space group P3121)
4NDI	;	1.9	;	Human Aprataxin (Aptx) AOA1 variant K197Q bound to RNA-DNA, AMP, and Zn - product complex
4NDH	;	1.848	;	Human Aprataxin (Aptx) bound to DNA, AMP, and Zn - product complex
6CVO	;	2.4	;	Human Aprataxin (Aptx) bound to nicked RNA-DNA, AMP and Zn product complex
4NDG	;	2.541	;	Human Aprataxin (Aptx) bound to RNA-DNA and Zn - adenosine vanadate transition state mimic complex
4NDF	;	1.944	;	Human Aprataxin (Aptx) bound to RNA-DNA, AMP, and Zn - product complex
6CVQ	;	1.65	;	Human Aprataxin (Aptx) H201Q bound to RNA-DNA, AMP and Zn product complex
6CVS	;	2.11	;	Human Aprataxin (Aptx) L248M bound to DNA, AMP and Zn product
6CVP	;	1.999	;	Human Aprataxin (Aptx) R199H bound to RNA-DNA, AMP and Zn product complex
6CVR	;	1.88	;	Human Aprataxin (Aptx) S242N bound to RNA-DNA, AMP and Zn product complex
6CVT	;	2.941	;	Human Aprataxin (Aptx) V263G bound to RNA-DNA, AMP and Zn product complex
4IEM	;	2.3936	;	Human apurinic/apyrimidinic endonuclease (APE1) with product DNA and Mg2+
1DE8	;	2.95	;	HUMAN APURINIC/APYRIMIDINIC ENDONUCLEASE-1 (APE1) BOUND TO ABASIC DNA
4CSK	;	3.28	;	human Aquaporin
3D9S	;	2.0	;	Human Aquaporin 5 (AQP5) - High Resolution X-ray Structure
7K4G	;	1.8	;	Human Arginase 1 in complex with compound 01.
7K4H	;	1.65	;	Human Arginase 1 in complex with compound 04.
7K4I	;	1.98	;	Human Arginase 1 in complex with compound 06.
7K4J	;	1.94	;	Human Arginase 1 in complex with compound 51.
7K4K	;	2.27	;	Human Arginase 1 in complex with compound 52.
1PQ3	;	2.7	;	Human Arginase II: Crystal Structure and Physiological Role in Male and Female Sexual Arousal
6V7D	;	1.82	;	Human Arginase1 Complexed with Bicyclic Inhibitor Compound 10
6V7E	;	1.99	;	Human Arginase1 Complexed with Bicyclic Inhibitor Compound 12
6V7F	;	2.02	;	Human Arginase1 Complexed with Bicyclic Inhibitor Compound 13
6V7C	;	1.8	;	Human Arginase1 Complexed with Bicyclic Inhibitor Compound 3
7KLL	;	2.22	;	Human Arginase1 Complexed with Inhibitor Compound 18
7KLM	;	2.27	;	Human Arginase1 Complexed with Inhibitor Compound 24a
7KLK	;	1.801	;	Human Arginase1 Complexed with Inhibitor Compound 3a
1AOS	;	4.2	;	HUMAN ARGININOSUCCINATE LYASE
8COG	;	3.499	;	Human arginylated beta-actin
4F3T	;	2.25	;	Human Argonaute-2 - miR-20a complex
5KI6	;	2.153	;	Human Argonaute-2 bound to a guide RNA with a nucleobase modification at position 1
5JS2	;	2.954	;	Human Argonaute-2 Bound to a Modified siRNA
6RA4	;	1.9	;	Human ARGONAUTE-2 PAZ DOMAIN (214-347) IN COMPLEX WITH CGUGACUCU
4Z4H	;	2.504	;	Human Argonaute2 A481T Mutant Bound to t1-A Target RNA
4Z4I	;	2.801	;	Human Argonaute2 A481T Mutant Bound to t1-G Target RNA
5JS1	;	2.499	;	Human Argonaute2 Bound to an siRNA
4Z4C	;	2.303	;	Human Argonaute2 Bound to t1-C Target RNA
4Z4F	;	2.8	;	Human Argonaute2 Bound to t1-DAP Target RNA
4Z4D	;	1.6	;	Human Argonaute2 Bound to t1-G Target RNA
4Z4G	;	2.7	;	Human Argonaute2 Bound to t1-Inosine Target RNA
4Z4E	;	1.8	;	Human Argonaute2 Bound to t1-U Target RNA
5WEA	;	3.12	;	Human Argonaute2 Helix-7 Mutant
6N4O	;	2.899	;	Human Argonaute2-miR-122 bound to a seed and supplementary paired target
6NIT	;	3.8	;	Human Argonaute2-miR-122 bound to a target RNA with four central mismatches (bu4)
6MFR	;	3.6	;	Human Argonaute2-miR-122 bound to a target RNA with three central mismatches (bu3)
6MDZ	;	3.4	;	Human Argonaute2-miR-122 bound to a target RNA with two central mismatches (bu2)
6MFN	;	2.5	;	Human Argonaute2-miR-27a bound to HSUR1 target RNA
7KI3	;	3.0	;	Human Argonaute2:miR-122 bound to the HCV genotype 1a site-1 RNA
5VM9	;	3.28	;	Human Argonaute3 bound to guide RNA
6OON	;	1.9	;	Human Argonaute4 bound to guide RNA
1X0O	;		;	human ARNT C-terminal PAS domain
2K7S	;		;	Human ARNT C-Terminal PAS Domain, 3 Residue IB slip
8G4A	;	1.97	;	Human ARNT PAS-B complexed with KG-548 small molecule
4GV7	;	2.89	;	Human ARTD1 (PARP1) - Catalytic domain in complex with inhibitor ME0328
4R6E	;	2.2	;	Human artd1 (parp1) - catalytic domain in complex with inhibitor niraparib
4UXB	;	3.22	;	Human ARTD1 (PARP1) - Catalytic domain in complex with inhibitor PJ34
4UND	;	2.2	;	HUMAN ARTD1 (PARP1) - CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR TALAZOPARIB
4R5W	;	2.84	;	Human artd1 (parp1) - catalytic domain in complex with inhibitor xav939
4RV6	;	3.19	;	Human ARTD1 (PARP1) catalytic domain in complex with inhibitor Rucaparib
4F0D	;	2.7	;	Human ARTD15/PARP16 IN COMPLEX WITH 3-AMINOBENZAMIDE
4TVJ	;	2.1	;	HUMAN ARTD2 (PARP2) - CATALYTIC DOMAIN IN COMPLEX WITH OLAPARIB
7AEO	;	2.8	;	Human ARTD2 in complex with DNA oligonucleotides
4GV4	;	1.8	;	Human ARTD3 (PARP3) - Catalytic domain in complex with inhibitor ME0328
4L70	;	2.0	;	Human artd3 (parp3) - catalytic domain in complex with inhibitor ME0352
4GV2	;	1.8	;	Human ARTD3 (PARP3) - Catalytic domain in complex with inhibitor ME0354
4GV0	;	1.9	;	Human ARTD3 (PARP3) - Catalytic domain in complex with inhibitor ME0355
4L7L	;	2.1	;	Human artd3 (parp3) - catalytic domain in complex with inhibitor ME0368
4L7P	;	2.3	;	Human artd3 (parp3) - catalytic domain in complex with inhibitor ME0395
4L7U	;	2.8	;	Human artd3 (parp3) - catalytic domain in complex with inhibitor ME0398
4L7R	;	2.2	;	Human artd3 (parp3) - catalytic domain in complex with inhibitor ME0400
4L6Z	;	2.0	;	Human artd3 (parp3) - catalytic domain in complex with inhibitor STO1168
4L7N	;	1.8	;	Human artd3 (parp3) - catalytic domain in complex with inhibitor STO1542
4L7O	;	2.0	;	Human artd3 (parp3) - catalytic domain in complex with inhibitor STO1542
4F1Q	;	2.8	;	Human Artd8 (Parp14, Bal2) - catalytic domain in complex with A16(E)
4F1L	;	1.9	;	Human Artd8 (Parp14, Bal2) - catalytic domain in complex with inhibitor A16(Z)
6WO0	;	1.97	;	human Artemis/SNM1C catalytic domain, crystal form 1
6WNL	;	2.37	;	human Artemis/SNM1C catalytic domain, crystal form 2
1AUK	;	2.1	;	HUMAN ARYLSULFATASE A
7RNN	;	2.86	;	Human ASIC1a-Nb.C1 complex
6GQ3	;	1.85	;	Human asparagine synthetase (ASNS) in complex with 6-diazo-5-oxo-L-norleucine (DON) at 1.85 A resolution
8TC8	;	1.9	;	Human asparaginyl-tRNA synthetase bound to adenosine 5'-sulfamate
8TC9	;	2.0	;	Human asparaginyl-tRNA synthetase bound to OSM-S-106
8H53	;	2.16	;	Human asparaginyl-tRNA synthetase in complex with asparagine-AMP
8TC7	;	1.9	;	Human asparaginyl-tRNA synthetase, apo form
1APY	;	2.0	;	HUMAN ASPARTYLGLUCOSAMINIDASE
1APZ	;	2.3	;	HUMAN ASPARTYLGLUCOSAMINIDASE COMPLEX WITH REACTION PRODUCT
8H3H	;	3.15	;	Human ATAD2 Walker B mutant, ATP state
8JUW	;	3.79	;	Human ATAD2 Walker B mutant-H3/H4K5Q complex, ATP state
8JUY	;	4.34	;	Human ATAD2 Walker B mutant-H3/H4K5Q complex, ATP state (Class II)
8JUZ	;	4.29	;	Human ATAD2 Walker B mutant-H3/H4K5Q complex, ATP state (Class III)
8FKM	;		;	Human Atg3 with deletions of residues 1 to 25 and 90 to 190
6B9G	;	3.0	;	human ATL1 GTPase domain bound to GDP
6B9F	;	1.9	;	Human ATL1 mutant - F151S bound to GDPAlF4-
6B9E	;	1.99	;	Human ATL1 mutant - R77A / F151S bound to GDP
6B9D	;	1.95	;	Human ATL1 mutant - R77A bound to GDP
7OL3	;	1.9	;	Human ATL1 N417ins (catalytic core)
6XJN	;	2.2	;	Human atlastin-1 (residues 1-439) bound to GDP-Mg2+ exhibits an ordered amino terminus
4IDO	;	2.091	;	human atlastin-1 1-446, C-his6, GDPAlF4-
4IDN	;	2.252	;	Human atlastin-1 1-446, C-his6, GppNHp
4IDQ	;	2.295	;	human atlastin-1 1-446, N440T, GDPAlF4-
4IDP	;	2.587	;	human atlastin-1 1-446, N440T, GppNHp
6XJO	;	2.1	;	Human atlastin-3 (residues 1-334) bound to GDP-Mg2+ exhibits an ordered amino terminus
5VGR	;	2.096	;	Human Atlastin-3, GDP-bound
7SIC	;	2.51	;	Human ATM Dimer
7SID	;	2.53	;	Human ATM Dimer Bound to Nbs1
7NI4	;	3.0	;	Human ATM kinase domain with bound M4076 inhibitor
7NI6	;	2.8	;	Human ATM kinase with bound ATPyS
7NI5	;	2.78	;	Human ATM kinase with bound inhibitor KU-55933
8H9E	;	2.53	;	Human ATP synthase F1 domain, state 1
8H9L	;	2.61	;	Human ATP synthase F1 domain, state 3a
8H9P	;	3.02	;	Human ATP synthase F1 domain, state 3b
8H9I	;	2.77	;	Human ATP synthase F1 domain, state2
8H9S	;	2.53	;	Human ATP synthase state 1 (combined)
8H9G	;	2.95	;	Human ATP synthase state 1 subregion 2
8H9F	;	2.69	;	Human ATP synthase state 1 subregion 3
8H9T	;	2.77	;	Human ATP synthase state 2 (combined)
8H9K	;	3.51	;	Human ATP synthase state 2 subregion 2
8H9U	;	2.61	;	Human ATP synthase state 3a (combined)
8H9N	;	3.56	;	Human ATP synthase state 3a subregion 2
8H9M	;	3.0	;	Human ATP synthase state 3a subregion 3
8H9V	;	3.02	;	Human ATP synthase state 3b (combined)
8H9R	;	3.97	;	Human ATP synthase state 3b subregion 2
8H9Q	;	3.47	;	Human ATP synthase state 3b subregion 3
8H9J	;	3.26	;	Human ATP synthase state2 subregion 3
7M5V	;	2.9	;	human ATP13A2 in the AMPPNP-bound occluded state
7M5X	;	2.7	;	Human ATP13A2 in the outward-facing E2 state bound to spermine and beryllium fluoride
7M5Y	;	3.0	;	human ATP13A2 in the outward-facing E2 state bound to spermine and magnesium fluoride
6GRA	;	2.6	;	Human AURKA bound to BRD-7880
6GR8	;	1.75	;	Human AURKC INCENP complex bound to BRD-7880
6GR9	;	2.25	;	Human AURKC INCENP complex bound to VX-680
4ZTR	;	2.85	;	Human Aurora A catalytic domain bound to FK1141
4ZTS	;	2.9	;	Human Aurora A catalytic domain bound to FK1142
4ZTQ	;	2.8	;	Human Aurora A catalytic domain bound to FK932
4ZS0	;	3.0	;	Human Aurora A catalytic domain bound to SB-6-OH
4AF3	;	2.75	;	Human Aurora B Kinase in complex with INCENP and VX-680
1I3E	;	1.86	;	HUMAN AZIDO-MET HEMOGLOBIN BART'S (GAMMA4)
1T2F	;	3.0	;	Human B lactate dehydrogenase complexed with NAD+ and 4-hydroxy-1,2,5-oxadiazole-3-carboxylic acid
4G9C	;	3.5	;	Human B-Raf Kinase Domain bound to a Type II Pyrazolopyridine Inhibitor
3TV6	;	3.3	;	Human B-Raf Kinase Domain in Complex with a Methoxypyrazolopyridinyl Benzamide Inhibitor
3TV4	;	3.4	;	Human B-Raf Kinase Domain in Complex with an Bromopyridine Benzamide Inhibitor
4MBJ	;	3.6	;	Human B-Raf Kinase Domain in Complex with an Imidazopyridine-based Inhibitor
3PPJ	;	3.7	;	Human B-Raf Kinase in Complex with a Furopyridine Inhibitor
3PPK	;	3.0	;	Human B-Raf Kinase in Complex with a Non-Oxime Furopyridine Inhibitor
3SKC	;	3.2	;	Human B-Raf Kinase in Complex with an Amide Linked Pyrazolopyridine Inhibitor
1I8L	;	3.0	;	HUMAN B7-1/CTLA-4 CO-STIMULATORY COMPLEX
2WJO	;	2.5	;	human Bace (beta secretase) in complex with Cyclohexanecarboxylic acid (2-(2-am ino-6-phenoxy-4H-quinazolin-3-yl)-2 -cyclohexyl-ethyl)- amide
3K5F	;	2.25	;	Human BACE-1 COMPLEX WITH AYH011
3K5G	;	2.0	;	Human bace-1 complex with bjc060
3K5C	;	2.12	;	Human BACE-1 complex with NB-216
2WEZ	;	1.7	;	Human BACE-1 in complex with 1-ethyl-N-((1S,2R)-2-hydroxy-3-(((3-(methyloxy)phenyl)methyl)amino)-1-(phenylmethyl)propyl)-4-(2-oxo-1- pyrrolidinyl)-1H-indole-6-carboxamide
2VNM	;	1.79	;	Human BACE-1 in complex with 3-(1,1-dioxidotetrahydro-2H-1,2-thiazin- 2-yl)-5-(ethylamino)-N-((1S,2R)-2-hydroxy-1-(phenylmethyl)-3-(((3-(trifluoromethyl)phenyl)methyl)amino)propyl)benzamide
2VIJ	;	1.6	;	Human BACE-1 in complex with 3-(1,1-dioxidotetrahydro-2H-1,2-thiazin- 2-yl)-5-(ethylamino)-N-((1S,2R)-2-hydroxy-1-(phenylmethyl)-3-(1,2,3,4- tetrahydro-1-naphthalenylamino)propyl)benzamide
2VJ7	;	1.6	;	Human BACE-1 in complex with 3-(ethylamino)-N-((1S,2R)-2-hydroxy-1-(phenylmethyl)-3-(((3-(trifluoromethyl)phenyl)methyl)amino)propyl)-5-(2-oxo-1-pyrrolidinyl)benzamide
2WF0	;	1.6	;	Human BACE-1 in complex with 4-ethyl-N-((1S,2R)-2-hydroxy-1-(phenylmethyl)-3-(((3-(trifluoromethyl)phenyl)methyl)amino)propyl)-8-(2-oxo-1-pyrrolidinyl)-6-quinolinecarboxamide
2WF3	;	2.08	;	Human BACE-1 in complex with 6-(ethylamino)-N-((1S,2R)-2-hydroxy-3-(((3-(methyloxy)phenyl)methyl)amino)-1-(phenylmethyl)propyl)-1-methyl-1, 3,4,5-tetrahydro-2,1-benzothiazepine-8-carboxamide 2,2-dioxide
2WF4	;	1.8	;	Human BACE-1 in complex with 6-ethyl-1-methyl-N-((1S)-2-oxo-1-(phenylmethyl)-3-(tetrahydro-2H-pyran-4-ylamino)propyl)-1,3,4,6- tetrahydro(1,2)thiazepino(5,4,3-cd)indole-8-carboxamide 2,2-dioxide
2VNN	;	1.87	;	Human BACE-1 in complex with 7-ethyl-N-((1S,2R)-2-hydroxy-1-(phenylmethyl)-3-(((3-(trifluoromethyl)phenyl)methyl)amino)propyl)-1- methyl-3,4-dihydro-1H-(1,2,5)thiadiazepino(3,4,5-hi)indole-9- carboxamide 2,2-dioxide
2WF1	;	1.6	;	Human BACE-1 in complex with 7-ethyl-N-((1S,2R)-2-hydroxy-3-(((3-(methyloxy)phenyl(methyl)amino)-1-(phenylmethyl)propyl)-1-methyl-3,4- dihydro-1H-(1,2,5)thiadiazepino(3,4,5-hi)indole-9-carboxamide 2,2- dioxide
2WF2	;	1.8	;	Human BACE-1 in complex with 8-ethyl-N-((1S,2R)-2-hydroxy-3-(((3-(methyloxy)phenyl)methyl)amino)-1-(phenylmethyl)propyl)-1-methyl-3,4,7, 8-tetrahydro-1H,6H-(1,2,5)thiadiazepino(5,4,3-de)quinoxaline-10- carboxamide 2,2-dioxide
2VIE	;	1.9	;	Human BACE-1 in complex with N-((1S,2R)-1-benzyl-2-hydroxy-3-((1,1,5- trimethylhexyl)amino)propyl)-3-(ethylamino)-5-(2-oxopyrrolidin-1-yl) benzamide
2XFI	;	1.73	;	Human BACE-1 in complex with N-((1S,2R)-3-(((1S)-2-(cyclohexylamino)- 1-methyl-2-oxoethyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-3-((methylsulfonyl)(phenyl)amino)benzamide
2VIZ	;	1.6	;	Human BACE-1 in complex with N-((1S,2R)-3-(((1S)-2-(cyclohexylamino)- 1-methyl-2-oxoethyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-3-(2-oxo- 1-pyrrolidinyl)-5-(propyloxy)benzamide
2XFK	;	1.8	;	Human BACE-1 in complex with N-((1S,2R)-3-(((1S)-2-(cyclohexylamino)- 1-methyl-2-oxoethyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-3-(ethylamino)-5-((methylsulfonyl)(phenyl)amino)benzamide
2VJ6	;	1.8	;	Human BACE-1 in complex with N-((1S,2R)-3-(((1S)-2-(cyclohexylamino)- 1-methyl-2-oxoethyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-3-(ethylamino)-5-(2-oxo-1-pyrrolidinyl)benzamide
2XFJ	;	1.8	;	Human BACE-1 in complex with N-((1S,2R)-3-(((1S)-2-(cyclohexylamino)- 1-methyl-2-oxoethyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-3-(ethylamino)-5-(2-oxo-1-pyrrolidinyl)benzamide
2VIY	;	1.82	;	Human BACE-1 in complex with N-((1S,2R)-3-(((1S)-2-(cyclohexylamino)- 1-methyl-2-oxoethyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-3-(pentylsulfonyl)benzamide
2VJ9	;	1.6	;	Human BACE-1 in complex with N-((1S,2R)-3-(cyclohexylamino)-2-hydroxy- 1-(phenylmethyl)propyl)-3-(ethylamino)-5-(2-oxo-1-pyrrolidinyl) benzamide
6FF4	;	3.4	;	human Bact spliceosome core structure
6FF7	;	4.5	;	human Bact spliceosome core structure
8CZF	;	1.3	;	Human BAK in complex with the dF2 peptide
8CZG	;	1.99	;	Human BAK in complex with the dF3 peptide
8CZH	;	1.3	;	Human BAK in complex with the dM2 peptide
5FMI	;	1.491	;	Human Bak Q77L
4AQ3	;	2.4	;	HUMAN BCL-2 WITH PHENYLACYLSULFONAMIDE INHIBITOR
1G5M	;		;	HUMAN BCL-2, ISOFORM 1
1GJH	;		;	HUMAN BCL-2, ISOFORM 2
1R2E	;	2.1	;	Human Bcl-XL containing a Glu to Leu mutation at position 92
1R2I	;	2.0	;	Human Bcl-XL containing a Phe to Leu mutation at position 146
1R2G	;	2.7	;	Human Bcl-XL containing a Phe to Trp mutation at position 97
3CVA	;	2.7	;	Human Bcl-xL containing a Trp to Ala mutation at position 137
1R2H	;	2.2	;	Human Bcl-XL containing an Ala to Leu mutation at position 142
2MB9	;		;	Human Bcl10 CARD
2VM6	;	2.2	;	Human Bcl2-A1 in complex with Bim-BH3 peptide
7BDE	;	2.044	;	HUMAN BCL6 BTB-DOMAIN IN COMPLEX WITH GSK137
5HHE	;	1.46	;	Human Beclin 1 coiled-coil domain
3CU0	;	1.9	;	human beta 1,3-glucuronyltransferase I (GlcAT-I) in complex with UDP and GAL-GAL(6-SO4)-XYL(2-PO4)-O-SER
5TBY	;	20.0	;	HUMAN BETA CARDIAC HEAVY MEROMYOSIN INTERACTING-HEADS MOTIF OBTAINED BY HOMOLOGY MODELING (USING SWISS-MODEL) OF HUMAN SEQUENCE FROM APHONOPELMA HOMOLOGY MODEL (PDB-3JBH), RIGIDLY FITTED TO HUMAN BETA-CARDIAC NEGATIVELY STAINED THICK FILAMENT 3D-RECONSTRUCTION (EMD-2240)
2GDD	;	2.35	;	Human beta II tryptase with inhibitor CRA-27592
2FXR	;	2.5	;	human beta tryptase II complexed with activated ketone inhibitor CRA-29382
2FS9	;	2.3	;	Human beta tryptase II with inhibitor CRA-28427
1HSZ	;	2.2	;	HUMAN BETA-1 ALCOHOL DEHYDROGENASE (ADH1B*1)
5WI6	;	2.72	;	Human beta-1 tryptase mutant Ile99Cys
5CKA	;	1.7	;	Human beta-2 microglobulin double mutant W60G-N83V
5CFH	;	1.49	;	human beta-2 microglobulin double mutant W60G-Y63W
5CKG	;	1.75	;	Human beta-2 microglobulin mutant V85E
8EFE	;	3.8	;	Human beta-cardiac myosin II bound to ADP-MG2+ and the associated essential light chain
8Y0G	;	2.5	;	Human beta-catenin crystal structure
1FD3	;	1.35	;	HUMAN BETA-DEFENSIN 2
1FD4	;	1.7	;	HUMAN BETA-DEFENSIN 2
1IJU	;	1.4	;	HUMAN BETA-DEFENSIN-1
1IJV	;	1.2	;	HUMAN BETA-DEFENSIN-1
2NLB	;	1.85	;	Human beta-defensin-1 (Mutant Asn4Ala)
2NLD	;	1.49	;	Human beta-defensin-1 (Mutant Gln11Ala)
2NLE	;	1.35	;	Human beta-defensin-1 (Mutant Gln11Ala)
2NLH	;	1.85	;	Human beta-defensin-1 (Mutant GLN24ALA)
2NLS	;	0.98	;	Human beta-defensin-1 (Mutant Gln24Ala)
2NLP	;	1.85	;	Human beta-defensin-1 (Mutant Gln24Glu)
2NLF	;	1.45	;	Human beta-defensin-1 (Mutant Leu13Glu)
2NLG	;	1.65	;	Human beta-defensin-1 (Mutant Lys22Glu)
2NLQ	;	1.8	;	Human beta-defensin-1 (Mutant Lys31Ala)
2NLC	;	1.65	;	Human beta-defensin-1 (mutant Ser8Ala)
3HN3	;	1.7	;	Human beta-glucuronidase at 1.7 A resolution
1BHG	;	2.53	;	HUMAN BETA-GLUCURONIDASE AT 2.6 A RESOLUTION
1O7A	;	2.25	;	Human beta-Hexosaminidase B
2BM2	;	2.2	;	human beta-II tryptase in complex with 4-(3-Aminomethyl-phenyl)- piperidin-1-yl-(5-phenethyl- pyridin-3-yl)-methanone
4MPV	;	2.305	;	Human beta-tryptase co-crystal structure with (2R,4S)-N,N'-bis[3-({4-[3-(aminomethyl)phenyl]piperidin-1-yl}carbonyl)phenyl]-4-hydroxy-2-(2-hydroxypropan-2-yl)-5,5-dimethyl-1,3-dioxolane-2,4-dicarboxamide
4MPU	;	1.649	;	Human beta-tryptase co-crystal structure with (6S,8R)-N,N'-bis[3-({4-[3-(aminomethyl)phenyl]piperidin-1-yl}carbonyl)phenyl]-8-hydroxy-6-(1-hydroxycyclobutyl)-5,7-dioxaspiro[3.4]octane-6,8-dicarboxamide
6P0P	;	2.55	;	Human beta-tryptase co-crystal structure with 5-{4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl}-2-(3'-{4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl}-[1,1'-biphenyl]-3-yl)-2-hydroxy-2H-1,3,2-benzodioxaborol-2-uide
4MPW	;	1.95	;	Human beta-tryptase co-crystal structure with [(1,1,3,3-tetramethyldisiloxane-1,3-diyl)di-1-benzofuran-3,5-diyl]bis({4-[3-(aminomethyl)phenyl]piperidin-1-yl}methanone)
4MPX	;	2.0	;	Human beta-tryptase co-crystal structure with [(1,1,3,3-tetramethyldisiloxane-1,3-diyl)di-1-benzothiene-4,2-diyl]bis({4-[3-(aminomethyl)phenyl]piperidin-1-yl}methanone)
4MQA	;	2.25	;	Human beta-tryptase co-crystal structure with {(1,1,3,3-tetramethyldisiloxane-1,3-diyl)bis[5-(methylsulfanyl)benzene-3,1-diyl]}bis({4-[3-(aminomethyl)phenyl]piperidin-1-yl}methanone)
2FWW	;	2.25	;	human beta-tryptase II complexed with 4-piperidinebutyrate to make acylenzyme
2FS8	;	2.5	;	Human beta-tryptase II with inhibitor CRA-29382
1A0L	;	3.0	;	HUMAN BETA-TRYPTASE: A RING-LIKE TETRAMER WITH ACTIVE SITES FACING A CENTRAL PORE
5UUP	;	1.726	;	Human Bfl-1 covalently cross-linked to an electrophilic variant of a Bfl-1-specific selected peptide
5UUK	;	1.199	;	Human Bfl-1 in complex with a Bfl-1-specific selected peptide
5UUL	;	1.33	;	Human Bfl-1 in complex with PUMA BH3
6E3J	;	1.482	;	Human Bfl-1 in complex with the Bfl-1-specific designed peptide srt.F10
6E3I	;	1.481	;	Human Bfl-1 in complex with the Bfl-1-specific designed peptide srt.F4
6MBB	;	1.59	;	Human Bfl-1 in complex with the designed peptide dF1
6MBC	;	1.752	;	Human Bfl-1 in complex with the designed peptide dF4
8PM6	;	3.22	;	Human bile salt export pump (BSEP) in complex with inhibitor GBM in nanodiscs
7DV5	;	3.7	;	Human bile salt exporter ABCB11 in complex with taurocholate
7E1A	;	3.66	;	Human bile salt exporter ABCB11 in complex with taurocholate
6OPL	;	1.37	;	Human biliverdin IX beta reductase Q14R mutant: NADP complex
1HDO	;	1.15	;	Human biliverdin IX beta reductase: NADP complex
1HE2	;	1.2	;	Human biliverdin IX beta reductase: NADP/biliverdin IX alpha ternary complex
5OOH	;	1.2	;	Human biliverdin IX beta reductase: NADP/Erythrosin extra bluish ternary complex
1HE4	;	1.4	;	Human biliverdin IX beta reductase: NADP/FMN ternary complex
1HE5	;	1.5	;	Human biliverdin IX beta reductase: NADP/Lumichrome ternary complex
1HE3	;	1.4	;	Human biliverdin IX beta reductase: NADP/mesobiliverdin IV alpha ternary complex
5OOG	;	1.33	;	Human biliverdin IX beta reductase: NADP/Phloxine B ternary complex
2VM5	;	1.8	;	HUMAN BIR2 DOMAIN OF BACULOVIRAL INHIBITOR OF APOPTOSIS REPEAT- CONTAINING 1 (BIRC1)
2UVL	;	1.91	;	Human BIR3 domain of Baculoviral Inhibitor of Apoptosis Repeat- Containing 3 (BIRC3)
7N3S	;	2.48	;	Human bisphosphoglycerate mutase complex with 2-phosphoglycolate
2H4X	;	1.85	;	Human bisphosphoglycerate mutase complex with 3-phosphoglycerate with crystal growth 90 days
2H4Z	;	2.0	;	Human bisphosphoglycerate mutase complexed with 2,3-bisphosphoglycerate
2HHJ	;	1.5	;	Human bisphosphoglycerate mutase complexed with 2,3-bisphosphoglycerate (15 days)
7THI	;	1.33	;	Human Bisphosphoglycerate Mutase complexed with 2-phosphoglycolate
2A9J	;	2.0	;	Human bisphosphoglycerate mutase complexed with 3-phosphoglycerate (17 days)
6ND0	;	3.5	;	human BK channel reconstituted into liposomes
2CB5	;	1.85	;	HUMAN BLEOMYCIN HYDROLASE, C73S/DELE455 MUTANT
1CB5	;	2.59	;	HUMAN BLEOMYCIN HYDROLASE.
6OML	;	2.7	;	Human BMP chimera BV261
6OMO	;	2.8	;	Human BMP6 homodimer
7L0Y	;	2.54	;	Human Bocavirus 1 (pH 2.6)
7L0W	;	2.74	;	Human Bocavirus 1 (pH 5.5)
7L0X	;	2.51	;	Human Bocavirus 2 (pH 2.6)
7L0U	;	2.74	;	Human Bocavirus 2 (pH 5.5)
7L0V	;	2.71	;	Human Bocavirus 2 (pH 7.4)
5US7	;	2.8	;	Human bocavirus 3
5US9	;	3.0	;	Human bocavirus 4
3BMP	;	2.7	;	HUMAN BONE MORPHOGENETIC PROTEIN-2 (BMP-2)
8DNO	;	3.4	;	Human Brain Aldehyde Dehydrogenase 1 family, member A1
2O4H	;	2.7	;	Human brain aspartoacylase complex with intermediate analog (N-phosphonomethyl-L-aspartate)
4NFR	;	3.0	;	Human brain aspartoacylase mutant E285A complex with intermediate analog (N-phosphonomethyl-L-aspartate)
4MRI	;	2.8	;	Human brain aspartoacylase mutant F295S complex with intermediate analog (N-phosphonomethyl-L-aspartate)
4MXU	;	2.6	;	Human brain aspartoacylase mutant K213E complex with intermediate analog (N-phosphonomethyl-L-aspartate)
4TNU	;	2.9	;	Human brain aspartoacylase mutant Y231C complex with intermediate analog (N-phosphonomethyl-L-aspartate)
8DNM	;	2.76	;	Human Brain Dihydropyrimidinase-related protein 2
8DNP	;	2.69	;	Human Brain Ferritin Heavy Chain
1XFB	;	3.0	;	Human Brain Fructose 1,6-(bis)phosphate Aldolase (C isozyme)
8DNU	;	2.73	;	Human Brain Glutamine Synthetase
8DNS	;	3.22	;	Human Brain Glyceraldehyde 3-phosphate dehydrogenase
1OJ6	;	1.95	;	Human brain neuroglobin three-dimensional structure
1KT8	;	1.9	;	HUMAN BRANCHED CHAIN AMINO ACID AMINOTRANSFERASE (MITOCHONDRIAL): THREE DIMENSIONAL STRUCTURE OF ENZYME IN ITS KETIMINE FORM WITH THE SUBSTRATE L-ISOLEUCINE
1EKV	;	2.25	;	HUMAN BRANCHED CHAIN AMINO ACID AMINOTRANSFERASE (MITOCHONDRIAL): THREE DIMENSIONAL STRUCTURE OF ENZYME INACTIVATED BY TRIS BOUND TO THE PYRIDOXAL-5'-PHOSPHATE ON ONE END AND ACTIVE SITE LYS202 NZ ON THE OTHER.
1KTA	;	1.9	;	HUMAN BRANCHED CHAIN AMINO ACID AMINOTRANSFERASE : THREE DIMENSIONAL STRUCTURE OF THE ENZYME IN ITS PYRIDOXAMINE PHOSPHATE FORM.
8F5F	;	3.149	;	human branched chain ketoacid dehydrogenase kinase in complex with inhibitors
8F5J	;	2.545	;	human branched chain ketoacid dehydrogenase kinase in complex with inhibitors
8F5S	;	2.793	;	human branched chain ketoacid dehydrogenase kinase in complex with inhibitors
1DTW	;	2.7	;	HUMAN BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE
2J9F	;	1.88	;	Human branched-chain alpha-ketoacid dehydrogenase-decarboxylase E1b
6FFG	;	1.59	;	Human BRD2 C-terminal bromodomain with (S)-1-(2-cyclopropyl-4-(2-(hydroxymethyl)benzyl)-6-(1,2,3,6-tetrahydropyridin-4-yl)-3,4-dihydroquinoxalin-1(2H)-yl)ethanone
6FFF	;	1.67	;	Human BRD2 C-terminal bromodomain with (S)-5-(1-acetyl-2-cyclopropyl-4-(2-(hydroxymethyl)benzyl)-1,2,3,4-tetrahydroquinoxalin-6-yl)pyrimidine-2-carboxamide
6FFE	;	1.76	;	Human BRD2 C-terminal bromodomain with 2-((4-acetyl-3-cyclopropyl-3,4-dihydroquinoxalin-1(2H)-yl)methyl)benzoic acid
6YTM	;	1.56	;	Human Brd2(BD2) L383V mutant in complex with ET-JQ1-OMe
5O3D	;	1.6	;	Human Brd2(BD2) mutant in complex with 9-ET
5O3C	;	1.6	;	Human Brd2(BD2) mutant in complex with 9-Me
5O3H	;	1.4	;	Human Brd2(BD2) mutant in complex with 9-ME-Am1
5O3B	;	1.95	;	Human Brd2(BD2) mutant in complex with AL
5O3G	;	1.85	;	Human Brd2(BD2) mutant in complex with AL-Am1
5O3I	;	1.2	;	Human Brd2(BD2) mutant in complex with AL-tBu
5O3A	;	2.4	;	Human Brd2(BD2) mutant in complex with ET
5O3F	;	1.75	;	Human Brd2(BD2) mutant in complex with ET-Am1
5O39	;	1.74	;	Human Brd2(BD2) mutant in complex with ME
5O3E	;	1.4	;	Human Brd2(BD2) mutant in complex with Me-Am1
5O38	;	1.2	;	Human Brd2(BD2) mutant in free form
8B5A	;	1.92	;	Human BRD3 bromodomain 2 in complex with a H4 peptide containing ApmTri (H4K20ApmTri)
8B5B	;	1.92	;	Human BRD4 bromdomain 1 in complex with a H4 peptide containing acetyl lysine and ApmTri (H4K5acK8ApmTri)
8B5C	;	1.58	;	Human BRD4 bromdomain 1 in complex with a H4 peptide containing ApmTri (H4K5/8ApmTri)
6FFD	;	1.83	;	Human BRD4 C-terminal bromodomain with 1-(4-(3-methylbenzyl)-3,4-dihydroquinoxalin-1(2H)-yl)ethanone
2N3K	;		;	Human Brd4 ET domain in complex with MLV Integrase C-term
5C6S	;	1.3	;	Human Bromodomain and PHD Finger Containing 1, PWWP domain in complex with XST005904a
6S9I	;	2.598	;	Human Brr2 Helicase Region D534C/N1866C in complex with C-tail deleted Jab1
6S8Q	;	2.391	;	Human Brr2 Helicase Region in complex with C-tail deleted Jab1
7BDK	;	2.52	;	Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and ADP
7BDI	;	2.8	;	Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and ATPgammaS
8BC8	;	2.39	;	Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and compound 18
8BC9	;	2.3	;	Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and compound 24
8BCA	;	2.8	;	Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and compound 26
8BCB	;	2.38	;	Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and compound 34
8BCC	;	2.35	;	Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and compound 39
8BCD	;	3.5	;	Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and compound 50
8BCE	;	2.05	;	Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and compound 76
8BCF	;	2.42	;	Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and compound 78
8BCG	;	2.39	;	Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and compound 86
7BDL	;	2.69	;	Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and mant-ADP
7BDJ	;	2.59	;	Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and mant-ATPgammaS
8BCH	;	2.87	;	Human Brr2 Helicase Region in complex with Sulfaguanidine
6S8O	;	3.172	;	Human Brr2 Helicase Region M641C/A1582C
6EZ2	;	2.7	;	Human butyrylcholinesterase carbamylated.
5LKR	;	2.52	;	Human Butyrylcholinesterase complexed with N-Propargyliperidines
6F7Q	;	2.6	;	Human Butyrylcholinesterase complexed with N-Propargyliperidines
6ZWI	;	1.85	;	Human butyrylcholinesterase in complex with ((6-((2E,4E)-5-(benzo[d][1,3]dioxol-5-yl)penta-2,4-dienamido)hexyl)triphenylphosphonium bromide)
6QAD	;	2.497	;	Human Butyrylcholinesterase in complex with ((S)-2-(butylamino)-N-(2-(4-(dimethylamino)cyclohexyl)ethyl)-3-(1H-indol-3-yl)propanamide
7QHD	;	2.04	;	Human Butyrylcholinesterase in complex with (S)-1-(4-((2-(1H-indol-3-yl)ethyl)carbamoyl)benzyl)-N-(3-((1,2,3,4-tetrahydroacridin-9-yl)amino)propyl)piperidine-3-carboxamide
7QHE	;	2.47	;	Human Butyrylcholinesterase in complex with (S)-1-(4-((naphthalen-1-yl)carbamoyl)benzyl)-N-(3-((1,2,3,4-tetrahydroacridin-9-yl)amino)propyl)piperidine-3-carboxamide
6QAA	;	1.897	;	Human Butyrylcholinesterase in complex with (S)-2-(butylamino)-N-(2-cycloheptylethyl)-3-(1H-indol-3-yl)propanamide
6QAC	;	2.771	;	Human Butyrylcholinesterase in complex with (S)-2-(butylamino)-N-(3-cycloheptylpropyl)-3-(1H-indol-3-yl)propanamide
6QAB	;	2.49	;	Human Butyrylcholinesterase in complex with (S)-N-(1-((2-cycloheptylethyl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-N,N-dimethylbutan-1-aminium
6QAE	;	2.487	;	Human Butyrylcholinesterase in complex with (S)-N2-butyl-N1-(2-cycloheptylethyl)-3-(1H-indol-3-yl)-N1,N2-dimethylpropane-1,2-diamine
7QBQ	;	2.49	;	Human butyrylcholinesterase in complex with (Z)-N-benzyl-1-(8-hydroxyquinolin-2-yl)methanimine oxide
7QBR	;	2.13	;	Human butyrylcholinesterase in complex with (Z)-N-tert-butyl-1-(8-(3-(4-(prop-2-yn-1-yl)piperazin-1-yl)propoxy)quinolin-2-yl)methanimine oxide
8AM2	;	2.5	;	Human butyrylcholinesterase in complex with 2,2'-(((1E,1'E)-(2-phenylpyrimidine-4,6-diyl)bis(methaneylylidene))bis(hydrazin-1-yl-2-ylidene))bis(N,N,N-trimethyl-2-oxoethan-1-aminium)
6T9P	;	2.7	;	Human Butyrylcholinesterase in complex with 2-(N-hydroxyimino)-N-[(1R)-3-{4-[(2-methyl-1H-imidazol-1-yl)methyl]-1H-1,2,3-triazol-1-yl}-1- phenylpropyl]acetamide
6T9S	;	2.7	;	Human Butyrylcholinesterase in complex with 2-(N-hydroxyimino)-N-[(1S)-3-{4-[(2-methyl-1H-imidazol-1-yl)methyl]-1H-1,2,3-triazol-1-yl}-1- phenylpropyl]acetamide
7BO4	;	2.401	;	Human Butyrylcholinesterase in complex with 3-(2-(butyl(2-cycloheptylethyl)amino)ethyl)-1H-indol-6-ol
7BGC	;	2.4	;	human butyrylcholinesterase in complex with a tacrine-methylanacardate hybrid inhibitor
6EP4	;	2.30005	;	Human butyrylcholinesterase in complex with decamethonium
6EQP	;	2.34942	;	Human butyrylcholinesterase in complex with ethopropazine
6EQQ	;	2.4	;	Human butyrylcholinesterase in complex with huprine 19
4TPK	;	2.7	;	Human butyrylcholinesterase in complex with N-((1-(2,3-dihydro-1H-inden-2-yl)piperidin-3-yl)methyl)-N-(2-methoxyethyl)-2-naphthamide
7BO3	;	2.2	;	Human Butyrylcholinesterase in complex with N-(2-(1H-Indol-3-yl)ethyl)-2-cycloheptyl-N-methylethan-1-amine
6ESJ	;	2.97985	;	Human butyrylcholinesterase in complex with propidium
4BDS	;	2.1	;	Human butyrylcholinesterase in complex with tacrine
6I0C	;	2.675	;	Human butyrylcholinesterase in complex with the R enantiomer of a chlorotacrine-tryptophan multi-target inhibitor.
6I0B	;	2.384	;	Human butyrylcholinesterase in complex with the S enantiomer of a chlorotacrine-tryptophan multi-target inhibitor.
6ESY	;	2.8	;	Human butyrylcholinesterase in complex with thioflavine T
8AM1	;	2.53	;	Human butyrylcholinesterase in complex with zinc and N,N,N-trimethyl-2-oxo-2-(2-(pyridin-2-ylmethylene)hydrazineyl)ethan-1-aminium
6ZYM	;	3.4	;	Human C Complex Spliceosome - High-resolution CORE
7A5P	;	5.0	;	Human C Complex Spliceosome - Medium-resolution PERIPHERY
1AA9	;		;	HUMAN C-HA-RAS(1-171)(DOT)GDP, NMR, MINIMIZED AVERAGE STRUCTURE
5T01	;	1.89	;	Human c-Jun DNA binding domain homodimer in complex with methylated DNA
3A4P	;	2.54	;	human c-MET kinase domain complexed with 6-benzyloxyquinoline inhibitor
2WD1	;	2.0	;	Human c-Met Kinase in complex with azaindole inhibitor
3F66	;	1.4	;	Human c-Met Kinase in complex with quinoxaline inhibitor
1GNH	;	3.0	;	HUMAN C-REACTIVE PROTEIN
1B09	;	2.5	;	HUMAN C-REACTIVE PROTEIN COMPLEXED WITH PHOSPHOCHOLINE
2LGQ	;		;	Human C30S/C59S-Cox17 mutant
2QKI	;	2.4	;	Human C3c in complex with the inhibitor compstatin
3QB5	;	2.95	;	Human C3PO complex in the presence of MnSO4
7BI5	;	1.74	;	Human CA II in complex with benzyl alcohol
4ITO	;	1.162	;	Human CA II inhibition by novel sulfonamide
3R16	;	1.6	;	Human CAII bound to N-(4-sulfamoylphenyl)-2-(thiophen-2-yl) acetamide
1AUI	;	2.1	;	HUMAN CALCINEURIN HETERODIMER
6WU5	;	1.88	;	Human Calcium and Integrin Binding Protein 3
6WUD	;	1.84	;	Human Calcium and Integrin Binding Protein 3 Bound to TMC1 Residues 303-347
6WU7	;	1.84	;	Human Calcium and Integrin Binding Protein 3 E150Q K151H
7DTT	;	3.8	;	Human Calcium-Sensing Receptor bound with calcium ions
8WPG	;	2.7	;	Human calcium-sensing receptor bound with cinacalcet in detergent
7DTU	;	4.4	;	Human Calcium-Sensing Receptor bound with L-Trp
7DTV	;	3.5	;	Human Calcium-Sensing Receptor bound with L-Trp and calcium ions
7DTW	;	4.5	;	Human Calcium-Sensing Receptor in the inactive close-close conformation
8WPU	;	3.1	;	Human calcium-sensing receptor(CaSR) bound to cinacalcet in complex with Gq protein
6SZ5	;	2.23	;	Human calmodulin bound to a peptide of human NADPH oxidase 5
4WQ3	;	1.79	;	Human calpain PEF(S) with (2Z,2Z')-2,2'-disulfanediylbis(3-(6-bromoindol-3-yl)acrylic acid) bound
5D69	;	1.97	;	Human calpain PEF(S) with (2Z,2Z')-2,2'-disulfanediylbis(3-(6-iodoindol-3-yl)acrylic acid) bound
4WQ2	;	1.64	;	Human calpain PEF(S) with (Z)-3-(6-bromondol-3-yl)-2-mercaptoacrylic acid bound
1ZCM	;	2.0	;	Human calpain protease core inhibited by ZLLYCH2F
6CMJ	;	2.4	;	Human CAMKK2 with GSK650393
3NX8	;	2.0	;	human cAMP dependent protein kinase in complex with phenol
3OOG	;	2.0	;	human cAMP-dependent protein kinase in complex with a small fragment
3OVV	;	1.58	;	Human cAMP-dependent protein kinase in complex with an inhibitor
3OWP	;	1.88	;	Human cAMP-dependent protein kinase in complex with an inhibitor
3OXT	;	2.2	;	Human cAMP-dependent protein kinase in complex with an inhibitor
3P0M	;	2.03	;	Human cAMP-dependent protein kinase in complex with an inhibitor
3POO	;	1.6	;	human cAMP-dependent protein kinase in complex with an inhibitor
2KOE	;		;	Human cannabinoid receptor 1 - helix 7/8 peptide
2KI9	;		;	Human cannabinoid receptor-2 helix 6
6FEC	;	6.3	;	Human cap-dependent 48S pre-initiation complex
5T74	;	1.2	;	Human carboanhydrase F131C_C206S double mutant in complex with 14
5T72	;	1.3	;	Human carboanhydrase F131C_C206S double mutant in complex with 2
5T71	;	1.3	;	Human carboanhydrase F131C_C206S double mutant in complex with SA-2
3MZC	;	1.498	;	Human carbonic ahydrase II in complex with a benzenesulfonamide inhibitor
6UGN	;	1.406	;	Human Carbonic Anhydrase 2 complexed with SB4-205
6UGP	;	1.306	;	Human Carbonic Anhydrase 2 complexed with SB4-206
6UGR	;	1.307	;	Human Carbonic Anhydrase 2 complexed with SB4-208
6UH0	;	1.306	;	Human Carbonic Anhydrase 2 in complex with SB4-202
7MU3	;	1.35	;	human carbonic anhydrase 9 mimic with compound
3P5L	;	1.498	;	Human Carbonic Anhydrase complexed with sodium 4-cyano-4-phenylpiperidine-1-carbodithioate
3P5A	;	1.49	;	Human Carbonic Anhydrase complexed with Sodium morpholinocarbodithioate
8CDZ	;	1.44	;	human carbonic anhydrase I complexed with 4-(3-butylureido)benzenesulfonamide
8CDX	;	1.335	;	Human carbonic anhydrase I complexed with 4-(3-ethylureido)benzenesulfonamide
2FOY	;	1.55	;	Human Carbonic Anhydrase I complexed with a two-prong inhibitor
8BOE	;	1.55	;	Human Carbonic Anhydrase I in complex with (S)-4-(3-(1-(6-nitropyridin-2-yl)pyrrolidin-3-yl)thioureido)benzenesulfonamide
7QOB	;	1.8	;	Human Carbonic Anhydrase I in complex with benzoselenoate
7PLF	;	1.461	;	Human Carbonic Anhydrase I in complex with clorsulon
7Q0D	;	1.24	;	Human carbonic anhydrase I in complex with Methyl 2-(benzenesulfonyl)-4-chloro-5-sulfamoylbenzoate
3LXE	;	1.9	;	Human Carbonic Anhydrase I in complex with topiramate
5JG3	;	1.21	;	Human carbonic anhydrase II (121T/N67Q) complexed with benzo[d]thiazole-2-sulfonamide
5JDV	;	1.34	;	Human carbonic anhydrase II (F131W) complexed with benzo[d]thiazole-2-sulfonamide
5JE7	;	1.15	;	Human carbonic anhydrase II (F131Y) complexed with benzo[d]thiazole-2-sulfonamide
5JGT	;	1.1	;	Human carbonic anhydrase II (F131Y/L198A) complexed with 1,3-thiazole-2-sulfonamide
5JGS	;	1.11	;	Human carbonic anhydrase II (F131Y/L198A) complexed with benzo[d]thiazole-2-sulfonamide
8R1I	;	1.46	;	Human Carbonic Anhydrase II (hCAII) in complex with (R)-N-(3-Indol-1-yl-2-methyl-propyl)-4-sulfamoyl-benzamide
5JEH	;	1.13	;	Human carbonic anhydrase II (L198A) complexed with benzo[d]thiazole-2-sulfonamide
5JEP	;	1.19	;	Human carbonic anhydrase II (T199S) complexed with benzo[d]thiazole-2-sulfonamide
5JEG	;	1.19	;	Human carbonic anhydrase II (V121I) complexed with benzo[d]thiazole-2-sulfonamide
5JES	;	1.205	;	Human carbonic anhydrase II (V121T) complexed with benzo[d]thiazole-2-sulfonamide
5JG5	;	1.19	;	Human carbonic anhydrase II (V121T/F131Y) complexed with benzo[d]thiazole-2-sulfonamide
3OKV	;	1.45	;	Human Carbonic Anhydrase II A65S, N67Q (CA IX mimic) bound with 2-Ethylestrone 3-O-sulfamate
3ZP9	;	1.31	;	Human Carbonic Anhydrase II as a Scaffold for an Artificial Transfer Hydrogenase
3PYK	;	1.3	;	Human Carbonic Anhydrase II as Host for Pianostool Complexes Bearing a Sulfonamide Anchor
6T4N	;	1.4	;	Human Carbonic anhydrase II bound by 2,4,6-trimethylbenzenesulfonamide
3OIM	;	1.45	;	Human Carbonic anhydrase II bound by 2-Ethylestradiol 3-O-sulfamate
6T81	;	0.98	;	Human Carbonic anhydrase II bound by 2-Naphthalenesulfonamide.
6T4O	;	1.133	;	Human Carbonic anhydrase II bound by 3,5-dimethylbenzenesulfonamide
6T5C	;	1.22	;	Human Carbonic anhydrase II bound by anthracene-9-sulfonamide
6T4P	;	1.75	;	Human Carbonic anhydrase II bound by napthalene-1-sulfonamide
8EXG	;	1.99	;	Human Carbonic Anhydrase II bound N-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl)-4-sulfamoylbenzamide
8EXC	;	1.9	;	Human Carbonic Anhydrase II bound tert-butyl (3-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propoxy)butoxy)propyl)carbamate
7QNV	;	1.278	;	human carbonic anhydrase II bound to 3-methylbenzoselenoate
6WKA	;	1.34	;	human carbonic anhydrase II bound to an inhibitor modified with azidothymidine
3D92	;	1.1	;	Human carbonic anhydrase II bound with substrate carbon dioxide
3OY0	;	1.6	;	Human Carbonic Anhydrase II complexed with 1-(4-(4-(2-(ISOPROPYLSULFONYL)PHENYLAMINO)-1H-PYRROLO[2,3-B]PYRIDIN-6-YLAMINO)-3-METHOXYPHENYL)PIPERIDIN-4-OL
3OYS	;	1.538	;	Human Carbonic Anhydrase II complexed with 2-{[4-AMINO-3-(3-HYDROXYPROP-1-YN-1-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]METHYL}-5-METHYL-3-(2-METHYLPHENYL)QUINAZOLIN-4(3H)-ONE
1TTM	;	1.95	;	Human carbonic anhydrase II complexed with 667-coumate
5EKH	;	1.34	;	Human Carbonic Anhydrase II complexed with a two-faced guest
5EKJ	;	1.129	;	Human Carbonic Anhydrase II complexed with a two-faced guest
5EKM	;	1.33	;	Human Carbonic Anhydrase II complexed with a two-faced guest
5WG7	;	1.45	;	Human Carbonic Anhydrase II complexed with AceK
3HS4	;	1.1	;	Human carbonic anhydrase II complexed with acetazolamide
3L14	;	1.22	;	Human Carbonic Anhydrase II complexed with Althiazide
4YX4	;	1.01	;	Human Carbonic Anhydrase II complexed with an inhibitor with a benzenesulfonamide group (1).
4YXI	;	0.96	;	Human Carbonic Anhydrase II complexed with an inhibitor with a benzenesulfonamide group (2).
4YXO	;	1.06	;	Human Carbonic Anhydrase II complexed with an inhibitor with a benzenesulfonamide group (3).
4YXU	;	1.08	;	Human Carbonic Anhydrase II complexed with an inhibitor with a benzenesulfonamide group (4).
4YYT	;	1.07	;	Human Carbonic Anhydrase II complexed with an inhibitor with a benzenesulfonamide group (5).
1A42	;	2.25	;	HUMAN CARBONIC ANHYDRASE II COMPLEXED WITH BRINZOLAMIDE
3CYU	;	1.7	;	Human Carbonic Anhydrase II complexed with Cryptophane biosensor and xenon
1KWR	;	2.25	;	HUMAN CARBONIC ANHYDRASE II COMPLEXED WITH INHIBITOR 0134-36
1KWQ	;	2.6	;	HUMAN CARBONIC ANHYDRASE II COMPLEXED WITH INHIBITOR 2000-07
3RJ7	;	1.2	;	Human carbonic anhydrase II complexed with its inhibitor rhenium(I)triscarbonyl-cyclopentadienyl-carboxy-4-aminomethylbenzene-sulfonamide
1AVN	;	2.0	;	HUMAN CARBONIC ANHYDRASE II COMPLEXED WITH THE HISTAMINE ACTIVATOR
3QYK	;	1.469	;	Human Carbonic Anhydrase II complexed with triple ring benzene sulfonamide inhibitor
2FOQ	;	1.25	;	Human Carbonic Anhydrase II complexed with two-prong inhibitors
2FOS	;	1.1	;	Human Carbonic Anhydrase II complexed with two-prong inhibitors
2FOU	;	0.99	;	Human Carbonic Anhydrase II complexed with two-prong inhibitors
2FOV	;	1.15	;	Human Carbonic Anhydrase II complexed with two-prong inhibitors
1BV3	;	1.85	;	HUMAN CARBONIC ANHYDRASE II COMPLEXED WITH UREA
8Q0C	;	1.3	;	Human carbonic anhydrase II containing 3-fluorotyrosine
8PHL	;	1.3	;	Human carbonic anhydrase II containing 4-fluorophenylalanine
8P6U	;	1.3	;	Human carbonic anhydrase II containing 5-fluorotryptophanes
8B29	;	1.7	;	Human carbonic anhydrase II containing 6-fluorotryptophanes.
5T75	;	1.5	;	Human carbonic anhydrase II G132C_C206S double mutant in complex with SA-2
4FIK	;	1.2	;	Human carbonic anhydrase II H64A complexed with thioxolone hydrolysis products
4JSW	;	1.9	;	Human carbonic anhydrase II H94C
4JSS	;	1.5	;	Human carbonic anhydrase II H94D bound to a bidentate inhibitor
8EMU	;	1.13	;	Human Carbonic Anhydrase II Heterobifunctional Degraders
3MWO	;	1.4	;	Human carbonic anhydrase II in a doubled monoclinic cell: a re-determination
3P4V	;	2.0	;	Human carbonic anhydrase II in complex with (+)-Xylariamide A
3HKN	;	1.8	;	Human carbonic anhydrase II in complex with (2,3,4,6-Tetra-O-acetyl-beta-D-galactopyranosyl) -(1-4)-1,2,3,6-tetra-O-acetyl-1-thio-beta-D-glucopyranosylsulfonamide
6SDJ	;	1.02	;	Human Carbonic Anhydrase II in complex with (R)-1-aminopropan-2-ol
6SDL	;	1.08	;	Human Carbonic Anhydrase II in complex with (R)-N-(3-(1H-indol-1-yl)-2-methylpropyl)-4-sulfamoylbenzamide
7M24	;	1.3	;	Human carbonic anhydrase II in complex with (R)-rosiglitazone
3HKQ	;	1.7	;	Human carbonic anhydrase II in complex with 1-S-D-Galactopyranosylsulfonamide
7AEQ	;	1.5	;	Human carbonic anhydrase II in complex with 2,3,5,6-tetrafluoro-4-(2-hydroxyethylsulfanyl)-N-methyl-benzenesulfonamide
7AES	;	1.4	;	Human carbonic anhydrase II in complex with 2,3,5,6-tetrafluoro-N-methyl-4-propylsulfanyl-benzenesulfonamide
3NB5	;	1.8	;	Human carbonic anhydrase II in complex with 2-(3-chloro-4-hydroxyphenyl)-N-(4-sulfamoylphenethyl)acetamide
3OKU	;	1.45	;	Human Carbonic Anhydrase II in complex with 2-Ethylestrone-3-O-sulfamate
6RIT	;	1.007	;	Human Carbonic Anhydrase II in complex with 2-Fluorobenzenesulfonamide
7QGY	;	1.5	;	Human carbonic anhydrase II in complex with 3-((5-(ethoxycarbonyl)-4-methylthiazol-2-yl)(4-sulfamoylphenyl)amino)propanoic acid
7QGX	;	1.19	;	Human carbonic anhydrase II in complex with 3-((5-chloro-4-(4-chlorophenyl)thiazol-2-yl)(4-sulfamoylphenyl)amino)propanoic acid
8OGF	;	1.321	;	Human Carbonic Anhydrase II in complex with 4-(((1-(3-((3aR,7R,7aS)-7-hydroxy-2,2-dimethyltetrahydro-[1,3]dioxolo[4,5-c]pyridin-5(4H)-yl)propyl)-1H-1,2,3-triazol-4-yl)methyl)amino)benzenesulfonamide
7ZWB	;	1.48	;	human Carbonic Anhydrase II in complex with 4-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)thio)benzenesulfonamide
7AGN	;	1.15	;	Human carbonic anhydrase II in complex with 4-(2-aminoethylsulfanyl)-2,3,5,6-tetrafluoro-N-methyl-benzenesulfonamide
6RG5	;	1.089	;	Human Carbonic Anhydrase II in complex with 4-(2-hydroxyethyl)benzenesulfonamide
7A6V	;	2.0	;	Human Carbonic Anhydrase II in complex with 4-(3-(3-phenoxypropyl)thioureido)benzenesulfonamide
4RFD	;	1.631	;	Human carbonic anhydrase II in complex with 4-(4-sulfamoyl-phenoxy)-butylammonium
6SBM	;	0.95	;	Human Carbonic Anhydrase II in complex with 4-(pentyloxy)benzenesulfonamide
6RL9	;	1.0	;	Human Carbonic Anhydrase II in complex with 4-Aminobenzenesulfonamide
6HXD	;	1.119	;	Human Carbonic Anhydrase II in complex with 4-Butylbenzenesulfonamide
6I3E	;	1.07	;	Human Carbonic Anhydrase II in complex with 4-Butylbenzenesulfonamide
6RFH	;	0.969	;	Human Carbonic Anhydrase II in complex with 4-Carboxybenzenesulfonamide
6ROB	;	0.929	;	Human Carbonic Anhydrase II in complex with 4-cyanobenzenesulfonamide
6I1U	;	1.08	;	Human Carbonic Anhydrase II in complex with 4-Ethoxybenzenesulfonamide
6HQX	;	1.097	;	Human Carbonic Anhydrase II in complex with 4-Ethylbenzenesulfonamide
6SBL	;	0.94	;	Human Carbonic Anhydrase II in complex with 4-hexylbenzenesulfonamide
6RIG	;	0.999	;	Human Carbonic Anhydrase II in complex with 4-Hydroxybenzenesulfonamide
6I0W	;	1.04	;	Human Carbonic Anhydrase II in complex with 4-Methoxybenzenesulfonamide
6GM9	;	1.089	;	Human Carbonic Anhydrase II in complex with 4-Methylbenzenesulfonamide
6RH4	;	0.948	;	Human Carbonic Anhydrase II in complex with 4-Nitrobenzenesulfonamide.
7R1X	;	1.35	;	human Carbonic Anhydrase II in complex with 4-oxo-N-(4-sulfamoylphenethyl)-1,3,4,6,7,11b-hexahydro-2H-pyrazino[2,1-a]isoquinoline-2-carbothioamide
7QZX	;	1.24	;	Human Carbonic Anhydrase II in complex with 4-oxo-N-(4-sulfamoylphenethyl)-1,3,4,6,7,11b-hexahydro-2H-pyrazino[2,1-a]isoquinoline-2-carboxamide
7YWT	;	1.106	;	human Carbonic Anhydrase II in complex with 4-oxo-N-(4-sulfamoylphenyl)-1,3,4,6,7,11b-hexahydro-2H-pyrazino[2,1-a]isoquinoline-2-carboxamide
6SBH	;	0.95	;	Human Carbonic Anhydrase II in complex with 4-pentylbenzenesulfonamide.
6I2F	;	1.198	;	Human Carbonic Anhydrase II in complex with 4-Propoxybenzenesulfonamide
6HR3	;	1.02	;	Human Carbonic Anhydrase II in complex with 4-Propylbenzenesulfonamide
4XE1	;	1.8	;	Human carbonic anhydrase II in complex with 6-SULFAMOYL-SACCHARIN
4R5B	;	1.5	;	Human Carbonic Anhydrase II in Complex with a Carbohydrate-Based Sulfamate
6RKN	;	0.959	;	Human Carbonic Anhydrase II in complex with a fluorinated Benzenesulfonamide.
6SFU	;	1.04	;	Human Carbonic Anhydrase II in complex with a furan-containing benzenesulfonamide
4ZWY	;	1.5	;	Human Carbonic Anhydrase II in complex with a glucosyl sulfamate inhibitor
4ZX0	;	1.6	;	Human Carbonic Anhydrase II in complex with a glucosyl sulfamate inhibitor
6SDS	;	1.26	;	HUMAN CARBONIC ANHYDRASE II IN COMPLEX WITH A SULFONAMIDE INHIBITOR
3T82	;	2.002	;	Human Carbonic Anhydrase II in complex with Acetylated Carbohydrate Sulfamates
3T83	;	1.8	;	Human Carbonic Anhydrase II in complex with Acetylated Carbohydrate Sulfamates
3T84	;	2.0	;	Human Carbonic Anhydrase II in complex with Acetylated Carbohydrate Sulfamates
3T85	;	2.4	;	Human Carbonic Anhydrase II in complex with Acetylated Carbohydrate Sulfamates
5LL8	;	1.03	;	Human Carbonic Anhydrase II in complex with aliphatic Benzenesulfonamide inhibitor.
6SEY	;	1.23	;	Human Carbonic Anhydrase II in complex with aliphatically substituted benzenesulfonamide
3HKT	;	2.36	;	Human carbonic anhydrase II in complex with alpha-D-Glucopyranosyl-(1->4)-1-thio-beta-D-glucopyranosylsulfonamide
6SDI	;	1.03	;	Human Carbonic Anhydrase II in complex with an inhibitor soaked at a concentration of 0.01 mM
6SDH	;	1.04	;	Human Carbonic Anhydrase II in complex with an inhibitor soaked at a concentration of 5 mM
6GDC	;	1.079	;	Human Carbonic Anhydrase II in complex with Benzenesulfonamide
6H29	;	1.46	;	HUMAN CARBONIC ANHYDRASE II IN COMPLEX WITH BENZYL CARBAMATE
2VVB	;	1.66	;	Human carbonic anhydrase II in complex with bicarbonate
4M2R	;	1.993	;	Human Carbonic Anhydrase II in complex with Brinzolamide
4E5Q	;	1.7024	;	Human Carbonic Anhydrase II in complex with cyanate
6RJJ	;	1.056	;	Human Carbonic Anhydrase II in complex with fluorinated benzenesulfonamide
6RNP	;	1.07	;	Human Carbonic Anhydrase II in complex with fluorinated benzenesulfonamide
6ROE	;	0.939	;	Human Carbonic Anhydrase II in complex with fluorinated benzenesulfonamide
6RQI	;	0.95	;	Human Carbonic Anhydrase II in complex with fluorinated benzenesulfonamide
6RRG	;	1.127	;	Human Carbonic Anhydrase II in complex with fluorinated benzenesulfonamide
6RRI	;	1.097	;	Human Carbonic Anhydrase II in complex with fluorinated benzenesulfonamide
6RS5	;	1.07	;	Human Carbonic Anhydrase II in complex with fluorinated benzenesulfonamide
6RSZ	;	1.089	;	Human Carbonic Anhydrase II in complex with fluorinated benzenesulfonamide
6S9G	;	1.14	;	Human Carbonic Anhydrase II in complex with fluorinated benzenesulfonamide
6SD7	;	1.05	;	Human Carbonic Anhydrase II in complex with fluorinated benzenesulfonamide and its dimer
5M78	;	1.077	;	Human Carbonic Anhydrase II in complex with fragment-like inhibitor.
6RM1	;	1.68	;	Human Carbonic Anhydrase II in complex with fragment.
6RMP	;	1.22	;	Human Carbonic Anhydrase II in complex with fragment.
6SAS	;	1.1	;	Human Carbonic Anhydrase II in complex with fragment.
6SAY	;	0.95	;	Human Carbonic Anhydrase II in complex with fragment.
6SB7	;	1.09	;	Human Carbonic Anhydrase II in complex with fragment.
6SG6	;	0.98	;	Human Carbonic Anhydrase II in complex with furan-containing benzenesulfonamide
7QSI	;	1.304	;	human Carbonic Anhydrase II in complex with indoline-1-sulfonamide
5EH5	;	1.207	;	human carbonic anhydrase II in complex with ligand
5EH7	;	1.425	;	human carbonic anhydrase II in complex with ligand
5EH8	;	1.381	;	human carbonic anhydrase II in complex with ligand
5EHV	;	1.208	;	human carbonic anhydrase II in complex with ligand
5EHW	;	1.392	;	human carbonic anhydrase II in complex with ligand
5J8Z	;	1.7	;	Human carbonic anhydrase II in complex with ligand
7Q0E	;	1.3	;	Human Carbonic Anhydrase II in complex with Methyl 2-(benzenesulfonyl)-4-chloro-5-sulfamoylbenzoate
7QGZ	;	1.13	;	Human carbonic anhydrase II in complex with Methyl 3-((4-methylthiazol-2-yl)(4-sulfamoylphenyl)amino)propanoate
7QSE	;	1.428	;	human Carbonic Anhydrase II in complex with N-(2-aminophenyl)-4-((2-oxo-2-((4-sulfamoylbenzyl)amino)ethyl)amino)benzamide
7QRK	;	1.428	;	Human Carbonic Anhydrase II in complex with N-(2-aminophenyl)-4-((2-oxo-2-((4-sulfamoylphenethyl)amino)ethyl)amino)benzamide
2EU2	;	1.15	;	Human Carbonic Anhydrase II in complex with novel inhibitors
2EU3	;	1.6	;	Human Carbonic anhydrase II in complex with novel inhibitors
3P55	;	2.0	;	Human carbonic anhydrase II in complex with p-(4-ferrocenyl-1H-1,2,3-triazol-1-yl)benzenesulfonamide
3P44	;	2.2	;	Human carbonic anhydrase II in complex with p-(4-ruthenocenyl-1H-1,2,3-triazol-1-yl)benzenesulfonamide
3P3H	;	1.5	;	Human carbonic anhydrase II in complex with p-(5-ferrocenyl-1H-1,2,3-triazol-1-yl)benzenesulfonamide
3P3J	;	1.6	;	Human carbonic anhydrase II in complex with p-(5-ruthenocenyl-1H-1,2,3-triazol-1-yl)benzenesulfonamide
7M26	;	1.3	;	Human carbonic anhydrase II in complex with pioglitazone
4RFC	;	1.645	;	Human carbonic anhydrase II in complex with tert-butyl 4-(4-sulfamoylphenoxy)butylcarbamate
3HKU	;	1.8	;	Human carbonic anhydrase II in complex with topiramate
7M23	;	1.3	;	Human carbonic anhydrase II in complex with troglitazone
3OIK	;	1.5	;	Human Carbonic anhydrase II mutant A65S, N67Q (CA IX mimic) bound by 2-Ethylestradiol 3,17-O,O-bis-sulfamate
3OIL	;	1.5	;	Human Carbonic anhydrase II mutant A65S, N67Q (CA IX mimic) bound by 2-Ethylestradiol 3-O-sulfamate
3MNH	;	1.65	;	Human Carbonic Anhydrase II Mutant K170A
3MNI	;	1.75	;	Human Carbonic Anhydrase II Mutant K170D
3MNJ	;	1.75	;	Human Carbonic Anhydrase II Mutant K170E
3MNK	;	1.75	;	Human Carbonic Anhydrase II Mutant K170H
6ROF	;	1.5	;	Human Carbonic anhydrase II mutant T199V bound by 2-(cyclooctylamino)-3,5,6-trifluoro-4-[(2-hydroxyethyl)thio]benzenesulfonamide
6RMX	;	1.6	;	Human Carbonic anhydrase II mutant T199V bound by 2-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]-3,5,6-trifluoro-4-[(2-hydroxyethyl)thio]benzenesulfonamide
6RMY	;	1.5	;	Human Carbonic anhydrase II mutant T199V bound by 3-(cyclooctylamino)-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide
6KM3	;	1.15	;	Human Carbonic Anhydrase II native 00 atm CO2
6KM4	;	1.15	;	Human Carbonic Anhydrase II native 07 atm CO2
6KM5	;	1.151	;	Human Carbonic Anhydrase II native 13 atm CO2
6KM6	;	1.15	;	Human Carbonic Anhydrase II native 15 atm CO2
3TVO	;	1.6	;	Human Carbonic Anhydrase II Proton Transfer Double Mutant
4IDR	;	1.6	;	Human Carbonic Anhydrase II Proton Transfer Double Mutant
3TVN	;	1.497	;	Human Carbonic Anhydrase II Proton Transfer Mutant
3U45	;	1.699	;	Human Carbonic Anhydrase II V143A
6KLZ	;	0.9	;	Human Carbonic Anhydrase II V143I variant 00 atm CO2
6KM0	;	0.93	;	Human Carbonic Anhydrase II V143I variant 07 atm CO2
6KM1	;	1.05	;	Human Carbonic Anhydrase II V143I variant 13 atm CO2
6KM2	;	0.9	;	Human Carbonic Anhydrase II V143I variant 15 atm CO2
3U47	;	1.6	;	Human Carbonic Anhydrase II V143L
4QEF	;	1.469	;	Human Carbonic Anhydrase II V207I - cyanate inhibitor complex
3K34	;	0.9	;	Human carbonic anhydrase II with a sulfonamide inhibitor
5BYI	;	1.15	;	Human carbonic anhydrase II with an azobenzene inhibitor (1d)
6QFX	;	1.32	;	Human carbonic anhydrase II with bound IrCp* complex (cofactor 10) to generate an artificial transfer hydrogenase (ATHase)
6QFU	;	1.8	;	Human carbonic anhydrase II with bound IrCp* complex (cofactor 7) to generate an artificial transfer hydrogenase (ATHase)
6QFV	;	1.45	;	Human carbonic anhydrase II with bound IrCp* complex (cofactor 8) to generate an artificial transfer hydrogenase (ATHase)
6QFW	;	1.2	;	Human carbonic anhydrase II with bound IrCp* complex (cofactor 9) to generate an artificial transfer hydrogenase (ATHase)
8EYL	;	1.18	;	Human Carbonic Anhydrase II with Tert-butyl (2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl)carbamate
1UGC	;	2.0	;	HUMAN CARBONIC ANHYDRASE II [HCAII] (E.C.4.2.1.1) MUTANT WITH ALA 65 REPLACED BY HIS (A65H)
1UGE	;	1.9	;	HUMAN CARBONIC ANHYDRASE II [HCAII] (E.C.4.2.1.1) MUTANT WITH ALA 65 REPLACED BY LEU (A65L)
1UGF	;	2.0	;	HUMAN CARBONIC ANHYDRASE II [HCAII] (E.C.4.2.1.1) MUTANT WITH ALA 65 REPLACED BY THR (A65T)
1Z97	;	2.1	;	Human Carbonic Anhydrase III: Structural and Kinetic Study of Catalysis and Proton Transfer.
1Z93	;	2.1	;	Human Carbonic Anhydrase III:Structural and Kinetic study of Catalysis and Proton Transfer.
1UGB	;	2.0	;	HUMAN CARBONIC ANHYDRASE II[HCAII] (E.C.4.2.1.1) MUTANT WITH ALA 65 REPLACED BY GLY (A65G)
1UGA	;	2.0	;	HUMAN CARBONIC ANHYDRASE II[HCAII] (E.C.4.2.1.1) MUTANT WITH ALA 65 REPLACED BY PHE (A65F)
1UGD	;	2.0	;	HUMAN CARBONIC ANHYDRASE II[HCAII] (E.C.4.2.1.1) MUTANT WITH ALA 65 REPLACED BY SER (A65S)
1UGG	;	2.2	;	HUMAN CARBONIC ANHYDRASE II[HCAII] (E.C.4.2.1.1) MUTANT WITH ALA 65 REPLACED BY SER (A65S)-ORTHORHOMBIC FORM
3P58	;	1.49	;	Human Carbonic Anhydrase in complex with Benzyl (Methyl) Carbamodithoic Acid
2VVA	;	1.56	;	Human carbonic anhydrase in complex with CO2
1ZNC	;	2.8	;	HUMAN CARBONIC ANHYDRASE IV
6VKG	;	1.37	;	Human carbonic anhydrase IX mimic with Epacadostat bound
5WGP	;	1.53	;	Human Carbonic Anhydrase IX-mimic complexed with AceK
6UGO	;	1.457	;	Human Carbonic Anhydrase IX-mimic complexed with SB4-205
6UGQ	;	1.305	;	Human Carbonic Anhydrase IX-mimic complexed with SB4-206
6UGZ	;	1.306	;	Human Carbonic Anhydrase IX-mimic complexed with SB4-208
6SDT	;	1.94	;	HUMAN CARBONIC ANHYDRASE VII IN COMPLEX WITH A SULFONAMIDE INHIBITOR
6T5P	;	1.5	;	Human Carbonic anhydrase XII bound by 3,5-Di-tert-butylbenzenesulfonamide
6T5Q	;	1.8	;	Human Carbonic anhydrase XII bound by 3,5-diphenylbenzenesulfonamide
4RN4	;	1.53	;	Human Carbonic anhydrases II in complex with a acetazolamide derivative comprising one hydrophobic and one hydrophilic tail moiety
3ML2	;	1.8	;	Human carbonic anhydsase II in complex with an aryl sulfonamide inhibitor
1I3D	;	1.7	;	HUMAN CARBONMONOXY HEMOGLOBIN BART'S (GAMMA4)
6HAL	;	2.2	;	Human carbonmonoxy hemoglobin SFX dataset
4Z3D	;	1.8	;	Human carbonyl reductase 1 with glutathione in a protective configuration
7PCQ	;	3.62	;	Human carboxyhemoglobin bound to Staphylococcus aureus hemophore IsdB - 1:1 complex
7PCH	;	2.89	;	Human carboxyhemoglobin bound to Staphylococcus aureus hemophore IsdB - 1:2 complex
2PCU	;	1.6	;	Human carboxypeptidase A4 in complex with a cleaved hexapeptide.
2BO9	;	1.6	;	Human carboxypeptidase A4 in complex with human latexin.
6G2T	;	9.0	;	human cardiac myosin binding protein C C1 Ig-domain bound to native cardiac thin filament
8EFD	;	3.8	;	Human cardiac myosin II and associated essential light chain in the rigor conformation
4LWD	;	1.792	;	Human CARMA1 CARD domain
6PXO	;	2.0	;	Human Casein Kinase 1 delta (anion-free crystallization conditions)
8D7P	;	2.25	;	Human Casein kinase 1 delta in complex with phosphorylated Drosophila PERIOD peptide
8D7M	;	2.25	;	Human Casein kinase 1 delta in complex with phosphorylated human PERIOD2 FASP peptide
8D7N	;	1.66	;	Human Casein kinase 1 delta in complex with phosphorylated human PERIOD2 FASP peptide
8D7O	;	1.65	;	Human Casein kinase 1 delta in complex with phosphorylated human PERIOD2 FASP peptide
6PXP	;	2.35	;	Human Casein Kinase 1 delta Site 2 mutant (K171E)
6PXN	;	1.551	;	Human Casein Kinase 1 delta Tau mutant (R178C)
5IH5	;	2.25	;	Human Casein Kinase 1 isoform delta (kinase domain) in complex with Epiblastin A
5IH6	;	2.3	;	Human Casein Kinase 1 isoform delta (kinase domain) in complex with Epiblastin A derivative
5IH4	;	1.9	;	Human Casein Kinase 1 isoform delta apo (kinase domain)
1KWA	;	1.93	;	HUMAN CASK/LIN-2 PDZ DOMAIN
3V3K	;	3.494	;	Human caspase 9 in complex with bacterial effector protein
6CL0	;	1.5	;	Human caspase-3 in complex with Ac-ATS009-KE
6CKZ	;	1.5	;	Human caspase-3 in complex with Ac-DW3-KE
6DEU	;	2.796	;	Human caspase-6 A109T
6DEV	;	2.348	;	Human caspase-6 E35K
8F48	;	2.9	;	Human CASQ1 mutant - S248E
5N5K	;	1.8	;	Human catalytic MMP-12 in complex with 5-(1,2-dithiolan-3-yl)-N-(3-hydroxypropyl)pentanamide
5LSA	;	1.5	;	human catechol O-methyltransferase in complex with SAM and DNC at 1.50A
1LV4	;		;	Human catestatin 21-mer
8B5F	;	1.7	;	Human cathepsin B in complex with the carbamate inhibitor 31
8B4T	;	1.45	;	Human cathepsin B in complex with the carbamate inhibitor 7
1AU8	;	1.9	;	HUMAN CATHEPSIN G
1CGH	;	1.8	;	Human cathepsin G
5JH3	;	1.75	;	Human cathepsin K mutant C25S
5J94	;	2.22002	;	Human cathepsin K mutant C25S in complex with the allosteric effector NSC13345
5JA7	;	1.61	;	Human cathepsin K mutant C25S in complex with the allosteric effector NSC94914
8C77	;	1.7	;	Human cathepsin L after reaction with the thiocarbazate inhibitor CID 16725315
4AXL	;	1.92	;	HUMAN CATHEPSIN L APO FORM WITH ZN
8OZA	;	1.8	;	Human cathepsin L in complex with covalently bound CA-074 methyl ester
2G6D	;	2.5	;	Human cathepsin S mutant with vinyl sulfone inhibitor CRA-14009
2FRA	;	1.9	;	Human Cathepsin S with CRA-27934, a Nitrile Inhibitor
2G7Y	;	2.0	;	Human Cathepsin S with inhibitor CRA-16981
2FRQ	;	1.6	;	Human Cathepsin S with Inhibitor CRA-26871
2FUD	;	1.95	;	Human Cathepsin S with Inhibitor CRA-27566
2FT2	;	1.7	;	Human Cathepsin S with Inhibitor CRA-29728
6IC6	;	1.898	;	Human cathepsin-C in complex with cyclopropyl peptidyl nitrile inhibitor 1
6IC5	;	2.0	;	Human cathepsin-C in complex with dipeptidyl cyclopropyl nitrile inhibitor 2
6IC7	;	2.0	;	Human cathepsin-C in complex with dipeptidyl cyclopropyl nitrile inhibitor 3
6VTM	;	1.6	;	Human Cathepsin-G Inhibited by S. aureus EapH1
6Z31	;	2.56	;	Human cation-independent mannose 6-phosphate/ IGF2 receptor domain 8
6Z30	;	1.5	;	Human cation-independent mannose 6-phosphate/ IGF2 receptor domains 9-10
6Z32	;	3.47	;	Human cation-independent mannose 6-phosphate/IGF2 receptor domains 7-11
7QE8	;	2.9	;	Human cationic trypsin (TRY1) complexed with serine protease inhibitor Kazal type 1 (SPINK1)
7QE9	;	2.1	;	Human cationic trypsin (TRY1) complexed with serine protease inhibitor Kazal type 1 N34S (SPINK1 N34S)
2RA3	;	1.46	;	Human cationic trypsin complexed with bovine pancreatic trypsin inhibitor (BPTI)
4WWY	;	1.7	;	human cationic trypsin G193R mutant in complex with bovine pancreatic trypsin inhibitor
4WXV	;	2.1	;	Human cationic trypsin K97D mutant in complex with bovine pancreatic trypsin inhibitor (BPTI)
8F2R	;	3.12	;	Human CCC complex
8F2U	;	3.53	;	Human CCC complex
2MLQ	;		;	Human CCR2 Membrane-Proximal C-Terminal Region (PRO-C) in a frount bound form
2MLO	;		;	Human CCR2 Membrane-Proximal C-Terminal Region (PRO-C) in a Membrane bound form
6QB8	;	3.97	;	Human CCT:mLST8 complex
2H26	;	1.8	;	human CD1b in complex with endogenous phosphatidylcholine and spacer
5C9J	;	2.4	;	Human CD1c with ligands in A' and F' channel
6V7Z	;	2.75	;	Human CD1d presenting alpha-Galactosylceramide in complex with VHH nanobody 1D22
6V7Y	;	2.4	;	Human CD1d presenting alpha-Galactosylceramide in complex with VHH nanobody 1D5
8SOS	;	2.33	;	Human CD1d presenting sphingomyelin C24:1 in complex with VHH nanobody 1D17
4XJS	;	2.8	;	Human CD38 complexed with inhibitor 1 [6-fluoro-2-methyl-4-[(2,3,6-trichlorobenzyl)amino]quinoline-8-carboxamide]
4XJT	;	2.6	;	Human CD38 complexed with inhibitor 2 [4-[(2,6-dimethylbenzyl)amino]-2-methylquinoline-8-carboxamide]
8D0M	;	2.04	;	Human CD38 ectodomain bound to a 78c-ADPR adduct
8P8C	;	1.653	;	HUMAN CD38 ECTODOMAIN BOUND TO COMPOUND 9-ADPR ADDUCT
5F1K	;	2.3	;	human CD38 in complex with nanobody MU1053
5F21	;	1.9	;	human CD38 in complex with nanobody MU375
5F1O	;	2.2	;	human CD38 in complex with nanobody MU551
6WVG	;	2.9	;	human CD53
1H03	;	1.7	;	Human CD55 domains 3 & 4
1H04	;	2.0	;	Human CD55 domains 3 & 4
1H2P	;	2.8	;	Human CD55 domains 3 & 4
1H2Q	;	3.0	;	Human CD55 domains 3 & 4
1UOT	;	3.0	;	HUMAN CD55 DOMAINS 3 & 4
3CCK	;	1.8	;	Human CD69
1E8I	;	1.95	;	HUMAN CD69 - TETRAGONAL FORM
1E87	;	1.5	;	Human CD69 - trigonal form
6S7F	;	2.05	;	Human CD73 (5'-nucleotidase) in complex with PSB12379 (an AOPCP derivative) in the closed state
6S7H	;	1.85	;	Human CD73 (5'-nucleotidase) in complex with PSB12489 (an AOPCP derivative) in the closed state
6TVG	;	1.48	;	Human CD73 (ecto 5'-nucleotidase) in complex with AMPCP in the open state
7JV9	;	2.7	;	Human CD73 (ecto 5'-nucleotidase) in complex with compound 12
7JV8	;	2.46	;	Human CD73 (ecto 5'-nucleotidase) in complex with compound 35
7QGM	;	2.9	;	Human CD73 (ecto 5'-nucleotidase) in complex with MRS4598 (a 3-methyl-CMPCP derivative, compound 16 in paper) in the closed state (crystal form III)
7QGA	;	1.5	;	Human CD73 (ecto 5'-nucleotidase) in complex with MRS4598 (a 3-methyl-CMPCP derivative, compound 16 in paper) in the open state
7QGO	;	2.206	;	Human CD73 (ecto 5'-nucleotidase) in complex with MRS4602 (a 3-methyl-CMPCP derivative, compound 21 in paper) in the closed state (crystal form III)
7QGL	;	1.5	;	Human CD73 (ecto 5'-nucleotidase) in complex with MRS4602 (a 3-methyl-CMPCP derivative, compound 21 in paper) in the open state
6TWF	;	2.5	;	Human CD73 (ecto 5'-nucleotidase) in complex with PSB12604 (an AOPCP derivative, compound 21 in publication) in the closed state
6TWA	;	2.0	;	Human CD73 (ecto 5'-nucleotidase) in complex with PSB12646 (an AOPCP derivative, compound 20 in publication) in the closed state
6TVX	;	2.6	;	Human CD73 (ecto 5'-nucleotidase) in complex with PSB12676 (an AOPCP derivative, compound 9 in paper) in the closed state
6TW0	;	2.5	;	Human CD73 (ecto 5'-nucleotidase) in complex with PSB12690 (an AOPCP derivative, compound 10 in publication) in the closed state
1B6E	;	2.6	;	HUMAN CD94
3BDW	;	2.5	;	Human CD94/NKG2A
3CDG	;	3.4	;	Human CD94/NKG2A in complex with HLA-E
1C25	;	2.3	;	HUMAN CDC25A CATALYTIC DOMAIN
1QB0	;	1.91	;	HUMAN CDC25B CATALYTIC DOMAIN
1CWT	;	2.3	;	HUMAN CDC25B CATALYTIC DOMAIN WITH METHYL MERCURY
1CWS	;	2.0	;	HUMAN CDC25B CATALYTIC DOMAIN WITH TUNGSTATE
1CWR	;	2.1	;	HUMAN CDC25B CATALYTIC DOMAIN WITHOUT ION IN CATALYTIC SITE
3RZ3	;	2.3	;	Human Cdc34 E2 in complex with CC0651 inhibitor
2K5B	;		;	Human CDC37-HSP90 docking model based on NMR
4F99	;	2.33	;	Human CDC7 kinase in complex with DBF4 and nucleotide
4F9A	;	2.17	;	Human CDC7 kinase in complex with DBF4 and nucleotide
4F9B	;	2.5	;	Human CDC7 kinase in complex with DBF4 and PHA767491
4F9C	;	2.08	;	Human CDC7 kinase in complex with DBF4 and XL413
4Y72	;	2.3	;	Human CDK1/CyclinB1/CKS2 With Inhibitor
2EXM	;	1.8	;	Human CDK2 in complex with isopentenyladenine
2A0C	;	1.95	;	Human CDK2 in complex with olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor
5A14	;	2.0	;	Human CDK2 with type II inhibitor
5XQX	;	2.3	;	Human CDK8-CYCC in complex with compound 4: N-methyl-4-(4-pyridyl)-1H-pyrrole-2-carboxamide
2WVR	;	3.3	;	Human Cdt1:Geminin complex
4WHD	;	2.5	;	Human CEACAM1 N-domain homodimer
4WHC	;	2.705	;	Human CEACAM6 N-domain
4WTZ	;	2.52	;	Human CEACAM6-CEACAM8 N-domain heterodimer complex
2LPW	;		;	human CEB25 minisatellite G-quadruplex
6HKR	;	1.5	;	Human Cellular Retinoic Acid Binding Protein II (CRABPII) with bound synthetic retinoid DC271.
5OGB	;	1.8	;	Human Cellular Retinoic Acid Binding Protein II (CRABPII) with bound synthetic retinoid DC360.
1GGL	;	2.31	;	HUMAN CELLULAR RETINOL BINDING PROTEIN III
2GGM	;	2.35	;	Human centrin 2 xeroderma pigmentosum group C protein complex
1BW6	;		;	HUMAN CENTROMERE PROTEIN B (CENP-B) DNA BINDIGN DOMAIN RP1
5NG4	;	2.14	;	Human CEP135 parallel dimeric coiled coil 82-144
5OI7	;	1.67	;	Human CEP85 - coiled coil domain 4
4WZ6	;	2.05	;	Human CFTR aa389-678 (NBD1), deltaF508 with three solubilizing mutations, bound ATP
6WBS	;	1.857	;	Human CFTR first nucleotide binding domain with dF508/V510D
8IMF	;	2.4	;	Human cGAS catalytic domain bound with baicalein
8IME	;	2.63	;	Human cGAS catalytic domain bound with baicalin
8IMG	;	1.8	;	Human cGAS catalytic domain bound with C20
6MJX	;	2.6	;	human cGAS catalytic domain bound with cGAMP
6LRI	;	2.5	;	Human cGAS catalytic domain bound with compound 17
6LRJ	;	3.0	;	Human cGAS catalytic domain bound with compound 23
6LRE	;	2.65	;	Human cGAS catalytic domain bound with compound 3
6LRK	;	2.25	;	Human cGAS catalytic domain bound with compound 40
6LRL	;	2.655	;	Human cGAS catalytic domain bound with compound s2
6MJU	;	2.45	;	human cGAS catalytic domain bound with the inhibitor G108
6MJW	;	2.405	;	human cGAS catalytic domain bound with the inhibitor G150
6LRC	;	1.831	;	Human cGAS catalytic domain bound with the inhibitor PF-06928215
6O47	;	2.196	;	human cGAS core domain (K427E/K428E) bound with RU-521
7C0M	;	3.9	;	Human cGAS-nucleosome complex
7MBY	;	2.44	;	Human Cholecystokinin 1 receptor (CCK1R) Gq chimera (mGsqi) complex
7MBX	;	1.95	;	Human Cholecystokinin 1 receptor (CCK1R) Gs complex
5FTG	;	1.45	;	Human choline kinase a1 in complex with compound 1-[[4-[2-[4-[[4-(dimethylamino)pyridin-1- yl]methyl]phenoxy]ethoxy]phenyl]methyl]-N,N- dimethyl-pyridin-4-amine (compound 10a)
4CG9	;	1.83	;	Human choline kinase a1 in complex with compound 12
4CG8	;	1.75	;	Human choline kinase a1 in complex with compound 14
5FUT	;	1.6	;	Human choline kinase a1 in complex with compound 4-(dimethylamino)-1-{4-[4-(4-{[4-(pyrrolidin- 1-yl)pyridinium-1-yl]methyl}phenyl)butyl]benzyl}pyridinium (compound BR25)
4CGA	;	1.74	;	Human choline kinase a1 in complex with compound 5
2GTR	;	1.9	;	Human chromodomain Y-like protein
4AFQ	;	1.51	;	Human Chymase - Fynomer Complex
4AFS	;	1.9	;	Human Chymase - Fynomer Complex
4AFU	;	1.82	;	Human Chymase - Fynomer Complex
4AFZ	;	2.25	;	Human Chymase - Fynomer Complex
4AG1	;	1.4	;	Human Chymase - Fynomer Complex
4AG2	;	1.8	;	Human Chymase - Fynomer Complex
5YJP	;	1.8	;	Human chymase in complex with 3-(ethoxyimino)-7-oxo-1,4-diazepane derivative
5YJM	;	1.9	;	Human chymase in complex with 7-oxo-3-(phenoxyimino)-1,4-diazepane derivative
8IZC	;	1.45	;	Human CK1 Delta Kinase structure bound to Inhibitor
3OWK	;	1.8	;	Human CK2 catalytic domain in complex with a benzopyridoindole derivative inhibitor
3OWL	;	2.1	;	Human CK2 catalytic domain in complex with a benzopyridoindole derivative inhibitor
3MB7	;	1.65	;	Human CK2 catalytic domain in complex with a difurane derivative inhibitor (AMR)
3MB6	;	1.75	;	Human CK2 catalytic domain in complex with a difurane derivative inhibitor (CPA)
3OWJ	;	1.85	;	Human CK2 catalytic domain in complex with a pyridocarbazole derivative inhibitor
3NSZ	;	1.3	;	Human CK2 catalytic domain in complex with AMPPN
3NGA	;	2.71	;	Human CK2 catalytic domain in complex with CX-4945
6TLL	;	1.88	;	HUMAN CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4,5,6,7-TETRABROMOBENZOTRIAZOLE (tBBT)
6TLO	;	1.69	;	HUMAN CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4,5,6-TRIBROMOBENZOTRIAZOLE
6TLU	;	1.81	;	HUMAN CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4,5-DIBROMOBENZOTRIAZOLE
6TLS	;	1.46	;	HUMAN CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4,6-DIBROMOBENZOTRIAZOLE
6TLR	;	1.64	;	HUMAN CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4,7-DIBROMOBENZOTRIAZOLE
6TLW	;	1.73	;	HUMAN CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4-BROMOBENZOTRIAZOLE
6TLP	;	1.93	;	HUMAN CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 5,6-DIBROMOBENZOTRIAZOLE
6TLV	;	1.67	;	HUMAN CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 5-BROMOBENZOTRIAZOLE
1CKS	;	2.1	;	HUMAN CKSHS2 ATOMIC STRUCTURE: A ROLE FOR ITS HEXAMERIC ASSEMBLY IN CELL CYCLE CONTROL
4OR2	;	2.8	;	Human class C G protein-coupled metabotropic glutamate receptor 1 in complex with a negative allosteric modulator
1QEW	;	2.2	;	HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A 0201) COMPLEX WITH A NONAMERIC PEPTIDE FROM MELANOMA-ASSOCIATED ANTIGEN 3 (RESIDUES 271-279)
1DUZ	;	1.8	;	HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A 0201) IN COMPLEX WITH A NONAMERIC PEPTIDE FROM HTLV-1 TAX PROTEIN
3HLA	;	2.6	;	HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN A2.1
6Z9V	;	2.01	;	Human Class I Major Histocompatibility Complex, A02 allele, presenting IIGWMWIPV
6Z9W	;	2.7	;	Human Class I Major Histocompatibility Complex, A02 allele, presenting LLGWVFAQV
6Z9X	;	2.68	;	Human Class I Major Histocompatibility Complex, A02 allele, presenting LLS (t-butyl)Y FGTPT
8U9G	;	2.87	;	Human Class I MHC HLA-A2 bound to sorting nexin 24 (127-135) neoantigen KLSHQLVLL
7U21	;	1.9	;	Human Class I MHC HLA-A2 in complex with AVGSYVYSV peptide
3QFD	;	1.68	;	Human Class I MHC HLA-A2 in complex with Mart-1(27-35) nonameric peptide
8TBV	;	2.64	;	Human Class I MHC HLA-A2 in complex with sorting nexin 24 (127-135) neoantigen KLSHQLVLL
8TBW	;	2.081	;	Human Class I MHC HLA-A2 in complex with sorting nexin 24 (127-135) peptide KLSHQPVLL
6AMT	;	2.496	;	Human Class I MHC HLA-A2 in complex with synthetic peptide MMWDRGLGMM
2GT9	;	1.75	;	Human Class I MHC HLA-A2 in complex with the decameric Melan-A/MART-1(26-35) peptide
3PWN	;	1.6	;	Human Class I MHC HLA-A2 in complex with the HuD (G2L) peptide variant
3PWJ	;	1.7	;	Human Class I MHC HLA-A2 in complex with the HuD (G2L,I9V) peptide variant
3PWL	;	1.65	;	Human Class I MHC HLA-A2 in complex with the HuD peptide
2GIT	;	1.7	;	Human Class I MHC HLA-A2 in complex with the modified HTLV-1 TAX (Y5K-4-[3-Indolyl]-butyric acid) peptide
2GUO	;	1.9	;	Human Class I MHC HLA-A2 in complex with the native nonameric Melan-A/MART-1(27-35) peptide
2GTW	;	1.548	;	Human Class I MHC HLA-A2 in complex with the nonameric Melan-A/MART-1(27-35) peptide having A27L substitution
2GTZ	;	1.7	;	Human Class I MHC HLA-A2 in complex with the nonameric Melan-A/MART-1(27-35) peptide having A28L substitution
3O3A	;	1.8	;	Human Class I MHC HLA-A2 in complex with the Peptidomimetic ELA-1
3O3B	;	1.9	;	Human Class I MHC HLA-A2 in complex with the Peptidomimetic ELA-1.1
3O3D	;	1.7	;	Human Class I MHC HLA-A2 in complex with the Peptidomimetic ELA-2
3O3E	;	1.85	;	Human Class I MHC HLA-A2 in complex with the Peptidomimetic ELA-2.1
3H7B	;	1.88	;	Human Class I MHC HLA-A2 in complex with the Tel1p peptide
3MYJ	;	1.89	;	Human Class I MHC HLA-A2 in complex with the WT-1 (126-134) (R1Y) peptide variant.
3HPJ	;	2.0	;	Human Class I MHC HLA-A2 in complex with the WT-1 (126-134) peptide
3IXA	;	2.1	;	Human Class I MHC HLA-A2(A150P) in complex with the Tax peptide
3H9H	;	2.0	;	Human Class I MHC HLA-A2(A150P) in complex with the Tel1p peptide
1PYW	;	2.1	;	Human class II MHC protein HLA-DR1 bound to a designed peptide related to influenza virus hemagglutinin, FVKQNA(MAA)AL, in complex with staphylococcal enterotoxin C3 variant 3B2 (SEC3-3B2)
6COZ	;	3.36	;	Human CLC-1 chloride ion channel, C-terminal cytosolic domain
6COY	;	3.36	;	Human CLC-1 chloride ion channel, transmembrane domain
7FBQ	;	1.8	;	Human CLIC1 in complex with NSC602247
6QPJ	;	2.315	;	Human CLOCK PAS-A domain
6WCC	;	3.24	;	Human closed state TMEM175 in CsCl
6WCA	;	3.03	;	Human closed state TMEM175 in KCl
8BFI	;	3.0	;	human CNOT1-CNOT10-CNOT11 module
8W8E	;	3.9	;	human co-transcriptional RNA capping enzyme RNGTT
8W8F	;	4.0	;	human co-transcriptional RNA capping enzyme RNGTT-CMTR1
6PCE	;	1.65	;	Human Coa6
6PCF	;	2.2	;	Human Coa6: W59C mutant protein
1RFN	;	2.8	;	HUMAN COAGULATION FACTOR IXA IN COMPLEX WITH P-AMINO BENZAMIDINE
1IQM	;	2.6	;	Human coagulation factor Xa in complex with M54471
1IQL	;	2.7	;	Human coagulation factor Xa in complex with M54476
1IQK	;	3.2	;	Human coagulation factor Xa in complex with M55113
1IQJ	;	3.0	;	Human coagulation factor Xa in complex with M55124
1IQI	;	2.9	;	Human coagulation factor Xa in complex with M55125
1IQH	;	3.0	;	Human coagulation factor Xa in complex with M55143
1IQG	;	2.6	;	Human coagulation factor Xa in complex with M55159
1IQF	;	3.2	;	Human coagulation factor Xa in complex with M55165
1IQN	;	2.6	;	Human coagulation factor Xa in complex with M55192
1IOE	;	2.9	;	Human coagulation factor Xa in complex with M55532
1IQE	;	2.9	;	Human coagulation factor Xa in complex with M55590
6L63	;	3.0	;	Human Coagulation Factor XIIa (FXIIa) bound with the macrocyclic peptide F3 containing two (1S,2S)-2-ACHC residues
6VAO	;	3.4	;	Human cofilin-1 decorated actin filament
4K6J	;	2.6205	;	Human cohesin inhibitor WapL
5HDT	;	2.711	;	Human cohesin regulator Pds5B bound to a Wapl peptide
4FVL	;	2.436	;	Human collagenase 3 (MMP-13) full form with peptides from pro-domain
4G0D	;	2.54	;	Human collagenase 3 (MMP-13) full form with peptides from pro-domain
4FU4	;	2.849	;	Human collagenase 3 (MMP-13) with peptide from pro-domain
7QVP	;	3.0	;	Human collided disome (di-ribosome) stalled on XBP1 mRNA
2W4C	;	1.52	;	Human common-type acylphosphatase variant, A99
2W4P	;	1.7	;	Human common-type acylphosphatase variant, A99G
6RU5	;	3.9	;	human complement C3 in complex with the hC3Nb1 nanobody
8OVB	;	3.4	;	Human Complement C3b in complex with Trypanosoma brucei ISG65.
3CU7	;	3.105	;	Human Complement Component 5
2A73	;	3.3	;	Human Complement Component C3
2I07	;	4.0	;	Human Complement Component C3b
7TV9	;	3.4	;	HUMAN COMPLEMENT COMPONENT C3B IN COMPLEX WITH APL-1030
2A74	;	2.4	;	Human Complement Component C3c
2OK5	;	2.3	;	Human Complement factor B
7JTN	;	3.1	;	Human Complement Factor B Inhibited by a Slow Off-Rate Modified Aptamer of 29 Bases
7JTQ	;	3.5	;	Human Complement Factor B Inhibited by a Slow Off-Rate Modified Aptamer of 31 Bases
1HFD	;	2.3	;	HUMAN COMPLEMENT FACTOR D IN A P21 CRYSTAL FORM
1BIO	;	1.5	;	HUMAN COMPLEMENT FACTOR D IN COMPLEX WITH ISATOIC ANHYDRIDE INHIBITOR
2XRC	;	2.69	;	Human complement factor I
2RD7	;	2.15	;	Human Complement Membrane Attack Proteins Share a Common Fold with Bacterial Cytolysins
7BL1	;	9.8	;	human complex II-BATS bound to membrane-attached Rab5a-GTP
4PYK	;	2.22	;	human COMT, double domain swap
7QES	;	2.6	;	human Connexin 26 at 55mm Hg PCO2, pH7.4: two masked subunits, class A
7QEO	;	2.9	;	human Connexin 26 at 55mm Hg PCO2, pH7.4: two masked subunits, class C
7QEV	;	2.9	;	human Connexin 26 at 55mm Hg PCO2, pH7.4:two masked subunits, class D
7QEU	;	2.7	;	human Connexin 26 at 55mmHg PCO2, pH7.4: two masked subunits, class B
7QEY	;	2.0	;	human Connexin 26 class 1 hexamer at 90mmHg PCO2, pH7.4
7QEW	;	2.1	;	human Connexin 26 class 2 hexamer at 90mmHg PCO2, pH7.4
7QET	;	2.1	;	human Connexin 26 dodecamer at 20mmHg PCO2, pH7.4
7QER	;	2.2	;	human Connexin 26 dodecamer at 55mm Hg PCO2, pH7.4
7QEQ	;	1.9	;	human Connexin 26 dodecamer at 90mmHg PCO2, pH7.4
5ERA	;	3.8	;	Human Connexin-26 (Calcium-free)
6UVT	;	7.5	;	Human Connexin-26 (Low pH closed conformation)
6UVS	;	4.2	;	Human Connexin-26 (Low pH open conformation)
6UVR	;	4.0	;	Human Connexin-26 (Neutral pH open conformation)
8W77	;	3.61	;	Human Consensus Olfactory Receptor OR52c in apo state, OR52c only
8J46	;	3.66	;	Human Consensus Olfactory Receptor OR52c in apo state, OR52c-bRIL
8HTI	;	2.97	;	Human Consensus Olfactory Receptor OR52c in Complex with Octanoic Acid (OCA) and G Protein
4R3O	;	2.6	;	Human Constitutive 20S Proteasome
4R67	;	2.89	;	Human constitutive 20S proteasome in complex with carfilzomib
1DO5	;	2.75	;	HUMAN COPPER CHAPERONE FOR SUPEROXIDE DISMUTASE DOMAIN II
5IVW	;	10.0	;	Human core TFIIH bound to DNA within the PIC
5IYA	;	5.4	;	Human core-PIC in the closed state
5IYC	;	3.9	;	Human core-PIC in the initial transcribing state
5IYD	;	3.9	;	Human core-PIC in the initial transcribing state (no IIS)
5IYB	;	3.9	;	Human core-PIC in the open state
2J97	;	1.75	;	Human coronavirus 229E non structural protein 9 (Nsp9)
2J98	;	1.8	;	Human coronavirus 229E non structural protein 9 cys69ala mutant (Nsp9)
6Y3Y	;	3.39	;	Human Coronavirus HKU1 Haemagglutinin-Esterase
8OHN	;	3.4	;	Human Coronavirus HKU1 spike glycoprotein
8OPN	;	4.7	;	Human Coronavirus HKU1 spike glycoprotein in complex with an alpha2,8-linked 9-O-acetylated disialoside (1-up state)
8OPO	;	3.6	;	Human Coronavirus HKU1 spike glycoprotein in complex with an alpha2,8-linked 9-O-acetylated disialoside (3-up state)
8OPM	;	3.7	;	Human Coronavirus HKU1 spike glycoprotein in complex with an alpha2,8-linked 9-O-acetylated disialoside (closed state)
7PNQ	;	3.7	;	Human coronavirus OC43 spike glycoprotein ectodomain in complex with the 43E6 antibody Fab fragment
7PNM	;	3.7	;	Human coronavirus OC43 spike glycoprotein ectodomain in complex with the 46C12 antibody Fab fragment
7PO5	;	3.9	;	Human coronavirus OC43 spike glycoprotein ectodomain in complex with the 47C9 antibody Fab fragment
6Y3C	;	3.361	;	Human COX-1 Crystal Structure
4GB3	;	2.74	;	Human coxsackievirus B3 strain RD coat protein
7QR4	;	2.83	;	human CPEB3 HDV-like ribozyme
1LPJ	;	2.0	;	Human cRBP IV
4ZCB	;	1.7	;	Human CRBPII mutant - Y60W dimer
6TVO	;	3.201	;	Human CRM1-RanGTP in complex with Leptomycin B
2VM8	;	1.9	;	Human CRMP-2 crystallised in the presence of Mg
6GRO	;	1.45	;	Human CSNK1G3 bound to SB-223133
6QY7	;	2.1	;	Human CSNK2A1 bound to ERB-041
6QY9	;	1.5	;	Human CSNK2A2 bound to a Pyrrolo[2,3-d]pyrimidinyl inhibitor
6QY8	;	1.7	;	Human CSNK2A2 bound to ERB-041
6C4S	;	1.5	;	Human cSrc SH3 Domain in complex with Choline Kinase fragment 60-69
8D0B	;	3.43	;	Human CST-DNA polymerase alpha/primase preinitiation complex bound to 4xTEL-foldback template
8D0K	;	4.27	;	Human CST-DNA polymerase alpha/primase preinitiation complex bound to 4xTEL-foldback template - PRIM2C advanced PIC
6TZE	;		;	Human CstF-64 RRM mutant - D50A
6V89	;	2.45	;	Human CtBP1 (28-375) in complex with AMP
6V8A	;	2.35	;	Human CtBP1 (28-375) in complex with AMP
6CDF	;	2.6	;	Human CtBP1 (28-378)
6CDR	;	2.399	;	Human CtBP1 (28-378)
8ATI	;	2.6	;	Human CtBP2(31-364) in complex with RAI2 peptide(315-322)
5T00	;	2.19	;	Human CTCF ZnF3-7 and methylated DNA complex
2VKT	;	2.5	;	HUMAN CTP SYNTHETASE 2 - GLUTAMINASE DOMAIN
2V4U	;	2.3	;	Human CTP synthetase 2 - glutaminase domain in complex with 5-OXO-L- NORLEUCINE
3ELB	;	2.0	;	Human CTP: Phosphoethanolamine Cytidylyltransferase in complex with CMP
4XSV	;	2.7	;	Human CTP: Phosphoethanolamine Cytidylyltransferase in complex with CTP
7MH0	;	6.2	;	Human CTPS1 bound to CTP
7MIF	;	3.1	;	Human CTPS1 bound to inhibitor R80
7MIG	;	2.9	;	Human CTPS1 bound to inhibitor T35
7MGZ	;	2.8	;	Human CTPS1 bound to UTP, AMPPNP, and glutamine
7MH1	;	2.8	;	Human CTPS2 bound to CTP
7MIH	;	2.8	;	Human CTPS2 bound to inhibitor R80
7MII	;	2.7	;	Human CTPS2 bound to inhibitor T35
3IHL	;	2.8	;	Human CTPS2 crystal structure
6L3T	;	2.34	;	Human Cx31.3/GJC3 connexin hemichannel in the absence of calcium
6L3U	;	2.53	;	Human Cx31.3/GJC3 connexin hemichannel in the presence of calcium
7XKT	;	2.2	;	Human Cx36/GJD2 (BRIL-fused mutant) gap junction channel in detergents at 2.2 Angstroms resolution
7XKI	;	3.4	;	Human Cx36/GJD2 (N-terminal deletion BRIL-fused mutant) gap junction channel in soybean lipids (D6 symmetry)
7XL8	;	3.0	;	Human Cx36/GJD2 (N-terminal deletion mutant) gap junction channel in soybean lipids (D6 symmetry)
7XKK	;	3.2	;	Human Cx36/GJD2 gap junction channel in detergents
7XNH	;	3.1	;	Human Cx36/GJD2 gap junction channel with pore-lining N-terminal helices in soybean lipids
3MVJ	;	2.49	;	Human cyclic AMP-dependent protein kinase PKA inhibitor complex
5VDO	;	3.218	;	Human cyclic GMP-AMP synthase (cGAS) in complex with 2',2'-cGAMP
5VDP	;	2.3	;	Human cyclic GMP-AMP synthase (cGAS) in complex with 2',3'-cGAMP
5VDQ	;	3.246	;	Human cyclic GMP-AMP synthase (cGAS) in complex with 2',5'-GpAp
5VDR	;	3.042	;	Human cyclic GMP-AMP synthase (cGAS) in complex with 3',3'-cdIMP
5VDS	;	2.766	;	Human cyclic GMP-AMP synthase (cGAS) in complex with 3',3'-cdUMP
5VDT	;	2.576	;	Human cyclic GMP-AMP synthase (cGAS) in complex with 3',3'-cGAMP
5VDW	;	2.711	;	Human cyclic GMP-AMP synthase (cGAS) in complex with Compound F1
5VDU	;	2.729	;	Human cyclic GMP-AMP synthase (cGAS) in complex with Compound F2
5VDV	;	2.998	;	Human cyclic GMP-AMP synthase (cGAS) in complex with Compound F3
4O67	;	2.444	;	Human cyclic GMP-AMP synthase (cGAS) in complex with GAMP
4O69	;	2.252	;	Human cyclic GMP-AMP synthase (cGAS) in complex with sulfate ion
3ULI	;	2.0	;	Human Cyclin Dependent Kinase 2 (CDK2) bound to azabenzimidazole derivative
2B53	;	2.0	;	Human cyclin dependent kinase 2 (CDK2) complexed with DIN-234325
2B52	;	1.88	;	Human cyclin dependent kinase 2 (CDK2) complexed with DPH-042562
2B55	;	1.85	;	Human cyclin dependent kinase 2 (cdk2) complexed with indenopyraxole DIN-101312
2B54	;	1.85	;	Human cyclin dependent kinase 2 (CKD2)complexed with DIN-232305
1GIH	;	2.8	;	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
1GII	;	2.0	;	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
1GIJ	;	2.2	;	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
2DS1	;	2.0	;	Human cyclin dependent kinase 2 complexed with the CDK4 inhibitor
1GZ8	;	1.3	;	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-Amino-6-(3'-methyl-2'-oxo)butoxypurine
1PXM	;	2.53	;	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(2,4-Dimethyl-thiazol-5-yl)-pyrimidin-2-ylamino]-phenol
1PXJ	;	2.3	;	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(2,4-Dimethyl-thiazol-5-yl)-pyrimidin-2-ylamine
1PXI	;	1.95	;	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(2,5-Dichloro-thiophen-3-yl)-pyrimidin-2-ylamine
1PXN	;	2.5	;	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-Methyl-2-methylamino-thiazol-5-yl)-pyrimidin-2-ylamino]-phenol
1PXP	;	2.3	;	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(2,4-Dimethyl-thiazol-5-yl)-pyrimidin-2-yl]-N',N'-dimethyl-benzene-1,4-diamine
1PXK	;	2.8	;	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(2,4-Dimethyl-thiazol-5-yl)pyrimidin-2-yl]-N'-hydroxyiminoformamide
1E1V	;	1.95	;	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058
1E1X	;	1.85	;	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027
1CKP	;	2.05	;	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B
1AQ1	;	2.0	;	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE
1PXL	;	2.5	;	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2,4-Dimethyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-trifluoromethyl-phenyl)-amine
1PXO	;	1.96	;	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine
1H0V	;	1.9	;	Human cyclin dependent protein kinase 2 in complex with the inhibitor 2-Amino-6-[(R)-pyrrolidino-5'-yl]methoxypurine
1H0W	;	2.1	;	Human cyclin dependent protein kinase 2 in complex with the inhibitor 2-Amino-6-[cyclohex-3-enyl]methoxypurine
2BHH	;	2.6	;	HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-INDIRUBINE
2BHE	;	1.9	;	HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINE
1B38	;	2.0	;	HUMAN CYCLIN-DEPENDENT KINASE 2
1HCK	;	1.9	;	HUMAN CYCLIN-DEPENDENT KINASE 2
1HCL	;	1.8	;	HUMAN CYCLIN-DEPENDENT KINASE 2
1DM2	;	2.1	;	HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE
8OY2	;	2.618	;	Human cyclin-dependent kinase 2 in complex with inhibitor HB-29260
2A4L	;	2.4	;	Human cyclin-dependent kinase 2 in complex with roscovitine
1B39	;	2.1	;	HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160
5KUL	;	1.7	;	Human cyclophilin A at 100K, Data set 1
5KUN	;	1.7	;	Human cyclophilin A at 100K, Data set 2
5KUO	;	1.7	;	Human cyclophilin A at 100K, Data set 3
5KUQ	;	1.7	;	Human cyclophilin A at 100K, Data set 4
5KUR	;	1.7	;	Human cyclophilin A at 100K, Data set 5
5KUS	;	1.7	;	Human cyclophilin A at 100K, Data set 6
5KUU	;	1.7	;	Human cyclophilin A at 100K, Data set 7
5KUV	;	1.7	;	Human cyclophilin A at 100K, Data set 8
5KUW	;	1.7	;	Human cyclophilin A at 100K, Data set 9
5KUZ	;	1.7	;	Human cyclophilin A at 278K, Data set 1
5KV0	;	1.7	;	Human cyclophilin A at 278K, Data set 2
5KV1	;	1.7	;	Human cyclophilin A at 278K, Data set 3
5KV2	;	1.7	;	Human cyclophilin A at 278K, Data set 4
5KV3	;	1.7	;	Human cyclophilin A at 278K, Data set 5
5KV4	;	1.7	;	Human cyclophilin A at 278K, Data set 6
5KV5	;	1.7	;	Human cyclophilin A at 278K, Data set 7
5KV6	;	1.7	;	Human cyclophilin A at 278K, Data set 8
5KV7	;	1.7	;	Human cyclophilin A at 278K, Data set 9
6X3R	;	1.8	;	Human cyclophilin A bound to a series of acylcic and macrocyclic inhibitors
6X3Y	;	1.4	;	Human cyclophilin A bound to a series of acylcic and macrocyclic inhibitors
6X4Q	;	1.8	;	Human cyclophilin A bound to a series of acylcic and macrocyclic inhibitors: (2R,5S,11S,14S,18E)-14-cyclobutyl-2,11,17,17-tetramethyl-15-oxa-3,9,12,26,29-pentaazatetracyclo[18.5.3.1~5,9~.0~23,27~]nonacosa-1(25),18,20(28),21,23,26-hexaene-4,10,13,16-tetrone (compound 33)
6X4P	;	1.5	;	Human cyclophilin A bound to a series of acylcic and macrocyclic inhibitors: (2R,5S,11S,14S,18E)-2,11,17,17-tetramethyl-14-(propan-2-yl)-15-oxa-3,9,12,26,29-pentaazatetracyclo[18.5.3.1~5,9~.0~23,27~]nonacosa-1(25),18,20(28),21,23,26-hexaene-4,10,13,16-tetrone (compound 28)
6X4N	;	1.51	;	Human cyclophilin A bound to a series of acylcic and macrocyclic inhibitors: (2R,5S,11S,14S,18E)-2,11,17,17-tetramethyl-14-(propan-2-yl)-3-oxa-9,12,15,26,29-pentaazatetracyclo[18.5.3.1~5,9~.0~23,27~]nonacosa-1(25),18,20(28),21,23,26-hexaene-4,10,13,16-tetrone (compound 24)
6X4O	;	1.5	;	Human cyclophilin A bound to a series of acylcic and macrocyclic inhibitors: (2R,5S,11S,14S,18E)-2,11-dimethyl-14-(propan-2-yl)-3-oxa-9,12,15,21,29-pentaazatetracyclo[18.5.3.1~5,9~.0~23,27~]nonacosa-1(26),18,20,22,24,27-hexaene-4,10,13,16-tetrone (compound 21)
6X4M	;	1.5	;	Human cyclophilin A bound to a series of acylcic and macrocyclic inhibitors: tert-butyl [(2S)-1-{[(3S,17S)-2,16-dioxo-10,15-dioxa-1,21-diazatricyclo[15.3.1.1~5,9~]docosa-5(22),6,8-trien-3-yl]amino}-3-methyl-1-oxobutan-2-yl]carbamate (compound 3)
1AK4	;	2.36	;	HUMAN CYCLOPHILIN A BOUND TO THE AMINO-TERMINAL DOMAIN OF HIV-1 CAPSID
1CWK	;	1.8	;	HUMAN CYCLOPHILIN A COMPLEXED WITH 1-(6,7-DIHYDRO)MEBMT 2-VAL 3-D-(2-S-METHYL)SARCOSINE CYCLOSPORIN
1BCK	;	1.8	;	HUMAN CYCLOPHILIN A COMPLEXED WITH 2-THR CYCLOSPORIN
1CWI	;	1.9	;	HUMAN CYCLOPHILIN A COMPLEXED WITH 2-VAL 3-(N-METHYL)-D-ALANINE CYCLOSPORIN
1CWJ	;	1.8	;	HUMAN CYCLOPHILIN A COMPLEXED WITH 2-VAL 3-S-METHYL-SARCOSINE CYCLOSPORIN
1CWF	;	1.86	;	HUMAN CYCLOPHILIN A COMPLEXED WITH 2-VAL CYCLOSPORIN
1CWH	;	1.86	;	HUMAN CYCLOPHILIN A COMPLEXED WITH 3-D-SER CYCLOSPORIN
1CWL	;	1.8	;	HUMAN CYCLOPHILIN A COMPLEXED WITH 4 4-HYDROXY-MELEU CYCLOSPORIN
1CWM	;	2.0	;	HUMAN CYCLOPHILIN A COMPLEXED WITH 4 MEILE CYCLOSPORIN
3RDD	;	2.14	;	Human Cyclophilin A Complexed with an Inhibitor
1CWO	;	1.86	;	HUMAN CYCLOPHILIN A COMPLEXED WITH THR2, LEU5, D-HIV8, LEU10 CYCLOSPORIN
7QBW	;	1.59	;	Human Cyclophilin A double mutant C52AK125C
1OCA	;		;	HUMAN CYCLOPHILIN A, UNLIGATED, NMR, 20 STRUCTURES
2ESL	;	1.9	;	Human Cyclophilin C in Complex with Cyclosporin A
3RCI	;	1.44	;	Human cyclophilin D complexed with 5-methyl-1,2-oxazol-3-amine
3R4G	;	1.05	;	Human Cyclophilin D Complexed with a Fragment
3R54	;	1.35	;	Human Cyclophilin D Complexed with a Fragment
3R56	;	1.4	;	Human Cyclophilin D Complexed with a Fragment
3R57	;	1.71	;	Human Cyclophilin D Complexed with a Fragment
3R59	;	1.1	;	Human Cyclophilin D Complexed with a Fragment
3RCK	;	1.26	;	Human Cyclophilin D Complexed with a Fragment
3RCL	;	1.7	;	Human Cyclophilin D Complexed with a Fragment
3RD9	;	1.4	;	Human Cyclophilin D Complexed with a Fragment
3RDA	;	1.07	;	Human Cyclophilin D Complexed with a Fragment
3RDB	;	1.55	;	Human Cyclophilin D Complexed with a Fragment
3RDC	;	1.94	;	Human Cyclophilin D Complexed with an Inhibitor
4J58	;	1.28	;	Human Cyclophilin D Complexed with an Inhibitor
4J59	;	1.92	;	Human Cyclophilin D Complexed with an Inhibitor
4J5A	;	1.58	;	Human Cyclophilin D Complexed with an Inhibitor
4J5B	;	2.01	;	Human Cyclophilin D Complexed with an Inhibitor
4J5C	;	1.03	;	Human Cyclophilin D Complexed with an Inhibitor
4J5D	;	1.32	;	Human Cyclophilin D Complexed with an Inhibitor
4J5E	;	0.99	;	Human Cyclophilin D Complexed with an Inhibitor
4ZSC	;	1.5	;	Human Cyclophilin D Complexed with an Inhibitor at room temperature
4ZSD	;	1.45	;	Human Cyclophilin D Complexed with an Inhibitor at room temperature
3RCG	;	0.97	;	Human cyclophilin D complexed with dimethylformamide
5CBT	;	1.45	;	Human Cyclophilin D Complexed with Inhibitor
5CBV	;	1.8	;	Human Cyclophilin D Complexed with Inhibitor
5CCN	;	1.8	;	Human Cyclophilin D Complexed with Inhibitor
5CCQ	;	1.8	;	Human Cyclophilin D Complexed with Inhibitor
5CCR	;	1.9	;	Human Cyclophilin D Complexed with Inhibitor
5CCS	;	2.1	;	Human Cyclophilin D Complexed with Inhibitor
5CBU	;	1.4	;	Human Cyclophilin D Complexed with Inhibitor.
5CBW	;	1.8	;	Human Cyclophilin D Complexed with Inhibitor.
3RCF	;	1.15	;	Human cyclophilin D complexed with N-[(4-aminophenyl)sulfonyl]benzamide
3R49	;	1.77	;	Human cyclophilin D complexed with quinolin-8-amine
6R8O	;	1.36	;	Human Cyclophilin D in complex with 1-(((2R,3S,6R)-3-hydroxy-2,3,4,6-tetrahydro-1H-2,6-methanobenzo[c][1,5]oxazocin-8-yl)methyl)-3-(2-((R)-2-(2-(methylthio)phenyl)pyrrolidin-1-yl)-2-oxoethyl)urea
6R8L	;	1.64	;	Human Cyclophilin D in complex with 1-((1S,9S,10S)-10-Hydroxy-12-oxa-8-aza-tricyclo[7.3.1.02,7]trideca-2,4,6-trien-4-ylmethyl)-3- {2-[(R)-2-(2-methylsulfanyl-phenyl)-pyrrolidin-1-yl]-2-oxo-ethyl}-urea
6R8W	;	1.4	;	Human Cyclophilin D in complex with 2-(exo-3,5-Dioxo-4-aza-tricyclo[5.2.1.02,6]dec-4-yl)-N-((1R,9R,10S)-10-hydroxy-12-oxa-8-aza-tricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ylmethyl)-acetamide
6R9S	;	2.0	;	Human Cyclophilin D in complex with bicyclic fragment
6R9U	;	1.26	;	Human Cyclophilin D in complex with fragment
7R2I	;	1.31	;	Human Cyclophilin D in complex with fragment
7ZDN	;	1.55	;	Human Cyclophilin D in complex with fragment
7R2J	;	1.26	;	Human Cyclophilin D in complex with N-(4-aminophenyl)-7-methyl-2-oxo-1H,2H-pyrazolo[1,5-a]pyrimidine-6-carboxamide
7R2L	;	1.1	;	Human Cyclophilin D in complex with N-(4-aminophenyl)-7-methyl-2-oxo-1H,2H-pyrazolo[1,5-a]pyrimidine-6-carboxamide
7OGI	;	1.01	;	Human Cyclophilin D in complex with N-(5-ethyl-4-oxo-1,2,3,4,5,6-hexahydro-1,5-benzodiazocin-8-yl)-7methyl-2-oxo-1H,2H-pyrazolo[1,5-a]pyrimidine-6-carboxamide
6R9X	;	1.66	;	Human Cyclophilin D in complex with N-cyclopentyl-N'-pyridin-2-ylmethyl-oxalamide
7PMT	;	0.98	;	Human Cyclophilin D in complex with N-[(5-ethyl-4-oxo-1,2,3,4,5,6- hexahydro-1,5-benzodiazocin-8-yl)methyl]-7-methyl-2-oxo-1H,2H-pyrazolo[1,5-a]pyrimidine-6-carboxamide
6RA1	;	2.0	;	Human Cyclophilin D in complex with norbornane fragment derivative
7E7F	;	1.4	;	Human CYP11B1 mutant in complex with metyrapone
7M8I	;	2.94	;	Human CYP11B2 and human adrenodoxin in complex with fadrozole
7M8V	;	3.08	;	Human CYP11B2 in complex with LCI699
6OO9	;	2.25	;	Human CYP3A4 bound to a drug mibefradil
6OOA	;	2.52	;	Human CYP3A4 bound to a drug substrate
8DYC	;	2.4	;	Human CYP3A4 bound to a substrate
8SO2	;	2.15	;	Human CYP3A4 bound to a substrate
6OOB	;	2.202	;	Human CYP3A4 bound to a suicide substrate
6DA2	;	2.65	;	Human CYP3A4 bound to an inhibitor
6DA3	;	2.37	;	Human CYP3A4 bound to an inhibitor
6DA5	;	2.25	;	Human CYP3A4 bound to an inhibitor
6DA8	;	2.802	;	Human CYP3A4 bound to an inhibitor
6DAA	;	2.15	;	Human CYP3A4 bound to an inhibitor
6DAB	;	2.35	;	Human CYP3A4 bound to an inhibitor
6DAC	;	2.55	;	Human CYP3A4 bound to an inhibitor
6DAG	;	2.8	;	Human CYP3A4 bound to an inhibitor
6DAJ	;	2.45	;	Human CYP3A4 bound to an inhibitor
6DAL	;	2.65	;	Human CYP3A4 bound to an inhibitor
6UNE	;	2.55	;	Human CYP3A4 bound to an inhibitor
6UNG	;	2.3	;	Human CYP3A4 bound to an inhibitor
6UNH	;	2.72	;	Human CYP3A4 bound to an inhibitor
6UNI	;	2.602	;	Human CYP3A4 bound to an inhibitor
6UNJ	;	2.6	;	Human CYP3A4 bound to an inhibitor
6UNK	;	2.75	;	Human CYP3A4 bound to an inhibitor
7KVH	;	2.791	;	Human CYP3A4 bound to an inhibitor
7KVI	;	2.55	;	Human CYP3A4 bound to an inhibitor
7KVJ	;	2.65	;	Human CYP3A4 bound to an inhibitor
7KVK	;	2.55	;	Human CYP3A4 bound to an inhibitor
7KVM	;	2.75	;	Human CYP3A4 bound to an inhibitor
7KVN	;	2.7	;	Human CYP3A4 bound to an inhibitor
7KVO	;	2.65	;	Human CYP3A4 bound to an inhibitor
7KVP	;	2.75	;	Human CYP3A4 bound to an inhibitor
7KVQ	;	2.75	;	Human CYP3A4 bound to an inhibitor
7KVS	;	2.5	;	Human CYP3A4 bound to an inhibitor
7UFC	;	2.35	;	Human CYP3A4 bound to an inhibitor
7UFD	;	2.9	;	Human CYP3A4 bound to an inhibitor
7UFE	;	2.4	;	Human CYP3A4 bound to an inhibitor
7UFF	;	2.7	;	Human CYP3A4 bound to an inhibitor
6MA7	;	2.09	;	Human CYP3A4 bound to an inhibitor fluconazole
6MA6	;	2.182	;	Human CYP3A4 bound to an inhibitor metyrapone
6MA8	;	1.83	;	Human CYP3A4 bound to PMSF
8SO1	;	2.05	;	Human CYP3A4 bound to three caffeine molecules
6FOI	;	2.0	;	Human Cys57/156Ala superoxide dismutase-1 (SOD1), as isolated.
5MMS	;	2.8	;	Human cystathionine beta-synthase (CBS) p.P49L delta409-551 variant
1G96	;	2.5	;	HUMAN CYSTATIN C; DIMERIC FORM WITH 3D DOMAIN SWAPPING
2JIS	;	1.6	;	Human cysteine sulfinic acid decarboxylase (CSAD) in complex with PLP.
3NWV	;	1.9	;	Human cytochrome c G41S
6ECJ	;	2.7	;	Human cytochrome c G41T
5EXQ	;	1.6	;	Human cytochrome c Y48H
3QM4	;	2.85	;	Human Cytochrome P450 (CYP) 2D6 - Prinomastat Complex
7SV2	;	2.46	;	Human Cytochrome P450 (CYP) 3A5 ternary complex with azamulin
5IRV	;	3.098	;	Human cytochrome P450 17A1 bound to inhibitor VT-464
5IRQ	;	2.202	;	Human cytochrome P450 17A1 bound to inhibitors (R)- and (S)- orteronel
6CHI	;	2.698	;	Human Cytochrome P450 17A1 in complex with inhibitor: abiraterone C6 amide
6CIZ	;	2.601	;	Human Cytochrome P450 17A1 in complex with inhibitor: abiraterone C6 nitrile
6CIR	;	2.648	;	Human Cytochrome P450 17A1 in complex with inhibitor: abiraterone C6 oxime
8FDA	;	2.2	;	Human Cytochrome P450 17A1 in complex with steroidal isonitrile inhibitor
3SWZ	;	2.4	;	Human Cytochrome P450 17A1 in complex with TOK-001
4I8V	;	2.6	;	Human Cytochrome P450 1A1 in complex with alpha-naphthoflavone
4EJH	;	2.35	;	Human Cytochrome P450 2A13 in complex with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)
4EJG	;	2.5	;	Human Cytochrome P450 2A13 in complex with Nicotine
3T3S	;	3.0	;	Human Cytochrome P450 2A13 in complex with Pilocarpine
4EJI	;	2.1	;	Human Cytochrome P450 2A13 in complex with two molecules of 4-(methylnitrosamino)-1-(3-puridyl)-1-butanone
3EBS	;	2.15	;	Human Cytochrome P450 2A6 I208S/I300F/G301A/S369G in complex with Phenacetin
3T3Q	;	2.1	;	Human Cytochrome P450 2A6 I208S/I300F/G301A/S369G in complex with Pilocarpine
4EJJ	;	2.3	;	Human Cytochrome P450 2A6 in complex with nicotine
3T3R	;	2.4	;	Human Cytochrome P450 2A6 in complex with Pilocarpine
4WNT	;	2.6	;	Human Cytochrome P450 2D6 Ajmalicine Complex
4XRY	;	2.5	;	Human Cytochrome P450 2D6 BACE1 Inhibitor 5 Complex
4XRZ	;	2.4	;	Human Cytochrome P450 2D6 BACE1 Inhibitor 6 Complex
4WNU	;	2.26	;	Human Cytochrome P450 2D6 Quinidine Complex
4WNV	;	2.35	;	Human Cytochrome P450 2D6 Quinine Complex
4WNW	;	3.299	;	Human Cytochrome P450 2D6 Thioridazine Complex
3TBG	;	2.1	;	Human cytochrome P450 2D6 with two thioridazines bound in active site
3GPH	;	2.7	;	Human cytochrome P450 2E1 in complex with omega-imidazolyl-decanoic acid
3LC4	;	3.1	;	Human Cytochrome P450 2E1 in Complex with Omega-Imidazolyl-Dodecanoic Acid
3T3Z	;	2.35	;	Human Cytochrome P450 2E1 in complex with pilocarpine
3E4E	;	2.6	;	Human cytochrome P450 2E1 in complex with the inhibitor 4-methylpyrazole
3E6I	;	2.2	;	Human cytochrome P450 2E1 in complex with the inhibitor indazole
5VEU	;	2.91	;	Human Cytochrome P450 3A5 (CYP3A5)
3RUK	;	2.6	;	Human Cytochrome P450 CYP17A1 in complex with Abiraterone
8TEW	;	3.02	;	Human cytomegalovirus penton vertex, CVSC-bound configuration
8TET	;	4.26	;	Human cytomegalovirus portal vertex, non-infectious enveloped particle (NIEP) configuration 1 (NC1)
8TEU	;	4.01	;	Human cytomegalovirus portal vertex, non-infectious enveloped particle (NIEP) configuration 2 - inverted (NC2-inv)
8TEP	;	3.5	;	Human cytomegalovirus portal vertex, virion configuration 1 (VC1)
8TES	;	3.27	;	Human cytomegalovirus portal vertex, virion configuration 2 (VC2)
1CMV	;	2.27	;	HUMAN CYTOMEGALOVIRUS PROTEASE
1JQ6	;	2.3	;	HUMAN CYTOMEGALOVIRUS PROTEASE DIMER-INTERFACE MUTANT, S225Y
7TCZ	;	2.67	;	Human cytomegalovirus protease mutant (C84A, C87A, C138A, C202A) in complex with inhibitor
3N4P	;	2.15	;	Human cytomegalovirus terminase nuclease domain
3N4Q	;	3.2	;	Human cytomegalovirus terminase nuclease domain, Mn soaked
6EY7	;	2.9	;	Human cytomegalovirus terminase nuclease domain, Mn soaked, inhibitor bound
7ET2	;	4.2	;	Human Cytomegalovirus, C12 portal
5OWO	;	1.79	;	Human cytoplasmic Dynein N-Terminus dimerization domain at 1.8 Angstrom resolution
5NW4	;	8.7	;	Human cytoplasmic dynein-1 bound to dynactin and an N-terminal construct of BICD2
5NVS	;	8.4	;	Human cytoplasmic dynein-1 tail in the twisted N-terminus state
7YJJ	;	6.31	;	Human Cytosolic 10-formyltetrahydrofolate dehydrogenase and Gossypol complex
7ZEE	;	1.36	;	Human cytosolic 5' nucleotidase IIIB
7ZEG	;	1.56	;	Human cytosolic 5' nucleotidase IIIB in complex with 3,4-diF-Bn7GMP
7ZEH	;	1.5	;	Human cytosolic 5' nucleotidase IIIB in complex with 3,4-diF-Bn7Guanine
6FIW	;	2.2	;	Human cytosolic 5'-nucleotidase II co-crystallized with 10mM Sodium ((4-(3'-((7H-purin-6-yl)carbamoyl)-[1,1'-biphenyl]-3-yl)-1H-imidazol-1-yl) methyl) phosphonate
5CQZ	;	2.9	;	Human cytosolic 5'-nucleotidase II in complex with 3-(3-Imidazol-1-ylphenyl)-N-(9H-purin-6-yl)benzamide
4H4B	;	2.9	;	Human cytosolic 5'-nucleotidase II in complex with Anthraquinone-2,6- disulfonic acid
5CR7	;	2.9	;	Human cytosolic 5'-nucleotidase II in complex with N-(9H-Purin-6-yl)-3-(3-pyrrol-1-ylphenyl)benzamide
6FIU	;	2.5	;	Human cytosolic 5'-nucleotidase II soaked with 10mM 2-(6-([1,1'-Biphenyl]-3-carboxamido)-9H-purin-9-yl)acetic acid
6FXH	;	2.3	;	Human cytosolic 5'-nucleotidase II soaked with 10mM 3-Phenyl-N-(9H-purin-6-yl)benzamide
6FIS	;	2.3	;	Human cytosolic 5'-nucleotidase II soaked with 10mM 7-Benzyloxymethyl-7H-adenine
6FIR	;	2.5	;	Human cytosolic 5'-nucleotidase II soaked with 5mM3-Phenyl-N-(9H-purin-6-yl)benzamide
1WL5	;	2.26	;	Human cytosolic acetoacetyl-CoA thiolase
1WL4	;	1.55	;	Human cytosolic acetoacetyl-CoA thiolase complexed with CoA
6O76	;	2.787	;	Human cytosolic Histidyl-tRNA synthetase (HisRS) with WHEP domain
1CJY	;	2.5	;	HUMAN CYTOSOLIC PHOSPHOLIPASE A2
5ZJA	;	2.6	;	human D-amino acid oxidase complexed with 5-chlorothiophene-2-carboxylic acid
5ZJ9	;	2.6	;	human D-amino acid oxidase complexed with 5-chlorothiophene-3-carboxylic acid
6C5F	;	1.4	;	Human D-Dopachrome tautomerase (D-DT)/ macrophage migration inhibitory factor 2 (MIF2) complexed with the selective inhibitor 4-CPPC
4Q3F	;	1.8	;	Human D-DT complexed with tartrate
4KCG	;	2.09	;	Human dCK C4S-S74E mutant in complex with UDP and the DI-39 inhibitor
4L5B	;	1.94	;	Human dCK C4S-S74E mutant in complex with UDP and the DI-43 inhibitor
4JLJ	;	2.0	;	Human dCK C4S-S74E mutant in complex with UDP and the F2.1.1 inhibitor (2-[({2-[3-(2-FLUOROETHOXY)-4-METHOXYPHENYL]-1,3-THIAZOL-4-YL}METHYL)SULFANYL]PYRIMIDINE-4,6-DIAMINE)
4JLK	;	1.89	;	Human dCK C4S-S74E mutant in complex with UDP and the F2.2.1 inhibitoR (2-[({2-[3-(2-FLUOROETHOXY)-4-METHOXYPHENYL]-5-METHYL-1,3-THIAZOL-4-YL}METHYL)SULFANYL]PYRIMIDINE-4,6-DIAMINE)
4JLM	;	2.18	;	Human dCK C4S-S74E mutant in complex with UDP and the F2.3.1 inhibitor (2-[({5-ETHYL-2-[3-(2-FLUOROETHOXY)-4-METHOXYPHENYL]-1,3-THIAZOL-4-YL}METHYL)SULFANYL]PYRIMIDINE-4,6-DIAMINE)
4JLN	;	2.15	;	Human dCK C4S-S74E mutant in complex with UDP and the F2.4.1 inhibitor (2-[({2-[3-(2-FLUOROETHOXY)-4-METHOXYPHENYL]-5-PROPYL-1,3-THIAZOL-4-YL}METHYL)SULFANYL]PYRIMIDINE-4,6-DIAMINE)
4Q1E	;	1.85	;	Human dCK C4S-S74E mutant in complex with UDP and the inhibitor 10 {2-{[(1R/S)-1-{2-[3-(2-fluoroethoxy)-4-methoxyphenyl]-5-methyl-1,3-thiazol 4-yl}ethyl]sulfanyl}pyrimidine-4,6-diamine}
4Q1F	;	2.1	;	Human dCK C4S-S74E mutant in complex with UDP and the inhibitor 12R {N-{2-[5-(4-{(1R)-1-[(4,6-diaminopyrimidin-2-yl)sulfanyl]ethyl}-5-methyl-1,3-thiazol-2-yl)-2-methoxyphenoxy]ethyl}methanesulfonamide}
4Q18	;	2.0	;	Human dCK C4S-S74E mutant in complex with UDP and the inhibitor 4 [1-[5-(4-{[(2,6-diaminopyrimidin-4-yl)sulfanyl]methyl}-5-propyl-1,3-thiazol-2-yl)-2-methoxyphenoxy]-2-methylpropan-2-ol]
4Q19	;	2.09	;	Human dCK C4S-S74E mutant in complex with UDP and the inhibitor 5 {5-(4-{[(4,6-DIAMINOPYRIMIDIN-2-YL)SULFANYL]METHYL}-5-PROPYL-1,3-THIAZOL-2-YL)-2-METHOXYPHENOL}
4Q1A	;	1.9	;	Human dCK C4S-S74E mutant in complex with UDP and the inhibitor 6 {2-[5-(4-{[(4,6-diaminopyrimidin-2-yl)sulfanyl]methyl}-5-propyl-1,3-thiazol-2-yl)-2-methoxyphenoxy]ethanol}
4Q1B	;	2.15	;	Human dCK C4S-S74E mutant in complex with UDP and the inhibitor 7 {N-(2-(3-(4-(((4,6-diaminopyrimidin-2-yl)thio)methyl)-5-propylthiazol-2-yl)phenoxy)ethyl)methanesulfonamide}
4Q1C	;	2.0	;	Human dCK C4S-S74E mutant in complex with UDP and the inhibitor 8 {2,2'-[{4-[(2R)-4-{[(4,6-diaminopyrimidin-2-yl)sulfanyl]methyl}-5-propyl-2,3-dihydro-1,3-thiazol-2-yl]benzene-1,2-diyl}bis(oxy)]diethanol}
4Q1D	;	2.0	;	Human dCK C4S-S74E mutant in complex with UDP and the inhibitor 9 {2-{[(1R)-1-{2-[3-(2-fluoroethoxy)-4-methoxyphenyl]-5-propyl-1,3-thiazol-4-yl}ethyl]sulfanyl}pyrimidine-4,6-diamine}
3KFX	;	1.96	;	Human dCK complex with 5-Me dC and ADP
3MJR	;	2.1	;	Human dCK complex with Acyclic Nucleoside
2W4L	;	2.1	;	Human dCMP deaminase
7MU5	;	2.2	;	Human DCTPP1 bound to Triptolide
7UT0	;	1.68	;	Human DDAH-1, apo form
7USZ	;	1.65	;	Human DDAH-1, holo (Zn-bound) form
7ULV	;	2.37	;	Human DDAH1 soaked with its inactivator S-((4-chloropyridin-2-yl)methyl)-L-cysteine
7ULU	;	2.2	;	Human DDAH1 soaked with its inhibitor ClPyrAA
7ULX	;	1.707	;	Human DDAH1 soaked with its inhibitor N4-(4-chloropyridin-2-yl)-L-asparagine
2PL3	;	2.15	;	Human DEAD-box RNA helicase DDX10, DEAD domain in complex with ADP
3G0H	;	2.7	;	Human dead-box RNA helicase DDX19, in complex with an ATP-analogue and RNA
3B7G	;	1.9	;	Human DEAD-box RNA helicase DDX20, Conserved domain I (DEAD) in complex with AMPPNP (Adenosine-(Beta,gamma)-imidotriphosphate)
2OXC	;	1.3	;	Human DEAD-box RNA helicase DDX20, DEAD domain in complex with ADP
2P6N	;	2.6	;	Human DEAD-box RNA helicase DDX41, helicase domain
3FE2	;	2.6	;	Human DEAD-BOX RNA helicase DDX5 (P68), conserved domain I in complex with ADP
3EWS	;	2.7	;	Human DEAD-box RNA-helicase DDX19 in complex with ADP
3BER	;	1.4	;	Human DEAD-box RNA-helicase DDX47, conserved domain I in complex with AMP
3DKP	;	2.1	;	Human DEAD-box RNA-helicase DDX52, conserved domain I in complex with ADP
2CKE	;	2.8	;	Human death-associated DRP-1 kinase in complex with inhibitor
1WMK	;	3.6	;	Human death-associated kinase DRP-1, mutant S308D d40
5OSY	;	2.06	;	Human Decapping Scavenger enzyme (hDcpS) in complex with m7G(5'S)ppSp(5'S)G mRNA 5' cap analog
7F5S	;	2.72	;	human delta-METTL18 60S ribosome
2BBS	;	2.05	;	Human deltaF508 NBD1 with three solubilizing mutations
2BBT	;	2.3	;	Human deltaF508 NBD1 with two solublizing mutations.
2QRO	;	3.45	;	Human Deoxycytidine kinase dAMP, UDP, Mg ion product complex
2QRN	;	3.4	;	Human Deoxycytidine kinase dCMP, UDP, Mg ion product complex
1B86	;	2.5	;	HUMAN DEOXYHAEMOGLOBIN-2,3-DIPHOSPHOGLYCERATE COMPLEX
8A0G	;	1.84	;	Human deoxyhypusine synthase with trapped transition state
7OWG	;	4.7	;	human DEPTOR in a complex with mutant human mTORC1 A1459P
3GYF	;	1.7	;	Human DHFR with Z-isomer in Orthorhombic lattice
6SYP	;	1.8	;	Human DHODH bound to inhibitor IPP/CNRS-A017
8SZP	;	2.62	;	Human DHX9 bound to ADP
6DFX	;	2.03	;	human diabetogenic TCR T1D3 in complex with DQ8-p8E9E peptide
6VP0	;	3.1	;	Human Diacylglycerol Acyltransferase 1 in complex with oleoyl-CoA
8FG1	;		;	Human diaphanous inhibitory domain bound to diaphanous autoregulatory domain
7XLM	;	3.73	;	Human diastrophic dysplasia sulfate transporter SLC26A2
3S7A	;	1.8	;	Human dihydrofolate reductase binary complex with PT684
5HQY	;	1.46	;	human dihydrofolate reductase complex with NADPH and 5-methyl-6-(2',3',4'-trifluorophenylthio)thieno[2,3-d]pyrimidine-2,4-diamine
5HPB	;	1.65	;	human dihydrofolate reductase complex with NADPH and 5-methyl-6-(phenylthio-4'trifluoromethyl)thieno[2,3-d]pyrimidine-2,4-diamine
1KMV	;	1.05	;	HUMAN DIHYDROFOLATE REDUCTASE COMPLEXED WITH NADPH AND (Z)-6-(2-[2,5-DIMETHOXYPHENYL]ETHEN-1-YL)-2,4-DIAMINO-5-METHYLPYRIDO[2,3-D]PYRIMIDINE (SRI-9662), A LIPOPHILIC ANTIFOLATE
2C2T	;	1.5	;	Human Dihydrofolate Reductase Complexed With NADPH and 2,4-Diamino-5-((7,8-dicarbaundecaboran-7-yl)methyl)-6-methylpyrimidine, a novel boron containing, nonclassical Antifolate
2C2S	;	1.4	;	Human Dihydrofolate Reductase Complexed With NADPH and 2,4-Diamino-5-(1-o-carboranylmethyl)-6-methylpyrimidine, A novel boron containing, nonclassical Antifolate
4KBN	;	1.84	;	human dihydrofolate reductase complexed with NADPH and 5-{3-[3-(3,5-pyrimidine)]-phenyl-prop-1-yn-1-yl}-6-ethyl-pyrimidine-2,4diamine
4KD7	;	2.715	;	Human dihydrofolate reductase complexed with NADPH and 5-{3-[3-methoxy-5(pyridine-4-yl)phenyl]prop-1-yn-1-yl}-6-ethyl-pyrimidine-2,4-diamine
4KEB	;	1.45	;	Human dihydrofolate reductase complexed with NADPH and 5-{3-[3-methoxy-5-(isoquin-5-yl)phenyl]but-1-yn-1-yl}6-ethylpyrimidine-2,4-diamine
4KFJ	;	1.76	;	Human dihydrofolate reductase complexed with NADPH and 5-{3-[3-methoxy-5-(isoquin-5-yl)phenyl]prop-1-yn-1-yl}6-ethylprimidine-2,4-diamine
1KMS	;	1.09	;	HUMAN DIHYDROFOLATE REDUCTASE COMPLEXED WITH NADPH AND 6-([5-QUINOLYLAMINO]METHYL)-2,4-DIAMINO-5-METHYLPYRIDO[2,3-D]PYRIMIDINE (SRI-9439), A LIPOPHILIC ANTIFOLATE
2W3B	;	1.27	;	HUMAN DIHYDROFOLATE REDUCTASE COMPLEXED WITH NADPH AND A LIPOPHILIC ANTIFOLATE SELECTIVE FOR MYCOBACTERIUM AVIUM DHFR, 6-((2,5- DIETHOXYPHENYL)AMINOMETHYL)-2,4-DIAMINO-5-METHYLPYRIDO(2,3-D) PYRIMIDINE (SRI-8686)
6A7C	;	2.06	;	Human dihydrofolate reductase complexed with NADPH and BT1
6A7E	;	1.85	;	Human dihydrofolate reductase complexed with NADPH and BT2
2W3M	;	1.6	;	HUMAN DIHYDROFOLATE REDUCTASE COMPLEXED WITH NADPH AND FOLATE
4DDR	;	2.05	;	Human dihydrofolate reductase complexed with NADPH and P218
2W3A	;	1.5	;	HUMAN DIHYDROFOLATE REDUCTASE COMPLEXED WITH NADPH AND TRIMETHOPRIM
7XI7	;	1.65	;	Human dihydrofolate reductase complexed with P39
3GHW	;	1.24	;	Human dihydrofolate reductase inhibitor complex
3GI2	;	1.53	;	Human dihydrofolate reductase Q35K mutant inhibitor complex
3S3V	;	1.53	;	human dihydrofolate reductase Q35K/N64F double mutant binary complex with trimethoprim
3GHV	;	1.3	;	Human dihydrofolate reductase Q35K/N64F double mutant inhibitor complex
3F8Z	;	2.01	;	Human Dihydrofolate Reductase Structural Data with Active Site Mutant Enzyme Complexes
4QJC	;	1.62	;	Human dihydrofolate reductase ternary complex with NADPH and inhibitor 26 (N~6~-METHYL-N~6~-(3,4,5-TRIFLUOROPHENYL)PYRIDO[2,3-D]PYRIMIDINE-2,4,6-TRIAMINE)
1OHJ	;	2.5	;	HUMAN DIHYDROFOLATE REDUCTASE, MONOCLINIC (P21) CRYSTAL FORM
1OHK	;	2.5	;	HUMAN DIHYDROFOLATE REDUCTASE, ORTHORHOMBIC (P21 21 21) CRYSTAL FORM
6HFI	;	1.45995	;	Human dihydroorotase mutant F1563A apo structure
6HFH	;	1.44871	;	Human dihydroorotase mutant F1563A co-crystallized with carbamoyl aspartate at pH 7.0
6HFJ	;	1.2	;	Human dihydroorotase mutant F1563A co-crystallized with carbamoyl aspartate at pH 7.5
6HFD	;	1.86997	;	Human dihydroorotase mutant F1563L apo structure
6HFK	;	1.45914	;	Human dihydroorotase mutant F1563L co-crystallized with carbamoyl aspartate at pH 6.5
6HFL	;	1.35	;	Human dihydroorotase mutant F1563L co-crystallized with carbamoyl aspartate at pH 7.0
6HFN	;	1.44965	;	Human dihydroorotase mutant F1563L co-crystallized with carbamoyl aspartate at pH 7.5
6HFE	;	1.47997	;	Human dihydroorotase mutant F1563T apo structure
6HFP	;	1.19823	;	Human dihydroorotase mutant F1563T co-crystallized with carbamoyl aspartate at pH 7.0
6HFQ	;	1.14542	;	Human dihydroorotase mutant F1563T co-crystallized with carbamoyl aspartate at pH 7.5
6HFF	;	1.51	;	Human dihydroorotase mutant F1563Y apo structure
6HFS	;	1.34905	;	Human dihydroorotase mutant F1563Y co-crystallized with carbamoyl aspartate at pH 6.5
6HFR	;	1.29949	;	Human dihydroorotase mutant F1563Y co-crystallized with carbamoyl aspartate at pH 7.0
6HFU	;	1.39971	;	Human dihydroorotase mutant F1563Y co-crystallized with carbamoyl aspartate at pH 7.5
6CJF	;	1.63	;	Human dihydroorotate dehydrogenase bound to 4-quinoline carboxylic acid inhibitor 43
2B0M	;	2.0	;	Human dihydroorotate dehydrogenase bound to a novel inhibitor
6CJG	;	2.851	;	Human dihydroorotate dehydrogenase bound to napthyridine inhibitor 46
1D3H	;	1.8	;	HUMAN DIHYDROOROTATE DEHYDROGENASE COMPLEXED WITH ANTIPROLIFERATIVE AGENT A771726
1D3G	;	1.6	;	HUMAN DIHYDROOROTATE DEHYDROGENASE COMPLEXED WITH BREQUINAR ANALOG
3F1Q	;	2.0	;	Human dihydroorotate dehydrogenase in complex with a leflunomide derivative inhibitor 1
3FJ6	;	1.8	;	Human dihydroorotate dehydrogenase in complex with a leflunomide derivative inhibitor 2
3FJL	;	1.9	;	Human dihydroorotate dehydrogenase in complex with a leflunomide derivative inhibitor 3
3G0U	;	2.0	;	Human dihydroorotate dehydrogenase in complex with a leflunomide derivative inhibitor 4
3G0X	;	1.8	;	Human dihydroorotate dehydrogenase in complex with a leflunomide derivative inhibitor 5
6GK0	;	1.85	;	HUMAN DIHYDROOROTATE DEHYDROGENASE IN COMPLEX WITH CLASS III HISTONE DEACETYLASE INHIBITOR
6ET4	;	1.7	;	HUMAN DIHYDROOROTATE DEHYDROGENASE IN COMPLEX WITH NOVEL INHIBITOR
2VR2	;	2.8	;	Human Dihydropyrimidinase
4BKN	;	2.1	;	Human Dihydropyrimidinase-related protein 3 (DPYSL3)
5NKS	;	1.8	;	Human Dihydropyrimidinase-related Protein 4 (DPYSL4, CRMP3, ULIP-4)
3N0T	;	2.45	;	Human dipeptidil peptidase DPP7 complexed with inhibitor GSK237826A
2IIT	;	2.35	;	Human dipeptidyl peptidase 4 in complex with a diazepan-2-one inhibitor
2IIV	;	2.15	;	Human dipeptidyl peptidase 4 in complex with a diazepan-2-one inhibitor
3JYH	;	2.19	;	Human dipeptidyl peptidase DPP7
2OQV	;	2.8	;	Human Dipeptidyl Peptidase IV (DPP4) with piperidine-constrained phenethylamine
2OQI	;	2.8	;	Human Dipeptidyl Peptidase IV (DPP4) with Piperidinone-constrained phenethylamine
2JID	;	2.8	;	Human Dipeptidyl peptidase IV in complex with 1-(3,4-Dimethoxy-phenyl) -3-m-tolyl-piperidine-4-ylamine
1RWQ	;	2.2	;	Human Dipeptidyl peptidase IV in complex with 5-aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,5-dimethoxy-phenyl)-pyrimidin-4-ylamine
1X70	;	2.1	;	HUMAN DIPEPTIDYL PEPTIDASE IV IN COMPLEX WITH A BETA AMINO ACID INHIBITOR
2QOE	;	2.3	;	Human Dipeptidyl Peptidase IV in complex with a Triazolopiperazine-based beta amino acid Inhibitor
2OPH	;	2.4	;	Human dipeptidyl peptidase IV in complex with an alpha amino acid inhibitor
2QT9	;	2.1	;	Human dipeptidyl peptidase iv/cd26 in complex with a 4-aryl cyclohexylalanine inhibitor
2QTB	;	2.25	;	Human dipeptidyl peptidase iv/cd26 in complex with a 4-aryl cyclohexylalanine inhibitor
2P8S	;	2.2	;	Human dipeptidyl peptidase IV/CD26 in complex with a cyclohexalamine inhibitor
3C43	;	2.3	;	Human dipeptidyl peptidase IV/CD26 in complex with a flouroolefin inhibitor
3C45	;	2.05	;	Human dipeptidyl peptidase IV/CD26 in complex with a fluoroolefin inhibitor
3D4L	;	2.0	;	Human dipeptidyl peptidase IV/CD26 in complex with a novel inhibitor
1N1M	;	2.5	;	Human Dipeptidyl Peptidase IV/CD26 in complex with an inhibitor
2FJP	;	2.4	;	Human dipeptidyl peptidase IV/CD26 in complex with an inhibitor
4PNZ	;	1.9	;	Human dipeptidyl peptidase IV/CD26 in complex with the long-acting inhibitor Omarigliptin (MK-3102)
1TKR	;	2.7	;	Human Dipeptidyl Peptidase IV/CD26 inhibited with Diisopropyl FluoroPhosphate
1U8E	;	2.2	;	HUMAN DIPEPTIDYL PEPTIDASE IV/CD26 MUTANT Y547F
2FVV	;	1.25	;	Human Diphosphoinositol polyphosphate phosphohydrolase 1
2Q9P	;	1.65	;	Human diphosphoinositol polyphosphate phosphohydrolase 1, Mg-F complex
8E28	;	3.1	;	Human Dis3L2 in complex with hairpin A-GCU14
8E29	;	3.1	;	Human Dis3L2 in complex with hairpin C-U12
8E2A	;	2.8	;	Human Dis3L2 in complex with hairpin D-U7
5IP5	;	1.66	;	Human DJ-1 complexed with Na-K-tartrate
1SOA	;	1.2	;	Human DJ-1 with sulfinic acid
5MVX	;	2.17	;	Human DLL4 C2-EGF3
7C98	;	3.47	;	Human DMC1 post-synaptic complexes
7C99	;	3.36	;	Human DMC1 post-synaptic complexes with mismatched dsDNA
7C9C	;	3.33	;	Human DMC1 pre-synaptic complexes
7CGY	;	3.2	;	Human DMC1 Q244M mutant of the post-synaptic complexes
4RGH	;	1.9	;	Human DNA Damage-Inducible Protein: From Protein Chemistry and 3D Structure to Deciphering its Cellular Role
6P0E	;	1.85	;	Human DNA Ligase 1 (E346A,E592A) bound to adenylated DNA containing an 8-oxo guanine:adenine base-pair
6P0B	;	2.203	;	Human DNA Ligase 1 (E346A/E592A) Bound to an Adenylated, dideoxy Terminated DNA nick with 200 mM Mg2+
6P0D	;	1.75	;	Human DNA Ligase 1 (E346A/E592A) Bound to an Adenylated, hydroxyl terminated DNA nick
6Q1V	;	1.85	;	Human DNA Ligase 1 (E592R) Bound to an Adenylated, hydroxyl terminated DNA nick
7L34	;	1.901	;	Human DNA Ligase 1 - R641L nicked DNA complex
7L35	;	2.0	;	Human DNA Ligase 1 - R771W nicked DNA complex
6P0A	;	2.05	;	Human DNA Ligase 1 Bound to an Adenylated, dideoxy Terminated DNA nick with 2 mM Mg2+
6P09	;	2.052	;	Human DNA Ligase 1 Bound to an Adenylated, dideoxy Terminated DNA nick with 200 mM Mg2+
6P0C	;	1.55	;	Human DNA Ligase 1 Bound to an Adenylated, hydroxyl terminated DNA nick in EDTA
7KR3	;	2.778	;	Human DNA Ligase 1(E346A/E592A) Bound to a bulged DNA substrate
7KR4	;	2.2	;	Human DNA Ligase 1(E346A/E592A) Bound to a nicked DNA substrate control duplex
3L2P	;	3.0	;	Human DNA Ligase III Recognizes DNA Ends by Dynamic Switching Between Two DNA Bound States
7M7P	;	1.8	;	Human DNA Pol eta S113A with dA-ended primer and dAMPNPP
7M83	;	1.55	;	Human DNA Pol eta S113A with dA-ended primer and dATP: in crystallo reaction for 0 s
7M86	;	1.55	;	Human DNA Pol eta S113A with dA-ended primer and dATP: in crystallo reaction for 140 s
7M87	;	1.85	;	Human DNA Pol eta S113A with dA-ended primer and dATP: in crystallo reaction for 230 s
7M88	;	1.66	;	Human DNA Pol eta S113A with dA-ended primer and dATP: in crystallo reaction for 300 s
7M84	;	1.47	;	Human DNA Pol eta S113A with dA-ended primer and dATP: in crystallo reaction for 40 s
7M85	;	1.75	;	Human DNA Pol eta S113A with dA-ended primer and dATP: in crystallo reaction for 80 s
7M7S	;	1.85	;	Human DNA Pol eta S113A with dT-ended primer and 0.1 mM dAMPNPP
7M7Q	;	2.27	;	Human DNA Pol eta S113A with dT-ended primer and dAMPNPP
7M7T	;	1.46	;	Human DNA Pol eta S113A with dT-ended primer and dATP: in crystallo reaction for 0 s
7M7U	;	1.94	;	Human DNA Pol eta S113A with dT-ended primer and dATP: in crystallo reaction for 480s
7M7R	;	1.81	;	Human DNA Pol eta S113A with rA-ended primer and dAMPNPP
7M89	;	1.83	;	Human DNA Pol eta S113A with rA-ended primer and dATP: in crystallo reaction for 0 s
7M8B	;	1.85	;	Human DNA Pol eta S113A with rA-ended primer and dATP: in crystallo reaction for 140 s
7M8C	;	1.85	;	Human DNA Pol eta S113A with rA-ended primer and dATP: in crystallo reaction for 230 s
7M8D	;	1.92	;	Human DNA Pol eta S113A with rA-ended primer and dATP: in crystallo reaction for 300 s
7M8A	;	1.91	;	Human DNA Pol eta S113A with rA-ended primer and dATP: in crystallo reaction for 40 s
7M7N	;	1.31	;	Human DNA Pol eta with 2'-FA-ended primer and dAMPNPP
7M7L	;	1.58	;	Human DNA Pol eta with dA-ended primer and dAMPNPP
7M7Y	;	1.8	;	Human DNA Pol eta with dA-ended primer and dATP: in crystallo reaction for 0 s
7M80	;	1.98	;	Human DNA Pol eta with dA-ended primer and dATP: in crystallo reaction for 100 s
7M81	;	2.05	;	Human DNA Pol eta with dA-ended primer and dATP: in crystallo reaction for 100 s
7M82	;	2.07	;	Human DNA Pol eta with dA-ended primer and dATP: in crystallo reaction for 300 s
7M7Z	;	1.82	;	Human DNA Pol eta with dA-ended primer and dATP: in crystallo reaction for 40 s
7M7O	;	1.8	;	Human DNA Pol eta with dT-ended primer and 0.1 mM dAMPNPP
7M7M	;	1.46	;	Human DNA Pol eta with rA-ended primer and dAMPNPP
5IUD	;	3.3	;	Human DNA polymerase alpha in binary complex with a DNA:DNA template-primer
8D96	;	3.35	;	Human DNA polymerase alpha/primase elongation complex I bound to primer/template
5VS4	;	1.87	;	Human DNA polymerase beta 8-oxoG:dA extension with dTTP after 120 s
5VS3	;	1.7	;	Human DNA polymerase beta 8-oxoG:dA extension with dTTP after 90 s
5VRY	;	1.9	;	Human DNA polymerase beta 8-oxoG:dC extension with dTTP after 20 s
5VRZ	;	2.05	;	Human DNA polymerase beta 8-oxoG:dC extension with dTTP after 60 s
5VS0	;	2.1	;	Human DNA polymerase beta 8-oxoG:dC extension with dTTP after 80 s
4O9M	;	2.295	;	Human DNA polymerase beta complexed with adenylated tetrahydrofuran (abasic site) containing DNA
1ZJM	;	2.1	;	Human DNA Polymerase beta complexed with DNA containing an A-A mismatched primer terminus
1ZJN	;	2.61	;	Human DNA Polymerase beta complexed with DNA containing an A-A mismatched primer terminus with dGTP
1BPY	;	2.2	;	HUMAN DNA POLYMERASE BETA COMPLEXED WITH GAPPED DNA AND DDCTP
1MQ2	;	3.1	;	Human DNA Polymerase Beta Complexed With Gapped DNA Containing an 8-oxo-7,8-dihydro-Guanine and dAMP
1MQ3	;	2.8	;	Human DNA Polymerase Beta Complexed With Gapped DNA Containing an 8-oxo-7,8-dihydro-Guanine Template Paired with dCTP
1BPZ	;	2.6	;	HUMAN DNA POLYMERASE BETA COMPLEXED WITH NICKED DNA
1TV9	;	2.0	;	HUMAN DNA POLYMERASE BETA COMPLEXED WITH NICKED DNA CONTAINING A MISMATCHED TEMPLATE ADENINE AND INCOMING CYTIDINE
1TVA	;	2.6	;	HUMAN DNA POLYMERASE BETA COMPLEXED WITH NICKED DNA CONTAINING A MISMATCHED TEMPLATE THYMIDINE AND INCOMING CYTIDINE
2P66	;	2.5	;	Human DNA Polymerase beta complexed with tetrahydrofuran (abasic site) containing DNA
7RBE	;	1.89	;	Human DNA polymerase beta crosslinked binary complex - A
7RBF	;	1.84	;	Human DNA polymerase beta crosslinked binary complex - B
7RBN	;	2.9	;	Human DNA polymerase beta crosslinked complex, 20 min Ca to Mg exchange
7RBI	;	1.93	;	Human DNA polymerase beta crosslinked complex, 20 s Ca to Mg exchange
7RBJ	;	1.91	;	Human DNA polymerase beta crosslinked complex, 30 s Ca to Mg exchange
7RBK	;	2.2	;	Human DNA polymerase beta crosslinked complex, 40 s Ca to Mg exchange
7RBO	;	2.96	;	Human DNA polymerase beta crosslinked complex, 60 min Ca to Mg exchange
7RBL	;	1.98	;	Human DNA polymerase beta crosslinked complex, 60 s Ca to Mg exchange
7RBM	;	2.21	;	Human DNA polymerase beta crosslinked complex, 60 s Ca to Mn exchange
7RBG	;	1.9	;	Human DNA polymerase beta crosslinked ternary complex 1
7RBH	;	1.75	;	Human DNA polymerase beta crosslinked ternary complex 2
7K97	;	2.4	;	Human DNA polymerase beta dGDP product complex with Mn2+
4TUQ	;	2.367	;	Human DNA polymerase beta inserting dCMPNPP opposite GG template (GG0b).
4TUR	;	2.169	;	Human DNA polymerase beta inserting dCMPNPP opposite the 5'G of cisplatin crosslinked Gs (Pt-GG2)
4TUS	;	2.42	;	Human DNA polymerase beta inserting dCMPNPP opposite the 5'G of cisplatin crosslinked Gs (Pt-GG2) WITH MANGANESE IN THE ACTIVE SITE.
5VS1	;	2.5	;	Human DNA polymerase beta pre-catalytic 8-oxoG:dA extension complex with dTTP bound in non-planar conformation
5VS2	;	2.33	;	Human DNA polymerase beta pre-catalytic 8-oxoG:dA extension complex with dTTP bound in Watson-Crick conformation
5VRW	;	2.58	;	Human DNA polymerase beta pre-catalytic 8-oxoG:dC extension complex with dTTP bound in non-planar conformation
5VRX	;	2.2	;	Human DNA polymerase beta pre-catalytic 8-oxoG:dC extension complex with dTTP bound in Watson-Crick conformation
7K96	;	2.1	;	Human DNA polymerase beta ternary complex with templating cytosine and incoming deoxyguanosine diphosphate
4RQ7	;	2.0	;	Human DNA Polymerase Beta With Gapped DNA Containing an 8-oxo-7,8-dihydro-Guanine (8-oxoG)and dATP soaked with MgCl2 for 1hr
4RQ5	;	2.32	;	Human DNA Polymerase Beta With Gapped DNA Containing an 8-oxo-7,8-dihydro-Guanine (8-oxoG)and dATP soaked with MgCl2 for 60 s
4RPZ	;	2.19	;	Human DNA Polymerase Beta With Gapped DNA Containing an 8-oxo-7,8-dihydro-Guanine (8-oxoG)and dCTP soaked with MgCl2 for 60 s
4RQ0	;	2.2	;	Human DNA Polymerase Beta With Gapped DNA Containing an 8-oxo-7,8-dihydro-Guanine (8-oxoG)and dCTP soaked with MgCl2 for 80 s
4RQ2	;	2.2	;	Human DNA Polymerase Beta With Gapped DNA Containing an 8-oxo-7,8-dihydro-Guanine (8-oxoG)and dCTP soaked with MnCl2 for 35 s
4RQ4	;	2.1	;	Human DNA Polymerase Beta With Gapped DNA Containing an 8-oxo-7,8-dihydro-Guanine(8-oxoG) and dATP soaked with MgCl2 for 30 s
4RQ6	;	2.25	;	Human DNA Polymerase Beta With Gapped DNA Containing an 8-oxo-7,8-dihydro-Guanine(8-oxoG) and dATP soaked with MgCl2 for 80 s
4RQ8	;	2.0	;	Human DNA Polymerase Beta With Gapped DNA Containing an 8-oxo-7,8-dihydro-Guanine(8-oxoG) and dATP soaked with MnCl2 for 35 s
4RQ1	;	2.7	;	Human DNA Polymerase Beta With Gapped DNA Containing an 8-oxo-7,8-dihydro-Guanine(8-oxoG) and dCTP soaked with MgCl2 for 1hr
4RPY	;	1.9	;	Human DNA Polymerase Beta With Gapped DNA Containing an 8-oxo-7,8-dihydro-Guanine(8-oxoG) and dCTP soaked with MgCl2 for 30 s
3MR5	;	1.8	;	Human DNA polymerase eta - DNA ternary complex with a CPD 1bp upstream of the active site (TT3)
3MR6	;	1.9	;	Human DNA polymerase eta - DNA ternary complex with a CPD 2bp upstream of the active site (TT4)
3MR3	;	1.75	;	Human DNA polymerase eta - DNA ternary complex with the 3'T of a CPD in the active site (TT1)
3SI8	;	2.15	;	Human DNA polymerase eta - DNA ternary complex with the 5'T of a CPD in the active site (TT2)
4ECY	;	1.943	;	Human DNA polymerase eta - DNA ternary complex: AT crystal at pH 6.0 (Na+ MES) with 1 Ca2+ ion
4ECZ	;	1.834	;	Human DNA polymerase eta - DNA ternary complex: AT crystal at pH 6.5 (Na+ MES) with 1 Ca2+ ion
4ED0	;	1.653	;	Human DNA polymerase eta - DNA ternary complex: AT crystal at pH 6.8 (Na+ MES) with 1 Ca2+ ion
4ED1	;	1.806	;	Human DNA polymerase eta - DNA ternary complex: AT crystal at pH 7.0 (Na+ MES) with 1 Ca2+ ion
4ED2	;	1.711	;	Human DNA polymerase eta - DNA ternary complex: AT crystal at pH 7.2 (Na+ HEPES) with 1 Ca2+ ion
4ED3	;	1.791	;	Human DNA polymerase eta - DNA ternary complex: AT crystal at pH 7.5 (Na+ HEPES) with 1 Ca2+ ion
4ED6	;	2.211	;	Human DNA polymerase eta - DNA ternary complex: Reaction in the AT crystal at pH 6.7 for 15 hr, Sideway translocation
4ECT	;	1.795	;	Human DNA polymerase eta - DNA ternary complex: Reaction in the AT crystal at pH 7.0 for 140 sec
4ECU	;	1.949	;	Human DNA polymerase eta - DNA ternary complex: Reaction in the AT crystal at pH 7.0 for 200 sec
4ECV	;	1.521	;	Human DNA polymerase eta - DNA ternary complex: Reaction in the AT crystal at pH 7.0 for 230 sec
4ECW	;	1.896	;	Human DNA polymerase eta - DNA ternary complex: Reaction in the AT crystal at pH 7.0 for 250 sec
4ECX	;	1.744	;	Human DNA polymerase eta - DNA ternary complex: Reaction in the AT crystal at pH 7.0 for 300 sec
4ECR	;	1.892	;	Human DNA polymerase eta - DNA ternary complex: Reaction in the AT crystal at pH 7.0 for 40 sec
4ECS	;	1.951	;	Human DNA polymerase eta - DNA ternary complex: Reaction in the AT crystal at pH 7.0 for 80 sec
4ED8	;	1.521	;	Human DNA polymerase eta - DNA ternary complex: Reaction in the TG crystal at pH 7.0, Normal translocation
4ED7	;	1.717	;	Human DNA polymerase eta - DNA ternary complex: TG crystal at pH 7.0 (K+ MES) with 1 Ca2+ ion
4Q8F	;	2.797	;	Human DNA polymerase eta extending primer immediately after a phenanthriplatin adducted G
4DL6	;	2.5	;	Human DNA polymerase eta extending primer immediately after cisplatin crosslink (Pt-GG3).
8EVF	;	2.87	;	HUMAN DNA POLYMERASE ETA EXTENSION COMPLEX WITH AN INCOMING DCTP
6M7V	;	3.062	;	Human DNA polymerase eta extension complex with cdA at the -1 position
6M7P	;	1.75	;	Human DNA polymerase eta extension complex with cdA at the -2 position
4DL7	;	1.97	;	Human DNA polymerase eta fails to extend primer 2 nucleotide after cisplatin crosslink (Pt-GG4).
6M7T	;	2.8	;	Human DNA polymerase eta in a non-productive ternary complex with Ca2+ and dTTP oppositing cdA
6M7U	;	3.4	;	Human DNA polymerase eta in a non-productive ternary complex with Mg2+ and dTMPNPP oppositing cdA
3TQ1	;	2.556	;	Human DNA Polymerase eta in binary complex with DNA
3JAA	;	22.0	;	HUMAN DNA POLYMERASE ETA in COMPLEX WITH NORMAL DNA AND INCO NUCLEOTIDE (NRM)
3MR2	;	1.83	;	Human DNA polymerase eta in complex with normal DNA and incoming nucleotide (Nrm)
4Q8E	;	1.549	;	Human DNA polymerase eta inserting dCMPNPP opposite a phenanthriplatin adducted G
4DL2	;	2.15	;	Human DNA polymerase eta inserting dCMPNPP opposite CG template (GG0a)
4DL3	;	2.1	;	Human DNA polymerase eta inserting dCMPNPP opposite GG template (GG0b).
4DL4	;	2.0	;	Human DNA polymerase eta inserting dCMPNPP opposite the 3'G of cisplatin crosslinked Gs (Pt-GG1).
4DL5	;	2.92	;	Human DNA polymerase eta inserting dCMPNPP opposite the 5'G of cisplatin crosslinked Gs (Pt-GG2).
8EVE	;	2.35	;	HUMAN DNA POLYMERASE ETA INSERTION COMPLEX
5KFS	;	1.46	;	Human DNA polymerase eta R61A-DNA ternary complex: ground state at pH7.0 (K+ MES) with 1 Ca2+ ion
5KFV	;	1.6	;	Human DNA polymerase eta R61A-DNA ternary complex: reaction with 1 mM Mg2+ for 140s
5KFW	;	1.62	;	Human DNA polymerase eta R61A-DNA ternary complex: reaction with 1 mM Mg2+ for 200s
5KFX	;	1.52	;	Human DNA polymerase eta R61A-DNA ternary complex: reaction with 1 mM Mg2+ for 300s
5KFT	;	1.52	;	Human DNA polymerase eta R61A-DNA ternary complex: reaction with 1 mM Mg2+ for 40s
5KFU	;	1.55	;	Human DNA polymerase eta R61A-DNA ternary complex: reaction with 1 mM Mg2+ for 80s
6M7O	;	3.0	;	Human DNA polymerase eta ternary complex with Mn2+ and dTMPNPP oppositing cdA
4ECQ	;	1.5	;	Human DNA polymerase eta- DNA ternary complex: AT crystal at pH6.8(K+ MES) with 1 Ca2+ ion
4J9P	;	2.3	;	Human DNA polymerase eta-DNA postinsertion binary complex with TA base pair
4J9Q	;	1.96	;	Human DNA polymerase eta-DNA postinsertion binary complex with TG mispair
5KFM	;	1.6	;	Human DNA polymerase eta-DNA ternary complex with Sp-dATP-alpha-S: ground state at pH7.0 (K+ MES) with 1 Ca2+ ion
5KFN	;	1.45	;	Human DNA polymerase eta-DNA ternary complex with Sp-dATP-alpha-S: reaction with 1 mM Mg2+ for 1800s
5KFO	;	1.52	;	Human DNA polymerase eta-DNA ternary complex with Sp-dATP-alpha-S: reaction with 1 mM Mn2+ for 1800s
5KFQ	;	1.55	;	Human DNA polymerase eta-DNA ternary complex with Sp-dATP-alpha-S: reaction with 10 mM Mn2+ for 600s
5KFP	;	1.7	;	Human DNA polymerase eta-DNA ternary complex with Sp-dATP-alpha-S: reaction with 20 mM Mg2+ for 600s
5KFR	;	1.75	;	Human DNA polymerase eta-DNA ternary complex with Sp-dATP-alpha-S: reaction with 20 mM Mn2+ for 600s
5KFA	;	1.51	;	Human DNA polymerase eta-DNA ternary complex: ground state at pH7.0 (K+ MES) with 1 Ca2+ ion
4J9L	;	1.85	;	Human DNA polymerase eta-DNA ternary complex: misincorporation G opposite T after a C at the primer 3' end (CA/G)
4J9N	;	1.956	;	Human DNA polymerase eta-DNA ternary complex: misincorporation G opposite T after a G at the primer 3' end (GA/G)
4J9K	;	2.03	;	Human DNA polymerase eta-DNA ternary complex: misincorporation G opposite T after a T at the primer 3' end (TA/G)
4J9M	;	2.25	;	Human DNA polymerase eta-DNA ternary complex: misincorporation G opposite T after an A at the primer 3' end (AA/G)
4J9O	;	2.597	;	Human DNA polymerase eta-DNA ternary complex: primer extension after a T:G mispair
5KG6	;	1.55	;	Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 10 mM Ca2+ for 60s
5KG5	;	1.6	;	Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 10 mM Cd2+ for 60s
5KG4	;	1.6	;	Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 10 mM Mg2+ for 60s
5KG3	;	1.7	;	Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 10 mM Mn2+ for 60s
5KG7	;	1.75	;	Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 10 mM Zn2+ for 60s
5KFZ	;	1.44	;	Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 5 mM Mn2+ for 60s at 14 degree
5KG0	;	1.6	;	Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 5 mM Mn2+ for 60s at 22 degree
5KG1	;	1.62	;	Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 5 mM Mn2+ for 60s at 30 degree
5KG2	;	1.6	;	Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 5 mM Mn2+ for 60s at 37 degree
5KFY	;	1.7	;	Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 5 mM Mn2+ for 60s at 4 degree
5KFF	;	1.7	;	Human DNA polymerase eta-DNA ternary complex: reaction with 1 mM Mn2+ for 1800s
5KFC	;	1.5	;	Human DNA polymerase eta-DNA ternary complex: reaction with 1 mM Mn2+ for 180s
5KFD	;	1.65	;	Human DNA polymerase eta-DNA ternary complex: reaction with 1 mM Mn2+ for 300s
5KFE	;	1.55	;	Human DNA polymerase eta-DNA ternary complex: reaction with 1 mM Mn2+ for 600s
5KFB	;	1.55	;	Human DNA polymerase eta-DNA ternary complex: reaction with 1 mM Mn2+ for 90s
5KFI	;	1.65	;	Human DNA polymerase eta-DNA ternary complex: reaction with 10 mM Mn2+ for 120s
5KFJ	;	1.7	;	Human DNA polymerase eta-DNA ternary complex: reaction with 10 mM Mn2+ for 180s
5KFK	;	1.7	;	Human DNA polymerase eta-DNA ternary complex: reaction with 10 mM Mn2+ for 300s
5KFG	;	1.55	;	Human DNA polymerase eta-DNA ternary complex: reaction with 10 mM Mn2+ for 30s
5KFL	;	1.65	;	Human DNA polymerase eta-DNA ternary complex: reaction with 10 mM Mn2+ for 600s
5L9X	;	1.9	;	Human DNA polymerase eta-DNA ternary complex: reaction with 10 mM Mn2+ for 60s
5KFH	;	1.72	;	Human DNA polymerase eta-DNA ternary complex: reaction with 10 mM Mn2+ for 90s
7U72	;	1.53	;	Human DNA polymerase eta-DNA ternary mismatch complex:ground state at pH7.0 (K+ MES) with 1 Ca2+ ion
7U73	;	1.56	;	Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 0.5 mM Mn2+ for 1800s
7U76	;	1.69	;	Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 0.5 mM Mn2+ for 1800s then with 10 mM Mn2+ for 300s
7U74	;	1.52	;	Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 0.5 mM Mn2+ for 1800s then with 10 mM Mn2+ for 30s
7U75	;	1.55	;	Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 0.5 mM Mn2+ for 1800s then with 10 mM Mn2+ for 90s
7U79	;	1.69	;	Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 1.0 mM Mg2+ for 140s
7U7A	;	1.58	;	Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 1.0 mM Mg2+ for 200s
7U7B	;	1.58	;	Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 1.0 mM Mg2+ for 250s
7U7C	;	1.55	;	Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 1.0 mM Mg2+ for 300s
7U7L	;	1.47	;	Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 1.0 mM Mg2+ for 300s with flipped-out product
7U77	;	1.58	;	Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 1.0 mM Mg2+ for 40s
7U78	;	1.61	;	Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 1.0 mM Mg2+ for 80s
7U7G	;	1.77	;	Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 10.0 mM Mn2+ for 120s
7U7I	;	1.57	;	Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 10.0 mM Mn2+ for 180s
7U7J	;	1.58	;	Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 10.0 mM Mn2+ for 300s
7U7D	;	1.57	;	Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 10.0 mM Mn2+ for 30s
7U7K	;	1.67	;	Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 10.0 mM Mn2+ for 600s
7U7E	;	1.58	;	Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 10.0 mM Mn2+ for 60s
7U7F	;	1.65	;	Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 10.0 mM Mn2+ for 90s
4J9R	;	2.35	;	Human DNA polymerase eta-DNA translocated binary complex with TG mispair
4J9S	;	1.95	;	Human DNA polymerase eta-DNA translocated binary complex: with TA base pair
7U7S	;	1.6	;	Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 0.025 mM Mg2+ for 600s
7U7T	;	1.55	;	Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 0.05 mM Mg2+ for 600s
7U7Y	;	1.78	;	Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 0.06 mM Mn2+ for 600s
7U7U	;	1.54	;	Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 0.1 mM Mg2+ for 600s
7U7Z	;	1.67	;	Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 0.12 mM Mn2+ for 600s
7U80	;	1.83	;	Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 0.25 mM Mn2+ for 600s
7U7V	;	1.65	;	Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 0.4 mM Mg2+ for 600s
7U81	;	1.6	;	Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 0.5 mM Mn2+ for 600s
7U7W	;	1.66	;	Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 1.0 mM Mg2+ for 600s
7U82	;	1.55	;	Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 1.0 mM Mn2+ for 600s
7U7X	;	1.65	;	Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 2.0 mM Mg2+ for 600s
7U83	;	1.55	;	Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 3.0 mM Mn2+ for 600s
7U84	;	1.71	;	Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 6.0 mM Mn2+ for 600s
7U7R	;	1.64	;	Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex:no Me2+ soaking
8E8A	;	1.8	;	Human DNA polymerase eta-DNA-dT-ended primer binary complex
8E87	;	2.19	;	Human DNA polymerase eta-DNA-rA-ended primer-dGMPNPP ternary mismatch complex with Mg2+
8E8K	;	2.4	;	Human DNA polymerase eta-DNA-rC-ended primer-dGMPNPP ternary mismatch complex with Mg2+
8E86	;	1.78	;	Human DNA polymerase eta-DNA-rC-ended primer-dGMPNPP ternary mismatch complex with Mn2+
8E8J	;	2.4	;	Human DNA polymerase eta-DNA-rG-ended primer-dGMPNPP ternary mismatch complex with Mg2+
8E85	;	1.72	;	Human DNA polymerase eta-DNA-rG-ended primer-dGMPNPP ternary mismatch complex with Mn2+
8E8B	;	2.2	;	Human DNA polymerase eta-DNA-rU-ended primer ternary mismatch complex:ground state at pH7.0 (K+ MES) with 1 Ca2+ ion
8E8F	;	2.14	;	Human DNA polymerase eta-DNA-rU-ended primer ternary mismatch complex:reaction with 10 mM Mn2+ for 120s
8E8G	;	2.13	;	Human DNA polymerase eta-DNA-rU-ended primer ternary mismatch complex:reaction with 10 mM Mn2+ for 180s
8E8H	;	2.13	;	Human DNA polymerase eta-DNA-rU-ended primer ternary mismatch complex:reaction with 10 mM Mn2+ for 300s
8E8C	;	2.25	;	Human DNA polymerase eta-DNA-rU-ended primer ternary mismatch complex:reaction with 10 mM Mn2+ for 30s
8E8D	;	2.09	;	Human DNA polymerase eta-DNA-rU-ended primer ternary mismatch complex:reaction with 10 mM Mn2+ for 60s
8E8E	;	2.05	;	Human DNA polymerase eta-DNA-rU-ended primer ternary mismatch complex:reaction with 10 mM Mn2+ for 90s
8E89	;	2.2	;	Human DNA polymerase eta-DNA-rU-ended primer-binary complex
8E88	;	2.4	;	Human DNA polymerase eta-DNA-rU-ended primer-dGMPNPP ternary mismatch complex with Mg2+
3GV5	;	2.0	;	Human DNA polymerase iota in complex with T template DNA and incoming ddADP
3GV8	;	2.0	;	Human DNA polymerase iota in complex with T template DNA and incoming dGTP
3GV7	;	2.2	;	Human DNA polymerase iota in complex with T template DNA and incoming dTTP
3Q8Q	;	2.031	;	Human DNA polymerase iota incorporating dATP opposite 8-oxo-guanine
4EYI	;	2.9	;	Human DNA polymerase iota incorporating dATP opposite N-(deoxyguanosin-8-yl)-1-aminopyrene lesion
3Q8P	;	1.95	;	Human DNA polymerase iota incorporating dCTP opposite 8-oxo-guanine
4EYH	;	2.9	;	Human DNA polymerase iota incorporating dCTP opposite N-(deoxyguanosin-8-yl)-1-aminopyrene lesion
3Q8R	;	2.45	;	Human DNA polymerase iota incorporating dGTP opposite 8-oxo-guanine
3Q8S	;	2.09	;	Human DNA polymerase iota incorporating dTTP opposite 8-oxo-guanine
3PZP	;	3.336	;	Human DNA polymerase kappa extending opposite a cis-syn thymine dimer
5CP2	;	2.36	;	Human DNA polymerase lambda L431A mutant- Apoenzyme and complex with 6 paired DNA
5CR0	;	2.75	;	Human DNA polymerase lambda L431A mutant- MgdCTP binary and complex with 6 paired DNA
5CHG	;	2.9	;	Human DNA polymerase lambda L431A mutant- MgdGTP binary and complex with 6 paired DNA
5CJ7	;	2.901	;	Human DNA polymerase lambda L431A mutant- MgdTTP binary and complex with 6 paired DNA
5DDM	;	2.802	;	Human DNA polymerase lambda- Apoenzyme and complex with 6 paired DNA
4XQ8	;	2.798	;	Human DNA polymerase lambda- MgdATP binary complex and complex with 6 paired DNA
5CA7	;	2.522	;	Human DNA polymerase lambda- MgdGTP binary and complex with 6 paired DNA
4XRH	;	3.0	;	Human DNA polymerase lambda- MgdTTP binary and complex with 6 paired DNA
4M0A	;	1.85	;	Human DNA Polymerase Mu post-catalytic complex
4M04	;	1.898	;	Human DNA Polymerase Mu ternary complex
4LZD	;	1.849	;	Human DNA polymerase mu- Apoenzyme
8E23	;	2.59	;	Human DNA polymerase theta in complex with allosteric inhibitor
8E24	;	2.34	;	Human DNA polymerase theta in complex with allosteric inhibitor
8D9D	;	3.59	;	Human DNA polymerase-alpha/primase elongation complex II bound to primer/template
1TL8	;	3.1	;	Human DNA topoisomerase I (70 kDa) in complex with the indenoisoquinoline AI-III-52 and covalent complex with a 22 base pair DNA duplex
1SC7	;	3.0	;	Human DNA Topoisomerase I (70 Kda) In Complex With The Indenoisoquinoline MJ-II-38 and Covalent Complex With A 22 Base Pair DNA Duplex
1SEU	;	3.0	;	Human DNA Topoisomerase I (70 Kda) In Complex With The Indolocarbazole SA315F and Covalent Complex With A 22 Base Pair DNA Duplex
1T8I	;	3.0	;	Human DNA Topoisomerase I (70 Kda) In Complex With The Poison Camptothecin and Covalent Complex With A 22 Base Pair DNA Duplex
1K4T	;	2.1	;	HUMAN DNA TOPOISOMERASE I (70 KDA) IN COMPLEX WITH THE POISON TOPOTECAN AND COVALENT COMPLEX WITH A 22 BASE PAIR DNA DUPLEX
1LPQ	;	3.14	;	Human DNA Topoisomerase I (70 Kda) In Non-Covalent Complex With A 22 Base Pair DNA Duplex Containing an 8-oxoG Lesion
1K4S	;	3.2	;	HUMAN DNA TOPOISOMERASE I IN COVALENT COMPLEX WITH A 22 BASE PAIR DNA DUPLEX
1ZXN	;	2.51	;	Human DNA topoisomerase IIa ATPase/ADP
6X9I	;	2.2	;	Human DNMT1(729-1600) Bound to Zebularine-Containing 12mer dsDNA
7SFG	;	2.43	;	Human DNMT1(729-1600) Bound to Zebularine-Containing 12mer dsDNA and Cofactor SAM
7SFD	;	2.09	;	Human DNMT1(729-1600) Bound to Zebularine-Containing 12mer dsDNA and Inhibitor GSK3543105A
6X9K	;	2.65	;	Human DNMT1(729-1600) Bound to Zebularine-Containing 12mer dsDNA and Inhibitor GSK3685032A
7SFC	;	1.97	;	Human DNMT1(729-1600) Bound to Zebularine-Containing 12mer dsDNA and Inhibitor GSK3735967A
6X9J	;	1.79	;	Human DNMT1(729-1600) Bound to Zebularine-Containing 12mer dsDNA and Inhibitor GSK3830052
7SFE	;	2.55	;	Human DNMT1(729-1600) Bound to Zebularine-Containing 12mer dsDNA and Inhibitor GSK3830334A
7SFF	;	2.05	;	Human DNMT1(729-1600) Bound to Zebularine-Containing 12mer dsDNA and Inhibitor GSK3852279B
5NV0	;	2.399	;	Human DNMT3B PWWP domain in complex with 4-(dipropylamino)butyronitrile
5NRR	;	1.7	;	Human DNMT3B PWWP domain in complex with 5-[(2-Hydroxyethyl)(propyl)amino]-1-pentanol
5NRV	;	2.075	;	Human DNMT3B PWWP domain in complex with 6-dipropylamino-1-hexanol
5NVO	;	2.4	;	Human DNMT3B PWWP domain in complex with choline
5NR3	;	2.3	;	Human DNMT3B PWWP domain in complex with ethambutol
5NRS	;	2.3	;	Human DNMT3B PWWP domain in complex with N,N-bis(2-hydroxypropyl)ethanolamine
5NV2	;	2.029	;	Human DNMT3B PWWP domain in complex with N-isopropyl-1,5-dimethylhexylamine (Metron S)
5NV7	;	2.568	;	Human DNMT3B PWWP domain in complex with N1-(2-hydroxyethyl)-2-methyl-1,2-propanediamine
6R3E	;	2.269	;	Human DNMT3B PWWP domain in complex with triisopropanolamine
4ZEL	;	2.9	;	Human dopamine beta-hydroxylase
7DFP	;	3.1	;	Human dopamine D2 receptor in complex with spiperone
2XRP	;	8.2	;	Human Doublecortin N-DC Repeat (1MJD) and Mammalian Tubulin (1JFF and 3HKE) Docked into the 8-Angstrom Cryo-EM Map of Doublecortin- Stabilised Microtubules
4ATU	;	8.3	;	Human doublecortin N-DC repeat plus linker, and tubulin (2XRP) docked into an 8A cryo-EM map of doublecortin-stabilised microtubules reconstructed in absence of kinesin
3KWF	;	2.4	;	human DPP-IV with carmegliptin (S)-1-((2S,3S,11bS)-2-Amino-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-3-yl)-4-fluoromethyl-pyrrolidin-2-one
4CDC	;	2.4	;	Human DPP1 in complex with (2S)-2-amino-N-((1S)-1-cyano-2-(4- phenylphenyl)ethyl)butanamide
4CDD	;	2.35	;	Human DPP1 in complex with (2S)-N-((1S)-1-cyano-2-(4-(4-cyanophenyl) phenyl)ethyl)piperidine-2-carboxamide
4CDF	;	2.2	;	Human DPP1 in complex with (2S,4S)-N-((1S)-1-cyano-2-(4-(4- cyanophenyl)phenyl)ethyl)-4-hydroxy-piperidine-2-carboxamide
4CDE	;	2.4	;	Human DPP1 in complex with 4-amino-N-((1S)-1-cyano-2-(4-(4- cyanophenyl)phenyl)ethyl)tetrahydropyran-4-carboxamide
5T4B	;	1.76	;	Human DPP4 in complex with a ligand 34a
5ISM	;	2.0	;	Human DPP4 in complex with a novel 5,5,6-tricyclic pyrrolidine inhibitor
5I7U	;	1.95	;	Human DPP4 in complex with a novel tricyclic hetero-cycle inhibitor
5T4E	;	1.77	;	Human DPP4 in complex with ligand 19a
5T4H	;	2.61	;	Human DPP4 in complex with ligand 34n
5T4F	;	1.9	;	Human DPP4 in complex with ligand 34p
7JKQ	;	3.3	;	Human DPP9-CARD8 complex
7JN7	;	3.3	;	Human DPP9-CARD8 complex
6V5B	;	3.7	;	Human Drosha and DGCR8 in complex with Primary MicroRNA (MP/RNA complex) - Active state
6V5C	;	4.4	;	Human Drosha and DGCR8 in complex with Primary MicroRNA (MP/RNA complex) - partially docked state
1Z9X	;	3.93	;	Human DRP-1 kinase, W305S S308A D40 mutant, crystal form with 3 monomers in the asymmetric unit
2A27	;	3.0	;	Human DRP-1 kinase, W305S S308A D40 mutant, crystal form with 8 monomers in the asymmetric unit
2WO6	;	2.5	;	Human Dual-Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A in complex with a consensus substrate peptide
5ZLE	;	2.6	;	Human duodenal cytochrome b (Dcytb) in substrate free form
5ZLG	;	2.8	;	Human duodenal cytochrome b (Dcytb) in zinc ion and ascorbate bound form
1Q5U	;	2.0	;	HUMAN DUTP PYROPHOSPHATASE
1Q5H	;	2.0	;	Human dUTP Pyrophosphatase complex with dUDP
3EHW	;	1.8	;	Human dUTPase in complex with alpha,beta-imido-dUTP and Mg2+: visualization of the full-length C-termini in all monomers and suggestion for an additional metal ion binding site
2HQU	;	2.2	;	Human dUTPase in complex with alpha,beta-iminodUTP and magnesium ion
3ARN	;	1.8	;	Human dUTPase in complex with novel uracil derivative
3ZYS	;	12.2	;	Human dynamin 1 deltaPRD polymer stabilized with GMPPCP
4UUD	;	12.5	;	Human dynamin 1 K44A superconstricted polymer stabilized with GTP
4UUK	;	12.5	;	Human dynamin 1 K44A superconstricted polymer stabilized with GTP strand 2
2XQQ	;	1.31	;	Human dynein light chain (DYNLL2) in complex with an in vitro evolved peptide (Ac-SRGTQTE).
3P8M	;	2.9	;	Human dynein light chain (DYNLL2) in complex with an in vitro evolved peptide dimerized by leucine zipper
5AIK	;	2.7	;	Human DYRK1A in complex with LDN-211898
4AZE	;	3.15	;	Human DYRK1A in complex with Leucettine L41
4NCT	;	2.597	;	Human DYRK1A in complex with PKC412
3ANR	;	2.6	;	human DYRK1A/harmine complex
3ANQ	;	2.6	;	human DYRK1A/inhibitor complex
6HDR	;	2.2	;	Human DYRK2 bound to Curcumin
6HDP	;	2.3	;	Human DYRK2 bound to Scorzodihydrostilbene A
4AZF	;	2.55	;	Human DYRK2 in complex with Leucettine L41
7MSS	;	1.75	;	Human E105Qa GTP-specific succinyl-CoA synthetase complexed with succinate, magnesium ion and CoA
7MSR	;	1.58	;	Human E105Qa GTP-specific succinyl-CoA synthetase complexed with succinyl-phosphate, magnesium ion and desulfo-coenzyme A
3LYR	;	2.51	;	Human Early B-cell Factor 1 (EBF1) DNA-binding domain
3MQI	;	2.3	;	Human early B-cell factor 1 (EBF1) IPT/TIG domain
3N50	;	3.102	;	Human Early B-cell factor 3 (EBF3) IPT/TIG and HLHLH domains
6XUQ	;	1.97	;	Human Ecto-5'-nucleotidase (CD73) in complex with A1618 (compound 1b in publication) in the closed state in crystal form III
6XUE	;	1.94	;	Human Ecto-5'-nucleotidase (CD73) in complex with A2396 (compound 74 in publication) in the closed form in crystal form IV
6XUG	;	2.09	;	Human Ecto-5'-nucleotidase (CD73) in complex with A2410 (compound 53 in publication) in the closed form in crystal form IV
6Z9B	;	2.17	;	Human Ecto-5'-nucleotidase (CD73) in complex with AOPCP derivative A830 (compound 16 in publication) in the closed form (crystal form III)
6Z9D	;	1.9	;	Human Ecto-5'-nucleotidase (CD73) in complex with AOPCP derivative AB680 (compound 55 in publication) in the closed form (crystal form III)
6YE2	;	2.44	;	Human Ecto-5'-nucleotidase (CD73) in complex with the AMPCP derivative A1202 (compound 4a in publication) in the closed form (crystal form IV)
6YE1	;	2.66	;	Human Ecto-5'-nucleotidase (CD73) in complex with the AMPCP derivative A894 (compound 2n in publication) in the closed form (crystal form IV)
4H2F	;	1.85	;	Human ecto-5'-nucleotidase (CD73): crystal form I (open) in complex with adenosine
4H2G	;	1.55	;	Human ecto-5'-nucleotidase (CD73): crystal form II (open) in complex with adenosine
4H2B	;	1.7	;	Human ecto-5'-nucleotidase (CD73): crystal form II (open) in complex with Baicalin
4H1Y	;	1.58	;	Human ecto-5'-nucleotidase (CD73): crystal form II (open) in complex with PSB11552
4H2I	;	2.0	;	Human ecto-5'-nucleotidase (CD73): crystal form III (closed) in complex with AMPCP
6WG5	;	2.6	;	Human ectonucleoside triphosphate diphosphohydrolase 4 (ENTPD4, NTPDase 4)
6C01	;	2.3	;	Human ectonucleotide pyrophosphatase / phosphodiesterase 3 (ENPP3, NPP3, CD203c)
6C02	;	1.942	;	Human ectonucleotide pyrophosphatase / phosphodiesterase 3 (ENPP3, NPP3, CD203c), inactive (T205A), N594S, with alpha,beta-methylene-ATP (AMPCPP)
5VEM	;	2.6	;	Human ectonucleotide pyrophosphatase / phosphodiesterase 5 (ENPP5, NPP5)
3KEN	;	2.5	;	Human Eg5 in complex with S-trityl-L-cysteine
1X88	;	1.8	;	Human Eg5 motor domain bound to Mg-ADP and monastrol
6TLE	;	1.75	;	Human Eg5 motor domain mutant E344K
6Y1I	;	3.0	;	Human Eg5 motor domain mutant R234C
6TRL	;	2.2	;	Human Eg5 motor domain mutant Y82F
1A9W	;	2.9	;	HUMAN EMBRYONIC GOWER II CARBONMONOXY HEMOGLOBIN
7SR6	;	2.62	;	Human Endogenous Retrovirus (HERV-K) reverse transcriptase ternary complex with dsDNA template Primer and dNTP
6SSK	;	3.18	;	Human endogenous retrovirus (HML2) mature capsid assembly, D5 capsule
6SSL	;	3.77	;	Human endogenous retrovirus (HML2) mature capsid assembly, D6 capsule
6SSJ	;	2.75	;	Human endogenous retrovirus (HML2) mature capsid assembly, T=1 icosahedron
6SSM	;	4.34	;	Human endogenous retrovirus (HML2) mature capsid assembly, T=3 icosahedron
6T6R	;	1.67	;	Human endoplasmic reticulum aminopeptidase 1 (ERAP1) in complex with (4aR,5S,6R,8S,8aR)-5-(2-(Furan-3-yl)ethyl)-8-hydroxy-5,6,8a-trimethyl-3,4,4a,5,6,7,8,8a-octahydronaphthalene-1-carboxylic acid
1M9R	;	2.56	;	human endothelial nitric oxide synthase with 3-Bromo-7-Nitroindazole bound
1M9Q	;	2.01	;	human endothelial nitric oxide synthase with 5-nitroindazole bound
1M9M	;	1.96	;	human endothelial nitric oxide synthase with 6-nitroindazole bound
1M9K	;	2.01	;	Human Endothelial Nitric Oxide Synthase with 7-Nitroindazole Bound
3NOS	;	2.4	;	HUMAN ENDOTHELIAL NITRIC OXIDE SYNTHASE WITH ARGININE SUBSTRATE
1M9J	;	2.43	;	human endothelial nitric oxide synthase with chlorzoxazone bound
5XPR	;	3.6	;	Human endothelin receptor type-B in complex with antagonist bosentan
5X93	;	2.2	;	Human endothelin receptor type-B in complex with antagonist K-8794
5GLH	;	2.8	;	Human endothelin receptor type-B in complex with ET-1
6K1Q	;	2.7	;	Human endothelin receptor type-B in complex with inverse agonist IRL2500
5GLI	;	2.5	;	Human endothelin receptor type-B in the ligand-free form
1EDN	;	2.18	;	HUMAN ENDOTHELIN-1
4MI0	;	2.0	;	Human Enhancer of Zeste (Drosophila) Homolog 2(EZH2)
2BZV	;	1.15	;	Human Enteric Adenovirus Serotype 41 Short Fiber Head (pH8)
3OSY	;	2.9923	;	Human enterovirus 71 3C protease
3QZR	;	1.039	;	Human enterovirus 71 3C protease mutant E71A in complex with rupintrivir
3QZQ	;	1.7001	;	Human enterovirus 71 3C protease mutant E71D in complex with rupintrivir
3R0F	;	1.3083	;	Human enterovirus 71 3C protease mutant H133G in complex with rupintrivir
3ZFE	;	2.7	;	Human enterovirus 71 in complex with capsid binding inhibitor WIN51711
3ZFF	;	3.4	;	Human enterovirus 71 in complex with capsid binding inhibitor WIN51711
3ZFG	;	3.2	;	Human enterovirus 71 in complex with capsid binding inhibitor WIN51711
4N43	;	3.8011	;	Human enterovirus 71 uncoating intermediate captured at atomic resolution
4N53	;	3.3063	;	Human enterovirus 71 uncoating intermediate captured at atomic resolution
3FY2	;	1.8	;	Human EphA3 Kinase and Juxtamembrane Region Bound to Substrate KQWDNYEFIW
3FXX	;	1.7	;	Human EphA3 Kinase and Juxtamembrane Region Bound to Substrate KQWDNYE[pTyr]IW
2QOQ	;	1.6	;	Human EphA3 kinase and juxtamembrane region, base, AMP-PNP bound structure
2QO7	;	1.605	;	Human EphA3 kinase and juxtamembrane region, dephosphorylated, AMP-PNP bound
2QO2	;	1.6	;	Human EphA3 kinase and juxtamembrane region, dephosphorylated, apo structure
2QO9	;	1.55	;	Human EphA3 kinase and juxtamembrane region, phosphorylated, AMP-PNP bound
2QOL	;	1.07	;	Human EphA3 kinase and juxtamembrane region, Y596:Y602:S768G triple mutant
2QOF	;	1.2	;	Human EphA3 kinase and juxtamembrane region, Y596F mutant
2QOI	;	1.25	;	Human EphA3 kinase and juxtamembrane region, Y596F:Y602F double mutant
2QOK	;	1.2	;	Human EphA3 kinase and juxtamembrane region, Y596F:Y602F:S768A triple mutant
2QON	;	1.79	;	Human EphA3 kinase and juxtamembrane region, Y596F:Y602F:Y742A triple mutant
2QOO	;	1.25	;	Human EphA3 kinase and juxtamembrane region, Y596F:Y602F:Y742F triple mutant
2QOD	;	1.15	;	Human EphA3 kinase and juxtamembrane region, Y602F mutant
4TWN	;	1.706	;	Human EphA3 Kinase domain in complex with Birb796
4TWO	;	2.047	;	Human EphA3 Kinase domain in complex with compound 164
4G2F	;	1.699	;	Human EphA3 kinase domain in complex with compound 7
3DZQ	;	1.75	;	Human EphA3 kinase domain in complex with inhibitor AWL-II-38.3
4GK2	;	2.195	;	Human EphA3 Kinase domain in complex with ligand 66
4GK3	;	1.898	;	Human EphA3 Kinase domain in complex with ligand 87
4GK4	;	2.1	;	Human EphA3 Kinase domain in complex with ligand 90
4P4C	;	1.599	;	Human EphA3 Kinase domain in complex with quinoxaline derivatives
4P5Q	;	1.35	;	Human EphA3 Kinase domain in complex with quinoxaline derivatives
4P5Z	;	2.002	;	Human EphA3 Kinase domain in complex with quinoxaline derivatives
2QOB	;	1.65	;	Human EphA3 kinase domain, base structure
2QOC	;	1.25	;	Human EphA3 kinase domain, phosphorylated, AMP-PNP bound structure
4AZR	;	2.95	;	Human epidermal fatty acid-binding protein (FABP5) in complex with the endocannabinoid anandamide
4AZM	;	2.75	;	Human epidermal fatty acid-binding protein (FABP5) in complex with the inhibitor BMS-309413
6OB7	;	2.3	;	Human equilibrative nucleoside transporter-1, dilazep bound
6OB6	;	2.9	;	Human equilibrative nucleoside transporter-1, S-(4-nitrobenzyl)-6-thioinosine bound, merohedrally twinned
6Z3W	;	6.4	;	Human ER membrane protein complex
6M8P	;	3.31	;	Human ERAP1 bound to phosphinic pseudotripeptide inhibitor DG013
5A8L	;	3.8	;	Human eRF1 and the hCMV nascent peptide in the translation termination complex
2KTU	;		;	Human eRF1 C-domain, ""closed"" conformer
2KTV	;		;	Human eRF1 C-domain, ""open"" conformer
4ZZN	;	1.33	;	Human ERK2 in complex with an inhibitor
4ZZM	;	1.89	;	Human ERK2 in complex with an irreversible inhibitor
4ZZO	;	1.63	;	Human ERK2 in complex with an irreversible inhibitor
5NGU	;	2.74	;	Human Erk2 with an Erk1/2 inhibitor
5NHF	;	2.14	;	Human Erk2 with an Erk1/2 inhibitor
5NHH	;	1.94	;	Human Erk2 with an Erk1/2 inhibitor
5NHJ	;	2.12	;	Human Erk2 with an Erk1/2 inhibitor
5NHL	;	2.07	;	Human Erk2 with an Erk1/2 inhibitor
5NHO	;	2.24	;	Human Erk2 with an Erk1/2 inhibitor
5NHP	;	1.99	;	Human Erk2 with an Erk1/2 inhibitor
5NHV	;	2.0	;	Human Erk2 with an Erk1/2 inhibitor
6SLG	;	1.33	;	HUMAN ERK2 WITH ERK1/2 INHIBITOR, AZD0364.
5XWM	;	2.45	;	human ERp44 zinc-bound form
1DGB	;	2.2	;	HUMAN ERYTHROCYTE CATALASE
1DGF	;	1.5	;	HUMAN ERYTHROCYTE CATALASE
1DGH	;	2.0	;	HUMAN ERYTHROCYTE CATALASE 3-AMINO-1,2,4-TRIAZOLE COMPLEX
7P8W	;	2.2	;	Human erythrocyte catalase cryoEM
8HID	;	2.2	;	HUMAN ERYTHROCYTE CATALSE COMPLEXED WITH BT-Br
1DGG	;	1.8	;	HUMAN ERYTHROCYTE CATALSE CYANIDE COMPLEX
2VGB	;	2.73	;	HUMAN ERYTHROCYTE PYRUVATE KINASE
2VGG	;	2.74	;	HUMAN ERYTHROCYTE PYRUVATE KINASE: R479H MUTANT
2VGI	;	2.87	;	HUMAN ERYTHROCYTE PYRUVATE KINASE: R486W MUTANT
2VGF	;	2.75	;	HUMAN ERYTHROCYTE PYRUVATE KINASE: T384M mutant
1BUY	;		;	HUMAN ERYTHROPOIETIN, NMR MINIMIZED AVERAGE STRUCTURE
4MXE	;	2.6	;	Human ESCO1 (Eco1/Ctf7 ortholog), acetyltransferase domain in complex with acetyl-CoA
3F1I	;	2.3	;	Human ESCRT-0 Core Complex
6VME	;	2.19	;	Human ESCRT-I heterotetramer headpiece
3DT3	;	2.4	;	Human Estrogen receptor alpha LBD with GW368
2B23	;	2.1	;	Human estrogen receptor alpha ligand-binding domain and a glucocorticoid receptor-interacting protein 1 NR box II peptide
1L2I	;	1.95	;	Human Estrogen Receptor alpha Ligand-binding Domain in Complex with (R,R)-5,11-cis-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol and a Glucocorticoid Receptor Interacting Protein 1 NR box II Peptide
2B1Z	;	1.78	;	Human estrogen receptor alpha ligand-binding domain in complex with 17methyl-17alpha-dihydroequilenin and a glucoc interacting protein 1 NR box II peptide
2G5O	;	2.3	;	Human estrogen receptor alpha ligand-binding domain in complex with 2-(but-1-enyl)-17beta-estradiol and a glucocorticoid receptor interacting protein 1 NR BOX II Peptide
3ERT	;	1.9	;	HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
2IOG	;	1.6	;	Human estrogen receptor alpha ligand-binding domain in complex with compound 11F
1XP1	;	1.8	;	HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 15
1XP6	;	1.7	;	HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 16
1XP9	;	1.8	;	HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 18
1XPC	;	1.6	;	HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 19
2IOK	;	2.4	;	Human estrogen receptor alpha ligand-binding domain in complex with compound 1D
1YIN	;	2.2	;	Human estrogen receptor alpha ligand-binding domain in complex with compound 3F
1YIM	;	1.9	;	Human estrogen receptor alpha ligand-binding domain in complex with compound 4
3ERD	;	2.03	;	HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DIETHYLSTILBESTROL AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
2OCF	;	2.95	;	Human estrogen receptor alpha ligand-binding domain in complex with estradiol and the E2#23 FN3 monobody
1R5K	;	2.7	;	Human Estrogen Receptor alpha Ligand-Binding Domain In Complex With GW5638
2B1V	;	1.8	;	Human estrogen receptor alpha ligand-binding domain in complex with OBCP-1M and a glucocorticoid receptor interacting protein 1 NR box II peptide
2G44	;	2.65	;	Human Estrogen Receptor Alpha Ligand-Binding Domain In Complex With OBCP-1M-G and A Glucocorticoid Receptor Interacting Protein 1 NR Box II Peptide
2FAI	;	2.1	;	Human Estrogen Receptor Alpha Ligand-Binding Domain In Complex With OBCP-2M and A Glucocorticoid Receptor Interacting Protein 1 NR Box II Peptide
1ZKY	;	2.25	;	Human Estrogen Receptor Alpha Ligand-Binding Domain In Complex With OBCP-3M and A Glucocorticoid Receptor Interacting Protein 1 Nr Box II Peptide
1SJ0	;	1.9	;	Human Estrogen Receptor Alpha Ligand-binding Domain in Complex with the Antagonist Ligand 4-D
7XWQ	;	1.89	;	Human Estrogen Receptor beta Ligand-binding Domain in Complex with (R)-2-(2-chloro-4-hydroxyphenyl)-3-(4-hydroxyphenyl)propanenitrile
7XVZ	;	2.08	;	Human Estrogen Receptor beta Ligand-binding Domain in Complex with (R)-3-(2-chloro-4-hydroxyphenyl)-2-(4-hydroxyphenyl)propanenitrile
1L2J	;	2.95	;	Human Estrogen Receptor beta Ligand-binding Domain in Complex with (R,R)-5,11-cis-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol
7XWR	;	2.164	;	Human Estrogen Receptor beta Ligand-binding Domain in Complex with (S)-2-(2-chloro-4-hydroxyphenyl)-3-(4-hydroxyphenyl)propanenitrile
7XWP	;	1.919	;	Human Estrogen Receptor beta Ligand-binding Domain in Complex with (S)-3-(2-chloro-4-hydroxyphenyl)-2-(4-hydroxyphenyl)propanenitrile
2GIU	;	2.2	;	Human estrogen receptor beta ligand-binding domain in complex with compound 45
4ZI1	;	2.1	;	HUMAN ESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH KB095285 AND CIA12 COACTIVATOR PEPTIDE
7XVY	;	1.544	;	Human Estrogen Receptor beta Ligand-binding Domain in Complex with S-DPN
1ERE	;	3.1	;	HUMAN ESTROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH 17BETA-ESTRADIOL
1ERR	;	2.6	;	HUMAN ESTROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH RALOXIFENE
1BHS	;	2.2	;	HUMAN ESTROGENIC 17BETA-HYDROXYSTEROID DEHYDROGENASE
4CHL	;	2.61	;	Human Ethylmalonic Encephalopathy Protein 1 (hETHE1)
2IGQ	;	2.0	;	Human euchromatic histone methyltransferase 1
2O8J	;	1.8	;	Human euchromatic histone methyltransferase 2
8CUI	;	2.55	;	Human excitatory amino acid transporter 3 (EAAT3) in an intermediate outward facing apo state
8CV2	;	2.44	;	Human excitatory amino acid transporter 3 (EAAT3) in an outward facing sodium-bound state
8CUJ	;	3.04	;	Human excitatory amino acid transporter 3 (EAAT3) protomer in an outward facing apo state in 150 mM NMDG-Cl
8CUD	;	2.94	;	Human excitatory amino acid transporter 3 (EAAT3) protomer in an outward facing apo state in 300 mM KCl
8CTD	;	3.42	;	Human excitatory amino acid transporter 3 (EAAT3) protomer with bound glutamate in an outward facing state
8CTC	;	2.8	;	Human excitatory amino acid transporter 3 (EAAT3) with bound glutamate in an intermediate outward facing state
8CUA	;	2.44	;	Human excitatory amino acid transporter 3 (EAAT3) with bound potassium in an intermediate outward facing state
8CV3	;	3.04	;	Human Excitatory excitatory amino acid transporter 3 (EAAT3) protomer at in an intermediate outward facing sodium-bound state
7R6T	;	2.9	;	Human EXOG complexed with dRP-containing DNA
7R6V	;	2.16	;	Human EXOG complexed with dRP-containing DNA
5ZKI	;	2.321	;	Human EXOG-H140A in complex with duplex DNA
6IID	;	2.986	;	Human EXOG-H140A in complex with RNA-DNA chimeric duplex
5ZKJ	;	2.798	;	Human EXOG-H140A in complex with RNA/DNA hybrid duplex
7LW7	;	2.5	;	Human Exonuclease 5 crystal structure
7LWA	;	2.85	;	Human Exonuclease 5 crystal structure (T88E) in complex with ssDNA and Mg
7LW8	;	2.88	;	Human Exonuclease 5 crystal structure in complex with a ssDNA
7LW9	;	2.71	;	Human Exonuclease 5 crystal structure in complex with ssDNA, Sm, and Na
6H2Y	;	2.65	;	human Fab 1E6 bound to fHbp variant 3 from Neisseria meningitidis serogroup B
5O1R	;	2.86	;	human Fab 5H2 bound to NHBA-C3 from Neisseria meningitidis serogroup B
5N4J	;	1.503	;	human Fab fragment 10C3 against NHBA from Neisseria meningitidis
5N4G	;	2.75	;	human Fab fragment 12E1 against NHBA from Neisseria meningitidis
5NYX	;	1.88	;	human Fab fragment 5H2 against NHBA from Neisseria meningitidis
5HZ9	;	2.3	;	human FABP3 in complex with 6-Chloro-2-methyl-4-phenyl-quinoline-3-carboxylic acid
5EDC	;	1.29	;	human FABP4 in complex with 6-Chloro-4-phenyl-2-piperidin-1-yl-quinoline-3-carboxylic acid at 1.29A
1DSU	;	2.0	;	HUMAN FACTOR D, COMPLEMENT ACTIVATING ENZYME
1MZE	;	2.2	;	Human Factor Inhibiting HIF (FIH1)
1MZF	;	2.4	;	Human Factor inhibiting HIF (FIH1) in Complex with 2-oxoglutarate
5PB4	;	2.43	;	human factor VIIa in complex with 1-[[3-[5-hydroxy-3-methyl-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]-3-phenylurea at 2.43A
5PB5	;	1.84	;	human factor VIIa in complex with 1-[[3-[5-hydroxy-4-(7H-pyrrolo[2,3-d]pyrimidin-6-yl)pyrazol-1-yl]phenyl]methyl]-3-phenylurea at 1.84A
5PAC	;	1.5	;	human factor VIIa in complex with 5-hydroxy-N-(4-oxo-3H-quinazolin-6-yl)-1-[3-[(phenylcarbamoylamino)methyl]phenyl]pyrazole-4-carboxamide at 1.50A
5PAI	;	1.73	;	human factor VIIa in complex with N-(2-amino-1H-benzimidazol-5-yl)-1-[3-[[(3,5-dimethyl-1,2-oxazol-4-yl)carbamoylamino]methyl]phenyl]-5-hydroxypyrazole-4-carboxamide at 1.73A
2ZP0	;	2.7	;	Human factor viia-tissue factor complexed with benzylsulfonamide-D-ile-gln-P-aminobenzamidine
2ZZU	;	2.5	;	Human Factor VIIA-Tissue Factor Complexed with ethylsulfonamide-D-5-(3-carboxybenzyloxy)-Trp-Gln-p-aminobenzamidine
1WV7	;	2.7	;	Human Factor Viia-Tissue Factor Complexed with ethylsulfonamide-D-5-propoxy-Trp-Gln-p-aminobenzamidine
1WTG	;	2.2	;	Human Factor Viia-Tissue Factor Complexed with ethylsulfonamide-D-biphenylalanine-Gln-p-aminobenzamidine
1WUN	;	2.4	;	Human Factor Viia-Tissue Factor Complexed with ethylsulfonamide-D-Trp-Gln-p-aminobenzamidine
2ZWL	;	2.2	;	Human factor viia-tissue factor complexed with highly selective peptide inhibitor
1WQV	;	2.5	;	Human Factor Viia-Tissue Factor Complexed with propylsulfonamide-D-Thr-Met-p-aminobenzamidine
1WSS	;	2.6	;	Human Factor Viia-Tissue Factor in Complex with peptide-mimetic inhibitor that has two charged groups in P2 and P4
1IQD	;	2.0	;	Human Factor VIII C2 Domain complexed to human monoclonal BO2C11 Fab.
5K0H	;	2.2	;	Human factor Xa in complex with synthetic inhibitor benzylsulfonyl-dSer(Benzyl)-Gly-4-amidinobenzylamide
1EVU	;	2.01	;	HUMAN FACTOR XIII WITH CALCIUM BOUND IN THE ION SITE
1GGU	;	2.1	;	HUMAN FACTOR XIII WITH CALCIUM BOUND IN THE ION SITE
1QRK	;	2.5	;	HUMAN FACTOR XIII WITH STRONTIUM BOUND IN THE ION SITE
1GGY	;	2.5	;	HUMAN FACTOR XIII WITH YTTERBIUM BOUND IN THE ION SITE
1EX0	;	2.0	;	HUMAN FACTOR XIII, MUTANT W279F ZYMOGEN
4RID	;	3.3	;	Human FAN1 nuclease
3ZQS	;	2.0	;	Human FANCL central domain
2OPM	;	2.4	;	Human Farnesyl Diphosphate Synthase Complexed with Bisphosphonate BPH-461
2OPN	;	2.7	;	Human Farnesyl Diphosphate Synthase Complexed with Bisphosphonate BPH-527
3B7L	;	1.95	;	Human farnesyl diphosphate synthase complexed with MG and minodronate
1YV5	;	2.0	;	Human farnesyl diphosphate synthase complexed with Mg and risedronate
1YQ7	;	2.2	;	Human farnesyl diphosphate synthase complexed with risedronate
4P0W	;	2.406	;	Human farnesyl diphosphate synthase in complex with Arenarone and zoledronate
4P0X	;	2.5	;	Human farnesyl diphosphate synthase in complex with Taxodione
5EDB	;	1.18	;	human fatty acid binding protein 4 in complex with 6-Chloro-2-methyl-4-phenyl-quinoline-3-carboxylic acid at 1.18A
8G7X	;	1.815	;	Human fatty acid synthase dehydratase domain
6NNA	;	2.26	;	Human Fatty Acid Synthase Psi/KR Tri-Domain with NADPH and Compound 22
4PIV	;	2.299	;	Human Fatty Acid Synthase Psi/KR Tri-Domain with NADPH and GSK2194069
1XKT	;	2.6	;	Human fatty acid synthase: Structure and substrate selectivity of the thioesterase domain
2FCB	;	1.74	;	HUMAN FC GAMMA RECEPTOR IIB ECTODOMAIN (CD32)
1H9V	;	3.0	;	Human Fc-gamma-Receptor IIa (FcgRIIa), monoclinic
4N0F	;	3.02	;	Human FcRn complexed with human serum albumin
6FGB	;	2.9	;	Human FcRn extra-cellular domain complexed with Fab fragment of Rozanolixizumab
3RYE	;	2.1	;	Human FDPS Synthase in Complex with a N-Methyl Pyridinum Bisphosphonate
3S4J	;	1.95	;	Human FDPS Synthase in Complex with a Rigid Analog of Risedronate
2VF6	;	2.1	;	Human FDPS synthase in complex with minodronate
2RAH	;	2.0	;	Human FDPS synthase in complex with novel inhibitor
5FV7	;	2.84	;	Human Fen1 in complex with an N-hydroxyurea compound
5XB1	;	3.0	;	human ferritin mutant - E-helix deletion
5YI5	;	3.0	;	human ferritin mutant - E-helix deletion
3HCO	;	1.8	;	Human ferrochelatase with Cd and protoporphyrin IX bound
3HCR	;	2.2	;	Human Ferrochelatase with deuteroporphyrin and Ni Bound
3HCP	;	2.0	;	Human ferrochelatase with Mn and deuteroporphyrin bound
5O49	;	1.91	;	Human FGF in complex with a covalent inhibitor
5O4A	;	2.01	;	Human FGF in complex with a covalent inhibitor
5B7V	;	2.15	;	Human FGFR1 kinase in complex with CH5183284
6YI8	;	2.13	;	HUMAN FGFR4 KINASE DOMAIN (447-753) IN COMPLEX WITH ROBLITINIB
2IPX	;	1.82	;	Human Fibrillarin
4XKI	;	2.0	;	Human Fibroblast Growth Factor - 1 (FGF-1) mutant S116R
2NTD	;	2.52	;	Human fibroblast growth factor-1 (140 amino acid form) with Cys117Val/Pro134Cys mutations
4YOL	;	1.97	;	Human fibroblast growth factor-1 C16S/A66C/C117A/P134A
3V8O	;	2.8	;	Human Filamin C Ig - like Domains 4 and 5
8CHJ	;	1.697	;	Human FKBP12 in complex with (1S,5S,6R)-10-((R)-(3,5-dichlorophenyl)sulfonimidoyl)-3-(pyridin-2-ylmethyl)-5-vinyl-3,10-diazabicyclo[4.3.1]decan-2-one
8CHM	;	1.12	;	Human FKBP12 in complex with (1S,5S,6R)-10-((S)-(3,5-dichlorophenyl)sulfinyl)-3-(pyridin-2-ylmethyl)-5-vinyl-3,10-diazabicyclo[4.3.1]decan-2-one
8CHK	;	1.55	;	Human FKBP12 in complex with (1S,5S,6R)-10-((S)-(3,5-dichlorophenyl)sulfonimidoyl)-3-(pyridin-2-ylmethyl)-5-vinyl-3,10-diazabicyclo[4.3.1]decan-2-one
8CHI	;	1.7	;	Human FKBP12 in complex with (1S,5S,6R)-10-((S)-3,5-dichloro-N-methylphenylsulfonimidoyl)-3-(pyridin-2-ylmethyl)-5-vinyl-3,10-diazabicyclo[4.3.1]decan-2-one
8CHL	;	1.4	;	Human FKBP12 in complex with (1S,5S,6R)-9-((3,5-dichlorophenyl)sulfonyl)-3-(pyridin-2-ylmethyl)-5-vinyl-3,9-diazabicyclo[4.2.1]nonan-2-one
5OMP	;	1.88	;	Human FKBP5 protein
5NJX	;	2.49	;	Human FKBP51 protein in complex with C-terminal peptide of Human HSP 90-alpha
5CMP	;	2.601	;	human FLRT3 LRR domain
2X74	;	2.34	;	Human foamy virus integrase - catalytic core.
2X78	;	2.0	;	Human foamy virus integrase - catalytic core.
2X6S	;	2.29	;	Human foamy virus integrase - catalytic core. Magnesium-bound structure.
2X6N	;	2.06	;	Human foamy virus integrase - catalytic core. Manganese-bound structure.
4KMX	;	2.2	;	Human folate receptor alpha (FOLR1) at acidic pH, hexagonal form
4KM6	;	1.55	;	Human folate receptor alpha (FOLR1) at acidic pH, orthorhombic form
4KM7	;	1.801	;	Human folate receptor alpha (FOLR1) at acidic pH, triclinic form
4KMY	;	1.795	;	Human folate receptor beta (FOLR2) at neutral pH
4KN2	;	2.6	;	Human folate receptor beta (FOLR2) in complex with antifolate pemetrexed
4KN1	;	2.301	;	Human folate receptor beta (FOLR2) in complex with the antifolate aminopterin
4KN0	;	2.1	;	Human folate receptor beta (FOLR2) in complex with the antifolate methotrexate
4KMZ	;	2.3	;	Human folate receptor beta (FOLR2) in complex with the folate
1FL7	;	3.0	;	HUMAN FOLLICLE STIMULATING HORMONE
1Y1E	;	1.73	;	human formylglycine generating enzyme
1Y1F	;	1.8	;	human formylglycine generating enzyme with cysteine sulfenic acid
2HI8	;	1.64	;	human formylglycine generating enzyme, C336S mutant, bromide co-crystallization
2HIB	;	2.0	;	human formylglycine generating enzyme, C336S mutant, iodide co-crystallization
1Y1G	;	1.67	;	Human formylglycine generating enzyme, double sulfonic acid form
1Y1H	;	1.67	;	human formylglycine generating enzyme, oxidised Cys refined as hydroperoxide
1Y1J	;	1.55	;	human formylglycine generating enzyme, sulfonic acid/desulfurated form
3N1V	;	2.18	;	Human FPPS COMPLEX WITH FBS_01
3N1W	;	2.56	;	Human FPPS COMPLEX WITH FBS_02
3N3L	;	2.74	;	Human FPPS complex with FBS_03
3N45	;	1.88	;	Human FPPS complex with FBS_04 and zoledronic acid/MG2+
3N49	;	2.5	;	Human FPPS COMPLEX WITH NOV_292
3N5H	;	2.2	;	Human fpps complex with NOV_304
3N5J	;	2.35	;	Human fpps complex with NOV_311
3N6K	;	2.25	;	Human FPPS complex with NOV_823
3N46	;	2.35	;	Human FPPS complex with NOV_980 and zoledronic acid/MG2+
7CWE	;	3.0	;	Human Fructose-1,6-bisphosphatase 1 in APO R-state
7CVH	;	2.09	;	Human Fructose-1,6-bisphosphatase 1 in complex with geranylgeranyl diphosphate
7WVB	;	2.09	;	Human Fructose-1,6-bisphosphatase 1 mutant R50A in APO R-state
8BJM	;	2.2	;	Human full length RAD52 undecamer.
5D6B	;	2.1	;	Human fumarase (wild type)
8D0U	;	1.29	;	Human FUT9 bound to GDP
8D0R	;	1.4	;	Human FUT9 bound to GDP and H-Type 2
8D0S	;	1.37	;	Human FUT9 bound to GDP and LNnT
8D0Q	;	1.39	;	Human FUT9 bound to GDP-CF3-Fucose and H-Type 2
8D0W	;	1.332	;	Human FUT9 bound to H-Type 2
8D0X	;	1.33	;	Human FUT9 bound to LNnT
8D0P	;	1.09	;	Human FUT9, unliganded
4D76	;	1.77	;	Human FXIa in complex with small molecule inhibitors.
4D7F	;	1.62	;	Human FXIa in complex with small molecule inhibitors.
4D7G	;	2.33	;	Human FXIa in complex with small molecule inhibitors.
2MQI	;		;	human Fyn SH2 free state
3H0H	;	1.76	;	human Fyn SH3 domain R96I mutant, crystal form I
3H0I	;	2.2	;	human Fyn SH3 domain R96I mutant, crystal form II
4U1P	;	1.4	;	Human Fyn-SH2 domain in complex with a synthetic high-affinity phospho-peptide
3V5W	;	2.07	;	Human G Protein-Coupled Receptor Kinase 2 in Complex with Soluble Gbetagamma Subunits and Paroxetine
4NVQ	;	2.03	;	Human G9a in Complex with Inhibitor A-366
3MO0	;	2.78	;	Human G9a-like (GLP, also known as EHMT1) in complex with inhibitor E11
3MO2	;	2.49	;	human G9a-like (GLP, also known as EHMT1) in complex with inhibitor E67
3MO5	;	2.14	;	Human G9a-like (GLP, also known as EHMT1) in complex with inhibitor E72
6D6U	;	3.92	;	Human GABA-A receptor alpha1-beta2-gamma2 subtype in complex with GABA and flumazenil, conformation A
6D6T	;	3.86	;	Human GABA-A receptor alpha1-beta2-gamma2 subtype in complex with GABA and flumazenil, conformation B
6X3S	;	3.12	;	Human GABAA receptor alpha1-beta2-gamma2 subtype in complex with bicuculline methbromide
6X3Z	;	3.23	;	Human GABAA receptor alpha1-beta2-gamma2 subtype in complex with GABA
8SI9	;	2.98	;	Human GABAA receptor alpha1-beta2-gamma2 subtype in complex with GABA plus allopregnanolone
8SID	;	2.71	;	Human GABAA receptor alpha1-beta2-gamma2 subtype in complex with GABA plus dehydroepiandrosterone sulfate
6X3X	;	2.92	;	Human GABAA receptor alpha1-beta2-gamma2 subtype in complex with GABA plus diazepam
8DD3	;	2.9	;	Human GABAA receptor alpha1-beta2-gamma2 subtype in complex with GABA plus DMCM
6X3V	;	3.5	;	Human GABAA receptor alpha1-beta2-gamma2 subtype in complex with GABA plus etomidate
6X3U	;	3.5	;	Human GABAA receptor alpha1-beta2-gamma2 subtype in complex with GABA plus flumazenil
6X3W	;	3.3	;	Human GABAA receptor alpha1-beta2-gamma2 subtype in complex with GABA plus phenobarbital
6X40	;	2.86	;	Human GABAA receptor alpha1-beta2-gamma2 subtype in complex with GABA plus picrotoxin
8SGO	;	2.65	;	Human GABAA receptor alpha1-beta2-gamma2 subtype in complex with GABA plus pregnenolone sulfate
6X3T	;	2.55	;	Human GABAA receptor alpha1-beta2-gamma2 subtype in complex with GABA plus propofol
8DD2	;	2.9	;	Human GABAA receptor alpha1-beta2-gamma2 subtype in complex with GABA plus Zolpidem
7ZKR	;	1.1	;	Human GABARAP in complex with stapled peptide Pen3-ortho
7ZL7	;	1.55	;	Human GABARAP in complex with stapled peptide Pen8-ortho
6K2Y	;	1.57	;	Human Galectin-14
6K2Z	;	2.0	;	Human Galectin-14 with lactose
6LJQ	;	1.49	;	human galectin-16 R55N
6LJR	;	2.0	;	human galectin-16 R55N/H57R
7DF5	;	1.08	;	Human Galectin-3 CRD in complex with novel tetrahydropyran-based thiodisaccharide mimic inhibitor
2XG3	;	1.2	;	Human galectin-3 in complex with a benzamido-N-acetyllactoseamine inhibitor
6G0V	;	1.09	;	Human Galectin-3 in complex with a TF tumor-associated antigen mimetic
7BE3	;	1.25	;	Human Galectin-3 in complex with LacdiNAc
6EOG	;	1.2	;	Human galectin-3c in complex with a galactose derivative
6EOL	;	1.5	;	Human galectin-3c in complex with a galactose derivative
6TF6	;	1.5	;	Human galectin-3c in complex with a galactose derivative
6TF7	;	1.4	;	Human galectin-3c in complex with a galactose derivative
7ZQX	;	1.05	;	Human galectin-3c in complex with a galactose derivative
4UW3	;	1.479	;	Human galectin-7 in complex with a galactose based dendron D1.
4UW4	;	1.766	;	Human galectin-7 in complex with a galactose based dendron D2-1.
4UW5	;	2.04	;	Human galectin-7 in complex with a galactose based dendron D2-2.
4UW6	;	1.79	;	Human galectin-7 in complex with a galactose based dendron D3
1HT0	;	2.0	;	HUMAN GAMMA-2 ALCOHOL DEHYDROGENSE
2JDF	;	1.7	;	Human gamma-B crystallin
4C8R	;	2.82	;	Human gamma-butyrobetaine dioxygenase (BBOX1) in complex with Ni(II) and N-(3-hydroxypicolinoyl)-S-(pyridin-2-ylmethyl)-L-cysteine (AR692B)
8BPI	;	2.0	;	Human Gamma-D crystallin R36S mutant after UV illumination
8BD0	;	2.0	;	Human Gamma-D crystallin R36S mutant with DTT-Cystein Protein modification
2G98	;	2.2	;	human gamma-D-crystallin
2PN7	;	2.41	;	Human gamma-glutamyl cyclotransferase
3JUB	;	1.2	;	Human gamma-glutamylamine cyclotransferase
3JUC	;	1.2	;	Human gamma-glutamylamine cyclotransferase complex with 5-oxoproline
3JUD	;	0.98	;	Human gamma-glutamylamine cyclotransferase, E82Q mutant
8K8E	;	2.6	;	Human gamma-secretase in complex with a substrate mimetic
6LQG	;	3.1	;	Human gamma-secretase in complex with small molecule Avagacestat
7C9I	;	3.1	;	Human gamma-secretase in complex with small molecule L-685,458
8IM7	;	3.4	;	Human gamma-secretase treated with ganglioside GM1
1H4A	;	1.15	;	Human GammaD Crystallin R58H mutant structure AT 1.15 A resolution
1HK0	;	1.25	;	Human GammaD Crystallin Structure at 1.25 A Resolution
1UOH	;	2.0	;	HUMAN GANKYRIN
1RBQ	;	2.104	;	Human GAR Tfase complex structure with 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid
1RBY	;	2.101	;	Human GAR Tfase complex structure with 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid and substrate beta-GAR
1RBM	;	2.3	;	Human GAR Tfase complex structure with polyglutamated 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid
1RBZ	;	2.1	;	Human GAR Tfase complex structure with polyglutamated 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid
1RC0	;	2.05	;	Human GAR Tfase complex structure with polyglutamated 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid
1RC1	;	2.25	;	Human GAR Tfase complex structure with polyglutamated 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid
1NJS	;	1.98	;	human GAR Tfase in complex with hydrolyzed form of 10-trifluoroacetyl-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid
5J9F	;	2.1	;	Human GAR transformylase in complex with GAR and (4-{[2-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethyl]amino}benzoyl)-L-glutamic acid (AGF183)
4ZYZ	;	1.6	;	Human GAR transformylase in complex with GAR and (S)-2-(7-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)heptanamido)pentanedioic acid (AGF145)
4ZZ0	;	1.65	;	Human GAR transformylase in complex with GAR and (S)-2-(8-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)octanamido)pentanedioic acid (AGF147)
4ZZ1	;	1.351	;	HUMAN GAR TRANSFORMYLASE IN COMPLEX WITH GAR AND (S)-2-({4-[3-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-6-YL)-PROPYL]-THIOPHENE-2-CARBONYL}-AMINO)-PENTANEDIOIC ACID
4ZYX	;	1.65	;	Human GAR transformylase in complex with GAR and (S)-2-({4-[4-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]-pyrimidin-6-yl)butyl]thiophene-2-carbonyl}amino)pentanedioic acid (AGF117)
4ZZ2	;	1.451	;	HUMAN GAR TRANSFORMYLASE IN COMPLEX WITH GAR AND (S)-2-({5-[3-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-6-YL)-PROPYL]-THIOPHENE-3-CARBONYL}-AMINO)-PENTANEDIOIC ACID
4ZYY	;	1.85	;	Human GAR transformylase in complex with GAR and (S)-2-({5-[4-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]-pyrimidin-6-yl)butyl]thiophene-3-carbonyl}amino)pentanedioic acid (AGF118)
4ZYV	;	2.053	;	Human GAR transformylase in complex with GAR and N-({5-[(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl]thiophen-2-yl}carbonyl)-L-glutamic acid (AGF71)
4ZYW	;	2.05	;	Human GAR transformylase in complex with GAR and N-({5-[(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl]thiophen-2-yl}carbonyl)-L-glutamic acid (AGF94)
4ZYU	;	1.95	;	Human GAR transformylase in complex with GAR and N-{4-[4-(2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)-butyl]benzoyl}-L-glutamic acid (AGF50)
4ZYT	;	1.702	;	Human GAR transformylase in complex with GAR and N-{4-[4-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)benzyl]benzoyl}-L-glutamic acid (AGF23)
4ZZ3	;	2.504	;	Human GAR transformylase in complex with GAR and pemetrexed
7JG0	;	1.984	;	Human GAR transformylase in complex with GAR substrate and AGF102 inhibitor
7JG3	;	2.091	;	Human GAR transformylase in complex with GAR substrate and AGF103 inhibitor
7JG4	;	2.455	;	Human GAR transformylase in complex with GAR substrate and AGF131 inhibitor
8FDY	;	2.06	;	Human GAR transformylase in complex with GAR substrate and AGF132 inhibitor
8FJY	;	2.98	;	Human GAR transformylase in complex with GAR substrate and AGF291 inhibitor
8FDZ	;	2.48	;	Human GAR transformylase in complex with GAR substrate and AGF302 inhibitor
8FE0	;	2.22	;	Human GAR transformylase in complex with GAR substrate and AGF305 inhibitor
8FJX	;	2.17	;	Human GAR transformylase in complex with GAR substrate and AGF320 inhibitor
8FJW	;	2.08	;	Human GAR transformylase in complex with GAR substrate and AGF347 inhibitor
8FJV	;	2.69	;	Human GAR transformylase in complex with GAR substrate and AGF362 inhibitor
7UHY	;	3.66	;	Human GATOR2 complex
7ALA	;	1.846	;	human GCH-GFRP inhibitory complex
7ALQ	;	2.205	;	human GCH-GFRP inhibitory complex 7-deaza-GTP bound
7ALC	;	1.726	;	human GCH-GFRP stimulatory complex
7ALB	;	1.979	;	human GCH-GFRP stimulatory complex 7-deaza-GTP bound
1Z4R	;	1.74	;	Human GCN5 Acetyltransferase
5H86	;	2.08	;	Human Gcn5 bound to butyryl-CoA
5H84	;	2.0	;	Human Gcn5 bound to propionyl-CoA
7YWD	;	3.2	;	Human GDAP1 core domain, trigonal crystal form
8A4J	;	2.68	;	Human GDAP1, A247V mutant
8A4K	;	1.95	;	Human GDAP1, R282H mutant
1KCQ	;	1.65	;	Human Gelsolin Domain 2 with a Cd2+ bound
5ZZ0	;	2.635	;	HUMAN GELSOLIN FROM RESIDUES GLU28 TO ARG161 WITH CALCIUM
7Q4Y	;	3.08	;	human Gid4 bound to a Gly/N-peptide
7Q50	;	3.16	;	human Gid4 bound to a Phe/N-peptide
6DKJ	;	1.95	;	human GIPR ECD and Fab complex
7KHD	;	2.9561	;	Human GITR-GITRL complex
5IZ5	;	2.2	;	Human GIVD cytosolic phospholipase A2
5IXC	;	2.65	;	Human GIVD cytosolic phospholipase A2 in complex with Methyl gamma-Linolenyl Fluorophosphonate
5IZR	;	3.25	;	Human GIVD cytosolic phospholipase A2 in complex with Methyl gamma-Linolenyl Fluorophosphonate inhibitor and Terbium Chloride
4PXS	;	2.6	;	Human GKRP bound to AMG-0265 (N-[(R)-(2-CHLOROPHENYL){7-[4-(2-HYDROXYPROPAN-2-YL) PYRIDIN-2-YL]-1-BENZOTHIOPHEN-2-YL}METHYL]CYCLOPROPANESULFONAMIDE) and Sorbitol-6-phosphate
4PX5	;	2.2	;	Human GKRP bound to AMG-0696 and Sorbitol-6-phosphate
4OHM	;	2.4	;	Human GKRP bound to AMG-0771 and sorbitol-6-phosphate
4OHK	;	2.8	;	Human GKRP bound to AMG-2526 and S6P
4OHO	;	2.58	;	Human GKRP bound to AMG-2668
4OHP	;	2.4	;	Human GKRP bound to AMG-3227 and S6P
4PX3	;	2.43	;	Human GKRP bound to AMG-3295 and Sorbitol-6-phosphate
4OP3	;	2.82	;	Human GKRP bound to AMG-5112 and Sorbitol-6-phosphate
4MRO	;	2.2	;	Human GKRP bound to AMG-5980 and S6P
4MSU	;	2.5	;	Human GKRP bound to AMG-6861 and Sorbitol-6-phosphate
4PX2	;	2.15	;	Human GKRP bound to AMG2882 and Sorbitol-6-Phosphate
4OLH	;	2.4	;	Human GKRP Bound to AMG5106 and Sorbitol-6-Phosphate
4LY9	;	2.35	;	Human GKRP complexed to AMG-1694 [(2R)-1,1,1-trifluoro-2-{4-[(2S)-2-{[(3S)-3-methylmorpholin-4-yl]methyl}-4-(thiophen-2-ylsulfonyl)piperazin-1-yl]phenyl}propan-2-ol] and sorbitol-6-phosphate
4MQU	;	2.22	;	Human GKRP complexed to AMG-3969 and S6P
8BSL	;	2.38	;	Human GLS in complex with compound 12
8BSM	;	2.782	;	Human GLS in complex with compound 18
8BSN	;	2.494	;	Human GLS in complex with compound 27
8BSK	;	2.1	;	Human GLS in complex with compound 3
3FR0	;	2.7	;	Human glucokinase in complex with 2-amino benzamide activator
4NO7	;	1.7	;	Human Glucokinase in complex with a nanomolar activator.
4MLH	;	2.9	;	Human Glucokinase in Complex with a Novel Amino Thiazole Allosteric Activator
3A0I	;	2.2	;	Human glucokinase in complex with a synthetic activator
3GOI	;	2.52	;	Human glucokinase in complex with a synthetic activator
3H1V	;	2.11	;	Human glucokinase in complex with a synthetic activator
4ISF	;	2.09	;	Human glucokinase in complex with novel activator (2S)-3-cyclohexyl-2-(6-fluoro-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)-N-(1,3-thiazol-2-yl)propanamide
4ISE	;	1.78	;	Human glucokinase in complex with novel activator (2S)-3-cyclohexyl-2-(6-fluoro-4-oxoquinazolin-3(4H)-yl)-N-(1,3-thiazol-2-yl)propanamide
4ISG	;	2.645	;	Human glucokinase in complex with novel activator (2S)-3-cyclohexyl-2-[4-(methylsulfonyl)-2-oxopiperazin-1-yl]-N-(1,3-thiazol-2-yl)propanamide
4MLE	;	2.6	;	Human Glucokinase in Complex with Novel Amino Thiazole Activator
5V4W	;	2.39	;	Human glucokinase in complex with novel indazole activator.
5V4X	;	2.08	;	Human glucokinase in complex with novel pyrazole activator.
1NE7	;	1.75	;	HUMAN GLUCOSAMINE-6-PHOSPHATE DEAMINASE ISOMERASE AT 1.75 A RESOLUTION COMPLEXED WITH N-ACETYL-GLUCOSAMINE-6-PHOSPHATE AND 2-DEOXY-2-AMINO-GLUCITOL-6-PHOSPHATE
1JLH	;	2.1	;	Human Glucose-6-phosphate Isomerase
8E99	;	4.24	;	Human GluN1a-GluN2A-GluN2C triheteromeric NMDA receptor in complex with Nb-4
5EQI	;	3.002	;	Human GLUT1 in complex with Cytochalasin B
5EQH	;	2.99	;	Human GLUT1 in complex with inhibitor (2~{S})-3-(2-bromophenyl)-2-[2-(4-methoxyphenyl)ethanoylamino]-~{N}-[(1~{S})-1-phenylethyl]propanamide
5EQG	;	2.9	;	Human GLUT1 in complex with inhibitor (2~{S})-3-(4-fluorophenyl)-2-[2-(3-hydroxyphenyl)ethanoylamino]-~{N}-[(1~{S})-1-phenylethyl]propanamide
3SJG	;	1.65	;	Human glutamate carboxypeptidase II (E424A inactive mutant ) in complex with N-acetyl-aspartyl-aminooctanoic acid
2XEI	;	1.69	;	Human glutamate carboxypeptidase II in complex with Antibody- Recruiting Molecule ARM-P2
2XEG	;	1.59	;	Human glutamate carboxypeptidase II in complex with Antibody- Recruiting Molecule ARM-P4
2XEF	;	1.59	;	Human glutamate carboxypeptidase II in complex with Antibody- Recruiting Molecule ARM-P8
2XEJ	;	1.78	;	Human glutamate carboxypeptidase II in complex with ARM-M4, urea- based inhibitor
8KGY	;	2.59	;	Human glutamate dehydrogenase I
6DQG	;	2.7	;	Human glutamate dehydrogenase, H454Y mutant
8SZJ	;	3.35	;	Human glutaminase C (Y466W) with L-Gln and Pi, filamentous form
7SBN	;	2.14	;	Human glutaminase C (Y466W) with L-Gln, closed conformation
7SBM	;	2.8	;	Human glutaminase C (Y466W) with L-Gln, open conformation
1JHB	;		;	HUMAN GLUTAREDOXIN IN FULLY REDUCED FORM, NMR, 20 STRUCTURES
5GRT	;	2.4	;	HUMAN GLUTATHIONE REDUCTASE A34E, R37W MUTANT, GLUTATHIONYLSPERMIDINE COMPLEX
4GRT	;	2.8	;	HUMAN GLUTATHIONE REDUCTASE A34E, R37W MUTANT, MIXED DISULFIDE BETWEEN TRYPANOTHIONE AND THE ENZYME
2GRT	;	2.7	;	HUMAN GLUTATHIONE REDUCTASE A34E, R37W MUTANT, OXIDIZED GLUTATHIONE COMPLEX
3GRT	;	2.5	;	HUMAN GLUTATHIONE REDUCTASE A34E, R37W MUTANT, OXIDIZED TRYPANOTHIONE COMPLEX
1GRT	;	2.3	;	HUMAN GLUTATHIONE REDUCTASE A34E/R37W MUTANT
1XAN	;	2.0	;	HUMAN GLUTATHIONE REDUCTASE IN COMPLEX WITH A XANTHENE INHIBITOR
1K4Q	;	1.9	;	Human Glutathione Reductase Inactivated by Peroxynitrite
1DNC	;	1.7	;	HUMAN GLUTATHIONE REDUCTASE MODIFIED BY DIGLUTATHIONE-DINITROSO-IRON
1GSN	;	1.7	;	HUMAN GLUTATHIONE REDUCTASE MODIFIED BY DINITROSOGLUTATHIONE
1YKC	;	2.1	;	human glutathione S-transferase m2-2 (E.C.2.5.1.18) complexed with glutathione-disulfide
2AB6	;	2.5	;	HUMAN GLUTATHIONE S-TRANSFERASE M2-2 (E.C.2.5.1.18) complexed with S-METHYLGLUTATHIONE
1XW5	;	1.8	;	Human glutathione s-transferase M2-2 (E.C.2.5.1.18)complexed with glutathione, monoclinic crystal form
5HWL	;	1.6	;	Human glutathione s-transferase Mu2 complexed with BDEA, monoclinic crystal form
3CSJ	;	1.9	;	Human glutathione s-transferase p1-1 in complex with chlorambucil
2GSS	;	1.9	;	HUMAN GLUTATHIONE S-TRANSFERASE P1-1 IN COMPLEX WITH ETHACRYNIC ACID
3GSS	;	1.9	;	HUMAN GLUTATHIONE S-TRANSFERASE P1-1 IN COMPLEX WITH ETHACRYNIC ACID-GLUTATHIONE CONJUGATE
4GSS	;	2.5	;	HUMAN GLUTATHIONE S-TRANSFERASE P1-1 Y108F MUTANT
22GS	;	1.9	;	HUMAN GLUTATHIONE S-TRANSFERASE P1-1 Y49F MUTANT
5GSS	;	1.95	;	HUMAN GLUTATHIONE S-TRANSFERASE P1-1, COMPLEX WITH GLUTATHIONE
6GSS	;	1.9	;	HUMAN GLUTATHIONE S-TRANSFERASE P1-1, COMPLEX WITH GLUTATHIONE
7GSS	;	2.2	;	Human glutathione S-transferase P1-1, complex with glutathione
8GSS	;	1.9	;	Human glutathione S-transferase P1-1, complex with glutathione
9GSS	;	1.97	;	HUMAN GLUTATHIONE S-TRANSFERASE P1-1, COMPLEX WITH S-HEXYL GLUTATHIONE
10GS	;	2.2	;	HUMAN GLUTATHIONE S-TRANSFERASE P1-1, COMPLEX WITH TER117
2HGS	;	2.1	;	HUMAN GLUTATHIONE SYNTHETASE
1GUL	;	2.7	;	HUMAN GLUTATHIONE TRANSFERASE A4-4 COMPLEX WITH IODOBENZYL GLUTATHIONE
3IK7	;	1.97	;	Human glutathione transferase a4-4 with GSDHN
1GUM	;	3.0	;	HUMAN GLUTATHIONE TRANSFERASE A4-4 WITHOUT LIGANDS
7BEU	;	1.59	;	Human glutathione transferase M1-1
3VLN	;	1.7	;	Human Glutathione Transferase O1-1 C32S Mutant in Complex with Ascorbic Acid
3Q18	;	1.7	;	Human Glutathione Transferase O2
3Q19	;	1.9	;	Human Glutathione Transferase O2
3QAG	;	2.0	;	Human Glutathione Transferase O2 with glutathione -new crystal form
5YVN	;	1.33	;	Human Glutathione Transferase Omega1
5YVO	;	1.8	;	Human Glutathione Transferase Omega1 covalently bound to ML175 inhibitor
1M6H	;	2.0	;	Human glutathione-dependent formaldehyde dehydrogenase
2C4J	;	1.35	;	Human glutathione-S-transferase M2-2 T210S mutant in complex with glutathione-styrene oxide conjugate
2C3Q	;	1.85	;	Human glutathione-S-transferase T1-1 W234R mutant, complex with S- hexylglutathione
2C3N	;	1.5	;	Human glutathione-S-transferase T1-1, apo form
2C3T	;	2.4	;	Human glutathione-S-transferase T1-1, W234R mutant, apo form
2QK4	;	2.45	;	Human glycinamide ribonucleotide synthetase
1MEO	;	1.72	;	human glycinamide ribonucleotide Transformylase at pH 4.2
1MEJ	;	2.0	;	Human Glycinamide Ribonucleotide Transformylase domain at pH 8.5
8WFJ	;	3.35	;	human glycine transporter 1 in complex with ALX-5407 in inward facing conformation
8WFI	;	2.58	;	human glycine transporter 1 in complex with glycine in occluded conformation
8WFL	;	3.03	;	human glycine transporter 1 in complex with PF-03463275 in outward facing conformation
8WFK	;	3.22	;	human glycine transporter 1 in complex with SSR504734 in outward facing conformation
3CEJ	;	3.3	;	Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE2865
3CEM	;	2.47	;	Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE9423
8CVY	;	3.6	;	Human glycogenin-1 and glycogen synthase-1 complex in the apo mobile state
8CVZ	;	3.52	;	Human glycogenin-1 and glycogen synthase-1 complex in the apo ordered state
8CVX	;	3.5	;	Human glycogenin-1 and glycogen synthase-1 complex in the presence of glucose-6-phosphate
1GIF	;	1.9	;	HUMAN GLYCOSYLATION-INHIBITING FACTOR
7WT0	;	2.0	;	human glyoxalase I (with C-ter His tag) in complex with TLSC702
7WSZ	;	1.52	;	human glyoxalase I (with C-ter His tag) in glycerol-bound form
7WT1	;	1.85	;	human glyoxalase I (with C-ter His tag) in inhibitor-free form
1QIN	;	2.0	;	HUMAN GLYOXALASE I COMPLEXED WITH S-(N-HYDROXY-N-P-IODOPHENYLCARBAMOYL) GLUTATHIONE
1QIP	;	1.72	;	HUMAN GLYOXALASE I COMPLEXED WITH S-P-NITROBENZYLOXYCARBONYLGLUTATHIONE
7WT2	;	2.0	;	human glyoxalase I in complex with TLSC702
1BH5	;	2.2	;	HUMAN GLYOXALASE I Q33E, E172Q DOUBLE MUTANT
3W0T	;	1.351	;	Human Glyoxalase I with an N-hydroxypyridone derivative inhibitor
3VW9	;	1.47	;	Human Glyoxalase I with an N-hydroxypyridone inhibitor
3W0U	;	1.7	;	human Glyoxalase I with an N-hydroxypyridone inhibitor
1FRO	;	2.2	;	HUMAN GLYOXALASE I WITH BENZYL-GLUTATHIONE INHIBITOR
1QH3	;	1.9	;	HUMAN GLYOXALASE II WITH CACODYLATE AND ACETATE IONS PRESENT IN THE ACTIVE SITE
1QH5	;	1.45	;	HUMAN GLYOXALASE II WITH S-(N-HYDROXY-N-BROMOPHENYLCARBAMOYL)GLUTATHIONE
1TJJ	;	2.0	;	Human GM2 Activator Protein PAF complex
1G13	;	2.0	;	HUMAN GM2 ACTIVATOR STRUCTURE
2VPI	;	2.4	;	Human GMP synthetase - glutaminase domain
2VXO	;	2.5	;	Human GMP synthetase in complex with XMP
8XBH	;	2.83	;	Human GPR34 -Gi complex bound to M1
8XBI	;	3.06	;	Human GPR34 -Gi complex bound to M1, receptor focused
6BW6	;	2.95	;	Human GPT (DPAGT1) H129 variant in complex with tunicamycin
6BW5	;	3.1	;	Human GPT (DPAGT1) in complex with tunicamycin
6HKQ	;	1.54	;	Human GPX4 in complex with covalent Inhibitor ML162 (S enantiomer)
6BQU	;	2.5	;	Human GR (418-507) in complex with monomeric DNA binding site
6BSF	;	2.4	;	Human GR (418-507) in complex with monomeric DNA binding site
2JYE	;		;	Human Granulin A
2JYT	;		;	Human Granulin C, isomer 1
2JYU	;		;	Human Granulin C, isomer 2
2JYV	;		;	Human Granulin F
2GMF	;	2.4	;	HUMAN GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR
1IAU	;	2.0	;	HUMAN GRANZYME B IN COMPLEX WITH AC-IEPD-CHO
3CIK	;	2.75	;	Human GRK2 in Complex with Gbetagamma subunits
5UKL	;	2.15	;	Human GRK2 in complex with Gbetagamma subunits and CCG222886 (14bd)
5WG5	;	3.1	;	Human GRK2 in complex with Gbetagamma subunits and CCG224061
5HE1	;	3.15	;	Human GRK2 in complex with Gbetagamma subunits and CCG224062
6C2Y	;	2.74	;	Human GRK2 in complex with Gbetagamma subunits and CCG257142
5WG4	;	2.31	;	Human GRK2 in complex with Gbetagamma subunits and CCG257284
6U7C	;	2.44	;	Human GRK2 in complex with Gbetagamma subunits and CCG258747
5WG3	;	2.896	;	Human GRK2 in complex with Gbetagamma subunits and CCG258748
3KRX	;	3.1	;	Human GRK2 in complex with Gbetgamma subunits and balanol (co-crystal)
3KRW	;	2.9	;	Human GRK2 in complex with Gbetgamma subunits and balanol (soak)
5UKK	;	2.6	;	Human GRK2 in complex with human G-beta-gamma subunits and CCG211998 (14ak)
5ZHG	;	1.799	;	Human group C rotavirus VP8*s recognize type A histo-blood group antigens as ligands
5ZHO	;	1.401	;	Human group C rotavirus VP8*s recognize type A histo-blood group antigens as ligands
1HGU	;	2.5	;	HUMAN GROWTH HORMONE
3HHR	;	2.8	;	HUMAN GROWTH HORMONE AND EXTRACELLULAR DOMAIN OF ITS RECEPTOR: CRYSTAL STRUCTURE OF THE COMPLEX
1A22	;	2.6	;	HUMAN GROWTH HORMONE BOUND TO SINGLE RECEPTOR
7ULL	;	2.31	;	Human Grp94 N-terminal domain in complex with 42C
3I6A	;	1.98	;	Human GST A1-1 GIMF mutant with Glutathione
1XWG	;	1.85	;	Human GST A1-1 T68E mutant
3IK9	;	2.2	;	Human GST A1-1-GIMF with GSDHN
5X79	;	1.9	;	Human GST Pi conjugated with novel inhibitor, GS-ESF
6PNM	;	1.82	;	Human GSTO1-1 complexed with 2-chloro-N-(4-chloro-3-(morpholinosulfonyl)phenyl)acetamide
6PNN	;	2.1	;	Human GSTO1-1 complexed with 2-chloro-N-(4-chloro-3-(N-(2-methoxyethyl)-N-methylsulfamoyl)phenyl)acetamide
6PNO	;	1.82	;	Human GSTO1-1 complexed with 2-chloro-N-(4-chloro-3-(N-isopropylsulfamoyl)phenyl)acetamide
5V3Q	;	2.25	;	Human GSTO1-1 complexed with ML175
6Z87	;	2.564	;	human GTP cyclohydrolase I
7ACC	;	2.04	;	human GTP cyclohydrolase I feedback regulatory protein (GFRP)
7AL9	;	1.745	;	human GTP cyclohydrolase I feedback regulatory protein (GFRP) in complex with phenylalanine
6Z86	;	2.206	;	human GTP cyclohydrolase I in complex with 7-deaza-GTP
6Z88	;	2.687	;	human GTP cyclohydrolase I in complex with allosteric inhibitor
6Z89	;	2.366	;	human GTP cyclohydrolase I in complex with allosteric inhibitor
3ORH	;	1.86	;	Human guanidinoacetate N-methyltransferase with SAH
2UZ9	;	2.3	;	Human guanine deaminase (guaD) in complex with zinc and its product Xanthine.
4AQL	;	1.99	;	HUMAN GUANINE DEAMINASE IN COMPLEX WITH VALACYCLOVIR
1F5N	;	1.7	;	HUMAN GUANYLATE BINDING PROTEIN-1 IN COMPLEX WITH THE GTP ANALOGUE, GMPPNP.
6NUI	;		;	Human Guanylate Kinase
7Q12	;	3.7	;	Human GYS1-GYG1 complex activated state bound to glucose-6-phosphate
7Q13	;	3.0	;	Human GYS1-GYG1 complex activated state bound to glucose-6-phosphate, uridine diphosphate, and glucose
7Q0B	;	3.0	;	Human GYS1-GYG1 complex inhibited state
7Q0S	;	4.0	;	Human GYS1-GYG1 complex inhibited-like state bound to glucose-6-phosphate
2FHA	;	1.9	;	HUMAN H CHAIN FERRITIN
6JPS	;	3.503	;	Human H chain ferritin mutant-MBP
6J4A	;	3.99	;	Human H chain ferritin with an extension peptide
6J7G	;	3.868	;	Human H-ferritin mutant-C90A/C102A/C130A/D144C
4BSD	;	2.4	;	Human H7N9 Influenza Virus Haemagglutinin (with Asn-133 Glycosylation) in Complex with Avian Receptor Analogue 3'-SLN
4BSC	;	2.55	;	Human H7N9 Influenza Virus Haemagglutinin (with Asn-133 Glycosylation) in Complex with Human Receptor Analogue 6'-SLN
4BSB	;	2.35	;	Human H7N9 Influenza Virus Haemagglutinin (with Asn-133 Glycosylation) in Complex with Human Receptor Analogue LSTc
4BSF	;	2.76	;	Human H7N9 Influenza Virus Haemagglutinin in Complex with Avian Receptor Analogue 3'-SLN
4BSE	;	2.55	;	Human H7N9 Influenza Virus Haemagglutinin in Complex with Human Receptor Analogue LSTc
4X0L	;	2.05	;	Human haptoglobin-haemoglobin complex
4HCK	;		;	HUMAN HCK SH3 DOMAIN, NMR, 25 STRUCTURES
5HCK	;		;	HUMAN HCK SH3 DOMAIN, NMR, MINIMIZED AVERAGE STRUCTURE
6UQF	;	3.04	;	Human HCN1 channel in a hyperpolarized conformation
6UQG	;	3.54	;	Human HCN1 channel Y289D mutant
5HTK	;	2.01	;	Human Heart 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase (PFKFB2)
1I0Z	;	2.1	;	HUMAN HEART L-LACTATE DEHYDROGENASE H CHAIN, TERNARY COMPLEX WITH NADH AND OXAMATE
5OCI	;	1.62	;	Human Heat Shock Protein 90 bound to 6-Hydroxy-3-(3-methyl-benzyl)-1H-indazole-5-carboxylic acid methyl-(4-morpholin-4-yl-phenyl)-amide
3HHU	;	1.59	;	Human heat-shock protein 90 (HSP90) in complex with {4-[3-(2,4-dihydroxy-5-isopropyl-phenyl)-5-thioxo- 1,5-dihydro-[1,2,4]triazol-4-yl]-benzyl}-carbamic acid ethyl ester {ZK 2819}
8AAV	;	2.0	;	Human heavy chain ferritin with introduced Cys residues modified with C10 ligand
4PGJ	;	2.6	;	Human heavy-chain domain antibody in complex with hen egg-white lysozyme
7MHZ	;	3.2	;	Human Hedgehog acyltransferase (HHAT) in complex with a palmitoylated Hedgehog peptide product and a Fab antibody fragment
7MHY	;	2.7	;	Human Hedgehog acyltransferase (HHAT) in complex with palmitoyl-CoA and two Fab antibody fragments
3VI5	;	2.0	;	Human hematopoietic prostaglandin D synthase inhibitor complex structures
3VI7	;	2.0	;	Human hematopoietic prostaglandin D synthase inhibitor complex structures
1T5P	;	2.11	;	Human Heme Oxygenase Oxidation of alpha- and gamma-meso-phenylhemes
1S13	;	2.29	;	Human Heme Oxygenase Oxidatition of alpha- and gamma-meso-Phenylhemes
3QJB	;	1.8	;	Human Hemoglobin A Mutant Alpha H58L Carbonmonoxy-Form
3QJD	;	1.56	;	Human Hemoglobin A Mutant Alpha H58L Deoxy-Form
3NMM	;	1.6	;	Human Hemoglobin A mutant alpha H58W deoxy-form
3QJC	;	2.001	;	Human Hemoglobin A Mutant Beta H63L Carbonmonoxy-Form
3QJE	;	1.8	;	Human Hemoglobin A Mutant Beta H63L Deoxy-Form
3NL7	;	1.8	;	Human Hemoglobin A mutant beta H63W carbonmonoxy-form
2YRS	;	2.3	;	Human hemoglobin D Los Angeles: crystal structure
5WOG	;	1.54	;	Human Hemoglobin immersed in Liquid Oxygen for 1 minute
5WOH	;	1.58	;	Human Hemoglobin Immersed in Liquid Oxygen for 20 seconds
7JJQ	;	2.15	;	Human Hemoglobin in Complex with Nitrosoamphetamine
8FDM	;	1.91	;	Human Hemoglobin in Complex with Nitrosomethane
4N8T	;	1.9	;	Human hemoglobin nitric oxide adduct
4M4B	;	2.0	;	Human Hemoglobin Nitroethane Modified
4M4A	;	2.05	;	Human Hemoglobin Nitromethane Modified
8FDN	;	2.2	;	Human Hemoglobin with N-tertbutylhydroxylamine
8FDL	;	1.75	;	Human Hemoglobin with Nitrosochloramphenicol
3D7O	;	1.8	;	Human hemoglobin, nitrogen dioxide anion modified
8CCY	;	2.7	;	Human heparan sulfate N-deacetylase-N-sulfotransferase 1 in complex with calcium and 3'-phosphoadenosine-5'-phosphosulfate
8CHS	;	3.15	;	Human heparan sulfate N-deacetylase-N-sulfotransferase 1 in complex with calcium, 3'-phosphoadenosine-5'-phosphosulfate and nanobody nAb13 (composite map and model).
8CD0	;	2.42	;	Human heparan sulfate N-deacetylase-N-sulfotransferase 1 in complex with calcium, 3'-phosphoadenosine-5'-phosphosulfate, and nanobody nAb7 (composite map and model)
7ZAY	;	2.8	;	Human heparan sulfate polymerase complex EXT1-EXT2
8CQI	;	2.1	;	Human heparanase in complex with inhibitor R3794
1AE5	;	2.3	;	HUMAN HEPARIN BINDING PROTEIN
1QGT	;	3.3	;	HUMAN HEPATITIS B VIRAL CAPSID (HBCAG)
2G34	;	5.053	;	Human hepatitis B virus T=4 capsid strain adyw complexed with assembly effector HAP1
2G33	;	3.96	;	Human Hepatitis B Virus T=4 capsid, strain adyw
3T2N	;	2.55	;	Human hepsin protease in complex with the Fab fragment of an inhibitory antibody
5WX8	;	2.5	;	Human herpesvirus 6A immediate early protein 2 C-terminal domain
5B1Q	;	1.85	;	Human herpesvirus 6B tegument protein U14
7B7N	;	2.69	;	Human herpesvirus-8 gH/gL in complex with EphA2
1QHA	;	2.25	;	HUMAN HEXOKINASE TYPE I COMPLEXED WITH ATP ANALOGUE AMP-PNP
5BSK	;	2.61	;	Human HGPRT in complex with (S)-HPEPG, an acyclic nucleoside phosphonate
5BRN	;	2.3	;	Human HGPRT in complex with (S)-HPEPHx, an acyclic nucleoside phosphonate
5W8V	;	2.346	;	HUMAN HGPRT in complex with [(2-[(guanin-9-yl)methyl]propane-1,3-diyl)bis(oxy)]bis(methylene)diphosphonic acid
1BZY	;	2.0	;	HUMAN HGPRTASE WITH TRANSITION STATE INHIBITOR
7URF	;	2.8	;	Human HHAT H379C in complex with SHH N-terminal peptide
1J87	;	3.2	;	HUMAN HIGH AFFINITY FC RECEPTOR FC(EPSILON)RI(ALPHA), HEXAGONAL CRYSTAL FORM 1
1J86	;	3.2	;	HUMAN HIGH AFFINITY FC RECEPTOR FC(EPSILON)RI(ALPHA), MONOCLINIC CRYSTAL FORM 2
1J88	;	3.2	;	HUMAN HIGH AFFINITY FC RECEPTOR FC(EPSILON)RI(ALPHA), TETRAGONAL CRYSTAL FORM 1
1J89	;	4.1	;	HUMAN HIGH AFFINITY FC RECEPTOR FC(EPSILON)RI(ALPHA), TETRAGONAL CRYSTAL FORM 2
8J77	;	3.7	;	Human high-affinity choline transporter CHT1 in the choline-bound inward-facing occluded conformation
8J74	;	3.6	;	Human high-affinity choline transporter CHT1 in the HC-3-bound outward-facing open conformation, dimeric state
8J75	;	3.6	;	Human high-affinity choline transporter CHT1 in the HC-3-bound outward-facing open conformation, monomeric state
8J76	;	3.7	;	Human high-affinity choline transporter CHT1 in the inward-facing apo-open conformation
4E1O	;	1.8	;	Human histidine decarboxylase complex with Histidine methyl ester (HME)
7EIX	;	1.9	;	Human histidine decarboxylase mutant Y334F
7EIW	;	2.1	;	Human histidine decarboxylase mutant Y334F reacted with histidine
7EIY	;	2.2	;	Human histidine decarboxylase mutant Y334F soaking with histidine
5KM0	;	1.533	;	Human Histidine Triad Nucleotide Binding Protein 1 (hHint) IMP complex
6B42	;	1.13	;	Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) 2'-deoxy-AMP complex at 1.13A resolution
5KLZ	;	1.5	;	Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) AMP catalytic product complex
5WAA	;	1.098	;	Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) C84R mutant
5KM2	;	1.25	;	Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) CMP catalytic product complex
5KM1	;	1.65	;	Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) GMP catalytic product complex
5IPB	;	1.55	;	Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) H112N mutant
5KLY	;	1.3	;	Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) H112N mutant adenosine nucleoside phosphoramidate substrate complex
5KM6	;	1.6	;	Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) H112N mutant Ara-A nucleoside phosphoramidate substrate complex
5WA9	;	1.15	;	Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) H112N mutant nucleoside D-Ala phosphoramidate substrate complex
5KMA	;	1.55	;	Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) H112N mutant nucleoside D-Trp phosphoramidate substrate complex
5WA8	;	1.3	;	Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) H112N mutant nucleoside L-Ala phosphoramidate substrate complex
5KMB	;	1.6	;	Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) H112N mutant nucleoside L-Trp phosphoramidate substrate complex
5IPC	;	1.3	;	Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) H112N mutant nucleoside thiophosphoramidate substrate complex
5KMC	;	1.35	;	Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) non-nucleotidic covalent intermediate complex
5IPE	;	1.45	;	Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) nucleoside thiophosphoramidate catalytic product complex
5IPD	;	1.75	;	Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) nucleoside thiophosphoramidate covalent intermediate complex
5KM3	;	1.2	;	Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) UMP catalytic product complex
5I2F	;	1.25	;	Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) with bound sulfamide inhibitor Bio-AMS
5KM4	;	1.4	;	Human Histidine Triad Nucleotide Binding Protein 1 (hHint1)-5-Iodo-UMP complex
5EMT	;	1.5	;	Human Histidine Triad Nucleotide Binding Protein 1 (hHint1)-copper complex
6N3Y	;	1.8	;	Human Histidine Triad Nucleotide Binding Protein 1 (Hint1) with Bound 5'-O-[(3-Indolyl)-1-Ethyl]Carbamoyl Guanosine
6N3X	;	1.1	;	Human Histidine Triad Nucleotide Binding Protein 1 (Hint1) with Bound 5'-O-[1-Benzyl]Carbamoyl Guanosine
6N3V	;	1.45	;	Human Histidine Triad Nucleotide Binding Protein 1 (Hint1) with Bound 5'-O-[1-Ethyl]Carbamoyl Guanosine
6N3W	;	1.75	;	Human Histidine Triad Nucleotide Binding Protein 1 (Hint1) with Bound 5'-O-[3-Phenyl-1-Ethyl]Carbamoyl Guanosine
5I2E	;	1.6	;	Human Histidine Triad Nucleotide Binding Protein 1 (Hint1) with Bound Sulfamate Inhibitor 3a:3-(5-O-{[3-(1H-indol-3-yl)propanoyl]sulfamoyl}-beta-D-ribofuranosyl)-3H-imidazo[2,1-i]purine
4INC	;	1.19	;	Human Histidine Triad Nucleotide Binding Protein 2
5KM9	;	1.45	;	Human Histidine Triad Nucleotide Binding Protein 2 (hHint2) adenosine complex
5KM8	;	2.0	;	Human Histidine Triad Nucleotide Binding Protein 2 (hHint2) Cidofovir complex
5KM5	;	2.1	;	Human Histidine Triad Nucleotide Binding Protein 2 (hHint2) triciribine 5'-monoposphate catalytic product complex
4INI	;	1.65	;	Human Histidine Triad Nucleotide Binding Protein 2 with Bound AMP
6YQM	;	1.02	;	Human histidine triad nucleotide-binding protein 1 (hHINT1) complexed with dGMP and refined to 1.02 A
6YVP	;	2.77	;	Human histidine triad nucleotide-binding protein 2 (hHINT2) complexed with dGMP and refined to 2.77 A
6YPR	;	1.26	;	Human histidine triad nucleotide-binding protein 2 (hHINT2) refined to 1.26 A in H32 space group
6YQD	;	1.407	;	Human histidine triad nucleotide-binding protein 2 (hHINT2) refined to 1.41 A in P212121 space group
6YI0	;	1.65	;	Human histidine triad nucleotide-binding protein 2 (hHINT2) refined to 1.65 A in P41212 space group
6YPX	;	2.11	;	Human histidine triad nucleotide-binding protein 2 (hHINT2) refined to 2.11 A in C2221 space group
4X5O	;	2.8	;	Human histidine tRNA synthetase
2P0W	;	1.9	;	Human histone acetyltransferase 1 (HAT1)
3UTQ	;	1.67	;	Human HLA-A*0201-ALWGPDPAAA
2FYT	;	2.0	;	Human HMT1 hnRNP methyltransferase-like 3 (S. cerevisiae) protein
4HC4	;	1.97	;	Human HMT1 hnRNP methyltransferase-like protein 6 (S. cerevisiae)
5E8R	;	2.55	;	Human HMT1 hnRNP methyltransferase-like protein 6 (S. cerevisiae)
5HZM	;	2.02	;	Human HMT1 hnRNP methyltransferase-like protein 6 (S. cerevisiae)
5WCF	;	1.98	;	Human HMT1 hnRNP methyltransferase-like protein 6 (S. cerevisiae)
4QQK	;	1.88	;	Human HMT1 hnRNP methyltransferase-like protein 6 (S. cerevisiae) with GMS
8ORA	;	2.4	;	Human holo aromatic L-amino acid decarboxylase (AADC) external aldimine with L-Dopa methylester
8OR9	;	1.9	;	Human holo aromatic L-amino acid decarboxylase (AADC) native structure at physiological pH
5IY6	;	7.2	;	Human holo-PIC in the closed state
6O9L	;	7.2	;	Human holo-PIC in the closed state
5IY8	;	7.9	;	Human holo-PIC in the initial transcribing state
5IY9	;	6.3	;	Human holo-PIC in the initial transcribing state (no IIS)
5IY7	;	8.6	;	Human holo-PIC in the open state
1EY2	;	2.3	;	HUMAN HOMOGENTISATE DIOXYGENASE WITH FE(II)
6TX2	;	2.09	;	Human HPF1
5D8L	;	2.069	;	Human HSF2 DNA Binding Domain in complex with 3-site HSE DNA at 2.1 Angstroms Resolution
5D8K	;	1.728	;	Human HSF2 DNA-Binding Domain bound to 2-site HSE DNA at 1.73 Angstroms Resolution
6GJH	;	2.1	;	Human Hsp27 (HspB1) alpha-crystallin domain in complex with a peptide mimic of its phosphorylatable N-terminal region
4MJH	;	2.599	;	Human Hsp27 core domain in complex with C-terminal peptide
1HDJ	;		;	HUMAN HSP40 (HDJ-1), NMR
2QLD	;	2.7	;	human Hsp40 Hdj1
8B7J	;		;	Human HSP90 alpha ATP Binding Domain, ATP-lid closed conformation, R46A
8B7I	;		;	Human HSP90 alpha ATP Binding Domain, ATP-lid open conformation, R60A
4CWF	;	2.0	;	Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor
4CWN	;	1.8	;	Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor
4CWO	;	2.31	;	Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor
4CWP	;	1.95	;	Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor
4CWQ	;	2.0	;	Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor
4CWR	;	2.0	;	Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor
4CWS	;	2.3	;	Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor
4CWT	;	1.9	;	Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor
6HFO	;	1.65	;	Human Hsp90 co-chaperone TTC4 C-domain
1YER	;	1.65	;	HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, ""CLOSED"" CONFORMATION
1YES	;	2.2	;	HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, ""OPEN"" CONFORMATION
1OSF	;	1.75	;	Human Hsp90 in complex with 17-desmethoxy-17-N,N-Dimethylaminoethylamino-Geldanamycin
2CCU	;	2.7	;	HUMAN HSP90 WITH 4-CHLORO-6-(4-(4-(4-METHANESULPHONYL-BENZYL)- PIERAZIN-1-YL)-1H-PYRAZOL-3-YL)-BENZENE-1,3-DIOL
2CCS	;	1.79	;	HUMAN HSP90 WITH 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-3-YL)- BENZENE-1,2-DIOL
2CCT	;	2.3	;	HUMAN HSP90 WITH 5-(5-CHLORO-2,4-DIHYDROXY-PHENYL)-4-PIPERAZIN-1-YL- 2H-PYRAZOLE-3-CARBOXYLIC ACID ETHYLAMIDE
4EGK	;	1.69	;	Human Hsp90-alpha ATPase domain bound to Radicicol
1UYI	;	2.2	;	Human Hsp90-alpha with 8-(2,5-dimethoxy-benzyl)-2-fluoro-9-pent-9H-purin-6-ylamine
1UYG	;	2.0	;	Human Hsp90-alpha with 8-(2,5-dimethoxy-benzyl)-2-fluoro-9H-purin-6-ylamine
1UYF	;	2.0	;	Human Hsp90-alpha with 8-(2-chloro-3,4,5-trimethoxy-benzyl)-2-fluoro-9-pent-4-ylnyl-9H-purin-6-ylamine
1UYE	;	2.0	;	Human Hsp90-alpha with 8-(2-chloro-3,4,5-trimethoxy-benzyl)-9-pent-4-ylnyl-9H-purin-6-ylamine
1UYK	;	2.2	;	Human Hsp90-alpha with 8-Benzo[1,3]dioxol-,5-ylmethyl-9-butyl-2-fluoro-9H-purin-6-ylamine
1UY9	;	2.0	;	Human Hsp90-alpha with 8-Benzo[1,3]dioxol-,5-ylmethyl-9-butyl-9H-purin-6-ylamine
1UYH	;	2.2	;	Human Hsp90-alpha with 9-Butyl-8-(2,5-dimethoxy-benzyl)-2-fluoro-9H-purin-6-ylamine
1UYC	;	2.0	;	Human Hsp90-alpha with 9-Butyl-8-(2,5-dimethoxy-benzyl)-9H-purin-6-ylamine
1UYD	;	2.2	;	Human Hsp90-alpha with 9-Butyl-8-(2-chloro-3,4,5-trimethoxy-benzyl)-9H-purin-6-ylamine
1UY6	;	1.9	;	Human Hsp90-alpha with 9-Butyl-8-(3,4,5-trimethoxy-benzyl)-9H-purin-6-ylamine
1UY8	;	1.98	;	Human Hsp90-alpha with 9-Butyl-8-(3-trimethoxy-benzyl)-9H-purin-6ylamine
1UY7	;	1.9	;	Human Hsp90-alpha with 9-Butyl-8-(4-methoxy-benzyl)-9H-purin-6-ylamine
1UYM	;	2.45	;	Human Hsp90-beta with PU3 (9-Butyl-8(3,4,5-trimethoxy-benzyl)-9H-purin-6-ylamine)
7RXZ	;	3.152	;	human Hsp90_MC domain structure
7RY0	;	2.2	;	human Hsp90_MC domain structure
7RY1	;	3.523	;	human Hsp90_MC domain structure
6EZ8	;	4.0	;	Human Huntingtin-HAP40 complex structure
3GEP	;	2.6	;	Human hypoxanthine guanine phosphoribosyltranserfase in complex with (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)guanine
6BNJ	;	1.909	;	Human hypoxanthine guanine phosphoribosyltransferase in complex with [3R,4R]-4-guanin-9-yl-3-((R)-2-hydroxy-2-phosphonoethyl)oxy-1-N-(phosphonopropionyl)pyrrolidine
3GGJ	;	2.6	;	Human hypoxanthine-guanine phosphoribosyltransferase in complex with 9-(2-phosphonoethoxyethyl)guanine
3GGC	;	2.78	;	Human hypoxanthine-guanine phosphoribosyltransferase in complex with 9-(2-phosphonoethoxyethyl)hypoxanthine
4IJQ	;	2.004	;	Human hypoxanthine-guanine phosphoribosyltransferase in complex with [(2-((Guanine-9H-yl)methyl)propane-1,3-diyl)bis(oxy)]bis(methylene))diphosphonic acid
5HIA	;	1.773	;	Human hypoxanthine-guanine phosphoribosyltransferase in complex with [3R,4R]-4-guanin-9-yl-3-((S)-2-hydroxy-2-phosphonoethyl)oxy-1-N-(phosphonopropionyl)pyrrolidine
3E4A	;	2.6	;	Human IDE-inhibitor complex at 2.6 angstrom resolution
6IO0	;	2.2	;	Human IDH1 R132C mutant complexed with compound A.
6PU7	;	2.43	;	Human IDO1 in complex with compound 17 (N-{2-[(4-{N-[(7S)-4-fluorobicyclo[4.2.0]octa-1,3,5-trien-7-yl]-N'-hydroxycarbamimidoyl}-1,2,5-oxadiazol-3-yl)sulfanyl]ethyl}acetamide)
6WPE	;	2.43	;	HUMAN IDO1 IN COMPLEX WITH COMPOUND 4
6WJY	;	1.91	;	HUMAN IDO1 IN COMPLEX WITH COMPOUND 4-A
4MJ4	;	2.172	;	Human iduronidase apo structure P21 form
5W5H	;	2.79	;	Human IFIT1 dimer with m7Gppp-AAAA
5W5I	;	2.65	;	Human IFIT1 dimer with PPP-AAAA
3SE3	;	4.0001	;	human IFNa2-IFNAR ternary complex
3S98	;	1.9	;	human IFNAR1
3SE4	;	3.5001	;	human IFNw-IFNAR ternary complex
8FGW	;	3.7	;	Human IFT-A complex structures provide molecular insights into ciliary transport
8FH3	;	4.3	;	Human IFT-A complex structures provide molecular insights into ciliary transport
3M8O	;	1.55	;	Human IgA1 Fab fragment
8Q6K	;	2.1	;	Human IgD Fab in complex with an orthosteric inhibitor of Phl p 7
4BUH	;	1.3	;	Human IgE against the major allergen Bet v 1 - Crystal structure of clone M0418 scFv
5MOL	;	1.75	;	Human IgE-Fc crystal structure
4D2R	;	2.1	;	Human IGF in complex with a Dyrk1B inhibitor
8PYK	;	2.23	;	Human IGF1R with inhibitor 47
8PYL	;	2.93	;	Human IGF1R with inhibitor 53
8PYM	;	2.652	;	Human IGF1R with inhibitor 54
8PYN	;	1.71	;	Human IGF1R with inhibitor 56
8PYI	;	3.06	;	Human IGF1R with inhibitor 6
8PYJ	;	2.702	;	Human IGF1R with inhibitor 8
1GP0	;	1.4	;	Human IGF2R domain 11
1GP3	;	1.95	;	Human IGF2R domain 11
4DZ8	;	1.91	;	human IgG1 Fc fragment Heterodimer
6P6D	;	2.31	;	HUMAN IGG1 FC FRAGMENT, C239 INSERTION MUTANT
7RHO	;	2.0	;	Human IgG1 Fc fragment, hinge-free, expressed in E. coli
6BZ4	;	2.4	;	Human IgG1 lacking complement-dependent cytotoxicity: hu3S193 Fc mutant K322A
4KIK	;	2.83	;	Human IkB kinase beta
1J7V	;	2.9	;	HUMAN IL-10 / IL-10R1 COMPLEX
8RYS	;	1.16	;	Human IL-1beta, unliganded
5UTZ	;	2.747	;	Human IL-2/Fab complex
7ZXK	;	2.2	;	Human IL-27 in complex with neutralizing SRF388 FAb fragment
1O1V	;		;	Human Ileal Lipid-Binding Protein (ILBP) in Complex with Cholyltaurine
1O1U	;		;	human ileal lipid-binding protein (ILBP) in free form
1DLO	;	2.7	;	HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
1HPZ	;	3.0	;	HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
1HQE	;	2.7	;	HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
1HQU	;	2.7	;	HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
2HMX	;		;	HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 MATRIX PROTEIN
1HVU	;	4.75	;	HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REVERSE TRANSCRIPTASE COMPLEXED WITH A 33-BASE NUCLEOTIDE RNA PSEUDOKNOT
3UPJ	;	2.5	;	HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 PROTEASE MUTANT WITH LYS 57 REPLACED BY LEU (K57L) COMPLEX WITH U096333 [4-HYDROXY-3-[1-(PHENYL)PROPYL]-7-METHOXYCOUMARIN]
4UPJ	;	1.9	;	HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 PROTEASE MUTANT WITH LYS 57 REPLACED BY LEU (K57L) COMPLEX WITH U097410 [4-HYDROXY-3-[1-[3-[[[[(TERT-BUTYLOXYCARBONYL) AMINOMETHYL]CARBONYL]AMINO]PHENYL]PROPYL]COUMARIN
1TAM	;		;	HUMAN IMMUNODEFICIENCY VIRUS, NMR, MINIMIZED AVERAGE STRUCTURE
1GTC	;		;	HUMAN IMMUNODEFICIENCY VIRUS-1 OKAZAKI FRAGMENT, DNA-RNA CHIMERA, NMR, 11 STRUCTURES
6E5B	;	2.77	;	Human Immunoproteasome 20S particle in complex with compound 1
7AWE	;	2.288	;	HUMAN IMMUNOPROTEASOME 20S PARTICLE IN COMPLEX WITH [(1R)-2-(1-benzofuran-3-yl)-1-{[(1S,2R,4R)-7-oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid
7B12	;	2.43	;	HUMAN IMMUNOPROTEASOME 20S PARTICLE IN COMPLEX WITH [2-(3-ethylphenyl)-1-[(2S)-3-phenyl-2-[(pyrazin-2-yl)formamido]propanamido]ethyl]boronic acid
6GIU	;	1.39	;	Human IMPase with L-690330
6GJ0	;	1.73	;	Human IMPase with Mn
7RER	;	2.6	;	HUMAN IMPDH1 TREATED WITH ATP, IMP, AND NAD+
7RES	;	3.05	;	HUMAN IMPDH1 TREATED WITH ATP, IMP, AND NAD+, OCTAMER-CENTERED
7RFG	;	2.6	;	HUMAN IMPDH1 TREATED WITH GTP, IMP, AND NAD+ OCTAMER-CENTERED
7RFE	;	2.6	;	HUMAN IMPDH1 TREATED WITH GTP, IMP, AND NAD+; INTERFACE-CENTERED
8G8F	;	2.6	;	Human IMPDH2 mutant - L245P, treated with ATP, IMP, and NAD+; extended filament segment reconstruction
8FOZ	;	2.0	;	Human IMPDH2 mutant - L245P, treated with ATP, IMP, and NAD+; filament assembly interface reconstruction
8G9B	;	3.0	;	Human IMPDH2 mutant - L245P, treated with GTP, ATP, IMP, and NAD+; compressed filament segment reconstruction
8FUZ	;	2.1	;	Human IMPDH2 mutant - L245P, treated with GTP, ATP, IMP, and NAD+; filament assembly interface reconstruction
6UC2	;	4.48	;	Human IMPDH2 treated with ATP and 2 mM GTP. Free canonical octamer reconstruction.
6UDP	;	2.95	;	Human IMPDH2 treated with ATP, IMP, and 20 mM GTP. Filament assembly interface reconstruction.
6UDQ	;	3.27	;	Human IMPDH2 treated with ATP, IMP, and 20 mM GTP. Fully compressed filament end reconstruction.
6UDO	;	3.21	;	Human IMPDH2 treated with ATP, IMP, and 20 mM GTP. Fully compressed filament segment reconstruction.
6U8R	;	3.91	;	Human IMPDH2 treated with ATP, IMP, and NAD+. Bent (1/4 compressed, 3/4 extended) segment reconstruction.
6U8E	;	3.03	;	Human IMPDH2 treated with ATP, IMP, and NAD+. Filament assembly interface reconstruction.
6U8N	;	3.29	;	Human IMPDH2 treated with ATP, IMP, and NAD+. Fully extended filament segment reconstruction.
6UA2	;	4.2	;	Human IMPDH2 treated with ATP, IMP, NAD+, and 2 mM GTP. Bent (2/4 compressed, 2/4 extended) segment reconstruction.
6UA4	;	3.65	;	Human IMPDH2 treated with ATP, IMP, NAD+, and 2 mM GTP. Bent (3/4 compressed, 1/4 extended) segment reconstruction.
6U8S	;	3.14	;	Human IMPDH2 treated with ATP, IMP, NAD+, and 2 mM GTP. Filament assembly interface reconstruction.
6UAJ	;	3.84	;	Human IMPDH2 treated with ATP, IMP, NAD+, and 2 mM GTP. Free canonical octamer reconstruction.
6UA5	;	3.79	;	Human IMPDH2 treated with ATP, IMP, NAD+, and 2 mM GTP. Free interfacial octamer reconstruction.
6U9O	;	3.36	;	Human IMPDH2 treated with ATP, IMP, NAD+, and 2 mM GTP. Fully compressed filament segment reconstruction.
7N8J	;	3.2	;	Human importin alpha 1 in complex with Bimax2 peptide
8FZM	;	3.0	;	Human importin alpha 3 in complex with Bimax2 peptide
4NOS	;	2.25	;	HUMAN INDUCIBLE NITRIC OXIDE SYNTHASE WITH INHIBITOR
1NSI	;	2.55	;	HUMAN INDUCIBLE NITRIC OXIDE SYNTHASE, ZN-BOUND, L-ARG COMPLEX
2NSI	;	3.0	;	HUMAN INDUCIBLE NITRIC OXIDE SYNTHASE, ZN-FREE, SEITU COMPLEX
6T0W	;	3.18	;	Human Influenza B polymerase recycling complex
3HR4	;	2.5	;	Human iNOS Reductase and Calmodulin Complex
1W2C	;	1.95	;	Human Inositol (1,4,5) trisphosphate 3-kinase complexed with Mn2+/AMPPNP/Ins(1,4,5)P3
1W2D	;	1.94	;	Human Inositol (1,4,5)-trisphosphate 3-kinase complexed with Mn2+/ADP/Ins(1,3,4,5)P4
1W2F	;	1.8	;	Human Inositol (1,4,5)-trisphosphate 3-kinase substituted with selenomethionine
8PPH	;	1.7	;	Human inositol 1,4,5-trisphosphate 3-kinase A (IP3K) catalytic domain in complex with alpha-D-glucopyranosyl 1,3,4-trisphosphate/ATP/Mn
8PPG	;	1.75	;	Human inositol 1,4,5-trisphosphate 3-kinase A (IP3K) catalytic domain in complex with beta-D-glucopyranosyl 1,3,4,6-tetrakisphosphate/ADP/Mn after reaction
8PPF	;	1.85	;	Human inositol 1,4,5-trisphosphate 3-kinase A (IP3K) catalytic domain in complex with beta-D-glucopyranosyl 1,3,4-trisphosphate/AMP-PNP/Mg
8PPI	;	1.65	;	Human inositol 1,4,5-trisphosphate 3-kinase A (IP3K) catalytic domain in complex with beta-D-glucopyranosylmethanol 3,4,1'-trisphosphate/ATP/Mn
8PPJ	;	1.75	;	Human inositol 1,4,5-trisphosphate 3-kinase A (IP3K) catalytic domain in complex with beta-D-glucopyranosylmethanol 3,4,6,1'-tetrakisphosphate/ADP/Mn after reaction
8PPB	;	1.8	;	Human inositol 1,4,5-trisphosphate 3-kinase A (IP3K) catalytic domain in complex with D-3-deoxy-myo-inositol 1,4,6-trisphosphate/ATP/Mn
8PPA	;	1.73	;	Human inositol 1,4,5-trisphosphate 3-kinase A (IP3K) catalytic domain in complex with D-myo-inositol 1,4,6-trisphosphate/AMP-PNP/Mn
8PPD	;	1.77	;	Human inositol 1,4,5-trisphosphate 3-kinase A (IP3K) catalytic domain in complex with DL-6-deoxy-6-hydroxy-methyl-scyllo-inositol 1,2,4-trisphosphate/ATP/Mn
8PPE	;	1.59	;	Human inositol 1,4,5-trisphosphate 3-kinase A (IP3K) catalytic domain in complex with DL-6-deoxy-6-phosphoryloxymethyl-scyllo-inositol 1,2,4-trisphosphate/ADP/Mn
8PPC	;	1.92	;	Human inositol 1,4,5-trisphosphate 3-kinase A (IP3K) catalytic domain in complex with L-chiro-inositol 2,3,5-trisphosphate/ATP/Mn
8PP8	;	1.59	;	Human inositol 1,4,5-trisphosphate 3-kinase A (IP3K) catalytic domain in complex with L-scyllo-inositol 1,2,4-trisphosphate/AMP-PNP/Mn
8PP9	;	1.73	;	Human inositol 1,4,5-trisphosphate 3-kinase A (IP3K) catalytic domain in complex with scyllo-inositol 1,2,3,5-tetrakisphosphate/ADP/Mn
2FVZ	;	2.4	;	Human Inositol Monophosphosphatase 2
3I3Z	;	1.6	;	Human insulin
3I40	;	1.85	;	Human insulin
4EWW	;	2.3	;	Human Insulin
4EWX	;	2.201	;	Human Insulin
4EWZ	;	1.791	;	Human Insulin
4EX0	;	1.86	;	Human Insulin
4EX1	;	1.657	;	Human Insulin
4EXX	;	1.55	;	Human Insulin
4EY1	;	1.471	;	Human Insulin
4EY9	;	1.471	;	Human Insulin
4EYD	;	1.471	;	Human Insulin
4EYN	;	1.532	;	Human Insulin
4EYP	;	1.591	;	Human Insulin
4F0N	;	1.679	;	Human Insulin
4F0O	;	1.672	;	Human Insulin
4F1A	;	1.8	;	Human Insulin
4F1B	;	1.591	;	Human Insulin
4F1C	;	1.7	;	Human Insulin
4F1D	;	1.637	;	Human Insulin
4F1F	;	1.684	;	Human Insulin
4F1G	;	1.637	;	Human insulin
4F4T	;	1.637	;	Human Insulin
4F4V	;	1.637	;	Human Insulin
4F51	;	1.637	;	Human Insulin
4F8F	;	1.676	;	Human Insulin
6VET	;	1.46	;	Human insulin analog: [GluB10,HisA8,ArgA9,TyrB20]-DOI
6VES	;	1.85	;	Human insulin analog: [GluB10,HisA8,ArgA9]-DOI
6VER	;	1.047	;	Human insulin analog: [GluB10,TyrB20]-DOI
4CXL	;	1.5	;	Human insulin analogue (D-ProB8)-insulin
4UNG	;	1.81	;	Human insulin B26Asn mutant crystal structure
4UNH	;	2.75	;	Human insulin B26Gly mutant crystal structure
4UNE	;	1.59	;	Human insulin B26Phe mutant crystal structure
2YPU	;	2.8	;	human insulin degrading enzyme E111Q in complex with inhibitor compound 41367
1XGL	;		;	HUMAN INSULIN DISULFIDE ISOMER, NMR, 10 STRUCTURES
1QJ0	;	2.4	;	HUMAN INSULIN HEXAMERS WITH CHAIN B HIS MUTATED TO TYR
1QIY	;	2.3	;	HUMAN INSULIN HEXAMERS WITH CHAIN B HIS MUTATED TO TYR COMPLEXED WITH PHENOL
1QIZ	;	2.0	;	HUMAN INSULIN HEXAMERS WITH CHAIN B HIS MUTATED TO TYR COMPLEXED WITH RESORCINOL
3Q6E	;	2.05	;	Human insulin in complex with cucurbit[7]uril
5MAM	;	2.2	;	Human insulin in complex with serotonin
5MT3	;	2.02	;	Human insulin in complex with serotonin and arginine
5MT9	;	1.88	;	Human insulin in complex with serotonin and arginine
6Z7W	;	2.42	;	Human insulin in complex with the analytical antibody HUI-018 Fab
6Z7Y	;	2.2	;	Human insulin in complex with the analytical antibody OXI-005 Fab
8ONI	;	2.3	;	Human insulin in complex with the analytical antibody S1 Fab
8ONK	;	3.403	;	Human insulin in complex with the analytical antibody S1 Fab and the analytical antibody HUI-001 Fab
6VEP	;	2.9	;	Human insulin in complex with the human insulin microreceptor in turn in complex with Fv 83-7
2KXK	;		;	Human Insulin Mutant A22Gly-B31Lys-B32Arg
1B9E	;	2.5	;	HUMAN INSULIN MUTANT SERB9GLU
7YQ3	;	3.6	;	human insulin receptor bound with A43 DNA aptamer and insulin
7YQ6	;	4.18	;	human insulin receptor bound with A62 DNA aptamer
7YQ5	;	4.27	;	human insulin receptor bound with A62 DNA aptamer and insulin
7YQ4	;	3.95	;	human insulin receptor bound with A62 DNA aptamer and insulin - locally refined
8GUY	;	4.18	;	human insulin receptor bound with two insulin molecules
5J3H	;	3.27	;	Human insulin receptor domains L1-CR in complex with peptide S519C16 and 83-7 Fv
6SOF	;	4.3	;	human insulin receptor ectodomain bound by 4 insulin
8ONP	;	1.77	;	Human insulin trans-HypB26-DTIA analogue
1VKT	;		;	HUMAN INSULIN TWO DISULFIDE MODEL, NMR, 10 STRUCTURES
5BOQ	;	1.7	;	Human insulin with intra-chain chemical crosslink between modified B24 and B29
5BPO	;	1.9	;	Human insulin with intra-chain chemical crosslink between modified B27 and B29
5BQQ	;	1.54	;	Human insulin with intra-chain chemical crosslink between modified B27 and B30
1GZR	;	2.0	;	Human Insulin-like growth factor; ESRF data
1GZZ	;	2.3	;	Human Insulin-like growth factor; Hamburg data
1GZY	;	2.54	;	Human Insulin-like growth factor; In-house data
1H02	;	2.0	;	Human Insulin-like growth factor; SRS Daresbury data
1AU1	;	2.2	;	HUMAN INTERFERON-BETA CRYSTAL STRUCTURE
4HR9	;	2.48	;	Human interleukin 17A
1JLI	;		;	HUMAN INTERLEUKIN 3 (IL-3) MUTANT WITH TRUNCATION AT BOTH N-AND C-TERMINI AND 14 RESIDUE CHANGES, NMR, MINIMIZED AVERAGE STRUCTURE
1ITL	;		;	HUMAN INTERLEUKIN 4: THE SOLUTION STRUCTURE OF A FOUR-HELIX-BUNDLE PROTEIN
9ILB	;	2.28	;	HUMAN INTERLEUKIN-1 BETA
1F45	;	2.8	;	HUMAN INTERLEUKIN-12
8CR8	;	2.0	;	human Interleukin-23
8A4F	;		;	Human Interleukin-4 mutant - C3T-IL4
1ALU	;	1.9	;	HUMAN INTERLEUKIN-6
2IL6	;		;	HUMAN INTERLEUKIN-6, NMR, 32 STRUCTURES
1IL6	;		;	HUMAN INTERLEUKIN-6, NMR, MINIMIZED AVERAGE STRUCTURE
1WLJ	;	1.9	;	human ISG20
5KO0	;	1.4	;	Human Islet Amyloid Polypeptide Segment 15-FLVHSSNNFGA-25 Determined by MicroED
5KNZ	;	1.9	;	Human Islet Amyloid Polypeptide Segment 19-SGNNFGAILSS-29 with Early Onset S20G Mutation Determined by MicroED
5YFN	;	2.5	;	Human isocitrate dehydrogenase 1 bound with isocitrate
5YFM	;	2.4	;	Human isocitrate dehydrogenase 1 bound with NADP
2ICK	;	1.93	;	Human isopentenyl diphophate isomerase complexed with substrate analog
2VJ2	;	2.5	;	Human Jagged-1, domains DSL and EGFs1-3
2KB9	;		;	Human Jagged-1, exon 6
5MW5	;	2.7	;	Human Jagged2 C2-EGF2
5MWF	;	2.8	;	Human Jagged2 C2-EGF2
5MW7	;	2.8	;	Human Jagged2 C2-EGF3
6WVD	;	2.25	;	Human JAGN1
6HZU	;	2.2	;	HUMAN JAK1 IN COMPLEX WITH LASW1393
6ELR	;	1.8	;	Human jak1 kinase domain in complex with compound 7
6GGH	;	1.7	;	Human jak1 kinase domain in complex with inhibitor
6SM8	;	1.85	;	Human jak1 kinase domain in complex with inhibitor
6SMB	;	2.04	;	Human jak1 kinase domain in complex with inhibitor
5E1E	;	2.3	;	Human JAK1 kinase in complex with compound 30 at 2.30 Angstroms resolution
6WTO	;	1.74	;	Human JAK2 JH1 domain in complex with Baricitinib
6WTP	;	2.5	;	Human JAK2 JH1 domain in complex with PROTAC-intermediate linker handle 3
6WTQ	;	1.79968	;	Human JAK2 JH1 domain in complex with PROTAC-intermediate linker handle 4
6WTN	;	1.83	;	Human JAK2 JH1 domain in complex with Ruxolitinib
6HZV	;	2.46	;	HUMAN JAK3 IN COMPLEX WITH LASW959 PROTEIN IN COMPLEX WITH LIGAND
7Q6H	;	1.749	;	HUMAN JAK3 KINASE DOMAIN WITH 1-(4-((2-((1-methyl-1H-pyrazol-4-yl)amino)quinazolin-8-yl)amino)piperidin-1-yl)ethan-1-one
2MKD	;		;	Human JAZ ZF3 Residues 168-227
6F4S	;	1.461	;	Human JMJD5 (N308C) in complex with Mn(II), 2OG and RCCD1 (139-143) (complex-4)
6F4R	;	1.3	;	Human JMJD5 (N308C) in complex with Mn(II), NOG and RCCD1 (139-143) (complex-3)
6F4Q	;	1.12	;	Human JMJD5 (Q275C) in complex with Mn(II), NOG and RPS6-A138C (129-144) (complex-2)
6F4T	;	1.22	;	Human JMJD5 (W414C) in complex with Mn(II), NOG and RCCD1 (139-143) (complex-5)
6F4N	;	2.541	;	Human JMJD5 in complex with MN and 2OG.
7DYX	;	2.27	;	Human JMJD5 in complex with MN and 5-((2-cyclopropylbenzyl)amino)pyridine-2,4-dicarboxylic acid.
7DYW	;	2.13	;	Human JMJD5 in complex with MN and 5-((2-methoxybenzyl)amino)pyridine-2,4-dicarboxylic acid.
7DYT	;	1.62	;	Human JMJD5 in complex with MN and 5-((4-methoxybenzyl)amino)pyridine-2,4-dicarboxylic acid.
7DYU	;	1.72	;	Human JMJD5 in complex with MN and 5-((4-phenylbutyl)amino)pyridine-2,4-dicarboxylic acid.
7DYV	;	1.92	;	Human JMJD5 in complex with MN and 5-(benzylamino)pyridine-2,4-dicarboxylic acid.
6F4O	;	1.28	;	Human JMJD5 in complex with Mn(II) and Succinate.
6F4P	;	1.45	;	Human JMJD5 in complex with MN, NOG and RPS6 (129-144) (complex-1)
6F4M	;	1.705	;	Human JMJD5 in its apo form.
5NFO	;	2.173	;	Human JMJD7 in complex with Mn and 2OG in the P21212 form
4AWI	;	1.91	;	Human Jnk1alpha kinase with 4-phenyl-7-azaindole IKK2 inhibitor.
8ELC	;	2.072	;	Human JNK2 bound to covalent inhibitor YL2056
6PGV	;	2.3	;	Human Josephin-2 in complex with ubiquitin
3GFT	;	2.27	;	Human K-Ras (Q61H) in complex with a GTP analogue
8JJS	;	1.534	;	Human K-Ras G12D (GDP-bound) in complex with cyclic peptide inhibitor AP10343
7YUZ	;	1.878	;	Human K-Ras G12D (GDP-bound) in complex with cyclic peptide inhibitor AP8784
7YV1	;	1.454	;	Human K-Ras G12D (GDP-bound) in complex with cyclic peptide inhibitor LUNA18 and KA30L Fab
4RUF	;	3.4	;	Human K2P4.1 (TRAAAK) potassium channel, W262S mutant
4RUE	;	3.3	;	Human K2P4.1 (TRAAK) potassium channel, G124I mutant
2BDI	;	3.0	;	Human Kallikrein 4 complex with cobalt and p-aminobenzamidine
2BDG	;	1.95	;	Human Kallikrein 4 complex with nickel and p-aminobenzamidine
2BDH	;	3.0	;	Human Kallikrein 4 complex with zinc and p-aminobenzamidine
1L2E	;	1.75	;	Human Kallikrein 6 (hK6) Active Form with benzamidine inhibitor
1LO6	;	1.56	;	Human Kallikrein 6 (hK6) active form with benzamidine inhibitor at 1.56 A resolution
4D8N	;	1.68	;	Human Kallikrein 6 Inhibitors with a para-Amidobenzylanmine P1 Group Carry a High Binding Efficiency
5Y9L	;	2.15	;	Human kallikrein 7 in complex with 1,3,6-trisubstituted 1,4-diazepane-7-one
5YJK	;	2.4	;	Human kallikrein 7 in complex with 1,4-diazepane-7-one 1-acetamide derivative
6SHH	;	2.0	;	Human kallikrein 7 with aromatic coumarinic ester compound 1 covalently bound to H57
6SHI	;	1.85	;	Human kallikrein 7 with aromatic coumarinic ester compound 2 covalently bound to H57
6SJU	;	1.97	;	Human kallikrein 7 with aromatic coumarinic ester compound 3 covalently bound to H57
4NFE	;	1.9	;	Human kallikrein-related peptidase 2 in complex with benzamidine
4NFF	;	1.9	;	Human kallikrein-related peptidase 2 in complex with PPACK
6Y4S	;	2.23	;	Human kallikrein-related peptidase 7 (KLK7) in the unliganded state
6XTE	;	2.27	;	Human karyopherin RanBP5 (isoform-1)
6XU2	;	2.834	;	Human karyopherin RanBP5 (isoform-3)
7S5T	;	3.1	;	Human KATP channel in open conformation, focused on Kir (C166S G334D double mutant) and SUR TMD0
7S5X	;	3.7	;	Human KATP channel in open conformation, focused on Kir and one SUR, position 1
7S5Y	;	3.9	;	Human KATP channel in open conformation, focused on Kir and one SUR, position 2
7S5Z	;	3.9	;	Human KATP channel in open conformation, focused on Kir and one SUR, position 3
7S60	;	3.7	;	Human KATP channel in open conformation, focused on Kir and one SUR, position 4
7S61	;	4.0	;	Human KATP channel in open conformation, focused on Kir and one SUR, position 5
7S5V	;	3.3	;	Human KATP channel in open conformation, focused on SUR
7TTI	;	3.5	;	Human KCC1 bound with VU0463271 In an outward-open state
6KKR	;	2.9	;	human KCC1 structure determined in KCl and detergent GDN
6KKT	;	2.9	;	human KCC1 structure determined in KCl and lipid nanodisc
6KKU	;	3.5	;	human KCC1 structure determined in NaCl and GDN
7YID	;	3.4	;	Human KCNH5 closed state 1
7YIH	;	3.5	;	Human KCNH5 open state
7YIJ	;	3.8	;	Human KCNH5 pore dilation but the non-conducting state
7YIF	;	3.5	;	Human KCNH5 pre-open state 1
7YIG	;	3.6	;	Human KCNH5 pre-open state 2
7YIE	;	3.4	;	Human KCNH5-closed state 2
7XNI	;	3.5	;	human KCNQ1-CaM in apo state
7XNK	;	2.6	;	human KCNQ1-CaM in complex with ML277
7XNL	;	3.1	;	human KCNQ1-CaM-ML277-PIP2 complex in state A
7XNN	;	2.5	;	human KCNQ1-CaM-ML277-PIP2 complex in state B
7CR0	;	3.1	;	human KCNQ2 in apo state
7CR2	;	3.2	;	human KCNQ2 in complex with retigabine
7CR1	;	3.4	;	human KCNQ2 in complex with ztz240
8J03	;	2.7	;	Human KCNQ2(F104A)-CaM-PIP2-CBD complex in state I
8J02	;	3.5	;	Human KCNQ2(F104A)-CaM-PIP2-CBD complex in state II
8J05	;	2.7	;	Human KCNQ2-CaM complex in the presence of PIP2
7CR3	;	3.6	;	human KCNQ2-CaM in apo state
8J00	;	3.0	;	Human KCNQ2-CaM in complex with CBD
8J01	;	3.1	;	Human KCNQ2-CaM in complex with CBD and PIP2
8IZY	;	2.5	;	Human KCNQ2-CaM in complex with HN37
8W4U	;	3.3	;	human KCNQ2-CaM in complex with PIP2 and HN37
7CR7	;	3.7	;	human KCNQ2-CaM in complex with retigabine
7CR4	;	3.9	;	human KCNQ2-CaM in complex with ztz240
8IJK	;	3.4	;	human KCNQ2-CaM-Ebio1 complex in the presence of PIP2
8X43	;	3.0	;	human KCNQ2-CaM-Ebio1-S1 complex in the presence of PIP2
8J04	;	2.7	;	Human KCNQ2-CaM-HN37 complex in the presence of PIP2
6FB4	;	2.41563	;	human KIBRA C2 domain mutant C771A
6FJC	;	2.598	;	Human KIBRA C2 domain mutant C771A in complex with phosphatidylinositol 3,4,5-trisphosphate
6FJD	;	2.898	;	Human KIBRA C2 domain mutant C771A in complex with phosphatidylinositol 4,5-bisphosphate
6FD0	;	2.64216	;	Human KIBRA C2 domain mutant M734I S735A
2XT3	;	1.882	;	HUMAN KIF7, A KINESIN INVOLVED IN HEDGEHOG SIGNALLING
4A14	;	1.6	;	HUMAN KIF7, A KINESIN INVOLVED IN HEDGEHOG SIGNALLING
2JAV	;	2.2	;	Human Kinase with pyrrole-indolinone ligand
3HQD	;	2.19	;	Human kinesin Eg5 motor domain in complex with AMPPNP and Mg2+
1MKJ	;	2.7	;	Human Kinesin Motor Domain With Docked Neck Linker
6TA4	;	6.1	;	Human kinesin-5 motor domain in the AMPPNP state bound to microtubules
6TIW	;	3.8	;	Human kinesin-5 motor domain in the GSK state bound to microtubules (Conformation 2)
6TA3	;	3.8	;	Human kinesin-5 motor domain in the GSK-1 state bound to microtubules (Conformation 1)
8Q5H	;	4.5	;	Human KMN network (outer kinetochore)
6H46	;	2.22	;	Human KRAS in complex with darpin K13
6H47	;	1.7	;	Human KRAS in complex with darpin K19
5O2S	;	3.22	;	Human KRAS in complex with darpin K27
5O2T	;	2.19	;	Human KRAS in complex with darpin K27
7UKF	;	3.02	;	Human Kv4.2-KChIP2 channel complex in a putative resting state, transmembrane region
7UKC	;	3.0	;	Human Kv4.2-KChIP2 channel complex in an inactivated state, class 1, transmembrane region
7UKD	;	2.88	;	Human Kv4.2-KChIP2 channel complex in an inactivated state, class 2, transmembrane region
7UKE	;	3.01	;	Human Kv4.2-KChIP2 channel complex in an intermediate state, transmembrane region
7UK5	;	2.76	;	Human Kv4.2-KChIP2 channel complex in an open state, transmembrane region
7UKH	;	2.33	;	Human Kv4.2-KChIP2-DPP6 channel complex in an open state, intracellular region
7UKG	;	2.24	;	Human Kv4.2-KChIP2-DPP6 channel complex in an open state, transmembrane region
3FVS	;	1.5	;	Human Kynurenine Aminotransferase I in complex with Glycerol
3FVX	;	1.5	;	Human kynurenine aminotransferase I in complex with tris
7NS7	;	2.2	;	Human L-alanine:glyoxylate aminotransferase minor allele variant: AGXT-Mi (P11L-I340M)
2LKK	;		;	Human L-FABP in complex with oleate
7Y1R	;	4.01	;	Human L-TGF-beta1 in complex with the anchor protein LRRC33
5LG8	;	1.98	;	Human L-type ferritin iron loaded for 60 minutes
8WE9	;	3.0	;	Human L-type voltage-gated calcium channel Cav1.2 (Class I) in the presence of pinaverium at 3.0 Angstrom resolution
8WEA	;	3.2	;	Human L-type voltage-gated calcium channel Cav1.2 (Class II) in the presence of pinaverium at 3.2 Angstrom resolution
8WE6	;	2.9	;	Human L-type voltage-gated calcium channel Cav1.2 at 2.9 Angstrom resolution
8FHS	;	3.3	;	Human L-type voltage-gated calcium channel Cav1.2 in the presence of amiodarone and sofosbuvir at 3.3 Angstrom resolution
8WE7	;	3.2	;	Human L-type voltage-gated calcium channel Cav1.2 in the presence of calciseptine at 3.2 Angstrom resolution
8WE8	;	2.9	;	Human L-type voltage-gated calcium channel Cav1.2 in the presence of calciseptine, amlodipine and pinaverium at 2.9 Angstrom resolution
7UHG	;	3.0	;	Human L-type voltage-gated calcium channel Cav1.3 at 3.0 Angstrom resolution
8E5B	;	3.3	;	Human L-type voltage-gated calcium channel Cav1.3 in the presence of Amiodarone and Sofosbuvir at 3.3 Angstrom resolution
8E59	;	3.1	;	Human L-type voltage-gated calcium channel Cav1.3 in the presence of Amiodarone at 3.1 Angstrom resolution
7UHF	;	3.1	;	Human L-type voltage-gated calcium channel Cav1.3 in the presence of cinnarizine at 3.1 Angstrom resolution
8E5A	;	3.3	;	Human L-type voltage-gated calcium channel Cav1.3 treated with 1.4 mM Sofosbuvir at 3.3 Angstrom resolution
1PR9	;	1.96	;	Human L-Xylulose Reductase Holoenzyme
8FW6	;	2.34	;	Human Lactate Dehydrogenase A in Complex with Inhibitor CHK-336
1Z6V	;		;	Human lactoferricin
1Z6W	;		;	Human Lactoferricin
1VFD	;	2.5	;	HUMAN LACTOFERRIN, N-TERMINAL LOBE MUTANT WITH ARG 121 REPLACED BY GLU (R121E)
1VFE	;	2.3	;	HUMAN LACTOFERRIN, N-TERMINAL LOBE MUTANT WITH ARG 121 REPLACED BY SER (R121S)
4L41	;	2.7	;	Human Lactose synthase: A 2:1 complex between human alpha-lactalbumin and human beta1,4-galactosyltransferase
2XV5	;	2.4	;	Human lamin A coil 2B fragment
1X8Y	;	2.2	;	Human lamin coil 2B
8D19	;	1.52	;	Human LanCL1 bound to GSH
8CZK	;	1.91	;	Human LanCL1 bound to GSH and Dhb-Erk peptide
8CZL	;	1.58	;	Human LanCL1 bound to methyl glutathione (MeGSH)
8D0V	;	1.79	;	Human LanCL1 C264A mutant bound to GSH
7YTQ	;	1.6	;	Human langerin carbohydrate recognition domain in complex with an alpha-mannoside ligand
6IRT	;	3.5	;	human LAT1-4F2hc complex bound with BCH
6IRS	;	3.3	;	human LAT1-4F2hc complex incubated with JPH203
7B00	;	3.98	;	Human LAT2-4F2hc complex in the apo-state
7D35	;	2.401	;	Human LC8 bound to ebola virus VP35(67-76)
4AJP	;	2.38	;	Human LDHA in complex with 2-((4-(4-((3-((2-methyl-1,3-benzothiazol- 6yl)amino)-3-oxo-propyl)amino)-4-oxo-butyl)phenyl)methyl)propanedioic acid
7EPM	;	3.0	;	human LDHC complexed with NAD+ and ethylamino acetic acid
8AVE	;	5.62	;	Human leptin in complex with the human LEP-R ectodomain fused to a C-terminal trimeric isoleucine GCN4 zipper (2:2 model)
8AVF	;	6.45	;	Human leptin in complex with the human LEP-R ectodomain fused to a C-terminal trimeric isoleucine GCN4 zipper (closed 3:3 model)
8AVO	;	6.84	;	Human leptin in complex with the human LEP-R ectodomain fused to a C-terminal trimeric isoleucine GCN4 zipper (open 3:3 model).
5HES	;	2.14	;	Human leucine zipper- and sterile alpha motif-containing kinase (ZAK, MLT, HCCS-4, MRK, AZK, MLTK) in complex with vemurafenib
7MKB	;	1.9	;	Human leukocyte antigen A*0201 in complex with SARS-CoV-2 epitope YLQPRTFLL
7LG2	;	2.4	;	Human leukocyte antigen A*0201 in complex with SARS-CoV2 epitope ALWEIQQVV
7LG3	;	2.3	;	Human leukocyte antigen A*0201 in complex with SARS-CoV2 epitope KLWAQCVQL
5MER	;	1.88	;	Human Leukocyte Antigen A02 presenting ILAKFLHEL
5MEQ	;	2.27	;	Human Leukocyte Antigen A02 presenting ILAKFLHTL
5MEN	;	2.81	;	Human Leukocyte Antigen A02 presenting ILAKFLHWL, in complex with cognate T-Cell Receptor
5MEP	;	2.71	;	Human Leukocyte Antigen A02 presenting ILGKFLHWL
7LFZ	;	1.9	;	Human leukocyte antigen B*07:02 in complex with SARS-CoV2 epitope IPRRNVATL
7LG0	;	2.3	;	Human leukocyte antigen B*07:02 in complex with SARS-CoV2 epitope SPRWYFYYL
6SS7	;	2.5	;	Human Leukocyte Antigen Class I A02 Carrying LLWAGPMAV
6SS8	;	2.24	;	Human Leukocyte Antigen Class I A02 Carrying LLWNGPIAV
6SS9	;	2.7	;	Human Leukocyte Antigen Class I A02 Carrying LLWNGPMHV
6SSA	;	2.11	;	Human Leukocyte Antigen Class I A02 Carrying LLWNGPMQV
5N6B	;	1.71	;	Human Leukocyte Antigen Class I A02 Carrying LLWNPGMAV
8CME	;	2.26	;	Human Leukocyte Antigen class II allotype DR1 presenting SARS-CoV-2 Membrane peptide M176-190
8CMG	;	1.64	;	Human Leukocyte Antigen class II allotype DR1 presenting SARS-CoV-2 nsp14 peptide (orf1ab)6420-6434
8CMF	;	2.2	;	Human Leukocyte Antigen class II allotype DR1 presenting SARS-CoV-2 nsp3 epitope (orf1ab)1350-1364
8CMH	;	1.64	;	Human Leukocyte Antigen class II allotype DR1 presenting SARS-CoV-2 Omicron (BA.1) Spike peptide S486-505
8CMI	;	2.6	;	Human Leukocyte Antigen class II allotype DR1 presenting SARS-CoV-2 Omicron (BA.1) Spike peptide S761-775
8CMB	;	1.84	;	Human Leukocyte Antigen class II allotype DR1 presenting SARS-CoV-2 Spike peptide S486-505
8CMC	;	1.42	;	Human Leukocyte Antigen class II allotype DR1 presenting SARS-CoV-2 Spike peptide S511-530
8CMD	;	2.54	;	Human Leukocyte Antigen class II allotype DR1 presenting SARS-CoV-2 Spike peptide S761-775
5IUE	;	2.62	;	Human leukocyte antigen F (HLA-F) presents peptides and regulates immunity through interactions with NK-cell receptors
5KNM	;	3.3	;	Human leukocyte antigen F (HLA-F) presents peptides and regulates immunity through interactions with NK-cell receptors
5MEO	;	1.772	;	Human Leukocyte Antigen presenting ILGKFLHRL
4L2L	;	1.648	;	Human Leukotriene A4 Hydrolase complexed with ligand 4-(4-benzylphenyl)thiazol-2-amine
4MS6	;	1.72	;	Human Leukotriene A4 Hydrolase in complex with Pro-Gly-Pro analogue
4MKT	;	1.618	;	Human Leukotriene A4 Hydrolase in complex with Pro-Gly-Pro analogue and 4-(4-benzylphenyl)thiazol-2-amine
3B29	;	3.2	;	Human leukotriene C4 synthase in complex with dodecyl-beta-D-selenomaltoside
7QNZ	;	4.58	;	human Lig1-DNA-PCNA complex reconstituted in absence of ATP
6BKG	;	2.402	;	Human LigIV catalytic domain with bound DNA-adenylate intermediate in closed conformation
5UDZ	;	2.0	;	Human LIN28A in complex with let-7f-1 microRNA pre-element
8UW3	;	3.2	;	Human LINE-1 retrotransposon ORF2 protein engaged with template RNA in elongation state
3QH9	;	2.01	;	Human Liprin-beta2 Coiled-Coil
1LIT	;	1.55	;	HUMAN LITHOSTATHINE
6MP4	;	2.502	;	Human liver FABP1 bound to tetrahydrocannabinol
8DHX	;	2.92	;	Human liver ferritin
5Q08	;	2.2	;	Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(1-benzothiophen-3-ylsulfonyl)-3-(5-bromo-1,3-thiazol-2-yl)urea
5PZR	;	1.9	;	Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(3-chlorophenyl)sulfonyl-3-[3-[3-[(3-chlorophenyl)sulfonylcarbamoylamino]propoxy]propyl]urea
5PZW	;	2.0	;	Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(3-chlorophenyl)sulfonyl-3-[5-[(3-chlorophenyl)sulfonylcarbamoylamino]pentyl]urea
5PZS	;	2.368	;	Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(3-chlorophenyl)sulfonyl-3-[6-[(3-chlorophenyl)sulfonylcarbamoylamino]hexyl]urea
5Q0B	;	2.3	;	Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(4-bromo-3-methyl-1,2-thiazol-5-yl)-3-(3-methylphenyl)sulfonylurea
5Q04	;	2.502	;	Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(4-bromo-5-chlorothiophen-2-yl)sulfonyl-3-(5-bromo-1,3-thiazol-2-yl)urea
5Q07	;	2.424	;	Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(4-bromo-6-morpholin-4-ylpyridin-2-yl)-3-[5-(2-methoxyethyl)-4-methylthiophen-2-yl]sulfonylurea
5PZV	;	2.0	;	Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(4-bromopyridin-2-yl)-3-(4-chlorophenyl)sulfonylurea
5PZY	;	2.21	;	Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-(2-chlorophenyl)sulfonylurea
5PZZ	;	2.5	;	Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-(3,4-dichlorophenyl)sulfonylurea
5PZT	;	2.8	;	Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-(3-ethyl-4-phenylphenyl)sulfonylurea
5Q06	;	2.4	;	Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-[4-(2-methyl-1,3-thiazol-4-yl)phenyl]sulfonylurea
5Q01	;	2.603	;	Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-[4-(4,5-dichloro-2-methylpyrazol-3-yl)oxyphenyl]sulfonylurea
5PZX	;	2.75	;	Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-[4-methoxy-3-(2-methylpropyl)phenyl]sulfonylurea
5Q02	;	2.095	;	Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-[5-(1,2-oxazol-3-yl)thiophen-2-yl]sulfonylurea
5Q05	;	2.2	;	Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-[5-(2-methoxyethyl)-4-methylthiophen-2-yl]sulfonylurea
5Q03	;	2.31	;	Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-[5-(2-methylpropyl)thiophen-2-yl]sulfonylurea
5Q0C	;	2.4	;	Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-[5-(4-methoxyphenyl)thiophen-2-yl]sulfonylurea and with fructose-2,6-diphosphate
5Q0A	;	2.3	;	Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(5-cyanopyrazin-2-yl)-3-[3-(difluoromethoxy)phenyl]sulfonylurea
5Q09	;	1.9	;	Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-[4-bromo-6-(carbamoylamino)pyridin-2-yl]-3-[5-(2-methoxyethyl)-4-methylthiophen-2-yl]sulfonylurea
5PZQ	;	2.7	;	Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 2-(4-methoxyphenyl)furan-3,4-dicarboxylic acid
5Q00	;	2.6	;	Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 2-[3-[(5-bromo-1,3-thiazol-2-yl)carbamoylsulfamoyl]-1-methylindol-7-yl]oxyacetamide
5PZU	;	1.901	;	Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor [5-[2-amino-5-(2-methylpropyl)-1,3-thiazol-4-yl]furan-2-yl]phosphonic acid
4MJO	;	2.4	;	Human liver fructose-1,6-bisphosphatase(d-fructose-1,6-bisphosphate, 1-phosphohydrolase) (e.c.3.1.3.11) complexed with the allosteric inhibitor 3
3CEH	;	2.8	;	Human liver glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE5688
1FA9	;	2.4	;	HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH AMP
1L5Q	;	2.25	;	Human liver glycogen phosphorylase a complexed with caffeine, N-Acetyl-beta-D-glucopyranosylamine, and CP-403700
1XOI	;	2.1	;	Human Liver Glycogen Phosphorylase A complexed with Chloroindoloyl glycine amide
1EXV	;	2.4	;	HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH GLCNAC AND CP-403,700
1EM6	;	2.2	;	HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH GLCNAC AND CP-526,423
2ZB2	;	2.45	;	Human liver glycogen phosphorylase a complexed with glcose and 5-chloro-N-[4-(1,2-dihydroxyethyl)phenyl]-1H-indole-2-carboxamide
1L5R	;	2.1	;	Human liver glycogen phosphorylase a complexed with riboflavin, N-Acetyl-beta-D-Glucopyranosylamine and CP-403,700
1L7X	;	2.3	;	Human liver glycogen phosphorylase b complexed with caffeine, N-acetyl-beta-D-glucopyranosylamine, and CP-403,700
1FC0	;	2.4	;	HUMAN LIVER GLYCOGEN PHOSPHORYLASE COMPLEXED WITH N-ACETYL-BETA-D-GLUCOPYRANOSYLAMINE
1L5S	;	2.1	;	Human liver glycogen phosphorylase complexed with uric acid, N-Acetyl-beta-D-glucopyranosylamine, and CP-403,700
2QLL	;	2.56	;	Human liver glycogen phosphorylase- GL complex
8SHS	;	2.66	;	human liver mitochondrial Aldehyde dehydrogenase ALDH2
8SKR	;	2.99	;	human liver mitochondrial Aspartate aminotransferase
8SGV	;	2.58	;	human liver mitochondrial Catalase
8SK6	;	2.96	;	human liver mitochondrial Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase
8SK8	;	2.31	;	human liver mitochondrial Glutamate dehydrogenase 1
8SGR	;	2.84	;	human liver mitochondrial Isovaleryl-CoA dehydrogenase
8SGP	;	2.69	;	human liver mitochondrial Medium-chain specific acyl-CoA dehydrogenase
8SGS	;	3.15	;	human liver mitochondrial Short-chain specific acyl-CoA dehydrogenase
8SKS	;	2.91	;	human liver mitochondrial Superoxide dismutase [Mn]
6OQX	;	2.004	;	Human Liver Receptor Homolog-1 bound to the agonist 5N and a fragment of the Tif2 coregulator
7JYD	;	2.3	;	Human Liver Receptor Homolog-1 in Complex with 10CA and a Fragment of Tif2
7JYE	;	2.551	;	Human Liver Receptor Homolog-1 in Complex with 9ChoP and a Fragment of Tif2
2A66	;	2.2	;	Human Liver Receptor Homologue DNA-Binding Domain (hLRH-1 DBD) in Complex with dsDNA from the hCYP7A1 Promoter
5SYZ	;	1.9261	;	Human Liver Receptor Homologue-1 (LRH-1) Bound to a RJW100 stereoisomer and a Fragment of TIF-2
5L11	;	1.849	;	Human Liver Receptor Homologue-1 (LRH-1) Bound to RJW100 and a Fragment of TIF-2
8SZL	;	3.12	;	Human liver-type glutaminase (Apo form)
8T0Z	;	3.3	;	Human liver-type glutaminase (K253A) with L-Gln, filamentous form
2K6O	;		;	Human LL-37 Structure
7KH8	;	1.3	;	Human LMPTP in complex with inhibitor
5AJQ	;	2.2	;	Human LOK (STK10) in complex with Bosutinib
7OXO	;	3.9	;	human LonP1, R-state, incubated in AMPPCP
6OR1	;	2.174	;	Human LRH-1 bound to the agonist 2N and a fragment of the Tif2 coregulator
6OQY	;	2.23	;	Human LRH-1 bound to the agonist 6N and a fragment of the Tif2 coregulator
7TT8	;	2.8	;	Human LRH-1 LBD bound to agonist 6N-10CA and fragment of Tif2 coactivator
6VIF	;	2.26	;	Human LRH-1 ligand-binding domain bound to agonist cpd 15 and fragment of coregulator TIF-2
3PLZ	;	1.75	;	Human LRH1 LBD bound to GR470
2UXX	;	2.74	;	Human LSD1 Histone Demethylase-CoREST in complex with an FAD- tranylcypromine adduct
6NQU	;	2.7	;	Human LSD1 in complex with GSK2879552
6NR5	;	2.9	;	Human LSD1 in complex with Phenelzine sulfate
6TUY	;	2.6	;	Human LSD1/CoREST bound to the quinazoline inhibitor MC4106
5L3B	;	3.3	;	Human LSD1/CoREST: LSD1 D556G mutation
5L3C	;	3.31	;	Human LSD1/CoREST: LSD1 E379K mutation
5L3D	;	2.6	;	Human LSD1/CoREST: LSD1 Y761H mutation
4J7T	;	3.203	;	Human LTC4 synthase in complex with product analogs - implications for enzyme catalysis
4J7Y	;	2.901	;	Human LTC4 synthase in complex with product analogs - implications for enzyme catalysis
4JC7	;	2.7	;	Human LTC4 synthase in complex with product analogs - implications for enzyme catalysis
4JCZ	;	2.75	;	Human LTC4 synthase in complex with product analogs - implications for enzyme catalysis
4JRZ	;	2.4	;	Human LTC4 synthase in complex with product analogs - implications for enzyme catalysis
5HV9	;	3.0	;	Human LTC4S mutant-S36E
1PQ6	;	2.4	;	HUMAN LXR BETA HORMONE RECEPTOR / GW3965 COMPLEX
1PQC	;	2.8	;	HUMAN LXR BETA HORMONE RECEPTOR COMPLEXED WITH T0901317
1PQ9	;	2.1	;	HUMAN LXR BETA HORMONE RECEPTOR COMPLEXED WITH T0901317 COMPLEX
6JIO	;	2.6	;	Human LXR-beta in complex with a ligand
6K9G	;	2.8	;	Human LXR-beta in complex with an agonist
6K9H	;	2.5	;	Human LXR-beta in complex with an agonist
6K9M	;	2.9	;	Human LXR-beta in complex with an agonist
3RIB	;	2.79	;	Human lysine methyltransferase Smyd2 in complex with AdoHcy
3OXF	;	2.82	;	Human lysine methyltransferase Smyd3 in complex with AdoHcy (Form I)
3OXL	;	3.6	;	Human lysine methyltransferase Smyd3 in complex with AdoHcy (Form II)
3OXG	;	3.41	;	human lysine methyltransferase Smyd3 in complex with AdoHcy (Form III)
7YU3	;	3.5	;	Human Lysophosphatidic Acid Receptor 1-Gi complex bound to ONO-0740556
7YU4	;	3.7	;	Human Lysophosphatidic Acid Receptor 1-Gi complex bound to ONO-0740556, focused on receptor
7YU5	;	3.7	;	Human Lysophosphatidic Acid Receptor 1-Gi complex bound to ONO-0740556, state1
7YU6	;	3.9	;	Human Lysophosphatidic Acid Receptor 1-Gi complex bound to ONO-0740556, state2
7YU7	;	4.5	;	Human Lysophosphatidic Acid Receptor 1-Gi complex bound to ONO-0740556, state3
7YU8	;	5.6	;	Human Lysophosphatidic Acid Receptor 1-Gi complex bound to ONO-0740556, state4
1NOW	;	2.2	;	Human lysosomal beta-hexosaminidase isoform B in complex with (2R,3R,4S,5R)-2-Acetamido-3,4-Dihydroxy-5-Hydroxymethyl-Piperidinium Chloride (GalNAc-isofagomine)
1NP0	;	2.5	;	Human lysosomal beta-hexosaminidase isoform B in complex with intermediate analogue NAG-thiazoline
5LVK	;	2.491	;	Human Lysozyme co-crystallized with [H2Ind][trans-RuCl4(DMSO)(HInd)]
1BB4	;	2.23	;	HUMAN LYSOZYME DOUBLE MUTANT A96L, W109H
1D6Q	;	1.96	;	HUMAN LYSOZYME E102 MUTANT LABELLED WITH 2',3'-EPOXYPROPYL GLYCOSIDE OF N-ACETYLLACTOSAMINE
5LSH	;	1.061	;	human lysozyme in complex with a tetrasaccharide fragment of the O-chain of LPS from Klebsiella pneumoniae
1D6P	;	2.23	;	HUMAN LYSOZYME L63 MUTANT LABELLED WITH 2',3'-EPOXYPROPYL N,N'-DIACETYLCHITOBIOSE
1RE2	;	2.3	;	HUMAN LYSOZYME LABELLED WITH TWO 2',3'-EPOXYPROPYL BETA-GLYCOSIDE OF N-ACETYLLACTOSAMINE
1BB3	;	1.8	;	HUMAN LYSOZYME MUTANT A96L
1BB5	;	1.8	;	HUMAN LYSOZYME MUTANT A96L COMPLEXED WITH CHITOTRIOSE
1JKB	;	1.66	;	HUMAN LYSOZYME MUTANT WITH GLU 35 REPLACED BY ALA
1JKA	;	1.66	;	HUMAN LYSOZYME MUTANT WITH GLU 35 REPLACED BY ASP
1JKD	;	1.8	;	HUMAN LYSOZYME MUTANT WITH TRP 109 REPLACED BY ALA
1JKC	;	1.6	;	HUMAN LYSOZYME MUTANT WITH TRP 109 REPLACED BY PHE
1REM	;	2.1	;	HUMAN LYSOZYME WITH MAN-B1,4-GLCNAC COVALENTLY ATTACHED TO ASP53
1REY	;	1.7	;	HUMAN LYSOZYME-N,N'-DIACETYLCHITOBIOSE COMPLEX
1REZ	;	1.7	;	HUMAN LYSOZYME-N-ACETYLLACTOSAMINE COMPLEX
6NYY	;	3.0	;	human m-AAA protease AFG3L2, substrate-bound
3SRF	;	2.845	;	Human M1 pyruvate kinase
3SRH	;	2.6	;	Human M2 pyruvate kinase
3SRD	;	2.902	;	Human M2 pyruvate kinase in complex with fructose 1-6 bisphosphate and Oxalate.
7TRK	;	2.8	;	Human M4 muscarinic acetylcholine receptor complex with Gi1 and the agonist iperoxo
7TRP	;	2.4	;	Human M4 muscarinic acetylcholine receptor complex with Gi1 and the agonist iperoxo and positive allosteric modulator LY2033298
7TRQ	;	2.5	;	Human M4 muscarinic acetylcholine receptor complex with Gi1 and the agonist iperoxo and positive allosteric modulator VU0467154
7TRS	;	2.8	;	Human M4 muscarinic acetylcholine receptor complex with Gi1 and the endogenous agonist acetylcholine
8FX5	;	2.45	;	Human M4 muscarinic acetylcholine receptor complex with Gi1 and xanomeline
7VF5	;	3.0	;	Human m6A-METTL associated complex (WTAP, VIRMA, and HAKAI)
7VF2	;	3.0	;	Human m6A-METTL associated complex (WTAP, VIRMA, ZC3H13, and HAKAI)
5MP0	;	1.63	;	Human m7GpppN-mRNA Hydrolase (DCP2, NUDT20) Catalytic Domain
6VYV	;	6.33	;	Human mAbs broadly protect against infection of arthritiogenic alphaviruses by recognizing conserved elements of the MXR8 receptor binding domain
6W09	;	5.3	;	Human mAbs broadly protect against infection of arthritiogenic alphaviruses by recognizing conserved elements of the MXR8 receptor binding domain
6W1C	;	5.3	;	Human mAbs broadly protect against infection of arthritiogenic alphaviruses by recognizing conserved elements of the MXR8 receptor binding domain
3KBX	;	2.652	;	Human macrophage inflammatory protein-1 alpha L3M_V63M
1GD0	;	1.5	;	HUMAN MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)
7ZUC	;	1.89	;	Human Major Histocompatibility Complex A2 allele presenting LLLGIGILV
7NMD	;	2.25	;	Human Major Histocompatibility Complex A24 Allele presenting QLPRLFPLL
2OB0	;	1.8	;	Human MAK3 homolog in complex with Acetyl-CoA
2PSW	;	2.1	;	Human MAK3 homolog in complex with CoA
7RM9	;	1.65	;	Human Malate Dehydrogenase I (MDHI)
1EFL	;	2.6	;	HUMAN MALIC ENZYME IN A QUATERNARY COMPLEX WITH NAD, MG, AND TARTRONATE
3V55	;	1.81	;	Human MALT1 (334-719) in its ligand free form
3V4O	;	2.1	;	Human MALT1 (caspase domain) in complex with an irreversible peptidic inhibitor
4I1P	;	2.403	;	Human MALT1 (caspase-IG3) in complex with activity based-probe
4I1R	;	2.7	;	Human MALT1 (caspase-IG3) in complex with thioridazine
6F7I	;	2.43	;	human MALT1(329-728) IN COMPLEX WITH MLT-747
6H4A	;	2.65	;	Human MALT1(329-728) in complex with MLT-748
7AK0	;	2.316	;	Human MALT1(329-729) in complex with a chromane urea containing inhibitor
7AK1	;	2.507	;	Human MALT1(329-729) in complex with a chromane urea containing inhibitor
6YN8	;	3.052	;	Human MALT1(334-719) in complex with a tetrazole containing compound
2ADQ	;	2.4	;	Human Manganese Superoxide Dismutase
1QNM	;	2.3	;	HUMAN MANGANESE SUPEROXIDE DISMUTASE MUTANT Q143N
1HUP	;	2.5	;	HUMAN MANNOSE BINDING PROTEIN CARBOHYDRATE RECOGNITION DOMAIN TRIMERIZES THROUGH A TRIPLE ALPHA-HELICAL COILED-COIL
2VZ2	;	2.3	;	Human MAO B in complex with mofegiline
8A3D	;	1.67	;	Human mature large subunit of the ribosome with eIF6 and homoharringtonine bound
7KZ1	;	1.62	;	Human MBD4 glycosylase domain bound to DNA containing an abasic site
7KZG	;	1.68	;	Human MBD4 glycosylase domain bound to DNA containing oxacarbenium-ion analog 1-aza-2'-deoxyribose
7KZ0	;	1.57	;	Human MBD4 glycosylase domain bound to DNA containing substrate analog 2'-deoxy-pseudouridine
5UUM	;	2.346	;	Human Mcl-1 in complex with a Bfl-1-specific selected peptide
6UA3	;	1.552	;	Human Mcl-1 in complex with a modified Bim BH3 peptide
6UAB	;	2.1	;	Human Mcl-1 in complex with a modified unnatural Bim BH3 peptide
6MBD	;	1.95	;	Human Mcl-1 in complex with the designed peptide dM1
6MBE	;	2.25	;	Human Mcl-1 in complex with the designed peptide dM7
7W1Y	;	2.59	;	Human MCM double hexamer bound to natural DNA duplex (polyAT/polyTA)
7DP3	;	2.55	;	Human MCM8 N-terminal domain
7DPD	;	2.55	;	Human MCM9 N-terminal domain
6K7X	;	3.27	;	Human MCU-EMRE complex
6O58	;	3.8	;	Human MCU-EMRE complex, dimer of channel
3JZR	;	2.1	;	Human MDM2 liganded with a 12mer peptide inhibitor (pDI6W)
3JZS	;	1.78	;	Human MDM2 liganded with a 12mer peptide inhibitor (pDIQ)
8BGU	;	4.1	;	human MDM2-5S RNP
3JZO	;	1.8	;	Human MDMX liganded with a 12mer peptide (pDI)
3JZP	;	1.74	;	Human MDMX liganded with a 12mer peptide inhibitor (pDI6W)
3JZQ	;	1.8	;	Human MDMX liganded with a 12mer peptide inhibitor (pDIQ)
7C3Q	;	1.801	;	Human MdmX protein in complex with Nutlin3a
5ODD	;		;	HUMAN MED26 N-TERMINAL DOMAIN (1-92)
7ENJ	;	4.4	;	Human Mediator (deletion of MED1-IDR) in a Tail-bent conformation (MED-B)
7EMF	;	3.5	;	Human Mediator (deletion of MED1-IDR) in a Tail-extended conformation
7NVR	;	4.5	;	Human Mediator with RNA Polymerase II Pre-initiation complex
3WIG	;	2.7	;	Human MEK1 kinase in complex with CH5126766 and MgAMP-PNP
7DB6	;	3.3	;	human melatonin receptor MT1 - Gi1 complex
8ERC	;	3.7	;	Human Membrane-bound O-acyltransferase 7
6S2K	;	3.1	;	Human Menin in complex with AJ21
8GPN	;	3.2	;	Human menin in complex with H3K79Me2 nucleosome
4GQ6	;	1.55	;	Human menin in complex with MLL peptide
4GQ3	;	1.56	;	Human menin with bound inhibitor MI-2
4GQ4	;	1.27	;	Human menin with bound inhibitor MI-2-2
4OG3	;	2.01	;	Human menin with bound inhibitor MIV-3R
4OG4	;	1.45	;	Human menin with bound inhibitor MIV-3S
4OG6	;	1.49	;	Human menin with bound inhibitor MIV-4
4OG5	;	1.63	;	Human menin with bound inhibitor MIV-5
4OG8	;	1.53	;	Human menin with bound inhibitor MIV-6R
4OG7	;	2.08	;	Human menin with bound inhibitor MIV-7
7UAE	;	2.6	;	Human meprin alpha (active state)
7UAF	;	2.4	;	Human meprin alpha inhibitory complex with compound 10d (N~3~,N~3~-bis[(2H-1,3-benzodioxol-5-yl)methyl]-N-hydroxy-beta-alaninamide)
3U8Z	;	2.64	;	human merlin FERM domain
2W51	;	2.8	;	Human mesencephalic astrocyte-derived neurotrophic factor (MANF)
6BX8	;	1.98	;	Human Mesotrypsin (PRSS3) Complexed with Tissue Factor Pathway Inhibitor Variant (TFPI1-KD1-K15R-I17C-I34C)
3L3T	;	2.378	;	Human mesotrypsin complexed with amyloid precursor protein inhibitor variant (APPIR15K)
3L33	;	2.48	;	Human mesotrypsin complexed with amyloid precursor protein inhibitor(APPI)
4U30	;	2.5	;	Human mesotrypsin complexed with bikunin Kunitz domain 2
3P95	;	1.2991	;	Human mesotrypsin complexed with bovine pancreatic trypsin inhibitor variant (BPTI-K15R/R17D)
3P92	;	1.5992	;	Human mesotrypsin complexed with bovine pancreatic trypsin inhibitor variant (BPTI-K15R/R17G)
2R9P	;	1.4	;	Human mesotrypsin complexed with bovine pancreatic trypsin inhibitor(BPTI)
4U32	;	1.65	;	Human mesotrypsin complexed with HAI-2 Kunitz domain 1
5C67	;	1.83	;	Human Mesotrypsin in complex with amyloid precursor protein inhibitor variant APPI-M17G/I18F/F34V
5TP0	;	1.25	;	Human mesotrypsin in complex with diminazene
4DG4	;	1.4	;	Human mesotrypsin-S39Y complexed with bovine pancreatic trypsin inhibitor (BPTI)
6UO8	;	3.63	;	Human metabotropic GABA(B) receptor bound to agonist SKF97541 and positive allosteric modulator GS39783
6UO9	;	4.8	;	Human metabotropic GABA(B) receptor bound to agonist SKF97541 in its intermediate state 2
6VJM	;	3.97	;	Human metabotropic GABA(B) receptor in its apo state
6UOA	;	6.3	;	Human metabotropic GABA(B) receptor in its intermediate state 1
5C5C	;	1.862	;	Human metabotropic glutamate receptor 7, extracellular ligand binding domain
4V0H	;	1.79	;	Human metallo beta lactamase domain containing protein 1 (hMBLAC1)
4FLJ	;	1.74	;	Human MetAP1 with bengamide analog Y08, in Mn form
4FLK	;	1.47	;	Human MetAP1 with bengamide analog Y10, in Mn form
4FLI	;	1.55	;	Human MetAP1 with bengamide analog Y16, in Mn form
4FLL	;	1.5	;	Human MetAP1 with bengamide analog YZ6, in Mn form
5FVD	;	1.86	;	Human metapneumovirus N0-P complex
5L0C	;	3.1	;	Human metavinculin (residues 959-1134) in complex with PIP2
5L0H	;	2.9	;	Human metavinculin MVt cardiomyopathy-associated mutant R975W (residues 959-1134) in complex with PIP2
5L0G	;	3.4	;	Human metavinculin MVt Q971R, R975D, T978R mutant (residues 959-1134) in complex with PIP2
5L0I	;	2.45	;	Human metavinculin MVt R975W cardiomyopathy-associated mutant (residues 959-1134)
5L0F	;	2.76	;	Human metavinculin quadruple mutant (residues 959-1134)
3MYI	;	2.2	;	Human metavinculin tail domain
5L0D	;	2.75	;	Human Metavinculin(residues 959-1130) in complex with PIP2
7PCF	;	5.82	;	Human methemoglobin bound to Staphylococcus aureus hemophore IsdB
4IJ2	;	4.24	;	Human methemoglobin in complex with the second and third NEAT domains of IsdH from Staphylococcus aureus
4XS0	;	2.55	;	Human methemoglobin in complex with the second and third NEAT domains of IsdH(F365Y/A369F/Y642A) from Staphylococcus aureus
6NBC	;	2.8	;	human methemoglobin state 1 determined using single-particle cryo-EM at 200 keV
6NBD	;	3.2	;	Human methemoglobin state 2 determined using single-particle cryo-EM at 200 keV
7RXW	;	1.07	;	Human Methionine Adenosyltransferase 2A bound to Methylthioadenosine and inhibitor imido-diphosphate (PNP)
7L1A	;	1.25	;	Human Methionine Adenosyltransferase 2A bound to Methylthioadenosine and inhibitor, di-imido triphosphate (PNPNP)
7RXX	;	1.25	;	Human Methionine Adenosyltransferase 2A bound to Methylthioadenosine and two sulfate in the active site
7RXV	;	1.07	;	Human Methionine Adenosyltransferase 2A bound to Methylthioadenosine, Malonate (MLA) and MgF3
6FCB	;	2.7	;	Human Methionine Adenosyltransferase II mutant (P115G)
6FBN	;	2.7	;	Human Methionine Adenosyltransferase II mutant (Q113A)
6FCD	;	1.7	;	Human Methionine Adenosyltransferase II mutant (R264A)
6FBO	;	1.8	;	Human Methionine Adenosyltransferase II mutant (S114A) in I222 crystal form
6FBP	;	1.65	;	Human Methionine Adenosyltransferase II mutant (S114A) in P22121 crystal form
6G6R	;	1.35	;	Human Methionine Adenosyltransferase II with SAMe and PPNP
1BN5	;	1.8	;	HUMAN METHIONINE AMINOPEPTIDASE 2
8ONY	;	2.92	;	Human Methionine Aminopeptidase 2 at the 80S ribosome
1BOA	;	1.8	;	HUMAN METHIONINE AMINOPEPTIDASE 2 COMPLEXED WITH ANGIOGENESIS INHIBITOR FUMAGILLIN
1B6A	;	1.6	;	HUMAN METHIONINE AMINOPEPTIDASE 2 COMPLEXED WITH TNP-470
2ADU	;	1.9	;	Human Methionine Aminopeptidase Complex with 4-Aryl-1,2,3-triazole Inhibitor
1QZY	;	1.6	;	Human Methionine Aminopeptidase in complex with bengamide inhibitor LAF153 and cobalt
4IU6	;	1.9	;	Human Methionine Aminopeptidase in complex with FZ1: Pyridinylquinazolines Selectively Inhibit Human Methionine Aminopeptidase-1
5YR7	;	2.06	;	Human methionine aminopeptidase type 1b (F309L mutant)
5YR5	;	1.6	;	Human methionine aminopeptidase type 1b (F309L mutant) in complex with Ovalicin
5YR6	;	1.75	;	Human methionine aminopeptidase type 1b (F309L mutant) in complex with TNP470
5YKP	;	1.68	;	Human methionine aminopeptidase type 1b (F309M mutant) in complex with ovalicin
5YR4	;	1.82	;	Human methionine aminopeptidase type 1b (F309M mutant) in complex with TNP470
1KQ0	;	2.0	;	Human methionine aminopeptidase type II in complex with D-methionine
1KQ9	;	1.9	;	Human methionine aminopeptidase type II in complex with L-methionine
2OAZ	;	1.9	;	Human Methionine Aminopeptidase-2 Complexed with SB-587094
1DIA	;	2.2	;	HUMAN METHYLENETETRAHYDROFOLATE DEHYDROGENASE / CYCLOHYDROLASE COMPLEXED WITH NADP AND INHIBITOR LY249543
1DIB	;	2.7	;	HUMAN METHYLENETETRAHYDROFOLATE DEHYDROGENASE / CYCLOHYDROLASE COMPLEXED WITH NADP AND INHIBITOR LY345899
1DIG	;	2.2	;	HUMAN METHYLENETETRAHYDROFOLATE DEHYDROGENASE / CYCLOHYDROLASE COMPLEXED WITH NADP AND INHIBITOR LY374571
2H00	;	2.0	;	Human methyltransferase 10 domain containing protein
4RFQ	;	2.4	;	Human Methyltransferase-Like 18
4LEC	;	2.28	;	Human Methyltransferase-Like Protein 21A
4MTL	;	1.65	;	Human Methyltransferase-Like Protein 21C
4LG1	;	1.8	;	Human Methyltransferase-Like Protein 21D
5TEY	;	1.8	;	Human METTL3-METTL14 complex
6E5V	;	2.95	;	human mGlu8 receptor amino terminal domain in complex with (S)-3,4-Dicarboxyphenylglycine (DCPG)
6BSZ	;	2.65	;	Human mGlu8 Receptor complexed with glutamate
6BT5	;	2.92	;	Human mGlu8 Receptor complexed with L-AP4
8XA9	;	2.32	;	Human MGME1 in complex with 5'-overhang DNA
7NMG	;	2.48	;	Human MHC Class I, A24 Allele presenting LWM, Complex with 4C6 TCR
7NME	;	2.2	;	Human MHC Class I, A24 Allele presenting QLPRLFPLL, Complex with 4C6 TCR
7NMF	;	2.98	;	Human MHC Class I, A24 Allele presenting QLPRLFPLL, Complex with 4C6 TCR, monoclinic form
4NE1	;	6.499	;	Human MHF1 MHF2 DNA complexes
4NE3	;	1.8007	;	Human MHF1-MHF2 complex
4NE5	;	2.5	;	Human MHF1-MHF2 complex
4NE6	;	2.1001	;	Human MHF1-MHF2 complex
4NDY	;	6.999	;	Human MHF1-MHF2 DNA complex
1XQ8	;		;	Human micelle-bound alpha-synuclein
2D58	;	1.9	;	Human microglia-specific protein Iba1
2CKJ	;	3.59	;	Human milk xanthine oxidoreductase
3WH2	;	1.3	;	Human Mincle in complex with citrate
3WH3	;	1.32	;	human Mincle, ligand free form
1M8A	;	1.7	;	Human MIP-3alpha/CCL20
1E6F	;	1.75	;	Human MIR-receptor, repeat 11
1GQB	;	1.8	;	HUMAN MIR-RECEPTOR, REPEAT 11
7UPR	;	3.2	;	Human mitochondrial AAA protein ATAD1 (with a catalytic dead mutation) in complex with a peptide substrate (closed conformation)
7UPT	;	3.5	;	Human mitochondrial AAA protein ATAD1 (with a catalytic dead mutation) in complex with a peptide substrate (open conformation)
2F2S	;	2.0	;	Human mitochondrial acetoacetyl-CoA thiolase
6NOW	;	4.099	;	Human Mitochondrial Alanyl-tRNA Synthetase C-Ala domain
6NLQ	;	1.15	;	Human Mitochondrial Alanyl-tRNA Synthetase C-terminal domain
1ZUM	;	2.1	;	Human Mitochondrial Aldehyde Dehydrogenase Asian Variant, ALDH2*2, Apo Form
3INL	;	1.862	;	Human Mitochondrial Aldehyde Dehydrogenase Asian Variant, ALDH2*2, complexed with agonist Alda-1
2ONM	;	2.5	;	Human Mitochondrial Aldehyde Dehydrogenase Asian Variant, ALDH2*2, complexed with NAD+
3INJ	;	1.688	;	Human Mitochondrial Aldehyde Dehydrogenase complexed with agonist Alda-1
1O01	;	2.15	;	Human mitochondrial aldehyde dehydrogenase complexed with crotonaldehyde, NAD(H) and Mg2+
1O00	;	2.6	;	Human mitochondrial aldehyde dehydrogenase complexed with NAD+ and Mg2+ showing dual NAD(H) conformations
1CW3	;	2.58	;	HUMAN MITOCHONDRIAL ALDEHYDE DEHYDROGENASE COMPLEXED WITH NAD+ AND MN2+
1NZX	;	2.45	;	Human mitochondrial aldehyde dehydrogenase complexed with NAD+ in the presence of low Mg2+
1NZZ	;	2.45	;	Human mitochondrial aldehyde dehydrogenase complexed with NADH in the presence of low Mg2+
1O02	;	1.9	;	Human mitochondrial aldehyde dehydrogenase complexed with NADH in the presence of Mg2+
3N80	;	1.5	;	Human mitochondrial aldehyde dehydrogenase, apo form
4AH6	;	3.7	;	Human mitochondrial aspartyl-tRNA synthetase
2IWY	;	2.06	;	Human mitochondrial beta-ketoacyl ACP synthase
2IWZ	;	1.65	;	Human mitochondrial beta-ketoacyl ACP synthase complexed with hexanoic acid
5KUI	;	2.701	;	Human mitochondrial calcium uniporter (residues 72-189) crystal structure with calcium.
5KUG	;	1.9	;	Human mitochondrial calcium uniporter (residues 72-189) crystal structure with lithium
5KUJ	;	1.6	;	Human mitochondrial calcium uniporter (residues 72-189) crystal structure with magnesium.
7L7S	;	3.5	;	Human mitochondrial chaperonin mHsp60
6DL7	;	2.0	;	Human mitochondrial ClpP in complex with ONC201 (TIC10)
8D33	;	2.46	;	Human mitochondrial DNA polymerase gamma ternary complex with GC basepair
8D42	;	2.91	;	Human mitochondrial DNA polymerase gamma ternary complex with GT basepair in editing conformer (composite)
8D3R	;	3.04	;	Human mitochondrial DNA polymerase gamma ternary complex with GT basepair in intermediate conformer
8D37	;	2.65	;	Human mitochondrial DNA polymerase gamma ternary complex with GT basepair in replication conformer
4A1N	;	2.8	;	Human Mitochondrial endo-exonuclease
5Z8U	;	1.9	;	Human mitochondrial ferritin mutant - C102A/C130A
5Z8S	;	1.973	;	Human Mitochondrial ferritin mutant - C102A/C130A/E27C/E61C/E62C
5Z8J	;	2.3	;	Human mitochondrial ferritin mutant - E27C/E62C/C102G/C130G
5Z91	;	3.004	;	Human mitochondrial ferritin mutant bound with gold ions
3RC3	;	2.08	;	Human Mitochondrial Helicase Suv3
3RC8	;	2.9	;	Human Mitochondrial Helicase Suv3 in Complex with Short RNA Fragment
7NGQ	;	12.0	;	Human mitochondrial Lon protease homolog, D2-state
7P0M	;	2.75	;	Human mitochondrial Lon protease with substrate in the ATPase and protease domains
7P09	;	2.7	;	Human mitochondrial Lon protease with substrate in the ATPase domain
7P0B	;	4.11	;	Human mitochondrial Lon protease without substrate
8OM7	;	3.74	;	Human Mitochondrial Lon Y186E Mutant ADP Bound
8OJL	;	2.88	;	Human Mitochondrial Lon Y394E Mutant ADP Bound
8OKA	;	3.89	;	Human Mitochondrial Lon Y394F Mutant ADP Bound
7KRZ	;	3.2	;	Human mitochondrial LONP1 in complex with Bortezomib
7KSM	;	3.2	;	Human mitochondrial LONP1 with endogenous substrate
1QR6	;	2.1	;	HUMAN MITOCHONDRIAL NAD(P)-DEPENDENT MALIC ENZYME
6J7Y	;	2.203	;	Human mitochondrial Oligoribonuclease in complex with DNA
6J80	;	1.812	;	Human mitochondrial Oligoribonuclease in complex with poly-dT DNA
6J7Z	;	2.005	;	Human mitochondrial Oligoribonuclease in complex with RNA
7QI4	;	2.21	;	Human mitochondrial ribosome at 2.2 A resolution (bound to partly built tRNAs and mRNA)
6ZSA	;	4.0	;	Human mitochondrial ribosome bound to mRNA, A-site tRNA and P-site tRNA
6ZSC	;	3.5	;	Human mitochondrial ribosome in complex with E-site tRNA
8ANY	;	2.85	;	Human mitochondrial ribosome in complex with LRPPRC, SLIRP, A-site, P-site, E-site tRNAs and mRNA
6ZSB	;	4.5	;	Human mitochondrial ribosome in complex with mRNA and P-site tRNA
6ZSG	;	4.0	;	Human mitochondrial ribosome in complex with mRNA, A-site tRNA, P-site tRNA and E-site tRNA
6ZM6	;	2.59	;	Human mitochondrial ribosome in complex with mRNA, A/A tRNA and P/P tRNA
7QI5	;	2.63	;	Human mitochondrial ribosome in complex with mRNA, A/A-, P/P- and E/E-tRNAs at 2.63 A resolution
7QI6	;	2.98	;	Human mitochondrial ribosome in complex with mRNA, A/P- and P/E-tRNAs at 2.98 A resolution
6ZSE	;	5.0	;	Human mitochondrial ribosome in complex with mRNA, A/P-tRNA and P/E-tRNA
6ZSD	;	3.7	;	Human mitochondrial ribosome in complex with mRNA, P-site tRNA and E-site tRNA
6ZM5	;	2.89	;	Human mitochondrial ribosome in complex with OXA1L, mRNA, A/A tRNA, P/P tRNA and nascent polypeptide
7OG4	;	3.8	;	Human mitochondrial ribosome in complex with P/E-tRNA
6ZS9	;	4.0	;	Human mitochondrial ribosome in complex with ribosome recycling factor
7O9M	;	2.6	;	Human mitochondrial ribosome large subunit assembly intermediate with MTERF4-NSUN4, MRM2, MTG1 and the MALSU module
7O9K	;	3.1	;	Human mitochondrial ribosome large subunit assembly intermediate with MTERF4-NSUN4, MRM2, MTG1, the MALSU module, GTPBP5 and mtEF-Tu
7PO3	;	2.92	;	Human mitochondrial ribosome small subunit
7P2E	;	2.4	;	Human mitochondrial ribosome small subunit in complex with IF3, GMPPMP and streptomycin
8GKS	;	2.99	;	Human mitochondrial serine hydroxymethyltransferase (SHMT2) in complex with PLP, glycine and AGF291 inhibitor
8GKT	;	2.64	;	Human mitochondrial serine hydroxymethyltransferase (SHMT2) in complex with PLP, glycine and AGF320 inhibitor
8FJU	;	2.51	;	Human mitochondrial serine hydroxymethyltransferase (SHMT2) in complex with PLP, glycine and AGF347 inhibitor
8T4O	;	2.68	;	Human mitochondrial serine hydroxymethyltransferase (SHMT2) in complex with PLP, glycine and AGF347 inhibitor with no glutamate
8GKU	;	3.06	;	Human mitochondrial serine hydroxymethyltransferase (SHMT2) in complex with PLP, glycine and AGF355 inhibitor
8GKW	;	2.38	;	Human mitochondrial serine hydroxymethyltransferase (SHMT2) in complex with PLP, glycine and AGF359 inhibitor
8FJT	;	2.47	;	Human mitochondrial serine hydroxymethyltransferase (SHMT2) in complex with PLP, glycine and AGF362 inhibitor
8T4P	;	2.801	;	Human mitochondrial serine hydroxymethyltransferase (SHMT2) in complex with PLP, glycine and di-glutamate AGF347 inhibitor
8TLC	;	2.72	;	Human mitochondrial serine hydroxymethyltransferase (SHMT2) in complex with PLP, glycine and tri-glutamate AGF347 inhibitor
8GKY	;	2.77	;	Human mitochondrial serine hydroxymethyltransferase (SHMT2) Y105F in complex with PLP, glycine and AGF359 inhibitor
8GKZ	;	2.75	;	Human mitochondrial serine hydroxymethyltransferase (SHMT2) Y105F in complex with PLP, glycine and AGF362 inhibitor
6DK3	;	2.04	;	HUMAN MITOCHONDRIAL SERINE HYDROXYMETHYLTRANSFERASe 2
1S3O	;	2.47	;	Human mitochondrial single strand DNA binding protein (hmSSB)
3ULL	;	2.4	;	HUMAN MITOCHONDRIAL SINGLE-STRANDED DNA BINDING PROTEIN
6RUP	;	2.1	;	Human mitochondrial single-stranded DNA binding protein, SSBP1, at 2.1 A resolution - elucidated sequence
8CSP	;	2.66	;	Human mitochondrial small subunit assembly intermediate (State A)
8CSQ	;	2.54	;	Human mitochondrial small subunit assembly intermediate (State B)
8CSR	;	2.54	;	Human mitochondrial small subunit assembly intermediate (State C)
8CSU	;	3.03	;	Human mitochondrial small subunit assembly intermediate (State C*)
8CSS	;	2.36	;	Human mitochondrial small subunit assembly intermediate (State D)
8CST	;	2.85	;	Human mitochondrial small subunit assembly intermediate (State E)
3FGH	;	1.35	;	Human mitochondrial transcription factor A box B
5EKD	;	1.82	;	Human mitochondrial tryptophanyl-tRNA synthetase bound by indolmycin and Mn*ATP.
3LPQ	;	1.7	;	Human MitoNEET with 2Fe-2S Coordinating Ligand His 87 Replaced With Cys
8PK0	;	3.03	;	human mitoribosomal large subunit assembly intermediate 1 with GTPBP10-GTPBP7
8QSJ	;	3.0	;	Human mitoribosomal large subunit assembly intermediate 2 with GTPBP7
3RTT	;	1.82	;	Human MMP-12 catalytic domain in complex with*(R)-N*-Hydroxy-1-(phenethylsulfonyl)pyrrolidine-2-carboxamide
3RTS	;	1.81	;	Human MMP-12 catalytic domain in complex with*N*-Hydroxy-2-(2-phenylethylsulfonamido)acetamide
2OXW	;	1.15	;	Human MMP-12 complexed with the peptide IAG
2OXZ	;	1.9	;	Human MMP-12 in complex with two peptides PQG and IAG
2OY2	;	1.5	;	Human MMP-8 in complex with peptide IAG
6RLY	;	2.2	;	Human MMP12 (catalytic domain) in complex with AP316
6RD0	;	1.9	;	Human MMP12 catalytic domain in complex with AP280
4GUY	;	2.0	;	Human MMP12 catalytic domain in complex with*N*-Hydroxy-2-(2-(4-methoxyphenyl)ethylsulfonamido)acetamide
5N5J	;	1.8	;	Human MMP12 in complex with 3-(5-(1,2-dithiolan-3-yl)pentanamido)propane-1-sulfonate
4I03	;	1.7	;	Human MMP12 in complex with a PEG-linked bifunctional L-glutamate motif inhibitor
3TS4	;	1.587	;	Human MMP12 in complex with L-glutamate motif inhibitor
3TSK	;	2.0	;	Human MMP12 in complex with L-glutamate motif inhibitor
4EFS	;	1.63	;	Human MMP12 in complex with L-glutamate motif inhibitor
3LIK	;	1.8	;	Human MMP12 in complex with non-zinc chelating inhibitor
3LIL	;	1.8	;	Human MMP12 in complex with non-zinc chelating inhibitor
3LIR	;	1.9	;	Human MMP12 in complex with non-zinc chelating inhibitor
3LJG	;	1.313	;	Human MMP12 in complex with non-zinc chelating inhibitor
3TVC	;	2.43	;	Human MMP13 in complex with L-glutamate motif inhibitor
3TT4	;	1.88	;	Human MMP8 in complex with L-glutamate motif inhibitor
5T30	;	1.77	;	Human MnSOD-azide complex
4JIZ	;	2.1	;	Human Mob1-phosphopeptide complex
5TWG	;	2.3	;	human MOB1A bound to human MST1 phosphorylated T353 peptide
5TWH	;	2.5	;	human MOB1A bound to MST1 phosphorylated T367 peptide
5J8C	;	2.17	;	Human MOF C316S, E350Q crystal structure
3TOA	;	3.004	;	Human MOF crystal structure with active site lysine partially acetylated
3TOB	;	2.703	;	Human MOF E350Q crystal structure with active site lysine partially acetylated
5J8F	;	2.6	;	Human MOF K274P crystal structure
2BXR	;	3.0	;	Human Monoamine Oxidase A in complex with Clorgyline, Crystal Form A
2BXS	;	3.15	;	Human Monoamine Oxidase A in complex with Clorgyline, Crystal Form B
1GOS	;	3.0	;	Human Monoamine Oxidase B
1OJ9	;	2.3	;	HUMAN MONOAMINE OXIDASE B IN COMPLEX WITH 1,4-DIPHENYL-2-BUTENE
2XFN	;	1.6	;	Human monoamine oxidase B in complex with 2-(2-benzofuranyl)-2- imidazoline
2BYB	;	2.2	;	Human Monoamine Oxidase B in complex with Deprenyl
2BK3	;	1.8	;	Human Monoamine Oxidase B in complex with Farnesol
1OJA	;	1.7	;	HUMAN MONOAMINE OXIDASE B IN COMPLEX WITH ISATIN
1OJD	;	3.1	;	HUMAN MONOAMINE OXIDASE B IN COMPLEX WITH Lauryldimethylamine-N-oxide (LDAO)
1OJC	;	2.4	;	HUMAN MONOAMINE OXIDASE B IN COMPLEX WITH N-(2-aminoethyl)-p-chlorobenzamide
3PO7	;	1.8	;	Human monoamine oxidase B in complex with zonisamide
2XFU	;	2.2	;	Human monoamine oxidase B with tranylcypromine
2BK5	;	1.83	;	Human Monoamine Oxidase B: I199F mutant in complex with isatin
2BK4	;	1.9	;	Human Monoamine Oxidase B: I199F mutant in complex with rasagiline
5NST	;	2.52	;	Human monoclonal antibody with a LAIR1 insertion
2P4N	;	9.0	;	Human Monomeric Kinesin (1BG2) and Bovine Tubulin (1JFF) Docked into the 9-Angstrom Cryo-EM Map of Nucleotide-Free Kinesin Complexed to the Microtubule
3SVM	;	2.31	;	Human MPP8 - human DNMT3AK47me2 peptide
2X9E	;	3.1	;	HUMAN MPS1 IN COMPLEX WITH NMS-P715
6GVJ	;	2.41	;	Human Mps1 kinase domain with ordered activation loop
7TXH	;	1.95	;	Human MRas Q71R in complex with human Shoc2 LRR domain M173I and human PP1Ca
8BAH	;	4.13	;	Human Mre11-Nbs1 complex
1IG6	;		;	HUMAN MRF-2 DOMAIN, NMR, 11 STRUCTURES
3OA6	;	2.35	;	Human MSL3 Chromodomain bound to DNA and H4K20me1 peptide
3ZHP	;	2.9	;	Human MST3 (STK24) in complex with MO25beta
8QLR	;	1.85	;	Human MST3 (STK24) kinase in complex with inhibitor MR24
8QLS	;	1.61	;	Human MST3 (STK24) kinase in complex with inhibitor MR26
8QLT	;	1.47	;	Human MST3 (STK24) kinase in complex with inhibitor MR30
8BZI	;	1.72	;	Human MST3 (STK24) kinase in complex with inhibitor MR39
8BZJ	;	2.52	;	Human MST3 (STK24) kinase in complex with inhibitor MRLW5
8QLQ	;	1.64	;	Human MST3 (STK24) kinase in complex with macrocyclic inhibitor JA310
3A7F	;	1.55	;	Human MST3 kinase
3A7G	;	2.0	;	Human MST3 kinase
3A7I	;	1.45	;	Human MST3 kinase in complex with adenine
3A7H	;	1.96	;	Human MST3 kinase in complex with ATP
3A7J	;	1.5	;	Human MST3 kinase in complex with MnADP
4FP9	;	2.9	;	Human MTERF4-NSUN4 protein complex
6JID	;	2.5	;	Human MTHFD2 in complex with Compound 1
6KG2	;	2.25	;	Human MTHFD2 in complex with Compound 18
7EHM	;	2.13	;	Human MTHFD2 in complex with compound 21 and 15
7EHV	;	2.61	;	Human MTHFD2 in complex with compound 21 and 3
7EHN	;	2.25	;	Human MTHFD2 in complex with compound 21 and 9
7EHJ	;	2.16	;	human MTHFD2 in complex with compound 21, cofactor and phosphate.
6JIB	;	2.25	;	Human MTHFD2 in complex with DS44960156
6C90	;	2.2	;	Human Mtr4 helicase in complex with ZCCHC8-CTD
7SA9	;	1.69	;	Human MUC16 SEA5 Domain
6TM2	;	2.95	;	Human MUC2 AAs 21-1397
7A5O	;	2.95	;	Human MUC2 AAs 21-1397
4P0R	;	6.501	;	human Mus81-Eme1-3'flap DNA complex
4P0S	;	6.0	;	human Mus81-Eme1-3'flap DNA complex
2ALD	;	2.1	;	HUMAN MUSCLE ALDOLASE
4ALD	;	2.8	;	HUMAN MUSCLE FRUCTOSE 1,6-BISPHOSPHATE ALDOLASE COMPLEXED WITH FRUCTOSE 1,6-BISPHOSPHATE
5K54	;	1.717	;	Human muscle fructose-1,6-bisphosphatase E69Q mutant in active R-state
5L0A	;	2.302	;	Human muscle fructose-1,6-bisphosphatase E69Q mutant in active R-state in complex with fructose-1,6-bisphosphate
5K55	;	1.977	;	Human muscle fructose-1,6-bisphosphatase E69Q mutant in active R-state in complex with fructose-6-phosphate
3IFA	;	1.93	;	Human muscle fructose-1,6-bisphosphatase E69Q mutant in complex with AMP
3IFC	;	1.97	;	Human muscle fructose-1,6-bisphosphatase E69Q mutant in complex with AMP and alpha fructose-6-phosphate
5ET5	;	1.67	;	Human muscle fructose-1,6-bisphosphatase in active R-state
5K56	;	2.198	;	Human muscle fructose-1,6-bisphosphatase in active R-state in complex with fructose-1,6-bisphosphate
5ET8	;	1.92	;	Human muscle fructose-1,6-bisphosphatase in active R-state in complex with fructose-6-phosphate
5ET7	;	2.989	;	Human muscle fructose-1,6-bisphosphatase in inactive T-state
5ET6	;	1.845	;	Human muscle fructose-1,6-bisphosphatase in inactive T-state in complex with AMP
5KY6	;	1.941	;	Human muscle fructose-1,6-bisphosphate aldolase
1I10	;	2.3	;	HUMAN MUSCLE L-LACTATE DEHYDROGENASE M CHAIN, TERNARY COMPLEX WITH NADH AND OXAMATE
8AG6	;	2.8	;	human MutSalpha (MSH2/MSH6) binding to DNA with a GT mismatch
2O8E	;	3.3	;	human MutSalpha (MSH2/MSH6) bound to a G T mispair, with ADP bound to MSH2 only
2O8D	;	3.0	;	human MutSalpha (MSH2/MSH6) bound to ADP and a G dU mispair
2O8B	;	2.75	;	human MutSalpha (MSH2/MSH6) bound to ADP and a G T mispair
2O8C	;	3.37	;	human MutSalpha (MSH2/MSH6) bound to ADP and an O6-methyl-guanine T mispair
2O8F	;	3.25	;	human MutSalpha (MSH2/MSH6) bound to DNA with a single base T insert
3THY	;	2.894	;	Human MutSbeta complexed with an IDL of 2 bases (Loop2) and ADP
3THX	;	2.7	;	Human MutSbeta complexed with an IDL of 3 bases (Loop3) and ADP
3THW	;	3.09	;	Human MutSbeta complexed with an IDL of 4 bases (Loop4) and ADP
3THZ	;	4.3	;	Human MutSbeta complexed with an IDL of 6 bases (Loop6) and ADP
7NTP	;	2.1	;	Human myelin P2 mutant V115A
4A8Z	;	1.801	;	Human myelin P2 protein, K112Q mutant
4A1H	;	2.201	;	Human myelin P2 protein, K45S mutant
4A1Y	;	1.2	;	Human myelin P2 protein, K65Q mutant
5N4P	;	1.533	;	Human myelin P2, mutant I52T
4D6A	;	1.45	;	Human myelin protein P2 after neutron scattering experiments
6EW4	;	1.271	;	Human myelin protein P2 F57A mutant, monoclinic crystal form
6EW5	;	1.95	;	Human myelin protein P2 F57A mutant, monoclinic crystal form
6EW2	;	1.588	;	Human myelin protein P2 F57A mutant, tetragonal crystal form
6XW9	;	2.9	;	Human myelin protein P2 mutant K120S
6XUA	;	2.3	;	Human myelin protein P2 mutant K21Q
6XVQ	;	1.8	;	Human myelin protein P2 mutant K31Q
6XU9	;	2.7	;	Human myelin protein P2 mutant K3N
6XUW	;	2.31	;	Human myelin protein P2 mutant L27D
6XVR	;	2.0	;	Human myelin protein P2 mutant L35S
7NRW	;	2.0	;	Human myelin protein P2 mutant M114T
6XU5	;	1.65	;	Human myelin protein P2 mutant N2D
6XVS	;	1.8	;	Human myelin protein P2 mutant P38G, unliganded
6STS	;	3.0	;	Human myelin protein P2 mutant R30Q
6XVY	;	1.8	;	Human myelin protein P2 mutant R88Q
5N4M	;	1.59	;	Human myelin protein P2, mutant I43N
4D6B	;	2.116	;	Human myelin protein P2, mutant P38G
5N4Q	;	1.72	;	Human myelin protein P2, mutant T51P
6SVK	;	1.604	;	human Myeloid-derived growth factor (MYDGF)
6SVL	;	1.58	;	human Myeloid-derived growth factor (MYDGF) in complex with neutralizing Fab
3ZS0	;	2.3	;	Human Myeloperoxidase inactivated by TX2
3ZS1	;	2.6	;	Human Myeloperoxidase inactivated by TX5
1DNW	;	1.9	;	HUMAN MYELOPEROXIDASE-CYANIDE-THIOCYANATE COMPLEX
1AWB	;	2.5	;	HUMAN MYO-INOSITOL MONOPHOSPHATASE IN COMPLEX WITH D-INOSITOL-1-PHOSPHATE AND CALCIUM
2YF0	;	2.65	;	Human Myotubularin related protein 6 (MTMR6)
2GIV	;	1.94	;	Human MYST histone acetyltransferase 1
5WCI	;	1.78	;	Human MYST histone acetyltransferase 1
2PQT	;	1.78	;	Human N-acetyltransferase 1
2IJA	;	1.701	;	Human N-acetyltransferase 1 F125S mutant
2PFR	;	1.92	;	Human N-acetyltransferase 2
6DXX	;	2.7	;	Human N-acylethanolamine-hydrolyzing acid amidase (NAAA) in complex with non-covalent benzothiazole-piperazine inhibitor ARN19702, in presence of Triton X-100
6DXW	;	2.3	;	Human N-acylethanolamine-hydrolyzing acid amidase (NAAA) precursor (C126A)
5MU6	;	1.88	;	Human N-myristoyltransferase (NMT1) with Myristoyl-CoA and IMP-1088 inhibitor bound
4C2Z	;	2.08	;	Human N-myristoyltransferase (NMT1) with Myristoyl-CoA and inhibitor bound
6FZ2	;	2.05	;	Human N-myristoyltransferase (NMT1) with Myristoyl-CoA and inhibitor bound
6FZ3	;	2.0	;	Human N-myristoyltransferase (NMT1) with Myristoyl-CoA and inhibitor bound
6FZ5	;	1.89	;	Human N-myristoyltransferase (NMT1) with Myristoyl-CoA and inhibitor bound
6EHJ	;	2.1	;	Human N-myristoyltransferase (NMT1) with Myristoyl-CoA and peptide bound
4C2Y	;	1.64	;	Human N-myristoyltransferase (NMT1) with Myristoyl-CoA co-factor
5NPQ	;	2.372	;	Human N-myristoyltransferase 1 (MNT1) with Myristoyl-CoA analogue X10 bound
4C2X	;	2.33	;	Human N-myristoyltransferase isoform 2 (NMT2)
5XM2	;	2.187	;	Human N-terminal domain of FACT complex subunit SPT16
7VFS	;	2.8	;	Human N-type voltage gated calcium channel CaV2.2-alpha2/delta1-beta1 complex, apo state
7VFW	;	3.3	;	Human N-type voltage gated calcium channel CaV2.2-alpha2/delta1-beta1 complex, bound to CaV2.2-blocker1
7VFV	;	3.0	;	Human N-type voltage gated calcium channel CaV2.2-alpha2/delta1-beta1 complex, bound to PD173212
7VFU	;	3.0	;	Human N-type voltage gated calcium channel CaV2.2-alpha2/delta1-beta1 complex, bound to ziconotide
7MIY	;	3.1	;	Human N-type voltage-gated calcium channel Cav2.2 at 3.1 Angstrom resolution
7MIX	;	3.0	;	Human N-type voltage-gated calcium channel Cav2.2 in the presence of ziconotide at 3.0 Angstrom resolution
4X5K	;	2.494	;	Human NAA50 complex with coenzyme A and an acetylated peptide
3LKX	;	2.5	;	Human nac dimerization domain
7SX3	;	3.1	;	Human NALCN-FAM155A-UNC79-UNC80 channelosome with CaM bound, conformation 1/2
7SX4	;	3.5	;	Human NALCN-FAM155A-UNC79-UNC80 channelosome with CaM bound, conformation 2/2
6TAC	;	1.6	;	Human NAMPT deletion mutant in complex with nicotinamide mononucleotide, pyrophosphate, and Mg2+
8DSM	;	2.75	;	Human NAMPT in complex with inhibitor ZN-4-3
6TA0	;	1.58	;	Human NAMPT in complex with nicotinic acid and phosphoribosyl pyrophosphate
6TA2	;	1.68	;	Human NAMPT in complex with nicotinic acid mononucleotide and phosphate
8DSH	;	2.2	;	Human NAMPT in complex with quercitrin and AMPcP
8DTJ	;	2.118	;	Human NAMPT in complex with small molecule activator ZN-43-S
8DSI	;	1.43	;	Human NAMPT in complex with substrate NAM
8DSE	;	1.428	;	Human NAMPT in complex with substrate NAM and activator quercitrin
8DSC	;	1.321	;	Human NAMPT in complex with substrate NAM and small molecule activator NP-A1-R
8DSD	;	1.429	;	Human NAMPT in complex with substrate NAM and small molecule activator NP-A1-S
8F7L	;	2.2	;	Human NAMPT in complex with substrate NAM and small molecule activator ZN-29-S
6J8E	;	3.0	;	Human Nav1.2-beta2-KIIIA ternary complex
7XVE	;	2.7	;	Human Nav1.7 mutant class-I
5EK0	;	3.53	;	Human Nav1.7-VSD4-NavAb in complex with GX-936.
7WE4	;	2.7	;	Human Nav1.8 with A-803467, class I
7WEL	;	3.2	;	Human Nav1.8 with A-803467, class II
7WFR	;	3.0	;	Human Nav1.8 with A-803467, class III
6GKD	;	2.99	;	human NBD1 of CFTR in complex with nanobodies D12 and G3a
6GJS	;	1.95	;	Human NBD1 of CFTR in complex with nanobodies D12 and T4
6GK4	;	2.91	;	Human NBD1 of CFTR in complex with nanobodies D12 and T8
6GJU	;	2.6	;	human NBD1 of CFTR in complex with nanobodies T2a and T4
6ZE1	;	2.705	;	human NBD1 of CFTR in complex with nanobody G11a
6GJQ	;	2.49	;	human NBD1 of CFTR in complex with nanobody T27
2BBO	;	2.55	;	Human NBD1 with Phe508
2VKW	;	2.3	;	Human NCAM, FN3 domains 1 and 2
2VKX	;	2.7	;	Human NCAM, FN3 domains 1 and 2, M610R mutant
2CIA	;	1.45	;	human nck2 sh2-domain in complex with a decaphosphopeptide from translocated intimin receptor (tir) of epec
3IZ0	;	8.6	;	Human Ndc80 Bonsai Decorated Microtubule
2KQ0	;		;	Human NEDD4 3rd WW Domain Complex with Ebola Zaire Virus Matrix Protein VP40 Derived Peptide ILPTAPPEYMEA
2KPZ	;		;	Human NEDD4 3RD WW Domain Complex with The Human T-cell Leukemia virus 1 GAG-Pro poliprotein Derived Peptide SDPQIPPPYVEP
2W5A	;	1.55	;	Human Nek2 kinase ADP-bound
2W5H	;	2.33	;	Human Nek2 kinase Apo
2W5B	;	2.4	;	Human Nek2 kinase ATPgammaS-bound
2QPJ	;	2.05	;	Human NEP complexed with a bifunctional NEP/DPP IV inhibitor
1HE7	;	2.0	;	Human Nerve growth factor receptor TrkA
7LWH	;	1.606	;	Human neurofibromin 2/merlin residues 1-339 in complex with LATS1
6CDS	;	2.62	;	Human neurofibromin 2/merlin/schwannomin residues 1-339 in complex with PIP2
7P00	;	2.71	;	Human Neurokinin 1 receptor (NK1R) substance P Gq chimera (mGsqi) complex
7P02	;	2.87	;	Human Neurokinin 1 receptor (NK1R) substance P Gs complex
8IYG	;	2.69	;	Human neuronal gap junction channel connexin 36
2E9S	;	1.78	;	human neuronal Rab6B in three intermediate forms
6OS9	;	3.0	;	human Neurotensin Receptor 1 (hNTSR1) - Gi1 Protein Complex in canonical conformation (C state)
6OSA	;	3.0	;	human Neurotensin Receptor 1 (hNTSR1) - Gi1 Protein Complex in non-canonical conformation (NC state)
1NT3	;	2.4	;	HUMAN NEUROTROPHIN-3
5NMZ	;	1.6	;	human Neurturin (97-197)
8J2F	;	3.07	;	Human neutral shpingomyelinase
7WHU	;	2.89	;	Human Neutrophil Elastase in-complex with Ecotin Peptide
1NGL	;		;	HUMAN NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (HNGAL), REGULARISED AVERAGE NMR STRUCTURE
7Z4Z	;	4.0	;	Human NEXT dimer - focused reconstruction of the dimerization module
7Z52	;	3.4	;	Human NEXT dimer - focused reconstruction of the single MTR4
7Z4Y	;	4.5	;	Human NEXT dimer - overall reconstruction of the core complex
1A3Q	;	2.1	;	HUMAN NF-KAPPA-B P52 BOUND TO DNA
2IIP	;	2.05	;	Human Nicotinamide N-methyltransferase
2QL6	;	2.7	;	human nicotinamide riboside kinase (NRK1)
2QSY	;	1.95	;	Human nicotinamide riboside kinase 1 in complex with ADP
2QSZ	;	1.9	;	Human nicotinamide riboside kinase 1 in complex with nicotinamide mononucleotide
2QT1	;	1.32	;	Human nicotinamide riboside kinase 1 in complex with nicotinamide riboside
2QT0	;	1.92	;	Human nicotinamide riboside kinase 1 in complex with nicotinamide riboside and an ATP analogue
2P0E	;	1.8	;	Human nicotinamide riboside kinase 1 in complex with tiazofurin
6WPP	;	2.55	;	HUMAN NIK IN COMPLEX WITH LIGAND COMPOUND X
7D10	;	3.52	;	Human NKCC1
7SFL	;	3.87	;	Human NKCC1 state Fu-II
7WGE	;	3.4	;	Human NLRP1 complexed with thioredoxin
7ZGU	;	3.4	;	Human NLRP3-deltaPYD hexamer
8OOV	;	1.7	;	human NME-1 in complex with CoA
5O6J	;	1.45	;	Human NMT1 in complex with myristoyl-CoA and inhibitor IMP-1031
5O6H	;	1.29	;	Human NMT1 in complex with myristoyl-CoA and inhibitor IMP-917
2G31	;		;	Human Nogo-A functional domain: nogo60
5IFM	;	2.6	;	Human NONO (p54nrb) Homodimer
4NRT	;	2.022	;	Human Norovirus polymerase bound to Compound 6 (suramin derivative)
5FM9	;	2.92	;	human Notch 1, EGF 4-7
5FMA	;	2.46	;	human Notch 1, EGF 4-7
2VJ3	;	2.6	;	Human Notch-1 EGFs 11-13
5MWB	;	1.86	;	Human Notch-2 EGF11-13
4CUD	;	1.85	;	Human Notch1 EGF domains 11-13 mutant fucosylated at T466
4D0E	;	1.61	;	Human Notch1 EGF domains 11-13 mutant GlcNAc-fucose disaccharide modified at T466
4D0F	;	2.8	;	Human Notch1 EGF domains 11-13 mutant T466A
4CUF	;	2.29	;	Human Notch1 EGF domains 11-13 mutant T466S
4CUE	;	3.0	;	Human Notch1 EGF domains 11-13 mutant T466V
2QW4	;	2.8	;	Human NR4A1 ligand-binding domain
5DN2	;	1.95	;	Human NRP2 b1 domain in complex with the peptide corresponding to the C-terminus of VEGF-A
2B9E	;	1.65	;	Human NSUN5 protein
7FCI	;	3.3	;	human NTCP in complex with YN69083 Fab
7S7C	;	3.62	;	Human Nuclear Exosome Targeting (NEXT) complex bound to RNA (substrate 2)
7S7B	;	4.06	;	Human Nuclear exosome targeting (NEXT) complex homodimer bound to RNA (substrate 1)
6D6R	;	3.45	;	Human nuclear exosome-MTR4 RNA complex - composite map after focused reconstruction
6D6Q	;	3.45	;	Human nuclear exosome-MTR4 RNA complex - overall reconstruction
5A9Q	;	23.0	;	Human nuclear pore complex
7R5K	;	12.0	;	Human nuclear pore complex (constricted)
7R5J	;	50.0	;	Human nuclear pore complex (dilated)
8IR1	;	3.3	;	human nuclear pre-60S ribosomal particle - State A
8IR3	;	3.5	;	human nuclear pre-60S ribosomal particle - State B'
8IPD	;	3.2	;	human nuclear pre-60S ribosomal particle - State C
8IPX	;	4.3	;	human nuclear pre-60S ribosomal particle - State C'
8INK	;	3.2	;	human nuclear pre-60S ribosomal particle - State D
8IPY	;	3.2	;	human nuclear pre-60S ribosomal particle - State D'
8IE3	;	3.3	;	human nuclear pre-60S ribosomal particle - State E
8IDY	;	3.0	;	human nuclear pre-60S ribosomal particle - State F
8INF	;	3.0	;	human nuclear pre-60S ribosomal particle - State F'
8IDT	;	2.8	;	human nuclear pre-60S ribosomal particle - State G
8INE	;	3.2	;	human nuclear pre-60S ribosomal particle - State G'
8FL2	;	2.67	;	Human nuclear pre-60S ribosomal subunit (State I1)
8FL3	;	2.53	;	Human nuclear pre-60S ribosomal subunit (State I2)
8FL4	;	2.89	;	Human nuclear pre-60S ribosomal subunit (State I3)
8FL6	;	2.62	;	Human nuclear pre-60S ribosomal subunit (State J1)
8FL7	;	2.55	;	Human nuclear pre-60S ribosomal subunit (State J2)
8FL9	;	2.75	;	Human nuclear pre-60S ribosomal subunit (State J3)
8FLA	;	2.63	;	Human nuclear pre-60S ribosomal subunit (State K1)
8FLB	;	2.55	;	Human nuclear pre-60S ribosomal subunit (State K2)
8FLC	;	2.76	;	Human nuclear pre-60S ribosomal subunit (State K3)
8FLD	;	2.58	;	Human nuclear pre-60S ribosomal subunit (State L1)
8FLE	;	2.48	;	Human nuclear pre-60S ribosomal subunit (State L2)
8FLF	;	2.65	;	Human nuclear pre-60S ribosomal subunit (State L3)
4PLE	;	1.752	;	Human Nuclear Receptor Liver Receptor Homologue-1, LRH-1, Bound to an E. Coli Phospholipid and a Fragment of TIF-2
4DOS	;	2.0	;	Human Nuclear Receptor Liver Receptor Homologue-1, LRH-1, Bound to DLPC and a Fragment of TIF-2
1YUC	;	1.9	;	Human Nuclear Receptor Liver Receptor Homologue-1, LRH-1, Bound to Phospholipid and a Fragment of Human SHP
4DOR	;	1.9	;	Human Nuclear Receptor Liver Receptor Homologue-1, LRH-1, in its apo State Bound to a Fragment of Human SHP Box1
4PLD	;	1.75	;	Human Nuclear Receptor Liver Receptor Homologue-1, LRH-1, in its apo State Bound to a Fragment of Human TIF-2
2AWH	;	2.0	;	Human Nuclear Receptor-Ligand Complex 1
2BAW	;	2.3	;	Human Nuclear Receptor-Ligand Complex 1
2B50	;	2.0	;	Human Nuclear Receptor-Ligand Complex 2
6H25	;	3.8	;	Human nuclear RNA exosome EXO-10-MPP6 complex
2X8A	;	2.6	;	Human Nuclear Valosin containing protein Like (NVL), C-terminal AAA- ATPase domain
8FKP	;	2.85	;	Human nucleolar pre-60S ribosomal subunit (State A1)
8FKQ	;	2.76	;	Human nucleolar pre-60S ribosomal subunit (State A2)
8FKR	;	2.89	;	Human nucleolar pre-60S ribosomal subunit (State B1)
8FKS	;	2.88	;	Human nucleolar pre-60S ribosomal subunit (State B2)
8FKT	;	2.81	;	Human nucleolar pre-60S ribosomal subunit (State C1)
8FKU	;	2.82	;	Human nucleolar pre-60S ribosomal subunit (State C2)
8FKV	;	2.47	;	Human nucleolar pre-60S ribosomal subunit (State D1)
8FKW	;	2.5	;	Human nucleolar pre-60S ribosomal subunit (State D2)
8FKX	;	2.59	;	Human nucleolar pre-60S ribosomal subunit (State E)
8FKY	;	2.67	;	Human nucleolar pre-60S ribosomal subunit (State F)
8FKZ	;	3.04	;	Human nucleolar pre-60S ribosomal subunit (State G)
8FL0	;	2.91	;	Human nucleolar pre-60S ribosomal subunit (State H)
3T30	;	1.9	;	Human nucleoplasmin (Npm2): a histone chaperone in oocytes and early embryos
1EHW	;	2.4	;	HUMAN NUCLEOSIDE DIPHOSPHATE KINASE 4
2HVD	;	2.15	;	Human nucleoside diphosphate kinase A complexed with ADP
5LF8	;	2.56	;	Human Nucleoside diphosphate-linked moiety X motif 17 (NUDT17)
5B2J	;	2.6	;	Human nucleosome containing CpG methylated DNA
5B2I	;	3.0	;	Human nucleosome containing CpG unmethylated DNA
5AV5	;	2.4	;	human nucleosome core particle
5AV6	;	2.2	;	human nucleosome core particle
5AV8	;	2.2	;	human nucleosome core particle
5AV9	;	2.2	;	human nucleosome core particle
5AVB	;	2.4	;	human nucleosome core particle
5AVC	;	2.4	;	human nucleosome core particle
8GUK	;	2.51	;	Human nucleosome core particle (free form)
6IPU	;	1.99	;	Human nucleosome core particle containing 145 bp of DNA
6JXD	;	2.25	;	Human nucleosome core particle with cohesive end DNA termini
6K1I	;	2.75	;	Human nucleosome core particle with gammaH2A.X variant
6K1K	;	2.2	;	Human nucleosome core particle with H2A.X S139E variant
6K1J	;	2.85	;	Human nucleosome core particle with H2A.X variant
5LOR	;	2.192	;	human NUDT22
5LOU	;	1.8	;	human NUDT22
3F0W	;	2.7	;	Human NUMB-like protein, phosphotyrosine interaction domain
7OU6	;	2.41	;	Human O-GlcNAc hydrolase in complex with DNJNAc-thiazolidines
7OU8	;	1.5	;	Human O-GlcNAc hydrolase in complex with DNJNAc-thiazolidines
4AY5	;	3.15	;	Human O-GlcNAc transferase (OGT) in complex with UDP and glycopeptide
4AY6	;	3.3	;	Human O-GlcNAc transferase (OGT) in complex with UDP-5SGlcNAc and substrate peptide
7YEA	;	3.82	;	Human O-GlcNAc transferase Dimer
4CDR	;	3.15	;	Human O-GlcNAc transferase in complex with a bisubstrate inhibitor, Goblin1
6TOR	;	2.05	;	human O-phosphoethanolamine phospho-lyase
1EH6	;	2.0	;	HUMAN O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE
1T38	;	3.2	;	HUMAN O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE BOUND TO DNA CONTAINING O6-METHYLGUANINE
1T39	;	3.3	;	HUMAN O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE COVALENTLY CROSSLINKED TO DNA
8PHW	;	3.6	;	Human OATP1B1
8PG0	;	2.97	;	Human OATP1B3
1AX8	;	2.4	;	Human obesity protein, leptin
7R68	;		;	Human obscurin Ig12
7R67	;		;	Human obscurin Ig13
6MG9	;		;	Human Obscurin Ig57 Domain
4RSV	;	2.41	;	Human Obscurin Ig58 Domain
8SC1	;	2.92	;	Human OCT1 (Apo) in inward-open conformation
8SC2	;	3.36	;	Human OCT1 bound to diltiazem in inward-open conformation
8SC3	;	3.24	;	Human OCT1 bound to fenoterol in inward-open conformation
8SC4	;	3.46	;	Human OCT1 bound to metformin in inward-open conformation
8SC6	;	3.13	;	Human OCT1 bound to thiamine in inward-open conformation
8G8E	;	3.9	;	Human Oct4 bound to nucleosome with human LIN28B sequence
8G88	;	2.3	;	Human Oct4 bound to nucleosome with human nMatn1 sequence
8G86	;	2.3	;	Human Oct4 bound to nucleosome with human nMatn1 sequence (focused refinement of nucleosome)
8G87	;	8.1	;	Human Oct4 bound to nucleosome with human nMatn1 sequence (focused refinement of Oct4 bound region)
6YB8	;	2.36	;	Human octameric PAICS in complex with CAIR and SAICAR
6YB9	;	2.406	;	Human octameric PAICS in complex with SAICAR, AMP-PNP, and magnesium
1GWR	;	2.4	;	HUMAN OESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH 17BETA-OESTRADIOL AND TIF2 NRBOX3 PEPTIDE
1GWQ	;	2.45	;	HUMAN OESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH RALOXIFENE CORE AND TIF2 NRBOX2 PEPTIDE
1QKM	;	1.8	;	HUMAN OESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH PARTIAL AGONIST GENISTEIN
5LWV	;	1.9	;	Human OGT in complex with UDP and fused substrate peptide (HCF1)
5LVV	;	2.54	;	Human OGT in complex with UDP and fused substrate peptide (Tab1)
4XIF	;	3.2	;	Human OGT in complex with UDP-5S-GlcNAc and substrate peptide (keratin-7)
5C1D	;	2.05	;	Human OGT in complex with UDP-5S-GlcNAc and substrate peptide (RB2L)
4XI9	;	3.1	;	Human OGT in complex with UDP-5S-GlcNAc and substrate peptide (RBL2)
8F76	;	3.1	;	Human olfactory receptor OR51E2 bound to propionate in complex with miniGs399
6YWT	;	1.05	;	Human OMPD-domain of UMPS (K314AcK) in complex with 6-hydroxy-UMP at 1.05 Angstroms resolution
6YWU	;	1.1	;	Human OMPD-domain of UMPS (K314AcK) in complex with UMP at 1.1 Angstroms resolution
7OUZ	;	0.9	;	Human OMPD-domain of UMPS in complex with 6-hydroxy-UMP at 0.9 Angstroms resolution, crystal 1
7OTU	;	0.95	;	Human OMPD-domain of UMPS in complex with 6-hydroxy-UMP at 0.95 Angstroms resolution, crystal 2
7OQF	;	1.05	;	Human OMPD-domain of UMPS in complex with OMP at 1.05 Angstrom resolution, 5 minutes soaking
7OQM	;	1.05	;	Human OMPD-domain of UMPS in complex with substrate OMP at 1.05 Angstroms resolution, 20 minutes soaking
7OQK	;	1.1	;	Human OMPD-domain of UMPS in complex with substrate OMP at 1.10 Angstroms resolution, 15 minutes soaking
7OQN	;	1.1	;	Human OMPD-domain of UMPS in complex with substrate OMP at 1.10 Angstroms resolution, 30 minutes soaking
7OQI	;	1.15	;	Human OMPD-domain of UMPS in complex with substrate OMP at 1.15 Angstrom resolution, 10 minutes soaking
6YVK	;	1.25	;	Human OMPD-domain of UMPS in complex with the substrate OMP at 1.25 Angstroms resolution, 0.71 MGy exposure
6YVL	;	1.25	;	Human OMPD-domain of UMPS in complex with the substrate OMP at 1.25 Angstroms resolution, 1.42 MGy exposure
6YVM	;	1.25	;	Human OMPD-domain of UMPS in complex with the substrate OMP at 1.25 Angstroms resolution, 2.13 MGy exposure
6YVN	;	1.25	;	Human OMPD-domain of UMPS in complex with the substrate OMP at 1.25 Angstroms resolution, 2.84 MGy exposure
6YVO	;	1.25	;	Human OMPD-domain of UMPS in complex with the substrate OMP at 1.25 Angstroms resolution, 3.55 MGy exposure
6WCB	;	3.17	;	Human open state TMEM175 in CsCl
6WC9	;	2.64	;	Human open state TMEM175 in KCl
7CTF	;	4.8	;	Human origin recognition complex 1-5 State II
5UJ8	;	6.0	;	Human Origin Recognition Complex subunits 2 and 3
7CTG	;	5.0	;	Human Origin Recognition Complex, ORC1-5 State I
7CTE	;	3.8	;	Human Origin Recognition Complex, ORC2-5
8EZ1	;	1.91	;	Human Ornithine Aminotransferase (hOAT) co-crystallized with its inactivator 3-Amino-4-fluorocyclopentenecarboxylic Acid
7T9Z	;	2.15	;	Human Ornithine Aminotransferase (hOAT) crystallized at pH 6.0
7TA0	;	2.33	;	Human Ornithine Aminotransferase (hOAT) soaked with 5-aminovaleric acid
7TA1	;	2.2	;	Human Ornithine Aminotransferase (hOAT) soaked with gamma-Aminobutyric acid
7TFP	;	2.71	;	Human Ornithine Aminotransferase cocrystallized with its inhibitor, (1S,3S)-3-amino-4-(difluoromethylene)cyclopentane-1-carboxylic acid.
7TEV	;	1.91	;	Human Ornithine Aminotransferase cocrystallized with its inhibitor, (3S,4R)-3-amino-4-(difluoromethyl)cyclopent-1-ene-1-carboxylate
7TED	;	2.63	;	Human Ornithine Aminotransferase cocrystallized with its inhibitor, (S,E)-3-amino-4-(fluoromethylene)cyclopent-1-ene-1-carboxylate
2CAN	;	2.3	;	HUMAN ORNITHINE AMINOTRANSFERASE COMPLEXED WITH L-CANALINE
1GBN	;	2.3	;	HUMAN ORNITHINE AMINOTRANSFERASE COMPLEXED WITH THE NEUROTOXIN GABACULINE
1C9Y	;	1.9	;	HUMAN ORNITHINE TRANSCARBAMYLASE: CRYSTALLOGRAPHIC INSIGHTS INTO SUBSTRATE RECOGNITION AND CATALYTIC MECHANISM
1EP9	;	2.4	;	HUMAN ORNITHINE TRANSCARBAMYLASE: CRYSTALLOGRAPHIC INSIGHTS INTO SUBSTRATE RECOGNITION AND CONFORMATIONAL CHANGE
2WNS	;	1.9	;	Human Orotate phosphoribosyltransferase (OPRTase) domain of Uridine 5' -monophosphate synthase (UMPS) in complex with its substrate orotidine 5'-monophosphate (OMP)
2V30	;	2.0	;	Human orotidine 5'-phosphate decarboxylase domain of uridine monophospate synthetase (UMPS) in complex with its product UMP.
3EWZ	;	1.4	;	human orotidyl-5'-monophosphate decarboxylase in complex with 5-cyano-UMP
3L0K	;	1.34	;	Human orotidyl-5'-monophosphate decarboxylase in complex with 6-acetyl-UMP
3EX3	;	1.45	;	human orotidyl-5'-monophosphate decarboxylase in complex with 6-azido-UMP, covalent adduct
3EX2	;	1.55	;	human orotidyl-5'-monophosphate decarboxylase in complex with 6-cyano-UMP
3L0N	;	1.74	;	Human orotidyl-5'-monophosphate decarboxylase in complex with 6-mercapto-UMP
3EX4	;	1.24	;	human orotidyl-5'-monophosphate decarboxylase in complex with BMP
3EX1	;	1.4	;	human orotidyl-5'-monophosphate decarboxylase soaked with 6-cyano-UMP, converted to UMP
3AIH	;	2.1	;	Human OS-9 MRH domain complexed with alpha3,alpha6-Man5
5EIQ	;	2.01	;	Human OSCAR ligand-binding domain
6GWJ	;	1.95	;	Human OSGEP / LAGE3 / GON7 complex
5CJ8	;	2.015	;	Human Osteoclast Associated Receptor (OSCAR) extracellular domain
5CJB	;	2.398	;	Human Osteoclast Associated Receptor (OSCAR) in complex with a collagen-like peptide
6OKM	;	2.1	;	Human OX40R (TNFRSF4) bound to Fab 3C8
1YPU	;	2.05	;	Human Oxidized Low Density Lipoprotein Receptor LOX-1 C2 Space Group
1YPQ	;	1.4	;	Human Oxidized Low Density Lipoprotein Receptor LOX-1 Dioxane Complex
1YPO	;	3.0	;	Human Oxidized Low Density Lipoprotein Receptor LOX-1 P3 1 21 Space Group
6BB5	;	2.28	;	Human Oxy-Hemoglobin
7QVM	;	3.25	;	Human Oxytocin receptor (OTR) oxytocin Gq chimera (mGoqi) complex
5JYM	;	2.45	;	Human P-cadherin EC12 with scFv TSP11 bound
5JYL	;	2.55	;	Human P-cadherin MEC1 with scFv TSP7 bound
7SSK	;	2.36	;	Human P300 complexed with a glycine-based inhibitor
7SS8	;	2.15	;	Human P300 complexed with a proline-based inhibitor
7SZQ	;	2.8	;	Human P300 complexed with an azaindazole inhibitor
4F9Y	;	1.85	;	Human P38 alpha MAPK In Complex With a Novel and Selective Small Molecule Inhibitor
4EWQ	;	2.1	;	Human p38 alpha MAPK in complex with a pyridazine based inhibitor
4FA2	;	2.0	;	Human P38 alpha Mitogen-Activated Kinase In Complex With SB239063
3ZYA	;	1.9	;	Human p38 MAP Kinase in Complex with 2-amino-phenylamino- dibenzosuberone
3QUD	;	2.0	;	Human p38 MAP Kinase in Complex with 2-amino-phenylamino-benzophenone
3UVP	;	2.4	;	Human p38 MAP Kinase in Complex with a Benzamide Substituted Benzosuberone
3IW6	;	2.1	;	Human p38 MAP Kinase in Complex with a Benzylpiperazin-Pyrrol
3UVQ	;	2.2	;	Human p38 MAP Kinase in Complex with a Dibenzosuberone Derivative
4L8M	;	2.1	;	Human p38 MAP kinase in complex with a Dibenzoxepinone
3IW7	;	2.4	;	Human p38 MAP Kinase in Complex with an Imidazo-pyridine
3IW5	;	2.5	;	Human p38 MAP Kinase in Complex with an Indole Derivative
1KV2	;	2.8	;	Human p38 MAP Kinase in Complex with BIRB 796
3L8S	;	2.35	;	Human p38 MAP Kinase in Complex with CP-547632
3LFA	;	2.1	;	Human p38 MAP Kinase in Complex with Dasatinib
5TCO	;	2.1	;	Human p38 MAP Kinase in Complex with Dibenzosuberone Compound 1
1ZYJ	;	2.0	;	Human P38 MAP Kinase in Complex with Inhibitor 1a
3UVR	;	2.1	;	Human p38 MAP Kinase in Complex with KM064
4EH2	;	2.0	;	Human p38 MAP kinase in complex with NP-F1 and RL87
4EHV	;	1.6	;	Human p38 MAP kinase in complex with NP-F10 and RL87
4EH9	;	2.1	;	Human p38 MAP kinase in complex with NP-F11 and RL87
4EH3	;	2.4	;	Human p38 MAP kinase in complex with NP-F2 and RL87
4EH4	;	2.5	;	Human p38 MAP kinase in complex with NP-F3 and RL87
4EH5	;	2.0	;	Human p38 MAP kinase in complex with NP-F4 and RL87
4EH6	;	2.1	;	Human p38 MAP kinase in complex with NP-F5 and RL87
4EH7	;	2.1	;	Human p38 MAP kinase in complex with NP-F6 and RL87
4EH8	;	2.2	;	Human p38 MAP kinase in complex with NP-F7 and RL87
3LFD	;	3.4	;	Human p38 MAP Kinase in Complex with RL113
3LFE	;	2.3	;	Human p38 MAP Kinase in Complex with RL116
4DLJ	;	2.6	;	Human p38 MAP kinase in complex with RL163
3LFF	;	1.5	;	Human p38 MAP Kinase in Complex with RL166
3PG3	;	2.0	;	Human p38 MAP Kinase in Complex with RL182
3HV5	;	2.25	;	Human p38 MAP Kinase in Complex with RL24
3HV7	;	2.4	;	Human p38 MAP Kinase in Complex with RL38
3HV6	;	1.95	;	Human p38 MAP Kinase in Complex with RL39
3HUC	;	1.8	;	Human p38 MAP Kinase in Complex with RL40
3GCQ	;	2.0	;	Human P38 MAP kinase in complex with RL45
3GCU	;	2.1	;	Human P38 MAP kinase in complex with RL48
3HV3	;	2.0	;	Human p38 MAP Kinase in Complex with RL49
3HV4	;	2.6	;	Human p38 MAP Kinase in Complex with RL51
3GCV	;	2.3	;	Human P38 MAP Kinase in Complex with RL62
4DLI	;	1.91	;	Human p38 MAP kinase in complex with RL87
3LFB	;	2.6	;	Human p38 MAP Kinase in Complex with RL98
3LFC	;	2.8	;	Human p38 MAP Kinase in Complex with RL99
3GCP	;	2.25	;	Human P38 MAP Kinase in Complex with SB203580
3HUB	;	2.25	;	Human p38 MAP Kinase in Complex with Scios-469
3QUE	;	2.7	;	Human p38 MAP Kinase in Complex with Skepinone-L
3GCS	;	2.1	;	Human P38 MAP kinase in complex with Sorafenib
1IAN	;	2.0	;	HUMAN P38 MAP KINASE INHIBITOR COMPLEX
5TBE	;	2.44	;	Human p38alpha MAP Kinase in Complex with Dibenzosuberone Compound 2
4F9W	;	2.0	;	Human P38alpha MAPK in Complex with a Novel and Selective Small Molecule Inhibitor
5ML5	;	1.9	;	Human p38alpha MAPK in complex with imidazolyl pyridine inhibitor 11b
1O7K	;	2.0	;	human p47 PX domain complex with sulphates
2OCJ	;	2.05	;	Human p53 core domain in the absence of DNA
2BIN	;	1.9	;	human p53 core domain mutant M133L-H168R-V203A-N239Y-N268D
2BIP	;	1.8	;	human p53 core domain mutant M133L-H168R-V203A-N239Y-R249S-N268D
2J1W	;	1.8	;	Human p53 core domain mutant M133L-V143A-V203A-N239Y-N268D
2J1Y	;	1.69	;	Human p53 core domain mutant M133L-V203A-N239Y-G245S-N268D
2J1Z	;	1.8	;	Human p53 core domain mutant M133L-V203A-N239Y-N268D-F270L
2J20	;	1.8	;	Human p53 core domain mutant M133L-V203A-N239Y-N268D-R273C
2BIM	;	1.98	;	human p53 core domain mutant M133L-V203A-N239Y-N268D-R273H
2J21	;	1.6	;	Human p53 core domain mutant M133L-V203A-N239Y-N268D-R282W
2BIO	;	1.9	;	human p53 core domain mutant M133L-V203A-N239Y-R249S-N268D
2J1X	;	1.65	;	Human p53 core domain mutant M133L-V203A-Y220C-N239Y-N268D
2WGX	;	1.75	;	HUMAN P53 CORE DOMAIN MUTANT M133L-V203A-Y236F-N239Y-T253I-N268D
4LO9	;	2.5	;	Human p53 Core Domain Mutant N235K
4LOE	;	1.85	;	Human p53 Core Domain Mutant N239Y
2BIQ	;	1.8	;	human p53 core domain mutant T123A-M133L-H168R-V203A-N239Y-R249S- N268D
4KVP	;	1.5	;	Human p53 Core Domain Mutant V157F
4LOF	;	2.0	;	Human p53 Core Domain Mutant V157F/N235K/N239Y
7EDS	;	1.77	;	Human p53 core domain with germline hot spot mutation M133T in complex with the natural PIG3 p53-response element and Arsenic
3D06	;	1.2	;	Human p53 core domain with hot spot mutation R249S (I)
3D05	;	1.7	;	Human p53 core domain with hot spot mutation R249S (II)
3D07	;	2.2	;	Human p53 core domain with hot spot mutation R249S (III)
3D0A	;	1.8	;	Human p53 core domain with hot spot mutation R249S and second site suppressor mutation H168R in sequence-specific complex with DNA
3D08	;	1.4	;	Human p53 core domain with hot spot mutation R249S and second-site suppressor mutation H168R
3D09	;	1.9	;	Human p53 core domain with hot spot mutation R249S and second-site suppressor mutations H168R and T123A
4IBQ	;	1.8	;	Human p53 core domain with hot spot mutation R273C
4IBV	;	2.1	;	Human p53 core domain with hot spot mutation R273C and second-site suppressor mutation S240R in sequence-specific complex with DNA
4IBZ	;	1.92	;	Human p53 core domain with hot spot mutation R273C and second-site suppressor mutation T284R
4IBU	;	1.7	;	Human p53 core domain with hot spot mutation R273C and second-site suppressor mutation T284R in sequence-specific complex with DNA
4IBS	;	1.78	;	Human p53 core domain with hot spot mutation R273H (form I)
4IJT	;	1.78	;	Human p53 core domain with hot spot mutation R273H (form II)
4IBY	;	1.45	;	Human p53 core domain with hot spot mutation R273H and second-site suppressor mutation S240R
4IBT	;	1.7	;	Human p53 core domain with hot spot mutation R273H and second-site suppressor mutation T284R
4IBW	;	1.791	;	Human p53 core domain with hot spot mutation R273H and second-site suppressor mutation T284R in sequence-specific complex with DNA
7EEU	;	2.9	;	Human p53 core domain with hot spot mutation R282W in complex with the natural CDKN1A(p21) p53-response element and Arsenic
1LKL	;	1.8	;	HUMAN P56-LCK TYROSINE KINASE SH2 DOMAIN IN COMPLEX WITH THE PHOSPHOTYROSYL PEPTIDE AC-PTYR-GLU-GLU-GLY (PYEEG PEPTIDE)
1LKK	;	1.0	;	HUMAN P56-LCK TYROSINE KINASE SH2 DOMAIN IN COMPLEX WITH THE PHOSPHOTYROSYL PEPTIDE AC-PTYR-GLU-GLU-ILE (PYEEI PEPTIDE)
1CWD	;	2.25	;	HUMAN P56LCK TYROSINE KINASE COMPLEXED WITH PHOSPHOPEPTIDE
1CWE	;	2.3	;	HUMAN P56LCK TYROSINE KINASE COMPLEXED WITH PHOSPHOPEPTIDE
4RLO	;	2.527	;	Human p70s6k1 with ruthenium-based inhibitor EM5
4RLP	;	2.79	;	Human p70s6k1 with ruthenium-based inhibitor FL772
7VCU	;	3.15	;	Human p97 double hexamer conformer I with D1-ATPgammaS and D2-ADP bound
7VCS	;	3.32	;	Human p97 double hexamer conformer II with ATPgammaS bound
7VCV	;	3.21	;	Human p97 single hexamer conformer I with ATPgammaS bound
7VCX	;	3.24	;	Human p97 single hexamer conformer II with ATPgammaS bound
7VCT	;	3.21	;	Human p97 single hexamer conformer III with D1-ATPgammaS and D2-ADP bound
6KWY	;	2.72	;	human PA200-20S complex
7NAQ	;	3.2	;	Human PA200-20S proteasome complex
8CVS	;	3.1	;	Human PA200-20S proteasome with MG-132
8CXB	;	2.9	;	Human PA28-20S (PA28-4a3b)
7NAO	;	2.9	;	Human PA28-20S proteasome complex
7NAP	;	3.2	;	Human PA28-20S-PA28 proteasome complex
8EQ4	;	2.71	;	Human PAC in nanodisc at pH 4.0 with PI(4,5)P2 diC8
8FBL	;	2.7	;	Human PAC in nanodisc at pH 4.0 with PI(4,5)P2 diC8
3GRO	;	2.53	;	Human palmitoyl-protein thioesterase 1
5VA9	;	2.55	;	Human pancreatic alpha amylase in complex with peptide inhibitor piHA-L5(d10Y)
3BAI	;	1.9	;	Human Pancreatic Alpha Amylase with Bound Nitrate
3BAW	;	2.0	;	Human pancreatic alpha-amylase complexed with azide
2QMK	;	2.3	;	Human pancreatic alpha-amylase complexed with nitrite
2QV4	;	1.97	;	Human pancreatic alpha-amylase complexed with nitrite and acarbose
1BSI	;	2.0	;	HUMAN PANCREATIC ALPHA-AMYLASE FROM PICHIA PASTORIS, GLYCOSYLATED PROTEIN
5E0F	;	1.4	;	Human pancreatic alpha-amylase in complex with mini-montbretin A
4W93	;	1.352	;	Human pancreatic alpha-amylase in complex with montbretin A
4GQR	;	1.2	;	Human Pancreatic alpha-amylase in complex with myricetin
3BAJ	;	2.1	;	Human Pancreatic Alpha-Amylase in Complex with Nitrate and Acarbose
5EMY	;	1.231	;	Human Pancreatic Alpha-Amylase in complex with the mechanism based inactivator glucosyl epi-cyclophellitol
4GQQ	;	1.35	;	Human pancreatic alpha-amylase with bound ethyl caffeate
3IDH	;	2.14	;	Human pancreatic glucokinase in complex with glucose
3F9M	;	1.5	;	Human pancreatic glucokinase in complex with glucose and activator showing a mobile flap
2PPL	;	2.2	;	Human Pancreatic lipase-related protein 1
7F8N	;	3.4	;	Human pannexin-1 showing a conformational change in the N-terminal domain and blocked pore
7DWB	;	3.15	;	Human Pannexin1 model
3SMS	;	2.2	;	Human Pantothenate kinase 3 in complex with a pantothenate analog
1JJ4	;	2.4	;	Human papillomavirus type 18 E2 DNA-binding domain bound to its DNA target
6VJO	;	2.0	;	Human parainfluenza virus type 3 fusion glycoprotein N-terminal heptad repeat domain+alpha/beta-VI
6NYX	;	1.85	;	Human parainfluenza virus type 3 fusion protein N-terminal heptad repeat domain+VI
6NRO	;	1.75	;	Human parainfluenza virus type 3 fusion protein N-terminal heptad repeat domain+VIQKI
6O40	;	1.2	;	Human parainfluenza virus type 3 fusion protein N-terminal heptad repeat domain+VIQKI I454F I456F
6KN4	;		;	HUMAN PARALLEL STRANDED 7-MER G-QUADRUPLEX COMPLEXED WITH 2 ADRIAMYCIN (DM2) MOLECULES
6KXZ	;		;	HUMAN PARALLEL STRANDED 7-MER G-QUADRUPLEX COMPLEXED WITH 2 EPIRUBICIN (EPI) MOLECULES
2QZ4	;	2.22	;	Human paraplegin, AAA domain in complex with ADP
8HAO	;	3.76	;	Human parathyroid hormone receptor-1 dimer
6BHV	;	2.3	;	Human PARP-1 bound to NAD+ analog benzamide adenine dinucleotide (BAD)
2L30	;		;	Human PARP-1 zinc finger 1
3OD8	;	2.4	;	Human PARP-1 zinc finger 1 (Zn1) bound to DNA
3ODA	;	2.64	;	Human PARP-1 zinc finger 1 (Zn1) bound to DNA
2L31	;		;	Human PARP-1 zinc finger 2
3ODC	;	2.8	;	Human PARP-1 zinc finger 2 (Zn2) bound to DNA
3ODE	;	2.95	;	Human PARP-1 zinc finger 2 (Zn2) bound to DNA
6GHK	;	2.28	;	Human PARP1 (ARTD1) - Catalytic domain in complex with inhibitor ME0527
7S6M	;	3.2	;	Human PARP1 deltaV687-E688 bound to a DNA double strand break.
7S6H	;	3.1	;	Human PARP1 deltaV687-E688 bound to NAD+ analog EB-47 and to a DNA double strand break.
8G0H	;	3.8	;	Human PARP1 deltaV687-E688 bound to UKTT5 (compound 10) and to a DNA double strand break.
6FXI	;	2.6	;	Human PARP10 (ARTD10), catalytic fragment in complex with 3-aminobenzamide and citrate
5LX6	;	1.25	;	Human PARP10 (ARTD10), catalytic fragment in complex with PARP inhibitor Veliparib
4X52	;	2.08	;	Human PARP13 (ZC3HAV1), C-Terminal PARP Domain (H810N; N830Y variant)
3Q71	;	2.2	;	Human parp14 (artd8) - macro domain 2 in complex with adenosine-5-diphosphoribose
5NQE	;	2.71	;	Human PARP14 (ARTD8), catalytic fragment in complex with an N-aryl piperazine inhibitor
6WE4	;	1.6	;	Human PARP14 (ARTD8), catalytic fragment in complex with compound 2
6WE3	;	1.95	;	Human PARP14 (ARTD8), catalytic fragment in complex with compound 3
5LYH	;	2.17	;	Human PARP14 (ARTD8), catalytic fragment in complex with inhibitor H10
5LXP	;	2.07	;	Human PARP14 (ARTD8), catalytic fragment in complex with inhibitor H5
6FYM	;	2.15	;	Human PARP14 (ARTD8), catalytic fragment in complex with inhibitor ITK1
6FZM	;	2.67	;	Human PARP14 (ARTD8), catalytic fragment in complex with inhibitor ITK6
6G0W	;	2.34	;	Human PARP14 (ARTD8), catalytic fragment in complex with inhibitor MCD72
7LUN	;	2.57	;	Human PARP14 (ARTD8), catalytic fragment in complex with RBN011980
7L9Y	;	2.25	;	Human PARP14 (ARTD8), catalytic fragment in complex with RBN012042
6WE2	;	2.66	;	Human PARP14 (ARTD8), catalytic fragment in complex with RBN012759
3Q6Z	;	2.23	;	HUman PARP14 (ARTD8)-Macro domain 1 in complex with adenosine-5-diphosphoribose
4ABL	;	1.15	;	HUMAN PARP14 (ARTD8, BAL2) - MACRO DOMAIN 3
4ABK	;	1.6	;	HUMAN PARP14 (ARTD8, BAL2) - MACRO DOMAIN 3 IN COMPLEX WITH ADENOSINE- 5-DIPHOSPHORIBOSE
4D86	;	2.0	;	Human PARP14 (ARTD8, BAL2) - macro domains 1 and 2 in complex with adenosine-5-diphosphate
3VFQ	;	2.8	;	Human PARP14 (ARTD8, BAL2) - macro domains 1 and 2 in complex with adenosine-5-diphosphoribose
6HXS	;	2.05	;	Human PARP16 (ARTD15) IN COMPLEX WITH CARBA-NAD
6HXR	;	2.9	;	Human PARP16 (ARTD15) IN COMPLEX WITH EB-47
6W65	;	2.13	;	Human PARP16 in complex with RBN010860
5AIL	;	1.55	;	Human PARP9 2nd macrodomain
8F2Q	;	2.7	;	Human Parvovirus B19 Nonstructural NS1 Protein NLS bound to Importin Alpha 2
1FJD	;		;	HUMAN PARVULIN-LIKE PEPTIDYL PROLYL CIS/TRANS ISOMERASE, HPAR14
2XEQ	;	3.1	;	Human PatL1 C-terminal domain
2XER	;	2.95	;	Human PatL1 C-terminal domain (loop variant with sulfates)
2XES	;	2.1	;	Human PatL1 C-terminal domain (loop variant)
1AXC	;	2.6	;	HUMAN PCNA
5E0T	;	2.6653	;	Human PCNA mutant - S228I
8E84	;	3.1	;	Human PCNA mutant- C148S
5E0V	;	2.074	;	Human PCNA variant (S228I) complexed with FEN1 at 2.1 Angstroms
5E0U	;	1.93	;	Human PCNA variant (S228I) complexed with p21 at 1.9 Angstroms
5JXE	;	2.9	;	Human PD-1 ectodomain complexed with Pembrolizumab Fab
6PV9	;	2.0	;	Human PD-L1 bound to a macrocyclic peptide which blocks the PD-1/PD-L1 interaction
2WEY	;	2.8	;	Human PDE-papaverine complex obtained by ligand soaking of cross- linked protein crystals
5EDE	;	2.2	;	human PDE10A in complex with 1-(4-Chloro-phenyl)-3-methyl-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide at 2.2A
5EDG	;	2.3	;	human PDE10A in complex with 3-(2-Chloro-5-phenyl-3H-imidazol-4-yl)-1-(3-trifluoromethoxy-phenyl)-1H-pyridazin-4-one at 2.30A
5I2R	;	2.5	;	human PDE10A in complex with 3-(2-phenylpyrazol-3-yl)-1-[3-(trifluoromethoxy)phenyl]pyridazin-4-one
5EDI	;	2.2	;	human PDE10A, 6-Chloro-5,8-dimethyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-2H-[1,2,4]triazol-3-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyridine, 2.20A, H3, Rfree=23.5%
5EDH	;	2.03	;	human PDE10A, 8-ethyl-5-methyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]triazolo[1,5-c]pyrimidine, 2.03A, H3, Rfree=22.7%
6L6E	;	1.92	;	Human PDE5 catalytic core in complex with avanafil
4G2J	;	2.4	;	Human pde9 in complex with selective compound
4G2L	;	3.0	;	Human PDE9 in complex with selective compound
3JSW	;	2.3	;	Human PDE9 in complex with selective inhibitor
5LVM	;	1.26	;	Human PDK1 Kinase Domain in Complex with Adenine Bound to the ATP-Binding Site
5LVN	;	1.379	;	Human PDK1 Kinase Domain in Complex with Adenosine Bound to the ATP-Binding Site
4A06	;	2.0	;	Human PDK1 Kinase Domain in Complex with Allosteric Activator PS114 Bound to the PIF-Pocket
4A07	;	1.85	;	Human PDK1 Kinase Domain in Complex with Allosteric Activator PS171 Bound to the PIF-Pocket
5ACK	;	1.24	;	Human PDK1 Kinase Domain in Complex with Allosteric Compound 7 Bound to the PIF-Pocket
4AW0	;	1.43	;	Human PDK1 Kinase Domain in Complex with Allosteric Compound PS182 Bound to the PIF-Pocket
4AW1	;	1.68	;	Human PDK1 Kinase Domain in Complex with Allosteric Compound PS210 Bound to the PIF-Pocket
5LVO	;	1.09	;	Human PDK1 Kinase Domain in Complex with Allosteric Compound PSE10 Bound to the PIF-Pocket
5LVP	;	2.5	;	Human PDK1 Kinase Domain in Complex with an HM-Peptide Bound to the PIF-Pocket
5LVL	;	1.4	;	Human PDK1 Kinase Domain in Complex with Compound PS653 Bound to the ATP-Binding Site
8DQT	;	1.31	;	Human PDK1 kinase domain in complex with Valsartan
5MRD	;	1.41	;	Human PDK1-PKCiota Kinase Chimera in Complex with Allosteric Compound PS267 Bound to the PIF-Pocket
4CT2	;	1.25	;	Human PDK1-PKCzeta Kinase Chimera
4CT1	;	1.85	;	Human PDK1-PKCzeta Kinase Chimera in Complex with Allosteric Compound PS315 Bound to the PIF-Pocket
4MMM	;	1.47	;	Human Pdrx5 complex with a ligand BP7
1QRP	;	1.96	;	Human pepsin 3A in complex with a phosphonate inhibitor IVA-VAL-VAL-LEU(P)-(O)PHE-ALA-ALA-OME
3UTL	;	2.61	;	Human pepsin 3b
7KJ1	;	2.15	;	human peroxiredoxin 2 - C172S mutant
5IJT	;	2.148	;	Human Peroxiredoxin 2 Oxidized (SS)
1HD2	;	1.5	;	Human peroxiredoxin 5
1OC3	;	2.0	;	HUMAN PEROXIREDOXIN 5
4K7I	;	2.25	;	HUMAN PEROXIREDOXIN 5 with a fragment
4K7N	;	2.3	;	HUMAN PEROXIREDOXIN 5 with a fragment
4K7O	;	1.98	;	HUMAN PEROXIREDOXIN 5 with a fragment
1URM	;	1.7	;	HUMAN PEROXIREDOXIN 5, C47S MUTANT
4XCS	;	2.1	;	Human peroxiredoxin-1 C83S mutant
5Y7X	;	1.699	;	Human Peroxisome proliferator-activated receptor (PPAR) delta in complexed with a potent and selective agonist
7VWH	;	2.1	;	human peroxisome proliferator-activated receptor (PPAR) delta ligand binding domain in complex with a synthetic agonist JKPL39
7VWF	;	1.9	;	Human peroxisome proliferator-activated receptor (PPAR) delta ligand binding domain in complex with a synthetic agonist TIPP204
7VWG	;	2.2	;	Human peroxisome proliferator-activated receptor (PPAR) delta ligand binding domain in complex with a synthetic alpha/delta dual agonist JKPL38
7VWE	;	3.0	;	Human peroxisome proliferator-activated receptor (PPAR) delta ligand binding domain in complex with a synthetic partial agonist JK122
4EMA	;	2.545	;	Human peroxisome proliferator-activated receptor gamma in complex with rosiglitazone
2ZK0	;	2.36	;	Human peroxisome proliferator-activated receptor gamma ligand binding domain
2ZK1	;	2.61	;	Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with 15-deoxy-delta12,14-prostaglandin J2
2ZK4	;	2.57	;	Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with 15-oxo-eicosatetraenoic acid
2ZK3	;	2.58	;	Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with 8-oxo-eicosatetraenoic acid
2ZK6	;	2.41	;	Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with C8-BODIPY
2ZK2	;	2.26	;	Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with glutathion conjugated 15-deoxy-delta12,14-prostaglandin J2
2ZK5	;	2.45	;	Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with nitro-233
7Z0I	;	1.8	;	human PEX13 SH3 domain
7Z0J	;	2.3	;	human PEX13 SH3 domain in complex with internal FxxxF motif
7Z0K	;	2.3	;	human PEX13 SH3 in complex with PEX5 W4 (WxxxF/Y) motif
6HVH	;	2.36	;	Human PFKFB3 in complex with a N-Aryl 6-Aminoquinoxaline inhibitor 1
6HVI	;	1.96	;	Human PFKFB3 in complex with a N-Aryl 6-Aminoquinoxaline inhibitor 2
6HVJ	;	2.28	;	Human PFKFB3 in complex with a N-Aryl 6-Aminoquinoxaline inhibitor 3
6IC0	;	2.6	;	Human PFKFB3 in complex with a N-Aryl 6-Aminoquinoxaline inhibitor 4
6IBX	;	2.11	;	Human PFKFB3 in complex with a N-Aryl 6-Aminoquinoxaline inhibitor 5
6IBY	;	2.51	;	Human PFKFB3 in complex with a N-Aryl 6-Aminoquinoxaline inhibitor 6
6IBZ	;	2.44	;	Human PFKFB3 in complex with a N-Aryl 6-Aminoquinoxaline inhibitor 7
4D4J	;	3.0	;	human PFKFB3 in complex with a pyrrolopyrimidone compound
4D4K	;	3.24	;	human PFKFB3 in complex with a pyrrolopyrimidone compound
4D4L	;	3.16	;	human PFKFB3 in complex with a pyrrolopyrimidone compound
4D4M	;	2.32	;	human PFKFB3 in complex with a pyrrolopyrimidone compound
5AJV	;	3.01	;	Human PFKFB3 in complex with an indole inhibitor 1
5AJW	;	2.5	;	Human PFKFB3 in complex with an indole inhibitor 2
5AJX	;	2.58	;	Human PFKFB3 in complex with an indole inhibitor 3
5AJY	;	2.37	;	Human PFKFB3 in complex with an indole inhibitor 4
5AJZ	;	2.35	;	Human PFKFB3 in complex with an indole inhibitor 5
5AK0	;	2.03	;	Human PFKFB3 in complex with an indole inhibitor 6
6ETJ	;	2.51	;	HUMAN PFKFB3 IN COMPLEX WITH KAN0438241
3PAH	;	2.0	;	HUMAN PHENYLALANINE HYDROXYLASE CATALYTIC DOMAIN DIMER WITH BOUND ADRENALINE INHIBITOR
5PAH	;	2.1	;	HUMAN PHENYLALANINE HYDROXYLASE CATALYTIC DOMAIN DIMER WITH BOUND DOPAMINE INHIBITOR
6PAH	;	2.15	;	HUMAN PHENYLALANINE HYDROXYLASE CATALYTIC DOMAIN DIMER WITH BOUND L-DOPA (3,4-DIHYDROXYPHENYLALANINE) INHIBITOR
4PAH	;	2.0	;	HUMAN PHENYLALANINE HYDROXYLASE CATALYTIC DOMAIN DIMER WITH BOUND NOR-ADRENALINE INHIBITOR
1PAH	;	2.0	;	HUMAN PHENYLALANINE HYDROXYLASE DIMER, RESIDUES 117-424
1BD9	;	2.05	;	HUMAN PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN
1BEH	;	1.75	;	HUMAN PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN IN COMPLEX WITH CACODYLATE
2GK9	;	2.8	;	Human Phosphatidylinositol-4-phosphate 5-kinase, type II, gamma
3DYL	;	2.7	;	human phosphdiesterase 9 substrate complex (ES complex)
5OHJ	;	1.6	;	Human phosphodiesterase 4B catalytic domain in complex with a pyrrolidinyl inhibitor.
3JSI	;	2.72	;	Human phosphodiesterase 9 in complex with inhibitor
4E90	;	2.5	;	Human phosphodiesterase 9 in complex with inhibitors
3DY8	;	2.15	;	Human Phosphodiesterase 9 in complex with product 5'-GMP (E+P complex)
3DYQ	;	2.5	;	human phosphodiestrase 9 (inhibited by omitting divalent cation) in complex with cGMP
3DYN	;	2.1	;	human phosphodiestrase 9 in complex with cGMP (Zn inhibited)
3DYS	;	2.3	;	human phosphodiestrase-5'GMP complex (EP), produced by soaking with 20mM cGMP+20 mM MnCl2+20 mM MgCl2 for 2 hours, and flash-cooled to liquid nitrogen temperature when substrate was still abudant.
7LW1	;	2.9	;	Human phosphofructokinase-1 liver type bound to activator NA-11
1KVO	;	2.0	;	HUMAN PHOSPHOLIPASE A2 COMPLEXED WITH A HIGHLY POTENT SUBSTRATE ANOLOGUE
1KQU	;	2.1	;	Human phospholipase A2 complexed with a substrate anologue
7O1B	;	3.08	;	Human phosphomannomutase 2 (PMM2) wild-type co-crystallized with the activator glucose 1,6-bisphosphate
7O0C	;	2.8	;	Human phosphomannomutase 2 (PMM2) wild-type in apo state
7O4G	;	2.66	;	Human phosphomannomutase 2 (PMM2) wild-type soaked with the activator glucose 1,6-bisphosphate
7O5Z	;	2.07	;	Human phosphomannomutase 2 (PMM2) with mutation T237M in apo state
7O58	;	1.97	;	Human phosphomannomutase 2 (PMM2) with mutation T237M in complex with the activator glucose 1,6-bisphosphate
2JBH	;	1.7	;	Human phosphoribosyl transferase domain containing 1
2JI4	;	2.55	;	Human phosphoribosylpyrophosphate synthetase - associated protein 41 (PAP41)
3E77	;	2.5	;	Human phosphoserine aminotransferase in complex with PLP
6HYY	;	1.566	;	Human phosphoserine phosphatase with serine and phosphate
6Q6J	;	1.985	;	Human phosphoserine phosphatase with substrate analogue homo-cysteic acid
5K6J	;	1.86	;	Human Phospodiesterase 4B in complex with pyridyloxy-benzoxaborole based inhibitor
8PTL	;		;	human PHOX2B C-terminal domain including the polyA fragment at 278K
8PUI	;		;	human PHOX2B C-terminal domain including the polyA fragment at 298K
2A1X	;	2.5	;	Human phytanoyl-coa 2-hydroxylase in complex with iron and 2-oxoglutarate
8TS7	;	2.71	;	Human PI3K p85alpha/p110alpha
8TSB	;	3.53	;	Human PI3K p85alpha/p110alpha bound to compound 2
8TSD	;	2.7	;	Human PI3K p85alpha/p110alpha bound to RLY-2608
8TS9	;	2.83	;	Human PI3K p85alpha/p110alpha H1047R bound to compound 1
8TSA	;	2.51	;	Human PI3K p85alpha/p110alpha H1047R bound to compound 2
8TSC	;	3.62	;	Human PI3K p85alpha/p110alpha H1047R bound to compound 3
6PYS	;	2.19	;	Human PI3Kalpha in complex with Compound 2-10 ((3S)-3-benzyl-3-methyl-5-[5-(2-methylpyrimidin-5-yl)pyrazolo[1,5-a]pyrimidin-3-yl]-1,3-dihydro-2H-indol-2-one)
8BCY	;	2.43	;	HUMAN PI3KDELTA IN COMPLEX WITH COMPOUND 13
6PYR	;	2.21	;	Human PI3Kdelta in complex with Compound 2-10 ((3S)-3-benzyl-3-methyl-5-[5-(2-methylpyrimidin-5-yl)pyrazolo[1,5-a]pyrimidin-3-yl]-1,3-dihydro-2H-indol-2-one)
7LQ1	;	2.96	;	HUMAN PI3KDELTA IN COMPLEX WITH COMPOUND 28
6OCU	;	2.77	;	HUMAN PI3KDELTA IN COMPLEX WITH COMPOUND 29
7JIS	;	2.42	;	HUMAN PI3KDELTA IN COMPLEX WITH COMPOUND 2F
7JIU	;	2.12	;	HUMAN PI3KDELTA IN COMPLEX WITH COMPOUND 2F
7LM2	;	2.79	;	HUMAN PI3KDELTA IN COMPLEX WITH COMPOUND 3C
6PYU	;	2.54	;	Human PI3Kdelta in complex with Compound 4-2 ((3S)-1'-(cyclopropanecarbonyl)-5-(quinoxalin-6-yl)spiro[indole-3,2'-pyrrolidin]-2(1H)-one)
6OCO	;	2.58	;	HUMAN PI3KDELTA IN COMPLEX WITH COMPOUND 6
5M6U	;	2.85	;	HUMAN PI3KDELTA IN COMPLEX WITH LASW1579
6G6W	;	2.72	;	HUMAN PI3KDELTA IN COMPLEX WITH LIGAND LASW1976
6BQ1	;	3.6	;	Human PI4KIIIa lipid kinase complex
8Q6H	;	1.94	;	HUMAN PI4KIIIB IN COMPLEX WITH COVALENTLY BOUND INHIBITOR (COMPOUND 11)
8Q6F	;	1.506	;	HUMAN PI4KIIIB IN COMPLEX WITH COVALENTLY BOUND INHIBITOR (COMPOUND 4)
8Q6G	;	1.541	;	HUMAN PI4KIIIB IN COMPLEX WITH COVALENTLY BOUND INHIBITOR (COMPOUND 8)
6Z8D	;	2.63	;	Human Picobirnavirus CP VLP
6Z8F	;	2.8	;	Human Picobirnavirus D45-CP VLP
6Z8E	;	2.8	;	Human Picobirnavirus Ht-CP VLP
3IHY	;	2.8	;	Human PIK3C3 crystal structure
7ZC9	;	2.1	;	Human Pikachurin/EGFLAM C-terminal Laminin-G domain (LG3)
7ZCB	;	2.5	;	Human Pikachurin/EGFLAM N-terminal Fibronectin-III (1-2) domains
3BGP	;	2.8	;	Human Pim-1 complexed with a benzoisoxazole inhibitor VX1
6YKD	;	1.86	;	Human Pim-1 kinase in complex with an inhibitor identified by virtual screening
3BGQ	;	2.0	;	Human Pim-1 kinase in complex with an triazolo pyridazine inhibitor VX2
3BGZ	;	2.4	;	Human Pim-1 kinase in complex with diphenyl indole inhibitor VX3
6PCW	;	2.2	;	Human PIM1 bound to benzothiophene inhibitor 213
6PDI	;	1.85	;	Human PIM1 bound to benzothiophene inhibitor 224
6PDN	;	2.4	;	Human PIM1 bound to benzothiophene inhibitor 292
6PDO	;	2.4	;	Human PIM1 bound to benzothiophene inhibitor 354
6PDP	;	2.5	;	Human PIM1 bound to benzothiophene inhibitor 379
6QXK	;	2.1	;	Human PIM1 bound to OX0999
6BSK	;	2.573	;	Human PIM1 kinase in complex with compound 12b
2BIK	;	1.8	;	Human Pim1 phosphorylated on Ser261
3TCZ	;	2.1	;	Human Pin1 bound to cis peptidomimetic inhibitor
2ITK	;	1.45	;	human Pin1 bound to D-PEPTIDE
2Q5A	;	1.5	;	human Pin1 bound to L-PEPTIDE
3TDB	;	2.267	;	Human Pin1 bound to trans peptidomimetic inhibitor
3NTP	;	1.762	;	Human Pin1 complexed with reduced amide inhibitor
2F21	;	1.5	;	human Pin1 Fip mutant
1ZCN	;	1.9	;	human Pin1 Ng mutant
4U85	;	1.7	;	Human Pin1 with cysteine sulfinic acid 113
4U86	;	1.6	;	Human Pin1 with cysteine sulfonic acid 113
4U84	;	1.78	;	Human Pin1 with S-hydroxyl-cysteine 113
5WC9	;	3.15	;	Human Pit-1 and 4xCATT DNA complex
6D1W	;	3.54	;	human PKD2 F604P mutant
8HGF	;	3.1	;	Human PKM2 mutant - C326S
4B2D	;	2.3	;	human PKM2 with L-serine and FBP bound.
5JKV	;	2.75	;	HUMAN PLACENTAL AROMATASE CYTOCHROME P450 (CYP19A1) AT 2.75 ANGSTROM WITH BOUND POLYETHYLENE GLYCOL
5JKW	;	3.0	;	HUMAN PLACENTAL AROMATASE CYTOCHROME P450 (CYP19A1) COMPLEXED WITH TESTOSTERONE
3S79	;	2.75	;	Human placental aromatase cytochrome P450 (CYP19A1) refined at 2.75 angstrom
5JL6	;	3.0	;	HUMAN PLACENTAL AROMATASE CYTOCHROME P450 (CYP19A1): ANDROSTENEDIONE COMPLEX #2
5JL7	;	3.1	;	HUMAN PLACENTAL AROMATASE CYTOCHROME P450 (CYP19A1): ANDROSTENEDIONE COMPLEX #3
5JL9	;	3.1	;	HUMAN PLACENTAL AROMATASE CYTOCHROME P450 (CYP19A1): ANDROSTENEDIONE COMPLEX #4
5EOK	;	2.8	;	Human Plasma Coagulation Factor XI in complex with peptide P39
5EOD	;	3.1	;	Human Plasma Coagulation FXI with peptide LP2
8A3Q	;	1.801	;	Human Plasma Kallekrein in complex with 14W
6T7P	;	1.416	;	human plasmakallikrein protease domain in complex with active site directed inhibitor
1A7C	;	1.95	;	HUMAN PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 IN COMPLEX WITH A PENTAPEPTIDE
1BY7	;	2.0	;	HUMAN PLASMINOGEN ACTIVATOR INHIBITOR-2. LOOP (66-98) DELETION MUTANT
2ARQ	;	1.85	;	Human plasminogen activator inhibitor-2.[loop (66-98) deletion mutant] complexed with peptide n-acetyl-teaaagdggvmtgr-oh
2ARR	;	1.55	;	Human plasminogen activator inhibitor-2.[loop (66-98) deletion mutant] complexed with peptide n-acetyl-teaaagmggvmtgr-oh
1JRR	;	1.6	;	HUMAN PLASMINOGEN ACTIVATOR INHIBITOR-2.[LOOP (66-98) DELETIONMUTANT] COMPLEXED WITH PEPTIDE MIMIckING THE REACTIVE CENTER LOOP
1RJX	;	2.3	;	Human PLASMINOGEN CATALYTIC DOMAIN, K698M MUTANT
4XZ2	;	2.67	;	Human platelet phosphofructokinase in an R-state in complex with ADP and F6P, crystal form I
1CF0	;	2.2	;	HUMAN PLATELET PROFILIN COMPLEXED WITH AN L-PRO10-IODOTYROSINE PEPTIDE
1AWI	;	2.2	;	HUMAN PLATELET PROFILIN COMPLEXED WITH THE L-PRO10 PEPTIDE
1FIL	;	2.0	;	HUMAN PLATELET PROFILIN I CRYSTALLIZED IN HIGH SALT ACTIN-BINDING PROTEIN
1FIK	;	2.3	;	HUMAN PLATELET PROFILIN I CRYSTALLIZED IN LOW SALT
7Y4P	;	3.5	;	Human Plexin A1, extracellular domains 1-4
4H71	;	1.93	;	Human Plk1-PBD in complex with Poloxime ((E)-4-(hydroxyimino)-2-isopropyl-5-methylcyclohexa-2,5-dienone)
4HCO	;	2.75	;	Human Plk1-PBD in complex with Thymoquinone at the phophopeptide binding site
4H5X	;	1.95	;	human Plk1-PBD with a glycerol bound at the phophopeptide binding site
5L0V	;	1.305	;	human POGLUT1 in complex with 2F-glucose modified EGF(+) and UDP
5L0T	;	1.43	;	human POGLUT1 in complex with EGF(+) and UDP
5L0U	;	1.8	;	human POGLUT1 in complex with EGF(+) and UDP-phosphono-glucose
5L0S	;	1.45	;	human POGLUT1 in complex with Factor VII EGF1 and UDP
5UB5	;	2.089	;	human POGLUT1 in complex with human Notch1 EGF12 S458T mutant and UDP
5L0R	;	1.5	;	human POGLUT1 in complex with Notch1 EGF12 and UDP
7FJI	;	3.6	;	human Pol III elongation complex
7FJJ	;	3.6	;	human Pol III pre-termination complex
7NV1	;	6.4	;	Human Pol Kappa holoenzyme with Ub-PCNA
7NV0	;	3.4	;	Human Pol Kappa holoenzyme with wt PCNA
6HH6	;	1.85	;	Human poly(ADP-ribose) glycohydrolase in complex with ADP-HPM
5A7R	;	1.95	;	Human poly(ADP-ribose) glycohydrolase in complex with synthetic dimeric ADP-ribose
3HKV	;	2.1	;	Human poly(ADP-ribose) polymerase 10, catalytic fragment in complex with an inhibitor 3-aminobenzamide
2PQF	;	2.2	;	Human Poly(ADP-Ribose) Polymerase 12, Catalytic fragment in complex with an inhibitor 3-Aminobenzoic acid
6V3W	;	2.04	;	Human Poly(ADP-Ribose) Polymerase 12, Catalytic fragment with four point mutations in complex with RBN-2397
3SE2	;	2.3	;	Human poly(ADP-ribose) polymerase 14 (PARP14/ARTD8) - catalytic domain in complex with 6(5H)-phenanthridinone
3SMJ	;	1.5	;	Human poly(ADP-ribose) polymerase 14 (Parp14/Artd8) - catalytic domain in complex with a pyrimidine-like inhibitor
3SMI	;	2.4	;	Human poly(ADP-ribose) polymerase 14 (Parp14/Artd8) - catalytic domain in complex with a quinazoline inhibitor
3V2B	;	2.2	;	Human poly(adp-ribose) polymerase 15 (ARTD7, BAL3), macro domain 2 in complex with adenosine-5-diphosphoribose
3KCZ	;	2.0	;	Human poly(ADP-ribose) polymerase 2, catalytic fragment in complex with an inhibitor 3-aminobenzamide
3KJD	;	1.95	;	Human poly(ADP-ribose) polymerase 2, catalytic fragment in complex with an inhibitor ABT-888
3FHB	;	2.3	;	Human poly(ADP-ribose) polymerase 3, catalytic fragment in complex with an inhibitor 3-aminobenzoic acid
3C4H	;	2.1	;	Human poly(ADP-ribose) polymerase 3, catalytic fragment in complex with an inhibitor DR2313
3C49	;	2.8	;	Human poly(ADP-ribose) polymerase 3, catalytic fragment in complex with an inhibitor KU0058948
3CE0	;	2.8	;	Human poly(ADP-ribose) polymerase 3, catalytic fragment in complex with an inhibitor PJ34
6WMM	;	1.548	;	Human poly-N-acetyl-lactosamine synthase structure demonstrates a modular assembly of catalytic subsites for GT-A glycosyltransferases
6WMN	;	2.04	;	Human poly-N-acetyl-lactosamine synthase structure demonstrates a modular assembly of catalytic subsites for GT-A glycosyltransferases
6WMO	;	1.85	;	Human poly-N-acetyl-lactosamine synthase structure demonstrates a modular assembly of catalytic subsites for GT-A glycosyltransferases
5WG6	;	3.901	;	Human Polycomb Repressive Complex 2 in complex with GSK126 inhibitor
6DU8	;	3.11	;	Human Polycsytin 2-l1
6S1M	;	4.27	;	Human polymerase delta holoenzyme Conformer 1
6S1N	;	4.86	;	Human polymerase delta holoenzyme Conformer 2
6S1O	;	8.1	;	Human polymerase delta holoenzyme Conformer 3
6TNZ	;	4.05	;	Human polymerase delta-FEN1-PCNA toolbelt
7URC	;	3.14	;	Human PORCN in complex with LGK974
7URD	;	2.92	;	Human PORCN in complex with LGK974 and WNT3A peptide
7URA	;	3.11	;	Human PORCN in complex with Palmitoleoyl-CoA
7URE	;	3.19	;	Human PORCN in complex with palmitoleoylated WNT3A peptide
7AAJ	;	1.8	;	Human porphobilinogen deaminase in complex with cofactor
5M7F	;	2.78	;	Human porphobilinogen deaminase in complex with DPM cofactor
5M6R	;	2.73	;	Human porphobilinogen deaminase in complex with reaction intermediate
7AAK	;	1.7	;	Human porphobilinogen deaminase R173W mutant crystallized in the ES2 intermediate state
6QDV	;	3.3	;	Human post-catalytic P complex spliceosome
7D8Z	;	3.4	;	human potassium-chloride co-transporter KCC2
7D90	;	3.6	;	human potassium-chloride co-transporter KCC3
7D99	;	2.9	;	human potassium-chloride co-transporter KCC4
7TTH	;	3.25	;	Human potassium-chloride cotransporter 1 in inward-open state
2JAK	;	2.6	;	Human PP2A regulatory subunit B56g
6B67	;	2.2	;	Human PP2Calpha (PPM1A) complexed with cyclic peptide c(MpSIpYVA)
6KXX	;	1.95	;	Human PPAR alpha ligand binding domain in complex with a synthetic agonist (compound A)
6KXY	;	2.0	;	Human PPAR alpha ligand binding domain in complex with a synthetic agonist (compound B)
3VI8	;	1.75	;	Human PPAR alpha ligand binding domain in complex with a synthetic agonist APHM13
2ZNN	;	2.01	;	Human PPAR alpha ligand binding domain in complex with a synthetic agonist TIPP703
7E5H	;	1.66	;	HUMAN PPAR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH APHM6 OBTAINED BY COCRYSTALLIZATION
7E5I	;	1.58	;	HUMAN PPAR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH APHM6 OBTAINED BY SOAKING
7E5F	;	1.79	;	HUMAN PPAR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH TIPP703 OBTAINED BY SOAKING
7E5G	;	1.66	;	HUMAN PPAR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH YN4pai OBTAINED BY SOAKING
7W0G	;	2.443	;	Human PPAR delta ligand binding domain in complex with a synthetic agonist H11
2ZNP	;	3.0	;	Human PPAR delta ligand binding domain in complex with a synthetic agonist TIPP204
2ZNQ	;	2.65	;	Human PPAR delta ligand binding domain in complex with a synthetic agonist TIPP401
8HF8	;	2.11	;	Human PPAR delta ligand binding domain in complex with a synthetic agonist V1
4EM9	;	2.1	;	Human PPAR gamma in complex with nonanoic acids
7LOT	;	2.29	;	Human PPAR Gamma LBD in Complex with Tetrazole Compound N-{3-[(4-methylbenzyl)oxy]benzyl}-2H-tetrazol-5-amine.
3B0R	;	2.15	;	Human PPAR gamma ligand binding dmain complexed with GW9662 in a covalent bonded form
3VSO	;	2.0	;	Human PPAR gamma ligand binding domain in complex with a gamma selective agonist mekt21
3VSP	;	2.4	;	Human PPAR gamma ligand binding domain in complex with a gamma selective agonist mekt28
3AN3	;	2.3	;	Human PPAR gamma ligand binding domain in complex with a gamma selective agonist MO3S
3AN4	;	2.3	;	Human PPAR gamma ligand binding domain in complex with a gamma selective agonist MO4R
3WMH	;	2.1	;	Human PPAR gamma ligand binding domain in complex with a gammma selective synthetic partial agonist MEKT75
4YT1	;	2.2	;	Human PPAR Gamma Ligand Binding Domain in complex with a Gammma Selective Synthetic Partial Agonist MEKT76
2ZNO	;	2.4	;	Human PPAR gamma ligand binding domain in complex with a synthetic agonist TIPP703
3VJH	;	2.22	;	Human PPAR GAMMA ligand binding domain in complex with JKPL35
3VJI	;	2.61	;	Human PPAR gamma ligand binding domain in complex with JKPL53
3SZ1	;	2.3	;	Human PPAR gamma ligand binding domain in complex with luteolin and myristic acid
3B0Q	;	2.1	;	Human PPAR gamma ligand binding domain in complex with MCC555
5U46	;	2.0	;	Human PPARdelta ligand-binding domain in complexed with GW501516
5U3Q	;	1.5	;	Human PPARdelta ligand-binding domain in complexed with specific agonist 1
5U3Z	;	1.72	;	Human PPARdelta ligand-binding domain in complexed with specific agonist 10
5U42	;	1.7	;	Human PPARdelta ligand-binding domain in complexed with specific agonist 11
5U43	;	1.9	;	Human PPARdelta ligand-binding domain in complexed with specific agonist 12
5U44	;	2.15	;	Human PPARdelta ligand-binding domain in complexed with specific agonist 13
5U45	;	1.95	;	Human PPARdelta ligand-binding domain in complexed with specific agonist 14
5U40	;	2.0	;	Human PPARdelta ligand-binding domain in complexed with specific agonist 15
5U41	;	1.9	;	Human PPARdelta ligand-binding domain in complexed with specific agonist 16
5U3R	;	1.95	;	Human PPARdelta ligand-binding domain in complexed with specific agonist 2
5U3S	;	2.0	;	Human PPARdelta ligand-binding domain in complexed with specific agonist 3
5U3T	;	1.7	;	Human PPARdelta ligand-binding domain in complexed with specific agonist 4
5U3U	;	2.1	;	Human PPARdelta ligand-binding domain in complexed with specific agonist 5
5U3V	;	1.84	;	Human PPARdelta ligand-binding domain in complexed with specific agonist 6
5U3W	;	1.8	;	Human PPARdelta ligand-binding domain in complexed with specific agonist 7
5U3X	;	2.1	;	Human PPARdelta ligand-binding domain in complexed with specific agonist 8
5U3Y	;	1.9	;	Human PPARdelta ligand-binding domain in complexed with specific agonist 9
8BF2	;	2.18	;	Human PPARgamma in complex with MEHP bound to the AF-2 and omega sub-pockets
8BFF	;	2.6	;	Human PPARgamma in complex with MINCH bound to the AF-2 sub-pocket
5GTN	;	1.85	;	Human PPARgamma ligand binding dmain complexed with R35
5GTO	;	2.1	;	Human PPARgamma ligand binding dmain complexed with S35
5DV6	;	2.8	;	Human PPARgamma ligand binding dmain complexed with SB1404 in a covalent bonded form
5DV3	;	2.75	;	Human PPARgamma ligand binding dmain complexed with SB1405 in a covalent bonded form
5DSH	;	2.95	;	Human PPARgamma ligand binding dmain complexed with SB1406 in a covalent bonded form
5DV8	;	2.75	;	Human PPARgamma ligand binding dmain complexed with SB1451 in a covalent bonded form
5DVC	;	2.3	;	Human PPARgamma ligand binding dmain complexed with SB1453 in a covalent bonded form
5DWL	;	2.2	;	Human PPARgamma ligand binding dmain in complex with SR1664
6L89	;	2.1	;	Human PPARgamma ligand binding domain complexed with Butyrolactone 1
5YCN	;	2.15	;	Human PPARgamma ligand binding domain complexed with Lobeglitazone
5YCP	;	2.0	;	Human PPARgamma ligand binding domain complexed with Rosiglitazone
6IJS	;	2.15	;	Human PPARgamma ligand binding domain complexed with SB1494
6IJR	;	2.85	;	Human PPARgamma ligand binding domain complexed with SB1495
3ADT	;	2.7	;	Human PPARgamma ligand-binding domain in complex with 5-hydroxy-indole acetate
3ADU	;	2.77	;	Human PPARgamma ligand-binding domain in complex with 5-methoxy-indole acetate
3ADW	;	2.07	;	Human PPARgamma ligand-binding domain in complex with 5-methoxy-indole acetate and 15-oxo-eicosatetraenoic acid
3ADS	;	2.25	;	Human PPARgamma ligand-binding domain in complex with indomethacin
3ADX	;	1.95	;	Human PPARgamma ligand-binding domain in complex with indomethacin and nitro-233
3ADV	;	2.27	;	Human PPARgamma ligand-binding domain in complex with serotonin
6KTN	;	2.752	;	Human PPARgamma ligand-binding domain R288A mutant in complex with imatinib
2FFV	;	2.75	;	Human ppGalNAcT-2 complexed with manganese and UDP
6E7I	;	1.8	;	Human ppGalNAcT2 I253A/L310A Mutant with EA2 and UDP
5EI9	;	1.921	;	Human PRDM9 allele-A ZnF Domain with Associated Recombination Hotspot DNA Sequence I
5EGB	;	1.977	;	Human PRDM9 allele-A ZnF Domain with Associated Recombination Hotspot DNA Sequence II
5EH2	;	2.05	;	Human PRDM9 allele-A ZnF Domain with Associated Recombination Hotspot DNA Sequence III
7ABG	;	7.8	;	Human pre-Bact-1 spliceosome
7ABF	;	3.9	;	Human pre-Bact-1 spliceosome core structure
7ABI	;	8.0	;	Human pre-Bact-2 spliceosome
7ABH	;	4.5	;	Human pre-Bact-2 spliceosome (SF3b/U2 snRNP portion)
7AAV	;	4.2	;	Human pre-Bact-2 spliceosome core structure
3OF6	;	2.8	;	Human pre-T cell receptor crystal structure
8QYS	;	3.89	;	Human preholo proteasome 20S core particle
7JL8	;	2.1	;	Human PrimPol extending from the correct primer base C opposite the 8-oxoguanine lesion
7JLG	;	2.07	;	Human PrimPol extending from the erroneous primer base A opposite the 8-oxoguanine lesion
7JK1	;	2.62	;	Human PrimPol inserting correct dCTP opposite the 8-oxoguanine lesion
7JKP	;	2.592	;	Human PrimPol misinserting dATP opposite the 8-oxoguanine lesion
7JKL	;	2.384	;	Human PrimPol misinserting dATP opposite the 8-oxoguanine lesion (3'-end base of the primer strand is 2',3'-dideoxy-terminated).
1QLX	;		;	Human prion protein
1QLZ	;		;	Human prion protein
1FKC	;		;	HUMAN PRION PROTEIN (MUTANT E200K) FRAGMENT 90-231
6SV2	;	2.3	;	Human prion protein (PrP) fragment 119-231 (G127V M129 variant) complexed to ICSM 18 (anti-Prp therapeutic antibody) Fab fragment
6SUZ	;	2.5	;	Human prion protein (PrP) fragment 119-231 (G127V V129 variant) complexed to ICSM 18 (anti-Prp therapeutic antibody) Fab fragment
1H0L	;		;	HUMAN PRION PROTEIN 121-230 M166C/E221C
1OEH	;		;	Human prion protein 61-68
1OEI	;		;	Human prion protein 61-84
1HJM	;		;	HUMAN PRION PROTEIN AT PH 7.0
1HJN	;		;	HUMAN PRION PROTEIN AT PH 7.0
6UUR	;	3.5	;	Human prion protein fibril, M129 variant
1QM2	;		;	Human prion protein fragment 121-230
1QM3	;		;	Human prion protein fragment 121-230
1QM0	;		;	Human prion protein fragment 90-230
1QM1	;		;	Human prion protein fragment 90-230
1FO7	;		;	HUMAN PRION PROTEIN MUTANT E200K FRAGMENT 90-231
2LEJ	;		;	human prion protein mutant HuPrP(90-231, M129, V210I)
3HEQ	;	1.8	;	Human prion protein variant D178N with M129
3HJX	;	2.0	;	Human prion protein variant D178N with V129
3HES	;	2.0	;	Human prion protein variant F198S with M129
3HER	;	1.85	;	Human prion protein variant F198S with V129
1E1G	;		;	Human prion protein variant M166V
1E1J	;		;	Human prion protein variant M166V
1E1U	;		;	Human prion protein variant R220K
1E1W	;		;	Human prion protein variant R220K
1E1P	;		;	Human prion protein variant S170N
1E1S	;		;	Human prion protein variant S170N
3HAK	;	1.8	;	Human prion protein variant V129
3HAF	;	2.26	;	Human prion protein variant V129 domain swapped dimer
3HJ5	;	3.1	;	Human prion protein variant V129 domain swapped dimer
2LFT	;		;	Human prion protein with E219K protective polymorphism
7UY1	;	2.66	;	HUMAN PRMT5:MEP50 COMPLEX WITH MTA and Fragment 5 Bound
7ZUQ	;	2.48	;	HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound
7ZUU	;	2.09	;	HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound
7ZUY	;	2.0	;	HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound
7ZV2	;	2.01	;	HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound
7ZVL	;	2.39	;	HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound
7ZVU	;	1.95	;	HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound
7ZUP	;	2.01	;	Human PRMT5:MEP50 structure with Fragment (Example 18) and MTA Bound
8CSG	;	2.48	;	Human PRMT5:MEP50 structure with Fragment 1 and MTA Bound
8CTB	;	2.61	;	Human PRMT5:MEP50 structure with Fragment 3 and MTA Bound
7UYF	;	2.82	;	Human PRMT5:MEP50 structure with Fragment 4 and MTA Bound
5EGS	;	2.15	;	Human PRMT6 with bound fragment-type inhibitor
2BID	;		;	HUMAN PRO-APOPTOTIC PROTEIN BID
1NN6	;	1.75	;	Human Pro-Chymase
7UAB	;	3.7	;	Human pro-meprin alpha (zymogen state)
7UAC	;	2.7	;	Human pro-meprin alpha (zymogen state)
1AYE	;	1.8	;	HUMAN PROCARBOXYPEPTIDASE A2
2BOA	;	2.2	;	Human procarboxypeptidase A4.
1KWM	;	1.6	;	Human procarboxypeptidase B: Three-dimensional structure and implications for thrombin-activatable fibrinolysis inhibitor (TAFI)
4JR0	;	1.796	;	Human procaspase-3 bound to Ac-DEVD-CMK
4JQY	;	2.495	;	Human procaspase-3, crystal form 1
4JQZ	;	2.889	;	Human procaspase-3, crystal form 2
4JR1	;	2.149	;	Human procaspase-7 bound to Ac-DEVD-CMK
4JR2	;	1.65	;	Human procaspase-7/caspase-7 heterodimer bound to Ac-DEVD-CMK
1E3K	;	2.8	;	Human Progesteron Receptor Ligand Binding Domain in complex with the ligand metribolone (R1881)
2M2D	;		;	Human programmed cell death 1 receptor
6IQE	;	1.701	;	Human prohibitin 2
1GVL	;	1.8	;	Human prokallikrein 6 (hK6)/ prozyme/ proprotease M/ proneurosin
7OSY	;	2.23	;	Human Prolyl-tRNA Synthetase in Complex with L-proline
7OT3	;	2.53	;	Human Prolyl-tRNA Synthetase in Complex with L-proline and Compound 3b
7OT1	;	2.71	;	Human Prolyl-tRNA Synthetase in Complex with L-proline and Compound 3c
7OSZ	;	2.46	;	Human Prolyl-tRNA Synthetase in Complex with L-proline and Compound 4d
7OT0	;	2.32	;	Human Prolyl-tRNA Synthetase in Complex with L-proline and Compound 4h
7OT2	;	2.48	;	Human Prolyl-tRNA Synthetase in Complex with L-proline and Compound 4j
7YBU	;	2.2	;	Human propionyl-coenzyme A carboxylase
8QYO	;	2.84	;	Human proteasome 20S core particle
4RYL	;	2.1	;	Human Protein Arginine Methyltransferase 3 in complex with 1-isoquinolin-6-yl-3-[2-oxo-2-(pyrrolidin-1-yl)ethyl]urea
1BJX	;		;	HUMAN PROTEIN DISULFIDE ISOMERASE, NMR, 24 STRUCTURES
1MEK	;		;	HUMAN PROTEIN DISULFIDE ISOMERASE, NMR, 40 STRUCTURES
1SA4	;	2.1	;	human protein farnesyltransferase complexed with FPP and R115777
2IEJ	;	1.8	;	Human Protein Farnesyltransferase Complexed with Inhibitor Compound STN-48 And FPP Analog at 1.8A Resolution
1S63	;	1.9	;	Human protein farnesyltransferase complexed with L-778,123 and FPP
4Q9Z	;	2.6	;	Human Protein Kinase C Theta in Complex with Compound35 ((1R)-9-(AZETIDIN-3-YLAMINO)-1,8-DIMETHYL-3,5-DIHYDRO[1,2,4]TRIAZINO[3,4-C][1,4]BENZOXAZIN-2(1H)-ONE)
4RA5	;	2.61	;	Human Protein Kinase C THETA IN COMPLEX WITH LIGAND COMPOUND 11a (6-[(1,3-Dimethyl-azetidin-3-yl)-methyl-amino]-4(R)-methyl-7-phenyl-2,10-dihydro-9-oxa-1,2,4a-triaza-phenanthren-3-one)
2FK9	;	1.75	;	Human protein kinase C, eta
6RB1	;	1.5	;	Human protein kinase CK2 alpha in complex with 2-cyano-2-propenamide compound 1
6RCB	;	2.05	;	Human protein kinase CK2 alpha in complex with 2-cyano-2-propenamide compound 14
6RCM	;	1.7	;	Human protein kinase CK2 alpha in complex with 2-cyano-2-propenamide compound 3
6RFE	;	1.54	;	Human protein kinase CK2 alpha in complex with 2-cyano-2-propenamide compound 4
6RFF	;	1.8	;	Human protein kinase CK2 alpha in complex with 2-cyano-2-propenamide compound 7
6HNY	;	1.65	;	Human protein kinase CK2 alpha in complex with boldine
6HNW	;	2.0	;	Human protein kinase CK2 alpha in complex with coumestrol
6HOP	;	1.55	;	Human protein kinase CK2 alpha in complex with curcumin degradation products
6HOQ	;	1.55	;	Human protein kinase CK2 alpha in complex with ferulic acid
6HOT	;	1.5	;	Human protein kinase CK2 alpha in complex with ferulic aldehyde
6HOR	;	1.8	;	Human protein kinase CK2 alpha in complex with feruloylmethane
6HOU	;	1.8	;	Human protein kinase CK2 alpha in complex with vanillin
4CRS	;	2.75	;	Human Protein Kinase N2 (PKN2, PRKCL2) in complex with ATPgammaS
1I1N	;	1.5	;	HUMAN PROTEIN L-ISOASPARTATE O-METHYLTRANSFERASE WITH S-ADENOSYL HOMOCYSTEINE
3ZV2	;	2.8	;	Human protein-tyrosine phosphatase 1b C215A, S216A mutant
4GW8	;	2.0	;	Human proto-oncogene serine threonine kinase (PIM1) in complex with a consensus peptide and Leucettine L41
6VG4	;	3.298	;	Human protocadherin 10 ectodomain
6PJJ	;	2.4	;	Human PRPF4B bound to benzothiophene inhibitor 224
6PK6	;	2.1	;	Human PRPF4B bound to benzothiophene inhibitor 329
6CNH	;	2.0	;	Human PRPF4B in complex with Rebastinib
7ZW1	;	3.7	;	Human PRPH2-ROM1 hetero-dimer
6WQX	;	2.53	;	Human PRPK-TPRKB complex
8DBF	;	2.2	;	Human PRPS1 with ADP; Filament Interface
8DBE	;	2.1	;	Human PRPS1 with ADP; Hexamer
8DBH	;	2.2	;	Human PRPS1 with Phosphate and ATP; Filament Interface
8DBG	;	2.2	;	Human PRPS1 with Phosphate and ATP; Hexamer
8DBM	;	2.4	;	Human PRPS1 with Phosphate and PRPP; Filament Interface
8DBL	;	2.4	;	Human PRPS1 with Phosphate and PRPP; Hexamer
8DBJ	;	2.0	;	Human PRPS1 with Phosphate, ATP, and R5P; Filament Interface
8DBI	;	2.0	;	Human PRPS1 with Phosphate, ATP, and R5P; Hexamer
8DBK	;	2.1	;	Human PRPS1 with Phosphate, ATP, and R5P; Hexamer with resolved catalytic loops
8DBD	;	3.2	;	Human PRPS1 with Phosphate; Filament Interface
8DBC	;	3.2	;	Human PRPS1 with Phosphate; Hexamer
8DBO	;	2.5	;	Human PRPS1-E307A engineered mutation with ADP; Hexamer
8DBN	;	2.4	;	Human PRPS1-E307A engineered mutation with Phosphate, ATP, and R5P; Hexamer
7LJ1	;	2.97	;	Human Prx1-Srx Decameric Complex
1PSR	;	1.05	;	HUMAN PSORIASIN (S100A7)
2PSR	;	2.05	;	HUMAN PSORIASIN (S100A7) CA2+ AND ZN2+ BOUND FORM (CRYSTAL FORM II)
3PSR	;	2.5	;	HUMAN PSORIASIN (S100A7) CA2+ BOUND FORM (CRYSTAL FORM I)
5IFN	;	3.17	;	Human PSPC1 Homodimer
8FLS	;	3.09	;	Human PTH1R in complex with Abaloparatide and Gs
8FLU	;	2.76	;	Human PTH1R in complex with LA-PTH and Gs
8FLT	;	3.03	;	Human PTH1R in complex with M-PTH(1-14) and Gs
8FLQ	;	2.55	;	Human PTH1R in complex with PTH(1-34) and Gs
8FLR	;	2.94	;	Human PTH1R in complex with PTHrP and Gs
1G7F	;	1.8	;	HUMAN PTP1B CATALYTIC DOMAIN COMPLEXED WITH PNU177496
1JF7	;	2.2	;	HUMAN PTP1B CATALYTIC DOMAIN COMPLEXED WITH PNU177836
1BZC	;	2.35	;	HUMAN PTP1B CATALYTIC DOMAIN COMPLEXED WITH TPI
1G7G	;	2.2	;	HUMAN PTP1B CATALYTIC DOMAIN COMPLEXES WITH PNU179326
1BZJ	;	2.25	;	Human ptp1b complexed with tpicooh
4NY3	;	1.797	;	Human PTPA in complex with peptide
8A1F	;	3.0	;	Human PTPRK N-terminal domains MAM-Ig-FN1
8A16	;	2.89	;	Human PTPRM domains FN3-4, in spacegroup P212121
8A17	;	3.09	;	Human PTPRM domains FN3-4, in spacegroup P3221
6SUC	;	1.97	;	Human PTPRU D1 domain, oxidised form
6SUB	;	1.72	;	Human PTPRU D1 domain, reduced form
5H08	;	2.53	;	Human PTPRZ D1 domain complexed with NAZ2329
8EQG	;	1.39	;	Human PU.1 ETS-Domain (165-270) Bound to d(AATAAA(DU)GGAAGTGGG)
8E3R	;	1.45	;	Human PU.1 ETS-Domain (165-270) Bound to d(AATAAAAGGAAGTGGG)
8EE9	;	1.22	;	Human PU.1 ETS-Domain (165-270) Bound to d(AATAAAAGGAATGGGG)
8EK8	;	2.63	;	Human PU.1 ETS-Domain (165-270) Bound to d(AATAAAAGGAGAAGGG)
8EKJ	;	1.54	;	Human PU.1 ETS-Domain (165-270) Bound to d(AATAAATGGAAGTGGG)
8EKU	;	1.52	;	Human PU.1 ETS-Domain (165-270) Bound to d(AATAAATGGAATGGGG)
8EQK	;	1.45	;	Human PU.1 ETS-Domain (165-270) Bound to d(AATAACCGGAAGTGGG)
8E4H	;	1.39	;	Human PU.1 ETS-Domain (165-270) Bound to d(AATAAGAGGAAGTGGG)
8EJ6	;	1.39	;	Human PU.1 ETS-Domain (165-270) Bound to d(AATAAGAGGAATGGGG)
8E3K	;	1.28	;	Human PU.1 ETS-Domain (165-270) Bound to d(AATAAGCGGAAGTGGG)
8EO4	;	1.24	;	Human PU.1 ETS-Domain (165-270) Bound to d(AATAAGCGGAAGTGGG) with Di-methylated CpG sites
8ENG	;	1.25	;	Human PU.1 ETS-Domain (165-270) Bound to d(AATAAGCGGAAGTGGG) with Hemi-methylated CpG (forward strand)
8EO1	;	1.28	;	Human PU.1 ETS-Domain (165-270) Bound to d(AATAAGCGGAAGTGGG) with Hemi-methylated CpG (reverse strand)
8EBH	;	1.33	;	Human PU.1 ETS-Domain (165-270) Bound to d(AATAAGCGGAATGGGG)
8EKV	;	1.62	;	Human PU.1 ETS-Domain (165-270) Bound to d(AATAAGCGGATGTGGG)
8EKZ	;	1.42	;	Human PU.1 ETS-Domain (165-270) Bound to d(AATAAGGAGAAGTAGG)
8EM9	;	2.341	;	Human PU.1 ETS-Domain (165-270) Bound to d(AATAGGAGAAGTAGGG)
8T9U	;	1.47	;	Human PU.1 ETS-domain (165-270) in complex with d(AATAAGCGIAAGTGGG)
8EJ8	;	1.45	;	Human PU.1 ETS-Domain (165-270) Q226E Mutant Bound to d(AATAAAAGGAAGTGGG)
8EQL	;	1.52	;	Human PU.1 ETS-Domain (165-270) Q226E Mutant Bound to d(AATAACCGGAAGTGGG)
8EMD	;	1.55	;	Human PU.1 ETS-Domain (165-270) Q226E Mutant Bound to d(AATAAGCGGAAGTGGG)
8EK3	;	1.38	;	Human PU.1 ETS-Domain (165-270) Q226E Mutant Bound to d(AATAAGCGGAATGGGG)
8E5Y	;	1.32	;	Human PU.1 ETS-Domain Bound to d(AATAAGCGGAAGTGGG) Acetate Free at pH 5.4
6LUR	;	2.0	;	Human PUF60 UHM domain (thioredoxin fusion) in complex with a small molecule binder
3GGS	;	2.52	;	Human purine nucleoside phosphorylase double mutant E201Q,N243D complexed with 2-fluoro-2'-deoxyadenosine
3GB9	;	2.3	;	Human purine nucleoside phosphorylase double mutant E201Q,N243D complexed with 2-fluoroadenine
7ZSL	;	1.8	;	human purine nucleoside phosphorylase in complex with JS-196
7ZSM	;	2.65	;	human purine nucleoside phosphorylase in complex with JS-375
7ZSN	;	2.36	;	human purine nucleoside phosphorylase in complex with JS-379
7ZSO	;	1.95	;	human purine nucleoside phosphorylase in complex with JS-554
7ZSP	;	2.29	;	human purine nucleoside phosphorylase in complex with JS-555
7ZSQ	;	1.77	;	human purine nucleoside phosphorylase in complex with JS-555
2PXX	;	1.3	;	Human putative methyltransferase MGC2408
2B25	;	2.5	;	Human putative tRNA(1-methyladenosine)methyltransferase
7N2A	;	2.26	;	human PXR LBD bound to compound 2
7RIV	;	2.2	;	human PXR LBD bound to GSK001
7RIU	;	2.05	;	human PXR LBD bound to GSK002
7RIO	;	2.48	;	human PXR LBD bound to GSK003
2YXT	;	2.0	;	Human Pyridoxal Kinase
2YXU	;	2.2	;	Human Pyridoxal Kinase
8QYT	;	1.69	;	Human Pyridoxine-5'-phosphate oxidase in complex with PLP
8QYW	;	2.746	;	Human Pyridoxine-5'-phosphate oxidase mutant R225H
8HWL	;	5.63	;	Human Pyruvate Carboxylase
1NI4	;	1.95	;	HUMAN PYRUVATE DEHYDROGENASE
6CER	;	2.69	;	Human pyruvate dehydrogenase complex E1 component V138M mutation
6CFO	;	2.7	;	HUMAN PYRUVATE DEHYDROGENASE E1 COMPONENT COMPLEX WITH COVALENT TDP ADDUCT ACETYL PHOSPHINATE
2OZL	;	1.9	;	Human pyruvate dehydrogenase S264E variant
1T5A	;	2.8	;	Human Pyruvate Kinase M2
4WJ8	;	2.87	;	Human Pyruvate Kinase M2 Mutant C424A
1ZX1	;	2.16	;	Human quinone oxidoreductase 2 (NQO2) in complex with the cytostatic prodrug CB1954
1QR2	;	2.1	;	HUMAN QUINONE REDUCTASE TYPE 2
2QR2	;	2.45	;	HUMAN QUINONE REDUCTASE TYPE 2, COMPLEX WITH MENADIONE
8EPL	;	3.1	;	Human R-type voltage-gated calcium channel Cav2.3 at 3.1 Angstrom resolution
8EPM	;	3.1	;	Human R-type voltage-gated calcium channel Cav2.3 CH2II-deleted mutant at 3.1 Angstrom resolution
6FO1	;	3.57	;	Human R2TP subcomplex containing 1 RUVBL1-RUVBL2 hexamer bound to 1 RBD domain from RPAP3.
5OEC	;	2.3	;	Human Rab32 (18-201):GDP in complex with Salmonella GtgE (21-214) C45A mutant
5OED	;	2.9	;	Human Rab32:GDP in complex with Salmonella GtgE C45A mutant
6STF	;	2.4	;	Human Rab8a phosphorylated at Ser111 in complex with GDP
6STG	;	2.5	;	Human Rab8a phosphorylated at Ser111 in complex with GPPNP
2C7M	;	2.4	;	Human Rabex-5 residues 1-74 in complex with Ubiquitin
2C7N	;	2.1	;	Human Rabex-5 residues 1-74 in complex with Ubiquitin
7EJE	;	3.98	;	human RAD51 post-synaptic complex
5H1C	;	4.5	;	Human RAD51 post-synaptic complexes
7C9A	;	3.43	;	Human RAD51 post-synaptic complexes mutant (V273P, D274G)
5H1B	;	4.4	;	Human RAD51 presynaptic complex
7EJC	;	2.97	;	human RAD51 presynaptic complex
8OUZ	;	2.2	;	Human RAD51B-RAD51C-RAD51D-XRCC2 (BCDX2) complex, 2.2 A resolution
8OUY	;	3.4	;	Human RAD51B-RAD51C-RAD51D-XRCC2 (BCDX2) complex, 3.4 A resolution
1H2I	;	2.7	;	Human Rad52 protein, N-terminal domain
8U61	;	4.0	;	Human RADX tetramer bound to ssDNA
8U5Y	;	3.01	;	human RADX trimer bound to ssDNA
2QYQ	;	1.948	;	Human raf kinase inhibitor protein (rkip) in complex with o-phosphotyrosine
5YK3	;	3.01	;	human Ragulator complex
3URF	;	2.701	;	Human RANKL/OPG complex
1U4L	;	2.0	;	human RANTES complexed to heparin-derived disaccharide I-S
1U4M	;	2.0	;	human RANTES complexed to heparin-derived disaccharide III-S
1HRJ	;		;	HUMAN RANTES, NMR, 13 STRUCTURES
1GUA	;	2.0	;	HUMAN RAP1A, RESIDUES 1-167, DOUBLE MUTANT (E30D,K31E) COMPLEXED WITH GPPNHP AND THE RAS-BINDING-DOMAIN OF HUMAN C-RAF1, RESIDUES 51-131
3H2V	;	2.9	;	Human raver1 RRM1 domain in complex with human vinculin tail domain Vt
3H2U	;	2.75	;	Human raver1 RRM1, RRM2, and RRM3 domains in complex with human vinculin tail domain Vt
3SMZ	;	1.99	;	Human raver1 RRM1-3 domains (residues 39-320)
5MGS	;	1.9	;	Human receptor NKR-P1 in deglycosylated form, extracellular domain
5MGR	;	1.8	;	Human receptor NKR-P1 in glycosylated form, extracellular domain
3QCB	;	2.1	;	Human receptor protein tyrosine phosphatase gamma, domain 1, apo
3QCL	;	2.4	;	Human receptor protein tyrosine phosphatase gamma, domain 1, in complex with 2-[(3,4-dichlorobenzyl)sulfanyl]-4-(4-hydroxybut-1-yn-1-yl)benzoic acid
3QCM	;	2.4	;	Human receptor protein tyrosine phosphatase gamma, domain 1, in complex with 2-[(3,4-dichlorobenzyl)sulfanyl]-4-{[3-({N-[2-(methylamino)ethyl]glycyl}amino)phenyl]ethynyl}benzoic acid
3QCK	;	2.05	;	Human receptor protein tyrosine phosphatase gamma, domain 1, in complex with 2-[(3,4-dichlorobenzyl)sulfanyl]benzoic acid
3QCH	;	2.4	;	Human receptor protein tyrosine phosphatase gamma, domain 1, in complex with 3-[(3,4-dichlorobenzyl)sulfanyl]-N-(methylsulfonyl)thiophene-2-carboxamide
3QCF	;	2.5	;	Human receptor protein tyrosine phosphatase gamma, domain 1, in complex with 3-[(3,4-dichlorobenzyl)sulfanyl]thiophene-2-carboxylic acid via co-crystallization
3QCE	;	2.1	;	Human receptor protein tyrosine phosphatase gamma, domain 1, in complex with 3-[(3,4-dichlorobenzyl)sulfanyl]thiophene-2-carboxylic acid via soaking
3QCG	;	2.05	;	Human receptor protein tyrosine phosphatase gamma, domain 1, in complex with 3-[(3-bromo-4-chlorobenzyl)sulfanyl]thiophene-2-carboxylic acid
3QCJ	;	2.26	;	Human receptor protein tyrosine phosphatase gamma, domain 1, in complex with 5-[({3-[(3,4-dichlorobenzyl)sulfanyl]thiophen-2-yl}carbonyl)sulfamoyl]-2-methoxybenzoic acid
3QCI	;	2.27	;	Human receptor protein tyrosine phosphatase gamma, domain 1, in complex with N-[(3-aminophenyl)sulfonyl]-3-[(3,4-dichlorobenzyl)sulfanyl]thiophene-2-carboxamide
3QCC	;	2.1	;	Human receptor protein tyrosine phosphatase gamma, domain 1, in complex with vanadate, orthorhombic crystal form
3QCD	;	1.8	;	Human receptor protein tyrosine phosphatase gamma, domain 1, in complex with vanadate, trigonal crystal form
3QCN	;	2.41	;	Human receptor protein tyrosine phosphatase gamma, domain 1, trigonal crystal form
1RPM	;	2.3	;	HUMAN RECEPTOR PROTEIN TYROSINE PHOSPHATASE MU, DOMAIN 1
7JIK	;	2.69	;	Human recombinant Beta-2-Glycoprotein 1
5I25	;	2.85	;	human recombinant coagulation FXI in complex with a peptide derived from human high molecular weight kininogen (HKP)
1B56	;	2.05	;	HUMAN RECOMBINANT EPIDERMAL FATTY ACID BINDING PROTEIN
1SCF	;	2.2	;	HUMAN RECOMBINANT STEM CELL FACTOR
1A31	;	2.1	;	HUMAN RECONSTITUTED DNA TOPOISOMERASE I IN COVALENT COMPLEX WITH A 22 BASE PAIR DNA DUPLEX
6YWA	;	2.311	;	Human REF STING in complex with 3',3'-c-[2'FdAMP-2'FdAM(PS)]
2KV3	;		;	Human Regenerating Gene Type IV (REG IV) PROTEIN, P91S mutant
1ITQ	;	2.3	;	HUMAN RENAL DIPEPTIDASE
1ITU	;	2.0	;	HUMAN RENAL DIPEPTIDASE COMPLEXED WITH CILASTATIN
3VSX	;	2.8	;	Human renin in complex with compound 18
3VUC	;	2.6	;	Human renin in complex with compound 5
3VSW	;	3.0	;	Human renin in complex with compound 8
7XGK	;	2.4	;	Human renin in complex with compound1
7XGO	;	2.1	;	Human renin in complex with compound2
7XGP	;	2.65	;	Human renin in complex with compound3
3VYD	;	2.81	;	Human renin in complex with inhibitor 6
3VYE	;	2.7	;	Human renin in complex with inhibitor 7
3VYF	;	2.8	;	Human renin in complex with inhibitor 9
3D91	;	2.2	;	Human renin in complex with remikiren
2I4Q	;	2.3	;	Human renin/PF02342674 complex
1EWI	;		;	HUMAN REPLICATION PROTEIN A: GLOBAL FOLD OF THE N-TERMINAL RPA-70 DOMAIN REVEALS A BASIC CLEFT AND FLEXIBLE C-TERMINAL LINKER
8B9D	;	3.4	;	Human replisome bound by Pol Alpha
1G2C	;	2.3	;	HUMAN RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEIN CORE
8FAV	;	1.85	;	HUMAN RETENOID-RELATED ORPHAN RECEPTOR-GAMMA (RORC2) LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 5 ANDINDAZOLE ACID BOUND IN H12-POCKET
8FB1	;	2.18	;	HUMAN RETENOID-RELATED ORPHAN RECEPTOR-GAMMA (RORC2) LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 6a ANDINDAZOLE ACID BOUND IN H12-POCKET
8FB2	;	2.3	;	HUMAN RETENOID-RELATED ORPHAN RECEPTOR-GAMMA (RORC2) LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 8 ANDINDAZOLE ACID BOUND IN H12-POCKET
6CN5	;	2.3	;	HUMAN RETENOID-RELATED ORPHAN RECEPTOR-GAMMA LIGAND- BINDING DOMAIN IN COMPLEX WITH INDOLE LIGAND CP9b IN INVERSE AGONIST CONFORMATION
7RGL	;	2.4	;	HUMAN RETINAL VARIANT IMPDH1(546) TREATED WITH ATP, IMP, NAD+, INTERFACE-CENTERED
7RGM	;	2.8	;	HUMAN RETINAL VARIANT IMPDH1(546) TREATED WITH ATP, IMP, NAD+, OCTAMER-CENTERED
7RGI	;	3.6	;	HUMAN RETINAL VARIANT IMPDH1(546) TREATED WITH GTP, ATP, IMP, NAD+; INTERFACE-CENTERED
7RGQ	;	3.9	;	HUMAN RETINAL VARIANT IMPDH1(546) TREATED WITH GTP, ATP, IMP, NAD+; INTERFACE-CENTERED
7RFH	;	3.7	;	HUMAN RETINAL VARIANT IMPDH1(595) TREATED WITH ATP, OCTAMER-CENTERED
7RFF	;	2.7	;	HUMAN RETINAL VARIANT IMPDH1(595) TREATED WITH ATP; INTERFACE-CENTERED
7RFI	;	2.6	;	HUMAN RETINAL VARIANT IMPDH1(595) TREATED WITH GTP, ATP, IMP, NAD+, INTERFACE-CENTERED
7RGD	;	3.0	;	HUMAN RETINAL VARIANT IMPDH1(595) TREATED WITH GTP, ATP, IMP, NAD+, OCTAMER-CENTERED
8U8Y	;	2.1	;	Human retinal variant phosphomimetic IMPDH1(546)-S477D filament bound by ATP, IMP, and NAD+, interface-centered
8U8O	;	2.4	;	Human retinal variant phosphomimetic IMPDH1(546)-S477D filament bound by ATP, IMP, and NAD+, octamer-centered
8U7V	;	3.3	;	Human retinal variant phosphomimetic IMPDH1(546)-S477D filament bound by GTP, ATP, IMP, and NAD+, interface-centered
8U7Q	;	3.3	;	Human retinal variant phosphomimetic IMPDH1(546)-S477D filament bound by GTP, ATP, IMP, and NAD+, octamer-centered
8U7M	;	3.1	;	Human retinal variant phosphomimetic IMPDH1(595)-S477D free octamer bound by GTP, ATP, IMP, and NAD+
2GL8	;	2.4	;	Human Retinoic acid receptor RXR-gamma ligand-binding domain
8SYO	;	2.94	;	Human Retriever VPS35L/VPS29/VPS26C Complex (Composite Map)
6N6J	;	1.317	;	Human REXO2 bound to pAA
6N6K	;	1.418	;	Human REXO2 bound to pAG
6N6I	;	1.431	;	Human REXO2 bound to pGG
6STY	;	3.15	;	Human REXO2 exonuclease in complex with RNA.
1R09	;	2.9	;	HUMAN RHINOVIRUS 14 COMPLEXED WITH ANTIVIRAL COMPOUND R 61837
1AYN	;	2.9	;	HUMAN RHINOVIRUS 16 COAT PROTEIN
1AYM	;	2.15	;	HUMAN RHINOVIRUS 16 COAT PROTEIN AT HIGH RESOLUTION
1QJU	;	2.8	;	HUMAN RHINOVIRUS 16 COAT PROTEIN IN COMPLEX WITH ANTIVIRAL COMPOUND VP61209
1QJY	;	2.8	;	HUMAN RHINOVIRUS 16 COAT PROTEIN IN COMPLEX WITH ANTIVIRAL COMPOUND VP65099
1QJX	;	2.8	;	HUMAN RHINOVIRUS 16 COAT PROTEIN IN COMPLEX WITH ANTIVIRAL COMPOUND WIN68934
3DPR	;	3.5	;	Human rhinovirus 2 bound to a concatamer of the VLDL receptor module V3
1V9U	;	3.6	;	Human Rhinovirus 2 bound to a fragment of its cellular receptor protein
8AY5	;	7.1	;	Human rhinovirus 2 empty particle in situ
8AY4	;	4.7	;	Human rhinovirus 2 virion in situ
1RHI	;	3.0	;	HUMAN RHINOVIRUS 3 COAT PROTEIN
1FPN	;	2.6	;	HUMAN RHINOVIRUS SEROTYPE 2 (HRV2)
3V8S	;	2.286	;	Human RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
3TV7	;	2.75	;	Human Rho-associated protein kinase 1 (ROCK 1) in COMPLEX WITH RKI1342
1A2B	;	2.4	;	HUMAN RHOA COMPLEXED WITH GTP ANALOGUE
6AUI	;	3.3	;	Human ribonucleotide reductase large subunit (alpha) with dATP and CDP
2WGH	;	2.3	;	Human Ribonucleotide reductase R1 subunit (RRM1) in complex with dATP and Mg.
2VUX	;	2.8	;	Human ribonucleotide reductase, subunit M2 B
6OLF	;	3.9	;	Human ribosome nascent chain complex (CDH1-RNC) stalled by a drug-like molecule with AA and PE tRNAs
6OLE	;	3.1	;	Human ribosome nascent chain complex (CDH1-RNC) stalled by a drug-like molecule with AP and PE tRNAs
6OM0	;	3.1	;	Human ribosome nascent chain complex (PCSK9-RNC) stalled by a drug-like molecule with AP and PE tRNAs
6OLZ	;	3.9	;	Human ribosome nascent chain complex (PCSK9-RNC) stalled by a drug-like molecule with PP tRNA
6OM7	;	3.7	;	Human ribosome nascent chain complex (PCSK9-RNC) stalled by a drug-like small molecule with AA and PE tRNAs
6OLG	;	3.4	;	Human ribosome nascent chain complex stalled by a drug-like small molecule (CDH1_RNC with PP tRNA)
6ZUO	;	3.1	;	Human RIO1(kd)-StHA late pre-40S particle, structural state A (pre 18S rRNA cleavage)
6ZV6	;	2.9	;	Human RIO1(kd)-StHA late pre-40S particle, structural state B (post 18S rRNA cleavage)
6FDM	;	2.1	;	Human Rio2 kinase structure
6HK6	;	2.35	;	Human RIOK2 bound to inhibitor
7DAC	;		;	Human RIPK3 amyloid fibril revealed by solid-state NMR
7UWF	;	2.7	;	Human Rix1 sub-complex scaffold
7P3B	;	2.3	;	Human RNA ligase RTCB in complex with GMP and Co(II)
8A43	;	4.09	;	Human RNA polymerase I
8ITY	;	3.9	;	human RNA polymerase III pre-initiation complex closed DNA 1
5VBB	;	1.94	;	Human RNA Pseudouridylate Synthase Domain Containing 1
5UBA	;	1.54	;	Human RNA Pseudouridylate Synthase Domain Containing 4
2QKK	;	3.2	;	Human RNase H catalytic domain mutant D210N in complex with 14-mer RNA/DNA hybrid
2QK9	;	2.55	;	Human RNase H catalytic domain mutant D210N in complex with 18-mer RNA/DNA hybrid
2QKB	;	2.4	;	Human RNase H catalytic domain mutant D210N in complex with 20-mer RNA/DNA hybrid
4PPE	;	2.0	;	human RNF4 RING domain
5NOI	;	2.4	;	human Robo2 extracellular domains 4-5
2XUB	;	2.8	;	Human RPC62 subunit structure
4Q94	;	1.85	;	human RPRD1B CID in complex with a RPB1-CTD derived Ser2 phosphorylated peptide
5OAF	;	4.06	;	Human Rvb1/Rvb2 heterohexamer in INO80 complex
8PP6	;	3.18	;	human RYBP-PRC1 bound to H2AK118ub1 nucleosome
8PP7	;	2.91	;	human RYBP-PRC1 bound to mononucleosome
7QPG	;	3.9	;	Human RZZ kinetochore corona complex.
1LI4	;	2.01	;	Human S-adenosylhomocysteine hydrolase complexed with neplanocin
1JEN	;	2.25	;	HUMAN S-ADENOSYLMETHIONINE DECARBOXYLASE
1I7M	;	2.24	;	HUMAN S-ADENOSYLMETHIONINE DECARBOXYLASE WITH COVALENTLY BOUND PYRUVOYL GROUP AND COMPLEXED WITH 4-AMIDINOINDAN-1-ONE-2'-AMIDINOHYDRAZONE
1I7C	;	2.4	;	HUMAN S-ADENOSYLMETHIONINE DECARBOXYLASE WITH COVALENTLY BOUND PYRUVOYL GROUP AND COMPLEXED WITH METHYLGLYOXAL BIS-(GUANYLHYDRAZONE)
1I79	;	2.01	;	HUMAN S-ADENOSYLMETHIONINE DECARBOXYLASE WITH COVALENTLY BOUND PYRUVOYL GROUP AND COVALENTLY BOUND 5'-DEOXY-5'-[(3-HYDRAZINOPROPYL)METHYLAMINO]ADENOSINE
1I72	;	2.0	;	HUMAN S-ADENOSYLMETHIONINE DECARBOXYLASE WITH COVALENTLY BOUND PYRUVOYL GROUP AND COVALENTLY BOUND 5'-DEOXY-5'-[N-METHYL-N-(2-AMINOOXYETHYL) AMINO]ADENOSINE
1I7B	;	1.9	;	HUMAN S-ADENOSYLMETHIONINE DECARBOXYLASE WITH COVALENTLY BOUND PYRUVOYL GROUP AND COVALENTLY BOUND S-ADENOSYLMETHIONINE METHYL ESTER
6WKB	;	2.55	;	Human S-adenosylmethionine synthetase co-crystallized with UppNHp and Met
1DB5	;	2.8	;	HUMAN S-PLA2 IN COMPLEX WITH INDOLE 6
1DB4	;	2.2	;	HUMAN S-PLA2 IN COMPLEX WITH INDOLE 8
8EX4	;	2.93	;	Human S1P transporter Spns2 in an inward-facing open conformation (state 1)
8EX6	;	3.54	;	Human S1P transporter Spns2 in an inward-facing open conformation (state 1*)
8EX5	;	3.47	;	Human S1P transporter Spns2 in an outward-facing open conformation (state 4)
8EX8	;	4.17	;	Human S1P transporter Spns2 in an outward-facing partially occluded conformation (state 2)
8EX7	;	3.53	;	Human S1P transporter Spns2 in an outward-facing partially occluded conformation (state 3)
3GVP	;	2.25	;	Human SAHH-like domain of human adenosylhomocysteinase 3
1SMD	;	1.6	;	HUMAN SALIVARY AMYLASE
6U6X	;	2.58	;	Human SAMHD1 bound to deoxyribo(C*G*C*C*T)-oligonucleotide
6U6Z	;	2.1	;	Human SAMHD1 bound to deoxyribo(TG*TTCA)-oligonucleotide
6U6Y	;	2.47	;	Human SAMHD1 bound to ribo(CGCCU)-oligonucleotide
9AXG	;	2.68	;	Human saposin B in the presence of globotriaosylceramide-NBD
8D0I	;	2.0	;	Human SARM1 bound to an NB-3 eADPR adduct
8GNI	;	3.74	;	Human SARM1 bounded with NMN and Nanobody-C6, Conformation 1
8GNJ	;	3.78	;	Human SARM1 bounded with NMN and Nanobody-C6, Conformation 2
8GQ5	;	2.7	;	Human SARM1 bounded with NMN and Nanobody-C6, double-layer structure
7DJT	;	2.8	;	Human SARM1 inhibitory state bounded with inhibitor dHNN
8D0D	;	1.96	;	Human SARM1 TIR domain bound to an NB-7-ADPR adduct
8D0F	;	1.74	;	Human SARM1 TIR domain bound to NB-2-ADPR
8D0C	;	2.09	;	Human SARM1 TIR domain bound to NB-3-ADPR
8D0G	;	1.99	;	Human SARM1 TIR domain bound to NB-3-ADPRP
8D0H	;	2.37	;	Human SARM1 TIR domain bound to NB-3-GDPR
8D0E	;	1.88	;	Human SARM1 TIR domain bound to NB-7
2W2G	;	2.22	;	Human SARS coronavirus unique domain
2WCT	;	2.79	;	human SARS coronavirus unique domain (triclinic form)
2OX8	;	2.5	;	Human Scavenger Receptor C-type Lectin carbohydrate-recognition domain.
5MRA	;	3.74	;	human SCBD (sorcin calcium binding domain) in complex with doxorubicin
1WP0	;	2.8	;	Human SCO1
1PL8	;	1.9	;	human SDH/NAD+ complex
1PL6	;	2.0	;	Human SDH/NADH/inhibitor complex
6MKY	;	2.9	;	Human SDS22
7D3S	;	2.9	;	Human SECR in complex with an engineered Gs heterotrimer
6WI9	;	4.3	;	Human secretin receptor Gs complex
6WZG	;	2.3	;	Human secretin receptor Gs complex
5MWA	;	1.55	;	human sEH Phosphatase in complex with 3-4-3,4-dichlorophenyl-5-phenyl-1,3-oxazol-2-yl-benzoic-acid
3GZD	;	1.8	;	Human selenocysteine lyase, P1 crystal form
5KUE	;	1.5	;	Human SeMet incorporated I141M/L146M mitochondrial calcium uniporter (residues 72-189) crystal structure with magnesium
4Z3K	;	2.35	;	Human sepiapterin reductase in complex with the cofactor NADP+ and the trypthophan metabolite xanthurenic acid
2QNR	;	2.6	;	Human septin 2 in complex with GDP
7M6J	;	3.6	;	Human Septin Hexameric Complex SEPT2G/SEPT6/SEPT7 by Single Particle Cryo-EM
7RUG	;	4.7	;	Human SERINC3-DeltaICL4
7V1Z	;	2.98	;	human Serine beta-lactamase-like protein LACTB
7V21	;	3.08	;	human Serine beta-lactamase-like protein LACTB truncation variant
7K0I	;	3.3	;	Human serine palmitoyltransferase complex SPTLC1/SPLTC2/ssSPTa
7K0J	;	3.1	;	Human serine palmitoyltransferase complex SPTLC1/SPLTC2/ssSPTa protomer
7K0K	;	2.6	;	Human serine palmitoyltransferase complex SPTLC1/SPLTC2/ssSPTa, 3KS-bound
7K0L	;	3.4	;	Human serine palmitoyltransferase complex SPTLC1/SPLTC2/ssSPTa, myriocin-bound
7K0M	;	2.9	;	Human serine palmitoyltransferase complex SPTLC1/SPLTC2/ssSPTa/ORMDL3, class 1
7K0N	;	3.1	;	Human serine palmitoyltransferase complex SPTLC1/SPLTC2/ssSPTa/ORMDL3, class 2
7K0O	;	3.1	;	Human serine palmitoyltransferase complex SPTLC1/SPLTC2/ssSPTa/ORMDL3, class 3
7K0P	;	3.1	;	Human serine palmitoyltransferase complex SPTLC1/SPLTC2/ssSPTa/ORMDL3, class 4
7K0Q	;	3.3	;	Human serine palmitoyltransferase complex SPTLC1/SPLTC2/ssSPTa/ORMDL3, myriocin-bound
6ZSP	;	1.6	;	Human serine racemase bound to ATP and malonate.
6ZUJ	;	1.8	;	Human serine racemase holoenzyme from 20% DMSO soak (XChem crystallographic fragment screen).
8AXD	;	2.98	;	Human serotonin 5-HT3A receptor (apo, resting conformation)
7DJN	;	2.04	;	Human Serum Albumin
7VR0	;	1.98	;	Human Serum Albumin
6M5D	;	2.6	;	Human serum albumin (apo form)
7A9C	;	2.75	;	Human serum albumin (HSA) crystallized in the presence of yttrium (III) chloride
7X7X	;	2.1	;	Human serum albumin complex with deschloro-aripiprazole
4E99	;	2.3	;	Human Serum Albumin Complex with Perfluorooctane Sulfonate Potassium
2BXA	;	2.35	;	Human serum albumin complexed with 3-carboxy-4-methyl-5-propyl-2- furanpropanoic acid (CMPF)
2VUE	;	2.42	;	Human serum albumin complexed with 4Z,15E-bilirubin-IX-alpha
6A7P	;	2.28	;	Human serum albumin complexed with aripiprazole
2BX8	;	2.7	;	Human serum albumin complexed with azapropazone
7D6J	;	3.29	;	Human serum albumin complexed with benzbromarone
1GNJ	;	2.6	;	HUMAN SERUM ALBUMIN COMPLEXED WITH cis-5,8,11,14-EICOSATETRAENOIC ACID (ARACHIDONIC ACID)
1GNI	;	2.4	;	HUMAN SERUM ALBUMIN COMPLEXED WITH cis-9-OCTADECENOIC ACID (OLEIC ACID)
2XVW	;	2.65	;	Human serum albumin complexed with dansyl-L-arginine and myristic acid
2XVU	;	2.6	;	Human serum albumin complexed with dansyl-L-asparagine
2XVV	;	2.4	;	Human serum albumin complexed with dansyl-L-asparagine and myristic acid
2XSI	;	2.7	;	Human serum albumin complexed with dansyl-L-glutamate and myristic acid
2XW1	;	2.5	;	Human serum albumin complexed with dansyl-L-norvaline
2XW0	;	2.4	;	Human serum albumin complexed with dansyl-L-phenylalanine
2XVQ	;	2.9	;	Human serum albumin complexed with dansyl-L-sarcosine
1E7E	;	2.5	;	HUMAN SERUM ALBUMIN COMPLEXED WITH DECANOIC ACID (CAPRIC ACID)
2BXF	;	2.95	;	Human serum albumin complexed with diazepam
2BXE	;	2.95	;	Human serum albumin complexed with diflunisal
1E7F	;	2.43	;	HUMAN SERUM ALBUMIN COMPLEXED WITH DODECANOIC ACID (LAURIC ACID)
2VUF	;	3.05	;	Human serum albumin complexed with fusidic acid
1E7H	;	2.43	;	HUMAN SERUM ALBUMIN COMPLEXED WITH HEXADECANOIC ACID (PALMITIC ACID)
2BXG	;	2.7	;	Human serum albumin complexed with ibuprofen
2BXH	;	2.25	;	Human serum albumin complexed with indoxyl sulfate
2YDF	;	2.75	;	HUMAN SERUM ALBUMIN COMPLEXED WITH IOPHENOXIC ACID
2BXL	;	2.6	;	Human serum albumin complexed with myristate and 3,5-diiodosalicylic acid
2I2Z	;	2.7	;	Human serum albumin complexed with myristate and aspirin
2BXI	;	2.5	;	Human serum albumin complexed with myristate and azapropazone
3B9L	;	2.6	;	Human serum albumin complexed with myristate and AZT
2BXM	;	2.5	;	Human serum albumin complexed with myristate and indomethacin
2BXN	;	2.65	;	Human serum albumin complexed with myristate and iodipamide
2BXO	;	2.6	;	Human serum albumin complexed with myristate and oxyphenbutazone
2BXP	;	2.3	;	Human serum albumin complexed with myristate and phenylbutazone
2I30	;	2.9	;	Human serum albumin complexed with myristate and salicylic acid
3B9M	;	2.7	;	Human serum albumin complexed with myristate, 3'-azido-3'-deoxythymidine (AZT) and salicylic acid
2BXK	;	2.4	;	Human serum albumin complexed with myristate, azapropazone and indomethacin
2BXQ	;	2.6	;	Human serum albumin complexed with myristate, phenylbutazone and indomethacin
1BJ5	;	2.5	;	HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTIC ACID
1E7C	;	2.4	;	HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTIC ACID and the general anesthetic halothane
1H9Z	;	2.5	;	Human Serum Albumin Complexed With Myristic Acid and the R-(+) enantiomer of warfarin
1HA2	;	2.5	;	Human Serum Albumin Complexed With Myristic Acid and the S-(-) enantiomer of warfarin
6EZQ	;	2.39	;	human Serum Albumin complexed with NBD-C12 fatty acid
1E7I	;	2.7	;	HUMAN SERUM ALBUMIN COMPLEXED WITH OCTADECANOIC ACID (STEARIC ACID)
5X52	;	3.005	;	Human serum albumin complexed with octanoate and N-acetyl-L-methionine
2BXB	;	3.2	;	Human serum albumin complexed with oxyphenbutazone
4Z69	;	2.187	;	Human serum albumin complexed with palmitic acid and diclofenac
2BXC	;	3.1	;	Human serum albumin complexed with phenylbutazone
5YOQ	;	2.65	;	Human serum albumin complexed with sodium 4-phenylbutyrate
1E7G	;	2.5	;	Human serum albumin complexed with tetradecanoic acid (myristic acid)
1O9X	;	3.2	;	HUMAN SERUM ALBUMIN COMPLEXED WITH TETRADECANOIC ACID (MYRISTIC ACID) AND HEMIN
1HK1	;	2.65	;	HUMAN SERUM ALBUMIN COMPLEXED WITH THYROXINE (3,3',5,5'-TETRAIODO-L-THYRONINE)
1HK4	;	2.4	;	HUMAN SERUM ALBUMIN COMPLEXED WITH THYROXINE (3,3',5,5'-TETRAIODO-L-THYRONINE) and myristic acid (tetradecanoic acid)
2BXD	;	3.05	;	Human serum albumin complexed with warfarin
1BKE	;	3.15	;	HUMAN SERUM ALBUMIN IN A COMPLEX WITH MYRISTIC ACID AND TRI-IODOBENZOIC ACID
3LU6	;	2.7	;	Human serum albumin in complex with compound 1
3LU7	;	2.8	;	Human serum albumin in complex with compound 2
3LU8	;	2.6	;	Human serum albumin in complex with compound 3
1HK2	;	2.8	;	HUMAN SERUM ALBUMIN MUTANT R218H COMPLEXED WITH THYROXINE (3,3',5,5'-TETRAIODO-L-THYRONINE)
1HK5	;	2.7	;	HUMAN SERUM ALBUMIN MUTANT R218H COMPLEXED WITH THYROXINE (3,3',5,5'-TETRAIODO-L-THYRONINE) and myristic acid (tetradecanoic acid)
1HK3	;	2.8	;	Human serum albumin mutant r218p complexed with thyroxine (3,3',5,5'-tetraiodo-l-thyronine)
3JRY	;	2.3	;	Human Serum albumin with bound Sulfate
8EW4	;	2.4	;	Human Serum Albumin with Cobalt (II) and Myristic Acid - crystal 1
8EW7	;	3.3	;	Human Serum Albumin with Cobalt (II) and Myristic Acid - crystal 2
8EY5	;	3.1	;	Human Serum Albumin with Cobalt (II) and Myristic Acid - crystal 3
6M5E	;	2.8	;	Human serum albumin with cyclic peptide dalbavancin
6R7S	;	2.21	;	Human Serum Albumin, complexed with Sulfasalazine
3UIV	;	2.2	;	Human serum albumin-myristate-amantadine hydrochloride complex
6L4K	;	2.09	;	Human serum albumin-Palmitic acid-Cu compound
5GIX	;	2.801	;	Human serum albumin-Palmitic acid-Fe(Hn3piT)Cl2
7FFS	;	2.05	;	Human Serum Albumin_1
7FFR	;	2.31	;	Human Serum Albumin_2
7PUE	;	2.506	;	Human serum and glucocorticoid-regulated kinase 1 in complex with pyrazolopyridine inhibitor 3a
1D3K	;	1.8	;	HUMAN SERUM TRANSFERRIN
1D4N	;	2.0	;	HUMAN SERUM TRANSFERRIN
5X5P	;	2.7	;	Human serum transferrin bound to ruthenium NTA
4X1B	;	2.45	;	Human serum transferrin with ferric ion bound at the C-lobe only
7FFM	;	3.06	;	Human serum transferrin with five osmium binding sites
6JAS	;	2.501	;	Human serum transferrin with iron citrate bound
1N84	;	2.05	;	HUMAN SERUM TRANSFERRIN, N-LOBE
1RYO	;	1.2	;	Human serum transferrin, N-lobe bound with oxalate
1N7X	;	2.1	;	HUMAN SERUM TRANSFERRIN, N-LOBE Y45E MUTANT
1B3E	;	2.5	;	HUMAN SERUM TRANSFERRIN, N-TERMINAL LOBE, EXPRESSED IN PICHIA PASTORIS
1A8E	;	1.6	;	HUMAN SERUM TRANSFERRIN, RECOMBINANT N-TERMINAL LOBE
1A8F	;	1.8	;	HUMAN SERUM TRANSFERRIN, RECOMBINANT N-TERMINAL LOBE
1BP5	;	2.2	;	HUMAN SERUM TRANSFERRIN, RECOMBINANT N-TERMINAL LOBE, APO FORM
1BTJ	;	3.2	;	HUMAN SERUM TRANSFERRIN, RECOMBINANT N-TERMINAL LOBE, APO FORM, CRYSTAL FORM 2
5Y6K	;	2.86	;	Human serum trnasferrin bound to a fluorescent probe
4RQF	;	3.503	;	human Seryl-tRNA synthetase dimer complexed with one molecule of tRNAsec
4RQE	;	4.0	;	human Seryl-tRNA synthetase dimer complexed with two molecules of tRNAsec
7EA8	;	3.1	;	Human SETD2 bound to a nucleosome containing oncohistone mutations
3QXY	;	2.09	;	Human SETD6 in complex with RelA Lys310
3RC0	;	2.19	;	Human SETD6 in complex with RelA Lys310 peptide
5T5G	;	2.1	;	human SETD8 in complex with MS2177
8DAF	;	2.59	;	Human SF-1 LBD bound to synthetic agonist 6N-10CA and bacterial phospholipid
5KAZ	;	1.7	;	Human SH2D1B structure
3I35	;	1.4	;	Human SH3 domain of protein LASP1
6XY7	;	1.086	;	Human SHIP1 with magnesium and phosphate bound to the active site
6QVG	;	2.32	;	Human SHMT2 in complex with lometrexol
6QVL	;	2.28	;	Human SHMT2 in complex with pemetrexed
4BWD	;	2.702	;	Human short coiled coil protein
4NC5	;	2.513	;	Human sialidase 2 in complex with 2,3-difluorosialic acid (covalent intermediate)
4NCS	;	2.201	;	Human sialidase 2 in complex with 2,3-difluorosialic acid (covalent intermediate)
6DK1	;	3.12	;	Human sigma-1 receptor bound to (+)-pentazocine
5HK2	;	3.2	;	Human sigma-1 receptor bound to 4-IBP
6DJZ	;	3.084	;	Human sigma-1 receptor bound to haloperidol
6DK0	;	2.9	;	Human sigma-1 receptor bound to NE-100
5HK1	;	2.5051	;	Human sigma-1 receptor bound to PD144418
7P2P	;	4.9	;	Human Signal Peptidase Complex Paralog A (SPC-A)
7P2Q	;	4.9	;	Human Signal Peptidase Complex Paralog C (SPC-C)
6BEV	;	1.043	;	Human Single Domain Sulfurtranferase TSTD1
7W68	;	4.4	;	human single hexameric Mcm2-7 complex
5G4C	;	2.1	;	Human SIRT2 catalyse short chain fatty acyl lysine
4R8M	;	2.1	;	Human SIRT2 crystal structure in complex with BHJH-TM1
1J8F	;	1.7	;	HUMAN SIRT2 HISTONE DEACETYLASE
4Y6Q	;	1.9	;	Human SIRT2 in complex with 2-O-myristoyl-ADP-ribose
5Y0Z	;	2.0	;	Human SIRT2 in complex with a specific inhibitor, NPD11033
4RMJ	;	1.87	;	Human Sirt2 in complex with ADP ribose and nicotinamide
6QCN	;	2.23	;	Human Sirt2 in complex with ADP-ribose and the inhibitor quercetin
7BOS	;	1.7	;	Human SIRT2 in complex with myristoyl thiourea inhibitor, No.13
7BOT	;	1.7	;	Human SIRT2 in complex with myristoyl thiourea inhibitor, No.23
4Y6L	;	1.6	;	Human SIRT2 in complex with myristoylated peptide (H3K9myr)
4Y6O	;	1.6	;	Human SIRT2 in complex with myristoylated peptide (TNF-alphaK20myr)
4RMI	;	1.45	;	Human Sirt2 in complex with SirReal1 and Ac-Lys-OTC peptide
4RMH	;	1.42	;	Human Sirt2 in complex with SirReal2 and Ac-Lys-H3 peptide
4RMG	;	1.88	;	Human Sirt2 in complex with SirReal2 and NAD+
7T1D	;	1.75	;	Human SIRT2 in complex with small molecule 359
4FVT	;	2.47	;	Human SIRT3 bound to Ac-ACS peptide and Carba-NAD
8V15	;	2.4	;	Human SIRT3 bound to p53-AMC peptide, Carba-NAD, and Honokiol
8V2N	;	1.74	;	Human SIRT3 co-crystallized with ligands, including p53-AMC peptide and Carba-NAD
5Y4H	;	2.6	;	Human SIRT3 in complex with halistanol sulfate
8HN9	;	3.7	;	Human SIRT3 Recognizing CCNE2K348la peptide
6ISO	;	2.95	;	Human SIRT3 Recognizing H3K4cr
4G1C	;	1.944	;	Human SIRT5 bound to Succ-IDH2 and Carba-NAD
6EQS	;	1.32	;	Human Sirt5 in complex with stalled peptidylimidate intermediate of inhibitory compound 29
6XUY	;	2.13	;	Human Sirt6 13-308 in complex with ADP-ribose
6ZU4	;	2.46	;	Human Sirt6 13-308 in complex with ADP-ribose and the activator fluvastatin
6XV1	;	1.95	;	Human Sirt6 13-308 in complex with ADP-ribose and the activator MDL-801
6XV6	;	1.75	;	Human Sirt6 3-318 in complex with ADP-ribose
6XVG	;	2.1	;	Human Sirt6 3-318 in complex with ADP-ribose and the activator MDL-801
3PKJ	;	2.12	;	Human SIRT6 crystal structure in complex with 2'-N-Acetyl ADP ribose
3PKI	;	2.04	;	Human SIRT6 crystal structure in complex with ADP ribose
5MF6	;	1.87	;	Human Sirt6 in complex with activator UBCS039
5MGN	;	2.07	;	Human Sirt6 in complex with activator UBCS38
5MFP	;	1.98	;	Human Sirt6 in complex with activator UBCS58
8AKD	;	1.76	;	Human Sirt6 in complex with ADP-ribose and fragment 1-methyl-L-histidine
8AKC	;	1.83	;	Human Sirt6 in complex with ADP-ribose and fragment 3-(acetylamino)thiophene-2-carboxylic acid
8AKF	;	1.97	;	Human Sirt6 in complex with ADP-ribose and fragment 3-aminobenzamide
8AKG	;	1.82	;	Human Sirt6 in complex with ADP-ribose and fragment 4-amino-6-chlorobenzene-1,3-disulfonamide
8AK8	;	1.73	;	Human Sirt6 in complex with ADP-ribose and fragment 4-hydroxybenzamide
8AKB	;	2.13	;	Human Sirt6 in complex with ADP-ribose and fragment 4-nitrocatechol
8AK7	;	1.81	;	Human Sirt6 in complex with ADP-ribose and fragment 6-O-methylguanine
8AKA	;	1.77	;	Human Sirt6 in complex with ADP-ribose and fragment cis-resveratrol
8AK9	;	1.95	;	Human Sirt6 in complex with ADP-ribose and fragment Isatin
8AKE	;	1.82	;	Human Sirt6 in complex with ADP-ribose and fragment nicotinamide
8AK5	;	2.12	;	Human Sirt6 in complex with ADP-ribose and fragment pyroglutamic acid
8AK6	;	1.98	;	Human Sirt6 in complex with ADP-ribose and fragment sulfamethoxazole
6QCH	;	2.1	;	Human Sirt6 in complex with ADP-ribose and the activator cyanidin
6QCE	;	1.9	;	Human Sirt6 in complex with ADP-ribose and the activator isoquercetin
6QCD	;	1.84	;	Human Sirt6 in complex with ADP-ribose and the activator quercetin
6QCJ	;	2.01	;	Human Sirt6 in complex with ADP-ribose and the inhibitor catechin gallate
6HOY	;	1.7	;	Human Sirt6 in complex with ADP-ribose and the inhibitor trichostatin A
5Y2F	;	2.53	;	Human SIRT6 in complex with allosteric activator MDL-801
7CL1	;	3.2	;	Human SIRT6 in complex with allosteric activator MDL-801 (3.2A)
8I2B	;	2.2	;	Human SIRT6 in complex with inhibitor 7702
5MFZ	;	2.1	;	Human Sirt6 in complex with small molecule UBCS40
8CNM	;	1.88	;	Human Sirt6 in complex with the inhibitor S6020 and ADP-ribose
8BL0	;	1.82	;	Human Sirt6 in complex with the inhibitor S6023 and ADP-ribose
8BL1	;	2.06	;	Human Sirt6 in complex with the inhibitor S6039 and ADP-ribose
5CRG	;	1.97	;	Human skeletal calsequestrin, D210G mutant high-calcium complex
5CRE	;	3.315	;	Human skeletal calsequestrin, D210G mutant low-calcium complex
5CRH	;	2.03	;	Human skeletal calsequestrin, M53T mutant high-calcium complex
7XUL	;	3.16	;	Human SLC26A3 in complex with Tenidap
7XUJ	;	2.8	;	Human SLC26A3 in complex with UK5099
8IET	;	3.5	;	Human SLC26A3 in the apo state
7ZEL	;	2.8	;	Human SLFN11 dimer apoenzyme
7ZES	;	3.1	;	Human SLFN11 dimer bound to ssDNA
7ZEP	;	3.2	;	Human SLFN11 E209A dimer
7PPJ	;	3.44	;	human SLFN5
6HVD	;	1.63	;	Human SLK bound to a maleimide inhibitor
4USF	;	1.75	;	Human SLK with SB-440719
7PW4	;	3.27	;	Human SMG1-8-9 kinase complex bound to a SMG1 inhibitor
7PW6	;	3.05	;	Human SMG1-8-9 kinase complex bound to a SMG1 inhibitor - SMG1 body
7PW8	;	2.82	;	Human SMG1-8-9 kinase complex bound to AMPPNP
7PW5	;	3.4	;	Human SMG1-8-9 kinase complex with AlphaFold predicted SMG8 C-terminus, bound to a SMG1 inhibitor
7PW7	;	3.59	;	Human SMG1-9 kinase complex bound to a SMG1 inhibitor
7PW9	;	3.12	;	Human SMG1-9 kinase complex bound to AMPPNP
4O9R	;	3.204	;	Human Smoothened Receptor structure in complex with cyclopamine
4GNB	;	1.5	;	human SMP30/GNL
4GNC	;	1.749	;	human SMP30/GNL-1,5-AG complex
5WY2	;	1.9	;	Human Snx5 PX domain in complex with Chlamydia IncE C terminus
3GZQ	;	1.401	;	HUMAN SOD1 A4V Metal-free Variant
4MCM	;	2.2	;	Human SOD1 C57S Mutant, As-isolated
4MCN	;	2.6	;	Human SOD1 C57S Mutant, Metal-free
3H2P	;	1.55	;	Human SOD1 D124V Variant
3CQP	;	1.95	;	Human SOD1 G85R Variant, Structure I
3CQQ	;	1.9	;	Human SOD1 G85R Variant, Structure II
3GZP	;	3.1	;	HUMAN SOD1 G93A Metal-free Variant
3GZO	;	2.1	;	HUMAN SOD1 G93A Variant
3H2Q	;	1.85	;	Human SOD1 H80R variant, P21 crystal form
3QQD	;	1.653	;	Human SOD1 H80R variant, P212121 crystal form
8CCX	;	1.665	;	Human SOD1 in complex with S-XL6 cross-linker
8Q6M	;	1.77	;	Human SOD1 low dose data collecton
4OYM	;	1.7	;	Human solAC Complexed with (4-Amino-furazan-3-yl)-(3-methoxy-phenyl)-methanone
4OYI	;	1.7	;	Human solAC Complexed with (4-Amino-furazan-3-yl)-phenyl-methanone
4OYA	;	2.03	;	Human solAC Complexed with (4-Aminofurazan-3-yl)-[3-(1H-benzoimidazol-2-ylmethoxy)phenyl]methanone
4OYP	;	2.28	;	Human solAC Complexed with 1-Benzofuran-2-carboxylic acid
4OYO	;	1.75	;	Human solAC Complexed with 4-(2-Chlorophenyl)-3-methyl-1H-pyrazole
4OZ2	;	2.1	;	Human solAC Complexed with 4-(4-Fluorophenyl)-3-methyl-1H-pyrazole
4OZ3	;	1.7	;	Human solAC Complexed with 4-phenyl-3-(trifluoromethyl)-1H-pyrazole
4OYX	;	1.89	;	Human solAC Complexed with AMPCPP
4OYZ	;	1.74	;	Human solAC Complexed with Bicarbonate
7OVD	;	2.2	;	Human soluble adenylyl cyclase in complex with the inhibitor TDI10229
1S8O	;	2.6	;	Human soluble Epoxide Hydrolase
1ZD3	;	2.3	;	Human soluble epoxide hydrolase 4-(3-cyclohexyluriedo)-butyric acid complex
1ZD2	;	3.0	;	Human soluble epoxide hydrolase 4-(3-cyclohexyluriedo)-ethanoic acid complex
1ZD5	;	2.6	;	Human soluble epoxide hydrolase 4-(3-cyclohexyluriedo)-heptanoic acid complex
1ZD4	;	2.7	;	Human soluble epoxide hydrolase 4-(3-cyclohexyluriedo)-hexanoic acid complex
4X6Y	;	2.1	;	Human soluble epoxide hydrolase in complex with a cyclopropyl urea derivative
3ANS	;	1.98	;	Human soluble epoxide hydrolase in complex with a synthetic inhibitor
3ANT	;	2.4	;	Human soluble epoxide hydrolase in complex with a synthetic inhibitor
4X6X	;	1.8	;	Human soluble epoxide hydrolase in complex with a three substituted cyclopropane derivative
1VJ5	;	2.35	;	Human soluble Epoxide Hydrolase- N-cyclohexyl-N'-(4-iodophenyl)urea complex
1PL7	;	2.2	;	Human Sorbitol Dehydrogenase (apo)
3IQ2	;	1.7	;	Human sorting nexin 7, phox homology (PX) domain
1AWE	;		;	HUMAN SOS1 PLECKSTRIN HOMOLOGY (PH) DOMAIN, NMR, 20 STRUCTURES
3VFD	;	3.301	;	Human spastin AAA domain
5FWC	;	1.4	;	Human Spectrin SH3 domain D48G, E7A, K60A
5FWB	;	1.5	;	Human Spectrin SH3 domain D48G, E7F, K60F
6RO9	;	1.814	;	Human spectrin SH3 domain D48G, E7V, K60V
5FW9	;	1.55	;	Human Spectrin SH3 domain D48G, E7Y, K60Y
7UX0	;	1.49	;	Human Sperm TMEM95 Ectodomain
2O05	;	2.0	;	Human spermidine synthase
2O06	;	2.0	;	Human spermidine synthase
2O07	;	1.89	;	Human spermidine synthase
2O0L	;	1.99	;	Human spermidine synthase
2FXF	;	2.0	;	Human spermidine/spermine N1-acetyltransferase
2B3U	;	1.85	;	Human Spermine spermidine acetyltransferase K26R mutant
5LMA	;	1.43	;	HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
5LMB	;	1.95	;	HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
8C6J	;	2.8	;	Human spliceosomal PM5 C* complex
1QGV	;	1.4	;	HUMAN SPLICEOSOMAL PROTEIN U5-15KD
4WIJ	;	3.49	;	HUMAN SPLICING FACTOR, CONSTRUCT 1
4WIK	;	3.0	;	HUMAN SPLICING FACTOR, CONSTRUCT 2
4WII	;	2.05	;	HUMAN SPLICING FACTOR, CONSTRUCT 3
6C6R	;	3.0	;	Human Squalene Epoxidase (SQLE, Squalene Monooxygenase) structure with FAD
6C6N	;	2.3	;	Human squalene epoxidase (SQLE, squalene monooxygenase) structure with FAD and Cmpd-4""
6C6P	;	2.5	;	Human squalene epoxidase (SQLE, squalene monooxygenase) structure with FAD and NB-598
3Q30	;	2.0	;	Human Squalene synthase in complex with (2R,3R)-2-Carboxymethoxy-3-[5-(2-naphthalenyl)pentyl]aminocarbonyl-3-[5-(2-naphthalenyl)pentyloxy]propionic acid
3ASX	;	2.0	;	Human Squalene synthase in complex with 1-{4-[{4-chloro-2-[(2-chlorophenyl)(hydroxy)methyl]phenyl}(2,2-dimethylpropyl)amino]-4-oxobutanoyl}piperidine-3-carboxylic acid
3V66	;	1.8	;	HUMAN SQUALENE SYNTHASE IN COMPLEX WITH 2-(1-{2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]acetyl}-4-piperidinyl)acetic acid
3Q2Z	;	2.0	;	Human Squalene synthase in complex with N-[(3R,5S)-7-Chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]-L-aspartic acid
4MXX	;	2.6	;	Human Src A403T mutant bound to kinase inhibitor bosutinib
4MXO	;	2.105	;	human Src kinase bound to kinase inhibitor bosutinib
1AM9	;	2.3	;	HUMAN SREBP-1A BOUND TO LDL RECEPTOR PROMOTER
1JID	;	1.8	;	Human SRP19 in complex with helix 6 of Human SRP RNA
2R55	;	2.5	;	Human StAR-related lipid transfer protein 5
2PSO	;	2.8	;	Human StarD13 (DLC2) lipid transfer and protein localization domain
3FO5	;	2.0	;	Human START domain of Acyl-coenzyme A thioesterase 11 (ACOT11)
6VVQ	;	3.09	;	Human START domain of Acyl-coenzyme A thioesterase 11 (ACOT11) bound to Myristic Acid
6HCY	;	3.1	;	human STEAP4 bound to NADP, FAD, heme and Fe(III)-NTA.
6HD1	;	3.8	;	human STEAP4 bound to NADPH, FAD and heme.
4NBO	;	2.807	;	Human steroid receptor RNA activator protein carboxy-terminal domain
3P0L	;	3.4	;	Human steroidogenic acute regulatory protein
4NKV	;	2.646	;	Human steroidogenic cytochrome P450 17A1 mutant A105L with inhibitor abiraterone
4NKZ	;	3.003	;	Human steroidogenic cytochrome P450 17A1 mutant A105L with substrate 17alpha-hydroxypregnenolone
4NKY	;	2.55	;	Human steroidogenic cytochrome P450 17A1 mutant A105L with substrate 17alpha-hydroxyprogesterone
4NKW	;	2.5	;	Human steroidogenic cytochrome P450 17A1 mutant A105L with substrate pregnenolone
4NKX	;	2.794	;	Human steroidogenic cytochrome P450 17A1 mutant A105L with substrate progesterone
6WR1	;	1.85	;	Human steroidogenic cytochrome P450 17A1 mutant N52Y with inhibitor abiraterone
6WW0	;	2.01	;	Human steroidogenic cytochrome P450 17A1 with 3-keto-5alpha-abiraterone analog
6WR0	;	2.7	;	Human steroidogenic cytochrome P450 17A1 with 3-keto-delta4-abiraterone analog
5UYS	;	2.392	;	Human steroidogenic cytochrome P450 17A1 with 3alphaOH-5alpha-abiraterone analog
1YOW	;	3.0	;	human Steroidogenic Factor 1 LBD with bound Co-factor Peptide
8SS0	;	2.25	;	Human sterol 14 alpha-demethylase (CYP51) in complex with the reaction intermediate 14 alpha-aldehyde dihydrolanosterol
4UHI	;	2.04	;	HUMAN STEROL 14-ALPHA DEMETHYLASE (CYP51) IN COMPLEX WITH VFV IN C121 SPACE GROUP
4UHL	;	2.5	;	HUMAN STEROL 14-ALPHA DEMETHYLASE (CYP51) IN COMPLEX WITH VFV IN P1 SPACE GROUP
6Q2T	;	2.8	;	Human sterol 14a-demethylase (CYP51) in complex with the functionally irreversible inhibitor (R)-N-(1-(3-chloro-4'-fluoro-[1,1'-biphenyl]-4-yl)-2-(1H-imidazol-1-yl)ethyl)-4-(5-(3-fluoro-5-(5-fluoropyrimidin-4-yl)phenyl)-1,3,4-oxadiazol-2-yl)benzamide
6UEZ	;	1.98	;	Human sterol 14a-demethylase (CYP51) in complex with the substrate lanosterol
8AF2	;	2.51	;	Human Sterol Carrier Protein with unnatural amino acid 2,2'-bipyridine alanine incorporated at position 111
6CY7	;	2.2	;	Human Stimulator of Interferon Genes
6DNK	;	1.95	;	Human Stimulator of Interferon Genes
7SII	;	3.45	;	Human STING bound to both cGAMP and 1-[(2-chloro-6-fluorophenyl)methyl]-3,3-dimethyl-2-oxo-N-[(2,4,6-trifluorophenyl)methyl]-2,3-dihydro-1H-indole-6-carboxamide (Compound 53)
8A2H	;	2.69	;	human STING in complex with 2',3'-cyclic-GMP-7-deazaphenyl-AMP
8A2I	;	2.16	;	human STING in complex with 2'-3'-cyclic-GMP-7-deaza(4-(2-naphthyl)phenyl)-AMP
8A2J	;	2.32	;	human STING in complex with 2'-3'-cyclic-GMP-7-deaza(4-biphenylyl)-AMP
8A2K	;	1.89	;	human STING in complex with 2'-3'-cyclic-GMP-7-deaza(4-[(2-naphthyloxy)methyl]phenyl)-AMP
8GT6	;	3.47	;	human STING With agonist HB3089
8STI	;	1.72	;	human STING with agonist XMT-1616
8STH	;	1.97	;	human STING with diABZI agonist 15
4EQU	;	2.0	;	Human STK-10 (LOK) kinase domain in DFG-out conformation with inhibitor DSA-7
4USD	;	3.05	;	Human STK10 (LOK) with SB-633825
4USE	;	2.65	;	Human STK10 (LOK) with SB-633825
6HXF	;	2.09	;	Human STK10 bound to a maleimide inhibitor
6GTT	;	2.25	;	Human STK10 bound to BIRB-796
5OWR	;	2.3	;	Human STK10 bound to dasatinib
5OWQ	;	2.7	;	Human STK10 bound to dovitinib
6I2Y	;	2.56	;	Human STK10 bound to Foretinib
6EIM	;	1.43	;	Human STK10 bound to GW683134A
7XRB	;	1.65	;	human STK19 dimer
1C8T	;	2.6	;	HUMAN STROMELYSIN-1 (E202Q) CATALYTIC DOMAIN COMPLEXED WITH RO-26-2812
1C3I	;	1.83	;	HUMAN STROMELYSIN-1 CATALYTIC DOMAIN COMPLEXED WITH RO-26-2812
8GXL	;	2.4	;	HUMAN SUGP1 433-577
8GXM	;	2.81	;	HUMAN SUGP1 433-586
1ZD1	;	2.24	;	Human Sulfortransferase SULT4A1
2GWH	;	1.8	;	Human Sulfotranferase SULT1C2 in complex with PAP and pentachlorophenol
2H8K	;	3.2	;	Human Sulfotranferase SULT1C3 in complex with PAP
2Z5F	;	2.1	;	Human sulfotransferase Sult1b1 in complex with PAP
2AD1	;	2.0	;	Human Sulfotransferase SULT1C2
2D06	;	2.3	;	Human Sult1A1 Complexed With Pap and estradiol
1LS6	;	1.9	;	Human SULT1A1 complexed with PAP and p-Nitrophenol
1CJM	;	2.4	;	HUMAN SULT1A3 WITH SULFATE BOUND
3KYC	;	2.45	;	Human SUMO E1 complex with a SUMO1-AMP mimic
3KYD	;	2.61	;	Human SUMO E1~SUMO1-AMP tetrahedral intermediate mimic
6WMG	;	1.9	;	Human Sun2 (500-717)
4DXT	;	2.22	;	Human SUN2 (AA 522-717)
4DXR	;	2.32	;	Human SUN2-KASH1 complex
4DXS	;	2.71	;	Human SUN2-KASH2 complex
6WME	;	1.53	;	Human Sun2-KASH3 complex
6WMD	;	1.5	;	Human Sun2-KASH4 complex
6WMF	;	2.6	;	Human Sun2-KASH5 complex
1M1L	;	2.65	;	Human Suppressor of Fused (N-terminal domain)
3DBZ	;	1.8	;	human surfactant protein D
7U4Q	;	1.56	;	Human Synaptotagmin-1 C2A Y181F Ca2+ bound
7TX9	;	1.34	;	Human Synaptotagmin-1 C2B Y312F Ca2+ bound
7TUA	;	1.35	;	Human Synaptotagmin-1 C2B Y312F without Ca2+
3IFD	;	1.9	;	Human synthetic monocyte chemoattractant protein 1 (MCP-1)
5F71	;	2.404	;	Human T-cell immunoglobulin and mucin domain protein 3 (hTIM-3)
5DZN	;	2.3	;	human T-cell immunoglobulin and mucin domain protein 4
5F7F	;	1.502	;	Human T-cell immunoglobulin and mucin domain protein 4 (hTIM-4)
5F7H	;	2.5	;	Human T-cell immunoglobulin and mucin domain protein 4 (hTIM-4) complex with phosphoserine
2IUL	;	2.01	;	Human tACE g13 mutant
2IUX	;	2.8	;	Human tACE mutant g1234
6U4K	;	2.555	;	Human talin2 residues 1-403
4W6E	;	1.95	;	Human Tankyrase 1 with small molecule inhibitor
3KR7	;	1.95	;	Human tankyrase 2 - catalytic PARP domain
3MHJ	;	1.8	;	Human tankyrase 2 - catalytic PARP domain in complex with 1-methyl-3-(trifluoromethyl)-5h-benzo[c][1,8]naphtyridine-6-one
3MHK	;	2.3	;	Human tankyrase 2 - catalytic PARP domain in complex with 2-(2-pyridyl)-7,8-dihydro-5h-thiino[4,3-d]pyrimidin-4-ol
3P0N	;	1.9	;	Human Tankyrase 2 - Catalytic PARP domain in complex with an inhibitor
3P0P	;	2.49	;	Human Tankyrase 2 - Catalytic PARP domain in complex with an inhibitor
3P0Q	;	1.9	;	Human Tankyrase 2 - Catalytic PARP domain in complex with an inhibitor
4M7B	;	1.95	;	Human tankyrase 2 - catalytic Parp domain in complex with an inhibitor UPF1854
3KR8	;	2.1	;	Human tankyrase 2 - catalytic PARP domain in complex with an inhibitor XAV939
5BXO	;	1.334	;	Human Tankyrase-2 in Complex with Macrocyclised Extended Peptide cp4n2m3
5BXU	;	1.35	;	Human Tankyrase-2 in Complex with Macrocyclised Extended Peptide cp4n4m5
4NFM	;	2.12	;	Human tau tubulin kinase 1 (TTBK1)
4NFN	;	1.42	;	Human tau tubulin kinase 1 (TTBK1) complexed with 3-({5-[(4-amino-4-methylpiperidin-1-yl)methyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-5-bromophenol
1CDW	;	1.9	;	HUMAN TBP CORE DOMAIN COMPLEXED WITH DNA
1H6F	;	1.7	;	Human TBX3, a transcription factor responsible for ulnar-mammary syndrome, bound to a palindromic DNA site
6OD4	;	1.699	;	Human TCF4 C-terminal bHLH domain in Complex with 11-bp Oligonucleotide Containing E-box Sequence
6OD5	;	2.05	;	Human TCF4 C-terminal bHLH domain in Complex with 12-bp Oligonucleotide Containing E-box Sequence with 5-carboxylcytosines
6OD3	;	1.494	;	Human TCF4 C-terminal bHLH domain in Complex with 13-bp Oligonucleotide Containing E-box Sequence
4FNC	;	2.493	;	Human TDG in a post-reactive complex with 5-hydroxymethyluracil (5hmU)
4JGC	;	2.582	;	Human TDG N140A mutant IN A COMPLEX WITH 5-carboxylcytosine (5caC)
7LU7	;	2.3	;	Human TDO (hTDO) in complex with NLG919 analog
5INO	;	3.205	;	Human Tdp2 reaction product (5'-phosphorylated DNA)-Mg2+ complex
5GVD	;	1.623	;	Human TDRD3 DUF1767-OB domains
3L15	;	2.0	;	Human Tead2 transcriptional factor
7ZJQ	;	2.095	;	Human TEAD3 in complex with 1-Cyclopentyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid
7TRF	;	3.7	;	Human telomerase catalytic core RNP with H2A/H2B
7TRD	;	3.3	;	Human telomerase catalytic core structure at 3.3 Angstrom
7TRE	;	3.5	;	Human telomerase catalytic core with shelterin protein TPP1
7TRC	;	3.3	;	Human telomerase H/ACA RNP at 3.3 Angstrom
2HY9	;		;	Human telomere DNA quadruplex structure in K+ solution hybrid-1 form
2JPZ	;		;	Human telomere DNA quadruplex structure in K+ solution hybrid-2 form
2KKA	;		;	Human telomere DNA two-tetrad quadruplex structure in K+ solution
8JIH	;		;	human telomere two-quartet G-quadruplex at pH 5.0
8JIC	;		;	human telomere two-quartet G-quadruplex at pH 7.0
7QVQ	;	2.4	;	Human telomeric DNA G-quadruplex of a gold(III) complex containing the 2,4,6-tris (2-pyrimidyl)-1,3,5-triazine ligand
2E4I	;		;	Human Telomeric DNA mixed-parallel/antiparallel quadruplex under Physiological Ionic Conditions Stabilized by Proper Incorporation of 8-Bromoguanosines
2MS6	;		;	Human Telomeric G-quadruplex DNA sequence (TTAGGGT)4 complexed with Flavonoid Quercetin
6IA0	;		;	Human telomeric G-quadruplex with 8-oxo-G substitution in the central G-quartet
6IA4	;		;	Human telomeric G-quadruplex with 8-oxo-G substitution in the outer G-quartet
6CMX	;	3.1	;	Human Teneurin 2 extra-cellular region
6VHH	;	2.97	;	Human Teneurin-2 and human Latrophilin-3 binary complex
7PLP	;	1.4	;	Human Teneurin-4 C-rich domain
7BAO	;	2.7	;	human Teneurin4 Mut C1
7BAN	;	2.7	;	human Teneurin4 Mut C2
7BAM	;	3.5	;	human Teneurin4 WT C2
4BZR	;	1.84	;	Human testis angiotensin converting enzyme in complex with K-26
7NE3	;	2.26	;	Human TET2 in complex with favourable DNA substrate.
7NE6	;	2.3	;	Human TET2 in complex with unfavourable DNA substrate.
1A4I	;	1.5	;	HUMAN TETRAHYDROFOLATE DEHYDROGENASE / CYCLOHYDROLASE
3ONZ	;	2.087	;	Human tetrameric hemoglobin: proximal nitrite ligand at beta
1HTN	;	2.8	;	HUMAN TETRANECTIN, A TRIMERIC PLASMINOGEN BINDING PROTEIN WITH AN ALPHA-HELICAL COILED COIL
1NVP	;	2.1	;	HUMAN TFIIA/TBP/DNA COMPLEX
4ROE	;	2.2	;	Human TFIIB-related factor 2 (Brf2) and TBP bound to RPPH1 promoter
4ROD	;	2.7	;	Human TFIIB-related factor 2 (Brf2) and TBP bound to TRNAU1 promoter
4ROC	;	1.9	;	Human TFIIB-related factor 2 (Brf2) and TBP bound to U6#2 promoter
6MZC	;	4.5	;	Human TFIID BC core
6MZM	;	7.5	;	Human TFIID bound to promoter DNA and TFIIA
6MZL	;	23.0	;	Human TFIID canonical state
6MZD	;	9.8	;	Human TFIID Lobe A canonical
6ZUY	;		;	Human TFIIS N-terminal domain (TND)
6ZV4	;		;	Human TFIIS N-terminal domain in complex with IWS1
1AIU	;	2.0	;	HUMAN THIOREDOXIN (D60N MUTANT, REDUCED FORM)
1ERU	;	2.1	;	HUMAN THIOREDOXIN (OXIDIZED FORM)
1AUC	;	2.1	;	HUMAN THIOREDOXIN (OXIDIZED WITH DIAMIDE)
1ERT	;	1.7	;	HUMAN THIOREDOXIN (REDUCED FORM)
3KD0	;	1.7	;	Human thioredoxin C35S,C62S,C69S,C73S mutant showing cadmium chloride bound to the active site
3E3E	;	2.01	;	Human Thioredoxin Double Mutant C35S,C73R
1ERW	;	1.8	;	HUMAN THIOREDOXIN DOUBLE MUTANT WITH CYS 32 REPLACED BY SER AND CYS 35 REPLACED BY SER
1ERV	;	1.65	;	HUMAN THIOREDOXIN MUTANT WITH CYS 73 REPLACED BY SER (REDUCED FORM)
4AYV	;	2.8	;	Human thrombin - inhibitor complex
4AYY	;	2.6	;	Human thrombin - inhibitor complex
4AZ2	;	2.6	;	Human thrombin - inhibitor complex
2OD3	;	1.75	;	Human thrombin chimera with human residues 184a, 186, 186a, 186b, 186c and 222 replaced by murine thrombin equivalents.
1HXF	;	2.1	;	HUMAN THROMBIN COMPLEX WITH HIRUDIN VARIANT
1O0D	;	2.44	;	Human Thrombin complexed with a d-Phe-Pro-Arg-type Inhibitor and a C-terminal Hirudin derived exo-site inhibitor
3U8T	;	1.861	;	Human thrombin complexed with D-Phe-Pro-D-Arg-Cys
3U8O	;	1.28	;	Human thrombin complexed with D-Phe-Pro-D-Arg-D-Thr
3U8R	;	1.47	;	Human thrombin complexed with D-Phe-Pro-D-Arg-Ile
2BVR	;	1.25	;	Human thrombin complexed with fragment-based small molecules occupying the S1 pocket
2BVS	;	1.4	;	Human thrombin complexed with fragment-based small molecules occupying the S1 pocket
4AX9	;	1.9	;	Human thrombin complexed with Napsagatran, RO0466240
1A5G	;	2.06	;	HUMAN THROMBIN COMPLEXED WITH NOVEL SYNTHETIC PEPTIDE MIMETIC INHIBITOR AND HIRUGEN
1B5G	;	2.07	;	HUMAN THROMBIN COMPLEXED WITH NOVEL SYNTHETIC PEPTIDE MIMETIC INHIBITOR AND HIRUGEN
2JH0	;	1.7	;	Human Thrombin Hirugen Inhibitor complex
2JH5	;	2.5	;	Human Thrombin Hirugen Inhibitor complex
2JH6	;	2.21	;	Human Thrombin Hirugen Inhibitor complex
3U98	;	1.45	;	Human Thrombin In Complex With MI001
3RM2	;	1.23	;	Human Thrombin in complex with MI003
3RMO	;	1.4	;	Human Thrombin in complex with MI004
3RLW	;	1.69	;	Human Thrombin in complex with MI328
3RLY	;	1.51	;	Human Thrombin in complex with MI329
3U9A	;	1.58	;	Human Thrombin In Complex With MI330
3RML	;	1.53	;	Human Thrombin in complex with MI331
3RMM	;	1.58	;	Human Thrombin in complex with MI332
3T5F	;	1.45	;	Human Thrombin In Complex With MI340
3RMN	;	1.78	;	Human Thrombin in complex with MI341
3UWJ	;	1.5	;	Human Thrombin In Complex With MI353
3RM0	;	1.34	;	Human Thrombin in complex with MI354
3SHC	;	1.9	;	Human Thrombin In Complex With UBTHR101
3SI3	;	1.55	;	Human Thrombin In Complex With UBTHR103
3SI4	;	1.27	;	Human Thrombin In Complex With UBTHR104
3SV2	;	1.3	;	Human Thrombin In Complex With UBTHR105
3SHA	;	1.52	;	Human Thrombin In Complex With UBTHR97
2PGQ	;	1.8	;	Human thrombin mutant C191A-C220A in complex with the inhibitor PPACK
5EW2	;	3.59	;	Human thrombin sandwiched between two DNA aptamers: HD22 and HD1-deltaT12
5EW1	;	2.95	;	Human thrombin sandwiched between two DNA aptamers: HD22 and HD1-deltaT3
1TBZ	;	2.3	;	HUMAN THROMBIN WITH ACTIVE SITE N-METHYL-D PHENYLALANYL-N-[5-(AMINOIMINOMETHYL)AMINO]-1-{{BENZOTHIAZOLYL)CARBONYL] BUTYL]-L-PROLINAMIDE TRIFLUROACETATE AND EXOSITE-HIRUGEN
3BIU	;	2.3	;	Human thrombin-in complex with UB-THR10
3BIV	;	1.8	;	Human thrombin-in complex with UB-THR11
1K21	;	1.86	;	HUMAN THROMBIN-INHIBITOR COMPLEX
1K22	;	1.93	;	HUMAN THROMBIN-INHIBITOR COMPLEX
1V7M	;	2.51	;	Human Thrombopoietin Functional Domain Complexed To Neutralizing Antibody TN1 Fab
1V7N	;	3.3	;	Human Thrombopoietin Functional Domain Complexed To Neutralizing Antibody TN1 Fab
2ZKH	;	2.04	;	Human thrombopoietin neutralizing antibody TN1 FAB
2ORV	;	2.3	;	human Thymidine Kinase 1 in complex with TP4A
1E2G	;	1.7	;	Human thymidylate kinase complexed with ADP, TDP and a magnesium-ion
1E99	;	1.8	;	Human thymidylate kinase complexed with AZTMP and ADP
1E9B	;	1.7	;	Human thymidylate kinase complexed with AZTMP and APPNP
1E9A	;	1.6	;	Human thymidylate kinase complexed with the bisubstrate inhibitor AZTP5A
2XX3	;	2.0	;	HUMAN THYMIDYLATE KINASE COMPLEXED WITH thymidine butenyl phosphonate monophosphate and ADP
1E2D	;	1.65	;	Human thymidylate kinase complexed with thymidine monophosphate, adenosine diphosphate and a magnesium-ion
1E2F	;	1.6	;	Human thymidylate kinase complexed with thymidine monophosphate, adenosine diphosphate and a magnesium-ion
1E2E	;	2.0	;	Human thymidylate kinase complexed with thymidine monophosphate, adenosine diphosphate,a magnesium-ion and ALf3
1E2Q	;	1.7	;	Human thymidylate kinase complexed with TP5A and a magnesium-ion
2ONB	;	2.7	;	Human Thymidylate Synthase at low salt conditions with PDPA bound
1JUJ	;	3.0	;	Human Thymidylate Synthase Bound to dUMP and LY231514, a Pyrrolo(2,3-d)pyrimidine-based Antifolate
5X5D	;	2.0	;	Human thymidylate synthase bound with dUMP
5X5A	;	2.39	;	Human thymidylate synthase bound with phosphate ion
1JU6	;	2.89	;	Human Thymidylate Synthase Complex with dUMP and LY231514, A Pyrrolo(2,3-d)pyrimidine-based Antifolate
5WRN	;	2.39	;	Human thymidylate synthase complexed with dCMP
5HS3	;	3.103	;	Human thymidylate synthase complexed with dUMP and 3-amino-2-benzoyl-4-methylthieno[2,3-b]pyridin-6-ol
5X5Q	;	2.79	;	Human thymidylate synthase complexed with dUMP and raltitrexed
1HVY	;	1.9	;	Human thymidylate synthase complexed with dUMP and Raltitrexed, an antifolate drug, is in the closed conformation
5X66	;	1.99	;	Human thymidylate synthase in complex with dUMP and methotrexate
5X67	;	2.13	;	Human thymidylate synthase in complex with dUMP and nolatrexed
4G6W	;	2.3	;	Human Thymidylate Synthase M190K with bound 4-Bromobenzene-1,2,3-triol
4G2O	;	2.25	;	Human Thymidylate Synthase M190K with bound Purpurogallin
3OB7	;	2.75	;	Human Thymidylate Synthase R163K with Cys 195 covalently modified by Glutathione
2RD8	;	2.5	;	Human Thymidylate Synthase Stabilized in Active Conformation by R163K Mutation: Asymmetry and Reactivity of Cys195
2RDA	;	2.67	;	Human Thymidylate Synthase Stabilized in Active Conformation by R163K Mutation: Asymmetry and Reactivity of Cys195
5X69	;	2.69	;	Human thymidylate synthase with a fragment bound in the dimer interface
6U17	;	1.55	;	Human thymine DNA glycosylase bound to DNA with 2'-F-5-carboxyl-dC substrate analog
3UFJ	;	2.967	;	Human Thymine DNA Glycosylase Bound to Substrate Analog 2'-fluoro-2'-deoxyuridine
6U15	;	2.4	;	Human thymine DNA glycosylase N140A mutant bound to DNA with 2'-F-5-carboxyl-dC substrate analog
6U16	;	1.6	;	Human thymine DNA glycosylase N140A mutant bound to DNA with 5-carboxyl-dC substrate
2J4A	;	2.2	;	Human Thyroid hormone receptor beta ligand binding domain in complex with KB131084
7UTZ	;	2.4	;	Human thyrotropin analog TR1402 bound to human Thyrotropin receptor in complex with miniGs399 (composite structure)
7T9M	;	3.1	;	Human Thyrotropin receptor bound by CS-17 Inverse Agonist Fab/Org 274179-0 Antagonist
1FAK	;	2.1	;	HUMAN TISSUE FACTOR COMPLEXED WITH COAGULATION FACTOR VIIA INHIBITED WITH A BPTI-MUTANT
5W06	;	2.6	;	HUMAN TISSUE FACTOR IN COMPLEX WITH ANTIBODY M1587
1BR9	;	2.1	;	HUMAN TISSUE INHIBITOR OF METALLOPROTEINASE-2
1KV3	;	2.8	;	HUMAN TISSUE TRANSGLUTAMINASE IN GDP BOUND FORM
8OVU	;	1.95	;	Human titin immunoglobulin-like 21 domain
6DL4	;		;	Human Titin ZIg10
6WML	;	2.5	;	Human TLR8 bound to the potent agonist, GS-9688 (Selgantolimod)
7UNM	;	2.61	;	Human TMEM175 in an closed state
7UNL	;	2.45	;	Human TMEM175 in an open state
8DHM	;	2.73	;	Human TMEM175 in complex with 4-aminopyridine
8FY5	;	3.5	;	Human TMEM175-LAMP1 full-length complex
8FYF	;	3.4	;	Human TMEM175-LAMP1 transmembrane domain only complex
8GRS	;	3.3	;	human TMEM63A
8VIS	;	1.59	;	Human TMPRSS11D complexed with a disulfide-linked autoinhibitory DDDDK peptide
7JRA	;	2.1	;	HUMAN TNF-ALPHA IN COMPLEX WITH 2-[5-(3-chloro-4-{[(1R)-1-(2-fluorophenyl)ethyl]amino}quinolin-6-yl)pyrimidin-2-yl]propan-2-ol
5MU8	;	3.0	;	HUMAN TNF-ALPHA IN COMPLEX WITH JNJ525
7KPB	;	3.0	;	Human TNF-alpha TNFR1 complex bound to conformationally selective antibody
4TWT	;	2.85	;	Human TNFa dimer in complex with the semi-synthetic bicyclic peptide M21
5YGS	;	2.691	;	Human TNFRSF25 death domain
5YGP	;	2.09	;	Human TNFRSF25 death domain mutant-D412E
6RA5	;	2.9	;	Human tnik in complex with compound 9
6RA7	;	1.2	;	Human tnik in complex with compound 9
7OCV	;	1.432	;	Human TNKS1 in complex with 3-[4-(1-Hydroxy-1-methyl-ethyl)-phenyl]-6-methyl-2H-pyrrolo[1,2-a]pyrazin-1-one
6QXU	;	1.2	;	Human TNKS1 in complex with 6,8-Difluoro-2-[4-(1-hydroxy-1-methyl-ethyl)-phenyl]-3H-quinazolin-4-one
1ZIW	;	2.1	;	Human Toll-like Receptor 3 extracellular domain structure
7VDD	;	3.74	;	Human TOM complex with cross-linking
7VD2	;	2.53	;	Human TOM complex without cross-linking
7KDT	;	3.05	;	Human Tom70 in complex with SARS CoV2 Orf9b
5GVE	;	3.606	;	Human TOP3B-TDRD3 complex
1ZXM	;	1.87	;	Human Topo IIa ATPase/AMP-PNP
1R49	;	3.13	;	Human topoisomerase I (Topo70) double mutant K532R/Y723F
1NH3	;	3.1	;	Human Topoisomerase I Ara-C Complex
1A35	;	2.5	;	HUMAN TOPOISOMERASE I/DNA COMPLEX
4FM9	;	2.901	;	Human topoisomerase II alpha bound to DNA
7QFN	;	2.621	;	Human Topoisomerase II Beta ATPase ADP
7ZBG	;	2.3	;	Human Topoisomerase II Beta ATPase ADP
7QFO	;	1.9	;	Human Topoisomerase II Beta ATPase AMPPNP
5ZAD	;	2.54	;	Human topoisomerase II beta in complex with DNA
5GWK	;	3.152	;	Human topoisomerase IIalpha in complex with DNA and etoposide
4J3N	;	2.3	;	Human Topoisomerase Iibeta in complex with DNA
4G0W	;	2.696	;	Human topoisomerase iibeta in complex with DNA and ametantrone
4G0U	;	2.7	;	Human topoisomerase IIbeta in complex with DNA and amsacrine
3QX3	;	2.162	;	Human topoisomerase IIbeta in complex with DNA and etoposide
4G0V	;	2.548	;	Human topoisomerase iibeta in complex with DNA and mitoxantrone
5GVC	;	2.436	;	Human Topoisomerase IIIb topo domain
7LJA	;	2.77	;	Human TRAAK K+ channel FHEIG mutant A198E in a Tl+ bound conductive conformation
7LJ4	;	2.782	;	Human TRAAK K+ channel FHEIG mutant A270P in a K+ bound conductive conformation
7LJ5	;	2.26	;	Human TRAAK K+ channel FHIEG mutant A198E in a K+ bound conductive conformation
4WFE	;	2.5	;	Human TRAAK K+ channel in a K+ bound conductive conformation
4WFF	;	2.5	;	Human TRAAK K+ channel in a K+ bound nonconductive conformation
4WFG	;	3.0	;	Human TRAAK K+ channel in a Tl+ bound conductive conformation
4WFH	;	3.01	;	Human TRAAK K+ channel in a Tl+ bound nonconductive conformation
7LJB	;	2.97	;	Human TRAAK K+ channel mutant G158D in a K+ bound conductive conformation
6YCS	;	3.05	;	Human Transcription Cofactor PC4 DNA-binding domain in complex with full phosphorothioate 5-10-5 2'-O-methyl DNA gapmer antisense oligonucleotide.
1NFA	;		;	HUMAN TRANSCRIPTION FACTOR NFATC DNA BINDING DOMAIN, NMR, 10 STRUCTURES
7E4W	;	2.9	;	Human Transcriptional Co-activator PC4 (C-terminal Domain) in space group P1211
1PCF	;	1.74	;	HUMAN TRANSCRIPTIONAL COACTIVATOR PC4 C-TERMINAL DOMAIN
1DTG	;	2.4	;	HUMAN TRANSFERRIN N-LOBE MUTANT H249E
1JQF	;	1.85	;	Human Transferrin N-Lobe Mutant H249Q
1TGK	;	3.3	;	HUMAN TRANSFORMING GROWTH FACTOR BETA 3, CRYSTALLIZED FROM PEG 4000
6I9J	;	2.0	;	Human transforming growth factor beta2 in a tetragonal crystal form
1TGJ	;	2.0	;	HUMAN TRANSFORMING GROWTH FACTOR-BETA 3, CRYSTALLIZED FROM DIOXANE
8WA8	;	1.48	;	Human transketolase in complex with phosphite
4KXY	;	1.26	;	Human transketolase in complex with ThDP analogue (R)-2-(1,2-dihydroxyethyl)-3-deaza-ThDP
4KXU	;	0.98	;	Human transketolase in covalent complex with donor ketose D-fructose-6-phosphate
4KXX	;	1.03	;	Human transketolase in covalent complex with donor ketose D-sedoheptulose-7-phosphate
4KXV	;	0.97	;	Human transketolase in covalent complex with donor ketose D-xylulose-5-phosphate, crystal 1
4KXW	;	0.97	;	Human transketolase in covalent complex with donor ketose D-xylulose-5-phosphate, crystal 2
8WA9	;	1.5	;	Human transketolase soaked with donor ketose D-fructose
8WAA	;	1.5	;	Human transketolase soaked with donor ketose D-xylulose
6HAD	;	1.04	;	Human transketolase variant E160Q
6HA3	;	1.08	;	Human transketolase variant E160Q in covalent complex with donor ketose D-fructose-6-phosphate
6RJB	;	1.15	;	Human transketolase variant T382E
2IF1	;		;	HUMAN TRANSLATION INITIATION FACTOR EIF1, NMR, 29 STRUCTURES
1D7Q	;		;	HUMAN TRANSLATION INITIATION FACTOR EIF1A
5OA9	;	1.8	;	Human translation re-initiation complex containing eIF2D
1Z7J	;	2.2	;	Human transthyretin (also called prealbumin) complex with 3, 3',5,5'-tetraiodothyroacetic acid (t4ac)
1BMZ	;	2.0	;	HUMAN TRANSTHYRETIN (PREALBUMIN)
1BM7	;	2.0	;	HUMAN TRANSTHYRETIN (PREALBUMIN) COMPLEX WITH FLUFENAMIC ACID (2-[[3-(TRIFLUOROMETHYL)PHENYL]AMINO] BENZOIC ACID)
5E23	;	1.41	;	Human transthyretin (TTR) complexed with (2,7-Dibromo-fluoren-9-ylideneaminooxy)-acetic acid
5E4A	;	1.33	;	Human transthyretin (TTR) complexed with (2,7-Dichloro-fluoren-9-ylideneaminooxy)-acetic acid.
6TI9	;	1.45	;	Human transthyretin (TTR) complexed with (E)-3-(((3,5-dibromo-2-hydroxybenzylidene)amino)oxy)propanoic acid.
6TJN	;	1.702	;	Human transthyretin (TTR) complexed with (E)-3-(((4-hydroxybenzylidene)amino)oxy)propanoic acid
3GS7	;	1.8	;	Human transthyretin (TTR) complexed with (E)-3-(2-methoxybenzylideneaminooxy)propanoic acid (inhibitor 13)
4TQP	;	1.58	;	Human transthyretin (TTR) complexed with (R)-3-(9H-fluoren-9-ylideneaminooxy)-2-methyl-N-(methylsulfonyl) propionamide in a dual binding mode
3GS0	;	1.85	;	Human transthyretin (TTR) complexed with (S)-3-(9H-fluoren-9-ylideneaminooxy)-2-methylpropanoic acid (inhibitor 16)
5E4O	;	1.5	;	Human transthyretin (TTR) complexed with (Z)-((3,4-Dichloro-phenyl)-methyleneaminooxy)-acetic acid
3P3S	;	1.6	;	Human transthyretin (TTR) complexed with (Z)-5-(3,5-dibromo-4-hydroxybenzylidene)-imino-1-methylimidazolidin-4-one
4PM1	;	1.23	;	Human transthyretin (TTR) complexed with 16-alpha-bromo-estradiol
3M1O	;	1.2	;	Human Transthyretin (TTR) complexed with 2-((3,5-dichloro-4-hydroxyphenyl)amino)benzoic acid
2QGD	;	1.5	;	Human transthyretin (TTR) complexed with 2-(3,5-Dibromo-4-hydroxyphenyl)benzoxazole
2QGC	;	1.3	;	Human transthyretin (TTR) complexed with 2-(3,5-Dimethyl-4-hydroxyphenyl)benzoxazole
2QGE	;	1.45	;	Human transthyretin (TTR) complexed with 2-(3,5-Dimethylphenyl)benzoxazole
4TQH	;	1.511	;	Human transthyretin (TTR) complexed with 3-(9H-fluoren-9-ylideneaminooxy)ethanoic acid
3GS4	;	1.78	;	Human transthyretin (TTR) complexed with 3-(9H-fluoren-9-ylideneaminooxy)propanoic acid (inhibitor 15)
4TQI	;	1.25	;	Human transthyretin (TTR) complexed with 3-(9H-fluoren-9-ylideneaminooxy)propanoic acid in a dual binding mode
3P3T	;	1.45	;	Human transthyretin (TTR) complexed with 4-(3-(2-flourophenoxy)propyl)-3,5-dimethyl-1H-pyrazole
5EZP	;	2.5	;	Human transthyretin (TTR) complexed with 4-hydroxy-chalcone
3P3U	;	1.5	;	Human transthyretin (TTR) complexed with 5-(2-ethoxyphenyl)-3-(pyridin-4-yl)-1,2,4-oxadiazole
3IPB	;	1.9	;	Human Transthyretin (TTR) complexed with a palindromic bivalent amyloid inhibitor (11 carbon linker).
3IPE	;	1.4	;	Human Transthyretin (TTR) complexed with a palindromic bivalent amyloid inhibitor (7 carbon linker).
2F8I	;	1.541	;	Human transthyretin (TTR) complexed with Benzoxazole
2FBR	;	1.46	;	Human transthyretin (TTR) complexed with bivalant amyloid inhibitor (4 carbon linker)
2FLM	;	1.65	;	Human transthyretin (TTR) complexed with bivalant amyloid inhibitor (6 carbon linker)
4PMF	;	1.35	;	Human transthyretin (TTR) complexed with curcumin
3D2T	;	1.85	;	Human transthyretin (ttr) complexed with diflunisal
2F7I	;	1.6	;	Human transthyretin (TTR) complexed with diflunisal analogues- TTR. 2',6'-Difluorobiphenyl-4-carboxylic Acid
2B77	;	1.7	;	Human transthyretin (TTR) complexed with Diflunisal analogues- TTR.2',4'-DICHLORO-4-HYDROXY-1,1'-BIPHENYL-3-CARBOXYLIC ACID
2B9A	;	1.54	;	Human transthyretin (TTR) complexed with diflunisal analogues- TTR.3',5'-difluorobiphenyl-4-carboxylic acid
4PME	;	1.264	;	Human transthyretin (TTR) complexed with ferulic acid and curcumin.
2G5U	;	1.8	;	Human Transthyretin (TTR) Complexed with Hydroxylated polychlorinated Biphenyl-4,4'-dihydroxy-3,3',5,5'-tetrachlorobiphenyl
2G9K	;	1.85	;	Human Transthyretin (TTR) Complexed with Hydroxylated polychlorinated Biphenyl-4-hydroxy-2',3,3',4',5-Pentachlorobiphenyl
2GAB	;	1.85	;	Human Transthyretin (TTR) Complexed with Hydroxylated polychlorinated Biphenyl-4-hydroxy-3,3',5,4'-tetrachlorobiphenyl
3ESO	;	1.31	;	Human transthyretin (TTR) complexed with N-(3,5-Dibromo-4-hydroxyphenyl)-2,5-dichlorobenzamide
3ESN	;	1.35	;	Human transthyretin (TTR) complexed with N-(3,5-Dibromo-4-hydroxyphenyl)-2,6-dimethylbenzamide
3ESP	;	1.31	;	Human transthyretin (TTR) complexed with N-(3,5-Dibromo-4-hydroxyphenyl)-3,5-dimethyl-4-hydroxybenzamide
7Z60	;	1.4	;	Human transthyretin (TTR) complexed with Quercetin 3-O-beta-D-galactoside
3GLZ	;	1.78	;	Human Transthyretin (TTR) complexed with(E)-3-(2-(trifluoromethyl)benzylideneaminooxy)propanoic acid (inhibitor 11)
2QGB	;	1.4	;	Human transthyretin (TTR) in Apo-form
3CN3	;	1.8	;	Human transthyretin (TTR) in complex with 1,3-Dibromo-2-hydroxy-5-phenoxybenzene
3CN2	;	1.52	;	Human transthyretin (TTR) in complex with 3,5-Dibromo-4-hydroxybiphenyl
3CN1	;	1.52	;	Human transthyretin (TTR) in complex with 3,5-Dibromo-4-hydroxystilbene
3CN0	;	1.52	;	Human transthyretin (TTR) in complex with 3,5-Dimethyl-4-hydroxystilbene
3CN4	;	1.4	;	Human transthyretin (TTR) in complex with N-(3,5-Dibromo-4-hydroxyphenyl)benzamide
8VE0	;	3.1	;	Human transthyretin covalently modified with A2-derived stilbene in the compressed conformation
7Q3I	;	1.55	;	Human Transthyretin expressed in Vibrio natriegens
4MRC	;	1.54	;	Human Transthyretin Ser52Pro Mutant
7ULK	;	2.34	;	Human TRAP1 NM in complex with 42C
8ETM	;	3.2	;	Human triacylglycerol synthesizing enzyme DGAT1 in complex with DGAT1IN1 inhibitor
8ESM	;	3.2	;	Human triacylglycerol synthesizing enzyme DGAT1 in complex with T863 inhibitor
7NVN	;	3.0	;	Human TRiC complex in closed state with nanobody and tubulin bound
7NVL	;	2.5	;	Human TRiC complex in closed state with nanobody bound (Consensus Map)
7NVM	;	3.1	;	Human TRiC complex in closed state with nanobody Nb18, actin and PhLP2A bound
7NVO	;	3.5	;	Human TRiC complex in open state with nanobody bound
7LUM	;	4.5	;	Human TRiC in ATP/AlFx closed state
8HKI	;	3.1	;	Human TRiC open state
8I1U	;	3.24	;	Human TRiC-PhLP2A complex in the closed state
8I9U	;	3.1	;	Human TRiC-PhLP2A complex in the open state
8IB8	;	4.42	;	Human TRiC-PhLP2A-actin complex in the closed state
7X0S	;	3.1	;	Human TRiC-tubulin-S3
7LUP	;	6.2	;	Human TRiC/CCT complex with reovirus outer capsid protein sigma-3
7SJ4	;	2.86	;	Human Trio residues 1284-1959 in complex with Rac1
7RDE	;	1.31	;	Human Triose Phosphate Isomerase Q181P
7UXB	;	2.0	;	Human triosephosphate isomerase mutant G122R
7UXV	;	2.15	;	human triosephosphate isomerase mutant G122R
7SX1	;	2.23	;	human triosephosphate isomerase mutant v154m
7T0Q	;	2.0	;	human triosephosphate isomerase mutant v154m
6C2G	;	2.3	;	Human triosephosphate isomerase mutant V231M
1WYI	;	2.2	;	human triosephosphate isomerase of new crystal form
4AOJ	;	2.75	;	Human TrkA in complex with the inhibitor AZ-23
8OMR	;	3.3	;	Human tRNA guanine transglycosylase (TGT) bound to tRNAAsp
7NQ4	;	2.88	;	Human tRNA guanine transglycosylase (TGT), RNA-bound covalent intermediate
7UXA	;	3.28	;	Human tRNA Splicing Endonuclease Complex bound to pre-tRNA-ARG
8SP8	;	2.79	;	Human TRP channel TRPV6 in cNW30 nanodiscs inhibited by tetrahydrocannabivarin (THCV)
7E4T	;	3.0	;	Human TRPC5 apo state structure at 3 angstrom
7WDB	;	2.4	;	Human TRPC5 channel in complex with riluzole
6YSN	;	3.0	;	Human TRPC5 in complex with Pico145 (HC-608)
6PUU	;	3.7	;	Human TRPM2 bound to 8-Br-cADPR and calcium
6PUR	;	4.4	;	Human TRPM2 bound to ADPR
6PUS	;	3.7	;	Human TRPM2 bound to ADPR and calcium
6PUO	;	3.3	;	Human TRPM2 in the apo state
6MJ2	;	6.36	;	Human TRPM2 ion channel in a calcium- and ADPR-bound state
6MIZ	;	6.1	;	Human TRPM2 ion channel in an ADPR-bound state
6MIX	;	3.6	;	Human TRPM2 ion channel in apo state
6BQV	;	3.1	;	Human TRPM4 ion channel in lipid nanodiscs in a calcium-bound state
6BQR	;	3.2	;	Human TRPM4 ion channel in lipid nanodiscs in a calcium-free state
5WJ9	;	3.49	;	Human TRPML1 channel structure in agonist-bound open conformation
5WJ5	;	3.72	;	Human TRPML1 channel structure in closed conformation
8GKG	;	4.38	;	Human TRPV3 pentamer structure
8GKA	;	2.55	;	Human TRPV3 tetramer structure, closed conformation
7AA5	;	4.18	;	Human TRPV4 structure in presence of 4a-PDD
2FPZ	;	2.0	;	Human tryptase with 2-amino benzimidazole
4PW8	;	2.902	;	Human tryptophan 2,3-dioxygenase
4D2S	;	2.5	;	Human TTK in complex with a Dyrk1B inhibitor
5K1N	;	1.81	;	Human TTR altered by a rhenium tris-carbonyl Pyta-C12 derivative
5K1J	;	1.69	;	Human TTR altered by a rhenium tris-carbonyl Pyta-C8 derivative
5N7C	;	2.45	;	Human TTR altered conformation from soaking in CuCl2.
5N5Q	;	2.53	;	Human TTR altered conformation from soaking in iron chloride.
5N62	;	1.8	;	Human TTR crystals soaked in manganese chloride.
1H7C	;	1.8	;	human tubulin chaperone cofactor a
4HT1	;	2.498	;	Human TWEAK in complex with the Fab fragment of a neutralizing antibody
4I9W	;	2.75	;	Human two pore domain K+ channel TRAAK (K2P4.1) - Fab complex structure
7AX4	;	2.12	;	Human TYK2 pseudokinase domain (575-869) in complex with 5-(4-Fluoro-phenyl)-2-ureido-thiophene-3-carboxylic acid amide.
3ZON	;	2.15	;	Human TYK2 pseudokinase domain bound to a kinase inhibitor
2GZ5	;	1.1	;	Human Type 1 methionine aminopeptidase in complex with ovalicin at 1.1 Ang
6DQJ	;	3.49	;	Human type 3 1,4,5-inositol trisphosphate receptor in a ligand-free state
8TKF	;	3.2	;	Human Type 3 IP3 Receptor - Activated State (+IP3/ATP/JD Ca2+)
8TLA	;	3.2	;	Human Type 3 IP3 Receptor - Higher-Order Inhibited State - Symmetry Mate 1
8TKH	;	3.5	;	Human Type 3 IP3 Receptor - Labile Resting State 1 (+IP3/ATP)
8TKI	;	3.6	;	Human Type 3 IP3 Receptor - Labile Resting State 2 (+IP3/ATP)
8TKD	;	3.7	;	Human Type 3 IP3 Receptor - Preactivated State (+IP3/ATP)
8TKE	;	3.6	;	Human Type 3 IP3 Receptor - Preactivated+Ca2+ State (+IP3/ATP/JD Ca2+)
8TK8	;	2.7	;	Human Type 3 IP3 Receptor - Resting State (+IP3/ATP)
8TKG	;	2.5	;	Human Type 3 IP3 Receptor - Resting State (+IP3/ATP)
8TL9	;	3.3	;	Human Type 3 IP3 Receptor - Resting State (+IP3/ATP)
3DYD	;	2.3	;	Human Tyrosine Aminotransferase
1KAK	;	2.5	;	Human Tyrosine Phosphatase 1B Complexed with an Inhibitor
1KAV	;	2.35	;	Human Tyrosine Phosphatase 1B Complexed with an Inhibitor
1QZQ	;	2.4	;	human Tyrosyl DNA phosphodiesterase
7LHX	;	2.2	;	Human U1A protein with F37M and F77M mutations for improved phasing
1A3S	;	2.8	;	HUMAN UBC9
6SYF	;	1.9	;	Human Ubc9 with covalent isopeptide ligand
1YQB	;	2.0	;	Human Ubiquilin 3
1Y6L	;	1.85	;	Human ubiquitin conjugating enzyme E2E2
5DK8	;	1.32	;	Human ubiquitin in the P1 space group
3GUC	;	2.25	;	Human Ubiquitin-activating Enzyme 5 in Complex with AMPPNP
3H8V	;	2.0	;	Human Ubiquitin-activating Enzyme 5 in Complex with ATP
2ESO	;	1.5	;	Human Ubiquitin-Conjugating Enzyme (E2) UbcH5b mutant Ile37Ala
2ESP	;	1.52	;	Human ubiquitin-conjugating enzyme (E2) UbcH5b mutant Ile88Ala
2ESQ	;	1.44	;	Human Ubiquitin-Conjugating Enzyme (E2) UbcH5b mutant Ser94Gly
2ESK	;	1.36	;	Human Ubiquitin-Conjugating Enzyme (E2) UbcH5b, wild-type
2OB4	;	2.4	;	Human Ubiquitin-Conjugating Enzyme CDC34
2Z5D	;	2.1	;	Human ubiquitin-conjugating enzyme E2 H
2F4W	;	2.0	;	Human ubiquitin-conjugating enzyme E2 J2
1U9A	;	2.0	;	HUMAN UBIQUITIN-CONJUGATING ENZYME UBC9
1BG2	;	1.8	;	HUMAN UBIQUITOUS KINESIN MOTOR DOMAIN
5TDD	;	1.55	;	Human UBR-box from UBR2 in complex with HIFS peptide
1HZJ	;	1.5	;	HUMAN UDP-GALACTOSE 4-EPIMERASE: ACCOMMODATION OF UDP-N-ACETYLGLUCOSAMINE WITHIN THE ACTIVE SITE
6C5Z	;	2.95	;	Human UDP-Glucose Dehydrogenase A225L substitutuion with UDP-glucose and NADH bound
6C58	;	2.198	;	Human UDP-Glucose Dehydrogenase A225L substitutuion with UDP-xylose bound
6C5A	;	2.3	;	Human UDP-Glucose Dehydrogenase with UDP- Glc and NADH bound
5VR8	;	1.999	;	Human UDP-Glucose Dehydrogenase with UDP-Xylose Bound to the Co-enzyme Site
4R7P	;	3.35	;	Human UDP-glucose pyrophosphorylase isoform 1 in complex with UDP-glucose
6W92	;	1.3	;	Human UHRF1 TTD domain
6VYJ	;	1.39	;	Human UHRF1 TTD domain in complex with a fragment
2EAW	;	2.88	;	Human UMP Synthase (C-terminal Domain- Orotidine 5'-Monophosphate Decarboxylase)
2P1F	;	1.76	;	Human UMP Synthase (C-terminal Domain-Orotidine 5'-Monophosphate Decarboxylase)
4V2A	;	2.4	;	human Unc5A ectodomain
3O23	;	2.1	;	Human unphosphorylated IGF1-R Kinase domain in complex with an hydantoin inhibitor
1AKZ	;	1.57	;	HUMAN URACIL-DNA GLYCOSYLASE
8BLO	;	2.9	;	Human Urea Transporter UT-A (N-Terminal Domain Model)
8BLP	;	2.6	;	Human Urea Transporter UT-B/UT1 in Complex with Inhibitor UTBinh-14
3NBQ	;	2.3	;	Human uridine phosphorylase 1 (hUPP1) with 5-fluorouracil
2RMF	;		;	Human Urocortin 1
2RMG	;		;	Human Urocortin 2
2RMH	;		;	Human Urocortin 3
3GW3	;	1.7	;	human UROD mutant K297N
4JK6	;	2.2	;	Human urokinase-type Plasminogen Activator (uPA) in complex with a bicyclic peptide inhibitor (UK18-D-Aba)
4JK5	;	1.55	;	Human urokinase-type Plasminogen Activator (uPA) in complex with a bicyclic peptide inhibitor (UK18-D-Ser)
4GLY	;	1.518	;	Human urokinase-type plasminogen activator uPA in complex with the two-disulfide bridge peptide UK504
6WM2	;	3.1	;	Human V-ATPase in state 1 with SidK and ADP
6WM3	;	3.4	;	Human V-ATPase in state 2 with SidK and ADP
7U4T	;	3.6	;	Human V-ATPase in state 2 with SidK and mEAK-7
6WM4	;	3.6	;	Human V-ATPase in state 3 with SidK and ADP
3OP5	;	2.4	;	Human vaccinia-related kinase 1
1VR2	;	2.4	;	HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN
5EW3	;	2.5	;	Human Vascular Endothelial Growth Factor Receptor 2 (KDR) Kinase Domain in complex with AAL993
6LPG	;	2.3	;	human VASH1-SVBP complex
1USE	;	1.3	;	human VASP tetramerisation domain
1USD	;	1.7	;	human VASP tetramerisation domain L352M
3B0T	;	1.3	;	Human VDR ligand binding domain in complex with maxacalcitol
3R4L	;	2.7	;	Human very long half life Plasminogen Activator Inhibitor type-1
1VHR	;	2.1	;	HUMAN VH1-RELATED DUAL-SPECIFICITY PHOSPHATASE
1J4X	;	2.75	;	HUMAN VH1-RELATED DUAL-SPECIFICITY PHOSPHATASE C124S MUTANT-PEPTIDE COMPLEX
1GK7	;	1.4	;	HUMAN VIMENTIN COIL 1A FRAGMENT (1A)
1GK4	;	2.3	;	HUMAN VIMENTIN COIL 2B FRAGMENT (CYS2)
1GK6	;	1.9	;	Human vimentin coil 2B fragment linked to GCN4 leucine zipper (Z2B)
2GWW	;	2.72	;	Human vinculin (head domain, Vh1, residues 1-258) in complex with Shigella's IpaA vinculin binding site (residues 602-633)
2HSQ	;	3.97	;	Human vinculin (head domain, Vh1, residues 1-258) in complex with Shigella's IpaA vinculin binding site 2 (residues 565-587)
4PR9	;	3.2	;	Human Vinculin (residues 891-1066) in complex with PIP
1RKE	;	2.35	;	Human vinculin head (1-258) in complex with human vinculin tail (879-1066)
1RKC	;	2.7	;	Human vinculin head (1-258) in complex with talin's vinculin binding site 3 (residues 1944-1969)
1YDI	;	1.8	;	Human Vinculin Head Domain (VH1, 1-258) in Complex with Human Alpha-Actinin's Vinculin-Binding Site (Residues 731-760)
3TJ6	;	2.76	;	human vinculin head domain (Vh1, residues 1-258) in complex with the vinculin binding site of the surface cell antigen 4 (sca4-VBS-C; residues 812-835) from Rickettsia rickettsii
3TJ5	;	1.99	;	human vinculin head domain (Vh1, residues 1-258) in complex with the vinculin binding site of the surface cell antigen 4 (sca4-VBS-N; residues 412-434) from Rickettsia rickettsii
3S90	;	1.97	;	Human vinculin head domain Vh1 (residues 1-252) in complex with murine talin (VBS33; residues 1512-1546)
4DJ9	;	2.25	;	Human vinculin head domain Vh1 (residues 1-258) in complex with the talin vinculin binding site 50 (VBS50, residues 2078-2099)
1SYQ	;	2.42	;	Human vinculin head domain VH1, residues 1-258, in complex with human talin's vinculin binding site 1, residues 607-636
5L0J	;	4.0	;	Human vinculin R903Q, D907R, R910T mutant(residues 891-1066)
2IBF	;	3.2	;	Human vinculin's head domain (Vh1, residues 1-258) in complex with two vinculin binding sites of Shigella flexneri's IpaA (residues 565-587)
6WV5	;	2.8	;	Human VKOR C43S mutant with vitamin K1 epoxide
6WV4	;	3.012	;	Human VKOR C43S with warfarin
6WVH	;	1.99	;	Human VKOR with Brodifacoum
6WV7	;	2.483	;	Human VKOR with Chlorophacinone
6WV6	;	2.7	;	Human VKOR with phenindione
6WV3	;	2.197	;	Human VKOR with warfarin
8JT9	;	2.97	;	Human VMAT2 complex with ketanserin
8JTC	;	3.52	;	Human VMAT2 complex with reserpine
8JSW	;	2.84	;	Human VMAT2 complex with serotonin
8JTA	;	3.36	;	Human VMAT2 complex with tetrabenazine
8T6A	;	3.17	;	Human VMAT2 in complex with reserpine
8T6B	;	3.72	;	Human VMAT2 in complex with serotonin
8T69	;	2.89	;	Human VMAT2 in complex with tetrabenazine
7EJ1	;	3.2	;	human voltage-gated potassium channel KV1.3
7EJ2	;	3.3	;	human voltage-gated potassium channel KV1.3 H451N mutant
7PHH	;	3.2	;	Human voltage-gated potassium channel Kv3.1 (apo condition)
7PHL	;	3.2	;	Human voltage-gated potassium channel Kv3.1 (with EDTA)
7PHI	;	3.1	;	Human voltage-gated potassium channel Kv3.1 (with Zn)
7PHK	;	3.1	;	Human voltage-gated potassium channel Kv3.1 in dimeric state (with Zn)
1ATZ	;	1.8	;	HUMAN VON WILLEBRAND FACTOR A3 DOMAIN
8SYM	;	3.2	;	Human VPS29/VPS35L Complex (Locally refined map)
4BX8	;	2.4	;	Human Vps33A
4BX9	;	2.6	;	Human Vps33A in complex with a fragment of human Vps16
8SYN	;	2.94	;	Human VPS35L/VPS29/VPS26C Complex
2Z2W	;	2.22	;	Human Wee1 kinase complexed with inhibitor PF0335770
8BJU	;	1.53	;	HUMAN WEE1 KINASE IN COMPLEX WITH INHIBITOR 1-[6-(1-Hydroxy-1-methyl-ethyl)-pyridin-2-yl]-2-(2-methoxy-phenyl)-6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-1,2-dihydro-pyrazolo[3,4-d]pyrimidin-3-one
8P5F	;	1.82	;	Human wild-type GAPDH,orthorhombic form
7SK2	;	3.82	;	Human wildtype GABA reuptake transporter 1 in complex with tiagabine, inward-open conformation
7KC4	;	3.19	;	Human WLS in complex with WNT8A
7DRT	;	2.2	;	Human Wntless in complex with Wnt3a
6YDB	;	2.801	;	Human wtSTING in complex with 2',2'-difluoro-3',3'-c-di-GMP
6YEA	;	2.805	;	Human wtSTING in complex with 2',2'-difluoro-3',3'-cGAMP
6Z0Z	;	2.499	;	Human wtSTING in complex with 3',3'-c-(2'FdAMP-2'FdAMP)
6Z15	;	2.5	;	Human wtSTING in complex with 3',3'-c-di-AMP
6YWB	;	2.503	;	Human wtSTING in complex with 3',3'-c-[2'FdAMP-2'FdAM(PS)]
6YDZ	;	2.9	;	Human wtSTING in complex with 3',3'-cGAMP
6S86	;	2.6	;	Human wtSTING in complex with 3'3'-c-di-GMP
6VBH	;	1.995	;	Human XPG endonuclease catalytic domain
6TUR	;	2.9	;	human XPG, Apo1 form
6TUS	;	2.5	;	human XPG, Apo2 form
6TUW	;	3.5	;	human XPG-DNA, Complex 1
6TUX	;	3.1	;	human XPG-DNA, Complex 2
6ABO	;	2.65	;	human XRCC4 and IFFO1 complex
6FOA	;	1.869	;	Human Xylosyltransferase 1 apo structure
6EJE	;	2.43	;	Human Xylosyltransferase 1 in complex with peptide PAAEGSGEQDFT
6EJB	;	2.557	;	Human Xylosyltransferase 1 in complex with peptide QEEEGSAGGQGG
6EJ8	;	2.09	;	Human Xylosyltransferase 1 in complex with peptide QEEEGSGGGQGG
6EJD	;	2.684	;	Human Xylosyltransferase 1 in complex with peptide QEEEGSGGPQGG
6EJC	;	2.057	;	Human Xylosyltransferase 1 in complex with peptide QEEEGSGVGQGG
6EJA	;	1.94	;	Human Xylosyltransferase 1 in complex with peptide QEEEYSGGGQGG
6EJ9	;	2.02	;	Human Xylosyltransferase 1 in complex with peptide QEPEGSGGGQGG
6EJ7	;	2.0	;	Human Xylosyltransferase 1 in complex with UDP-xylose and peptide QEEEGAGGGQGG
4AY1	;	1.95	;	Human YKL-39 is a pseudo-chitinase with retained chitooligosaccharide binding properties
2X5Y	;	1.05	;	Human ZC3HAV1 (ARTD13), C-terminal domain
3W4U	;	1.95	;	Human zeta-2 beta-2-s hemoglobin
1ZAG	;	2.8	;	HUMAN ZINC-ALPHA-2-GLYCOPROTEIN
7Z5H	;	2.5	;	human Zn MATCAP
6G2A	;	1.8	;	Human [protein ADP-ribosylargenine] hydrolase ARH1 in complex with ADP-HPM
6G28	;	1.23	;	Human [protein ADP-ribosylargenine] hydrolase ARH1 in complex with ADP-ribose
6R0C	;	4.2	;	Human-D02 Nucleosome Core Particle with biotin-streptavidin label
4XQ5	;	2.592	;	Human-infecting H10N8 influenza virus retains strong preference for avian-type receptors
3GTV	;	2.2	;	Human-mouse SOD1 chimera
4OJF	;	1.998	;	Humanised 3D6 Fab complexed to amyloid beta 1-8
4B34	;	1.55	;	Humanised monomeric RadA in complex with 2-amino benzothiazole
4B35	;	1.4	;	Humanised monomeric RadA in complex with 4-methylester indole
4B3C	;	1.9	;	Humanised monomeric RadA in complex with 5-hydroxy indole
4B3D	;	1.589	;	Humanised monomeric RadA in complex with 5-methyl indole
5FOX	;	1.3	;	HUMANISED MONOMERIC RADA IN COMPLEX WITH FHAA TETRAPEPTIDE
5FOU	;	1.5	;	HUMANISED MONOMERIC RADA IN COMPLEX WITH FHPA TETRAPEPTIDE
4B3B	;	1.193	;	Humanised monomeric RadA in complex with FHTA tetrapeptide
5FOV	;	1.739	;	HUMANISED MONOMERIC RADA IN COMPLEX WITH FHTG TETRAPEPTIDE
5FOT	;	1.189	;	HUMANISED MONOMERIC RADA IN COMPLEX WITH FHTU TETRAPEPTIDE
4B2I	;	1.3	;	Humanised monomeric RadA in complex with indazole
4B2L	;	1.5	;	Humanised monomeric RadA in complex with L-methylester tryptophan
4B32	;	1.5	;	Humanised monomeric RadA in complex with napht-1-ol
4B33	;	1.499	;	Humanised monomeric RadA in complex with napht-2-ol
5FOS	;	1.35	;	HUMANISED MONOMERIC RADA IN COMPLEX WITH OLIGOMERISATION PEPTIDE
5FOW	;	1.797	;	HUMANISED MONOMERIC RADA IN COMPLEX WITH WHTA TETRAPEPTIDE
6HQU	;	1.97	;	Humanised RadA mutant HumRadA22 in complex with a recombined BRC repeat 8-2
5KVL	;	1.74	;	Humanized 10G4 anti-leukotriene C4 antibody Fab fragment in complex with leukotriene C4
5OUI	;	3.1	;	Humanized alpha-AChBP (acetylcholine binding protein) in complex with allosteric binder fragment CU2017
5OUG	;	2.57	;	Humanized alpha-AChBP (acetylcholine binding protein) in complex with lobeline and allosteric binder fragment 4.
5OUH	;	2.5	;	Humanized alpha-AChBP (acetylcholine binding protein) in complex with lobeline.
1BVL	;	2.87	;	HUMANIZED ANTI-LYSOZYME FV
1BVK	;	2.7	;	HUMANIZED ANTI-LYSOZYME FV COMPLEXED WITH LYSOZYME
4LKX	;	1.92	;	Humanized antibody 4B12 Fab complexed with a CemX segment
2GCY	;	2.5	;	humanized antibody C25 Fab fragment
5LS9	;	2.93	;	Humanized Archaeal ferritin
1YZZ	;	2.7	;	Humanized caban33 at room temperature
5PA3	;	1.6	;	humanized COMT in complex with 8-hydroxy-6-[2-(methoxymethyl)phenyl]-3H-quinazolin-4-one
4KY1	;	2.97	;	humanized HP1/2 Fab
5WFD	;	2.654	;	Humanized mutant of the Chaetomium thermophilum Polycomb Repressive Complex 2 bound to the inhibitor GSK126
5WFC	;	2.282	;	Humanized mutant of the Chaetomium thermophilum Polycomb Repressive Complex 2 bound to the inhibitor GSK343
4PYM	;	1.19	;	humanized rat apo-COMT bound to sulphate
4PYQ	;	1.39	;	Humanized rat apo-COMT in complex with a ureido-benzamidine
5P92	;	1.61	;	humanized rat catechol O-methyltransferase in complex with 5-(4-fluorophenyl)-2,3-dihydroxy-N-(4-thieno[2,3-c]pyridin-2-ylbutyl)benzamide at 1.61A
5P8Z	;	1.42	;	humanized rat catechol O-methyltransferase in complex with 5-(4-fluorophenyl)-2,3-dihydroxy-N-(4-thieno[3,2-c]pyridin-2-ylbutyl)benzamide at 1.42A
5P90	;	1.24	;	humanized rat catechol O-methyltransferase in complex with 5-(4-fluorophenyl)-2,3-dihydroxy-N-[(E)-5-pyrrolo[3,2-c]pyridin-1-ylpent-3-enyl]benzamide at 1.24A
5P91	;	1.2	;	humanized rat catechol O-methyltransferase in complex with 5-(4-fluorophenyl)-2,3-dihydroxy-N-[2-[5-(2-methylpyridin-4-yl)-4H-1,2,4-triazol-3-yl]ethyl]benzamide at 1.20A
5P8Y	;	1.42	;	humanized rat catechol O-methyltransferase in complex with 5-(4-fluorophenyl)-2,3-dihydroxy-N-[3-(pyrrolo[3,2-c]pyridin-1-ylmethoxy)propyl]benzamide at 1.42A
5P94	;	1.2	;	humanized rat catechol O-methyltransferase in complex with 5-(4-fluorophenyl)-2,3-dihydroxy-N-[[3-[(1H-indazol-5-ylamino)methyl]phenyl]methyl]benzamide at 1.20A
5P9Y	;	1.2	;	humanized rat catechol O-methyltransferase in complex with 6-(4-fluorophenyl)-8-hydroxy-3-(5-pyrrolo[3,2-c]pyridin-1-ylpentyl)quinazolin-4-one
5P9T	;	1.24	;	humanized rat catechol O-methyltransferase in complex with 6-(4-fluorophenyl)-8-hydroxy-3H-quinazolin-4-one
5P9X	;	1.12	;	humanized rat catechol O-methyltransferase in complex with N-[1-[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]propan-2-yl]-5-(4-fluorophenyl)-2,3-dihydroxybenzamide
5P8X	;	1.31	;	humanized rat catechol O-methyltransferase in complex with N-[2-[5-(1H-benzimidazol-5-yl)-4H-1,2,4-triazol-3-yl]ethyl]-5-(4-fluorophenyl)-2,3-dihydroxybenzamide at 1.31A
5P9U	;	1.42	;	humanized rat catechol O-methyltransferase in complex with SAH and 6-bromo-8-hydroxy-3H-quinazolin-4-one
5P93	;	1.24	;	humanized rat catechol O-methyltransferase in complex with single conformation of 5-(4-fluorophenyl)-2,3-dihydroxy-N-[2-(3-pyridin-4-yl-1H-1,2,4-triazol-5-yl)ethyl]benzamide at 1.24A
4PYO	;	2.1	;	Humanized rat COMT bound to SAH, semi-holo form
5PA0	;	1.26	;	humanized rat COMT in complex with 3-hydroxy-1-methyl-5-phenylpyridin-2-one
5P9P	;	1.12	;	humanized rat COMT in complex with 5,6-bis(4-fluorophenyl)-8-hydroxy-3H-quinazolin-4-one
5P9N	;	1.17	;	humanized rat COMT in complex with 5-(4-fluorophenyl)-2,3-dihydroxy-N-[[3-[hydroxy-(1-methylindazol-5-yl)methyl]phenyl]methyl]benzamide at 1.17A
5P9R	;	1.7	;	humanized rat COMT in complex with 5-chloro-6-(4-fluorophenyl)-8-hydroxy-3H-quinazolin-4-one
5P9Q	;	1.63	;	humanized rat COMT in complex with 6-(2,4-dimethyl-1,3-thiazol-5-yl)-8-hydroxy-3H-quinazolin-4-one
5PA5	;	1.63	;	humanized rat COMT in complex with 6-(2,4-dimethyl-1,3-thiazol-5-yl)-8-hydroxy-3H-quinazolin-4-one
5PA4	;	1.99	;	humanized rat COMT in complex with 6-(4-fluorophenyl)-8-hydroxy-3H-quinazolin-4-one
5P9Z	;	1.6	;	humanized rat COMT in complex with 6-(4-fluorophenyl)quinazolin-8-ol
5PA7	;	2.12	;	humanized rat COMT in complex with 6-bromo-3-chloroquinolin-8-ol
5PA6	;	1.29	;	humanized rat COMT in complex with 7-(4-fluorophenyl)quinoxalin-5-ol
5P9O	;	1.1	;	humanized rat COMT in complex with 7-fluoro-5,6-bis(4-fluorophenyl)-8-hydroxy-3H-quinazolin-4-one
5PA2	;	1.12	;	humanized rat COMT in complex with 7-fluoro-6-(4-fluorophenyl)-8-hydroxy-3H-quinazolin-4-one
5P9V	;	1.04	;	humanized rat COMT in complex with 8-hydroxy-6-(2-methylpyridin-3-yl)-3H-quinazolin-4-one
5P9S	;	2.3	;	humanized rat COMT in complex with 8-hydroxy-6-[3-methyl-5-(4-methylpiperazine-1-carbonyl)thiophen-2-yl]-3H-quinazolin-4-one
4PYN	;	1.2	;	Humanized rat COMT in complex with SAH
4PYL	;	2.2	;	Humanized rat COMT in complex with sinefungin, Mg2+, and tolcapone
4YZN	;	1.55	;	Humanized Roco4 bound to Compound 19
4YZM	;	3.0	;	Humanized Roco4 bound to LRRK2-In1
5CTE	;	2.34	;	Humanized yeast ACC carboxyltransferase domain bound to 2,2-dimethylpropyl (1S)-1-methyl-8-[(7-methyl-1H-indazol-5-yl)carbonyl]-2,8-diazaspiro[4.5]decane-2-carboxylate
5CTB	;	2.4	;	Humanized yeast ACC carboxyltransferase domain bound to 6,7-dimethyl-1'-[(7-methyl-1H-indazol-5-yl)carbonyl]spiro[chromene-2,4'-piperidin]-4(3H)-one
5CTC	;	2.7	;	Humanized yeast ACC carboxyltransferase domain bound to tert-butyl 7-[(7-methyl-1H-indazol-5-yl)carbonyl]-2,7-diazaspiro[3.5]nonane-2-carboxylate
3FAL	;	2.36	;	humanRXR alpha & mouse LXR alpha complexed with Retenoic acid and GSK2186
4OYY	;	3.0	;	Humicola insolens cutinase
4OYL	;	2.05	;	Humicola insolens cutinase in complex with mono-ethylphosphate
1DYM	;	1.75	;	Humicola insolens Endocellulase Cel7B (EG 1) E197A Mutant
2A39	;	2.2	;	HUMICOLA INSOLENS ENDOCELLULASE EGI NATIVE STRUCTURE
1A39	;	2.2	;	HUMICOLA INSOLENS ENDOCELLULASE EGI S37W, P39W DOUBLE-MUTANT
5QUU	;	1.248	;	HumRadA1 as soaking control with 10% DMSO
6TV3	;	1.5	;	HumRadA1 in complex with 3-amino-2-naphthoic acid
6XUF	;	1.241	;	HumRadA1 in complex with 5-Ethyl-N-(1H-indol-5-ylmethyl)-1,3,4-thiadiazol-2-amine in P21
6XUJ	;	1.54	;	HumRadA1 in complex with 5-Ethyl-N-(1H-indol-5-ylmethyl)-1,3,4-thiadiazol-2-amine in P21212
5QUO	;	1.342	;	HumRadA1 soaked with 0.2 mM indazole in 10% DMSO
5QUP	;	1.25	;	HumRadA1 soaked with 0.5 mM indazole in 10% DMSO
5QUQ	;	1.249	;	HumRadA1 soaked with 1 mM indazole in 10% DMSO
5QUT	;	1.248	;	HumRadA1 soaked with 10 mM indazole in 10% DMSO
5QUR	;	1.247	;	HumRadA1 soaked with 2 mM indazole in 10% DMSO
5QUS	;	1.247	;	HumRadA1 soaked with 5 mM indazole in 10% DMSO
5QUE	;	1.3	;	HumRadA1.2 soaked with napht-2,3-diol for 10 minutes at 20 mM
5QUB	;	1.35	;	HumRadA1.2 soaked with napht-2,3-diol for 30 seconds at 20 mM
5QUD	;	1.3	;	HumRadA1.2 soaked with napht-2,3-diol for 5 minutes at 20 mM
5QUC	;	1.43	;	HumRadA1.2 soaked with napht-2,3-diol for 60 seconds at 20 mM
5QUJ	;	1.42	;	HumRadA1.2 soaked with napht-2,3-diol overnight 10 mM
5QUG	;	1.48	;	HumRadA1.2 soaked with napht-2,3-diol overnight at 1 mM
5QUH	;	1.38	;	HumRadA1.2 soaked with napht-2,3-diol overnight at 2 mM
5QUF	;	1.35	;	HumRadA1.2 soaked with napht-2,3-diol overnight at 20 mM
5QUI	;	1.4	;	HumRadA1.2 soaked with napht-2,3-diol overnight at 5 mM
6TW3	;	1.352	;	HumRadA2 in complex with Naphthyl-HPA fragment-peptide chimera
6TW9	;	1.52	;	HumRadA22F in complex with CAM833
6TW4	;	1.73	;	HumRadA22F in complex with compound 6
6XTW	;	2.31	;	HumRadA33F in complex with peptidic inhibitor 6
3IO4	;	3.63	;	Huntingtin amino-terminal region with 17 Gln residues - Crystal C90
3IO6	;	3.7	;	Huntingtin amino-terminal region with 17 Gln residues - crystal C92-a
3IOT	;	3.5	;	Huntingtin amino-terminal region with 17 Gln residues - crystal C92-b
3IOU	;	3.7	;	Huntingtin amino-terminal region with 17 Gln residues - crystal C94
3IOR	;	3.6	;	Huntingtin amino-terminal region with 17 Gln residues - crystal C95
3IOV	;	3.7	;	Huntingtin amino-terminal region with 17 Gln residues - crystal C99
3IOW	;	3.5	;	Huntingtin amino-terminal region with 17 Gln residues - crystal C99-Hg
8SAH	;	3.2	;	Huntingtin C-HEAT domain in complex with HAP40
6BQS	;		;	HusA haemophore from Porphyromonas gingivalis
6CRL	;		;	HusA haemophore from Porphyromonas gingivalis
7MWD	;	3.7	;	HUWE1 in map with focus on HECT
7MWF	;	3.3	;	HUWE1 in map with focus on interface
7MWE	;	3.4	;	HUWE1 in map with focus on WWE
5Z5X	;		;	HVF18 in complex with LPS micelles
2LAI	;		;	Hyaloperonospora arabidopsidis Effector Protein ATR13
1UUH	;	2.2	;	Hyaluronan binding domain of human CD44
4D0Q	;	1.2	;	Hyaluronan Binding Module of the Streptococcal Pneumoniae Hyaluronate Lyase
2I83	;		;	hyaluronan-binding domain of CD44 in its ligand-bound form
2BVK	;		;	Hyaluronan: the local solution conformation determined by NMR and computer modelling is close to a contracted left-handed four-fold helix
2HYA	;	3.0	;	HYALURONIC ACID, MOLECULAR CONFORMATIONS AND INTERACTIONS IN TWO SODIUM SALTS
3HYA	;	3.0	;	HYALURONIC ACID, MOLECULAR CONFORMATIONS AND INTERACTIONS IN TWO SODIUM SALTS
1HYA	;	3.0	;	HYALURONIC ACID, STRUCTURE OF A FULLY EXTENDED 3-FOLD HELICAL SODIUM SALT AND COMPARISON WITH THE LESS EXTENDED 4-FOLD HELICAL FORMS
4HYA	;	3.0	;	HYALURONIC ACID, THE ROLE OF DIVALENT CATIONS IN CONFORMATION AND PACKING
2J88	;	2.6	;	Hyaluronidase in complex with a monoclonal IgG Fab fragment
6WO1	;	3.3	;	Hybrid acetohydroxyacid synthase complex structure with Cryptococcus neoformans AHAS catalytic subunit and Saccharomyces cerevisiae AHAS regulatory subunit
8G27	;	3.3	;	Hybrid aspen cellulose synthase-8 bound to UDP
8G2J	;	3.3	;	Hybrid aspen cellulose synthase-8 bound to UDP-glucose
7DE4	;	3.61	;	Hybrid cluster protein (HCP) from Escherichia coli
1GN9	;	2.6	;	Hybrid Cluster Protein from Desulfovibrio desulfuricans ATCC 27774 X-ray structure at 2.6A resolution using synchrotron radiation at a wavelength of 1.722A
1GNL	;	1.25	;	Hybrid Cluster Protein from Desulfovibrio desulfuricans X-ray structure at 1.25A resolution using synchrotron radiation at a wavelength of 0.933A
1E1D	;	1.72	;	Hybrid Cluster Protein from Desulfovibrio vulgaris
1GNT	;	1.25	;	Hybrid Cluster Protein from Desulfovibrio vulgaris. X-ray structure at 1.25A resolution using synchrotron radiation.
8CNR	;	1.45	;	Hybrid Cluster Protein from the thermophilic methanogen Methanothermococcus thermolithotrophicus as isolated in a reduced state at 1.45-A resolution
7C8L	;	1.45	;	Hybrid designing of potent inhibitors of Striga strigolactone receptor ShHTL7
6HG1	;	2.12	;	Hybrid dihydroorotase domain of human CAD with E. coli flexible loop in apo state
6HG3	;	1.97	;	Hybrid dihydroorotase domain of human CAD with E. coli flexible loop, bound to dihydroorotate
6HG2	;	1.83	;	Hybrid dihydroorotase domain of human CAD with E. coli flexible loop, bound to fluoroorotate
7Q1I	;	1.65	;	Hybrid form of uridine phosphorylase from E. coli and Salmonella typhimurium in the presence glycerol
7Q1J	;	1.71	;	Hybrid form of uridine phosphorylase from E. coli and Salmonella typhimurium in the presence PEG
6DJS	;	5.8	;	Hybrid model of TRPC3 in GDN
6BG9	;	9.0	;	HYBRID NMR/CRYO-EM STRUCTURE OF THE HIV-1 RNA DIMERIZATION SIGNAL
2KYV	;		;	Hybrid solution and solid-state NMR structure ensemble of phospholamban pentamer
2KB7	;		;	Hybrid solution and solid-state NMR structure of monomeric phospholamban in lipid bilayers
4Z68	;	1.859	;	Hybrid structural analysis of the Arp2/3 regulator Arpin identifies its acidic tail as a primary binding epitope
6GVT	;		;	Hybrid structure of the pRN1 helix bundle domain in complex with DNA and 2 ATP molecules
2MME	;	7.7	;	Hybrid structure of the Shigella flexneri MxiH Type three secretion system needle
6YEG	;	4.0	;	Hybrid structure of the SPP1 tail tube by solid-state NMR and cryo EM - Final EM Refinement
6YQ5	;	4.0	;	Hybrid structure of the SPP1 tail tube by solid-state NMR and cryo EM - NMR Ensemble
2N7H	;		;	Hybrid structure of the Type 1 Pilus of Uropathogenic E.coli
8R4E	;		;	Hybrid-1R G-quadruplex with a +(lpp) loop progression
6CCW	;		;	Hybrid-2 form Human Telomeric G Quadruplex in Complex with Epiberberine
7O1H	;		;	Hybrid-2R quadruplex-duplex with (-p-p-l) topology and 3 syn residues
3BSU	;	2.1	;	Hybrid-binding domain of human RNase H1 in complex with 12-mer RNA/DNA
6KYJ	;	1.7	;	Hybrid-Rubisco (rice RbcL and sorghum RbcS) in complex with sulfate ions
5FES	;	1.27	;	HydE from T. maritima in complex with (2R,4R)-MeSeTDA
5FEZ	;	1.35	;	HydE from T. maritima in complex with (2R,4R)-MeSeTDA, 5'-deoxyadenosine and methionine
5FEP	;	1.45	;	HydE from T. maritima in complex with (2R,4R)-MeTDA
5FF2	;	1.47	;	HydE from T. maritima in complex with (2R,4R)-TDA
5FF4	;	1.35	;	HydE from T. maritima in complex with (2R,4R)-TMeTDA
5FF3	;	1.18	;	HydE from T. maritima in complex with 4R-TCA
5FEW	;	1.17	;	HydE from T. maritima in complex with S-adenosyl-L-cysteine (final product)
5FF0	;	1.49	;	HydE from T. maritima in complex with S-adenosyl-L-cysteine and methionine
5FEX	;	1.32	;	HydE from T. maritima in complex with Se-adenosyl-L-selenocysteine (tfinal of the reaction)
5XOM	;	2.2	;	Hydra Fam20
6L0L	;		;	Hydra-1ubq de nova designed by Hydra based on ubiquitin
2K35	;		;	Hydramacin-1: Structure and antibacterial activity of a peptide from the basal metazoan Hydra
4IA5	;	2.22	;	Hydratase from Lactobacillus acidophilus - SeMet derivative (apo LAH)
4IA6	;	1.8	;	Hydratase from lactobacillus acidophilus in a ligand bound form (LA LAH)
383D	;	1.7	;	Hydration and recognition of methylated CPG steps in DNA
384D	;	2.15	;	HYDRATION AND RECOGNITION OF METHYLATED CPG STEPS IN DNA
382D	;	2.2	;	HYDRATION AND RECOGNITION OF METHYLATED CPG STEPS IN DNA.
2MB5	;	1.8	;	HYDRATION IN PROTEIN CRYSTALS. A NEUTRON DIFFRACTION ANALYSIS OF CARBONMONOXYMYOGLOBIN
187D	;	2.25	;	HYDRATION PATTERNS AND INTERMOLECULAR INTERACTIONS IN A-DNA CRYSTAL STRUCTURES. IMPLICATIONS FOR DNA RECOGNITION
188D	;	2.2	;	HYDRATION PATTERNS AND INTERMOLECULAR INTERACTIONS IN A-DNA CRYSTAL STRUCTURES. IMPLICATIONS FOR DNA RECOGNITION
189D	;	2.1	;	HYDRATION PATTERNS AND INTERMOLECULAR INTERACTIONS IN A-DNA CRYSTAL STRUCTURES. IMPLICATIONS FOR DNA RECOGNITION
1CGD	;	1.85	;	HYDRATION STRUCTURE OF A COLLAGEN PEPTIDE
6PW8	;	1.95	;	Hydrocarbon-Stapled Paxillin Peptide Bound to the Focal Adhesion Targeting (FAT) Domain of the Focal Adhesion Kinase (FAK)
1TOI	;	1.9	;	Hydrocinnamic acid-bound structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase
1TOG	;	2.31	;	Hydrocinnamic acid-bound structure of SRHEPT + A293D mutant of E. coli aspartate aminotransferase
1TOJ	;	1.9	;	Hydrocinnamic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase
1IO5	;	2.0	;	HYDROGEN AND HYDRATION OF HEN EGG-WHITE LYSOZYME DETERMINED BY NEUTRON DIFFRACTION
1C5H	;	1.55	;	HYDROGEN BONDING AND CATALYSIS: AN UNEXPECTED EXPLANATION FOR HOW A SINGLE AMINO ACID SUBSTITUTION CAN CHANGE THE PH OPTIMUM OF A GLYCOSIDASE
1C5I	;	1.8	;	HYDROGEN BONDING AND CATALYSIS: AN UNEXPECTED EXPLANATION FOR HOW A SINGLE AMINO ACID SUBSTITUTION CAN CHANGE THE PH OPTIMUM OF A GLYCOSIDASE
6B1Q	;	1.9	;	Hydrogen Bonding Complementary, not size complementarity is key in the formation of the double helix
6B1R	;	1.69	;	Hydrogen Bonding Complementary, not size complementarity is key in the formation of the double helix
6B1S	;	2.0	;	Hydrogen Bonding Complementary, not size complementarity is key in the formation of the double helix
1XDC	;	1.85	;	Hydrogen Bonding in Human Manganese Superoxide Dismutase containing 3-Fluorotyrosine
1XIL	;	1.53	;	HYDROGEN BONDING IN HUMAN MANGANESE SUPEROXIDE DISMUTASE CONTAINING 3-FLUOROTYROSINE
1GJN	;	1.35	;	Hydrogen Peroxide Derived Myoglobin Compound II at pH 5.2
3SB1	;	1.67	;	Hydrogenase expression protein HupH from Thiobacillus denitrificans ATCC 25259
1CFZ	;	2.2	;	HYDROGENASE MATURATING ENDOPEPTIDASE HYBD FROM E. COLI
1GXU	;	1.27	;	Hydrogenase Maturation Protein HypF ""acylphosphatase-like"" N-terminal domain (HypF-ACP) in complex with a substrate. Crystal grown in the presence of carbamoylphosphate
1GXT	;	1.27	;	Hydrogenase Maturation Protein HypF ""acylphosphatase-like"" N-terminal domain (HypF-ACP) in complex with Sulfate
7NEM	;	1.35	;	Hydrogenase-2 variant R479K - anaerobically oxidised form
6SYO	;	1.25	;	Hydrogenase-2 variant R479K - As Isolated form
6SZD	;	1.5	;	Hydrogenase-2 variant R479K - hydrogen reduced form
6SZK	;	1.2	;	Hydrogenase-2 variant R479K - hydrogen reduced form treated with CO
6SYX	;	1.3	;	Hydrogenase-2 variant R479K - reduced sample exposed to pure oxygen
1ZIE	;	1.44	;	Hydrogenated gammaE crystallin in D2O solvent
6S2S	;	0.86	;	Hydrogenated human myelin protein P2 at 0.86-A resolution
7P6M	;	0.89	;	Hydrogenated refolded hen egg-white lysozyme
5AUS	;	1.3	;	Hydrogenobacter thermophilus cytochrome c552 dimer formed by domain swapping at C-terminal region
5AUR	;	1.26	;	Hydrogenobacter thermophilus cytochrome c552 dimer formed by domain swapping at N-terminal region
7M1O	;	1.98389	;	Hydrogenobacter thermophilus ferredoxin 1 S64A variant
1YTN	;	2.4	;	HYDROLASE
255L	;	1.8	;	HYDROLASE
1LBU	;	1.8	;	HYDROLASE METALLO (ZN) DD-PEPTIDASE
1BEL	;	1.6	;	HYDROLASE PHOSPHORIC DIESTER, RNA
5HDF	;	2.71	;	Hydrolase SeMet-StnA
5HDP	;	2.9	;	Hydrolase StnA mutant - S185A
1GOY	;	2.0	;	HYDROLASE(ENDORIBONUCLEASE)RIBONUCLEASE BI(G SPECIFIC ENDONUCLEASE) (E.C.3.1.27.-) COMPLEXED WITH GUANOSINE-3'-PHOSPHATE (3'-GMP)
1RGE	;	1.15	;	HYDROLASE, GUANYLORIBONUCLEASE
1RGF	;	1.2	;	HYDROLASE, GUANYLORIBONUCLEASE
1RGG	;	1.2	;	HYDROLASE, GUANYLORIBONUCLEASE
1RGH	;	1.2	;	HYDROLASE, GUANYLORIBONUCLEASE
2AH5	;	1.74	;	Hydrolase, haloacid dehalogenase-like family protein SP0104 from Streptococcus pneumoniae
1RDQ	;	1.26	;	Hydrolysis of ATP in the crystal of Y204A mutant of cAMP-dependent protein kinase
3P32	;	1.9	;	Hydrolysis of GTP to GDP by an MCM-associated and MeaB- and MMAA-like G-protein from Mycobacterium tuberculosis
3PBJ	;	2.2	;	Hydrolytic catalysis and structural stabilization in a designed metalloprotein
1WPO	;	2.0	;	HYDROLYTIC ENZYME HUMAN CYTOMEGALOVIRUS PROTEASE
1CV2	;	1.58	;	Hydrolytic haloalkane dehalogenase linb from sphingomonas paucimobilis UT26 AT 1.6 A resolution
1K5P	;	1.8	;	Hydrolytic haloalkane dehalogenase LINB from sphingomonas paucimobilis UT26 at 1.8A resolution
1D07	;	2.0	;	Hydrolytic haloalkane dehalogenase linb from sphingomonas paucimobilis UT26 with 1,3-propanediol, a product of debromidation of dibrompropane, at 2.0A resolution
5A62	;	1.5	;	Hydrolytic potential of the ammonia-oxidizing Thaumarchaeon Nitrososphaera gargenis - crystal structure and activity profiles of carboxylesterases linked to their metabolic function
1HYM	;		;	HYDROLYZED TRYPSIN INHIBITOR (CMTI-V, MINIMIZED AVERAGE NMR STRUCTURE)
1TLA	;	2.0	;	HYDROPHOBIC CORE REPACKING AND AROMATIC-AROMATIC INTERACTION IN THE THERMOSTABLE MUTANT OF T4 LYSOZYME SER 117 (RIGHT ARROW) PHE
5B5H	;	1.0	;	Hydrophobic ice-binding site confer hyperactivity on antifreeze protein from a snow mold fungus
8AQD	;	1.45	;	Hydrophobic probe bound to Streptavidin - 1
8AQJ	;	1.85	;	Hydrophobic probe bound to Streptavidin - 2
1L17	;	1.7	;	HYDROPHOBIC STABILIZATION IN T4 LYSOZYME DETERMINED DIRECTLY BY MULTIPLE SUBSTITUTIONS OF ILE 3
1L18	;	1.7	;	HYDROPHOBIC STABILIZATION IN T4 LYSOZYME DETERMINED DIRECTLY BY MULTIPLE SUBSTITUTIONS OF ILE 3
1LL1	;	2.55	;	HYDROXO BRIDGE MET FORM HEMOCYANIN FROM LIMULUS
1A7E	;	1.8	;	HYDROXOMET MYOHEMERYTHRIN FROM THEMISTE ZOSTERICOLA
4K8S	;	2.39	;	Hydroxyethylamine-based inhibitors of BACE1: P1-P3 macrocyclization can improve potency, selectivity, and cell activity
1AAQ	;	2.5	;	HYDROXYETHYLENE ISOSTERE INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS-1 PROTEASE: STRUCTURE-ACTIVITY ANALYSIS USING ENZYME KINETICS, X-RAY CRYSTALLOGRAPHY, AND INFECTED T-CELL ASSAYS
6T5E	;	3.3	;	Hydroxylamine Oxidoreductase from Brocadia fulgida
6M0Q	;	1.99	;	Hydroxylamine oxidoreductase from Nitrosomonas europaea
6M0P	;	2.78	;	Hydroxylamine oxidoreductase in complex with juglone
4ZR1	;	2.6008	;	Hydroxylase domain of scs7p
7JSD	;	2.5	;	Hydroxylase homolog of BesD with Fe(II), alpha-ketoglutarate, and lysine
2R5V	;	2.3	;	Hydroxymandelate Synthase Crystal Structure
2YPN	;	2.3	;	Hydroxymethylbilane synthase
3YAS	;	1.85	;	HYDROXYNITRILE LYASE COMPLEXED WITH ACETONE
4YAS	;	2.0	;	HYDROXYNITRILE LYASE COMPLEXED WITH CHLORALHYDRATE
5YAS	;	2.2	;	HYDROXYNITRILE LYASE COMPLEXED WITH HEXAFLUOROACETONE
1YAS	;	1.9	;	HYDROXYNITRILE LYASE COMPLEXED WITH HISTIDINE
3GDP	;	1.57	;	Hydroxynitrile lyase from almond, monoclinic crystal form
2YAS	;	1.72	;	HYDROXYNITRILE LYASE FROM HEVEA BRASILIENSIS COMPLEXED WITH RHODANIDE
1YB7	;	1.76	;	Hydroxynitrile lyase from hevea brasiliensis in complex with 2,3-dimethyl-2-hydroxy-butyronitrile
1YB6	;	1.54	;	Hydroxynitrile lyase from hevea brasiliensis in complex with mandelonitrile
1SC9	;	1.8	;	Hydroxynitrile Lyase from Hevea brasiliensis in complex with the natural substrate acetone cyanohydrin
8SNI	;	1.99	;	Hydroxynitrile Lyase from Hevea brasiliensis with Forty Mutations
8EUO	;	1.99	;	Hydroxynitrile Lyase from Hevea brasiliensis with Seven Mutations
6YAS	;	2.2	;	HYDROXYNITRILE LYASE FROM HEVEA BRASILIENSIS, ROOM TEMPERATURE STRUCTURE
7BR1	;	1.25	;	Hydroxynitrile lyase from Parafontaria laminate complexed with benzaldehyde prepared by cocrystallization
7BOW	;	1.42	;	Hydroxynitrile lyase from Parafonteria laminate
7BPO	;	1.37	;	Hydroxynitrile lyase from Parafonteria laminate complexed with benzaldehyde
5XZQ	;	2.8	;	Hydroxynitrile lyase from Passiflora edulis (PeHNL)
5E46	;	1.854	;	Hydroxynitrile lyase from the fern Davallia tyermanii
5E4B	;	1.5	;	Hydroxynitrile lyase from the fern Davallia tyermanii in complex with (R)-mandelonitrile / benzaldehyde
5E4D	;	1.85	;	Hydroxynitrile lyase from the fern Davallia tyermanii in complex with benzoic acid
5E4M	;	1.801	;	Hydroxynitrile lyase from the fern Davallia tyermanii in complex with p-hydroxybenzaldehyde
7YCB	;	2.01	;	HYDROXYNITRILE LYASE FROM THE MILLIPEDE
7YAX	;	2.01	;	HYDROXYNITRILE LYASE FROM THE MILLIPEDE,
6JHC	;	1.6	;	Hydroxynitrile lyase from the millipede, Chamberlinius hualienensis (ligand free)
6KFE	;	2.0	;	Hydroxynitrile lyase from the millipede, Chamberlinius hualienensis (recombinant)
6KFA	;	1.5	;	Hydroxynitrile lyase from the millipede, Chamberlinius hualienensis bound with acetate
6KFB	;	1.55	;	Hydroxynitrile lyase from the millipede, Chamberlinius hualienensis bound with thiocyanate
6KFC	;	2.1	;	Hydroxynitrile lyase from the millipede, Chamberlinius hualienensis, complexed with cyanide ion
6KFD	;	1.55	;	Hydroxynitrile lyase from the millipede, Chamberlinius hualienensis, complexed with iodoacetate
7YCD	;	2.01	;	HYDROXYNITRILE LYASE FROM THE MILLIPEDE, Oxidus gracilis bound with (R)-(+)-ALPHA-HYDROXYBENZENE-ACETONITRILE
7YCT	;	2.01	;	HYDROXYNITRILE LYASE FROM THE MILLIPEDE, Oxidus gracilis complexed with (R)-2-Chloromandelonitrile
7YCF	;	2.01	;	HYDROXYNITRILE LYASE FROM THE MILLIPEDE, Oxidus gracilis IN ACETONITRILE
7YAS	;	1.75	;	HYDROXYNITRILE LYASE, LOW TEMPERATURE NATIVE STRUCTURE
1QJ4	;	1.1	;	HYDROXYNITRILE-LYASE FROM HEVEA BRASILIENSIS AT ATOMIC RESOLUTION
7WBC	;	2.0	;	Hydroxysteroid dehydrogenase wild-type complexed with NAD+ and (4S)-2-2-methyl-2,4-pentanediol
7RIH	;	1.35	;	hyen D
7RN3	;		;	hyen D solution structure
6P4C	;	1.85	;	HyHEL10 Fab carrying four heavy chain mutations (HyHEL10-4x): L4F, Y33H, S56N, and Y58F
8GQ1	;	3.13	;	HyHEL10 Fab complexed with hen egg lysozyme carrying arginine cluster in framework region of light chain.
6P4A	;	2.2	;	HyHEL10 Fab complexed with hen egg lysozyme carrying two mutations (HEL2x-rigid): R21Q and R73E
6P4B	;	1.9	;	HyHEL10 fab variant HyHEL10-4x (heavy chain mutations L4F, Y33H, S56N, and Y58F) bound to hen egg lysozyme variant HEL2x-flex (mutations R21Q, R73E, C76S, and C94S)
5MMK	;		;	HYL-20
5MML	;		;	HYL-20k
6TTM	;	1.91	;	Hyoscyamine 6-hydroxylase in complex with N-oxalylglycine and hyoscyamine
8JHE	;	2.201	;	Hyper-thermostable ancestral L-amino acid oxidase 2 (HTAncLAAO2)
3AHQ	;	2.35	;	hyperactive human Ero1
7V5E	;		;	Hyperdisulfide peptide from Schisandra chinensis
7TVH	;	1.71	;	Hyperlytic variant of Tae1, Type VI secretion amidase effector 1, from Pseudomonas aeruginosa (Cys110Ser)
1FL8	;		;	HYPERMODIFIED NUCLEOSIDES IN THE ANTICODON OF TRNALYS STABILIZE A CANONICAL U-TURN STRUCTURE
7KJ0	;	2.29	;	hyperoxidized human peroxiredoxin 2
6WVS	;	2.202	;	Hyperstable de novo TIM barrel variant DeNovoTIM15
4EB1	;	2.8	;	Hyperstable in-frame insertion variant of antithrombin
1AZP	;	1.6	;	HYPERTHERMOPHILE CHROMOSOMAL PROTEIN SAC7D BOUND WITH KINKED DNA DUPLEX
1AZQ	;	1.94	;	HYPERTHERMOPHILE CHROMOSOMAL PROTEIN SAC7D BOUND WITH KINKED DNA DUPLEX
1WTO	;	1.5	;	Hyperthermophile chromosomal protein SAC7D double mutant V26F/M29F in complex with DNA GCGATCGC
1XYI	;	1.45	;	Hyperthermophile chromosomal protein Sac7d double mutant Val26Ala/Met29Ala in complex with DNA GCGATCGC
1WTR	;	1.8	;	Hyperthermophile chromosomal protein SAC7D single mutant M29A in complex with DNA GCGATCGC
1WTV	;	1.6	;	Hyperthermophile chromosomal protein SAC7D single mutant M29A in complex with DNA GTAATTAC
1WTP	;	1.9	;	Hyperthermophile chromosomal protein SAC7D single mutant M29F in complex with DNA GCGA(UBr)CGC
1WTQ	;	1.7	;	Hyperthermophile chromosomal protein SAC7D single mutant M29F in complex with DNA GTAATTAC
1WTW	;	2.2	;	Hyperthermophile chromosomal protein SAC7D single mutant V26A in complex with DNA GCGATCGC
1WTX	;	2.2	;	Hyperthermophile chromosomal protein SAC7D single mutant V26A in complex with DNA GTAATTAC
1SAP	;		;	HYPERTHERMOPHILE PROTEIN, RELAXATION MATRIX REFINEMENT STRUCTURE
4XB1	;	2.3	;	Hyperthermophilic archaeal homoserine dehydrogenase in complex with NADPH
4XB2	;	2.43	;	Hyperthermophilic archaeal homoserine dehydrogenase mutant in complex with NADPH
3ZWQ	;	2.0	;	HYPERTHERMOPHILIC ESTERASE FROM THE ARCHEON PYROBACULUM CALIDIFONTIS
6K52	;	1.68	;	Hyperthermophilic GH6 cellobiohydrolase (HmCel6A) from the microbial flora of a Japanese hot spring
6K54	;	1.905	;	Hyperthermophilic GH6 cellobiohydrolase II (HmCel6A) in complex with trisaccharide
6KLS	;	3.3	;	Hyperthermophilic respiratory Complex III
6KLV	;	3.2	;	Hyperthermophilic respiratory Complex III
2DFV	;	2.05	;	Hyperthermophilic threonine dehydrogenase from Pyrococcus horikoshii
1GB4	;		;	HYPERTHERMOPHILIC VARIANT OF THE B1 DOMAIN FROM STREPTOCOCCAL PROTEIN G, NMR, 47 STRUCTURES
5AYJ	;	2.05	;	Hyperthermostable mutant of Bacillus sp. TB-90 Urate Oxidase - R298C
4AX7	;	1.7	;	Hypocrea jecorina Cel6A D221A mutant soaked with 4-Methylumbelliferyl- beta-D-cellobioside
4AU0	;	1.7	;	Hypocrea jecorina Cel6A D221A mutant soaked with 6-chloro-4- methylumbelliferyl-beta-cellobioside
4AX6	;	2.3	;	HYPOCREA JECORINA CEL6A D221A MUTANT SOAKED WITH 6-CHLORO-4- PHENYLUMBELLIFERYL-BETA-CELLOBIOSIDE
4D5Q	;	1.68	;	Hypocrea jecorina Cel7A (wild type) soaked with xylopentaose.
4UWT	;	1.2	;	Hypocrea jecorina Cel7A E212Q mutant in complex with p-nitrophenyl cellobioside
2V3I	;	1.05	;	Hypocrea jecorina Cel7A in complex with (R)-dihydroxy-phenanthrenolol
2V3R	;	1.6	;	Hypocrea jecorina Cel7A in complex with (S)-dihydroxy-phenanthrenolol
4D5O	;	1.52	;	Hypocrea jecorina cellobiohydrolase Cel7A E212Q soaked with xylopentaose.
4D5I	;	1.42	;	Hypocrea jecorina cellobiohydrolase Cel7A E212Q soaked with xylotriose.
4D5P	;	1.89	;	Hypocrea jecorina cellobiohydrolase Cel7A E217Q soaked with xylopentaose.
4D5V	;	1.62	;	Hypocrea jecorina cellobiohydrolase Cel7A E217Q soaked with xylotetraose.
4D5J	;	1.5	;	Hypocrea jecorina cellobiohydrolase Cel7A E217Q soaked with xylotriose.
6C1P	;	2.9	;	HypoPP mutant
6C1K	;	2.7	;	HypoPP mutant with ligand1
8EVQ	;	2.72	;	Hypopseudouridylated Ribosome bound with TSV IRES, eEF2, GDP, and sordarin, Structure I
8EVT	;	2.2	;	Hypopseudouridylated yeast 80S bound with Taura syndrome virus (TSV) internal ribosome entry site (IRES) refined against a composite map
8EUB	;	2.52	;	Hypopseudouridylated yeast 80S bound with Taura syndrome virus (TSV) internal ribosome entry site (IRES), eEF2 and GDP, Structure I
8EVS	;	2.62	;	Hypopseudouridylated yeast 80S bound with Taura syndrome virus (TSV) internal ribosome entry site (IRES), eEF2 and GDP, Structure II
8EWB	;	2.87	;	Hypopseudouridylated yeast 80S bound with Taura syndrome virus (TSV) internal ribosome entry site (IRES), eEF2 and GDP, Structure III
8EVR	;	2.87	;	Hypopseudouridylated yeast 80S bound with Taura syndrome virus (TSV) internal ribosome entry site (IRES), eEF2, GDP, and sordarin, Structure II
8EVP	;	2.38	;	Hypopseudouridylated yeast 80S bound with Taura syndrome virus (TSV) internal ribosome entry site (IRES), Structure I
8EWC	;	2.45	;	Hypopseudouridylated yeast 80S bound with Taura syndrome virus (TSV) internal ribosome entry site (IRES), Structure II
8H0H	;	2.74	;	Hypotethical protein from Mycobacterium tuberculsosis
1YVO	;	1.9	;	hypothetical acetyltransferase from P.aeruginosa PA01
2YRR	;	1.86	;	hypothetical alanine aminotransferase (TTH0173) from Thermus thermophilus HB8
8FIP	;	1.7	;	Hypothetical anthocyanidin reducatase from Sorghum bicolor- NADP+ complex
8FIO	;	1.97	;	Hypothetical anthocyanidin reductase from Sorghum bicolor-NADP(H) and naringenin complex
2EMQ	;	2.5	;	Hypothetical Conserved Protein (GK1048) from Geobacillus Kaustophilus
1UC2	;	2.15	;	Hypothetical Extein Protein of PH1602 from Pyrococcus horikoshii
4QO5	;	1.697	;	Hypothetical multiheme protein
2OM6	;	2.2	;	Hypothetical Protein (Probable Phosphoserine Phosph (PH0253) from Pyrococcus Horikoshii OT3
1PZX	;	2.0	;	Hypothetical protein APC36103 from Bacillus stearothermophilus: a lipid binding protein
1T0G	;		;	Hypothetical protein At2g24940.1 from Arabidopsis thaliana has a cytochrome b5 like fold
3I3F	;	1.35	;	Hypothetical protein from Giardia lamblia GL50803_14299
2B4W	;	1.98	;	Hypothetical protein from leishmania major
3KSV	;	1.9	;	Hypothetical protein from Leishmania major
3M3I	;	2.35	;	Hypothetical protein from Leishmania major
1YQF	;	2.3	;	Hypothetical protein from leishmania major unknown function sequence homologue to human p32 protein
1ZSO	;	2.17	;	Hypothetical protein from plasmodium falciparum
1NNW	;	1.9	;	hypothetical protein from Pyrococcus furiosus Pfu-1218608
1NNH	;	1.65	;	Hypothetical protein from Pyrococcus furiosus Pfu-1801964
1XE1	;	2.0	;	Hypothetical Protein From Pyrococcus Furiosus Pfu-880080-001
2D59	;	1.65	;	hypothetical protein from Pyrococcus horikoshii OT3
2D5A	;	1.7	;	hypothetical protein from Pyrococcus horikoshii OT3
1YZV	;	2.001	;	HYPOTHETICAL PROTEIN FROM TRYPANOSOMA CRUZI
7O9V	;	1.99	;	hypothetical protein OMM_04225 residues 244-274 from Candidatus Magnetoglobus multicellularis fused to GCN4 adaptors
3STQ	;	2.284	;	Hypothetical protein PA2703 Pseudomonas aeruginosa PAO1
1YRE	;	2.15	;	Hypothetical protein PA3270 from Pseudomonas aeruginosa in complex with CoA
2I0X	;	2.7	;	Hypothetical protein PF1117 from Pyrococcus furiosus
4TNO	;	2.14	;	Hypothetical protein PF1117 from Pyrococcus Furiosus: Structure solved by sulfur-SAD using Swiss Light Source Data
2FZF	;	2.7	;	Hypothetical Protein Pfu-1136390-001 From Pyrococcus furiosus
1ZTD	;	2.0	;	Hypothetical Protein Pfu-631545-001 From Pyrococcus furiosus
2P8T	;	1.8	;	Hypothetical protein PH0730 from Pyrococcus horikoshii OT3
4PAU	;	2.0	;	Hypothetical protein SA1058 from S. aureus.
5EUR	;	1.698	;	Hypothetical protein SF216 from shigella flexneri 5a M90T
1MGP	;	2.0	;	Hypothetical protein TM841 from Thermotoga maritima reveals fatty acid binding function
7O97	;	2.0	;	hypothetical protein UY81_C0065G0003 from Candidatus Giovannonibacteria bacterium converted into a canonical coiled coil
7O92	;	2.7	;	hypothetical protein UY81_C0065G0003 residues 18-54 from Candidatus Giovannonibacteria bacterium fused to GCN4 adaptors
1Q6Y	;	1.99	;	Hypothetical protein YfdW from E. coli bound to Coenzyme A
1DBR	;	2.4	;	HYPOXANTHINE GUANINE XANTHINE
1GRV	;	2.9	;	Hypoxanthine Phosphoribosyltransferase from E. coli
1P19	;	2.3	;	Hypoxanthine Phosphoribosyltransferase from Trypanosoma cruzi, in complex with the product IMP
1P17	;	2.7	;	Hypoxanthine Phosphoribosyltransferase from Trypanosoma cruzi, K68R mutant, complexed with the product IMP
1P18	;	2.0	;	Hypoxanthine Phosphoribosyltransferase from Trypanosoma cruzi, K68R mutant, ternary substrates complex
8CAG	;	2.4	;	Hypoxanthine-guanine phosphoribosyltransferase from E. coli
4ZFN	;	1.901	;	Hypoxanthine-guanine-xanthine phosphoribosyltransferase (HGXPRT) from Sulfolobus solfataricus containing GMP complexed in two different ways together with one or two MG2+
4Z1O	;	2.15	;	Hypoxanthine-guanine-xanthine phosphoribosyltransferase (HGXPRT) from Sulfolobus solfataricus in complex with alpha-phosphoribosylpyrophosphoric acid (PRPP) and Magnesium
5BQO	;	2.394	;	Hypoxanthine-guanine-xanthine phosphoribosyltransferase (HGXPRT) from Sulfolobus solfataricus with sulfate bound in the 5-phosphoribosyl binding site.
5BQP	;	1.7	;	Hypoxanthine-guanine-xanthine phosphoribosyltransferase (HGXPRT) from Sulfolobus solfataricus with xanthosine and phosphate bound in the nucleotide binding site and with sulfate bound in the pyrophosphate binding site
1HGX	;	1.9	;	HYPOXANTHINE-GUANINE-XANTHINE PHOSPHORIBOSYLTRANSFERASE (HGXPRTASE)
6NMQ	;	1.58	;	Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase 2 (PHD2) in Complex with the Carboxamide Analog JNJ43058171
1Y1I	;	2.61	;	hyuman formylglycine generating enzyme, reduced form
1PT6	;	1.87	;	I domain from human integrin alpha1-beta1
1QC5	;	2.0	;	I Domain from Integrin Alpha1-Beta1
1AOX	;	2.1	;	I DOMAIN FROM INTEGRIN ALPHA2-BETA1
3V3Z	;	2.9	;	I(L177)H mutant structure of photosynthetic reaction center from Rhodobacter sphaeroides
8EKH	;	2.7	;	I-2 Y35N H35N (unbound) Fab from CH65-CH67 lineage
2P24	;	2.15	;	I-Au/MBP125-135
3B43	;	3.3	;	I-band fragment I65-I70 from titin
2RIK	;	1.6	;	I-band fragment I67-I69 from titin
3OK8	;	2.25	;	I-BAR OF PinkBAR
1CAR	;	3.0	;	I-CARRAGEENAN. MOLECULAR STRUCTURE AND PACKING OF POLYSACCHARIDE DOUBLE HELICES IN ORIENTED FIBRES OF DIVALENT CATION SALTS
1T9I	;	1.6	;	I-CreI(D20N)/DNA complex
1T9J	;	2.0	;	I-CreI(Q47E)/DNA complex
1B24	;	2.2	;	I-DMOI, INTRON-ENCODED ENDONUCLEASE
1IDO	;	1.7	;	I-DOMAIN FROM INTEGRIN CR3, MG2+ BOUND
1JLM	;	2.0	;	I-DOMAIN FROM INTEGRIN CR3, MN2+ BOUND
7U5D	;	3.52	;	I-F3b Cascade-TniQ full R-loop complex
7U5E	;	4.03	;	I-F3b Cascade-TniQ partial R-loop complex
5TJB	;	2.4	;	I-II linker of TRPML1 channel at pH 4.5
5TJA	;	2.3	;	I-II linker of TRPML1 channel at pH 6
5TJC	;	2.4	;	I-II linker of TRPML1 channel at pH 7.5
1NFI	;	2.7	;	I-KAPPA-B-ALPHA/NF-KAPPA-B COMPLEX
7O3T	;	3.1	;	I-layer structure (TrwF/VirB9NTD, TrwE/VirB10NTD) of the outer membrane core complex from the fully-assembled R388 type IV secretion system determined by cryo-EM.
6BCG	;	2.9	;	I-LtrI A28G bound to cognate substrate (pre-cleavage complex)
6BCN	;	2.5	;	I-LtrI E184D bound to cognate substrate (pre-cleavage complex)
6BCT	;	2.73	;	I-LtrI E184D bound to non-cognate C4 substrate (pre-cleavage complex)
6BCH	;	3.0	;	I-LtrI E29D bound to cognate substrate (nicked complex)
6BCF	;	2.92	;	I-LtrI G183A bound to cognate substrate (pre-cleavage complex)
6TQI	;	2.95	;	I-MOTIF STRUCTURE FORMED FROM THE C STRAND OF A HUMAN TELOMERE FRAGMENT
2FLD	;	2.0	;	I-MsoI Re-Designed for Altered DNA Cleavage Specificity
3KO2	;	2.9	;	I-MsoI re-designed for altered DNA cleavage specificity (-7C)
3MIS	;	2.3	;	I-MsoI re-designed for altered DNA cleavage specificity (-8G)
3MIP	;	2.4	;	I-MsoI re-designed for altered DNA cleavage specificity (-8GCG)
6BDB	;	1.5	;	I-OnuI K227Y, D236A bound to A3G substrate (pre-cleavage complex)
6BD0	;	1.45	;	I-OnuI K227Y, D236A bound to cognate substrate (pre-cleavage complex)
7RCG	;	2.368	;	I-OnuI_e-hPD1-f final stage reengineered variant of I-OnuI
1A74	;	2.2	;	I-PPOL HOMING ENDONUCLEASE/DNA COMPLEX
3OOL	;	2.3	;	I-SceI complexed with C/G+4 DNA substrate
3C0W	;	2.2	;	I-SceI in complex with a bottom nicked DNA substrate
3C0X	;	2.3	;	I-SceI in complex with a top nicked DNA substrate
3OOR	;	2.5	;	I-SceI mutant (K86R/G100T)complexed with C/G+4 DNA substrate
5E5O	;	2.36	;	I-SmaMI bound to uncleaved DNA target in the presence of Calcium ions
5E5S	;	2.29	;	I-SmaMI K103A mutant
3SKA	;	1.73	;	I. Novel HCV NS5B Polymerase Inhibitors: Discovery of Indole 2- Carboxylic Acids with C3-Heterocycles
3SKE	;	1.97	;	I. Novel HCV NS5B Polymerase Inhibitors: Discovery of Indole 2- Carboxylic Acids with C3-Heterocycles
3SKH	;	2.5	;	I. Novel HCV NS5B Polymerase Inhibitors: Discovery of Indole 2- Carboxylic Acids with C3-Heterocycles
1G1C	;	2.1	;	I1 DOMAIN FROM TITIN
1UXL	;	1.6	;	I113T mutant of human SOD1
1TS5	;	3.1	;	I140T MUTANT OF TOXIC SHOCK SYNDROME TOXIN-1 FROM S. AUREUS
7LNW	;	2.29	;	I146A mutant of the isopentenyl phosphate kinase from Candidatus methanomethylophilus alvus
7LNX	;	2.3	;	I146A mutant of the isopentenyl phosphate kinase from Candidatus methanomethylophilus alvus
4QHN	;	3.0	;	I2 (unbound) from CH103 Lineage
4HK3	;	3.0	;	I2 Fab (unbound) from CH65-CH67 Lineage
3MPQ	;	2.25	;	I204R1 mutant of LeuT
5CDG	;	1.4	;	I220F horse liver alcohol dehydrogenase complexed with NAD and pentafluorobenzyl alcohol
5CDS	;	1.4	;	I220L horse liver alcohol dehydrogenase complexed with NAD and pentafluorobenzyl alcohol
5CDT	;	1.7	;	I220V horse liver alcohol dehydrogenase complexed with NAD and pentafluorobenzyl alcohol
5CDU	;	1.6	;	I220V horse liver alcohol dehydrogenase complexed with NAD and pyrazole
3PZG	;	1.4	;	I222 crystal form of the hyperthermostable endo-1,4-beta-D-mannanase from Thermotoga petrophila RKU-1
4QHM	;	3.23	;	I3.1 (unbound) from CH103 Lineage
4QHL	;	3.153	;	I3.2 (unbound) from CH103 Lineage
4Y3C	;	3.2	;	I304V 3D polymerase mutant of EMCV
6VPY	;	2.36	;	I33M (I3.2 mutant from CH103 Lineage)
5VP8	;	2.2	;	I38T mutant of 2009 H1N1 PA Endonuclease
5VPX	;	2.303	;	I38T mutant of 2009 H1N1 PA Endonuclease in complex with RO-7
1B0V	;	2.8	;	I40N MUTANT OF AZOTOBACTER VINELANDII FDI
4OX2	;	2.0	;	I45T cytosolic phosphoenolpyruvate carboxykinase in complex with beta-sulfopyruvate and GTP
4AHJ	;	2.032	;	I46V - Angiogenin mutants and amyotrophic lateral sclerosis - a biochemical and biological analysis
6QO0	;	1.65	;	I47W mutated sulfur oxygenase reductase from Acidianus ambivaens
2R43	;	1.58	;	I50V HIV-1 protease in complex with an amino decorated pyrrolidine-based inhibitor
2R3T	;	1.8	;	I50V HIV-1 protease mutant in complex with a carbamoyl decorated pyrrolidine-based inhibitor
7SGE	;	3.67	;	I53-50 nanoparticle core reconstructed from GPC-I53-50NP by focused refinement
1JXB	;	1.6	;	I53A, a point mutant of the cysteine-free variant of E. coli Rnase HI
8UR5	;	3.7	;	I53_dn5 nanoparticle displaying the trimeric HA heads with heptad domain, TH-1heptad-I53_dn5 (local refinement of TH-1heptad)
8UR7	;	3.9	;	I53_dn5 nanoparticle displaying the trimeric HA heads with heptad domain, TH-6heptad-I53_dn5 (local refinement of TH-6heptad)
7ZY1	;	1.434	;	I567A Mutant of Recombinant CODH-II
7ZX6	;	1.447	;	I567L Mutant of Recombinant CODH-II
7ZX5	;	1.544	;	I567T Mutant of Recombinant CODH-II
1IX0	;	1.8	;	I59A-3SS human lysozyme
3SJ5	;	1.673	;	I5F Mutant Structure of T. Tengcongensis H-NOX
7RUL	;		;	I5R8 Mastoparano is a peptide synthetic, modified of Mastoparano (extracted from wasp venom)
7N9D	;	2.1	;	I74A mutant of the isopentenyl phosphate kinase from Candidatus methanomethylophilus alvus
2R3W	;	1.92	;	I84V HIV-1 protease in complex with a amino decorated pyrrolidine-based inhibitor
3BC4	;	1.82	;	I84V HIV-1 protease in complex with a pyrrolidine diester
2R38	;	1.81	;	I84V HIV-1 protease mutant in complex with a carbamoyl decorated pyrrolidine-based inhibitor
2V5U	;	1.99	;	I92A FLAVODOXIN FROM ANABAENA
1Y9K	;	2.39	;	IAA acetyltransferase from Bacillus cereus ATCC 14579
7XXB	;	2.93	;	IAA bound state of AtPIN3
1U0I	;		;	IAAL-E3/K3 heterodimer
6URU	;	2.6	;	iAChSnFR Fluorescent Acetylcholine Sensor precursor
3T6P	;	1.897	;	IAP antagonist-induced conformational change in cIAP1 promotes E3 ligase activation via dimerization
8AZ1	;	3.1	;	IAPP S20G growth-phase fibril polymorph 2PF-C
8AZ0	;	3.4	;	IAPP S20G growth-phase fibril polymorph 2PF-L
8AZ2	;	3.4	;	IAPP S20G growth-phase fibril polymorph 3PF-CU
8AZ3	;	3.4	;	IAPP S20G growth-phase fibril polymorph 4PF-CU
8AWT	;	3.0	;	IAPP S20G lag-phase fibril polymorph 2PF-P
8AZ4	;	2.2	;	IAPP S20G plateau-phase fibril polymorph 2PF-L
8AZ5	;	2.3	;	IAPP S20G plateau-phase fibril polymorph 4PF-CU
8AZ7	;	2.9	;	IAPP S20G plateau-phase fibril polymorph 4PF-LJ
8AZ6	;	3.1	;	IAPP S20G plateau-phase fibril polymorph 4PF-LU
6DCX	;	3.408	;	iASPP-PP-1c structure and targeting of p53
2JMO	;		;	IBR domain of Human Parkin
3EWO	;	1.8	;	IBV Nsp3 ADRP domain
7DB9	;	2.845	;	IC1 in complex with tubulin
6SWD	;	3.2	;	IC2 body model of cryo-EM structure of a full archaeal ribosomal translation initiation complex devoid of aIF1 in P. abyssi
6SWE	;	3.1	;	IC2 head of cryo-EM structure of a full archaeal ribosomal translation initiation complex devoid of aIF1 in P. abyssi
6SW9	;	4.2	;	IC2A model of cryo-EM structure of a full archaeal ribosomal translation initiation complex devoid of aIF1 in P. abyssi
6SWC	;	3.3	;	IC2B model of cryo-EM structure of a full archaeal ribosomal translation initiation complex devoid of aIF1 in P. abyssi
1LVR	;		;	IC3 of CB1 (L431A,A432L) Bound to G(alpha)i
1LVQ	;		;	IC3 of CB1 Bound to G(alpha)i
4DX9	;	2.99	;	ICAP1 in complex with integrin beta 1 cytoplasmic tail
4DX8	;	2.54	;	ICAP1 in complex with KRIT1 N-terminus
1OPS	;	2.0	;	ICE-BINDING SURFACE ON A TYPE III ANTIFREEZE PROTEIN FROM OCEAN POUT
7CUO	;	2.0	;	IclR transcription factor complexed with 4-hydroxybenzoic acid from Microbacterium hydrocarbonoxydans
6ITF	;	4.7	;	Icosahedral asymmetric unit (iASU) model of the less refined, coarse part of FHV eluted particle
6ITB	;	4.7	;	Icosahedral asymmetric unit (iASU) model of the well-refined part of FHV eluted particle
7QOF	;	3.01	;	Icosahedral capsid of the phicrAss001 virion
2WBH	;	4.7	;	Icosahedral particle of covalent coat protein dimer of bacteriophage MS2
6O3H	;	2.8	;	Icosahedral reconstruction of the thermophilic bacteriophage P74-26 capsid
6VOC	;	3.1	;	icosahedral symmetry reconstruction of brome mosaic virus (RNA 3+4)
6IAT	;	3.3	;	Icosahedrally averaged capsid of bacteriophage P68
6IB1	;	3.5	;	Icosahedrally averaged capsid of empty particle of bacteriophage P68
7WWU	;	3.5	;	ICP1 Csy complex
7WKO	;	2.3	;	ICP1 Csy1-2 complex
7WKP	;	2.0	;	ICP1 Csy4
5MHK	;	2.28	;	ICP4 DNA-binding domain in complex with 19mer DNA duplex from its own promoter
5MHJ	;	2.117	;	ICP4 DNA-binding domain, lacking intrinsically disordered region, in complex with 12mer DNA duplex from its own promoter
2M1O	;		;	ID3 stem
3RQD	;	2.143	;	Ideal Thiolate-Zinc Coordination Geometry in Depsipeptide Binding to Histone Deacetylase 8
4XE0	;	2.434	;	Idelalisib bound to the p110 subunit of PI3K delta
1DBP	;	2.2	;	IDENTICAL MUTATIONS AT CORRESPONDING POSITIONS IN TWO HOMOLOGOUS PROTEINS WITH NON-IDENTICAL EFFECTS
6NAD	;	2.90197	;	Identification and biological evaluation of tertiary ALCOHOL-based inverse agonists of RORgt
6CVH	;	3.5	;	Identification and biological evaluation of thiazole-based inverse agonists of RORgt
6JIC	;		;	Identification and Characterization of a carboxypeptidase inhibitor from Lycium barbarum
3HK1	;	1.7	;	Identification and Characterization of a Small Molecule Inhibitor of Fatty Acid Binding Proteins
4RKX	;	1.59	;	Identification and characterization of a small molecule inhibitor of S. pyogenes SpeB.
7QZP	;	1.65	;	Identification and characterization of an RRM-containing, ELAV-like, RNA binding protein in Acinetobacter Baumannii
8JVE	;	1.76	;	Identification and characterization of inhibitors covalently modifying catalytic cysteine of UBE2T and blocking ubiquitin transfer
8JVL	;	2.06	;	Identification and characterization of inhibitors covalently modifying catalytic cysteine of UBE2T and blocking ubiquitin transfer
5CUQ	;	1.696	;	Identification and characterization of novel broad spectrum inhibitors of the flavivirus methyltransferase
1VYA	;	2.05	;	Identification and characterization of the first plant G-quadruplex binding protein encoded by the Zea mays L. nucleoside diphosphate1 gene, ZmNDPK1
2QP3	;	2.6	;	Identification and Characterization of Two Amino Acids Critical for the Substrate Inhibition of SULT2A1
2QP4	;	3.0	;	Identification and Characterization of Two Amino Acids Critical for the Substrate Inhibition of SULT2A1
8Q0T	;	1.8	;	Identification and optimisation of novel inhibitors of the Polyketide synthetase 13 thioesterase domain with antitubercular activity
8Q0U	;	1.8	;	Identification and optimisation of novel inhibitors of the Polyketide synthetase 13 thioesterase domain with antitubercular activity
8Q17	;	1.71	;	Identification and optimisation of novel inhibitors of the Polyketide synthetase 13 thioesterase domain with antitubercular activity
4R1Y	;	2.0	;	Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitor
4R1V	;	1.2	;	Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors
5W4W	;	1.99	;	Identification and Profiling of a Selective and Brain Penetrant Radioligand for In Vivo Target Occupancy Measurement of Casein Kinase 1 (CK1) Inhibitors
2LNW	;		;	Identification and structural basis for a novel interaction between Vav2 and Arap3
1C50	;	2.3	;	IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF A NOVEL ALLOSTERIC BINDING SITE OF GLYCOGEN PHOSPHORYLASE B
5KQB	;		;	Identification and structural characterization of LytU
5KQC	;		;	Identification and structural characterization of LytU
4AJD	;	2.3	;	Identification and structural characterization of PDE10 fragment inhibitors
4AJF	;	1.9	;	Identification and structural characterization of PDE10 fragment inhibitors
4AJG	;	2.3	;	Identification and structural characterization of PDE10 fragment inhibitors
4KFP	;	1.84	;	Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived Ureas as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT)
3ZRK	;	2.37	;	Identification of 2-(4-pyridyl)thienopyridinones as GSK-3beta inhibitors
3ZRL	;	2.48	;	Identification of 2-(4-pyridyl)thienopyridinones as GSK-3beta inhibitors
3ZRM	;	2.49	;	Identification of 2-(4-pyridyl)thienopyridinones as GSK-3beta inhibitors
2C3J	;	2.1	;	Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verification
2C3K	;	2.6	;	Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verification
2C3L	;	2.35	;	Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verification
8EDH	;	3.111	;	Identification of a class of WNK isoform-specific inhibitors through high-throughput screening
1XZO	;	1.702	;	Identification of a disulfide switch in BsSco, a member of the Sco family of cytochrome c oxidase assembly proteins
6GZV	;	4.0	;	Identification of a druggable VP1-VP3 interprotomer pocket in the capsid of enteroviruses
3SD0	;	2.7	;	Identification of a Glycogen Synthase Kinase-3b Inhibitor that Attenuates Hyperactivity in CLOCK Mutant Mice
5U7Q	;	3.15	;	Identification of A New Class of Potent Cdc7 Inhibitors Designed by Putative Pharmacophore Model: Synthesis and Biological Evaluation of 2,3-Dihydrothieno[3,2-d]pyrimidin-4(1H)-ones
5U7R	;	3.33	;	Identification of A New Class of Potent Cdc7 Inhibitors Designed by Putative Pharmacophore Model: Synthesis and Biological Evaluation of 2,3-Dihydrothieno[3,2-d]pyrimidin-4(1H)-ones
5DUI	;	2.306	;	Identification of a new FoxO1 binding site that precludes CREB binding at the glucose-6-phosphatase catalytic subunit gene promoter
5TY1	;	1.6	;	Identification of a New Zinc Binding Chemotype by Fragment Screening
5TY8	;	1.45	;	Identification of a New Zinc Binding Chemotype by Fragment Screening
5TY9	;	1.53	;	Identification of a New Zinc Binding Chemotype by Fragment Screening
5TYA	;	1.5	;	Identification of a New Zinc Binding Chemotype by Fragment Screening
5U0D	;	1.59	;	Identification of a New Zinc Binding Chemotype by Fragment Screening
5U0E	;	1.27	;	Identification of a New Zinc Binding Chemotype by Fragment Screening
5U0F	;	1.21	;	Identification of a New Zinc Binding Chemotype by Fragment Screening
5U0G	;	1.54	;	Identification of a New Zinc Binding Chemotype by Fragment Screening
5VGY	;	1.39	;	Identification of a New Zinc Binding Chemotype by Fragment Screening
5TXY	;	1.206	;	Identification of a New Zinc Binding Chemotype of by Fragment Screening on human carbonic anhydrase
5C4O	;	2.24	;	Identification of a Novel Allosteric Binding Site for RORgt Inhibitors
5C4S	;	2.23	;	Identification of a Novel Allosteric Binding Site for RORgt Inhibitors
5C4T	;	1.77	;	Identification of a Novel Allosteric Binding Site for RORgt Inhibitors
5C4U	;	2.08	;	Identification of a Novel Allosteric Binding Site for RORgt Inhibitors
4WVD	;	2.9	;	Identification of a novel FXR ligand that regulates metabolism
2ESF	;	2.25	;	Identification of a Novel Non-Catalytic Bicarbonate Binding Site in Eubacterial beta-Carbonic Anhydrase
4Y29	;	1.98	;	Identification of a novel PPARg ligand that regulates metabolism
2QVD	;	1.93	;	Identification of a potent anti-inflammatory agent from the natural extract of plant Cardiospermun helicacabum: Crystal structure of the complex of phospholipase A2 with Benzo(g)-1,3-benzodioxolo(5,6-a)quinolizinium, 5,6-dihydro-9,10-dimethoxy at 1.93 A resolution
1UNS	;	2.0	;	IDENTIFICATION OF A SECONDARY ZINC-BINDING SITE IN STAPHYLOCOCCAL ENTEROTOXIN C2: IMPLICATIONS FOR SUPERANTIGEN RECOGNITION
5YJ8	;	1.762	;	Identification of a small molecule inhibitor for the Tudor domain of TDRD3
4FGY	;	2.84	;	Identification of a unique PPAR ligand with an unexpected binding mode and antibetic activity
4M6P	;	1.75	;	Identification of Amides Derived From 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT)
4M6Q	;	2.406	;	Identification of Amides Derived From 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT)
3Q37	;	1.65	;	Identification of Amino Acids that Account for Long-Range Interactions in Proteins Using Two Triosephosphate Isomerases from Pathogenic Trypanosomes.
5WAL	;	2.45	;	Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model
5WEV	;	1.854	;	Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model
8F5N	;	1.9	;	Identification of an Immunodominant region on a Group A Streptococcus T-antigen Reveals Temperature-Dependent Motion in Pili
8F70	;	2.29	;	Identification of an Immunodominant region on a Group A Streptococcus T-antigen Reveals Temperature-Dependent Motion in Pili
8C12	;	1.549	;	Identification of an intermediate activation state of PAK5 reveals a novel mechanism of kinase inhibition.
3FXV	;	2.26	;	Identification of an N-oxide pyridine GW4064 analogue as a potent FXR agonist
6BN6	;	2.4	;	IDENTIFICATION OF BICYCLIC HEXAFLUOROISOPROPYL ALCOHOL SULFONAMIDES AS RORGT/RORC INVERSE AGONISTS
1AY0	;	2.6	;	IDENTIFICATION OF CATALYTICALLY IMPORTANT RESIDUES IN YEAST TRANSKETOLASE
2CGU	;	2.5	;	Identification of chemically diverse Chk1 inhibitors by receptor- based virtual screening
2CGV	;	2.6	;	Identification of chemically diverse Chk1 inhibitors by receptor- based virtual screening
2CGW	;	2.2	;	Identification of chemically diverse Chk1 inhibitors by receptor- based virtual screening
2CGX	;	2.2	;	Identification of chemically diverse Chk1 inhibitors by receptor- based virtual screening
4H6J	;	1.52	;	Identification of Cys 255 in HIF-1 as a novel site for development of covalent inhibitors of HIF-1 /ARNT PasB domain protein-protein interaction.
3DWK	;	3.1	;	Identification of Dynamic Structural Motifs Involved in Peptidoglycan Glycosyltransfer
4HRW	;	2.43	;	Identification of function and Mechanistic insights of Guanine deaminase from Nitrosomonas europaea
4HRQ	;	1.9	;	Identification of Function and Mechanistic Insights of Guanine Deaminase from Nitrosomonas europaea: Role of the C-terminal Loop in Catalysis
8T6D	;	2.4	;	Identification of GDC-1971 (RLY-1971), a SHP2 inhibitor designed for the treatment of solid tumors
8T6G	;	1.84	;	Identification of GDC-1971 (RLY-1971), a SHP2 inhibitor designed for the treatment of solid tumors
8T7Q	;	2.1	;	Identification of GDC-1971 (RLY-1971), a SHP2 inhibitor designed for the treatment of solid tumors
8T8Q	;	2.27	;	Identification of GDC-1971 (RLY-1971), a SHP2 inhibitor designed for the treatment of solid tumors
1YNK	;	2.1	;	Identification of Key residues of the NC6.8 Fab antibody fragment binding to synthetic sweeteners: Crystal structure of NC6.8 co-crystalized with high potency sweetener compound SC45647
1YNL	;	1.7	;	Identification of Key residues of the NC6.8 Fab antibody fragment binding to synthetic sweeterners: Crystal structure of NC6.8 co-crystalized with high potency sweetener compound SC45647
1C04	;	5.0	;	IDENTIFICATION OF KNOWN PROTEIN AND RNA STRUCTURES IN A 5 A MAP OF THE LARGE RIBOSOMAL SUBUNIT FROM HALOARCULA MARISMORTUI
7P2G	;	2.5	;	Identification of low micromolar SARS-CoV-2 Mpro inhibitors from hits identified by in silico screens
5HJP	;	2.6	;	Identification of LXRbeta selective agonists for the treatment of Alzheimer's Disease
5HJS	;	1.72	;	Identification of LXRbeta selective agonists for the treatment of Alzheimer's Disease
7ZW8	;	2.119	;	Identification of M4205 a highly selective inhibitor of cKIT mutations for unresectable metastatic or recurrent GIST
7ZY6	;	3.09	;	Identification of M4205 a highly selective inhibitor of cKIT mutations for unresectable metastatic or recurrent GIST
5DWR	;	2.0	;	Identification of N-(4-((1R,3S,5S)-3-amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1,2 and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies
2VTJ	;	2.2	;	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design
2VTL	;	2.0	;	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design
2VTR	;	1.89	;	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design
2VTA	;	2.0	;	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design.
2VTI	;	2.0	;	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design.
2VTM	;	2.25	;	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design.
2VTN	;	2.2	;	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design.
2VTO	;	2.19	;	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design.
2VTP	;	2.15	;	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design.
2VTQ	;	1.9	;	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design.
2VTS	;	1.9	;	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design.
2VTT	;	1.68	;	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design.
2VU3	;	1.85	;	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design.
2VTH	;	1.9	;	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design
2WRM	;	1.95	;	Identification of Novel Allosteric Inhibitors of Hepatitis C Virus NS5B Polymerase Thumb Domain (Site II) by Structure-Based Design
4O09	;	1.96	;	Identification of novel HSP90 / isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington s disease
4O04	;	1.82	;	Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease
4O05	;	1.79	;	Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease
4O07	;	1.86	;	Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease
4O0B	;	1.93	;	Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease
1WBS	;	1.8	;	Identification of novel p38 alpha MAP Kinase inhibitors using fragment-based lead generation.
1WBT	;	2.0	;	Identification of novel p38 alpha MAP Kinase inhibitors using fragment-based lead generation.
1WBV	;	2.0	;	Identification of novel p38 alpha MAP Kinase inhibitors using fragment-based lead generation.
1WBW	;	2.41	;	Identification of novel p38 alpha MAP Kinase inhibitors using fragment-based lead generation.
1S17	;	1.95	;	Identification of Novel Potent Bicyclic Peptide Deformylase Inhibitors
5DLS	;	2.15	;	Identification of Novel, in vivo Active Chk1 Inhibitors Utilizing Structure Guided Drug Design
6N3L	;	2.61	;	Identification of novel, potent and selective GCN2 inhibitors as first-in-class anti-tumor agents
6N3N	;	3.01	;	Identification of novel, potent and selective GCN2 inhibitors as first-in-class anti-tumor agents
6N3O	;	2.4	;	Identification of novel, potent and selective GCN2 inhibitors as first-in-class anti-tumor agents
5W5J	;	2.85	;	Identification of potent and selective RIPK2 inhibitors for the treatment of inflammatory diseases
5W5O	;	2.89	;	Identification of potent and selective RIPK2 inhibitors for the treatment of inflammatory diseases.
1Y1N	;	1.51	;	Identification of SH3 motif in M. Tuberculosis methionine aminopeptidase suggests a mode of interaction with the ribosome
4BV5	;	2.1	;	Identification of small molecule inhibitors selective for apo(a) kringles KIV-7, KIV-10 and KV.
4BV7	;	1.7	;	Identification of small molecule inhibitors selective for apo(a) kringles KIV-7, KIV-10 and KV.
4BVC	;	1.6	;	Identification of small molecule inhibitors selective for apo(a) kringles KIV-7, KIV-10 and KV.
4BVD	;	1.68	;	Identification of small molecule inhibitors selective for apo(a) kringles KIV-7, KIV-10 and KV.
4BVV	;	1.8	;	Identification of small molecule inhibitors selective for apo(a) kringles KIV-7, KIV-10 and KV.
4BVW	;	2.0	;	Identification of small molecule inhibitors selective for apo(a) kringles KIV-7, KIV-10 and KV.
8JUC	;	1.54	;	Identification of small-molecule binding sites of a ubiquitin-conjugating enzyme-UBE2T through fragment-based screening
8JVD	;	1.696	;	Identification of small-molecule binding sites of a ubiquitin-conjugating enzyme-UBE2T through fragment-based screening
5HCV	;	2.5	;	Identification of Spirooxindole and Dibenzoxazepine Motifs as Potent Mineralocorticoid Receptor Antagonists
4FKD	;	1.633	;	Identification of the Activator Binding Residues in the Second Cysteine-Rich Regulatory Domain of Protein Kinase C Theta
3J6Q	;	3.8	;	Identification of the active sites in the methyltransferases of a transcribing dsRNA virus
6USX	;	2.27	;	Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer
6USZ	;	2.03	;	Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer
6UT0	;	1.94	;	Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer
5Z9I	;	2.199	;	Identification of the functions of unusual cytochrome p450-like monooxygenases involved in microbial secondary metablism
5Z9J	;	2.0	;	Identification of the functions of unusual cytochrome p450-like monooxygenases involved in microbial secondary metablism
2WKK	;	1.5	;	Identification of the glycan target of the nematotoxic fungal galectin CGL2 in Caenorhabditis elegans
2LFN	;		;	Identification of the key regions that drive functional amyloid formation by the fungal hydrophobin EAS
4ZGS	;	2.461	;	Identification of the pyruvate reductase of Chlamydomonas reinhardtii
1SMN	;	2.04	;	IDENTIFICATION OF THE SERRATIA ENDONUCLEASE DIMER: STRUCTURAL BASIS AND IMPLICATIONS FOR CATALYSIS
2LXO	;		;	Identification of the Structural Traits Mediating the Antimicrobial Activity of a Chimeric Peptide of HBD2 and HBD3
2UX1	;	1.8	;	Identification of two zinc-binding sites in the Streptococcus suis Dpr protein
2FZ0	;		;	Identification of yeast R-SNARE Nyv1p as a novel longin domain protein
3K5U	;	2.35	;	Identification, SAR Studies and X-ray Cocrystal Analysis of a Novel Furano-pyrimidine Aurora Kinase A Inhibitor
3HDZ	;	1.8	;	Identification, Synthesis, and SAR of Amino Substituted Pyrido[3,2b]pryaziones as Potent and Selective PDE5 Inhibitors
6QJZ	;	2.7	;	Identificationand Characterization of an Oxalylfrom Grass pea (Lathyrus sativusCoA-Synthetase L.)
4LBV	;	2.03	;	Identifying ligand binding hot spots in proteins using brominated fragments
4LBW	;	1.741	;	Identifying ligand binding hot spots in proteins using brominated fragments
4LBY	;	2.692	;	Identifying ligand binding hot spots in proteins using brominated fragments
4LBZ	;	2.223	;	Identifying ligand binding hot spots in proteins using brominated fragments
4LC0	;	2.221	;	Identifying ligand binding hot spots in proteins using brominated fragments
1CYF	;	2.35	;	IDENTIFYING THE PHYSIOLOGICAL ELECTRON TRANSFER SITE OF CYTOCHROME C PEROXIDASE BY STRUCTURE-BASED ENGINEERING
8A47	;	2.338	;	IdeS in complex with IgG1 Fc
4UMX	;	1.88	;	IDH1 R132H in complex with cpd 1
4UMY	;	2.07	;	IDH1 R132H in complex with cpd 1
5SVF	;	2.34	;	IDH1 R132H in complex with IDH125
5SUN	;	2.477	;	IDH1 R132H in complex with IDH146
6B0Z	;	2.334	;	IDH1 R132H mutant in complex with IDH305
5TQH	;	2.2	;	IDH1 R132H mutant in complex with IDH889
1CIC	;	2.5	;	IDIOTOPE-ANTI-IDIOTOPE FAB-FAB COMPLEX; D1.3-E225
1DVF	;	1.9	;	IDIOTOPIC ANTIBODY D1.3 FV FRAGMENT-ANTIIDIOTOPIC ANTIBODY E5.2 FV FRAGMENT COMPLEX
1IAI	;	2.9	;	IDIOTYPE-ANTI-IDIOTYPE FAB COMPLEX
6V52	;	1.78	;	IDO1 IN COMPLEX WITH COMPOUND 1
7RRC	;	2.18	;	IDO1 IN COMPLEX WITH COMPOUND 14
6X5Y	;	2.65	;	IDO1 in complex with compound 4
7RRB	;	2.69	;	IDO1 IN COMPLEX WITH COMPOUND 9
7RRD	;	2.76	;	IDO1 IN COMPLEX WITH COMPOUND S-1
6AZV	;	2.755	;	IDO1/BMS-978587 crystal structure
6AZW	;	2.78	;	IDO1/FXB-001116 crystal structure
6QLZ	;	2.343	;	IDOL F3ab subdomain
6QLY	;	2.5	;	IDOL FERM domain
6N4M	;	1.58	;	IDS-oxidized ADP-bound form of the nitrogenase Fe-protein from A. vinelandii
6TGZ	;	3.2	;	IE1 from human cytomegalovirus
6TH1	;	3.4	;	IE1 from rat cytomegalovirus
7ZD5	;	3.17	;	IF(apo/as isolated) conformation of CydDC (Dataset-1)
7ZDE	;	3.17	;	IF(apo/as isolated) conformation of CydDC in AMP-PNP(CydD) bound state (Dataset-4)
7ZDS	;	3.26	;	IF(apo/as isolated) conformation of CydDC mutant (E500Q.C) (Dataset-18)
7ZDV	;	3.05	;	IF(apo/as isolated) conformation of CydDC mutant (E500Q.C) in AMP-PNP(CydD) bound state (Dataset-20)
7ZDR	;	3.05	;	IF(apo/as isolated) conformation of CydDC mutant (H85A.C) in AMP-PNP(CydD) bound state (Dataset-16)
7ZDA	;	3.17	;	IF(apo/asym) conformation of CydDC in ADP+Pi(CydC)/ATP(CydD) bound state (Dataset-2)
7ZDK	;	3.01	;	IF(apo/asym) conformation of CydDC in AMP-PNP(CydC)/AMP-PNP(CydD) bound state (Dataset-8)
7ZDB	;	3.35	;	IF(heme/bound) conformation of CydDC in ADP+Pi(CydC)/ATP(CydD) bound state (Dataset-2)
7ZDG	;	2.77	;	IF(heme/confined) conformation of CydDC (Dataset-5)
7ZDC	;	3.13	;	IF(heme/confined) conformation of CydDC in ADP(CydD) bound state (Dataset-3)
7ZDF	;	2.94	;	IF(heme/confined) conformation of CydDC in AMP-PNP(CydD) bound state (Dataset-4)
7ZEC	;	3.05	;	IF(heme/confined) conformation of CydDC in ATP(CydD) bound state (Dataset-15)
7ZDW	;	3.35	;	IF(heme/confined) conformation of CydDC mutant (E500Q.C) in AMP-PNP(CydD) bound state (Dataset-22)
7ZDL	;	3.35	;	IF(heme/coordinated) conformation of CydDC in AMP-PNP(CydC)/AMP-PNP(CydD) bound state (Dataset-8)
1ZO1	;	13.8	;	IF2, IF1, and tRNA fitted to cryo-EM data OF E. COLI 70S initiation complex
2LKD	;		;	IF2-G2 GDP complex
5UDJ	;	1.69	;	IFIT1 monomeric mutant (L457E/L464E) with Gppp-AAAA
5UDI	;	1.58	;	IFIT1 monomeric mutant (L457E/L464E) with m7Gppp-AAAA (syn and anti conformations of cap)
5UDK	;	1.65	;	IFIT1 monomeric mutant (L457E/L464E) with PPP-AAAA
5UDL	;	1.65	;	IFIT1 N216A monomeric mutant (L457E/L464E) with m7Gppp-AAAA (anti conformation of cap)
4R0P	;	1.52	;	Ifqins, an amyloid forming segment from human lysozyme spanning residues 56-61
8BDA	;	20.7	;	IFTA complex in anterograde intraflagellar transport trains (Chlamydomonas reinhardtii)
8BD7	;	9.9	;	IFTB1 subcomplex of anterograde Intraflagellar transport trains (Chlamydomonas reinhardtii)
1WAA	;	1.8	;	IG27 protein domain
2N56	;		;	Ig59 domain of human obscurin A
6XJB	;	3.8	;	IgA1 Protease
6OH1	;		;	IgA1 Protease G5 domain structure
7JGJ	;	4.8	;	IgA1 Protease in complex with neutralizing mAb
7UVL	;	3.56	;	IgA1 Protease with IgA1 substrate
6DGV	;	2.8	;	iGABASnFR Fluorescent GABA Sensor precursor
6C6M	;	2.5	;	IgCam3 of human MLCK1
1OAZ	;	2.78	;	IgE Fv SPE7 complexed with a recombinant thioredoxin
7SI0	;	3.0	;	IgE-Fc in complex with 813
7MXI	;	2.8	;	IgE-Fc in complex with DARPins E2_79 and E3_53
7SHZ	;	3.0	;	IgE-Fc in complex with HAE
7SHY	;	3.0	;	IgE-Fc in complex with omalizumab scFv
7SHU	;	2.75	;	IgE-Fc in complex with omalizumab variant C02
5NQW	;	3.4	;	IgE-Fc in complex with single domain antibody 026
1JQH	;	2.1	;	IGF-1 receptor kinase domain
3LW0	;	1.79	;	IGF-1RK in complex with ligand MSC1609119A-1
1LB7	;		;	IGF-F1-1, A PEPTIDE ANTAGONIST OF IGF-1
5FXQ	;	2.3	;	IGFR-1R complex with a pyrimidine inhibitor.
5FXR	;	2.4	;	IGFR-1R complex with a pyrimidine inhibitor.
5FXS	;	1.9	;	IGFR-1R complex with a pyrimidine inhibitor.
1CLY	;	2.5	;	IGG FAB (HUMAN IGG1, KAPPA) CHIMERIC FRAGMENT (CBR96) COMPLEXED WITH LEWIS Y NONOATE METHYL ESTER
1CLZ	;	2.8	;	IGG FAB (IGG3, KAPPA) FRAGMENT (MBR96) COMPLEXED WITH LEWIS Y NONOATE METHYL ESTER
1MIM	;	2.6	;	IGG FAB FRAGMENT (CD25-BINDING)
5U4Y	;	2.4994	;	IgG Fc bound to 3 helix of the B-domain from Protein A
1AD9	;	2.8	;	IGG-FAB FRAGMENT OF ENGINEERED HUMAN MONOCLONAL ANTIBODY CTM01
1AE6	;	3.0	;	IGG-FAB FRAGMENT OF MOUSE MONOCLONAL ANTIBODY CTM01
3FZU	;	2.5	;	IgG1 Fab characterized by H/D exchange
3F58	;	2.8	;	IGG1 FAB FRAGMENT (58.2) COMPLEX WITH 12-RESIDUE CYCLIC PEPTIDE (INCLUDING RESIDUES 315-324 OF HIV-1 GP120 (MN ISOLATE); H315S MUTATION
2F58	;	2.8	;	IGG1 FAB FRAGMENT (58.2) COMPLEX WITH 12-RESIDUE CYCLIC PEPTIDE (INCLUDING RESIDUES 315-324 OF HIV-1 GP120) (MN ISOLATE)
1F58	;	2.0	;	IGG1 FAB FRAGMENT (58.2) COMPLEX WITH 24-RESIDUE PEPTIDE (RESIDUES 308-333 OF HIV-1 GP120 (MN ISOLATE) WITH ALA TO AIB SUBSTITUTION AT POSITION 323
1NAK	;	2.57	;	IGG1 FAB FRAGMENT (83.1) COMPLEX WITH 16-RESIDUE PEPTIDE (RESIDUES 304-321 OF HIV-1 GP120 (MN ISOLATE))
1IGC	;	2.6	;	IGG1 FAB FRAGMENT (MOPC21) COMPLEX WITH DOMAIN III OF PROTEIN G FROM STREPTOCOCCUS
1WEJ	;	1.8	;	IGG1 FAB FRAGMENT (OF E8 ANTIBODY) COMPLEXED WITH HORSE CYTOCHROME C AT 1.8 A RESOLUTION
4ZNE	;	2.42	;	IgG1 Fc-FcgammaRI ecd complex
7LUS	;	2.45	;	IgG2 Fc Charge Pair Mutation version 1 (CPMv1)
5AMU	;	2.2	;	IglE I39A,Y40A,V44A
8E4C	;	4.0	;	IgM BCR fab truncated form
4JVU	;	1.3	;	IgM C2-domain from mouse
4JVW	;	2.0	;	IgM C4-domain from mouse
8GZN	;	3.6	;	IgM-var2CSA complex
4Q97	;	2.4	;	IgNAR antibody domain C1
4Q9B	;	1.5	;	IgNAR antibody domain C2
4Q9C	;	2.8	;	IgNAR antibody domain C3
7OSK	;	2.65	;	Ignisphaera aggregans GH53 catalytic domain
6Y88	;	2.09983	;	IGPS (Indole-3-glycerol phosphate synthase) from Pseudomonas aeruginosa in complex with substrate inhibitor rCdRP
6NM8	;	2.792	;	IgV-V76T BMS compound 105
2HT0	;	2.0	;	IHF bound to doubly nicked DNA
2F3G	;	2.13	;	IIAGLC CRYSTAL FORM III
1F3Z	;	1.98	;	IIAGLC-ZN COMPLEX
3NVF	;	1.8	;	IIHFGS segment 138-143 from human prion
8Q1B	;	3.4	;	III2-IV1 respiratory supercomplex from S. pombe
6HU9	;	3.35	;	III2-IV2 mitochondrial respiratory supercomplex from S. cerevisiae
7Q21	;	2.9	;	III2-IV2 respiratory supercomplex from Corynebacterium glutamicum
8EC0	;	3.3	;	III2IV respiratory supercomplex from Saccharomyces cerevisiae cardiolipin-lacking mutant
8E7S	;	3.2	;	III2IV2 respiratory supercomplex from Saccharomyces cerevisiae with 4 bound UQ6
7CS3	;	2.40022	;	IiPLR1 with NADP+
7CS4	;	2.30509	;	IiPLR1 with NADP+ and (+)pinoresinol
7CS7	;	2.29765	;	IiPLR1 with NADP+ and (+)secoisolariciresinol
7CS6	;	2.2014	;	IiPLR1 with NADP+ and (-)lariciresinol
7CS5	;	2.18993	;	IiPLR1 with NADP+ and (-)pinoresinol
7CS8	;	2.60003	;	IiPLR1 with NADP+ and (-)secoisolariciresinol
1IKN	;	2.3	;	IKAPPABALPHA/NF-KAPPAB COMPLEX
1G0Y	;	3.0	;	IL-1 RECEPTOR TYPE 1 COMPLEXED WITH ANTAGONIST PEPTIDE AF10847
8PPM	;	2.03	;	IL-12Rb1 neutralizing Fab4, crystal kappa variant
5VB9	;	1.7	;	IL-17A in complex with peptide
7AMA	;	2.48	;	IL-17A in complex with small molecule modulators
7AMG	;	3.18	;	IL-17A in complex with small molecule modulators
7WKX	;	2.81	;	IL-17A in complex with the humanized antibody HB0017
4R6U	;	2.8	;	IL-18 receptor complex
7FCH	;	1.883	;	IL-18Rbeta TIR domain
7FCC	;	2.144	;	IL-1RAcPb TIR domain
7FD3	;	2.99	;	IL-1RAPL2 TIR domain
6YE3	;	2.89	;	IL-2 in complex with a Fab fragment from UFKA-20
3QAZ	;	3.802	;	IL-2 mutant D10 ternary complex
3TGX	;	2.8	;	IL-21:IL21R complex
6WEO	;	2.6	;	IL-22 Signaling Complex with IL-22R1 and IL-10Rbeta
5MZV	;	2.8	;	IL-23:IL-23R:Nb22E11 complex
7U7N	;	3.47	;	IL-27 quaternary receptor signaling complex
7Z0L	;	4.0	;	IL-27 signalling complex
5VI4	;	2.792	;	IL-33/ST2/IL-1RAcP ternary complex structure
6N2U	;	1.254	;	IL-8 Structure from Bacterial Expression Source
5L6Y	;	1.99	;	il13 in complex with tralokinumab
8USS	;	1.47	;	IL17A complexed to Compound 7
8DYF	;	2.02	;	IL17A homodimer bound to Compound 10
8DYI	;	2.28	;	IL17A homodimer bound to Compound 5
8DYH	;	1.94	;	IL17A homodimer bound to Compound 6
8DYG	;	1.49	;	IL17A homodimer bound to Compound 7
8USR	;	1.83	;	IL17A homodimer complexed to Compound 23
4DOH	;	2.8	;	IL20/IL201/IL20R2 Ternary Complex
6WDQ	;	3.4	;	IL23/IL23R/IL12Rb1 signaling complex
6U6U	;	2.31	;	IL36R extracellular domain in complex with BI655130 Fab
7OPB	;	2.144	;	IL7R in complex with an antagonist
3ZJM	;	1.5	;	Ile(149)G11Phe mutation of M.acetivorans protoglobin in complex with cyanide
1JPH	;	2.1	;	Ile260Thr mutant of Human UroD, human uroporphyrinogen III decarboxylase
1EIO	;		;	ILEAL LIPID BINDING PROTEIN IN COMPLEX WITH GLYCOCHOLATE
7D5C	;	1.895	;	IleRS in complex with a tRNA site inhibitor
6L2S	;	2.29	;	IlvC, a ketol-acid reductoisomerase, from Streptococcus pneumoniae_D83G
6L2R	;	2.02	;	IlvC, a ketol-acid reductoisomerase, from Streptococcus pneumoniae_E195S
6L2K	;	1.95	;	IlvC, a ketol-acid reductoisomerase, from Streptococcus pneumoniae_R49E
6L2I	;	1.69	;	IlvC, a ketol-acid reductoisomerase, from Streptococcus pneumoniae_WT
6L2Z	;	2.02	;	IlvC, a ketol-acid reductoisomerase, from Streptococcus pnuemoniae_D191G
1IR7	;	1.9	;	IM mutant of lysozyme
1IR8	;	1.63	;	IM mutant of lysozyme
1IR9	;	1.9	;	IM mutant of lysozyme
5OE1	;		;	Im polyamide in complex with 5'CGATGTACATCG3'- hairpin polyamides studies
3VHB	;	2.1	;	IMIDAZOLE ADDUCT OF THE BACTERIAL HEMOGLOBIN FROM VITREOSCILLA SP.
1NI1	;	2.3	;	Imidazole and cyanophenyl farnesyl transferase inhibitors
1KA9	;	2.3	;	Imidazole Glycerol Phosphate Synthase
6YMU	;	2.11	;	Imidazole Glycerol Phosphate Synthase
6RIO	;		;	Imidazole Polyamide-DNA complex NMR structure (5'-CGATGTACATCG-3')
6U9L	;	1.7	;	Imidazole-triggered RAS-specific subtilisin SUBT_BACAM
6UAO	;	1.63	;	Imidazole-triggered RAS-specific subtilisin SUBT_BACAM complexed with the peptide EEYSAM
6UAI	;	1.2	;	Imidazole-triggered RAS-specific subtilisin SUBT_BACAM complexed with YSAM peptide
6EZJ	;	3.1	;	Imidazoleglycerol-phosphate dehydratase
6EZM	;	3.2	;	Imidazoleglycerol-phosphate dehydratase from Saccharomyces cerevisiae
1OIQ	;	2.31	;	Imidazopyridines: a potent and selective class of Cyclin-dependent Kinase inhibitors identified through Structure-based hybridisation
1OIR	;	1.91	;	Imidazopyridines: a potent and selective class of Cyclin-dependent Kinase inhibitors identified through Structure-based hybridisation
1OIT	;	1.6	;	Imidazopyridines: a potent and selective class of Cyclin-dependent Kinase inhibitors identified through Structure-based hybridisation
3NRM	;	3.05	;	Imidazo[1,2-a]pyrazine-based Aurora Kinase Inhibitors
8OZW	;	2.01	;	Imine Reductase from Ajellomyces dermatitidis in complex NADPH4
8OZV	;	1.52	;	Imine Reductase from Ajellomyces dermatitidis in complex with 2,2-difluoroacetophenone
8P2J	;	1.73	;	Imine Reductase from Ajellomyces dermatitidis in space group C21
5A9T	;	1.5	;	Imine Reductase from Amycolatopsis orientalis in complex with (R)- Methyltetrahydroisoquinoline
5FWN	;	2.14	;	Imine Reductase from Amycolatopsis orientalis. Closed form in in complex with (R)- Methyltetrahydroisoquinoline
5G6R	;	1.82	;	Imine reductase from Aspergillus oryzae
5G6S	;	2.35	;	Imine reductase from Aspergillus oryzae in complex with NADP(H) and (R)-rasagiline
5OJL	;	1.56	;	Imine Reductase from Aspergillus terreus in complex with NADPH4 and dibenz[c,e]azepine
8A5Z	;	2.31	;	Imine Reductase from Ensifer adhaerens A208N mutant in complex with NADP+
8A3X	;	2.58	;	Imine Reductase from Ensifer adhaerens in complex with NADP+
6TO4	;	2.29	;	Imine Reductase from Myxococcus stipitatus in complex with NADP+
6TOE	;	2.78	;	Imine Reductase from Myxococcus stipitatus V8 variant in complex with NAD+
4D3S	;	2.24	;	Imine reductase from Nocardiopsis halophila
5OCM	;	1.81	;	Imine Reductase from Streptosporangium roseum in complex with NADP+ and 2,2,2-trifluoroacetophenone hydrate
8BJ5	;	2.72	;	Imine Reductase IR007 from Amycolatopsis azurea
3Q81	;	2.0	;	Imipenem acylated BlaR1 sensor domain from Staphylococcus aureus
4H8R	;	1.25	;	Imipenem complex of GES-5 carbapenemase
5F83	;	1.38	;	Imipenem complex of the GES-5 C69G mutant
7T7G	;	2.5	;	Imipenem-OXA-23 2 minute complex
6FMW	;	2.6	;	IMISX-EP of Hg-BacA cocrystallization
6FMT	;	3.0	;	IMISX-EP of Hg-BacA Soaking SAD
6FMV	;	2.3	;	IMISX-EP of Hg-BacA soaking SIRAS
6FMY	;	2.7	;	IMISX-EP of S-PepTSt
6FMS	;	3.0	;	IMISX-EP of Se-LspA
6FMR	;	2.7	;	IMISX-EP of Se-PepTSt
6FMX	;	1.79	;	IMISX-EP of W-PgpB
5I4T	;	3.273	;	Immature hexagonal lattice of HIV-1 Gag
7R7P	;		;	Immature HIV-1 CACTD-SP1 lattice with Bevirimat (BVM) and Inositol hexakisphosphate (IP6)
7R7Q	;		;	Immature HIV-1 CACTD-SP1 lattice with Inositol hexakisphosphate (IP6)
7OVQ	;	7.2	;	Immature HIV-1 matrix structure
6HWI	;	7.2	;	Immature M-PMV capsid hexamer structure in intact virus particles
6HWW	;	6.6	;	Immature MLV capsid hexamer structure in intact virus particles
4WIC	;	2.85	;	Immediate-early 1 protein (IE1) of rhesus macaque cytomegalovirus
1SLS	;		;	IMMOBILE SLIPPED-LOOP STRUCTURE (SLS) OF DNA HOMODIMER IN SOLUTION, NMR, 9 STRUCTURES
4JC5	;	2.75	;	Immune activator bound to receptor
4Y19	;	2.5	;	immune complex
4Y1A	;	4.0	;	immune complex
7FAH	;	3.151	;	Immune complex of head region of CA09 HA and neutralizing antibody 12H5
7EW5	;	3.606	;	immune complex of HPV6 L1 pentamer and neutralizing antibody 13H5
7EAN	;	1.91	;	immune complex of SARS-CoV-2 RBD and cross-neutralizing antibody 6D6
7EAM	;	1.4	;	immune complex of SARS-CoV-2 RBD and cross-neutralizing antibody 7D6
5UZU	;	2.403	;	Immune evasion by a Staphylococcal Peroxidase Inhibitor that blocks myeloperoxidase
1KGC	;	1.5	;	Immune Receptor
1YPZ	;	3.4	;	Immune receptor
4GG8	;	3.2	;	Immune Receptor
4MCY	;	2.3	;	Immune Receptor
4MCZ	;	2.41	;	Immune Receptor
4MD0	;	2.194	;	Immune Receptor
4MD4	;	1.95	;	Immune Receptor
4MD5	;	1.65	;	Immune Receptor
4MDI	;	2.0	;	Immune Receptor
4MDJ	;	1.7	;	Immune Receptor
6V0Y	;	2.7	;	immune receptor complex
6V13	;	2.75	;	immune receptor complex
6V15	;	2.8	;	immune receptor complex
6V18	;	2.35	;	immune receptor complex
6V19	;	2.6	;	immune receptor complex
6V1A	;	2.29	;	immune receptor complex
6XC9	;	2.4	;	Immune receptor complex
6XCO	;	2.9	;	Immune receptor complex
6XCP	;	3.3	;	Immune receptor complex
1AXT	;	2.15	;	IMMUNE VERSUS NATURAL SELECTION: ANTIBODY ALDOLASES WITH THE RATES OF NATURAL ENZYMES
1AJ7	;	2.1	;	IMMUNOGLOBULIN 48G7 GERMLINE FAB ANTIBODY COMPLEXED WITH HAPTEN 5-(PARA-NITROPHENYL PHOSPHONATE)-PENTANOIC ACID. AFFINITY MATURATION OF AN ESTEROLYTIC ANTIBODY
2RCS	;	2.1	;	IMMUNOGLOBULIN 48G7 GERMLINE FAB-AFFINITY MATURATION OF AN ESTEROLYTIC ANTIBODY
3JXA	;	2.403	;	Immunoglobulin domains 1-4 of mouse CNTN4
4X98	;	2.499	;	Immunoglobulin Fc heterodimer variant
4X99	;	2.498	;	Immunoglobulin Fc heterodimers variant
1A8J	;	2.7	;	IMMUNOGLOBULIN LAMBDA LIGHT CHAIN DIMER (MCG) COMPLEX WITH ASPARTAME
4K3G	;	1.93	;	Immunoglobulin lambda variable domain L5(L89S) fluorogen activating protein
4K3H	;	2.45	;	Immunoglobulin lambda variable domain L5(L89S) fluorogen activationg protein in complex with malachite green
1BRE	;	2.0	;	IMMUNOGLOBULIN LIGHT CHAIN PROTEIN
5T93	;	1.9	;	Immunoglobulin light chain variable domain AL-T05
1CMO	;		;	IMMUNOGLOBULIN MOTIF DNA-RECOGNITION AND HETERODIMERIZATION FOR THE PEBP2/CBF RUNT-DOMAIN
1BM3	;	2.0	;	IMMUNOGLOBULIN OPG2 FAB-PEPTIDE COMPLEX
1KJX	;	2.6	;	IMP Complex of E. Coli Adenylosuccinate Synthetase
1IWE	;	2.1	;	IMP Complex of the Recombinant Mouse-Muscle Adenylosuccinate Synthetase
1JJT	;	1.8	;	IMP-1 METALLO BETA-LACTAMASE FROM PSEUDOMONAS AERUGINOSA IN COMPLEX WITH A BIARYL SUCCINIC ACID INHIBITOR (1)
1JJE	;	1.8	;	IMP-1 METALLO BETA-LACTAMASE FROM PSEUDOMONAS AERUGINOSA IN COMPLEX WITH A BIARYL SUCCINIC ACID INHIBITOR (11)
1DD6	;	2.0	;	IMP-1 METALLO BETA-LACTAMASE FROM PSEUDOMONAS AERUGINOSA IN COMPLEX WITH A MERCAPTOCARBOXYLATE INHIBITOR
5AHN	;	1.652	;	IMP-bound form of the D199N mutant of IMPDH from Pseudomonas aeruginosa
5AHM	;	1.74	;	IMP-bound form of the DeltaCBS mutant of IMPDH from Pseudomonas aeruginosa
6QEY	;	2.2	;	IMP1 KH1 and KH2 domains create a structural platform with unique RNA recognition and re-modelling properties
3KRM	;	2.75	;	Imp1 kh34
5KDV	;	1.93	;	IMPa metallopeptidase from Pseudomonas aeruginosa
5KDW	;	1.85	;	IMPa metallopeptidase from Pseudomonas aeruginosa
5KDX	;	2.4	;	IMPa metallopeptidase in complex with T-antigen
3PXE	;	2.85	;	Impact of BRCA1 BRCT domain missense substitutions on phospho-peptide recognition: E1836K
3PXA	;	2.55	;	Impact of BRCA1 BRCT domain missense substitutions on phospho-peptide recognition: G1656D
3PXC	;	2.8	;	Impact of BRCA1 BRCT domain missense substitutions on phospho-peptide recognition: R1699Q
3PXD	;	2.8	;	Impact of BRCA1 BRCT domain missense substitutions on phospho-peptide recognition: R1835P
3PXB	;	2.5	;	Impact of BRCA1 BRCT domain missense substitutions on phospho-peptide recognition: T1700A
5W72	;		;	Impact of IR active probes on PDZ3 and its ligand binding studied by NMR and X-ray crystallography
3CU8	;	2.4	;	Impaired binding of 14-3-3 to Raf1 is linked to Noonan and LEOPARD syndrome
3NKX	;	2.4	;	Impaired binding of 14-3-3 to Raf1 is linked to Noonan and LEOPARD syndrome
6B65	;	2.702	;	IMPase (AF2372) R92Q/K164E
6B66	;	2.5	;	IMPase (AF2372) R92Q/K164E with 400 mM Glutamate
6B5Z	;	2.3	;	IMPase (AF2372) with 25 mM Asp
6B61	;	2.7	;	IMPase (AF2372) with 25 mM Asp
6B63	;	2.696	;	IMPase (AF2372) with 25 mM Asp
6B64	;	2.6	;	IMPase (AF2372) with 25 mM Asp
6B60	;	2.7	;	IMPase (AF2372) with 25 mM Glutamate
6B62	;	2.003	;	IMPase (AF2372) with 400 mM Glutamate
8GH5	;	2.64	;	Implementing Logic Gates in DNA Crystal Engineering
1BR8	;	2.9	;	IMPLICATIONS FOR FUNCTION AND THERAPY OF A 2.9A STRUCTURE OF BINARY-COMPLEXED ANTITHROMBIN
1YA7	;	2.3	;	Implications for interactions of proteasome with PAN and PA700 from the 1.9 A structure of a proteasome-11S activator complex
2X7L	;	3.17	;	Implications of the HIV-1 Rev dimer structure at 3.2A resolution for multimeric binding to the Rev response element
4LGY	;	1.48	;	Importance of Hydrophobic Cavities in Allosteric Regulation of Formylglycinamide Synthetase: Insight from Xenon Trapping and Statistical Coupling Analysis
4MGH	;	2.65	;	Importance of Hydrophobic Cavities in Allosteric Regulation of Formylglycinamide Synthetase: Insight from Xenon Trapping and Statistical Coupling Analysis
3JTC	;	1.6	;	Importance of Mg2+ in the Ca2+-Dependent Folding of the gamma-Carboxyglutamic Acid Domains of Vitamin K-Dependent clotting and anticlotting Proteins
7UMI	;	1.99	;	Importin a1 bound to Cp183-CTD
4UAF	;	1.698	;	Importin alpha 1 delta IBB in complex with Influenza PB2 nuclear localization domain
6BVT	;	2.5	;	Importin alpha 1 in cargo free state
7RFZ	;	1.95	;	Importin alpha 2 in complex with MERS ORF4B NLS peptide
4UAE	;	2.7	;	Importin alpha 3 delta IBB in complex with Influenza PB2 Nuclear Localization Domain
6BVZ	;	2.3	;	Importin alpha 3 in cargo free state
7RHT	;	2.5	;	Importin alpha 7 delta IBB (KPNA6)
4UAD	;	2.42	;	Importin alpha 7 delta IBB in complex with Influenza PB2 Nuclear Localization Domain
5E6Q	;	2.305	;	Importin alpha binding to XRCC1 NLS peptide
7JVO	;	2.2	;	Importin alpha bound to the C-terminus of ACE2
4OIH	;	2.1	;	Importin Alpha in Complex with the Bipartite NLS of Prp20
1IAL	;	2.5	;	IMPORTIN ALPHA, MOUSE
7RFX	;	2.1	;	Importin alpha2 in complex with MERS ORF4B
7RG1	;	1.85	;	Importin alpha2 in complex with MERS ORF4B H26A mutant
7RG0	;	2.0	;	Importin alpha2 in complex with MERS ORF4B R24A mutant
7RG2	;	2.0	;	Importin alpha2 in complex with MERS ORF4B R33A mutant
7RG3	;	2.0	;	Importin alpha2 in complex with MERS ORF4B R37A mutant
7RG6	;	2.1	;	Importin alpha2 in complex with ORF4B Bat coronavirus HKU5
7RG4	;	2.6	;	Importin alpha2 in complex with p50 NLS
7RFY	;	2.5	;	Importin alpha3 in complex with MERS ORF4B
7RG5	;	2.15	;	Importin alpha3 in complex with p50 NLS
5GXW	;	2.394	;	Importin and NuMA complex
1O6O	;	2.8	;	Importin Beta aa1-442 bound to five FxFG repeats from yeast Nsp1p. Second crystal form
1O6P	;	2.8	;	Importin Beta bound to a GLFG Nucleoporin peptide
5W4G	;	2.038	;	Importin binding to NLS peptide of DNA polymerase lambda
5W4F	;	1.984	;	Importin binding to pol Mu NLS peptide
5W4E	;	2.18	;	Importin binding to Tdt NLS peptide
6N1Z	;	2.7	;	Importin-9 bound to H2A-H2B
5K9S	;	2.4	;	Importin-alpha in complex with HNF1-beta peptide
4U54	;	2.41	;	IMPORTIN-ALPHA MINOR NLS SITE INHIBITOR
4U58	;	2.56	;	IMPORTIN-ALPHA MINOR NLS SITE INHIBITOR
4U5L	;	2.53	;	IMPORTIN-ALPHA MINOR NLS SITE INHIBITOR
4U5N	;	2.31	;	IMPORTIN-ALPHA MINOR NLS SITE INHIBITOR
4U5O	;	2.0	;	IMPORTIN-ALPHA MINOR NLS SITE INHIBITOR
4U5S	;	2.12	;	IMPORTIN-ALPHA MINOR NLS SITE INHIBITOR
4U5U	;	1.96	;	IMPORTIN-ALPHA MINOR NLS SITE INHIBITOR
4U5V	;	1.968	;	IMPORTIN-ALPHA MINOR NLS SITE INHIBITOR
1F59	;	2.8	;	IMPORTIN-BETA-FXFG NUCLEOPORIN COMPLEX
3ZKV	;	3.0	;	Importin13 cytosolic state
6DF2	;	2.6	;	Improved anti-phosphotyrosine antibody 4G10-S5-4D5 Fab complexed with phosphotyrosine peptide
1CWC	;	1.86	;	IMPROVED BINDING AFFINITY FOR CYCLOPHILIN A BY A CYCLOSPORIN DERIVATIVE SINGLY MODIFIED AT ITS EFFECTOR DOMAIN
1YAT	;	2.5	;	IMPROVED CALCINEURIN INHIBITION BY YEAST FKBP12-DRUG COMPLEXES. CRYSTALLOGRAPHIC AND FUNCTIONAL ANALYSIS
8CNO	;	1.75	;	Improved complex structure of human Sirtuin 6 with its inhibitor cis-resveratrol
4CDP	;	1.45	;	Improved coordinates for Escherichia coli O157:H7 heme degrading enzyme ChuS.
6B1T	;	3.2	;	Improved cryoEM structure of human adenovirus type 5 with atomic details of minor proteins VI and VII
1X0C	;	1.7	;	Improved Crystal Structure of Isopullulanase from Aspergillus niger ATCC 9642
2ZY9	;	2.94	;	Improved crystal structure of magnesium transporter MgtE
3SYS	;	1.65	;	Improved crystal structure of Pseudomonas aeruginosa OccK1 (OpdK)
3SY7	;	2.15	;	Improved crystal structure of Pseudomonas aeruginosa OprD
4AZA	;	2.16	;	Improved eIF4E binding peptides by phage display guided design.
7LCO	;	1.9	;	Improved Feline Drugs as SARS-CoV-2 Mpro Inhibitors: Structure-Activity Studies & Micellar Solubilization for Enhanced Bioavailability
7LCR	;	1.95	;	Improved Feline Drugs as SARS-CoV-2 Mpro Inhibitors: Structure-Activity Studies & Micellar Solubilization for Enhanced Bioavailability
7LCS	;	1.85	;	Improved Feline Drugs as SARS-CoV-2 Mpro Inhibitors: Structure-Activity Studies & Micellar Solubilization for Enhanced Bioavailability
7LCT	;	1.93	;	Improved Feline Drugs as SARS-CoV-2 Mpro Inhibitors: Structure-Activity Studies & Micellar Solubilization for Enhanced Bioavailability
7LDL	;	2.0	;	Improved Feline Drugs as SARS-CoV-2 Mpro Inhibitors: Structure-Activity Studies & Micellar Solubilization for Enhanced Bioavailability
6T3Y	;	1.7	;	Improved High Resolution Structure of MHC Class II complex
7MGU	;	1.4	;	Improved ligand discovery using micro-beam data collection at the edge of protein crystals
6R69	;	3.65	;	Improved map of the FliPQR complex that forms the core of the Salmonella type III secretion system export apparatus.
6HMA	;	2.65	;	Improved model derived from cryo-EM map of Staphylococcus aureus large ribosomal subunit
4Q4A	;	2.6	;	Improved model of AMP-PNP bound TM287/288
6MF2	;	3.60936	;	Improved Model of Human Coagulation Factor VIII
2WSC	;	3.3	;	Improved Model of Plant Photosystem I
2WSE	;	3.49	;	Improved Model of Plant Photosystem I
2WSF	;	3.48	;	Improved Model of Plant Photosystem I
3LW5	;	3.3	;	Improved model of plant photosystem I
3P19	;	2.05	;	Improved NADPH-dependent Blue Fluorescent Protein
4QU4	;	3.392	;	Improved refinement of the Mtr4 apo crystal structure
1SCZ	;	2.2	;	Improved structural model for the catalytic domain of E.coli dihydrolipoamide succinyltransferase
1G8W	;	2.8	;	IMPROVED STRUCTURE OF PHYTOHEMAGGLUTININ-L FROM THE KIDNEY BEAN
3FUS	;	4.0	;	Improved Structure of the Unliganded Simian Immunodeficiency Virus gp120 Core
4I0U	;	2.7	;	Improved structure of Thermotoga maritima CorA at 2.7 A resolution
8HT0	;	2.0	;	Improved thermostability of a glucose-tolerant glycosidase based on its X-ray crystal structure
4UXA	;	2.1	;	Improved variant of (R)-selective manganese-dependent hydroxynitrile lyase from bacteria
1JI2	;	2.3	;	Improved X-ray Structure of Thermoactinomyces vulgaris R-47 alpha-Amylase 2
256B	;	1.4	;	IMPROVEMENT OF THE 2.5 ANGSTROMS RESOLUTION MODEL OF CYTOCHROME B562 BY REDETERMINING THE PRIMARY STRUCTURE AND USING MOLECULAR GRAPHICS
8U5A	;	2.0	;	Improving protein expression, stability, and function with ProteinMPNN
4FE1	;	4.9228	;	Improving the Accuracy of Macromolecular Structure Refinement at 7 A Resolution
8FBI	;	3.61	;	Improving the secretion of designed protein assemblies through negative design of cryptic transmembrane domains
8FBJ	;	3.25	;	Improving the secretion of designed protein assemblies through negative design of cryptic transmembrane domains
8FBK	;	3.15	;	Improving the secretion of designed protein assemblies through negative design of cryptic transmembrane domains
8FBN	;	3.04	;	Improving the secretion of designed protein assemblies through negative design of cryptic transmembrane domains
8FBO	;	3.4	;	Improving the secretion of designed protein assemblies through negative design of cryptic transmembrane domains
2SNM	;	1.97	;	IN A STAPHYLOCOCCAL NUCLEASE MUTANT THE SIDE-CHAIN of A LYSINE REPLACING VALINE 66 IS FULLY BURIED IN THE HYDROPHOBIC CORE
4OCD	;	2.1	;	In and Out the minor groove: Interaction of an AT rich-DNA with the CD27 drug
4XBR	;	2.94	;	In cellulo Crystal Structure of PAK4 in complex with Inka
6RFU	;	2.8	;	In cellulo crystallization of Trypanosoma brucei IMP dehydrogenase enables the identification of ATP and GMP as genuine co-factors
2GUF	;	1.95	;	In meso crystal structure of the cobalamin transporter, BtuB
4UVM	;	3.0	;	In meso crystal structure of the POT family transporter PepTSo
6LKD	;	3.0	;	in meso full-length rat KMO in complex with a pyrazoyl benzoic acid inhibitor
6LKE	;	3.0	;	in meso full-length rat KMO in complex with an inhibitor identified via DNA-encoded chemical library screening
5D5D	;	2.4	;	In meso in situ serial X-ray crystallography structure of AlgE at 100 K
5D56	;	2.8	;	In meso in situ serial X-ray crystallography structure of diacylglycerol kinase, DgkA, at 100 K
5D53	;	1.5	;	In meso in situ serial X-ray crystallography structure of insulin at 100 K
5D52	;	1.8	;	In meso in situ serial X-ray crystallography structure of insulin at room temperature
5D5E	;	2.407	;	In meso in situ serial X-ray crystallography structure of insulin by sulfur-SAD at 100 K
5D5C	;	1.7	;	In meso in situ serial X-ray crystallography structure of lysozyme at 100 K
5D5F	;	1.5	;	In meso in situ serial X-ray crystallography structure of lysozyme by bromine-SAD at 100 K
5D5A	;	2.4826	;	In meso in situ serial X-ray crystallography structure of the Beta2-adrenergic receptor at 100 K
5D58	;	2.4	;	In meso in situ serial X-ray crystallography structure of the PepTSt-Ala-Phe complex at 100 K
4AZL	;	2.8	;	In meso structure of alginate transporter, AlgE, from Pseudomoas aeruginosa, PAO1, crystal form 2.
4B61	;	2.402	;	In meso structure of alginate transporter, AlgE, from Pseudomoas aeruginosa, PAO1. Crystal form 3.
4AFK	;	1.897	;	In meso structure of alginate transporter, AlgE, from Pseudomonas aeruginosa, PAO1
8RQR	;	2.19	;	In meso structure of apolipoprotein N-acyltransferase, Lnt, from Escherichia coli in 7.10 monoacylglycerol
7ACI	;	2.3	;	In meso structure of apolipoprotein N-acyltransferase, Lnt, from Escherichia coli in 9.8 monoacylglycerol
8RQQ	;	2.37	;	In meso structure of the adenosine A2a G protein-coupled receptor, A2aR, in 7.10 monoacylglycerol
8RQP	;	1.45	;	In meso structure of the alginate exporter, AlgE, from Pseudomonas aeruginosa in 7.10 monoacylglycerol
7ACG	;	1.85	;	In meso structure of the alginate exporter, AlgE, from Pseudomonas aeruginosa in 9.8 monoacylglycerol
7B0O	;	2.33	;	In meso structure of the membrane integral lipoprotein intramolecular transacylase Lit from Bacillus cereus in space group P21
7B0P	;	1.935	;	In meso structure of the membrane integral lipoprotein intramolecular transacylase Lit from Bacillus cereus in space group P21212
7B0Q	;	2.42	;	In meso structure of the membrane integral lipoprotein intramolecular transacylase Lit from Bacillus cereus with H85A mutation
7B0R	;	2.2	;	In meso structure of the membrane integral lipoprotein intramolecular transacylase Lit from Bacillus cereus with H85R mutation
8AQ2	;	2.6	;	In meso structure of the membrane integral lipoprotein N-acyltransferase Lnt from P. aeruginosa covalently linked with TITC
5D57	;	2.8	;	In meso X-ray crystallography structure of diacylglycerol kinase, DgkA, at 100 K
5D54	;	1.5	;	In meso X-ray crystallography structure of insulin at 100 K
5D5B	;	3.8	;	In meso X-ray crystallography structure of the Beta2-adrenergic receptor at 100 K
5D59	;	2.4	;	In meso X-ray crystallography structure of the PepTSt-Ala-Phe complex at 100 K
3Q9N	;	2.0	;	In silico and in vitro co-evolution of a high affinity complementary protein-protein interface
3Q9U	;	2.3	;	In silico and in vitro co-evolution of a high affinity complementary protein-protein interface
2N8D	;		;	In silico designed antimicrobial peptide Lavracin
3NPW	;	2.14	;	In silico designed of an improved Kemp eliminase KE70 mutant by computational design and directed evolution
5L7P	;	1.9	;	In silico-powered specific incorporation of photocaged Dopa at multiple protein sites
7BHQ	;	3.2	;	In situ assembled Salmonella FlgD hook cap complex
7AMD	;	2.25	;	In situ assembly of choline acetyltransferase ligands by a hydrothiolation reaction reveals key determinants for inhibitor design
5LCB	;	26.5	;	In situ atomic-resolution structure of the baseplate antenna complex in Chlorobaculum tepidum obtained combining solid-state NMR spectroscopy, cryo electron microscopy and polarization spectroscopy
8U10	;	3.2	;	In situ cryo-EM structure of bacteriophage P22 gp1:gp4:gp5:gp10:gp9 N-term complex in conformation 1 at 3.2A resolution
8U11	;	3.1	;	In situ cryo-EM structure of bacteriophage P22 gp1:gp5:gp4: gp10: gp9 N-term complex in conformation 2 at 3.1A resolution
8TVU	;	3.0	;	In situ cryo-EM structure of bacteriophage P22 portal protein: head-to-tail protein complex at 3.0A resolution
8TVR	;	2.8	;	In situ cryo-EM structure of bacteriophage P22 tail hub protein: tailspike protein complex at 2.8A resolution
8U1O	;	3.4	;	In situ cryo-EM structure of bacteriophage P22 tailspike protein complex at 3.4A resolution
7SPU	;	3.73	;	In situ cryo-EM structure of bacteriophage Sf6 gp3:gp7:gp5 complex in conformation 1 at 3.73A resolution
7SP4	;	3.71	;	In situ cryo-EM structure of bacteriophage Sf6 gp3:gp7:gp5 complex in conformation 2 at 3.71A resolution
7SG7	;	2.83	;	In situ cryo-EM structure of bacteriophage Sf6 gp8:gp14N complex at 2.8 A resolution
7SFS	;	2.76	;	In situ cryo-EM structure of bacteriophage Sf6 portal:gp7 complex at 2.7A resolution
7UKJ	;	3.6	;	In situ cryo-EM structure of bacteriophage Sf6 portal:gp7 complex at 2.7A resolution
8ENV	;	3.42	;	In situ cryo-EM structure of Pseudomonas phage E217 tail baseplate in C6 map
7Y7A	;	4.3	;	In situ double-PBS-PSII-PSI-LHCs megacomplex from Porphyridium purpureum.
1U33	;	1.95	;	In situ extension as an approach for identifying novel alpha-amylase inhibitors
1U2Y	;	1.95	;	In situ extension as an approach for identifying novel alpha-amylase inhibitors, structure containing D-gluconhydroximo-1,5-lactam
1U30	;	1.9	;	In situ extension as an approach for identifying novel alpha-amylase inhibitors, structure containing maltosyl-alpha (1,4)-D-gluconhydroximo-1,5-lactam
4N8Z	;	1.2	;	In situ lysozyme crystallized on a MiTeGen micromesh with benzamidine ligand
8BWY	;	38.0	;	In situ outer dynein arm from Chlamydomonas reinhardtii in a pre-power stroke state
8BX8	;	30.3	;	In situ outer dynein arm from Chlamydomonas reinhardtii in the post-power stroke state
8W6K	;	2.0	;	in situ room temperature Laue crystallography
8Y1R	;	2.0	;	in situ room temperature Laue crystallography
7Y5E	;	3.3	;	In situ single-PBS-PSII-PSI-LHCs megacomplex.
7QIN	;	6.6	;	In situ structure of actomyosin complex in skeletal sarcomere
8I7O	;	4.5	;	In situ structure of axonemal doublet microtubules in mouse sperm with 16-nm repeat
8I7R	;	6.5	;	In situ structure of axonemal doublet microtubules in mouse sperm with 48-nm repeat
6TY9	;	2.9	;	In situ structure of BmCPV RNA dependent RNA polymerase at initiation state
6TY8	;	3.0	;	In situ structure of BmCPV RNA dependent RNA polymerase at quiescent state
6TZ0	;	2.8	;	In situ structure of BmCPV RNA-dependent RNA polymerase at abortive state
6TZ1	;	3.4	;	In situ structure of BmCPV RNA-dependent RNA polymerase at early-elongation state
6TZ2	;	3.5	;	In situ structure of BmCPV RNA-dependent RNA polymerase at elongation state
6PO2	;	3.6	;	In situ structure of BTV RNA-dependent RNA polymerase in BTV core
6PNS	;	3.7	;	In situ structure of BTV RNA-dependent RNA polymerase in BTV virion
7ELL	;	3.8	;	In situ structure of capping enzyme lambda2, penetration protein mu1 of mammalian reovirus capsid asymmetric unit.
7QIM	;	4.5	;	In situ structure of nebulin bound to actin filament in skeletal sarcomere
7YF0	;	3.4	;	In situ structure of polymerase complex of mammalian reovirus in the core
7YED	;	3.0	;	In situ structure of polymerase complex of mammalian reovirus in the elongation state
7YEV	;	3.6	;	In situ structure of polymerase complex of mammalian reovirus in the pre-elongation state
7YEZ	;	3.4	;	In situ structure of polymerase complex of mammalian reovirus in the reloaded state
7YFE	;	3.4	;	In situ structure of polymerase complex of mammalian reovirus in virion
8K43	;	3.0	;	In situ structure of RNA-dependent RNA polymerase in full BAV particles
6OGY	;	3.4	;	In situ structure of Rotavirus RNA-dependent RNA polymerase at duplex-open state
6OGZ	;	3.6	;	In situ structure of Rotavirus RNA-dependent RNA polymerase at transcript-elongated state
6OJ4	;	3.3	;	In situ structure of rotavirus VP1 RNA-dependent RNA polymerase (DLP)
6OJ6	;	4.2	;	In situ structure of rotavirus VP1 RNA-dependent RNA polymerase (DLP_RNA)
6OJ3	;	4.5	;	In situ structure of rotavirus VP1 RNA-dependent RNA polymerase (TLP)
6OJ5	;	5.2	;	In situ structure of rotavirus VP1 RNA-dependent RNA polymerase (TLP_RNA)
8BQE	;	3.5	;	In situ structure of the Caulobacter crescentus S-layer
8C8N	;	3.4	;	In situ structure of the Nitrosopumilus maritimus S-layer - Two-fold symmetry (C2)
8R5I	;	9.7	;	In situ structure of the Vaccinia virus (WR) A4/A10 palisade trimer in mature virions by flexible fitting into a cryoET map
6M99	;	3.4	;	In situ structure of transcriptional enzyme complex and asymmetric inner capsid protein of aquareovirus at primed state
7ELH	;	3.3	;	In situ structure of transcriptional enzyme complex and capsid shell protein of mammalian reovirus at initiation state
5TC1	;	3.6	;	In situ structures of the genome and genome-delivery apparatus in ssRNA bacteriophage MS2
3JB6	;	3.3	;	In situ structures of the segmented genome and RNA polymerase complex inside a dsRNA virus
3JB7	;	4.0	;	In situ structures of the segmented genome and RNA polymerase complex inside a dsRNA virus
8JAJ	;	3.9	;	In situ structures of the ultra-long contracted tail of Myoviridae phage P1
8JAN	;	3.3	;	In situ structures of the ultra-long extended tail of Myoviridae phage P1
8COA	;	4.5	;	in situ Subtomogram average of Immature Rotavirus TLP spike
8ARH	;	19.2	;	In situ subtomogram average of Vaccinia virus (WR) D13 lattice, on immature virions
4M65	;	1.6	;	In situ thermolysin crystallized on a MiTeGen micromesh with asparagine ligand
4NCY	;	1.42	;	In situ trypsin crystallized on a MiTeGen micromesh with imidazole ligand
8AQ3	;	2.395	;	In surfo structure of the membrane integral lipoprotein N-acyltransferase Lnt from E. coli in complex with PE
8AQ4	;	2.62	;	In surfo structure of the membrane integral lipoprotein N-acyltransferase Lnt from E. coli in complex with TITC and lyso-PE
6GGN	;	2.0	;	In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor
3ZNN	;	1.9	;	IN VITRO AND IN VIVO INHIBITION OF HUMAN D-AMINO ACID OXIDASE: REGULATION OF D-SERINE CONCENTRATION IN THE BRAIN
3ZNO	;	2.3	;	IN VITRO AND IN VIVO INHIBITION OF HUMAN D-AMINO ACID OXIDASE: REGULATION OF D-SERINE CONCENTRATION IN THE BRAIN
3ZNP	;	2.4	;	IN VITRO AND IN VIVO INHIBITION OF HUMAN D-AMINO ACID OXIDASE: REGULATION OF D-SERINE CONCENTRATION IN THE BRAIN
3ZNQ	;	2.75	;	IN VITRO AND IN VIVO INHIBITION OF HUMAN D-AMINO ACID OXIDASE: REGULATION OF D-SERINE CONCENTRATION IN THE BRAIN
7QKY	;	1.86	;	In vitro assembled 0N4R tau filaments with phosphoserine (47a)
7QL2	;	2.95	;	In vitro assembled 244-391 tau filaments with Na2P2O7 (20a)
7QK6	;	2.27	;	In vitro assembled 258-391 tau filaments with heparan sulfate, 700 rpm (40a)
7QKG	;	3.36	;	In vitro assembled 258-391 tau filaments with phosphoglycerate, 700 rpm (39a)
7QKK	;	2.8	;	In vitro assembled 258-391 tau filaments with phosphoglycerate, 700 rpm (39a)
7QKH	;	3.17	;	In vitro assembled 258-391 tau filaments with sodium azide, (41a)
7QK3	;	2.44	;	In vitro assembled 258-391 tau filaments, 700 rpm (38a)
7QKW	;	2.32	;	In vitro assembled 266-391 S356D tau filaments with KCl (44a)
7QKM	;	2.66	;	In vitro assembled 266-391 S356D tau filaments with NaCl (45a)
7QL1	;	3.34	;	In vitro assembled 266-391 tau filaments in PBS (23a)
7QKF	;	2.83	;	In vitro assembled 266/297 - 391 tau filaments with CuCl2 (12a)
7QK5	;	1.92	;	In vitro assembled 266/297 - 391 tau filaments with KCl (10a)
7R5H	;	2.59	;	In vitro assembled 266/297 - 391 tau filaments with KCl (10b)
7QJY	;	3.14	;	In vitro assembled 266/297 - 391 tau filaments with LiCl (9a)
7QJZ	;	3.4	;	In vitro assembled 266/297 - 391 tau filaments with LiCl (9b)
7QKU	;	2.57	;	in vitro assembled 266/297 - 391 tau filaments with MgCl2 and NaCl (14a)
7QKJ	;	3.26	;	In vitro assembled 266/297 - 391 tau filaments with MgCl2 and NaCl (14b)
7QKX	;	3.16	;	In vitro assembled 266/297 - 391 tau filaments with MgSO4 and NaCl (15b)
7QL0	;	3.13	;	In vitro assembled 266/297 - 391 tau filaments with MgSO4 and NaCl (15c)
7QL3	;	3.32	;	in vitro assembled 266/297 - 391 tau filaments with NaCl (8b)
7R4T	;	2.75	;	In vitro assembled 266/297 - 391 tau filaments with NaHCO3 and NaCl (16a)
7QKL	;	2.07	;	In vitro assembled 266/297 - 391 tau filaments with ZnCl2 (11a)
7QK1	;	3.03	;	In vitro assembled 297-394 tau filaments in PBS (35d)
7QJX	;	2.99	;	In vitro assembled 297-394 tau filaments, 700 rpm (34b)
7QKI	;	3.13	;	In vitro assembled 297-408 S396D S400D T403D S404D tau filaments (42a)
7QK2	;	2.61	;	In vitro assembled 300-391 tau filaments in PBS (36a)
7QKZ	;	2.65	;	In vitro assembled 305-379 tau filaments (27a)
5HX2	;	3.8	;	In vitro assembled star-shaped hubless T4 baseplate
7QJV	;	3.29	;	In vitro assembled tau filaments into Quadruple Helical Filaments type 1 (2c)
7QKV	;	3.23	;	In vitro assembled tau filaments with MgSO4 and NaCl (15a)
7QJW	;	2.81	;	In vitro assembled tau filaments with structures like chronic traumatic encephalopathy type II (8a)
7QL4	;	3.2	;	in vitro assembled tau filaments with structures like Paired Helical Filaments from Alzheimer's Disease
4XBU	;	2.06	;	In vitro Crystal Structure of PAK4 in complex with Inka peptide
4MEH	;	3.12	;	In vitro evolved glmS ribozyme triple mutant, calcium ion complex
4MEG	;	3.1	;	In vitro evolved glmS ribozyme triple mutant, magnesium ion complex
6OFG	;	2.9	;	In vitro polymerized PrgI V67A filaments
7BL4	;	2.4	;	in vitro reconstituted 50S-ObgE-GMPPNP-RsfS particle
8C8M	;	2.87	;	In vitro structure of the Nitrosopumilus maritimus S-layer - Composite map between two and six-fold symmetrised
8C8K	;	2.87	;	In vitro structure of the Nitrosopumilus maritimus S-layer - Six-fold symmetry (C6)
8C8L	;	2.71	;	In vitro structure of the Nitrosopumilus maritimus S-layer - Two-fold symmetry (C2)
6RXH	;	2.0	;	In-flow serial synchrotron crystallography using a 3D-printed microfluidic device (3D-MiXD): Aspartate alpha-decarboxylase
6RXI	;	2.0	;	In-flow serial synchrotron crystallography using a 3D-printed microfluidic device (3D-MiXD): Lysozyme
5LCJ	;	1.78	;	In-Gel Activity-Based Protein Profiling of a Clickable Covalent Erk 1/2 Inhibitor
5II7	;	1.66	;	In-house sulfur-SAD structure of orthorhombic red abalone lysin at 1.66 A resolution
5HNL	;	2.424	;	In-house X-ray single crystal diffraction from protein microcrystals via magnetically oriented microcrystal arrays in gels
7PTT	;	7.968	;	In-situ structure of hexameric S-layer protein
7PTP	;	11.58	;	In-situ structure of pentameric S-layer protein
6YI5	;	9.1	;	In-situ structure of the trimeric HEF from influenza C by flexible fitting into a cryo-ET map.
4ZG3	;	1.2	;	In-vacuum long-wavelength crystallography
4NYQ	;	1.2	;	In-vivo crystallisation (midguts of a viviparous cockroach) and structure at 1.2 A resolution of a glycosylated, lipid-binding, lipocalin-like protein
4NYR	;	2.49	;	In-vivo crystallisation (midguts of a viviparous cockroach) and structure at 2.5 A resolution of a glycosylated, lipid-binding, lipocalin-like protein
8FEX	;	3.07	;	Inactivate state of Maribacter polysiphoniae Argonuate (short pAgo system)
6K55	;	2.883	;	Inactivated mutant (D140A) of Hyperthermophilic GH6 cellobiohydrolase II (HmCel6A) in complex with hexasaccharide
7T38	;	3.8	;	Inactivated state of 2-APB and CBD-bound wildtype rat TRPV2 in nanodiscs
7N0M	;	3.5	;	Inactivated state of 2-APB-bound wildtype rat TRPV2 in nanodiscs
1ZTN	;		;	INACTIVATION GATE OF POTASSIUM CHANNEL RAW3, NMR, 8 STRUCTURES
1ZTO	;		;	INACTIVATION GATE OF POTASSIUM CHANNEL RCK4, NMR, 8 STRUCTURES
1SCN	;	1.9	;	INACTIVATION OF SUBTILISIN CARLSBERG BY N-(TERT-BUTOXYCARBONYL-ALANYL-PROLYL-PHENYLALANYL)-O-BENZOL HYDROXYLAMINE: FORMATION OF COVALENT ENZYME-INHIBITOR LINKAGE IN THE FORM OF A CARBAMATE DERIVATIVE
1KEE	;	2.1	;	Inactivation of the Amidotransferase Activity of Carbamoyl Phosphate Synthetase by the Antibiotic Acivicin
4Z10	;	1.93	;	Inactive aurone synthase (polyphenol oxidase) co-crystallized with 1,4-resorcinol
4Z0Z	;	1.6	;	Inactive aurone synthase (polyphenol oxidase) from natural source, sulfohistidine ~ 90 %
6BK5	;	2.401	;	Inactive choanoflagellate E3 ubiquitin ligase Cbl TKB
7KY0	;	3.1	;	Inactive conformation of EGFR (T790M/V948R) kinase in complex with BI-4020
5TT2	;	2.949	;	Inactive conformation of engineered human cystathionine gamma lyase (E59N, R119L, E339V) to depleting methionine
3FWQ	;	2.3	;	Inactive conformation of human protein kinase CK2 catalytic subunit
7ZNR	;	2.65	;	Inactive D62N mutant of BT1760 Endo-acting levanase from Bacteroides thetaiotaomicron VPI-5482
7ZNS	;	2.3	;	Inactive D62N mutant of BT1760 Endo-acting levanase from Bacteroides thetaiotaomicron VPI-5482
5NNL	;	2.13	;	Inactive dihydroorotase-like domain of Chaetomium thermophilum CAD-like multifunctional protein
6G0J	;	2.1	;	Inactive Fe-PP1
7LZ9	;	2.3	;	Inactive form of VanR from S. coelicolor
3AHR	;	3.07	;	Inactive human Ero1
8AA2	;	3.1	;	Inactive levan utilisation machinery (utilisome) in the presence of levan fructo-oligosaccharides DP 15-25
1DCN	;	2.3	;	INACTIVE MUTANT H162N OF DELTA 2 CRYSTALLIN WITH BOUND ARGININOSUCCINATE
3HB6	;	2.3	;	Inactive mutant H54F of Proteus mirabilis catalase
8IBI	;	2.14	;	Inactive mutant of CtPL-H210S/F214I
8IBJ	;	1.92	;	Inactive mutant of CtPL-H210S/F214I/N181A/F235L
1QIL	;	2.5	;	INACTIVE MUTANT TOXIC SHOCK SYNDROME TOXIN-1 AT 2.5 A
5UBK	;	2.55	;	Inactive S1A/N269D-cpPvdQ mutant in complex with the pyoverdine precursor PVDIq reveals a specific binding pocket for the D-Tyr of this substrate
6PAS	;	5.1	;	Inactive State of Manduca sexta soluble guanylate cyclase
5ZO4	;	2.5	;	inactive state of the nuclease
4U7N	;	3.2	;	Inactive structure of histidine kinase
3KWD	;	1.1	;	Inactive truncation of the beta-carboxysomal gamma-Carbonic Anhydrase, CcmM, form 1
3KWE	;	1.1	;	Inactive truncation of the beta-carboxysomal gamma-Carbonic Anhydrase, CcmM, form 2
1W1U	;	2.23	;	Inactive Urocanase-SA cocrystallized with urocanate
4Q2N	;	2.0	;	INADL PDZ3 in Complex with a Phage-Derived Peptide
7M0A	;	1.83	;	Incomplete in crystallo incorporation by DNA Polymerase Lambda bound to blunt-ended DSB substrate and incoming dTTP
3QCR	;	3.2	;	Incomplete structural model of a human telomeric DNA quadruplex-acridine complex.
5I0U	;	1.25	;	Incompletely interpreted D-cysteine soak of Cysteine Dioxygenase at pH 7.0
1IOP	;	1.9	;	INCORPORATION OF A HEMIN WITH THE SHORTEST ACID SIDE-CHAINS INTO MYOGLOBIN
3DR9	;	1.26	;	Increased Distal Histidine Conformational Flexibility in the Deoxy Form of Dehaloperoxidase from Amphitrite ornata
3DTM	;	2.0	;	Increased folding stability of TEM-1 beta-lactamase by in-vitro selection
4JFK	;	1.15	;	Increasing the Efficiency Efficiency of Ligands for the FK506-Binding Protein 51 by Conformational Control: Complex of FKBP51 with (1S,6R)-3-[2-(3,4-dimethoxyphenoxy)ethyl]-10-[(2-oxo-2,3-dihydro-1,3-benzothiazol-6-yl)sulfonyl]-3,10-diazabicyclo[4.3.1]decan-2-one
4JFM	;	1.02	;	Increasing the Efficiency Efficiency of Ligands for the FK506-Binding Protein 51 by Conformational Control: Complex of FKBP51 with 2-(3,4-dimethoxyphenoxy)ethyl (2S)-1-[(2-oxo-2,3-dihydro-1,3-benzothiazol-6-yl)sulfonyl]piperidine-2-carboxylate
4JFL	;	1.2	;	Increasing the Efficiency Efficiency of Ligands for the FK506-Binding Protein 51 by Conformational Control: Complex of FKBP51 with 6-({(1S,5R)-3-[2-(3,4-dimethoxyphenoxy)ethyl]-2-oxo-3,9-diazabicyclo[3.3.1]non-9-yl}sulfonyl)-1,3-benzothiazol-2(3H)-one
4JFJ	;	1.08	;	Increasing the Efficiency Efficiency of Ligands for the FK506-Binding Protein 51 by Conformational Control: Complex of FKBP51 with compound (1S,6R)-10-(1,3-benzothiazol-6-ylsulfonyl)-3-[2-(3,4-dimethoxyphenoxy)ethyl]-3,10-diazabicyclo[4.3.1]decan-2-one
4JFI	;	1.05	;	Increasing the Efficiency Efficiency of Ligands for the FK506-Binding Protein 51 by Conformational Control: Complex of FKBP51 with compound 1-[(9S,13R,13aR)-1,3-dimethoxy-8-oxo-5,8,9,10,11,12,13,13a-octahydro-6H-9,13-epiminoazocino[2,1-a]isoquinolin-14-yl]-2-(3,4,5-trimethoxyphenyl)ethane-1,2-dione
7XQN	;	1.98	;	InDel-mutant malate dehydrogenase from E. coli
7XQM	;	2.71	;	InDel-mutant short chain Dehydrogenase bound to SAH
3J3X	;	4.3	;	Independent reconstruction of Mm-cpn cryo-EM density map from half dataset in the closed state (training map)
3FHJ	;	2.65	;	Independent saturation of three TrpRS subsites generates a partially-assembled state similar to those observed in molecular simulations
2M7W	;		;	Independently verified structure of gp41-M-MAT, a membrane associated MPER trimer from HIV-1 gp41
5EH9	;	1.29	;	Indirect contributions of mutations underlie optimization of new enzyme function
5EHT	;	1.29	;	Indirect contributions of mutations underlie optimization of new enzyme function
1Z62	;	1.9	;	Indirubin-3'-aminooxy-acetate inhibits glycogen phosphorylase by binding at the inhibitor and the allosteric site. Broad specificities of the two sites
5OW8	;	1.9	;	Indole-2 carboxamides as selective secreted phospholipase A2 type X (sPLA2-X) inhibitors
5OWC	;	1.75	;	Indole-2 carboxamides as selective secreted phospholipase A2 type X (sPLA2-X) inhibitors
7EZF	;	2.76	;	Indole-2-carboxylic acid derivatives as allosteric inhibitors of fructose-1,6-bisphosphatase
7EZP	;	2.8	;	Indole-2-carboxylic acid derivatives as allosteric inhibitors of fructose-1,6-bisphosphatase
7EZR	;	3.27	;	Indole-2-carboxylic acid derivatives as allosteric inhibitors of fructose-1,6-bisphosphatase
1IGS	;	2.0	;	INDOLE-3-GLYCEROLPHOSPHATE SYNTHASE FROM SULFOLOBUS SOLFATARICUS AT 2.0 A RESOLUTION
1JUL	;	2.0	;	INDOLE-3-GLYCEROLPHOSPHATE SYNTHASE FROM SULFOLOBUS SOLFATARICUS IN A SECOND ORTHORHOMBIC CRYSTAL FORM
1JUK	;	2.5	;	INDOLE-3-GLYCEROLPHOSPHATE SYNTHASE FROM SULFOLOBUS SOLFATARICUS IN A TRIGONAL CRYSTAL FORM
2G5N	;	1.51	;	Indole-amidine Complexes with Bovine Trypsin
2G5V	;	1.45	;	Indole-amidine Complexes with Bovine Trypsin
2G8T	;	1.41	;	Indole-amidine Complexes with Bovine Trypsin
2OYE	;	2.85	;	Indomethacin-(R)-alpha-ethyl-ethanolamide bound to Cyclooxygenase-1
2OYU	;	2.7	;	Indomethacin-(S)-alpha-ethyl-ethanolamide bound to Cyclooxygenase-1
7VOO	;	3.9	;	Induced alpha-2-macroglobulin monomer
4U66	;	2.9	;	Induced Dimer Structure of Methionine Sulfoxide Reductase U16C from Clostridium Oremlandii
6LTZ	;	1.973	;	Induced DNA bending by unique dimerization of HigA antitoxin
4UNT	;	2.7	;	Induced monomer of the Mcg variable domain
6FS0	;	2.25	;	INDUCED MYELOID LEUKEMIA CELL DIFFERENTIATION PROTEIN FABCOMPLEX IN COMPLEX WITH AZD5991
8AV9	;	1.99	;	INDUCED MYELOID LEUKEMIA CELL DIFFERENTIATION PROTEIN FABCOMPLEX IN COMPLEX WITH COMPOUND 1
4K1H	;	1.797	;	Induced opening of influenza virus neuraminidase N2 150-loop suggests an important role in inhibitor binding
4K1I	;	1.8	;	Induced opening of influenza virus neuraminidase N2 150-loop suggests an important role in inhibitor binding
4K1J	;	2.2	;	Induced opening of influenza virus neuraminidase N2 150-loop suggests an important role in inhibitor binding
4K1K	;	1.6	;	Induced opening of influenza virus neuraminidase N2 150-loop suggests an important role in inhibitor binding
2XEM	;	2.1	;	Induced-fit and allosteric effects upon polyene binding revealed by crystal structures of the Dynemicin thioesterase
2XFL	;	2.9	;	Induced-fit and allosteric effects upon polyene binding revealed by crystal structures of the Dynemicin thioesterase
6YN5	;	2.7	;	Inducible lysine decarboxylase LdcI decamer, pH 7.0
6YN6	;	3.28	;	Inducible lysine decarboxylase LdcI stacks, pH 5.7
1VAF	;	2.9	;	Inducible nitric oxide synthase oxygenase domain complexed with the inhibitor AR-R17477
1M9T	;	2.4	;	Inducible Nitric Oxide Synthase with 3-Bromo-7-Nitroindazole bound
1M8I	;	2.7	;	inducible nitric oxide synthase with 5-nitroindazole bound
1M8H	;	2.85	;	inducible nitric oxide synthase with 6-nitroindazole bound
1M8E	;	2.9	;	inducible nitric oxide synthase with 7-nitroindazole bound
1M8D	;	2.35	;	inducible nitric oxide synthase with Chlorzoxazone bound
5C94	;	2.438	;	Infectious bronchitis virus nsp9
7LNA	;	3.14	;	Infectious mammalian prion fibril (263K scrapie)
8A00	;	2.6	;	Infectious mouse-adapted ME7 scrapie prion fibril purified from terminally-infected mouse brains
7QIG	;	2.7	;	Infectious mouse-adapted RML scrapie prion fibril purified from terminally-infected mouse brains
1ZBJ	;		;	Inferential Structure Determination of the Fyn SH3 domain using NOESY data from a 15N,H2 enriched protein
5NPU	;	3.5	;	Inferred ancestral pyruvate decarboxylase
6Q19	;	1.58	;	Inferred intermediate (I-6) of the human antibody lineage 652
6Q0H	;	2.75	;	Inferred intermediate I-7 (I-7-0) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1)
6Q0L	;	2.5	;	Inferred intermediate I-7 (I-7-1) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1)
6Q0I	;	2.702	;	Inferred intermediate I-7 (I-7-6) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1)
6Q1K	;	2.2	;	Inferred intermediate I-7 of the human antibody lineage 652
6Q1A	;	2.001	;	Inferred intermediate mutant (I-6V) of the human antibody lineage 652
6Q1E	;	2.5	;	Inferred precursor (UCA) of the human antibody lineage 652
6Q0E	;	2.15	;	Inferred precursor (UCA) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1)
5W0D	;	1.899	;	Inferred precursor (UCA) of the human antibody lineage K03.12 in complex with influenza hemagglutinin H1 Solomon Islands/03/2006
6W5Y	;	2.5	;	Inferred receptor binding domain of human endogenous retrovirus envelope EnvP(b)1
1D37	;	1.8	;	INFLUENCE OF AGLYCONE MODIFICATIONS ON THE BINDING OF ANTHRACYCLINE DRUGS TO DNA: THE MOLECULAR STRUCTURE OF IDARUBICIN AND 4-O-DEMETHYL-11-DEOXYDOXORUBICIN COMPLEXED TO D(CGATCG)
1D38	;	1.7	;	INFLUENCE OF AGLYCONE MODIFICATIONS ON THE BINDING OF ANTHRACYCLINE DRUGS TO DNA: THE MOLECULAR STRUCTURE OF IDARUBICIN AND 4-O-DEMETHYL-11-DEOXYDOXORUBICIN COMPLEXED TO D(CGATCG)
4AMH	;	2.3	;	Influence of circular permutation on the folding pathway of a PDZ domain
212D	;	1.9	;	INFLUENCE OF COUNTER-IONS ON THE CRYSTAL STRUCTURES OF DNA DECAMERS: BINDING OF [CO(NH3)6]3+ AND BA2+ TO A-DNA
220D	;	2.0	;	INFLUENCE OF COUNTER-IONS ON THE CRYSTAL STRUCTURES OF DNA DECAMERS: BINDING OF [CO(NH3)6]3+ AND BA2+ TO A-DNA
221D	;	1.9	;	INFLUENCE OF COUNTER-IONS ON THE CRYSTAL STRUCTURES OF DNA DECAMERS: BINDING OF [CO(NH3)6]3+ AND BA2+ TO A-DNA
222D	;	1.9	;	INFLUENCE OF COUNTER-IONS ON THE CRYSTAL STRUCTURES OF DNA DECAMERS: BINDING OF [CO(NH3)6]3+ AND BA2+ TO A-DNA
1S1K	;	1.9	;	INFLUENCE OF GROOVE INTERACTIONS ON DNA HOLLIDAY JUNCTION FORMATION
1S1L	;	2.2	;	Influence of Groove Interactions on the Formation of DNA Holliday Junctions
1HVI	;	1.8	;	INFLUENCE OF STEREOCHEMISTRY ON ACTIVITY AND BINDING MODES FOR C2 SYMMETRY-BASED DIOL INHIBITORS OF HIV-1 PROTEASE
1HVJ	;	2.0	;	INFLUENCE OF STEREOCHEMISTRY ON ACTIVITY AND BINDING MODES FOR C2 SYMMETRY-BASED DIOL INHIBITORS OF HIV-1 PROTEASE
1HVK	;	1.8	;	INFLUENCE OF STEREOCHEMISTRY ON ACTIVITY AND BINDING MODES FOR C2 SYMMETRY-BASED DIOL INHIBITORS OF HIV-1 PROTEASE
1HVL	;	1.8	;	INFLUENCE OF STEREOCHEMISTRY ON ACTIVITY AND BINDING MODES FOR C2 SYMMETRY-BASED DIOL INHIBITORS OF HIV-1 PROTEASE
3FL6	;	1.17	;	Influence of the incorporation of a cyclohexenyl nucleic acid (CeNA) residue onto the sequence d(GCGTGCG)/d(CGCACGC)
4M5V	;	1.8	;	Influenza 2009 H1N1 endonuclease with 100 millimolar calcium
4P1U	;	2.52	;	Influenza A (flu) virus polymerase basic protein 2 (PB2) bound to VX787, an azaindole inhibitor
8G5B	;	3.1	;	Influenza A H3N2 X-31 Hemagglutinin in complex with FL-1061
6US9	;	2.0	;	Influenza A M2 proton channel wild type TM domain bound to R-rimantadine
6US8	;	1.7	;	Influenza A M2 proton channel wild type TM domain bound to S-rimantadine
6BMZ	;	2.634	;	Influenza A M2 transmembrane domain bound to a spiroadamantane inhibitor
6BKK	;	1.995	;	Influenza A M2 transmembrane domain bound to amantadine
6BKL	;	1.995	;	Influenza A M2 transmembrane domain bound to rimantadine
6BOC	;	2.25	;	Influenza A M2 transmembrane domain bound to rimantadine in the Inward(open) conformation
5C02	;	1.591	;	Influenza A M2 transmembrane domain drug-resistant S31N mutant at pH 8.0
4QK7	;	1.1	;	Influenza A M2 wild type TM domain at high pH in the lipidic cubic phase under cryo diffraction conditions
4QKL	;	1.711	;	Influenza A M2 wild type TM domain at high pH in the lipidic cubic phase under room temperature diffraction conditions
4QKC	;	1.1	;	Influenza A M2 wild type TM domain at low pH in the lipidic cubic phase under cryo diffraction conditions
4QKM	;	1.44	;	Influenza A M2 wild type TM domain at low pH in the lipidic cubic phase under room temperature diffraction conditions
1PD3	;	2.6	;	Influenza A NEP M1-binding domain
6H9G	;	11.0	;	Influenza A nucleoprotein docked into 3D helical structure of the wild type ribonucleoprotein complex obtained using cryoEM. Conformation 1.
6I54	;	10.0	;	Influenza A nucleoprotein docked into 3D helical structure of the wild type ribonucleoprotein complex obtained using cryoEM. Conformation 2.
6I7B	;	10.0	;	Influenza A nucleoprotein docked into 3D helical structure of the wild type ribonucleoprotein complex obtained using cryoEM. Conformation 3.
6I7M	;	10.0	;	Influenza A nucleoprotein docked into 3D helical structure of the wild type ribonucleoprotein complex obtained using cryoEM. Conformation 4.
6I85	;	24.0	;	Influenza A nucleoprotein docked into the 3D helical structure of the wild type ribonucleoprotein complex obtained using cryoEM. Conformation 5.
7AS1	;	1.5	;	Influenza A PB2 (F404Y mutation) in complex with VX-787
7AS3	;	1.65	;	Influenza A PB2 (H357N mutation) in complex with VX-787
7AS2	;	1.75	;	Influenza A PB2 (M431 mutation) in complex with VX-787
7AS0	;	1.55	;	Influenza A PB2 in complex with VX-787
6QNW	;	3.31	;	Influenza A Polymerase Heterotrimer Human H3N2 Northern Territory 1968
1ING	;	2.4	;	INFLUENZA A SUBTYPE N2 NEURAMINIDASE COMPLEXED WITH AROMATIC BANA109 INHIBITOR
1INH	;	2.4	;	INFLUENZA A SUBTYPE N2 NEURAMINIDASE COMPLEXED WITH AROMATIC BANA111 INHIBITOR
6QXE	;	4.15	;	Influenza A virus (A/NT/60/1968) polymerase dimer of hetermotrimer in complex with 3'5' cRNA promoter and Nb8205
6QX8	;	4.07	;	Influenza A virus (A/NT/60/1968) polymerase dimer of heterotrimer in complex with 5' cRNA promoter
6QX3	;	3.79	;	Influenza A virus (A/NT/60/1968) polymerase Hetermotrimer in complex with 3'5' cRNA promoter and Nb8205
6RR7	;	3.01	;	Influenza A virus (A/NT/60/1968) polymerase Heterotrimer bound to 3'5' vRNA promoter and capped RNA primer
5DUT	;	1.5	;	Influenza A virus H5 hemagglutinin globular head
5DUR	;	2.82	;	Influenza A virus H5 hemagglutinin globular head in complex with antibody 100F4
5DUP	;	3.052	;	Influenza A virus H5 hemagglutinin globular head in complex with antibody AVFluIgG03
4F23	;	1.7	;	Influenza A virus hemagglutinin H16 HA0 structure with an alpha-helix conformation in the cleavage site: a potential drug target
6HFY	;	1.65	;	Influenza A virus N6 neuraminidase complex with DANA (Duck/England/56).
6HG5	;	1.6	;	Influenza A virus N6 neuraminidase complex with Oseltamivir (Duck/England/56).
6HGB	;	1.5	;	Influenza A virus N6 neuraminidase native structure (Duck/England/56).
6HG0	;	1.3	;	Influenza A Virus N9 Neuraminidase complex with NANA (Tern/Australia).
6HEB	;	1.75	;	Influenza A Virus N9 Neuraminidase complex with Oseltamivir (Tern).
6HFC	;	1.29	;	Influenza A Virus N9 Neuraminidase Native (Tern).
5TJW	;	3.231	;	Influenza A virus Nucleoprotein in Complex with Inhibitory Nanobody
2IQH	;	3.2	;	Influenza A virus nucleoprotein NP at 3.2A resolution
6QPF	;	3.634	;	Influenza A virus Polymerase Heterotrimer A/duck/Fujian/01/2002(H5N1)
6QPG	;	3.34	;	Influenza A virus Polymerase Heterotrimer A/nt/60/1968(H3N2) in complex with Nanobody NB8205
4IRY	;	2.8	;	Influenza A virus tail-loop free nucleoprotein at 2.8 A resolution
6FS6	;	2.291	;	Influenza A/California/04/2009 (pH1N1) endonuclease with bound inhibitor, baloxavir acid (BXA)
6FS7	;	1.96	;	Influenza A/California/04/2009 (pH1N1) endonuclease with I38T mutation with bound inhibitor, baloxavir acid (BXA)
7NUG	;	1.9	;	Influenza A/California/07/2009(H1N1) endonuclease in complex with orientin
7NUH	;	2.2	;	Influenza A/California/07/2009(H1N1) endonuclease with I38T mutation in complex with orientin
7ZPM	;	2.81	;	Influenza A/H7N9 polymerase apo-protein dimer complex
6TU5	;	3.325	;	Influenza A/H7N9 polymerase core (apo)
7Z4O	;	3.412	;	Influenza A/H7N9 polymerase core dimer with Pol II pSer5 CTD peptide mimic bound in site 2A
7QTL	;	2.48	;	Influenza A/H7N9 polymerase elongation complex
8PNQ	;	2.88	;	Influenza A/H7N9 polymerase in elongation state with continuous Pol II pS5 CTD peptide mimic bound in site 1A/2A
8PNP	;	2.49	;	Influenza A/H7N9 polymerase in pre-initiation state with continuous Pol II pS5 CTD peptide mimic bound in site 1A/2A
8R3L	;	3.25	;	Influenza A/H7N9 polymerase in pre-initiation state, intermediate conformation (I) with PB2-C(I), ENDO(T), and Pol II pS5 CTD peptide mimic bound in site 1A/2A
8PM0	;	2.9	;	Influenza A/H7N9 polymerase in replicase-like conformation in pre-initiation state with Pol II pS5 CTD peptide mimic bound in site 1A/2A
8R3K	;	3.43	;	Influenza A/H7N9 polymerase in self-stalled pre-termination state, with Pol II pS5 CTD peptide mimic bound in site 1A/2A.
8POH	;	3.3	;	Influenza A/H7N9 polymerase symmetric dimer bound to the promoter (PA K289A/C489R)
4FQL	;	1.898	;	Influenza B HA Antibody (Fab) CR8033
6PVR	;		;	Influenza B M2 Proton Channel in the Closed State - SSNMR Structure at pH 7.5
6PVT	;		;	Influenza B M2 Proton Channel in the Open State - SSNMR Structure at pH 4.5
5M3J	;	3.5	;	Influenza B polymerase bound to four heptad repeats of serine 5 phosphorylated Pol II CTD
5MSG	;	3.8	;	Influenza B polymerase bound to vRNA promoter and capped RNA primer
6QCT	;	3.2	;	Influenza B polymerase elongation complex
6QCS	;	3.1	;	Influenza B polymerase pre-initiation complex
7Z43	;	3.123	;	Influenza B polymerase with Pol II pSer5 CTD peptide mimic bound in site 1B and 2B
7Z42	;	2.418	;	Influenza B polymerase with Pol II pSer5 CTD peptide mimic bound in site 2B
6QWL	;	4.1	;	Influenza B virus (B/Panama/45) polymerase Hetermotrimer in complex with 3'5' cRNA promoter
1NSC	;	1.7	;	INFLUENZA B VIRUS NEURAMINIDASE CAN SYNTHESIZE ITS OWN INHIBITOR
1NSD	;	1.8	;	INFLUENZA B VIRUS NEURAMINIDASE CAN SYNTHESIZE ITS OWN INHIBITOR
1VCJ	;	2.4	;	Influenza B virus neuraminidase complexed with 1-(4-Carboxy-2-(3-pentylamino)phenyl)-5-aminomethyl-5-hydroxymethyl-pyrrolidin-2-one
6CNV	;	4.1	;	INFLUENZA B/BRISBANE HEMAGGLUTININ FAB CR9115 SD84H COMPLEX
4FQK	;	5.65	;	Influenza B/Brisbane/60/2008 hemagglutinin Fab CR8059 complex
4FQJ	;	2.5	;	Influenza B/Florida/4/2006 hemagglutinin Fab CR8071 complex
6FS8	;	1.8	;	Influenza B/Memphis/13/03 endonuclease with bound inhibitor, baloxavir acid (BXA)
6FSB	;	1.8	;	Influenza B/Memphis/13/03 endonuclease with I38T mutation
6FS9	;	2.28	;	Influenza B/Memphis/13/03 endonuclease with I38T mutation with bound inhibitor, baloxavir acid (BXA)
6XZD	;	3.4	;	Influenza C virus polymerase complex without chicken ANP32A - Subclass 2
6XZR	;	3.3	;	Influenza C virus polymerase in complex with chicken ANP32A - Subclass 1
6XZG	;	3.8	;	Influenza C virus polymerase in complex with chicken ANP32A - Subclass 3
6XZP	;	3.3	;	Influenza C virus polymerase in complex with chicken ANP32A - Subclass 4
6XZQ	;	3.6	;	Influenza C virus polymerase in complex with human ANP32A - Subclass 1
6Y0C	;	3.2	;	Influenza C virus polymerase in complex with human ANP32A - Subclass 2
5D9A	;	4.3	;	Influenza C Virus RNA-dependent RNA Polymerase - Space group P212121
5D98	;	3.9	;	Influenza C Virus RNA-dependent RNA Polymerase - Space group P43212
5N2U	;	2.4	;	Influenza D virus nucleoprotein
5CXR	;	2.002	;	Influenza endonuclease complexed with 4-bromopyrazole
7DKG	;	3.0	;	Influenza H5N1 nucleoprotein (truncated) in complex with nucleotides
7DXP	;	2.3	;	Influenza H5N1 nucleoprotein in complex with nucleotides
2L4G	;		;	Influenza Haemagglutinin fusion peptide mutant G13A
6XPO	;	3.0	;	Influenza hemagglutinin A/Bangkok/01/1979(H3N2)
3UBQ	;	2.0	;	Influenza hemagglutinin from the 2009 pandemic in complex with ligand 3SLN
3UBN	;	2.5079	;	Influenza hemagglutinin from the 2009 pandemic in complex with ligand 6SLN
3UBJ	;	2.25	;	Influenza hemagglutinin from the 2009 pandemic in complex with ligand LSTa
3UBE	;	2.15	;	Influenza hemagglutinin from the 2009 pandemic in complex with ligand LSTc
2JRD	;		;	Influenza Hemagglutinin Fusion Domain Mutant F9A
5VMC	;	2.15	;	Influenza hemagglutinin H1 mutant DH1 in complex with 6'SLN
5VMF	;	2.35	;	Influenza hemagglutinin H1 mutant DH1D in complex with 6'SLN
5VMJ	;	2.95	;	Influenza hemagglutinin H1 mutant DH1E in complex with 3'SLN
5VMG	;	2.45	;	Influenza hemagglutinin H1 mutant DH1E in complex with 6'SLN
5KUY	;	2.598	;	Influenza hemagglutinin H3 A/Hong Kong/1/1968 in complex with designed inhibitor protein HSB.2A
5UGY	;	2.801	;	Influenza hemagglutinin in complex with a neutralizing antibody
4HKX	;	2.5	;	Influenza hemagglutinin in complex with CH67 Fab
4H53	;	1.5	;	Influenza N2-Tyr406Asp neuraminidase in complex with beta-Neu5Ac
4D8S	;	2.398	;	Influenza NA in complex with antiviral compound
3O9J	;	2.0002	;	Influenza NA in complex with compound 5
3O9K	;	2.4945	;	Influenza NA in complex with compound 6
4MJU	;	2.35	;	Influenza Neuraminidase in complex with a novel antiviral compound
4MJV	;	2.65	;	Influenza Neuraminidase in complex with a novel antiviral compound
4M3M	;	2.1	;	Influenza Neuraminidase in complex with a stereomutated analogue of Oseltamivir carboxylate
4KS1	;	2.2	;	Influenza neuraminidase in complex with antiviral compound (3S,4R,5R)-4-(acetylamino)-3-amino-5-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylic acid
4KS2	;	2.595	;	Influenza Neuraminidase in complex with antiviral compound (3S,4R,5R)-4-(acetylamino)-3-carbamimidamido-5-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylic acid
4KS5	;	2.699	;	Influenza neuraminidase in complex with antiviral compound (3S,4R,5R)-4-(acetylamino)-3-[4-(2-hydroxypropan-2-yl)-1H-1,2,3-triazol-1-yl]-5-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylic acid
4KS3	;	2.6	;	Influenza Neuraminidase in complex with antiviral compound (3S,4R,5R)-4-(acetylamino)-3-[4-(3-hydroxypropyl)-1H-1,2,3-triazol-1-yl]-5-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylic acid
4KS4	;	2.495	;	Influenza Neuraminidase in complex with antiviral compound (3S,4R,5R)-4-(acetylamino)-3-{4-[(1R)-1-hydroxypropyl]-1H-1,2,3-triazol-1-yl}-5-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylic acid
7U2Q	;	3.2	;	Influenza Neuraminidase N1-CA09-sNAp-155
7U2T	;	3.25	;	Influenza Neuraminidase N1-MI15-sNAp-174
8VGZ	;	2.09	;	Influenza PA-N Endonuclease E23K Mutant (amino acids 52-74 truncation)
5BUH	;	2.55	;	Influenza PB2 bound to a hydroxymethyl azaindole inhibitor
5F79	;	2.4	;	Influenza PB2 bound to an azaindole inhibitor
7ZPY	;	1.9	;	Influenza polymerase A C-terminal domain of PA subunit with optimized small peptide inhibitor
4NCE	;	2.3	;	Influenza polymerase basic protein 2 (PB2) bound to 7-methyl-GTP
4NCM	;	2.82	;	Influenza polymerase basic protein 2 (PB2) bound to a small-molecule inhibitor
4YD0	;	2.62	;	Influenza polymerase basic protein 2 (PB2) bound to an azaindole-tetrazole inhibitor
2W69	;	2.05	;	Influenza polymerase fragment
4AVQ	;	2.1	;	Influenza strain pH1N1 2009 polymerase subunit PA endonuclease
4AWM	;	2.6	;	Influenza strain pH1N1 2009 polymerase subunit PA endonuclease in complex with (-)-epigallocatechin gallate from green tea
4AWF	;	2.3	;	Influenza strain pH1N1 2009 polymerase subunit PA endonuclease in complex with 2 4-dioxo-4-phenylbutanoic acid DPBA
4AWK	;	1.9	;	Influenza strain pH1N1 2009 polymerase subunit PA endonuclease in complex with diketo compound 1
4AVG	;	2.2	;	Influenza strain pH1N1 2009 polymerase subunit PA endonuclease in complex with diketo compound 2
4AWG	;	2.6	;	Influenza strain pH1N1 2009 polymerase subunit PA endonuclease in complex with diketo compound 3
4AVL	;	1.87	;	Influenza strain pH1N1 2009 polymerase subunit PA endonuclease in complex with dTMP
4AWH	;	2.05	;	Influenza strain pH1N1 2009 polymerase subunit PA endonuclease in complex with rUMP
4DGR	;	1.551	;	Influenza Subtype 9 Neuraminidase Benzoic Acid Inhibitor Complex
3ZPB	;	2.6	;	INFLUENZA VIRUS (VN1194) H5 E190D mutant HA with LSTa
3ZP6	;	2.6	;	INFLUENZA VIRUS (VN1194) H5 E190D mutant HA with LSTc
2IBX	;	2.8	;	Influenza virus (VN1194) H5 HA
3ZP2	;	2.5	;	INFLUENZA VIRUS (VN1194) H5 HA A138V mutant with LSTa
3ZP3	;	2.65	;	INFLUENZA VIRUS (VN1194) H5 HA A138V mutant with LSTc
3ZP0	;	2.51	;	INFLUENZA VIRUS (VN1194) H5 HA with LSTa
3ZP1	;	2.6	;	INFLUENZA VIRUS (VN1194) H5 HA with LSTc
3ZPA	;	2.5	;	INFLUENZA VIRUS (VN1194) H5 I155F mutant HA
1A4Q	;	1.9	;	INFLUENZA VIRUS B/BEIJING/1/87 NEURAMINIDASE COMPLEXED WITH DIHYDROPYRAN-PHENETHYL-PROPYL-CARBOXAMIDE
1A4G	;	2.2	;	INFLUENZA VIRUS B/BEIJING/1/87 NEURAMINIDASE COMPLEXED WITH ZANAMIVIR
1INF	;	2.4	;	INFLUENZA VIRUS B/LEE/40 NEURAMINIDASE COMPLEXED WITH BANA113 INHIBITOR
7NT8	;	2.22	;	Influenza virus H3N2 nucleoprotein - R416A mutant
2VIU	;	2.5	;	INFLUENZA VIRUS HEMAGGLUTININ
1EO8	;	2.8	;	INFLUENZA VIRUS HEMAGGLUTININ COMPLEXED WITH A NEUTRALIZING ANTIBODY
1QFU	;	2.8	;	INFLUENZA VIRUS HEMAGGLUTININ COMPLEXED WITH A NEUTRALIZING ANTIBODY
2VIR	;	3.25	;	INFLUENZA VIRUS HEMAGGLUTININ COMPLEXED WITH A NEUTRALIZING ANTIBODY
1KEN	;	3.5	;	INFLUENZA VIRUS HEMAGGLUTININ COMPLEXED WITH AN ANTIBODY THAT PREVENTS THE HEMAGGLUTININ LOW PH FUSOGENIC TRANSITION
2VIS	;	3.25	;	INFLUENZA VIRUS HEMAGGLUTININ, (ESCAPE) MUTANT WITH THR 131 REPLACED BY ILE, COMPLEXED WITH A NEUTRALIZING ANTIBODY
2VIT	;	3.25	;	INFLUENZA VIRUS HEMAGGLUTININ, MUTANT WITH THR 155 REPLACED BY ILE, COMPLEXED WITH A NEUTRALIZING ANTIBODY
1EA3	;	2.3	;	Influenza virus M1 protein
1AA7	;	2.08	;	INFLUENZA VIRUS MATRIX PROTEIN CRYSTAL STRUCTURE AT PH 4.0
6HCX	;	1.3	;	Influenza Virus N9 Neuraminidase A complex with Zanamivir molecule (Tern).
4WEG	;	2.1	;	influenza virus neuraminidase N9 in complex 2,3-difluorosialic acid
5W26	;	1.9	;	INFLUENZA VIRUS NEURAMINIDASE N9 IN COMPLEX WITH 4-DEOXYGENATED 2,3-DIFLUORO-N-ACETYLNEURAMINIC ACID
5W2U	;	2.0	;	INFLUENZA VIRUS NEURAMINIDASE N9 IN COMPLEX WITH 7-DEOXYGENATED 2,3-DIFLUORO-N-ACETYLNEURAMINIC ACID
5W2W	;	1.85	;	INFLUENZA VIRUS NEURAMINIDASE N9 IN COMPLEX WITH 8-DEOXYGENATED 2,3-DIFLUORO-N-ACETYLNEURAMINIC ACID
5W2Y	;	2.39	;	INFLUENZA VIRUS NEURAMINIDASE N9 IN COMPLEX WITH 9-DEOXYGENATED 2,3-DIFLUORO-N-ACETYLNEURAMINIC ACID
6D3B	;	1.4	;	INFLUENZA VIRUS NEURAMINIDASE SUBTYPE N9 (TERN) APO FORM
3W09	;	2.0	;	Influenza virus neuraminidase subtype N9 (TERN) complexed with 2,3-dif guanidino-neu5ac2en inhibitor
1NNC	;	1.8	;	INFLUENZA VIRUS NEURAMINIDASE SUBTYPE N9 (TERN) COMPLEXED WITH 4-GUANIDINO-NEU5AC2EN INHIBITOR
6MCX	;	2.3	;	INFLUENZA VIRUS NEURAMINIDASE SUBTYPE N9 (TERN) RECOMBINANT HEAD DOMAIN
6CRD	;	2.57	;	INFLUENZA VIRUS NEURAMINIDASE SUBTYPE N9 (TERN) with tetrabrachion (TB) domain stalk
6J1U	;	2.8	;	influenza virus nucleoprotein with a specific inhibitor
5OIC	;	1.87	;	InhA (T2A mutant) complexed with (4-((1H-pyrazol-1-yl)methyl)phenyl)methanol
5OIP	;	1.71	;	InhA (T2A mutant) complexed with 1-(Pyridin-3-ylmethyl)-3-(1-(pyrimidin-2-yl)piperidin-4-yl)urea
5OIF	;	2.03	;	InhA (T2A mutant) complexed with 1-benzyl-3-methyl-1H-pyrazol-5-amine
5OIL	;	2.76	;	InhA (T2A mutant) complexed with 1-cyclohexyl-3-(pyridin-3-ylmethyl)urea
5OIR	;	1.97	;	InhA (T2A mutant) complexed with 2,6-Dimethyl-3-(1-(pyrimidin-2-yl)piperidin-4-yl)pyridin-4(1H)-one
5OIQ	;	2.65	;	InhA (T2A mutant) complexed with 2,6-dimethyl-3-phenylpyridin-4(1H)-one
5OIS	;	2.24	;	InhA (T2A mutant) complexed with 4-((5-Amino-3-methyl-1H-pyrazol-1-yl)methyl)-N-(2-chloro-4-fluorobenzyl)benzamide
5OIO	;	2.74	;	InhA (T2A mutant) complexed with 5-((3,5-dimethyl-1H-pyrazol-1-yl)methyl)-N-ethyl-1,3,4-thiadiazol-2-amine
5OIT	;	2.58	;	InhA (T2A mutant) complexed with 5-((5-Amino-3-methyl-1H-pyrazol-1-yl)methyl)-N-(1-(2-chloro-6-fluorobenzyl)-1H-pyrazol-3-yl)-1,3,4-thiadiazol-2-amine
5OIM	;	1.91	;	InhA (T2A mutant) complexed with ethyl 2-methyl-4,5,6,7-tetrahydrobenzo[d]thiazole-6-carboxylate
5OIN	;	2.82	;	InhA (T2A mutant) complexed with N-(1-(pyrimidin-2-yl)piperidin-4-yl)acetamide
5G0S	;	1.74	;	InhA in complex with a DNA encoded library hit
5G0T	;	1.54	;	InhA in complex with a DNA encoded library hit
5G0U	;	1.73	;	InhA in complex with a DNA encoded library hit
5G0V	;	1.79	;	InhA in complex with a DNA encoded library hit
5G0W	;	1.79	;	InhA in complex with a DNA encoded library hit
6EP8	;	1.8	;	InhA Y158F mutant in complex with NADH from Mycobacterium tuberculosis
4V08	;	2.03	;	Inhibited dimeric pseudorabies virus protease pUL26N at 2 A resolution
1MDM	;	2.8	;	INHIBITED FRAGMENT OF ETS-1 AND PAIRED DOMAIN OF PAX5 BOUND TO DNA
5SUL	;	3.3	;	Inhibited state structure of yGsy2p
6GK9	;	2.54	;	Inhibited structure of IMPDH from Pseudomonas aeruginosa
4D9Q	;	2.28	;	Inhibiting Alternative Pathway Complement Activation by Targeting the Exosite on Factor D
4D9R	;	2.42	;	Inhibiting Alternative Pathway Complement Activation by Targeting the Exosite on Factor D
5HHV	;	2.2	;	Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide
5HHX	;	3.0	;	Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide
7PJE	;	1.75	;	Inhibiting parasite proliferation using a rationally designed anti-tubulin agent
7PJF	;	1.862	;	Inhibiting parasite proliferation using a rationally designed anti-tubulin agent
3MU6	;	2.434	;	Inhibiting the Binding of Class IIa Histone Deacetylases to Myocyte Enhancer Factor-2 by Small Molecules
4DFU	;	1.98	;	Inhibition of an antibiotic resistance enzyme: crystal structure of aminoglycoside phosphotransferase APH(2"")-ID/APH(2"")-IVA in complex with kanamycin inhibited with quercetin
1BLC	;	2.2	;	INHIBITION OF BETA-LACTAMASE BY CLAVULANATE: TRAPPED INTERMEDIATES IN CRYOCRYSTALLOGRAPHIC STUDIES
2OSF	;	1.6	;	Inhibition of Carbonic Anhydrase II by Thioxolone: A Mechanistic and Structural Study
2OSM	;	1.6	;	Inhibition of Carbonic Anhydrase II by Thioxolone: A Mechanistic and Structural Study
2P2C	;	3.24	;	Inhibition of caspase-2 by a designed ankyrin repeat protein (DARPin)
3V6M	;	2.692	;	Inhibition of caspase-6 activity by single mutation outside the active site
1EO3	;	2.0	;	INHIBITION OF ECORV ENDONUCLEASE BY DEOXYRIBO-3'-S-PHOSPHOROTHIOLATES: A HIGH RESOLUTION X-RAY CRYSTALLOGRAPHIC STUDY
5ENL	;	2.2	;	INHIBITION OF ENOLASE: THE CRYSTAL STRUCTURES OF ENOLASE-CA2+-PHOSPHOGLYCERATE AND ENOLASE-ZN2+-PHOSPHOGLYCOLATE COMPLEXES AT 2.2-ANGSTROMS RESOLUTION
6ENL	;	2.2	;	INHIBITION OF ENOLASE: THE CRYSTAL STRUCTURES OF ENOLASE-CA2+-PHOSPHOGLYCERATE AND ENOLASE-ZN2+-PHOSPHOGLYCOLATE COMPLEXES AT 2.2-ANGSTROMS RESOLUTION
1QR8	;	2.1	;	INHIBITION OF HIV-1 INFECTIVITY BY THE GP41 CORE: ROLE OF A CONSERVED HYDROPHOBIC CAVITY IN MEMBRANE FUSION
1QR9	;	1.6	;	INHIBITION OF HIV-1 INFECTIVITY BY THE GP41 CORE: ROLE OF A CONSERVED HYDROPHOBIC CAVITY IN MEMBRANE FUSION
1GRH	;	3.0	;	INHIBITION OF HUMAN GLUTATHIONE REDUCTASE BY THE NITROSOUREA DRUGS 1,3-BIS(2-CHLOROETHYL)-1-NITROSOUREA AND 1-(2-CHLOROETHYL)-3-(2-HYDROXYETHYL)-1-NITROSOUREA
1HOS	;	2.3	;	INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS-1 PROTEASE BY A C2-SYMMETRIC PHOSPHINATE SYNTHESIS AND CRYSTALLOGRAPHIC ANALYSIS
7UJ4	;	1.96	;	Inhibition of Human Menin by SNDX-5613
8E90	;	1.85	;	Inhibition of Human Menin by SNDX-5613
6PKC	;	1.9	;	Inhibition of Human Menin by VTP-50469
1W0C	;	2.6	;	Inhibition of Leishmania major pteridine reductase (PTR1) by 2,4,6-triaminoquinazoline; structure of the NADP ternary complex.
1XBP	;	3.5	;	Inhibition of peptide bond formation by pleuromutilins: The structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with Tiamulin
1OXL	;	1.8	;	INHIBITION OF PHOSPHOLIPASE A2 (PLA2) BY (2-CARBAMOYLMETHYL-5-PROPYL-OCTAHYDRO-INDOL-7-YL)-ACETIC ACID (INDOLE): CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN PLA2 FROM RUSSELL'S VIPER AND INDOLE AT 1.8 RESOLUTION
2XDW	;	1.35	;	Inhibition of Prolyl Oligopeptidase with a Synthetic Unnatural Dipeptide
3PRK	;	2.2	;	INHIBITION OF PROTEINASE K BY METHOXYSUCCINYL-ALA-ALA-PRO-ALA-CHLOROMETHYL KETONE. AN X-RAY STUDY AT 2.2-ANGSTROMS RESOLUTION
1K0U	;	3.0	;	Inhibition of S-adenosylhomocysteine Hydrolase by ""acyclic sugar"" Adenosine Analogue D-eritadenine
4KLZ	;	2.3	;	Inhibition of Small GTPases by Stabilization of the GDP Complex, a Novel Approach applied to Rit1, a Target for Rheumatoid Arthritis
2X05	;	2.3	;	Inhibition of the exo-beta-D-glucosaminidase CsxA by a glucosamine- configured castanospermine and an amino-australine analogue
2X09	;	2.4	;	Inhibition of the exo-beta-D-glucosaminidase CsxA by a glucosamine- configured castanospermine and an amino-australine analogue
359D	;	2.9	;	INHIBITION OF THE HAMMERHEAD RIBOZYME CLEAVAGE REACTION BY SITE-SPECIFIC BINDING OF TB(III)
1DXP	;	2.4	;	Inhibition of the Hepatitis C Virus NS3/4A Protease. The Crystal Structures of Two Protease-Inhibitor Complexes (apo structure)
1DY9	;	2.1	;	Inhibition of the Hepatitis C Virus NS3/4A Protease. The Crystal Structures of Two Protease-Inhibitor Complexes (inhibitor I)
1DY8	;	2.4	;	Inhibition of the Hepatitis C Virus NS3/4A Protease. The Crystal Structures of Two Protease-Inhibitor Complexes (inhibitor II)
2UWD	;	1.9	;	Inhibition of the HSP90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole, isoxazole amide analogs
2XBN	;	1.4	;	Inhibition of the PLP-dependent enzyme serine palmitoyltransferase by cycloserine: evidence for a novel decarboxylative mechanism of inactivation
2YL5	;	2.15	;	Inhibition of the pneumococcal virulence factor StrH and molecular insights into N-glycan recognition and hydrolysis
2YL6	;	1.6	;	Inhibition of the pneumococcal virulence factor StrH and molecular insights into N-glycan recognition and hydrolysis
2YL8	;	1.75	;	Inhibition of the pneumococcal virulence factor StrH and molecular insights into N-glycan recognition and hydrolysis
2YL9	;	2.65	;	INHIBITION OF THE PNEUMOCOCCAL VIRULENCE FACTOR STRH AND MOLECULAR INSIGHTS INTO N-GLYCAN RECOGNITION AND HYDROLYSIS
2YLA	;	2.7	;	INHIBITION OF THE PNEUMOCOCCAL VIRULENCE FACTOR STRH AND MOLECULAR INSIGHTS INTO N-GLYCAN RECOGNITION AND HYDROLYSIS
2YLL	;	1.85	;	Inhibition of the pneumococcal virulence factor StrH and molecular insights into N-glycan recognition and hydrolysis
1YQS	;	1.05	;	Inhibition of the R61 DD-Peptidase by N-benzoyl-beta-sultam
1ALW	;	2.03	;	INHIBITOR AND CALCIUM BOUND DOMAIN VI OF PORCINE CALPAIN
8A0B	;	1.746	;	Inhibitor binding to HDAC2
5D2R	;	1.9	;	Inhibitor Bound Cell Shape Determinant Protein Csd4 from Helicobacter pylori
5ZRN	;	2.37	;	Inhibitor bound crystal structure of N-terminal domain of FACL13 from Mycobacterium tuberculosis
1R4L	;	3.0	;	Inhibitor Bound Human Angiotensin Converting Enzyme-Related Carboxypeptidase (ACE2)
3QUP	;	1.9	;	Inhibitor bound structure of the kinase domain of the murine receptor tyrosine kinase TYRO3 (Sky)
4FEQ	;	2.2	;	Inhibitor bound structure of the kinase domain of the murine receptor tyrosine kinase TYRO3 (Sky)
4FF8	;	2.4	;	Inhibitor bound structure of the kinase domain of the murine receptor tyrosine kinase TYRO3 (Sky)
3LCD	;	2.5	;	Inhibitor Bound to A DFG-In structure of the Kinase Domain of CSF-1R
3LCO	;	3.4	;	Inhibitor Bound to A DFG-Out structure of the Kinase Domain of CSF-1R
7UYA	;	1.01	;	Inhibitor bound VIM1
7UYB	;	1.11	;	Inhibitor bound VIM1
7UYC	;	1.02	;	Inhibitor bound VIM1
7UYD	;	1.0	;	Inhibitor bound VIM1
2B1P	;	1.9	;	inhibitor complex of JNK3
2EXC	;	2.75	;	Inhibitor complex of JNK3
7NEE	;	2.55	;	Inhibitor Complex with Thrombin Activatable Fibrinolysis inhibitor (TAFIa)
7NEU	;	2.8	;	Inhibitor Complex with Thrombin Activatable Fibrinolysis Inhibitor (TAFIa)
6WI8	;	3.092	;	Inhibitor compound-induced confrontational change in Ring1b-Bmi1 domain structure
2C4B	;	1.3	;	Inhibitor cystine knot protein McoEeTI fused to the catalytically inactive barnase mutant H102A
2KTZ	;		;	Inhibitor Induced Structural Change in the HCV IRES Domain IIa RNA
2KU0	;		;	Inhibitor Induced Structural Change in the HCV IRES Domain IIa RNA
6RQ4	;	1.96	;	Inhibitor of ERK2
1IZH	;	1.9	;	Inhibitor of HIV protease with unusual binding mode potently inhibiting multi-resistant protease mutants
1IZI	;	2.15	;	Inhibitor of HIV protease with unusual binding mode potently inhibiting multi-resistant protease mutants
7BIR	;	2.02	;	Inhibitor of MDM2-p53 Interaction
7BIT	;	2.13	;	Inhibitor of MDM2-p53 Interaction
7BIV	;	1.64	;	Inhibitor of MDM2-p53 Interaction
7BJ0	;	2.0	;	Inhibitor of MDM2-p53 Interaction
7BJ6	;	1.59	;	Inhibitor of MDM2-p53 Interaction
7BMG	;	1.83	;	Inhibitor of MDM2-p53 Interaction
1E0H	;		;	Inhibitor Protein Im9 bound to its partner E9 DNase
4JLF	;	2.1	;	Inhibitor resistant (R220A) substitution in the Mycobacterium tuberculosis beta-lactamase
5JL4	;	1.758	;	Inhibitor resistant mutant catalytic core domain of HIV-1 Integrase
8DWL	;	2.0	;	Inhibitor-3:PP1 coexpressed complex
8DWK	;	2.5	;	Inhibitor-3:PP1 reconstituted complex
4J2T	;	3.2	;	Inhibitor-bound Ca2+ ATPase
8H3U	;	4.7	;	Inhibitor-bound EP, polyA model
2IWK	;	1.7	;	Inhibitor-bound form of nitrous oxide reductase from Achromobacter Cycloclastes at 1.7 Angstrom resolution
2ZDX	;	2.54	;	Inhibitor-bound structures of human pyruvate dehydrogenase kinase 4
2ZDY	;	2.4	;	Inhibitor-bound structures of human pyruvate dehydrogenase kinase 4
1AYK	;		;	INHIBITOR-FREE CATALYTIC FRAGMENT OF HUMAN FIBROBLAST COLLAGENASE, NMR, 30 STRUCTURES
2AYK	;		;	INHIBITOR-FREE CATALYTIC FRAGMENT OF HUMAN FIBROBLAST COLLAGENASE, NMR, MINIMIZED AVERAGE STRUCTURE
2PGB	;	1.54	;	Inhibitor-free human thrombin mutant C191A-C220A
1PHA	;	1.63	;	INHIBITOR-INDUCED CONFORMATIONAL CHANGE IN CYTOCHROME P450-CAM
1PHB	;	1.6	;	INHIBITOR-INDUCED CONFORMATIONAL CHANGE IN CYTOCHROME P450-CAM
7QG0	;	4.02	;	Inhibitor-induced hSARM1 duplex
3LTN	;	3.1	;	Inhibitor-stabilized topoisomerase IV-DNA cleavage complex (S. pneumoniae)
4NAT	;	1.72	;	Inhibitors of 4-Phosphopanthetheine Adenylyltransferase
4NAH	;	2.38	;	Inhibitors of 4-Phosphopanthetheine Adenylyltransferase (PPAT)
3LKH	;	2.05	;	Inhibitors of Hepatitis C Virus Polymerase: Synthesis and Characterization of Novel 6-Fluoro-N-[2-Hydroxy-1(S)-Benzamides
2YCM	;	1.8	;	Inhibitors of herbicidal target IspD
2XA4	;	2.04	;	Inhibitors of Jak2 Kinase domain
3ZMM	;	2.51	;	Inhibitors of Jak2 Kinase domain
4C61	;	2.45	;	Inhibitors of Jak2 Kinase domain
4C62	;	2.75	;	Inhibitors of Jak2 Kinase domain
5ANQ	;	2.0	;	inhibitors of JumonjiC domain-containing histone demethylases
2YC3	;	1.4	;	Inhibitors of the herbicidal target IspD
2YC5	;	1.6	;	Inhibitors of the herbicidal target IspD
7AUW	;	2.8	;	Inhibitory complex of human meprin beta with mouse fetuin-B.
6Z85	;	2.9	;	inhibitory human GTP cyclohydrolase I - GFRP complex
7LLJ	;	3.15	;	Inhibitory immune receptor protein complex
7ZZU	;	1.85	;	Inhibitory Ligand binding to HDAC2
4LF3	;	2.735	;	Inhibitory Mechanism of an Allosteric Antibody Targeting the Glucagon Receptor
1NKR	;	1.7	;	INHIBITORY RECEPTOR (P58-CL42) FOR HUMAN NATURAL KILLER CELLS
6V6A	;	2.1	;	Inhibitory scaffolding of the ancient MAPK, ERK7
7S7T	;	3.2	;	iNicSnFR3a Nicotine Sensor comprising Periplasmic Binding sequence plus Fluorescent Sequence with varenicline bound
5U1F	;	6.8	;	Initial contact of HIV-1 Env with CD4: Cryo-EM structure of BG505 DS-SOSIP trimer in complex with CD4 and antibody PGT145
1Y63	;	1.7	;	Initial crystal structural analysis of a probable kinase from Leishmania major Friedlin
2IRT	;	3.2	;	INITIAL CRYSTALLOGRAPHIC ANALYSES OF A RECOMBINANT INTERLEUKIN-1 RECEPTOR ANTAGONIST PROTEIN
2B30	;	2.7	;	Initial Crystallographic Structural Analysis of a putative HAD/COF-like hydrolase from Plasmodium vivax
8EBV	;	7.1	;	Initial DNA-lesion (AP) binding by XPC and TFIIH complex 1
8EBW	;	5.6	;	Initial DNA-lesion (AP) binding by XPC and TFIIH complex2
8EBS	;	4.0	;	Initial DNA-lesion (Cy5) binding by XPC and TFIIH
1UWP	;	1.2	;	Initial Events in the Photocycle of Photoactive Yellow Protein
1YJ8	;	2.85	;	Initial structural analysis of Plasmodium falciparum Glycerol-3-phosphate dehydrogenase
1SYR	;	2.95	;	Initial Structural Analysis of Plasmodium falciparum thioredoxin
1SVV	;	2.1	;	Initial Stuctural Analysis of Leishmania major Threonine Aldolase
4EKB	;	1.52	;	Initial Thaumatin Structure for Radiation Damage Experiment at 100 K
4EKO	;	1.52	;	Initial Thaumatin Structure for Radiation Damage Experiment at 180 K
4EL2	;	1.52	;	Initial Thaumatin Structure for Radiation Damage Experiment at 240 K
4EK0	;	1.52	;	Initial Thaumatin Structure for Radiation Damage Experiment at 25 K
4EL7	;	1.52	;	Initial Thaumatin Structure for Radiation Damage Experiment at 300 K
4EP8	;	1.55	;	Initial Urease Structure for Radiation Damage Experiment at 100 K
4EPD	;	1.7	;	Initial Urease Structure for Radiation Damage Experiment at 300 K
7NWT	;	2.66	;	Initiated 70S ribosome in complex with 2A protein from encephalomyocarditis virus (EMCV)
4V6G	;	3.5	;	Initiation complex of 70S ribosome with two tRNAs and mRNA.
7PO2	;	3.09	;	Initiation complex of human mitochondrial ribosome small subunit with IF2, fMet-tRNAMet and mRNA
7PO1	;	2.92	;	Initiation complex of human mitochondrial ribosome small subunit with IF3
1N1H	;	2.8	;	Initiation complex of polymerase lambda3 from reovirus
8BIL	;	2.04	;	Initiation complex of the E. coli 70S ribosome with mRNA containing AAA codon in the A-site.
8BIM	;	2.04	;	Initiation complex of the E. coli 70S ribosome with mRNA containing AAm6A codon in the A-site
1BKB	;	1.75	;	INITIATION FACTOR 5A FROM ARCHEBACTERIUM PYROBACULUM AEROPHILUM
2WQX	;	2.03	;	InlB321_4R: S199R, D200R, G206R, A227R, C242A mutant of the Listeria monocytogenes InlB internalin domain
7NMS	;	1.8	;	InlB392_T332E: T332E variant of Listeria monocytogenes InlB (internalin B) residues 36-392
7PV8	;	2.05	;	InlB392_T332E: T332E variant of Listeria monocytogenes InlB (internalin B) residues 36-392
1FYC	;		;	INNER LIPOYL DOMAIN FROM HUMAN PYRUVATE DEHYDROGENASE (PDH) COMPLEX, NMR, 1 STRUCTURE
8TV9	;	8.15	;	Inner Mat-T4P complex
7OIU	;	3.7	;	Inner Membrane Complex (IMC) protomer structure (TrwM/VirB3, TrwK/VirB4, TrwG/VirB8tails) from the fully-assembled R388 type IV secretion system determined by cryo-EM.
8AXN	;	3.34	;	Inner membrane ring and secretin N0 N1 domains of the type 3 secretion system of Shigella flexneri
7N85	;	7.6	;	Inner ring spoke from the isolated yeast NPC
8TJ5	;	6.6	;	Inner spoke ring of the yeast NPC
1QJO	;		;	INNERMOST LIPOYL DOMAIN OF THE PYRUVATE DEHYDROGENASE FROM ESCHERICHIA COLI
1FAJ	;	2.15	;	INORGANIC PYROPHOSPHATASE
2EIP	;	2.2	;	INORGANIC PYROPHOSPHATASE
1K23	;	3.0	;	Inorganic Pyrophosphatase (Family II) from Bacillus subtilis
1K20	;	1.5	;	Inorganic Pyrophosphatase (family II) from Streptococcus gordonii at 1.5 A resolution
2AUU	;	1.22	;	Inorganic pyrophosphatase complexed with magnesium pyrophosphate and fluoride
2AU9	;	1.3	;	Inorganic pyrophosphatase complexed with substrate
1IPW	;	2.3	;	INORGANIC PYROPHOSPHATASE FROM ESCHERICHIA COLI WITH THREE MAGNESIUM IONS
5KDE	;	2.65	;	Inorganic pyrophosphatase from Mycobacterium tuberculosis in complex with inhibitor 1 and inorganic pyrophosphate
5KDF	;	2.45	;	Inorganic pyrophosphatase from Mycobacterium tuberculosis in complex with inhibitor 6 and inorganic pyrophosphate
1TWL	;	2.201	;	Inorganic pyrophosphatase from Pyrococcus furiosus Pfu-264096-001
2BQX	;	1.9	;	Inorganic Pyrophosphatase from the Pathogenic Bacterium Helicobacter pylori-Kinetic and Structural Properties
2BQY	;	2.3	;	Inorganic Pyrophosphatase from the Pathogenic Bacterium Helicobacter pylori-Kinetic and Structural Properties
1BWD	;	3.1	;	INOSAMINE-PHOSPHATE AMIDINOTRANSFERASE STRB1 FROM STREPTOMYCES GRISEUS
4FXS	;	2.24	;	Inosine 5'-monophosphate dehydrogenase from Vibrio cholerae complexed with IMP and mycophenolic acid
4FEZ	;	2.16	;	Inosine 5'-monophosphate dehydrogenase from Vibrio cholerae, deletion mutant
4IX2	;	2.146	;	Inosine 5'-monophosphate dehydrogenase from Vibrio cholerae, deletion mutant, complexed with IMP
4FO4	;	2.03	;	Inosine 5'-monophosphate dehydrogenase from Vibrio cholerae, deletion mutant, complexed with IMP and mycophenolic acid
4QNE	;	2.32	;	Inosine 5'-monophosphate dehydrogenase from Vibrio cholerae, deletion mutant, in complex with NAD and IMP
4QQ3	;	1.72	;	Inosine 5'-monophosphate dehydrogenase from Vibrio cholerae, deletion mutant, in complex with XMP
4X3Z	;	1.62	;	Inosine 5'-monophosphate dehydrogenase from Vibrio cholerae, deletion mutant, in complex with XMP and NAD
1AK5	;	2.3	;	INOSINE MONOPHOSPHATE DEHYDROGENASE (IMPDH) FROM TRITRICHOMONAS FOETUS
1MEH	;	1.95	;	Inosine Monophosphate Dehydrogenase (IMPDH) From Tritrichomonas Foetus with IMP and MOA bound
1ME9	;	2.2	;	Inosine Monophosphate Dehydrogenase (IMPDH) From Tritrichomonas Foetus with IMP bound
1ME7	;	2.15	;	Inosine Monophosphate Dehydrogenase (IMPDH) From Tritrichomonas Foetus with RVP and MOA bound
1ME8	;	1.9	;	Inosine Monophosphate Dehydrogenase (IMPDH) From Tritrichomonas Foetus with RVP bound
1MEI	;	2.2	;	Inosine Monophosphate Dehydrogenase (IMPDH) From Tritrichomonas Foetus with XMP and mycophenolic acid bound
1MEW	;	2.15	;	Inosine Monophosphate Dehydrogenase (IMPDH) From Tritrichomonas Foetus with XMP and NAD bound
1ZFJ	;	1.9	;	INOSINE MONOPHOSPHATE DEHYDROGENASE (IMPDH; EC 1.1.1.205) FROM STREPTOCOCCUS PYOGENES
114D	;	2.5	;	INOSINE-ADENINE BASE PAIRS IN A B-DNA DUPLEX
1KIE	;	2.0	;	Inosine-adenosine-guanosine preferring nucleoside hydrolase from Trypanosoma vivax: Asp10Ala mutant in complex with 3-deaza-adenosine
1KIC	;	1.6	;	Inosine-adenosine-guanosine preferring nucleoside hydrolase from Trypanosoma vivax: Asp10Ala mutant in complex with inosine
1R4F	;	2.3	;	Inosine-Adenosine-Guanosine Preferring Nucleoside Hydrolase From Trypanosoma vivax: Trp260Ala Mutant In Complex With 3-Deaza-Adenosine
3FZ0	;	2.5	;	Inosine-Guanosine Nucleoside Hydrolase (IG-NH)
4AXC	;	2.25	;	Inositol 1,3,4,5,6-pentakisphosphate 2-kinase apo form
3UDT	;	3.1	;	Inositol 1,3,4,5,6-pentakisphosphate 2-kinase from A. thaliana in complex with ADP and IP5.
2XAM	;	2.2	;	Inositol 1,3,4,5,6-pentakisphosphate 2-kinase from A. thaliana in complex with ADP and IP6.
3UDZ	;	2.5	;	Inositol 1,3,4,5,6-pentakisphosphate 2-kinase from A. thaliana in complex with ADP and IP6.
3UDS	;	3.1	;	Inositol 1,3,4,5,6-pentakisphosphate 2-kinase from A. thaliana in complex with ADP.
2XAN	;	2.2	;	inositol 1,3,4,5,6-pentakisphosphate 2-kinase from A. thaliana in complex with AMP PNP and IP5
6GFG	;	3.0	;	Inositol 1,3,4,5,6-pentakisphosphate 2-kinase from A. thaliana in complex with D-chiro-IP6 and ADP
2XAO	;	2.9	;	Inositol 1,3,4,5,6-pentakisphosphate 2-kinase from A. thaliana in complex with IP5
2XAR	;	3.1	;	Inositol 1,3,4,5,6-pentakisphosphate 2-kinase from A. thaliana in complex with IP6.
6FL3	;	2.36	;	Inositol 1,3,4,5,6-pentakisphosphate 2-kinase from A. thaliana in complex with myo-IP5 and ADP
6FJK	;	2.025	;	Inositol 1,3,4,5,6-pentakisphosphate 2-kinase from A. thaliana in complex with myo-IP6 and ADP
6GFH	;	2.65	;	Inositol 1,3,4,5,6-pentakisphosphate 2-kinase from A. thaliana in complex with neo-IP5 and ATP
6FL8	;	2.1	;	Inositol 1,3,4,5,6-pentakisphosphate 2-kinase from A. thaliana in complex with purpurogallin and ADP
5MW8	;	2.4	;	INOSITOL 1,3,4,5,6-PENTAKISPHOSPHATE 2-KINASE FROM M. MUSCULUS IN COMPLEX WITH ATP and IP5
5MWL	;	3.2	;	INOSITOL 1,3,4,5,6-PENTAKISPHOSPHATE 2-KINASE FROM M. MUSCULUS IN COMPLEX WITH ATP and IP5
5MWM	;	2.6	;	INOSITOL 1,3,4,5,6-PENTAKISPHOSPHATE 2-KINASE FROM M. MUSCULUS IN COMPLEX WITH IP6
4AXE	;	2.5	;	Inositol 1,3,4,5,6-pentakisphosphate 2-kinase in complex with ADP
4AQK	;	2.4	;	Inositol 1,3,4,5,6-pentakisphosphate 2-kinase in complex with ADP and IP6
4AXD	;	2.05	;	Inositol 1,3,4,5,6-pentakisphosphate 2-kinase in complex with AMPPNP
8OXE	;	2.26	;	Inositol 1,3,4-trisphosphate 5/6-kinase 1 from Solanum tuberosum (StITPK1) in complex with ADP/Mg2+
7PUP	;	1.91	;	INOSITOL 1,3,4-TRISPHOSPHATE 5/6-KINASE 4 from Arabidopsis thaliana (AtITPK4) in complex with ATP
1Z2N	;	1.2	;	Inositol 1,3,4-trisphosphate 5/6-kinase complexed Mg2+/ADP
1Z2O	;	1.24	;	Inositol 1,3,4-trisphosphate 5/6-Kinase in complex with mg2+/ADP/Ins(1,3,4,6)P4
1Z2P	;	1.22	;	Inositol 1,3,4-trisphosphate 5/6-Kinase in complex with Mg2+/AMP-PCP/Ins(1,3,4)P3
6X7Z	;	1.0	;	Inositol-bound structure of Marinomonas primoryensis PA14 carbohydrate-binding domain
1QL1	;	3.1	;	INOVIRUS (FILAMENTOUS BACTERIOPHAGE) STRAIN PF1 MAJOR COAT PROTEIN ASSEMBLY
1QL2	;	3.1	;	Inovirus (Filamentous Bacteriophage) Strain PF1 Major Coat Protein Assembly
1IFP	;	3.1	;	INOVIRUS (FILAMENTOUS BACTERIOPHAGE) STRAIN PF3 MAJOR COAT PROTEIN ASSEMBLY
5RWV	;	1.25	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1103351268
5RXD	;	1.33	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z111810692
5RXR	;	1.4	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1148747945
5RWH	;	1.56	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1152242726
5RYH	;	1.72	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1212984951
5RWY	;	1.35	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1259335913
5RX3	;	1.45	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1262327505
5RYF	;	1.49	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1266823232
5RY7	;	1.6	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1267773591
5RWK	;	1.32	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1267881672
5RXX	;	1.43	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1275599911
5RWN	;	1.38	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1310876699
5RYK	;	1.55	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1346370629
5RWL	;	1.37	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1348371854
5RWM	;	1.36	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z136583524
5RY8	;	1.43	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1374778753
5RWS	;	1.28	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1478435544
5RX7	;	1.36	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1545196403
5RX4	;	1.35	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1593306637
5RY5	;	1.54	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z166605480
5RXL	;	1.49	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1673618163
5RWD	;	1.29	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1675346324
5RYG	;	1.47	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z168883358
5RXJ	;	1.52	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1722836661
5RYA	;	1.32	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1741973467
5RYL	;	1.55	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1745658474
5RWG	;	1.46	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z17497990
5RXS	;	1.37	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1818332938
5RYC	;	1.56	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z18197050
5RX2	;	1.27	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1827898537
5RY2	;	1.54	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z19727416
5RW4	;	1.31	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z19735192
5RXZ	;	1.56	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z19739650
5RY6	;	1.74	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z198194394
5RWF	;	1.35	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1983897532
5RY3	;	1.5	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2027158783
5RW9	;	1.45	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z203581214
5RW3	;	1.37	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2064898339
5RXF	;	1.26	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2074076908
5RYJ	;	1.42	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2177153697
5RWW	;	1.16	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2241115980
5RXE	;	1.25	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z240654968
5RX5	;	1.28	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2443429438
5RXI	;	1.74	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2447286438
5RX1	;	1.31	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2466069494
5RXQ	;	1.65	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z26548083
5RW2	;	1.22	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2737076969
5RYI	;	1.45	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z274555794
5RY9	;	1.52	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z274575916
5RY0	;	1.98	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z275165822
5RW8	;	1.27	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z28290384
5RWR	;	1.43	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434783
5RWA	;	1.29	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434812
5RW6	;	1.32	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434816
5RXB	;	1.58	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434821
5RWJ	;	1.26	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434824
5RXA	;	1.24	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434829
5RXK	;	1.46	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434840
5RXW	;	1.34	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434856
5RXU	;	1.64	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434858
5RWE	;	1.34	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434865
5RXC	;	1.59	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434868
5RWC	;	1.4	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434879
5RX8	;	1.34	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434884
5RXM	;	1.46	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434894
5RWO	;	1.29	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434898
5RWB	;	1.25	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434899
5RXG	;	1.52	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434909
5RWI	;	1.29	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434926
5RXP	;	1.53	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434944
5RY1	;	1.52	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2940170964
5RY4	;	1.47	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z300245038
5RX6	;	1.45	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z30620520
5RXT	;	1.63	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z319545618
5RXY	;	1.4	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z32014663
5RWT	;	1.43	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z32327641
5RYE	;	1.7	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z33545544
5RWX	;	1.34	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z44567722
5RWQ	;	1.32	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z44592329
5RXV	;	1.5	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z45527714
5RX9	;	1.29	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z54226095
5RX0	;	1.43	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z57258487
5RWZ	;	1.42	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z57299529
5RWU	;	1.37	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z57778470
5RXO	;	1.71	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z68299550
5RW5	;	1.38	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z69092635
5RW7	;	1.23	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z86622311
5RWP	;	1.48	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z915492990
5RYB	;	1.55	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z927400026
5RXH	;	1.42	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z939944666
5RYD	;	1.6	;	INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z955369596
5ZNS	;	2.396	;	Insect chitin deacetylase
5ZNT	;	1.979	;	Insect chitin deacetylase
8TFV	;		;	INSECT DEFENSE PEPTIDE
1LQI	;		;	INSECTICIDAL ALPHA SCORPION TOXIN ISOLATED FROM THE VENOM OF SCORPION LEIURUS QUINQUESTRIATUS HEBRAEUS, NMR, 29 STRUCTURES
1LQH	;		;	INSECTICIDAL ALPHA SCORPION TOXIN ISOLATED FROM THE VENOM OF SCORPION LEIURUS QUINQUESTRIATUS HEBRAEUS, NMR, MINIMIZED AVERAGE STRUCTURE
1I5P	;	2.2	;	INSECTICIDAL CRYSTAL PROTEIN CRY2AA
1CIY	;	2.25	;	INSECTICIDAL TOXIN: STRUCTURE AND CHANNEL FORMATION
2WZQ	;	2.8	;	Insertion Mutant E173GP174 of the NS3 protease-helicase from dengue virus
3BQ1	;	2.7	;	Insertion ternary complex of Dbh DNA polymerase
5OWX	;	5.2	;	Inside-out FMDV A10 capsid
1S5J	;	2.4	;	Insight in DNA Replication: The crystal structure of DNA Polymerase B1 from the archaeon Sulfolobus solfataricus
1C12	;	2.6	;	INSIGHT IN ODORANT PERCEPTION: THE CRYSTAL STRUCTURE AND BINDING CHARACTERISTICS OF ANTIBODY FRAGMENTS DIRECTED AGAINST THE MUSK ODORANT TRASEOLIDE
1ESL	;	2.0	;	INSIGHT INTO E-SELECTIN(SLASH)LIGAND INTERACTION FROM THE CRYSTAL STRUCTURE AND MUTAGENESIS OF THE LEC(SLASH)EGF DOMAINS
3G78	;	2.8	;	Insight into group II intron catalysis from revised crystal structure
4LVH	;	2.8	;	Insight into highly conserved H1 subtype-specific epitopes in influenza virus hemagglutinin
6O44	;	1.83	;	Insight into subtilisin E-S7 cleavage pattern based on crystal structure and hydrolysates peptide analysis
6PAK	;	1.98	;	Insight into subtilisin E-S7 cleavage pattern based on crystal structure and hydrolysates peptide analysis
2LN4	;		;	Insight into the antimicrobial activities based on the Structure-activity relationships of coprisin isolated from the Dung Beetle, Copris tripartitus
7Y4N	;		;	Insight into the C-terminal SH3 domain mediated binding of Drosophila Drk to Sos and Dos
2WTX	;	2.2	;	Insight into the mechanism of enzymatic glycosyltransfer with retention through the synthesis and analysis of bisubstrate glycomimetics of trehalose-6-phosphate synthase
7B73	;	1.6	;	Insight into the molecular determinants of thermal stability in halohydrin dehalogenase HheD2.
5NWM	;		;	Insight into the molecular recognition mechanism of the coactivator NCoA1 by STAT6
5NWX	;	2.51	;	Insight into the molecular recognition mechanism of the coactivator NCoA1 by STAT6
3JB8	;	3.6	;	Insight into Three-dimensional structure of Maize Chlorotic Mottle Virus Revealed by Single Particle Analysis
2Z84	;	1.7	;	Insights from crystal and solution structures of mouse UfSP1
2FNQ	;	3.2	;	Insights from the X-ray crystal structure of coral 8R-lipoxygenase: calcium activation via A C2-like domain and a structural basis of product chirality
6SQX	;	1.4	;	Insights into a novel NlpC/P60 Endopeptidase from Photobacterium damselae subsp. piscicida
3HYM	;	2.8	;	Insights into Anaphase Promoting Complex TPR subdomain assembly from a CDC26-APC6 structure
3NRY	;	2.0	;	Insights into anti-parallel microtubule crosslinking by PRC1, a conserved microtubule binding protein
3NRX	;	1.75	;	Insights into anti-parallel microtubule crosslinking by PRC1, a conserved non-motor microtubule binding protein
2CIK	;	1.75	;	Insights Into Crossreactivity in Human Allorecognition: The Structure of HLA-B35011 Presenting an Epitope derived from Cytochrome P450.
4BH6	;	2.9	;	Insights into degron recognition by APC coactivators from the structure of an Acm1-Cdh1 complex
1J49	;	2.2	;	INSIGHTS INTO DOMAIN CLOSURE, SUBSTRATE SPECIFICITY AND CATALYSIS OF D-LACTATE DEHYDROGENASE FROM LACTOBACILLUS BULGARICUS
1J4A	;	1.9	;	INSIGHTS INTO DOMAIN CLOSURE, SUBSTRATE SPECIFICITY AND CATALYSIS OF D-LACTATE DEHYDROGENASE FROM LACTOBACILLUS BULGARICUS
3L7H	;	1.95	;	Insights into dynein assembly from a dynein intermediate chain light chain Roadblock structure
3L9K	;	3.0	;	Insights into dynein assembly from a dynein intermediate chain-light chain roadblock structure
1FFY	;	2.2	;	INSIGHTS INTO EDITING FROM AN ILE-TRNA SYNTHETASE STRUCTURE WITH TRNA(ILE) AND MUPIROCIN
1QU2	;	2.2	;	INSIGHTS INTO EDITING FROM AN ILE-TRNA SYNTHETASE STRUCTURE WITH TRNA(ILE) AND MUPIROCIN
1QU3	;	2.9	;	INSIGHTS INTO EDITING FROM AN ILE-TRNA SYNTHETASE STRUCTURE WITH TRNA(ILE) AND MUPIROCIN
1S78	;	3.25	;	Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
4YLF	;	2.301	;	Insights into flavin-based electron bifurcation via the NADH-dependent reduced ferredoxin-NADP oxidoreductase structure
4YRY	;	2.4	;	Insights into flavin-based electron bifurcation via the NADH-dependent reduced ferredoxin-NADP oxidoreductase structure
2KV1	;		;	Insights into Function, Catalytic Mechanism and Fold Evolution of Mouse Selenoprotein Methionine Sulfoxide Reductase B1 through Structural Analysis
4DCH	;	1.79	;	Insights into Glucokinase Activation Mechanism: Observation of Multiple Distinct Protein Conformations
5FQL	;	2.3	;	Insights into Hunter syndrome from the structure of iduronate-2- sulfatase
1CRL	;	2.06	;	INSIGHTS INTO INTERFACIAL ACTIVATION FROM AN 'OPEN' STRUCTURE OF CANDIDA RUGOSA LIPASE
2VEQ	;	2.49	;	Insights into kinetochore-DNA interactions from the structure of Cep3p
3D0P	;	1.8	;	Insights into RNA/DNA hybrid recognition and processing by RNase H from the crystal structure of a non-specific enzyme-dsDNA complex
1FQV	;	2.8	;	Insights into scf ubiquitin ligases from the structure of the skp1-skp2 complex
1FS1	;	1.8	;	INSIGHTS INTO SCF UBIQUITIN LIGASES FROM THE STRUCTURE OF THE SKP1-SKP2 COMPLEX
1FS2	;	2.9	;	INSIGHTS INTO SCF UBIQUITIN LIGASES FROM THE STRUCTURE OF THE SKP1-SKP2 COMPLEX
4FBN	;	2.4	;	Insights into structural integration of the PLCgamma regulatory region and mechanism of autoinhibition and activation based on key roles of SH2 domains
4PGI	;	2.08	;	Insights into Substrate and Metal Binding from the Crystal Structure of Cyanobacterial Aldehyde Deformylating Oxygenase with Substrate Analogs Bound
4PG0	;	1.9	;	Insights into Substrate and Metal Binding from the Crystal Structure of Cyanobacterial Aldehyde Deformylating Oxygenase with Substrate Bound
4PG1	;	1.7	;	Insights into Substrate and Metal Binding from the Crystal Structure of Cyanobacterial Aldehyde Deformylating Oxygenase with Substrate Bound
4PGK	;	2.17	;	Insights into Substrate and Metal Binding from the Crystal Structure of Cyanobacterial Aldehyde Deformylating Oxygenase with Substrate Bound
4TW3	;	1.6	;	Insights into Substrate and Metal Binding from the Crystal Structure of Cyanobacterial Aldehyde Deformylating Oxygenase with Substrate Bound
3K1A	;	2.23	;	Insights into substrate binding at FeMo-cofactor in nitrogenase from the structure of an alpha-70Ile MoFe protein variant
5I0K	;	3.197	;	Insights into Substrate Modification by Dehydratases from Type I Polyketide Synthases
3GKK	;	1.83	;	Insights into the Alkyl Peroxide Reduction Activity of Xanthomonas campestris Bacterioferritin Comigratory Protein from the Trapped Intermediate/Ligand Complex Structures
3GKM	;	1.53	;	Insights into the Alkyl Peroxide Reduction Activity of Xanthomonas campestris Bacterioferritin Comigratory Protein from the Trapped Intermediate/Ligand Complex Structures
3GKN	;	1.47	;	Insights into the Alkyl Peroxide Reduction Activity of Xanthomonas campestris Bacterioferritin Comigratory Protein from the Trapped Intermediate/Ligand Complex Structures
3MYH	;	2.01	;	Insights into the Importance of Hydrogen Bonding in the Gamma-Phosphate Binding Pocket of Myosin: Structural and Functional Studies of Ser236
3MYK	;	1.84	;	Insights into the Importance of Hydrogen Bonding in the Gamma-Phosphate Binding Pocket of Myosin: Structural and Functional Studies of Ser236
3MYL	;	2.0	;	Insights into the Importance of Hydrogen Bonding in the Gamma-Phosphate Binding Pocket of Myosin: Structural and Functional Studies of Ser236
4PQT	;	2.05	;	Insights into the mechanism of deubiquitination by JAMM deubiquitinases from co-crystal structures of enzyme with substrate and product
3E0D	;	4.6	;	Insights into the Replisome from the Crystral Structure of the Ternary Complex of the Eubacterial DNA Polymerase III alpha-subunit
2C8V	;	2.5	;	Insights into the role of nucleotide-dependent conformational change in nitrogenase catalysis: Structural characterization of the nitrogenase Fe protein Leu127 deletion variant with bound MgATP
3N4N	;	1.92	;	Insights into the stabilizing contributions of a bicyclic cytosine analogue: crystal structures of DNA duplexes containing 7,8-dihydropyrido[2,3-d]pyrimidin-2-one
3N4O	;	2.9	;	Insights into the stabilizing contributions of a bicyclic cytosine analogue: crystal structures of DNA duplexes containing 7,8-dihydropyrido[2,3-d]pyrimidin-2-one
1YOV	;	2.6	;	Insights into the Ubiquitin Transfer Cascade from the refined structure of the activating enzyme for NEDD8
4V5E	;	3.45	;	Insights into translational termination from the structure of RF2 bound to the ribosome
5UZD	;		;	Insights into Watson-Crick/Hoogsteen Breathing Dynamics and Damage Repair from the Solution Structure and Dynamic Ensemble of DNA Duplexes containing m1A - A2-DNA structure
5UZF	;		;	Insights into Watson-Crick/Hoogsteen Breathing Dynamics and Damage Repair from the Solution Structure and Dynamic Ensemble of DNA Duplexes containing m1A - A6-DNA structure
5UZI	;		;	Insights into Watson-Crick/Hoogsteen Breathing Dynamics and Damage Repair from the Solution Structure and Dynamic Ensemble of DNA Duplexes containing m1A - A6-DNAm1A16 structure
6ATG	;	1.8	;	Insights to complement factor H recruitment by the borrelial CspZ protein as revealed by structural analysis
4AXF	;	2.93	;	InsP5 2-K in complex with Ins(3,4,5,6)P4 plus AMPPNP
1ZNI	;	1.498	;	INSULIN
2BN1	;	1.4	;	Insulin after a high dose x-ray burn
6CK2	;	2.25	;	Insulin analog containing a YB26W mutation
6Z7X	;	2.15	;	Insulin analytical antibody OXI-005 Fab
1GUJ	;	1.62	;	Insulin at pH 2: structural analysis of the conditions promoting insulin fibre formation.
2BN3	;	1.4	;	Insulin before a high dose x-ray burn
4XC4	;	1.499	;	Insulin co-crystallizes in the presence of it beta-cell chaperone sulfatide
2G4M	;	1.8	;	Insulin collected at 2.0 A wavelength
1BEN	;	1.4	;	INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE
7RZH	;	3.8	;	Insulin Degrading Enzyme O/O
7RZF	;	3.4	;	Insulin Degrading Enzyme O/pC
7RZG	;	4.1	;	Insulin Degrading Enzyme O/pO
7RZI	;	3.0	;	Insulin Degrading Enzyme pC/pC
7RZE	;	3.3	;	Insulin Degrading Enzyme pO/pC
3P2X	;	2.0	;	Insulin fibrillation is the Janus face of induced fit. A chiaral clamp stabilizes the native state at the expense of activity
3P33	;	2.3	;	Insulin fibrillation is the Janus face of induced fit. A chiral clamp stabilizes the native state at the expense of activity
4IYD	;	1.66	;	Insulin glargine crystal structure 1
4IYF	;	1.8	;	Insulin glargine crystal structure 2
6GV0	;	1.26	;	Insulin glulisine
4OGA	;	3.5	;	Insulin in complex with Site 1 of the human insulin receptor
6NWV	;	1.601	;	Insulin Lispro Analog
1HUI	;		;	INSULIN MUTANT (B1, B10, B16, B27)GLU, DES-B30, NMR, 25 STRUCTURES
1IOG	;		;	INSULIN MUTANT A3 GLY,(B1, B10, B16, B27)GLU, DES-B30, NMR, 19 STRUCTURES
1IOH	;		;	INSULIN MUTANT A8 HIS,(B1, B10, B16, B27)GLU, DES-B30, NMR, 26 STRUCTURES
1A7F	;		;	INSULIN MUTANT B16 GLU, B24 GLY, DES-B30, NMR, 20 STRUCTURES
4I5Y	;	1.8	;	Insulin protein crystallization via langmuir-blodgett
4I5Z	;	1.8	;	Insulin protein crystallization via langmuir-blodgett
2HR7	;	2.32	;	Insulin receptor (domains 1-3)
5KQV	;	4.4	;	Insulin receptor ectodomain construct comprising domains L1,CR,L2, FnIII-1 and alphaCT peptide in complex with bovine insulin and FAB 83-14 (REVISED STRUCTURE)
3W12	;	4.301	;	Insulin receptor ectodomain construct comprising domains L1-CR in complex with high-affinity insulin analogue [D-PRO-B26]-DTI-NH2, alpha-CT peptide(704-719) and FAB 83-7
3W13	;	4.303	;	Insulin receptor ectodomain construct comprising domains L1-CR in complex with high-affinity insulin analogue [D-PRO-B26]-DTI-NH2, alphact peptide(693-719) and FAB 83-7
3W11	;	3.9	;	Insulin receptor ectodomain construct comprising domains L1-CR in complex with human insulin, Alpha-CT peptide(704-719) and FAB 83-7
7MD4	;	4.5	;	Insulin receptor ectodomain dimer complexed with two IRPA-3 partial agonists
7MD5	;	5.2	;	Insulin receptor ectodomain dimer complexed with two IRPA-9 partial agonists
6CE7	;	7.4	;	Insulin Receptor ectodomain in complex with one insulin molecule
6CE9	;	4.3	;	Insulin Receptor ectodomain in complex with two insulin molecules
6CEB	;	4.7	;	Insulin Receptor ectodomain in complex with two insulin molecules - C1 symmetry
3EKK	;	2.1	;	Insulin receptor kinase complexed with an inhibitor
3EKN	;	2.2	;	Insulin receptor kinase complexed with an inhibitor
7KD6	;	2.6	;	Insulin Receptor L1-CR plus alphaCT fragment in co-complex with Fv 83-7 and single-chain insulin SCI-b
5C97	;	3.37	;	Insulin regulated aminopeptidase
7ZYF	;	2.81	;	Insulin regulated aminopeptidase (IRAP) in complex with a nanomolar alpha hydroxy beta amino acid based inhibitor.
8CGP	;	2.62	;	Insulin regulated aminopeptidase (IRAP) in complex with an allosteric aryl sulfonamide inhibitor
8HSK	;	1.64	;	Insulin single mutant INS-Q
5LIS	;	2.293	;	Insulin solved by Native SAD from a dataset collected in one second
8HSF	;	2.9	;	Insulin triple mutant INS-RQD
5USV	;	1.3	;	Insulin with proline analog AzeP at position B28 in the T2 state
5UU3	;	2.25	;	Insulin with proline analog DfP at position B28 in the R6 state
5URU	;	2.41	;	Insulin with proline analog DhP at position B28 in the R6 state
5URT	;	1.18	;	Insulin with proline analog DhP at position B28 in the T2 state
5UOZ	;	1.17464	;	Insulin with proline analog FyP at position B28 in the T2 state
5UQA	;	1.31	;	Insulin with proline analog FzP at position B28 in the R6 state
5HPU	;	2.2	;	Insulin with proline analog HyP at position B28 in the R6 state
5HPR	;	1.33	;	Insulin with proline analog HyP at position B28 in the T2 state
5HRQ	;	1.28	;	Insulin with proline analog HzP at position B28 in the R6 state
5HQI	;	0.97	;	Insulin with proline analog HzP at position B28 in the T2 state
5USS	;	2.061	;	Insulin with proline analog PiP at position B28 in the R6 state
5USP	;	1.174	;	Insulin with proline analog Pip at position B28 in the T2 state
5UU4	;	1.973	;	Insulin with proline analog ThioP at position B28 in the R6 state
5UU2	;	1.223	;	Insulin with proline analog ThioP at position B28 in the T2 state
3JSD	;	2.5	;	Insulin's biosynthesis and activity have opposing structural requirements: a new factor in neonatal diabetes mellitus
3ROV	;	2.3	;	Insulin's biosynthesis and activity have opposing structural requirements: a new factor in neonatal diabetes mellitus
1ZNJ	;	2.0	;	INSULIN, MONOCLINIC CRYSTAL FORM
7XRX	;	1.882	;	insulin-cleaving membrane protease-ICMP
4XSS	;	3.0	;	Insulin-like growth factor I in complex with site 1 of a hybrid insulin receptor / Type 1 insulin-like growth factor receptor
1PMX	;		;	INSULIN-LIKE GROWTH FACTOR-I BOUND TO A PHAGE-DERIVED PEPTIDE
1B9G	;		;	INSULIN-LIKE-GROWTH-FACTOR-1
8CGW	;	3.03	;	Insulin-regulated aminopeptidase (IRAP) in complex with an allosteric benzopyran-based inhibitor
6YDX	;	3.2	;	Insulin-regulated aminopeptidase complexed with a macrocyclic peptidic inhibitor
2C8Q	;	1.95	;	insuline(1sec) and UV laser excited fluorescence
2C8R	;	1.5	;	insuline(60sec) and UV laser excited fluorescence
5X6O	;	3.9	;	Intact ATR/Mec1-ATRIP/Ddc2 complex
6WSI	;	1.749	;	Intact cis-2,3-epoxysuccinic acid bound to Isocitrate Lyase-1 from Mycobacterium tuberculosis
1EFC	;	2.05	;	INTACT ELONGATION FACTOR FROM E.COLI
1TUI	;	2.7	;	INTACT ELONGATION FACTOR TU IN COMPLEX WITH GDP
6K7Y	;	3.6	;	Intact human mitochondrial calcium uniporter complex with MICU1/MICU2 subunits
1LBH	;	3.2	;	INTACT LACTOSE OPERON REPRESSOR WITH GRATUITOUS INDUCER IPTG
5D4I	;	1.6	;	Intact nitrite complex of a copper nitrite reductase determined by serial femtosecond crystallography
3DZU	;	3.2	;	Intact PPAR gamma - RXR alpha Nuclear Receptor Complex on DNA bound with BVT.13, 9-cis Retinoic Acid and NCOA2 Peptide
3E00	;	3.1	;	Intact PPAR gamma - RXR alpha Nuclear Receptor Complex on DNA bound with GW9662, 9-cis Retinoic Acid and NCOA2 Peptide
3DZY	;	3.1	;	Intact PPAR gamma - RXR alpha Nuclear Receptor Complex on DNA bound with Rosiglitazone, 9-cis Retinoic Acid and NCOA2 Peptide
1PSI	;	2.92	;	Intact recombined alpha1-antitrypsin mutant PHE 51 to LEU
4G8K	;	2.4	;	Intact sensor domain of human RNase L in the inactive signaling state
7E8S	;	4.36	;	Intact TRAPPII (state I).
7E94	;	4.67	;	Intact TRAPPII (State II)
7E93	;	6.54	;	Intact TRAPPII (state III).
7EA3	;	4.31	;	Intact Ypt32-TRAPPII (dimer).
8SMU	;	2.45	;	Integral fusion of the HtaA CR2 domain from Corynebacterium diphtheriae within EGFP
2LJ2	;		;	Integral membrane core domain of the mercury transporter MerF in lipid bilayer membranes
3AEH	;	2.0	;	Integral membrane domain of autotransporter Hbp
1KZU	;	2.5	;	INTEGRAL MEMBRANE PERIPHERAL LIGHT HARVESTING COMPLEX FROM RHODOPSEUDOMONAS ACIDOPHILA STRAIN 10050
5FGN	;	2.75	;	Integral membrane protein lipooligosaccharide phosphoethanolamine transferase A (EptA) from Neisseria meningitidis
5VFZ	;	1.847	;	Integrase from mycobacterium phage Brujita
5YLX	;	2.2	;	Integrated illustration of a valid epitope based on the SLA class I structure and tetramer technique could carry forward the development of molecular vaccine in swine species
8CLR	;		;	Integrated NMR/MD structure determination of a dynamic and thermodynamically stable CUUG RNA tetraloop
2ZME	;	2.9	;	Integrated structural and functional model of the human ESCRT-II complex
3CUQ	;	2.61	;	Integrated structural and functional model of the human ESCRT-II complex
1IHF	;	2.5	;	INTEGRATION HOST FACTOR/DNA COMPLEX
6XR4	;	14.0	;	Integrative in situ structure of Parkinsons disease-linked human LRRK2
8GBS	;	8.0	;	Integrative model of the native Ana GV shell
7UKP	;	2.80113	;	Integrin alaphIIBbeta3 complex with a gantofiban analog
7TMZ	;	2.20002	;	Integrin alaphIIBbeta3 complex with BMS compound 4
7U9F	;	2.70001	;	Integrin alaphIIBbeta3 complex with BMS compound 4 in Mn2+
7U9V	;	2.25492	;	Integrin alaphIIBbeta3 complex with BMS4-1
7UDH	;	1.99999	;	Integrin alaphIIBbeta3 complex with BMS4-3
7UKT	;	2.36994	;	Integrin alaphIIBbeta3 complex with BMS4.2
7U60	;	2.55	;	Integrin alaphIIBbeta3 complex with cRGDfV
7TPD	;	2.6	;	Integrin alaphIIBbeta3 complex with EF5154
7THO	;	2.75	;	Integrin alaphIIBbeta3 complex with Eptifibatide
7UE0	;	2.74196	;	Integrin alaphIIBbeta3 complex with fradafiban
7UFH	;	2.99768	;	Integrin alaphIIBbeta3 complex with fradafiban (Mn/Ca)
7UCY	;	2.34996	;	Integrin alaphIIBbeta3 complex with gantofiban
7UBR	;	2.04993	;	Integrin alaphIIBbeta3 complex with GR144053
7UJK	;	2.43266	;	Integrin alaphIIBbeta3 complex with lamifiban
7UK9	;	2.60002	;	Integrin alaphIIBbeta3 complex with lamifiban (Mn)
7UDG	;	2.80007	;	Integrin alaphIIBbeta3 complex with lotrafiban
7UH8	;	2.75002	;	Integrin alaphIIBbeta3 complex with roxifiban (Mn/Ca)
7UKO	;	2.604	;	Integrin alaphIIBbeta3 complex with sibrafiban (Mn)
7TD8	;	2.6	;	Integrin alaphIIBbeta3 complex with Tirofiban
7TCT	;	2.501	;	Integrin alaphIIBbeta3 complex with UR2922
7UJE	;	2.49997	;	Integrin alaphIIBbeta3 complex with UR2922 in Mn2+
1MF7	;	1.25	;	INTEGRIN ALPHA M I DOMAIN
1NA5	;	1.5	;	INTEGRIN ALPHA M I DOMAIN
1N9Z	;	2.5	;	INTEGRIN ALPHA M I DOMAIN MUTANT
5FFO	;	3.49	;	Integrin alpha V beta 6 in complex with pro-TGF-beta
8TCG	;	3.4	;	Integrin alpha-v beta-6 in complex with minibinder B6_BP_dslf
8TCF	;	2.9	;	Integrin alpha-v beta-8 in complex with minibinder B8_BP_dsulf
6UJA	;	3.3	;	Integrin alpha-v beta-8 in complex with pro-TGF-beta1
6DJP	;	4.8	;	Integrin alpha-v beta-8 in complex with the Fabs 8B8 and 68
6UJC	;	3.56	;	Integrin alpha-v beta-8 in complex with the Fabs C6-RGD3 and 11D12v2
6UJB	;	3.51	;	Integrin alpha-v beta-8 in complex with the Fabs C6D4 and 11D12v2
1DZI	;	2.1	;	integrin alpha2 I domain / collagen complex
4BJ3	;	3.042	;	Integrin alpha2 I domain E318W-collagen complex
5HJ2	;	2.153	;	Integrin alpha2beta1 I-domain
3ZDX	;	2.45	;	Integrin alphaIIB beta3 headpiece and RGD peptide complex
3ZDY	;	2.45	;	Integrin alphaIIB beta3 headpiece and RGD peptide complex
3ZDZ	;	2.75	;	Integrin alphaIIB beta3 headpiece and RGD peptide complex
3ZE0	;	2.95	;	Integrin alphaIIB beta3 headpiece and RGD peptide complex
3ZE1	;	3.0	;	Integrin alphaIIB beta3 headpiece and RGD peptide complex
3ZE2	;	2.35	;	Integrin alphaIIB beta3 headpiece and RGD peptide complex
2K9J	;		;	Integrin alphaIIb-beta3 transmembrane complex
2VDQ	;	2.59	;	Integrin AlphaIIbBeta3 Headpiece Bound to a Chimeric Fibrinogen Gamma chain peptide, HHLGGAKQRGDV
2VDR	;	2.4	;	Integrin AlphaIIbBeta3 Headpiece Bound to a chimeric Fibrinogen Gamma chain peptide, LGGAKQRGDV
2VDO	;	2.51	;	Integrin AlphaIIbBeta3 Headpiece Bound to Fibrinogen Gamma chain peptide, HHLGGAKQAGDV
2VDP	;	2.8	;	Integrin AlphaIIbBeta3 Headpiece Bound to Fibrinogen Gamma chain peptide,LGGAKQAGDV
4Z7N	;	2.599	;	Integrin alphaIIbbeta3 in complex with AGDV peptide
4Z7O	;	2.85	;	Integrin alphaIIbbeta3 in complex with AGDV peptide
4Z7Q	;	2.7	;	Integrin alphaIIbbeta3 in complex with AGDV-NH2 peptide
5HDB	;	2.7012	;	Integrin alphaIIbbeta3 in complex with Ro-435054
7L8P	;	2.34995	;	Integrin alphaIIbbeta3 in complex with sibrafiban
7LA4	;	3.3	;	Integrin AlphaIIbBeta3-PT25-2 Complex
7USM	;	2.7	;	Integrin alphaM/beta2 ectodomain
7USL	;	2.7	;	Integrin alphaM/beta2 ectodomain in complex with adenylate cyclase toxin RTX751 and M1F5 Fab
4MMZ	;	3.1	;	Integrin AlphaVBeta3 ectodomain bound to an antagonistic tenth domain of Fibronectin
6MK0	;	3.005	;	Integrin AlphaVBeta3 ectodomain bound to antagonist TDI-4161
6MSL	;	3.104	;	Integrin AlphaVBeta3 ectodomain bound to EETI-II 2.5D
6NAJ	;	3.1	;	Integrin AlphaVBeta3 ectodomain bound to Hr10 variant of the 10th domain of Fibronectin.
4MMX	;	3.32	;	Integrin AlphaVBeta3 ectodomain bound to the tenth domain of Fibronectin
4MMY	;	3.183	;	Integrin AlphaVBeta3 ectodomain bound to the tenth domain of Fibronectin with the IAKGDWND motif
6MSU	;	3.11	;	Integrin alphaVBeta3 in complex with EETI-II 2.5F
2KV9	;		;	Integrin beta3 subunit in a disulfide linked alphaIIb-beta3 cytosolic domain
7S47	;	2.0	;	Integrin beta5(743-774)-linker-PAK4cat(D440N/S474E)
1UZQ	;	2.4	;	Integrin binding cbEGF22-TB4-cbEGF33 fragment of human fibrillin-1, apo form cbEGF23 domain only.
1UZK	;	1.35	;	Integrin binding cbEGF22-TB4-cbEGF33 fragment of human fibrillin-1, Ca bound to cbEGF23 domain only
1UZJ	;	2.25	;	Integrin binding cbEGF22-TB4-cbEGF33 fragment of human fibrillin-1, holo form.
1UZP	;	1.78	;	Integrin binding cbEGF22-TB4-cbEGF33 fragment of human fibrillin-1, Sm bound form cbEGF23 domain only.
3P46	;	1.7	;	Integrin binding collagen peptide
1L3Y	;		;	INTEGRIN EGF-LIKE MODULE 3 FROM THE BETA-2 SUBUNIT
4M76	;	2.804	;	Integrin I domain of complement receptor 3 in complex with C3d
6FPZ	;	2.2	;	Inter-alpha-inhibitor heavy chain 1, D298A
6FPY	;	2.339	;	Inter-alpha-inhibitor heavy chain 1, wild type
6RJS	;	2.6	;	Inter-dimeric interface controls function and stability of S-methionine adenosyltransferase from U. urealiticum
6RK5	;	2.6	;	Inter-dimeric interface controls function and stability of S-methionine adenosyltransferase from U. urealiticum
6RK7	;	1.8	;	Inter-dimeric interface controls function and stability of S-methionine adenosyltransferase from U. urealiticum
6RKA	;	2.5	;	Inter-dimeric interface controls function and stability of S-methionine adenosyltransferase from U. urealiticum
6RKC	;	2.56	;	Inter-dimeric interface controls function and stability of S-methionine adenosyltransferase from U. urealiticum
2KZ1	;		;	Inter-molecular interactions in a 44 kDa interferon-receptor complex detected by asymmetric back-protonation and 2D NOESY
3A5C	;	4.51	;	Inter-subunit interaction and quaternary rearrangement defined by the central stalk of prokaryotic V1-ATPase
3A5D	;	4.8	;	Inter-subunit interaction and quaternary rearrangement defined by the central stalk of prokaryotic V1-ATPase
2HOY	;	2.2	;	Inter-subunit signaling in GSAM
2HOZ	;	2.2	;	Inter-subunit signaling in GSAM
2HP1	;	2.08	;	Inter-subunit signaling in GSAM
2HP2	;	2.7	;	Inter-subunit signaling in GSAM
7FHI	;		;	Interaction between a fluoroquinolone derivative and RNAs with a single bulge
7FJ0	;		;	Interaction between a fluoroquinolone derivative and RNAs with a single bulge
8I43	;		;	Interaction between a fluoroquinolone derivative KG022 and RNAs: effect of base pairs 3' adjacent to the bulge out residues
8I44	;		;	Interaction between a fluoroquinolone derivative KG022 and RNAs: effect of base pairs 3' adjacent to the bulge out residues
8I45	;		;	Interaction between a fluoroquinolone derivative KG022 and RNAs: effect of base pairs 3' adjacent to the bulge out residues
8I46	;		;	Interaction between a fluoroquinolone derivative KG022 and RNAs: effect of base pairs 3' adjacent to the bulge out residues
336D	;	1.0	;	INTERACTION BETWEEN LEFT-HANDED Z-DNA AND POLYAMINE-3 THE CRYSTAL STRUCTURE OF THE D(CG)3 AND THERMOSPERMINE COMPLEX
1BEJ	;	2.4	;	INTERACTION BETWEEN PROXIMAL AND DISTALS REGIONS OF CYTOCHROME C PEROXIDASE
1BEM	;	2.2	;	INTERACTION BETWEEN PROXIMAL AND DISTALS REGIONS OF CYTOCHROME C PEROXIDASE
1BEQ	;	2.16	;	INTERACTION BETWEEN PROXIMAL AND DISTALS REGIONS OF CYTOCHROME C PEROXIDASE
1BES	;	2.0	;	INTERACTION BETWEEN PROXIMAL AND DISTALS REGIONS OF CYTOCHROME C PEROXIDASE
293D	;	1.0	;	INTERACTION BETWEEN THE LEFT-HANDED Z-DNA AND POLYAMINE-2: THE CRYSTAL STRUCTURE OF THE D(CG)3 AND SPERMIDINE COMPLEX
292D	;	1.0	;	INTERACTION BETWEEN THE LEFT-HANDED Z-DNA AND POLYAMINE:THE CRYSTAL STRUCTURE OF THE D(CG)3 AND N-(2-AMINOETHYL)-1,4-DIAMINOBUTANE COMPLEX
5ZWI	;	2.4	;	Interaction between Vitamin D receptor (VDR) and a ligand having a dienone group
5H1E	;	2.6	;	Interaction between vitamin D receptor and coactivator peptide SRC2-3
1LGB	;	3.3	;	INTERACTION OF A LEGUME LECTIN WITH THE N2 FRAGMENT OF HUMAN LACTOTRANSFERRIN OR WITH THE ISOLATED BIANTENNARY GLYCOPEPTIDE: ROLE OF THE FUCOSE MOIETY
1LGC	;	2.8	;	INTERACTION OF A LEGUME LECTIN WITH THE N2 FRAGMENT OF HUMAN LACTOTRANSFERRIN OR WITH THE ISOLATED BIANTENNARY GLYCOPEPTIDE: ROLE OF THE FUCOSE MOIETY
1LOC	;	2.05	;	INTERACTION OF A LEGUME LECTIN WITH TWO COMPONENTS OF THE BACTERIAL CELL WALL
1LOD	;	2.05	;	INTERACTION OF A LEGUME LECTIN WITH TWO COMPONENTS OF THE BACTERIAL CELL WALL
1X1L	;	13.5	;	Interaction of ERA,a GTPase protein, with the 3'minor domain of the 16S rRNA within the THERMUS THERMOPHILUS 30S subunit.
1DE7	;	2.0	;	INTERACTION OF FACTOR XIII ACTIVATION PEPTIDE WITH ALPHA-THROMBIN: CRYSTAL STRUCTURE OF THE ENZYME-SUBSTRATE COMPLEX
8G8G	;	3.2	;	Interaction of H3 tail in LIN28B nucleosome with Oct4
2M1K	;		;	Interaction of Human S100A6 (C3S) with V domain of Receptor for Advanced Glycation End products (RAGE)
2ZJQ	;	3.3	;	Interaction of L7 with L11 induced by Microccocin binding to the Deinococcus radiodurans 50S subunit
2WH8	;	1.7	;	Interaction of Mycobacterium tuberculosis CYP130 with heterocyclic arylamines
2WHF	;	1.58	;	Interaction of Mycobacterium tuberculosis CYP130 with heterocyclic arylamines
1CN3	;	2.2	;	INTERACTION OF POLYOMAVIRUS INTERNAL PROTEIN VP2 WITH MAJOR CAPSID PROTEIN VP1 AND IMPLICATIONS FOR PARTICIPATION OF VP2 IN VIRAL ENTRY
6EST	;	1.8	;	INTERACTION OF THE PEPTIDE CF3-LEU-ALA-NH-C6H4-CF3(TFLA) WITH PORCINE PANCREATIC ELASTASE. X-RAY STUDIES AT 1.8 ANGSTROMS
7EST	;	1.8	;	Interaction of the peptide CF3-LEU-ALA-NH-C6H4-CF3(TFLA) with porcine pancreatic elastase. X-ray studies at 1.8 Angstroms
6G5C	;	1.8	;	Interaction of TiO2 nanoparticles (NM-101) with Lysozyme
3F81	;	1.9	;	Interaction of VHR with SA3
4H11	;	1.67	;	Interaction partners of PSD-93 studied by X-ray crystallography and fluorescent polarization spectroscopy
1MNH	;	2.3	;	INTERACTIONS AMONG RESIDUES CD3, E7, E10 AND E11 IN MYOGLOBINS: ATTEMPTS TO SIMULATE THE O2 AND CO BINDING PROPERTIES OF APLYSIA MYOGLOBIN
1MNJ	;	2.2	;	INTERACTIONS AMONG RESIDUES CD3, E7, E10 AND E11 IN MYOGLOBINS: ATTEMPTS TO SIMULATE THE O2 AND CO BINDING PROPERTIES OF APLYSIA MYOGLOBIN
1MNK	;	2.2	;	INTERACTIONS AMONG RESIDUES CD3, E7, E10 AND E11 IN MYOGLOBINS: ATTEMPTS TO SIMULATE THE O2 AND CO BINDING PROPERTIES OF APLYSIA MYOGLOBIN
4V4J	;	3.83	;	Interactions and Dynamics of the Shine-Dalgarno Helix in the 70S Ribosome.
1D11	;	1.18	;	INTERACTIONS BETWEEN AN ANTHRACYCLINE ANTIBIOTIC AND DNA MOLECULAR STRUCTURE OF DAUNOMYCIN COMPLEXED TO D(CPGPTPAPCPG) AT 1.2-ANGSTROMS RESOLUTION
1DF4	;	1.45	;	INTERACTIONS BETWEEN HIV-1 GP41 CORE AND DETERGENTS AND THEIR IMPLICATIONS FOR MEMBRANE FUSION
1DF5	;	2.7	;	INTERACTIONS BETWEEN HIV-1 GP41 CORE AND DETERGENTS AND THEIR IMPLICATIONS FOR MEMBRANE FUSION
2DES	;	1.5	;	INTERACTIONS BETWEEN MORPHOLINYL ANTHRACYCLINES AND DNA: THE CRYSTAL STRUCTURE OF A MORPHOLINO DOXORUBICIN BOUND TO D(CGTACG)
5M9E	;	2.83	;	Interactions between the Mal3 EB1-like domain and Dis1
1IZ2	;	2.2	;	Interactions causing the kinetic trap in serpin protein folding
1UR8	;	1.9	;	Interactions of a family 18 chitinase with the designed inhibitor HM508, and its degradation product, chitobiono-delta-lactone
1UR9	;	1.8	;	Interactions of a family 18 chitinase with the designed inhibitor HM508, and its degradation product, chitobiono-delta-lactone
1TD7	;	2.5	;	Interactions of a specific non-steroidal anti-inflammatory drug (NSAID) with group I phospholipase A2 (PLA2): Crystal structure of the complex formed between PLA2 and niflumic acid at 2.5 A resolution
3GO3	;	1.1	;	Interactions of an echinomycin-DNA complex with manganese(II) ions
4E2R	;	1.67	;	Interactions of Ba2+ with a non-self-complementary Z-type DNA duplex
4E4O	;	1.72	;	Interactions of Ba2+ with a non-self-complementary Z-type DNA duplex
4E60	;	1.86	;	Interactions of Ba2+ with a non-self-complementary Z-type DNA duplex
1AO1	;		;	INTERACTIONS OF DEGLYCOSYLATED COBALT(III)-PEPLEOMYCIN WITH DNA, NMR, MINIMIZED AVERAGE STRUCTURE
1D4U	;		;	INTERACTIONS OF HUMAN NUCLEOTIDE EXCISION REPAIR PROTEIN XPA WITH RPA70 AND DNA: CHEMICAL SHIFT MAPPING AND 15N NMR RELAXATION STUDIES
4DWY	;	1.61	;	Interactions of Mn2+ with a non-self-complementary Z-type DNA duplex
4DY8	;	1.76	;	Interactions of Mn2+ with a non-self-complementary Z-type DNA duplex
1LGR	;	2.79	;	INTERACTIONS OF NUCLEOTIDES WITH FULLY UNADENYLYLATED GLUTAMINE SYNTHETASE FROM SALMONELLA TYPHIMURIUM
2DSV	;	2.54	;	Interactions of protective signalling factor with chitin-like polysaccharide: Crystal structure of the complex between signalling protein from sheep (SPS-40) and a hexasaccharide at 2.5A resolution
1VS2	;	2.0	;	Interactions of quinoxaline antibiotic and DNA: the molecular structure of a TRIOSTIN A-D(GCGTACGC) complex
294D	;	2.5	;	INTERCALATED CYTOSINE MOTIF AND NOVEL ADENINE CLUSTERS IN THE CRYSTAL STRUCTURE OF TETRAHYMENA TELOMERE
1C11	;		;	INTERCALATED D(TCCCGTTTCCA) DIMER, NMR, 7 STRUCTURES
454D	;	1.2	;	INTERCALATION AND MAJOR GROOVE RECOGNITION IN THE 1.2 A RESOLUTION CRYSTAL STRUCTURE OF RH[ME2TRIEN]PHI BOUND TO 5'-G(5IU)TGCAAC-3'
1G3X	;	2.7	;	INTERCALATION OF AN 9ACRIDINE-PEPTIDE DRUG IN A DNA DODECAMER
6SX3	;		;	Intercalation of heterocyclic ligand between quartets in G-rich tetrahelical structure
3U38	;	2.13	;	Intercalation of lambda-[Ru(phen)2(dppz)]2+ into d(CCGGTACCGG)2
6GLD	;	1.061	;	Intercalation of [Ru(TAP)2(11-Br-dppz)]2+ bound to d(TCGGCGCCGA)2
1CA5	;	2.2	;	INTERCALATION SITE OF HYPERTHERMOPHILE CHROMOSOMAL PROTEIN SSO7D/SAC7D BOUND TO DNA
1CA6	;	2.2	;	INTERCALATION SITE OF HYPERTHERMOPHILE CHROMOSOMAL PROTEIN SSO7D/SAC7D BOUND TO DNA
3LX9	;	2.04	;	Interconversion of Human Lysosomal Enzyme Specificities
3LXA	;	3.04	;	Interconversion of Human Lysosomal Enzyme Specificities
3LXB	;	2.85	;	Interconversion of Human Lysosomal Enzyme Specificities
3LXC	;	2.35	;	Interconversion of Human Lysosomal Enzyme Specificities
4F5H	;	1.6	;	Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.
3IFQ	;	2.8	;	Interction of plakoglobin and beta-catenin with desmosomal cadherins
5ADH	;	2.9	;	INTERDOMAIN MOTION IN LIVER ALCOHOL DEHYDROGENASE. STRUCTURAL AND ENERGETIC ANALYSIS OF THE HINGE BENDING MODE
8ADH	;	2.4	;	INTERDOMAIN MOTION IN LIVER ALCOHOL DEHYDROGENASE. STRUCTURAL AND ENERGETIC ANALYSIS OF THE HINGE BENDING MODE
2KM8	;		;	Interdomain RRM packing contributes to RNA recognition in the rna15, hrp1, anchor RNA 3' processing ternary complex
7Y0O	;	4.4	;	Interface of SARS-CoV-2 WT Spike in complex with R15 Fab and P14 Nanobody
1LPA	;	3.04	;	INTERFACIAL ACTIVATION OF THE LIPASE-PROCOLIPASE COMPLEX BY MIXED MICELLES REVEALED BY X-RAY CRYSTALLOGRAPHY
1POA	;	1.5	;	INTERFACIAL CATALYSIS: THE MECHANISM OF PHOSPHOLIPASE A2
1ITF	;		;	INTERFERON ALPHA-2A, NMR, 24 STRUCTURES
6E3K	;	3.25	;	Interferon gamma signalling complex with IFNGR1 and IFNGR2
6E3L	;	3.8	;	Interferon gamma signalling complex with IFNGR1 and IFNGR2
1IF1	;	3.0	;	INTERFERON REGULATORY FACTOR 1 (IRF-1) COMPLEX WITH DNA
1IRG	;		;	INTERFERON REGULATORY FACTOR-2 DNA BINDING DOMAIN, NMR, 20 STRUCTURES
1IRF	;		;	INTERFERON REGULATORY FACTOR-2 DNA BINDING DOMAIN, NMR, MINIMIZED AVERAGE STRUCTURE
7E58	;	2.6	;	interferon-inducible anti-viral protein 2
7E5A	;	2.5	;	interferon-inducible anti-viral protein R356A
7E59	;	3.0	;	interferon-inducible anti-viral protein truncated
3HHC	;	2.8	;	Interferon-lambda is functionally an interferon but structurally related to the IL-10 family
1T4Q	;	2.1	;	Interleukin 1 beta F101W
1TWE	;	2.1	;	INTERLEUKIN 1 BETA MUTANT F101Y
1S0L	;	2.34	;	Interleukin 1 beta mutant F42W
6WDP	;	2.01	;	Interleukin 12 receptor subunit beta-1
8C7M	;	2.56	;	Interleukin 12 receptor subunit beta-1 Fn domains in complex with antagonistic FAb fragment.
8ODX	;	4.4	;	Interleukin 12 receptor subunit beta-1 Fn domains in complex with antagonistic FAb4 fragment and VHH.
1TOO	;	2.1	;	Interleukin 1B Mutant F146W
4NZD	;	2.75	;	Interleukin 21 receptor
21BI	;	2.0	;	INTERLEUKIN-1 BETA (IL-1 BETA) (MUTANT WITH CYS 71 REPLACED BY ALA) (C71A)
31BI	;	2.0	;	INTERLEUKIN-1 BETA (IL-1 BETA) (MUTANT WITH CYS 71 REPLACED BY SER) (C71S)
41BI	;	2.9	;	INTERLEUKIN-1 BETA (IL-1 BETA) (MUTANT WITH CYS 8 REPLACED BY ALA (C8A)
1IOB	;	2.0	;	INTERLEUKIN-1 BETA FROM JOINT X-RAY AND NMR REFINEMENT
1TWM	;	2.26	;	Interleukin-1 Beta Mutant F146Y
3POK	;	1.7	;	Interleukin-1-beta LBT L3 Mutant
1ILK	;	1.8	;	INTERLEUKIN-10 CRYSTAL STRUCTURE REVEALS THE FUNCTIONAL DIMER WITH AN UNEXPECTED TOPOLOGICAL SIMILARITY TO INTERFERON GAMMA
6X93	;	3.5	;	Interleukin-10 signaling complex with IL-10RA and IL-10RB
7M2G	;	1.79	;	INTERLEUKIN-2 (human) mutant P65K, C125S
3QB1	;	3.1	;	Interleukin-2 mutant D10
8ENT	;	2.83	;	Interleukin-21 signaling complex with IL-21R and IL-2Rg
5MJ3	;	1.74	;	INTERLEUKIN-23 COMPLEX WITH AN ANTAGONISTIC ALPHABODY, CRYSTAL FORM 1
5MJ4	;	3.4	;	INTERLEUKIN-23 COMPLEX WITH AN ANTAGONISTIC ALPHABODY, CRYSTAL FORM 2
5UV8	;	2.7	;	Interleukin-3 Receptor Complex
6NCU	;	3.5	;	Interleukin-37 residues 53-206- dimer
8CGF	;		;	Interleukin-4 (wild type) pH 2.4
1HIK	;	2.6	;	INTERLEUKIN-4 (WILD-TYPE)
1IAR	;	2.3	;	INTERLEUKIN-4 / RECEPTOR ALPHA CHAIN COMPLEX
1HZI	;	2.05	;	INTERLEUKIN-4 MUTANT E9A
3QB7	;	3.245	;	Interleukin-4 mutant RGA bound to cytokine receptor common gamma
1HIJ	;	3.0	;	INTERLEUKIN-4 MUTANT WITH ARG 88 REPLACED WITH GLN (R88Q)
1QE6	;	2.35	;	INTERLEUKIN-8 WITH AN ADDED DISULFIDE BETWEEN RESIDUES 5 AND 33 (L5C/H33C)
1ICW	;	2.01	;	INTERLEUKIN-8, MUTANT WITH GLU 38 REPLACED BY CYS AND CYS 50 REPLACED BY ALA
3FZN	;	1.62	;	Intermediate analogue in benzoylformate decarboxylase
2WOG	;	2.0	;	Intermediate and final states of human kinesin Eg5 in complex with S-trityl-L-cysteine
7AM2	;	3.4	;	Intermediate assembly of the Large subunit from Leishmania major mitochondrial ribosome
8PPV	;	3.02	;	Intermediate conformer of Pyrococcus abyssi DNA polymerase D (PolD) bound to a primer/template substrate containing three consecutive mismatches
6UWH	;	2.299	;	Intermediate engineered variant of I-OnuI meganuclease with improved thermostability and partially altered specificity
6UWJ	;	1.852	;	Intermediate engineered variant of I-OnuI meganuclease with improved thermostability and partially altered specificity
1XL4	;	2.6	;	Intermediate gating structure 1 of the inwardly rectifying K+ channel KirBac3.1
1XL6	;	2.85	;	Intermediate gating structure 2 of the inwardly rectifying K+ channel KirBac3.1
5TDV	;	2.001	;	Intermediate O2 diiron complex in the Q228A variant of Toluene 4-moonoxygenase (T4moHD)
7DZF	;	1.7	;	Intermediate of FABP with a delay time of 10 ns
7DZH	;	1.65	;	intermediate of FABP with a delay time of 100 ns
7DZG	;	1.6	;	Intermediate of FABP with a delay time of 30 ns
7DZI	;	1.65	;	intermediate of FABP with a delay time of 300 ns
2RKW	;	2.81	;	Intermediate position of ATP on its trail to the binding pocket inside the subunit B mutant R416W of the energy converter A1Ao ATP synthase
3B2Q	;	2.1	;	Intermediate position of ATP on its trail to the binding pocket inside the subunit B mutant R416W of the energy converter A1Ao ATP synthase
8DQK	;	4.0	;	Intermediate resolution structure of barley (1,3;1,4)-beta-glucan synthase CslF6.
7KZI	;	2.82	;	Intermediate state (QQQ) of near full-length DnaK alternatively fused with a substrate peptide
5J2W	;		;	Intermediate state lying on the pathway of release of Tat from HIV-1 TAR.
7DGE	;	3.65	;	intermediate state of class C GPCR
4A5Y	;	2.45	;	Intermediate state of human kinesin Eg5 in complex with Ispinesib
8DQZ	;	2.92	;	Intermediate state of RFC:PCNA bound to a 3' ss/dsDNA junction
3EVJ	;	3.0	;	Intermediate structure of antithrombin bound to the natural pentasaccharide
5HBC	;	2.79	;	Intermediate structure of iron-saturated C-lobe of bovine lactoferrin at 2.79 Angstrom resolution indicates the softening of iron coordination
1ZRN	;	1.83	;	INTERMEDIATE STRUCTURE OF L-2-HALOACID DEHALOGENASE WITH MONOCHLOROACETATE
7OSM	;	3.0	;	Intermediate translocation complex of 80 S.cerevisiae ribosome with eEF2 and ligands
7S64	;	6.43	;	Intermediate-form oocyte/egg Alpha-2-Macroglobulin (A2Moo) tetramer
2LYW	;		;	Intermolecular interactions between neurotensin and the third extracellular loop of human neurotensin 1 receptor
4H10	;	2.402	;	Intermolecular recognition revealed by the complex structure of human CLOCK-BMAL1 basic Helix-Loop-Helix domains with E-box DNA
4OGQ	;	2.501	;	Internal Lipid Architecture of the Hetero-Oligomeric Cytochrome b6f Complex
1E5B	;		;	Internal xylan binding domain from C. fimi Xyn10A, R262G mutant
1E5C	;		;	Internal xylan binding domain from C. fimi Xyn10A, R262G mutant
1XBD	;		;	INTERNAL XYLAN BINDING DOMAIN FROM CELLULOMONAS FIMI XYLANASE D, NMR, 5 STRUCTURES
2XBD	;		;	INTERNAL XYLAN BINDING DOMAIN FROM CELLULOMONAS FIMI XYLANASE D, NMR, MINIMIZED AVERAGE STRUCTURE
1O6T	;	1.6	;	Internalin (INLA, Listeria monocytogenes) - functional domain, uncomplexed
1O6V	;	1.5	;	Internalin (INLA, Listeria monocytogenes) - functional domain, uncomplexed
1O6S	;	1.8	;	Internalin (Listeria monocytogenes) / E-Cadherin (human) Recognition Complex
1D0B	;	1.86	;	INTERNALIN B LEUCINE RICH REPEAT DOMAIN
1H6T	;	1.6	;	Internalin B: crystal structure of fused N-terminal domains.
2WQV	;	2.8	;	Internalin domain of Listeria monocytogenes InlB: rhombohedral crystal form
2WQU	;	2.6	;	Internalin domain of Listeria monocytogenes InlB: triclinic crystal form
1H6U	;	1.8	;	Internalin H: crystal structure of fused N-terminal domains.
7JTI	;	7.4	;	Interphotoreceptor retinoid-binding protein (IRBP) in complex with a monoclonal antibody (F3F5 mAb5)
2RRM	;		;	Interplay between phosphatidyl-inositol-phosphates and claudins upon binding to the 1st PDZ domain of zonula occludens 1
3HR3	;	1.75	;	Interplay of Structure, Hydration and Thermal Stability in Formacetal Modified Oligonucleotides: RNA May Tolerate Hydrophobic Modifications Better than DNA
4CE9	;	2.1	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CEA	;	1.8	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CEB	;	1.75	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CEC	;	1.75	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CED	;	1.75	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CEE	;	1.8	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CEF	;	1.7	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CEO	;	1.9	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CEQ	;	1.7	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CER	;	1.7	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CES	;	1.85	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CEZ	;	1.7	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CF0	;	1.85	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CF1	;	1.95	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CF2	;	1.95	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CF8	;	1.65	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CF9	;	2.1	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CFA	;	2.05	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CFB	;	1.95	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CFC	;	1.9	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CFD	;	2.15	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CGD	;	2.0	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CGF	;	1.7	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CGG	;	1.75	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CGH	;	1.76	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CGI	;	2.07	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CGJ	;	2.15	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CHN	;	2.0	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CHO	;	1.7	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CHP	;	1.9	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CHQ	;	1.95	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CHY	;	1.7	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CHZ	;	1.8	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CIE	;	1.7	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CIF	;	1.8	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CIG	;	1.7	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CJ3	;	1.7	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CJ4	;	1.8	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CJ5	;	1.95	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CJE	;	1.9	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CJF	;	1.9	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CJK	;	1.75	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CJL	;	1.77	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CJP	;	2.0	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CJQ	;	1.7	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CJR	;	1.8	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CJS	;	1.8	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CJT	;	1.71	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CJU	;	1.7	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CJV	;	1.95	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CJW	;	1.95	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CK1	;	1.75	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CK2	;	1.85	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4CK3	;	1.79	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
4OVL	;	1.7	;	Interrogating HIV integrase for compounds that bind- a SAMPL challenge
2GDS	;	2.3	;	Interrupting the Hydrogen Bonding Network at the Active Site of Human Manganese Superoxide Dismutase
3HS8	;	1.9	;	Intersectin 1-peptide-AP2 alpha ear complex
3HS9	;	2.15	;	Intersectin 1-peptide-AP2 beta ear complex
6H5T	;	1.689	;	Intersectin SH3A short isoform
1XZ4	;	2.0	;	Intersubunit Interactions Associated with Tyr42alpha Stabilize the Quaternary-T Tetramer but are not Major Quaternary Constraints in Deoxyhemoglobin: alphaY42A deoxyhemoglobin no-salt
7A3B	;	1.91	;	Intertwined dimer of the c-Src SH3 domain mutant E106D
7A30	;	1.67	;	Intertwined dimer of the c-Src SH3 domain mutant Q128E
7A3D	;	2.2	;	Intertwined dimer of the c-Src SH3 domain mutant T125S
7A3E	;	1.52	;	Intertwined dimer of the c-Src SH3 domain mutant T126S
7A34	;	1.85	;	Intertwined dimer of the c-Src SH3 domain mutant V111L-N113S-T114S
7A3A	;	1.8	;	Intertwined dimer of the c-Src SH3 domain mutant V111L-N113S-T114S-Q128E at pH 6.0
6UTC	;	1.249	;	Intra-chain disulfide bonded ToxR periplasmic domain from Vibrio vulnificus
5AMT	;	1.62	;	Intracellular growth locus protein E
8PZY	;	1.97	;	Intracellular leucine aminopeptidase of Pseudomonas aeruginosa PA14 - hexameric assembly with manganese bound
8PZM	;	1.7	;	Intracellular leucine aminopeptidase of Pseudomonas aeruginosa PA14 bound to bestatin inhibitor and manganese
8PZ0	;	1.8	;	Intracellular leucine aminopeptidase of Pseudomonas aeruginosa PA14.
1MRU	;	3.0	;	Intracellular Ser/Thr protein kinase domain of Mycobacterium tuberculosis PknB.
7Y6M	;	2.703	;	Intracellular Subtilisin from Bacillus sp.
2WV7	;	2.45	;	Intracellular subtilisin precursor from B. clausii
2WWT	;	2.68	;	Intracellular subtilisin precursor from B. clausii
2X8J	;	1.56	;	Intracellular subtilisin precursor from B. clausii
5VG2	;	2.46	;	Intradiol ring-cleavage Dioxygenase from Tetranychus urticae
2YC2	;	2.588	;	Intraflagellar Transport Complex 25-27 from Chlamydomonas
2YC4	;	2.8	;	Intraflagellar Transport Complex 25-27 from Chlamydomonas
8DDC	;		;	Intramembrane recognition between transmembrane domains of IL-7R and common gamma chain
8DDD	;		;	Intramembrane recognition between transmembrane domains of IL-9R and common gamma chain
3GW6	;	2.6	;	Intramolecular Chaperone
1AO9	;		;	INTRAMOLECULAR DNA DUPLEX CONTAINING A NON-NUCLEOTIDE LINKER (GAGAGA-X-TCTCCT), NMR, 12 STRUCTURES
1AT4	;		;	INTRAMOLECULAR DNA TRIPLEX CONTAINING A NON-NUCLEOTIDE LINKER (GAGAGA-X-TCTCCT-X-CTCTCT), NMR, 7 STRUCTURES
1P3X	;		;	INTRAMOLECULAR DNA TRIPLEX WITH 1-PROPYNYL DEOXYURIDINE IN THE THIRD STRAND, NMR, 10 STRUCTURES
1R3X	;		;	INTRAMOLECULAR DNA TRIPLEX WITH RNA THIRD STRAND, NMR, 10 STRUCTURES
1D3X	;		;	INTRAMOLECULAR DNA TRIPLEX, NMR, 10 STRUCTURES
8DJ2	;	1.5	;	Intramolecular ester bond-containing repeat domain from Chlamydia trachomatis adhesin
7UI8	;	2.373	;	Intramolecular ester bond-containing repeat domain from E. columbae adhesin (split and religated)
7UC3	;	1.442	;	Intramolecular ester bond-containing repeat domain from G. bergeri adhesin
1OZ8	;		;	Intramolecular higher-order packing of parallel quadruplexes comprising a G:G:G:G tetrad and a G(:A):G(:A):G(:A):G heptad of GGA triplet repeat DNA
1A83	;		;	INTRAMOLECULAR I-MOTIF, NMR, 6 STRUCTURES
1AWJ	;		;	INTRAMOLECULAR ITK-PROLINE COMPLEX, NMR, MINIMIZED AVERAGE STRUCTURE
1FQP	;		;	INTRAMOLECULAR QUADRUPLEX DNA WITH THREE GGGG REPEATS, NMR, PH 6.7, 0.1 M NA+ AND 4 MM (STRAND CONCENTRATION), 5 STRUCTURES
2LF7	;		;	Intramolecular regulation of the ETS Domain within ETV6 sequence R335 to Q436
2LF8	;		;	Intramolecular regulation of the ETS Domain within ETV6 sequence R335 to R458
1BCB	;		;	INTRAMOLECULAR TRIPLEX, NMR, 10 STRUCTURES
1BCE	;		;	INTRAMOLECULAR TRIPLEX, NMR, 10 STRUCTURES
5CXO	;	1.8	;	Intriguing role of epoxide hydrolase/cyclase-like enzyme SalBIII in pyran ring formation in polyether salinomycin
1IKK	;	1.6	;	Intrinsic Bending and Deformability at the T-A step of CCTTTAAAGG: A Comparative Analysis of T-A and A-T steps within A-tracts
6XRY	;		;	Intrinsically disordered bacterial polar organizing protein Z, PopZ, interacts with protein binding partners through an N-terminal Molecular Recognition Feature
3MN0	;	1.65	;	Introducing a 2-His-1-Glu Non-Heme Iron Center into Myoglobin confers Nitric Oxide Reductase activity: Cu(II)-CN-FeBMb(-His) form
6H3K	;	2.48	;	Introduction of a methyl group curbs metabolism of pyrido[3,4-d]pyrimidine MPS1 inhibitors and enables the discovery of the Phase 1 clinical candidate BOS172722.
1AEV	;	2.1	;	INTRODUCTION OF NOVEL SUBSTRATE OXIDATION INTO CYTOCHROME C PEROXIDASE BY CAVITY COMPLEMENTATION: OXIDATION OF 2-AMINOTHIAZOLE AND COVALENT MODIFICATION OF THE ENZYME (2-AMINOTHIAZOLE)
1CYQ	;	1.93	;	INTRON ENCODED HOMING ENDONUCLEASE I-PPOI (H98A)/DNA HOMING SITE COMPLEX
1CZ0	;	2.1	;	INTRON ENCODED HOMING ENDONUCLEASE I-PPOI/DNA COMPLEX LACKING CATALYTIC METAL ION
1A73	;	1.8	;	INTRON-ENCODED ENDONUCLEASE I-PPOI COMPLEXED WITH DNA
6WLG	;	3.111	;	Ints3 C-terminal Domain
7BV7	;	2.4	;	INTS3 complexed with INTS6
7BJ5	;	2.75	;	Inulosucrase from Halalkalicoccus jeotgali
7BJ4	;	2.72	;	Inulosucrase from Halalkalicoccus jeotgali bound to kestose
7BJC	;	3.11	;	Inulosucrase from Halalkalicoccus jeotgali in complex with sucrose
2J7J	;	1.65	;	Invariance of the zinc finger module: a comparison of the free structure with those in nucleic-acid complexes
4HP2	;	0.64	;	Invariom refinement of a new dimeric monoclinic 2 solvate of thiostrepton at 0.64 angstrom resolution
4KOB	;	1.867	;	Investigating the functional significance of the interlocked pair structural determinants in Pseudomonas aeruginosa azurin (V31I/V95I)
4KOC	;	1.459	;	Investigating the functional significance of the interlocked pair structural determinants in Pseudomonas aeruginosa azurin (V31I/V95I/Y108F)
4KO6	;	1.738	;	Investigating the functional significance of the interlocked pair structural determinants in Pseudomonas aeruginosa azurin (V31I/V95K/Y108F)
4KO7	;	2.07	;	Investigating the functional significance of the interlocked pair structural determinants in Pseudomonas aeruginosa azurin (V31I/W48F/V95I)
4KO5	;	1.79	;	Investigating the functional significance of the interlocked pair structural determinants in Pseudomonas aeruginosa azurin (V31I/W48L/V95I/Y108F)
4KO9	;	2.054	;	Investigating the functional significance of the interlocked pair structural determinants in Pseudomonas aeruginosa azurin (V95I/Y108F)
1HEY	;	2.24	;	INVESTIGATING THE STRUCTURAL DETERMINANTS OF THE P21-LIKE TRIPHOSPHATE AND MG2+ BINDING SITE
3HC8	;	1.79	;	Investigation of Aminopyridiopyrazinones as PDE5 Inhibitors: Evaluation of Modifications to the Central Ring System.
3MOC	;	1.82	;	Investigation of global and local effects of radiation damage on porcine pancreatic elastase. Eighth stage of radiation damage
3MO3	;	1.805	;	Investigation of global and local effects of radiation damage on porcine pancreatic elastase. Fifth stage of radiation damage
3MNB	;	1.198	;	Investigation of global and local effects of radiation damage on porcine pancreatic elastase. First stage of radiation damage
3MNX	;	1.386	;	Investigation of global and local effects of radiation damage on porcine pancreatic elastase. Fourth stage of radiation damage
3MNC	;	1.119	;	Investigation of global and local effects of radiation damage on porcine pancreatic elastase. Second stage of radiation damage
3MO9	;	2.003	;	Investigation of global and local effects of radiation damage on porcine pancreatic elastase. Seventh stage of radiation damage
3MO6	;	1.66	;	Investigation of global and local effects of radiation damage on porcine pancreatic elastase. Sixth stage of radiation damage
3MNS	;	1.497	;	Investigation of global and local effects of radiation damage on porcine pancreatic elastase. Third stage of radiation damage
5CW0	;	4.6	;	Investigation of RNA structure in satellite panicum mosaic virus
5CVZ	;	3.3	;	Investigation of RNA structure in satellite panicum mosaic virus - glutaraldehyde treated
2DRC	;	1.9	;	INVESTIGATION OF THE FUNCTIONAL ROLE OF TRYPTOPHAN-22 IN ESCHERICHIA COLI DIHYDROFOLATE REDUCTASE BY SITE-DIRECTED MUTAGENESIS
3DRC	;	1.9	;	INVESTIGATION OF THE FUNCTIONAL ROLE OF TRYPTOPHAN-22 IN ESCHERICHIA COLI DIHYDROFOLATE REDUCTASE BY SITE-DIRECTED MUTAGENESIS
1L0C	;	2.3	;	Investigation of the Roles of Catalytic Residues in Serotonin N-Acetyltransferase
1COR	;		;	INVESTIGATION OF THE SOLUTION CONFORMATION OF CYTOCHROME C-551 FROM PSEUDOMONAS STUTZERI
6PEE	;	3.42	;	InvG secretin domain beta-barrel from Salmonella SPI-1 injectisome NC-base
1GYL	;	3.0	;	INVOLVEMENT OF TYR24 AND TRP108 IN SUBSTRATE BINDING AND SUBSTRATE SPECIFICITY OF GLYCOLATE OXIDASE
2X79	;	3.8	;	Inward facing conformation of Mhp1
7MC0	;	3.3	;	Inward facing conformation of the MetNI methionine ABC transporter
4C7R	;	2.7	;	Inward facing conformation of the trimeric betaine transporter BetP in complex with lipids
3TUI	;	2.9	;	Inward facing conformations of the MetNI methionine ABC transporter: CY5 native crystal form
3TUZ	;	3.4	;	Inward facing conformations of the MetNI methionine ABC transporter: CY5 SeMet soak crystal form
3TUJ	;	4.0	;	Inward facing conformations of the MetNI methionine ABC transporter: DM crystal form
4JA4	;	4.2	;	Inward open conformation of the xylose transporter XylE from E. coli
5MMT	;	3.4	;	Inward open PepTSt from Streptococcus thermophilus crystallized in space group P3121
3SPH	;	3.003	;	Inward rectifier potassium channel Kir2.2 I223L mutant in complex with PIP2
3SPC	;	2.454	;	Inward rectifier potassium channel Kir2.2 in complex with dioctanoylglycerol pyrophosphate (DGPP)
3SPI	;	3.307	;	Inward rectifier potassium channel Kir2.2 in complex with PIP2
3SPG	;	2.613	;	Inward rectifier potassium channel Kir2.2 R186A mutant in complex with PIP2
6X12	;	3.52	;	Inward-facing Apo-open state of the glutamate transporter homologue GltPh
6FHZ	;	2.8	;	Inward-facing conformation of a multidrug resistance MATE family transporter of the MOP superfamily.
5B57	;	2.8	;	Inward-facing conformation of ABC heme importer BhuUV from Burkholderia cenocepacia
5B58	;	3.21	;	Inward-facing conformation of ABC heme importer BhuUV in complex with periplasmic heme binding protein BhuT from Burkholderia cenocepacia
5ZOV	;	3.333	;	Inward-facing conformation of L-ascorbate transporter UlaA
8QOE	;	3.16	;	Inward-facing conformation of the ABC transporter BmrA
8CHB	;	3.14	;	Inward-facing conformation of the ABC transporter BmrA C436S/A582C cross-linked mutant
3J1Z	;	13.0	;	Inward-Facing Conformation of the Zinc Transporter YiiP revealed by Cryo-electron Microscopy
8SX9	;	3.3	;	Inward-facing narrow conformation of bovine multidrug resistance protein 4 (MRP4) in MSP lipid nanodisc
7QPC	;	3.44	;	Inward-facing NPA bound form of auxin transporter PIN8
6X13	;	3.66	;	Inward-facing sodium-bound state of the glutamate transporter homologue GltPh
6X15	;	3.05	;	Inward-facing state of the glutamate transporter homologue GltPh in complex with L-aspartate and sodium ions
6X16	;	3.39	;	Inward-facing state of the glutamate transporter homologue GltPh in complex with TBOA
6X14	;	3.71	;	Inward-facing state of the glutamate transporter homologue GltPh in complex with TFB-TBOA
7VR8	;	3.58	;	Inward-facing structure of human EAAT2 in the substrate-free state
7VR7	;	3.49	;	Inward-facing structure of human EAAT2 in the WAY213613-bound state
8SXA	;	3.3	;	Inward-facing wide conformation of bovine multidrug resistance protein 4 (MRP4) in MSP lipid nanodisc
6ZBV	;	3.4	;	Inward-open structure of human glycine transporter 1 in complex with a benzoylisoindoline inhibitor and sybody Sb_GlyT1#7
6ZPL	;	3.945	;	Inward-open structure of human glycine transporter 1 in complex with a benzoylisoindoline inhibitor, sybody Sb_GlyT1#7 and bound Na and Cl ions.
6RVY	;	4.13	;	Inward-open structure of the ASCT2 (SLC1A5) mutant C467R in absence of substrate
6RVX	;	3.61	;	Inward-open structure of the ASCT2 (SLC1A5) mutant C467R in presence of TBOA
3B2I	;	1.86	;	Iodide derivative of human LFABP
3B2J	;	2.0	;	Iodide derivative of human LFABP
3B2K	;	1.73	;	Iodide derivative of human LFABP
3B2L	;	2.25	;	Iodide derivative of human LFABP
3VG2	;	2.4	;	Iodide derivative of human LFABP
3B2H	;	1.55	;	Iodide derivative of human LFABP at high resolution
4HJH	;	2.1	;	Iodide SAD phased crystal structure of a phosphoglucomutase from Brucella melitensis complexed with glucose-6-phosphate
6I1Q	;	1.99	;	Iodide structure of Trichoderma reesei Carbohydrate-Active Enzymes Family AA12
2AXE	;	1.8	;	IODINATED COMPLEX OF ACETYL XYLAN ESTERASE AT 1.80 ANGSTROMS
5N1C	;	2.6	;	Iodinated form of the Mycobacterium tuberculosis repressor EthR2
1VAT	;	1.6	;	Iodine derivative of hen egg-white lysozyme
2YAX	;	1.8	;	IODOACETAMIDE INHIBITED SULFUR OXYGENASE REDUCTASE
3DN4	;	1.8	;	Iodobenzene binding in the hydrophobic cavity of T4 lysozyme L99A mutant
3DNA	;	1.7	;	Iodobenzene binding in the hydrophobic cavity of T4 lysozyme L99A mutant (seleno version)
3DN3	;	1.8	;	Iodopentafluorobenzene binding in the hydrophobic cavity of T4 lysozyme L99A mutant
3DN8	;	1.7	;	Iodopentafluorobenzene binding in the hydrophobic cavity of T4 lysozyme L99A mutant (seleno version)
3T96	;	1.872	;	Iodowillardiine bound to a double cysteine mutant (A452C/S652C) of the ligand binding domain of GluA2
7U04	;	2.31	;	IOMA class antibody ACS101
7U0K	;	1.73	;	IOMA class antibody Fab ACS124
8HKF	;	2.66	;	ion channel
8HKK	;	2.84	;	ion channel
8HKM	;	2.95	;	ion channel
8HKQ	;	2.9	;	ion channel
5XA6	;		;	Ion channel modulation by scorpion haemolymph and its defensin ingredients uncovers origin of neurotoxins in telson formed in Paleozoic scorpion
2IH1	;	2.4	;	Ion selectivity in a semi-synthetic K+ channel locked in the conductive conformation
2IH3	;	1.72	;	Ion selectivity in a semi-synthetic K+ channel locked in the conductive conformation
4LSH	;	2.2	;	Ion selectivity of OmpF porin soaked in 0.2M KBr
4LSE	;	2.1	;	Ion selectivity of OmpF porin soaked in 0.2M NaBr
4LSI	;	2.089	;	Ion selectivity of OmpF porin soaked in 0.3M KBr
4LSF	;	1.9	;	Ion selectivity of OmpF soaked in 0.1M KBr
1PAL	;	1.65	;	IONIC INTERACTIONS WITH PARVALBUMINS. CRYSTAL STRUCTURE DETERMINATION OF PIKE 4.10 PARVALBUMIN IN FOUR DIFFERENT IONIC ENVIRONMENTS
2PAL	;	1.8	;	IONIC INTERACTIONS WITH PARVALBUMINS. CRYSTAL STRUCTURE DETERMINATION OF PIKE 4.10 PARVALBUMIN IN FOUR DIFFERENT IONIC ENVIRONMENTS
3PAL	;	2.4	;	IONIC INTERACTIONS WITH PARVALBUMINS. CRYSTAL STRUCTURE DETERMINATION OF PIKE 4.10 PARVALBUMIN IN FOUR DIFFERENT IONIC ENVIRONMENTS
4PAL	;	1.8	;	IONIC INTERACTIONS WITH PARVALBUMINS. CRYSTAL STRUCTURE DETERMINATION OF PIKE 4.10 PARVALBUMIN IN FOUR DIFFERENT IONIC ENVIRONMENTS
1KTW	;	2.0	;	IOTA-CARRAGEENASE COMPLEXED TO IOTA-CARRAGEENAN FRAGMENTS
7T3P	;	3.2	;	IP3 and ATP bound type 3 IP3 receptor in the pre-active A state
7T3Q	;	3.3	;	IP3 and ATP bound type 3 IP3 receptor in the pre-active B state
7T3R	;	3.4	;	IP3 and ATP bound type 3 IP3 receptor in the pre-active C state
7T3T	;	3.8	;	IP3, ATP, and Ca2+ bound type 3 IP3 receptor in the active state
7T3U	;	3.7	;	IP3, ATP, and Ca2+ bound type 3 IP3 receptor in the inactive state
7JWZ	;	2.65	;	IPI-549 bound to the PI3Kg catalytic subunit p110 gamma
8BBB	;	1.57	;	IPNS H270A variant in complex with ACV exposed to O2
8BBC	;	1.71	;	IPNS H270A variant in complex with Fe and ACV under anaerobic conditions
8BSX	;	1.38	;	IPNS H270D variant in complex with Fe and ACV after 10 min O2 exposure
8BSY	;	1.4	;	IPNS H270D variant in complex with Fe and ACV after 30s O2 exposure
8BSV	;	1.53	;	IPNS H270D variant in complex with Fe and ACV under anaerobic conditions
8A4G	;	1.97	;	IPNS H270E variant in complex with Cd and ACV
8ALJ	;	1.68	;	IPNS H270E variant in complex with Fe and ACV after 3 hours O2 exposure
8ALI	;	1.6	;	IPNS H270E variant in complex with Fe and ACV after 30 min O2 exposure
7ZOE	;	1.5	;	IPNS H270E variant in complex with Fe and ACV under anaerobic conditions
8BB9	;	1.68	;	IPNS H270N variant in complex with Fe and ACV after O2 exposure
8BBA	;	1.5	;	IPNS H270N variant in complex with Fe and ACV under anaerobic conditions
8BBD	;	1.81	;	IPNS H270Q variant in complex with ACV after O2 exposure
8BSW	;	1.58	;	IPNS H270Q variant in complex with Fe and ACV under anaerobic conditions
1X84	;	1.78	;	IPP isomerase (wt) reacted with (S)-bromohydrine of IPP
1P0K	;	1.9	;	IPP:DMAPP isomerase type II apo structure
1P0N	;	2.8	;	IPP:DMAPP isomerase type II, FMN complex
4AKA	;		;	IPSE alpha-1, an IgE-binding crystallin
5L0O	;	2.36	;	IQGAP1 calponin homology domain fragment (CHDF) mutant K161C under oxidizing conditions
6OD1	;	2.0	;	IraD-bound to RssB D58P variant
3CGF	;	3.0	;	IRAK-4 Inhibitors (Part II)- A structure based assessment of imidazo[1,2 a]pyridine binding
3CGO	;	3.0	;	IRAK-4 Inhibitors (Part II)- A structure based assessment of imidazo[1,2 a]pyridine binding
6N8G	;	2.0	;	IRAK4 bound to benzoxazole compound
6EGA	;	2.512	;	IRAK4 in complex with a type II inhibitor
5K7G	;	2.23	;	IRAK4 in complex with AZ3862
5K7I	;	2.31	;	IRAK4 in complex with AZ3864
8DKS	;	2.45	;	IRAK4 IN COMPLEX WITH COMPOUND #3
5K75	;	2.03	;	IRAK4 in complex with Compound 1
5K72	;	2.22	;	IRAK4 in complex with Compound 21
5K76	;	2.74	;	IRAK4 in complex with Compound 28
6F3D	;	2.38	;	IRAK4 IN COMPLEX WITH inhibitor
6F3E	;	2.67	;	IRAK4 IN COMPLEX WITH inhibitor
6F3G	;	2.37	;	IRAK4 IN COMPLEX WITH inhibitor
6F3I	;	2.14	;	IRAK4 IN COMPLEX WITH inhibitor
6LXY	;	2.19	;	IRAK4 in complex with inhibitor
6RFI	;	2.31	;	IRAK4 IN COMPLEX WITH inhibitor
6RFJ	;	2.61	;	IRAK4 IN COMPLEX WITH inhibitor
6THW	;	2.44	;	IRAK4 in complex with inhibitor
6THX	;	1.99	;	IRAK4 in complex with inhibitor
6THZ	;	2.38	;	IRAK4 IN COMPLEX WITH inhibitor
6TI8	;	2.32	;	IRAK4 IN COMPLEX WITH inhibitor
6TIA	;	2.52	;	IRAK4 IN COMPLEX WITH inhibitor
7QG1	;	2.07	;	IRAK4 in complex with inhibitor
7QG2	;	3.031	;	IRAK4 in complex with inhibitor
7QG3	;	2.11	;	IRAK4 in complex with inhibitor
7QG5	;	2.3	;	IRAK4 in complex with inhibitor
6EG9	;	2.414	;	IRAK4 in complex with Ponatinib
5T1S	;	2.3	;	Irak4 kinase - compound 1 co-structure
5T1T	;	2.34	;	Irak4 kinase - compound 1 co-structure
4XS2	;	2.73	;	Irak4-inhibitor co-structure
4YO6	;	2.32	;	Irak4-inhibitor co-structure
4YP8	;	2.641	;	Irak4-inhibitor co-structure
4ZTL	;	2.39	;	Irak4-inhibitor co-structure
4ZTM	;	2.66	;	Irak4-inhibitor co-structure
4ZTN	;	2.23	;	Irak4-inhibitor co-structure
5KX7	;	2.8	;	Irak4-inhibitor co-structure
5KX8	;	2.671	;	Irak4-inhibitor co-structure
6HX1	;	2.14	;	IRE1 ALPHA IN COMPLEX WITH imidazo[1,2-b]pyridazin-8-amine compound 2
3LJ0	;	3.2	;	IRE1 complexed with ADP and Quercetin
3LJ1	;	3.33	;	IRE1 complexed with Cdk1/2 Inhibitor III
3LJ2	;	3.33	;	IRE1 complexed with JAK Inhibitor I
6HV0	;	2.73	;	IRE1 kinase/RNase in complex with imidazo[1,2-b]pyridazin-8-amine compound 33
7OG3	;	1.904	;	IRED-88
7OSN	;	2.55	;	IRED361 from Micromonospora sp. in complex with NADP+
4XEJ	;	3.8	;	IRES bound to bacterial Ribosome
6XB7	;		;	IRES-targeting Small Molecule Inhibits Enterovirus 71 Replication via Allosteric Stabilization of a Ternary Complex
7JM4	;	2.95	;	IRF Transcription Factor
1ZOQ	;	2.37	;	IRF3-CBP complex
8JKL	;	2.94	;	IRF4 DNA-binding domain bound to an DNA containing GATA motif
6TD4	;	1.71	;	IRF4 DNA-binding domain surface entropy mutant apo structure
7RH2	;	2.47	;	IRF4 Transcription factor mutant -K59R
5DCW	;	1.9	;	Iridoid synthase from Catharanthus roseus - ligand free structure
5DF1	;	1.75	;	Iridoid synthase from Catharanthus roseus - ternary complex with NADP+ and geranic acid
5DCU	;	1.4	;	Iridoid synthase from Catharanthus roseus - ternary complex with NADP+ and triethylene glycol carboxylic acid
5DCY	;	1.45	;	Iridoid synthase G150A mutant from Catharanthus roseus - binary complex with NADP+
2VVH	;	1.8	;	IrisFP fluorescent protein in its green form, cis conformation
2VVI	;	2.0	;	IrisFP fluorescent protein in its green form, trans conformation
2VVJ	;	2.0	;	IrisFP fluorescent protein in its red form, cis conformation
3TMT	;	2.0	;	IrisFP, distorted chromophore
3TMR	;	2.0	;	IrisFP, planar chromophore
7DE2	;	1.9	;	iron and alpha-ketoglutarate-dependent endoperoxidase NvfI
7EMZ	;	2.3	;	iron and alpha-ketoglutarate-dependent endoperoxidase NvfI W199F variant
7ENB	;	2.3	;	iron and alpha-ketoglutarate-dependent endoperoxidase NvfI with different conformation
5I0V	;	1.65	;	IRON AND COPPER-BOUND P19 FROM CAMPYLOBACTER JEJUNI UNDER OXIDIZING CONDITIONS
5I0W	;	1.55	;	IRON AND COPPER-BOUND P19 FROM CAMPYLOBACTER JEJUNI UNDER REDUCING CONDITIONS
4JPY	;	2.13	;	Iron and phenylalanine bound crystal structure of phenylalanine hydroxylase from Chromobacterium violaceum
5FNN	;	2.09	;	Iron and Selenomethionine containing Iron sulfur cluster repair protein YtfE
6MSX	;	1.43	;	Iron containing ferritin at 1.43A
1B1B	;	2.6	;	IRON DEPENDENT REGULATOR
5FDB	;	1.75	;	Iron free rat cysteine dioxygenase R60QC164R variant
4YNI	;	2.404	;	Iron free succinate bound rat cysteine dioxygenase
4YT4	;	2.2	;	Iron guanylylpyridinol (FeGP) cofactor-reconstituted HmdII from Methanocaldococcus jannaschii
3RGD	;	2.89	;	Iron loaded frog M ferritin. Short soaking time
8OIE	;	2.35	;	Iron Nitrogenase Complex from Rhodobacter capsulatus
3E13	;	1.6	;	Iron reconstituted ferric binding protein from Campylobacter jejuni
1AQO	;		;	IRON RESPONSIVE ELEMENT RNA HAIRPIN, NMR, 15 STRUCTURES
1NBR	;		;	Iron Responsive Element RNA Hairpin, NMR, 15 Structures
6GKB	;	1.9	;	Iron soak structure of Y40F SynFtn
1BFR	;	2.94	;	IRON STORAGE AND ELECTRON TRANSPORT
1WB8	;	2.3	;	Iron Superoxide Dismutase (FE-SOD) from the Hyperthermophile SULFOLOBUS SOLFATARICUS. 2.3 A Resolution Structure of Recombinant Protein with a Covalently Modified Tyrosine in the Active Site.
1WB7	;	2.24	;	Iron Superoxide Dismutase (Fe-SOD) From The Hyperthermophile Sulfolobus Solfataricus. Crystal Structure of the Y41F mutant.
6DYK	;	1.955	;	Iron- and Nitric Oxide-bound structure of the engineered cyt b562 variant, CH3Y*
2BW1	;	1.81	;	Iron-bound crystal structure of Dps-like peroxide resistance protein (Dpr) from Streptococcus suis.
2WLU	;	1.94	;	Iron-bound crystal structure of Streptococcus pyogenes Dpr
6DYJ	;	1.96	;	Iron-bound structure of the engineered cyt b562 variant, CH3Y*
3O1M	;	1.75	;	Iron-Catalyzed Oxidation Intermediates Captured in A DNA Repair Dioxygenase
3O1O	;	1.92	;	Iron-Catalyzed Oxidation Intermediates Captured in A DNA Repair Dioxygenase
3O1P	;	1.51	;	Iron-Catalyzed Oxidation Intermediates Captured in A DNA Repair Dioxygenase
3O1R	;	1.77	;	Iron-Catalyzed Oxidation Intermediates Captured in A DNA Repair Dioxygenase
3O1S	;	1.58	;	Iron-Catalyzed Oxidation Intermediates Captured in A DNA Repair Dioxygenase
3O1T	;	1.48	;	Iron-Catalyzed Oxidation Intermediates Captured in A DNA Repair Dioxygenase
3O1U	;	1.54	;	Iron-Catalyzed Oxidation Intermediates Captured in A DNA Repair Dioxygenase
3O1V	;	1.9	;	Iron-Catalyzed Oxidation Intermediates Captured in A DNA Repair Dioxygenase
5J8S	;	1.5	;	Iron-free state of Rana Catesbeiana H' ferritin variant E57A/E136A/D140A
6I9P	;	1.25	;	Iron-free state of Rana catesbeiana H' ferritin variant H54N
1TJO	;	1.6	;	Iron-oxo clusters biomineralizing on protein surfaces. Structural analysis of H.salinarum DpsA in its low and high iron states
1TK6	;	2.2	;	Iron-oxo clusters biomineralizing on protein surfaces. Structural analysis of H.salinarum DpsA in its low and high iron states
1TKO	;	2.9	;	Iron-oxo clusters biomineralizing on protein surfaces. Structural analysis of H.salinarum DpsA in its low and high iron states
1TKP	;	2.2	;	Iron-oxo clusters biomineralizing on protein surfaces. Structural analysis of H.salinarum DpsA in its low and high iron states
4V2Q	;	1.95	;	Ironing out their differences: Dissecting the structural determinants of a phenylalanine aminomutase and ammonia lyase
4V2R	;	2.2	;	Ironing out their differences: Dissecting the structural determinants of a phenylalanine aminomutase and ammonia lyase
4ZIO	;	2.0	;	Irradiated state of mCherry143azF
4J8A	;	1.26	;	Irradiated-state structure of sfGFP containing the unnatural amino acid p-azido-phenylalanine at residue 145
3PDS	;	3.5	;	Irreversible Agonist-Beta2 Adrenoceptor Complex
4GS6	;	2.2	;	Irreversible Inhibition of TAK1 Kinase by 5Z-7-Oxozeaenol
1IRS	;		;	IRS-1 PTB DOMAIN COMPLEXED WITH A IL-4 RECEPTOR PHOSPHOPEPTIDE, NMR, MINIMIZED AVERAGE STRUCTURE
2BX5	;	2.7	;	Is FR1 the antibody's Achillies heel
1GCT	;	1.6	;	IS GAMMA-CHYMOTRYPSIN A TETRAPEPTIDE ACYL-ENZYME ADDUCT OF GAMMA-CHYMOTRYPSIN?
2BXY	;	1.75	;	Is radiation damage dependent on the dose-rate used during macromolecular crystallography data collection
2BXZ	;	1.75	;	Is radiation damage dependent on the dose-rate used during macromolecular crystallography data collection
2BY0	;	1.55	;	Is radiation damage dependent on the dose-rate used during macromolecular crystallography data collection
2BY1	;	1.55	;	Is radiation damage dependent on the dose-rate used during macromolecular crystallography data collection
2BY2	;	1.5	;	Is radiation damage dependent on the dose-rate used during macromolecular crystallography data collection
2BY3	;	1.5	;	Is radiation damage dependent on the dose-rate used during macromolecular crystallography data collection
2BY5	;	1.3	;	Is radiation damage dependent on the dose-rate used during macromolecular crystallography data collection
2BY6	;	1.3	;	Is radiation damage dependent on the dose-rate used during macromolecular crystallography data collection
2BY7	;	1.3	;	Is radiation damage dependent on the dose-rate used during macromolecular crystallography data collection
2BY8	;	1.3	;	Is radiation damage dependent on the dose-rate used during macromolecular crystallography data collection
2BY9	;	1.3	;	Is radiation damage dependent on the dose-rate used during macromolecular crystallography data collection
2BYA	;	1.3	;	Is radiation damage dependent on the dose-rate used during macromolecular crystallography data collection
5NNA	;	1.5	;	Isatin hydrolase A (IHA) from Labrenzia aggregata bound to benzyl benzoate
5NNB	;	1.8	;	Isatin hydrolase A (IHA) from Labrenzia aggregata with isatinate bound
5NMP	;	2.65	;	Isatin hydrolase A (IHA) from Ralstonia solanacearum
2XFP	;	1.66	;	Isatin-inhibited human monoamine oxidase B in complex with 2-(2- benzofuranyl)-2-imidazoline
6UX0	;	2.93	;	Isavuconazole bound complex of Acanthamoeba castellanii CYP51
7UTN	;	2.74	;	IscB and wRNA bound to Target DNA
8CSZ	;	3.2	;	IscB and wRNA bound to Target DNA
8CTL	;	3.1	;	IscB and wRNA bound to Target DNA (locked state)
6XG8	;	3.5	;	ISCth4 transposase, pre-cleaved complex, PCC
6XGW	;	3.5	;	ISCth4 transposase, pre-reaction complex, PRC
6XGX	;	3.5	;	ISCth4 transposase, strand transfer complex 1, STC1
5D1Z	;	3.17	;	IsdB NEAT1 bound by clone D4-10
5D1Q	;	3.22	;	IsdB NEAT2 bound by clone D2-06
5D1X	;	3.21	;	IsdB NEAT2 bound by D4-30
8BF8	;	2.8	;	ISDra2 TnpB in complex with reRNA
8EXA	;	3.14	;	ISDra2 TnpB in complex with reRNA and cognate DNA, conformation 1 (RuvC domain resolved)
8EX9	;	2.96	;	ISDra2 TnpB in complex with reRNA and cognate DNA, conformation 2 (RuvC domain unresolved)
3SZ6	;	1.8	;	IsdX1, an anthrax hemophore
2KLE	;		;	ISIC Refined Solution Structure of the Calcium Binding Domain of the C-terminal Cytosolic Domain of Polycystin-2
3G7V	;	1.86	;	Islet Amyloid Polypeptide (IAPP or Amylin) fused to Maltose Binding Protein
3G7W	;	1.75	;	Islet Amyloid Polypeptide (IAPP or Amylin) Residues 1 to 22 fused to Maltose Binding Protein
5XGW	;	1.85	;	Isoaspartyl dipeptidase from Colwellia psychrerythraea strain 34H
1POJ	;	3.3	;	Isoaspartyl Dipeptidase with bound inhibitor
8STA	;	7.3	;	Isobutyryl-CoA mutase fused in the presence of GMPPCP
4XC6	;	3.35	;	Isobutyryl-CoA mutase fused with bound adenosylcobalamin, GDP, and Mg (holo-IcmF/GDP)
5CJT	;	3.4	;	Isobutyryl-CoA mutase fused with bound adenosylcobalamin, GDP, Mg (holo-IcmF/GDP), and substrate isobutyryl-coenzyme A
5CJV	;	3.45	;	Isobutyryl-CoA mutase fused with bound adenosylcobalamin, GDP, Mg (holo-IcmF/GDP), and substrate isovaleryl-coenzyme A
5CJU	;	3.5	;	Isobutyryl-CoA mutase fused with bound adenosylcobalamin, GDP, Mg (holo-IcmF/GDP), and substrate n-butyryl-coenzyme A
5CJW	;	3.4	;	Isobutyryl-CoA mutase fused with bound adenosylcobalamin, GDP, Mg (holo-IcmF/GDP), and substrate pivalyl-coenzyme A
4XC7	;	3.45	;	Isobutyryl-CoA mutase fused with bound butyryl-CoA and without cobalamin or GDP (apo-IcmF)
4XC8	;	3.25	;	Isobutyryl-CoA mutase fused with bound butyryl-CoA, GDP, and Mg and without cobalamin (apo-IcmF/GDP)
1AI2	;	1.9	;	ISOCITRATE DEHYDROGENASE COMPLEXED WITH ISOCITRATE, NADP+, AND CALCIUM (FLASH-COOLED)
1BL5	;	2.5	;	ISOCITRATE DEHYDROGENASE FROM E. COLI SINGLE TURNOVER LAUE STRUCTURE OF RATE-LIMITED PRODUCT COMPLEX, 10 MSEC TIME RESOLUTION
1IDC	;	2.5	;	ISOCITRATE DEHYDROGENASE FROM E.COLI (MUTANT K230M), STEADY-STATE INTERMEDIATE COMPLEX DETERMINED BY LAUE CRYSTALLOGRAPHY
1XGV	;	2.2	;	Isocitrate Dehydrogenase from the hyperthermophile Aeropyrum pernix
1TYO	;	2.15	;	Isocitrate Dehydrogenase from the hyperthermophile Aeropyrum pernix in complex with etheno-NADP
1ZOR	;	2.24	;	Isocitrate dehydrogenase from the hyperthermophile Thermotoga maritima
2UXQ	;	1.75	;	Isocitrate dehydrogenase from the psychrophilic bacterium Desulfotalea psychrophila: biochemical properties and crystal structure analysis
1IDF	;	2.5	;	ISOCITRATE DEHYDROGENASE K230M MUTANT APO ENZYME
1HJ6	;	2.0	;	ISOCITRATE DEHYDROGENASE S113E MUTANT COMPLEXED WITH ISOPROPYLMALATE, NADP+ AND MAGNESIUM (FLASH-COOLED)
1IDD	;	2.5	;	ISOCITRATE DEHYDROGENASE Y160F MUTANT APO ENZYME
1IDE	;	2.5	;	ISOCITRATE DEHYDROGENASE Y160F MUTANT STEADY-STATE INTERMEDIATE COMPLEX (LAUE DETERMINATION)
1ISO	;	1.9	;	ISOCITRATE DEHYDROGENASE: STRUCTURE OF AN ENGINEERED NADP+--> NAD+ SPECIFICITY-REVERSAL MUTANT
7CMX	;	1.79	;	Isocitrate lyase from Bacillus cereus ATCC 14579
7CMY	;	2.5	;	Isocitrate lyase from Bacillus cereus ATCC 14579 in complex with Magnessium ion, glyoxylate, and succinate
7RB1	;	1.9	;	Isocitrate Lyase-1 from Mycobacterium tuberculosis covalently modified by 5-descarboxy-5-nitro-D-isocitric acid
5ELJ	;	1.983	;	Isoform-specific inhibition of SUMO-dependent protein-protein interactions
5ELU	;	2.35	;	Isoform-specific inhibition of SUMO-dependent protein-protein interactions
5EQL	;	2.49	;	Isoform-specific inhibition of SUMO-dependent protein-protein interactions
263D	;	2.2	;	ISOHELICITY AND PHASING IN DRUG-DNA SEQUENCE RECOGNITION: CRYSTAL STRUCTURE OF A TRIS(BENZIMIDAZOLE)-OLIGONUCLEOTIDE COMPLEX
6UBY	;	7.5	;	Isolated cofilin bound to an actin filament
6QA9	;	4.1	;	Isolated complex I class refinement from Ovine respiratory supercomplex I+III2
6I2Z	;	3.2	;	Isolated globin domain of the Bordetella pertussis globin-coupled sensor
4UIQ	;	1.55	;	Isolated globin domain of the Bordetella pertussis globin-coupled sensor with a heme at the dimer interface
3KGC	;	1.55	;	Isolated ligand binding domain dimer of GluA2 ionotropic glutamate receptor in complex with glutamate, LY 404187 and ZK 200775
4TUU	;	2.64	;	Isolated p110a subunit of PI3Ka provides a platform for structure-based drug design
4TV3	;	2.85	;	Isolated p110a subunit of PI3Ka provides a platform for structure-based drug design
2MT5	;		;	Isolated Ring domain
6UC0	;	7.5	;	Isolated S3D-cofilin bound to an actin filament
5E85	;	2.57	;	isolated SBD of BiP
5E86	;	2.681	;	isolated SBD of BiP with loop34 modification
4LSC	;	1.529	;	Isolated SERK1 co-receptor ectodomain at high resolution
1W9N	;		;	Isolation and characterization of epilancin 15X, a novel antibiotic from a clinical strain of Staphylococcus epidermidis
2KNP	;		;	Isolation and characterization of peptides from Momordica cochinchinensis seeds.
6TYB	;	2.301	;	Isolation and Structure of an Antibody that Fully Neutralizes Isolate SIVmac239 Reveals Functional Similarity of SIV and HIV Glycan Shields
6CFB	;		;	Isolation, Characterization, and Synthesis of the Barrettides: Disulfide-Containing Peptides from the Marine Sponge Geodia barretti
4JC2	;	2.35	;	Isolation, Cloning and Biophysical Analysis of a Novel Hexameric Green Fluorescent Protein from a Philippine Soft Coral
1CPC	;	1.66	;	ISOLATION, CRYSTALLIZATION, CRYSTAL STRUCTURE ANALYSIS AND REFINEMENT OF CONSTITUTIVE C-PHYCOCYANIN FROM THE CHROMATICALLY ADAPTING CYANOBACTERIUM FREMYELLA DIPLOSIPHON AT 1.66 ANGSTROMS RESOLUTION
1N47	;	2.7	;	Isolectin B4 from Vicia villosa in complex with the Tn antigen
1ILE	;	2.5	;	ISOLEUCYL-TRNA SYNTHETASE
1JZQ	;	3.0	;	Isoleucyl-tRNA synthetase Complexed with Isoleucyl-adenylate analogue
1JZS	;	2.5	;	Isoleucyl-tRNA synthetase Complexed with mupirocin
1UDZ	;	1.8	;	Isoleucyl-tRNA synthetase editing domain
1WNY	;	1.6	;	Isoleucyl-tRNA synthetase editing domain
1UE0	;	2.0	;	Isoleucyl-tRNA synthetase editing domain complexed with L-Valine
1WNZ	;	1.7	;	Isoleucyl-tRNA synthetase editing domain complexed with the post-transfer editing substrate analogue, Val-2AA
1WK8	;	1.7	;	Isoleucyl-tRNA synthetase editing domain complexed with the pre-transfer editing substrate analogue, Val-AMS
6LDK	;	2.9	;	Isoleucyl-tRNA synthetase from Candida albicans complexed with a isoleucyl-adenylate
5YX4	;	2.1	;	Isoliquiritigenin-complexed Chalcone isomerase (S189A) from the Antarctic vascular plant Deschampsia Antarctica (DaCHI1)
1MOS	;	2.0	;	ISOMERASE DOMAIN OF GLUCOSAMINE 6-PHOSPHATE SYNTHASE COMPLEXED WITH 2-AMINO-2-DEOXYGLUCITOL 6-PHOSPHATE
1MOQ	;	1.57	;	ISOMERASE DOMAIN OF GLUCOSAMINE 6-PHOSPHATE SYNTHASE COMPLEXED WITH GLUCOSAMINE 6-PHOSPHATE
1MOR	;	1.9	;	ISOMERASE DOMAIN OF GLUCOSAMINE 6-PHOSPHATE SYNTHASE COMPLEXED WITH GLUCOSE 6-PHOSPHATE
2ZJ3	;	1.9	;	Isomerase domain of human glucose:fructose-6-phosphate amidotransferase
2ZJ4	;	2.2	;	Isomerase domain of human glucose:fructose-6-phosphate amidotransferase
8X6P	;	1.05	;	Isomerase Protein
6TSW	;	4.03	;	Isometric capsid of empty GTA particle computed with I4(I,n25r) symmetry
2W49	;	35.0	;	ISOMETRICALLY CONTRACTING INSECT ASYNCHRONOUS FLIGHT MUSCLE
2W4A	;	35.0	;	ISOMETRICALLY CONTRACTING INSECT ASYNCHRONOUS FLIGHT MUSCLE
2W4T	;	35.0	;	ISOMETRICALLY CONTRACTING INSECT ASYNCHRONOUS FLIGHT MUSCLE
2W4U	;	35.0	;	Isometrically contracting insect asynchronous flight muscle quick frozen after a length step
2W4H	;	35.0	;	Isometrically contracting insect asynchronous flight muscle quick frozen after a quick release step
2W4V	;	35.0	;	Isometrically contracting insect asynchronous flight muscle quick frozen after a quick release step
2W4G	;	35.0	;	ISOMETRICALLY CONTRACTING INSECT ASYNCHRONOUS FLIGHT MUSCLE QUICK FROZEN AFTER A QUICK STRETCH STEP
2W4W	;	35.0	;	Isometrically contracting insect asynchronous flight muscle quick frozen after a quick stretch step
1DRH	;	2.3	;	ISOMORPHOUS CRYSTAL STRUCTURES OF ESCHERICHIA COLI DIHYDROFOLATE REDUCTASE COMPLEXED WITH FOLATE, 5-DEAZAFOLATE AND 5,10-DIDEAZATETRAHYDROFOLATE: MECHANISTIC IMPLICATIONS
1DYH	;	1.9	;	ISOMORPHOUS CRYSTAL STRUCTURES OF ESCHERICHIA COLI DIHYDROFOLATE REDUCTASE COMPLEXED WITH FOLATE, 5-DEAZAFOLATE AND 5,10-DIDEAZATETRAHYDROFOLATE: MECHANISTIC IMPLICATIONS
1DYI	;	1.9	;	ISOMORPHOUS CRYSTAL STRUCTURES OF ESCHERICHIA COLI DIHYDROFOLATE REDUCTASE COMPLEXED WITH FOLATE, 5-DEAZAFOLATE AND 5,10-DIDEAZATETRAHYDROFOLATE: MECHANISTIC IMPLICATIONS
1DYJ	;	1.85	;	ISOMORPHOUS CRYSTAL STRUCTURES OF ESCHERICHIA COLI DIHYDROFOLATE REDUCTASE COMPLEXED WITH FOLATE, 5-DEAZAFOLATE AND 5,10-DIDEAZATETRAHYDROFOLATE: MECHANISTIC IMPLICATIONS
1W05	;	2.46	;	Isopenicillin N Synthase Aminoadipoyl-Cysteinyl-Alanine-Fe Complex
1W06	;	1.65	;	Isopenicillin N Synthase Aminoadipoyl-Cysteinyl-Alanine-Fe NO Complex
1OC1	;	2.2	;	ISOPENICILLIN N SYNTHASE aminoadipoyl-cysteinyl-aminobutyrate-FE COMPLEX
1OBN	;	1.3	;	ISOPENICILLIN N SYNTHASE aminoadipoyl-cysteinyl-aminobutyrate-FE-NO COMPLEX
1W03	;	2.1	;	Isopenicillin N Synthase Aminoadipoyl-Cysteinyl-Glycine-Fe Complex
1W04	;	1.28	;	Isopenicillin N Synthase Aminoadipoyl-Cysteinyl-Glycine-Fe-NO Complex
2BJS	;	1.3	;	Isopenicillin N synthase C-terminal truncation mutant
2BU9	;	1.3	;	Isopenicillin N synthase complexed with L-aminoadipoyl-L-cysteinyl-L- hexafluorovaline
1W3V	;	1.4	;	Isopenicillin N synthase d-(L-a-aminoadipoyl)-(3R)-methyl-L-cysteine D-a-hydroxyisovaleryl ester complex (anaerobic)
1W3X	;	1.46	;	Isopenicillin N synthase d-(L-a-aminoadipoyl)-(3R)-methyl-L-cysteine D-a-hydroxyisovaleryl ester complex (Oxygen exposed 5 minutes 20 bar)
1QIQ	;	1.5	;	ISOPENICILLIN N SYNTHASE FROM ASPERGILLUS NIDULANS (ACmC Fe COMPLEX)
1BK0	;	1.3	;	ISOPENICILLIN N SYNTHASE FROM ASPERGILLUS NIDULANS (ACV-FE COMPLEX)
1BLZ	;	1.45	;	ISOPENICILLIN N SYNTHASE FROM ASPERGILLUS NIDULANS (ACV-FE-NO COMPLEX)
2IVJ	;	1.46	;	Isopenicillin N Synthase From Aspergillus Nidulans (Anaerobic Ac- cyclopropylglycine Fe Complex)
2IVI	;	1.3	;	Isopenicillin N Synthase From Aspergillus Nidulans (Anaerobic Ac- methyl-cyclopropylglycine Fe Complex)
1ODM	;	1.15	;	ISOPENICILLIN N SYNTHASE FROM ASPERGILLUS NIDULANS (ANAEROBIC AC-VINYLGLYCINE FE COMPLEX)
1HB1	;	1.55	;	ISOPENICILLIN N SYNTHASE FROM ASPERGILLUS NIDULANS (ANAEROBIC ACOV FE COMPLEX)
1QJE	;	1.35	;	Isopenicillin N synthase from Aspergillus nidulans (IP1 - Fe complex)
1IPS	;	2.5	;	ISOPENICILLIN N SYNTHASE FROM ASPERGILLUS NIDULANS (MANGANESE COMPLEX)
1QJF	;	1.4	;	ISOPENICILLIN N SYNTHASE FROM ASPERGILLUS NIDULANS (Monocyclic Sulfoxide - Fe COMPLEX)
1HB2	;	1.3	;	ISOPENICILLIN N SYNTHASE FROM ASPERGILLUS NIDULANS (OXYGEN EXPOSED PRODUCT FROM ANAEROBIC ACOV FE COMPLEX)
1HB3	;	1.4	;	ISOPENICILLIN N SYNTHASE FROM ASPERGILLUS NIDULANS (OXYGEN EXPOSED PRODUCT FROM ANAEROBIC ACOV FE COMPLEX)
1HB4	;	1.5	;	ISOPENICILLIN N SYNTHASE FROM ASPERGILLUS NIDULANS (OXYGEN EXPOSED PRODUCT FROM ANAEROBIC ACOV FE COMPLEX)
1ODN	;	1.6	;	ISOPENICILLIN N SYNTHASE FROM ASPERGILLUS NIDULANS (OXYGEN-EXPOSED PRODUCT FROM ANAEROBIC AC-VINYLGLYCINE FE COMPLEX)
6Y0O	;	2.2	;	isopenicillin N synthase in complex with ACV and Fe under anaerobic environment using FT-SSX methods
6ZW8	;	1.22	;	Isopenicillin N synthase in complex with Cd and ACV.
7P3L	;	1.32	;	Isopenicillin N synthase in complex with Fe and the substrate analogue AadCyshomoCys
6ZAP	;	1.36	;	Isopenicillin N synthase in complex with Fe, O2 and ACV under cryo conditions.
6ZAN	;	1.35	;	Isopenicillin N synthase in complex with Fe, the oxygen surrogate NO and ACV.
6Y0P	;	1.98	;	isopenicillin N synthase in complex with IPN and Fe using FT-SSX methods
6ZAO	;	1.66	;	Isopenicillin N synthase structure in complex with Fe and IPN exposed to dioxygen.
2JB4	;	1.3	;	Isopenicillin N synthase with a 2-thiabicycloheptan-6-one product analogue
2Y60	;	1.4	;	Isopenicillin N synthase with AC-D-methionine
2Y6F	;	1.79	;	Isopenicillin N synthase with AC-D-S-methyl-3R-methylcysteine
3ZOI	;	1.82	;	ISOPENICILLIN N SYNTHASE WITH AC-O-METHYL-D-THREONINE
1UZW	;	1.3	;	ISOPENICILLIN N SYNTHASE WITH L-D-(A-AMINOADIPOYL)-L-CYSTEINYL-D-ISODEHYDROVALINE
2VBB	;	1.4	;	Isopenicillin N synthase with substrate analogue ACOMP (35minutes oxygen exposure)
2VAU	;	1.8	;	Isopenicillin N synthase with substrate analogue ACOMP (unexposed)
3ZKY	;	1.45	;	Isopenicillin N synthase with substrate analogue AhCmC
3ZKU	;	1.4	;	Isopenicillin N synthase with substrate analogue AhCV
2VCM	;	1.65	;	Isopenicillin N synthase with substrate analogue AsMCOV
2VE1	;	2.2	;	Isopenicillin N synthase with substrate analogue AsMCOV (oxygen exposed 1min 20bar)
2WO7	;	2.5	;	Isopenicillin N synthase with substrate analogue L,L,D-ACd2Ab (unexposed)
2VBP	;	1.5	;	Isopenicillin N synthase with substrate analogue L,L,L-ACAB (unexposed)
2VBD	;	2.0	;	Isopenicillin N synthase with substrate analogue L,L,L-ACOMP (unexposed)
4BB3	;	1.4	;	Isopenicillin N synthase with the dipeptide substrate analogue AhC
1PPV	;	1.7	;	ISOPENTENYLPYROPHOSPHATE-DIMETHYLALLYLPYROPHOSPHATE ISOMERASE IN COMPLEX WITH THE BROMOHYDRINE OF IPP
1PPW	;	2.21	;	ISOPENTENYLPYROPHOSPHATE-DIMETHYLALLYLPYROPHOSPHATE ISOMERASE IN COMPLEX WITH THE BROMOHYDRINE OF IPP
5LDG	;	1.3	;	Isopiperitenone reductase from Mentha piperita in complex with Isopiperitenone and NADP
5LCX	;	1.709	;	Isopiperitenone reductase from Mentha piperita in complex with NADP
5L4S	;	1.41	;	Isopiperitenone reductase from Mentha piperita in complex with NADP and beta-Cyclocitral
5YOT	;	1.98	;	Isoprimeverose-producing enzyme from Aspergillus oryzae in complex with isoprimeverose
5YQS	;	2.4	;	Isoprimeverose-producing enzyme from Aspergillus oryzae in complex with isoprimeverose
5J32	;	1.933	;	Isopropylmalate dehydrogenase in complex with isopropylmalate
5J33	;	3.492	;	Isopropylmalate dehydrogenase in complex with NAD+
5J34	;	1.827	;	Isopropylmalate dehydrogenase K232M mutant
3Q3W	;	1.89	;	Isopropylmalate isomerase small subunit from Campylobacter jejuni.
4OV4	;	2.0	;	Isopropylmalate synthase binding with ketoisovalerate
7S0F	;	2.96	;	Isoproterenol bound beta1 adrenergic receptor in complex with heterotrimeric Gi protein
7S0G	;	3.86	;	Isoproterenol bound beta1 adrenergic receptor in complex with heterotrimeric Gi/s chimera protein
7XJH	;	3.3	;	Isoproterenol-activated dog beta3 adrenergic receptor
7UXY	;	3.15	;	Isoreticular, interpenetrating co-crystal of protein variant Replication Initiator Protein REPE54 (L53G,Q54G,E55G) and symmetrical expanded duplex (31mer) containing the cognate REPE54 sequence and an additional G-C rich sequence.
7UOG	;	2.63	;	Isoreticular, interpenetrating co-crystal of Replication Initiator Protein REPE54 and asymmetrical expanded duplex (31mer) containing the cognate REPE54 sequence and an additional G-C rich sequence.
7UV6	;	2.72	;	Isoreticular, interpenetrating co-crystal of Replication Initiator Protein REPE54 and scaffold duplex (21mer) containing the cognate REPE54 sequence and an insert duplex (10mer) with guest TAMRA-labelled thymine and G-C rich sequence.
7UV7	;	3.02	;	Isoreticular, interpenetrating co-crystal of Replication Initiator Protein REPE54 and scaffold duplex (21mer) containing the cognate REPE54 sequence and an insert duplex (10mer) with guest TAMRA-labelled thymine and T-A rich sequence.
7UFX	;	2.8	;	Isoreticular, interpenetrating co-crystal of Replication Initiator Protein REPE54 and scaffold-insert duplexes (21mer and 10mer) containing the cognate REPE54 sequence and an additional G-C rich sequence, respectively.
7UR0	;	3.3	;	Isoreticular, interpenetrating co-crystal of Replication Initiator Protein REPE54 and scaffold-insert duplexes (21mer and 10mer) containing the cognate REPE54 sequence and an additional T-A rich sequence, respectively.
8D86	;	3.12	;	Isoreticular, interpenetrating co-crystal of Replication Initiator Protein REPE54 and symmetrical expanded duplex (31mer) containing the cognate REPE54 sequence and an additional G-C rich sequence co-crystallized with a guest small molecule, netropsin.
8D8M	;	3.1	;	Isoreticular, interpenetrating co-crystal of Replication Initiator Protein REPE54 and symmetrical expanded duplex (31mer) containing the cognate REPE54 sequence and an additional G-C rich sequence grown in a calcium chloride crystallization solution.
8TIY	;	3.11	;	Isoreticular, interpenetrating co-crystal of Replication Initiator Protein REPE54 and symmetrical expanded duplex (31mer) containing the cognate REPE54 sequence and an additional G-C rich sequence with 1 sticky bases and 3' terminal phosphates and crosslinked with EDC.
8TIS	;	2.54	;	Isoreticular, interpenetrating co-crystal of Replication Initiator Protein REPE54 and symmetrical expanded duplex (31mer) containing the cognate REPE54 sequence and an additional G-C rich sequence with 1 sticky bases and 3' terminal phosphates.
8TIX	;	2.91	;	Isoreticular, interpenetrating co-crystal of Replication Initiator Protein REPE54 and symmetrical expanded duplex (31mer) containing the cognate REPE54 sequence and an additional G-C rich sequence with 1 sticky bases and 5' terminal phosphates and crosslinked with EDC.
8TIR	;	3.11	;	Isoreticular, interpenetrating co-crystal of Replication Initiator Protein REPE54 and symmetrical expanded duplex (31mer) containing the cognate REPE54 sequence and an additional G-C rich sequence with 1 sticky bases and 5' terminal phosphates.
8TJ1	;	3.15	;	Isoreticular, interpenetrating co-crystal of Replication Initiator Protein REPE54 and symmetrical expanded duplex (31mer) containing the cognate REPE54 sequence and an additional G-C rich sequence with 2 sticky base overhangs and 3' terminal phosphates and crosslinked with EDC.
8TIU	;	3.9	;	Isoreticular, interpenetrating co-crystal of Replication Initiator Protein REPE54 and symmetrical expanded duplex (31mer) containing the cognate REPE54 sequence and an additional G-C rich sequence with 2 sticky base overhangs and 3' terminal phosphates.
8TJ0	;	3.24	;	Isoreticular, interpenetrating co-crystal of Replication Initiator Protein REPE54 and symmetrical expanded duplex (31mer) containing the cognate REPE54 sequence and an additional G-C rich sequence with 2 sticky base overhangs and 5' terminal phosphates and crosslinked with EDC.
8TIZ	;	3.11	;	Isoreticular, interpenetrating co-crystal of Replication Initiator Protein REPE54 and symmetrical expanded duplex (31mer) containing the cognate REPE54 sequence and an additional G-C rich sequence with 2 sticky base overhangs and no terminal phosphates and crosslinked with EDC.
8TIT	;	2.84	;	Isoreticular, interpenetrating co-crystal of Replication Initiator Protein REPE54 and symmetrical expanded duplex (31mer) containing the cognate REPE54 sequence and an additional G-C rich sequence with 2 sticky base overhangs and no terminal phosphates.
8TIW	;	3.11	;	Isoreticular, interpenetrating co-crystal of Replication Initiator Protein REPE54 and symmetrical expanded duplex (31mer) containing the cognate REPE54 sequence and an additional G-C rich sequence with blunt ends and 3' terminal phosphates and crosslinked with EDC.
8TIQ	;	2.45	;	Isoreticular, interpenetrating co-crystal of Replication Initiator Protein REPE54 and symmetrical expanded duplex (31mer) containing the cognate REPE54 sequence and an additional G-C rich sequence with blunt ends and 3' terminal phosphates.
8TIV	;	3.35	;	Isoreticular, interpenetrating co-crystal of Replication Initiator Protein REPE54 and symmetrical expanded duplex (31mer) containing the cognate REPE54 sequence and an additional G-C rich sequence with blunt ends and 5' terminal phosphates and crosslinked with EDC.
8TIP	;	2.79	;	Isoreticular, interpenetrating co-crystal of Replication Initiator Protein REPE54 and symmetrical expanded duplex (31mer) containing the cognate REPE54 sequence and an additional G-C rich sequence with blunt ends and 5' terminal phosphates.
7U6K	;	2.38	;	Isoreticular, interpenetrating co-crystal of Replication Initiator Protein REPE54 and symmetrical expanded duplex (31mer) containing the cognate REPE54 sequence and an additional G-C rich sequence.
7U7O	;	2.97	;	Isoreticular, interpenetrating co-crystal of Replication Initiator Protein REPE54 and symmetrical expanded duplex (31mer) containing the cognate REPE54 sequence and an additional T-A rich sequence.
2IJN	;	2.2	;	Isothiazoles as active-site inhibitors of HCV NS5B polymerase
5F6M	;	1.1	;	Isotropic Trypsin Model for Comparison of Diffuse Scattering
1FCZ	;	1.38	;	ISOTYPE SELECTIVITY OF THE HUMAN RETINOIC ACID NUCLEAR RECEPTOR HRAR: THE COMPLEX WITH THE PANAGONIST RETINOID BMS181156
1FCY	;	1.3	;	ISOTYPE SELECTIVITY OF THE HUMAN RETINOIC ACID NUCLEAR RECEPTOR HRAR: THE COMPLEX WITH THE RARBETA/GAMMA-SELECTIVE RETINOID CD564
1FCX	;	1.47	;	ISOTYPE SELECTIVITY OF THE HUMAN RETINOIC ACID NUCLEAR RECEPTOR HRAR: THE COMPLEX WITH THE RARGAMMA-SELECTIVE RETINOID BMS184394
1FD0	;	1.38	;	ISOTYPE SELECTIVITY OF THE HUMAN RETINOIC ACID NUCLEAR RECEPTOR HRAR: THE COMPLEX WITH THE RARGAMMA-SELECTIVE RETINOID SR11254
3GD2	;	3.2	;	isoxazole ligand bound to farnesoid X receptor (FXR)
1ONN	;	2.6	;	IspC apo structure
1ONP	;	2.5	;	IspC complex with Mn2+ and fosmidomycin
3R0I	;	2.1	;	IspC in complex with an N-methyl-substituted hydroxamic acid
1ONO	;	2.5	;	IspC Mn2+ complex
2V8P	;	2.1	;	IspE in complex with ADP and CDP
2V2Z	;	2.25	;	IspE in complex with ADP and CDPME
2V34	;	2.3	;	IspE in complex with cytidine and ligand
2V2Q	;	2.3	;	IspE in complex with ligand
2V2V	;	2.4	;	IspE in complex with ligand
4C8E	;	1.9	;	IspF (Burkholderia cenocepacia) 2CMP complex
4C8I	;	2.0	;	IspF (Burkholderia cenocepacia) citrate complex
4C8G	;	2.0	;	IspF (Burkholderia cenocepacia) CMP complex
4C81	;	1.56	;	IspF (Plasmodium falciparum) CDP complex
4C82	;	2.0	;	IspF (Plasmodium falciparum) unliganded structure
1U3P	;	2.85	;	IspF native
1U40	;	2.8	;	IspF with 4-diphosphocytidyl-2C-methyl-D-erythritol
1U43	;	3.2	;	IspF with 4-diphosphocytidyl-2c-methyl-D-erythritol 2-phosphate
1U3L	;	2.5	;	IspF with Mg and CDP
4S38	;	1.4	;	IspG in complex MEcPP
4S3C	;	1.45	;	IspG in complex with Epoxide Intermediate
4S39	;	1.3	;	IspG in complex with HMBPP
4S3E	;	1.35	;	IspG in complex with Inhibitor 7 (compound 1061)
4S3F	;	1.7	;	IspG in complex with Inhibitor 8 (compound 1077)
4S3A	;	1.6	;	IspG in complex with Intermediate I
4S3B	;	1.8	;	IspG in complex with Intermediate II
4S3D	;	1.8	;	IspG in complex with PPi
4H4D	;	1.35	;	IspH in complex with (E)-4-amino-3-methylbut-2-enyl diphosphate
4H4C	;	1.8	;	IspH in complex with (E)-4-fluoro-3-methylbut-2-enyl diphosphate
4H4E	;	1.7	;	IspH in complex with (E)-4-mercapto-3-methylbut-2-enyl diphosphate
4MV5	;	1.9	;	IspH in complex with 6-chloropyridin-3-ylmethyl diphosphate
3URK	;	1.5	;	IspH in complex with propynyl diphosphate (1061)
4MV0	;	1.9	;	IspH in complex with pyridin-2-ylmethyl diphosphate
4MUX	;	1.7	;	IspH in complex with pyridin-3-ylmethyl diphosphate
4MUY	;	1.8	;	IspH in complex with pyridin-4-ylmethyl diphosphate
3T0F	;	1.9	;	IspH:HMBPP (substrate) structure of the E126D mutant
3T0G	;	2.1	;	IspH:HMBPP (substrate) structure of the T167C mutant
3SZO	;	1.6	;	IspH:HMBPP complex after 3 minutes X-ray pre-exposure
3SZU	;	1.4	;	IspH:HMBPP complex structure of E126Q mutant
3SZL	;	1.6	;	IspH:Ligand Mutants - wt 70sec
5OB3	;	2.004	;	iSpinach aptamer
5LWI	;	3.2	;	Israeli acute paralysis virus heated to 63 degree - empty particle
5LWG	;	3.2	;	Israeli acute paralysis virus heated to 63 degree - full particle
8B4H	;	3.35	;	IstA transposase cleaved donor complex
7W08	;	3.25	;	Itaconate inducible LysR-Type Transcriptional regulator (ITCR) in APO form, Space group P1.
7W06	;	1.5	;	Itaconate inducible LysR-Type Transcriptional regulator (ITCR) in complex with itaconate (SeMet labeled), Space group C121.
7W07	;	1.48	;	Itaconate inducible LysR-Type Transcriptional regulator (ITCR) in complex with itaconate, Space group C121.
1YIU	;		;	Itch E3 ubiquitin ligase WW3 domain
4MF1	;	2.113	;	ITK kinase domain in complex with benzothiazole inhibitor 12b (1S,2S)-2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-1,3-BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
4MF0	;	2.67	;	ITK kinase domain in complex with benzothiazole inhibitor compound 12a (1S,2S)-2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(PYRIDIN-3-YL)-1,3-BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE (12a)
4RFM	;	2.1	;	ITK kinase domain in complex with compound 1 N-{1-[(1,1-dioxo-1-thian-2-yl)(phenyl)methyl]-1H- pyrazol-4-yl}-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-carboxamide
4QD6	;	2.45	;	ITK kinase domain in complex with inhibitor compound
4PP9	;	2.58	;	ITK kinase domain with compound 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4-YL]-2H-INDAZOLE-3-CARBOXAMIDE)
4PPA	;	2.67	;	ITK kinase domain with compound 11 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4-YL]-6-(1H-PYRAZOL-4-YL)-1H-INDAZOLE-3-CARBOXAMIDE)
4PPC	;	2.95	;	ITK kinase domain with compound 27 (N-{1-[(1R)-3-(DIMETHYLAMINO)-1-PHENYLPROPYL]-1H-PYRAZOL-4-YL}-6-(1H-PYRAZOL-4-YL)-1H-INDAZOLE-3-CARBOXAMIDE)
4PPB	;	2.82	;	ITK kinase domain with compound 28 (N-{1-[(1S)-3-(DIMETHYLAMINO)-1-PHENYLPROPYL]-1H-PYRAZOL-4-YL}-6-(1H-PYRAZOL-4-YL)-1H-INDAZOLE-3-CARBOXAMIDE)
4PQN	;	1.71	;	ITK kinase domain with compound GNE-9822
2RNA	;		;	Itk SH3 average minimized
2LMJ	;		;	Itk-sh3
7TZ3	;		;	Iturin from Bacillus subtilis ATCC 19659
2UW1	;	1.95	;	Ivy Desaturase Structure
1UUZ	;	1.8	;	IVY:A NEW FAMILY OF PROTEIN
7DAF	;	2.4	;	IXA in complex with tubulin
1BQ0	;		;	J-DOMAIN (RESIDUES 1-77) OF THE ESCHERICHIA COLI N-TERMINAL FRAGMENT (RESIDUES 1-104) OF THE MOLECULAR CHAPERONE DNAJ, NMR, 20 STRUCTURES
1BQZ	;		;	J-DOMAIN (RESIDUES 1-77) OF THE ESCHERICHIA COLI N-TERMINAL FRAGMENT (RESIDUES 1-78) OF THE MOLECULAR CHAPERONE DNAJ, NMR, 20 STRUCTURES
2OCH	;	1.86	;	J-domain of dnj-12 from Caenorhabditis elegans
4RWU	;	1.25	;	J-domain of Sis1 protein, Hsp40 co-chaperone from Saccharomyces cerevisiae
7S6J	;	3.4	;	J08 fragment antigen binding in complex with SARS-CoV-2-6P-Mut2 S protein (conformation 1)
7S6K	;	3.4	;	J08 fragment antigen binding in complex with SARS-CoV-2-6P-Mut2 S protein (conformation 2)
7S6L	;	4.0	;	J08 fragment antigen binding in complex with SARS-CoV-2-6P-Mut7 S protein (conformation 3)
8QYA	;	2.72	;	J22.9-FNY, fully humanized, CDR optimized Fab Fragment based on chimeric J22.9-xi IgG against BCMA; with VH CDR2 glycosylation
8QY9	;	3.1	;	J22.9-H, fully humanized Fab Fragment based on chimeric J22.9-xi IgG against BCMA
8QYB	;	3.09	;	J22.9-ISY, fully humanized and CDR optimized Fab Fragment based on chimeric J22.9-xi IgG against BCMA
4ZFO	;	1.895	;	J22.9-xi: chimeric mouse/human antibody against human BCMA (CD269)
1TUT	;		;	J4/5 Loop from the Candida albicans and Candida dubliniensis Group I Introns
4P23	;	2.25	;	J809.B5 TCR bound to IAb/3K
4P46	;	2.851	;	J809.B5 Y31A TCR bound to IAb3K
3UO2	;	2.13	;	Jac1 co-chaperone from Saccharomyces cerevisiae
3UO3	;	1.85	;	Jac1 co-chaperone from Saccharomyces cerevisiae, 5-182 clone
4R6N	;	1.67	;	Jacalin-carbohydrate interactions. Distortion of the ligand as a determinant of affinity
4R6O	;	1.6	;	Jacalin-carbohydrate interactions. Distortion of the ligand as a determinant of affinity.
4R6P	;	1.7	;	Jacalin-carbohydrate interactions. Distortion of the ligand as a determinant of affinity.
4R6Q	;	1.6	;	Jacalin-carbohydrate interactions. Distortion of the ligand as a determinant of affinity.
4R6R	;	1.38	;	Jacalin-carbohydrate interactions. Distortion of the ligand as a determinant of affinity.
6XT5	;	2.69	;	Jack bean asparaginyl endopeptidase
5HX8	;	2.2	;	Jak1 complex with 4-[(4-aminocyclohexyl)amino]-3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one
5WO4	;	1.84	;	JAK1 complexed with compound 28
4EI4	;	2.22	;	JAK1 kinase (JH1 domain) in complex with compound 20
4E5W	;	1.86	;	JAK1 kinase (JH1 domain) in complex with compound 26
4E4L	;	2.0	;	JAK1 kinase (JH1 domain) in complex with compound 30
4IVD	;	1.93	;	JAK1 kinase (JH1 domain) in complex with compound 34
4E4N	;	1.9	;	JAK1 kinase (JH1 domain) in complex with compound 49
4K77	;	2.4	;	JAK1 kinase (JH1 domain) in complex with compound 6
4FK6	;	2.2	;	JAK1 kinase (JH1 domain) in complex with compound 72
4IVC	;	2.35	;	JAK1 kinase (JH1 domain) in complex with the inhibitor (TRANS-4-{2-[(1R)-1-HYDROXYETHYL]IMIDAZO[4,5-D]PYRROLO[2,3-B]PYRIDIN-1(6H)-YL}CYCLOHEXYL)ACETONITRILE
4IVB	;	1.9	;	JAK1 kinase (JH1 domain) in complex with the inhibitor TRANS-4-{2-[(1R)-1-HYDROXYETHYL]IMIDAZO[4,5-D]PYRROLO[2,3-B]PYRIDIN-1(6H)-YL}CYCLOHEXANECARBONITRILE
6DBN	;	2.48	;	Jak1 with compound 23
8G6Z	;	2.45	;	JAK2 crystal structure in complex with Compound 13
7Q7K	;	1.61	;	JAK2 in complex with 4-(2-amino-8-methoxyquinazolin-6-yl)phenol
7Q7L	;	1.97	;	JAK2 in complex with 4-(2-amino-8-{[(2S)-1-hydroxypropan-2-yl]amino}quinazolin-6-yl)-5-ethyl-2-fluorophenol
7Q7W	;	1.85	;	JAK2 in complex with 4-(2-{[5-(dimethylamino)pentyl]amino}-8-{[(2S)-1-hydroxypropan-2-yl]amino}quinazolin-6-yl)-5-ethyl-2-fluorophenol
7Q7I	;	1.78	;	JAK2 in complex with 4-{8-methoxy-2-[(1-methyl-1H-pyrazol-4-yl)amino]quinazolin-6-yl}phenol
6VN8	;	1.9	;	JAK2 JH1 in complex with baricitinib
6VS3	;	2.0	;	JAK2 JH1 in complex with BL2-057
6VNB	;	2.19	;	JAK2 JH1 in complex with BL2-084
6VNC	;	2.3	;	JAK2 JH1 in complex with BL2-096
6VSN	;	2.5	;	JAK2 JH1 in complex with BL2-110
6VNE	;	2.32	;	JAK2 JH1 in complex with Fedratinib
5USY	;	2.0	;	JAK2 JH1 in complex with JNJ-7706621
6DRW	;	2.303	;	JAK2 JH1 in complex with JNJ-7706621 (Crystal Form 2)
6VNF	;	2.06	;	JAK2 JH1 in complex with MA9-086
6VNG	;	2.5	;	JAK2 JH1 in complex with PN2-118
6VNH	;	2.4	;	JAK2 JH1 in complex with PN2-123
6VNI	;	2.1	;	JAK2 JH1 in complex with PN3-115
6VNJ	;	1.9	;	JAK2 JH1 in complex with PN4-014
6VNK	;	2.0	;	JAK2 JH1 in complex with PN4-073
6VGL	;	1.9	;	JAK2 JH1 in complex with ruxolitinib
6VNL	;	2.4	;	JAK2 JH1 in complex with SG3-179
6VNM	;	2.2	;	JAK2 JH1 in complex with SY5-103
6BS0	;	1.541	;	JAK2 JH2 in complex with 63552444
5UT6	;	1.645	;	JAK2 JH2 in complex with a diaminopyrimidine
5UT0	;	2.102	;	JAK2 JH2 in complex with AT9283
5UT1	;	1.95	;	JAK2 JH2 in complex with BI-D1870
6M9H	;	1.79	;	JAK2 JH2 in complex with diaminopyrimidine JAK040
5UT5	;	1.9	;	JAK2 JH2 in complex with GLPG0634
5UT3	;	1.501	;	JAK2 JH2 in complex with IKK-2 Inhibitor VI
7JYQ	;	1.85942	;	JAK2 JH2 in complex with JAK020
7JYO	;	2.16127	;	JAK2 JH2 in complex with JAK064
6XJK	;	2.02351	;	JAK2 JH2 in complex with JAK067
6OAV	;	1.939	;	JAK2 JH2 in complex with JAK146
6OBL	;	2.061	;	JAK2 JH2 in complex with JAK168
6OBB	;	1.904	;	JAK2 JH2 in complex with JAK170
6OBF	;	1.71	;	JAK2 JH2 in complex with JAK179
6OCC	;	2.03	;	JAK2 JH2 in complex with JAK190
7T1T	;	2.08	;	JAK2 JH2 IN COMPLEX WITH JAK292
7T0P	;	2.04	;	JAK2 JH2 IN COMPLEX WITH JAK315
5USZ	;	2.103	;	JAK2 JH2 in complex with JNJ-7706621
6BSS	;	2.1	;	JAK2 JH2 in complex with NU6102
5UT4	;	2.0	;	JAK2 JH2 in complex with NVP-BSK805
5UT2	;	1.75	;	JAK2 JH2 in complex with PRT062607
6BRW	;	2.031	;	JAK2 JH2 in complex with XMU-MP-1
4GMY	;	2.403	;	JAK2 kinase (JH1 domain) in complex with 2,6-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
4E4M	;	2.25	;	JAK2 kinase (JH1 domain) in complex with compound 30
4HGE	;	2.3	;	JAK2 kinase (JH1 domain) in complex with compound 8
4JIA	;	1.85	;	JAK2 kinase (JH1 domain) in complex with compound 9
4JI9	;	2.4	;	JAK2 kinase (JH1 domain) in complex with TG101209
4IVA	;	1.5	;	JAK2 kinase (JH1 domain) in complex with the inhibitor TRANS-4-[(8AS)-2-[(1R)-1-HYDROXYETHYL]IMIDAZO[4,5-D]PYRROLO[2,3-B]PYRIDIN-1(8AH)-YL]CYCLOHEXANECARBONITRILE
5HEZ	;	2.66	;	JAK2 kinase (JH1 domain) mutant P1057A in complex with TG101209
4E6Q	;	1.948	;	JAK2 kinase (JH1 domain) triple mutant in complex with compound 12
4E6D	;	2.22	;	JAK2 kinase (JH1 domain) triple mutant in complex with compound 7
4GFM	;	2.3	;	JAK2 kinase (JH1 domain) with 2,6-DICHLORO-N-(2-OXO-2,5-DIHYDROPYRIDIN-4-YL)BENZAMIDE
5WIM	;	2.55	;	JAK2 Pseudokinase in complex with AT9283
5WIL	;	2.2	;	JAK2 Pseudokinase in complex with AZD7762
5WIK	;	2.6	;	JAK2 Pseudokinase in complex with BI-D1870
5WIN	;	2.38	;	JAK2 Pseudokinase in complex with JNJ7706621
5WIJ	;	2.04	;	JAK2 Pseudokinase in complex with NU6140
6D2I	;	3.192	;	JAK2 Pseudokinase V617F in complex with AT9283
7F7W	;	1.83	;	JAK2-JH2
4V0G	;	3.0	;	JAK3 in complex with a covalent EGFR inhibitor
4QT1	;	2.4	;	JAK3 kinase domain in complex with 1-[(3S)-1-isobutylsulfonyl-3-piperidyl]-3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)urea
4HVI	;	2.4	;	JAK3 kinase domain in complex with 2-Cyclopropyl-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-methyl-2-oxo-2-piperidin-1-yl-ethyl)-amide
4HVH	;	2.3	;	JAK3 kinase domain in complex with 2-Cyclopropyl-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2-hydroxy-1,2-dimethyl-propyl
4HVD	;	1.85	;	JAK3 kinase domain in complex with 2-Cyclopropyl-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-1,2,2-trimethyl-propyl)-amide
4HVG	;	2.75	;	JAK3 kinase domain in complex with 2-Cyclopropyl-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-hydroxy-1,2-dimethyl-propyl)-amide
4I6Q	;	1.85	;	JAK3 kinase domain in complex with 2-Phenoxy-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-1-cyclopropyl-ethyl)-amide
5TTS	;	2.34	;	Jak3 with covalent inhibitor 4
5TTV	;	1.93	;	Jak3 with covalent inhibitor 6
5TTU	;	1.72	;	Jak3 with covalent inhibitor 7
5TOZ	;	1.98	;	JAK3 with covalent inhibitor PF-06651600
6DA4	;	2.9	;	JAK3 with Cyanamide CP10
6DUD	;	1.66	;	JAK3 with cyanamide CP12
6DB3	;	1.97	;	JAK3 with Cyanamide CP23
6DB4	;	1.662	;	JAK3 with Cyanamide CP34
1R5X	;	2.3	;	JAMM: A Metalloprotease-like Zinc Site in the Proteasome and Signalosome
3JY9	;	2.1	;	Janus Kinase 2 Inhibitors
5OW2	;	1.98	;	Japanese encephalitis virus capsid protein
5O19	;	2.1	;	Japanese encephalitis virus non-structural protein 1 C-terminal domain
5O36	;	2.6	;	Japanese encephalitis virus non-structural protein 1' C-terminal domain
1AOC	;	2.0	;	JAPANESE HORSESHOE CRAB COAGULOGEN
4PDT	;	1.4	;	Japanese Marasmius oreades lectin
4TKC	;	1.29	;	Japanese Marasmius oreades lectin complexed with mannose
4BQU	;	2.36	;	Japanin from Rhipicephalus appendiculatus bound to cholesterol: Orthorhombic crystal form
4BOE	;	2.24	;	Japanin from Rhipicephalus appendiculatus bound to cholesterol: Tetragonal crystal form
7SBZ	;	2.9	;	JAR5 Fab bound to fHbp v1.1 crystallized in space group I422
8CCO	;	3.28	;	JAS-stabilized F-ActinII from Plasmodium falciparum
4X16	;	1.8	;	JC Mad-1 polyomavirus VP1 in complex with GD1a oligosaccharide
4X17	;	1.75	;	JC Mad-1 polyomavirus VP1 in complex with GD1b oligosaccharide
4X14	;	2.3	;	JC Mad-1 polyomavirus VP1 in complex with GM1 oligosaccharide
4X15	;	2.11	;	JC Mad-1 polyomavirus VP1 in complex with GM2 oligosaccharide
4X11	;	2.3	;	JC Polyomavirus genotype 3 VP1 in complex with GD1a oligosaccharide
4X12	;	1.9	;	JC Polyomavirus genotype 3 VP1 in complex with GD1b oligosaccharide
4X0Z	;	1.85	;	JC Polyomavirus genotype 3 VP1 in complex with GM1 oligosaccharide
4X10	;	1.9	;	JC Polyomavirus genotype 3 VP1 in complex with GM2 oligosaccharide
4X13	;	2.0	;	JC Polyomavirus genotype 3 VP1 in complex with LSTc pentasaccharide
8SUD	;	2.1	;	JC Polyomavirus LTA NLS bound to importin alpha 2
3NXG	;	1.95	;	JC polyomavirus VP1
4WDY	;	1.9	;	JC Polyomavirus VP1 five-fold pore mutant N221Q
4WDZ	;	1.8	;	JC Polyomavirus VP1 five-fold pore mutant N221W
4WE0	;	2.1	;	JC Polyomavirus VP1 five-fold pore mutant P223M
4X0Y	;	1.7	;	JC polyomavirus VP1 from a genotype 3 strain
7ZIL	;	1.24	;	JC Polyomavirus VP1 in complex with 3'-Sialyllactose glycomacromolecules (aliphatic linker)
7ZIP	;	1.9	;	JC Polyomavirus VP1 in complex with 3'-Sialyllactose glycomacromolecules (aliphatic linker)
7ZIM	;	1.55	;	JC Polyomavirus VP1 in complex with 3'-Sialyllactose glycomacromolecules (aromatic linker)
7ZIN	;	1.648	;	JC Polyomavirus VP1 in complex with 6'-Sialyllactose glycomacromolecules (aliphatic linker)
7ZIO	;	1.751	;	JC Polyomavirus VP1 in complex with 6'-Sialyllactose glycomacromolecules (aromatic linker)
7PA8	;	3.15	;	JC polyomavirus VP1 in complex with Fab 27C2
7PA9	;	2.75	;	JC polyomavirus VP1 in complex with Fab 98D3
3NXD	;	2.0	;	JC polyomavirus VP1 in complex with LSTc
7PA6	;	1.9	;	JC polyomavirus VP1 in complex with scFv 27C11
7PAA	;	3.102	;	JC polyomavirus VP1 in complex with scFv 29B1
5CYN	;	2.7	;	JC Virus large T-antigen origin binding domain F258L mutant
1KZK	;	1.09	;	JE-2147-HIV Protease Complex
2JEL	;	2.5	;	JEL42 FAB/HPR COMPLEX
5YWP	;	4.6	;	JEV-2H4 Fab complex
7UQ3	;	1.49	;	JmjC domain-containing protein 5 (JMJD5) in complex with Mn and (S)-2-(1-hydroxy-2,5-dioxopyrrolidin-3-yl)acetic acid
6I9N	;	1.361	;	JmjC domain-containing protein 5 (JMJD5) in complex with Mn and L-2-hydroxyglutarate
6I9L	;	1.53	;	JmjC domain-containing protein 5 (JMJD5) in complex with Mn and pyridine-2,4-dicarboxylic acid (2,4-PDCA)
6I9M	;	1.65	;	JmjC domain-containing protein 5 (JMJD5) in complex with Mn and R-2-hydroxyglutarate
4BIS	;	2.493	;	JMJD2A COMPLEXED WITH 8-HYDROXYQUINOLINE-4-CARBOXYLIC ACID
4AI9	;	2.25	;	JMJD2A Complexed with Daminozide
4V2W	;	1.81	;	JMJD2A COMPLEXED WITH NI(II), NOG AND HISTONE H3K27me3 PEPTIDE (16-35)
4V2V	;	2.0	;	JMJD2A COMPLEXED WITH NI(II), NOG AND HISTONE H3K27me3 PEPTIDE (25-29) ARK(me3)SA
5FWE	;	2.05	;	JMJD2A COMPLEXED WITH NI(II), NOG AND HISTONE H4(1-15)R3me2s PEPTIDE
2YBK	;	2.4	;	JMJD2A COMPLEXED WITH R-2-HYDROXYGLUTARATE
2YBP	;	2.02	;	JMJD2A COMPLEXED WITH R-2-HYDROXYGLUTARATE AND HISTONE H3K36me3 PEPTIDE (30-41)
2YBS	;	2.32	;	JMJD2A COMPLEXED WITH S-2-HYDROXYGLUTARATE AND HISTONE H3K36me3 PEPTIDE (30-41)
2QQR	;	1.8	;	JMJD2A hybrid tudor domains
5TVS	;	2.745	;	JMJD2A in complex with Ni(II)
5TVR	;	2.093	;	JMJD2A in complex with Ni(II) and alpha-Ketoglutarate
2QQS	;	2.82	;	JMJD2A tandem tudor domains in complex with a trimethylated histone H4-K20 peptide
5LY1	;	2.5	;	JMJD2A/ KDM4A COMPLEXED WITH NI(II) AND Macrocyclic PEPTIDE Inhibitor CP2 (13-mer)
6H8P	;	1.983	;	JMJD2A/ KDM4A COMPLEXED WITH NI(II), NOG AND Histone H1.4(18-32)K26me3 peptide (15-mer)
5LY2	;	2.43	;	JMJD2A/ KDM4A COMPLEXED WITH NI(II), NOG AND Macrocyclic PEPTIDE Inhibitor CP2_R6Kme3 (13-mer)
4GJZ	;	1.0481	;	JMJD5 in complex with 2-oxoglutarate
4GJY	;	1.2492	;	JMJD5 in complex with N-Oxalylglycine
5NFN	;	2.982	;	JMJD7 IN COMPLEX WITH MN AND 2OG IN THE H32 FORM
3G90	;	2.4	;	JNK-3 bound to (Z)-5-fluoro-1-((6-fluoro-4H-benzo[d][1,3]dioxin-8-yl)methyl)-3-(hydroxyimino)indolin-2-one
3ELJ	;	1.8	;	Jnk1 complexed with a bis-anilino-pyrrolopyrimidine inhibitor.
3PZE	;	2.0	;	JNK1 in complex with inhibitor
4W4V	;	2.01	;	JNK2/3 in complex with 3-(4-{[(2-chlorophenyl)carbamoyl]amino}-1H-pyrazol-1-yl)-N-(2-methylpyridin-4-yl)benzamide
4W4X	;	2.65	;	JNK2/3 in complex with 3-(4-{[(4-fluorophenyl)carbamoyl]amino}-1H-pyrazol-1-yl)-N-(2-methylpyridin-4-yl)benzamide
4W4Y	;	2.3	;	JNK2/3 in complex with 3-(4-{[(4-methylphenyl)carbamoyl]amino}-1H-pyrazol-1-yl)-N-(2-methylpyridin-4-yl)benzamide
4W4W	;	1.9	;	JNK2/3 in complex with N-(2-methylpyridin-4-yl)-3-{4-[(phenylcarbamoyl)amino]-1H-pyrazol-1-yl}benzamide
8BZP	;	1.86	;	JNK3 (Mitogen-activated protein kinase 10) in Complex with Compound 23 bearing a C(sp3)F2Br moiety
3G9N	;	2.8	;	JNK3 bound to (Z)-1-((6-fluoro-4H-benzo[d][1,3]dioxin-8-yl)methyl)-3-(hydroxyimino)-4-phenylindolin-2-one
3G9L	;	2.2	;	JNK3 bound to (Z)-1-((6-fluoro-4H-benzo[d][1,3]dioxin-8-yl)methyl)-3-(hydroxyimino)-4-styrylindolin-2-one
3KVX	;	2.4	;	JNK3 bound to aminopyrimidine inhibitor, SR-3562
3FV8	;	2.28	;	JNK3 bound to piperazine amide inhibitor, SR2774.
6AJZ	;	1.847	;	Joint nentron and X-ray structure of BRD4 in complex with colchicin
6AJZ	;	1.301	;	Joint nentron and X-ray structure of BRD4 in complex with colchicin
6FJI	;	2.033	;	Joint neutron and x-ray crystal structure of human carbonic anhydrase IX mimic (apo).
6FJI	;	1.6	;	Joint neutron and x-ray crystal structure of human carbonic anhydrase IX mimic (apo).
6FJJ	;	2.0	;	Joint neutron and x-ray crystal structure of human carbonic anhydrase IX mimic (saccharin).
6FJJ	;	1.5	;	Joint neutron and x-ray crystal structure of human carbonic anhydrase IX mimic (saccharin).
6GCY	;	2.0	;	Joint neutron and x-ray crystal structure of human carbonic anhydrase IX mimic (saccharin-sugar conjugate complex)
6GCY	;	1.3	;	Joint neutron and x-ray crystal structure of human carbonic anhydrase IX mimic (saccharin-sugar conjugate complex)
7F4X	;	2.199	;	Joint neutron and X-ray crystal structure of the nucleotide-binding domain of Hsp72 in complex with ADP
7F4X	;	1.6	;	Joint neutron and X-ray crystal structure of the nucleotide-binding domain of Hsp72 in complex with ADP
3QZA	;	2.0	;	Joint neutron and X-ray structure of apo-D-Xylose Isomerase at pH=5.9
3QZA	;	1.7	;	Joint neutron and X-ray structure of apo-D-Xylose Isomerase at pH=5.9
3R98	;	2.4	;	Joint Neutron and X-ray structure of Cytochrome c peroxidase
3R98	;	2.1	;	Joint Neutron and X-ray structure of Cytochrome c peroxidase
3R99	;	2.4	;	Joint Neutron and X-ray structure of Cytochrome c peroxidase
3R99	;	2.1	;	Joint Neutron and X-ray structure of Cytochrome c peroxidase
3BYC	;	2.2	;	Joint neutron and X-ray structure of diisopropyl fluorophosphatase. Deuterium occupancies are 1-Q, where Q is occupancy of H
3BYC	;	2.2	;	Joint neutron and X-ray structure of diisopropyl fluorophosphatase. Deuterium occupancies are 1-Q, where Q is occupancy of H
4JEC	;	2.0	;	Joint neutron and X-ray structure of per-deuterated HIV-1 protease in complex with clinical inhibitor amprenavir
4JEC	;	2.01	;	Joint neutron and X-ray structure of per-deuterated HIV-1 protease in complex with clinical inhibitor amprenavir
7A0L	;	2.1	;	Joint neutron/X-ray room temperature structure of perdeuterated Aspergillus flavus urate oxidase in complex with the 8-azaxanthine inhibitor and catalytic water bound in the peroxo hole
7A0L	;	1.33	;	Joint neutron/X-ray room temperature structure of perdeuterated Aspergillus flavus urate oxidase in complex with the 8-azaxanthine inhibitor and catalytic water bound in the peroxo hole
7A0L	;		;	Joint neutron/X-ray room temperature structure of perdeuterated Aspergillus flavus urate oxidase in complex with the 8-azaxanthine inhibitor and catalytic water bound in the peroxo hole
5NKU	;	2.35	;	Joint neutron/X-ray structure of dimeric chlorite dismutase from Cyanothece sp. PCC7425
5NKU	;	2.0	;	Joint neutron/X-ray structure of dimeric chlorite dismutase from Cyanothece sp. PCC7425
7KCU	;	2.215	;	Joint neutron/X-ray structure of Oxyferrous Dehaloperoxidase B
7KCU	;	2.2	;	Joint neutron/X-ray structure of Oxyferrous Dehaloperoxidase B
7JUN	;	2.5	;	Joint neutron/X-ray structure of SARS-CoV-2 3CL Mpro at room temperature
7JUN	;	2.3	;	Joint neutron/X-ray structure of SARS-CoV-2 3CL Mpro at room temperature
4N3M	;	1.904	;	Joint neutron/X-ray structure of urate oxidase in complex with 8-azaxanthine
4N3M	;	1.919	;	Joint neutron/X-ray structure of urate oxidase in complex with 8-azaxanthine
4N9M	;	2.298	;	Joint neutron/x-ray structure of urate oxidase in complex with 8-hydroxyxanthine
4N9M	;	2.023	;	Joint neutron/x-ray structure of urate oxidase in complex with 8-hydroxyxanthine
2LGC	;		;	Joint NMR and X-ray refinement reveals the structure of a novel dibenzo[a,d]cycloheptenone inhibitor/p38 MAP kinase complex in solution
2JPR	;		;	Joint refinement of the HIV-1 CA-NTD in complex with the assembly inhibitor CAP-1
4QDP	;	2.0	;	Joint X-ray and neutron structure of Streptomyces rubiginosus D-xylose isomerase in complex with two Cd2+ ions and cyclic beta-L-arabinose
4QDW	;	1.8	;	Joint X-ray and neutron structure of Streptomyces rubiginosus D-xylose isomerase in complex with two Ni2+ ions and linear L-arabinose
1T0K	;	3.24	;	Joint X-ray and NMR Refinement of Yeast L30e-mRNA complex
5KWF	;	2.214	;	Joint X-ray Neutron Structure of Cholesterol Oxidase
5KWF	;	1.499	;	Joint X-ray Neutron Structure of Cholesterol Oxidase
7BBI	;	2.2	;	Joint X-ray/neutron room temperature structure of H/D-exchanged PLL lectin
7BBI	;	1.7	;	Joint X-ray/neutron room temperature structure of H/D-exchanged PLL lectin
7BBI	;		;	Joint X-ray/neutron room temperature structure of H/D-exchanged PLL lectin
7PRG	;	1.9	;	Joint X-ray/neutron room temperature structure of perdeuterated LecB lectin in complex with perdeuterated fucose
7PRG	;	1.85	;	Joint X-ray/neutron room temperature structure of perdeuterated LecB lectin in complex with perdeuterated fucose
7BBC	;	2.2	;	Joint X-ray/neutron room temperature structure of perdeuterated PLL lectin in complex with perdeuterated L-fucose
7BBC	;	1.84	;	Joint X-ray/neutron room temperature structure of perdeuterated PLL lectin in complex with perdeuterated L-fucose
5VJZ	;	2.21	;	Joint X-ray/neutron structure of aspartate aminotransferase with alpha-methyl-aspartate at pH 7.5
5VJZ	;	2.0	;	Joint X-ray/neutron structure of aspartate aminotransferase with alpha-methyl-aspartate at pH 7.5
7TUR	;	2.22	;	Joint X-ray/neutron structure of aspastate aminotransferase (AAT) in complex with pyridoxamine 5'-phosphate (PMP)
7TUR	;	1.7	;	Joint X-ray/neutron structure of aspastate aminotransferase (AAT) in complex with pyridoxamine 5'-phosphate (PMP)
5MON	;	1.42	;	Joint X-ray/neutron structure of cationic trypsin in complex with 2-aminopyridine
5MON	;	0.939	;	Joint X-ray/neutron structure of cationic trypsin in complex with 2-aminopyridine
5MOO	;	1.43	;	Joint X-ray/neutron structure of cationic trypsin in complex with aniline
5MOO	;	1.441	;	Joint X-ray/neutron structure of cationic trypsin in complex with aniline
5MOQ	;	1.502	;	Joint X-ray/neutron structure of cationic trypsin in complex with benzamidine
5MOQ	;	0.93	;	Joint X-ray/neutron structure of cationic trypsin in complex with benzamidine
5MOR	;	1.49	;	Joint X-ray/neutron structure of cationic trypsin in complex with benzylamine
5MOR	;	0.98	;	Joint X-ray/neutron structure of cationic trypsin in complex with benzylamine
5MOS	;	1.5	;	Joint X-ray/neutron structure of cationic trypsin in complex with N-amidinopiperidine
5MOS	;	0.96	;	Joint X-ray/neutron structure of cationic trypsin in complex with N-amidinopiperidine
5MOP	;	1.45	;	Joint X-ray/neutron structure of cationic trypsin in its apo form
5MOP	;	0.99	;	Joint X-ray/neutron structure of cationic trypsin in its apo form
5WEY	;	2.5	;	Joint X-ray/neutron structure of Concanavalin A with alpha1-2 D-mannobiose
5WEY	;	1.8	;	Joint X-ray/neutron structure of Concanavalin A with alpha1-2 D-mannobiose
6D4L	;	2.0	;	Joint X-ray/neutron structure of DNA oligonucleotide d(GTGGCCAC)2 with 2'-SeCH3 modification on Cyt5
6D4L	;	1.56	;	Joint X-ray/neutron structure of DNA oligonucleotide d(GTGGCCAC)2 with 2'-SeCH3 modification on Cyt5
5C6E	;	2.0	;	Joint X-ray/neutron structure of equine cyanomet hemoglobin in R state
5C6E	;	1.7	;	Joint X-ray/neutron structure of equine cyanomet hemoglobin in R state
5T8H	;	2.2	;	Joint X-ray/neutron structure of HIV-1 protease triple mutant (V32I,I47V,V82I) with amprenavir at pH 6.0
5T8H	;	1.85	;	Joint X-ray/neutron structure of HIV-1 protease triple mutant (V32I,I47V,V82I) with amprenavir at pH 6.0
5E5K	;	2.3	;	Joint X-ray/neutron structure of HIV-1 protease triple mutant (V32I,I47V,V82I) with darunavir at pH 4.3
5E5K	;	1.75	;	Joint X-ray/neutron structure of HIV-1 protease triple mutant (V32I,I47V,V82I) with darunavir at pH 4.3
5E5J	;	2.0	;	Joint X-ray/neutron structure of HIV-1 protease triple mutant (V32I,I47V,V82I) with darunavir at pH 6.0
5E5J	;	1.85	;	Joint X-ray/neutron structure of HIV-1 protease triple mutant (V32I,I47V,V82I) with darunavir at pH 6.0
6PTP	;	2.2	;	Joint X-ray/neutron structure of HIV-1 protease triple mutant (V32I,I47V,V82I) with tetrahedral intermediate mimic KVS-1
6PTP	;	1.85	;	Joint X-ray/neutron structure of HIV-1 protease triple mutant (V32I,I47V,V82I) with tetrahedral intermediate mimic KVS-1
3TMJ	;	2.0	;	Joint X-ray/neutron structure of human carbonic anhydrase II at pH 7.8
6BBS	;	2.0	;	Joint X-ray/neutron structure of human carbonic anhydrase II in complex with brinzolamide
6BC9	;		;	Joint X-ray/neutron structure of human carbonic anhydrase II in complex with dorzolamide
6BC9	;	1.8	;	Joint X-ray/neutron structure of human carbonic anhydrase II in complex with dorzolamide
6BCC	;	1.8	;	Joint X-ray/neutron structure of human carbonic anhydrase II in complex with ethoxzolamide
5C8I	;	2.2	;	Joint X-ray/neutron structure of Human Carbonic Anhydrase II in complex with Methazolamide
5C8I	;	1.56	;	Joint X-ray/neutron structure of Human Carbonic Anhydrase II in complex with Methazolamide
5JPC	;	2.5	;	Joint X-ray/neutron structure of MTAN complex with Formycin A
5JPC	;	2.1	;	Joint X-ray/neutron structure of MTAN complex with Formycin A
5K1Z	;	2.6	;	Joint X-ray/neutron structure of MTAN complex with p-ClPh-Thio-DADMe-ImmA
5K1Z	;	2.25	;	Joint X-ray/neutron structure of MTAN complex with p-ClPh-Thio-DADMe-ImmA
5CCD	;	2.6	;	Joint X-ray/neutron structure of MTAN D198N complex with SAH
5CCD	;	2.2	;	Joint X-ray/neutron structure of MTAN D198N complex with SAH
6E21	;	2.5	;	Joint X-ray/neutron structure of PKAc with products Sr2-ADP and phosphorylated peptide SP20
6E21	;	2.0	;	Joint X-ray/neutron structure of PKAc with products Sr2-ADP and phosphorylated peptide SP20
6BQ8	;	2.2	;	Joint X-ray/neutron structure of PKG II CNB-B domain in complex with 8-pCPT-cGMP
6BQ8	;	2.0	;	Joint X-ray/neutron structure of PKG II CNB-B domain in complex with 8-pCPT-cGMP
4QXK	;	2.2	;	Joint X-ray/neutron structure of PKGIbeta in complex with cGMP
5ZN0	;	1.9	;	Joint X-ray/neutron structure of protein kinase ck2 alpha subunit
5ZN0	;	1.1	;	Joint X-ray/neutron structure of protein kinase ck2 alpha subunit
5EBJ	;	2.5	;	Joint X-ray/neutron structure of reversibly photoswitching chromogenic protein, Dathail
5EBJ	;	2.1	;	Joint X-ray/neutron structure of reversibly photoswitching chromogenic protein, Dathail
8EYP	;	2.1	;	Joint X-ray/neutron structure of Salmonella typhimurium tryptophan synthase internal aldimine from microgravity-grown crystal
8EYP	;	1.8	;	Joint X-ray/neutron structure of Salmonella typhimurium tryptophan synthase internal aldimine from microgravity-grown crystal
7TDU	;	2.2	;	Joint X-ray/neutron structure of SARS-CoV-2 main protease (3CL Mpro) in complex with BBH-1
7TDU	;	1.85	;	Joint X-ray/neutron structure of SARS-CoV-2 main protease (3CL Mpro) in complex with BBH-1
7LB7	;	2.4	;	Joint X-ray/neutron structure of SARS-CoV-2 main protease (3CL Mpro) in complex with Telaprevir
7LB7	;	2.0	;	Joint X-ray/neutron structure of SARS-CoV-2 main protease (3CL Mpro) in complex with Telaprevir
7N8C	;	2.5	;	Joint X-ray/neutron structure of SARS-CoV-2 main protease (Mpro) in complex with Mcule5948770040
7N8C	;	2.2	;	Joint X-ray/neutron structure of SARS-CoV-2 main protease (Mpro) in complex with Mcule5948770040
7UCR	;	2.25	;	Joint X-ray/neutron structure of the Sarcin-Ricin loop RNA
7UCR	;	1.0	;	Joint X-ray/neutron structure of the Sarcin-Ricin loop RNA
8SUJ	;	2.3	;	Joint X-ray/neutron structure of Thermus thermophilus serine hydroxymethyltransferase (TthSHMT) in internal aldimine state
8SUJ	;	2.0	;	Joint X-ray/neutron structure of Thermus thermophilus serine hydroxymethyltransferase (TthSHMT) in internal aldimine state
8SUI	;	2.3	;	Joint X-ray/neutron structure of Thermus thermophilus serine hydroxymethyltransferase (TthSHMT) in internal aldimine state with L-Ser bound in a pre-Michalis complex
8SUI	;	2.0	;	Joint X-ray/neutron structure of Thermus thermophilus serine hydroxymethyltransferase (TthSHMT) in internal aldimine state with L-Ser bound in a pre-Michalis complex
4S2F	;	2.0	;	Joint X-ray/neutron structure of Trichoderma reesei xylanase II at pH 4.4
4S2F	;	1.7	;	Joint X-ray/neutron structure of Trichoderma reesei xylanase II at pH 4.4
4S2G	;	2.0	;	Joint X-ray/neutron structure of Trichoderma reesei xylanase II at pH 5.8
4S2G	;	1.6	;	Joint X-ray/neutron structure of Trichoderma reesei xylanase II at pH 5.8
4S2H	;	1.7	;	Joint X-ray/neutron structure of Trichoderma reesei xylanase II at pH 8.5
4S2H	;	1.6	;	Joint X-ray/neutron structure of Trichoderma reesei xylanase II at pH 8.5
4S2D	;	2.0	;	Joint X-ray/neutron structure of Trichoderma reesei xylanase II in complex with MES at pH 5.7
4S2D	;	1.6	;	Joint X-ray/neutron structure of Trichoderma reesei xylanase II in complex with MES at pH 5.7
5CCE	;	2.5	;	Joint X-ray/neutron structure of wild type MTAN complexed with SRH and adenine
5CCE	;	1.82	;	Joint X-ray/neutron structure of wild type MTAN complexed with SRH and adenine
3KYX	;	1.675	;	Joint Xray/neutron crystal structure determination of fully perdeuterated rubredoxin at 295K
3KYY	;	1.66	;	Joint Xray/neutron crystal structure determination of H-labeled perdeuterated rubredoxin at 295K
3KYY	;	1.1	;	Joint Xray/neutron crystal structure determination of H-labeled perdeuterated rubredoxin at 295K
2XLR	;	2.55	;	Joint-functions of protein residues and NADP(H) in oxygen-activation by flavin-containing monooxygenase: Asn78Asp mutant
2XLS	;	3.0	;	Joint-functions of protein residues and NADP(H) in oxygen-activation by flavin-containing monooxygenase: Asn78Lys mutant
2XLP	;	2.8	;	Joint-functions of protein residues and NADP(H) in oxygen-activation by flavin-containing monooxygenase: Asn78Ser mutant
2XLT	;	2.2	;	Joint-functions of protein residues and NADP(H) in oxygen-activation by flavin-containing monooxygenase: complex with 3-Acetylpyridine adenine dinucleotide phosphate (APADP)
2XLU	;	2.6	;	Joint-functions of protein residues and NADP(H) in oxygen-activation by flavin-containing monooxygenase: complex with thioNADP
4OZF	;	2.7	;	JR5.1 protein complex
6U3O	;	2.743	;	JR51 DQ2-p.aeru-alpha2a complex
7LVF	;		;	Jug R 2 Leader Sequence Residues 1-57
7LVE	;		;	Jug r 2 Leader Sequence Residues 117-161
7LVG	;		;	Jug r 2 Leader Sequence Residues 69-111
8BFL	;	4.1	;	Jumbo Phage phi-kp24 empty capsid hexamers
8BFP	;	4.1	;	Jumbo Phage phi-kp24 empty capsid pentamer hexamers
8BFK	;	3.0	;	Jumbo Phage phi-kp24 tail inner tube
8AU1	;	3.0	;	Jumbo Phage phi-kp24 tail outer sheath
6W2R	;	2.344	;	Junction 19, DHR54-DHR79
6W2V	;	2.399	;	Junction 23, DHR14-DHR18
6W2W	;	2.21	;	Junction 24, DHR14-DHR18
6W2Q	;	1.8	;	Junction 34, DHR53-DHR4
5NUZ	;	1.85	;	Junin virus GP1 glycoprotein in complex with an antibody Fab fragment
7QU2	;	2.5	;	Junin virus GP1 glycoprotein in complex with Fab fragment of antibody JUN1
7EJU	;	3.5	;	Junin virus(JUNV) RNA polymerase L complexed with Z protein
5W1K	;	3.99	;	JUNV GP1 CR1-10 Fab CR1-28 Fab complex
8CIQ	;		;	JzTx-34 toxin peptide
8CJQ	;		;	JzTx-34 toxin peptide E20A mutant
8CJP	;		;	JzTx-34 toxin peptide H18A mutant
8CJR	;		;	JzTx-34 toxin peptide W25A mutant
8CJS	;		;	JzTx-34 toxin peptide W31A mutant
8CJT	;		;	JzTx-34 toxin peptide W33A mutant
6CHC	;		;	JzTx-V toxin peptide, wild-type
2F93	;	2.0	;	K Intermediate Structure of Sensory Rhodopsin II/Transducer Complex in Combination with the Ground State Structure
2AHZ	;	2.8	;	K+ complex of the NaK Channel
6JXH	;	2.5	;	K+-bound E2-MgF state of the gastric proton pump (Tyr799Trp)
5UFQ	;	2.199	;	K-RasG12D(GNP)/R11.1.6 complex
4ZY8	;	2.14	;	K. lactis Lst4 longin domain
7LHZ	;	3.3	;	K. pneumoniae Topoisomerase IV (ParE-ParC) in complex with DNA and (3S)-10-[(3R)-3-(1-aminocyclopropyl)pyrrolidin-1-yl]-9-fluoro-3-methyl-5-oxo-2,3-dihydro-5H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid (compound 25)
6WAA	;	3.2	;	K. pneumoniae Topoisomerase IV (ParE-ParC) in complex with DNA and compound 34 (7-[(1S,5R)-1-amino-3-azabicyclo[3.1.0]hexan-3-yl]-4-(aminomethyl)-1-cyclopropyl-3,6-difluoro-8-methylquinolin-2(1H)-one)
6UZ7	;	3.6	;	K.lactis 80S ribosome with p/PE tRNA and eIF5B
5E67	;	2.2	;	K103A/K262A double mutant of I-SmaMI
1IKV	;	3.0	;	K103N Mutant HIV-1 Reverse Transcriptase in Complex with Efivarenz
1IKX	;	2.8	;	K103N Mutant HIV-1 Reverse Transcriptase in Complex with the Inhibitor PNU142721
6W6N	;	2.25	;	K106L/A131E mutant of cytochrome P460 from Nitrosomonas sp. AL212
2MBO	;		;	K11-linked Diubiquitin average solution structure at pH 6.8, 0 mM NaCl
2MBQ	;		;	K11-linked Diubiquitin average solution structure at pH 6.8, 150 mM NaCl
5XDP	;	2.376	;	K11/48-branched teraubiquitin
5GOK	;	1.84	;	K11/K63-branched tri-Ubiquitin
8IVB	;		;	K113-Ubiquitinated BAK
4RRH	;	1.55	;	K116M mutant of N-terminal editing domain of threonyl-tRNA synthetase from Aeropyrum pernix with L-Ser3AA
4RRI	;	1.5	;	K116M mutant of N-terminal editing domain of threonyl-tRNA synthetase from Aeropyrum pernix with L-Thr3AA
4RRQ	;	1.79	;	K121M mutant of N-terminal editing domain of threonyl-tRNA synthetase from Pyrococcus abyssi with L-Ser3AA
4RRR	;	1.86	;	K121M mutant of N-terminal editing domain of threonyl-tRNA synthetase from Pyrococcus abyssi with L-Thr3AA
4NFG	;	2.11	;	K13R mutant of horse cytochrome c and yeast cytochrome c peroxidase complex
8BHC	;	1.56	;	K141H and S142H double mutant of hGSTA1-1
8BHE	;	1.87	;	K141H and S142H double mutant of hGSTA1-1
6H90	;	1.31	;	K145A variant of beta-phosphoglucomutase from Lactococcus lactis inhibited by beryllium trifluoride to 1.3 A.
4RNX	;	1.25	;	K154 Circular Permutation of Old Yellow Enzyme
1E6C	;	1.8	;	K15M MUTANT OF SHIKIMATE KINASE FROM ERWINIA CHRYSANTHEMI
8SLJ	;	2.101	;	K164A mutant of a chlorogenic acid esterase from Lactobacillus helveticus
5X8J	;	1.8	;	K16M mutant of thermus thermophilus HB8 thymidylate kinase
2VS6	;	2.4	;	K173A, R174A, K177A-trichosanthin
4AHF	;	2.115	;	K17E - Angiogenin mutants and amyotrophic lateral sclerosis - a biochemical and biological analysis
4AHE	;	2.08	;	K17I - Angiogenin mutants and amyotrophic lateral sclerosis - a biochemical and biological analysis
1XWF	;	2.8	;	K185N mutated S-adenosylhomocysteine hydrolase
7OCL	;	1.8	;	K1K1, a potent recombinant minimal hepatocyte growth factor/scatter factor mimic
7OCM	;	1.7	;	K1K1H6, a potent recombinant minimal hepatocyte growth factor/scatter factor mimic
6JEU	;	2.1	;	K1U bound crystal peptide deformylase from Acinetobacter baumanii
6JF4	;	2.0	;	K1U bound crystal structure of class I type b peptide deformylase from Acinetobacter baumannii
6JFD	;	2.4	;	K1U bound crystal structure of class I type b peptide deformylase from Pseudomonas aeruginosa
6JFG	;	2.6	;	K1U bound crystal structure of class II peptide deformylase from methicillin resistant Staphylococcus aureus
6IKT	;	1.9	;	K1U complex structure of peptide deformylase from Xanthomonas oryzae pv. oryzae
4X2B	;	2.94	;	K20A RNA dependent RNA polymerase mutant from Foot-and-Mouth disease Virus complexed with an RNA
1A5M	;	2.0	;	K217A VARIANT OF KLEBSIELLA AEROGENES UREASE
1A5N	;	2.4	;	K217A VARIANT OF KLEBSIELLA AEROGENES UREASE, CHEMICALLY RESCUED BY FORMATE AND NICKEL
1A5L	;	2.2	;	K217C VARIANT OF KLEBSIELLA AEROGENES UREASE
1A5O	;	2.5	;	K217C VARIANT OF KLEBSIELLA AEROGENES UREASE, CHEMICALLY RESCUED BY FORMATE AND NICKEL
1A5K	;	2.2	;	K217E VARIANT OF KLEBSIELLA AEROGENES UREASE
1YJZ	;	2.1	;	K226M Mutant Of Serine Hydroxymethyltransferase From B. Stearothermophilus
1YJY	;	2.25	;	K226M Mutant Of Serine Hydroxymethyltransferase From B. Stearothermophilus, Complex With Serine
1YJS	;	2.0	;	K226Q Mutant Of Serine Hydroxymethyltransferase From B. Stearothermophilus, Complex With Glycine
1JDE	;	2.8	;	K22A mutant of pyruvate, phosphate dikinase
4FCF	;	1.09	;	K234R: apo structure of inhibitor resistant beta-lactamase
1SCI	;	2.18	;	K236L mutant of hydroxynitrile lyase from Hevea brasiliensis
1SCK	;	1.7	;	K236L mutant of hydroxynitrile lyase from Hevea brasiliensis in complex with acetone
1SCQ	;	2.9	;	K236L mutant of hydroxynitrile lyase from Hevea brasiliensis in complex with acetonecyanohydrin
6LDT	;	1.93	;	K245A mutant of L-tyrosine decarboxylase from Methanocaldococcus jannaschii complexed with a post-decarboxylation quinonoid-like intermediate formed with L-tyrosine
2R0P	;	2.1	;	K252c-soaked RebC
5E63	;	2.6	;	K262A mutant of I-SmaMI
3B0X	;	1.36	;	K263A mutant of PolX from Thermus thermophilus HB8 complexed with Ca-dGTP
3B0Y	;	1.45	;	K263D mutant of PolX from Thermus thermophilus HB8 complexed with Ca-dGTP
2I3P	;	2.3	;	K28R mutant of Homing Endonuclease I-CreI
3ESZ	;	1.94	;	K2AK3A Flavodoxin from Anabaena
6W7B	;	3.88	;	K2P2.1 (TREK-1), 0 mM K+
6W7C	;	3.4	;	K2P2.1 (TREK-1), 1 mM K+
6W7D	;	3.5	;	K2P2.1 (TREK-1), 10 mM K+
6W83	;	3.901	;	K2P2.1 (TREK-1), 100 mM K+
6W84	;	3.7	;	K2P2.1 (TREK-1), 200 mM K+
6W7E	;	3.29	;	K2P2.1 (TREK-1), 30 mM K+
6W82	;	3.6	;	K2P2.1 (TREK-1), 50 mM K+
6W8F	;	3.4	;	K2P2.1 (TREK-1):ML335 complex, 0 mM K+
6W8C	;	2.6	;	K2P2.1 (TREK-1):ML335 complex, 1 mM K+
6W8A	;	3.002	;	K2P2.1 (TREK-1):ML335 complex, 10 mM K+
6W86	;	3.299	;	K2P2.1 (TREK-1):ML335 complex, 100 mM K+
6W85	;	3.8	;	K2P2.1 (TREK-1):ML335 complex, 200 mM K+
6W88	;	3.2	;	K2P2.1 (TREK-1):ML335 complex, 30 mM K+
6W87	;	3.2	;	K2P2.1 (TREK-1):ML335 complex, 50 mM K+
6CQ6	;	3.1	;	K2P2.1(TREK-1) apo structure
6CQ8	;	3.0	;	K2P2.1(TREK-1):ML335 complex
6CQ9	;	2.8	;	K2P2.1(TREK-1):ML402 complex
6V36	;	3.4	;	K2P2.1(TREK-1)I110D apo channel structure
6V3C	;	3.51	;	K2P2.1(TREK-1)I110D:Ru360 bound channel structure
6V3I	;	3.4	;	K2P2.1(TREK-1)I110D:RuR bound channel structure
6V37	;	2.8	;	K2P2.1(TREK-1)I110D:RuR:ML335 bound channel structure
2XTH	;	1.8	;	K2PtBr6 binding to lysozyme
6JEV	;	1.9	;	K2U bound crystal structure of class I type a peptide deformylase from Acinetobacter baumanii
6JF5	;	2.0	;	K2U bound crystal structure of class I type b peptide deformylase from Acinetobacter baumannii
6JFE	;	2.1	;	K2U bound crystal structure of class I type b peptide deformylase from Pseudomonas aeruginosa
6JFQ	;	2.2	;	K2U bound crystal structure of class II peptide deformylase from methicillin resistant Staphylococcus aureus
6IKY	;	1.9	;	K2U complex structure of peptide deformylase from Xanthomonas oryzae pv. oryzae
3EWX	;	1.4	;	K314A mutant of human orotidyl-5'-monophosphate decarboxylase in complex with 6-azido-UMP, degraded to BMP
3EWY	;	1.1	;	K314A mutant of human orotidyl-5'-monophosphate decarboxylase soaked with OMP, decarboxylated to UMP
3AM5	;	2.05	;	K316A mutant of Enoyl-ACP Reductase from Plasmodium falciparum (PfENR) in complex with triclosan
5OHM	;	3.8	;	K33-specific affimer bound to K33 diUb
5OHV	;	2.801	;	K33-specific affimer bound to K33 diUb
8AFG	;	2.45	;	K352D oxalyl-CoA synthetase Pcs60p
8STW	;	2.4	;	K384N HUMAN CYSTATHIONINE BETA-SYNTHASE (delta 411-551)
1SX5	;	1.5	;	K38A EcoRV bound to cleaved DNA and Mn2+: P1 crystal form
1J9M	;	1.65	;	K38H mutant of Streptomyces K15 DD-transpeptidase
7ZSK	;	6.8	;	K3DAK4 bimodule core of BGC11 from Brevibacillus brevis.
6JEW	;	2.0	;	K3U bound crystal peptide deformylase from Acinetobacter baumanii
6JF7	;	2.0	;	K3U bound crystal structure of class I type b peptide deformylase from Acinetobacter baumannii
6JFF	;	2.1	;	K3U bound crystal structure of class I type b peptide deformylase from Pseudomonas aeruginosa
6JFR	;	2.4	;	K3U bound crystal structure of class II peptide deformylase from methicillin resistant Staphylococcus aureus
6IL0	;	1.93	;	K3U complex structure of peptide deformylase from Xanthomonas oryzae pv. oryzae
7ZVE	;	2.28	;	K403 acetylated glucose-6-phosphate dehydrogenase (G6PD)
4AHI	;	2.798	;	K40I - Angiogenin mutants and amyotrophic lateral sclerosis - a biochemical and biological analysis
5C2D	;	1.59	;	K428A mutant gp2c of large terminase subunit from bacteriophage sf6 with calcium
5C15	;	1.57	;	K428A mutant nuclease domain of the large terminase subunit gp2 of bacterial virus Sf6 with Manganese
5C2F	;	1.86	;	K428A mutant nuclease domain of the large terminase subunit gp2 of bacterial virus Sf6 with Manganese and beta-thujaplicinol
1NZ2	;	1.9	;	K45E Variant of Horse Heart Myoglobin
1NZ3	;	1.6	;	K45E-K63E Variant of Horse Heart Myoglobin
6NO6	;	1.911	;	K46bE&K114bD mutant ATP-grasp fold of Blastocystis hominis succinyl-CoA synthetase
8PQL	;	3.76	;	K48-linked ubiquitin chain formation with a cullin-RING E3 ligase and Cdc34: NEDD8-CUL2-RBX1-ELOB/C-FEM1C with trapped UBE2R2-donor UB-acceptor UB-SIL1 peptide
6JEX	;	2.11	;	K4U bound crystal peptide deformylase from Acinetobacter baumanii
6JF8	;	1.7	;	K4U bound crystal structure of class I type b peptide deformylase from Acinetobacter baumannii
6JFN	;	2.04	;	K4U bound crystal structure of class I type b peptide deformylase from Pseudomonas aeruginosa
6JFS	;	2.25	;	K4U bound crystal structure of class II peptide deformylase from methicillin resistant Staphylococcus aureus
6IL2	;	2.41	;	K4U complex structure of peptide deformylase from Xanthomonas oryzae pv. oryzae
4AHK	;	1.97	;	K54E - Angiogenin mutants and amyotrophic lateral sclerosis - a biochemical and biological analysis
7ZXJ	;	1.249	;	K563A Mutant of Recombinant CODH-II
7ZXX	;	1.4	;	K563H Mutant of Recombinant CODH-II
5OHL	;	2.5	;	K6-specific affimer bound to K6 diUb
7DNJ	;	3.3	;	K63-polyUb MDA5CARDs complex
3JYT	;	3.3	;	K65R mutant HIV-1 reverse transcriptase cross-linked to DS-DNA and complexed with DATP as the incoming nucleotide substrate
3JSM	;	3.0	;	K65R mutant HIV-1 reverse transcriptase cross-linked to DS-DNA and complexed with tenofovir-diphosphate as the incoming nucleotide substrate
7ZVD	;	2.46	;	K89 acetylated glucose-6-phosphate dehydrogenase (G6PD) in a complex with structural NADP+
1K89	;	2.05	;	K89L MUTANT OF GLUTAMATE DEHYDROGENASE
2VLO	;	1.8	;	K97A mutant of E9 DNase domain in complex with Im9
3NJG	;	1.92	;	K98A mutant of SO1698 protein, an aspartic peptidase from Shewanella oneidensis.
5N8Y	;	4.7	;	KaiCBA circadian clock backbone model based on a Cryo-EM density
3T9H	;	2.015	;	Kainate bound to a double cysteine mutant (A452C/S652C) of the ligand binding domain of GluA2
4F31	;	2.286	;	Kainate bound to the D655A mutant of the ligand binding domain of GluA3
4F22	;	2.06	;	Kainate bound to the K660A mutant of the ligand binding domain of GluA3
4F39	;	1.834	;	Kainate bound to the ligand binding domain of GluA3
4F3G	;	2.064	;	Kainate bound to the ligand binding domain of GluA3i
7F57	;	3.8	;	Kainate-bound GluK2-1xNeto2 complex, at the desensitized state
6DFA	;	1.908	;	Kaiso (ZBTB33) E535A zinc finger DNA binding domain in complex with the specific Kaiso binding sequence (KBS)
5VMZ	;	2.319	;	Kaiso (ZBTB33) E535Q mutant zinc finger DNA binding domain in complex with a double CpG-methylated DNA resembling the specific Kaiso binding sequence (KBS)
6DF9	;	2.319	;	Kaiso (ZBTB33) E535Q zinc finger DNA binding domain in complex with the specific Kaiso binding sequence (KBS)
6DFB	;	1.66	;	Kaiso (ZBTB33) K539A zinc finger DNA binding domain in complex with the specific Kaiso binding sequence (KBS)
5VMU	;	2.346	;	Kaiso (ZBTB33) zinc finger DNA binding domain in complex with a double CpG-methylated DNA resembling the specific Kaiso binding sequence (KBS)
5VMW	;	2.397	;	Kaiso (ZBTB33) zinc finger DNA binding domain in complex with a double CpG-methylated DNA resembling the specific Kaiso binding sequence (KBS)
5VMX	;	2.05	;	Kaiso (ZBTB33) zinc finger DNA binding domain in complex with a hemi CpG-methylated DNA resembling the specific Kaiso binding sequence (KBS)
5VMY	;	2.002	;	Kaiso (ZBTB33) zinc finger DNA binding domain in complex with a hemi CpG-methylated DNA resembling the specific Kaiso binding sequence (KBS)
6V8U	;	2.103	;	Kaiso (ZBTB33) zinc finger DNA binding domain in complex with a modified Kaiso binding sequence (KBS)
5VMV	;	2.313	;	Kaiso (ZBTB33) zinc finger DNA binding domain in complex with its double CpG-methylated DNA consensus binding site
6DF5	;	1.819	;	Kaiso (ZBTB33) zinc finger DNA binding domain in complex with the specific Kaiso binding sequence (KBS)
6DFC	;	1.85	;	Kaiso (ZBTB33) zinc finger DNA binding domain in complex with the specific Kaiso binding sequence (KBS) with a T-to-U substitution
6DF8	;	2.536	;	Kaiso (ZBTB33) zinc finger DNA binding domain in complex with the specific Kaiso binding sequence (KBS), pH 6.5
2MW0	;		;	Kalata B7 Ser mutant
1KTX	;		;	KALIOTOXIN (1-37) SHOWS STRUCTURAL DIFFERENCES WITH RELATED POTASSIUM CHANNEL BLOCKERS
2KR9	;		;	Kalirin DH1 NMR structure
8GI8	;	2.88	;	Kalium channelrhodopsin 1 from Hyphochytrium catenoides (HcKCR1) embedded in peptidisc
1HIA	;	2.4	;	KALLIKREIN COMPLEXED WITH HIRUSTASIN
5FAH	;	1.1	;	KALLIKREIN-7 IN COMPLEX WITH COMPOUND1
5LPF	;	2.7	;	Kallikrein-related peptidase 10
5LPE	;	2.65	;	Kallikrein-related peptidase 10 complex with Zn2+
5MS3	;	2.3	;	Kallikrein-related peptidase 8 calcium complex
5MS4	;	2.1	;	Kallikrein-related peptidase 8 leupeptin inhibitor complex
1KNY	;	2.5	;	KANAMYCIN NUCLEOTIDYLTRANSFERASE
5OWU	;	2.0	;	Kap95:Nup1 complex
3EA5	;	2.5	;	Kap95p Binding Induces the Switch Loops of RanGDP to adopt the GTP-bound Conformation: Implications for Nuclear Import Complex Assembly Dynamics
2BKU	;	2.7	;	Kap95p:RanGTP complex
7QTX	;	2.11599	;	Kaposi sarcoma associated herpes virus (KSHV) encoded apoptosis inhibitor, KsBcl-2 in complex with Puma BH3
7QTW	;	1.41	;	Kaposi sarcoma associated herpes virus(KSHV) encoded apoptosis inhibitor, KsBcl-2 in complex with Bid BH3
5UR3	;	1.8	;	Kaposi's Sarcoma Herpesvirus Protease in Complex with Allosteric Inhibitor
5UTE	;	2.05	;	Kaposi's Sarcoma Herpesvirus Protease in Complex with Allosteric Inhibitor
5UTN	;	1.8	;	Kaposi's Sarcoma Herpesvirus Protease in Complex with Allosteric Inhibitor
5UV3	;	1.95	;	Kaposi's Sarcoma Herpesvirus Protease in Complex with Allosteric Inhibitor
5UVP	;	1.94	;	Kaposi's Sarcoma Herpesvirus Protease in Complex with Allosteric Inhibitor
6PPD	;	3.7	;	Kaposi's sarcoma-associated herpesvirus (KSHV), C1 penton vertex register, CATC-absent structure
6PPH	;	3.8	;	Kaposi's sarcoma-associated herpesvirus (KSHV), C1 penton vertex register, CATC-binding structure
6PPI	;	4.7	;	Kaposi's sarcoma-associated herpesvirus (KSHV), C12 portal dodecamer structure
6PPB	;	4.3	;	Kaposi's sarcoma-associated herpesvirus (KSHV), C5 portal vertex structure
1QP1	;	2.06	;	KAPPA VARIABLE LIGHT CHAIN
1EK3	;	1.9	;	KAPPA-4 IMMUNOGLOBULIN VL, REC
1HP9	;		;	kappa-Hefutoxins: a novel Class of Potassium Channel Toxins from Scorpion venom
1BK6	;	2.8	;	KARYOPHERIN ALPHA (YEAST) + SV40 T ANTIGEN NLS
1BK5	;	2.2	;	KARYOPHERIN ALPHA FROM SACCHAROMYCES CEREVISIAE
2QMR	;	3.0	;	Karyopherin beta2/transportin
2OT8	;	3.1	;	Karyopherin Beta2/Transportin-hnRNPM NLS Complex
2H4M	;	3.05	;	Karyopherin Beta2/Transportin-M9NLS
3IBV	;	3.1	;	Karyopherin cytosolic state
3ICQ	;	3.2	;	Karyopherin nuclear state
2BYX	;	2.0	;	KAS I LYS328ALA Mutant in complex with fatty acid
7BE9	;	4.2	;	Kashmir bee virus empty particle at acidic pH
5WC1	;	3.3	;	katanin AAA ATPase domain
5WC0	;	4.4	;	katanin hexamer in spiral conformation
5WCB	;	6.0	;	Katanin hexamer in the ring conformation
6UGE	;	3.6	;	Katanin hexamer in the ring conformation in complex with substrate
6UGF	;	4.2	;	Katanin hexamer in the ring conformation with resolved protomer one in complex with substrate
6UGD	;	3.5	;	Katanin hexamer in the spiral conformation in complex with substrate
6JQQ	;	2.4	;	KatE H392C from Escherichia coli
5DAE	;	1.4	;	Kazal type inhibitor from salivary glands of Aedes aegypti mosquito
7BG8	;	4.0	;	KBV activated particle at acidic pH
6M22	;	2.7	;	KCC3 bound with DIOA
8SIN	;	6.8	;	KCNQ1 with voltage sensor in the down conformation
8SIM	;	6.2	;	KCNQ1 with voltage sensor in the intermediate conformation
8SIK	;	2.9	;	KCNQ1 with voltage sensor in the up conformation
6H9L	;	2.19	;	Kcr_0859 delta TM from Korarchaeum cryptofilum
3OGC	;	3.8	;	KcsA E71A variant in presence of Na+
3HPL	;	3.2	;	KcsA E71H-F103A mutant in the closed state
7MHX	;	2.85	;	KcsA E71V closed gate with Ba2+
7MHR	;	2.77	;	KcsA E71V closed gate with K+
5J9P	;	2.85	;	KcsA in vitro
8THN	;	2.9	;	KcsA M96V mutant with Y78ester in High K+
7MUB	;	3.0	;	KcsA Open gate E71V mutant in Potassium
7MJT	;	3.3	;	KcsA open gate E71V mutant with Barium
7MK6	;	3.1	;	KcsA open gate E71V mutant with sodium
3FB8	;	3.4	;	KcsA Potassium channel in the open-conductive state with 20 A opening at T112 in the presence of Rb+ ion
3F7V	;	3.2	;	KcsA Potassium channel in the open-inactivated state with 23 A opening at T112
3F5W	;	3.3	;	KcsA Potassium channel in the open-inactivated state with 32 A opening at T112
3FB5	;	2.8	;	KcsA potassium channel in the partially open state with 14.5 A opening at T112
3FB6	;	3.0	;	KcsA Potassium channel in the partially open state with 16 A opening at T112
3F7Y	;	3.4	;	KcsA Potassium channel in the partially open state with 17 A opening at T112
3STL	;	2.4	;	KcsA potassium channel mutant Y82C with Cadmium bound
3STZ	;	2.5	;	KcsA potassium channel mutant Y82C with nitroxide spin label
1J95	;	2.8	;	KCSA potassium channel with TBA (tetrabutylammonium) and potassium
1JVM	;	2.8	;	KCSA POTASSIUM CHANNEL WITH TBA (TETRABUTYLAMMONIUM) AND RUBIDIUM
5EBL	;	2.3	;	KcsA T75G in the Conductive State
5EBM	;	2.5	;	KcsA T75G mutant in the nonconductive state
5EBW	;	2.3	;	KcsA with G77ester mutation
5EC1	;	2.75	;	KcsA with V76ester mutation
5EC2	;	2.3	;	KcsA with V76ester+G77dA mutations
8U80	;	3.6	;	KCTD5/Cullin3/Gbeta1gamma2 Complex: Local Refinment of KCTD5(BTB)/Cullin3(NTD)
8U7Z	;	2.97	;	KCTD5/Cullin3/Gbeta1gamma2 Complex: Local Refinment of KCTD5(CTD)/Gbeta1gamma2
8U81	;	3.82	;	KCTD5/Cullin3/Gbeta1gamma2 Complex: State A From Composite RELION Multi-body Refinement Map
8U82	;	3.84	;	KCTD5/Cullin3/Gbeta1gamma2 Complex: State B From Composite RELION Multi-body Refinement Map
8U83	;	3.975	;	KCTD5/Cullin3/Gbeta1gamma2 Complex: State C From Composite RELION Multi-body Refinement Map
8U84	;	3.88	;	KCTD5/Cullin3/Gbeta1gamma2 Complex: State D From Composite RELION Multi-body Refinement Map
4BQD	;	2.48	;	KD1 of human TFPI in complex with a synthetic peptide
4FQE	;	1.93	;	KdgM porin
4PR7	;	2.1	;	KdgM porin in complex with disordered oligogalacturonate
7UV9	;	3.2	;	KDM2A-nucleosome structure stabilized by H3K36C-UNC8015 covalent conjugate
5KR7	;	1.9	;	KDM4C bound to pyrazolo-pyrimidine scaffold
1X6U	;	2.7	;	KDO8P synthase in it's binary complex with the product KDO8P
6U57	;	2.8	;	KDO8PS Structure Determined at the EuXFEL using Segmented Flow Injection
1FQ0	;	2.1	;	KDPG ALDOLASE FROM ESCHERICHIA COLI
2V82	;	2.1	;	KDPGal complexed to KDPGal
3WZD	;	1.57	;	KDR in complex with ligand lenvatinib
3WZE	;	1.9	;	KDR in complex with ligand sorafenib
6HWS	;	1.75	;	Keap1 - inhibitor complex
6FMP	;	2.92	;	Keap1 - peptide complex
6FMQ	;	2.1	;	Keap1 - peptide complex
7Q5H	;	2.31	;	Keap1 compound complex
7Q6Q	;	2.55	;	Keap1 compound complex
7Q6S	;	2.143	;	Keap1 compound complex
7Q8R	;	2.282	;	Keap1 compound complex
7Q96	;	2.415	;	Keap1 compound complex
6SP4	;	2.59	;	KEAP1 IN COMPLEX WITH COMPOUND 23
6T7Z	;	2.0	;	KEAP1 IN COMPLEX WITH COMPOUND 44
6SP1	;	2.57	;	KEAP1 IN COMPLEX WITH COMPOUND 6
6T7V	;	2.6	;	KEAP1 IN COMPLEX WITH PEPTIDE 8
7XM5	;	2.4	;	Keap1 Kelch domain (residues 322-609) in complex with 6i
6ZEW	;	1.38	;	Keap1 kelch domain bound to a small molecule fragment
6ZEX	;	1.98	;	Keap1 kelch domain bound to a small molecule fragment
7OF8	;	1.78	;	Keap1 kelch domain bound to a small molecule fragment
7OF9	;	1.8	;	Keap1 kelch domain bound to a small molecule fragment
7OFA	;	2.22	;	Keap1 kelch domain bound to a small molecule fragment
7OFB	;	2.4	;	Keap1 kelch domain bound to a small molecule fragment
7OFC	;	1.97	;	Keap1 kelch domain bound to a small molecule fragment
7OFD	;	1.25	;	Keap1 kelch domain bound to a small molecule fragment
6ZEY	;	1.801	;	Keap1 kelch domain bound to a small molecule inhibitor of the Keap1-Nrf2 protein-protein interaction
6ZEZ	;	2.55	;	Keap1 kelch domain bound to a small molecule inhibitor of the Keap1-Nrf2 protein-protein interaction
6ZF0	;	1.6	;	Keap1 kelch domain bound to a small molecule inhibitor of the Keap1-Nrf2 protein-protein interaction
6ZF1	;	1.74	;	Keap1 kelch domain bound to a small molecule inhibitor of the Keap1-Nrf2 protein-protein interaction
6ZF2	;	2.2	;	Keap1 kelch domain bound to a small molecule inhibitor of the Keap1-Nrf2 protein-protein interaction
6ZF3	;	1.28	;	Keap1 kelch domain bound to a small molecule inhibitor of the Keap1-Nrf2 protein-protein interaction
6ZF4	;	1.21	;	Keap1 kelch domain bound to a small molecule inhibitor of the Keap1-Nrf2 protein-protein interaction
6ZF5	;	1.29	;	Keap1 kelch domain bound to a small molecule inhibitor of the Keap1-Nrf2 protein-protein interaction
6ZF6	;	1.38	;	Keap1 kelch domain bound to a small molecule inhibitor of the Keap1-Nrf2 protein-protein interaction
6ZF7	;	1.37	;	Keap1 kelch domain bound to a small molecule inhibitor of the Keap1-Nrf2 protein-protein interaction
6ZF8	;	1.75	;	Keap1 kelch domain bound to a small molecule inhibitor of the Keap1-Nrf2 protein-protein interaction
7OFE	;	1.19	;	Keap1 kelch domain bound to a small molecule inhibitor of the Keap1-Nrf2 protein-protein interaction
7OFF	;	1.37	;	Keap1 kelch domain bound to a small molecule inhibitor of the Keap1-Nrf2 protein-protein interaction
6TYP	;	2.5	;	KEAP1 Kelch domain in complex with Compound 2
6TYM	;	1.422	;	KEAP1 Kelch domain in complex with Compound 9
6Z6A	;	2.37	;	Keap1 macrocycle complex
3L9X	;	2.1	;	KefC C-terminal domain in complex with KefF and ESG
3L9W	;	1.75	;	KefC C-terminal domain in complex with KefF and GSH
5WHL	;	2.5	;	Kelch domain of human Keap1 bound to inhibitory small molecule fragment: hydroxyphenyl propionic acid
5WG1	;	2.021	;	Kelch domain of human Keap1 bound to mutant Nrf2 EAGE peptide
7K2Q	;	2.37	;	Kelch domain of human KEAP1 bound to Nrf2 cyclic peptide, c[Ahx-DPETGE]
7K2K	;	1.98	;	Kelch domain of human KEAP1 bound to Nrf2 cyclic peptide, c[BAL-DEETGE]
7K2L	;	1.98	;	Kelch domain of human KEAP1 bound to Nrf2 cyclic peptide, c[BAL-NPETGE]
8EHV	;	2.29	;	Kelch domain of human KEAP1 bound to Nrf2 cyclic peptide, c[DhA-GDPET(bAla)E]
7K2S	;	2.13	;	Kelch domain of human KEAP1 bound to Nrf2 cyclic peptide, c[DhA-GDPETGE]
7K2F	;	2.37	;	Kelch domain of human KEAP1 bound to Nrf2 cyclic peptide, c[GAEETGE]
7K2I	;	2.42	;	Kelch domain of human KEAP1 bound to Nrf2 cyclic peptide, c[GAPETGE]
7K2G	;	2.15	;	Kelch domain of human KEAP1 bound to Nrf2 cyclic peptide, c[GDEEAGE]
7K2J	;	2.52	;	Kelch domain of human KEAP1 bound to Nrf2 cyclic peptide, c[GDPEAGE]
7K2H	;	2.09	;	Kelch domain of human KEAP1 bound to Nrf2 cyclic peptide, c[GDPETGE]
7K2M	;	2.02	;	Kelch domain of human KEAP1 bound to Nrf2 cyclic peptide, c[GEPETGE]
5WFV	;	1.91	;	Kelch domain of human Keap1 bound to Nrf2 ETGE peptide
8EJS	;	2.82	;	Kelch domain of human KEAP1 bound to Nrf2 linear peptide, Ac-(BAla)DPETGE-NH2
7K2D	;	2.21	;	Kelch domain of human KEAP1 bound to Nrf2 linear peptide, Ac-GDEETGE-NH2
8EJR	;	2.08	;	Kelch domain of human KEAP1 bound to Nrf2 linear peptide, Ac-GDPETGE-NH2
7K2C	;	2.11	;	Kelch domain of human KEAP1 bound to Nrf2 peptide, ADEETGEAA
7K2B	;	2.31	;	Kelch domain of human KEAP1 bound to Nrf2 peptide, ADEETGEFA
7K28	;	2.15	;	Kelch domain of human KEAP1 bound to Nrf2 peptide, ADEETGEFL
7K29	;	2.2	;	Kelch domain of human KEAP1 bound to Nrf2 peptide, LDEETGEAL
7K2A	;	1.9	;	Kelch domain of human KEAP1 bound to Nrf2 peptide, LDEETGEFA
7K2P	;	2.11	;	Kelch domain of human KEAP1 bound to Nrf2-based cyclic peptide, c[AVA-DPETGE]
7K2N	;	2.22	;	Kelch domain of human KEAP1 bound to Nrf2-based cyclic peptide, c[BAL-DEETGE]
7K2O	;	2.11	;	Kelch domain of human KEAP1 bound to Nrf2-based cyclic peptide, c[GABA-DPETGE]
7K2E	;	2.03	;	Kelch domain of human KEAP1 bound to Nrf2-based cyclic peptide, c[GDEETGE]
7K2R	;	2.1	;	Kelch domain of human KEAP1 bound to Nrf2-based cyclic peptide, c[LhA-DEETGE]
5WIY	;	2.23	;	Kelch domain of human Keap1 bound to small molecule inhibitor fragment: 4-amino-1,7-dihydro-6H-pyrazolo[3,4-d]pyrimidine-6-thione
5WHO	;	2.23	;	Kelch domain of human Keap1 bound to small molecule inhibitor fragment: 4-oxo-4H-1-benzopyran-2-carboxylic acid
5WFL	;	1.93	;	Kelch domain of human Keap1 in open unliganded conformation
8PKX	;	1.79	;	Kelch domain of KEAP1 in complex with a ortho-dimethylbenzene linked cyclic peptide 11 (ortho-WRCNPETaEC).
8PKV	;	1.55	;	Kelch domain of KEAP1 in complex with a ortho-dimethylbenzene linked cyclic peptide 4 (ortho-WRCDEETGEC).
8PKW	;	1.54	;	Kelch domain of KEAP1 in complex with a ortho-dimethylbenzene linked cyclic peptide 5 (ortho-WRCDPETaEC).
8PKU	;	1.73	;	Kelch domain of KEAP1 in complex with ortho-dimethylbenzene linked cyclic peptide 3 (ortho-WRCDEETGEC).
6SS1	;	1.1	;	Kemp Eliminase HG3.17 mutant Q50A, E47N, N300D Complexed with Transition State Analog 6-Nitrobenzotriazole
6SRW	;	1.45	;	Kemp Eliminase HG3.17 mutant Q50F, E47N, N300D Complexed with Transition State Analog 6-Nitrobenzotriazole
6SRZ	;	1.4	;	Kemp Eliminase HG3.17 mutant Q50H, E47N, N300D Complexed with Transition State Analog 6-Nitrobenzotriazole
6SS3	;	1.15	;	Kemp Eliminase HG3.17 mutant Q50K, E47N, N300D Complexed with Transition State Analog 6-Nitrobenzotriazole
6TU6	;	1.05	;	Kemp Eliminase HG3.17 mutant Q50M, E47N, N300D Complexed with Transition State Analog 6-Nitrobenzotriazole
6SRY	;	0.95	;	Kemp Eliminase HG3.17 mutant Q50S, E47N, N300D Complexed with Transition State Analog 6-Nitrobenzotriazole
7KJT	;	3.34	;	KEOPS tRNA modifying sub-complex of archaeal Cgi121 and tRNA
3FR7	;	1.55	;	ketol-acid reductoisomerase (KARI) in complex with Mg2+
4TSK	;	2.5	;	Ketol-acid reductoisomerase from Alicyclobacillus acidocaldarius
7Q03	;	2.1	;	Ketol-acid reductoisomerase from Methanothermococcus thermolithotrophicus in the close state with NADP and Mg2+
7Q07	;	2.2	;	Ketol-acid reductoisomerase from Methanothermococcus thermolithotrophicus in the open state with NADP and tartrate
1KS9	;	1.7	;	Ketopantoate Reductase from Escherichia coli
2G1N	;	2.9	;	Ketopiperazine-based renin inhibitors: Optimization of the ""C"" ring
2G1O	;	2.7	;	Ketopiperazine-Based Renin Inhibitors: Optimization of the ""C"" Ring
2G1Y	;	2.5	;	Ketopiperazine-Based Renin Inhibitors: Optimization of the ""C"" Ring
2G21	;	2.2	;	Ketopiperazine-Based Renin Inhibitors: Optimization of the ""C"" Ring
2G22	;	2.5	;	Ketopiperazine-Based Renin Inhibitors: Optimization of the ""C"" Ring
2G24	;	1.9	;	Ketopiperazine-Based Renin Inhibitors: Optimization of the ""C"" Ring
2G26	;	2.1	;	Ketopiperazine-Based Renin Inhibitors: Optimization of the ""C"" Ring
2G27	;	2.9	;	Ketopiperazine-Based Renin Inhibitors: Optimization of the ""C"" Ring
2FS4	;	2.2	;	Ketopiperazine-Based Renin Inhibitors: Optimization of the C ring
2G1R	;	2.42	;	Ketopiperazine-Based Renin Inhibitors: Optimization of the C Ring
2G1S	;	2.5	;	Ketopiperazine-Based Renin Inhibitors: Optimization of the C Ring
2G20	;	2.4	;	Ketopiperazine-Based Renin Inhibitors: Optimization of the C Ring
7XWU	;	2.0	;	Ketoreductase CpKR mutant - M1
8H61	;	1.9	;	Ketoreductase CpKR mutant - M2
6WH9	;	2.75	;	Ketoreductase from module 1 of the 6-deoxyerythronolide B synthase (KR1) in complex with antibody fragment (Fab) 1D10
6W7S	;	2.25	;	Ketoreductase from module 1 of the 6-deoxyerythronolide B synthase (KR1) in complex with antibody fragment (Fab) 2G10
5KTK	;	1.98	;	Ketoreductase from module 3 of the bacillaene synthase from Bacillus subtilis 168
5ZFM	;	2.0	;	Ketoreductase LbCR mutant - M6
5ZI0	;	2.302	;	Ketoreductase LbCR mutant - M8
1E3J	;	2.3	;	Ketose reductase (sorbitol dehydrogenase) from silverleaf whitefly
6UAD	;	1.75	;	Ketosteroid isomerase (C. testosteroni) with truncated & designed loop for precise positioning of a catalytic E38
6UAE	;	1.93	;	Ketosteroid isomerase (C. testosteroni) with truncated & designed loop for precise positioning of a catalytic E38
7EPN	;	1.9	;	Ketosteroid Isomerase KSI native
7EPO	;	2.35	;	Ketosteroid Isomerase KSI with 5-nitrobenzoxazole (5NBI)
6QSP	;	1.45	;	Ketosynthase (ApeO) in Complex with its Chain Length Factor (ApeC) from Xenorhabdus doucetiae
7ZM9	;	1.62	;	Ketosynthase domain 3 of Brevibacillus Brevis orphan BGC11
6KOG	;	1.68	;	Ketosynthase domain in tenuazonic acid synthetase 1 (TAS1).
7ZMD	;	2.93	;	Ketosynthase domain of module 3 from Brevibacillus Brevis orphan BGC11
7ZMA	;	2.9	;	Ketosynthase domain of module 4 from Brevibacillus Brevis orphan BGC11
7ZMC	;	3.1	;	Ketosynthase domain of module 4 from Brevibacillus Brevis orphan BGC11
5ELP	;	2.93	;	Ketosynthase from module 1 of the bacillaene synthase from Bacillus amyloliquefaciens FZB42
5ERB	;	4.2	;	Ketosynthase from module 5 of the bacillaene synthase from Bacillus amyloliquefaciens FZB42
5ENY	;	4.0	;	Ketosynthase from module 6 connected to acyl carrier protein from module 5 (unobservable) of the bacillaene synthase from Bacillus subtilis 168
5ERF	;	3.1	;	Ketosynthase from module 6 of the bacillaene synthase from Bacillus subtilis 168
5E5N	;	2.0	;	Ketosynthase from module 6 of the bacillaene synthase from Bacillus subtilis 168 (C167S mutant, crystal form 1)
5E6K	;	2.16	;	Ketosynthase from module 6 of the bacillaene synthase from Bacillus subtilis 168 (C167S mutant, crystal form 2)
4V2P	;	1.67	;	Ketosynthase MxnB
2GKW	;	2.7	;	Key contacts promote recongnito of BAFF-R by TRAF3
6F8N	;	1.45	;	Key residues affecting transglycosylation activity in family 18 chitinases - Insights into donor and acceptor subsites
1MDV	;	2.3	;	KEY ROLE OF PHENYLALANINE 20 IN CYTOCHROME C3: STRUCTURE, STABILITY AND FUNCTION STUDIES
4BED	;	9.0	;	Keyhole limpet hemocyanin (KLH): 9A cryoEM structure and molecular model of the KLH1 didecamer reveal the interfaces and intricate topology of the 160 functional units
5X3I	;	2.1	;	Kfla1895 D451A mutant
5X3J	;	2.3	;	Kfla1895 D451A mutant in complex with cyclobis-(1->6)-alpha-nigerosyl
5X3K	;	2.5	;	Kfla1895 D451A mutant in complex with isomaltose
3N89	;	2.789	;	KH domains
2FMR	;		;	KH1 FROM THE FRAGILE X PROTEIN FMR1, NMR, 18 STRUCTURES
3CDC	;	1.53	;	kI O18/O8 N34I/Y87H immunoglobulin light chain variable domain
3CDF	;	1.53	;	kI O18/O8 Y87H immunoglobulin light chain variable domain
8Q8K	;	2.7	;	KI Polyomavirus LTA NLS bound to importin alpha 2
5J28	;	2.0	;	Ki67-PP1g (protein phosphatase 1, gamma isoform) holoenzyme complex
6NMU	;	2.55	;	Kick-Off Fab 115 anti-SIRP-alpha antibody in complex with SIRP-alpha Variant 1
1M1F	;	1.4	;	Kid toxin protein from E.coli plasmid R1
1KBP	;	2.65	;	KIDNEY BEAN PURPLE ACID PHOSPHATASE
3KBP	;	3.0	;	KIDNEY BEAN PURPLE ACID PHOSPHATASE
4KBP	;	2.7	;	KIDNEY BEAN PURPLE ACID PHOSPHATASE
6WWU	;	2.7	;	KIF14[391-735] - ADP-AlFx in complex with a microtubule
6WWV	;	3.1	;	KIF14[391-735] - ANP-PNP in complex with a microtubule
6WWQ	;	3.0	;	KIF14[391-743] - ADP in complex with a microtubule
7LVR	;	2.9	;	KIF14[391-743] - ADP-AlFx closed state class in complex with a microtubule
6WWR	;	2.7	;	Kif14[391-743] - ADP-AlFx open state class in complex with a microtubule
7LVQ	;	2.9	;	KIF14[391-743] - AMP-PNP closed state class in complex with a microtubule
6WWS	;	2.7	;	Kif14[391-743] - AMP-PNP open state class in complex with a microtubule
6WWM	;	2.8	;	KIF14[391-748] - ADP in complex with a microtubule
6WWN	;	3.5	;	KIF14[391-748] - ADP-AlFx in complex with a microtubule
6WWO	;	2.8	;	KIF14[391-748] - AMP-PNP in complex with a microtubule
6WWJ	;	3.4	;	KIF14[391-755] - ADP in complex with a microtubule
6WWK	;	3.0	;	KIF14[391-755] dimer two-heads-bound state - ADP-AlFx in complex with a microtubule
6WWL	;	3.1	;	KIF14[391-755] dimer two-heads-bound state - AMP-PNP in complex with a microtubule
6WWF	;	3.3	;	KIF14[391-772] - ADP in complex with a microtubule
6WWG	;	2.9	;	KIF14[391-772] dimer two-heads-bound state - ADP-AlFx in complex with a microtubule
6WWH	;	3.8	;	KIF14[391-772] dimer two-heads-bound state - AMP-PNP in complex with a microtubule
2HXH	;	11.0	;	KIF1A head-microtubule complex structure in adp-form
2HXF	;	10.0	;	KIF1A head-microtubule complex structure in amppnp-form
1IA0	;	15.0	;	KIF1A HEAD-MICROTUBULE COMPLEX STRUCTURE IN ATP-FORM
5D3A	;	2.495	;	KIF21A regulatory coiled coil
4Y05	;	2.59	;	KIF2C short Loop2 construct
5MIO	;	3.19	;	KIF2C-DARPIN FUSION PROTEIN BOUND TO TUBULIN
6IGV	;	2.999	;	Kif5b stalk I coiled-coil
6PA1	;	3.01	;	Killer cell immunoglobulin-like receptor 2DL2 in complex with HLA-C*07:02
6PAG	;	2.501	;	Killer cell immunoglobulin-like receptor 2DL3 in complex with HLA-C*07:02
2DL2	;	3.0	;	KILLER IMMUNOGLOBULIN RECEPTOR 2DL2
2DLI	;	2.9	;	KILLER IMMUNOGLOBULIN RECEPTOR 2DL2,TRIGONAL FORM
1KVD	;	1.8	;	KILLER TOXIN FROM HALOTOLERANT YEAST
1KVE	;	1.8	;	KILLER TOXIN FROM HALOTOLERANT YEAST
8B70	;	3.3	;	KimA from B. subtilis with nucleotide second-messenger c-di-AMP bound
6S3K	;	3.7	;	KimA from Bacillus subtilis in inward-facing, occluded state
2VLG	;	1.7	;	KinA PAS-A domain, homodimer
4XIV	;	3.0	;	Kinase and Dimerization (P3P4) of the Thermotoga maritima CheA kinase
2QNJ	;	2.7	;	Kinase and Ubiquitin-associated domains of MARK3/Par-1
4KIO	;	2.18	;	Kinase domain mutant of human Itk in complex with a covalently-binding inhibitor
4L7S	;	2.03	;	Kinase domain mutant of human Itk in complex with an aminobenzothiazole inhibitor
6UNR	;	2.2	;	Kinase domain of ALK2-K492A/K493A with AMPPNP
6UNS	;	2.3	;	Kinase domain of ALK2-K492A/K493A with LDN-193189
6UNQ	;	2.4	;	Kinase domain of ALK2-K493A with AMPPNP
4FIC	;	2.5	;	Kinase domain of cSrc in complex with a hinge region-binding fragment
7AH3	;	1.95	;	Kinase domain of cSrc in complex with a pyrazolopyrimidine
4O2P	;	2.1	;	Kinase domain of cSrc in complex with a substituted pyrazolopyrimidine
6HVF	;	2.1	;	Kinase domain of cSrc in complex with compound 29B
6HVE	;	1.9	;	Kinase domain of cSrc in complex with compound 9
3G5D	;	2.2	;	Kinase domain of cSrc in complex with Dasatinib
3F3U	;	2.5	;	Kinase domain of cSrc in complex with inhibitor RL37 (Type III)
3F3T	;	2.5	;	Kinase domain of cSrc in complex with inhibitor RL38 (Type III)
3F3V	;	2.6	;	Kinase domain of cSrc in complex with inhibitor RL45 (Type II)
3TZ7	;	3.3	;	Kinase domain of cSrc in complex with RL103
3TZ8	;	2.7	;	Kinase domain of cSrc in complex with RL104
3TZ9	;	3.1	;	Kinase domain of cSrc in complex with RL130
5D11	;	2.3	;	Kinase domain of cSrc in complex with RL235
5D10	;	2.7	;	Kinase domain of cSrc in complex with RL236
5D12	;	3.0	;	Kinase domain of cSrc in complex with RL40
1BYG	;	2.4	;	KINASE DOMAIN OF HUMAN C-TERMINAL SRC KINASE (CSK) IN COMPLEX WITH INHIBITOR STAUROSPORINE
5MJA	;	2.14	;	Kinase domain of human EphB1 bound to a quinazoline-based inhibitor
5MJB	;	2.23	;	Kinase domain of human EphB1, G703C mutant, covalently bound to a quinazoline-based inhibitor
2R2P	;	2.4	;	Kinase domain of human ephrin type-A receptor 5 (EphA5)
2REI	;	1.6	;	Kinase domain of human ephrin type-A receptor 7 (Epha7)
3KUL	;	2.15	;	Kinase domain of human ephrin type-A receptor 8 (EPHA8)
5LOH	;	3.1	;	Kinase domain of human Greatwall
3ETA	;	2.6	;	Kinase domain of insulin receptor complexed with a pyrrolo pyridine inhibitor
7OAM	;	2.65	;	Kinase domain of MERTK in complex with compound 8
1W53	;	1.6	;	Kinase recruitment domain of the stress phosphatase RsbU
6V9G	;	2.35	;	Kindlin-3 double deletion mutant long form
6V97	;	2.381	;	Kindlin-3 double deletion mutant short form
3KIN	;	3.1	;	KINESIN (DIMERIC) FROM RATTUS NORVEGICUS
2KIN	;	2.0	;	KINESIN (MONOMERIC) FROM RATTUS NORVEGICUS
2V14	;	2.2	;	Kinesin 16B Phox-homology domain (KIF16B)
5X3E	;	2.61	;	kinesin 6
6ZPG	;	4.6	;	Kinesin binding protein (KBP)
6ZPH	;	6.9	;	Kinesin binding protein complexed with Kif15 motor domain
4HNA	;	3.19	;	Kinesin motor domain in the ADP-MG-ALFX state in complex with tubulin and a DARPIN
3WPN	;	2.8	;	Kinesin spindle protein Eg5 in complex with ATP-competitive inhibitor PVZB1194
5ZO7	;	2.6	;	Kinesin spindle protein Eg5 in complex with STLC-type inhibitor PVEI0138
3J2U	;	10.8	;	Kinesin-13 KLP10A HD in complex with CS-tubulin and a microtubule
3L1C	;	2.75	;	Kinesin-14 Protein Ncd, T436S Mutant
2WBE	;	9.4	;	Kinesin-5-Tubulin Complex with AMPPNP
5GSY	;	7.0	;	Kinesin-8 motor, KIF19A, in the nucleotide-free state complexed with GDP-taxol microtubule
7LXR	;	1.744	;	Kinesin-like protein at 61F (Klp61f) bound to AMPPNP
3EDL	;	28.0	;	Kinesin13-Microtubule Ring complex
1JA8	;	2.12	;	Kinetic Analysis of Product Inhibition in Human Manganese Superoxide Dismutase
2IA8	;	1.48	;	Kinetic and Crystallographic Studies of a Redesigned Manganese-Binding Site in Cytochrome c Peroxidase
2ICV	;	1.6	;	Kinetic and Crystallographic Studies of a Redesigned Manganese-Binding Site in Cytochrome c Peroxidase
1XKX	;	1.93	;	Kinetic and crystallographic studies on 2-(beta-D-glucopyranosyl)-5-methyl-1,3,4-oxadiazole,-benzothiazole, and-benzimidazole, inhibitors of muscle glycogen phosphorylase b. Evidence for a new binding site.
1XL0	;	1.92	;	Kinetic and crystallographic studies on 2-(beta-D-glucopyranosyl)-5-methyl-1,3,4-oxadiazole,-benzothiazole, and-benzimidazole, inhibitors of muscle glycogen phosphorylase b. Evidence for a new binding site.
1XL1	;	2.1	;	Kinetic and crystallographic studies on 2-(beta-D-glucopyranosyl)-5-methyl-1,3,4-oxadiazole,-benzothiazole, and-benzimidazole, inhibitors of muscle glycogen phosphorylase b. Evidence for a new binding site.
7FBG	;	1.6	;	Kinetic and structural analysis by Peptidoglycan editing factor from Bacillus cereus ATCC 14579
3J6L	;	9.0	;	Kinetic and Structural Analysis of Coxsackievirus B3 Receptor Interactions and Formation of the A-particle
3J6M	;	9.0	;	Kinetic and Structural Analysis of Coxsackievirus B3 Receptor Interactions and Formation of the A-particle
3J6N	;	9.0	;	Kinetic and Structural Analysis of Coxsackievirus B3 Receptor Interactions and Formation of the A-particle
3J6O	;	9.0	;	Kinetic and Structural Analysis of Coxsackievirus B3 Receptor Interactions and Formation of the A-particle
5MGU	;	1.89	;	Kinetic and Structural Changes in HsmtPheRS, Induced by Pathogenic Mutations in Human FARS2
5MGV	;	2.05	;	Kinetic and Structural Changes in HsmtPheRS, Induced by Pathogenic Mutations in Human FARS2
5MGW	;	1.46	;	Kinetic and Structural Changes in HsmtPheRS, Induced by Pathogenic Mutations in Human FARS2
3MB2	;	2.41	;	Kinetic and Structural Characterization of a Heterohexamer 4-Oxalocrotonate Tautomerase from Chloroflexus aurantiacus J-10-fl: Implications for Functional and Structural Diversity in the Tautomerase Superfamily
3R3J	;	3.1	;	Kinetic and structural characterization of Plasmodium falciparum glutamate dehydrogenase 2
4FAZ	;	1.57	;	Kinetic and structural characterization of the 4-oxalocrotonate tautomerase isozymes from Methylibium petroleiphilum
4FDX	;	1.64	;	Kinetic and structural characterization of the 4-oxalocrotonate tautomerase isozymes from Methylibium petroleiphilum
7LUU	;	1.68	;	Kinetic and Structural Characterization of the First B3 Metallo-beta-Lactamase with an Active Site Glutamic Acid
3V3F	;	2.0	;	Kinetic and structural studies of thermostabilized mutants of HCA II.
3V3G	;	1.5581	;	Kinetic and structural studies of thermostabilized mutants of HCA II.
3V3H	;	1.85	;	Kinetic and structural studies of thermostabilized mutants of HCA II.
3V3I	;	1.73	;	Kinetic and structural studies of thermostabilized mutants of HCA II.
3V3J	;	1.63	;	Kinetic and structural studies of thermostabilized mutants of HCA II.
4QWM	;	2.17	;	KINETIC CRYSTALLOGRAPHY of ALPHA_E7-CARBOXYLESTERSE FROM LUCILLA CUPRINA - ABSORBED X-RAY DOSE 1.85 MGy
4UBN	;	2.02	;	KINETIC CRYSTALLOGRAPHY OF ALPHA_E7-CARBOXYLESTERSE FROM LUCILLA CUPRINA - ABSORBED X-RAY DOSE 1.85 MGy TEMP 150K
4W1S	;	2.3	;	KINETIC CRYSTALLOGRAPHY OF ALPHA_E7-CARBOXYLESTERSE FROM LUCILLA CUPRINA - ABSORBED X-RAY DOSE 11.09 MGy TEMP 150K
4UBM	;	2.4	;	KINETIC CRYSTALLOGRAPHY OF ALPHA_E7-CARBOXYLESTERSE FROM LUCILLA CUPRINA - ABSORBED X-RAY DOSE 11.11 MGy at 100K
4UBI	;	2.24	;	KINETIC CRYSTALLOGRAPHY OF ALPHA_E7-CARBOXYLESTERSE FROM LUCILLA CUPRINA - ABSORBED X-RAY DOSE 3.70 MGy at 100K
4UBO	;	2.02	;	KINETIC CRYSTALLOGRAPHY OF ALPHA_E7-CARBOXYLESTERSE FROM LUCILLA CUPRINA - ABSORBED X-RAY DOSE 3.70 MGy TEMP 150K
4W1P	;	2.1	;	KINETIC CRYSTALLOGRAPHY OF ALPHA_E7-CARBOXYLESTERSE FROM LUCILLA CUPRINA - ABSORBED X-RAY DOSE 5.54 MGy TEMP 150K
4UBJ	;	2.3	;	KINETIC CRYSTALLOGRAPHY OF ALPHA_E7-CARBOXYLESTERSE FROM LUCILLA CUPRINA - ABSORBED X-RAY DOSE 5.55 MGy at 100K
4W1Q	;	2.12	;	KINETIC CRYSTALLOGRAPHY OF ALPHA_E7-CARBOXYLESTERSE FROM LUCILLA CUPRINA - ABSORBED X-RAY DOSE 7.39 MGy TEMP 150K
4UBK	;	2.33	;	KINETIC CRYSTALLOGRAPHY OF ALPHA_E7-CARBOXYLESTERSE FROM LUCILLA CUPRINA - ABSORBED X-RAY DOSE 7.40 MGy at 100K
4W1R	;	2.23	;	KINETIC CRYSTALLOGRAPHY OF ALPHA_E7-CARBOXYLESTERSE FROM LUCILLA CUPRINA - ABSORBED X-RAY DOSE 9.24 MGy TEMP 150K
4UBL	;	2.36	;	KINETIC CRYSTALLOGRAPHY OF ALPHA_E7-CARBOXYLESTERSE FROM LUCILLA CUPRINA - ABSORBED X-RAY DOSE 9.26 MGy
1OB0	;	1.83	;	Kinetic stabilization of Bacillus licheniformis alpha-amylase through introduction of hydrophobic residues at the surface
4HJS	;	1.22	;	Kinetic stabilization of transthyretin through covalent modification of K15 by (E)-N-(4-(4-hydroxy-3,5-dimethylstyryl)ethanesulfonamide
4HJT	;	1.45	;	Kinetic stabilization of transthyretin through covalent modification of K15 by (E)-N-(4-(4-hydroxy-3,5-dimethylstyryl)phenyl)propionamide
4FI7	;	1.402	;	Kinetic Stabilization of transthyretin through covalent modification of K15 by 3-(5-(3,5-dichloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)-benzenesulfonamide
4FI6	;	1.46	;	Kinetic Stabilization of transthyretin through covalent modification of K15 by 3-(5-(3,5-dichlorophenyl)-1,3,4-oxadiazol-2-yl)-benzenesulfonamide
4FI8	;	1.22	;	Kinetic Stabilization of transthyretin through covalent modification of K15 by 4-bromo-3-(5-(3,5-dichloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)-benzenesulfonamide
5T25	;	1.991	;	Kinetic, Spectral and Structural Characterization of the Slow Binding Inhibitor Acetopyruvate with Dihydrodipicolinate Synthase from Escherichia coli.
5T26	;	2.1	;	Kinetic, Spectral and Structural Characterization of the Slow Binding Inhibitor Acetopyruvate with Dihydrodipicolinate Synthase from Escherichia coli.
7UVT	;	3.9	;	Kinetically trapped misfolded state of the Tetrahymena ribozyme
7SZ4	;	4.8	;	Kinetically trapped Pseudomonas-phage PaP3 portal protein - delta barrel mutant class-2
7SZ6	;	6.24	;	Kinetically trapped Pseudomonas-phage PaP3 portal protein - delta barrel mutant class-3
7SXK	;	3.4	;	Kinetically trapped Pseudomonas-phage PaP3 portal protein - Full Length
7SYA	;	3.5	;	Kinetically trapped Pseudomonas-phage PaP3 portal protein - Full Length
1ALH	;	2.5	;	KINETICS AND CRYSTAL STRUCTURE OF A MUTANT E. COLI ALKALINE PHOSPHATASE (ASP-369-->ASN): A MECHANISM INVOLVING ONE ZINC PER ACTIVE SITE
1OF1	;	1.95	;	KINETICS AND CRYSTAL STRUCTURE OF THE HERPES SIMPLEX VIRUS TYPE 1 THYMIDINE KINASE INTERACTING WITH (SOUTH)-METHANOCARBA-THYMIDINE
1E2K	;	1.7	;	Kinetics and crystal structure of the wild-type and the engineered Y101F mutant of Herpes simplex virus type 1 thymidine kinase interacting with (North)-methanocarba-thymidine
1E2L	;	2.4	;	Kinetics and crystal structure of the wild-type and the engineered Y101F mutant of Herpes simplex virus type 1 thymidine kinase interacting with (North)-methanocarba-thymidine
2JGQ	;	2.3	;	Kinetics and structural properties of triosephosphate isomerase from Helicobacter pylori
5AW8	;	2.8	;	Kinetics by X-ray crystallography: E2.MgF42-.2RB+ crystal
5AW9	;	2.8	;	Kinetics by X-ray crystallography: native E2.MgF42-.2K+ crystal for Rb+ bound crystals
5AW4	;	2.8	;	Kinetics by X-ray crystallography: Rb+-substitution of bound K+ in the E2.MgF42-.2K+ crystal after 1.5 min
5AW7	;	2.9	;	Kinetics by X-ray crystallography: Rb+-substitution of bound K+ in the E2.MgF42-.2K+ crystal after 11.3 min
5AW5	;	2.9	;	Kinetics by X-ray crystallography: Rb+-substitution of bound K+ in the E2.MgF42-.2K+ crystal after 2.2 min
5AW6	;	2.8	;	Kinetics by X-ray crystallography: Rb+-substitution of bound K+ in the E2.MgF42-.2K+ crystal after 5.5 min
5AVQ	;	2.6	;	Kinetics by X-ray crystallography: Tl+-substitution of bound K+ in the E2.MgF42-.2K+ crystal after 0.75 min.
5AVR	;	2.7	;	Kinetics by X-ray crystallography: Tl+-substitution of bound K+ in the E2.MgF42-.2K+ crystal after 1.5 min
5AW3	;	3.35	;	Kinetics by X-ray crystallography: Tl+-substitution of bound K+ in the E2.MgF42-.2K+ crystal after 100 min
5AVW	;	2.6	;	Kinetics by X-ray crystallography: Tl+-substitution of bound K+ in the E2.MgF42-.2K+ crystal after 16.5 min
5AVX	;	3.3	;	Kinetics by X-ray crystallography: Tl+-substitution of bound K+ in the E2.MgF42-.2K+ crystal after 20 min
5AVY	;	3.45	;	Kinetics by X-ray crystallography: Tl+-substitution of bound K+ in the E2.MgF42-.2K+ crystal after 20 min
5AVS	;	2.9	;	Kinetics by X-ray crystallography: Tl+-substitution of bound K+ in the E2.MgF42-.2K+ crystal after 3.5 min
5AVT	;	2.9	;	Kinetics by X-ray crystallography: Tl+-substitution of bound K+ in the E2.MgF42-.2K+ crystal after 5 min
5AVZ	;	3.2	;	Kinetics by X-ray crystallography: Tl+-substitution of bound K+ in the E2.MgF42-.2K+ crystal after 55 min
5AW0	;	3.3	;	Kinetics by X-ray crystallography: Tl+-substitution of bound K+ in the E2.MgF42-.2K+ crystal after 55 min
5AVU	;	2.55	;	Kinetics by X-ray crystallography: Tl+-substitution of bound K+ in the E2.MgF42-.2K+ crystal after 7.0 min
5AVV	;	2.9	;	Kinetics by X-ray crystallography: Tl+-substitution of bound K+ in the E2.MgF42-.2K+ crystal after 8.5 min
5AW1	;	3.35	;	Kinetics by X-ray crystallography: Tl+-substitution of bound K+ in the E2.MgF42-.2K+ crystal after 85 min
5AW2	;	3.2	;	Kinetics by X-ray crystallography: Tl+-substitution of bound K+ in the E2.MgF42-.2K+ crystal after 85 min
2AVM	;	1.1	;	Kinetics, stability, and structural changes in high resolution crystal structures of HIV-1 protease with drug resistant mutations L24I, I50V, AND G73S
2AVO	;	1.1	;	Kinetics, stability, and structural changes in high resolution crystal structures of HIV-1 protease with drug resistant mutations L24I, I50V, AND G73S
2AVQ	;	1.3	;	Kinetics, stability, and structural changes in high resolution crystal structures of HIV-1 protease with drug resistant mutations L24I, I50V, AND G73S
2AVS	;	1.1	;	kinetics, stability, and structural changes in high resolution crystal structures of HIV-1 protease with drug resistant mutations L24I, I50V, and G73S
2AVV	;	1.5	;	Kinetics, stability, and structural changes in high resolution crystal structures of HIV-1 protease with drug resistant mutations L24I, I50V, and G73S
8IRP	;	2.8	;	kinetin bound state of Arabidopsis AZG1
3SI5	;	2.2	;	Kinetochore-BUBR1 kinase complex
3VH8	;	1.8	;	KIR3DL1 in complex with HLA-B*5701
5T70	;	2.1	;	KIR3DL1 in complex with HLA-B*57:01 presenting TSNLQEQIGW
5T6Z	;	2.0	;	KIR3DL1 in complex with HLA-B*57:01-TW10
3WUW	;	2.0	;	KIR3DL1 in complex with HLA-B*57:01.I80T
6V3J	;	1.98	;	KIR3DL1 in complex with HLA-B*57:03 presenting the peptide LSSPVTKSF
7K80	;	2.4	;	KIR3DL1*001 in complex with HLA-A*24:02 presenting the RYPLTFGW peptide
7K81	;	2.0	;	KIR3DL1*005 in complex with HLA-A*24:02 presenting the RYPLTFGW peptide
5B38	;	2.3	;	KIR3DL1*005 in complex with HLA-B*57:01
5B39	;	2.5	;	KIR3DL1*015 in complex with HLA-B*57:01
7SWJ	;		;	KirBac1.1 mutant - I131C
6O9U	;	2.0	;	KirBac3.1 at a resolution of 2 Angstroms
7N9L	;	2.4	;	KirBac3.1 C71S C262S
7N9K	;	2.72	;	KirBac3.1 L124M mutant
6O9V	;	3.094	;	KirBac3.1 mutant at a resolution of 3.1 Angstroms
6O9T	;	4.01	;	KirBac3.1 mutant at a resolution of 4.1 Angstroms
7ADI	;	2.8	;	KirBac3.1 W46R: role of a highly conserved tryptophan at the membrane-water interface of Kir channel
3G0E	;	1.6	;	KIT kinase domain in complex with sunitinib
3G0F	;	2.6	;	KIT kinase domain mutant D816H in complex with sunitinib
1KDX	;		;	KIX DOMAIN OF MOUSE CBP (CREB BINDING PROTEIN) IN COMPLEX WITH PHOSPHORYLATED KINASE INDUCIBLE DOMAIN (PKID) OF RAT CREB (CYCLIC AMP RESPONSE ELEMENT BINDING PROTEIN), NMR 17 STRUCTURES
1DHY	;	2.3	;	KKS102 BPHC ENZYME
8HQ3	;	2.1	;	KL1 in complex with CRM1-Ran-RanBP1
8HQ6	;	2.03	;	KL2 in complex with CRM1-Ran-RanBP1
8ITV	;	2.3	;	KL2.1 in complex with CRM1-Ran-RanBP1
1FWB	;	2.0	;	KLEBSIELLA AEROGENES UREASE, C319A VARIANT AT PH 6.5
1FWA	;	2.0	;	KLEBSIELLA AEROGENES UREASE, C319A VARIANT AT PH 7.5
1FWC	;	2.0	;	KLEBSIELLA AEROGENES UREASE, C319A VARIANT AT PH 8.5
1FWD	;	2.0	;	KLEBSIELLA AEROGENES UREASE, C319A VARIANT AT PH 9.4
1FWE	;	2.0	;	KLEBSIELLA AEROGENES UREASE, C319A VARIANT WITH ACETOHYDROXAMIC ACID (AHA) BOUND
1FWF	;	2.0	;	KLEBSIELLA AEROGENES UREASE, C319D VARIANT
1FWG	;	2.0	;	KLEBSIELLA AEROGENES UREASE, C319S VARIANT
1FWH	;	2.0	;	KLEBSIELLA AEROGENES UREASE, C319Y VARIANT
1FWI	;	2.0	;	KLEBSIELLA AEROGENES UREASE, H134A VARIANT
1FWJ	;	2.2	;	KLEBSIELLA AEROGENES UREASE, NATIVE
6VHV	;	2.89	;	Klebsiella oxytoca NpsA in complex with 3-hydroxyanthranilyl-AMSN
6VHX	;	1.7	;	Klebsiella oxytoca NpsA N-terminal subdomain in complex with 3-hydroxyanthranilyl-AMSN
6VHW	;	1.83	;	Klebsiella oxytoca NpsA N-terminal subdomain in complex with 3-hydroxybenzoyl-AMSN
6VHZ	;	2.12	;	Klebsiella oxytoca NpsA N-terminal subdomain in complex with anthranilyl-AMSN
6VHT	;	1.84	;	Klebsiella oxytoca NpsA N-terminal subdomain in space group C2
6VHU	;	1.6	;	Klebsiella oxytoca NpsA N-terminal subdomain in space group P21
8FFK	;	2.82	;	Klebsiella pneumoniae AcrB multidrug efflux pump apo form
7UWQ	;	3.05	;	Klebsiella pneumoniae adenosine monophosphate nucleosidase
3GFX	;	2.4	;	Klebsiella pneumoniae BlrP1 pH 4.5 calcium/cy-diGMP complex
3GFZ	;	2.05	;	Klebsiella pneumoniae BlrP1 pH 6 manganese/cy-diGMP complex
3GG1	;	2.3	;	Klebsiella pneumoniae BlrP1 pH 8.0 calcium/cy-diGMP complex
3GG0	;	2.55	;	Klebsiella pneumoniae BlrP1 pH 9.0 manganese/cy-diGMP complex
3GFY	;	2.6	;	Klebsiella pneumoniae BlrP1 with FMN and cyclic diGMP, no metal ions
4OSG	;	2.7	;	Klebsiella pneumoniae complexed with NADPH and 6-ethyl-5-[(3R)-3-[3-methoxyl-5-(pyridine-4-yl)phenyl]but-1-yn-1-yl]pyrimidine-2,4-diamine (UCP1006)
5ECC	;	1.87	;	Klebsiella pneumoniae DfrA1 complexed with NADPH and 6-ethyl-5-(3-(2-methoxy-5-(pyridin-4-yl)phenyl)prop-1-yn-1-yl)pyrimidine-2,4-diamine
5ECX	;	1.95	;	Klebsiella pneumoniae DfrA1 complexed with NADPH and 6-ethyl-5-(3-(6-(pyridin-4-yl)benzo[d][1,3]dioxol-4-yl)but-1-yn-1-yl)pyrimidine-2,4-diamine
4OR7	;	1.76	;	Klebsiella pneumoniae dihydrofolate reductase complexed with NADPH and 6-ethyl-5-{3-[3-(pyrimidin-5-yl)phenyl]prop-1-yn-1-yl}pyrimidine-2,4-diamine
8R37	;	1.48	;	Klebsiella pneumoniae fosfomycin-resistance protein (FosAKP)
8GZW	;	2.5	;	Klebsiella pneumoniae FtsZ complexed with monobody (P21)
8GZV	;	2.2	;	Klebsiella pneumoniae FtsZ complexed with monobody (P212121)
5O77	;	1.5	;	Klebsiella pneumoniae OmpK35
5O79	;	1.65	;	Klebsiella pneumoniae OmpK36
6HHZ	;	2.15	;	Klebsiella pneumoniae Seryl-tRNA Synthetase in Complex with 5'-O-(N-(L-seryl)-sulfamoyl)cytidine
6HHY	;	2.27	;	Klebsiella pneumoniae Seryl-tRNA Synthetase in Complex with 5'-O-(N-(L-seryl)-sulfamoyl)N3-methyluridine
6HI0	;	2.25	;	Klebsiella pneumoniae Seryl-tRNA Synthetase in Complex with 5'-O-(N-(L-seryl)-Sulfamoyl)uridine
7AP1	;	2.18	;	Klebsiella pneumoniae Seryl-tRNA synthetase in Complex with Compound SerS7HMDDA
6H9X	;	2.1	;	Klebsiella pneumoniae Seryl-tRNA Synthetase in Complex with the Intermediate Analog 5'-O-(N-(L-Seryl)-Sulfamoyl)Adenosine
6HCG	;	4.3	;	Klebsiella pneumoniae type II secretion system outer membrane complex. PulD, PulS and PulC HR domain.
5XKT	;	1.8	;	Klebsiella pneumoniae UreG in complex with GMPPNP and nickel
1QSL	;	2.2	;	KLENOW FRAGMENT COMPLEXED WITH SINGLE-STRANDED SUBSTRATE AND EUROPIUM (III) ION
2KFN	;	2.03	;	KLENOW FRAGMENT WITH BRIDGING-SULFUR SUBSTRATE AND MANGANESE
2KFZ	;	2.03	;	KLENOW FRAGMENT WITH BRIDGING-SULFUR SUBSTRATE AND ZINC ONLY
2KZM	;	2.6	;	KLENOW FRAGMENT WITH NORMAL SUBSTRATE AND ZINC AND MANGANESE
2KZZ	;	2.25	;	KLENOW FRAGMENT WITH NORMAL SUBSTRATE AND ZINC ONLY
6Q4U	;	2.005	;	KlenTaq DNA pol in a closed ternary complex with 7-deaza-7-(2-(2-hydroxyethoxy)-N-(prop-2-yn-1-yl)acetamide)-2-dATP
6FBI	;	1.9	;	KlenTaq DNA polymerase in a closed, ternary complex with dGpNHpp bound in the active site
7OWF	;	1.91	;	KlenTaq DNA polymerase in a ternary complex with primer/template and the fluorescent nucleotide analog BFdUTP
6Q4V	;	2.006	;	KlenTaq DNA polymerase in complex with dATP
6FBC	;	1.54	;	KlenTaq DNA polymerase processing a modified primer - bearing the modification at the 3'-terminus of the primer.
6FBG	;	1.702	;	KlenTaq DNA polymerase processing a modified primer - bearing the modification upstream at the fifth primer nucleotide.
6FBF	;	2.001	;	KlenTaq DNA polymerase processing a modified primer - bearing the modification upstream at the fourth primer nucleotide.
6FBD	;	2.099	;	KlenTaq DNA polymerase processing a modified primer - bearing the modification upstream at the second primer nucleotide.
6FBH	;	1.8	;	KlenTaq DNA polymerase processing a modified primer - bearing the modification upstream at the sixth primer nucleotide.
6FBE	;	1.589	;	KlenTaq DNA polymerase processing a modified primer - bearing the modification upstream at the third primer nucleotide.
4BWM	;	1.749	;	KlenTaq mutant in complex with a RNA/DNA hybrid
4BWJ	;	1.55	;	KlenTaq mutant in complex with DNA and ddCTP
8SH2	;	3.74	;	KLHDC2 in complex with EloB and EloC
8SGF	;	1.418	;	KLHDC2 Kelch Domain with KLHDC2 c-terminal peptide bound
8SGE	;	1.509	;	KLHDC2 Kelch Domain with ligand KDRLKZ-1
6DO3	;	2.165	;	KLHDC2 ubiquitin ligase in complex with SelK C-end degron
6DO4	;	2.2	;	KLHDC2 ubiquitin ligase in complex with SelS C-end degron
6DO5	;	2.5	;	KLHDC2 ubiquitin ligase in complex with USP1 C-end degron
4V16	;	2.8	;	KlHsv2 with loop 6CD replaced by a Gly-Ser linker
6B0L	;	3.98	;	KLP10A-AMPPNP in complex with a microtubule
6B0C	;	3.51	;	KLP10A-AMPPNP in complex with curved tubulin and a microtubule
4V91	;	3.7	;	Kluyveromyces lactis 80S ribosome in complex with CrPV-IRES
4V92	;	3.7	;	Kluyveromyces lactis 80S ribosome in complex with CrPV-IRES
4AV9	;	3.001	;	Kluyveromyces lactis Hsv2
4AV8	;	3.35	;	Kluyveromyces lactis Hsv2 complete loop 6CD
1NOB	;	2.6	;	KNOB DOMAIN FROM ADENOVIRUS SEROTYPE 12
1KAC	;	2.6	;	KNOB DOMAIN FROM ADENOVIRUS SEROTYPE 12 IN COMPLEX WITH DOMAIN 1 OF ITS CELLULAR RECEPTOR CAR
4NQS	;	2.64	;	Knob-into-hole IgG Fc
3EGK	;	2.2	;	KNOBLE Inhibitor
6Q4T	;	1.997	;	KOD DNA pol in a closed ternary complex with 7-deaza-7-(2-(2-hydroxyethoxy)-N-(prop-2-yn-1-yl)acetamide)-2-dATP
4K8Z	;	2.29	;	KOD Polymerase in binary complex with dsDNA
7TQW	;	3.01	;	Kod RSGA incorporating PMT, n+2
7RSS	;	2.71	;	Kod-RI incorporating DNA, n+2
7RSR	;	1.98	;	Kod-RI incorporating PMT, n+2
2V6I	;	2.1	;	Kokobera Virus Helicase
2V6J	;	2.3	;	Kokobera Virus Helicase: Mutant Met47Thr
7FJ7	;	2.5	;	KpAckA (PduW) native structure
7FJ8	;	2.1	;	KpAckA (PduW) with AMP complex structure
7FJ9	;	2.3	;	KpAckA (PduW) with AMPPNP complex structure
7FJA	;	2.2	;	KpAckA (PduW) with AMPPNP, ethylene glycol complex structure
7FJB	;	2.44	;	KpAckA (PduW) with AMPPNP, sodium acetate complex structure
3RXX	;	1.62	;	KPC-2 carbapenemase in complex with 3-NPBA
3RXW	;	1.26	;	KPC-2 carbapenemase in complex with PSR3-226
7UTB	;	1.38	;	KPC-2 CARBAPENEMASE IN COMPLEX WITH THE BORONIC ACID INHIBITOR MB_076
7LLH	;	2.1	;	KPC-2 F72Y mutant with acylated imipenem
6XD7	;	1.65	;	KPC-2 N170A mutant bound to hydrolyzed ampicillin at 1.65 A
6XJ8	;	2.05	;	KPC-2 N170A mutant bound to hydrolyzed imipenem at 2.05 A
5FV5	;	1.4	;	KpFlo11 presents a novel member of the Flo11 family with a unique recognition pattern for homophilic interactions
5FV6	;	2.0	;	KpFlo11 presents a novel member of the Flo11 family with a unique recognition pattern for homophilic interactions
8FUX	;	1.2	;	KpsC D160C ternary complex
8FUW	;	1.9	;	KpsC D160N Kdo adduct
6M0Y	;		;	KR-12 analog derived from human LL-37
6GOF	;	1.98	;	KRAS full length G12D GPPNHP
6GOE	;	1.6	;	KRAS full length G12V GPPNHP
6GOD	;	1.71	;	KRAS full length wild-type GPPNHP
7SCW	;	1.98	;	KRAS full length wild-type in complex with RGL1 Ras association domain
7SCX	;	1.96	;	KRAS full-length G12V in complex with RGL1 Ras association domain
6WCK	;	1.801	;	KRAS G-quadruplex G16T mutant with Bromo Uracil replacing T8 and T16.
6N65	;	1.6	;	KRAS G-quadruplex G16T mutant.
8G47	;	3.19	;	KRAS G12C complex with GDP and AMG 510 imaged on a cryo-EM imaging scaffold
8G42	;	3.02	;	KRAS G12C complex with GDP imaged on a cryo-EM imaging scaffold
5V71	;	2.228	;	KRAS G12C in bound to quinazoline based switch II pocket (SWIIP) binder
5V9L	;	1.981	;	KRAS G12C in bound to quinazoline based switch II pocket (SWIIP) binder
7YCC	;	1.79	;	KRas G12C in complex with Compound 5c
7YCE	;	1.8	;	KRas G12C in complex with Compound 7b
7MDP	;	1.96	;	KRas G12C in complex with G-2897
8AQ5	;	1.8	;	KRAS G12C IN COMPLEX WITH GDP AND COMPOUND 16
8AQ7	;	1.65	;	KRAS G12C IN COMPLEX WITH GDP AND COMPOUND 9
5V9O	;	1.56	;	KRAS G12C inhibitor
7T47	;	1.27	;	KRAS G12D (GppCp) with MRTX-1133
7RT4	;	2.1	;	KRAS G12D in complex with Compound 5B (7-(8-chloronaphthalen-1-yl)-8-fluoro-2-{[(2S)-1-methylpyrrolidin-2-yl]methoxy}-4-(piperazin-1-yl)pyrido[4,3-d]pyrimidine)
7RPZ	;	1.3	;	KRAS G12D in complex with MRTX-1133
7ROV	;	1.32	;	KRAS G12D Mutant in complex with GMPPCP and cyclic peptide MP-9903
7C41	;	2.276	;	KRAS G12V and H-REV107 peptide complex
7W5R	;	3.87	;	KRAS G12V and peptide complex
8G4F	;	2.91	;	KRAS G12V complex with GDP imaged on a cryo-EM imaging scaffold
5WHA	;	2.04	;	KRas G12V, bound to GDP and miniprotein 225-11
5WHB	;	2.18	;	KRas G12V, bound to GDP and miniprotein 225-11(A30R)
5WPL	;	2.15	;	KRas G12V, bound to GppNHp and miniprotein 225-11
5WPM	;	1.72	;	KRas G12V, bound to GppNHp and miniprotein 225-11(A30R)
5WLB	;	1.72	;	KRas G12V, bound to GppNHp and miniprotein 225-15a/b
5WHE	;	1.91	;	KRas G12V/D38P, bound to GppNHp and miniprotein 225-11
8G4H	;	2.87	;	KRAS G13C complex with GDP imaged on a cryo-EM imaging scaffold
6E6G	;	1.93	;	KRAS G13D bound to GDP (K13GDP)
6E6F	;	3.401	;	KRAS G13D bound to GppNHp (K13GNP)
8AZV	;	1.05	;	KRAS in complex with BI-2865
8AZR	;	1.6	;	KRAS in complex with precursor 1
6ASE	;	1.554	;	KRAS mutant-A59G in GDP-bound
6ASA	;	2.545	;	KRAS mutant-D33E in GDP-bound
6MTA	;	2.15	;	KRAS P34R mutant structure in complex with GTP analogue
6GOG	;	2.05	;	KRAS-169 Q61H GPPNHP
6GQW	;	2.8	;	KRAS-169 Q61H GPPNHP + CH-1
6GQX	;	2.2	;	KRAS-169 Q61H GPPNHP + CH-2
6GQY	;	2.75	;	KRAS-169 Q61H GPPNHP + CH-3
6GOM	;	1.63	;	KRAS-169 Q61H GPPNHP + PPIN-1
6GQT	;	1.69	;	KRAS-169 Q61H GPPNHP + PPIN-2
8AZX	;	1.04	;	KRAS-G12C in complex with BI-2865
8QUG	;	1.56	;	KRAS-G12C in Complex with Compound 1
8AZY	;	1.09	;	KRAS-G12D in complex with BI-2865
7SU9	;	1.99	;	KRAS-G12D specific TCR9a in complex with C*05-GADGVGKSL
7XKJ	;	3.0	;	Kras-G12D-GDP-MRTX1133 by FIB-MicroED
8AZZ	;	1.02	;	KRAS-G12V in complex with BI-2865
8ONV	;	1.01	;	KRAS-G13D in complex with BI-2493
8B00	;	1.04	;	KRAS-G13D in complex with BI-2865
8UN4	;	1.57	;	KRAS-G13D-GDP in complex with Cpd36 ((E)-1-((3S)-4-(7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((S)-2-methylenetetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)-3-(4-((dimethylamino)methyl)-5-methylpyridin-2-yl)prop-2-en-1-one)
8UN5	;	1.31	;	KRAS-G13D-GDP in complex with Cpd38 ((E)-1-((3S)-4-(7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((S)-2-methylenetetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)-3-(1,2,3,4-tetrahydroisoquinolin-8-yl)prop-2-en-1-one)
8UN3	;	2.07	;	KRAS-G13D-GDP in complex with Cpd5 (1-((S)-10-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-11-chloro-7-(((2S,4R)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-3,4,13,13a-tetrahydropyrazino[2',1':3,4][1,4]oxazepino[5,6,7-de]quinazolin-2(1H)-yl)prop-2-en-1-one)
8EDY	;	1.18	;	KRAS4b A146T 1-185 bound to GDP
8EER	;	1.18	;	KRAS4B A146V 1-185 bound to GDP
8EIE	;	1.41	;	KRAS4b K117N 1-185 bound to GNP-Mg2+
8ECR	;	1.42	;	KRAS4b WT 1-185 bound to GDP-Mg2+
7A1X	;	1.32	;	KRASG12C GDP form in complex with Cpd1
7A1Y	;	2.004	;	KRASG12C GDP form in complex with Cpd2
7A1W	;	1.76	;	KRASG12C GDP form in complex with Cpd3
7A47	;	2.16	;	KRASG12C GDP form in complex with Cpd4
7R0N	;	1.2	;	KRasG12C in complex with GDP and compound 2
7R0Q	;	1.95	;	KRasG12C in complex with GDP and compound 3
7R0M	;	1.611	;	KRasG12C in complex with GDP and JDQ443
8X6R	;	1.85	;	KRasG12C in complex with inhibitor
6T5B	;	1.37	;	KRasG12C ligand complex
6T5U	;	1.72	;	KRasG12C ligand complex
6T5V	;	1.31	;	KRasG12C ligand complex
7O70	;	1.18	;	KRasG12C ligand complex
7O83	;	2.38	;	KRasG12C ligand complex
7OO7	;	1.48	;	KRasG12C ligand complex
8B6I	;	1.7	;	KRasG12C ligand complex
8B78	;	1.11	;	KRasG12C ligand complex
1B2I	;		;	KRINGLE 2 DOMAIN OF HUMAN PLASMINOGEN: NMR SOLUTION STRUCTURE OF TRANS-4-AMINOMETHYLCYCLOHEXANE-1-CARBOXYLIC ACID (AMCHA) COMPLEX
7TNG	;	1.4	;	Kringle domain of human Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1)
1PMK	;	2.25	;	KRINGLE-KRINGLE INTERACTIONS IN MULTIMER KRINGLE STRUCTURES
1PML	;	2.38	;	KRINGLE-KRINGLE INTERACTIONS IN MULTIMER KRINGLE STRUCTURES
8CL8	;	2.4	;	Krokinobacter eikastus rhodopsin 2 (KR2) extrapolated map 1us after light activation
8CL7	;	1.76	;	Krokinobacter eikastus rhodopsin 2 (KR2) in dark state
5D51	;	1.47	;	Krypton derivatization of an O2-tolerant membrane-bound [NiFe] hydrogenase reveals a hydrophobic gas tunnel network
7UK4	;	1.94	;	KS-AT di-domain of mycobacterial Pks13 with endogenous KS ligand bound
8EE0	;	2.65	;	KS-AT didomain from module 2 of the 6-deoxyerythronolide B synthase in complex with antibody fragment 1B2
8EE1	;	2.7	;	KS-AT didomain from module 2 of the 6-deoxyerythronolide B synthase in complex with antibody fragment AA5
8CUZ	;	3.0	;	KS-AT domains of mycobacterial Pks13 with inward AT conformation
8CV0	;	3.1	;	KS-AT domains of mycobacterial Pks13 with outward AT conformation
5MY2	;	2.7	;	KS-MAT DI-DOMAIN OF MOUSE FAS
5MY0	;	2.94	;	KS-MAT DI-DOMAIN OF MOUSE FAS WITH MALONYL-COA
6ROP	;	2.7	;	KS-MAT DI-DOMAIN OF MOUSE FAS WITH OCTANOYL COA
6IFS	;	2.27	;	KsgA from Bacillus subtilis 168
6IFT	;	1.9	;	KsgA from Bacillus subtilis in complex with SAM
4UZB	;	2.865	;	KSHV LANA (ORF73) C-terminal domain mutant bound to LBS1 DNA (R1039Q, R1040Q, K1055E, K1109A, D1110A, A1121E, K1138S, K1140D, K1141D)
2YPY	;	2.453	;	KSHV LANA (ORF73) C-terminal domain, decameric ring: monoclinic crystal form
2YPZ	;	3.199	;	KSHV LANA (ORF73) C-terminal domain, decameric ring: orthorhombic crystal form
2YQ0	;	3.911	;	KSHV LANA (ORF73) C-terminal domain, octameric ring: cubic crystal form
5A76	;	3.8	;	KSHV LANA (ORF73) C-terminal domain, open non-ring conformation: orthorhombic crystal form
4UZC	;	3.7	;	KSHV LANA (ORF73) C-terminal domain, spiral: hexagonal crystal form
6HAU	;	1.86	;	KSHV PAN RNA Mta-response element fragment complexed with the globular domain of herpesvirus saimiri ORF57
1FL1	;	2.2	;	KSHV PROTEASE
5HSW	;	3.3	;	KSHV SOX RNA complex
5NN7	;	2.5	;	KSHV uracil-DNA glycosylase, apo form
5NNH	;	2.2	;	KSHV uracil-DNA glycosylase, apo form
5NNU	;	2.97	;	KSHV uracil-DNA glycosylase, product complex with dsDNA exhibiting duplex nucleotide flipping
1OPY	;	1.9	;	KSI
7UWR	;	2.61	;	KSQ+AT from first module of the pikromycin synthase
2Y4I	;	3.46	;	KSR2-MEK1 heterodimer
5KKR	;	3.509	;	KSR2:MEK1 Complex Bound to the Small Molecule APS-2-79
5AQC	;	1.66	;	KstR, transcriptional repressor of cholesterol degradation in Mycobacterium tuberculosis, bound to the cholesterol coenzyme A derivative, (25R)-3-oxocholest-4-en-26-oyl-CoA.
5FMP	;	2.26	;	KstR, transcriptional repressor of cholesterol degradation in Mycobacterium tuberculosis, bound to the DNA operator
1LSU	;	2.85	;	KTN Bsu222 Crystal Structure in Complex with NADH
1LSS	;	2.3	;	KTN Mja218 CRYSTAL STRUCTURE IN COMPLEX WITH NAD+
8K1K	;	3.0	;	KtrA bound with ATP and sodium
8K16	;	3.1	;	KtrA bound with ATP and thallium
7ZP9	;	2.82	;	KtrAB complex - KtrA8 ring with a KtrB dimer on each side
7ZPR	;	3.56	;	KtrAB complex with N-terminal deletion of KtrB 1-19
4J7C	;	3.5	;	KtrAB potassium transporter from Bacillus subtilis
6I8V	;	1.991	;	KtrC with ATP bound
8ASC	;	2.95	;	Ku70/80 binds to the Ku-binding motif of PAXX
7AXZ	;	3.2	;	Ku70/80 complex apo form
6HIF	;	2.8	;	Kuenenia stuttgartiensis hydrazine dehydrogenase complex
5C2V	;	2.7	;	Kuenenia stuttgartiensis Hydrazine Synthase
5C2W	;	3.2	;	Kuenenia stuttgartiensis Hydrazine Synthase Pressurized with 20 bar Xenon
4N4J	;	1.8	;	Kuenenia stuttgartiensis hydroxylamine oxidoreductase
4RWM	;	1.8	;	Kuenenia stuttgartiensis hydroxylamine oxidoreductase cryoprotected with ethylene glycol
4N4L	;	1.9	;	Kuenenia stuttgartiensis hydroxylamine oxidoreductase soaked in hydrazine
4N4K	;	2.2	;	Kuenenia stuttgartiensis hydroxylamine oxidoreductase soaked in hydroxylamine
4N4M	;	2.1	;	Kuenenia stuttgartiensis hydroxylamine oxidoreductase soaked in phenyl hydrazine
6H5L	;	2.6	;	Kuenenia stuttgartiensis reducing HAO-like protein complex Kustc0457/Kustc0458
1SIU	;	2.31	;	KUMAMOLISIN-AS E78H MUTANT
1SN7	;	2.0	;	KUMAMOLISIN-AS, APOENZYME
8AJ7	;	1.6	;	Kunitz domain of Amblyomin-X
4AN7	;	2.23	;	Kunitz type trypsin inhibitor complex with porcine trypsin
4AN6	;	1.94	;	Kuntiz type trypsin inhibitor with factor Xa inhibitory activity
6R6M	;	1.7	;	Kusta0087/Kusta0088 Complex purified from Kuenenia stuttgartiensis
5MXY	;	1.9	;	KustC0563 c-type cytochrome
5MXZ	;	1.9	;	Kustc0563 Y40F mutant
4TM3	;	2.09	;	Kutzneria sp. 744 ornithine N-hydroxylase, KtzI-FADox-Br
4TLZ	;	2.411	;	Kutzneria sp. 744 ornithine N-hydroxylase, KtzI-FADox-NADP+-L-orn
4TM4	;	2.632	;	Kutzneria sp. 744 ornithine N-hydroxylase, KtzI-FADox-red-NADP+-Br
4TM1	;	2.39	;	Kutzneria sp. 744 ornithine N-hydroxylase, KtzI-FADred-NADP+-Br
4TLX	;	2.23	;	Kutzneria sp. 744 ornithine N-hydroxylase, KtzI-FADred-NADP+-L-orn
4TM0	;	2.74	;	Kutzneria sp. 744 ornithine N-hydroxylase, KtzI-FADred-ox-NADP+-L-orn
1DSX	;	1.6	;	KV1.2 T1 DOMAIN, RESIDUES 33-119, T46V MUTANT
6NK4	;	1.994	;	KVQIINKKL, crystal structure of a tau protein fragment
5V5B	;	1.5	;	KVQIINKKLD, Structure of the amyloid spine from microtubule associated protein tau Repeat 2
5WMJ	;	1.4	;	KVWGSI segment from Superoxide Dismutase 1,residues 30-35
3UE8	;	3.22	;	Kynurenine Aminotransferase II Inhibitors
4GDY	;	2.89	;	Kynurenine Aminotransferase II inhibitors
4GE4	;	2.41	;	Kynurenine Aminotransferase II Inhibitors
4GE7	;	2.1	;	Kynurenine Aminotransferase II Inhibitors
4GE9	;	2.43	;	Kynurenine Aminotransferase II Inhibitors
4GEB	;	2.15	;	Kynurenine Aminotransferase II Inhibitors
1E0P	;	2.1	;	L intermediate of bacteriorhodopsin
4LWY	;	2.903	;	L(M196)H,H(M202)L Double Mutant Structure of Photosynthetic Reaction Center From Rhodobacter Sphaeroides strain RV
4LZH	;	1.9	;	L,D-transpeptidase from Klebsiella pneumoniae
4XVO	;	2.6	;	L,D-transpeptidase from Mycobacterium smegmatis
3QGU	;	1.55	;	L,L-Diaminopimelate aminotransferase from Chlamydomonas reinhardtii
2YN4	;	1.74	;	L-2-chlorobutryic acid bound complex L-haloacid dehalogenase from a Rhodobacteraceae family bacterium
1JUD	;	2.5	;	L-2-HALOACID DEHALOGENASE
7ASZ	;	1.88	;	L-2-haloacid dehalogenase H190A mutant from Zobellia galactanivorans
1F14	;	2.3	;	L-3-HYDROXYACYL-COA DEHYDROGENASE (APO)
1F12	;	2.4	;	L-3-HYDROXYACYL-COA DEHYDROGENASE COMPLEXED WITH 3-HYDROXYBUTYRYL-COA
1F0Y	;	1.8	;	L-3-HYDROXYACYL-COA DEHYDROGENASE COMPLEXED WITH ACETOACETYL-COA AND NAD+
1F17	;	2.3	;	L-3-HYDROXYACYL-COA DEHYDROGENASE COMPLEXED WITH NADH
1JPD	;	2.6	;	L-Ala-D/L-Glu Epimerase
1JPM	;	2.25	;	L-Ala-D/L-Glu Epimerase
1PJB	;	2.1	;	L-ALANINE DEHYDROGENASE
1PJC	;	2.0	;	L-ALANINE DEHYDROGENASE COMPLEXED WITH NAD
1SAY	;	2.1	;	L-ALANINE DEHYDROGENASE COMPLEXED WITH PYRUVATE
5HXW	;	2.63	;	L-amino acid deaminase from Proteus vulgaris
1TDO	;	3.0	;	L-amino acid oxidae from Agkistrodon halys in complex with L-phenylalanine
1TDN	;	2.7	;	L-amino acid oxidase from Agkistrodon halys in complex with L-leucine
1TDK	;	2.7	;	L-amino acid oxidase from Agkistrodon halys in complex with suicide substrate L-vinylglycine
1REO	;	2.31	;	L-amino acid oxidase from Agkistrodon halys pallas
3WE0	;	1.9	;	L-Amino acid oxidase/monooxygenase from Pseudomonas sp. AIU 813
5YB8	;	2.3	;	L-Amino acid oxidase/monooxygenase from Pseudomonas sp. AIU 813 - L-arginine complex
5YB6	;	2.1	;	L-Amino acid oxidase/monooxygenase from Pseudomonas sp. AIU 813 - L-lysine complex
5YB7	;	2.0	;	L-Amino acid oxidase/monooxygenase from Pseudomonas sp. AIU 813 - L-ornithine complex
4CNJ	;	2.7	;	L-Aminoacetone oxidase from Streptococcus oligofermentans belongs to a new 3-domain family of bacterial flavoproteins
4CNK	;	2.0	;	L-Aminoacetone oxidase from Streptococcus oligofermentans belongs to a new 3-domain family of bacterial flavoproteins
3M6I	;	2.6	;	L-arabinitol 4-dehydrogenase
1ZCF	;	3.0	;	L-asparaginase from Erwinia carotovora
2GVN	;	1.9	;	L-asparaginase from Erwinia carotovora in complex with aspartic acid
2HLN	;	2.2	;	L-asparaginase from Erwinia carotovora in complex with glutamic acid
6V5F	;	2.1	;	L-asparaginase from Escherichia coli
7M11	;	1.83	;	L-asparaginase from Escherichia coli with bound Aspartic acid
1NNS	;	1.95	;	L-asparaginase of E. coli in C2 space group and 1.95 A resolution
1KNR	;	2.5	;	L-aspartate oxidase: R386L mutant
1AEW	;	1.95	;	L-CHAIN HORSE APOFERRITIN
5WT4	;	2.92	;	L-Cysteine-PLP intermediate of NifS from Helicobacter pylori
5ZSS	;	3.17	;	L-Cysteine-PLP reaction intermediate of NifS from Hydrogenimonas thermophila
7KW4	;	1.03	;	L-DNA containing 2'-fluoro modification
6Z3D	;	1.7	;	L-FerritinMSA
2J3G	;	2.5	;	L-ficolin
2J0H	;	2.85	;	L-ficolin complexed to acetyl-choline
2J0Y	;	2.35	;	L-ficolin complexed to b-1,3-D-glucan
2J3U	;	2.15	;	L-ficolin complexed to galactose
4R9J	;	2.1	;	L-ficolin complexed to glucosamine-6-sulfate
2J1G	;	1.95	;	L-ficolin complexed to N-acetyl-cystein
2J2P	;	2.8	;	L-ficolin complexed to N-acetyl-cystein (150mM)
2J3F	;	2.8	;	L-ficolin complexed to N-acetyl-D-galactosamine
2J3O	;	2.65	;	L-ficolin complexed to N-acetyl-D-glucosamine
2J0G	;	2.85	;	L-ficolin complexed to N-acetyl-mannosamine
2J61	;	2.7	;	L-ficolin complexed to N-acetylglucosamine (forme C)
4NYT	;	2.25	;	L-Ficolin Complexed to Phosphocholine
4R9T	;	2.25	;	L-ficolin complexed to sulphates
4C20	;	2.41	;	L-Fucose Isomerase
1FUI	;	2.5	;	L-FUCOSE ISOMERASE FROM ESCHERICHIA COLI
4C21	;	2.55	;	L-Fucose Isomerase In Complex With Fucitol
4C22	;	2.7	;	L-Fucose Isomerase In Complex With Fuculose
4C24	;	1.5	;	L-fuculose 1-phosphate aldolase
4C25	;	2.03	;	L-fuculose 1-phosphate aldolase
7X78	;	1.85	;	L-fuculose 1-phosphate aldolase
1FUA	;	1.92	;	L-FUCULOSE 1-PHOSPHATE ALDOLASE CRYSTAL FORM T
2FUA	;	2.0	;	L-FUCULOSE 1-PHOSPHATE ALDOLASE CRYSTAL FORM T WITH COBALT
1E4A	;	2.15	;	L-Fuculose 1-Phosphate Aldolase from Escherichia coli Mutant Del(27)
1E47	;	2.15	;	L-Fuculose 1-Phosphate Aldolase from Escherichia coli Mutant E73Q
1E48	;	1.97	;	L-Fuculose 1-Phosphate Aldolase from Escherichia coli Mutant E73Q/Y113F/Y209F
1E46	;	2.55	;	L-Fuculose 1-Phosphate Aldolase from Escherichia coli Mutant E73S
1E49	;	2.53	;	L-Fuculose 1-Phosphate Aldolase from Escherichia coli Mutant N29L/S71A
1E4B	;	1.84	;	L-Fuculose 1-Phosphate Aldolase from Escherichia coli Mutant N29Q
1E4C	;	1.66	;	L-Fuculose 1-Phosphate Aldolase from Escherichia coli Mutant S71Q
4XXF	;	1.34	;	L-fuculose 1-phosphate aldolase from Glaciozyma antarctica PI12
4C23	;	2.0	;	L-fuculose kinase
4FUA	;	2.43	;	L-FUCULOSE-1-PHOSPHATE ALDOLASE COMPLEX WITH PGH
3FUA	;	2.67	;	L-FUCULOSE-1-PHOSPHATE ALDOLASE CRYSTAL FORM K
1DZY	;	2.44	;	L-Fuculose-1-Phosphate Aldolase from Escherichia coli Mutant E214A
1DZW	;	2.17	;	L-Fuculose-1-Phosphate Aldolase from Escherichia coli Mutant F131A
1DZX	;	2.18	;	L-Fuculose-1-Phosphate Aldolase from Escherichia coli Mutant R212A
1DZU	;	2.09	;	L-Fuculose-1-Phosphate Aldolase from Escherichia coli Mutant T26A
1DZZ	;	1.92	;	L-Fuculose-1-Phosphate Aldolase from Escherichia coli Mutant Y113F
1DZV	;	1.86	;	L-Fuculose-1-Phosphate Aldolase from Escherichia coli Mutant Y113F/Y209F
1V9L	;	2.8	;	L-glutamate dehydrogenase from Pyrobaculum islandicum complexed with NAD
7ULF	;	1.61	;	l-glutamate/GTP complex of F420-gamma glutamyl ligase (CofE) from Archaeoglobus fulgidus
5DDP	;	2.302	;	L-glutamine riboswitch bound with L-glutamine
5DDR	;	2.605	;	L-glutamine riboswitch bound with L-glutamine soaked with Cs+
5DDQ	;	2.4	;	L-glutamine riboswitch bound with L-glutamine soaked with Mn2+
6EEX	;	1.1	;	L-GSTSTA from degenerate octameric repeats in InaZ, residues 707-712
6M9I	;	0.9	;	L-GSTSTA from degenerate octameric repeats in InaZ, residues 707-712
1KAR	;	2.1	;	L-HISTIDINOL DEHYDROGENASE (HISD) STRUCTURE COMPLEXED WITH HISTAMINE (INHIBITOR), ZINC AND NAD (COFACTOR)
1KAH	;	2.1	;	L-HISTIDINOL DEHYDROGENASE (HISD) STRUCTURE COMPLEXED WITH L-HISTIDINE (PRODUCT), ZN AND NAD (COFACTOR)
1KAE	;	1.7	;	L-HISTIDINOL DEHYDROGENASE (HISD) STRUCTURE COMPLEXED WITH L-HISTIDINOL (SUBSTRATE), ZINC AND NAD (COFACTOR)
5WT5	;	1.9	;	L-homocysteine-bound NifS from Helicobacter pylori
1GKR	;	2.6	;	L-Hydantoinase (Dihydropyrimidinase) from Arthrobacter aurescens
3LCX	;	1.98	;	L-KDO aldolase
3LCW	;	2.35	;	L-KDO aldolase complexed with hydroxypyruvate
1Y6J	;	3.01	;	L-Lactate Dehydrogenase from Clostridium Thermocellum Cth-1135
5KKC	;	1.859	;	l-lactate dehydrogenase from rabbit muscle with the inhibitor 6DHNAD
3VPG	;	1.8	;	L-lactate dehydrogenase from Thermus caldophilus GK24
3VPH	;	2.0	;	L-lactate dehydrogenase from Thermus caldophilus GK24 complexed with oxamate, NADH and FBP
7F21	;	1.38	;	L-lactate oxidase with D-lactate
7F20	;	1.3	;	L-lactate oxidase with L-lactate
7F22	;	1.41	;	L-lactate oxidase with pyruvate
7F1Y	;	1.33	;	L-lactate oxidase without substrate
8GXD	;	3.02	;	L-LEUCINE DEHYDROGENASE FROM EXIGUOBACTERIUM SIBIRICUM
1USK	;	2.0	;	L-leucine-binding protein with leucine bound
1USI	;	1.8	;	L-leucine-binding protein with phenylalanine bound
1USG	;	1.53	;	L-leucine-binding protein, apo form
6OVG	;	2.719	;	L-Methionine Depletion with an Engineered Human Enzyme Disrupts Prostate Cancer Metabolism
4P7Y	;	1.96	;	L-methionine gamma-lyase from Citrobacter freundii with Y58F substitution
3QVW	;	2.0	;	L-myo-inositol 1-phosphate synthase from Archaeoglobus fulgidus mutant K278A
3QVX	;	1.9	;	L-myo-inositol 1-phosphate synthase from Archaeoglobus fulgidus mutant K367A
3QVS	;	1.7	;	L-myo-inositol 1-phosphate synthase from Archaeoglobus fulgidus wild type
3QVT	;	2.0	;	L-myo-inositol 1-phosphate synthase from Archaeoglobus fulgidus wild-type with the intermediate 5-keto 1-phospho glucose
3QW2	;	2.59	;	L-myo-inositol 1-phosphate synthase from Archaeoglobus mutant N255A
1C1X	;	1.4	;	L-PHENYLALANINE DEHYDROGENASE STRUCTURE IN TERNARY COMPLEX WITH NAD+ AND L-3-PHENYLLACTATE
1C1D	;	1.25	;	L-PHENYLALANINE DEHYDROGENASE STRUCTURE IN TERNARY COMPLEX WITH NADH AND L-PHENYLALANINE
7LSO	;		;	L-Phenylseptin
4P7X	;	1.3	;	L-pipecolic acid-bound L-proline cis-4-hydroxylase
4P7W	;	1.8	;	L-proline-bound L-proline cis-4-hydroxylase
1D8W	;	1.6	;	L-RHAMNOSE ISOMERASE
1DE5	;	2.2	;	L-RHAMNOSE ISOMERASE
1DE6	;	2.1	;	L-RHAMNOSE ISOMERASE
1GT7	;	2.7	;	L-rhamnulose-1-phosphate aldolase from Escherichia coli
2V9M	;	1.3	;	L-RHAMNULOSE-1-PHOSPHATE ALDOLASE FROM ESCHERICHIA COLI (MUTANT A87M- T109F-E192A)
2V9O	;	1.95	;	L-RHAMNULOSE-1-PHOSPHATE ALDOLASE FROM ESCHERICHIA COLI (MUTANT A87M- T109F-E192A)
2UYU	;	1.96	;	L-RHAMNULOSE-1-PHOSPHATE ALDOLASE FROM ESCHERICHIA COLI (MUTANT A88F- E192A)
2V9N	;	1.4	;	L-RHAMNULOSE-1-PHOSPHATE ALDOLASE FROM ESCHERICHIA COLI (MUTANT A88F- E192A)
2V2B	;	1.5	;	L-RHAMNULOSE-1-PHOSPHATE ALDOLASE FROM ESCHERICHIA COLI (MUTANT E117S- E192A-K248G-R253A-E254A)
1OJR	;	1.35	;	L-rhamnulose-1-phosphate aldolase from Escherichia coli (mutant E192A)
2V2A	;	1.75	;	L-RHAMNULOSE-1-PHOSPHATE ALDOLASE FROM ESCHERICHIA COLI (MUTANT E192A- K248G-R253A-E254A)
2V9E	;	1.58	;	L-RHAMNULOSE-1-PHOSPHATE ALDOLASE FROM ESCHERICHIA COLI (MUTANT E192A- K248W-A273S)
2V9F	;	2.1	;	L-RHAMNULOSE-1-PHOSPHATE ALDOLASE FROM ESCHERICHIA COLI (MUTANT E192A- K248W-A273S)
2V9I	;	1.8	;	L-RHAMNULOSE-1-PHOSPHATE ALDOLASE FROM ESCHERICHIA COLI (MUTANT E192A- K248W-L274stop)
2V29	;	2.0	;	L-RHAMNULOSE-1-PHOSPHATE ALDOLASE FROM ESCHERICHIA COLI (MUTANT K15W)
2UYV	;	2.2	;	L-RHAMNULOSE-1-PHOSPHATE ALDOLASE FROM ESCHERICHIA COLI (MUTANT Q6Y- E192A)
2V9L	;	1.23	;	L-RHAMNULOSE-1-PHOSPHATE ALDOLASE FROM ESCHERICHIA COLI (MUTANT Q6Y- E192A)
2V9G	;	2.7	;	L-RHAMNULOSE-1-PHOSPHATE ALDOLASE FROM ESCHERICHIA COLI (MUTANT Q6Y- L84W-E192A)
3CFW	;	2.2	;	L-selectin lectin and EGF domains
8GIL	;	2.1	;	L-threonine 3-Dehydrogenase from Trypanosoma cruzi (apo form)
8GJB	;	1.75	;	L-threonine 3-Dehydrogenase from Trypanosoma cruzi in complex with NAD and acetate
3GFB	;	2.4	;	L-Threonine Dehydrogenase (TkTDH) from the hyperthermophilic archaeon Thermococcus kodakaraensis
5LC1	;	2.1	;	L-threonine dehydrogenase from Trypanosoma brucei with NAD and the inhibitor pyruvate bound.
5L9A	;	1.45	;	L-threonine dehydrogenase from trypanosoma brucei.
3BWN	;	2.25	;	L-tryptophan aminotransferase
3BWO	;	2.4	;	L-tryptophan aminotransferase
7MOO	;	1.35	;	L-type DNA containing 2'-fluoro-2'-deoxycytidine
3A5X	;	4.0	;	L-type straight flagellar filament made of full-length flagellin
6RSP	;	1.91	;	L-[Ru(phen)2(11-NO2-dppz)]2+ bound to the Oligonucleotide sequence d(TCGGCGCCGA)
6RNL	;	1.88	;	L-[Ru(TAP)2(dppz)]2+ bound to the G-quadruplex forming sequence d(TAGGGTT)
1VZB	;	2.5	;	L. CASEI THYMIDYLATE SYNTHASE MUTANT E60Q BINARY COMPLEX WITH DUMP
1VZC	;	2.5	;	L. CASEI THYMIDYLATE SYNTHASE MUTANT E60Q BINARY COMPLEX WITH FDUMP
1VZE	;	2.3	;	L. CASEI THYMIDYLATE SYNTHASE MUTANT E60Q TERNARY COMPLEX WITH DUMP AND CB3717
1VZD	;	2.5	;	L. CASEI THYMIDYLATE SYNTHASE MUTANT E60Q TERNARY COMPLEX WITH FDUMP AND CB3717
1TSL	;	2.5	;	L. CASEI THYMIDYLATE SYNTHASE WITH SPECIES SPECIFIC INHIBITOR
1TSM	;	3.0	;	L. CASEI THYMIDYLATE SYNTHASE WITH SPECIES SPECIFIC INHIBITOR
2G89	;	2.5	;	L. casei thymidylate synthase Y261A in complex with substrate, dUMP
2G86	;	2.4	;	L. casei thymidylate synthase Y261F in complex with substrate, dUMP
7TFE	;	2.85	;	L. monocytogenes GS(12) - apo
7TF9	;	2.61	;	L. monocytogenes GS(14)-Q-GlnR peptide
6MCP	;	2.5	;	L. pneumophila effector kinase LegK7 (AMP-PNP bound) in complex with human MOB1A
6MCQ	;	2.57	;	L. pneumophila effector kinase LegK7 in complex with human MOB1A
7OVB	;	3.61	;	L. pneumophila Type IV Coupling Complex (T4CC) with density for DotY N-terminal and middle domains
5NXK	;	1.918	;	L. reuteri 53608 SRRP
5NY0	;	2.0	;	L. reuters 100-23 SRRP
1KKL	;	2.8	;	L.casei HprK/P in complex with B.subtilis HPr
1KKM	;	2.8	;	L.casei HprK/P in complex with B.subtilis P-Ser-HPr
7AFZ	;	1.5	;	L1 metallo-b-lactamase with compound EBL-1306
7ZO2	;	1.49	;	L1 metallo-beta-lactamase complex with hydrolysed doripenem
7ZO5	;	1.43	;	L1 metallo-beta-lactamase in complex with a mecillinam degradation product
7ZO7	;	1.63	;	L1 metallo-beta-lactamase in complex with hydrolysed cefmetazole
7ZO6	;	1.61	;	L1 metallo-beta-lactamase in complex with hydrolysed cefoxitin
7ZO4	;	1.43	;	L1 metallo-beta-lactamase in complex with hydrolysed panipenem
7ZO3	;	1.43	;	L1 metallo-beta-lactamase in complex with hydrolysed tebipenem
1DZL	;	3.5	;	L1 protein of human papillomavirus 16
6L31	;	4.18	;	L1 protein of human papillomavirus 6
2OIU	;	2.6	;	L1 Ribozyme Ligase circular adduct
2JAG	;	1.93	;	L1-intermediate of halorhodopsin T203V
1ACI	;		;	L11 RIBOSOMAL PROTEIN RNA BINDING DOMAIN, NMR, 20 STRUCTURES
2E34	;		;	L11 structure with RDC and RG refinement
2E36	;		;	L11 with SANS refinement
1EVW	;	3.1	;	L116A MUTANT OF THE HOMING ENDONUCLEASE I-PPOI COMPLEXED TO HOMING SITE DNA.
1WLK	;	1.9	;	L122E mutant of FMN-binding protein from Desulfovibrio vulgaris (Miyazaki F)
3A20	;	1.6	;	L122K mutant of FMN-binding protein from Desulfovibrio vulgaris (Miyazaki F)
1WLI	;	1.6	;	L122Y mutant of FMN-binding protein from Desulfovibrio vulgaris (Miyazaki F)
5JT4	;	1.25	;	L16A mutant of cytochrome c prime from Alcaligenes xylosoxidans: Ferrous state
5JVE	;	1.12	;	L16I mutant of cytochrome c prime from Alcaligenes xylosoxidans: Ferrous state
7AH1	;	2.0	;	L19 diabody fragment from immunocytokine L19-IL2
5NE2	;	1.19	;	L2 class A serine-beta-lactamase
5NE3	;	1.35	;	L2 class A serine-beta-lactamase complexed with avibactam
5NE1	;	2.09	;	L2 class A serine-beta-lactamase in complex with cyclic boronate 2
2DAB	;	2.0	;	L201A MUTANT OF D-AMINO ACID AMINOTRANSFERASE COMPLEXED WITH PYRIDOXAL-5'-PHOSPHATE
1A0G	;	2.0	;	L201A MUTANT OF D-AMINO ACID AMINOTRANSFERASE COMPLEXED WITH PYRIDOXAMINE-5'-PHOSPHATE
8QVO	;	1.96	;	L211Q, L254N, T262G mutant of carboxypeptidase T from Thermoactinomyces vulgaris
1SZE	;	3.0	;	L230A mutant flavocytochrome b2 with benzoylformate
2H7S	;	2.15	;	L244A mutant of Cytochrome P450cam
2H7R	;	2.1	;	L244A mutant of Cytochrome P450cam complexed with imidazole
7ARU	;	2.05	;	L254N mutant of carboxypeptidase T from Thermoactinomyces vulgaris N-sulfamoyl-L-valine
5W3Q	;	1.401	;	L28F E.coli DHFR in complex with NADPH
5CC9	;	1.199	;	L28F E.coli dihydrofolate reductase complexed with 5,10-dideazatetrahydrofolate and oxidized nicotinamide adenine dinucleotide phosphate
1UWA	;	2.3	;	L290F mutant rubisco from chlamydomonas
1UW9	;	2.05	;	L290F-A222T chlamydomonas Rubisco mutant
3T4U	;	2.02	;	L29I Mutation in an Aryl Esterase from Pseudomonas fluorescens Leads to Unique Peptide Flip and Increased Activity
3T52	;	2.0	;	L29I Mutation in an Aryl Esterase from Pseudomonas fluorescens Leads to Unique Peptide Flip and Increased Activity
2BLI	;	1.7	;	L29W Mb deoxy
4Z7V	;	2.65	;	L3-12 complex
2WZ0	;	1.72	;	L38V SOD1 mutant complexed with aniline.
2WZ5	;	1.5	;	L38V SOD1 mutant complexed with L-methionine.
2WYZ	;	1.7	;	L38V SOD1 mutant complexed with UMP
4YEP	;	1.19	;	L4b Domain of Human Laminin alpha-2
4YEQ	;	3.2	;	L4b Domain of Human Laminin alpha-2
4JCE	;	1.9	;	L54F Variant of JC Polyomavirus Major Capsid Protein VP1
3DKH	;	2.4	;	L559A mutant of Melanocarpus albomyces laccase
7VU8	;	3.0	;	L7-Tir domain with bound ligand
4LXW	;	2.092	;	L72V Epi-isozizaene synthase: Complex with Mg, inorganic pyrophosphate and benzyl triethyl ammonium cation
7QSV	;	2.1	;	L8-complex forming RubisCO derived from ancestral sequence reconstruction of the last common ancestor of Form I'' and Form I RubisCOs
6D45	;	1.779	;	L89S Mutant of FeBMb Sperm Whale Myoglobin
1MP3	;	2.2	;	L89T VARIANT OF S. ENTERICA RmlA
2YGF	;	2.0	;	L89V, L93I and V136M Mutant of N-Term HSP90 complexed with Geldanamycin
7QSW	;	1.8	;	L8S8-complex forming RubisCO derived from ancestral sequence reconstruction of the last common ancestor of SSU-bearing Form I RubisCOs
1QUO	;	1.9	;	L99A/E108V MUTANT OF T4 LYSOZYME
1QUD	;	1.75	;	L99G MUTANT OF T4 LYSOZYME
1QUH	;	1.85	;	L99G/E108V MUTANT OF T4 LYSOZYME
1S29	;	1.6	;	La autoantigen N-terminal domain
7A57	;	3.155	;	La Crosse Virus Envelope Glycoprotein Gc W1066H Mutant Fusion Domains in Postfusion Conformation
6H3W	;	2.098	;	La Crosse Virus Glycoprotein Gc Head Domain
6Z8K	;	3.02	;	La Crosse virus polymerase at elongation mimicking stage
7ORO	;	2.9	;	La Crosse virus polymerase at replication early-elongation stage
7ORN	;	2.8	;	La Crosse virus polymerase at replication initiation stage
7ORI	;	3.9	;	La Crosse virus polymerase at replication late-elongation stage
7ORJ	;	3.9	;	La Crosse virus polymerase at transcription capped RNA cleavage stage
7ORM	;	3.3	;	La Crosse virus polymerase at transcription early-elongation stage
7ORL	;	3.6	;	La Crosse virus polymerase at transcription initiation stage
7ORK	;	3.1	;	La Crosse virus polymerase in transcription mode with cleaved capped RNA entering the polymerase active site
4UHB	;	1.8	;	Laboratory evolved variant R-C1 of potato epoxide hydrolase StEH1
4UFN	;	2.0	;	Laboratory evolved variant R-C1B1 of potato epoxide hydrolase StEH1
4UFP	;	2.95	;	Laboratory evolved variant R-C1B1D33 of potato epoxide hydrolase StEH1
4UFO	;	2.02	;	Laboratory evolved variant R-C1B1D33E6 of potato epoxide hydrolase StEH1
7TDS	;	2.2	;	Labrum-interacting protein from saliva LIPS-2 (34K-2) from Aedes albopictus, native data
7TDR	;	2.28	;	Labrum-interacting protein from saliva LIPS-2 (34K-2) from Aedes albopictus, selenomethionine derivative
1LBI	;	2.7	;	LAC REPRESSOR
4RZT	;	3.1	;	Lac repressor engineered to bind sucralose, sucralose-bound tetramer
4RZS	;	2.71	;	Lac repressor engineered to bind sucralose, unliganded tetramer
1LQC	;		;	LAC REPRESSOR HEADPIECE (RESIDUES 1-56), NMR, 32 STRUCTURES
5EHF	;	1.75	;	Laccase from Antrodiella faginea
3CG8	;	2.679	;	Laccase from Streptomyces coelicolor
1K6C	;	2.2	;	LACK OF SYNERGY FOR INHIBITORS TARGETING A MULTI-DRUG RESISTANT HIV-1 PROTEASE
1K6P	;	2.2	;	LACK OF SYNERGY FOR INHIBITORS TARGETING A MULTI-DRUG RESISTANT HIV-1 PROTEASE
1K6T	;	2.25	;	LACK OF SYNERGY FOR INHIBITORS TARGETING A MULTI-DRUG RESISTANT HIV-1 PROTEASE
1K6V	;	2.0	;	LACK OF SYNERGY FOR INHIBITORS TARGETING A MULTI-DRUG RESISTANT HIV-1 PROTEASE
2TGD	;	2.1	;	LACK OF THE TRANSITION STATE STABILIZATION SITE IS A FACTOR IN THE INACTIVITY OF TRYPSINOGEN, A SERINE PROTEASE ZYMOGEN. STRUCTURE OF DFP INHIBITED BOVINE TRYPSINOGEN AT 2.1 ANGSTROMS RESOLUTION
2BI4	;	2.85	;	Lactaldehyde:1,2-propanediol oxidoreductase of Escherichia coli
2BL4	;	2.85	;	Lactaldehyde:1,2-propanediol oxidoreductase of Escherichia coli
6CIV	;		;	Lactam cyclised mimetic of a fragment of p21
6CIX	;		;	Lactam cyclised mimetic of a fragment of p21
4M49	;	2.052	;	Lactate Dehydrogenase A in complex with a substituted pyrazine inhibitor compound 18
4ZVV	;	2.2	;	Lactate dehydrogenase A in complex with a trisubstituted piperidine-2,4-dione inhibitor GNE-140
4JNK	;	1.896	;	Lactate Dehydrogenase A in complex with inhibitor compound 22
4QO8	;	2.001	;	Lactate Dehydrogenase A in complex with substituted 3-Hydroxy-2-mercaptocyclohex-2-enone compound 104
4QO7	;	2.14	;	Lactate Dehydrogenase A in complex with substituted 3-Hydroxy-2-mercaptocyclohex-2-enone compound 7
1OC4	;	2.3	;	Lactate dehydrogenase from Plasmodium berghei
1A5Z	;	2.1	;	LACTATE DEHYDROGENASE FROM THERMOTOGA MARITIMA (TMLDH)
5IXY	;	3.0	;	Lactate Dehydrogenase in complex with hydroxylactam inhibitor compound 31: (2~{S})-5-(2-chlorophenyl)sulfanyl-2-(4-morpholin-4-ylphenyl)-4-oxidanyl-2-thiophen-3-yl-1,3-dihydropyridin-6-one
5IXS	;	2.05	;	Lactate Dehydrogenase in complex with hydroxylactam inhibitor compound 9: (6R)-3-[(2-chlorophenyl)sulfanyl]-4-hydroxy-6-(3-hydroxyphenyl)-6-(thiophen-3-yl)-5,6-dihydropyridin-2(1H)-one
6BAD	;	2.1	;	Lactate Dehydrogenase in complex with inhibitor (R)-3-((2-chlorophenyl)thio)-6-(3-((4-fluorophenyl)amino)phenyl)-4-hydroxy-6-(thiophen-3-yl)-5,6-dihydro-2H-pyran-2-one
6BB0	;	1.95	;	Lactate Dehydrogenase in complex with inhibitor (R)-3-((2-chlorophenyl)thio)-6-(3-((4-fluorophenyl)amino)phenyl)-4-hydroxy-6-(thiophen-3-yl)-5,6-dihydro-2H-pyran-2-one
6BAG	;	2.4	;	Lactate Dehydrogenase in complex with inhibitor (R)-5-((2-chlorophenyl)thio)-6'-((4-fluorophenyl)amino)-4-hydroxy-2-(thiophen-3-yl)-2,3-dihydro-[2,2'-bipyridin]-6(1H)-one
6BB1	;	2.3	;	Lactate Dehydrogenase in complex with inhibitor (R)-5-((2-chlorophenyl)thio)-6'-(4-fluorophenoxy)-4-hydroxy-2-(thiophen-3-yl)-2,3-dihydro-[2,2'-bipyridin]-6(1H)-one
6BAZ	;	2.7	;	Lactate Dehydrogenase in complex with inhibitor (S)-5-((2-chlorophenyl)thio)-6'-((4-fluorophenyl)amino)-4-hydroxy-2-(thiophen-3-yl)-2,3-dihydro-[2,2'-bipyridin]-6(1H)-one
6BB2	;	2.47	;	Lactate Dehydrogenase in complex with inhibitor (S)-5-((2-chlorophenyl)thio)-6'-(4-fluorophenoxy)-4-hydroxy-2-(thiophen-3-yl)-2,3-dihydro-[2,2'-bipyridin]-6(1H)-one
6BB3	;	2.4	;	Lactate Dehydrogenase in complex with inhibitor 3-((2-chlorophenyl)thio)-6-(6-((4-fluorophenyl)amino)pyridin-2-yl)-4-hydroxy-6-(thiophen-3-yl)-5,6-dihydro-2H-pyran-2-one
6BAX	;	2.05	;	Lactate Dehydrogenase in complex with inhibitor 6-(3-aminophenyl)-3-((2-chlorophenyl)thio)-4-hydroxy-6-(thiophen-3-yl)-5,6-dihydro-2H-pyran-2-one
4R69	;	3.19	;	Lactate Dehydrogenase in complex with inhibitor compound 13
4R68	;	2.112	;	Lactate Dehydrogenase in complex with inhibitor compound 31
4RLS	;	1.91	;	Lactate Dehydrogenase in complex with inhibitor compound 47
5ZJD	;	2.394	;	Lactate dehydrogenase with NADH and MLA
6DVH	;	1.7	;	Lactate Monooxygenase from Mycobacterium smegmatis - C203A mutant
8H25	;	2.295	;	Lacticaseibacillus casei GH35 beta-galactosidase LBCZ_0230
4H04	;	1.8	;	Lacto-N-biosidase from Bifidobacterium bifidum
5GP4	;	2.16	;	Lactobacillus brevis CGMCC 1306 Glutamate decarboxylase
1JB1	;	2.8	;	Lactobacillus casei HprK/P Bound to Phosphate
3IK1	;	2.25	;	Lactobacillus casei Thymidylate Synthase in Ternary Complex with dUMP and the Phtalimidic Derivative 20C
3IK0	;	2.1	;	Lactobacillus casei Thymidylate Synthase in Ternary Complex with dUMP and the Phtalimidic Derivative 7C1
1LCB	;	2.5	;	LACTOBACILLUS CASEI THYMIDYLATE SYNTHASE TERNARY COMPLEX WITH DTMP AND H2FOLATE
1LCA	;	2.5	;	LACTOBACILLUS CASEI THYMIDYLATE SYNTHASE TERNARY COMPLEX WITH DUMP AND CB3717
1LCE	;	2.5	;	LACTOBACILLUS CASEI THYMIDYLATE SYNTHASE TERNARY COMPLEX WITH DUMP AND CH2THF
3IJZ	;	2.21	;	Lactobacillus casei Thymidylate Synthase ternary complex with dUMP and Pthalimidic derivative 15C
3C06	;	2.6	;	Lactobacillus CASEI Thymidylate Synthase Ternary Complex With DUMP and the Phtalimidic Derivative 14C in Multiple Binding Modes-Mode 1
3C0A	;	2.4	;	Lactobacillus CASEI Thymidylate Synthase Ternary Complex with DUMP and the Phtalimidic Derivative 14C in Multiple Binding Modes-Mode 2
3BZ0	;	2.7	;	Lactobacillus Casei Thymidylate Synthase Ternary Complex with DUMP and the Phtalimidic Derivative C00
3BYX	;	2.4	;	Lactobacillus CASEI Thymidylate Synthase Ternary Complex with DUMP and the Phtalimidic Derivative C00 in Multiple Binding Modes
2G8D	;	2.4	;	Lactobacillus casei thymidylate synthase Y261W-dUMP complex
2G8A	;	2.4	;	Lactobacillus casei Y261M in complex with substrate, dUMP
8PO5	;	2.1	;	Lactobacillus plantarum LpdD
4AYG	;	2.0	;	Lactobacillus reuteri N-terminally truncated glucansucrase GTF180 in orthorhombic apo-form
3HZ3	;	2.22	;	Lactobacillus reuteri N-terminally truncated glucansucrase GTF180(D1025N)-sucrose complex
6ECA	;	2.853	;	Lactobacillus rhamnosus Beta-glucuronidase
3DRF	;	1.3	;	Lactococcal OppA complexed with an endogenous peptide in the closed conformation
3DRG	;	2.5	;	Lactococcal OppA complexed with bradykinin in the closed conformation
3RYA	;	2.9	;	Lactococcal OppA complexed with SLSQLSSQS
3RYB	;	1.5	;	Lactococcal OppA complexed with SLSQSLSQS
2LGN	;		;	Lactococcin 972
5LFI	;		;	lactococcin A immunity protein
2JPJ	;		;	Lactococcin G-a in DPC
2JPL	;		;	Lactococcin G-a in TFE
2JPK	;		;	Lactococcin G-b in DPC
2JPM	;		;	Lactococcin G-b in TFE
4Y1J	;	2.24	;	Lactococcus lactis yybP-ykoY Mn riboswitch A41U binding site mutant in presence of Mn2+
4Y1I	;	2.85	;	Lactococcus lactis yybP-ykoY Mn riboswitch bound to Mn2+
4KTZ	;	1.9	;	Lactococcus phage 67 RuvC
4KTW	;	1.68	;	Lactococcus phage 67 RuvC - apo form
1IS3	;	1.45	;	LACTOSE AND MES-LIGANDED CONGERIN II
1LTT	;	2.3	;	LACTOSE BINDING TO HEAT-LABILE ENTEROTOXIN REVEALED BY X-RAY CRYSTALLOGRAPHY
1LBG	;	4.8	;	LACTOSE OPERON REPRESSOR BOUND TO 21-BASE PAIR SYMMETRIC OPERATOR DNA, ALPHA CARBONS ONLY
6VBG	;	2.8	;	Lactose permease complex with thiodigalactoside and nanobody 9043
3S4D	;	3.3	;	Lactose phosphorylase in a ternary complex with cellobiose and sulfate
3S4C	;	2.4	;	Lactose phosphorylase in complex with sulfate
1C1L	;	1.5	;	LACTOSE-LIGANDED CONGERIN I
1IS4	;	1.9	;	LACTOSE-LIGANDED CONGERIN II
1G9Z	;	1.8	;	LAGLIDADG HOMING ENDONUCLEASE I-CREI / DNA PRODUCT COMPLEX WITH MAGNESIUM
6UAK	;	2.01	;	LahSb - C-terminal methyltransferase involved in RiPP biosynthesis
7SOO	;	1.65	;	LaM domain of human LARP1
7SOQ	;	1.15	;	LaM domain of human LARP1 in complex with AAA RNA
7SOR	;	1.35	;	LaM domain of human LARP1 in complex with AAA RNA
7SOS	;	1.25	;	LaM domain of human LARP1 in complex with AAAA RNA
7SOT	;	1.52	;	LaM domain of human LARP1 in complex with AAAAAA oligonucleotide
7SOU	;	1.45	;	LaM domain of human LARP1 in complex with AAAAAA polynucleotide
7SOV	;	1.45	;	LaM domain of human LARP1 in complex with AAAAAAAAAAA RNA polynucleotide
8EY6	;	1.63	;	LaM domain of human LARP1 in complex with AAAAAG RNA
8EY8	;	1.3	;	LaM domain of human LARP1 in complex with AAAAGA RNA
8EY7	;	1.35	;	LaM domain of human LARP1 in complex with AAAGAA RNA
7SOP	;	1.55	;	LaM domain of human LARP1 in complex with AAAUAA RNA
7SOW	;	1.3	;	LaM domain of human LARP1 in complex with UUUUUU
8DSB	;		;	Lambda Bacteriophage Orf63
2ECS	;	1.4	;	Lambda Cro mutant Q27P/A29S/K32Q at 1.4 A in space group C2
2OVG	;	1.35	;	Lambda Cro Q27P/A29S/K32Q triple mutant at 1.35 A in space group P3221
5J0N	;	11.0	;	Lambda excision HJ intermediate
5ET2	;	1.39	;	Lambda-Ru(TAP)2(dppz)]2+ bound to d(TTGGCGCCAA)
5IP8	;	1.76	;	Lambda-Ru(TAP)2dppz bound to d(CCGGCTCCGG)
1Q5B	;	30.0	;	lambda-shaped TRANS and CIS interactions of cadherins model based on fitting C-cadherin (1L3W) to 3D map of desmosomes obtained by electron tomography
5LFS	;	1.85	;	Lambda-[Ru(bpy)2(dppz)]2+ bound to brominated DNA
5LFW	;	1.28	;	Lambda-[Ru(phen)2(dppz)]2+ bound to a short substituted DNA sequence
4E7Y	;	1.7	;	Lambda-[Ru(phen)2(dppz)]2+ Bound to CCGGATCCGG
5LFX	;	1.56	;	Lambda-[Ru(phen)2(dppz-11,12-Me)]2+ bound to a short substituted DNA sequence
4III	;	1.02	;	Lambda-[Ru(TAP)2(11-Cl-dppz)] with a DNA decamer at atomic resolution
4YMC	;	1.88	;	Lambda-[Ru(TAP)2(dppz)]2+ bound to d(CCGGATCCGG)2
5IWJ	;	1.88	;	LAmbda-[Ru(TAP)2(dppz)]2+ bound to d(CCGGGCCCGG
4QIO	;	0.95	;	Lambda-[Ru(TAP)2(dppz)]2+ bound to d(TCGGCGCCIA) at high resolution
5IU5	;	1.9	;	Lambda-[Ru(TAP)2(dppz)]2+ bound to d(TCGGCICCGA)2
4RE7	;	2.181	;	Lambda-[Ru(TAP)2(dppz)]2+ bound to d(TCIGCGCCGA)
4E95	;	1.94	;	Lambda-[Ru(TAP)2(dppz-(Me)2)]2+ bound to CCGGATCCGG
4E8X	;	2.18	;	Lambda-[Ru(TAP)2(dppz-(Me)2)]2+ bound to d(CCGGCGCCGG)2
4X1A	;	0.89	;	Lambda-[Ru(TAP)2(dppz-10,12-Me)]2+ bound to d(TCGGCGCCGA)
4MJ9	;	0.97	;	lambda-[Ru(TAP)2(dppz-10-Me)]2+ bound to a synthetic DNA oligomer
4MS5	;	2.23	;	Lambda-[Ru(TAP)2(dppz-11,12-(F)2)]2+ bound to CCGGATCCGG
4E8S	;	1.24	;	Lambda-[Ru(TAP)2(dppz{Me2}2)]2+ bound to TCGGCGCCGA at high resolution
1N35	;	2.5	;	lambda3 elongation complex with four phosphodiester bond formed
6YSH	;	2.83	;	Lamin A 1-70 coil1A dimer stabilized by C-terminal capping
6YF5	;	1.83	;	Lamin A 17-70 coil1A dimer stabilized by C-terminal capping
6YJD	;	2.9	;	Lamin A coil2 dimer stabilized by N-terminal capping
6GCZ	;	1.8	;	Laminarin binding SusD-like protein
5IK4	;	1.27	;	Laminin A2LG45 C-form, Apo.
5IK5	;	1.39	;	Laminin A2LG45 C-form, G6/7 bound.
5IK7	;	2.0	;	Laminin A2LG45 I-form, Apo.
5IK8	;	2.0	;	Laminin A2LG45 I-form, G6/7 bound.
1DYK	;	2.0	;	Laminin alpha 2 chain LG4-5 domain pair
1OKQ	;	2.8	;	LAMININ ALPHA 2 CHAIN LG4-5 DOMAIN PAIR, CA1 SITE MUTANT
2Y38	;	2.9	;	LAMININ ALPHA5 CHAIN N-TERMINAL FRAGMENT
4AQS	;	3.109	;	Laminin beta1 LN-LE1-4 structure
3SH4	;	1.5	;	Laminin G like domain 3 from human perlecan
4AQT	;	3.2	;	Laminin gamma1 LN-LE1-2 structure
7E1E	;	3.34	;	Lamprey serum virus-like lectin-LSVL
7Q5G	;	0.83	;	LAN-DAP5 DERIVATIVE OF LANREOTIDE: L-DIAMINO PROPIONIC ACID IN POSITION 5 IN PLACE OF L-LYSINE
4RIE	;	2.162	;	Landomycin Glycosyltransferase LanGT2
4RIF	;	1.85	;	Landomycin Glycosyltransferase LanGT2, carbasugar substrate complex
8FMX	;	3.37	;	Langya virus F glycoprotein ectodomain in prefusion form
8FEL	;	4.64	;	Langya Virus Fusion Protein (LayV-F) in Post-Fusion Conformation
8FEJ	;	4.64	;	Langya Virus Fusion Protein (LayV-F) in Pre-Fusion Conformation
7SNM	;	2.55	;	Lanosterol-bound P450 domain of the CYP51-ferredoxin fusion protein from Methylococcus capsulatus
7Q5A	;	2.46	;	Lanreotide nanotube
6OC5	;	2.8	;	Lanthanide-dependent methanol dehydrogenase XoxF from Methylobacterium extorquens, in complex with Lanthanum
6OC6	;	2.89	;	Lanthanide-dependent methanol dehydrogenase XoxF from Methylobacterium extorquens, in complex with Lanthanum and Pyrroloquinoline quinone
5XBO	;		;	Lanthanoid tagging via an unnatural amino acid for protein structure characterization
4TVS	;	1.6	;	LAP1(aa356-583), H.sapiens, bound to VHH-BS1
6EP3	;	2.2	;	Lar controls the expression of the Listeria monocytogenes agr system and mediates virulence.
7MJ0	;	3.01	;	LarB, a carboxylase/hydrolase involved in synthesis of the cofactor for lactate racemase, in complex with adenosine monophosphate AMP
7MJ1	;	3.402	;	LarB, a carboxylase/hydrolase involved in synthesis of the cofactor for lactate racemase, in complex with NAD
7MJ2	;	2.8	;	LarB, a carboxylase/hydrolase involved in synthesis of the cofactor for lactate racemase, in complex with Zn
6BWO	;	2.03	;	LarC2, the C-terminal domain of a cyclometallase involved in the synthesis of the NPN cofactor of lactate racemase, apo form
6BWQ	;	1.85	;	LarC2, the C-terminal domain of a cyclometallase involved in the synthesis of the NPN cofactor of lactate racemase, in complex with MnCTP
6BWR	;	1.81	;	LarC2, the C-terminal domain of a cyclometallase involved in the synthesis of the NPN cofactor of lactate racemase, in complex with nickel
6UTQ	;	2.39	;	LarE, a sulfur transferase involved in synthesis of the cofactor for lactate racemase in complex with cadmium
6UTT	;	2.49	;	LarE, a sulfur transferase involved in synthesis of the cofactor for lactate racemase in complex with calcium
6UTP	;	3.55	;	LarE, a sulfur transferase involved in synthesis of the cofactor for lactate racemase in complex with cobalt
6B2M	;	2.088	;	LarE, a sulfur transferase involved in synthesis of the cofactor for lactate racemase in complex with coenzyme A
6UTR	;	2.41	;	LarE, a sulfur transferase involved in synthesis of the cofactor for lactate racemase in complex with copper
5UDR	;	2.62	;	LarE, a sulfur transferase involved in synthesis of the cofactor for lactate racemase in complex with nicotinamide mononucleotid NMN
5UDQ	;	2.09	;	LarE, a sulfur transferase involved in synthesis of the cofactor for lactate racemase, apo form
6B2O	;	2.35	;	LarE, a sulfur transferase involved in synthesis of the cofactor for lactate racemase, C176A variant
5UDT	;	3.188	;	LarE, a sulfur transferase involved in synthesis of the cofactor for lactate racemase, in complex with AMP
6DG3	;	2.944	;	LarE, a sulfur transferase involved in synthesis of the cofactor for lactate racemase, in complex with caesium
5UDV	;	2.621	;	LarE, a sulfur transferase involved in synthesis of the cofactor for lactate racemase, in complex with iron
5UDU	;	2.792	;	LarE, a sulfur transferase involved in synthesis of the cofactor for lactate racemase, in complex with manganese
5UDS	;	2.37	;	LarE, a sulfur transferase involved in synthesis of the cofactor for lactate racemase, in complex with MgATP
5UDW	;	2.698	;	LarE, a sulfur transferase involved in synthesis of the cofactor for lactate racemase, in complex with nickel
5UDX	;	2.784	;	LarE, a sulfur transferase involved in synthesis of the cofactor for lactate racemase, in complex with zinc
5UNM	;	2.58	;	LarE, a sulfur transferase involved in synthesis of the cofactor for lactate racemase, substrate free form with flexible loop
3CW4	;	2.7	;	Large c-terminal domain of influenza a virus RNA-dependent polymerase PB2
2UWE	;	2.4	;	Large CDR3a loop alteration as a function of MHC mutation
2J8U	;	2.88	;	Large CDR3a loop alteration as a function of MHC mutation.
4DFK	;	1.647	;	large fragment of DNA Polymerase I from Thermus aquaticus in a closed ternary complex with 5-(N-(10-hydroxydecanoyl)-aminopentinyl)-2-dUTP
5YTD	;	2.0	;	large fragment of DNA Polymerase I from Thermus aquaticus in a closed ternary complex with the natural base pair 5fC:dGTP
5YTC	;	2.28	;	Large fragment of DNA Polymerase I from Thermus aquaticus in a closed ternary complex with the unnatural base M-fC pair with dATP in the active site
5YTE	;	2.21	;	Large fragment of DNA Polymerase I from Thermus aquaticus in a closed ternary complex with with natural dT:dATP base pair
5KTQ	;	2.5	;	LARGE FRAGMENT OF TAQ DNA POLYMERASE BOUND TO DCTP
1UXH	;	2.1	;	Large improvement in the thermal stability of a tetrameric malate dehydrogenase by single point mutations at the dimer-dimer interface
1UXI	;	2.1	;	Large improvement in the thermal stability of a tetrameric malate dehydrogenase by single point mutations at the dimer-dimer interface
1UXJ	;	1.75	;	Large improvement in the thermal stability of a tetrameric malate dehydrogenase by single point mutations at the dimer-dimer interface
1UXK	;	1.8	;	Large improvement in the thermal stability of a tetrameric malate dehydrogenase by single point mutations at the dimer-dimer interface
1UXG	;	1.9	;	Large improvement in the thermal stability of a tetrameric malate dehydrogenase by single point mutations at the dimer-dimer interface.
1S01	;	1.7	;	LARGE INCREASES IN GENERAL STABILITY FOR SUBTILISIN BPN(PRIME) THROUGH INCREMENTAL CHANGES IN THE FREE ENERGY OF UNFOLDING
1FG0	;	3.0	;	LARGE RIBOSOMAL SUBUNIT COMPLEXED WITH A 13 BP MINIHELIX-PUROMYCIN COMPOUND
1FFZ	;	3.2	;	LARGE RIBOSOMAL SUBUNIT COMPLEXED WITH R(CC)-DA-PUROMYCIN
1MSS	;	2.4	;	LARGE SCALE STRUCTURAL REARRANGEMENTS OF THE FRONT LOOPS IN MONOMERISED TRIOSEPHOSPHATE ISOMERASE, AS DEDUCED FROM THE COMPARISON OF THE STRUCTURAL PROPERTIES OF MONOTIM AND ITS POINT MUTATION VARIANT MONOSS
5XYM	;	3.08	;	Large subunit of Mycobacterium smegmatis
7PKT	;	3.0	;	Large subunit of the Chlamydomonas reinhardtii mitoribosome
6I9R	;	3.9	;	Large subunit of the human mitochondrial ribosome in complex with Virginiamycin M and Quinupristin
5XXB	;	3.17	;	Large subunit of Toxoplasma gondii ribosome
5XY3	;	3.2	;	Large subunit of Trichomonas vaginalis ribosome
6GYV	;	2.50004	;	Lariat-capping ribozyme (circular permutation form)
6G7Z	;	3.33595	;	Lariat-capping ribozyme with a shortened DP2 stem loop
8IRQ	;	1.49	;	Larimichthys crocea IFNd
7WZ5	;	1.39	;	Larimichthys crocea IFNi
6PW3	;	2.34	;	LARP1 DM15 FYRE (F844Y, R847E) mutant bound to m7GpppG dinucleotide (capG)
4WKR	;	3.2	;	LaRP7 wrapping up the 3' hairpin of 7SK non-coding RNA (302-332)
4NG0	;	1.501	;	Lar_0958 a cell surface adhesin from lactobacillus reuteri
8CC4	;	2.7	;	LasB bound to phosphonic acid based inhibitor
6F8B	;	1.3	;	LasB bound to thiol based inhibitor
7OC7	;	1.95	;	LasB, alpha-alkyl-N-aryl mercaptoacetamide
6FZX	;	2.1	;	LasB, hydroxymate Inhibitor Complex
7NLK	;	1.7	;	LasB, N-aryl-2-butylmercaptoacetamide
7NLM	;	1.65	;	LasB, N-aryl-2-butylmercaptoacetamide
8CW8	;	1.57	;	Laser Off Temperature-Jump XFEL structure of Lysozyme
8CWB	;	1.51	;	Laser Off Temperature-Jump XFEL structure of Lysozyme Bound to N,N'-diacetylchitobiose
4HV1	;	2.3	;	Laser-induced microfragmentation of lysozyme crystals allows X-ray nanodiffraction characterization of individual domains (lb4)
4HV2	;	2.501	;	Laser-induced microfragmentation of lysozyme crystals allows X-ray nanodiffraction characterization of individual domains (lb5)
2MBD	;		;	Lasiocepsin
7EXD	;	3.4	;	Lasmiditan-bound serotonin 1F (5-HT1F) receptor-Gi protein complex
6MVN	;	2.2	;	LasR LBD L130F:3OC10HSL complex
6MVM	;	1.895	;	LasR LBD L130F:3OC14HSL complex
6MWZ	;	1.657	;	LasR LBD T75V/Y93F/A127W:BB0126
6MWH	;	2.2	;	LasR LBD:BB0020 complex
6MWW	;	2.76	;	LasR LBD:BB0126 complex
6MWL	;	1.5	;	LasR LBD:mBTL complex
3IX3	;	1.4	;	LasR-OC12 HSL complex
3IX4	;	1.8	;	LasR-TP1 complex
3IX8	;	1.8	;	LasR-TP3 complex
3JPU	;	2.3	;	LasR-TP4 complex
3MX2	;	1.983	;	Lassa fever virus Nucleoprotein complexed with dTTP
3MX5	;	1.903	;	Lassa fever virus nucleoprotein complexed with UTP
8T5C	;	4.7	;	Lassa GPC Trimer in complex with Fab 8.11G and nanobody D5
4GV9	;	2.46	;	Lassa nucleoprotein C-terminal domain in complex with triphosphated dsRNA soaking for 5 min
4G9Z	;	2.03	;	Lassa nucleoprotein with dsRNA reveals novel mechanism for immune suppression
8EJH	;	3.71	;	Lassa virus glycoprotein complex (Josiah) bound to 12.1F Fab
8EJI	;	3.81	;	Lassa virus glycoprotein complex (Josiah) bound to 19.7E Fab
8EJJ	;	3.22	;	Lassa virus glycoprotein complex (Josiah) bound to S370.7 Fab
7SGF	;	4.41	;	Lassa virus glycoprotein construct (Josiah GPC-I53-50A) in complex with LAVA01 antibody
7SGD	;	3.97	;	Lassa virus glycoprotein construct(Josiah GPCysR4) recovered from GPC-I53-50 nanoparticle by localized reconstruction
7OEB	;	3.04	;	Lassa virus L protein bound to 3' promoter RNA (well-resolved endonuclease) [3END-ENDO]
7OEA	;	2.7	;	Lassa virus L protein bound to 3' promoter RNA (well-resolved polymerase core) [3END-CORE]
7OJK	;	3.89	;	Lassa virus L protein bound to the distal promoter duplex [DISTAL-PROMOTER]
5IZH	;	1.85	;	Lassa virus L protein cap-snatching endonuclease. apo form
5J1N	;	1.09	;	Lassa virus L protein cap-snatching endonuclease. Bound to one manganese ion
5J1P	;	2.36	;	Lassa virus L protein cap-snatching endonuclease. Bound to two manganese ions
7OJL	;	3.3	;	Lassa virus L protein in a pre-initiation conformation [PREINITIATION]
7OJN	;	2.92	;	Lassa virus L protein in an elongation conformation [ELONGATION]
7OJJ	;	3.5	;	Lassa virus L protein with endonuclease and C-terminal domains in close proximity [MID-LINK]
2MMW	;		;	LASSO PEPTIDE BASED INTEGRIN INHIBITOR: MICROCIN J25 VARIANT WITH RGD SUBSTITUTION of GLY12-ILE13-GLY14
7CU6	;		;	lasso peptide C24 mutant - A11V2C
6Q1X	;		;	Lasso peptide pandonodin
6JX3	;	1.7	;	Lasso peptide synthetase B1 complexed with the leader peptide
2MMT	;		;	Lasso peptide-based integrin inhibitor: Microcin J25 variant with RGDF substitution of Gly12-Ile13-Gly14-Thr15
6C8Z	;	2.86	;	Last common ancestor of ADP-dependent phosphofructokinases from Methanosarcinales
5FQM	;	1.5	;	Last common ancestor of Gram Negative Bacteria (GNCA) Class A beta- lactamase
5FQQ	;	2.12	;	Last common ancestor of Gram-negative bacteria (GNCA4) beta-lactamase class A
7L07	;	2.0	;	Last common ancestor of HMPPK and PLK/HMPPK vitamin kinases
2OWO	;	2.3	;	Last Stop on the Road to Repair: Structure of E.coli DNA Ligase Bound to Nicked DNA-Adenylate
6JMQ	;	3.31	;	LAT1-CD98hc complex bound to MEM-108 Fab
8XJM	;	2.85	;	Latanoprost acid bound Prostaglandin F2-alpha receptor-Gq Protein Complex
8RI9	;	3.3	;	Late alpha-Synuclein fibril structure from liquid-liquid phase separations.
7ZKP	;	3.2	;	Late assembly intermediate of the proximal proton pumping module of complex I with assembly factors NDUFAF1 and CIA84
7PUB	;	3.7	;	Late assembly intermediate of the Trypanosoma brucei mitoribosomal small subunit
1T1A	;	1.6	;	Late intermediate IL1 from time-resolved crystallography of the E46Q mutant of PYP
1T1B	;	1.6	;	Late intermediate IL2 from time-resolved crystallography of the E46Q mutant of PYP
1T1C	;	1.6	;	Late intermediate IL3 from time-resolved crystallography of the E46Q mutant of PYP
7SSW	;	3.8	;	Late translocation intermediate with EF-G dissociated (Structure VI)
7SS9	;	3.9	;	Late translocation intermediate with EF-G partially dissociated (Structure V)
4Z11	;	2.5	;	Latent aurone synthase (polyphenol oxidase) from natural source
1DVN	;	2.1	;	LATENT FORM OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1)
1QWY	;	1.3	;	Latent LytM at 1.3 A resolution
7Y1A	;	6.3	;	Lateral hexamer
3MP7	;	2.9	;	Lateral opening of a translocon upon entry of protein suggests the mechanism of insertion into membranes
7BNQ	;	4.1	;	Lateral-closed conformation of the lid-locked BAM complex (BamA E435C S665C, BamBDCE) by cryoEM
7NCS	;	7.1	;	Lateral-open conformation of the lid-locked BAM complex (BamA E435C S665C, BamBDCE) bound by a bactericidal Fab fragment
7NBX	;	4.8	;	Lateral-open conformation of the lid-locked BAM complex (BamA E435C S665C, BamBDCE) by cryoEM
7ND0	;	5.2	;	lateral-open conformation of the wild-type BAM complex (BamABCDE) bound to a bactericidal Fab fragment
4B2N	;	1.8	;	Latex Oxygenase RoxA
1G5U	;	3.1	;	LATEX PROFILIN HEVB8
1EBE	;	2.2	;	Laue diffraction study on the structure of cytochrome c peroxidase compound I
2BWH	;	1.9	;	Laue Structure of a Short Lived State of L29W Myoglobin
2BW9	;	1.68	;	Laue Structure of L29W MbCO
2C7K	;	3.2	;	Laue structure of phycoerythrocyanin from Mastigocladus laminosus
3UBR	;	2.59	;	Laue structure of Shewanella oneidensis cytochrome-c Nitrite Reductase
6XV0	;	3.0	;	lauric acid functionalized hexamolybdoaluminate bound to human serum albumin
8I54	;	3.95	;	Lb2Cas12a RNA DNA complex
5EY5	;	1.972	;	LBCATS
8FQ2	;	3.14	;	LBD conformation 1 (LBDconf1) of GluA2 flip Q isoform N619K mutant of AMPA receptor in complex with gain-of-function TARP gamma-2, with 10mM CaCl2, 150mM NaCl, 1mM MgCl2, 330uM CTZ, and 100mM glutamate (Open-CaNaMg/N619K)
8FQG	;	3.01	;	LBD conformation 1 (LBDconf1) of GluA2 flip Q isoform of AMPA receptor in complex with gain-of-function TARP gamma-2, with 150mM NaCl, 330uM CTZ, and 100mM glutamate (Open-Na260)
8FPV	;	3.08	;	LBD conformation 1 (LBDconf1) of GluA2 flip Q isoform of AMPA receptor in complex with gain-of-function TARP gamma-2, with 500mM NaCl, 330uM CTZ, and 100mM glutamate (Open-Na610)
8FQD	;	3.01	;	LBD conformation 1 (LBDconf1) of GluA2 flip Q isoform of AMPA receptor in complex with gain-of-function TARP gamma2, with 10mM CaCl2, 140mM NMDG, 330uM CTZ, and 100mM L-glutamate (Open-Ca10)
8FQ8	;	3.11	;	LBD conformation 1 (LBDconf1) of GluA2 flip Q isoform of AMPA receptor in complex with gain-of-function TARP gamma2, with 140mM NMDG, 330uM CTZ, and 100mM L-glutamate (Open-Na110)
8FPK	;	2.76	;	LBD conformation 1 of GluA2 flip Q isoform of AMPA receptor in complex with gain-of-function TARP gamma-2, with 10mM CaCl2, 150mM NaCl, 1mM MgCl2, 330uM CTZ, and 100uM CNQX (Closed-CaNaMg)
8FQ3	;	3.17	;	LBD conformation 2 (LBDconf2) of GluA2 flip Q isoform N619K mutant of AMPA receptor in complex with gain-of-function TARP gamma-2, with 10mM CaCl2, 150mM NaCl, 1mM MgCl2, 330uM CTZ, and 100mM glutamate (Open-CaNaMg/N619K)
8FPL	;	2.81	;	LBD conformation 2 (LBDconf2) of GluA2 flip Q isoform of AMPA receptor in complex with gain-of-function TARP gamma-2, with 10mM CaCl2, 150mM NaCl, 1mM MgCl2, 330uM CTZ, and 100uM CNQX (Closed-CaNaMg)
8FQH	;	3.43	;	LBD conformation 2 (LBDconf2) of GluA2 flip Q isoform of AMPA receptor in complex with gain-of-function TARP gamma-2, with 150mM NaCl, 330uM CTZ, and 100mM glutamate (Open-Na260)
8FPY	;	2.98	;	LBD conformation 2 (LBDconf2) of GluA2 flip Q isoform of AMPA receptor in complex with gain-of-function TARP gamma-2, with 500mM NaCl, 330uM CTZ, and 100mM glutamate (Open-Na610)
8FQE	;	3.14	;	LBD conformation 2 (LBDconf2) of GluA2 flip Q isoform of AMPA receptor in complex with gain-of-function TARP gamma2, with 10mM CaCl2, 140mM NMDG, 330uM CTZ, and 100mM L-glutamate (Open-Ca10)
8FQA	;	3.35	;	LBD conformation 2 (LBDconf2) of GluA2 flip Q isoform of AMPA receptor in complex with gain-of-function TARP gamma2, with 140mM NMDG, 330uM CTZ, and 100mM L-glutamate (Open-Na110)
8FR0	;	3.04	;	LBD conformation 3 (LBDconf3) of GluA2 flip Q isoform of AMPA receptor in complex with gain-of-function TARP gamma-2, with 150mM NaCl, 330uM CTZ, and 100mM glutamate (Open-Na260)
8FPZ	;	3.01	;	LBD conformation 3 (LBDconf3) of GluA2 flip Q isoform of AMPA receptor in complex with gain-of-function TARP gamma-2, with 500mM NaCl, 330uM CTZ, and 100mM glutamate (Open-Na610)
8FQ6	;	3.14	;	LBD of GluA2 flip Q isoform of AMPA receptor in complex with gain-of-function TARP gamma2, with 150mM CaCl2, 330uM CTZ, and 100mM L-glutamate (Open-Ca150)
7F5B	;	3.9	;	LBD-TMD focused reconstruction of DNQX-bound GluK2-1xNeto2 complex
5H91	;	1.77	;	LbDERA mutant-T29L/F163Y
7LZP	;	2.86	;	LC/A-JPU-B9-JPU-A11-JPU-G11
2N9X	;		;	LC3 FUNDC1 complex structure
2K6Q	;		;	LC3 p62 complex structure
6TBE	;	1.67008	;	LC3A in complex with (3R,4S,5R,6R)-5-hydroxy-6-((4-hydroxy-3-(4-hydroxy-3-isopentylbenzamido)-8-methyl-2-oxo-2H-chromen-7-yl)oxy)-3-methoxy-2,2-dimethyltetrahydro-2H-pyran-4-yl carbamate
7R9W	;	1.75	;	LC3A in complex with Fragment 1-1
7RA0	;	1.36	;	LC3A in complex with Fragment 2-10
7R9Z	;	1.72	;	LC3A in complex with Fragment 2-3
7ELG	;	1.599	;	LC3B modificated with a covalent probe
2LUE	;		;	LC3B OPTN-LIR Ptot complex structure
5GMV	;	2.25	;	LC3B-FUNDC1 complex
4QH7	;	1.829	;	LC8 - Ana2 (159-168) Complex
4QH8	;	1.9	;	LC8 - Ana2 (237-246) Complex
5E0L	;	1.31	;	LC8 - Chica (415-424) Complex
5E0M	;	1.65	;	LC8 - Chica (468-476) Complex
3DVH	;	2.0	;	LC8 Point mutant K36P
7V6L	;	1.948	;	LcCOMT in complex with SAH
7V6J	;	1.799	;	LcCOMT in complex with SAM
5W10	;	2.15	;	Lcd1 GAF domain in complex with cAMP ligand
2PL0	;	2.8	;	LCK bound to imatinib
3MPM	;	1.95	;	LCK complexed with a pyrazolopyrimidine
6PQ4	;	2.0	;	LCP-embedded Proteinase K treated with lipase
6PQ0	;	2.0	;	LCP-embedded Proteinase K treated with MPD
6ADZ	;	2.431	;	LdCoroCC Double mutant- I486A-L493A
6ICR	;	2.04	;	LdCoroCC mutant- C482A
6ADO	;	2.502	;	LdCoroCC mutant-I486A
8I5Z	;	2.65	;	LDH Mutant P101Q-(An unexpected single-point mutation triggers the unleashing of catalytic potential of a NADH-dependent dehydrogenase)
6MV8	;	1.95	;	LDHA structure in complex with inhibitor 14
6MVA	;	2.02	;	LDHA structure in complex with inhibitor 14
5ZJF	;	2.602	;	LDHA-MA
5ZJE	;	2.929	;	LDHA-mla
1AJJ	;	1.7	;	LDL RECEPTOR LIGAND-BINDING MODULE 5, CALCIUM-COORDINATING
1D2J	;		;	LDL RECEPTOR LIGAND-BINDING MODULE 6
7A1C	;	1.77	;	LdtMT2 with covalent adduct derived from N-Thio-beta-lactam 1a
1TLE	;		;	LE (LAMININ-TYPE EGF-LIKE) MODULE GIII4 IN SOLUTION AT PH 3.5 AND 290 K, NMR, 14 STRUCTURES
2XAL	;	3.2	;	Lead derivative of Inositol 1,3,4,5,6-pentakisphosphate 2-kinase from A. thaliana in complex with ADP and IP6.
4B0Q	;	1.87	;	Lead Generation of BACE1 Inhibitors by Coupling Non-amidine New Warheads to a Known Binding Scaffold
2JQG	;		;	Leader Protease
4J1J	;	2.65	;	Leanyer orthobunyavirus nucleoprotein-ssDNA complex
4J1G	;	2.789	;	Leanyer orthobunyavirus nucleoprotein-ssRNA complex
1Q01	;		;	Lebetin peptides, a new class of potent aggregation inhibitors
4I77	;	1.9	;	Lebrikizumab Fab bound to IL-13
7FJH	;	1.79	;	LecA from Pseudomonas aeruginosa in complex with 4-Phenylbutyryl hydroxamic acid (CAS: 32153-46-1)
6YOH	;	1.84	;	LecA from Pseudomonas aeruginosa in complex with a catechol CAS no. 61445-50-9
6YO3	;	1.84	;	LecA from Pseudomonas aeruginosa in complex with a catechol CAS no. 67984-81-0
7FIO	;	1.5	;	LecA from Pseudomonas aeruginosa in complex with a synthetic monovalent galactosidic inhibitor
8GUV	;	1.32	;	LecA from Pseudomonas aeruginosa in complex with tolcapone (CAS: 134308-13-7)
1OUS	;	1.2	;	Lecb (PA-LII) calcium-free
1OVS	;	1.75	;	LecB (PA-LII) in complex with core trimannoside
1OVP	;	1.4	;	LecB (PA-LII) in complex with fructose
1OXC	;	1.2	;	LecB (PA-LII) in complex with FUCOSE
1OUR	;	1.42	;	LecB (PA-LII) in complex with mannose
3DCQ	;	1.8	;	LECB (PA-LII) in complex with the synthetic ligand 2G0
1OUX	;	2.0	;	LecB (PA-LII) sugar-free
1GSL	;	2.0	;	LECTIN (FOURTH ISOLATED FROM (GRIFFONIA SIMPLICIFOLIA)) COMPLEX WITH Y HUMAN BLOOD GROUP DETERMINANT
8G1L	;	1.06	;	Lectin domain of Aap (Staphylococcus epidermidis Accumulation Associated Protein)
5LNG	;	2.09	;	Lectin domain of E. coli F9 pilus adhesin FmlH
3LEI	;	1.9	;	Lectin Domain of Lectinolysin complexed with Fucose
3LE0	;	1.91	;	Lectin Domain of Lectinolysin complexed with Glycerol
3LEK	;	2.0	;	Lectin Domain of Lectinolysin complexed with Lewis B Antigen
3LEG	;	2.01	;	Lectin Domain of Lectinolysin complexed with Lewis Y Antigen
8G1M	;	1.93	;	Lectin domain of SasG (Staphylococcus aureus Surface protein G)
5T54	;	1.65	;	LECTIN FROM BAUHINIA FORFICATA IN COMPLEX WITH BLOOD GROUP A ANTIGEN
5T52	;	1.7	;	LECTIN FROM BAUHINIA FORFICATA IN COMPLEX WITH GALNAC
5T55	;	1.43	;	LECTIN FROM BAUHINIA FORFICATA IN COMPLEX WITH GLOBOTETRAOSE
5T5J	;	1.35	;	LECTIN FROM BAUHINIA FORFICATA IN COMPLEX WITH TN-PEPTIDE
5T5L	;	1.17	;	LECTIN FROM BAUHINIA FORFICATA IN COMPLEX WITH TN-PEPTIDE
5T5O	;	2.75	;	LECTIN FROM BAUHINIA FORFICATA IN COMPLEX WITH TN-PEPTIDE
5T5P	;	1.66	;	LECTIN FROM BAUHINIA FORFICATA IN COMPLEX WITH TN-PEPTIDE
1DGL	;	2.4	;	LECTIN FROM DIOCLEA GRANDIFLORA COMPLEXED TO TRIMANNOSIDE
2BS5	;	2.1	;	LECTIN FROM RALSTONIA SOLANACEARUM COMPLEXED WITH 2-FUCOSYLLACTOSE
2BT9	;	0.94	;	Lectin from Ralstonia solanacearum complexed with Me-fucoside
2BS6	;	1.8	;	LECTIN FROM RALSTONIA SOLANACEARUM COMPLEXED WITH XYLOGLUCAN FRAGMENT
1GNZ	;	2.5	;	LECTIN I-B4 FROM GRIFFONIA SIMPLICIFOLIA (GS I-B4)METAL FREE FORM
1QNW	;	2.35	;	lectin II from Ulex europaeus
2JDH	;	1.1	;	Lectin PA-IIL of P.aeruginosa complexed with disaccharide derivative
2JDK	;	1.1	;	Lectin PA-IIL of P.aeruginosa complexed with disaccharide derivative
1QOS	;	2.95	;	lectin UEA-II complexed with chitobiose
1QOT	;	3.0	;	lectin UEA-II complexed with fucosyllactose and fucosylgalactose
1DZQ	;	2.85	;	LECTIN UEA-II COMPLEXED WITH GALACTOSE
1QOO	;	2.75	;	lectin UEA-II complexed with NAG
6TVM	;		;	LEDGF/p75 dimer (residues 345-467)
6TRJ	;	1.3	;	LEDGF/p75 IBD dimer
3SLI	;	1.8	;	LEECH INTRAMOLECULAR TRANS-SIALIDASE COMPLEXED WITH 2,7-ANHYDRO-NEU5AC PREPARED BY SOAKING WITH 3'-SIALYLLACTOSE
2SLI	;	1.8	;	LEECH INTRAMOLECULAR TRANS-SIALIDASE COMPLEXED WITH 2,7-ANHYDRO-NEU5AC, THE REACTION PRODUCT
4SLI	;	1.8	;	LEECH INTRAMOLECULAR TRANS-SIALIDASE COMPLEXED WITH 2-PROPENYL-NEU5AC, AN INACTIVE SUBSTRATE ANALOGUE
1SLI	;	2.0	;	LEECH INTRAMOLECULAR TRANS-SIALIDASE COMPLEXED WITH DANA
1AN1	;	2.03	;	LEECH-DERIVED TRYPTASE INHIBITOR/TRYPSIN COMPLEX
2LEF	;		;	LEF1 HMG DOMAIN (FROM MOUSE), COMPLEXED WITH DNA (15BP), NMR, 12 STRUCTURES
2ZUB	;	2.9	;	Left handed RadA
7WFD	;	3.25	;	Left PSI in the cyclic electron transport supercomplex NDH-PSI from Arabidopsis
7YVX	;	2.99	;	Left-handed DNA duplex containing consecutive G-G base pairs
7D5F	;		;	Left-handed G-quadruplex containing 3 bulges
7D5D	;	1.18	;	Left-handed G-quadruplex containing one bulge
7D5E	;	1.296	;	Left-handed G-quadruplex containing two bulges
1ICK	;	0.95	;	LEFT-HANDED Z-DNA HEXAMER DUPLEX D(CGCGCG)2
7S8V	;	3.73	;	Leg region of a complex of IGF-I with the ectodomain of a hybrid insulin receptor / type 1 insulin-like growth factor receptor
6VWJ	;	4.21	;	Leg region of the closed conformation of the human type 1 insulin-like growth factor receptor ectodomain in complex with human insulin-like growth factor II
6VWH	;	4.26	;	Leg region of the open conformation of the human type 1 insulin-like growth factor receptor ectodomain in complex with human insulin-like growth factor II.
2GDM	;	1.7	;	LEGHEMOGLOBIN (OXY)
1BIN	;	2.2	;	LEGHEMOGLOBIN A (ACETOMET)
6SKU	;	3.2	;	Legionella effector AnkX in complex with human Rab1b
8ANP	;	2.2	;	Legionella effector Lem3 mutant D190A in complex with Mg2+
8JHU	;	3.1	;	Legionella effector protein SidI
7XGV	;	2.27	;	Legionella glucosyltransferase
2WZG	;	1.9	;	Legionella glucosyltransferase (Lgt1) crystal structure
8HCY	;	2.64	;	Legionella glycosyltransferase
6E8H	;	1.68	;	Legionella Longbeachae LeSH (Llo2327)
6E8I	;	1.68	;	Legionella Longbeachae LeSH (Llo2327) bound to phosphotyrosine
6E8M	;	1.61	;	Legionella Longbeachae LeSH (Llo2327) bound to the human DnaJ-A1 pTyr381 peptide
6E8K	;	1.71	;	Legionella Longbeachae LeSH (Llo2327) bound to the human interleukin-2 receptor beta pTyr387 peptide
8DMR	;	1.86	;	Legionella macrodomain effector MavL R370A in complex with ADP-ribose
8GOK	;	1.52	;	Legionella OTU deubiquitinase LotA OTU1 domain
6X66	;	4.2	;	Legionella pneumophila dDot T4SS OMC
4NQ1	;	1.65	;	Legionella pneumophila dihydrodipicolinate synthase with first substrate pyruvate bound in the active site
6X62	;	3.5	;	Legionella pneumophila Dot T4SS OMC
6X64	;	3.7	;	Legionella pneumophila Dot T4SS PR
6X65	;	3.7	;	Legionella pneumophila Dot/Icm T4SS
7MUC	;	3.8	;	Legionella pneumophila Dot/Icm T4SS C1 Reconstruction
7MUD	;	2.8	;	Legionella pneumophila Dot/Icm T4SS OMC
7MUE	;	2.8	;	Legionella pneumophila Dot/Icm T4SS PR
4IIK	;	1.6	;	Legionella pneumophila effector
4IIP	;	1.9	;	Legionella pneumophila effector
7EW8	;	2.594	;	Legionella pneumophila effector AnkD
7X2P	;	2.89	;	Legionella pneumophila effector RavL
2WZF	;	2.1	;	Legionella pneumophila glucosyltransferase crystal structure
3JSZ	;	1.7	;	Legionella pneumophila glucosyltransferase Lgt1 N293A with UDP-Glc
3JT1	;	2.3	;	Legionella pneumophila glucosyltransferase Lgt1, UDP-bound form
4FGQ	;	1.645	;	Legionella pneumophila LapG
4FGO	;	1.903	;	Legionella pneumophila LapG (calcium-bound)
4FGP	;	1.73	;	Legionella pneumophila LapG (EGTA-treated)
6VVC	;	2.1	;	Legionella pneumophila Lpg2603 kinase
6VVD	;	2.65	;	Legionella pneumophila Lpg2603 kinase bound to IP6
6VVE	;	1.85	;	Legionella pneumophila Lpg2603 kinase bound to IP6, Mn2+, and ADP
7M7A	;	3.2	;	Legionella pneumophila MavQ lipid kinase
4BR7	;	1.8	;	Legionella pneumophila NTPDase1 crystal form I, open, AMPNP complex
4BR4	;	1.45	;	Legionella pneumophila NTPDase1 crystal form I, open, apo
4BRF	;	1.6	;	Legionella pneumophila NTPDase1 crystal form II (closed) in complex with a distorted orthomolybdate ion and AMP
4BVP	;	1.49	;	Legionella pneumophila NTPDase1 crystal form II (closed) in complex with heptamolybdate and octamolybdate
4BRH	;	1.69	;	Legionella pneumophila NTPDase1 crystal form II (closed) in complex with MG AND THIAMINE PHOSPHOVANADATE
4BRG	;	1.45	;	Legionella pneumophila NTPDase1 crystal form II (closed) in complex with MG GMPPNP
4BRI	;	1.75	;	Legionella pneumophila NTPDase1 crystal form II (closed) in complex with MG UMPPNP
4BRE	;	1.6	;	Legionella pneumophila NTPDase1 crystal form II (closed) in complex with transition state mimic adenosine 5'phosphovanadate
4BR9	;	1.4	;	Legionella pneumophila NTPDase1 crystal form II, closed, apo
4BRQ	;	1.45	;	LEGIONELLA PNEUMOPHILA NTPDASE1 CRYSTAL FORM II, CLOSED, IN COMPLEX WITH TWO PHOSPHATES BOUND TO ACTIVE SITE MG AND PRODUCT AMP
4BRC	;	1.3	;	Legionella pneumophila NTPDase1 crystal form II, closed, Mg AMPNP complex
4BRA	;	1.6	;	Legionella pneumophila NTPDase1 crystal form II, closed, Mg AMPPNP complex
4BRN	;	1.69	;	Legionella pneumophila NTPDase1 crystal form III (closed) in complex with Mg AMP
4BRL	;	1.6	;	Legionella pneumophila NTPDase1 crystal form III (closed) in complex with transition state mimic guanosine 5'-phosphovanadate
4BRO	;	1.99	;	Legionella pneumophila NTPDase1 crystal form IV (part-open)
4BRP	;	2.5	;	Legionella pneumophila NTPDase1 crystal form V (part-open)
4BVO	;	1.7	;	Legionella pneumophila NTPDase1 crystal form VI (part-open) in complex with polytungstate POM-1
4BRK	;	1.5	;	Legionella pneumophila NTPDase1 N302Y variant crystal form III (closed) in complex with MG UMPPNP
4BRD	;	1.5	;	Legionella pneumophila NTPDase1 Q193E crystal form II, closed, Mg AMPPNP complex
5OH6	;	2.05	;	Legionella pneumophila RidL N-terminal domain lacking beta hairpin
5OH5	;	1.9	;	Legionella pneumophila RidL N-terminal retromer binding domain
6S5T	;	4.15	;	Legionella pneumophila SidJ-Human calmodulin complex
6PLM	;	2.592	;	Legionella pneumophila SidJ/ Calmodulin 2 complex
6OQQ	;	2.102	;	Legionella pneumophila SidJ/Saccharomyces cerevisiae calmodulin complex
1FNY	;	1.81	;	LEGUME LECTIN OF THE BARK OF ROBINIA PSEUDOACACIA.
2DDL	;		;	Lei4P
7V1Q	;	1.58	;	Leifsonia Alcohol Dehydrogenases LnADH
7V1R	;	2.81	;	Leifsonia Alcohol Dehydrogenases LnADH
4Z79	;	1.54	;	Leiomodin-1 Actin-Binding Site 2 (ABS2)
8C47	;	2.2	;	Leishmania ATP-actin monomer in complex with Leishmania profilin
7ZHX	;	1.9	;	Leishmania donovani Glucose 6-Phosphate Dehydrogenase (N-terminal deletion variant)complexed with NADP(H)
7ZHT	;	2.8	;	Leishmania donovani Glucose 6-Phosphate Dehydrogenase apo form
7ZHY	;	1.99	;	Leishmania donovani Glucose 6-Phosphate Dehydrogenase C138S mutant complexed with NADP(H)
7ZHV	;	3.3	;	Leishmania donovani Glucose 6-Phosphate Dehydrogenase complexed with Glucose 6-Phosphate
7ZHU	;	1.7	;	Leishmania donovani Glucose 6-Phosphate Dehydrogenase complexed with NADP(H)
7ZHW	;	3.3	;	Leishmania donovani Glucose 6-Phosphate Dehydrogenase complexed with NADP(H) and Glucose 6-Phosphate
7ZHZ	;	2.5	;	Leishmania donovani Glucose 6-Phosphate Dehydrogenase mutant C138S complexed with G6P and NADP(H)
5USF	;	2.75	;	Leishmania donovani tyrosyl-tRNA synthetase in complex with nanobody and inhibitor
5WB5	;	2.7	;	Leishmania IF4E-1 bound to Leishmania 4E-IP1
7QV8	;	2.15	;	Leishmania infantum BRC1 repeat in complex with LiRAD51
7S6U	;	1.74	;	Leishmania infantum Glycogen Synthase Kinase 3 beta bound to AZD5438
7S6V	;	1.66	;	Leishmania infantum Glycogen Synthase Kinase 3 beta bound to CGP60474
6TUU	;	1.74	;	Leishmania infantum Rad51 surrogate LiRadA10 in complex with 5,6,7,8-tetrahydro-2-naphthoic acid
7Q8B	;	3.3	;	Leishmania major actin filament in ADP-Pi state
7Q8C	;	2.72	;	Leishmania major actin filament in ADP-state
7Q8S	;	3.4	;	Leishmania major ADP-actin filament decorated with Leishmania major cofilin
3DWR	;	1.66	;	Leishmania major coproporphyrinogen III oxidase with bound ligand
3DWS	;	2.5	;	Leishmania major Coproporphyrinogen III Oxidase with bound ligand
4AIR	;	1.8	;	Leishmania major cysteine synthase
7MYD	;	2.15	;	Leishmania major dihydroorotate dehydrogenase in complex with 5-amino-2-(1H-pyrrol-1-yl)benzonitrile
3GZ3	;	1.9	;	Leishmania major Dihydroorotate Dehydrogenase in complex with orotate
7MX6	;	1.8	;	Leishmania major dihydroorotate dehydrogenase in complex with [4-(1H-pyrrol-1-yl)phenyl]methanol
1R75	;	1.86	;	Leishmania major hypothetical protein
6SWX	;	1.95	;	Leishmania major methionyl-tRNA synthetase in complex with an allosteric inhibitor
3KFL	;	2.0	;	Leishmania major methionyl-tRNA synthetase in complex with methionyladenylate and pyrophosphate
7ANE	;	3.9	;	Leishmania Major mitochondrial ribosome
4CGM	;	1.7	;	Leishmania major N-myristoyltransferase in complex with a biphenyl- derivative inhibitor
5A27	;	1.37	;	Leishmania major N-myristoyltransferase in complex with a chlorophenyl 1,2,4-oxadiazole inhibitor.
5A28	;	1.48	;	Leishmania major N-myristoyltransferase in complex with a chlorophenyl 1,3,4-oxadiazole inhibitor.
4CYO	;	1.5	;	Leishmania major N-myristoyltransferase in complex with a hybrid inhibitor (compound 21).
4CYQ	;	1.65	;	Leishmania major N-myristoyltransferase in complex with a hybrid inhibitor (compound 45).
4CGN	;	1.69	;	Leishmania major N-myristoyltransferase in complex with a piperidinylindole inhibitor
4CYP	;	1.55	;	Leishmania major N-myristoyltransferase in complex with a pyrrolidine inhibitor.
5G20	;	1.52	;	Leishmania major N-myristoyltransferase in complex with a quinoline inhibitor (compound 19).
5G21	;	1.5	;	Leishmania major N-myristoyltransferase in complex with a quinoline inhibitor (compound 26).
4CGO	;	1.3	;	Leishmania major N-myristoyltransferase in complex with a thienopyrimidine inhibitor
4CGL	;	1.48	;	Leishmania major N-myristoyltransferase in complex with an aminoacylpyrrolidine inhibitor
4CYN	;	1.4	;	Leishmania major N-myristoyltransferase in complex with an aminoacylpyrrolidine inhibitor (2b)
4CGP	;	1.4	;	Leishmania major N-myristoyltransferase in complex with cofactor
6TW8	;	1.79	;	Leishmania major N-myristoyltransferase in complex with indazole inhibitor IMP-917
6TW7	;	1.4	;	Leishmania major N-myristoyltransferase in complex with indazole inhibitor IMP-918
6QDG	;	1.98	;	Leishmania major N-myristoyltransferase in complex with quinazoline inhibitor IMP-0000169
6QDA	;	1.6	;	Leishmania major N-myristoyltransferase in complex with quinazoline inhibitor IMP-0000811
6QDH	;	1.45	;	Leishmania major N-myristoyltransferase in complex with quinazoline inhibitor IMP-0000906
6QD9	;	1.46	;	Leishmania major N-myristoyltransferase in complex with thienopyrimidine inhibitor IMP-0000065
6QDB	;	1.4	;	Leishmania major N-myristoyltransferase in complex with thienopyrimidine inhibitor IMP-0000081
6QDF	;	1.49	;	Leishmania major N-myristoyltransferase in complex with thienopyrimidine inhibitor IMP-0000096
6QDC	;	1.4	;	Leishmania major N-myristoyltransferase in complex with thienopyrimidine inhibitor IMP-0000101
6QDD	;	1.65	;	Leishmania major N-myristoyltransferase in complex with thienopyrimidine inhibitor IMP-0000105
6QDE	;	1.45	;	Leishmania major N-myristoyltransferase in complex with thienopyrimidine inhibitor IMP-0000877
6EU5	;	1.49608	;	Leishmania major N-myristoyltransferase with bound myristoyl-CoA and inhibitor
6EWF	;	1.53517	;	Leishmania major N-myristoyltransferase with bound myristoyl-CoA and inhibitor
4DY9	;	2.082	;	Leishmania major Peroxidase is a Cytochrome c Peroxidase
6VMT	;	2.501	;	Leishmania major Programmed Cell Death Protein 5 Homolog
6RXC	;	2.1	;	Leishmania major pteridine reductase 1 (LmPTR1) in complex with inhibitor 4 (NMT-C0026)
5L4N	;	2.35	;	Leishmania major Pteridine reductase 1 (PTR1) in complex with compound 1
5L42	;	2.1	;	Leishmania major Pteridine reductase 1 (PTR1) in complex with compound 3
2BF7	;	2.4	;	Leishmania major pteridine reductase 1 in complex with NADP and biopterin
2BFA	;	2.7	;	Leishmania major pteridine reductase 1 in complex with NADP and CB3717
2BFP	;	2.55	;	Leishmania major pteridine reductase 1 in complex with NADP and tetrahydrobiopterin
2BFM	;	2.6	;	Leishmania major pteridine reductase 1 in complex with NADP and trimethoprim
2BFO	;	2.6	;	Leishmania major pteridine reductase 1 in complex with NADPH
4UXH	;	2.4	;	Leishmania major Thymidine Kinase in complex with AP5dT
4UXJ	;	3.0	;	Leishmania major Thymidine Kinase in complex with dTTP
4UXI	;	2.74	;	Leishmania major Thymidine Kinase in complex with thymidine
3P0H	;	3.0	;	Leishmania major Tyrosyl-tRNA synthetase in complex with fisetin, cubic crystal form
3P0I	;	3.13	;	Leishmania major Tyrosyl-tRNA synthetase in complex with tyrosinol, cubic crystal form
3P0J	;	2.89	;	Leishmania major Tyrosyl-tRNA synthetase in complex with tyrosinol, triclinic crystal form 1
6P4E	;	1.35	;	Leishmania mexicana CPB in complex with an aza-nitrile inhibitor
1I32	;	2.6	;	LEISHMANIA MEXICANA GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE IN COMPLEX WITH INHIBITORS
1I33	;	3.0	;	LEISHMANIA MEXICANA GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE IN COMPLEX WITH INHIBITORS
2C34	;		;	Leishmania mexicana ICP
1AMK	;	1.83	;	LEISHMANIA MEXICANA TRIOSE PHOSPHATE ISOMERASE
3CXM	;	1.5	;	Leishmania naiffi uracil-DNA glycosylase in complex with 5-bromouracil
7Z90	;	3.88	;	Leishmania RNA virus 1 virion
5CG7	;	1.88	;	Leishmania siamensis Triosephosphate isomerase
3IY9	;	14.1	;	Leishmania Tarentolae Mitochondrial Large Ribosomal Subunit Model
3IY8	;	14.1	;	Leishmania tarentolae Mitonchondrial Ribosome small subunit
8SGX	;	10.3	;	Leishmania tarentolae propionyl-CoA carboxylase (alpha-4-beta-6)
8SGY	;	8.62	;	Leishmania tarentolae propionyl-CoA carboxylase (alpha-5-beta-6)
8SGZ	;	3.2	;	Leishmania tarentolae propionyl-CoA carboxylase (alpha-6-beta-6)
6QM8	;	3.3	;	Leishmania tarentolae proteasome 20S subunit apo structure
6QM7	;	2.8	;	Leishmania tarentolae proteasome 20S subunit complexed with GSK3494245
6TCZ	;	3.4	;	Leishmania tarentolae proteasome 20S subunit complexed with LXE408
6TD5	;	3.2	;	Leishmania tarentolae proteasome 20S subunit complexed with LXE408 and bortezomib
8OLU	;	2.59	;	Leishmania tarentolae proteasome 20S subunit in complex with 1-Benzyl-N-(3-(cyclopropylcarbamoyl)phenyl)-6-oxo-1,6-dihydropyridazine-3-carboxamide
7ZYJ	;	2.7	;	Leishmania tarentolae proteasome 20S subunit in complex with compound 2
4AGS	;	2.3	;	Leishmania TDR1 - a unique trimeric glutathione transferase
1LML	;	1.86	;	LEISHMANOLYSIN
4C7H	;	1.4	;	Leismania major N-myristoyltransferase in complex with a peptidomimetic (-NH2) molecule
4C7I	;	1.3	;	Leismania major N-myristoyltransferase in complex with a peptidomimetic (-OH) molecule
1HDL	;		;	LEKTI domain one
1H0Z	;		;	LEKTI domain six
6RPR	;	2.26	;	LEM domain of Emerin mutant T43I in complex with BAF dimer and the Igfold of the lamin A/C
1JEI	;		;	LEM DOMAIN OF HUMAN INNER NUCLEAR MEMBRANE PROTEIN EMERIN
1H9F	;		;	LEM DOMAIN OF HUMAN INNER NUCLEAR MEMBRANE PROTEIN LAP2
2ODC	;		;	LEM-domain of the nuclear envelope protein emerin
1H9E	;		;	LEM-LIKE DOMAIN OF HUMAN INNER NUCLEAR MEMBRANE PROTEIN LAP2
6SEQ	;	2.1	;	Lemur tyrosine kinase 3 (LMTK3)
4LVE	;	2.3	;	LEN K30T MUTANT: A DOMAIN FLIP AS A RESULT OF A SINGLE AMINO ACID SUBSTITUTION
3LVE	;	2.0	;	LEN Q38E MUTANT: A DOMAIN FLIP FROM A SINGLE AMINO ACID SUBSTITUTION
2J9I	;	17.0	;	Lengsin is a survivor of an ancient family of class I glutamine synthetases in eukaryotes that has undergone evolutionary re- engineering for a tissue-specific role in the vertebrate eye lens.
1LES	;	1.9	;	LENTIL LECTIN COMPLEXED WITH SUCROSE
4AUR	;	2.7	;	LeoA bacterial dynamin GTPase from ETEC
4OHD	;	2.7	;	LEOPARD Syndrome-Associated SHP2/A461T mutant
4OHE	;	2.506	;	LEOPARD Syndrome-Associated SHP2/G464A mutant
4OHH	;	2.7	;	LEOPARD Syndrome-Associated SHP2/Q506P mutant
4OHI	;	2.2	;	LEOPARD Syndrome-Associated SHP2/Q510E mutant
4OHL	;	2.4	;	LEOPARD Syndrome-Associated SHP2/T468M mutant
4DGX	;	2.3	;	LEOPARD Syndrome-Associated SHP2/Y279C mutant
6J46	;	2.621	;	LepI-SAH complex structure
4ARX	;	2.35	;	Lepidoptera-specific toxin Cry1Ac from Bacillus thuringiensis ssp. kurstaki HD-73
4ARY	;	2.95	;	Lepidopteran-specific toxin Cry1Ac in complex with receptor specificity determinant GalNAc
3V6O	;	1.95	;	Leptin Receptor-antibody complex
8DHA	;	3.8	;	Leptin-bound leptin receptor complex- focused interaction
8DH9	;	4.5	;	Leptin-bound leptin receptor complex-D3-D7
8DH8	;	5.9	;	Leptin-bound leptin receptor complex-full ECD
3B2G	;	1.76	;	Leptolyngbya boryana Ferredoxin
8A48	;	3.044	;	Less crystallisable"" IgG1 Fc fragment (E382S variant)
7KOG	;	4.25	;	Lethocerus Myosin II complete coiled-coil domain resolved in its native environment
3T4R	;	2.0	;	Lettuce Necrotic Yellow Virus Phosphoprotein C-Terminal Domain
1SGR	;	1.8	;	LEU 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B
5TTR	;	2.7	;	LEU 55 PRO TRANSTHYRETIN CRYSTAL STRUCTURE
3ZJL	;	1.5	;	Leu(142)G4Ala mutation of M.acetivorans protoglobin in complex with cyanide
2QPM	;	1.85	;	Leu492Ala mutant of Maize cytokinin oxidase/dehydrogenase complexed with benzylurea inhibitor CPBU
3KJM	;	1.9	;	Leu492Ala mutant of Maize cytokinin oxidase/dehydrogenase complexed with phenylurea inhibitor CPPU
1LAM	;	1.6	;	LEUCINE AMINOPEPTIDASE (UNLIGATED)
7OEZ	;	2.48	;	Leucine Aminopeptidase A mature enzyme in a complex with leucine
1LAN	;	1.9	;	LEUCINE AMINOPEPTIDASE COMPLEX WITH L-LEUCINAL
1LEH	;	2.2	;	LEUCINE DEHYDROGENASE FROM BACILLUS SPHAERICUS
8HR6	;	3.52	;	leucine DEHYDROGENASE STRUCTURE IN TERNARY COMPLEX WITH NAD+ from Bacillus thuringiensis
5IL7	;	2.3	;	Leucine rich repeat domain of the Chlorobium tepidum Roco protein
3GWV	;	2.35	;	Leucine transporter LeuT in complex with R-fluoxetine
3GWW	;	2.46	;	Leucine transporter LeuT in complex with S-fluoxetine
3GWU	;	2.14	;	Leucine transporter LeuT in complex with sertraline
2SSP	;	2.25	;	LEUCINE-272-ALANINE URACIL-DNA GLYCOSYLASE BOUND TO ABASIC SITE-CONTAINING DNA
5DJ4	;	2.697	;	Leucine-bound Sestrin2 from Homo sapiens
8H24	;	2.45	;	Leucine-rich alpha-2-glycoprotein 1
6HN4	;	4.2	;	Leucine-zippered human insulin receptor ectodomain with single bound insulin - ""lower"" membrane-proximal part
6HN5	;	3.2	;	Leucine-zippered human insulin receptor ectodomain with single bound insulin - ""upper"" membrane-distal part
1OBC	;	2.1	;	LEUCYL-TRNA SYNTHETASE FROM THERMUS THERMOPHILUS COMPLEXED WITH A POST-TRANSFER EDITING SUBSTRATE ANALOGUE
1OBH	;	2.2	;	LEUCYL-TRNA SYNTHETASE FROM THERMUS THERMOPHILUS COMPLEXED WITH A PRE-TRANSFER EDITING SUBSTRATE ANALOGUE IN BOTH SYNTHETIC ACTIVE SITE AND EDITING SITE
1H3N	;	2.0	;	Leucyl-tRNA synthetase from Thermus thermophilus complexed with a sulphamoyl analogue of leucyl-adenylate
2V0C	;	1.85	;	LEUCYL-TRNA SYNTHETASE FROM THERMUS THERMOPHILUS COMPLEXED WITH A SULPHAMOYL ANALOGUE OF LEUCYL-ADENYLATE In the synthetic site and an adduct of AMP with 5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690) in the editing site
2V0G	;	3.5	;	LEUCYL-TRNA SYNTHETASE FROM THERMUS THERMOPHILUS COMPLEXED WITH A tRNA(leu) transcript with 5-FLUORO-1,3-DIHYDRO-1-HYDROXY-2,1- BENZOXABOROLE (AN2690) forming an adduct to the ribose of adenosine- 76 in the enzyme editing site.
2DPT	;	2.75	;	Leucyl/phenylalanyl-tRNA-protein transferase complexed with puromycin
3H5E	;	2.0	;	LeuD_1-156 small subunit of isopropylmalate isomerase (Rv2987c) from mycobacterium tuberculosis
3H5J	;	1.2	;	LeuD_1-168 small subunit of isopropylmalate isomerase (Rv2987c) from mycobacterium tuberculosis
3H5H	;	2.5	;	LeuD_1-186 small subunit of isopropylmalate isomerase (Rv2987c) from mycobacterium tuberculosis
1A7M	;		;	LEUKAEMIA INHIBITORY FACTOR CHIMERA (MH35-LIF), NMR, 20 STRUCTURES
1LKF	;	1.9	;	LEUKOCIDIN F (HLGB) FROM STAPHYLOCOCCUS AUREUS
2LKF	;	2.5	;	LEUKOCIDIN F (HLGB) FROM STAPHYLOCOCCUS AUREUS
3LKF	;	1.9	;	LEUKOCIDIN F (HLGB) FROM STAPHYLOCOCCUS AUREUS WITH PHOSPHOCHOLINE BOUND
3FH5	;	1.63	;	Leukotriene A4 Hydrolase complexed with inhibitor (2R)-2-[(4-benzylphenoxy)methyl]pyrrolidine.
3FH8	;	1.67	;	Leukotriene A4 Hydrolase complexed with inhibitor 1-[2-(4-benzylphenoxy)ethyl]pyrrolidine.
3FH7	;	2.05	;	Leukotriene A4 Hydrolase complexed with inhibitor 4-[(2S)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}pyrrolidin-1-yl]butanoate.
3FHE	;	2.16	;	Leukotriene A4 Hydrolase complexed with inhibitor N-[3-(4-benzylphenoxy)propyl]-N-methyl-beta-alanine.
3B7R	;	1.811	;	Leukotriene A4 Hydrolase Complexed with Inhibitor RB3040
2R59	;	1.89	;	Leukotriene A4 hydrolase complexed with inhibitor RB3041
3B7U	;	1.9	;	Leukotriene A4 Hydrolase Complexed with KELatorphan
3FU5	;	2.3	;	Leukotriene A4 hydrolase in complex with (5-thiophen-2-ylthiophen-2-yl)methylamine
3FUM	;	2.15	;	Leukotriene A4 hydrolase in complex with (R)-pyridin-4-yl[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanol
3FUK	;	1.95	;	Leukotriene A4 hydrolase in complex with 1-[2-(1H-indol-5-yloxy)ethyl]piperidine-4-carboxylic acid
8AVA	;	1.354	;	Leukotriene A4 hydrolase in complex with 4-(4-benzylphenyl)-oxazol-2-amine
8AWH	;	1.42	;	Leukotriene A4 hydrolase in complex with 4-(4-Benzylphenyl)-selenazol-2-amine
3FUJ	;	1.9	;	Leukotriene A4 hydrolase in complex with 5-[2-(1H-pyrrol-1-yl)ethoxy]-1H-indole
3FTU	;	1.9	;	Leukotriene A4 hydrolase in complex with dihydroresveratrol
3FTX	;	1.96	;	Leukotriene A4 hydrolase in complex with dihydroresveratrol and bestatin
3FU6	;	2.05	;	Leukotriene A4 hydrolase in complex with fragment (4-thiophen-2-ylphenyl)methanamine
3FTZ	;	2.0	;	Leukotriene A4 hydrolase in complex with fragment 2-(pyridin-3-ylmethoxy)aniline
3FTY	;	2.15	;	Leukotriene A4 hydrolase in complex with fragment 3-(benzyloxy)pyridin-2-amine
3FU3	;	2.0	;	Leukotriene A4 hydrolase in complex with fragment 4-(2-amino-1,3-thiazol-4-yl)phenol
3FU0	;	1.8	;	Leukotriene A4 hydrolase in complex with fragment 4-(4-fluorobenzoyl)pyridine
3FUE	;	2.38	;	Leukotriene A4 hydrolase in complex with fragment 5-chloroindole and bestatin
3FUF	;	2.6	;	Leukotriene A4 hydrolase in complex with fragment 5-fluoroindole and bestatin
3FUH	;	1.8	;	Leukotriene A4 hydrolase in complex with fragment 5-hydroxyindole and bestatin
3FTV	;	1.7	;	Leukotriene A4 hydrolase in complex with fragment N-(pyridin-3-ylmethyl)aniline
3FTW	;	1.85	;	Leukotriene A4 hydrolase in complex with fragments N-(pyridin-3-ylmethyl)aniline and acetate
3FUI	;	2.2	;	Leukotriene A4 hydrolase in complex with N-benzyl-4-[(2R)-pyrrolidin-2-ylmethoxy]aniline
3FUD	;	2.2	;	Leukotriene A4 hydrolase in complex with N-methyl-1-(2-thiophen-2-ylphenyl)methanamine
3FUL	;	2.39	;	Leukotriene A4 hydrolase in complex with pyridin-4-yl[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone
3FTS	;	2.33	;	Leukotriene A4 hydrolase in complex with resveratrol
3FUN	;	1.58	;	Leukotriene A4 hydrolase in complex with {4-[(2R)-pyrrolidin-2-ylmethoxy]phenyl}(4-thiophen-3-ylphenyl)methanone
5X33	;	3.7	;	Leukotriene B4 receptor BLT1 in complex with BIIL260
5JAE	;	2.5	;	LeuT in the outward-oriented, Na+-free return state, P21 form at pH 6.5
5JAF	;	3.021	;	LeuT Na+-free Return State, C2 form at pH 5
5JAG	;	2.58	;	LeuT T354H mutant in the outward-oriented, Na+-free Return State
8AA0	;	3.2	;	Levan utilisation machinery (utilisome) with levan fructo-oligosaccharides DP 8-12
7EHS	;	1.6	;	Levansucrase from Brenneria sp. EniD 312
7EHT	;	1.45	;	Levansucrase from Brenneria sp. EniD 312
7EHR	;	1.33	;	Levansucrase from Brenneria sp. EniD 312 at 1.33 angstroms resolution
7FDZ	;	1.35	;	Levansucrase from Brenneria sp. EniD 312 with sucrose
8E2O	;		;	Leveraging the Structure of DNAJA1 to Discover Novel Pancreatic Cancer Therapies
7B8T	;	2.7	;	Levofloxacin bound structure of bacterial efflux pump.
6A3F	;	1.8	;	Levoglucosan dehydrogenase, apo form
6A3G	;	1.9	;	Levoglucosan dehydrogenase, complex with NADH
6A3J	;	1.9	;	Levoglucosan dehydrogenase, complex with NADH and L-sorbose
6A3I	;	2.41	;	Levoglucosan dehydrogenase, complex with NADH and levoglucosan
1JHF	;	1.8	;	LEXA G85D MUTANT
1JHE	;	2.5	;	LEXA L89P Q92W E152A K156A MUTANT
1JHC	;	2.0	;	LEXA S119A C-TERMINAL TRYPTIC FRAGMENT
1JHH	;	2.1	;	LEXA S119A MUTANT
3BQM	;	1.95	;	LFA-1 I domain bound to inhibitors
3BQN	;	1.8	;	LFA-1 I domain bound to inhibitors
3E2M	;	2.0	;	LFA-1 I domain bound to inhibitors
5ZPU	;	2.6	;	LFS829 in complex with CRM1-Ran-RanBP1
6ZXA	;	2.38	;	LH2 complex from Marichromatium purpuratum
7TUW	;	8.2	;	LH2-LH3 antenna in anti parallel configuration embedded in a nanodisc
8FB9	;	6.4	;	LH2-LH3 antenna in anti parallel configuration embedded in a nanodisc
7TV3	;	11.4	;	LH2-LH3 antenna in parallel configuration embedded in a nanodisc
8FBB	;	11.3	;	LH2-LH3 antenna in parallel configuration embedded in a nanodisc
7E0J	;	3.13	;	LHCII-1 in the state transition supercomplex PSI-LHCI-LHCII from the double phosphatase mutant pph1;pbcp of Chlamydomonas reinhardti.
7E0H	;	3.75	;	LHCII-1 in the state transition supercomplex PSI-LHCI-LHCII from the LhcbM1 lacking mutant of Chlamydomonas reinhardtii
7E0K	;	3.09	;	LHCII-2 in the state transition supercomplex PSI-LHCI-LHCII from the double phosphatase mutant pph1;pbcp of Chlamydomonas reinhardti.
7E0I	;	3.53	;	LHCII-2 in the state transition supercomplex PSI-LHCI-LHCII from the LhcbM1 lacking mutant of Chlamydomonas reinhardti
2VI0	;	1.51	;	Lichenase CtLic26 in complex with a thio-oligosaccharide
7ACW	;	1.5	;	LID/HID (LMW SLP and HMW SLP interacting domains) from C. difficile (R7404 strain)
3TNF	;	2.5	;	LidA from Legionella in complex with active Rab8a
3J02	;	8.0	;	Lidless D386A Mm-cpn in the pre-hydrolysis ATP-bound state
3J03	;	4.8	;	Lidless Mm-cpn in the closed state with ATP/AlFx
3J31	;	4.5	;	Life in the extremes: atomic structure of Sulfolobus Turreted Icosahedral Virus
7BTE	;	4.2	;	Lifeact-F-actin complex
6YOA	;	2.83	;	Lig v 1 structure and the inflammatory response to the Ole e 1 protein family
1M18	;	2.45	;	LIGAND BINDING ALTERS THE STRUCTURE AND DYNAMICS OF NUCLEOSOMAL DNA
1M19	;	2.3	;	LIGAND BINDING ALTERS THE STRUCTURE AND DYNAMICS OF NUCLEOSOMAL DNA
1M1A	;	2.65	;	LIGAND BINDING ALTERS THE STRUCTURE AND DYNAMICS OF NUCLEOSOMAL DNA
6FU4	;	2.45	;	Ligand binding domain (LBD) of the p. aeruginosa histamine receptor TlpQ
6GCV	;	1.3	;	Ligand binding domain (LBD) of the p. aeruginosa nitrate receptor McpN
3M3K	;	1.793	;	Ligand binding domain (S1S2) of GluA3 (flop)
7K5N	;	1.8	;	Ligand binding domain (tandem PAS/dCache) of Aeromonas caviae diguanylate cyclase with proline bound
6J6F	;	4.2	;	Ligand binding domain 1 and 2 of Talaromyces marneffei Mp1 protein
5ECF	;	2.6	;	Ligand binding domain 1 of Penicillium marneffei MP1 protein complexed with arachidonic acids
5E7X	;	1.8	;	Ligand binding domain 1 of Penicillium marneffei MP1 protein in complex with palmitic acid
5FB7	;	1.5	;	Ligand binding domain 2 of Penicillium marneffei MP1 protein complexed with multiple arachidonic acids
5CSD	;	1.45	;	Ligand binding domain 2 of Penicillium marneffei MP1 protein in complex with arachidonic acids
4B7W	;	4.0	;	Ligand binding domain human hepatocyte nuclear factor 4alpha: Apo form
3NRU	;	2.3	;	Ligand binding domain of EPHA7
4GXS	;	1.9634	;	Ligand binding domain of GluA2 (AMPA/glutamate receptor) bound to (-)-kaitocephalin
3P1I	;	2.1	;	Ligand binding domain of human ephrin type-B receptor 3
3PRG	;	2.9	;	LIGAND BINDING DOMAIN OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR
2YFE	;	2.0	;	Ligand binding domain of human PPAR gamma in complex with amorfrutin 1
4A4V	;	2.0	;	Ligand binding domain of human PPAR gamma in complex with amorfrutin 2
4A4W	;	2.0	;	Ligand binding domain of human PPAR gamma in complex with amorfrutin B
2XKW	;	2.02	;	LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST PIOGLITAZONE
1WWB	;	2.1	;	LIGAND BINDING DOMAIN OF HUMAN TRKB RECEPTOR
3LMK	;	2.44	;	Ligand Binding Domain of Metabotropoc glutamate receptor mGluR5 complexed with glutamate
6F9G	;	2.388	;	Ligand binding domain of P. putida KT2440 polyamine chemorecpetors McpU in complex putrescine.
2Q5G	;	2.7	;	Ligand binding domain of PPAR delta receptor in complex with a partial agonist
3S9S	;	2.55	;	Ligand binding domain of PPARgamma complexed with a benzimidazole partial agonist
3U9Q	;	1.522	;	Ligand binding domain of PPARgamma complexed with Decanoic Acid and PGC-1a peptide
5T65	;	2.2	;	LIGAND BINDING DOMAIN OF PSEUDOMONAS AERUGINOSA PAO1 AMINO ACID CHEMORECEPTOR PCTA IN COMPLEX WITH L-ILE
5LTX	;	2.02	;	LIGAND BINDING DOMAIN OF PSEUDOMONAS AERUGINOSA PAO1 AMINO ACID CHEMORECEPTOR PCTA IN COMPLEX WITH L-MET
5T7M	;	2.25	;	LIGAND BINDING DOMAIN OF PSEUDOMONAS AERUGINOSA PAO1 AMINO ACID CHEMORECEPTOR PCTA IN COMPLEX WITH L-TRP
5LT9	;	3.0	;	Ligand binding domain of Pseudomonas aeruginosa PAO1 amino acid chemoreceptors PctB in complex with L-Arg
5LTO	;	3.459	;	Ligand binding domain of Pseudomonas aeruginosa PAO1 amino acid chemoreceptors PctB in complex with L-Gln
5LTV	;	2.31	;	LIGAND BINDING DOMAIN OF PSEUDOMONAS AERUGINOSA PAO1 AMINO ACID CHEMORECPETOR PCTC IN COMPLEX WITH GABA
3CLD	;	2.84	;	Ligand binding domain of the glucocorticoid receptor complexed with fluticazone furoate
1PRG	;	2.2	;	LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA
1KNU	;	2.5	;	LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA IN COMPLEX WITH A SYNTHETIC AGONIST
1NYX	;	2.65	;	Ligand binding domain of the human peroxisome proliferator activated receptor gamma in complex with an agonist
6S1A	;	2.112	;	Ligand binding domain of the P. putida receptor PcaY_PP
6S3B	;	1.95	;	Ligand binding domain of the P. putida receptor PcaY_PP in complex with benzoate
6S18	;	1.6	;	Ligand binding domain of the P. putida receptor PcaY_PP in complex with glycerol
6S33	;	1.56	;	Ligand binding domain of the P. putida receptor PcaY_PP in complex with Protocatechuate
6S38	;	2.15	;	Ligand binding domain of the P. putida receptor PcaY_PP in complex with quinate
6S37	;	2.3	;	Ligand binding domain of the P. putida receptor PcaY_PP in complex with salicylic acid
1VLS	;	1.85	;	LIGAND BINDING DOMAIN OF THE WILD-TYPE ASPARTATE RECEPTOR
1VLT	;	2.2	;	LIGAND BINDING DOMAIN OF THE WILD-TYPE ASPARTATE RECEPTOR WITH ASPARTATE
5Q0I	;	1.7	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q0J	;	2.0	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q0K	;	1.8	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q0L	;	2.5	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q0M	;	2.2	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q0N	;	2.4	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q0O	;	1.9	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q0P	;	1.8	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q0Q	;	2.6	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q0R	;	1.91	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q0S	;	2.5	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q0T	;	2.14	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q0U	;	1.9	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q0V	;	1.87	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q0W	;	1.9	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q0X	;	2.26	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q0Y	;	2.2	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q0Z	;	2.26	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q10	;	2.2	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q11	;	2.2	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q12	;	2.0	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q13	;	1.9	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q14	;	1.85	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q15	;	1.9	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q16	;	2.0	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q17	;	2.1	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q18	;	1.9	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q19	;	1.98	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q1A	;	2.0	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q1B	;	2.3	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q1C	;	2.3	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q1D	;	1.89	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q1E	;	1.85	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q1F	;	2.3	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q1G	;	2.0	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q1H	;	2.2	;	Ligand binding to FARNESOID-X-RECEPTOR
5Q1I	;	1.95	;	Ligand binding to FARNESOID-X-RECEPTOR
7ZZT	;	1.56	;	Ligand binding to HDAC2
7ZZW	;	1.73	;	Ligand binding to HDAC2
2RFC	;	3.1	;	Ligand bound (4-phenylimidazole) Crystal Structure of a Cytochrome P450 from the Thermoacidophilic Archaeon Picrophilus Torridus
6C4J	;	2.53	;	Ligand bound full length hUGDH with A104L substitution
7ZJ4	;	4.43	;	Ligand bound state of a brocolli-pepper aptamer FRET tile
2KP8	;		;	Ligand bound to a model peptide that mimics the open fusogenic form
5APH	;	1.54	;	Ligand complex of RORg LBD
5APJ	;	2.08	;	Ligand complex of RORg LBD
5APK	;	2.1	;	Ligand complex of RORg LBD
5G42	;	1.72	;	Ligand complex of RORg LBD
5G43	;	2.58	;	Ligand complex of RORg LBD
5G44	;	1.84	;	Ligand complex of RORg LBD
5G45	;	2.07	;	Ligand complex of RORg LBD
5G46	;	1.76	;	Ligand complex of RORg LBD
5NI5	;	2.3	;	Ligand complex of RORg LBD
5NI7	;	2.45	;	Ligand complex of RORg LBD
5NI8	;	1.94	;	Ligand complex of RORg LBD
5NIB	;	1.82	;	Ligand complex of RORg LBD
6ESN	;	1.84	;	Ligand complex of RORg LBD
6FGQ	;	2.37	;	Ligand complex of RORg LBD
6R7A	;	2.13	;	Ligand complex of RORg LBD
6R7J	;	1.84	;	Ligand complex of RORg LBD
6R7K	;	1.54	;	Ligand complex of RORg LBD
7OFI	;	1.953	;	Ligand complex of RORg LBD
7OFK	;	1.61	;	Ligand complex of RORg LBD
5ZA1	;	2.52	;	Ligand complex of RORgt LBD
6JDY	;	1.5	;	Ligand complex structure of GH10 family xylanase XynAF1, soaking for 120 minutes
6JDZ	;	1.16	;	Ligand complex structure of GH10 family xylanase XynAF1, soaking for 20 minutes
6JE0	;	1.43	;	Ligand complex structure of GH10 family xylanase XynAF1, soaking for 30 minutes
6JE1	;	1.18	;	Ligand complex structure of GH10 family xylanase XynAF1, soaking for 40 minutes
6JE2	;	1.22	;	Ligand complex structure of GH10 family xylanase XynAF1, soaking for 80 minutes
5AI0	;	1.75	;	Ligand complex structure of soluble epoxide hydrolase
5AI4	;	1.93	;	ligand complex structure of soluble epoxide hydrolase
5AI5	;	2.28	;	ligand complex structure of soluble epoxide hydrolase
5AI6	;	2.3	;	ligand complex structure of soluble epoxide hydrolase
5AI8	;	1.85	;	ligand complex structure of soluble epoxide hydrolase
5AI9	;	1.8	;	ligand complex structure of soluble epoxide hydrolase
5AIA	;	2.26	;	ligand complex structure of soluble epoxide hydrolase
5AIB	;	1.95	;	ligand complex structure of soluble epoxide hydrolase
5AIC	;	1.89	;	ligand complex structure of soluble epoxide hydrolase
5AK3	;	2.28	;	ligand complex structure of soluble epoxide hydrolase
5AK4	;	1.79	;	ligand complex structure of soluble epoxide hydrolase
5AK5	;	2.22	;	ligand complex structure of soluble epoxide hydrolase
5AK6	;	2.15	;	ligand complex structure of soluble epoxide hydrolase
5AKE	;	2.26	;	ligand complex structure of soluble epoxide hydrolase
5AKG	;	2.51	;	ligand complex structure of soluble epoxide hydrolase
5AKH	;	2.1	;	ligand complex structure of soluble epoxide hydrolase
5AKI	;	1.81	;	ligand complex structure of soluble epoxide hydrolase
5AKJ	;	2.03	;	ligand complex structure of soluble epoxide hydrolase
5AKK	;	1.9	;	ligand complex structure of soluble epoxide hydrolase
5AKL	;	2.0	;	ligand complex structure of soluble epoxide hydrolase
5AKX	;	2.09	;	ligand complex structure of soluble epoxide hydrolase
5AKY	;	2.18	;	ligand complex structure of soluble epoxide hydrolase
5AKZ	;	2.18	;	ligand complex structure of soluble epoxide hydrolase
5ALD	;	2.26	;	ligand complex structure of soluble epoxide hydrolase
5ALE	;	1.95	;	ligand complex structure of soluble epoxide hydrolase
5ALF	;	2.32	;	ligand complex structure of soluble epoxide hydrolase
5ALG	;	2.4	;	ligand complex structure of soluble epoxide hydrolase
5ALH	;	1.9	;	ligand complex structure of soluble epoxide hydrolase
5ALI	;	1.85	;	ligand complex structure of soluble epoxide hydrolase
5ALJ	;	2.1	;	ligand complex structure of soluble epoxide hydrolase
5ALK	;	2.33	;	ligand complex structure of soluble epoxide hydrolase
5ALL	;	2.2	;	ligand complex structure of soluble epoxide hydrolase
5ALM	;	2.0	;	ligand complex structure of soluble epoxide hydrolase
5ALN	;	2.0	;	ligand complex structure of soluble epoxide hydrolase
5ALO	;	2.0	;	ligand complex structure of soluble epoxide hydrolase
5ALP	;	2.06	;	ligand complex structure of soluble epoxide hydrolase
5ALQ	;	2.78	;	ligand complex structure of soluble epoxide hydrolase
5ALR	;	2.6	;	ligand complex structure of soluble epoxide hydrolase
5ALS	;	2.57	;	ligand complex structure of soluble epoxide hydrolase
5ALT	;	2.15	;	ligand complex structure of soluble epoxide hydrolase
5ALU	;	1.87	;	ligand complex structure of soluble epoxide hydrolase
5ALV	;	1.8	;	ligand complex structure of soluble epoxide hydrolase
5ALW	;	2.2	;	ligand complex structure of soluble epoxide hydrolase
5ALX	;	2.23	;	ligand complex structure of soluble epoxide hydrolase
5ALY	;	1.9	;	ligand complex structure of soluble epoxide hydrolase
5ALZ	;	2.3	;	ligand complex structure of soluble epoxide hydrolase
5AM0	;	1.88	;	ligand complex structure of soluble epoxide hydrolase
5AM1	;	2.15	;	ligand complex structure of soluble epoxide hydrolase
5AM2	;	1.7	;	ligand complex structure of soluble epoxide hydrolase
5AM3	;	2.2	;	ligand complex structure of soluble epoxide hydrolase
5AM4	;	1.87	;	ligand complex structure of soluble epoxide hydrolase
5AM5	;	2.26	;	ligand complex structure of soluble epoxide hydrolase
5FP0	;	2.35	;	ligand complex structure of soluble epoxide hydrolase
4JG4	;	2.296	;	Ligand concentration regulates the pathways of coupled protein folding and binding
4AJX	;	1.2	;	Ligand controlled assembly of hexamers, dihexamers, and linear multihexamer structures by an engineered acylated insulin
4AJZ	;	1.8	;	Ligand controlled assembly of hexamers, dihexamers, and linear multihexamer structures by an engineered acylated insulin
4AK0	;	2.28	;	Ligand controlled assembly of hexamers, dihexamers, and linear multihexamer structures by an engineered acylated insulin
4AKJ	;	2.01	;	Ligand controlled assembly of hexamers, dihexamers, and linear multihexamer structures by an engineered acylated insulin
1IS5	;	2.0	;	Ligand free Congerin II
7XSY	;	2.5	;	Ligand free structure of branching enzyme isoform 3 (BE3) from Crocosphaera subtropica ATCC 51142
5VWS	;	2.411	;	Ligand free structure of Cytochrome P450 TbtJ1
2R0F	;	2.0	;	Ligand free structure of fungal lectin CGL3
7A0U	;	2.26049	;	LIGAND FREE TYPE II E. COLI ASPARAGINASE T12S/T89S DOUBLE MUTANT
1CD2	;	2.2	;	LIGAND INDUCED CONFORMATIONAL CHANGES IN THE CRYSTAL STRUCTURES OF PNEUMOCYSTIS CARINII DIHYDROFOLATE REDUCTASE COMPLEXES WITH FOLATE AND NADP+
2CD2	;	1.9	;	LIGAND INDUCED CONFORMATIONAL CHANGES IN THE CRYSTAL STRUCTURES OF PNEUMOCYSTIS CARINII DIHYDROFOLATE REDUCTASE COMPLEXES WITH FOLATE AND NADP+
3CD2	;	2.5	;	LIGAND INDUCED CONFORMATIONAL CHANGES IN THE CRYSTAL STRUCTURES OF PNEUMOCYSTIS CARINII DIHYDROFOLATE REDUCTASE COMPLEXES WITH FOLATE AND NADP+
4CD2	;	2.0	;	LIGAND INDUCED CONFORMATIONAL CHANGES IN THE CRYSTAL STRUCTURES OF PNEUMOCYSTIS CARINII DIHYDROFOLATE REDUCTASE COMPLEXES WITH FOLATE AND NADP+
1TBW	;	2.15	;	Ligand Induced Conformational Shift in the N-terminal Domain of GRP94, Open Conformation
1TC6	;	1.87	;	Ligand Induced Conformational Shift in the N-terminal Domain of GRP94, Open Conformation ADP-Complex
1TC0	;	2.2	;	Ligand Induced Conformational Shifts in the N-terminal Domain of GRP94, Open Conformation Complexed with the physiological partner ATP
5X5S	;		;	Ligand induced structure of AmyP-SBD
2R4X	;	2.1	;	Ligand Migration and Binding in The Dimeric Hemoglobin of Scapharca Inaequivalvis: H69V/I114M co complex
2R4Y	;	2.0	;	Ligand Migration and Binding in The Dimeric Hemoglobin of Scapharca Inaequivalvis: H69V/I114M unliganded
2Z8A	;	1.06	;	Ligand Migration and Binding in The Dimeric Hemoglobin of Scapharca Inaequivalvis: I25W with CO Bound to HEME and in the Presence of 3 Atoms of XE
2Z85	;	1.6	;	Ligand Migration and Binding in The Dimeric Hemoglobin of Scapharca Inaequivalvis: M37F Unliganded
2R4W	;	1.8	;	Ligand Migration and Binding in The Dimeric Hemoglobin of Scapharca Inaequivalvis: M37F with CO bound
2R4Z	;	1.6	;	Ligand Migration and Binding in The Dimeric Hemoglobin of Scapharca Inaequivalvis: Structure of I25W with CO
3G4W	;	1.9	;	Ligand migration and cavities within scapharca dimeric hemoglobin: wild type with co bound to heme and chlorobenzene bound to the XE4 cavity
3G52	;	1.65	;	Ligand migration and cavities within scapharca dimeric hemoglobin: wild type with co bound to heme and chloroethyl benzene bound to the XE4 cavity
3G46	;	0.91	;	Ligand migration and cavities within scapharca dimeric hemoglobin: wild type with co bound to heme and chloroform bound to the XE4 cavity
3G4Q	;	1.6	;	Ligand migration and cavities within scapharca dimeric hemoglobin: wild type with co bound to heme and chloroform bound to the XE4 cavity
3G4Y	;	1.7	;	Ligand migration and cavities within scapharca dimeric hemoglobin: wild type with co bound to heme and chloromethyl benzene bound to the XE4 cavity
3G4V	;	2.1	;	Ligand migration and cavities within scapharca dimeric hemoglobin: wild type with co bound to heme and chloropentane bound to the XE4 cavity
3G53	;	1.64	;	Ligand migration and cavities within scapharca dimeric hemoglobin: wild type with co bound to heme and chloropropyl benzene bound to the XE4 cavity
3G4R	;	1.6	;	Ligand migration and cavities within scapharca dimeric hemoglobin: wild type with co bound to HEME and dichloroethane bound to the XE4 cavity
3G4U	;	2.1	;	Ligand migration and cavities within scapharca dimeric hemoglobin: wild type with co bound to heme and dichloropropane bound to the XE4 cavity
2BLH	;	1.77	;	Ligand Migration and Protein Fluctuations in Myoglobin Mutant L29W
5F8U	;	3.35	;	Ligand occupancy in crystal structure of beta1-adrenergic receptor previously submitted by Huang et al
3HEI	;	2.0	;	Ligand Recognition by A-Class Eph Receptors: Crystal Structures of the EphA2 Ligand-Binding Domain and the EphA2/ephrin-A1 Complex
3HPN	;	2.52	;	Ligand recognition by A-class EPH receptors: crystal structures of the EPHA2 ligand-binding domain and the EPHA2/EPHRIN-A1 complex
2R9J	;	2.55	;	Ligand recognition in C-lobe: The crystal structure of the complex of lactoferrin C-lobe with nicotinamide at 2.5 A resolution
2G93	;	1.9	;	Ligand recognition site in C-lobe of lactoferrin: Crystal structure of the complex of C-lobe of bovine lactoferrin with methyl alpha-D-mannopyranoside at 1.9 A resolution
5OLF	;		;	Ligand-Based NMR Study of C-X-C Chemokine Receptor Type 4 (CXCR4)-Ligand Interactions in Living Cancer Cells
1PDU	;	2.3	;	Ligand-binding domain of Drosophila orphan nuclear receptor DHR38
3O28	;	2.0	;	Ligand-binding domain of GluA2 (flip) ionotropic glutamate receptor in complex with an allosteric modulator
3O29	;	2.02	;	Ligand-binding domain of GluA2 (flip) ionotropic glutamate receptor in complex with an allosteric modulator
3O2A	;	1.9	;	Ligand-binding domain of GluA2 (flip) ionotropic glutamate receptor in complex with an allosteric modulator
3O6G	;	1.8	;	Ligand-binding domain of GluA2 (flip) ionotropic glutamate receptor in complex with an allosteric modulator
3O6H	;	2.1	;	Ligand-binding domain of GluA2 (flip) ionotropic glutamate receptor in complex with an allosteric modulator
3O6I	;	1.8	;	Ligand-binding domain of GluA2 (flip) ionotropic glutamate receptor in complex with an allosteric modulator
3PMV	;	1.8	;	Ligand-binding domain of GluA2 (flip) ionotropic glutamate receptor in complex with an allosteric modulator
3PMW	;	2.2	;	Ligand-binding domain of GluA2 (flip) ionotropic glutamate receptor in complex with an allosteric modulator
3PMX	;	1.87	;	Ligand-binding domain of GluA2 (flip) ionotropic glutamate receptor in complex with an allosteric modulator
4FAT	;	1.4	;	Ligand-binding domain of GluA2 (flip) ionotropic glutamate receptor in complex with an allosteric modulator
2PRG	;	2.3	;	LIGAND-BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA
3LBD	;	2.4	;	LIGAND-BINDING DOMAIN OF THE HUMAN RETINOIC ACID RECEPTOR GAMMA BOUND TO 9-CIS RETINOIC ACID
2LBD	;	2.06	;	LIGAND-BINDING DOMAIN OF THE HUMAN RETINOIC ACID RECEPTOR GAMMA BOUND TO ALL-TRANS RETINOIC ACID
4LBD	;	2.5	;	LIGAND-BINDING DOMAIN OF THE HUMAN RETINOIC ACID RECEPTOR GAMMA BOUND TO THE SYNTHETIC AGONIST BMS961
1DJS	;	2.4	;	LIGAND-BINDING PORTION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 IN COMPLEX WITH FGF1
3AQ0	;	2.65	;	Ligand-bound form of Arabidopsis medium/long-chain length prenyl pyrophosphate synthase (surface polar residue mutant)
7PQU	;	3.03	;	Ligand-bound human Kv3.1 cryo-EM structure (Lu AG00563)
5WFO	;	1.99	;	Ligand-bound Ras:SOS:Ras complex
5WFP	;	2.08	;	Ligand-bound Ras:SOS:Ras complex
5WFQ	;	2.26	;	Ligand-bound Ras:SOS:Ras complex
5WFR	;	2.46	;	Ligand-bound Ras:SOS:Ras complex
5SWE	;	3.0	;	Ligand-bound structure of adenine riboswitch aptamer domain converted in crystal from its ligand-free state using ligand mixing serial femtosecond crystallography
5LAK	;	2.299	;	Ligand-bound structure of Cavally Virus 3CL Protease
1C1F	;	1.6	;	LIGAND-FREE CONGERIN I
7PQ1	;	2.46	;	Ligand-free crystal structure of a staphylococcal orthologue of CYP134A1
8C4I	;	3.2	;	Ligand-free Crystal Structure of the decameric Sulfofructose Transaldolase BmSF-TAL
2Y2Z	;	1.95	;	ligand-free form of TetR-like repressor SimR
3GTU	;	2.8	;	LIGAND-FREE HETERODIMERIC HUMAN GLUTATHIONE S-TRANSFERASE M2-3 (EC 2.5.1.18), MONOCLINIC CRYSTAL FORM
1N3X	;	2.5	;	Ligand-free High-Affinity Maltose-Binding Protein
1PEB	;	2.6	;	LIGAND-FREE HIGH-AFFINITY MALTOSE-BINDING PROTEIN
4GTU	;	3.3	;	LIGAND-FREE HOMODIMERIC HUMAN GLUTATHIONE S-TRANSFERASE M4-4
1GTU	;	2.68	;	LIGAND-FREE HUMAN GLUTATHIONE S-TRANSFERASE M1A-1A
2GTU	;	2.55	;	LIGAND-FREE HUMAN GLUTATHIONE S-TRANSFERASE M2-2 (E.C.2.5.1.18), MONOCLINIC CRYSTAL FORM
6V23	;	1.75	;	Ligand-free L-aspraginase II from E. coli (EcAII)
5T50	;	1.43	;	LIGAND-FREE LECTIN FROM BAUHINIA FORFICATA
7L0C	;	1.8	;	Ligand-free PTP1B T177G
8PCZ	;	3.21	;	Ligand-free SpSLC9C1 in lipid nanodiscs, dimer
8PD2	;	3.25	;	Ligand-free SpSLC9C1 in lipid nanodiscs, protomer state 1
8PD3	;	3.3	;	Ligand-free SpSLC9C1 in lipid nanodiscs, protomer state 2
8PD5	;	3.4	;	Ligand-free SpSLC9C1 in lipid nanodiscs, protomer state 3
8PD7	;	3.4	;	Ligand-free SpSLC9C1 in lipid nanodiscs, protomer state 4
6TLG	;	2.4	;	Ligand-free state of human 14-3-3 sigma isoform
3ZBY	;	1.93	;	Ligand-free structure of CYP142 from Mycobacterium smegmatis
2BVJ	;	2.1	;	Ligand-free structure of cytochrome P450 PikC (CYP107L1)
4WL0	;	2.89	;	Ligand-free structure of human platelet phosphofructokinase in an R-state, crystal form I
2BZ9	;	2.21	;	Ligand-free structure of sterol 14alpha-demethylase from Mycobacterium tuberculosis in P2(1) space group
8BC2	;	2.6	;	Ligand-Free Structure of the decameric sulfofructose transaldolase BmSF-TAL
4OLO	;	2.5	;	Ligand-free structure of the GrpU microcompartment shell protein from Clostridiales bacterium 1_7_47FAA
4OLP	;	2.79	;	Ligand-free structure of the GrpU microcompartment shell protein from Pectobacterium wasabiae
3ASY	;	2.4	;	ligand-free structure of uridine kinase from thermus thermophilus HB8
5WB1	;	3.508	;	Ligand-free US28 with stabilizing intracellular nanobody
7L0I	;	2.02	;	Ligand-free YopH G352T
4R17	;	2.1	;	Ligand-induced aziridine-formation at subunit beta5 of the yeast 20S proteasome
5LAI	;	2.5	;	Ligand-induced aziridine-formation at the yeast proteasomal subunit beta5 by sulfonate esters
5MJ6	;	2.53	;	Ligand-induced conformational change of Insulin-regulated aminopeptidase: insights on catalytic mechanism and active site plasticity.
2MSW	;		;	Ligand-induced folding of a receiver domain
4R18	;	2.4	;	Ligand-induced Lys33-Thr1 crosslinking at subunit beta5 of the yeast 20S proteasome
5LAJ	;	2.9	;	Ligand-induced Lys33-Thr1 crosslinking at the yeast proteasomal subunit beta5 by sulfonate esters
1HJX	;	1.85	;	Ligand-induced signalling and conformational change of the 39 kD glycoprotein from human articular chondrocytes
1NXF	;	1.85	;	Ligand-linked transitions of deoxyHbI crystals exposed to CO.
5MR4	;	2.4	;	Ligand-receptor complex.
5MR5	;	2.0	;	Ligand-receptor complex.
5MR9	;	2.4	;	Ligand-receptor complex.
3IJ2	;	3.75	;	Ligand-receptor structure
6J5U	;	3.9	;	Ligand-triggered allosteric ADP release primes a plant NLR complex
6J5V	;	4.25	;	Ligand-triggered allosteric ADP release primes a plant NLR complex
6J5W	;	3.7	;	Ligand-triggered allosteric ADP release primes a plant NLR complex
5BVQ	;	2.1	;	Ligand-unbound pFABP4
1IKT	;	1.75	;	LIGANDED STEROL CARRIER PROTEIN TYPE 2 (SCP-2) LIKE DOMAIN OF HUMAN MULTIFUNCTIONAL ENZYME TYPE 2 (MFE-2)
4AUA	;	2.31	;	Liganded X-ray crystal structure of cyclin dependent kinase 6 (CDK6)
4ZXG	;	1.7	;	Ligandin binding site of PfGST
2LZE	;		;	Ligase 10C
4G10	;	1.2	;	LigG from Sphingobium sp. SYK-6 is related to the glutathione transferase omega class
4LM6	;	1.7	;	Light harvesting complex PC612 from the cryptophyte Hemiselmis virescens M1635
4LMS	;	1.35	;	Light harvesting complex PC645 from the cryptophyte Chroomonas sp. CCMP270
4LMX	;	1.8	;	Light harvesting complex PE555 from the cryptophyte Hemiselmis andersenii CCMP644
7T7U	;	1.8	;	Light Harvesting complex phycocyanin PC 630, from the cryptophyte Chroomonas sp. M1627
7T89	;	1.0	;	Light harvesting complex Phycocyanin PC577 from the cryptophyte Hemiselmis pacifica CCMP 706
7T8S	;	2.0	;	Light Harvesting complex phycoerythrin PE 566, from the cryptophyte Cryptomonas pyrenoidifera
8EL3	;	1.57	;	Light harvesting phycobiliprotein HaPE555 from the cryptophyte Hemiselmis andersenii CCMP644 in a loose interface filament
8EL4	;	1.73	;	Light harvesting phycobiliprotein HaPE555 from the cryptophyte Hemiselmis andersenii CCMP644 in a tight interface filament
8EL5	;	1.67	;	Light harvesting phycobiliprotein HaPE555 from the cryptophyte Hemiselmis andersenii CCMP644 in an alternating tight to loose interface filament
8EL6	;	1.95	;	Light harvesting phycobiliprotein HaPE555 from the cryptophyte Hemiselmis andersenii CCMP644 with an altered helix hA/hY conformation
7SSF	;	1.45	;	Light harvesting phycobiliprotein HaPE560 from the cryptophyte Hemiselmis andersenii CCMP644
7SUT	;	1.49	;	Light harvesting phycobiliprotein HaPE645 from the cryptophyte Hemiselmis andersenii CCMP644
3BSD	;	2.3	;	Light harvesting protein from RC of Chlorobium tepidum
4Q70	;	1.85	;	Light Harvesting Protein Phycocyanin in high resolution using a femtosecond X-Ray laser
8C69	;	1.9	;	Light SFX structure of D.m(6-4)photolyase at 100 microsecond time delay
8C6A	;	1.9	;	Light SFX structure of D.m(6-4)photolyase at 1ps time delay
8C6B	;	1.9	;	Light SFX structure of D.m(6-4)photolyase at 20ps time delay
8C6H	;	1.9	;	Light SFX structure of D.m(6-4)photolyase at 2ps time delay
8C6C	;	1.9	;	Light SFX structure of D.m(6-4)photolyase at 300ps time delay
8C6F	;	1.9	;	Light SFX structure of D.m(6-4)photolyase at 400fs time delay
5LS8	;	1.78	;	Light-activated ruthenium complex bound to a DNA quadruplex
8C36	;	2.0	;	Light-adapted 2.0 Angstrom crystal structure of H132A variant of cobalamin binding domain belonging to a light-dependent transcription regulator TtCarH obtained under aerobic conditions
1XRD	;		;	Light-Harvesting Complex 1 Alfa Subunit from Wild-Type Rhodospirillum rubrum
1DX7	;		;	Light-harvesting complex 1 beta subunit from Rhodobacter sphaeroides
1WRG	;		;	Light-Harvesting Complex 1 Beta Subunit from Wild-Type Rhodospirillum rubrum
3NOP	;	2.8	;	Light-induced intermediate structure L1 of Pseudomonas aeruginosa bacteriophytochrome
3NOT	;	2.7	;	Light-induced intermediate structure L2 of P. aeruginosa bacteriophytochrome
3NOU	;	3.0	;	Light-induced intermediate structure L3 of P. aeruginosa bacteriophytochrome
6RTZ	;	2.87	;	Light-Regulation of Imidazole Glycerol Phosphate Synthase by Interference with its Allosteric Machinery through Photo-Sensitive Unnatural Amino Acids
6RU0	;	2.648	;	Light-Regulation of Imidazole Glycerol Phosphate Synthase by Interference with its Allosteric Machinery through Photo-Sensitive Unnatural Amino Acids
5VP3	;	2.151	;	Light-sensitive photoprotein
8C76	;	2.5	;	Light-state 2.5 Angstrom wild-type X-ray crystal structure of the cobalamin binding domain belonging to a light-dependent transcription regulator TtCarH obtained under aerobic conditions from a form 2 crystal illuminated during 5 s
5SVW	;	2.29	;	Light-state Structure of Arabidopsis Thaliana Zeitlupe
1B85	;	1.85	;	LIGNIN PEROXIDASE
1LLP	;	1.7	;	LIGNIN PEROXIDASE (ISOZYME H2) PI 4.15
6ISS	;	1.53	;	Lignin peroxidase H8 triple mutant S49C/A67C/H239
1QPA	;	1.8	;	LIGNIN PEROXIDASE ISOZYME LIP4.65 (PI 4.65)
6BCS	;	2.1	;	LilrB2 D1D2 domains complexed with benzamidine
8AAU	;	1.74	;	LIM Domain Kinase 1 (LIMK1) bound to LIMKi3
5NXC	;	2.25	;	LIM Domain Kinase 1 (LIMK1) In Complex With PF-00477736
8S3X	;	2.59	;	LIM Domain Kinase 2 (LIMK2) bound to compound 52
5NXD	;	1.9	;	LIM Domain Kinase 2 (LIMK2) In Complex With TH-300
7QHG	;	1.45	;	LIM domain kinase 2 (LIMK2) in complex with TH-470
6MIF	;		;	Lim5 domain of PINCH1 protein
7P6A	;	1.9	;	Limbic-predominant neuronal inclusion body 4R tauopathy type 1a tau filament
7P6B	;	2.2	;	Limbic-predominant neuronal inclusion body 4R tauopathy type 1b tau filament
7P6C	;	2.5	;	Limbic-predominant neuronal inclusion body 4R tauopathy type 2 tau filament
8AGM	;	1.966	;	Limonene epoxide low pH soak of epoxide hydrolase from metagenomic source ch65
1NWW	;	1.2	;	Limonene-1,2-epoxide hydrolase
1NU3	;	1.75	;	Limonene-1,2-epoxide hydrolase in complex with valpromide
8HU4	;	2.76	;	Limosilactobacillus reuteri N1 GtfB
8HW3	;	2.66	;	Limosilactobacillus reuteri N1 GtfB-acarbose
8HWK	;	2.9	;	Limosilactobacillus reuteri N1 GtfB-maltohexaose
6TFT	;	2.52	;	Linalool Dehydratase Isomerase C171A mutant
6TFR	;	1.45	;	Linalool Dehydratase Isomerase C180A mutant
7AD2	;	1.83	;	Linalool Dehydratase Isomerase G107T mutant
5G1U	;	2.57	;	Linalool Dehydratase Isomerase in complex with Geraniol
6TFN	;	2.18	;	Linalool Dehydratase Isomerase in complex with Myrcene
6THM	;	1.99	;	Linalool Dehydratase Isomerase M125A mutant
5G1V	;	2.68	;	Linalool Dehydratase Isomerase: Selenomethionine Derivative
5HSS	;	2.5	;	Linalool dehydratase/isomerase: Ldi with monoterpene substrate
5HLR	;	1.911	;	Linalool dehydratase/isomerase: Ldi-apo
1MJ5	;	0.95	;	LINB (haloalkane dehalogenase) from sphingomonas paucimobilis UT26 at atomic resolution
1G4H	;	1.8	;	LINB COMPLEXED WITH BUTAN-1-OL
3JZ0	;	2.0	;	LinB complexed with clindamycin and AMPCPP
8CGK	;	1.64	;	Lincomycin and Avilamycin bound to the 50S subunit
7N8S	;	2.79	;	LINE-1 endonuclease domain complex with DNA
7N94	;	2.85	;	LINE-1 endonuclease domain complex with DNA
7N8K	;	2.01	;	LINE-1 endonuclease domain complex with Mg
7UL7	;	3.59	;	Lineage I (Pinneo) Lassa virus glycoprotein bound to 18.5C-M30 Fab
2XRW	;	1.33	;	Linear binding motifs for JNK and for calcineurin antagonistically control the nuclear shuttling of NFAT4
2XS0	;	2.6	;	Linear binding motifs for JNK and for calcineurin antagonistically control the nuclear shuttling of NFAT4
2GM0	;		;	Linear dimer of stemloop SL1 from HIV-1
8CMR	;	2.24	;	Linear specific OTU-type DUB SnOTU from the pathogen S. negenvensis in complex with linear di-ubiquitin
4KWX	;	1.3	;	Linear structure of the Holliday junction sequence (TCGGCGCCGA)
5GO8	;	2.21	;	Linear tetra-ubiquitin
5GO7	;	1.801	;	Linear tri-ubiquitin
4OQT	;	3.23	;	LINGO-1/Li81 Fab complex
3Q16	;	4.1	;	Linkage between the Bacterial Acid Stress and Stringent Responses: The Structure of the Inducible Lysine Decarboxylase
6DXL	;	2.45	;	Linked amidobenzimidazole STING agonist
6DQA	;	1.888	;	Linked KDM5A JMJ Domain Bound to Inhibitor N70 i.e.[2-((3-aminophenyl)(2-(piperidin-1-yl)ethoxy)methyl)thieno[3,2-b]pyridine-7-carboxylic acid]
6DQ9	;	1.748	;	Linked KDM5A JMJ Domain Bound to the Covalent Inhibitor N69 i.e. [2-((3-acrylamidophenyl)(2-(piperidin-1-yl)ethoxy)methyl)thieno[3,2-b]pyridine-7-carboxylic acid]
6BH0	;	1.985	;	LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR (R)-2-((2-chlorophenyl)(2-(piperidin-1-yl)ethoxy)methyl)-1l2-pyrrolo[3,2-b]pyridine-7-carboxylic acid (Compound N51)
6BH2	;	1.447	;	LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR (R)-N-(1-(3-isopropyl-1H-pyrazole-5-carbonyl)pyrrolidin-3-yl)cyclopropanecarboxamide (Compound N54)
6BH1	;	1.932	;	LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR (S)-2-((2-chlorophenyl)(2-(piperidin-1-yl)ethoxy)methyl)-1l2-pyrrolo[3,2-b]pyridine-7-carboxylic acid (Compound N52)
6BH3	;	1.701	;	LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR (S)-N-(1-(3-isopropyl-1H-pyrazole-5-carbonyl)pyrrolidin-3-yl)cyclopropanecarboxamide (Compound N55)
5IWF	;	2.289	;	Linked KDM5A Jmj Domain Bound to the Inhibitor 2-(((2-((2-(dimethylamino)ethyl)(ethyl)amino)-2-oxoethyl)amino)methyl)isonicotinamid
6BGX	;	1.882	;	LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR 2-((2-chlorophenyl)((4,4-difluorocyclohexyl)methoxy)methyl)-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid(Compound N42)
6BGZ	;	1.688	;	LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR 2-((2-chlorophenyl)(2-(1-methyl-1H-imidazol-2-yl)ethoxy)methyl)-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid (Compound N47)
6BGY	;	1.22	;	LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR 2-((2-chlorophenyl)(2-(1-methylpyrrolidin-2-yl)ethoxy)methyl)-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid(Compound 46)
6BGW	;	1.644	;	LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR 2-((2-chlorophenyl)(2-(4,4-difluoropiperidin-1-yl)ethoxy)methyl)-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid(Compound N41)
6BGV	;	1.592	;	LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR 2-((2-chlorophenyl)(2-(piperidin-1-yl)ethoxy)methyl)-1l2-pyrrolo[3,2-b]pyridine-7-carboxylic acid (Compound N40)
6BH5	;	1.651	;	LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR 2-((2-chlorophenyl)(3-(piperidin-1-yl)propoxy)methyl)-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid (Compound N48)
6BGU	;	1.684	;	LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR 2-((2-chlorophenyl)(propoxy)methyl)-1H-pyrrolo[3,2-b]pyridine (Compound N9)
6BH4	;	2.047	;	LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR 5-(1-(tert-butyl)-1H-pyrazol-4-yl)-6-isopropyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbonitrile (Compound N75/CPI-48)
5ISL	;	1.694	;	Linked KDM5A Jmj Domain Bound to the Inhibitor C49 (2-{[(2-{[(E)-2-(dimethylamino)ethenyl](ethyl)amino}-2-oxoethyl)amino]methyl}pyridine-4-carboxylic acid)
6DQ4	;	1.392	;	LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR GSK-J1
5IVF	;	1.683	;	Linked KDM5A Jmj Domain Bound to the Inhibitor N10 8-(1-methyl-1H-imidazol-4-yl)-2-(4,4,4-trifluorobutoxy)pyrido[3,4-d]pyrimidin-4-ol
5IVJ	;	1.569	;	Linked KDM5A Jmj Domain Bound to the Inhibitor N11 [3-({1-[2-(4,4-difluoropiperidin-1-yl)ethyl]-5-fluoro-1H-indazol-3-yl}amino)pyridine-4-carboxylic acid]
5IVV	;	1.848	;	Linked KDM5A Jmj Domain Bound to the Inhibitor N12 [3-((1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)amino)isonicotinic acid]
5IVY	;	1.45	;	Linked KDM5A Jmj Domain Bound to the Inhibitor N16 [3-(2-(4-chlorophenyl)acetamido)isonicotinic acid]
5IW0	;	1.63	;	Linked KDM5A Jmj Domain Bound to the Inhibitor N19 [2-(5-((4-chloro-2-methylbenzyl)oxy)-1H-pyrazol-1-yl)isonicotinic acid]
5IVC	;	1.573	;	Linked KDM5A Jmj Domain Bound to the Inhibitor N3 (4'-[(2-phenylethyl)carbamoyl][2,2'-bipyridine]-4-carboxylic acid)
6DQ5	;	1.89	;	LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR N43 i.e. 3-((6-(4-acryloyl-1,4-diazepan-1-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid
6DQ6	;	1.587	;	LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR N44 i.e. 3-((2-(pyridin-2-yl)-6-(4-(vinylsulfonyl)-1,4-diazepan-1-yl)pyrimidin-4-yl)amino)propanoic acid
6DQ8	;	1.46	;	LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR N49 i.e. 2-((2-chlorophenyl)(2-(1-methylpyrrolidin-2-yl)ethoxy)methyl)thieno[3,2-b]pyridine-7-carboxylic acid
6DQC	;	1.755	;	LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR N50 i.e. 2-(4-((2-(dimethylamino)ethyl)(ethyl)carbamoyl)-5-(4-methoxyphenyl)-1H-pyrazol-1-yl)isonicotinic acid
6DQD	;	1.987	;	LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR N53 i.e. 2-(5-([1,1'-biphenyl]-3-yl)-4-(1-(2-(piperidin-1-yl)ethoxy)ethyl)-1H-pyrazol-1-yl)isonicotinic acid
6DQE	;	1.689	;	LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR N67 i.e. 2-(5-phenyl-4-(phenyl(2-(piperidin-1-yl)ethoxy)methyl)-1H-pyrazol-1-yl)isonicotinic acid
6DQF	;	1.688	;	LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR N68 i.e. 2-(1-(2-(piperidin-1-yl)ethyl)-1H-benzo[d]imidazol-2-yl)thieno[3,2-b]pyridine-7-carboxylic acid
5IVE	;	1.783	;	Linked KDM5A Jmj Domain Bound to the Inhibitor N8 ( 5-methyl-7-oxo-6-(propan-2-yl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbonitrile)
6DQ7	;	1.852	;	LINKED KDM5A JMJ DOMAIN BOUND TO THE POTENTIAL HYDROLYSIS PRODUCT OF INHIBITOR N45 i.e. 3-((6-(4-(2-cyano-3-methylbut-2-enoyl)-1,4-diazepan-1-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid
6DQB	;	1.791	;	LINKED KDM5A JMJ DOMAIN FORMING COVALENT BOND TO INHIBITOR N71 i.e. 2-((3-(4-(dimethylamino)but-2-enamido)phenyl)(2-(piperidin-1-yl)ethoxy)methyl)thieno[3,2-b]pyridine-7-carboxylic acid
7LJ0	;	2.8	;	Linker 3 and scaffolded phycoerythrin beta subunit from the phycobilisome of Porphyridium purpureum
8TH8	;	7.4	;	Linker domain of Nexin-dynein regulatory complex from Tetrahymena thermophila
7DBP	;	4.5	;	Linker histone defines structure and self-association behaviour of the 177 bp human chromosome
8JNN	;	3.3	;	linker protein LPP1 from red algal Porphyridium purpureum.
5BVS	;	2.2	;	Linoleate-bound pFABP4
2Q9S	;	2.3	;	Linoleic Acid Bound to Fatty Acid Binding Protein 4
2LXL	;		;	Lip5(mit)2
2LXM	;		;	Lip5-chmp5
6KHL	;	1.6	;	Lipase (Blocked form)
6KHK	;	1.75	;	Lipase (Closed form)
1LBS	;	2.6	;	LIPASE (E.C.3.1.1.3) (TRIACYLGLYCEROL HYDROLASE)
1LBT	;	2.5	;	LIPASE (E.C.3.1.1.3) (TRIACYLGLYCEROL HYDROLASE)
6KHM	;	2.4	;	Lipase (Open form)
1LGY	;	2.2	;	LIPASE II FROM RHIZOPUS NIVEUS
6CL4	;	2.64	;	LipC12 - Lipase from metagenomics
5W8N	;	2.02	;	Lipid A Disaccharide Synthase (LpxB)-6 solubilizing mutations
5W8S	;	2.1	;	Lipid A Disaccharide Synthase (LpxB)-7 solubilizing mutations
5W8X	;	1.98	;	Lipid A Disaccharide Synthase (LpxB)-7 solubilizing mutations-Bound to UDP
5KN7	;	1.99	;	Lipid A secondary acyltransferase LpxM from Acinetobacter baumannii
5KNK	;	1.9	;	Lipid A secondary acyltransferase LpxM from Acinetobacter baumannii with catalytic residue substitution (E127A)
6O30	;	4.47	;	Lipid A transporter MsbA from Salmonella typhimurium
1UVA	;	2.5	;	Lipid Binding in Rice Nonspecific Lipid Transfer Protein-1 Complexes from Oryza sativa
1UVB	;	2.1	;	Lipid Binding in Rice Nonspecific Lipid Transfer Protein-1 Complexes from Oryza sativa
1UVC	;	2.0	;	Lipid Binding in Rice Nonspecific Lipid Transfer Protein-1 Complexes from Oryza sativa
6NC6	;	3.2	;	Lipid II flippase MurJ, inward closed conformation
6NC8	;	2.601	;	Lipid II flippase MurJ, inward occluded conformation
6NC7	;	3.0	;	Lipid II flippase MurJ, inward open conformation
6NC9	;	1.8	;	Lipid II flippase MurJ, outward-facing conformation
1MYU	;		;	Lipid induced conformation of the tachykinin peptide Kassinin
1BE2	;		;	LIPID TRANSFER PROTEIN COMPLEXED WITH PALMITATE, NMR, 10 STRUCTURES
1JTB	;		;	LIPID TRANSFER PROTEIN COMPLEXED WITH PALMITOYL COENZYME A, NMR, 16 STRUCTURES
1AFH	;		;	LIPID TRANSFER PROTEIN FROM MAIZE SEEDLINGS, NMR, 15 STRUCTURES
1BV2	;		;	LIPID TRANSFER PROTEIN FROM RICE SEEDS, NMR, 14 STRUCTURES
6DMR	;	3.9	;	Lipid-bound full-length rbTRPV5
2KOG	;		;	lipid-bound synaptobrevin solution NMR structure
3KYQ	;	2.443	;	Lipid-induced Conformational Switch Controls Fusion Activity of Longin Domain SNARE Ykt6
1LSH	;	1.9	;	LIPID-PROTEIN INTERACTIONS IN LIPOVITELLIN
8ADU	;	3.24	;	Lipidic alpha-synuclein fibril - polymorph L1A
8ADV	;	2.98	;	Lipidic alpha-synuclein fibril - polymorph L1B
8ADW	;	2.95	;	Lipidic alpha-synuclein fibril - polymorph L1C
8A4L	;	2.68	;	Lipidic alpha-synuclein fibril - polymorph L2A
8ADS	;	3.05	;	Lipidic alpha-synuclein fibril - polymorph L2B
8AEX	;	2.76	;	Lipidic alpha-synuclein fibril - polymorph L3A
8OVK	;	2.88	;	Lipidic amyloid-beta(1-40) fibril - polymorph L1
8OVM	;	3.24	;	Lipidic amyloid-beta(1-40) fibril - polymorph L2
8OWJ	;	3.75	;	Lipidic amyloid-beta(1-40) fibril - polymorph L2-L2
8OWE	;	3.75	;	Lipidic amyloid-beta(1-40) fibril - polymorph L2-L3
8OWD	;	3.28	;	Lipidic amyloid-beta(1-40) fibril - polymorph L3
8OWK	;	3.86	;	Lipidic amyloid-beta(1-40) fibril - polymorph L3-L3
1OGV	;	2.35	;	Lipidic cubic phase crystal structure of the photosynthetic reaction centre from Rhodobacter sphaeroides
2BNS	;	2.5	;	Lipidic cubic phase grown reaction centre from Rhodobacter sphaeroides, excited state
2BNP	;	2.7	;	Lipidic cubic phase grown reaction centre from Rhodobacter sphaeroides, ground state
7Q7P	;	2.4	;	LIPIDIC CUBIC PHASE SERIAL FEMTOSECOND CRYSTALLOGRAPHY STRUCTURE OF A PHOTOSYNTHETIC REACTION CENTRE
7Q7Q	;	2.25	;	LIPIDIC CUBIC PHASE SERIAL FEMTOSECOND CRYSTALLOGRAPHY STRUCTURE OF A PHOTOSYNTHETIC REACTION CENTRE
2WJN	;	1.86	;	Lipidic sponge phase crystal structure of photosynthetic reaction centre from Blastochloris viridis (high dose)
4AC5	;	8.2	;	Lipidic sponge phase crystal structure of the Bl. viridis reaction centre solved using serial femtosecond crystallography
2WJM	;	1.95	;	Lipidic sponge phase crystal structure of the photosynthetic reaction centre from Blastochloris viridis (low dose)
5UPH	;	3.0	;	Lipids bound lysosomal integral membrane protein 2
6EVH	;	0.9	;	Lipoaminopeptide helioferin A and B from Mycogone rosea
2KT4	;		;	Lipocalin Q83 is a Siderocalin
8F0Y	;	2.1	;	Lipocalin-like Milk protein-1
8F0V	;	2.951	;	Lipocalin-like Milk protein-2 - E38A mutant
2CZT	;	2.0	;	lipocalin-type prostaglandin D synthase
2CZU	;	2.1	;	lipocalin-type prostaglandin D synthase
4ZFV	;	1.5	;	Lipomyces starkeyi levoglucosan kinase bound to ADP and magnesium.
4YH5	;	1.9	;	Lipomyces starkeyi levoglucosan kinase bound to ADP and Manganese
5BSB	;	1.85	;	Lipomyces starkeyi levoglucosan kinase bound to levoglucosan
4ZLU	;	1.8	;	Lipomyces starkeyi levoglucosan kinase bound to levoglucosan, ADP and magnesium.
6V0C	;	3.46	;	Lipophilic Envelope-spanning Tunnel B (LetB), Model 1
6V0D	;	3.49	;	Lipophilic Envelope-spanning Tunnel B (LetB), Model 2
6V0E	;	3.06	;	Lipophilic Envelope-spanning Tunnel B (LetB), Model 3
6V0F	;	2.96	;	Lipophilic Envelope-spanning Tunnel B (LetB), Model 4
6V0G	;	3.03	;	Lipophilic Envelope-spanning Tunnel B (LetB), Model 5
6V0H	;	3.6	;	Lipophilic Envelope-spanning Tunnel B (LetB), Model 6
6V0I	;	3.43	;	Lipophilic Envelope-spanning Tunnel B (LetB), Model 7
6V0J	;	3.78	;	Lipophilic Envelope-spanning Tunnel B (LetB), Model 8
6VCI	;	2.15	;	Lipophilic envelope-spanning tunnel protein (LetB), domains MCE2-MCE3
7WZB	;	2.7	;	lipopolysaccharide assembly protein LapB (open)
6Y6I	;	1.92	;	lipopolysaccharide outer core galactosyltransferase WaaB and UDP complex
6Y6G	;	1.81	;	lipopolysaccharide outer core galactosyltransferase WaaB apo form
8JB4	;		;	lipopolysaccharide-binding domain-LBDB
8OKV	;	2.6	;	lipoprotein BT2095 from Bacteroides thetaiotamicron bound to cyanocobalamin CnCbl
5NAA	;	1.88	;	Lipoprotein-releasing system transmembrane protein LolC
6S7V	;	3.301	;	Lipoteichoic acids flippase LtaA
1N8Q	;	2.1	;	LIPOXYGENASE IN COMPLEX WITH PROTOCATECHUIC ACID
1YGE	;	1.4	;	LIPOXYGENASE-1 (SOYBEAN) AT 100K
1Y4K	;	1.95	;	Lipoxygenase-1 (Soybean) at 100K, N694G Mutant
1FGM	;	1.9	;	LIPOXYGENASE-1 (SOYBEAN) AT 100K, N694H MUTANT
1F8N	;	1.4	;	LIPOXYGENASE-1 (SOYBEAN) AT 100K, NEW REFINEMENT
1FGO	;	1.62	;	LIPOXYGENASE-1 (SOYBEAN) AT 100K, Q495A MUTANT
1FGQ	;	1.85	;	LIPOXYGENASE-1 (SOYBEAN) AT 100K, Q495E MUTANT
1FGR	;	1.6	;	LIPOXYGENASE-1 (SOYBEAN) AT 100K, Q697E MUTANT
1FGT	;	1.62	;	LIPOXYGENASE-1 (SOYBEAN) AT 100K, Q697N MUTANT
5T5V	;	1.8	;	LIPOXYGENASE-1 (SOYBEAN) AT 293K
3BNE	;	1.4	;	Lipoxygenase-1 (Soybean) I553A Mutant
3BNC	;	1.65	;	Lipoxygenase-1 (Soybean) I553G Mutant
5TQP	;	1.7	;	LIPOXYGENASE-1 (SOYBEAN) I553G MUTANT AT 300K
3BNB	;	1.45	;	Lipoxygenase-1 (Soybean) I553L Mutant
5TQN	;	1.8	;	Lipoxygenase-1 (soybean) L546A mutant at 293K
4WHA	;	1.7	;	Lipoxygenase-1 (soybean) L546A/L754A mutant
5TQO	;	1.7	;	Lipoxygenase-1 (soybean) L546A/L754A mutant at 300K
5TR0	;	1.85	;	Lipoxygenase-1 (soybean) L754A mutant at 293K
3BND	;	1.6	;	Lipoxygenase-1 (Soybean), I553V Mutant
1IK3	;	2.0	;	LIPOXYGENASE-3 (SOYBEAN) COMPLEX WITH 13(S)-HYDROPEROXY-9(Z),11(E)-OCTADECADIENOIC ACID
1HU9	;	2.2	;	LIPOXYGENASE-3 (SOYBEAN) COMPLEX WITH 4-HYDROPEROXY-2-METHOXY-PHENOL
1JNQ	;	2.1	;	LIPOXYGENASE-3 (SOYBEAN) COMPLEX WITH EPIGALLOCATHECHIN (EGC)
1ROV	;	2.0	;	Lipoxygenase-3 Treated with Cumene Hydroperoxide
1LNH	;	2.6	;	LIPOXYGENASE-3(SOYBEAN) NON-HEME FE(II) METALLOPROTEIN
1PMR	;		;	LIPOYL DOMAIN FROM THE DIHYDROLIPOYL SUCCINYLTRANSFERASE COMPONENT OF THE 2-OXOGLUTARATE DEHYDROGENASE MULTIENZYME COMPLEX OF ESCHERICHIA COLI, NMR, 25 STRUCTURES
1IYV	;		;	LIPOYL DOMAIN OF PYRUVATE DEHYDROGENASE COMPLEX, NMR, 29 STRUCTURES
1IYU	;		;	LIPOYL DOMAIN OF PYRUVATE DEHYDROGENASE COMPLEX, NMR, MINIMIZED AVERAGE STRUCTURE
4FBL	;	1.99	;	LipS and LipT, two metagenome-derived lipolytic enzymes increase the diversity of known lipase and esterase families
4FBM	;	2.8	;	LipS and LipT, two metagenome-derived lipolytic enzymes increase the diversity of known lipase and esterase families
6QNB	;	1.7	;	Liquid Application Method for time-resolved Analyses (LAMA) by serial synchrotron crystallography, Lysozyme with GlcNAc3
6RNC	;	1.799	;	Liquid Application Method for time-resolved Analyses (LAMA) by serial synchrotron crystallography, Lysozyme with GlcNAc3 - 100ms diffusion time.
6RNB	;	1.699	;	Liquid Application Method for time-resolved Analyses (LAMA) by serial synchrotron crystallography, Lysozyme with GlcNAc3 50ms diffusion time
6QNC	;	1.897	;	Liquid Application Method for time-resolved Analyses (LAMA) by serial synchrotron crystallography, Xylose Isomerase 0.1 s timepoint
6QNH	;	1.849	;	Liquid Application Method for time-resolved Analyses (LAMA) by serial synchrotron crystallography, Xylose Isomerase 0ms timepoint
6QNI	;	1.846	;	Liquid Application Method for time-resolved Analyses (LAMA) by serial synchrotron crystallography, Xylose Isomerase 1.0 s timepoint
6RND	;	1.7	;	Liquid Application Method for time-resolved Analyses (LAMA) by serial synchrotron crystallography, Xylose Isomerase 15 ms timepoint
6RNF	;	1.7	;	Liquid Application Method for time-resolved Analyses (LAMA) by serial synchrotron crystallography, Xylose Isomerase 30 ms timepoint
6QNJ	;	1.851	;	Liquid Application Method for time-resolved Analyses (LAMA) by serial synchrotron crystallography, Xylose Isomerase 4.5 s timepoint
6QND	;	2.001	;	Liquid Application Method for time-resolved Analyses (LAMA) by serial synchrotron crystallography, Xylose Isomerase 60 s timepoint
2RN1	;		;	Liquid crystal solution structure of the kissing complex formed by the apical loop of the HIV TAR RNA and a high affinity RNA aptamer optimized by SELEX
4APD	;		;	Liraglutide
7PV9	;	3.3	;	Listeria monocytogene InlB (internalin B) residues 36-392 (internalin domain and B-repeat)
4ACV	;	2.401	;	Listeria monocytogenes Antigen B
2Y5Q	;	3.2	;	Listeria monocytogenes InlB (internalin B) residues 36-392
5KZS	;	2.3	;	Listeria monocytogenes internalin-like protein lmo2027
5KZT	;	1.85	;	Listeria monocytogenes OppA bound to peptide
8EOR	;	2.67	;	Liver carboxylesterase 1
1LFO	;	2.3	;	LIVER FATTY ACID BINDING PROTEIN-OLEATE COMPLEX
2ACL	;	2.8	;	Liver X-Receptor alpha Ligand Binding Domain with SB313987
6ANA	;	1.7	;	LL2 Fab in complex with anti-Kappa VHH domain
1HCV	;	1.85	;	LLAMA HEAVY CHAIN VARIABLE DOMAIN AGAINST ALPHA SUBUNIT OF HCG (HUMAN CHORIONIC GONADOTROPIN)
4QLR	;	1.7	;	Llama nanobody n02 raised against EAEC T6SS TssM
7BNP	;	1.7	;	Llama nanobody nb17 raised against GldL from Flavobacterium jonhsoniae
7BNW	;	2.59	;	Llama nanobody nb18 raised against GldL from Flavobacterium jonhsoniae
5LZ0	;	1.6	;	Llama nanobody PorM_01
5LMW	;	1.5	;	Llama nanobody PorM_02
6GZP	;	2.1	;	Llama nanobody PorM_02 structure determined at room temperature by in-situ diffraction in ChipX microfluidic device
5FWO	;	1.7	;	Llama nanobody PorM_130
5LMJ	;	2.1	;	Llama nanobody PorM_19
7YZW	;	1.6	;	Llama nanobody VHH15 raised against the glycoprotein of Ebola virus
5HM1	;	2.962	;	Llama VHH 2E7 in complex with gp41
5O2U	;	2.76	;	Llama VHH in complex with p24
4HEM	;	1.65	;	Llama vHH-02 binder of ORF49 (RBP) from lactococcal phage TP901-1
7YR8	;	3.2	;	Lloviu cuevavirus nucleoprotein(1-450 residues)-RNA complex
7YPW	;	3.0356	;	Lloviu cuevavirus nucleoprotein-RNA complex
7QJF	;		;	Llp mutant C1G, lytic conversion lipoprotein of phage T5
8DT8	;	3.34	;	LM18/Nb136 bispecific tetra-nanobody immunoglobulin in complex with SARS-CoV-2-6P-Mut7 S protein (focused refinement)
6W7I	;	2.1	;	LmFPPS mutant T164W in complex with 476A, IPP & Ca
6VJC	;	1.8	;	LmFPPS mutant T164Y in complex with 476A, IPP & Ca
4HTL	;	1.64	;	Lmo2764 protein, a putative N-acetylmannosamine kinase, from Listeria monocytogenes
2MBV	;		;	LMO4-LIM2 in complex with DEAF1 (404-418)
1ZMS	;	2.8	;	LMP1 Protein binds to TRAF3 as a structural CD40
6T1Z	;	2.9	;	LmrP from L. lactis, in an outward-open conformation, bound to Hoechst 33342
1LMW	;	2.5	;	LMW U-PA Structure complexed with EGRCMK (GLU-GLY-ARG Chloromethyl Ketone)
7AJ6	;	1.9	;	LN02 Fab
7KUM	;	1.714	;	LNA modification at 3' end of RNA primer complex with guanosine dinucleotide ligand G(5')ppp(5')G
6YEP	;		;	LNA modified G-quadruplex with flipped G-tract and central tetrad
5BXP	;	1.7	;	LNBase in complex with LNB-LOGNAc
5BXT	;	1.8	;	LNBase in complex with LNB-NHAcAUS
5BXS	;	2.2	;	LNBase in complex with LNB-NHAcCAS
5BXR	;	1.6	;	LNBase in complex with LNB-NHAcDNJ
6X7N	;	1.42	;	LnmK in complex with 2-nitronate-propionyl-amino(dethia)-CoA
6X7L	;	1.77	;	LnmK in complex with 2-nitronate-propionyl-CoA
6X7M	;	1.61	;	LnmK in complex with 2-nitronate-propionyl-oxa(dethia)-CoA
6X7O	;	1.55	;	LnmK in complex with 2-sulfonate-propionyl-CoA
6X7P	;	1.55	;	LnmK in complex with 2-sulfonate-propionyl-oxa(dethia)-CoA
5BMO	;	1.92	;	LnmX protein, a putative GlcNAc-PI de-N-acetylase from Streptomyces atroolivaceus
2XL4	;	2.3	;	LntA, a virulence factor from Listeria monocytogenes
5HGQ	;	3.283	;	Loa loa Lysyl-tRNA synthetase in complex with Cladosporin.
4ZOF	;	1.8	;	Lobenzarit-like inhibitor bound in the active site of Mycobacterium tuberculosis anthranilate phosphoribosyltransferase (AnPRT; trpD)
1BJM	;	2.2	;	LOC NAKS, A LAMBDA 1 TYPE LIGHT-CHAIN DIMER (BENCE-JONES PROTEIN) CRYSTALLIZED IN NAKSO4
3BJL	;	2.3	;	LOC, A LAMBDA 1 TYPE LIGHT-CHAIN DIMER (BENCE-JONES PROTEIN) CRYSTALLIZED IN AMMONIUM SULFATE
1CGS	;	2.6	;	LOCAL AND TRANSMITTED CONFORMATIONAL CHANGES ON COMPLEXATION OF AN ANTI-SWEETENER FAB
2CGR	;	2.2	;	LOCAL AND TRANSMITTED CONFORMATIONAL CHANGES ON COMPLEXATION OF AN ANTI-SWEETENER FAB
7EY4	;	3.69	;	Local CryoEM of the SARS-CoV-2 S6PV2 in complex with BD-667
7V22	;	3.38	;	Local CryoEM structure del68-76/del679-688 prefusion-stabilized spike
7V24	;	3.29	;	Local CryoEM structure of del68-76/del679-688 prefusion-stabilized spike in complex with the Fab of N12-9
7WR9	;	3.24	;	Local CryoEM structure of the SARS-CoV S2P in complex with BD55-3152 Fab
8I3U	;	3.6	;	Local CryoEM structure of the SARS-CoV-2 S6P in complex with 14B1 Fab
8I3S	;	3.9	;	Local CryoEM structure of the SARS-CoV-2 S6P in complex with 7B3 Fab
7WR8	;	3.5	;	Local CryoEM structure of the SARS-CoV-2 S6P(B.1.1.529) in complex with BD55-3152 Fab
7WRJ	;	4.08	;	Local CryoEM structure of the SARS-CoV-2 S6P(B.1.1.529) in complex with BD55-4637 Fab
7WCK	;	3.49	;	Local CryoEM structure of the SARS-CoV-2 S6P(B.1.617.2) in complex with SWA9 Fab
7WCU	;	3.09	;	Local CryoEM structure of the SARS-CoV-2 S6P(B.1.617.2) in complex with SWC11 Fab
7EY5	;	3.4	;	Local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-771 Fab and BD-821 Fab
7EYA	;	3.77	;	Local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-804 Fab
7EZV	;	3.3	;	local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-812 Fab and BD-836 Fab
7EY0	;	3.2	;	Local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-813 Fab and BD-744 Fab
1CB3	;		;	LOCAL INTERACTIONS DRIVE THE FORMATION OF NON-NATIVE STRUCTURE IN THE DENATURED STATE OF HUMAN ALPHA-LACTALBUMIN: A HIGH RESOLUTION STRUCTURAL CHARACTERIZATION OF A PEPTIDE MODEL IN AQUEOUS SOLUTION
7WK0	;	3.32	;	Local refine of Omicron spike bitrimer with 6m6 antibody
8J1T	;	3.3	;	Local refined cryo-EM structure of Omicron BA.5 RBD in complex with 8-9D Fab
7V0X	;	3.0	;	Local refinement of ankyrin-1 (C-terminal half), class 1 of erythrocyte ankyrin-1 complex
7V0M	;	2.7	;	Local refinement of ankyrin-1 (N-terminal half), class 1 of erythrocyte ankyrin-1 complex
8CSV	;	2.7	;	Local refinement of Anykyrin-1 (N-terminal half of membrane binding domain) in Class 2 of erythrocyte ankyrin-1 complex
8CT2	;	3.1	;	Local refinement of AQP1 tetramer (C1; refinement mask included D1 of protein 4.2 and Ankyrin-1 AR1-5) in Class 2 of erythrocyte ankyrin-1 complex
7V0T	;	2.7	;	Local refinement of Band 3-I cytoplasmic domains, class 1 of erythrocyte ankyrin-1 complex
8CRQ	;	3.2	;	Local refinement of Band 3-I transmembrane domains, class 1 of erythrocyte ankyrin-1 complex
7V0U	;	3.0	;	Local refinement of Band 3-II cytoplasmic domains, class 1 of erythrocyte ankyrin-1 complex
7V19	;	3.3	;	Local refinement of Band 3-II transmembrane domains, class 1 of erythrocyte ankyrin-1 complex
7V0Y	;	3.0	;	Local refinement of Band 3-III cytoplasmic domains, class 1 of erythrocyte ankyrin-1 complex
8CRR	;	3.0	;	Local refinement of Band 3-III transmembrane domains, class 1 of erythrocyte ankyrin-1 complex
8CT3	;	3.3	;	Local refinement of band3-I transmembrane region from class 2 of erythrocyte ankyrin-1 complex
7U0D	;	4.8	;	Local refinement of cryo-EM structure of the interface of the Omicron RBD in complex with antibodies B-182.1 and A19-46.1
8OPK	;	3.16	;	Local refinement of cubic assembly from truncated PVY coat protein with K176C mutation
8CSY	;	2.7	;	Local refinement of cytoplasmic domains of band3-I in class 2 of erythrocyte ankyrin-1 complex
8PDS	;	2.9	;	Local refinement of dimeric HMPV N-RNA bound to the C-terminal region of P
8PDO	;	3.1	;	Local refinement of dimeric human metapneumovirus (HMPV) N-RNA
8WQD	;	3.55	;	Local refinement of FEM1B bound with the C-degron of CCC89
8WQI	;	3.5	;	Local refinement of FEM1B bound with the C-degron of CUX1
7LIW	;	2.85	;	Local refinement of human ATP citrate lyase E599Q mutant ASH domain
8CSW	;	2.5	;	Local refinement of protein 4.2 in Class 2 of erythrocyte ankyrin-1 complex
7V0Q	;	2.5	;	Local refinement of protein 4.2, class 1 of erythrocyte ankyrin-1 complex
8WGW	;	2.9	;	Local refinement of RBD-ACE2
8CRT	;	3.0	;	Local refinement of Rh trimer, glycophorin B and Band3-III transmembrane region, class 1a of erythrocyte ankyrin-1 complex
7UZQ	;	2.17	;	Local refinement of RhAG-RhCE-ANK1(AR1-5), from consensus refinement of all classes
8CSX	;	2.4	;	Local refinement of RhAG/CE trimer in class 2 of erythrocyte ankyrin-1 complex
7V0S	;	2.5	;	Local refinement of RhAG/CE trimer, class 1 of erythrocyte ankyrin-1 complex
8GZZ	;	3.52	;	Local refinement of SARS-CoV-2 Omicron BA.1 Spike glycoprotein in complex with rabbit monoclonal antibody 1H1 Fab
7YD1	;	2.99	;	Local refinement of SARS-CoV-2 Omicron S trimer complexed with XG005
7V80	;	3.9	;	Local refinement of SARS-CoV-2 S-Beta variant (B.1.351) RBD and Angiotensin-converting enzyme 2 (ACE2) ectodomain
7V8B	;	3.2	;	Local refinement of SARS-CoV-2 S-Delta variant (B.1.617.2) RBD and Angiotensin-converting enzyme 2 (ACE2) ectodomain
7V84	;	3.0	;	Local refinement of SARS-CoV-2 S-Gamma variant (P.1) RBD and Angiotensin-converting enzyme 2 (ACE2) ectodomain
7V87	;	3.3	;	Local refinement of SARS-CoV-2 S-Kappa variant (B.1.617.1) RBD and Angiotensin-converting enzyme 2 (ACE2) ectodomain
8G78	;	3.4	;	Local refinement of SARS-CoV-2 spike/nanobody mixture complex around NTD
8G79	;	6.1	;	Local refinement of SARS-CoV-2 spike/nanobody mixture complex around RBD
8G7C	;	4.1	;	local refinement of SARS-CoV-2 spike/Nb4 complex with 2 RBDs up and 3 Nb4 bound
8DPZ	;	3.38	;	Local refinement of SARS-CoV-2 vaccine induced antibody DH1338 bound to SARS-CoV-2 HexaPro RBD Spike ectodomain
7WWK	;	3.4	;	Local refinement of the SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab
7XJ9	;	3.27	;	Local refinement of the SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab and 58G6 Fab
8HED	;	3.59	;	Local refinement of the SARS-CoV-2 Spike trimer in complex with RmAb 9H1 Fab
7Q4E	;	3.63	;	Local refinement structure of a single N-domain of full-length, dimeric, soluble somatic angiotensin I-converting enzyme
7Q4C	;	4.08	;	Local refinement structure of the C-domain of full-length, monomeric, soluble somatic angiotensin I-converting enzyme
7Q49	;	3.72	;	Local refinement structure of the N-domain of full-length, monomeric, soluble somatic angiotensin I-converting enzyme
7Q4D	;	3.78	;	Local refinement structure of the two interacting N-domains of full-length, dimeric, soluble somatic angiotensin I-converting enzyme
7WRZ	;	3.26	;	Local resolution of BD55-5840 Fab and SARS-COV2 Omicron RBD
7WRL	;	3.51	;	Local structure of BD55-1239 Fab and SARS-COV2 Omicron RBD complex
7WRO	;	3.4	;	Local structure of BD55-3372 and delta spike
7WSC	;	3.78	;	Local structure of BD55-3500 and omicron RBD complex
7WRY	;	3.28	;	Local structure of BD55-3546 Fab and SARS-COV2 Delta RBD complex
7Y0W	;	3.42	;	Local structure of BD55-5514 and BD55-5840 Fab and Omicron BA.1 RBD complex
7WB5	;	3.7	;	local structure of hu33 and spike
1RE6	;		;	Localisation of Dynein Light Chains 1 and 2 and their Pro-apoptotic Ligands
5NER	;	11.5	;	Localised reconstruction of alpha v beta 6 bound to Foot and Mouth Disease Virus O PanAsia - Pose A prime.
5NEM	;	10.8	;	Localised reconstruction of alpha v beta 6 bound to Foot and Mouth Disease Virus O PanAsia - Pose A.
5NET	;	8.6	;	Localised Reconstruction of Integrin alpha V beta 6 bound to Foot and Mouth Disease Virus O1 Manisa - Pose A.
5NEU	;	12.3	;	Localised Reconstruction of Integrin alpha V beta 6 bound to Foot and Mouth Disease Virus O1 Manisa - Pose B.
1YSH	;	9.5	;	Localization and dynamic behavior of ribosomal protein L30e
4V6I	;	8.8	;	Localization of the small subunit ribosomal proteins into a 6.1 A cryo-EM map of Saccharomyces cerevisiae translating 80S ribosome
6LHT	;	3.67	;	Localized reconstruction of coxsackievirus A16 mature virion in complex with Fab 18A7
7KNA	;	3.3	;	Localized reconstruction of the H1 A/Michigan/45/2015 ectodomain displayed at the surface of I53_dn5 nanoparticle
1BG7	;	1.85	;	LOCALIZED UNFOLDING AT THE JUNCTION OF THREE FERRITIN SUBUNITS. A MECHANISM FOR IRON RELEASE?
8GGI	;	3.5	;	Locally refined cryoEM structure of receptor from beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #1 of 20)
8GGR	;	3.4	;	Locally refined cryoEM structure of receptor from beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #10 of 20)
8GGS	;	3.5	;	Locally refined cryoEM structure of receptor from beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #11 of 20)
8GGT	;	3.5	;	Locally refined cryoEM structure of receptor from beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #12 of 20)
8GGU	;	3.4	;	Locally refined cryoEM structure of receptor from beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #13 of 20)
8GGV	;	3.5	;	Locally refined cryoEM structure of receptor from beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #14 of 20)
8GGW	;	3.6	;	Locally refined cryoEM structure of receptor from beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #15 of 20)
8GGX	;	3.6	;	Locally refined cryoEM structure of receptor from beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #16 of 20)
8GGY	;	3.9	;	Locally refined cryoEM structure of receptor from beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #17 of 20)
8GGZ	;	3.9	;	Locally refined cryoEM structure of receptor from beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #18 of 20)
8GH0	;	4.0	;	Locally refined cryoEM structure of receptor from beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #19 of 20)
8GGJ	;	3.5	;	Locally refined cryoEM structure of receptor from beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #2 of 20)
8GH1	;	4.1	;	Locally refined cryoEM structure of receptor from beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #20 of 20)
8GGK	;	3.3	;	Locally refined cryoEM structure of receptor from beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #3 of 20)
8GGL	;	3.2	;	Locally refined cryoEM structure of receptor from beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #4 of 20)
8GGM	;	3.2	;	Locally refined cryoEM structure of receptor from beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #5 of 20)
8GGN	;	3.3	;	Locally refined cryoEM structure of receptor from beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #6 of 20)
8GGO	;	3.2	;	Locally refined cryoEM structure of receptor from beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #7 of 20)
8GGP	;	3.2	;	Locally refined cryoEM structure of receptor from beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #8 of 20)
8GGQ	;	3.4	;	Locally refined cryoEM structure of receptor from beta-2-adrenergic receptor in complex with GTP-bound Gs heterotrimer (transition intermediate #9 of 20)
7S62	;	3.65	;	Locally refined protomer structure of native-form oocyte/egg Alpha-2-Macroglobulin (A2Moo) tetramer
7TBF	;	3.1	;	Locally refined region of SARS-CoV-2 spike in complex with antibodies B1-182.1 and A19-61.1
7TC9	;	5.08	;	Locally refined region of SARS-CoV-2 spike in complex with antibody A19-46.1
7WO7	;	3.8	;	Locally refined region of SARS-CoV-2 Spike in complex with IgG 553-15
7WOC	;	3.35	;	Locally refined region of SARS-CoV-2 Spike in complex with IgG 553-60
3GGI	;	0.98	;	Locating monovalent cations in one turn of G/C rich B-DNA
3GGK	;	0.87	;	Locating monovalent cations in one turn of G/C rich B-DNA
4AU6	;	6.0	;	Location of the dsRNA-dependent polymerase, VP1, in rotavirus particles
4F5X	;	5.0	;	Location of the dsRNA-dependent polymerase, VP1, in rotavirus particles
7Z3Z	;	3.1	;	Locked Wuhan SARS-CoV2 Prefusion Spike ectodomain with lipid bound
1DQ0	;	1.7	;	Locked, metal-free concanavalin A, a minor species in solution
4BJL	;	2.4	;	LOCW, A LAMBDA 1 TYPE LIGHT-CHAIN DIMER (BENCE-JONES PROTEIN) CRYSTALLIZED IN DISTILLED WATER
8H8J	;	3.2	;	Lodoxamide-bound GPR35 in complex with G13
6C8S	;	2.2	;	Loganic acid methyltransferase with SAH
6C8R	;	1.951	;	Loganic acid O-methyltransferase complexed with SAH and loganic acid
1LHS	;	2.0	;	LOGGERHEAD SEA TURTLE MYOGLOBIN (AQUO-MET)
1LHT	;	2.0	;	LOGGERHEAD SEA TURTLE MYOGLOBIN (CYANO-MET)
7WHG	;	3.25	;	Lokiarchaeota gelsolin (2DGel) bound to two molecules of rabbit actin
5ZZB	;	2.3	;	LokiProfilin2/Rabbit Actin Complex
8CM1	;	1.46	;	Lol B - Localization of lipoprotein B from Vibrio cholera
7V8I	;	3.6	;	LolCD(E171Q)E with bound AMPPNP in nanodiscs
7ARI	;	3.4	;	LolCDE apo structure
7ARK	;	4.1	;	LolCDE in complex with AMP-PNP in the closed NBD state
7ARH	;	3.3	;	LolCDE in complex with lipoprotein
7ARL	;	3.2	;	LolCDE in complex with lipoprotein and ADP
7ARJ	;	3.2	;	LolCDE in complex with lipoprotein and AMPPNP complex undimerized form
7ARM	;	3.6	;	LolCDE in complex with lipoprotein and LolA
7MDY	;	3.5	;	LolCDE nucleotide-bound
7MDX	;	3.8	;	LolCDE nucleotide-free
7V8L	;	3.5	;	LolCDE with bound RcsF in nanodiscs
7V8M	;	4.2	;	LolCDE-apo in nanodiscs
6N2I	;	3.5	;	Lon protease AAA+ domain
7P6U	;	3.9	;	Lon protease from Thermus Thermophilus
6V11	;	3.8	;	Lon Protease from Yersinia pestis
6ON2	;	3.0	;	Lon Protease from Yersinia pestis with Y2853 substrate
6WYS	;	2.229	;	Lon protease proteolytic domain
6WZV	;	2.51	;	Lon protease proteolytic domain
6X27	;	2.12	;	Lon protease proteolytic domain complexed with bortezomib
6X1M	;	3.51	;	Lon protease proteolytic domain complexed with covalent boronic acid inhibitor
1ZID	;	2.7	;	LONG FATTY ACID CHAIN ENOYL-ACP REDUCTASE (INHA) IN COMPLEX WITH AN ISONICOTINIC-ACYL-NADH INHIBITOR
7TX8	;	2.51	;	Long form D7 protein from Anopheles darlingi with U46619 and serotonin bound
8C8J	;	2.1	;	Long Interspersed Nuclear Element 1 (LINE-1) reverse transcriptase ternary complex with hybrid duplex and dTTP
5AFO	;	1.82	;	Long Polar Fimbriae adhesin LpfD from the adherent invasive E. coli strain LF82
6H2M	;	1.929	;	Long wavelength Mesh&Collect native SAD phasing on microcrystals
6I59	;	2.95	;	Long wavelength native-SAD phasing of Sen1 helicase
6I5C	;	2.95	;	Long wavelength native-SAD phasing of Tubulin-Stathmin-TTL complex
2YOP	;	2.3	;	Long wavelength S-SAD structure of FAM3B PANDER
3B9O	;	1.9	;	long-chain alkane monooxygenase (LadA) in complex with coenzyme FMN
1OYU	;	2.5	;	Long-Distance conformational changes in a protein engineered by modulated sequence duplication
1DHI	;	1.9	;	LONG-RANGE STRUCTURAL EFFECTS IN A SECOND-SITE REVERTANT OF A MUTANT DIHYDROFOLATE REDUCTASE
1DHJ	;	1.8	;	LONG-RANGE STRUCTURAL EFFECTS IN A SECOND-SITE REVERTANT OF A MUTANT DIHYDROFOLATE REDUCTASE
5KIC	;	2.7	;	Long-sought stabilization of berkelium(IV) in solution: An anomaly within the heavy actinide series
3I70	;	2.3	;	Long-wavelength structure of NtA
1A51	;		;	LOOP D/LOOP E ARM OF E. COLI 5S RRNA, NMR, 9 STRUCTURES
1A4D	;		;	LOOP D/LOOP E ARM OF ESCHERICHIA COLI 5S RRNA, NMR, MINIMIZED AVERAGE STRUCTURE
6IEI	;	2.4	;	Loop deletion and proline insertion mutant (deleting six residues and inserted five proline residues)
6IDC	;	2.007	;	Loop deletion and proline insertion mutant (deleting six residues and inserted six proline residues)
6IYS	;	3.0	;	Loop deletion and proline insertion mutant (deleting six residues and inserted three proline residues)
6ICS	;	1.4	;	Loop deletion mutant (deleting four residues)
6AIS	;	1.3	;	Loop deletion mutant (deleting two residues)
5KZJ	;	2.2	;	Loop Deletion mutant of Paracoccus denitrificans AztC
3UPG	;	3.2	;	Loop deletion mutant of Salmonella typhi osmoporin (OmpC):an Outer Membrane Protein.
5J7K	;	2.46	;	Loop grafting onto a highly stable FN3 scaffold
1JTI	;	2.3	;	Loop-inserted Structure of P1-P1' Cleaved Ovalbumin Mutant R339T
2AMO	;	2.6	;	Loose Dimer of a Bacillus subtilis Nitric Oxide Synthase
2EIG	;	2.0	;	Lotus tetragonolobus seed lectin (Isoform)
6J5C	;	3.6	;	Louping ill virus envelope protein
4R38	;	1.6	;	LOV domain from Erythrobacter litoralis EL346 blue-light activated histidine kinase
8C05	;	2.5	;	LOV-activated diguanylate cyclase, dark-state structure
6PH3	;	2.74	;	LOV-PAS construct from the LOV-HK sensory protein from Brucella abortus (dark-adapted, construct 15-273)
7QNL	;	1.71	;	LOV2-DARPIN FUSION - D4_DeltaLOV
7TBN	;	1.76	;	LOV2-DARPIN fusion : D11
7TBO	;	2.32	;	LOV2-DARPIN fusion : D12
7TAL	;	1.1	;	LOV2-DARPIN fusion : D4_deltaDARP
7TBQ	;	2.678	;	LOV2-DARPIN fusion : D7
7TCD	;	1.7	;	LOV2-DARPIN fusion: D13
6KJE	;	2.484	;	lovastatin esterase PcEST in complex with monacolin J
6KJF	;	2.4	;	lovastatin esterase PcEST in complex with simvastatin
6KJD	;	2.299	;	lovastatin esterase PcEST inactive mutant S57A in complex with lovastatin
6KJC	;	2.297	;	lovastatin esterase PcEST, wild type
7CPX	;	2.91	;	Lovastatin nonaketide synthase
7CPY	;	3.6	;	Lovastatin nonaketide synthase with LovC
3B6Z	;	1.88	;	Lovastatin polyketide enoyl reductase (LovC) complexed with 2'-phosphoadenosyl isomer of crotonoyl-CoA
3GQV	;	1.74	;	Lovastatin polyketide enoyl reductase (LovC) mutant K54S with bound NADP
3J1U	;	9.7	;	Low affinity dynein microtubule binding domain - tubulin complex
7N4T	;	2.4	;	Low conductance mechanosensitive channel YnaI
6WVL	;	3.2	;	Low curvature lateral interaction within a 13-protofilament, Taxol stabilized microtubule
1CR8	;		;	LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN COMPLEMENT REPEAT 8
5LH0	;	1.88	;	Low dose Thaumatin - 0-40 ms.
5LH1	;	1.9	;	Low dose Thaumatin - 360-400 ms.
5LN0	;	1.95	;	Low dose Thaumatin - 760-800 ms.
6DRA	;	3.96	;	Low IP3 Ca2+ human type 3 1,4,5-inositol trisphosphate receptor
4IDL	;	2.09	;	Low melting temperature Anti-Cholera Toxin Llama VHH domain
1PW6	;	2.6	;	Low Micromolar Small Molecule Inhibitor of IL-2
3IG6	;	1.83	;	Low molecular weigth human Urokinase type Plasminogen activator 2-[6-(3'-Aminomethyl-biphenyl-3-yloxy)-4-(3-dimethylamino-pyrrolidin-1-yl)-3,5-difluoro-pyridin-2-yloxy]-4-dimethylamino-benzoic acid complex
2TIO	;	1.93	;	LOW PACKING DENSITY FORM OF BOVINE BETA-TRYPSIN IN CYCLOHEXANE
3MKG	;	2.2	;	Low pH as-isolated tomato chloroplast superoxide dismutase
4GOB	;	1.53	;	Low pH Crystal Structure of a reconstructed Kaede-type Red Fluorescent Protein, Least Evolved Ancestor (LEA)
3C6R	;	25.0	;	Low pH Immature Dengue Virus
1URZ	;	2.7	;	Low pH induced, membrane fusion conformation of the envelope protein of tick-borne encephalitis virus
3H8E	;	2.75	;	Low pH native structure of leucine aminopeptidase from Pseudomonas putida
4GF4	;	3.1	;	Low pH structure of Pseudomonas putida OprB
3FOU	;	2.1	;	Low pH structure of the Rieske protein from Thermus thermophilus at 2.1 A
3C13	;	1.95	;	Low pH-value crystal structure of emodin in complex with the catalytic subunit of protein kinase CK2
2J42	;	3.13	;	low quality crystal structure of the transport component C2-II of the C2-toxin from Clostridium botulinum
2WTH	;	2.8	;	Low resolution 3D structure of C.elegans globin-like protein (GLB-1): P3121 crystal form
6LQJ	;	3.24	;	Low resolution architecture of curli complex
7PG0	;	7.6	;	Low resolution Cryo-EM structure of full-length insulin receptor bound to 3 insulin with visible ddm micelle, conf 1
7PG2	;	6.7	;	Low resolution Cryo-EM structure of full-length insulin receptor bound to 3 insulin, conf 1
7PG4	;	9.1	;	Low resolution Cryo-EM structure of the full-length insulin receptor bound to 2 insulin, conf 3
7PG3	;	7.3	;	Low resolution Cryo-EM structure of the full-length insulin receptor bound to 3 insulin, conf 2
6UJI	;	5.5	;	Low resolution crystal structure (5.5 A) of the anthrax toxin protective antigen heptamer prepore D425A mutant
1L3D	;	2.85	;	Low Resolution Crystal Structure of a Viral RNA Pseudoknot
5D1Y	;	9.005	;	Low resolution crystal structure of human ribonucleotide reductase alpha6 hexamer in complex with dATP
4X96	;	8.69	;	Low resolution crystal structure of Lecithin:Cholesterol Acyltransferase (LCAT; residues 21-397)
4IM8	;	3.503	;	low resolution crystal structure of mouse RAGE
6NZI	;	4.44	;	Low resolution crystal structure of the bacterial multidrug efflux transporter AcrB in the presence of cadmium
4J23	;	3.882	;	Low resolution crystal structure of the FGFR2D2D3/FGF1/SR128545 complex
4IIA	;	3.3	;	Low resolution crystal structure of the NTF2-like domain of human G3BP1
7JZT	;	3.77	;	Low resolution crystal structure of Zaire Ebola virus VP40 in space group P6422
1IUF	;		;	LOW RESOLUTION SOLUTION STRUCTURE OF THE TWO DNA-BINDING DOMAINS IN Schizosaccharomyces pombe ABP1 PROTEIN
4DG7	;	4.195	;	Low resolution structure of Drosophila Translin
4LDI	;	4.15	;	Low resolution structure of Ebola virus M241R mutant
4XX1	;	3.6	;	Low resolution structure of LCAT in complex with Fab1
6FWF	;	4.2	;	Low resolution structure of Neisseria meningitidis qNOR
1FB5	;	3.5	;	LOW RESOLUTION STRUCTURE OF OVINE ORNITHINE TRANSCARBMOYLASE IN THE UNLIGANDED STATE
1ZN2	;	2.91	;	Low Resolution Structure of Response Regulator StyR
6Z3B	;	2.58	;	Low resolution structure of RgNanOx
2LLI	;		;	Low resolution structure of RNA-binding subunit of the TRAMP complex
2JGT	;	3.0	;	Low resolution structure of SPT
3S4G	;	6.0	;	Low Resolution Structure of STNV complexed with RNA
5OBZ	;	3.7	;	low resolution structure of the p34ct/p44ct minimal complex
4UW0	;	3.87	;	Low resolution structure of WbdD with C-terminal bundle ordered to residue 505
4UFS	;	4.8	;	Low resolution structure R-spondin-2 (Fu1Fu2) in complex with the ectodomains of LGR5 and ZNRF3
2W6F	;	6.0	;	Low resolution structures of bovine mitochondrial F1-ATPase during controlled dehydration: Hydration State 2.
2W6G	;	6.0	;	Low resolution structures of bovine mitochondrial F1-ATPase during controlled dehydration: Hydration State 3.
2W6H	;	5.0	;	Low resolution structures of bovine mitochondrial F1-ATPase during controlled dehydration: Hydration State 4A.
2W6I	;	4.0	;	Low resolution structures of bovine mitochondrial F1-ATPase during controlled dehydration: Hydration State 4B.
2W6J	;	3.84	;	Low resolution structures of bovine mitochondrial F1-ATPase during controlled dehydration: Hydration State 5.
2W6E	;	6.5	;	Low resolution structures of bovine mitochondrial F1-ATPase during controlled dehydration:hydration state 1.
3PAW	;	6.61	;	Low resolution X-ray crystal structure of Yeast Rnr1p with dATP bound in the A-site
3HR2	;	5.16	;	Low resolution, molecular envelope structure of type I collagen in situ determined by fiber diffraction. Single type I collagen molecule, post rigid body refinement, 'relaxed'
3HQV	;	5.16	;	Low resolution, molecular envelope structure of type I collagen in situ determined by fiber diffraction. Single type I collagen molecule, rigid body refinement
5OWL	;	2.23	;	Low salt structure of human protein kinase CK2alpha in complex with 3-aminopropyl-4,5,6,7-tetrabromobenzimidazol
5FNY	;	2.01	;	Low solvent content crystal form of Zn containing Iron sulfur cluster repair protein YtfE
1J9E	;	1.44	;	Low Temperature (100K) Crystal Structure of Flavodoxin D. vulgaris S35C Mutant at 1.44 Angstrom Resolution
1J9G	;	2.4	;	Low Temperature (100K) Crystal Structure of Flavodoxin D. vulgaris S64C Mutant, monomer oxidised, at 2.4 Angstrom Resolution
1J8Q	;	1.35	;	Low Temperature (100K) Crystal Structure of Flavodoxin D. vulgaris Wild-type at 1.35 Angstrom Resolution
1WSW	;	1.69	;	Low Temperature (100K) Crystal Structure Of Flavodoxin Mutant S64C, dimer, semiquinone state
1XYY	;	1.7	;	Low Temperature (100K) Crystal Structure Of Flavodoxin Mutant S64C, homodimer, oxidised state
1XYV	;	1.79	;	Low Temperature (100K) Crystal Structure Of Flavodoxin Mutant S64C, monomer, semiquinone state
1QCJ	;	2.1	;	LOW TEMPERATURE COMPLEX OF POKEWEED ANTIVIRAL PROTEIN WITH PTEORIC ACID
1LPU	;	1.86	;	Low Temperature Crystal Structure of the Apo-form of the catalytic subunit of protein kinase CK2 from Zea mays
6D54	;	1.9	;	Low Temperature joint X-ray/neutron structure of DNA oligonucleotide d(GTGGCCAC)2 with 2'-SeCH3 modification on Cyt5
6D54	;	1.65	;	Low Temperature joint X-ray/neutron structure of DNA oligonucleotide d(GTGGCCAC)2 with 2'-SeCH3 modification on Cyt5
1BHZ	;	3.9	;	LOW TEMPERATURE MIDDLE RESOLUTION STRUCTURE OF HEN EGG WHITE LYSOZYME FROM MASC DATA
1BHY	;	4.18	;	LOW TEMPERATURE MIDDLE RESOLUTION STRUCTURE OF P64K FROM MASC DATA
1BHW	;	4.1	;	LOW TEMPERATURE MIDDLE RESOLUTION STRUCTURE OF XYLOSE ISOMERASE FROM MASC DATA
1JPO	;	2.1	;	LOW TEMPERATURE ORTHORHOMBIC LYSOZYME
7RB6	;	2.4	;	Low temperature structure of hAChE in complex with substrate analog 4K-TMA
1E2U	;	1.6	;	Low Temperature Structure of Hybrid Cluster Protein from Desulfovibrio vulgaris to 1.6A
2VFM	;	1.5	;	Low Temperature Structure of P22 Tailspike Protein Fragment (109-666)
2VFN	;	1.5	;	Low Temperature Structure of P22 Tailspike Protein Fragment (109-666), Mutant V125A
2VFO	;	1.5	;	Low Temperature Structure of P22 Tailspike Protein Fragment (109-666), Mutant V125L
2VFP	;	1.55	;	Low Temperature Structure of P22 Tailspike Protein Fragment (109-666), Mutant V349L
2VFQ	;	1.55	;	Low Temperature Structure of P22 Tailspike Protein Fragment (109-666), Mutant V450A
2C7L	;	2.85	;	Low temperature structure of phycoerythrocyanin from Mastigocladus laminosus
1QCG	;	2.1	;	LOW TEMPERATURE STRUCTURE OF POKEWEED ANTIVIRAL PROTEIN
1QCI	;	2.0	;	LOW TEMPERATURE STRUCTURE OF POKEWEED ANTIVIRAL PROTEIN COMPLEXED WITH ADENINE
1CW7	;	2.6	;	LOW TEMPERATURE STRUCTURE OF WILD-TYPE IDH COMPLEXED WITH MG-ISOCITRATE
4DH7	;	1.8	;	Low temperature X-ray structure of cAMP dependent Protein Kinase A catalytic subunit with high Mg2+, AMP-PNP and IP20'
4DH3	;	2.2	;	Low temperature X-ray structure of cAMP dependent Protein Kinase A catalytic subunit with high Mg2+, ATP and IP20
4DH1	;	2.0	;	Low temperature X-ray structure of cAMP dependent Protein Kinase A catalytic subunit with low Mg2+, ATP and IP20
4IAD	;	1.9	;	Low temperature X-ray Structure OF cAMP dependent protein kinase A in complex with high Mg2+ concentration, ADP and phosphorylated peptide pSP20
4IAK	;	1.6	;	Low temperature X-ray structure of cAMP dependent protein kinase A in complex with high Sr2+ concentration, ADP and phosphorylated peptide pSP20
4UPV	;	1.52	;	Low X-ray dose structure of a Ni-A Ni-Sox mixture of the D. fructosovorans NiFe-hydrogenase L122A mutant
4KO3	;	1.7	;	Low X-ray dose structure of anaerobically purified Dm. baculatum [NiFeSe]-hydrogenase after crystallization under air
4KO2	;	1.6	;	Low X-ray dose structure of H2-activated anaerobically purified Dm. baculatum [NiFeSe]-hydrogenase after crystallization under air
6YRX	;	1.87	;	Low-dose crystal structure of FAP at room temperature
5M3S	;	1.8	;	Low-dose fixed target serial synchrotron crystallography structure of Metmyoglobin
5O41	;	1.8	;	Low-dose fixed target serial synchrotron crystallography structure of sperm whale myoglobin
6J8M	;	1.9	;	Low-dose structure of bovine heart cytochrome c oxidase in the fully oxidized state determined using 30 keV X-ray
3A8Q	;	3.2	;	Low-resolution crystal structure of the Tiam2 PHCCEx domain
6BQE	;	3.2	;	Low-resolution structure of cyclohexadienyl dehydratase from Pseudomonas aeruginosa in space group P4322.
7AHM	;	3.14	;	Low-resolution structure of the K+/H+ antiporter subunit KhtT in complex with c-di-AMP
4CH2	;	1.6	;	Low-salt crystal structure of a thrombin-GpIbalpha peptide complex
5ONI	;	2.0	;	LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
6HME	;	1.85	;	LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA; CSNK2A1 gene product) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR THN27
4UBA	;	2.995	;	Low-salt structure of protein kinase CK2 catalytic subunit with 4'-carboxy-6,8-bromo-flavonol (FLC26)
5MS5	;	1.53	;	Low-salt structure of RavZ LIR2-fused human LC3B
2D95	;	2.0	;	LOW-TEMPERATURE STUDY OF THE A-DNA FRAGMENT D(GGGCGCCC)
3UR8	;	1.26	;	Lower-density crystal structure of potato endo-1,3-beta-glucanase
7R8U	;	1.901	;	LOX-1 - Structural and Functional Studies of a Receptor Implicated in Atherosclerosis
7D2F	;	2.6	;	Lp major histidine acid phosphatase mutant D281A/5'-AMP
7DOQ	;	2.2	;	Lp major histidine acid phosphatase mutant D281A/5'-AMP
5JPL	;		;	LP2006, a handcuff-topology lasso peptide antibiotic
7X4T	;	2.2	;	LpCdnE UMPNPP Mg complex
7X4Q	;	1.95	;	LpCdnE UTP Mg complex
8PZO	;	2.0	;	LpdD
8PZH	;	2.02	;	LpdD (H61A) mutant
7SF7	;	2.9	;	LPHN3 (ADGRL3) 7TM domain bound to tethered agonist in complex with G protein heterotrimer
7PXW	;	1.4	;	LPMO, expressed in E.coli, in complex with Cellotetraose
3CKM	;	1.35	;	LpoA (YraM) C-domain from Haemophilus influenzae, a regulator of PBP1A
6DCJ	;	1.35	;	LpoA N-terminal domain from Haemophilus influenzae; monoclinic form at 1.35 A resolution
4Q6Z	;	2.8	;	LpoB C-terminal domain from Escherichia coli
4Q6L	;	2.2	;	LpoB C-terminal domain from Salmonella enterica (Native)
4Q6V	;	1.97	;	LpoB C-terminal domain from Salmonella enterica (Sel-Met)
7A0Z	;	1.45	;	LppS with covalent adduct derived from 1b
7A1E	;	1.77	;	LppS with covalent adduct derived from 1c
7A11	;	1.65	;	LppS with covalent adduct derived from 1E
7A10	;	1.85	;	LppS with covalent adduct derived from 1g
8HPL	;	4.29	;	LpqY-SugABC in state 1
8HPM	;	3.82	;	LpqY-SugABC in state 2
8HPN	;	4.55	;	LpqY-SugABC in state 3
8HPR	;	3.75	;	LpqY-SugABC in state 4
8HPS	;	3.51	;	LpqY-SugABC in state 5
5Z32	;		;	LPS bound solution NMR structure of WS2-VR18
5Z31	;		;	LPS bound solution structure of WS2-KG18
2O0S	;		;	LPS-bound structure of a designed peptide
6MBN	;	1.957	;	LptB E163Q in complex with ATP
6MJP	;	2.85	;	LptB(E163Q)FGC from Vibrio cholerae
7EFO	;	3.85	;	LptB2FG-LPS from Klebsiella pneumoniae in nanodiscs
6MIT	;	3.2	;	LptBFGC from Enterobacter cloacae
4U3D	;	1.25	;	LpxC from A.Aaeolicus in complex with 4-[[4-[2-[4-(morpholinomethyl)phenyl]ethynyl]phenoxy]methyl]tetrahydropyran-4-carbohydroxamic acid (compound 9)
4U3B	;	1.34	;	LpxC from A.Aaeolicus in complex with the MMP inhibitor 4-[[4-(4-chlorophenoxy)phenyl]sulfanylmethyl]tetrahydropyran-4-carbohydroxamic acid - compound 2
4OKG	;	2.06	;	LpxC from P.aeruginosa with the inhibitor 6-(benzimidazol-1-yl)-5-[4-[2-[6-[(4-methylpiperazin-1-yl)methyl]-3-pyridyl]ethynyl]phenyl]pyridine-3-carbohydroxamic acid
7PHJ	;	2.45	;	LpxC Inhibitors With Fluoroproline As A Novel Zinc-Binding Group Can Serve As A Novel Class of Antibiotic With Activity Against Multidrug-Resistant Gram-Negative Bacteria
7PHN	;	1.9	;	LpxC Inhibitors With Fluoroproline As A Novel Zinc-Binding Group Can Serve As A Novel Class of Antibiotic With Activity Against Multidrug-Resistant Gram-Negative Bacteria
7PJ2	;	1.8	;	LpxC Inhibitors With Fluoroproline As A Novel Zinc-Binding Group Can Serve As A Novel Class of Antibiotic With Activity Against Multidrug-Resistant Gram-Negative Bacteria
7PJG	;	2.04	;	LpxC Inhibitors With Fluoroproline As A Novel Zinc-Binding Group Can Serve As A Novel Class of Antibiotic With Activity Against Multidrug-Resistant Gram-Negative Bacteria
7PK8	;	2.3	;	LpxC Inhibitors With Fluoroproline As A Novel Zinc-Binding Group Can Serve As A Novel Class of Antibiotic With Activity Against Multidrug-Resistant Gram-Negative Bacteria
7PKK	;	2.55	;	LpxC Inhibitors With Fluoroproline As A Novel Zinc-Binding Group Can Serve As A Novel Class of Antibiotic With Activity Against Multidrug-Resistant Gram-Negative Bacteria
7PKM	;	2.1	;	LpxC Inhibitors With Fluoroproline As A Novel Zinc-Binding Group Can Serve As A Novel Class of Antibiotic With Activity Against Multidrug-Resistant Gram-Negative Bacteria
7PZS	;	2.45	;	LpxC Inhibitors With Fluoroproline As A Novel Zinc-Binding Group Can Serve As A Novel Class of Antibiotic With Activity Against Multidrug-Resistant Gram-Negative Bacteria
7PZU	;	2.15	;	LpxC Inhibitors With Fluoroproline As A Novel Zinc-Binding Group Can Serve As A Novel Class of Antibiotic With Activity Against Multidrug-Resistant Gram-Negative Bacteria
7PZV	;	1.92	;	LpxC Inhibitors With Fluoroproline As A Novel Zinc-Binding Group Can Serve As A Novel Class of Antibiotic With Activity Against Multidrug-Resistant Gram-Negative Bacteria
7PZW	;	2.0	;	LpxC Inhibitors With Fluoroproline As A Novel Zinc-Binding Group Can Serve As A Novel Class of Antibiotic With Activity Against Multidrug-Resistant Gram-Negative Bacteria
7PZX	;	2.39	;	LpxC Inhibitors With Fluoroproline As A Novel Zinc-Binding Group Can Serve As A Novel Class of Antibiotic With Activity Against Multidrug-Resistant Gram-Negative Bacteria
7Q01	;	2.01	;	LpxC Inhibitors With Fluoroproline As A Novel Zinc-Binding Group Can Serve As A Novel Class of Antibiotic With Activity Against Multidrug-Resistant Gram-Negative Bacteria
3FID	;	1.9	;	LpxR from Salmonella typhimurium
1LIR	;		;	LQ2 FROM LEIURUS QUINQUESTRIATUS, NMR, 22 STRUCTURES
7LIZ	;	2.8	;	LR6 rod linker and scaffolded phycoerythrin beta subunits from the phycobilisome of Porphyridium purpureum
8F8M	;	2.6	;	LRH-1 bound to small molecule Tet and fragment of coactivator Tif2
6VC2	;	1.697	;	LRH-1 bound to SS-RJW100 and a fragment of the Tif2 Coactivator
4U7L	;	2.3	;	LRIG1 extracellular domain: Structure and Function Analysis
4U7M	;	2.757	;	LRIG1 extracellular domain: Structure and Function Analysis
7NAM	;	1.6	;	LRP6_E1 in complex with Lr-EET-3.5
7UCX	;	1.72	;	LRP8 11H1 Fab complexed to a cyclized CR1 peptide
4IM6	;	1.65	;	LRR domain from human NLRP1
8BEN	;	3.1	;	LRR domain Structure of the LRRC8C protein
7SA1	;	3.21	;	LRR-F-Box plant ubiquitin ligase
8F75	;	4.0	;	LRRC8A(T48D):C conformation 2 LRR focus
8F74	;	3.1	;	LRRC8A(T48D):C conformation 2 top focus
8F77	;	3.15	;	LRRC8A(T48D):C conformation 2 top focus
8F79	;	3.15	;	LRRC8A(T48D):C conformation 2 top focus
8F7B	;	3.15	;	LRRC8A(T48D):C conformation 2 top focus
8F7D	;	4.2	;	LRRC8A(T48D):C conformation 2 top focus
8F7E	;	4.13	;	LRRC8A(T48D):C conformation 2 top focus
8F7J	;	4.32	;	LRRC8A(T48D):C conformation 2 top focus
6NZW	;	3.21	;	LRRC8A-DCPIB in MSP1E3D1 nanodisc constricted state
6NZZ	;	3.32	;	LRRC8A-DCPIB in MSP1E3D1 nanodisc expanded state
8DS3	;	3.07	;	LRRC8A:C conformation 1 (round)
8DRN	;	4.12	;	LRRC8A:C conformation 1 (round) LRR focus 1
8DRO	;	4.06	;	LRRC8A:C conformation 1 (round) LRR focus 2
8DRQ	;	4.16	;	LRRC8A:C conformation 1 (round) LRR focus 3
8DRK	;	2.95	;	LRRC8A:C conformation 1 (round) top focus
8DRE	;	3.18	;	LRRC8A:C conformation 2 (oblong)
8DRA	;	3.98	;	LRRC8A:C conformation 2 (oblong) LRR mask
8DR8	;	3.04	;	LRRC8A:C conformation 2 (oblong) top mask
8DSA	;	3.48	;	LRRC8A:C in MSP1E3D1 nanodisc
8DS9	;	3.17	;	LRRC8A:C in MSPE3D1 nanodisc top focus
6U3N	;	2.8	;	LS2.8/3.15 - DQ2-P.fluor-alpha1a complex
7NHK	;	2.9	;	LsaA, an antibiotic resistance ABCF, in complex with 70S ribosome from Enterococcus faecalis
7PQR	;	1.3	;	LsAA9A expressed in E. coli
7PXV	;	1.5	;	LsAA9_A chemically reduced with ascorbic acid (high X-ray dose)
7PXU	;	1.8	;	LsAA9_A chemically reduced with ascorbic acid (low X-ray dose)
8INL	;	2.62	;	LSD1 in complex with S2172
4UV8	;	2.8	;	LSD1(KDM1A)-CoREST in complex with 1-Benzyl-Tranylcypromine
4UV9	;	3.0	;	LSD1(KDM1A)-CoREST in complex with 1-Ethyl-Tranylcypromine
4UVA	;	2.9	;	LSD1(KDM1A)-CoREST in complex with 1-Methyl-Tranylcypromine (1R,2S)
4UVB	;	2.8	;	LSD1(KDM1A)-CoREST in complex with 1-Methyl-Tranylcypromine (1S,2R)
4UVC	;	3.1	;	LSD1(KDM1A)-CoREST in complex with 1-Phenyl-Tranylcypromine
4UXN	;	2.85	;	LSD1(KDM1A)-CoREST in complex with Z-Pro derivative of MC2580
5YJB	;	2.96	;	LSD1-CoREST in complex with 4-[5-(piperidin-4-ylmethoxy)-2-(p-tolyl)pyridin-3-yl]benzonitrile
3ZMS	;	2.96	;	LSD1-CoREST in complex with INSM1 peptide
3ZMU	;	3.2	;	LSD1-CoREST in complex with PKSFLV peptide
3ZMV	;	3.0	;	LSD1-CoREST in complex with PLSFLV peptide
3ZN1	;	3.1	;	LSD1-CoREST in complex with PRLYLV peptide
3ZN0	;	2.8	;	LSD1-CoREST in complex with PRSFAA peptide
3ZMZ	;	3.0	;	LSD1-CoREST in complex with PRSFAV peptide
3ZMT	;	3.1	;	LSD1-CoREST in complex with PRSFLV peptide
6KGK	;	2.7	;	LSD1-CoREST-S2101 five-membered ring adduct model
6KGL	;	2.7	;	LSD1-CoREST-S2101 N5 adduct model
6KGM	;	2.62	;	LSD1-CoREST-S2116 five-membered ring adduct model
6KGN	;	2.62	;	LSD1-CoREST-S2116 N5 adduct model
5L3F	;	3.5	;	LSD1-CoREST1 in complex with polymyxin B
5L3G	;	3.1	;	LSD1-CoREST1 in complex with polymyxin E (colistin)
5L3E	;	2.8	;	LSD1-CoREST1 in complex with quinazoline-derivative reversible inhibitor
5LBQ	;	3.3	;	LSD1-CoREST1 in complex with quinazoline-derivative reversible inhibitor
6KGQ	;	2.32	;	LSD1-FCPA-MPE five-membered ring adduct model
6KGR	;	2.32	;	LSD1-FCPA-MPE N5 adduct model
6KGO	;	2.25	;	LSD1-S2157 five-membered ring adduct model
6KGP	;	2.25	;	LSD1-S2157 N5 adduct model
2EJR	;	2.7	;	LSD1-tranylcypromine complex
6K3E	;	2.87	;	LSD1/Co-Rest structure with an inhibitor
6S35	;	3.1	;	LSD1/CoREST1 complex with macrocyclic peptide inhibitor
6P0W	;	2.4	;	LsfA from P. aeruginosa, a 1-Cys Prx in reduced form
7KUU	;	2.0	;	LsfA from P. aeruginosa, a 1-Cys Prx in Sulfonic acid form
1LSI	;		;	LSIII (NMR, 23 STRUCTURES)
6TFL	;	2.397	;	Lsm protein (SmAP) from Halobacterium salinarum
6DSP	;	1.37	;	LsrB from Clostridium saccharobutylicum in complex with AI-2
5LX2	;	2.579	;	Lt 14-3-3 in complex with PI4KIIIB peptide
4FNF	;	1.75	;	LT-IIB-B5 S74D mutant
6VRT	;	2.555	;	LT1009 humanized antibody Fab fragment in complex with calcium
7QEH	;	1.67	;	LTA-binding domain of SlpA, the S-layer protein from Lactobacillus amylovorus
6ENB	;	1.84	;	LTA4 hydrolase (E297Q) mutant in complex with Pro-Gly-Pro peptide
8QOW	;	2.35	;	LTA4 hydrolase in complex with compound 2(S)
8QQ4	;	1.6	;	LTA4 hydrolase in complex with compound 6(R)
8QPN	;	2.0	;	LTA4 hydrolase in complex with compound 6(S)
7AUZ	;	1.9	;	LTA4 hydrolase in complex with compound LYS006
7AV0	;	1.9	;	LTA4 hydrolase in complex with compound R(13)
6ENC	;	1.95	;	LTA4 hydrolase in complex with Compound11
6END	;	2.24	;	LTA4 hydrolase in complex with Compound15
8RX7	;	1.85	;	LTA4 hydrolase in complex with compound2
8RX9	;	2.9	;	LTA4 hydrolase in complex with compound3
8RX3	;	1.85	;	LTA4 hydrolase in complex with CTX-4430
7AV2	;	1.95	;	LTA4 hydrolase in complex with fragment1
7AV1	;	1.79	;	LTA4 hydrolase in complex with fragment2
6H5F	;	2.0	;	LtgA disordered Helix
7NX0	;	1.95	;	LTK:ALKAL1 complex stabilized by a Nanobody
6OK1	;	1.7	;	Ltp2-ChsH2(DUF35) aldolase
5GYZ	;	2.4	;	luciferase AMP/7-cy-L complex
5GZ2	;	2.0	;	luciferase complex with 7-cy-L
5WYS	;	2.999	;	luciferase with inhibitor 3i
5GTQ	;	1.13	;	Luciferin-regenerating enzyme at cryogenic temperature
5GX1	;	1.6	;	Luciferin-regenerating enzyme collected with serial synchrotron rotational crystallography with accumulated dose of 1.1 MGy (1st measurement)
5GX4	;	1.6	;	Luciferin-regenerating enzyme collected with serial synchrotron rotational crystallography with accumulated dose of 14 MGy (12th measurement)
5GX5	;	1.6	;	Luciferin-regenerating enzyme collected with serial synchrotron rotational crystallography with accumulated dose of 26 MGy (23rd measurement)
5GX2	;	1.6	;	Luciferin-regenerating enzyme collected with serial synchrotron rotational crystallography with accumulated dose of 3.4 MGy (3rd measurement)
5GX3	;	1.6	;	Luciferin-regenerating enzyme collected with serial synchrotron rotational crystallography with accumulated dose of 6.9 MGy (6th measurement)
5D9D	;	1.701	;	Luciferin-regenerating enzyme solved by SAD using synchrotron radiation at room temperature
5XFE	;	1.5	;	Luciferin-regenerating enzyme solved by SAD using XFEL (refined against 11,000 patterns)
5D9C	;	1.6	;	Luciferin-regenerating enzyme solved by SIRAS using XFEL (refined against Hg derivative data)
5D9B	;	1.5	;	Luciferin-regenerating enzyme solved by SIRAS using XFEL (refined against native data)
5C8V	;	2.01	;	Lucilia cuprina alpha esterase 7: Gly137Asp
8EO2	;	2.31	;	Lufaxin a bifunctional inhibitor of complement and coagulation
7X7M	;	2.33	;	Lumazine Synthase from Aquifex aeolicus
2C94	;	1.9	;	LUMAZINE SYNTHASE FROM MYCOBACTERIUM TUBERCULOSIS BOUND TO 3-(1,3,7- TRIHYDRO-9-D-RIBITYL-2,6,8-PURINETRIONE-7-YL) 1,1 difluoropentane-1- PHOSPHATE
2C92	;	1.6	;	LUMAZINE SYNTHASE FROM MYCOBACTERIUM TUBERCULOSIS BOUND TO 3-(1,3,7- TRIHYDRO-9-D-RIBITYL-2,6,8-PURINETRIONE-7-YL) PENTANE 1 PHOSPHATE
1W29	;	2.3	;	Lumazine Synthase from Mycobacterium tuberculosis bound to 3-(1,3,7- trihydro-9-D-ribityl-2,6,8-purinetrione-7-yl)butane 1-phosphate
2C9D	;	2.8	;	Lumazine Synthase from Mycobacterium tuberculosis Bound to 3-(1,3,7- TRIHYDRO-9-D-RIBITYL-2,6,8-PURINETRIONE-7-YL)HEXANE 1-PHOSPHATE
1W19	;	2.0	;	Lumazine Synthase from Mycobacterium tuberculosis bound to 3-(1,3,7- trihydro-9-D-ribityl-2,6,8-purinetrione-7-yl)propane 1-phosphate
2C97	;	2.0	;	LUMAZINE SYNTHASE FROM MYCOBACTERIUM TUBERCULOSIS BOUND TO 4-(6- chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)butyl phosphate
2VI5	;	2.3	;	LUMAZINE SYNTHASE FROM MYCOBACTERIUM TUBERCULOSIS BOUND TO N-6-(ribitylamino)pyrimidine-2,4(1H,3H)-dione-5-yl-propionamide
2C9B	;	2.75	;	Lumazine Synthase from Mycobacterium tuberculosus Bound to 3-(1,3,7- TRIHYDRO-9-D-RIBITYL-2,6,8-PURINETRIONE-7-YL)
1KYX	;	2.6	;	Lumazine Synthase from S.pombe bound to carboxyethyllumazine
1KYY	;	2.4	;	Lumazine Synthase from S.pombe bound to nitropyrimidinedione
1KYV	;	2.4	;	Lumazine Synthase from S.pombe bound to riboflavin
1EJB	;	1.85	;	LUMAZINE SYNTHASE FROM SACCHAROMYCES CEREVISIAE
2I0F	;	2.22	;	Lumazine synthase RibH1 from Brucella abortus (Gene BruAb1_0785, Swiss-Prot entry Q57DY1)
2F59	;	2.3	;	Lumazine synthase RibH1 from Brucella abortus (Gene BruAb1_0785, Swiss-Prot entry Q57DY1) complexed with inhibitor 5-Nitro-6-(D-Ribitylamino)-2,4(1H,3H) Pyrimidinedione
2O6H	;	2.7	;	Lumazine synthase RibH1 from Brucella melitensis (Gene BMEI1187, Swiss-Prot entry Q8YGH2) complexed with inhibitor 5-Nitro-6-(D-Ribitylamino)-2,4(1H,3H) Pyrimidinedione
2OBX	;	2.53	;	Lumazine synthase RibH2 from Mesorhizobium loti (Gene mll7281, Swiss-Prot entry Q986N2) complexed with inhibitor 5-Nitro-6-(D-Ribitylamino)-2,4(1H,3H) Pyrimidinedione
2GTL	;	3.5	;	Lumbricus Erythrocruorin at 3.5A resolution
1HCZ	;	1.96	;	LUMEN-SIDE DOMAIN OF REDUCED CYTOCHROME F AT-35 DEGREES CELSIUS
8B7D	;	2.59	;	Luminal domain of TMEM106B
1B08	;	2.3	;	LUNG SURFACTANT PROTEIN D (SP-D) (FRAGMENT)
7FIJ	;	3.8	;	luteinizing hormone/choriogonadotropin receptor
7FIG	;	3.9	;	luteinizing hormone/choriogonadotropin receptor(S277I)-chorionic gonadotropin-Gs complex
7FIH	;	3.2	;	luteinizing hormone/choriogonadotropin receptor(S277I)-chorionic gonadotropin-Gs-Org43553 complex
7FII	;	4.3	;	luteinizing hormone/choriogonadotropin receptor-chorionic gonadotropin-Gs complex
2PF6	;	2.2	;	Lutheran glycoprotein, N-terminal domains 1 and 2
2PET	;	1.7	;	Lutheran glycoprotein, N-terminal domains 1 and 2.
3HYD	;	1.0	;	LVEALYL peptide derived from human insulin chain B, residues 11-17
3Q9H	;	2.25	;	LVFFA segment from Alzheimer's Amyloid-Beta displayed on 42-membered macrocycle scaffold
3Q9I	;	1.99	;	LVFFA segment from Alzheimer's Amyloid-Beta displayed on 42-membered macrocycle scaffold, bromide derivative
8H6R	;	2.6	;	LW Domain of Arabidopsis thaliana TFIIS
7UH4	;	2.2	;	LXG-associated alpha-helical protein D2 (LapD2)
6S4N	;	1.9	;	LXRbeta ligand binding domain in comlpex with small molecule inhibitors
6S4T	;	2.0	;	LXRbeta ligand binding domain in comlpex with small molecule inhibitors
6S4U	;	2.81	;	LXRbeta ligand binding domain in comlpex with small molecule inhibitors
6S5K	;	1.6	;	LXRbeta ligand binding domain in complex with small molecule inhibitors
7MMO	;	2.427	;	LY-CoV1404 neutralizing antibody against SARS-CoV-2
7KMI	;	1.73	;	LY-CoV481 neutralizing antibody against SARS-CoV-2
7KMH	;	1.72	;	LY-CoV488 neutralizing antibody against SARS-CoV-2
7KMG	;	2.16	;	LY-CoV555 neutralizing antibody against SARS-CoV-2
6WZJ	;	2.37	;	LY3041658 Fab bound to CXCL2
6WZK	;	1.8	;	LY3041658 Fab bound to CXCL3
6WZL	;	2.29	;	LY3041658 Fab bound to CXCL7
6WZM	;	2.28	;	LY3041658 Fab bound to CXCL8
5NGN	;	1.48	;	Lybatide 2, a cystine-rich peptide from Lycium barbarum
7MMM	;		;	LyeTx I
6CL3	;		;	LyeTxI-b, a synthetic peptide derived from Lycosa erythrognatha spider venom, shows potent antibiotic activity, in vitro and in vivo
1FJ1	;	2.68	;	LYME DISEASE ANTIGEN OSPA IN COMPLEX WITH NEUTRALIZING ANTIBODY FAB LA-2
4BG5	;	3.4	;	Lyme disease associated outer surface protein BBA65 from Borrelia burgdorferi
4ZR6	;	2.6	;	Lymnaea Stagnalis Acetylcholine Binding Protein in Complex with 3-[(4E)-4-[(3-methylimidazol-4-yl)methylene]-2,3-dihydropyrrol-5-yl]pyridine
8DMI	;	3.26	;	Lymphocytic choriomeningitis virus glycoprotein
8DMH	;	3.19	;	Lymphocytic choriomeningitis virus glycoprotein in complex with neutralizing antibody M28
7X6V	;	3.6	;	lymphocytic choriomeningitis virus polymerase- Matrix Z Protein Complex (LCMV L-Z Complex)
7X6S	;	3.4	;	lymphocytic choriomeningitis virus RNA-dependent RNA polymerase (LCMV-L protein)
3A4O	;	3.0	;	Lyn kinase domain
2ZV7	;	2.5	;	Lyn Tyrosine Kinase Domain, apo form
2ZV8	;	2.7	;	Lyn Tyrosine Kinase Domain-AMP-PNP complex
2ZVA	;	2.6	;	Lyn Tyrosine Kinase Domain-Dasatinib complex
2ZV9	;	2.76	;	Lyn Tyrosine Kinase Domain-PP2 complex
4GVU	;	1.55	;	Lyngbyastatin 7-Porcine Pancreatic Elastase Co-crystal Structure
2OMP	;	1.9	;	LYQLEN peptide derived from human insulin chain A, residues 13-18
1HJA	;	2.3	;	LYS 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH ALPHA-CHYMOTRYPSIN
1LPH	;	2.3	;	LYS(B28)PRO(B29)-HUMAN INSULIN
5GOC	;	1.733	;	Lys11-linked diubiquitin
5GOD	;	1.15	;	Lys27-linked di-ubiquitin
5J8P	;	1.554	;	Lys27-linked diubiquitin
5JBV	;	2.104	;	Lys27-linked triubiquitin
5JBY	;	1.987	;	Lys27-linked triubiquitin
5GOG	;	1.977	;	Lys29-linked di-ubiquitin
5GOH	;	1.946	;	Lys33-linked di-ubiquitin
5GOI	;	1.594	;	Lys48-linked di-ubiquitin
8IC9	;	1.25	;	Lys48-linked K48C-diubiquitin
6AL3	;	2.57	;	Lys49 PLA2 BPII derived from the venom of Protobothrops flavoviridis.
2IFJ	;		;	Lys6 deamidated variant of ImI conotoxin
2IFZ	;		;	Lys6 Variant of ImI Conotoxin
5GOB	;	1.153	;	Lys6-linked di-ubiquitin
3ZLZ	;	2.9	;	Lys6-linked tri-ubiquitin
5GOJ	;	1.549	;	Lys63-linked di-ubiquitin
3ZXG	;	3.12	;	lysenin sphingomyelin complex
5O1Q	;		;	LysF1 sh3b domain structure
5BUA	;	1.812	;	Lysine 120-acetylated P53 DNA binding domain in a complex with DNA.
5LGY	;	2.92	;	Lysine 120-acetylated P53 DNA binding domain in a complex with the BAX response element.
6QHD	;	2.85	;	Lysine acetylated and tyrosine phosphorylated STAT3 in a complex with DNA
2CJG	;	1.95	;	Lysine aminotransferase from M. tuberculosis in bound PMP form
2CJD	;	2.0	;	Lysine aminotransferase from M. tuberculosis in external aldimine form
2CIN	;	1.98	;	Lysine aminotransferase from M. tuberculosis in the internal aldimine form
2CJH	;	2.0	;	Lysine aminotransferase from M. tuberculosis in the internal aldimine form with bound substrate 2-ketoglutarate
6Q6I	;	3.7	;	Lysine decarboxylase A from Pseudomonas aeruginosa
2ND5	;		;	Lysine dimethylated FKBP12
4QAO	;	2.103	;	Lysine-ligated cytochrome c with F82H
4Q5P	;	1.87	;	Lysine-Ligated Yeast Iso-1 Cytochrome C
6YW0	;	2.2	;	Lysine-N,N-Dimethylated HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with BB-287
6NDX	;	3.04	;	Lysinoalanine cross-linked FlgE dimer from Treponema denticola
6C0G	;	2.145	;	Lysinoalanine synthase, DurN, from duramycin biosynthesis
6C0H	;	1.9	;	Lysinoalanine synthase, DurN, from duramycin biosynthesis bound to 1-Dha6Ala
6C0Y	;	1.66	;	Lysinoalanine synthase, DurN, from duramycin biosynthesis bound to duramycin
1E0G	;		;	LYSM Domain from E.coli MLTD
4NSV	;	0.9	;	Lysobacter enzymogenes lysc endoproteinase K30R mutant covalently inhibited by TLCK
7TD0	;	2.83	;	Lysophosphatidic acid receptor 1-Gi complex bound to LPA
7TD1	;	3.08	;	Lysophosphatidic acid receptor 1-Gi complex bound to LPA, state a
7TD2	;	3.11	;	Lysophosphatidic acid receptor 1-Gi complex bound to LPA, state a
8IZB	;	3.06	;	Lysophosphatidylserine receptor GPR174-Gs complex
8IZ4	;	2.93	;	Lysophosphatidylserine receptor GPR34-Gi complex
8WRB	;	2.91	;	Lysophosphatidylserine receptor GPR34-Gi complex
8A26	;	1.45	;	Lysophospholipase PlaA from Legionella pneumophila str. Corby - complex with palmitate
8A25	;	1.73	;	Lysophospholipase PlaA from Legionella pneumophila str. Corby - complex with PEG fragment
8A24	;	2.36	;	Lysophospholipase PlaA from Legionella pneumophila str. Corby - iodide soak
7F40	;	3.49	;	Lysophospholipid acyltransferase LPCAT3 in a complex with Arachidonoyl-CoA
7F3X	;	3.57	;	Lysophospholipid acyltransferase LPCAT3 in complex with lysophosphatidylcholine
7YM0	;	2.91	;	Lysoplasmalogen-specific phospholipase D (LyPls-PLD) with Ca2+
6MTW	;	1.999	;	Lysosomal Phospholipase A2 in complex with Zinc
6RJE	;	2.5	;	Lysostaphin SH3b P4-G5 complex, homesource dataset
6RK4	;	1.43	;	Lysostaphin SH3b P4-G5 complex, synchrotron dataset
253L	;	2.0	;	LYSOZYME
254L	;	1.9	;	LYSOZYME
2CDS	;	2.0	;	LYSOZYME
2C8O	;	1.5	;	lysozyme (1sec) and UV lasr excited fluorescence
2C8P	;	1.5	;	lysozyme (60sec) and UV laser excited fluorescence
5B05	;	1.8	;	Lysozyme (control experiment)
5B07	;	1.8	;	Lysozyme (denatured by DCl and refolded)
5B06	;	1.8	;	Lysozyme (denatured by NaOD and refolded)
2IHL	;	1.4	;	LYSOZYME (E.C.3.2.1.17) (JAPANESE QUAIL)
1HSW	;	2.0	;	LYSOZYME (MUCOPEPTIDE N-ACETYLMURAMYL HYDROLASE)
7RGR	;	2.48	;	Lysozyme 056 from Deep neural language modeling
7DER	;	1.03	;	Lysozyme alone in H2O
8EZO	;	1.9	;	Lysozyme Anomalous Dataset at 220 K and 7.1 keV
8F0B	;	1.9	;	Lysozyme Anomalous Dataset at 240 K and 7.1 keV
8EZP	;	1.9	;	Lysozyme Anomalous Dataset at 260 K and 7.1 keV
8EZU	;	1.901	;	Lysozyme Anomalous Dataset at 273 K and 7.1 keV
8F00	;	1.2	;	Lysozyme Anomalous Dataset at 293 K and 12 keV
8EZX	;	1.9	;	Lysozyme Anomalous Dataset at 293 K and 7.1 keV
4D9Z	;	1.709	;	Lysozyme at 318K
6MX9	;	1.35	;	Lysozyme bound to 3-Aminophenol
8DCU	;	2.0	;	Lysozyme cluster 0028 (benzamidine ligand)
8DCV	;	2.0	;	Lysozyme cluster 0043, NAG ligand
8DCW	;	2.0	;	Lysozyme cluster 0062 (NAG and benzamidine ligands)
8DCT	;	2.0	;	Lysozyme cluster 3 dual apo structure
2PC2	;	1.538	;	Lysozyme Cocrystallized with Tris-dipicolinate Eu complex
1BB7	;	2.0	;	LYSOZYME COMPLEX WITH 4-METHYL-UMBELLIFERYL CHITOBIOSE
1BB6	;	2.0	;	LYSOZYME COMPLEX WITH 4-METHYL-UMBELLIFERYL CHITOTRIOSE
3ULR	;	1.65	;	Lysozyme contamination facilitates crystallization of a hetero-trimericCortactin:Arg:Lysozyme complex
8SCY	;	1.45	;	Lysozyme crystallized in cyclic olefin copolymer-based microfluidic chips
8SIL	;	1.7	;	Lysozyme crystallized in cyclic olefin copolymer-based microfluidic chips
6F9Y	;	1.2	;	Lysozyme crystallized in presence of 10 mM lithium sulphate at pH 4.5
6FA0	;	1.3	;	Lysozyme crystallized in presence of 100 mM ammonium sulphate at pH 4.5
6F9X	;	1.25	;	Lysozyme crystallized in presence of 100 mM lithium sulphate at pH 4.5
6F1L	;	1.3	;	Lysozyme crystallized in presence of 100 mM sodium phosphate at pH 4.5
6F1M	;	1.48	;	Lysozyme crystallized in presence of 100 mM sodium phosphate at pH 4.5: low-humidity form
6F9Z	;	1.2	;	Lysozyme crystallized in presence of 5 mM ammonium sulphate at pH 4.5
7BB1	;	1.3	;	Lysozyme crystallized in the presence of the hydrated deep eutectic solvent Choline chloride-Glutamic acid 2:1
7BAZ	;	1.3	;	Lysozyme crystallized in the presence of the hydrated deep eutectic solvent Choline chloride-Glycerol 1:2
7B9J	;	2.2	;	Lysozyme crystallized in the presence of the hydrated deep eutectic solvent Choline chloride-Urea 1:2
4RDS	;	1.23	;	Lysozyme crystallized with red food coloring dye
1AM7	;	2.3	;	Lysozyme from bacteriophage lambda
1JUG	;	1.9	;	LYSOZYME FROM ECHIDNA MILK (TACHYGLOSSUS ACULEATUS)
1HSX	;	1.9	;	LYSOZYME GROWN AT BASIC PH AND ITS LOW HUMIDITY VARIANT
7CQO	;	1.71	;	Lysozyme grown in LCP soaked with selenourea for 6 min
3SP3	;	1.801	;	Lysozyme in 20% sucrose
3RT5	;	1.75	;	Lysozyme in 30% propanol
8CL6	;	1.32	;	Lysozyme in matrix of hydroxyethylcellulose (HEC)
8CL5	;	1.31	;	Lysozyme in matrix of lipidic cubic phase of monoolein (LCP)
4EOF	;	1.83	;	Lysozyme in the presence of arginine
4WOA	;	1.8	;	Lysozyme Multiple Crystals After Surface Acoustic Wave Alignment
1LZ8	;	1.53	;	LYSOZYME PHASED ON ANOMALOUS SIGNAL OF SULFURS AND CHLORINES
4WO9	;	1.99	;	Lysozyme Post-Surface Acoustic Waves
4WO6	;	2.001	;	Lysozyme Pre-surface acoustic wave
6LT5	;	1.32	;	Lysozyme protected by alginate gel
7WXS	;	1.25	;	Lysozyme protected by polyacrylamide gel
5NJM	;	1.5	;	Lysozyme room-temperature structure determined by serial millisecond crystallography
7CDU	;	1.8	;	Lysozyme room-temperature structure determined by SS-ROX combined with HAG method, 1700 kGy (3000 images)
7CDO	;	1.8	;	Lysozyme room-temperature structure determined by SS-ROX combined with HAG method, 21 kGy (3000 images)
7CDR	;	1.8	;	Lysozyme room-temperature structure determined by SS-ROX combined with HAG method, 210 kGy (3000 images)
7CDP	;	1.8	;	Lysozyme room-temperature structure determined by SS-ROX combined with HAG method, 42 kGy (3000 images)
7CDK	;	1.7	;	Lysozyme room-temperature structure determined by SS-ROX combined with HAG method, 42 kGy (4500 images from 1st half of data set)
7CDM	;	1.7	;	Lysozyme room-temperature structure determined by SS-ROX combined with HAG method, 42 kGy (4500 images from 2nd half of data set)
7CDN	;	1.7	;	Lysozyme room-temperature structure determined by SS-ROX combined with HAG method, 42 kGy (9000 images)
7CDS	;	1.8	;	Lysozyme room-temperature structure determined by SS-ROX combined with HAG method, 420 kGy (3000 images)
7CDQ	;	1.8	;	Lysozyme room-temperature structure determined by SS-ROX combined with HAG method, 83 kGy (3000 images)
7CDT	;	1.8	;	Lysozyme room-temperature structure determined by SS-ROX combined with HAG method, 830 kGy (3000 images)
4UWN	;	1.67	;	Lysozyme soaked with a ruthenium based CORM with a methione oxide ligand (complex 6b)
4UWU	;	1.78	;	Lysozyme soaked with a ruthenium based CORM with a pyridine ligand (complex 7)
4UWV	;	1.77	;	Lysozyme soaked with a ruthenium based CORM with a pyridine ligand (complex 8)
7Q0T	;	1.34	;	Lysozyme soaked with V(IV)OSO4
7Q0U	;	1.19	;	Lysozyme soaked with V(IV)OSO4 and bipy
7Q0V	;	1.12	;	Lysozyme soaked with V(IV)OSO4 and phen
6G8A	;	1.143	;	Lysozyme solved by Native SAD from a dataset collected in 5 seconds at 1 A wavelength with JUNGFRAU detector
8RPM	;	1.8	;	Lysozyme structure based on automated real-time serial crystallography data processing using CrystFEL
5TK0	;	1.795	;	Lysozyme structure collected with 3D printed polymer mounts
2AUB	;	1.7	;	Lysozyme structure derived from thin-film-based crystals
6GF0	;	2.07	;	Lysozyme structure determined from SFX data using a Sheet-on-Sheet chipless chip
7O2O	;	1.833	;	Lysozyme structure from microfluidic-based in situ data collection
7BYP	;	1.6	;	Lysozyme structure SASE1 from SASE mode
7D02	;	1.65	;	Lysozyme structure SASE2 from SASE mode
7D05	;	1.7	;	Lysozyme structure SASE3 from SASE mode
8P1C	;	1.58	;	Lysozyme structure solved from serial crystallography data collected at 1 kHz with JUNGFRAU detector at MAXIV
8P1D	;	1.6	;	Lysozyme structure solved from serial crystallography data collected at 100 Hz with JUNGFRAU detector at MAXIV
8P1A	;	2.05	;	Lysozyme structure solved from serial crystallography data collected at 2 kHz for 5 seconds with JUNGFRAU detector at MAXIV
8P1B	;	1.7	;	Lysozyme structure solved from serial crystallography data collected at 2 kHz with JUNGFRAU detector at MAXIV
7BYO	;	1.6	;	Lysozyme structure SS1 from SS mode
7D01	;	1.65	;	Lysozyme structure SS2 from SS mode
7D04	;	1.7	;	Lysozyme structure SS3 from SS mode
8F28	;	1.2	;	Lysozyme Structures from Single-Entity Crystallization Method NanoAC
4DC4	;	2.654	;	Lysozyme Trimer
4NWE	;	1.58	;	Lysozyme UNDER 30 BAR PRESSURE OF NITROUS OXIDE
4NWH	;	1.65	;	Lysozyme UNDER 30 BAR PRESSURE OF XENON
4HSF	;	1.82	;	Lysozyme with Arginine at 318K
4II8	;	1.88	;	Lysozyme with Benzyl alcohol
5K2N	;	1.4	;	lysozyme with nano particles
5K2Q	;	1.1	;	Lysozyme with nano particles
5K2S	;	1.55	;	Lysozyme with nano particles
8A9E	;	1.665	;	Lysozyme, 9-11 fs FEL pulses as determined by XTCAV
5LIN	;	1.496	;	Lysozyme, collected at rotation 1 degree per second
5LIO	;	1.496	;	Lysozyme, collected at rotation 360 degree per second
6MUZ	;	1.839	;	Lysozyme, room temperature structure solved by serial 3 degree oscillation crystallography
4ETB	;	1.908	;	lysozyme, room temperature, 200 kGy dose
4ETC	;	1.906	;	Lysozyme, room temperature, 24 kGy dose
4ETA	;	1.91	;	Lysozyme, room temperature, 400 kGy dose
4ETE	;	1.905	;	Lysozyme, room-temperature, rotating anode, 0.0021 MGy
4ETD	;	1.904	;	Lysozyme, room-temperature, rotating anode, 0.0026 MGy
2XJW	;	1.67	;	Lysozyme-CO releasing molecule adduct
7DEQ	;	1.03	;	Lysozyme-sugar complex in D2O
7BR5	;	1.0	;	Lysozyme-sugar complex in H2O
6H3B	;	1.9	;	Lysozyme: Machining protein microcrystals for structure determination by electron diffraction
7V5V	;	2.37	;	LysR family transcriptional regulator RipR from Salmonella Typhimurium
7XRO	;	2.8	;	LysR-family transcriptional regulator RipR effector binding domain with its effector, 3-phenylpropionic acid
3VPD	;	1.95	;	LysX from Thermus thermophilus complexed with AMP-PNP
6BKF	;	3.25	;	Lysyl-adenylate form of human LigIV catalytic domain with bound DNA substrate in open conformation
1BBW	;	2.7	;	LYSYL-TRNA SYNTHETASE (LYSS)
1BBU	;	2.7	;	LYSYL-TRNA SYNTHETASE (LYSS) COMPLEXED WITH LYSINE
1LYL	;	2.8	;	LYSYL-TRNA SYNTHETASE (LYSU) (E.C.6.1.1.6) COMPLEXED WITH LYSINE
1E24	;	2.35	;	LYSYL-TRNA SYNTHETASE (LYSU) HEXAGONAL FORM complexed with lysine and ATP and MN2+
1E22	;	2.43	;	LYSYL-TRNA SYNTHETASE (LYSU) HEXAGONAL FORM complexed with lysine and the non-hydrolysable atp analogue amp-pcp
1E1T	;	2.4	;	LYSYL-TRNA SYNTHETASE (LYSU) HEXAGONAL FORM COMPLEXED WITH THE LYSYL_ADENYLATE INTERMEDIATE
1E1O	;	2.12	;	lysyl-tRNA Synthetase (LYSU) hexagonal form, complexed with lysine
3A74	;	1.8	;	Lysyl-tRNA synthetase from Bacillus stearothermophilus complexed with Diadenosine Tetraphosphate (AP4A)
3E9I	;	2.2	;	Lysyl-tRNA synthetase from Bacillus stearothermophilus complexed with L-Lysine hydroxamate-AMP
3E9H	;	2.1	;	Lysyl-tRNA synthetase from Bacillus stearothermophilus complexed with L-Lysylsulfamoyl adenosine
4QI8	;	1.1	;	Lytic polysaccharide monooxygenase 9F from Neurospora crassa, NcLPMO9F
5MSZ	;	1.1	;	Lytic Polysaccharide Monooxygenase AA15 from Thermobia domestica in the Cu(I) State
5O1J	;	1.9	;	Lytic transglycosylase in action
5O24	;	1.429	;	Lytic transglycosylase in action
5O29	;	1.3785	;	Lytic transglycosylase in action
5O2N	;	1.513	;	Lytic transglycosylase in action
5O2O	;	1.43	;	Lytic transglycosylase in action
6FPN	;	1.44	;	Lytic transglycosylase in action
6QK4	;	1.73	;	Lytic transglycosylase, LtgG, of Burkholderia pseudomallei.
7QRL	;	2.25	;	LytM domain of DipM, a coordinator of a complex net of autolysins in Caulobacter crescentus
4BH5	;	1.57	;	LytM domain of EnvC, an activator of cell wall amidases in Escherichia coli
4DE8	;	1.95	;	LytR-Cps2a-Psr family protein with bound octaprenyl monophosphate lipid
3TFL	;	2.05	;	LytR-Cps2a-Psr family protein with bound octaprenyl pyrophosphate lipid
3TEP	;	2.03	;	LytR-CPS2a-Psr family protein with bound octaprenyl pyrophosphate lipid and magnesium ion
3TEL	;	1.8	;	LytR-CPS2A-Psr family protein with bound octaprenyl pyrophosphate lipid and manganese ion
4DE9	;	1.787	;	LytR-CPS2A-psr family protein YwtF (TagT) with bound octaprenyl pyrophosphate lipid
5V8C	;	2.51	;	LytR-Csp2A-Psr enzyme from Actinomyces oris
3D6W	;	2.4	;	LytTr DNA-binding domain of putative methyl-accepting/DNA response regulator from Bacillus cereus.
2F95	;	2.2	;	M intermediate structure of sensory rhodopsin II/transducer complex in combination with the ground state structure
1CWQ	;	2.25	;	M INTERMEDIATE STRUCTURE OF THE WILD TYPE BACTERIORHODOPSIN IN COMBINATION WITH THE GROUND STATE STRUCTURE
6HF3	;	2.2	;	M tuberculosis DprE1 in complex with a covalently bound nitrobenzothiazinone
6HEZ	;	2.3	;	M tuberculosis DprE1 in complex with BTZ043
6GFV	;	1.96	;	M tuberculosis LpqI
6SAB	;		;	M-BUTX-Ptr1a (Parabuthus transvaalicus)
1A6S	;		;	M-DOMAIN FROM GAG POLYPROTEIN OF ROUS SARCOMA VIRUS, NMR, 20 STRUCTURES
2WNP	;	1.21	;	M-ficolin mutant Y271F
6SAA	;		;	M-TRTX-Preg1a (Poecilotheria regalis)
3K6V	;	1.69	;	M. acetivorans Molybdate-Binding Protein (ModA) in Citrate-Bound Open Form
3K6X	;	2.25	;	M. acetivorans Molybdate-Binding Protein (ModA) in Molybdate-Bound Close Form with 2 Molecules in Asymmetric Unit Forming Beta Barrel
3K6U	;	1.95	;	M. acetivorans Molybdate-Binding Protein (ModA) in Unliganded Open Form
3EEO	;	1.94	;	M. HhaI co-crystallized with synthetic dsDNA containing a propane diol in place of the deoxycytidine residue targeted for methylation.
2QJI	;	2.8	;	M. jannaschii ADH synthase complexed with dihydroxyacetone phosphate and glycerol
2QJG	;	2.6	;	M. jannaschii ADH synthase complexed with F1,6P
2QJH	;	2.6	;	M. jannaschii ADH synthase covalently bound to dihydroxyacetone phosphate
3PAF	;	1.7	;	M. jannaschii L7Ae mutant
3BBE	;	2.2	;	M. jannaschii Nep1
3BBD	;	2.15	;	M. jannaschii Nep1 complexed with S-adenosyl-homocysteine
3BBH	;	2.25	;	M. jannaschii Nep1 complexed with Sinefungin
1U12	;	2.7	;	M. loti cyclic nucleotide binding domain mutant
3CLP	;	2.0	;	M. loti cyclic-nucleotide binding domain mutant 2
4MUV	;	1.25	;	M. loti cyclic-nucleotide binding domain mutant displaying inverted ligand selectivity, cyclic-GMP bound
3CL1	;	2.4	;	M. loti cyclic-nucleotide binding domain, cyclic-GMP bound
3AQB	;	2.4	;	M. luteus B-P 26 heterodimeric hexaprenyl diphosphate synthase in complex with magnesium
3AQC	;	2.61	;	M. luteus B-P 26 heterodimeric hexaprenyl diphosphate synthase in complex with magnesium and FPP analogue
5JHJ	;		;	M. Oryzae effector AVR-Pia mutant H3
5ZRP	;	1.74	;	M. smegmatis antimutator protein MutT2 form 3
5ZRI	;	1.58	;	M. smegmatis antimutator protein MutT2 in complex with 5m-dCMP
5ZRO	;	1.41	;	M. smegmatis antimutator protein MutT2 in complex with 5mdCTP
5ZRL	;	1.61	;	M. smegmatis antimutator protein MutT2 in complex with CDP
5ZRH	;	1.54	;	M. smegmatis antimutator protein MutT2 in complex with CMP
5ZRG	;	1.3	;	M. smegmatis antimutator protein MutT2 in complex with dCMP
5ZRK	;	1.49	;	M. smegmatis antimutator protein MutT2 in complex with dCTP
1GX3	;	1.7	;	M. smegmatis arylamine N-acetyl transferase
5ZEP	;	3.4	;	M. smegmatis hibernating state 70S ribosome structure
5ZEU	;	3.7	;	M. smegmatis P/P state 30S ribosomal subunit
5ZET	;	3.2	;	M. smegmatis P/P state 50S ribosomal subunit
5ZEB	;	3.4	;	M. Smegmatis P/P state 70S ribosome structure
5ZEY	;	12.5	;	M. smegmatis Trans-translation state 70S ribosome
7MYG	;	2.51	;	M. tb Ag85C modified by THL-10d
7SCF	;	2.67	;	M. tb EgtD in complex with HD2
7SF5	;	2.52	;	M. tb EgtD in complex with HD3
7SEW	;	1.72	;	M. tb EgtD in complex with HD6
7SF4	;	2.39	;	M. tb EgtD in complex with imatinib
7SEY	;	2.39	;	M. tb EgtD in complex with SGH
7SEX	;	2.2	;	M. tb EgtD in complex with TGX221
6MJY	;	1.56	;	M. thermoresistible GuaB2 delta-CBS in complex with 6Cl-IMP
6D4Q	;	1.71	;	M. thermoresistible GuaB2 delta-CBS in complex with inhibitor Compound 14 (VCC900455)
6D4R	;	1.34	;	M. thermoresistible GuaB2 delta-CBS in complex with inhibitor Compound 18 (VCC399134)
6D4V	;	2.02	;	M. thermoresistible GuaB2 delta-CBS in complex with inhibitor Compound 22 (VCC061422)
6D4U	;	1.7	;	M. thermoresistible GuaB2 delta-CBS in complex with inhibitor Compound 27 (VCC663664)
6D4W	;	1.8	;	M. thermoresistible GuaB2 delta-CBS in complex with inhibitor Compound 35 (VCC620637)
6D4S	;	1.63	;	M. thermoresistible GuaB2 delta-CBS in complex with inhibitor Compound 37 (VCC670597)
6D4T	;	1.54	;	M. thermoresistible GuaB2 delta-CBS in complex with inhibitor Compound 45 (VCC117054)
5J5R	;	1.6	;	M. thermoresistible GuaB2 delta-CBS in complex with inhibitor VCC234718
5K4X	;	1.37	;	M. thermoresistible IMPDH in complex with IMP and Compound 1
5OU1	;	1.78	;	M. thermoresistible IMPDH in complex with IMP and Compound 1 (7759844)
5OU2	;	1.45	;	M. thermoresistible IMPDH in complex with IMP and Compound 2 (NMR744)
5OU3	;	1.6	;	M. thermoresistible IMPDH in complex with IMP and Compound 31 (AT080)
5K4Z	;	1.64	;	M. thermoresistible IMPDH in complex with IMP and Compound 6
4RCV	;	2.294	;	M. tuberculosis 1-deoxy-d-xylulose-5-phosphate reductoisomerase bound to 1-deoxy-L-erythrulose
4OOF	;	2.3	;	M. tuberculosis 1-deoxy-d-xylulose-5-phosphate reductoisomerase W203F mutant bound to fosmidomycin and NADPH
4OOE	;	1.826	;	M. tuberculosis 1-deoxy-d-xylulose-5-phosphate reductoisomerase W203Y mutant bound to fosmidomycin and NADPH
7UGW	;	3.0	;	M. tuberculosis DNA gyrase cleavage core bound to DNA and evybactin
6HF0	;	2.384	;	M. tuberculosis DprE1 covalently bound to a nitrobenzoxacinone.
4KW5	;	2.612	;	M. tuberculosis DprE1 in complex with inhibitor TCA1
1SM8	;	2.9	;	M. tuberculosis dUTPase complexed with chromium and dUTP
3PKA	;	1.25	;	M. tuberculosis MetAP with bengamide analog Y02, in Mn form
3PKC	;	1.47	;	M. tuberculosis MetAP with bengamide analog Y08, in Mn form
3PKD	;	1.47	;	M. tuberculosis MetAP with bengamide analog Y10, in Mn form
3PKE	;	1.6	;	M. tuberculosis MetAP with bengamide analog Y10, in Ni form
3PKB	;	1.25	;	M. tuberculosis MetAP with bengamide analog Y16, in Mn form
3IU7	;	1.4	;	M. tuberculosis methionine aminopeptidase with Mn inhibitor A02
3IU8	;	1.85	;	M. tuberculosis methionine aminopeptidase with Ni inhibitor T03
3IU9	;	1.75	;	M. tuberculosis methionine aminopeptidase with Ni inhibitor T07
7KAB	;	2.5	;	M. tuberculosis PheRS complex with cognate precursor tRNA and phenylalanine
7S0S	;	3.05	;	M. tuberculosis ribosomal RNA methyltransferase TlyA bound to M. smegmatis 50S ribosomal subunit
8EOT	;	3.3	;	M. tuberculosis RNAP elongation complex with NusG
8EOS	;	3.1	;	M. tuberculosis RNAP elongation complex with NusG and CMPCPP
8EJ3	;	3.13	;	M. tuberculosis RNAP pause escaped complex with Bacillus subtilis NusG and GMPCPP
8EXY	;	3.2	;	M. tuberculosis RNAP paused complex with B. subtilis NusG and GMPCPP
2W24	;	2.5	;	M. tuberculosis Rv3291c complexed to Lysine
8QC4	;	1.578	;	M. tuberculosis salicylate synthase MbtI in complex with 5-(3-carboxyphenyl)furan-2-carboxylic acid
6ZA4	;	2.092	;	M. tuberculosis salicylate synthase MbtI in complex with 5-(3-cyanophenyl)furan-2-carboxylate
6ZA6	;	1.804	;	M. tuberculosis salicylate synthase MbtI in complex with Ba2+
8QN5	;	1.544	;	M. tuberculosis salicylate synthase MbtI in complex with methyl-AMT (new crystal form)
6ZA5	;	2.109	;	M. tuberculosis salicylate synthase MbtI in complex with salicylate and Mg2+
5OAY	;		;	M. tuberculosis [4Fe-4S] protein WhiB1 is a four-helix bundle that forms a NO-sensitive complex with sigmaA and regulates the major virulence factor ESX-1
7S2T	;	3.45	;	M. xanthus encapsulin EncA bound to EncB targeting peptide
7S4Q	;	3.12	;	M. xanthus encapsulin EncA bound to EncC targeting peptide
7S21	;	3.4	;	M. xanthus encapsulin shell protein EncA with T=1 symmetry
7S20	;	3.4	;	M. xanthus encapsulin shell protein EncA with T=3 symmetry
7S5C	;	1.86	;	M. xanthus ferritin-like protein EncB
7S5K	;	1.95	;	M. xanthus ferritin-like protein EncB
7S8T	;	2.49	;	M. xanthus ferritin-like protein EncC
3ZOM	;	2.2	;	M.acetivorans protoglobin F145W mutant
3ZOL	;	1.6	;	M.acetivorans protoglobin F93Y mutant in complex with cyanide
3ZJO	;	1.8	;	M.acetivorans protoglobin in complex with azide
3ZJS	;	2.3	;	M.acetivorans protoglobin in complex with azide and Xenon
3ZJN	;	1.6	;	M.acetivorans protoglobin in complex with cyanide
3ZJR	;	3.0	;	M.acetivorans protoglobin in complex with cyanide and Xenon
3ZJP	;	1.38	;	M.acetivorans protoglobin in complex with imidazole
3ZJQ	;	1.9	;	M.acetivorans protoglobin in complex with nicotinamide
1VP6	;	1.7	;	M.loti ion channel cylic nucleotide binding domain
5KWI	;	1.3	;	M.tb Ag85C modified at C209 by adamantyl-ebselen
5KWJ	;	2.01	;	M.tb Ag85C modified at C209 by amino-ebselen
5VNS	;	1.45	;	M.tb Antigen 85C Acyl-Enzyme Intermediate with Tetrahydrolipstatin
6O0G	;	2.4	;	M.tb MenD bound to Intermediate I and Inhibitor
6O04	;	2.5	;	M.tb MenD IntII bound with Inhibitor
6O0N	;	3.03	;	M.tb MenD with Inhibitor
6O0J	;	2.35	;	M.tb MenD with ThDP and Inhibitor bound
1BVR	;	2.8	;	M.TB. ENOYL-ACP REDUCTASE (INHA) IN COMPLEX WITH NAD+ AND C16-FATTY-ACYL-SUBSTRATE
4X6T	;	1.4	;	M.tuberculosis betalactamase complexed with inhibitor EC19
6R3Y	;	1.6	;	M.tuberculosis nitrobindin with a cyanide molecule coordinated to the heme iron atom
6R3W	;	1.2	;	M.tuberculosis nitrobindin with a water molecule coordinated to the heme iron atom
2BK8	;	1.69	;	M1 domain from titin
7WWY	;	1.5	;	M117L variant of Cu/Zn-superoxide dismutase from dog (Canis familiaris)
6VU2	;	2.19	;	M1214_N1 Fab structure
7TNC	;	1.47	;	M13F/G116F Pseudomonas aeruginosa azurin
2BP0	;	1.9	;	M144L mutant of nitrite reductase from Alcaligenes xylosoxidans
2JFC	;	2.4	;	M144L mutant of Nitrite Reductase from Alcaligenes xylosoxidans in space group P212121
2BP8	;	1.9	;	M144Q Structure of nitrite reductase from Alcaligenes xylosoxidans
3B0J	;	1.7	;	M175E mutant of assimilatory nitrite reductase (Nii3) from tobbaco leaf
3B0L	;	1.7	;	M175G mutant of assimilatory nitrite reductase (Nii3) from tobbaco leaf
3B0M	;	1.9	;	M175K mutant of assimilatory nitrite reductase (Nii3) from tobbaco leaf
5C1I	;	3.1	;	m1A58 tRNA methyltransferase mutant - D170A
5C0O	;	2.62	;	m1A58 tRNA methyltransferase mutant - Y78A
3HR5	;	2.4	;	M1prime peptide from IgE bound by humanized antibody 47H4 Fab
6KGJ	;	1.8	;	M1Q-hNTAQ1 C28S
5NYU	;		;	M2 G-quadruplex 10 wt% PEG8000
5NYT	;		;	M2 G-quadruplex 20 wt% ethylene glycol
5NYS	;		;	M2 G-quadruplex dilute solution
6Z2U	;	2.4	;	M2 mutant (R111K:Y134F:T54V:R132Q:P39Y:R59Y) of human cellular retinoic acid binding protein II
6Z2Z	;	2.55	;	M2 mutant (R111K:Y134F:T54V:R132Q:P39Y:R59Y) of human cellular retinoic acid binding protein II - 2a conjugate
6ZSX	;	2.4	;	M2 mutant (R111K:Y134F:T54V:R132Q:P39Y:R59Y) of human cellular retinoic acid binding protein II - 4 conjugate
6ZSW	;	2.08	;	M2 mutant (R111K:Y134F:T54V:R132Q:P39Y:R59Y) of human cellular retinoic acid binding protein II - 6 conjugate
1DXZ	;		;	M2 TRANSMEMBRANE SEGMENT OF ALPHA-SUBUNIT OF NICOTINIC ACETYLCHOLINE RECEPTOR FROM TORPEDO CALIFORNICA, NMR, 20 STRUCTURES
7T9N	;	2.9	;	M22 Agonist Autoantibody bound to Human Thyrotropin receptor in complex with miniGs399 (composite structure)
3FQ8	;	2.0	;	M248I mutant of GSAM
8QMM	;	1.2	;	M291I variant of the [FeFe]-hydrogenase maturase HydE from Thermotoga maritima
3KLV	;	2.6	;	M296I G62S mutant of foot-and-mouth disease virus RNA-polymerase in complex with a template- primer RNA
3KNA	;	2.8	;	M296I mutant of foot-and-mouth disease virus RNA-polymerase in complex with a template- primer RNA
3KOA	;	2.4	;	M296I mutant of foot-and-mouth disease virus RNA-polymerase in complex with a template- primer RNA and GTP
5ZHP	;	3.1	;	M3 muscarinic acetylcholine receptor in complex with a selective antagonist
3MRA	;		;	M3 TRANSMEMBRANE SEGMENT OF ALPHA-SUBUNIT OF NICOTINIC ACETYLCHOLINE RECEPTOR FROM TORPEDO CALIFORNICA, NMR, 15 STRUCTURES
4U16	;	3.7	;	M3-mT4L receptor bound to NMS
4U15	;	2.8	;	M3-mT4L receptor bound to tiotropium
4Y2C	;	2.2	;	M300V 3D polymerase mutant of EMCV
4N8I	;	2.011	;	M31G mutant, RipA structure
1XMD	;	2.1	;	M335V mutant structure of mouse carnitine octanoyltransferase
7TDL	;	1.6	;	M379A mutant tyrosine phenol-lyase complexed with 3-bromo-DL-phenylalanine
7TCS	;	1.37	;	M379A mutant tyrosine phenol-lyase complexed with L-methionine
2GRH	;	1.5	;	M37V mutant of Scapharca dimeric hemoglobin, with CO bound
7JKA	;	1.53	;	m3DLH
7ECC	;	2.0	;	M4 family peptidase PlM4P-mature form
5K0Y	;	5.8	;	m48S late-stage initiation complex, purified from rabbit reticulocytes lysates, displaying eIF2 ternary complex and eIF3 i and g subunits relocated to the intersubunit face
1EEU	;	1.6	;	M4L/Y(27D)D/Q89D/T94H mutant of LEN
1EEQ	;	1.5	;	M4L/Y(27D)D/T94H Mutant of LEN
6AH6	;	2.5	;	M500V mutant of Coronin coiled coil domain
2X51	;	2.2	;	M6 delta Insert1
1OV6	;	2.4	;	M64V PNP + ALLO
1OVG	;	2.2	;	M64V PNP +MePdr
1OUM	;	2.4	;	M64V PNP +Talo
4KMM	;	2.6	;	M76H variant of human ferrochelatase
5H3T	;	2.571	;	m7G cap bound to GEMIN5-WD
7O4Y	;	1.6	;	m971 Fab in complex with anti-Kappa VHH domain
1RGQ	;	2.9	;	M9A HCV Protease complex with pentapeptide keto-amide inhibitor
7T7F	;	2.3	;	MA-1-206-OXA-23 25 minute complex
7T7E	;	2.4	;	MA-1-206-OXA-23 3 minute complex
7T7D	;	2.65	;	MA-1-206-OXA-23 30s complex
7TR4	;	2.3	;	MA2-MART1-HLAA0201
1DBN	;	2.75	;	MAACKIA AMURENSIS LEUKOAGGLUTININ (LECTIN) WITH SIALYLLACTOSE
1UZL	;	2.0	;	MabA from Mycobacterium tuberculosis
1UZM	;	1.49	;	MabA from Mycobacterium tuberculosis
1UZN	;	1.91	;	MabA from Mycobacterium tuberculosis
1BHQ	;	2.7	;	MAC-1 I DOMAIN CADMIUM COMPLEX
1BHO	;	2.7	;	MAC-1 I DOMAIN MAGNESIUM COMPLEX
1IDN	;	2.7	;	MAC-1 I DOMAIN METAL FREE
4AAN	;	1.22	;	MacA wild-type fully reduced
4AAM	;	2.17	;	MacA wild-type mixed-valence
4AAL	;	1.84	;	MacA wild-type oxidized
4AAO	;	2.3	;	MacA-H93G
7XXU	;	1.8	;	Macaca fascicularis galectin-10/Charcot-Leyden crystal protein
7XXW	;	1.63	;	Macaca fascicularis galectin-10/Charcot-Leyden crystal protein with glycerol
7XXV	;	1.6	;	Macaca fascicularis galectin-10/Charcot-Leyden crystal protein with lactose
7XXX	;	1.94	;	Macaca mulatta galectin-10/Charcot-Leyden crystal protein
7XXZ	;	1.83	;	Macaca mulatta galectin-10/Charcot-Leyden crystal protein with glycerol
7XXY	;	1.92	;	Macaca mulatta galectin-10/Charcot-Leyden crystal protein with lactose
5EHQ	;	2.5	;	mAChE-anti TZ2PA5 complex
5EIA	;	2.7	;	mACHE-anti TZ2PA5 complex from a 1:6 mixture of the syn/anti isomers
5EHN	;	2.6	;	mAChE-syn TZ2PA5 complex
5EHZ	;	2.5	;	mAChE-syn TZ2PA5 complex from an equimolar mixture of the syn/anti isomers
5EIE	;	2.1	;	mAChE-TZ2 complex
5EIH	;	2.7	;	mAChE-TZ2/PA5 complex
3KAS	;	2.4	;	Machupo virus GP1 bound to human transferrin receptor 1
7QU1	;	1.91	;	Machupo virus GP1 glycoprotein in complex with Fab fragment of antibody MAC1
7C33	;	3.83	;	Macro domain of SARS-CoV-2 in complex with ADP-ribose
2BFQ	;	1.5	;	MACRO DOMAINS ARE ADP-RIBOSE BINDING MOLECULES
7ZB0	;	2.47	;	macrocyclase OphP with 15mer
7ZAZ	;	2.0	;	macrocyclase OphP with ZPP
3R91	;	1.579	;	Macrocyclic lactams as potent Hsp90 inhibitors with excellent tumor exposure and extended biomarker activity.
6CG3	;	2.03	;	Macrocyclic peptide derived from Abeta(17-36) - (ORN)LV(PHI)FAED(ORN)AII(2-nitrobenzylglycine)L(ORN)V
6WNK	;	2.28	;	Macrocyclic peptides TDI5575 that selectively inhibit the Mycobacterium tuberculosis proteasome
7THS	;	1.8	;	Macrocyclic plasmin inhibitor
7UAH	;	1.57	;	Macrocyclic plasmin inhibitor
8F7U	;	1.47	;	Macrocyclic Plasmin Inhibitor
8F7V	;	1.65	;	Macrocyclic plasmin inhibitor
4COE	;	2.45	;	Macrocyclic Transition-State Mimicking HIV-1 Protease Inhibitors Encompassing a Tertiary Alcohol
4CP7	;	1.8	;	Macrocyclic Transition-State Mimicking HIV-1 Protease Inhibitors Encompassing a Tertiary Alcohol
4CPQ	;	2.35	;	Macrocyclic Transition-State Mimicking HIV-1 Protease Inhibitors Encompassing a Tertiary Alcohol
4CPR	;	1.8	;	Macrocyclic Transition-State Mimicking HIV-1 Protease Inhibitors Encompassing a Tertiary Alcohol
4CPS	;	1.55	;	Macrocyclic Transition-State Mimicking HIV-1 Protease Inhibitors Encompassing a Tertiary Alcohol
4CPT	;	1.7	;	Macrocyclic Transition-State Mimicking HIV-1 Protease Inhibitors Encompassing a Tertiary Alcohol
4CPU	;	1.82	;	Macrocyclic Transition-State Mimicking HIV-1 Protease Inhibitors Encompassing a Tertiary Alcohol
4CPW	;	1.7	;	Macrocyclic Transition-State Mimicking HIV-1 Protease Inhibitors Encompassing a Tertiary Alcohol
4CPX	;	1.85	;	Macrocyclic Transition-State Mimicking HIV-1 Protease Inhibitors Encompassing a Tertiary Alcohol
6KZU	;	1.79	;	Macrocyclization of an all-D linear peptide improves target affinity and imparts cellular activity: A novel stapled alpha-helical peptide modality
3H6Q	;	1.643	;	Macrocypin, a beta-trefoil cysteine protease inhibitor
5M3I	;	2.17	;	Macrodomain of Mycobacterium tuberculosis DarG
5M31	;	1.67	;	Macrodomain of Thermus aquaticus DarG
5M3E	;	2.5	;	Macrodomain of Thermus aquaticus DarG in complex with ADP-ribose
2XX2	;	1.85	;	Macrolactone Inhibitor bound to HSP90 N-term
2XX4	;	2.199	;	Macrolactone Inhibitor bound to HSP90 N-term
2XX5	;	2.0	;	Macrolactone Inhibitor bound to HSP90 N-term
4ION	;	1.6	;	Macrolepiota procera ricin B-like lectin (MPL)
4J2S	;	1.4	;	Macrolepiota procera ricin B-like lectin (MPL) in complex with Di-LacNAc
4IYB	;	1.59	;	Macrolepiota procera ricin B-like lectin (MPL) in complex with galactose
4IZX	;	1.1	;	Macrolepiota procera ricin B-like lectin (MPL) in complex with lactose
5IGH	;	1.55	;	Macrolide 2'-phosphotransferase type I
5IGP	;	1.6	;	Macrolide 2'-phosphotransferase type I - complex with GDP and erythromycin
5IGR	;	1.6	;	Macrolide 2'-phosphotransferase type I - complex with GDP and oleandomycin
5IGI	;	1.2	;	Macrolide 2'-phosphotransferase type I - complex with guanosine and azithromycin
5IGJ	;	1.4	;	Macrolide 2'-phosphotransferase type I - complex with guanosine and clarithromycin
5IGT	;	1.39	;	Macrolide 2'-phosphotransferase type I - complex with guanosine and erythromycin
5IGS	;	1.38	;	Macrolide 2'-phosphotransferase type I - complex with guanosine and oleandomycin
5IGU	;	2.1	;	Macrolide 2'-phosphotransferase type II
5IGV	;	1.55	;	Macrolide 2'-phosphotransferase type II - complex with GDP and azithromycin
5IGW	;	2.096	;	Macrolide 2'-phosphotransferase type II - complex with GDP and clarithromycin
5IGY	;	1.45	;	Macrolide 2'-phosphotransferase type II - complex with GDP and erythromycin
5IH1	;	1.31	;	Macrolide 2'-phosphotransferase type II - complex with GDP and phosphorylated josamycin
5IGZ	;	1.6	;	Macrolide 2'-phosphotransferase type II - complex with GDP and spiramycin
5IWU	;	1.3	;	Macrolide 2'-phosphotransferase type II complexed with erythromycin
5IH0	;	1.65	;	Macrolide 2'-phosphotransferase type II Y92M mutant - complex with GDP and erythromycin
5E79	;	3.5	;	Macromolecular diffractive imaging using imperfect crystals
5E7C	;	4.5	;	Macromolecular diffractive imaging using imperfect crystals - Bragg data
1HDS	;	1.98	;	MACROMOLECULAR STRUCTURE REFINEMENT BY RESTRAINED LEAST-SQUARES AND INTERACTIVE GRAPHICS AS APPLIED TO SICKLING DEER TYPE III HEMOGLOBIN
2MCM	;	1.5	;	MACROMOMYCIN
8CA0	;		;	Macrophage inhibitory factor (MIF) in complex with small molecule PAV174
1FIM	;	2.2	;	MACROPHAGE MIGRATION INHIBITORY FACTOR
1MIF	;	2.6	;	MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)
3DJH	;	1.25	;	Macrophage Migration Inhibitory Factor (MIF) at 1.25 A Resolution
3IJG	;	1.7	;	Macrophage Migration Inhibitory Factor (MIF) Bound to the (R)-Stereoisomer of AV1013
3B9S	;	1.8	;	Macrophage Migration Inhibitory Factor (MIF) complexed with Inhibitor, 4-IPP.
1GCZ	;	1.9	;	MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) COMPLEXED WITH INHIBITOR.
2OOZ	;	1.8	;	Macrophage Migration Inhibitory Factor (MIF) Complexed with OXIM6 (an OXIM Derivative Not Containing a Ring in its R-group)
3B64	;	1.03	;	Macrophage Migration Inhibitory Factor (MIF) From /Leishmania Major
1CGQ	;	2.0	;	MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) WITH ALANINE INSERTED BETWEEN PRO-1 AND MET-2
6FVE	;	1.41	;	Macrophage Migration Inhibitory Factor (MIF) with Covalently Bound FITC
3SMC	;	1.8	;	Macrophage Migration Inhibitory Factor (MIF) with Covalently Bound L-sulforaphane
6FVH	;	1.4	;	Macrophage Migration Inhibitory Factor (MIF) with Covalently Bound PITC
1CA7	;	2.5	;	MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) WITH HYDROXPHENYLPYRUVATE
1P1G	;	2.5	;	MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) WITH PRO-1 MUTATED TO GLY-1
5J7P	;	1.85	;	Macrophage Migration Inhibitory Factor bound to Covalent Inhibitor RDR03785
5J7Q	;	2.05	;	Macrophage Migration Inhibitory Factor bound to Inhibitor K664 Derivative
4F2K	;	1.53	;	Macrophage Migration Inhibitory Factor covalently complexed with phenethylisothiocyanate
2OS5	;	1.6	;	Macrophage migration inhibitory factor from Ancylostoma ceylanicum
4WR8	;	2.6	;	Macrophage Migration Inhibitory Factor in complex with a biaryltriazole inhibitor (3b-180)
4WRB	;	1.81	;	Macrophage Migration Inhibitory Factor in complex with a biaryltriazole inhibitor (3b-190)
6B1K	;	1.17	;	Macrophage Migration Inhibitory Factor in Complex with a Naphthyridinone Inhibitor (3a)
6B1C	;	2.163	;	Macrophage Migration Inhibitory Factor in complex with a Naphthyridinone Inhibitor (4a)
6B2C	;	2.0	;	Macrophage Migration Inhibitory Factor in Complex with a Naphthyridinone Inhibitor (4b)
6CBG	;	2.0	;	Macrophage Migration Inhibitory Factor in Complex with a Pyrazole Inhibitor (5)
6CBF	;	2.3	;	Macrophage Migration Inhibitory Factor in Complex with a Pyrazole Inhibitor (6a)
6CB5	;	1.78	;	Macrophage Migration Inhibitory Factor in complex with a Pyrazole Inhibitor (8g)
6CBH	;	2.0	;	Macrophage Migration Inhibitory Factor in Complex with a Pyrazole Inhibitor (8m)
4DH4	;	1.82	;	Macrophage migration inhibitory factor Toxoplasma gondii
1MFF	;	2.0	;	MACROPHAGE MIGRATION INHIBITORY FACTOR Y95F MUTANT
5W1M	;	3.91	;	MACV GP1 CR1-07 Fab complex
1F6Y	;	2.2	;	MAD CRYSTAL STRUCTURE ANALYSIS OF METHYLTETRAHYDROFOLATE: CORRINOID/IRON-SULFUR PROTEIN METHYLTRANSFERASE (METR)
242D	;	1.65	;	MAD PHASING STRATEGIES EXPLORED WITH A BROMINATED OLIGONUCLEOTIDE CRYSTAL AT 1.65 A RESOLUTION.
1E3U	;	1.66	;	MAD structure of OXA10 class D beta-lactamase
1OAP	;	1.93	;	Mad structure of the periplasmique domain of the Escherichia coli PAL protein
4BOH	;	2.595	;	Madanins (MEROPS I53) are cleaved by thrombin and factor Xa
7PZE	;	2.6	;	MademoiseLLE domain 2 of Rrm4 from Ustilago maydis
6ZNG	;	2.72	;	MaeB full-length acetyl-CoA bound state
6ZNJ	;	3.7	;	MaeB full-length enzyme apoprotein form
6ZN4	;	1.679	;	MaeB malic enzyme domain apoprotein
6ZN7	;	1.67	;	MaeB malic enzyme domain apoprotein
6ZN9	;	2.72	;	MaeB PTA domain apoprotein
6ZNU	;	2.33	;	MaeB PTA domain E544R mutant
6ZNK	;	3.039	;	MaeB PTA domain N718D mutant
6ZNR	;	2.217	;	MaeB PTA domain R535A mutant
6ZNE	;	2.393	;	MaeB PTA domain R535E mutant
6ZNT	;	1.96	;	MaeB PTA domain, acetyl-CoA bound form
7UPN	;	3.5	;	Maedi visna virus Vif in complex with CypA and E3 ubiquitin ligase
5LLJ	;	1.78	;	Maedi-Visna virus (MVV) integrase C-terminal domain (residues 220-276)
5T3A	;	2.501	;	Maedi-Visna virus (MVV) integrase CCD-CTD (residues 60-275)
5AF0	;	2.401	;	MAEL domain from Bombyx mori Maelstrom
5LWL	;	3.1	;	MaeR D54A mutant response regulator bound to sulfate
5LWK	;	2.11	;	MaeR response regulator bound to beryllium trifluoride
7Q4Q	;	1.65	;	Magacizumab Fab fragment in complex with human LRG1 epitope
2LSA	;		;	Magainin
3MDS	;	1.8	;	MAGANESE SUPEROXIDE DISMUTASE FROM THERMUS THERMOPHILUS
5BRZ	;	2.62	;	MAGE-A3 reactive TCR in complex with MAGE-A3 in HLA-A1
5BS0	;	2.4	;	MAGE-A3 Reactive TCR in complex with Titin Epitope in HLA-A1
7UOA	;	3.5	;	MAGEA4-MTP1 linear peptide complex
5N7F	;	2.3	;	MAGI-1 complexed with a pRSK1 peptide
5N7D	;	2.3	;	MAGI-1 complexed with a RSK1 peptide
5N7G	;	2.95	;	MAGI-1 complexed with a synthetic pRSK1 peptide
2KPK	;		;	MAGI-1 PDZ1
2KPL	;		;	MAGI-1 PDZ1 / E6CT
6TWQ	;	2.65	;	MAGI1_2 complexed with a 16E6 peptide
6TWU	;	2.4	;	MAGI1_2 complexed with a phosphomimetic 16E6 peptide
6TWY	;	2.3	;	MAGI1_2 complexed with a phosphomimetic RSK1 peptide
6TWX	;	2.3	;	MAGI1_2 complexed with a phosphorylated 16E6 peptide
7M0G	;		;	Magic Angle Spinning NMR Structure of Human Cofilin-2 Assembled on Actin Filaments
7U8K	;		;	Magic Angle Spinning NMR Structure of Human Cofilin-2 Assembled on Actin Filaments
7QI2	;		;	Magic-angle spinning NMR structure of the human voltage-dependent anion channel 1 (E73V/C127A/C232S) in DMPC lipid bilayers
7RIK	;		;	Magic-Angle-Spinning NMR Structure of Kinesin-1 Motor Domain Assembled with Microtubules
2KAD	;		;	Magic-Angle-Spinning Solid-State NMR Structure of Influenza A M2 Transmembrane Domain
3Q46	;	0.99	;	Magnesium activated Inorganic pyrophosphatase from Thermococcus thioreducens bound to hydrolyzed product at 0.99 Angstrom resolution
1CHN	;	1.76	;	MAGNESIUM BINDING TO THE BACTERIAL CHEMOTAXIS PROTEIN CHEY RESULTS IN LARGE CONFORMATIONAL CHANGES INVOLVING ITS FUNCTIONAL SURFACE
5XT8	;	2.01	;	Magnesium bound apo structure of thymidylate kinase (form I) from Thermus thermophilus HB8
6YTJ	;	2.79	;	Magnesium chelatase H subunit (ChlH) E625K variant from Synechocystis sp.PCC6803
6YT0	;	2.85	;	Magnesium chelatase H subunit (ChlH) E660D variant from Synechocystis sp.PCC6803
6YTN	;	2.7	;	Magnesium chelatase H subunit (ChlH) E660W variant from Synechocystis sp.PCC6803
6YSG	;	2.54	;	Magnesium chelatase H subunit (ChlH) from Synechocystis sp.PCC6803 to 2.54 A resolution
1U7O	;	1.9	;	Magnesium Dependent Phosphatase 1 (MDP-1)
6LB9	;	2.227	;	Magnesium ion-bound SspB crystal structure
5C2L	;	2.009	;	Magnesium soaked into the active site of Mycobacterium tuberculosis anthranilate phosphoribosyltransferase (AnPRT; trpD)
1QSH	;	1.7	;	MAGNESIUM(II)-AND ZINC(II)-PROTOPORPHYRIN IX'S STABILIZE THE LOWEST OXYGEN AFFINITY STATE OF HUMAN HEMOGLOBIN EVEN MORE STRONGLY THAN DEOXYHEME
1QSI	;	1.7	;	MAGNESIUM(II)-AND ZINC(II)-PROTOPORPHYRIN IX'S STABILIZE THE LOWEST OXYGEN AFFINITY STATE OF HUMAN HEMOGLOBIN EVEN MORE STRONGLY THAN DEOXYHEME
3EJA	;	1.902	;	Magnesium-bound glycoside hydrolase 61 isoform E from Thielavia terrestris
1UUN	;	2.5	;	Main porin from Mycobacterium smegmatis (MspA)
3D23	;	2.5	;	Main protease of HCoV-HKU1
3DQ0	;	1.9	;	Maize cytokinin oxidase/dehydrogenase complexed with N6-(3-methoxy-phenyl)adenine
3S1C	;	2.09	;	Maize cytokinin oxidase/dehydrogenase complexed with N6-isopentenyladenosine
3BW7	;	1.95	;	Maize cytokinin oxidase/dehydrogenase complexed with the allenic cytokinin analog HA-1
3C0P	;	1.95	;	Maize cytokinin oxidase/dehydrogenase complexed with the allenic cytokinin analog HA-8
3B2F	;	1.7	;	Maize Ferredoxin 1
1MZL	;	1.9	;	MAIZE NONSPECIFIC LIPID TRANSFER PROTEIN
1MZM	;	1.78	;	MAIZE NONSPECIFIC LIPID TRANSFER PROTEIN COMPLEXED WITH PALMITATE
7MIA	;	1.9	;	Maize rayado fino virus protease
7MIC	;	2.09	;	Maize rayado fino virus protease in complex with Ubiquitin
1ITZ	;	2.3	;	Maize Transketolase in complex with TPP
8CI0	;	1.902	;	Maize Transketolase in complex with TPP and hydrolyzed (+)-Cornexistin
1GGB	;	2.8	;	MAJOR ANTIGEN-INDUCED DOMAIN REARRANGEMENTS IN AN ANTIBODY
1GGC	;	2.8	;	MAJOR ANTIGEN-INDUCED DOMAIN REARRANGEMENTS IN AN ANTIBODY
6R5H	;	1.75	;	Major aspartyl peptidase 1 from C. neoformans
6R6A	;	1.8	;	Major aspartyl peptidase 1 from C. neoformans
6R61	;	1.81	;	Major aspartyl peptidase 1 from C. neoformans in complex with Inhibitor LP258
4K7H	;	3.5964	;	Major capsid protein P1 of the Pseudomonas phage phi6
3MEF	;		;	MAJOR COLD-SHOCK PROTEIN FROM ESCHERICHIA COLI SOLUTION NMR STRUCTURE
1NMF	;		;	MAJOR COLD-SHOCK PROTEIN, NMR, 20 STRUCTURES
1NMG	;		;	MAJOR COLD-SHOCK PROTEIN, NMR, MINIMIZED AVERAGE STRUCTURE
2LX1	;		;	Major Conformation of the Internal Loop 5'GAGU/3'UGAG
7FG3	;	3.9	;	Major cryo-EM structure of S protein trimer of SARS-CoV2 with K-874, composite map
1XAV	;		;	Major G-quadruplex structure formed in human c-MYC promoter, a monomeric parallel-stranded quadruplex
2M27	;		;	Major G-quadruplex structure formed in human VEGF promoter, a monomeric parallel-stranded quadruplex
2MNX	;		;	Major groove orientation of the (2S)-N6-(2-hydroxy-3-buten-1-yl)-2'-deoxyadenosine DNA adduct induced by 1,2-epoxy-3-butene
8UOP	;	3.8	;	Major interface of Streptococcal surface enolase dimer from AP53 group A streptococcus bound to a lipid vesicle
8UOY	;	3.4	;	Major interface of Streptococcal surface enolase dimer from AP53 group A streptococcus bound to a lipid vesicle
3KFI	;	1.42	;	Major mouse urinary protein IV complexed with 2,5-dimethylpyrazine
3KFH	;	1.02	;	Major mouse urinary protein IV complexed with 2-ethylhexanol
3KFG	;	1.43	;	Major mouse urinary protein IV complexed with 2-heptanone
3KFF	;	0.96	;	Major mouse urinary protein IV complexed with 2-sec-butyl-4,5-dihydrothiazole
7XO1	;	3.0	;	Major polymorph in alpha-synuclein fibril seeded by cerebrospinal fluid from a mid-to-late stage (mid-PD-1) Parkinson's disease patient
8H04	;	3.0	;	Major polymorph in alpha-synuclein fibril seeded by cerebrospinal fluid from a postmortal Parkinson's disease patient
8H03	;	2.8	;	Major polymorph in alpha-synuclein fibril seeded by cerebrospinal fluid from a preclinical Parkinson's disease patient
7OVT	;	2.69	;	major seeded in vitro fibril morphology from murine SAA1.1 protein
1MSP	;	2.5	;	MAJOR SPERM PROTEIN, ALPHA ISOFORM (RECOMBINANT), PH 4.6
2MSP	;	3.3	;	MAJOR SPERM PROTEIN, BETA ISOFORM, ENGINEERED C59S/T90C MUTANT, PUTATIVE SUBFILAMENT STRUCTURE, PH 8.5
6Y1H	;		;	Major subunit ComGC from S. pneumoniae Com pseudopili
6TXT	;		;	Major subunit ComGC from S. sanguinis Com pseudopili
1YU3	;	2.52	;	Major Tropism Determinant I1 Variant
1YU2	;	1.86	;	Major Tropism Determinant M1 Variant
2IOU	;	3.16	;	Major Tropism Determinant P1 (Mtd-P1) Variant Complexed with Bordetella brochiseptica Virulence Factor Pertactin extracellular domain (Prn-E).
1YU0	;	1.56	;	Major Tropism Determinant P1 Variant
1YU1	;	2.07	;	Major Tropism Determinant P3c Variant
1YU4	;	1.87	;	Major Tropism Determinant U1 Variant
6TCT	;	2.02	;	MakD from the mak operon of Vibrio cholerae
2EXG	;		;	Making Protein-Protein Interactions Drugable: Discovery of Low-Molecular-Weight Ligands for the AF6 PDZ Domain
4ABO	;	8.6	;	Mal3 CH domain homology model and mammalian tubulin (2XRP) docked into the 8.6-Angstrom cryo-EM map of Mal3-GTPgammaS-microtubules
4GGN	;	2.29	;	Malaria invasion machinery protein complex
4GFT	;	1.6	;	Malaria invasion machinery protein-Nanobody complex
2RJI	;	1.8	;	Malarial EBA-175 region VI crystallographic structure reveals a KIX-like binding interface
2NQ8	;	2.5	;	Malarial enoyl acyl ACP reductase bound with INH-NAD adduct
1CJB	;	2.0	;	MALARIAL PURINE PHOSPHORIBOSYLTRANSFERASE
5Z3W	;	2.29	;	Malate dehydrogenase binds silver at C113
1B8P	;	1.9	;	MALATE DEHYDROGENASE FROM AQUASPIRILLUM ARCTICUM
1B8U	;	2.5	;	MALATE DEHYDROGENASE FROM AQUASPIRILLUM ARCTICUM
1B8V	;	2.1	;	Malate dehydrogenase from Aquaspirillum arcticum
7BY8	;	1.945	;	Malate Dehydrogenase from Geobacillus stearothermophilus (gs-MDH)
7BYA	;	2.2	;	Malate Dehydrogenase from Geobacillus stearothermophilus (gs-MDH) complexed with Oxaloacetic Acid (OAA) and Adenosine 5'-Diphosphoribose (APR)
7BY9	;	2.2	;	Malate Dehydrogenase from Geobacillus stearothermophilus (gs-MDH) complexed with Oxaloacetic Acid (OAA) and Nicotinamide Adenine Dinucleotide (NAD)
7X1L	;	2.28	;	Malate dehydrogenase from Geobacillus stearothermophilus (gs-MDH) delta E311 mutant complexed with Nicotinamide Adenine Dinucleotide (NAD+)
7F8D	;	2.4	;	Malate Dehydrogenase from Geobacillus stearothermophilus (gs-MDH) G218Y mutant
5ULV	;	1.66	;	Malate dehydrogenase from Methylobacterium extorquens
5UJK	;	1.53	;	Malate dehydrogenase from Methylobacterium extorquens, complexed with NAD
3HHP	;	1.45	;	Malate dehydrogenase open conformation
1D8C	;	2.0	;	MALATE SYNTHASE G COMPLEXED WITH MAGNESIUM AND GLYOXYLATE
2JWP	;		;	Malectin
1TOK	;	1.85	;	Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase
5CEE	;	2.498	;	Malic enzyme from Candidatus Phytoplasma AYWB in complex with NAD and Mg2+
6URF	;	3.6	;	Malic enzyme from Mycobacterium tuberculosis
1GQ2	;	2.5	;	Malic Enzyme from Pigeon Liver
1G29	;	1.9	;	MALK
2ZO9	;	2.2	;	Malonate-bound structure of the glycerophosphodiesterase from Enterobacter aerogenes (GpdQ) and characterization of the native Fe2+ metal ion preference
2ZOA	;	2.4	;	Malonate-bound structure of the glycerophosphodiesterase from Enterobacter aerogenes (GpdQ) COLLECTED AT 1.280 ANGSTROM
3NYR	;	1.45	;	Malonyl-CoA Ligase Ternary Product Complex with Malonyl-CoA and AMP bound
3NYQ	;	1.43	;	Malonyl-CoA Ligase Ternary Product Complex with Methylmalonyl-CoA and AMP bound
8A30	;	1.45	;	Malonyl-CoA reductase from Chloroflexus aurantiacus - C-terminal Apo
8AET	;	2.0	;	Malonyl-CoA reductase from Chloroflexus aurantiacus - C-terminal E779W variant
8A8T	;	2.11	;	Malonyl-CoA reductase from Chloroflexus aurantiacus - C-terminal NADP and malonate bound
8A7S	;	1.542	;	Malonyl-CoA reductase from Chloroflexus aurantiacus - C-terminal NADP bound
8AEO	;	1.76	;	Malonyl-CoA reductase from Chloroflexus aurantiacus - C-terminal R773A variant
8AEQ	;	1.64	;	Malonyl-CoA reductase from Chloroflexus aurantiacus - C-terminal R773Q variant
8AER	;	1.77	;	Malonyl-CoA reductase from Chloroflexus aurantiacus - C-terminal Y731A variant
8AEW	;	2.72	;	Malonyl-CoA reductase from Chloroflexus aurantiacus - N-terminal Apo
1NM2	;	2.0	;	Malonyl-CoA:ACP Transacylase
7A41	;	2.13	;	MALT1 in complex with a NVS-MALT1 chemical probe
7PAV	;	2.199	;	MALT1 in complex with compound 1
7PAW	;	2.19	;	MALT1 in complex with compound 1
6YN9	;	2.558	;	MALT1(329-728) in complex with a sulfonamide containing compound
3RT1	;	2.8	;	Maltodextarn bound activated state form of yeast glycogen synthase isoform 2
3RSZ	;	3.009	;	Maltodextran bound basal state conformation of yeast glycogen synthase isoform 2
5MTU	;	0.999	;	Maltodextrin binding protein MalE1 from L. casei BL23 bound to alpha-cyclodextrin
5MK9	;	0.919	;	Maltodextrin binding protein MalE1 from L. casei BL23 bound to beta-cyclodextrin
5MKA	;	1.149	;	Maltodextrin binding protein MalE1 from L. casei BL23 bound to gamma-cyclodextrin
5MTT	;	1.12	;	Maltodextrin binding protein MalE1 from L. casei BL23 bound to maltotetraose
5M28	;	1.079	;	Maltodextrin binding protein MalE1 from L. casei BL23 bound to maltotriose
5MKB	;	1.698	;	Maltodextrin binding protein MalE1 from L. casei BL23 without ligand
4MBP	;	1.7	;	MALTODEXTRIN BINDING PROTEIN WITH BOUND MALTETROSE
1ANF	;	1.67	;	MALTODEXTRIN BINDING PROTEIN WITH BOUND MALTOSE
1MPB	;	2.0	;	MALTODEXTRIN-BINDING PROTEIN (MALTOSE-BINDING PROTEIN) MUTANT, WITH ARGININE REPLACING TRYPTOPHAN AT POSITION 230 (TRP-230-ARG)
1MPC	;	2.1	;	MALTODEXTRIN-BINDING PROTEIN (MALTOSE-BINDING PROTEIN) MUTANT, WITH ARGININE REPLACING TRYPTOPHAN AT POSITION 230 (TRP-230-ARG)
1MPD	;	2.3	;	MALTODEXTRIN-BINDING PROTEIN (MALTOSE-BINDING PROTEIN) MUTANT, WITH ARGININE REPLACING TRYPTOPHAN AT POSITION 230 (TRP-230-ARG), COMPLEXED WITH MALTOSE
1IUD	;	2.7	;	MALTODEXTRIN-BINDING PROTEIN INSERTION/DELETION MUTANT WITH AN INSERTED B-CELL EPITOPE FROM THE PRES2 REGION OF HEPATITIS B VIRUS
1JVX	;	2.5	;	Maltodextrin-binding protein variant D207C/A301GS/P316C cross-linked in crystal
1JVY	;	1.9	;	Maltodextrin-binding protein variant D207C/A301GS/P316C with beta-mercaptoethanol mixed disulfides
3MBP	;	1.7	;	MALTODEXTRIN-BINDING PROTEIN WITH BOUND MALTOTRIOSE
1MPR	;	2.8	;	MALTOPORIN FROM SALMONELLA TYPHIMURIUM
2MPR	;	2.4	;	MALTOPORIN FROM SALMONELLA TYPHIMURIUM
1MPO	;	2.8	;	MALTOPORIN MALTOHEXAOSE COMPLEX
1MPM	;	2.6	;	MALTOPORIN MALTOSE COMPLEX
1MPN	;	3.2	;	MALTOPORIN MALTOTRIOSE COMPLEX
1AF6	;	2.4	;	MALTOPORIN SUCROSE COMPLEX
1MPQ	;	3.0	;	MALTOPORIN TREHALOSE COMPLEX
3DM0	;	2.4	;	Maltose Binding Protein fusion with RACK1 from A. thaliana
5LDF	;	6.2	;	Maltose binding protein genetically fused to dodecameric glutamine synthetase
1MH3	;	2.1	;	maltose binding-a1 homeodomain protein chimera, crystal form I
1MH4	;	2.3	;	maltose binding-a1 homeodomain protein chimera, crystal form II
6DTQ	;	2.15	;	Maltose bound T. maritima MalE3
1H54	;	2.15	;	Maltose phosphorylase from Lactobacillus brevis
1YTV	;	1.8	;	Maltose-binding protein fusion to a C-terminal fragment of the V1a vasopressin receptor
3OSQ	;	1.9	;	Maltose-bound maltose sensor engineered by insertion of circularly permuted green fluorescent protein into E. coli maltose binding protein at position 175
3OSR	;	2.0	;	Maltose-bound maltose sensor engineered by insertion of circularly permuted green fluorescent protein into E. coli maltose binding protein at position 311
1SO7	;	1.49	;	Maltose-induced structure of the human cytolsolic sialidase Neu2
6FFL	;	1.707	;	Maltose/maltodextrin-binding domain MalE from Bdellovibrio bacteriovorus bound to maltotriose
1GJU	;	2.4	;	Maltosyltransferase from Thermotoga maritima
6DTU	;	1.5	;	Maltotetraose bound T. maritima MalE1
6DTS	;	1.5	;	Maltotetraose bound T. maritima MalE2
1JDA	;	2.2	;	MALTOTETRAOSE-FORMING EXO-AMYLASE
5CGT	;	2.5	;	MALTOTRIOSE COMPLEX OF PRECONDITIONED CYCLODEXTRIN GLYCOSYLTRANSFERASE MUTANT
5UGR	;	1.56	;	Malyl-CoA lyase from Methylobacterium extorquens
5L73	;	2.24	;	MAM domain of human neuropilin-1
4XI0	;	2.88	;	MamA 41-end from Desulfovibrio magneticus RS-1
3AS4	;	2.33	;	MamA AMB-1 C2221
3AS5	;	2.0	;	MamA AMB-1 P212121
3ASH	;	2.41	;	MamA D159K mutant 1
3ASG	;	2.33	;	MamA D159K mutant 2
3ASF	;	2.39	;	MamA MSR-1 C2
3AS8	;	2.0	;	MamA MSR-1 P41212
3ASD	;	2.45	;	MamA R50E mutant
5LFL	;	3.37	;	MamA RS-1 ArsTM double mutant
5LFM	;	3.28	;	MamA RS-1 ArsTM double mutant
5HO3	;	2.15	;	MamB
5HO5	;	1.99	;	MamB
6QFJ	;	2.13	;	MamB CTD magnetosome protein [Desulfamplus magnetovallimortis BW-1]
5HO1	;	2.53	;	MamB-CTD
5HOK	;	1.7	;	MamB-CTD mutant - D247A
1IMT	;		;	MAMBA INTESTINAL TOXIN 1, NMR, 39 STRUCTURES
2MFA	;		;	Mambalgin-2
5LJV	;	3.64	;	MamK double helical filament
5LJW	;	1.8	;	MamK non-polymerising A278D mutant bound to AMPPNP
6GMT	;	1.59	;	MamM CTD - Cadmium form
6GP6	;	2.146	;	MamM CTD - Copper form
6GMV	;	1.59	;	MamM CTD - Nickel form
6G55	;	1.65	;	MamM CTD C267S
6H9Q	;	1.5	;	MamM CTD D249E - Cadmium form
6H5K	;	1.54	;	MamM CTD D249E - Zinc form
6H84	;	2.04	;	MamM CTD D249H - Cadmium form
6H83	;	1.5	;	MamM CTD D249H - Copper form
6HA2	;	1.5	;	MamM CTD D249H-H285D
6H88	;	1.5	;	MamM CTD D249N
6H8A	;	1.8	;	MamM CTD D249N - Cadmium form
6H89	;	1.7	;	MamM CTD D249N - Copper form
6H8D	;	1.62	;	MamM CTD D249N - Nickel form
6H87	;	1.5	;	MamM CTD D249N - Zinc form
6HHS	;	2.7	;	MamM CTD E289D - Cadmium form
6H9P	;	2.1	;	MamM CTD E289D - Manganese form
6H81	;	1.5	;	MamM CTD E289H - Nickel form
6G64	;	1.9	;	MamM CTD H264A-E289A
6G5E	;	1.6	;	MamM CTD H264A-E289A-C267S
6H5V	;	1.49	;	MamM CTD H264E
6H8G	;	1.35	;	MamM CTD H264E - Cadmium form 1
6HAO	;	2.4	;	MamM CTD H264E - Cadmium form 2
6H5M	;	1.6	;	MamM CTD H264E - Zinc form 1
6H5U	;	2.0	;	MamM CTD H264E - Zinc form 2
6HAN	;	2.6	;	MamM CTD H264E-E289H
6H85	;	2.0	;	MamM CTD H264E-E289H - Cadmium form
6H8I	;	1.4	;	MamM CTD H285D
6H9T	;	1.7	;	MamM CTD H285D - Cadmium form
5HSP	;	1.79	;	MamM CTD M250L
6G6I	;	2.4	;	MamM CTD W247A
3W8G	;	2.05	;	MamM V260R
3W5X	;	1.6	;	MamM-CTD
3W5Y	;	1.95	;	MamM-CTD
3W63	;	1.9	;	MamM-CTD 215-293
3W64	;	2.85	;	MamM-CTD 215-293
3W5Z	;	1.66	;	MamM-CTD D249A
3W65	;	2.37	;	MamM-CTD D249A and H264A
3W66	;	2.05	;	MamM-CTD D249A and H285A
3W8P	;	1.8	;	MamM-CTD D249A&H28A mutant
3W62	;	1.64	;	MamM-CTD E289A
3W60	;	1.82	;	MamM-CTD H264A
3W61	;	1.59	;	MamM-CTD H285A
5FLX	;	3.9	;	Mammalian 40S HCV-IRES complex
6YAL	;	3.0	;	Mammalian 48S late-stage initiation complex with beta-globin mRNA
6YAM	;	3.6	;	Mammalian 48S late-stage translation initiation complex (LS48S+eIF3 IC) with beta-globin mRNA
6YAN	;	3.48	;	Mammalian 48S late-stage translation initiation complex with histone 4 mRNA
4UJC	;	9.5	;	mammalian 80S HCV-IRES initiation complex with eIF5B POST-like state
4UJD	;	8.9	;	mammalian 80S HCV-IRES initiation complex with eIF5B PRE-like state
7TOR	;	2.9	;	Mammalian 80S ribosome bound with the ALS/FTD-associated dipeptide repeat protein GR20
7TOQ	;	3.1	;	Mammalian 80S ribosome bound with the ALS/FTD-associated dipeptide repeat protein poly-PR
6D90	;	3.2	;	Mammalian 80S ribosome with a double translocated CrPV-IRES, P-site tRNA and eRF1.
6D9J	;	3.2	;	Mammalian 80S ribosome with a double translocated CrPV-IRES, P-sitetRNA and eRF1.
7UCJ	;	3.1	;	Mammalian 80S translation initiation complex with mRNA and Harringtonine
4BC7	;	2.4	;	MAMMALIAN ALKYLDIHYDROXYACETONEPHOSPHATE SYNTHASE: Arg419His mutant
4BCA	;	2.4	;	MAMMALIAN ALKYLDIHYDROXYACETONEPHOSPHATE SYNTHASE: Tyr578Phe mutant
4BBY	;	1.9	;	MAMMALIAN ALKYLDIHYDROXYACETONEPHOSPHATE SYNTHASE: WILD-TYPE
4BC9	;	2.41	;	MAMMALIAN ALKYLDIHYDROXYACETONEPHOSPHATE SYNTHASE: WILD-TYPE, ADDUCT WITH CYANOETHYL
1QHU	;	2.3	;	MAMMALIAN BLOOD SERUM HAEMOPEXIN DEGLYCOSYLATED AND IN COMPLEX WITH ITS LIGAND HAEM
1QJS	;	2.9	;	mammalian blood serum haemopexin glycosylated-native protein and in complex with its ligand haem
8D4T	;	3.1	;	Mammalian CIV with GDN bound
3GDI	;	2.4	;	Mammalian Clock Protein mPER2 - Crystal Structure of a PAS Domain Fragment
4MLP	;	1.943	;	Mammalian cryptochrome in complex with a small molecule competitor of its ubiquitin ligase
7ZPI	;	5.91	;	Mammalian Dicer in the ""dicing state"" with pre-miR-15a substrate
7YYM	;	4.19	;	Mammalian Dicer in the ""pre-dicing state"" with pre-miR-15a substrate
7ZPJ	;	3.81	;	Mammalian Dicer in the ""pre-dicing state"" with pre-miR-15a substrate and TARBP2 subunit
7ZPK	;	3.81	;	Mammalian Dicer in the ""pre-dicing state"" with pre-miR-15a substrate and TARBP2 subunit
7YYN	;	6.21	;	Mammalian Dicer in the dicing state with pre-miR-15a substrate
5YE2	;	5.8	;	mammalian endo-lysosomal TRPML1 channel inserting into amphipol
3IZY	;	10.8	;	Mammalian mitochondrial translation initiation factor 2
7NWI	;	3.13	;	Mammalian pre-termination 80S ribosome with Empty-A site bound by Blasticidin S
7NWH	;	4.1	;	Mammalian pre-termination 80S ribosome with eRF1 and eRF3 bound by Blasticidin S.
7NWG	;	3.8	;	Mammalian pre-termination 80S ribosome with Hybrid P/E- and A/P-site tRNA's bound by Blasticidin S.
7NFX	;	3.2	;	Mammalian ribosome nascent chain complex with SRP and SRP receptor in early state A
1Y7Q	;		;	Mammalian SCAN domain dimer is a domain-swapped homologue of the HIV capsid C-terminal domain
2A79	;	2.9	;	Mammalian Shaker Kv1.2 potassium channel- beta subunit complex
1H6V	;	3.0	;	Mammalian thioredoxin reductase
4C0S	;	2.703	;	Mammalian translation elongation factor eEF1A2
6VQ6	;	3.9	;	Mammalian V-ATPase from rat brain - composite model of rotational state 1 bound to ADP and SidK (built from focused refinement models)
6VQ7	;	4.0	;	Mammalian V-ATPase from rat brain - composite model of rotational state 2 bound to ADP and SidK (built from focused refinement models)
6VQ8	;	3.9	;	Mammalian V-ATPase from rat brain - composite model of rotational state 3 bound to ADP and SidK (built from focused refinement models)
6VQI	;	4.3	;	Mammalian V-ATPase from rat brain collar and peripheral stalks rotational state 1 (from focused refinement)
6VQJ	;	5.7	;	Mammalian V-ATPase from rat brain collar and peripheral stalks rotational state 2 (from focused refinement)
6VQK	;	5.7	;	Mammalian V-ATPase from rat brain collar and peripheral stalks rotational state 3 (from focused refinement)
6VQC	;	3.8	;	Mammalian V-ATPase from rat brain membrane-embedded Vo region rotational state 1 (from focused refinement)
6VQG	;	4.2	;	Mammalian V-ATPase from rat brain membrane-embedded Vo region rotational state 2 (from focused refinement)
6VQH	;	4.4	;	Mammalian V-ATPase from rat brain membrane-embedded Vo region rotational state 3 (from focused refinement)
6VQ9	;	3.6	;	Mammalian V-ATPase from rat brain soluble V1 region rotational state 1 with SidK and ADP (from focused refinement)
6VQA	;	3.7	;	Mammalian V-ATPase from rat brain soluble V1 region rotational state 2 with SidK and ADP (from focused refinement)
6VQB	;	3.6	;	Mammalian V-ATPase from rat brain soluble V1 region rotational state 2 with SidK and ADP (from focused refinement)
1QDO	;	2.8	;	MAN(APLHA1-3)MAN(ALPHA1-O)METHYL CONCANAVALIN A COMPLEX
1QDC	;	2.0	;	MAN(APLHA1-6)MAN(ALPHA1-O)METHYL CONCANAVALIN A COMPLEX
6A13	;	1.7	;	Mandelate oxidase mutant-Y128F
6A1N	;	1.421	;	Mandelate oxidase mutant-Y128F with (2R,3S)-3-fluoro-2-hydroxy-3-phenylpropanoic acid
6A0V	;	1.39	;	Mandelate oxidase mutant-Y128F with (S)-mandelic acid
6A0M	;	1.75	;	Mandelate oxidase mutant-Y128F with 2-Phenylacetic acid
6A1B	;	1.47	;	Mandelate oxidase mutant-Y128F with 3,3,3-trifluoro-2,2-dihydroxypropanoic acid
6A1A	;	1.35	;	Mandelate oxidase mutant-Y128F with 4-hydroxymandelic acid
6A1H	;	1.36	;	Mandelate oxidase mutant-Y128F with 5-deazariboflavin mononucleotide
6A1L	;	1.4	;	Mandelate oxidase mutant-Y128F with 5-deazariboflavin mononucleotide and benzoic acid
6A1M	;	1.55	;	Mandelate oxidase mutant-Y128F with 5-deazariboflavin mononucleotide and benzoylformic acid
6A1P	;	1.51	;	Mandelate oxidase mutant-Y128F with 5-deazariboflavin mononucleotide and phenylpyruvic acid
6A0O	;	1.55	;	Mandelate oxidase mutant-Y128F with benzaldehyde
6A0Y	;	1.7	;	Mandelate oxidase mutant-Y128F with Benzoic acid
6A19	;	1.55	;	Mandelate oxidase mutant-Y128F with Benzoylformic acid
6A11	;	1.45	;	Mandelate oxidase mutant-Y128F with phenylpyruvic acid
6A36	;	1.44	;	Mandelate oxidase mutant-Y128F with the 3-fluoropyruvic acid FMN adduct
6AI7	;	2.07	;	Mandelate oxidase mutant-Y128F with the C4a-OH-FMN adduct
6A4G	;	2.04	;	Mandelate oxidase mutant-Y128F with the monooxide FMN adduct
6A23	;	1.65	;	Mandelate oxidase mutant-Y128F with the N5-benzyl-FMN adduct
6A21	;	1.501	;	Mandelate oxidase mutant-Y128F with the N5-malonyl-FMN adduct
6A1R	;	1.652	;	Mandelate oxidase mutant-Y128F with the N5-phenylacetyl-FMN adduct
6A4H	;	1.99	;	Mandelate oxidase mutant-Y128F with the peroxide FMN adduct
7BSR	;	1.894	;	Mandelate oxidase with the 2-Hydroxy-3-oxosuccinic acid
6A1W	;	1.7	;	Mandelate oxidase with the enoyl FMN epoxide adduct
1DTN	;	2.1	;	MANDELATE RACEMASE MUTANT D270N CO-CRYSTALLIZED WITH (S)-ATROLACTATE
1MRA	;	2.1	;	MANDELATE RACEMASE MUTANT D270N CO-CRYSTALLIZED WITH (S)-ATROLACTATE
1MDL	;	1.85	;	MANDELATE RACEMASE MUTANT K166R CO-CRYSTALLIZED WITH (R)-MANDELATE
6CKH	;	2.1	;	Manduca sexta Peptidoglycan Recognition Protein-1
1BVA	;	1.89	;	MANGANESE BINDING MUTANT IN CYTOCHROME C PEROXIDASE
2O5M	;	1.65	;	Manganese horse heart myoglobin, azide modified
2O5L	;	1.7	;	Manganese horse heart myoglobin, methanol modified
2O5Q	;	1.9	;	Manganese horse heart myoglobin, nitric oxide modified
2O5O	;	1.6	;	Manganese horse heart myoglobin, nitrite modified
2O5B	;	2.0	;	Manganese horse heart myoglobin, reduced
5FNO	;	2.038	;	Manganese Lipoxygenase
1MNP	;	2.0	;	MANGANESE PEROXIDASE
1YYG	;	1.6	;	Manganese peroxidase complexed with Cd(II) inhibitor
1MN1	;	2.0	;	MANGANESE PEROXIDASE SUBSTRATE BINDING SITE MUTANT D179N
1MN2	;	2.0	;	MANGANESE PEROXIDASE SUBSTRATE BINDING SITE MUTANT E35Q, D179N
1YZR	;	1.6	;	Manganese peroxidase-Sm(III) complex
2PFQ	;	2.1	;	Manganese promotes catalysis in a DNA polymerase lambda-DNA crystal
6N2V	;	2.85	;	Manganese riboswitch from Xanthmonas oryzae bound to Mn(II)
2CDY	;	2.0	;	Manganese Superoxide Dismutase (Mn-SOD) from Deinococcus radiodurans
2CE4	;	2.2	;	Manganese Superoxide Dismutase (Mn-SOD) from Deinococcus radiodurans
1VEW	;	2.1	;	MANGANESE SUPEROXIDE DISMUTASE FROM ESCHERICHIA COLI
5A9G	;	1.35	;	Manganese Superoxide Dismutase from Sphingobacterium sp. T2
5FD5	;	1.91	;	manganese uptake regulator
3S6V	;	2.6	;	Manganese-bound Ac-ASP-7
5ZR4	;	3.1	;	Manganese-dependent transcriptional repressor
5ZR6	;	3.0	;	Manganese-dependent transcriptional repressor complex with manganese
5MEG	;	2.0	;	Manganese-substituted Cyanothece lipoxygenase 2 (Mn-CspLOX2)
4WFO	;	1.14	;	manganese-substituted soybean lipoxygenase-1
1DQ5	;	2.0	;	Manganese;Manganese concanavalin A at pH 5.0
1DQ6	;	1.9	;	Manganese;Manganese concanavalin A at pH 7.0
3BVG	;	2.0	;	Manipulating the coupled folding and binding process drives affinity maturation in a protein-protein complex
3BVM	;	2.0	;	Manipulating the coupled folding and binding process drives affinity maturation in a protein-protein complex
3BVZ	;	2.3	;	Manipulating the coupled folding and binding process drives affinity maturation in a protein-protein complex
3BYY	;	2.2	;	Manipulating the coupled folding and binding process drives affinity maturation in a protein-protein complex
3BZD	;	2.3	;	Manipulating the coupled folding and binding process drives affinity maturation in a protein-protein complex
2YII	;	2.18	;	Manipulating the regioselectivity of phenylalanine aminomutase: new insights into the reaction mechanism of MIO-dependent enzymes from structure-guided directed evolution
2BGO	;		;	Mannan Binding Module from Man5C
2BGP	;		;	Mannan Binding Module from Man5C in bound conformation
7EET	;	2.57	;	Mannanase KMAN from Klebsiella oxytoca KUB-CW2-3
5XTJ	;	2.22	;	Mannanase(RmMan134A)
1H5Q	;	1.5	;	Mannitol dehydrogenase from Agaricus bisporus
7OCS	;	2.3	;	Mannitol-1-phosphate bound to the phosphatase domain of the bifunctional mannitol-1-phosphate dehydrogenase/phosphatase MtlD-D16A from Acinetobacter baumannii
7OCU	;	2.7	;	Mannitol-1-phosphate bound to the phosphatase domain of the bifunctional mannitol-1-phosphate dehydrogenase/phosphatase MtlD-N374A from Acinetobacter baumannii
7RK5	;	2.1	;	Mannitol-2-dehydrogenase bound to NADH from Aspergillus fumigatus
7RK4	;	1.8	;	Mannitol-2-dehydrogenase from Aspergillus fumigatus
3MAN	;	1.6	;	MANNOHEXAOSE COMPLEX OF THERMOMONOSPORA FUSCA BETA-MANNANASE
1RDO	;	1.7	;	MANNOSE-BINDING PROTEIN, SUBTILISIN DIGEST FRAGMENT
1RDL	;	1.7	;	MANNOSE-BINDING PROTEIN, SUBTILISIN DIGEST FRAGMENT COMPLEX WITH ALPHA-METHYL-D-MANNOPYRANOSIDE (0.2 M)
1RDM	;	1.9	;	MANNOSE-BINDING PROTEIN, SUBTILISIN DIGEST FRAGMENT COMPLEX WITH ALPHA-METHYL-D-MANNOPYRANOSIDE (1.3 M)
1RDN	;	1.8	;	MANNOSE-BINDING PROTEIN, SUBTILISIN DIGEST FRAGMENT COMPLEX WITH ALPHA-METHYL-D-N-ACETYLGLUCOSAMINIDE
1RDI	;	1.8	;	MANNOSE-BINDING PROTEIN, SUBTILISIN DIGEST FRAGMENT COMPLEX WITH ALPHA-METHYL-L-FUCOPYRANOSIDE
1RDJ	;	1.8	;	MANNOSE-BINDING PROTEIN, SUBTILISIN DIGEST FRAGMENT COMPLEX WITH BETA-METHYL-L-FUCOPYRANOSIDE
1RDK	;	1.8	;	MANNOSE-BINDING PROTEIN, SUBTILISIN DIGEST FRAGMENT COMPLEX WITH D-GALACTOSE
1BCH	;	2.0	;	MANNOSE-BINDING PROTEIN-A MUTANT (QPDWGH) COMPLEXED WITH N-ACETYL-D-GALACTOSAMINE
1BCJ	;	2.1	;	MANNOSE-BINDING PROTEIN-A MUTANT (QPDWGHV) COMPLEXED WITH N-ACETYL-D-GALACTOSAMINE
6X7X	;	1.3	;	mannose-bound structure of Marinomonas primoryensis PA14 carbohydrate-binding domain
1NPL	;	2.0	;	MANNOSE-SPECIFIC AGGLUTININ (LECTIN) FROM DAFFODIL (NARCISSUS PSEUDONARCISSUS) BULBS IN COMPLEX WITH MANNOSE-ALPHA1,3-MANNOSE
1BWU	;	2.8	;	MANNOSE-SPECIFIC AGGLUTININ (LECTIN) FROM GARLIC (ALLIUM SATIVUM) BULBS COMPLEXED WITH ALPHA-D-MANNOSE
1KJ1	;	2.2	;	MANNOSE-SPECIFIC AGGLUTININ (LECTIN) FROM GARLIC (ALLIUM SATIVUM) BULBS COMPLEXED WITH ALPHA-D-MANNOSE
1MSA	;	2.29	;	MANNOSE-SPECIFIC AGGLUTININ (LECTIN) FROM SNOWDROP (GALANTHUS NIVALIS) BULBS COMPLEXED WITH METHYL-ALPHA-D-MANNOSIDE
1NIV	;	3.0	;	MANNOSE-SPECIFIC AGGLUTININ (LECTIN) FROM SNOWDROP (GALANTHUS NIVALIS) BULBS IN COMPLEX WITH MANNOSE-ALPHA 1,3-METHYL-D-MANNOSE
1JPC	;	2.0	;	MANNOSE-SPECIFIC AGGLUTININ (LECTIN) FROM SNOWDROP (GALANTHUS NIVALIS) BULBS IN COMPLEX WITH MANNOSE-ALPHA1,6-(MANNOSE-ALPHA1,3)-MANNOSE-ALPHA1,6-(MANNOSE-ALPHA1,3)-MANNOSE
3BED	;	1.45	;	Mannose/sorbose specific IIA subunit of phosphotransferase system from Enterococcus faecalis
3F1Y	;	2.2	;	Mannosyl-3-phosphoglycerate synthase from Rubrobacter xylanophilus
2WVK	;	2.97	;	Mannosyl-3-phosphoglycerate synthase from Thermus thermophilus HB27 apoprotein
2WVL	;	2.806	;	Mannosyl-3-phosphoglycerate synthase from Thermus thermophilus HB27 in complex with GDP-alpha-D-Mannose and Mg(II)
2Y4M	;	2.7	;	MANNOSYLGLYCERATE SYNTHASE IN COMPLEX WITH GDP-Mannose
2Y4J	;	2.3	;	MANNOSYLGLYCERATE SYNTHASE IN COMPLEX WITH LACTATE
2Y4L	;	2.8	;	MANNOSYLGLYCERATE SYNTHASE IN COMPLEX WITH Manganese and GDP
2Y4K	;	2.45	;	MANNOSYLGLYCERATE SYNTHASE IN COMPLEX WITH MG-GDP
6YV7	;	2.7	;	Mannosyltransferase PcManGT from Pyrobaculum calidifontis
6YV8	;	2.6	;	Mannosyltransferase PcManGT from Pyrobaculum calidifontis in complex with GDP and Mn2+
6YV9	;	2.7	;	Mannosyltransferase PcManGT from Pyrobaculum calidifontis in complex with GDP-Man and Mn2+
2MAN	;	1.9	;	MANNOTRIOSE COMPLEX OF THERMOMONOSPORA FUSCA BETA-MANNANASE
2C64	;	2.2	;	MAO inhibition by rasagiline analogues
2C65	;	1.7	;	MAO inhibition by rasagiline analogues
2C66	;	2.5	;	MAO inhibition by rasagiline analogues
2C67	;	1.7	;	MAO inhibition by rasagiline analogues
5I7N	;	1.65	;	MaoC-like dehydratase
3PG1	;	1.95	;	MAP kinase LmaMPK10 from Leishmania major (1.95 angs resolution)
3UIB	;	2.65	;	Map kinase LMAMPK10 from leishmania major in complex with SB203580
7PHG	;	4.3	;	MaP OF P5C3RBD Interface
5Z1E	;	2.3	;	MAP2K7 C218S mutant-inhibitor
5Z1D	;	2.28	;	MAP2K7 C276S mutant-inhibitor
5Y90	;	1.3	;	MAP2K7 mutant -C218S
6Z1T	;	2.31	;	MAP3K14 (NIK) in complex with 4S/3694
6Z1Q	;	2.42	;	MAP3K14 (NIK) in complex with DesF-3R/4076
4U41	;	2.2	;	MAP4K4 Bound to inhibitor compound 1
4RVT	;	2.4	;	MAP4K4 in complex with a pyridin-2(1H)-one derivative
5DI1	;	2.9	;	MAP4K4 in complex with an inhibitor
4ZP5	;	2.29	;	MAP4K4 in complex with inhibitor
5J95	;	2.5	;	MAP4K4 in complex with inhibitor
4U44	;	2.43	;	MAP4K4 in complex with inhibitor (compound 16)
4OBO	;	2.1	;	MAP4K4 in complex with inhibitor (compound 22), 6-(3-CHLOROPHENYL)QUINAZOLIN-4-AMINE
4U45	;	2.58	;	MAP4K4 in complex with inhibitor (compound 25)
4OBP	;	2.27	;	MAP4K4 in complex with inhibitor (compound 29), 6-(2-FLUOROPYRIDIN-4-YL)PYRIDO[3,2-D]PYRIMIDIN-4-AMINE
4OBQ	;	2.19	;	MAP4K4 in complex with inhibitor (compound 31), N-[3-(4-AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
4U43	;	2.18	;	MAP4K4 in complex with inhibitor (compound 6)
5W5Q	;	2.33	;	MAP4K4 in complex with inhibitor compound 12 (N3-methyl-10-(3-methyl-3-(5-methyloxazol-2-yl)but-1-yn-1-yl)-6,7-dihydro-5H-5,7-methanobenzo[c]imidazo[1,2-a]azepine-2,3-dicarboxamide)
4ZK5	;	2.89	;	MAP4K4 in complex with inhibitor GNE-495
4U42	;	2.504	;	MAP4K4 T181E Mutant Bound to inhibitor compound 1
8RC1	;	3.7	;	MAP7 MTBD (microtubule binding domain) decorated microtubule protofilament
7CD5	;	2.7	;	mAPE1-blunt-ended dsDNA product complex
7CD6	;	2.701	;	mAPE1-recessed dsDNA product complex
4EYJ	;	2.102	;	MAPK13 Complex with inhibitor
4EYM	;	2.353	;	MAPK13 complex with inhibitor
4MYG	;	2.594	;	MAPK13, active form
7BDQ	;	2.75	;	MAPK14 bound with SR300
7BDO	;	2.7	;	MAPK14 bound with SR302
6SFO	;	1.75	;	MAPK14 with bound inhibitor SR-318
3DHS	;	3.6	;	Mapping metal-binding sites in the catalytic domain of bacterial RNase P RNA
7JX3	;	2.65	;	Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology
7JXC	;	2.47	;	Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology
7JXD	;	2.5	;	Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology
7JXE	;	2.043	;	Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology
1UX9	;	2.4	;	Mapping protein matrix cavities in human cytoglobin through Xe atom binding: a crystallographic investigation
6QUR	;	1.792	;	Mapping the allosteric communication network of aminodeoxychorismate synthase
6DPQ	;	2.94	;	Mapping the binding trajectory of a suicide inhibitor in human indoleamine 2,3-dioxygenase 1
6DPR	;	3.2	;	Mapping the binding trajectory of a suicide inhibitor in human indoleamine 2,3-dioxygenase 1
6MQ6	;	3.05	;	Mapping the binding trajectory of a suicide inhibitor in human indoleamine 2,3-dioxygenase 1
1Z8Y	;	9.0	;	Mapping the E2 Glycoprotein of Alphaviruses
6TSQ	;	1.85	;	Marasmius oreades agglutinin (MOA) activated by manganese (II)
6TSR	;	1.85	;	Marasmius oreades agglutinin (MOA) activated by manganese (II) and calcium
6TSL	;	1.4	;	Marasmius oreades agglutinin (MOA) in complex with the truncated PVPRAHS synthetic substrate
6YH0	;	1.56	;	Marasmius oreades agglutinin (MOA) in complex with the truncated PVPRAHS synthetic substrate
6TSM	;	1.4	;	Marasmius oreades agglutinin (MOA) in complex with the truncated PVVRAHS synthetic substrate
6TSO	;	2.1	;	Marasmius oreades agglutinin (MOA) inhibited by cadmium
6TSP	;	1.85	;	Marasmius oreades agglutinin (MOA) inhibited by zinc
6TSN	;	1.6	;	Marasmius oreades agglutinin (MOA), papain back.swap W208Q-Q276W variant
7F1M	;	3.1	;	Marburg virus nucleoprotein-RNA complex
5T3W	;	3.25	;	Marburg virus VP30 bound to nucleoprotein
7FGZ	;	2.2	;	Marine bacterial GH16 hydrolase
6JIA	;	1.9	;	Marine bacterial laminarinase mutant E135A complex with laminaritetraose
6AH8	;	2.61	;	Marine bacterial prolidase with promiscuous organophosphorus hydrolase activity
7C4D	;	2.03	;	Marine microorganism esterase
5KZ7	;	3.2	;	Mark2 complex with 7-[(1S)-1-(4-fluorophenyl)ethyl]-5,5-dimethyl-2-(3-pyridylamino)pyrrolo[2,3-d]pyrimidin-6-one
5KZ8	;	3.21	;	Mark2 complex with 7-[(1S)-1-(4-fluorophenyl)ethyl]-5,5-dimethyl-2-(3-pyridylamino)pyrrolo[2,3-d]pyrimidin-6-one
5ERI	;	2.3	;	MarR Protein from Peptoclostridium difficile DA00132
7LV9	;	4.5	;	Marseillevirus heterotrimeric (hexameric) nucleosome
6LRU	;	2.4	;	Marsupenaeus japonicus ferritin mutant (T158H)
6LS2	;	1.6	;	Marsupenaeus japonicus ferritin mutant (T158H) pH 4.0
6LRX	;	1.702	;	Marsupenaeus japonicus ferritin mutant(T158H)
6LRW	;	2.4	;	Marsupenaeus japonicus ferritin mutant(T158H) pH 7.0
6LRV	;	2.3	;	Marsupenaeus japonicus ferritin mutant(T158H) pH9.0
7DQO	;	1.701	;	Marsupenaeus japonicus ferritin mutant-D132R
7L15	;	2.25	;	Marsupial T cell receptor Spl_118
7K0X	;	3.1	;	Marsupial T cell receptor Spl_145
7K0Z	;	3.2	;	Marsupial T cell receptor Spl_157
5CP0	;	2.0	;	MAS complex structure of peptide deformylase from Xanthomonas oryzae pv oryzae
8FAU	;	1.44	;	Masking thiol reactivity with thioamide-based MBPs- carbonic anhydrase II complexed with 4-phenylthiazole-2(3H)-thione
8FAL	;	1.37	;	Masking thiol reactivity with thioamide-based MBPs- carbonic anhydrase II complexed with benzo[d]thiazole-2(3H)-thione
1BAX	;		;	MASON-PFIZER MONKEY VIRUS MATRIX PROTEIN, NMR, AVERAGE STRUCTURE
7BGT	;	1.93	;	Mason-Pfizer Monkey Virus Protease mutant C7A/D26N/C106A in complex with peptidomimetic inhibitor
7BGU	;	2.433	;	Mason-Pfizer Monkey Virus Protease mutant C7A/D26N/C106A in complex with peptidomimetic inhibitor
6XL3	;	2.33	;	Mastigocladopsis repens rhodopsin chloride pump
1AKH	;	2.5	;	MAT A1/ALPHA2/DNA TERNARY COMPLEX
7OCK	;	3.6	;	MAT in complex with SAMH
1K61	;	2.1	;	MATALPHA2 HOMEODOMAIN BOUND TO DNA
6HKE	;	2.11	;	MatC (Rpa3494) from Rhodopseudomonas palustris with bound malate
7Z6S	;	2.9	;	MATCAP bound to a human 14 protofilament microtubule
4Z3P	;	3.3	;	MATE transporter ClbM in complex with Rb+
4HUL	;	3.81	;	MATE transporter NorM-NG in complex with Cs+ and monobody
4HUM	;	3.49	;	MATE transporter NorM-NG in complex with ethidium and monobody
4HUN	;	3.59	;	MATE transporter NorM-NG in complex with R6G and monobody
4HUK	;	3.59	;	MATE transporter NorM-NG in complex with TPP and monobody
1MMP	;	2.3	;	MATRILYSIN COMPLEXED WITH CARBOXYLATE INHIBITOR
1MMQ	;	1.9	;	MATRILYSIN COMPLEXED WITH HYDROXAMATE INHIBITOR
1MMR	;	2.4	;	MATRILYSIN COMPLEXED WITH SULFODIIMINE INHIBITOR
6T9T	;	1.69	;	Matriptase in complex with the synthetic inhibitor (S)-3-(3-(4-(3-(tert-butyl)ureido)piperidin-1-yl)-2-((3'-fluoro-4'-(hydroxymethyl)-[1,1'-biphenyl])-3-sulfonamido)-3-oxopropyl)benzimidamide (MI-1904)
7VB7	;	2.4	;	Matrix arm of active state CI from DQ-NADH dataset
7VYN	;	2.4	;	Matrix arm of active state CI from Q1-NADH dataset
7VXP	;	2.7	;	Matrix arm of active state CI from Q10 dataset
7VY8	;	2.6	;	Matrix arm of active state CI from Q10-NADH dataset
7VYF	;	2.8	;	Matrix arm of active state CI from Rotenone dataset
7VBZ	;	2.4	;	Matrix arm of active state CI from Rotenone-NADH dataset
7VBN	;	2.4	;	Matrix arm of deactive state CI from DQ-NADH dataset
7VZ1	;	2.5	;	Matrix arm of deactive state CI from Q1-NADH dataset
7VXU	;	2.8	;	Matrix arm of deactive state CI from Q10 dataset
7VYA	;	2.8	;	Matrix arm of deactive state CI from Q10-NADH dataset
7VYH	;	2.9	;	Matrix arm of deactive state CI from Rotenone dataset
7VWJ	;	2.6	;	Matrix arm of deactive state CI from rotenone-NADH dataset
1XUC	;	1.7	;	Matrix metalloproteinase-13 complexed with non-zinc binding inhibitor
1XUD	;	1.8	;	Matrix metalloproteinase-13 complexed with non-zinc binding inhibitor
1XUR	;	1.85	;	Matrix metalloproteinase-13 complexed with non-zinc binding inhibitor
5UWM	;	1.62	;	Matrix metalloproteinase-13 complexed with selective inhibitor compound (R)-17a
5UWK	;	1.6	;	Matrix metalloproteinase-13 complexed with selective inhibitor compound (S)-10a
5UWL	;	2.55	;	Matrix metalloproteinase-13 complexed with selective inhibitor compound (S)-17a
5UWN	;	3.2	;	Matrix metalloproteinase-13 complexed with selective inhibitor compound 10d
4L19	;	1.66	;	Matrix metalloproteinase-13 complexed with selective inhibitor compound Q1
5WCO	;	2.604	;	Matrix Protein (M1) of Infectious Salmon Anaemia Virus
8B2M	;	1.7	;	Matrix-metallopeptidase inhibitor Potempin A (PotA) from Tannerella forsythia
8B2Q	;	1.35	;	Matrix-metallopeptidase inhibitor Potempin A (PotA) from Tannerella forsythia in complex with T. forsythia karilysin.
8BH6	;	3.7	;	Mature 30S ribosomal subunit from Staphylococcus aureus
7BV8	;	3.14	;	Mature 50S ribosomal subunit from RrmJ knock out E.coli strain
1SEV	;	2.55	;	Mature and translocatable forms of glyoxysomal malate dehydrogenase have different activities and stabilities but similar crystal structures
1SMK	;	2.5	;	Mature and translocatable forms of glyoxysomal malate dehydrogenase have different activities and stabilities but similar crystal structures
7BOX	;	3.8	;	Mature bacteriorphage t7 tail adaptor protein gp11
7BOY	;	3.8	;	Mature bacteriorphage t7 tail nozzle protein gp12
7OZ4	;	3.9	;	Mature capsid of bacteriophage phiRSA1
3H1P	;	2.61	;	Mature Caspase-7 I213A with DEVD-CHO inhibitor bound to active site
7PTL	;	4.9	;	Mature conformer of a 6-helix bundle of RNA with clasp
7ESD	;	3.9	;	Mature Donggang virus
7OVR	;	7.0	;	Mature HIV-1 matrix structure
1EKG	;	1.8	;	MATURE HUMAN FRATAXIN
3FCT	;	2.4	;	MATURE METAL CHELATASE CATALYTIC ANTIBODY WITH HAPTEN
6HWX	;	7.2	;	Mature MLV capsid hexamer structure in intact virus particles
6HWY	;	8.6	;	Mature MLV capsid pentamer structure in intact virus particles
4PH2	;	1.44	;	mature N-terminal domain of capsid protein from bovine leukemia virus
1AXS	;	2.6	;	MATURE OXY-COPE CATALYTIC ANTIBODY WITH HAPTEN
6TJL	;	1.87	;	Mature primitive pytochelatin synthase Alr0975 from Nostoc species bound to glutathione
2QZ0	;	1.2	;	Mature Q183E variant of Green Fluorescent Protein Chromophore
2AWL	;	1.85	;	Mature R96K GFP mutant
6XUO	;	2.803	;	mature recombinant horse NGF
8XOW	;	3.32	;	Mature virion portal of bacteriophage lambda
8XPM	;	3.9	;	Mature virion portal of phage lambda with DNA
8XQB	;	4.07	;	Mature virion portal vertex of bacteriophage lambda
1C6W	;		;	MAUROCALCIN FROM SCORPIO MAURUS
2KQL	;		;	Maurocalcine in D configuration from Scorpio maurus palmatus
7BXH	;	2.7	;	MavC-Lpg2149 complex
7BXG	;	2.705	;	MavC-UBE2N-Ub complex
2N1E	;		;	MAX1 peptide fibril
6W2U	;	4.8	;	Mayaro Virus glycoprotein E1 ectodomain and glycoportien E2 ectodomain asymmetric unit
1MVF	;	1.65	;	MazE addiction antidote
4MZM	;	2.1	;	MazF from S. aureus crystal form I, P212121, 2.1 A
4MZT	;	2.303	;	MazF from S. aureus crystal form II, C2221, 2.3 A
4MZP	;	2.702	;	MazF from S. aureus crystal form III, C2221, 2.7 A
7YH5	;	2.7	;	MazG(Mycobacterium tuberculosis)
6SM5	;	2.75	;	MbC/SHP1-C-SH2 complex
6C1Y	;	2.3	;	mbd of human mecp2 in complex with methylated DNA
6C1U	;	2.3	;	MBD2 in complex with a deoxy-oligonucleotide
6C1T	;	1.84	;	MBD2 in complex with a partially methylated DNA
6C1V	;	2.3	;	MBD2 in complex with double-stranded DNA
6C1A	;	2.05	;	MBD2 in complex with methylated DNA
6C2F	;	2.65	;	MBD2 in complex with methylated DNA
6CNQ	;	2.151	;	MBD2 in complex with methylated DNA
6CEU	;	2.005	;	MBD3 MBD in complex with methylated, non-palindromic CpG DNA: alternative interpretation of crystallographic data
6CEV	;	2.005	;	MBD3 MBD in complex with methylated, non-palindromic CpG DNA: alternative interpretation of crystallographic data
7XEO	;	2.89	;	MbetaCD treated state of mTRPV2
6ZVI	;	3.0	;	Mbf1-ribosome complex
5Z1Y	;		;	mBjAMP1 structure
4AQB	;	4.2	;	MBL-Ficolin Associated Protein-1, MAP-1 aka MAP44
7DZ9	;	2.2	;	MbnABC complex
7L6G	;	2.04	;	MbnP from Methylosinus trichosporium
5JST	;	2.199	;	MBP fused MDV1 coiled coil
4PE2	;	1.724	;	MBP PilA1 CD160
4EDQ	;	1.641	;	MBP-fusion protein of myosin-binding protein c residues 149-269
4TSM	;	1.899	;	MBP-fusion protein of PilA1 from C. difficile R20291 residues 26-166
4OGM	;	2.234	;	MBP-fusion protein of PilA1 residues 26-159
3OB4	;	2.706	;	MBP-fusion protein of the major peanut allergen Ara h 2
6N84	;	1.75	;	MBP-fusion protein of transducin-alpha residues 327-350
1NMU	;	2.31	;	MBP-L30
5E7U	;	2.8	;	MBP-MamC loop structure, a magnetite biomineralizing protein from Magnetospirillium magneticum AMB-1
5I69	;	2.7	;	MBP-MamC magnetite-interaction component mutant-D70A
8SVY	;	1.47	;	MBP-Mcl1 in complex with ligand 10
8G3S	;	1.4	;	MBP-Mcl1 in complex with ligand 11
8G3T	;	1.83	;	MBP-Mcl1 in complex with ligand 12
8G3U	;	1.94	;	MBP-Mcl1 in complex with ligand 21
8G3W	;	1.78	;	MBP-Mcl1 in complex with ligand 28
8G3X	;	1.46	;	MBP-Mcl1 in complex with ligand 32
8G3Y	;	1.7	;	MBP-Mcl1 in complex with ligand 34
1MB1	;	2.1	;	MBP1 FROM SACCHAROMYCES CEREVISIAE
6NFX	;	1.95	;	MBTD1 MBT repeats
5ENO	;	2.2	;	MBX2319 bound structure of bacterial efflux pump.
5ENP	;	1.9	;	MBX2931 bound structure of bacterial efflux pump.
5ENQ	;	1.8	;	MBX3132 bound structure of bacterial efflux pump.
5ENR	;	2.3	;	MBX3135 bound structure of bacterial efflux pump.
6ZZC	;	2.93	;	MB_CRS6-1 bound to CrSAS-6_6HR
6ZZG	;	2.93	;	MB_CRS6-1 bound to CrSAS-6_N
6ZZD	;	2.05	;	MB_CRS6-13 bound to CrSAS-6_N
6ZZ8	;	3.73	;	MB_CRS6-15 bound to CrSAS-6_6HR
4OJ0	;	1.7	;	mCardinal V218E
6ISA	;	2.0	;	mCD226
4UNU	;	0.95	;	MCG - a dimer of lambda variable domains
5ACM	;	1.05	;	Mcg immunoglobulin variable domain with methylene blue
5ACL	;	1.49	;	Mcg immunoglobulin variable domain with sulfasalazine
1DCL	;	2.3	;	MCG, A LAMBDA V TYPE LIGHT-CHAIN DIMER (BENCE-JONES PROTEIN), CRYSTALLIZED FROM AMMONIUM SULFATE
7BUQ	;	3.091	;	mcGAS bound with 23-cGAMP
7BUM	;	3.047	;	mcGAS bound with pGpA
7BUJ	;	2.13	;	mcGAS bound with pppGpG
1NAN	;	2.3	;	MCH CLASS I H-2KB MOLECULE COMPLEXED WITH PBM1 PEPTIDE
6YLM	;	1.6	;	mCherry
6MZ3	;	1.088	;	mCherry pH sensitive mutant - M66T (mCherryTYG)
8IM1	;	2.05	;	mCherry-LaM1 complex
8ILX	;	3.29	;	mCherry-LaM3 complex
8IM0	;	1.31	;	mCherry-LaM8 complex
4BPI	;	1.982	;	Mcl-1 bound to alpha beta Puma BH3 peptide 2
4BPJ	;	1.599	;	Mcl-1 bound to alpha beta Puma BH3 peptide 3
6U63	;	2.75	;	Mcl-1 bound to compound 17
6U64	;	2.55	;	Mcl-1 bound to compound 17
6U65	;	2.09	;	Mcl-1 bound to compound 19
6U67	;	1.84	;	Mcl-1 bound to compound 24
3KZ0	;	2.349	;	MCL-1 complex with MCL-1-specific selected peptide
5C6H	;	2.05	;	Mcl-1 complexed with Mule
5FC4	;	1.5	;	Mcl-1 complexed with small molecule inhibitor
5FDO	;	2.8	;	Mcl-1 complexed with small molecule inhibitor
5FDR	;	2.6	;	Mcl-1 complexed with small molecule inhibitor
4ZBF	;	2.2	;	Mcl-1 complexed with small molecules
4ZBI	;	2.5	;	Mcl-1 complexed with small molecules
6BW2	;	2.75	;	Mcl-1 complexed with small molecules
6BW8	;	2.9	;	Mcl-1 complexed with small molecules
4G35	;	2.0	;	Mcl-1 in complex with a biphenyl cross-linked Noxa peptide.
3KJ2	;	2.351	;	Mcl-1 in complex with Bim BH3 mutant F4aE
3KJ1	;	1.945	;	Mcl-1 in complex with Bim BH3 mutant I2dA
3KJ0	;	1.7	;	Mcl-1 in complex with Bim BH3 mutant I2dY
5VX2	;	1.851	;	Mcl-1 in complex with Bim-h3Pc-RT
5MEV	;	2.94	;	MCL1 FAB COMPLEX IN COMPLEX WITH COMPOUND 21
5MES	;	2.24	;	MCL1 FAB COMPLEX IN COMPLEX WITH COMPOUND 29
6QB6	;	2.24	;	Mcl1 in complex with a Fab
6FS1	;	1.6	;	MCL1 in complex with an indole acid ligand
6FS2	;	2.55	;	MCL1 in complex with indole acid ligand
6QB4	;	2.38	;	Mcl1-scFv complex with an indole acid inhibitor
8X7U	;	3.57	;	MCM in complex with dsDNA in presence of ATP.
8X7T	;	3.26	;	MCM in the Apo state.
4POG	;	3.203	;	MCM-ssDNA co-crystal structure
2KWQ	;		;	Mcm10 C-terminal DNA binding domain
4UUZ	;	2.9	;	MCM2-histone complex
5L7E	;	1.86	;	MCR IN COMPLEX WITH ligand
5L7G	;	2.01	;	MCR IN COMPLEX WITH ligand
5L7H	;	1.84	;	MCR IN COMPLEX WITH ligand
5YLF	;	1.5	;	MCR-1 complex with D-glucose
5YLE	;	1.85	;	MCR-1 complex with ethanolamine (ETA)
8GF5	;	3.0	;	McrD binds asymmetrically to methyl-coenzyme M reductase improving active site accessibility during assembly
1U60	;	1.61	;	MCSG APC5046 Probable glutaminase ybaS
6XJV	;	4.17	;	MCU holocomplex in High-calcium state
6XJX	;	4.6	;	MCU holocomplex in Low-calcium blocking state
6X4S	;	3.5	;	MCU-EMRE complex of a metazoan mitochondrial calcium uniporter
8AIN	;	2.7	;	MCUGI SAUNG complex
5MIZ	;		;	MD ensemble of bovine insulin
7DNI	;	3.2	;	MDA5 CARDs-MAVS CARD polyUb complex
4Z7X	;	1.55	;	MdbA protein, a thiol-disulfide oxidoreductase from Actinomyces oris.
5C00	;	1.77	;	MdbA protein, a thiol-disulfide oxidoreductase from Corynebacterium diphtheriae
6BO0	;	1.2	;	MdbA protein, a thiol-disulfide oxidoreductase from Corynebacterium matruchotii
6E2T	;	1.692	;	MDDEF in complex with MVAPP
6E2W	;	1.95	;	MDDEF in complex with MVAPP, ADP, sulfate and cobalt
6E2Y	;	2.34	;	MDDEF in complex with MVAPP, ADP, sulfate and cobalt. Anomalous data
6E2V	;	2.1	;	MDDEF in complex with MVAPP, ADPBeF3 and magnesium
6E2U	;	2.05	;	MDDEF in complex with MVAPP, AMPPCP and Magnesium
6EUQ	;	2.2	;	MdfA(Q131R/L339E)
3JBI	;	8.5	;	MDFF model of the vinculin tail domain bound to F-actin
5ZI3	;	2.1	;	MDH3 wild type, apo-form
5ZI2	;	2.0	;	MDH3 wild type, nad-form
5ZI4	;	2.1	;	MDH3 wild type, nad-oaa-form
5H55	;	3.5	;	Mdm12 from K. lactis
5H5A	;	2.26	;	Mdm12 from K. lactis (1-239), Lys residues are uniformly dimethyl modified
5H5C	;	3.31	;	Mdm12 from K. lactis (1-239), uniformly Lys dimethyl modified, crystallized in FOS-MEA-10
5H54	;	3.1	;	Mdm12 from K. lactis 1-239
6IM9	;	3.3	;	MDM2 bound CueO-PM2 sensor
1YCR	;	2.6	;	MDM2 BOUND TO THE TRANSACTIVATION DOMAIN OF P53
6AAW	;	2.0	;	Mdm2 in complex with a D amino Acid Containing Stapled Peptide
2GV2	;	1.8	;	MDM2 in complex with an 8-mer p53 peptide analogue
5TRF	;	2.1	;	MDM2 in complex with SAR405838
3SKQ	;	2.1	;	Mdm38 is a 14-3-3-like receptor and associates with the protein synthesis machinery at the inner mitochondrial membrane
2N0U	;		;	Mdmx-057
2N14	;		;	Mdmx-295
2N06	;		;	Mdmx-298
2MWY	;		;	Mdmx-p53
2N0W	;		;	Mdmx-SJ212
4GYE	;	2.27	;	MDR 769 HIV-1 Protease in Complex with Reduced P1F
3OUD	;	1.8	;	MDR769 HIV-1 protease complexed with CA/p2 hepta-peptide
3OTS	;	1.7	;	MDR769 HIV-1 protease complexed with MA/CA hepta-peptide
3OUB	;	1.6	;	MDR769 HIV-1 protease complexed with NC/p1 hepta-peptide
3OUA	;	1.7	;	MDR769 HIV-1 protease complexed with p1/p6 hepta-peptide
3OUC	;	2.0	;	MDR769 HIV-1 protease complexed with p2/NC hepta-peptide
3OU3	;	1.7	;	MDR769 HIV-1 protease complexed with PR/RT hepta-peptide
3OU1	;	1.8	;	MDR769 HIV-1 protease complexed with RH/IN hepta-peptide
3OTY	;	1.75	;	MDR769 HIV-1 protease complexed with RT/RH hepta-peptide
3OU4	;	1.6	;	MDR769 HIV-1 protease complexed with TF/PR hepta-peptide
3DNV	;	2.68	;	MDT Protein
2XU6	;	2.7	;	MDV1 coiled coil domain
8DPB	;	2.72	;	MeaB in complex with the cobalamin-binding domain of its target mutase with GMPPCP bound
2QM7	;	1.85	;	MeaB, A Bacterial Homolog of MMAA, Bound to GDP
4LC1	;	1.8	;	MeaB, A Bacterial Homolog of MMAA, Bound to GDP and crystallized in the presence of GDP and [AlF4]-
4JYB	;	2.1	;	MeaB, A Bacterial Homolog of MMAA, Bound to GMPPNP
4JYC	;	2.2	;	MeaB, A Bacterial Homolog of MMAA, in its Apo form
2QM8	;	1.7	;	MeaB, A Bacterial Homolog of MMAA, in the Nucleotide Free Form
6HTL	;	2.3	;	Measles Phosphoprotein Coiled-Coil Domain IPKI Variant
4BHV	;	2.1	;	Measles virus phosphoprotein tetramerization domain
4C5Q	;	2.2	;	measles virus phosphoprotein tetramerization domain
2I3V	;	2.4	;	Measurement of conformational changes accompanying desensitization in an ionotropic glutamate receptor: Structure of G725C mutant
2I3W	;	2.3	;	Measurement of conformational changes accompanying desensitization in an ionotropic glutamate receptor: Structure of S729C mutant
6DG0	;	2.457	;	MEC-8 C-terminal RRM domain bound to AGCACA
5TKZ	;	1.529	;	MEC-8 N-terminal RRM bound to tandem GCAC ligand
6Z2W	;	2.82	;	Mec1-Ddc2 (F2244L mutant) in complex with Mg AMP-PNP
6Z2X	;	3.2	;	Mec1-Ddc2 (F2244L mutant) in complex with Mg AMP-PNP (State II)
6Z3A	;	3.8	;	Mec1-Ddc2 (wild-type) in complex with AMP-PNP
3QOB	;	1.6	;	Mechanical Coupling Controls Cooperative Ligand Binding in a Homodimeric Hemoglobin
1XLA	;	2.3	;	MECHANISM FOR ALDOSE-KETOSE INTERCONVERSION BY D-XYLOSE ISOMERASE INVOLVING RING OPENING FOLLOWED BY A 1,2-HYDRIDE SHIFT
1XLB	;	2.5	;	MECHANISM FOR ALDOSE-KETOSE INTERCONVERSION BY D-XYLOSE ISOMERASE INVOLVING RING OPENING FOLLOWED BY A 1,2-HYDRIDE SHIFT
1XLC	;	2.5	;	MECHANISM FOR ALDOSE-KETOSE INTERCONVERSION BY D-XYLOSE ISOMERASE INVOLVING RING OPENING FOLLOWED BY A 1,2-HYDRIDE SHIFT
1XLD	;	2.5	;	MECHANISM FOR ALDOSE-KETOSE INTERCONVERSION BY D-XYLOSE ISOMERASE INVOLVING RING OPENING FOLLOWED BY A 1,2-HYDRIDE SHIFT
1XLE	;	2.5	;	MECHANISM FOR ALDOSE-KETOSE INTERCONVERSION BY D-XYLOSE ISOMERASE INVOLVING RING OPENING FOLLOWED BY A 1,2-HYDRIDE SHIFT
1XLF	;	2.5	;	MECHANISM FOR ALDOSE-KETOSE INTERCONVERSION BY D-XYLOSE ISOMERASE INVOLVING RING OPENING FOLLOWED BY A 1,2-HYDRIDE SHIFT
1XLG	;	2.5	;	MECHANISM FOR ALDOSE-KETOSE INTERCONVERSION BY D-XYLOSE ISOMERASE INVOLVING RING OPENING FOLLOWED BY A 1,2-HYDRIDE SHIFT
1XLH	;	2.5	;	MECHANISM FOR ALDOSE-KETOSE INTERCONVERSION BY D-XYLOSE ISOMERASE INVOLVING RING OPENING FOLLOWED BY A 1,2-HYDRIDE SHIFT
1XLI	;	2.5	;	MECHANISM FOR ALDOSE-KETOSE INTERCONVERSION BY D-XYLOSE ISOMERASE INVOLVING RING OPENING FOLLOWED BY A 1,2-HYDRIDE SHIFT
1XLJ	;	2.5	;	MECHANISM FOR ALDOSE-KETOSE INTERCONVERSION BY D-XYLOSE ISOMERASE INVOLVING RING OPENING FOLLOWED BY A 1,2-HYDRIDE SHIFT
1XLK	;	2.5	;	MECHANISM FOR ALDOSE-KETOSE INTERCONVERSION BY D-XYLOSE ISOMERASE INVOLVING RING OPENING FOLLOWED BY A 1,2-HYDRIDE SHIFT
1XLL	;	2.5	;	MECHANISM FOR ALDOSE-KETOSE INTERCONVERSION BY D-XYLOSE ISOMERASE INVOLVING RING OPENING FOLLOWED BY A 1,2-HYDRIDE SHIFT
6PCO	;	2.75	;	Mechanism for regulation of DNA binding of Bordetella bronchiseptica BpsR by 6-hydroxynicotinic acid
6PCP	;	3.2	;	Mechanism for regulation of DNA binding of Bordetella bronchiseptica BpsR by 6-hydroxynicotinic acid
2KSP	;		;	Mechanism for the selective interaction of C-terminal EH-domain proteins with specific NPF-containing partners
7CCF	;	2.8	;	Mechanism insights on steroselective oxidation of phosphorylated ethylphenols with cytochrome P450 CreJ
3PJS	;	3.8	;	Mechanism of Activation Gating in the Full-Length KcsA K+ Channel
5SVB	;	2.645	;	Mechanism of ATP-Dependent Acetone Carboxylation, Acetone Carboxylase AMP bound structure
5SVC	;	2.7	;	Mechanism of ATP-Dependent Acetone Carboxylation, Acetone Carboxylase nucleotide-free structure
2BFX	;	1.8	;	Mechanism of Aurora-B activation by INCENP and inhibition by Hesperadin.
2P1O	;	1.9	;	Mechanism of Auxin Perception by the TIR1 ubiquitin ligase
2P1P	;	2.21	;	Mechanism of Auxin Perception by the TIR1 ubiquitin ligase
2P1Q	;	1.91	;	Mechanism of Auxin Perception by the TIR1 ubiquitin ligase
2P1N	;	2.5	;	Mechanism of Auxin Perception by the TIR1 Ubiqutin Ligase
1SZ1	;	6.21	;	Mechanism of CCA-adding enzymes specificity revealed by crystal structures of ternary complexes
2CJM	;	2.3	;	Mechanism of CDK inhibition by active site phosphorylation: CDK2 Y15p T160p in complex with cyclin A structure
6DZU	;	3.3	;	Mechanism of cellular recognition by PCV2
6E2R	;	2.8	;	Mechanism of cellular recognition by PCV2
6E2X	;	3.5	;	Mechanism of cellular recognition by PCV2
6E2Z	;	3.4	;	Mechanism of cellular recognition by PCV2
6E30	;	3.5	;	Mechanism of cellular recognition by PCV2
4HTM	;	2.0	;	Mechanism of CREB Recognition and Coactivation by the CREB Regulated Transcriptional Coactivator CRTC2
2F3B	;	1.8	;	Mechanism of displacement of a catalytically essential loop from the active site of fructose-1,6-bisphosphatase
2F3D	;	1.83	;	Mechanism of displacement of a catalytically essential loop from the active site of fructose-1,6-bisphosphatase
5AN9	;	3.3	;	Mechanism of eIF6 release from the nascent 60S ribosomal subunit
5ANB	;	4.1	;	Mechanism of eIF6 release from the nascent 60S ribosomal subunit
5ANC	;	4.2	;	Mechanism of eIF6 release from the nascent 60S ribosomal subunit
6QKL	;	3.3	;	Mechanism of eIF6 release from the nascent 60S ribosomal subunit
2X7N	;	11.8	;	Mechanism of eIF6s anti-association activity
7ENL	;	2.2	;	MECHANISM OF ENOLASE: THE CRYSTAL STRUCTURE OF ENOLASE-MG2+-PHOSPHOGLYCERATE(SLASH) PHOSPHOENOLPYRUVATE COMPLEX AT 2.2-ANGSTROMS RESOLUTION
4CAD	;	2.5	;	Mechanism of farnesylated CAAX protein processing by the integral membrane protease Rce1
1BI7	;	3.4	;	MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURE OF THE CDK6-P16INK4A TUMOR SUPPRESSOR COMPLEX
1BI8	;	2.8	;	MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURES CDK6-P19INK4D INHIBITOR COMPLEX
3CMT	;	3.15	;	Mechanism of homologous recombination from the RecA-ssDNA/dsDNA structures
3CMU	;	4.2	;	Mechanism of homologous recombination from the RecA-ssDNA/dsDNA structures
3CMV	;	4.3	;	Mechanism of homologous recombination from the RecA-ssDNA/dsDNA structures
3CMW	;	2.8	;	Mechanism of homologous recombination from the RecA-ssDNA/dsDNA structures
3CMX	;	3.4	;	Mechanism of homologous recombination from the RecA-ssDNA/dsDNA structures
1C82	;	1.7	;	MECHANISM OF HYALURONAN BINDING AND DEGRADATION: STRUCTURE OF STREPTOCOCCUS PNEUMONIAE HYALURONATE LYASE IN COMPLEX WITH HYALURONIC ACID DISACCHARIDE AT 1.7 A RESOLUTION
5A4M	;	1.7	;	Mechanism of Hydrogen activation by NiFe-hydrogenases
3PA9	;	1.7	;	Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5
3PAA	;	1.9	;	Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0
1HDC	;	2.2	;	MECHANISM OF INHIBITION OF 3ALPHA,20BETA-HYDROXYSTEROID DEHYDROGENASE BY A LICORICE-DERIVED STEROIDAL INHIBITOR
1RTJ	;	2.35	;	MECHANISM OF INHIBITION OF HIV-1 REVERSE TRANSCRIPTASE BY NON-NUCLEOSIDE INHIBITORS
5M50	;	5.3	;	Mechanism of microtubule minus-end recognition and protection by CAMSAP proteins
5M54	;	8.0	;	Mechanism of microtubule minus-end recognition and protection by CAMSAP proteins
5M5C	;	4.8	;	Mechanism of microtubule minus-end recognition and protection by CAMSAP proteins
1THA	;	2.0	;	MECHANISM OF MOLECULAR RECOGNITION. STRUCTURAL ASPECTS OF 3,3'-DIIODO-L-THYRONINE BINDING TO HUMAN SERUM TRANSTHYRETIN
2V55	;	3.705	;	Mechanism of multi-site phosphorylation from a ROCK-I:RhoE complex structure
7E40	;	2.6	;	Mechanism of Phosphate Sensing and Signaling Revealed by Rice SPX1-PHR2 Complex Structure
1NSP	;	2.1	;	MECHANISM OF PHOSPHATE TRANSFER BY NUCLEOSIDE DIPHOSPHATE KINASE: X-RAY STRUCTURES OF A PHOSPHO-HISTIDINE INTERMEDIATE OF THE ENZYMES FROM DROSOPHILA AND DICTYOSTELIUM
1NSQ	;	2.18	;	MECHANISM OF PHOSPHATE TRANSFER BY NUCLEOSIDE DIPHOSPHATE KINASE: X-RAY STRUCTURES OF A PHOSPHO-HISTIDINE INTERMEDIATE OF THE ENZYMES FROM DROSOPHILA AND DICTYOSTELIUM
1JQL	;	2.5	;	Mechanism of Processivity Clamp Opening by the Delta Subunit Wrench of the Clamp Loader Complex of E. coli DNA Polymerase III: Structure of beta-delta (1-140)
1JQJ	;	2.9	;	Mechanism of Processivity Clamp Opening by the Delta Subunit Wrench of the Clamp Loader Complex of E. coli DNA Polymerase III: Structure of the beta-delta complex
6MDW	;	1.5	;	Mechanism of protease dependent DPC repair
6MDX	;	1.55	;	Mechanism of protease dependent DPC repair
1TQE	;	2.7	;	Mechanism of recruitment of class II histone deacetylases by myocyte enhancer factor-2
8DOL	;	2.8	;	Mechanism of regulation of the Helicobacter pylori Cagbeta ATPase by CagZ
6XWM	;	2.6	;	Mechanism of substrate release in neurotransmitter:sodium symporters: the structure of LeuT in an inward-facing occluded conformation
3PMH	;	3.2	;	Mechanism of Sulfotyrosine-Mediated Glycoprotein Ib Interaction with Two Distinct alpha-Thrombin Sites
2IMW	;	2.05	;	Mechanism of Template-Independent Nucleotide Incorporation Catalyzed by a Template-Dependent DNA Polymerase
1WA3	;	1.9	;	Mechanism of the Class I KDPG aldolase
2C0A	;	1.55	;	Mechanism of the Class I KDPG aldolase
2MNR	;	1.9	;	MECHANISM OF THE REACTION CATALYZED BY MANDELATE RACEMASE. 2. CRYSTAL STRUCTURE OF MANDELATE RACEMASE AT 2.5 ANGSTROMS RESOLUTION: IDENTIFICATION OF THE ACTIVE SITE AND POSSIBLE CATALYTIC RESIDUES
4O9T	;	3.079	;	Mechanism of transhydrogenase coupling proton translocation and hydride transfer
4O9U	;	6.926	;	Mechanism of transhydrogenase coupling proton translocation and hydride transfer
1P3Q	;	1.7	;	Mechanism of Ubiquitin Recognition by the CUE Domain of VPS9
2YLM	;	2.7	;	Mechanism of USP7 (HAUSP) activation by its C-terminal ubiquitin-like domain (HUBL) and allosteric regulation by GMP-synthetase.
4CI6	;	2.651	;	Mechanisms of crippling actin-dependent phagocytosis by YopO
2AD5	;	2.8	;	Mechanisms of feedback regulation and drug resistance of CTP synthetases: structure of the E. coli CTPS/CTP complex at 2.8-Angstrom resolution.
8BRD	;	2.48	;	Mechanisms of ion selectivity and rotor coupling in the bacterial flagellar sodium-driven stator unit
4U6V	;	2.56	;	Mechanisms of Neutralization of a Human Anti-Alpha Toxin Antibody
6BBM	;	4.1	;	Mechanisms of Opening and Closing of the Bacterial Replicative Helicase: The DnaB Helicase and Lambda P Helicase Loader Complex
4XTA	;	2.5	;	MECHANISMS OF PPARgamma ACTIVATION BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
3JBU	;	3.64	;	Mechanisms of Ribosome Stalling by SecM at Multiple Elongation Steps
3JBV	;	3.32	;	Mechanisms of Ribosome Stalling by SecM at Multiple Elongation Steps
1KBB	;	1.9	;	Mechanistic Analyses of Catalysis in Human Pancreatic alpha-Amylase: Detailed Kinetic and Structural Studies of Mutants of Three Conserved Carboxylic Acids
1KBK	;	1.9	;	Mechanistic Analyses of Catalysis in Human Pancreatic Alpha-Amylase: Detailed Kinetic and Structural Studies of Mutants of Three Conserved Carboxylic Acids
2REH	;	2.4	;	Mechanistic and Structural Analyses of the Roles of Arg409 and Asp402 in the Reaction of the Flavoprotein Nitroalkane Oxidase
2ZAF	;	2.5	;	Mechanistic and Structural Analyses of the Roles of Arg409 and Asp402 in the Reaction of the Flavoprotein Nitroalkane Oxidase
5IAT	;	1.67	;	Mechanistic and Structural Analysis of Substrate Recognition and Cofactor Binding by an Unusual Bacterial Prolyl Hydroxylase - apo-BaP4H
5IAV	;	1.7	;	Mechanistic and Structural Analysis of Substrate Recognition and Cofactor Binding by an Unusual Bacterial Prolyl Hydroxylase - Co-BaP4H-MLI
5IAX	;	2.1	;	Mechanistic and Structural Analysis of Substrate Recognition and Cofactor Binding by an Unusual Bacterial Prolyl Hydroxylase - Co-BaP4H-PPG
2OZ0	;	2.8	;	Mechanistic and Structural Studies of H373Q Flavocytochrome b2: Effects of Mutating the Active Site Base
4HVA	;	2.074	;	Mechanistic and Structural Understanding of Uncompetitive Inhibitors of Caspase-6
1E8D	;	2.2	;	MECHANISTIC ASPECTS OF CYANOGENESIS FROM ACTIVE SITE MUTANT SER80ALA OF HYDROXYNITRILE LYASE FROM MANIHOT ESCULENTA IN COMPLEX WITH ACETONE CYANOHYDRIN
4QPO	;	1.999	;	Mechanistic basis of plasmid-specific DNA binding of the F plasmid regulatory protein, TraM
4QPQ	;	3.106	;	Mechanistic basis of plasmid-specific DNA binding of the F plasmid regulatory protein, TraM
1DBS	;	1.8	;	MECHANISTIC IMPLICATIONS AND FAMILY RELATIONSHIPS FROM THE STRUCTURE OF DETHIOBIOTIN SYNTHETASE
4M4W	;	6.1	;	Mechanistic implications for the bacterial primosome assembly of the structure of a helicase-helicase loader complex
1MML	;	1.8	;	MECHANISTIC IMPLICATIONS FROM THE STRUCTURE OF A CATALYTIC FRAGMENT OF MMLV REVERSE TRANSCRIPTASE
5YEI	;	2.301	;	Mechanistic insight into the regulation of Pseudomonas aeruginosa aspartate kinase
4TL3	;	2.3	;	Mechanistic insights from the crystal structure of an inward proton-transporting Anabaena sensory rhodopsin mutant
4XH3	;	2.1	;	Mechanistic insights into anchorage of the contractile ring from yeast to humans
4XOH	;	2.801	;	Mechanistic insights into anchorage of the contractile ring from yeast to humans
5H5U	;	3.01	;	Mechanistic insights into the alternative translation termination by ArfA and RF2
8VSI	;	3.1	;	Mechanistic Insights Revealed by YbtPQ in the Occluded State
7PKL	;	2.35	;	Mechanistic understanding of antibody masking with anti-idiotypic antibody fragments
7DLU	;	2.5	;	Mechanosensitive channel MscS K180R mutant
7ONL	;	3.9	;	Mechanosensitive channel MscS solubilized with DDM in closed conformation
7OO6	;	3.1	;	Mechanosensitive channel MscS solubilized with DDM in closed conformation with added lipid
7OO0	;	3.1	;	Mechanosensitive channel MscS solubilized with DDM in open conformation
7OO8	;	3.7	;	Mechanosensitive channel MscS solubilized with LMNG in closed conformation with added lipid
7ONJ	;	2.3	;	Mechanosensitive channel MscS solubilized with LMNG in open conformation
7OOA	;	2.7	;	Mechanosensitive channel MscS solubilized with LMNG in open conformation with added lipid
2OAR	;	3.5	;	Mechanosensitive Channel of Large Conductance (MscL)
2OAU	;	3.7	;	Mechanosensitive Channel of Small Conductance (MscS)
6YWW	;	2.102	;	MeCP2 is a microsatellite binding protein that protects CA repeats from nucleosome invasion
5BT2	;	2.2	;	MeCP2 MBD domain (A140V) in complex with methylated DNA
6OGJ	;	1.8	;	MeCP2 MBD in complex with DNA
6OGK	;	1.65	;	MeCP2 MBD in complex with DNA
2IWB	;	1.8	;	MecR1 unbound extracellular antibiotic-sensor domain.
7UIO	;	3.3	;	Mediator-PIC Early (Composite Model)
7UIF	;	4.6	;	Mediator-PIC Early (Core B)
7UIG	;	4.3	;	Mediator-PIC Early (Mediator A)
7UIK	;	7.7	;	Mediator-PIC Early (Tail A + Upstream DNA & Activator)
7UIC	;	3.7	;	Mediator-PIC Early (Tail A)
7UIL	;	4.3	;	Mediator-PIC Early (Tail A/B Dimer)
5SVA	;	15.3	;	Mediator-RNA Polymerase II Pre-Initiation Complex
7RBP	;	2.1	;	Medicago truncatula D-1-piperideine-2-carboxylic acid reductase
8QAV	;	2.23	;	Medicago truncatula HISN5 (IGPD) in complex with MN and IG2
8QAY	;	2.2	;	Medicago truncatula HISN5 (IGPD) in complex with MN, FMT, ACT, CIT, EDO, SO4
8QAX	;	1.69	;	Medicago truncatula HISN5 (IGPD) in complex with MN, FMT, GOL and TRS
8QAW	;	1.55	;	Medicago truncatula HISN5 (IGPD) in complex with MN, IMD, EDO, FMT, GOL and TRS
5U5F	;	1.81	;	MEDITOPE ENABLED TRASTUZUMAB I83E VARIANT IN COMPLEX WITH (Ac) CQFDA(PH)2STRRLRCGGSK
4HJG	;	2.0	;	Meditope-enabled trastuzumab
4IOI	;	1.95	;	Meditope-enabled trastuzumab in complex with CQFDLSTRRLKC
4P13	;	1.73	;	Medium chain acyl-CoA dehydrogenase, K304E mutant
2A9P	;	1.82	;	Medium Resolution BeF3 bound RR02-rec
2V6S	;	2.22	;	Medium resolution crystal structure of pterin-4a-carbinolamine dehydratase from Toxoplasma gondii
4AX8	;	3.0	;	Medium resolution structure of the bifunctional kinase- methyltransferase WbdD
5AFE	;	2.6	;	Medium Resolution structure of the C-terminal family 65 Carbohydrate Binding Module (CBM65B) of endoglucanase Cel5A from Eubacterium cellulosolvens with a bound xyloglucan heptasaccharide (XXXG)
1UDY	;	2.4	;	Medium-Chain Acyl-CoA Dehydrogenase with 3-Thiaoctanoyl-CoA
6BZ1	;	2.97	;	MEF2 Chimera D83V mutant/DNA complex
6BYY	;	2.3	;	MEF2 CHIMERA/DNA Complex
6C9L	;	2.3	;	MEF2B Apo Protein Structure
4U4I	;	2.2	;	Megavirus chilensis superoxide dismutase
8VTT	;	2.45	;	Meis1 homeobox domain bound to neomycin fragment
8VTS	;	1.91	;	Meis1 homeobox domain bound to paromomycin fragment
4U80	;	2.8	;	MEK 1 kinase bound to G799
5HZE	;	2.4	;	Mek1 adopts DFG-out conformation when bound to an analog of E6201.
7XLP	;	2.1	;	MEK1 bound to DS03090629
7XNC	;	2.1	;	MEK1 bound to DS94070624
5EYM	;	2.7	;	MEK1 IN COMPLEX WITH BI 847325
7B9L	;	1.7	;	MEK1 in complex with compound 23
7B7R	;	1.7	;	MEK1 in complex with compound 4
7B3M	;	2.3	;	MEK1 in complex with compound 6
7B94	;	2.0	;	MEK1 in complex with compound 6
7PQV	;	2.13	;	MEK1 IN COMPLEX WITH COMPOUND 7
4U81	;	2.701	;	MEK1 Kinase bound to small molecule inhibitor G659
3DV3	;	2.3	;	MEK1 with PF-04622664 Bound
6WHB	;	1.90032	;	MEKK1 TOG domain (548-867)
1F9B	;	2.7	;	MELANIN PROTEIN INTERACTION: X-RAY STRUCTURE OF THE COMPLEX OF MARE LACTOFERRIN WITH MELANIN MONOMERS
3FU8	;	1.8	;	Melanocarpus albomyces laccase crystal soaked (10 sec) with 2,6-dimethoxyphenol
3FU9	;	2.0	;	Melanocarpus albomyces laccase crystal soaked (20 min) with 2,6-dimethoxyphenol
3FU7	;	1.67	;	Melanocarpus albomyces laccase crystal soaked (4 sec) with 2,6-dimethoxyphenol
7AUE	;	2.97	;	Melanocortin receptor 4 (MC4R) Gs protein complex
4I1S	;	2.293	;	Melanoma differentiation associated protein-5 Helicase domain complex with inhibitor Non-structural protein V
1HJD	;		;	Melanoma inhibitory activity (MIA) protein
1B6B	;	2.5	;	MELATONIN BIOSYNTHESIS: THE STRUCTURE OF SEROTONIN N-ACETYLTRANSFERASE AT 2.5 A RESOLUTION SUGGESTS A CATALYTIC MECHANISM
7VGY	;	3.1	;	Melatonin receptor1-2-Iodomelatonin-Gicomplex
6TR5	;	1.509	;	Melatonin-Notum complex
7YJL	;	4.42	;	Melbournevirus major capsid protein built from 4.4A reconstruction
7N8N	;	3.89	;	Melbournevirus nucleosome like particle
2MLT	;	2.0	;	MELITTIN
5IH8	;	1.85	;	MELK in complex with NVS-MELK1
5IHC	;	2.14	;	MELK in complex with NVS-MELK12B
5K00	;	1.77	;	MELK in complex with NVS-MELK5
5IH9	;	1.79	;	MELK in complex with NVS-MELK8A
5IHA	;	1.96	;	MELK in complex with NVS-MELK8F
7SAD	;	3.96	;	Memantine-bound GluN1a-GluN2B NMDA receptors
5YH1	;	2.18	;	Member of s1p family of ribosomal proteins PF0399 DHH domain
1SAZ	;	2.5	;	Membership in the ASKHA Superfamily: Enzymological Properties and Crystal Structure of Butyrate Kinase 2 from Thermotoga maritima
7VBL	;	2.6	;	Membrane arm of active state CI from DQ-NADH dataset
7VYS	;	2.5	;	Membrane arm of active state CI from Q1-NADH dataset
7VXS	;	2.9	;	Membrane arm of active state CI from Q10 dataset
7VY9	;	2.9	;	Membrane arm of active state CI from Q10-NADH dataset
7VYG	;	2.9	;	Membrane arm of active state CI from rotenone dataset
7VC0	;	2.6	;	Membrane arm of active state CI from Rotenone-NADH dataset
7VBP	;	2.8	;	Membrane arm of deactive state CI from DQ-NADH dataset
7VZ8	;	2.7	;	Membrane arm of deactive state CI from Q1-NADH dataset
7VY1	;	3.3	;	Membrane arm of deactive state CI from Q10 dataset
7VYE	;	3.1	;	Membrane arm of deactive state CI from Q10-NADH dataset
7VYI	;	3.1	;	Membrane arm of deactive state CI from Rotenone dataset
7VWL	;	2.7	;	Membrane arm of deactive state CI from rotenone-NADH dataset
2MLR	;		;	Membrane Bilayer complex with Matrix Metalloproteinase-12 at its Alpha-face
2MLS	;		;	Membrane Bilayer complex with Matrix Metalloproteinase-12 at its Beta-face
4V3A	;	15.0	;	Membrane bound pleurotolysin prepore (TMH1 lock) trapped with engineered disulphide cross-link
4V3M	;	17.0	;	Membrane bound pleurotolysin prepore (TMH2 helix lock) trapped with engineered disulphide cross-link
4V3N	;	14.0	;	Membrane bound pleurotolysin prepore (TMH2 strand lock) trapped with engineered disulphide cross-link
8J8K	;	3.36	;	Membrane bound PRTase, C3 symmetry, acceptor bound
8J8J	;	2.76	;	Membrane bound PRTase, C3 symmetry, donor bound
7R95	;		;	Membrane bound structure of HR1 domain of SARS-CoV-2 spike protein
6ZKB	;	2.9	;	Membrane domain of closed complex I during turnover
6ZKA	;	2.5	;	Membrane domain of open complex I during turnover
1B9U	;		;	MEMBRANE DOMAIN OF THE SUBUNIT B OF THE E.COLI ATP SYNTHASE
4V2T	;	11.0	;	Membrane embedded pleurotolysin pore with 13 fold symmetry
2MOC	;		;	Membrane induced structure of novel human tachykinin Hemokinin-1 (hHK1)
2NOU	;		;	Membrane induced structure of Scyliorhinin I: A Dual NK1/NK2 agonist
2MCE	;		;	Membrane induced structure of the mammalian tachykinin neuropeptide gamma
1FGP	;		;	MEMBRANE PENETRATION DOMAIN OF THE MINOR COAT PROTEIN G3P OF PHAGE FD, NMR, 15 STRUCTURES
6KZO	;	3.3	;	membrane protein
5DIR	;	2.8	;	membrane protein at 2.8 Angstroms
2LEG	;		;	Membrane protein complex DsbB-DsbA structure by joint calculations with solid-state NMR and X-ray experimental data
6PFY	;	2.9	;	Membrane Protein Megahertz Crystallography at the European XFEL, Photosystem I at synchrotron to 2.9 A
6PGK	;	2.9	;	Membrane Protein Megahertz Crystallography at the European XFEL, Photosystem I XFEL at 2.9 A
7B0K	;	3.8	;	membrane protein structure
1DEP	;		;	MEMBRANE PROTEIN, NMR, 1 STRUCTURE
8AP7	;	2.7	;	membrane region of the Trypanosoma brucei mitochondrial ATP synthase dimer
8T4C	;	1.5	;	Membrane-associated thioredoxin oxidoreductase FetE from Campylobacter jejuni
1CFG	;		;	MEMBRANE-BINDING PEPTIDE FROM THE C2 DOMAIN OF FACTOR VIII FORMS AN AMPHIPATHIC STRUCTURE AS DETERMINED BY NMR SPECTROSCOPY
6L8V	;		;	membrane-bound Bax helix2-helix5 domain
1ZY6	;		;	Membrane-bound dimer structure of Protegrin-1 (PG-1), a beta-Hairpin Antimicrobial Peptide in Lipid Bilayers from Rotational-Echo Double-Resonance Solid-State NMR
3J2S	;	15.0	;	Membrane-bound factor VIII light chain
2JBJ	;	2.19	;	membrane-bound glutamate carboxypeptidase II (GCPII) in complex with 2-PMPA (2-phosphonoMethyl-pentanedioic acid)
2C6C	;	2.0	;	membrane-bound glutamate carboxypeptidase II (GCPII) in complex with GPI-18431 (S)-2-(4-iodobenzylphosphonomethyl)-pentanedioic acid
2C6P	;	2.39	;	Membrane-bound glutamate carboxypeptidase II (GCPII) in complex with phosphate anion
2JBK	;	2.99	;	membrane-bound glutamate carboxypeptidase II (GCPII) in complex with quisqualic acid (quisqualate, alpha-amino-3,5-dioxo-1,2,4- oxadiazolidine-2-propanoic acid)
2C6G	;	2.2	;	Membrane-bound glutamate carboxypeptidase II (GCPII) with bound glutamate
2CIJ	;	2.4	;	membrane-bound glutamate carboxypeptidase II (GCPII) with bound methionine
2NAE	;		;	Membrane-bound mouse CD28 cytoplasmic tail
6L8R	;		;	membrane-bound PD-L1-CD
3AYZ	;	1.22	;	Membrane-bound respiratory [NiFe] hydrogenase from Hydrogenovibrio marinus in an air-oxidized condition
3AYX	;	1.18	;	Membrane-bound respiratory [NiFe] hydrogenase from Hydrogenovibrio marinus in an H2-reduced condition
5Y34	;	1.32	;	Membrane-bound respiratory [NiFe]-hydrogenase from Hydrogenovibrio marinus in a ferricyanide-oxidized condition
2KLV	;		;	Membrane-bound structure of the Pf1 major coat protein in DHPC micelle
2XCU	;	2.42	;	Membrane-embedded monofunctional glycosyltransferase WaaA of Aquifex aeolicus, complex with CMP
2XCI	;	2.0	;	Membrane-embedded monofunctional glycosyltransferase WaaA of Aquifex aeolicus, substrate-free form
8AN5	;	1.44	;	MenAT1 toxin-antitoxin complex (rv0078a-rv0078b) from Mycobacterium tuberculosis H37Rv
2MMI	;		;	Mengovirus Leader: Structural Characterization of the Mengovirus Leader Protein Bound to Ran GTPase by Nuclear Magnetic Resonance
6WNH	;	2.1	;	Menin bound to inhibitor M-808
7M4T	;	2.74	;	Menin bound to M-1121
6B41	;	2.61	;	Menin bound to M-525
6E1A	;	3.1	;	Menin bound to M-89
4X5Z	;	1.86	;	menin in complex with MI-136
6BXY	;	1.82	;	Menin in complex with MI-1481
6BY8	;	1.9	;	Menin in complex with MI-1482
5DDC	;	1.62	;	Menin in complex with MI-2-3
5DDF	;	1.66	;	Menin in complex with MI-273
5DDB	;	1.54	;	Menin in complex with MI-319
5DD9	;	1.62	;	Menin in complex with MI-326
5DDA	;	1.83	;	Menin in complex with MI-333
5DB1	;	1.86	;	Menin in complex with MI-336
6O5I	;	1.24026	;	Menin in complex with MI-3454
5DB0	;	1.5	;	Menin in complex with MI-352
5DB2	;	1.54	;	Menin in complex with MI-389
4X5Y	;	1.59	;	Menin in complex with MI-503
5DB3	;	1.71	;	Menin in complex with MI-574
5DDD	;	2.14	;	menin in complex with MI-836
6BXH	;	2.445	;	Menin in complex with MI-853
5DDE	;	1.78	;	Menin in complex with MI-859
6OPJ	;	1.50066	;	Menin in complex with peptide inhibitor 25
4Z3T	;	1.62	;	Meningococcal Factor H binding protein mutant L130R/G133D
8AN4	;	1.65	;	MenT1 toxin (rv0078a) from Mycobacterium tuberculosis H37Rv
6Y5U	;	1.59	;	MenT3 (aka TglT), nucleotidyltransferase toxin Rv1045 from Mycobacterium tuberculosis
6Y56	;	1.23	;	MenT4, nucleotidyltransferase toxin Rv2826c from Mycobacterium tuberculosis H37Rv
5L51	;	2.66	;	Menthone neomenthol reductase from Mentha piperita
5L53	;	2.24	;	Menthone neomenthol reductase from Mentha piperita in complex with NADP
3S05	;	2.204	;	mEos2 Fluorescent Protein-Green Form
6YLS	;	1.55	;	mEos4b - Directionality of Optical Properties of Fluorescent Proteins
1U10	;	2.4	;	MEPA, active form with ZN in P1
1TZP	;	1.4	;	MEPA, inactive form without ZN in P21
7UAI	;	2.8	;	Meprin alpha helix in complex with fetuin-B
4YWO	;	1.62	;	Mercuric reductase from Metallosphaera sedula
4JC6	;	2.152	;	Mercury activation of the plant aquaporin SoPIP2;1 - structural and functional characterization
1HT3	;	1.8	;	MERCURY INDUCED MODIFICATIONS IN THE STEREOCHEMISTRY OF THE ACTIVE SITE THROUGH CYS-73 IN A SERINE PROTEASE: CRYSTAL STRUCTURE OF THE COMPLEX OF A PARTIALLY MODIFIED PROTEINASE K WITH MERCURY AT 1.8 A RESOLUTION
4JKN	;	1.536	;	Mercury Metallated Pseudomonas aeruginosa Azurin at 1.54 A
2WIU	;	2.35	;	Mercury-modified bacterial persistence regulator hipBA
1R0G	;	1.6	;	mercury-substituted rubredoxin
8TUR	;	2.15	;	Merkel Cell Polyomavirus LTA bipartite NLS bound to importin alpha 2
8TUT	;	2.55	;	Merkel Cell Polyomavirus LTA NLSct bound to importin alpha 2
8TUV	;	2.3	;	Merkel Cell Polyomavirus LTA NLSm bound to importin alpha 2
4FMI	;	2.0	;	Merkel cell polyomavirus VP1 in complex with 3'-sialyllactosamine
4FMH	;	1.85	;	Merkel Cell Polyomavirus VP1 in complex with Disialyllactose
4FMJ	;	2.4	;	Merkel cell polyomavirus VP1 in complex with GD1a oligosaccharide
4FMG	;	2.1	;	Merkel Cell Polyomavirus VP1 Unassembled Pentamer
4ZRK	;	2.316	;	Merlin-FERM and Lats1 complex
3TQ2	;	1.1	;	Merohedral twinning in protein crystals revealed a new synthetic three helix bundle motif
3Q82	;	2.1	;	Meropenem acylated BlaR1 sensor domain from Staphylococcus aureus
3DWZ	;	1.8	;	Meropenem Covalent Adduct with TB Beta-lactamase
6ZBE	;	3.3	;	Merozoite surface protein 1 (MSP-1) from Plasmodium falciparum, alternative conformation 1
6ZBD	;	3.21	;	Merozoite surface protein 1 (MSP-1) from Plasmodium falciparum, alternative conformation 2
6ZBF	;	3.2	;	Merozoite surface protein 1 (MSP-1) from Plasmodium falciparum, alternative conformation 3
6ZBG	;	3.2	;	Merozoite surface protein 1 (MSP-1) from Plasmodium falciparum, alternative conformation 4
6ZBH	;	3.6	;	Merozoite surface protein 1 (MSP-1) from Plasmodium falciparum, alternative conformation 5
6ZBC	;	3.1	;	Merozoite surface protein 1 (MSP-1) from Plasmodium falciparum, main conformation
8UYK	;	6.9	;	MERS 5' proximal stem-loop 5, conformation 1
8UYL	;	6.4	;	MERS 5' proximal stem-loop 5, conformation 2
8UYM	;	6.4	;	MERS 5' proximal stem-loop 5, conformation 3
7V5K	;	2.8	;	MERS S ectodomain trimer in complex with neutralizing antibody 0722 (state 1)
7V5J	;	2.8	;	MERS S ectodomain trimer in complex with neutralizing antibody 0722(state 2)
7V6O	;	4.56	;	MERS S ectodomain trimer in complex with neutralizing antibody 111 (state 2)
7V6N	;	3.99	;	MERS S ectodomain trimer in complex with neutralizing antibody 111 state1
7V3L	;	3.47	;	MERS S ectodomain trimer in complex with neutralizing antibody 6516
5W9H	;	4.0	;	MERS S ectodomain trimer in complex with variable domain of neutralizing antibody G4
5W9I	;	3.6	;	MERS S ectodomain trimer in complex with variable domain of neutralizing antibody G4
5W9J	;	4.8	;	MERS S ectodomain trimer in complex with variable domain of neutralizing antibody G4
5W9K	;	4.6	;	MERS S ectodomain trimer in complex with variable domain of neutralizing antibody G4
5W9L	;	4.8	;	MERS S ectodomain trimer in complex with variable domain of neutralizing antibody G4
5W9M	;	4.7	;	MERS S ectodomain trimer in complex with variable domain of neutralizing antibody G4
5W9N	;	5.0	;	MERS S ectodomain trimer in complex with variable domain of neutralizing antibody G4
5W9O	;	4.5	;	MERS S ectodomain trimer in complex with variable domain of neutralizing antibody G4
5W9P	;	4.0	;	MERS S ectodomain trimer in complex with variable domain of neutralizing antibody G4
6PZ8	;	4.19	;	MERS S0 trimer in complex with variable domain of antibody G2
6NB3	;	3.5	;	MERS-CoV complex with human neutralizing LCA60 antibody Fab fragment (state 1)
8PPL	;	2.65	;	MERS-CoV Nsp1 bound to the human 43S pre-initiation complex
8T4S	;	2.6	;	MERS-CoV Nsp1 protein bound to the Human 40S Ribosomal subunit
7M5E	;	2.5	;	MERS-CoV S bound to the broadly neutralizing B6 Fab fragment (C3 refinement)
6NB4	;	3.6	;	MERS-CoV S complex with human neutralizing LCA60 antibody Fab fragment (state 2)
7S3M	;	2.4	;	MERS-CoV S stem helix peptide bound to Fab22
6Q06	;	2.7	;	MERS-CoV S structure in complex with 2,3-sialyl-N-acetyl-lactosamine
6Q07	;	2.9	;	MERS-CoV S structure in complex with 2,6-sialyl-N-acetyl-lactosamine
6Q04	;	2.5	;	MERS-CoV S structure in complex with 5-N-acetyl neuraminic acid
6Q05	;	2.8	;	MERS-CoV S structure in complex with sialyl-lewisX
7X27	;	2.49	;	MERS-CoV spike complex
7X2A	;	2.49	;	MERS-CoV spike complex with S41 neutralizing antibody Fab Class1 (1u2d RBD with 1Fab)
7X29	;	2.49	;	MERS-CoV spike complex with S41 neutralizing antibody Fab Class2 (1u2d RBD with 2Fab)
7X28	;	2.49	;	MERS-CoV spike complex with S41 neutralizing antibody Fab Class3 (2u1d RBD with 2Fab)
7X25	;	2.49	;	MERS-CoV spike complex with S41 neutralizing antibody Fab Class4 (2u1d RBD with 3Fab)
6J11	;	3.0	;	MERS-CoV spike N-terminal domain and 7D10 scFv complex
8IFN	;	2.81	;	MERS-CoV spike trimer in complex with nanobody VHH-T148
1QOW	;	1.06	;	Mersacidin from Bacillus
7AVZ	;	2.04	;	MerTK kinase domain in complex with a bisaminopyrimidine inhibitor
7AW1	;	1.98	;	MerTK kinase domain in complex with a type 2 inhibitor
7AVX	;	2.44	;	MerTK kinase domain in complex with NPS-1034
7AW0	;	1.893	;	MerTK kinase domain in complex with purine inhibitor
7AVY	;	2.31	;	MerTK kinase domain in complex with quinazoline-based inhbitor
7AW3	;	1.99	;	MerTK kinase domain with type 1 inhibitor from a DNA-encoded library
7OLS	;	1.89	;	MerTK kinase domain with type 1.5 inhibitor containing a di-methyl pyrazole group
7OLV	;	2.13	;	MerTK kinase domain with type 1.5 inhibitor containing a di-methyl, cyano pyrazole group
7OLX	;	1.98	;	MerTK kinase domain with type 1.5 inhibitor containing a tri-methyl pyrazole group
7AW2	;	2.1	;	MerTK kinase domain with type 1.5 inhibitor from a DNA-encoded library
7AW4	;	1.98	;	MerTK kinase domain with type 3 inhibitor from a DNA-encoded library
8IBL	;	2.6	;	MES bound form of PET-degrading cutinase Cut190 with thermostability-improving mutations of S226P/R228S/Q138A/D250C-E296C/Q123H/N202H and S176A inactivation
1IS6	;	1.7	;	MES-Liganded Congerin II
2KMI	;		;	MESD(12-155), The Core Structural Domain of MESD that Is Essential for Proper Folding of LRP5/6
2KVD	;		;	Mesencephalic astrocyte-derived neurotrophic factor (MANF)
6N2A	;	1.88	;	Meso-Diaminopimelate Decarboxylase from Arabidopsis thaliana (Isoform 1)
6N2F	;	2.27	;	Meso-Diaminopimelate Decarboxylase from Arabidopsis thaliana (Isoform 2)
8I78	;	2.64	;	Meso-Diaminopimelate dehydrogenase
8I7H	;	3.02	;	Meso-Diaminopimelate dehydrogenase
5JBT	;	1.4	;	Mesotrypsin in complex with cleaved amyloid precursor like protein 2 inhibitor (APLP2)
5UTB	;	1.78	;	Met form of sperm whale myoglobin V68A/I107Y
6GCU	;	6.001	;	MET receptor in complex with InlB internalin domain and DARPin A3A
1CMA	;	2.8	;	MET REPRESSOR/DNA COMPLEX + S-ADENOSYL-METHIONINE
5UAB	;	1.9	;	MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody
5UAD	;	2.25	;	MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody
6UBW	;	2.0	;	MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody
6JF6	;	2.35	;	Met-ala-ser bound crystal structure of class I type b peptide deformylase from Acinetobacter baumannii
6JFA	;	1.93	;	Met-Ala-Ser bound crystal structure of class I type b peptide deformylase from Pseudomonas aeruginosa
5XL0	;	1.25	;	met-aquo form of sperm whale myoglobin reconstituted with 7-PF, a heme possesseing CF3 group as side chain
2AVK	;	1.53	;	met-azido-DcrH-Hr
2AWY	;	2.1	;	met-DcrH-Hr
2LWC	;		;	Met-enkephalin in DPMC SUV
1XQ5	;	1.9	;	Met-Perch Hemoglobin at 1.9A
3BJ1	;	1.9	;	met-Perch Hemoglobin at pH 5.7
3BJ2	;	2.0	;	met-Perch Hemoglobin at pH 6.3
3BJ3	;	2.1	;	met-Perch hemoglobin at pH 8.0
1EQT	;	1.6	;	MET-RANTES
2R1H	;	1.9	;	met-Trout IV hemoglobin at pH 6.3
3H56	;	1.5	;	Met150Leu/Phe312Cys variant of nitrite reductase from Alcaligenes faecalis
3H4F	;	2.1	;	Met62Leu variant of nitrite reductase from Alcaligenes faeclis
1KYQ	;	2.2	;	Met8p: A bifunctional NAD-dependent dehydrogenase and ferrochelatase involved in siroheme synthesis.
3H4H	;	1.6	;	Met94Thr/Phe312Cys variant of nitrite reductase from Alcaligenes faecalis
4MDL	;	1.516	;	Meta Carborane Carbonic Anhydrase Inhibitor
6YOI	;	1.2	;	Meta-Carborane di-propyl-sulfonamide in complex with CA IX mimic
6YO2	;	1.2	;	Meta-Carborane propyl-sulfonamide in complex with CA IX mimic
1IUO	;	2.0	;	meta-Cleavage product hydrolase from Pseudomonas fluorescens IP01 (CumD) S103A mutant complexed with acetates
1IUP	;	1.6	;	meta-Cleavage product hydrolase from Pseudomonas fluorescens IP01 (CumD) S103A mutant complexed with isobutyrates
1IUN	;	2.8	;	meta-Cleavage product hydrolase from Pseudomonas fluorescens IP01 (CumD) S103A mutant hexagonal
302D	;	2.2	;	META-HYDROXY ANALOGUE OF HOECHST 33258 ('HYDROXYL IN' CONFORMATION) BOUND TO D(CGCGAATTCGCG)2
303D	;	2.2	;	META-HYDROXY ANALOGUE OF HOECHST 33258 ('HYDROXYL OUT' CONFORMATION) BOUND TO D(CGCGAATTCGCG)2
6YOL	;	1.15	;	Meta-Nidocarborane propyl-sulfonamide in complex with CA IX mimic
6S20	;	1.98	;	Metabolism of multiple glycosaminoglycans by bacteroides thetaiotaomicron is orchestrated by a versatile core genetic locus (BT33336S-sulf)
6S21	;	2.8	;	Metabolism of multiple glycosaminoglycans by bacteroides thetaiotaomicron is orchestrated by a versatile core genetic locus (BT33494S-sulf)
6VUI	;	2.681	;	Metabolite-bound PreQ1 riboswitch with Mn2+
7OTT	;	3.84	;	Metabolon-embedded pyruvate dehydrogenase complex E2 core at near-atomic resolution
5KZN	;	2.8	;	Metabotropic Glutamate Receptor
6N52	;	4.0	;	Metabotropic Glutamate Receptor 5 Apo Form
6N4X	;	4.0	;	Metabotropic Glutamate Receptor 5 Apo Form Ligand Binding Domain
6N51	;	4.0	;	Metabotropic Glutamate Receptor 5 bound to L-quisqualate and Nb43
6N50	;	3.751	;	Metabotropic Glutamate Receptor 5 Extracellular Domain in Complex with Nb43 and L-quisqualic acid
6N4Y	;	3.262	;	Metabotropic Glutamate Receptor 5 Extracellular Domain with Nb43
5KZQ	;	2.8	;	Metabotropic Glutamate Receptor in complex with antagonist (1~{S},2~{R},3~{S},4~{S},5~{R},6~{R})-2-azanyl-3-[[3,4-bis(fluoranyl)phenyl]sulfanylmethyl]-4-oxidanyl-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid
3KS9	;	1.9	;	Metabotropic glutamate receptor mGluR1 complexed with LY341495 antagonist
3MQ4	;	2.8	;	Metabotropic glutamate receptor mGluR7 complexed with LY341495 antagonist
6QHN	;	1.9	;	Metagenome-derived salicylaldehyde dehydrogenase from alpine soil in complex with protocatechuic acid
8OI4	;	1.76	;	Metagenomic Beta-galactosidase from Glycoside Hydrolase family GH154
7ZOB	;	1.2	;	Metagenomic cytidine deaminase Cdd
8BWK	;	2.29	;	Metagenomic derived PL6 alginate lyase
5XGZ	;	1.75	;	Metagenomic glucose-tolerant glycosidase
5HX7	;	1.75	;	Metal ABC transporter from Listeria monocytogenes
5JPD	;	1.72	;	Metal ABC transporter from Listeria monocytogenes with cadmium
5I4K	;	1.79	;	Metal ABC transporter from Listeria monocytogenes with manganese
2LI9	;		;	Metal binding domain of rat beta-amyloid
2MZC	;		;	Metal Binding of Glutaredoxins
2LQB	;		;	Metal binding repeat 2 of the Wilson disease protein (ATP7B)
7SRV	;	2.03	;	Metal dependent activation of Plasmodium falciparum M17 aminopeptidase (inactive form), spacegroup P22121
7T3V	;	2.3	;	Metal dependent activation of Plasmodium falciparum M17 aminopeptidase, spacegroup P22121 after crystals soaked with Zn2+
3EIM	;	1.88	;	Metal exchange in Thermolysin
3FB0	;	1.6	;	Metal exchange in thermolysin
3FBO	;	1.92	;	Metal exchange in Thermolysin
3FXS	;	1.55	;	Metal exchange in thermolysin
5I7G	;	1.21	;	Metal free Glucose Isomerase collected at room temperature using the HC1b humidity controller
5OUW	;	2.05	;	Metal free structure of SynFtn
6SOM	;	2.15	;	Metal free structure of SynFtn variant D137A
6SOP	;	1.93	;	Metal free structure of SynFtn variant E62A
5OUZ	;	2.081	;	Metal free structure of Y40F SynFtn
4WJK	;	1.85	;	Metal Ion and Ligand Binding of Integrin
4WK0	;	1.78	;	Metal Ion and Ligand Binding of Integrin
4WK2	;	2.5	;	Metal Ion and Ligand Binding of Integrin
4WK4	;	2.5	;	Metal Ion and Ligand Binding of Integrin
1WRN	;	2.3	;	Metal Ion dependency of the antiterminator protein, HutP, for binding to the terminator region of hut mRNA- A structural basis
1WRO	;	2.35	;	Metal Ion dependency of the antiterminator protein, HutP, for binding to the terminator region of hut mRNA- A structural basis
1O7T	;	1.65	;	Metal nanoclusters bound to the Ferric Binding Protein from Neisseria gonorrhoeae.
6Q28	;	2.2	;	Metal ROK rebel: Characterisation of N-acetylmannosamine kinase from the pathogen Staphylococcus aureus
8DTA	;	1.81	;	Metal sensitive GFP (mseGFP) complexed with phenylarsine oxide.
6H0D	;	1.598	;	Metal soaked Flv1 flavodiiron core from Synechocystis sp. PCC6803
1LFI	;	2.1	;	METAL SUBSTITUTION IN TRANSFERRINS: THE CRYSTAL STRUCTURE OF HUMAN COPPER-LACTOFERRIN AT 2.1 ANGSTROMS RESOLUTION
4G1A	;	1.85	;	Metal-binding properties of a self-assembled coiled coil: formation of a polynuclear Cd-thiolated cluster
6VD8	;	2.3	;	Metal-bound C-terminal domain of CzcD transporter from Pseudomonas aeruginosa
6VDA	;	2.4	;	Metal-bound C-terminal domain of CzcD transporter from Thermotoga maritima
6VD9	;	1.75	;	Metal-bound C-terminal domain of the CzcD transporter from Cuprividus metallidurans
2FQZ	;	2.0	;	Metal-depleted Ecl18kI in complex with uncleaved DNA
2GB7	;	1.7	;	Metal-depleted Ecl18kI in complex with uncleaved, modified DNA
2GME	;	1.75	;	Metal-free (apo) P. angolensis seed lectin
2GMP	;	2.5	;	Metal-free (apo) P. angolensis seed lectin in complex with GlcNAC-beta(1-2)Man
2GMM	;	2.15	;	Metal-free (apo) P. angolensis seed lectin in complex with Man-alpha(1-2)Man
2GN7	;	2.9	;	Metal-free (apo) P. angolensis seed lectin in complex with Man-alpha(1-3)Man-alpha(1-6)Man
2GN3	;	1.97	;	Metal-free (apo-PAL) in complex with alpha-D-Met-Man
3KBE	;	1.1	;	Metal-free C. elegans Cu,Zn Superoxide Dismutase
3SXM	;	1.55	;	Metal-free FCD domain of TM0439 a putative transcriptional regulator
3SXZ	;	2.322	;	Metal-free FCD domain of TM0439 a putative transcriptional regulator
3ITY	;	1.84	;	Metal-free form of Pseudomonas stutzeri L-rhamnose isomerase
3SXY	;	1.647	;	Metal-free full-length structure of Tm0439, a metal-binding FCD family transcriptional regulator
1IJ5	;	3.0	;	METAL-FREE STRUCTURE OF MULTIDOMAIN EF-HAND PROTEIN, CBP40, FROM TRUE SLIME MOLD
6DYB	;	2.75	;	Metal-free structure of the engineered cyt cb562 variant, CH3
3HOG	;	1.85	;	Metal-free Tomato Chloroplast Superoxide Dismutase
5KKV	;	1.9	;	Metal-mediated coiled-coil GCN4-p2L peptide assembly crystal
6YKH	;	1.1	;	Metala-Carborane di-ethyl-sulfonamide (cis isomer) in complex with CA IX mimic
6YKC	;	1.2	;	Metala-Carborane di-ethyl-sulfonamide (trans isomer) in complex with CA IX mimic
6YJ3	;	1.55	;	Metala-Carborane di-propyl-sulfonamide
5OGN	;	1.1	;	Metalacarborane inhibitors of Carbonic Anhydrase IX
5OGP	;	1.1	;	Metalacarborane inhibitors of Carbonic Anhydrase IX
1SML	;	1.7	;	METALLO BETA LACTAMASE L1 FROM STENOTROPHOMONAS MALTOPHILIA
2AIO	;	1.7	;	Metallo beta lactamase L1 from Stenotrophomonas maltophilia complexed with hydrolyzed moxalactam
7E3W	;	1.55	;	Metallo beta-lactamase fold protein (cAMP bound)
7E3V	;	2.05	;	Metallo beta-lactamase fold protein (cAMP free)
3BC2	;	1.7	;	METALLO BETA-LACTAMASE II FROM BACILLUS CEREUS 569/H/9 AT PH 6.0, MONOCLINIC CRYSTAL FORM
2BC2	;	1.7	;	METALLO BETA-LACTAMASE II FROM BACILLUS CEREUS 569/H/9 AT PH 6.0, TRIGONAL CRYSTAL FORM
8PJM	;	1.44	;	Metallo beta-lactamase VIM2 with compound AK4
7AYJ	;	1.21	;	Metallo beta-lactamse Vim-1 with a sulfamoyl inhibitor.
1ZNB	;	1.85	;	METALLO-BETA-LACTAMASE
2BMI	;	2.0	;	METALLO-BETA-LACTAMASE
2UYX	;	1.95	;	metallo-beta-lactamase (1BC2) single point mutant D120S
4ZNB	;	2.65	;	METALLO-BETA-LACTAMASE (C181S MUTANT)
2ZNB	;	2.15	;	METALLO-BETA-LACTAMASE (CADMIUM-BOUND FORM)
3ZNB	;	2.7	;	METALLO-BETA-LACTAMASE (ZN, HG-BOUND FORM)
1MQO	;	1.35	;	Metallo-beta-lactamase BcII Cd substituted from Bacillus cereus at 1.35 angstroms resolution
1BVT	;	1.85	;	METALLO-BETA-LACTAMASE FROM BACILLUS CEREUS 569/H/9
1DXK	;	1.85	;	Metallo-beta-lactamase from Bacillus cereus 569/H/9 C168S mutant
1HLK	;	2.5	;	METALLO-BETA-LACTAMASE FROM BACTEROIDES FRAGILIS IN COMPLEX WITH A TRICYCLIC INHIBITOR
6DR8	;	1.476	;	Metallo-beta-lactamase from Cronobacter sakazakii (Enterobacter sakazakii) HARLDQ motif mutant S60/R118H/Q121H/K254H
6XFR	;	2.608	;	Metallo-beta-lactamase from Pontibacter korlensis
1A8T	;	2.55	;	METALLO-BETA-LACTAMASE IN COMPLEX WITH L-159,061
8A76	;	1.5	;	Metallo-beta-lactamase NDM-1 in complex with 1,2,4-Triazole-3-thione compound 26
7CJL	;	1.789	;	Metallo-Beta-Lactamase VIM-2 in complex with (S)-N-(3-(2H-tetrazol-5-yl)phenyl)-3-mercapto-2-methylpropanamide
7CHV	;	2.174	;	Metallo-Beta-Lactamase VIM-2 in complex with 1-benzyl-1H-imidazole-2-carboxylic acid
6J8R	;	1.575	;	Metallo-Beta-Lactamase VIM-2 in complex with Dual MBL/SBL Inhibitor MS01
6JN6	;	1.602	;	Metallo-Beta-Lactamase VIM-2 in complex with Dual MBL/SBL Inhibitor MS19
1A7T	;	1.85	;	METALLO-BETA-LACTAMASE WITH MES
4A37	;	1.6	;	Metallo-carboxypeptidase from Pseudomonas Aeruginosa
4A39	;	1.6	;	Metallo-carboxypeptidase from Pseudomonas Aeruginosa in complex with (2-guanidinoethylmercapto)succinic acid
4A38	;	2.0	;	METALLO-CARBOXYPEPTIDASE FROM PSEUDOMONAS AUREGINOSA IN COMPLEX WITH L-BENZYLSUCCINIC ACID
1DTH	;	2.0	;	METALLOPROTEASE
6QIG	;	2.8	;	Metalloproteinase
4D80	;	3.6	;	Metallosphera sedula Vps4 crystal structure
4D81	;	2.4	;	Metallosphera sedula Vps4 crystal structure
4D82	;	3.2	;	Metallosphera sedula Vps4 crystal structure
1QJK	;		;	Metallothionein MTA from sea urchin (alpha domain)
1QJL	;		;	METALLOTHIONEIN MTA FROM SEA URCHIN (BETA DOMAIN)
1LVZ	;		;	METARHODOPSIN II BOUND STRUCTURE OF C-TERMINAL PEPTIDE OF ALPHA-SUBUNIT OF TRANSDUCIN
6UPW	;	2.9	;	Metavinculin ABD-F-actin complex
7RU9	;	3.3	;	Metazoan pre-targeting GET complex (cBUGG-in)
7RUA	;	3.4	;	Metazoan pre-targeting GET complex (cBUGG-out)
7RUC	;	3.6	;	Metazoan pre-targeting GET complex with SGTA (cBUGGS)
2MOB	;		;	METHANE MONOOXYGENASE COMPONENT B
1MHY	;	2.0	;	METHANE MONOOXYGENASE HYDROXYLASE
1MHZ	;	2.7	;	METHANE MONOOXYGENASE HYDROXYLASE
1MTY	;	1.7	;	METHANE MONOOXYGENASE HYDROXYLASE FROM METHYLOCOCCUS CAPSULATUS (BATH)
1FZI	;	3.3	;	METHANE MONOOXYGENASE HYDROXYLASE, FORM I PRESSURIZED WITH XENON GAS
1FZ8	;	2.1	;	METHANE MONOOXYGENASE HYDROXYLASE, FORM II COCRYSTALLIZED WITH DIBROMOMETHANE
1FZ9	;	2.3	;	Methane monooxygenase hydroxylase, form II cocrystallized with iodoethane
1FZ5	;	2.4	;	METHANE MONOOXYGENASE HYDROXYLASE, FORM II CRYSTALLIZED ANAEROBICALLY FROM REDUCED ENZYME
1FZ2	;	2.15	;	METHANE MONOOXYGENASE HYDROXYLASE, FORM II MIXED-VALENT GENERATED BY CRYSTAL SOAKING
1FZ0	;	2.07	;	METHANE MONOOXYGENASE HYDROXYLASE, FORM II MIXED-VALENT GROWN ANAEROBICALLY
1FZH	;	2.6	;	METHANE MONOOXYGENASE HYDROXYLASE, FORM II PRESSURIZED WITH XENON GAS
1FYZ	;	2.15	;	METHANE MONOOXYGENASE HYDROXYLASE, FORM II REDUCED BY SOAKING
1FZ6	;	2.05	;	METHANE MONOOXYGENASE HYDROXYLASE, FORM II SOAKED IN 1 M METHANOL
1FZ1	;	1.96	;	METHANE MONOOXYGENASE HYDROXYLASE, FORM III OXIDIZED
1FZ3	;	2.03	;	METHANE MONOOXYGENASE HYDROXYLASE, FORM III SOAK AT PH 6.2 (0.1 M PIPES)
1FZ4	;	2.38	;	METHANE MONOOXYGENASE HYDROXYLASE, FORM III SOAKED AT PH 8.5 (0.1 M TRIS)
1FZ7	;	1.96	;	METHANE MONOOXYGENASE HYDROXYLASE, FORM III SOAKED IN 0.9 M ETHANOL
8JNG	;	3.2	;	Methanesulfonate monooxygenase ferredoxin subunit of PBS-PSII-PSI-LHCs from Porphyridium purpureum.
2GYO	;	2.0	;	Methanethiol-Cys 112 Inhibition Complex of E. Coli Ketoacyl Synthase III (FabH) and Coenzyme A
2EFT	;	2.0	;	Methanethiol-CYS 112 inhibition complex of E. coli ketoacyl synthase III (FABH) and Coenzyme A (high concentration (1.7mM) soak)
7TCX	;	2.21	;	Methanobactin biosynthetic protein complex of MbnB and MbnC from Methylosinus trichosporium OB3b at 2.21 Angstrom resolution
7TCU	;	2.31	;	Methanobactin biosynthetic protein complex of MbnB and MbnC from Methylosinus trichosporium OB3b at 2.31 Angstrom resolution
7TCR	;	2.62	;	Methanobactin biosynthetic protein complex of MbnB and MbnC from Methylosinus trichosporium OB3b at 2.62 Angstrom resolution
7TCW	;	2.67	;	Methanobactin biosynthetic protein complex of MbnB and MbnC from Methylosinus trichosporium OB3b, H210S mutant
2YGI	;	0.8	;	Methanobactin HM1
2YGJ	;	0.8	;	Methanobactin MB4
5ICQ	;	1.9	;	Methanobactin periplasmic binding protein
4OZ7	;	1.65	;	Methanobactin production by methanotrophic bacteria and their structural diversity from Methylosinus strains: Insights into copper release
6VZ6	;	2.1	;	Methanococcoides burtonii cytochrome b5 domain protein (WP 011499504.1)
1G8S	;	1.6	;	METHANOCOCCUS JANNASCHII FIBRILLARIN PRE-RRNA PROCESSING PROTEIN
4UQV	;	3.0	;	methanococcus jannaschii serine hydroxymethyl-transferase in complex with PLP
4BHD	;	2.83	;	Methanococcus jannaschii serine hydroxymethyl-transferase, apo form
2Z8U	;	1.9	;	Methanococcus jannaschii TBP
7RAK	;	3.9	;	Methanococcus maripaludis chaperonin complex in open conformation
7R9O	;	4.0	;	Methanococcus maripaludis chaperonin, closed conformation 1
7R9M	;	4.0	;	Methanococcus maripaludis chaperonin, closed conformation 2
7R9U	;	4.4	;	Methanococcus maripaludis chaperonin, closed conformation 3
7R9K	;	4.1	;	Methanococcus maripaludis chaperonin, closed conformation 4
7R9E	;	4.0	;	Methanococcus maripaludis chaperonin, open conformation 1
7R9H	;	6.3	;	Methanococcus maripaludis chaperonin, open conformation 2
7R9I	;	6.4	;	Methanococcus maripaludis chaperonin, open conformation 2
7R9J	;	6.3	;	Methanococcus maripaludis chaperonin, open conformation 4
2ODR	;	3.228	;	Methanococcus Maripaludis Phosphoseryl-tRNA synthetase
4MAE	;	1.6	;	Methanol dehydrogenase from Methylacidiphilum fumariolicum SolV
4AAH	;	2.4	;	METHANOL DEHYDROGENASE FROM METHYLOPHILUS W3A1
4HS9	;	1.8	;	Methanol tolerant mutant of the Proteus mirabilis lipase
7CE5	;	1.8	;	Methanol-PQQ bound methanol dehydrogenase (MDH) from Methylococcus capsulatus (Bath)
4N0L	;	2.37	;	Methanopyrus kandleri Csm3 crystal structure
4WA8	;	2.2	;	Methanopyrus Kandleri FEN-1 nuclease
6ZNW	;	2.121	;	Methanosaeta concilii ATP citrate lyase (D541A mutant) in complex with (3S)-citryl-CoA.
8PUQ	;	1.95	;	MetHemoglobin structure from serial synchrotron crystallography with fixed target
5T7V	;	3.6	;	Methicillin Resistant, Linezolid resistant Staphylococcus aureus 70S ribosome (delta S145 uL3)
5TCU	;	3.9	;	Methicillin sensitive Staphylococcus aureus 70S ribosome
4TO8	;	2.1	;	Methicillin-Resistant Staphylococcus Aureus Class IIb Fructose 1,6-Bisphosphate Aldolase
4L4Q	;	2.0	;	Methionine Adenosyltransferase
1O90	;	3.1	;	Methionine Adenosyltransferase complexed with a L-methionine analogue
1QM4	;	2.66	;	Methionine Adenosyltransferase Complexed with a L-Methionine Analogue
1O92	;	3.19	;	Methionine Adenosyltransferase complexed with ADP and a L-methionine analogue
1O93	;	3.49	;	Methionine Adenosyltransferase complexed with ATP and a L-methionine analogue
1O9T	;	2.9	;	Methionine adenosyltransferase complexed with both substrates ATP and methionine
1XGM	;	2.8	;	METHIONINE AMINOPEPTIDASE FROM HYPERTHERMOPHILE PYROCOCCUS FURIOSUS
1XGN	;	2.9	;	METHIONINE AMINOPEPTIDASE FROM HYPERTHERMOPHILE PYROCOCCUS FURIOSUS
1XGO	;	3.5	;	METHIONINE AMINOPEPTIDASE FROM HYPERTHERMOPHILE PYROCOCCUS FURIOSUS
1XGS	;	1.75	;	METHIONINE AMINOPEPTIDASE FROM HYPERTHERMOPHILE PYROCOCCUS FURIOSUS
1MJM	;	2.2	;	METHIONINE APOREPRESSOR MUTANT (Q44K) COMPLEXED TO HALF OF THE CONSENSUS OPERATOR SEQUENCE
1MJP	;	3.4	;	METHIONINE APOREPRESSOR MUTANT (Q44K) COMPLEXED TO THE MINIMAL MET CONSENSUS OPERATOR
1CUP	;	1.89	;	METHIONINE CORE MUTANT OF T4 LYSOZYME
1KS3	;	2.16	;	METHIONINE CORE MUTANT OF T4 LYSOZYME
1KW5	;	1.75	;	METHIONINE CORE MUTANT OF T4 LYSOZYME
1KW7	;	1.89	;	METHIONINE CORE MUTANT OF T4 LYSOZYME
1KY0	;	1.97	;	METHIONINE CORE MUTANT OF T4 LYSOZYME
1KY1	;	2.05	;	METHIONINE CORE MUTANT OF T4 LYSOZYME
1L0J	;	1.98	;	METHIONINE CORE MUTANT OF T4 LYSOZYME
1L0K	;	2.02	;	METHIONINE CORE MUTANT OF T4 LYSOZYME
1D3M	;	2.12	;	METHIONINE CORE MUTATION
1D3N	;	2.0	;	METHIONINE CORE MUTATION
1E5F	;	2.18	;	METHIONINE GAMMA-LYASE (MGL) FROM TRICHOMONAS VAGINALIS
1E5E	;	2.18	;	METHIONINE GAMMA-LYASE (MGL) FROM TRICHOMONAS VAGINALIS IN COMPLEX WITH PROPARGYLGLYCINE
3MKJ	;	1.65	;	Methionine gamma-lyase from Citrobacter freundii with pyridoximine-5'-phosphate
1MJO	;	2.1	;	METHIONINE HOLOREPRESSOR MUTANT (Q44K) PLUS COREPRESSOR (S-ADENOSYL METHIONINE) COMPLEXED TO THE MINIMAL MET CONSENSUS OPERATOR WITH THE CENTRAL TA STEP MUTATED TO AT
1MJL	;	2.1	;	METHIONINE REPRESSOR MUTANT (Q44K) COMPLEX WITH THE COREPRESSOR SAM (S-ADENOSYL METHIONINE) FROM ESCHERICHIA COLI
1MJ2	;	2.4	;	METHIONINE REPRESSOR MUTANT (Q44K) PLUS COREPRESSOR (S-ADENOSYL METHIONINE) COMPLEXED TO A CONSENSUS OPERATOR SEQUENCE
1MJQ	;	2.4	;	METHIONINE REPRESSOR MUTANT (Q44K) PLUS COREPRESSOR (S-ADENOSYL METHIONINE) COMPLEXED TO AN ALTERED MET CONSENSUS OPERATOR SEQUENCE
1MJK	;	2.15	;	METHIONINE REPRESSOR MUTANT APOREPRESSOR (Q44K) FROM ESCHERICHIA COLI
4D7L	;	1.895	;	Methionine sulfoxide reductase A of Corynebacterium diphtheriae
1MSK	;	1.8	;	METHIONINE SYNTHASE (ACTIVATION DOMAIN)
5VON	;	2.1	;	Methionine synthase folate-binding domain from Thermus thermophilus HB8
5VOP	;	2.1	;	Methionine synthase folate-binding domain from Thermus thermophilus HB8 native
5VOO	;	2.4	;	Methionine synthase folate-binding domain with methyltetrahydrofolate from Thermus thermophilus HB8
8SSD	;	2.4	;	Methionine synthase, C-terminal fragment, Cobalamin and Reactivation Domains from Thermus thermophilus HB8
8SSE	;	3.15	;	Methionine synthase, C-terminal fragment, Cobalamin and Reactivation Domains from Thermus thermophilus HB8
3SO4	;	3.18	;	Methionine-adenosyltransferase from Entamoeba histolytica
5CPD	;	2.2	;	Methionine-alanine complex structure of peptide deformylase from Xanthomonas oryzae pv. oryzae
2D0K	;	1.9	;	Methionine-free mutant of Escherichia coli dihydrofolate reductase
1ZGH	;	2.05	;	Methionyl-tRNA formyltransferase from Clostridium thermocellum
3Q0I	;	1.89	;	Methionyl-tRNA formyltransferase from Vibrio cholerae
1QQT	;	2.03	;	METHIONYL-TRNA SYNTHETASE FROM ESCHERICHIA COLI
1PFV	;	1.7	;	METHIONYL-TRNA SYNTHETASE FROM ESCHERICHIA COLI COMPLEXED WITH DIFLUOROMETHIONINE
1PG2	;	1.75	;	METHIONYL-TRNA SYNTHETASE FROM ESCHERICHIA COLI COMPLEXED WITH METHIONINE AND ADENOSINE
1PFU	;	1.91	;	METHIONYL-TRNA SYNTHETASE FROM ESCHERICHIA COLI COMPLEXED WITH METHIONINE PHOSPHINATE
1P7P	;	1.8	;	Methionyl-tRNA synthetase from Escherichia coli complexed with methionine phosphonate
1PG0	;	1.9	;	Methionyl-trna synthetase from escherichia coli complexed with methioninyl adenylate
1PFY	;	1.93	;	METHIONYL-TRNA SYNTHETASE FROM ESCHERICHIA COLI COMPLEXED WITH METHIONYL SULPHAMOYL ADENOSINE
1PFW	;	1.78	;	METHIONYL-TRNA SYNTHETASE FROM ESCHERICHIA COLI COMPLEXED WITH TRIFLUOROMETHIONINE
1RQG	;	2.9	;	Methionyl-tRNA synthetase from Pyrococcus abyssi
7WPJ	;	2.65	;	Methionyl-tRNA synthetase from Staphylococcus aureus
7WPM	;	2.8	;	Methionyl-tRNA synthetase from Staphylococcus aureus complexed with a fragment and ATP
7WPX	;	2.4	;	Methionyl-tRNA synthetase from Staphylococcus aureus complexed with a fragment and ATP
7WQ0	;	2.09	;	Methionyl-tRNA synthetase from Staphylococcus aureus complexed with a fragment and ATP
7WPT	;	2.26	;	Methionyl-tRNA synthetase from Staphylococcus aureus complexed with a fragment M2-80 and ATP
7WPI	;	1.92	;	Methionyl-tRNA synthetase from Staphylococcus aureus complexed with a phenylbenzimidazole inhibitor
7WPN	;	2.4	;	Methionyl-tRNA synthetase from Staphylococcus aureus complexed with a phenylbenzimidazole inhibitor and ATP
7WPL	;	2.5	;	Methionyl-tRNA synthetase from Staphylococcus aureus complexed with ATP
7WPK	;	2.8	;	Methionyl-tRNA synthetase from Staphylococcus aureus complexed with L-Met
1A8H	;	2.0	;	METHIONYL-TRNA SYNTHETASE FROM THERMUS THERMOPHILUS
1MEA	;		;	METHIONYL-TRNA SYNTHETASE ZINC BINDING DOMAIN. 3D STRUCTURE AND HOMOLOGY WITH RUBREDOXIN AND GAG RETROVIRAL PROTEINS
1MED	;		;	METHIONYL-TRNA SYNTHETASE ZINC BINDING DOMAIN. 3D STRUCTURE AND HOMOLOGY WITH RUBREDOXIN AND GAG RETROVIRAL PROTEINS
2FMT	;	2.8	;	METHIONYL-TRNAFMET FORMYLTRANSFERASE COMPLEXED WITH FORMYL-METHIONYL-TRNAFMET
1FMT	;	2.0	;	METHIONYL-TRNAFMET FORMYLTRANSFERASE FROM ESCHERICHIA COLI
1BBT	;	2.6	;	METHODS USED IN THE STRUCTURE DETERMINATION OF FOOT AND MOUTH DISEASE VIRUS
1DLR	;	2.3	;	METHOTREXATE-RESISTANT VARIANTS OF HUMAN DIHYDROFOLATE REDUCTASE WITH SUBSTITUTION OF LEUCINE 22: KINETICS, CRYSTALLOGRAPHY AND POTENTIAL AS SELECTABLE MARKERS
1DLS	;	2.3	;	METHOTREXATE-RESISTANT VARIANTS OF HUMAN DIHYDROFOLATE REDUCTASE WITH SUBSTITUTION OF LEUCINE 22: KINETICS, CRYSTALLOGRAPHY AND POTENTIAL AS SELECTABLE MARKERS
8IVG	;	1.8	;	Methyl and Fluorine Effects in Novel Orally Bioavailable Keap1/Nrf2 PPI Inhibitor for Treatment of Chronic Kidney Disease
8IVR	;	1.5	;	Methyl and Fluorine Effects in Novel Orally Bioavailable Keap1/Nrf2 PPI Inhibitor for Treatment of Chronic Kidney Disease
8IXS	;	1.48	;	Methyl and Fluorine Effects in Novel Orally Bioavailable Keap1/Nrf2 PPI Inhibitor for Treatment of Chronic Kidney Disease
6D8V	;	2.8	;	Methyl-accepting Chemotaxis protein X
1HBN	;	1.16	;	METHYL-COENZYME M REDUCTASE
1MRO	;	1.16	;	METHYL-COENZYME M REDUCTASE
1HBM	;	1.8	;	METHYL-COENZYME M REDUCTASE ENZYME PRODUCT COMPLEX
1E6V	;	2.7	;	Methyl-coenzyme M reductase from Methanopyrus kandleri
1E6Y	;	1.6	;	Methyl-coenzyme M reductase from Methanosarcina barkeri
5A0Y	;	1.1	;	METHYL-COENZYME M REDUCTASE FROM METHANOTHERMOBACTER MARBURGENSIS AT 1.1 A RESOLUTION
5A8K	;	1.41	;	METHYL-COENZYME M REDUCTASE FROM METHANOTHERMOBACTER WOLFEII AT 1.4 A RESOLUTION
7NKG	;	1.6	;	Methyl-coenzyme M reductase from Methermicoccus shengliensis at 1.6-A resolution
5G0R	;	1.25	;	METHYL-COENZYME M REDUCTASE I FROM METHANOTHERMOBACTER MARBURGENSIS EXPOSED TO 3-NITROOXYPROPANOL
5A8R	;	2.15	;	METHYL-COENZYME M REDUCTASE II FROM METHANOTHERMOBACTER MARBURGENSIS AT 2.15 A RESOLUTION
5A8W	;	1.8	;	METHYL-COENZYME M REDUCTASE II FROM METHANOTHERMOBACTER WOLFEII AT 1. 8 A RESOLUTION
5N1Q	;	1.9	;	METHYL-COENZYME M REDUCTASE III FROM METHANOTHERMOCOCCUS THERMOLITHOTROPHICUS AT 1.9 A RESOLUTION
5N28	;	2.8	;	METHYL-COENZYME M REDUCTASE III FROM METHANOTORRIS FORMICICUS MONOCLINIC FORM
5N2A	;	2.8	;	METHYL-COENZYME M REDUCTASE III FROM METHANOTORRIS FORMICICUS TRIGONAL FORM
1HBU	;	1.9	;	METHYL-COENZYME M REDUCTASE IN THE MCR-RED1-SILENT STATE IN COMPLEX with COENZYME M
1HBO	;	1.78	;	METHYL-COENZYME M REDUCTASE MCR-RED1-SILENT
3ZVI	;	1.9	;	Methylaspartate ammonia lyase from Clostridium tetanomorphum mutant L384A
3ZVH	;	1.99	;	Methylaspartate ammonia lyase from Clostridium tetanomorphum mutant Q73A
1WPK	;		;	Methylated Form of N-terminal Transcriptional Regulator Domain of Escherichia Coli Ada Protein
1EH7	;	2.0	;	METHYLATED HUMAN O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE
7MJW	;	1.4	;	Methylated MiaB in the complex with 5'-deoxyadenosine, methionine and RNA
6OJY	;	3.3	;	Methylated PilT4 from Geobacter metallireducens bound to sulfate: C3ocococ conformation
2VIX	;	2.85	;	Methylated Shigella flexneri MxiC
2VJ4	;	2.5	;	Methylated Shigella flexneri MxiC
5GM8	;	2.2	;	Methylation at position 32 of tRNA catalyzed by TrmJ alters oxidative stress response in Pseudomonas aeruiginosa
5GMB	;	1.62	;	Methylation at position 32 of tRNA catalyzed by TrmJ alters oxidative stress response in Pseudomonas aeruiginosa
5GMC	;	1.7	;	Methylation at position 32 of tRNA catalyzed by TrmJ alters oxidative stress response in Pseudomonas aeruiginosa
1Y9H	;		;	Methylation of cytosine at C5 in a CpG sequence context causes a conformational switch of a benzo[a]pyrene diol epoxide-N2-guanine adduct in DNA from a minor groove alignment to intercalation with base displacement
4DNB	;	2.0	;	METHYLATION OF THE ECORI RECOGNITION SITE DOES NOT ALTER DNA CONFORMATION. THE CRYSTAL STRUCTURE OF D(CGCGAM6ATTCGCG) AT 2.0 ANGSTROMS RESOLUTION
3L07	;	1.88	;	Methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase, putative bifunctional protein folD from Francisella tularensis.
6GOC	;	1.9	;	Methylesterase BT1017
1B93	;	1.9	;	METHYLGLYOXAL SYNTHASE FROM ESCHERICHIA COLI
6F2C	;	2.34	;	Methylglyoxal synthase MgsA from Bacillus subtilis
6N94	;	1.75	;	Methylmalonyl-CoA decarboxylase in complex with 2-nitronate-propionyl-amino(dethia)-CoA
6N92	;	1.7	;	Methylmalonyl-CoA decarboxylase in complex with 2-nitronate-propionyl-CoA
6N93	;	1.7	;	Methylmalonyl-CoA decarboxylase in complex with 2-nitronate-propionyl-oxa(dethia)-CoA
6N97	;	1.75	;	Methylmalonyl-CoA decarboxylase in complex with 2-sulfonate-propionyl-amino(dethia)-CoA
6N95	;	1.798	;	Methylmalonyl-CoA decarboxylase in complex with 2-sulfonate-propionyl-CoA
6N96	;	1.7	;	Methylmalonyl-CoA decarboxylase in complex with 2-sulfonate-propionyl-oxa(dethia)-CoA
6WFI	;	1.37	;	Methylmalonyl-CoA epimerase in complex with 2-nitronate-propionyl-CoA
6WF7	;	1.55	;	Methylmalonyl-CoA epimerase in complex with methylmalonyl-CoA and NH4+
1REQ	;	2.0	;	METHYLMALONYL-COA MUTASE
1E1C	;	2.62	;	METHYLMALONYL-COA MUTASE H244A Mutant
4REQ	;	2.2	;	Methylmalonyl-COA Mutase substrate complex
7REQ	;	2.2	;	METHYLMALONYL-COA MUTASE, 2-CARBOXYPROPYL-COA INHIBITOR COMPLEX
6REQ	;	2.2	;	METHYLMALONYL-COA MUTASE, 3-CARBOXYPROPYL-COA INHIBITOR COMPLEX
2REQ	;	2.5	;	METHYLMALONYL-COA MUTASE, NON-PRODUCTIVE COA COMPLEX, IN OPEN CONFORMATION REPRESENTING SUBSTRATE-FREE STATE
3REQ	;	2.7	;	METHYLMALONYL-COA MUTASE, SUBSTRATE-FREE STATE (POOR QUALITY STRUCTURE)
5REQ	;	2.2	;	Methylmalonyl-COA MUTASE, Y89F Mutant, substrate complex
7QSJ	;	1.35	;	Methylmannose polysaccharide hydrolase MmpH from M. hassiacum
7QSG	;	2.75	;	Methylmannose polysaccharide mannosyltransferase from M. hassiacum
4CT3	;	1.69	;	Methylmercury chloride derivative structure of the lytic CHAPK domain of the endolysin LysK from Staphylococcus aureus bacteriophage K
1H4I	;	1.94	;	Methylobacterium extorquens methanol dehydrogenase
1H4J	;	3.0	;	Methylobacterium extorquens methanol dehydrogenase D303E mutant
1VXO	;	2.4	;	METHYLPHOSPHONYLATED ACETYLCHOLINESTERASE (AGED) OBTAINED BY REACTION WITH O-ETHYL-S-[2-[BIS(1-METHYLETHYL)AMINO]ETHYL] METHYLPHOSPHONOTHIOATE (VX)
1CFJ	;	2.6	;	METHYLPHOSPHONYLATED ACETYLCHOLINESTERASE (AGED) OBTAINED BY REACTION WITH O-ISOPROPYLMETHYLPHOSPHONOFLUORIDATE (GB, SARIN)
8CIW	;	1.93	;	Methylsuccinyl-CoA dehydrogenase from Pseudomonas migulae with bound FAD and (2S)-methylsuccinyl-CoA
6ES9	;	1.37	;	Methylsuccinyl-CoA dehydrogenase of Paracoccus denitrificans with bound flavin adenine dinucleotide
4ZOJ	;	1.96	;	Methylsulfanyl-containing inhibitor bound in the active site of Mycobacterium tuberculosis anthranilate phosphoribosyltransferase (AnPRT; trpD)
4ZOK	;	2.34	;	Methylsulfonyl-containing inhibitor bound in the substrate capture site of Mycobacterium tuberculosis anthranilate phosphoribosyltransferase (AnPRT; trpD)
4L5Y	;	2.0957	;	Methylthioadenosine phosphorylase from Schistosoma mansoni in APO form
4L6I	;	2.1	;	Methylthioadenosine phosphorylase from Schistosoma mansoni in complex with adenine
4L5C	;	2.075	;	Methylthioadenosine phosphorylase from Schistosoma mansoni in complex with adenine in space group P212121
4L5A	;	2.2993	;	Methylthioadenosine phosphorylase from Schistosoma mansoni in complex with tubercidin
1D2C	;	2.5	;	METHYLTRANSFERASE
1XVA	;	2.2	;	METHYLTRANSFERASE
3ROD	;	2.72	;	Methyltransferase
2YCJ	;	1.96	;	methyltransferase bound with methyltetrahydrofolate
2YCK	;	2.15	;	methyltransferase bound with tetrahydrofolate
4RG1	;	1.86	;	Methyltransferase domain of C9orf114
4I51	;	1.9	;	Methyltransferase domain of HUMAN EUCHROMATIC HISTONE METHYLTRANSFERASE 1, mutant Y1211A
3DAL	;	1.65	;	Methyltransferase domain of human PR domain-containing protein 1
3IHX	;	2.5	;	Methyltransferase domain of human PR domain-containing protein 10
3EP0	;	2.1	;	Methyltransferase domain of human PR domain-containing protein 12
2QPW	;	1.79	;	Methyltransferase domain of human PR domain-containing protein 2
2R3A	;	2.0	;	Methyltransferase domain of human suppressor of variegation 3-9 homolog 2
6P0R	;	2.4	;	Methyltransferase domain of human suppressor of variegation 3-9 homolog 2 (SUV39H2) in complex with OTS186935 inhibitor
2HA8	;	1.6	;	Methyltransferase Domain of Human TAR (HIV-1) RNA binding protein 1
3GDH	;	2.0	;	Methyltransferase domain of human Trimethylguanosine Synthase 1 (TGS1) bound to m7GTP and adenosyl-homocysteine (active form)
3EGI	;	2.21	;	Methyltransferase domain of human trimethylguanosine synthase TGS1 bound to m7GpppA (inactive form)
5UPD	;	1.8	;	Methyltransferase domain of human Wolf-Hirschhorn Syndrome Candidate 1-Like protein 1 (WHSC1L1)
4XCX	;	2.84	;	METHYLTRANSFERASE DOMAIN OF SMALL RNA 2'-O-METHYLTRANSFERASE
4AY7	;	1.8	;	methyltransferase from Methanosarcina mazei
6SJK	;	1.85	;	Methyltransferase MtgA from Desulfitobacterium hafniense
6SK4	;	1.55	;	Methyltransferase MtgA from Desulfitobacterium hafniense in complex with methyl-tetrahydrofolate (P21)
6SJN	;	1.75	;	Methyltransferase MtgA from Desulfitobacterium hafniense in complex with methyl-tetrahydrofolate (P212121)
6SJ8	;	1.35	;	Methyltransferase MtgA from Desulfitobacterium hafniense in complex with tetrahydrofolate
2YCI	;	1.78	;	methyltransferase native
6SJO	;	1.95	;	Methyltransferase of the MtgA D102A mutant from Desulfitobacterium hafniense in complex with methyl-tetrahydrofolate
6SJP	;	1.9	;	Methyltransferase of the MtgA N227A mutant from Desulfitobacterium hafniense
6SJS	;	1.8	;	Methyltransferase of the MtgA N227A mutant from Desulfitobacterium hafniense in complex with methyl-tetrahydrofolate
6SJR	;	1.75	;	Methyltransferase of the MtgA N227A mutant from Desulfitobacterium hafniense in complex with tetrahydrofolate
8GHU	;	3.0	;	Methyltransferase RmtC bound to the 30S ribosomal subunit
3VU8	;	2.2	;	Metionyl-tRNA synthetase from Thermus thermophilus complexed with methionyl-adenylate analogue
5MJC	;	1.62	;	metNeuroglobin under oxygen at 50 bar
5MJD	;	1.7	;	metNgb under oxygen at 80 bar
6GFN	;	2.86	;	METTL16 MTase domain
6GT5	;	2.45	;	METTL16 MTase domain (crystal form 2)
7O2I	;	3.0	;	METTL3-METTL14 heterodimer bound to the SAM competitive small molecule inhibitor STM2457
8BN8	;	2.213	;	METTL3-METTL14 heterodimer bound to the SAM competitive small molecule inhibitor STM3006
2HKE	;	1.8	;	Mevalonate diphosphate decarboxylase from Trypanosoma brucei
5V2L	;	2.1	;	Mevalonate diphosphate mediated ATP binding mechanism of the mevalonate diphosphate decarboxylase from Enterococcus faecalis
5V2M	;	1.989	;	Mevalonate diphosphate mediated ATP binding mechanism of the mevalonate diphosphate decarboxylase from Enterococcus faecalis
6MDF	;	2.46	;	Mevalonate kinase from Methanosarcina mazei with 5-phosphomevalonate bound
6MDE	;	2.1	;	Mevalonate kinase from Methanosarcina mazei with mevalonate bound
7OEQ	;	1.36	;	Mevalonyl-coenzyme A hydratase (Sid H)
7BSM	;	2.8	;	Mevo lectin complex with 2alpha-mannobiose
7BSN	;	2.6	;	Mevo lectin complex with 3alpha-mannobiose
7BT9	;	2.45	;	Mevo lectin complex with alpha-mannose
7DED	;	2.228	;	Mevo lectin complex with mannoheptose (Man7)
7BTL	;	2.25	;	Mevo lectin complex with mannopentose
7W62	;	2.0	;	Mevo lectin complex with mannotetraose (Man4)
7BT8	;	2.7	;	Mevo lectin complex with mannotriose
7WAP	;	3.1	;	Mevo lectin mutant D134A
7BTH	;	2.6	;	Mevo lectin- Native form-1
7BSB	;	2.45	;	Mevo lectin- Native form-2
6TA6	;	3.2	;	MexAB assembly of the Pseudomonas MexAB-OprM efflux pump reconstituted in nanodiscs
6IIA	;	2.91	;	MexB in complex with LMNG
6T7S	;	4.5	;	MexB structure solved by cryo-EM in nanodisc in absence of its protein partners
2BDZ	;	2.1	;	Mexicain from Jacaratia mexicana
4ZZL	;	2.19	;	MexR R21W derepressor mutant causing multidrug resistance in P. aeruginosa by mexAB-oprM efflux pump expression
6EY3	;		;	mf2
7SSG	;	5.2	;	Mfd DNA complex
6X2N	;	3.9	;	Mfd-bound E.coli RNA polymerase elongation complex - I state
6X43	;	3.6	;	Mfd-bound E.coli RNA polymerase elongation complex - II state
6X4W	;	3.8	;	Mfd-bound E.coli RNA polymerase elongation complex - III state
6X4Y	;	3.6	;	Mfd-bound E.coli RNA polymerase elongation complex - IV state
6X26	;	4.1	;	Mfd-bound E.coli RNA polymerase elongation complex - L1 state
6X2F	;	4.0	;	Mfd-bound E.coli RNA polymerase elongation complex - L2 state
6X50	;	3.3	;	Mfd-bound E.coli RNA polymerase elongation complex - V state
1QOK	;	2.4	;	MFE-23 AN ANTI-CARCINOEMBRYONIC ANTIGEN SINGLE-CHAIN FV ANTIBODY
2BHD	;	2.5	;	Mg substituted E. coli Aminopeptidase P in complex with product
1L8P	;	2.1	;	Mg-phosphonoacetohydroxamate complex of S39A yeast enolase 1
1WL6	;	2.0	;	Mg-substituted form of E. coli aminopeptidase P
1RVA	;	2.0	;	MG2+ BINDING TO THE ACTIVE SITE OF ECO RV ENDONUCLEASE: A CRYSTALLOGRAPHIC STUDY OF COMPLEXES WITH SUBSTRATE AND PRODUCT DNA AT 2 ANGSTROMS RESOLUTION
1RVB	;	2.1	;	MG2+ BINDING TO THE ACTIVE SITE OF ECO RV ENDONUCLEASE: A CRYSTALLOGRAPHIC STUDY OF COMPLEXES WITH SUBSTRATE AND PRODUCT DNA AT 2 ANGSTROMS RESOLUTION
1RVC	;	2.1	;	MG2+ BINDING TO THE ACTIVE SITE OF ECO RV ENDONUCLEASE: A CRYSTALLOGRAPHIC STUDY OF COMPLEXES WITH SUBSTRATE AND PRODUCT DNA AT 2 ANGSTROMS RESOLUTION
4JP1	;	2.46	;	Mg2+ bound structure of Vibrio Cholerae CheY3
3TH2	;	1.72	;	Mg2+ Is Required for Optimal Folding of the Gamma-Carboxyglutamic Acid (Gla) Domains of Vitamin K-Dependent Clotting Factors At Physiological Ca2+
3TH3	;	2.7	;	Mg2+ Is Required for Optimal Folding of the Gamma-Carboxyglutamic Acid (Gla) Domains of Vitamin K-Dependent Clotting Factors At Physiological Ca2+
3TH4	;	1.8	;	Mg2+ Is Required for Optimal Folding of the Gamma-Carboxyglutamic Acid (Gla) Domains of Vitamin K-Dependent Clotting Factors At Physiological Ca2+
7K2T	;	3.6	;	Mg2+/ATP-bound structure of the full-length WzmWzt O antigen ABC transporter in lipid nanodiscs
7YZQ	;	1.96	;	MgADP-AlF4-bound DCCP:DCCP-R complex
7QQA	;	1.79	;	MgADP-bound Fe protein of the iron-only nitrogenase from Azotobacter vinelandii
6Q93	;	2.2	;	MgADP-bound Fe protein of Vanadium nitrogenase from Azotobacter vinelandii
7YZM	;	1.82	;	MgADPNP-bound DCCP:DCCP-R complex
5WAY	;	2.09	;	MgaSpn protein, Mga regulator from Streptococcus pneumoniae
1G20	;	2.2	;	MGATP-BOUND AND NUCLEOTIDE-FREE STRUCTURES OF A NITROGENASE PROTEIN COMPLEX BETWEEN LEU127DEL-FE PROTEIN AND THE MOFE PROTEIN
1G21	;	3.0	;	MGATP-BOUND AND NUCLEOTIDE-FREE STRUCTURES OF A NITROGENASE PROTEIN COMPLEX BETWEEN LEU127DEL-FE PROTEIN AND THE MOFE PROTEIN
6BQB	;	1.769	;	MGG4 Fab in complex with peptide
7C40	;	2.516	;	MgGDP bound KRAS G12V
3T1O	;	1.9	;	MglA bound to GDP
3T1T	;	1.9	;	MglA bound to GDP in P1 tetrameric arrangement
3T1V	;	2.4	;	MglA bound to GDP in P2(1) tetrameric arrangement
3T1Q	;	2.7	;	MglA bound to GppNHp in complex with MglB
3T12	;	2.2	;	MglA in complex with MglB in transition state
3T1S	;	1.67	;	MglB Homodimer
3T1X	;	2.91	;	MglB R124A E127A Monomer
3T1R	;	2.0	;	MglB with tetrameric arrangement
5CNI	;	2.69	;	mGlu2 with Glutamate
4XAR	;	2.26	;	mGluR2 ECD and mGluR3 ECD complex with ligands
4XAQ	;	2.21	;	mGluR2 ECD and mGluR3 ECD with ligands
4XAS	;	2.35	;	mGluR2 ECD ligand complex
5CNJ	;	2.65	;	mGlur2 with glutamate analog
5CNM	;	2.84	;	mGluR3 complexed with glutamate analog
5CNK	;	3.15	;	mglur3 with glutamate
1MJS	;	1.91	;	MH2 domain of transcriptional factor SMAD3
6G3K	;	2.9	;	MHC A02 Allele presenting MTSAIGILPV
6G3J	;	2.45	;	MHC A02 Allele presenting MTSAIGILVP
7Q9B	;	3.24	;	MHC Class I A02 Allele presenting EAAGIGILTV, in complex with Mel8 TCR
7Q9A	;	2.1	;	MHC Class I A02 Allele presenting LLLGIGILVL, in complex with Mel5 TCR
7Q98	;	2.5	;	MHC Class I A02 Allele presenting NLSALGIFST
7Q99	;	2.55	;	MHC Class I A02 Allele presenting NLSALGIFST, in complex with Mel5 TCR
7ZQI	;	2.15	;	MHC class I from a wild bird in complex with a nonameric peptide P2
7ZQJ	;	2.25	;	MHC class I from a wild bird in complex with a nonameric peptide P3
1CE6	;	2.9	;	MHC CLASS I H-2DB COMPLEXED WITH A SENDAI VIRUS NUCLEOPROTEIN PEPTIDE
1QLF	;	2.65	;	MHC CLASS I H-2DB COMPLEXED WITH GLYCOPEPTIDE K3G
3E6F	;	2.41	;	MHC CLASS I H-2Dd Heavy chain complexed with Beta-2 Microglobulin and a variant peptide, PA9, from the Human immunodeficiency virus (BaL) envelope glycoprotein 120
3E6H	;	2.1	;	MHC CLASS I H-2Dd heavy chain complexed with Beta-2 Microglobulin and a variant peptide, PI10, from the human immunodeficiency virus (BaL) envelope glycoprotein 120
1DDH	;	3.1	;	MHC CLASS I H-2DD HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND AN IMMUNODOMINANT PEPTIDE P18-I10 FROM THE HUMAN IMMUNODEFICIENCY VIRUS ENVELOPE GLYCOPROTEIN 120
1OSZ	;	2.1	;	MHC CLASS I H-2KB HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND AN (L4V) MUTANT OF THE VESICULAR STOMATITIS VIRUS NUCLEOPROTEIN
1VAC	;	2.5	;	MHC CLASS I H-2KB HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND CHICKEN OVALBUMIN
1RK0	;	2.61	;	Mhc Class I H-2Kb Heavy Chain Complexed With beta-2 Microglobulin and Herpes Simplex Virus Glycoprotein B peptide
2VAB	;	2.5	;	MHC CLASS I H-2KB HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND SENDAI VIRUS NUCLEOPROTEIN
2VAA	;	2.3	;	MHC CLASS I H-2KB HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND VESICULAR STOMATITIS VIRUS NUCLEOPROTEIN
1VAD	;	2.5	;	MHC CLASS I H-2KB HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND YEAST ALPHA-GLUCOSIDASE
1KJ3	;	2.3	;	Mhc Class I H-2Kb molecule complexed with pKB1 peptide
1KBG	;	2.2	;	MHC Class I H-2KB Presented Glycopeptide RGY8-6H-GAL2
2FWO	;	2.6	;	MHC Class I H-2Kd heavy chain in complex with beta-2microglobulin and peptide derived from influenza nucleoprotein
4PGC	;	2.3	;	MHC Class I in complex with modified Sendai virus nucleoprotein peptide FAPGN(3,5-diiodotyrosine)PAL
4PGB	;	2.8	;	MHC Class I in complex with modified Sendai virus nucleoprotein peptide FAPGNWPAL
4PGD	;	2.7	;	MHC Class I in complex with modified Sendai virus nucleoprotein peptide FAPGNYPAF
4PGE	;	2.0	;	MHC Class I in complex with modified Sendai virus nucleoprotein peptide FAPGNYPAW
4PG9	;	2.4	;	MHC Class I in complex with Sendai virus nucleoprotein peptide FAPGNYPAL
1A1N	;	2.0	;	MHC CLASS I MOLECULE B*3501 COMPLEXED WITH PEPTIDE VPLRPMTY FROM THE NEF PROTEIN (75-82) OF HIV1
1A1O	;	2.3	;	MHC CLASS I MOLECULE B*5301 COMPLEXED WITH PEPTIDE LS6 (KPIVQYDNF) FROM THE MALARIA PARASITE P. FALCIPARUM
1A1M	;	2.3	;	MHC CLASS I MOLECULE B*5301 COMPLEXED WITH PEPTIDE TPYDINQML FROM GAG PROTEIN OF HIV2
1RK1	;	2.1	;	Mhc Class I Natural H-2Kb Heavy Chain Complexed With beta-2 Microglobulin and Herpes Simplex Virus Mutant Glycoprotein B Peptide
1FZK	;	1.7	;	MHC CLASS I NATURAL MUTANT H-2KBM1 HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND SENDAI VIRUS NUCLEOPROTEIN
1FZJ	;	1.9	;	MHC CLASS I NATURAL MUTANT H-2KBM1 HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND VESICULAR STOMATITIS VIRUS NUCLEOPROTEIN
1RJY	;	1.9	;	Mhc Class I Natural Mutant H-2Kbm8 Heavy Chain Complexed With beta-2 Microglobulin and Herpes Simplex Virus Glycoprotein B Peptide
1RJZ	;	2.6	;	Mhc Class I Natural Mutant H-2Kbm8 Heavy Chain Complexed With beta-2 Microglobulin and Herpies Simplex Virus Mutant Glycoprotein B Peptide
2CLZ	;	1.9	;	Mhc Class I Natural Mutant H-2Kbm8 Heavy Chain Complexed With beta-2 Microglobulin and pBM1 peptide
2CLV	;	1.9	;	MHC Class I Natural Mutant H-2Kbm8 Heavy Chain Complexed With beta-2 Microglobulin and pBM8 peptide
1FZO	;	1.8	;	MHC CLASS I NATURAL MUTANT H-2KBM8 HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND SENDAI VIRUS NUCLEOPROTEIN
1FZM	;	1.8	;	MHC CLASS I NATURAL MUTANT H-2KBM8 HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND VESICULAR STOMATITIS VIRUS NUCLEOPROTEIN
5F1N	;	2.0	;	MHC complexed to 11mer peptide
7P3E	;	2.0	;	MHC I A02 Allele presenting YLQLRTFLL
7P3D	;	1.67	;	MHC I A02 Allele presenting YLQPRTFLL
4P57	;	2.6	;	MHC TCR peptide complex
5F1I	;	2.904	;	MHC with 9-mer peptide
3BUY	;	2.6	;	MHC-I in complex with peptide
7YX9	;	1.76	;	MHC-II dynamics are maintained in HLA-DR allotypes to ensure catalyzed peptide exchange
7YXB	;	2.095	;	MHC-II dynamics are maintained in HLA-DR allotypes to ensure catalyzed peptide exchange
7Z0Q	;	2.1	;	MHC-II dynamics are maintained in HLA-DR allotypes to ensure catalyzed peptide exchange
6C68	;	2.59	;	MHC-independent t cell receptor A11
6C61	;	2.43	;	MHC-independent T-cell receptor B12A
6XNG	;	2.79	;	MHC-like protein complex structure
7M72	;	2.4	;	MHC-like protein complex structure
6JTT	;	2.51	;	MHETase in complex with BHET
8EKG	;	2.65	;	MHETase variant Thr159Val, Met192Tyr, Tyr252Phe, Tyr503Trp
2RPD	;		;	Mhr1p-bound ssDNA
3HD4	;	1.747	;	MHV Nucleocapsid Protein NTD
2YQ1	;	2.3	;	MHV-68 LANA (ORF73) C-terminal domain: triclinic crystal form
7MJX	;	1.5	;	MiaB in the complex with 5'-deoxyadenosine, methionine and RNA
7MJY	;	1.86	;	MiaB in the complex with s-adenosyl-L-homocysteine and RNA
7MJV	;	2.24	;	MiaB in the complex with s-adenosylmethionine and RNA
2LU2	;		;	MIC5 regulates the activity of Toxoplasma subtilisin 1 by mimicking a subtilisin prodomain
5UBO	;	2.39	;	Mical-oxidized Actin complex with Gelsolin Segment 1
5LE0	;	3.3	;	MICAL1 Cterminal domain
1NXT	;	2.34	;	MicArec pH 4.0
1NXV	;	2.0	;	MicArec pH 4.2
1NXW	;	1.92	;	MicArec pH 5.1
1NXX	;	1.9	;	MicArec pH 5.5
1NXP	;	1.82	;	MicArec pH4.5
1NXS	;	1.92	;	MicArec pH4.9
1NXO	;	1.85	;	MicArec pH7.0
2EQT	;		;	Micelle-bound structure of growth-blocking peptide of the armyworm, Pseudaletia separata
2RN0	;		;	Micelle-embedded integrin beta3 transmembrane segment
1D3C	;	1.78	;	MICHAELIS COMPLEX OF BACILLUS CIRCULANS STRAIN 251 CYCLODEXTRIN GLYCOSYLTRANSFERASE WITH GAMMA-CYCLODEXTRIN
3X2W	;	1.7	;	Michaelis complex of cAMP-dependent Protein Kinase Catalytic Subunit
1C81	;	2.5	;	MICHAELIS COMPLEX OF FRUCTOSE-2,6-BISPHOSPHATASE
4C4C	;	1.45	;	Michaelis complex of Hypocrea jecorina CEL7A E217Q mutant with cellononaose spanning the active site
1IKG	;	1.9	;	MICHAELIS COMPLEX OF STREPTOMYCES R61 DD-PEPTIDASE WITH A SPECIFIC PEPTIDOGLYCAN SUBSTRATE FRAGMENT
5BRR	;	3.16	;	Michaelis complex of tPA-S195A:PAI-1
3X2V	;	1.77	;	Michaelis-like complex of cAMP-dependent Protein Kinase Catalytic Subunit
3X2U	;	2.4	;	Michaelis-like initial complex of cAMP-dependent Protein Kinase Catalytic Subunit.
4PVV	;	2.5	;	Micobacterial Adenosine Kinase in complex with inhibitor
8T1N	;	3.0	;	Micro-ED Structure of a Novel Domain of Unknown Function Solved with AlphaFold
8ECO	;	2.2	;	Microbacterium phage Oxtober96
3VSR	;	2.0	;	Microbacterium saccharophilum K-1 beta-fructofuranosidase catalytic domain
3VSS	;	1.97	;	Microbacterium saccharophilum K-1 beta-fructofuranosidase catalytic domain complexed with fructose
3WPV	;	1.81	;	Microbacterium saccharophilum K-1 beta-fructofuranosidase mutant T47S/F447V/F470Y/P500S
3WPZ	;	2.27	;	Microbacterium saccharophilum K-1 beta-fructofuranosidase mutant T47S/S200T/F447P/F470Y/P500S
3WPY	;	2.0	;	Microbacterium saccharophilum K-1 beta-fructofuranosidase mutant T47S/S200T/F447V/P500S
7X8L	;	1.77	;	Microbial family VII carboxylesterase E93 Wild-type
6KF5	;	2.09	;	Microbial Hormone-sensitive lipase E53 mutant I256L
7CI0	;	1.7	;	Microbial Hormone-sensitive lipase E53 mutant S162A
6KF7	;	1.8	;	Microbial Hormone-sensitive lipase E53 mutant S285G
7CIH	;	1.789	;	Microbial Hormone-sensitive lipase E53 mutant S285G
7CIP	;	1.752	;	Microbial Hormone-sensitive lipase E53 wild type
7W8N	;	1.75	;	Microbial Hormone-sensitive lipase E53 wild type
6KF1	;	1.996	;	Microbial Hormone-sensitive lipase- E53 mutant S162A
6WB5	;	3.102	;	Microbiome-derived Acarbose Kinase Mak1 as a Complex with Acarbose and AMP-PNP
6WB4	;	2.593	;	Microbiome-derived Acarbose Kinase Mak1 Labeled with selenomethionine
3TLY	;	1.7	;	Microcin C7 self immunity protein MccF active site mutant S118A/N220A/K247A in the apo state
3TLB	;	1.501	;	Microcin C7 self immunity protein MccF in complex aspartyl sulfamoyl adenosine
3TLE	;	1.3	;	Microcin C7 self immunity protein MccF in complex with glutamyl sulfamoyl adenylate
3TLC	;	1.3	;	Microcin C7 self immunity protein MccF in complex with Microcin C7 antibiotic
3TLG	;	1.4993	;	Microcin C7 self immunity protein MccF in the inactive mutant APO state
3TLA	;	1.201	;	Microcin C7 self immunity protein MccF in the wild type APO state
3TLZ	;	1.5	;	Microcin C7 self immunity protein MccF mutant W186F in complex with Adenosine Monophosphate
2MLP	;		;	MICROCIN LEADER PEPTIDE FROM E. COLI, NMR, 25 STRUCTURES
5TY4	;	2.9	;	MicroED structure of a complex between monomeric TGF-b and its receptor, TbRII, at 2.9 A resolution
6U5G	;	2.5	;	MicroED structure of a FIB-milled CypA Crystal
7N2L	;	0.9	;	MicroED structure of a mutant mammalian prion segment
7N2J	;	1.5	;	MicroED structure of a mutant mammalian prion segment phased by ARCIMBOLDO-BORGES
6PO6	;	1.0	;	MicroED Structure of a Natural Product VFAThiaGlu
8FYN	;	2.0	;	MicroED structure of A2A from plasma milled lamellae
6YMA	;	2.5	;	MicroED structure of acetazolamide-bound human carbonic anhydrase II
7UTE	;	2.1	;	MicroED structure of Aeropyrum pernix protoglobin mutant
8EUN	;	2.5	;	MicroED structure of an Aeropyrum pernix protoglobin metallo-carbene complex
8EUM	;	2.1	;	MicroED structure of an Aeropyrum pernix protoglobin mutant
7C4V	;	1.05	;	MicroED structure of anorthic Vancomycin at 1.05 A resolution
8SKW	;	1.1	;	MicroED structure of d(CGCGCG)2 Z-DNA
7T3H	;	1.05	;	MicroED structure of Dynobactin
6YNG	;	2.8	;	MicroED structure of granulin determined from five native nanocrystalline granulovirus occlusion bodies
6YMB	;	2.5	;	MicroED structure of human carbonic anhydrase II
7N2E	;	1.0	;	MicroED structure of human CPEB3 segment (154-161) straight polymorph
7N2F	;	1.2	;	MicroED structure of human CPEB3 segment (154-161) straight polymorph phased by ARCIMBOLDO-BORGES
7N2G	;	1.201	;	MicroED structure of human CPEB3 segment(154-161) kinked polymorph phased by ARCIMBOLDO-BORGES
7N2I	;	1.402	;	MicroED structure of human LECT2 (45-53) phased by ARCIMBOLDO-BORGES
7N2D	;	1.503	;	MicroED structure of human zinc finger protein 292 segment (534-542) phased by ARCIMBOLDO-BORGES
6LAV	;	1.73	;	MicroED structure of lysozyme at 1.73A determained using crystal lamellas prepared by focused ion beam milling
5K7O	;	1.8	;	MicroED structure of lysozyme at 1.8 A resolution
7MRP	;	1.75	;	MicroED structure of lysozyme from milled crystals at 1.75A
7KUH	;	3.12	;	MicroED structure of mVDAC
6CPV	;	2.5002	;	MicroED structure of NaK ion channel reveals a process of Na+ partition into the selectivity filter
7C4U	;	1.2	;	MicroED structure of orthorhombic Vancomycin at 1.2 A resolution
6UOW	;	1.2	;	MicroED structure of OsPYL/RCAR5 (24-29) at 12 e-/A^2
6UOR	;	0.9	;	MicroED structure of OsPYL/RCAR5 (24-29) at 3 e-/A^2
6UOS	;	0.9	;	MicroED structure of OsPYL/RCAR5 (24-29) at 6 e-/A^2
6UOU	;	1.04	;	MicroED structure of OsPYL/RCAR5 (24-29) at 9 e-/A^2
6LAW	;	1.5	;	MicroED structure of proteinase K at 1.50A determained using crystal lamellas prepared by focused ion beam milling
5K7S	;	1.6	;	MicroED structure of proteinase K at 1.6 A resolution
5I9S	;	1.75	;	MicroED structure of proteinase K at 1.75 A resolution
6N4U	;	2.75	;	MicroED structure of Proteinase K at 2.75A resolution from a single milled crystal.
7SW1	;	1.85	;	MicroED structure of proteinase K from a 115 nm thick lamella measured at 200 kV
7SVY	;	2.3	;	MicroED structure of proteinase K from a 130 nm thick lamella measured at 120 kV
7SW2	;	1.95	;	MicroED structure of proteinase K from a 130 nm thick lamella measured at 200 kV
7SW8	;	1.9	;	MicroED structure of proteinase K from a 150 nm thick lamella measured at 300 kV
7SW9	;	2.1	;	MicroED structure of proteinase K from a 170 nm thick lamella measured at 300 kV
7SVZ	;	2.0	;	MicroED structure of proteinase K from a 200 nm thick lamella measured at 120 kV
7SW6	;	1.95	;	MicroED structure of proteinase K from a 260 nm thick lamella measured at 200 kV
7SWA	;	2.1	;	MicroED structure of proteinase K from a 320 nm thick lamella measured at 300 kV
7SW0	;	2.7	;	MicroED structure of proteinase K from a 325 nm thick lamella measured at 120 kV
7SWB	;	2.05	;	MicroED structure of proteinase K from a 360 nm thick lamella measured at 300 kV
7SW5	;	1.95	;	MicroED structure of proteinase K from a 460 nm thick lamella measured at 200 kV
7SW7	;	2.3	;	MicroED structure of proteinase K from a 530 nm thick lamella measured at 200 kV
7SW4	;	2.4	;	MicroED structure of proteinase K from a 540 nm thick lamella measured at 200 kV
7SWC	;	2.9	;	MicroED structure of proteinase K from a 550 nm thick lamella measured at 300 kV
7SW3	;	2.35	;	MicroED structure of proteinase K from a 95 nm thick lamella measured at 200 kV
6PKO	;	2.07	;	MicroED structure of proteinase K from a platinum coated, unpolished, single lamella at 2.07A resolution (#12)
6PKR	;	1.79	;	MicroED structure of proteinase K from a platinum-coated, polished, single lamella at 1.79A resolution (#13)
6PKQ	;	1.85	;	MicroED structure of proteinase K from a platinum-coated, polished, single lamella at 1.85A resolution (#11)
6PKP	;	1.91	;	MicroED structure of proteinase K from a platinum-coated, polished, single lamella at 1.91A resolution (#10)
6PKJ	;	2.17	;	MicroED structure of proteinase K from an uncoated, single lamella at 2.17A resolution (#2)
6PKM	;	2.17	;	MicroED structure of proteinase K from an uncoated, single lamella at 2.17A resolution (#8)
6PKK	;	2.176	;	MicroED structure of proteinase K from an uncoated, single lamella at 2.18A resolution (#5)
6PKL	;	2.59	;	MicroED structure of proteinase K from an uncoated, single lamella at 2.59A resolution (#7)
6PKN	;	2.08	;	MicroED structure of proteinase K from an unpolished, platinum-coated, single lamella at 2.08A resolution (#9)
8FYQ	;	1.4	;	MicroED structure of Proteinase K from argon milled lamellae
8FYO	;	1.39	;	MicroED structure of Proteinase K from lamellae milled from multiple plasma sources
6PKS	;	2.16	;	MicroED structure of proteinase K from low-dose merged lamellae that were not pre-coated with platinum 2.16A resolution (LD)
6PKT	;	1.85	;	MicroED structure of proteinase K from merging low-dose, platinum pre-coated lamellae at 1.85A resolution (LDPT)
8FYS	;	1.8	;	MicroED structure of Proteinase K from nitrogen milled lamellae
8FYR	;	1.5	;	MicroED structure of Proteinase K from oxygen milled lamellae
8FYP	;	1.45	;	MicroED structure of Proteinase K from xenon milled lamellae
6PU5	;	2.7	;	MicroED structure of proteinase K recorded on CetaD
6PU4	;	2.1	;	MicroED structure of proteinase K recorded on Falcon III
8E52	;	2.8	;	MicroED structure of proteinase K recorded on K2
8E53	;	1.7	;	MicroED structure of proteinase K recorded on K3
7N2K	;	1.301	;	MicroED structure of sequence variant of repeat segment of the yeast prion New1p phased by ARCIMBOLDO-BORGES
5K7N	;	1.1	;	MicroED structure of tau VQIVYK peptide at 1.1 A resolution
5K7Q	;	2.5	;	MicroED structure of thaumatin at 2.5 A resolution
6N3J	;	3.0	;	MicroED Structure of the CTD-SP1 fragment of HIV-1 Gag
6N3U	;	2.9	;	MicroED Structure of the CTD-SP1 fragment of HIV-1 Gag with bound maturation inhibitor Bevirimat.
6N3U	;		;	MicroED Structure of the CTD-SP1 fragment of HIV-1 Gag with bound maturation inhibitor Bevirimat.
7RM5	;	2.79	;	MicroED structure of the human adenosine receptor at 2.8A
7BEQ	;	3.0	;	MicroED structure of the MyD88 TIR domain higher-order assembly
5W52	;	1.4	;	MicroED structure of the segment, DLIIKGISVHI, from the RRM2 of TDP-43, residues 247-257
4ZNN	;	1.41	;	MicroED structure of the segment, GVVHGVTTVA, from the A53T familial mutant of Parkinson's disease protein, alpha-synuclein residues 47-56
5WKB	;	1.0	;	MicroED structure of the segment, NFGEFS, from the A315E familial variant of the low complexity domain of TDP-43, residues 312-317
5K7T	;	2.5	;	MicroED structure of thermolysin at 2.5 A resolution
6MXF	;	1.91	;	MicroED structure of thiostrepton at 1.9 A resolution
7ULY	;	0.87	;	MicroED structure of triclinic lysozyme
8E54	;	1.2	;	MicroED structure of triclinic lysozyme recorded on K3
5K7R	;	1.7	;	MicroED structure of trypsin at 1.7 A resolution
5K7P	;	2.3	;	MicroED structure of xylanase at 2.3 A resolution
3QY5	;	1.25	;	Microfluidic crystallization of Thaumatin using the Crystal Former
4BY8	;	0.94	;	Microheterogeneous Paracelsin-X from Trichoderma reesei
2XQS	;	3.0	;	Microscopic rotary mechanism of ion translocation in the Fo complex of ATP synthases
2XQT	;	2.2	;	Microscopic rotary mechanism of ion translocation in the Fo complex of ATP synthases
2XQU	;	1.84	;	Microscopic rotary mechanism of ion translocation in the Fo complex of ATP synthases
1N6B	;	2.3	;	Microsomal Cytochrome P450 2C5/3LVdH Complex with a dimethyl derivative of sulfaphenazole
1NR6	;	2.1	;	MICROSOMAL CYTOCHROME P450 2C5/3LVDH COMPLEX WITH DICLOFENAC
2FDY	;	1.95	;	Microsomal P450 2A6 with the inhibitor Adrithiol bound
2FDU	;	1.85	;	Microsomal P450 2A6 with the inhibitor N,N-Dimethyl(5-(pyridin-3-yl)furan-2-yl)methanamine bound
2FDV	;	1.65	;	Microsomal P450 2A6 with the inhibitor N-Methyl(5-(pyridin-3-yl)furan-2-yl)methanamine bound
1Z9H	;	2.6	;	Microsomal prostaglandin E synthase type-2
6I7S	;	2.5	;	Microsomal triglyceride transfer protein
8EOJ	;	3.07	;	Microsomal triglyceride transfer protein
3ERR	;	2.27	;	Microtubule binding domain from mouse cytoplasmic dynein as a fusion with seryl-tRNA synthetase
2RR7	;		;	Microtubule Binding Domain of DYNEIN-C
5FCN	;	1.8	;	microtubule binding domain of human CEP135
6ZPI	;	4.5	;	Microtubule complexed with Kif15 motor domain. Symmetrised asymmetric unit
8C5C	;	5.3	;	microtubule decorated with tubulin oligomers in presence of APC C-terminal domain. (here only map corresponding to the 13-pf microtubule is represented)
5JCB	;	2.3	;	Microtubule depolymerizing agent podophyllotoxin derivative YJTSF1
5N74	;	2.3	;	Microtubule end binding protein complex
3ECI	;	2.65	;	Microtubule-associated protein 1 light chain 3 alpha isoform A (MAP1ALC3)
5ND2	;	5.8	;	Microtubule-bound MKLP2 motor domain in the presence of ADP
5ND4	;	4.4	;	Microtubule-bound MKLP2 motor domain in the presence of ADP.AlFx
5ND7	;	7.9	;	Microtubule-bound MKLP2 motor domain in the presence of AMPPNP
5ND3	;	6.1	;	Microtubule-bound MKLP2 motor domain in the with no nucleotide
2Y1S	;		;	Microvirin lectin
2YHH	;		;	Microvirin:mannobiose complex
7SSD	;	3.3	;	Mid translocation intermediate with EF-G bound with GDP (Structure IV)
7K54	;	3.2	;	Mid-translocated +1-frameshifting(CCC-A) complex with EF-G and GDPCP (Structure II-FS)
7K51	;	3.5	;	Mid-translocated non-frameshifting(CCA-A) complex with EF-G and GDPCP (Structure II)
3E1R	;	2.0	;	Midbody targeting of the ESCRT machinery by a non-canonical coiled-coil in CEP55
7PUA	;	3.6	;	Middle assembly intermediate of the Trypanosoma brucei mitoribosomal small subunit
4J8E	;	2.6	;	Middle domain of Hsc70-interacting protein, crystal form I
4J8D	;	2.8	;	Middle domain of Hsc70-interacting protein, crystal form II
1HK7	;	2.5	;	Middle Domain of HSP90
1HU3	;	2.37	;	MIDDLE DOMAIN OF HUMAN EIF4GII
6KSQ	;	2.202	;	Middle Domain of Human HSP90 Alpha
4J2R	;	2.42	;	Middle domain of influenza A virus RNA-dependent polymerase PB2
1Y6Z	;	1.88	;	Middle domain of Plasmodium falciparum putative heat shock protein PF14_0417
4M02	;	1.59	;	Middle fragment(residues 494-663) of the binding region of SraP
8PHR	;	2.65	;	Middle part of the Borrelia bacteriophage BB1 procapsid, tenfold-symmetrized outer shell
8IXJ	;	3.1	;	Middle segment of the bacteriophage M13 mini variant
8D5A	;	3.1	;	Middle state of SARS-CoV-2 BA.2 variant spike protein
2OOW	;	1.75	;	MIF Bound to a Fluorinated OXIM Derivative
4Z1U	;	2.05	;	MIF in complex with 1-(4-methylphenyl)-3-phenylprop-2-yn-1-one
4Z15	;	1.6	;	MIF in complex with 3-(2-furylmethyl)-2-thioxo-1,3-thiazolan-4-one
4Z1T	;	1.5	;	MIF in complex with 4-[(4-oxo-2-thioxo-1,3-thiazolan-3-yl)methyl]benzonitrile
6PEG	;	2.0	;	MIF with a allosteric inhibitor
7KQX	;	1.6	;	MIF Y99C homotrimeric mutant
4IUL	;	2.3	;	MIF4G domain of DAP5
4B89	;	1.5	;	MIF4G domain of the yeast Not1
1MR8	;	1.9	;	MIGRATION INHIBITORY FACTOR-RELATED PROTEIN 8 FROM HUMAN
3NVG	;	1.48	;	MIHFGN segment 137-142 from mouse prion
3NVH	;	1.61	;	MIHFGND segment 137-143 from mouse prion
8B2V	;	1.73	;	Millisecond cryo-trapping by the spitrobot crystal plunger, CTX-M-14 E166A Ampicillin, 1 sec
8B2O	;	1.86	;	Millisecond cryo-trapping by the spitrobot crystal plunger, CTX-M-14 E166A, Ampicillin, 5 sec
8B2W	;	1.78	;	Millisecond cryo-trapping by the spitrobot crystal plunger, CTX-M-14 E166A, Ampicillin, 500 MS
8B3M	;	1.97	;	Millisecond cryo-trapping by the spitrobot crystal plunger, CTXM-14 Avibactam complex, SSX, 1 sec
8AWY	;	1.6	;	Millisecond cryo-trapping by the spitrobot crystal plunger, Serial measurement Xylose Isomerase with 2,3-butanediol at 50ms
8AWX	;	1.96	;	Millisecond cryo-trapping by the spitrobot crystal plunger, Xylose Isomerase with Glucose at 1s
8AWU	;	1.47	;	Millisecond cryo-trapping by the spitrobot crystal plunger, Xylose Isomerase with Glucose at 250ms
8AWV	;	2.08	;	Millisecond cryo-trapping by the spitrobot crystal plunger, Xylose Isomerase with Glucose at 500ms
8AWS	;	2.26	;	Millisecond cryo-trapping by the spitrobot crystal plunger, Xylose Isomerase with Glucose at 50ms
6MFI	;	1.839	;	MIM-2 Metallo-Beta-Lactamase
8ODR	;	2.85	;	Mimetic of UBC9-SUMO1
7Q0C	;	1.12	;	Mimic carbonic anhydrase IX in complex with Methyl 2-chloro-4-(cyclohexylsulfanyl)-5-sulfamoylbenzoate
3BBK	;	2.75	;	Miminally Junctioned Hairpin Ribozyme Incorporates A38C and 2'5'-phosphodiester Linkage within Active Site
4Z24	;	2.0	;	Mimivirus R135 (residues 51-702)
4Z25	;	3.339	;	Mimivirus R135 (residues 51-702)
4Z26	;	2.915	;	Mimivirus R135 (residues 51-702)
4BA3	;	2.1	;	mImp_alphadIBB_A89NLS
2YNR	;	2.3	;	mImp_alphadIBB_B54NLS
4V02	;	2.7	;	MinC:MinD cell division protein complex, Aquifex aeolicus
6RIQ	;	3.1	;	MinCD filament from Pseudomonas aeruginosa
8H4V	;	2.4	;	Mincle CRD complex with PGL trisaccharide
1HYQ	;	2.6	;	MIND BACTERIAL CELL DIVISION REGULATOR FROM A. FULGIDUS
4V03	;	1.9	;	MinD cell division protein, Aquifex aeolicus
2AAX	;	1.75	;	Mineralocorticoid Receptor Double Mutant with Bound Cortisone
2AB2	;	1.85	;	Mineralocorticoid Receptor Double Mutant with Bound Spironolactone
6GEV	;	1.54	;	Mineralocorticoid receptor in complex with (s)-13
6GG8	;	1.8	;	Mineralocorticoid receptor in complex with (s)-13
6GGG	;	1.71	;	Mineralocorticoid receptor in complex with (s)-13
3WFF	;	2.05	;	Mineralocorticoid receptor ligand-binding domain with compound 2b
3WFG	;	1.4	;	Mineralocorticoid receptor ligand-binding domain with compuond 2e
4PF3	;	1.1	;	Mineralocorticoid receptor ligand-binding domain with compuond 37a
3VHV	;	1.35	;	Mineralocorticoid receptor ligand-binding domain with non-steroidal antagonist
3VHU	;	2.11	;	Mineralocorticoid receptor ligand-binding domain with spironolactone
2AA6	;	1.95	;	Mineralocorticoid Receptor S810L Mutant with Bound Progesterone
2AA2	;	1.95	;	Mineralocorticoid Receptor with Bound Aldosterone
2AA7	;	2.2	;	Mineralocorticoid Receptor with Bound Deoxycorticosterone
2AA5	;	2.2	;	Mineralocorticoid Receptor with Bound Progesterone
5EIU	;	1.908	;	Mini TRIM5 B-box 2 dimer C2 crystal form
2L13	;		;	mini-haipin of AT basepairs having a C12-alkyl linker forming the loop region
1SJU	;		;	MINI-PROINSULIN, SINGLE CHAIN INSULIN ANALOG MUTANT: DES B30, HIS(B 10)ASP, PRO(B 28)ASP AND PEPTIDE BOND BETWEEN LYS B 29 AND GLY A 1, NMR, 20 STRUCTURES
1SJT	;		;	MINI-PROINSULIN, TWO CHAIN INSULIN ANALOG MUTANT: DES B30, HIS(B 10)ASP, PRO(B 28)ASP, NMR, 20 STRUCTURES
6TNN	;	3.07	;	Mini-RNase III (Mini-III) bound to 50S ribosome with precursor 23S rRNA
5TX2	;	1.82	;	Miniature TGF-beta2 3-mutant monomer
8C9N	;	2.36	;	MiniCoV-ADDomer, a SARS-CoV-2 epitope presenting viral like particle
8CTA	;	2.93	;	Minimal 2:2 Ternary Complex between BI-224436 bound HIV-1 Integrase Catalytic Core Domain Dimer and Carboxy Terminal Domains
1G2G	;		;	MINIMAL CONFORMATION OF THE ALPHA-CONOTOXIN IMI FOR THE ALPHA7 NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR RECOGNITION
2KWB	;		;	Minimal Constraint Solution NMR Structure of Translationally-controlled tumor protein (TCTP) from C.elegans, Northeast Structural Genomics Consortium Target WR73
2LMD	;		;	Minimal Constraints Solution NMR Structure of Prospero Homeobox protein 1 from Homo sapiens, Northeast Structural Genomics Consortium Target HR4660B
6YA6	;	1.44	;	Minimal construct of Cdc7-Dbf4 bound to XL413
4G6P	;	2.641	;	Minimal Hairpin Ribozyme in the Precatalytic State with A38P Variation
4G6S	;	2.84	;	Minimal Hairpin Ribozyme in the Transition State with A38P Variation
4G6R	;	2.832	;	Minimal Hairpin Ribozyme in the Transition State with G8I Variation
2PZE	;	1.7	;	Minimal human CFTR first nucleotide binding domain as a head-to-tail dimer
2PZF	;	2.0	;	Minimal human CFTR first nucleotide binding domain as a head-to-tail dimer with delta F508
2PZG	;	1.8	;	Minimal human CFTR first nucleotide binding domain as a monomer
8PMB	;		;	Minimal I-motif comprising three cytosine-cytosine+ base-pairs
8SSF	;	2.5	;	Minimal protein-only/RNA-free Ribonuclease P from Hydrogenobacter thermophilus
8SSG	;	3.2	;	Minimal protein-only/RNA-free Ribonuclease P from Hydrogenobacter thermophilus
8DKO	;	1.8	;	Minimal PutA proline dehydrogenase domain (design #1) complexed with S-(-)-tetrahydro-2-furoic acid
8DKQ	;	1.72	;	Minimal PutA proline dehydrogenase domain (design #2) complexed with 2-(Furan-2-yl)acetic acid
8DKP	;	1.23	;	Minimal PutA proline dehydrogenase domain (design #2) complexed with S-(-)-tetrahydro-2-furoic acid
3CJS	;	1.37	;	Minimal Recognition Complex between PrmA and Ribosomal Protein L11
4PJO	;	3.3	;	Minimal U1 snRNP
3B5S	;	2.25	;	Minimally Hinged Hairpin Ribozyme Incorporates A38DAP Mutation and 2'-O-methyl Modification at the Active Site
3B91	;	2.75	;	Minimally Hinged Hairpin Ribozyme Incorporates Ade38(2AP) and 2',5'-Phosphodiester Linkage Mutations at the Active Site
3BBM	;	2.65	;	Minimally Junctioned Hairpin Ribozyme Incorporates A38C and 2'O-Me Modification at Active Site
3B58	;	2.65	;	Minimally Junctioned Hairpin Ribozyme Incorporates A38G Mutation and a 2',5'-Phosphodiester Linkage at the Active Site
3BBI	;	2.35	;	Minimally Junctioned Hairpin Ribozyme Incorporating A38(2AP) and A-1 2'-O-Me Modifications near Active Site
6WHK	;	2.6	;	Minimally mutated anti-influenza broadly neutralizing antibody
1K18	;		;	Minimized Average NMR Structure of the Zinc Finger Domain of Human DNA Polymerase-alpha
1KX2	;		;	Minimized average structure of a mono-heme ferrocytochrome c from Shewanella putrefaciens
1J56	;		;	MINIMIZED AVERAGE STRUCTURE OF BERYLLOFLUORIDE-ACTIVATED NTRC RECEIVER DOMAIN: MODEL STRUCTURE INCORPORATING ACTIVE SITE CONTACTS
1JY9	;		;	MINIMIZED AVERAGE STRUCTURE OF DP-TT2
3J6F	;	4.9	;	Minimized average structure of GDP-bound dynamic microtubules
3J6G	;	5.5	;	Minimized average structure of microtubules stabilized by taxol
1IQS	;		;	Minimized average structure of MTH1880 from Methanobacterium Thermoautotrophicum
1J4M	;		;	Minimized average structure of the 14-residue peptide RG-KWTY-NG-ITYE-GR (MBH12)
1L2M	;		;	Minimized Average Structure of the N-terminal, DNA-binding domain of the replication initiation protein from a geminivirus (Tomato yellow leaf curl virus-Sardinia)
2JU2	;		;	Minimized mean solution structure of the acyl carrier protein domain from module 2 of 6-deoxyerythronolide B synthase (DEBS)
1JXC	;		;	Minimized NMR structure of ATT, an Arabidopsis trypsin/chymotrypsin inhibitor
1JFK	;		;	MINIMUM ENERGY REPRESENTATIVE STRUCTURE OF A CALCIUM BOUND EF-HAND PROTEIN FROM ENTAMOEBA HISTOLYTICA
1HY2	;	2.0	;	MINIPROTEIN MP-1 COMPLEX WITH STREPTAVIDIN
1HQQ	;	1.7	;	MINIPROTEIN MP-2 (M9A) COMPLEX WITH STREPTAVIDIN
1HXL	;	1.8	;	MINIPROTEIN MP-2 (V10A) COMPLEX WITH STREPTAVIDIN
1HXZ	;	1.8	;	MINIPROTEIN MP-2 COMPLEX WITH STREPTAVIDIN
7LWM	;	2.83	;	Mink Cluster 5-associated SARS-CoV-2 spike protein (S-GSAS-D614G-delFV) in the 1-RBD up conformation
7LWN	;	2.94	;	Mink Cluster 5-associated SARS-CoV-2 spike protein (S-GSAS-D614G-delFV) in the 1-RBD up conformation
7LWO	;	2.85	;	Mink Cluster 5-associated SARS-CoV-2 spike protein (S-GSAS-D614G-delFV) in the 1-RBD up conformation
7LWP	;	3.01	;	Mink Cluster 5-associated SARS-CoV-2 spike protein (S-GSAS-D614G-delFV) in the 2-RBD up conformation
7LWI	;	3.07	;	Mink Cluster 5-associated SARS-CoV-2 spike protein (S-GSAS-D614G-delFV) in the 3-RBD down conformation
7LWJ	;	3.24	;	Mink Cluster 5-associated SARS-CoV-2 spike protein (S-GSAS-D614G-delFV) in the 3-RBD down conformation
7LWK	;	2.92	;	Mink Cluster 5-associated SARS-CoV-2 spike protein (S-GSAS-D614G-delFV) in the 3-RBD down conformation
7LWL	;	2.84	;	Mink Cluster 5-associated SARS-CoV-2 spike protein (S-GSAS-D614G-delFV) in the 3-RBD down conformation
7LWQ	;	3.44	;	Mink Cluster 5-associated SARS-CoV-2 spike protein(S-GSAS-D614G-delFV) missing the S1 subunit and SD2 subdomain of one protomer
7R18	;	3.0	;	Mink Variant SARS-CoV-2 Spike in Closed conformation
7R1B	;	2.8	;	Mink Variant SARS-CoV-2 Spike with 1 Erect RBD
7R19	;	3.3	;	Mink Variant SARS-CoV-2 Spike with 2 Erect RBDs
6ZO6	;	2.35	;	Minocycline binding to the deep binding pocket of AcrB-G619P
6ZO8	;	2.5	;	Minocycline binding to the deep binding pocket of AcrB-G621P
6ZOG	;	2.75	;	Minocycline binding to the deep binding pocket of AcrB-I38F_I671T
5ENT	;	2.5	;	Minocycline bound structure of bacterial efflux pump.
1BPS	;		;	MINOR CONFORMER OF A BENZO[A]PYRENE DIOL EPOXIDE ADDUCT OF DA IN DUPLEX DNA
7FG2	;	4.4	;	Minor cryo-EM structure of S protein trimer of SARS-CoV2 with K-874A VHH, composite map
3HJ4	;	1.56	;	Minor Editosome-Associated TUTase 1
3HJ1	;	1.95	;	Minor Editosome-Associated TUTase 1 with bound UTP
3HIY	;	2.3	;	Minor Editosome-Associated TUTase 1 with bound UTP and Mg
5LUE	;		;	Minor form of the recombinant cytotoxin-1 from N. oxiana
144D	;	2.25	;	MINOR GROOVE BINDING OF SN6999 TO AN ALKYLATED DNA: MOLECULAR STRUCTURE OF D(CGC[E6G]AATTCGCG)-SN6999 COMPLEX
5TTD	;	2.0	;	Minor pilin FctB from S. pyogenes with engineered intramolecular isopeptide bond
7XO2	;	3.0	;	Minor polymorph in alpha-synuclein fibril seeded by cerebrospinal fluid from a mid-to-late stage (mid-PD-4) Parkinson's disease patient
8H05	;	3.4	;	Minor polymorph in alpha-synuclein fibril seeded by cerebrospinal fluid from a postmortal Parkinson's disease patient
7XO0	;	3.0	;	Minor polymorph inalpha-synuclein fibril seeded by cerebrospinal fluid from a mid-to-late stage (mid-PD-1) Parkinson's disease patient
3ZIO	;	2.1	;	minor-site specific NLS (A28)
3ZIP	;	2.4	;	minor-site specific NLS (A58)
3ZIR	;	2.3	;	minor-site specific NLS (B141)
3ZIQ	;	2.1	;	minor-site specific NLS (B6)
3OAB	;	2.3	;	Mint deletion mutant of heterotetrameric geranyl pyrophosphate synthase in complex with ligands
3OAC	;	2.6	;	Mint deletion mutant of heterotetrameric geranyl pyrophosphate synthase in complex with ligands
3KRC	;	2.3	;	Mint heterotetrameric geranyl pyrophosphate synthase in complex with IPP
3KRA	;	1.9	;	Mint heterotetrameric geranyl pyrophosphate synthase in complex with magnesium
3KRP	;	2.42	;	Mint heterotetrameric geranyl pyrophosphate synthase in complex with magnesium and GPP
3KRF	;	2.2	;	Mint heterotetrameric geranyl pyrophosphate synthase in complex with magnesium, IPP, and DMASPP (I)
3KRO	;	1.95	;	Mint heterotetrameric geranyl pyrophosphate synthase in complex with magnesium, IPP, and DMASPP (II)
3WRN	;	1.52	;	Minute virus of mice non-structural protein-1N-terminal nuclease domain reveals a unique Zn2+ coordination in the active site pocket and shows a novel mode of DNA recognition at the origin of replication
3WRO	;	1.48	;	Minute virus of mice non-structural protein-1N-terminal nuclease domain reveals a unique Zn2+ coordination in the active site pocket and shows a novel mode of DNA recognition at the origin of replication
3WRQ	;	1.53	;	Minute virus of mice non-structural protein-1N-terminal nuclease domain reveals a unique Zn2+ coordination in the active site pocket and shows a novel mode of DNA recognition at the origin of replication
3WRR	;	1.62	;	Minute virus of mice non-structural protein-1N-terminal nuclease domain reveals a unique Zn2+ coordination in the active site pocket and shows a novel mode of DNA recognition at the origin of replication
3WRS	;	1.58	;	Minute virus of mice non-structural protein-1N-terminal nuclease domain reveals a unique Zn2+ coordination in the active site pocket and shows a novel mode of DNA recognition at the origin of replication
4PP4	;	1.45	;	Minute virus of mice non-structural protein-1N-terminal nuclease domain reveals a unique Zn2+ coordination in the active site pocket and shows a novel mode of DNA recognition at the origin of replication
5YH4	;	1.3	;	Miraculin-like protein from Vitis vinifera
1T6D	;	2.15	;	MIRAS phasing of the Aquifex aeolicus Ppx/GppA phosphatase: crystal structure of the type II variant
2CA6	;	2.2	;	MIRAS structure determination from hemihedrally twinned crystals
7OD0	;	2.1	;	Mirolysin in complex with compound 9
8F5C	;	1.15	;	Mirror-image DNA containing 2'-OMe-L-dC modification
8F27	;	1.6	;	Mirror-image DNA containing 2'-OMe-L-uridine residue
8F24	;	3.2	;	Mirror-image RNA octamer containing 2'-OMe-L-uridine
5KTV	;	2.35	;	Mis-pairing of unnatural base Z-G DNA duplex at pH 8.5
4XYI	;	3.0	;	Mis16 with H4 peptide
7XSK	;	3.53	;	Misfolded Tetrahymena ribozyme conformation 1
7XSL	;	3.84	;	Misfolded Tetrahymena ribozyme conformation 2
7XSM	;	4.01	;	Misfolded Tetrahymena ribozyme conformation 3
1NGN	;	2.1	;	Mismatch repair in methylated DNA. Structure of the mismatch-specific thymine glycosylase domain of methyl-CpG-binding protein MBD4
5X9W	;	3.3	;	Mismatch Repair Protein
5YK4	;	2.97	;	Mismatch Repair Protein
1XCI	;		;	Mispair Aligned N3T-Butyl-N3T Interstrand Crosslink
1U6O	;		;	Mispairing of a Site-Specific Major Groove (2S,3S)-N6-(2,3,4-Trihydroxybutyl)-2-deoxyadenosyl DNA Adduct of Butadiene Diol Epoxide with Deoxyguanosine: Formation of a dA(anti)dG(anti) Pairing Interaction
6BIE	;	1.77	;	MISREADING CHAPERONE-SUBSTRATE COMPLEXES FROM RANDOM NOISE
4YP1	;	2.65	;	Misting with CDA
1CE7	;	2.7	;	MISTLETOE LECTIN I FROM VISCUM ALBUM
1ONK	;	2.1	;	Mistletoe lectin I from viscum album
2MLL	;	2.7	;	MISTLETOE LECTIN I FROM VISCUM ALBUM
1OQL	;	3.0	;	Mistletoe Lectin I from Viscum album complexed with galactose
1M2T	;	1.89	;	Mistletoe Lectin I from Viscum album in Complex with Adenine Monophosphate. Crystal Structure at 1.9 A Resolution
1SZ6	;	2.05	;	MISTLETOE LECTIN I FROM VISCUM ALBUM. CRYSTAL STRUCTURE AT 2.05 A RESOLUTION
1PUM	;	2.3	;	Mistletoe lectin I in complex with galactose
1PUU	;	2.3	;	Mistletoe lectin I in complex with lactose
3D7W	;	2.49	;	Mistletoe Lectin I in Complex with Zeatin
7PZO	;	2.25	;	mite allergen Der p 3 from Dermatophagoides pteronyssinus
3N9C	;	1.5	;	Mite-y Lysozyme: Marmite
3N9E	;	1.38	;	Mite-y Lysozyme: Promite
3N9A	;	1.4	;	Mite-y Lysozyme: Vegemite
4ATH	;	1.95	;	MITF apo structure
7D8S	;	2.28	;	MITF bHLHLZ apo structure
7D8T	;	3.201	;	MITF bHLHLZ complex with M-box DNA
6FX5	;	2.05	;	MITF dimerization mutant
7EOD	;	1.9	;	MITF HLHLZ Delta AKE
7D8R	;	3.0	;	MITF HLHLZ structure
6G1L	;	2.4	;	MITF/CLEARbox structure
4ATK	;	2.95	;	MITF:E-box complex
4ATI	;	2.6	;	MITF:M-box complex
4HTN	;	1.3	;	Mitigation of X-ray damage in macromolecular crystallography by submicrometer line focusing; total dose 1.32 x 10e+12 X-ray photons
4HTK	;	1.2	;	Mitigation of X-ray damage in macromolecular crystallography by submicrometer line focusing; total dose 2.17 x 10e+12 X-ray photons
4HTQ	;	1.399	;	Mitigation of X-ray damage in macromolecular crystallography by submicrometer line focusing; total dose 6.70 x 10e+11 X-ray photons
1N9G	;	1.98	;	Mitochondrial 2-enoyl thioester reductase Etr1p/Etr2p heterodimer from Candida tropicalis
4PED	;	1.64	;	Mitochondrial ADCK3 employs an atypical protein kinase-like fold to enable coenzyme Q biosynthes
6AZ0	;	3.4	;	Mitochondrial ATPase Protease YME1
8OM1	;	2.39	;	Mitochondrial complex I from Mus musculus in the active state
8OLT	;	2.84	;	Mitochondrial complex I from Mus musculus in the active state bound with piericidin A
5O31	;	4.13	;	Mitochondrial complex I in the deactive state
1CRK	;	3.0	;	MITOCHONDRIAL CREATINE KINASE
7PZP	;	3.5	;	Mitochondrial DNA dependent RNA polymerase homodimer.
1VAR	;	2.5	;	MITOCHONDRIAL MANGANESE SUPEROXIDE DISMUTASE VARIANT WITH ILE 58 REPLACED BY THR
7EKL	;	3.5	;	Mitochondrial outer membrane protein
7EKM	;	3.6	;	Mitochondrial outer membrane protein
6E0G	;	2.9	;	Mitochondrial peroxiredoxin from Leishmania infantum after heat stress without unfolding client protein
6E0F	;	3.7	;	Mitochondrial peroxiredoxin from Leishmania infantum in complex with unfolding client protein after heat stress
3VR8	;	2.81	;	Mitochondrial rhodoquinol-fumarate reductase from the parasitic nematode Ascaris suum
3VRA	;	3.44	;	Mitochondrial rhodoquinol-fumarate reductase from the parasitic nematode Ascaris suum with the specific inhibitor Atpenin A5
3VR9	;	3.01	;	Mitochondrial rhodoquinol-fumarate reductase from the parasitic nematode Ascaris suum with the specific inhibitor flutolanil
3VRB	;	2.91	;	Mitochondrial rhodoquinol-fumarate reductase from the parasitic nematode Ascaris suum with the specific inhibitor flutolanil and substrate fumarate
6WUL	;	3.2	;	Mitochondrial SAM complex - dimer 1 in detergent
6WUM	;	3.6	;	Mitochondrial SAM complex - dimer 2 in detergent
6WUN	;	3.9	;	Mitochondrial SAM complex - dimer 3 in detergent
6WUT	;	3.0	;	Mitochondrial SAM complex - high resolution monomer in detergent
6WUJ	;	3.7	;	Mitochondrial SAM complex - monomer in detergent
6WUH	;	3.4	;	Mitochondrial SAM complex in lipid nanodiscs
1T3J	;	2.5	;	Mitofusin domain HR2 V686M/I708M mutant
6JFM	;	2.09	;	Mitofusin2 (MFN2)_T111D
4ZSG	;	1.79	;	MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
4ZSJ	;	2.48	;	MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
4ZSL	;	2.25	;	MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
2FSO	;	1.83	;	mitogen activated protein kinase p38alpha (D176A) activating mutant
2FST	;	1.45	;	mitogen activated protein kinase p38alpha (D176A+F327L) activating mutant
2FSL	;	1.7	;	mitogen activated protein kinase p38alpha (D176A+F327S) activating mutant form-A
2FSM	;	1.86	;	mitogen activated protein kinase p38alpha (D176A+F327S) activating mutant form-B
6DTL	;	2.753	;	Mitogen-activated protein kinase 6
4U7Z	;	2.805	;	Mitogen-Activated Protein Kinase Kinase (MEK1) bound to G805
3OS3	;	2.8	;	Mitogen-activated protein kinase kinase 1 (MEK1) in complex with CH4858061 and MgATP
3ORN	;	2.8	;	Mitogen-activated protein kinase kinase 1 (MEK1) in complex with CH4987655 and MgAMP-PNP
4U40	;	2.3	;	Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) Bound to AMPPNP
8EDV	;	3.3	;	Mitoguardin homolog (MIGA) delta TM residues 106-496 from Caenorhabditis elegans bound to modelled lipid phosphatidylethanolamine
6DE9	;	1.95	;	mitoNEET bound to furosemide
7P0O	;	1.65	;	mitoNEET bound to M1 molecule
2QH7	;	1.5	;	MitoNEET is a uniquely folded 2Fe-2S outer mitochondrial membrane protein stabilized by pioglitazone
5NJP	;	1.7	;	Mix-and-diffuse serial synchrotron crystallography: structure of N,N',N''-Triacetylchitotriose bound to Lysozyme with 1s time-delay, phased with 1HEW
5NJQ	;	1.7	;	Mix-and-diffuse serial synchrotron crystallography: structure of N,N',N''-Triacetylchitotriose bound to Lysozyme with 1s time-delay, phased with 4ET8
5NJS	;	1.7	;	Mix-and-diffuse serial synchrotron crystallography: structure of N,N',N''-Triacetylchitotriose bound to Lysozyme with 50s time-delay, phased with 1HEW
5NJR	;	1.7	;	Mix-and-diffuse serial synchrotron crystallography: structure of N,N',N''-Triacetylchitotriose bound to Lysozyme with 50s time-delay, phased with 4ET8
1YUX	;	1.6	;	Mixed valant state of nigerythrin
2Y5Z	;	2.06	;	Mixed-function P450 MycG in complex with mycinamicin III in C2221 space group
2YCA	;	1.8	;	Mixed-function P450 MycG in complex with mycinamicin III in P21212 space group
7ZS8	;	1.4	;	Mixed-valence, active form, of cytochrome c peroxidase from obligate human pathogenic bacterium Neisseria gonorrhoeae at 1.4 Angstrom resolution
6TI6	;		;	Mixing Abeta(1-40) and Abeta(1-42) peptides generates unique amyloid fibrils
6TI7	;		;	Mixing Abeta(1-40) and Abeta(1-42) peptides generates unique amyloid fibrils
2AEU	;	1.7	;	MJ0158, apo form
2AEV	;	2.0	;	MJ0158, NaBH4-reduced form
1DUS	;	1.8	;	MJ0882-A hypothetical protein from M. jannaschii
3KA0	;	2.9	;	MK2 complex with inhibitor 6-(5-(2-aminopyrimidin-4-ylamino)-2-hydroxyphenyl)-N-methylbenzo[b]thiophene-2-carboxamide
3KC3	;	2.9	;	MK2 complexed to inhibitor N4-(7-(benzofuran-2-yl)-1H-indazol-5-yl)pyrimidine-2,4-diamine
3R2Y	;	3.0	;	MK2 kinase bound to Compound 1
3R30	;	3.2	;	MK2 kinase bound to Compound 2
3R2B	;	2.9	;	MK2 kinase bound to Compound 5b
3R1N	;	2.09	;	MK3 kinase bound to Compound 5b
5T1Y	;	2.05	;	MLA10 coiled-coil fragment
6MW0	;	0.78	;	Mle-Phe-Mle-D-Phe. Linear tetrapeptide related to pseudoxylallemycin A.
6MVZ	;	0.83	;	Mle-Phe-Mle-Phe. Linear precursor of pseudoxylallemycin A.
7ANG	;	2.14	;	MlghB, GDP-mannoheptose C3,5 epimerase from Campylobacter jejuni
7AN4	;	2.6	;	MlghB, GDP-mannoheptose C3,5 epimerase from Campylobacter jejuni complex with GDP-mannose
7ANC	;	1.66	;	MlghC, GDP-mannoheptose C4 reductase from Campylobacter jejuni with NADP bound
6LK6	;	2.41	;	MLKL mutant - T357AS358A
6LK5	;	2.5	;	MLKL mutant - T357ES358D
6U9R	;	2.1	;	MLL1 SET N3861I/Q3867L bound to inhibitor 12 (TC-5140)
6U9N	;	1.95	;	MLL1 SET N3861I/Q3867L bound to inhibitor 14 (TC-5139)
6U9M	;	2.05	;	MLL1 SET N3861I/Q3867L bound to inhibitor 16 (TC-5109)
6U9K	;	2.0	;	MLL1 SET N3861I/Q3867L bound to inhibitor 18 (TC-5153)
8PJI	;	1.7	;	MLLT1 in complex with compound 10a
8PJ7	;	1.26	;	MLLT3 in complex with compound PFI-6
7QCR	;	2.28	;	MLLT4/Afadin PDZ domain in complex with the C-terminal peptide from protein E of SARS-CoV-2
6I9D	;	4.0	;	MloK1 consensus structure from single particle analysis of 2D crystals
6IAX	;	5.2	;	MloK1 model from single particle analysis of 2D crystals, class 1 (extended conformation)
6QCY	;	4.7	;	MloK1 model from single particle analysis of 2D crystals, class 2 (intermediate conformation)
6QCZ	;	4.4	;	MloK1 model from single particle analysis of 2D crystals, class 3 (intermediate extended conformation)
6QD0	;	4.5	;	MloK1 model from single particle analysis of 2D crystals, class 4 (compact/open conformation)
6QD1	;	5.4	;	MloK1 model from single particle analysis of 2D crystals, class 5 (intermediate compact conformation)
6QD2	;	4.8	;	MloK1 model from single particle analysis of 2D crystals, class 6 (intermediate compact conformation)
6QD3	;	5.0	;	MloK1 model from single particle analysis of 2D crystals, class 7 (intermediate conformation)
6QD4	;	5.6	;	MloK1 model from single particle analysis of 2D crystals, class 8 (intermediate conformation)
3CO2	;	2.9	;	Mlotik1 ion channel cyclic-nucleotide binding domain mutant
7XJR	;	1.85	;	MLXase AlXyn26A
3IZH	;	11.0	;	Mm-cpn D386A with ATP
3IZN	;	6.4	;	Mm-cpn deltalid with ATP
3IZK	;	4.9	;	Mm-cpn rls deltalid with ATP
3IZL	;	6.2	;	Mm-cpn rls deltalid with ATP and AlFx
3IZI	;	6.7	;	Mm-cpn rls with ATP
3IZJ	;	6.9	;	Mm-cpn rls with ATP and AlFx
3IZM	;	7.2	;	Mm-cpn wildtype with ATP
8KCM	;	2.5	;	MmCPDII-DNA complex containing low-dosage, light induced repaired DNA.
3NVE	;	1.7	;	MMHFGN segment 138-143 from Syrian Hamster prion
5H8A	;	1.751	;	Mmi1 YTH domain
5HFZ	;	1.96	;	Mmi1 YTH domain
5FMS	;	3.488	;	mmIFT52 N-terminal domain
5FMU	;	1.593	;	MmIFT54 CH-domain
8CNZ	;	3.6	;	mmLarE-[4Fe-4S] phased by Fe-SAD
3ZXH	;	1.3	;	MMP-13 complexed with 2-Napthylsulfonamide hydroxamic acid inhibitor
3I7G	;	1.95	;	MMP-13 in complex with a non zinc-chelating inhibitor
3I7I	;	2.208	;	MMP-13 in complex with a non zinc-chelating inhibitor
3O2X	;	1.9	;	MMP-13 in complex with selective tetrazole core inhibitor
6HV2	;	1.709	;	MMP-13 in complex with the peptide IMISF
1UEA	;	2.8	;	MMP-3/TIMP-1 COMPLEX
2OVX	;	2.0	;	MMP-9 active site mutant with barbiturate inhibitor
2OW2	;	2.9	;	MMP-9 active site mutant with difluoro butanoic acid inhibitor
2OW0	;	2.0	;	MMP-9 active site mutant with iodine-labeled carboxylate inhibitor
2OVZ	;	2.0	;	MMP-9 active site mutant with phosphinate inhibitor
2OW1	;	2.2	;	MMP-9 active site mutant with trifluoromethyl hydroxamate inhibitor
2WO8	;	2.0	;	MMP12 complex with a beta hydroxy carboxylic acid
2WO9	;	1.7	;	MMP12 complex with a beta hydroxy carboxylic acid
2WOA	;	2.3	;	MMP12 complex with a beta hydroxy carboxylic acid
3UVC	;	1.3	;	MMP12 in a complex with the dimeric adduct: 5-(5-phenylhydantoin)-5-phenylhydantoin
2OZR	;	2.3	;	MMP13 Catalytic Domain Complexed with 4-{[1-methyl-2,4-dioxo-6-(3-phenylprop-1-yn-1-yl)-1,4-dihydroquinazolin-3(2H)-yl]methyl}benzoic acid
2YIG	;	1.7	;	MMP13 in complex with a novel selective non zinc binding inhibitor
4A7B	;	2.2	;	MMP13 IN COMPLEX WITH A NOVEL SELECTIVE NON ZINC BINDING INHIBITOR CMPD22
4JPA	;	2.0	;	Mmp13 in complex with a piperazine hydantoin ligand
4JP4	;	1.43	;	Mmp13 in complex with a reverse hydroxamate Zn-binder
1A85	;	2.0	;	MMP8 WITH MALONIC AND ASPARAGINE BASED INHIBITOR
1A86	;	2.0	;	MMP8 WITH MALONIC AND ASPARTIC ACID BASED INHIBITOR
1GKD	;	2.1	;	MMP9 active site mutant-inhibitor complex
1GKC	;	2.3	;	MMP9-inhibitor complex
6OR2	;	2.59	;	MmpL3 is a lipid transporter that binds trehalose monomycolate and phosphatidylethanolamine
1JAT	;	1.6	;	Mms2/Ubc13 Ubiquitin Conjugating Enzyme Complex
2GMI	;	2.5	;	Mms2/Ubc13~Ubiquitin
7VVX	;	2.51	;	MmtN-SAH-Met complex
7VVW	;	2.11	;	MmtN-SAM complex
2XZ5	;	2.8	;	MMTS-modified Y53C mutant of Aplysia AChBP in complex with acetylcholine
2BB7	;	1.7	;	Mn Form Of E. coli Methionine Aminopeptidase In Complex With a quinolinyl sulfonamide inhibitor
2BN7	;	2.4	;	Mn substituted E. coli Aminopeptidase P in complex with product and Zn
1JQC	;	1.61	;	Mn substituted Ribonucleotide reductase R2 from E. Coli oxidized by hydrogen peroxide and hydroxylamine
1JPR	;	1.88	;	Mn substituted Ribonucleotide reductase R2 from E. coli oxidized by nitric oxide
2IND	;	2.2	;	Mn(II) Reconstituted Toluene/o-xylene Monooxygenase Hydroxylase X-ray Crystal Structure
6DY6	;	1.8	;	Mn(II)-bound structure of the engineered cyt cb562 variant, CH2E
6DY8	;	1.9	;	Mn(II)-bound structure of the engineered cyt cb562 variant, CH2EY
5D6M	;	1.653	;	Mn(II)-loaded MnCcP.1
4IT2	;	2.097	;	Mn(III)-PPIX bound Tt H-NOX
6WZ7	;	2.3	;	Mn-bound structure of a TriCyt3 variant
6WZ1	;	1.999	;	Mn-bound structure of an engineered protein trimer, TriCyt3
6SF5	;	1.9	;	Mn-containing form of the ribonucleotide reductase NrdB protein from Leeuwenhoekiella blandensis
5UKI	;	1.8	;	Mn2+ and Zn2+ requirements for the lariat debranching enzyme, Dbr1
3ITX	;	1.8	;	Mn2+ bound form of Pseudomonas stutzeri L-rhamnose isomerase
3W5W	;	2.95	;	Mn2+-GMP complex of nanoRNase (Nrn) from Bacteroides fragilis
5K8O	;	2.893	;	Mn2+/5NSA-bound 5-nitroanthranilate aminohydrolase
4YKJ	;	1.401	;	Mnemiopsis leidyi ML032222a iGluR LBD complex with Alanine
4YKK	;	1.38	;	Mnemiopsis leidyi ML032222a iGluR LBD D-serine complex
5CMC	;	1.28	;	Mnemiopsis leidyi ML032222a iGluR LBD E423S mutant glycine complex
4YKI	;	1.21	;	Mnemiopsis leidyi ML032222a iGluR LBD glycine complex
5CMB	;	1.34	;	Mnemiopsis leidyi ML032222a iGluR LBD R703K mutant glycine complex
4YKP	;	1.46	;	Mnemiopsis leidyi ML032222a iGluR LBD serine complex
6PRO	;	2.263	;	MnSOD from Geobacillus stearothermophilus
4X9Q	;	1.77	;	MnSOD-3 Room Temperature Structure
5HDQ	;	1.83	;	MntC co-structure with mAB 305-78-7
5MU9	;	1.3	;	MOA-E-64 complex
5D61	;	1.6	;	MOA-Z-VAD-fmk complex, direct orientation
5D62	;	1.7	;	MOA-Z-VAD-fmk complex, inverted orientation
5D63	;	1.65	;	MOA-Z-VAD-fmk inhibitor complex, direct/inverted dual orientation
4PYD	;	3.186	;	MoaC in complex with cPMP crystallized in space group P212121
4PYA	;	1.789	;	MoaC K51A in complex with 3',8-cH2GTP
1EKR	;	2.0	;	MOAC PROTEIN FROM E. COLI
7LGC	;	1.85	;	MOAP1 CA-like C-terminal domain
6P3E	;	5.4	;	Mobile loops and electrostatic interactions maintain the flexible lambda tail tube
1B92	;	2.02	;	MOBILITY OF AN HIV-1 INTEGRASE ACTIVE SITE LOOP IS CORRELATED WITH CATALYTIC ACTIVITY
1B9D	;	1.7	;	MOBILITY OF AN HIV-1 INTEGRASE ACTIVE SITE LOOP IS CORRELATED WITH CATALYTIC ACTIVITY
1B9F	;	1.7	;	MOBILITY OF AN HIV-1 INTEGRASE ACTIVE SITE LOOP IS CORRELATED WITH CATALYTIC ACTIVITY
5N2Q	;	2.0	;	MobM Relaxase Domain (MOBV; Mob_Pre) bound to 26nt pMV158 oriT DNA
4LVI	;	1.9	;	MobM Relaxase Domain (MOBV; Mob_Pre) bound to plasmid pMV158 oriT DNA (22nt). Mn-bound crystal structure at pH 4.6
4LVJ	;	2.17	;	MobM Relaxase Domain (MOBV; Mob_Pre) bound to plasmid pMV158 oriT DNA (22nt). Mn-bound crystal structure at pH 5.5
4LVK	;	2.37	;	MobM Relaxase Domain (MOBV; Mob_Pre) bound to plasmid pMV158 oriT DNA (22nt+3'Phosphate). Mn-bound crystal structure at pH 4.6
4LVL	;	2.2	;	MobM Relaxase Domain (MOBV; Mob_Pre) bound to plasmid pMV158 oriT DNA (22nt+3'Thiophosphate). Mn-bound crystal structure at pH 6.8
4LVM	;	3.1	;	MobM Relaxase Domain (MOBV; Mob_Pre) bound to plasmid pMV158 oriT DNA (23nt). Mn-bound crystal structure at pH 6.5
4XXU	;	1.43	;	ModA - chromate bound
3D31	;	3.0	;	ModBC from Methanosarcina acetivorans
3BYP	;	1.7	;	Mode of Action of a Putative Zinc Transporter CzrB
3BYR	;	1.8	;	Mode of Action of a Putative Zinc Transporter CzrB (Zn form)
5HPW	;	2.5	;	Mode of binding of antithyroid drug, propylthiouracil to lactoperoxidase: Binding studies and structure determination
3I6N	;	2.7	;	Mode of Binding of the Tuberculosis Prodrug Isoniazid to Peroxidases: Crystal Structure of Bovine Lactoperoxidase with Isoniazid at 2.7 Resolution
4FJR	;	1.86	;	Mode of interaction of Merocyanine 540 with HEW Lysozyme
3GCJ	;	2.34	;	Mode of ligand binding and assignment of subsites in mammalian peroxidases: crystal structure of lactoperoxidase complexes with acetyl salycylic acid, salicylhydroxamic acid and benzylhydroxamic acid
3GCK	;	2.9	;	Mode of ligand binding and assignment of subsites in mammalian peroxidases: crystal structure of lactoperoxidase complexes with acetyl salycylic acid, salicylhydroxamic acid and benzylhydroxamic acid
3GCL	;	2.5	;	Mode of ligand binding and assignment of subsites in mammalian peroxidases: crystal structure of lactoperoxidase complexes with acetyl salycylic acid, salicylhydroxamic acid and benzylhydroxamic acid
4A0W	;	13.9	;	model built against symmetry-free cryo-EM map of TRiC-ADP-AlFx
1GDR	;	3.5	;	MODEL FOR A DNA MEDIATED SYNAPTIC COMPLEX SUGGESTED BY CRYSTAL PACKING OF GAMMA DELTA RESOLVASE SUBUNITS
1N03	;	20.0	;	Model for Active RecA Filament
2QU4	;	16.0	;	Model for Bacterial ParM Filament
2HI5	;	8.0	;	Model for bacteriophage fd from cryo-EM
6BBP	;	35.0	;	Model for compact volume of truncated monomeric Cytohesin-3 (Grp1; amino acids 63-399) E161A 6GS Arf6 Q67L fusion protein
2IX8	;	9.9	;	MODEL FOR EEF3 BOUND TO AN 80S RIBOSOME
6BBQ	;	35.0	;	Model for extended volume of truncated monomeric Cytohesin-3 (Grp1; amino acids 63-399) E161A Arf6 Q67L fusion protein
8PZQ	;	5.3	;	Model for focused reconstruction of influenza A RNP-like particle
8PZP	;	8.7	;	Model for influenza A virus helical ribonucleoprotein-like structure
2ZWH	;	3.3	;	Model for the F-actin structure
1BRD	;	3.5	;	Model for the structure of Bacteriorhodopsin based on high-resolution Electron Cryo-microscopy
1OLN	;		;	Model for thiostrepton antibiotic binding to L11 substrate from 50S ribosomal RNA
2JQ7	;		;	Model for thiostrepton binding to the ribosomal L11-RNA
2PHE	;		;	Model for VP16 binding to PC4
2PHG	;		;	Model for VP16 binding to TFIIB
3J07	;	20.0	;	Model of a 24mer alphaB-crystallin multimer
3J0R	;	7.7	;	Model of a type III secretion system needle based on a 7 Angstrom resolution cryoEM map
3BYH	;	12.0	;	Model of actin-fimbrin ABD2 complex
3LUE	;	15.0	;	Model of alpha-actinin CH1 bound to F-actin
7OE2	;	2.4	;	Model of closed pentamer of the Haliangium ochraceum encapsulin from symmetry expansion of icosahedral single particle reconstruction
4CKD	;	13.0	;	Model of complex between the E.coli enzyme beta-galactosidase and four single chain Fv antibody domains scFv13R4.
2J28	;	9.5	;	MODEL OF E. COLI SRP BOUND TO 70S RNCS
3J4J	;	11.5	;	Model of full-length T. thermophilus Translation Initiation Factor 2 refined against its cryo-EM density from a 30S Initiation Complex map
6FCZ	;	10.0	;	Model of gC1q-Fc complex based on 7A EM map
3J70	;	20.0	;	Model of gp120, including variable regions, in complex with CD4 and 17b
7ODW	;	2.5	;	Model of Haliangium ochraceum encapsulin from icosahedral single particle reconstruction
3ZW6	;	20.0	;	MODEL OF HEXAMERIC AAA DOMAIN ARRANGEMENT OF GREEN-TYPE RUBISCO ACTIVASE FROM TOBACCO.
3C9K	;	20.0	;	Model of Histone Octamer Tubular Crystals
5L9U	;	6.4	;	Model of human Anaphase-promoting complex/Cyclosome (APC/C-CDH1) with a cross linked Ubiquitin variant-substrate-UBE2C (UBCH10) complex representing key features of multiubiquitination
5L9T	;	6.4	;	Model of human Anaphase-promoting complex/Cyclosome (APC/C-CDH1) with E2 UBE2S poised for polyubiquitination where UBE2S, APC2, and APC11 are modeled into low resolution density
5KHU	;	4.8	;	Model of human Anaphase-promoting complex/Cyclosome (APC15 deletion mutant), in complex with the Mitotic checkpoint complex (APC/C-CDC20-MCC) based on cryo EM data at 4.8 Angstrom resolution
5KHR	;	6.1	;	Model of human Anaphase-promoting complex/Cyclosome complex (APC15 deletion mutant) in complex with the E2 UBE2C/UBCH10 poised for ubiquitin ligation to substrate (APC/C-CDC20-substrate-UBE2C)
1E07	;		;	Model of human carcinoembryonic antigen by homology modelling and curve-fitting to experimental solution scattering data
1IGA	;		;	MODEL OF HUMAN IGA1 DETERMINED BY SOLUTION SCATTERING CURVE-FITTING AND HOMOLOGY MODELLING
1R70	;	30.0	;	Model of human IgA2 determined by solution scattering, curve fitting and homology modelling
4AQW	;	9.5	;	Model of human kinesin-5 motor domain (1II6, 3HQD) and mammalian tubulin heterodimer (1JFF) docked into the 9.5-angstrom cryo-EM map of microtubule-bound kinesin-5 motor domain in the rigor state.
4AQV	;	9.7	;	Model of human kinesin-5 motor domain (3HQD) and mammalian tubulin heterodimer (1JFF) docked into the 9.7-angstrom cryo-EM map of microtubule-bound kinesin-5 motor domain in the AMPPPNP state.
2YH1	;		;	Model of human U2AF65 tandem RRM1 and RRM2 domains with eight-site uridine binding
2J37	;	8.7	;	MODEL OF MAMMALIAN SRP BOUND TO 80S RNCS
3J2Q	;	15.0	;	Model of membrane-bound factor VIII organized in 2D crystals
1MHC	;	2.1	;	MODEL OF MHC CLASS I H2-M3 WITH NONAPEPTIDE FROM RAT ND1 REFINED AT 2.3 ANGSTROMS RESOLUTION
7LFI	;	1.7	;	MODEL OF MHC CLASS Ib H2-M3 WITH MOUSE ND1 N-TERMINAL HEPTAPEPTIDE REFINED AT 1.70 ANGSTROMS RESOLUTION
7LFJ	;	1.7	;	MODEL OF MHC CLASS Ib H2-M3 WITH MOUSE ND1 N-TERMINAL HEPTAPEPTIDE, ALA MUTANT, REFINED AT 1.70 ANGSTROMS RESOLUTION
7LFK	;	1.6	;	MODEL OF MHC CLASS Ib H2-M3 WITH MOUSE ND1 N-TERMINAL HEPTAPEPTIDE, THR MUTANT, REFINED AT 1.60 ANGSTROMS RESOLUTION
7LFL	;	1.6	;	MODEL OF MHC CLASS Ib H2-M3 WITH MOUSE ND1 N-TERMINAL HEPTAPEPTIDE, VAL MUTANT, MONOCLINIC CELL, REFINED AT 1.60 ANGSTROMS RESOLUTION
7LFM	;	1.6	;	MODEL OF MHC CLASS Ib H2-M3 WITH MOUSE ND1 N-TERMINAL HEPTAPEPTIDE, VAL MUTANT, TRICLINIC CELL, REFINED AT 1.60 ANGSTROMS RESOLUTION
1NTL	;	30.0	;	Model of mouse Crry-Ig determined by solution scattering, curve fitting and homology modelling
7T81	;	10.0	;	Model of Munc13-1 C1-C2B-MUN-C2C 2D crystal between lipid bilayers.
1MHS	;	8.0	;	Model of Neurospora crassa proton ATPase
7OEU	;	2.64	;	Model of open pentamer of the Haliangium ochraceum encapsulin from symmetry expansion of icosahedral single particle reconstruction
3EP2	;	9.0	;	Model of Phe-tRNA(Phe) in the ribosomal pre-accommodated state revealed by cryo-EM
1NTJ	;	30.0	;	Model of rat Crry determined by solution scattering, curve fitting and homology modelling
6H7W	;	11.4	;	Model of retromer-Vps5 complex assembled on membrane.
3J15	;	6.6	;	Model of ribosome-bound archaeal Pelota and ABCE1
6CVJ	;	3.2	;	Model of synthetic tau (four tandem repeats of first repeat sequence) bound to the microtubule
6CVN	;	3.9	;	Model of synthetic tau (R2x4) bound to the microtubule
7RNO	;		;	Model of the Ac-6-FP/hpMR1/bB2m/TAPBPR complex from integrated docking, NMR and restrained MD
7AQK	;	9.0	;	Model of the actin filament Arp2/3 complex branch junction in cells
3J2O	;	25.0	;	Model of the bacteriophage T4 fibritin based on the cryo-EM reconstruction of the contracted T4 tail containing the phage collar and whiskers
6EHM	;	7.3	;	Model of the Ebola virus nucleocapsid subunit from recombinant virus-like particles
6EHL	;	6.6	;	Model of the Ebola virus nucleoprotein in recombinant nucleocapsid-like assemblies
3IZO	;	3.6	;	Model of the fiber tail and its interactions with the penton base of human adenovirus by cryo-electron microscopy
7LOI	;		;	Model of the HIV-1 gp41 membrane-proximal external region, transmembrane domain and cytoplasmic tail
6UJV	;		;	Model of the HIV-1 gp41 membrane-proximal external region, transmembrane domain and cytoplasmic tail (LLP2)
3J8C	;	11.6	;	Model of the human eIF3 PCI-MPN octamer docked into the 43S EM map
3J8B	;	9.3	;	Model of the human eIF3 PCI-MPN octamer docked into the 43S-HCV IRES EM map
7PER	;	35.0	;	Model of the inner ring of the human nuclear pore complex
3IZD	;	8.6	;	Model of the large subunit RNA expansion segment ES27L-out based on a 6.1 A cryo-EM map of Saccharomyces cerevisiae translating 80S ribosome. 3IZD is a small part (an expansion segment) which is in an alternative conformation to what is in already 3IZF.
8R1A	;	26.8	;	Model of the membrane-bound GBP1 oligomer
7PEQ	;	35.0	;	Model of the outer rings of the human nuclear pore complex
3J6D	;	11.7	;	Model of the PrgH-PrgK periplasmic rings
6F9C	;	8.0	;	Model of the Rift Valley fever virus glycoprotein hexamer type 1
6F9D	;	13.3	;	Model of the Rift Valley fever virus glycoprotein hexamer type 2
6F9E	;	13.3	;	Model of the Rift Valley fever virus glycoprotein hexamer type 3
6F9F	;	13.3	;	Model of the Rift Valley fever virus glycoprotein pentamer
2VAZ	;	10.0	;	Model of the S15-mRNA complex fitted into the cryo-EM map of the 70S entrapment complex.
4V7E	;	5.5	;	Model of the small subunit RNA based on a 5.5 A cryo-EM map of Triticum aestivum translating 80S ribosome
4B2Q	;	37.0	;	Model of the yeast F1Fo-ATP synthase dimer based on subtomogram average
3EQ4	;	12.0	;	Model of tRNA(Leu)-EF-Tu in the ribosomal pre-accommodated state revealed by cryo-EM
3EQ3	;	9.0	;	Model of tRNA(Trp)-EF-Tu in the ribosomal pre-accommodated state revealed by cryo-EM
4A13	;	11.3	;	model refined against symmetry-free cryo-EM map of TRiC-ADP
4A0V	;	10.7	;	model refined against the Symmetry-free cryo-EM map of TRiC-AMP-PNP
1EKY	;		;	MODEL STRUCTURE FROM NON-NOE BASED NMR STRUCTURE CALCULATION
5TLQ	;		;	Model structure of the oxidized PaDsbA1 and 3-[(2-methylbenzyl)sulfanyl]-4H-1,2,4-triazol-4-amine complex
1IFD	;	4.0	;	MODEL-BUILDING STUDIES OF INOVIRUS: GENETIC VARIATIONS ON A GEOMETRIC THEME
2IFO	;		;	MODEL-BUILDING STUDIES OF INOVIRUS: GENETIC VARIATIONS ON A GEOMETRIC THEME
2YEW	;	5.0	;	Modeling Barmah Forest virus structural proteins
2BMH	;	2.0	;	MODELING PROTEIN-SUBSTRATE INTERACTIONS IN THE HEME DOMAIN OF CYTOCHROME P450BM-3
2X31	;	7.5	;	Modelling of the complex between subunits BchI and BchD of magnesium chelatase based on single-particle cryo-EM reconstruction at 7.5 ang
7SPI	;	2.97	;	Models for C13 reconstruction of Outer Membrane Core Complex (OMCC) of Type IV Secretion System (T4SS) encoded by a plasmid overproducing TraV, TraK and TraB of pED208
7SPB	;	3.31	;	Models for C13 reconstruction of Outer Membrane Core Complex (OMCC) of Type IV Secretion System (T4SS) encoded by F-plasmid (pED208).
7SPK	;	3.9	;	Models for C16 reconstruction of Outer Membrane Core Complex (OMCC) of Type IV Secretion System (T4SS) encoded by a plasmid overproducing TraV, TraK and TraB of pED208
7SPJ	;	3.56	;	Models for C17 reconstruction of Outer Membrane Core Complex (OMCC) of Type IV Secretion System (T4SS) encoded by a plasmid overproducing TraV, TraK and TraB of pED208
7SPC	;	2.95	;	Models for C17 reconstruction of Outer Membrane Core Complex (OMCC) of Type IV Secretion System (T4SS) encoded by F-plasmid (pED208).
3IZZ	;	10.8	;	Models for ribosome components that are nearest neighbors to the bovine mitochondrial initiation factor2 bound to the E. Coli ribosome
3J0E	;	9.9	;	Models for the T. thermophilus ribosome recycling factor and the E. coli elongation factor G bound to the E. coli post-termination complex
3J0D	;	11.1	;	Models for the T. thermophilus ribosome recycling factor bound to the E. coli post-termination complex
3J0C	;	4.8	;	Models of E1, E2 and CP of Venezuelan Equine Encephalitis Virus TC-83 strain restrained by a near atomic resolution cryo-EM map
3J16	;	7.2	;	Models of ribosome-bound Dom34p and Rli1p and their ribosomal binding partners
1XIB	;	1.6	;	MODES OF BINDING SUBSTRATES AND THEIR ANALOGUES TO THE ENZYME D-XYLOSE ISOMERASE
1XIC	;	1.6	;	MODES OF BINDING SUBSTRATES AND THEIR ANALOGUES TO THE ENZYME D-XYLOSE ISOMERASE
1XID	;	1.7	;	MODES OF BINDING SUBSTRATES AND THEIR ANALOGUES TO THE ENZYME D-XYLOSE ISOMERASE
1XIE	;	1.7	;	MODES OF BINDING SUBSTRATES AND THEIR ANALOGUES TO THE ENZYME D-XYLOSE ISOMERASE
1XIF	;	1.6	;	MODES OF BINDING SUBSTRATES AND THEIR ANALOGUES TO THE ENZYME D-XYLOSE ISOMERASE
1XIG	;	1.7	;	MODES OF BINDING SUBSTRATES AND THEIR ANALOGUES TO THE ENZYME D-XYLOSE ISOMERASE
1XIH	;	1.7	;	MODES OF BINDING SUBSTRATES AND THEIR ANALOGUES TO THE ENZYME D-XYLOSE ISOMERASE
1XII	;	1.7	;	MODES OF BINDING SUBSTRATES AND THEIR ANALOGUES TO THE ENZYME D-XYLOSE ISOMERASE
1XIJ	;	1.7	;	MODES OF BINDING SUBSTRATES AND THEIR ANALOGUES TO THE ENZYME D-XYLOSE ISOMERASE
6GHC	;	2.85	;	Modification dependent EcoKMcrA restriction endonuclease
6GHS	;	2.92	;	Modification dependent TagI restriction endonuclease
4PCJ	;	1.9	;	Modifications to toxic CUG RNAs induce structural stability and rescue mis-splicing in Myotonic Dystrophy
2LGB	;		;	Modified A22Gly-B31Arg Human Insulin
6NTA	;	3.1	;	Modified ASL proline bound to Thermus thermophilus 70S (cognate)
6NSH	;	3.397	;	Modified ASL proline bound to Thermus thermophilus 70S (near-cognate)
6ORQ	;	4.4	;	Modified BG505 SOSIP-based immunogen RC1 in complex with the elicited V3-glycan patch antibody Ab275MUR
6ORO	;	3.9	;	Modified BG505 SOSIP-based immunogen RC1 in complex with the elicited V3-glycan patch antibody Ab874NHP
6ORP	;	4.4	;	Modified BG505 SOSIP-based immunogen RC1 in complex with the elicited V3-glycan patch antibody Ab897NHP
6ORN	;	4.05	;	Modified BG505 SOSIP-based immunogen RC1 in complex with the elicited V3-glycan patch bNAb 10-1074
3IZ4	;	13.6	;	Modified E. coli tmRNA in the resume state with the tRNA-like domain in the ribosomal P site interacting with the SmpB
1K2A	;	1.0	;	Modified Form of Eosinophil-derived Neurotoxin
1GTI	;	3.0	;	MODIFIED GLUTATHIONE S-TRANSFERASE (PI) COMPLEXED WITH S (P-NITROBENZYL)GLUTATHIONE
5GTM	;	2.896	;	Modified human MxA, nucleotide-free form
4R6D	;	1.55	;	Modified mTFP* for enhanced metal binding: co-crystallization with CuCl2
8ONO	;	1.65	;	Modified oligopeptidase B from S. proteamaculans in intermediate conformation with 5 spermine molecule at 1.65 A resolution
7YX7	;	1.72	;	Modified oligopeptidase B from S. proteomaculans in intermediate conformation with 1 spermine molecule at 1.72 A resolution
7YWS	;	1.7	;	Modified oligopeptidase B from S. proteomaculans in intermediate conformation with 3 spermine molecules at 1.7 A resolution
7YWZ	;	1.75	;	Modified oligopeptidase B from S. proteomaculans in intermediate conformation with 4 spermine molecules at 1.75 A resolution
1JZP	;		;	Modified Peptide A (D18-A1) of the Rabbit Skeletal Dihydropyridine Receptor
2G9C	;	1.7	;	Modified pyrimidines Specifically bind the purine riboswitch
5U66	;	1.7	;	Modified single helix from the B-domain of protein A bound to IgG1 Fc
6NUO	;	3.2	;	Modified tRNA(Pro) bound to Thermus thermophilus 70S (cognate)
6NWY	;	3.5	;	Modified tRNA(Pro) bound to Thermus thermophilus 70S (near-cognate)
2VQE	;	2.5	;	Modified uridines with C5-methylene substituents at the first position of the tRNA anticodon stabilize U-G wobble pairing during decoding
2VQF	;	2.9	;	Modified uridines with C5-methylene substituents at the first position of the tRNA anticodon stabilize U-G wobble pairing during decoding
5BP4	;	3.75	;	Modifying region (DH-ER-KR) of a mycocerosic acid synthase-like (MAS-like) PKS
6FN6	;	2.7	;	Modifying region (DH-ER-KR) of an insect fatty acid synthase (FAS)
4J4L	;	2.3	;	Modular evolution and design of the protein binding interface
1TMH	;	2.8	;	MODULAR MUTAGENESIS OF A TIM-BARREL ENZYME: THE CRYSTAL STRUCTURE OF A CHIMERIC E. COLI TIM HAVING THE EIGHTH (BETA-ALPHA)-UNIT REPLACED BY THE EQUIVALENT UNIT OF CHICKEN TIM
7XVK	;	2.29	;	Modularity of Phytophthora effectors enables host mimicry of a principal phosphatase
3NVR	;	2.148	;	Modulating Heme Redox Potential Through Protein-Induced Porphyrin Distortion
3NVU	;	2.038	;	Modulating Heme Redox Potential Through Protein-Induced Porphyrin Distortion
6IAM	;	1.51	;	Modulating Protein-Protein Interactions with Visible Light Peptide Backbone Switches
4H27	;	1.3	;	Modulating the function of human serine racemase and human serine dehydratase by protein engineering
4NJ3	;	1.848	;	Modulating the interaction between CDK2 and Cyclin A with a Quinoline-based inhibitor
1DE0	;	2.4	;	MODULATING THE MIDPOINT POTENTIAL OF THE [4FE-4S] CLUSTER OF THE NITROGENASE FE PROTEIN
1PZ7	;	1.421	;	Modulation of agrin function by alternative splicing and Ca2+ binding
1PZ8	;	2.35	;	Modulation of agrin function by alternative splicing and Ca2+ binding
1PZ9	;	2.8	;	Modulation of agrin function by alternative splicing and Ca2+ binding
1CDM	;	2.0	;	MODULATION OF CALMODULIN PLASTICITY IN MOLECULAR RECOGNITION ON THE BASIS OF X-RAY STRUCTURES
5M23	;	1.97	;	Modulation of MLL1 Methyltransferase Activity
5M25	;	2.43	;	Modulation of MLL1 Methyltransferase Activity
6EHT	;	3.2	;	Modulation of PCNA sliding surface by p15PAF suggests a suppressive mechanism for cisplatin-induced DNA lesion bypass by pol eta holoenzyme
4F2B	;	2.16	;	Modulation of S.Aureus Phosphatidylinositol-Specific Phospholipase C Membrane Binding
4F2T	;	2.3	;	Modulation of S.aureus Phosphatidylinositol-Specific Phospholipase C Membrane Binding.
5GIK	;	1.49	;	Modulation of the affinity of a HIV-1 capsid-directed ankyrin towards its viral target through critical amino acid editing
1CH4	;	2.5	;	MODULE-SUBSTITUTED CHIMERA HEMOGLOBIN BETA-ALPHA (F133V)
1G8R	;	2.65	;	MOEA
2NQR	;	2.2	;	MoeA D142N
2NQV	;	2.82	;	MoeA D228A
2NQK	;	2.9	;	MoeA D59N mutant
2NQS	;	2.5	;	MoeA E188A
2NQU	;	2.7	;	MoeA E188Q
2NRO	;	2.5	;	MoeA K279Q
2NQQ	;	2.4	;	MoeA R137Q
2NRP	;	3.0	;	MoeA R350A
2NRS	;	2.8	;	MoeA S371W
2NQM	;	3.0	;	MoeA T100A mutant
2NQN	;	2.2	;	MoeA T100W
8BVE	;	2.14	;	MoeA2 from Corynebacterium glutamicum
8BVF	;	2.68	;	MoeA2 from Corynebacterium glutamicum in complex with FtsZ-CTD
6KVC	;	1.66	;	MoeE5 in complex with UDP-glucose and NAD
6KV9	;	1.48	;	MoeE5 in complex with UDP-glucuronic acid and NAD
1SGH	;	3.5	;	Moesin FERM domain bound to EBP50 C-terminal peptide
2I1J	;	2.1	;	Moesin from Spodoptera frugiperda at 2.1 angstroms resolution
2I1K	;	3.0	;	Moesin from Spodoptera frugiperda reveals the coiled-coil domain at 3.0 angstrom resolution
6Y06	;		;	Moevan: a designed granulopoietic protein by topological rescaffolding
7MCI	;	1.65	;	MoFe protein from Azotobacter vinelandii with a sulfur-replenished cofactor
8FMY	;	2.66	;	Mojiang virus F ectodomain in prefusion form
6TMR	;	2.893	;	Mokola virus glycoprotein, monomeric post-fusion conformation
4F8K	;	1.7	;	Molecular analysis of the interaction between the prostacyclin receptor and the first PDZ domain of PDZK1
3NGH	;	1.8	;	Molecular Analysis of the Interaction of the HDL Receptor SR-BI with the Adaptor Protein PDZK1
3R69	;	1.499	;	Molecular analysis of the interaction of the HDL-receptor SR-BI with the PDZ3 domain of its adaptor protein PDZK1
3R68	;	1.3	;	Molecular Analysis of the PDZ3 domain of PDZK1
4R2Z	;	1.7	;	Molecular Analysis of the PDZ4 Domain of Mouse PDZK1
1BYH	;	2.8	;	MOLECULAR AND ACTIVE-SITE STRUCTURE OF A BACILLUS (1-3,1-4)-BETA-GLUCANASE
1J8L	;	1.6	;	Molecular and Crystal Structure of D(CGCAAATTMO4CGCG): the Watson-Crick Type N4-Methoxycytidine/Adenosine Base Pair in B-DNA
1G75	;	1.57	;	MOLECULAR AND CRYSTAL STRUCTURE OF D(CGCGAATF5UCGCG): 5-FORMYLURIDINE/ ADENOSINE BASE-PAIRS IN B-DNA
1G8N	;	1.55	;	MOLECULAR AND CRYSTAL STRUCTURE OF D(CGCGAATF5UCGCG):5-FORMYLURIDINE/ ADENOSINE BASE-PAIRS IN B-DNA
1G8U	;	1.85	;	MOLECULAR AND CRYSTAL STRUCTURE OF D(CGCGAATF5UCGCG):5-FORMYLURIDINE/ ADENOSINE BASE-PAIRS IN B-DNA
1G8V	;	1.8	;	MOLECULAR AND CRYSTAL STRUCTURE OF D(CGCGAATF5UCGCG):5-FORMYLURIDINE/ ADENOSINE BASE-PAIRS IN B-DNA
1I3T	;	1.6	;	MOLECULAR AND CRYSTAL STRUCTURE OF D(CGCGAATT(MO4)CGCG): THE WATSON-CRICK TYPE AND WOBBLE N4-METHOXYCYTIDINE/GUANOSINE BASE PAIRS IN B-DNA
1I47	;	2.1	;	MOLECULAR AND CRYSTAL STRUCTURE OF D(CGCGAATT(MO4)CGCG): THE WATSON-CRICK TYPE AND WOBBLE N4-METHOXYCYTIDINE/GUANOSINE BASE PAIRS IN B-DNA
1DA2	;	1.7	;	MOLECULAR AND CRYSTAL STRUCTURE OF D(CGCGMO4CG): N4-METHOXYCYTOSINE/GUANINE BASE-PAIRS IN Z-DNA
456D	;	1.6	;	MOLECULAR AND CRYSTAL STRUCTURE OF D(CGCGMO6AATCCGCG): THE WATSON-CRICK TYPE N6-METHOXYADENOSINE/CYTIDINE BASE-PAIRS IN B-DNA
1EDR	;	1.6	;	MOLECULAR AND CRYSTAL STRUCTURE OF D(CGCGMO6AATTCGCG) AT 1.6 ANGSTROM
457D	;	2.0	;	MOLECULAR AND CRYSTAL STRUCTURE OF D(CGCGMO6AATTCGCG): N6-METHOXYADENOSINE/ THYMIDINE BASE-PAIRS IN B-DNA
2XVC	;	2.15	;	Molecular and structural basis of ESCRT-III recruitment to membranes during archaeal cell division
4C0R	;	1.547	;	Molecular and structural basis of glutathione import in Gram-positive bacteria via GshT and the cystine ABC importer TcyBC of Streptococcus mutans.
2OGQ	;	1.95	;	Molecular and structural basis of Plk1 substrate recognition: Implications in centrosomal localization
2OJX	;	2.85	;	Molecular and structural basis of polo-like kinase 1 substrate recognition: Implications in centrosomal localization
3BZI	;	2.1	;	Molecular and structural basis of polo-like kinase 1 substrate recognition: Implications in centrosomal localization
2P5T	;	3.2	;	Molecular and structural characterization of the PezAT chromosomal toxin-antitoxin system of the human pathogen Streptococcus pneumoniae
4ESR	;	1.53	;	Molecular and Structural Characterization of the SH3 Domain of AHI-1 in Regulation of Cellular Resistance of BCR-ABL+ Chronic Myeloid Leukemia Cells to Tyrosine Kinase Inhibitors
3C7K	;	2.9	;	Molecular architecture of Galphao and the structural basis for RGS16-mediated deactivation
3C7L	;	1.89	;	Molecular architecture of Galphao and the structural basis for RGS16-mediated deactivation
1YJ5	;	2.8	;	Molecular architecture of mammalian polynucleotide kinase, a DNA repair enzyme
7Y38	;	2.8	;	Molecular architecture of the chikungunya virus replication complex
3WLW	;	3.088	;	Molecular Architecture of the ErbB2 Extracellular Domain Homodimer
4V94	;	3.8	;	Molecular architecture of the eukaryotic chaperonin TRiC/CCT derived by a combination of chemical crosslinking and mass-spectrometry, XL-MS
1QO1	;	3.9	;	Molecular Architecture of the Rotary Motor in ATP Synthase from Yeast Mitochondria
2VY9	;	2.3	;	Molecular architecture of the stressosome, a signal integration and transduction hub
3T98	;	2.5	;	Molecular Architecture of the Transport Channel of the Nuclear Pore Complex: Nup54/Nup58
3T97	;	2.8	;	Molecular Architecture of the Transport Channel of the Nuclear Pore Complex: Nup62/Nup54
2YGD	;	9.4	;	Molecular architectures of the 24meric eye lens chaperone alphaB- crystallin elucidated by a triple hybrid approach
6H9Z	;	1.51	;	Molecular bases of histo-blood group antigen recognition by the most common human rotavirus
7C01	;	2.88	;	Molecular basis for a potent human neutralizing antibody targeting SARS-CoV-2 RBD
4JBK	;	2.963	;	Molecular basis for abrogation of activation of pro-inflammatory cytokines
2BFI	;	1.1	;	Molecular basis for amyloid fibril formation and stability
5EN2	;	1.821	;	Molecular basis for antibody-mediated neutralization of New World hemorrhagic fever mammarenaviruses
6GC5	;	1.9	;	Molecular basis for AU-rich element recognition and dimerization by the HuR C-terminal RRM
1FLK	;	2.8	;	MOLECULAR BASIS FOR CD40 SIGNALING MEDIATED BY TRAF3
1FLL	;	3.5	;	MOLECULAR BASIS FOR CD40 SIGNALING MEDIATED BY TRAF3
5T53	;	2.699	;	MOLECULAR BASIS FOR COHESIN ACETYLATION BY ESTABLISHMENT OF SISTER CHROMATID COHESION N-ACETYLTRANSFERASE ESCO1
3OHX	;	3.503	;	Molecular Basis for Complement Recognition and Inhibition Determined by Crystallographic Studies of the Staphylococcal Complement Inhibitor (SCIN) Bound to C3c and C3b
6CGO	;	2.0	;	Molecular basis for condensation domain-mediated chain release from the enacyloxin polyketide synthase
7KY1	;	1.50003	;	Molecular basis for control of antibiotic production by a bacterial hormones
4QD2	;	2.4	;	Molecular basis for disruption of E-cadherin adhesion by botulinum neurotoxin A complex
6AGL	;	2.5	;	Molecular basis for feedback inhibition of tyrosine-regulated 3-deoxy-d-arabino-heptulosonate-7-phosphate synthase from Escherichia coli
6AGM	;	2.0	;	Molecular basis for feedback inhibition of tyrosine-regulated 3-deoxy-d-arabino-heptulosonate-7-phosphate synthase from Escherichia coli
6LR4	;	3.0	;	Molecular basis for inhibition of human gamma-secretase by small molecule
3V1W	;	1.908	;	Molecular Basis for Multiple Ligand Binding of Calsequestrin and Potential Inhibition by Caffeine and Gallocatecin
7E5Y	;	3.59	;	Molecular basis for neutralizing antibody 2B11 targeting SARS-CoV-2 RBD
5JPW	;		;	Molecular basis for protein recognition specificity of the DYNLT1/Tctex1 canonical binding groove. Characterization of the interaction with activin receptor IIB
1I3K	;	1.5	;	MOLECULAR BASIS FOR SEVERE EPIMERASE-DEFICIENCY GALACTOSEMIA: X-RAY STRUCTURE OF THE HUMAN V94M-SUBSTITUTED UDP-GALACTOSE 4-EPIMERASE
1I3L	;	1.5	;	MOLECULAR BASIS FOR SEVERE EPIMERASE-DEFICIENCY GALACTOSEMIA: X-RAY STRUCTURE OF THE HUMAN V94M-SUBSTITUTED UDP-GALACTOSE 4-EPIMERASE
1I3M	;	1.5	;	MOLECULAR BASIS FOR SEVERE EPIMERASE-DEFICIENCY GALACTOSEMIA: X-RAY STRUCTURE OF THE HUMAN V94M-SUBSTITUTED UDP-GALACTOSE 4-EPIMERASE
1I3N	;	1.5	;	MOLECULAR BASIS FOR SEVERE EPIMERASE-DEFICIENCY GALACTOSEMIA: X-RAY STRUCTURE OF THE HUMAN V94M-SUBSTITUTED UDP-GALACTOSE 4-EPIMERASE
5F5P	;	3.568	;	Molecular Basis for Shroom2 Recognition by Rock1
3ZHA	;	2.55	;	Molecular basis for the action of the collagen-specific chaperone Hsp47 SERPINH1 and its structure-specific client recognition.
3H85	;	2.6	;	Molecular basis for the association of PIPKI gamma-p90 with the clathrin adaptor AP-2
3H1Z	;	1.83	;	Molecular basis for the association of PIPKIgamma -p90 with the clathrin adaptor AP-2
6WQH	;	3.6	;	Molecular basis for the ATPase-powered substrate translocation by the Lon AAA+ protease
3CZ7	;	2.0	;	Molecular Basis for the Autoregulation of the Protein Acetyl Transferase Rtt109
1TMB	;	2.3	;	MOLECULAR BASIS FOR THE INHIBITION OF HUMAN ALPHA-THROMBIN BY THE MACROCYCLIC PEPTIDE CYCLOTHEONAMIDE A
2Z5S	;	2.3	;	Molecular basis for the inhibition of p53 by Mdmx
2Z5T	;	2.3	;	Molecular basis for the inhibition of p53 by Mdmx
1L8L	;	2.51	;	Molecular basis for the local confomational rearrangement of human phosphoserine phosphatase
1L8O	;	2.8	;	Molecular basis for the local conformational rearrangement of human phosphoserine phosphatase
3T3O	;	2.5	;	Molecular basis for the recognition and cleavage of RNA (CUGG) by the bifunctional 5'-3' exo/endoribonuclease RNase J
3T3N	;	3.09	;	Molecular basis for the recognition and cleavage of RNA (UUCCGU) by the bifunctional 5'-3' exo/endoribonuclease RNase J
2C1J	;	2.6	;	Molecular basis for the recognition of phosphorylated and phosphoacetylated histone H3 by 14-3-3
2C1N	;	2.0	;	Molecular basis for the recognition of phosphorylated and phosphoacetylated histone H3 by 14-3-3
4UY8	;	3.8	;	Molecular basis for the ribosome functioning as a L-tryptophan sensor - Cryo-EM structure of a TnaC stalled E.coli ribosome
7AC8	;	2.06	;	Molecular basis for the unique allosteric activation mechanism of the heterodimeric imidazole glycerol phosphate synthase complex.
6ULI	;	1.88	;	Molecular basis for tumor infiltrating TCR recognition of hotspot KRAS-G12D mutation
6ULK	;	1.9	;	Molecular basis for tumor infiltrating TCR recognition of hotspot KRAS-G12D mutation
6ULN	;	2.01	;	Molecular basis for tumor infiltrating TCR recognition of hotspot KRAS-G12D mutation
6ULR	;	3.2	;	Molecular basis for tumor infiltrating TCR recognition of hotspot KRAS-G12D mutation
6UON	;	3.5	;	Molecular basis for tumor infiltrating TCR recognition of hotspot KRAS-G12D mutation
2IZX	;	1.3	;	Molecular Basis of AKAP Specificity for PKA Regulatory Subunits
2IZY	;	2.2	;	Molecular Basis of AKAP Specificity for PKA Regulatory Subunits
1LLD	;	2.0	;	MOLECULAR BASIS OF ALLOSTERIC ACTIVATION OF BACTERIAL L-LACTATE DEHYDROGENASE
1RLG	;	2.7	;	Molecular basis of Box C/D RNA-protein interaction: co-crystal structure of the Archaeal sRNP intiation complex
1DBJ	;	2.7	;	MOLECULAR BASIS OF CROSS-REACTIVITY AND THE LIMITS OF ANTIBODY-ANTIGEN COMPLEMENTARITY
1DBK	;	3.0	;	MOLECULAR BASIS OF CROSS-REACTIVITY AND THE LIMITS OF ANTIBODY-ANTIGEN COMPLEMENTARITY
1DBM	;	2.7	;	MOLECULAR BASIS OF CROSS-REACTIVITY AND THE LIMITS OF ANTIBODY-ANTIGEN COMPLEMENTARITY
2DBL	;	2.9	;	MOLECULAR BASIS OF CROSS-REACTIVITY AND THE LIMITS OF ANTIBODY-ANTIGEN COMPLEMENTARITY
6GF6	;	2.3	;	Molecular basis of egg coat filament cross-linking: high-resolution structure of the partially deglycosylated ZP1 ZP-N1 domain homodimer
6GF8	;	3.1	;	Molecular basis of egg coat filament cross-linking: structure of the glycosylated ZP1 ZP-N1 domain homodimer
6GF7	;	2.7	;	Molecular basis of egg coat filament cross-linking: Zn-SAD structure of the partially deglycosylated ZP1 ZP-N1 domain homodimer
2XE0	;	2.31	;	Molecular basis of engineered meganuclease targeting of the endogenous human RAG1 locus
3MX9	;	2.6	;	Molecular basis of engineered meganuclease targeting of the endogenous human RAG1 locus
3MXA	;	2.3	;	Molecular basis of engineered meganuclease targeting of the endogenous human RAG1 locus
3MXB	;	2.3	;	Molecular basis of engineered meganuclease targeting of the endogenous human RAG1 locus
2X35	;	2.0	;	Molecular basis of Histone H3K36me3 recognition by the PWWP domain of BRPF1.
2X4W	;	1.5	;	Molecular basis of Histone H3K36me3 recognition by the PWWP domain of BRPF1.
2X4X	;	1.85	;	Molecular basis of Histone H3K36me3 recognition by the PWWP domain of BRPF1.
2X4Y	;	1.7	;	Molecular basis of Histone H3K36me3 recognition by the PWWP domain of BRPF1.
2VNF	;	1.76	;	MOLECULAR BASIS OF HISTONE H3K4ME3 RECOGNITION BY ING4
5OAM	;	5.5	;	Molecular basis of human kinesin-8 function and inhibition
5OCU	;	5.2	;	Molecular basis of human kinesin-8 function and inhibition
5OGC	;	4.8	;	Molecular basis of human kinesin-8 function and inhibition
2VBJ	;	1.95	;	Molecular basis of human XPC gene recognition and cleavage by engineered homing endonuclease heterodimers
2VBL	;	1.8	;	Molecular basis of human XPC gene recognition and cleavage by engineered homing endonuclease heterodimers
2VBN	;	1.9	;	Molecular basis of human XPC gene recognition and cleavage by engineered homing endonuclease heterodimers
2VBO	;	1.8	;	Molecular basis of human XPC gene recognition and cleavage by engineered homing endonuclease heterodimers
4F15	;	2.81	;	Molecular basis of infectivity of 2009 pandemic H1N1 influenza A viruses
2FHZ	;	1.15	;	Molecular Basis of Inhibition of the Ribonuclease Activity in Colicin E5 by Its Cognate Immunity Protein
1KLL	;	1.5	;	Molecular basis of mitomycin C resictance in streptomyces: Crystal structures of the MRD protein with and without a drug derivative
1KMZ	;	1.5	;	MOLECULAR BASIS OF MITOMYCIN C RESICTANCE IN STREPTOMYCES: CRYSTAL STRUCTURES OF THE MRD PROTEIN WITH AND WITHOUT A DRUG DERIVATIVE
2KE1	;		;	Molecular Basis of non-modified histone H3 tail Recognition by the First PHD Finger of Autoimmune Regulator
4TQX	;	1.37	;	Molecular Basis of Streptococcus mutans Sortase A Inhibition by Chalcone.
6FAH	;	3.133	;	Molecular basis of the flavin-based electron-bifurcating caffeyl-CoA reductase reaction
3N27	;	1.8	;	Molecular Basis of the Inhibition of Henipa Viruses
1H2S	;	1.93	;	Molecular basis of transmenbrane signalling by sensory rhodopsin II-transducer complex
4HT4	;	2.907	;	Molecular Basis of Vancomycin Resistance Transfer in Staphylococcus aureus
8BQU	;	2.7	;	Molecular basis of ZP3/ZP1 heteropolymerization: crystal structure of a native vertebrate egg coat filament
8RKI	;	4.2	;	Molecular basis of ZP3/ZP1 heteropolymerization: crystal structure of a native vertebrate egg coat filament fragment
2GQE	;		;	Molecular characterization of the Ran binding zinc finger domain
2K9K	;		;	Molecular characterization of the tonb2 protein from vibrio anguillarum
1YIQ	;	2.2	;	Molecular cloning and structural analysis of quinohemoprotein alcohol dehydrogenase ADHIIG from Pseudomonas putida HK5. Compariison to the other quinohemoprotein alcohol dehydrogenase ADHIIB found in the same microorganism.
1D6G	;		;	MOLECULAR COMPLEX OF CHOLECYSTOKININ-8 AND N-TERMINUS OF THE CHOLECYSTOKININ A RECEPTOR BY NMR SPECTROSCOPY
2LAS	;		;	Molecular Determinants of Paralogue-Specific SUMO-SIM Recognition
8POI	;		;	Molecular Docking of SPF30 Tudor domain with synthetic inhibitor 4-(pyridin-2-yl)thiazol-2-amine
5TSK	;	6.5	;	Molecular Dynamics Flexible Fitting Model of Coxsackievirus A16 empty Procapsid VP1 Subunit
5TSL	;	6.5	;	Molecular Dynamics Flexible Fitting Model of Coxsackievirus A16 empty Procapsid VP3 Subunit
2LPT	;		;	Molecular dynamics re-refinement of domain 5 of the Pylaiella littoralis group II intron
2LPS	;		;	Molecular dynamics re-refinement of domain 5 of the yeast ai5(gamma) group II intron
2TEC	;	1.98	;	MOLECULAR DYNAMICS REFINEMENT OF A THERMITASE-EGLIN-C COMPLEX AT 1.98 ANGSTROMS RESOLUTION AND COMPARISON OF TWO CRYSTAL FORMS THAT DIFFER IN CALCIUM CONTENT
1TOR	;		;	MOLECULAR DYNAMICS SIMULATION FROM 2D-NMR DATA OF THE FREE ACHR MIR DECAPEPTIDE AND THE ANTIBODY-BOUND [A76]MIR ANALOGUE
4J2M	;	1.786	;	Molecular Engineering of Organophosphate Hydrolysis Activity from a Weak Promiscuous Lactonase Template
4J35	;	1.783	;	Molecular Engineering of Organophosphate Hydrolysis Activity from a Weak Promiscuous Lactonase Template
6QDJ	;	1.884	;	Molecular features of the UNC-45 chaperone critical for binding and folding muscle myosin
6QDK	;	3.4	;	Molecular features of the UNC-45 chaperone critical for binding and folding muscle myosin
6QDL	;	2.929	;	Molecular features of the UNC-45 chaperone critical for binding and folding muscle myosin
6QDM	;	3.8	;	Molecular features of the UNC-45 chaperone critical for binding and folding muscle myosin
4URE	;	1.4	;	Molecular Genetic and Crystal Structural Analysis of 1-(4- Hydroxyphenyl)-Ethanol Dehydrogenase from Aromatoleum aromaticum EbN1
4URF	;	1.1	;	Molecular Genetic and Crystal Structural Analysis of 1-(4- Hydroxyphenyl)-Ethanol Dehydrogenase from Aromatoleum aromaticum EbN1
6SGF	;	1.756	;	Molecular insight into a new low affinity xylan binding module CBM86, from the xylanolytic gut symbiont Roseburia intestinalis.
5J2Y	;	2.4	;	Molecular insight into the regulatory mechanism of the quorum-sensing repressor RsaL in Pseudomonas aeruginosa
2XE1	;	2.5	;	Molecular insights into clinically isolated OmpC mutants and their role in multi-drug resistance
2XG6	;	3.47	;	Molecular insights into clinically isolated OmpC mutants and their role in multi-drug resistance
2XE5	;	2.28	;	Molecular insights into clinically isolated OmpC mutants and their role in multi-drug resistance (OmpC26)
2XE2	;	2.5	;	Molecular insights into clinically isolated OmpC20 mutants and their role in multi-drug resistance
3AX1	;	2.74	;	Molecular insights into miRNA processing by Arabidopsis Serrate
1CL3	;		;	MOLECULAR INSIGHTS INTO PEBP2/CBF-SMMHC ASSOCIATED ACUTE LEUKEMIA REVEALED FROM THE THREE-DIMENSIONAL STRUCTURE OF PEBP2/CBF BETA
3AQ2	;	1.65	;	Molecular insights into plant cell proliferation disturbance by Agrobacterium protein 6b
3AQ3	;	2.1	;	Molecular insights into plant cell proliferation disturbance by Agrobacterium protein 6b
3AQ4	;	1.8	;	Molecular insights into plant cell proliferation disturbance by Agrobacterium protein 6b
5C2Z	;	1.9553	;	Molecular insights into the specificity of exfoliative toxins from Staphylococcus aureus
7CIO	;	1.1	;	Molecular interactions of cytoplasmic region of CTLA-4 with SH2 domains of PI3-kinase
4QRH	;	1.65	;	Molecular mechanism and evolution of guanylate kinase regulation by (p)ppGpp
6X9H	;	3.01	;	Molecular mechanism and structural basis of small-molecule modulation of acid-sensing ion channel 1 (ASIC1)
3NXC	;	2.5	;	Molecular mechanism by which the Escherichia coli nucleoid occlusion factor, SlmA, keeps cytokinesis in check
4NOO	;	2.3	;	Molecular mechanism for self-protection against type VI secretion system in Vibrio cholerae
5X0W	;	3.0	;	Molecular mechanism for the binding between Sharpin and HOIP
1GZ3	;	2.3	;	Molecular mechanism for the regulation of human mitochondrial NAD(P)+-dependent malic enzyme by ATP and fumarate
1GZK	;	2.3	;	Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation
6F7U	;	1.4	;	Molecular Mechanism of ATP versus GTP Selectivity of Adenylate Kinase
7YIT	;	3.3	;	Molecular mechanism of biased signaling at the kappa opioid receptor
1UWE	;	2.67	;	MOLECULAR MECHANISM OF ENANTIOSELECTIVE PROTON TRANSFER TO CARBON IN CATALYTIC ANTIBODY 14D9
1UWG	;	2.79	;	Molecular Mechanism of Enantioselective Proton Transfer to Carbon in Catalytic Antibody 14D9
3NVN	;	2.26	;	Molecular mechanism of guidance cue recognition
3NVQ	;	2.4	;	Molecular mechanism of guidance cue recognition
3NVX	;	2.0	;	Molecular mechanism of guidance cue recognition
5V5W	;	2.718	;	Molecular Mechanism of MDGA1: Regulation of Neuroligin 2:Neurexin Trans-synaptic Bridges
8G8W	;	3.8	;	Molecular mechanism of nucleotide inhibition of human uncoupling protein 1
2XEL	;	2.5	;	Molecular Mechanism of Pentachloropseudilin Mediated Inhibition of Myosin Motor Activity
8DWI	;	3.4	;	Molecular Mechanism of Sialic Acid Transport Mediated by Sialin
8JU9	;	2.0	;	Molecular mechanism of the one-component regulator RccR on bacterial metabolism and virulence
1GZ4	;	2.2	;	molecular mechanism of the regulation of human mitochondrial NAD(P)+-dependent malic enzyme by ATP and fumarate
7SR8	;	3.3	;	Molecular mechanism of the the wake-promoting agent TAK-925
3RC4	;	1.5	;	Molecular mechanisms of viral and host-cell substrate recognition by HCV NS3/4A protease
3RC5	;	1.6	;	Molecular mechanisms of viral and host-cell substrate recognition by HCV NS3/4A protease
3RC6	;	1.3	;	Molecular mechanisms of viral and host-cell substrate recognition by HCV NS3/4A protease
3GOE	;	0.97	;	Molecular Mimicry of SUMO promotes DNA repair
2V6L	;	16.0	;	Molecular Model of a Type III Secretion System Needle
3LU0	;	11.2	;	Molecular model of Escherichia coli core RNA polymerase
7D6Z	;	3.4	;	Molecular model of the cryo-EM structure of 70S ribosome in complex with peptide deformylase and trigger factor
7D80	;	4.1	;	Molecular model of the cryo-EM structure of 70S ribosome in complex with peptide deformylase, trigger factor, and methionine aminopeptidase
1IFI	;	3.3	;	MOLECULAR MODELS AND STRUCTURAL COMPARISONS OF NATIVE AND MUTANT CLASS I FILAMENTOUS BACTERIOPHAGES FF (FD, F1, M13), IF1 AND IKE
1IFJ	;	3.3	;	MOLECULAR MODELS AND STRUCTURAL COMPARISONS OF NATIVE AND MUTANT CLASS I FILAMENTOUS BACTERIOPHAGES FF (FD, F1, M13), IF1 AND IKE
1IFK	;	5.0	;	MOLECULAR MODELS AND STRUCTURAL COMPARISONS OF NATIVE AND MUTANT CLASS I FILAMENTOUS BACTERIOPHAGES FF (FD, F1, M13), IF1 AND IKE
1IFL	;	5.0	;	MOLECULAR MODELS AND STRUCTURAL COMPARISONS OF NATIVE AND MUTANT CLASS I FILAMENTOUS BACTERIOPHAGES FF (FD, F1, M13), IF1 AND IKE
1M8Q	;	70.0	;	Molecular Models of Averaged Rigor Crossbridges from Tomograms of Insect Flight Muscle
1MVW	;	70.0	;	MOLECULAR MODELS OF AVERAGED RIGOR CROSSBRIDGES FROM TOMOGRAMS OF INSECT FLIGHT MUSCLE
1O18	;	70.0	;	MOLECULAR MODELS OF AVERAGED RIGOR CROSSBRIDGES FROM TOMOGRAMS OF INSECT FLIGHT MUSCLE
1O19	;	70.0	;	MOLECULAR MODELS OF AVERAGED RIGOR CROSSBRIDGES FROM TOMOGRAMS OF INSECT FLIGHT MUSCLE
1O1A	;	70.0	;	MOLECULAR MODELS OF AVERAGED RIGOR CROSSBRIDGES FROM TOMOGRAMS OF INSECT FLIGHT MUSCLE
1O1B	;	70.0	;	MOLECULAR MODELS OF AVERAGED RIGOR CROSSBRIDGES FROM TOMOGRAMS OF INSECT FLIGHT MUSCLE
1O1C	;	70.0	;	MOLECULAR MODELS OF AVERAGED RIGOR CROSSBRIDGES FROM TOMOGRAMS OF INSECT FLIGHT MUSCLE
1O1D	;	70.0	;	MOLECULAR MODELS OF AVERAGED RIGOR CROSSBRIDGES FROM TOMOGRAMS OF INSECT FLIGHT MUSCLE
1O1E	;	70.0	;	MOLECULAR MODELS OF AVERAGED RIGOR CROSSBRIDGES FROM TOMOGRAMS OF INSECT FLIGHT MUSCLE
1O1F	;	70.0	;	MOLECULAR MODELS OF AVERAGED RIGOR CROSSBRIDGES FROM TOMOGRAMS OF INSECT FLIGHT MUSCLE
1O1G	;	70.0	;	MOLECULAR MODELS OF AVERAGED RIGOR CROSSBRIDGES FROM TOMOGRAMS OF INSECT FLIGHT MUSCLE
3SIC	;	1.8	;	MOLECULAR RECOGNITION AT THE ACTIVE SITE OF SUBTILISIN BPN': CRYSTALLOGRAPHIC STUDIES USING GENETICALLY ENGINEERED PROTEINACEOUS INHIBITOR SSI (STREPTOMYCES SUBTILISIN INHIBITOR)
5SIC	;	2.2	;	MOLECULAR RECOGNITION AT THE ACTIVE SITE OF SUBTILISIN BPN': CRYSTALLOGRAPHIC STUDIES USING GENETICALLY ENGINEERED PROTEINACEOUS INHIBITOR SSI (STREPTOMYCES SUBTILISIN INHIBITOR)
1DDY	;	3.0	;	MOLECULAR RECOGNITION BY THE VITAMIN B12 RNA APTAMER
1MPW	;	2.34	;	Molecular Recognition in (+)-a-Pinene Oxidation by Cytochrome P450cam
2BOV	;	2.66	;	Molecular recognition of an ADP-ribosylating Clostridium botulinum C3 exoenzyme by RalA GTPase
2Y6T	;	2.74	;	Molecular Recognition of Chymotrypsin by the Serine Protease Inhibitor Ecotin from Yersinia pestis
1HWR	;	1.8	;	MOLECULAR RECOGNITION OF CYCLIC UREA HIV PROTEASE INHIBITORS
1GWX	;	2.5	;	MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS
2GWX	;	2.3	;	MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS
3GWX	;	2.4	;	MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS
3CWD	;	2.4	;	Molecular recognition of nitro-fatty acids by PPAR gamma
1ZX7	;	2.15	;	Molecular Recognition of RNA by Neomycin and a Restricted Neomycin Derivative
1ZZ5	;	3.0	;	Molecular Recognition of RNA by Neomycin and a Restricted Neomycin Derivative
2A04	;	2.95	;	Molecular Recognition of RNA by Neomycin and a Restricted Neomycin Derivative
1S32	;	2.05	;	Molecular Recognition of the Nucleosomal 'Supergroove'
8HA0	;	2.62	;	Molecular recognition of two endogenous hormones by the human parathyroid hormone receptor-1
1LFH	;	2.8	;	MOLECULAR REPLACEMENT SOLUTION OF THE STRUCTURE OF APOLACTOFERRIN, A PROTEIN DISPLAYING LARGE-SCALE CONFORMATIONAL CHANGE
6QD6	;	2.84	;	Molecular scaffolds expand the nanobody toolkit for cryo-EM applications: crystal structure of Mb-cHopQ-Nb207
7YYY	;	2.2	;	Molecular snapshots of drug release from tubulin: 1 microsecond after photoactivation
7YZ1	;	2.2	;	Molecular snapshots of drug release from tubulin: 1 millisecond after photoactivation.
7YYV	;	2.2	;	Molecular snapshots of drug release from tubulin: 1 nanosecond after photoactivation.
7YYZ	;	2.2	;	Molecular snapshots of drug release from tubulin: 10 microseconds after photoactivation.
7YZ2	;	2.2	;	Molecular snapshots of drug release from tubulin: 10 milliseconds after photoactivation.
7YYW	;	2.2	;	Molecular snapshots of drug release from tubulin: 10 nanoseconds after photoactivation.
7YZ0	;	2.2	;	Molecular snapshots of drug release from tubulin: 100 microseconds after photoactivation.
7YZ5	;	2.11	;	Molecular snapshots of drug release from tubulin: 100 milliseconds (steady state)
7YYX	;	2.2	;	Molecular snapshots of drug release from tubulin: 100 nanoseconds after photoactivation.
7YZ3	;	1.8	;	Molecular snapshots of drug release from tubulin: Apo state
7YZ6	;	2.1	;	Molecular snapshots of drug release from tubulin: Dark (steady state)
7YYQ	;	1.7	;	Molecular snapshots of drug release from tubulin: Dark state
2GLR	;	2.2	;	MOLECULAR STRUCTURE AT 1.8 ANGSTROMS OF MOUSE LIVER CLASS PI GLUTATHIONE S-TRANSFERASE COMPLEXED WITH S-(P-NITROBENZYL)GLUTATHIONE AND OTHER INHIBITORS
3DNL	;	20.0	;	Molecular structure for the HIV-1 gp120 trimer in the b12-bound state
3DNO	;	20.0	;	Molecular structure for the HIV-1 gp120 trimer in the CD4-bound state
3DNN	;	20.0	;	Molecular structure for the HIV-1 gp120 trimer in the unliganded state
1VTV	;	1.3	;	Molecular structure of (M5DC-DG)3: The role of the methyl group on 5-methyl cytosine in stabilizing Z-DNA
2D47	;	2.0	;	MOLECULAR STRUCTURE OF A COMPLETE TURN OF A-DNA
1HRO	;	2.2	;	MOLECULAR STRUCTURE OF A HIGH POTENTIAL CYTOCHROME C2 ISOLATED FROM RHODOPILA GLOBIFORMIS
2DCG	;	0.9	;	MOLECULAR STRUCTURE OF A LEFT-HANDED DOUBLE HELICAL DNA FRAGMENT AT ATOMIC RESOLUTION
4AYJ	;	3.0	;	Molecular structure of a metal-independent bacterial glycosyltransferase that catalyzes the synthesis of histo-blood group A antigen
4AYL	;	1.919	;	Molecular structure of a metal-independent bacterial glycosyltransferase that catalyzes the synthesis of histo-blood group A antigen
5ZF1	;	1.75	;	Molecular structure of a novel 5,10-methylenetetrahydrofolate dehydrogenase from the silkworm, Bombyx mori
6IVE	;	2.3	;	Molecular structure of a thermostable and a Zinc ion binding gamma-class carbonic anhydrase
1D13	;	2.0	;	MOLECULAR STRUCTURE OF AN A-DNA DECAMER D(ACCGGCCGGT)
1AEP	;	2.7	;	MOLECULAR STRUCTURE OF AN APOLIPOPROTEIN DETERMINED AT 2.5-ANGSTROMS RESOLUTION
2AT2	;	3.0	;	MOLECULAR STRUCTURE OF BACILLUS SUBTILIS ASPARTATE TRANSCARBAMOYLASE AT 3.0 ANGSTROMS RESOLUTION
8B9Q	;		;	Molecular structure of Cu(II)-bound amyloid-beta monomer implicated in inhibition of peptide self-assembly in Alzheimer's disease
8B9R	;		;	Molecular structure of Cu(II)-bound amyloid-beta monomer implicated in inhibition of peptide self-assembly in Alzheimer's disease
1C2R	;	2.5	;	MOLECULAR STRUCTURE OF CYTOCHROME C2 ISOLATED FROM RHODOBACTER CAPSULATUS DETERMINED AT 2.5 ANGSTROMS RESOLUTION
128D	;	2.5	;	MOLECULAR STRUCTURE OF D(CGC[E6G]AATTCGCG) COMPLEXED WITH HOECHST 33258
130D	;	2.5	;	MOLECULAR STRUCTURE OF D(CGC[E6G]AATTCGCG) COMPLEXED WITH HOECHST 33342
1YNY	;	2.3	;	Molecular Structure of D-Hydantoinase from a Bacillus sp. AR9: Evidence for mercury inhibition
1J79	;	1.7	;	Molecular Structure of Dihydroorotase: A Paradigm for Catalysis Through the Use of a Binuclear Metal Center
2C0W	;	3.2	;	Molecular Structure of fd Filamentous Bacteriophage Refined with Respect to X-ray Fibre Diffraction
2C0X	;		;	MOLECULAR STRUCTURE OF FD FILAMENTOUS BACTERIOPHAGE REFINED WITH RESPECT TO X-RAY FIBRE DIFFRACTION AND SOLID-STATE NMR DATA
1FCB	;	2.4	;	MOLECULAR STRUCTURE OF FLAVOCYTOCHROME B2 AT 2.4 ANGSTROMS RESOLUTION
5W3N	;		;	Molecular structure of FUS low sequence complexity domain protein fibrils
6C0V	;	3.4	;	Molecular structure of human P-glycoprotein in the ATP-bound, outward-facing conformation
1KAN	;	3.0	;	MOLECULAR STRUCTURE OF KANAMYCIN NUCLEOTIDYLTRANSFERASE DETERMINED TO 3.0-ANGSTROMS RESOLUTION
8HNR	;	1.42	;	Molecular structure of Kunitz-type trypsin inhibitor from seeds of Albizia procera
1LAP	;	2.7	;	MOLECULAR STRUCTURE OF LEUCINE AMINOPEPTIDASE AT 2.7-ANGSTROMS RESOLUTION
6SHT	;	2.73	;	Molecular structure of mouse apoferritin resolved at 2.7 Angstroms with the Glacios cryo-microscope
1VTE	;	3.0	;	MOLECULAR STRUCTURE OF NICKED DNA. MODEL A4
1NDN	;	3.0	;	MOLECULAR STRUCTURE OF NICKED DNA. MODEL T4
6HQA	;	7.1	;	Molecular structure of promoter-bound yeast TFIID
1D96	;	2.0	;	MOLECULAR STRUCTURE OF R(GCG)D(TATACGC): A DNA-RNA HYBRID HELIX JOINED TO DOUBLE HELICAL DNA
121D	;	2.2	;	MOLECULAR STRUCTURE OF THE A-TRACT DNA DODECAMER D(CGCAAATTTGCG) COMPLEXED WITH THE MINOR GROOVE BINDING DRUG NETROPSIN
1FQG	;	1.7	;	MOLECULAR STRUCTURE OF THE ACYL-ENZYME INTERMEDIATE IN TEM-1 BETA-LACTAMASE
1D65	;	2.2	;	MOLECULAR STRUCTURE OF THE B-DNA DODECAMER D(CGCAAATTTGCG)2; AN EXAMINATION OF PROPELLER TWIST AND MINOR-GROOVE WATER STRUCTURE AT 2.2 ANGSTROMS RESOLUTION
1BBP	;	2.0	;	MOLECULAR STRUCTURE OF THE BILIN BINDING PROTEIN (BBP) FROM PIERIS BRASSICAE AFTER REFINEMENT AT 2.0 ANGSTROMS RESOLUTION.
6XFM	;	2.62	;	Molecular structure of the core of amyloid-like fibrils formed by residues 111-214 of FUS
112D	;	2.5	;	MOLECULAR STRUCTURE OF THE G.A BASE PAIR IN DNA AND ITS IMPLICATIONS FOR THE MECHANISM OF TRANSVERSION MUTATIONS
1IMR	;	1.6	;	MOLECULAR STRUCTURE OF THE HALOGENATED ANTI-CANCER DRUG IODODOXORUBICIN COMPLEXED WITH D(TGTACA) AND D(CGATCG)
1IMS	;	1.5	;	MOLECULAR STRUCTURE OF THE HALOGENATED ANTI-CANCER DRUG IODODOXORUBICIN COMPLEXED WITH D(TGTACA) AND D(CGATCG)
2A9I	;	1.7	;	Molecular Structure of the Interleukin-1 Receptor-Associated Kinase-4 Death Domain
1VTJ	;	2.4	;	MOLECULAR STRUCTURE OF THE NETROPSIN-D(CGCGATATCGCG) COMPLEX: DNA CONFORMATION IN AN ALTERNATING AT SEGMENT; CONFORMATION 1
1DNE	;	2.4	;	MOLECULAR STRUCTURE OF THE NETROPSIN-D(CGCGATATCGCG) COMPLEX: DNA CONFORMATION IN AN ALTERNATING AT SEGMENT; CONFORMATION 2
1VT6	;	2.25	;	Molecular structure of the octamer D(G-G-C-C-G-G-C-C) modified A-DNA
1VTC	;	2.25	;	MOLECULAR STRUCTURE OF THE OCTAMER D(G-G-C-C-G-G-C-C) MODIFIED A-DNA
1HPI	;	1.8	;	MOLECULAR STRUCTURE OF THE OXIDIZED HIGH-POTENTIAL IRON-SULFUR PROTEIN ISOLATED FROM ECTOTHIORHODOSPIRA VACUOLATA
1FRD	;	1.7	;	MOLECULAR STRUCTURE OF THE OXIDIZED, RECOMBINANT, HETEROCYST (2FE-2S) FERREDOXIN FROM ANABAENA 7120 DETERMINED TO 1.7 ANGSTROMS RESOLUTION
1WLH	;	2.8	;	Molecular structure of the rod domain of Dictyostelium filamin
1ETN	;	0.89	;	MOLECULAR STRUCTURE OF THE TOXIC DOMAIN OF HEAT-STABLE ENTEROTOXIN PRODUCED BY A PATHOGENIC STRAIN OF ESCHERICHIA COLI
1O55	;	1.04	;	MOLECULAR STRUCTURE OF TWO CRYSTAL FORMS OF CYCLIC TRIADENYLIC ACID AT 1 ANGSTROM RESOLUTION
1O56	;	0.9	;	MOLECULAR STRUCTURE OF TWO CRYSTAL FORMS OF CYCLIC TRIADENYLIC ACID AT 1 ANGSTROM RESOLUTION
2NU1	;	1.8	;	Molecular structures of the complexes of SGPB with OMTKY3 aromatic P1 variants Trp18I, His18I, Phe18I and Tyr18I
2NU0	;	1.95	;	Molecular structures of the complexes of SGPB with OMTKY3 aromatic P1 variants Trp18I, His18I, Phe18I, and Tyr18I
4Q21	;	2.0	;	MOLECULAR SWITCH FOR SIGNAL TRANSDUCTION: STRUCTURAL DIFFERENCES BETWEEN ACTIVE AND INACTIVE FORMS OF PROTOONCOGENIC RAS PROTEINS
6Q21	;	1.95	;	MOLECULAR SWITCH FOR SIGNAL TRANSDUCTION: STRUCTURAL DIFFERENCES BETWEEN ACTIVE AND INACTIVE FORMS OF PROTOONCOGENIC RAS PROTEINS
1HWV	;		;	MOLECULAR TOPOLOGY OF POLYCYCLIC AROMATIC CARCINOGENS DETERMINES DNA ADDUCT CONFORMATION: A LINK TO TUMORIGENIC ACTIVITY
1HX4	;		;	MOLECULAR TOPOLOGY OF POLYCYCLIC AROMATIC CARCINOGENS DETERMINES DNA ADDUCT CONFORMATION: A LINK TO TUMORIGENIC ACTIVITY
5OEG	;	3.15	;	Molecular tweezers modulate 14-3-3 protein-protein interactions
5OEH	;	2.35	;	Molecular tweezers modulate 14-3-3 protein-protein interactions.
5J7T	;	3.2001	;	Molecular Understanding of USP7 Substrate Recognition and C-Terminal Activation
8BF9	;	2.69	;	Molecular view of ER membrane remodeling by the Sec61/TRAP translocon.
1PFC	;	3.125	;	MOLECULAR-REPLACEMENT STRUCTURE OF GUINEA PIG IGG1 P*FC(PRIME) REFINED AT 3.1 ANGSTROMS RESOLUTION
1DDS	;	2.2	;	MOLECULE: DIHYDROFOLATE REDUCTASE (E.C.1.5.1.3) COMPLEXED WITH METHOTREXATE
1DDR	;	2.45	;	MOLECULE: DIHYDROFOLATE REDUCTASE (E.C.1.5.1.3) COMPLEXED WITH METHOTREXATE AND UREA
1H9S	;	1.82	;	Molybdate bound complex of Dimop domain of ModE from E.coli
1O7L	;	2.75	;	Molybdate-activated form of ModE from Escherichia coli
1XI8	;	2.504	;	Molybdenum cofactor biosynthesis protein from Pyrococcus furiosus Pfu-1657500-001
6H8H	;	1.901	;	Molybdenum storage protein - in a recombinant and in vivo-like form
7ZQQ	;	1.75	;	Molybdenum storage protein - LB131H
6RKE	;	1.7	;	Molybdenum storage protein - P212121, ADP, molybdate
6RJ4	;	1.9	;	Molybdenum storage protein - P6422, ADP
6H73	;	2.3	;	Molybdenum storage protein - recombinantly produced and loaded with molybdate under in vitro conditions
7ZSE	;	1.4	;	Molybdenum storage protein in complex with polyoxotungstates in the in-vitro state
7ZR4	;	1.701	;	Molybdenum storage protein loaded with polyoxotungstates in the in vivo-like state
6H8B	;	1.9	;	Molybdenum storage protein prepared under in vivo-like conditions and incubated with ATP and molybdate at 303 K
5O5W	;	1.7	;	Molybdenum storage protein room-temperature structure determined by serial millisecond crystallography
6RKD	;	3.2	;	Molybdenum storage protein under turnover conditions
6GUJ	;	2.102	;	Molybdenum storage protein with two occupied ATP binding sites
6GWV	;	2.8	;	Molybdenum storage protein without polymolybdate clusters and ATP
6GWB	;	1.9	;	Molybdenum storage protein without polyoxomolybdate clusters
6H6W	;	1.9	;	Molybdenum storage protein- H156A
7L32	;	1.9	;	Molybdopterin biosynthesis MoaE protein from Burkholderia ambifaria MC40-6
7L2A	;	1.85	;	Molybdopterin cofactor biosynthesis protein E from Burkholderia multivorans ATCC 17616
1FM0	;	1.45	;	MOLYBDOPTERIN SYNTHASE (MOAD/MOAE)
1FMA	;	1.58	;	MOLYBDOPTERIN SYNTHASE (MOAD/MOAE)
1BM4	;		;	MOMLV CAPSID PROTEIN MAJOR HOMOLOGY REGION PEPTIDE ANALOG
8DZP	;	2.71	;	momSalB bound Kappa Opioid Receptor in complex with Gi1
8DZQ	;	2.82	;	momSalB bound Kappa Opioid Receptor in complex with GoA
2W10	;	1.9	;	Mona SH3C in complex
1OEB	;	1.76	;	Mona/Gads SH3C domain
1UTI	;	1.5	;	Mona/Gads SH3C in complex with HPK derived peptide
2O9U	;	1.15	;	Monellin (MNEI) at 1.15 resolution
1GO9	;		;	Monitoring the structural Consequences of Phe12-->D-Phe12 and Leu15-->Aib15 substitution in h/r Corticotropin Releasing Hormone: Implications for Design of CRH antagonists.
1GOE	;		;	Monitoring the structural Consequences of Phe12-->D-Phe12 and Leu15-->Aib15 substitution in h/r Corticotropin Releasing Hormone: Implications for Design of CRH antagonists.
8HPA	;	3.01	;	Monkeypox virus DNA replication holoenzyme F8, A22 and E4 complex in a DNA binding form
8HDZ	;	3.05	;	Monkeypox virus DNA replication holoenzyme F8, A22 and E4 complex in an apo form
8CGB	;	2.47	;	Monkeypox virus VP39 in complex with SAH
8OIV	;	2.12	;	Monkeypox virus VP39 in complex with SAH and cap0
6FN9	;	2.27	;	Mono- and bivalent 14-3-3 inhibitors for characterizing supramolecular lysine-PEG interactions in proteins
6FNA	;	2.12	;	Mono- and bivalent 14-3-3 inhibitors for characterizing supramolecular lysine-PEG interactions in proteins
6FNB	;	2.3	;	Mono- and bivalent 14-3-3 inhibitors for characterizing supramolecular lysine-PEG interactions in proteins
6FNC	;	2.12	;	Mono- and bivalent 14-3-3 inhibitors for characterizing supramolecular lysine-PEG interactions in proteins
6BO1	;	1.24	;	Mono-adduct formed after 3 days in the reaction of dichlorido(1,3-dimethylbenzimidazol-2-ylidene)(eta6-p-cymene)ruthenium(II) with HEWL
7O90	;	1.49	;	Mono-Fe-sulerythrin
2LI0	;		;	Mono-O-GalNAc glycosylated Mucin sequence based on MUC2 Mucin glycoprotein tandem repeat
2LI1	;		;	Mono-O-GalNAc glycosylated Mucin sequence based on MUC2 Mucin glycoprotein tandem repeat
2LI2	;		;	Mono-O-GalNAc glycosylated Mucin sequence based on MUC2 Mucin glycoprotein tandem repeat
6VAE	;	3.6	;	Mono-ubiquitinated Fanconi Anemia ID complex bound to ICL DNA
4UWR	;	1.55	;	Mono-zinc VIM-26. Leu224 in VIM-26 from Klebsiella pneumoniae has implications for drug binding.
5NAI	;	1.15	;	mono-Zinc VIM-5 metallo-beta-lactamase in complex with (1-chloro-4-hydroxyisoquinoline-3-carbonyl)-D-tryptophan (Compound 1)
5N55	;	1.99	;	mono-Zinc VIM-5 metallo-beta-lactamase in complex with (1-chloro-4-hydroxyisoquinoline-3-carbonyl)-L-tryptophan (Compound 2)
1QXK	;	2.3	;	Monoacid-Based, Cell Permeable, Selective Inhibitors of Protein Tyrosine Phosphatase 1B
6O03	;	3.3	;	Monobody (MC17) bound to tyrosine kinase binding domain of E3 ubiquitin ligase CBL
6O02	;	2.953	;	Monobody (MC3) bound to tyrosine kinase binding domain of E3 ubiquitin ligase CBL
8EZG	;	2.52	;	Monobody 12D1 bound to KRAS(G12D)
8F0M	;	2.44	;	Monobody 12D5 bound to KRAS(G12D)
7L0G	;	2.54	;	Monobody 12VC1 Bound to HRAS(G12C)
7L0F	;	1.98	;	Monobody 12VC3 Bound to HRAS(WT)
5MTN	;	2.85	;	Monobody Mb(Lck_1) bound to Lck-Sh2
5MTM	;	2.405	;	Monobody Mb(Lck_3) bound to Lck-SH2 domain
3QL9	;	0.93	;	Monoclinic complex structure of ATRX ADD bound to histone H3K9me3 peptide
5M56	;	2.237	;	Monoclinic complex structure of human protein kinase CK2 catalytic subunit (isoform CK2alpha') with the inhibitor 4'-carboxy-6,8-chloro-flavonol (FLC21)
5CQU	;	2.35	;	Monoclinic Complex Structure of Protein Kinase CK2 Catalytic Subunit with a Benzotriazole-Based Inhibitor Generated by click-chemistry
2GVY	;	1.8	;	Monoclinic crystal form of Aspergillus niger alpha-amylase in complex with maltose at 1.8 A resolution
4CJ8	;	3.5	;	monoclinic crystal form of Bogt6a E192Q in complex with UDP-GalNAc, UDP and GalNAc
4GSB	;	1.8	;	Monoclinic crystal form of the apo-ERK2
5T7Z	;	2.03	;	Monoclinic crystal form of the EpoB NRPS cyclization-docking bidomain from Sorangium cellulosum
4D7C	;	1.45	;	Monoclinic crystal form of the extracellular olfactomedin domain from gliomedin
1RG0	;	1.8	;	Monoclinic crystal form of the truncated K122-4 pilin from Pseudomonas aeruginosa
4TLH	;	1.7	;	Monoclinic Crystal Structure of EutL from Clostridium Perfringens
3SMP	;	1.9	;	Monoclinic crystal structure of human pantothenate kinase 1 alpha
2PL6	;	2.2	;	Monoclinic crystal structure of hydrophobin HFBII in presence of a detergent
7QFA	;	2.0	;	Monoclinic crystal structure of PTG CBM21 in complex with beta-cyclodextrin
5II9	;	2.11	;	Monoclinic crystal structure of red abalone lysin at 2.11 A resolution
3VKI	;	2.3	;	Monoclinic Crystal Structure of Salmonella FlgA in closed form
6GNQ	;	2.2	;	Monoclinic crystalline form of human insulin, complexed with meta-cresol
6ARC	;	1.9	;	Monoclinic EutL - structure determined from merged ""Group 1"" data
6ARD	;	2.0	;	Monoclinic EutL - structure determined from merged ""Group 2"" data
5EYX	;	2.25	;	Monoclinic Form of Centrolobium tomentosum seed lectin (CTL) complexed with Man1-3Man-OMe.
3PVO	;	3.0	;	Monoclinic form of Human C-Reactive Protein
3QNY	;	2.3	;	Monoclinic form of human IgA1 Fab fragment, sharing same Fv as IgG
1H4O	;	1.95	;	Monoclinic form of human peroxiredoxin 5
1ICT	;	3.0	;	MONOCLINIC FORM OF HUMAN TRANSTHYRETIN COMPLEXED WITH THYROXINE (T4)
2VNP	;	2.19	;	Monoclinic form of IDI-1
2VNQ	;	2.2	;	Monoclinic form of IDI-1
3QO1	;	2.4	;	Monoclinic form of IgG1 Fab fragment (apo form) sharing same Fv as IgA
3QO0	;	2.3	;	Monoclinic form of IgG1 Fab fragment (in complex with antigenic peptide) sharing same Fv as IgA
6C7N	;	2.0	;	Monoclinic form of malic enzyme from sorghum at 2 angstroms resolution
1KHP	;	2.0	;	Monoclinic form of papain/ZLFG-DAM covalent complex
1MS3	;	1.65	;	Monoclinic form of Trypanosoma cruzi trans-sialidase
1MS1	;	1.8	;	Monoclinic form of Trypanosoma cruzi trans-sialidase, in complex with 3-deoxy-2,3-dehydro-N-acetylneuraminic acid (DANA)
1MS0	;	2.5	;	Monoclinic form of Trypanosoma cruzi trans-sialidase, in complex with 3-deoxy-2,3-dehydro-N-acetylneuraminic acid (DANA)and lactose
1LKR	;	1.6	;	MONOCLINIC HEN EGG WHITE LYSOZYME IODIDE
1LCN	;	1.63	;	Monoclinic hen egg white lysozyme, thiocyanate complex
2D4K	;	1.15	;	Monoclinic hen egg-white lysozyme crystallized at 313K
2D4I	;	1.16	;	Monoclinic hen egg-white lysozyme crystallized at pH4.5 form heavy water solution
6TC2	;	1.36	;	Monoclinic human insulin in complex with p-coumaric acid
3WL2	;	0.96	;	Monoclinic Lysozyme at 0.96 A resolution
2QZE	;	2.9	;	Monoclinic Mimivirus Capping Enzyme Triphosphatase.
4OFN	;	2.69	;	Monoclinic NaGST1
7B1H	;	2.4	;	Monoclinic P21 Structure of Human Mad1 C-terminal Domain in Complex with Phosphorylated Bub1 CD1 Domain
7B8H	;	1.34	;	Monoclinic structure of human protein kinase CK2 catalytic subunit in complex with a heparin oligo saccharide
3N9D	;	2.3	;	Monoclinic Structure of P. aeruginosa LigD phosphoesterase domain
5EFZ	;	1.82	;	Monoclinic structure of the acetyl esterase MekB
7QON	;	1.51	;	Monoclinic triose phosphate isomerase from Fasciola hepatica.
1MLB	;	2.1	;	MONOCLONAL ANTIBODY FAB D44.1 RAISED AGAINST CHICKEN EGG-WHITE LYSOZYME
1MLC	;	2.5	;	MONOCLONAL ANTIBODY FAB D44.1 RAISED AGAINST CHICKEN EGG-WHITE LYSOZYME COMPLEXED WITH LYSOZYME
1BFV	;	2.1	;	MONOCLONAL ANTIBODY FRAGMENT FV4155 FROM E. COLI
1CFV	;	2.1	;	MONOCLONAL ANTIBODY FRAGMENT FV4155 FROM E. COLI
2BFV	;	2.5	;	MONOCLONAL ANTIBODY FRAGMENT FV4155 FROM E. COLI
6FBJ	;	2.3	;	monoclonal antibody targeting Matrix metalloproteinase 7
1FGN	;	2.5	;	MONOCLONAL MURINE ANTIBODY 5G9-ANTI-HUMAN TISSUE FACTOR
7R5Z	;	1.75	;	Monocot chimeric jacalin JAC1 from Oryza sativa: dirigent domain (crystal form 1)
7YWE	;	2.15	;	Monocot chimeric jacalin JAC1 from Oryza sativa: dirigent domain (crystal form 2)
7YWF	;	2.6	;	Monocot chimeric jacalin JAC1 from Oryza sativa: dirigent domain with bound galactobiose
7YWG	;	1.1	;	Monocot chimeric jacalin JAC1 from Oryza sativa: lectin domain (crystal form 1)
7YWW	;	1.4	;	Monocot chimeric jacalin JAC1 from Oryza sativa: lectin domain (crystal form 2)
1DOL	;	2.4	;	MONOCYTE CHEMOATTRACTANT PROTEIN 1, I-FORM
1DOK	;	1.85	;	MONOCYTE CHEMOATTRACTANT PROTEIN 1, P-FORM
1BO0	;		;	MONOCYTE CHEMOATTRACTANT PROTEIN-3, NMR, MINIMIZED AVERAGE STRUCTURE
6KRT	;	2.2	;	monodehydroascorbate reductase, MDHAR, from Antarctic hairgrass Deschampsia antarctica
6MOL	;	3.163	;	Monoextended DARPin M_R12 complex with EpoR
1AG1	;	2.36	;	MONOHYDROGEN PHOSPHATE BINDING TO TRYPANOSOMAL TRIOSEPHOSPHATE ISOMERASE
5CVJ	;	1.8	;	Monolignol 4-O-methyltransferase 5 - coniferyl alcohol
7W26	;	2.43	;	monolignol ferulate transferase
3REO	;	1.9	;	Monolignol O-methyltransferase (MOMT)
3TKY	;	2.47	;	Monolignol o-methyltransferase (momt)
5XLM	;	2.2	;	Monomer form of M.tuberculosis PknI sensor domain
6O5B	;	3.6	;	Monomer of a cation channel
5BNG	;	3.5	;	monomer of TALE type homeobox transcription factor MEIS1 complexes with specific DNA
7E2D	;	3.71	;	Monomer of TRAPPII (Closed)
7E2C	;	4.18	;	Monomer of TRAPPII (open)
7E8T	;	3.8	;	Monomer of Ypt32-TRAPPII
7XS2	;	2.15	;	Monomer structure of HtrA from Helicobacter pylori
3WQ8	;	2.81	;	Monomer structure of hyperthermophilic beta-glucosidase mutant forming a dodecameric structure in the crystal form
6L4J	;	2.3	;	Monomer structure of monellin loop1 mutant (YEPKG)
6FV6	;	3.8	;	Monomer structure of the MATE family multidrug resistance transporter Aq_128 from Aquifex aeolicus in the outward-facing state
8HGA	;		;	Monomer structure of transforming growth factor beta induced protein (TGFBIp) G623R fibril
6CP3	;	3.8	;	Monomer yeast ATP synthase (F1Fo) reconstituted in nanodisc with inhibitor of oligomycin bound.
6CP6	;	3.6	;	Monomer yeast ATP synthase (F1Fo) reconstituted in nanodisc.
6CP7	;	4.1	;	Monomer yeast ATP synthase Fo reconstituted in nanodisc generated from masked refinement.
6WTD	;	4.2	;	Monomer yeast ATP synthase Fo reconstituted in nanodisc with inhibitor of Bedaquiline bound
6CP5	;	4.2	;	Monomer yeast ATP synthase Fo reconstituted in nanodisc with inhibitor of oligomycin bound generated from focused refinement.
2LK7	;		;	Monomer-dimer equilibrium for 5'-5' stacking of propeller-type parallel-stranded G-quadruplexes: NMR structural study
7NYP	;	2.1	;	monomeric acetyl-CoA synthase in closed conformation
7NYS	;	2.0	;	monomeric acetyl-CoA synthase in closed conformation with carbon monoxide bound to the Ni proximal of cluster A
7O0D	;	2.3	;	monomeric acetyl-CoA synthase in open conformation with methanethiol moiety of CoA bound to nickel proximal
7NZ5	;	1.9	;	monomeric acetyl-CoA synthase with Zn at the proximal position of cluster A
7RRW	;	2.0	;	Monomeric CRM197 expressed in E. coli
5ZB1	;	3.061	;	Monomeric crystal structure of orf57 from KSHV
5OY5	;	2.6	;	Monomeric crystal structure of RpBphP1 photosensory core domain from the bacterium Rhodopseudomonas palustris
6AOA	;	1.4	;	Monomeric crystal structure of the E497/C566D double mutant of the guanylyl cyclase domain of the RhoGC fusion protein from the aquatic fungus Blastocladiella emersonii
1ESO	;	2.0	;	MONOMERIC CU,ZN SUPEROXIDE DISMUTASE FROM ESCHERICHIA COLI
6HQB	;	4.0	;	Monomeric cyanobacterial photosystem I
6MOE	;	2.091	;	Monomeric DARPin E2 complex with EpoR
6MOF	;	2.894	;	Monomeric DARPin G2 complex with EpoR
8R1F	;	3.67	;	Monomeric E6AP-E6-p53 ternary complex
3BX9	;	1.8	;	Monomeric Far-red Fluorescent Protein mKate Crystallized at pH 2.0
3BXA	;	1.75	;	Monomeric Far-red Fluorescent Protein mKate Crystallized at pH 4.2
3BXB	;	2.6	;	Monomeric Far-red Fluorescent Protein mKate Crystallized at pH 7.0
3BXC	;	2.6	;	Monomeric Far-red Fluorescent Protein mKate Crystallized at pH 9.0
4J12	;	1.9	;	monomeric Fc
4P2F	;	2.05	;	Monomeric form of a single mutant (F363R) of Mycobacterial Adenylyl cyclase Rv1625c
6JY3	;	1.85	;	Monomeric Form of Bovine Heart Cytochrome c Oxidase in the Fully Oxidized State
6JY4	;	1.95	;	Monomeric Form of Bovine Heart Cytochrome c Oxidase in the Fully Reduced State
4QKG	;	1.95	;	Monomeric form of human LLT1, a ligand for NKR-P1
2O3M	;		;	Monomeric G-DNA tetraplex from human C-kit promoter
3LL2	;	0.97	;	Monomeric Griffithsin in Complex with a High-Mannose Branched Carbohydrate
3LKY	;	1.11	;	Monomeric Griffithsin with a Single Gly-Ser Insertion
3LL1	;	0.97	;	Monomeric Griffithsin with a Single Gly-Ser Insertion and Mutations to Remove Residual Self-Association
3LL0	;	1.7	;	Monomeric Griffithsin with two Gly-Ser Insertions
8Y4Z	;		;	Monomeric HERC5 HECT c-lobe structure in solution
6K9K	;	7.82	;	Monomeric human ATM (Ataxia telangiectasia mutated) kinase
2KYP	;		;	Monomeric Human CKIT-2 proto-oncogene promoter quadruplex DNA NMR, 12 structures
2XJK	;	1.45	;	Monomeric Human Cu,Zn Superoxide dismutase
2XJL	;	1.55	;	Monomeric Human Cu,Zn Superoxide dismutase without Cu ligands
3HFF	;	2.2	;	Monomeric human Cu,Zn Superoxide dismutase without Zn ligands
5J07	;	2.0	;	Monomeric Human Cu,Zn Superoxide dismutase, loops IV and VII deleted, apo form, circular permutant P1/2
5J0C	;	1.6	;	Monomeric Human Cu,Zn Superoxide dismutase, loops IV and VII deleted, apo form, circular permutant P2/3
5J0F	;	1.25	;	Monomeric Human Cu,Zn Superoxide dismutase, loops IV and VII deleted, apo form, circular permutant P4/5
5J0G	;	2.5	;	Monomeric Human Cu,Zn Superoxide dismutase, loops IV and VII deleted, apo form, circular permutant P7/8
4BD4	;	2.78	;	Monomeric Human Cu,Zn Superoxide dismutase, loops IV and VII deleted, apo form, mutant H43F
4XCR	;	3.602	;	Monomeric Human Cu,Zn Superoxide dismutase, loops IV and VII deleted, apo form, mutant I35A
4BCZ	;	1.93	;	Monomeric Human Cu,Zn Superoxide dismutase, loops IV and VII deleted, apo form.
4BCY	;	1.272	;	Monomeric Human Cu,Zn Superoxide dismutase, mutation H43F
6FLH	;	1.79	;	Monomeric Human Cu,Zn Superoxide dismutase, SOD1 7+7, apo form
1MFM	;	1.02	;	MONOMERIC HUMAN SOD MUTANT F50E/G51E/E133Q AT ATOMIC RESOLUTION
8YCM	;	1.32	;	Monomeric Human STK19
2JSK	;		;	Monomeric Human Telomere DNA Tetraplex with 3+1 Strand Fold Topology, Two Edgewise Loops and Double-Chain Reversal Loop, 16 G Form 1, NMR, 10 Structures
2JSQ	;		;	Monomeric Human Telomere DNA Tetraplex with 3+1 Strand Fold Topology, Two Edgewise Loops and Double-Chain Reversal Loop, Form 2 15BrG, NMR, 10 Structures
2JSL	;		;	Monomeric Human Telomere DNA Tetraplex with 3+1 Strand Fold Topology, Two Edgewise Loops and Double-Chain Reversal Loop, Form 2 Natural, NMR, 10 Structures
2JSM	;		;	MONOMERIC HUMAN TELOMERE DNA TETRAPLEX WITH 3+1 STRAND FOLD TOPOLOGY, TWO EDGEWISE LOOPS AND DOUBLE-CHAIN REVERSAL LOOP, NMR, 10 STRUCTURES, Form 1 Natural
2GKU	;		;	Monomeric human telomere DNA tetraplex with 3+1 strand fold topology, two edgewise loops and double-chain reversal loop, NMR, 12 structures
5HVW	;	1.95	;	Monomeric IgG4 Fc
2KPR	;		;	Monomeric intronic human chl1 gene quadruplex DNA NMR, 17 structures
6OJQ	;	3.67	;	Monomeric kinesin-1 motor domain in no-nucleotide state bound to GMPCPP-stabilized microtubule
5Y1G	;	1.35	;	Monomeric L-threonine 3-dehydrogenase from metagenome database (AKB and NADH bound form)
5Y1D	;	1.9	;	Monomeric L-threonine 3-dehydrogenase from metagenome database (apo form)
5Y1E	;	1.9	;	monomeric L-threonine 3-dehydrogenase from metagenome database (L-Ser and NAD+ bound form)
5Y1F	;	1.25	;	Monomeric L-threonine 3-dehydrogenase from metagenome database (NAD+ bound form)
6NRE	;	2.06	;	Monomeric Lipocalin Can F 6
6TME	;	2.33	;	Monomeric LRX8 in complex with RALF4.
1GOD	;	2.8	;	MONOMERIC LYS-49 PHOSPHOLIPASE A2 HOMOLOGUE ISOLATED FROM THE VENOM OF CERROPHIDION (BOTHROPS) GODMANI
1MC2	;	0.85	;	monomeric LYS-49 phospholipase A2 homologue purified from AG
8SQU	;	3.28	;	Monomeric MapSPARTA bound with guide RNA and target DNA hybrid
2LEM	;		;	Monomeric Mouse ApoAI(1-216)
5NMR	;	2.1	;	Monomeric mouse Sortilin extracellular domain
2A5P	;		;	Monomeric parallel-stranded DNA tetraplex with snap-back 3+1 3' G-tetrad, single-residue chain reversal loops, GAG triad in the context of GAAG diagonal loop, NMR, 8 struct.
5DA7	;	2.802	;	monomeric PCNA bound to a small protein inhibitor
2LXQ	;		;	Monomeric PilE G-Quadruplex DNA from Neisseria Gonorrhoeae
5OTJ	;	2.35	;	Monomeric polcalcin (Phl p 7) in complex with two identical allergen-specific antibodies
7R3F	;	1.65	;	Monomeric PqsE mutant E187R
1K53	;	2.1	;	Monomeric Protein L B1 Domain with a G15A Mutation
1K52	;	1.8	;	Monomeric Protein L B1 Domain with a K54G mutation
4V0T	;	2.05	;	Monomeric pseudorabies virus protease pUL26N at 2.1 A resolution
4CX8	;	2.53	;	Monomeric pseudorabies virus protease pUL26N at 2.5 A resolution
7ZQC	;	2.31	;	Monomeric PSI of Chlamydomonas reinhardtii at 2.31 A resolution
5FPK	;	1.343	;	MONOMERIC RADA IN COMPLEX WITH FATA TETRAPEPTIDE
2VAD	;	1.59	;	Monomeric red fluorescent protein, DsRed.M1
7Z10	;	3.87	;	Monomeric respiratory complex IV isolated from S. cerevisiae
5LMX	;	4.9	;	Monomeric RNA polymerase I at 4.9 A resolution
2A89	;	1.85	;	Monomeric Sarcosine Oxidase: Structure of a covalently flavinylated amine oxidizing enzyme
2GB0	;	1.85	;	Monomeric sarcosine oxidase: structure of a covalently flavinylated amine oxidizing enzyme
7M2Z	;	3.7	;	Monomeric single-particle reconstruction of the Yeast gamma-TuSC
6ZYT	;	1.8	;	Monomeric streptavidin with a conjugated biotinylated pyrrolidine
5YGM	;	1.6	;	Monomeric structure of concanavalin A at pH 7.5 from Carnivalia ensiformis
6KLE	;	4.5	;	Monomeric structure of Machupo virus polymerase bound to vRNA promoter
6L4I	;	2.2	;	Monomeric structure of monellin loop1 mutant with QEPKG motif
6L44	;	2.492	;	Monomeric structure of monellin loop1 mutant with QVPAG motif
1MD8	;	2.8	;	Monomeric structure of the active catalytic domain of complement protease C1r
1F0M	;	2.2	;	MONOMERIC STRUCTURE OF THE HUMAN EPHB2 SAM (STERILE ALPHA MOTIF) DOMAIN
3UNN	;	1.7	;	Monomeric structure of the human MDC1 FHA domain in complex with an MDC1 phospho-T4 peptide
1MD7	;	3.2	;	Monomeric structure of the zymogen of complement protease C1r
3ZBP	;	2.0	;	Monomeric subunit of TubZ from Bacteriophage PhiKZ
2LJF	;		;	Monophosphorylated (747pY) beta3 integrin cytoplasmic tail under aqueous conditions
2LJD	;		;	monophosphorylated (747pY) beta3 integrin cytoplasmic tail under membrane mimetic conditions
6M94	;	2.7	;	Monophosphorylated pSer33 b-Catenin peptide bound to b-TrCP/Skp1 Complex
6M91	;	2.4	;	Monophosphorylated pSer33 b-Catenin peptide, b-TrCP/Skp1, NRX-103094 ternary complex
6M93	;	2.5	;	Monophosphorylated pSer33 b-Catenin peptide, b-TrCP/Skp1, NRX-1933 ternary complex
6M92	;	2.35	;	Monophosphorylated pSer33 b-Catenin peptide, b-TrCP/Skp1, NRX-2663 ternary complex
6M90	;	2.05	;	Monophosphorylated pSer33 b-Catenin peptide, b-TrCP/Skp1, NRX-2776 ternary complex
2WSQ	;	2.1	;	MonoTIM mutant RMM0-1, dimeric form.
2WSR	;	1.65	;	MONOTIM MUTANT RMM0-1, MONOMERIC FORM.
8TI4	;	2.1	;	monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the CH1-CL interface
8TJF	;	2.3	;	monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the CH1-CL interface
9INS	;	1.7	;	MONOVALENT CATION BINDING IN CUBIC INSULIN CRYSTALS
1FP7	;	3.2	;	MONOVALENT CATION BINDING SITES IN N10-FORMYLTETRAHYDROFOLATE SYNTHETASE FROM MOORELLA THERMOACETICA
1FPM	;	3.0	;	MONOVALENT CATION BINDING SITES IN N10-FORMYLTETRAHYDROFOLATE SYNTHETASE FROM MOORELLA THERMOACETICA
1DOU	;	1.82	;	MONOVALENT CATIONS SEQUESTER WITHIN THE A-TRACT MINOR GROOVE OF [D(CGCGAATTCGCG)]2
6OCN	;	1.147	;	Montbretin A analogue M06-MbA in complex with Human pancreatic alpha-amylase
6OBX	;	1.3	;	Montbretin A analogue M10-MbA in complex with Human pancreatic alpha-amylase
4AWX	;	2.3	;	Moonlighting functions of FeoC in the regulation of ferrous iron transport in Feo
3ZXN	;	1.9	;	Moorella thermoacetica RsbS S58E
7EM9	;	1.9	;	Mooring Stone-Like Arg114 Pulls Diverse Bulged Peptides: First Insight into African Swine Fever Virus-Derived T Cell Epitopes Presented by Swine Major Histocompatibility Complex Class I
7EMA	;	1.8	;	Mooring Stone-Like Arg114 Pulls Diverse Bulged Peptides: First Insight into African Swine Fever Virus-Derived T Cell Epitopes Presented by Swine Major Histocompatibility Complex Class I
7EMB	;	1.97	;	Mooring Stone-Like Arg114 Pulls Diverse Bulged Peptides: First Insight into African Swine Fever Virus-Derived T Cell Epitopes Presented by Swine Major Histocompatibility Complex Class I
7EMC	;	1.9	;	Mooring Stone-Like Arg114 Pulls Diverse Bulged Peptides: First Insight into African Swine Fever Virus-Derived T Cell Epitopes Presented by Swine Major Histocompatibility Complex Class I
7EMD	;	1.7	;	Mooring Stone-Like Arg114 Pulls Diverse Bulged Peptides: First Insight into African Swine Fever Virus-Derived T Cell Epitopes Presented by Swine Major Histocompatibility Complex Class I
7RJF	;	1.8	;	MOPD-1 mutant-L47W
6T6L	;	1.757	;	Mopeia Virus Exonuclease domain complexed soak with Alendronate
5LS4	;	1.469	;	Mopeia virus exonuclease domain complexed with Calcium
5LRP	;	1.941	;	Mopeia Virus Exonuclease domain complexed with Magnesium
6SX8	;	1.8	;	Mopeia Virus Exonuclease domain complexed with Manganese
6SY8	;	2.08	;	Mopeia Virus Exonuclease domain fully depleted of Manganese un ALD compound
6T2A	;	2.0	;	Mopeia Virus Exonuclease domain partially complexed with Manganese
1GUS	;	1.8	;	MopII from Clostridium pasteurianum (apo1)
1GUT	;	1.5	;	MopII from Clostridium pasteurianum (apo2)
1GUO	;	2.5	;	MopII from Clostridium pasteurianum complexed with molybdate
1GUN	;	1.83	;	MopII from Clostridium pasteurianum complexed with molybdate (partial)
1GUG	;	1.6	;	MopII from Clostridium pasteurianum complexed with tungstate
5SVI	;	1.613	;	MORC3 CW domain in complex with unmodified histone H3
5SVY	;	1.05	;	MORC3 CW in complex with histone H3K4me1
5SVX	;	1.56	;	MORC3 CW in complex with histone H3K4me3
5U2J	;	1.6	;	MORF double PHD finger (DPF) in complex with histone H3K14bu
6YEW	;	3.2	;	Morganella morganii TcdA4 in complex with porcine mucosa heparin
6S3F	;	1.68	;	Moringa seed protein Mo-CBP3-4
5WUZ	;		;	Morintides mO1
3IA5	;	2.1	;	Moritella profunda dihydrofolate reductase (DHFR)
3IA4	;	1.7	;	Moritella profunda dihydrofolate reductase (DHFR) in complex with NADPH and methotrexate (MTX)
2ZZA	;	2.0	;	Moritella profunda Dihydrofolate reductase complex with NADP+ and Folate
8EF6	;	3.2	;	Morphine-bound mu-opioid receptor-Gi complex
1GWJ	;	2.2	;	Morphinone reductase
3BV3	;	2.59	;	Morpholino pyrrolotriazine P38 Alpha Map Kinase inhibitor compound 2
3BV2	;	2.4	;	Morpholino pyrrolotriazine P38 Alpha map kinase inhibitor compound 30
6NHK	;	2.777	;	Mortalin nucleotide binding domain in the ADP-bound state
4R79	;	3.1	;	Mos1 transposase paired-end complex with left transposon end
6B8H	;	3.6	;	Mosaic model of yeast mitochondrial ATP synthase monomer
5V13	;	1.84	;	Mosquito juvenile hormone-binding protein
1W99	;	1.75	;	Mosquito-larvicidal toxin Cry4Ba from Bacillus thuringiensis ssp. Israelensis
7QX4	;	2.6	;	mosquitocidal Cry11Aa determined at pH 7 from naturally-occurring nanocrystals by Serial femtosecond crystallography
7QX6	;	3.3	;	mosquitocidal Cry11Aa-E583Q determined at pH 7 from naturally-occurring nanocrystals by Serial femtosecond crystallography
7QX7	;	3.4	;	mosquitocidal Cry11Aa-F17Y determined at pH 7 from naturally-occurring nanocrystals by Serial femtosecond crystallography
7QX5	;	3.1	;	mosquitocidal Cry11Aa-Y449F determined at pH 7 from naturally-occurring nanocrystals by Serial femtosecond crystallography
7R1E	;	2.65	;	Mosquitocidal Cry11Ba determined at pH 10.4 from naturally-occurring nanocrystals by Serial femtosecond crystallography
7QYD	;	2.4	;	mosquitocidal Cry11Ba determined at pH 6.5 from naturally-occurring nanocrystals by Serial femtosecond crystallography
7ZHC	;	1.819	;	Moss spermine/spermidine acetyl transferase (PpSSAT) in complex with AcetylCoA and polyethylen glycol
7ZKT	;	2.06	;	Moss spermine/spermidine acetyl transferase (PpSSAT) in complex with CoA and lysine
6GU5	;	1.9	;	Mosto containing the core POM clusters
7ZB5	;	2.8	;	Mot1(1-1836):TBP:DNA - post-hydrolysis complex dimer
7Z8S	;	3.9	;	Mot1:TBP:DNA - post hydrolysis state
7ZKE	;	3.6	;	Mot1:TBP:DNA - pre-hydrolysis state
7Z7N	;	5.1	;	Mot1E1434Q:TBP:DNA - substrate recognition state
3MSP	;		;	MOTILE MAJOR SPERM PROTEIN (MSP) OF ASCARIS SUUM, NMR, 20 STRUCTURES
1CM4	;	2.0	;	Motions of calmodulin-four-conformer refinement
1CM1	;	2.0	;	MOTIONS OF CALMODULIN-SINGLE-CONFORMER REFINEMENT
5WDH	;	2.248	;	Motor domain of human kinesin family member C1
1LKX	;	3.0	;	MOTOR DOMAIN OF MYOE, A CLASS-I MYOSIN
2OWM	;	3.25	;	Motor domain of Neurospora crassa kinesin-3 (NcKin3)
3T0Q	;	2.35	;	Motor Domain Structure of the Kar3-like kinesin from Ashbya gossypii
5NUG	;	3.8	;	Motor domains from human cytoplasmic dynein-1 in the phi-particle conformation
3UNH	;	3.2	;	Mouse 20S immunoproteasome
3UNF	;	2.9	;	Mouse 20S immunoproteasome in complex with PR-957
1MAA	;	2.9	;	MOUSE ACETYLCHOLINESTERASE CATALYTIC DOMAIN, GLYCOSYLATED PROTEIN
8FRA	;	1.95	;	Mouse acidic mammalian chitinase, catalytic domain in complex with diacetylchitobiose at pH 5.60
8GCA	;	1.7	;	Mouse acidic mammalian chitinase, catalytic domain in complex with N,N',N''-triacetylchitotriose at pH 4.74
8FRC	;	1.92	;	Mouse acidic mammalian chitinase, catalytic domain in complex with N,N'-diacetylchitobiose at pH 4.91
8FR9	;	1.5	;	Mouse acidic mammalian chitinase, catalytic domain in complex with N,N'-diacetylchitobiose at pH 5.08
8FRB	;	1.7	;	Mouse acidic mammalian chitinase, catalytic domain in complex with N,N'-diacetylchitobiose at pH 5.25
8FRD	;	1.68	;	Mouse acidic mammalian chitinase, catalytic domain in complex with N,N'-diacetylchitobiose at pH 5.25
8FRG	;	1.74	;	Mouse acidic mammalian chitinase, catalytic domain in complex with N,N'-diacetylchitobiose at pH 5.43
5CK7	;	2.99	;	Mouse ADP-dependent Glucokinase; AMP bound
6O3E	;	4.001	;	mouse aE-catenin 82-883
2Q76	;	2.0	;	Mouse anti-hen egg white lysozyme antibody F10.6.6 Fab fragment
6JWC	;	2.297	;	Mouse antibody 2B5 Fab in complex with PEG
6JU0	;	2.601	;	Mouse antibody 3.3 Fab in complex with PEG
4P7F	;	1.37	;	Mouse apo-COMT
8EMQ	;	1.66	;	Mouse apoferritin heavy chain with zinc determined using single-particle cryo-EM with Apollo camera.
8EN7	;	1.68	;	Mouse apoferritin heavy chain without zinc determined using single-particle cryo-EM with Apollo camera.
6DDT	;	2.1	;	mouse beta-mannosidase (MANBA)
6DDU	;	2.668	;	mouse beta-mannosidase bound to beta-D-mannose (MANBA)
1MBE	;		;	MOUSE C-MYB DNA-BINDING DOMAIN REPEAT 1
1MBF	;		;	MOUSE C-MYB DNA-BINDING DOMAIN REPEAT 1
1MBG	;		;	MOUSE C-MYB DNA-BINDING DOMAIN REPEAT 2
1MBH	;		;	MOUSE C-MYB DNA-BINDING DOMAIN REPEAT 2
1MBJ	;		;	MOUSE C-MYB DNA-BINDING DOMAIN REPEAT 3
1MBK	;		;	MOUSE C-MYB DNA-BINDING DOMAIN REPEAT 3
3RS1	;	1.94	;	Mouse C-type lectin-related protein Clrg
2OAC	;	2.2	;	Mouse C14A Glutathione-S-Transferase Mutant in Complex with S-(p-nitrobenzyl) Glutathione
2OA7	;	2.2	;	Mouse C14A Glutathione-S-Transferase Mutant in Complex with S-hexyl glutathione
6CG6	;	2.707	;	mouse cadherin-10 EC1-2 adhesive fragment
6CG7	;	2.705	;	mouse cadherin-22 EC1-2 adhesive fragment
6CGU	;	1.9	;	mouse cadherin-6 EC1-2 adhesive fragment
6CGS	;	1.72	;	mouse cadherin-7 EC1-2 adhesive fragment
4BPV	;	2.0	;	MOUSE CATHEPSIN S WITH COVALENT LIGAND
4BQV	;	1.7	;	MOUSE CATHEPSIN S WITH COVALENT LIGAND
4BS5	;	1.25	;	MOUSE CATHEPSIN S WITH COVALENT LIGAND
4BS6	;	1.2	;	MOUSE CATHEPSIN S WITH COVALENT LIGAND
4BSQ	;	1.96	;	MOUSE CATHEPSIN S WITH COVALENT LIGAND
4MZS	;	1.85	;	Mouse cathepsin s with covalent ligand (3S,4S)-1-[(2-CHLOROPHENYL)SULFONYL]-N-[(2E)-2-IMINOETHYL]-4-(MORPHOLIN-4-YLCARBONYL)PYRROLIDINE-3-CARBOXAMIDE
4MZO	;	1.47	;	Mouse cathepsin s with covalent ligand (3S,4S)-N-[(2E)-2-IMINOETHYL]-4-(MORPHOLIN-4-YLCARBONYL)-1-(PHENYLSULFONYL)PYRROLIDINE-3-CARBOXAMIDE
2K4F	;		;	Mouse CD3epsilon Cytoplasmic Tail
5YJ1	;	2.0	;	Mouse Cereblon thalidomide binding domain complexed with R-form thalidomide
5YIZ	;	2.0	;	Mouse Cereblon thalidomide binding domain complexed with racemic thalidomide
5YJ0	;	1.8	;	Mouse Cereblon thalidomide binding domain complexed with S-form thalidomide
3WX2	;	2.0	;	Mouse Cereblon thalidomide binding domain, native
3WX1	;	1.93	;	Mouse Cereblon thalidomide binding domain, selenomethionine derivative
1Q3H	;	2.5	;	mouse CFTR NBD1 with AMP.PNP
5XZE	;	2.177	;	Mouse cGAS bound to the inhibitor RU332
5XZB	;	2.13	;	Mouse cGAS bound to the inhibitor RU365
5XZG	;	1.828	;	Mouse cGAS bound to the inhibitor RU521
1E3E	;	2.12	;	Mouse class II alcohol dehydrogenase complex with NADH
1E3I	;	2.08	;	Mouse class II alcohol dehydrogenase complex with NADH and inhibitor
7MRN	;	3.5	;	Mouse CNTN5 APP complex
5FCR	;	1.25	;	MOUSE COMPLEMENT FACTOR D
3UNE	;	3.2	;	Mouse constitutive 20S proteasome
3UNB	;	2.9	;	Mouse constitutive 20S proteasome in complex with PR-957
7OL4	;	4.8	;	Mouse contactin-1 neurofascin-155 immunoglobulin domains adhesion complex
7MIP	;	2.4	;	Mouse CTPS1 bound to inhibitor R80
7MIU	;	2.6	;	Mouse CTPS2 bound to inhibitor R80
7MIV	;	2.8	;	Mouse CTPS2-I250T bound to inhibitor R80
4O6A	;	1.859	;	Mouse cyclic GMP-AMP synthase (cGAS) in complex with DNA
6SQW	;	1.8	;	Mouse dCTPase in complex with 5-Me-dCMP
6SQY	;	1.9	;	Mouse dCTPase in complex with dCMP
6SQZ	;	1.9	;	Mouse dCTPase in complex with dCMPNPP
6DFV	;	1.71	;	Mouse diabetogenic TCR 8F10
6DFQ	;	2.6	;	mouse diabetogenic TCR I.29
1Z65	;		;	Mouse Doppel 1-30 peptide
2QVF	;	2.4	;	mouse E-cadherin domains 1,2
3Q2N	;	2.73	;	Mouse E-cadherin EC1-2 L175D mutant
3Q2L	;	2.7	;	Mouse E-cadherin EC1-2 V81D mutant
6O9H	;	2.1	;	Mouse ECD with Fab1
6NJT	;	2.07	;	Mouse endonuclease G mutant - H97A
6NJU	;	2.35	;	Mouse endonuclease G mutant H97A bound to A-DNA
7YZ4	;	3.84	;	Mouse endoribonuclease Dicer (composite structure)
6HT9	;	3.1	;	Mouse fetuin-B in complex with crayfish astacin
4V2C	;	4.0	;	mouse FLRT2 LRR domain in complex with rat Unc5D Ig1 domain
8EMA	;	8.2	;	mouse full length B cell receptor
2HZY	;	1.35	;	Mouse fumarylacetoacetate hydrolase complexes with a transition-state mimic of the complete substrate
1AWC	;	2.15	;	MOUSE GABP ALPHA/BETA DOMAIN BOUND TO DNA
4UFM	;	2.4	;	Mouse Galactocerebrosidase complexed with 1-deoxy-galacto-nojirimycin DGJ
4UFI	;	2.4	;	Mouse Galactocerebrosidase complexed with aza-galacto-fagomine AGF
4UFL	;	2.4	;	Mouse Galactocerebrosidase complexed with deoxy-galacto-noeurostegine DGN
4UFK	;	2.402	;	Mouse Galactocerebrosidase complexed with dideoxy-imino-lyxitol DIL
6Y6T	;	2.25	;	Mouse Galactocerebrosidase complexed with galacto-noeurostegine GNS at pH 4.6
6Y6S	;	2.1	;	Mouse Galactocerebrosidase complexed with galacto-noeurostegine GNS at pH 6.8
4UFH	;	2.16	;	Mouse Galactocerebrosidase complexed with iso-galacto-fagomine IGF
4UFJ	;	2.2	;	Mouse Galactocerebrosidase complexed with iso-galacto-fagomine lactam IGL
5NXB	;	3.6	;	Mouse galactocerebrosidase in complex with saposin A
7DF6	;	1.8	;	Mouse Galectin-3 CRD in complex with novel tetrahydropyran-based thiodisaccharide mimic inhibitor
6MYG	;	2.919	;	Mouse Gamma S Crystallin L16 Octamer
7RJ0	;	2.919	;	Mouse Gamma S Crystallin L16 Octamer
7RFP	;	4.4	;	Mouse GITR (mGITR) with DTA-1 Fab fragment
7KHX	;	3.2057	;	Mouse GITR-GITRL complex
1AO5	;	2.6	;	MOUSE GLANDULAR KALLIKREIN-13 (PRORENIN CONVERTING ENZYME)
6V21	;	1.75	;	Mouse heavy chain apoferritin determined using single-particle cryo-EM at 200 keV
1DZ1	;		;	Mouse HP1 (M31) C terminal (shadow chromo) domain
6MGN	;	1.901	;	mouse Id1 (51-104) - human hE47 (348-399) complex
6UQC	;	1.87	;	Mouse IgG2a Bispecific Fc
3ZO0	;	1.99	;	Mouse IgG2a in complex with mouse TRIM21 PRYSPRY
4YQX	;	2.826	;	Mouse IL-2 Bound to JES6-1 scFv Fragment
4YUE	;	2.194	;	Mouse IL-2 Bound to S4B6 Fab Fragment
6BHQ	;	2.05	;	Mouse Immunoglobulin G 2c Fc fragment with complex-type glycan
6BHY	;	2.04	;	Mouse Immunoglobulin G 2c Fc fragment with single GlcNAc
1Q1S	;	2.3	;	Mouse Importin alpha- phosphorylated SV40 CN peptide complex
1PJM	;	2.5	;	Mouse Importin alpha-bipartite NLS from human retinoblastoma protein Complex
1PJN	;	2.5	;	Mouse Importin alpha-bipartite NLS N1N2 from Xenopus laevis phosphoprotein Complex
3RZX	;	2.61	;	Mouse importin alpha-Ku70 NLS peptide complex
3RZ9	;	2.29	;	Mouse importin alpha-Ku80 NLS peptide complex
1EJY	;	2.9	;	MOUSE IMPORTIN ALPHA-NUCLEOPLASMIN NLS PEPTIDE COMPLEX
3L3Q	;	2.3	;	Mouse importin alpha-pepTM NLS peptide complex
1EJL	;	2.8	;	MOUSE IMPORTIN ALPHA-SV40 LARGE T ANTIGEN NLS PEPTIDE COMPLEX
4HTV	;	3.0	;	Mouse importin alpha: BFDV Cap NLS peptide complex
3UKW	;	2.1	;	Mouse importin alpha: Bimax1 peptide complex
3UKX	;	2.2	;	Mouse importin alpha: Bimax2 peptide complex
5HHG	;	2.2	;	Mouse importin alpha: Dengue 2 NS5 C-terminal NLS peptide complex
5FC8	;	2.1	;	Mouse importin alpha: Dengue 3 NS5 C-terminal NLS peptide complex
3UKZ	;	2.3	;	Mouse importin alpha: mouse CBP80 cNLS complex
3UL0	;	2.0	;	Mouse importin alpha: mouse CBP80Y8D cNLS complex
1Q1T	;	2.5	;	Mouse Importin alpha: non-phosphorylated SV40 CN peptide complex
3UL1	;	1.9	;	Mouse importin alpha: nucleoplasmin cNLS peptide complex
3UKY	;	2.35	;	Mouse importin alpha: yeast CBP80 cNLS complex
8CR6	;	2.85	;	mouse Interleukin-12
6SFF	;	2.4	;	mouse Interleukin-12 subunit beta - p80 homodimer in space group I41
6SMC	;	3.5	;	mouse Interleukin-12 subunit beta - p80 homodimer in space group P1
6SP3	;	3.0	;	mouse Interleukin-12 subunit beta - p80 homodimer in space group P21 crystal form 1
7PUR	;	3.9	;	mouse Interleukin-12 subunit beta - p80 homodimer in space group P21 crystal form 2
7R3N	;	3.16	;	mouse Interleukin-12 subunit beta - p80 homodimer in space group P21 crystal form 3
7OX4	;	1.8	;	Mouse interleukin-9 in complex with Fab 35D8.
4TR4	;	1.93	;	Mouse iodothyronine deiodinase 3 catalytic core, active site mutant SeCys->Cys
4TR3	;	1.9	;	Mouse iodothyronine deiodinase 3 catalytic core, SeMet-labeled active site mutant SeCys->Cys
2JOC	;		;	Mouse Itch 3rd domain phosphorylated in T30
2JO9	;		;	Mouse Itch 3rd WW domain complex with the Epstein-Barr virus latent membrane protein 2A derived peptide EEPPPPYED
5ZFH	;	1.93	;	Mouse Kallikrein 7
5ZFI	;	1.8	;	Mouse kallikrein 7 in complex with 6-benzyl-1,4-diazepan-7-one derivative
6AHS	;	1.75	;	Mouse Kallikrein 7 in complex with imidazolinylindole derivative
7D14	;	3.8	;	Mouse KCC2
8Q1Q	;	1.378	;	mouse Keap1 in complex with stapled peptide
8Q1R	;	1.33	;	mouse Keap1 in complex with stapled peptide
5KE8	;	2.45	;	mouse Klf4 E446P ZnF1-3 and MpG/MpG sequence DNA complex structure
5KE9	;	2.336	;	mouse Klf4 E446P ZnF1-3 and TpG/CpA sequence DNA complex structure
5KEA	;	2.458	;	mouse Klf4 ZnF1-3 (E446D) and CpG/CpG sequence DNA complex structure: Form I
5KEB	;	2.453	;	mouse Klf4 ZnF1-3 (E446D) and CpG/CpG sequence DNA complex structure: Form II
5KE6	;	1.99	;	mouse Klf4 ZnF1-3 and TpG/CpA sequence DNA complex structure
5KE7	;	2.06	;	mouse Klf4 ZnF1-3 and TpG/MpA sequence DNA complex structure
5VEP	;	2.59	;	MOUSE KYNURENINE AMINOTRANSFERASE III, RE-REFINEMENT OF THE PDB STRUCTURE 3E2F
5VEQ	;	2.26	;	MOUSE KYNURENINE AMINOTRANSFERASE III, RE-REFINEMENT OF THE PDB STRUCTURE 3E2Y
5VER	;	2.81	;	MOUSE KYNURENINE AMINOTRANSFERASE III, RE-REFINEMENT OF THE PDB STRUCTURE 3E2Z
2JD4	;	1.9	;	Mouse laminin alpha1 chain, domains LG4-5
2JXA	;		;	Mouse Latrophilin-1 GPCR Gal_lectin domain in complex with Rhamnose
8AVC	;	4.6	;	Mouse leptin:LEP-R complex cryoEM structure (3:3 model)
3TRZ	;	2.9	;	Mouse Lin28A in complex with let-7d microRNA pre-element
3TS0	;	2.763	;	Mouse Lin28A in complex with let-7f-1 microRNA pre-element
3TS2	;	2.01	;	Mouse Lin28A in complex with let-7g microRNA pre-element
3V4L	;	3.15	;	Mouse MALT1(caspase-IG3 domains) in complex with a irreversible peptidic inhibitor
7USF	;	3.5	;	Mouse mammary tumor virus strand transfer complex intasome
4EW0	;	2.39	;	mouse MBD4 glycosylase domain in complex with a G:5hmU (5-hydroxymethyluracil) mismatch
4EVV	;	2.39	;	mouse MBD4 glycosylase domain in complex with a G:T mismatch
4EW4	;	2.791	;	mouse MBD4 glycosylase domain in complex with DNA containing a ribose sugar
5GSX	;	2.5	;	Mouse MHC class I H-2Kd with a MERS-CoV-derived peptide 142-2
5GSV	;	1.996	;	Mouse MHC class I H-2Kd with a MERS-CoV-derived peptide 142-5
5GR7	;	2.4	;	Mouse MHC class I H-2Kd with a MERS-CoV-derived peptide 37-1
5GSB	;	1.801	;	Mouse MHC class I H-2Kd with a MERS-CoV-derived peptide 37-3
5GSR	;	2.198	;	Mouse MHC class I H-2Kd with a MERS-CoV-derived peptide I5A
6G2J	;	3.3	;	Mouse mitochondrial complex I in the active state
6G72	;	3.9	;	Mouse mitochondrial complex I in the deactive state
7PNW	;	3.09	;	Mouse mitochondrial ribosome small subunit lacking m5U modification
2DGN	;	2.4	;	Mouse Muscle Adenylosuccinate Synthetase partially ligated complex with GTP, 2'-deoxy-IMP
5VR2	;	1.922	;	mouse myocilin leucine zipper C-terminal 7 heptad repeat
5KPI	;	4.01	;	Mouse native PGP
2VRY	;	1.87	;	Mouse Neuroglobin with heme iron in the reduced ferrous state
4GZ9	;	2.7	;	Mouse Neuropilin-1, extracellular domains 1-4 (a1a2b1b2)
4EAX	;	2.3	;	Mouse NGF in complex with Lyso-PS
2I62	;	1.8	;	Mouse Nicotinamide N-methyltransferase
7N6Y	;	3.3	;	Mouse norovirus (MNV-1) capsid at pH 5.0
7N7F	;	3.0	;	Mouse norovirus (MNV-1) capsid at pH 7.5
6P4J	;	3.1	;	Mouse norovirus complexed with GCDCA
6P4K	;	3.1	;	mouse norovirus complexed with TCA
6CRJ	;	8.0	;	Mouse norovirus model using the crystal structure of MNV P domain and the Norwalkvirus shell domain
7L5J	;	3.2	;	Mouse Norovirus Protruding domain complexed with neutralizing Fab fragment from mAb A6.2
2QC9	;	2.35	;	Mouse Notch 1 Ankyrin Repeat Intracellular Domain
2ZO0	;	2.19	;	mouse NP95 SRA domain DNA specific complex 1
2ZO1	;	1.96	;	Mouse NP95 SRA domain DNA specific complex 2
2ZO2	;	3.09	;	Mouse NP95 SRA domain non-specific DNA complex
2IOM	;	2.0	;	Mouse p53 core domain soaked with 2-propanol
2P52	;	1.5	;	mouse p53 DNA-binding domain in zinc-free oxidized state
5MSJ	;	3.5	;	Mouse PA28alpha
5MX5	;	2.9	;	Mouse PA28alpha-beta
5MSK	;	3.6	;	Mouse PA28beta
3QE6	;	2.6	;	Mouse PACSIN 3 F-BAR domain structure
7SZ3	;	2.2	;	Mouse PARP13/ZAP ZnF5-WWE1-WWE2 bound to ADPr
7SZ2	;	2.2	;	Mouse PARP13/ZAP ZnF5-WWE1-WWE2 bound to ATP
7WK7	;	3.49	;	Mouse Pendrin bound bicarbonate in inward state
7WK1	;	3.25	;	Mouse Pendrin bound chloride in inward state
8HZN	;	3.25	;	Mouse Pendrin bound chloride in inward state
7WLA	;	3.76	;	Mouse Pendrin in bicarbonate and iodide buffer in asymmetric state
7WL2	;	3.25	;	Mouse Pendrin in bicarbonate and iodide buffer in inward state
7WL7	;	3.51	;	Mouse Pendrin in chloride and bicarbonate buffer in inward state
7WLE	;	3.62	;	Mouse Pendrin in chloride and bicarbonate buffer in outward state
7WL9	;	3.78	;	Mouse Pendrin in chloride and bicarbonate in asymmetric state
7WLB	;	4.1	;	Mouse Pendrin in chloride and iodide buffer in asymmetric state
7WL8	;	3.4	;	Mouse Pendrin in chloride and iodide buffer in inward state
5KOY	;	3.85	;	Mouse pgp 34 linker deleted bound with ATP
5KPD	;	3.35	;	Mouse pgp 34 linker deleted double EQ mutant
5KO2	;	3.3	;	Mouse pgp 34 linker deleted mutant Hg derivative
5KPJ	;	3.5	;	Mouse pgp methylated protein
6UWA	;	1.2	;	Mouse PKC C1B and C2 domains
3LW2	;	1.93	;	Mouse Plasminogen Activator Inhibitor-1 (PAI-1)
3AL9	;	2.1	;	Mouse Plexin A2 extracellular domain
3OKT	;	2.296	;	Mouse Plexin A2, extracellular domains 1-4
5KY5	;	1.5	;	mouse POFUT1 in complex with EGF(+) and GDP
5KXQ	;	1.9	;	mouse POFUT1 in complex with GDP
5KXH	;	1.33	;	mouse POFUT1 in complex with mouse Factor VII EGF1 and GDP
5KY3	;	1.53	;	mouse POFUT1 in complex with mouse Factor VII EGF1 mutant (T101A) and GDP-fucose
5KY9	;	1.83	;	mouse POFUT1 in complex with mouse Notch1 EGF12 mutant (D464G/A465G) and GDP
5KY0	;	1.53	;	mouse POFUT1 in complex with mouse Notch1 EGF12(D464G) and GDP
5KY4	;	1.472	;	mouse POFUT1 in complex with mouse Notch1 EGF26 and GDP
5KY7	;	1.6	;	mouse POFUT1 in complex with O-glucosylated EGF(+) and GDP
5KY2	;	1.47	;	mouse POFUT1 in complex with O-glucosylated mouse Factor VII EGF1 and GDP
5KY8	;	1.65	;	mouse POFUT1 in complex with O-glucosylated mouse Notch1 EGF12 mutant (D464G) and GDP
5DMS	;	1.89999	;	Mouse Polo-box domain and Emi2 (169-177)
5DNJ	;	2.3	;	Mouse Polo-box domain and Peptide analog 702
2L1E	;		;	Mouse prion protein (121-231) containing the substitution F175A
2L40	;		;	Mouse prion protein (121-231) containing the substitution Y169A
2L1D	;		;	Mouse prion protein (121-231) containing the substitution Y169G
2L1K	;		;	Mouse prion protein (121-231) containing the substitutions Y169A, Y225A, and Y226A
2KU5	;		;	Mouse Prion Protein (121-231) with mutation D167S
2K5O	;		;	Mouse Prion Protein (121-231) with Mutation S170N
2KFO	;		;	Mouse Prion Protein (121-231) with Mutation V166A
2KU6	;		;	Mouse Prion Protein (121-231) with mutations D167S and N173K
2KFM	;		;	Mouse Prion Protein (121-231) with Mutations Y225A and Y226A
1XYX	;		;	mouse prion protein fragment 121-231
2L1H	;		;	Mouse prion protein fragment 121-231 at 20 C
2L39	;		;	Mouse prion protein fragment 121-231 AT 37 C
6HER	;	1.199	;	Mouse prion protein in complex with Nanobody 484
6HHD	;	2.102	;	Mouse Prion Protein in complex with Nanobody 484
1Y15	;		;	Mouse Prion Protein with mutation N174T
1Y16	;		;	mouse prion protein with mutations S170N and N174T
2V8F	;	1.1	;	Mouse Profilin IIa in complex with a double repeat from the FH1 domain of mDia1
2V8C	;	1.98	;	Mouse Profilin IIa in complex with the proline-rich domain of VASP
6CV7	;	1.692	;	Mouse Protocadherin-15 Extracellular Cadherin Domains 1 through 3
7DMP	;	3.2	;	Mouse radial spoke complex
1S55	;	1.9	;	Mouse RANKL Structure at 1.9A Resolution
6SOE	;		;	Mouse RBM20 RRM domain
6SO9	;		;	Mouse RBM20 RRM domain in complex with AUCUUA RNA
6JPD	;		;	Mouse receptor-interacting protein kinase 3 (RIP3) amyloid structure by solid-state NMR
6VAC	;	5.7	;	Mouse retromer (VPS26/VPS35/VPS29) heterotrimer
7U6F	;	4.9	;	Mouse retromer (VPS26/VPS35/VPS29) heterotrimers
6VAB	;	4.9	;	Mouse retromer sub-structure: VPS35/VPS35 flat dimer
3TBK	;	2.14	;	Mouse RIG-I ATPase Domain
3KIO	;	2.9	;	mouse RNase H2 complex
6TAY	;	3.2	;	Mouse RNF213 mutant R4753K modeling the Moyamoya-disease-related Human variant R4810K
6TAX	;	3.2	;	Mouse RNF213 wild type protein
7OIM	;	4.0	;	Mouse RNF213, with mixed nucleotides bound
7OIK	;	3.5	;	Mouse RNF213:UBE2L3 transthiolation intermediate, chemically stabilized
2OX9	;	1.95	;	Mouse Scavenger Receptor C-type Lectin carbohydrate-recognition domain.
4GZ8	;	3.3	;	Mouse Semaphorin 3A, domains Sema-PSI-IG
3AFC	;	2.5	;	Mouse Semaphorin 6A extracellular domain
3OKW	;	2.299	;	Mouse Semaphorin 6A, extracellular domains 1-2
1OAA	;	1.25	;	MOUSE SEPIAPTERIN REDUCTASE COMPLEXED WITH NADP AND OXALOACETATE
1SEP	;	1.95	;	MOUSE SEPIAPTERIN REDUCTASE COMPLEXED WITH NADP AND SEPIAPTERIN
6HIN	;	4.1	;	Mouse serotonin 5-HT3 receptor, serotonin-bound, F conformation
6HIO	;	4.2	;	Mouse serotonin 5-HT3 receptor, serotonin-bound, I1 conformation
6HIQ	;	3.2	;	Mouse serotonin 5-HT3 receptor, serotonin-bound, I2 conformation
6HIS	;	4.5	;	Mouse serotonin 5-HT3 receptor, tropisetron-bound, T conformation
8CC6	;	3.2	;	Mouse serotonin 5-HT3A receptor in complex with PZ-1922
8CC7	;	3.0	;	Mouse serotonin 5-HT3A receptor in complex with PZ-1939
8AW2	;	3.01	;	Mouse serotonin 5-HT3A receptor in complex with vortioxetine
6Y1Z	;	2.82	;	Mouse serotonin 5HT3 receptor in complex with palonosetron
1YMT	;	1.2	;	Mouse SF-1 LBD
4GN7	;	1.95	;	mouse SMP30/GNL
4GN8	;	1.7	;	mouse SMP30/GNL-1,5-AG complex
4GN9	;	2.0	;	mouse SMP30/GNL-glucose complex
4GNA	;	1.85	;	mouse SMP30/GNL-xylitol complex
3GTT	;	2.4	;	Mouse SOD1
6FG9	;	4.2	;	Mouse SORCS2 ectodomain (sortilin related VPS10 domain containing receptor 2)
5C7I	;	2.0098	;	Mouse sperm Glyceraldehyde-3-phosphate dehydrogenase: apo enzyme
2C91	;	2.3	;	mouse succinic semialdehyde reductase, AKR7A5
1M4M	;	2.8	;	Mouse Survivin
7YTY	;	3.5	;	Mouse SVCT1 in an apo state
7E62	;	1.99	;	Mouse TAB2 NZF in complex with Lys6-linked diubiquitin
6MFS	;	2.85	;	Mouse talin1 residues 1-138 fused to residues 169-400 in complex with phosphatidylinositol 4,5-bisphosphate (PIP2)
6DFS	;	3.1	;	mouse TCR I.29 in complex with IAg7-p8E9E6ss
8D5P	;	2.75	;	Mouse TCR TG6
4YRA	;	2.65	;	mouse TDH in the apo form
4YRB	;	3.25	;	mouse TDH mutant R180K with NAD+ bound
4YR9	;	2.8	;	mouse TDH with NAD+ bound
5TVQ	;	2.35	;	Mouse Tdp2 catalytic domain bound to SUMO2
5INN	;	2.8	;	Mouse Tdp2 D358N protein, apo state with increased disorder amongst variable DNA-binding grasp conformations
5INM	;	2.4	;	Mouse Tdp2 protein, apo state with variable DNA-binding grasp conformations
5INK	;	2.15	;	Mouse Tdp2 reaction product (5'-phosphorylated DNA)-abasic/THF-Mg2+ complex
5INQ	;	1.848	;	Mouse Tdp2 reaction product (5'-phosphorylated DNA)-Ca2+ complex
5HT2	;	1.43	;	Mouse Tdp2 reaction product (5'-phosphorylated DNA)-Mg2+ complex with 1-N6-etheno-adenine
5INL	;	1.551	;	Mouse Tdp2 reaction product (5'-phosphorylated DNA)-Mg2+ complex with deoxyadenosine
5INP	;	1.947	;	Mouse Tdp2 reaction product (5'-phosphorylated DNA)-Mn2+ complex
4QZ9	;	2.05	;	Mouse Tdt in complex with a DSB substrate, C-A base pair
4QZA	;	2.15	;	Mouse Tdt in complex with a DSB substrate, C-C base pair
4QZ8	;	2.7	;	Mouse Tdt in complex with a DSB substrate, C-G base pair
4QZB	;	2.15	;	Mouse Tdt in complex with a DSB substrate, C-T base pair
4QZI	;	2.65	;	Mouse Tdt, F401A mutant, in complex with a DSB substrate and Zn2+
4QZF	;	2.6	;	Mouse Tdt, F401A mutant, in complex with a DSB substrate, C-A base pair
4QZG	;	2.75	;	Mouse Tdt, F401A mutant, in complex with a DSB substrate, C-C base pair
4QZE	;	2.25	;	Mouse Tdt, F401A mutant, in complex with a DSB substrate, C-G base pair
4QZH	;	2.6	;	Mouse Tdt, F401A mutant, in complex with a DSB substrate, C-T base pair
4QZD	;	2.7	;	Mouse Tdt, F405A mutant, in complex with a DSB substrate, C-C base pair
4QZC	;	2.75	;	Mouse Tdt, F405A mutant, in complex with a DSB substrate, C-G base pair
1IG3	;	1.9	;	Mouse Thiamin Pyrophosphokinase Complexed with Thiamin
2F17	;	2.5	;	Mouse Thiamin Pyrophosphokinase in a Ternary Complex with Pyrithiamin Pyrophosphate and AMP at 2.5 angstrom
6GKO	;	1.839	;	Mouse thymidylate synthase cocrystallized with dUMP and soaked in phenolphthalein
6Y08	;	2.297	;	Mouse thymidylate synthase cocrystallized with dUMP and soaked in sulfamethoxazole
6F6Z	;	2.127	;	Mouse Thymidylate Synthase Cocrystallized with N(4)OHdCMP and Soaked in Methylenetetrahydrofolate
6GYJ	;	1.75	;	Mouse thymidylate synthase crystal soaked in phenolphthalein
5FCT	;	1.55	;	Mouse thymidylate synthase in ternary complex with FdUMP and methylenetetrahydrofolate.
3CIY	;	3.41	;	Mouse Toll-like receptor 3 ectodomain complexed with double-stranded RNA
7DA7	;	3.47	;	Mouse Toll-like receptor 3 ectodomain in complex with lncRNA Rmrp in elongated form
7DAS	;	3.64	;	Mouse Toll-like receptor 3 ectodomain in complex with lncRNA Rmrp in lapped form
3U3Y	;	2.28	;	Mouse TREX1 D200H mutant
3U6F	;	2.3	;	Mouse TREX1 D200N mutant
7EBK	;	1.74	;	Mouse Trim66 PHD-Bromo dual domain complexed with the H3(1-24)K9me3K18ac peptide
7WRE	;	2.52	;	Mouse TRPM8 in lipid nanodiscs in the presence of calcium and icilin
7WRF	;	3.04	;	Mouse TRPM8 in lipid nanodiscs in the presence of calcium, icilin and PI(4,5)P2
7WRA	;	2.98	;	Mouse TRPM8 in LMNG in ligand-free state
7WRB	;	2.88	;	Mouse TRPM8 in LMNG in the presence of calcium
7WRD	;	2.98	;	Mouse TRPM8 in LMNG in the presence of calcium and icilin
7WRC	;	3.21	;	Mouse TRPM8 in LMNG in the presence of calcium, icilin and PI(4,5)P2
8E4P	;	3.59	;	Mouse TRPM8 structure determined in the ligand- and PI(4,5)P2-free condition, Class I , C0 state
7MIM	;	3.42	;	Mouse TRPV3 in cNW11 nanodiscs, closed state at 4 degrees Celsius
7MIN	;	3.09	;	Mouse TRPV3 in cNW11 nanodiscs, closed state at 42 degrees Celsius
7MIO	;	3.48	;	Mouse TRPV3 in cNW11 nanodiscs, open state at 42 degrees Celsius
7MIJ	;	1.98	;	Mouse TRPV3 in MSP2N2 nanodiscs, closed state at 4 degrees Celsius
7MIK	;	3.12	;	Mouse TRPV3 in MSP2N2 nanodiscs, closed state at 42 degrees Celsius
7MIL	;	3.86	;	Mouse TRPV3 in MSP2N2 nanodiscs, sensitized state at 42 degrees Celsius
6PIS	;	2.77	;	Mouse two pore domain K+ channel TRAAK (K2P4.1) - Fab complex structure
3FDE	;	1.41	;	Mouse UHRF1 SRA domain bound with hemi-methylated CpG DNA, crystal structure in space group C222(1) at 1.4 A resolution
3F8J	;	1.99	;	Mouse UHRF1 SRA domain bound with hemi-methylated CpG, crystal structure in space group C222(1)
3F8I	;	2.29	;	Mouse UHRF1 SRA domain bound with hemi-methylated CpG, crystal structure in space group P21
4GZN	;	0.99	;	Mouse ZFP57 zinc fingers in complex with methylated DNA
4C86	;	2.0	;	mouse ZNRF3 ectodomain crystal form I
4C8A	;	2.7	;	mouse ZNRF3 ectodomain crystal form II
4C8C	;	2.4	;	mouse ZNRF3 ectodomain crystal form III
4C8F	;	2.69	;	mouse ZNRF3 ectodomain crystal form IV
4C8P	;	2.1	;	mouse ZNRF3 ectodomain crystal form V, disulfide-bridged S90C variant
4C99	;	2.8	;	Mouse ZNRF3 ectodomain in complex with mouse RSPO2 Fu1-Fu2 crystal form I
4C9A	;	2.4	;	Mouse ZNRF3 ectodomain in complex with Xenopus RSPO2 Fu1-Fu2 (Seleno Met) crystal form I
4C9E	;	3.0	;	Mouse ZNRF3 ectodomain in complex with Xenopus RSPO2 Fu1-Fu2 (Seleno Met) crystal form II
3LTV	;	2.453	;	Mouse-human sod1 chimera
5V3J	;	2.064	;	mouseZFP568-ZnF1-10 in complex with DNA
5V3M	;	2.091	;	mouseZFP568-ZnF1-11 in complex with DNA
5WJQ	;	2.794	;	mouseZFP568-ZnF2-11 in complex with DNA
6SZA	;	6.0	;	MoxR AAA-ATPase RavA, C2-symmetric closed ring conformation
6SZB	;	7.0	;	MoxR AAA-ATPase RavA, spiral open ring conformation
5DSS	;	2.8	;	MP-4 contributes to snake venom neutralization by Mucuna pruriens seeds through stimulation of cross-reactive antibodies
1SKO	;	2.0	;	MP1-p14 Complex
2ZL1	;	2.0	;	MP1-p14 Scaffolding complex
3CPT	;	1.9	;	MP1-p14 Scaffolding complex
8B6V	;	3.1	;	Mp2Ba1 pre-pore
2X0A	;	1.52	;	MPD-Lysozyme structure at 55.5 keV using a TRIXXEL CsI-aSi based digital imager and the new ESRF U22 undulator source at ID15
6X58	;	3.26	;	MPER-Fluc-Ec2 bound to 10E8v4 antibody
6E8W	;		;	MPER-TM Domain of HIV-1 envelope glycoprotein (Env)
6V4T	;		;	MPER-TMD of HIV-1 Env bound with the entry inhibitor S2C3
8B6U	;	2.134	;	Mpf2Ba1 monomer
8B6W	;	2.6	;	Mpf2Ba1 pore
5K0I	;	1.3	;	mpges1 bound to an inhibitor
5T27	;	2.6	;	mPI3Kd IN COMPLEX WITH 5d
5T2B	;	2.3	;	mPI3Kd IN COMPLEX WITH 5e
5T28	;	2.8	;	mPI3Kd IN COMPLEX WITH 5k
5T2G	;	2.55	;	mPI3Kd IN COMPLEX WITH 7i
5T2D	;	2.9	;	mPI3Kd IN COMPLEX WITH 7j
5T2I	;	2.3	;	mPI3Kd IN COMPLEX WITH 7k
5T2L	;	2.55	;	mPI3Kd IN COMPLEX WITH 7l
5T2M	;	2.8	;	mPI3Kd IN COMPLEX WITH 7m
7OIJ	;	1.8	;	mPI3Kd in complex with an inhibitor
6FTN	;	2.0	;	mPI3Kd IN COMPLEX WITH AZ2
6GY0	;	2.55	;	mPI3Kd IN COMPLEX WITH AZ3
7OI4	;	1.8	;	mPI3Kd in complex with compound 12
7OIL	;	1.95	;	mPI3Kd in complex with compound 58
7OIS	;	2.3	;	mPI3Kd in complex with compound 7
5NCY	;	1.9	;	mPI3Kd IN COMPLEX WITH inh1
5NCZ	;	1.94	;	mPI3Kd IN COMPLEX WITH inh1
2QLG	;	1.8	;	mPlum
2QLI	;	1.34	;	mPlum E16Q mutant
2QLH	;	1.9	;	mPlum I65L mutant
4H3L	;	1.65	;	mPlum-E16P
3NF0	;	1.75	;	mPlum-TTN
4H3N	;	1.75	;	mPlumAYC
4H3M	;	2.0	;	mPlumAYC-E16A
6B9S	;	2.373	;	MPnS crystallized in the absence of substrate
4TOZ	;	1.5	;	MppA Periplasmic Murein Tripeptide Binding Protein, Unliganded Open Form
8YA5	;	2.72	;	Mpro from SARS-CoV-2
8S9Z	;	1.6	;	Mpro inhibitors of SARS-CoV-2
8AIV	;	2.6	;	Mpro of SARS COV-2 in complex with the MG-100 inhibitor
8AIQ	;	2.19	;	Mpro of SARS COV-2 in complex with the MG-87 inhibitor
8AIU	;	1.997	;	Mpro of SARS COV-2 in complex with the MG-97 inhibitor
8AJ0	;	2.519	;	Mpro of SARS COV-2 in complex with the RK-90 inhibitor
8AIZ	;	1.992	;	Mpro of SARS-CoV-2 in complex with the RK-68 inhibitor
4CV8	;	3.0	;	MPS1 kinase with 3-aminopyridin-2-one inhibitors
4CV9	;	2.5	;	MPS1 kinase with 3-aminopyridin-2-one inhibitors
4CVA	;	2.5	;	MPS1 kinase with 3-aminopyridin-2-one inhibitors
6IGW	;	1.979	;	MPZL1 mutant - S86G, V145G, Q146K,P147T,G148S
6IGT	;	2.404	;	MPZL1 mutant - V145G, Q146K, P147T and G148S
4UDB	;	2.36	;	MR in complex with desisobutyrylciclesonide
4UDA	;	2.03	;	MR in complex with dexamethasone
5G37	;	2.5	;	MR structure of the binary mosquito larvicide BinAB at pH 5
5JNQ	;	2.6	;	MraY tunicamycin complex
4UAK	;	1.73	;	MRCK beta in complex with ADP
5OTE	;	1.68	;	MRCK beta in complex with BDP-00008900
5OTF	;	2.0	;	MRCK beta in complex with BDP-00009066
4UAL	;	1.71	;	MRCK beta in complex with BDP00005290
3TKU	;	2.15	;	MRCK beta in complex with fasudil
3QFV	;	2.65	;	MRCK beta in complex with TPCA-1
8X79	;	2.41	;	MRE-269 bound Prostacyclin Receptor G protein complex
4HD0	;	2.3	;	Mre11 ATLD17/18 mutation retains Tel1/ATM activity but blocks DNA double-strand break repair
6ASC	;	2.15	;	Mre11 dimer in complex with Endonuclease inhibitor PFM04
6X1Y	;	2.35	;	Mre11 dimer in complex with small molecule modulator PFMI
6X1Z	;	1.9	;	Mre11 dimer in complex with small molecule modulator PFMJ
3QKR	;	3.4	;	Mre11 Rad50 binding domain bound to Rad50
3QKS	;	2.1	;	Mre11 Rad50 binding domain bound to Rad50
3QKU	;	3.3	;	Mre11 Rad50 binding domain in complex with Rad50 and AMP-PNP
1JCE	;	2.1	;	MREB FROM THERMOTOGA MARITIMA
1JCG	;	3.1	;	MREB FROM THERMOTOGA MARITIMA, AMPPNP
1JCF	;	2.1	;	MREB FROM THERMOTOGA MARITIMA, TRIGONAL
6ZLV	;	3.5	;	MreC
2J5U	;	2.5	;	MreC Lysteria monocytogenes
7S4A	;	2.693	;	MRG15 complex with PALB2 peptide
2LVX	;		;	MRH domain of the Glucosidase II beta subunit from S. pombe
5EJL	;	2.3	;	MrkH, A novel c-di-GMP dependence transcription regulatory factor.
8G61	;	2.94	;	mRNA decoding in human is kinetically and structurally distinct from bacteria (AC state)
8GLP	;	1.67	;	mRNA decoding in human is kinetically and structurally distinct from bacteria (Consensus LSU focused refined structure)
8G60	;	2.54	;	mRNA decoding in human is kinetically and structurally distinct from bacteria (CR state)
8G6J	;	2.8	;	mRNA decoding in human is kinetically and structurally distinct from bacteria (GA state 2)
8G5Z	;	2.64	;	mRNA decoding in human is kinetically and structurally distinct from bacteria (GA state)
8G5Y	;	2.29	;	mRNA decoding in human is kinetically and structurally distinct from bacteria (IC state)
7BXY	;	1.98	;	mRNA interferase from Bacillus cereus
7DNT	;	2.5	;	mRNA-decapping enzyme g5Rp
7DNU	;	2.245	;	mRNA-decapping enzyme g5Rp with inhibitor insp6 complex
3NEZ	;	1.7	;	mRojoA
3NED	;	0.95	;	mRouge
1P3Y	;	2.54	;	MrsD from Bacillus sp. HIL-Y85/54728
7Q6B	;	1.8	;	mRubyFT/S148I, a mutant of blue-to-red fluorescent timer in its blue state
2LQO	;		;	Mrx1 reduced
2BNY	;	3.0	;	MS2 (N87A mutant) - RNA hairpin complex
2BS1	;	2.8	;	MS2 (N87AE89K mutant) - Qbeta RNA hairpin complex
2BQ5	;	2.91	;	MS2 (N87AE89K mutant) - RNA hairpin complex
2BS0	;	2.45	;	MS2 (N87AE89K mutant) - Variant Qbeta RNA hairpin complex
1ZDH	;	2.7	;	MS2 COAT PROTEIN/RNA COMPLEX
5MSF	;	2.8	;	MS2 PROTEIN CAPSID/RNA COMPLEX
7MSF	;	2.8	;	MS2 PROTEIN CAPSID/RNA COMPLEX
2B2G	;	3.02	;	MS2 Wild-type RNA stemloop complexed with an N87S mutant MS2 capsid
2C4Q	;	2.38	;	MS2-RNA HAIRPIN (2ONE -5) COMPLEX
2C4Z	;	2.6	;	MS2-RNA HAIRPIN (2SU -5-6) COMPLEX
2C4Y	;	2.68	;	MS2-RNA HAIRPIN (2THIOURACIL-5) COMPLEX
2IZ9	;	2.85	;	MS2-RNA HAIRPIN (4ONE -5) COMPLEX
2BU1	;	2.2	;	MS2-RNA HAIRPIN (5BRU -5) COMPLEX
2C50	;	2.65	;	MS2-RNA HAIRPIN (A -5) COMPLEX
2IZM	;	2.7	;	MS2-RNA HAIRPIN (C-10) COMPLEX
2IZ8	;	3.3	;	MS2-RNA HAIRPIN (C-7) COMPLEX
2C51	;	2.8	;	MS2-RNA HAIRPIN (G -5) COMPLEX
2IZN	;	2.56	;	MS2-RNA HAIRPIN (G-10) COMPLEX
7RY2	;	2.05	;	mSandy2
5AJI	;	2.99	;	MscS D67R1 high resolution
6PWO	;	3.4	;	MscS DDM
6PWP	;	4.1	;	MscS Nanodisc
6PWN	;	3.1	;	MscS Nanodisc with N-terminal His-Tag
6JUL	;	2.3	;	MsDpo4-DNA complex 1
6JUM	;	1.78	;	MsDpo4-DNA complex 2
6JUN	;	2.51	;	MsDpo4-DNA complex 3
6JUO	;	2.16	;	MsDpo4-DNA complex 4
6JUR	;	2.06	;	MsDpo4-DNA complex 5
6JUS	;	2.5	;	MsDpo4-DNA complex 6
5GL6	;	2.2	;	Msmeg rimP
6XRI	;	2.37	;	MSMEG_2027 domain-swapped dimer
3H96	;	2.0	;	Msmeg_3358 F420 Reductase
3F7E	;	1.23	;	MSMEG_3380 F420 Reductase
8IIQ	;	2.1	;	MsmUdgX H109S/E52N double mutant
8IIR	;	2.28	;	MsmUdgX H109S/Q53A double mutant
8IIS	;	1.61	;	MsmUdgX H109S/R184A double mutant
6PE0	;	3.5	;	Msp1 (E214Q)-substrate complex
6PDW	;	3.1	;	Msp1-substrate complex in closed conformation
6PDY	;	3.7	;	Msp1-substrate complex in open conformation
4F0Q	;	2.046	;	MspJI Restriction Endonuclease - P21 Form
4F0P	;	2.79	;	MspJI Restriction Endonuclease - P31 Form
4R28	;	3.055	;	MspJI Restriction Endonuclease in Complex with 27-mer Oligonucleotide
6Q9V	;	1.85	;	MSRB3
6QA0	;	1.709	;	MSRB3 - AA 1-137
2ZRO	;	2.9	;	MsRecA ADP form IV
2ZRP	;	3.3	;	MsRecA dATP form II'
2ZRM	;	2.8	;	MsRecA dATP form IV
2ZRN	;	3.3	;	MsRecA Form IV
2ZR7	;	3.6	;	Msreca native form II'
2ZRI	;	3.3	;	MsRecA Q196A ADP form IV
2ZRJ	;	2.6	;	MsRecA Q196A ATPgS form IV
2ZRL	;	3.7	;	MsRecA Q196A dATP FORM II'
2ZRK	;	3.2	;	MsRecA Q196A dATP form IV
2ZRH	;	3.2	;	MsRecA Q196A form IV
2ZRA	;	3.1	;	MsRecA Q196E ATPgS
2ZR9	;	2.5	;	MsRecA Q196E dATP form IV
2ZRB	;	3.25	;	MsRecA Q196E Form II'
2ZRD	;	3.1	;	MsRecA Q196N ADP form IV
2ZRE	;	2.9	;	MsRecA Q196N ATPgS form IV
2ZRG	;	3.5	;	MsRecA Q196N dATP form II'
2ZRF	;	3.0	;	MsRecA Q196N dATP form IV
2ZRC	;	3.1	;	MsRecA Q196N Form IV
1UBE	;	3.3	;	MsRecA-ADP Complex
2OEP	;	3.1	;	MSrecA-ADP-complex
2ODW	;	3.3	;	MSrecA-ATP-GAMA-S complex
1UBF	;	3.5	;	MsREcA-ATPgS complex
1UBG	;	3.5	;	MsREcA-dATP complex
2G88	;	3.2	;	MSRECA-dATP COMPLEX
2ODN	;	3.1	;	MSRECA-dATP complex
2OFO	;	3.16	;	MSrecA-native
2OE2	;	3.45	;	MSrecA-native-low humidity 95%
2OES	;	3.5	;	MSrecA-native-SSB
2ZR0	;	3.0	;	MSRECA-Q196E mutant
4DB4	;	3.599	;	Mss116p DEAD-box helicase domain 2 bound to a chimaeric RNA-DNA duplex
4DB2	;	3.157	;	Mss116p DEAD-box helicase domain 2 bound to an RNA duplex
4QNA	;	1.849	;	MST3 IN COMPLEX WITH 2-(4,6-Diamino-1,3,5-triazin-2-yl)phenol
4QML	;	1.882	;	MST3 in complex with AMP-PNP
4QMM	;	1.852	;	MST3 IN COMPLEX WITH AT-9283, 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
4QMN	;	2.091	;	MST3 in complex with BOSUTINIB
4QMP	;	2.0	;	MST3 IN COMPLEX WITH CDK1/2 INHIBITOR III, 5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE
7B30	;	2.1	;	MST3 in complex with compound G-5555
7B34	;	2.1	;	MST3 in complex with compound MRIA12
7B35	;	2.40005	;	MST3 in complex with compound MRIA13
7B31	;	1.8	;	MST3 in complex with compound MRIA9
4QMQ	;	1.769	;	MST3 in complex with CP-673451
4QO9	;	2.2	;	MST3 IN COMPLEX WITH Danusertib
4QMS	;	1.883	;	MST3 in complex with DASATINIB
4QMT	;	1.5	;	MST3 in complex with HESPERADIN
4QMO	;	1.898	;	MST3 IN COMPLEX WITH Imidazolo-oxindole PKR inhibitor C16
4QMU	;	1.546	;	MST3 IN COMPLEX WITH JNJ-7706621, 4-({5-AMINO-1-[(2,6-DIFLUOROPHENYL)CARBONYL]-1H-1,2,4-TRIAZOL-3-YL}AMINO)BENZENESULFONAMIDE
7B33	;	1.9	;	MST3 in complex with MRIA11
7B32	;	1.75	;	MST3 in complex with MRIA7
4QMV	;	2.4	;	MST3 IN COMPLEX WITH PF-03814735, N-{2-[(1S,4R)-6-{[4-(CYCLOBUTYLAMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL]AMINO}-1,2,3,4-TETRAHYDRO-1,4-EPIMINONAPHTHALEN-9-YL]-2-OXOETHYL}ACETAMIDE
4QMW	;	1.6	;	MST3 IN COMPLEX WITH PP-121, 1-CYCLOPENTYL-3-(1H-PYRROLO[2,3-B]PYRIDIN-5-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
4QMX	;	1.882	;	MST3 in complex with SARACATINIB
4QMY	;	1.883	;	MST3 IN COMPLEX WITH STAUROSPORINE
4QMZ	;	1.88	;	MST3 IN COMPLEX WITH SUNITINIB
7B36	;	2.10681	;	MST4 in complex with compound G-5555
4KC0	;	2.2	;	mSTING
4KBY	;	2.36	;	mSTING/c-di-GMP
1IG7	;	2.2	;	Msx-1 Homeodomain/DNA Complex Structure
6SGB	;	3.3	;	mt-SSU assemblosome of Trypanosoma brucei
7AOR	;	3.5	;	mt-SSU from Trypanosoma cruzi in complex with mt-IF-3.
1L3I	;	1.95	;	MT0146, THE PRECORRIN-6Y METHYLTRANSFERASE (CBIT) HOMOLOG FROM M. THERMOAUTOTROPHICUM, ADOHCY BINARY COMPLEX
1L3B	;	2.65	;	MT0146, THE PRECORRIN-6Y METHYLTRANSFERASE (CBIT) HOMOLOG FROM M. THERMOAUTOTROPHICUM, C2 SPACEGROUP W/ LONG CELL
1L3C	;	2.31	;	MT0146, THE PRECORRIN-6Y METHYLTRANSFERASE (CBIT) HOMOLOG FROM M. THERMOAUTOTROPHICUM, C2 SPACEGROUP WITH SHORT CELL
1KXZ	;	2.7	;	MT0146, the Precorrin-6y methyltransferase (CbiT) homolog from M. Thermoautotrophicum, P1 spacegroup
6CM1	;		;	MT1-MMP HPX Domain with Blade 2 Loop Bound to Nanodiscs
6CLZ	;		;	MT1-MMP HPX domain with Blade 4 Loop Bound to Nanodiscs
4P3C	;	1.943	;	MT1-MMP:Fab complex (Form I)
4P3D	;	1.949	;	MT1-MMP:Fab complex (Form II)
7VGZ	;	3.3	;	MT1-remalteon-Gi complex
7VH0	;	3.46	;	MT2-remalteon-Gi complex
1IHN	;	2.2	;	MT938
7YUX	;	3.8	;	MtaLon-ADP for the spiral oligomers of hexamer
7YUW	;	3.6	;	MtaLon-ADP for the spiral oligomers of pentamer
7YUV	;	3.8	;	MtaLon-ADP for the spiral oligomers of tetramer
7YUU	;	5.8	;	MtaLon-ADP for the spiral oligomers of trimer
7YUT	;	4.1	;	MtaLon-Apo for the spiral oligomers of hexamer
7YUP	;	3.7	;	MtaLon-Apo for the spiral oligomers of pentamer
7YUM	;	3.8	;	MtaLon-Apo for the spiral oligomers of tetramer
7YUH	;	3.7	;	MtaLon-Apo for the spiral oligomers of trimer
2JG3	;	1.9	;	MtaqI with BAZ
7MT2	;	2.76	;	Mtb 70S initiation complex
7MT7	;	2.71	;	Mtb 70S with P and E site tRNAs
7MT3	;	2.8	;	Mtb 70S with P/E tRNA
7MSC	;	2.97	;	Mtb 70SIC in complex with MtbEttA at Pre_R0 state
7MSH	;	3.23	;	Mtb 70SIC in complex with MtbEttA at Pre_R1 state
7MSM	;	2.79	;	Mtb 70SIC in complex with MtbEttA at Trans_R0 state
7MSZ	;	3.1	;	Mtb 70SIC in complex with MtbEttA at Trans_R1 state
4O1G	;	1.5	;	MTB adenosine kinase in complex with gamma-Thio-ATP
6ED3	;	6.3	;	Mtb ClpB in complex with AMPPNP
6DJU	;	3.8	;	Mtb ClpB in complex with ATPgammaS and casein, Conformer 1
6DJV	;	3.9	;	Mtb ClpB in complex with ATPgammaS and casein, Conformer 2
4BQR	;	2.05	;	Mtb InhA complex with Methyl-thiazole compound 11
4BQP	;	1.89	;	Mtb InhA complex with Methyl-thiazole compound 7
4D0R	;	2.75	;	Mtb InhA complex with Pyradizinone compound 1
4D0S	;	1.64	;	Mtb InhA complex with Pyradizinone compound 14
6C04	;	3.27	;	Mtb RNAP Holo/RbpA/double fork DNA -closed clamp
6BZO	;	3.38	;	Mtb RNAP Holo/RbpA/Fidaxomicin/upstream fork DNA
5W95	;	1.723	;	Mtb Rv3802c with PEG bound
5NQ5	;	2.85	;	Mtb TMK crystal structure in complex with compound 1
6YT1	;	1.9	;	Mtb TMK crystal structure in complex with compound 26
5NRN	;	2.2	;	Mtb TMK crystal structure in complex with compound 3
5NRQ	;	2.1	;	Mtb TMK crystal structure in complex with compound 33
5NR7	;	2.35	;	Mtb TMK crystal structure in complex with compound 43
4UNR	;	1.98	;	Mtb TMK in complex with compound 23
4UNP	;	2.3	;	Mtb TMK in complex with compound 34
4UNQ	;	2.3	;	Mtb TMK in complex with compound 36
4UNS	;	2.18	;	Mtb TMK in complex with compound 40
4UNN	;	2.5	;	Mtb TMK in complex with compound 8
7MU0	;	2.9	;	MtbEttA in the ADP bound state
6QSL	;	1.6	;	mTFP* closed conformation: I197C-Y200H-Y204H mutant for enhanced metal binding
6QSO	;	1.8	;	mTFP* closed conformation: I197E-Y200H-Y204H mutant for enhanced metal binding
6QSM	;	1.65	;	mTFP* open conformation: I197C-Y200H-Y204H mutant for enhanced metal binding
4Q9X	;	1.9	;	mTFP* PdCl2 soak
4Q9W	;	1.0	;	mTFP*: a robust and versatile host protein at 1.00 A resolution
6FP8	;	1.855	;	mTFP1/DARPin 1238_E11 complex in space group C2
6FP7	;	1.576	;	mTFP1/DARPin 1238_E11 complex in space group P6522
3G1K	;	3.1	;	Mth0212 (WT) crystallized in a monoclinic space group
3G3C	;	3.04	;	Mth0212 (WT) in complex with a 6bp dsDNA containing a single one nucleotide long 3'-overhang
3G4T	;	2.64	;	Mth0212 (WT) in complex with a 7bp dsDNA
3G00	;	1.74	;	Mth0212 in complex with a 9bp blunt end dsDNA at 1.7 Angstrom
3G2C	;	2.3	;	Mth0212 in complex with a short ssDNA (CGTA)
3G3Y	;	2.5	;	Mth0212 in complex with ssDNA in space group P32
3GA6	;	1.898	;	Mth0212 in complex with two DNA helices
3G0A	;	2.6	;	Mth0212 with two bound manganese ions
5ANU	;	1.8	;	MTH1 in complex with compound 15
5ANV	;	1.16	;	MTH1 in complex with compound 15
5ANW	;	1.37	;	MTH1 in complex with compound 24
6US4	;	1.95033	;	MTH1 in complex with compound 32
6US3	;	1.47029	;	MTH1 in complex with compound 4
6US2	;	1.80013	;	MTH1 in complex with compound 5
6EQ6	;	2.002	;	MTH1 in complex with fragment 1
6EQ7	;	1.5	;	MTH1 in complex with fragment 11
6EQ5	;	1.801	;	MTH1 in complex with fragment 4
6EQ2	;	1.802	;	MTH1 in complex with fragment 6
6EQ4	;	1.4	;	MTH1 in complex with fragment 8
6EQ3	;	1.798	;	MTH1 in complex with fragment 9
3WHW	;	2.701	;	MTH1 in complex with Ruthenium-based inhibitor
8A07	;	2.19	;	MTH1 in complex with TH001969
8A0T	;	1.9	;	MTH1 in complex with TH012532
8A34	;	1.9	;	MTH1 in complex with TH013071
8A3A	;	1.6	;	MTH1 in complex with TH013074
8A0S	;	1.4	;	MTH1 in complex with TH013350
5FSI	;	1.63	;	MTH1 substrate recognition: Complex with 8-oxo-dGTP.
5FSK	;	1.56	;	MTH1 substrate recognition: Complex with 8-oxo-dGTP.
5FSN	;	1.69	;	MTH1 substrate recognition: Complex with a aminomethylpyrimidinyl oxypropanol.
5FSL	;	1.24	;	MTH1 substrate recognition: Complex with a methylaminopurinone
5FSO	;	1.67	;	MTH1 substrate recognition: Complex with a methylaminopyrimidinedione.
5FSM	;	1.67	;	MTH1 substrate recognition: Complex with a methylbenzimidazolyl acetamide.
1PM3	;	3.15	;	MTH1859
8QA5	;	3.14	;	MTHFR + SAH asymmetric dis-inhibited state
8QA4	;	2.8	;	MTHFR + SAH symmetric dis-inhibited state
8QA6	;	2.91	;	MTHFR + SAM inhibited state
6PEY	;	2.88	;	MTHFR with mutation Asp120Ala
3R65	;	1.8	;	MthK channel pore E92Q mutant
3OUS	;	1.75	;	MthK channel pore T59A mutant
3RBZ	;	3.4	;	MthK channel, Ca2+-bound
6U6D	;	3.6	;	MthK closed state with EDTA
6UWN	;	3.5	;	MthK N-terminal truncation RCK domain state 1 bound with calcium
6UX4	;	3.5	;	MthK N-terminal truncation RCK domain state 2 bound with calcium
6UX7	;	6.7	;	MthK N-terminal truncation state 1 bound with calcium
6UXA	;	4.5	;	MthK N-terminal truncation state 2 bound with calcium
6UXB	;	4.9	;	MthK N-terminal truncation state 3 bound with calcium
4HZ3	;	1.7	;	MthK pore crystallized in presence of TBSb
3RBX	;	2.8	;	MthK RCK domain D184N mutant, Ca2+-bound
8DJB	;	3.18	;	MthK-A90L mutant in closed state with 0 Ca2+
8G7J	;	3.4	;	mtHsp60 V72I apo
8G7K	;	3.8	;	mtHsp60 V72I apo focus
4AOM	;	1.939	;	MTIP and MyoA complex
4JSV	;	3.5	;	mTOR kinase structure, mechanism and regulation.
6BCX	;	3.23	;	mTORC1 structure refined to 3.0 angstroms
4JT5	;	3.45	;	mTORdeltaN-mLST8-pp242 complex
7JU3	;	2.7	;	MtrR bound to the mtrCDE operator from Neisseria gonorrhoeae
7JNP	;	2.6	;	MtrR bound to the rpoH operator from Neisseria gonorrhoeae
8FW0	;	2.37	;	MtrR from Neisseria gonorrhoeae bound to beta-Estradiol
8SSH	;	3.2	;	MtrR from Neisseria gonorrhoeae bound to Ethinyl Estradiol
8FW8	;	2.31	;	MtrR from Neisseria gonorrhoeae bound to Progesterone
8FW3	;	2.22	;	MtrR from Neisseria gonorrhoeae bound to Testosterone
2ZTC	;	2.8	;	MtRuvA Form II
2ZTD	;	2.4	;	MtRuvA Form III
2ZTE	;	3.2	;	MtRuvA Form IV
2XZ6	;	3.137	;	MTSET-modified Y53C mutant of Aplysia AChBP
6PGY	;	2.0	;	MTSL labelled T4 lysozyme pseudo-wild type K65C mutant
6PGZ	;	2.0	;	MTSL labelled T4 lysozyme pseudo-wild type V75C mutant
2XGA	;	2.3	;	MTSL spin-labelled Shigella Flexneri Spa15
4AGE	;	4.84	;	MTSSL spin labeled D67C mutant of MscS in the open form
4AGF	;	4.7	;	MTSSL spin labeled L124C mutant of MscS in the open form
6YLO	;	1.7	;	mTurquoise2 - Directionality of Optical Properties of Fluorescent Proteins
6YLN	;	1.85	;	mTurquoise2 SG P212121 - Directional optical properties of fluorescent proteins
6DDE	;	3.5	;	Mu Opioid Receptor-Gi Protein Complex
6DDF	;	3.5	;	Mu Opioid Receptor-Gi Protein Complex
5YDN	;	1.6	;	Mu pahge neck subunit
8JU3	;	2.0	;	Mu phage tail fiber
1GIB	;		;	MU-CONOTOXIN GIIIB, NMR
7SAW	;		;	Mu-conotoxin KIIIA isomer 2
1H6E	;	3.6	;	MU2 ADAPTIN SUBUNIT (AP50) OF AP2 ADAPTOR (SECOND DOMAIN), COMPLEXED WITH CTLA-4 INTERNALIZATION PEPTIDE TTGVYVKMPPT
1BW8	;	2.65	;	MU2 ADAPTIN SUBUNIT (AP50) OF AP2 ADAPTOR (SECOND DOMAIN), COMPLEXED WITH EGFR INTERNALIZATION PEPTIDE FYRALM
2PR9	;	2.51	;	Mu2 adaptin subunit (AP50) of AP2 adaptor (second domain), complexed with GABAA receptor-gamma2 subunit-derived internalization peptide DEEYGYECL
2BP5	;	2.8	;	MU2 ADAPTIN SUBUNIT (AP50) OF AP2 ADAPTOR (SECOND DOMAIN), COMPLEXED WITH NON-CANONICAL INTERNALIZATION PEPTIDE VEDYEQGLSG
1HES	;	3.0	;	MU2 ADAPTIN SUBUNIT (AP50) OF AP2 ADAPTOR (SECOND DOMAIN), COMPLEXED WITH P-selectin INTERNALIZATION PEPTIDE SHLGTYGVFTNAA
1BXX	;	2.7	;	MU2 ADAPTIN SUBUNIT (AP50) OF AP2 ADAPTOR (SECOND DOMAIN), COMPLEXED WITH TGN38 INTERNALIZATION PEPTIDE DYQRLN
1I31	;	2.5	;	MU2 ADAPTIN SUBUNIT (AP50) OF AP2 CLATHRIN ADAPTOR, COMPLEXED WITH EGFR INTERNALIZATION PEPTIDE FYRALM AT 2.5 A RESOLUTION
5FPI	;	2.77	;	Mu2 adaptin subunit of the AP2 adaptor (C-terminal domain) complexed with Integrin alpha4 internalisation peptide QYKSILQE
5WRK	;	2.62	;	Mu2 subunit of the clathrin adaptor complex AP2 in complex with IRS-1 Y608 peptide
5WRL	;	3.095	;	Mu2 subunit of the clathrin adaptor complex AP2 in complex with IRS-1 Y628 peptide
5WRM	;	2.597	;	Mu2 subunit of the clathrin adaptor complex AP2 in complex with IRS-1 Y658 peptide
4BS1	;	18.0	;	MuB is an AAAplus ATPase that forms helical filaments to control target selection for DNA transposition
4BT0	;	17.0	;	MuB is an AAAplus ATPase that forms helical filaments to control target selection for DNA transposition
4BT1	;	16.0	;	MuB is an AAAplus ATPase that forms helical filaments to control target selection for DNA transposition
6TM6	;	1.63	;	MUC2 CysD1 domain
8CK2	;	1.5	;	MUC2 CysD1 G1352S
7PRL	;	2.48	;	MUC2 D1 with Cu(II)
7POV	;	3.8	;	MUC2 Tubules of D1D2D3 domains
7PP6	;	3.4	;	MUC2 Tubules of D1D2D3 domains
8OV0	;	1.7	;	MUC5AC CysD7 amino acids 3518-3626
8OER	;	3.0	;	MUC5B amino acids 26-1435
8OES	;	3.0	;	MUC5B amino acids 26-1435 Three beads
8VRS	;	2.47	;	Mucin 16 peptide fused to MBP in complex with 4H11-scFv antibody
6RBF	;	2.704	;	Mucin 2 D3 domain
2LHV	;		;	Mucin sequence based on MUC2 Mucin glycoprotein tandem repeat
2MUC	;	2.3	;	MUCONATE CYCLOISOMERASE VARIANT F329I
3MUC	;	2.3	;	MUCONATE CYCLOISOMERASE VARIANT I54V
1BKH	;	2.1	;	MUCONATE LACTONIZING ENZYME FROM PSEUDOMONAS PUTIDA
6VCT	;	1.94	;	Mucor circinelloides FKBP12 protein bound with APX879 in C2221 space group
6VRX	;	2.54	;	Mucor circinelloides FKBP12 protein bound with FK506 in P3221 space group
4DZB	;	1.7	;	Mucosal-associated invariant T cell receptor, Valpha7.2Jalpha33-Vbeta2
7XFS	;	1.06	;	MucP PDZ1 domain
7XFT	;	1.21	;	MucP PDZ2 domain
7XFU	;	1.53	;	MucP PDZ2 domain with peptide GPAVLA
6H2X	;	2.6	;	MukB coiled-coil elbow from E. coli
6M2D	;	1.795	;	MUL1-RING domain
5MJP	;	2.11	;	Multi-bunch pink beam serial crystallography: Phycocyanin (One chip)
1IH6	;	1.45	;	Multi-Conformation Crystal Structure of GGBr5CGCC
1IH4	;	1.9	;	Multi-Conformation Crystal Structure of GGm5CGCC
1IH3	;	2.4	;	Multi-conformation crystal structure of GGm5CGm5CC
6UCW	;	1.25	;	Multi-conformer model of Apo Ketosteroid Isomerase from Pseudomonas Putida (pKSI) at 250 K
7RXK	;	1.1	;	Multi-conformer model of Apo Ketosteroid Isomerase Y32F/Y57F mutant from Pseudomonas Putida (pKSI) at 250 K
7RXF	;	1.16	;	Multi-conformer model of Apo Ketosteroid Isomerase Y57F mutant from Pseudomonas Putida (pKSI) at 250 K
6UCY	;	1.15	;	Multi-conformer model of Ketosteroid Isomerase from Pseudomonas Putida (pKSI) bound to 4-Androstenedione at 250 K
6UCN	;	1.32	;	Multi-conformer model of Ketosteroid Isomerase from Pseudomonas Putida (pKSI) bound to Equilenin at 250 K
7RY4	;	1.11	;	Multi-conformer model of Ketosteroid Isomerase Y57F/D40N mutant from Pseudomonas Putida (pKSI) bound to a transition state analog at 250 K
3BBG	;		;	MULTI-CONFORMER STRUCTURE OF RAGWEED POLLEN ALLERGEN FROM AMBROSIA TRIFIDA V, NMR, 2 STRUCTURES
7NSN	;	2.29	;	Multi-domain GH92 alpha-1,2-mannosidase from Neobacillus novalis: mannoimidazole complex
4IQR	;	2.9	;	Multi-Domain Organization of the HNF4alpha Nuclear Receptor Complex on DNA
8GJJ	;	3.08	;	Multi-drug efflux pump RE-CmeB Apo form
8GJK	;	3.16	;	Multi-drug efflux pump RE-CmeB bound with ampicillin
8GK4	;	3.12	;	Multi-drug efflux pump RE-CmeB bound with Chloramphenicol
8GJL	;	3.44	;	multi-drug efflux pump RE-CmeB bound with Ciprofloxacin
8GK0	;	3.44	;	Multi-drug efflux pump RE-CmeB bound with Erythromycin
5NG5	;	6.5	;	multi-drug efflux; membrane transport; RND superfamily; Drug resistance
5V5S	;	6.5	;	multi-drug efflux; membrane transport; RND superfamily; Drug resistance
4GZF	;	2.05	;	Multi-drug resistant HIV-1 protease 769 variant with reduced LrF peptide
3PR7	;	2.94	;	Multi-functional and mechanosensitive receptor binding activity of the Moraxella catarrhalis adhesin UspA1
6WEB	;	2.1	;	Multi-Hit SFX using MHz XFEL sources
6WEC	;	2.1	;	Multi-Hit SFX using MHz XFEL sources
7TUM	;	3.202	;	Multi-Hit SFX using MHz XFEL sources- first hit
5F4N	;	1.91	;	Multi-parameter lead optimization to give an oral CHK1 inhibitor clinical candidate: (R)-5-((4-((morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)
4FA8	;	2.2	;	Multi-pronged modulation of cytokine signaling
3M6U	;	1.402	;	Multi-site-specific 16S rRNA methyltransferase RsmF from Thermus thermophilus in space group 43
3M6V	;	1.82	;	Multi-site-specific 16S rRNA methyltransferase RsmF from Thermus thermophilus in space group P2 in complex with S-Adenosyl-L-Methionine
3M6X	;	1.676	;	Multi-site-specific 16S rRNA methyltransferase RsmF from Thermus thermophilus in space group P21212
3M6W	;	1.3	;	Multi-site-specific 16S rRNA methyltransferase RsmF from Thermus thermophilus in space group P21212 in complex with S-Adenosyl-L-Methionine
8FIH	;	2.2	;	Multi-state design of two-state switchable hinge proteins
8FIN	;	2.3	;	Multi-state design of two-state switchable hinge proteins
8FIQ	;	2.66	;	Multi-state design of two-state switchable hinge proteins
8FIT	;	2.75	;	Multi-state design of two-state switchable hinge proteins
8FVT	;	3.07	;	Multi-state design of two-state switchable hinge proteins
7EN4	;		;	Multi-state structure determination and dynamics analysis elucidate a new ubiquitin-recognition mechanism of yeast ubiquitin C-terminal hydrolase.
6W6P	;	2.9	;	MultiBody Refinement of 70S Ribosome from Enterococcus faecalis
6T2D	;	1.8	;	Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Protein-Protein Interactions
6T2E	;	2.4	;	Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Protein-Protein Interactions
6T2F	;	2.09	;	Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Protein-Protein Interactions
4YUP	;	1.75	;	Multiconformer fixed-target X-ray free electron (XFEL) model of CypA at 273 K
4PSS	;	0.849	;	Multiconformer model for Escherichia coli dihydrofolate reductase at 100K
4PST	;	1.05	;	Multiconformer model for Escherichia coli dihydrofolate reductase at 277 K
6BAI	;	1.95	;	Multiconformer model of apo K197C PTP1B at 100 K
6B90	;	1.95	;	Multiconformer model of apo WT PTP1B with glycerol at 100 K (ALTERNATIVE REFINEMENT OF PDB 1SUG showing conformational heterogeneity)
6B8E	;	1.82	;	Multiconformer model of apo WT PTP1B with glycerol at 180 K
6B8T	;	1.85	;	Multiconformer model of apo WT PTP1B with glycerol at 240 K
6B8X	;	1.74	;	Multiconformer model of apo WT PTP1B with glycerol at 278 K
6B95	;	1.95	;	Multiconformer model of K197C PTP1B tethered to compound 2 at 100 K
6B8Z	;	1.8	;	Multiconformer model of WT PTP1B with BB3 at 273 K
4YUG	;	1.48	;	Multiconformer synchrotron model of CypA at 100 K
4YUH	;	1.34	;	Multiconformer synchrotron model of CypA at 150 K
4YUI	;	1.38	;	Multiconformer synchrotron model of CypA at 180 K
4YUJ	;	1.42	;	Multiconformer synchrotron model of CypA at 240 K
4YUK	;	1.48	;	Multiconformer synchrotron model of CypA at 260 K
4YUL	;	1.42	;	Multiconformer synchrotron model of CypA at 280 K
4YUM	;	1.5	;	Multiconformer synchrotron model of CypA at 300 K
4YUN	;	1.58	;	Multiconformer synchrotron model of CypA at 310 K
4EF3	;	1.9	;	Multicopper Oxidase CueO (Citrate buffer)
4NER	;	1.6	;	Multicopper Oxidase CueO (data1)
4E9Q	;	1.3	;	Multicopper Oxidase CueO (data2)
4E9R	;	1.3	;	Multicopper Oxidase CueO (data4)
4E9S	;	1.06	;	Multicopper Oxidase CueO (data5)
4E9T	;	1.3	;	Multicopper Oxidase CueO (data6)
3UAA	;	1.7	;	Multicopper Oxidase CueO mutant C500SE506Q (data1)
3UAB	;	1.3	;	Multicopper Oxidase CueO mutant C500SE506Q (data2)
3UAC	;	1.3	;	Multicopper Oxidase CueO mutant C500SE506Q (data4)
3UAD	;	1.1	;	Multicopper Oxidase CueO mutant C500SE506Q (data5)
3UAE	;	1.3	;	Multicopper Oxidase CueO mutant C500SE506Q (data6)
4HAK	;	1.4	;	Multicopper Oxidase CueO mutant E506A
4HAL	;	1.4	;	Multicopper Oxidase CueO mutant E506I
3ZX1	;	1.95	;	Multicopper oxidase from Campylobacter jejuni: a metallo-oxidase
4E9V	;	1.8	;	Multicopper Oxidase mgLAC (data1)
4E9W	;	1.45	;	Multicopper Oxidase mgLAC (data2)
4E9X	;	1.14	;	Multicopper Oxidase mgLAC (data3)
4E9Y	;	1.5	;	Multicopper Oxidase mgLAC (data4)
1HTQ	;	2.4	;	Multicopy crystallographic structure of a relaxed glutamine synthetase from Mycobacterium tuberculosis
8RAA	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 101 mJ/cm2 laser fluence, 1023 fs time delay
8RAB	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 101 mJ/cm2 laser fluence, 1112 fs time delay
8RAC	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 101 mJ/cm2 laser fluence, 1174 fs time delay
8RAD	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 101 mJ/cm2 laser fluence, 1235 fs time delay
8RAE	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 101 mJ/cm2 laser fluence, 1303 fs time delay
8RA1	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 101 mJ/cm2 laser fluence, 312 fs time delay
8RA2	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 101 mJ/cm2 laser fluence, 392 fs time delay
8RA3	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 101 mJ/cm2 laser fluence, 462 fs time delay
8RA4	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 101 mJ/cm2 laser fluence, 527 fs time delay
8RA5	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 101 mJ/cm2 laser fluence, 590 fs time delay
8RA6	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 101 mJ/cm2 laser fluence, 655 fs time delay
8RA7	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 101 mJ/cm2 laser fluence, 722 fs time delay
8RA8	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 101 mJ/cm2 laser fluence, 802 fs time delay
8RA9	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 101 mJ/cm2 laser fluence, 907 fs time delay
8R9L	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 23 mJ/cm2 laser fluence, 1036 fs time delay
8R9M	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 23 mJ/cm2 laser fluence, 1143 fs time delay
8R9N	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 23 mJ/cm2 laser fluence, 1224 fs time delay
8R9P	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 23 mJ/cm2 laser fluence, 1297 fs time delay
8R9Q	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 23 mJ/cm2 laser fluence, 1373 fs time delay
8R9C	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 23 mJ/cm2 laser fluence, 320 fs time delay
8R9D	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 23 mJ/cm2 laser fluence, 399 fs time delay
8R9E	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 23 mJ/cm2 laser fluence, 469 fs time delay
8R9F	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 23 mJ/cm2 laser fluence, 537 fs time delay
8R9G	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 23 mJ/cm2 laser fluence, 600 fs time delay
8R9H	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 23 mJ/cm2 laser fluence, 661 fs time delay
8R9I	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 23 mJ/cm2 laser fluence, 733 fs time delay
8R9J	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 23 mJ/cm2 laser fluence, 822 fs time delay
8R9K	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 23 mJ/cm2 laser fluence, 922 fs time delay
8R94	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 5 mJ/cm2 laser fluence, 1001 fs time delay
8R95	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 5 mJ/cm2 laser fluence, 1401 fs time delay
8R8W	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 5 mJ/cm2 laser fluence, 254 fs time delay
8R8X	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 5 mJ/cm2 laser fluence, 327 fs time delay
8R8Y	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 5 mJ/cm2 laser fluence, 402 fs time delay
8R8Z	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 5 mJ/cm2 laser fluence, 471 fs time delay
8R90	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 5 mJ/cm2 laser fluence, 604 fs time delay
8R91	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 5 mJ/cm2 laser fluence, 627 fs time delay
8R92	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 5 mJ/cm2 laser fluence, 702 fs time delay
8R93	;	1.4	;	Multicopy-refined carboxymyoglobin photolysis time series at 5 mJ/cm2 laser fluence, 847 fs time delay
6RVO	;	1.97	;	Multicrystal dataset of thaumatin collected using a multilayer monochromator.
8A9D	;	2.1	;	Multicrystal room temperature structure of Lysozyme collected using a double multilayer monochromator.
6SVA	;	1.92	;	Multicrystal structure of equine Haemoglobin at room temperature using a multilayer monochromator.
8FT4	;	4.0	;	Multicrystal structure of Na+, leucine-bound LeuT determined at 5 keV
6RZP	;	2.2	;	Multicrystal structure of Proteinase K at room temperature using a multilayer monochromator.
6SEL	;	2.2	;	Multicrystal structure of Thermolysin at room temperature using a multilayer monochromator.
5UQE	;	3.6	;	Multidomain structure of human kidney-type glutaminase(KGA/GLS)
2HYD	;	3.0	;	Multidrug ABC transporter SAV1866
7M4Q	;	2.87	;	Multidrug Efflux pump AdeJ
7M4P	;	2.86	;	Multidrug Efflux pump AdeJ with Eravacycline bound
7RY3	;	2.91	;	Multidrug Efflux pump AdeJ with TP-6076 bound
7RR6	;	3.1	;	Multidrug efflux pump subunit AcrB
7RR7	;	3.05	;	Multidrug efflux pump subunit AcrB
7RR8	;	3.51	;	Multidrug efflux pump subunit AcrB
6R81	;	3.9	;	Multidrug resistance transporter BmrA mutant E504A bound with ATP and Mg solved by Cryo-EM
7BG4	;	4.2	;	Multidrug resistance transporter BmrA mutant E504A bound with ATP, Mg, and Rhodamine 6G solved by Cryo-EM
8IZP	;	3.31	;	Multidrug resistance-associated protein 3
8IZR	;	3.62	;	Multidrug resistance-associated protein 3
1BOW	;	2.7	;	MULTIDRUG-BINDING DOMAIN OF TRANSCRIPTION ACTIVATOR BMRR (APO FORM)
2BOW	;	2.8	;	MULTIDRUG-BINDING DOMAIN OF TRANSCRIPTION ACTIVATOR BMRR IN COMPLEX WITH A LIGAND, TETRAPHENYLPHOSPHONIUM
2JUG	;		;	Multienzyme Docking in Hybrid Megasynthetases
4IM4	;	2.42	;	Multifunctional cellulase, xylanase, mannanase
8JUA	;	2.00001	;	Multifunctional cytochrome P450 enzyme IkaD from Streptomyces sp. ZJ306, in complex with epoxyikarugamycin
8BS7	;	3.2	;	Multimerisation domain of Borna disease virus 1
8B8A	;	2.75	;	Multimerization domain of borna disease virus 1 phosphoprotein
8B8D	;	2.4	;	multimerization domain of Gaboon Viper Virus 1
8B8B	;	2.15	;	Multimerization domain of Munia virus 1 phosphoprotein
1H09	;	2.1	;	Multimodular Pneumococcal Cell Wall Endolysin from phage Cp-1
1OBA	;	2.45	;	Multimodular Pneumococcal Cell Wall Endolysin from phage Cp-1 complexed with choline
2HS7	;		;	Multipattern rietveld refinement with protein powder data: An approach to higher resolution
2HS9	;		;	Multipattern Rietveld refinement with protein powder data: An approach to higher resolution
2HSO	;		;	Multipattern rietveld refinement with protein powder data: An approach to higher resolution
1BL0	;	2.3	;	MULTIPLE ANTIBIOTIC RESISTANCE PROTEIN (MARA)/DNA COMPLEX
1JGS	;	2.3	;	Multiple Antibiotic Resistance Repressor, MarR
172D	;	3.0	;	MULTIPLE BINDING MODES OF ANTICANCER DRUG ACTINOMYCIN D: X-RAY, MOLECULAR MODELING, AND SPECTROSCOPIC STUDIES OF D(GAAGCTTC)2-ACTINOMYCIN D COMPLEXES AND ITS HOST DNA
173D	;	3.0	;	MULTIPLE BINDING MODES OF ANTICANCER DRUG ACTINOMYCIN D: X-RAY, MOLECULAR MODELING, AND SPECTROSCOPIC STUDIES OF D(GAAGCTTC)2-ACTINOMYCIN D COMPLEXES AND ITS HOST DNA
3WNR	;	2.008	;	Multiple binding modes of benzyl isothiocyanate inhibitor complexed with Macrophage Migration Inhibitory Factor
3WNT	;	2.074	;	Multiple binding modes of benzyl isothiocyanate inhibitor complexed with Macrophage Migration Inhibitory Factor
4OXK	;	1.8429	;	Multiple binding modes of inhibitor PT155 to the Mycobacterium tuberculosis enoyl-ACP reductase InhA within a tetramer
5APM	;	4.3	;	Multiple capsid-stabilizing protein-RNA and protein-protein interactions revealed in a high-resolution structure of an emerging picornavirus causing neonatal sepsis
2ULL	;	1.5	;	MULTIPLE CONFORMATION STRUCTURE OF ALPHA-LYTIC PROTEASE AT 120 K
2AIV	;		;	Multiple conformations in the ligand-binding site of the yeast nuclear pore targeting domain of NUP116P
4J2I	;	2.98	;	Multiple crystal structures of an all-AT DNA dodecamer stabilized by weak interactions
4HW1	;	3.1	;	Multiple Crystal structures of an all-AT DNA dodecamer stabilized by weak interactions.
1ZKL	;	1.67	;	Multiple Determinants for Inhibitor Selectivity of Cyclic Nucleotide Phosphodiesterases
2H50	;	10.8	;	Multiple distinct assemblies reveal conformational flexibility in the small heat shock protein Hsp26
2H53	;	11.5	;	Multiple distinct assemblies reveal conformational flexibility in the small heat shock protein Hsp26
6THD	;	2.23	;	Multiple Genomic RNA-Coat Protein Contacts Play Vital Roles in the Assembly of Infectious Enterovirus-E
6THN	;	2.6	;	Multiple Genomic RNA-Coat Protein Contacts Play Vital Roles in the Assembly of Infectious Enterovirus-E symmetry expansion+2fold focused classification
1LW9	;	1.45	;	Multiple methionine substitutions are tolerated in T4 lysozyme and have coupled effects on folding and stability
1LWG	;	1.7	;	Multiple Methionine Substitutions are Tolerated in T4 Lysozyme and have Coupled Effects on Folding and Stability
1LWK	;	2.1	;	Multiple Methionine Substitutions are Tolerated in T4 Lysozyme and have Coupled Effects on Folding and Stability
1LPY	;	1.65	;	Multiple Methionine Substitutions in T4 Lysozyme
2XBZ	;	2.65	;	Multiple oligomeric forms of the Pseudomonas aeruginosa RetS sensor domain modulate accessibility to the ligand-binding site
1L69	;	1.9	;	MULTIPLE STABILIZING ALANINE REPLACEMENTS WITHIN ALPHA-HELIX 126-134 OF T4 LYSOZYME HAVE INDEPENDENT, ADDITIVE EFFECTS ON BOTH STRUCTURE AND STABILITY
1L70	;	1.9	;	MULTIPLE STABILIZING ALANINE REPLACEMENTS WITHIN ALPHA-HELIX 126-134 OF T4 LYSOZYME HAVE INDEPENDENT, ADDITIVE EFFECTS ON BOTH STRUCTURE AND STABILITY
1L71	;	1.85	;	MULTIPLE STABILIZING ALANINE REPLACEMENTS WITHIN ALPHA-HELIX 126-134 OF T4 LYSOZYME HAVE INDEPENDENT, ADDITIVE EFFECTS ON BOTH STRUCTURE AND STABILITY
1L72	;	1.85	;	MULTIPLE STABILIZING ALANINE REPLACEMENTS WITHIN ALPHA-HELIX 126-134 OF T4 LYSOZYME HAVE INDEPENDENT, ADDITIVE EFFECTS ON BOTH STRUCTURE AND STABILITY
1L73	;	2.05	;	MULTIPLE STABILIZING ALANINE REPLACEMENTS WITHIN ALPHA-HELIX 126-134 OF T4 LYSOZYME HAVE INDEPENDENT, ADDITIVE EFFECTS ON BOTH STRUCTURE AND STABILITY
1L74	;	1.7	;	MULTIPLE STABILIZING ALANINE REPLACEMENTS WITHIN ALPHA-HELIX 126-134 OF T4 LYSOZYME HAVE INDEPENDENT, ADDITIVE EFFECTS ON BOTH STRUCTURE AND STABILITY
1L75	;	1.9	;	MULTIPLE STABILIZING ALANINE REPLACEMENTS WITHIN ALPHA-HELIX 126-134 OF T4 LYSOZYME HAVE INDEPENDENT, ADDITIVE EFFECTS ON BOTH STRUCTURE AND STABILITY
6XYO	;	2.6	;	Multiple system atrophy Type I alpha-synuclein filament
6XYP	;	3.29	;	Multiple system atrophy Type II-1 alpha-synuclein filament
6XYQ	;	3.09	;	Multiple system atrophy Type II-2 alpha-synuclein filament
7TN1	;	3.1	;	Multistate design to stabilize viral class I fusion proteins
5D21	;	1.9	;	Multivalency Effects in Glycopeptide Dendrimer Inhibitors of Pseudomonas aeruginosa Biofilms Targeting Lectin LecA
7T7V	;	10.0	;	Munc13-1 C1-C2B-MUN-C2C Lateral conformation on lipid bilayer surface
7T7X	;	10.0	;	Munc13-1 C1-C2B-MUN-C2C Upright conformation spanning two lipid bilayers
6NYT	;	1.369	;	Munc13-1 C2B-domain, calcium bound
6NYC	;	1.893	;	Munc13-1 C2B-domain, calcium free
3SWH	;	2.65	;	Munc13-1, MUN domain, C-terminal module
2L22	;		;	Mupirocin didomain ACP
4YXF	;	2.7	;	MupS, a 3-oxoacyl (ACP) reductase involved in Mupirocin biosynthesis
1Q3G	;	2.65	;	MurA (Asp305Ala) liganded with tetrahedral reaction intermediate
3KQJ	;	1.7	;	MurA binary complex with UDP-N-acetylglucosamine
3KR6	;	1.7	;	MurA dead-end complex with fosfomycin
3KQA	;	2.25	;	MurA dead-end complex with terreic acid
1YBG	;	2.6	;	MurA inhibited by a derivative of 5-sulfonoxy-anthranilic acid
2Z2C	;	2.05	;	MURA inhibited by unag-cnicin adduct
6H9D	;	1.9	;	Muramidase domain of SpmX from Asticaccaulis excentricus
8B2E	;	1.1	;	Muramidase from Kionochaeta sp natural catalytic core
8B2H	;	2.36	;	Muramidase from Thermothielavioides terrestris, catalytic domain
1UXY	;	1.8	;	MURB MUTANT WITH SER 229 REPLACED BY ALA, COMPLEX WITH ENOLPYRUVYL-UDP-N-ACETYLGLUCOSAMINE
2MBR	;	1.8	;	MURB WILD TYPE, COMPLEX WITH ENOLPYRUVYL-UDP-N-ACETYLGLUCOSAMINE
1GQQ	;	3.1	;	MURC - Crystal structure of the apo-enzyme from Haemophilus influenzae
1GQY	;	1.8	;	MURC - CRYSTAL STRUCTURE OF THE ENZYME FROM HAEMOPHILUS INFLUENZAE COMPLEXED WITH AMPPCP
2WTZ	;	3.0	;	MurE ligase of Mycobacterium Tuberculosis
5L7M	;		;	Murin CXCL13 solution structure
5IZB	;		;	Murin CXCL13 solution structure featuring a folded N-terminal domain
1PG7	;	2.5	;	Murine 6A6 Fab in complex with humanized anti-Tissue Factor D3H44 Fab
5KAR	;	1.142	;	Murine acid sphingomyelinase-like phosphodiesterase 3b (SMPDL3B)
5KAS	;	1.619	;	Murine acid sphingomyelinase-like phosphodiesterase 3b (SMPDL3B) with phosphocholine
5W7D	;	1.75	;	Murine acyloxyacyl hydrolase (AOAH), S262A mutant
5W7E	;	1.83	;	Murine acyloxyacyl hydrolase (AOAH), S262A mutant, with dimyristoyl phosphatidylcholine
5W7F	;	2.8	;	Murine acyloxyacyl hydrolase (AOAH), S262A mutant, with lipid A
1FKW	;	2.4	;	MURINE ADENOSINE DEAMINASE (D295E)
1FKX	;	2.4	;	MURINE ADENOSINE DEAMINASE (D296A)
1FO0	;	2.5	;	MURINE ALLOREACTIVE SCFV TCR-PEPTIDE-MHC CLASS I MOLECULE COMPLEX
1KJ2	;	2.71	;	Murine Alloreactive ScFv TCR-Peptide-MHC Class I Molecule Complex
1NAM	;	2.7	;	MURINE ALLOREACTIVE SCFV TCR-PEPTIDE-MHC CLASS I MOLECULE COMPLEX
8BG9	;	3.5	;	Murine amyloid-beta filaments with the Arctic mutation (E22G) from APP(NL-G-F) mouse brains | ABeta
2BWL	;	1.62	;	Murine angiogenin, phosphate complex
2BWK	;	1.5	;	Murine angiogenin, sulphate complex
7JIX	;	3.901	;	Murine antibody that engages the influenza hemagglutinin receptor binding site
1GV4	;	2.0	;	Murine apoptosis-inducing factor (AIF)
2ZNC	;	2.8	;	MURINE CARBONIC ANHYDRASE IV
3ZNC	;	2.8	;	MURINE CARBONIC ANHYDRASE IV COMPLEXED WITH BRINZOLAMIDE
1URT	;	2.8	;	MURINE CARBONIC ANHYDRASE V
1BQH	;	2.8	;	MURINE CD8AA ECTODOMAIN FRAGMENT IN COMPLEX WITH H-2KB/VSV8
8UMO	;	2.6	;	Murine CD94-NKG2A receptor in complex with Qa-1b presenting AMAPRTLLL
7O3H	;	2.6	;	Murine CIII2 focus-refined from supercomplex CICIII2
5TIL	;	2.83	;	Murine class I major histocompatibility complex H-2 Db in complex with LCMV-derived GP33 altered peptide V3P and T-cell receptor P14
6G9R	;	2.7	;	Murine class I major histocompatibility complex H-2 Db in complex with self-antigen derived from dopamine monooxygenase.
5TJE	;	3.2	;	Murine class I major histocompatibility complex H-2Db in complex with LCMV-derived gp33 and T cell receptor P14
3ROO	;	2.0	;	Murine class I major histocompatibility complex H-2Kb in complex with immunodominant LCMV-derived gp34-41 peptide
3ROL	;	2.6	;	Murine class I major histocompatibility complex H-2Kb in complex with post-translationally modified LCMV-derived gp34-41 peptide, comprising a nitrotyrosine at position 3
1DY2	;	2.0	;	Murine collagen alpha1(XV), endostatin domain
7KDV	;	4.59	;	Murine core lysosomal multienzyme complex (LMC) composed of acid beta-galactosidase (GLB1) and protective protein cathepsin A (PPCA, CTSA)
5FDQ	;	1.9	;	Murine COX-2 S530T mutant
1PQZ	;	2.1	;	MURINE CYTOMEGALOVIRUS IMMUNOMODULATORY PROTEIN M144
8BTJ	;	1.94	;	Murine cytomegalovirus protein M35
5YEV	;	2.5	;	Murine DR3 death domain
1I3Z	;	2.15	;	MURINE EAT2 SH2 DOMAIN IN COMPLEX WITH SLAM PHOSPHOPEPTIDE
5VEN	;	1.69	;	Murine ectonucleotide pyrophosphatase / phosphodiesterase 5 (ENPP5, NPP5)
5VEO	;	1.53	;	Murine ectonucleotide pyrophosphatase / phosphodiesterase 5 (ENPP5, NPP5), inactive (T72A), in complex with AMP
5MHF	;	2.1	;	Murine endoplasmic reticulum alpha-glucosidase I with N-9'-methoxynonyl-1-deoxynojirimycin
5F0E	;	1.74	;	Murine endoplasmic reticulum alpha-glucosidase II
5IEE	;	1.92	;	Murine endoplasmic reticulum alpha-glucosidase II with 1-deoxynojirimycin
5HJR	;	2.4	;	Murine endoplasmic reticulum alpha-glucosidase II with bound covalent intermediate
5HJO	;	2.29	;	Murine endoplasmic reticulum alpha-glucosidase II with bound substrate analogue
5IED	;	1.81	;	Murine endoplasmic reticulum alpha-glucosidase II with castanospermine
5IEG	;	1.822	;	Murine endoplasmic reticulum alpha-glucosidase II with N-9'-methoxynonyl-1-deoxynojirimycin
5IEF	;	2.38	;	Murine endoplasmic reticulum alpha-glucosidase II with N-butyl-1-deoxynojirimycin
1DY0	;	2.2	;	Murine endostatin, crystal form II
1DY1	;	2.2	;	Murine endostatin, crystal form III
4AZQ	;	2.0	;	Murine epidermal fatty acid-binding protein (FABP5) in complex with the endocannabinoid 2-arachidonoylglycerol
4AZP	;	2.1	;	Murine epidermal fatty acid-binding protein (FABP5) in complex with the endocannabinoid anandamide
4AZO	;	2.33	;	Murine epidermal fatty acid-binding protein (FABP5), apo form, poly- his tag removed
4AZN	;	2.51	;	Murine epidermal fatty acid-binding protein (FABP5), apo form, poly- his tag-mediated crystal packing
7SD2	;	3.75	;	Murine Fab that recognizes Hev b 8 (profilin for Hevea brasiliensis)
7SBD	;	3.04	;	Murine Fab/IgE in complex with profilin from Hevea brasieliensis (Hev b 8)
7SBG	;	3.34	;	Murine Fab/IgE in complex with profilin from Hevea brasieliensis (Hev b 8)
3WCY	;	2.9	;	Murine Ifnar1 in complex with interferon-beta
7ZG0	;	3.18	;	Murine IL-27 in complex with IL-27Ra and a non-competing Nb
1QOM	;	2.7	;	MURINE INDUCIBLE NITRIC OXIDE SYNTHASE OXYGENASE DIMER (DELTA 65) WITH SWAPPED N-TERMINAL HOOK
3NOD	;	2.7	;	MURINE INDUCIBLE NITRIC OXIDE SYNTHASE OXYGENASE DIMER (DELTA 65) WITH TETRAHYDROBIOPTERIN AND PRODUCT ANALOGUE L-THIOCITRULLINE
1NOD	;	2.6	;	MURINE INDUCIBLE NITRIC OXIDE SYNTHASE OXYGENASE DIMER (DELTA 65) WITH TETRAHYDROBIOPTERIN AND SUBSTRATE L-ARGININE
2NOD	;	2.6	;	MURINE INDUCIBLE NITRIC OXIDE SYNTHASE OXYGENASE DIMER (DELTA 65) WITH TETRAHYDROBIOPTERIN AND WATER BOUND IN ACTIVE CENTER
1JWK	;	2.3	;	Murine Inducible Nitric Oxide Synthase Oxygenase Dimer (Delta 65) with W457A Mutation at Tetrahydrobiopterin Binding Site
1JWJ	;	2.6	;	Murine Inducible Nitric Oxide Synthase Oxygenase Dimer (Delta 65) with W457F Mutation at Tetrahydrobiopterin Binding Site
1DWV	;	2.35	;	MURINE INDUCIBLE NITRIC OXIDE SYNTHASE OXYGENASE DIMER N-hydroxyarginine and 4-amino tetrahydrobiopterin
1DWW	;	2.35	;	MURINE INDUCIBLE NITRIC OXIDE SYNTHASE OXYGENASE DIMER N-hydroxyarginine and dihydrobiopterin
1DWX	;	2.6	;	MURINE INDUCIBLE NITRIC OXIDE SYNTHASE OXYGENASE DIMER N-hydroxyarginine and tetrahydrobiopterin
1R35	;	2.3	;	MURINE INDUCIBLE NITRIC OXIDE SYNTHASE OXYGENASE DIMER, TETRAHYDROBIOPTERIN AND 4R-FLUORO-N6-ETHANIMIDOYL-L-LYSINE
1DD7	;	2.25	;	MURINE INDUCIBLE NITRIC OXIDE SYNTHASE OXYGENASE DOMAIN (DELTA 114) (N-[(1,3-BENZODIOXOL-5-YL)METHYL]-1-[2-(1H-IMIDAZOL-1-YL)PYRIMIDIN-4-YL]-4-(METHOXYCARBONYL)-PIPERAZINE-2-ACETAMIDE COMPLEX
2ORO	;	2.0	;	Murine inducible nitric oxide synthase oxygenase domain (delta 114) (r)-1-(2-imidazol-1-yl-6-methyl-pyrimidin-4-yl)-pyrrolidine-2-carboxylic acid (2-benzo[1,3]dioxol-5-yl-ethyl)-amide complex
2ORT	;	1.87	;	Murine Inducible Nitric Oxide Synthase Oxygenase Domain (Delta 114) 1-Benzo[1,3]dioxol-5-ylmethyl-3S-(4-imidazol-1-yl-phenoxy)-piperidine Complex
2ORP	;	1.97	;	Murine inducible nitric oxide synthase oxygenase domain (delta 114) 2-[4-(2-Imidazol-1-yl-6-methyl-pyrimidin-4-yl)-1-isobutyryl-piperazin-2-yl]-N-[2-(4-methoxy-phenyl)-ethyl]-acetamide complex
2ORS	;	2.0	;	Murine Inducible Nitric Oxide Synthase Oxygenase Domain (DELTA 114) 4-(Benzo[1,3]dioxol-5-yloxy)-2-(4-imidazol-1-yl-phenoxy)-6-methyl-pyrimidine Complex
2ORR	;	2.0	;	Murine Inducible Nitric Oxide Synthase Oxygenase Domain (Delta 114) 4-(Benzo[1,3]dioxol-5-yloxy)-2-(4-imidazol-1-yl-phenoxy)-pyrimidine Complex
2ORQ	;	2.1	;	Murine Inducible Nitric Oxide Synthase Oxygenase Domain (DELTA 114) 4-(imidazol-1-yl)phenol and piperonylamine Complex
1NOC	;	2.6	;	MURINE INDUCIBLE NITRIC OXIDE SYNTHASE OXYGENASE DOMAIN (DELTA 114) COMPLEXED WITH TYPE I E. COLI CHLORAMPHENICOL ACETYL TRANSFERASE AND IMIDAZOLE
2NOS	;	2.3	;	MURINE INDUCIBLE NITRIC OXIDE SYNTHASE OXYGENASE DOMAIN (DELTA 114), AMINOGUANIDINE COMPLEX
1NOS	;	2.1	;	MURINE INDUCIBLE NITRIC OXIDE SYNTHASE OXYGENASE DOMAIN (DELTA 114), IMIDAZOLE COMPLEX
1QW5	;	2.7	;	Murine inducible nitric oxide synthase oxygenase domain in complex with W1400 inhibitor.
2BHJ	;	3.2	;	murine iNO synthase with coumarin inhibitor
3E65	;	2.05	;	Murine INOS dimer with HEME, pterin and inhibitor AR-C120011
3E67	;	2.6	;	Murine inos dimer with inhibitor 4-MAP bound
1DF1	;	2.35	;	MURINE INOSOXY DIMER WITH ISOTHIOUREA BOUND IN THE ACTIVE SITE
8CR5	;	2.15	;	Murine Interleukin-12 receptor beta 1 domain 1 in complex with murine Interleukin-12 beta.
4LV5	;	1.7	;	Murine IRGa6 bound to Toxoplasma ROP5B, a pseudokinase GDI
4LV8	;	1.72	;	Murine IRGa6 bound to Toxoplasma ROP5C, a pseudokinase GDI
7TLH	;	1.74	;	Murine meteorin C-terminal NTR domain
7TL6	;	2.3	;	Murine meteorin N-terminal CUB domain
7TLW	;	1.75	;	Murine Meteorin-like C-terminal NTR domain
2F74	;	2.7	;	Murine MHC class I H-2Db in complex with human b2-microglobulin and LCMV-derived immunodminant peptide gp33
1DMX	;	2.45	;	MURINE MITOCHONDRIAL CARBONIC ANYHDRASE V AT 2.45 ANGSTROMS RESOLUTION
6DXY	;	1.851	;	Murine N-acylethanolamine-hydrolyzing acid amidase (NAAA)
6R1Q	;	1.95	;	murine Neuroglobin under 2 kBar of argon
4O4Z	;	1.7	;	MURINE NEUROGLOBIN UNDER 30 BAR PRESSURE NITROUS Oxide
4O4T	;	1.9	;	MURINE NEUROGLOBIN UNDER XENON PRESSURE 30 bar
8TKN	;	2.8	;	Murine NF-kappaB p50 Rel Homology Region homodimer in complex with 10-mer kappaB DNA from human Neutrophil Gelatinase-associated Lipocalin (NGAL) promoter
8TKM	;	2.8	;	Murine NF-kappaB p50 Rel Homology Region homodimer in complex with 17-mer kappaB DNA from human interleukin-6 (IL-6) promoter
8TKL	;	3.0	;	Murine NF-kappaB p50 Rel Homology Region homodimer in complex with a Test 16-mer kappaB-like DNA
8UV3	;	2.72	;	Murine norovirus capsid protein + 1 mM MgCl2
8UUX	;	2.74	;	Murine norovirus capsid protein in the presence of 1mM calcium
6H6L	;	2.5	;	Murine norovirus protruding domain (CW3 strain) in complex with the CD300lf receptor and glycochenodeoxycholate (GCDCA)
4O4R	;	2.4	;	Murine Norovirus RdRp in complex with PPNDS
4NRU	;	2.3	;	Murine Norovirus RNA-dependent-RNA-polymerase in complex with Compound 6, a suramin derivative
1KN3	;	1.8	;	Murine PEBP-2 (phosphatidylethanolamine-binding protein-2)
6MUL	;	3.09	;	Murine PI3K delta kinsae domain - cpd 1
6MUM	;	3.06	;	Murine PI3K delta kinsae domain - cpd 3
1SID	;	3.65	;	MURINE POLYOMAVIRUS COMPLEXED WITH 3'SIALYL LACTOSE
1SIE	;	3.65	;	MURINE POLYOMAVIRUS COMPLEXED WITH A DISIALYLATED OLIGOSACCHARIDE
7K23	;	3.3	;	Murine polyomavirus hexavalent capsomer with 8A7H5 Fab, subparticle reconstruction
7K25	;	2.9	;	Murine polyomavirus hexavalent capsomer, subparticle reconstruction
7K22	;	3.2	;	Murine polyomavirus pentavalent capsomer with 8A7H5 Fab, subparticle reconstruction
7K24	;	2.9	;	Murine polyomavirus pentavalent capsomer, subparticle reconstruction
6GBD	;		;	Murine Protein Tyrosine Phosphatase PTPN13 PDZ3 Domain
6GBE	;		;	Murine Protein Tyrosine Phosphatase PTPN13 PDZ3 Domain-PRK2 Peptide Complex
8S9W	;	1.69	;	Murine S100A7/S100A15 in presence of calcium
1MBY	;	2.0	;	Murine Sak Polo Domain
5U85	;	1.65	;	Murine saposin-D (SapD), open conformation
8DU5	;	3.5	;	Murine sialidase-1 (NEU1)
8W6R	;	1.95	;	murine SMPDL3A bound to sulfate
5FC6	;	1.658	;	Murine SMPDL3A in complex with ADP analog AMPCP
5FCB	;	1.55	;	Murine SMPDL3A in complex with AMP
5FC5	;	1.678	;	Murine SMPDL3A in complex with phosphocholine
5FC1	;	1.389	;	Murine SMPDL3A in complex with sulfate
5FC7	;	1.456	;	Murine SMPDL3A in complex with sulfate (tetragonal)
5FCA	;	1.924	;	Murine SMPDL3A in presence of excess zinc
7O37	;	3.2	;	Murine supercomplex CIII2CIV in the assembled locked conformation
7O3E	;	3.6	;	Murine supercomplex CIII2CIV in the intermediate locked conformation
7O3C	;	3.3	;	Murine supercomplex CIII2CIV in the mature unlocked conformation
1TCR	;	2.5	;	MURINE T-CELL ANTIGEN RECEPTOR 2C CLONE
1KB5	;	2.5	;	MURINE T-CELL RECEPTOR VARIABLE DOMAIN/FAB COMPLEX
2VOK	;	1.3	;	Murine TRIM21
6O5K	;	1.6	;	Murine TRIM28 Bbox1 domain
8OL2	;	3.0	;	Murine type II Abeta fibril from APP23 mouse
8OL5	;	3.4	;	Murine type II Abeta fibril from ARTE10 mouse
8OL6	;	3.8	;	Murine type II Abeta fibril from tgAPPSwe mouse
8OL3	;	3.5	;	Murine type III Abeta fibril from APP/PS1 mouse
8OLO	;	3.5	;	Murine type III Abeta fibril from ARTE10 mouse
3HKF	;	2.5	;	Murine unglycosylated IgG Fc fragment
3AXL	;	2.9	;	Murine Valpha 10 Vbeta 8.1 T-cell receptor
1U9B	;	2.0	;	MURINE/HUMAN UBIQUITIN-CONJUGATING ENZYME UBC9
8OL7	;	3.0	;	MurineArc type I Abeta fibril from tg-APPArcSwe mouse
7WAW	;	2.8	;	MurJ inward closed form
7WAX	;	2.35	;	MurJ inward occluded form
6FQB	;	3.0	;	MurT/GatD peptidoglycan amidotransferase complex from Streptococcus pneumoniae R6
5DQ6	;	2.8	;	Mus musculus A20 OTU domain
4ARA	;	2.5	;	Mus musculus Acetylcholinesterase in complex with (R)-C5685 at 2.5 A resolution.
4ARB	;	2.25	;	Mus musculus Acetylcholinesterase in complex with (S)-C5685 at 2.25 A resolution.
6FSE	;	2.7	;	Mus musculus acetylcholinesterase in complex with 1-(4-(4-Ethylpiperazin-1-yl)piperidin-1-yl)-2-((4'-methoxy-[1,1'-biphenyl]-4-yl)oxy)ethanone dihydrochloride (15)
4B81	;	2.8	;	Mus musculus Acetylcholinesterase in complex with 1-(4-Chloro-phenyl)- N-(2-diethylamino-ethyl)-methanesulfonamide
7QYN	;	2.5	;	Mus musculus acetylcholinesterase in complex with 2-((hydroxyimino)methyl)-1-(5-(4-methyl-3-nitrobenzamido)pentyl)pyridinium
6FSD	;	2.7	;	Mus musculus acetylcholinesterase in complex with 2-(4-Biphenylyloxy)-N-[3-(1-piperidinyl)propyl]-acetamide hydrochloride (10)
4B85	;	2.1	;	Mus musculus Acetylcholinesterase in complex with 4-Chloranyl-N-(2- diethylamino-ethyl)-benzenesulfonamide
7QB4	;	2.50001	;	Mus Musculus Acetylcholinesterase in complex with 7-[(1-benzylpiperidin-3-yl)methoxy]-3,4-dimethyl-2H-chromen-2-one
7QAK	;	2.6	;	Mus Musculus Acetylcholinesterase in complex with 7-[(4-{[benzyl(methyl)amino]methyl}benzyl)oxy]-4-(hydroxymethyl)-2H-chromen-2-one
5FUM	;	2.5	;	Mus musculus acetylcholinesterase in complex with AL200
2JEY	;	2.7	;	Mus musculus acetylcholinesterase in complex with HLo-7
6TD2	;	2.8	;	Mus musculus Acetylcholinesterase in complex with N-(2-(diethylamino)ethyl)-1-(4-(trifluoromethyl)phenyl)methanesulfonamide
4B82	;	2.1	;	Mus musculus Acetylcholinesterase in complex with N-(2-Diethylamino- ethyl)-2-fluoranyl-benzenesulfonamide
4B83	;	2.4	;	Mus musculus Acetylcholinesterase in complex with N-(2-Diethylamino- ethyl)-3-methoxy-benzenesulfonamide
4B84	;	2.6	;	Mus musculus Acetylcholinesterase in complex with N-(2-Diethylamino- ethyl)-3-trifluoromethyl-benzenesulfonamide
4B80	;	2.5	;	Mus musculus Acetylcholinesterase in complex with N-(2-Diethylamino-ethyl)-1-(4-fluoro-phenyl)-methanesulfonamide
4B7Z	;	2.3	;	Mus musculus Acetylcholinesterase in complex with N-(2-Diethylamino-ethyl)-1-(4-methylphenyl)-methanesulfonamide
7R02	;	2.3	;	Mus musculus acetylcholinesterase in complex with N-(3-(diethylamino)propyl)-4-methyl-3-nitrobenzamide
4A23	;	2.4	;	Mus musculus Acetylcholinesterase in complex with racemic C5685
2JEZ	;	2.6	;	Mus musculus acetylcholinesterase in complex with tabun and HLo-7
2JF0	;	2.5	;	Mus musculus acetylcholinesterase in complex with tabun and Ortho-7
6BAQ	;	2.50261	;	Mus musculus BPIFA1
6SWA	;	3.1	;	Mus musculus brain neocortex ribosome 60S bound to Ebp1
6EWP	;	1.85	;	Mus musculus CEP120 third C2 domain (C2C)
4NTA	;	2.7	;	Mus Musculus LTC4 synthase in apo form
4NTB	;	2.7	;	Mus Musculus LTC4 synthase in GSH complex form
4NTF	;	2.65	;	Mus Musculus LTC4 synthase in S-hexyl-GSH complex form
3F0N	;	1.9	;	Mus Musculus Mevalonate Pyrophosphate Decarboxylase
4GYZ	;	2.556	;	Mus Musculus Tdp2 Bound to dAMP and Mg2+
4GZ2	;	1.85	;	Mus Musculus Tdp2 excluded ssDNA complex
4GZ1	;	1.5	;	Mus Musculus Tdp2 reaction product (5'-phosphorylated DNA)-Mg2+ complex at 1.5 Angstroms resolution
4PUQ	;	1.6	;	Mus Musculus Tdp2 reaction product complex with 5'-phosphorylated RNA/DNA, glycerol, and Mg2+
4GZ0	;	2.113	;	Mus Musculus Tdp2-DNA Substrate Analog (5'-6-aminohexanol) Complex
2MSS	;		;	MUSASHI1 RBD2, NMR
2MST	;		;	MUSASHI1 RBD2, NMR
6WJC	;	2.55	;	Muscarinic acetylcholine receptor 1 - muscarinic toxin 7 complex
6OIJ	;	3.3	;	Muscarinic acetylcholine receptor 1-G11 protein complex
6OIK	;	3.6	;	Muscarinic acetylcholine receptor 2-Go complex
2CRK	;	2.35	;	MUSCLE CREATINE KINASE
7KIJ	;	1.69	;	Muscovy duck circovirus Rep domain complexed with a single-stranded DNA 10-mer comprising the cleavage site
7KII	;	1.3	;	Muscovy duck circovirus Rep domain complexed with a single-stranded DNA 10-mer comprising the cleavage site and Mn2+
1EFZ	;	2.0	;	MUTAGENESIS AND CRYSTALLOGRAPHIC STUDIES OF ZYMOMONAS MOBILIS TRNA-GUANINE TRANSGLYCOSYLASE TO ELUCIDATE THE ROLE OF SERINE 103 FOR ENZYMATIC ACTIVITY
4CE6	;	2.05	;	Mutagenesis of a Rhodobacteraceae L-haloacid dehalogenase
4CF3	;	2.16	;	Mutagenesis of a Rhodobacteraceae L-haloacid dehalogenase
4CF4	;	2.14	;	Mutagenesis of a Rhodobacteraceae L-haloacid dehalogenase
4CF5	;	2.34	;	Mutagenesis of a Rhodobacteraceae L-haloacid dehalogenase
4CNQ	;	1.84	;	Mutagenesis of a Rhodobacteraceae L-haloacid dehalogenase
3MGY	;	2.1	;	Mutagenesis of p38 MAP Kinase eshtablishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-out state
3MH0	;	2.0	;	Mutagenesis of p38 MAP Kinase eshtablishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-out state
3MH1	;	2.2	;	Mutagenesis of p38 MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-out state
3MH2	;	2.3	;	Mutagenesis of p38 MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-out state
3MH3	;	2.2	;	Mutagenesis of p38 MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-out state
1WCQ	;	2.1	;	Mutagenesis of the Nucleophilic Tyrosine in a Bacterial Sialidase to Phenylalanine.
4F6H	;	1.744	;	Mutagenesis of zinc ligand residue Cys221 reveals plasticity in the IMP-1 metallo-b-lactamase active site
4F6Z	;	2.0	;	Mutagenesis of zinc ligand residue Cys221 reveals plasticity in the IMP-1 metallo-b-lactamase active site
5EOZ	;	2.088	;	Mutagenicity of 7-Benzyl guanine lesion and Replication by Human DNA Polymerase beta
7XZ7	;	1.98	;	Mutant (D137A) of the N-terminal domain of fucoidan lyase FdlA
1QPK	;	2.0	;	MUTANT (D193G) MALTOTETRAOSE-FORMING EXO-AMYLASE IN COMPLEX WITH MALTOTETRAOSE
1QI3	;	2.0	;	MUTANT (D193N) MALTOTETRAOSE-FORMING EXO-AMYLASE IN COMPLEX WITH MALTOTETRAOSE
1QI5	;	2.0	;	MUTANT (D294N) MALTOTETRAOSE-FORMING EXO-AMYLASE IN COMPLEX WITH MALTOTETRAOSE
5E1Q	;	1.943	;	Mutant (D415G) GH97 alpha-galactosidase in complex with Gal-Lac
1QI4	;	2.0	;	MUTANT (E219G) MALTOTETRAOSE-FORMING EXO-AMYLASE IN COMPLEX WITH MALTOTETRAOSE
1JDC	;	1.9	;	MUTANT (E219Q) MALTOTETRAOSE-FORMING EXO-AMYLASE COCRYSTALLIZED WITH MALTOTETRAOSE (CRYSTAL TYPE 1)
1JDD	;	1.9	;	MUTANT (E219Q) MALTOTETRAOSE-FORMING EXO-AMYLASE COCRYSTALLIZED WITH MALTOTETRAOSE (CRYSTAL TYPE 2)
7XZ9	;	1.54	;	Mutant (E236A) of the N-terminal domain of fucoidan lyase FdlA
2V2P	;	1.15	;	Mutant (E53,56,57,60Q and R59M) recombinant horse spleen apoferritin cocrystallized with haemin in acidic conditions
2V2R	;	1.9	;	Mutant (E53,56,57,60Q and R59M) recombinant horse spleen apoferritin cocrystallized with haemin in basic conditions
2V2L	;	1.9	;	Mutant (E53,56,57,60Q) recombinant horse spleen apoferritin cocrystallized with haemin in acidic conditions
2V2M	;	1.65	;	Mutant (E53,56,57,60Q) recombinant horse spleen apoferritin cocrystallized with haemin in basic conditions
7XZD	;	1.75	;	Mutant (F179A) of the N-terminal domain of fucoidan lyase FdlA
2JDU	;	1.5	;	Mutant (G24N) of Pseudomonas aeruginosa lectin II (PA-IIL) complexed with methyl-a-L-fucopyranoside
2JDY	;	1.7	;	Mutant (G24N) of Pseudomonas aeruginosa lectin II (PA-IIL) complexed with methyl-b-D-mannoyranoside
7XZE	;	1.8	;	Mutant (H176A) of the N-terminal domain of fucoidan lyase FdlA
7XZ8	;	1.89	;	Mutant (K141A) of the N-terminal domain of fucoidan lyase FdlA
4BEC	;	2.84	;	MUTANT (K220A) OF THE HSDR SUBUNIT OF THE ECOR124I RESTRICTION ENZYME IN COMPLEX WITH ATP
4BEB	;	2.989	;	MUTANT (K220E) OF THE HSDR SUBUNIT OF THE ECOR124I RESTRICTION ENZYME IN COMPLEX WITH ATP
4BE7	;	2.744	;	MUTANT (K220R) OF THE HSDR SUBUNIT OF THE ECOR124I RESTRICTION ENZYME IN COMPLEX WITH ATP
7XZC	;	1.7	;	Mutant (R240A) of the N-terminal domain of fucoidan lyase FdlA
5Z03	;	1.755	;	Mutant (S106A) Escherichia coli L,D-carboxypeptidase A (LdcA)
2JDM	;	1.7	;	Mutant (S22A) of Pseudomonas aeruginosa lectin II (PA-IIL) complexed with methyl-a-L-fucopyranoside
2JDN	;	1.3	;	Mutant (S22A) of Pseudomonas aeruginosa lectin II (PA-IIL) complexed with methyl-a-L-mannopyranoside
2JDP	;	1.3	;	Mutant (S23A) of Pseudomonas aeruginosa lectin II (PA-IIL) complexed with methyl-a-L-fucopyranoside
7XZB	;	2.25	;	Mutant (Y242A) of the N-terminal domain of fucoidan lyase FdlA
7XZA	;	2.08	;	Mutant (Y242F) of the N-terminal domain of fucoidan lyase FdlA
2ZYH	;	1.83	;	mutant A. Fulgidus lipase S136A complexed with fatty acid fragment
7NYO	;	1.4	;	Mutant A541L of SH3 domain of JNK-interacting Protein 1 (JIP1)
1XZ6	;	1.55	;	Mutant ABO(H) blood group glycosyltransferase A
1WT1	;	1.55	;	Mutant ABO(H) blood group glycosyltransferase with bound UDP and acceptor
2VYZ	;	1.8	;	Mutant Ala55Phe of Cerebratulus lacteus mini-hemoglobin
2VYY	;	1.6	;	Mutant Ala55Trp of Cerebratuls lacteus mini-hemoglobin
8G0Z	;	3.61	;	Mutant bacteriophage T4 gp41 helicase hexamer bound with single strand DNA and ATPgammaS in the stalled primosome
2DQX	;	2.2	;	mutant beta-amylase (W55R) from soy bean
3KIG	;	1.39	;	Mutant carbonic anhydrase II in complex with an azide and an alkyne
6R0Q	;	1.5	;	Mutant cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with thalidomide metabolite alpha-(o-carboxybenzamido)glutarimide
1GXO	;	2.05	;	Mutant D189A of Family 10 polysaccharide lyase from Cellvibrio cellulosa in complex with trigalaturonic acid
7Q31	;	1.75	;	Mutant D24G of uridine phosphorylase from E. coli
7Q32	;	1.7	;	Mutant D24G of uridine phosphorylase from E. coli
1OCN	;	1.31	;	Mutant D416A of the CELLOBIOHYDROLASE CEL6A FROM HUMICOLA INSOLENS in complex with a cellobio-derived isofagomine at 1.3 angstrom resolution
1OCJ	;	1.3	;	Mutant D416A of the CELLOBIOHYDROLASE CEL6A FROM HUMICOLA INSOLENS in complex with a THIOPENTASACCHARIDE at 1.3 angstrom resolution
1GZ1	;	1.9	;	Mutant D416A of the CELLOBIOHYDROLASE CEL6A FROM HUMICOLA INSOLENS in complex with methyl-cellobiosyl-4-deoxy-4-thio-beta-D-cellobioside
6FVM	;	1.631	;	Mutant DNA polymerase sliding clamp from Escherichia coli with bound P7 peptide
6FVO	;	2.689	;	Mutant DNA polymerase sliding clamp from Mycobacterium tuberculosis with bound P7 peptide
1U3A	;	2.0	;	mutant DsbA
5UDG	;	2.5	;	Mutant E97Q crystal structure of Bacillus subtilis QueF with a disulfide Cys 55-99
3HMB	;	2.7	;	Mutant endolysin from Bacillus subtilis
4J1L	;	2.6	;	Mutant Endotoxin TeNT
1KZ9	;	3.1	;	Mutant Enzyme L119F Lumazine Synthase from S.pombe
1KZ1	;	2.0	;	Mutant enzyme W27G Lumazine Synthase from S.pombe
1KZ4	;	3.1	;	Mutant enzyme W63Y Lumazine Synthase from S.pombe
1KZ6	;	2.7	;	Mutant enzyme W63Y/L119F Lumazine Synthase from S.pombe
1QKT	;	2.2	;	MUTANT ESTROGEN NUCLEAR RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH ESTRADIOL
6OWC	;	1.85	;	Mutant estrogen receptor alpha (ERa) Y537S covalently bound to H3B-6545.
7BGA	;	1.9	;	Mutant F105A of recombinant beta-lactoglobulin in complex with endogenous ligand
7BGX	;	2.0	;	Mutant F105L of recombinant beta-lactoglobulin
2ENI	;	2.5	;	Mutant F197M structure of PH0725 from Pyrococcus horikoshii OT3
1GYR	;	2.6	;	Mutant form of enoyl thioester reductase from Candida tropicalis
1E4V	;	1.85	;	Mutant G10V of adenylate kinase from E. coli, modified in the Gly-loop
5JXS	;	2.8	;	Mutant GC216/7AA of 3D polymerase from Foot-and-Mouth Disease Virus
1CJ2	;	2.8	;	MUTANT GLN34ARG OF PARA-HYDROXYBENZOATE HYDROXYLASE
5J77	;	2.1	;	Mutant glyceraldehyde dehydrogenase (F34M+S405N) from Thermoplasma acidophilum
5M4X	;	3.56	;	Mutant glyceraldehyde dehydrogenase (F34M+Y399C+S405N) from Thermoplasma acidophilum
1B0Y	;	0.93	;	MUTANT H42Q OF HIPIP FROM CHROMATIUM VINOSUM AT 0.93A
7NYL	;	1.95	;	Mutant H493A of SH3 domain of JNK-interacting Protein 1 (JIP1)
1WT0	;	1.8	;	Mutant human ABO(H) blood group glycosyltransferase A
1WT2	;	1.9	;	Mutant human ABO(H) blood group glycosyltransferase A with bound UDP and inhibitor
1WT3	;	1.8	;	Mutant human ABO(H) blood group glycosyltransferase with bound UDP and acceptor
1WSZ	;	1.59	;	Mutant human ABO(H) blood group transferase A
2FYE	;	2.2	;	Mutant Human Cathepsin S with irreversible inhibitor CRA-14013
4YP3	;	1.89	;	Mutant Human DNA Polymerase Eta Q38A/R61A Inserting dCTP Opposite an 8-Oxoguanine Lesion
4YQW	;	2.064	;	Mutant Human DNA Polymerase Eta Q38A/R61A Inserting dCTP Opposite Template G
4YR2	;	1.95	;	Mutant Human DNA Polymerase Eta R61M Inserting dATP Opposite an 8-Oxoguanine Lesion
4YR0	;	1.78	;	Mutant Human DNA Polymerase Eta R61M Inserting dCTP Opposite an 8-Oxoguanine Lesion
4YR3	;	2.0	;	Mutant Human DNA Polymerase Eta R61M Inserting dCTP Opposite Template G
1I22	;	1.8	;	MUTANT HUMAN LYSOZYME (A83K/Q86D/A92D)
1I20	;	1.9	;	MUTANT HUMAN LYSOZYME (A92D)
1I1Z	;	1.8	;	MUTANT HUMAN LYSOZYME (Q86D)
207L	;	1.8	;	MUTANT HUMAN LYSOZYME C77A
208L	;	2.2	;	MUTANT HUMAN LYSOZYME C77A
1C43	;	1.8	;	MUTANT HUMAN LYSOZYME WITH FOREIGN N-TERMINAL RESIDUES
1C45	;	1.8	;	MUTANT HUMAN LYSOZYME WITH FOREIGN N-TERMINAL RESIDUES
1C46	;	2.2	;	MUTANT HUMAN LYSOZYME WITH FOREIGN N-TERMINAL RESIDUES
2E0L	;	1.6	;	Mutant Human Ribonuclease 1 (Q28L, R31L, R32L)
2E0J	;	1.6	;	Mutant Human Ribonuclease 1 (R31L, R32L)
2E0M	;	1.7	;	Mutant Human Ribonuclease 1 (T24L, Q28L, R31L, R32L)
2E0O	;	2.0	;	Mutant Human Ribonuclease 1 (V52L, D53L, N56L, F59L)
1E9D	;	1.7	;	Mutant human thymidylate kinase (F105Y) complexed with AZTMP and ADP
1E9E	;	1.6	;	Mutant human thymidylate kinase (F105Y) complexed with dTMP and ADP
1E9F	;	1.9	;	Mutant human thymidylate kinase complexed with TMP and ADP
1E9C	;	1.6	;	Mutant human thymidylate kinase complexed with TMP and APPNP
5X4X	;	2.31	;	Mutant human thymidylate synthase A191K crystallized in a sulfate-containing condition
5X4W	;	2.1	;	Mutant human thymidylate synthase A191K crystallized in a sulfate-free condition
5X4Y	;	2.2	;	Mutant human thymidylate synthase M190K crystallized in a sulfate-containing condition
8P35	;	2.2	;	Mutant human titin immunoglobulin-like 21 domain - C3575S
2ED3	;	2.5	;	Mutant I127M structure of PH0725 from Pyrococcus horikoshii OT3
2E4R	;	2.2	;	Mutant I253M structure of PH0725 from Pyrococcus horikoshii OT3
7BF8	;	1.8	;	Mutant I56F of recombinant bovine beta-lactoglobulin in complex with tetracaine
8BK1	;	2.7	;	Mutant Imine Reductase IR007-143 from Amycolatopsis azurea, E120A, M197W, M206S, A213P, D238G, I240L
6SM2	;	2.5	;	Mutant immunoglobulin light chain causing amyloidosis (Pat-1)
2EJJ	;	2.1	;	Mutant K129M structure of PH0725 from Pyrococcus horikoshii OT3
8PBU	;	1.67	;	Mutant K1482M of the dihydroorotase domain of human CAD protein bound to the inhibitor fluoorotate
8PBT	;	1.43	;	Mutant K1482M of the dihydroorotase domain of human CAD protein bound to the substrate dihydroorotate
8PBS	;	2.05	;	Mutant K1482M of the dihydroorotase domain of human CAD protein in apo form
8PBG	;	1.46	;	Mutant K1556T of the dihydroorotase domain of human CAD protein bound to the inhibitor fluoroorotate
8PBE	;	1.71	;	Mutant K1556T of the dihydroorotase domain of human CAD protein bound to the substrate carbamoyl aspartate
4WYL	;	2.0	;	Mutant K18E of 3D polymerase from Foot-and-Moth Disease Virus
4WZM	;	2.52	;	Mutant K18E of RNA dependent RNA polymerase from Foot-and-Mouth Disease Virus complexed with RNA
4WYW	;	1.8	;	Mutant K20E of 3D polymerase from Foot-and-Mouth Disease Virus
4WZQ	;	2.8	;	Mutant K20E of RNA dependent RNA polymerase 3D from Foot-and-Mouth disease Virus complexed with RNA
6J6W	;	1.693	;	Mutant K23N of heat shock factor 4-DBD
1GKH	;	1.7	;	MUTANT K69H OF GENE V PROTEIN (SINGLE-STRANDED DNA BINDING PROTEIN)
3C81	;	1.85	;	Mutant K85A of T4 lysozyme in wildtype background at room temperature
2ENU	;	1.7	;	Mutant L121M structure of TTHB049 from Thermus thermophilus HB8
2ELD	;	2.3	;	Mutant L160M structure of PH0725 from Pyrococcus horikoshii OT3
2EH5	;	2.3	;	Mutant L184M structure of PH0725 from Pyrococcus horikoshii OT3
2EMU	;	2.2	;	Mutant L21H structure of PH0725 from Pyrococcus horikoshii OT3
1AE2	;	2.0	;	MUTANT L32R OF GENE V PROTEIN (SINGLE-STRANDED DNA BINDING PROTEIN)
6LR8	;	1.595	;	Mutant L331A of deglycosylated hydroxynitrile lyase isozyme 5 from Prunus communis
2EJK	;	2.4	;	Mutant L38M structure of PH0725 from Pyrococcus horikoshii OT3
7BGZ	;	2.401	;	Mutant L39K of recombinant beta-lactoglobulin in complex with endogenous ligand
7BH0	;	2.1	;	Mutant L39Y of recombinant beta-lactoglobulin in complex with endogenous ligand
7Z9Z	;	2.5	;	Mutant L39Y of recombinant bovine beta-lactoglobulin in complex with pramocaine
7ZLF	;	2.1	;	Mutant L39Y-L58F of recombinant bovine beta-lactoglobulin in complex with endogenous fatty acid
7ZCD	;	2.1	;	Mutant L39Y-L58F of recombinant bovine beta-lactoglobulin in complex with pramocaine
7ZA0	;	2.1	;	Mutant L58F of recombinant bovine beta-lactoglobulin in complex with pramocaine
7BF7	;	2.1	;	Mutant L58F of recombinant bovine beta-lactoglobulin in complex with tetracaine
2EMR	;	2.4	;	Mutant L65M structure of PH0725 from Pyrococcus horikoshii OT3
2WNE	;	2.124	;	Mutant Laminarinase 16A cyclizes laminariheptaose
7BF9	;	1.8	;	Mutant M107L of recombinant bovine beta-lactoglobulin in complex with tetracaine
6GVV	;	2.35	;	Mutant M16A of RNA dependent RNA polymerase 3D from Foot-and-Mouth disease Virus
6GVY	;	2.2	;	Mutant M16A of RNA dependent RNA polymerase 3D from Foot-and-Mouth disease Virus complexed with an template -primer RNA
4H0J	;	2.0	;	Mutant M58C of Nostoc sp Cytochrome c6
4H0K	;	1.95	;	Mutant m58h of Nostoc sp cytochrome c6
1CZA	;	1.9	;	MUTANT MONOMER OF RECOMBINANT HUMAN HEXOKINASE TYPE I COMPLEXED WITH GLUCOSE, GLUCOSE-6-PHOSPHATE, AND ADP
1DGK	;	2.8	;	MUTANT MONOMER OF RECOMBINANT HUMAN HEXOKINASE TYPE I WITH GLUCOSE AND ADP IN THE ACTIVE SITE
2GHL	;	2.099	;	Mutant Mus Musculus P38 Kinase Domain in Complex with Inhibitor PG-874743
7B19	;	2.55	;	Mutant Myosin-II-GGG motor domain
3WDD	;	1.18	;	Mutant N-terminal domain of Mycobacterium tuberculosis ClpC1, F2Y, bound to Cyclomarin A
3WDE	;	1.44	;	Mutant N-terminal domain of Mycobacterium tuberculosis ClpC1, F80Y, bound to Cyclomarin A
2DSL	;	1.7	;	Mutant N33D structure of phenylacetic acid degradation protein PaaI from Thermus thermophilus HB8
7BBM	;	1.14	;	Mutant nitrobindin M75L/H76L/Q96C/M148L (NB4H) from Arabidopsis thaliana with cofactor MnPPIX
5O86	;	1.687	;	Mutant of claas II CPD photolyase from Methanosarcina mazei - W388F
5O8E	;	1.7	;	Mutant of class II CPD photolyase from Methanosarcina mazei
5O8D	;	2.0	;	Mutant of class II CPD photolyase from Methanosarcina mazei - Y345F
1DST	;	2.0	;	MUTANT OF FACTOR D WITH ENHANCED CATALYTIC ACTIVITY
6IB5	;	2.12	;	Mutant of flavin-dependent tryptophan halogenase Thal with altered regioselectivity (Thal-RebH5)
6F56	;	1.9402	;	Mutant of Human N-myristoyltransferase with bound myristoyl-CoA
1D1T	;	2.4	;	MUTANT OF HUMAN SIGMA ALCOHOL DEHYDROGENASE WITH LEUCINE AT POSITION 141
1FXH	;	1.97	;	MUTANT OF PENICILLIN ACYLASE IMPAIRED IN CATALYSIS WITH PHENYLACETIC ACID IN THE ACTIVE SITE
8AVN	;	1.65	;	Mutant of Superoxide dismutase SodFM1 from CPR Parcubacteria Wolfebacteria
8AVM	;	2.0	;	Mutant of Superoxide Dismutase sodfm2 from Bacteroides fragilis
3PRT	;	1.66	;	Mutant of the Carboxypeptidase T
2BVZ	;	2.2	;	Mutant of the Ribosomal Protein S6
2LPA	;		;	Mutant of the sub-genomic promoter from Brome Mosaic Virus
3HFY	;	2.0	;	Mutant of tRNA-guanine transglycosylase (K52M)
6HF1	;	1.94	;	Mutant oxidoreductase fragment of mouse QSOX1 in complex with an antibody Fab
3NMA	;	2.6	;	Mutant P169S of Foot-and-mouth disease Virus RNA dependent RNA-polymerase
4D4F	;	2.34	;	Mutant P250A of bacterial chalcone isomerase from Eubacterium ramulus
3NL0	;	2.6	;	Mutant P44S M296I of Foot-and-mouth disease Virus RNA-dependent RNA polymerase
4IQX	;	2.5	;	Mutant P44S P169S M296I of Foot-and-mouth disease Virus RNA-dependent RNA polymerase
1E4Y	;	1.85	;	Mutant P9L of adenylate kinase from E. coli, modified in the Gly-loop
1E0Q	;		;	Mutant Peptide from the first N-terminal 17 amino-acid of Ubiquitin
6JUP	;	2.44	;	Mutant PolIV-DNA incoming nucleotide complex
6JUQ	;	2.74	;	mutant PolIV-DNA incoming nucleotide complex 2
1CJ4	;	2.4	;	MUTANT Q34T OF PARA-HYDROXYBENZOATE HYDROXYLASE
1CXX	;		;	MUTANT R122A OF QUAIL CYSTEINE AND GLYCINE-RICH PROTEIN, NMR, MINIMIZED STRUCTURE
8PBR	;	2.06	;	Mutant R1475Q of the dihydroorotase domain of human CAD protein in apo form
4ZGD	;	2.25	;	Mutant R157A of Fe-Type Nitrile Hydratase from Comamonas testosteroni Ni1
8PBI	;	1.5	;	Mutant R1617Q of the dihydroorotase domain of human CAD protein bound to the inhibitor fluoroorotate
8PBH	;	1.87	;	Mutant R1617Q of the dihydroorotase domain of human CAD protein bound to the substrate carbamoyl aspartate
8PBK	;	1.69	;	Mutant R1722W of the dihydroorotase domain of human CAD protein bound to the inhibitor fluoorotate
8PBJ	;	1.55	;	Mutant R1722W of the dihydroorotase domain of human CAD protein bound to the substrate carbamoyl aspartate
8PBP	;	1.54	;	Mutant R1785C of the dihydroorotase domain of human CAD protein bound to the substrate carbamoyl aspartate
8PBN	;	1.71	;	Mutant R1789Q of the dihydroorotase domain of human CAD protein bound to the inhibitor fluoorotate
8PBM	;	1.28	;	Mutant R1789Q of the dihydroorotase domain of human CAD protein bound to the substrate dihydroorotate
8PBQ	;	1.54	;	Mutant R1810Q of the dihydroorotase domain of human CAD protein bound to the substrates
2FEM	;	1.9	;	Mutant R188M of the Cytidine Monophosphate Kinase From E. Coli
2FEO	;	2.8	;	Mutant R188M of The Cytidine Monophosphate Kinase from E. coli complexed with dCMP
2EN5	;	1.9	;	Mutant R262H structure of PH0725 from Pyrococcus horikoshii OT3
6FF9	;	2.0	;	Mutant R280K of human P53
2V2N	;	1.55	;	Mutant R59M recombinant horse spleen apoferritin cocrystallized with haemin in acidic conditions
2V2O	;	1.87	;	Mutant R59M recombinant horse spleen apoferritin cocrystallized with haemin in basic conditions
2V2S	;	1.37	;	Mutant R59M recombinant horse spleen apoferritin crystallized in acidic conditions
1AE3	;	2.0	;	MUTANT R82C OF GENE V PROTEIN (SINGLE-STRANDED DNA BINDING PROTEIN)
3C7Y	;	1.95	;	Mutant R96A OF T4 lysozyme in wildtype background at 298K
4REO	;	1.35	;	Mutant ribosomal protein l1 from thermus thermophilus with threonine 217 replaced by valine
3TG8	;	1.95	;	Mutant ribosomal protein L1 lacking ala158 from thermus thermophilus
8JZI	;	1.76	;	Mutant S-adenosylmethionine synthase from C. glutamicum
7R2W	;	1.6	;	Mutant S-adenosylmethionine synthetase from E.coli complexed with AMPPNP and methionine
2ED5	;	2.1	;	Mutant S147M structure of PH0725 from Pyrococcus horikoshii OT3
4KQX	;	1.8	;	Mutant Slackia exigua KARI DDV in complex with NAD and an inhibitor
7ENO	;	3.15	;	Mutant strain M3 of foot-and-mouth disease virus type O
1M03	;	1.9	;	Mutant Streptomyces plicatus beta-hexosaminidase (D313A) in complex with product (GlcNAc)
1M04	;	1.95	;	Mutant Streptomyces plicatus beta-hexosaminidase (D313N) in complex with product (GlcNAc)
4H0F	;	2.4	;	Mutant Structure of laminin-binding adhesin (Lmb) from Streptococcus agalactiae
4M72	;	2.1	;	Mutant structure of methyltransferase from Streptomyces hygroscopicus
4M73	;	2.0	;	Mutant structure of methyltransferase from Streptomyces hygroscopicus
4M74	;	2.2	;	Mutant structure of methyltransferase from Streptomyces hygroscopicus
4M6X	;	2.3	;	Mutant structure of methyltransferase from Streptomyces hygroscopicus complexed with S-adenosyl-L-homocysteine and methylphenylpyruvic acid
4M6Y	;	2.5	;	Mutant structure of methyltransferase from Streptomyces hygroscopicus complexed with S-adenosyl-L-homocysteine and methylphenylpyruvic acid
4M71	;	2.21	;	Mutant structure of methyltransferase from Streptomyces hygroscopicus complexed with S-adenosyl-L-homocysteine and methylphenylpyruvic acid
3W8R	;	2.5	;	Mutant structure of Thermus thermophilus HB8 uridine-cytidine kinase
5UTL	;	1.92	;	Mutant Structures of Streptococcus Agalactiae GBS Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH)
5UTM	;	1.77	;	Mutant Structures of Streptococcus Agalactiae GBS Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH)
5V8X	;	2.95	;	Mutant Structures of Streptococcus Agalactiae GBS Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH)
5V8Y	;	1.95	;	Mutant Structures of Streptococcus Agalactiae GBS Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH)
2EH4	;	2.1	;	Mutant T146M structure of PH0725 from Pyrococcus horikoshii OT3
5OMW	;	2.6	;	Mutant T252A of E. coli leucyl-tRNA synthetase, tRNA(leu) and leucyl-adenylate analogue in the aminoacylation conformation
7Q30	;	1.901	;	Mutant T91A of uridine phosphorylase from Shewanella oneidensis
7Q2W	;	1.654	;	Mutant T91S of uridine phosphorylase from Shewanella oneidensis
5DIM	;	3.32	;	Mutant toxin in 'native' space group
3KXC	;	2.0	;	Mutant transport protein
1O8X	;	1.3	;	Mutant tryparedoxin-I Cys43Ala
1CJ3	;	2.5	;	MUTANT TYR38GLU OF PARA-HYDROXYBENZOATE HYDROXYLASE
2ELE	;	2.4	;	Mutant V18C structure of PH0725 from Pyrococcus horikoshii OT3
2EH2	;	2.0	;	Mutant V18M structure of PH0725 from Pyrococcus horikoshii OT3
2E4N	;	1.8	;	Mutant V251M structure of PH0725 from Pyrococcus horikoshii OT3
7DHB	;	3.02	;	mutant V507M coiled coil domain of Trypanosoma brucei coronin
7NYM	;	1.614	;	Mutant V517A - SH3 domain of JNK-interacting Protein 1 (JIP1)
7NZB	;	1.959	;	Mutant V517L of the SH3 domain of JNK-interacting protein 1 (JIP1)
2VNL	;	1.8	;	MUTANT Y108Wdel OF THE HEADBINDING DOMAIN OF PHAGE P22 TAILSPIKE C- TERMINally fused to ISOLEUCINE ZIPPER pIIGCN4 (chimera II)
2EEQ	;	2.5	;	Mutant Y29M structure of PH0725 from Pyrococcus horikoshii OT3
7NYN	;	1.537	;	Mutant Y526A of SH3 domain of JNK-interacting Protein 1 (JIP1)
2ENW	;	2.1	;	Mutant Y92H structure of TTHB049 from Thermus thermophilus HB8
1UCI	;	1.8	;	Mutants of RNase Sa
1UCJ	;	1.81	;	Mutants of RNase Sa
1UCK	;	1.8	;	Mutants of RNase Sa
1UCL	;	1.82	;	Mutants of RNase Sa
1UYQ	;	2.2	;	mutated b-glucosidase A from Paenibacillus polymyxa showing increased stability
2L2A	;		;	Mutated Domain 11 of the Cytoplasmic region of the Cation-independent mannose-6-phosphate receptor
2GHM	;	2.35	;	Mutated MAP kinase P38 (Mus Musculus) in complex with Inhbitor PG-895449
2GTN	;	1.8	;	Mutated MAP kinase P38 (Mus Musculus) in complex with Inhbitor PG-951717
2GTM	;	1.9	;	Mutated Mouse P38 MAP Kinase Domain in complex with Inhibitor PG-892579
1YW2	;	2.01	;	Mutated Mus Musculus P38 Kinase (mP38)
3KBD	;		;	MUTATED NF KAPPA-B SITE, BI MODEL
1D1K	;	2.0	;	MUTATED SHIGA-LIKE TOXIN B SUBUNIT (D17E/W34A) COMPLEXED WITH RECEPTOR GB3 ANALOGUE
1C4Q	;	1.52	;	MUTATED SHIGA-LIKE TOXIN B SUBUNIT (F30A/W34A) COMPLEXED WITH RECEPTOR GB3 ANALOGUE
1C48	;	1.6	;	MUTATED SHIGA-LIKE TOXIN B SUBUNIT (G62T)
1D1I	;	1.7	;	MUTATED SHIGA-LIKE TOXIN B SUBUNIT (W34A) COMPLEXED WITH RECEPTOR GB3 ANALOGUE
6MFH	;	2.04	;	Mutated Uronate Dehydrogenase
5ZLM	;	1.7	;	Mutation in the trinuclear site of CotA-laccase: H491C mutant, PH 8.0
5ZLK	;	2.6	;	Mutation in the trinuclear site of CotA-laccase: H493A mutant, PH 8.0
5ZLL	;	2.6	;	Mutation in the trinuclear site of CotA-laccase: H493C mutant, PH 8.0
1HTL	;	2.5	;	MUTATION OF A BURIED RESIDUE CAUSES LACK OF ACTIVITY BUT NO CONFORMATIONAL CHANGE: CRYSTAL STRUCTURE OF E. COLI HEAT-LABILE ENTEROTOXIN MUTANT VAL 97--> LYS
1MG2	;	2.25	;	MUTATION OF ALPHA PHE55 OF METHYLAMINE DEHYDROGENASE ALTERS THE REORGANIZATION ENERGY AND ELECTRONIC COUPLING FOR ITS ELECTRON TRANSFER REACTION WITH AMICYANIN
1MG3	;	2.4	;	MUTATION OF ALPHA PHE55 OF METHYLAMINE DEHYDROGENASE ALTERS THE REORGANIZATION ENERGY AND ELECTRONIC COUPLING FOR ITS ELECTRON TRANSFER REACTION WITH AMICYANIN
3FZD	;	2.35	;	Mutation of Asn28 disrupts the enzymatic activity and dimerization of SARS 3CLpro
3MYM	;	1.72	;	Mutation of Methionine-86 in Dehaloperoxidase-hemoglobin: Effects of the Asp-His-Fe Triad in a 3/3 Globin
3MYN	;	2.194	;	Mutation of Methionine-86 in Dehaloperoxidase-hemoglobin: Effects of the Asp-His-Fe Triad in a 3/3 Globin
2GTI	;	2.15	;	mutation of MHV coronavirus non-structural protein nsp15 (F307L)
3TK0	;	1.611	;	mutation of sfALR
2WVJ	;	2.2	;	Mutation of Thr163 to Ser in Human Thymidine Kinase Shifts the Specificity from Thymidine towards the Nucleoside Analogue Azidothymidine
1CTY	;	2.2	;	MUTATION OF TYROSINE-67 IN CYTOCHROME C SIGNIFICANTLY ALTERS THE LOCAL HEME ENVIRONMENT
1CTZ	;	1.9	;	MUTATION OF TYROSINE-67 IN CYTOCHROME C SIGNIFICANTLY ALTERS THE LOCAL HEME ENVIRONMENT
1JQ0	;	1.7	;	Mutation that destabilize the gp41 core: determinants for stabilizing the SIV/CPmac envelope glycoprotein complex. Mutant structure.
1JPX	;	2.3	;	Mutation that destabilize the gp41 core: determinants for stabilizing the SIV/CPmac envelope glycoprotein complex. Wild type.
4G38	;	1.56	;	Mutational analysis of sulfite reductase hemoprotein reveals the mechanism for coordinated electron and proton transfer
4G39	;	2.4	;	Mutational analysis of sulfite reductase hemoprotein reveals the mechanism for coordinated electron and proton transfer
1BCX	;	1.81	;	MUTATIONAL AND CRYSTALLOGRAPHIC ANALYSES OF THE ACTIVE SITE RESIDUES OF THE BACILLUS CIRCULANS XYLANASE
7ANV	;	1.65	;	Mutational and structural analysis of an ancestral D-type dye decolorizing peroxidase
2R49	;	2.2	;	Mutational and Structural Studies of E85I Reveal the Flexible Loops of Fibrobacter succinogenes 1,3-1,4-beta-D-GlucanaseGlucanase
2ZCF	;	1.43	;	Mutational study on Alpha-Gln90 of Fe-type nitrile hydratase from Rhodococcus sp. N771
3JTQ	;	2.2	;	Mutations in Cephalosporin Acylase Affecting Stability and Autoproteolysis
3JTR	;	2.5	;	Mutations in Cephalosporin Acylase Affecting Stability and Autoproteolysis
6SLC	;	2.3	;	Mutations in SsgB correlate to longitudinal cell division during sporulation of Streptomyces coelicolor
6SUJ	;	3.2	;	Mutations in SsgB correlate to longitudinal cell division during sporulation of Streptomyces coelicolor
5A36	;	2.0	;	Mutations in the Calponin homology domain of Alpha-Actinin-2 affect Actin binding and incorporation in muscle.
5A37	;	1.88	;	Mutations in the Calponin homology domain of Alpha-Actinin-2 affect Actin binding and incorporation in muscle.
5A38	;	1.9	;	Mutations in the Calponin homology domain of Alpha-Actinin-2 affect Actin binding and incorporation in muscle.
5A4B	;	2.01	;	Mutations in the Calponin homology domain of Alpha-Actinin-2 affect Actin binding and incorporation in muscle.
2JWZ	;		;	Mutations in the hydrophobic core of ubiquitin differentially affect its recognition by receptor proteins
4A66	;	1.95	;	Mutations in the neighbourhood of CotA-laccase trinuclear site: D116A mutant
4A67	;	2.1	;	Mutations in the neighbourhood of CotA-laccase trinuclear site: D116E mutant
4A68	;	2.0	;	Mutations in the neighbourhood of CotA-laccase trinuclear site: D116N mutant
4AKQ	;	2.1	;	Mutations in the neighbourhood of CotA-laccase trinuclear site: E498D mutant
4AKO	;	1.7	;	Mutations in the neighbourhood of CotA-laccase trinuclear site: E498L mutant
4AKP	;	2.0	;	Mutations in the neighbourhood of CotA-laccase trinuclear site: E498T mutant
1OOC	;	2.94	;	Mutations in the T1.5 loop of pectate lyase A
1PE9	;	1.6	;	MUTATIONS IN THE T1.5 LOOP OF PECTATE LYASE A
2FUS	;	2.2	;	MUTATIONS OF FUMARASE THAT DISTINGUISH BETWEEN THE ACTIVE SITE AND A NEARBY DICARBOXYLIC ACID BINDING SITE
4Q1W	;	1.85	;	Mutations Outside the Active Site of HIV-1 Protease Alter Enzyme Structure and Dynamic Ensemble of the Active Site to Confer Drug Resistance
4Q1X	;	1.9	;	Mutations Outside the Active Site of HIV-1 Protease Alter Enzyme Structure and Dynamic Ensemble of the Active Site to Confer Drug Resistance
4Q1Y	;	1.5	;	Mutations Outside the Active Site of HIV-1 Protease Alter Enzyme Structure and Dynamic Ensemble of the Active Site to Confer Drug Resistance
4H7V	;	1.8	;	MUTB inactive double mutant D200A-D415N in complex with GLUCOSE
4HA1	;	2.2	;	MutB inactive double mutant D200A-D415N in complex with isomaltulose
4H8U	;	2.0	;	MUTB inactive double mutant D200A-D415N soaked with sucrose and having as bound ligands sucrose in molecule A and the reaction product trehalulose in molecule B
4H8H	;	2.0	;	MUTB inactive double mutant E254Q-D415N
1B62	;	2.1	;	MUTL COMPLEXED WITH ADP
1B63	;	1.9	;	MUTL COMPLEXED WITH ADPNP
1R2Z	;	1.63	;	MutM (Fpg) bound to 5,6-dihydrouracil (DHU) containing DNA
1R2Y	;	2.34	;	MutM (Fpg) bound to 8-oxoguanine (oxoG) containing DNA
1L1T	;	1.8	;	MutM (Fpg) Bound to Abasic-Site Containing DNA
1L1Z	;	1.7	;	MutM (Fpg) Covalent-DNA Intermediate
1L2B	;	2.4	;	MutM (Fpg) DNA End-Product Structure
1L2D	;	2.0	;	MutM (Fpg)-DNA Estranged Guanine Mismatch Recognition Complex
1L2C	;	2.2	;	MutM (Fpg)-DNA Estranged Thymine Mismatch Recognition Complex
4G4R	;	1.95	;	MutM containing F114A mutation bound to oxoG-containing DNA
4G4Q	;	1.86	;	MutM containing F114A mutation bound to undamaged DNA
4G4O	;	1.95	;	MutM containing M77A mutation bound to oxoG-containing DNA
4G4N	;	1.85	;	MutM containing M77A mutation bound to undamaged DNA
2F5N	;	2.0	;	MutM crosslinked to undamaged DNA sampling A:T base pair IC1
2F5P	;	2.0	;	MutM crosslinked to undamaged DNA sampling A:T base pair IC2
2F5O	;	2.05	;	MutM crosslinked to undamaged DNA sampling G:C base pair IC3
3GO8	;	1.89	;	MutM encountering an intrahelical 8-oxoguanine (oxoG) lesion in EC3-loop deletion complex
3GPP	;	2.15	;	MutM encountering an intrahelical 8-oxoguanine (oxoG) lesion in EC3-T224P complex
3GP1	;	2.05	;	MutM encountering an intrahelical 8-oxoguanine (oxoG) lesion in EC3-V222P complex
3GPU	;	1.62	;	MutM encountering an intrahelical 8-oxoguanine (oxoG) lesion in EC4-loop deletion complex
3GQ3	;	1.83	;	MutM encountering an intrahelical 8-oxoguanine (oxoG) lesion in EC5-loop deletion complex
3JR4	;	2.601	;	MutM interrogating an extrahelical G
3SAU	;	1.65	;	MUTM Interrogation complex 6
3JR5	;	1.704	;	MutM lesion recognition control complex with N174C crosslinking site
3U6O	;	1.9	;	MutM set 1 ApG
3U6C	;	1.8	;	MutM set 1 ApGo
3U6P	;	1.6	;	MutM set 1 GpG
3U6D	;	1.87	;	MutM set 1 GpGo
3U6S	;	1.77	;	MutM set 1 TpG
3U6E	;	1.7	;	MutM set 1 TpGo
3U6Q	;	1.981	;	MutM set 2 ApGo
3U6L	;	1.97	;	MutM set 2 CpGo
3SAR	;	1.95	;	MUTM Slanted complex 1
3SAS	;	2.05	;	MUTM Slanted complex 4 with R112A mutation
3SAT	;	2.15	;	MUTM Slanted complex 6 with R112A mutation
3SBJ	;	2.1	;	MutM slanted complex 7
3SAV	;	2.125	;	MUTM Slanted complex 8
3SAW	;	2.35	;	MUTM Slanted complex 8 with R112A mutation
5XAE	;	1.996	;	mutNLIR_LC3B
2OK2	;	2.0	;	MutS C-terminal domain fused to Maltose Binding Protein
5AKB	;	4.71	;	MutS in complex with the N-terminal domain of MutL - crystal form 1
5AKC	;	6.6	;	MutS in complex with the N-terminal domain of MutL - crystal form 2
5AKD	;	7.6	;	MutS in complex with the N-terminal domain of MutL - crystal form 3
7AI7	;	3.9	;	MutS in Intermediate state
7AI6	;	6.9	;	MutS in mismatch bound state
7AI5	;	4.4	;	MutS in Scanning state
7AIB	;	4.7	;	MutS-MutL in clamp state
7AIC	;	5.0	;	MutS-MutL in clamp state (kinked clamp domain)
8OLX	;	3.1	;	MutSbeta bound to (CAG)2 DNA (canonical form)
8OM9	;	3.32	;	MutSbeta bound to (CAG)2 DNA (open form)
8OMA	;	3.29	;	MutSbeta bound to 61bp homoduplex DNA
1TUM	;		;	MUTT PYROPHOSPHOHYDROLASE-METAL-NUCLEOTIDE-METAL COMPLEX, NMR, 16 STRUCTURES
1KBH	;		;	Mutual Synergistic Folding in the Interaction Between Nuclear Receptor Coactivators CBP and ACTR
6U7T	;	2.0	;	MutY adenine glycosylase bound to DNA containing a transition state analog (1N) paired with d(8-oxo-G)
6Q0C	;	2.0	;	MutY adenine glycosylase bound to DNA containing a transition state analog (1N) paired with undamaged dG
1VRL	;	2.5	;	MutY adenine glycosylase in complex with DNA and soaked adenine free base
1RRQ	;	2.22	;	MutY adenine glycosylase in complex with DNA containing an A:oxoG pair
1RRS	;	2.4	;	MutY adenine glycosylase in complex with DNA containing an abasic site
5KN9	;	1.93	;	MutY N-terminal domain in complex with DNA containing an intrahelical oxoG:A base-pair
5KN8	;	1.81	;	MutY N-terminal domain in complex with undamaged DNA
5HWO	;	1.48	;	MvaS in complex with 3-hydroxy-3-methylglutaryl coenzyme A
5HWQ	;	1.5	;	MvaS in complex with acetoacetyl coenzyme A
5HWR	;	1.5	;	MvaS in complex with coenzyme A
5HWP	;	2.2	;	MvaS with acetylated Cys115 in complex with coenzyme A
7BXF	;	2.7	;	MvcA-Lpg2149 complex
7PNN	;	1.43	;	mVenus released from fusion protein.
2OKZ	;	1.8	;	MVGGVV peptide derived from Alzheimer's A-beta
2ONA	;	2.03	;	MVGGVV peptide derived from Alzheimer's A-beta, residues 35-40
6A3C	;	2.35	;	MVM NES mutant Nm12 in complex with CRM1-Ran-RanBP1
6A3B	;	2.51	;	MVM NES mutant Nm13 in complex with CRM1-Ran-RanBP1
6A3E	;	2.7	;	MVM NES mutant Nm15 in complex with CRM1-Ran-RanBP1
6A3A	;	2.3	;	MVM NES mutant Nm2 in complex with CRM1-Ran-RanBP1
6KFT	;	2.51	;	MVM NS2 mutant Nm42 in complex with CRM1-Ran-RanBP1
6A38	;	2.69	;	MVM NS2 NES in complex with CRM1-Ran-RanBP1
1MVM	;	3.5	;	MVM(STRAIN I), COMPLEX(VIRAL COAT/DNA), VP2, PH=7.5, T=4 DEGREES C
4NRW	;	2.845	;	MvNei1-G86D
7U32	;	3.46	;	MVV cleaved synaptic complex (CSC) intasome at 3.4 A resolution
7Z1Z	;	3.5	;	MVV strand transfer complex (STC) intasome in complex with LEDGF/p75 at 3.5 A resolution
8TUU	;	2.5	;	MW Polyomavirus LTA bipartite NLS bound to importin alpha 2
6RWK	;	3.86	;	MxiD N0 N1 and MxiG C-terminal domains of the Shigella type 3 secretion system
2CA5	;	2.1	;	MxiH needle protein of Shigella Flexneri (monomeric form, residues 1- 78)
6NEB	;		;	MYC Promoter G-Quadruplex with 1:6:1 loop length
8OTT	;	3.3	;	MYC-MAX bound to a nucleosome at SHL+5.8
4RRU	;	2.1	;	Myc3 N-terminal JAZ-binding domain[5-242] from arabidopsis
3SSM	;	2.247	;	MycE Methyltransferase from the Mycinamycin Biosynthetic Pathway in Complex with Mg and SAH, Crystal form 1
3SSO	;	1.895	;	MycE Methyltransferase from the Mycinamycin Biosynthetic Pathway in Complex with Mg and SAH, Crystal form 2
3SSN	;	2.392	;	MycE Methyltransferase from the Mycinamycin Biosynthetic Pathway in Complex with Mg, SAH, and Mycinamycin VI
4X7X	;	1.75	;	MycF mycinamicin III 3'-O-methyltransferase (E35Q, E139A variant) in complex with Mg, SAH and macrocin
4X7V	;	1.45	;	MycF mycinamicin III 3'-O-methyltransferase (E35Q, E139A variant) in complex with Mg, SAH and mycinamicin IV (product)
4X7W	;	1.75	;	MycF mycinamicin III 3'-O-methyltransferase (E35Q, E139A variant) in complex with Mg, SAH and mycinamicin VI (MycE substrate)
4X7Y	;	1.4	;	MycF mycinamicin III 3'-O-methyltransferase (E35Q, M56A, E139A variant) in complex with Mg and SAH
4X7Z	;	1.44	;	MycF mycinamicin III 3'-O-methyltransferase (E35Q, M56A, E139A variant) in complex with Mg, SAH and mycinamicin III (substrate)
4X81	;	1.59	;	MycF mycinamicin III 3'-O-methyltransferase (E35Q, M56A, E139A variant) in complex with Mg, SAH and mycinamicin VI (MycE substrate)
4XVZ	;	2.49	;	MycF mycinamicin III 3'-O-methyltransferase in complex with Mg
4X7U	;	1.65	;	MycF mycinamicin III 3'-O-methyltransferase in complex with Mg, SAH and mycinamicin III (substrate)
4XVY	;	2.42	;	MycF mycinamicin III 3'-O-methyltransferase in complex with SAH
6RCX	;	2.0	;	Mycobacterial 4'-phosphopantetheinyl transferase PptAb in complex with the ACP domain of PpsC.
1Y11	;	3.3	;	Mycobacterial adenylyl cyclase Rv1264, holoenzyme, active state
1Y10	;	2.3	;	Mycobacterial adenylyl cyclase Rv1264, holoenzyme, inhibited state
7RH5	;	3.0	;	Mycobacterial CIII2CIV2 supercomplex, Inhibitor free
7RH6	;	3.5	;	Mycobacterial CIII2CIV2 supercomplex, inhibitor free, -Lpqe cyt cc open
7RH7	;	3.0	;	Mycobacterial CIII2CIV2 supercomplex, Telacebec (Q203) bound
6NHX	;	1.4	;	mycobacterial DNA ligase D complexed with ATP and MES
6NHZ	;	1.8	;	mycobacterial DNA ligase D complexed with ATP and Mg
6DZS	;	2.62	;	Mycobacterial homoserine dehydrogenase ThrA in complex with NADP
6CYZ	;	2.04	;	Mycobacterial homoserine kinase ThrB in complex with AMPPNP
6S2Q	;	2.5	;	Mycobacterial hydrolase 1
6S2R	;	1.45	;	Mycobacterial hydrolase 2
6G3N	;	2.32	;	Mycobacterial hydrolase complex 14.
2GAZ	;	2.61	;	Mycobacterial lipoglycan presentation by CD1d
4Y0L	;	2.4	;	Mycobacterial membrane protein MmpL11D2
4WJ2	;	2.8	;	Mycobacterial protein
4Y6U	;	2.271	;	Mycobacterial protein
8E9G	;	2.6	;	Mycobacterial respiratory complex I with both quinone positions modelled
8E9H	;	2.7	;	Mycobacterial respiratory complex I, fully-inserted quinone
8E9I	;	2.8	;	Mycobacterial respiratory complex I, semi-inserted quinone
7P5X	;	3.2	;	Mycobacterial RNAP with transcriptional activator PafBC
6BLK	;	1.552	;	Mycobacterial sensor histidine kinase MprB
8EDU	;	2.7	;	Mycobacteriophage Muddy capsid
5DB4	;	2.28	;	Mycobacterium abscessus NadD in complex with Mg-ATP, space group I41
5DEO	;	2.22	;	Mycobacterium abscessus NadD in complex with nicotinic acid adenine dinucleotide
7YY1	;	1.697	;	Mycobacterium abscessus Phosphopantetheine adenylyltransferase ternary complex with 4'-phosphopantetheine & non-hydrolyzable ATP analogue (AMPCPP)
7REY	;	1.87	;	MYCOBACTERIUM ABSCESSUS TRNA METHYLTRANSFERASE IN APO FORM
7REZ	;	1.64	;	MYCOBACTERIUM ABSCESSUS TRNA METHYLTRANSFERASE IN COMPLEX WITH S-ADENOSYL-L-HOMOCYSTEINE
7RF0	;	1.59	;	MYCOBACTERIUM ABSCESSUS TRNA METHYLTRANSFERASE IN COMPLEX WITH S-ADENOSYL-L-HOMOCYSTEINE AND MAGNESIUM
2W3W	;	1.6	;	MYCOBACTERIUM AVIUM DIHYDROFOLATE REDUCTASE COMPLEXED WITH NADPH AND A LIPOPHILIC ANTIFOLATE SELECTIVE FOR M. AVIUM DHFR, 6-((2,5- DIETHOXYPHENYL)AMINOMETHYL)-2,4-DIAMINO-5-METHYLPYRIDO(2,3-D) PYRIMIDINE (SRI-8686)
2W3V	;	1.89	;	MYCOBACTERIUM AVIUM DIHYDROFOLATE REDUCTASE COMPLEXED WITH NADPH AND TRIMETHOPRIM
4R9Z	;	2.6	;	Mycobacterium avium subs paratuberculosis tesB protein MAP1729c
7BZ6	;	3.302	;	Mycobacterium bovis AhpC
1HKV	;	2.6	;	mycobacterium diaminopimelate dicarboxylase (lysa)
1HKW	;	2.8	;	MYCOBACTERIUM DIAMINOPIMELATE DICARBOXYLASE (LysA)
2NTV	;	2.1	;	Mycobacterium leprae InhA bound with PTH-NAD adduct
6CVC	;	2.2	;	Mycobacterium marinum cytochrome P450 CYP124A1 in the substrate-free form
6DCD	;	1.55	;	Mycobacterium marinum cytochrome P450 CYP150A6 in the substrate-free form
6BLD	;	1.997	;	Mycobacterium marinum cytochrome P450 CYP268A2 in complex with pseudoionone
8EC2	;	2.4	;	Mycobacterium phage Adephagia
8SAJ	;	2.66	;	Mycobacterium phage Adjutor
8EC8	;	2.5	;	Mycobacterium phage Bobi
8ECJ	;	2.9	;	Mycobacterium phage Cain
8E16	;	2.5	;	Mycobacterium phage Che8
8ECN	;	2.7	;	Mycobacterium phage Ogopogo
8GIU	;	2.39	;	Mycobacterium phage Patience
2UZH	;	2.2	;	Mycobacterium smegmatis 2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase (IspF)
7Y41	;	4.1	;	Mycobacterium smegmatis 50S ribosomal subunit from Log Phase of growth
7XAM	;	3.5	;	Mycobacterium smegmatis 50S ribosomal subunit from Stationary phase of growth
7BWR	;	3.5	;	Mycobacterium smegmatis arabinosyltransferase complex EmbB2-AcpM2 in substrate DPA bound asymmetric ""active state""
7BX8	;	3.6	;	Mycobacterium smegmatis arabinosyltransferase complex EmbB2-AcpM2 in symmetric ""resting state""
7NKD	;	3.12	;	Mycobacterium smegmatis ATP synthase b-delta state 1
7NKL	;	3.67	;	Mycobacterium smegmatis ATP synthase b-delta state 2
7NKQ	;	2.98	;	Mycobacterium smegmatis ATP synthase b-delta state 3
7NK7	;	2.11	;	Mycobacterium smegmatis ATP synthase F1 state 1
7NKH	;	2.78	;	Mycobacterium smegmatis ATP synthase F1 state 2
7NKJ	;	2.17	;	Mycobacterium smegmatis ATP synthase F1 state 3
7NJT	;	2.75	;	Mycobacterium smegmatis ATP synthase Fo combined all classes
7NJU	;	3.74	;	Mycobacterium smegmatis ATP synthase Fo combined class 1
7NJV	;	2.9	;	Mycobacterium smegmatis ATP synthase Fo combined class 2
7NJW	;	3.67	;	Mycobacterium smegmatis ATP synthase Fo combined class 3
7NJX	;	4.32	;	Mycobacterium smegmatis ATP synthase Fo combined class 4
7NJY	;	2.94	;	Mycobacterium smegmatis ATP synthase Fo combined class 5
7NK9	;	2.9	;	Mycobacterium smegmatis ATP synthase Fo domain state 1
7NKP	;	4.06	;	Mycobacterium smegmatis ATP synthase Fo state 2
7NL9	;	2.86	;	Mycobacterium smegmatis ATP synthase Fo state 3
7NKB	;	2.9	;	Mycobacterium smegmatis ATP synthase rotor state 1
7NKK	;	3.6	;	Mycobacterium smegmatis ATP synthase rotor state 2
7NKN	;	2.71	;	Mycobacterium smegmatis ATP synthase rotor state 3
7NJK	;	2.52	;	Mycobacterium smegmatis ATP synthase state 1a
7NJL	;	2.71	;	Mycobacterium smegmatis ATP synthase state 1b
7NJM	;	2.84	;	Mycobacterium smegmatis ATP synthase state 1c
7NJN	;	2.64	;	Mycobacterium smegmatis ATP synthase state 1d
7NJO	;	2.92	;	Mycobacterium smegmatis ATP synthase state 1e
7NJP	;	2.84	;	Mycobacterium smegmatis ATP synthase state 2
7NJQ	;	2.67	;	Mycobacterium smegmatis ATP synthase state 3a
7NJR	;	2.56	;	Mycobacterium smegmatis ATP synthase state 3b
7NJS	;	2.46	;	Mycobacterium smegmatis ATP synthase state 3c
6C33	;	1.8	;	Mycobacterium smegmatis DNA flap endonuclease
6C34	;	2.2	;	Mycobacterium smegmatis DNA flap endonuclease mutant D125N
4G3T	;	2.346	;	Mycobacterium smegmatis DprE1 - hexagonal crystal form
4G3U	;	2.689	;	Mycobacterium smegmatis DprE1 - monoclinic crystal form
1VEI	;	2.85	;	Mycobacterium smegmatis Dps
1VEQ	;	3.98	;	Mycobacterium smegmatis Dps Hexagonal form
1VEL	;	2.99	;	Mycobacterium smegmatis Dps tetragonal form
5H46	;	2.85	;	Mycobacterium smegmatis Dps1 mutant - F47E
6C35	;	1.803	;	Mycobacterium smegmatis flap endonuclease mutant D148N
6C36	;	1.9	;	Mycobacterium smegmatis flap endonuclease mutant D208N
6Y8O	;	1.6	;	Mycobacterium smegmatis GyrB 22kDa ATPase sub-domain in complex with novobiocin
7CAG	;	3.78	;	Mycobacterium smegmatis LpqY-SugABC complex in the catalytic intermediate state
7CAF	;	3.3	;	Mycobacterium smegmatis LpqY-SugABC complex in the pre-translocation state
7CAE	;	3.44	;	Mycobacterium smegmatis LpqY-SugABC complex in the resting state
5KEI	;	2.325	;	Mycobacterium smegmatis MbtA apo structure
6C30	;	1.397	;	Mycobacterium smegmatis RimJ (apo form)
6C37	;	1.696	;	Mycobacterium smegmatis RimJ in complex with CoA-disulfide
6C32	;	1.898	;	Mycobacterium smegmatis RimJ with AcCoA
7D6X	;	2.88	;	Mycobacterium smegmatis Sdh1 complex in the apo form
7D6V	;	2.53	;	Mycobacterium smegmatis Sdh1 in complex with UQ1
1TEX	;	2.6	;	Mycobacterium smegmatis Stf0 Sulfotransferase with Trehalose
7CAD	;	3.41	;	Mycobacterium smegmatis SugABC complex
6Y8L	;	1.4	;	Mycobacterium thermoresistibile GyrB21 in complex with novobiocin
6Y8N	;	1.5	;	Mycobacterium thermoresistibile GyrB21 in complex with Redx03863
8EM5	;	1.95	;	Mycobacterium thermoresistible MmpS5
7CLL	;	1.99	;	Mycobacterium tubeculosis enolase in complex with 2-Phosphoglycerate
5Y8G	;	2.01	;	Mycobacterium tuberculosis 3-Hydroxyisobutyrate Dehydrogenase (MtHIBADH)
5Y8J	;	1.86	;	Mycobacterium tuberculosis 3-Hydroxyisobutyrate dehydrogenase (MtHIBADH) + (R)-3-hydroxyisobutyrate (R-HIBA)
5Y8I	;	2.04	;	Mycobacterium tuberculosis 3-Hydroxyisobutyrate dehydrogenase (MtHIBADH) + (S)-3-hydroxyisobutyrate (S-HIBA)
5Y8P	;	2.15	;	Mycobacterium tuberculosis 3-Hydroxyisobutyrate dehydrogenase (MtHIBADH) + 3-Hydroxy propionate (3-HP)
5Y8K	;	2.04	;	Mycobacterium tuberculosis 3-Hydroxyisobutyrate dehydrogenase (MtHIBADH) + L-serine
5Y8M	;	2.04	;	Mycobacterium tuberculosis 3-Hydroxyisobutyrate dehydrogenase (MtHIBADH) + NAD + (R)-3-hydroxyisobutyrate (R-HIBA)
5Y8O	;	2.05	;	Mycobacterium tuberculosis 3-Hydroxyisobutyrate dehydrogenase (MtHIBADH) + NAD + 3-Hydroxy propionate (3-HP)
5Y8N	;	2.68	;	Mycobacterium tuberculosis 3-Hydroxyisobutyrate dehydrogenase (MtHIBADH) + NAD + L-serine
5Y8L	;	1.85	;	Mycobacterium tuberculosis 3-Hydroxyisobutyrate dehydrogenase (MtHIBADH) + NAD +(S)-3-hydroxyisobutyrate (S-HIBA)
5Y8H	;	2.1	;	Mycobacterium tuberculosis 3-Hydroxyisobutyrate dehydrogenase (MtHIBADH) + NAD+
7SVT	;	2.4	;	Mycobacterium tuberculosis 3-hydroxyl-ACP dehydratase HadAB in complex with 1,3-diarylpyrazolyl-acylsulfonamide inhibitor
3PYG	;	1.99	;	Mycobacterium tuberculosis 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase (IspE) in complex with ADP
3PYF	;	1.7	;	Mycobacterium tuberculosis 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase (IspE) in complex with AMP-PNP
3PYE	;	2.0	;	Mycobacterium tuberculosis 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase (IspE) in complex with CDPME
3NE3	;	1.9	;	Mycobacterium tuberculosis Acyl Carrier Protein Synthase Apo structure
3NE1	;	2.51	;	Mycobacterium tuberculosis Acyl Carrier Protein Synthase in complex with sulfate ion
6C9S	;	2.23	;	Mycobacterium tuberculosis adenosine kinase bound to (2R,3R,4S,5R)-2-(6-([1,1'-biphenyl]-4-ylethynyl)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
6C9V	;	1.7	;	Mycobacterium tuberculosis adenosine kinase bound to (2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(4-phenylpiperazin-1-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
6C9R	;	2.1	;	Mycobacterium tuberculosis adenosine kinase bound to (2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(thiophen-3-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
6C9Q	;	1.95	;	Mycobacterium tuberculosis adenosine kinase bound to 5'-aminoadenosine
6C9P	;	2.0	;	Mycobacterium tuberculosis adenosine kinase bound to 6-methylmercaptopurine riboside
6C67	;	2.11	;	Mycobacterium tuberculosis adenosine kinase bound to iodotubercidin
6C9N	;	2.1	;	Mycobacterium tuberculosis adenosine kinase bound to sangivamycin
1YBU	;	2.4	;	Mycobacterium tuberculosis adenylyl cyclase Rv1900c CHD, in complex with a substrate analog.
1YBT	;	2.31	;	MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE, RV1900C CHD
2BMX	;	2.4	;	Mycobacterium tuberculosis AhpC
6SCZ	;	1.57	;	Mycobacterium tuberculosis alanine racemase inhibited by DCS
1F0N	;	1.8	;	MYCOBACTERIUM TUBERCULOSIS ANTIGEN 85B
1F0P	;	1.9	;	MYCOBACTERIUM TUBERCULOSIS ANTIGEN 85B WITH TREHALOSE
3QB9	;	2.11	;	Mycobacterium tuberculosis bacterioferritin, BfrA
3UOF	;	2.902	;	Mycobacterium tuberculosis bacterioferritin, BfrA
3UOI	;	1.9	;	Mycobacterium tuberculosis bacterioferritin, BfrA
4XTU	;	1.65003	;	Mycobacterium tuberculosis biotin ligase complexed with bisubstrate inhibitor (N-({[(1R,2S,3R,4R)-4-(6-amino-9H-purin-9-yl)-2,3-dihydroxycyclopentyl]methyl}sulfamoyl)-5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide)
4XTV	;	1.45001	;	Mycobacterium tuberculosis biotin ligase complexed with bisubstrate inhibitor 36 (N-({[(1R,3S)-3-(6-amino-9H-purin-9-yl)cyclopentyl]methyl}sulfamoyl)-5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanamide)
4XTW	;	2.30014	;	Mycobacterium tuberculosis biotin ligase complexed with bisubstrate inhibitor 46 with azide in place of 2'OH
4XTX	;	2.3001	;	Mycobacterium tuberculosis biotin ligase complexed with bisubstrate inhibitor 57 with azide in place of ribose 2'OH
4XTY	;	1.80003	;	Mycobacterium tuberculosis biotin ligase complexed with bisubstrate inhibitor 63 with Fluorine in place of 2'OH
4XTZ	;	1.90001	;	Mycobacterium tuberculosis biotin ligase complexed with bisubstrate inhibitor 69 that has a fluorine in place of the ribose 2'OH
4XU0	;	1.6	;	Mycobacterium tuberculosis biotin ligase complexed with bisubstrate inhibitor 73 that has a 2'-methyl on the ribose
4XU1	;	1.70001	;	Mycobacterium tuberculosis biotin ligase complexed with bisubstrate inhibitor 82 that incorporates a morpholine in place of the ribose
4XU2	;	1.85003	;	Mycobacterium tuberculosis biotin ligase complexed with bisubstrate inhibitor 87 with a 3'deoxy ribose
4XU3	;	2.24268	;	Mycobacterium tuberculosis biotin ligase complexed with bisubstrate inhibitor 90 that has an acyclic ether in place of the ribose
1SJP	;	3.2	;	Mycobacterium tuberculosis Chaperonin60.2
2O11	;	1.65	;	Mycobacterium tuberculosis Chorismate synthase
4BAJ	;	2.3	;	MYCOBACTERIUM TUBERCULOSIS CHORISMATE SYNTHASE after exposure to 266nm UV laser
4BAI	;	2.3	;	Mycobacterium tuberculosis Chorismate synthase before exposure to 266 nm UV laser
2O12	;	1.72	;	Mycobacterium tuberculosis Chorismate synthase in complex with FMN
2QHF	;	1.65	;	Mycobacterium tuberculosis Chorismate synthase in complex with NCA
8A8U	;	3.62	;	Mycobacterium tuberculosis ClpC1 hexamer structure
8A8V	;	3.34	;	Mycobacterium tuberculosis ClpC1 hexamer structure bound to the natural product antibiotic Cyclomarin
8A8W	;	4.29	;	Mycobacterium tuberculosis ClpC1 hexamer structure bound to the natural product antibiotic Ecumycin (class 1)
5I7A	;	2.08	;	Mycobacterium tuberculosis CysM in complex with the Urea-scaffold inhibitor 1 [3-(3-(3,4-Dichlorophenyl)ureido)benzoic acid]
5I7R	;	1.73	;	Mycobacterium tuberculosis CysM in complex with the Urea-scaffold inhibitor 2 [3-(3-([1,1'-biphenyl]-3-yl)ureido)benzoic acid]
5IWC	;	2.7	;	Mycobacterium tuberculosis CysM in complex with the Urea-scaffold inhibitor 3 [4-(3-([1,1'-Biphenyl]-3-yl)ureido)-2-hydroxybenzoic acid]
5IW8	;	2.04	;	Mycobacterium tuberculosis CysM in complex with the Urea-scaffold inhibitor 4 [5-(3-([1,1'-Biphenyl]-3-yl)ureido)-2-hydroxybenzoic acid]
5I6D	;	1.64	;	Mycobacterium tuberculosis CysM in complex with the Urea-scaffold inhibitor 5 [3-(3-(p-Tolyl)ureido) benzoic acid]
5I7H	;	2.57	;	Mycobacterium tuberculosis CysM in complex with the Urea-scaffold inhibitor 6 [3-(3-(4-Bromophenyl)ureido)benzoic acid]
5I7O	;	2.49	;	Mycobacterium tuberculosis CysM in complex with the Urea-scaffold inhibitor 7 [3-(3-(4-Chlorophenyl)ureido)benzoic acid]
7NQM	;	1.6	;	Mycobacterium tuberculosis Cytochrome P450 CYP121 in complex with lead compound 10
7NQN	;	1.6	;	Mycobacterium tuberculosis Cytochrome P450 CYP121 in complex with lead compound 14
7NQO	;	1.6	;	Mycobacterium tuberculosis Cytochrome P450 CYP121 in complex with lead compound 21
7JT5	;	2.0	;	Mycobacterium tuberculosis dethiobiotin synthetase in complex with fragment analogue 9
7L1J	;	1.6	;	Mycobacterium tuberculosis dethiobiotin synthetase in complex with Tetrazole 1
7JT6	;	2.0	;	Mycobacterium tuberculosis dethiobiotin synthetase in complex with Tetrazole 2
5JA3	;	1.814	;	Mycobacterium tuberculosis Dihydrofolate Reductase complexed with beta- NADPH and 3'-(3-(2,4-diamino-6-ethylpyrimidin-5-yl)prop-2-yn-1-yl)-4'-methoxy-[1,1'-b iphenyl]-4-carboxylic acid (UCP1106)
6DDP	;	1.49	;	Mycobacterium tuberculosis Dihydrofolate Reductase complexed with beta-NADPH and 3'-[(2R)-4-(2,4-diamino-6-ethylpyrimidin-5-yl)but-3-yn-2-yl]-5'-methoxy[1,1'-biphenyl]-4-carboxylic acid
6DDS	;	1.72	;	Mycobacterium tuberculosis Dihydrofolate Reductase complexed with beta-NADPH and 4-[3-[3-[2,4-bis(azanyl)-6-ethyl-pyrimidin-5-yl]prop-2-ynyl]-5-methoxy-phenyl]benzoic acid
6DDW	;	1.4	;	Mycobacterium tuberculosis Dihydrofolate Reductase complexed with beta-NADPH and N-(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}-2-hydroxybenzene-1-carbonyl)-L-glutamic acid
4M2X	;	2.26	;	Mycobacterium tuberculosis dihydrofolate reductase complexed with trimetrexate (TMQ)
6VSD	;	1.693	;	Mycobacterium tuberculosis dihydrofolate reductase in complex with 3-((thiophen-2-ylthio)methyl)benzoic acid (fragment 13)
6VS6	;	1.853	;	Mycobacterium tuberculosis dihydrofolate reductase in complex with 3-(furan-2-yl)-1-methyl-1H-pyrazole-5-carboxylic acid (fragment 2)
6VSE	;	1.758	;	Mycobacterium tuberculosis dihydrofolate reductase in complex with 3-(phenoxymethyl)benzoic acid(fragment 14)
6VS9	;	1.842	;	Mycobacterium tuberculosis dihydrofolate reductase in complex with 3-(piperidin-1-ylmethyl)benzoic acid(fragment 11)
6VSF	;	2.012	;	Mycobacterium tuberculosis dihydrofolate reductase in complex with 4-(3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-4-oxobutanoic acid(fragment 16)
6VSG	;	2.304	;	Mycobacterium tuberculosis dihydrofolate reductase in complex with 4-(trifluoromethyl)benzene-1,2-diamine(fragment 17)
8COW	;	1.6	;	Mycobacterium tuberculosis dihydrofolate reductase in complex with 5-(cyclopropylethynyl)-6-(2-fluorophenyl)pyrimidine-2,4-diamine
8COQ	;	1.7	;	Mycobacterium tuberculosis dihydrofolate reductase in complex with 5-(cyclopropylethynyl)-6-(2-methoxyphenyl)pyrimidine-2,4-diamine
8CQ9	;	1.75	;	Mycobacterium tuberculosis dihydrofolate reductase in complex with 5-(cyclopropylethynyl)-6-(4-(trifluoromethyl)phenyl)pyrimidine-2,4-diamine
6VS5	;	1.758	;	Mycobacterium tuberculosis dihydrofolate reductase in complex with 5-methyl-1-phenyl-1H-pyrazole-4-carboxylic acid (fragment 1)
6VVB	;	1.45	;	Mycobacterium tuberculosis dihydrofolate reductase in complex with 6-methyl-5-(4-phenylthiazol-2-yl)-2- (trifluoromethyl)nicotinic acid (fragment 10)
6VS8	;	1.829	;	Mycobacterium tuberculosis dihydrofolate reductase in complex with ethyl 2-methyl thiazole-4-carboxylate(fragment 3)
6VV6	;	2.235	;	Mycobacterium tuberculosis dihydrofolate reductase in complex with JEB113
6VV7	;	1.999	;	Mycobacterium tuberculosis dihydrofolate reductase in complex with JEB136
6VV8	;	2.683	;	Mycobacterium tuberculosis dihydrofolate reductase in complex with JEB285
6VV9	;	2.18	;	Mycobacterium tuberculosis dihydrofolate reductase in complex with JEB300
8CQ8	;	1.8	;	Mycobacterium tuberculosis dihydrofolate reductase in complex with methyl 4-(2,6-diamino-5-(cyclopropylethynyl)pyrimidin-4-yl)benzoate
8COX	;	2.1	;	Mycobacterium tuberculosis dihydrofolate reductase in complex with N-(2-(2,6-diamino-5-(cyclopropylethynyl)pyrimidin-4-yl)phenyl)methanesulfonamide
8CQA	;	2.0	;	Mycobacterium tuberculosis dihydrofolate reductase in complex with N-(4-(2,6-diamino-5-(cyclopropylethynyl)pyrimidin-4-yl)phenyl)acetamide
8COP	;	1.8	;	Mycobacterium tuberculosis dihydrofolate reductase in complex with N-(4-(2,6-diamino-5-(cyclopropylethynyl)pyrimidin-4-yl)phenyl)methanesulfonamide
4FEH	;	2.035	;	Mycobacterium tuberculosis DprE1 - hexagonal crystal form
4FDP	;	2.23	;	Mycobacterium tuberculosis DprE1 - monoclinic crystal form
6HFW	;	2.47	;	Mycobacterium tuberculosis DprE1 in complex with CMP1
6HFV	;	2.05	;	Mycobacterium tuberculosis DprE1 in complex with CMP2
4FDO	;	2.403	;	Mycobacterium tuberculosis DprE1 in complex with CT319
4FDN	;	2.4	;	Mycobacterium tuberculosis DprE1 in complex with CT325 - hexagonal crystal form
4FF6	;	2.6	;	Mycobacterium tuberculosis DprE1 in complex with CT325 - monoclinic crystal form
5OEQ	;	2.25	;	Mycobacterium tuberculosis DprE1 in complex with inhibitor TCA020
5OEP	;	2.35	;	Mycobacterium tuberculosis DprE1 in complex with inhibitor TCA481
5OEL	;	2.2	;	Mycobacterium tuberculosis DprE1 mutant Y314C in complex with TCA1
1SMC	;	2.1	;	Mycobacterium tuberculosis dUTPase complexed with dUTP in the absence of metal ion.
1SIX	;	1.3	;	Mycobacterium tuberculosis dUTPase complexed with magnesium and alpha,beta-imido-dUTP
1SJN	;	1.8	;	Mycobacterium tuberculosis dUTPase complexed with magnesium and alpha,beta-imido-dUTP
1SNF	;	1.85	;	MYCOBACTERIUM TUBERCULOSIS DUTPASE COMPLEXED WITH MAGNESIUM AND DEOXYURIDINE 5'-MONOPHOSPHATE
1SLH	;	3.0	;	Mycobacterium tuberculosis dUTPase complexed with magnesium and dUDP
5ECT	;	1.3	;	Mycobacterium tuberculosis dUTPase G143STOP mutant
3SXN	;	2.03	;	Mycobacterium tuberculosis Eis protein initiates modulation of host immune responses by acetylation of DUSP16/MKP-7
3SXO	;	2.5	;	Mycobacterium tuberculosis Eis protein initiates modulation of host immune responses by acetylation of DUSP16/MKP-7
2FEZ	;	2.0	;	Mycobacterium tuberculosis EmbR
2FF4	;	1.9	;	Mycobacterium tuberculosis EmbR in complex with low affinity phosphopeptide
7CKP	;	2.9	;	Mycobacterium tuberculosis Enolase
7CLK	;	2.15	;	Mycobacterium tuberculosis enolase in complex with alternate 2-phosphoglycerate
7DLR	;	2.25	;	Mycobacterium tuberculosis enolase mutant - E163A
7E4F	;	2.3	;	Mycobacterium tuberculosis enolase mutant - E204A complex with phosphoenolpyruvate
6L7D	;	3.0	;	Mycobacterium tuberculosis enolase mutant - S42A
2O15	;	1.95	;	Mycobacterium tuberculosis epsp synthase after partial products withdrawal
2O0X	;	1.96	;	Mycobacterium tuberculosis epsp synthase in complex with intermediate
2O0Z	;	2.0	;	Mycobacterium tuberculosis epsp synthase in complex with product (EPS)
2O0D	;	1.6	;	Mycobacterium tuberculosis epsp synthase in complex with s3p
2O0B	;	1.15	;	Mycobacterium tuberculosis epsp synthase in complex with S3P (partially photolyzed)
2O0E	;	1.81	;	Mycobacterium tuberculosis epsp synthase in complex with S3P and PEP
2BJB	;	1.8	;	Mycobacterium Tuberculosis Epsp Synthase In Unliganded State
2QJ3	;	3.0	;	Mycobacterium tuberculosis FabD
3R44	;	1.8	;	Mycobacterium tuberculosis fatty acyl CoA synthetase
3OJ5	;	2.845	;	Mycobacterium tuberculosis ferritin homolog, BfrB
3UNO	;	2.503	;	Mycobacterium tuberculosis ferritin homolog, BfrB
2VOS	;	2.0	;	Mycobacterium tuberculosis Folylpolyglutamate synthase complexed with ADP
1LQU	;	1.25	;	Mycobacterium tuberculosis FprA in complex with NADPH
1RQ2	;	1.86	;	MYCOBACTERIUM TUBERCULOSIS FTSZ IN COMPLEX WITH CITRATE
1RQ7	;	2.6	;	MYCOBACTERIUM TUBERCULOSIS FTSZ IN COMPLEX WITH GDP
6YM1	;	1.7	;	Mycobacterium tuberculosis FtsZ in complex with GDP
1RLU	;	2.08	;	Mycobacterium tuberculosis FtsZ in complex with GTP-gamma-S
6YM9	;	2.03	;	Mycobacterium tuberculosis FtsZ in complex with GTP-gamma-S
6Y1U	;	1.68	;	Mycobacterium tuberculosis FtsZ-GDP in complex with 4-hydroxycoumarin
6Y1V	;	2.4	;	Mycobacterium tuberculosis FtsZ-GTP-gamma-S in complex with 4-hydroxycoumarin
2JA2	;	1.65	;	Mycobacterium tuberculosis glutamyl-tRNA synthetase
3UC1	;	1.65	;	Mycobacterium tuberculosis gyrase type IIA topoisomerase C-terminal domain
4G3N	;	1.4	;	Mycobacterium tuberculosis gyrase type IIA topoisomerase C-terminal domain at 1.4 A resolution
4NL5	;	1.9	;	Mycobacterium tuberculosis heme-degrading protein MhuD in complex with heme and cyanide
7EWC	;	2.05	;	Mycobacterium tuberculosis HigA2 (Form I)
7EWD	;	3.2	;	Mycobacterium tuberculosis HigA2 (Form II)
7EWE	;	3.41	;	Mycobacterium tuberculosis HigA2 (Form III)
7SFM	;	2.149	;	Mycobacterium tuberculosis Hip1 crystal structure
2NV6	;	1.9	;	Mycobacterium tuberculosis InhA (S94A) bound with INH-NAD adduct
4R9R	;	2.9	;	Mycobacterium tuberculosis InhA bound to NITD-564
4R9S	;	3.2	;	Mycobacterium tuberculosis InhA bound to NITD-916
2H9I	;	2.2	;	Mycobacterium tuberculosis InhA bound with ETH-NAD adduct
2NTJ	;	2.5	;	Mycobacterium tuberculosis InhA bound with PTH-NAD adduct
4DRE	;	2.4	;	Mycobacterium tuberculosis InhA in complex with NADH
4DQU	;	2.45	;	Mycobacterium tuberculosis InhA-D148G mutant in complex with NADH
4DTI	;	1.9	;	Mycobacterium tuberculosis InhA-S94A mutant in complex with NADH
6KOQ	;	3.353	;	Mycobacterium tuberculosis initial transcription complex comprising sigma H and 5'-OH RNA of 10 nt
6KON	;	3.0	;	Mycobacterium tuberculosis initial transcription complex comprising sigma H and 5'-OH RNA of 5 nt
6KOO	;	2.8	;	Mycobacterium tuberculosis initial transcription complex comprising sigma H and 5'-OH RNA of 7 nt
6KOP	;	3.303	;	Mycobacterium tuberculosis initial transcription complex comprising sigma H and 5'-OH RNA of 9 nt
3OXH	;	1.75	;	Mycobacterium tuberculosis kinase inhibitor homolog RV0577
5UA1	;	2.9	;	Mycobacterium tuberculosis KstR in complex with a 18-bp DNA operator
5UA2	;	2.9002	;	Mycobacterium tuberculosis KstR in complex with a 26-bp DNA operator
6O7F	;	2.303	;	Mycobacterium tuberculosis L-alanine dehydrogenase x-ray structure in complex with N6-isobutyl adenosine
4LMP	;	1.95	;	Mycobacterium tuberculosis L-alanine dehydrogenase x-ray structure in complex with N6-methyl adenosine
6A2Q	;	1.48	;	Mycobacterium tuberculosis LexA C-domain I
6A2R	;	2.25	;	Mycobacterium tuberculosis LexA C-domain II
6A2T	;	1.9	;	Mycobacterium tuberculosis LexA C-domain K197A
6A2S	;	2.5	;	Mycobacterium tuberculosis LexA C-domain S160A
2GQ3	;	2.3	;	mycobacterium tuberculosis malate synthase in complex with magnesium, malate, and coenzyme A
5YXF	;	1.61	;	Mycobacterium Tuberculosis Methionine aminopeptidase type 1c (C105L mutant) in complex with Methionine
5YOH	;	1.63	;	Mycobacterium Tuberculosis Methionine aminopeptidase type 1c (C105M mutant) in complex with Methionine
5YPD	;	1.62	;	Mycobacterium Tuberculosis Methionine aminopeptidase type 1c (C105N mutant) in complex with Methionine
5YPJ	;	2.01	;	Mycobacterium Tuberculosis Methionine aminopeptidase type 1c (C105N mutant).
5YOI	;	1.63	;	Mycobacterium Tuberculosis Methionine aminopeptidase type 1c (C105T mutant) in complex with Methionine
4IDY	;	2.0	;	Mycobacterium Tuberculosis Methionine aminopeptidase Type 1c in complex with 2-hydroxyethyl disulfide
4IF7	;	2.0	;	Mycobacterium Tuberculosis Methionine aminopeptidase Type 1c in complex with homocysteine-methyl disulfide
6AX8	;	2.6	;	Mycobacterium tuberculosis methionyl-tRNA synthetase in complex with methionyl-adenylate
1K44	;	2.6	;	Mycobacterium tuberculosis Nucleoside Diphosphate Kinase
5XMB	;	3.2	;	Mycobacterium tuberculosis Pantothenate kinase mutant F247A
5XLW	;	2.26	;	Mycobacterium tuberculosis Pantothenate kinase mutant F247A/F254A
5XLV	;	1.8	;	Mycobacterium tuberculosis Pantothenate kinase mutant F254A
8EHQ	;	3.0	;	Mycobacterium tuberculosis paused transcription complex with Bacillus subtilis NusG
6WGU	;	1.65	;	Mycobacterium tuberculosis pduO-type ATP:cobalamin adenosyltransferase
8D32	;	1.85	;	Mycobacterium tuberculosis pduO-type ATP:cobalamin adenosyltransferase bound to 5-deoxyadenosylrhodibalamin and PPPi
6WGS	;	1.5	;	Mycobacterium tuberculosis pduO-type ATP:cobalamin adenosyltransferase bound to adenosylcobalamin
6WGV	;	2.151	;	Mycobacterium tuberculosis pduO-type ATP:cobalamin adenosyltransferase bound to adenosylcobalamin and PPPi
6WH5	;	1.866	;	Mycobacterium tuberculosis pduO-type ATP:cobalamin adenosyltransferase bound to cob(II)alamin and PPPi
3ORM	;	2.5	;	Mycobacterium tuberculosis PknB kinase domain D76A mutant
3ORI	;	2.0	;	Mycobacterium tuberculosis PknB kinase domain L33D mutant (crystal form 1)
3ORK	;	1.6	;	Mycobacterium tuberculosis PknB kinase domain L33D mutant (crystal form 2)
3ORL	;	2.9	;	Mycobacterium tuberculosis PknB kinase domain L33D mutant (crystal form 3)
3ORO	;	1.9	;	Mycobacterium tuberculosis PknB kinase domain L33D mutant (crystal form 4)
3ORP	;	2.1	;	Mycobacterium tuberculosis PknB kinase domain L33D mutant (crystal form 5)
3ORT	;	1.9	;	Mycobacterium tuberculosis PknB kinase domain L33D mutant (crystal form 6)
6D8I	;	1.65	;	Mycobacterium tuberculosis polyketide synthase 13 N-terminal acyl carrier protein domain
6D8J	;	1.63	;	Mycobacterium tuberculosis polyketide synthase 13 N-terminal acyl carrier protein domain
4QVB	;	2.3	;	Mycobacterium tuberculosis protein Rv1155 in complex with co-enzyme F420
4X8K	;	2.202	;	Mycobacterium tuberculosis RbpA-SID in complex with SigmaA domain 2
4PPN	;	2.6	;	Mycobacterium tuberculosis RecA citrate bound low temperature structure IIA-BN
4PPG	;	3.0	;	Mycobacterium tuberculosis RecA citrate bound low temperature structure IIA-BR
4PPQ	;	2.85	;	Mycobacterium tuberculosis RecA citrate bound low temperature structure IIA-CR
4PPF	;	2.3	;	Mycobacterium tuberculosis RecA citrate bound low temperature structure IIA-N
4PQR	;	2.8	;	Mycobacterium tuberculosis RecA glycerol bound low temperature structure IIB-BN
4PQF	;	2.8	;	Mycobacterium tuberculosis RecA glycerol bound low temperature structure IIB-CR
4OQF	;	2.8	;	Mycobacterium tuberculosis RecA glycerol bound low temperature structure IIB-SR
4POA	;	2.95	;	Mycobacterium tuberculosis RecA glycerol bound low temperature structure IIC-BN
4PO9	;	2.75	;	Mycobacterium tuberculosis RecA glycerol bound low temperature structure IIC-BR
4PO8	;	2.7	;	Mycobacterium tuberculosis RecA glycerol bound low temperature structure IIC-CR
4PTL	;	2.5	;	Mycobacterium tuberculosis RecA glycerol bound low temperature structure IIC-GM
4PSA	;	2.65	;	Mycobacterium tuberculosis RecA glycerol bound low temperature structure IIC-N1
4PR0	;	2.6	;	Mycobacterium tuberculosis RecA glycerol bound low temperature structure IIC-N3
4PQY	;	2.95	;	Mycobacterium tuberculosis RecA glycerol bound low temperature structure IIC-N4
4PO1	;	3.4	;	Mycobacterium tuberculosis RecA glycerol bound room temperature structure IIC-RT
4PSK	;	2.8	;	Mycobacterium tuberculosis RecA phosphate bound low temperature structure I-LT
4PSV	;	2.6	;	Mycobacterium tuberculosis RecA phosphate bound room temperature structure I-RT
6B5E	;	1.85	;	Mycobacterium tuberculosis RmlA in complex with dTDP-glucose
6B5K	;	1.6	;	Mycobacterium tuberculosis RmlA in complex with Mg/dTTP
1UPI	;	1.7	;	Mycobacterium tuberculosis rmlC epimerase (Rv3465)
2M4V	;		;	Mycobacterium tuberculosis RNA polymerase binding protein A (RbpA) and its interactions with sigma factors
5ZX3	;	2.751	;	Mycobacterium tuberculosis RNA polymerase holoenzyme with ECF sigma factor sigma H
7U22	;	3.87	;	Mycobacterium tuberculosis RNA polymerase sigma A holoenzyme open promoter complex containing UMN-7
7RWI	;	3.7	;	Mycobacterium tuberculosis RNA polymerase sigma L holoenzyme open promoter complex containing TNP-2198
5ZX2	;	2.8	;	Mycobacterium tuberculosis RNA polymerase transcription initiation complex with ECF sigma factor sigma H and 7nt RNA
6JCY	;	3.106	;	Mycobacterium tuberculosis RNA polymerase transcription initiation open complex with a chimeric ECF sigma factor sigH/E
8E95	;	2.9	;	Mycobacterium tuberculosis RNAP elongation complex
8E82	;	3.03	;	Mycobacterium tuberculosis RNAP elongation complex with NusG transcription factor
6C05	;	5.15	;	Mycobacterium tuberculosis RNAP Holo/RbpA in relaxed state
6C06	;	5.15	;	Mycobacterium tuberculosis RNAP Holo/RbpA/Fidaxomicin
6EDT	;		;	Mycobacterium tuberculosis RNAP open promoter complex with RbpA/CarD and AP3 promoter
8E8M	;	3.13	;	Mycobacterium tuberculosis RNAP paused elongation complex
8E79	;	3.71	;	Mycobacterium tuberculosis RNAP paused elongation complex with Escherichia coli NusG transcription factor
8E74	;	2.94	;	Mycobacterium tuberculosis RNAP paused elongation complex with NusG transcription factor
6EE8	;	3.92	;	Mycobacterium tuberculosis RNAP promoter unwinding intermediate complex with RbpA/CarD and AP3 promoter
6EEC	;	3.55	;	Mycobacterium tuberculosis RNAP promoter unwinding intermediate complex with RbpA/CarD and AP3 promoter captured by Corallopyronin
6VW0	;	3.59	;	Mycobacterium tuberculosis RNAP S456L mutant open promoter complex
6VVZ	;	3.72	;	Mycobacterium tuberculosis RNAP S456L mutant transcription initiation intermediate structure with Sorangicin
6M7J	;	4.4	;	Mycobacterium tuberculosis RNAP with RbpA/us fork and Corallopyronin
7WNU	;	3.2	;	Mycobacterium tuberculosis Rnase J complex with 7nt RNA
5MTW	;	1.84	;	Mycobacterium tuberculosis Rv1957 SecB-like chaperone in complex with a ChAD peptide from Rv1956 HigA1 antitoxin
4HC6	;	1.8	;	Mycobacterium tuberculosis Rv2523cE77A x-ray structure solved with 1.8 angstrom resolution
6DE5	;	2.3	;	Mycobacterium tuberculosis Rv2671 complexed with beta-NADPH and 6-ethyl-5-{(3S)-3-[2-methoxy-5-(pyridin-4-yl)phenyl]but-1-yn-1-yl}pyrimidine-2,4-diamine
2Q74	;	2.6	;	Mycobacterium tuberculosis SuhB
2I1U	;	1.3	;	Mycobacterium tuberculosis thioredoxin C
3NOF	;	1.6	;	Mycobacterium tuberculosis thioredoxin C C40S mutant
3O6T	;	2.4	;	Mycobacterium tuberculosis thioredoxin C C40S mutant in Complex with Quinol Inhibitor PMX464
2GQ2	;	2.1	;	Mycobacterium tuberculosis ThyX-NADP complex
5UCT	;	2.7	;	Mycobacterium tuberculosis toxin MazF-mt6
8EOE	;	3.2	;	Mycobacterium tuberculosis transcription elongation complex with Bacillus subtilis NusG (EC_LG)
8EOF	;	3.3	;	Mycobacterium tuberculosis transcription elongation complex with Bacillus subtilis NusG (EC_PG)
6JCX	;	2.903	;	Mycobacterium tuberculosis transcription initiation complex with ECF sigma factor sigma H and 6nt RNA
6CYJ	;	2.699	;	Mycobacterium tuberculosis transcriptional regulator
6CYY	;	2.506	;	Mycobacterium tuberculosis transcriptional regulator
6CZ6	;	2.7	;	Mycobacterium tuberculosis transcriptional regulator
6D2S	;	1.819	;	Mycobacterium tuberculosis transcriptional regulator
7NGD	;	1.47	;	Mycobacterium tuberculosis transcriptional regulator EthR with bound inhibitory compound
7NGG	;	1.17	;	Mycobacterium tuberculosis transcriptional regulator EthR with bound inhibitory compound
7NGI	;	1.7	;	Mycobacterium tuberculosis transcriptional regulator EthR with bound inhibitory compound
7NGJ	;	1.89	;	Mycobacterium tuberculosis transcriptional regulator EthR with bound inhibitory compound
7NGK	;	1.89	;	Mycobacterium tuberculosis transcriptional regulator EthR with bound inhibitory compound
7NGM	;	1.76	;	Mycobacterium tuberculosis transcriptional regulator EthR with bound inhibitory compound
7NGN	;	1.55	;	Mycobacterium tuberculosis transcriptional regulator EthR with bound inhibitory compound
7NGO	;	2.37	;	Mycobacterium tuberculosis transcriptional regulator EthR with bound inhibitory compound
7NGR	;	1.92	;	Mycobacterium tuberculosis transcriptional regulator EthR with bound inhibitory compound
7NGS	;	2.5	;	Mycobacterium tuberculosis transcriptional regulator EthR with bound inhibitory compound
7NGT	;	2.49	;	Mycobacterium tuberculosis transcriptional regulator EthR with bound inhibitory compound
7NGU	;	1.26	;	Mycobacterium tuberculosis transcriptional regulator EthR with bound inhibitory compound
7NGW	;	1.26	;	Mycobacterium tuberculosis transcriptional regulator EthR with bound inhibitory compound
7NGX	;	1.24	;	Mycobacterium tuberculosis transcriptional regulator EthR with bound inhibitory compound
7NGY	;	1.27	;	Mycobacterium tuberculosis transcriptional regulator EthR with bound inhibitory compound
2O2J	;	2.56	;	Mycobacterium tuberculosis tryptophan synthase beta chain dimer (apoform)
2O2E	;	2.2	;	Mycobacterium tuberculosis tryptophan synthase beta subunit dimer (apoform)
3ZQJ	;	3.4	;	Mycobacterium tuberculosis UvrA
7KIM	;	3.38	;	Mycobacterium tuberculosis WT RNAP transcription closed promoter complex with WhiB7 transcription factor
6VVX	;	3.39	;	Mycobacterium tuberculosis WT RNAP transcription initiation intermediate structure with Sorangicin
6VVY	;	3.42	;	Mycobacterium tuberculosis WT RNAP transcription open promoter complex with Sorangicin
7KIN	;	2.74	;	Mycobacterium tuberculosis WT RNAP transcription open promoter complex with WhiB7 promoter
7KIF	;	2.94	;	Mycobacterium tuberculosis WT RNAP transcription open promoter complex with WhiB7 transcription factor
2N5Z	;		;	Mycobacterium tuberculosis: a dynamic view of the resuscitation promoting factor RpfC catalytic domain
4CXR	;	1.7	;	Mycobaterium tuberculosis transaminase BioA complexed with 1-(1,3- benzothiazol-2-yl)methanamine
4MQP	;	1.83	;	Mycobaterium tuberculosis transaminase BioA complexed with 2-hydrazinylbenzo[d]thiazole
4MQQ	;	1.7	;	Mycobaterium tuberculosis transaminase BioA complexed with benzo[d]thiazole-2-carbohydrazide
4MQR	;	2.1	;	Mycobaterium tuberculosis transaminase BioA complexed with E)-5-hydroxy-4-(((Z)-isonicotinoyldiazenyl)methylene)-6-methyl-1,4-dihydropyridin-3-yl)methyl phosphate
4CXQ	;	1.8	;	Mycobaterium tuberculosis transaminase BioA complexed with substrate KAPA
7Q2B	;	1.85	;	mycolic acid methyltransferase Hma (MmaA4) from Mycobac-terium tuberculosis in complex with ZT218
7Q2C	;	1.9	;	mycolic acid methyltransferase Hma (MmaA4) from Mycobac-terium tuberculosis in complex with ZT260
7Q2H	;	1.75	;	mycolic acid methyltransferase Hma (MmaA4) from Mycobac-terium tuberculosis in complex with ZT275
7Q2D	;	1.89	;	mycolic acid methyltransferase Hma (MmaA4) from Mycobac-terium tuberculosis in complex with ZT320
7Q2E	;	1.93	;	mycolic acid methyltransferase Hma (MmaA4) from Mycobac-terium tuberculosis in complex with ZT424
7Q2F	;	1.85	;	mycolic acid methyltransferase Hma (MmaA4) from Mycobac-terium tuberculosis in complex with ZT585
7Q2G	;	2.0	;	mycolic acid methyltransferase Hma (MmaA4) from Mycobac-terium tuberculosis in complex with ZT726
2OJE	;	3.0	;	Mycoplasma arthritidis-derived mitogen complexed with class II MHC molecule HLA-DR1/HA complex in the presence of EDTA
5OBV	;	2.49	;	Mycoplasma genitalium DnaK deletion mutant lacking SBDalpha in complex with ADP and Pi.
5OBU	;	2.0	;	Mycoplasma genitalium DnaK deletion mutant lacking SBDalpha in complex with AMPPNP.
5OBX	;	1.78	;	Mycoplasma genitalium DnaK-NBD
5OBY	;	1.3	;	Mycoplasma genitalium DnaK-NBD in complex with AMP-PNP
5OBW	;	1.4	;	Mycoplasma genitalium DnaK-NBD in complex with ATP
6RUT	;	2.65	;	Mycoplasma Genitalium Heterodimer Nap Complex (P140-P110 globular)
3MYU	;	1.95	;	Mycoplasma genitalium MG289
7DOL	;	2.002	;	Mycoplasma genitalium RNase R in complex with double-stranded RNA
7DID	;	1.9	;	Mycoplasma genitalium RNase R in complex with ribose methylated single-stranded RNA
7DIC	;	2.242	;	Mycoplasma genitalium RNase R in complex with single-stranded RNA
7OOC	;	3.7	;	Mycoplasma pneumoniae 30S subunit of ribosomes in chloramphenicol-treated cells
7OOD	;	3.4	;	Mycoplasma pneumoniae 50S subunit of ribosomes in chloramphenicol-treated cells
7P6Z	;	3.5	;	Mycoplasma pneumoniae 70S ribosome in untreated cells
8OFJ	;	2.25	;	Mycoplasma pneumoniae CdaM
7NPU	;	4.48	;	MycP5-free ESX-5 inner membrane complex, state I
7NPV	;	6.66	;	MycP5-free ESX-5 inner membrane complex, State II
1PKO	;	1.45	;	Myelin Oligodendrocyte Glycoprotein (MOG)
1PKQ	;	3.0	;	Myelin Oligodendrocyte Glycoprotein-(8-18C5) Fab-complex
7NSR	;	1.5	;	Myelin protein P2 I50del
5LF5	;	3.8	;	Myelin-associated glycoprotein (MAG) deglycosylated full extracellular domain with co-purified ligand
5LFU	;	4.3	;	Myelin-associated glycoprotein (MAG) glycosylated and lysine-methylated full extracellular domain
4C1M	;	2.0	;	Myeloperoxidase in complex with the revesible inhibitor HX1
6T5L	;	2.17	;	MYO-1 from Myroides odoratimimus. Environmental metallo-beta-lactamases exhibit high enzymatic activity under zinc deprivation
1GR0	;	1.95	;	myo-inositol 1-phosphate synthase from Mycobacterium tuberculosis in complex with NAD and zinc.
4XF6	;	2.08	;	myo-inositol 3-kinase bound with its products (ADP and 1D-myo-inositol 3-phosphate)
4XF7	;	1.93	;	myo-inositol 3-kinase bound with its substrates (AMPPCP and myo-inositol)
3W4S	;	1.78	;	Myo-inositol kinase from Thermococcus kodakarensis
1U1I	;	1.9	;	Myo-inositol phosphate synthase mIPS from A. fulgidus
1JKI	;	2.2	;	myo-Inositol-1-phosphate Synthase Complexed with an Inhibitor, 2-deoxy-glucitol-6-phosphate
7SKF	;	1.282	;	Myocilin OLF mutant A445V
7SIJ	;	1.54	;	Myocilin OLF mutant E352K
7SJT	;	1.54	;	Myocilin OLF mutant K398R
7SIB	;	1.78	;	Myocilin OLF mutant K500R
7SJW	;	1.38	;	Myocilin OLF mutant L303I
6PKD	;	1.9	;	Myocilin OLF mutant N428D/D478H
6PKF	;	1.484	;	Myocilin OLF mutant N428E/D478K
6PKE	;	1.88	;	Myocilin OLF mutant N428E/D478S
7SKE	;	1.24	;	Myocilin OLF mutant R296H
7SKD	;	1.712	;	Myocilin OLF mutant S331L
7SJU	;	1.391	;	Myocilin OLF mutant T293K
7SJV	;	1.39	;	Myocilin OLF mutant T353I
7SKG	;	1.33	;	Myocilin OLF mutant V329M
7T8D	;	1.38	;	Myocilin OLF mutant V449I
1XCH	;	1.7	;	MYOGLOBIN (HORSE HEART) MUTANT WITH LEU 104 REPLACED BY ASN (L104N)
1RSE	;	1.7	;	MYOGLOBIN (HORSE HEART) MUTANT WITH SER 92 REPLACED BY ASP (S92D)
1WLA	;	1.7	;	MYOGLOBIN (HORSE HEART) RECOMBINANT WILD-TYPE
1AZI	;	2.0	;	MYOGLOBIN (HORSE HEART) RECOMBINANT WILD-TYPE COMPLEXED WITH AZIDE
1DWR	;	1.45	;	MYOGLOBIN (HORSE HEART) WILD-TYPE COMPLEXED WITH CO
1NPF	;	1.9	;	MYOGLOBIN (HORSE HEART) WILD-TYPE COMPLEXED WITH NITRIC OXIDE
1NPG	;	1.7	;	MYOGLOBIN (HORSE HEART) WILD-TYPE COMPLEXED WITH NITROSOETHANE
2OHA	;	1.8	;	Myoglobin cavity mutant F138W
3H57	;	1.7	;	Myoglobin Cavity Mutant H64LV68N Deoxy form
3H58	;	1.8	;	Myoglobin Cavity Mutant H64LV68N Met form
2OHB	;	1.8	;	Myoglobin cavity mutant I107W
2OH8	;	1.8	;	Myoglobin cavity mutant I28W
2OH9	;	1.8	;	Myoglobin cavity mutant V68W
7YLK	;	1.63	;	Myoglobin containing Ir complex
6G5T	;	1.5	;	Myoglobin H64V/V68A in the resting state, 1.5 Angstrom resolution
5XKW	;	1.7	;	myoglobin mutant F43Y/F46Y
7VUC	;	1.4	;	Myoglobin mutant L29I/H64G/V68A
3VAU	;	1.7	;	Myoglobin nitrite structure: nitriheme modified
8ESS	;	1.4	;	Myoglobin variant Mb-cIII complex
8ESU	;	1.04	;	Myoglobin variant Mb-imi complex
4LSD	;	2.28	;	Myokine structure
2XMF	;	1.5	;	Myosin 1e SH3
1B7T	;	2.5	;	MYOSIN DIGESTED BY PAPAIN
1W9L	;	1.95	;	Myosin II Dictyostelium discoideum motor domain S456E bound with MgADP-AlF4
1W9J	;	2.0	;	Myosin II Dictyostelium discoideum motor domain S456Y bound with MgADP-AlF4
1W9I	;	1.75	;	Myosin II Dictyostelium discoideum motor domain S456Y bound with MgADP-BeFx
3GN4	;	2.7	;	Myosin lever arm
5VT9	;	1.85	;	Myosin Light chain 1 and MyoA complex
2MYS	;	2.8	;	MYOSIN SUBFRAGMENT-1, ALPHA CARBON COORDINATES ONLY FOR THE TWO LIGHT CHAINS
2F6H	;	2.25	;	Myosin V cargo binding domain
4ZG4	;	2.36	;	Myosin Vc Pre-powerstroke
5HMP	;	2.397	;	Myosin Vc pre-powerstroke state
2V26	;	1.75	;	Myosin VI (MD) pre-powerstroke state (Mg.ADP.VO4)
4E7Z	;	2.3	;	Myosin VI (MD) pre-powerstroke state, P21 crystal form
2VB6	;	2.3	;	Myosin VI (MD-insert2-CaM, Delta Insert1) Post-rigor state (crystal form 2)
2VAS	;	2.4	;	Myosin VI (MD-insert2-CaM, Delta-Insert1) Post-rigor state
4PJJ	;	2.4	;	MYOSIN VI (MD-INSERT2-CAM, DELTA-INSERT1) post-rigor state - long soaking with PO4
4ANJ	;	2.6	;	MYOSIN VI (MDinsert2-GFP fusion) PRE-POWERSTROKE STATE (MG.ADP.AlF4)
4DBR	;	1.95	;	Myosin VI D179Y (MD) pre-powerstroke state
4DBQ	;	2.6	;	MYOSIN VI D179Y (MD-INSERT2-CAM, DELTA-INSERT1) post-rigor state
4E7S	;	2.25	;	Myosin VI D23R I24R R569E (MD) pre-powerstroke state
4PJL	;	2.1	;	Myosin VI motor domain A458E mutant in the Pi release state, space group P212121 -
4PFP	;	2.32	;	Myosin VI motor domain in the Pi release state (with Pi) space group P21
4PFO	;	1.75	;	Myosin VI motor domain in the Pi release state, space group P212121
4PJN	;	2.0	;	Myosin VI motor domain in the Pi release state, space group P212121 - shortly soaked with PO4
4PJM	;	2.05	;	Myosin VI motor domain in the Pi release state, space group P212121 - soaked with PO4 - located in the active site
4PK4	;	2.78	;	Myosin VI motor domain in the PPS state - from a Pi release state crystal, space group P212121 after long soaking with PO4
5O2L	;	2.2	;	Myosin VI motor domain in the Pre-Transition State
2BKH	;	2.4	;	Myosin VI nucleotide-free (MDInsert2) crystal structure
4DBP	;	2.2	;	Myosin VI nucleotide-free (MDINSERT2) D179Y crystal structure
3L9I	;	2.2	;	Myosin VI nucleotide-free (mdinsert2) L310G mutant crystal structure
2BKI	;	2.9	;	Myosin VI nucleotide-free (MDinsert2-IQ) crystal structure
8ARD	;	2.219	;	Myosin VI proximal tail domain, dimeric
5HMO	;	3.493	;	myosin X motor activity
3TFM	;	2.53	;	Myosin X PH1N-PH2-PH1C tandem
7KCH	;	4.33	;	Myosin XI-F-actin complex
6Z7U	;	2.58	;	Myosin-II motor domain complexed with blebbistatin in a new ADP-release conformation
7B1A	;	2.6	;	Myosin-II-AA mutant motor domain
4K27	;	2.35	;	Myotonic Dystrophy Type 2 RNA: Structural Studies and Designed Small Molecules that Modulate RNA Function
7LYE	;	1.758	;	Myotoxin I from Bothrops moojeni co-crystallized with synthetic inhibitor Varespladib (LY315920)
6MQF	;	1.693	;	Myotoxin II from Bothrops moojeni complexed with Acetylsalicylic acid
6MQD	;	1.6	;	Myotoxin II from Bothrops moojeni complexed with Rosmarinic Acid
5C16	;	2.07	;	Myotubularin-related proetin 1
5GNH	;	2.6	;	Myotubularin-related protein 2
7KLN	;	3.6	;	Myoviridae Phage XM1 Neck Region (12-fold)
2KJY	;		;	MYPT1(658-714)
2NMT	;	2.9	;	MYRISTOYL-COA:PROTEIN N-MYRISTOYLTRANSFERASE BOUND TO MYRISTOYL-COA AND PEPTIDE ANALOGS
2R2I	;	2.0	;	Myristoylated Guanylate Cyclase Activating Protein-1 with Calcium Bound
1QA5	;		;	MYRISTOYLATED HIV-1 NEF ANCHOR DOMAIN, NMR, 2 STRUCTURES
1IKU	;		;	myristoylated recoverin in the calcium-free state, NMR, 22 structures
1JSA	;		;	MYRISTOYLATED RECOVERIN WITH TWO CALCIUMS BOUND, NMR, 24 STRUCTURES
5LDL	;		;	Myristoylated T41I/T78I mutant of M-PMV matrix protein
1E4M	;	1.2	;	MYROSINASE FROM SINAPIS ALBA
1MYR	;	1.64	;	MYROSINASE FROM SINAPIS ALBA
1E6X	;	1.6	;	MYROSINASE FROM SINAPIS ALBA with a bound transition state analogue,D-glucono-1,5-lactone
1E71	;	1.5	;	MYROSINASE FROM SINAPIS ALBA with bound ascorbate
1E6S	;	1.35	;	MYROSINASE FROM SINAPIS ALBA with bound gluco-hydroximolactam and sulfate
1E72	;	1.6	;	Myrosinase from Sinapis alba with bound gluco-hydroximolactam and sulfate or ascorbate
1E6Q	;	1.35	;	MYROSINASE FROM SINAPIS ALBA with the bound transition state analogue gluco-tetrazole
5DYJ	;	2.5	;	Mysosin heavy chain kinase A catalytic domain mutant - D663A
2PQ8	;	1.45	;	MYST histone acetyltransferase 1
6CT2	;	2.128	;	MYST histone acetyltransferase KAT6A/B in complex with WM-1119
8TK7	;	2.53	;	Myxococcus xanthus EncA protein shell with compartmentalized SNAP-tag cargo protein
4PT2	;	4.6	;	Myxococcus xanthus encapsulin protein (EncA)
6HJH	;	3.3	;	Myxococcus xanthus MglA bound to GDP
6HJO	;	1.98	;	Myxococcus xanthus MglA bound to GDP
6H35	;	2.3	;	Myxococcus xanthus MglA bound to GDP and Pi with mixed inactive and active switch region conformations
6IZW	;	2.4	;	Myxococcus xanthus MglA bound to GTP-gamma-S and MglB
6H17	;	1.275	;	Myxococcus xanthus MglA bound to GTPgammaS
6H5B	;	2.8	;	Myxococcus xanthus MglA in complex with its GAP MglB and GTPgammaS
5YMX	;	1.35	;	Myxococcus xanthus MglA in GDP bound conformation
6HJM	;	2.39	;	Myxococcus xanthus MglB
4WHJ	;	3.2	;	Myxovirus Resistance Protein 2 (MxB)
1FFH	;	2.05	;	N AND GTPASE DOMAINS OF THE SIGNAL SEQUENCE RECOGNITION PROTEIN FFH FROM THERMUS AQUATICUS
1NG1	;	2.03	;	N AND GTPASE DOMAINS OF THE SIGNAL SEQUENCE RECOGNITION PROTEIN FFH FROM THERMUS AQUATICUS
2NG1	;	2.02	;	N AND GTPASE DOMAINS OF THE SIGNAL SEQUENCE RECOGNITION PROTEIN FFH FROM THERMUS AQUATICUS
3NG1	;	2.3	;	N AND GTPASE DOMAINS OF THE SIGNAL SEQUENCE RECOGNITION PROTEIN FFH FROM THERMUS AQUATICUS
2MKP	;		;	N domain of cardiac troponin C bound to the switch fragment of fast skeletal troponin I at pH 6
6IHG	;	2.397	;	N terminal domain of Mycobacterium avium complex Lon protease
7VBG	;		;	N Terminal Domain of PRC1
4M01	;	2.1	;	N terminal fragment(residues 245-575) of binding region of SraP
6F1U	;	3.4	;	N terminal region of dynein tail domains in complex with dynactin filament and BICDR-1
6OZZ	;	3.304	;	N terminally deleted GapR crystal structure from C. crescentus
7QF6	;	1.87	;	N(5)-hydroxyornithine:cis-anhydromevalonyl coenzyme A-N(5)-transacylase sidF
6LVV	;	2.8	;	N, N-dimethylformamidase
3WL4	;	1.54	;	N,N'-diacetylchitobiose deacetylase (Se-derivative) from Pyrococcus furiosus
4XM0	;	2.8	;	N,N'-diacetylchitobiose deacetylase (SeMet derivative) from Pyrococcus furiosus in the absence of cadmium
4XLZ	;	1.51	;	N,N'-diacetylchitobiose deacetylase (SeMet derivative) from Pyrococcus furiosus in the presence of cadmium
4XM2	;	2.3	;	N,N'-diacetylchitobiose deacetylase from Pyrococcus furiosus in the absence of cadmium
4XM1	;	1.8	;	N,N'-diacetylchitobiose deacetylase from Pyrococcus furiosus in the presence of cadmium
3WL3	;	2.0	;	N,N'-diacetylchitobiose deacetylase from Pyrococcus horikoshii
5B2E	;	1.8	;	N,N'-diacetylchitobiose deacetylase from Pyrococcus horikoshii complexed with its inhibitor MPG (acetate-containing condition)
5B2F	;	1.9	;	N,N'-diacetylchitobiose deacetylase from Pyrococcus horikoshii complexed with its inhibitor MPG (phosphate-containing condition)
8BGN	;	2.76	;	N,N-diacetylchitobiose deacetylase from Pyrococcus chitonophagus
8BGP	;	2.51	;	N,N-diacetylchitobiose deacetylase from Pyrococcus chitonophagus anomalous data
8BGO	;	3.08	;	N,N-diacetylchitobiose deacetylase from Pyrococcus chitonophagus with substrate N,N-diacetylchitobiose
2V0W	;	1.7	;	N- and C-terminal helices of oat LOV2 (404-546) are involved in light- induced signal transduction (cryo-trapped light structure of LOV2 (404-546))
2V0U	;	1.4	;	n- and c-terminal helices of oat lov2 (404-546) are involved in light-induced signal transduction (cryo dark structure of lov2 (404-546))
2V1A	;	1.65	;	N- and C-terminal helices of oat LOV2 (404-546) are involved in light-induced signal transduction (room temperature (293K) dark structure of LOV2 (404-546))
2V1B	;	1.55	;	N- and C-terminal helices of oat LOV2 (404-546) are involved in light-induced signal transduction (room temperature (293K) light structure of LOV2 (404-546))
3G49	;	2.5	;	N-(Pyridin-2-yl) Arylsulfonamide Inhibitors of 11b-Hydroxysteroid Dehydrogenase Type 1: Discovery of PF-915275
2QKX	;	2.75	;	N-acetyl glucosamine 1-phosphate uridyltransferase from Mycobacterium tuberculosis complex with N-acetyl glucosamine 1-phosphate
8HUY	;	2.45	;	N-acetyl-(R)-beta-phenylalanine acylase
8I5A	;	2.75	;	N-acetyl-(R)-beta-phenylalanine acylase, 2.75 angstrom resolution
8I59	;	3.21	;	N-acetyl-(R)-beta-phenylalanine acylase, selenomethionyl derivative
2EPM	;	2.04	;	N-acetyl-B-D-glucoasminidase (GCNA) from Stretococcus gordonii
2EPK	;	1.85	;	N-acetyl-B-D-glucosaminidase (GCNA) from Streptococcus gordonii
2EPL	;	1.4	;	N-acetyl-B-D-glucosaminidase (GCNA) from Streptococcus gordonii
2EPN	;	1.61	;	N-acetyl-B-D-glucosaminidase (GCNA) from Streptococcus gordonii
2EPO	;	1.56	;	N-acetyl-B-D-glucosaminidase (GCNA) from Streptococcus gordonii
6X7Y	;	1.0	;	N-acetyl-glucosamine-bound structure of Marinomonas primoryensis PA14 carbohydrate-binding domain
1GS5	;	1.5	;	N-acetyl-L-glutamate kinase from Escherichia coli complexed with its substrate N-acetylglutamate and its substrate analog AMPPNP
1FIH	;	1.95	;	N-ACETYLGALACTOSAMINE BINDING MUTANT OF MANNOSE-BINDING PROTEIN A (QPDWG-HDRPY), COMPLEX WITH N-ACETYLGALACTOSAMINE
1FIF	;	1.95	;	N-ACETYLGALACTOSAMINE-SELECTIVE MUTANT OF MANNOSE-BINDING PROTEIN-A (QPDWG-HDRPY)
7P9Y	;	1.94	;	N-acetylglucosamine kinase from Plesiomonas shigelloides compexed with alpha-N-acetylglucosamine
7P7W	;	1.57	;	N-acetylglucosamine kinase from Plesiomonas shigelloides compexed with alpha-N-acetylglucosamine and ADP
7P9P	;	2.11	;	N-acetylglucosamine kinase from Plesiomonas shigelloides compexed with alpha-N-acetylglucosamine and AMP-PNP inhibitor
7P9L	;	1.75	;	N-acetylglucosamine kinase from Plesiomonas shigelloides compexed with alpha-N-acetylglucosamine-6-phosphate
7S6N	;	2.7	;	N-acetylglucosamine-1-phosphotransferase (GNPT) alpha and beta subunits (GNPTAB) catalytic domain, from zebrafish
7SJ2	;	2.3	;	N-acetylglucosamine-1-phosphotransferase (GNPT) alpha and beta subunits (GNPTAB) catalytic domain, from zebrafish, in complex with uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) and magnesium
7S69	;	3.04	;	N-acetylglucosamine-1-phosphotransferase (GNPT) gamma subunit (GNPTG), from clawed frog
6F04	;	1.699	;	N-acetylglucosamine-2-epimerase
3IV8	;	2.53	;	N-acetylglucosamine-6-phosphate deacetylase from Vibrio cholerae complexed with fructose 6-phosphate
3EGJ	;	2.9	;	N-acetylglucosamine-6-phosphate deacetylase from Vibrio cholerae.
4USJ	;	2.85	;	N-acetylglutamate kinase from Arabidopsis thaliana in complex with PII from Chlamydomonas reinhardtii
4WH1	;	2.05	;	N-Acetylhexosamine 1-kinase (ligand free)
4WH2	;	1.847	;	N-acetylhexosamine 1-kinase in complex with ADP
4WH3	;	1.8	;	N-acetylhexosamine 1-kinase in complex with ATP
4OCQ	;	1.878	;	N-acetylhexosamine 1-phosphate kinase in complex with GalNAc
4OCJ	;	1.571	;	N-acetylhexosamine 1-phosphate kinase in complex with GlcNAc
4OCK	;	1.72	;	N-acetylhexosamine 1-phosphate kinase in complex with GlcNAc and AMPPNP
4OCO	;	2.16	;	N-acetylhexosamine 1-phosphate kinase in complex with GlcNAc-1-phosphate
4OCP	;	1.938	;	N-acetylhexosamine 1-phosphate kinase in complex with GlcNAc-1-phosphate and ADP
4OCU	;	1.904	;	N-acetylhexosamine 1-phosphate kinase_ATCC15697 in complex with GlcNAc
4OCV	;	1.472	;	N-acetylhexosamine 1-phosphate kinase_ATCC15697 in complex with GlcNAc and AMPPNP
6Q26	;	2.328	;	N-Acetylmannosamine kinase from Staphylococcus aureus
6Q27	;	2.2	;	N-acetylmannosamine kinase with N-acetylmannosamine from Staphylococcus aureus
7MFN	;	1.55	;	N-Acetylmannosamine-6-phosphate 2-epimerase E180A from Staphylococcus aureus (strain MRSA USA300)
6VVA	;	1.84	;	N-Acetylmannosamine-6-phosphate 2-epimerase from Staphylococcus aureus (strain MRSA USA300)
7MQT	;	1.88	;	N-Acetylmannosamine-6-phosphate 2-epimerase from Staphylococcus aureus (strain MRSA USA300) with 5-deoxy substrate bound
7MFS	;	1.51	;	N-Acetylmannosamine-6-phosphate 2-epimerase from Staphylococcus aureus (strain MRSA USA300) with substrate and product bound
5EMI	;	1.12	;	N-acetylmuramoyl-L-alanine amidase AmiC2 of Nostoc punctiforme
8C4D	;	1.97	;	N-acetylmuramoyl-L-alanine amidase from Enterococcus faecium prophage genome
6SSC	;	1.21	;	N-acetylmuramoyl-L-alanine amidase LysC from Clostridium intestinale URNW
5KZE	;	1.74	;	N-acetylneuraminate lyase from methicillin-resistant Staphylococcus aureus
5KZD	;	2.334	;	N-acetylneuraminate lyase from methicillin-resistant Staphylococcus aureus with bound sialic acid alditol
1FDY	;	2.45	;	N-ACETYLNEURAMINATE LYASE IN COMPLEX WITH HYDROXYPYRUVATE
1FDZ	;	2.6	;	N-ACETYLNEURAMINATE LYASE IN COMPLEX WITH PYRUVATE VIA BOROHYDRIDE REDUCTION
4JEV	;	1.67	;	N-acetylornithine aminotransferase from S. typhimurium complexed with gabaculine
4JEW	;	1.48	;	N-acetylornithine aminotransferase from S. typhimurium complexed with L-canaline
6TR6	;	1.35	;	N-acetylserotonin-Notum complex
4A6G	;	2.71	;	N-acyl amino acid racemase from Amycalotopsis sp. Ts-1-60: G291D- F323Y mutant in complex with N-acetyl methionine
5FJP	;	2.58	;	N-acyl amino acid racemase from Amycolatopsis sp Ts-1-60: G291D F323Y I293G mutant in complex with N-acetyl naphthylalanine
5FJT	;	2.11	;	N-acyl amino acid racemase from Amycolatopsis sp. Ts-1-60: G291D F323 mutant in complex with N-acetyl phenylalanine
5FJO	;	2.08	;	N-acyl amino acid racemase from Amycolatopsis sp. Ts-1-60: G291D- F323Y mutant in complex with N-acetyl naphthylalanine
5FJR	;	2.44	;	N-acyl amino acid racemase from Amycolatopsis sp. Ts-1-60: Q26A M50I G291D F323Y mutant in complex with N-acetyl napthylalanine
5FJU	;	2.52	;	N-acyl amino acid racemase from Amycolatopsis sp. Ts-1-60: Q26A M50I G291D F323Y mutant in complex with N-acetyl phenylalanine
4WKS	;	1.629	;	n-Alkylboronic Acid Inhibitors Reveal Determinants of Ligand Specificity in the Quorum-Quenching and Siderophore Biosynthetic Enzyme PvdQ
4WKT	;	1.782	;	n-Alkylboronic Acid Inhibitors Reveal Determinants of Ligand Specificity in the Quorum-Quenching and Siderophore Biosynthetic Enzyme PvdQ
4WKU	;	2.0	;	n-Alkylboronic Acid Inhibitors Reveal Determinants of Ligand Specificity in the Quorum-Quenching and Siderophore Biosynthetic Enzyme PvdQ
4WKV	;	2.1434	;	n-Alkylboronic Acid Inhibitors Reveal Determinants of Ligand Specificity in the Quorum-Quenching and Siderophore Biosynthetic Enzyme PvdQ
7S1N	;	2.11	;	N-Aromatic-Substituted Indazole Derivatives as Brain Penetrant and Orally Bioavailable JNK3 Inhibitors
3FR2	;	2.2	;	N-Benzyl-indolo carboxylic acids: Design and synthesis of potent and selective adipocyte Fatty-Acid Binding Protein (A-FABP) inhibitors
3FR4	;	2.16	;	N-Benzyl-indolo carboxylic acids: Design and synthesis of potent and selective adipocyte Fatty-Acid Binding Protein (A-FABP) inhibitors
3FR5	;	2.2	;	N-Benzyl-indolo carboxylic acids: Design and synthesis of potent and selective adipocyte Fatty-Acid Binding Protein (A-FABP) inhibitors
1NBB	;	2.4	;	N-BUTYLISOCYANIDE BOUND RHODOBACTER CAPSULATUS CYTOCHROME C'
1NCJ	;	3.4	;	N-CADHERIN, TWO-DOMAIN FRAGMENT
8C46	;	2.0	;	N-Carbamoyl-beta-Alanine Amidohydrolases from Rhizobium radiobacter MDC 8606
8I99	;	3.17	;	N-carbamoyl-D-amino-acid hydrolase mutant - M4Th3
6P29	;	1.5	;	N-demethylindolmycin synthase (PluN2) in complex with N-demethylindolmycin
3ZRI	;	1.8	;	N-domain of ClpV from Vibrio cholerae
2H8M	;	1.8	;	N-Domain Of Grp94 In Complex With the 2-Iodo-NECA
2HCH	;	2.3	;	N-Domain Of Grp94 In Complex With the Novel Ligand N-(2-amino)ethyl Carboxyamido Adenosine
2HG1	;	2.3	;	N-Domain Of Grp94 In Complex With the Novel Ligand N-(2-hydroxyl)ethyl Carboxyamido Adenosine
2GQP	;	1.5	;	N-Domain Of Grp94 In Complex With the Novel Ligand N-Propyl Carboxyamido Adenosine
1U0Z	;	1.9	;	N-Domain Of Grp94 Lacking The Charged Domain In Complex With Radicicol
6D1X	;	2.3	;	N-Domain Of Grp94, with the Charged Domain, In Complex With the Novel Ligand N-Propyl Carboxyamido Adenosine
3TJQ	;	2.001	;	N-domain of HtrA1
3LSD	;	2.03	;	N-Domain of human adhesion/growth-regulatory galectin-9
3LSE	;	2.69	;	N-Domain of human adhesion/growth-regulatory galectin-9 in complex with lactose
1ZAC	;		;	N-DOMAIN OF TROPONIN C FROM CHICKEN SKELETAL MUSCLE, NMR, MINIMIZED AVERAGE STRUCTURE
6RJ1	;	2.65	;	N-Domain P40/P90 Mycoplasma pneumoniae
6TLZ	;	3.1	;	N-Domain P40/P90 Mycoplasma pneumoniae complexed with 3'SL
6TM0	;	2.8	;	N-Domain P40/P90 Mycoplasma pneumoniae complexed with 6'SL
1GYA	;		;	N-GLYCAN AND POLYPEPTIDE NMR SOLUTION STRUCTURES OF THE ADHESION DOMAIN OF HUMAN CD2
7CU5	;	2.81	;	N-Glycosylation of PD-1 and glycosylation dependent binding of PD-1 specific monoclonal antibody camrelizumab
6D4G	;	2.8	;	N-GTPase domain of p190RhoGAP-A
2GEH	;	2.0	;	N-Hydroxyurea, a versatile zinc binding function in the design of metalloenzyme inhibitors
2OTZ	;	2.07	;	N-methylaniline in complex with T4 Lysozyme L99A
2RBT	;	1.24	;	n-methylbenzylamine in complex with Cytochrome C Peroxidase W191G
1NMT	;	2.45	;	N-MYRISTOYL TRANSFERASE FROM CANDIDA ALBICANS AT 2.45 A
5UUT	;	2.252	;	N-myristoyltransferase 1 (NMT) bound to myristoyl-CoA
2KIC	;		;	n-NafY. N-terminal domain of NafY
2RBN	;	1.29	;	N-phenylglycinonitrile in complex with T4 lysozyme L99A/M102Q
2FG7	;	2.9	;	N-succinyl-L-ornithine transcarbamylase from B. fragilis complexed with carbamoyl phosphate and N-succinyl-L-norvaline
2FG6	;	2.8	;	N-succinyl-L-ornithine transcarbamylase from B. fragilis complexed with sulfate and N-succinyl-L-norvaline
7BOZ	;	3.8	;	N-teminal of mature bacteriophage T7 tail fiber protein gp17
1SKH	;		;	N-terminal (1-30) of bovine Prion protein
1SYO	;	2.2	;	N-terminal 3 domains of CI-MPR bound to mannose 6-phosphate
1SZ0	;	2.1	;	N-terminal 3 domains of CI-MPR bound to mannose 6-phosphate
1H7S	;	1.95	;	N-terminal 40kDa fragment of human PMS2
1EA6	;	2.7	;	N-terminal 40kDa fragment of NhPMS2 complexed with ADP
4WUB	;	1.75	;	N-terminal 43 kDa fragment of the E. coli DNA gyrase B subunit grown from 100 mM KCl condition
4XTJ	;	1.92	;	N-terminal 43 kDa fragment of the E. coli DNA gyrase B subunit grown from 100 mM KCl plus 100 mM NaCl condition
4WUC	;	1.9	;	N-terminal 43 kDa fragment of the E. coli DNA gyrase B subunit grown from 100 mM NaCl condition
4WUD	;	1.95	;	N-terminal 43 kDa fragment of the E. coli DNA gyrase B subunit grown from no salt condition
6ZT3	;	1.56	;	N-terminal 47 kDa fragment of the Mycobacterium smegmatis DNA Gyrase B subunit complexed with ADPNP
6V02	;	2.46	;	N-terminal 5 domains of CI-MPR
6P8I	;	2.54	;	N-terminal 5 domains of IGFIIR
3U1A	;	2.0	;	N-terminal 81-aa fragment of smooth muscle tropomyosin alpha
3U59	;	2.5	;	N-terminal 98-aa fragment of smooth muscle tropomyosin beta
3TDU	;	1.5	;	N-terminal acetylation acts as an avidity enhancer within an interconnected multiprotein complex: Structure of a human Cul1WHB-Dcn1P-acetylated Ubc12N complex
3TDZ	;	2.0	;	N-terminal acetylation acts as an avidity enhancer within an interconnected multiprotein complex: Structure of a human Cul1WHB-Dcn1P-stapled acetylated Ubc12N complex
1DXX	;	2.6	;	N-terminal Actin-binding Domain of Human Dystrophin
1AOA	;	2.4	;	N-TERMINAL ACTIN-CROSSLINKING DOMAIN FROM HUMAN FIMBRIN
4M6A	;	2.71	;	N-Terminal beta-Strand Swapping in a Consensus Derived Alternative Scaffold Driven by Stabilizing Hydrophobic Interactions
8B97	;	0.97	;	N-terminal beta-trefoil lectin domain of the Laccaria bicolor lectin in complex with N-acetyl-lactosamine
5WMD	;	1.27	;	N-terminal bromodomain of BRD4 in complex with OTX-015
5WMG	;	1.19	;	N-terminal bromodomain of BRD4 in complex with OTX-015
5WMA	;	1.401	;	N-terminal bromodomain of BRD4 in complex with PLX5981
6MO8	;	1.8	;	N-terminal bromodomain of human BRD2 in complex with 4,4'-(quinoline-5,7-diyl)bis(3,5-dimethylisoxazole) inhibitor
6MO9	;	1.801	;	N-terminal bromodomain of human BRD2 in complex with N-cyclopentyl-7-(3,5-dimethylisoxazol-4-yl)quinoline-5-sulfonamide inhibitor
4UYH	;	1.73	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 1-((2R,4S)-2-methyl-4-(phenylamino)-6-(4-(piperidin-1-ylmethyl)phenyl)-3,4-dihydroquinolin-1(2H)-yl)ethanone
4A9H	;	2.05	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 1-(2-methyl-1,2,3,4-tetrahydroquinolin-1-yl)ethan-1-one
4A9F	;	1.73	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 1-METHYLPYRROLIDIN-2-ONE
4ALH	;	1.97	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 3,5 dimethyl-4-phenyl-1,2- oxazole
4A9E	;	1.91	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 3-methyl-1,2,3,4- tetrahydroquinazolin-2-one
4A9I	;	2.25	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 3-methyl-1,2,3,4- tetrahydroquinazolin-2-one
4A9O	;	1.78	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 5 ethyl-3-methyl-4-phenyl-1, 2-oxazole
6TQ2	;	2.26	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 5-(4-(4-fluorophenyl)-1H-imidazol-5-yl)-1-methylpyridin-2(1H)-one
6DB0	;	1.7	;	N-Terminal bromodomain of Human BRD2 with a Tetrahydroquinoline analogue
4UYF	;	1.6	;	N-Terminal bromodomain of Human BRD2 with I-BET726 (GSK1324726A)
4ALG	;	1.6	;	N-Terminal Bromodomain of Human BRD2 With IBET-151
6MO7	;	1.85	;	N-terminal bromodomain of human BRD2 with N-((4-(3-(N-cyclopentylsulfamoyl)-4-methylphenyl)-3-methylisoxazol-5-yl)methyl)acetamide inhibitor
4A9J	;	1.9	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N-(4-hydroxyphenyl) acetamide
4A9M	;	2.06	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N-cyclopentyl-5-(3,5- dimethyl-1,2-oxazol-4-yl)-2-methylbenzene-1-sulfonamide
4A9N	;	1.85	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N-cyclopropyl-5-(3,5- dimethyl-1,2-oxazol-4-yl)-2-methylbenzene-1-sulfonamide
4AKN	;	1.82	;	N-Terminal Bromodomain of Human BRD2 With tbutyl-phenyl-amino- dimethyl-oxazolyl-quinoline-carboxylic acid
6Z7M	;	1.26	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 (3R,4R)-N-cyclohexyl-4-((3-methyl-2-oxo-1,2-dihydro-1,7-naphthyridin-8-yl)amino)piperidine-3-carboxamide
8PXN	;	1.952	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH (1R,1'R)-7,7'-(ethane-1,2-diylbis(oxy))bis(1,3-dimethyl-1,3-dihydro-2H-benzo[d]azepin-2-one)
8PXM	;	2.378	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH (1R,1'R)-7,7'-(pentane-1,5-diylbis(oxy))bis(1,3-dimethyl-1,3-dihydro-2H-benzo[d]azepin-2-one)
8PXA	;	1.3	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH (S)-5-(1-((1-(1-isopropylpiperidine-4-carbonyl)piperidin-3-yl)methyl)-1H-benzo[d]imidazol-2-yl)-1,3-dimethylpyridin-2(1H)-one
4UYD	;	1.37	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 1,3-dimethyl-2-oxo-2,3- dihydro-1H-1,3-benzodiazole-5-carboxamide
6TPY	;	1.8	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 1,3-dimethyl-5-(1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one
4A9L	;	1.6	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 1,3-DIMETHYL-6-(MORPHOLINE- 4-SULFONYL)-1,2,3,4-TETRAHYDROQUINAZOLIN-2-ONE
6TPX	;	1.48	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 1-((1-acetylpiperidin-4-yl)methyl)-2-(4-hydroxy-3,5-dimethylphenyl)-N-methyl-1H-benzo[d]imidazole-5-carboxamide
5ACY	;	2.01	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 1-(2R,4S)-2-methyl-4-(phenylamino)-6-4-(piperidin-1-ylmethyl)phenyl-1,2,3,4- tetrahydroquinolin-1-yl-ethan-1-one
7A9U	;	1.444	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 3-(3-(but-3-yn-1-yl)-3H-diazirin-3-yl)-N-(3-methyl-[1,2,4]triazolo[4,3-a]pyridin-8-yl)propanamide
5MKZ	;	1.62	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 4-chloro-2-methyl-5-(((3-methylthiophen-2-yl)methyl)amino)pyridazin-3(2H)-one
5MLI	;	1.63	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 4-chloro-2-methyl-5-(methylamino)pyridazin-3(2H)-one
6TPZ	;	1.299	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 5-(1-(1,3-dimethoxypropan-2-yl)-5-morpholino-1H-benzo[d]imidazol-2-yl)-1,3-dimethylpyridin-2(1H)-one
6TQ1	;	1.9	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 5-(1-(1,3-dimethoxypropan-2-yl)-5-morpholino-1H-benzo[d]imidazol-2-yl)-1,3-dimethylpyridin-2(1H)-one
5LJ2	;	1.19	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 5-(5-aminopyridin-3-yl)-8-(((3R,4R)-3-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)methoxy)piperidin-4-yl)amino)-3-methyl-1,7-naphthyridin-2(1H)-one
4UIZ	;	1.19	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 7-(3,4-dimethoxyphenyl)-2-(4-methanesulfonylpiperazine-1-carbonyl)-5-methyl-4H,5H-thieno-3,2-c- pyridin-4-one
4UIX	;	1.58	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 7-(3,4-dimethoxyphenyl)-N-(1,1-dioxo-1-thian-4-yl)-5-methyl-4-oxo-4H,5H-thieno-3,2-c-pyridine-2- carboxamide
5LJ1	;	1.9	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 8-(((3R,4R,5S)-3-((4,4-difluorocyclohexyl)methoxy)-5-methoxypiperidin-4-yl)amino)-3-methyl-5-(5-methylpyridin-3-yl)-1,7-naphthyridin-2(1H)-one
5A85	;	1.72	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 8-(3R,4R)-3-(cyclohexylmethoxy)piperidin-4-ylamino-3-methyl-1,2-dihydro-1,7- naphthyridin-2-one
6HDQ	;	1.7	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH : 8-(((1R,2R,3R,5S)-2-(2-(4,4-difluorocyclohexyl)ethyl)-8-azabicyclo[3.2.1]octan-3-yl)amino)-3-methyl-5-(5-methylpyridin-3-yl)-1,7-naphthyridin-2(1H)-one
7P6V	;	1.17	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH compound 3ag
7P6W	;	1.31	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH compound 3bg
7P6Y	;	1.881	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH compound 5ef
4BJX	;	1.59	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH GSK1324726A (I-BET726)
6ZB3	;	1.419	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH GSK620
6Z7L	;	1.624	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 with GSK789
7O18	;	1.7	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH I-BET282
4CL9	;	1.4	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH I-BET295
7QDL	;	1.67	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 with I-BET567
4CLB	;	1.6	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH IBET-295
6SWN	;	1.28	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH iBET-BD1 (GSK778)
6SWQ	;	1.601	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH iBET-BD2 (GSK046)
4CFK	;	1.55	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH LY294002
4CFL	;	1.32	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH LY303511
4UIY	;	1.3	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH N-(1,1-dioxo-1-thian-4-yl)- 5-methyl-4-oxo-7-3-(trifluoromethyl)phenyl-4H,5H-thieno-3,2-c- pyridine-2-carboximidamide
6Z7G	;	1.59	;	N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH N-(2-(1H-imidazol-4-yl)ethyl)-4-acetamido-3-(benzyloxy)benzamide
4ICW	;	2.2	;	N-terminal C2 domain of human CEP120
4ICX	;	2.7	;	N-terminal C2 domain of human CEP120
7NF9	;		;	N-terminal C2H2 Zn-finger domain of Clamp
2PQ3	;	1.3	;	N-Terminal Calmodulin Zn-Trapped Intermediate
1ULP	;		;	N-TERMINAL CELLULOSE-BINDING DOMAIN FROM CELLULOMONAS FIMI BETA-1,4-GLUCANASE C, NMR, 25 STRUCTURES
1ULO	;		;	N-TERMINAL CELLULOSE-BINDING DOMAIN FROM CELLULOMONAS FIMI BETA-1,4-GLUCANASE C, NMR, MINIMIZED AVERAGE STRUCTURE
3Q0X	;	3.02	;	N-terminal coiled-coil dimer domain of C. reinhardtii SAS-6 homolog Bld12p
4GFA	;	3.55	;	N-terminal coiled-coil dimer of C.elegans SAS-6, crystal form A
4GFC	;	2.85	;	N-terminal coiled-coil dimer of C.elegans SAS-6, crystal form B
1GJJ	;		;	N-TERMINAL CONSTANT REGION OF THE NUCLEAR ENVELOPE PROTEIN LAP2
3I8T	;	2.1	;	N-terminal CRD1 domain of mouse Galectin-4 in complex with lactose
4B2F	;	1.88	;	N-terminal deletion mutant of an outer surface protein BBA73 from Borrelia burgdorferi
2NZ8	;	2.0	;	N-terminal DHPH cassette of Trio in complex with nucleotide-free Rac1
4ICG	;	2.9217	;	N-terminal dimerization domain of H-NS in complex with Hha (Salmonella Typhimurium)
1BB8	;		;	N-TERMINAL DNA BINDING DOMAIN FROM TN916 INTEGRASE, NMR, 25 STRUCTURES
2BB8	;		;	N-TERMINAL DNA BINDING DOMAIN FROM TN916 INTEGRASE, NMR, MINIMIZED AVERAGE STRUCTURE
4ZLX	;	2.31	;	N-terminal DNA binding domain of the antitoxin Phd from phage P1
4HH5	;	2.0	;	N-terminal domain (1-163) of ClpV1 ATPase from E.coli EAEC Sci1 T6SS.
7BUT	;		;	N-terminal domain (NTD) Solution structure of aciniform spidroin (AcSpN) from Nephila antipodiana.
1D2W	;	1.89	;	N-TERMINAL DOMAIN CORE METHIONINE MUTATION
1D2Y	;	2.06	;	N-TERMINAL DOMAIN CORE METHIONINE MUTATION
1D3F	;	2.05	;	N-TERMINAL DOMAIN CORE METHIONINE MUTATION
1D3J	;	1.97	;	N-TERMINAL DOMAIN CORE METHIONINE MUTATION
7UJB	;	4.12	;	N-terminal domain deletion variant of Eta
2WHN	;	2.05	;	N-terminal domain from the PilC type IV pilus biogenesis protein
6HS5	;	1.8	;	N-terminal domain including the conserved ImpA_N region of the TssA component of the type VI secretion system from Burkholderia cenocepacia
5N4K	;	1.49	;	N-terminal domain of a human Coronavirus NL63 nucleocapsid protein
8JFR	;	3.1	;	N-terminal domain of AcrIIA15 in complex with palindromic DNA substrate
2WQ4	;	1.42	;	N-terminal domain of BC2L-C Lectin from Burkholderia cenocepacia
5HM6	;	2.0	;	N-terminal domain of BfmR from Acinetobacter baumannii
2MEK	;		;	N-terminal domain of Bilbo1 from Trypanosoma brucei
3UA0	;	3.0	;	N-Terminal Domain of Bombyx mori Fibroin Mediates the Assembly of Silk in Response to pH Decrease
6YQZ	;	1.39	;	N-terminal domain of BRD4 with biphenyl-methyamino-dimethylpyridazinone
4GQT	;	2.15	;	N-terminal domain of C. elegans Hsp90
3Q0Y	;	2.1	;	N-terminal domain of C. reinhardtii SAS-6 homolog Bld12p
4TPZ	;	1.8	;	N-terminal domain of C. Reinhardtii SAS-6 homolog bld12p F145W (NN2)
4TTY	;	1.9	;	N-terminal domain of C. Reinhardtii SAS-6 homolog bld12p G94D F145W Q147R (NN25)
4TTW	;	1.2	;	N-terminal domain of C. Reinhardtii SAS-6 homolog bld12p K105C F145C (NN18)
4TQ7	;	2.643	;	N-terminal domain of C. Reinhardtii SAS-6 homolog bld12p Q93E (NN10)
4TO7	;	1.252	;	N-Terminal domain of C. Reinhardtii SAS-6 homolog bld12p Q93E F145W K146R (NN24)
4TTX	;	2.498	;	N-terminal domain of C. Reinhardtii SAS-6 homolog bld12p variant G94C K146C (NN19)
4TTZ	;	2.5	;	N-terminal domain of C. Reinhardtii SAS-6 homolog bld12p variant G94E F145W Q147K (NN26)
4U2J	;	2.0	;	N-terminal domain of C. Reinhardtii SAS-6 homolog bld12p variant Q93E F145W (NN27)
4U2I	;	2.281	;	N-terminal domain of C. Rheinhardtii SAS-6 homolog bld12p Q93E G94D K146R Q147R (NN23)
2KGF	;		;	N-terminal domain of capsid protein from the Mason-Pfizer monkey virus
2CBL	;	2.1	;	N-TERMINAL DOMAIN OF CBL IN COMPLEX WITH ITS BINDING SITE ON ZAP-70
7P3A	;	2.0	;	N-terminal domain of CGI-99
4NC7	;	2.0	;	N-terminal domain of delta-subunit of RNA polymerase complexed with I3C and nickel ions
4NC8	;	2.17	;	N-terminal domain of delta-subunit of RNA polymerase complexed with nickel ions
4PQL	;	2.444	;	N-Terminal domain of DNA binding protein
1B79	;	2.3	;	N-TERMINAL DOMAIN OF DNA REPLICATION PROTEIN DNAB
8U1J	;	3.0	;	N-Terminal domain of DNA-Damage Response Protein C (DdrC) from Deinococcus radiodurans - Crystal form xMJ7102
6SHW	;	2.0	;	N-terminal domain of Drosophila X Virus VP3
6SI6	;	1.98	;	N-terminal domain of Drosophila X virus VP3
6PQT	;		;	N-terminal domain of dynein intermediate chain from Chaetomium thermophilum
6T22	;	2.21	;	N-terminal domain of EcoKMcrA restriction endonuclease (NEco) in complex with T5hmCGA target sequence
6T21	;	2.07	;	N-terminal domain of EcoKMcrA restriction endonuclease (NEco) in complex with T5mCGA target sequence
2M7M	;		;	N-terminal domain of EhCaBP1 structure
5T12	;	2.299	;	N-terminal domain of Enzyme 1 - Nitrogen
1AOY	;		;	N-TERMINAL DOMAIN OF ESCHERICHIA COLI ARGININE REPRESSOR NMR, 23 STRUCTURES
5CE6	;	1.7	;	N-terminal domain of FACT complex subunit SPT16 from Cicer arietinum (chickpea)
6A8M	;	1.7	;	N-terminal domain of FACT complex subunit SPT16 from Eremothecium gossypii (Ashbya gossypii)
2F4E	;	2.32	;	N-terminal domain of FKBP42 from Arabidopsis thaliana
7OOM	;	1.8	;	N-terminal domain of FlSp spidroin from Nephila clavipes
4X9L	;	3.1	;	N-terminal domain of Heat shock protein 90 from Oryza sativa
6C5D	;	1.97	;	N-terminal domain of Helicobacter pylori LlaJI.R1
7CZO	;	2.7	;	N-terminal domain of HipA toxin
4YTE	;	2.15	;	N-terminal domain of HmdIII from Methanocaldococcus jannaschii
4XC0	;	1.77	;	N-terminal domain of Hsp90 from Dictyostelium discoideum in complex with ACP
4XCJ	;	1.75	;	N-terminal domain of Hsp90 from Dictyostelium discoideum in complex with ADP
4XCL	;	1.21	;	N-terminal domain of Hsp90 from Dictyostelium discoideum in complex with AGS
4XD8	;	1.55	;	N-terminal domain of Hsp90 from Dictyostelium discoideum in complex with ANP
4XDM	;	1.5	;	N-terminal domain of Hsp90 from Dictyostelium discoideum in complex with Geldanamycin
4XE2	;	1.199	;	N-terminal domain of Hsp90 from Dictyostelium discoideum in complex with peptide
4XKA	;	2.0	;	N-terminal domain of Hsp90 from Dictyostelium discoideum in hexagonal form with glycerol
4XKO	;	2.455	;	N-terminal domain of Hsp90 from Dictyostelium discoideum in hexagonal form with PEG
8CDY	;	1.9	;	N-terminal domain of human apolipoprotein E
8CE0	;	1.75	;	N-terminal domain of human apolipoprotein E
2W50	;	1.6	;	N-terminal domain of human conserved dopamine neurotrophic factor (CDNF)
1UUJ	;	1.75	;	N-terminal domain of Lissencephaly-1 protein (Lis-1)
6R64	;	2.64	;	N-terminal domain of modification dependent EcoKMcrA restriction endonuclease (NEco) in complex with C5mCGG target sequence
5M0W	;	1.39	;	N-terminal domain of mouse Shisa 3
6VZD	;	1.88	;	N-terminal domain of mouse surfactant protein B (K46E/R51E mutant) with bound lipid
6VYN	;	2.2	;	N-terminal domain of mouse surfactant protein B with bound lipid, wild type
6W1B	;	2.31	;	N-terminal domain of mouse surfactant protein B with bound lipid, Y59A/H79A mutant
7MBK	;	2.17	;	N-terminal domain of mouse surfactant protein B, 6W mutant
3WDB	;	1.37	;	N-terminal domain of Mycobacterium tuberculosis ClpC1
3WDC	;	1.18	;	N-terminal domain of Mycobacterium tuberculosis ClpC1 bound to Cyclomarin A
1QCS	;	1.9	;	N-TERMINAL DOMAIN OF N-ETHYLMALEIMIDE SENSITIVE FACTOR (NSF)
2V75	;	1.8	;	N-terminal domain of Nab2
4YE7	;	1.4	;	N-terminal domain of Orf22, a Cydia pomonella granulovirus envelope protein
3UH8	;	2.3	;	N-terminal domain of phage TP901-1 ORF48
8BCQ	;	2.7	;	N-terminal domain of Plasmodium berghei glutamyl-tRNA synthetase (native crystal structure)
8BHD	;	3.17	;	N-terminal domain of Plasmodium berghei glutamyl-tRNA synthetase (Tbxo4 derivative crystal structure)
7M0S	;	1.64	;	N-terminal domain of PmrA from Acinetobacter baumannii
3ZFJ	;		;	N-terminal domain of pneumococcal PhtD protein with bound Zn(II)
3IC5	;	2.08	;	N-terminal domain of putative saccharopine dehydrogenase from Ruegeria pomeroyi.
8E2B	;	1.95	;	N-terminal domain of S. aureus GpsB
8E2C	;	2.4	;	N-terminal domain of S. aureus GpsB in complex with PBP4 fragment
3ZN3	;	1.9	;	N-terminal domain of S. pombe Cdc23 APC subunit
1QHK	;		;	N-TERMINAL DOMAIN OF SACCHAROMYCES CEREVISIAE RNASE HI REVEALS A FOLD WITH A RESEMBLANCE TO THE N-TERMINAL DOMAIN OF RIBOSOMAL PROTEIN L9
1CR5	;	2.3	;	N-TERMINAL DOMAIN OF SEC18P
1QFP	;	2.8	;	N-TERMINAL DOMAIN OF SIALOADHESIN (MOUSE)
1QFO	;	1.85	;	N-TERMINAL DOMAIN OF SIALOADHESIN (MOUSE) IN COMPLEX WITH 3'SIALYLLACTOSE
1URL	;	2.4	;	N-TERMINAL DOMAIN OF SIALOADHESIN (MOUSE) IN COMPLEX WITH GLYCOPEPTIDE
6N0S	;	1.92	;	N-terminal domain of Staphylothermus marinus McrB
4GCN	;	1.85	;	N-terminal domain of stress-induced protein-1 (STI-1) from C.elegans
1PFT	;		;	N-TERMINAL DOMAIN OF TFIIB, NMR
1MWP	;	1.8	;	N-TERMINAL DOMAIN OF THE AMYLOID PRECURSOR PROTEIN
2K7R	;		;	N-terminal domain of the Bacillus subtilis helicase-loading protein DnaI
4PH3	;	2.44	;	N-terminal domain of the capsid protein from bovine leukaemia virus (with no beta-hairpin)
3ZHI	;	1.6	;	N-terminal domain of the CI repressor from bacteriophage TP901-1
3ZHM	;	2.6	;	N-terminal domain of the CI repressor from bacteriophage TP901-1 in complex with the OL2 operator half-site
1ABV	;		;	N-TERMINAL DOMAIN OF THE DELTA SUBUNIT OF THE F1F0-ATP SYNTHASE FROM ESCHERICHIA COLI, NMR, MINIMIZED AVERAGE STRUCTURE
2KXE	;		;	N-terminal domain of the DP1 subunit of an archaeal D-family DNA polymerase
5ME8	;	3.2	;	N-terminal domain of the human tumor suppressor ING5
5MTO	;	3.1	;	N-terminal domain of the human tumor suppressor ING5 C19S mutant
3H43	;	2.1	;	N-terminal domain of the proteasome-activating nucleotidase of Methanocaldococcus jannaschii
2B29	;	1.6	;	N-terminal domain of the RPA70 subunit of human replication protein A.
5CHS	;	1.8	;	N-terminal domain of the vesicular stomatitis virus L protein
4B8B	;	2.801	;	N-Terminal domain of the yeast Not1
6P0F	;	1.683	;	N-terminal domain of Thermococcus Gammatolerans McrB
6P0G	;	2.27	;	N-terminal domain of Thermococcus Gammatolerans McrB bound to m5C DNA
3PFU	;	1.8	;	N-terminal domain of Thiol:disulfide interchange protein DsbD in its reduced form
2TMP	;		;	N-TERMINAL DOMAIN OF TISSUE INHIBITOR OF METALLOPROTEINASE-2 (N-TIMP-2), NMR, 49 STRUCTURES
2C5K	;	2.05	;	N-terminal domain of tlg1 complexed with N-terminus of vps51
2C5I	;	2.3	;	N-terminal domain of tlg1 complexed with N-terminus of vps51 in distorted conformation
2C5J	;	2.1	;	N-terminal domain of tlg1, domain-swapped dimer
6O6D	;	1.82	;	N-terminal domain of translation initiation factor IF-3 from Helicobacter pylori
2JHE	;	2.3	;	N-terminal domain of TyrR transcription factor (residues 1 - 190)
4GEI	;	1.5	;	N-terminal domain of VDUP-1
4GEJ	;	2.9	;	N-terminal domain of VDUP-1
7VE6	;	2.77	;	N-terminal domain of VraR
3I7M	;	1.46	;	N-terminal domain of Xaa-Pro dipeptidase from Lactobacillus brevis.
4CHH	;	2.03	;	N-terminal domain of yeast PIH1p
8HCZ	;	1.48	;	N-terminal domain structure of mycobacterium tuberculosis FadD23
1QDW	;	2.1	;	N-TERMINAL DOMAIN, VOLTAGE-GATED POTASSIUM CHANNEL KV1.2 RESIDUES 33-119
1QDV	;	1.6	;	N-TERMINAL DOMAIN, VOLTAGE-GATED POTASSIUM CHANNEL KV1.2 RESIDUES 33-131
4RR6	;	1.88	;	N-terminal editing domain of threonyl-tRNA synthetase from Aeropyrum pernix with L-Ser3AA (snapshot 1)
4RR7	;	1.86	;	N-terminal editing domain of threonyl-tRNA synthetase from Aeropyrum pernix with L-Ser3AA (snapshot 2)
4RR8	;	1.86	;	N-terminal editing domain of threonyl-tRNA synthetase from Aeropyrum pernix with L-Ser3AA (snapshot 3)
4RR9	;	1.67	;	N-terminal editing domain of threonyl-tRNA synthetase from Aeropyrum pernix with L-Ser3AA (snapshot 4)
4RRA	;	1.7	;	N-terminal editing domain of threonyl-tRNA synthetase from Aeropyrum pernix with L-Thr3AA (snapshot 1)
4RRB	;	2.1	;	N-terminal editing domain of threonyl-tRNA synthetase from Aeropyrum pernix with L-Thr3AA (snapshot 2)
4RRC	;	1.86	;	N-terminal editing domain of threonyl-tRNA synthetase from Aeropyrum pernix with L-Thr3AA (snapshot 3)
4RRD	;	1.86	;	N-terminal editing domain of threonyl-tRNA synthetase from Aeropyrum pernix with L-Thr3AA (snapshot 4)
1BF9	;		;	N-TERMINAL EGF-LIKE DOMAIN FROM HUMAN FACTOR VII, NMR, 23 STRUCTURES
2XI5	;	2.2	;	N-terminal endonuclease domain of La Crosse virus L-protein
2XI7	;	2.2	;	N-terminal endonuclease domain of La Crosse virus L-protein
6SAC	;	1.02	;	N-terminal expression tag remainder of human Carbonic Anhydrase II covalently modified by fragment
5FWH	;	2.06	;	N-terminal FHA domain from EssC a component of the bacterial Type VII secretion apparatus
7LCP	;	1.9	;	N-terminal finger stabilizes feline drug GC376 in coronavirus 3CL protease
7LCQ	;	2.15	;	N-terminal finger stabilizes feline drug GC376 in coronavirus 3CL protease
2BLN	;	1.2	;	N-terminal formyltransferase domain of ArnA in complex with N-5- formyltetrahydrofolate and UMP
1CS6	;	1.8	;	N-TERMINAL FRAGMENT OF AXONIN-1 FROM CHICKEN
5AL7	;	2.92	;	N-terminal fragment of Drosophila melanogaster Sas-6 (F143D), dimerised via the coiled-coil domain.
5AFR	;	5.0	;	N-terminal fragment of dynein heavy chain
2OM5	;	3.07	;	N-Terminal Fragment of Human TAX1
1GCJ	;	2.6	;	N-TERMINAL FRAGMENT OF IMPORTIN-BETA
8DHY	;	2.15	;	N-terminal fragment of MsbA fused to GFP in complex with copper(II)
1AIL	;	1.9	;	N-TERMINAL FRAGMENT OF NS1 PROTEIN FROM INFLUENZA A VIRUS
3JSY	;	1.6	;	N-terminal fragment of ribosomal protein L10 from Methanococcus jannaschii
1H3L	;	2.375	;	N-terminal fragment of SigR from Streptomyces coelicolor
2OTO	;	3.04	;	N-terminal fragment of Streptococcus pyogenes M1 protein
2GX5	;	1.74	;	N-terminal GAF domain of transcriptional pleiotropic repressor CodY
2HGV	;	2.3	;	N-terminal GAF domain of transcriptional pleiotropic repressor CodY
2B18	;	1.8	;	N-terminal GAF domain of transcriptional pleiotropic repressor CodY.
4UC6	;	2.1	;	N-terminal globular domain of the RSV Nucleoprotein
4UC7	;	2.45	;	N-terminal globular domain of the RSV Nucleoprotein
4UC9	;	2.4	;	N-terminal globular domain of the RSV Nucleoprotein in complex with C- terminal dipeptide of the Phosphoprotein
4UCA	;	3.22	;	N-terminal globular domain of the RSV Nucleoprotein in complex with C- terminal peptide of the Phosphoprotein
4UCB	;	2.79	;	N-terminal globular domain of the RSV Nucleoprotein in complex with C- terminal peptide of the Phosphoprotein
4UC8	;	2.0	;	N-terminal globular domain of the RSV Nucleoprotein in complex with C- terminal phenylalanine of the Phosphoprotein
4UCE	;	2.95	;	N-terminal globular domain of the RSV Nucleoprotein in complex with the Nucleoprotein Phosphoprotein interaction inhibitor M72
4UCC	;	2.05	;	N-terminal globular domain of the RSV Nucleoprotein in complex with the Nucleoprotein Phosphoprotein interaction inhibitor M76
4UCD	;	2.66	;	N-terminal globular domain of the RSV Nucleoprotein in complex with the Nucleoprotein Phosphoprotein interaction inhibitor M81
1MKN	;		;	N-TERMINAL HALF OF MIDKINE
2Y3W	;	1.98	;	N-terminal head domain and beginning of coiled coil domain of Danio rerio SAS-6
2Y3V	;	1.92	;	N-terminal head domain of Danio rerio SAS-6
1Z0H	;	2.0	;	N-terminal helix reorients in recombinant C-fragment of Clostridium botulinum type B
5DKT	;	2.9	;	N-terminal His tagged apPOL exonuclease mutant
1BY0	;		;	N-TERMINAL LEUCINE-REPEAT REGION OF HEPATITIS DELTA ANTIGEN
5TCE	;		;	N-terminal microdomain of 34-mers from HsDHODH - N-t(DH)
5LV6	;		;	N-terminal motif dimerization of EGFR transmembrane domain in bicellar environment
6WIH	;	1.9	;	N-terminal mutation of ISCU2 (L35H36) traps Nfs1 Cys loop in the active site of ISCU2 without metal present. Structure of human mitochondrial complex Nfs1-ISCU2(L35H36)-ISD11 with E.coli ACP1 at 1.9 A resolution (NIAU)2.
2UUR	;	1.8	;	N-terminal NC4 domain of collagen IX
1L6P	;	1.65	;	N-terminal of DsbD (residues 20-144) from E. coli.
1ODA	;	3.31	;	N-terminal of Sialoadhesin in complex with Me-a-9-N-(biphenyl-4-carbonyl)-amino-9-deoxy-Neu5Ac (BIP compound)
1OD7	;	3.0	;	N-terminal of Sialoadhesin in complex with Me-a-9-N-(naphthyl-2-carbonyl)-amino-9-deoxy-Neu5Ac (NAP compound)
1OD9	;	2.1	;	N-terminal of Sialoadhesin in complex with Me-a-9-N-benzoyl-amino-9-deoxy-Neu5Ac (BENZ compound)
6EY0	;	2.4	;	N-terminal part (residues 30-212) of PorM with the llama nanobody nb01
5IU1	;	1.7	;	N-terminal PAS domain homodimer of PpANR MAP3K from Physcomitrella patens.
1S6J	;		;	N-terminal Region of the Ca2+-saturated calcium regulatory domain (CLD) from Soybean Calcium-dependent Protein Kinase-alpha (CDPK)
2LE3	;		;	N-terminal regulatory segment of carnitine palmitoyltransferase 1A
1E4U	;		;	N-terminal RING finger domain of human NOT-4
3HST	;	2.25	;	N-Terminal RNASE H domain of rv2228c from mycobacterium tuberculosis as a fusion protein with maltose binding protein
6PXB	;	1.747	;	N-Terminal SH2 domain of the p120RasGAP
6PXC	;	1.6	;	N-Terminal SH2 domain of the p120RasGAP bound to a p190RhoGAP phosphotyrosine peptide
2BZ8	;	2.0	;	N-terminal Sh3 domain of CIN85 bound to Cbl-b peptide
2J6K	;	2.77	;	N-TERMINAL SH3 DOMAIN OF CMS (CD2AP HUMAN HOMOLOG)
2J6F	;	1.7	;	N-TERMINAL SH3 DOMAIN OF CMS (CD2AP HUMAN HOMOLOG) BOUND TO CBL-B PEPTIDE
2EYW	;		;	N-terminal SH3 domain of CT10-Regulated Kinase
6SDF	;	2.5	;	N-terminal SH3 domain of Grb2 protein
1LOI	;		;	N-TERMINAL SPLICE REGION OF RAT C-AMP PHOSPHODIESTERASE, NMR, 7 STRUCTURES
4ZHB	;	1.3	;	N-terminal structure of ankyrin repeat-containing protein legA11 from Legionella pneumophila
5DUK	;	2.352	;	N-terminal structure of putative DNA binding transcription factor from Thermoplasmatales archaeon SCGC AB-539-N05
4GBR	;	3.993	;	N-Terminal T4 Lysozyme Fusion Facilitates Crystallization of a G Protein Coupled Receptor
5A0L	;	1.35	;	N-terminal thioester domain of fibronectin-binding protein SfbI from Streptococcus pyogenes
5A0N	;	1.3	;	N-terminal thioester domain of protein F2 like fibronectin-binding protein from Streptococcus pneumoniae
5A0G	;	2.62	;	N-terminal thioester domain of surface protein from Clostridium perfringens
5A0D	;	1.6	;	N-terminal thioester domain of surface protein from Clostridium perfringens, Cys138Ala mutant
4LGI	;	2.301	;	N-terminal truncated NleC structure
3ZFK	;	1.7	;	N-terminal truncated Nuclease Domain of Colicin E7
8V44	;	2.9	;	N-terminal truncation of CRISPR-associated DinG
1CKL	;	3.1	;	N-TERMINAL TWO DOMAINS OF HUMAN CD46 (MEMBRANE COFACTOR PROTEIN, MCP)
6VGJ	;	2.52	;	N-terminal variant of CXCL13
8F0E	;	1.31	;	N-terminal WD40 domain of beta'-COPI subunit with four chains in the asymmetric unit
8EWX	;	1.24	;	N-terminal WD40 domain of beta'-COPI subunit with two chains in the asymmetric unit
5X6T	;		;	N-terminal Zinc Finger of Synaptotagmin-like Protein 4
1E0E	;		;	N-terminal zinc-binding HHCC domain of HIV-2 integrase
3RBU	;	1.6	;	N-terminally AviTEV-tagged Human Glutamate Carboxypeptidase II in complex with 2-PMPA
6R74	;	1.81	;	N-terminally reversed variant of FimA E. coli
6R7E	;	1.79	;	N-terminally reversed variant of FimA E. coli with alanine insertion at position 20
1QQF	;	1.45	;	N-TERMINALLY TRUNCATED C3D,G FRAGMENT OF THE COMPLEMENT SYSTEM
1QSJ	;	1.9	;	N-TERMINALLY TRUNCATED C3DG FRAGMENT
4TVD	;	2.3	;	N-terminally truncated dextransucrase DSR-E from Leuconostoc mesenteroides NRRL B-1299 in complex with D-glucose
4TVC	;	1.85	;	N-terminally truncated dextransucrase DSR-E from Leuconostoc mesenteroides NRRL B-1299 in complex with gluco-oligosaccharides
4TTU	;	2.18	;	N-terminally truncated dextransucrase DSR-E from Leuconostoc mesenteroides NRRL B-1299 in complex with isomaltotriose
6BBK	;	1.73	;	N-terminally truncated group I PilA from Pseudomonas aeruginosa strain 1244
6TTO	;	1.31	;	N-terminally truncated hyoscyamine 6-hydroxylase (tH6H) in complex with 2-oxoglutarate
6TTN	;	1.12	;	N-terminally truncated hyoscyamine 6-hydroxylase (tH6H) in complex with N-oxalylglycine and hyoscyamine
1BOI	;	2.2	;	N-TERMINALLY TRUNCATED RHODANESE
7LUO	;	3.17	;	N-terminus of Skp2 bound to Cyclin A
1R4C	;	2.18	;	N-Truncated Human Cystatin C; Dimeric Form With 3D Domain Swapping
1MVJ	;		;	N-TYPE CALCIUM CHANNEL BLOCKER, OMEGA-CONOTOXIN MVIIA NMR, 15 STRUCTURES
1MVI	;		;	N-TYPE CALCIUM CHANNEL BLOCKER, OMEGA-CONOTOXIN MVIIA, NMR, 15 STRUCTURES
6TR7	;	1.47	;	N-[2-(5-fluoro-1H-indol-3-yl)ethyl]acetamide-Notum complex
5O8O	;	6.8	;	N. crassa Tom40 model based on cryo-EM structure of the TOM core complex at 6.8 A
6CKL	;	2.684	;	N. meningitidis CMP-sialic acid synthetase in the presence of CMP and Neu5Ac2en
6CKM	;	1.543	;	N. meningitidis CMP-sialic acid synthetase in the presence of CMP-sialic acid and Ca2+
6CKK	;	1.8	;	N. meningitidis CMP-sialic acid synthetase in the presence of CTP and Ca2+
6CKJ	;	1.75	;	N. meningitidis CMP-sialic acid synthetase, ligand-free
1HPN	;		;	N.M.R. AND MOLECULAR-MODELLING STUDIES OF THE SOLUTION CONFORMATION OF HEPARIN
8JN0	;	1.22826	;	N/F domain of alkaline amylase Amy703
4AR0	;		;	N0 domain of Neisseria meningitidis Pilus assembly protein PilQ
2HTY	;	2.5	;	N1 neuraminidase
3CL0	;	2.2	;	N1 Neuraminidase H274Y + oseltamivir
3CKZ	;	1.9	;	N1 Neuraminidase H274Y + Zanamivir
2HU0	;	2.95	;	N1 neuraminidase in complex with oseltamivir 1
2HU4	;	2.5	;	N1 neuraminidase in complex with oseltamivir 2
3CL2	;	2.538	;	N1 Neuraminidase N294S + Oseltamivir
4IOK	;	2.497	;	N10-formyltetrahydrofolate synthetase from Moorella thermoacetica with ADP, XPO
4IOL	;	2.563	;	N10-formyltetrahydrofolate synthetase from Moorella thermoacetica with ADP/ZD9 and XPO
4IOM	;	2.999	;	N10-formyltetrahydrofolate synthetase from Moorella thermoacetica with folate
4IOJ	;	2.202	;	N10-formyltetrahydrofolate synthetase from Moorella thermoacetica with sulfate
2W8W	;	2.14	;	N100Y SPT with PLP-ser
8CZ5	;	2.645	;	N11 P domain 2D9 Fab P complex
6UBI	;	1.903	;	N123-VRC34.05 HIV neutralizing antibody in complex with HIV fusion peptide residue 512-519
6UCE	;	1.382	;	N123-VRC34_pI3 HIV neutralizing antibody in complex with HIV fusion peptide residue 512-519
6UCF	;	1.29	;	N123-VRC34_pI4 HIV neutralizing antibody in complex with HIV fusion peptide residue 512-519
6W5B	;	1.15	;	N124D Deamidation Mutant of Human gammaD-Crystallin
1DZG	;	2.8	;	N135Q-S380C-ANTITHROMBIN-III
4HTR	;	1.6	;	N149W variant of SiRHP bound to sulfite
1E2V	;	1.85	;	N153Q mutant of cytochrome f from Chlamydomonas reinhardtii
6WCY	;	1.204	;	N160D Deamidation Mutant of Human gammaD-Crystallin
1E2W	;	1.6	;	N168F mutant of cytochrome f from Chlamydomonas reinhardtii
5FAF	;	1.05	;	N184K pathological variant of gelsolin domain 2 (orthorhombic form)
5FAE	;	1.7	;	N184K pathological variant of gelsolin domain 2 (trigonal form)
6NEH	;	1.52	;	N191D, F205S mutant of scoulerine 9-O-methyltransferase from Thalictrum flavum complexed with (13aS)-3,10-dimethoxy-5,8,13,13a-tetrahydro-6H-isoquino[3,2-a]isoquinoline-2,9-diol and S-ADENOSYL-L-HOMOCYSTEINE
6NEG	;	1.95	;	N191D, F205S mutant of scoulerine-9-O methyltransferase from Thalictrum flavum complexed with S-ADENOSYL-L-HOMOCYSTEINE
1NGQ	;	2.4	;	N1G9 (IGG1-LAMBDA) FAB FRAGMENT
1NGP	;	2.4	;	N1G9 (IGG1-LAMBDA) FAB FRAGMENT COMPLEXED WITH (4-HYDROXY-3-NITROPHENYL) ACETATE
4GZW	;	2.45	;	N2 neuraminidase D151G mutant of A/Tanzania/205/2010 H3N2 in complex with avian sialic acid receptor
4GZS	;	2.35	;	N2 neuraminidase D151G mutant of a/Tanzania/205/2010 H3N2 in complex with hepes
4GZX	;	2.45	;	N2 neuraminidase D151G mutant of A/Tanzania/205/2010 H3N2 in complex with human sialic acid receptor
4GZT	;	2.19	;	N2 neuraminidase D151G mutant of A/Tanzania/205/2010 H3N2 in complex with oseltamivir carboxylate
6BR5	;	2.03791	;	N2 neuraminidase in complex with a novel antiviral compound
6BR6	;	2.03984	;	N2 neuraminidase in complex with a novel antiviral compound
8G40	;	2.8	;	N2 neuraminidase of A/Hong_Kong/2671/2019 in complex with 3 FNI19 Fab molecules
8G3O	;	3.1	;	N2 neuraminidase of A/Hong_Kong/2671/2019 in complex with 3 FNI9 Fab molecules
8G3V	;	2.2	;	N2 neuraminidase of A/Hong_Kong/2671/2019 in complex with 4 FNI19 Fab molecules
8G3P	;	2.5	;	N2 neuraminidase of A/Hong_Kong/2671/2019 in complex with 4 FNI9 Fab molecules
8G3Q	;	2.3	;	N2 neuraminidase of A/Tanzania/205/2010 H3N2 in complex with 3 FNI17 Fab molecules
8G3M	;	3.0	;	N2 neuraminidase of A/Tanzania/205/2010 H3N2 in complex with 3 FNI9 Fab molecules
8G30	;	3.1	;	N2 neuraminidase of A/Tanzania/205/2010 H3N2 in complex with 4 FNI19 Fab molecules
8G3N	;	2.9	;	N2 neuraminidase of A/Tanzania/205/2010 H3N2 in complex with 4 FNI9 Fab molecules
4GZO	;	2.6	;	N2 neuraminidase of A/Tanzania/205/2010 H3N2 in complex with hepes
4GZP	;	2.3	;	N2 Neuraminidase of A/Tanzania/205/2010 H3N2 in complex with oseltamivir carboxylate
4GZQ	;	2.2	;	N2 neuraminidase of A/Tanzania/205/2010 H3N2 in complex with sialic acid
8G3R	;	2.3	;	N2 neuraminidase of A/Tanzania/205/2010 H3N2 with S245N S247T mutations in complex with one FNI17 Fab molecule
7UIU	;	2.8	;	N2 sub-domain of IF2 bound to the 30S subunit in the Pseudomonas aeruginosa 70S ribosome initiation complex (focused classification and refinement)
6UG0	;	1.83	;	N2-bound Nitrogenase MoFe-protein from Azotobacter vinelandii
2N0Q	;		;	N2-dG-IQ modified DNA at the G1 position of the NarI recognition sequence
2LBI	;		;	N2-dG:N2-dG interstrand cross-link induced by trans-4-hydroxynonenal
1HM4	;	3.47	;	N219L PENTALENENE SYNTHASE
1HM7	;	2.9	;	N219L PENTALENENE SYNTHASE
6KIL	;	1.6	;	N21Q mutant thioredoxin from Halobacterium salinarum NRC-1
2PS4	;	2.46	;	N225D trichodiene synthase
2PS5	;	2.1	;	N225D Trichodiene Synthase: Complex With Mg and Pyrophosphate
2PS6	;	2.6	;	N225D/S229T trichodiene synthase
1NTO	;	1.94	;	N249Y MUTANT OF ALCOHOL DEHYDROGENASE FROM THE ARCHAEON SULFOLOBUS SOLFATARICUS-MONOCLINIC CRYSTAL FORM
1NVG	;	2.5	;	N249Y MUTANT OF THE ALCOHOL DEHYDROGENASE FROM THE ARCHAEON SULFOLOBUS SOLFATARICUS-TETRAGONAL CRYSTAL FORM
1CK3	;	2.28	;	N276D MUTANT OF ESCHERICHIA COLI TEM-1 BETA-LACTAMASE
3WS0	;	2.0	;	N288Q-N321Q mutant BETA-LACTAMASE DERIVED FROM CHROMOHALOBACTER SP.560 (Condition-1A)
3WS1	;	1.8	;	N288Q-N321Q mutant BETA-LACTAMASE DERIVED FROM CHROMOHALOBACTER SP.560 (Condition-1B)
3WS2	;	2.1	;	N288Q-N321Q mutant BETA-LACTAMASE DERIVED FROM CHROMOHALOBACTER SP.560 (Condition-1C)
3WS4	;	1.9	;	N288Q-N321Q mutant BETA-LACTAMASE DERIVED FROM CHROMOHALOBACTER SP.560 (Condition-2A)
3WS5	;	2.8	;	N288Q-N321Q mutant BETA-LACTAMASE DERIVED FROM CHROMOHALOBACTER SP.560 (Condition-2B)
3WRZ	;	1.8	;	N288Q-N321Q mutant BETA-LACTAMASE DERIVED FROM CHROMOHALOBACTER SP.560 (without soaking)
3BAK	;	1.9	;	N298S mutant of Human Pancreatic Alpha-Amylase in complex with nitrate
3BAX	;	1.9	;	N298S Variant of Human Pancreatic Alpha-Amylase in Complex with Azide
3BAY	;	1.99	;	N298S Variant of Human Pancreatic Alpha-Amylase in Complex with Nitrate and Acarbose
2JJF	;	1.95	;	N328A mutant of M. tuberculosis Rv3290c
3VY2	;	1.6	;	N33D mutant of FMN-binding protein from Desulfovibrio vulgaris (Miyazaki F)
3VY5	;	1.4	;	N33Q mutant of FMN-binding protein from Desulfovibrio vulgaris (Miyazaki F)
1BOX	;	1.6	;	N39S MUTANT OF RNASE SA FROM STREPTOMYCES AUREOFACIENS
4FF1	;	2.47	;	N4 mini-vRNAP transcription initiation complex, 1 min after soaking GTP, ATP and Mn
4FF2	;	2.0	;	N4 mini-vRNAP transcription initiation complex, 2 min after soaking GTP, ATP and Mn
4FF3	;	1.997	;	N4 mini-vRNAP transcription initiation complex, 3 min after soaking GTP, ATP and Mn
4FF4	;	2.026	;	N4 mini-vRNAP transcription initiation complex, 4 min after soaking GTP, ATP and Mn
2HTV	;	2.8	;	N4 neuraminidase
2HTW	;	3.5	;	N4 neuraminidase in complex with DANA
6LZT	;	1.853	;	N409A mutant of chitin-specific solute binding protein from Vibrio harveyi co-crystalized with chitobiose
2QQD	;	2.0	;	N47A mutant of Pyruvoyl-dependent Arginine Decarboxylase from Methanococcus jannashii
1B6R	;	2.1	;	N5-CARBOXYAMINOIMIDAZOLE RIBONUCLEOTIDE SYNTHETASE FROM E. COLI
1NV8	;	2.2	;	N5-glutamine methyltransferase, HemK
2WAZ	;	2.3	;	N512P mutant of the DNA binding domain of the Adenovirus 5 ssDNA binding protein
3CQT	;	1.6	;	N53I V55L MUTANT of FYN SH3 DOMAIN
5LR5	;	2.4	;	N6-methyladenine is accommodated in a conventional A-U basepair
2MVS	;		;	N6-Methyladenosine RNA
1JO1	;		;	N7-Guanine Adduct of 2,7-diaminomitosene with DNA
7MN0	;	2.9	;	N74D mutant of the HIV-1 capsid protein
7MKC	;	2.65	;	N74D mutant of the HIV-1 capsid protein in complex with PF-3450074 (PF74)
2VLN	;	1.6	;	N75A mutant of E9 DNase domain in complex with Im9
1GY7	;	1.6	;	N77Y point mutant of S.Cerevisiae NTF2
1GYB	;	1.9	;	N77Y point mutant of yNTF2 bound to FxFG nucleoporin repeat
4JF0	;	2.1	;	N79R mutant of N-acetylornithine aminotransferase
4JEZ	;	1.55	;	N79R mutant of N-acetylornithine aminotransferase complexed with L-canaline
2HT5	;	2.4	;	N8 Neuraminidase
2HTR	;	2.5	;	N8 neuraminidase in complex with DANA
2HT8	;	2.4	;	N8 neuraminidase in complex with oseltamivir
2HTU	;	2.2	;	N8 neuraminidase in complex with peramivir
2HTQ	;	2.2	;	N8 neuraminidase in complex with zanamivir
2HT7	;	2.6	;	N8 neuraminidase in open complex with oseltamivir
8CAF	;	2.66	;	N8C_Fab3b in complex with NEDD8-CUL1(WHB)
1NMA	;	3.0	;	N9 NEURAMINIDASE COMPLEXES WITH ANTIBODIES NC41 AND NC10: EMPIRICAL FREE-ENERGY CALCULATIONS CAPTURE SPECIFICITY TRENDS OBSERVED WITH MUTANT BINDING DATA
1XOE	;	2.2	;	N9 Tern influenza neuraminidase complexed with (2R,4R,5R)-5-(1-Acetylamino-3-methyl-butyl-pyrrolidine-2, 4-dicarobyxylic acid 4-methyl esterdase complexed with
1XOG	;	2.8	;	N9 Tern Influenza neuraminidase complexed with a 2,5-Disubstituted tetrahydrofuran-5-carboxylic acid
2PFN	;	1.9	;	Na in the active site of DNA Polymerase lambda
2BHC	;	2.4	;	Na substituted E. coli Aminopeptidase P
7ZC6	;	4.27	;	Na+ - translocating ferredoxin: NAD+ reductase (Rnf) of C. tetanomorphum
2AHY	;	2.4	;	Na+ complex of the NaK Channel
3BEU	;	1.05	;	Na+-Dependent Allostery Mediates Coagulation Factor Protease Active Site Selectivity
4HYT	;	3.404	;	Na,K-ATPase in the E2P state with bound ouabain and Mg2+ in the cation-binding site
3TFY	;	2.75	;	Naa50p amino-terminal acetyltransferase bound to substrate peptide fragment and CoA
2JPS	;		;	NAB2 N-terminal domain
5L2L	;	1.55	;	Nab2 Zn fingers 5-7 bound to A11G RNA
4LJ0	;	2.15	;	Nab2 Zn fingers complexed with polyadenosine
3LCN	;	2.0	;	Nab2:Gfd1 complex
2L41	;		;	Nab3 RRM - UCUU complex
4YGJ	;	1.1	;	NaBr--Interactions between Hofmeister Anions and the Binding Pocket of a Protein
6VX3	;	3.7	;	NaChBac in GDN
6VWX	;	3.1	;	NaChBac in lipid nanodisc
6W6O	;	3.2	;	NaChBac-Nav1.7VSDII chimera and HWTX-IV complex
6VXO	;	3.5	;	NaChBac-Nav1.7VSDII chimera in nanodisc
4YGL	;	1.51	;	NaClO4--Interactions between Hofmeister Anions and the Binding Pocket of a Protein
2DVM	;	1.6	;	NAD complex structure of PH1275 protein from Pyrococcus horikoshii
4R81	;	1.5	;	NAD(P)H:quinone oxidoreductase from Methanothermobacter marburgensis
6K23	;	2.8	;	NAD+ bound structure of enoyl-acyl carrier protein reductase (FabI) from Acinetobacter baumanii
5GTK	;	2.6	;	NAD+ complex structure of aldehyde dehydrogenase from bacillus cereus
2PZB	;	1.9	;	NAD+ Synthetase from Bacillus anthracis
2PZA	;	2.4	;	NAD+ Synthetase from Bacillus anthracis with AMP + PPi and Mg2+
2PZ8	;	2.0	;	NAD+ Synthetase from Bacillus anthracis with AMP-CPP and Mg2+
7CM7	;	2.6	;	NAD+-bound Sarm1 E642A in the self-inhibited state
7CM6	;	3.0	;	NAD+-bound Sarm1 in the self-inhibited state
1XDW	;	1.98	;	NAD+-dependent (R)-2-Hydroxyglutarate Dehydrogenase from Acidaminococcus fermentans
6T92	;	1.12	;	NAD+-dependent fungal formate dehydrogenase from Chaetomium thermophilum: A complex of N120C mutant protein with the reduced form of the cofactor NADH and the substrate formate at a secondary site.
6T94	;	1.15	;	NAD+-dependent fungal formate dehydrogenase from Chaetomium thermophilum: A complex of N120C mutant protein with the reduced form of the cofactor NADH.
6T8Y	;	1.26	;	NAD+-dependent fungal formate dehydrogenase from Chaetomium thermophilum: A complex with the reduced form of the cofactor NADH and the substrate formate at a secondary site.
6T8Z	;	1.21	;	NAD+-dependent fungal formate dehydrogenase from Chaetomium thermophilum: A ternary complex with the oxidised form of the cofactor NAD+ and the substrate formate both at a primary and secondary sites.
2GSD	;	1.95	;	NAD-dependent formate dehydrogenase from bacterium Moraxella sp.C2 in complex with NAD and azide
3N7U	;	2.0	;	NAD-dependent formate dehydrogenase from higher-plant Arabidopsis thaliana in complex with NAD and azide
2GO1	;	2.1	;	NAD-dependent formate dehydrogenase from Pseudomonas sp.101
2GUG	;	2.28	;	NAD-dependent formate dehydrogenase from Pseudomonas sp.101 in complex with formate
6EXI	;	1.918	;	NAD-free crystal structure of S-adenosyl-L-homocysteine hydrolase from Bradyrhizobium elkanii complexed with adenosine
7CFX	;	2.5	;	NAD-soaked Holo-methanol dehydrogenase (MDH) from Methylococcus capsulatus (Bath)
7SWK	;	1.8	;	NAD/NADP-dependent betaine aldehyde dehydrogenase from Klebsiella pneumoniae subsp. pneumoniae
6YGE	;	1.6	;	NADase from Aspergillus fumigatus
6YGG	;	1.85	;	NADase from Aspergillus fumigatus complexed with a substrate anologue
8PMR	;	1.94	;	NADase from Aspergillus fumigatus with mutated calcium binding motif (D219A/E220A)
8PMS	;	2.4	;	NADase from Aspergillus fumigatus with replaced C-terminus from Neurospora crassa
6YGF	;	1.7	;	NADase from Aspergillus fumigatus with trapped reaction products
2NPX	;	2.4	;	NADH BINDING SITE AND CATALYSIS OF NADH PEROXIDASE
6KIA	;	1.59798	;	NADH bound structure of FabMG, novel type of Enoyl-acyl carrier protein reductase
7OCQ	;	2.9	;	NADH bound to the dehydrogenase domain of the bifunctional mannitol-1-phosphate dehydrogenase/phosphatase MtlD from Acinetobacter baumannii
1XHC	;	2.35	;	NADH oxidase /nitrite reductase from Pyrococcus furiosus Pfu-1140779-001
1NOX	;	1.59	;	NADH OXIDASE FROM THERMUS THERMOPHILUS
1JOA	;	2.8	;	NADH PEROXIDASE WITH CYSTEINE-SULFENIC ACID
6RUZ	;	2.9	;	NADH-dependent Coenzyme A Disulfide Reductase
6RVH	;	3.0	;	NADH-dependent Coenzyme A Disulfide Reductase soaked with Menadione
6RVB	;	2.9	;	NADH-dependent Coenzyme A Disulfide Reductase soaked with NADH
5JFC	;	1.598	;	NADH-dependent Ferredoxin:NADP Oxidoreductase (NfnI) from Pyrococcus furiosus
6SCH	;	2.2	;	NADH-dependent variant of CBADH
6SDM	;	2.85	;	NADH-dependent variant of TBADH
4XHY	;	1.53	;	NADH:FMN oxidoreductase from Paracoccus denitrificans
5NA4	;	2.55	;	NADH:quinone oxidoreductase (NDH-II) from Staphylococcus aureus - E172S mutant
5NA1	;	2.32	;	NADH:quinone oxidoreductase (NDH-II) from Staphylococcus aureus - holoprotein structure - 2.32 A resolution
2AG8	;	2.1	;	NADP complex of Pyrroline-5-carboxylate reductase from Neisseria meningitidis
6TGE	;	1.5	;	NADP dependent methylene-tetrahydromethanopterin dehydrogenase-NADP+-methenyl-H4MPT+ complex
5JCA	;	1.5	;	NADP(H) bound NADH-dependent Ferredoxin:NADP Oxidoreductase (NfnI) from Pyrococcus furiosus
4GMG	;	2.31	;	NADP+ bound structure of a Thiazolinyl Imine Reductase from Yersinia enterocolitica (Irp3)
5KVQ	;	1.45	;	NADP+ bound structure of Irp3, a Thiazolinyl Imine Reductase from Yersinia enterocolitica
5VW6	;	1.5	;	NADP+ soak of Y316A mutant of corn root ferredoxin:NADP+ reductase
5VW3	;	1.453	;	NADP+ soak of Y316S mutant of corn root ferredoxin:NADP+ reductase
5VW8	;	1.808	;	NADP+ soak of Y316S mutant of corn root ferredoxin:NADP+ reductase in alternate space group
1YKF	;	2.5	;	NADP-DEPENDENT ALCOHOL DEHYDROGENASE FROM THERMOANAEROBIUM BROCKII
7OCR	;	2.6	;	NADPH and fructose-6-phosphate bound to the dehydrogenase domain of the bifunctional mannitol-1-phosphate dehydrogenase/phosphatase MtlD from Acinetobacter baumannii
3LF2	;	2.3	;	NADPH Bound Structure of the Short Chain Oxidoreductase Q9HYA2 from Pseudomonas aeruginosa PAO1 Containing an Atypical Catalytic Center
7OCP	;	2.75	;	NADPH bound to the dehydrogenase domain of the bifunctional mannitol-1-phosphate dehydrogenase/phosphatase MtlD from Acinetobacter baumannii
7OCT	;	2.85	;	NADPH bound to the dehydrogenase domain of the bifunctional mannitol-1-phosphate dehydrogenase/phosphatase MtlD-N374A from Acinetobacter baumannii
5A9S	;	2.06	;	NADPH complex of Imine Reductase from Amycolatopsis orientalis
5GTL	;	2.0	;	NADPH complex structure of Aldehyde Dehydrogenase from Bacillus cereus
1MOK	;	2.8	;	NADPH DEPENDENT 2-KETOPROPYL COENZYME M OXIDOREDUCTASE/CARBOXYLASE
1MO9	;	1.65	;	NADPH DEPENDENT 2-KETOPROPYL COENZYME M OXIDOREDUCTASE/CARBOXYLASE COMPLEXED WITH 2-KETOPROPYL COENZYME M
5VW7	;	1.608	;	NADPH soak of Y316A mutant of corn root ferredoxin:NADP+ reductase
5VW2	;	1.451	;	NADPH soak of Y316S mutant of corn root ferredoxin:NADP+ reductase
1XK2	;	2.2	;	NADPH- and Ascorbate-Supported Heme Oxygenase Reactions are Distinct. Regiospecificity of Heme Cleavage by the R183E Mutant
1XK3	;	2.08	;	NADPH- and Ascorbate-Supported Heme Oxygenase Reactions are Distinct. Regiospecificity of Heme Cleavage by the R183E Mutant
7W1W	;	1.82	;	NADPH-bound AKR4C17 mutant F291D
3ES9	;	3.4	;	NADPH-Cytochrome P450 Reductase in an Open Conformation
7SUZ	;	2.5	;	NADPH-dependent cytochrome P450 reductase 2b from Sorghum bicolor (SbCPR2b)
7SUX	;	2.36	;	NADPH-dependent cytochrome P450 reductase 2b from Sorghum bicolor (SbCPR2b) -NADP+ complex
7SV0	;	2.7	;	NADPH-dependent cytochrome P450 reductase 2b from Sorghum bicolor (SbCPR2b) -oxidized form of NADP+ complex
5Z2F	;	2.1	;	NADPH/PDA bound Dihydrodipicolinate reductase from Paenisporosarcina sp. TG-14
1BKJ	;	1.8	;	NADPH:FMN OXIDOREDUCTASE FROM VIBRIO HARVEYI
2BKJ	;	2.08	;	NADPH:FMN OXIDOREDUCTASE FROM VIBRIO HARVEYI COMPLEXED WITH NAD+
1LW7	;	2.9	;	NADR PROTEIN FROM HAEMOPHILUS INFLUENZAE
7RKT	;	2.1	;	Naegleria fowleri CYP51 (NfCYP51) complex with (S)-1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethyl 3-(trifluoromethyl)benzoate
7RKR	;	1.76	;	Naegleria fowleri CYP51 (NfCYP51) complex with (S)-1-(4-fluorophenyl)-2-(1H-imidazol-1-yl)ethyl 3-(trifluoromethyl)benzoate
7RKW	;	1.81	;	Naegleria fowleri CYP51(NfCYP51) complex with (S)-1-(4-fluorophenyl)-2-(1H-imidazol-1-yl)ethyl 3,5-dichlorobenzoate
6AY4	;	2.7	;	Naegleria fowleri CYP51-fluconazole complex
6AYC	;	2.6	;	Naegleria fowleri CYP51-itraconazole complex
6AYB	;	1.87	;	Naegleria fowleri CYP51-ketoconazole complex
5TL8	;	1.71	;	Naegleria fowleri CYP51-posaconazole complex
6AY6	;	2.4	;	Naegleria fowleri CYP51-voriconazole complex
6VT1	;	2.381	;	Naegleria gruberi RNA ligase D172A mutant apo
6VTG	;	2.49	;	Naegleria gruberi RNA ligase E227A mutant apo
6VT9	;	2.49	;	Naegleria gruberi RNA ligase E227A mutant with ATP and Mn
6VT8	;	1.998	;	Naegleria gruberi RNA ligase E312A mutant with AMP and Mn
6VT0	;	2.002	;	Naegleria gruberi RNA ligase K170A mutant apo
6VT6	;	1.969	;	Naegleria gruberi RNA ligase K170A mutant with ATP and Mn
6VTE	;	2.1	;	Naegleria gruberi RNA Ligase K170M mutant with AMP and Mn
6VT3	;	1.844	;	Naegleria gruberi RNA ligase K326A mutant apo
6VTB	;	1.547	;	Naegleria gruberi RNA ligase K326A mutant with ATP and Mn
6VT4	;	2.16	;	Naegleria gruberi RNA ligase R149A mutant apo
6VTD	;	2.4	;	Naegleria gruberi RNA ligase R149A mutant with ATP and Mn
6VT5	;	1.8	;	Naegleria gruberi RNA ligase R4a K121A mutant apo
6VTF	;	2.71	;	Naegleria gruberi RNA ligase with PPi
7P0P	;	1.74	;	NAF-1 bound to M1 molecule
2C4N	;	1.8	;	NagD from E.coli K-12 strain
6DAO	;	1.939	;	NahE WT selenomethionine
1CQW	;	1.5	;	NAI COCRYSTALLISED WITH HALOALKANE DEHALOGENASE FROM A RHODOCOCCUS SPECIES
4YGN	;	1.23	;	NaI--Interactions between Hofmeister Anions and the Binding Pocket of a Protein
8A7X	;	2.1	;	NaK C-DI F92A mutant soaked in Cs+
7PA0	;	1.95	;	NaK C-DI F92A mutant with Rb+ and K+
7OOU	;	1.8	;	NaK C-DI mutant with Li+ and K+
7OOR	;	1.47	;	NaK C-DI mutant with Na+ and K+
8AYP	;	2.1	;	NaK C-DI mutant with Rb+ and Ba2+
8AYQ	;	2.75	;	NaK C-DI mutant with Rb+ and Ca2+
8A35	;	2.05	;	NaK C-DI mutant with Rb+ and Na+
7OQ2	;	1.7	;	NaK S-DI mutant soaked in Na+
7OPH	;	1.42	;	NaK S-DI mutant with Na+ and K+
7OQ1	;	1.85	;	NaK S-ELM mutant with Na+ and K+
6SLF	;	1.75	;	Nalpha-acylglutamine aminoacylase from Corynebacterium sp.releasing human axilla odorants co-crystallised with high affinity inhibitor
6E68	;	1.5	;	NAMPT co-crystal with inhibitor compound 2
4XYX	;	2.1	;	NanB plus Optactamide
2WJQ	;	2.0	;	NanC porin structure in hexagonal crystal form.
2WJR	;	1.8	;	NanC porin structure in rhombohedral crystal form.
5F53	;	1.8	;	Nano-ring of cadmium ions coordinated by nvPizza2-S16S58
7OZT	;	1.74	;	Nanobodies restore stability to cancer-associated mutants of tumor suppressor protein p16INK4a
6XYF	;	1.11097	;	Nanobody 22
8DQU	;	2.45003	;	Nanobody bound SARS-CoV-2 Nsp9
7S2R	;	2.49	;	nanobody bound to IL-2Rg
7S2S	;	1.93	;	nanobody bound to Interleukin-2Rbeta
7OAU	;	1.65	;	Nanobody C5 bound to Kent variant RBD (N501Y)
7OAO	;	1.5	;	Nanobody C5 bound to RBD
7OAN	;	3.0	;	Nanobody C5 bound to Spike
4I13	;	1.6	;	Nanobody ca1697 binding to the DHFR.folate binary complex
7B14	;	3.79	;	Nanobody E bound to Spike-RBD in a localized reconstruction
7OM4	;	6.05	;	Nanobody EgB4 bound to the full extracellular EGFR-EGF complex
7OAY	;	2.34	;	Nanobody F2 bound to RBD
7Z1A	;	2.59	;	Nanobody H11 and F2 bound to RBD
7Z1B	;	2.3	;	Nanobody H11-A10 and F2 bound to RBD
7Z1C	;	1.9	;	Nanobody H11-B5 and H11-F2 bound to RBD
7Z1E	;	1.59	;	Nanobody H11-H4 Q98R H100E bound to RBD
7Z1D	;	1.55	;	Nanobody H11-H6 bound to RBD
7OAP	;	1.901	;	Nanobody H3 AND C1 bound to RBD
7OAQ	;	1.55	;	Nanobody H3 AND C1 bound to RBD with Kent mutation
6XZF	;	1.8	;	Nanobody in complex with eGFP
5IMK	;	1.227	;	Nanobody targeting human Vsig4 in Spacegroup C2
5IML	;	1.8	;	Nanobody targeting human Vsig4 in Spacegroup P212121
6S0Y	;	1.81	;	Nanobody targeting influenza A matrix protein 2 ectodomain (M2e)
5IMM	;	1.2	;	Nanobody targeting mouse Vsig4 in Spacegroup P212121
5IMO	;	2.1	;	Nanobody targeting mouse Vsig4 in Spacegroup P3221
8FQ7	;	1.4	;	Nanobody with WIW inserted in CDR3 loop to Inhibit Growth of Alzheimer's Tau fibrils
3CFI	;	2.58	;	Nanobody-aided structure determination of the EPSI:EPSJ pseudopilin heterdimer from Vibrio Vulnificus
5OCL	;	2.2	;	Nanobody-anti-VGLUT nanobody complex
5OVW	;	2.653	;	Nanobody-bound BtuF, the vitamin B12 binding protein in Escherichia coli
6VI4	;	3.3	;	Nanobody-Enabled Monitoring of Kappa Opioid Receptor States
4KRM	;	2.655	;	Nanobody/VHH domain 7D12 in complex with domain III of the extracellular region of EGFR, pH 3.5
4KRL	;	2.849	;	Nanobody/VHH domain 7D12 in complex with domain III of the extracellular region of EGFR, pH 6.0
4KRP	;	2.823	;	Nanobody/VHH domain 9G8 in complex with the extracellular region of EGFR
4KRN	;	1.553	;	Nanobody/VHH domain EgA1
4KRO	;	3.054	;	Nanobody/VHH domain EgA1 in complex with the extracellular region of EGFR
8HXQ	;	2.4	;	Nanobody1 in complex with human BCMA ECD
8HXR	;	2.7	;	Nanobody2 in complex with human BCMA ECD
7UMB	;	3.231	;	NanoBRET tracer Tram-bo bound to a KSR2-MEK1 complex
6VPX	;	5.0	;	Nanodisc of full-length HIV-1 Envelope glycoprotein clone AMC011 in complex with one PGT151 Fab and three 10E8 Fabs
7A6C	;	3.6	;	Nanodisc reconstituted human ABCB1 in complex with MRK16 Fab and elacridar
7A6E	;	3.6	;	Nanodisc reconstituted human ABCB1 in complex with MRK16 Fab and tariquidar
7A69	;	3.2	;	Nanodisc reconstituted human ABCB1 in complex with MRK16 Fab and vincristine
7A6F	;	3.5	;	Nanodisc reconstituted human ABCB1 in complex with MRK16 Fab and zosuquidar
6QEX	;	3.6	;	Nanodisc reconstituted human ABCB1 in complex with UIC2 fab and taxol
7NIW	;	3.8	;	Nanodisc reconstituted human ABCB4 in complex with 4B1-Fab (posaconazole-bound, inward-open conformation)
7NIU	;	4.2	;	Nanodisc reconstituted human ABCB4 in complex with 4B1-Fab and QA2-Fab (apo-inward-open conformation)
7NIV	;	3.6	;	Nanodisc reconstituted human ABCB4 in complex with 4B1-Fab and QA2-Fab (phosphatidylcholine-bound, occluded conformation)
6QEE	;	3.9	;	Nanodisc reconstituted Human-mouse chimeric ABCB1 (ABCB1HM)-EQ mutant in complex with UIC2 Fab and Zosuquidar.
7PH2	;	3.7	;	Nanodisc reconstituted MsbA in complex with nanobodies, spin-labeled at position A60C
7PH7	;	4.1	;	Nanodisc reconstituted MsbA in complex with nanobodies, spin-labeled at position T68C
7A65	;	3.9	;	Nanodisc reconstituted, drug-free human ABCB1 in complex with MRK16 Fab
8AQI	;	1.99	;	NanoLuc luciferase with bound coelenteramide in surface allosteric site
8AQ6	;	1.69	;	NanoLuc luciferase with bound furimamide in surface allosteric site
8BO9	;	3.1	;	NanoLuc-D9R/H57A/K89R mutant complexed with azacoelenterazine bound in intra-barrel catalytic site
8AQH	;	2.798	;	NanoLuc-Y94A luciferase mutant
7E9T	;	10.9	;	Nanometer resolution in situ structure of SARS-CoV-2 post-fusion spike
4XYC	;	3.3	;	NANOMOLAR INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS GLUTAMINE SYNTHETASE 1: SYNTHESIS, BIOLOGICAL EVALUATION AND X-RAY CRYSTALLOGRAPHIC STUDIES
2INY	;	3.9	;	Nanoporous Crystals of Chicken Embryo Lethal Orphan (CELO) Adenovirus Major Coat Protein, Hexon
8D6G	;	2.2	;	Nanorana parkeri saxiphilin
8D6O	;	2.2	;	Nanorana parkeri saxiphilin:F-STX (soaked)
8D6M	;	2.0	;	Nanorana parkeri saxiphilin:STX (co-crystal)
6WFQ	;	3.9	;	NanR dimer-DNA hetero-complex
1JI4	;	2.52	;	NAP protein from helicobacter pylori
2PYB	;	2.6	;	Napa protein from borrelia burgdorferi
1NDO	;	2.25	;	NAPHTHALENE 1,2-DIOXYGENASE
4HJL	;	1.5	;	Naphthalene 1,2-Dioxygenase bound to 1-chloronaphthalene
4HM1	;	1.5	;	Naphthalene 1,2-Dioxygenase bound to 1-indanone
4HKV	;	1.65	;	Naphthalene 1,2-Dioxygenase bound to benzamide
4HM3	;	1.5	;	Naphthalene 1,2-Dioxygenase bound to ethylbenzene
4HM2	;	1.6	;	Naphthalene 1,2-Dioxygenase bound to ethylphenylsulfide
4HM4	;	1.5	;	Naphthalene 1,2-Dioxygenase bound to indan
4HM5	;	1.5	;	Naphthalene 1,2-Dioxygenase bound to indene
4HM0	;	1.8	;	Naphthalene 1,2-Dioxygenase bound to indole-3-acetate
4HM6	;	1.499	;	Naphthalene 1,2-Dioxygenase bound to phenetole
4HM7	;	1.5	;	Naphthalene 1,2-Dioxygenase bound to styrene
4HM8	;	1.3	;	Naphthalene 1,2-Dioxygenase bound to thioanisole
2QPZ	;	1.85	;	Naphthalene 1,2-dioxygenase Rieske ferredoxin
1EG9	;	1.6	;	NAPHTHALENE 1,2-DIOXYGENASE WITH INDOLE BOUND IN THE ACTIVE SITE.
1O7G	;	1.7	;	NAPHTHALENE 1,2-DIOXYGENASE WITH NAPHTHALENE BOUND IN THE ACTIVE SITE.
1UUV	;	1.65	;	NAPHTHALENE 1,2-DIOXYGENASE WITH NITRIC OXIDE AND INDOLE BOUND IN THE ACTIVE SITE.
1UUW	;	2.3	;	NAPHTHALENE 1,2-DIOXYGENASE WITH NITRIC OXIDE BOUND IN THE ACTIVE SITE.
1O7H	;	2.2	;	NAPHTHALENE 1,2-DIOXYGENASE WITH OXIDIZED RIESKE IRON SULPHUR CENTER SITE.
1O7M	;	1.75	;	NAPHTHALENE 1,2-DIOXYGENASE, BINARY COMPLEX WITH DIOXYGEN
1O7W	;	1.9	;	NAPHTHALENE 1,2-DIOXYGENASE, FULLY REDUCED FORM
1O7P	;	1.95	;	NAPHTHALENE 1,2-DIOXYGENASE, PRODUCT COMPLEX
1O7N	;	1.4	;	NAPHTHALENE 1,2-DIOXYGENASE, TERNARY COMPLEX WITH DIOXYGEN AND INDOLE
7ZM6	;	2.07	;	Nariva virus receptor binding protein
1ZG5	;	2.3	;	NarL complexed to narG-89 promoter palindromic tail-to-tail DNA site
1ZG1	;	2.3	;	NarL complexed to nirB promoter non-palindromic tail-to-tail DNA site
6GX5	;	3.2	;	Narrow Pick Filament from Pick's disease brain
4YGK	;	1.5	;	NaSCN--Interactions between Hofmeister Anions and the Binding Pocket of a Protein
8B4A	;	3.06	;	Nativ complex of PqsE and RhlR with autoinducer C4-HSL
7R3J	;	3.06	;	Nativ complex of PqsE and RhlR with the synthetic antagonist mBTL
1QG8	;	1.5	;	NATIVE (MAGNESIUM-CONTAINING) SPSA FROM BACILLUS SUBTILIS
1A80	;	2.1	;	Native 2,5-DIKETO-D-GLUCONIC acid reductase a from CORYNBACTERIUM SP. complexed with nadph
1GQN	;	1.78	;	Native 3-dehydroquinase from Salmonella typhi
8CDC	;	1.54	;	Native 3CLpro from SARS-CoV-2 at 1.54 A
4U37	;	1.55	;	Native 7mer-RNA duplex
2ACE	;	2.5	;	NATIVE ACETYLCHOLINESTERASE (E.C. 3.1.1.7) FROM TORPEDO CALIFORNICA
1EA5	;	1.8	;	NATIVE ACETYLCHOLINESTERASE (E.C. 3.1.1.7) FROM TORPEDO CALIFORNICA at 1.8A resolution
8PI2	;	1.48	;	Native alpha-1-antitrypsin at 1.5 Angstrom (Cys232Ser)
7VON	;	5.2	;	Native alpha-2-macroglobulin monomer
7LDD	;	3.4	;	native AMPA receptor
7LDE	;	3.9	;	native AMPA receptor
6OKJ	;	1.73	;	Native ananain from Ananas comosus
6MIS	;	1.98	;	Native ananain in complex with E-64
4EIP	;	2.332	;	Native and K252c bound RebC-10x
4K37	;	1.62	;	Native anSMEcpe with bound AdoMet
4K39	;	1.783	;	Native anSMEcpe with bound AdoMet and Cp18Cys peptide
4K38	;	1.831	;	Native anSMEcpe with bound AdoMet and Kp18Cys peptide
3CZ4	;	1.7	;	Native AphA class B acid phosphatase/phosphotransferase from E. coli
1R12	;	1.7	;	Native Aplysia ADP ribosyl cyclase
5O2K	;	2.1	;	Native apo-structure of Pseudomonas stutzeri PtxB to 2.1 A resolution
1UV4	;	1.5	;	Native Bacillus subtilis Arabinanase Arb43A
4YHE	;	1.85	;	NATIVE BACTEROIDETES-AFFILIATED GH5 CELLULASE LINKED WITH A POLYSACCHARIDE UTILIZATION LOCUS
4YHG	;	2.4	;	NATIVE BACTEROIDETES-AFFILIATED GH5 CELLULASE LINKED WITH A POLYSACCHARIDE UTILIZATION LOCUS
6MAF	;	3.79	;	native BbvCI A2B2 tetramer at low resolution
6MAG	;	2.07	;	native BbvCI B2 dimer in space group C222
7V9G	;	3.5	;	Native BEN4 domain of protein Bend3 with DNA
1ZOL	;	1.9	;	native beta-PGM
1S0Q	;	1.02	;	Native Bovine Pancreatic Trypsin
5KN2	;	2.601	;	Native bovine skeletal calsequestrin, high-Ca2+ form
5KN0	;	2.729	;	Native bovine skeletal calsequestrin, low-Ca2+ form
6T4E	;	1.66	;	Native C3-like protease from Southampton virus complexed with FMOPL000287a.
1B5F	;	1.72	;	NATIVE CARDOSIN A FROM CYNARA CARDUNCULUS L.
7X4A	;	2.21	;	Native CD-NTase ClCdnE
7X4C	;	1.75	;	Native CD-NTase EfCdnE
7X4F	;	2.46	;	Native CD-NTase LpCdnE
6ZKO	;	3.8	;	Native complex I, closed
6ZKP	;	3.2	;	Native complex I, open1
6ZKQ	;	3.3	;	Native complex I, open2
6ZKR	;	3.5	;	Native complex I, open3
8AT5	;	2.9	;	native Coxsackievirus A9
2PC5	;	2.2	;	Native crystal structure analysis on Arabidopsis dUTPase
2BS9	;	2.2	;	Native crystal structure of a GH39 beta-xylosidase XynB1 from Geobacillus stearothermophilus
6H98	;	1.8	;	Native crystal structure of anaerobic ergothioneine biosynthesis enzyme from Chlorobium limicola.
6ZK8	;	1.83	;	Native crystal structure of anaerobic F420H2-Oxidase from Methanothermococcus thermolithotrophicus at 1.8A resolution
4AK5	;	1.7	;	Native crystal structure of BpGH117
6S7J	;	2.2	;	Native crystal structure of ergothioneine degrading enzyme Ergothionase from Treponema denticola
6ILB	;	2.51	;	Native crystal structure of fructuronate-tagaturonate epimerase UxaE from Cohnella laeviribosi
3O1Q	;	1.85	;	Native Crystal Structure of Helicobacter pylori Urease Accessory Protein UreF
4P11	;	1.891	;	Native crystal structure of MltF Pseudomonas aeruginosa
4JIM	;	2.1	;	Native Crystal Structure of N10-Formyltetrahydrofolate Synthetase
2CWM	;	1.95	;	Native Crystal Structure of NO releasing inductive lectin from seeds of the Canavalia maritima (ConM)
7EWM	;	2.9	;	Native crystal structure of S. cerevisiae Csn12 in complex with Thp3 and Sem1
1TW0	;	2.2	;	Native crystal structure of SPE16
2H9C	;	2.35	;	Native Crystal Structure of the Isochorismate-Pyruvate Lyase from Pseudomonas aeruginosa
8AQR	;	1.46	;	Native crystal structure of the N-terminal beta-hairpin docking (bHD) domain of the AerJ halogenase, from the aeruginosin biosynthetic assembly line
1I9I	;	2.72	;	NATIVE CRYSTAL STRUCTURE OF THE RECOMBINANT MONOCLONAL WILD TYPE ANTI-TESTOSTERONE FAB FRAGMENT
2BSJ	;	1.83	;	Native Crystal Structure of the Type III Secretion chaperone SycT from Yersinia enterocolitica
3OG2	;	1.2	;	Native crystal structure of Trichoderma reesei beta-galactosidase
7XNZ	;	3.6	;	Native cystathionine beta-synthase of Mycobacterium tuberculosis.
6TR1	;	1.7	;	Native cytochrome c6 from Thermosynechococcus elongatus in space group H3
1W1O	;	1.7	;	Native Cytokinin Dehydrogenase
4UWO	;	1.555	;	Native di-zinc VIM-26. Leu224 in VIM-26 from Klebsiella pneumoniae has implications for drug binding.
1H9W	;	2.0	;	Native Dioclea Guianensis seed lectin
2H46	;	1.9	;	Native domain-swapped dimer crystal structure of the Grb2 SH2 domain
2GBC	;	2.8	;	Native DPP-IV (CD26) from Rat
6UTM	;	2.14	;	Native E. coli Glyceraldehyde 3-phosphate dehydrogenase
6UTN	;	1.79	;	Native E. coli Glyceraldehyde 3-phosphate dehydrogenase
6UTO	;	1.64	;	Native E. coli Glyceraldehyde 3-phosphate dehydrogenase
7A3H	;	0.95	;	NATIVE ENDOGLUCANASE CEL5A CATALYTIC CORE DOMAIN AT 0.95 ANGSTROMS RESOLUTION
5Z01	;	1.75	;	Native Escherichia coli L,D-carboxypeptidase A (LdcA)
2JEM	;	1.78	;	Native family 12 xyloglucanase from Bacillus licheniformis
2JEP	;	1.4	;	Native family 5 xyloglucanase from Paenibacillus pabuli
1K07	;	1.65	;	Native FEZ-1 metallo-beta-lactamase from Legionella gormanii
5WCK	;	1.65	;	Native FEZ-1 metallo-beta-lactamase from Legionella gormanii
5AM6	;	1.96	;	Native FGFR1 with an inhibitor
1D6O	;	1.85	;	NATIVE FKBP
1PV2	;	2.71	;	Native Form 2 E.coli Chaperone Hsp31
8B9S	;	2.42	;	NATIVE FORM, THERMOSTABLE LIPASE FROM THERMOANAEROBACTER THERMOHYDROSULFURICUS
3FPX	;	1.8	;	Native fungus laccase from Trametes hirsuta
8G4O	;	3.06	;	Native GABA-A receptor from the mouse brain, alpha1-beta2-gamma2 subtype, in complex with didesethylflurazepam and endogenous GABA
8FOI	;	2.5	;	Native GABA-A receptor from the mouse brain, alpha1-beta2-gamma2 subtype, in complex with GABA and allopregnanolone
8G4N	;	2.67	;	Native GABA-A receptor from the mouse brain, alpha1-beta2-gamma2 subtype, in complex with GABA, Zolpidem, and endogenous neurosteroids
8G4X	;	2.56	;	Native GABA-A receptor from the mouse brain, meta-alpha1-alpha3-beta2-gamma2 subtype, in complex with GABA and allopregnanolone
8G5G	;	2.94	;	Native GABA-A receptor from the mouse brain, meta-alpha1-alpha3-beta2-gamma2 subtype, in complex with GABA, Zolpidem, and endogenous neurosteroid
8G5F	;	2.64	;	Native GABA-A receptor from the mouse brain, ortho-alpha1-alpha3-beta2-gamma2 subtype, in complex with GABA and allopregnanolone
8G5H	;	2.89	;	Native GABA-A receptor from the mouse brain, ortho-alpha1-alpha3-beta2-gamma2 subtype, in complex with GABA, Zolpidem, and endogenous neurosteroid
6GS0	;	1.34	;	Native Glucuronoyl Esterase from Opitutus terrae
1ODW	;	2.1	;	Native HIV-1 Proteinase
5LE5	;	1.8	;	Native human 20S proteasome at 1.8 Angstrom
5LEX	;	2.2	;	Native human 20S proteasome in Mg-Acetate at 2.2 Angstrom
1R42	;	2.2	;	Native Human Angiotensin Converting Enzyme-Related Carboxypeptidase (ACE2)
1NOU	;	2.4	;	Native human lysosomal beta-hexosaminidase isoform B
1REX	;	1.5	;	NATIVE HUMAN LYSOZYME
5VF9	;	1.82	;	Native human manganese superoxide dismutase
1VYM	;	2.3	;	NATIVE HUMAN PCNA
1W60	;	3.15	;	NATIVE HUMAN PCNA
2YB6	;	1.5	;	Native human Rad6
7T9I	;	2.9	;	Native human TSH bound to human Thyrotropin receptor in complex with miniGs399 (composite structure)
1F8E	;	1.4	;	Native Influenza Neuraminidase in Complex with 4,9-diamino-2-deoxy-2,3-dehydro-N-acetyl-neuraminic Acid
1F8C	;	1.7	;	Native Influenza Neuraminidase in Complex with 4-amino-2-deoxy-2,3-dehydro-N-neuraminic Acid
1F8D	;	1.4	;	Native Influenza Neuraminidase in Complex with 9-amino-2-deoxy-2,3-dehydro-N-neuraminic Acid
1F8B	;	1.8	;	Native Influenza Virus Neuraminidase in Complex with NEU5AC2EN
7NN9	;	2.0	;	NATIVE INFLUENZA VIRUS NEURAMINIDASE SUBTYPE N9 (TERN)
2V81	;	2.4	;	Native KDPGal structure
7ZPO	;	3.24	;	native KtrAB complex
7ARP	;	1.78	;	Native L-2-haloacid dehalogenase from Zobellia galactanivorans
1JSW	;	2.7	;	NATIVE L-ASPARTATE AMMONIA LYASE
2YML	;	1.79	;	Native L-haloacid dehalogenase from a Rhodobacteraceae family bacterium
7UOV	;	2.75	;	Native Lassa glycoprotein in complex with neutralizing antibodies 12.1F and 37.2D
7UOT	;	2.77	;	Native Lassa glycoprotein in complex with neutralizing antibodies 8.9F and 37.2D
5A6U	;	9.0	;	Native mammalian ribosome-bound Sec61 protein-conducting channel in the 'non-inserting' state
1B2P	;	1.7	;	NATIVE MANNOSE-SPECIFIC BULB LECTIN FROM SCILLA CAMPANULATA (BLUEBELL) AT 1.7 ANGSTROMS RESOLUTION
2J3D	;	2.6	;	Native monoclinic form of Torpedo acetylcholinesterase
7SAV	;		;	Native mu-conotoxin KIIIA isomer
7CRR	;	3.48	;	Native NSD3 bound to 187-bp nucleosome
1W75	;	2.4	;	Native Orthorhombic form of Torpedo californica acetylcholinesterase (AChE)
7WYI	;	3.9	;	Native Photosystem I of Chlamydomonas reinhardtii
3G7D	;	1.8	;	Native PhpD with Cadmium Atoms
1OTY	;	2.5	;	Native PNP +ALLO
1OU4	;	2.5	;	Native PNP +Talo
1PPY	;	1.95	;	Native precursor of pyruvoyl dependent Aspartate decarboxylase
2C45	;	2.99	;	NATIVE PRECURSOR OF PYRUVOYL DEPENDENT ASPARTATE DECARBOXYLASE
5HBL	;	1.617	;	Native rhodanese domain of YgaP prepared with 1mM DDT is S-nitrosylated
5HBO	;	1.66	;	Native rhodanese domain of YgaP prepared without DDT is both S-nitrosylated and S-sulfhydrated
7MRW	;	3.72	;	Native RhopH complex of the malaria parasite Plasmodium falciparum
4MS9	;	1.32	;	Native RNA-10mer Structure: ccggcgccgg
8DE3	;	3.3	;	Native serotonin transporter in complex with 15B8 Fab antibody in the presence of cocaine
8DE4	;	2.9	;	Native serotonin transporter in complex with 15B8 Fab in the presence of methamphetamine
1VXA	;	2.0	;	NATIVE SPERM WHALE MYOGLOBIN
1VXB	;	2.0	;	NATIVE SPERM WHALE MYOGLOBIN
1VXC	;	1.7	;	NATIVE SPERM WHALE MYOGLOBIN
1VXD	;	1.7	;	NATIVE SPERM WHALE MYOGLOBIN
1VXE	;	1.7	;	NATIVE SPERM WHALE MYOGLOBIN
1VXF	;	1.7	;	NATIVE SPERM WHALE MYOGLOBIN
1VXG	;	1.7	;	NATIVE SPERM WHALE MYOGLOBIN
1VXH	;	1.7	;	NATIVE SPERM WHALE MYOGLOBIN
5FLO	;	1.66	;	Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination
5FLP	;	1.71	;	Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination
5FLQ	;	1.7	;	Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination
5FLR	;	1.68	;	Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination
5FLS	;	1.67	;	Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination
5FLT	;	1.67	;	Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination
5FNG	;	2.05	;	Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination
5FNH	;	1.66	;	Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination
5FNI	;	1.6	;	Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination
5FNJ	;	1.67	;	Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination
5FNK	;	1.59	;	Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination
5FNL	;	1.59	;	Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination
5FNM	;	1.59	;	Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination
3MXH	;	2.3	;	Native structure of a c-di-GMP riboswitch from V. cholerae
2W1W	;	1.55	;	Native structure of a family 35 carbohydrate binding module from Clostridium thermocellum
2JKA	;	1.9	;	Native structure of a family 97 alpha-glucosidase from Bacteroides thetaiotaomicron
4AO6	;	1.6	;	Native structure of a novel cold-adapted esterase from an Arctic intertidal metagenomic library
7QOD	;	1.85	;	Native structure of a small alarmone hydrolase (RelH) from Corynebacterium glutamicum
1TG7	;	1.9	;	Native structure of beta-galactosidase from Penicillium sp.
1XC6	;	2.1	;	Native Structure Of Beta-Galactosidase from Penicillium sp. in complex with Galactose
3I01	;	2.15	;	Native structure of bifunctional carbon monoxide dehydrogenase/acetyl-CoA synthase from Moorella thermoacetica, water-bound C-cluster.
1L0N	;	2.6	;	native structure of bovine mitochondrial cytochrome bc1 complex
1E43	;	1.7	;	Native structure of chimaeric amylase from B. amyloliquefaciens and B. licheniformis at 1.7A
1E3X	;	1.9	;	Native structure of chimaeric amylase from B. amyloliquefaciens and B. licheniformis at 1.92A
6RYG	;	0.974	;	native structure of conglutinin carbohydrate recognition domain
4IXZ	;	2.07	;	Native structure of cystathionine gamma lyase (XometC) from xanthomonas oryzae pv. oryzae at pH 9.0
6LD7	;	2.1	;	Native Structure of cystathionine gamma synthase (XometB) from Xanthomonas oryzae pv. oryzae
8OHY	;	1.95	;	Native Structure of Dictyostelium discoideum dye-decolorizing peroxidase
3RRD	;	2.46	;	Native structure of Dioclea virgata lectin
6QKI	;	2.04	;	Native structure of EgtB from Chloracidobacterium thermophilum, a type II sulfoxide synthase
3PZ9	;	1.42	;	Native structure of endo-1,4-beta-D-mannanase from Thermotoga petrophila RKU-1
2X8F	;	1.9	;	Native structure of Endo-1,5-alpha-L-arabinanases from Bacillus subtilis
2BW8	;	1.54	;	Native structure of Endoglucanase 12A (Cel12A) from Rhodothermus marinus
3ZOU	;	1.55	;	Native structure of Farnesyl Pyrophosphate Synthase from Pseudomonas aeruginosa PA01, with bound fragment SPB02696, and substrate geranyl pyrophosphate.
3ZMB	;	1.9	;	Native structure of Farnesyl Pyrophosphate Synthase from Pseudomonas aeruginosa PA01, with bound fragment SPB02696.
4UMJ	;	1.85	;	Native structure of Farnesyl Pyrophosphate Synthase from Pseudomonas aeruginosa PA01, with bound ibandronic acid molecules.
3ZMC	;	1.87	;	Native structure of Farnesyl Pyrophosphate Synthase from Pseudomonas aeruginosa PA01, with bound substrate molecule Geranyl pyrophosphate.
3ZCD	;	1.55	;	Native structure of Farnesyl Pyrophosphate Synthase from Pseudomonas aeruginosa PA01.
3ZL6	;	1.85	;	Native structure of Farnesyl Pyrophosphate Synthase from Pseudomonas aeruginosa PAO1, with bound fragment KM10833.
5GK3	;	1.8	;	Native structure of fructose 1,6-bisphosphate aldolase from Escherichia coli at 1.8 Angstrom resolution
5GK4	;	2.0	;	Native structure of fructose 1,6-bisphosphate aldolase from Escherichia coli at 2.0 Angstrom resolution
4BMX	;	1.76	;	Native structure of futalosine hydrolase of Helicobacter pylori strain 26695
5YUL	;	1.9	;	Native Structure of hSOD1 in P6322 space group
4RIM	;	2.3	;	Native structure of intercalation-locked DNA tetraplex
3MVG	;	1.25	;	Native structure of IRIP, a type I ribosome inactivating protein from Iris hollandica var. at 1.25 A
4FWE	;	2.13	;	Native structure of LSD2 /AOF1/KDM1b in spacegroup of C2221 at 2.13A
4FWJ	;	2.9	;	Native structure of LSD2/AOF1/KDM1b in spacegroup of I222 at 2.9A
2QCJ	;	3.0	;	Native Structure of Lyp
6T14	;	1.86	;	Native structure of mosquitocidal Cyt1A protoxin obtained by Serial Femtosecond Crystallography on in vivo grown crystals at pH 7
7P7I	;	1.7	;	Native structure of N-acetylglucosamine kinase from Plesiomonas shigelloides
2R8V	;	2.5	;	Native structure of N-acetylglutamate synthase from Neisseria gonorrhoeae
5AFD	;	1.65	;	Native structure of N-acetylneuramininate lyase (sialic acid aldolase) from Aliivibrio salmonicida
5XP6	;	0.95	;	native structure of NDM-1 crystallized at pH5.5
4UB6	;	1.95	;	Native structure of photosystem II (dataset-1) by a femtosecond X-ray laser
4UB8	;	1.95	;	Native structure of photosystem II (dataset-2) by a femtosecond X-ray laser
1R8W	;	2.5	;	Native structure of the B12-independent glycerol dehydratase from clostridium butyricum
2W94	;	1.8	;	Native structure of the Discoidin I from Dictyostelium discoideum at 1.8 angstrom resolution
1ERN	;	2.4	;	NATIVE STRUCTURE OF THE EXTRACELLULAR DOMAIN OF ERYTHROPOIETIN (EPO) RECEPTOR [EBP]
2LP5	;		;	Native Structure of the Fyn SH3 A39V/N53P/V55L
2W5N	;	1.85	;	Native structure of the GH93 alpha-L-arabinofuranosidase of Fusarium graminearum
1KO9	;	2.15	;	Native Structure of the Human 8-oxoguanine DNA Glycosylase hOGG1
5A6Q	;	1.7	;	Native structure of the LecB lectin from Pseudomonas aeruginosa strain PA14
5I3T	;	2.1	;	Native Structure of the Linalool Dehydratase-Isomerase from Castellaniella defragrans
4CSH	;	1.79	;	Native structure of the lytic CHAPK domain of the endolysin LysK from Staphylococcus aureus bacteriophage K
6G3X	;	2.1	;	Native Structure of the mouse 8-oxoguanine DNA Glycosylase mOGG1
4P12	;	1.6011	;	Native Structure of the P domain from a GI.7 Norovirus variant.
2VM9	;	1.75	;	Native structure of the recombinant discoidin II of Dictyostelium discoideum at 1.75 angstrom
3OJL	;	2.8	;	Native structure of the UDP-N-acetyl-mannosamine dehydrogenase Cap5O from Staphylococcus aureus
3N8T	;	2.4	;	Native structure of TK1436, a GH57 branching enzyme from hyperthermophilic archaeon Thermococcus kodakaraensis
6H7T	;	2.1	;	Native structure of Trichoderma reesei Carbohydrate-Active Enzymes Family AA12
4IXS	;	2.29	;	Native structure of xometc at ph 5.2
5E5D	;	2.6	;	Native structure of Xoo1075, a peptide deformylase from Xanthomonas oryzae pv. oryzae
1ZCK	;	1.9	;	native structure prl-1 (ptp4a1)
8JHF	;	3.68	;	Native SUV420H1 bound to 167-bp nucleosome
8JHG	;	3.58	;	Native SUV420H1 bound to 167-bp nucleosome
3H8J	;	1.8	;	Native T4 RNase H in the absence of divalent metal ions
2VBK	;	1.25	;	NATIVE TAILSPIKE PROTEIN OF BACTERIOPHAGE SF6
6RT1	;	1.336	;	Native tetragonal lysozyme - home source data
6RT3	;	1.05	;	Native tetragonal lysozyme - synchrotron data
1QHZ	;	1.95	;	NATIVE TETRAGONAL STRUCTURE OF THE ENDOGLUCANASE CEL5A FROM BACILLUS AGARADHAERENS
7XSN	;	3.01	;	Native Tetrahymena ribozyme conformation
8B3Y	;	1.25	;	Native Thermogutta terrifontis endoglucanase catalytic domain with a linker at C-terminal from glycoside hydrolase family 5 (TtEnd5A-CDC)
8BBT	;	1.69	;	Native Tipula oleracea Nudivirus polyhedrin - 1960
2INC	;	1.85	;	Native Toluene/o-xylene Monooxygenase Hydroxylase X-ray Crystal Structure
2VT7	;	2.2	;	Native Torpedo californica acetylcholinesterase collected with a cumulated dose of 800000 Gy
2VT6	;	2.4	;	Native Torpedo californica acetylcholinesterase collected with a cumulated dose of 9400000 Gy
2Y87	;	1.86	;	Native VIM-7. Structural and computational investigations of VIM-7: Insights into the substrate specificity of VIM metallo-beta- lactamases
8AHZ	;	1.7	;	Native VirD of Streptomyces virginiae
7BC3	;	2.9	;	Native virion of Kashmir bee virus at acidic pH
7BGK	;	2.8	;	Native virion of Kashmir bee virus at neutral pH
5GTH	;	2.5	;	Native XFEL structure of photosystem II (dark dataset)
5WS5	;	2.35	;	Native XFEL structure of photosystem II (preflash dark dataset)
5WS6	;	2.35	;	Native XFEL structure of Photosystem II (preflash two-flash dataset
5GTI	;	2.5	;	Native XFEL structure of photosystem II (two flash dataset)
1US3	;	1.85	;	Native xylanase10C from Cellvibrio japonicus
5ONK	;	1.03	;	Native YndL
6HRI	;	1.03	;	Native YndL
5Y42	;	2.9	;	Native-crystal structure of three chain non-toxic type II ribosome inactivating protein purified from the seeds of Trichosanthes anguina
7E1F	;	1.447	;	Native-DBD
7S63	;	4.12	;	Native-form oocyte/egg Alpha-2-Macroglobulin (A2Moo) tetramer
7AL3	;	4.8	;	Native-like genome-containing particle of DWV in acidic pH
1CPM	;	2.0	;	NATIVE-LIKE IN VIVO FOLDING OF A CIRCULARLY PERMUTED JELLYROLL PROTEIN SHOWN BY CRYSTAL STRUCTURE ANALYSIS
1CPN	;	1.8	;	NATIVE-LIKE IN VIVO FOLDING OF A CIRCULARLY PERMUTED JELLYROLL PROTEIN SHOWN BY CRYSTAL STRUCTURE ANALYSIS
4TKS	;	3.2017	;	Native-SAD phasing for human EGFR kinase domain.
4TKR	;	3.0023	;	Native-SAD phasing for ThiT from Listeria monocytogenes serovar.
4TKQ	;	2.8025	;	Native-SAD phasing for YetJ from Bacillus Subtilis
6U42	;	3.4	;	Natively decorated ciliary doublet microtubule
6TM4	;	1.89	;	NatL2 in complex with two molecules of salicylic acid
7ODU	;	3.0	;	Natural killer cell receptor NKR-P1B from Rattus norvegicus in complex with its cognate ligand Clr-11
2O1F	;	1.99	;	Natural Occuring Mutation of Human ABO(H) galactosyltransferase: GTB/M214R
2O1G	;	1.71	;	Natural occurring mutant of Human ABO(H) Galactosyltransferase: GTB/M214T
2XUC	;	2.3	;	Natural product-guided discovery of a fungal chitinase inhibitor
2O1H	;	1.67	;	Naturally occurring mutation of Humna ABO(H) Galactosyltransferase in complex with UDP: GTB/M214T_UDP
5AP0	;	2.15	;	Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
5AP1	;	2.05	;	Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
5AP2	;	2.8	;	Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
5AP3	;	2.7	;	Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
5AP4	;	2.85	;	Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
5AP5	;	2.8	;	Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
5AP6	;	2.1	;	Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
5AP7	;	2.45	;	Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
1ELF	;	1.7	;	NATURE OF THE INACTIVATION OF ELASTASE BY N-PEPTIDYL-O-AROYL HYDROXYLAMINE AS A FUNCTION OF PH
1ELG	;	1.65	;	NATURE OF THE INACTIVATION OF ELASTASE BY N-PEPTIDYL-O-AROYL HYDROXYLAMINE AS A FUNCTION OF PH
7XVF	;	2.8	;	Nav1.7 mutant class2
6C1E	;	2.86	;	NavAb NormoPP mutant
6C1M	;	2.518	;	NavAb NormoPP mutant
6MVX	;	3.455	;	NavAb Voltage-gated Sodium Channel, I217C, in Complex with Class 1C Anti-arrhythmic Flecainide
6MVV	;	2.9	;	NavAb voltage-gated sodium channel, I217C/F203A
6MVW	;	3.198	;	NavAb voltage-gated sodium channel, I217C/F203W
6MVY	;	3.002	;	NavAb voltage-gated sodium channel, residues 1-226, crystallized in the presence of Class 1B Anti-arrhythmic drug Lidocaine
6MWA	;	2.4	;	NavAb Voltage-gated Sodium Channel, residues 1-239
6MWB	;	2.6	;	NavAb Voltage-gated Sodium Channel, residues 1-239 with mutation T206A
6MWD	;	2.327	;	NavAb Voltage-gated Sodium Channel, residues 1-239 with mutation T206S
6MWG	;	2.501	;	NavAb Voltage-gated Sodium Channel, residues 1-239, with mutation T206V
7PGI	;	3.638	;	NaVAb1p (bicelles)
7PGG	;	2.85	;	NaVAb1p detergent (DM)
7PGH	;	4.194	;	NaVAe1/Sp1CTDp (DDM)
7X5V	;	2.83	;	NaVEh Sodium channel, and NaVEh from the coccolithophore Emiliania huxleyi
4X8A	;	3.02	;	NavMS pore and C-terminal domain grown from protein purified in LiCl
4X89	;	2.62	;	NavMs voltage-gated sodium channal pore and C-terminal domain soaked with Silver nitrate
5BZB	;	2.7	;	NavMs voltage-gated sodium channel pore and C-terminal domain
7PG8	;	4.5	;	NaV_Ae1/Sp1CTD_pore-ANT05 complex
7PGB	;	3.6	;	NaV_Ae1/Sp1CTD_pore-SAT09 complex
6Y1R	;	1.85	;	Nb22-LBT
5NML	;	2.5	;	Nb36 Ser85Cys with Hg bound
5NM0	;	1.5	;	Nb36 Ser85Cys with Hg, crystal form 1
7R63	;	2.0	;	Nb82, a nanobody against voltage gated sodium channels Nav1.4 and Nav1.5
3EAK	;	1.95	;	NbBCII10 humanized (FGLA mutant)
6Y0E	;	1.5	;	Nbe LBM
6XYM	;	1.2	;	Nbe-LBM
8E0E	;	2.0	;	nbF3:CaV beta subunit 2a complex
8DAM	;	2.0	;	nbF3:nbE8:CaV beta subunit 1b complex
3CS5	;	2.2	;	NblA protein from Synechococcus elongatus PCC 7942
2QDO	;	2.5	;	NblA protein from T. vulcanus
2Q8V	;	2.5	;	NblA protein from T. vulcanus crystallized with urea
8C5H	;	1.68	;	NbSyt1 anti-(rat Synaptotagmin-1) nanobody bound to target cytosolic domain of Synaptotagmin-1
2NCD	;	2.5	;	NCD (NON-CLARET DISJUNCTIONAL) DIMER FROM D. MELANOGASTER
7CND	;	1.8	;	NCI-1 in complex with CRM1-Ran-RanBP1
2CI9	;	1.5	;	Nck1 SH2-domain in complex with a dodecaphosphopeptide from EPEC protein Tir
4UDY	;	1.09	;	NCO- bound to cluster C of Ni,Fe-CO dehydrogenase at true-atomic resolution
6QI4	;	1.78	;	NCS-1 bound to a ligand
1KVH	;		;	NCSi-gb-bulge-DNA complex induced formation of a DNA bulge structure by a molecular wedge ligand-post-activated neocarzinostatin chromophore
6EFF	;	1.6	;	NCTC10712
3T79	;	3.6113	;	Ndc10: a platform for inner kinetochore assembly in budding yeast
6C89	;	1.75006	;	NDM-1 Beta-Lactamase Exhibits Differential Active Site Sequence Requirements for the Hydrolysis of Penicillin versus Carbapenem Antibiotics
8B1W	;	1.7	;	NDM-1 metallo-beta-lactamase in complex with triazole-based inhibitor CP35
8B1Z	;	1.6	;	NDM-1 metallo-beta-lactamase in complex with triazole-based inhibitor CP56
8B20	;	1.78	;	NDM-1 metallo-beta-lactamase in complex with triazole-based inhibitor CP57
5NBK	;	2.6	;	NDM-1 metallo-beta-lactamase: a parsimonious interpretation of the diffraction data
7UOX	;	0.99	;	NDM1-inhibitor co-structure
7UOY	;	1.47	;	NDM1-inhibitor co-structure
7UP1	;	1.11	;	NDM1-inhibitor co-structure
7UP2	;	1.13	;	NDM1-inhibitor co-structure
7UP3	;	1.4	;	NDM1-inhibitor co-structure
1S5Z	;	2.0	;	NDP kinase in complex with adenosine phosphonoacetic acid
1MN9	;	2.9	;	NDP kinase mutant (H122G) complex with RTP
1MN7	;	2.15	;	NDP kinase mutant (H122G;N119S;F64W) in complex with aBAZTTP
3VVW	;	2.5	;	NDP52 in complex with LC3C
4CP5	;	2.32	;	ndpK in complex with (Rp)-SPMPApp
1M77	;	1.25	;	Near Atomic Resolution Crystal Structure of an A-DNA Decamer d(CCCGATCGGG): Cobalt Hexammine Interactions with A-DNA
4B8X	;	1.25	;	Near atomic resolution crystal structure of Sco5413, a MarR family transcriptional regulator from Streptomyces coelicolor
6QI5	;	3.4	;	Near Atomic Structure of an Atadenovirus Shows a possible gene duplication event and Intergenera Variations in Cementing Proteins
5JUL	;	4.4	;	Near atomic structure of the Dark apoptosome
8GWR	;	2.801	;	Near full length Kidney type Glutaminase in complex with 2,2-Dimethyl-2,3-Dihydrobenzo[a] Phenanthridin-4(1H)-one (DDP)
7K55	;	3.3	;	Near post-translocated +1-frameshifting(CCC-A) complex with EF-G and GDPCP (Structure III-FS)
7K52	;	3.4	;	Near post-translocated non-frameshifting(CCA-A) complex with EF-G and GDPCP (Structure III)
5KMG	;	3.5	;	Near-atomic cryo-EM structure of PRC1 bound to the microtubule
3NFT	;	1.51	;	Near-atomic resolution analysis of BipD- A component of the type-III secretion system of Burkholderia pseudomallei
5SYE	;	3.5	;	Near-atomic resolution cryo-EM reconstruction of doubly bound Taxol- and peloruside-stabilized microtubule
5SYC	;	3.5	;	Near-atomic resolution cryo-EM reconstruction of peloruside-stabilized microtubule
4CBF	;	4.1	;	Near-atomic resolution cryo-EM structure of Dengue serotype 4 virus
5TCP	;	4.3	;	Near-atomic resolution cryo-EM structure of the periplasmic domains of PrgH and PrgK
5TCQ	;	3.6	;	Near-atomic resolution cryo-EM structure of the Salmonella SPI-1 type III secretion injectisome secretin InvG
5OQV	;	4.0	;	Near-atomic resolution fibril structure of complete amyloid-beta(1-42) by cryo-EM
3J8I	;	4.7	;	Near-Atomic Resolution for One State of F-Actin
4AR3	;	1.05	;	Near-atomic resolution neutron crystallography on the oxidised form perdeuterated Pyrococcus furiosus rubredoxin.
2Q9O	;	1.3	;	Near-atomic resolution structure of a Melanocarpus albomyces laccase
6EK5	;	4.2	;	Near-atomic resolution structure of a plant geminivirus determined by electron cryo-microscopy.
6JLV	;	1.22	;	Near-Atomic Resolution Structure of the CYP102A1 Haem Domain with N-Abietoyl-L-Tryptophan
8H2I	;	3.8	;	Near-atomic structure of five-fold averaged PBCV-1 capsid
6NCL	;	3.5	;	Near-atomic structure of icosahedrally averaged PBCV-1 capsid
6HPS	;	3.1	;	Near-infrared dual bioluminescence imaging in vivo using infra-luciferin
4H8P	;	2.05	;	NEAT5 domain of IsdX2, a B. anthracis hemophore in complex with heme
8HQO	;	3.2	;	Neck of DT57C bacteriophage in the full state
6TO8	;	3.36	;	Neck of empty GTA particle computed with C12 symmetry
6TOA	;	3.47	;	Neck of empty GTA particle computed with C6 symmetry
6TE8	;	3.32	;	Neck of native GTA particle computed with C12 symmetry
6TE9	;	3.58	;	Neck of native GTA particle computed with C6 symmetry
8FWE	;	3.46	;	Neck structure of Agrobacterium phage Milano, C3 symmetry
8C6Z	;	1.85	;	necrotic enteritis associated Clostridium p. chitinase F8UNI4 in complex with inhibitor bisdionin C
4BE8	;	2.996	;	NEDD4 HECT A889F structure
2XBF	;	2.503	;	Nedd4 HECT structure
5C91	;	2.44	;	NEDD4 HECT with covalently bound indole-based inhibitor
4BBN	;	2.51	;	NEDD4 HECT-Ub:Ub complex
2XBB	;	2.68	;	Nedd4 HECT:Ub complex
2LTY	;		;	NEDD4L WW2 domain in complex with a Smad7 derived peptide
2BKR	;	1.9	;	NEDD8 NEDP1 complex
2BKQ	;	2.0	;	NEDD8 protease
2KO3	;		;	Nedd8 solution structure
8F2P	;	2.63	;	Nef SF2 dimerization mutant bound to Hck SH3
2QEX	;	2.9	;	Negamycin Binds to the Wall of the Nascent Chain Exit Tunnel of the 50S Ribosomal Subunit
8T2I	;	10.4	;	Negative stain EM assembly of MYC, JAZ, and NINJA complex
3ZUH	;	21.0	;	Negative stain EM Map of the AAA protein CbbX, a red-type Rubisco activase from R. sphaeroides
5A7X	;	17.0	;	negative stain EM of BG505 SOSIP.664 in complex with sCD4, 17b, and 8ANC195
2BYU	;	16.5	;	Negative stain EM reconstruction of M.tuberculosis Acr1(Hsp 16.3) fitted with wheat sHSP dimer
7KTS	;	19.09	;	Negative stain EM structure of the human SAGA coactivator complex (TRRAP, core, splicing module)
6VKL	;	15.0	;	Negative stain reconstruction of the yeast exocyst octameric complex.
5KC2	;	28.0	;	Negative stain structure of Vps15/Vps34 complex
4D2U	;	17.0	;	Negative-stain electron microscopy of E. coli ClpB (BAP form bound to ClpP)
4D2Q	;	18.0	;	Negative-stain electron microscopy of E. coli ClpB mutant E432A (BAP form bound to ClpP)
4D2X	;	20.0	;	Negative-stain electron microscopy of E. coli ClpB of Y503D hyperactive mutant (BAP form bound to ClpP)
8AJO	;	30.6	;	Negative-stain electron microscopy structure of DDB1-DCAF12-CCT5
4B5M	;	2.758	;	Neisseria AP endonuclease bound to the substrate with a cytosine orphan base
4B5J	;	2.1	;	Neisseria AP endonuclease bound to the substrate with an orphan Adenine base
3W1O	;	1.85	;	Neisseria DNA mimic protein DMP12
7OEY	;	1.35	;	Neisseria gonnorhoeae variant E93Q at 1.35 angstrom resolution
6GQ4	;	1.65	;	Neisseria gonorrhoeae Adhesin Complex Protein
1KOP	;	1.9	;	NEISSERIA GONORRHOEAE CARBONIC ANHYDRASE
1KOQ	;	1.9	;	NEISSERIA GONORRHOEAE CARBONIC ANHYDRASE
1D9Y	;	2.2	;	NEISSERIA GONORRHOEAE FERRIC BINDING PROTEIN
6Q8A	;	2.11	;	Neisseria gonorrhoeae Leucyl-tRNA Synthetase in Complex with 5'-O-(N-(L-Leucyl)-Sulfamoyl)Cytidine
6Q8B	;	2.2	;	Neisseria gonorrhoeae Leucyl-tRNA Synthetase in Complex with 5'-O-(N-(L-Leucyl)-Sulfamoyl)N3-methyluridine
6Q8C	;	2.31	;	Neisseria gonorrhoeae Leucyl-tRNA Synthetase in Complex with 5'-O-(N-(L-Leucyl)-Sulfamoyl)Uridine
6YKO	;	2.21	;	Neisseria gonorrhoeae Leucyl-tRNA Synthetase in Complex with Compound 11a
6YKN	;	2.63	;	Neisseria gonorrhoeae Leucyl-tRNA Synthetase in Complex with Compound 11b
6YKQ	;	1.94	;	Neisseria gonorrhoeae Leucyl-tRNA Synthetase in Complex with Compound 11c
6YKS	;	1.97	;	Neisseria gonorrhoeae Leucyl-tRNA Synthetase in Complex with Compound 11d
6YKT	;	2.32	;	Neisseria gonorrhoeae Leucyl-tRNA Synthetase in Complex with Compound 11e
6YKU	;	2.14	;	Neisseria gonorrhoeae Leucyl-tRNA Synthetase in Complex with Compound 11f
6YKV	;	2.43	;	Neisseria gonorrhoeae Leucyl-tRNA Synthetase in Complex with Compound 11g
6YKW	;	2.46	;	Neisseria gonorrhoeae Leucyl-tRNA Synthetase in Complex with Compound 11h
7A0P	;	2.18	;	Neisseria gonorrhoeae Leucyl-tRNA Synthetase in Complex with Compound 11i
6YKX	;	2.41	;	Neisseria gonorrhoeae Leucyl-tRNA Synthetase in Complex with Compound 11j
6YKL	;	2.27	;	Neisseria gonorrhoeae Leucyl-tRNA Synthetase in Complex with Compound 11k
6YKK	;	2.236	;	Neisseria gonorrhoeae Leucyl-tRNA Synthetase in Complex with Compound 15
7AP2	;	2.25	;	Neisseria gonorrhoeae Leucyl-tRNA Synthetase in Complex with Compound LeuS7HMDDA
7YP8	;	2.1	;	Neisseria gonorrhoeae Leucyl-tRNA Synthetase in Complex with Leucyl-sulfamoyl 3-deazaadenosine
6Q89	;	2.21	;	Neisseria gonorrhoeae Leucyl-tRNA Synthetase in Complex with the Intermediate Analog 5'-O-(N-(L-Leucyl)-Sulfamoyl)Adenosine
8AXP	;	1.83	;	Neisseria gonorrhoeae peptidyl-tRNA hydrolase complexed with an XChem hit.
3K8A	;	2.7	;	Neisseria gonorrhoeae PriB
6ZWF	;	1.05	;	Neisseria gonorrhoeae transaldolase
6ZX4	;	0.96	;	Neisseria gonorrhoeae transaldolase
7ODO	;	1.4	;	Neisseria gonorrhoeae transaldolase at 0.27 MGy dose
6ZWJ	;	1.35	;	Neisseria gonorrhoeae transaldolase at 1.35 Angstrom resolution
6ZWH	;	1.5	;	Neisseria gonorrhoeae transaldolase at 1.5 Angstrom resolution
7ODP	;	1.4	;	Neisseria gonorrhoeae transaldolase at 2.7 MGy dose
7ODQ	;	1.4	;	Neisseria gonorrhoeae transaldolase at 5.4 MGy dose
7B0L	;	1.65	;	Neisseria gonorrhoeae transaldolase, low-dose inhouse
7BBW	;	1.25	;	Neisseria gonorrhoeae transaldolase, variant C38S
7BBX	;	0.85	;	Neisseria gonorrhoeae transaldolase, variant K8A
5D02	;	1.87	;	Neisseria meningitidis 3 deoxy-D-arabino-heptulosonate 7-phosphate synthase Glu176Gln variant
5D05	;	1.75	;	Neisseria meningitidis 3 deoxy-D-arabino-heptulosonate 7-phosphate synthase Lys107Ala variant regulated
5D09	;	2.35	;	Neisseria meningitidis 3 deoxy-D-arabino-heptulosonate 7-phosphate synthase Phe211Ala variant
5D03	;	1.84	;	Neisseria meningitidis 3 deoxy-D-arabino-heptulosonate 7-phosphate synthase Val223Ala variant
5D04	;	1.7	;	Neisseria meningitidis 3 deoxy-D-arabino-heptulosonate 7-phosphate synthase Val223Ala variant regulated
5CZT	;	2.04	;	Neisseria meningitidis 3 dexy-D-arabino-heptulosonate 7-phosphate synthase Glu176Ala variant
5CZ0	;	2.5	;	Neisseria meningitidis 3 dexy-D-arabino-heptulosonate 7-phosphate synthase Glu98Ala variant
5CZS	;	2.42	;	Neisseria meningitidis 3 dexy-D-arabino-heptulosonate 7-phosphate synthase Glu98Ala variant regulated
5DCE	;	2.23	;	Neisseria meningitidis 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase regulated (Tryptophan)
5DCD	;	2.31	;	Neisseria meningitidis 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase regulated (Tyrosine)
5DCB	;	2.05	;	Neisseria meningitidis 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase regulated and complexed with PEP
4UC5	;	2.19	;	Neisseria Meningitidis DAH7PS-Phenylalanine regulated
5T5F	;	2.98	;	Neisseria meningitidis factor H binding protein in complex with monoclonal antibody JAR5
7RML	;	2.7	;	Neisseria meningitidis Methylenetetrahydrofolate reductase in complex with FAD
8PJP	;	2.92	;	Neisseria meningitidis PilE, SB-GATDH variant, bound to the F10 nanobody
8P3B	;	3.15	;	Neisseria meningitidis Type IV pilus SA-GATDH variant
8P36	;	2.51	;	Neisseria meningitidis Type IV pilus SB-DATDH variant
8PIZ	;	2.75	;	Neisseria meningitidis Type IV pilus SB-DATDH variant bound to the C24 nanobody
8P2V	;	2.99	;	Neisseria meningitidis Type IV pilus SB-GATDH variant
8PIJ	;	2.9	;	Neisseria meningitidis Type IV pilus SB-GATDH variant bound to the C24 nanobody
5M57	;	2.3	;	Nek2 bound to arylaminopurine 6
5M55	;	2.4	;	Nek2 bound to arylaminopurine 71
5M51	;	1.899	;	Nek2 bound to arylaminopurine compound 8
5M53	;	1.9	;	Nek2 bound to arylaminopurine inhibitor 11
4AFE	;	2.597	;	Nek2 bound to hybrid compound 21
6SK9	;	2.0	;	Nek2 bound to purine compound 51
6SGK	;	2.0	;	Nek2 kinase bound to inhibitor 102
6SGI	;	2.3	;	Nek2 kinase bound to inhibitor 96
6SGD	;	2.0	;	Nek2 kinase covalently bound to 2-arylamino-6-ethynylpurine inhibitor 24
6SGH	;	3.0	;	Nek2 kinase covalently bound to 2-arylamino-6-ethynylpurine inhibitor 66
4A4X	;	2.4	;	NEK2-EDE bound to CCT248662
7NH3	;	6.37	;	Nematocida Huwe1 in open conformation.
2HM3	;		;	Nematocyst outer wall antigen, cysteine rich domain NW1
2HM6	;		;	Nematocyst outer wall antigen, NW1 G11V K21P
2HM4	;		;	Nematocyst Outer Wall Antigen, NW1 K21P
6ENA	;		;	Nemertide alpha-1
4BWN	;	2.27	;	NEMO CC2-LZ DOMAIN
2V4H	;	2.9	;	NEMO CC2-LZ domain - 1D5 DARPin complex
3F89	;	2.8	;	NEMO CoZi domain
2ZVO	;	2.9	;	NEMO CoZi domain in complex with diubiquitin in C2 space group
2ZVN	;	3.0	;	NEMO CoZi domain incomplex with diubiquitin in P212121 space group
3BRT	;	2.25	;	NEMO/IKK association domain structure
3BRV	;	2.2	;	NEMO/IKKb association domain structure
7RM4	;	3.33	;	Neoantigen p53R175H-specific TCR 6-11 binds to p53R175H-HLA-A2
8DZ8	;	2.972	;	Neoleukin 4, a de novo designed IL-4 mimetic
3FRU	;	2.2	;	NEONATAL FC RECEPTOR, PH 6.5
5JMY	;	2.0	;	NEPRILYSIN COMPLEXED WITH LBQ657
6THP	;	2.54	;	Neprilysin in complex with the inhibitor (R)-4-(1-carboxy-3-(3'-chlorobiphenyl-4-yl)propan-2-ylamino)-4-oxobutanoic acid
4CTH	;	2.15	;	Neprilysin variant G399V,G714K in complex with phosphoramidon
5N6G	;	1.58	;	NerA from Agrobacterium radiobacter in complex with 2-phenylacrylic acid
5Z0C	;	1.54	;	Nerol dehydrogenase from Persicaria minor
7D16	;		;	NERP-2 in a DPC solution
7D13	;		;	NERP-2 in a HFIP solution
4EDW	;	2.48	;	Nerve Growth Factor in Complex with Fab from humanized version of mouse mAb 911 (tanezumab)
4EDX	;	2.5	;	Nerve Growth Factor in Complex with Fab from mouse mAb 911
7VPC	;	1.94	;	Neryl diphosphate synthase from Solanum lycopersicum
8X37	;	1.98	;	Neryl diphosphate synthase from Solanum lycopersicum complexed with DMSAPP
8X35	;	1.92	;	Neryl diphosphate synthase from Solanum lycopersicum complexed with DMSAPP, IPP, and magnesium ion (form A)
8X36	;	2.28	;	Neryl diphosphate synthase from Solanum lycopersicum complexed with DMSAPP, IPP, and magnesium ion (form B)
6XF2	;	7.11	;	Nesprin-1G (aa2070-2200)-FHOD1(aa1-339) complex, H. sapiens
6XF1	;	2.8	;	Nesprin-2G(aa1425-1649)-FHOD1(aa1-339) complex, H. sapiens
4WNX	;	2.723	;	Netrin 4 lacking the C-terminal Domain
7LER	;	5.99	;	Netrin-1 filament assembly
7LRF	;	3.21	;	Netrin-1 in complex with SOS
3ZYJ	;	3.25	;	NetrinG1 in complex with NGL1
3ZYI	;	2.6	;	NetrinG2 in complex with NGL2
3ZYG	;	2.2	;	NETRING2 LAM AND EGF1 DOMAINS
1ZTT	;	1.85	;	Netropsin bound to d(CTTAATTCGAATTAAG) in complex with MMLV RT catalytic fragment
3NCM	;		;	NEURAL CELL ADHESION MOLECULE, MODULE 2, NMR, 20 STRUCTURES
2NCM	;		;	NEURAL CELL ADHESION MOLECULE, NMR, 20 STRUCTURES
7U4E	;	1.54	;	Neuraminidase from influenza virus A/Bilthoven/17938/1969(H3N2)
7U4F	;	1.4	;	Neuraminidase from influenza virus A/Moscow/10/1999(H3N2)
8DWB	;	1.602	;	Neuraminidase from influenza virus A/Moscow/10/1999(H3N2) in complex with sialic acid
7U4G	;	1.65	;	Neuraminidase from influenza virus A/Shandong/9/1993(H3N2)
7CM1	;	2.14	;	Neuraminidase from the Wuhan Asiatic toad influenza virus
4QN5	;	1.7	;	Neuraminidase N5 binds LSTa at the second SIA binding site
3BEQ	;	1.64	;	Neuraminidase of A/Brevig Mission/1/1918 H1N1 strain
3B7E	;	1.45	;	Neuraminidase of A/Brevig Mission/1/1918 H1N1 strain in complex with zanamivir
8G3Z	;	2.3	;	Neuraminidase of B/Massachusetts/02/2012 (Yamagata) in complex with 4 FNI17 Fab molecules
7MOC	;	4.56	;	Neurofibromin core
7MP6	;	6.25	;	Neurofibromin homodimer
7R04	;	3.7	;	Neurofibromin in open conformation
7R03	;	3.6	;	Neurofibromin occluded conformation
7XWO	;	2.7	;	Neurokinin A bound to active human neurokinin 2 receptor in complex with G324
8JBG	;	2.8	;	Neurokinin B bound to active human neurokinin 3 receptor in complex with Gq
1I1I	;	2.3	;	NEUROLYSIN (ENDOPEPTIDASE 24.16) CRYSTAL STRUCTURE
2NBT	;		;	NEURONAL BUNGAROTOXIN, NMR, 10 STRUCTURES
5AEQ	;	1.95	;	Neuronal calcium sensor (NCS-1)from Rattus norvegicus
5AER	;	2.19	;	Neuronal calcium sensor-1 (NCS-1)from Rattus norvegicus complex with D2 dopamine receptor peptide from Homo sapiens
5AFP	;	2.3	;	Neuronal calcium sensor-1 (NCS-1)from Rattus norvegicus complex with rhodopsin kinase peptide from Homo sapiens
6U6T	;	3.01	;	Neuronal growth regulator 1 (NEGR1)
1VAG	;	2.0	;	Neuronal nitric oxide synthase oxygenase domain complexed with the inhibitor AR-R17477
7QGG	;	2.86	;	Neuronal RNA granules are ribosome complexes stalled at the pre-translocation state
1SFC	;	2.4	;	NEURONAL SYNAPTIC FUSION COMPLEX
7VGX	;	3.2	;	Neuropeptide Y Y1 Receptor (NPY1R) in Complex with G Protein and its endogeneous Peptide-Agonist Neuropeptide Y (NPY)
6TKK	;	1.06	;	Neuropilin 1-b1 domain in a complex with the C-terminal VEGFB186 peptide
2QQN	;	2.2	;	Neuropilin-1 b1 Domain in Complex with a VEGF-Blocking Fab
6FMF	;	2.811	;	Neuropilin-1 b1 domain in complex with EG01377; 2.8 Angstrom structure
2QQK	;	2.75	;	Neuropilin-2 a1a2b1b2 Domains in Complex with a Semaphorin-Blocking Fab
2QQL	;	3.1	;	Neuropilin-2 a1a2b1b2 Domains in Complex with a Semaphorin-Blocking Fab
7P5U	;	1.6	;	Neuropilin-b1 in a complex with a VEGFB-derived peptide
6FMC	;	0.9	;	Neuropilin1-b1 domain in complex with EG01377, 0.9 Angstrom structure
6TDB	;	2.45	;	Neuropilin2-b1 domain in a complex with the C-terminal VEGFB167 peptide
6TJT	;	1.31	;	Neuropilin2-b1 domain in a complex with the C-terminal VEGFC peptide
2WV3	;	1.95	;	Neuroplastin-55 binds to and signals through the fibroblast growth factor receptor
1NPM	;	2.1	;	NEUROPSIN, A SERINE PROTEASE EXPRESSED IN THE LIMBIC SYSTEM OF MOUSE BRAIN
1JOF	;	2.5	;	Neurospora crassa 3-carboxy-cis,cis-mucoante lactonizing enzyme
3EJ6	;	2.3	;	Neurospora Crassa Catalase-3 Crystal Structure
3ZJ5	;	1.95	;	NEUROSPORA CRASSA CATALASE-3 EXPRESSED IN E. COLI, ORTHORHOMBIC FORM.
3ZJ4	;	3.098	;	Neurospora Crassa Catalase-3 expressed in E. coli, triclinic form.
4ZTY	;	1.88	;	Neurospora crassa cobalamin-independent methionine synthase complexed with Cd2+
4ZTX	;	2.1	;	Neurospora crassa cobalamin-independent methionine synthase complexed with Zn2+
5TKH	;	1.2	;	Neurospora crassa polysaccharide monooxygenase 2 ascorbate treated
5TKF	;	2.1	;	Neurospora crassa polysaccharide monooxygenase 2 high mannosylation
5TKG	;	1.2	;	Neurospora crassa polysaccharide monooxygenase 2 resting state
5TKI	;	2.115	;	Neurospora crassa polysaccharide monooxygenase 2 resting state joint X-ray/neutron refinement
5TKI	;	1.5	;	Neurospora crassa polysaccharide monooxygenase 2 resting state joint X-ray/neutron refinement
2LNF	;		;	Neurotensin 40 structures in DMPC/CHAPS(q=0.25) bicelle pH 5.5 & 298K. NMR data & Structures
2LNG	;		;	Neurotensin 40 structures in DMPC:CHAPS:GM1(q= 0.25) bicelle pH 5.5 & 298K. NMR data & Structures
2LNE	;		;	Neurotensin 40 structures in water pH 5.5 298 K. NMR data & structures
2OYV	;		;	Neurotensin in DPC micelles
2OYW	;		;	Neurotensin in TFE:H2O (80:20)
8FMZ	;	2.59	;	Neurotensin receptor allosterism revealed in complex with a biased allosteric modulator
6UP7	;	4.2	;	neurotensin receptor and arrestin2 complex
1B7D	;	1.73	;	NEUROTOXIN (TS1) FROM BRAZILIAN SCORPION TITYUS SERRULATUS
1XTF	;	2.2	;	neurotoxin BoNT/A E224Q Y366F mutant
1VYC	;		;	Neurotoxin from Bungarus candidus
2MJ4	;		;	Neurotoxin II from snake venom Naja Oxiana in solution
1B98	;	2.75	;	NEUROTROPHIN 4 (HOMODIMER)
4F42	;	2.38	;	Neurotrophin p75NTR intracellular domain
4F44	;	2.4	;	Neurotrophin p75NTR intracellular domain
1B8K	;	2.15	;	Neurotrophin-3 from Human
6GL7	;	6.3	;	Neurturin-GFRa2-RET extracellular complex
6TTJ	;	3.392	;	Neutral invertase 2 from Arabidopsis thaliana
7WG6	;	3.4	;	Neutral Omicron Spike Trimer
7WGB	;	3.5	;	Neutral Omicron Spike Trimer in complex with ACE2
7WGC	;	3.6	;	Neutral Omicron Spike Trimer in complex with ACE2.
1ESP	;	2.8	;	NEUTRAL PROTEASE MUTANT E144S
5JTA	;	2.72	;	Neutral trehalase Nth1 from Saccharomyces cerevisiae
5NIS	;	3.155	;	Neutral trehalase Nth1 from Saccharomyces cerevisiae
5M4A	;	2.9	;	Neutral trehalase Nth1 from Saccharomyces cerevisiae in complex with trehalose
6L62	;	7.2	;	Neutralization mechanism of a monoclonal antibody targeting a porcine circovirus type 2 Cap protein conformational epitope
6LM3	;	6.7	;	Neutralization mechanism of a monoclonal antibody targeting a porcine circovirus type 2 Cap protein conformational epitope
2R29	;	3.0	;	Neutralization of dengue virus by a serotype cross-reactive antibody elucidated by cryoelectron microscopy and x-ray crystallography
4HZL	;	2.85	;	Neutralizing antibody mAb#8 in complex with the Epitope II of HCV E2 envelope protein
4NCC	;	2.49	;	Neutralizing antibody to murine norovirus
3X2O	;	1.5	;	Neutron and X-ray joint refined structure of PcCel45A apo form at 298K.
3X2O	;	1.0	;	Neutron and X-ray joint refined structure of PcCel45A apo form at 298K.
3X2P	;	1.518	;	Neutron and X-ray joint refined structure of PcCel45A with cellopentaose at 298K.
3X2P	;	0.99	;	Neutron and X-ray joint refined structure of PcCel45A with cellopentaose at 298K.
8W48	;	1.9	;	Neutron and X-ray joint structure of WT-TTR in complex with piceatannol
8W48	;	1.19	;	Neutron and X-ray joint structure of WT-TTR in complex with piceatannol
2QWS	;	2.5	;	Neutron and X-ray structural studies of short hydrogen bonds in Photoactive Yellow Protein (PYP)
4XPV	;	2.0	;	Neutron and X-ray structure analysis of xylanase: N44D at pH6
4XPV	;	1.7	;	Neutron and X-ray structure analysis of xylanase: N44D at pH6
3A1R	;	1.7	;	Neutron crystal structure analysis of bovine pancreatic ribonuclease A
6GTJ	;	1.801	;	Neutron crystal structure for copper nitrite reductase from Achromobacter Cycloclastes at 1.8 A resolution
2EFA	;	2.7	;	Neutron crystal structure of cubic insulin at pD6.6
2ZPP	;	2.5	;	Neutron crystal structure of cubic insulin at pD9
1WQ2	;	2.4	;	Neutron Crystal Structure Of Dissimilatory Sulfite Reductase D (DsrD)
4PDJ	;	1.994	;	Neutron crystal Structure of E.coli Dihydrofolate Reductase complexed with folate and NADP+
4PDJ	;	1.599	;	Neutron crystal Structure of E.coli Dihydrofolate Reductase complexed with folate and NADP+
7D6G	;	2.1	;	Neutron crystal Structure of E.coli Dihydrofolate Reductase complexed with folate and NADP+ at pH4.5
7D6G	;	1.65	;	Neutron crystal Structure of E.coli Dihydrofolate Reductase complexed with folate and NADP+ at pH4.5
2INQ	;	2.2	;	Neutron Crystal Structure of Escherichia coli Dihydrofolate Reductase Bound to the Anti-cancer drug, Methotrexate
5D97	;	1.8	;	Neutron crystal structure of H2O-solvent ribonuclease A
5CG5	;	2.4	;	Neutron crystal structure of human farnesyl pyrophosphate synthase in complex with risedronate
5CG5	;	1.402	;	Neutron crystal structure of human farnesyl pyrophosphate synthase in complex with risedronate
5CG6	;	2.4	;	Neutron crystal structure of human farnesyl pyrophosphate synthase in complex with risedronate and isopentenyl pyrophosphate
5CG6	;	1.7	;	Neutron crystal structure of human farnesyl pyrophosphate synthase in complex with risedronate and isopentenyl pyrophosphate
7XVX	;	2.0	;	Neutron crystal structure of human macrophage migration inhibitory factor
7XVX	;	1.6	;	Neutron crystal structure of human macrophage migration inhibitory factor
3U2J	;	2.0	;	Neutron crystal structure of human Transthyretin
8DHD	;	2.106	;	Neutron crystal structure of maltotetraose bound tmMBP
8DHD	;	1.7	;	Neutron crystal structure of maltotetraose bound tmMBP
8E1W	;	2.8	;	Neutron crystal structure of Panus similis AA9A at room temperature
8E1W	;	2.1	;	Neutron crystal structure of Panus similis AA9A at room temperature
6EXY	;	1.7	;	Neutron crystal structure of perdeuterated galectin-3C in complex with glycerol
6EXY	;	1.1	;	Neutron crystal structure of perdeuterated galectin-3C in complex with glycerol
6EYM	;	1.7	;	Neutron crystal structure of perdeuterated galectin-3C in complex with lactose
6EYM	;	1.1	;	Neutron crystal structure of perdeuterated galectin-3C in complex with lactose
6F2Q	;	1.757	;	Neutron crystal structure of perdeuterated galectin-3C in the ligand-free form
6F2Q	;	1.03	;	Neutron crystal structure of perdeuterated galectin-3C in the ligand-free form
2ZOI	;	1.5	;	Neutron Crystal Structure of Photoactive Yellow Protein, Wild type, at 295K
4QCD	;	1.932	;	Neutron crystal structure of phycocyanobilin:ferredoxin oxidoreductase in complex with biliverdin IXalpha at room temperature.
4QCD	;	1.551	;	Neutron crystal structure of phycocyanobilin:ferredoxin oxidoreductase in complex with biliverdin IXalpha at room temperature.
4RSG	;	1.907	;	Neutron crystal structure of Ras bound to the GTP analogue GppNHp
4ZZ4	;	1.798	;	Neutron crystal structure of ribonuclease A determined by the real space D/H contrast method
7TX4	;	2.35	;	Neutron crystal structure of SARS-CoV-2 NSP3 macrodomain at 293 K (P21 crystal form)
7TX4	;	1.9	;	Neutron crystal structure of SARS-CoV-2 NSP3 macrodomain at 293 K (P21 crystal form)
7TX3	;	1.89	;	Neutron crystal structure of SARS-CoV-2 NSP3 macrodomain at 293 K (P43 crystal form)
7TX3	;	1.6	;	Neutron crystal structure of SARS-CoV-2 NSP3 macrodomain at 293 K (P43 crystal form)
7TX5	;	2.3	;	Neutron crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ADP-ribose at 293 K (C2 crystal form)
7TX5	;	1.95	;	Neutron crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ADP-ribose at 293 K (C2 crystal form)
6U0F	;	2.0	;	Neutron crystal structure of T4L L99AE
6U0F	;	2.053	;	Neutron crystal structure of T4L L99AE
6U0E	;	1.889	;	Neutron crystal structure of T4L M6AE
6U0E	;	2.106	;	Neutron crystal structure of T4L M6AE
6L26	;	1.444	;	Neutron crystal structure of the mutant green fluorescent protein (EGFP)
1IU6	;	1.6	;	Neutron Crystal Structure of the rubredoxin mutant from Pyrococcus Furiosus
1VCX	;	1.5	;	Neutron Crystal Structure of the Wild Type Rubredoxin from Pyrococcus Furiosus at 1.5A Resolution
2ZWB	;	1.8	;	Neutron crystal structure of wild type human lysozyme in D2O
6U0B	;	2.101	;	Neutron crystal structure of wtT4LD
6U0B	;	1.951	;	Neutron crystal structure of wtT4LD
6U0C	;	2.1	;	Neutron crystal structure of wtT4LE
6U0C	;	2.0	;	Neutron crystal structure of wtT4LE
1V9G	;	1.8	;	Neutron Crystallographic analysis of the Z-DNA hexamer CGCGCG
5VG1	;	2.1	;	Neutron crystallographic structure of a Jonesia denitrificans lytic polysaccharide monooxygenase
5VNQ	;	2.2	;	Neutron crystallographic structure of perdeuterated T4 lysozyme cysteine-free pseudo-wild type at cryogenic temperature
4AR4	;	1.381	;	Neutron crystallographic structure of the reduced form perdeuterated Pyrococcus furiosus rubredoxin to 1.38 Angstrom resolution.
4QX5	;	1.318	;	Neutron diffraction reveals hydrogen bonds critical for cGMP-selective activation: Insights for PKG agonist design
2VS2	;	2.0	;	Neutron diffraction structure of endothiapepsin in complex with a gem- diol inhibitor.
1GKT	;	2.1	;	Neutron Laue diffraction structure of endothiapepsin complexed with transition state analogue inhibitor H261
2DXM	;	2.1	;	Neutron Structure Analysis of Deoxy Human Hemoglobin
1L2K	;	1.5	;	Neutron Structure Determination of Sperm Whale Met-Myoglobin at 1.5A Resolution.
5TY5	;	2.3	;	Neutron structure from microgravity-grown crystals of Inorganic Pyrophosphatase from Thermococcus theoreducens
2WYX	;	2.1	;	Neutron structure of a class A Beta-lactamase Toho-1 E166A R274N R276N triple mutant
7YQS	;	1.8	;	Neutron structure of a L-rhamnose-alpha-1,4-D-glucuronate lyase from Fusarium oxysporum 12S, L-Rha complex
7YQS	;	1.25	;	Neutron structure of a L-rhamnose-alpha-1,4-D-glucuronate lyase from Fusarium oxysporum 12S, L-Rha complex
4BD1	;	2.002	;	Neutron structure of a perdeuterated Toho-1 R274N R276N double mutant Beta-lactamase in complex with a fully deuterated boronic acid (BZB)
4C3Q	;	2.2	;	Neutron structure of a perdeuterated Toho-1 R274N R276N double mutant Beta-lactamase in complex with a fully deuterated boronic acid (BZB) at 100K
4G0C	;	2.0	;	Neutron structure of acetazolamide-bound human carbonic anhydrase II reveal molecular details of drug binding.
8RBR	;	1.8	;	Neutron structure of alginate lyase PsPL7C from Paradendryphiella salina
8RBN	;	2.1	;	Neutron structure of alginate lysase PsPL7C from Paradendryphiella salina soaked with penta-mannuronic acid
7YL8	;	1.6	;	Neutron structure of Bacillus thermoproteolyticus Ferredoxin at room temperature
7YL8	;	1.45	;	Neutron structure of Bacillus thermoproteolyticus Ferredoxin at room temperature
5MNX	;	1.42	;	Neutron structure of cationic trypsin in complex with 2-aminopyridine
5MNY	;	1.43	;	Neutron structure of cationic trypsin in complex with aniline
5MO0	;	1.502	;	Neutron structure of cationic trypsin in complex with benzamidine
5MO1	;	1.491	;	Neutron structure of cationic trypsin in complex with benzylamine
5MO2	;	1.5	;	Neutron structure of cationic trypsin in complex with N-amidinopiperidine
5MNZ	;	1.45	;	Neutron structure of cationic trypsin in its apo form
4CVJ	;	2.501	;	Neutron Structure of Compound I intermediate of Cytochrome c Peroxidase - Deuterium exchanged 100 K
4CVJ	;	2.182	;	Neutron Structure of Compound I intermediate of Cytochrome c Peroxidase - Deuterium exchanged 100 K
5JPR	;	2.202	;	Neutron Structure of Compound II of Ascorbate Peroxidase
5JPR	;	1.806	;	Neutron Structure of Compound II of Ascorbate Peroxidase
6L9C	;	1.72	;	Neutron structure of copper amine oxidase from Arthrobacter glibiformis at pD 7.4
6L9C	;	1.14	;	Neutron structure of copper amine oxidase from Arthrobacter glibiformis at pD 7.4
8J6G	;	1.67	;	Neutron structure of copper amine oxidase from Arthrobacter globiformis anaerobically reduced by phenylethylamine at pD 9.0
8J6G	;	1.09	;	Neutron structure of copper amine oxidase from Arthrobacter globiformis anaerobically reduced by phenylethylamine at pD 9.0
7VEI	;	2.0	;	Neutron structure of D2O-solvent lysozyme
6TAE	;	2.222	;	Neutron structure of ferric ascorbate peroxidase
6TAE	;	1.9	;	Neutron structure of ferric ascorbate peroxidase
6XV4	;	2.09	;	Neutron structure of ferric ascorbate peroxidase-ascorbate complex
6XV4	;	1.9	;	Neutron structure of ferric ascorbate peroxidase-ascorbate complex
4CVI	;	2.407	;	Neutron Structure of Ferric Cytochrome c Peroxidase - Deuterium exchanged at room temperature
4CVI	;	2.1	;	Neutron Structure of Ferric Cytochrome c Peroxidase - Deuterium exchanged at room temperature
7JOR	;	2.05	;	Neutron structure of ferric Dehaloperoxidase B
1CQ2	;	2.0	;	NEUTRON STRUCTURE OF FULLY DEUTERATED SPERM WHALE MYOGLOBIN AT 2.0 ANGSTROM
1LZN	;	1.7	;	NEUTRON STRUCTURE OF HEN EGG-WHITE LYSOZYME
3KKX	;	2.0	;	Neutron structure of human carbonic anhydrase II
4PVM	;	2.0	;	Neutron structure of human transthyretin (TTR) at room temperature to 2.0A resolution (Laue)
4PVM	;	1.95	;	Neutron structure of human transthyretin (TTR) at room temperature to 2.0A resolution (Laue)
4PVN	;	2.3	;	Neutron structure of human transthyretin (TTR) at room temperature to 2.3A resolution (monochromatic)
4PVN	;	1.95	;	Neutron structure of human transthyretin (TTR) at room temperature to 2.3A resolution (monochromatic)
5NFW	;	1.8	;	Neutron structure of human transthyretin (TTR) S52P mutant at room temperature to 1.8A resolution (quasi-Laue)
5NFW	;	1.8	;	Neutron structure of human transthyretin (TTR) S52P mutant at room temperature to 1.8A resolution (quasi-Laue)
6FFT	;	2.0	;	Neutron structure of human transthyretin (TTR) S52P mutant in complex with tafamidis at room temperature to 2A resolution (quasi-Laue)
6FFT	;	2.0	;	Neutron structure of human transthyretin (TTR) S52P mutant in complex with tafamidis at room temperature to 2A resolution (quasi-Laue)
5NFE	;	1.85	;	Neutron structure of human transthyretin (TTR) T119M mutant at room temperature to 1.85A resolution
5NFE	;	1.853	;	Neutron structure of human transthyretin (TTR) T119M mutant at room temperature to 1.85A resolution
6H1M	;	2.15	;	Neutron structure of Lactobacillus brevis alcohol dehydrogenase
4NY6	;	1.85	;	Neutron structure of leucine and valine methyl protonated type III antifreeze
4NY6	;	1.05	;	Neutron structure of leucine and valine methyl protonated type III antifreeze
7T5D	;	2.4	;	Neutron structure of Neurospora crassa Lytic Polysaccharide Monooxygenase 9D (NcLPMO9D) ascorbate soak
7T5E	;	2.144	;	Neutron structure of Neurospora crassa Polysaccharide Monooxygenase 9D (NcLPMO9D) low pH vapor exchange
7T5E	;	1.9	;	Neutron structure of Neurospora crassa Polysaccharide Monooxygenase 9D (NcLPMO9D) low pH vapor exchange
7KKS	;	2.2	;	Neutron structure of Oxidized Human MnSOD
7YKB	;	2.1	;	Neutron Structure of PcyA D105N Mutant Complexed with Biliverdin at Room Temperature
7YKB	;	1.38	;	Neutron Structure of PcyA D105N Mutant Complexed with Biliverdin at Room Temperature
7YK9	;	2.0	;	Neutron Structure of PcyA I86D Mutant Complexed with Biliverdin at Room Temperature
7YK9	;	1.9	;	Neutron Structure of PcyA I86D Mutant Complexed with Biliverdin at Room Temperature
4K9F	;	1.75	;	Neutron structure of Perdeuterated Rubredoxin refined against 1.75 resolution data collected on the new IMAGINE instrument at HFIR, ORNL
3RZ6	;	1.75	;	Neutron structure of perdeuterated rubredoxin using 40 hours 1st pass data
3SS2	;	1.75	;	Neutron structure of perdeuterated rubredoxin using 48 hours 3rd pass data
3RZT	;	1.7504	;	Neutron structure of perdeuterated rubredoxin using rapid (14 hours) data
7KKW	;	2.3	;	Neutron structure of Reduced Human MnSOD
4LNC	;	2.19	;	Neutron structure of the cyclic glucose bound Xylose Isomerase E186Q mutant
4LNC	;	1.84	;	Neutron structure of the cyclic glucose bound Xylose Isomerase E186Q mutant
2XQZ	;	2.1	;	Neutron structure of the perdeuterated Toho-1 R274N R276N double mutant beta-lactamase
5XPE	;	2.09	;	Neutron structure of the T26H mutant of T4 lysozyme
5XPE	;	1.648	;	Neutron structure of the T26H mutant of T4 lysozyme
3QF6	;	1.85	;	Neutron structure of type-III Antifreeze Protein allows the reconstruction of AFP-ice interface
5ZO0	;	1.648	;	Neutron structure of xylanase at pD5.4
8W6X	;	2.2	;	Neutron structure of [NiFe]-hydrogenase from D. vulgaris Miyazaki F in its oxidized state
8W6X	;	1.04	;	Neutron structure of [NiFe]-hydrogenase from D. vulgaris Miyazaki F in its oxidized state
8K9P	;	1.9	;	Neutron X-ray joint structure of pseudoazurin from Alcaligenes faecalis
8K9P	;	1.5	;	Neutron X-ray joint structure of pseudoazurin from Alcaligenes faecalis
6NTJ	;	2.35	;	Neutron/X-ray crystal structure of AAC-VIa bound to gentamicin C1A
6NTJ	;	1.9	;	Neutron/X-ray crystal structure of AAC-VIa bound to gentamicin C1A
6NTI	;		;	Neutron/X-ray crystal structure of AAC-VIa bound to kanamycin b
6NTI	;	2.3	;	Neutron/X-ray crystal structure of AAC-VIa bound to kanamycin b
1TVX	;	1.75	;	NEUTROPHIL ACTIVATING PEPTIDE-2 VARIANT FORM M6L WITH FIVE ADDITIONAL AMINO TERMINAL RESIDUES (DSDLY)
5ABW	;	1.6	;	Neutrophil elastase inhibitors for the treatment of (cardio)pulmonary diseases
1QQS	;	2.4	;	NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN HOMODIMER
1L6M	;	2.4	;	Neutrophil Gelatinase-associated Lipocalin is a Novel Bacteriostatic Agent that Interferes with Siderophore-mediated Iron Acquisition
4Q7X	;	2.55	;	Neutrophil serine protease 4 (PRSS57) apo form 1
4Q7Y	;	2.7	;	Neutrophil serine protease 4 (PRSS57) apo form 2
4Q7Z	;	1.4	;	Neutrophil serine protease 4 (PRSS57) with phe-phe-arg-chloromethylketone (FFR-cmk)
4Q80	;	3.07	;	Neutrophil serine protease 4 (PRSS57) with val-leu-lys-chloromethylketone (VLK-cmk)
2Y66	;	1.49	;	New 5-Benzylidenethiazolidine-4-one Inhibitors of Bacterial MurD Ligase: Design, Synthesis, Crystal Structures, and Biological Evaluation
2Y67	;	1.85	;	New 5-Benzylidenethiazolidine-4-one Inhibitors of Bacterial MurD Ligase: Design, Synthesis, Crystal Structures, and Biological Evaluation
4B1C	;	1.95	;	New Aminoimidazoles as BACE-1 Inhibitors: From Rational Design to Ab- lowering in Brain
4B1D	;	1.95	;	New Aminoimidazoles as BACE-1 Inhibitors: From Rational Design to Ab- lowering in Brain
4B1E	;	1.95	;	New Aminoimidazoles as BACE-1 Inhibitors: From Rational Design to Ab- lowering in Brain
6T73	;	3.435	;	New antiparallel dimer of aureochrome 1a LOV domain mutants from Phaeodactylum tricornutum
6T74	;	1.9	;	New antiparallel dimer of aureochrome 1a LOV domain mutants from Phaeodactylum tricornutum
3HH3	;	1.25	;	New azaborine compounds bind to the T4 lysozyme L99A cavity - 1,2-dihydro-1,2-azaborine
3HH5	;	1.25	;	New azaborine compounds bind to the T4 lysozyme L99A cavity - 1-ethyl-2-hydro-1,2-azaborine
3HH4	;	1.25	;	New azaborine compounds bind to the T4 lysozyme L99A cavity - Benzene as control
3HH6	;	1.25	;	New azaborine compounds bind to the T4 lysozyme L99A cavity -ethylbenzene as control
1HO0	;		;	NEW B-CHAIN MUTANT OF BOVINE INSULIN
3K1W	;	1.5	;	New Classes of Potent and Bioavailable Human Renin Inhibitors
4ZQS	;	1.804	;	New compact conformation of linear Ub2 structure
3WT3	;	1.68	;	New crystal form of a hyperthermophilic endocellulase
4US6	;	1.2	;	New Crystal Form of Glucose Isomerase Grown in Short Peptide Supramolecular Hydrogels
3K4V	;	1.39	;	New crystal form of HIV-1 Protease/Saquinavir structure reveals carbamylation of N-terminal proline
1IV5	;	2.6	;	New Crystal Form of Human CD81 Large Extracellular Loop.
1QGE	;	1.7	;	NEW CRYSTAL FORM OF PSEUDOMONAS GLUMAE (FORMERLY CHROMOBACTERIUM VISCOSUM ATCC 6918) LIPASE
3IMP	;	2.5	;	New crystal form of the C-terminal domain of Helicobacter pylori MotB (residues 125-256)
3WQ7	;	1.68	;	New crystal form of the hyperthermophilic family 12 endo-cellulase from Pyrococcus furiosus
2BP7	;	2.9	;	New crystal form of the Pseudomonas putida branched-chain dehydrogenase (E1)
2IEK	;	1.83	;	New crystal form of transcriptional regulator tm1030 from Thermotoga maritima
4GUK	;	1.75	;	New crystal form structure of human NCS1
1GSB	;	2.5	;	NEW CRYSTAL FORMS OF A MU CLASS GLUTATHIONE S-TRANSFERASE FROM RAT LIVER
1GSC	;	2.5	;	NEW CRYSTAL FORMS OF A MU CLASS GLUTATHIONE S-TRANSFERASE FROM RAT LIVER
1P8L	;	2.95	;	New Crystal Structure of Chlorella Virus DNA Ligase-Adenylate
3EYC	;	2.6	;	New crystal structure of human tear lipocalin in complex with 1,4-butanediol in space group P21
4Z2Z	;	1.8	;	New crystal structure of yeast Ddi1 aspartyl protease reveals substrate engagement mode
2MLW	;		;	New Cyt-like delta-endotoxins from Dickeya dadantii - CytC protein
7CT2	;	1.95	;	New Delhi metallo-beta-lactamase 1 (NDM1) mutant - H116Q
4HL2	;	1.05	;	New Delhi Metallo-beta-Lactamase-1 1.05 A structure Complexed with Hydrolyzed Ampicillin
3SRX	;	2.5	;	New Delhi Metallo-beta-Lactamase-1 Complexed with Cd
4H0D	;	1.498	;	New Delhi Metallo-beta-Lactamase-1 Complexed with Mn from Klebsiella pneumoniae
4HKY	;	2.004	;	New Delhi Metallo-beta-Lactamase-1, Complexed with Cd and Faropenem
4UB0	;	2.2	;	New design for monovalent bispecific IgG through cysteine engineering of the CH1-CL interface
2L6Q	;		;	New high resolution NMR structure of gpW (W protein of bacteriophage lambda) at neutral pH
4I2L	;	1.426	;	New HIV entry inhibitor MTSFT/T23 complex
5JX8	;	2.0	;	New improved structure of D4 in trigonal space group
2FZI	;	1.6	;	New Insights into DHFR Interactions: Analysis of Pneumocystis carinii and Mouse DHFR Complexes with NADPH and Two Highly Potent Trimethoprim Derivatives
2FZJ	;	2.0	;	New Insights into DHFR Interactions: Analysis of Pneumocystis carinii and Mouse DHFR Complexes with NADPH and Two Highly Potent Trimethoprim Derivatives
2FZH	;	2.1	;	New Insights into Dihydrofolate Reductase Interactions: Analysis of Pneumocystis carinii and Mouse DHFR Complexes with NADPH and Two Highly Potent Trimethoprim Derivatives
1C2T	;	2.1	;	NEW INSIGHTS INTO INHIBITOR DESIGN FROM THE CRYSTAL STRUCTURE AND NMR STUDIES OF E. COLI GAR TRANSFORMYLASE IN COMPLEX WITH BETA-GAR AND 10-FORMYL-5,8,10-TRIDEAZAFOLIC ACID.
1C3E	;	2.1	;	NEW INSIGHTS INTO INHIBITOR DESIGN FROM THE CRYSTAL STRUCTURE AND NMR STUDIES OF E. COLI GAR TRANSFORMYLATE IN COMPLEX WITH BETA-GAR AND 10-FORMYL-5,8,10-TRIDEAZAFOLIC ACID.
4ATO	;	2.2	;	New insights into the mechanism of bacterial Type III toxin-antitoxin systems: selective toxin inhibition by a non-coding RNA pseudoknot
8DAX	;	1.61	;	New insights into the P186 flip and oligomeric state of Staphylococcus aureus exfoliative toxin E: implications for the exfoliative mechanism
6FJ5	;	2.051	;	New Insights into the Role of DNA Shape on Its Recognition by p53 Proteins (complex p53DBD-AGG-HG)
5MF7	;	1.59	;	New Insights into the Role of DNA Shape on Its Recognition by p53 Proteins (complex p53DBD-GADD45)
5MCT	;	1.446	;	New Insights into the Role of DNA Shape on Its Recognition by p53 Proteins (complex p53DBD-LHG1)
5MCU	;	1.7	;	New Insights into the Role of DNA Shape on Its Recognition by p53 Proteins (complex p53DBD-LHG2)
5MCV	;	1.6	;	New Insights into the Role of DNA Shape on Its Recognition by p53 Proteins (complex p53DBD-LWC1)
5MCW	;	1.897	;	New Insights into the Role of DNA Shape on Its Recognition by p53 Proteins (complex p53DBD-LWC2)
5MG7	;	1.45	;	New Insights into the Role of DNA Shape on Its Recognition by p53 Proteins (complex p53DBD-p53R2)
1H98	;	1.64	;	New Insights into Thermostability of Bacterial Ferredoxins: High Resolution Crystal Structure of the Seven-Iron Ferredoxin from Thermus thermophilus
6I6R	;	2.02	;	New Irreversible a-l-Iduronidase Inhibitors and Activity-Based Probes
6I6X	;	2.39	;	New Irreversible a-l-Iduronidase Inhibitors and Activity-Based Probes
4TVT	;	1.2	;	New ligand for thaumatin discovered using acoustic high throughput screening
4QPF	;	1.59	;	New lower bone affinity bisphosphonate drug design for effective use in diseases characterized by abnormal bone resorption
6R5J	;	1.38	;	New MAX Effector from Magnaporthe oryzae
5JSP	;	2.2	;	New Mechanistic Insight from Substrate and Product Bound Structures of the Metal-dependent Dimethylsulfoniopropionate Lyase DddQ
5JSR	;	2.5	;	New Mechanistic Insight from Substrate and Product Bound Structures of the Metal-dependent Dimethylsulfoniopropionate Lyase DddQ
5TFX	;	1.5	;	New method for synthesis of benzoxazole amide inhibitors of carbonic anhydrase
2NWN	;	2.15	;	New Pharmacophore for Serine Protease Inhibition Revealed by Crystal Structure of Human Urokinase-type Plasminogen Activator Complexed with a Cyclic Peptidyl Inhibitor, upain-1
7NUY	;	1.65	;	New polymorhp of proteinase K obtained by free interface diffusion technique
1BET	;	2.3	;	NEW PROTEIN FOLD REVEALED BY A 2.3 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF NERVE GROWTH FACTOR
3LVZ	;	1.4	;	New refinement of the crystal structure of BJP-1, a subclass B3 metallo-beta-lactamase of Bradyrhizobium japonicum
3RUM	;	1.851	;	New strategy to analyze structures of glycopeptide antibiotic-target complexes
3RUN	;	1.4	;	New strategy to analyze structures of glycopeptide antibiotic-target complexes
3RUL	;	2.5	;	New strategy to analyze structures of glycopeptide-target complexes
4W5H	;	1.96	;	New structural conformations of adenylate kinase from Streptococcus pneumoniae D39
4W5J	;	1.65	;	New structural conformations of adenylate kinase from Streptococcus pneumoniae D39 with Ap5A
1RO3	;		;	New structural insights on short disintegrin echistatin by NMR
2Z72	;	1.1	;	New Structure Of Cold-Active Protein Tyrosine Phosphatase At 1.1 Angstrom
1XN2	;	1.9	;	New substrate binding pockets for beta-secretase.
4AX2	;	1.88	;	New Type VI-secreted toxins and self-resistance proteins in Serratia marcescens
1USR	;	2.0	;	Newcastle disease virus hemagglutinin-neuraminidase: Evidence for a second sialic acid binding site and implications for fusion
3I6K	;	2.8	;	Newly identified epitope from SARS-CoV membrane protein complexed with HLA-A*0201
3I6G	;	2.201	;	Newly identified epitope Mn2 from SARS-CoV M protein complexed withHLA-A*0201
3I6L	;	2.4	;	Newly identified epitope N1 derived from SARS-CoV N protein complexed with HLA-A*2402
4K7F	;	2.0	;	Newly identified epitope V60 from HBV core protein complexed with HLA-A*0201
1RNC	;	1.5	;	NEWLY OBSERVED BINDING MODE IN PANCREATIC RIBONUCLEASE
1RND	;	1.5	;	NEWLY OBSERVED BINDING MODE IN PANCREATIC RIBONUCLEASE
6WIB	;	2.55	;	Next generation monomeric IgG4 Fc
6WMH	;	2.3	;	Next generation monomeric IgG4 Fc
6WNA	;	2.4	;	Next generation monomeric IgG4 Fc
6WOL	;	2.49	;	Next generation monomeric IgG4 Fc bound to neonatal Fc receptor
1MY5	;	1.8	;	NF-kappaB p65 subunit dimerization domain homodimer
1MY7	;	1.49	;	NF-kappaB p65 subunit dimerization domain homodimer N202R mutation
1ZK9	;	2.18	;	NF-kB RelB forms an intertwined homodimer
1ZKA	;	2.2	;	NF-kB RelB forms an intertwined homodimer, Y300S mutant
7AH8	;	2.70001	;	NF-Y bound to suramin inhibitor
8QU3	;	1.41	;	NF-YB/C Heterodimer in Complex with a 13-mer NF-YA-derived Peptide Stabilized with C8-Hydrocarbon Linker
8QU4	;	1.38	;	NF-YB/C Heterodimer in Complex with a 13-mer NF-YA-derived Peptide Stabilized with C8-Hydrocarbon Linker in an alternative binding pose
8QU2	;	1.45	;	NF-YB/C Heterodimer in Complex with a 16-mer NF-YA-derived Peptide Stabilized with C8-Hydrocarbon Linker
6QMP	;	2.0	;	NF-YB/C Heterodimer in Complex with NF-YA Peptide
6QMS	;	1.8	;	NF-YB/C Heterodimer in Complex with NF-YA-derived Peptide Stabilized with C11-Hydrocarbon Linker
6QMQ	;	2.5	;	NF-YB/C Heterodimer in Complex with NF-YA-derived Peptide Stabilized with C8-Hydrocarbon Linker
1SVC	;	2.6	;	NFKB P50 HOMODIMER BOUND TO DNA
3FR1	;	1.85	;	NFLVHS segment from Islet Amyloid Polypeptide (IAPP or Amylin)
3FTH	;	1.84	;	NFLVHSS segment from Islet Amyloid Polypeptide (IAPP or Amylin)
6DIX	;	1.0	;	NFVFGT segment from Human Immunoglobulin Light-Chain Variable Domain, Residues 98-103, assembled as an amyloid fibril
6Y2Z	;	2.15	;	NG domain of human SRP54
6Y30	;	2.65	;	NG domain of human SRP54 T115A mutant
6Y31	;	4.001	;	NG domain of human SRP54 T117 deletion mutant
6QUY	;	3.8	;	NgCKK (N.Gruberi CKK) decorated 13pf taxol-GDP microtubule
6QVE	;	3.7	;	NgCKK (Naegleria Gruberi CKK) decorated 14pf taxol-GDP microtubule
1WWA	;	2.5	;	NGF BINDING DOMAIN OF HUMAN TRKA RECEPTOR
1WWW	;	2.2	;	NGF IN COMPLEX WITH DOMAIN 5 OF THE TRKA RECEPTOR
5JZ7	;	3.4	;	NGF IN COMPLEX WITH MEDI578 scFv
3NCV	;	2.4	;	NgoL
5CG8	;	2.702	;	NgTET1 in complex with 5hmC DNA
5CG9	;	2.693	;	NgTET1 in complex with 5mC DNA in space group P3221
5KAI	;	2.80001	;	NH3-bound RT XFEL structure of Photosystem II 500 ms after the 2nd illumination (2F) at 2.8 A resolution
3P52	;	2.74	;	NH3-dependent NAD synthetase from Campylobacter jejuni subsp. jejuni NCTC 11168 in complex with the nitrate ion
1KQP	;	1.03	;	NH3-DEPENDENT NAD+ SYNTHETASE FROM BACILLUS SUBTILIS AT 1 A RESOLUTION
1IH8	;	1.9	;	NH3-dependent NAD+ Synthetase from Bacillus subtilis Complexed with AMP-CPP and Mg2+ ions.
3FI1	;	7.0	;	NhaA dimer model
8EZB	;	8.9	;	NHEJ Long-range complex with ATP
8EZA	;	4.39	;	NHEJ Long-range complex with PAXX
7LT3	;	4.6	;	NHEJ Long-range synaptic complex
7LSY	;	8.4	;	NHEJ Short-range synaptic complex
4Q2P	;	2.05	;	NHERF3 PDZ2 in Complex with a Phage-Derived Peptide
7B96	;	1.8	;	NHL domain of human TRIM2
6OY3	;	4.0	;	nhTMEM16 L302A +Ca2+ in nanodiscs
1DKE	;	2.1	;	NI BETA HEME HUMAN HEMOGLOBIN
8DRD	;	1.89	;	Ni(II)-bound B2 dimer (H60/H100/H104)
6HY6	;	1.87	;	Ni(II)-substituted Wells-Dawson binding to Hen Egg-White Lysozyme (HEWL)
8ON3	;	1.74	;	NI,FE-CODH -320mV + CN state : 24 h Dioxygen Exposure
8OMX	;	1.5	;	NI,FE-CODH -600mV state : 1 min Dioxygen Exposure
8ON2	;	1.58	;	NI,FE-CODH -600mV state : 24 h Dioxygen Exposure
8OMY	;	1.37	;	NI,FE-CODH -600mV state : 35 min Dioxygen Exposure
8ON1	;	1.37	;	NI,FE-CODH -600mV state : 4 h Dioxygen Exposure
8ON0	;	1.29	;	NI,FE-CODH -600mV state : 90 min Dioxygen Exposure
2YIV	;	1.28	;	NI,FE-CODH with n-butylisocyanate state
3B53	;	1.5	;	Ni,Fe-CODH-320 mV state
3I39	;	1.36	;	NI,FE-CODH-320 MV+CN state
3B51	;	1.4	;	Ni,Fe-CODH-600 mV state
3B52	;	1.5	;	Ni,Fe-CODH-600 mV state + CO2
4MTS	;	1.8	;	Ni- and Zn-bound GloA2 at high resolution
4MTT	;	2.17	;	Ni- and Zn-bound GloA2 at low resolution
6LV7	;	1.2	;	Ni- Carbonic Anhydrase II pH 11.0 0 atm CO2
6LV8	;	1.2	;	Ni- Carbonic Anhydrase II pH 11.0 20 atm CO2
6LV5	;	1.2	;	Ni- Carbonic Anhydrase II pH 7.8 0 atm CO2
6LV6	;	1.2	;	Ni- Carbonic Anhydrase II pH 7.8 20 atm CO2
7N4F	;	1.8	;	Ni-bound crystal structure of the engineered cyt cb562 variant, AB2-H100A, crystallized in the presence of Ni(II)
7LSN	;	1.52	;	Ni-bound crystal structure of the engineered cyt cb562 variant, DiCyt2 - H63A, crystallized in the presence of Ni(II)
7LRA	;	1.7	;	Ni-bound crystal structure of the engineered cyt cb562 variant, DiCyt2, crystallized in the presence of Cu(II) (M1) and Ni(II) (M2)
7LRV	;	1.4	;	Ni-bound crystal structure of the engineered cyt cb562 variant, DiCyt2, crystallized in the presence of Ni(II)
7LR5	;	1.7	;	Ni-bound crystal structure of the engineered cyt cb562 variant, DiCyt2, crystallized in the presence of Ni(II) (M1) and Cu(II) (M2)
7LRB	;	1.78	;	Ni-bound crystal structure of the engineered cyt cb562 variant, DiCyt2, crystallized in the presence of Ni(II) (M1) and Cu(II) (M2)
5U7H	;	2.0	;	Ni-bound dihydroneopterin triphosphate pyrophosphohydrolase from E. coli
2Y39	;	1.41	;	Ni-bound form of Cupriavidus metallidurans CH34 CnrXs
3ZG1	;	1.85	;	NI-BOUND FORM OF M123A MUTANT OF CUPRIAVIDUS METALLIDURANS CH34 CNRXS
4MTQ	;	2.17	;	Ni-bound GloA2
6WZA	;	2.5	;	Ni-bound structure of an engineered metal-dependent protein trimer, TriCyt1
6WZC	;	2.195	;	Ni-bound structure of an engineered protein trimer, TriCyt3
7Y2S	;	1.2	;	Ni-Carbonic Anhydrase II complexed with 3NPA after UV at 100 K
7Y2T	;	1.2	;	Ni-Carbonic Anhydrase II complexed with 3NPA after UV at 120 K
7Y2U	;	1.2	;	Ni-Carbonic Anhydrase II complexed with 3NPA after UV at 140 K
7Y2V	;	1.2	;	Ni-Carbonic Anhydrase II complexed with 3NPA after UV at 160 K
7Y2W	;	1.2	;	Ni-Carbonic Anhydrase II complexed with 3NPA after UV at 180 K
7Y2X	;	1.5	;	Ni-Carbonic Anhydrase II complexed with 3NPA after UV at 200 K
7Y2R	;	1.2	;	Ni-Carbonic Anhydrase II complexed with 3NPA before UV at 100 K
3SET	;	1.9	;	Ni-mediated Dimer of Maltose-binding Protein A216H/K220H by Synthetic Symmetrization (Form I)
3SEX	;	1.95	;	Ni-mediated Dimer of Maltose-binding Protein A216H/K220H by Synthetic Symmetrization (Form II)
6RUH	;	1.1	;	Ni-substituted alpha-Keggin bound to Proteinase K solved by MR
7A9M	;	1.62	;	Ni-substituted Keggin silicotungstate with covalent bond to proteinase K
473D	;	1.58	;	NI2+/GUANINE INTERACTIONS AND NETROPSIN/GUANINE STACKING IN D(CGTATATACG)2
8BAL	;	2.27	;	Niako3494, a bacterial protein structure in glycoside hydrolase family 20
6X07	;	2.1	;	Nic96 from S. cerevisiae bound by VHH-SAN12
7KHO	;	2.69	;	NicA2 variant N462V in complex with (S)-nicotine
7KHN	;	2.31	;	NicA2 variant N462Y/W427Y in complex with (S)-nicotine
7C4A	;	2.05	;	nicA2 with cofactor FAD
7C49	;	2.25	;	nicA2 with cofactor FAD and substrate nicotine
4YD2	;	2.471	;	Nicked complex of human DNA Polymerase Mu with 2-nt gapped DNA substrate
1G1N	;		;	NICKED DECAMER DNA WITH PEG6 TETHER, NMR, 30 STRUCTURES
3QSI	;	3.08	;	Nickel binding domain of NikR from Helicobacter pylori disclosing partial metal occupancy
1T6I	;	2.81	;	Nickel Superoxide Dismutase (NiSOD) Apo Structure
1T6Q	;	2.05	;	Nickel Superoxide Dismutase (NiSOD) CN-treated Apo Structure
1T6U	;	1.3	;	Nickel Superoxide Dismutase (NiSOD) Native 1.30 A Structure
8ASO	;	1.19	;	Nickel(II) bound to a non-canonical quadruplex
1Q5Y	;	1.4	;	Nickel-Bound C-terminal Regulatory Domain of NikR
6F5N	;	2.2	;	Nickel-Bound Crystal Structure of a GB1 Variant
2HZA	;	2.1	;	Nickel-bound full-length Escherichia coli NikR
8E3U	;	1.99	;	Nickel-reconstituted nitrogenase MoFeP mutant S188A from Azotobacter vinelandii after IDS oxidation
1R0J	;	2.0	;	nickel-substituted rubredoxin
6HN9	;		;	Nicomicin-1 -- Novel antimicrobial peptides from the Arctic polychaeta Nicomache minor provide new molecular insight into biological role of the BRICHOS domain
6F4C	;	2.8	;	Nicotiana benthamiana alpha-galactosidase
5DHK	;	2.43	;	Nicotiana tabacum 5-epi-aristolochene synthase mutant W273E - alkylated
5DHI	;	2.25	;	Nicotiana tabacum 5-epi-aristolochene synthase mutant W273E - nonalkylated
5VW5	;	1.953	;	Nicotinamide soak of Y316A mutant of corn root ferredoxin:NADP+ reductase
5VW4	;	1.351	;	Nicotinamide soak of Y316S mutant of corn root ferredoxin:NADP+ reductase
5VW9	;	1.894	;	Nicotinamide soak of Y316S mutant of corn root ferredoxin:NADP+ reductase in alternate space group
6C71	;	2.649	;	Nicotine Oxidoreductase in Complex with S-nicotine
3E27	;	2.2	;	Nicotinic acid mononucleotide (NaMN) adenylyltransferase from Bacillus anthracis: product complex
6Z04	;	1.05	;	Nido-carborane butyl-sulfonamide in complex with CA IX mimic
4MDM	;	1.55	;	Nido-Carborane Carbonic Anhydrase Inhibitor
6T9Z	;	1.12	;	Nidocarborane inhibitor of Carbonic Anhydrase IX
1GL4	;	2.0	;	Nidogen-1 G2/Perlecan IG3 Complex
5WT2	;	2.301	;	NifS from Helicobacter pylori
6KG0	;	2.78	;	NifS from Helicobacter pylori, soaked with L-cysteine for 118 sec
6KG1	;	2.7	;	NifS from Helicobacter pylori, soaked with L-cysteine for 180 sec
5ZSP	;	2.57	;	NifS from Hydrogenimonas thermophila
5ZSQ	;	3.211	;	NifS from Hydrogenimonas thermophila, soaked with L-cysteine for 4 min
5ZSR	;	2.61	;	NifS from Hydrogenimonas thermophila, soaked with L-cysteine for 8 min
5ZST	;	3.1	;	NifS from Hydrogenimonas thermopile in a persulfurated form
7XEQ	;	2.9	;	NifS with D-cysteine
7XES	;	3.0	;	NifS with L-penicillamine
1ECX	;	2.7	;	NIFS-LIKE PROTEIN
1EG5	;	2.0	;	NIFS-LIKE PROTEIN
2NB2	;		;	Nigellin-1.1
4BEY	;	2.9	;	Night blindness causing G90D rhodopsin in complex with GaCT2 peptide
4BEZ	;	3.3	;	Night blindness causing G90D rhodopsin in the active conformation
7SZR	;	2.8	;	NIK bound to inhibitor G02792917
2OLN	;	1.15	;	NikD, an unusual amino acid oxidase essential for nikkomycin biosynthesis: closed form at 1.15 A resolution
2OLO	;	1.9	;	NikD, an unusual amino acid oxidase essential for nikkomycin biosynthesis: open form at 1.9A resolution
2CAD	;	2.3	;	NikR from Helicobacter pylori in closed trans-conformation and nickel bound to 2F, 2X and 2I sites.
2CAJ	;	2.35	;	NikR from Helicobacter pylori in closed trans-conformation and nickel bound to 4 intermediary sites
2BJ8	;	2.1	;	NIKR IN CLOSED CONFORMATION AND NICKEL BOUND TO HIGH and LOW-AFFINITY SITES
2BJ7	;	2.1	;	NIKR IN CLOSED CONFORMATION AND NICKEL BOUND TO HIGH-AFFINITY SITES
2BJ1	;	3.0	;	NIKR IN OPEN CONFORMATION AND NICKEL BOUND TO HIGH-AFFINITY SITES
2BJ9	;	3.0	;	NIKR with bound NICKEL and phosphate
2BJ3	;	2.2	;	NIKR-apo
2HZV	;	3.1	;	NikR-operator DNA complex
1W3P	;	1.8	;	NimA from D. radiodurans with a His71-Pyruvate residue
1W3Q	;	1.88	;	NimA from D. radiodurans with covalenly bound lactate
1W3R	;	1.9	;	NimA from D. radiodurans with Metronidazole and Pyruvate
19HC	;	1.8	;	NINE-HAEM CYTOCHROME C FROM DESULFOVIBRIO DESULFURICANS ATCC 27774
3RD2	;	1.6	;	NIP45 SUMO-like Domain 2
7TXZ	;	3.2	;	Nipah Virus attachment (G) glycoprotein ectodomain in complex with nAH1.3 neutralizing antibody Fab fragment (local refinement of the distal region)
7TY0	;	3.5	;	Nipah Virus attachment (G) glycoprotein ectodomain in complex with nAH1.3 neutralizing antibody Fab fragment (local refinement of the stalk region)
2VWD	;	2.25	;	Nipah Virus Attachment Glycoprotein
8XC4	;	3.24	;	Nipah virus attachment glycoprotein head domain in complex with a broadly neutralizing antibody 1E5
2VSM	;	1.8	;	Nipah virus attachment glycoprotein in complex with human cell surface receptor ephrinB2
7SKU	;	2.117	;	Nipah virus matrix protein in complex with PI(4,5)P2
6BW0	;	2.1	;	Nipah virus W protein C-terminus in complex with Importin alpha 1
6BVV	;	2.3	;	Nipah virus W protein C-terminus in complex with Importin alpha 3
3P0C	;	2.273	;	Nischarin PX-domain
2G02	;	2.5	;	Nisin cyclase
2G0D	;	2.21	;	Nisin cyclase
5K8A	;	1.999	;	NIST FAB
5JQN	;	1.19	;	NitN Amidase from Neterenkonia sp. AN1 after thrombin His-tag removal.
2PP9	;	1.8	;	Nitrate bound wild type oxidized AfNiR
4BJO	;	2.06	;	Nitrate in the active site of PTP1b is a putative mimetic of the transition state
2YBJ	;	2.0	;	Nitrate X-ray induced reduction on HEWL crystals (12.31 MGy)
2YBL	;	2.0	;	Nitrate X-ray induced reduction on HEWL crystals (17.9 MGy)
2YBH	;	2.0	;	Nitrate X-ray induced reduction on HEWL crystals (2.31 MGy).
2YBM	;	2.0	;	Nitrate X-ray induced reduction on HEWL crystals (23.3 MGy)
2YBN	;	2.0	;	Nitrate X-ray induced reduction on HEWL crystals (28.6 MGy)
2YBI	;	2.0	;	Nitrate X-ray induced reduction on HEWL crystals (6.62 MGy)
1S8J	;	2.3	;	Nitrate-bound D85S mutant of bacteriorhodopsin
2ADP	;	2.4	;	Nitrated Human Manganese Superoxide Dismutase
1SNR	;	1.31	;	Nitric oxide bound to Cu nitrite reductase
5JLI	;	1.55	;	Nitric oxide complex of the L16A mutant of cytochrome c prime from Alcaligenes xylosoxidans
5JS5	;	1.7	;	Nitric oxide complex of the L16F mutant of cytochrome c prime from Alcaligenes xylosoxidans
5JUA	;	1.13	;	Nitric oxide complex of the L16I mutant of cytochrome c prime from Alcaligenes xylosoxidans
5JRA	;	1.38	;	Nitric oxide complex of the L16V mutant of cytochrome c prime from Alcaligenes xylosoxidans
1MLU	;	1.9	;	NITRIC OXIDE RECOMBINATION TO DOUBLE MUTANTS OF MYOGLOBIN: THE ROLE OF LIGAND DIFFUSION IN A FLUCTUATING HEME POCKET
4XYD	;	2.85	;	Nitric oxide reductase from Roseobacter denitrificans (RdNOR)
6XK6	;	1.84	;	Nitric Oxide Synthase from Bacillus subtilis in complex with 7-((3-(((2-(pyridin-2-yl)ethyl)amino)methyl)phenoxy)methyl)quinolin-2-amine
6XK4	;	2.13	;	Nitric Oxide Synthase from Bacillus subtilis in complex with 7-((3-(((3-(6-aminopyridin-2-yl)propyl)amino)methyl)phenoxy)methyl)quinolin-2-amine
6XK5	;	1.87	;	Nitric Oxide Synthase from Bacillus subtilis in complex with 7-((3-(((4-(6-aminopyridin-2-yl)butyl)amino)methyl)phenoxy)methyl)quinolin-2-amine
6XK3	;	1.95	;	Nitric Oxide Synthase from Bacillus subtilis in complex with 7-((3-(((pyridin-2-ylmethyl)amino)methyl)phenoxy)methyl)quinolin-2-amine
6XK7	;	1.85	;	Nitric Oxide Synthase from Bacillus subtilis in complex with 7-((3-(2-(6-aminopyridin-2-yl)ethyl)phenoxy)methyl)quinolin-2-amine
6XMC	;	1.85	;	Nitric Oxide Synthase from Bacillus subtilis in complex with 7-((3-(2-(6-aminopyridin-2-yl)ethyl)phenoxy)methyl)quinolin-2-amine
6XCX	;	2.25203	;	Nitric Oxide Synthase from Bacillus subtilis in complex with N2-((3-((2-aminoquinolin-7-yl)methoxy)phenoxy)methyl)pyridine-2,6-diamine
3K2F	;	1.98	;	Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma
7ELF	;	2.2	;	Nitrilase-Like Protein Nit2 from Kluyve-romyces lactis
1AHJ	;	2.65	;	NITRILE HYDRATASE
2AHJ	;	1.7	;	NITRILE HYDRATASE COMPLEXED WITH NITRIC OXIDE
3V2V	;	1.65	;	Nitrite Bound Chlorin Substituted Myoglobin- Method 1
3V2Z	;	1.65	;	Nitrite Bound Chlorin Substituted Myoglobin- Method 2
1SJM	;	1.4	;	Nitrite bound copper containing nitrite reductase
4L3X	;	1.85	;	Nitrite complex of TvNiR, first middle dose data set
4L3Y	;	1.95	;	Nitrite complex of TvNiR, high dose data set (NO complex)
4L38	;	1.8	;	Nitrite complex of TvNiR, low dose data set
4L3Z	;	1.85	;	Nitrite complex of TvNiR, second middle dose data set
5F7A	;	1.54	;	Nitrite complex structure of copper nitrite reductase from Alcaligenes faecalis determined at 293 K
1NDT	;	2.1	;	NITRITE REDUCTASE FROM ALCALIGENES XYLOSOXIDANS
2VN3	;	2.35	;	Nitrite Reductase from Alcaligenes xylosoxidans
2VW7	;	1.9	;	Nitrite reductase from Alcaligenes xylosoxidans - 1 of 3
2VW4	;	1.9	;	NITRITE REDUCTASE FROM ALCALIGENES XYLOSOXIDANS - 2 OF 3
2VW6	;	1.9	;	NITRITE REDUCTASE FROM ALCALIGENES XYLOSOXIDANS - 3 OF 3
1BQ5	;	2.05	;	NITRITE REDUCTASE FROM ALCALIGENES XYLOSOXIDANS GIFU 1051
2DY2	;	2.26	;	Nitrite reductase pH 6.0
6GT0	;	1.5	;	Nitrite-bound copper nitrite reductase from Achromobacter cycloclastes determined by serial femtosecond rotation crystallography
6ZAT	;	1.0	;	Nitrite-bound copper nitrite reductase from Bradyrhizobium sp. ORS 375 (two-domain) at 1.0 A resolution (unrestrained full matrix refinement by SHELX)
6ZAX	;	1.48	;	Nitrite-bound copper nitrite reductase from Bradyrhizobium sp. ORS 375 (two-domain) at low dose (0.5 MGy)
7ZCN	;	1.19	;	Nitrite-bound MSOX movie series dataset 1 (0.8 MGy) of the copper nitrite reductase from Bradyrhizobium sp. ORS 375 (two-domain) - nitrite (start)
7ZCP	;	1.29	;	Nitrite-bound MSOX movie series dataset 17 (13.6 MGy) of the copper nitrite reductase from Bradyrhizobium sp. ORS 375 (two-domain) - nitric oxide (NO) intermediate
7ZCQ	;	1.35	;	Nitrite-bound MSOX movie series dataset 25 (20 MGy) of the copper nitrite reductase from Bradyrhizobium sp. ORS 375 (two-domain) - NO/water intermediate
7ZCR	;	1.45	;	Nitrite-bound MSOX movie series dataset 38 (30.4 MGy) of the copper nitrite reductase from Bradyrhizobium sp. ORS 375 (two-domain) - water ligand
7ZCS	;	1.61	;	Nitrite-bound MSOX movie series dataset 65 (52 MGy) of the copper nitrite reductase from Bradyrhizobium sp. ORS 375 (two-domain) - water ligand (final)
7ZCO	;	1.22	;	Nitrite-bound MSOX movie series dataset 8 (6.4 MGy) of the copper nitrite reductase from Bradyrhizobium sp. ORS 375 (two-domain) - nitrite/NO intermediate
3X1N	;	1.55	;	Nitrite-bound thermostable copper nitrite reductase at 320 K
1KBV	;	1.95	;	NITRITE-SOAKED CRYSTAL STRUCTURE OF THE SOLUBLE DOMAIN OF ANIA FROM NEISSERIA GONORRHOEAE
3D9E	;	2.2	;	Nitroalkane oxidase: active site mutant D402N crystallized with 1-nitrooctane
3D9F	;	2.2	;	Nitroalkane oxidase: active site mutant S276A crystallized with 1-nitrohexane
3D9D	;	2.1	;	Nitroalkane oxidase: mutant D402N crystallized with 1-nitrohexane
3FCJ	;	2.4	;	Nitroalkane oxidase: mutant402N crystallized with nitroethane
3D9G	;	2.15	;	Nitroalkane oxidase: wild type crystallized in a trapped state forming a cyanoadduct with FAD
2NSS	;	2.0	;	Nitrobenzene Modified Horse Heart Myoglobin
6HR9	;	1.99	;	Nitrocefin acylation of both catalytic serines of the Y409 mutant of penicillin-binding protein 3 from P. aeruginosa
6HR6	;	2.53	;	Nitrocefin reacted with catalytic serine (Ser294) of penicillin-binding protein 3 from Pseudomonas aeruginosa
1A6J	;	2.35	;	NITROGEN REGULATORY BACTERIAL PROTEIN IIA-NITROGEN
4USI	;	1.45	;	Nitrogen regulatory protein PII from Chlamydomonas reinhardtii in complex with MgATP and 2-oxoglutarate
4USH	;	1.6	;	Nitrogen regulatory protein PII from Chlamydomonas reinhardtii in unliganded state
5VQ4	;	2.3	;	Nitrogenase Av1 at pH 5
1M34	;	2.3	;	Nitrogenase Complex From Azotobacter Vinelandii Stabilized By ADP-Tetrafluoroaluminate
1N2C	;	3.0	;	NITROGENASE COMPLEX FROM AZOTOBACTER VINELANDII STABILIZED BY ADP-TETRAFLUOROALUMINATE
5VPW	;	1.85	;	Nitrogenase Cp1 at pH 5
5VQ3	;	1.72	;	Nitrogenase Cp1 at pH 6.5
1RW4	;	2.5	;	Nitrogenase Fe protein l127 deletion variant
1G5P	;	2.2	;	NITROGENASE IRON PROTEIN FROM AZOTOBACTER VINELANDII
2NIP	;	2.2	;	NITROGENASE IRON PROTEIN FROM AZOTOBACTER VINELANDII
1CP2	;	1.93	;	NITROGENASE IRON PROTEIN FROM CLOSTRIDIUM PASTEURIANUM
1QGU	;	1.6	;	NITROGENASE MO-FE PROTEIN FROM KLEBSIELLA PNEUMONIAE, DITHIONITE-REDUCED STATE
1H1L	;	1.9	;	NITROGENASE MO-FE PROTEIN FROM KLEBSIELLA PNEUMONIAE, NIFV MUTANT
8BTS	;	3.03	;	Nitrogenase MoFe protein from A. vinelandii alpha double mutant C45A/L158C
8P8G	;	1.55	;	Nitrogenase MoFe protein from A. vinelandii beta double mutant D353G/D357G
1M1N	;	1.16	;	Nitrogenase MoFe protein from Azotobacter vinelandii
2MIN	;	2.03	;	NITROGENASE MOFE PROTEIN FROM AZOTOBACTER VINELANDII, OXIDIZED STATE
3MIN	;	2.03	;	NITROGENASE MOFE PROTEIN FROM AZOTOBACTER VINELANDII, OXIDIZED STATE
1QH8	;	1.6	;	NITROGENASE MOFE PROTEIN FROM KLEBSIELLA PNEUMONIAE, AS-CRYSTALLIZED (MIXED OXIDATION) STATE
1QH1	;	1.6	;	NITROGENASE MOFE PROTEIN FROM KLEBSIELLA PNEUMONIAE, PHENOSAFRANIN OXIDIZED STATE
5KOH	;	1.83	;	Nitrogenase MoFeP from Gluconacetobacter diazotrophicus in dithionite reduced state
6O7P	;	1.7	;	Nitrogenase MoFeP mutant F99Y from Azotobacter vinelandii in the dithionite reduced state
6O7M	;	1.4	;	Nitrogenase MoFeP mutant F99Y from Azotobacter vinelandii in the indigo carmine oxidized state
6O7R	;	2.27	;	Nitrogenase MoFeP mutant F99Y, S188A from Azotobacter vinelandii in the dithionite reduced state
6O7O	;	1.89	;	Nitrogenase MoFeP mutant F99Y/S188A from Azotobacter vinelandii in the dithionite reduced state after redox cycling
6O7N	;	1.75	;	Nitrogenase MoFeP mutant F99Y/S188A from Azotobacter vinelandii in the indigo carmine oxidized state
6O7L	;	2.26	;	Nitrogenase MoFeP mutant S188A from Azotobacter vinelandii in the dithionite reduced state after redox cycling
6O7Q	;	2.0	;	Nitrogenase MoFeP mutant S188A from Azotobacter vinelandii in the dithionite reduced state after redox cycling
6O7S	;	2.27	;	Nitrogenase MoFeP mutant S188A from Azotobacter vinelandii in the indigo carmine oxidized state
5KOJ	;	2.592	;	Nitrogenase MoFeP protein in the IDS oxidized state
5CX1	;	1.7476	;	Nitrogenase molybdenum-iron protein beta-K400E mutant
4WES	;	1.08	;	Nitrogenase molybdenum-iron protein from Clostridium pasteurianum at 1.08 A resolution
2NSR	;	1.9	;	Nitromethane Modified Horse Heart Myoglobin
4NP1	;	2.3	;	NITROPHORIN 1 COMPLEX WITH NITRIC OXIDE
4BN7	;	1.723	;	Nitroreductase CinD from Lactococcus lactis in complex with 2,6- dichlorophenolindophenol
4BN8	;	1.895	;	Nitroreductase CinD from Lactococcus lactis in complex with 4- nitrophenol
4BNB	;	1.478	;	Nitroreductase CinD from Lactococcus lactis in complex with 4- nitroquinoline 1-oxide
4BN6	;	1.462	;	Nitroreductase CinD from Lactococcus lactis in complex with chloramphenicol
4BN9	;	2.084	;	Nitroreductase CinD from Lactococcus lactis in complex with nicotinic acid
1OO6	;	2.0	;	Nitroreductase from e-coli in complex with the dinitrobenzamide prodrug SN23862
1OON	;	2.49	;	Nitroreductase from e-coli in complex with the dinitrobenzamide prodrug SN27217
1OOQ	;	2.0	;	Nitroreductase from e-coli in complex with the inhibitor dicoumarol
1NEC	;	1.95	;	NITROREDUCTASE FROM ENTEROBACTER CLOACAE
3HU9	;	1.46	;	Nitrosobenzene in complex with T4 lysozyme L99A/M102Q
8GAR	;	1.55	;	Nitrosomonas europaea Cytochrome P460 Arg44Ala
3BHS	;	1.99	;	Nitrosomonas europaea Rh50 and mechanism of conduction by Rhesus protein family of channels
4N4N	;	2.2	;	Nitrosomonas europea HAO
4N4O	;	2.472	;	Nitrosomonas europea HAO soaked in NH2OH
4D4N	;	1.45	;	Nitrosyl complex of the D121A variant of cytochrome c prime from Alcaligenes xylosoxidans
4D4X	;	1.3	;	Nitrosyl complex of the D121I variant of cytochrome c prime from Alcaligenes xylosoxidans
5AGF	;	1.09	;	Nitrosyl complex of the D121Q variant of cytochrome c prime from Alcaligenes xylosoxidans
2FRK	;	1.3	;	Nitrosyl Horse Heart Myoglobin, Nitric Oxide Gas Method
2FRJ	;	1.3	;	Nitrosyl Horse Heart Myoglobin, Nitrite/Dithionite Method
2ZPB	;	1.3	;	nitrosylated Fe-type nitrile hydratase
2ZPE	;	1.48	;	nitrosylated Fe-type nitrile hydratase with tert-butylisonitrile
3RTW	;	2.095	;	Nitrowillardiine bound to the ligand binding domain of GluA2
4Q30	;	2.03	;	Nitrowillardiine bound to the ligand binding domain of GluA2 at pH 3.5
5BMG	;	2.2	;	Nitroxide Spin Labels in Protein GB1: E15 Mutant
3V3X	;	2.0	;	Nitroxide Spin Labels in Protein GB1: N8/K28 Double Mutant
5BMI	;	2.5	;	Nitroxide Spin Labels in Protein GB1: T44 Mutant, Crystal Form A
5BMH	;	1.6	;	Nitroxide Spin Labels in Protein GB1: T44 Mutant, Crystal Form B
1OAO	;	1.9	;	NiZn[Fe4S4] and NiNi[Fe4S4] clusters in closed and open alpha subunits of acetyl-CoA synthase/carbon monoxide dehydrogenase
2NAB	;		;	Nizp1-C2HR zinc finger structure
1NKL	;		;	NK-LYSIN FROM PIG, NMR, 20 STRUCTURES
1BHT	;	2.0	;	NK1 FRAGMENT OF HUMAN HEPATOCYTE GROWTH FACTOR
1NK1	;	2.5	;	NK1 FRAGMENT OF HUMAN HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR (HGF/SF) AT 2.5 ANGSTROM RESOLUTION
8SE5	;	1.43	;	NKG2D complexed with inhibitor 14
8EA5	;	1.63	;	NKG2D complexed with inhibitor 1a
8SE6	;	1.36	;	NKG2D complexed with inhibitor 36
8EA6	;	1.73	;	NKG2D complexed with inhibitor 3e
8EA7	;	1.28	;	NKG2D complexed with inhibitor 3g
8EA8	;	1.77	;	NKG2D complexed with inhibitor 4a
8EA9	;	1.58	;	NKG2D complexed with inhibitor 4d
8EAA	;	1.57	;	NKG2D complexed with inhibitor 4e
8EAB	;	1.44	;	NKG2D complexed with inhibitor 4f
1KCG	;	2.6	;	NKG2D in complex with ULBP3
5J2S	;	2.0	;	NKR-P1B from Rattus norvegicus
3RKQ	;	1.7	;	NKX2.5 Homeodomain dimer bound to ANF-242 DNA
6QM2	;	2.8	;	NlaIV restriction endonuclease
5XAD	;	1.88	;	NLIR - LC3B fusion protein
8EV4	;	1.3	;	NlpC B3 - Trichomonas Vaginalis
8EV5	;	1.65	;	NlpC B3 covalently bound with E64 inhibitor fragment
5NNW	;	1.54	;	NLPPya in complex with glucosamine
5NO9	;	1.75	;	NLPPya in complex with mannosamine
8WSM	;	2.7	;	NLRP3 NACHT domain in complex with compound 32
8ERT	;	3.3	;	NLRP3 PYD filament
7QVK	;	3.1	;	NM-02 in complex with HER2-ECD
2P0N	;	1.41	;	NMB1532 protein from Neisseria meningitidis, unknown function
1BUE	;	1.64	;	NMC-A CARBAPENEMASE FROM ENTEROBACTER CLOACAE
5T6R	;	4.2	;	Nmd3 is a structural mimic of eIF5A, and activates the cpGTPase Lsg1 during 60S ribosome biogenesis: 60S-Nmd3 Complex
5T62	;	3.3	;	Nmd3 is a structural mimic of eIF5A, and activates the cpGTPase Lsg1 during 60S ribosome biogenesis: 60S-Nmd3-Tif6-Lsg1 Complex
2M7R	;		;	Nmda receptor antagonist, conantokin bk-b, nmr, 20 structure
1ONU	;		;	NMDA RECEPTOR ANTAGONIST, CONANTOKIN-G, NMR, 17 STRUCTURES
1ONT	;		;	NMDA RECEPTOR ANTAGONIST, CONANTOKIN-T, NMR, 17 STRUCTURES
7ZLW	;	2.2	;	NME1 in complex with ADP
7ZTK	;	2.6	;	NME1 in complex with CoA
7ZL8	;	1.96	;	NME1 in complex with succinyl-CoA
7KPF	;	2.23	;	NME2 bound to myristoyl-CoA
6J9M	;	2.394	;	NmeBH+AcrIIC2
4UCG	;	2.0	;	NmeDAH7PS R126S variant
6J9N	;	2.606	;	NmeHNH+AcrIIC3
3ZQR	;	1.9	;	NMePheB25 insulin analogue crystal structure
7O8F	;	1.45	;	NmHR dark state structure determined by serial femtosecond crystallography
7O8L	;	1.8	;	NmHR dark state structure determined by serial millisecond crystallography
7O8I	;	1.8	;	NmHR light state structure at 1 us after photoexcitation determined by serial femtosecond crystallography (with extrapolated, dark and light dataset)
7O8H	;	1.8	;	NmHR light state structure at 10 ns after photoexcitation determined by serial femtosecond crystallography (with extrapolated, dark and light dataset)
7O8G	;	1.9	;	NmHR light state structure at 10 ps after photoexcitation determined by serial femtosecond crystallography (with extrapolated, dark and light dataset)
7O8O	;	2.2	;	NmHR light state structure at 12.5 ms (10 - 15 ms) after photoexcitation determined by serial millisecond crystallography
7O8P	;	2.4	;	NmHR light state structure at 17.5 ms (15 - 20 ms) after photoexcitation determined by serial millisecond crystallography
7O8M	;	2.2	;	NmHR light state structure at 2.5 ms (0 - 5 ms) after photoexcitation determined by serial millisecond crystallography
7O8J	;	1.8	;	NmHR light state structure at 20 us after photoexcitation determined by serial femtosecond crystallography (with extrapolated, dark and light dataset)
7O8Q	;	2.6	;	NmHR light state structure at 22.5 ms (20 - 25 ms) after photoexcitation determined by serial millisecond crystallography
7O8R	;	2.7	;	NmHR light state structure at 27.5 ms (25 - 30 ms) after photoexcitation determined by serial millisecond crystallography
7O8K	;	1.9	;	NmHR light state structure at 300 us after photoexcitation determined by serial femtosecond crystallography (with extrapolated, dark and light dataset)
7O8S	;	2.5	;	NmHR light state structure at 32.5 ms (30 - 35 ms) after photoexcitation determined by serial millisecond crystallography
7O8T	;	2.5	;	NmHR light state structure at 37.5 ms (35 - 40 ms) after photoexcitation determined by serial millisecond crystallography
7O8U	;	2.5	;	NmHR light state structure at 45 ms (40 - 50 ms) after photoexcitation determined by serial millisecond crystallography
7O8V	;	2.5	;	NmHR light state structure at 55 ms (50 - 60 ms) after photoexcitation determined by serial millisecond crystallography
7O8N	;	2.1	;	NmHR light state structure at 7.5 ms (5 - 10 ms) after photoexcitation determined by serial millisecond crystallography
5Z9R	;	2.0	;	NMNAT as a specific chaperone antagonizing pathological condensation of phosphorylated tau
1AB7	;		;	NMR 15N RELAXATION AND STRUCTURAL STUDIES REVEAL CONFORMATIONAL EXCHANGE IN BARSTAR C40/82A, 30 STRUCTURES
1QWP	;		;	NMR analysis of 25-35 fragment of beta amyloid peptide
1ELH	;		;	NMR ANALYSIS OF HELIX I FROM THE 5S RNA OF ESCHERICHIA COLI
2J5H	;		;	NMR analysis of mouse CRIPTO CFC domain
2M61	;		;	NMR and Mass Spectrometric Studies of M-2 Branch Mini-M Conotoxins from Indian Cone Snails
2KVJ	;		;	NMR and MD solution structure of a Gamma-Methylated PNA duplex
1EKA	;		;	NMR AND MOLECULAR MODELING REVEAL THAT DIFFERENT HYDROGEN BONDING PATTERNS ARE POSSIBLE FOR GU PAIRS: ONE HYDROGEN BOND FOR EACH GU PAIR IN R(GGCGUGCC)2 AND TWO FOR EACH GU PAIR IN R(GAGUGCUC)2
1EKD	;		;	NMR AND MOLECULAR MODELING REVEAL THAT DIFFERENT HYDROGEN BONDING PATTERNS ARE POSSIBLE FOR GU PAIRS: ONE HYDROGEN BOND FOR EACH GU PAIR IN R(GGCGUGCC)2 AND TWO FOR EACH GU PAIR IN R(GAGUGCUC)2
6AST	;		;	NMR and Restrained Molecular Dynamics Determination of the Structure of an Aza-Benzimidazole Derivative Complex with the DNA Minor Groove of an -AAGATA Sequence
6ASF	;		;	NMR and Restrained Molecular Dynamics Determination of the Structure of an Aza-Benzimidazole Derivative Complex with the DNA Minor Groove of an -AAGATA- Sequence
1TFS	;		;	NMR AND RESTRAINED MOLECULAR DYNAMICS STUDY OF THE THREE-DIMENSIONAL SOLUTION STRUCTURE OF TOXIN FS2, A SPECIFIC BLOCKER OF THE L-TYPE CALCIUM CHANNEL, ISOLATED FROM BLACK MAMBA VENOM
2PVE	;	0.79	;	NMR and X-ray Analysis of Structural Additivity in Metal Binding Site-Swapped Hybrids of Rubredoxin
2PVX	;	1.04	;	NMR and X-ray Analysis of Structural Additivity in Metal Binding Site-Swapped Hybrids of Rubredoxin
2N6T	;		;	NMR Assignment and NMR Structure of CssA3 (top stem) of CssA thermometer
5NVP	;		;	NMR assignment and structure of a peptide derived from the fusion peptide of HIV-1 gp41 in the presence of dodecylphosphocholine micelles
5NWV	;		;	NMR assignment and structure of a peptide derived from the fusion peptide of HIV-1 gp41 in the presence of dodecylphosphocholine micelles
5NWW	;		;	NMR assignment and structure of a peptide derived from the fusion peptide of HIV-1 gp41 in the presence of dodecylphosphocholine micelles
5NWU	;		;	NMR assignment and structure of a peptide derived from the fusion peptide of HIV-1 gp41 in the presence of hexafluoroisopropanol
2M8O	;		;	NMR assignment and structure of a peptide derived from the membrane proximal external region of HIV-1 gp41 in DPC
8B6X	;		;	NMR assignment and structure of a peptide derived from the membrane proximal external region of HIV-1 gp41 in DPC micelles
2MG3	;		;	NMR assignment and structure of a peptide derived from the membrane proximal external region of HIV-1 gp41 in the presence of dodecylphosphocholine micelles
2NCS	;		;	NMR assignment and structure of a peptide derived from the membrane proximal external region of HIV-1 gp41 in the presence of dodecylphosphocholine micelles
2M8M	;		;	NMR assignment and structure of a peptide derived from the membrane proximal external region of HIV-1 gp41 in the presence of hexafluoroisopropanol
2MG2	;		;	NMR assignment and structure of a peptide derived from the membrane proximal external region of HIV-1 gp41 in the presence of hexafluoroisopropanol
2NCT	;		;	NMR assignment and structure of a peptide derived from the membrane proximal external region of HIV-1 gp41 in the presence of hexafluoroisopropanol
8B6Y	;		;	NMR assignment and structure of a peptide derived from the membrane proximal external region of HIV-1 gp41 in the presence of hexafluoroisopropanol
2MG1	;		;	NMR assignment and structure of a peptide derived from the trans-membrane region of HIV-1 gp41 in the presence of hexafluoroisopropanol
2N6W	;		;	NMR Assignment and structure of CssA Thermometer from Neisseria meningitidis
2N6X	;		;	NMR Assignment and structure of CssA5 (middle region) of CssA thermometer from Neisseria meningitidis
5VO7	;		;	NMR Assignment and Structure of Thioredoxin (Rv1471 ortholog) from Mycobacterium smegmatis ATCC 700084 / mc(2)155
2M1S	;		;	NMR assignment of the arenaviral protein Z from Lassa fever virus
2N34	;		;	NMR assignments and solution structure of the JAK interaction region of SOCS5
8TT7	;		;	NMR Assignments and Structure for the Dimeric Kinesin Neck Domain
2N3S	;		;	NMR Assignments and structure of Translation initiation factor IF-1 from Burkholderia thailandensis E264.
2HYM	;		;	NMR based Docking Model of the Complex between the Human Type I Interferon Receptor and Human Interferon alpha-2
5GQS	;		;	NMR based solution structure of PTS system, galactitol-specific IIB component from methicillin resistant Staphylococcus aureus
1UR6	;		;	NMR based structural model of the UbcH5B-CNOT4 complex
2KJH	;		;	NMR based structural model of the UBCH8-UBIQUITIN complex
2PEA	;		;	NMR Based Structure of the Closed Conformation of LYS48-Linked Di-Ubiquitin Using Experimental Global Rotational Diffusion Tensor from NMR Relaxation Measurements
2PE9	;		;	NMR Based Structure of the Open Conformation of LYS48-Linked Di-UBiquitin Using Experimental Global Rotational Diffusion Tensor from NMR Relaxation Measurements
1JWW	;		;	NMR characterization of the N-terminal domain of a potential copper-translocating P-type ATPase from Bacillus subtilis
1YY1	;		;	NMR Conformational Analysis of LHRH and its analogues
1YY2	;		;	NMR Conformational Analysis of LHRH and its analogues
2JZF	;		;	NMR Conformer closest to the mean coordinates of the domain 513-651 of the SARS-CoV nonstructural protein nsp3
1RFL	;		;	NMR data driven structural model of G-domain of MnmE protein
2MSC	;		;	NMR data-driven model of GTPase KRas-GDP tethered to a lipid-bilayer nanodisc
6CCH	;		;	NMR data-driven model of GTPase KRas-GMPPNP tethered to a nanodisc (E3 state)
6CC9	;		;	NMR data-driven model of GTPase KRas-GMPPNP:Cmpd2 complex tethered to a nanodisc
6CCX	;		;	NMR data-driven model of GTPase KRas-GMPPNP:Cmpd2 complex tethered to a nanodisc
2MSD	;		;	NMR data-driven model of GTPase KRas-GNP tethered to a lipid-bilayer nanodisc
2MSE	;		;	NMR data-driven model of GTPase KRas-GNP:ARafRBD complex tethered to a lipid-bilayer nanodisc
6PTS	;		;	NMR data-driven model of KRas-GMPPNP:RBD-CRD complex tethered to a nanodisc (state A)
6PTW	;		;	NMR data-driven model of KRas-GMPPNP:RBD-CRD complex tethered to a nanodisc (state B)
5OR0	;		;	NMR derived model of the 5'-splice site of SMN2 in complex with the 5'-end of U1 snRNA
2JNX	;		;	NMR derived solution structure of an EF-hand Calcium Binding Protein from Entamoeba Histolytica
5J7J	;		;	NMR Derived Structure of Ca2+ Calmodulin bound to Phosphorylated PSD-95
7YVW	;		;	NMR determination of the 2:1 binding motif structure involving cytosine flipping out for the recognition of the CGG/CGG triad DNA
2LK6	;		;	NMR determination of the global structure of the Cd-113 derivative of desulforedoxin
2KNV	;		;	NMR dimer structure of the UBA domain of p62 (SQSTM1)
1BLK	;		;	NMR ENSEMBLE OF BLK SH2 DOMAIN USING CHEMICAL SHIFT REFINEMENT, 20 STRUCTURES
1BLJ	;		;	NMR ENSEMBLE OF BLK SH2 DOMAIN, 20 STRUCTURES
6O0I	;		;	NMR ensemble of computationally designed protein XAA
6O0C	;		;	NMR ensemble of computationally designed protein XAA_GVDQ mutant M4L
1W7E	;		;	NMR Ensemble OF Fasciclin-Like Protein From Rhodobacter sphaeroides
1I6Y	;		;	NMR ENSEMBLE OF ION-SELECTIVE LIGAND A1 FOR PLATELET INTEGRIN ALPHAIIB-BETA3
1I8E	;		;	NMR ENSEMBLE OF ION-SELECTIVE LIGAND A22 FOR PLATELET INTEGRIN ALPHAIIB-BETA3
1I93	;		;	NMR ENSEMBLE OF ION-SELECTIVE LIGAND D16 FOR PLATELET INTEGRIN ALPHAIIB-BETA3
1I98	;		;	NMR ENSEMBLE OF ION-SELECTIVE LIGAND D18 FOR PLATELET INTEGRIN ALPHAIIB-BETA3
6FCE	;		;	NMR ensemble of Macrocyclic Peptidomimetic Containing Constrained a,a-dialkylated Amino Acids with Potent and Selective Activity at Human Melanocortin Receptors
1EIJ	;		;	NMR ENSEMBLE OF METHANOBACTERIUM THERMOAUTOTROPHICUM PROTEIN 1615
2JUY	;		;	NMR ensemble of Neopetrosiamide A
3HCK	;		;	NMR ensemble of the uncomplexed human HCK SH2 domain, 20 structures
2FH0	;		;	NMR Ensemble of The Yeast Saccharomyces cerevisiae protein Ymr074cp core region
6B34	;		;	NMR ensemble of Tyrocidine A analogue AC3.27
6B35	;		;	NMR ensemble of Tyrocidine A analogue AC3.28
1ORM	;		;	NMR FOLD OF THE OUTER MEMBRANE PROTEIN OMPX IN DHPC MICELLES
8HCK	;	2.0	;	NMR fragment-based screening against the two PDZ do-mains of MDA-9
1L1K	;		;	NMR Identification and Characterization of the Flexible Regions in the 160 KD Molten Globule-like Aggregate of Barstar at Low pH
2MIS	;		;	NMR Localization of Divalent Cations at the Active Site of the Neurospora VS Ribozyme Provides Insights Into RNA-Metal Ion Interactions
1K2J	;		;	NMR MINIMIZED AVERAGE STRUCTURE OF d(CGTACG)2
1K2K	;		;	NMR MINIMIZED AVERAGE STRUCTURE OF d(CGTACG)2
1LCM	;		;	NMR minimized average structure of microcystin-LR
2KPV	;		;	NMR model of the first let-7 miRNA complementary site (LCS1) in 3'-UTR of lin-41 mRNA from C. elegans
1EVO	;		;	NMR OBSERVATION OF A NOVEL C-TETRAD
1EVM	;		;	NMR OBSERVATION OF A-TETRAD
1EVN	;		;	NMR OBSERVATION OF A-TETRAD
1EMQ	;		;	NMR OBSERVATION OF T-TETRADS IN A PARALLEL STRANDED DNA QUADRUPLEX FORMED BY SACCHAROMYCES CEREVISIAE TELOMERE REPEATS
1MKL	;		;	NMR REFINED STRUCTURE OF THE 8,9-DIHYDRO-8-(N7-GUANYL)-9-HYDROXY-AFLATOXIN B1 ADDUCT IN A 5'-CPAFBG-3' SEQUENCE
1E5U	;		;	NMR Representative Structure of Intimin-190 (Int190) from Enteropathogenic E. coli
2KOX	;		;	NMR residual dipolar couplings identify long range correlated motions in the backbone of the protein ubiquitin
2MXG	;		;	NMR resolved structure of VG16KRKP, an antimicrobial peptide in D8PG micelles
2MXH	;		;	NMR resolved structure of VG16KRKP, an antimicrobial peptide in SDS
2JSE	;		;	NMR reveals absence of hydrogen bonding in adjacent UU and AG mismatches in an isolated internal loop from ribosomal RNA.
1CHL	;		;	NMR SEQUENTIAL ASSIGNMENTS AND SOLUTION STRUCTURE OF CHLOROTOXIN, A SMALL SCORPION TOXIN THAT BLOCKS CHLORIDE CHANNELS
8DFZ	;		;	NMR shows why a small chemical change almost abolishes the antimicrobial activity of GccF
6WUX	;		;	NMR soltution structure of homotarsinin homodimer - Htr
6JCE	;		;	NMR solution and X-ray crystal structures of a DNA containing both right-and left-handed parallel-stranded G-quadruplexes
1QS3	;		;	NMR SOLUTION CONFORMATION OF AN ANTITOXIC ANALOG OF ALPHA-CONOTOXIN GI
2F4X	;		;	NMR Solution of HIV-1 Lai Kissing Complex
2FJ3	;		;	NMR solution of rabbit Prion Protein (91-228)
2KGB	;		;	NMR solution of the regulatory domain cardiac F77W-Troponin C in complex with the cardiac Troponin I 144-163 switch peptide
7O2K	;		;	NMR solution structue of cytotoxin 2 from Naja Kaouthia
1BZF	;		;	NMR SOLUTION STRUCTURE AND DYNAMICS OF THE COMPLEX OF LACTOBACILLUS CASEI DIHYDROFOLATE REDUCTASE WITH THE NEW LIPOPHILIC ANTIFOLATE DRUG TRIMETREXATE, 22 STRUCTURES
1PAJ	;		;	NMR SOLUTION STRUCTURE AND FLEXIBILITY OF A PEPTIDE ANTIGEN REPRESENTING THE RECEPTOR BINDING DOMAIN OF PSEUDOMONAS AERUGINOSA
1PAK	;		;	NMR SOLUTION STRUCTURE AND FLEXIBILITY OF A PEPTIDE ANTIGEN REPRESENTING THE RECEPTOR BINDING DOMAIN OF PSEUDOMONAS AERUGINOSA
2N0O	;		;	NMR Solution Structure and Model Membrane Interaction Studies of the Peptide Hylin a1 from the Arboreal South American Frog Hypsiboas albopunctatus
2M6T	;		;	NMR solution structure ensemble of 3-4D mutant domain 11 IGF2R
2M68	;		;	NMR solution structure ensemble of 3-4D mutant domain 11 IGF2R in complex with IGF2 (domain 11 structure only)
2LLA	;		;	NMR solution structure ensemble of domain 11 of the echidna M6P/IGF2R receptor
2N0I	;		;	NMR solution structure for di-sulfide 11mer peptide
7SXB	;		;	NMR Solution Structure for Domain 3 of Heligmosomoides polygyrus protein Transforming Growth Factor Beta Mimic 1 (TGM-1 D3)
2N0N	;		;	NMR solution structure for lactam (5,9) 11mer
2K9E	;		;	NMR Solution Structure for ShK-192: A Potent KV1.3-Specific Immunosuppressive Polypeptide
2NCO	;		;	NMR solution structure for the C-terminal domain of Tetrahymena Tcb2 in the absence of calcium
2NCP	;		;	NMR solution structure for the C-terminal domain of Tetrahymena Tcb2 in the presence of calcium
7A64	;		;	NMR solution structure for Tsp1a
2LWJ	;		;	NMR solution structure Myxoccoccus xanthus CdnL
2KOC	;		;	NMR solution structure of a 14-mer hairpin RNA with cUUCGg tetraloop
3BTB	;		;	NMR SOLUTION STRUCTURE OF A BAND 3 PEPTIDE INHIBITOR BOUND TO GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE, 20 STRUCTURES
1MVZ	;		;	NMR solution structure of a Bowman Birk inhibitor isolated from snail medic seeds (Medicago Scutellata)
6M6O	;		;	NMR SOLUTION STRUCTURE OF A C-FLIPs
2N39	;		;	NMR solution structure of a C-terminal domain of the chromodomain helicase DNA-binding protein 1
2LQC	;		;	NMR solution structure of a Ca2+-Calmodulin with a binding motif (NSCaTE) peptide from the N-terminal cytoplasmic domain of the L-type Voltage-Cated Calcium Channel alpha1C subunit
7WGW	;		;	NMR Solution Structure of a cGMP Fill-in Vacancy G-quadruplex Formed in the Oxidized BLM Gene Promoter
1FC8	;		;	NMR SOLUTION STRUCTURE OF A CHIMERIC OLIGONUCLEOTIDE HAIRPIN R(GGAC)D(TTCG)2'F-A(GTCC)
1CMR	;		;	NMR SOLUTION STRUCTURE OF A CHIMERIC PROTEIN, DESIGNED BY TRANSFERRING A FUNCTIONAL SNAKE BETA-HAIRPIN INTO A SCORPION ALPHA/BETA SCAFFOLD (PH 3.5, 20C), NMR, 18 STRUCTURES
2OFQ	;		;	NMR Solution Structure of a complex between the VirB9/VirB7 interaction domains of the pKM101 type IV secretion system
1CFF	;		;	NMR SOLUTION STRUCTURE OF A COMPLEX OF CALMODULIN WITH A BINDING PEPTIDE OF THE CA2+-PUMP
2N77	;		;	NMR solution structure of a complex of PEP-19 bound to the C-domain of apo calmodulin
2MN4	;		;	NMR solution structure of a computational designed protein based on structure template 1cy5
2MLB	;		;	NMR solution structure of a computational designed protein based on template of human erythrocytic ubiquitin
2LVS	;		;	NMR solution structure of a CRISPR repeat binding protein
7M7X	;		;	NMR Solution Structure of a CsrA-binding peptide
1FMH	;		;	NMR SOLUTION STRUCTURE OF A DESIGNED HETERODIMERIC LEUCINE ZIPPER
1U2U	;		;	Nmr solution structure of a designed heterodimeric leucine zipper
2KLB	;		;	NMR Solution structure of a diflavin flavoprotein A3 from Nostoc sp. PCC 7120, Northeast Structural Genomics Consortium Target NsR431C
1T9E	;		;	NMR solution structure of a disulfide analogue of the cyclic sunflower trypsin inhibitor SFTI-1
1A84	;		;	NMR SOLUTION STRUCTURE OF A DNA DODECAMER DUPLEX CONTAINING A CIS-DIAMMINEPLATINUM(II) D(GPG) INTRASTRAND CROSS-LINK, THE MAJOR ADDUCT OF THE ANTICANCER DRUG CISPLATIN, 1 STRUCTURE
1JU0	;		;	NMR solution structure of a DNA kissing complex
6M6K	;		;	NMR solution structure of a DNA minidumbbell containing an abasic bulge between two CCTG repeats
6M6J	;		;	NMR solution structure of a DNA minidumbbell containing an abasic bulge between two CTTG repeats
1H0Q	;		;	NMR solution structure of a fully modified locked nucleic acid (LNA) hybridized to RNA
2H5M	;		;	NMR Solution Structure of a GCN5-like putative N-acetyltransferase from Staphylococcus aureus complexed with acetyl-CoA. Northeast Structural Genomics Consortium Target ZR31
1R57	;		;	NMR Solution Structure of a GCN5-like putative N-acetyltransferase from Staphylococcus aureus. Northeast Structural Genomics Consortium Target ZR31
2JTN	;		;	NMR Solution Structure of a ldb1-LID:Lhx3-LIM complex
1ZA8	;		;	NMR solution structure of a leaf-specific-expressed cyclotide vhl-1
2JMM	;		;	NMR solution structure of a minimal transmembrane beta-barrel platform protein
2M3A	;		;	NMR solution structure of a MYB-like DNA binding domain of KNL-2 from C. Elegans
7S7P	;		;	NMR solution structure of a neurotoxic thionin from Urtica ferox
2HLG	;		;	NMR solution structure of a new tomato peptide
1S9L	;		;	NMR Solution Structure of a Parallel LNA Quadruplex
1Q2F	;		;	NMR SOLUTION STRUCTURE OF A PEPTIDE FROM THE MDM-2 BINDING DOMAIN OF THE P53 PROTEIN THAT IS SELECTIVELY CYTOTOXIC TO CANCER CELLS
1Q2I	;		;	NMR SOLUTION STRUCTURE OF A PEPTIDE FROM THE MDM-2 BINDING DOMAIN OF THE P53 PROTEIN THAT IS SELECTIVELY CYTOTOXIC TO CANCER CELLS
176D	;		;	NMR SOLUTION STRUCTURE OF A PEPTIDE NUCLEIC ACID COMPLEXED WITH RNA
6S10	;		;	NMR solution structure of a ProQ homolog from Legionella pneumophila
2BZB	;		;	NMR Solution Structure of a protein aspartic acid phosphate phosphatase from Bacillus Anthracis
2C0S	;		;	NMR Solution Structure of a protein aspartic acid phosphate phosphatase from Bacillus Anthracis
2KK8	;		;	NMR Solution Structure of a Putative Uncharacterized Protein obtained from Arabidopsis thaliana: Northeast Structural Genomics Consortium target AR3449A
2KV7	;		;	NMR solution structure of a soluble PrgI mutant from Salmonella Typhimurium
5JWJ	;		;	NMR solution structure of a thermophilic lysine methyl transferase from Sulfolobus islandicus
2K5P	;		;	NMR Solution Structure of a Thiamine Biosynthesis Protein from Geobacter Metallireducens: Northeast Structural Genomics Consortium Target GmR137
2L0K	;		;	NMR solution structure of a transcription factor SpoIIID in complex with DNA
6U7W	;		;	NMR solution structure of a triazole bridged KLK7 inhibitor
6VY8	;		;	NMR solution structure of a triazole bridged trypsin inhibitor based on the framework of SFTI-1
2KJ6	;		;	NMR Solution Structure of a Tubulin folding cofactor B obtained from Arabidopsis thaliana: Northeast Structural Genomics Consortium target AR3436A
5WOT	;		;	NMR solution structure of a-lytic protease using two 4D-spectra
2KL2	;		;	NMR solution structure of A2LD1 (gi:13879369)
2K53	;		;	NMR solution structure of A3DK08 protein from Clostridium thermocellum: Northeast Structural Genomics Consortium Target CmR9
6DRI	;		;	NMR solution structure of Acan1 from the Ancylostoma caninum hookworm
7KPD	;		;	NMR Solution Structure of Acyclotide ribe 31
2N00	;		;	NMR Solution structure of AIM2 PYD from Mus musculus
2KS6	;		;	NMR solution structure of ALG13 --- obtained with iterative CS-Rosetta from backbone NMR data.
2JZC	;		;	NMR solution structure of ALG13: The sugar donor subunit of a yeast N-acetylglucosamine transferase. Northeast Structural Genomics Consortium target YG1
2MD6	;		;	NMR SOLUTION STRUCTURE OF ALPHA CONOTOXIN LO1A FROM Conus longurionis
1QFD	;		;	NMR SOLUTION STRUCTURE OF ALPHA-AMYLASE INHIBITOR (AAI)
6XYI	;		;	NMR solution structure of alpha-AnmTX- Ms11a-3 (Ms11a-3)
6XYH	;		;	NMR solution structure of alpha-AnmTX-Ms11a-2 (Ms11a-2)
5UG3	;		;	NMR SOLUTION STRUCTURE OF ALPHA-CONOTOXIN GID MUTANT A10V
1E76	;		;	NMR SOLUTION STRUCTURE OF ALPHA-CONOTOXIN IM1 POINT MUTATION VARIANT D5N
1E74	;		;	NMR SOLUTION STRUCTURE OF ALPHA-CONOTOXIN IM1 POINT MUTATION VARIANT R11E
1E75	;		;	NMR SOLUTION STRUCTURE OF ALPHA-CONOTOXIN IM1 POINT MUTATION VARIANT R7L
1IM1	;		;	NMR SOLUTION STRUCTURE OF ALPHA-CONOTOXIN IM1, 20 STRUCTURES
1ABT	;		;	NMR SOLUTION STRUCTURE OF AN ALPHA-BUNGAROTOXIN(SLASH)NICOTINIC RECEPTOR PEPTIDE COMPLEX
5B7X	;		;	NMR Solution structure of an EF-hand Calcium binding protein (EhCaBP6) from Entamoeba Histolytica
1JFJ	;		;	NMR SOLUTION STRUCTURE OF AN EF-HAND CALCIUM BINDING PROTEIN FROM ENTAMOEBA HISTOLYTICA
1IE1	;		;	NMR Solution Structure of an In Vitro Selected RNA which is Sequence Specifically Recognized by Hamster Nucleolin RBD12.
2LZK	;		;	NMR solution structure of an N2-guanine DNA adduct derived from the potent tumorigen dibenzo[a,l]pyrene: Intercalation from the minor groove with ruptured Watson-Crick base pairing
1PG9	;		;	NMR Solution Structure of an Oxaliplatin 1,2-d(GG) Intrastrand Cross-Link in a DNA Dodecamer Duplex
1PGC	;		;	NMR Solution Structure of an Oxaliplatin 1,2-d(GG) Intrastrand Cross-Link in a DNA Dodecamer Duplex
2KCU	;		;	NMR solution structure of an uncharacterized protein from Chlorobium tepidum. Northeast Structural Genomics target CtR107
1CCV	;		;	NMR SOLUTION STRUCTURE OF APIS MELLIFERA CHYMOTRYPSIN INHIBITOR (AMCI).
1T50	;		;	NMR SOLUTION STRUCTURE OF APLYSIA ATTRACTIN
1KCY	;		;	NMR solution structure of apo calbindin D9k (F36G + P43M mutant)
1CMF	;		;	NMR SOLUTION STRUCTURE OF APO CALMODULIN CARBOXY-TERMINAL DOMAIN
2LUO	;		;	NMR solution structure of apo-MptpA
2KG5	;		;	NMR Solution structure of ARAP3-SAM
6X46	;		;	NMR solution structure of Asterix/Gtsf1 from mouse (CHHC zinc finger domains)
2N8O	;		;	NMR Solution Structure of Aureocin A53
1ZK6	;		;	NMR solution structure of B. subtilis PrsA PPIase
1FSP	;		;	NMR SOLUTION STRUCTURE OF BACILLUS SUBTILIS SPO0F PROTEIN, 20 STRUCTURES
2FSP	;		;	NMR SOLUTION STRUCTURE OF BACILLUS SUBTILIS SPO0F PROTEIN, MINIMIZED AVERAGE STRUCTURE
2JQO	;		;	NMR solution structure of Bacillus subtilis YobA 21-120: Northeast Structural Genomics Consortium target SR547
5LWC	;		;	NMR solution structure of bacteriocin BacSp222 from Staphylococcus pseudintermedius 222
6NZ2	;		;	NMR solution structure of Bcd1p120-303 from Saccharomyces cerevisiae
7PQW	;		;	NMR solution structure of BCR4
1PUX	;		;	NMR Solution Structure of BeF3-Activated Spo0F, 20 conformers
1MXJ	;		;	NMR solution structure of benz[a]anthracene-dG in ras codon 12,2; GGCAGXTGGTG
2JMH	;		;	NMR solution structure of Blo t 5, a major mite allergen from Blomia tropicalis
1WWN	;		;	NMR Solution Structure of BmK-betaIT, an Excitatory Scorpion Toxin from Buthus martensi Karsch
1GIO	;		;	NMR SOLUTION STRUCTURE OF BOVINE ANGIOGENIN, 10 STRUCTURES
2M2I	;		;	NMR solution structure of BRCT domain of yeast REV1
7EDK	;		;	NMR solution structure of Bt14.12, a novel A-family conotoxin from Conus betulinus
1C55	;		;	NMR SOLUTION STRUCTURE OF BUTANTOXIN
1C56	;		;	NMR SOLUTION STRUCTURE OF BUTANTOXIN
2LIZ	;		;	NMR solution structure of C-terminal domain of SARS-CoV main protease in 2.5M urea
8DJ4	;		;	NMR Solution Structure of C-terminally amidated, Full-length Human Galanin
1KJS	;		;	NMR SOLUTION STRUCTURE OF C5A AT PH 5.2, 303K, 20 STRUCTURES
2F33	;		;	NMR solution structure of Ca2+-loaded calbindin D28K
2G9B	;		;	NMR solution structure of CA2+-loaded calbindin D28K
1TNW	;		;	NMR SOLUTION STRUCTURE OF CALCIUM SATURATED SKELETAL MUSCLE TROPONIN C
1TNX	;		;	NMR SOLUTION STRUCTURE OF CALCIUM SATURATED SKELETAL MUSCLE TROPONIN C
1CMG	;		;	NMR SOLUTION STRUCTURE OF CALCIUM-LOADED CALMODULIN CARBOXY-TERMINAL DOMAIN
2FYJ	;		;	NMR Solution structure of calcium-loaded LRP double module
1NYA	;		;	NMR SOLUTION STRUCTURE OF CALERYTHRIN, AN EF-HAND CALCIUM-BINDING PROTEIN
1G6M	;		;	NMR SOLUTION STRUCTURE OF CBT2
1AK8	;		;	NMR SOLUTION STRUCTURE OF CERIUM-LOADED CALMODULIN AMINO-TERMINAL DOMAIN (CE2-TR1C), 23 STRUCTURES
5UKZ	;		;	NMR Solution structure of chemically synthesized antilisterial Pediocin PA-1 M31L analog.
1MVG	;		;	NMR solution structure of chicken Liver basic Fatty Acid Binding Protein (Lb-FABP)
7P27	;		;	NMR solution structure of Chikungunya virus macro domain
2MFK	;		;	NMR solution structure of chitin-binding domain from dust mite group XII allergen Blo t 12
2M6E	;		;	NMR solution structure of cis (minor) form of In936 in Methanol
2M6C	;		;	NMR solution structure of cis (minor) form of In936 in water
6XTH	;		;	NMR solution structure of class IV lasso peptide felipeptin A1 from Amycolatopsis sp. YIM10
6XTI	;		;	NMR solution structure of class IV lasso peptide felipeptin A2 from Amycolatopsis sp. YIM10
1DEY	;		;	NMR SOLUTION STRUCTURE OF CO(II)-BLEOMYCIN A2
1D2L	;		;	NMR SOLUTION STRUCTURE OF COMPLEMENT-LIKE REPEAT CR3 FROM THE LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN (LRP). EVIDENCE FOR SPECIFIC BINDING TO THE RECEPTOR BINDING DOMAIN OF HUMAN ALPHA-2 MACROGLOBULIN
2KC3	;		;	NMR solution structure of complete receptor binding domain of human apolipoprotein E
2MRY	;		;	NMR solution structure of copper binding protein in the apo form
1YVA	;		;	NMR solution structure of crambin in DPC micelles
2GVS	;		;	NMR solution structure of CSPsg4
7S55	;		;	NMR Solution Structure of Cter 27
2KON	;		;	NMR solution structure of CV_2116 from Chromobacterium violaceum. Northeast Structural Genomics Consortium Target CvT4(1-82)
6PIN	;		;	NMR Solution structure of cyclic tachyplesin I
6PIO	;		;	NMR Solution structure of cyclic tachyplesin II
6PIP	;		;	NMR Solution structure of cyclic tachyplesin III
1KKV	;		;	NMR Solution Structure of d(CCACGCGTGG)2, parent to G-T mismatch structure
1KKW	;		;	NMR Solution Structure of d(CCATGCGTGG)2, G-T mismatch structure
1G7Z	;		;	NMR SOLUTION STRUCTURE OF D(CGCTAGCG)2
1G80	;		;	NMR SOLUTION STRUCTURE OF D(GCGTACGC)2
6B9W	;		;	NMR solution structure of Defensin1 from Centruroides limpidus limpidus
6BAM	;		;	NMR solution structure of Defensin1 from Centruroides limpidus limpidus
6BB6	;		;	NMR solution structure of Defensin1 from Centruroides limpidus limpidus
6BI5	;		;	NMR solution structure of Defensin1 from Centruroides limpidus limpidus
1HS5	;		;	NMR SOLUTION STRUCTURE OF DESIGNED P53 DIMER
5KX2	;		;	NMR Solution Structure of Designed Peptide NC_cEE_D1
5KX1	;		;	NMR Solution Structure of Designed Peptide NC_cHHH_D1
5KWZ	;		;	NMR Solution Structure of Designed Peptide NC_cHH_D1
5KX0	;		;	NMR Solution Structure of Designed Peptide NC_cHh_DL_D1
5KWX	;		;	NMR Solution Structure of Designed Peptide NC_EEH_D1
5KWP	;		;	NMR Solution Structure of Designed Peptide NC_EEH_D2
5KWO	;		;	NMR Solution Structure of Designed Peptide NC_EHE_D1
5KVN	;		;	NMR Solution Structure of Designed Peptide NC_HEE_D1
1BO9	;		;	NMR SOLUTION STRUCTURE OF DOMAIN 1 OF HUMAN ANNEXIN I
2M57	;		;	NMR solution structure of domain 5 from Azotobacter vinelandii Intron 5 at pH 7.8
1Z66	;		;	NMR solution structure of domain III of E-protein of tick-borne Langat flavivirus (no RDC restraints)
2GG1	;		;	NMR solution structure of domain III of the E-protein of tick-borne Langat flavivirus (includes RDC restraints)
1Q27	;		;	NMR Solution Structure of DR0079: An hypothetical Nudix protein from D. radiodurans
2KDC	;		;	NMR Solution Structure of E. coli diacylglycerol kinase (DAGK) in DPC micelles
5TCZ	;		;	NMR solution structure of engineered Protoxin-II analog
5WOY	;		;	NMR solution structure of Enzyme I (nEIt) protein using two 4D-spectra
2LW8	;		;	NMR solution structure of Eph receptor
2NAV	;		;	NMR solution structure of Ex-4[1-16]/pl14a
6VH8	;		;	NMR Solution Structure of Excelsatoxin A
2NAW	;		;	NMR solution structure of Exendin-4/conotoxin chimera (Ex-4[1-27]/pl14a)
2WCY	;		;	NMR solution structure of factor I-like modules of complement C7.
2L6F	;		;	NMR Solution structure of FAT domain of FAK complexed with LD2 and LD4 motifs of PAXILLIN
6MJD	;		;	NMR Solution structure of GIIIC
2L71	;		;	NMR solution structure of GIP in Bicellular media
2L70	;		;	NMR solution structure of GIP in micellular media
2L63	;		;	NMR solution structure of GLP-2 in 2,2,2 trifluroethanol
2L64	;		;	NMR Solution structure of GLP-2 in DHPC micelles
1KX6	;		;	NMR solution structure of Glucagon in a lipid-water interphase
6VK2	;		;	NMR solution structure of Grb2-SH2 domain at pH 7
1GHU	;		;	NMR solution structure of growth factor receptor-bound protein 2 (GRB2) SH2 domain, 24 structures
5M9Y	;		;	NMR solution structure of Harzianin HK-VI in DPC micelles
5MF3	;		;	NMR solution structure of Harzianin HK-VI in SDS micelles
5MF8	;		;	NMR solution structure of Harzianin HK-VI in trifluoroethanol
6SLY	;		;	NMR solution structure of Helicobacter pylori TonB-CTD (residues 179-285)
5LW8	;		;	NMR solution structure of Helicobacter pylori TonB-CTD (residues 194-285)
1E8L	;		;	NMR solution structure of hen lysozyme
7S3Q	;		;	NMR Solution Structure of hGal(1-12)KK, a solubility-tagged truncation of the human neuropeptide galanin
7S3R	;		;	NMR Solution Structure of hGal(1-12)KK, a solubility-tagged truncation of the human neuropeptide galanin
7S3O	;		;	NMR Solution Structure of hGal(2-12)KK, a solubility-tagged truncation of the human neuropeptide galanin
2JV7	;		;	NMR Solution Structure of Histoplasma capsulatum CBP Homodimer
2M3Z	;		;	NMR solution structure of HIV-1 nucleocapsid protein in complex with an inhibitor displaying a 2 inhibitors:1 NC stoichiometry
6SAI	;		;	NMR solution structure of Hml-2 C-terminal dimer domain
2JUW	;		;	NMR solution structure of homodimer protein SO_2176 from Shewanella oneidensis. Northeast Structural Genomics Consortium target SoR77
2N2Q	;		;	NMR solution structure of HsAFP1
1BLR	;		;	NMR SOLUTION STRUCTURE OF HUMAN CELLULAR RETINOIC ACID BINDING PROTEIN-TYPE II, 22 STRUCTURES
2I85	;		;	NMR solution structure of Human ephrinB2 ectodomain
5LKN	;		;	NMR solution structure of human FNIII domain 2 of NCAM
2LW7	;		;	NMR solution structure of human HisRS splice variant
2JYO	;		;	NMR Solution structure of Human MIP-3alpha/CCL20
1RON	;		;	NMR SOLUTION STRUCTURE OF HUMAN NEUROPEPTIDE Y
2GO0	;		;	NMR solution structure of human pancreatitis-associated protein
2HKY	;		;	NMR solution structure of human RNase 7
1M12	;		;	NMR solution structure of human Saposin C
1SN6	;		;	NMR solution structure of human Saposin C in SDS micelles
2KLC	;		;	NMR solution structure of human ubiquitin-like domain of ubiquilin 1, Northeast Structural Genomics Consortium (NESG) target HT5A
2LAV	;		;	NMR solution structure of human Vaccinia-Related Kinase 1
2JOI	;		;	NMR solution structure of hypothetical protein TA0095 from Thermoplasma acidophilum
5WOX	;		;	NMR solution structure of KanY protein (ms6282) using two 4D-spectra
2LUR	;		;	NMR solution structure of Kb1[ghrw;23-28]
2JXU	;		;	NMR solution structure of KP-TerB, a tellurite resistance protein from Klebsiella pneumoniae
2JZP	;		;	NMR solution structure of Kx5Q ProtL mutant
2KAC	;		;	NMR solution structure of KX6E protL mutant
8F2F	;		;	NMR solution structure of lambda-MeuKTx-1
2KPW	;		;	NMR solution structure of Lamin-B1 protein from Homo sapiens: Northeast Structural Genomics Consortium MEGA target, HR5546A (439-549)
6MI5	;		;	NMR solution structure of lanmodulin (LanM) complexed with yttrium(III) ions
6WQR	;		;	NMR solution structure of leech peptide HSTX-I
2MWH	;		;	NMR solution structure of ligand-free OAA
7RFA	;		;	NMR Solution structure of linear [T20K]kalataB1
6QKP	;		;	NMR solution structure of LSR2 binding domain.
6QKQ	;		;	NMR solution structure of LSR2-T112D binding domain.
6O3S	;		;	NMR solution structure of Luffin P1
8FLP	;		;	NMR Solution Structure of LvIC analogue
5NMY	;		;	NMR solution structure of lysostaphin
2K1X	;		;	NMR solution structure of M-crystallin in calcium free form (apo).
2K1W	;		;	NMR solution structure of M-crystallin in calcium loaded form(holo).
5ISN	;		;	NMR solution structure of macro domain from Venezuelan equine encephalitis virus
5MQX	;		;	NMR solution structure of macro domain from Venezuelan equine encephalitis virus(VEEV) in complex with ADP-ribose
2NDH	;		;	NMR solution structure of MAL/TIRAP TIR domain (C116A)
5IQ5	;		;	NMR solution structure of Mayaro virus macro domain
2L9F	;		;	NMR solution structure of meACP
2K5Q	;		;	NMR Solution structure of membrane associated protein from Bacillus cereus: Northeast Structural Genomics Consortium Target: BcR97A
2KGL	;		;	NMR solution structure of MESD
2RQK	;		;	NMR Solution Structure of Mesoderm Development (MESD) - closed conformation
2RQM	;		;	NMR Solution Structure of Mesoderm Development (MESD) - open conformation
2KE8	;		;	NMR solution structure of metal-modified DNA
2LU6	;		;	NMR solution structure of Midi peptide designed based on m-conotoxins
2LUT	;		;	NMR solution structure of midkine-a
2LUU	;		;	NMR solution structure of midkine-b, mdkb
6FBL	;		;	NMR Solution Structure of MINA-1(254-334)
2K67	;		;	NMR solution structure of modified DNA containing imidazole nucleosides at acidic pH
2K69	;		;	NMR solution structure of modified DNA containing imidazole nucleosides at basic pH
2K68	;		;	NMR solution structure of modified DNA containing imidazole nucleosides at neutral pH
6FGP	;		;	NMR solution structure of monomeric CCL5 in complex with a doubly-sulfated N-terminal segment of CCR5
1LBJ	;		;	NMR solution structure of motilin in phospholipid bicellar solution
2NPB	;		;	NMR solution structure of mouse SelW
2MDK	;		;	NMR Solution Structure of MSP-P56S Domain/VAPB in DPC
2LXG	;		;	NMR solution structure of Mu-conotoxin KIIIA
2LO9	;		;	NMR solution structure of Mu-contoxin BuIIIB
2N7F	;		;	NMR solution structure of muO-conotoxin MfVIA
1HA6	;		;	NMR Solution Structure of Murine CCL20/MIP-3a Chemokine
6EHZ	;		;	NMR solution structure of murine CXCL12 gamma isoform
7QAB	;		;	NMR Solution Structure of mussel adhesive protein Pvfp-5b
2LW9	;		;	NMR solution structure of Myo10 anti-CC
2M7K	;		;	NMR solution structure of N-terminal domain of (Y81F)-EhCaBP1
2JOJ	;		;	NMR solution structure of N-terminal domain of Euplotes octocarinatus centrin
7L2G	;		;	NMR solution structure of Nak1 from the Necator americanus hookworm
2PQ4	;		;	NMR solution structure of NapD in complex with NapA1-35 signal peptide
6PI2	;		;	NMR Solution structure of native tachyplesin II peptide
6PI3	;		;	NMR Solution structure of native tachyplesin III peptide
2LFK	;		;	NMR solution structure of native TdPI-short
1MPZ	;		;	NMR solution structure of native Viperidae lebetina obtusa protein
6VXW	;		;	NMR solution structure of natural scorpion toxin Cl13
7L83	;		;	NMR solution structure of Nav1.5 DIV S3b-S4a paddle motif in DPC micelle
1ZEC	;		;	NMR Solution structure of NEF1-25, 20 structures
1L0R	;		;	NMR Solution Structure of Nogalamycin Intercalation Between Co-Axially Stacked Hairpins
6F27	;		;	NMR solution structure of non-bound [des-Arg10]-kallidin (DAKD)
1JE9	;		;	NMR SOLUTION STRUCTURE OF NT2
2N1B	;		;	NMR solution structure of nucleotide-free Ran GTPase
2KD0	;		;	NMR solution structure of O64736 protein from Arabidopsis thaliana. Northeast Structural Genomics Consortium MEGA Target AR3445A
1TTK	;		;	NMR solution structure of omega-conotoxin MVIIA, a N-type calcium channel blocker
1TR6	;		;	NMR solution structure of omega-conotoxin [K10]GVIA, a cyclic cysteine knot peptide
2PXG	;		;	NMR Solution Structure of OmlA
2MLH	;		;	NMR Solution Structure of Opa60 from N. Gonorrhoeae in FC-12 Micelles
2LO4	;		;	NMR Solution Structure of Optineurin Zinc-finger Domain
1G90	;		;	NMR Solution Structure of Outer Membrane Protein A Transmembrane Domain: 10 conformers
1K3G	;		;	NMR Solution Structure of Oxidized Cytochrome c-553 from Bacillus pasteurii
1K3H	;		;	NMR Solution Structure of Oxidized Cytochrome c-553 from Bacillus pasteurii
2MBS	;		;	NMR solution structure of oxidized KpDsbA
2MGO	;		;	NMR solution structure of oxytocin
2LV5	;		;	NMR solution structure of PA1075 from Pseudomonas Aeruginosa
4CSQ	;		;	NMR solution structure of PA3793 from Pseudomonas aeruginosa
2JUF	;		;	NMR solution structure of PARC CPH Domain. NESG Target HR3443B/SGC-Toronto
2NB6	;		;	NMR solution structure of PawS Derived Peptide 10 (PDP-10)
2LWQ	;		;	NMR solution structure of PawS derived peptide 11 (PDP-11)
2NDN	;		;	NMR solution structure of PawS Derived Peptide 20 (PDP-20)
2NDM	;		;	NMR solution structure of PawS Derived Peptide 21 (PDP-21)
2NDL	;		;	NMR solution structure of PawS Derived Peptide 22 (PDP-22)
2LWS	;		;	NMR solution structure of PawS Derived Peptide 4 (PDP-4)
2LWT	;		;	NMR solution structure of PawS Derived Peptide 5 (PDP-5)
2LWV	;		;	NMR solution structure of PawS Derived Peptide 6 (PDP-6)
2LWU	;		;	NMR solution structure of PawS Derived Peptide 7 (PDP-7)
2NB5	;		;	NMR solution structure of PawS Derived Peptide 9 (PDP-9)
7OSD	;		;	NMR Solution Structure of Peptide 12: First-in-class cyclic Temporin L analogue with antibacterial and antibiofilm activities
2LX4	;		;	NMR solution structure of peptide a2N(1-17) from Mus musculus V-ATPase
2LX5	;		;	NMR solution structure of peptide epsilon(103-120) from Mycobacterium tuberculosis F-ATPsynthase
2JVA	;		;	NMR solution structure of peptidyl-tRNA hydrolase domain protein from Pseudomonas syringae pv. tomato. Northeast Structural Genomics Consortium target PsR211
2FUI	;		;	NMR solution structure of PHD finger fragment of human BPTF in free state
2JMI	;		;	NMR solution structure of PHD finger fragment of Yeast Yng1 protein in free state
1QFR	;		;	NMR SOLUTION STRUCTURE OF PHOSPHOCARRIER PROTEIN HPR FROM ENTEROCOCCUS FAECALIS
1FJK	;		;	NMR Solution Structure of Phospholamban (C41F)
1FJP	;		;	NMR Solution Structure of Phospholamban (C41F)
2BYE	;		;	NMR solution structure of phospholipase c epsilon RA 1 domain
2BYF	;		;	NMR solution structure of phospholipase c epsilon RA 2 domain
1R9I	;		;	NMR Solution Structure of PIIIA toxin, NMR, 20 structures
2M9E	;		;	NMR solution structure of Pin1 WW domain mutant 5-1
2M9F	;		;	NMR solution structure of Pin1 WW domain mutant 5-1g
2M9J	;		;	NMR solution structure of Pin1 WW domain mutant 6-1g
2KBU	;		;	NMR solution structure of Pin1 WW domain mutant with beta turn mimic at position 12
2M9I	;		;	NMR solution structure of Pin1 WW domain variant 6-1
2K19	;		;	NMR solution structure of PisI
1JKZ	;		;	NMR Solution Structure of Pisum sativum defensin 1 (Psd1)
6NOM	;		;	NMR solution structure of Pisum sativum defensin 2 (Psd2) provides evidence for the presence of hydrophobic surface clusters
7JN6	;		;	NMR Solution Structure of plant defensin AtD90
7JNN	;		;	NMR Solution Structure of plant defensin SlD26
2B3I	;		;	NMR SOLUTION STRUCTURE OF PLASTOCYANIN FROM THE PHOTOSYNTHETIC PROKARYOTE, PROCHLOROTHRIX HOLLANDICA (19 STRUCTURES)
1B3I	;		;	NMR SOLUTION STRUCTURE OF PLASTOCYANIN FROM THE PHOTOSYNTHETIC PROKARYOTE, PROCHLOROTHRIX HOLLANDICA (MINIMIZED AVERAGE STRUCTURE)
1Z64	;		;	NMR Solution Structure of Pleurocidin in DPC Micelles
1QBF	;		;	NMR SOLUTION STRUCTURE OF PORCINE PEPTIDE YY
2JYA	;		;	NMR solution structure of protein ATU1810 from Agrobacterium tumefaciens. Northeast Structural Genomics Consortium target AtR23, Ontario Centre for Structural Proteomics Target ATC1776
2FB7	;		;	NMR Solution Structure of protein from Zebra Fish Dr.13312
2JZ5	;		;	NMR solution structure of protein VPA0419 from Vibrio parahaemolyticus. Northeast Structural Genomics target VpR68
6N68	;		;	NMR solution structure of Protonectin (Agelaia pallipes pallipes) interacting with SDS micelles: an antimicrobial peptide with anticancer activity on breast cancer cells
2N9T	;		;	NMR solution structure of ProTx-II
7LNS	;		;	NMR solution structure of PsDef2 defensin from P. sylvestris
2KVS	;		;	NMR Solution Structure of Q7A1E8 protein from Staphylococcus aureus: Northeast Structural Genomics Consortium target: ZR215
1XYD	;		;	NMR Solution Structure of Rat Zinc-Calcium-S100B, 20 Structures
2LU9	;		;	NMR solution structure of recombinant Tamapin
1TAP	;		;	NMR SOLUTION STRUCTURE OF RECOMBINANT TICK ANTICOAGULANT PROTEIN (RTAP), A FACTOR XA INHIBITOR FROM THE TICK ORNITHODOROS MOUBATA
1G7O	;		;	NMR SOLUTION STRUCTURE OF REDUCED E. COLI GLUTAREDOXIN 2
6LXG	;		;	NMR solution structure of regulatory ACT domain of the Mycobacterium tuberculosis Rel protein
6DHR	;		;	NMR Solution structure of Rivi3
6KLM	;		;	NMR solution structure of Roseltide rT7
2N2R	;		;	NMR solution structure of RsAFP2
5WOZ	;		;	NMR solution structure of Rtt103 (RTT) protein using two 4D-spectra
2N8Q	;		;	NMR solution structure of S114A mutant of a UV inducible protein from Chlamydomonas reinhardtii
2MSF	;		;	NMR SOLUTION STRUCTURE OF SCORPION VENOM TOXIN Ts11 (TsPep1) FROM Tityus serrulatus
7N82	;		;	NMR Solution structure of Se0862
6U7S	;		;	NMR solution structure of SFTI-1 based plasmin inhibitor
6U7Q	;		;	NMR solution structure of SFTI-R10
6U7R	;		;	NMR solution structure of SFTI1 based KLK7 protease inhibitor
2KNO	;		;	NMR Solution Structure of SH2 Domain of the Human Tensin Like C1 Domain Containing Phosphatase (TENC1)
1ROO	;		;	NMR SOLUTION STRUCTURE OF SHK TOXIN, NMR, 20 STRUCTURES
5XQM	;		;	NMR solution structure of SMO1, Sumo homologue in Caenorhabditis elegans
7OJ9	;		;	NMR solution structure of SNX9 SH3 - EEEV nsP3 peptide complex
2K7H	;		;	NMR solution structure of soybean allergen Gly m 4
2CVR	;		;	NMR solution structure of sso7d mutant, K12L, 12 conformers
6SOW	;		;	NMR solution structure of staphylococcal protein A, C domain
2K3A	;		;	NMR solution structure of Staphylococcus saprophyticus CHAP (cysteine, histidine-dependent amidohydrolases/peptidases) domain protein. Northeast Structural Genomics Consortium target SyR11
2LRJ	;		;	NMR solution structure of staphyloxanthin biosynthesis protein
1K7B	;		;	NMR Solution Structure of sTva47, the Viral-Binding Domain of Tva
1S3A	;		;	NMR Solution Structure of Subunit B8 from Human NADH-Ubiquinone Oxidoreductase Complex I (CI-B8)
8HGX	;		;	NMR solution structure of subunit epsilon of the Acinetobacter baumannii F-ATP synthase
5YIO	;		;	NMR solution structure of subunit epsilon of the Mycobacterium tuberculosis F-ATP synthase
7P2O	;		;	NMR solution structure of SUD-C domain of SARS-CoV-2
6D3T	;		;	NMR solution structure of tamapin, mutant DP30
6D8Q	;		;	NMR solution structure of tamapin, mutant DP30/Y31+N
6D9O	;		;	NMR solution structure of tamapin, mutant E25A
6D8R	;		;	NMR solution structure of tamapin, mutant E25K
6D8T	;		;	NMR solution structure of tamapin, mutant E25K/K27E
6VNZ	;		;	NMR solution structure of tamapin, mutant K20A
6D8U	;		;	NMR solution structure of tamapin, mutant K20E
6D9P	;		;	NMR solution structure of tamapin, mutant K27A
6D8S	;		;	NMR solution structure of tamapin, mutant K27E
6D8H	;		;	NMR solution structure of tamapin, mutant Y31+N
6D93	;		;	NMR solution structure of tamapin, mutant Y31A
6D8Y	;		;	NMR solution structure of tamapin, mutant Y31H
7AY8	;		;	NMR solution structure of Tbo-IT2
1U6F	;		;	NMR solution structure of TcUBP1, a single RBD-unit from Trypanosoma cruzi
2GJY	;		;	NMR Solution Structure of Tensin1 PTB Domain
8IJC	;		;	NMR solution structure of the 1:1 complex of a platinum(II) ligand L1-transpt covalently bound to a G-quadruplex MYT1L
7X3A	;		;	NMR solution structure of the 1:1 complex of a pyridostatin (PDS) bound to a G-quadruplex MYT1L
7X2Z	;		;	NMR solution structure of the 1:1 complex of a pyridostatin derivative (PyPDS) bound to a G-quadruplex MYT1L
7EL7	;		;	NMR solution structure of the 1:1 complex of a quadruplex-duplex hybrid MYT1L and a platinum(II) ligand L1Pt(dien)
6KFI	;		;	NMR solution structure of the 1:1 complex of Tel26 G-quadruplex and a tripodal cationic fluorescent probe NBTE
6KFJ	;		;	NMR solution structure of the 1:1 complex of wtTel26 G-quadruplex and a tripodal cationic fluorescent probe NBTE
7X8M	;		;	NMR Solution Structure of the 2:1 Berberine-KRAS-G4 Complex
7X8O	;		;	NMR Solution Structure of the 2:1 Coptisine-KRAS-G4 Complex
2KVY	;		;	NMR solution structure of the 4:1 complex between an uncharged distamycin A analogue and [d(TGGGGT)]4
2JT7	;		;	NMR solution structure of the 4:1 distamycin A/[d(TGGGGT)]4 complex
1D6K	;		;	NMR SOLUTION STRUCTURE OF THE 5S RRNA E-LOOP/L25 COMPLEX
1O6X	;		;	NMR solution structure of the activation domain of human procarboxypeptidase A2
2GV1	;		;	NMR solution structure of the Acylphosphatase from Eschaerichia Coli
5UG5	;		;	NMR SOLUTION STRUCTURE OF THE ALPHA-CONOTOXIN GID MUTANT V13Y
1N37	;		;	NMR Solution Structure of the Anthracycline Respinomycin D Intercalation Complex with a Double Stranded DNA Molecule (AGACGTCT)2
2JRQ	;		;	NMR solution structure of the anticodon of E. coli TRNA-VAL3 with 1 modification (cmo5U34)
2JRG	;		;	NMR solution structure of the anticodon of E. coli TRNA-VAL3 with 2 modifications (cmo5U34 M6A37)
2JSG	;		;	NMR solution structure of the anticodon of E.coli TRNA-VAL3 with 1 modification (M6A37)
2JR4	;		;	NMR Solution Structure of the Anticodon of E.coli TRNA-VAL3 With no Modifications
1FEQ	;		;	NMR SOLUTION STRUCTURE OF THE ANTICODON OF TRNA(LYS3) WITH T6A MODIFICATION AT POSITION 37
1LUX	;		;	NMR SOLUTION STRUCTURE OF THE ANTICODON OF YEAST TRNA-PHE WITH 3 MODIFICATIONS (OMC32 OMG34 M5C40)
1LUU	;		;	NMR SOLUTION STRUCTURE OF THE ANTICODON OF YEAST TRNA-PHE WITH 4 MODIFICATIONS (OMC32 OMG34 1MG37 5MC40)
5LW4	;		;	NMR solution structure of the apo-form of the chitin-active lytic polysaccharide monooxygenase BlLPMO10A
1T23	;		;	NMR Solution Structure of the Archaebacterial Chromosomal Protein MC1
5XEE	;		;	NMR solution structure of the aromatic mutant H43F H67F cytochrome b5
5XE4	;		;	NMR solution structure of the aromatic mutant H43W H67F cytochrome b5
1PV3	;		;	NMR Solution Structure of the Avian FAT-domain of Focal Adhesion Kinase
2KHK	;		;	NMR solution structure of the b30-82 domain of subunit b of Escherichia coli F1FO ATP synthase
2K77	;		;	NMR solution structure of the Bacillus subtilis ClpC N-domain
1ZQ3	;		;	NMR Solution Structure of the Bicoid Homeodomain Bound to the Consensus DNA Binding Site TAATCC
1F68	;		;	NMR SOLUTION STRUCTURE OF THE BROMODOMAIN FROM HUMAN GCN5
2A93	;		;	NMR SOLUTION STRUCTURE OF THE C-MYC-MAX HETERODIMERIC LEUCINE ZIPPER, 40 STRUCTURES
1A93	;		;	NMR SOLUTION STRUCTURE OF THE C-MYC-MAX HETERODIMERIC LEUCINE ZIPPER, NMR, MINIMIZED AVERAGE STRUCTURE
2K2I	;		;	NMR Solution structure of the C-terminal domain (T94-Y172) of the human centrin 2 in complex with a repeat sequence of human Sfi1 (R641-T660)
2N2E	;		;	NMR solution structure of the C-terminal domain of NisI, a lipoprotein from Lactococcus lactis which confers immunity against nisin
2LAE	;		;	NMR solution structure of the C-terminal domain of the E. coli lipoprotein BamC
1TRL	;		;	NMR SOLUTION STRUCTURE OF THE C-TERMINAL FRAGMENT 255-316 OF THERMOLYSIN: A DIMER FORMED BY SUBUNITS HAVING THE NATIVE STRUCTURE
1P9C	;		;	NMR solution structure of the C-terminal ubiquitin-interacting motif of the proteasome subunit S5a
2MA3	;		;	NMR solution structure of the C-terminus of the minichromosome maintenance protein MCM from Methanothermobacter thermautotrophicus
2M45	;		;	NMR solution structure of the C-terminus of the minichromosome maintenance protein MCM from Sulfolobus solfataricus
6HYK	;		;	NMR solution structure of the C/D box snoRNA U14
7P4N	;		;	NMR solution structure of the C6 domain of von Willebrand Factor
2LQP	;		;	NMR solution structure of the Ca2+-Calmodulin C-terminal domain in a complex with a peptide (NSCaTE) from the L-type Voltage-Gated Calcium Channel alpha1C subunit
1SNL	;		;	NMR Solution Structure of the Calcium-binding Domain of Nucleobindin (CALNUC)
1C7V	;		;	NMR SOLUTION STRUCTURE OF THE CALCIUM-BOUND C-TERMINAL DOMAIN (W81-S161) OF CALCIUM VECTOR PROTEIN FROM AMPHIOXUS
1C7W	;		;	NMR SOLUTION STRUCTURE OF THE CALCIUM-BOUND C-TERMINAL DOMAIN (W81-S161) OF CALCIUM VECTOR PROTEIN FROM AMPHIOXUS
1D1D	;		;	NMR SOLUTION STRUCTURE OF THE CAPSID PROTEIN FROM ROUS SARCOMA VIRUS
6Z40	;		;	NMR solution structure of the carbohydrate-binding module family 5 (CBM5) from Cellvibrio japonicus CjLPMO10A
6Z41	;		;	NMR solution structure of the carbohydrate-binding module family 73 (CBM73) from Cellvibrio japonicus CjLPMO10A
6E26	;		;	NMR solution structure of the CARD9 CARD
6E25	;		;	NMR solution structure of the CARD9 CARD bound to zinc
1TDP	;		;	NMR solution structure of the carnobacteriocin B2 immunity protein
2KE9	;		;	NMR solution structure of the CASKIN SH3 domain
6F7E	;		;	NMR solution structure of the cellulose-binding family 2 carbohydrate binding domain (CBM2) from ScLPMO10C
1K19	;		;	NMR Solution Structure of the Chemosensory Protein CSP2 from Moth Mamestra brassicae
1KQH	;		;	NMR Solution Structure of the cis Pro30 Isomer of ACTX-Hi:OB4219
1GP8	;		;	NMR SOLUTION STRUCTURE OF THE COAT PROTEIN-BINDING DOMAIN OF BACTERIOPHAGE P22 SCAFFOLDING PROTEIN
2GP8	;		;	NMR SOLUTION STRUCTURE OF THE COAT PROTEIN-BINDING DOMAIN OF BACTERIOPHAGE P22 SCAFFOLDING PROTEIN
2M1V	;		;	NMR solution structure of the d3'-hairpin from the Sc.ai5gamma group II intron including the EBS1:dIBS1 RNA:DNA hybrid
2M24	;		;	NMR solution structure of the d3'-hairpin including the exon binding site 1 (EBS1) of the group II intron Sc.ai5gamma
2M23	;		;	NMR solution structure of the d3'-hairpin of the group II intron Sc.ai5gamma including EBS1 bound to IBS1
2K66	;		;	NMR solution structure of the d3'-stem closed by a GAAA tetraloop of the group II intron Sc.ai5(gamma)
7UWY	;		;	NMR solution structure of the De novo designed small beta-barrel protein 29_bp_sh3
7UWZ	;		;	NMR solution structure of the De novo designed small beta-barrel protein 33_bp_sh3
2DCX	;		;	NMR solution structure of the Dermaseptin antimicrobial peptide analog NC12-K4S4(1-13)a
1IC9	;		;	NMR SOLUTION STRUCTURE OF THE DESIGNED BETA-SHEET MINI-PROTEIN TH10AOX
1HI7	;		;	NMR SOLUTION STRUCTURE OF THE DISULPHIDE-LINKED HOMODIMER OF HUMAN TFF1, 10 STRUCTURES
2KRF	;		;	NMR solution structure of the DNA binding domain of Competence protein A
1FZX	;		;	NMR SOLUTION STRUCTURE OF THE DNA DODECAMER GGCAAAAAACGG
1G14	;		;	NMR SOLUTION STRUCTURE OF THE DNA DODECAMER GGCAAGAAACGG
1DHH	;		;	NMR SOLUTION STRUCTURE OF THE DNA DUPLEX CONTAINING DNA/RNA HYBRID REGION, D(GG)R(AGAU)D(GAC)/D(GTCATCTCC)
1DRN	;		;	NMR SOLUTION STRUCTURE OF THE DNA DUPLEX CONTAINING DNA/RNA HYBRID REGION, D(GGAGA)R(UGAC)/D(GTCATCTCC)
2MEO	;		;	NMR solution structure of the double GS-Tamapin mutation R6A/R7A
2A7U	;		;	NMR solution structure of the E.coli F-ATPase delta subunit N-terminal domain in complex with alpha subunit N-terminal 22 residues
2MHL	;		;	NMR solution Structure of the E.coli Outer Membrane Protein W
2KHN	;		;	NMR solution structure of the EH 1 domain from human intersectin-1 protein. Northeast Structural Genomics Consortium target HR3646E.
1T0V	;		;	NMR Solution Structure of the Engineered Lipocalin FluA(R95K) Northeast Structural Genomics Target OR17
2K65	;		;	NMR solution structure of the exon/intron binding site 1 (EBS1/IBS1) of the group II intron Sc.ai5(gamma)
1LFU	;		;	NMR Solution Structure of the Extended PBX Homeodomain Bound to DNA
5OUN	;		;	NMR solution structure of the external DII domain of Rvb2 from Saccharomyces cerevisiae
2HRJ	;		;	NMR solution structure of the F2 subdomain of talin
6SO0	;		;	NMR solution structure of the family 14 carbohydrate binding module (CBM14) from human chitotriosidase
2KFT	;		;	NMR Solution structure of the first PHD finger domain of human Autoimmune Regulator (AIRE) in complex with Histone H3(1-20Cys) Peptide
2GAQ	;		;	NMR SOLUTION STRUCTURE OF THE FRB DOMAIN OF mTOR
1NAU	;		;	NMR Solution Structure of the Glucagon Antagonist [desHis1, desPhe6, Glu9]Glucagon Amide in the Presence of Perdeuterated Dodecylphosphocholine Micelles
8QHI	;		;	NMR solution structure of the golden kiwi fruit allergen Act c 8.0101
8QHH	;		;	NMR solution structure of the green kiwi fruit allergen Act d 8.0101
2MEN	;		;	NMR solution structure of the GS-TAMAPIN MUTATION R13A
2ME7	;		;	NMR solution structure of the GS-TAMAPIN MUTATION R6A
2MEL	;		;	NMR solution structure of the GS-TAMAPIN MUTATION R7A
6Y3H	;		;	NMR solution structure of the hazelnut allergen Cor a 1.0401
6Y3I	;		;	NMR solution structure of the hazelnut allergen Cor a 1.0402
6Y3K	;		;	NMR solution structure of the hazelnut allergen Cor a 1.0403
6Y3L	;		;	NMR solution structure of the hazelnut allergen Cor a 1.0404
8OVL	;		;	NMR solution structure of the heavy metal binding domain of P1B-ATPase LpCopA.
1VPU	;		;	NMR SOLUTION STRUCTURE OF THE HIV-1 VPU CYTOPLASMIC DOMAIN, 9 STRUCTURES
6N2M	;		;	NMR solution structure of the homodimeric, autoinhibited state of the CARD9 CARD and first coiled-coil
1JNJ	;		;	NMR solution structure of the human beta2-microglobulin
2FHO	;		;	NMR solution structure of the human spliceosomal protein complex p14-SF3b155
6Q2Z	;		;	NMR solution structure of the HVO_2922 protein from Haloferax volcanii
2JVI	;		;	NMR Solution Structure of the Hyper-Sporulation Response Regulator Spo0F Mutant H101A from Bacillus subtilis
2JVJ	;		;	NMR Solution Structure of the Hyper-Sporulation Response Regulator Spo0F Mutant I90A from Bacillus subtilis
2JVK	;		;	NMR Solution Structure of the Hyper-Sporulation Response Regulator Spo0F Mutant L66A from Bacillus subtilis
1R4H	;		;	NMR Solution structure of the IIIc domain of GB Virus B IRES Element
2POJ	;		;	NMR Solution Structure of the Inhibitor-Free State of Macrophage Metalloelastase (MMP-12)
1I6F	;		;	NMR SOLUTION STRUCTURE OF THE INSECT-SPECIFIC NEUROTOXIN VARIANT 5 (CSE-V5) FROM THE SCORPION CENTRUROIDES SCULPTURATUS EWING
1I6G	;		;	NMR SOLUTION STRUCTURE OF THE INSECT-SPECIFIC NEUROTOXIN VARIANT 5 (CSE-V5) FROM THE SCORPION CENTRUROIDES SCULPTURATUS EWING
1DGQ	;		;	NMR SOLUTION STRUCTURE OF THE INSERTED DOMAIN OF HUMAN LEUKOCYTE FUNCTION ASSOCIATED ANTIGEN-1
2LFL	;		;	NMR solution structure of the intermediate IIIb of TdPI-short
6XYV	;		;	NMR solution structure of the Iron-Sulfur protein PioC from Rhodopseudomonas palustris TIE-1
2LU0	;		;	NMR solution structure of the kappa-zeta region of S.cerevisiae group II intron ai5(gamma)
5Z55	;		;	NMR Solution Structure of the Kringle domain of human receptor tyrosine kinase-like orphan receptor 1 (ROR1)
2M5W	;		;	NMR Solution Structure of the La motif (N-terminal Domain, NTD) of Dictyostelium discoideum La protein
1EHX	;		;	NMR SOLUTION STRUCTURE OF THE LAST UNKNOWN MODULE OF THE CELLULOSOMAL SCAFFOLDIN PROTEIN CIPC OF CLOSTRIDUM CELLULOLYTICUM
5MMU	;		;	NMR solution structure of the major apple allergen Mal d 1
6ALK	;		;	NMR solution structure of the major beech pollen allergen Fag s 1
2HWT	;		;	NMR solution structure of the Master-Rep protein nuclease domain (2-95) from the Faba Bean Necrotic Yellows Virus
1PYV	;		;	NMR solution structure of the mitochondrial F1b presequence peptide from Nicotiana plumbaginifolia
6E3C	;		;	NMR Solution Structure of the Monomeric Form of the Phage L Decoration Protein
2KK7	;		;	NMR solution structure of the N terminal domain of subunit E (E1-52) of A1AO ATP synthase from Methanocaldococcus jannaschii
2JX3	;		;	NMR solution structure of the N-terminal domain of DEK
1BNP	;		;	NMR SOLUTION STRUCTURE OF THE N-TERMINAL DOMAIN OF DNA POLYMERASE BETA, 55 STRUCTURES
1BNO	;		;	NMR SOLUTION STRUCTURE OF THE N-TERMINAL DOMAIN OF DNA POLYMERASE BETA, MINIMIZED AVERAGE STRUCTURE
2L1P	;		;	NMR solution structure of the N-terminal domain of DNA-binding protein SATB1 from Homo sapiens: Northeast Structural Genomics Target HR4435B(179-250)
2LVA	;		;	NMR solution structure of the N-terminal domain of human USP28, Northeast structural genomics consortium target HT8470A
2N32	;		;	NMR solution structure of the N-terminal domain of NisI, a lipoprotein from Lactococcus lactis which confers immunity against nisin
2LQK	;		;	NMR solution structure of the N-terminal domain of the CdnL protein from Thermus thermophilus
2KEB	;		;	NMR solution structure of the N-terminal domain of the DNA polymerase alpha p68 subunit
2LAF	;		;	NMR solution structure of the N-terminal domain of the E. coli lipoprotein BamC
2L4R	;		;	NMR solution structure of the N-terminal PAS domain of hERG
8BGF	;		;	NMR solution structure of the N-terminal RRM and flanking linker regions of Polypyrimidine tract binding protein 1 using the CYANA CONSENSUS method.
2JW4	;		;	NMR solution structure of the N-terminal SH3 domain of human Nckalpha
5T4R	;		;	NMR solution structure of the Nav1.7 selective spider venom-derived peptide Pn3a
1VIB	;		;	NMR SOLUTION STRUCTURE OF THE NEUROTOXIN B-IV, 20 STRUCTURES
2K4R	;		;	NMR solution structure of the neurotrypsin kringle domain
2K51	;		;	NMR Solution Structure of the Neurotrypsin Kringle Domain
2KCK	;		;	NMR solution structure of the Northeast Structural Genomics Consortium (NESG) target MrR121A
2HW0	;		;	NMR Solution Structure of the nuclease domain from the Replicator Initiator Protein from porcine circovirus PCV2
2HQI	;		;	NMR SOLUTION STRUCTURE OF THE OXIDIZED FORM OF MERP, 14 STRUCTURES
1WVK	;		;	NMR Solution Structure of the Partially Disordered Protein At2g23090 from Arabidopsis thaliana
6Z98	;		;	NMR solution structure of the peach allergen Pru p 1.0101
2FUU	;		;	NMR solution structure of the PHD domain from the human BPTF in complex with H3(1-15)K4me3 peptide
2JMJ	;		;	NMR solution structure of the PHD domain from the yeast YNG1 protein in complex with H3(1-9)K4me3 peptide
2NSV	;		;	NMR Solution Structure of the Pheromone En-1
2KC6	;		;	NMR solution structure of the pheromone En-1 of Euplotes nobilii at -1.5 C
2NSW	;		;	NMR Solution Structure of the Pheromone En-2
2KK2	;		;	NMR solution structure of the pheromone En-A1 from Euplotes nobilii
2N2S	;		;	NMR solution structure of the pheromone Ep-1 from Euplotes petzi
2L1L	;		;	NMR Solution Structure of the Phi0 PKI NES Peptide in Complex with CRM1-RanGTP
7TUJ	;		;	NMR solution structure of the phosphorylated MUS81-binding region from human SLX4
1RY3	;		;	NMR Solution Structure of the Precursor for Carnobacteriocin B2, an Antimicrobial Peptide from Carnobacterium piscicola
2MZE	;		;	NMR Solution Structure of the PRO Form of Human Matrilysin (proMMP-7)
2MZI	;		;	NMR Solution Structure of the PRO Form of Human Matrilysin (proMMP-7) in Complex with Anionic Membrane
2MZH	;		;	NMR Solution Structure of the PRO Form of Human Matrilysin (proMMP-7) in Complex with Zwitterionic Membrane
1D1R	;		;	NMR SOLUTION STRUCTURE OF THE PRODUCT OF THE E. COLI YCIH GENE.
2JRT	;		;	NMR solution structure of the protein coded by gene RHOS4_12090 of Rhodobacter sphaeroides. Northeast Structural Genomics target RhR5
2L6P	;		;	NMR solution structure of the protein NP_253742.1
1T2Y	;		;	NMR solution structure of the protein part of Cu6-Neurospora crassa MT
2L6N	;		;	NMR solution structure of the protein YP_001092504.1
1SG7	;		;	NMR solution structure of the putative cation transport regulator ChaB
5AIW	;		;	NMR solution structure of the putative transfer protein TraH from Gram-positive conjugative plasmid pIP501
2GFU	;		;	NMR solution structure of the PWWP domain of Mismatch repair protein hMSH6
1RFA	;		;	NMR SOLUTION STRUCTURE OF THE RAS-BINDING DOMAIN OF C-RAF-1
2I9H	;		;	NMR solution structure of the reduced form of thioredoxin 1 from yeast (Trx1)
1YLB	;		;	NMR solution structure of the reduced spinach plastocyanin
2JPH	;		;	NMR solution structure of the Rho GTPase binding domain of human plexin-b1
1JU7	;		;	NMR Solution Structure of the RNA Hairpin Binding Site for the Histone Stem-loop Binding Protein
1JWC	;		;	NMR SOLUTION STRUCTURE OF THE RNA HAIRPIN BINDING SITE FOR THE HISTONE STEM-LOOP BINDING PROTEIN
5SZW	;		;	NMR solution structure of the RRM1 domain of the post-transcriptional regulator HuR
3ZGK	;		;	NMR solution structure of the RXLR effector AVR3a11 from Phytophthora Capsici
1XNA	;		;	NMR SOLUTION STRUCTURE OF THE SINGLE-STRAND BREAK REPAIR PROTEIN XRCC1-N-TERMINAL DOMAIN
1XNT	;		;	NMR SOLUTION STRUCTURE OF THE SINGLE-STRAND BREAK REPAIR PROTEIN XRCC1-N-TERMINAL DOMAIN
2K2J	;		;	NMR solution structure of the split PH domain from Phospholipase C gamma 2
2K62	;		;	NMR solution structure of the supramolecular adduct between a liver cytosolic bile acid binding protein and a bile acid-based Gd(III)-chelate
7OFN	;		;	NMR solution structure of the SYLF domain of Burkholderia pseudomallei BPSL1445
1PES	;		;	NMR SOLUTION STRUCTURE OF THE TETRAMERIC MINIMUM TRANSFORMING DOMAIN OF P53
1PET	;		;	NMR SOLUTION STRUCTURE OF THE TETRAMERIC MINIMUM TRANSFORMING DOMAIN OF P53
1HZN	;		;	NMR SOLUTION STRUCTURE OF THE THIRD EXTRACELLULAR LOOP OF THE CHOLECYSTOKININ A RECEPTOR
1KQI	;		;	NMR Solution Structure of the trans Pro30 Isomer of ACTX-Hi:OB4219
1JAU	;		;	NMR Solution Structure of the Trp-Rich Peptide of HIV gp41 Bound to DPC Micelles
5N5C	;		;	NMR solution structure of the TSL2 RNA hairpin
2BBX	;		;	NMR solution structure of the TSR domain of malaria TRAP protein
2M2A	;		;	NMR solution structure of the two domain PPIase SlpA from Escherichia coli
5UJQ	;		;	NMR Solution Structure of the Two-component Bacteriocin CbnXY
5UJR	;		;	NMR Solution Structure of the Two-component Bacteriocin CbnXY
1T1H	;		;	NMR solution structure of the U box domain from AtPUB14, an armadillo repeat containing protein from Arabidopsis thaliana
1W4U	;		;	NMR solution structure of the ubiquitin conjugating enzyme UbcH5B
2MRP	;		;	NMR solution structure of the Ubiquitin like domain (UBL) of DNA-damage-inducible 1 protein (Ddi1)
2PPZ	;		;	NMR solution Structure of the Villin Headpiece Mutant G34L
1JRF	;		;	NMR Solution Structure of the Viral Receptor Domain of Tva
7X8N	;		;	NMR Solution Structure of the Wild-type Bulge-containing KRAS-G4
2MC3	;		;	NMR solution structure of the winged-helix domain from MUS81 structure-specific endonuclease
2FV4	;		;	NMR solution structure of the yeast kinetochore Spc24/Spc25 globular domain
2MNJ	;		;	NMR solution structure of the yeast Pih1 and Tah1 C-terminal domains complex
8R6T	;		;	NMR solution structure of thyropin IrThy-Cd from the hard tick Ixodes ricinus
2KA7	;		;	NMR solution structure of TM0212 at 40 C
2RN7	;		;	NMR solution structure of TnpE protein from Shigella flexneri. Northeast Structural Genomics Target SfR125
2M6F	;		;	NMR solution structure of trans (major) form of In936 in Methanol
2M6D	;		;	NMR solution structure of trans (major) form of In936 in water
6U7U	;		;	NMR solution structure of triazole bridged matriptase inhibitor
6U7X	;		;	NMR solution structure of triazole bridged plasmin inhibitor
6U24	;		;	NMR solution structure of triazole bridged SFTI-1
2MXM	;		;	NMR solution structure of TRTX-Tp1a from the tarantula Thrixopelma pruriens
1MQZ	;		;	NMR solution structure of type-B lantibiotics mersacidin bound to lipid II in DPC micelles
1MQY	;		;	NMR solution structure of type-B lantibiotics mersacidin in DPC micelles
1MQX	;		;	NMR Solution Structure of Type-B Lantibiotics Mersacidin in MeOH/H2O Mixture
6BL9	;		;	NMR Solution structure of U-SLPTX15-Sm2a
5OBN	;		;	NMR solution structure of U11/U12 65K protein's C-terminal RRM domain (381-516)
2JVC	;		;	NMR solution structure of ubiquitin like protein
2JXX	;		;	NMR solution structure of Ubiquitin-like domain of NFATC2IP. Northeast Structural Genomics Consortium target HR5627
5N9V	;		;	NMR solution structure of ubl5 domain from polyubiquitin locus of T.thermophila.
6YW8	;		;	NMR solution structure of unbound recombinant human Nerve Growth Factor (rhNGF)
1K0T	;		;	NMR SOLUTION STRUCTURE OF UNBOUND, OXIDIZED PHOTOSYSTEM I SUBUNIT PSAC, CONTAINING [4FE-4S] CLUSTERS FA AND FB
6LNZ	;		;	NMR solution structure of VEGF G-quadruplex bound a non-planar cyclometalated-carbene platinum(II) complex
2KMT	;		;	NMR solution structure of Vibrio fischeri CcdB
2L0Q	;		;	NMR Solution Structure of Vibrio harveyi Acyl Carrier Protein (ACP)
6O3Q	;		;	NMR solution structure of vicilin-buried peptide-8 (VBP-8)
2GL1	;		;	NMR solution structure of Vigna radiata Defensin 2 (VrD2)
6EFE	;		;	NMR Solution Structure of vil14a
2NA5	;		;	NMR solution structure of vitamin B12 conjugates of PYY3-36
1HFG	;		;	NMR solution structure of vMIP-II 1-71 from Kaposi's sarcoma-associated herpesvirus (minimized average structure).
2GJI	;		;	NMR solution structure of VP9 from White Spot Syndrome Virus
1DSJ	;		;	NMR SOLUTION STRUCTURE OF VPR50_75, 20 STRUCTURES
1DSK	;		;	NMR SOLUTION STRUCTURE OF VPR59_86, 20 STRUCTURES
6DO6	;		;	NMR solution structure of wild type apo hFABP1 at 308 K
6DO7	;		;	NMR solution structure of wild type hFABP1 with GW7647
6DRG	;		;	NMR solution structure of wild type hFABP1 with GW7647
7UNX	;		;	NMR solution structure of xanthusin-1
2LIR	;		;	NMR Solution Structure of Yeast Iso-1-cytochrome c Mutant P71H in oxidized states
2LIT	;		;	NMR Solution Structure of Yeast Iso-1-cytochrome c Mutant P71H in reduced states
6G03	;		;	NMR Solution Structure of yeast TSR2(1-152)
6G04	;		;	NMR Solution Structure of Yeast TSR2(1-152) in Complex with S26A(100-119)
6OWR	;		;	NMR solution structure of YfiD
2JN9	;		;	NMR solution structure of YkvR protein from Bacillus subtilis: NESG target SR358
2LDI	;		;	NMR solution structure of ZiaAN sub mutant
1NKU	;		;	NMR Solution Structure of Zinc-binding protein 3-methyladenine DNA glycosylase I (TAG)
1BX5	;		;	NMR SOLUTION STRUCTURE OF [D(GCGAAT-3'-3'-ALPHAT-5'-5'-CGC)2]
1BWT	;		;	NMR SOLUTION STRUCTURE OF [D(GCGAATCGC)2]
2RU2	;		;	NMR solution structure of [G5,T7,S9]-oxytocin
7OS8	;		;	NMR SOLUTION STRUCTURE OF [Pro3,DLeu9]TL
5J3F	;		;	NMR solution structure of [Rp, Rp]-PT dsDNA
5J3I	;		;	NMR solution structure of [Sp, Sp]-PT dsDNA
7LHC	;		;	NMR Solution Structure of [T20K]kalata B1
2HV4	;		;	NMR solution structure refinement of yeast iso-1-ferrocytochrome c
7SXD	;		;	NMR solution structure TnC-TnI chimera
2FEB	;		;	NMR Solution Structure, Dynamics and Binding Properties of the Kringle IV Type 8 module of apolipoprotein(a)
2JOR	;		;	NMR Solution Structure, Stability, and Interaction of the Recombinant Bovine Fibrinogen alphaC-Domain Fragment
2L2U	;		;	NMR Solution Structures of +3 (5' staggered) Bistranded Abasic Site Lesions in DNA
2L2V	;		;	NMR Solution Structures of -3 (3' staggered) Bistranded Abasic Site Lesions in DNA
2KOR	;		;	NMR solution structures of 2-octenoyl-ACP from Streptomyces coelicolor Fatty Acid Synthase
2KGE	;		;	NMR Solution Structures of 3,5-dioxohexyl ACP (a triketide mimic) from the actinorhodin polyketide synthase in Streptomyces coelicolor
2KOQ	;		;	NMR solution structures of 3-hydroxyoctanoyl-ACP from Streptomyces coelicolor Fatty Acid Synthase
2KGD	;		;	NMR Solution Structures of 3-oxo-butyl-ACP, an intermediate mimic from the actinorhodin polyketide synthase in Streptomyces coelicolor
2KOP	;		;	NMR solution structures of 3-oxooctanyl-ACP from Streptomyces coelicolor Fatty Acid Synthase
6IY5	;		;	NMR solution structures of 5'-ATTCTATTCT-3
1X2O	;		;	NMR solution structures of a DNA dodecamer containing a tandem GT mismatches using NOE and residual dipolar couplings
1X2S	;		;	NMR solution structures of a DNA dodecamer containing a tandem GT mismatches using NOE and residual dipolar couplings
1X2U	;		;	NMR solution structures of a DNA dodecamer containing a tandem GT mismatches using NOE and residual dipolar couplings
1X2V	;		;	NMR solution structures of a DNA dodecamer containing a tandem GT mismatches using NOE and residual dipolar couplings
1X2X	;		;	NMR solution structures of a DNA dodecamer containing a tandem GT mismatches using NOE and residual dipolar couplings
1X2Y	;		;	NMR Solution structures of a DNA dodecamer containing a tandem GT mismatches using NOE and residual dipolar couplings
1X2Z	;		;	NMR solution structures of a DNA dodecamer containing a tandem GT mismatches using NOE and residual dipolar couplings
1X30	;		;	NMR Solution structures of a DNA dodecamer containing a tandem GT mismatches using NOE and residual dipolar couplings
7VCK	;		;	NMR solution structures of a hairpin formed by GGCCTG repeats
1I2V	;		;	NMR SOLUTION STRUCTURES OF AN ANTIFUNGAL AND ANTIBACTERIAL MUTANT OF HELIOMICIN
1I2U	;		;	NMR SOLUTION STRUCTURES OF ANTIFUNGAL HELIOMICIN
2EVN	;		;	NMR solution structures of At1g77540
2KG9	;		;	NMR Solution Structures of butyryl-ACP (a non-polar, non pathway intermediate) from the actinorhodin polyketide synthase in Streptomyces coelicolor
7D12	;		;	NMR solution structures of CAG RNA-DB213 binding complex
1G1P	;		;	NMR Solution Structures of delta-Conotoxin EVIA from Conus ermineus that Selectively Acts on Vertebrate Neuronal Na+ Channels
1G1Z	;		;	NMR Solution Structures of delta-Conotoxin EVIA from Conus ermineus that Selectively Acts on Vertebrate Neuronal Na+ Channels, LEU12-PRO13 Cis isomer
7E4E	;		;	NMR solution structures of DNA minidumbbell containing a N1-methyladenine
2MFQ	;		;	NMR solution structures of FRS2a PTB domain with neurotrophin receptor TrkB
2KMY	;		;	NMR Solution structures of fully oxidised cytochrome c3 from Desulfovibrio desulfuricans ATCC 27774
2KGA	;		;	NMR Solution Structures of hexanoyl ACP (a non natural intermediate) from the actinorhodin polyketide synthase in Streptomyces coelicolor
2KOO	;		;	NMR solution structures of hexanoyl-ACP from the Streptomyces coelicolor Fatty Acid Synthase
2RO1	;		;	NMR Solution Structures of Human KAP1 PHD finger-bromodomain
2KG8	;		;	NMR Solution Structures of malonyl ACP from the actinorhodin polyketide synthase in Streptomyces coelicolor
2KGC	;		;	NMR Solution Structures of octanoyl ACP (a non-natural intermediate) from the actinorhodin polyketide synthase in Streptomyces coelicolor
2KOS	;		;	NMR solution structures of octanoyl-ACP from Streptomyces coelicolor Fatty Acid Synthase
7XFG	;		;	NMR solution structures of p300 TAZ2 domain in complex with BRD4-NUT F1c domain binding motif #1
7XEZ	;		;	NMR solution structures of p300 TAZ2 domain in complex with BRD4-NUT F1c domain binding motif #2
6MNL	;		;	NMR solution structures of second bromodomain of BRD4 with FOXO3a peptide
7D0X	;		;	NMR solution structures of the DNA minidumbbell formed by 5'-mCTTGXmCTTG-3'
7YF7	;		;	NMR solution structures of the DNA minidumbbell formed by two ATTTT repeats
7D0Z	;		;	NMR solution structures of the DNA minidumbbell formed by two CCTG repeats at pH 5
7D0Y	;		;	NMR solution structures of the DNA minidumbbell formed by two CmCTG repeats at pH 5
1KRI	;		;	NMR Solution Structures of the Rhesus Rotavirus VP4 Sialic Acid Binding Domain without Ligand
1HFF	;		;	NMR solution structures of the vMIP-II 1-10 peptide from Kaposi's sarcoma-associated herpesvirus.
7KAA	;		;	NMR solution structures of tirasemtiv drug bound to a fast skeletal troponin C-troponin I complex
1HFN	;		;	NMR solution structures of vMIP-II 1-71 from Kaposi's sarcoma-associated herpesvirus.
1TT3	;		;	NMR soulution structure of omega-conotoxin [K10]MVIIA
2JWM	;		;	NMR spatial srtucture of ternary complex kalata B7/Mn2+/DPC micelle
5OB4	;		;	NMR spatial structure of HER2 TM domain dimer in DPC micelles.
2MEU	;		;	NMR spatial structure of mutant dimeric TM domain of VEGFR2 receptor
2N2Z	;		;	NMR spatial structure of nonspecific lipid transfer protein from the dill Anethum graveolens L.
5MOU	;		;	NMR spatial structure of scorpion alpha-like toxin BeM9
2M6A	;		;	NMR spatial structure of the antimicrobial peptide Tk-Amp-X2
2MET	;		;	NMR spatial structure of the trimeric mutant TM domain of VEGFR2 receptor.
2LQX	;		;	NMR spatial structure of the trypsin inhibitor BWI-2c from the buckwheat seeds
5LM0	;		;	NMR spatial structure of Tk-hefu peptide
2L8U	;		;	NMR Spectroscopy and Molecular Dynamics Simulation of r(CCGCUGCGG)2 Reveal a Dynamic UU Internal Loop Found in Myotonic Dystrophy Type 1 - UU pair with one hydrogen bond pair
2L8C	;		;	NMR Spectroscopy and Molecular Dynamics Simulation of r(CCGCUGCGG)2 Reveal a Dynamic UU Internal Loop Found in Myotonic Dystrophy Type 1 - UU pair with zero hydrogen bond pairs
1XY4	;		;	NMR strcutre of sst1-selective somatostatin (SRIF) analog 1
1XY5	;		;	NMR strcutre of sst1-selective somatostatin (SRIF) analog 1
1XY6	;		;	NMR strcutre of sst1-selective somatostatin (SRIF) analog 1
1XY8	;		;	NMR strcutre of sst1-selective somatostatin (SRIF) analog 1
1XY9	;		;	NMR strcutre of sst1-selective somatostatin (SRIF) analog 1
1G5K	;		;	NMR Structrure of d(CCAAAGXACTGGG), X is a 3'-phosphoglycolate, 5'-phosphate gapped lesion, 10 structures
1K64	;		;	NMR Structue of alpha-conotoxin EI
2A2Y	;		;	NMR Structue of Sso10b2 from Sulfolobus solfataricus
1ZRY	;		;	NMR structural analysis of apo chicken liver bile acid binding protein
2AQC	;		;	NMR Structural analysis of archaeal Nop10
2AQA	;		;	NMR structural analysis of Nop10p from Saccharomyces cerevisiae
1KC4	;		;	NMR Structural Analysis of the Complex Formed Between alpha-Bungarotoxin and the Principal alpha-Neurotoxin Binding Sequence on the alpha7 Subunit of a Neuronal Nicotinic Acetylcholine Receptor
1KL8	;		;	NMR STRUCTURAL ANALYSIS OF THE COMPLEX FORMED BETWEEN ALPHA-BUNGAROTOXIN AND THE PRINCIPAL ALPHA-NEUROTOXIN BINDING SEQUENCE ON THE ALPHA7 SUBUNIT OF A NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR
2AWV	;		;	NMR Structural Analysis of the dimer of 5MCCTCATCC
6ZDB	;		;	NMR structural analysis of yeast Cox13 reveals its C-terminus in interaction with ATP
6BJF	;		;	NMR Structural and biophysical functional analysis of intracellular loop 5 of the NHE1 isoform of the Na+/H+ exchanger.
5NDA	;		;	NMR Structural Characterisation of Pharmaceutically Relevant Proteins Obtained Through a Novel Recombinant Production: The Case of The Pulmonary Surfactant Polypeptide C Analogue rSP-C33Leu.
1LM2	;		;	NMR structural characterization of the reduction of chromium(VI) to chromium(III) by cytochrome c7
1ED0	;		;	NMR structural determination of viscotoxin A3 from Viscum album L.
2A9H	;		;	NMR structural studies of a potassium channel / charybdotoxin complex
2KY7	;		;	NMR Structural Studies on the Covalent DNA Binding of a Pyrrolobenzodiazepine-Naphthalimide Conjugate
2K3G	;		;	NMR structure analysis of a BMP receptor
1TUQ	;		;	NMR Structure Analysis of the B-DNA Dodecamer CTCtCACGTGGAG with a tricyclic cytosin base analogue
2NO8	;		;	NMR Structure analysis of the colicin immuntiy protein IM2
1DK6	;		;	NMR structure analysis of the DNA nine base pair duplex D(CATGAGTAC) D(GTAC(NP3)CATG)
2OI3	;		;	NMR Structure Analysis of the Hematopoetic Cell Kinase SH3 Domain complexed with an artificial high affinity ligand (PD1)
2OJ2	;		;	NMR Structure Analysis of the Hematopoetic Cell Kinase SH3 Domain complexed with an artificial high affinity ligand (PD1)
1U62	;		;	NMR structure analysis of the lactoferrin-based peptide FQWQRNIRKVR in complex with lipopolysaccharide
1K8B	;		;	NMR Structure Analysis of the N-terminal Domain of Archaeal Translation Initiation Factor 2 Subunit beta
2NZZ	;		;	NMR structure analysis of the Penetratin conjugated Gas (374-394) peptide
2O00	;		;	NMR structure analysis of the Penetratin conjugated Gas (374-394) peptide
2MRC	;		;	NMR Structure and 1H, 13C and 15N Chemical Shift Assignments for High mobility group protein from Plasmodium falciparum 3D7.
5NR6	;		;	NMR structure and 1H, 13C and 15N signal assignments for Dictyostelium discoidans MATB protein S71A mutant
5NR5	;		;	NMR structure and 1H, 13C and 15N signal assignments for Dictyostelium discoideum MATA protein
2KXT	;		;	NMR structure and calcium-binding properties of the tellurite resistance protein TerD from Klebsiella pneumoniae
2KXV	;		;	NMR structure and calcium-binding properties of the tellurite resistance protein TerD from Klebsiella pneumoniae
5KGQ	;		;	NMR structure and dynamics of Q4DY78, a conserved kinetoplasid-specific protein from Trypanosoma cruzi
6LUL	;		;	NMR structure and dynamics studies of yeast respiratory super-complex factor 2 in micelles
2JRK	;		;	NMR Structure and Epitope Mapping of Blo t 5
5XJK	;		;	NMR Structure and Localization of a Large Fragment of the SARS-CoV Fusion Protein: Implications in Viral Cell Fusion
2HEM	;		;	NMR structure and Mg2+ binding of an RNA segment that underlies the L7/L12 stalk in the E.coli 50S ribosomal subunit.
1SJ6	;		;	NMR Structure and Regulated Expression in APL Cell of Human SH3BGRL3
5N14	;		;	NMR structure calculation of a composite Cys2His2 type zinc finger protein containing a non-peptide (or oligourea) helical domain
2IH0	;		;	NMR structure determination of a synthetic analogue of the iturinic antibiotic bacillomycin Lc
2JQP	;		;	NMR structure determination of Bungatoxin from Bungarus candidus (Malayan Krait)
6NAN	;		;	NMR structure determination of Ixolaris and Factor X interaction reveals a noncanonical mechanism of Kunitz inhibition
1WAZ	;		;	NMR Structure Determination of the bacterial mercury transporter, MerF, in micelles
2PFU	;		;	NMR structure determination of the periplasmic domain of ExbD from E.coli
1QXB	;		;	NMR structure determination of the self complementary DNA Dodecamer CGCGAATT*CGCG in which a ribose is inserted between the 3'-OH of T8 and the 5'-phosphate group of C9
1QEY	;		;	NMR Structure Determination of the Tetramerization Domain of the MNT Repressor: An Asymmetric A-Helical Assembly in Slow Exchange
1TCP	;		;	NMR STRUCTURE DETERMINATION OF TICK ANTICOAGULANT PEPTIDE (TAP)
1WWD	;		;	NMR structure determined for MLV NC complex with RNA sequence AACAGU
1WWF	;		;	NMR Structure Determined for MLV NC Complex with RNA Sequence CCUCCGU
1WWG	;		;	NMR Structure Determined for MLV NC Complex with RNA Sequence UAUCUG
1WWE	;		;	NMR Structure Determined for MLV NC complex with RNA Sequence UUUUGCU
2IJY	;		;	NMR structure ensemble for the reduced DsbA disulphide oxidoreductase from Vibrio Cholerae
1IYR	;		;	NMR Structure Ensemble Of Dff-C Domain
1Y7J	;		;	NMR structure family of Human Agouti Signalling Protein (80-132: Q115Y, S124Y)
1Y7K	;		;	NMR structure family of Human Agouti Signalling Protein (80-132: Q115Y, S124Y)
2N6H	;		;	NMR structure for a 2-stranded parallel beta-sheet
2N6I	;		;	NMR structure for a 2-stranded parallel beta-sheet
2N4N	;		;	NMR structure for a 3-stranded parallel beta-sheet
1N1K	;		;	NMR Structure for d(CCGCGG)2
2LGX	;		;	NMR structure for Kindle-2 N-terminus
2K5C	;		;	NMR Structure for PF0385
6DVT	;		;	NMR structure for Sp1 transcription factor duplex 5'-d(GGGGCGGGA)
6DM7	;		;	NMR structure for Sp1 transcription factor duplex 5'-d(GGGGCGGGG)
6ED9	;		;	NMR structure for Sp1 transcription factor duplex 5'-d(TGGGCGGGA)
6DXM	;		;	NMR structure for Sp1 transcription factor duplex 5'-d(TGGGCGGGG)
2H9X	;		;	NMR structure for the CgNa toxin from the sea anemone Condylactis gigantea
2L3H	;		;	NMR Structure in a Membrane Environment Reveals Putative Amyloidogenic Regions of the SEVI Precursor Peptide PAP248-286
2RN8	;		;	NMR structure note: murine Itk SH3 domain
2M5H	;		;	NMR structure note: solution structure of monomeric human FAM96A
1P82	;		;	NMR STRUCTURE OF 1-25 FRAGMENT OF MYCOBACTERIUM TUBERCULOSIS CPN10
1P83	;		;	NMR STRUCTURE OF 1-25 FRAGMENT OF MYCOBACTERIUM TUBERCULOSIS CPN10
2HSK	;		;	NMR Structure of 13mer Duplex DNA containing an abasic site (Y) in 5'-CCAAAGYACCGGG-3' (10 structures, alpha anomer)
2HSL	;		;	NMR structure of 13mer duplex DNA containing an abasic site, averaged structure (alpha anomer)
1FW7	;		;	NMR STRUCTURE OF 15N-LABELED BARNASE
1PPQ	;		;	NMR structure of 16th module of Immune Adherence Receptor, Cr1 (Cd35)
1DVW	;		;	NMR structure of 18 residue peptide from merp protein
2LXY	;		;	NMR structure of 2-MERCAPTOPHENOL-ALPHA3C
1OLD	;		;	NMR STRUCTURE OF 24-MER DEOXYRIBONUCLEIC ACID, 7 STRUCTURES
2FQ5	;		;	NMR structure of 2F associated with lipid disc
2FQ8	;		;	NMR structure of 2F associated with lipid disc
1QWB	;		;	NMR structure of 5'-r(GGACACGAAAUCCCGAAGUAGUGUCC)-3' : an RNA hairpin containing the in vitro selected consensus sequence for nucleolin RBD12
1QWA	;		;	NMR structure of 5'-r(GGAUGCCUCCCGAGUGCAUCC): an RNA hairpin derived from the mouse 5'ETS that binds nucleolin RBD12.
2JOY	;		;	NMR Structure of 50S Ribosomal Protein L14e from Sulfolobus Solfataricus: Northeast Structural Genomics Consortium Target SSR105
1BDZ	;		;	NMR STRUCTURE OF A 14 MER EXTENDED C-MYB COGNATE DNA SEQUENCE 5'D(APCPAPAP CPTPGPCP APGPTPTP GPT)3', MINIMIZED AVERAGE STRUCTURE
5A4G	;		;	NMR structure of a 180 residue construct encompassing the N-terminal metal-binding site and the membrane proximal domain of SilB from Cupriavidus metallidurans CH34
1LEJ	;		;	NMR Structure of a 1:1 Complex of Polyamide (Im-Py-Beta-Im-Beta-Im-Py-Beta-Dp) with the Tridecamer DNA Duplex 5'-CCAAAGAGAAGCG-3'
2JYK	;		;	NMR Structure of a 21 bp DNA duplex preferentially cleaved by Human Topoisomerase II
2ADT	;		;	NMR structure of a 30 kDa GAAA tetraloop-receptor complex.
1G3F	;		;	NMR STRUCTURE OF A 9 RESIDUE PEPTIDE FROM SMAC/DIABLO COMPLEXED TO THE BIR3 DOMAIN OF XIAP
8X1V	;		;	NMR structure of a bimolecular parallel G-quadruplex formed by AAGGG repeats from pathogenic RFC1 gene
2MCQ	;		;	NMR structure of a BolA-like hypothetical protein RP812 from Rickettsia prowazekii, Seattle structural genomics center for infectious disease (SSGCID)
1T3K	;		;	NMR structure of a CDC25-like dual-specificity tyrosine phosphatase of Arabidopsis thaliana
1A60	;		;	NMR STRUCTURE OF A CLASSICAL PSEUDOKNOT: INTERPLAY OF SINGLE-AND DOUBLE-STRANDED RNA, 24 STRUCTURES
1TTV	;		;	NMR Structure of a Complex Between MDM2 and a Small Molecule Inhibitor
1ONV	;		;	NMR Structure of a Complex Containing the TFIIF Subunit RAP74 and the RNAP II CTD Phosphatase FCP1
2K7L	;		;	NMR structure of a complex formed by the C-terminal domain of human RAP74 and a phosphorylated peptide from the central domain of the FCP1
1F5Y	;		;	NMR STRUCTURE OF A CONCATEMER OF THE FIRST AND SECOND LIGAND-BINDING MODULES OF THE HUMAN LDL RECEPTOR
1PQQ	;		;	NMR Structure of a Cyclic Polyamide-DNA Complex
1S4A	;		;	NMR Structure of a D,L alternating decamer of norleucine: double antiparallel beta-helix
1S1O	;		;	NMR Structure of a D,L Alternating pentadecamer of norleucine: double antiparallel beta-helix
1R9V	;		;	NMR Structure of a D,L-Alternating Dodecamer of Norleucine
2KI0	;		;	NMR Structure of a de novo designed beta alpha beta
7T03	;		;	NMR structure of a designed cold unfolding four helix bundle
1S88	;		;	NMR structure of a DNA duplex with two INA nucleotides inserted opposite each other, dCTCAACXCAAGCT:dAGCTTGXGTTGAG
7ALU	;		;	NMR structure of a DNA G-quadruplex containing two SP1 binding sites from HIV-1 promoter
1EKW	;		;	NMR STRUCTURE OF A DNA THREE-WAY JUNCTION
2CYU	;		;	NMR structure of a downhill folding protein
2N6E	;		;	NMR structure of a DUF1491 family protein (CC_1065) from Caulobacter crescentus CB15
2N6A	;		;	NMR structure of a human calmodulin/connexin-36 peptide hybrid
2N17	;		;	NMR structure of a Kazal-type serine protease inhibitor from the subterranean termite defense gland of Coptotermes formosanus Shiraki soldiers
2PN9	;		;	NMR structure of a kissing complex formed between the TAR RNA element of HIV-1 and a LNA modified aptamer
2OOM	;		;	NMR structure of a kissing complex formed between the TAR RNA element of HIV-1 and a LNA/RNA aptamer
2LR6	;		;	NMR structure of a LINE-1 type transposase domain-containing protein 1 (L1TD1) from Homo sapiens
1DNG	;		;	NMR STRUCTURE OF A MODEL HYDROPHILIC AMPHIPATHIC HELICAL ACIDIC PEPTIDE
1DJF	;		;	NMR STRUCTURE OF A MODEL HYDROPHILIC AMPHIPATHIC HELICAL BASIC PEPTIDE
1DN3	;		;	NMR STRUCTURE OF A MODEL HYDROPHILIC AMPHIPATHIC HELICAL BASIC PEPTIDE
2KBL	;		;	NMR Structure of a Monomeric Folding Intermediate Reveals the Structural Basis for Rapid Assembly of an Evolutionary Optimized Trimerization Module
2LPI	;		;	NMR structure of a monomeric mutant (A72R) of major ampullate spidroin 1 N-terminal domain
2K0D	;		;	NMR structure of a mutant colicin e7 immunity protein im7 with an extended helix III
2RVD	;		;	NMR STRUCTURE of A MUTANT OF CHIGNOLIN, CLN025
5I2V	;		;	NMR structure of a new G-quadruplex forming sequence within the KRAS proto-oncogene promoter region
2IDN	;		;	NMR structure of a new modified Thrombin Binding Aptamer containing a 5'-5' inversion of polarity site
1QU5	;		;	NMR STRUCTURE OF A NEW PHOSPHOTYROSINE BINDING DOMAIN CONTAINING THE FHA2 DOMAIN OF RAD 53
2G9P	;		;	NMR structure of a novel antimicrobial peptide, latarcin 2a, from spider (Lachesana tarabaevi) venom
1JUU	;		;	NMR Structure of a Parallel Stranded DNA Duplex at Atomic Resolution
1SBU	;		;	NMR structure of a peptide containing a dimetylthiazolidine : an analog of delta conotoxin EVIA loop 2
7P5Q	;		;	NMR structure of a peptide deriving from SARS-CoV-2 Lineage B.1.1.7 S RBD 482-506 fragment in HFIP/H2O
7P5S	;		;	NMR structure of a peptide deriving from SARS-CoV-2 Lineages P.1 and B.1.351 S RBD 482-506 fragment in HFIP/H2O
7P5G	;		;	NMR structure of a peptide deriving from SARS-CoV-2 S RBD 482-506 fragment in HFIP/H2O
2MN8	;		;	NMR structure of a peptoid analogue of maculatin G15 containing cis-Nleu at position 13
1TBO	;		;	NMR STRUCTURE OF A PROTEIN KINASE C-G PHORBOL-BINDING DOMAIN, 30 STRUCTURES
1TBN	;		;	NMR STRUCTURE OF A PROTEIN KINASE C-G PHORBOL-BINDING DOMAIN, MINIMIZED AVERAGE STRUCTURE
1UWD	;		;	NMR STRUCTURE OF A PROTEIN WITH UNKNOWN FUNCTION FROM THERMOTOGA MARITIMA (TM0487), WHICH BELONGS TO THE DUF59 FAMILY.
2BJC	;		;	NMR structure of a protein-DNA complex of an altered specificity mutant of the lac repressor headpiece that mimics the gal repressor
1PB5	;		;	NMR Structure of a Prototype LNR Module from Human Notch1
2KLA	;		;	NMR STRUCTURE OF A PUTATIVE DINITROGENASE (MJ0327) FROM METHANOCOCCUS JANNASCHII
1RDU	;		;	NMR STRUCTURE OF A PUTATIVE NIFB PROTEIN FROM THERMOTOGA (TM1290), WHICH BELONGS TO THE DUF35 FAMILY
2MSN	;		;	NMR structure of a putative phosphoglycolate phosphatase (NP_346487.1) from Streptococcus pneumoniae TIGR4
2K87	;		;	NMR STRUCTURE OF A PUTATIVE RNA BINDING PROTEIN (SARS1) FROM SARS CORONAVIRUS
1K5I	;		;	NMR Structure of a Ribosomal RNA Hairpin Containing a Conserved CUCAA Pentaloop
2N08	;		;	NMR structure of a short hydrophobic 11mer peptide in 25 mM SDS solution
2N09	;		;	NMR structure of a short hydrophobic 11mer peptide in DMSO-d6/H2O (1:3) solution
1L1W	;		;	NMR structure of a SRP19 binding domain in human SRP RNA
8CWX	;		;	NMR structure of a Stapled Lanthipeptide Natural Product
2MDW	;		;	NMR structure of a strand-swapped dimer of the WW domain
1UUI	;		;	NMR structure of a synthetic small molecule, rbt158, bound to HIV-1 TAR RNA
1UUD	;		;	NMR structure of a synthetic small molecule, rbt203, bound to HIV-1 TAR RNA
1ILO	;		;	NMR structure of a thioredoxin, MtH895, from the archeon Methanobacterium thermoautotrophicum strain delta H.
7KW8	;		;	NMR Structure of a tRNA 2'-phosphotransferase from Runella slithyformis
7KW9	;		;	NMR Structure of a tRNA 2'-phosphotransferase from Runella slithyformis in complex with NAD+
2M88	;		;	NMR structure of a two-domain RNA-binding fragment of Nrd1
2MDF	;		;	NMR structure of a two-transmembrane segment TM VI-VII of NHE1
1U6U	;		;	NMR structure of a V3 (IIIB isolate) peptide bound to 447-52D, a human HIV-1 neutralizing antibody
1U6V	;		;	NMR structure of a V3 (IIIB isolate) peptide bound to 447-52D, a human HIV-1 neutralizing antibody
1NIZ	;		;	NMR structure of a V3 (MN isolate) peptide bound to 447-52D, a human HIV-1 neutralizing antibody
1NJ0	;		;	NMR structure of a V3 (MN isolate) peptide bound to 447-52D, a human HIV-1 neutralizing antibody
1SP2	;		;	NMR STRUCTURE OF A ZINC FINGER DOMAIN FROM TRANSCRIPTION FACTOR SP1F2, MINIMIZED AVERAGE STRUCTURE
1SP1	;		;	NMR STRUCTURE OF A ZINC FINGER DOMAIN FROM TRANSCRIPTION FACTOR SP1F3, MINIMIZED AVERAGE STRUCTURE
1XRZ	;		;	NMR Structure of a Zinc Finger with Cyclohexanylalanine Substituted for the Central Aromatic Residue
2L7Z	;		;	NMR Structure of A13 homedomain
8DHZ	;		;	NMR Structure of Ac-hGal(17-30)NH2, an N-terminally acetylated fragment of the C-terminus of human galanin
1OVF	;		;	NMR Structure of ActD/5'-CCGTTTTGTGG-3' Complex
2N57	;		;	NMR structure of Acyl carrier protein from Brucella melitensis
2K3Z	;		;	NMR structure of adenosine bulged RNA duplex with C:G-A triple
2KH3	;		;	NMR Structure of Aflatoxin Formamidopyrimidine alpha-anomer in duplex DNA
2KPQ	;		;	NMR Structure of Agrobacterium tumefaciens protein Atu1219: Northeast Structural Genomics Consortium target AtT14
2Z3S	;		;	NMR structure of AgTx2-MTX
2LCR	;		;	NMR Structure of Alk1 extracellular domain
1YX3	;		;	NMR structure of Allochromatium vinosum DsrC: Northeast Structural Genomics Consortium target OP4
6OTB	;		;	NMR structure of alpha conotoxin SII
1IK8	;		;	NMR structure of Alpha-Bungarotoxin
1IKC	;		;	NMR Structure of alpha-Bungarotoxin
2LLR	;		;	NMR structure of Alvinellacin
1L4W	;		;	NMR structure of an AChR-peptide (Torpedo Californica, alpha-subunit residues 182-202) in complex with alpha-Bungarotoxin
1LJZ	;		;	NMR structure of an AChR-peptide (Torpedo Californica, alpha-subunit residues 182-202) in complex with alpha-Bungarotoxin
2LOL	;		;	NMR structure of an acyl-carrier protein from Rickettsia prowazekii, Seattle Structural Genomics Center for Infectious Disease (SSGCID)
1OKF	;		;	NMR structure of an alpha-L-LNA:RNA hybrid
1TFQ	;		;	NMR Structure of an Antagonists of the XIAP-Caspase-9 Interaction Complexed to the BIR3 domain of XIAP
1TFT	;		;	NMR Structure of an Antagonists of the XIAP-Caspase-9 Interaction Complexed to the BIR3 domain of XIAP
1JVE	;		;	NMR Structure of an AT-Rich DNA with the GAA-Hairpin Loop
1D7T	;		;	NMR STRUCTURE OF AN ENGINEERED CONTRYPHAN CYCLIC PEPTIDE (MOTIF CPXXPXC)
5NZ9	;		;	NMR structure of an EphA2-Sam fragment
1EQ1	;		;	NMR STRUCTURE OF AN EXCHANGEABLE APOLIPOPROTEIN-MANDUCA SEXTA APOLIPOPHORIN-III
2M9P	;		;	NMR structure of an inhibitor bound dengue NS3 protease
2M9Q	;		;	NMR structure of an inhibitor bound dengue NS3 protease
1GN7	;		;	NMR STRUCTURE OF AN INTRAMOLECULAR DNA TRIPLEX CONTAINING AN N7-GLYCOSYLATED GUANINE, 8 STRUCTURES
2G2K	;		;	NMR structure of an N-terminal fragment of the eukaryotic initiation factor 5 (eIF5)
2MYQ	;		;	NMR structure of an Odin-Sam1 fragment
6F7O	;		;	NMR structure of an Odin-Sam1 stapled peptide
1G5D	;		;	NMR STRUCTURE OF AN OLIGONUCLEOTIDE CONTAINING AN ABASIC SITE: ALPHA ANOMER
1GIZ	;		;	NMR STRUCTURE OF AN OLIGONUCLEOTIDE CONTAINING AN ABASIC SITE: ALPHA ANOMER
1G5E	;		;	NMR STRUCTURE OF AN OLIGONUCLEOTIDE CONTAINING AN ABASIC SITE: BETA ANOMER
1GJ0	;		;	NMR STRUCTURE OF AN OLIGONUCLEOTIDE CONTAINING AN ABASIC SITE: BETA ANOMER
7BEV	;		;	NMR structure of an optimized version of the first TPR domain of the human SPAG1 protein
2K6H	;		;	NMR structure of an unusually 28 kDa Active Mutant of Maize Ribosome-Inactivating protein (MOD)
2LMT	;		;	NMR structure of Androcam
7N21	;		;	NMR structure of AnIB-OH
7N22	;		;	NMR structure of AnIB[Y(SO3)16Y]-NH2
7N23	;		;	NMR structure of AnIB[Y(SO3)16Y]-OH
2JPO	;		;	NMR structure of Antheraea polyphemus pheromone-binding protein 1 at pH 4.5
2M1F	;		;	NMR Structure of Antiamoebin I (peptaibol antibiotic) bound to DMPC/DHPC bicelles
2NY8	;		;	NMR structure of antibacterial defensin DEF-AAA from the insect anopheles gambiae
5IX5	;		;	NMR structure of antibacterial factor-2
1OZZ	;		;	NMR structure of antifungal defensin ARD1 from Archaeoprepona demophon
1XKM	;		;	NMR structure of antimicrobial peptide distinctin in water
1ZO0	;		;	NMR structure of antizyme isoform 1 from rat
1LKJ	;		;	NMR Structure of Apo Calmodulin from Yeast Saccharomyces cerevisiae
1ILF	;		;	NMR STRUCTURE OF APO CBFB
1B4M	;		;	NMR STRUCTURE OF APO CELLULAR RETINOL-BINDING PROTEIN II, 24 STRUCTURES
1AEL	;		;	NMR STRUCTURE OF APO INTESTINAL FATTY ACID-BINDING PROTEIN, 20 STRUCTURES
5T43	;		;	NMR Structure of Apo-form Human Tear Lipocalin
5TGW	;		;	NMR structure of apo-PS1
2MZZ	;		;	NMR structure of APOBEC3G NTD variant, sNTD
1LS4	;		;	NMR structure of apolipophorin-III from Locusta migratoria
1SOU	;		;	NMR structure of Aquifex aeolicus 5,10-methenyltetrahydrofolate synthetase: Northeast Structural Genomics Consortium Target QR46
1GAC	;		;	NMR structure of asymmetric homodimer of a82846b, a glycopeptide antibiotic, complexed with its cell wall pentapeptide fragment
2LI5	;		;	NMR structure of Atg8-Atg7C30 complex
2KPH	;		;	NMR Structure of AtraPBP1 at pH 4.5
6GS9	;		;	NMR structure of aurein 2.5 in SDS micelles
2MLI	;		;	NMR structure of B25-(alpha, beta)-dehydro-phenylalanine insulin
2MPB	;		;	NMR structure of BA42 protein from the psychrophilic bacteria Bizionia argentinensis sp. nov
2LT2	;		;	NMR structure of BA42 protein from the psychrophilic bacteria Bizionia argentinensis sp. nov.
2HEQ	;		;	NMR Structure of Bacillus subtilis protein YorP, Northeast Structural Genomics Target SR399.
2DSM	;		;	NMR Structure of Bacillus Subtilis Protein YqaI, Northeast Structural Genomics Target SR450
2HJQ	;		;	NMR Structure of Bacillus Subtilis Protein YqbF, Northeast Structural Genomics Target SR449
1T8J	;		;	NMR Structure of BBA5, A Compact, Independently Folded BBA Motif
6QS0	;		;	NMR structure of BB_A03, Borrelia burgdorferi outer surface lipoprotein
6QBI	;		;	NMR structure of BB_P28, Borrelia burgdorferi outer surface lipoprotein
2LCU	;		;	NMR structure of BC28.1
2LPC	;		;	NMR STRUCTURE of Bcl-XL
1LXL	;		;	NMR STRUCTURE OF BCL-XL, AN INHIBITOR OF PROGRAMMED CELL DEATH, MINIMIZED AVERAGE STRUCTURE
2M98	;		;	NMR Structure of BeF3 Activated Sma0114
2MDV	;		;	NMR structure of beta alpha alpha 38
7LGV	;		;	NMR structure of Beta-KTx14.3
6QBL	;		;	NMR Structure of Big-defensin 1 from oyster Crassostrea gigas
6QBK	;		;	NMR Structure of Big-defensin 1 [44-93] from oyster Crassostrea gigas
8BGK	;		;	NMR Structure of Big-defensin 5 from oyster Crassostrea gigas
6UF2	;		;	NMR structure of biofilm-related Se0862 from Synechococcus elongatus
2J5D	;		;	NMR structure of BNIP3 transmembrane domain in lipid bicelles
1HKO	;		;	NMR structure of bovine cytochrome b5
1JV8	;		;	NMR Structure of BPTI Mutant G37A
1JV9	;		;	NMR Structure of BPTI Mutant G37A
6OQ2	;		;	NMR Structure of Branched K11/K48-Linked Tri-Ubiquitin
1BI6	;		;	NMR STRUCTURE OF BROMELAIN INHIBITOR VI FROM PINEAPPLE STEM
2MFZ	;		;	NMR structure of C-terminal domain from A. ventricosus minor ampullate spidroin (MiSp)
2J8P	;		;	NMR structure of C-terminal domain of human CstF-64
6V1W	;		;	NMR Structure of C-terminal Domain of phi29 ATPase
1RQS	;		;	NMR structure of C-terminal domain of ribosomal protein L7 from E.coli
1XWE	;		;	NMR Structure of C345C (NTR) domain of C5 of complement
2M28	;		;	NMR structure of Ca2+ bound CaBP4 C-domain
2M29	;		;	NMR structure of Ca2+ bound CaBP4 N-domain
2K7D	;		;	NMR Structure of Ca2+-bound CaBP1 C-domain
2LAP	;		;	NMR structure of Ca2+-bound CaBP1 C-domain with RDC
2LAN	;		;	NMR structure of Ca2+-bound CaBP1 N-domain with RDC
1AWY	;		;	NMR STRUCTURE OF CALCIUM BOUND CONFORMER OF CONANTOKIN G, MINIMIZED AVERAGE STRUCTURE
1CFI	;		;	NMR STRUCTURE OF CALCIUM ION-BOUND GAMMA-CARBOXY-GLUTAMIC ACID-RICH DOMAIN OF FACTOR IX
2LCP	;		;	NMR structure of calcium loaded, un-myristoylated human NCS-1
2K60	;		;	NMR structure of calcium-loaded STIM1 EF-SAM
2L5Y	;		;	NMR structure of calcium-loaded STIM2 EF-SAM.
8DGH	;		;	NMR Structure of calmodulin bound to C-terminal site in the beta-subunit of cyclic nucleotide-gated channel
8DGK	;		;	NMR structure of calmodulin bound to N-terminal site in the beta-subunit of cyclic nucleotide-gated channel
1YX8	;		;	NMR structure of Calsensin, 20 low energy structures.
1YX7	;		;	NMR structure of Calsensin, energy minimized average structure.
2LUS	;		;	NMR structure of Carcinoscorpius rotundicauda thioredoxin related protein 16 and its role in regulating transcription factor NF-kB activity
2NPL	;		;	NMR Structure of CARD d2 Domain
1FFJ	;		;	NMR STRUCTURE OF CARDIOTOXIN IN DPC-MICELLE
6FS5	;		;	NMR structure of Casocidin-I antimicrobial peptide in 60% TFE
6FS4	;		;	NMR structure of Casocidin-II antimicrobial peptide in 60% TFE
2HGO	;		;	NMR structure of Cassiicolin
2WC2	;		;	Nmr structure of catabolite activator protein in the unliganded state
1JSP	;		;	NMR Structure of CBP Bromodomain in complex with p53 peptide
1R8U	;		;	NMR structure of CBP TAZ1/CITED2 complex
2KJE	;		;	NMR structure of CBP TAZ2 and adenoviral E1A complex
2M6U	;		;	NMR Structure of CbpAN from Streptococcus pneumoniae
2AVG	;		;	NMR structure of cC1 domain from Human Cardiac Myosin Binding Protein C
2RLP	;		;	NMR structure of CCP modules 1-2 of complement factor H
2RLQ	;		;	NMR structure of CCP modules 2-3 of complement factor H
2N5R	;		;	NMR structure of cFLIP-derived calmodulin binding peptide
2GJH	;		;	NMR Structure of CFr (C-terminal fragment of computationally designed novel-topology protein Top7)
2JSS	;		;	NMR structure of chaperone Chz1 complexed with histone H2A.Z-H2B
2LG5	;		;	NMR structure of Chicken AvBD2 defensin
2LG6	;		;	NMR structure of chicken AvBD2-K31A mutant
5LCS	;		;	NMR structure of Chicken AvBD7 defensin
6R2X	;		;	NMR structure of Chromogranin A (F39-D63)
2KNZ	;		;	NMR structure of CIP75 UBA domain
2JN3	;		;	NMR structure of cl-BABP complexed to chenodeoxycholic acid
2LFO	;		;	NMR structure of cl-BABP/SS complexed with glycochenodeoxycholic and glycocholic acids
2JOV	;		;	NMR Structure of Clostridium Perfringens Protein CPE0013. Northeast Structural Genomics Target CpR31.
2N71	;		;	NMR structure of CmPI-II, a serin protease inhibitor isolated from mollusk Cenchitis muricatus
5O6F	;		;	NMR structure of cold shock protein A from Corynebacterium pseudotuberculosis
1DFY	;		;	NMR STRUCTURE OF CONTRYPHAN-SM CYCLIC PEPTIDE (MAJOR FORM-CIS)
1DFZ	;		;	NMR STRUCTURE OF CONTRYPHAN-SM CYCLIC PEPTIDE (MINOR FORM-TRANS)
2MN5	;		;	NMR structure of Copsin
1S4J	;		;	NMR structure of cross-reactive peptides from Homo sapiens
1S4H	;		;	NMR structure of cross-reactive peptides from L. braziliensis
7TA8	;		;	NMR structure of crosslinked cyclophilin A
2MWT	;		;	NMR structure of crotalicidin in DPC micelles
7SUP	;		;	NMR structure of cTnC-TnI chimera bound to calcium and A1
7SVC	;		;	NMR structure of cTnC-TnI chimera bound to calcium and A2
1I02	;		;	NMR STRUCTURE OF CTX A3 AT NEUTRAL PH (20 STRUCTURES)
1RJT	;		;	NMR Structure of CXC Chemokine CXCL11/ITAC
1EVA	;		;	NMR structure of cyanobacterial toxin, phosphatase-1/-2A inhibitor
1EVB	;		;	NMR structure of cyanobacterial toxin, phosphatase-1/-2A inhibitor
1EVC	;		;	NMR structure of CYANOBACTERIAL TOXIN, PHOSPHATASE-1/-2A INHIBITOR
1EVD	;		;	NMR structure of CYANOBACTERIAL TOXIN, PHOSPHATASE-1/-2A INHIBITOR
1H9C	;		;	NMR structure of cysteinyl-phosphorylated enzyme IIB of the N,N'-diacetylchitobiose specific phosphoenolpyruvate-dependent phosphotransferase system of Escherichia coli.
6RC7	;		;	NMR structure of cytotoxin 3 from Naja kaouthia in solution, major form
1GJ1	;		;	NMR structure of d(CCAAAGXACTGGG), X is a 3'phosphoglycolate, 5'phosphate gapped lesion
1N0O	;		;	NMR Structure of d(CCAAGGXCTTGGG), X is a 3'-phosphoglycolate, 5'-phosphate gapped lesion, 10 structures
1SKP	;		;	NMR STRUCTURE OF D(GCATATGATAG)(DOT)D(CTATCATATGC): A CONSENSUS SEQUENCE FOR PROMOTERS RECOGNIZED BY SIGMA-K RNA POLYMERASE, 4 STRUCTURES
1EKH	;		;	NMR STRUCTURE OF D(TTGGCCAA)2 BOUND TO CHROMOMYCIN-A3 AND COBALT
1HOD	;		;	NMR STRUCTURE OF D130I MUTANT T3-I2, A 32 RESIDUE PEPTIDE FROM THE ALPHA 2A ADRENERGIC RECEPTOR
7A05	;		;	NMR structure of D3-D4 domains of Vibrio vulnificus ribosomal protein S1
2E4E	;		;	NMR structure of D4P/K7G mutant of GPM12
6MK8	;		;	NMR structure of Database designed and improved anti-Staphylococcal peptide DFT503 bound to micelles
2NY9	;		;	NMR structure of DEF-ABB, a mutant of anopheles defensin DEF-AAA
2NZ3	;		;	NMR structure of DEF-AcAA, a mutant of anopheles defensin DEF-AAA
2E3F	;		;	NMR structure of DEF-BAT, a mutant of anopheles defensin DEF-AAA
2E3E	;		;	NMR structure of DEF-BBB, a mutant of anopheles defensin DEF-AAA
2E3G	;		;	NMR structure of DEF-DAA, a mutant of anopheles defensin DEF-AAA
2KAM	;		;	NMR structure of delta-toxin from Staphylococcus aureus in CD3OH
2RT4	;		;	NMR Structure of designed protein, AF.2A1, (Ensembles)
1UAO	;		;	NMR Structure of designed protein, Chignolin, consisting of only ten amino acids (Ensembles)
1DG0	;		;	NMR STRUCTURE OF DES[GLY1]-CONTRYPHAN-R CYCLIC PEPTIDE (MAJOR FORM)
1KOY	;		;	NMR structure of DFF-C domain
1IBX	;		;	NMR STRUCTURE OF DFF40 AND DFF45 N-TERMINAL DOMAIN COMPLEX
1RQT	;		;	NMR structure of dimeric N-terminal domain of ribosomal protein L7 from E.coli
2W1O	;		;	NMR structure of dimerization domain of human ribosomal protein P2
1CP8	;		;	NMR STRUCTURE OF DNA (5'-D(TTGGCCAA)2-3') COMPLEXED WITH NOVEL ANTITUMOR DRUG UCH9
1TQR	;		;	NMR Structure of DNA 17-mer GGAAAATCTCTAGCAGT corresponding to the extremity of the U5 LTR of the HIV-1 genome
2MCI	;		;	NMR structure of DNA duplex
1K9H	;		;	NMR structure of DNA TGTGAGCGCTCACA
1S6N	;		;	NMR Structure of Domain III of the West Nile Virus Envelope Protein, Strain 385-99
2LJH	;		;	NMR structure of Double-stranded RNA-specific editase Adar
2DX3	;		;	NMR structure of DP5_conformation1: monomeric alpha-helix
2DX4	;		;	NMR structure of DP5_conformation2: monomeric beta-hairpin
2JUL	;		;	NMR Structure of DREAM
2LSZ	;		;	NMR structure of duplex DNA containing the alpha-OH-PdG dA base pair: A mutagenic intermediate of acrolein
2LT0	;		;	NMR structure of duplex DNA containing the beta-OH-PdG dA base pair: A mutagenic intermediate of acrolein
1N0K	;		;	NMR Structure of duplex DNA d(CCAAGGXCTTGGG), X is a 3' phosphoglycolate, 5'phosphate gapped lesion
1ZGW	;		;	NMR structure of E. Coli Ada protein in complex with DNA
2MII	;		;	NMR structure of E. coli LpoB
2M4Q	;		;	NMR structure of E. coli ribosomela decoding site with apramycin
2MLY	;		;	NMR structure of E. coli Trigger Factor in complex with unfolded PhoA1-150
2MLX	;		;	NMR structure of E. coli Trigger Factor in complex with unfolded PhoA220-310
2MLZ	;		;	NMR structure of E. coli Trigger Factor in complex with unfolded PhoA365-471
2JOE	;		;	NMR Structure of E. Coli YehR Protein. Northeast Structural Genomics Target ER538.
2HTJ	;		;	NMR structure of E.coli PapI
2JNE	;		;	NMR structure of E.coli YfgJ modelled with two Zn+2 bound. Northeast Structural Genomics Consortium Target ER317.
2RLJ	;		;	NMR Structure of Ebola fusion peptide in SDS micelles at pH 7
2RVH	;		;	NMR structure of eIF1
5H7U	;		;	NMR structure of eIF3 36-163
2MBH	;		;	NMR structure of EKLF(22-40)/Ubiquitin Complex
2JMS	;		;	NMR Structure of En-6 pheromone from the Antarctic Ciliate Euplotes nobilii
5L82	;		;	NMR Structure of Enterocin K1 in 50%/50% TFE/Water
1TVM	;		;	NMR structure of enzyme GatB of the galactitol-specific phosphoenolpyruvate-dependent phosphotransferase system
6F7M	;		;	NMR structure of EphA2-Sam stapled peptides (S13ST)
6F7N	;		;	NMR structure of EphA2-Sam stapled peptides (S13STshort)
7N25	;		;	NMR structure of EpI-OH
7N26	;		;	NMR structure of EpI-[Y(SO3)15Y]-NH2
2RVJ	;		;	NMR structure of Epithelial splicing regulatory protein 1
7N0T	;		;	NMR structure of EpI[Y(SO)315Y]-OH
1G7D	;		;	NMR STRUCTURE OF ERP29 C-DOMAIN
2KXX	;		;	NMR Structure of Escherichia coli BamE, a Lipoprotein Component of the beta-Barrel Assembly Machinery Complex
3GRX	;		;	NMR STRUCTURE OF ESCHERICHIA COLI GLUTAREDOXIN 3-GLUTATHIONE MIXED DISULFIDE COMPLEX, 20 STRUCTURES
1P0A	;		;	NMR structure of ETD135, mutant of the antifungal defensin ARD1 from Archaeoprepona demophon
1P00	;		;	NMR structure of ETD151, mutant of the antifungal defensin ARD1 from Archaeoprepona demophon
5J8T	;		;	NMR structure of Excalibur domain of CbpL
1MOT	;		;	NMR Structure Of Extended Second Transmembrane Domain Of Glycine Receptor alpha1 Subunit in SDS Micelles
2KD2	;		;	NMR Structure of FAIM-CTD
1W7D	;		;	NMR Structure of Fasciclin-Like Protein From Rhodobacter sphaeroides
2N4U	;		;	NMR structure of Fbp28 WW domain E454Y mutant
2N4R	;		;	NMR structure of Fbp28 WW domain L453D mutant
2N4S	;		;	NMR structure of Fbp28 WW domain L453E mutant
2N4T	;		;	NMR structure of Fbp28 WW domain L453W mutant
2N4V	;		;	NMR structure of Fbp28 WW domain T456D mutant
2N4W	;		;	NMR structure of Fbp28 WW domain T456Y mutant
2MWF	;		;	NMR structure of FBP28 WW2 mutant Y438R DN
2MWD	;		;	NMR structure of FBP28 WW2 mutant Y438R DNDC
2MWE	;		;	NMR structure of FBP28 WW2 mutant Y438R, L453A DNDC
2MWA	;		;	NMR structure of FBP28 WW2 mutant Y446L
2MW9	;		;	NMR structure of FBP28 WW2 Y438R mutant
2K4Y	;		;	NMR Structure of FeoA-like protein from Clostridium acetobutylicum: Northeast Structural Genomics Consortium Target CaR178
2RSE	;		;	NMR structure of FKBP12-mTOR FRB domain-rapamycin complex structure determined based on PCS
7A0O	;		;	NMR structure of flagelliform spidroin (FlagSp) N-terminal domain from Trichonephila clavipes at pH 5.5
7A0I	;		;	NMR structure of flagelliform spidroin (FlagSp) N-terminal domain from Trichonephila clavipes at pH 7.2
1VDB	;		;	NMR structure of FMBP-1 tandem repeat 1 in 30%(v/v) TFE solution
1WNM	;		;	NMR structure of FMBP-1 tandem repeat 2 in 30%(v/v) TFE solution
1WNK	;		;	NMR Structure of FMBP-1 Tandem repeat 3 in 30%(V/V) TFE solution
1WNN	;		;	NMR structure of fmbp-1 tandem repeat 4 in 30%(v/v) TFE solution
5JYT	;		;	NMR structure of foldswitch-stablized KaiB from Thermosynechococcus elongatus
5JYV	;		;	NMR structure of foldswitch-stablized KaiB in complex with pseudo receiver domain of CikA from Thermosynechococcus elongatus
2LQH	;		;	NMR structure of FOXO3a transactivation domains (CR2C-CR3) in complex with CBP KIX domain (2b3l conformation)
2LQI	;		;	NMR structure of FOXO3a transactivation domains (CR2C-CR3) in complex with CBP KIX domain (2l3b conformation)
2KFQ	;		;	NMR Structure of FP1
2KJ8	;		;	NMR structure of fragment 87-196 from the putative phage integrase IntS of E. coli: Northeast Structural Genomics Consortium target ER652A, PSI-2
2L7B	;		;	NMR Structure of full length apoE3
2KAL	;		;	NMR structure of fully methylated GATC site
2L4Z	;		;	NMR structure of fusion of CtIP (641-685) to LMO4-LIM1 (18-82)
1XOO	;		;	NMR structure of G1S mutant of influenza hemagglutinin fusion peptide in DPC micelles at pH 5
1XOP	;		;	NMR structure of G1V mutant of influenza hemagglutinin fusion peptide in DPC micelles at pH 5
2KAJ	;		;	NMR structure of gallium substituted ferredoxin
2ABO	;		;	NMR structure of gamma herpesvirus 68 a viral Bcl-2 homolog
7M2M	;		;	NMR Structure of GCAP5
1TM9	;		;	NMR Structure of gene target number gi3844938 from Mycoplasma genitalium: Berkeley Structural Genomics Center
7NRN	;		;	NMR structure of GIPC1-GH2 domain
1IYY	;		;	NMR STRUCTURE OF Gln25-RIBONUCLEASE T1, 24 STRUCTURES
1ID8	;		;	NMR STRUCTURE OF GLUTAMATE MUTASE (B12-BINDING SUBUNIT) COMPLEXED WITH THE VITAMIN B12 NUCLEOTIDE
1EGS	;		;	NMR STRUCTURE OF GROES MOBILE LOOP RESIDUES 19-27 IN THE SYNTHETIC PEPTIDE (RESIDUES 13-32) BOUND TO GROEL, 20 STRUCTURES
1X0N	;		;	NMR structure of growth factor receptor binding protein SH2 domain complexed with the inhibitor
2NA0	;		;	NMR structure of Guanylyl Cyclase Activator Protein 1 (GCAP1) mutant V77E in a Ca2+-free/Mg2+-bound Activator State
2L2F	;		;	NMR Structure of GzCVNH (Gibberella zeae CVNH)
2KP5	;		;	NMR structure of Hahellin, a beta-gamma crystallin
7L8V	;		;	NMR Structure of half-calcified calmodulin mutant (CaMEF12) bound to the IQ-motif of CaV1.2
2ITH	;		;	NMR Structure of Haloferax volcanii DHFR
1IDV	;		;	NMR structure of HCV ires RNA domain IIIC
2LVG	;		;	NMR structure of HCV Non-structural protein AB, NS4B(1-40)
2KYZ	;		;	NMR structure of heavy metal binding protein TM0320 from Thermotoga maritima
1X93	;		;	NMR Structure of Helicobacter pylori HP0222
2K1O	;		;	NMR Structure of Helicobacter pylori JHP0511 (HP0564).
1NBL	;		;	NMR Structure of Hellethionin D
1IBN	;		;	NMR STRUCTURE OF HEMAGGLUTININ FUSION PEPTIDE IN DPC MICELLES AT PH 5
1IBO	;		;	NMR STRUCTURE OF HEMAGGLUTININ FUSION PEPTIDE IN DPC MICELLES AT PH 7.4
1OQ2	;		;	NMR structure of hemimethylated GATC site
1UAB	;		;	NMR structure of hemimethylated GATC site
2MJK	;		;	Nmr structure of hen egg beta-defensin gallin (chicken ovo-defensin)
1B9P	;		;	NMR STRUCTURE OF HEPARIN BINDING SITE OF NON COLLAGENOUS DOMAIN I (NC1) OF COLLAGEN FACIT XIV
1B9Q	;		;	NMR STRUCTURE OF HEPARIN BINDING SITE OF NON COLLAGENOUS DOMAIN I (NC1) OF COLLAGEN FACIT XIV
2K1Q	;		;	NMR structure of hepatitis c virus ns3 serine protease complexed with the non-covalently bound phenethylamide inhibitor
2K40	;		;	NMR structure of HESX-1 homeodomain double mutant R31L/E42L
2KMZ	;		;	NMR Structure of hFn14
1XAX	;		;	NMR structure of HI0004, a putative essential gene product from Haemophilus influenzae
1JEM	;		;	NMR STRUCTURE OF HISTIDINE PHOSPHORYLATED FORM OF THE PHOSPHOCARRIER HISTIDINE CONTAINING PROTEIN FROM BACILLUS SUBTILIS, NMR, 25 STRUCTURES
1LB0	;		;	NMR Structure of HIV-1 gp41 659-671 13-mer peptide
1LCX	;		;	NMR structure of HIV-1 gp41 659-671 13mer peptide
2LIW	;		;	NMR structure of HMG-ACPI domain from CurA module from Lyngbya majuscula
1MTG	;		;	NMR Structure of HO2-Co(III)bleomycin A(2) bound to d(GAGCTC)(2)
1MXK	;		;	NMR Structure of HO2-Co(III)bleomycin A(2) Bound to d(GGAAGCTTCC)(2)
1EII	;		;	NMR STRUCTURE OF HOLO CELLULAR RETINOL-BINDING PROTEIN II
8A7Z	;		;	NMR structure of holo-acp
8AIG	;		;	NMR structure of holo-acp
8ALL	;		;	NMR structure of holo-acp
2LIU	;		;	NMR structure of holo-ACPI domain from CurA module from Lyngbya majuscula
5TGY	;		;	NMR structure of holo-PS1
6WPO	;		;	NMR Structure of HSP-4 antimicrobial peptide in presence of DPC-d38 micelles
6WPD	;		;	NMR Structure of HSP1-NH2 antimicrobial peptide in presence of DPC-d38 micelles
6WPB	;		;	NMR Structure of HSP1-NH2 antimicrobial peptide in presence of SDS-d25 micelles
2LJL	;		;	NMR structure of Hsp12 in the presence of DPC
4AXP	;		;	NMR structure of Hsp12, a protein induced by and required for dietary restriction-induced lifespan extension in yeast.
7P55	;		;	NMR structure of human ACE2 21-42 fragment in HFIP/water 50/50 v/v
2KHT	;		;	NMR Structure of human alpha defensin HNP-1
5KI0	;		;	NMR structure of human antimicrobial peptide KAMP-19
1I5J	;		;	NMR STRUCTURE OF HUMAN APOLIPOPROTEIN C-II IN THE PRESENCE OF SDS
2PRU	;		;	NMR Structure of Human apoS100B at 10C
1IOX	;		;	NMR Structure of human Betacellulin-2
1IP0	;		;	NMR STRUCTURE OF HUMAN BETACELLULIN-2
1WNJ	;		;	NMR structure of human coactosin-like protein
1Q8G	;		;	NMR structure of human Cofilin
1Q8X	;		;	NMR structure of human cofilin
2NAN	;		;	NMR structure of human DCL-1 (CD302) extracellular domain
1IMO	;		;	NMR STRUCTURE OF HUMAN DNA LIGASE IIIALPHA BRCT DOMAIN
1IN1	;		;	NMR STRUCTURE OF HUMAN DNA LIGASE IIIALPHA BRCT DOMAIN
1K36	;		;	NMR Structure of human Epiregulin
1K37	;		;	NMR Structure of human Epiregulin
1TEY	;		;	NMR structure of human histone chaperone, ASF1A
2HIU	;		;	NMR STRUCTURE OF HUMAN INSULIN IN 20% ACETIC ACID, ZINC-FREE, 10 STRUCTURES
2JV1	;		;	NMR structure of human insulin monomer in 35% CD3CN zinc free, 50 structures
2KJU	;		;	NMR structure of human insulin mutant glu-b21-d-glu, his-b10 asp pro-b28-lys, lys-b29-pro, 20 structures
2L1Y	;		;	NMR Structure of human insulin mutant GLY-B20-D-ALA, GLY-B23-D-ALA PRO-B28-LYS, LYS-B29-PRO, 20 Structures
2L1Z	;		;	NMR Structure of human insulin mutant GLY-B20-D-ALA, GLY-B23-D-ALA PRO-B28-LYS, LYS-B29-PRO, 20 Structures
2KQQ	;		;	NMR structure of human insulin mutant gly-b8-d-ala, his-b10-asp, pro-b28-lys, lys-b29-pro, 20 structures
2HH4	;		;	NMR structure of human insulin mutant GLY-B8-D-SER, HIS-B10-ASP PRO-B28-LYS, LYS-B29-PRO, 20 structures
2HHO	;		;	NMR structure of human insulin mutant GLY-B8-SER, HIS-B10-ASP PRO-B28-LYS, LYS-B29-PRO, 20 structures
2JMN	;		;	NMR structure of human insulin mutant His-B10-Asp, Pro-B28-Lys, Lys-B29-Pro, 20 structures
1T1Q	;		;	NMR STRUCTURE OF HUMAN INSULIN MUTANT HIS-B10-ASP, VAL-B12-ABA, PRO-B28-LYS, LYS-B29-PRO, 15 STRUCTURES
1T1K	;		;	NMR STRUCTURE OF HUMAN INSULIN MUTANT HIS-B10-ASP, VAL-B12-ALA, PRO-B28-LYS, LYS-B29-PRO, 15 STRUCTURES
1T1P	;		;	NMR STRUCTURE OF HUMAN INSULIN MUTANT HIS-B10-ASP, VAL-B12-THR, PRO-B28-LYS, LYS-B29-PRO, 15 STRUCTURES
2H67	;		;	NMR structure of human insulin mutant HIS-B5-ALA, HIS-B10-ASP PRO-B28-LYS, LYS-B29-PRO, 20 structures
1K3M	;		;	NMR STRUCTURE OF HUMAN INSULIN MUTANT ILE-A2-ALA, HIS-B10-ASP, PRO-B28-LYS, LYS-B29-PRO, 15 STRUCTURES
1KMF	;		;	NMR STRUCTURE OF HUMAN INSULIN MUTANT ILE-A2-ALLO-ILE, HIS-B10-ASP, PRO-B28-LYS, LYS-B29-PRO, 15 STRUCTURES
1LKQ	;		;	NMR STRUCTURE OF HUMAN INSULIN MUTANT ILE-A2-GLY, VAL-A3-GLY, HIS-B10-ASP, PRO-B28-LYS, LYS-B29-PRO, 20 STRUCTURES
1SF1	;		;	NMR STRUCTURE OF HUMAN INSULIN under Amyloidogenic Condition, 15 STRUCTURES
2K21	;		;	NMR structure of human KCNE1 in LMPG micelles at pH 6.0 and 40 degree C
8K6Z	;		;	NMR structure of human leptin
2MHS	;		;	NMR Structure of human Mcl-1
1B50	;		;	NMR STRUCTURE OF HUMAN MIP-1A D26A, 10 STRUCTURES
1B53	;		;	NMR STRUCTURE OF HUMAN MIP-1A D26A, MINIMIZED AVERAGE STRUCTURE
1EQ3	;		;	NMR STRUCTURE OF HUMAN PARVULIN HPAR14
2M65	;		;	NMR structure of human restriction factor APOBEC3A
2BZE	;		;	NMR Structure of human RTF1 PLUS3 domain.
2JXD	;		;	NMR structure of human Serine protease inhibitor Kazal type II (SPINK2)
2MD7	;		;	NMR structure of human Sp140 PHD finger trans conformer
4BS2	;		;	NMR structure of human TDP-43 tandem RRMs in complex with UG-rich RNA
2KXN	;		;	NMR structure of human Tra2beta1 RRM in complex with AAGAAC RNA
1Y32	;		;	NMR structure of humanin in 30% TFE solution
2FQH	;		;	NMR structure of hypothetical protein TA0938 from Termoplasma acidophilum
2LBQ	;		;	NMR structure of i6A37_tyrASL
1JJS	;		;	NMR Structure of IBiD, A Domain of CBP/p300
2N78	;		;	NMR structure of IF1 from Pseudomonas aeruginosa
2LQR	;		;	NMR structure of Ig3 domain of palladin
2JT9	;		;	NMR structure of immunosuppressory peptide containing cyclolinopeptide X and antennapedia(43-58) sequences
2JTA	;		;	NMR structure of immunosuppressory ubiquitin fragment is similar to related ubiquitin region.
2DCI	;		;	NMR structure of influenza HA fusion peptide mutant W14A in DPC in pH5
2KJ9	;		;	NMR structure of IntB phage-integrase-like protein fragment 90-199 from Erwinia carotova subsp. atroseptica: Northeast Structural Genomics Consortium target EwR217E
1GA3	;		;	NMR STRUCTURE OF INTERLEUKIN-13
1URE	;		;	NMR STRUCTURE OF INTESTINAL FATTY ACID-BINDING PROTEIN COMPLEXED WITH PALMITATE, 20 STRUCTURES
1C89	;		;	NMR STRUCTURE OF INTRAMOLECULAR DIMER ANTIFREEZE PROTEIN RD3, 40 SA STRUCTURES
1C8A	;		;	NMR STRUCTURE OF INTRAMOLECULAR DIMER ANTIFREEZE PROTEIN RD3, 40 SA STRUCTURES
2JTU	;		;	NMR structure of iota-RXIA(38)
5ZFO	;		;	NMR structure of IRD12 from Capsicum annum.
2MNY	;		;	NMR Structure of KDM5B PHD1 finger
2MNZ	;		;	NMR Structure of KDM5B PHD1 finger in complex with H3K4me0(1-10aa)
1F53	;		;	NMR STRUCTURE OF KILLER TOXIN-LIKE PROTEIN SKLP
1MZK	;		;	NMR structure of kinase-interacting FHA domain of kinase associated protein phosphatase, KAPP in Arabidopsis
2MSU	;		;	NMR structure of Kindlin-2 F2 339-358
5Y70	;		;	NMR structure of KMP11 in DPC micelle
2N5G	;		;	NMR structure of KorA, a plasmid-encoded, global transcription regulator KorA
2NA3	;		;	NMR Structure of KR-12: A minimalized domain derived from the human cathelicidin LL-37
6T51	;		;	NMR structure of KRAS22RT G-quadruplex forming within KRAS promoter region at physological temperature
6T2G	;		;	NMR structure of KRAS32R G25T conformer G-quadruplex within KRAS promoter region
6SUU	;		;	NMR structure of KRAS32R G9T conformer G-quadruplex within KRAS promoter region
2NCU	;		;	NMR structure of KYE21 in LPS micelles
1FOX	;		;	NMR STRUCTURE OF L11-C76, THE C-TERMINAL DOMAIN OF 50S RIBOSOMAL PROTEIN L11, 33 STRUCTURES
1FOW	;		;	NMR STRUCTURE OF L11-C76, THE C-TERMINAL DOMAIN OF 50S RIBOSOMAL PROTEIN L11, MINIMIZED AVERAGE STRUCTURE
1ZL8	;		;	NMR structure of L27 heterodimer from C. elegans Lin-7 and H. sapiens Lin-2 scaffold proteins
8TYI	;		;	NMR structure of L5pG ([p23W, G24W]kalata B1)
1RQU	;		;	NMR structure of L7 dimer from E.coli
1CJG	;		;	NMR STRUCTURE OF LAC REPRESSOR HP62-DNA COMPLEX
2MAI	;		;	NMR structure of lassomycin
2RRS	;		;	NMR Structure of LC4 transmembrane segment of CCR5
2KDY	;		;	NMR structure of LP2086-B01
2BGF	;		;	NMR structure of Lys48-linked di-ubiquitin using chemical shift perturbation data together with RDCs and 15N-relaxation data
2MAG	;		;	NMR STRUCTURE OF MAGAININ 2 IN DPC MICELLES, 10 STRUCTURES
2LTH	;		;	NMR structure of major ampullate spidroin 1 N-terminal domain at pH 5.5
2LPJ	;		;	NMR structure of major ampullate spidroin 1 N-terminal domain at pH 7.2
2KDE	;		;	NMR structure of major S5a (196-306):K48 linked diubiquitin species
1ZPX	;		;	NMR Structure of Mcol1-[13-33] from Hydra
2LZG	;		;	NMR Structure of Mdm2 (6-125) with Pip-1
1A11	;		;	NMR STRUCTURE OF MEMBRANE SPANNING SEGMENT 2 OF THE ACETYLCHOLINE RECEPTOR IN DPC MICELLES, 10 STRUCTURES
2N7Y	;		;	NMR structure of metal-binding domain 1 of ATP7B
1AD7	;		;	NMR STRUCTURE OF METAL-FREE CONANTOKIN G, 1 STRUCTURE
1PLX	;		;	NMR structure of Methionine-Enkephalin in fast tumbling Bicelles/DMPG
1PLW	;		;	NMR structure of Methionine-Enkephalin in fast tumbling DMPC/DHPC bicelles
2K7C	;		;	NMR Structure of Mg2+-bound CaBP1 C-domain
2K7B	;		;	NMR structure of Mg2+-bound CaBP1 N-domain
2KNJ	;		;	NMR structure of microplusin a antimicrobial peptide from Rhipicephalus (Boophilus) microplus
2DWF	;		;	NMR structure of Mini-B, an N-terminal- C-terminal construct from human Surfactant Protein B (SP-B), in Sodium dodecyl sulfate (SDS) micelles
2JOU	;		;	NMR structure of Mini-B, an N-terminal- C-terminal construct from human Surfactant Protein-B (SP-B), in Hexafluoroisopropanol (HFIP)
2KDF	;		;	NMR structure of minor S5a (196-306):K48 linked diubiquitin species
1YGM	;		;	NMR structure of Mistic
6SGO	;		;	NMR structure of MLP124017
1RSF	;		;	NMR Structure of Monomeric CAR d1 domain
2GTV	;		;	NMR structure of monomeric chorismate mutase from Methanococcus jannaschii
5UKE	;		;	NMR structure of monomeric human IRAK-M Death Domain R56D, Y61E mutant
2L2C	;		;	NMR Structure of mosquito odorant binding protein bound to MOP pheromone
1I17	;		;	NMR STRUCTURE OF MOUSE DOPPEL 51-157
2KOH	;		;	NMR structure of mouse Par3-PDZ3 in complex with VE-Cadherin C-terminus
1JRM	;		;	NMR structure of MTH0637. Ontario Centre for Structural Proteomics target MTH0637_1_104; Northeast Structural Genomics Target TT135
1SIY	;		;	NMR structure of mung bean non-specific lipid transfer protein 1
1ZWM	;		;	NMR structure of murine gamma-S crystallin
1ZWO	;		;	NMR structure of murine gamma-S crystallin
2A5M	;		;	NMR structure of murine gamma-S crystallin from joint refinement with SAXS data
2BTT	;		;	NMR Structure of MYO3-SH3 domain from Myosin-typeI from S. cerevisiae
2KSS	;		;	NMR structure of Myxococcus xanthus antirepressor CarS1
1G7E	;		;	NMR STRUCTURE OF N-DOMAIN OF ERP29 PROTEIN
1YSM	;		;	NMR Structure of N-terminal domain (Residues 1-77) of Siah-Interacting Protein.
6TV5	;		;	NMR structure of N-terminal domain from A. argentata tubuliform spidroin (TuSp) at pH 5.5
2MX9	;		;	NMR structure of N-terminal domain from A. ventricosus minor ampullate spidroin (MiSp) at pH 5.5
2MX8	;		;	NMR structure of N-terminal domain from A. ventricosus minor ampullate spidroin (MiSp) at pH 7.2
1G03	;		;	NMR STRUCTURE OF N-TERMINAL DOMAIN OF HTLV-I CA1-134
7WIO	;		;	NMR structure of N-terminal domain of Triconephila clavipes of major ampullate spidroin 1
2MAV	;		;	NMR Structure of N2-IQ-dG at the G3 position in the NarI recognition sequence
7N20	;		;	NMR structure of native AnIB
7N24	;		;	NMR structure of native EpI
7N1Z	;		;	NMR structure of native PnIA
1P9F	;		;	NMR Structure of Neurokinin B from DYANA
2N0C	;		;	NMR structure of Neuromedin C in 10% TFE
2N0D	;		;	NMR structure of Neuromedin C in 25% TFE
2N0E	;		;	NMR structure of Neuromedin C in 40% TFE
2N0F	;		;	NMR structure of Neuromedin C in 60% TFE
2N0G	;		;	NMR structure of Neuromedin C in 90% TFE
2N0B	;		;	NMR structure of Neuromedin C in aqueous solution
2N0H	;		;	NMR structure of Neuromedin C in presence of SDS micelles
2KKD	;		;	NMR Structure of Ni Substitued Desulfovibrio vulgaris Rubredoxin
2BA3	;		;	NMR Structure of NikA N-terminal Fragment
2MP8	;		;	NMR structure of NKR-5-3B
2N69	;		;	NMR structure of non-sweet mutant (ins18RI19) of sweet protein Brazzein
7QDD	;		;	NMR structure of Npl3 RRM1 bound to the AUCCAA RNA
7QDE	;		;	NMR structure of Npl3 RRM12 bound to the AUCCAGUGGAA RNA
2LLH	;		;	NMR structure of Npm1_c70
6HT4	;		;	NMR Structure of NS5A-D2 (JFH1) peptide (304-323)
1WN8	;		;	NMR Structure of OaNTR
2NDB	;		;	NMR structure of omega-agatoxin IVA in DPC micelles
1DW4	;		;	NMR STRUCTURE OF OMEGA-CONOTOXIN MVIIA: CONSTRAINTS ON DISULPHIDE BRIDGES
1DW5	;		;	NMR STRUCTURE OF OMEGA-CONOTOXIN MVIIA: NO CONSTRAINTS ON DISULPHIDE BRIDGES
2M07	;		;	NMR structure of OmpX in DPC micelles
2M06	;		;	NMR structure of OmpX in phopspholipid nanodiscs
6OBK	;		;	NMR structure of Orf47 from Lactococcus virus P2
8HQB	;		;	NMR Structure of OsCIE1-Ubox
8HPB	;		;	NMR Structure of OsCIE1-Ubox S237D mutant
6XCR	;		;	NMR structure of Ost4 in DPC micelles
6XCU	;		;	NMR structure of Ost4V23D, a critical mutant of Ost4, in DPC micelles
2N85	;		;	NMR structure of OtTx1a - AMP in DPC micelles
2N86	;		;	NMR structure of OtTx1a - ICK
1L6U	;		;	NMR STRUCTURE OF OXIDIZED ADRENODOXIN
1EGO	;		;	NMR STRUCTURE OF OXIDIZED ESCHERICHIA COLI GLUTAREDOXIN: COMPARISON WITH REDUCED E. COLI GLUTAREDOXIN AND FUNCTIONALLY RELATED PROTEINS
1XPN	;		;	NMR structure of P. aeruginosa protein PA1324: Northeast Structural Genomics Consortium target PaP1
1YWW	;		;	NMR structure of P. aeruginosa protein PA4738: Northeast Structural Genomics Consortium target PaP2
1JM4	;		;	NMR Structure of P/CAF Bromodomain in Complex with HIV-1 Tat Peptide
1L3H	;		;	NMR structure of P41icf, a potent inhibitor of human cathepsin L
2KTR	;		;	NMR structure of p62 PB1 dimer determined based on PCS
2MJO	;		;	NMR structure of p75 transmembrane domain C257A mutant in DPC micelles
2MIC	;		;	NMR structure of p75 transmembrane domain in DPC micelles
8X8T	;		;	NMR structure of p75NTR juxtamembrane domain in complex with RhoGDI N-terminal domain containing a phosphorylation-mimicking S34D mutation
5ZGG	;		;	NMR structure of p75NTR transmembrane domain in complex with NSC49652
2JPI	;		;	NMR structure of PA4090 from Pseudomonas aeruginosa
1P94	;		;	NMR Structure of ParG symmetric dimer
2MGV	;		;	NMR structure of PASTA domain of PonA2 from Mycobacterium tuberculosis
1X5V	;		;	NMR Structure of PcFK1
2IMU	;		;	NMR structure of pep46 from the infectious bursal disease virus (IBDV) in dodecylphosphocholin (DPC).
5LFH	;		;	NMR structure of peptide 10 targeting CXCR4
5LFF	;		;	NMR structure of peptide 2 targeting CXCR4
6QXB	;		;	NMR structure of peptide 7, characterized by a cis-4-amino-Pro residue, with a significant lower MIC on E. coli
6QXC	;		;	NMR structure of peptide 8, characterized by a trans-4-cyclohexyl-Pro, with a dramatic reduction in activity on E. coli ATCC and lost effect on P. aeruginosa.
2N7N	;		;	NMR structure of Peptide PG-989 in DPC micelles
2N7O	;		;	NMR Structure of Peptide PG-990 in DPC micelles
2N7T	;		;	NMR structure of Peptide PG-992 in DPC micelles
1YT6	;		;	NMR structure of peptide SD
7UO6	;		;	NMR structure of Pheromone-binding protein 2 in Ostrinia furnacalis
2MX4	;		;	NMR structure of Phosphorylated 4E-BP2
2N5D	;		;	NMR structure of PKS domains
1YTR	;		;	NMR structure of plantaricin a in dpc micelles, 20 structures
2KEG	;		;	NMR structure of Plantaricin K in DPC-micelles
2K9I	;		;	NMR structure of plasmid copy control protein ORF56 from sulfolobus islandicus
6RSF	;		;	NMR structure of pleurocidin KR in SDS micelles
6RSG	;		;	NMR structure of pleurocidin VA in SDS micelles
2KQP	;		;	NMR Structure of Proinsulin
2MZ6	;		;	NMR structure of Protegrin-3 (PG3) in the presence of DPC micelles
2KBZ	;		;	NMR structure of protein gp15 of bacteriophage SPP1
2HFD	;		;	NMR structure of protein Hydrogenase-1 operon protein hyaE from Escherichia coli: Northeast Structural Genomics Consortium Target ER415
2HFQ	;		;	NMR structure of protein NE1680 from Nitrosomonas europaea: Northeast Structural Genomics Consortium target NeT5
2MHG	;		;	NMR structure of protein NP_254181.1 from Pseudomonas aeruginosa PA01
2K4N	;		;	NMR structure of protein PF0246 from Pyrococcus furiosus: target PfR75 from the Northeast Structural Genomics Consortium
2JS5	;		;	NMR Structure of protein Q60C73_METCA. Northeast Structural Genomics Consortium target McR1
2JS3	;		;	NMR Structure of protein Q6N9A4_RHOPA. Northeast Structural Genomics Consortium target RpT8
2MC8	;		;	NMR structure of protein RUMGNA_01855 from Ruminococcus gnavus ATCC 29149
2NWT	;		;	NMR Structure of Protein UPF0165 protein AF_2212 from Archaeoglobus Fulgidus; Northeast Structural Genomics Consortium Target GR83
2FKI	;		;	NMR Structure of Protein yjbR from Escherichia coli; Northeast Structural Genomics Consortium Target ER226
2ML5	;		;	NMR structure of protein ZP_02064002.1 from Bacteroides ovatus ATCC 8483
2ML6	;		;	NMR structure of protein ZP_02069618.1 from Bacteroides uniformis ATCC 8492
4A1M	;		;	NMR Structure of protoporphyrin-IX bound murine p22HBP
5JYU	;		;	NMR structure of pseudo receiver domain of CikA from Thermosynechococcus elongatus
2LA9	;		;	NMR structure of Pseudouridine_ASL_Tyr
1B1V	;		;	NMR STRUCTURE OF PSP1, PLASMATOCYTE-SPREADING PEPTIDE FROM PSEUDOPLUSIA INCLUDENS
1B5N	;		;	NMR STRUCTURE OF PSP1, PLASMATOCYTE-SPREADING PEPTIDE FROM PSEUDOPLUSIA INCLUDENS
6F61	;		;	NMR structure of purotoxin-6
1NGO	;		;	NMR Structure of Putative 3' Terminator for B. Anthracis pagA Gene Coding Strand
1NGU	;		;	NMR Structure of Putative 3'Terminator for B. Anthracis pagA Gene Noncoding Strand
2MQB	;		;	NMR structure of putative beta-lactamase (NP_372339.1) from Staphylococcus aureus Mu50
2JY9	;		;	NMR structure of putative tRNA hydrolase domain from Salmonella typhimurium. NorthEast Structural Genomics Consortium target StR220
1M02	;		;	NMR Structure of PW2 Bound to SDS Micelles: A Tryptophan-rich Anticocidial Peptide Selected from Phage Display Libraries
2JOM	;		;	NMR structure of rabbit prion protein mutation I214V
2JOH	;		;	NMR structure of rabbit prion protein mutation S173N
1AAB	;		;	NMR STRUCTURE OF RAT HMG1 HMGA FRAGMENT
2MTM	;		;	NMR structure of RCB-1 peptide
2KLH	;		;	NMR Structure of RCL in complex with GMP
2I94	;		;	NMR Structure of recoverin bound to rhodopsin kinase
2MAO	;		;	NMR structure of region 2 of E. coli sigmaE
2LWW	;		;	NMR structure of RelA-TAD/CBP-TAZ1 complex
6SZC	;		;	NMR structure of repeat domain 13 of the fibrillar adhesin CshA from Streptococcus gordonii.
2NAL	;		;	NMR Structure of retro-KR-12: A reversed sequence of a minimalized domain derived from human cathelicidin LL-37
2ATG	;		;	NMR structure of Retrocyclin-2 in SDS
7PQ4	;		;	NMR Structure of RgpB C-terminal Domain
1YGW	;		;	NMR STRUCTURE OF RIBONUCLEASE T1, 34 STRUCTURES
1GO0	;		;	NMR Structure of Ribosomal Protein L30e from Thermococcus celer
1GO1	;		;	NMR Structure of Ribosomal Protein L30e from Thermococcus celer.
1DFE	;		;	NMR STRUCTURE OF RIBOSOMAL PROTEIN L36 FROM THERMUS THERMOPHILUS
1KKG	;		;	NMR Structure of Ribosome-Binding Factor A (RbfA)
2JXQ	;		;	NMR structure of RNA duplex
2JXS	;		;	NMR structure of RNA duplex containing single adenosine bulge
2M7S	;		;	NMR structure of RNA recognition motif 2 (RRM2) of Homo sapiens splicing factor, arginine/serine-rich 1
2GBS	;		;	NMR structure of Rpa0253 from Rhodopseudomonas palustris. Northeast structural genomics consortium target RpR3
2OSQ	;		;	NMR Structure of RRM-1 of Yeast NPL3 Protein
2OSR	;		;	NMR Structure of RRM-2 of Yeast NPL3 Protein
2MY8	;		;	NMR Structure of RRM-3 domain of ETR-3
1SJQ	;		;	NMR Structure of RRM1 from Human Polypyrimidine Tract Binding Protein Isoform 1 (PTB1)
1SJR	;		;	NMR Structure of RRM2 from Human Polypyrimidine Tract Binding Protein Isoform 1 (PTB1)
2MBY	;		;	NMR Structure of Rrp7 C-terminal Domain
2M3F	;		;	NMR structure of Rsa1p238-259 from S. Cerevisiae
7NHZ	;		;	NMR structure of Rv1813c from Mycobacterium tuberculosis
2KFS	;		;	NMR structure of Rv2175c
2NCV	;		;	NMR structure of RWS21 structure in LPS micelles
2GD3	;		;	NMR structure of S14G-humanin in 30% TFE solution
2LCM	;		;	NMR structure of S3-4 peptide
8E6Y	;		;	NMR structure of Sa1_V90T at 30 degrees Celsius
2ML8	;		;	NMR structure of Saccharomyces cerevisiae Acyl Carrier Protein.
6CJD	;		;	NMR Structure of Salmonella Type III Secretion system protein OrgC
1JDM	;		;	NMR Structure of Sarcolipin
2ACF	;	1.4	;	NMR STRUCTURE OF SARS-COV NON-STRUCTURAL PROTEIN NSP3A (SARS1) FROM SARS CORONAVIRUS
7M67	;		;	NMR Structure of Schistocin-1 antimicrobial peptide in presence of DPC-d38 micelles
7M73	;		;	NMR Structure of Schistocin-2 antimicrobial peptide in presence of DPC-d38 micelles
7M77	;		;	NMR Structure of Schistocin-3 antimicrobial peptide in presence of DPC-d38 micelles
7M79	;		;	NMR Structure of Schistocin-3.1 antimicrobial peptide in presence of DPC-d38 micelles
6AZA	;		;	NMR structure of sea anemone toxin Kappa-actitoxin-Ate1a
2K8Q	;		;	NMR Structure of Shq1p N-terminal domain
2LRA	;		;	NMR Structure of Signal Sequence Deleted (SSD) Rv0603 Protein from Mycobacterium tuberculosis without N-terminal His-tag
5H1H	;		;	NMR structure of SLBA, a chimera of SFTI
1K8H	;		;	NMR Structure of Small Protein B (SmpB) from Aquifex aeolicus
2FE0	;		;	NMR structure of SMP-1 (Small Myristoylated Protein) from Leishmania major
6BV7	;		;	NMR structure of Sodium/Calcium Exchanger 1 (NCX1) Two-helix Bundle (THB) domain
2MD8	;		;	NMR structure of Sp140 PHD finger cis conformer
2MCJ	;		;	NMR structure of spermine modified DNA duplex
1AG4	;		;	NMR STRUCTURE OF SPHERULIN 3A (S3A) FROM PHYSARUM POLYCEPHALUM, MINIMIZED AVERAGE STRUCTURE
2N6R	;		;	NMR structure of spider toxin U4-hexatoxin-Hi1a
2MXO	;		;	NMR structure of spider toxin- G7W/N24S mutant of TRTX-Hhn2b
2MQF	;		;	NMR structure of spider toxin-TRTX-Hhn2b
2FFT	;		;	NMR structure of Spinach Thylakoid Soluble Phosphoprotein of 9 kDa in SDS Micelles
2MGX	;		;	NMR structure of SRA1p C-terminal domain
1CQ5	;		;	NMR STRUCTURE OF SRP RNA DOMAIN IV
1CQL	;		;	NMR STRUCTURE OF SRP RNA DOMAIN IV
1XSX	;		;	NMR Structure of Sso10a, a Hyperthermophile DNA-binding Protein with an Extended Anti-parallel Coiled Coil
1ESY	;		;	NMR STRUCTURE OF STEM LOOP SL2 OF THE HIV-1 PSI RNA PACKAGING SIGNAL REVEALS A NOVEL A-U-A BASE-TRIPLE PLATFORM
2GBH	;		;	NMR structure of stem region of helix-35 of 23S E.coli ribosomal RNA (residues 736-760)
2KX8	;		;	NMR structure of stem-loop 4 from the human 7SK snRNA in complex with arginine
2D21	;		;	NMR Structure of stereo-array isotope labelled (SAIL) maltodextrin-binding protein (MBP)
2RS4	;		;	NMR structure of stereo-array isotope labelled (SAIL) peptidyl-prolyl cis-trans isomerase from E. coli (EPPIb)
8DIJ	;		;	NMR Structure of Streptococcal Protein GB1 Backbone Modified Variant: beta-ACPC24, beta-3-Lys28, beta-3-Lys31, beta-ACPC35
2N66	;		;	NMR Structure of sweeter mutant (D40K) of sweet protein Brazzein,
1HLL	;		;	NMR STRUCTURE OF T3-I2, A 32 RESIDUE PEPTIDE FROM THE ALPHA-2A ADRENERGIC RECEPTOR
1HOF	;		;	NMR STRUCTURE OF T3-I2, A 32 RESIDUE PEPTIDE FROM THE ALPHA-2A ADRENERGIC RECEPTOR
2G35	;		;	NMR structure of talin-PTB in complex with PIPKI
1QC8	;		;	NMR STRUCTURE OF TAU EXON 10 SPLICING REGULATORY ELEMENT RNA
2LVV	;		;	NMR structure of TB24
2N2C	;		;	NMR Structure of TDP-43 prion-like hydrophobic helix in DPC
6GIL	;		;	NMR structure of temporin B in SDS micelles
6GIJ	;		;	NMR structure of temporin B KKG6A in SDS micelles
6GIK	;		;	NMR structure of temporin B L1FK in SDS micelles
6GS5	;		;	NMR structure of temporin L in SDS micelles
8TV4	;		;	NMR structure of temporin L in solution
2MAA	;		;	NMR structure of Temporin-1 Ta in lipopolysaccharide micelles: Mechanistic insight into inactivation by outer memebrane
2MCF	;		;	NMR structure of TGAM_1934
2CHJ	;		;	NMR structure of TGLGLT quadruplex
8IKQ	;		;	NMR structure of Thanatin IM14 in LPS
1CEU	;		;	NMR STRUCTURE OF THE (1-51) N-TERMINAL DOMAIN OF THE HIV-1 REGULATORY PROTEIN
1U57	;		;	NMR structure of the (345-392)Gag sequence from HIV-1
1QNZ	;		;	NMR structure of the 0.5b anti-HIV antibody complex with the gp120 V3 peptide
1R84	;		;	NMR structure of the 13-cis-15-syn retinal in dark_adapted bacteriorhodopsin
2N6D	;		;	NMR structure of the 140-315 fragment of the N-acetylglucosamine-1-phosphate transferase, alpha and beta subunits
6JJ0	;		;	NMR structure of the 1:1 complex of a carbazole derivative BMVC bound to c-MYC G-quadruplex
1HZ0	;		;	NMR STRUCTURE OF THE 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE (PHIP) C8-DEOXYGUANOSINE ADDUCT IN DUPLEX DNA
6O2L	;		;	NMR structure of the 2:1 complex of a carbazole derivative BMVC bound to c-MYC G-quadruplex
1RFR	;		;	NMR structure of the 30mer stemloop-D of coxsackieviral RNA
5IEM	;		;	NMR structure of the 5'-terminal hairpin of the 7SK snRNA
1FHK	;		;	NMR STRUCTURE OF THE 690 LOOP OF 16 S RRNA OF E. COLI
2L5Z	;		;	NMR structure of the A730 loop of the Neurospora VS ribozyme
2L23	;		;	NMR structure of the ACID (ACtivator Interacting Domain) of the human mediator Med25 protein
2NBB	;		;	NMR structure of the Acidic domain of SYNCRIP (24-140)
2MXT	;		;	NMR structure of the acidic domain of SYNCRIP (hnRNPQ)
1OW9	;		;	NMR Structure of the Active Conformation of the VS Ribozyme Cleavage Site
1JQR	;		;	NMR structure of the African swine fever virus DNA polymerase X
1R2N	;		;	NMR structure of the all-trans retinal in dark-adapted Bacteriorhodopsin
2FRB	;		;	NMR structure of the alpha-conotoxin GI (ASN4)-benzoylphenylalanine derivative
2FR9	;		;	NMR structure of the alpha-conotoxin GI (SER12)-benzoylphenylalanine derivative
1EI0	;		;	NMR STRUCTURE OF THE ALPHA-HELICAL HAIRPIN OF P8MTCP1
1Y5O	;		;	NMR structure of the amino-terminal domain from the Tfb1 subunit of yeast TFIIH
7OD2	;		;	NMR structure of the Anemonia erythraea AeTX-K toxin
2JQ2	;		;	NMR structure of the anticoccidial peptide PW2 in DPC micelles
8B1L	;		;	NMR structure of the antimicrobial peptide Of-Pis1 in DPC micelles
2RLH	;		;	NMR structure of the antimicrobial peptide RP-1 bound to DPC micelles
2RLG	;		;	NMR structure of the antimicrobial peptide RP-1 bound to SDS micelles
7OB2	;		;	NMR structure of the antimicrobial RiLK1 peptide in SDS micelles
1Z30	;		;	NMR structure of the apical part of stemloop D from cloverleaf 1 of bovine enterovirus 1 RNA
2IN2	;		;	NMR Structure of the Apo Human Rhinovirus 3C Protease (serotype 14)
2JYQ	;		;	NMR structure of the apo v-Src SH2 domain
6TPB	;		;	NMR structure of the apo-form of Pseudomonas fluorescens CopC
2N1M	;		;	NMR structure of the apo-form of the flavoprotein YP_193882.1 from Lactobacillus acidophilus NCFM
1YLG	;		;	NMR structure of the apoB mRNA stem-loop and its interaction with the C to U editing APOBEC1 complementary factor
1YNC	;		;	NMR structure of the apoB mRNA stem-loop and its interaction with the C to U editing APOBEC1 complementary factor
1YNE	;		;	NMR structure of the apoB mRNA stem-loop and its interaction with the C to U editing APOBEC1 complementary factor
1YNG	;		;	NMR structure of the apoB mRNA stem-loop and its interaction with the C to U editing APOBEC1 complementary factor
2G1W	;		;	NMR structure of the Aquifex aeolicus tmRNA pseudoknot PK1
1PC0	;		;	NMR Structure of the Archaeal Homologue of RNase P Protein Rpp29
2JXJ	;		;	NMR structure of the ARID domain from the histone H3K4 demethylase RBP2
2L8K	;		;	NMR Structure of the Arterivirus nonstructural protein 7 alpha (nsp7 alpha)
2HKB	;		;	NMR Structure of the B-DNA Dodecamer CTCGGCGCCATC
1Q56	;		;	NMR structure of the B0 isoform of the agrin G3 domain in its Ca2+ bound state
2BZT	;		;	NMR structure of the bacterial protein YFHJ from E. coli
8DSX	;		;	NMR STRUCTURE OF THE BACTERIOPHAGE LAMBDA EA22 C-TERMINAL DOMAIN
7OFM	;		;	NMR structure of the Bak transmembrane helix in DPC micelles
7OFO	;		;	NMR structure of the Bak transmembrane helix in lipid nanodiscs
2MH3	;		;	NMR structure of the basic helix-loop-helix region of the transcriptional repressor HES-1
1P6U	;		;	NMR structure of the BeF3-activated structure of the response regulator Chey2-Mg2+ from Sinorhizobium meliloti
1SCV	;		;	NMR STRUCTURE OF THE C TERMINAL DOMAIN OF CARDIAC TROPONIN C BOUND TO THE N TERMINAL DOMAIN OF CARDIAC TROPONIN I
1FI5	;		;	NMR STRUCTURE OF THE C TERMINAL DOMAIN OF CARDIAC TROPONIN C BOUND TO THE N TERMINAL DOMAIN OF CARDIAC TROPONIN I.
2MLE	;		;	NMR structure of the C-domain of troponin C bound to the anchoring region of troponin I
2N64	;		;	NMR Structure of the C-terminal Coiled-Coil Domain of CIN85
2F8B	;		;	NMR structure of the C-terminal domain (dimer) of HPV45 oncoprotein E7
2RST	;		;	NMR structure of the C-terminal domain of EW29
2NBQ	;		;	NMR Structure of the C-Terminal Domain of human APOBEC3B
2JVL	;		;	NMR structure of the C-terminal domain of MBF1 of Trichoderma reesei
2KN8	;		;	NMR structure of the C-terminal domain of pUL89
5LXK	;		;	NMR structure of the C-terminal domain of the Bacteriophage T5 decoration protein pb10.
6EZ4	;		;	NMR structure of the C-terminal domain of the human RPAP3 protein
1GCF	;		;	NMR STRUCTURE OF THE C-TERMINAL DOMAIN OF THE LIGAND-BINDING REGION OF MURINE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR, 12 STRUCTURES
1CTO	;		;	NMR STRUCTURE OF THE C-TERMINAL DOMAIN OF THE LIGAND-BINDING REGION OF MURINE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR, MINIMIZED AVERAGE STRUCTURE
2M26	;		;	NMR structure of the C-terminal domain of the protein HCFC1 from Mus musculus
2KVL	;		;	NMR structure of the C-terminal domain of VP7
2LM7	;		;	NMR structure of the C-terminal domain of VP7 in membrane mimicking micelles
1P97	;		;	NMR structure of the C-terminal PAS domain of HIF2a
2N51	;		;	NMR structure of the C-terminal region of human eukaryotic elongation factor 1B
2LA4	;		;	NMR structure of the C-terminal RRM domain of poly(U) binding 1
7PVM	;		;	NMR structure of the C. thermophilum Xrn2 zinc finger
1E2B	;		;	NMR STRUCTURE OF THE C10S MUTANT OF ENZYME IIB CELLOBIOSE OF THE PHOSPHOENOL-PYRUVATE DEPENDENT PHOSPHOTRANSFERASE SYSTEM OF ESCHERICHIA COLI, 17 STRUCTURES
2MQ0	;		;	NMR structure of the c3 domain of human cardiac myosin binding protein-c
2MQ3	;		;	NMR structure of the c3 domain of human cardiac myosin binding protein-c with a hypertrophic cardiomyopathy-related mutation R502W.
1C9F	;		;	NMR STRUCTURE OF THE CAD DOMAIN OF CASPASE-ACTIVATED DNASE
2JSC	;		;	NMR structure of the cadmium metal-sensor CMTR from Mycobacterium tuberculosis
5O2Y	;		;	NMR structure of the calcium bound form of PulG, major pseudopilin from Klebsiella oxytoca T2SS
2LGE	;		;	NMR structure of the calcium-bound form of the protein YP_001302112.1 from Parabacteroides distasonis
1XYK	;		;	NMR Structure of the canine prion protein
2MU2	;		;	NMR structure of the cap domain of NP_346487.1, a putative phosphoglycolate phosphatase from Streptococcus pneumoniae TIGR4
1XI7	;		;	NMR structure of the carboxyl-terminal cysteine domain of the VHv1.1 polydnaviral gene product
1WCL	;		;	NMR structure of the carboxyterminal domains of Escherichia coli NusA
1WCN	;		;	NMR structure of the carboxyterminal domains of Escherichia coli NusA
1XYJ	;		;	NMR Structure of the cat prion protein
3ZG4	;		;	NMR structure of the catalytic domain from E. faecium L,D- transpeptidase
3ZGP	;		;	NMR structure of the catalytic domain from E. faecium L,D- transpeptidase acylated by ertapenem
2JOK	;		;	NMR structure of the catalytic domain of guanine nucleotide exchange factor BopE from Burkholderia pseudomallei
2MHC	;		;	NMR structure of the catalytic domain of the large serine resolvase TnpX
2KA4	;		;	NMR structure of the CBP-TAZ1/STAT2-TAD complex
2KA6	;		;	NMR structure of the CBP-TAZ2/STAT1-TAD complex
1H67	;		;	NMR Structure of the CH Domain of Calponin
2MIM	;		;	NMR structure of the chicken CD3 epsilon delta/gamma heterodimer
1U3M	;		;	NMR structure of the chicken prion protein fragment 128-242
1K8J	;		;	NMR STRUCTURE OF THE CK14 DNA DUPLEX: A PORTION OF THE KNOWN NF-kB SEQUENCE CK1
7JGI	;		;	NMR structure of the cNTnC-cTnI chimera bound to A7
6MV3	;		;	NMR structure of the cNTnC-cTnI chimera bound to calcium desensitizer W7
7UHA	;		;	NMR structure of the cNTnC-cTnI chimera bound to W6
7UH9	;		;	NMR structure of the cNTnC-cTnI chimera bound to W8
2LCY	;		;	NMR Structure of the Complete Internal Fusion Loop from Ebolavirus GP2 at pH 5.5
2LCZ	;		;	NMR Structure of the Complete Internal Fusion Loop from Ebolavirus GP2 at pH 7.0
2MB1	;		;	NMR Structure of the Complete Internal Fusion Loop mutant I544A from Ebolavirus GP2 at pH 5.5
2M5F	;		;	NMR Structure of the Complete Internal Fusion Loop mutant L529A/I544A from Ebolavirus GP2 at pH 5.5
1HOY	;		;	NMR STRUCTURE OF THE COMPLEX BETWEEN A-BUNGAROTOXIN AND A MIMOTOPE OF THE NICOTINIC ACETYLCHOLINE RECEPTOR
1JBD	;		;	NMR Structure of the Complex Between alpha-bungarotoxin and a Mimotope of the Nicotinic Acetylcholine Receptor
1RGJ	;		;	NMR STRUCTURE OF THE COMPLEX BETWEEN ALPHA-BUNGAROTOXIN AND MIMOTOPE OF THE NICOTINIC ACETYLCHOLINE RECEPTOR WITH ENHANCED ACTIVITY
1U5S	;		;	NMR structure of the complex between Nck-2 SH3 domain and PINCH-1 LIM4 domain
2K2U	;		;	NMR Structure of the complex between Tfb1 subunit of TFIIH and the activation domain of VP16
2N0Y	;		;	NMR structure of the complex between the C-terminal domain of the Rift Valley fever virus protein NSs and the PH domain of the Tfb1 subunit of TFIIH
1AZE	;		;	NMR STRUCTURE OF THE COMPLEX BETWEEN THE C32S-Y7V MUTANT OF THE NSH3 DOMAIN OF GRB2 WITH A PEPTIDE FROM SOS, 10 STRUCTURES
5U4K	;		;	NMR structure of the complex between the KIX domain of CBP and the transactivation domain 1 of p65
2LOX	;		;	NMR structure of the complex between the PH domain of the Tfb1 subunit from TFIIH and Rad2
2M14	;		;	NMR structure of the complex between the PH domain of the Tfb1 subunit from TFIIH and Rad4
2GS0	;		;	NMR structure of the complex between the PH domain of the Tfb1 subunit from TFIIH and the activation domain of p53
2N23	;		;	NMR structure of the complex between the PH domain of the Tfb1 subunit from TFIIH and the N-terminal activation domain of EKLF (TAD1)
5URN	;		;	NMR structure of the complex between the PH domain of the Tfb1 subunit from TFIIH and the transactivation domain 1 of p65
2L2I	;		;	NMR Structure of the complex between the Tfb1 subunit of TFIIH and the activation domain of EKLF
1EKZ	;		;	NMR STRUCTURE OF THE COMPLEX BETWEEN THE THIRD DSRBD FROM DROSOPHILA STAUFEN AND A RNA HAIRPIN
1A6B	;		;	NMR STRUCTURE OF THE COMPLEX BETWEEN THE ZINC FINGER PROTEIN NCP10 OF MOLONEY MURINE LEUKEMIA VIRUS AND A SEQUENCE OF THE PSI-PACKAGING DOMAIN OF HIV-1, 20 STRUCTURES
5OR5	;		;	NMR structure of the complex formed by an engineered region 2 of sigmaE in complex with GTAAAA
2M55	;		;	NMR structure of the complex of an N-terminally acetylated alpha-synuclein peptide with calmodulin
2GJF	;		;	NMR structure of the computationally designed procarboxypeptidase-A (1AYE) domain
2H7A	;		;	NMR Structure of the Conserved Protein YcgL from Escherichia coli representing the DUF709 Family Reveals a Novel a/b/a Sandwich Fold
2MU1	;		;	NMR structure of the core domain of NP_346487.1, a putative phosphoglycolate phosphatase from Streptococcus pneumoniae TIGR4
1RY4	;		;	NMR Structure of the CRIB-PDZ module of Par-6
1JJD	;		;	NMR structure of the Cyanobacterial Metallothionein SmtA
1Q3Y	;		;	NMR structure of the Cys28His mutant (D form) of the nucleocapsid protein NCp7 of HIV-1.
1Q3Z	;		;	NMR structure of the Cys28His mutant (E form) of the nucleocapsid protein NCp7 of HIV-1.
2L8N	;		;	NMR structure of the cytidine repressor DNA binding domain in presence of operator half-site DNA
1S4W	;		;	NMR structure of the cytoplasmic domain of integrin AIIb in DPC micelles
2M8S	;		;	NMR Structure of the Cytoplasmic Tail of the Membrane Form of Heparin-binding EGF-like Growth Factor (proHB-EGF-CT) Complexed with the Ubiquitin Homology Domain of Bcl-2-associated Athanogene 1 from Mus musculus (mBAG-1-UBH)
1DRO	;		;	NMR STRUCTURE OF THE CYTOSKELETON/SIGNAL TRANSDUCTION PROTEIN
1Z2K	;		;	NMR structure of the D1 domain of the Natural Killer Cell Receptor, 2B4
2N6B	;		;	NMR structure of the de-novo toxin Hui1
2H0P	;		;	NMR Structure of the Dengue-4 virus Envelope Protein Domain III
1TUZ	;		;	NMR Structure of the Diacylglycerol kinase alpha, NESGC target HR532
2MLF	;		;	NMR structure of the dilated cardiomyopathy mutation G159D in troponin C bound to the anchoring region of troponin I
1BAU	;		;	NMR STRUCTURE OF THE DIMER INITIATION COMPLEX OF HIV-1 GENOMIC RNA, MINIMIZED AVERAGE STRUCTURE
6NVZ	;		;	NMR Structure of the DNA binding domain of EhMybS3
1BUT	;		;	NMR STRUCTURE OF THE DNA DECAMER D(CATGGCCATG)2, 10 STRUCTURES
1L3G	;		;	NMR Structure of the DNA-binding Domain of Cell Cycle Protein, Mbp1(2-124) from Saccharomyces cerevisiae
2L4A	;		;	NMR structure of the DNA-binding domain of E.coli Lrp
2HZD	;		;	NMR structure of the DNA-binding TEA domain and insights into TEF-1 function
6GVU	;		;	NMR structure of the DNA-bound helix bundle domain from the functional pRN1 primase
2KHI	;		;	NMR structure of the domain 4 of the E. coli ribosomal protein S1
5XQ5	;		;	NMR structure of the domain 5 of the E. coli ribosomal protein S1
2RNK	;		;	NMR structure of the domain 513-651 of the SARS-CoV nonstructural protein nsp3
2JZD	;		;	NMR structure of the domain 527-651 of the SARS-CoV nonstructural protein nsp3
2JZE	;		;	NMR structure of the domain 527-651 of the SARS-CoV nonstructural protein nsp3, single conformer closest to the mean coordinates of an ensemble of twenty energy minimized conformers
2KHJ	;		;	NMR structure of the domain 6 of the E. coli ribosomal protein S1
1KMA	;		;	NMR Structure of the Domain-I of the Kazal-type Thrombin Inhibitor Dipetalin
1OVX	;		;	NMR structure of the E. coli ClpX chaperone zinc binding domain dimer
1JNS	;		;	NMR Structure of the E. coli Peptidyl-Prolyl cis/trans-Isomerase Parvulin 10
1JNT	;		;	NMR Structure of the E. coli Peptidyl-Prolyl cis/trans-Isomerase Parvulin 10
5T17	;		;	NMR structure of the E. coli protein NPr, residues 1-85
2JMR	;		;	NMR structure of the E. coli type 1 pilus subunit FimF
2JO6	;		;	NMR structure of the E.coli protein NirD, Northeast Structural Genomics target ET100
2B3W	;		;	NMR structure of the E.coli protein YbiA, Northeast Structural Genomics target ET24.
2L27	;		;	NMR Structure of the ECD1 of CRF-R1 in complex with a peptide agonist
2KC1	;		;	NMR structure of the F0 domain (residues 0-85) of the talin ferm domain
2KMA	;		;	NMR structure of the F0F1 double domain (residues 1-202) of the talin ferm domain
2KC2	;		;	NMR structure of the F1 domain (residues 86-202) of the talin
2ASE	;		;	NMR structure of the F28L mutant of Cdc42Hs
1MZT	;		;	NMR structure of the fd bacteriophage pVIII coat protein in lipid bilayer membranes
2L9V	;		;	NMR structure of the FF domain L24A mutant's folding transition state
2A0T	;		;	NMR structure of the FHA1 domain of Rad53 in complex with a biological relevant phosphopeptide derived from Madt1
1J4P	;		;	NMR STRUCTURE OF THE FHA1 DOMAIN OF RAD53 IN COMPLEX WITH A RAD9-DERIVED PHOSPHOTHREONINE (AT T155) PEPTIDE
1K3N	;		;	NMR Structure of the FHA1 Domain of Rad53 in Complex with a Rad9-derived Phosphothreonine (at T155) Peptide
1J4Q	;		;	NMR STRUCTURE OF THE FHA1 DOMAIN OF RAD53 IN COMPLEX WITH A RAD9-DERIVED PHOSPHOTHREONINE (AT T192) PEPTIDE
1K3Q	;		;	NMR structure of the FHA1 Domain of Rad53 in Complex with a Rad9-derived Phosphothreonine (at T192) Peptide
1G3G	;		;	NMR STRUCTURE OF THE FHA1 DOMAIN OF YEAST RAD53
2FNB	;		;	NMR STRUCTURE OF THE FIBRONECTIN ED-B DOMAIN, NMR, 20 STRUCTURES
1J8K	;		;	NMR STRUCTURE OF THE FIBRONECTIN EDA DOMAIN, NMR, 20 STRUCTURES
1G4F	;		;	NMR STRUCTURE OF THE FIFTH DOMAIN OF HUMAN BETA2-GLYCOPROTEIN I
1G4G	;		;	NMR STRUCTURE OF THE FIFTH DOMAIN OF HUMAN BETA2-GLYCOPROTEIN I
2CKN	;		;	NMR Structure of the First Ig Module of mouse FGFR1
2LH9	;		;	NMR structure of the first lotus domain of tudor domain-containing protein 7
1XWH	;		;	NMR structure of the first phd finger of autoimmune regulator protein (AIRE1): insights into apeced
2HGL	;		;	NMR structure of the first qRRM domain of human hnRNP F
2KFY	;		;	NMR structure of the first qRRM of hnRNP F in complex with AGGGAU G-tract RNA
2MHN	;		;	NMR structure of the first RRM domain of the protein RBM39 from Homo sapiens
2KE7	;		;	NMR structure of the first SAM domain from AIDA1
6FD7	;		;	NMR structure of the first TPR domain of the human RPAP3 protein
1M9O	;		;	NMR structure of the first Zinc Binding domain of Nup475/TTP/TIS11
2MXV	;		;	NMR structure of the first Zinc Finger domain of RBM10
1QXC	;		;	NMR structure of the fragment 25-35 of beta amyloid peptide in 20/80 v:v hexafluoroisopropanol/water mixture
6GT7	;		;	NMR structure of the free helix bundle domain from the functional pRN1 primase
1TM6	;		;	NMR Structure of the Free Zinc Binding C-terminal Domain of SecA
8UWF	;		;	NMR structure of the funnel-web spider toxin Hc3a
1AOU	;		;	NMR STRUCTURE OF THE FYN SH2 DOMAIN COMPLEXED WITH A PHOSPHOTYROSYL PEPTIDE, 22 STRUCTURES
1AOT	;		;	NMR STRUCTURE OF THE FYN SH2 DOMAIN COMPLEXED WITH A PHOSPHOTYROSYL PEPTIDE, MINIMIZED AVERAGE STRUCTURE
1CYZ	;		;	NMR STRUCTURE OF THE GAACTGGTTC/TRI-IMIDAZOLE POLYAMIDE COMPLEX
2JU4	;		;	NMR structure of the gamma subunit of cGMP phosphodiesterase
2OVN	;		;	NMR structure of the GCN4 trigger peptide
2L56	;		;	NMR structure of the GCN4 trigger peptide refined using biased molecular dynamics simulations
4B1Q	;		;	NMR structure of the glycosylated conotoxin CcTx from Conus consors
1Z1Z	;		;	NMR structure of the gpu tail protein from lambda bacteriophage
1XFN	;		;	NMR structure of the ground state of the photoactive yellow protein lacking the N-terminal part
2M3D	;		;	NMR structure of the GUCT domain from human DEAD box polypeptide 21
2KIL	;		;	NMR structure of the H103G mutant SO2144 H-NOX domain from Shewanella oneidensis in the Fe(II)CO ligation state
6UZJ	;		;	NMR structure of the HACS1 SH3 domain
1F2R	;		;	NMR STRUCTURE OF THE HETERODIMERIC COMPLEX BETWEEN CAD DOMAINS OF CAD AND ICAD
2LHJ	;		;	NMR structure of the high mobility group protein-like protein NHP1 from Babesia bovis T2Bo (BaboA.00841.a)
1BXD	;		;	NMR STRUCTURE OF THE HISTIDINE KINASE DOMAIN OF THE E. COLI OSMOSENSOR ENVZ
2LH0	;		;	NMR structure of the histone-interacting N-terminal homodimeric region of Rtt106
1F6U	;		;	NMR structure of the HIV-1 nucleocapsid protein bound to stem-loop sl2 of the psi-RNA packaging signal. Implications for genome recognition
1M8L	;		;	NMR structure of the HIV-1 Regulatory Protein Vpr
2DI2	;		;	NMR structure of the HIV-2 nucleocapsid protein
2E1X	;		;	NMR structure of the HIV-2 nucleocapsid protein
5K5F	;		;	NMR structure of the HLTF HIRAN domain
2MZN	;		;	NMR structure of the HLTF HIRAN domain in its DNA-bound conformation
2LKX	;		;	NMR structure of the homeodomain of Pitx2 in complex with a TAATCC DNA binding site
2M34	;		;	NMR Structure of the homeodomain transcription factor Gbx1 from Homo sapiens
2ME6	;		;	NMR Structure of the homeodomain transcription factor Gbx1 from Homo sapiens in complex with the DNA sequence CGACTAATTAGTCG
2ME0	;		;	NMR Structure of the homeodomain transcription factor Gbx1 from Homo sapiens solved in the presence of the DNA sequence CGACTAATTAGTCG
2N8G	;		;	NMR Structure of the homeodomain transcription factor Gbx1[E23R,R58E] from Homo sapiens
1D8B	;		;	NMR STRUCTURE OF THE HRDC DOMAIN FROM SACCHAROMYCES CEREVISIAE RECQ HELICASE
2G2B	;		;	NMR structure of the human allograft inflammatory factor 1
1SGO	;		;	NMR Structure of the human C14orf129 gene product, HSPC210. Northeast Structural Genomics target HR969.
1QZP	;		;	NMR structure of the human dematin headpiece domain
1ZV6	;		;	NMR structure of the human dematin headpiece S74E mutant
1LG4	;		;	NMR structure of the human doppel protein fragment 24-152
1HLS	;		;	NMR STRUCTURE OF THE HUMAN INSULIN-HIS(B16)
1G1E	;		;	NMR STRUCTURE OF THE HUMAN MAD1 TRANSREPRESSION DOMAIN SID IN COMPLEX WITH MAMMALIAN SIN3A PAH2 DOMAIN
1TOZ	;		;	NMR structure of the human NOTCH-1 ligand binding region
2B0F	;		;	NMR Structure of the Human Rhinovirus 3C Protease (serotype 14) with covalently bound Ace-LEALFQ-ethylpropionate inhibitor
1HCS	;		;	NMR STRUCTURE OF THE HUMAN SRC SH2 DOMAIN COMPLEX
1HCT	;		;	NMR STRUCTURE OF THE HUMAN SRC SH2 DOMAIN COMPLEX
7M1W	;		;	NMR structure of the Human T-cell leukemia virus 1 matrix protein
2GW6	;		;	NMR structure of the human tRNA endonuclease SEN15 subunit
2K7E	;		;	NMR structure of the human tRNALys3 bound to the HIV genome Loop I
2MQD	;		;	NMR structure of the hypotheical protein Lreu_0056 from Lactobacillus reuteri
1VDY	;		;	NMR Structure of the hypothetical ENTH-VHS domain At3g16270 from Arabidopsis thaliana
1VEE	;		;	NMR structure of the hypothetical rhodanese domain At4g01050 from Arabidopsis thaliana
1M6A	;		;	NMR structure of the i-Motif Tetramer Formed by XC2
1YBL	;		;	NMR structure of the i-motif tetramer of d(AACCCC)
2MI0	;		;	NMR structure of the I-V kissing-loop interaction of the Neurospora VS ribozyme
2N3Q	;		;	NMR structure of the II-III-VI three-way junction from the VS ribozyme
2N3R	;		;	NMR structure of the II-III-VI three-way junction from the VS ribozyme and identification of magnesium-binding sites using paramagnetic relaxation enhancement
2WWV	;		;	NMR structure of the IIAchitobiose-IIBchitobiose complex of the N,N'- diacetylchitoboise brance of the E. coli phosphotransferase system.
2WY2	;		;	NMR structure of the IIAchitobiose-IIBchitobiose phosphoryl transition state complex of the N,N'-diacetylchitoboise brance of the E. coli phosphotransferase system.
2MTJ	;		;	NMR structure of the III-IV-V three-way junction from the VS ribozyme
2MTK	;		;	NMR structure of the III-IV-V three-way junction from the VS ribozyme and identification of magnesium-binding sites using paramagnetic relaxation enhancement
4A52	;		;	NMR structure of the imipenem-acylated L,D-transpeptidase from Bacillus subtilis
2AJJ	;		;	NMR structure of the in-plane membrane anchor domain [1-28] of the monotopic Non Structural Protein 5A (NS5A) of Bovine Viral Diarrhea Virus (BVDV)
2AJM	;		;	NMR structure of the in-plane membrane anchor domain [1-28] of the monotopic NonStructural Protein 5A (NS5A) from the Bovine Viral Diarrhea Virus (BVDV)
2AJN	;		;	NMR structure of the in-plane membrane anchor domain [1-28] of the monotopic NonStructural Protein 5A (NS5A) from the Bovine Viral Diarrhea Virus (BVDV)
2AJO	;		;	NMR structure of the in-plane membrane anchor domain [1-28] of the monotopic NonStructural Protein 5A (NS5A) from the Bovine Viral Diarrhea Virus (BVDV)
1S4X	;		;	NMR Structure of the integrin B3 cytoplasmic domain in DPC micelles
1N6U	;		;	NMR structure of the interferon-binding ectodomain of the human interferon receptor
2JX4	;		;	NMR structure of the intracellular loop (i3) of the vasopressin V2 receptor (GPCR)
2HKC	;		;	NMR Structure of the IQ-modified Dodecamer CTCGGC[IQ]GCCATC
2Z2H	;		;	NMR Structure of the IQ-modified Dodecamer CTCG[IQ]GCGCCATC
2Z2G	;		;	NMR Structure of the IQ-modified Dodecamer CTC[IQ]GGCGCCATC
1J5L	;		;	NMR STRUCTURE OF THE ISOLATED BETA_C DOMAIN OF LOBSTER METALLOTHIONEIN-1
1LUK	;		;	NMR Structure of the Itk SH2 domain, Pro287cis, Energy minimized average structure
1LUM	;		;	NMR Structure of the Itk SH2 domain, Pro287trans, 20 low energy structures
1LUN	;		;	NMR Structure of the Itk SH2 domain, Pro287trans, energy minimized average structure
2KQX	;		;	NMR structure of the J-domain (residues 2-72) in the Escherichia coli CbpA
1XBL	;		;	NMR STRUCTURE OF THE J-DOMAIN (RESIDUES 2-76) IN THE ESCHERICHIA COLI N-TERMINAL FRAGMENT (RESIDUES 2-108) OF THE MOLECULAR CHAPERONE DNAJ, 20 STRUCTURES
1N4C	;		;	NMR Structure of the J-Domain and Clathrin Substrate Binding Domain of Bovine Auxilin
6I9B	;		;	NMR structure of the La module from human LARP4A
1S7A	;		;	NMR structure of the La motif of human La protein
2LKQ	;		;	NMR structure of the lambda 5 22-45 peptide
1AJ1	;		;	NMR STRUCTURE OF THE LANTIBIOTIC ACTAGARDINE
7EES	;		;	NMR structure of the lasso peptide rubrivimycin
1JBI	;		;	NMR structure of the LCCL domain
2LIE	;		;	NMR structure of the lectin CCL2
1DTV	;		;	NMR STRUCTURE OF THE LEECH CARBOXYPEPTIDASE INHIBITOR (LCI)
1C8P	;		;	NMR STRUCTURE OF THE LIGAND BINDING DOMAIN OF THE COMMON BETA-CHAIN IN THE GM-CSF, IL-3 AND IL-5 RECEPTORS
5ML1	;		;	NMR Structure of the Littorina littorea metallothionein, a snail MT folding into three distinct domains
5MN3	;		;	NMR structure of the Littorina littorea metallothionein, a snail MT folding into three distinct domains
1JOX	;		;	NMR Structure of the LP5.1 Hairpin from Bacillus RNase P RNA Refined with Residual Dipolar Couplings
1JP0	;		;	NMR Structure of the LP5.1 Hairpin from Bacillus RNase P RNA Refined WITHOUT Residual Dipolar Couplings
2M94	;		;	NMR structure of the lymphocyte receptor NKR-P1A
2MTI	;		;	NMR structure of the lymphocyte receptor NKR-P1A
2MXN	;		;	NMR Structure of the mature form of Trypanosoma brucei 1CGrx1
2KAW	;		;	NMR structure of the mDvl1 PDZ domain in complex with its inhibitor
1R7F	;		;	NMR structure of the membrane anchor domain (1-31) of the nonstructural protein 5A (NS5A) of hepatitis C virus (Ensemble of 43 structures. Sample in 100mM SDS)
1R7D	;		;	NMR structure of the membrane anchor domain (1-31) of the nonstructural protein 5A (NS5A) of hepatitis C virus (Ensemble of 51 structures, sample in 50% tfe)
1R7G	;		;	NMR structure of the membrane anchor domain (1-31) of the nonstructural protein 5A (NS5A) of hepatitis C virus (Minimized average structure, Sample in 100mM DPC)
1R7C	;		;	NMR structure of the membrane anchor domain (1-31) of the nonstructural protein 5A (NS5A) of hepatitis C virus (Minimized average structure, Sample in 50% tfe)
1R7E	;		;	NMR structure of the membrane anchor domain (1-31) of the nonstructural protein 5A (NS5A) of hepatitis C virus (Minimized average structure. Sample in 100mM SDS).
1PEH	;		;	NMR STRUCTURE OF THE MEMBRANE-BINDING DOMAIN OF CTP PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE, 10 STRUCTURES
1PEI	;		;	NMR STRUCTURE OF THE MEMBRANE-BINDING DOMAIN OF CTP PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE, 10 STRUCTURES
2JP7	;		;	NMR structure of the Mex67 UBA domain
1SBJ	;		;	NMR Structure of the Mg2+-loaded C Terminal Domain of Cardiac Troponin C Bound to the N Terminal Domain of Cardiac Troponin I
1U6P	;		;	NMR Structure of the MLV encapsidation signal bound to the Nucleocapsid protein
2L6E	;		;	NMR Structure of the monomeric mutant C-terminal domain of HIV-1 Capsid in complex with stapled peptide Inhibitor
28SP	;		;	NMR STRUCTURE OF THE MOST CONSERVED RNA MOTIF IN SRP RNA
28SR	;		;	NMR STRUCTURE OF THE MOST CONSERVED RNA MOTIF IN SRP RNA
2L9L	;		;	NMR Structure of the Mouse MFG-E8 C2 Domain
2JMU	;		;	NMR structure of the mouse thiamine triphosphatase
1QPM	;		;	NMR STRUCTURE OF THE MU BACTERIOPHAGE REPRESSOR DNA-BINDING DOMAIN
1G4D	;		;	NMR STRUCTURE OF THE MU BACTERIOPHAGE REPRESSOR DNA-BINDING DOMAIN/DNA COMPLEX
2NC8	;		;	NMR structure of the Mycobacterium tuberculosis LppM (Rv2171) protein folded domain
2N1R	;		;	NMR Structure of the Myristylated Feline Immunodeficiency Virus Matrix Protein
1R2U	;		;	NMR structure of the N domain of trout cardiac troponin C at 30 C
5VLN	;		;	NMR structure of the N-domain of troponin C bound to switch region of troponin I
5W88	;		;	NMR structure of the N-domain of troponin C bound to switch region of troponin I and 3-methyldiphenylamine (peptide mode)
5WCL	;		;	NMR structure of the N-domain of troponin C bound to switch region of troponin I and 3-methyldiphenylamine (solvent exposed mode)
2N7L	;		;	NMR structure of the N-domain of troponin C bound to the switch region of troponin I and the covalent levosimendan analog i9
1FU6	;		;	NMR STRUCTURE OF THE N-SH2 DOMAIN OF THE P85 SUBUNIT OF PI3-KINASE
1FU5	;		;	NMR STRUCTURE OF THE N-SH2 DOMAIN OF THE P85 SUBUNIT OF PI3-KINASE COMPLEXED TO A DOUBLY PHOSPHORYLATED PEPTIDE DERIVED FROM POLYOMAVIRUS MIDDLE T ANTIGEN
2K48	;		;	NMR Structure of the N-terminal Coiled Coil Domain of the Andes Hantavirus Nucleocapsid Protein
2ALB	;		;	NMR structure of the N-terminal domain a of the glycoprotein chaperone ERp57
1JWE	;		;	NMR Structure of the N-Terminal Domain of E. Coli Dnab Helicase
7YWR	;		;	NMR structure of the N-terminal domain of Nsp8 from SARS-CoV-2
5LXL	;		;	NMR structure of the N-terminal domain of the Bacteriophage T5 decoration protein pb10
1R6P	;		;	NMR structure of the N-terminal domain of trout cardiac troponin C at 7 C
3NLA	;		;	NMR STRUCTURE OF THE N-TERMINAL DOMAIN WITH A LINKER PORTION OF ANTARCTIC EEL POUT ANTIFREEZE PROTEIN RD3, 40 STRUCTURES
3RDN	;		;	NMR STRUCTURE OF THE N-TERMINAL DOMAIN WITH A LINKER PORTION OF ANTARCTIC EEL POUT ANTIFREEZE PROTEIN RD3, MINIMIZED AVERAGE STRUCTURE
1RI0	;		;	NMR structure of the N-terminal hath domain of human HDGF
1FAF	;		;	NMR STRUCTURE OF THE N-TERMINAL J DOMAIN OF MURINE POLYOMAVIRUS T ANTIGENS.
2LXI	;		;	NMR structure of the N-terminal RNA Binding domain 1 (RRM1) of the protein RBM10 from Homo sapiens
1P1T	;		;	NMR Structure of the N-terminal RRM domain of Cleavage stimulation factor 64 KDa subunit
2AZS	;		;	NMR structure of the N-terminal SH3 domain of Drk (calculated without NOE restraints)
1PN5	;		;	NMR structure of the NALP1 Pyrin domain (PYD)
2FN5	;		;	NMR Structure of the Neurabin PDZ domain (502-594)
1KG1	;		;	NMR structure of the NIP1 elicitor protein from Rhynchosporium secalis
2KM6	;		;	NMR structure of the NLRP7 Pyrin domain
2GDT	;		;	NMR Structure of the nonstructural protein 1 (nsp1) from the SARS coronavirus
2HSX	;		;	NMR Structure of the nonstructural protein 1 (nsp1) from the SARS coronavirus
1YSY	;		;	NMR Structure of the nonstructural Protein 7 (nsP7) from the SARS CoronaVirus
1UAP	;		;	NMR structure of the NTR domain from human PCOLCE1
2KKG	;		;	NMR structure of the octarepeat region of prion protein bound to pentosan polysulfate
1Q9F	;		;	NMR STRUCTURE OF THE OUTER MEMBRANE PROTEIN OMPX IN DHPC MICELLES
1Q9G	;		;	NMR STRUCTURE OF THE OUTER MEMBRANE PROTEIN OMPX IN DHPC MICELLES
2KIO	;		;	NMR structure of the oxidized yeast TOR1 FATC domain bound to DPC micelles at 318K
2M5U	;		;	NMR structure of the P4 hairpin of the CPEB3 ribozyme
2KKC	;		;	NMR structure of the p62 PB1 domain
2M8E	;		;	NMR structure of the PAI subdomain of Sleeping Beauty transposase
1CQO	;		;	NMR STRUCTURE OF THE PALINDROMIC DNA DECAMER D(GCGTTAACGC)2
2MDZ	;		;	NMR structure of the Paracoccus denitrificans Z-subunit determined in the presence of ADP
1NZM	;		;	NMR structure of the parallel-stranded DNA quadruplex d(TTAGGGT)4 complexed with the telomerase inhibitor RHPS4
2KUD	;		;	NMR structure of the PASTA domain 1 and 2 of Mycobacterium tuberculosis of PknB
2KUE	;		;	NMR structure of the PASTA domain 2 and 3 of Mycobacterium tuberculosis of PknB
2KUF	;		;	NMR structure of the PASTA domain 3 and 4 of Mycobacterium tuberculosis of PknB
2KUI	;		;	NMR structure of the PASTA domain of Mycobacterium tuberculosis of PknB
1EE7	;		;	NMR STRUCTURE OF THE PEPTAIBOL CHRYSOSPERMIN C BOUND TO DPC MICELLES
1W3D	;		;	NMR structure of the peripheral-subunit binding domain of Bacillus stearothermophilus E2p
1TWO	;		;	NMR structure of the pheromone binding protein from Antheraea polyphemus at acidic pH
2FM4	;		;	NMR structure of the phosphoryl carrier domain of pyruvate phosphate dikinase
2KB3	;		;	NMR Structure of the phosphorylated form of OdhI, pOdhI.
2LFW	;		;	NMR structure of the PhyRSL-NepR complex from Sphingomonas sp. Fr1
1XYQ	;		;	NMR structure of the pig prion protein
2LIC	;		;	NMR Structure of the Polyserine Tract of Apis mellifera Vitellogenin, residues 358-392
1HO2	;		;	NMR STRUCTURE OF THE POTASSIUM CHANNEL FRAGMENT L45 IN MICELLES
1HO7	;		;	NMR STRUCTURE OF THE POTASSIUM CHANNEL FRAGMENT L45 IN TFE
5U87	;		;	NMR structure of the precursor protein PawS1 comprising SFTI-1 and a seed storage albumin
6HPI	;		;	NMR structure of the pro-inflammatory cytokine interleukin-36alpha
2N7I	;		;	NMR structure of the prolactin receptor transmembrane domain
2MHD	;		;	NMR structure of the protein BACUNI_03114 from Bacteroides uniformis ATCC 8492
2LO1	;		;	NMR structure of the protein BC008182, a DNAJ-like domain from Homo sapiens
2LMI	;		;	NMR structure of the protein BC040485 from Homo sapiens
2M4L	;		;	NMR structure of the protein BT_0846 from Bacteroides thetaiotaomicron VPI-5482 (NP_809759.1)
2MQC	;		;	NMR structure of the protein BVU_0925 from Bacteroides vulgatus ATCC 8482
2KL4	;		;	NMR structure of the protein NB7804A
2LYY	;		;	NMR structure of the protein NB7890A from Shewanella sp
2MVB	;		;	NMR structure of the protein NP_344732.1 from Streptococcus pneumoniae TIGR4
2M7O	;		;	NMR Structure of the protein NP_346341.1 from Streptococcus pneumoniae
2LR4	;		;	NMR structure of the protein NP_390037.1 from Bacillus subtilis
2LYX	;		;	NMR structure of the protein NP_390345.1 from Bacilus subtilis
2KTS	;		;	NMR structure of the protein NP_415897.1
2MHE	;		;	NMR structure of the protein NP_419126.1 from Caulobacter crescentus
2MW1	;		;	NMR structure of the protein NP_809137.1 from Bacteroides thetaiotaomicron
2LLG	;		;	NMR structure of the protein NP_814968.1 from Enterococcus faecalis
2KA5	;		;	NMR Structure of the protein TM1081
2K9Z	;		;	NMR structure of the protein TM1112
2KA0	;		;	NMR structure of the protein TM1367
2LRG	;		;	NMR structure of the protein YP_001300941.1 from Bacteroides vulgatus
2LG7	;		;	NMR structure of the protein YP_001302112.1 from Parabacteroides Distasonis
2MMB	;		;	NMR structure of the protein YP_001712342.1 from Acinetobacter baumannii
2MCA	;		;	NMR structure of the protein YP_002937094.1 from Eubacterium rectale
2MWM	;		;	NMR structure of the protein YP_193882.1 from Lactobacillus acidophilus NCFM in presence of FMN
2LA7	;		;	NMR structure of the protein YP_557733.1 from Burkholderia xenovorans
2L6O	;		;	NMR structure of the protein YP_926445.1 from Shewanella Amazonensis
2LZ0	;		;	NMR structure of the protein ZP_02034617.1 from Bacteroides capillosus ATCC 29799
2MCT	;		;	NMR structure of the protein ZP_02042476.1 from Ruminococcus gnavus
2XEB	;		;	NMR STRUCTURE OF THE PROTEIN-UNBOUND SPLICEOSOMAL U4 SNRNA 5' STEM LOOP
2J48	;		;	NMR structure of the pseudo-receiver domain of the CikA protein.
2LL0	;		;	NMR structure of the putative ATPase regulatory protein YP_916642.1 from Paracoccus denitrificans
6X6N	;		;	NMR structure of the putative GTPase-Activating (GAP) domain of VopE
1UCP	;		;	NMR structure of the PYRIN domain of human ASC
1R7W	;		;	NMR STRUCTURE OF THE R(GGAGGACAUCCCUCACGGGUGACCGUGGUCCUCC), DOMAIN IV STEM-LOOP B OF ENTEROVIRAL IRES WITH AUCCCU BULGE
1R7Z	;		;	NMR STRUCTURE OF THE R(GGAGGACAUUCCUCACGGGUGACCGUGGUCCUCC), DOMAIN IV STEM-LOOP B OF ENTEROVIRAL IRES WITH AUUCCU BULGE
1UG8	;		;	NMR structure of the R3H domain from Poly(A)-specific Ribonuclease
2MRE	;		;	NMR structure of the Rad18-UBZ/ubiquitin complex
2JQI	;		;	NMR Structure of the Rad53 FHA1 domain in complex with a phosphothreonien peptide derived from Rad53 SCD1
3CRD	;		;	NMR STRUCTURE OF THE RAIDD CARD DOMAIN, 15 STRUCTURES
5UNK	;		;	NMR structure of the RED subdomain of the Sleeping Beauty transposase
1XJH	;		;	NMR structure of the redox switch domain of the E. coli Hsp33
1P6Q	;		;	NMR Structure of the Response regulator CheY2 from Sinorhizobium meliloti, complexed with Mg++
1AQG	;		;	NMR STRUCTURE OF THE RHODOPSIN-BOUND C-TERMINAL PEPTIDE OF THE TRANSDUCIN ALPHA-SUBUNIT, 20 STRUCTURES
1N88	;		;	NMR structure of the ribosomal protein L23 from Thermus thermophilus.
2LXH	;		;	NMR structure of the RING domain in ubiquitin ligase gp78
2ERR	;		;	NMR Structure of the RNA Binding Domain of Human Fox-1 in Complex with UGCAUGU
2LQ5	;		;	NMR structure of the RNA binding motif 39 (RBM39) from Mus musculus
2MAX	;		;	NMR structure of the RNA polymerase alpha subunit C-terminal domain from Helicobacter pylori
6CCJ	;		;	NMR structure of the Rous sarcoma virus matrix protein (M domain)
6CE5	;		;	NMR structure of the Rous sarcoma virus matrix protein (M-domain) in the presence of myo-inositol hexakisphosphate
2FVT	;		;	NMR Structure of the Rpa2829 protein from Rhodopseudomonas palustris: Northeast Structural Genomics Target RpR43
2MKS	;		;	NMR structure of the RRM domain of RBMX from homo sapiens
2MZR	;		;	NMR structure of the RRM1 domain of Hrb1
2MZS	;		;	NMR structure of the RRM2 domain of Hrb1
2M2B	;		;	NMR structure of the RRM2 domain of the protein RBM10 from Homo sapiens
2MZQ	;		;	NMR structure of the RRM3 domain of Gbp2
2MZT	;		;	NMR structure of the RRM3 domain of Hrb1
2MIJ	;		;	NMR structure of the S-linked glycopeptide sublancin 168
2RNJ	;		;	NMR Structure of The S. Aureus VraR DNA Binding Domain
1OW5	;		;	NMR structure of the Saccharomyces cerevisiae SAM (Sterile Alpha Motif) domain
1Z1V	;		;	NMR structure of the Saccharomyces cerevisiae Ste50 SAM domain
5X29	;		;	NMR structure of the SARS Coronavirus E protein pentameric ion channel
2KYS	;		;	NMR Structure of the SARS Coronavirus Nonstructural Protein Nsp7 in Solution at pH 6.5
2GRI	;		;	NMR Structure of the SARS-CoV non-structural protein nsp3a
2IDY	;		;	NMR Structure of the SARS-CoV non-structural protein nsp3a
6GGZ	;		;	NMR structure of the scorpion toxin AmmTx3
2KS4	;		;	NMR structure of the sea anemone actinoporin Sticholysin
5LAH	;		;	NMR structure of the sea anemone peptide tau-AnmTx Ueq 12-1 with an uncommon fold
2LY1	;		;	NMR structure of the second and third lotus domains of tudor domain-containing protein 7 (NMR ensemble overlay for Lotus #2)
2LY2	;		;	NMR structure of the second and third lotus domains of tudor domain-containing protein 7 (NMR ensemble overlay for Lotus #3)
2DDI	;		;	NMR structure of the second Kunitz domain of human WFIKKN1
2DDJ	;		;	NMR structure of the second Kunitz domain of human WFIKKN1
2LRI	;		;	NMR structure of the second PHD finger of AIRE (AIRE-PHD2)
2HGM	;		;	NMR structure of the second qRRM domain of human hnRNP F
6DG1	;		;	NMR structure of the second qRRM2 domain of human hnRNP H
6FDT	;		;	NMR structure of the second TPR domain of the human RPAP3 protein in complex with HSP70 peptide SGPTIEEVD
6FDP	;		;	NMR structure of the second TPR domain of the human RPAP3 protein in complex with HSP90 peptide DTSRMEEVD
2LWH	;		;	NMR Structure of the Self-Complementary 10 mer DNA Duplex 5'-GGATATATCC-3' in Complex with Netropsin
2LWG	;		;	NMR Structure of the Self-Complementary 10 mer DNA Oligonucleotide 5'-GGATATATCC-3'.
1GL5	;		;	NMR structure of the SH3 domain from the Tec protein tyrosine kinase
2M51	;		;	NMR structure of the SH3 domain of human RAS p21 protein activator (GTPase activating protein) 1
2O8K	;		;	NMR Structure of the Sigma-54 RpoN Domain Bound to the-24 Promoter Element
1NJQ	;		;	NMR structure of the single QALGGH zinc finger domain from Arabidopsis thaliana SUPERMAN protein
1F8Z	;		;	NMR STRUCTURE OF THE SIXTH LIGAND-BINDING MODULE OF THE LDL RECEPTOR
2KII	;		;	NMR structure of the SO2144 H-NOX domain from Shewanella oneidensis in the Fe(II)CO ligation state
2MJ1	;		;	NMR structure of the soluble A beta 17-34 peptide
2IGZ	;		;	NMR structure of the sterol-dependent antifungal antibiotic bacillomycin Lc
7JI1	;		;	NMR structure of the Streptococcus pyogenes NAD+-glycohydrolase translocation domain
1Q5L	;		;	NMR structure of the substrate binding domain of DnaK bound to the peptide NRLLLTG
1DG4	;		;	NMR STRUCTURE OF THE SUBSTRATE BINDING DOMAIN OF DNAK IN THE APO FORM
2BPR	;		;	NMR STRUCTURE OF THE SUBSTRATE BINDING DOMAIN OF DNAK, 25 STRUCTURES
1BPR	;		;	NMR STRUCTURE OF THE SUBSTRATE BINDING DOMAIN OF DNAK, MINIMIZED AVERAGE STRUCTURE
1XV3	;		;	NMR structure of the synthetic penaeidin 4
2JTX	;		;	NMR structure of the TFIIE-alpha carboxyl terminus
1IE5	;		;	NMR STRUCTURE OF THE THIRD IMMUNOGLOBULIN DOMAIN FROM THE NEURAL CELL ADHESION MOLECULE.
2HGN	;		;	NMR structure of the third qRRM domain of human hnRNP F
2M52	;		;	NMR Structure of the third RNA Recognition Motif (RRM) of U2 small nuclear ribonucleoprotein auxiliary factor (U2AF) 2
6I57	;		;	NMR structure of the third TPR domain of the human SPAG1 protein
1SV1	;		;	NMR structure of the ThKaiA180C-CIIABD complex (25-structure ensemble)
1SUY	;		;	NMR structure of the ThKaiA180C-CIIABD complex (average minimized structure)
1RDE	;		;	NMR structure of the thrombin-binding DNA aptamer stabilized by Sr2+
2KLU	;		;	NMR structure of the transmembrane and cytoplasmic domains of human CD4
2K0L	;		;	NMR structure of the transmembrane domain of the Outer Membrane Protein A from Klebsiella pneumoniae in DHPC micelles.
1MUZ	;		;	NMR STRUCTURE OF THE TUMOR SUPPRESSOR BIN1: ALTERNATIVE SPLICING IN MELANOMA AND INTERACTION WITH C-MYC
1MV0	;		;	NMR STRUCTURE OF THE TUMOR SUPPRESSOR BIN1: ALTERNATIVE SPLICING IN MELANOMA AND INTERACTION WITH C-MYC
1MV3	;		;	NMR STRUCTURE OF THE TUMOR SUPPRESSOR BIN1: ALTERNATIVE SPLICING IN MELANOMA AND INTERACTION WITH C-MYC
1M0V	;		;	NMR STRUCTURE OF THE TYPE III SECRETORY DOMAIN OF YERSINIA YOPH COMPLEXED WITH THE SKAP-HOM PHOSPHO-PEPTIDE N-acetyl-DEpYDDPF-NH2
7PS8	;		;	NMR Structure of the U3 RNA G-quadruplex
1Q02	;		;	NMR structure of the UBA domain of p62 (SQSTM1)
2K0B	;		;	NMR structure of the UBA domain of p62 (SQSTM1)
2L4E	;		;	NMR structure of the UBA domain of S. cerevisiae Dcn1
2L4F	;		;	NMR structure of the UBA domain of S. cerevisiae Dcn1 bound to ubiquitin
2JY8	;		;	NMR structure of the ubiquitin associated (UBA) domain of p62 (SQSTM1) in complex with ubiquitin. RDC refined
2JY7	;		;	NMR structure of the ubiquitin associated (UBA) domain of p62 (SQSTM1). RDC refined
2MRF	;		;	NMR structure of the ubiquitin-binding zinc finger (UBZ) domain from human Rad18
1I42	;		;	NMR STRUCTURE OF THE UBX DOMAIN FROM P47
1JRU	;		;	NMR STRUCTURE OF THE UBX DOMAIN FROM P47 (ENERGY MINIMISED AVERAGE)
2OJ7	;		;	NMR structure of the UGUU tetraloop of Duck Epsilon apical stem loop
2OJ8	;		;	NMR structure of the UGUU tetraloop of Duck Epsilon apical stem loop of the Hepatitis B virus
2LGL	;		;	NMR structure of the UHRF1 PHD domain
1LS8	;		;	NMR structure of the unliganded Bombyx mori pheromone-binding protein at physiological pH
2KB4	;		;	NMR structure of the unphosphorylated form of OdhI, OdhI.
1TBK	;		;	NMR structure of the VS ribozyme stem-loop V RNA in the absence of multivalent ions.
2LUH	;		;	NMR structure of the Vta1-Vps60 complex
5H7P	;		;	NMR structure of the Vta1NTD-Did2(176-204) complex
1XX8	;		;	NMR Structure of the W24A Mutant of the Hyperthermophile Sac7d Protein
2D3J	;		;	NMR structure of the WIF domain from human WIF-1
2KD3	;		;	NMR structure of the Wnt modulator protein Sclerostin
2L4W	;		;	NMR structure of the Xanthomonas VirB7
1K8N	;		;	NMR structure of the XBY2 DNA duplex, an analog of CK14 containing phosphorodithioate groups at C22 and C24
1F5X	;		;	NMR STRUCTURE OF THE Y174 AUTOINHIBITED DBL HOMOLOGY DOMAIN
2N3Y	;		;	NMR structure of the Y48pCMF variant of human cytochrome c in its reduced state
2JQL	;		;	NMR structure of the yeast Dun1 FHA domain in complex with a doubly phosphorylated (pT) peptide derived from Rad53 SCD1
1QGP	;		;	NMR STRUCTURE OF THE Z-ALPHA DOMAIN OF ADAR1, 15 STRUCTURES
7VKV	;		;	NMR structure of the zeta-subunit of the F1F0-ATPase from Sinorhizobium meliloti
1KLR	;		;	NMR Structure of the ZFY-6T[Y10F] Zinc Finger
1KLS	;		;	NMR Structure of the ZFY-6T[Y10L] Zinc Finger
1K81	;		;	NMR Structure of the Zinc-Ribbon Domain within Translation Initiation Factor 2 Subunit beta
8SXM	;		;	NMR structure of the ZNF750 zinc finger domain, Z*
2GLG	;		;	NMR structure of the [L23,A24]-sCT mutant
1DQB	;		;	NMR STRUCTURE OF THROMBOMODULIN EGF(4-5)
2L9I	;		;	NMR structure of thymosin alpha-1
5O2V	;		;	NMR structure of TIA-1 RRM1 domain
5H1I	;		;	NMR structure of TIBA, a chimera of SFTI
2CHK	;		;	NMR structure of TLLLLT quadruplex
5NAO	;		;	NMR structure of TLR4 transmembrane domain (624-657) in DPC micelles
5NAM	;		;	NMR structure of TLR4 transmembrane domain (624-670) in DMPG/DHPC bicelles
8I26	;		;	NMR structure of Toxoplasma gondii PDCD5 (cis form)
8I25	;		;	NMR structure of Toxoplasma gondii PDCD5 (trans form)
2DX2	;		;	NMR structure of TP (Target Peptide): monomeric 3_10 helix
2I2H	;		;	NMR structure of TPC3 in TFE
1Y4E	;		;	NMR structure of transmembrane segment IV of the NHE1 isoform of the Na+/H+ exchanger
1L2Y	;		;	NMR Structure of Trp-Cage Miniprotein Construct TC5b
6OVJ	;		;	NMR structure of truncated alpha conotoxin SII: Ile-SII(3-14)
1LE0	;		;	NMR structure of Tryptophan Zipper 1: a stable, monomeric beta-hairpin with a type II' turn
1LE1	;		;	NMR Structure of Tryptophan Zipper 2: A stable, Monomeric Beta-Hairpin with a Type I' Turn
1LE3	;		;	NMR Structure of Tryptophan Zipper 4: A Stable Beta-Hairpin Peptide Based on the C-terminal Hairpin of the B1 Domain of Protein G
7DFE	;		;	NMR structure of TuSp2-RP
2LXP	;		;	NMR structure of two domains in ubiquitin ligase gp78, RING and G2BR, bound to its conjugating enzyme Ube2g
1Q5F	;		;	NMR Structure of Type IVb pilin (PilS) from Salmonella typhi
6BA3	;		;	NMR structure of U21-hexatoxin-Hi1a toxin from Australian Funnel-web spider Hadronyche infensa
2KF0	;		;	NMR structure of U6 ISL at pH 7.0
2KEZ	;		;	NMR structure of U6 ISL at pH 8.0
2I2J	;		;	NMR structure of UA159sp in TFE
6FZK	;		;	NMR structure of UB2H, regulatory domain of PBP1b from E. coli
2MR9	;		;	NMR structure of UBA domain of DNA-damage-inducible 1 protein (Ddi1)
2JY5	;		;	NMR structure of Ubiquilin 1 UBA domain
1MG8	;		;	NMR structure of ubiquitin-like domain in murine Parkin
1P1A	;		;	NMR structure of ubiquitin-like domain of hHR23B
2LGK	;		;	NMR Structure of UHRF1 PHD domains in a complex with histone H3 peptide
2L3R	;		;	NMR structure of UHRF1 Tandem Tudor Domains in a complex with Histone H3 peptide
5IAY	;		;	NMR structure of UHRF1 Tandem Tudor Domains in a complex with Spacer peptide
5JTK	;		;	NMR structure of Uncharacterized protein from Pseudomonas aeruginosa PAO1
2MY7	;		;	NMR Structure of unfolding intermediate state of RRM-3 domain of ETR-3
1Z1M	;		;	NMR structure of unliganded MDM2
1OPQ	;		;	NMR structure of unmethylated GATC site
2LAC	;		;	NMR structure of unmodified_ASL_Tyr
1ZLL	;		;	NMR Structure of Unphosphorylated Human Phospholamban Pentamer
2GZO	;		;	NMR structure of UPF0301 PROTEIN SO3346 from Shewanella oneidensis: Northeast Structural Genomics Consortium target SOR39
2K41	;		;	NMR structure of uridine bulged RNA duplex
6HVB	;		;	NMR structure of Urotensin Peptide Asp-c[Cys-Phe-(N-Me)Trp-Lys-Tyr-Cys]-Val in SDS solution
6HVC	;		;	NMR structure of Urotensin Peptide Asp-c[Cys-Phe-Trp-(N-Me)Lys-Tyr-Cys]-Val in SDS solution
5ZB6	;		;	NMR structure of UVI31+
2RRI	;		;	NMR structure of vasoactive intestinal peptide in DPC Micelle
2RRH	;		;	NMR structure of vasoactive intestinal peptide in Methanol
1CZ4	;		;	NMR STRUCTURE OF VAT-N: THE N-TERMINAL DOMAIN OF VAT (VCP-LIKE ATPASE OF THERMOPLASMA)
1CZ5	;		;	NMR STRUCTURE OF VAT-N: THE N-TERMINAL DOMAIN OF VAT (VCP-LIKE ATPASE OF THERMOPLASMA)
2MWL	;		;	NMR structure of VG16KRKP, an antimicrobial peptide in LPS
2N01	;		;	NMR structure of VirB9 C-terminal domain in complex with VirB7 N-terminal domain from Xanthomonas citri's T4SS
1WN4	;		;	NMR Structure of VoNTR
1YXR	;		;	NMR Structure of VPS4A MIT Domain
2K3W	;		;	NMR structure of VPS4A-MIT-CHMP6
6ZSS	;		;	NMR structure of water-soluble domain of human Lynx2 (Lypd1) protein
1TK7	;		;	NMR structure of WW domains (WW3-4) from Suppressor of Deltex
6NM2	;		;	NMR Structure of WW291
6NM3	;		;	NMR structure of WW295
2NCW	;		;	NMR structure of WWWKYE21 structure in LPS micelles
2GM2	;		;	NMR structure of Xanthomonas campestris XCC1710: Northeast Structural Genomics Consortium target XcR35
2MPJ	;		;	NMR structure of Xenopus RecQ4 zinc knuckle
5YDX	;		;	NMR structure of YAP1-2 WW1 domain with LATS1 PPxY motif complex
5YDY	;		;	NMR structure of YAP1-2 WW2 domain with LATS1 PPxY motif complex
2KPU	;		;	NMR Structure of YbbR family protein Dhaf_0833 (residues 32-118) from Desulfitobacterium hafniense DCB-2: Northeast Structural Genomics Consortium target DhR29B
2L5N	;		;	NMR Structure of YbbR family protein Dhaf_0833 (residues 32-118) from Desulfitobacterium hafniense DCB-2: Northeast Structural Genomics Consortium target DhR29B
5VSO	;		;	NMR structure of Ydj1 J-domain, a cytosolic Hsp40 from Saccharomyces cerevisiae
2N94	;		;	NMR structure of yeast Bcd1 protein zinc finger
2JQJ	;		;	NMR structure of yeast Dun1 FHA domain
2N95	;		;	NMR structure of yeast Hit1 protein zinc finger
1RKL	;		;	NMR structure of yeast oligosaccharyltransferase subunit Ost4p
2N2M	;		;	NMR structure of yersinia pestis Ail (attachment invasion locus) in decylphosphocholine micelles
2N2L	;		;	NMR structure of yersinia pestis ail (attachment invasion locus) in decylphosphocholine micelles calculated with implicit membrane solvation
1IH9	;		;	NMR Structure of Zervamicin IIB (peptaibol antibiotic) Bound to DPC Micelles
1N1U	;		;	NMR structure of [Ala1,15]kalata B1
1DUM	;		;	NMR STRUCTURE OF [F5Y, F16W] MAGAININ 2 BOUND TO PHOSPHOLIPID VESICLES
1Z2T	;		;	NMR structure study of anchor peptide Ser65-Leu87 of enzyme acholeplasma laidlawii Monoglycosyldiacyl Glycerol Synthase (alMGS) in DHPC micelles
2LVL	;		;	NMR Structure the lantibiotic immunity protein SpaI
1RL5	;		;	NMR structure with tightly bound water molecule of cytotoxin I from Naja oxiana in aqueous solution (major form)
1CB9	;		;	NMR STRUCTURE WITH TIGHTLY BOUND WATER MOLECULES OF CYTOTOXIN II (CARDIOTOXIN) FROM NAJA NAJA OXIANA IN AQUEOUS SOLUTION (MAJOR FORM).
1CCQ	;		;	NMR STRUCTURE WITH TIGHTLY BOUND WATER MOLECULES OF CYTOTOXIN II (CARDIOTOXIN) FROM NAJA NAJA OXIANA IN AQUEOUS SOLUTION (MINOR FORM).
2RSW	;		;	NMR structure, Localization and Vesicle fusion of Chikungunya virus Fusion peptide
2KJL	;		;	NMR structures of a designed Cyanovirin-N homolog lectin; LKAMG
1CS2	;		;	NMR STRUCTURES OF B-DNA D(CTACTGCTTTAG).D(CTAAAGCAGTAG)
1DBY	;		;	NMR STRUCTURES OF CHLOROPLAST THIOREDOXIN M CH2 FROM THE GREEN ALGA CHLAMYDOMONAS REINHARDTII
2K1K	;		;	NMR structures of dimeric transmembrane domain of the receptor tyrosine kinase EphA1 in lipid bicelles at pH 4.3
2K1L	;		;	NMR structures of dimeric transmembrane domain of the receptor tyrosine kinase EphA1 in lipid bicelles at pH 6.3
1FCT	;		;	NMR STRUCTURES OF FERREDOXIN CHLOROPLASTIC TRANSIT PEPTIDE FROM CHLAMYDOMONAS REINHARDTII PROMOTED BY TRIFLUOROETHANOL IN AQUEOUS SOLUTION
2KDL	;		;	NMR structures of GA95 and GB95, two designed proteins with 95% sequence identity but different folds and functions
2KDM	;		;	NMR structures of GA95 and GB95, two designed proteins with 95% sequence identity but different folds and functions
2M5I	;		;	NMR structures of human apoptotic protein tBid in LPPG micelle
5J6T	;		;	NMR structures of hylin-a1 analogs: Hylin-Ac
5J6V	;		;	NMR structures of hylin-a1 analogs: Hylin-D
5J6W	;		;	NMR structures of hylin-a1 analogs: Hylin-K
1LUI	;		;	NMR Structures of Itk SH2 domain, Pro287cis isoform, ensemble of 20 low energy structures
1FH3	;		;	NMR STRUCTURES OF LQH III ALPHA-LIKE SCORPION TOXIN FROM LEIURUS QUINQUESTRIATUS CORRESPONDING TO THE MAJOR CONFORMER IN SOLUTION
1DE1	;		;	NMR STRUCTURES OF OXIDIZED BACTERIOPHAGE T4 GLUTAREDOXIN
1NZS	;		;	NMR structures of phosphorylated carboxy terminus of bovine rhodopsin in arrestin-bound state
1DE2	;		;	NMR STRUCTURES OF REDUCED BACTERIOPHAGE T4 GLUTAREDOXIN
2H80	;		;	NMR structures of SAM domain of Deleted in Liver Cancer 2 (DLC2)
2LWZ	;		;	NMR Structures of Single-chain Insulin
2MAW	;		;	NMR structures of the alpha7 nAChR transmembrane domain.
1IVT	;		;	NMR structures of the C-terminal globular domain of human lamin A/C
1AIW	;		;	NMR STRUCTURES OF THE CELLULOSE-BINDING DOMAIN OF THE ENDOGLUCANASE Z FROM ERWINIA CHRYSANTHEMI, 23 STRUCTURES
2ICZ	;		;	NMR Structures of the Expanded DNA 10bp xTGxTAxCxGCxAxGT:xACTxGCGxTAxCA
2K58	;		;	NMR structures of the first transmembrane domain of the neuronal acetylcholine receptor beta 2 subunit
1L3E	;		;	NMR Structures of the HIF-1alpha CTAD/p300 CH1 Complex
2BBP	;		;	NMR structures of the peptide linked to the genome (VPg) of poliovirus
2BBL	;		;	NMR structures of the peptide linked to the genome (VPg) of poliovirus in a stabilizing solvent
2K59	;		;	NMR structures of the second transmembrane domain of the neuronal acetylcholine receptor beta 2 subunit
2LM2	;		;	NMR structures of the transmembrane domains of the AChR b2 subunit
2LLY	;		;	NMR structures of the transmembrane domains of the nAChR a4 subunit
1K0P	;		;	NMR Structures of the Zinc Finger Domain of Human DNA Polymerase-alpha
1N5G	;		;	NMR Structures of the Zinc Finger Domain of Human DNA Polymerase-alpha
2KSR	;		;	NMR structures of TM domain of the n-Acetylcholine receptor b2 subunit
2NVJ	;		;	NMR structures of transmembrane segment from subunit a from the yeast proton V-ATPase
1GH1	;		;	NMR STRUCTURES OF WHEAT NONSPECIFIC LIPID TRANSFER PROTEIN
2Z4D	;		;	NMR Structures of Yeast Proteasome Component Rpn13
5IEW	;		;	NMR Structures Show Unwinding of the GCN4p Coiled Coil Superhelix Accompanying Disruption of Ion Pairs at Acidic pH
5IIR	;		;	NMR Structures Show Unwinding of the GCN4p Coiled Coil Superhelix Accompanying Disruption of Ion Pairs at Acidic pH
7XGA	;		;	NMR strucutre of chimeric protein for model of PHD-Stella complex
1CYA	;		;	NMR STUDIES OF (U-13C)CYCLOSPORIN A BOUND TO CYCLOPHILIN: BOUND CONFORMATION AND PORTIONS OF CYCLOSPORIN INVOLVED IN BINDING
1CYB	;		;	NMR STUDIES OF (U-13C)CYCLOSPORIN A BOUND TO CYCLOPHILIN: BOUND CONFORMATION AND PORTIONS OF CYCLOSPORIN INVOLVED IN BINDING
2KB1	;		;	NMR studies of a channel protein without membrane: structure and dynamics of water-solubilized KcsA
2K1E	;		;	NMR studies of a channel protein without membranes: structure and dynamics of water-solubilized KcsA
2K1D	;		;	NMR Studies of a Pathogenic Mutant (D178N) of the Human Prion Protein
1TFB	;		;	NMR STUDIES OF HUMAN GENERAL TRANSCRIPTION FACTOR TFIIB: DYNAMICS AND INTERACTION WITH VP16 ACTIVATION DOMAIN, 20 STRUCTURES
2MIV	;		;	NMR studies of N2-guanine adducts derived from the tumorigen dibenzo[a,l]pyrene in DNA: Impact of adduct stereochemistry, size, and local DNA structure on solution conformations
2CNJ	;		;	NMR studies on the interaction of Insulin-Growth Factor II (IGF-II) with IGF2R domain 11
1ROE	;		;	NMR STUDY OF 2FE-2S FERREDOXIN OF SYNECHOCOCCUS ELONGATUS
1ROF	;		;	NMR STUDY OF 4FE-4S FERREDOXIN OF THERMATOGA MARITIMA
2MMX	;		;	NMR study of 6aJL2
1EMO	;		;	NMR STUDY OF A PAIR OF FIBRILLIN CA2+ BINDING EPIDERMAL GROWTH FACTOR-LIKE DOMAINS, 22 STRUCTURES
1EMN	;		;	NMR STUDY OF A PAIR OF FIBRILLIN CA2+ BINDING EPIDERMAL GROWTH FACTOR-LIKE DOMAINS, MINIMIZED AVERAGE STRUCTURE
1HJ7	;		;	NMR study of a pair of LDL receptor Ca2+ binding epidermal growth factor-like domains, 20 structures
1RML	;		;	NMR STUDY OF ACID FIBROBLAST GROWTH FACTOR BOUND TO 1,3,6-NAPHTHALENE TRISULPHONATE, 26 STRUCTURES
1FJB	;		;	NMR Study of an 11-Mer DNA Duplex Containing 7,8-Dihydro-8-Oxoadenine (AOXO) Opposite Thymine
1FV8	;		;	NMR STUDY OF AN HETEROCHIRAL HAIRPIN
1WRT	;		;	NMR STUDY OF APO TRP REPRESSOR
1FKY	;		;	NMR STUDY OF B-DNA CONTAINING A MISMATCHED BASE PAIR IN THE 29-39 K-RAS GENE SEQUENCE: CC CT C+C C+T, 2 STRUCTURES
1FKZ	;		;	NMR STUDY OF B-DNA CONTAINING A MISMATCHED BASE PAIR IN THE 29-39 K-RAS GENE SEQUENCE: CC CT C+C C+T, 2 STRUCTURES
1KXS	;		;	NMR STUDY OF B-DNA CONTAINING A MODIFIED BASE PAIR: THE 2'-DEOXYADENOSINE 3-(2-HYDROXYETHYL-2'-DEOXYURIDINE)
1BWY	;		;	NMR STUDY OF BOVINE HEART FATTY ACID BINDING PROTEIN
2BI6	;		;	NMR STUDY OF BROMELAIN INHIBITOR VI FROM PINEAPPLE STEM
1JUN	;		;	NMR STUDY OF C-JUN HOMODIMER
1FJA	;		;	NMR STUDY OF DEOXYRIBONUCLEIC ACID COMPLEXED WITH ACTINOMYCIN D
1AL9	;		;	NMR STUDY OF DNA (5'-D(*AP*CP*GP*TP*AP*CP*GP*T)-3') SELF-COMPLEMENTARY DUPLEX COMPLEXED WITH A BIS-DAUNORUBICIN, MINIMIZED AVERAGE STRUCTURE
1DSC	;		;	NMR STUDY OF DNA (5'-D(*GP*AP*AP*GP*CP*TP*TP*C)-3') SELF-COMPLEMENTARY DUPLEX COMPLEXED WITH ACTINOMYCIN D, MINIMIZED AVERAGE STRUCTURE
1DSD	;		;	NMR STUDY OF DNA (5'-D(*GP*AP*TP*GP*CP*TP*TP*C)-3') T:T MISMATCHED DUPLEX COMPLEXED WITH ACTINOMYCIN D, MINIMIZED AVERAGE STRUCTURE
1AMD	;		;	NMR STUDY OF DNA (5'-D(*TP*GP*TP*AP*CP*A)-3') SELF-COMPLEMENTARY DUPLEX COMPLEXED WITH A BIS-DAUNORUBICIN WP-652, MINIMIZED AVERAGE STRUCTURE
1WRS	;		;	NMR STUDY OF HOLO TRP REPRESSOR
3IFB	;		;	NMR STUDY OF HUMAN INTESTINAL FATTY ACID BINDING PROTEIN
1EAL	;		;	NMR STUDY OF ILEAL LIPID BINDING PROTEIN
1CV9	;		;	NMR STUDY OF ITAM PEPTIDE SUBSTRATE
2M35	;		;	NMR study of k-Ssm1a
1IKM	;		;	NMR study of monomeric human interleukin-8 (30 structures)
1IKL	;		;	NMR study of monomeric human interleukin-8 (minimized average structure)
1EIT	;		;	NMR STUDY OF MU-AGATOXIN
1MUT	;		;	NMR STUDY OF MUTT ENZYME, A NUCLEOSIDE TRIPHOSPHATE PYROPHOSPHOHYDROLASE
2BTA	;		;	NMR STUDY OF N-TERMINAL HUMAN BAND 3 PEPTIDE, RESIDUES 1-15
2BTB	;		;	NMR STUDY OF N-TERMINAL HUMAN BAND 3 PEPTIDE, RESIDUES 1-15
1OMG	;		;	NMR STUDY OF OMEGA-CONOTOXIN MVIIA
2MBT	;		;	NMR study of PaDsbA
1NOE	;		;	NMR STUDY OF REDUCED HIGH POTENTIAL IRON SULFUR PROTEIN
1B4O	;		;	NMR STUDY OF SSO7D MUTANT (F31A) MINIMIZED AVERAGE STRUCTURE
1NCS	;		;	NMR STUDY OF SWI5 ZINC FINGER DOMAIN 1
1SOC	;		;	NMR STUDY OF THE BACKBONE CONFORMATIONAL EQUILIBRIA OF SANDOSTATIN, MINIMIZED AVERAGE BETA-SHEET STRUCTURE
2SOC	;		;	NMR STUDY OF THE BACKBONE CONFORMATIONAL EQUILIBRIA OF SANDOSTATIN, TWO REPRESENTATIVE MINIMUM ENERGY PARTIALLY HELICAL STRUCTURES
1LMJ	;		;	NMR Study of the Fibrillin-1 cbEGF12-13 Pair of Ca2+ Binding Epidermal Growth Factor-like Domains
1SUT	;		;	NMR STUDY OF THE PROLINE REPEAT FROM TUS
1QLY	;		;	NMR Study of the SH3 Domain From Bruton's Tyrosine Kinase, 20 Structures
1A0N	;		;	NMR STUDY OF THE SH3 DOMAIN FROM FYN PROTO-ONCOGENE TYROSINE KINASE COMPLEXED WITH THE SYNTHETIC PEPTIDE P2L CORRESPONDING TO RESIDUES 91-104 OF THE P85 SUBUNIT OF PI3-KINASE, FAMILY OF 25 STRUCTURES
1AZG	;		;	NMR STUDY OF THE SH3 DOMAIN FROM FYN PROTO-ONCOGENE TYROSINE KINASE KINASE COMPLEXED WITH THE SYNTHETIC PEPTIDE P2L CORRESPONDING TO RESIDUES 91-104 OF THE P85 SUBUNIT OF PI3-KINASE, MINIMIZED AVERAGE (PROBMAP) STRUCTURE
1NYG	;		;	NMR STUDY OF THE SH3 DOMAIN FROM FYN PROTO-ONCOGENE TYROSINE KINASE, FAMILY OF 20 STRUCTURES
1NYF	;		;	NMR STUDY OF THE SH3 DOMAIN FROM FYN PROTO-ONCOGENE TYROSINE KINASE, MINIMIZED AVERAGE (PROBMAP) STRUCTURE
1KSQ	;		;	NMR Study of the Third TB Domain from Latent Transforming Growth Factor-beta Binding Protein-1
1APJ	;		;	NMR STUDY OF THE TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN-LIKE DOMAIN (TB MODULE/8-CYS DOMAIN), NMR, 21 STRUCTURES
1CO0	;		;	NMR STUDY OF TRP REPRESSOR-MTR OPERATOR DNA COMPLEX
1RCS	;		;	NMR STUDY OF TRP REPRESSOR-OPERATOR DNA COMPLEX
1VIG	;		;	NMR STUDY OF VIGILIN, REPEAT 6, 40 STRUCTURES
1VIH	;		;	NMR STUDY OF VIGILIN, REPEAT 6, MINIMIZED AVERAGE STRUCTURE
1TNE	;		;	NMR STUDY OF Z-DNA AT PHYSIOLOGICAL SALT CONDITIONS, MINIMIZED AVERAGE STRUCTURE
1FQZ	;		;	NMR VALIDATED MODEL OF DOMAIN IIID OF HEPATITIS C VIRUS INTERNAL RIBOSOME ENTRY SITE
1QM9	;		;	NMR, REPRESENTATIVE STRUCTURE
2MMA	;		;	NMR-based docking model of GrxS14-BolA2 apo-heterodimer from Arabidopsis thaliana
5Y22	;		;	NMR-Based Model of the 22 Amino Acid Peptide in Polysialyltransferase Domain (PSTD) of the Polysialyltransferase ST8Sia IV
5Y3U	;		;	NMR-Based Model of the 22 Amino Acid Peptide in Polysialyltransferase Domain (PSTD) of the Polysialyltransferase ST8Sia IV in the Presence of Polysialic Acid (PolySia)
2C06	;		;	NMR-based model of the complex of the toxin Kid and a 5-nucleotide substrate RNA fragment (AUACA)
1R36	;		;	NMR-based structure of autoinhibited murine Ets-1 deltaN301
1IIO	;		;	NMR-Based Structure of the Conserved Protein MTH865 from the Archea Methanobacterium thermoautotrophicum
6CAH	;		;	NMR-based structure of the FHA-2 domain from Mycobacterium tuberculosis ABC transporter Rv1747
8E1D	;		;	NMR-derived ensemble of the TAZ2 domain of p300 bound to the microphthalmia-associated transcription factor
1QSK	;		;	NMR-DERIVED SOLUTION STRUCTURE OF A FIVE-ADENINE BULGE LOOP WITHIN A DNA DUPLEX
1PRR	;		;	NMR-DERIVED THREE-DIMENSIONAL SOLUTION STRUCTURE OF PROTEIN S COMPLEXED WITH CALCIUM
1PRS	;		;	NMR-DERIVED THREE-DIMENSIONAL SOLUTION STRUCTURE OF PROTEIN S COMPLEXED WITH CALCIUM
6W4F	;		;	NMR-driven structure of KRAS4B-GDP homodimer on a lipid bilayer nanodisc
6W4E	;		;	NMR-driven structure of KRAS4B-GTP homodimer on a lipid bilayer nanodisc
7RSC	;		;	NMR-driven structure of the KRAS4B-G12D ""alpha-alpha"" dimer on a lipid bilayer nanodisc
7RSE	;		;	NMR-driven structure of the KRAS4B-G12D ""alpha-beta"" dimer on a lipid bilayer nanodisc
7OFV	;	1.43	;	NMR-guided design of potent and selective EphA4 agonistic ligands
2KHO	;		;	NMR-RDC / XRAY structure of E. coli HSP70 (DNAK) chaperone (1-605) complexed with ADP and substrate
2N7M	;		;	NMR-SAXS/WAXS Structure of the core of the U4/U6 di-snRNA
2GMO	;		;	NMR-structure of an independently folded C-terminal domain of influenza polymerase subunit PB2
2MZJ	;		;	NMR-structure of the Nop6-RBD from S. cerevisiae
1OKD	;		;	NMR-structure of tryparedoxin 1
1S05	;		;	NMR-validated structural model for oxidized R.palustris cytochrome c556
7AQT	;		;	NMR2 structure of BRD4-BD2 in complex with iBET-762
7B9X	;		;	NMR2 structure of TRIM24-BD in complex with a precursor of IACS-9571
5A5S	;	1.36	;	NN-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 5-5-methoxypyridin-3-yl-3- methyl-8-piperidin-4-ylamino-1,2-dihydro-1,7-naphthyridin-2-one
6LUN	;	1.9	;	NN2101 Antibody Fab fragment
6X3I	;	2.268	;	NNAS Fc mutant
3DGJ	;	1.8	;	NNFGAIL segment from Islet Amyloid Polypeptide (IAPP or amylin)
3FVA	;	1.458	;	NNQNTF segment from elk prion
2ONX	;	1.52	;	NNQQ peptide corresponding to residues 8-11 of yeast prion sup35 (alternate crystal form)
4GFL	;	2.3	;	NO mechanism, slma
6ZAV	;	1.19	;	NO-bound copper nitrite reductase from Bradyrhizobium sp. ORS 375 (two-domain) at 1.19 A resolution (unrestrained, full matrix refinement by SHELX)
2FC2	;	2.2	;	NO-HEME complex in a bacterial nitric oxide synthase. An Fe(III)-NO may cause nitrosation.
2XEC	;	2.2	;	Nocardia farcinica maleate cis-trans isomerase bound to TRIS
2XED	;	1.95	;	Nocardia farcinica maleate cis-trans isomerase C194S mutant with a covalently bound succinylcysteine intermediate
6NF0	;	2.7	;	Nocturnin with bound NADPH substrate
4E9M	;	2.15	;	NOD1 card domain with three disulfide-clinched, domain-swapped dimers in the asymmetric unit
6MRY	;	2.3	;	NoD173 plant defensin
4N1D	;	1.912	;	Nodal/BMP2 chimera NB250
1NOV	;	3.5	;	NODAMURA VIRUS
3G80	;	2.5	;	Nodamura virus protein b2, RNA-binding domain
8FMB	;	6.3	;	Nodavirus RNA replication protein A polymerase domain, local refinement
8FMA	;	3.1	;	Nodavirus RNA replication proto-crown, detergent-solubliized C11 multimer
8FM9	;	3.2	;	Nodavirus RNA replication proto-crown, detergent-solubliized C12 multimer
1AY3	;		;	Nodularin from Nodularia spumigena
6TIR	;		;	NOE based model of hVDAC-1 bound to beta-NADH in detergent micelles
2LYK	;		;	NOE-based 3D structure of the CylR2 homodimer at 270K (-3 Celsius degrees)
2LYJ	;		;	NOE-based 3D structure of the CylR2 homodimer at 298K
2LYP	;		;	NOE-based 3D structure of the monomer of CylR2 in equilibrium with predissociated homodimer at 266K (-7 Celsius degrees)
2LYQ	;		;	NOE-based 3D structure of the monomeric intermediate of CylR2 at 262K (-11 Celsius degrees)
2LYS	;		;	NOE-based 3D structure of the monomeric partially-folded intermediate of CylR2 at 257K (-16 Celsius degrees)
2LYR	;		;	NOE-based 3D structure of the monomeric partially-folded intermediate of CylR2 at 259K (-14 Celsius degrees)
2LYL	;		;	NOE-based 3D structure of the predissociated homodimer of CylR2 in equilibrium with monomer at 266K (-7 Celsius degrees)
2MUV	;		;	NOE-based model of the influenza A virus M2 (19-49) bound to drug 11
2MUW	;		;	NOE-based model of the influenza A virus N31S mutant (19-49) bound to drug 11
1ZRI	;		;	NOE-based solution structure with dipolar coupling restraints of rat OMP (olfactory marker protein)
7A58	;		;	NOE-only solution structure of the Iron-Sulfur protein PioC from Rhodopseudomonas palustris TIE-1
7OF1	;	3.1	;	Nog1-TAP associated immature ribosomal particle population A from S. cerevisiae
7OH3	;	3.4	;	Nog1-TAP associated immature ribosomal particle population B from S. cerevisiae
7OHQ	;	3.1	;	Nog1-TAP associated immature ribosomal particle population C from S. cerevisiae
7OHR	;	4.72	;	Nog1-TAP associated immature ribosomal particle population E from S. cerevisiae
7OHS	;	4.38	;	Nog1-TAP associated immature ribosomal particle population F from S. cerevisiae
7OHT	;	4.7	;	Nog1-TAP associated immature ribosomal particles from S. cerevisiae after rpL2 expression shut down, population A
7OHU	;	3.7	;	Nog1-TAP associated immature ribosomal particles from S. cerevisiae after rpL2 expression shut down, population B
7OHV	;	3.9	;	Nog1-TAP associated immature ribosomal particles from S. cerevisiae after rpL2 expression shut down, population C
7OHP	;	3.9	;	Nog1-TAP associated immature ribosomal particles from S. cerevisiae after rpL25 expression shut down, population A
7OHW	;	3.5	;	Nog1-TAP associated immature ribosomal particles from S. cerevisiae after rpL25 expression shut down, population B
7OHX	;	3.3	;	Nog1-TAP associated immature ribosomal particles from S. cerevisiae after rpL34 expression shut down, population A
7OHY	;	3.9	;	Nog1-TAP associated immature ribosomal particles from S. cerevisiae after rpL34 expression shut down, population B
2JV5	;		;	Nogo54
2KO2	;		;	NOGO66
6X19	;	2.1	;	Non peptide agonist CHU-128, bound to Glucagon-Like peptide-1 (GLP-1) Receptor
6X1A	;	2.5	;	Non peptide agonist PF-06882961, bound to Glucagon-Like peptide-1 (GLP-1) Receptor
3GJ1	;	1.8	;	Non photoactivated state of PA-GFP
5MKP	;	2.5	;	Non redox thiolation in transfer RNAs occuring via sulfur activation by a [4Fe-4S] cluster
7KW3	;	2.3	;	Non Ribosomal PCP domain
1L9V	;	2.6	;	Non Structural protein encoded by gene segment 8 of rotavirus (NSP2), an NTPase, ssRNA binding and nucleic acid helix-destabilizing protein
6K10	;	1.78962	;	Non substrate bound state of Staphylococcus Aureus AldH
1RCX	;	2.4	;	NON-ACTIVATED SPINACH RUBISCO IN COMPLEX WITH ITS SUBSTRATE RIBULOSE-1,5-BISPHOSPHATE
2WFZ	;	1.95	;	NON-AGED CONJUGATE OF TORPEDO CALIFORNICA ACETYLCHOLINESTERASE WITH SOMAN
2WG2	;	1.95	;	NON-AGED CONJUGATE OF TORPEDO CALIFORNICA ACETYLCHOLINESTERASE WITH SOMAN (ALTERNATIVE REFINEMENT)
2C0Q	;	2.5	;	non-aged form of mouse acetylcholinesterase inhibited by tabun
3DL4	;	2.5	;	Non-Aged Form of Mouse Acetylcholinesterase Inhibited by Tabun- Update
6G17	;	2.2	;	Non-aged form of Torpedo californica acetylcholinesterase inhibited by nerve agent tabun
6G4O	;	2.78	;	Non-aged form of Torpedo californica acetylcholinesterase inhibited by tabun analog NEDPA bound to uncharged reactivator 1
6G4P	;	2.83	;	Non-aged form of Torpedo californica acetylcholinesterase inhibited by tabun analog NEDPA bound to uncharged reactivator 2
4ZTV	;	2.01	;	Non-anthranilate-like inhibitor (TAMU-A7) complexed with anthranilate phosphoribosyltransferase (trpD) from Mycobacterium tuberculosis in absence of PRPP
2WQ5	;	1.65	;	Non-antibiotic properties of tetracyclines: structural basis for inhibition of secretory phospholipase A2.
6NMV	;	2.61	;	Non-Blocking Fab 218 anti-SIRP-alpha antibody in complex with SIRP-alpha Variant 1
6NMT	;	1.83	;	Non-Blocking Fab 3 anti-SIRP-alpha antibody in complex with SIRP-alpha Variant 1
8BAF	;	1.6	;	Non-canonical quadruplex containing the oxidation product 8-oxoguanine
7ZVI	;	2.973	;	Non-canonical Staphylococcus aureus pathogenicity island repression
7P4A	;	2.901	;	Non-canonical Staphylococcus aureus pathogenicity island repression.
1PH0	;	2.2	;	Non-carboxylic Acid-Containing Inhibitor of PTP1B Targeting the Second Phosphotyrosine Site
2YPJ	;	2.35	;	Non-catalytic carbohydrate binding module CBM65B
4A8F	;	3.3	;	Non-Catalytic Ions Direct the RNA-Dependent RNA Polymerase of Bacterial dsRNA virus phi6 from De Novo Initiation to Elongation
4A8K	;	3.5	;	Non-Catalytic Ions Direct the RNA-Dependent RNA Polymerase of Bacterial dsRNA virus phi6 from De Novo Initiation to Elongation
4A8M	;	2.92	;	Non-Catalytic Ions Direct the RNA-Dependent RNA Polymerase of Bacterial dsRNA virus phi6 from De Novo Initiation to Elongation
4A8O	;	2.67	;	Non-Catalytic Ions Direct the RNA-Dependent RNA Polymerase of Bacterial dsRNA virus phi6 from De Novo Initiation to Elongation
4A8Q	;	3.06	;	Non-Catalytic Ions Direct the RNA-Dependent RNA Polymerase of Bacterial dsRNA virus phi6 from De Novo Initiation to Elongation
4A8S	;	2.9	;	Non-Catalytic Ions Direct the RNA-Dependent RNA Polymerase of Bacterial dsRNA virus phi6 from De Novo Initiation to Elongation
4A8W	;	3.04	;	Non-Catalytic Ions Direct the RNA-Dependent RNA Polymerase of Bacterial dsRNA virus phi6 from De Novo Initiation to Elongation
4A8Y	;	3.41	;	Non-Catalytic Ions Direct the RNA-Dependent RNA Polymerase of Bacterial dsRNA virus phi6 from De Novo Initiation to Elongation
2XDH	;	1.96	;	Non-cellulosomal cohesin from the hyperthermophilic archaeon Archaeoglobus fulgidus
6TKL	;	1.3	;	Non-cleavable tsetse thrombin inhibitor in complex with human alpha-thrombin
1GXG	;		;	Non-cognate protein-protein interactions: the NMR structure of the colicin E8 inhibitor protein Im8 and its interaction with the DNase domain of colicin E9
5OKS	;	1.96	;	Non-conservatively refined structure of Gan1D, a 6-phospho-beta-galactosidase from Geobacillus stearothermophilus, in complex with 6-phospho-beta-glucose
5OKA	;	1.25	;	Non-conservatively refined structure of Gan1D-E170Q, a catalytic mutant of a 6-phospho-beta-galactosidase from Geobacillus stearothermophilus
5OKG	;	1.25	;	Non-conservatively refined structure of Gan1D-E170Q, a catalytic mutant of a putative 6-phospho-beta-galactosidase from Geobacillus stearothermophilus, in complex with cellobiose-6-phosphate
5OKQ	;	1.85	;	Non-conservatively refined structure of Gan1D-WT, a putative 6-phospho-beta-galactosidase from Geobacillus stearothermophilus, in complex with 6-phospho-beta-galactose
5OKJ	;	1.76	;	Non-conservatively refined structure of Gan1D-WT, a putative 6-phospho-beta-galactosidase from Geobacillus stearothermophilus, in the C2 spacegroup
4Z9S	;	2.3	;	Non-covalent assembly of monoubiquitin that mimics K11 poly-ubiquitin
1OPH	;	2.3	;	NON-COVALENT COMPLEX BETWEEN ALPHA-1-PI-PITTSBURGH AND S195A TRYPSIN
2W19	;	2.15	;	Non-covalent complex between dahp synthase and chorismate mutase from Mycobacterium tuberculosis
2W1A	;	2.35	;	Non-covalent complex between dahp synthase and chorismate mutase from Mycobacterium tuberculosis with bound tsa
2PE6	;	2.4	;	Non-covalent complex between human SUMO-1 and human Ubc9
2UYZ	;	1.4	;	Non-covalent complex between Ubc9 and SUMO1
5HUD	;	2.15	;	Non-covalent complex of and DAHP synthase and chorismate mutase from Corynebacterium glutamicum with bound transition state analog
5CKX	;	2.7	;	Non-covalent complex of DAHP synthase and chorismate mutase from Mycobacterium tuberculosis with bound transition state analog and feedback effectors tyrosine and phenylalanine
1PW1	;	1.2	;	Non-Covalent Complex Of Streptomyces R61 DD-Peptidase With A Highly Specific Penicillin
6NUH	;	1.594	;	Non-covalent DNA-protein complex between E. coli YedK and ssDNA containing an abasic site analog
2XYA	;	2.4	;	Non-covalent inhibtors of rhinovirus 3C protease.
6NNQ	;	2.621	;	Non-covalent structure of SENP1 in complex with SUMO2
1TQ9	;	2.0	;	Non-covalent swapped dimer of Bovine Seminal Ribonuclease in complex with 2'-DEOXYCYTIDINE-2'-DEOXYADENOSINE-3',5'-MONOPHOSPHATE
6U4V	;	2.3	;	Non-crosslinked wild type cysteine dioxygenase
5ZTL	;	1.85	;	Non-cryogenic structure of light-driven chloride pump having an NTQ motif
6OMA	;	7.2	;	non-decorated head of the phage T5
2CFO	;	2.45	;	Non-Discriminating Glutamyl-tRNA Synthetase from Thermosynechococcus elongatus in Complex with Glu
6RPK	;	2.84	;	non-expanded bat circovirus with DNA VLP
1I1C	;	2.7	;	NON-FCRN BINDING FC FRAGMENT OF RAT IGG2A
1UA5	;	2.5	;	Non-fusion GST from S. japonicum in complex with glutathione
4ZBN	;	2.447	;	Non-helical DNA Triplex Forms a Unique Aptamer Scaffold for High Affinity Recognition of Nerve Growth Factor
6ZYK	;	2.55	;	Non-heme monooxygenase, ThoJ-Ni complex
6ZYL	;	2.09	;	non-heme monooxygenase; ThoJ apo
7LSV	;	1.58	;	Non-kinase domain of Legionella effector protein kinase LegK2
4YCI	;	3.25	;	non-latent pro-bone morphogenetic protein 9
7ZTC	;	3.9	;	Non-muscle F-actin decorated with non-muscle tropomyosin 1.6
7ZTD	;	4.6	;	Non-muscle F-actin decorated with non-muscle tropomyosin 3.2
1OMV	;	1.9	;	non-myristoylated bovine recoverin (E85Q mutant) with calcium bound to EF-hand 3
2HET	;	3.0	;	Non-myristoylated bovine recoverin (truncated at C-terminus) with calcium bound to EF-hand 3
1RRG	;	2.4	;	NON-MYRISTOYLATED RAT ADP-RIBOSYLATION FACTOR-1 COMPLEXED WITH GDP, DIMERIC CRYSTAL FORM
1RRF	;	3.0	;	NON-MYRISTOYLATED RAT ADP-RIBOSYLATION FACTOR-1 COMPLEXED WITH GDP, MONOMERIC CRYSTAL FORM
1OMR	;	1.5	;	non-myristoylated wild-type bovine recoverin with calcium bound to EF-hand 3
6IPQ	;	3.103	;	Non-native ferritin 8-mer mutant-C90A/C102A/C130A
6IPP	;	2.699	;	Non-native ferritin 8-mer mutant-C90A/C102A/C130A/D144C
6ZE9	;	2.9	;	Non-native fold of the putative VPS39 zinc finger domain
6IPC	;	4.443	;	Non-native human ferritin 8-mer
1LIQ	;		;	Non-native Solution Structure of a fragment of the CH1 domain of CBP
5I4S	;	2.46	;	Non-natural DNA pair Z (6-amino-5-nitro-2[1H] pyridone heterocycle)-Guanosine
7QSX	;	2.7	;	Non-obligately L8S8-complex forming RubisCO derived from ancestral sequence reconstruction and rational engineering in L8 complex
7QSZ	;	2.25	;	Non-obligately L8S8-complex forming RubisCO derived from ancestral sequence reconstruction and rational engineering in L8 complex with substitution e170N
7QSY	;	2.1	;	Non-obligately L8S8-complex forming RubisCO derived from ancestral sequence reconstruction and rational engineering in L8S8 complex
7QT1	;	2.1	;	Non-obligately L8S8-complex forming RubisCO derived from ancestral sequence reconstruction and rational engineering in L8S8 complex with substitution e170N
4YN7	;	2.6	;	Non-oxidized YfiR
3PSD	;	3.6	;	Non-oxime pyrazole based inhibitors of B-Raf kinase
6ORV	;	3.0	;	Non-peptide agonist (TT-OAD2) bound to the Glucagon-Like peptide-1 (GLP-1) Receptor
6C9H	;	2.65	;	non-phosphorylated AMP-activated protein kinase bound to pharmacological activator R734
4Q7E	;	1.441	;	Non-phosphorylated HemR Receiver Domain from Leptospira biflexa
6QTY	;	1.65	;	Non-phosphorylated human CLK1 in complex with an indole inhibitor to 1.65 Ang
3NYX	;	2.5	;	Non-phosphorylated TYK2 JH1 domain with Quinoline-Thiadiazole-Thiophene Inhibitor
3NZ0	;	2.0	;	Non-phosphorylated TYK2 kinase with CMP6
2V4R	;	2.5	;	Non-productive complex of the Y-family DNA polymerase Dpo4 with dGTP skipping the M1dG adduct to pair with the next template cytosine
1MTL	;	2.8	;	Non-productive MUG-DNA complex
6BN5	;	2.22	;	Non-receptor Protein Tyrosine Phosphatase SHP2 F285S in Complex with Allosteric Inhibitor JLR-2
7JVN	;	1.917	;	Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor Compound 24
6MDD	;	2.05	;	Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor Imidazo-pyridine 24
6MD9	;	2.12	;	NON-RECEPTOR PROTEIN TYROSINE PHOSPHATASE SHP2 IN COMPLEX WITH ALLOSTERIC INHIBITOR Isoxazolo-pyridinone 3
6MDA	;	2.21	;	Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor Pyrazolo-pyridine 4
6MDC	;	2.14	;	Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor Pyrazolo-pyrimidinone 1 SHP389
6MDB	;	2.34	;	Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor Pyrazolo-pyrimidinone 5
6MD7	;	1.96	;	Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor Pyrimidinone 7
7RCT	;	1.8	;	Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor RMC-4550
5EHR	;	1.7	;	Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor SHP099
6BMR	;	2.205	;	Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor SHP244
6BMV	;	2.053	;	Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor SHP504
5EHP	;	1.85	;	Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor SHP836
6BMX	;	2.424	;	Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor SHP844
7VXG	;	2.1	;	Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor TK-453
7JVM	;	2.166	;	Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor TNO155
6BMU	;	2.12	;	Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitors SHP099 and SHP244
6BMW	;	2.1	;	Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitors SHP099 and SHP504
6BMY	;	2.09	;	Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitors SHP099 and SHP844
2MTO	;		;	Non-reducible analogues of alpha-conotoxin RgIA: [2,8]-cis dicarba RgIA
2MTT	;		;	Non-reducible analogues of alpha-conotoxin RgIA: [3,12]-cis dicarba RgIA
2MTU	;		;	Non-reducible analogues of alpha-conotoxin RgIA: [3,12]-trans dicarba RgIA
2MFX	;		;	Non-reducible analogues of alpha-conotoxin Vc1.1: [2,8]-cis dicarba Vc1.1
2MFY	;		;	Non-reducible analogues of alpha-conotoxin Vc1.1: [2,8]-trans dicarba Vc1.1
2MG6	;		;	Non-reducible analogues of alpha-conotoxin Vc1.1: [3,16]-trans dicarba Vc1.1
7KVW	;	2.18	;	Non-ribosomal didomain (holo-PCP-C) acceptor bound state
7KW2	;	2.0	;	Non-ribosomal didomain (holo-PCP-C) acceptor bound state, R2577G
7KW0	;	1.9	;	Non-ribosomal didomain (stabilised glycine-PCP-C) acceptor bound state
8FX6	;	2.2	;	Non-ribosomal PCP-C didomain (amide stabilised leucine) acceptor bound state
8FX7	;	2.2	;	Non-ribosomal PCP-C didomain (ester stabilised leucine) acceptor bound state
8G3I	;	3.02	;	Non-ribosomal PCP-C didomain (thioether stabilised glycolic acid) acceptor bound state
8G3J	;	2.1	;	Non-ribosomal PCP-C didomain R2577G (thioether stabilised glycolic acid) acceptor bound state
7E3Z	;	1.45	;	Non-Ribosomal Peptide Synthetases, Thioesterase
8CGN	;	2.28	;	Non-rotated 80S S. cerevisiae ribosome with ligands
6OFX	;	3.3	;	Non-rotated ribosome (Structure I)
7D3V	;		;	Non-specific and specific interactions work cooperatively to promote cytidine deamination catalyzed by APOBEC3A
7D3W	;		;	Non-specific and specific interactions work cooperatively to promote cytidine deamination catalyzed by APOBEC3A
7D3X	;		;	Non-specific and specific interactions work cooperatively to promote cytidine deamination catalyzed by APOBEC3A
1TDV	;	1.7	;	Non-specific binding to phospholipase A2:Crystal structure of the complex of PLA2 with a designed peptide Tyr-Trp-Ala-Ala-Ala-Ala at 1.7A resolution
7CLE	;	2.342	;	Non-Specific Class-c acidphosphatase from Sphingobium sp. RSMS
8AOG	;	1.603	;	Non-specific covalent inhibitor(17) of ERK2
6ZLC	;	2.3	;	Non-specific dsRNA recognition by wildtype H7N1 RNA-binding domain
1MID	;	1.71	;	Non-specific lipid transfer protein 1 from barley in complex with L-alfa-lysophosphatidylcholine, Laudoyl
1BBX	;		;	NON-SPECIFIC PROTEIN-DNA INTERACTIONS IN THE SSO7D-DNA COMPLEX, NMR, 1 STRUCTURE
6S5G	;	4.33	;	Non-square conformation of KtrA A80P mutant ring with bound ADP
6S5E	;	3.893	;	Non-square conformation of KtrA A80P mutant ring with bound ATP
6S5B	;	3.052	;	Non-square conformation of KtrA R16K mutant ring with bound ADP
6S5O	;	3.983	;	Non-square conformations of KtrA E125Q mutant rings with bound ADP
6S5N	;	4.09	;	Non-square conformations of KtrA E125Q mutant rings with bound ATP
6S7R	;	3.73	;	Non-square conformations of KtrA R16A mutant rings with bound ADP
1JCA	;	2.5	;	Non-standard Design of Unstable Insulin Analogues with Enhanced Activity
7ORR	;	1.79	;	Non-structural protein 10 (nsp10) from SARS CoV-2 in complex with fragment VT00022
7ORU	;	1.67	;	Non-structural protein 10 (nsp10) from SARS CoV-2 in complex with fragment VT00221
7ORV	;	1.95	;	Non-structural protein 10 (nsp10) from SARS CoV-2 in complex with fragment VT00239
7ORW	;	1.95	;	Non-structural protein 10 (nsp10) from SARS CoV-2 in complex with fragment VT00265
6SV6	;	1.15	;	Non-terahertz irradiated structure of bovine trypsin (even frames of crystal x38)
6SV9	;	1.15	;	Non-terahertz irradiated structure of bovine trypsin (even frames of crystal x40)
6SVD	;	1.15	;	Non-terahertz irradiated structure of bovine trypsin (even frames of crystal x41)
6SVI	;	1.16	;	Non-terahertz irradiated structure of bovine trypsin (even frames of crystal x42)
6SV0	;	1.16	;	Non-terahertz irradiated structure of bovine trypsin (odd frames of crystal x37)
3DJY	;	2.1	;	Nonaged Form of Human Butyrylcholinesterase Inhibited by Tabun
2WID	;	2.3	;	NONAGED FORM OF HUMAN BUTYRYLCHOLINESTERASE INHIBITED BY TABUN ANALOGUE TA1
2WIG	;	2.15	;	NONAGED FORM OF HUMAN BUTYRYLCHOLINESTERASE INHIBITED BY TABUN ANALOGUE TA4
2WIJ	;	2.1	;	NONAGED FORM OF HUMAN BUTYRYLCHOLINESTERASE INHIBITED BY TABUN ANALOGUE TA5
2WIK	;	2.1	;	NONAGED FORM OF HUMAN BUTYRYLCHOLINESTERASE INHIBITED BY TABUN ANALOGUE TA6
2Y2V	;	2.45	;	Nonaged form of Mouse Acetylcholinesterase inhibited by sarin-Update
2Y2U	;	2.6	;	Nonaged form of Mouse Acetylcholinesterase inhibited by VX-Update
7AMY	;	3.75	;	Nonameric cytoplasmic domain of FlhA from Vibrio parahaemolyticus
7ALW	;	3.7	;	Nonameric cytoplasmic domain of SctV from Yersinia enterocolitica
1XM1	;	2.3	;	Nonbasic Thrombin Inhibitor Complex
6UZ1	;	3.14	;	Noncanonical binding of single-chain A6 TCR variant S3-4 in complex with Tax/HLA-A2
1I7D	;	2.05	;	NONCOVALENT COMPLEX OF E.COLI DNA TOPOISOMERASE III WITH AN 8-BASE SINGLE-STRANDED DNA OLIGONUCLEOTIDE
4JEI	;	2.6	;	Nonglycosylated Yarrowia lipolytica LIP2 lipase
5VRT	;	1.995	;	Nonheme Iron Replacement in a Biosynthetic Nitric Oxide Reductase Model Performing O2 Reduction to Water: Co-bound FeBMb
5VNU	;	1.584	;	Nonheme Iron Replacement in a Biosynthetic Nitric Oxide Reductase Model Performing O2 Reduction to Water: Mn-bound FeBMb
1HVH	;	1.8	;	NONPEPTIDE CYCLIC CYANOGUANIDINES AS HIV PROTEASE INHIBITORS
1EAS	;	1.8	;	NONPEPTIDIC INHIBITORS OF HUMAN LEUKOCYTE ELASTASE. 3. DESIGN, SYNTHESIS, X-RAY CRYSTALLOGRAPHIC ANALYSIS, AND STRUCTURE-ACTIVITY RELATIONSHIPS FOR A SERIES OF ORALLY ACTIVE 3-AMINO-6-PHENYLPYRIDIN-2-ONE TRIFLUOROMETHYL KETONES
1EAT	;	2.0	;	NONPEPTIDIC INHIBITORS OF HUMAN LEUKOCYTE ELASTASE. 5. DESIGN, SYNTHESIS, AND X-RAY CRYSTALLOGRAPHY OF A SERIES OF ORALLY ACTIVE 5-AMINO-PYRIMIDIN-6-ONE-CONTAINING TRIFLUOROMETHYLKETONES
1EAU	;	2.0	;	NONPEPTIDIC INHIBITORS OF HUMAN LEUKOCYTE ELASTASE. 6. DESIGN OF A POTENT, INTRATRACHEALLY ACTIVE, PYRIDONE-BASED TRIFLUOROMETHYL KETONE
1OJ1	;	2.1	;	Nonproductive and Novel Binding Modes in Cytotoxic Ribonucleases from Rana catesbeiana of Two Crystal Structures Complexed with (2,5 CpG) and d(ApCpGpA)
1E27	;	2.2	;	Nonstandard peptide binding of HLA-B*5101 complexed with HIV immunodominant epitope KM1(LPPVVAKEI)
1E28	;	3.0	;	Nonstandard peptide binding of HLA-B*5101 complexed with HIV immunodominant epitope KM2(TAFTIPSI)
5M1J	;	3.3	;	Nonstop ribosomal complex bound with Dom34 and Hbs1
6ZCT	;	2.55	;	Nonstructural protein 10 (nsp10) from SARS CoV-2
6ZPE	;	1.58	;	Nonstructural protein 10 (nsp10) from SARS CoV-2
7DCD	;	2.57	;	Nonstructural protein 7 and 8 complex of SARS-CoV-2
7OFZ	;	2.62	;	Nontypeable Haemophillus influenzae SapA in complex with double stranded RNA
7OFW	;	3.15	;	Nontypeable Haemophillus influenzae SapA in complex with heme
7OG0	;	2.61	;	Nontypeable Haemophillus influenzae SapA in open and closed conformations, in complex with double stranded RNA
5SVD	;	2.1	;	Nop9, a new PUF-like protein, prevents premature pre-rRNA cleavage to correctly process mature 18S rRNA
7LO7	;	3.74	;	NorA in complex with Fab25
7LO8	;	3.16	;	NorA in complex with Fab36
5MM2	;	2.7	;	nora virus structure
2R1V	;	1.7	;	Norepinephrine quinone conjugation to DJ-1
2AKH	;	14.9	;	Normal mode-based flexible fitted coordinates of a non-translocating SecYEG protein-conducting channel into the cryo-EM map of a SecYEG-nascent chain-70S ribosome complex from E. coli
2AKI	;	14.9	;	Normal mode-based flexible fitted coordinates of a translocating SecYEG protein-conducting channel into the cryo-EM map of a SecYEG-nascent chain-70S ribosome complex from E. coli
3H5Y	;	1.77	;	Norovirus polymerase+primer/template+CTP complex at 6 mM MnCl2
7MRY	;	3.8	;	Norovirus T=3 GII.4 HOV VLP
5FEU	;	1.73	;	Noroxomaritidine/Norcraugsodine Reductase in complex with NADP+
5FFF	;	1.501	;	Noroxomaritidine/Norcraugsodine Reductase in complex with NADP+ and piperonal
5FF9	;	1.814	;	Noroxomaritidine/Norcraugsodine Reductase in Complex with NADP+ and tyramine
1KDE	;		;	NORTH-ATLANTIC OCEAN POUT ANTIFREEZE PROTEIN TYPE III ISOFORM HPLC12 MUTANT, NMR, 22 STRUCTURES
1KDF	;		;	NORTH-ATLANTIC OCEAN POUT ANTIFREEZE PROTEIN TYPE III ISOFORM HPLC12 MUTANT, NMR, MINIMIZED AVERAGE STRUCTURE
1NI7	;		;	NORTHEAST STRUCTURAL GENOMIC CONSORTIUM TARGET ER75
1M0S	;	1.9	;	NORTHEAST STRUCTURAL GENOMICS CONSORTIUM (NESG ID IR21)
1GTD	;	2.56	;	NORTHEAST STRUCTURAL GENOMICS CONSORTIUM (NESG ID TT50) STRUCTURE OF MTH169, THE PURS SUBUNIT OF FGAM SYNTHETASE
2JN7	;		;	Northeast Structural Genomics Consortium Target ER411
3D26	;	2.3	;	Norwalk P domain A-trisaccharide complex
3BY2	;	2.6	;	Norwalk P polypeptide (228-523)
3BSN	;	1.8	;	Norwalk Virus polymerase bound to 5-nitrocytidine triphosphate and primer-template RNA
3BSO	;	1.74	;	Norwalk Virus polymerase bound to cytidine 5'-triphosphate and primer-template RNA
2WKG	;	3.0	;	Nostoc punctiforme Debranching Enzyme (NPDE)(Native form)
4GYD	;	1.8	;	Nostoc sp Cytochrome c6
5FU6	;	2.9	;	NOT module of the human CCR4-NOT complex (Crystallization mutant)
5AJD	;	3.62	;	Not1 C-terminal domain in complex with Not4
5AIE	;	2.8	;	Not4 ring domain in complex with Ubc4
4CBZ	;	2.5	;	Notch ligand, Jagged-1, contains an N-terminal C2 domain
4CC0	;	2.32	;	Notch ligand, Jagged-1, contains an N-terminal C2 domain
4CC1	;	2.84	;	Notch ligand, Jagged-1, contains an N-terminal C2 domain
5KZO	;		;	Notch1 transmembrane and associated juxtamembrane segment
2NOT	;	3.0	;	NOTECHIS II-5, NEUROTOXIC PHOSPHOLIPASE A2 FROM NOTECHIS SCUTATUS SCUTATUS
1AE7	;	2.0	;	NOTEXIN, A PRESYNAPTIC NEUROTOXIC PHOSPHOLIPASE A2
7YPC	;	2.66	;	Notothenia coriiceps TRAF4
6KU5	;	3.299	;	Notothenia coriiceps TRAF5
7BNL	;	1.23	;	Notum ARUK3003710
7B4X	;	1.24	;	Notum complex with ARUK3002697
7B37	;	1.34	;	Notum complex with ARUK3003718
7B3X	;	1.34	;	Notum complex with ARUK3003748
7B3P	;	1.28	;	Notum complex with ARUK3003775
7B3I	;	1.34	;	Notum complex with ARUK3003776
7B50	;	1.33	;	Notum complex with ARUK3003778
7B3G	;	1.28	;	Notum complex with ARUK3003902
7B2V	;	1.24	;	Notum complex with ARUK3003906
7B2Z	;	1.24	;	Notum complex with ARUK3003907
7B3H	;	1.28	;	Notum complex with ARUK3003909
7B2Y	;	1.23	;	Notum complex with ARUK3003910
7B45	;	1.38	;	Notum complex with ARUK3003934
7BNF	;	1.45	;	Notum Cotinine
7B98	;	1.53	;	Notum Fragment 282
7B99	;	1.81	;	Notum Fragment 283
6ZUV	;	1.54	;	Notum fragment 286
7B9D	;	1.93	;	Notum Fragment 290
7B9I	;	1.34	;	Notum Fragment 297
7B9N	;	1.38	;	Notum Fragment 588
7BM7	;	1.87	;	Notum fragment 5e
7B9U	;	1.5	;	Notum Fragment 609
7BA1	;	1.93	;	Notum Fragment 634
7BAC	;	1.54	;	Notum Fragment 646
7BAP	;	1.53	;	Notum Fragment 648
7BC8	;	1.74	;	Notum Fragment 658
7BC9	;	1.73	;	Notum Fragment 690
7BCC	;	1.58	;	Notum Fragment 705
7BCD	;	1.51	;	Notum Fragment 714
7BCF	;	1.86	;	Notum Fragment 722
6R8P	;	1.45	;	Notum fragment 723
7BCH	;	1.7	;	Notum Fragment 772
7BCI	;	1.94	;	Notum Fragment 784
7BCK	;	1.7	;	Notum Fragment 791
7BCL	;	1.84	;	Notum Fragment 792
7BD2	;	1.52	;	Notum Fragment 810
7BD3	;	1.91	;	Notum Fragment 823
7BD4	;	1.8	;	Notum Fragment 828
7BD5	;	1.69	;	Notum Fragment 830
7BD6	;	1.7	;	Notum Fragment 863
7BD8	;	1.42	;	Notum Fragment 872
7BD9	;	1.59	;	Notum Fragment 886
7BDA	;	1.47	;	Notum Fragment 900
7BDB	;	1.46	;	Notum Fragment 916
7BDC	;	1.32	;	Notum Fragment 923
7BDD	;	1.47	;	Notum Fragment 924
7BDF	;	1.4	;	Notum Fragment 927
7BDG	;	1.6	;	Notum Fragment 934
7BDH	;	1.54	;	Notum Fragment 955
7BN5	;	2.22	;	Notum fragment_1 (2-(isoquinolin-1-ylsulfanyl)acetic acid)
7BNC	;	1.86	;	Notum fragment_126 (2-(1,2-dihydroacenaphthylen-5-ylsulfanyl)acetic acid)
7BO2	;	1.21	;	Notum Fragment_130 (4H-thieno[3,2-c]chromene-2-carboxylic acid)
7BO5	;	1.38	;	Notum Fragment_130_methyEster (methyl 4H-thieno[3,2-c]chromene-2-carboxylate)
7BO1	;	1.4	;	Notum Fragment_274 [(4-fluorophenyl)amino]thiourea
7BN8	;	1.78	;	Notum fragment_3 (4H,5H-naphtho[1,2-b]thiophene-2-carboxylic acid)
7BNB	;	1.16	;	Notum fragment_50 (3-(quinazolin-4-ylsulfanyl)propanoic acid)
7ARG	;	1.24	;	Notum in complex with ARUK3002704
8BT8	;	1.28	;	Notum Inhibitor ARUK3004048
8BTA	;	1.34	;	Notum Inhibitor ARUK3004308
8BTE	;	1.62	;	Notum Inhibitor ARUK3004470
8BTH	;	1.3	;	Notum Inhibitor ARUK3004552
8BTI	;	1.31	;	Notum Inhibitor ARUK3004556
8BTC	;	1.54	;	Notum Inhibitor ARUK3004558
8BT2	;	1.7	;	Notum Inhibitor ARUK3004876
8BT5	;	1.4	;	Notum Inhibitor ARUK3004877
8BT7	;	1.4	;	Notum Inhibitor ARUK3004903
8BT0	;	1.6	;	Notum Inhibitor ARUK3005518
8BSZ	;	1.7	;	Notum Inhibitor ARUK3005522
8BSP	;	1.55	;	Notum Inhibitor ARUK3006560
8BSQ	;	1.45	;	Notum Inhibitor ARUK3006561
8BSR	;	1.45	;	Notum Inhibitor ARUK3006562
7BNE	;	1.7	;	Notum Nicotine
7BMB	;	1.83	;	Notum PPOH complex
7BNJ	;	1.49	;	Notum Riluzole
7BM3	;	1.4	;	Notum Rosmarinic acid complex
7B3F	;	1.39	;	Notum S232A in complex with ARUK3003718
7BMD	;	1.45	;	Notum TDZD8 complex
7BLI	;	1.47	;	Notum-Bepridil complex
7B8A	;	1.23	;	Notum-Fragment 110
7B8C	;	1.43	;	Notum-Fragment 147
7B8D	;	1.62	;	Notum-Fragment 151
7B8F	;	1.62	;	Notum-Fragment 154
7B8G	;	1.58	;	Notum-Fragment 159
7B8J	;	1.75	;	Notum-Fragment 163
7B8K	;	1.6	;	Notum-Fragment 173
7B8L	;	1.45	;	Notum-Fragment 174
7B8M	;	1.48	;	Notum-Fragment 193
7B8N	;	1.56	;	Notum-Fragment 197
7B8O	;	1.5	;	Notum-Fragment 199
7B8U	;	1.54	;	Notum-Fragment 201
7B8X	;	1.51	;	Notum-Fragment 210
7B8Y	;	1.57	;	Notum-Fragment 276
7B8Z	;	1.73	;	Notum-Fragment 277
7B7W	;	1.6	;	Notum-Fragment049
7B7X	;	2.41	;	Notum-Fragment063
7B7Y	;	1.48	;	Notum-Fragment064
7B84	;	1.36	;	Notum-Fragment065
7B86	;	1.4	;	Notum-Fragment067
7B87	;	1.58	;	Notum-Fragment074
7B89	;	1.84	;	Notum-Fragment077
7BLS	;	1.19	;	Notum-maybridge_18
7PJR	;	1.51	;	Notum_ARUK3000438
7PK3	;	1.41	;	Notum_ARUK3001185
7BND	;	2.1	;	Notum_Fragment41 (N-methyl-4,5-dihydronaphtho,2-bthiophene-2-carboxamide)
6ZYF	;	2.19	;	Notum_Ghrelin complex
7PKV	;	1.68	;	Notum_Inhibitor ARUK3000223
7BLT	;	1.2	;	Notum_Maybridge_4
7BLU	;	1.21	;	Notum_Maybridge_56
7BLW	;	1.45	;	Notum_Piperine complex
7BM1	;	1.37	;	Notum_Valsartan complex
2NO3	;	3.2	;	Novel 4-anilinopyrimidines as potent JNK1 Inhibitors
2FLR	;	2.35	;	Novel 5-Azaindole Factor VIIa Inhibitors
1OJ8	;	1.7	;	Novel and retro Binding Modes in Cytotoxic Ribonucleases from Rana catesbeiana of Two Crystal Structures Complexed with d(ApCpGpA) and (2',5'CpG)
4DTK	;	1.86	;	Novel and selective pan-PIM kinase inhibitor
8CXC	;	4.31	;	Novel Anti-Mesothelin Antibodies Enable Crystallography of the Intact Mesothelin Ectodo- main and Engineering of Potent, T cell-engaging Bispecific Therapeutics
8CYH	;	3.38	;	Novel Anti-Mesothelin Antibodies Enable Crystallography of the Intact Mesothelin Ectodo- main and Engineering of Potent, T cell-engaging Bispecific Therapeutics
8CZ8	;	2.6	;	Novel Anti-Mesothelin Antibodies Enable Crystallography of the Intact Mesothelin Ectodo- main and Engineering of Potent, T cell-engaging Bispecific Therapeutics
8JQ9	;	2.66	;	Novel Anti-phage System
8JQC	;	3.39	;	Novel Anti-phage System
2N9R	;		;	Novel antimicrobial peptide PaDBS1R1 designed from the ribosomal protein L39E from Pyrobaculum aerophilum using bioinformatics
5T4S	;	2.64	;	Novel Approach of Fragment-Based Lead Discovery applied to Renin Inhibitors
1B9V	;	2.35	;	NOVEL AROMATIC INHIBITORS OF INFLUENZA VIRUS NEURAMINIDASE MAKE SELECTIVE INTERACTIONS WITH CONSERVED RESIDUES AND WATER MOLECULES IN TEH ACTIVE SITE
1B9S	;	2.5	;	NOVEL AROMATIC INHIBITORS OF INFLUENZA VIRUS NEURAMINIDASE MAKE SELECTIVE INTERACTIONS WITH CONSERVED RESIDUES AND WATER MOLECULES IN THE ACTIVE SITE
1B9T	;	2.4	;	NOVEL AROMATIC INHIBITORS OF INFLUENZA VIRUS NEURAMINIDASE MAKE SELECTIVE INTERACTIONS WITH CONSERVED RESIDUES AND WATER MOLECULES IN THE ACTIVE SITE
3SHE	;	2.25	;	Novel ATP-competitive MK2 inhibitors with potent biochemical and cell-based activity throughout the series
4JBO	;	2.493	;	Novel Aurora kinase inhibitors reveal mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules
4JBP	;	2.45	;	Novel Aurora kinase inhibitors reveal mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules
4JBQ	;	2.3	;	Novel Aurora kinase inhibitors reveal mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules
2GG0	;	1.28	;	Novel bacterial methionine aminopeptidase inhibitors
2GG2	;	1.0	;	Novel bacterial methionine aminopeptidase inhibitors
2GG3	;	1.45	;	Novel bacterial methionine aminopeptidase inhibitors
2GG5	;	2.12	;	Novel bacterial methionine aminopeptidase inhibitors
2GG7	;	1.12	;	Novel bacterial methionine aminopeptidase inhibitors
2GG8	;	1.8	;	Novel bacterial methionine aminopeptidase inhibitors
2GG9	;	1.05	;	Novel bacterial methionine aminopeptidase inhibitors
2GGB	;	2.13	;	Novel bacterial methionine aminopeptidase inhibitors
2GGC	;	1.0	;	Novel bacterial methionine aminopeptidase inhibitors
3PN1	;	2.0	;	Novel Bacterial NAD+-dependent DNA Ligase Inhibitors with Broad Spectrum Potency and Antibacterial Efficacy In Vivo
3P2V	;	1.69	;	Novel Benzothiazepine Inhibitor in Complex with human Aldose Reductase
6BKY	;	2.17	;	Novel Binding Modes of Inhibition of Wild-Type IDH1: Allosteric Inhibition with Cmpd2
4QOY	;	2.8	;	Novel binding motif and new flexibility revealed by structural analysis of a pyruvate dehydrogenase-dihydrolipoyl acetyltransferase sub-complex from the escherichia coli pyruvate dehydrogenase multi-enzyme complex
4ZHX	;	2.99	;	Novel binding site for allosteric activation of AMPK
3EFX	;	1.94	;	Novel binding site identified in a hybrid between cholera toxin and heat-labile enterotoxin, 1.9A crystal structure reveals the details
2D6B	;	1.25	;	Novel Bromate Species trapped within a Protein Crystal
3IG7	;	1.8	;	Novel CDK-5 inhibitors - crystal structure of inhibitor EFP with CDK-2
3IGG	;	1.8	;	Novel CDK-5 inhibitors - crystal structure of inhibitor EFQ with CDK-2
1QHR	;	2.2	;	NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS
1QJ1	;	2.0	;	Novel Covalent Active Site Thrombin Inhibitors
1QJ6	;	2.2	;	Novel Covalent Active Site Thrombin Inhibitors
1QJ7	;	2.2	;	Novel Covalent Active Site Thrombin Inhibitors
1AWF	;	2.2	;	NOVEL COVALENT THROMBIN INHIBITOR FROM PLANT EXTRACT
1AWH	;	3.0	;	NOVEL COVALENT THROMBIN INHIBITOR FROM PLANT EXTRACT
2GHY	;	2.5	;	Novel Crystal Form of the ColE1 Rom Protein
5UEB	;	1.5	;	Novel crystal structure of a hypothetical protein from Neisseria gonorrhoeae
6FDG	;	1.3	;	Novel crystal structure of DHNA-CoA Thioesterase from Staphylococcus aureus
3SFM	;	1.4	;	Novel crystallization conditions for tandem variant R67 DHFR yields wild-type crystal structure
2LE2	;		;	Novel dimeric structure of phage phi29-encoded protein p56: Insights into Uracil-DNA glycosylase inhibition
3EAQ	;	2.3	;	Novel dimerization motif in the DEAD box RNA helicase Hera form 2, complete dimer, symmetric
3EAS	;	2.8	;	Novel dimerization motif in the DEAD box RNA helicase Hera: form 1, complete dimer, asymmetric
3EAR	;	2.3	;	Novel dimerization motif in the DEAD box RNA helicase Hera: form 1, partial dimer
8T0B	;	2.1	;	Novel Domain of Unknown Function Solved with AlphaFold
8T1M	;	3.0	;	Novel Domain of Unknown Function Solved with AlphaFold
5NFQ	;	1.6	;	Novel epoxide hydrolases belonging to the alpha/beta hydrolases superfamily in metagenomes from hot environments
5NG7	;	1.39	;	Novel epoxide hydrolases belonging to the alpha/beta hydrolases superfamily in metagenomes from hot environments
4KPE	;	3.43	;	Novel fluoroquinolones in complex with topoisomerase IV from S. pneumoniae and E-site G-gate
4KPF	;	3.24	;	Novel fluoroquinolones in complex with topoisomerase IV from S. pneumoniae and E-site G-gate
4IWB	;	1.75	;	Novel Fold of FliC/FliS Fusion Protein
3EE1	;	3.01	;	Novel fold of VirA, a type III secretion system effector protein from Shigella flexneri
1O70	;	2.6	;	Novel Fold Revealed by the Structure of a FAS1 Domain Pair from the Insect Cell Adhesion Molecule Fasciclin I
5C86	;	1.51	;	Novel fungal alcohol oxidase with catalytic diversity among the AA5 family, apo form
5C92	;	2.1	;	Novel fungal alcohol oxidase with catalytic diversity among the AA5 family, in complex with copper
7P1Z	;	2.17	;	Novel GH12 endogluconase from Aspergillus cervinus
3U4O	;	1.77	;	Novel HCV NS5B polymerase Inhibitors: Discovery of Indole C2 Acyl sulfonamides
3U4R	;	2.0	;	Novel HCV NS5B polymerase Inhibitors: Discovery of Indole C2 Acyl sulfonamides
3VTQ	;	1.53	;	Novel HIV fusion inhibitor
4BUL	;	2.6	;	Novel hydroxyl tricyclics (e.g. GSK966587) as potent inhibitors of bacterial type IIA topoisomerases
5M7M	;	2.7	;	Novel Imidazo[1,2-a]pyridine Derivatives with Potent Autotaxin/ENPP2 Inhibitor Activity
5MHP	;	2.43	;	Novel Imidazo[1,2-a]pyridine Derivatives with Potent Autotaxin/ENPP2 Inhibitor Activity
1YFZ	;	2.2	;	Novel IMP Binding in Feedback Inhibition of Hypoxanthine-Guanine Phosphoribosyltransferase from Thermoanaerobacter tengcongensis
2JLE	;	2.9	;	Novel indazole nnrtis created using molecular template hybridization based on crystallographic overlays
4QXU	;	2.3	;	Novel Inhibition Mechanism of Membrane Metalloprotease by an Exosite-Swiveling Conformational antibody
4Z7M	;	1.43	;	Novel Inhibitors of Bacterial Methionine Aminopeptidase with Broad-Spectrum Biochemical Activity
5FX5	;	1.7	;	Novel inhibitors of human rhinovirus 3C protease
5FX6	;	1.45	;	Novel inhibitors of human rhinovirus 3C protease
1VYQ	;	2.4	;	Novel inhibitors of Plasmodium Falciparum dUTPase provide a platform for anti-malarial drug design
5A79	;	4.1	;	Novel inter-subunit contacts in Barley Stripe Mosaic Virus revealed by cryo-EM
5A7A	;	4.1	;	Novel inter-subunit contacts in Barley Stripe Mosaic Virus revealed by cryo-EM
3SC1	;	2.7	;	Novel Isoquinolone PDK1 Inhibitors Discovered through Fragment-Based Lead Discovery
3NLB	;	1.9	;	Novel kinase profile highlights the temporal basis of context dependent checkpoint pathways to cell death
4DIN	;	3.7	;	Novel Localization and Quaternary Structure of the PKA RI beta Holoenzyme
2M5X	;		;	Novel method of protein purification for structural research. Example of ultra high resolution structure of SPI-2 inhibitor by X-ray and NMR spectroscopy.
6BKX	;	1.65	;	Novel Modes of Inhibition of Wild-Type IDH1: Direct Covalent Modification of His315 with Cmpd1
6BL1	;	2.02	;	Novel Modes of Inhibition of Wild-Type IDH1: Direct Covalent Modification of His315 with Cmpd13
6BL2	;	1.92	;	Novel Modes of Inhibition of Wild-Type IDH1: Direct Covalent Modification of His315 with Cmpd15
6BKZ	;	2.01	;	Novel Modes of Inhibition of Wild-Type IDH1: Non-equivalent Allosteric Inhibition with Cmpd3
6BL0	;	2.17	;	Novel Modes of Inhibition of Wild-Type IDH1:Direct Covalent Modification of His315 with Cmpd11
4IMI	;	2.35	;	Novel Modifications on C-terminal Domain of RNA Polymerase II can Fine- tune the Phosphatase Activity of Ssu72.
4IMJ	;	2.58	;	Novel Modifications on C-terminal Domain of RNA Polymerase II can Fine-tune the Phosphatase Activity of Ssu72
1JL5	;	2.1	;	Novel Molecular Architecture of YopM-a Leucine-rich Effector Protein from Yersinia pestis
7DFY	;	1.69	;	Novel motif for left-handed G-quadruplex formation
4DW6	;	2.0	;	Novel N-phenyl-phenoxyacetamide derivatives as potential EthR inhibitors and ethionamide boosters. Discovery and optimization using High-Throughput Synthesis.
1DLA	;	3.0	;	NOVEL NADPH-BINDING DOMAIN REVEALED BY THE CRYSTAL STRUCTURE OF ALDOSE REDUCTASE
3NW2	;	2.8	;	Novel nanomolar Imidazopyridines as selective Nitric Oxide Synthase (iNOS) inhibitors: SAR and structural insights
5IAW	;	2.58	;	Novel natural FXR modulator with a unique binding mode
7C6Q	;	2.76	;	Novel natural PPARalpha agonist with a unique binding mode
6BRB	;	2.82	;	Novel non-antibody protein scaffold targeting CD40L
1SB1	;	1.9	;	Novel Non-Covalent Thrombin Inhibitors Incorporating P1 4,5,6,7-Tetrahydrobenzothiazole Arginine Side Chain Mimetics
5XSR	;	2.3	;	novel orally efficacious inhibitors complexed with PARP1
5XST	;	2.3	;	novel orally efficacious inhibitors complexed with PARP1
5XSU	;	2.4	;	novel orally efficacious inhibitors complexed with PARP1
6Y8H	;	1.37	;	Novel p38-alpha crystal lattice with highly exposed p38/TAB1 non-canonical PPI surface.
1W6H	;	2.24	;	Novel plasmepsin II-inhibitor complex
5FC9	;	1.6	;	Novel Purple Cupredoxin from Nitrosopumilus maritimus
4UY1	;	2.2	;	Novel pyrazole series of group X Secretory Phospholipase A2 (sPLA2-X) inhibitors
5AEP	;	1.95	;	Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders
4KJI	;	3.2	;	Novel re-arrangement of an RsmA/cSRa family protein to create a structurally distinct new RNA-binding family member
4KRW	;	2.01	;	Novel re-arrangement of an RsmA/cSRa family protein to create a structurally distinct new RNA-binding family member
6A51	;	2.6	;	Novel Regulators CheP and CheQ Specifically Control Chemotaxis Core Gene cheVAW Transcription in Bacterial Pathogen Campylobacter jejuni
2W4S	;	2.45	;	novel RNA-binding domain in Cryptosporidium parvum at 2.5 angstrom resolution
7YSS	;		;	Novel salt-resistant antimicrobial peptide, RR14
8GVN	;		;	Novel salt-resistant antimicrobial peptide, RR14
5LAW	;	1.64	;	Novel Spiro[3H-indole-3,2 -pyrrolidin]-2(1H)-one Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2) IN COMPLEX WITH COMPOUND 14
5LAV	;	1.73	;	Novel Spiro[3H-indole-3,2 -pyrrolidin]-2(1H)-one Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2) in complex with compound 6b
5LAZ	;	1.66	;	Novel Spiro[3H-indole-3,2 -pyrrolidin]-2(1H)-one Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2) IN COMPLEX WITH COMPOUND BI-0252
1ABE	;	1.7	;	NOVEL STEREOSPECIFICITY OF THE L-ARABINOSE-BINDING PROTEIN
2N50	;		;	Novel Structural Components Contribute to the High Thermal Stability of Acyl Carrier Protein from Enterococcus faecalis
6RA9	;	2.7	;	Novel structural features and post-translational modifications in eukaryotic elongation factor 1A2 from Oryctolagus cuniculus
7SO5	;	1.797	;	Novel structural insights for a pair of monoclonal antibodies recognizing non-overlapping epitopes of the glucosyltransferase domain of Clostridium difficile toxin B
7SO7	;	3.59	;	Novel structural insights for a pair of monoclonal antibodies recognizing non-overlapping epitopes of the glucosyltransferase domain of Clostridium difficile toxin B
5SZU	;	2.8	;	Novel Structural Insights into GDP-Mediated Regulation of Acyl-CoA Thioesterases
5SZV	;	2.0	;	Novel Structural Insights into GDP-Mediated Regulation of Acyl-CoA Thioesterases
5SZY	;	2.0	;	Novel Structural Insights into GDP-Mediated Regulation of Acyl-CoA Thioesterases
5SZZ	;	2.3	;	Novel Structural Insights into GDP-Mediated Regulation of Acyl-CoA Thioesterases
5V3A	;	2.0	;	Novel Structural Insights into GDP-Mediated Regulation of Acyl-CoA Thioesterases
6POO	;	3.03	;	Novel structure of the N-terminal helical domain of BibA, a group B streptococcus immunogenic bacterial adhesin
2XYJ	;	2.3	;	Novel Sulfonylthiadiazoles with an Unusual Binding Mode as Partial Dual Peroxisome Proliferator-Activated Receptor (PPAR) gamma-delta Agonists with High Potency and In-vivo Efficacy
2XYW	;	3.14	;	Novel Sulfonylthiadiazoles with an Unusual Binding Mode as Partial Dual Peroxisome Proliferator-Activated Receptor (PPAR) gamma-delta Agonists with High Potency and In-vivo Efficacy
2XYX	;	2.7	;	Novel Sulfonylthiadiazoles with an Unusual Binding Mode as Partial Dual Peroxisome Proliferator-Activated Receptor (PPAR) gamma-delta Agonists with High Potency and In-vivo Efficacy
2I1R	;	2.2	;	Novel Thiazolones as HCV NS5B Polymerase Inhibitors: Further Designs, Synthesis, SAR and X-ray Complex Structure
3B92	;	2.0	;	Novel thio-based TACE inhibitors Part 2: Rational design, synthesis and SAR of thiol-contaning aryl sufones
1GOF	;	1.7	;	NOVEL THIOETHER BOND REVEALED BY A 1.7 ANGSTROMS CRYSTAL STRUCTURE OF GALACTOSE OXIDASE
1GOG	;	1.9	;	NOVEL THIOETHER BOND REVEALED BY A 1.7 ANGSTROMS CRYSTAL STRUCTURE OF GALACTOSE OXIDASE
1GOH	;	2.2	;	NOVEL THIOETHER BOND REVEALED BY A 1.7 ANGSTROMS CRYSTAL STRUCTURE OF GALACTOSE OXIDASE
1YRV	;	2.18	;	Novel Ubiquitin-Conjugating Enzyme
1U53	;	1.56	;	Novel X-Ray Structure of Na-ASP-2, a PR-1 protein from the nematode parasite Necator americanus and a vaccine antigen for human hookworm infection
2FFG	;	2.31	;	Novel x-ray structure of the YkuJ protein from Bacillus subtilis. Northeast Structural Genomics target SR360.
2BSM	;	2.05	;	Novel, potent small molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design
2BT0	;	1.9	;	Novel, potent small molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design
6MSA	;	2.06	;	Novel, potent, selective and brain penetrant phosphodiesterase 10A inhibitors
6MSC	;	2.36	;	Novel, potent, selective and brain penetrant phosphodiesterase 10A inhibitors
1AJ6	;	2.3	;	NOVOBIOCIN-RESISTANT MUTANT (R136H) OF THE N-TERMINAL 24 KDA FRAGMENT OF DNA GYRASE B COMPLEXED WITH NOVOBIOCIN AT 2.3 ANGSTROMS RESOLUTION
1Z6U	;	2.1	;	Np95-like ring finger protein isoform b [Homo sapiens]
7WKW	;	2.62	;	NPA bound state of AtPIN3
8HFR	;	2.64	;	NPC-trapped pre-60S particle
6W5T	;	3.7	;	NPC1 structure in GDN micelles at pH 5.5, conformation a
6W5U	;	3.9	;	NPC1 structure in GDN micelles at pH 5.5, conformation b
6W5S	;	3.0	;	NPC1 structure in GDN micelles at pH 8.0
6W5R	;	3.6	;	NPC1 structure in Nanodisc
3GKH	;	1.81	;	NPC1(NTD)
3GKI	;	1.8	;	NPC1(NTD):cholesterol
6W5V	;	4.0	;	NPC1-NPC2 complex structure at pH 5.5
3GKJ	;	1.6	;	NPC1D(NTD):25hydroxycholesterol
3QNT	;	2.83	;	NPC1L1 (NTD) Structure
6JWJ	;	1.58	;	Npl4 in complex with Ufd1
6CDD	;	2.58234	;	Npl4 zinc finger and MPN domains (Chaetomium thermophilum)
6VHY	;	3.0	;	NpsA-ThdA, an artificially fused Adenylation-PCP di-domain NRPS from Klebsiella oxytoca
2L25	;		;	Np_888769.1
8PQN	;	3.8	;	NQO1 bound to RBS-10
5B3P	;	1.652	;	Nqo5 of the trypsin-resistant fragment (1-134) in P212121 form
5B3Q	;	3.003	;	Nqo5 of the trypsin-resistant fragment (1-134) in P63 form
8C5L	;	2.6	;	NR2F6 ligand binding domain in complex with NSD1 peptide
6E6H	;	1.99	;	NRAS G13D bound to GppNHp (N13GNP)
2N9C	;		;	NRAS Isoform 5
2L6B	;		;	NRC consensus ankyrin repeat protein solution structure
7AEX	;	1.95	;	NRD-HEPN domains (N-terminal truncation) of Escherichia coli RnlA endoribonuclease
1R7H	;	2.69	;	NrdH-redoxin of Corynebacterium ammoniagenes forms a domain-swapped dimer
7X5G	;	2.3	;	Nrf2 (A510Y)-MafG heterodimer bound with CsMBE2
7X5E	;	2.3	;	Nrf2-MafG heterodimer bound with CsMBE1
7X5F	;	2.6	;	Nrf2-MafG heterodimer bound with CsMBE2
8C0T	;	1.28	;	NRS 1.2: Fluorescent Sensors for Imaging Interstitial Calcium
4M9K	;	1.46	;	NS2B-NS3 protease from dengue virus at pH 5.5
4M9M	;	1.53	;	NS2B-NS3 protease from dengue virus at pH 8.5
4M9T	;	1.74	;	NS2B-NS3 protease from dengue virus in the presence of DTNB, a covalent allosteric inhibitor
4KTC	;	2.3	;	NS3/NS4A protease with inhibitor
2M5L	;		;	Ns5a308
4TLR	;	1.86	;	NS5b in complex with lactam-thiophene carboxylic acids
4TN2	;	2.7	;	NS5b in complex with lactam-thiophene carboxylic acids
4NZB	;	2.68	;	NS9283 bound to Ls-AChBP
6KQQ	;	1.8	;	NSD1 SET domain in complex with BT3 and SAM
6KQP	;	2.4	;	NSD1 SET domain in complex with SAM
2NAA	;		;	NSD1-PHD_5-C5HCH tandem domain structure
7CRO	;	3.75	;	NSD2 bearing E1099K/T1150A dual mutation in complex with 187-bp NCP
7E8D	;	2.8	;	NSD2 E1099K mutant bound to nucleosome
7VLN	;	3.09	;	NSD2-PWWP1 domain bound with an imidazol-5-yl benzonitrile compound
7CRP	;	3.2	;	NSD3 bearing E1181K/T1232A dual mutation in complex with 187-bp NCP (1:1 binding mode)
7CRQ	;	3.15	;	NSD3 bearing E1181K/T1232A dual mutation in complex with 187-bp NCP (2:1 binding mode)
7DG2	;	1.7	;	Nse1-Nse3-Nse4 complex
7LTO	;	3.2	;	Nse5-6 complex
7OGG	;	3.29	;	Nse5/6 complex
6IP2	;	3.7	;	NSF-D1D2 part in the whole 20S complex
7RNS	;	1.14	;	nSH2 domain of p85-alpha subunit of phosphatidylinositol 3-kinase in complex with an actin peptide with phosphorylated tyrosine 53
7RNU	;	1.45	;	nSH2 domain of p85-beta subunit of phosphatidylinositol 3-kinase in complex with an actin peptide with phosphorylated tyrosine 53
7PKP	;	3.1	;	NSP2 RNP complex
1MBM	;	2.0	;	NSP4 proteinase from Equine Arteritis Virus
7AAP	;	2.5	;	Nsp7-Nsp8-Nsp12 SARS-CoV2 RNA-dependent RNA polymerase in complex with template:primer dsRNA and favipiravir-RTP
1UW7	;	2.8	;	Nsp9 protein from SARS-coronavirus.
6TY0	;	2.1	;	NT PART CRYSTAL STRUCTURE OF THE RYMV-ENCODED VIRAL RNA SILENCING SUPPRESSOR P1
7WVJ	;	3.26	;	NT-mut(K117D,K139D,K145D) TLR3 -poly I:C complex
6G7B	;	1.76	;	Nt2 domain of the TssA component from the type VI secretion system of Aeromonas hydrophila.
6G7C	;	3.13	;	Nt2-CTD domains of the TssA component from the type VI secretion system of Aeromonas hydrophila.
1WWC	;	1.9	;	NT3 BINDING DOMAIN OF HUMAN TRKC RECEPTOR
8BXK	;	2.31	;	Ntaya virus methyltransferase
8CQH	;	2.0	;	Ntaya virus methyltransferase in complex with GTP and SAH
2XKP	;	3.05	;	NtcA from Synechococcus elongatus: active and inactive
6U6I	;	3.12	;	NTD of GluA2 in complex with CNIH3 - with antagonist ZK200775 - in asymmetric global conformation
6U5S	;	3.07	;	NTD of GluA2 in complex with CNIH3 - with antagonist ZK200775 - in pseudo-symmetric global conformation
7OCC	;	3.4	;	NTD of resting state GluA1/A2 heterotertramer
6Q8F	;	1.9	;	Nterminal domain of human SMU1
6Q8I	;	3.17	;	Nterminal domain of human SMU1 in complex with human REDmid
6Q8J	;	1.8	;	Nterminal domain of human SMU1 in complex with LSP641
1GY6	;	1.6	;	NTF2 from rat, ammonium sulphate conditions
3UB1	;	1.8	;	Ntf2 like protein involved in plasmid conjugation
4EC6	;	2.5	;	Ntf2-like, potential transfer protein TraM from Gram-positive conjugative plasmid pIP501
5ODM	;		;	NtiPr polyamide in complex with 5'CGATGTACTACG3
5ODF	;		;	NtMe polyamide in complex with 5'CGATGTACATCG3'- hairpin polyamides studies
5E1D	;	1.45	;	NTMT1 in complex with YPKRIA peptide
3ZX2	;	1.81	;	NTPDase1 in complex with Decavanadate
3ZX0	;	2.5	;	NTPDase1 in complex with Heptamolybdate
8CHD	;	2.34	;	NtUGT1 in two conformations
7VVZ	;	8.8	;	NuA4 bound to the nucleosome
7VVU	;	3.4	;	NuA4 HAT module bound to the nucleosome
7ZVW	;	3.4	;	NuA4 Histone Acetyltransferase Complex
5Y81	;	4.7	;	NuA4 TEEAA sub-complex
7SCZ	;	3.5	;	Nuc147 bound to multiple BRCTs
7SCY	;	4.1	;	Nuc147 bound to single BRCT
1H6K	;	2.0	;	nuclear Cap Binding Complex
7QQD	;	2.7	;	Nuclear factor one X - NFIX in P21
7QQE	;	3.5	;	Nuclear factor one X - NFIX in P41212
6RSA	;	2.0	;	NUCLEAR MAGNETIC RESONANCE AND NEUTRON DIFFRACTION STUDIES OF THE COMPLEX OF RIBONUCLEASE*A WITH URIDINE VANADATE, A TRANSITION-STATE ANALOGUE
1FTZ	;		;	NUCLEAR MAGNETIC RESONANCE SOLUTION STRUCTURE OF THE FUSHI TARAZU HOMEODOMAIN FROM DROSOPHILA AND COMPARISON WITH THE ANTENNAPEDIA HOMEODOMAIN
1ERP	;		;	NUCLEAR MAGNETIC RESONANCE SOLUTION STRUCTURE OF THE PHEROMONE ER-10 FROM THE CILIATED PROTOZOAN EUPLOTES RAIKOVI
2PLD	;		;	NUCLEAR MAGNETIC RESONANCE STRUCTURE OF AN SH2 DOMAIN OF PHOSPHOLIPASE C-GAMMA1 COMPLEXED WITH A HIGH AFFINITY BINDING PEPTIDE
2PLE	;		;	NUCLEAR MAGNETIC RESONANCE STRUCTURE OF AN SH2 DOMAIN OF PHOSPHOLIPASE C-GAMMA1 COMPLEXED WITH A HIGH AFFINITY BINDING PEPTIDE
5NHQ	;		;	Nuclear Magnetic Resonance Structure of the Human Polyoma JC Virus Agnoprotein
2MIW	;		;	Nuclear magnetic resonance studies of N2-guanine adducts derived from the tumorigen dibenzo[a,l]pyrene in DNA: Impact of adduct stereochemistry, size, and local DNA structure on solution conformations
2JOT	;		;	Nuclear Magnetic Resonance Studies on Huwentoxin-XI from the Chinese Bird Spider Ornithoctonus huwena
1WFI	;		;	Nuclear move domain of nuclear distribution gene C homolog
2O30	;	1.66	;	Nuclear movement protein from E. cuniculi GB-M1
3UP3	;	1.25	;	Nuclear receptor DAF-12 from hookworm Ancylostoma ceylanicum in complex with (25S)-cholestenoic acid
3UP0	;	1.6	;	Nuclear receptor DAF-12 from hookworm Ancylostoma ceylanicum in complex with (25S)-delta7-dafachronic acid
3GYT	;	2.4	;	Nuclear receptor DAF-12 from parasitic nematode Strongyloides stercoralis in complex with its physiological ligand dafachronic acid delta 4
3GYU	;	2.4	;	Nuclear receptor DAF-12 from parasitic nematode Strongyloides stercoralis in complex with its physiological ligand dafachronic acid delta 7
1AR0	;	2.3	;	NUCLEAR TRANSPORT FACTOR 2 (NTF2) E42K MUTANT
1ASK	;	2.3	;	NUCLEAR TRANSPORT FACTOR 2 (NTF2) H66A MUTANT
1QMA	;	2.5	;	Nuclear Transport Factor 2 (NTF2) W7A mutant
3SOY	;	2.0	;	Nuclear transport factor 2 (NTF2-like) superfamily protein from Salmonella enterica subsp. enterica serovar Typhimurium str. LT2
5VQI	;	2.501	;	Nuclear transport of the Neurospora crassa NIT2 transcription factor is mediated by Importin-alpha
5C10	;	1.55	;	Nuclease domain of the large terminase subunit gp2 of bacterial virus Sf6
5C12	;	1.517	;	Nuclease domain of the large terminase subunit gp2 of bacterial virus Sf6
8B7F	;	4.6	;	Nuclease from C. glutamicum
4B8C	;	3.41	;	nuclease module of the yeast Ccr4-Not complex
6EJU	;	1.9	;	Nuclease NucB from Bacillus licheniformis in P1 space group
6EJT	;	1.7	;	Nuclease NucB from Bacillus licheniformis in P21 space group
6EJS	;	1.6	;	Nuclease NucB from Bacillus licheniformis in P212121 space group
6EJV	;	1.75	;	Nuclease NucB from Bacillus licheniformis in sulphate free conditions
4ZT9	;	3.1	;	Nuclease-inactive Streptococcus pyogenes Cas9 (D10A/H840A, dCas9) in complex with single-guide RNA at 3.1 Angstrom resolution
8FD5	;	4.57	;	Nucleocapsid monomer structure from SARS-CoV-2
1CL4	;		;	NUCLEOCAPSID PROTEIN FROM MASON-PFIZER MONKEY VIRUS (MPMV)
1AAF	;		;	NUCLEOCAPSID ZINC FINGERS DETECTED IN RETROVIRUSES: EXAFS STUDIES ON INTACT VIRUSES AND THE SOLUTION-STATE STRUCTURE OF THE NUCLEOCAPSID PROTEIN FROM HIV-1
1T6O	;	2.0	;	Nucleocapsid-binding domain of the measles virus P protein (amino acids 457-507) in complex with amino acids 486-505 of the measles virus N protein
4UOQ	;	2.7	;	Nucleophile mutant (E324A) of beta-(1,6)-galactosidase from Bifidobacterium animalis subsp. lactis Bl-04
4E3D	;	1.6	;	Nucleophile recognition as an alternative inhibition mode for benzoic acid based carbonic anhydrase inhibitors
4E3F	;	1.5	;	Nucleophile recognition as an alternative inhibition mode for benzoic acid based carbonic anhydrase inhibitors
4E3G	;	1.55	;	Nucleophile recognition as an alternative inhibition mode for benzoic acid based carbonic anhydrase inhibitors
4E3H	;	1.5	;	Nucleophile recognition as an alternative inhibition mode for benzoic acid based carbonic anhydrase inhibitors
4E49	;	1.45	;	Nucleophile recognition as an alternative inhibition mode for benzoic acid based carbonic anhydrase inhibitors
4E4A	;	1.45	;	Nucleophile recognition as an alternative inhibition mode for benzoic acid based carbonic anhydrase inhibitors
2WLQ	;	1.4	;	Nucleophile-disabled Lam16A mutant holds laminariheptaose (L7) in a cyclical conformation
1V1D	;		;	Nucleophilic and General Acid Catalysis at Physiological pH by a Designed Miniature Esterase
7UUI	;	2.9	;	Nucleoplasmic pre-60S intermediate of the Nog2 containing post-rotation state from a SPB1 D52A strain
7UOO	;	2.34	;	Nucleoplasmic pre-60S intermediate of the Nog2 containing pre-rotation state
7UQZ	;	2.44	;	Nucleoplasmic pre-60S intermediate of the Nog2 containing pre-rotation state from a SPB1 D52A strain
7V08	;	2.36	;	Nucleoplasmic pre-60S intermediate of the Nog2 containing pre-rotation state from a Spb1 D52A suppressor 3 strain
7UQB	;	2.43	;	Nucleoplasmic pre-60S intermediate of the Nog2 containing pre-rotation state from a SPB1-D52A strain with AlF4
4I0O	;	1.9	;	Nucleoporin ELYS (aa1-494), Mus musculus
3CQC	;	2.53	;	Nucleoporin Nup107/Nup133 interaction complex
3CQG	;	3.0	;	Nucleoporin Nup107/Nup133 interaction complex, delta finger mutant
3HXR	;	3.0	;	Nucleoporin Nup120 from S.cerevisiae (aa 1-757)
4FHL	;	2.6	;	Nucleoporin Nup37 from Schizosaccharomyces pombe
3MWP	;	1.795	;	Nucleoprotein structure of lassa fever virus
8PQP	;	1.709	;	Nucleoside 2'deoxyribosyltransferase from Chroococcidiopsis thermalis PCC 7203 D62N Mutant bound to ImmH-Forodesine
8PQS	;	1.95	;	Nucleoside 2'deoxyribosyltransferase from Chroococcidiopsis thermalis PCC 7203 E88A Mutant
8PQQ	;	2.23	;	Nucleoside 2'deoxyribosyltransferase from Chroococcidiopsis thermalis PCC 7203 E88Q Mutant bound to Clofarabine
8PQT	;	1.7	;	Nucleoside 2'deoxyribosyltransferase from Chroococcidiopsis thermalis PCC 7203 WT bound to Bis-Tris
8PQR	;	1.586	;	Nucleoside 2'deoxyribosyltransferase from Chroococcidiopsis thermalis PCC 7203 WT bound to DAD_Immucillin-H
8RH3	;	1.96	;	Nucleoside 2'deoxyribosyltransferase from Chroococcidiopsis thermalis PCC 7203 WT bound to Gemcitabine
8QC0	;	2.02	;	Nucleoside 2'deoxyribosyltransferase from Chroococcidiopsis thermalis PCC 7203 WT ribosylated
1PAE	;	2.7	;	nucleoside diphosphate kinase
3PRV	;	2.69	;	Nucleoside diphosphate kinase B from Trypanosoma cruzi
6XP4	;	2.0	;	Nucleoside Diphosphate Kinase from Aspergillus fumgiatus Af293
6XP7	;	2.2	;	Nucleoside Diphosphate Kinase from Aspergillus fumgiatus Af293 bound to ADP
6XPW	;	1.9	;	Nucleoside Diphosphate Kinase from Aspergillus fumgiatus Af293 bound to CDP
6XPV	;	2.3	;	Nucleoside Diphosphate Kinase from Aspergillus fumgiatus Af293 bound to dTDP
6XPS	;	1.644	;	Nucleoside Diphosphate Kinase from Aspergillus fumgiatus Af293 bound to GDP
6XPU	;	1.9	;	Nucleoside Diphosphate Kinase from Aspergillus fumgiatus Af293 bound to IDP
6XPT	;	2.3	;	Nucleoside Diphosphate Kinase from Aspergillus fumgiatus Af293 bound to UDP
5X00	;	3.06	;	Nucleoside Diphosphate Kinase from Vibrio cholerae is a Thermolabile Type II tetramer
1BHN	;	2.4	;	NUCLEOSIDE DIPHOSPHATE KINASE ISOFORM A FROM BOVINE RETINA
1BE4	;	2.4	;	NUCLEOSIDE DIPHOSPHATE KINASE ISOFORM B FROM BOVINE RETINA
7PEW	;	4.6	;	Nucleosome 1 of the 4x177 nucleosome array containing H1
7PF6	;	4.0	;	Nucleosome 1 of the 4x187 nucleosome array containing H1
7PFD	;	4.4	;	Nucleosome 1 of the 4x197 nucleosome array containing H1
7PFV	;	4.4	;	Nucleosome 1 of the 4x207 nucleosome array containing H1
7PEX	;	5.1	;	Nucleosome 2 of the 4x177 nucleosome array containing H1
7PF5	;	3.8	;	Nucleosome 2 of the 4x187 nucleosome array containing H1
7PFE	;	4.4	;	Nucleosome 2 of the 4x197 nucleosome array containing H1
7PFW	;	5.2	;	Nucleosome 2 of the 4x207 nucleosome array containing H1
7PEY	;	4.5	;	Nucleosome 3 of the 4x177 nucleosome array containing H1
7PF4	;	4.0	;	Nucleosome 3 of the 4x187 nucleosome array containing H1
7PFF	;	4.3	;	Nucleosome 3 of the 4x197 nucleosome array containing H1
7PFX	;	4.3	;	Nucleosome 3 of the 4x207 nucleosome array containing H1
7PEZ	;	7.9	;	Nucleosome 4 of the 4x177 nucleosome array containing H1
7PF3	;	4.0	;	Nucleosome 4 of the 4x187 nucleosome array containing H1
6ESF	;	3.7	;	Nucleosome : Class 1
7K7G	;	4.2	;	nucleosome and Gal4 complex
3HFD	;	2.8	;	Nucleosome Assembly Protein 1 from Plasmodium knowlesi
2Z2R	;	3.2	;	Nucleosome assembly proteins I (NAP-1, 74-365)
8OF4	;	2.94	;	Nucleosome Bound human SIRT6 (Composite)
6ESG	;	5.4	;	Nucleosome breathing : Class 2
6ESH	;	5.1	;	Nucleosome breathing : Class 3
6ESI	;	6.3	;	Nucleosome breathing : Class 4
5CPK	;	2.632	;	Nucleosome containing methylated Sat2L DNA
5CPJ	;	3.15	;	Nucleosome containing methylated Sat2R DNA
5CPI	;	2.902	;	Nucleosome containing unmethylated Sat2R DNA
4KGC	;	2.69	;	Nucleosome Core Particle Containing (ETA6-P-CYMENE)-(1, 2-ETHYLENEDIAMINE)-RUTHENIUM
2NZD	;	2.65	;	Nucleosome core particle containing 145 bp of DNA
4XUJ	;	3.18	;	Nucleosome core particle containing adducts from treatment with a thiomorpholine-substituted [(eta-6-p-cymene)Ru(3-hydroxy-2-pyridone)Cl] compound
5DNN	;	2.8	;	Nucleosome core particle containing adducts of gold(I)-triethylphosphane and ruthenium(II)-toluene PTA complexes
5DNM	;	2.81	;	Nucleosome core particle containing adducts of ruthenium(II)-toluene PTA complex
6IQ4	;	2.25	;	Nucleosome core particle cross-linked with a hetero-binuclear molecule possessing RAPTA and gold(I) 4-(diphenylphosphino)benzoic acid groups.
3O62	;	3.216	;	Nucleosome core particle modified with a cisplatin 1,3-cis-{Pt(NH3)2}2+-d(GpTpG) intrastrand cross-link
3B6F	;	3.45	;	Nucleosome core particle treated with cisplatin
3B6G	;	3.45	;	Nucleosome core particle treated with oxaliplatin
5CP6	;	2.6	;	Nucleosome Core Particle with Adducts from the Anticancer Compound, [(eta6-5,8,9,10-tetrahydroanthracene)Ru(ethylenediamine)Cl][PF6]
5XF3	;	2.6	;	Nucleosome core particle with an adduct of a binuclear RAPTA (Ru-arene-phosphaadamantane) compound having a 1,2-diphenylethylenediamine linker (R,R-configuration)
5XF5	;	2.82	;	Nucleosome core particle with an adduct of a binuclear RAPTA (Ru-arene-phosphaadamantane) compound having a 1,2-diphenylethylenediamine linker (R,S-configuration)
5XF4	;	2.87	;	Nucleosome core particle with an adduct of a binuclear RAPTA (Ru-arene-phosphaadamantane) compound having a 1,2-diphenylethylenediamine linker (S,S-configuration)
5XF6	;	2.63	;	Nucleosome core particle with an adduct of a binuclear RAPTA (Ru-arene-phosphaadamantane) compound having an ethylenediamine linker
7U51	;	3.1	;	Nucleosome core particle with AP-site at SHL-6
7U52	;	3.4	;	nucleosome core particle with AP-site at SHL-6.5
7U53	;	4.0	;	Nucleosome core particle with AP-site at SHL0
4XZQ	;	2.4	;	Nucleosome disassembly by RSC and SWI/SNF is enhanced by H3 acetylation near the nucleosome dyad axis
4YS3	;	3.0	;	Nucleosome disassembly by RSC and SWI/SNF is enhanced by H3 acetylation near the nucleosome dyad axis
4Z66	;	2.5	;	Nucleosome disassembly by RSC and SWI/SNF is enhanced by H3 acetylation near the nucleosome dyad axis
7KTQ	;	3.3	;	Nucleosome from a dimeric PRC2 bound to a nucleosome
7KBD	;	3.38	;	Nucleosome in interphase chromosome formed in Xenopus egg extract (oligo fraction)
7KBE	;	3.5	;	Nucleosome isolated from metaphase chromosome formed in Xenopus egg extract (oligo fraction)
1OFC	;	1.9	;	nucleosome recognition module of ISWI ATPase
7PEV	;	6.0	;	Nucleosome stack of the 4x177 nucleosome array containing H1
7PF2	;	5.1	;	Nucleosome stack of the 4x187 nucleosome array containing H1
7PFC	;	6.4	;	Nucleosome stack of the 4x197 nucleosome array containing H1
7PFU	;	5.0	;	Nucleosome stack of the 4x207 nucleosome array containing H1
8G8B	;	4.3	;	Nucleosome with human nMatn1 sequence in complex with Human Oct4
6T93	;	3.49	;	Nucleosome with OCT4-SOX2 motif at SHL-6
7OHA	;	2.9	;	nucleosome with TBP and TFIIA bound at SHL +2
7OH9	;	3.0	;	Nucleosome with TBP and TFIIA bound at SHL -6
8ATF	;	3.45	;	Nucleosome-bound Ino80 ATPase
6RYR	;	3.1	;	Nucleosome-CHD4 complex structure (single CHD4 copy)
6RYU	;	4.0	;	Nucleosome-CHD4 complex structure (two CHD4 copies)
3NHB	;	2.15	;	Nucleotide Binding Domain of Human ABCB6 (ADP bound structure)
3NHA	;	2.1	;	Nucleotide Binding Domain of Human ABCB6 (ADP Mg bound structure)
3NH6	;	2.0	;	Nucleotide Binding Domain of human ABCB6 (apo structure)
3NH9	;	2.1	;	Nucleotide Binding Domain of Human ABCB6 (ATP bound structure)
6S7P	;	3.2	;	Nucleotide bound ABCB4
1NJF	;	2.3	;	Nucleotide bound form of an isolated E. coli clamp loader gamma subunit
7K0R	;	3.3	;	Nucleotide bound SARS-CoV-2 Nsp15
1IJE	;	2.4	;	Nucleotide Exchange Intermediates in the eEF1A-eEF1Ba Complex
1IJF	;	3.0	;	Nucleotide exchange mechanisms in the eEF1A-eEF1Ba complex
7M2U	;	8.2	;	Nucleotide Excision Repair complex TFIIH Rad4-33
6WID	;	1.5	;	Nucleotide incorporation intermediate into quaternary complex of human Polymerase Mu on a complementary DNA double-strand break substrate
1UDI	;	2.7	;	NUCLEOTIDE MIMICRY IN THE CRYSTAL STRUCTURE OF THE URACIL-DNA GLYCOSYLASE-URACIL GLYCOSYLASE INHIBITOR PROTEIN COMPLEX
1CDG	;	2.0	;	NUCLEOTIDE SEQUENCE AND X-RAY STRUCTURE OF CYCLODEXTRIN GLYCOSYLTRANSFERASE FROM BACILLUS CIRCULANS STRAIN 251 IN A MALTOSE-DEPENDENT CRYSTAL FORM
2JF2	;	1.8	;	Nucleotide substrate binding by UDP-N-acetylglucosamine acyltransferase
2JF3	;	3.0	;	Nucleotide substrate binding by UDP-N-acetylglucosamine acyltransferase
1HXP	;	1.8	;	NUCLEOTIDE TRANSFERASE
4WOP	;	2.393	;	Nucleotide Triphosphate Promiscuity in Mycobacterium tuberculosis Dethiobiotin Synthetase
5TFG	;	1.91	;	Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with 5-methyl-UTP
5TFB	;	1.87	;	Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with 7-methyl-GTP
5TF7	;	1.931	;	Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with ATP
5TFD	;	1.891	;	Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with CTP
5TGK	;	1.912	;	Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with dATP
5TFJ	;	1.85	;	Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with dCTP
5TFI	;	1.891	;	Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with dGTP
5TF8	;	1.861	;	Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with dTTP
5TFA	;	1.87	;	Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with dUTP
5TFC	;	1.92	;	Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with GTP
5TFF	;	1.891	;	Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with UTP
8PMD	;	2.95	;	Nucleotide-bound BSEP in nanodiscs
4BGB	;	1.34	;	Nucleotide-bound closed form of a putative sugar kinase MK0840 from Methanopyrus kandleri
4BGA	;	2.6	;	Nucleotide-bound open form of a putative sugar kinase MK0840 from Methanopyrus kandleri
8FNY	;	2.22	;	Nucleotide-bound structure of a functional construct of eukaryotic elongation factor 2 kinase.
2XCL	;	2.1	;	Nucleotide-bound Structures of Bacillus subtilis Glycinamide Ribonucleotide Synthetase
2XD4	;	2.65	;	Nucleotide-bound Structures of Bacillus subtilis Glycinamide Ribonucleotide Synthetase
1HQY	;	2.8	;	Nucleotide-Dependent Conformational Changes in a Protease-Associated ATPase HslU
1HT1	;	2.8	;	Nucleotide-Dependent Conformational Changes in a Protease-Associated ATPase HslU
1HT2	;	2.8	;	Nucleotide-Dependent Conformational Changes in a Protease-Associated ATPase HslU
7XKH	;	3.1	;	Nucleotide-depleted F1 domain of FoF1-ATPase from Bacillus PS3, state1
5VFO	;	3.5	;	Nucleotide-driven Triple-state Remodeling of the AAA-ATPase Channel in the Activated Human 26S Proteasome
5VFP	;	4.2	;	Nucleotide-driven Triple-state Remodeling of the AAA-ATPase Channel in the Activated Human 26S Proteasome
5VFQ	;	4.2	;	Nucleotide-driven Triple-state Remodeling of the AAA-ATPase Channel in the Activated Human 26S Proteasome
5VFR	;	4.9	;	Nucleotide-driven Triple-state Remodeling of the AAA-ATPase Channel in the Activated Human 26S Proteasome
5VFS	;	3.6	;	Nucleotide-Driven Triple-State Remodeling of the AAA-ATPase Channel in the Activated Human 26S Proteasome
5VFT	;	7.0	;	Nucleotide-driven Triple-state Remodeling of the AAA-ATPase Channel in the Activated Human 26S Proteasome
5VFU	;	5.8	;	Nucleotide-driven Triple-state Remodeling of the AAA-ATPase Channel in the Activated Human 26S Proteasome
6MHU	;	4.0	;	Nucleotide-free Cryo-EM Structure of E.coli LptB2FG Transporter
6MI7	;	4.2	;	Nucleotide-free Cryo-EM Structure of E.coli LptB2FGC
4C3Z	;	2.1	;	Nucleotide-free crystal structure of nucleotide-binding domain 1 from human MRP1 supports a general-base catalysis mechanism for ATP hydrolysis.
7YYL	;	3.25	;	nucleotide-free DCCP:DCCP-R complex
1SGK	;	2.3	;	NUCLEOTIDE-FREE DIPHTHERIA TOXIN
4BEJ	;	3.483	;	Nucleotide-free Dynamin 1-like protein (DNM1L, DRP1, DLP1)
1NJG	;	2.2	;	Nucleotide-free form of an Isolated E. coli Clamp Loader Gamma Subunit
5ZME	;	3.603	;	Nucleotide-free form of C. reinhardtii ArsA1
2WOO	;	3.006	;	Nucleotide-free form of S. pombe Get3
7SPZ	;	3.0	;	Nucleotide-free Get3 in two open forms
4H1U	;	2.3	;	Nucleotide-free human dynamin-1-like protein GTPase-GED fusion
2MMC	;		;	Nucleotide-free human ran gtpase
3J6H	;	8.1	;	Nucleotide-free Kinesin motor domain complexed with GMPCPP-microtubule
4LNU	;	2.19	;	Nucleotide-free kinesin motor domain in complex with tubulin and a DARPin
5LT3	;	2.59	;	nucleotide-free kinesin-1 motor domain T87A mutant, P1 crystal form
5LT4	;	2.881	;	nucleotide-free kinesin-1 motor domain T92V mutant, P1 crystal form
5LT1	;	1.949	;	nucleotide-free kinesin-1 motor domain T92V mutant, P21 crystal form
5LT2	;	2.6	;	nucleotide-free kinesin-1 motor domain, P1 crystal form
5LT0	;	2.0	;	nucleotide-free kinesin-1 motor domain, P212121 crystal form
6JFL	;	2.806	;	Nucleotide-free Mitofusin2 (MFN2)
6Z7T	;	1.88	;	Nucleotide-free Myosin-II motor domain
7A40	;	2.297	;	Nucleotide-free OSM-3 kinesin motor domain
1DFK	;	4.2	;	NUCLEOTIDE-FREE SCALLOP MYOSIN S1-NEAR RIGOR STATE
4P4U	;	1.9	;	Nucleotide-free stalkless-MxA
8FO6	;	2.553	;	Nucleotide-free structure of a functional construct of eukaryotic elongation factor 2 kinase.
7VAJ	;	3.1	;	Nucleotide-free V1EG domain of V/A-ATPase from Thermus thermophilus, state1-2
7VAK	;	4.7	;	Nucleotide-free V1EG domain of V/A-ATPase from Thermus thermophilus, state2
4LY6	;	3.6	;	Nucleotide-induced asymmetry within ATPase activator ring drives s54-RNAP interaction and ATP hydrolysis
4LZZ	;	3.21	;	Nucleotide-induced asymmetry within atpase activator ring drives s54-RNAP interaction and ATP hydrolysis
2VAN	;	2.1	;	Nucleotidyl Transfer Mechanism of Mismatched dNTP Incorporation by DNA Polymerase b by Structural and Kinetic Analyses
6EHI	;	1.58	;	NucT from Helicobacter pylori
7ANM	;	2.72	;	Nudaurelia capensis omega virus capsid: virus-like particles expressed in Nicotiana benthamiana
8ACH	;	3.91	;	Nudaurelia capensis omega virus maturation intermediate captured at pH5.6 (insect cell expressed VLPs): large class from symmetry expansion
8AC6	;	3.63	;	Nudaurelia capensis omega virus maturation intermediate captured at pH5.6 (insect cell expressed VLPs): medium class from symmetry expansion
8AAY	;	3.39	;	Nudaurelia capensis omega virus maturation intermediate captured at pH5.6 (insect cell expressed VLPs): small class from symmetry expansion
8A3C	;	3.92	;	Nudaurelia capensis omega virus maturation intermediate captured at pH5.9 (insect cell expressed VLPs)
8A6J	;	4.8	;	Nudaurelia capensis omega virus maturation intermediate captured at pH6.25 (insect cell expressed VLPs)
8A41	;	4.88	;	Nudaurelia capensis omega virus procapsid at pH7.6 (insect cell expressed VLPs)
7ATA	;	6.63	;	Nudaurelia capensis omega virus procapsid: virus-like particles expressed in Nicotiana benthamiana
2B0V	;	1.55	;	NUDIX hydrolase from Nitrosomonas europaea.
6YPB	;	1.7	;	NUDIX1 hydrolase from Rosa x hybrida
6YPF	;	1.45	;	NUDIX1 hydrolase from Rosa x hybrida in complex with geranyl pyrophosphate
1J57	;		;	NuiA
1KTU	;		;	NuiA
5Z5Q	;		;	Nukacin ISK-1 in active state
5Z5R	;		;	Nukacin ISK-1 in inactive state
3I4R	;	3.53	;	Nup107(aa658-925)/Nup133(aa517-1156) complex, H.sapiens
6X06	;	4.27	;	Nup120 (aa1-757) from S. cerevisiae bound by VHH-SAN11
6X05	;	2.1	;	Nup133 (aa55-481) from S. cerevisiae bound by VHH-SAN4
6X04	;	2.68	;	Nup133 (aa55-481) from S. cerevisiae bound by VHH-SAN5
3I5Q	;	2.204	;	Nup170(aa1253-1502) at 2.2 A, S.cerevisiae
3I5P	;	3.2	;	Nup170(aa979-1502), S.cerevisiae
4KF7	;	2.65	;	Nup188(aa1-1160) from Myceliophthora thermophila
4KF8	;	3.0	;	Nup188(aa1445-1827) from Myceliophthora thermophila
4C31	;	3.0	;	Nup1:Sac3:Sus1 complex
4GQ1	;	2.4	;	Nup37 of S. pombe
4FHN	;	6.989	;	Nup37-Nup120 full-length complex from Schizosaccharomyces pombe
4FHM	;	4.339	;	Nup37-Nup120(aa1-961) complex from Schizosaccharomyces pombe
2C1M	;	2.2	;	Nup50:importin-alpha complex
6X02	;	6.38	;	Nup84-Nup133 (aa521-1157) from S. cerevisiae bound by VHH-SAN8
6X03	;	7.3	;	Nup84-Nup133 (aa521-1157) from S. cerevisiae bound by VHH-SAN8 and VHH-SAN9
3JRO	;	4.004	;	NUP84-NUP145C-SEC13 edge element of the NPC lattice
6X08	;	4.19	;	Nup85-Seh1 from S. cerevisiae bound by VHH-SAN2
7ZOX	;	4.4	;	Nup93 in complex with xhNup93-Nb4i and xNup93-Nb2t
8CYO	;	2.41	;	Nurr1 Covalently Bound to a Synthetic Ligand, 10.25, via a Disulfide Bond
6DDA	;	3.2	;	Nurr1 Covalently Modified by a Dopamine Metabolite
8F5G	;	2.7	;	NusG-RNA complex
4QPX	;	1.86	;	NV polymerase post-incorporation-like complex
3FTL	;	1.6	;	NVGSNTY segment from Islet Amyloid Polypeptide (IAPP or Amylin), dehydrated crystal form
3FTK	;	1.5	;	NVGSNTY segment from Islet Amyloid Polypeptide (IAPP or Amylin), hydrated crystal form
5I1Y	;	1.95	;	NvPizza2-H16S58 with cobalt
7JX0	;	3.15	;	NVS-PI3-4 bound to the PI3Kg catalytic subunit p110 gamma
2HM5	;		;	NW1, K21P, Structural Species II
7F32	;		;	Ny-Hydroxyasparagine: A Multifunctional Unnatural Amino Acid That is a Good P1 Substrate of Asparaginyl Peptide Ligases
6R2L	;	2.3	;	NYBR1-A2-SLSKILDTV
7S3T	;	1.4	;	NzeB Diketopiperazine Dimerase Mutant: Q68I-G87A-A89G-I90V
8PHA	;	2.02	;	O(S)-methyltransferase from Pleurotus sapidus
7KB0	;	1.85	;	O-acety-L-homoserine aminocarboxypropyltransferase (MetY) from Thermotoga maritima with pyridoxal-5-phosphate (PLP) bound in the internal aldimine state
1Y7L	;	1.55	;	O-Acetylserine Sulfhydrylase Complex
7N2T	;	1.55	;	O-acetylserine sulfhydrylase from Citrullus vulgaris in the internal aldimine state, with citrate bound
1OAS	;	2.2	;	O-ACETYLSERINE SULFHYDRYLASE FROM SALMONELLA TYPHIMURIUM
4O8V	;	1.815	;	O-Acetyltransferase Domain of Pseudomonas putida AlgJ
4DRJ	;	1.8	;	o-crystal structure of the PPIase domain of FKBP52, Rapamycin and the FRB fragment of mTOR
1VXR	;	2.2	;	O-ETHYLMETHYLPHOSPHONYLATED ACETYLCHOLINESTERASE OBTAINED BY REACTION WITH O-ETHYL-S-[2-[BIS(1-METHYLETHYL)AMINO]ETHYL] METHYLPHOSPHONOTHIOATE (VX)
5A01	;	2.66	;	O-GlcNAc transferase from Drososphila melanogaster
6E37	;	2.531	;	O-GlcNAc Transferase in complex with covalent inhibitor
6EOU	;	1.75	;	O-GlcNAc transferase TPR domain with the intellectual disability associated mutation L254F
3WV0	;	2.3	;	O-glycan attached to herpes simplex virus type 1 glycoprotein gB is recognized by the Ig V-set domain of human paired immunoglobulin-like type 2 receptor alpha
7O3J	;	2.6	;	O-layer structure (TrwH/VirB7, TrwF/VirB9CTD, TrwE/VirB10CTD) of the outer membrane core complex from the fully-assembled R388 type IV secretion system determined by cryo-EM.
3GEL	;	2.39	;	O-Methylphosphorylated Torpedo Acetylcholinesterase Obtained by Reaction with Methyl Paraoxon (AGED)
8C9V	;	1.5	;	O-methyltransferase from Desulfuromonas acetoxidans
8BGZ	;	2.0	;	O-Methyltransferase Plu4890 (mutant H229N) in complex with SAH and AQ-256
8BID	;	1.75	;	O-Methyltransferase Plu4890 (mutant H229N) in complex with SAH and AQ-270a
8BIB	;	2.3	;	O-Methyltransferase Plu4890 in complex with SAH and AQ-256
8BGX	;	1.9	;	O-Methyltransferase Plu4890 in complex with SAH and AQ-270a
8BH0	;	1.7	;	O-Methyltransferase Plu4890 in complex with SAH and AQ-270b
8BGY	;	1.95	;	O-Methyltransferase Plu4890 in complex with SAH and AQ-284a
8BIH	;	2.4	;	O-Methyltransferase Plu4890 in complex with SAH and AQ-284b
8BGT	;	2.15	;	O-Methyltransferase Plu4890 in complex with SAM
8BIC	;	1.85	;	O-Methyltransferase Plu4891 in complex with SAH
8BIF	;	2.0	;	O-Methyltransferase Plu4892 in complex with SAH
8BIJ	;	1.55	;	O-Methyltransferase Plu4894 (mutant I88M, W91L, C97Y, S142L, G146V, Y258M, L270F, S309Y) in complex with SAH
8BIE	;	2.25	;	O-Methyltransferase Plu4894 in complex with SAH
8BII	;	2.8	;	O-Methyltransferase Plu4895 (mutant H229N) in complex with SAH
8BIG	;	2.8	;	O-Methyltransferase Plu4895 in complex with SAH
8BIR	;	2.4	;	O-Methyltransferase Plu4895 in complex with SAH and AQ-256
4V0Z	;	1.7	;	o-nitrophenyl Cellobioside as an Active Site Probe for Family 7 Cellobiohydrolases
5GTD	;	2.69	;	o-Succinylbenzoate CoA Synthetase (MenE) from Bacillus Subtilis in Complex with the Acyl-adenylate Intermediate OSB-AMP
5BUS	;	2.603	;	O-succinylbenzoate Coenzyme A Synthetase (MenE) from Bacillus Subtilis, in complex with AMP
5BUR	;	2.82	;	O-succinylbenzoate Coenzyme A Synthetase (MenE) from Bacillus Subtilis, in Complex with ATP and Magnesium Ion
7N79	;	1.98	;	O2-, PLP-dependent desaturase Plu4 holo-enzyme
7RF9	;	1.926	;	O2-, PLP-dependent desaturase Plu4 intermediate-bound enzyme
7RGB	;	2.5	;	O2-, PLP-dependent desaturase Plu4 product-bound enzyme
6C3A	;	1.53	;	O2-, PLP-dependent L-arginine hydroxylase RohP 4-hydroxy-2-ketoarginine complex
6C3B	;	1.51	;	O2-, PLP-Dependent L-Arginine Hydroxylase RohP Holoenzyme
6C3D	;	1.55	;	O2-, PLP-dependent L-arginine hydroxylase RohP quinonoid II complex
7LA7	;	1.55101	;	O6 variable lymphocyte receptor ectodomain
7LA8	;	1.8965	;	O6 variable lymphocyte receptor ectodomain bound to 3-HSO3-Gal-4GlcNAc
4O5W	;	1.6	;	O6-carboxymethylguanine in DNA forms a sequence context dependent wobble base pair structure with thymine
4O5Y	;	1.75	;	O6-carboxymethylguanine in DNA forms a sequence context dependent wobble base pair structure with thymine
4O5Z	;	1.75	;	O6-carboxymethylguanine in DNA forms a sequence context dependent wobble base pair structure with thymine
4O5X	;	1.6	;	O6-carboxymethylguanine in DNA forms a sequence context dependent wobble base pair structure with thymine.
2HHX	;	2.26	;	O6-methyl-guanine in the polymerase template preinsertion site
2HHQ	;	1.8	;	O6-methyl-guanine:T pair in the polymerase-10 basepair position
2HHS	;	1.8	;	O6-methyl:C pair in the polymerase-10 basepair position
8AMT	;	1.5	;	OBD-RepB pMV158 domain
1SL9	;	1.17	;	Obelin from Obelia longissima
2JSJ	;		;	Obestatin in water solution
2JSH	;		;	obestatin NMR structure in SDS/DPC micellar solution
4GN3	;	1.95	;	OBody AM1L10 bound to hen egg-white lysozyme
4GN4	;	1.861	;	OBody AM2EP06 bound to hen egg-white lysozyme
4GLV	;	2.574	;	OBody AM3L09 bound to hen egg-white lysozyme
4GN5	;	1.86	;	OBody AM3L15 bound to hen egg-white lysozyme
4GLA	;	2.75	;	OBody NL8 bound to hen egg-white lysozyme
6HDD	;	4.5	;	OBP chaperonin in the nucleotide-free state
1JCJ	;	1.1	;	OBSERVATION OF COVALENT INTERMEDIATES IN AN ENZYME MECHANISM AT ATOMIC RESOLUTION
1JCL	;	1.05	;	OBSERVATION OF COVALENT INTERMEDIATES IN AN ENZYME MECHANISM AT ATOMIC RESOLUTION
1DID	;	2.5	;	OBSERVATIONS OF REACTION INTERMEDIATES AND THE MECHANISM OF ALDOSE-KETOSE INTERCONVERSION BY D-XYLOSE ISOMERASE
1DIE	;	2.5	;	OBSERVATIONS OF REACTION INTERMEDIATES AND THE MECHANISM OF ALDOSE-KETOSE INTERCONVERSION BY D-XYLOSE ISOMERASE
4KLQ	;	1.999	;	Observing a DNA polymerase choose right from wrong.
6VI5	;	1.604	;	Observing a ring-cleaving dioxygenase in action through a crystalline lens - a resting state structure
6VIA	;	1.591	;	Observing a ring-cleaving dioxygenase in action through a crystalline lens - a seven-membered lactone bound structure
6VI6	;	1.901	;	Observing a ring-cleaving dioxygenase in action through a crystalline lens - a substrate monodentately bound structure
6VI8	;	1.95	;	Observing a ring-cleaving dioxygenase in action through a crystalline lens - a superoxo bound structure
6VI9	;	2.31	;	Observing a ring-cleaving dioxygenase in action through a crystalline lens - an alkylperoxo bound structure
6X11	;	2.097	;	Observing a ring-cleaving dioxygenase in action through a crystalline lens - an enol tautomer of ACMS monodentately bound structure
6VIB	;	1.84	;	Observing a ring-cleaving dioxygenase in action through a crystalline lens - enol tautomers of ACMS bidentately bound structure
4XOL	;	2.91	;	Observing the overall rocking motion of a protein in a crystal - Cubic Ubiquitin crystals.
4XOF	;	1.15	;	Observing the overall rocking motion of a protein in a crystal - Orthorhombic Ubiquitin crystals without Zinc.
4XOK	;	2.2	;	Observing the overall rocking motion of a protein in a crystal.
3J42	;	21.0	;	Obstruction of Dengue Virus Maturation by Fab Fragments of the 2H2 Antibody
7NH7	;	2.2	;	OC43 coronavirus methyltransferase
7ZDT	;	2.71	;	Occ(apo/return) conformation of CydDC mutant (E500Q.C) in ATP(CydC) bound state (Dataset-18)
7ZE5	;	2.94	;	Occ(apo/return) conformation of CydDC mutant (E500Q.C) in ATP(CydC)/AMP-PNP(CydD) bound state (Dataset-23)
7ZDU	;	2.98	;	Occ(apo/return) conformation of CydDC mutant (E500Q.C) in ATP(CydC)/ATP(CydD) bound state (Dataset-19)
4Y1O	;	2.95	;	Oceanobacillus iheyensis group II intron domain 1
4Y1N	;	3.0	;	Oceanobacillus iheyensis group II intron domain 1 with iridium hexamine
5LCC	;	2.0	;	Oceanobacillus iheyensis macrodomain mutant D40A
5LAU	;	1.35	;	Oceanobacillus iheyensis macrodomain mutant G37V with ADPR
5LBP	;	1.76	;	Oceanobacillus iheyensis macrodomain mutant N30A
5L9Q	;	1.75	;	OCEANOBACILLUS IHEYENSIS MACRODOMAIN WITH ADP
5L9K	;	1.77	;	OCEANOBACILLUS IHEYENSIS MACRODOMAIN WITH ADPR
5FUD	;	1.9	;	Oceanobacillus iheyensis macrodomain with MES bound
5U9Y	;		;	Ocellatin-F1
5UA8	;		;	Ocellatin-F1, solution structure in SDS micelle by NMR spectroscopy
5U9S	;		;	Ocellatin-F1, solution structure in TFE by NMR spectroscopy
5U9Q	;		;	Ocellatin-LB1
5U9V	;		;	Ocellatin-LB1, solution structure in DPC micelle by NMR spectroscopy
5UA6	;		;	Ocellatin-LB1, solution structure in SDS micelle by NMR spectroscopy
5U9X	;		;	Ocellatin-LB2
5UA7	;		;	Ocellatin-LB2, solution structure in SDS micelle by NMR spectroscopy
5U9R	;		;	Ocellatin-LB2, solution structure in TFE by NMR spectroscopy
3E5X	;	1.999	;	OCPA complexed CprK
3E5U	;	1.83	;	OCPA complexed CprK (C200S)
3E6B	;	2.01	;	OCPA complexed CprK (C200S)
8OTS	;	3.3	;	OCT4 and MYC-MAX co-bound to a nucleosome
6YOV	;	3.42	;	OCT4-SOX2-bound nucleosome - SHL+6
6T90	;	3.05	;	OCT4-SOX2-bound nucleosome - SHL-6
8BX1	;	2.5	;	Oct4/Sox2 protein:DNA complex
8BX2	;	3.14	;	Oct4/Sox2 protein:DNA complex
6HT5	;	3.451	;	Oct4/Sox2:UTF1 structure
1EBH	;	1.9	;	OCTAHEDRAL COORDINATION AT THE HIGH AFFINITY METAL SITE IN ENOLASE; CRYSTALLOGRAPHIC ANALYSIS OF THE MG++-ENZYME FROM YEAST AT 1.9 ANGSTROMS RESOLUTION
8GZ7	;	3.5	;	Octahedral supramolecular assembly of the bicomponent gamma-hemolysin octameric pore complexes from Staphylococcus aureus Newman.
419D	;	2.2	;	OCTAMER 5'-R(*GP*UP*AP*UP*AP*CP*A)-D(P*C)-3' WITH SIX WATSON-CRICK BASE-PAIRS AND TWO 3' OVERHANG RESIDUES
6RCD	;	1.98	;	Octamer C-Domain P140 Mycoplasma genitalium.
5FTT	;	3.4	;	Octameric complex of Latrophilin 3 (Lec, Olf) , Unc5D (Ig, Ig2, TSP1) and FLRT2 (LRR)
1L4X	;	2.0	;	Octameric de novo designed peptide
7T8B	;	3.8	;	Octameric Human Twinkle Helicase Clinical Variant W315L
3LA6	;	3.2	;	Octameric kinase domain of the E. coli tyrosine kinase Wzc with bound ADP
6TV6	;	2.5	;	Octameric McsB from Bacillus subtilis.
8EAX	;	3.73	;	Octameric prenyltransferase domain of fusicoccadiene Synthase with C2 symmetry sans transiently associating cyclase domains
4U3L	;	1.482	;	octameric RNA duplex co-crystallized in calcium(II)chloride
4U3R	;	1.701	;	Octameric RNA duplex co-crystallized with cobalt(II)chloride
4U3P	;	1.866	;	Octameric RNA duplex co-crystallized with strontium(II)chloride
4U78	;	1.501	;	Octameric RNA duplex soaked in copper(II)chloride
4U3O	;	1.8	;	Octameric RNA duplex soaked in manganese(II)chloride
4U47	;	1.952	;	Octameric RNA duplex soaked in terbium(III)chloride
3OOW	;	1.75	;	Octameric structure of the phosphoribosylaminoimidazole carboxylase catalytic subunit from Francisella tularensis subsp. tularensis SCHU S4.
4P4Z	;	1.31	;	Octomer formed by a macrocyclic peptide derived from beta-2-microglobulin (63-69) - (ORN)YLL(PHI)YTE(ORN)KVT(MVA)TVK
6VC1	;		;	Octreotide oxalate
7YAE	;	3.37	;	Octreotide-bound SSTR2-Gi complex
7OWL	;	2.9	;	Odinarchaeota Adenylate kinase (OdinAK) in complex with CTP
7OWK	;	3.1	;	Odinarchaeota Adenylate kinase (OdinAK) in complex with dTTP
7OWJ	;	2.5	;	Odinarchaeota Adenylate kinase (OdinAK) in complex with GTP
7OWE	;	2.75	;	Odinarchaeota Adenylate kinase (OdinAK) in complex with inhibitor Ap5a
7OWH	;	1.85	;	Odinarchaeota Adenylate kinase (OdinAK) native structure
7F1A	;	1.9	;	Odinarchaeota tubulin (OdinTubulin) H393D mutant, in a protofilament arrangement, bound 78% GTP/22% GDP 1 K+, 1 Mg2+
7EVE	;	2.0	;	Odinarchaeota tubulin (OdinTubulin) H393D mutant, in a protofilament arrangement, bound to 100% GDP and 2 Na+
7EVD	;	1.45	;	Odinarchaeota tubulin (OdinTubulin) H393D mutant, in a protofilament arrangement, bound to 53% GTP/47% and 2 Na+
7EVC	;	1.25	;	Odinarchaeota tubulin (OdinTubulin) H393D mutant, in a protofilament arrangement, bound to 60% GTP/40% GDP and 2 Na+
7EVL	;	2.15	;	Odinarchaeota tubulin (OdinTubulin) H393D mutant, in a protofilament arrangement, bound to 64% GTP/36% GDP and 2 Na+ in a small unit cell
7EVB	;	1.62	;	Odinarchaeota tubulin (OdinTubulin) H393D mutant, in a protofilament arrangement, bound to 77% GTP/23% and 2 Na+
7EVK	;	1.75	;	Odinarchaeota tubulin (OdinTubulin) H393D mutant, in a protofilament arrangement, bound to 78% GTP, 22% GDP, Na+
7EVI	;	1.55	;	Odinarchaeota tubulin (OdinTubulin) H393D mutant, in a protofilament arrangement, bound to 79% GTP, 21% GDP, Na+, Mg2+
7F1B	;	2.4	;	Odinarchaeota tubulin H393D mutant, in a pseudo protofilament arrangement, after GTP hydrolysis and phosphate release
7EVH	;	2.5	;	Odinarchaeota tubulin H393D mutant, in a psuedo protofilament arrangement, bound to 59% GDP, 41% phosphate
5ZZA	;	1.53	;	OdinProfilin/Rabbit Actin Complex
3R1O	;	2.1	;	Odorant Binding Protein 7 from Anopheles gambiae with Four Disulfide Bridges
3R1P	;	1.85	;	Odorant Binding Protein 7 from Anopheles gambiae with Four Disulfide Bridges, form P1
3R1V	;	2.19	;	Odorant Binding Protein 7 from Anopheles gambiae with Four Disulfide Bridges, in complex with an azo compound
1A3Y	;	2.25	;	ODORANT BINDING PROTEIN FROM NASAL MUCOSA OF PIG
3FIQ	;	1.599	;	Odorant Binding Protein OBP1
6QQ4	;	1.998	;	Odorant-binding protein dmelOBP28a from Drosophila melanogaster
1OBP	;	2.0	;	ODORANT-BINDING PROTEIN FROM BOVINE NASAL MUCOSA
6ZOQ	;	1.8	;	Oestrogen receptor ligand binding domain in complex with compound 16
6ZOS	;	2.0	;	Oestrogen receptor ligand binding domain in complex with compound 18
6ZOR	;	1.97	;	Oestrogen receptor ligand binding domain in complex with compound 28
7QVL	;	1.9	;	OESTROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH COMPOUND 38
1TPB	;	1.9	;	OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE
1TPC	;	1.9	;	OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE
2BML	;	2.6	;	Ofloxacin-like antibiotics inhibit pneumococcal cell wall degrading virulence factors
2XSA	;	2.0	;	OgOGA apostructure
7KHS	;	1.78	;	OgOGA IN COMPLEX WITH LIGAND 55
2XSB	;	2.11	;	OgOGA PUGNAc complex
5NCR	;	1.89	;	OH1 from the Orf virus: a tyrosine phosphatase that displays distinct structural features and triple substrate specificity
6EBG	;	2.15	;	Ohr (Organic Hydroperoxide Resistance protein) mutant - C60S interacting with dihydrolipoamide
4XX2	;	2.15	;	Ohr from Xylella fastidiosa in oxidized state
6ED0	;	1.44	;	OhrA (Organic Hydroperoxide Resistance protein) mutant (C61S) in the ""open conformation"" from chromobacterium violaceum
6ECY	;	1.4	;	OhrA (Organic Hydroperoxide Resistance protein) wild type from chromobacterium violaceum
6EB4	;	2.1	;	OhrB (Organic Hydroperoxide Resistance protein) from Chromobacterium violaceum
6EBD	;	2.61	;	OhrB (Organic Hydroperoxide Resistance protein) mutant (C60A) from Chromobacterium violaceum, interacting with dihydrolipoamide
6EBC	;	1.87	;	OhrB (Organic Hydroperoxide Resistance protein) wild type from Chromobacterium violaceum and reduced by DTT
6P74	;	2.2	;	OLD nuclease from Thermus Scotoductus
1BWL	;	2.7	;	OLD YELLOW ENZYME (OYE1) DOUBLE MUTANT H191N:N194H
1BWK	;	2.3	;	OLD YELLOW ENZYME (OYE1) MUTANT H191N
8E5I	;	1.7	;	Old Yellow Enzyme 1 (NpOYE1) from Neptuniibacter sp.
8E5H	;	1.27	;	Old Yellow Enzyme 5 (PcOYE5) from Pseudomonas chloritidismutans
1OYA	;	2.0	;	OLD YELLOW ENZYME AT 2 ANGSTROMS RESOLUTION: OVERALL STRUCTURE, LIGAND BINDING AND COMPARISON WITH RELATED FLAVOPROTEINS
1OYB	;	2.0	;	OLD YELLOW ENZYME AT 2 ANGSTROMS RESOLUTION: OVERALL STRUCTURE, LIGAND BINDING AND COMPARISON WITH RELATED FLAVOPROTEINS
1OYC	;	2.0	;	OLD YELLOW ENZYME AT 2 ANGSTROMS RESOLUTION: OVERALL STRUCTURE, LIGAND BINDING AND COMPARISON WITH RELATED FLAVOPROTEINS
8PUN	;	2.3	;	Old Yellow Enzyme from the thermophilic Ferrovum sp. JA12
3HF3	;	2.2	;	Old Yellow Enzyme from Thermus scotoductus SA-01
3HGJ	;	2.0	;	Old Yellow Enzyme from Thermus scotoductus SA-01 complexed with p-hydroxy-benzaldehyde
7Q6R	;	2.44	;	OleP mutant E89Y in complex with 6DEB
7Q89	;	2.08	;	OleP mutant G92W in complex with 6DEB
7Q6X	;	2.7	;	OleP mutant S240Y in complex with 6DEB
4XE3	;	2.65	;	OleP, the cytochrome P450 epoxidase from Streptomyces antibioticus involved in Oleandomycin biosynthesis: functional analysis and crystallographic structure in complex with clotrimazole.
6ZHZ	;	2.2	;	OleP-oleandolide(DEO) in high salt crystallization conditions
6ZI2	;	2.93	;	OleP-oleandolide(DEO) in low salt crystallization conditions
6NAX	;	1.551	;	Olfactomedin domain of mouse myocilin
8EFB	;	3.2	;	Oliceridine-bound mu-opioid receptor-Gi complex
1JET	;	1.2	;	OLIGO-PEPTIDE BINDING PROTEIN (OPPA) COMPLEXED WITH KAK
1B4Z	;	1.75	;	OLIGO-PEPTIDE BINDING PROTEIN (OPPA) COMPLEXED WITH KDK
1JEU	;	1.25	;	OLIGO-PEPTIDE BINDING PROTEIN (OPPA) COMPLEXED WITH KEK
1B40	;	2.2	;	OLIGO-PEPTIDE BINDING PROTEIN (OPPA) COMPLEXED WITH KFK
1B3L	;	2.0	;	OLIGO-PEPTIDE BINDING PROTEIN (OPPA) COMPLEXED WITH KGK
1B3F	;	1.8	;	OLIGO-PEPTIDE BINDING PROTEIN (OPPA) COMPLEXED WITH KHK
1B3G	;	2.0	;	OLIGO-PEPTIDE BINDING PROTEIN (OPPA) COMPLEXED WITH KIK
1B9J	;	1.8	;	OLIGO-PEPTIDE BINDING PROTEIN (OPPA) COMPLEXED WITH KLK
1B32	;	1.75	;	OLIGO-PEPTIDE BINDING PROTEIN (OPPA) COMPLEXED WITH KMK
1B5I	;	1.9	;	OLIGO-PEPTIDE BINDING PROTEIN (OPPA) COMPLEXED WITH KNK
1B46	;	1.8	;	OLIGO-PEPTIDE BINDING PROTEIN (OPPA) COMPLEXED WITH KPK
1B5J	;	1.8	;	OLIGO-PEPTIDE BINDING PROTEIN (OPPA) COMPLEXED WITH KQK
1QKA	;	1.8	;	OLIGO-PEPTIDE BINDING PROTEIN (OPPA) COMPLEXED WITH KRK
1B51	;	1.8	;	OLIGO-PEPTIDE BINDING PROTEIN (OPPA) COMPLEXED WITH KSK
1B52	;	2.3	;	OLIGO-PEPTIDE BINDING PROTEIN (OPPA) COMPLEXED WITH KTK
1QKB	;	1.8	;	OLIGO-PEPTIDE BINDING PROTEIN (OPPA) COMPLEXED WITH KVK
1JEV	;	1.3	;	OLIGO-PEPTIDE BINDING PROTEIN (OPPA) COMPLEXED WITH KWK
1B58	;	1.8	;	OLIGO-PEPTIDE BINDING PROTEIN (OPPA) COMPLEXED WITH KYK
1OLC	;	2.1	;	OLIGO-PEPTIDE BINDING PROTEIN (OPPA) COMPLEXED WITH LYS-LYS-LYS-ALA
1B3H	;	2.0	;	OLIGO-PEPTIDE BINDING PROTEIN COMPLEXED WITH LYSYL-CYCLOHEXYLALANYL-LYSINE
1B4H	;	1.9	;	OLIGO-PEPTIDE BINDING PROTEIN COMPLEXED WITH LYSYL-DIAMINOBUTYRIC ACID-LYSINE
1B5H	;	1.9	;	OLIGO-PEPTIDE BINDING PROTEIN COMPLEXED WITH LYSYL-DIAMINOPROPANOIC ACID-LYSINE
1B0H	;	1.9	;	OLIGO-PEPTIDE BINDING PROTEIN COMPLEXED WITH LYSYL-NAPTHYLALANYL-LYSINE
1B7H	;	2.0	;	OLIGO-PEPTIDE BINDING PROTEIN COMPLEXED WITH LYSYL-NORLEUCYL-LYSINE
1B6H	;	1.8	;	OLIGO-PEPTIDE BINDING PROTEIN COMPLEXED WITH LYSYL-NORVALYL-LYSINE
1B2H	;	1.9	;	Oligo-Peptide Binding Protein Complexed with Lysyl-Ornithyl-Lysine
1B1H	;	1.8	;	OLIGO-PEPTIDE BINDING PROTEIN/TRIPEPTIDE (LYS HPE LYS) COMPLEX
3PE7	;	1.65	;	Oligogalacturonate lyase in complex with manganese
4GPO	;	3.5	;	Oligomeic Turkey Beta1-Adrenergic G Protein-Coupled Receptor
5CMD	;	3.086	;	Oligomer crystal structure of CC chemokine 5 (CCL5)
5L2U	;	2.28	;	Oligomer crystal structure of CC chemokine 5 (CCL5)
2YJE	;	3.1	;	Oligomeric assembly of actin bound to MRTF-A
2YJF	;	3.5	;	Oligomeric assembly of actin bound to MRTF-A
8DE6	;	3.2	;	Oligomeric C9 in complex with aE11 Fab
6DV5	;	3.58	;	Oligomeric complex of a Hsp27 24-mer at 3.6 A resolution
2OF5	;	3.2	;	Oligomeric Death Domain complex
7ZW6	;	3.7	;	Oligomeric structure of SynDLP
2L9H	;		;	Oligomeric Structure of the Chemokine CCL5/RANTES from NMR, MS, and SAXS Data
3LMN	;	2.15	;	Oligomeric structure of the DUSP domain of human USP15
6DLN	;		;	Oligomeric Structure of the HIV gp41 MPER-TMD in Phospholipid Bilayers
1B4F	;	1.95	;	OLIGOMERIC STRUCTURE OF THE HUMAN EPHB2 RECEPTOR SAM DOMAIN
1A92	;	1.8	;	OLIGOMERIZATION DOMAIN OF HEPATITIS DELTA ANTIGEN
1XCU	;	2.0	;	oligonucleotid/drug complex
2LFA	;		;	Oligonucleotide duplex contaning (5'S)-8,5'-cyclo-2'-deoxyguansine
2MNC	;		;	oligonucleotide model of miR-21 pre-element
7OB1	;	2.0	;	OLIGOPEPTIDASE B FROM S. PROTEOMACULANS WITH MODIFIED HINGE
7NE7	;	2.3	;	oligopeptidase B from S. proteomaculans with modified hinge region in complex with N-[(1S)-5-amino-1-(chloroacetyl)pentyl]-4-methylbenzenesulfonamide
4BP8	;	2.4	;	Oligopeptidase B from Trypanosoma brucei - open form
4BP9	;	2.85	;	Oligopeptidase B from Trypanosoma brucei with covalently bound antipain - closed form
2OLB	;	1.4	;	OLIGOPEPTIDE BINDING PROTEIN (OPPA) COMPLEXED WITH TRI-LYSINE
5IPW	;	2.6	;	oligopeptide-binding protein OppA
1J9A	;	2.5	;	OLIGORIBONUCLEASE
6A4A	;	2.7	;	Oligoribonuclease (ORN) from Colwellia psychrerythraea strain 34H
1AHP	;	3.0	;	OLIGOSACCHARIDE SUBSTRATE BINDING IN ESCHERICHIA COLI MALTODEXTRIN PHSPHORYLASE
1H4G	;	1.1	;	Oligosaccharide-binding to family 11 xylanases: both covalent intermediate and mutant-product complexes display 2,5B conformations at the active-centre
1H4H	;	1.9	;	Oligosaccharide-binding to family 11 xylanases: both covalent intermediate and mutant-product complexes display 2,5B conformations at the active-centre
8CA7	;	2.06	;	Omadacycline and spectinomycin bound to the 30S ribosomal subunit head
3CU4	;	1.3	;	OmcF, Outer membrance cytochrome F from Geobacter sulfurreducens
3ZUO	;	1.86	;	OMCI in complex with leukotriene B4
3ZUI	;	1.71	;	OMCI in complex with palmitoleic acid
4PA0	;	2.25	;	Omecamtiv Mercarbil binding site on the Human Beta-Cardiac Myosin Motor Domain
2KM9	;		;	Omega conotoxin-FVIA
7LI2	;		;	Omega ester peptide pre-fuscimiditide
1OAV	;		;	OMEGA-AGATOXIN IVA
1OAW	;		;	OMEGA-AGATOXIN IVA
1TTL	;		;	Omega-conotoxin GVIA, a N-type calcium channel blocker
1CNN	;		;	OMEGA-CONOTOXIN MVIIC FROM CONUS MAGUS
2MYH	;		;	Omega-Tbo-IT1: selective inhibitor of insect calcium channels isolated from Tibellus oblongus spider venom
7ZF6	;	2.21	;	Omi-12 Fab
7ZR9	;	4.0	;	OMI-2 FAB IN COMPLEX WITH SARS-COV-2 BETA SPIKE GLYCOPROTEIN
7ZRC	;	3.5	;	OMI-38 FAB IN COMPLEX WITH SARS-COV-2 BETA SPIKE
7ZR8	;	3.7	;	OMI-38 FAB IN COMPLEX WITH SARS-COV-2 BETA SPIKE RBD (local refinement)
7ZFF	;	2.32	;	Omi-42 Fab
7ZR7	;	3.7	;	OMI-42 FAB IN COMPLEX WITH SARS-COV-2 BETA SPIKE GLYCOPROTEIN
8C5R	;	3.7	;	Omicron B.1.1.529 2 RBD up conformation
8GOU	;	3.7	;	Omicron BA.4/5 SARS-CoV-2 S in complex with TH003 Fab
7YVE	;	3.4	;	Omicron BA.4/5 SARS-CoV-2 S in complex with TH027 Fab
7YVO	;	3.3	;	Omicron BA.4/5 SARS-CoV-2 S in complex with TH027/132 Fab
7YVG	;	3.4	;	Omicron BA.4/5 SARS-CoV-2 S in complex with TH132 Fab
7YVI	;	3.7	;	Omicron BA.4/5 SARS-CoV-2 S in complex with TH236 Fab
7YVK	;	3.2	;	Omicron BA.4/5 SARS-CoV-2 S in complex with TH272 Fab
7YVP	;	3.8	;	Omicron BA.4/5 SARS-CoV-2 S in complex with TH272/281 Fab
7YVN	;	3.4	;	Omicron BA.4/5 SARS-CoV-2 S in complex with TH281 Fab
7YVF	;	3.4	;	Omicron BA.4/5 SARS-CoV-2 S RBD in complex with TH027 Fab
7YVH	;	3.6	;	Omicron BA.4/5 SARS-CoV-2 S RBD in complex with TH132 Fab
7YVJ	;	3.6	;	Omicron BA.4/5 SARS-CoV-2 S RBD in complex with TH236 Fab
7YVL	;	3.3	;	Omicron BA.4/5 SARS-CoV-2 S RBD in complex with TH272 Fab
7YVM	;	3.5	;	Omicron BA.4/5 SARS-CoV-2 S RBD in complex with TH272 Fab
7YKJ	;	3.5	;	Omicron RBDs bound with P3E6 Fab (one up and one down)
7TGW	;	3.0	;	Omicron spike at 3.0 A (open form)
7WJZ	;	3.34	;	Omicron Spike bitrimer with 6m6 antibody
7WJY	;	3.24	;	Omicron spike trimer with 6m6 antibody
8I4H	;	3.81	;	Omicron spike variant BA.1 with Bn03
8I4G	;	3.68	;	Omicron spike variant BQ.1.1 with n3130v-Fc
8I4E	;	3.98	;	Omicron spike variant XBB with Bn03
8I4F	;	3.44	;	Omicron spike variant XBB with n3130v-Fc
6U83	;	2.3566	;	OmpA-like domain of FopA1 from Francisella tularensis subsp. tularensis SCHU S4
2XE3	;	2.85	;	OmpC28
6ZX1	;	1.0	;	OMPD-domain of human UMPS in complex with 6-Aza-UMP at 1.0 Angstroms resolution
6ZX2	;	1.2	;	OMPD-domain of human UMPS in complex with 6-carboxamido-UMP at 1.2 Angstroms resolution
6ZX3	;	1.15	;	OMPD-domain of human UMPS in complex with 6-thiocarboxamido-UMP at 1.15 Angstroms resolution
7AM9	;	0.99	;	OMPD-domain of human UMPS in complex with the substrate OMP at 0.99 Angstroms resolution
6ZX0	;	1.25	;	OMPD-domain of human UMPS in complex with the substrate OMP at 1.25 Angstroms resolution
6ZWY	;	1.0	;	OMPD-domain of human UMPS in complex with UMP at 1.0 Angstroms resolution
6ENE	;	2.3	;	OmpF orthologue from Enterobacter cloacae (OmpE35)
2OMF	;	2.4	;	OMPF PORIN
3K19	;	3.79	;	OmpF porin
1GFM	;	3.5	;	OMPF PORIN (MUTANT D113G)
1GFO	;	3.3	;	OMPF PORIN (MUTANT R132P)
1GFP	;	2.7	;	OMPF PORIN (MUTANT R42C)
1GFQ	;	2.8	;	OMPF PORIN (MUTANT R82C)
1GFN	;	3.1	;	OMPF PORIN DELETION (MUTANT DELTA 109-114)
1BT9	;	3.0	;	OMPF PORIN MUTANT D74A
1HXU	;	3.0	;	OMPF PORIN MUTANT KK
1HXT	;	2.4	;	OMPF PORIN MUTANT NQAAA
1HXX	;	2.2	;	OMPF PORIN MUTANT Y106F
6V78	;	2.6	;	OmpK37 porin
1ODD	;	2.2	;	OMPR C-TERMINAL DOMAIN (OMPR-C) FROM ESCHERICHIA COLI
1OPC	;	1.95	;	OMPR DNA-BINDING DOMAIN, ESCHERICHIA COLI
6EHD	;	1.66	;	OmpT (in-vitro folded), an outer membrane protein of Vibrio cholerae
6EHF	;	2.72	;	OmpT (in-vitro folded), an outer membrane protein Vibrio cholerae (trimer form)
6EHE	;	2.312	;	OmpTdeltaL8 (loop L8 deletion mutant of OmpT), an outer membrane protein of Vibrio cholerae
6EHB	;	1.55	;	OmpU, an outer membrane protein, of Vibrio cholerae
6EHC	;	2.02	;	OmpUdeltaN (N-terminus deletion mutant of OmpU), outer membrane protein of Vibrio cholerae
3WYZ	;	2.21	;	On archaeal homologs of the human RNase P protein Rpp30 in the hyperthermophilic archaeon Thermococcus kodakarensis
3WZ0	;	2.79	;	On archaeal homologs of the human RNase P proteins Pop5 and Rpp30 in the hyperthermophilic archaeon Thermococcus kodakarensis
1TGC	;	1.8	;	ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
1TGT	;	1.7	;	ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
2PTN	;	1.55	;	ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
2TGA	;	1.8	;	ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
2TGT	;	1.7	;	ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
2TPI	;	2.1	;	ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
3PTN	;	1.7	;	ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
1E89	;	2.1	;	ON THE MECHANISM OF CYANOGENESIS CATALYZED BY HYDROXYNITRILE LYASE FROM MANIHOT ESCULENTA. CRYSTAL STRUCTURE OF ACTIVE SITE MUTANT SER80ALA IN COMPLEX WITH ACETONE CYANOHYDRIN
1MNS	;	2.0	;	ON THE ROLE OF LYSINE 166 IN THE MECHANISM OF MANDELATE RACEMASE FROM PSEUDOMONAS PUTIDA: MECHANISTIC AND CRYSTALLOGRAPHIC EVIDENCE FOR STEREOSPECIFIC ALKYLATION BY (R)-ALPHA-PHENYLGLYCIDATE
2A7A	;	1.75	;	On the Routine Use of Soft X-Rays in Macromolecular Crystallography, Part III- The Optimal Data Collection Wavelength
2A7B	;	1.65	;	On the Routine Use of Soft X-Rays in Macromolecular Crystallography, Part III- The Optimal Data Collection Wavelength
2A7C	;	1.65	;	On the Routine Use of Soft X-Rays in Macromolecular Crystallography, Part III- The Optimal Data Collection Wavelength
2A7D	;	1.66	;	On the Routine Use of Soft X-Rays in Macromolecular Crystallography, Part III- The Optimal Data Collection Wavelength
2A7E	;	1.66	;	On the Routine Use of Soft X-Rays in Macromolecular Crystallography, Part III- The Optimal Data Collection Wavelength
2A7F	;	1.85	;	On the Routine Use of Soft X-Rays in Macromolecular Crystallography, Part III- The Optimal Data Collection Wavelength
2A7G	;	1.85	;	On the Routine Use of Soft X-Rays in Macromolecular Crystallography, Part III- The Optimal Data Collection Wavelength
2A7H	;	2.1	;	On the Routine Use of Soft X-Rays in Macromolecular Crystallography, Part III- The Optimal Data Collection Wavelength
2A7I	;	1.75	;	On the Routine Use of Soft X-Rays in Macromolecular Crystallography, Part III- The Optimal Data Collection Wavelength
2A7J	;	1.65	;	On the Routine Use of Soft X-Rays in Macromolecular Crystallography, Part III- The Optimal Data Collection Wavelength
3OR7	;	2.3	;	On the structural basis of modal gating behavior in K+channels - E71I
3OR6	;	2.7	;	On the structural basis of modal gating behavior in K+channels - E71Q
6FEK	;	2.3	;	Oncogenic point mutation of RET receptor tyrosine kinase
3SNF	;	1.1	;	Onconase, atomic resolution crystal structure
1E7W	;	1.75	;	One active site, two modes of reduction correlate the mechanism of leishmania pteridine reductase with pterin metabolism and antifolate drug resistance in trpanosomes
8HIF	;	3.5	;	One asymmetric unit of Singapore grouper iridovirus capsid
3FGW	;	2.8	;	One chain form of the 66.3 kDa protein
8HEY	;	4.1	;	One CVSC-binding penton vertex in HCMV B-capsid
6IL9	;	1.72005	;	One Glycerol complexed Crystal structure of fructuronate-tagaturonate epimerase UxaE from Cohnella laeviribosi
1BUU	;	1.9	;	ONE HO3+ FORM OF RAT MANNOSE-BINDING PROTEIN A
2GND	;	2.25	;	One hour EDTA treatment, P. angolensis lectin
4LPJ	;	1.27	;	One minute iron loaded frog M ferritin
4ML5	;	1.22	;	one minute iron loaded frog M ferritin mutant H54Q
4Y08	;	1.34	;	ONE MINUTE IRON LOADED HUMAN H FERRITIN
5J8W	;	1.11	;	One minute iron loaded Rana Catesbeiana H' ferritin variant E57A/E136A/D140A
3QJJ	;	2.8049	;	One RAMP protein binding different RNA substrates
3QJL	;	2.7009	;	One RAMP protein binding different RNA substrates
7SBL	;	3.4	;	One RBD-up 1 of pre-fusion SARS-CoV-2 Delta variant spike protein
7SBS	;	3.8	;	One RBD-up 1 of pre-fusion SARS-CoV-2 Gamma variant spike protein
7SBQ	;	3.7	;	One RBD-up 1 of pre-fusion SARS-CoV-2 Kappa variant spike protein
7SBO	;	4.3	;	One RBD-up 2 of pre-fusion SARS-CoV-2 Delta variant spike protein
7SBT	;	4.4	;	One RBD-up 2 of pre-fusion SARS-CoV-2 Gamma variant spike protein
7SBR	;	4.3	;	One RBD-up 2 of pre-fusion SARS-CoV-2 Kappa variant spike protein
8D56	;	3.0	;	One RBD-up state of SARS-CoV-2 BA.2 variant spike protein
2DID	;		;	One sequence two fold ? : Correct fold of the zf-B-box domain from human tripartite motif protein 39
2DIF	;		;	One sequence two fold ? : Miss fold of the zf-B-box domain from human tripartite motif protein 39
1PWF	;	1.16	;	One Sugar Pucker Fits All: Pairing Versatility Despite Conformational Uniformity in TNA
6IES	;	1.8	;	Onion lachrymatory factor synthase (LFS) containing (E)-2-propen 1-ol (crotyl alcohol)
4LRN	;	1.89	;	Ontogeny of recognition specificity and functionality for the anti-HIV antibody 4E10
4M62	;	1.8	;	Ontogeny of recognition specificity and functionality for the anti-HIV neutralizing antibody 4E10
4M8Q	;	2.89	;	Ontogeny of recognition specificity and functionality for the anti-HIV neutralizing antibody 4E10
4OB5	;	1.7	;	Ontogeny of recognition specificity and functionality for the broadly neutralizing anti-HIV antibody 4E10
2R1K	;	2.1	;	OpdA from Agrobacterium radiobacter with bound diethyl phosphate from crystal soaking with the compound- 1.9 A
2R1L	;	1.95	;	OpdA from Agrobacterium radiobacter with bound diethyl thiophosphate from crystal soaking with the compound- 1.95 A
2D2H	;	1.8	;	OpdA from Agrobacterium radiobacter with bound inhibitor trimethyl phosphate at 1.8 A resolution
2R1M	;	2.5	;	OpdA from Agrobacterium radiobacter with bound product diethyl phosphate from crystal soaking with diethyl 4-methoxyphenyl phosphate (450h)- 2.5 A
2R1P	;	1.8	;	OpdA from Agrobacterium radiobacter with bound product diethyl thiophosphate from co-crystallisation with tetraethyl dithiopyrophosphate- 1.8 A
3C86	;	1.8	;	OpdA from agrobacterium radiobacter with bound product diethyl thiophosphate from crystal soaking with tetraethyl dithiopyrophosphate- 1.8 A
2D2G	;	1.85	;	OpdA from Agrobacterium radiobacter with bound product dimethylthiophosphate
2R1N	;	1.7	;	OpdA from Agrobacterium radiobacter with bound slow substrate diethyl 4-methoxyphenyl phosphate (20h)- 1.7 A
2D2J	;	1.75	;	OpdA from Agrobacterium radiobacter without inhibitor/product present at 1.75 A resolution
5A71	;	0.91	;	Open and closed conformations and protonation states of Candida antarctica Lipase B: atomic resolution native
5A6V	;	2.28	;	Open and closed conformations and protonation states of Candida antarctica Lipase B: Xenon complex
4JKH	;	1.8	;	Open and closed forms of D1781E human PRP8 RNase H-like domain with bound Mg ion
4JKD	;	1.55	;	Open and closed forms of I1790Y human PRP8 RNase H-like domain with bound Mg ion
4JKG	;	1.8	;	Open and closed forms of mixed T1789P+R1865A and R1865A human PRP8 RNase H-like domain with bound Mg ion
4JKA	;	1.32	;	Open and closed forms of R1865A human PRP8 RNase H-like domain with bound Co ion
4JK8	;	1.15	;	Open and closed forms of R1865A human PRP8 RNase H-like domain with bound Mg ion
4JKE	;	1.65	;	Open and closed forms of T1789P human PRP8 RNase H-like domain with bound Mg ion
4JKF	;	1.95	;	Open and closed forms of T1791P+R1865A human PRP8 RNase H-like domain with bound Mg ion
4JKC	;	1.5	;	Open and closed forms of T1800E human PRP8 RNase H-like domain with bound Mg ion
4JKB	;	1.3	;	Open and closed forms of V1788D human PRP8 RNase H-like domain with bound Mg ion
4JK9	;	1.5	;	Open and closed forms of wild-type human PRP8 RNase H-like domain with bound Co ion
4JK7	;	1.4	;	Open and closed forms of wild-type human PRP8 RNase H-like domain with bound Mg ion
2OEF	;	2.4	;	Open and Closed Structures of the UDP-Glucose Pyrophosphorylase from Leishmania major
2OEG	;	2.3	;	Open and Closed Structures of the UDP-Glucose Pyrophosphorylase from Leishmania major
4F5R	;	2.2	;	Open and closed ternary complex of R283K DNA polymerase beta with a dCTP analog in the same asymmetric unit
6BY3	;	2.37	;	Open and conductive conformation of KcsA-T75A mutant
7S89	;	2.54	;	Open apo-state cryo-EM structure of human TRPV6 in cNW11 nanodiscs
7S88	;	2.69	;	Open apo-state cryo-EM structure of human TRPV6 in glyco-diosgenin detergent
4F4L	;	3.49	;	Open Channel Conformation of a Voltage Gated Sodium Channel
4B9Q	;	2.4	;	Open conformation of ATP-bound Hsp70 homolog DnaK
7BNN	;	3.5	;	Open conformation of D614G SARS-CoV-2 spike with 1 Erect RBD
7BNO	;	4.2	;	Open conformation of D614G SARS-CoV-2 spike with 2 Erect RBDs
5G1S	;	1.7	;	Open conformation of Francisella tularensis ClpP at 1.7 A
5G1R	;	1.9	;	Open conformation of Francisella tularensis ClpP at 1.9 A
3LHS	;	1.3	;	Open Conformation of HtsA Complexed with Staphyloferrin A
5VKE	;	2.37	;	Open conformation of KcsA deep-inactivated
5VK6	;	2.25	;	Open conformation of KcsA non-inactivating E71A mutant
4BE9	;	2.0	;	Open conformation of O. piceae sterol esterase
4UPD	;	2.4	;	Open conformation of O. piceae sterol esterase mutant I544W
3LIP	;	2.0	;	OPEN CONFORMATION OF PSEUDOMONAS CEPACIA LIPASE
8B8T	;	4.2	;	Open conformation of the complex of DNA ligase I on PCNA and DNA in the presence of ATP
6H03	;	5.6	;	OPEN CONFORMATION OF THE MEMBRANE ATTACK COMPLEX
7M2X	;	3.6	;	Open conformation of the Yeast wild-type gamma-TuRC
3GWF	;	2.2	;	Open crystal structure of cyclohexanone monooxygenase
3R1B	;	3.0	;	Open crystal structure of cytochrome P450 2B4 covalently bound to the mechanism-based inactivator tert-butylphenylacetylene
4AOY	;	2.35	;	Open CtIDH. The complex structures of Isocitrate dehydrogenase from Clostridium thermocellum and Desulfotalea psychrophila, support a new active site locking mechanism
6UG4	;	2.295	;	Open Dimer of Y77A Mutant Putative Ryanodine Receptor from Bacteroides thetaiotaomicron VPI-5482
2FFF	;	2.23	;	Open Form of a Class A Transpeptidase Domain
5FIB	;	2.8	;	Open form of murine Acid Sphingomyelinase
5FIC	;	2.8	;	Open form of murine Acid Sphingomyelinase in presence of lipid
7CTS	;	1.1	;	Open form of PET-degrading cutinase Cut190 with thermostability-improving mutations of S226P/R228S/Q138A/D250C-E296C/Q123H/N202H and S176A inactivation
7R8P	;	1.37	;	Open form of SAOUHSC_02373 in complex with ADP, Mg2+ and Na+
3W8N	;	2.2	;	Open form structure of CMP kinase in complex with CMP from Thermus thermophilus HB8
3FB7	;	3.3	;	Open KcsA potassium channel in the presence of Rb+ ion
3M9W	;	2.15	;	Open ligand-free crystal structure of xylose binding protein from Escherichia coli
3M9X	;	2.2	;	Open liganded crystal structure of xylose binding protein from Escherichia coli
5MLX	;	1.6	;	Open loop conformation of PhaZ7 Y105E mutant
8DDJ	;	3.1	;	Open MscS in PC14.1 Nanodiscs
4QE9	;	2.15	;	Open MthK pore structure soaked in 10 mM Ba2+/100 mM K+
4QE7	;	2.4	;	Open MthK pore structure soaked in 10 mM Ba2+/100 mM Na+
8RWZ	;	4.0	;	Open non-crosslinked structure Brd4BD2-MZ1-(NEDD8)-CRL2VHL
5NP1	;	5.7	;	Open protomer of human ATM (Ataxia telangiectasia mutated)
6A4V	;	2.2	;	Open Reading frame 49
8SFE	;	3.36	;	Open state CCT-G beta 5 complex
8AYO	;	3.3	;	Open state GluA1/A2 AMPA receptor in complex with TARP gamma 8 and ligand JNJ-61432059
6DLZ	;	3.9	;	Open state GluA2 in complex with STZ after micelle signal subtraction
6O9G	;	4.8	;	Open state GluA2 in complex with STZ and blocked by AgTx-636, after micelle signal subtraction
6DM0	;	4.4	;	Open state GluA2 in complex with STZ and blocked by IEM-1460, after micelle signal subtraction
6DM1	;	4.2	;	Open state GluA2 in complex with STZ and blocked by NASPM, after micelle signal subtraction
3AQ1	;	2.746	;	Open state monomer of a group II chaperonin from methanococcoides burtonii
4UEO	;	2.0	;	Open state of galactitol-1-phosphate 5-dehydrogenase from E. coli, with zinc in the catalytic site.
5IK1	;	1.53	;	Open state of P450cam after soaking in camphor
7ST9	;	2.2	;	Open state of Rad24-RFC:9-1-1 bound to a 5' ss/dsDNA junction
8DQW	;	2.1	;	Open state of Rad24-RFC:9-1-1 bound to a 5' ss/dsDNA junction
8DQX	;	2.1	;	Open state of RFC:PCNA bound to a 3' ss/dsDNA junction
8DR5	;	2.76	;	Open state of RFC:PCNA bound to a 3' ss/dsDNA junction (DNA2) with NTD
8DR4	;	2.45	;	Open state of RFC:PCNA bound to a 3' ss/dsDNA junction (DNA2) without NTD
8DR7	;	2.7	;	Open state of RFC:PCNA bound to a nicked dsDNA
7W92	;	3.1	;	Open state of SARS-CoV-2 Delta variant spike protein
8DUE	;	2.9	;	Open state of T4 bacteriophage gp41 hexamer bound with single strand DNA
8SUZ	;		;	Open State of the SARS-CoV-2 Envelope Protein Transmembrane Domain, Determined by Solid-State NMR
6BO4	;	4.0	;	Open state structure of the full-length TRPV2 cation channel with a resolved pore turret domain
3U6N	;	3.61	;	Open Structure of the BK channel Gating Ring
4F5N	;	1.8	;	Open ternary complex of R283K DNA polymerase beta with a metal free dCTP analog
4F5O	;	2.0	;	Open ternary complex of R283K DNA polymerase beta with a one metal bound dCTP analog
2KTQ	;	2.3	;	OPEN TERNARY COMPLEX OF THE LARGE FRAGMENT OF DNA POLYMERASE I FROM THERMUS AQUATICUS
4F5P	;	1.85	;	Open ternary mismatch complex of R283K DNA polymerase beta with a dATP analog
6ZM1	;	4.7	;	Open-closed state of the Bt1762-Bt1763 levan transport system
6UHS	;	2.46	;	Open-form Crystal Structure of Chimera Bt-hRyR_12 from Bacteroides thetaiotaomicron /human
6UHA	;	2.855	;	Open-form Crystal Structure of Human RYR Receptor 3 ( 848-1055)
3ZJZ	;	2.92	;	Open-form NavMS Sodium Channel Pore (with C-terminal Domain)
4CBC	;	2.664	;	Open-form NavMS Sodium Channel Pore (with C-terminal Domain) after thallium soak
6W0A	;	3.237	;	Open-gate KcsA soaked in 1 mM BaCl2
6W0E	;	3.512	;	Open-gate KcsA soaked in 10 mM BaCl2
6W0B	;	3.604	;	Open-gate KcsA soaked in 2 mM BaCl2
6W0C	;	3.556	;	Open-gate KcsA soaked in 4 mM BaCl2
6W0D	;	3.639	;	Open-gate KcsA soaked in 5 mM BaCl2
7PXA	;	2.8	;	Open-gate mycobacterium 20S CP proteasome in complex MPA - global 3D refinement
6ZLT	;	3.9	;	Open-open state of the Bt1762-Bt1763 levan transport system
7YPH	;	3.68	;	Open-spiral pentamer of the substrate-free Lon protease with a Y224S mutation
8T1D	;	3.35	;	Open-state cryo-EM structure of full-length human TRPV4 in complex with agonist 4a-PDD
7WHN	;	3.3	;	Opened spike of Bombyx mori cytoplasmic polyhedrosis virus
1OPG	;	2.0	;	OPG2 FAB FRAGMENT
6R00	;	1.74	;	OphA DeltaC6 V404F complex with SAH
6GEW	;	2.1	;	OphA Y63F-sinefungin complex
6TSC	;	2.19	;	OphMA I407P complex with SAH
3DFX	;	2.7	;	Opposite GATA DNA binding
8QN3	;	1.75	;	OPR3 wildtype in complex with NADH4
8QMX	;	1.4	;	OPR3 wildtype in complex with NADPH4
8AUL	;	1.5	;	OPR3 Y190F in complex with 2-methoxyethyl (Z)-2-(hydroxyimino)-3-oxobutanoate
8AUJ	;	1.57	;	OPR3 Y190F variant in complex with ethyl (Z)-2-(hydroxyimino)-3-oxobutanoate
8AUM	;	1.35	;	OPR3 Y190F variant in complex with ethyl (Z)-2-(hydroxyimino)-3-oxopentanoate
8AUO	;	1.58	;	OPR3 Y370F variant in complex with 2-methoxyethyl (Z)-2-(hydroxyimino)-3-oxobutanoate
8AUN	;	1.49	;	OPR3 Y370F variant in complex with ethyl (Z)-2-(hydroxyimino)-3-oxobutanoate
8AUQ	;	1.42	;	OPR3 Y370F variant in complex with ethyl (Z)-2-(hydroxyimino)-3-oxopentanoate
6TA5	;	3.2	;	OprM-MexA complex from the MexAB-OprM Pseudomonas aeruginosa whole assembly reconstituted in nanodiscs
4X1H	;	2.29	;	Opsin/G(alpha) peptide complex stabilized by nonyl-glucoside
1QMQ	;	1.55	;	Optical detection of cytochrome P450 by sensitizer-linked substrates
2WPA	;	2.51	;	Optimisation of 6,6-Dimethyl Pyrrolo 3,4-c pyrazoles: Identification of PHA-793887, a Potent CDK Inhibitor Suitable for Intravenous Dosing
4BAE	;	2.35	;	Optimisation of pyrroleamides as mycobacterial GyrB ATPase inhibitors: Structure Activity Relationship and in vivo efficacy in the mouse model of tuberculosis
1YUO	;	1.95	;	Optimisation of the surface electrostatics as a strategy for cold adaptation of uracil-DNA N-glycosylase (UNG)from atlantic cod (Gadus morhua)
6VSW	;	3.202	;	Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORgt
5TMG	;	2.2	;	Optimization of 3,5-Disubstitued Piperidine: Discovery of Non-Peptide mimetics as an Orally Active Renin Inhibitor
5TMK	;	2.65	;	Optimization of 3,5-Disubstitued Piperidine: Discovery of Non-Peptide mimetics as an Orally Active Renin Inhibitor
5AAU	;	1.9	;	Optimization of a novel binding motif to to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H- pyrido(3,4-b)indol-1-yl)phenyl)acrylic acid (AZD9496), a potent and orally bioavailable selective estrogen receptor downregulator and antagonist
5AAV	;	1.95	;	Optimization of a novel binding motif to to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H- pyrido(3,4-b)indol-1-yl)phenyl)acrylic acid (AZD9496), a potent and orally bioavailable selective estrogen receptor downregulator and antagonist
5EAK	;	2.8	;	Optimization of Microtubule Affinity Regulating Kinase (MARK) Inhibitors with Improved Physical Properties
3KM4	;	1.9	;	Optimization of Orally Bioavailable Alkyl Amine Renin Inhibitors
6I3U	;	2.09	;	Optimization of potent and selective ATM inhibitors suitable for a proof-of-concept study in Huntington's disease models
3R4M	;	1.7	;	Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide
3R4N	;	2.0	;	Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide
3R4O	;	2.65	;	Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide
3R4P	;	1.7	;	Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide
5TPG	;	1.5	;	Optimization of spirocyclic proline tryptophanhydroxylase-1 inhibitors
7ZJP	;	2.19	;	Optimization of TEAD P-Site Binding Fragment Hit into In Vivo Active Lead MSC-4106
3NPU	;	2.25	;	Optimization of the in silico designed Kemp eliminase KE70 by computational design and directed evolution
3NPV	;	1.48	;	Optimization of the in silico designed Kemp eliminase KE70 by computational design and directed evolution
3NPX	;	1.79	;	Optimization of the in silico designed Kemp eliminase KE70 by computational design and directed evolution
3Q2D	;	2.19	;	Optimization of the in silico designed Kemp eliminase KE70 by computational design and directed evolution
3NQ2	;	2.02	;	Optimization of the in silico designed Kemp eliminase KE70 by computational design and directed evolution R2 3/5G
3NQ8	;	1.4	;	Optimization of the in silico designed Kemp eliminase KE70 by computational design and directed evolution R4 8/5A
3NQV	;	1.7	;	Optimization of the in silico designed Kemp eliminase KE70 by computational design and directed evolution R5 7/4A
3NR0	;	2.19	;	Optimization of the in silico designed Kemp eliminase KE70 by computational design and directed evolution R6 6/10A
2M97	;		;	Optimized Ratiometric Calcium Sensors For Functional In Vivo Imaging of Neurons and T-Lymphocytes
6HR0	;	1.04	;	Optimizing electroactive organisms: the effect of orthologous proteins
7AHD	;	3.4	;	OpuA (E190Q) occluded
7AHC	;	3.3	;	OpuA apo inward-facing
7AHE	;	4.1	;	OpuA inhibited inward facing
7AHH	;	3.5	;	OpuA inhibited inward-facing, SBD docked
2WI1	;	2.3	;	Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone
2WI2	;	2.09	;	Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone
2WI3	;	1.9	;	Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone
2WI4	;	2.4	;	Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone
2WI5	;	2.1	;	Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone
2WI6	;	2.18	;	Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone
2WI7	;	2.5	;	Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone
2Y5K	;	2.1	;	Orally active aminopyridines as inhibitors of tetrameric fructose 1,6- bisphosphatase
2Y5L	;	2.2	;	orally active aminopyridines as inhibitors of tetrameric fructose 1,6- bisphosphatase
2FEQ	;	2.44	;	orally active thrombin inhibitors
2FES	;	2.42	;	Orally active thrombin inhibitors
2ANK	;	2.46	;	orally active thrombin inhibitors in complex with thrombin and an exosite decapeptide
2A2X	;	2.44	;	Orally Active Thrombin Inhibitors in Complex with Thrombin Inh12
2BZ6	;	1.6	;	Orally available Factor7a inhibitor
7ZXV	;	1.8	;	Orange Carotenoid Protein Trp-288 BTA mutant
4MD1	;	1.73	;	Orange species of bacteriorhodopsin from Halobacterium salinarum
7SXN	;	1.05	;	Orb2A residues 1-9 MYNKFVNFI
1AI3	;	1.9	;	ORBITAL STEERING IN THE CATALYTIC POWER OF ENZYMES: SMALL STRUCTURAL CHANGES WITH LARGE CATALYTIC CONSEQUENCES
7JPS	;	4.4	;	ORC-DNA: Human Origin Recognition Complex (ORC) with DNA bound in the core
7JPO	;	3.2	;	ORC-O1AAA: Human Origin Recognition Complex (ORC) with dynamic/unresolved ORC2 WH
7JPQ	;	3.5	;	ORC-O2-5: Human Origin Recognition Complex (ORC) with subunits 2,3,4,5
7JPP	;	3.7	;	ORC-O2WH: Human Origin Recognition Complex (ORC) with dynamic/unresolved ORC1 AAA+ domain
7JPR	;	4.0	;	ORC-OPEN: Human Origin Recognition Complex (ORC) in an open conformation
3H1R	;	2.41	;	Order-disorder structure of fluorescent protein FP480
115D	;	1.7	;	ORDERED WATER STRUCTURE IN AN A-DNA OCTAMER AT 1.7 ANGSTROMS RESOLUTION
4HBM	;	1.9	;	Ordering of the N Terminus of Human MDM2 by Small Molecule Inhibitors
6EWG	;	1.6	;	Oreochromis niloticus CEP120 second C2 domain (C2B)
6EWI	;	2.1	;	Oreochromis niloticus CEP120 second C2 domain (C2B) A200P + G307S mutant
6EWH	;	1.5	;	Oreochromis niloticus CEP120 second C2 domain (C2B) G307S mutant
7L1U	;	3.2	;	Orexin Receptor 2 (OX2R) in Complex with G Protein and Natural Peptide-Agonist Orexin B (OxB)
7L1V	;	3.0	;	Orexin Receptor 2 (OX2R) in Complex with G Protein and Small-Molecule Agonist Compound 1
2X4I	;	2.2	;	ORF 114a from Sulfolobus islandicus rudivirus 1
2X48	;	2.6	;	ORF 55 from Sulfolobus islandicus rudivirus 1
2M7B	;		;	ORF PP_3909 from Pseudomonas putida KT2440 encoding a protein similar to bacteriophage lambda ea8.5
7ADS	;	2.22032	;	Orf virus Apoptosis inhibitor ORFV125
7ADT	;	2.21004	;	Orf virus Apoptosis inhibitor ORFV125
7P0S	;	2.50316	;	ORF virus encoded Bcl-2 homolog ORFV125 in complex with Puma BH3 peptide
7P0U	;	1.99374	;	ORF virus encoded Bcl-2 homolog ORFV125 in complex with Puma BH3 peptide
7XXR	;	2.4	;	Orf1 R342A-glycylthricin complex
8GRI	;	2.365	;	Orf1-E312A-glycine-glycylthricin
7XQA	;	1.93	;	Orf1-glycine complex
7Y0X	;	2.05	;	Orf1-glycine complex
7XXM	;	2.119	;	Orf1-glycine-4-aminobutylthricin complex
7XXC	;	1.989	;	Orf1-glycine-glycylthricin complex
7XXD	;	1.982	;	Orf1-sarcosine complex
7YPU	;	2.357	;	OrfE-CoA-glycylthricin complex
1USP	;	1.9	;	Organic Hydroperoxide Resistance Protein from Deinococcus radiodurans
6LY5	;	2.38	;	Organization and energy transfer in a huge diatom PSI-FCPI supercomplex
2YMN	;	20.0	;	Organization of the Influenza Virus Replication Machinery
2FO0	;	2.27	;	Organization of the SH3-SH2 Unit in Active and Inactive Forms of the c-Abl Tyrosine Kinase
6QJA	;	1.54	;	Organizational principles of the NuMA-Dynein interaction interface and implications for mitotic spindle functions
3SO7	;	2.2	;	Organophoshatedegrading enzyme (OpdA)-phosphate complex
2ZC1	;	1.9	;	Organophosphorus Hydrolase from Deinococcus radiodurans
3HTW	;	1.9	;	Organophosphorus hydrolase from Deinococcus radiodurans with cacodylate bound
2PL7	;	1.0	;	Orhorhombic crystal structure of hydrophobin HFBII in the presence of a detergent
6M6X	;	2.88	;	Oridonin in complex with CRM1#-Ran-RanBP1
7N3K	;	3.0	;	Oridonin-bound SARS-CoV-2 Nsp9
1OO9	;		;	Orientation in Solution of MMP-3 Catalytic Domain and N-TIMP-1 from Residual Dipolar Couplings
1GBR	;		;	ORIENTATION OF PEPTIDE FRAGMENTS FROM SOS PROTEINS BOUND TO THE N-TERMINAL SH3 DOMAIN OF GRB2 DETERMINED BY NMR SPECTROSCOPY
3J0K	;	36.0	;	Orientation of RNA polymerase II within the human VP16-Mediator-pol II-TFIIF assembly
2V3L	;		;	Orientational and dynamical heterogeneity of Rhodamine 6G terminally attached to a DNA helix
2IPR	;	1.5	;	Origin binding domain of the SV40 large T antigen (residues 131-259). P21 crystal form
2ITJ	;	2.5	;	Origin binding domain of the SV40 large T antigen (residues 131-259). P212121 crystal form
1HSY	;	1.9	;	ORIGIN OF THE PH-DEPENDENT SPECTROSCOPIC PROPERTIES OF PENTACOORDINATE METMYOGLOBIN VARIANTS
8SIY	;	2.9	;	Origin Recognition Complex Associated (ORCA) protein bound to H4K20me3-nucleosome
8SIU	;	1.8	;	Origin Recognition Complex Associated (ORCA) protein bound to Orc2
5V0Q	;	2.4	;	Original engineered variant of I-OnuI meganuclease targeting the HIV integrase gene; harbors 49 point mutations relative to wild-type I-OnuI
1VZ6	;	2.75	;	Ornithine Acetyltransferase (ORF6 Gene Product - Clavulanic Acid Biosynthesis) from Streptomyces clavuligerus
1VZ7	;	3.0	;	Ornithine Acetyltransferase (ORF6 Gene Product - Clavulanic Acid Biosynthesis) from Streptomyces clavuligerus
1VZ8	;	2.75	;	Ornithine Acetyltransferase (ORF6 Gene Product - Clavulanic Acid Biosynthesis) from Streptomyces clavuligerus (SeMet structure)
1OAT	;	2.5	;	ORNITHINE AMINOTRANSFERASE
7LON	;	1.95	;	Ornithine Aminotransferase (OAT) cocrystallized with its inactivator - (1S,3S)-3-amino-4-(difluoromethylene)cyclohexene-1-carboxylic acid
7LNM	;	2.0	;	Ornithine Aminotransferase (OAT) cocrystallized with its inactivator - (1S,3S)-3-amino-4-(difluoromethylene)cyclopentene-1-carboxylic acid
7LK0	;	1.96	;	Ornithine Aminotransferase (OAT) cocrystallized with its potent inhibitor - (S)-3-amino-4,4-difluorocyclopent-1-enecarboxylic acid (SS-1-148)
7LOM	;	2.1	;	Ornithine Aminotransferase (OAT) soaked with its inactivator - (1S,3S)-3-amino-4-(difluoromethylene)cyclohexene-1-carboxylic acid
7LK1	;	1.79	;	Ornithine Aminotransferase (OAT) with its potent inhibitor - (S)-3-amino-4,4-difluorocyclopent-1-enecarboxylic acid (SS-1-148) - 1 Hour Soaking
2OAT	;	1.95	;	ORNITHINE AMINOTRANSFERASE COMPLEXED WITH 5-FLUOROMETHYLORNITHINE
5VWO	;	1.773	;	Ornithine aminotransferase inactivated by (1R,3S,4S)-3-amino-4-fluorocyclopentane-1-carboxylic acid (FCP)
2BYJ	;	3.02	;	Ornithine aminotransferase mutant Y85I
1Z7D	;	2.1	;	Ornithine aminotransferase PY00104 from Plasmodium Yoelii
1A1S	;	2.7	;	ORNITHINE CARBAMOYLTRANSFERASE FROM PYROCOCCUS FURIOSUS
2TOD	;	2.0	;	ORNITHINE DECARBOXYLASE FROM TRYPANOSOMA BRUCEI K69A MUTANT IN COMPLEX WITH ALPHA-DIFLUOROMETHYLORNITHINE
1C4K	;	2.7	;	ORNITHINE DECARBOXYLASE MUTANT (GLY121TYR)
3S5W	;	1.9	;	Ornithine Hydroxylase (PvdA) from Pseudomonas aeruginosa
2OTC	;	2.8	;	ORNITHINE TRANSCARBAMOYLASE COMPLEXED WITH N-(PHOSPHONACETYL)-L-ORNITHINE
1ORT	;	3.0	;	ORNITHINE TRANSCARBAMOYLASE FROM PSEUDOMONAS AERUGINOSA
1AKM	;	2.8	;	ORNITHINE TRANSCARBAMYLASE FROM ESCHERICHIA COLI
6H3X	;	2.092	;	Oropouche Virus Glycoprotein Gc Head Domain
5HY0	;	2.4	;	orotic acid hydrolase
1X1Z	;	1.45	;	Orotidine 5'-monophosphate decarboxylase (odcase) complexed with BMP (produced from 6-cyanoump)
3WJZ	;	1.39	;	Orotidine 5'-monophosphate decarboxylase D75N mutant from M. thermoautotrophicus complexed with 6-amino-UMP
1L2U	;	2.5	;	Orotidine 5'-monophosphate decarboxylase from E. coli
3WJY	;	1.72	;	Orotidine 5'-monophosphate decarboxylase K72A mutant from M. thermoautotrophicus complexed with 6-amino-UMP
3WK3	;	1.26	;	Orotidine 5'-monophosphate decarboxylase K72A mutant from M. thermoautotrophicus complexed with orotidine 5'-monophosphate ethyl ester
3WK2	;	1.69	;	Orotidine 5'-monophosphate decarboxylase K72A mutant from M. thermoautotrophicus complexed with orotidine 5'-monophosphate methyl ester
7ASQ	;	0.95	;	Orotidine 5'-monophosphate decarboxylase-domain of human UMPS in complex with the reaction product UMP at 0.95 Angstrom resolution
7OV0	;	0.95	;	Orotidine 5'-monophosphate decarboxylase-domain of human UMPS in resting state at 0.95 Angstrom resolution
2ZZ5	;	1.56	;	Orotidine Monophosphate Deacarboxylase D70A/K72A double mutant from M. thermoautotrophicum complexed with 6- cyano-UMP
1KLY	;	1.5	;	Orotidine monophosphate decarboxylase D70G mutant complexed with 6-azaUMP
2ZZ7	;	1.58	;	Orotidine Monophosphate Decarboxylase K72A mutant complexed with BMP (produced from 6-Iodo-UMP)
2ZZ2	;	1.53	;	Orotidine Monophosphate Decarboxylase K72A mutant from M. thermoautotrophicum complexed with 6-cyano-UMP
1KM1	;	1.6	;	Orotidine monophosphate decarboxylase mutant S127A crystal structure
8HS2	;	3.08	;	Orphan GPR20 in complex with Fab046
6YO7	;	1.17	;	Ortho-Carborane di-propyl-sulfonamide in complex with CA IX mimic
6E69	;	2.33	;	Ortho-substituted phenyl sulfonyl fluoride and fluorosulfate as potent elastase inhibitory fragments
5M4U	;	2.195	;	ORTHORHOMBIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA') WITH THE INHIBITOR 4'-CARBOXY-6,8-CHLORO- FLAVONOL (FLC21)
3ZTO	;	1.47	;	Orthorhombic crystal form C222 of the Aquifex aeolicus nucleoside diphosphate kinase
1OK6	;	2.4	;	Orthorhombic crystal form of an Archaeal fructose 1,6-bisphosphate aldolase
4CJB	;	2.78	;	orthorhombic crystal form of Bogt6a E192Q in complex with GalNAc
4CJC	;	3.42	;	orthorhombic crystal form of Bogt6a E192Q in complex with UDP-GalNAc, UDP, GalNAc
2UUZ	;	2.3	;	Orthorhombic crystal form of GamS from bacteriophage lambda.
1DO0	;	3.0	;	ORTHORHOMBIC CRYSTAL FORM OF HEAT SHOCK LOCUS U (HSLU) FROM ESCHERICHIA COLI
1NVI	;	1.9	;	Orthorhombic Crystal Form of Molybdopterin Synthase
4NYH	;	1.2	;	Orthorhombic crystal form of pir1 dual specificity phosphatase core
6XFO	;	1.58	;	Orthorhombic crystal form of Striga hermonthica Dwarf14 (ShD14)
3ZTP	;	1.37	;	Orthorhombic crystal form P21212 of the Aquifex aeolicus nucleoside diphosphate kinase
2GUY	;	1.59	;	Orthorhombic crystal structure (space group P21212) of Aspergillus niger alpha-amylase at 1.6 A resolution
6YB5	;	1.59	;	Orthorhombic crystal structure of a native BcsRQ complex crystallized in the presence of ADP
5D6O	;	1.8	;	Orthorhombic Crystal Structure of an acetylester hydrolase from Corynebacterium glutamicum
2QYP	;	2.45	;	Orthorhombic Crystal Structure of Human Saposin C Dimer in Open Conformation
5FQU	;	2.74	;	Orthorhombic crystal structure of of PlpD (selenomethionine derivative)
2ZAK	;	2.01	;	Orthorhombic crystal structure of precursor E. coli isoaspartyl peptidase/L-asparaginase (EcAIII) with active-site T179A mutation
7QF7	;	1.47	;	Orthorhombic crystal structure of PTG CBM21 in complex with beta-cyclodextrin
5II8	;	0.99	;	Orthorhombic crystal structure of red abalone lysin at 0.99 A resolution
3VJP	;	2.7	;	Orthorhombic Crystal Structure of Salmonella FlgA in closed form
197D	;	2.19	;	ORTHORHOMBIC CRYSTAL STRUCTURE OF THE A-DNA OCTAMER D(GTACGTAC). COMPARISON WITH THE TETRAGONAL STRUCTURE
1ZK2	;	1.55	;	Orthorhombic crystal structure of the apo-form of R-specific alcohol dehydrogenase (mutant G37D) from Lactobacillus brevis
6ZE0	;	1.99	;	Orthorhombic crystal structure of the bulky-bulky ketone specific alcohol dehydrogenase from Comamonas testosteroni
3QNX	;	2.2	;	Orthorhombic form of human IgA1 Fab fragment, sharing same Fv as IgG
3QNZ	;	2.2	;	Orthorhombic form of IgG1 Fab fragment (in complex with antigenic tubulin peptide) sharing same Fv as IgA
1JRN	;	2.0	;	Orthorhombic form of Oxytricha telomeric DNA at 2.0A
1KHQ	;	1.6	;	ORTHORHOMBIC FORM OF PAPAIN/ZLFG-DAM COVALENT COMPLEX
1W76	;	2.3	;	Orthorhombic form of Torpedo californica acetylcholinesterase (AChE) complexed with bis-acting galanthamine derivative
1MR5	;	2.25	;	Orthorhombic form of Trypanosoma cruzi trans-sialidase
1Y6E	;	3.0	;	Orthorhombic glutathione S-transferase of Schistosoma japonicum
4XEI	;	3.874	;	Orthorhombic isomorph of bovine Arp2/3 complex
6F1O	;	0.96	;	Orthorhombic Lysozyme crystallized at 298 K and pH 4.5
1BGI	;	1.7	;	ORTHORHOMBIC LYSOZYME CRYSTALLIZED AT HIGH TEMPERATURE (310K)
6RT9	;	1.55	;	Orthorhombic lysozyme grown with 300g/L sucrose
4MON	;	2.3	;	ORTHORHOMBIC MONELLIN
7B1J	;	2.9	;	Orthorhombic P21212 Structure of Human Mad1 C-terminal Domain in Complex with Phosphorylated Bub1 CD1 Domain
7B1F	;	1.75	;	Orthorhombic P212121 Structure of Human Mad1 C-terminal Domain in Complex with Phosphorylated Bub1 CD1 Domain
5E4Y	;	2.8	;	Orthorhombic structure of the acetyl esterase MekB
2I6T	;	2.1	;	Orthorhombic Structure of the LDH domain of Human Ubiquitin-conjugating Enzyme E2-like Isoform A
6B6N	;	2.0	;	Orthorhombic trypsin (295 K) in the presence of 50% mpd
6AVL	;	2.0	;	Orthorhombic Trypsin (295 K) in the presence of 50% xylose
3T27	;	1.95	;	Orthorhombic trypsin (bovine) in the presence of betaine
3T26	;	1.7	;	Orthorhombic trypsin (bovine) in the presence of sarcosine
6B6O	;	2.40008	;	Orthorhombic trypsin cryocooled to 100 K with 20% xylose as cryoprotectant
6DZF	;	2.2	;	Orthorhombic trypsin cryocooled to 100 K with 20% xylose as cryoprotectant
6B6P	;	2.00006	;	Orthorhombic trypsin cryocooled to 100 K with 30% xylose as cryoprotectant
6B6S	;	2.00023	;	Orthorhombic trypsin cryocooled to 100 K with 50% ethanol as cryoprotectant
6B6T	;	2.0	;	Orthorhombic trypsin cryocooled to 100 K with 50% methanol as cryoprotectant
6B6R	;	2.00006	;	Orthorhombic trypsin cryocooled to 100 K with 50% mpd as cryoprotectant
6B6Q	;	2.00007	;	Orthorhombic trypsin cryocooled to 100 K with 50% xylose as cryoprotectant
7YYE	;	2.0	;	Orthorombic crystal structure of YTHDF1 YTH domain (G459N mutant) form I
7YYF	;	2.3	;	Orthorombic crystal structure of YTHDF1 YTH domain (G459N mutant) form II
5LW0	;	1.65	;	Oryza sativa APL macrodomain in complex with ADP-ribose
6ELX	;	1.35	;	Oryza sativa DWARF14
5MOG	;	2.77	;	Oryza sativa phytoene desaturase inhibited by norflurazon
6KF8	;	3.6	;	OsACBP2 in complex with C18:3-CoA
2JMX	;		;	OSCP-NT (1-120) in complex with N-terminal (1-25) alpha subunit from F1-ATPase
4JCH	;	1.7	;	OSH4 bound to an electrophilic oxysterol
7A3Z	;	2.095	;	OSM-3 kinesin motor domain complexed with Mg.ADP
7A5E	;	1.904	;	OSM-3 kinesin motor domain complexed with Mg.AMPPNP
6KU6	;	2.007	;	OSM1 mutant - R326A
5V4I	;	1.5	;	Osmium(II)(cymene)(chlorido)2-lysozyme adduct with one binding site
7FFU	;	2.601	;	Osmium-bound human serum transferrin
1J7Z	;	2.25	;	Osmolyte Stabilization of Ribonuclease
1J80	;	2.1	;	Osmolyte Stabilization of RNase
1J81	;	2.2	;	Osmolyte Stabilization of RNase
1J82	;	2.3	;	Osmolyte Stabilization of RNase
1OSM	;	3.2	;	OSMOPORIN (OMPK36) FROM KLEBSIELLA PNEUMONIAE
2J1N	;	2.0	;	osmoporin OmpC
7JZ3	;	2.56	;	Osmoporin OmpC from E.coli K12
7NL4	;	3.0	;	OsNIP2;1 silicon transporter from rice
6J5M	;	1.85	;	OspA mutant, PSAM-VLGDV1-form3, grafted short chameleon sequence from alpha-B crystallin
6J5N	;	1.73	;	OspA mutant, PSAM-VLGDV1-form4, grafted short chameleon sequence from alpha-B crystallin
6J5O	;	1.9	;	OspA mutant, PSAM-VLGDV1-form5, grafted short chameleon sequence from alpha-B crystallin
6J5P	;	1.8	;	OspA mutant, PSAM-VLGDV1-form6, grafted short chameleon sequence from alpha-B crystallin
6J5Q	;	1.798	;	OspA mutant, PSAM-VLGDV1-form7, grafted short chameleon sequence from alpha-B crystallin
6J5R	;	1.85	;	OspA mutant, PSAM-VLGDV1-form8, grafted short chameleon sequence from alpha-B crystallin
6J47	;	1.9	;	OspA variant with a short chameleon sequence from alpha B crystallin
7JWG	;	3.05	;	OspA-Fab 221-7 complex structure
7T25	;	2.25	;	OspA-Fab 319-44 complex structure
7UJ2	;	1.503	;	OspC Type B
6UOP	;	1.351	;	OsPYL/RCAR5 (24 - 29) solved by nanobeam diffraction tomography
6UOQ	;	1.007	;	OsPYL/RCAR5 residues 24-29 solved from electron diffraction stills
1VZM	;	1.4	;	OSTEOCALCIN FROM FISH ARGYROSOMUS REGIUS
6JAK	;	2.41	;	OtsA apo structure
3PHU	;	2.2	;	OTU Domain of Crimean Congo Hemorrhagic Fever Virus
3PHX	;	1.6	;	OTU Domain of Crimean Congo Hemorrhagic Fever Virus in complex with ISG15
3PHW	;	2.0	;	OTU Domain of Crimean Congo Hemorrhagic Fever Virus in complex with Ubiquitin
6DRM	;	2.06	;	OTU domain of Fam105A
5V5I	;	2.201	;	OTU protease of Crimean Congo Hemorrhagic Fever Virus bound to ubiquitin variant CC.1
5V5H	;	1.5	;	OTU protease of Crimean Congo Hemorrhagic Fever Virus bound to ubiquitin variant CC.2
5V5G	;	2.1	;	OTU protease of Crimean Congo Hemorrhagic Fever Virus bound to ubiquitin variant CC.4
6YK8	;	2.42	;	OTU-like deubiquitinase from Legionella -Lpg2529
8CMS	;	1.77	;	OTUB2 in covalent complex with LN5P45
7KZM	;	7.5	;	Outer dynein arm bound to doublet microtubules from C. reinhardtii
7KZN	;	4.0	;	Outer dynein arm core subcomplex from C. reinhardtii
7KZO	;	3.3	;	Outer dynein arm docking complex bound to doublet microtubules from C. reinhardtii
6ZYY	;	4.4	;	Outer Dynein Arm-Shulin complex - Dyh3 motor region (Tetrahymena thermophila)
6ZYW	;	8.78	;	Outer Dynein Arm-Shulin complex - overall structure (Tetrahymena thermophila)
6ZYX	;	4.3	;	Outer Dynein Arm-Shulin complex - Shulin region from Tetrahymena thermophila
8Q84	;	3.15	;	Outer kinetochore Dam1 protomer dimer Ndc80-Nuf2 coiled-coil complex
8Q85	;	3.97	;	Outer kinetochore Dam1 protomer monomer Ndc80-Nuf2 coiled-coil complex
8QAU	;	3.54	;	Outer kinetochore Ndc80-Dam1 alpha/beta-tubulin complex
8TVA	;	8.55	;	Outer Mat-T4P complex
8BYM	;	3.15	;	Outer membrane attachment porin OmpM1 from Veillonella parvula
8BYT	;	2.78	;	Outer membrane attachment porin OmpM1 from Veillonella parvula, C3 symmetry
8BYS	;	3.28	;	Outer membrane attachment porin OmpM1 from Veillonella parvula, native
1NQE	;	2.0	;	OUTER MEMBRANE COBALAMIN TRANSPORTER (BTUB) FROM E. COLI
1NQF	;	2.7	;	OUTER MEMBRANE COBALAMIN TRANSPORTER (BTUB) FROM E. COLI, METHIONINE SUBSTIUTION CONSTRUCT FOR SE-MET SAD PHASING
1NQG	;	3.31	;	OUTER MEMBRANE COBALAMIN TRANSPORTER (BTUB) FROM E. COLI, WITH BOUND CALCIUM
1NQH	;	3.1	;	OUTER MEMBRANE COBALAMIN TRANSPORTER (BTUB) FROM E. COLI, WITH BOUND CALCIUM AND CYANOCOBALAMIN (VITAMIN B12) SUBSTRATE
6NEF	;	3.4	;	Outer Membrane Cytochrome S Filament from Geobacter Sulfurreducens
3UCP	;	1.76	;	Outer membrane Endecaheme cytochrome UndA from Shewanella sp. HRCR-6
6Z8A	;	2.95	;	Outer membrane FoxA in complex with nocardamine
7X6F	;	2.3	;	Outer membrane lipoprotein QseG of Escherichia coli O157:H7
7X6G	;	2.35	;	Outer membrane lipoprotein QseG of Escherichia coli O157:H7
7X6H	;	2.6	;	Outer membrane lipoprotein QseG of Escherichia coli O157:H7
1FW2	;	2.6	;	OUTER MEMBRANE PHOSPHOLIPASE A FROM ESCHERICHIA COLI
1FW3	;	2.8	;	OUTER MEMBRANE PHOSPHOLIPASE A FROM ESCHERICHIA COLI
1QD5	;	2.17	;	OUTER MEMBRANE PHOSPHOLIPASE A FROM ESCHERICHIA COLI
1QD6	;	2.1	;	OUTER MEMBRANE PHOSPHOLIPASE A FROM ESCHERICHIA COLI
1ILD	;	2.8	;	OUTER MEMBRANE PHOSPHOLIPASE A FROM ESCHERICHIA COLI N156A ACTIVE SITE MUTANT pH 4.6
1ILZ	;	2.5	;	OUTER MEMBRANE PHOSPHOLIPASE A FROM ESCHERICHIA COLI N156A ACTIVE SITE MUTANT pH 6.1
1IM0	;	2.98	;	OUTER MEMBRANE PHOSPHOLIPASE A FROM ESCHERICHIA COLI N156A ACTIVE SITE MUTANT PH 8.3
1BXW	;	2.5	;	OUTER MEMBRANE PROTEIN A (OMPA) TRANSMEMBRANE DOMAIN
3PIK	;	2.3	;	Outer membrane protein CusC
2JQY	;		;	Outer Membrane Protein G
2F1T	;	3.0	;	Outer membrane protein OmpW
2F1V	;	2.7	;	Outer membrane protein OmpW
8AXL	;	3.42	;	Outer membrane secretin pore of the type 3 secretion system of Shigella flexneri
8I8B	;	4.31	;	Outer shell and inner layer structures of Autographa californica multiple nucleopolyhedrovirus (AcMNPV)
1P4P	;	2.0	;	Outer Surface Protein B of B. burgdorferi: crystal structure of the C-terminal fragment
4D53	;	1.85	;	Outer surface protein BB0689 from Borrelia burgdorferi
1GGQ	;	2.51	;	OUTER SURFACE PROTEIN C (OSPC) OF BORRELIA BURGDORFERI STRAIN B31
7UJ6	;	1.951	;	Outer Surface Protein C Type K
5OYK	;	3.2	;	Outer-membrane expressed OmpT of Vibrio cholerae
7MBZ	;	6.4	;	Outward facing conformation of the MetNI methionine ABC transporter in complex with lipo-MetQ
6I1Z	;	3.4	;	Outward facing structure of apo CST
7QP9	;	2.89	;	Outward-facing apo-form of auxin transporter PIN8
7QPA	;	3.18	;	Outward-facing auxin bound form of auxin transporter PIN8
6GWH	;	2.8	;	Outward-facing conformation of a multidrug resistance MATE family transporter of the MOP superfamily.
6HFB	;	3.495	;	Outward-facing conformation of a multidrug resistance MATE family transporter of the MOP superfamily.
6HRC	;	3.3	;	Outward-facing PglK with ATPgammaS bound
8JZS	;	2.95	;	Outward-facing SLC15A4 dimer
6X17	;	3.66	;	Outward-facing state of the glutamate transporter homologue GltPh in complex with TBOA
8K7C	;	3.9	;	Outward-facing structure of human ABCB6 W546A mutant (ADP/VO4-bound)
8PNL	;	2.7	;	Outward-open conformation of a Major Facilitator Superfamily (MFS) transporter MHAS2168, a homologue of Rv1410 from M. tuberculosis, in complex with an alpaca nanobody
8JZR	;	3.25	;	Outward_facing SLC15A4 monomer
5UJH	;		;	ov-GRN12-34
7EPZ	;	3.4	;	Overall structure of Erastin-bound xCT-4F2hc complex
7WBH	;	3.7	;	overall structure of hu33 and spike
6M23	;	3.2	;	Overall structure of KCC2
3UIT	;	2.05	;	Overall structure of Patj/Pals1/Mals complex
7DSQ	;	3.4	;	Overall structure of the LAT1-4F2hc bound with 3,5-diiodo-L-tyrosine
7DSK	;	2.9	;	Overall structure of the LAT1-4F2hc bound with JX-075
7DSL	;	2.9	;	Overall structure of the LAT1-4F2hc bound with JX-078
7DSN	;	3.1	;	Overall structure of the LAT1-4F2hc bound with JX-119
5LJ5	;	10.0	;	Overall structure of the yeast spliceosome immediately after branching.
8IHL	;	7.64	;	Overlapping tri-nucleosome
5UJG	;		;	ovGRN12-35_3s
7NF8	;	2.83	;	Ovine (b0,+AT-rBAT)2 hetero-tetramer, asymmetric unit, rigid-body fitted
6TT7	;	3.5	;	Ovine ATP synthase 1a state
7NF6	;	3.05	;	Ovine b0,+AT-rBAT heterodimer
4CK4	;	1.12	;	Ovine beta-Lactoglobulin at Atomic Resolution
7JXT	;	3.35	;	Ovine COX-1 in complex with the subtype-selective derivative 2a
2M1J	;		;	Ovine Doppel Signal peptide (1-30)
1B5L	;	2.1	;	OVINE INTERFERON TAU
6T44	;	2.0	;	Ovine lactoglobulin complex with decanol
1EBV	;	3.2	;	OVINE PGHS-1 COMPLEXED WITH SALICYL HYDROXAMIC ACID
1Y2S	;		;	Ovine Prion Protein Variant R168
7NF7	;	2.68	;	Ovine rBAT ectodomain homodimer, asymmetric unit
1TPX	;	2.56	;	Ovine recombinant PrP(114-234), ARQ variant in complex with the Fab of the VRQ14 antibody
1TQC	;	2.8	;	Ovine recombinant PrP(114-234), ARR variant in complex with the VRQ14 Fab fragment (IgG2a)
1TQB	;	2.55	;	Ovine recombinant PrP(114-234), VRQ variant in complex with the Fab of the VRQ14 antibody
6QC5	;	4.3	;	Ovine respiratory complex I FRC closed class 1
6QC6	;	4.1	;	Ovine respiratory complex I FRC open class 1
6QC8	;	4.2	;	Ovine respiratory complex I FRC open class 2
6QC7	;	4.4	;	Ovine respiratory complex I FRC open class 3
6QC9	;	5.7	;	Ovine respiratory complex I FRC open class 4
6QCA	;	6.2	;	Ovine respiratory complex I FRC open class 5
6QCF	;	6.5	;	Ovine respiratory complex I FRC open class 6
6QBX	;	4.2	;	Ovine respiratory supercomplex I+III2 closed class.
6QC3	;	4.2	;	Ovine respiratory supercomplex I+III2 open class 1
6QC2	;	4.2	;	Ovine respiratory supercomplex I+III2 open class 2
6QC4	;	4.6	;	Ovine respiratory supercomplex I+III2 open class 3
5AC0	;	1.9	;	ovis aries Aldehyde Dehydrogenase 1A1 in complex with a duocarmycin analog
1IQ7	;	2.3	;	Ovotransferrin, C-Terminal Lobe, Apo Form
1TFA	;	1.9	;	OVOTRANSFERRIN, N-TERMINAL LOBE, APO FORM
1IEJ	;	1.65	;	OVOTRANSFERRIN, N-TERMINAL LOBE, HOLO FORM, AT 1.65 A RESOLUTION
1NFT	;	2.1	;	OVOTRANSFERRIN, N-TERMINAL LOBE, IRON LOADED OPEN FORM
7YK4	;	2.7	;	ox40-antibody
6OKN	;	3.25	;	OX40R (TNFRSF4) bound to Fab 1A7
1K57	;	1.9	;	OXA 10 class D beta-lactamase at pH 6.0
1K56	;	1.7	;	OXA 10 class D beta-lactamase at pH 6.5
1K55	;	1.39	;	OXA 10 class D beta-lactamase at pH 7.5
5MNU	;	1.56	;	OXA-10 Avibactam complex with bound bromide
5MOX	;	1.41	;	OXA-10 Avibactam complex with bound CO2
5MOZ	;	1.34	;	OXA-10 Avibactam complex with bound Iodide
7B3U	;	1.598	;	OXA-10 beta-lactamase with covalent modification
7B3R	;	1.83	;	OXA-10 beta-lactamase with S64Dha modification and lysinoalanine crosslink
7B3S	;	1.85	;	OXA-10 beta-lactamase with S67Dha modification
1K54	;	1.7	;	OXA-10 class D beta-lactamase partially acylated with reacted 6beta-(1-hydroxy-1-methylethyl) penicillanic acid
4S2O	;	1.7	;	OXA-10 in complex with Avibactam
6SKR	;	1.85	;	OXA-10_ETP. Structural insight to the enhanced carbapenem efficiency of OXA-655 compared to OXA-10.
6SKP	;	1.891	;	OXA-10_IPM. Structural insight to the enhanced carbapenem efficiency of OXA-655 compared to OXA-10.
5HAR	;	1.74	;	OXA-163 beta-lactamase - S70G mutant
4JF4	;	2.14	;	OXA-23 meropenem complex
6N6T	;	1.25	;	OXA-23 mutant F110A/M221A low pH form
6N6U	;	1.55	;	OXA-23 mutant F110A/M221A low pH form imipenem complex
6N6V	;	1.55	;	OXA-23 mutant F110A/M221A low pH form meropenem complex
6N6W	;	3.25	;	OXA-23 mutant F110A/M221A neutral pH form
6N6X	;	3.1	;	OXA-23 mutant F110A/M221A neutral pH form imipenem complex
6N6Y	;	3.501	;	OXA-23 mutant F110A/M221A neutral pH form meropenem complex
3G4P	;	1.97	;	OXA-24 beta-lactamase at pH 7.5
3MBZ	;	2.6	;	OXA-24 beta-lactamase complex soaked with 10mM SA4-17 inhibitor for 15min
3FZC	;	2.0	;	OXA-24 beta-lactamase complex with SA3-53 inhibitor
3FYZ	;	2.1	;	OXA-24 beta-lactamase complex with SA4-17 inhibitor
3FV7	;	2.0	;	OXA-24 beta-lactamase complex with SA4-44 inhibitor
5TG4	;	1.44	;	OXA-24/40 in Complex with Boronic Acid BA16
5TG7	;	2.28	;	OXA-24/40 in Complex with Boronic Acid BA3
5TG6	;	1.78	;	OXA-24/40 in Complex with Boronic Acid BA4
5TG5	;	1.75	;	OXA-24/40 in Complex with Boronic Acid BA8
5HAP	;	1.89	;	OXA-48 beta-lactamase - S70A mutant
5HAQ	;	2.14	;	OXa-48 beta-lactamase mutant - S70G
6XQR	;	2.2	;	OXA-48 bound by Compound 2.2
7JHQ	;	2.0	;	OXA-48 bound by Compound 2.3
7K5V	;	2.8	;	OXA-48 bound by Compound 3.1
7R6Z	;	2.1	;	OXA-48 bound by Compound 3.3
7L8O	;	2.7	;	OXA-48 bound by Compound 4.3
6UVK	;	2.2	;	OXA-48 bound by inhibitor CDD-97
8SQF	;	2.3	;	OXA-48 bound to inhibitor CDD-2725
8SQG	;	2.03	;	OXA-48 bound to inhibitor CDD-2801
6P96	;	1.6	;	OXA-48 carbapanemase, apo form
6P9C	;	1.9	;	OXA-48 carbapanemase, doripenem complex
6P99	;	2.25	;	OXA-48 carbapanemase, ertapenem complex
6P97	;	1.8	;	OXA-48 carbapanemase, imipenem complex
6P98	;	1.75	;	OXA-48 carbapanemase, meropenem complex
7DML	;	1.936	;	OXA-48 carbapenemase in complex with (R)-2-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-3-yl)acrylic acid
4WMC	;	2.3	;	OXA-48 covalent complex with Avibactam inhibitor
4S2J	;	2.54	;	OXA-48 in complex with Avibactam at pH 6.5
4S2K	;	2.1	;	OXA-48 in complex with Avibactam at pH 7.5
4S2N	;	2.0	;	OXA-48 in complex with Avibactam at pH 8.5
5QAL	;	1.95	;	OXA-48 IN COMPLEX WITH COMPOUND 11b
5QAI	;	1.9	;	OXA-48 IN COMPLEX WITH COMPOUND 12a
5QAJ	;	2.0	;	OXA-48 IN COMPLEX WITH COMPOUND 13
5QAK	;	1.9	;	OXA-48 IN COMPLEX WITH COMPOUND 14
5QAM	;	1.87	;	OXA-48 IN COMPLEX WITH COMPOUND 17
5QAN	;	2.3	;	OXA-48 IN COMPLEX WITH COMPOUND 19a
5QAO	;	2.0	;	OXA-48 IN COMPLEX WITH COMPOUND 19b
5QAP	;	1.79	;	OXA-48 IN COMPLEX WITH COMPOUND 21a
5QAQ	;	2.4	;	OXA-48 IN COMPLEX WITH COMPOUND 21b
5QAR	;	2.1	;	OXA-48 IN COMPLEX WITH COMPOUND 23a
5QAS	;	1.9	;	OXA-48 IN COMPLEX WITH COMPOUND 23b
5QAT	;	1.9	;	OXA-48 IN COMPLEX WITH COMPOUND 24
5QAU	;	1.75	;	OXA-48 IN COMPLEX WITH COMPOUND 26a
5QAV	;	1.72	;	OXA-48 IN COMPLEX WITH COMPOUND 26b
5QAW	;	2.2	;	OXA-48 IN COMPLEX WITH COMPOUND 27
5QAX	;	2.31	;	OXA-48 IN COMPLEX WITH COMPOUND 28
5QAY	;	1.7	;	OXA-48 IN COMPLEX WITH COMPOUND 32
5QAZ	;	2.2	;	OXA-48 IN COMPLEX WITH COMPOUND 34
5QB0	;	1.95	;	OXA-48 IN COMPLEX WITH COMPOUND 35
5QB1	;	1.8	;	OXA-48 IN COMPLEX WITH COMPOUND 36
5QB2	;	1.75	;	OXA-48 IN COMPLEX WITH COMPOUND 38
5QA4	;	1.95	;	OXA-48 IN COMPLEX WITH COMPOUND 3a
5QA5	;	1.95	;	OXA-48 IN COMPLEX WITH COMPOUND 3b
5QB3	;	2.0	;	OXA-48 IN COMPLEX WITH COMPOUND 40
5QA6	;	1.95	;	OXA-48 IN COMPLEX WITH COMPOUND 4a
5QA7	;	1.82	;	OXA-48 IN COMPLEX WITH COMPOUND 4b
5QA8	;	2.5	;	OXA-48 IN COMPLEX WITH COMPOUND 4c
5QA9	;	1.9	;	OXA-48 IN COMPLEX WITH COMPOUND 5
5QAA	;	1.95	;	OXA-48 IN COMPLEX WITH COMPOUND 6a
5QAB	;	2.15	;	OXA-48 IN COMPLEX WITH COMPOUND 6b
5QAC	;	2.0	;	OXA-48 IN COMPLEX WITH COMPOUND 6c
5QAD	;	1.75	;	OXA-48 IN COMPLEX WITH COMPOUND 8a
5QAE	;	2.1	;	OXA-48 IN COMPLEX WITH COMPOUND 8b
5QAF	;	2.15	;	OXA-48 IN COMPLEX WITH COMPOUND 8c
5QAG	;	2.3	;	OXA-48 IN COMPLEX WITH COMPOUND 9a
5QAH	;	1.95	;	OXA-48 IN COMPLEX WITH COMPOUND 9b
5FAQ	;	1.96	;	OXA-48 in complex with FPI-1465
5FAS	;	1.74	;	OXA-48 in complex with FPI-1523
5FAT	;	2.09	;	OXA-48 in complex with FPI-1602
5QB4	;	1.95	;	OXA-48 IN COMPLEX WITH SUBSTRATE IMIPENEM
7ODA	;	1.796	;	OXA-48-like Beta-lactamase OXA-436
8FAJ	;	1.75	;	OXA-48-NA-1-157 inhibitor complex
8PEA	;	1.97	;	OXA-48_F72L. Epistasis Arises from Shifting the Rate-Limiting Step during Enzyme Evolution
7ASS	;	1.91	;	OXA-48_L67F_CAZ. What Doesnt Kill You Makes You Stronger: Sub-MIC Selection Drives Cryptic Evolution of OXA-48
6Q5B	;	2.22	;	OXA-48_P68A-AVI. Evolutionary trade-offs of OXA-48 mediated ceftazidime-avibactam resistance
6Q5F	;	2.5	;	OXA-48_P68A-CAZ. Evolutionary trade-offs of OXA-48 mediated ceftazidime-avibactam resistance
8PEC	;	2.66	;	OXA-48_Q5-CAZ. Epistasis Arises from Shifting the Rate-Limiting Step during Enzyme Evolution
8PEB	;	1.17	;	OXA-48_Q5. Epistasis Arises from Shifting the Rate-Limiting Step during Enzyme Evolution
6T1H	;	2.1	;	OXA-51-like beta-lactamase OXA-66
7VVI	;	1.4	;	OXA-58 crystal structure of acylated meropenem complex
7VX3	;	1.8	;	OXA-58 crystal structure of acylated meropenem complex 2
7VX6	;	1.7	;	OXA-58 crystal structure of acylated meropenem complex 2
6SKQ	;	2.1	;	OXA-655_MEM. Structural insights into the enhanced carbapenemase efficiency of OXA-655 compared to OXA-10.
2IWD	;	2.4	;	Oxacilloyl-acylated MecR1 extracellular antibiotic-sensor domain.
2ET1	;	1.6	;	Oxalate oxidase in complex with substrate analogue glycolate
1BKA	;	2.4	;	OXALATE-SUBSTITUTED DIFERRIC LACTOFERRIN
1ONY	;	2.15	;	Oxalyl-Aryl-Amino Benzoic Acid inhibitors of PTP1B, compound 17
1ONZ	;	2.4	;	Oxalyl-aryl-Amino Benzoic acid Inhibitors of PTP1B, compound 8b
7AYG	;	1.9	;	oxalyl-CoA decarboxylase from Methylorubrum extorquens with bound TPP and ADP
6A4Z	;	1.7	;	Oxidase ChaP
7W5E	;	1.65	;	Oxidase ChaP D49L mutant
7WCC	;	1.5	;	Oxidase ChaP-D49L/Q91C mutant
7WB2	;	1.8	;	Oxidase ChaP-D49L/Y109F mutant
6A52	;	2.0	;	Oxidase ChaP-H1
6A4X	;	1.63	;	Oxidase ChaP-H2
2ZCT	;	1.7	;	Oxidation of archaeal peroxiredoxin involves a hypervalent sulfur intermediate
1OES	;	2.2	;	Oxidation state of protein tyrosine phosphatase 1B
1OET	;	2.3	;	Oxidation state of protein tyrosine phosphatase 1B
1OEU	;	2.5	;	Oxidation state of protein tyrosine phosphatase 1B
1OEV	;	2.2	;	Oxidation state of protein tyrosine phosphatase 1B
2YCC	;	1.9	;	OXIDATION STATE-DEPENDENT CONFORMATIONAL CHANGES IN CYTOCHROME C
4QIB	;	1.865	;	Oxidation-Mediated Inhibition of the Peptidyl-Prolyl Isomerase Pin1
1DYZ	;	1.75	;	OXIDISED AZURIN II FROM ALCALIGENES XYLOSOXIDANS
6GSQ	;	1.5	;	Oxidised copper nitrite reductase from Achromobacter cycloclastes determined by serial femtosecond rotation crystallography
1DFD	;		;	OXIDISED DESULFOVIBRIO AFRICANUS FERREDOXIN I, NMR, 19 STRUCTURES
1DAX	;		;	OXIDISED DESULFOVIBRIO AFRICANUS FERREDOXIN I, NMR, MINIMIZED AVERAGE STRUCTURE
2Y2Y	;	2.0	;	Oxidised form of E. coli CsgC
1H51	;	1.6	;	Oxidised Pentaerythritol Tetranitrate Reductase (SCN complex)
1H31	;	2.55	;	Oxidised SoxAX complex from Rhodovulum sulfidophilum
1H33	;	1.75	;	Oxidised SoxAX complex from Rhodovulum sulfidophilum
1GM4	;	2.05	;	OXIDISED STRUCTURE OF CYTOCHROME C3 FROM DESULFOVIBRIO DESULFURICANS ATCC 27774 at pH 7.6
3CAO	;	1.6	;	OXIDISED STRUCTURE OF THE ACIDIC CYTOCHROME C3 FROM DESULFOVIBRIO AFRICANUS
2XPE	;	2.5	;	Oxidised Thiol peroxidase (Tpx) from Yersinia pseudotuberculosis
3ZRD	;	1.74	;	Oxidised Thiol peroxidase (Tpx) from Yersinia pseudotuberculosis
2FL0	;	2.7	;	Oxidized (All ferric) form of the Azotobacter vinelandii bacterioferritin
4E4Z	;	1.98	;	Oxidized (Cu2+) peptidylglycine alpha-hydroxylating monooxygenase (PHM) in complex with hydrogen peroxide (1.98 A)
3MIC	;	2.42	;	Oxidized (Cu2+) peptidylglycine alpha-hydroxylating monooxygenase (PHM) with bound azide obtained by co-crystallization
3MID	;	3.06	;	Oxidized (Cu2+) peptidylglycine alpha-hydroxylating monooxygenase (PHM) with bound azide obtained by soaking (100mM NaN3)
3MIE	;	3.26	;	Oxidized (Cu2+) peptidylglycine alpha-hydroxylating monooxygenase (PHM) with bound azide obtained by soaking (50mM NaN3)
3MIH	;	2.74	;	Oxidized (Cu2+) peptidylglycine alpha-hydroxylating monooxygenase (PHM) with bound azide, obtained in the presence of substrate
3MIF	;	2.0	;	Oxidized (Cu2+) peptidylglycine alpha-hydroxylating monooxygenase (PHM) with bound carbon monooxide (CO)
3MIB	;	2.35	;	Oxidized (Cu2+) peptidylglycine alpha-hydroxylating monooxygenase (PHM) with bound nitrite
3MIG	;	2.7	;	Oxidized (Cu2+) peptidylglycine alpha-hydroxylating monooxygenase (PHM) with bound nitrite, obtained in the presence of substrate
1OPM	;	2.1	;	OXIDIZED (CU2+) PEPTIDYLGLYCINE ALPHA-HYDROXYLATING MONOOXYGENASE (PHM) WITH BOUND SUBSTRATE
1YCF	;	3.0	;	Oxidized (di-ferric) FprA from Moorella thermoacetica
2VL2	;	1.925	;	Oxidized and reduced forms of human peroxiredoxin 5
2VL3	;	1.83	;	Oxidized and reduced forms of human peroxiredoxin 5
2BZ7	;	1.76	;	Oxidized and reduced structures of a mutant Plastocyanin of fern
2BZC	;	1.79	;	Oxidized and reduced structures of a mutant Plastocyanin of fern
4PUH	;	1.898	;	Oxidized BolA2 from Arabidopsis thaliana
3HPM	;	2.8	;	Oxidized dimeric PICK1 PDZ C46G mutant in complex with the carboxyl tail peptide of GluR2
3HPK	;	2.2	;	Oxidized dimeric PICK1 PDZ in complex with the carboxyl tail peptide of GluR2
1E60	;	2.0	;	OXIDIZED DMSO REDUCTASE EXPOSED TO HEPES - Structure II BUFFER
1E61	;	1.9	;	OXIDIZED DMSO REDUCTASE EXPOSED TO HEPES - Structure II BUFFER
1E5V	;	2.4	;	OXIDIZED DMSO REDUCTASE EXPOSED TO HEPES BUFFER
1DMR	;	1.82	;	OXIDIZED DMSO REDUCTASE FROM RHODOBACTER CAPSULATUS
1A2M	;	2.7	;	OXIDIZED DSBA AT 2.7 ANGSTROMS RESOLUTION, CRYSTAL FORM III
1A2J	;	2.0	;	OXIDIZED DSBA CRYSTAL FORM II
3WU6	;	1.8	;	Oxidized E.coli Lon Proteolytic domain
5LMC	;	1.9	;	Oxidized flavodiiron core of Escherichia coli flavorubredoxin, including the Fe-4SG atoms from its rubredoxin domain
2GTO	;		;	Oxidized form of ADAP hSH3-N
1SFD	;	0.99	;	oxidized form of amicyanin mutant P94F
1FDO	;	2.8	;	OXIDIZED FORM OF FORMATE DEHYDROGENASE H FROM E. COLI
1FDI	;	2.9	;	OXIDIZED FORM OF FORMATE DEHYDROGENASE H FROM E. COLI COMPLEXED WITH THE INHIBITOR NITRITE
2VL9	;	2.7	;	Oxidized form of human peroxiredoxin 5
1KDJ	;	1.7	;	OXIDIZED FORM OF PLASTOCYANIN FROM DRYOPTERIS CRASSIRHIZOMA
7PZQ	;	2.25	;	Oxidized form of SARS-CoV-2 Main Protease determined by XFEL radiation
2PPD	;	1.8	;	Oxidized H145A mutant of AfNiR bound to nitric oxide
3WSD	;	2.5	;	Oxidized HcgD from Methanocaldococcus jannaschii
3WSF	;	2.0	;	Oxidized HcgD from Methanocaldococcus jannaschii with citrate
1LT7	;	2.15	;	Oxidized Homo sapiens betaine-homocysteine S-methyltransferase in complex with four Sm(III) ions
6PRX	;	3.25	;	oxidized Human Branched Chain Aminotransferase mutant C318A
4X9M	;	2.4	;	Oxidized L-alpha-Glycerophosphate Oxidase from Mycoplasma pneumoniae with FAD bound
2LQQ	;		;	Oxidized Mrx1
4PAZ	;	1.76	;	OXIDIZED MUTANT P80A PSEUDOAZURIN FROM A. FAECALIS
6PAZ	;	1.91	;	OXIDIZED MUTANT P80I PSEUDOAZURIN FROM A. FAECALIS
8PAZ	;	1.6	;	OXIDIZED NATIVE PSEUDOAZURIN FROM A. FAECALIS
1D9Q	;	2.4	;	OXIDIZED PEA FRUCTOSE-1,6-BISPHOSPHATASE FORM 1
2PVA	;	2.5	;	OXIDIZED PENICILLIN V ACYLASE FROM B. SPHAERICUS
1YIP	;	2.2	;	Oxidized Peptidylglycine Alpha-Hydroxylating Monooxygenase (PHM) in a New Crystal Form
7N8Y	;	3.65	;	Oxidized PheRS G318W from Salmonella enterica serovar Typhimurium
1BXU	;	1.9	;	OXIDIZED PLASTOCYANIN FROM SYNECHOCOCCUS SP.
1H6D	;	2.05	;	Oxidized Precursor Form of Glucose-Fructose Oxidoreductase from Zymomonas mobilis complexed with glycerol
1H6C	;	2.2	;	Oxidized Precursor Form of Glucose-Fructose Oxidoreductase from Zymomonas mobilis complexed with succinate
1BQK	;	1.35	;	OXIDIZED PSEUDOAZURIN
1ZIA	;	1.54	;	OXIDIZED PSEUDOAZURIN
4ZVL	;	1.899	;	Oxidized quinone reductase 2 in complex with acridine orange
4FGK	;	1.401	;	Oxidized quinone reductase 2 in complex with chloroquine
4U7H	;	1.48	;	Oxidized quinone reductase 2 in complex with CK2 inhibitor DMAT
4U7G	;	1.96	;	Oxidized quinone reductase 2 in complex with CK2 inhibitor TBBz
4ZVM	;	1.973	;	Oxidized quinone reductase 2 in complex with doxorubicin
5BUC	;	1.867	;	Oxidized quinone reductase 2 in complex with ethidium
4FGJ	;	1.346	;	Oxidized quinone reductase 2 in complex with primaquine
7LJX	;	1.31	;	Oxidized rat cytochrome c mutant (K53Q)
6N1O	;	1.55	;	Oxidized rat cytochrome c mutant (S47E)
1PIU	;	2.2	;	OXIDIZED RIBONUCLEOTIDE REDUCTASE R2-D84E MUTANT CONTAINING OXO-BRIDGED DIFERRIC CLUSTER
6ATD	;	2.5	;	Oxidized SHP2 forms a disulfide bond between Cys367 and Cys459
4AOS	;	2.5	;	Oxidized steroid monooxygenase bound to NADP
4AOX	;	2.42	;	Oxidized steroid monooxygenase bound to NADP
4AP1	;	2.95	;	Oxidized steroid monooxygenase bound to NADP
4AP3	;	2.39	;	Oxidized steroid monooxygenase bound to NADP
1UPD	;	1.4	;	Oxidized STRUCTURE OF CYTOCHROME C3 FROM DESULFOVIBRIO DESULFURICANS ATCC 27774 AT PH 7.6
7TXM	;	2.16	;	Oxidized Structure of RexT
2W3E	;	1.6	;	Oxidized structure of the first GAF domain of Mycobacterium tuberculosis DosS
1ZYN	;	2.3	;	Oxidized structure of the N-terminal domain of Salmonella typhimurium AhpF
6ZOM	;		;	Oxidized thioredoxin 1 from the anaerobic bacteria Desulfovibrio vulgaris Hildenborough
2X8G	;	1.9	;	Oxidized thioredoxin glutathione reductase from Schistosoma mansoni
2Q0K	;	1.7	;	Oxidized thioredoxin reductase from Helicobacter pylori in complex with NADP+
2PPC	;	1.58	;	Oxidized wild type AfNiR exposed to NO (nitrite bound)
2MJD	;		;	Oxidized Yeast Adrenodoxin Homolog 1
4YNA	;	3.2	;	Oxidized YfiR
1QT9	;	1.3	;	OXIDIZED [2FE-2S] FERREDOXIN FROM ANABAENA PCC7119
1IQZ	;	0.92	;	OXIDIZED [4Fe-4S] FERREDOXIN FROM BACILLUS THERMOPROTEOLYTICUS (FORM I)
1IR0	;	1.0	;	OXIDIZED [4Fe-4S] FERREDOXIN FROM BACILLUS THERMOPROTEOLYTICUS (FORM II)
3KWC	;	2.0	;	Oxidized, active structure of the beta-carboxysomal gamma-Carbonic Anhydrase, CcmM
3WU4	;	1.7	;	Oxidized-form structure of E.coli Lon Proteolytic domain
1MBB	;	2.3	;	OXIDOREDUCTASE
1MBT	;	3.0	;	OXIDOREDUCTASE
3Q6O	;	2.05	;	Oxidoreductase Fragment of Human QSOX1
4IJ3	;	2.7	;	Oxidoreductase Fragment of Human QSOX1 in Complex with a FAB Fragment from an Anti- Human QSOX1 Antibody
8AON	;	2.1	;	Oxidoreductase fragment of human QSOX1 in complex with a Fab fragment of a humanized anti-QSOX1 antibody
5D93	;	2.201	;	Oxidoreductase Fragment of Mouse QSOX1 in Complex with a FAb Fragment from a Mouse QSOX1-Specific Antibody
5D96	;	2.3	;	Oxidoreductase Fragment of Mouse QSOX1 in Complex with a FAb Fragment from an Antibody Targeting Mouse and Human QSOX1
5TWC	;	2.31	;	Oxidoreductase IruO in the oxidized form
5TWB	;	1.822	;	Oxidoreductase IruO in the reduced form
2ZNM	;	2.3	;	Oxidoreductase NmDsbA3 from Neisseria meningitidis
4HU6	;	2.3	;	Oxime side-chain cross-links in the GCN4-p1 dimeric coiled coil: Cyclic product
4HU5	;	2.3	;	Oxime side-chain cross-links in the GCN4-p1 dimeric coiled coil: Linear precursor
4DFW	;	1.55	;	Oxime-based Post Solid-phase Peptide Diversification: Identification of High Affinity Polo-like Kinase 1 (Plk1) Polo-box Domain Binding Peptides
2L3I	;		;	Oxki4a, spider derived antimicrobial peptide
1XC1	;	1.51	;	Oxo Zirconium(IV) Cluster in the Ferric Binding Protein (FBP)
2C07	;	1.5	;	Oxoacyl-ACP reductase of Plasmodium falciparum
2ASD	;	1.95	;	oxoG-modified Insertion Ternary Complex
2ASL	;	2.65	;	oxoG-modified Postinsertion Binary Complex
2ASJ	;	2.35	;	oxoG-modified Preinsertion Binary Complex
1AAT	;	2.8	;	OXOGLUTARATE-INDUCED CONFORMATIONAL CHANGES IN CYTOSOLIC ASPARTATE AMINOTRANSFERASE
1LFZ	;	3.1	;	OXY HEMOGLOBIN (25% METHANOL)
1LFY	;	3.3	;	OXY HEMOGLOBIN (84% RELATIVE HUMIDITY)
1LFV	;	2.8	;	OXY HEMOGLOBIN (88% RELATIVE HUMIDITY)
1LFT	;	2.6	;	OXY HEMOGLOBIN (90% RELATIVE HUMIDITY)
1LFQ	;	2.6	;	OXY HEMOGLOBIN (93% RELATIVE HUMIDITY)
4F6D	;	1.8	;	Oxy structure of His100Phe Cerebratulus lacteus mini-hemoglobin
4F6I	;	1.56	;	Oxy Structure of His100Trp Cerebratulus lacteus mini-hemoglobin
4F68	;	1.8	;	Oxy structure of Tyr11Phe/Gln44Leu/Thr48Val/Ala55Trp Cerebratulus lacteus mini-hemoglobin
1GZX	;	2.1	;	Oxy T State Haemoglobin - Oxygen bound at all four haems
7E99	;	2.1	;	Oxy-deoxy intermediate of 400 kDa giant hemoglobin at 13% oxygen saturation
7E98	;	2.2	;	Oxy-deoxy intermediate of 400 kDa giant hemoglobin at 21% oxygen saturation
7E97	;	2.7	;	Oxy-deoxy intermediate of 400 kDa giant hemoglobin at 58% oxygen saturation
7E96	;	2.4	;	Oxy-deoxy intermediate of 400 kDa giant hemoglobin at 69% oxygen saturation
7VLF	;	2.4	;	Oxy-deoxy intermediate of V2 hemoglobin at 26% oxygen saturation
7VLE	;	2.3	;	Oxy-deoxy intermediate of V2 hemoglobin at 55% oxygen saturation
7VLD	;	2.1	;	Oxy-deoxy intermediate of V2 hemoglobin at 69% oxygen saturation
7VLC	;	2.2	;	Oxy-deoxy intermediate of V2 hemoglobin at 78% oxygen saturation
1A6M	;	1.0	;	OXY-MYOGLOBIN, ATOMIC RESOLUTION
5HH3	;	2.1	;	OxyA from Actinoplanes teichomyceticus
4TVF	;	1.9	;	OxyB from Actinoplanes teichomyceticus
8F91	;	2.8	;	OxyB, a cytochrome P450 involved in keratinimicin biosynthesis
1NIR	;	2.15	;	OXYDIZED NITRITE REDUCTASE FROM PSEUDOMONAS AERUGINOSA
5V5J	;	1.814	;	oxyferrous Dehaloperoxidase B
2HHE	;	2.2	;	OXYGEN AFFINITY MODULATION BY THE N-TERMINI OF THE BETA CHAINS IN HUMAN AND BOVINE HEMOGLOBIN
2HHD	;	2.2	;	OXYGEN AFFINITY MODULATION BY THE N-TERMINI OF THE BETA-CHAINS IN HUMAN AND BOVINE HEMOGLOBIN
1TES	;	1.7	;	OXYGEN BINDING MUSCLE PROTEIN
1DZ8	;	1.9	;	oxygen complex of p450cam from pseudomonas putida
6VJR	;	1.55	;	Oxygen tolerant Archeal 4hydroxybutyrylCoA dehydratase (4HBD) from N. maritimus
8T7J	;	2.4	;	Oxygen- and PLP-dependent Cap15 holoenzyme bound with phosphate anion
1DP6	;	2.3	;	OXYGEN-BINDING COMPLEX OF FIXL HEME DOMAIN
3VMH	;	1.85	;	Oxygen-bound complex between oxygenase and ferredoxin in carbazole 1,9a-dioxygenase
3UBV	;	3.2	;	Oxygen-bound hell's gate globin I by classical hanging drop
3UBC	;	1.65	;	Oxygen-bound hell's gate globin I by LB nanotemplate method
6LL4	;	2.2	;	Oxygen-exposed carbazole-soaked reduced terminal oxygenase of carbazole 1,9a-dioxygenase
6LL1	;	2.15	;	Oxygen-exposed reduced terminal oxygenase in carbazole 1,9a-dioxygenase
5XBP	;	2.9	;	Oxygenase component of 3-nitrotoluene dioxygenase from Diaphorobacter sp. strain DS2
4NBF	;	2.0	;	Oxygenase with Gln282 replaced by Asn and ferredoxin complex of carbazole 1,9a-dioxygenase
4NBG	;	1.85	;	Oxygenase with Gln282 replaced by Tyr and ferredoxin complex of carbazole 1,9a-dioxygenase
4NB8	;	2.01	;	Oxygenase with Ile262 replaced by Leu and ferredoxin complex of carbazole 1,9a-dioxygenase
4NB9	;	2.05	;	Oxygenase with Ile262 replaced by Val and ferredoxin complex of carbazole 1,9a-dioxygenase
4NBC	;	1.945	;	Oxygenase with Phe275 replaced by Trp and ferredoxin complex of carbazole 1,9a-dioxygenase (form1)
1NOL	;	2.4	;	OXYGENATED HEMOCYANIN (SUBUNIT TYPE II)
5TDT	;	1.818	;	Oxygenated toluene intermediate in toluene 4-monooxygenase (T4moHD) after reaction in the crystal
7LLY	;	3.3	;	Oxyntomodulin-bound Glucagon-Like Peptide-1 (GLP-1) Receptor in complex with Gs protein
5AK2	;	2.19	;	Oxyphenylpropenoic acids as Oral Selective Estrogen Receptor Down- Regulators.
4XWS	;	3.006	;	OxyR regulatory domain C199D mutant from pseudomonas aeruginosa
5B7D	;	1.52	;	OxyR2 E204G mutant regulatory domain from Vibrio vulnificus (sulfate-bound)
5B70	;	2.3	;	OxyR2 E204G regulatory domain from Vibrio vulnificus
5X0Q	;	1.55	;	OxyR2 E204G variant (Cl-bound) from Vibrio vulnificus
5B7H	;	1.492	;	OxyR2 regulatory domain C206S mutant from Vibrio vulnificus
4K2X	;	2.55	;	OxyS anhydrotetracycline hydroxylase from Streptomyces rimosus
7OFG	;		;	Oxytocin NMR solution structure
7OTD	;		;	Oxytocin NMR solution structure
7RYC	;	2.9	;	Oxytocin receptor (OTR) bound to oxytocin in complex with a heterotrimeric Gq protein
3TX9	;	1.999	;	OYE1 complexed with 2-(Hydroxymethyl)-cyclopent-2-enone
4YIL	;	1.461	;	OYE1 W116A COMPLEXED WITH (Z)-METHYL 3-CYANO-3-(4-FLUOROPHENYL)ACRYLATE IN A NON PRODUCTIVE BINDING MODE
4YNC	;	1.498	;	OYE1 W116A COMPLEXED WITH (Z)-METHYL-3-CYANO-3-PHENYLACRYLATE IN A NON PRODUCTIVE BINDING MODE
4K7V	;	1.516	;	OYE1-W116A complexed with (R)-carvone
4GBU	;	1.179	;	OYE1-W116A in complex with aromatic product of S-carvone dismutation
4GE8	;	1.499	;	OYE1-W116I complexed with (s)-Carvone
4GXM	;	1.362	;	OYE1-W116L in complex with aromatic product of R-carvone dismutation
3TXZ	;	1.7	;	OYE1-W116Q complexed with R-carvone
4K7Y	;	1.199	;	Oye1-w116t
4K8H	;	1.55	;	OYE1-W116V complexed with (R)-carvone
4K8E	;	1.269	;	OYE1-W116V complexed with the aromatic product of (R)-carvone dismutation
4H4I	;	1.25	;	OYE1-W116V complexed with the dismutation product of (S)-carvone
4M5P	;	1.503	;	OYE2.6 Y78W, I113C
5ZV9	;	1.8	;	P domain of GII.13 norovirus capsid
5ZVC	;	1.8	;	P domain of GII.13 norovirus capsid complexed with Lewis A trisaccharide
5ZUQ	;	1.99	;	P domain of GII.17-1978
5ZUS	;	2.0	;	P domain of GII.17-2014/15
5ZV5	;	2.1	;	P domain of GII.17-2014/15 complexed with A-trisaccharide
5ZV7	;	1.95	;	P domain of GII.17-2014/15 complexed with B-trisaccharide
6IR5	;	2.6	;	P domain of GII.3-TV24
6IS5	;	2.501	;	P domain of GII.3-TV24 with A-tetrasaccharide complex
1WVE	;	1.85	;	p-Cresol Methylhydroxylase: Alteration of the Structure of the Flavoprotein Subunit upon its Binding to the Cytochrome Subunit
1WVF	;	1.3	;	p-Cresol Methylhydroxylase: Alteration of the Structure of the Flavoprotein Subunit upon its Binding to the Cytochrome Subunit
6JLZ	;	3.35	;	P-eIF2a - eIF2B complex
2BN6	;		;	P-Element Somatic Inhibitor Protein
2BN5	;		;	P-Element Somatic Inhibitor Protein Complex with U1-70k proline-rich peptide
4Q9H	;	3.4	;	P-glycoprotein at 3.4 A resolution
4XWK	;	3.5	;	P-glycoprotein co-crystallized with BDE-100
4Q9I	;	3.781	;	P-glycoprotein cocrystallised with QZ-Ala
4Q9K	;	3.8	;	P-glycoprotein cocrystallised with QZ-Leu
4Q9L	;	3.8	;	P-glycoprotein cocrystallised with QZ-Phe
4Q9J	;	3.6	;	P-glycoprotein cocrystallised with QZ-Val
6UJN	;	3.98	;	P-glycoprotein mutant-C952A-with BDE100
6UJR	;	4.1	;	P-glycoprotein mutant-F724A and C952A-with BDE100
6UJS	;	4.17	;	P-glycoprotein mutant-F728A and C952A-with BDE100
6UJP	;	3.98	;	P-glycoprotein mutant-F979A and C952A-with BDE100
6UJT	;	4.17	;	P-glycoprotein mutant-Y303A and C952A-with BDE100
6UJW	;	4.15	;	P-glycoprotein mutant-Y306A and C952A-with BDE100
1BGN	;	2.0	;	P-HYDROXYBENZOATE HYDROXYLASE (PHBH) MUTANT WITH CYS 116 REPLACED BY SER (C116S) AND ARG 269 REPLACED BY THR (R269T), IN COMPLEX WITH FAD AND 4-HYDROXYBENZOIC ACID
1BF3	;	2.2	;	P-HYDROXYBENZOATE HYDROXYLASE (PHBH) MUTANT WITH CYS 116 REPLACED BY SER (C116S) AND ARG 42 REPLACED BY LYS (R42K), IN COMPLEX WITH FAD AND 4-HYDROXYBENZOIC ACID
1BGJ	;	3.0	;	P-HYDROXYBENZOATE HYDROXYLASE (PHBH) MUTANT WITH CYS 116 REPLACED BY SER (C116S) AND HIS 162 REPLACED BY ARG (H162R), IN COMPLEX WITH FAD AND 4-HYDROXYBENZOIC ACID
1BKW	;	2.2	;	p-Hydroxybenzoate hydroxylase (phbh) mutant with cys116 replaced by ser (c116s) and arg44 replaced by lys (r44k), in complex with fad and 4-hydroxybenzoic acid
1IUV	;	2.5	;	P-HYDROXYBENZOATE HYDROXYLASE COMPLEXED WITH 4-4-HYDROXYBENZOATE AT PH 5.0
1IUW	;	2.0	;	P-HYDROXYBENZOATE HYDROXYLASE COMPLEXED WITH 4-4-HYDROXYBENZOATE AT PH 7.4
1IUX	;	2.0	;	P-HYDROXYBENZOATE HYDROXYLASE COMPLEXED WITH 4-4-HYDROXYBENZOATE AT PH 9.4
1IUS	;	2.2	;	P-HYDROXYBENZOATE HYDROXYLASE COMPLEXED WITH 4-AMINOBENZOATE AT PH 5.0
1IUT	;	2.0	;	P-HYDROXYBENZOATE HYDROXYLASE COMPLEXED WITH 4-AMINOBENZOATE AT PH 7.4
1IUU	;	2.0	;	P-HYDROXYBENZOATE HYDROXYLASE COMPLEXED WITH 4-AMINOBENZOATE AT PH 9.4
6JU1	;	1.6	;	p-Hydroxybenzoate hydroxylase Y385F mutant complexed with 3,4-dihydroxybenzoate
3QGM	;	2.0	;	p-nitrophenyl phosphatase from Archaeoglobus fulgidus
4YON	;	1.95	;	P-Rex1:Rac1 complex
1G1S	;	1.9	;	P-SELECTIN LECTIN/EGF DOMAINS COMPLEXED WITH PSGL-1 PEPTIDE
2IDF	;	2.25	;	P. aeruginosa azurin N42C/M64E double mutant, BMME-linked dimer
2IUT	;	2.25	;	P. aeruginosa FtsK motor domain, dimeric
2IUU	;	2.9	;	P. aeruginosa FtsK motor domain, hexamer
7T5S	;	3.0	;	P. aeruginosa LpxA in complex with ligand H16
7T5R	;	1.95	;	P. aeruginosa LpxA in complex with ligand H7
7T60	;	2.0	;	P. aeruginosa LpxA in complex with ligand L13
7T61	;	2.1	;	P. aeruginosa LpxA in complex with ligand L15
7T5X	;	2.2	;	P. aeruginosa LpxA in complex with ligand L6
7T5Z	;	2.25	;	P. aeruginosa LpxA in complex with ligand L8
5AIJ	;	1.95	;	P. aeruginosa SdsA hexagonal polymorph
2GNM	;	1.95	;	P. angolensis lectin (PAL) treated with EDTA for 39 hours
7Z2B	;	3.3	;	P. berghei kinesin-8B motor domain in AMPPNP state bound to tubulin dimer
7Z2A	;	4.3	;	P. berghei kinesin-8B motor domain in no nucleotide state bound to tubulin dimer
5LY3	;	1.6	;	P. calidifontis crenactin in complex with arcadin-2 C-terminal peptide
7K3Z	;	3.69	;	P. falciparum Cpn60 D474A mutant bound to ATP
6TJ3	;		;	P. falciparum essential light chain, N-terminal domain
6TJ4	;	1.5	;	P. falciparum essential light chain, N-terminal domain
7Z2C	;	4.1	;	P. falciparum kinesin-8B motor domain in no nucleotide bound to tubulin dimer
8DKC	;	3.5	;	P. gingivalis RNA Polymerase
6PYK	;	1.35	;	P. mirabilis hemolysin A mutant - F80L
6PZL	;	1.17	;	P. mirabilis hemolysin A mutant - Q125A
6Q0P	;	1.542	;	P. mirabilis hemolysin A mutant - Y134S
5IZ3	;	1.3	;	P. patens sedoheptulose-1,7-bisphosphatase
7TFD	;	3.16	;	P. polymyxa GS(12) - apo
7TFA	;	2.07	;	P. polymyxa GS(12)-Q-GlnR peptide
7TFB	;	2.28	;	P. polymyxa GS(14)-Q-GlnR peptide
4HNC	;	1.889	;	P. putida C92S/K166C/C264S mandelate racemase co-crystallized with benzilic acid
4FP1	;	1.68	;	P. putida mandelate racemase co-crystallized with 3,3,3-trifluoro-2-hydroxy-2-(trifluoromethyl) propionic acid
6VIM	;	2.0	;	P. putida mandelate racemase co-crystallized with phenylboronic acid
4M6U	;	1.8	;	P. putida mandelate racemase co-crystallized with tartronic acid
3UXK	;	2.201	;	P. putida mandelate racemase co-crystallized with the intermediate analogue benzohydroxamate
3UXL	;	2.201	;	P. putida mandelate racemase co-crystallized with the intermediate analogue cupferron
7MQX	;	1.914	;	P. putida mandelate racemase forms an oxobenzoxaborole adduct with 2-formylphenylboronic acid
4X2P	;	1.65	;	P. putida mandelate racemase in complex with 3-hydroxypyruvate
4DF2	;	2.021	;	P. stipitis OYE2.6 complexed with p-Chlorophenol
4QAI	;	2.75	;	P. stipitis OYE2.6-Y78W
7JSO	;	2.848	;	P. syringae AldA Indole-3-Acetaldehyde Dehydrogenase C302A mutant in complex with NAD+ and IAA
4MCT	;	2.8	;	P. vulgaris HIGBA structure, crystal form 1
4MCX	;	2.1	;	P. vulgaris HIGBA structure, crystal form 2
2QDX	;	1.55	;	P.Aeruginosa Fpr with FAD
1BSM	;	1.35	;	P.SHERMANII SOD(FE+3) 140K PH8
1BS3	;	1.55	;	P.SHERMANII SOD(FE+3) FLUORIDE
1BT8	;	1.85	;	P.SHERMANII SOD(FE+3) PH 10.0
5O4V	;	1.7	;	P.vivax NMT with aminomethylindazole and quinoline inhibitors bound
5O48	;	1.69	;	P.vivax NMT with an aminomethylindazole inhibitor bound
8X90	;	2.95	;	P/Q type calcium channel
8X93	;	2.92	;	P/Q type calcium channel in complex with omega-Agatoxin IVA
8X91	;	3.11	;	P/Q type calcium channel in complex with omega-conotoxin MVIIC
3O1F	;	1.4	;	P1 crystal form of E. coli ClpS at 1.4 A resolution
3GNF	;	2.1	;	P1 Crystal structure of the N-terminal R1-R7 of murine MVP
1HLX	;		;	P1 HELIX NUCLEIC ACIDS (DNA/RNA) RIBONUCLEIC ACID
6RC9	;	1.94	;	P1 Mycoplasma pneumoniae
1AK0	;	1.8	;	P1 NUCLEASE IN COMPLEX WITH A SUBSTRATE ANALOG
2CEJ	;	2.5	;	P1' Extended HIV-1 Protease Inhibitors Encompassing a Tertiary Alcohol in the Transition-State Mimicking Scaffold
2CEM	;	1.8	;	P1' Extended HIV-1 Protease Inhibitors Encompassing a Tertiary Alcohol in the Transition-State Mimicking Scaffold
2CEN	;	1.7	;	P1' Extended HIV-1 Protease Inhibitors Encompassing a Tertiary Alcohol in the Transition-State Mimicking Scaffold
1UWX	;	2.2	;	P1.2 serosubtype antigen derived from N. meningitidis PorA in complex with Fab fragment
1ASJ	;	2.9	;	P1/MAHONEY POLIOVIRUS, AT CRYOGENIC TEMPERATURE
1AR7	;	2.9	;	P1/MAHONEY POLIOVIRUS, DOUBLE MUTANT P1095S + H2142Y
1AR6	;	2.9	;	P1/MAHONEY POLIOVIRUS, DOUBLE MUTANT V1160I +P1095S
1AR8	;	2.9	;	P1/MAHONEY POLIOVIRUS, MUTANT P1095S
1AR9	;	2.9	;	P1/MAHONEY POLIOVIRUS, SINGLE SITE MUTANT H2142Y
1AL2	;	2.9	;	P1/MAHONEY POLIOVIRUS, SINGLE SITE MUTANT V1160I
1LEO	;	2.6	;	P100S NUCLEOSIDE DIPHOSPHATE KINASE
7SMC	;	2.7	;	p107 pocket domain complexed with ARID4A peptide
7SMD	;	2.15	;	p107 pocket domain complexed with EID1 peptide
7SME	;	2.64	;	p107 pocket domain complexed with HDAC1 peptide
4YOS	;	2.3	;	p107 pocket domain complexed with LIN52 peptide
7SMF	;	3.0	;	p107 pocket domain complexed with mutated HDAC1-3X peptide
4YOZ	;	2.245	;	p107 pocket domain in complex with HPV E7 peptide
4YOO	;	2.4	;	p107 pocket domain in complex with LIN52 P29A peptide
1A4P	;	2.25	;	P11 (S100A10), LIGAND OF ANNEXIN II
1BT6	;	2.4	;	P11 (S100A10), LIGAND OF ANNEXIN II IN COMPLEX WITH ANNEXIN II N-TERMINUS
5DXT	;	2.25	;	p110alpha with GDC-0326
5DXH	;	3.0	;	p110alpha/p85alpha with compound 5
5DXU	;	2.64	;	p110delta/p85alpha with GDC-0326
5T8F	;	2.91	;	p110delta/p85alpha with taselisib (GDC-0032)
4AHL	;	2.053	;	P112L - Angiogenin mutants and amyotrophic lateral sclerosis - a biochemical and biological analysis
4ITG	;	1.74	;	P113S mutant of E. coli Cystathionine beta-lyase MetC
4ITX	;	1.61	;	P113S mutant of E. coli Cystathionine beta-lyase MetC inhibited by reaction with L-Ala-P
3NJJ	;	1.56	;	P115A mutant of SO1698 protein, an aspartic peptidase from Shewanella oneidensis
3NJM	;	1.64	;	P117A mutant of SO1698 protein, an aspartic peptidase from Shewanella oneidensis.
7TPB	;	3.2	;	p120RasGAP SH3 domain in complex with DLC1 RhoGAP domain
5W93	;	2.001	;	p130Cas complex with paxillin LD1
5O2M	;		;	p130Cas SH3 domain
5O2P	;		;	p130Cas SH3 domain PTP-PEST peptide chimera
5O2Q	;		;	p130Cas SH3 domain Vinculin peptide chimera
8FSD	;	1.49	;	P130R mutant of soybean SHMT8 in complex with PLP-glycine and formylTHF
6PQZ	;	2.23	;	P133G/S128A S. typhimurium siroheme synthase
6PR0	;	1.9	;	P133H-S128A S. typhimurium siroheme synthase
1PUC	;	1.95	;	P13SUC1 IN A STRAND-EXCHANGED DIMER
1DZH	;	2.85	;	P14-FLUORESCEIN-N135Q-S380C-ANTITHROMBIN-III
6YRK	;	4.1	;	P140-P110 complex fitted into the cryo-electron density map of the heterodimer
6YDJ	;	1.04	;	P146A variant of beta-phosphoglucomutase from Lactococcus lactis in complex with glucose 6-phosphate and trifluoromagnesate
1CFE	;		;	P14A, NMR, 20 STRUCTURES
3LP3	;	2.8	;	p15 HIV RNaseH domain with inhibitor MK3
8W52	;	2.38	;	p17 protein structure of HIV2 when OLA1 existing
7CWN	;	3.2	;	P17-H014 Fab cocktail in complex with SARS-CoV-2 spike protein
1AP7	;		;	P19-INK4D FROM MOUSE, NMR, 20 STRUCTURES
2K85	;		;	p190-A RhoGAP FF1 domain
5IRC	;	1.72	;	p190A GAP domain complex with RhoA
1BLX	;	1.9	;	P19INK4D/CDK6 COMPLEX
7NFY	;	3.9	;	P1a-state of wild type human mitochondrial LONP1 protease with bound substrate protein and ATPgS
7KKH	;	2.0	;	P1A4 Fab in complex with ARS1620
7NG4	;	4.4	;	P1b-state of wild type human mitochondrial LONP1 protease with bound endogenous substrate protein and in presence of ATP/ADP mix
7NG5	;	3.8	;	P1c-state of wild type human mitochondrial LONP1 protease with bound substrate protein in presence of ATP/ADP mix
5DOR	;	2.5	;	P2 Integrase catalytic domain in space group P21
5K1Y	;	2.97	;	P2(1) Structure of pNOB8 AspA-DNA complex
6KN1	;	1.9	;	P20/P12 of caspase-11 mutant C254A
4L5S	;	2.94	;	p202 HIN1 in complex with 12-mer dsDNA
5Z7D	;	4.5	;	p204HINab-dsDNA complex structure
4IQ2	;	1.7	;	P21 crystal form of FKBP12.6
2EAR	;	3.1	;	P21 crystal of the SR CA2+-ATPase with bound TG
1M1P	;	1.55	;	P21 crystal structure of the tetraheme cytochrome c3 from Shewanella oneidensis MR1
4YRH	;	2.861	;	p21 isoform of MEC-17 from Danio Rerio
6B16	;	2.285	;	P21-activated kinase 1 in complex with a 4-azaindole inhibitor
3PZU	;	2.1	;	P212121 crystal form of the endo-1,4-beta-glucanase from Bacillus subtilis 168
3GNG	;	3.0	;	P21B crystal structure of R1-R7 of Murine MVP
3IYI	;	9.1	;	P22 expanded head coat protein structures reveal a novel mechanism for capsid maturation: Stability without auxiliary proteins or chemical cross-links
3IYH	;	8.2	;	P22 procapsid coat protein structures reveal a novel mechanism for capsid maturation: Stability without auxiliary proteins or chemical cross-links
4ZXQ	;	2.75	;	P22 Tail Needle Gp26 1-140 crystallized at pH 3.9
4ZKU	;	2.5	;	P22 Tail Needle Gp26 crystallized at pH 10.0
4ZKP	;	2.1	;	P22 Tail Needle Gp26 crystallized at pH 7.0
3TH0	;	1.75	;	P22 Tailspike complexed with S.Paratyphi O antigen octasaccharide
6KMU	;	2.1	;	P22/P10 complex of caspase-11 mutant C254A
1M1Q	;	0.97	;	P222 oxidized structure of the tetraheme cytochrome c from Shewanella oneidensis MR1
1JSU	;	2.3	;	P27(KIP1)/CYCLIN A/CDK2 COMPLEX
7NGC	;	7.5	;	P2a-state of wild type human mitochondrial LONP1 protease with bound substrate protein and in presence of ATPgS
7NGF	;	5.6	;	P2c-state of wild type human mitochondrial LONP1 protease with bound endogenous substrate protein and in presence of ATP/ADP mix
1F4M	;	2.25	;	P3(2) CRYSTAL STRUCTURE OF ALA2ILE2-6, A VERSION OF ROP WITH A REPACKED HYDROPHOBIC CORE AND A NEW FOLD.
1HX6	;	1.65	;	P3, THE MAJOR COAT PROTEIN OF THE LIPID-CONTAINING BACTERIOPHAGE PRD1.
8Q92	;	3.05	;	P301S Tau Filaments from the Brains of PS19 Transgenic Mouse Line
8Q96	;	3.09	;	P301S Tau Filaments from the Brains of Tg2541 Transgenic Mouse Line
6QAX	;		;	P31-43
4IQC	;	1.903	;	P3121 crystal form of FKBP12.6
6KMT	;	2.6	;	P32 of caspase-11 mutant C254A
7WR0	;	2.8	;	P32 of caspase-4 C258A mutant
7WR1	;	2.13	;	P32 of caspase-4 C258A mutant in complex with OspC3 C-terminal ankyrin-repeat domain
6S1C	;	6.1	;	P3221 crystal form of the Ctf18-1-8/Pol2(1-528) complex
2AN2	;	2.6	;	P332G, A333S Double mutant of the Bacillus subtilis Nitric Oxide Synthase
5O85	;	3.4	;	p34-p44 complex
6QDZ	;	1.73	;	P38 alpha complex with AR117045
6QE1	;	1.85	;	P38 alpha complex with AR117046
3NWW	;	2.09	;	P38 Alpha kinase complexed with a 2-aminothiazol-5-yl-pyrimidine based inhibitor
3OCG	;	2.21	;	P38 Alpha kinase complexed with a 5-amino-pyrazole based inhibitor
3L8X	;	2.4	;	P38 alpha kinase complexed with a pyrazolo-pyrimidine based inhibitor
3S4Q	;	2.27	;	P38 alpha kinase complexed with a pyrazolo-triazine based inhibitor
3C5U	;	2.8	;	P38 ALPHA map kinase complexed with a benzothiazole based inhibitor
3BX5	;	2.4	;	P38 alpha map kinase complexed with BMS-640994
3MVL	;	2.8	;	P38 Alpha Map Kinase complexed with pyrrolotriazine inhibitor 7K
3MVM	;	2.0	;	P38 Alpha Map Kinase complexed with pyrrolotriazine inhibitor 7V
2QD9	;	1.7	;	P38 Alpha Map Kinase inhibitor based on heterobicyclic scaffolds
5MZ3	;	2.15	;	P38 ALPHA MUTANT C162S IN COMPLEX WITH CMPD2 [N-(4-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide]
3DS6	;	2.9	;	P38 complex with a phthalazine inhibitor
3DT1	;	2.8	;	P38 Complexed with a quinazoline inhibitor
3HEC	;	2.5	;	P38 in complex with Imatinib
3HEG	;	2.2	;	P38 in complex with Sorafenib
6OHD	;	2.5	;	P38 in complex with T-3220137
3P5K	;	2.09	;	P38 inhibitor-bound
3P78	;	2.3	;	P38 inhibitor-bound
3P79	;	2.1	;	P38 inhibitor-bound
3P7A	;	2.31	;	p38 inhibitor-bound
3P7B	;	1.9	;	p38 inhibitor-bound
3P7C	;	2.3	;	p38 inhibitor-bound
3FSF	;	2.1	;	P38 kinase crystal structure in complex with 3-(2,6-Dichloro-phenyl)-7-[4-(2-diethylamino-ethoxy)-phenylamino]-1-methyl-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one
3FMJ	;	2.0	;	P38 kinase crystal structure in complex with 4-(5-Methyl-3-phenyl-isoxazol-4-yl)-pyrimidin-2-ylamine
3FLS	;	2.3	;	P38 kinase crystal structure in complex with 6-(2,4-Difluoro-phenoxy)-2-((R)-2-methanesulfonyl-1-methyl-ethylamino)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
3FLQ	;	1.9	;	P38 kinase crystal structure in complex with 6-(2,4-difluoro-phenoxy)-2-((s)-2-methanesulfonyl-1-methyl-ethylamino)-8-methyl-8h-pyrido[2,3-d]pyrimidin
3FLY	;	1.8	;	P38 kinase crystal structure in complex with 6-(2,4-difluoro-phenoxy)-2-isopropylamino-8-methyl-8h-pyrido[2,3-d]pyrimidin-7-one
3FMH	;	1.9	;	P38 kinase crystal structure in complex with 6-(2,4-Difluoro-phenoxy)-8-methyl-2-((R)-1-methyl-2-tetrazol-2-yl-ethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
3FMK	;	1.7	;	P38 kinase crystal structure in complex with 6-(2,4-Difluoro-phenoxy)-8-methyl-2-((S)-1-methyl-2-tetrazol-2-yl-ethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
3FLZ	;	2.23	;	P38 kinase crystal structure in complex WITH 8-Methyl-6-phenoxy-2-(tetrahydro-pyran-4-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
3FLW	;	2.1	;	P38 kinase crystal structure in complex with pamapimod
3FLN	;	1.9	;	P38 kinase crystal structure in complex with R1487
3FMN	;	1.9	;	P38 kinase crystal structure in complex with RO2530
2GFS	;	1.752	;	P38 Kinase Crystal Structure in complex with RO3201195
3FKO	;	2.0	;	P38 kinase crystal structure in complex with RO3668
3FI4	;	2.2	;	P38 kinase crystal structure in complex with RO4499
3FL4	;	1.8	;	P38 kinase crystal structure in complex with RO5634
3FML	;	2.1	;	P38 kinase crystal structure in complex with RO6224
3FMM	;	2.0	;	P38 kinase crystal structure in complex with RO6226
3FSK	;	2.0	;	P38 kinase crystal structure in complex with RO6257
3FKN	;	2.0	;	P38 kinase crystal structure in complex with RO7125
3FKL	;	2.0	;	P38 kinase crystal structure in complex with RO9552
1W7H	;	2.214	;	p38 Kinase crystal structure in complex with small molecule inhibitor
1W82	;	2.2	;	p38 Kinase crystal structure in complex with small molecule inhibitor
1W83	;	2.5	;	p38 Kinase crystal structure in complex with small molecule inhibitor
1W84	;	2.2	;	p38 Kinase crystal structure in complex with small molecule inhibitor
3HRB	;	2.2	;	p38 kinase Crystal structure in complex with small molecule inhibitor
3MW1	;	2.8	;	p38 kinase Crystal structure in complex with small molecule inhibitor
3RIN	;	2.2	;	p38 kinase crystal structure in complex with small molecule inhibitor
3S3I	;	1.8	;	p38 kinase crystal structure in complex with small molecule inhibitor
1KV1	;	2.5	;	p38 MAP Kinase in Complex with Inhibitor 1
1OZ1	;	2.1	;	P38 MITOGEN-ACTIVATED KINASE IN COMPLEX WITH 4-AZAINDOLE INHIBITOR
6QYX	;	1.66	;	p38(alpha) MAP kinase with the activation loop of ERK2
3NEW	;	2.51	;	p38-alpha complexed with Compound 10
6Y6V	;	2.1	;	p38a bound with MCP-81
6ZWP	;	1.9	;	p38a bound with SR348
6ZWR	;	1.9	;	p38a bound with SR92
4GEO	;	1.66	;	P38a MAP kinase DEF-pocket penta mutant (M194A, L195A, H228A, I229A, Y258A)
6B2G	;	2.407	;	P38A mutant of HIV-1 capsid protein
4E6C	;	2.39	;	p38a-perifosine Complex
4E6A	;	2.09	;	p38a-PIA23 complex
6B2H	;	2.6	;	P38A/T216I mutant of the HIV-1 capsid protein
3K3J	;	1.995	;	P38alpha bound to novel DFG-out compound PF-00416121
3K3I	;	1.7	;	p38alpha bound to novel DGF-out compound PF-00215955
2BAJ	;	2.25	;	p38alpha bound to pyrazolourea
2BAQ	;	2.8	;	p38alpha bound to Ro3201195
5OMH	;	2.5	;	p38alpha in complex with pyrazolobenzothiazine inhibitor COXH11
5OMG	;	2.0	;	p38alpha in complex with pyrazolobenzothiazine inhibitor COXP4M12
4AA0	;	1.8	;	P38ALPHA MAP KINASE BOUND TO CMPD 2
4AA4	;	2.3	;	P38ALPHA MAP KINASE BOUND TO CMPD 22
4AAC	;	2.5	;	P38ALPHA MAP KINASE BOUND TO CMPD 29
4AA5	;	2.38	;	P38ALPHA MAP KINASE BOUND TO CMPD 33
4A9Y	;	2.2	;	P38ALPHA MAP KINASE BOUND TO CMPD 8
2BAK	;	2.2	;	p38alpha MAP kinase bound to MPAQ
2BAL	;	2.1	;	p38alpha MAP kinase bound to pyrazoloamine
1OO3	;		;	P395S mutant of the p85 regulatory subunit of the N-terminal src homology 2 domain of PI3-Kinase
1OO4	;		;	P395S mutant of the p85 regulatory subunit of the N-terminal src homology 2 domain of PI3-Kinase complexed to a peptide derived from PDGFr
1W4C	;	2.5	;	P4 protein from Bacteriophage PHI12 apo state
1W44	;	2.0	;	P4 protein from Bacteriophage PHI12 in complex with ADP
1W46	;	2.7	;	P4 protein from Bacteriophage PHI12 in complex with ADP and MG
1W47	;	2.5	;	P4 protein from Bacteriophage PHI12 in complex with ADP and MN
1W48	;	2.3	;	P4 protein from Bacteriophage PHI12 in complex with AMPcPP
1W49	;	2.4	;	P4 protein from Bacteriophage PHI12 in complex with AMPcPP and Mg
4BLR	;	1.9	;	P4 PROTEIN FROM BACTERIOPHAGE PHI12 IN COMPLEX WITH UTP
2VHU	;	2.75	;	P4 PROTEIN FROM BACTERIOPHAGE PHI12 K241C mutant in complex with ADP and MgCl
2VHC	;	2.35	;	P4 PROTEIN FROM BACTERIOPHAGE PHI12 N234G mutant in complex with AMPCPP and MN
4BLS	;	2.6	;	P4 PROTEIN FROM BACTERIOPHAGE PHI12 Q278A MUTANT IN COMPLEX WITH AMPcPP
2VHT	;	3.0	;	P4 PROTEIN FROM BACTERIOPHAGE PHI12 R279A mutant in complex with ATP
2VHJ	;	1.8	;	P4 PROTEIN FROM BACTERIOPHAGE PHI12 S252A mutant in complex with ADP
2VHQ	;	2.15	;	P4 PROTEIN FROM BACTERIOPHAGE PHI12 S252A mutant in complex with ATP AND MG
4BLT	;	2.4	;	P4 PROTEIN FROM BACTERIOPHAGE PHI12 S292A MUTANT IN COMPLEX WITH AMPcPP
4BLP	;	1.7	;	P4 PROTEIN FROM BACTERIOPHAGE PHI13
4BLO	;	2.8	;	P4 PROTEIN FROM BACTERIOPHAGE PHI6 IN COMPLEX WITH ADP
4BLQ	;	2.79	;	P4 PROTEIN FROM BACTERIOPHAGE PHI8
4BWY	;	3.1	;	P4 PROTEIN FROM BACTERIOPHAGE PHI8 (R32)
1W4A	;	2.4	;	P4 protein from PHI12 in complex with AMPcPP and Mn
1W4B	;	2.3	;	P4 protein from PHI12 in complex with product (AMPcPP Mg 22C)
8DSG	;	1.87	;	P411-PFA carbene transferase
4WG2	;	2.66	;	P411BM3-CIS T438S I263F regioselective C-H amination catalyst
2ZBB	;	2.5	;	P43 crystal of DctBp
7TTQ	;	1.62	;	P450 (OxyA) from kistamicin biosynthesis, imidazole complex
7TTO	;	1.6	;	P450 (OxyA) from kistamicin biosynthesis, mixed heme conformation
7TTP	;	1.8	;	P450 (OxyA) from kistamicin biosynthesis, mixed heme conformation
7TTA	;	2.001	;	P450 (OxyA) from kistamicin biosynthesis, mixed heme conformation, attenuated beam
7TTB	;	1.80159	;	P450 (OxyA) from kistamicin biosynthesis, Y99F mutant
2X7Y	;	2.1	;	P450 BM3 F87A in complex with DMSO
2X80	;	2.3	;	P450 BM3 F87A in complex with DMSO
2J1M	;	1.7	;	P450 BM3 Heme domain in complex with DMSO
2J4S	;	2.1	;	P450 BM3 heme domain in complex with DMSO
6CP4	;	1.9	;	P450CAM D251N MUTANT
2FE6	;	1.5	;	P450CAM from Pseudomonas putida reconstituted with manganic protoporphyrin IX
2FER	;	1.7	;	P450CAM from Pseudomonas putida reconstituted with manganic protoporphyrin IX
2FEU	;	1.7	;	P450CAM from Pseudomonas putida reconstituted with manganic protoporphyrin IX
5WK7	;	1.983	;	P450cam mutant R186A
4L77	;	1.379	;	P450cin Active Site Water: Implications for Substrate Binding and Solvent Accessibility
1JIP	;	2.0	;	P450eryF(A245S)/ketoconazole
1JIO	;	2.1	;	P450eryF/6DEB
1JIN	;	2.3	;	P450eryF/ketoconazole
3WI0	;	1.998	;	P453H/I471T mutant of PB2 middle domain from influenza virus A/Puerto Rico/8/34(H1N1)
3WI1	;	1.931	;	P453H/I471T mutant of PB2 middle domain from influenza virus A/Puerto Rico/8/34(H1N1) with m7GTP
6RNN	;	1.95	;	P46, an immunodominant surface protein from Mycoplasma hyopneumoniae
6RQG	;	3.1	;	P46, an immunodominant surface protein from Mycoplasma hyopneumoniae
6RUX	;	2.5	;	P46, an immunodominant surface protein from Mycoplasma hyopneumoniae
6S3T	;	3.5	;	P46, an immunodominant surface protein from Mycoplasma hyopneumoniae
7R7T	;	4.5	;	p47-bound p97-R155H mutant with ADP
7R7S	;	4.23	;	p47-bound p97-R155H mutant with ATPgammaS
1E3L	;	2.5	;	P47H mutant of mouse class II alcohol dehydrogenase complex with NADH
1KQ6	;	1.18	;	p47phox PX domain
6SHZ	;	1.24	;	p53 cancer mutant Y220C
5O1E	;	1.3	;	p53 cancer mutant Y220C im complex with compound MB577
5O1C	;	1.32	;	p53 cancer mutant Y220C in complex with compound MB184
5O1A	;	1.44	;	p53 cancer mutant Y220C in complex with compound MB240
5O1D	;	1.36	;	p53 cancer mutant Y220C in complex with compound MB481
5O1G	;	1.35	;	p53 cancer mutant Y220C in complex with compound MB487
5O1H	;	1.32	;	p53 cancer mutant Y220C in complex with compound MB539
5O1F	;	1.38	;	p53 cancer mutant Y220C in complex with compound MB582
5O1I	;	1.4	;	p53 cancer mutant Y220C in complex with compound MB710
5O1B	;	1.43	;	p53 cancer mutant Y220C in complex with compound MB84
8A31	;	1.46	;	p53 cancer mutant Y220C in complex with iodophenol-based small-molecule stabilizer JC694
8A32	;	1.47	;	p53 cancer mutant Y220C in complex with iodophenol-based small-molecule stabilizer JC769
6GGA	;	1.55	;	p53 cancer mutant Y220C in complex with small-molecule stabilizer PK9284
6GGB	;	1.32	;	p53 cancer mutant Y220C in complex with small-molecule stabilizer PK9318
6GGC	;	1.24	;	p53 cancer mutant Y220C in complex with small-molecule stabilizer PK9320
6SI0	;	1.53	;	p53 cancer mutant Y220C in complex with small-molecule stabilizer PK9323
6GGD	;	1.40001	;	p53 cancer mutant Y220C in complex with small-molecule stabilizer PK9324
6GGE	;	1.25001	;	p53 cancer mutant Y220C in complex with small-molecule stabilizer PK9327
5LAP	;	1.42	;	p53 cancer mutant Y220C with Cys182 alkylation
6SI1	;	1.44	;	p53 cancer mutant Y220H
6SI2	;	1.5	;	p53 cancer mutant Y220S
6SI3	;	1.4	;	p53 cancer mutant Y220S in complex with small-molecule stabilizer PK9301
6SI4	;	1.8	;	p53 cancer mutant Y220S in complex with small-molecule stabilizer PK9323
6SL6	;	1.67	;	p53 charged core
1TSR	;	2.2	;	P53 CORE DOMAIN IN COMPLEX WITH DNA
4QO1	;	1.924	;	p53 DNA binding domain in complex with Nb139
8F2I	;	5.0	;	P53 monomer structure
1AIE	;	1.5	;	P53 TETRAMERIZATION DOMAIN CRYSTAL STRUCTURE
2J10	;		;	p53 tetramerization domain mutant T329F Q331K
2J11	;		;	p53 tetramerization domain mutant Y327S T329G Q331G
2J0Z	;		;	p53 tetramerization domain wild type
1YCS	;	2.2	;	P53-53BP2 COMPLEX
7EDX	;	4.5	;	p53-bound TFIID-based core PIC on HDM2 promoter
7EGC	;	3.9	;	p53-bound TFIID-based holo PIC on HDM2 promoter
6VTC	;	1.83	;	p53-specific T cell receptor
6VTH	;	2.36	;	p53-specific T cell receptor
8A92	;	1.37	;	p53-Y220C Core Domain in Complex with a Bromo-trifluoro-pyrazole-amine
2B3G	;	1.6	;	p53N (fragment 33-60) bound to RPA70N
1BHF	;	1.8	;	P56LCK SH2 DOMAIN INHIBITOR COMPLEX
1GV9	;	1.46	;	p58/ERGIC-53
7P40	;	3.5	;	P5C3 is a potent fab neutralizer
1OQ0	;		;	P6.1 stem loop from the activation domain of hTR
5OW5	;	1.7	;	p60p80-CAMSAP complex
7R1O	;	2.202	;	p62-ZZ domain of the human sequestosome in complex with dusquetide
5YP7	;	1.424	;	p62/SQSTM1 ZZ domain
5YP8	;	1.448	;	p62/SQSTM1 ZZ domain with Arg-peptide
6KHZ	;	2.8	;	p62/SQSTM1 ZZ domain with Gly-peptide
5YPB	;	2.9	;	p62/SQSTM1 ZZ domain with His-peptide
5YPH	;	1.629	;	p62/SQSTM1 ZZ domain with Ile-peptide
5YPG	;	2.199	;	p62/SQSTM1 ZZ domain with Leu-peptide
5YPA	;	2.502	;	p62/SQSTM1 ZZ domain with Lys-peptide
5YPC	;	1.962	;	p62/SQSTM1 ZZ domain with Phe-peptide
5YPF	;	2.951	;	p62/SQSTM1 ZZ domain with Trp-peptide
5YPE	;	2.851	;	p62/SQSTM1 ZZ domain with Tyr-peptide
7BMX	;	1.9	;	p62PH in cesium chloride (0.25 M CsCl in protein buffer and 0.75 M CsCl in cryo protectant)
7BMV	;	1.9	;	p62PH in cesium chloride (0.25 M CsCl in protein buffer and cryo protectant)
7BMU	;	1.9	;	p62PH in cesium chloride (0.25 M CsCl in protein buffer)
7BMY	;	1.8	;	p62PH in cesium chloride (0.7 M CsCl in crystallization condition and cryo protectant)
7BMW	;	1.9	;	p62PH in cesium chloride (0.75 M CsCl in cryo protectant)
7BMZ	;	2.5	;	p62PH in potassium chloride
2NB1	;		;	P63/p73 hetero-tetramerisation domain
8TPK	;	3.46	;	P6522 crystal form of C. crescentus DriD-ssDNA-DNA complex
7N91	;	3.0	;	P70 S6K1 IN COMPLEX WITH MSC2317067A-1
7N93	;	2.74	;	P70 S6K1 IN COMPLEX WITH MSC2363318A-1
5HOB	;	1.22001	;	p73 homo-tetramerization domain mutant I
5HOC	;	1.36008	;	p73 homo-tetramerization domain mutant II
2M16	;		;	P75/LEDGF PWWP Domain
2N80	;		;	p75NTR DD:RhoGDI
2N83	;		;	p75NTR DD:RIP2 CARD
8TS8	;	2.72	;	p85alpha/p110alpha heterodimer H1047R mutant
1A5Q	;	2.3	;	P93A VARIANT OF BOVINE PANCREATIC RIBONUCLEASE A
2RHR	;	2.5	;	P94L actinorhodin ketordeuctase mutant, with NADPH and Inhibitor Emodin
6MCK	;	3.77	;	p97 D1D2 with CB5083 bound
5KIY	;	2.79	;	p97 ND1-A232E in complex with VIMP
5KIW	;	3.41	;	p97 ND1-L198W in complex with VIMP
5C19	;	4.2	;	p97 variant 2 in the apo state
5C1B	;	3.08	;	p97-delta709-728 in complex with a UFD1-SHP peptide
5C18	;	3.3	;	p97-delta709-728 in complex with ATP-gamma-S
5C1A	;	3.8	;	p97-N750D/R753D/M757D/Q760D in complex with ATP-gamma-S
8B5R	;	6.1	;	p97-p37-SPI substrate complex
7L5W	;	3.34	;	p97-R155H mutant dodecamer I
7L5X	;	6.1	;	p97-R155H mutant dodecamer II
5HAI	;	2.74	;	P99 beta-lactamase mutant - S64G
2VUC	;	1.3	;	PA-IIL lectin from Pseudomonas aeruginosa complexed with Fucose- derived glycomimetics
2VUD	;	1.7	;	PA-IIL lectin from pseudomonas aeruginosa complexed with fucose- derived glycomimetics
8CNE	;	1.57	;	Pa.FabF-C164A in complex with N-(propan-2-yl)-1H-pyrazole-3-carboxamide
8COU	;	1.68	;	Pa.FabF-C164Q in complex with 3-acetamido-4-methoxybenzoic acid
8CN4	;	1.67	;	Pa.FabF-C164Q in complex with 5-acetamido-2-chlorobenzoic acid
8COV	;	1.8	;	Pa.FabF-C164Q in complex with 6-chloro-2-methyl-1H-indole-5-carboxylic acid
8CN2	;	1.88	;	Pa.FabF-C164Q in complex with N-isobutyl-1H-pyrazole-3-carboxamide
8CN7	;	2.1	;	Pa.FabF-C164Q in complex with platencin
8CN5	;	1.93	;	Pa.FabF-C164Q in complex with propan-2-yl 1~{H}-pyrazole-3-carboxylate
8CNG	;	2.1	;	Pa.FabF-C164Q in complex with ~{N}-cyclopentyl-3-methyl-1~{H}-pyrazole-5-carboxamide
8ECX	;	2.03	;	PA0709 with glyoxal and BME modifications
6M8M	;	1.2	;	PA14 sugar-binding domain from RTX adhesin
8Q8O	;	2.7	;	PA14_16140 protein: the regulator of an operon involved in the biofilm formation in PA14 P. aeruginosa
3QY3	;	1.75	;	PA2801 protein, a putative Thioesterase from Pseudomonas aeruginosa
7DR6	;	4.1	;	PA28alpha-beta in complex with immunoproteasome
4Y8E	;	1.61	;	PA3825-EAL Ca-Apo Structure
4Y9P	;	2.44	;	PA3825-EAL Ca-CdG Structure
5MKG	;	2.44	;	PA3825-EAL Ca-CdG Structure
4Y9M	;	1.6	;	PA3825-EAL Metal-Free-Apo Structure
4Y9N	;	1.92	;	PA3825-EAL Metal-Free-Apo Structure - Magnesium Co-crystallisation
4Y9O	;	1.81	;	PA3825-EAL Metal-Free-Apo Structure - Manganese Co-crystallisation
5MF5	;	1.77	;	PA3825-EAL Mg-CdG Structure
5MFU	;	2.15	;	PA3825-EAL Mn-pGpG Structure
5IB0	;	1.65	;	PA4534: acetyl CoA complex
6SIW	;	1.96	;	PaaK family AMP-ligase with AMP
6SIY	;	1.95	;	PaaK family AMP-ligase with AMP and substrate
6SIX	;	1.88	;	PaaK family AMP-ligase with ANP
6SIZ	;	1.77	;	PaaK family AMP-ligase with ANP and substrate
2Y4N	;	1.92	;	PaaK1 in complex with phenylacetyl adenylate
8C3L	;	1.5971	;	PaaR2 N-terminal domain in complex with nanobody 33
8C3K	;	1.74972	;	PaaR2 N-terminal domin in complex with nanobody 33
7NKV	;		;	PaaR2 regulator N-terminal domain
3R6W	;	2.085	;	paAzoR1 binding to nitrofurazone
1YR6	;	2.15	;	PAB0955 crystal structure : a GTPase in Apo form from Pyrococcus abyssi
1YRB	;	1.75	;	PAB0955 crystal structure : a GTPase in GDP and Mg bound form from Pyrococcus abyssi
2OXR	;	2.4	;	PAB0955 crystal structure : a GTPase in GDP and Mg bound form from Pyrococcus abyssi (after GTP hydrolysis)
1YR9	;	2.8	;	PAB0955 crystal structure : a GTPase in GDP and PO4 bound form from Pyrococcus abyssi
1YRA	;	2.3	;	PAB0955 crystal structure : a GTPase in GDP bound form from Pyrococcus abyssi
1YR8	;	2.4	;	PAB0955 crystal structure : a GTPase in GTP bound form from Pyrococcus abyssi
1YR7	;	2.08	;	PAB0955 crystal structure : a GTPase in GTP-gamma-S bound form from Pyrococcus abyssi
8AHH	;	2.037	;	PAC FragmentDEL: Photoactivated covalent capture of DNA encoded fragments for hit discovery
5X4T	;	1.601	;	PAC from Oscillatoria acuminata after 20 seconds photoactivation
5X4U	;	1.8	;	PAC from Oscillatoriaacuminata after 60 seconds photoactivation
8AHE	;	2.108	;	PAC-FragmentDEL: Photoactivated covalent capture of DNA encoded fragments for hit discovery
8AHF	;	2.271	;	PAC-FragmentDEL: Photoactivated covalent capture of DNA encoded fragments for hit discovery
8AHG	;	1.885	;	PAC-FragmentDEL: Photoactivated covalent capture of DNA encoded fragments for hit discovery
8AHI	;	2.69	;	PAC-FragmentDEL: Photoactivated covalent capture of DNA encoded fragments for hit discovery
6P9Y	;	3.01	;	PAC1 GPCR Receptor complex
2JOD	;		;	Pac1-Rshort N-terminal EC domain Pacap(6-38) complex
7SNC	;	2.5	;	Pacifastin related protease inhibitors
7SND	;	1.79	;	Pacifastin related protease inhibitors
7BP0	;	4.6	;	Packing Bacteriophage T7 portal protein GP8
2XMW	;	1.8	;	PacS, N-terminal domain, from Synechocystis PCC6803
4BNE	;	2.57	;	Pacsin2 Interacts with Membranes and Actin-Filaments
2IUE	;		;	Pactolus I-domain: Functional Switching of the Rossmann Fold
7VRX	;	1.96635	;	Pad-1 in the absence of substrate
3ZUF	;	2.2	;	Padron off (non-fluorescent) Btrans
3ZUJ	;	2.345	;	Padron on (fluorescent) ABcis
3ZUL	;	2.3	;	Padron on (fluorescent) Icis intermediate state
3LSA	;	1.79	;	Padron0.9-OFF (non-fluorescent state)
3LS3	;	1.65	;	Padron0.9-ON (fluorescent state)
2JB7	;	1.65	;	PAE2307 with AMP
6GH2	;	2.5	;	Paenibacillus sp. YM1 laminaribiose phosphorylase with alpha-glc-1-phosphate bound
6GH3	;	1.82	;	Paenibacillus sp. YM1 laminaribiose phosphorylase with alpha-man-1-phosphate bound
6GGY	;	1.95	;	Paenibacillus sp. YM1 laminaribiose phosphorylase with sulphate bound
7PGD	;		;	PAF in 50 v/v % DMSO-water solution
1VYH	;	3.4	;	PAF-AH Holoenzyme: Lis1/Alfa2
7NXI	;		;	PAF-D19S in 50 v/v % DMSO-water solution
5TTY	;	1.8	;	PagF prenyltransferase
5TU6	;	2.22	;	PagF prenyltransferase with cyclic[INPYLYP] and DMSPP
5TU5	;	1.9	;	PagF prenyltransferase with Tyr-Tyr-Tyr and DMSPP
6PGN	;	1.85	;	PagF single mutant with GPP
5TU4	;	2.1	;	PagF with Boc-Tyr and DMSPP
7MKF	;	3.0	;	Paired helical filament extracted from PrP-CAA Patient brain tissue
6VHL	;	3.3	;	Paired Helical Filament from Alzheimer's Disease Human Brain Tissue
7NRV	;	3.0	;	Paired helical filament from Alzheimer's disease with PET ligand APN-1607
7NRQ	;	2.76	;	Paired helical filament from primary age-related tauopathy brain
6HRE	;	3.2	;	Paired helical filament from sporadic Alzheimer's disease brain
5O3L	;	3.4	;	Paired helical filament in Alzheimer's disease brain
7MKH	;	3.3	;	Paired helical tau filament extracted from GSS Patient brain tissue | tau filament from Gerstmann Straussler Scheinker disease | PHF Tau
8AZU	;	3.1	;	Paired helical tau filaments from high-spin supernatants of aqueous extracts from Alzheimer's disease brains | PHF Tau
6GRQ	;	3.3	;	Paired immunoglobulin-like receptor B (PirB) or Leukocyte immunoglobulin-like receptor subfamily B member 3 (LILRB3) full extracellular domain
6GRS	;	3.4	;	Paired immunoglobulin-like receptor B (PirB) or Leukocyte immunoglobulin-like receptor subfamily B member 3 (LILRB3) full extracellular domain
6GRT	;	4.504	;	Paired immunoglobulin-like receptor B (PirB) or Leukocyte immunoglobulin-like receptor subfamily B member 3 (LILRB3) full extracellular domain
2HY8	;	2.0	;	PAK1 complex with ST2001
4ZJJ	;	2.2	;	PAK1 in complex with (S)-N-(tert-butyl)-3-((2-chloro-5-ethyl-8-fluoro-dibenzodiazepin-11-yl)amino)pyrrolidine-1-carboxamide
4ZJI	;	1.99	;	PAK1 in complex with 2-chloro-5-ethyl-8-fluoro-11-(4-methylpiperazin-1-yl)-dibenzodiazepine
5KBR	;	2.36	;	Pak1 in complex with 7-azaindole inhibitor
5KBQ	;	2.58	;	Pak1 in complex with bis-anilino pyrimidine inhibitor
3DVP	;	2.5	;	Pak1 peptide bound LC8
6WLX	;	2.2	;	PAK4 kinase domain in complex with beta-catenin Ser675 substrate peptide
5VEF	;	1.752	;	PAK4 kinase domain in complex with fasudil
5VEE	;	2.5	;	PAK4 kinase domain in complex with FRAX486
6WLY	;	1.9	;	PAK4 kinase domain in complex with LIMK1 Thr508 substrate peptide
5VED	;	2.301	;	PAK4 kinase domain in complex with Staurosporine
7S46	;	2.1	;	PAK4cat (D440N/S474E) in complex with Integrin beta5 760-770 peptide
7S48	;	1.9	;	PAK4cat in complex with Integrin beta5 760-770 peptide
4KS7	;	1.4	;	PAK6 kinase domain in complex with PF-3758309
4KS8	;	1.95	;	PAK6 kinase domain in complex with sunitinib
5BVT	;	2.31	;	Palmitate-bound pFABP5
4Y1K	;	3.8	;	PALMITOYLATED OPRM OUTER MEMBRANE FACTOR
6BMS	;	2.441	;	Palmitoyltransferase structure
7NTJ	;	1.74	;	PALS1 PDZ1 domain with SARS-CoV-1_E PBM complex
7NTK	;	1.9	;	PALS1 PDZ1 domain with SARS-CoV-2_E PBM complex
7QCS	;	2.804	;	PALS1/MPP5 PDZ domain in complex with SARS-CoV-2_E PBM peptide
7YAC	;	3.24	;	Paltusotine-bound SSTR2-Gi complex
4RNI	;	2.17	;	PaMorA dimeric phosphodiesterase. apo form
4RNJ	;	2.32	;	PaMorA phosphodiesterase domain, apo form
4RNF	;	2.85	;	PaMorA tandem diguanylate cyclase - mutant phosphodiesterase, apo form
4RNH	;	2.45	;	PaMorA tandem diguanylate cyclase - phosphodiesterase, c-di-GMP complex
5M1T	;	2.27	;	PaMucR Phosphodiesterase, c-di-GMP complex
4CVL	;	2.98	;	PaMurF in complex with AMP-PNP
4CVM	;	2.06	;	PaMurF in complex with AMP-PNP and UDP-MurNAc-tripeptide (mDAP)
4CVK	;	1.92	;	PaMurF in complex with UDP-MurNAc-tripeptide (mDAP)
6DZN	;	2.1	;	Pan-ebolavirus human antibody ADI-15878 Fab
6HE8	;	6.86	;	PAN-proteasome in state 1
6HE9	;	6.35	;	PAN-proteasome in state 2
6HEA	;	7.04	;	PAN-proteasome in state 3
6HEC	;	6.95	;	PAN-proteasome in state 4
6HED	;	6.95	;	PAN-proteasome in state 5
6QIH	;	1.42	;	Pancreatic Bovine Trypsin with a boronic acid inhibitor
1J1A	;	2.2	;	PANCREATIC SECRETORY PHOSPHOLIPASE A2 (IIa) WITH ANTI-INFLAMMATORY ACTIVITY
1PSP	;	2.5	;	PANCREATIC SPASMOLYTIC POLYPEPTIDE: FIRST THREE-DIMENSIONAL STRUCTURE OF A MEMBER OF THE MAMMALIAN TREFOIL FAMILY OF PEPTIDES
1UV0	;	1.78	;	Pancreatitis-associated protein 1 from human
8BW2	;	1.35	;	PanDDA analysis -- Crystal Structure of PHIP in complex with Z198194396 synthetic derivative
8BW3	;	1.3	;	PanDDA analysis -- Crystal Structure of PHIP in complex with Z198194396 synthetic derivative
8BW4	;	1.55	;	PanDDA analysis -- Crystal Structure of PHIP in complex with Z198194396 synthetic derivative
8ERS	;	1.05	;	PanDDA analysis -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z4718398507 - (R,S) isomer
8UM3	;	1.925	;	PanDDA analysis -- Crystal Structure of Zika virus NS3 Helicase in complex with Z203039992
8V7R	;	1.41	;	PanDDA analysis -- Crystal Structure of Zika virus NS3 Helicase in complex with Z56772132
8V7U	;	1.82	;	PanDDA analysis -- Crystal Structure of Zika virus NS3 Helicase in complex with Z729726784
5R08	;	1.7	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry A07, DMSO-free
5QY1	;	1.72	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry A07a
5QY2	;	1.36	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry A12b
5R09	;	1.56	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry B03, DMSO-free
5QY3	;	1.58	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry B03a
5QY4	;	1.57	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry B08a
5R0A	;	1.54	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry C02, DMSO-free
5QY5	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry C02a
5R0B	;	1.82	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry C05, DMSO-free
5QY6	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry C05a
5R0C	;	1.6	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry C08, DMSO-free
5QY7	;	1.67	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry C08a
5QY8	;	1.59	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry C10a
5R0D	;	1.27	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry C11, DMSO-free
5QY9	;	1.4	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry C11b
5R0E	;	1.59	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry D02, DMSO-free
5QYA	;	1.55	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry D02a
5R0F	;	1.97	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry D06, DMSO-free
5QYB	;	2.1	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry D06a
5R0G	;	1.73	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry D07, DMSO-free
5QYC	;	1.7	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry D07a
5R0H	;	1.57	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry E05, DMSO-free
5QYD	;	1.67	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry E05a
5R0I	;	1.86	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry E12, DMSO-free
5QYE	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry E12a
5QYF	;	1.49	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry F02a
5R0J	;	1.81	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry F08, DMSO-free
5QYG	;	1.67	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry F08a
5QYH	;	1.47	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry G04a
5R0K	;	1.8	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry G12, DMSO-free
5QYI	;	1.58	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry G12a
5R0L	;	1.7	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry H11, DMSO-free
5QYJ	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry H11a
5R0M	;	1.7	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry H12, DMSO-free
5QYK	;	1.63	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry H12a
5ST0	;	1.54	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P02B04 from the F2X-Universal Library
5ST1	;	1.58	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P02C03 from the F2X-Universal Library
5ST2	;	1.53	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P02C06 from the F2X-Universal Library
5ST3	;	1.47	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P02C09 from the F2X-Universal Library
5ST4	;	1.44	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P02D05 from the F2X-Universal Library
5ST5	;	1.61	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P02D06 from the F2X-Universal Library
5ST6	;	1.62	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P02D07 from the F2X-Universal Library
5ST7	;	1.46	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P02E03 from the F2X-Universal Library
5ST8	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P02E09 from the F2X-Universal Library
5ST9	;	1.4	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P02F01 from the F2X-Universal Library
5STA	;	1.58	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P02F03 from the F2X-Universal Library
5STB	;	1.55	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P02F05 from the F2X-Universal Library
5STC	;	1.44	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P02F09 from the F2X-Universal Library
5STE	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P02F11 from the F2X-Universal Library
5STF	;	1.45	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P02H02 from the F2X-Universal Library
5STG	;	1.61	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P02H08 from the F2X-Universal Library
5STH	;	1.67	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P02H09 from the F2X-Universal Library
5STI	;	1.76	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P02H11 from the F2X-Universal Library
5STJ	;	1.76	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P02H11 from the F2X-Universal Library
5STK	;	1.8	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P02H12 from the F2X-Universal Library
5STL	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03A02 from the F2X-Universal Library
5STM	;	1.65	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03A03 from the F2X-Universal Library
5STN	;	1.56	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03A11 from the F2X-Universal Library
5STO	;	1.55	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03A12 from the F2X-Universal Library
5STP	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03B02 from the F2X-Universal Library
5STQ	;	1.5	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03B03 from the F2X-Universal Library
5STR	;	1.45	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03B04 from the F2X-Universal Library
5STS	;	1.57	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03B11 from the F2X-Universal Library
5STT	;	1.49	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03C03 from the F2X-Universal Library
5STU	;	1.55	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03C07 from the F2X-Universal Library
5STV	;	1.5	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03C11 from the F2X-Universal Library
5STW	;	1.89	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03C12 from the F2X-Universal Library
5STX	;	1.5	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03D01 from the F2X-Universal Library
5STY	;	1.57	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03D02 from the F2X-Universal Library
5STZ	;	1.44	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03D04 from the F2X-Universal Library
5SU0	;	1.54	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03D07 from the F2X-Universal Library
5SU1	;	1.57	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03D08 from the F2X-Universal Library
5SU2	;	1.85	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03D10 from the F2X-Universal Library
5SU3	;	1.65	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03D12 from the F2X-Universal Library
5SU4	;	1.66	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03E02 from the F2X-Universal Library
5SU5	;	1.81	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03E05 from the F2X-Universal Library
5SU6	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03E08 from the F2X-Universal Library
5SU7	;	1.81	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03E12 from the F2X-Universal Library
5SU8	;	1.79	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03F01 from the F2X-Universal Library
5SU9	;	1.66	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03F06 from the F2X-Universal Library
5SUA	;	1.53	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03F12 from the F2X-Universal Library
5SUB	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03G01 from the F2X-Universal Library
5SUC	;	1.54	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03G02 from the F2X-Universal Library
5SUD	;	1.48	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03G05 from the F2X-Universal Library
5SUE	;	1.7	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03G10 from the F2X-Universal Library
5SUF	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03H03 from the F2X-Universal Library
5SUG	;	1.53	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03H05 from the F2X-Universal Library
7FJU	;	1.63	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03H10 from the F2X-Universal Library
7FJV	;	1.63	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03H10 from the F2X-Universal Library
7FJW	;	1.63	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P03H12 from the F2X-Universal Library
7FJX	;	1.59	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04A01 from the F2X-Universal Library
7FJY	;	1.63	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04A02 from the F2X-Universal Library
7FJZ	;	1.54	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04A04 from the F2X-Universal Library
7FK0	;	1.69	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04A05 from the F2X-Universal Library
7FK1	;	1.76	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04A06 from the F2X-Universal Library
7FK2	;	1.35	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04A07 from the F2X-Universal Library
7FK3	;	1.59	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04A09 from the F2X-Universal Library
7FK4	;	1.59	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04A11 from the F2X-Universal Library
7FK5	;	1.53	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04A12 from the F2X-Universal Library
7FK6	;	1.61	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04B02 from the F2X-Universal Library
7FK7	;	1.72	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04B04 from the F2X-Universal Library
7FK8	;	1.67	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04B07 from the F2X-Universal Library
7FK9	;	1.35	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04B12 from the F2X-Universal Library
7FKA	;	1.55	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04C04 from the F2X-Universal Library
7FKB	;	1.68	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04C07 from the F2X-Universal Library
7FKC	;	1.54	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04C10 from the F2X-Universal Library
7FKD	;	1.45	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04C11 from the F2X-Universal Library
7FKE	;	1.48	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04C12 from the F2X-Universal Library
7FKF	;	1.69	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04D04 from the F2X-Universal Library
7FKG	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04D05 from the F2X-Universal Library
7FKH	;	1.44	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04D06 from the F2X-Universal Library
7FKI	;	1.47	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04D08 from the F2X-Universal Library
7FKJ	;	1.74	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04D11 from the F2X-Universal Library
7FKK	;	1.63	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04D12 from the F2X-Universal Library
7FKL	;	1.63	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04E02 from the F2X-Universal Library
7FKM	;	1.53	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04E03 from the F2X-Universal Library
7FKN	;	1.55	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04E05 from the F2X-Universal Library
7FKO	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04E07 from the F2X-Universal Library
7FKP	;	1.52	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04E08 from the F2X-Universal Library
7FKQ	;	1.68	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04E09 from the F2X-Universal Library
7FKR	;	1.69	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04E11 from the F2X-Universal Library
7FKS	;	1.58	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04F01 from the F2X-Universal Library
7FKT	;	1.44	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04F02 from the F2X-Universal Library
7FKU	;	1.55	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04F03 from the F2X-Universal Library
7FKV	;	1.75	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04F08 from the F2X-Universal Library
7FKW	;	1.47	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04F09 from the F2X-Universal Library
7FKX	;	1.85	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04G02 from the F2X-Universal Library
7FKY	;	1.59	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04G05 from the F2X-Universal Library
7FKZ	;	1.58	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04G08 from the F2X-Universal Library
7FL0	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04G11 from the F2X-Universal Library
7FL1	;	1.55	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04H03 from the F2X-Universal Library
7FL2	;	1.58	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04H05 from the F2X-Universal Library
7FL3	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04H06 from the F2X-Universal Library
7FL4	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04H06 from the F2X-Universal Library
7FL5	;	1.89	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04H07 from the F2X-Universal Library
7FL6	;	1.58	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P04H10 from the F2X-Universal Library
7FL7	;	1.72	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05A01 from the F2X-Universal Library
7FL8	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05A03 from the F2X-Universal Library
7FL9	;	1.59	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05A08 from the F2X-Universal Library
7FLA	;	1.87	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05A09 from the F2X-Universal Library
7FLB	;	1.57	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05A10 from the F2X-Universal Library
7FLC	;	1.95	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05B08 from the F2X-Universal Library
7FLD	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05B11 from the F2X-Universal Library
7FLE	;	1.57	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05C05 from the F2X-Universal Library
7FLF	;	1.54	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05C06 from the F2X-Universal Library
7FLG	;	1.58	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05D01 from the F2X-Universal Library
7FLH	;	1.67	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05D03 from the F2X-Universal Library
7FLI	;	1.75	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05D09 from the F2X-Universal Library
7FLJ	;	1.47	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05E05 from the F2X-Universal Library
7FLK	;	1.62	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05E08 from the F2X-Universal Library
7FLL	;	1.48	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05E12 from the F2X-Universal Library
7FLM	;	1.55	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05F01 from the F2X-Universal Library
7FLN	;	1.57	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05F09 from the F2X-Universal Library
7FLO	;	1.58	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05F11 from the F2X-Universal Library
7FLP	;	1.58	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05F11 from the F2X-Universal Library
7FLQ	;	1.73	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05F12 from the F2X-Universal Library
7FLR	;	1.63	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05G01 from the F2X-Universal Library
7FLS	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05G02 from the F2X-Universal Library
7FLT	;	1.73	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05G04 from the F2X-Universal Library
7FLU	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05G05 from the F2X-Universal Library
7FLV	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05G05 from the F2X-Universal Library
7FLW	;	1.55	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05G07 from the F2X-Universal Library
7FLX	;	1.75	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05G08 from the F2X-Universal Library
7FLY	;	1.55	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05G10 from the F2X-Universal Library
7FLZ	;	1.52	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05G11 from the F2X-Universal Library
7FM0	;	1.61	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05H01 from the F2X-Universal Library
7FM1	;	1.5	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05H02 from the F2X-Universal Library
7FM2	;	1.72	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05H04 from the F2X-Universal Library
7FM3	;	1.65	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P05H09 from the F2X-Universal Library
7FM4	;	1.62	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06A01 from the F2X-Universal Library
7FM5	;	1.56	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06A02 from the F2X-Universal Library
7FM6	;	1.55	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06A03 from the F2X-Universal Library
7FM7	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06A04 from the F2X-Universal Library
7FM8	;	1.55	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06A09 from the F2X-Universal Library
7FM9	;	1.59	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06B02 from the F2X-Universal Library
7FMA	;	1.41	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06B04 from the F2X-Universal Library
7FMB	;	1.55	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06B06 from the F2X-Universal Library
7FMC	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06B07 from the F2X-Universal Library
7FMD	;	1.68	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06B12 from the F2X-Universal Library
7FME	;	1.44	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06C01 from the F2X-Universal Library
7FMF	;	1.65	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06C06 from the F2X-Universal Library
7FMG	;	1.71	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06C09 from the F2X-Universal Library
7FMH	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06C10 from the F2X-Universal Library
7FMI	;	1.34	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06C11 from the F2X-Universal Library
7FMJ	;	1.5	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06C12 from the F2X-Universal Library
7FMK	;	1.47	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06D03 from the F2X-Universal Library
7FML	;	1.58	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06D04 from the F2X-Universal Library
7FMM	;	1.69	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06D09 from the F2X-Universal Library
7FMN	;	1.6	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06D11 from the F2X-Universal Library
7FMO	;	1.67	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06D12 from the F2X-Universal Library
7FMP	;	1.72	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06E01 from the F2X-Universal Library
7FMQ	;	1.58	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06E04 from the F2X-Universal Library
7FMR	;	1.58	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06E05 from the F2X-Universal Library
7FMS	;	1.58	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06E05 from the F2X-Universal Library
7FMT	;	1.67	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06E09 from the F2X-Universal Library
7FMU	;	1.81	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06E11 from the F2X-Universal Library
7FMV	;	1.61	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06E12 from the F2X-Universal Library
7FMW	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06F06 from the F2X-Universal Library
7FMX	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06F06 from the F2X-Universal Library
7FMY	;	1.65	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06F07 from the F2X-Universal Library
7FMZ	;	1.67	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06F08 from the F2X-Universal Library
7FN0	;	1.59	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06G05 from the F2X-Universal Library
7FN1	;	1.44	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06G06 from the F2X-Universal Library
7FN2	;	1.62	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06G08 from the F2X-Universal Library
7FN3	;	1.63	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06G09 from the F2X-Universal Library
7FN4	;	1.72	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06G11 from the F2X-Universal Library
7FN5	;	1.69	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06H04 from the F2X-Universal Library
7FN6	;	1.5	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06H06 from the F2X-Universal Library
7FN7	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P06H08 from the F2X-Universal Library
7FN8	;	1.41	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07A01 from the F2X-Universal Library
7FN9	;	1.55	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07A05 from the F2X-Universal Library
7FNA	;	1.69	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07A11 from the F2X-Universal Library
7FNB	;	1.55	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07A12 from the F2X-Universal Library
7FNC	;	1.55	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07B01 from the F2X-Universal Library
7FND	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07B06 from the F2X-Universal Library
7FNE	;	1.57	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07B07 from the F2X-Universal Library
7FNF	;	1.54	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07B10 from the F2X-Universal Library
7FNG	;	1.6	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07B12 from the F2X-Universal Library
7FNH	;	1.57	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07C05 from the F2X-Universal Library
7FNI	;	1.55	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07C09 from the F2X-Universal Library
7FNJ	;	1.57	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07C10 from the F2X-Universal Library
7FNK	;	1.57	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07C12 from the F2X-Universal Library
7FNL	;	1.67	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07D01 from the F2X-Universal Library
7FNM	;	1.72	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07D05 from the F2X-Universal Library
7FNN	;	1.65	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07D07 from the F2X-Universal Library
7FNO	;	1.65	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07D12 from the F2X-Universal Library
7FNP	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07E01 from the F2X-Universal Library
7FNQ	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07E01 from the F2X-Universal Library
7FNR	;	1.6	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07E02 from the F2X-Universal Library
7FNS	;	1.45	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07E03 from the F2X-Universal Library
7FNT	;	1.61	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07E12 from the F2X-Universal Library
7FNU	;	1.54	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07F03 from the F2X-Universal Library
7FNV	;	1.54	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07F04 from the F2X-Universal Library
7FNW	;	1.9	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07F07 from the F2X-Universal Library
7FNX	;	1.72	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07F08 from the F2X-Universal Library
7FNY	;	1.71	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07F10 from the F2X-Universal Library
7FNZ	;	1.66	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07F12 from the F2X-Universal Library
7FO0	;	1.83	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07G02 from the F2X-Universal Library
7FO1	;	1.5	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07G03 from the F2X-Universal Library
7FO2	;	2.01	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07G04 from the F2X-Universal Library
7FO3	;	1.59	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07G06 from the F2X-Universal Library
7FO4	;	1.53	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07G08 from the F2X-Universal Library
7FO5	;	1.71	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07G11 from the F2X-Universal Library
7FO6	;	1.57	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07H04 from the F2X-Universal Library
7FO7	;	1.45	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07H05 from the F2X-Universal Library
7FO8	;	1.72	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07H06 from the F2X-Universal Library
7FO9	;	1.67	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07H07 from the F2X-Universal Library
7FOA	;	1.67	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07H07 from the F2X-Universal Library
7FOB	;	1.72	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P07H11 from the F2X-Universal Library
7FOC	;	1.9	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08A01 from the F2X-Universal Library
7FOD	;	1.59	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08A07 from the F2X-Universal Library
7FOE	;	1.65	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08A08 from the F2X-Universal Library
7FOF	;	1.77	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08A10 from the F2X-Universal Library
7FOG	;	1.41	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08B02 from the F2X-Universal Library
7FOH	;	1.69	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08B05 from the F2X-Universal Library
7FOI	;	1.55	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08B06 from the F2X-Universal Library
7FOJ	;	1.65	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08B08 from the F2X-Universal Library
7FOK	;	1.72	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08B09 from the F2X-Universal Library
7FOL	;	1.55	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08C01 from the F2X-Universal Library
7FOM	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08C04 from the F2X-Universal Library
7FON	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08C04 from the F2X-Universal Library
7FOO	;	1.59	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08C06 from the F2X-Universal Library
7FOP	;	1.66	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08C08 from the F2X-Universal Library
7FOQ	;	1.74	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08C10 from the F2X-Universal Library
7FOR	;	2.03	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08C12 from the F2X-Universal Library
7FOS	;	1.67	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08D01 from the F2X-Universal Library
7FOT	;	1.56	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08D03 from the F2X-Universal Library
7FOU	;	1.59	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08E01 from the F2X-Universal Library
7FOV	;	1.48	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08E03 from the F2X-Universal Library
7FOW	;	1.51	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08E04 from the F2X-Universal Library
7FOX	;	1.47	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08E08 from the F2X-Universal Library
7FOY	;	1.55	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08E10 from the F2X-Universal Library
7FOZ	;	1.83	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08F01 from the F2X-Universal Library
7FP0	;	1.54	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08F02 from the F2X-Universal Library
7FP1	;	1.43	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08F04 from the F2X-Universal Library
7FP2	;	1.64	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08F10 from the F2X-Universal Library
7FP3	;	1.76	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08F11 from the F2X-Universal Library
7FP4	;	1.45	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08G02 from the F2X-Universal Library
7FP5	;	1.53	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08G04 from the F2X-Universal Library
7FP6	;	1.61	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08G05 from the F2X-Universal Library
7FP7	;	1.47	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08G09 from the F2X-Universal Library
7FP8	;	1.59	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P08H12 from the F2X-Universal Library
7FP9	;	1.9	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P09A12 from the F2X-Universal Library
7FPA	;	1.86	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P09C01 from the F2X-Universal Library
7FPB	;	2.02	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P09C03 from the F2X-Universal Library
7FPC	;	1.55	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P09D07 from the F2X-Universal Library
7FPD	;	1.61	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P09E01 from the F2X-Universal Library
7FPE	;	1.55	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P09E03 from the F2X-Universal Library
7FPF	;	1.55	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P09E08 from the F2X-Universal Library
7FPG	;	1.6	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P09F06 from the F2X-Universal Library
7FPH	;	1.91	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P09G03 from the F2X-Universal Library
7FPI	;	1.63	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P10C11 from the F2X-Universal Library
7FPJ	;	1.59	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P10D05 from the F2X-Universal Library
7FPK	;	1.59	;	PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment P10E03 from the F2X-Universal Library
5QYL	;	1.56	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 01
5R0N	;	1.78	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 01, DMSO-free
5QYM	;	1.47	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 02
5R0O	;	1.86	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 02, DMSO-free
5QYN	;	1.65	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 03
5R0P	;	1.73	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 03, DMSO-free
5QYO	;	1.58	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 04
5R0Q	;	1.91	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 04, DMSO-free
5QYP	;	1.61	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 05
5R0R	;	1.73	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 05, DMSO-free
5QYQ	;	1.67	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 06
5R0S	;	1.81	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 06, DMSO-free
5QYR	;	1.54	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 07
5R0T	;	1.96	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 07, DMSO-free
5QYS	;	1.52	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 08
5R0U	;	1.86	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 08, DMSO-free
5QYT	;	1.52	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 09
5R0V	;	1.81	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 09, DMSO-free
5QYU	;	1.51	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 10
5R0W	;	1.86	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 10, DMSO-free
5QYV	;	1.59	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 11
5R0X	;	1.84	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 11, DMSO-free
5QYW	;	1.63	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 12
5R0Y	;	1.75	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 12, DMSO-free
5QYX	;	1.597	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 13
5R0Z	;	1.86	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 13, DMSO-free
5QYY	;	1.71	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 14
5R10	;	1.7	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 14, DMSO-free
5QYZ	;	1.37	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 15
5R11	;	1.82	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 15, DMSO-free
5QZ0	;	1.57	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 16
5R12	;	1.7	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 16, DMSO-free
5QZ1	;	1.58	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 17
5QZ2	;	1.54	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 17
5QZ3	;	1.53	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 18
5R13	;	1.87	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 18, DMSO-free
5QZ4	;	1.75	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 19
5R14	;	1.74	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 19, DMSO-free
5QZ5	;	1.51	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 20
5R15	;	1.79	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 20, DMSO-free
5QZ6	;	1.32	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 21
5R16	;	1.84	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 21, DMSO-free
5QZ7	;	1.48	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 22
5R17	;	1.87	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 22, DMSO-free
5QZ8	;	1.62	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 23
5R18	;	1.79	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 23, DMSO-free
5QZ9	;	1.43	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 24
5R19	;	1.7	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 24, DMSO-free
5QZA	;	1.51	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 25
5R1A	;	1.73	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 25, DMSO-free
5QZB	;	1.69	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 26
5R1B	;	1.89	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 26, DMSO-free
5QZC	;	1.72	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 27
5R1C	;	1.91	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 27, DMSO-free
5QZD	;	1.589	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 28
5R1D	;	1.82	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 28, DMSO-free
5QZE	;	1.55	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 29
5R1E	;	1.7	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 29, DMSO-free
5QZF	;	1.68	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 30
5R1F	;	1.8	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 30, DMSO-free
5QZG	;	1.55	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 31
5R1G	;	1.81	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 31, DMSO-free
5QZH	;	1.77	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 32
5R1H	;	2.06	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 32, DMSO-free
5QZI	;	1.51	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 33
5R1I	;	2.01	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 33, DMSO-free
5QZJ	;	1.51	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 34
5R1J	;	1.96	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 34, DMSO-free
5QZK	;	1.73	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 35
5R1K	;	1.99	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 35, DMSO-free
5QZL	;	1.54	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 36
5R1L	;	1.94	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 36, DMSO-free
5QZM	;	1.66	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 37
5R1M	;	1.9	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 37, DMSO-free
5QZN	;	1.44	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 38
5R1N	;	1.94	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 38, DMSO-free
5QZO	;	1.39	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 39
5R1O	;	1.9	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 39, DMSO-free
5QZP	;	1.5	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 40
5R1P	;	1.95	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 40, DMSO-free
5QZQ	;	2.11	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 41
5R1Q	;	1.86	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 41, DMSO-free
5QZR	;	1.59	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 42
5R1S	;	2.05	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 42, DMSO-free
5QZS	;	1.58	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 43
5QZT	;	1.535	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 44
5QZU	;	1.54	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 45
5QZV	;	2.11	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 46
5QZW	;	1.36	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 47
5QZX	;	1.55	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 48
5QZY	;	1.66	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 49
5QZZ	;	1.59	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 50
5R00	;	1.72	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 51
5R01	;	1.72	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 52
5R02	;	1.66	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 53
5R03	;	1.51	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 54
5R04	;	1.34	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 55
5R05	;	1.57	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 56
5R06	;	1.67	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 57
5R07	;	1.71	;	PanDDA analysis group deposition -- Auto-refined data of Aar2/RNaseH for ground state model 58
5R2E	;	1.098	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 01, DMSO-Free
5R2F	;	1.119	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 02, DMSO-Free
5R2G	;	0.998	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 03, DMSO-Free
5R2H	;	1.018	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 04, DMSO-Free
5R2I	;	1.008	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 05, DMSO-Free
5R2J	;	1.007	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 06, DMSO-Free
5R2K	;	1.029	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 07, DMSO-Free
5R2L	;	0.999	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 09, DMSO-Free
5R2M	;	1.008	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 10, DMSO-Free
5R2N	;	1.078	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 11, DMSO-Free
5R2O	;	0.969	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 12, DMSO-Free
5R2P	;	1.179	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 13, DMSO-Free
5R2Q	;	1.038	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 14, DMSO-Free
5R2R	;	1.048	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 15, DMSO-Free
5R2S	;	1.149	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 16, DMSO-Free
5R2T	;	1.009	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 17, DMSO-Free
5R2U	;	1.138	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 18, DMSO-Free
5R2V	;	1.048	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 19, DMSO-Free
5R2W	;	1.285	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 20, DMSO-Free
5R2X	;	1.129	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 21, DMSO-Free
5R2Y	;	1.008	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 22, DMSO-Free
5R2Z	;	0.969	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 23, DMSO-Free
5R30	;	1.038	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 24, DMSO-Free
5R31	;	0.92	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 25, DMSO-Free
5R32	;	0.9	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 26, DMSO-Free
5R33	;	0.92	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 27, DMSO-Free
5R34	;	0.999	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 28, DMSO-Free
5R35	;	0.91	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 29, DMSO-Free
5R36	;	1.008	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 30, DMSO-Free
5R37	;	1.038	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 31, DMSO-Free
5R38	;	1.076	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 32, DMSO-Free
5R39	;	0.919	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 33, DMSO-Free
5R3A	;	1.088	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 34, DMSO-Free
5R3B	;	1.17	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 35, DMSO-Free
5R3C	;	0.949	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 36, DMSO-Free
5R3D	;	0.979	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 37, DMSO-Free
5R3E	;	1.008	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 38, DMSO-Free
5R3F	;	1.187	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 39, DMSO-Free
5R3G	;	1.106	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 40, DMSO-Free
5R3H	;	1.039	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 41, DMSO-Free
5R3I	;	1.039	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 42, DMSO-Free
5R3J	;	1.077	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 43, DMSO-Free
5R3K	;	1.207	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 44, DMSO-Free
5R3L	;	0.94	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 45, DMSO-Free
5R3M	;	1.038	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 46, DMSO-Free
5R3N	;	1.059	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 47, DMSO-Free
5R3O	;	1.217	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 48, DMSO-Free
5R3P	;	1.077	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 49, DMSO-Free
5R3Q	;	1.009	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 50, DMSO-Free
5R3R	;	0.979	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 51, DMSO-Free
5R3S	;	1.048	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 52, DMSO-Free
5R3T	;	1.069	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 53, DMSO-Free
5R3U	;	1.088	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 54, DMSO-Free
5R3V	;	1.118	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 55, DMSO-Free
5R3W	;	1.188	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 56, DMSO-Free
5R3X	;	1.165	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 57, DMSO-Free
5R3Y	;	1.038	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 58, DMSO-Free
5R3Z	;	1.067	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 59, DMSO-Free
5R40	;	1.069	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 60, DMSO-Free
5R41	;	1.077	;	PanDDA analysis group deposition -- Auto-refined data of Endothiapepsin for ground state model 61, DMSO-Free
8OGN	;	1.29	;	PanDDA analysis group deposition -- CdaA in complex with fragment F2X-Entry A09
8OGO	;	1.21	;	PanDDA analysis group deposition -- CdaA in complex with fragment F2X-Entry A12
8OGP	;	1.22	;	PanDDA analysis group deposition -- CdaA in complex with fragment F2X-Entry B03
8OGQ	;	1.42	;	PanDDA analysis group deposition -- CdaA in complex with fragment F2X-Entry B06
8OGR	;	1.35	;	PanDDA analysis group deposition -- CdaA in complex with fragment F2X-Entry B07
8OGS	;	1.25	;	PanDDA analysis group deposition -- CdaA in complex with fragment F2X-Entry B08
8OGT	;	1.5	;	PanDDA analysis group deposition -- CdaA in complex with fragment F2X-Entry C04
8OGU	;	1.41	;	PanDDA analysis group deposition -- CdaA in complex with fragment F2X-Entry C07
8OGV	;	1.25	;	PanDDA analysis group deposition -- CdaA in complex with fragment F2X-Entry C08
8OGW	;	1.17	;	PanDDA analysis group deposition -- CdaA in complex with fragment F2X-Entry D02
8OGY	;	1.23	;	PanDDA analysis group deposition -- CdaA in complex with fragment F2X-Entry D04
8OGZ	;	1.14	;	PanDDA analysis group deposition -- CdaA in complex with fragment F2X-Entry D06
8OH0	;	1.27	;	PanDDA analysis group deposition -- CdaA in complex with fragment F2X-Entry D08
8OH1	;	1.22	;	PanDDA analysis group deposition -- CdaA in complex with fragment F2X-Entry E04
8OHB	;	1.11	;	PanDDA analysis group deposition -- CdaA in complex with fragment F2X-Entry E08
8OHC	;	1.17	;	PanDDA analysis group deposition -- CdaA in complex with fragment F2X-Entry E12
8OHE	;	1.15	;	PanDDA analysis group deposition -- CdaA in complex with fragment F2X-Entry F03
8OHF	;	1.22	;	PanDDA analysis group deposition -- CdaA in complex with fragment F2X-Entry F04
8OHG	;	1.25	;	PanDDA analysis group deposition -- CdaA in complex with fragment F2X-Entry F09
8OHH	;	1.3	;	PanDDA analysis group deposition -- CdaA in complex with fragment F2X-Entry G05
8OHJ	;	1.22	;	PanDDA analysis group deposition -- CdaA in complex with fragment F2X-Entry G08
8OHK	;	1.26	;	PanDDA analysis group deposition -- CdaA in complex with fragment F2X-Entry H01
8OHL	;	1.29	;	PanDDA analysis group deposition -- CdaA in complex with fragment F2X-Entry H09
8OHO	;	1.32	;	PanDDA analysis group deposition -- CdaA in complex with fragment F2X-Entry H11
5QXL	;	1.57	;	PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with DF776
5QXM	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with DF789
5QXN	;	1.41	;	PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with DF826
5QXO	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with DF848
5QXR	;	1.66	;	PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with DF849
5QXS	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with DF852
5QXZ	;	1.64	;	PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with DF853
5QXT	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with JKH47
5QXY	;	1.54	;	PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with JKH93A
5QXJ	;	1.46	;	PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with PC578
5QXK	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with PC581
5QXI	;	1.64	;	PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with PC587
5QY0	;	1.89	;	PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with PC591
5QXV	;	1.74	;	PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with PC631
5QXW	;	1.78	;	PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with RZ189
5R4E	;	1.83	;	PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with RZ201
5QXU	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with RZ373
5QXX	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with RZ99
5QXP	;	1.41	;	PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with TCJ732
5QXQ	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with TCJ779
5PBG	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 1)
5PBP	;	1.88	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 10)
5PE7	;	1.81	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 100)
5PE8	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 101)
5PE9	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 102)
5PEA	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 103)
5PEB	;	2.11	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 104)
5PEC	;	1.85	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 105)
5PED	;	1.8	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 106)
5PEE	;	1.75	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 107)
5PEF	;	1.73	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 108)
5PEG	;	1.69	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 109)
5PBQ	;	1.93	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 11)
5PEH	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 110)
5PEI	;	1.66	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 111)
5PEJ	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 112)
5PEK	;	1.79	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 113)
5PEL	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 114)
5PEM	;	1.97	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 115)
5PEN	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 116)
5PEO	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 118)
5PEQ	;	1.75	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 119)
5PBR	;	1.81	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 12)
5PER	;	2.0	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 120)
5PES	;	1.8	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 121)
5PET	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 122)
5PEU	;	1.9	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 123)
5PEV	;	1.81	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 124)
5PEW	;	1.77	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 125)
5PEX	;	1.79	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 126)
5PEY	;	1.8	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 127)
5PEZ	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 128)
5PF0	;	1.95	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 129)
5PBS	;	1.77	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 13)
5PF1	;	1.78	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 130)
5PF2	;	1.89	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 131)
5PF3	;	1.83	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 132)
5PF4	;	2.01	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 133)
5PF5	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 134)
5PF6	;	1.75	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 135)
5PF7	;	1.79	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 136)
5PF8	;	1.78	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 137)
5PF9	;	1.91	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 138)
5PFA	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 139)
5PBT	;	1.79	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 14)
5PFB	;	1.8	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 140)
5PFC	;	1.75	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 141)
5PFD	;	1.88	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 142)
5PFE	;	1.79	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 143)
5PFF	;	1.96	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 144)
5PFG	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 145)
5PFH	;	1.66	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 146)
5PFI	;	1.66	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 147)
5PFJ	;	2.07	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 148)
5PFL	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 149)
5PBU	;	1.88	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 15)
5PFM	;	1.54	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 150)
5PFN	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 151)
5PFO	;	1.82	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 152)
5PFP	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 153)
5PFQ	;	1.78	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 154)
5PFR	;	1.89	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 155)
5PFS	;	2.0	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 156)
5PFT	;	2.02	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 157)
5PFU	;	1.75	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 158)
5PFV	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 159)
5PBV	;	1.74	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 16)
5PFW	;	1.64	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 160)
5PFX	;	1.9	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 161)
5PFY	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 162)
5PFZ	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 163)
5PG0	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 164)
5PG1	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 165)
5PG2	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 166)
5PG3	;	1.66	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 167)
5PG4	;	2.49	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 168)
5PG5	;	1.75	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 169)
5PBW	;	1.84	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 17)
5PG6	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 170)
5PG7	;	1.96	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 171)
5PG8	;	1.69	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 172)
5PG9	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 173)
5PGA	;	1.59	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 174)
5PGB	;	1.57	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 175)
5PGC	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 176)
5PGD	;	1.79	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 177)
5PGE	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 178)
5PGF	;	1.82	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 179)
5PBX	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 18)
5PGG	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 180)
5PGH	;	1.93	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 181)
5PGI	;	1.88	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 182)
5PGJ	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 183)
5PGK	;	1.83	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 184)
5PGL	;	2.23	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 185)
5PGN	;	1.79	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 186)
5PGO	;	1.88	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 187)
5PGP	;	1.76	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 188)
5PGQ	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 189)
5PBY	;	1.75	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 19)
5PGR	;	2.0	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 190)
5PGS	;	1.64	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 191)
5PGT	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 192)
5PBH	;	1.69	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 2)
5PBZ	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 20)
5PC0	;	1.79	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 21)
5PC1	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 22)
5PC2	;	1.79	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 23)
5PC3	;	1.8	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 24)
5PC4	;	1.86	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 25)
5PC5	;	1.85	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 26)
5PC6	;	1.74	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 27)
5PC7	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 28)
5PC8	;	1.85	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 29)
5PBI	;	1.78	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 3)
5PC9	;	1.76	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 30)
5PCA	;	1.84	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 31)
5PCB	;	1.8	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 32)
5PCC	;	1.83	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 33)
5PCD	;	1.76	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 34)
5PCE	;	2.16	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 35)
5PCF	;	2.02	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 36)
5PCG	;	1.98	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 37)
5PCH	;	1.75	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 38)
5PCI	;	1.88	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 39)
5PBJ	;	1.79	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 4)
5PCJ	;	1.97	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 40)
5PCK	;	1.75	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 41)
5PCL	;	2.19	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 42)
5PCM	;	1.69	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 43)
5PCN	;	1.84	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 44)
5PCO	;	1.77	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 45)
5PCP	;	1.69	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 46)
5PCQ	;	2.29	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 47)
5PCR	;	1.9	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 48)
5PCS	;	1.83	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 49)
5PBK	;	1.77	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 5)
5PCT	;	1.78	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 50)
5PCU	;	1.75	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 51)
5PCV	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 52)
5PCW	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 53)
5PCX	;	1.79	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 54)
5PCZ	;	1.84	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 55)
5PD0	;	1.84	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 56)
5PD1	;	1.79	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 57)
5PD2	;	1.79	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 58)
5PD3	;	1.69	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 59)
5PBL	;	1.84	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 6)
5PD4	;	1.8	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 60)
5PD5	;	1.89	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 61)
5PD6	;	2.01	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 62)
5PD7	;	1.69	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 63)
5PD8	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 64)
5PD9	;	1.86	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 65)
5PDA	;	1.77	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 66)
5PDB	;	1.8	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 67)
5PDC	;	1.74	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 68)
5PDD	;	1.77	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 69)
5PBM	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 7)
5PDE	;	1.88	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 70)
5PDF	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 71)
5PDG	;	1.63	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 72)
5PDH	;	1.78	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 73)
5PDI	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 74)
5PDJ	;	1.84	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 76)
5PDK	;	1.74	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 77)
5PDL	;	1.8	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 78)
5PDM	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 79)
5PBN	;	1.86	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 8)
5PDN	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 80)
5PDO	;	1.78	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 81)
5PDP	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 82)
5PDQ	;	2.26	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 83)
5PDR	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 84)
5PDS	;	1.78	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 85)
5PDT	;	1.79	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 86)
5PDU	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 87)
5PDV	;	1.69	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 88)
5PDW	;	1.88	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 89)
5PBO	;	1.95	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 9)
5PDX	;	1.69	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 90)
5PDY	;	1.93	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 91)
5PDZ	;	1.9	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 92)
5PE0	;	1.76	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 93)
5PE1	;	1.91	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 94)
5PE2	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 95)
5PE3	;	1.76	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 96)
5PE4	;	1.74	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 97)
5PE5	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 98)
5PE6	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 99)
5PBE	;	1.835	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B in complex with N09428a
5PB7	;	1.655	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B in complex with N09440a
5PBA	;	1.925	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B in complex with N09460a
5PBB	;	1.783	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B in complex with N09496a
5PB9	;	1.782	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B in complex with N09521a
5PB8	;	1.649	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B in complex with N09522a
5PBF	;	1.801	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B in complex with N09645a
5PBD	;	1.776	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B in complex with N09682a
5PBC	;	1.771	;	PanDDA analysis group deposition -- Crystal Structure of BAZ2B in complex with N09724a
5PP1	;	2.35	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 1)
5PPA	;	1.91	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 10)
5PRT	;	1.89	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 100)
5PRU	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 101)
5PRV	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 102)
5PRW	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 103)
5PRX	;	1.87	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 104)
5PRY	;	1.8	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 105)
5PRZ	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 106)
5PS0	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 107)
5PS1	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 108)
5PS2	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 109)
5PPB	;	1.48	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 11)
5PS3	;	1.93	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 110)
5PS4	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 111)
5PS5	;	2.15	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 113)
5PS6	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 114)
5PS7	;	2.21	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 115)
5PS8	;	1.93	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 116)
5PS9	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 117)
5PSA	;	1.64	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 118)
5PSB	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 119)
5PPC	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 12)
5PSC	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 120)
5PSD	;	1.63	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 121)
5PSE	;	2.19	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 122)
5PSF	;	2.31	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 123)
5PSG	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 124)
5PSH	;	3.43	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 125)
5PSI	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 126)
5PSJ	;	1.38	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 127)
5PSK	;	1.38	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 128)
5PSL	;	1.39	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 129)
5PPD	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 13)
5PSM	;	1.53	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 130)
5PSN	;	1.48	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 131)
5PSO	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 132)
5PSP	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 133)
5PSQ	;	1.43	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 134)
5PSR	;	1.59	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 135)
5PSS	;	1.59	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 136)
5PST	;	1.39	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 137)
5PSU	;	1.56	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 138)
5PSV	;	1.53	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 139)
5PPE	;	1.46	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 14)
5PSW	;	1.53	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 140)
5PSX	;	1.59	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 141)
5PSY	;	1.82	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 142)
5PSZ	;	1.53	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 143)
5PT0	;	1.43	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 144)
5PT1	;	1.54	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 145)
5PT2	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 146)
5PT3	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 147)
5PT4	;	1.54	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 148)
5PT5	;	1.76	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 149)
5PT6	;	1.53	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 150)
5PT7	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 151)
5PT8	;	1.66	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 152)
5PT9	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 153)
5PTA	;	2.19	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 154)
5PTB	;	1.88	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 155)
5PTC	;	1.78	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 156)
5PTE	;	1.63	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 157)
5PTF	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 158)
5PTG	;	1.46	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 159)
5PPF	;	1.64	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 16)
5PTH	;	1.56	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 160)
5PTJ	;	1.69	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 161)
5PTK	;	1.48	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 162)
5PTL	;	1.53	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 163)
5PTM	;	1.41	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 164)
5PTN	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 165)
5PTO	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 167)
5PTQ	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 168)
5PTR	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 169)
5PPG	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 17)
5PTS	;	1.45	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 170)
5PTT	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 171)
5PTU	;	1.69	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 172)
5PTV	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 173)
5PTW	;	1.82	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 174)
5PTX	;	1.6	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 175)
5PTY	;	2.1	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 176)
5PTZ	;	1.51	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 177)
5PU0	;	1.89	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 178)
5PU1	;	1.73	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 179)
5PPH	;	1.89	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 18)
5PU2	;	1.59	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 180)
5PU3	;	2.37	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 181)
5PU4	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 182)
5PU5	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 183)
5PU6	;	1.74	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 184)
5PU7	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 185)
5PU8	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 186)
5PU9	;	1.56	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 187)
5PUA	;	1.63	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 188)
5PUB	;	2.23	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 189)
5PPI	;	1.56	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 19)
5PUC	;	1.64	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 190)
5PUD	;	2.01	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 191)
5PUE	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 192)
5PUF	;	1.82	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 193)
5PUG	;	2.0	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 194)
5PUH	;	1.92	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 195)
5PUI	;	1.51	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 196)
5PUJ	;	1.9	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 197)
5PUK	;	1.64	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 198)
5PUL	;	1.95	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 199)
5PP2	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 2)
5PPJ	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 20)
5PUM	;	2.15	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 200)
5PUN	;	1.84	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 201)
5PUO	;	2.06	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 202)
5PUP	;	1.6	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 203)
5PUQ	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 204)
5PUR	;	1.73	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 205)
5PUS	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 206)
5PUT	;	2.32	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 207)
5PUU	;	1.69	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 208)
5PUV	;	1.69	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 209)
5PPK	;	1.87	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 21)
5PUW	;	1.82	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 210)
5PUX	;	1.51	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 211)
5PUY	;	2.01	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 212)
5PUZ	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 213)
5PV0	;	1.76	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 214)
5PV1	;	1.73	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 215)
5PV2	;	1.63	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 216)
5PV3	;	1.48	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 217)
5PV4	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 218)
5PV5	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 219)
5PPL	;	1.63	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 22)
5PV6	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 220)
5PV7	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 221)
5PV8	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 222)
5PV9	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 223)
5PVA	;	1.98	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 224)
5PVB	;	1.53	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 225)
5PVC	;	1.56	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 226)
5PVD	;	1.53	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 227)
5PVE	;	2.29	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 228)
5PVF	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 229)
5PPM	;	1.87	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 23)
5PVG	;	1.69	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 230)
5PVH	;	1.69	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 232)
5PVI	;	2.19	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 233)
5PVJ	;	1.57	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 234)
5PVK	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 235)
5PVL	;	1.53	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 236)
5PVM	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 237)
5PVN	;	1.63	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 238)
5PVO	;	1.96	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 239)
5PPN	;	1.8	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 24)
5PVP	;	1.69	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 240)
5PVQ	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 241)
5PVR	;	1.57	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 242)
5PVS	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 243)
5PVT	;	1.48	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 244)
5PVU	;	3.01	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 245)
5PVV	;	1.8	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 246)
5PVW	;	2.18	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 247)
5PVX	;	1.74	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 248)
5PVY	;	2.49	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 249)
5PPO	;	1.84	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 25)
5PVZ	;	1.64	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 250)
5PW0	;	2.13	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 251)
5PW1	;	1.57	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 252)
5PW2	;	2.32	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 253)
5PW3	;	2.21	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 254)
5PW4	;	1.91	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 255)
5PW5	;	2.09	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 256)
5PW6	;	2.75	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 257)
5PW7	;	1.85	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 258)
5PW8	;	2.08	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 259)
5PPP	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 26)
5PW9	;	3.44	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 260)
5PWA	;	1.86	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 261)
5PWB	;	2.09	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 262)
5PPQ	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 27)
5PPR	;	2.69	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 28)
5PPS	;	1.53	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 29)
5PP3	;	2.58	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 3)
5PPT	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 30)
5PPU	;	1.63	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 31)
5PPV	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 32)
5PPW	;	1.45	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 33)
5PPX	;	1.44	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 34)
5PPY	;	1.45	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 35)
5PPZ	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 36)
5PQ0	;	1.81	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 37)
5PQ1	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 38)
5PQ2	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 39)
5PP4	;	1.92	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 4)
5PQ3	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 40)
5PQ4	;	1.63	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 41)
5PQ5	;	1.6	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 42)
5PQ6	;	1.64	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 43)
5PQ7	;	1.56	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 44)
5PQ8	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 45)
5PQ9	;	1.6	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 46)
5PQA	;	1.78	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 47)
5PQB	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 48)
5PQC	;	1.45	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 49)
5PP5	;	1.87	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 5)
5PQD	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 50)
5PQE	;	1.53	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 51)
5PQF	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 52)
5PQG	;	1.82	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 53)
5PQH	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 54)
5PQI	;	1.33	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 55)
5PQJ	;	1.59	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 56)
5PQK	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 57)
5PQL	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 58)
5PQM	;	2.56	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 59)
5PP6	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 6)
5PQN	;	2.0	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 60)
5PQO	;	1.75	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 61)
5PQP	;	1.97	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 62)
5PQQ	;	2.3	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 63)
5PQR	;	2.43	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 64)
5PQS	;	1.82	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 65)
5PQT	;	1.89	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 66)
5PQU	;	2.0	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 67)
5PQV	;	1.97	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 68)
5PQW	;	2.0	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 69)
5PP7	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 7)
5PQX	;	1.95	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 70)
5PQY	;	1.89	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 71)
5PQZ	;	2.58	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 72)
5PR0	;	2.23	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 73)
5PR1	;	2.1	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 74)
5PR2	;	2.1	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 75)
5PR4	;	1.82	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 77)
5PR5	;	1.95	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 78)
5PR6	;	1.8	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 79)
5PP8	;	1.74	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 8)
5PR7	;	1.8	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 80)
5PR8	;	1.92	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 81)
5PR9	;	1.82	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 82)
5PRA	;	1.87	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 83)
5PRB	;	2.23	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 84)
5PRD	;	1.9	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 85)
5PRE	;	1.73	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 86)
5PRF	;	1.82	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 87)
5PRG	;	2.68	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 88)
5PRH	;	1.95	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 89)
5PP9	;	1.82	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 9)
5PRI	;	1.9	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 90)
5PRJ	;	2.17	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 91)
5PRK	;	2.23	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 92)
5PRL	;	1.75	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 93)
5PRM	;	3.58	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 94)
5PRO	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 95)
5PRP	;	1.45	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 96)
5PRQ	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 97)
5PRR	;	1.63	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 98)
5PRS	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 99)
5POB	;	1.779	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with E13683b
5POD	;	1.56	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N07807b
5PO8	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N07808b
5PO9	;	2.116	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N07950b
5PNX	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10128a
5PO2	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10132a
5PO0	;	1.458	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10146a
5PO1	;	1.517	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10152a
5PO6	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10157a
5PNZ	;	1.557	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10162a
5PO3	;	1.699	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10164a
5PO4	;	1.487	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10170a
5PNY	;	1.479	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10174a
5POA	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10186a
5POE	;	1.518	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10188a and N07807b
5PO5	;	1.439	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10192a
5POW	;	1.768	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10894b
5POK	;	1.56	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10908a
5POS	;	1.75	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10919a
5POT	;	1.628	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10931a
5POF	;	2.27	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10941a
5POJ	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10941a
5POU	;	1.43	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10954a
5POM	;	1.54	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10958a
5POO	;	1.499	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10966a
5POL	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10971a
5POQ	;	1.97	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10974a
5PON	;	1.519	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10980a
5POR	;	1.578	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10982a
5POP	;	1.579	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10987a
5PP0	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N11009a
5POI	;	2.365	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N11016a
5POH	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N11029a
5POY	;	1.758	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N11029a
5POZ	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N11039a
5POG	;	1.77	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N11063a
5POV	;	1.57	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N11063a
5POX	;	1.75	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N11075a
5POC	;	1.478	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N11081a
5PO7	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N11083a
5R81	;	1.95	;	PanDDA analysis group deposition -- Crystal Structure of COVID-19 main protease in complex with Z1367324110
5R82	;	1.31	;	PanDDA analysis group deposition -- Crystal Structure of COVID-19 main protease in complex with Z219104216
5R84	;	1.83	;	PanDDA analysis group deposition -- Crystal Structure of COVID-19 main protease in complex with Z31792168
5R7Y	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of COVID-19 main protease in complex with Z45617795
5Q2A	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 1)
5Q2I	;	2.33	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 10)
5Q4Z	;	1.6	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 100)
5Q50	;	2.0	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 101)
5Q51	;	1.34	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 102)
5Q52	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 103)
5Q53	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 104)
5Q54	;	1.3	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 105)
5Q55	;	1.39	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 106)
5Q56	;	1.87	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 107)
5Q57	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 108)
5Q58	;	1.75	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 109)
5Q2J	;	1.3	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 11)
5Q59	;	1.86	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 110)
5Q5A	;	2.26	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 111)
5Q5B	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 112)
5Q5C	;	1.38	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 113)
5Q5D	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 114)
5Q5E	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 115)
5Q5F	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 116)
5Q5G	;	2.0	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 117)
5Q5H	;	1.36	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 118)
5Q5I	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 119)
5Q2K	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 12)
5Q5J	;	2.0	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 120)
5Q5K	;	2.81	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 121)
5Q5L	;	2.0	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 122)
5Q5M	;	1.57	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 123)
5Q5N	;	2.42	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 124)
5Q5O	;	2.07	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 125)
5Q5P	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 126)
5Q5Q	;	1.45	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 127)
5Q5R	;	1.39	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 128)
5Q5S	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 129)
5Q2L	;	1.42	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 13)
5Q5T	;	1.8	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 130)
5Q5U	;	1.88	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 131)
5Q5V	;	1.86	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 132)
5Q5W	;	1.42	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 133)
5Q5X	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 134)
5Q5Y	;	1.82	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 135)
5Q5Z	;	1.48	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 136)
5Q60	;	1.4	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 137)
5Q61	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 138)
5Q62	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 139)
5Q2M	;	1.28	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 14)
5Q63	;	1.82	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 140)
5Q64	;	1.42	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 141)
5Q65	;	1.78	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 142)
5Q66	;	1.51	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 143)
5Q67	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 144)
5Q68	;	1.86	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 145)
5Q69	;	1.84	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 146)
5Q6A	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 147)
5Q6B	;	2.62	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 148)
5Q6C	;	1.53	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 149)
5Q2N	;	1.38	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 15)
5Q6D	;	1.48	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 150)
5Q6E	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 151)
5Q6F	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 152)
5Q6G	;	1.48	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 153)
5Q6H	;	1.42	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 154)
5Q6I	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 155)
5Q6J	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 156)
5Q6K	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 157)
5Q6L	;	1.82	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 158)
5Q6M	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 159)
5Q2O	;	1.75	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 16)
5Q6N	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 160)
5Q6O	;	1.4	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 161)
5Q6P	;	1.54	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 162)
5Q6Q	;	1.36	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 163)
5Q6R	;	1.42	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 164)
5Q6S	;	1.56	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 165)
5Q6T	;	1.59	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 166)
5Q6U	;	1.33	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 167)
5Q6V	;	1.29	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 168)
5Q6W	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 169)
5Q2P	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 17)
5Q6X	;	1.43	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 170)
5Q6Y	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 171)
5Q6Z	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 172)
5Q70	;	1.31	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 173)
5Q71	;	2.0	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 174)
5Q72	;	1.31	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 175)
5Q73	;	1.36	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 176)
5Q74	;	1.21	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 177)
5Q75	;	1.36	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 178)
5Q76	;	1.28	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 179)
5Q2Q	;	1.44	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 18)
5Q77	;	2.0	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 180)
5Q78	;	1.25	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 181)
5Q79	;	1.83	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 182)
5Q7A	;	1.39	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 183)
5Q7B	;	1.25	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 184)
5Q7C	;	1.2	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 185)
5Q7D	;	1.32	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 186)
5Q7E	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 187)
5Q7F	;	1.64	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 188)
5Q7G	;	2.0	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 189)
5Q2R	;	1.37	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 19)
5Q7H	;	2.0	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 190)
5Q7I	;	1.26	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 191)
5Q7J	;	1.54	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 192)
5Q7K	;	2.0	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 193)
5Q7L	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 194)
5Q7M	;	1.26	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 195)
5Q7N	;	2.0	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 196)
5Q7O	;	1.32	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 197)
5Q7P	;	2.0	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 198)
5Q7Q	;	1.76	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 199)
5Q2S	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 20)
5Q7R	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 200)
5Q7S	;	1.31	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 201)
5Q7T	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 202)
5Q7U	;	2.11	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 203)
5Q7V	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 204)
5Q7W	;	1.27	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 205)
5Q7X	;	1.69	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 206)
5Q7Y	;	1.39	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 207)
5Q7Z	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 208)
5Q80	;	1.43	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 209)
5Q2T	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 21)
5Q81	;	1.51	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 210)
5Q82	;	1.2	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 211)
5Q83	;	1.28	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 212)
5Q84	;	1.88	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 213)
5Q85	;	1.8	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 214)
5Q86	;	1.31	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 215)
5Q87	;	1.34	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 216)
5Q88	;	1.78	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 217)
5Q89	;	1.91	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 218)
5Q8A	;	1.43	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 219)
5Q2U	;	1.37	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 22)
5Q8B	;	1.63	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 220)
5Q8C	;	2.0	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 221)
5Q8D	;	1.23	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 222)
5Q8E	;	1.63	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 223)
5Q8F	;	1.36	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 224)
5Q8G	;	2.0	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 225)
5Q8H	;	1.9	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 227)
5Q8I	;	1.35	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 228)
5Q8J	;	1.79	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 229)
5Q2V	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 23)
5Q8K	;	1.79	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 230)
5Q8L	;	1.42	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 231)
5Q8M	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 232)
5Q8N	;	1.41	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 233)
5Q8O	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 234)
5Q8P	;	1.45	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 235)
5Q8Q	;	1.89	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 236)
5Q8R	;	1.9	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 237)
5Q8S	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 238)
5Q8T	;	2.0	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 239)
5Q2W	;	1.53	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 24)
5Q8U	;	1.54	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 240)
5Q8V	;	1.32	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 241)
5Q8W	;	1.57	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 242)
5Q8X	;	1.23	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 243)
5Q8Y	;	1.51	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 244)
5Q8Z	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 245)
5Q90	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 246)
5Q91	;	1.46	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 247)
5Q92	;	2.11	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 248)
5Q93	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 249)
5Q2X	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 25)
5Q94	;	1.9	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 250)
5Q95	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 251)
5Q96	;	1.83	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 252)
5Q97	;	1.97	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 253)
5Q98	;	1.76	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 254)
5Q99	;	1.31	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 255)
5Q9A	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 256)
5Q9B	;	1.45	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 257)
5Q9C	;	1.46	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 258)
5Q9D	;	1.69	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 259)
5Q2Y	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 26)
5Q9E	;	1.45	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 260)
5Q9F	;	1.28	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 261)
5Q9G	;	1.6	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 262)
5Q9H	;	1.81	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 263)
5Q9I	;	1.46	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 264)
5Q9J	;	1.76	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 265)
5Q9K	;	1.78	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 266)
5Q9L	;	1.59	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 267)
5Q9M	;	1.3	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 268)
5Q9N	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 269)
5Q2Z	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 27)
5Q9O	;	1.37	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 270)
5Q9P	;	1.48	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 271)
5Q9Q	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 272)
5Q9R	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 273)
5Q9S	;	1.43	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 274)
5Q9T	;	1.37	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 275)
5Q9U	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 276)
5Q9V	;	1.43	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 277)
5Q9W	;	1.53	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 278)
5Q9X	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 279)
5Q30	;	1.8	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 28)
5Q9Y	;	1.64	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 280)
5Q9Z	;	1.77	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 281)
5QA0	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 282)
5QA1	;	1.46	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 283)
5QA2	;	1.56	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 284)
5Q31	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 29)
5Q2B	;	1.33	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 3)
5Q32	;	1.87	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 30)
5Q33	;	1.37	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 31)
5Q34	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 32)
5Q35	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 33)
5Q36	;	1.39	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 34)
5Q37	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 35)
5Q38	;	1.39	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 36)
5Q39	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 37)
5Q3A	;	1.48	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 38)
5Q3B	;	2.52	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 39)
5Q2C	;	1.53	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 4)
5Q3C	;	1.41	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 40)
5Q3D	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 41)
5Q3E	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 42)
5Q3F	;	1.39	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 43)
5Q3G	;	1.29	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 44)
5Q3H	;	1.56	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 45)
5Q3I	;	1.53	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 46)
5Q3J	;	1.44	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 47)
5Q3K	;	1.39	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 48)
5Q3L	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 49)
5Q2D	;	1.4	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 5)
5Q3M	;	1.34	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 50)
5Q3N	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 51)
5Q3O	;	1.6	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 52)
5Q3P	;	1.44	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 53)
5Q3Q	;	1.39	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 54)
5Q3R	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 55)
5Q3S	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 56)
5Q3T	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 57)
5Q3U	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 58)
5Q3V	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 59)
5Q2E	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 6)
5Q3W	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 60)
5Q3X	;	1.38	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 61)
5Q3Y	;	1.45	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 62)
5Q3Z	;	1.84	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 63)
5Q40	;	2.04	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 64)
5Q41	;	1.95	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 65)
5Q42	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 66)
5Q43	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 67)
5Q44	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 69)
5Q2F	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 7)
5Q45	;	1.64	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 70)
5Q46	;	2.01	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 71)
5Q47	;	1.38	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 72)
5Q48	;	1.44	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 73)
5Q49	;	1.38	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 74)
5Q4A	;	1.83	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 75)
5Q4B	;	1.6	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 76)
5Q4C	;	2.73	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 77)
5Q4D	;	1.8	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 78)
5Q4E	;	1.39	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 79)
5Q2G	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 8)
5Q4F	;	1.97	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 80)
5Q4G	;	1.75	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 81)
5Q4H	;	1.53	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 82)
5Q4I	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 83)
5Q4J	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 84)
5Q4K	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 85)
5Q4L	;	1.6	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 86)
5Q4M	;	1.6	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 87)
5Q4N	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 88)
5Q4O	;	1.83	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 89)
5Q2H	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 9)
5Q4P	;	1.4	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 90)
5Q4Q	;	1.42	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 91)
5Q4R	;	2.0	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 92)
5Q4S	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 93)
5Q4T	;	1.77	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 94)
5Q4U	;	2.0	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 95)
5Q4V	;	1.59	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 96)
5Q4W	;	1.8	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 97)
5Q4X	;	1.66	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 98)
5Q4Y	;	1.69	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A after initial refinement with no ligand modelled (structure 99)
5Q1S	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with BDOOA011525c
5Q1Y	;	1.42	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000032a
5Q29	;	1.46	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000058a
5Q1L	;	1.76	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000073a
5Q1K	;	1.42	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000074a
5Q1X	;	1.42	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000085a
5Q1Z	;	1.41	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000150a
5Q1V	;	1.57	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000166a
5Q28	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000186a
5Q1R	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000291a
5Q1Q	;	1.44	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000294a
5Q1N	;	1.38	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000295a
5Q1P	;	1.56	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000299a
5Q1U	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000351a
5Q27	;	1.83	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000421a
5Q1O	;	1.25	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000478a
5Q1T	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000492a
5Q20	;	1.76	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000524a
5Q25	;	1.43	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000532a
5Q23	;	1.32	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000543a
5Q1W	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000546a
5Q24	;	1.35	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000676a
5Q26	;	1.66	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000710a
5Q22	;	1.18	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000728a
5Q1M	;	1.56	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000740a
5Q1J	;	1.42	;	PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMSOA000341b
5QOJ	;	2.05	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with FMOCR000171b
5QOO	;	1.56	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with FMOPL000144a
5QOI	;	1.99	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with FMOPL000213a
5QOK	;	2.28	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with FMOPL000294a
5QOL	;	1.85	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with FMOPL000435a
5QON	;	1.8	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with FMOPL000446a
5QPA	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with FMOPL000449a
5QOM	;	1.87	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with FMOPL000576a
5QPB	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with FMOPL000701a
5QOP	;	1.86	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with NUOOA000023a
5QP7	;	1.88	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with PB1230873739
5QOZ	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with PB1787571279
5QP8	;	1.64	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with PB1787571279
5QOH	;	1.93	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with XST00000847b
5QOY	;	1.69	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with YW-FY-378
5QP9	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z100435060
5QP2	;	1.83	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z1170065264
5QOS	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z1187701032
5QP1	;	1.79	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z1190363272
5QOR	;	1.95	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z1203490773
5QP3	;	1.75	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z1494850193
5QOT	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z1592710382
5QP6	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z1662802141
5QOV	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z1699011516
5QOX	;	1.95	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z2212124043
5QOW	;	1.82	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z2895259675
5QOQ	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z2895259680
5QP5	;	1.9	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z2895259681
5QOU	;	2.19	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z296300542
5QP4	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z450133538
5QP0	;	2.0	;	PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z454376544
5RVW	;	1.614	;	PanDDA analysis group deposition -- Crystal Structure of DHTKD1 in complex with Z1587220559
5RVZ	;	1.98	;	PanDDA analysis group deposition -- Crystal Structure of DHTKD1 in complex with Z1929757385
5RW0	;	1.673	;	PanDDA analysis group deposition -- Crystal Structure of DHTKD1 in complex with Z2444997446
5RVY	;	1.609	;	PanDDA analysis group deposition -- Crystal Structure of DHTKD1 in complex with Z437516460
5RVX	;	1.661	;	PanDDA analysis group deposition -- Crystal Structure of DHTKD1 in complex with Z804566442
7GPV	;	1.23	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with NCL-00023820
7GPW	;	1.42	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with NCL-00023824
7GPX	;	1.2	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with NCL-00024661
7GPY	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with NCL-00024667
7GPZ	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with NCL-00024673
7GQ0	;	1.51	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with NCL-00025345
7GPQ	;	1.37	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with POB0008
7GPT	;	1.36	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with POB0026
7GPP	;	1.57	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with POB0050
7GPO	;	1.48	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with POB0066
7GPR	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with POB0095
7GPS	;	1.48	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with POB0120
7GPU	;	1.42	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with POB0122
7GNV	;	1.42	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z104474228
7GNW	;	1.44	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z104475702
7GNX	;	1.48	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1082839290
7GNY	;	1.45	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1102357527
7GNZ	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1129283193
7GO0	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1137725943
7GO1	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1143279263
7GO2	;	1.34	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1182328459
7GQP	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1198152494
7GO3	;	1.53	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1198162455
7GQQ	;	1.44	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1198183601
7GO4	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1198233191
7GO5	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1198275935
7GQN	;	1.44	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1201621250
7GO6	;	1.41	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1203586731
7GO7	;	1.42	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1220452176
7GO8	;	1.42	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1230013388
7GO9	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1266933824
7GOA	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1269184613
7GOB	;	1.45	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1295863442
7GOC	;	1.56	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1318110042
7GOD	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1331830630
7GOE	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1342868616
7GOF	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z137811222
7GOG	;	1.39	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1398461996
7GOH	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1439422127
7GOI	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1456069604
7GQH	;	1.41	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1509711879
7GQ1	;	1.32	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z166605460
7GOJ	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1685106505
7GOK	;	1.44	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1696091761
7GOL	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1827602749
7GOM	;	1.39	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z19234337
7GQ2	;	1.35	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1954800348
7GON	;	1.39	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z19755216
7GOO	;	1.45	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z1980894300
7GOP	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z2033637875
7GOQ	;	1.3	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z220996120
7GOR	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z2273972081
7GQG	;	1.3	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z228589380
7GQ5	;	1.43	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z2301685688
7GQR	;	1.35	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z235343929
7GOS	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z235449082
7GQ3	;	1.42	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z241119328
7GOT	;	1.41	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z26781952
7GQI	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z27782662
7GQ9	;	1.37	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z281773378
7GOU	;	1.46	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z285782452
7GOV	;	1.34	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z30904160
7GOW	;	1.28	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z31432964
7GQC	;	1.36	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z315923746
7GQO	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z3227118860
7GOX	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z33452106
7GQF	;	1.34	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z362020366
7GQM	;	1.39	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z362043378
7GOY	;	1.63	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z375990520
7GOZ	;	1.66	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z381474098
7GP0	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z385450668
7GP1	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z401437758
7GQ6	;	1.44	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z425338146
7GP2	;	1.31	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z425757818
7GP3	;	1.48	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z437516460
7GQB	;	1.35	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z44548882
7GP4	;	1.51	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z44585777
7GQ7	;	1.28	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z45636695
7GP5	;	1.43	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z50145861
7GP6	;	1.73	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z53116498
7GP7	;	1.3	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z53825020
7GP8	;	1.35	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z53825177
7GQL	;	1.48	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z53833304
7GP9	;	1.4	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z53860899
7GQ4	;	1.37	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z56761437
7GQD	;	1.41	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z56862798
7GPA	;	1.25	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z56978034
7GQA	;	1.66	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z57299966
7GPC	;	1.32	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z57328552
7GPD	;	1.4	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z57472297
7GQE	;	1.44	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z57473948
7GQ8	;	1.38	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z57965168
7GQK	;	1.41	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z635046794
7GQJ	;	1.41	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z667925512
7GPE	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z760031264
7GPF	;	1.28	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z760048004
7GPG	;	1.31	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z802540802
7GPH	;	1.44	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z822382694
7GPI	;	1.3	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z839157334
7GPJ	;	1.4	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z85249949
7GPK	;	1.39	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z905434478
7GPL	;	1.42	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z975817026
7GPM	;	1.46	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z979742720
7GPN	;	1.54	;	PanDDA analysis group deposition -- Crystal Structure of Enterovirus D68 3C Protease in complex with Z992916756
5R5T	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of FIBRINOGEN-LIKE GLOBE DOMAIN OF HUMAN TENASCIN-C in complex with Z1251207602
5R5X	;	1.56	;	PanDDA analysis group deposition -- Crystal Structure of FIBRINOGEN-LIKE GLOBE DOMAIN OF HUMAN TENASCIN-C in complex with Z1259335913
5R5U	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of FIBRINOGEN-LIKE GLOBE DOMAIN OF HUMAN TENASCIN-C in complex with Z1545312521
5R61	;	1.38	;	PanDDA analysis group deposition -- Crystal Structure of FIBRINOGEN-LIKE GLOBE DOMAIN OF HUMAN TENASCIN-C in complex with Z1578665941
5R60	;	1.79	;	PanDDA analysis group deposition -- Crystal Structure of FIBRINOGEN-LIKE GLOBE DOMAIN OF HUMAN TENASCIN-C in complex with Z19735067
5R5Z	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of FIBRINOGEN-LIKE GLOBE DOMAIN OF HUMAN TENASCIN-C in complex with Z2856434821
5R5V	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of FIBRINOGEN-LIKE GLOBE DOMAIN OF HUMAN TENASCIN-C in complex with Z2856434824
5R62	;	1.4	;	PanDDA analysis group deposition -- Crystal Structure of FIBRINOGEN-LIKE GLOBE DOMAIN OF HUMAN TENASCIN-C in complex with Z2856434840
5R5W	;	1.6	;	PanDDA analysis group deposition -- Crystal Structure of FIBRINOGEN-LIKE GLOBE DOMAIN OF HUMAN TENASCIN-C in complex with Z2856434942
5R63	;	1.59	;	PanDDA analysis group deposition -- Crystal Structure of FIBRINOGEN-LIKE GLOBE DOMAIN OF HUMAN TENASCIN-C in complex with Z319545618
5R5Y	;	1.57	;	PanDDA analysis group deposition -- Crystal Structure of FIBRINOGEN-LIKE GLOBE DOMAIN OF HUMAN TENASCIN-C in complex with Z509756472
5QRA	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of human ALAS2A in complex with Z1101755952
5QQR	;	1.46	;	PanDDA analysis group deposition -- Crystal Structure of human ALAS2A in complex with Z1171217421
5QRE	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of human ALAS2A in complex with Z117233350
5QRD	;	1.76	;	PanDDA analysis group deposition -- Crystal Structure of human ALAS2A in complex with Z1328968520
5QQU	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of human ALAS2A in complex with Z1348371854
5QR2	;	1.66	;	PanDDA analysis group deposition -- Crystal Structure of human ALAS2A in complex with Z1348371854
5QQW	;	1.56	;	PanDDA analysis group deposition -- Crystal Structure of human ALAS2A in complex with Z136583524
5QQV	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of human ALAS2A in complex with Z1545312521
5QQZ	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of human ALAS2A in complex with Z1675346324
5QR5	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of human ALAS2A in complex with Z2241115980
5QQS	;	1.85	;	PanDDA analysis group deposition -- Crystal Structure of human ALAS2A in complex with Z275151340
5QR4	;	1.57	;	PanDDA analysis group deposition -- Crystal Structure of human ALAS2A in complex with Z2856434826
5QQT	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of human ALAS2A in complex with Z2856434834
5QQQ	;	1.93	;	PanDDA analysis group deposition -- Crystal Structure of human ALAS2A in complex with Z2856434857
5QRB	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of human ALAS2A in complex with Z2856434868
5QQY	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of human ALAS2A in complex with Z2856434899
5QR9	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of human ALAS2A in complex with Z31478129
5QRC	;	1.82	;	PanDDA analysis group deposition -- Crystal Structure of human ALAS2A in complex with Z31721798
5QQX	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of human ALAS2A in complex with Z373768900
5QR1	;	1.44	;	PanDDA analysis group deposition -- Crystal Structure of human ALAS2A in complex with Z396380540
5QR6	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of human ALAS2A in complex with Z44567722
5QR8	;	1.85	;	PanDDA analysis group deposition -- Crystal Structure of human ALAS2A in complex with Z57258487
5QR7	;	1.74	;	PanDDA analysis group deposition -- Crystal Structure of human ALAS2A in complex with Z57299529
5QR0	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of human ALAS2A in complex with Z730649594
5QR3	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of human ALAS2A in complex with Z915492990
5QS8	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury G177D variant in complex with Z1432018343
5QSJ	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury G177D variant in complex with Z198194394
5QSE	;	2.01	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury G177D variant in complex with Z2017168803
5QSA	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury G177D variant in complex with Z2856434778
5QSF	;	1.96	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury G177D variant in complex with Z2856434814
5QSH	;	1.9	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury G177D variant in complex with Z2856434868
5QSB	;	1.82	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury G177D variant in complex with Z2856434874
5QSG	;	1.87	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury G177D variant in complex with Z2856434903
5QSK	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury G177D variant in complex with Z2856434906
5QSC	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury G177D variant in complex with Z300245038
5QT0	;	2.1	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury G177D variant in complex with Z321318226
5QS7	;	1.66	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury G177D variant in complex with Z32327641
5QS6	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury G177D variant in complex with Z44592329
5QS9	;	1.43	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury G177D variant in complex with Z48847594
5QSD	;	1.87	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury G177D variant in complex with Z54571979
5QSI	;	1.64	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury G177D variant in complex with Z933326822
5QSL	;	2.2	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury in complex with Z1273312153
5QRO	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury in complex with Z1506050651
5QRW	;	1.74	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury in complex with Z1509882419
5QRS	;	2.06	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury in complex with Z1891773393
5QRM	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury in complex with Z1899842917
5QS1	;	1.66	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury in complex with Z1954800564
5QRV	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury in complex with Z198194396
5QS3	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury in complex with Z198195770
5QRZ	;	1.96	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury in complex with Z1998104358
5QRU	;	1.76	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury in complex with Z235341991
5QRP	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury in complex with Z2442270563
5QS0	;	1.6	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury in complex with Z274555794
5QRG	;	1.95	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury in complex with Z275151340
5QRK	;	1.63	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury in complex with Z275179758
5QRI	;	1.83	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury in complex with Z2856434826
5QRY	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury in complex with Z2856434890
5QS2	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury in complex with Z291279160
5QS4	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury in complex with Z30820160
5QRR	;	1.69	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury in complex with Z31720228
5QRT	;	1.77	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury in complex with Z31735562
5QRH	;	1.81	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury in complex with Z32327641
5QS5	;	1.81	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury in complex with Z32400357
5QRX	;	1.87	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury in complex with Z364328788
5QRF	;	2.03	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury in complex with Z373768900
5QRJ	;	1.81	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury in complex with Z416341642
5QRL	;	1.76	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury in complex with Z437516460
5QRN	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury in complex with Z54226006
5QRQ	;	2.1	;	PanDDA analysis group deposition -- Crystal Structure of human Brachyury in complex with Z645232558
5R4R	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of HUMAN CLEAVAGE FACTOR IM in complex with EN08775-42
5R4U	;	1.92	;	PanDDA analysis group deposition -- Crystal Structure of HUMAN CLEAVAGE FACTOR IM in complex with EN08775-43
5R4S	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of HUMAN CLEAVAGE FACTOR IM in complex with EN08775-45
5R66	;	2.02	;	PanDDA analysis group deposition -- Crystal Structure of HUMAN CLEAVAGE FACTOR IM in complex with FMOPL000198a
5R65	;	2.28	;	PanDDA analysis group deposition -- Crystal Structure of HUMAN CLEAVAGE FACTOR IM in complex with FMOPL000387a
5R64	;	1.84	;	PanDDA analysis group deposition -- Crystal Structure of HUMAN CLEAVAGE FACTOR IM in complex with FMOPL000464a
5R67	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of HUMAN CLEAVAGE FACTOR IM in complex with FMOPL000589a
5R4P	;	1.78	;	PanDDA analysis group deposition -- Crystal Structure of HUMAN CLEAVAGE FACTOR IM in complex with NM450-1
5R4Q	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of HUMAN CLEAVAGE FACTOR IM in complex with NM466-1
5R4T	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of HUMAN CLEAVAGE FACTOR IM in complex with SK-430
5R5I	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N06325b
5R57	;	1.44	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N08253b
5R55	;	1.48	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13369a
5R50	;	1.87	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13371a
5R59	;	2.11	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13441a
5R58	;	1.98	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13542a
5R5D	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13564a
5R54	;	1.79	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13582a
5R5L	;	1.63	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13589a
5R5N	;	1.87	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13595a
5R5A	;	1.44	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13663a
5R56	;	1.51	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13688a
5R5H	;	1.79	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13706a
5R5G	;	1.77	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13707a
5R5B	;	1.53	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13725a
5R5S	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13775a
5R5F	;	1.63	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13793a
5R5E	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13848a
5R53	;	1.4	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13854a
5R5P	;	1.53	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13910a
5R5Q	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13920a
5R5C	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13956a
5R5K	;	1.6	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13960a
5R5J	;	1.98	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13964a
5R51	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N14003a
5R52	;	1.48	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N14004a
5R5O	;	1.79	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N14027a
5R5R	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N14078a
5R5M	;	1.6	;	PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N14123a
5QHT	;	1.05	;	PanDDA analysis group deposition -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000065a
5QHV	;	1.05	;	PanDDA analysis group deposition -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000299a
5QI4	;	1.2	;	PanDDA analysis group deposition -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000466a
5QI6	;	1.1	;	PanDDA analysis group deposition -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000597a
5QI8	;	1.09	;	PanDDA analysis group deposition -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000605a
5QI9	;	1.05	;	PanDDA analysis group deposition -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000711a
5QSZ	;	3.08	;	PanDDA analysis group deposition -- Crystal Structure of human STAG1 in complex with Z1267773786
5QSN	;	2.66	;	PanDDA analysis group deposition -- Crystal Structure of human STAG1 in complex with Z1272480091
5QSR	;	3.28	;	PanDDA analysis group deposition -- Crystal Structure of human STAG1 in complex with Z136583524
5QST	;	2.58	;	PanDDA analysis group deposition -- Crystal Structure of human STAG1 in complex with Z2447286438
5QSV	;	2.76	;	PanDDA analysis group deposition -- Crystal Structure of human STAG1 in complex with Z2856434783
5QSX	;	2.34	;	PanDDA analysis group deposition -- Crystal Structure of human STAG1 in complex with Z2856434812
5QSW	;	3.03	;	PanDDA analysis group deposition -- Crystal Structure of human STAG1 in complex with Z2856434884
5QSU	;	2.73	;	PanDDA analysis group deposition -- Crystal Structure of human STAG1 in complex with Z2856434926
5QSP	;	2.89	;	PanDDA analysis group deposition -- Crystal Structure of human STAG1 in complex with Z2856434929
5QSS	;	3.08	;	PanDDA analysis group deposition -- Crystal Structure of human STAG1 in complex with Z33452282
5QSQ	;	2.48	;	PanDDA analysis group deposition -- Crystal Structure of human STAG1 in complex with Z396380540
5QSO	;	2.7	;	PanDDA analysis group deposition -- Crystal Structure of human STAG1 in complex with Z466628048
5QSM	;	2.74	;	PanDDA analysis group deposition -- Crystal Structure of human STAG1 in complex with Z57261895
5QSY	;	2.4	;	PanDDA analysis group deposition -- Crystal Structure of human STAG1 in complex with Z755044716
5RAJ	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with BD009815a
5RAU	;	1.73	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with DA000165b
5RAP	;	1.9	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM000707a
5RAO	;	1.59	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001084a
5RAY	;	1.63	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001469a
5RAE	;	1.88	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001558a
5RAF	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001559a
5RAD	;	1.9	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001568a
5RB6	;	1.63	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001569a
5RAQ	;	1.85	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001577a
5RB7	;	1.57	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001648a
5RB4	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001677a
5RB1	;	1.76	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001700a
5RAB	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001726a
5RAV	;	1.77	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001763a
5RAG	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001767a
5RB2	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001784a
5RAC	;	1.73	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001810a
5RAW	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM009970a
5RAA	;	1.57	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM009990a
5RB5	;	1.51	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM010010a
5RAZ	;	1.81	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM010013a
5RB0	;	1.95	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM010020a
5RAH	;	1.66	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM010032a
5RAX	;	2.01	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM010054a
5RAR	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with TD000005c
5RAS	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with XS036302b
5RAM	;	2.05	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with XS038544d
5RAN	;	1.95	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with XS039080d
5RB3	;	1.53	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with XS039249d
5RAL	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with XS039332c
5RAI	;	1.54	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with XS040404c
5RAK	;	1.69	;	PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with XS040486b
5PHO	;	1.4	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 1)
5PHX	;	1.27	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 10)
5PKF	;	1.34	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 100)
5PKG	;	1.54	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 101)
5PKH	;	1.19	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 102)
5PKI	;	1.19	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 103)
5PKJ	;	1.22	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 104)
5PKK	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 105)
5PKL	;	1.35	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 106)
5PKM	;	1.37	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 107)
5PKN	;	1.3	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 108)
5PKO	;	2.38	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 109)
5PHY	;	1.34	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 11)
5PKP	;	1.3	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 110)
5PKQ	;	1.28	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 111)
5PKR	;	1.31	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 112)
5PKS	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 113)
5PKT	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 114)
5PKU	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 115)
5PKV	;	1.35	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 116)
5PKW	;	1.35	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 117)
5PKX	;	1.45	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 118)
5PKY	;	1.25	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 119)
5PHZ	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 12)
5PKZ	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 120)
5PL0	;	1.27	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 121)
5PL1	;	1.42	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 122)
5PL2	;	1.34	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 123)
5PL3	;	1.27	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 124)
5PL4	;	1.21	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 125)
5PL5	;	1.57	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 126)
5PL6	;	1.29	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 127)
5PL7	;	1.3	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 128)
5PL8	;	1.54	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 129)
5PI0	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 13)
5PL9	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 130)
5PLA	;	1.37	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 131)
5PLB	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 132)
5PLC	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 133)
5PLD	;	1.46	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 134)
5PLE	;	1.45	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 135)
5PLF	;	1.33	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 136)
5PLG	;	1.31	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 137)
5PLH	;	1.46	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 138)
5PLI	;	1.39	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 139)
5PI1	;	1.34	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 14)
5PLJ	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 140)
5PLK	;	1.14	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 141)
5PLL	;	1.28	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 142)
5PLM	;	1.14	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 143)
5PLN	;	1.14	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 144)
5PLO	;	1.14	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 145)
5PLP	;	1.46	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 146)
5PLQ	;	1.36	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 147)
5PLR	;	1.53	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 148)
5PLS	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 149)
5PI2	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 15)
5PLT	;	1.53	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 150)
5PLU	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 151)
5PLV	;	1.14	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 152)
5PLW	;	1.31	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 153)
5PLX	;	1.29	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 155)
5PLY	;	1.38	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 156)
5PLZ	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 157)
5PM0	;	2.14	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 158)
5PM1	;	1.54	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 159)
5PI3	;	1.29	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 16)
5PM2	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 160)
5PM3	;	1.46	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 161)
5PM4	;	1.44	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 162)
5PM5	;	1.76	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 163)
5PM6	;	1.78	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 164)
5PM7	;	1.43	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 165)
5PM8	;	1.54	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 166)
5PM9	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 167)
5PMA	;	1.29	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 168)
5PMB	;	1.63	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 169)
5PI4	;	1.35	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 17)
5PMC	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 170)
5PMD	;	1.63	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 171)
5PME	;	1.39	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 172)
5PMF	;	1.36	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 173)
5PMG	;	1.51	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 174)
5PMH	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 175)
5PMI	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 176)
5PMJ	;	1.37	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 177)
5PMK	;	1.44	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 178)
5PML	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 179)
5PI5	;	1.42	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 18)
5PMM	;	1.39	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 180)
5PMN	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 181)
5PMO	;	1.53	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 182)
5PMP	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 183)
5PMQ	;	1.46	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 184)
5PMR	;	1.51	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 185)
5PMS	;	1.24	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 186)
5PMT	;	1.22	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 187)
5PMU	;	1.48	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 188)
5PMV	;	1.34	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 189)
5PI6	;	1.29	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 19)
5PMW	;	1.19	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 190)
5PMX	;	1.14	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 191)
5PMY	;	1.29	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 192)
5PMZ	;	1.15	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 193)
5PN0	;	1.14	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 194)
5PN1	;	1.41	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 195)
5PN2	;	1.41	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 196)
5PN3	;	1.6	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 197)
5PN4	;	1.37	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 198)
5PN5	;	1.3	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 199)
5PHP	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 2)
5PI7	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 20)
5PN6	;	1.42	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 200)
5PN7	;	1.25	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 201)
5PN8	;	1.34	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 202)
5PN9	;	1.48	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 203)
5PNA	;	1.78	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 204)
5PNB	;	1.23	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 205)
5PNC	;	1.35	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 206)
5PND	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 207)
5PNE	;	1.29	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 208)
5PNF	;	1.24	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 209)
5PI8	;	1.27	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 21)
5PNG	;	1.38	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 210)
5PNH	;	1.14	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 211)
5PNI	;	1.45	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 212)
5PNJ	;	1.4	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 213)
5PNK	;	1.27	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 214)
5PNL	;	1.44	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 215)
5PNM	;	1.25	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 216)
5PNN	;	1.21	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 217)
5PNO	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 218)
5PNP	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 219)
5PI9	;	1.45	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 22)
5PNQ	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 220)
5PNR	;	1.14	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 221)
5PNS	;	1.36	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 222)
5PNU	;	1.14	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 223)
5PNV	;	1.6	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 224)
5PNW	;	1.4	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 225)
5PIA	;	1.18	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 23)
5PIB	;	1.64	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 24)
5PIC	;	1.29	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 25)
5PID	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 26)
5PIE	;	1.42	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 27)
5PIF	;	1.37	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 28)
5PIG	;	1.44	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 29)
5PHQ	;	2.23	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 3)
5PIH	;	1.79	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 30)
5PII	;	1.45	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 31)
5PIJ	;	1.45	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 32)
5PIK	;	1.8	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 33)
5PIL	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 34)
5PIM	;	1.25	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 35)
5PIN	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 36)
5PIO	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 37)
5PIP	;	1.42	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 38)
5PIQ	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 39)
5PHR	;	1.66	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 4)
5PIR	;	1.45	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 40)
5PIS	;	1.3	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 41)
5PIT	;	1.79	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 42)
5PIU	;	1.48	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 43)
5PIV	;	1.43	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 44)
5PIW	;	1.23	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 45)
5PIX	;	1.35	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 46)
5PIY	;	1.31	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 47)
5PIZ	;	1.38	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 48)
5PJ0	;	1.31	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 49)
5PHS	;	2.54	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 5)
5PJ1	;	1.35	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 50)
5PJ2	;	1.44	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 51)
5PJ3	;	1.3	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 52)
5PJ4	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 53)
5PJ5	;	1.24	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 54)
5PJ6	;	1.35	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 55)
5PJ7	;	1.39	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 56)
5PJ8	;	1.4	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 57)
5PJ9	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 58)
5PJA	;	1.89	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 59)
5PHT	;	1.83	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 6)
5PJB	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 60)
5PJC	;	1.4	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 61)
5PJD	;	1.43	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 62)
5PJE	;	1.37	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 63)
5PJF	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 64)
5PJG	;	1.4	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 65)
5PJH	;	1.18	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 66)
5PJI	;	1.34	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 67)
5PJJ	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 68)
5PJK	;	1.69	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 69)
5PHU	;	1.79	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 7)
5PJL	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 70)
5PJM	;	1.43	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 71)
5PJN	;	1.48	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 72)
5PJO	;	1.35	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 73)
5PJP	;	1.39	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 74)
5PJQ	;	1.38	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 75)
5PJR	;	1.29	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 76)
5PJS	;	1.64	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 77)
5PJT	;	1.54	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 78)
5PJU	;	1.27	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 79)
5PHV	;	1.83	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 8)
5PJV	;	1.34	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 80)
5PJW	;	1.56	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 81)
5PJX	;	1.35	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 82)
5PJY	;	1.34	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 83)
5PJZ	;	1.29	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 84)
5PK0	;	1.28	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 85)
5PK1	;	1.35	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 86)
5PK2	;	1.42	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 87)
5PK3	;	1.42	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 88)
5PK4	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 89)
5PHW	;	1.31	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 9)
5PK5	;	1.39	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 90)
5PK6	;	2.38	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 91)
5PK7	;	1.29	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 92)
5PK8	;	1.44	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 93)
5PK9	;	1.34	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 94)
5PKA	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 95)
5PKB	;	1.4	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 96)
5PKC	;	1.29	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 97)
5PKD	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 98)
5PKE	;	1.44	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 99)
5PHA	;	1.45	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09398a
5PHJ	;	1.15	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09400a
5PHD	;	1.359	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09419a
5PHB	;	1.338	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09447a
5PH1	;	1.249	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09449a
5PHE	;	1.351	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09453a
5PHM	;	1.398	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09455a
5PHH	;	1.604	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09457a
5PHI	;	1.971	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09480a
5PH0	;	1.341	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09484a
5PH7	;	1.431	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09504a
5PHL	;	1.141	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09506a
5PHN	;	1.29	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09522a
5PH8	;	1.396	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09552a
5PH3	;	1.24	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09575a
5PH2	;	1.454	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09597a
5PH4	;	1.269	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09597a
5PHC	;	1.29	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09649a
5PHF	;	1.389	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09688a
5PHG	;	1.398	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09689a
5PH9	;	1.48	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09701a
5PHK	;	1.25	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09720a
5PH5	;	1.349	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09724a
5PH6	;	1.742	;	PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09736a
5QQF	;	2.26	;	PanDDA analysis group deposition -- Crystal Structure of Kalirin/Rac1 in complex with MolPort-004-412-710
5QQI	;	2.08	;	PanDDA analysis group deposition -- Crystal Structure of Kalirin/Rac1 in complex with MolPort-009-178-994
5QQK	;	2.24	;	PanDDA analysis group deposition -- Crystal Structure of Kalirin/Rac1 in complex with MolPort-009-359-835
5QQE	;	1.95	;	PanDDA analysis group deposition -- Crystal Structure of Kalirin/Rac1 in complex with MolPort-009-531-494
5QQG	;	2.23	;	PanDDA analysis group deposition -- Crystal Structure of Kalirin/Rac1 in complex with MolPort-009-541-216
5QQL	;	2.25	;	PanDDA analysis group deposition -- Crystal Structure of Kalirin/Rac1 in complex with MolPort-009-565-301
5QQM	;	2.02	;	PanDDA analysis group deposition -- Crystal Structure of Kalirin/Rac1 in complex with MolPort-009-565-325
5QQJ	;	1.9	;	PanDDA analysis group deposition -- Crystal Structure of Kalirin/Rac1 in complex with MolPort-009-587-558
5QQN	;	2.26	;	PanDDA analysis group deposition -- Crystal Structure of Kalirin/Rac1 in complex with MolPort-010-382-606
5QQH	;	2.09	;	PanDDA analysis group deposition -- Crystal Structure of Kalirin/Rac1 in complex with MolPort-020-096-465
5QQD	;	1.91	;	PanDDA analysis group deposition -- Crystal Structure of Kalirin/Rac1 in complex with Z56880342
5QTO	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of NUDT5 in complex with 1R-0641
5QTS	;	1.85	;	PanDDA analysis group deposition -- Crystal Structure of NUDT5 in complex with 8J-537S
5QTP	;	1.73	;	PanDDA analysis group deposition -- Crystal Structure of NUDT5 in complex with AE-0227
5QTQ	;	1.82	;	PanDDA analysis group deposition -- Crystal Structure of NUDT5 in complex with FS-1169
5QTM	;	1.79	;	PanDDA analysis group deposition -- Crystal Structure of NUDT5 in complex with FS-2639
5QTR	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of NUDT5 in complex with FS-3764
5QTL	;	1.73	;	PanDDA analysis group deposition -- Crystal Structure of NUDT5 in complex with GB-0804
5QTN	;	1.83	;	PanDDA analysis group deposition -- Crystal Structure of NUDT5 in complex with SS-4432
5QJ5	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of NUDT5 in complex with Z44592329
5RJO	;	1.22	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with NCL-00023827
5RJJ	;	1.151	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with NCL-00023833
5RJK	;	1.21	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with NCL-00024661
5RJL	;	1.31	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with NCL-00024662
5RJQ	;	1.35	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with NCL-00024665
5RJM	;	1.407	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with NCL-00024671
5RJP	;	1.242	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with NCL-00024672
5RJN	;	1.435	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with NCL-00024673
5S8X	;	1.15	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with starting material
5S96	;	1.17	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with starting material
5S98	;	1.1	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with starting material
5S99	;	1.18	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with starting material
5S9G	;	1.091	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with starting material
5S9J	;	1.15	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with starting material
5RKP	;	1.35	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z1079512010
5RKG	;	1.282	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z1124201124
5RKT	;	1.241	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z1266933824
5RKA	;	1.33	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z126932614
5RKX	;	1.24	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z1324080698
5RKR	;	1.37	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z1432018343
5RK3	;	1.31	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z1501469697
5RK1	;	1.271	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z1507502062
5RKQ	;	1.3	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z1545196101
5RKL	;	1.36	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z1545196403
5RKF	;	1.264	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z1674937530
5RKS	;	1.24	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z1696844792
5RKY	;	1.38	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z1796014543
5RK6	;	1.241	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z198194394
5RKI	;	1.268	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z198194396
5S8R	;	1.22	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z198194396 synthetic derivative
5S8S	;	1.22	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z198194396 synthetic derivative
5S8T	;	1.22	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z198194396 synthetic derivative
5S8U	;	1.33	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z198194396 synthetic derivative
5S8V	;	1.18	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z198194396 synthetic derivative
5S8W	;	1.2	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z198194396 synthetic derivative
5S8Y	;	1.24	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z198194396 synthetic derivative
5S8Z	;	1.25	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z198194396 synthetic derivative
5S90	;	1.1	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z198194396 synthetic derivative
5S91	;	1.29	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z198194396 synthetic derivative
5S92	;	1.19	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z198194396 synthetic derivative
5S93	;	1.19	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z198194396 synthetic derivative
5S94	;	1.2	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z198194396 synthetic derivative
5S95	;	1.21	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z198194396 synthetic derivative
5S97	;	1.15	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z198194396 synthetic derivative
5S9A	;	1.36	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z198194396 synthetic derivative
5S9C	;	1.14	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z198194396 synthetic derivative
5S9D	;	1.19	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z198194396 synthetic derivative
5S9E	;	1.18	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z198194396 synthetic derivative
5RKB	;	1.279	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z2004563941
5RKM	;	1.28	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z2017168803
5RKD	;	1.237	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z2168282707
5RKC	;	1.24	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z234898257
5RJW	;	1.514	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z256709556
5RKK	;	1.43	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z275181224
5RKW	;	1.242	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z27678561
5RJS	;	1.37	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z285642082
5RJX	;	1.291	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z285782452
5RKO	;	1.42	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z30620520
5RK0	;	1.24	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z30932204
5RKH	;	1.252	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z31432917
5RK7	;	1.304	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z31721097
5RKU	;	1.4	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z32367954
5RKJ	;	1.46	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z373768898
5RKN	;	1.23	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z373768900
5RJY	;	1.25	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z383325512
5RJT	;	1.169	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z404993336
5RJR	;	1.27	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z45705015
5RK9	;	1.48	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z461898648
5RK8	;	1.272	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z53116498
5RK2	;	1.235	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z54633859
5RK4	;	1.284	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z56791867
5RKV	;	1.277	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z56877838
5RJV	;	1.45	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z57190020
5RJU	;	1.32	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z57261895
5RK5	;	1.243	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z57478994
5RJZ	;	1.275	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z755044716
5RKE	;	1.291	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z906021418
5S9B	;	1.153	;	PanDDA analysis group deposition -- Crystal Structure of PHIP in complex withstarting material
5SDR	;	2.077	;	PanDDA analysis group deposition -- Crystal Structure of Porphyromonas gingivalis in complex with Z1273312153
5SDM	;	2.039	;	PanDDA analysis group deposition -- Crystal Structure of Porphyromonas gingivalis in complex with Z1328078283
5SDG	;	1.95	;	PanDDA analysis group deposition -- Crystal Structure of Porphyromonas gingivalis in complex with Z136583524
5SDE	;	1.854	;	PanDDA analysis group deposition -- Crystal Structure of Porphyromonas gingivalis in complex with Z1619978933
5SDO	;	2.051	;	PanDDA analysis group deposition -- Crystal Structure of Porphyromonas gingivalis in complex with Z19735067
5SDP	;	2.195	;	PanDDA analysis group deposition -- Crystal Structure of Porphyromonas gingivalis in complex with Z2277255954
5SDF	;	1.877	;	PanDDA analysis group deposition -- Crystal Structure of Porphyromonas gingivalis in complex with Z2856434834
5SDH	;	2.313	;	PanDDA analysis group deposition -- Crystal Structure of Porphyromonas gingivalis in complex with Z2856434854
5SDD	;	1.839	;	PanDDA analysis group deposition -- Crystal Structure of Porphyromonas gingivalis in complex with Z2856434879
5SDQ	;	1.92	;	PanDDA analysis group deposition -- Crystal Structure of Porphyromonas gingivalis in complex with Z2856434887
5SDC	;	1.928	;	PanDDA analysis group deposition -- Crystal Structure of Porphyromonas gingivalis in complex with Z2856434912
5SDL	;	2.44	;	PanDDA analysis group deposition -- Crystal Structure of Porphyromonas gingivalis in complex with Z321318226
5SDJ	;	2.041	;	PanDDA analysis group deposition -- Crystal Structure of Porphyromonas gingivalis in complex with Z32327641
5SDK	;	1.977	;	PanDDA analysis group deposition -- Crystal Structure of Porphyromonas gingivalis in complex with Z416341642
5SDN	;	2.023	;	PanDDA analysis group deposition -- Crystal Structure of Porphyromonas gingivalis in complex with Z437584380
5SDI	;	1.898	;	PanDDA analysis group deposition -- Crystal Structure of Porphyromonas gingivalis in complex with Z44592329
5SO3	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with JKH100B
5SO4	;	1.59	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with JKH93A
5SO5	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with JKH93B
5SND	;	1.69	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z1217960891
5SNX	;	1.99	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z1267881672
5SNM	;	1.63	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z135439900
5SNS	;	2.16	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z1354416068
5SOE	;	1.59	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z1429867185
5SOC	;	1.51	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z1530301542
5SNB	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z1545313172
5SOA	;	1.54	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z1613492358
5SO9	;	1.51	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z1622626423
5SOD	;	1.64	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z1730522163
5SNY	;	1.97	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z1827602749
5SNQ	;	2.16	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z1891773476
5SNE	;	1.96	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z192955056
5SNN	;	2.08	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z1954800564
5SNH	;	1.95	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z198194394
5SNR	;	1.75	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z198195770
5SNL	;	2.05	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z2027049478
5SO7	;	1.57	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z219104216
5SOB	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z2204875953
5SO0	;	2.28	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z24758179
5SO6	;	1.51	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z26968795
5SNU	;	1.98	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z2856434770
5SN5	;	1.57	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z2856434897
5SNK	;	1.98	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z2856434941
5SN6	;	1.75	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z2856434942
5SNI	;	2.11	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z285782452
5SNV	;	1.9	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z295848548
5SNA	;	1.83	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z30620520
5SO1	;	2.07	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z30620520
5SNT	;	2.16	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z30820160
5SOH	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z31432226
5SO2	;	2.38	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z31504642
5SN7	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z32327641
5SNO	;	1.86	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z364368134
5SOF	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z373768900
5SN8	;	1.8	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z375990520
5SNP	;	1.95	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z381729066
5SNG	;	1.94	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z383325512
5SNZ	;	1.84	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z44567722
5SN9	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z57258487
5SOG	;	1.63	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z57328997
5SNW	;	1.8	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z730649594
5SNC	;	1.78	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z768399682
5SO8	;	1.64	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z85895198
5SNF	;	1.99	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z87615031
5SNJ	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of Pseudomonas Aeruginosa FabF-C164Q mutant protein in complex with Z906021418
7FRE	;	1.85	;	PanDDA analysis group deposition -- Crystal structure of PTP1B after initial refinement with no ligand modeled
5QDO	;	1.792	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOCR000171b
5QET	;	1.724	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOMB000017a
5QF8	;	1.987	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOMB000114a
5QFC	;	1.841	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOMB000140a
5QES	;	1.745	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOMB000141a
5QF4	;	1.832	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOMB000144a
5QEU	;	1.735	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOMB000149a
5QF2	;	1.772	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOMB000187a
5QF3	;	1.563	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOMB000194a
5QFL	;	1.824	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOMB000206a
5QF9	;	1.94	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOMB000242a
5QFM	;	1.83	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOMB000269a
5QFP	;	1.771	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOMB000293a
5QFS	;	1.853	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOMB000293a
5QFU	;	1.613	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000487a
5QFQ	;	1.621	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000491a
5QFV	;	1.641	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000491a
5QFR	;	1.622	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000497a
5QFW	;	1.662	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000497a
5QFD	;	1.693	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000505a
5QFE	;	1.563	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000509a
5QFK	;	1.594	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000509a
5QFF	;	1.703	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000515a
5QFG	;	1.654	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000523a
5QFH	;	1.591	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000525a
5QFI	;	1.68	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000531a
5QGF	;	1.513	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000539a
5QGA	;	1.653	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000540a
5QG8	;	1.634	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000555a
5QG9	;	1.671	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000595a
5QG7	;	1.811	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000611a
5QGD	;	1.661	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000611a
5QGB	;	1.552	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000628a
5QGC	;	1.586	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000650a
5QG3	;	1.654	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000662a
5QG4	;	1.788	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000666a
5QDH	;	1.682	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000004a
5QDK	;	1.555	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000069a
5QDL	;	1.833	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000072a
5QDM	;	2.647	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000074a
5QDR	;	1.784	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000089a
5QDS	;	1.751	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000108a
5QEX	;	1.673	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000123a
5QE8	;	1.813	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000127a
5QEF	;	1.605	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000134a
5QDI	;	1.623	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000157a
5QDN	;	1.821	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000163a
5QDP	;	1.744	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000207a
5QDJ	;	1.761	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000211a
5QE9	;	1.692	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000232a
5QEE	;	1.932	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000240a
5QEC	;	1.673	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000270a
5QG2	;	2.122	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000275a
5QEG	;	1.97	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000278a
5QDG	;	1.79	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000294a
5QDF	;	1.712	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000295a
5QEH	;	1.941	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000323a
5QFN	;	1.675	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000324a
5QFY	;	1.769	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000396a
5QE2	;	1.787	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000398a
5QDZ	;	2.141	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000435a
5QE3	;	1.742	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000449a
5QDW	;	2.212	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000465a
5QDU	;	1.672	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000466a
5QDT	;	1.821	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000475a
5QDX	;	2.062	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000484a
5QE4	;	1.852	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000514a
5QED	;	1.755	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000538a
5QDV	;	1.773	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000574a
5QE7	;	1.713	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000601a
5QE6	;	1.774	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000608a
5QG1	;	2.209	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000619a
5QGE	;	1.703	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000619a
5QE5	;	1.773	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000632a
5QEB	;	1.733	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000639a
5QE1	;	1.685	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000645a
5QE0	;	1.98	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000648a
5QEY	;	1.775	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000708a
5QFZ	;	1.723	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000711a
5QEA	;	1.743	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000733a
5QDE	;	1.764	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000740a
5QEK	;	1.904	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOZE000092b
5QF1	;	1.844	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA000272b
5QF6	;	1.765	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA000281b
5QEW	;	1.826	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA000470b
5QEO	;	1.721	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA000657b
5QEL	;	1.654	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA000675b
5QFT	;	1.96	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA000683b
5QG5	;	2.07	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA000811b
5QFJ	;	1.954	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA000814b
5QER	;	1.733	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA000847b
5QF7	;	1.75	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA000951b
5QFX	;	1.824	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA000953b
5QEN	;	1.775	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA000955b
5QG6	;	1.734	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA001176b
5QEJ	;	1.924	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA001247b
5QF5	;	1.725	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA001440b
5QFB	;	1.851	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_PKOOA000283c
5QEI	;	1.743	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_PKTTA024495b
5QF0	;	1.707	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_XST00000216b
5QEM	;	1.754	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_XST00000217b
5QEQ	;	1.972	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_XST00000245b
5QG0	;	1.753	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_XST00000280c
5QDY	;	1.835	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_XST00000599c
5QEV	;	1.723	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_XST00000603b
5QFO	;	1.851	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_XST00000644b
5QEP	;	1.774	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_XST00000692b
5QEZ	;	1.654	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_XST00000713b
5QFA	;	1.742	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_XST00000752b
5QDQ	;	1.575	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_XST00000847b
7FQW	;	2.17	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMOCR000171b
7GSO	;	1.72	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOMB000029a
7GST	;	1.64	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOMB000056a
7GTA	;	2.06	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOMB000065a
7GTD	;	1.91	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOMB000110a
7GSQ	;	1.73	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOMB000149a
7FQZ	;	2.09	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMOMB000203a
7GT1	;	1.91	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOMB000209a
7GT0	;	1.76	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOMB000275a
7FQT	;	2.54	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMOMB000293a
7GTU	;	2.08	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOMB000297a
7FQN	;	2.04	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000497a
7FQP	;	1.88	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000505a
7FQO	;	1.93	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000523a
7GT3	;	1.59	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000527a
7GT4	;	1.75	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000528a
7GT5	;	1.61	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000529a
7GT6	;	1.66	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000530a
7GTM	;	1.72	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000543a
7GTK	;	1.76	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000552a
7GTL	;	1.83	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000554a
7FQS	;	2.12	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000555a
7GTI	;	1.66	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000571a
7GTO	;	1.65	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000602a
7FQQ	;	1.88	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000611a
7GTN	;	1.66	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000625a
7GTH	;	1.66	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000637a
7FQR	;	1.9	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000666a
7GTG	;	1.69	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000684a
7FRF	;	2.15	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000089a
7GTT	;	1.93	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000148a
7GSA	;	1.72	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000260a
7FQY	;	2.13	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000278a
7GSK	;	1.84	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000279a
7GTQ	;	2.09	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000311a
7GSG	;	1.9	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000316a
7GSU	;	1.65	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000382a
7GSE	;	1.89	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000383a
7GSF	;	1.78	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000421a
7GSB	;	1.72	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000438a
7GS8	;	1.67	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000466a
7GSH	;	1.88	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000530a
7GSJ	;	1.77	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000543a
7GTR	;	1.78	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000587a
7FQX	;	2.46	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000601a
7GTS	;	1.8	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000604a
7GSD	;	1.8	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000605a
7FQM	;	1.94	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000619a
7GS7	;	1.66	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000621a
7GS9	;	1.96	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000631a
7GTP	;	2.47	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000688a
7GSC	;	1.69	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000729a
7GSL	;	1.77	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMSOA000274b
7GT9	;	1.9	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMSOA000463b
7FQU	;	1.86	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMSOA000470b
7GSZ	;	1.91	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMSOA000686b
7GSV	;	1.92	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMSOA000830b
7GTB	;	1.86	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMSOA000899b
7GSY	;	1.97	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMSOA001175b
7GT7	;	1.84	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMSOA001181b
7GT8	;	1.91	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMSOA001439b
7GSX	;	1.67	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMSOA001440b
7GSI	;	1.71	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with XST00000046b
7GSR	;	1.69	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with XST00000055b
7FRQ	;	2.01	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with XST00000217b
7FRP	;	1.77	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with XST00000245b
7GTJ	;	1.83	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with XST00000280c
7GSW	;	1.79	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with XST00000422b
7GSM	;	2.03	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with XST00000437b
7GSN	;	1.87	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with XST00000519b
7GTE	;	1.9	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with XST00000646b
7GT2	;	1.9	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with XST00000752b
7GTF	;	1.97	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with XST00000754b
7GTV	;	1.72	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with XST00000765c
7FQV	;	2.04	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with XST00000847b
7GTC	;	1.92	;	PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with XST00001145b
7FRH	;	1.84	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with Z2856434762
7FRJ	;	1.8	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with Z2856434770
7FRR	;	1.83	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with Z2856434906
7FRL	;	1.79	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with Z2856434917
7FRK	;	1.8	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with Z30820160
7FRG	;	1.84	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with Z31222641
7FRI	;	1.86	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with Z321318226
7FRM	;	1.91	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with Z509756472
7FRO	;	1.93	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with Z744754722
7FRN	;	1.85	;	PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with Z915492990
5RMM	;	2.2	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with POB0066
5RMH	;	2.021	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z1101755952
5RMK	;	2.08	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z1273312153
5RLJ	;	1.879	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z1407673036
5RLE	;	2.268	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z1429867185
5RLO	;	2.097	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z1454310449
5RM0	;	1.909	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z1492796719
5RLK	;	1.956	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z1509882419
5RM8	;	2.143	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z1614545742
5RM4	;	2.96	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z1639162606
5RLM	;	1.858	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z1650168321
5RLP	;	2.562	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z166605480
5RL9	;	1.788	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z1703168683
5RM2	;	1.82	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z1741964527
5RM3	;	2.09	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z1745658474
5RLD	;	2.233	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z19735981
5RLG	;	1.96	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z19739650
5RL6	;	1.921	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z198195770
5RLY	;	2.434	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z2027049478
5RLB	;	1.98	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z216450634
5RLZ	;	1.97	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z2293643386
5RLF	;	2.235	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z235341991
5RLV	;	2.21	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z2467208649
5RMC	;	2.15	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z24758179
5RME	;	2.23	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z26333434
5RLH	;	2.379	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z2856434778
5RMB	;	2.206	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z2856434920
5RM9	;	2.076	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z2856434942
5RMG	;	2.115	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z285675722
5RLQ	;	2.225	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z285782452
5RMA	;	1.89	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z321318226
5RL7	;	1.89	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z364321922
5RLN	;	2.147	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z364328788
5RM5	;	2.06	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z373768900
5RM6	;	2.128	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z396380540
5RLL	;	2.08	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z425387594
5RM1	;	1.896	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z426041412
5RLI	;	2.26	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z45617795
5RLW	;	1.97	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z45705015
5RLT	;	2.43	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z53116498
5RL8	;	2.21	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z53825177
5RMI	;	2.116	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z53860899
5RMF	;	2.23	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z54226006
5RLC	;	1.92	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z56923284
5RMD	;	1.92	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z57614330
5RLS	;	2.278	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z59181945
5RMJ	;	2.1	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z68299550
5RM7	;	1.84	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z69118333
5RLU	;	2.347	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z744754722
5RLR	;	2.32	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z822382694
5RML	;	2.43	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z85956652
5RF1	;	1.73	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with NCL-00023830
5RFU	;	1.53	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102121
5RFR	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102169
5RFQ	;	1.76	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102179
5RFP	;	2.03	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102190
5REP	;	1.81	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102201
5REJ	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102241
5RFW	;	1.43	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102243
5RFX	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102254
5RET	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102269
5RFZ	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102274
5REW	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102275
5RFH	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102277
5RES	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102281
5REX	;	2.07	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102287
5RFV	;	1.48	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102306
5REK	;	1.74	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102327
5REL	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102340
5RFI	;	1.69	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102353
5RFG	;	2.32	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102372
5RFL	;	1.64	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102389
5REU	;	1.69	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102395
5REN	;	2.15	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102425
5RFT	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102432
5RG0	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102535
5RFM	;	2.06	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102539
5RFK	;	1.75	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102575
5REO	;	1.88	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102578
5RER	;	1.88	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102615
5RFF	;	1.78	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102704
5RFS	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102739
5RFN	;	1.8	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102868
5REY	;	1.96	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102911
5RFO	;	1.83	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102972
5RFY	;	1.9	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102974
5REM	;	1.96	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0103016
5RFJ	;	1.8	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0103067
5REV	;	1.6	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0103072
5RF0	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with POB0073
5REZ	;	1.79	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with POB0129
5REH	;	1.8	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z111507846
5RE4	;	1.88	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1129283193
5R7Z	;	1.59	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1220452176
5RFD	;	1.41	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z126932614
5RFB	;	1.48	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1271660837
5RF6	;	1.45	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1348371854
5REG	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1545313172
5REC	;	1.73	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1587220559
5RF2	;	1.53	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1741969146
5RF3	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1741970824
5RF4	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1741982125
5R80	;	1.93	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z18197050
5RF9	;	1.43	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z217038356
5REE	;	1.77	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z2217052426
5REF	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z24758179
5RFA	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z2643472210
5RF8	;	1.44	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z271004858
5RE8	;	1.81	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z2737076969
5RE9	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z2856434836
5REI	;	1.82	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z2856434856
5RED	;	1.47	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z2856434865
5REB	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z2856434899
5RE7	;	1.79	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z30932204
5REA	;	1.63	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z31432226
5RF7	;	1.54	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z316425948_minor
5RF5	;	1.74	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z3241250482
5RE5	;	2.07	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z33545544
5R83	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z44592329
5RFE	;	1.46	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z509756472
5RE6	;	1.87	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z54571979
5RFC	;	1.4	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z979145504
5S72	;	2.512	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with BBL029427
5SAH	;	2.16	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with EN300-100112
5SAG	;	1.881	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with EN300-1605072
5S70	;	2.327	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with EN300-181428
5SAF	;	2.11	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with EN300-321461
5S71	;	1.941	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with FUZS-5
5S6Z	;	2.28	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with PB2255187532
5SAI	;	2.022	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with Z1424343998
5SA5	;	2.09	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with Z1530301542
5SA7	;	2.222	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with Z1673618163
5SA4	;	2.046	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with Z239136710
5SA9	;	1.92	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with Z2697514548
5SA6	;	2.517	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with Z2856434783
5S6X	;	2.32	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with Z2889976755
5SAB	;	2.486	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with Z31504642
5SAA	;	2.239	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with Z319891284
5SAE	;	2.12	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with Z3219959731
5SAD	;	1.961	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with Z425449682
5S6Y	;	2.32	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with Z56900771
5SAC	;	2.029	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with Z59181945
5SA8	;	2.298	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with Z68299550
5SLI	;	2.3	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z1003146540
5SLA	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z1003207278
5SL2	;	1.739	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z100643660
5SL7	;	1.841	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z1186029914
5SLD	;	1.581	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z1246465616
5SM7	;	1.95	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z1247413608
5SKX	;	2.342	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z126932614
5SKW	;	2.093	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z1272494722
5SL1	;	2.383	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z1273312153
5SLW	;	2.05	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z1310876699
5SLK	;	2.21	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z1354370680
5SLS	;	2.29	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z1373445602
5SLJ	;	2.31	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z1430613393
5SLY	;	2.018	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z1526504764
5SLU	;	2.09	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z1796014543
5SLT	;	1.901	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z1816233707
5SLC	;	1.668	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z1849009686
5SM6	;	2.29	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z1899842917
5SLF	;	2.01	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z198195770
5SM8	;	1.95	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z2027158783
5SMC	;	2.19	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z2033637875
5SLZ	;	2.54	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z2072621991
5SLR	;	1.86	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z2073741691
5SMG	;	1.87	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z2092370954
5SM9	;	2.01	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z2234920345
5SL3	;	1.99	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z223688272
5SL6	;	2.289	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z256709556
5SMD	;	1.826	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z274575916
5SLM	;	2.05	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z28290384
5SL8	;	2.07	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z2856434762
5SM5	;	1.95	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z2856434807
5SLQ	;	2.112	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z2856434829
5SMA	;	2.011	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z2856434890
5SMH	;	2.64	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z2856434938
5SLV	;	2.049	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z2856434942
5SM4	;	2.16	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z2856434944
5SM2	;	1.781	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z3006151474
5SL5	;	2.36	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z32014663
5SLG	;	1.97	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z32400357
5SM0	;	2.086	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z32665176
5SLP	;	1.819	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z373768898
5SL4	;	1.936	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z383202616
5SMB	;	2.181	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z419995480
5SME	;	1.91	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z437584380
5SKY	;	2.25	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z466628048
5SL9	;	1.749	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z54571979
5SLL	;	1.807	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z54615640
5SMF	;	2.011	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z56791867
5SLE	;	2.009	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z56880342
5SLO	;	1.829	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z56983806
5SKZ	;	1.96	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z57258487
5SL0	;	2.001	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z57260516
5SLN	;	2.208	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z57299529
5SLH	;	1.819	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z65532537
5SM1	;	1.941	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z68277692
5SMI	;	2.08	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z71580604
5SLB	;	1.8	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z744930860
5SLX	;	1.76	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z752989138
5SM3	;	2.198	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z943693514
5S1E	;	1.172	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with AB-601_30915014
5S1K	;	1.076	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with EN300-105873
5S1G	;	1.11	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with EN300-108952
5S1Q	;	1.127	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with EN300-17035
5S1I	;	1.068	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with EN300-301084
5S18	;	1.13	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with EN300-321461
5SR2	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with EN300-36602160
5S1A	;	1.079	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with EN300-43406
5S1U	;	1.08	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with EN300-52144
5S24	;	1.14	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with EN300-697611
5S4K	;	1.076	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with FMOOA000509a
5SPM	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with FRESH00002410346
5SPW	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with FRESH00004674769 - (R,S,R) isomer
5SPN	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with FRESH00010608284
5SPS	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with FRESH00012962804 - (S) isomer
5SPQ	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with FRESH00014134848 - (R) isomer
5SQQ	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with FRESH00014649046
5SPO	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with FRESH00020289192 - (S) isomer
5S40	;	1.187	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with NCL-00023824
5S41	;	1.186	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with NCL-00023825
5S42	;	1.09	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with NCL-00023833
5S43	;	1.11	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with NCL-00024661
5S45	;	1.16	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with NCL-00024773
5S44	;	1.059	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with NCL-00024890
5S20	;	1.037	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with PB1827975385
5S3Y	;	1.113	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with POB0012
5S3Q	;	1.09	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with POB0013
5S3R	;	1.038	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with POB0014
5S3U	;	1.078	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with POB0041
5S3S	;	1.039	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with POB0103
5S3V	;	1.119	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with POB0120
5S3T	;	1.085	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with POB0128
5S3W	;	0.987	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with POB0135
5S3X	;	1.13	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with POB0136
5S3Z	;	1.31	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with POB0140
7FR3	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with PTERA_A01A - (S) isomer
7FRC	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with PTERA_A05 - (R) isomer
7FRD	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with PTERA_A25A - (S) isomer
7FR4	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with PTERA_A26A - (S) isomer
5SQF	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with REAL250000548538 - (R) isomer
5SPZ	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with REAL250001448407 - (S) isomer
5SPP	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with REAL250002155324
5SPR	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with REAL250002852032 - (S) isomer
5SPK	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with REAL250003296134 - (R) isomer
5SPV	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with REAL250003774401
5SPX	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with REAL250003958539
5SQU	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with REAL250004627335
5SQ0	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with REAL300007260658 - (S,S) isomer
5SQR	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with REAL300016493575 - (R,S) isomer
5SPY	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with REAL300019621104
5S4F	;	1.131	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with SF003
5S4G	;	1.172	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with SF005
5S4H	;	1.175	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with SF048
5S4I	;	1.131	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with SF051
5S4J	;	1.124	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with SF054
5S1Y	;	1.091	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with STK346965
5S1M	;	1.184	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with STK497968
5S1O	;	1.09	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with STL414928
5S3O	;	1.188	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z102768020
5SQZ	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z1039058598
5S2X	;	1.06	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z1139246057
5S2E	;	1.116	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z1152242726
5S2V	;	1.081	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z1186029914
5S3P	;	1.1	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z1238477790
5S27	;	1.126	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z1262398530
5S2A	;	1.08	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z1263529624
5S2Z	;	1.07	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z126932614
5SR1	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z1272415642 - (R) isomer
5S3J	;	1.087	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z1324853681
7FRA	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z1343520564
7FR9	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z1367095370
5S2W	;	1.081	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z1407672867
7FR1	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z1423250928
5SQ7	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z1445235880
5SQ8	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z1445261766
5S22	;	1.175	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z145120524
5S3A	;	1.178	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z1562205518
5S1S	;	1.16	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z1613477500
5S39	;	1.164	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z165170770
5S31	;	1.145	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z1741959530
5S3B	;	1.091	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z1741966151
5S48	;	1.074	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z1741982125
5S4D	;	1.22	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z1741982441
5S38	;	1.072	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z1745658474
5S2N	;	1.133	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z1787627869
5S4C	;	1.01	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z1954800348
5S37	;	1.22	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z1954800564
5S2Y	;	1.052	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z19727416
5S29	;	1.3	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z199959602
5S3K	;	1.17	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z219104216
5S2L	;	1.085	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z2234920345
5S4E	;	1.07	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z2301685688
5SRW	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z2364914118 - (S) isomer
5SQ4	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z2364980062 - (R) isomer
5SRN	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z2466029596 - (R) and (S) isomers
5SR4	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z2479779298 - (R,S) and (S,R) isomers
5SQK	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z2479782408 - (R,S) isomer
5SRS	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z2614735107 - (R) and (S) isomers
5S32	;	1.166	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z26781943
5S2Q	;	1.28	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z26781952
5S2T	;	1.108	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z26781964
5SQL	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z2689779890
5S3E	;	1.05	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z274553586
5S3H	;	1.19	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z2856434892
5S2S	;	1.104	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z2856434894
5S2H	;	1.068	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z2856434920
5S3C	;	1.185	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z2856434937
5S36	;	1.058	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z2856434938
5S34	;	1.057	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z2856434941
5S3N	;	1.185	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z287484230
7FR6	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z2890147894
7FR0	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z2890182452
7FR5	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z2890189003
7FR8	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z2890408258 - (R) isomer
5SQ2	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z2976440814 - (S) isomer
5SR6	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z3011799020 - (R) isomer
5S1C	;	1.174	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z3034471507
5S3D	;	1.187	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z30820160
5S2G	;	1.19	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z321318226
5S4B	;	1.185	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z3219959731
5SP9	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z3508769536 - (S) isomer
5SR9	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z3562259556 - (R) isomer
5SR0	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z3649721459 - (R,S) and (S,R) isomers
5S2D	;	1.06	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z369936976
5S2B	;	1.11	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z373769142
5SRQ	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z3831836449 - (R) isomer
5S3G	;	1.14	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z384468096
5SRM	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z3860662215 - (R) and (S) isomers
5S28	;	1.09	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z409974522
5SRR	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z4158218973 - (S,S) isomer
5SRF	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z4175156780 - (R) isomer
7FR7	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z431872694
5S2K	;	1.097	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z445856640
5S2F	;	1.186	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z44592329
5S2C	;	1.092	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z45612755
5S3M	;	1.26	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z45656995
5SPI	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z4574659604 - (R,R) and (S,S) isomers
5SPH	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z4718398515 - (R,S) isomer
5SPE	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z4718398531 - (S,S) isomer
5SPD	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z4718398539 - (R,R) and (S,S) isomers
5SPF	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z4718398569
5SP4	;	1.06	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z4718398572
5SP6	;	1.07	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z4718398580
5SPG	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z4718398585
5SQN	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z4914649780 - (S) isomer
5SR7	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z4914649782 - (R,R,S) and (S,S,R) isomers
5SR8	;	1.1	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z4914650235 - (S) isomer
5SQD	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5010894382 - (R,R) and (S,S) isomers
5SSN	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5010894382 - (R,S) isomer
5SPC	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5010894387 - (R,R) and (S,S) isomers
5SQC	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5010894388 - (R,R) and (S,S) isomers
5SQB	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5010894390 - (R,R) and (S,S) isomers
5SQE	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5010894392- (S,S) isomer
5SQA	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5010894395 - (R,R) and (S,S) isomers
5SQV	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5010894399 - (S,S) isomer
5SPB	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5010894404 - (R,R) and (S,S) isomers
5SQ6	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5010894406
5SQ5	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5010894407 - (R,S) and (S,S) isomers
5SP8	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5010894415 - (S) isomer
5SPA	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5010894417 - (R,R) and (S,S) isomers
5SQ9	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5010894420 - (R,R) and (S,S) isomers
5SQG	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5010894430 - (R,R) and (S,S) isomers
5SQH	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5010894431- (S,S) isomer
5SP7	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5010903509 - (S,S) isomer
5SQW	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5014193706 - (R,R) and (S,S) isomers
5S3I	;	1.17	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z50145861
5SQI	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5016127255 - (R,R) and (S,S) isomers
5SQJ	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5021668601
5SR3	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5021669050 - (S,S) isomer
5SQ3	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5028367848 - (R) isomer
5SQM	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5028367849 - (S) isomer
5SQP	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5028367859 - (S) isomer
5SQO	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5030903496 - (R) isomer
5S2J	;	1.111	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z509756472
5SQX	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5183357278 - (R,R) and (S,S) isomers
5SRC	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5198562500 - (R,R) and (R,S) isomers
5SRX	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5198562503 - (R) isomer
5SRO	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5198562509 - (R) and (S) isomers
5SSO	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5198562519 - (R) and (S) isomers
5SRU	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5198562523 - (S) isomer
5SRE	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5198562530 - (R) isomer
5SRB	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5198562532 - (R) and (S) isomers
5SRV	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5198562533 - (R,R) isomer
5SRT	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5198562791 - (R) isomer
5SQY	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5211314110 - (S,S) isomer
5SRY	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5265428218
5SRJ	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5265428226
5SRG	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5265428403
5SR5	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5265454473 - (R) isomer
5SRH	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5265470867 - pyrimido-indole core only
5SRI	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5278734565 - pyrimido-indole core only
5SRZ	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5281440906 - (R,S) and (S,R) isomers
5SRP	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5340019182 - (R) isomer
5SRL	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5352447655 - (R,R) isomer
5SRA	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5372052920 - (R) isomer
5SRD	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5373433723 - (S) isomer
5SRK	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5373433775 - (R) isomer
5SSM	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5459166256 - (R,R) and (S,S) isomers
5SSP	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5459166285 - (R,R) and (S,S) isomers
5SSQ	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5459166291
5SSR	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5459166300
5S3L	;	1.091	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z54628578
7FR2	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5551425673 - (S) isomer
7FRB	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z5551426009 - (S) isomer
5S2M	;	1.136	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z56827661
5S49	;	1.03	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z56866006
5S46	;	1.191	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z57131035
5S2R	;	1.132	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z57292369
5S2I	;	1.085	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z57299529
5S3F	;	1.16	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z57446103
5S26	;	1.125	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z605596346
5S2O	;	1.091	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z645232558
5S30	;	1.19	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z65532537
5S35	;	1.099	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z68404778
5S1W	;	1.135	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z838838708
5S2U	;	1.034	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z85956652
5S33	;	1.06	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z906021418
5S2P	;	1.033	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z927746322
5S47	;	1.09	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z940713508
5S4A	;	1.081	;	PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex with Z955123498
5RSO	;	1.03	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000000226
5RUE	;	1.02	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000000922
5RSM	;	1.02	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000001099
5RS8	;	1.01	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000001601
5RTM	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000002005
5RSU	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000002055
5RUC	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000005878
5RU1	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000034687
5RUG	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000038389
5RV4	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000039224
5RV8	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000039575
5RT1	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000039810
5RV0	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000039994
5RT4	;	1.02	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000051581
5RV3	;	1.02	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000057162
5RT5	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000058111
5RSN	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000064576
5RTX	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000090873
5RUH	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000123600
5RVL	;	1.36	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000149580
5RU8	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000154817
5RVP	;	1.04	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000154817
5RT6	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000156509
5RTH	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000156863
5RTY	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000157088
5RVM	;	1.03	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000157088
5RTD	;	1.04	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000157108
5RSQ	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000158490
5RV6	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000158540
5RSR	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000158650
5RTS	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000159004
5RVS	;	1.52	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000159004
5RTU	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000159056
5RUK	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000161692
5RU3	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000161696
5RT8	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000161908
5RUT	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000161958
5RUL	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000163774
5RTK	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000164504
5RTW	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000164777
5RU9	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000165882
5RUN	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000194295
5RV1	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000251609
5RVH	;	0.98	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000265642
5RV2	;	1.01	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000311783
5RU2	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000331715
5RSD	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000331945
5RTA	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000332540
5RUI	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000332651
5RST	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000332673
5RVN	;	1.26	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000332748
5RTJ	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000332752
5RSW	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000337835
5RSV	;	1.03	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000340465
5RTL	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000388056
5RUS	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000388081
5RV9	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000388150
5RSX	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000388262
5RT9	;	1.01	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000388280
5RTO	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000388302
5RU0	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000388514
5RTG	;	1.01	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000395673
5RTZ	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000404062
5RUJ	;	1.01	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000404314
5RUU	;	1.01	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000438614
5RTT	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000000873830
5RU6	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000001442764
5RVJ	;	1.2	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000001612349
5RSB	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000001674697
5RTP	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000001679336
5RUO	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000001683100
5RU4	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000001688638
5RTV	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000001698894
5RUX	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000002020050
5RTF	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000002047514
5RVU	;	1.2	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000002506130
5RVQ	;	1.08	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000002508153
5RSP	;	1.02	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000002560357
5RT0	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000002582714
5RVT	;	1.26	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000002582714
5RVK	;	1.46	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000002977810
5RU7	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000003591110
5RSC	;	1.01	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000003888754
5RV7	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000003954002
5RSZ	;	1.02	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000004218283
5RTI	;	1.01	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000004219237
5RSY	;	1.04	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000004787230
5RUP	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000004976927
5RTC	;	1.06	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000006490906
5RTB	;	1.04	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000006534965
5RSS	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000006691828
5RS9	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000007636250
5RV5	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000008578948
5RUD	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000008615114
5RT2	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000008652361
5RUM	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000008861082
5RTE	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000013283576
5RTN	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000013514509
5RVO	;	1.52	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000013514509
5RUY	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000013517187
5RVB	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000014419577
5RT7	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000015442276
5RVR	;	1.04	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000016052862
5RVA	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000016343276
5RUF	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000016989831
5RUR	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000017744334
5RTR	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000018169763
5RTQ	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000019015078
5RUV	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000019015194
5RUZ	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000019685960
5RVV	;	1.42	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000020269197
5RSF	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000026180281
5RUQ	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000032199226
5RUA	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000033986325
5RS7	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000034618676
5RT3	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000039281982
5SOX	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000043461211
5RUW	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000045014941
5SOI	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000078036511 - (R) and (S) isomers
5RVF	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000082473428_N3
5RVI	;	0.94	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000084843283
5RSJ	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000089254160_N3
5RU5	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000098208711
5SOR	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000110510893
5SOW	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000118179920
5SOY	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000222377450
5RSG	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000263392672
5RVD	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000263980802
5RSH	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000274438208
5SOU	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000285507655 - (R) and (S) isomers
5SOT	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000292637864 - (R) and (S) isomers
5SOK	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000302059710 - (R) isomer
5RSE	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000336438345
5RSL	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000365052868
5RSI	;	1.01	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000374420934
5RVG	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000400552187_N3
5SP3	;	1.01	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000450476923 - (S,R) isomer
5SOS	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000559260078
5SP2	;	0.97	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000579359572 - (R) and (S) isomers
5SPL	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000611664196 - (S,S) isomer
5SOJ	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000642067873 - (R) isomer
5SP0	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000681764827
5RVE	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000736709772
5SOZ	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000827900828
5SQT	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000833624464 - (R,R) and (S,S) isomers
5SOM	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000835985505 - (S) isomer
5SPT	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000850008207
5SPJ	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000893101964
5SOV	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000893191027 - (S) and (R) isomers
5SOQ	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000896845531 - (R) isomer
5SOO	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000897286891 - (R) isomer
5RSK	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000901381520_N3
5SOL	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000910475722 - (S,R) isomer
5SON	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000920153280 - (R) isomer
5RVC	;	1.0	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000933940912
5SQS	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC001240411747
5SOP	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC001364194305 - (R) isomer
5SPU	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC001364774273 - (S) isomer
5SP1	;	1.03	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC001472868186
5SQ1	;	1.05	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC001601221314 - (S) isomer
5SSC	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINCk500000doQ8X
5SSK	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINCkk00000cjQyM - (R,S) isomer
5SS6	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINClf00000cdzal
5SSA	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINClv000001jcNa - (r,r) isomer
5SSD	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINCm4000007vvRA - (R,S) isomer
5SSB	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINCmk000007RhkC
5SSF	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINCmr000000sTGN
5SSI	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINCn500000bifGU
5SS0	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINCn9000000uj1v
5SSJ	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINCno00000broQT
5SS4	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINCns000000RJoU
5SS2	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINCnt000006kx7L
5SS3	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINCnu000001eLaQ
5SS8	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINCny000002NPIr
5SS7	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINCnz000004Qo8S
5SSE	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINCoD000001aHBe
5SSL	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINCoj00000doMWF
5SS1	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINCou000000a2Hm
5SS9	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINCow000000AiWv - (R) isomer
5SS5	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINCpE000000mAwk - (S) isomer
5SSG	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINCpv000006Li5M - (R,R) isomer
5SSH	;	1.15	;	PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINCpx000006Mh4L - (S) isomer
5PWE	;	1.69	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 1)
5PWN	;	1.64	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 10)
5PZ4	;	1.94	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 100)
5PZ5	;	2.64	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 101)
5PZ6	;	1.87	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 102)
5PZ7	;	1.54	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 103)
5PZ8	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 104)
5PZ9	;	2.01	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 105)
5PZA	;	1.59	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 106)
5PZB	;	2.05	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 107)
5PZC	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 108)
5PZD	;	1.74	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 109)
5PWO	;	1.85	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 11)
5PZE	;	1.82	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 110)
5PZF	;	1.84	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 111)
5PZG	;	1.88	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 112)
5PZH	;	1.63	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 113)
5PZI	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 114)
5PZJ	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 115)
5PWP	;	1.51	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 13)
5PWQ	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 14)
5PWR	;	1.46	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 15)
5PWS	;	1.4	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 16)
5PWT	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 17)
5PWU	;	1.44	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 18)
5PWV	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 19)
5PWF	;	1.48	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 2)
5PWW	;	1.59	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 20)
5PWX	;	1.69	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 21)
5PWY	;	1.98	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 22)
5PWZ	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 23)
5PX0	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 24)
5PX1	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 25)
5PX2	;	1.43	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 26)
5PX3	;	1.57	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 27)
5PX4	;	1.45	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 28)
5PX5	;	1.74	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 29)
5PWG	;	1.46	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 3)
5PX6	;	1.43	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 30)
5PX7	;	1.74	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 31)
5PX8	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 32)
5PX9	;	1.89	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 33)
5PXA	;	1.43	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 34)
5PXB	;	1.46	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 35)
5PXC	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 36)
5PXD	;	1.64	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 37)
5PXE	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 38)
5PXF	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 39)
5PWH	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 4)
5PXG	;	1.98	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 40)
5PXH	;	2.25	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 41)
5PXI	;	1.76	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 42)
5PXJ	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 43)
5PXK	;	1.98	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 44)
5PXL	;	1.35	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 45)
5PXM	;	1.59	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 46)
5PXN	;	1.43	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 47)
5PXO	;	1.78	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 48)
5PXP	;	1.86	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 49)
5PWI	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 5)
5PXQ	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 50)
5PXR	;	1.81	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 51)
5PXS	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 52)
5PXT	;	1.4	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 53)
5PXU	;	1.76	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 54)
5PXV	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 55)
5PXW	;	2.01	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 56)
5PXX	;	1.57	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 57)
5PXY	;	2.14	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 58)
5PXZ	;	1.65	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 59)
5PWJ	;	1.89	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 6)
5PY0	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 60)
5PY1	;	1.74	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 61)
5PY2	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 62)
5PY3	;	1.78	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 63)
5PY4	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 64)
5PY5	;	1.44	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 65)
5PY6	;	1.74	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 66)
5PY7	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 67)
5PY8	;	1.66	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 68)
5PY9	;	1.73	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 69)
5PWK	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 7)
5PYA	;	1.55	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 70)
5PYB	;	1.74	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 71)
5PYC	;	1.87	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 72)
5PYD	;	2.02	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 73)
5PYE	;	1.81	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 74)
5PYF	;	1.83	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 75)
5PYG	;	1.95	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 76)
5PYH	;	1.74	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 77)
5PYI	;	2.29	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 78)
5PYJ	;	1.97	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 79)
5PWL	;	1.83	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 8)
5PYK	;	1.88	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 80)
5PYL	;	1.53	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 81)
5PYM	;	1.7	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 82)
5PYN	;	1.89	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 83)
5PYO	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 84)
5PYP	;	1.63	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 85)
5PYQ	;	1.97	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 86)
5PYR	;	1.94	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 87)
5PYS	;	2.09	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 88)
5PYT	;	2.13	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 89)
5PWM	;	1.54	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 9)
5PYU	;	1.74	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 90)
5PYV	;	1.94	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 91)
5PYW	;	1.45	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 92)
5PYX	;	1.57	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 93)
5PYY	;	1.64	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 94)
5PYZ	;	1.59	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 95)
5PZ0	;	2.13	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 96)
5PZ1	;	2.13	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 97)
5PZ2	;	1.88	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 98)
5PZ3	;	1.93	;	PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 99)
5PWC	;	1.549	;	PanDDA analysis group deposition -- Crystal Structure of SP100 in complex with E48115b
5PWD	;	1.569	;	PanDDA analysis group deposition -- Crystal Structure of SP100 in complex with N09600b
5QQ6	;	1.94	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOOA000530a
5QQ7	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOOA000562a
5QQ8	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOOA000563a
5QQ9	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOOA000567a
5QQA	;	2.2	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOOA000648a
5QQB	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOOA000676a
5QQ4	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOPL000276a
5QPG	;	1.58	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOPL000291a
5QPD	;	1.93	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOPL000293a
5QPE	;	1.77	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOPL000295a
5QPH	;	1.86	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOPL000315a
5QPV	;	1.6	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOPL000416a
5QPY	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOPL000449a
5QPL	;	1.41	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOPL000464a
5QPJ	;	1.41	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOPL000465a
5QPF	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOPL000478a
5QPM	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOPL000500a
5QPP	;	1.48	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOPL000512a
5QPZ	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOPL000524a
5QPX	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOPL000534a
5QPI	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOPL000554a
5QPO	;	1.6	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOPL000574a
5QPN	;	1.45	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOPL000576a
5QPK	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOPL000586a
5QPQ	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOPL000631a
5QPW	;	1.72	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOPL000632a
5QPT	;	1.46	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOPL000642a
5QPS	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOPL000644a
5QQ3	;	1.6	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOPL000672a
5QQ2	;	1.73	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOPL000693a
5QQ1	;	1.97	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOPL000699a
5QPU	;	1.44	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with FMOPL000733a
5QQ5	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with PKTTA024495b
5QQ0	;	1.6	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with XST00000046b
5QPR	;	1.67	;	PanDDA analysis group deposition -- Crystal Structure of T. cruzi FPPS in complex with XST00001145b
5R4N	;	1.28	;	PanDDA analysis group deposition -- CRYSTAL STRUCTURE OF THE BROMODOMAIN OF HUMAN NUCLEOSOME-REMODELING FACTOR SUBUNIT BPTF in complex with FMOPL000061a
5R4J	;	1.39	;	PanDDA analysis group deposition -- CRYSTAL STRUCTURE OF THE BROMODOMAIN OF HUMAN NUCLEOSOME-REMODELING FACTOR SUBUNIT BPTF in complex with FMOPL000280a
5R4H	;	1.18	;	PanDDA analysis group deposition -- CRYSTAL STRUCTURE OF THE BROMODOMAIN OF HUMAN NUCLEOSOME-REMODELING FACTOR SUBUNIT BPTF in complex with FMOPL000287a
5R4K	;	1.17	;	PanDDA analysis group deposition -- CRYSTAL STRUCTURE OF THE BROMODOMAIN OF HUMAN NUCLEOSOME-REMODELING FACTOR SUBUNIT BPTF in complex with FMOPL000292a
5R4L	;	1.13	;	PanDDA analysis group deposition -- CRYSTAL STRUCTURE OF THE BROMODOMAIN OF HUMAN NUCLEOSOME-REMODELING FACTOR SUBUNIT BPTF in complex with FMOPL000349a
5R4I	;	1.28	;	PanDDA analysis group deposition -- CRYSTAL STRUCTURE OF THE BROMODOMAIN OF HUMAN NUCLEOSOME-REMODELING FACTOR SUBUNIT BPTF in complex with FMOPL000443a
5R4M	;	1.11	;	PanDDA analysis group deposition -- CRYSTAL STRUCTURE OF THE BROMODOMAIN OF HUMAN NUCLEOSOME-REMODELING FACTOR SUBUNIT BPTF in complex with FMOPL000513a
5R4G	;	1.25	;	PanDDA analysis group deposition -- CRYSTAL STRUCTURE OF THE BROMODOMAIN OF HUMAN NUCLEOSOME-REMODELING FACTOR SUBUNIT BPTF in complex with FMOPL000621a
5SA2	;	1.78	;	PanDDA analysis group deposition -- Crystal Structure of Trypanosoma brucei Trypanothione reductase in complex with Z1148747945
5SA0	;	1.97	;	PanDDA analysis group deposition -- Crystal Structure of Trypanosoma brucei Trypanothione reductase in complex with Z1506050651
5S9T	;	1.66	;	PanDDA analysis group deposition -- Crystal Structure of Trypanosoma brucei Trypanothione reductase in complex with Z1614545742
5S9X	;	1.84	;	PanDDA analysis group deposition -- Crystal Structure of Trypanosoma brucei Trypanothione reductase in complex with Z1899842917
5S9Y	;	1.75	;	PanDDA analysis group deposition -- Crystal Structure of Trypanosoma brucei Trypanothione reductase in complex with Z24758179
5S9W	;	1.96	;	PanDDA analysis group deposition -- Crystal Structure of Trypanosoma brucei Trypanothione reductase in complex with Z26769872
5S9V	;	1.9	;	PanDDA analysis group deposition -- Crystal Structure of Trypanosoma brucei Trypanothione reductase in complex with Z2856434826
5SA3	;	1.74	;	PanDDA analysis group deposition -- Crystal Structure of Trypanosoma brucei Trypanothione reductase in complex with Z2856434874
5S9Z	;	1.73	;	PanDDA analysis group deposition -- Crystal Structure of Trypanosoma brucei Trypanothione reductase in complex with Z2856434884
5S9S	;	1.8	;	PanDDA analysis group deposition -- Crystal Structure of Trypanosoma brucei Trypanothione reductase in complex with Z2856434898
5SA1	;	1.84	;	PanDDA analysis group deposition -- Crystal Structure of Trypanosoma brucei Trypanothione reductase in complex with Z2856434944
5S9U	;	1.73	;	PanDDA analysis group deposition -- Crystal Structure of Trypanosoma brucei Trypanothione reductase in complex with Z32327641
7GA2	;	2.034	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with POB0008
7GA1	;	2.093	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with POB0128
7G9L	;	1.541	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z111782404
7GA5	;	1.843	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z119989094
7G9Z	;	1.622	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z1216822028
7G9K	;	1.551	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z1262246195
5RHJ	;	1.5	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z126932614
5RHX	;	1.73	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z1324080698
7G9O	;	1.931	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z133716556
5RHR	;	1.46	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z1348559502
5RHO	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z1444783243
5RHM	;	1.68	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z1454310449
7GA6	;	1.749	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z1509711879
5RHH	;	1.59	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z1515654336
7G9P	;	1.743	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z1619958679
5RHU	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z1703168683
7G9T	;	1.904	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z18618496
5RHI	;	1.45	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z198194396
7GA0	;	1.967	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z2048325751
5RHG	;	1.41	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z235341991
5RHQ	;	1.49	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z235449082
7G9Y	;	1.83	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z2678251369
5RHS	;	1.53	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z274555794
5RHP	;	1.61	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z2856434938
5RHT	;	1.63	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z291279160
5RHW	;	1.62	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z31222641
7GA3	;	1.809	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z3241250482
7G9V	;	1.74	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z383202616
7G9R	;	1.798	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z385450668
5RHL	;	1.43	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z425387594
7G9W	;	1.855	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z444860982
7G9M	;	1.541	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z44584886
7G9U	;	1.689	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z55222357
7GA4	;	1.749	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z56823075
7G9N	;	1.422	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z57821475
5RHV	;	1.71	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z62645406
7G9Q	;	2.131	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z751811134
7G9S	;	2.09	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z758198920
7GA7	;	1.42	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z85933875
5RHK	;	1.52	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z87615031
7G9X	;	1.809	;	PanDDA analysis group deposition -- Crystal Structure of Zika virus NS3 Helicase in complex with Z905065822
5RBO	;	1.08	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library A07a
5RBP	;	1.05	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library B03a
5RBQ	;	1.04	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library B06b
5RBR	;	0.9	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library C04a
5RBS	;	1.0	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library C08a
5RBT	;	1.12	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library C11b
5RBU	;	1.01	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library D01a
5RBV	;	0.98	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library D04a
5RBW	;	0.95	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library D06b
5RBX	;	1.0	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library D10a
5RBY	;	1.1	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library D11b
5RBZ	;	1.14	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library E05a
5RC0	;	1.03	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library E06a
5RC1	;	1.05	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library E07a
5RC2	;	0.97	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library E11b
5RC3	;	0.98	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library F03a
5RC4	;	1.0	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library F04a
5RC5	;	1.03	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library F06b
5RC6	;	1.18	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library F08b
5RC7	;	0.97	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library F11a
5RC8	;	1.04	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library G02a
5RC9	;	1.08	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library G03b
5RCA	;	1.04	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library G08b
5RCB	;	0.99	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library G09a
5RCC	;	1.04	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library H02b
5RCD	;	1.02	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library H03a
5RCE	;	1.05	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library H05a
5RCF	;	1.0	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library H10b
5RCG	;	1.23	;	PanDDA analysis group deposition -- Endothiapepsin changed state model for fragment F2X-Entry Library H11a
5RDO	;	1.06	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 01
5RCH	;	1.22	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 02
5RCI	;	1.23	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 03
5RCJ	;	1.0	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 04
5RCK	;	0.92	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 05
5RCL	;	1.01	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 06
5RCM	;	1.03	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 07
5RCN	;	1.03	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 08
5RCO	;	1.21	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 09
5RCP	;	1.08	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 10
5RCQ	;	1.34	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 11
5RE3	;	1.09	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 12
5RCR	;	1.05	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 13
5RCS	;	0.97	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 14
5RCT	;	1.01	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 15
5RCU	;	1.1	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 16
5RCV	;	0.95	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 17
5RCW	;	1.04	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 18
5RCX	;	1.04	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 19
5RCY	;	1.11	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 20
5RCZ	;	1.04	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 21
5RD0	;	1.04	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 22
5RD1	;	1.0	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 23
5RD2	;	1.08	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 24
5RD3	;	0.93	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 25
5RD4	;	1.18	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 26
5RD5	;	1.15	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 27
5RD6	;	1.13	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 28
5RD7	;	1.03	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 29
5RD8	;	0.98	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 30
5RD9	;	1.11	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 31
5RDA	;	0.98	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 32
5RDB	;	1.04	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 33
5RDC	;	1.02	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 34
5RDD	;	1.03	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 35
5RDE	;	1.01	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 36
5RDF	;	0.97	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 37
5RDG	;	1.12	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 38
5RDH	;	0.85	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 39
5RDI	;	1.0	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 40
5RDP	;	0.97	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 41
5RDQ	;	1.04	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 42
5RDJ	;	0.93	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 43
5RDK	;	1.03	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 44
5RDL	;	1.09	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 45
5RDM	;	1.01	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 46
5RDN	;	0.98	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 47
5RDR	;	1.03	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 48
5RDS	;	0.97	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 49
5RDT	;	1.04	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 50
5RDU	;	1.05	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 51
5RDV	;	1.08	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 52
5RDW	;	1.03	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 53
5RDX	;	0.98	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 54
5RDY	;	1.13	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 55
5RDZ	;	1.14	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 56
5RE0	;	1.03	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 57
5RE1	;	0.97	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 58
5RE2	;	1.0	;	PanDDA analysis group deposition -- Endothiapepsin ground state model 59
5R1T	;	1.187	;	PanDDA analysis group deposition -- Endothiapepsin in complex with fragment F2X-Entry A07, DMSO-free
5R1U	;	1.039	;	PanDDA analysis group deposition -- Endothiapepsin in complex with fragment F2X-Entry B03, DMSO-free
5R1V	;	0.94	;	PanDDA analysis group deposition -- Endothiapepsin in complex with fragment F2X-Entry C04, DMSO-free
5R1W	;	1.077	;	PanDDA analysis group deposition -- Endothiapepsin in complex with fragment F2X-Entry C11, DMSO-free
5R1X	;	1.069	;	PanDDA analysis group deposition -- Endothiapepsin in complex with fragment F2X-Entry D04, DMSO-free
5R1Y	;	1.038	;	PanDDA analysis group deposition -- Endothiapepsin in complex with fragment F2X-Entry D10, DMSO-free
5R1Z	;	1.067	;	PanDDA analysis group deposition -- Endothiapepsin in complex with fragment F2X-Entry D11, DMSO-free
5R20	;	1.009	;	PanDDA analysis group deposition -- Endothiapepsin in complex with fragment F2X-Entry E06, DMSO-free
5R21	;	1.047	;	PanDDA analysis group deposition -- Endothiapepsin in complex with fragment F2X-Entry E07, DMSO-free
5R22	;	1.098	;	PanDDA analysis group deposition -- Endothiapepsin in complex with fragment F2X-Entry E11, DMSO-free
5R23	;	1.029	;	PanDDA analysis group deposition -- Endothiapepsin in complex with fragment F2X-Entry F03, DMSO-free
5R24	;	1.19	;	PanDDA analysis group deposition -- Endothiapepsin in complex with fragment F2X-Entry F04, DMSO-free
5R25	;	1.078	;	PanDDA analysis group deposition -- Endothiapepsin in complex with fragment F2X-Entry F08, DMSO-free
5R26	;	1.058	;	PanDDA analysis group deposition -- Endothiapepsin in complex with fragment F2X-Entry G02, DMSO-free
5R27	;	1.029	;	PanDDA analysis group deposition -- Endothiapepsin in complex with fragment F2X-Entry G03, DMSO-free
5R28	;	1.019	;	PanDDA analysis group deposition -- Endothiapepsin in complex with fragment F2X-Entry G08, DMSO-free
5R29	;	1.105	;	PanDDA analysis group deposition -- Endothiapepsin in complex with fragment F2X-Entry G09, DMSO-free
5R2A	;	1.049	;	PanDDA analysis group deposition -- Endothiapepsin in complex with fragment F2X-Entry H02, DMSO-free
5R2B	;	1.019	;	PanDDA analysis group deposition -- Endothiapepsin in complex with fragment F2X-Entry H03, DMSO-free
5R2C	;	1.184	;	PanDDA analysis group deposition -- Endothiapepsin in complex with fragment F2X-Entry H05, DMSO-free
5R2D	;	0.919	;	PanDDA analysis group deposition -- Endothiapepsin in complex with fragment F2X-Entry H11, DMSO-free
5QT1	;	1.58	;	PanDDA analysis group deposition -- Partial occupancy interpretation of PanDDA event map: SETDB1 in complex with FMOMB000017a
5QT2	;	1.59	;	PanDDA analysis group deposition -- Partial occupancy interpretation of PanDDA event map: SETDB1 in complex with FMOPL000074a
7FV9	;	1.17	;	PanDDA analysis group deposition -- PHIP in complex with Z1004253138
7FVP	;	1.15	;	PanDDA analysis group deposition -- PHIP in complex with Z1004277578
7FVF	;	1.15	;	PanDDA analysis group deposition -- PHIP in complex with Z123605878
7FUY	;	1.15	;	PanDDA analysis group deposition -- PHIP in complex with Z1284554279
7FV6	;	1.19	;	PanDDA analysis group deposition -- PHIP in complex with Z1334218055
7FVD	;	1.36	;	PanDDA analysis group deposition -- PHIP in complex with Z1424453050
7FVO	;	1.19	;	PanDDA analysis group deposition -- PHIP in complex with Z1435810807
7FVM	;	1.26	;	PanDDA analysis group deposition -- PHIP in complex with Z1590917771
7FVR	;	1.19	;	PanDDA analysis group deposition -- PHIP in complex with Z166737374
7FVI	;	1.18	;	PanDDA analysis group deposition -- PHIP in complex with Z183306756
7FUV	;	1.19	;	PanDDA analysis group deposition -- PHIP in complex with Z183376720
7FUX	;	1.22	;	PanDDA analysis group deposition -- PHIP in complex with Z183480798
7FV7	;	1.25	;	PanDDA analysis group deposition -- PHIP in complex with Z1929967066
7FVN	;	1.15	;	PanDDA analysis group deposition -- PHIP in complex with Z371875396
7FVK	;	1.15	;	PanDDA analysis group deposition -- PHIP in complex with Z409964562
7FVL	;	1.15	;	PanDDA analysis group deposition -- PHIP in complex with Z4140355932
7FUZ	;	1.43	;	PanDDA analysis group deposition -- PHIP in complex with Z4307421429
7FV2	;	1.15	;	PanDDA analysis group deposition -- PHIP in complex with Z445899798
7FUU	;	1.16	;	PanDDA analysis group deposition -- PHIP in complex with Z445977856
7FV0	;	1.21	;	PanDDA analysis group deposition -- PHIP in complex with Z44602337
7FV4	;	1.15	;	PanDDA analysis group deposition -- PHIP in complex with Z44602341
7FUT	;	1.18	;	PanDDA analysis group deposition -- PHIP in complex with Z44602357
7FUS	;	1.15	;	PanDDA analysis group deposition -- PHIP in complex with Z44602363
7FVE	;	1.19	;	PanDDA analysis group deposition -- PHIP in complex with Z488932160
7FV1	;	1.19	;	PanDDA analysis group deposition -- PHIP in complex with Z4912742920
7FV3	;	1.15	;	PanDDA analysis group deposition -- PHIP in complex with Z4912742924
7FVA	;	1.19	;	PanDDA analysis group deposition -- PHIP in complex with Z4913872963
7FVJ	;	1.19	;	PanDDA analysis group deposition -- PHIP in complex with Z4913873236
7FVC	;	1.18	;	PanDDA analysis group deposition -- PHIP in complex with Z495704106
7FVH	;	1.15	;	PanDDA analysis group deposition -- PHIP in complex with Z5067911819
7FV5	;	1.15	;	PanDDA analysis group deposition -- PHIP in complex with Z606695272
7FVB	;	1.38	;	PanDDA analysis group deposition -- PHIP in complex with Z6617539657
7FVQ	;	1.15	;	PanDDA analysis group deposition -- PHIP in complex with Z68576046
7FUW	;	1.19	;	PanDDA analysis group deposition -- PHIP in complex with Z961579360
7FV8	;	1.15	;	PanDDA analysis group deposition -- PHIP in complex with Z964297186
7FVG	;	1.15	;	PanDDA analysis group deposition -- PHIP in complex with Z992453336
5RPH	;	1.38	;	PanDDA analysis group deposition -- Proteinase K changed state model for fragment Frag Xtal Screen A11a
5ROQ	;	1.02	;	PanDDA analysis group deposition -- Proteinase K changed state model for fragment Frag Xtal Screen A12a
5ROP	;	1.64	;	PanDDA analysis group deposition -- Proteinase K changed state model for fragment Frag Xtal Screen A12a at Room Temperature
5RPJ	;	1.27	;	PanDDA analysis group deposition -- Proteinase K changed state model for fragment Frag Xtal Screen B12a
5ROL	;	1.22	;	PanDDA analysis group deposition -- Proteinase K changed state model for fragment Frag Xtal Screen B5a
5RP9	;	1.48	;	PanDDA analysis group deposition -- Proteinase K changed state model for fragment Frag Xtal Screen B7a
5RPK	;	1.78	;	PanDDA analysis group deposition -- Proteinase K changed state model for fragment Frag Xtal Screen B9a
5ROF	;	1.08	;	PanDDA analysis group deposition -- Proteinase K changed state model for fragment Frag Xtal Screen C11a
5RP6	;	1.17	;	PanDDA analysis group deposition -- Proteinase K changed state model for fragment Frag Xtal Screen C2a
5RPL	;	1.09	;	PanDDA analysis group deposition -- Proteinase K changed state model for fragment Frag Xtal Screen C8a
5RP7	;	1.15	;	PanDDA analysis group deposition -- Proteinase K changed state model for fragment Frag Xtal Screen D12a
5RPA	;	1.25	;	PanDDA analysis group deposition -- Proteinase K changed state model for fragment Frag Xtal Screen E3a
5RON	;	1.22	;	PanDDA analysis group deposition -- Proteinase K changed state model for fragment Frag Xtal Screen E4a
5RPD	;	1.02	;	PanDDA analysis group deposition -- Proteinase K changed state model for fragment Frag Xtal Screen F12a
5ROR	;	1.22	;	PanDDA analysis group deposition -- Proteinase K changed state model for fragment Frag Xtal Screen F1a
5ROW	;	1.21	;	PanDDA analysis group deposition -- Proteinase K changed state model for fragment Frag Xtal Screen F6a
5RPG	;	1.5	;	PanDDA analysis group deposition -- Proteinase K changed state model for fragment Frag Xtal Screen H2a
5RPC	;	1.23	;	PanDDA analysis group deposition -- Proteinase K changed state model for fragment Frag Xtal Screen H3a
5RPM	;	1.22	;	PanDDA analysis group deposition -- Proteinase K changed state model for fragment Frag Xtal Screen H5a
5ROT	;	1.05	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo1
5RPY	;	1.09	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo10
5RP3	;	1.09	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo14
5RPR	;	1.16	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo15
5RP2	;	1.1	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo20
5ROY	;	1.05	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo22
5ROX	;	1.12	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo24
5RPI	;	1.03	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo26
5RPF	;	1.39	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo27
5ROI	;	1.05	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo30
5RPQ	;	1.07	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo32
5ROS	;	1.45	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo34
5RPV	;	1.1	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo35
5RP1	;	1.11	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo36
5ROK	;	1.04	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo37
5RPE	;	1.02	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo40
5ROZ	;	1.14	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo41
5RPX	;	1.05	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo43
5RPP	;	1.08	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo44
5ROM	;	1.07	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo45
5RP8	;	1.03	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo46
5RP5	;	1.09	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo48
5ROG	;	1.08	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo51
5RP0	;	1.03	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo57
5RPZ	;	1.22	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo58
5ROJ	;	1.02	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo59
5ROE	;	1.5	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo6
5RPS	;	1.04	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo60
5ROH	;	1.04	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo61
5ROV	;	1.04	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo62
5RPW	;	1.02	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo63
5RPN	;	1.02	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo64
5ROC	;	1.523	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo65
5RPU	;	1.55	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo67
5RPB	;	1.64	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo68
5RPO	;	1.5	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo7
5RP4	;	1.05	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo70
5ROD	;	1.04	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo71
5ROU	;	1.06	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo72
5ROO	;	1.41	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo73
5RPT	;	1.98	;	PanDDA analysis group deposition -- Proteinase K crystal structure Apo9
5R8W	;	1.5	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment K00283c in complex with MAP kinase p38-alpha
5R91	;	1.731	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment KCL057 in complex with MAP kinase p38-alpha
5R92	;	1.66	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment KCL063 in complex with MAP kinase p38-alpha
5R93	;	1.489	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment KCL077 in complex with MAP kinase p38-alpha
5R94	;	1.45	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment KCL081 in complex with MAP kinase p38-alpha
5R95	;	1.59	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment KCL093 in complex with MAP kinase p38-alpha
5R96	;	1.767	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment KCL095 in complex with MAP kinase p38-alpha
5R8Z	;	1.65	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N01381c in complex with MAP kinase p38-alpha
5R8U	;	1.48	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N05703b in complex with MAP kinase p38-alpha
5RA8	;	1.78	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N05711b in complex with MAP kinase p38-alpha
5R9O	;	1.6	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N06122b in complex with MAP kinase p38-alpha
5R9Q	;	1.645	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N07422b in complex with MAP kinase p38-alpha
5RA9	;	1.68	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N08051b in complex with MAP kinase p38-alpha
5R8Y	;	1.679	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N08078b in complex with MAP kinase p38-alpha
5RA1	;	1.61	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N08141b in complex with MAP kinase p38-alpha
5RA2	;	1.57	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N09036b in complex with MAP kinase p38-alpha
5R8V	;	1.479	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N09139b in complex with MAP kinase p38-alpha
5RA3	;	1.57	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N10836b in complex with MAP kinase p38-alpha
5R90	;	1.619	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N11145a in complex with MAP kinase p38-alpha
5RA5	;	1.54	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N11302a in complex with MAP kinase p38-alpha
5RA4	;	1.59	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N11337a in complex with MAP kinase p38-alpha
5RA6	;	1.86	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N11338a in complex with MAP kinase p38-alpha
5RA7	;	1.92	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N11351a in complex with MAP kinase p38-alpha
5R8X	;	1.73	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N11396a in complex with MAP kinase p38-alpha
5R9R	;	1.76	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13413a in complex with MAP kinase p38-alpha
5R9M	;	1.809	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13418a in complex with MAP kinase p38-alpha
5R9N	;	1.688	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13421a in complex with MAP kinase p38-alpha
5RA0	;	1.91	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13421a in complex with MAP kinase p38-alpha
5R9P	;	1.72	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13430a in complex with MAP kinase p38-alpha
5R9S	;	1.7	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13470a in complex with MAP kinase p38-alpha
5R9U	;	1.67	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13475a in complex with MAP kinase p38-alpha
5R9T	;	1.8	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13477a in complex with MAP kinase p38-alpha
5R9Z	;	1.66	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13502a in complex with MAP kinase p38-alpha
5R9V	;	1.45	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13596a in complex with MAP kinase p38-alpha
5R9W	;	1.89	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13598a in complex with MAP kinase p38-alpha
5R9X	;	1.72	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13611a in complex with MAP kinase p38-alpha
5R99	;	1.89	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13619a in complex with MAP kinase p38-alpha
5R9Y	;	1.57	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13619a in complex with MAP kinase p38-alpha
5R97	;	1.438	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13662a in complex with MAP kinase p38-alpha
5R9E	;	1.775	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13693a in complex with MAP kinase p38-alpha
5R9F	;	1.986	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13724a in complex with MAP kinase p38-alpha
5R9A	;	1.53	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13838a in complex with MAP kinase p38-alpha
5R9B	;	1.657	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13866a in complex with MAP kinase p38-alpha
5R9C	;	1.74	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N14074a in complex with MAP kinase p38-alpha
5R98	;	1.68	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N14109a in complex with MAP kinase p38-alpha
5R9J	;	1.52	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N14231a in complex with MAP kinase p38-alpha
5R9K	;	1.498	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N14246a in complex with MAP kinase p38-alpha
5R9L	;	1.47	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N14274a in complex with MAP kinase p38-alpha
5R9G	;	1.73	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment PC587 in complex with MAP kinase p38-alpha
5R9D	;	1.69	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment S00888c in complex with MAP kinase p38-alpha
5R9H	;	1.49	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment TCJ658 in complex with MAP kinase p38-alpha
5R9I	;	1.813	;	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment TCJ795 in complex with MAP kinase p38-alpha
5R8H	;	1.5	;	PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z111716368 in complex with INTERLEUKIN-1 BETA
5R8G	;	1.43	;	PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z1259086950 in complex with INTERLEUKIN-1 BETA
5R85	;	1.44	;	PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z1262246195 in complex with INTERLEUKIN-1 BETA
5R8A	;	1.47	;	PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z1492796719 in complex with INTERLEUKIN-1 BETA
5R88	;	1.48	;	PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z1545313172 in complex with INTERLEUKIN-1 BETA
5R8D	;	1.47	;	PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z1745658474 in complex with INTERLEUKIN-1 BETA
5R8M	;	1.39	;	PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z1818332938 in complex with INTERLEUKIN-1 BETA
5R8O	;	1.42	;	PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z1881545321 in complex with INTERLEUKIN-1 BETA
5R8L	;	1.56	;	PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z1891773393 in complex with INTERLEUKIN-1 BETA
5R8B	;	1.49	;	PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z2027049478 in complex with INTERLEUKIN-1 BETA
5R8I	;	1.47	;	PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z210803634 in complex with INTERLEUKIN-1 BETA
5R89	;	1.65	;	PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z217038356 in complex with INTERLEUKIN-1 BETA
5R8F	;	1.41	;	PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z2377835233 in complex with INTERLEUKIN-1 BETA
5R8Q	;	1.23	;	PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z2643472210 in complex with INTERLEUKIN-1 BETA
5R8C	;	1.54	;	PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z30857828 in complex with INTERLEUKIN-1 BETA
5R8J	;	1.62	;	PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z355728146 in complex with INTERLEUKIN-1 BETA
5R8K	;	1.47	;	PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z355728146 in complex with INTERLEUKIN-1 BETA
5R87	;	1.47	;	PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z44592329 in complex with INTERLEUKIN-1 BETA
5R8N	;	1.48	;	PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z57292400 in complex with INTERLEUKIN-1 BETA
5R8E	;	1.35	;	PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z57475877 in complex with INTERLEUKIN-1 BETA
5R8P	;	1.53	;	PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z818727262 in complex with INTERLEUKIN-1 BETA
5R86	;	1.5	;	PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z943693514 in complex with INTERLEUKIN-1 BETA
5RL0	;	1.69	;	PanDDA analysis group deposition of computational designs of SARS-CoV-2 main protease covalent inhibitors -- Crystal Structure of SARS-CoV-2 main protease in complex with LON-WEI-adc59df6-2 (Mpro-x3110)
5RL2	;	1.48	;	PanDDA analysis group deposition of computational designs of SARS-CoV-2 main protease covalent inhibitors -- Crystal Structure of SARS-CoV-2 main protease in complex with LON-WEI-adc59df6-26 (Mpro-x3115)
5RL1	;	1.65	;	PanDDA analysis group deposition of computational designs of SARS-CoV-2 main protease covalent inhibitors -- Crystal Structure of SARS-CoV-2 main protease in complex with LON-WEI-adc59df6-27 (Mpro-x3113)
5RL4	;	1.53	;	PanDDA analysis group deposition of computational designs of SARS-CoV-2 main protease covalent inhibitors -- Crystal Structure of SARS-CoV-2 main protease in complex with LON-WEI-adc59df6-3 (Mpro-x3124)
5RL5	;	1.58	;	PanDDA analysis group deposition of computational designs of SARS-CoV-2 main protease covalent inhibitors -- Crystal Structure of SARS-CoV-2 main protease in complex with LON-WEI-adc59df6-30 (Mpro-x3359)
5RL3	;	1.51	;	PanDDA analysis group deposition of computational designs of SARS-CoV-2 main protease covalent inhibitors -- Crystal Structure of SARS-CoV-2 main protease in complex with LON-WEI-adc59df6-39 (Mpro-x3117)
5R4F	;	1.44	;	PanDDA analysis group deposition of ground-state model of ATAD2
5R4O	;	1.05	;	PanDDA analysis group deposition of ground-state model of BROMODOMAIN OF HUMAN NUCLEOSOME-REMODELING FACTOR SUBUNIT BPTF
5RW1	;	1.52	;	PanDDA analysis group deposition of ground-state model of DHTKD1
5R7X	;	1.44	;	PanDDA analysis group deposition of ground-state model of Human JMJD1B
5RKZ	;	1.38	;	PanDDA analysis group deposition of ground-state model of human NUDT22 screened against the DSPL fragment library by X-ray Crystallography
5R7W	;	1.27	;	PanDDA analysis group deposition of ground-state model of INTERLEUKIN-1 BETA
5QU9	;	2.0	;	PanDDA analysis group deposition of ground-state model of Kalirin/Rac1 screened against a customized urea fragment library by X-ray Crystallography at the XChem facility of Diamond Light Source beamline I04-1
5RJI	;	1.24	;	PanDDA analysis group deposition of ground-state model of PHIP
5SDS	;	1.91	;	PanDDA analysis group deposition of ground-state model of Porphyromonas gingivalis DPP11
7FRS	;	1.83	;	PanDDA analysis group deposition of ground-state model of PTP1B
7FRT	;	1.86	;	PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster 1
7FRU	;	1.98	;	PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster 2
7GTW	;	1.51	;	PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster1
7GU4	;	1.59	;	PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster11
7GU5	;	1.52	;	PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster12
7GU6	;	1.56	;	PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster14
7GU7	;	1.7	;	PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster15
7GU8	;	1.59	;	PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster16
7GU9	;	1.53	;	PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster17
7GUA	;	1.63	;	PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster18
7GUB	;	1.94	;	PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster19
7GTX	;	1.51	;	PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster2
7GUC	;	1.78	;	PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster20
7GTY	;	1.54	;	PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster3
7GTZ	;	1.6	;	PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster5
7GU0	;	1.66	;	PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster6
7GU1	;	1.59	;	PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster7
7GU2	;	1.8	;	PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster8
7GU3	;	1.74	;	PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster9
5ROB	;	1.87	;	PanDDA analysis group deposition of ground-state model of SARS-CoV-2 helicase
5R8T	;	1.27	;	PanDDA analysis group deposition of ground-state model of SARS-CoV-2 main protease screened against DSI poised (Enamine), Fraglites and Peplites (Newcastle university), Mini Frags (Astex), York 3D (York university), electrophile cysteine covalent (Weizman institute) fragment libraries
5SBF	;	1.64	;	PanDDA analysis group deposition of ground-state model of SARS-CoV-2 NendoU
5SMK	;	1.65	;	PanDDA analysis group deposition of ground-state model of SARS-CoV-2 NSP14
5S73	;	1.06	;	PanDDA analysis group deposition of ground-state model of SARS-CoV-2 Nsp3 macrodomain
5S74	;	0.96	;	PanDDA analysis group deposition of ground-state model of SARS-CoV-2 Nsp3 macrodomain
5RHY	;	1.36	;	PanDDA analysis group deposition of ground-state model of Zika Virus NS3 Helicase
5QIB	;	1.48	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of HAO1 in complex with FMOPL000388a
5QIG	;	1.42	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of HAO1 in complex with Z1407672867
5QID	;	1.45	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of HAO1 in complex with Z1787627869
5QIH	;	1.33	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of HAO1 in complex with Z2697514548
5QIE	;	1.34	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of HAO1 in complex with Z2856434894
5QIC	;	1.34	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of HAO1 in complex with Z30620520
5QIF	;	1.2	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of HAO1 in complex with Z31792168
5QHS	;	1.95	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human FAM83B in complex with FF000014a
5QHK	;	1.61	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human FAM83B in complex with FMOPL000010a
5QHO	;	1.66	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human FAM83B in complex with FMOPL000010a
5QHI	;	1.73	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human FAM83B in complex with FMOPL000271a
5QHL	;	1.68	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human FAM83B in complex with FMOPL000551a
5QHP	;	2.06	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human FAM83B in complex with FMOPL000554a
5QHQ	;	1.96	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human FAM83B in complex with FMOPL000574a
5QHN	;	1.73	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human FAM83B in complex with FMOPL000622a
5QHR	;	1.68	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human FAM83B in complex with FMOPL000635a
5QHJ	;	1.68	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human FAM83B in complex with FMOPL000709a
5QHM	;	1.79	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human FAM83B in complex with OX-145
5QI2	;	1.08	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000110a
5QIA	;	1.14	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000242a
5QHX	;	1.11	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000278a
5QHW	;	1.12	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000347a
5QI0	;	1.05	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000352a
5QHZ	;	1.15	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000385a
5QHY	;	1.17	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000462a
5QI1	;	1.05	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000474a
5QI3	;	1.05	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000475a
5QI7	;	1.05	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000506a
5QI5	;	1.05	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000633a
5QHU	;	1.05	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMSOA000341b
5QK9	;	1.56	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z102895082
5QK5	;	1.63	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z1267773786
5QK0	;	1.44	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z1270312110
5QK8	;	1.71	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z1271660837
5QK6	;	1.51	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z1343633025
5QJN	;	1.77	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z1439422127
5QJA	;	1.64	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z1497321453
5QJP	;	1.5	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z1578665941
5QJ6	;	1.65	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z1614545742
5QJZ	;	1.52	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z1696822287
5QJB	;	1.66	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z1787627869
5QJ4	;	1.89	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z1827602749
5QJI	;	1.69	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z1899842917
5QK7	;	1.66	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z1918536193
5QJW	;	1.57	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z198194396
5QK1	;	1.49	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z2027049478
5QJR	;	1.62	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z220816104
5QKA	;	1.55	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z2377835233
5QK3	;	1.71	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z239136710
5QJD	;	1.61	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z240297434
5QJJ	;	1.71	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z24758179
5QJE	;	1.75	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z275181224
5QJV	;	1.61	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z281802060
5QJX	;	1.73	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z2856434778
5QJ8	;	1.76	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z2856434829
5QJ7	;	1.56	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z32327641
5QJM	;	1.75	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z328695024
5QJK	;	1.65	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z373221060
5QJH	;	2.03	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z375990520
5QJG	;	1.57	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z44567722
5QK4	;	1.62	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z44590919
5QJF	;	1.63	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z52425517
5QK2	;	1.65	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z54628578
5QJQ	;	1.55	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z56791867
5QJL	;	1.66	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z56983806
5QJO	;	1.98	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z57292369
5QJC	;	1.47	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z755044716
5QJ9	;	1.85	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z768399682
5QJU	;	1.77	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z906021418
5QJY	;	1.77	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z94597856
5QJT	;	1.62	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z969560582
5QJS	;	1.58	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT5 in complex with Z979145504
5QGR	;	1.96	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with FMOPL000022a
5QGL	;	2.27	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with FMOPL000275a
5QGH	;	1.82	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with FMOPL000420a
5QGS	;	1.55	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with FMOPL000476a
5QGT	;	1.97	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with FMOPL000609a
5QGK	;	1.81	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with FMOPL000679a
5QGG	;	1.91	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with FMOPL000693a
5QGJ	;	1.95	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with FMOPL000706a
5QGI	;	1.95	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with FMOPL000710a
5QGU	;	1.71	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with FMOPL000747a
5QHG	;	1.92	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NU000442a
5QHH	;	1.52	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NU000443a
5QGW	;	1.94	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NUOOA000154
5QGX	;	1.61	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NUOOA000155
5QGY	;	1.72	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NUOOA000158
5QGZ	;	1.65	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NUOOA000161
5QH0	;	1.57	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NUOOA000180
5QH1	;	1.65	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NUOOA000181
5QH2	;	1.74	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NUOOA000188
5QH3	;	1.65	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NUOOA000191
5QH7	;	1.74	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NUOOA000194a
5QH4	;	1.67	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NUOOA000220a
5QH5	;	1.85	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NUOOA000224a
5QH6	;	2.0	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NUOOA000259a
5QHF	;	1.67	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NUOOA000301a
5QGM	;	1.96	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with OX-160
5QGN	;	1.95	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with OX-210
5QGO	;	1.82	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with OX-220
5QGP	;	2.09	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with OX-221
5QGQ	;	1.95	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with OX-65
5QH8	;	1.75	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with PCM-0102558
5QH9	;	1.72	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with PCM-0102716
5QHA	;	1.57	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with PCM-0102951
5QHB	;	1.57	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with RK4-332
5QHC	;	2.21	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with RK4-337
5QHE	;	1.74	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with RK4-350
5QGV	;	1.59	;	PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with UNUYB062989
5SMN	;	1.36	;	PanDDA analysis group deposition of SARS-CoV-2 main protease ligands identified from single sequence-guideddeep generative framework -- Crystal structure of SARS-CoV-2 main protease in complex with Z1365651030 (Mpro-IBM0078)
5SMM	;	1.58	;	PanDDA analysis group deposition of SARS-CoV-2 main protease ligands identified from single sequence-guideddeep generative framework -- Crystal structure of SARS-CoV-2 main protease in complex with Z1633315555 (Mpro-IBM0058)
5SML	;	1.53	;	PanDDA analysis group deposition of SARS-CoV-2 main protease ligands identified from single sequence-guideddeep generative framework -- Crystal structure of SARS-CoV-2 main protease in complex with Z68337194 (Mpro-IBM0045)
5RHB	;	1.43	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Cov_HetLib030 (Mpro-x2097)
5RHC	;	1.58	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Cov_HetLib053 (Mpro-x2119)
5RG1	;	1.65	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with NCL-00024905
5RG2	;	1.63	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with NCL-00025058
5RG3	;	1.58	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with NCL-00025412
5RGM	;	2.04	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102142 (Mpro-x0708)
5RGO	;	1.74	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102248 (Mpro-x0736)
5RGP	;	2.07	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102628 (Mpro-x0771)
5RGN	;	1.86	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102759 (Mpro-x0731)
5RGL	;	1.76	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with PCM-0102962 (Mpro-x0705)
5RHF	;	1.76	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with PG-COV-34 (Mpro-x2754)
5RHE	;	1.56	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with PG-COV-42 (Mpro-x2052)
5RHD	;	1.57	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with SF013 (Mpro-x2193)
5RH2	;	1.827	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1129289650 (Mpro-x2646)
5RGS	;	1.72	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1259086950 (Mpro-x1163)
5RH3	;	1.69	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1264525706 (Mpro-x2649)
5RH0	;	1.916	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1286870272 (Mpro-x2608)
5RGK	;	1.43	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1310876699 (Mpro-x0426)
5RGZ	;	1.52	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1343543528 (Mpro-x2600)
5RGX	;	1.69	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1344037997 (Mpro-x2572)
5RGJ	;	1.34	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1401276297 (Mpro-x0425)
5RHA	;	1.51	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z147647874 (Mpro-x2779)
5RH4	;	1.34	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1530425063 (Mpro-x2659)
5RGY	;	1.976	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1535580916 (Mpro-x2581)
5RGH	;	1.7	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1619978933 (Mpro-x0395)
5RGQ	;	2.15	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z1849009686 (Mpro-x1086)
5RH1	;	1.96	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z2010253653 (Mpro-x2643)
5RGG	;	2.26	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z2856434890 (Mpro-x0165)
5RGR	;	1.41	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z328695024 (Mpro-x1101)
5RGI	;	1.57	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z369936976 (Mpro-x0397)
5RH9	;	1.91	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z4438424255 (Mpro-x2776)
5RH5	;	1.72	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z4439011520 (Mpro-x2694)
5RH7	;	1.71	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z4439011584 (Mpro-x2705)
5RH6	;	1.6	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z4439011588 (Mpro-x2703)
5RGT	;	2.22	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z4439011607 (Mpro-x2540)
5RGW	;	1.43	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z4444621910 (Mpro-x2569)
5RH8	;	1.81	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z4444621965 (Mpro-x2764)
5RGV	;	1.82	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z4444622066 (Mpro-x2563)
5RGU	;	2.108	;	PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of SARS-CoV-2 main protease in complex with Z4444622180 (Mpro-x2562)
2PTA	;		;	PANDINUS TOXIN K-A (PITX-KA) FROM PANDINUS IMPERATOR, NMR, 20 STRUCTURES
8FEM	;	2.34	;	Panicum vigratum Dihydroflavonol 4-reductase complexed with NADP
8FEN	;	2.55	;	Panicum vigratum Dihydroflavonol 4-reductase complexed with NADP and DHQ
6X4J	;	2.3	;	PANK3 complex structure with compound PZ-2863
6X4K	;	2.1	;	PANK3 complex structure with compound PZ-2890
6PE6	;	1.6	;	PANK3 complex structure with compound PZ-3022
6X4L	;	2.0	;	PANK3 complex structure with compound PZ-3565
7UE5	;	1.63	;	PANK3 complex structure with compound PZ-3741
7UE6	;	1.74	;	PANK3 complex structure with compound PZ-3802
7UE3	;	1.56	;	PANK3 complex structure with compound PZ-3804
7UE4	;	1.94	;	PANK3 complex structure with compound PZ-3855
7UEP	;	2.0	;	PANK3 complex structure with compound PZ-3860
7UE7	;	1.55	;	PANK3 complex structure with compound PZ-3883
7UE8	;	2.01	;	PANK3 complex structure with compound PZ-3890
7UEO	;	1.8	;	PANK3 complex structure with compound PZ-3977
7UEQ	;	1.7	;	PANK3 complex structure with compound PZ-4061
7UER	;	1.7	;	PANK3 complex structure with compound PZ-4071
7UEX	;	1.9	;	PANK3 complex structure with compound PZ-4127
7UEY	;	1.7	;	PANK3 complex structure with compound PZ-4128
7UET	;	1.9	;	PANK3 complex structure with compound PZ-4140
7UEV	;	1.8	;	PANK3 complex structure with compound PZ-4200
7UES	;	1.8	;	PANK3 complex structure with compound PZ-4202
7UEU	;	2.0	;	PANK3 complex structure with compound PZ-4215
6B3V	;	1.601	;	PANK3 complex with compound PZ-2891
5KPZ	;	2.4	;	PANK3-ADP-PhosphoPantothenate complex
5KQ8	;	2.002	;	PANK3-AMPPN complex
5KPT	;	2.301	;	PANK3-AMPPNP complex
5KPR	;	1.827	;	PANK3-AMPPNP-Pantothenate complex
5KQD	;	2.6	;	PANK3:Palmitoyl-CoA complex
3Q10	;	1.83	;	Pantoate-beta-alanine ligase from Yersinia pestis
3Q12	;	1.58	;	Pantoate-beta-alanine ligase from Yersinia pestis in complex with pantoate.
3UNV	;	1.54	;	Pantoea agglomerans Phenylalanine Aminomutase
6TGF	;	2.55	;	Pantoea stewartii WceF is a glycan biofilm modifying enzyme with a bacteriophage tailspike-like parallel beta-helix fold
4NE2	;	1.9	;	Pantothenamide-bound Pantothenate Kinase from Klebsiella pneumoniae
4NB4	;	2.25	;	Pantothenamide-bound Pantothenate kinase from Staphylococcus aureus
2ZS8	;	2.8	;	Pantothenate kinase from Mycobacterium tuberculosis (MtPanK) co-crystallized with ADP
2GET	;	2.35	;	Pantothenate kinase from Mycobacterium tuberculosis (MtPanK) in complex with a coenzyme A derivative, Form-I (LT)
2GES	;	2.4	;	Pantothenate kinase from Mycobacterium tuberculosis (MtPanK) in complex with a coenzyme A derivative, Form-I (RT)
2GEV	;	2.35	;	Pantothenate kinase from Mycobacterium tuberculosis (MtPanK) in complex with a coenzyme A derivative, Form-II (LT)
2GEU	;	2.9	;	Pantothenate kinase from Mycobacterium tuberculosis (MtPanK) in complex with a coenzyme A derivative, Form-II (RT)
2ZS9	;	2.7	;	Pantothenate kinase from Mycobacterium tuberculosis (MtPanK) in complex with ADP and Pantothenate
2ZSA	;	2.5	;	Pantothenate kinase from Mycobacterium tuberculosis (MtPanK) in complex with ADP and Phosphopantothenate
2ZSB	;	2.75	;	Pantothenate kinase from Mycobacterium tuberculosis (MtPanK) in complex with ADP, obtained through soaking of native enzyme crystals with the ligand
3AF2	;	2.3	;	Pantothenate kinase from Mycobacterium tuberculosis (MtPanK) in complex with AMPPCP
2ZSE	;	2.5	;	Pantothenate kinase from Mycobacterium tuberculosis (MtPanK) in complex with AMPPCP and Pantothenate
2ZSF	;	2.8	;	Pantothenate kinase from Mycobacterium tuberculosis (MtPanK) in complex with ATP and ADP
2ZS7	;	2.65	;	Pantothenate kinase from Mycobacterium tuberculosis (MtPanK) in complex with citrate anion
2ZSD	;	2.5	;	Pantothenate kinase from Mycobacterium tuberculosis (MtPanK) in complex with Coenzyme A
3AF1	;	2.5	;	Pantothenate kinase from Mycobacterium tuberculosis (MtPanK) in complex with GDP
3AF0	;	2.5	;	Pantothenate kinase from Mycobacterium tuberculosis (MtPanK) in complex with GDP and Pantothenate
3AEZ	;	2.2	;	Pantothenate kinase from Mycobacterium tuberculosis (MtPanK) in complex with GDP and Phosphopantothenate
3AF4	;	2.6	;	Pantothenate kinase from Mycobacterium tuberculosis (MtPanK) in complex with GMPPCP
3AF3	;	2.35	;	Pantothenate kinase from Mycobacterium tuberculosis (MtPanK) in complex with GMPPCP and Pantothenate
3AVQ	;	3.0	;	Pantothenate kinase from Mycobacterium tuberculosis (MtPanK) in complex with N9-Pan
3AVO	;	2.55	;	Pantothenate kinase from Mycobacterium tuberculosis (MtPanK) in complex with Pantothenate
3AVP	;	2.6	;	Pantothenate kinase from Mycobacterium tuberculosis (MtPanK) in complex with Pantothenol
4MQ6	;	1.7	;	Pantothenate synthase in complex with 2-(5-methoxy-2-(tosylcarbamoyl)-1H-indol-1-yl)acetic acid
4DDK	;	1.75	;	Pantothenate synthetase in complex with 1,3-benzodioxole-5-carboxylic acid
4FZJ	;	1.63	;	Pantothenate synthetase in complex with 1,3-DIMETHYL-1H-THIENO[2,3-C]PYRAZOLE-5-CARBOXYLIC ACID
4DDM	;	1.83	;	Pantothenate synthetase in complex with 2,1,3-benzothiadiazole-5-carboxylic acid
4DDH	;	2.07	;	Pantothenate synthetase in complex with 6-methoxy-1-benzofuran-3-yl acetic acid
4DE5	;	2.25	;	Pantothenate synthetase in complex with fragment 6
4EFK	;	1.7	;	Pantothenate synthetase in complex with N,N-DIMETHYLTHIOPHENE-3-SULFONAMIDE
4G5F	;	2.33	;	Pantothenate synthetase in complex with racemate (2S)-2,3-DIHYDRO-1,4-BENZODIOXINE-2-CARBOXYLIC ACID and (2R)-2,3-DIHYDRO-1,4-BENZODIOXINE-2-CARBOXYLIC ACID
6QHK	;	1.96	;	PAO-linked dimer of the catalytic domain of the human ubiquitin-conjugating enzyme UBE2S
7VA2	;	2.3	;	PaOrn Oligoribonuclease D11A mutant with product GMP complex structure
7VA6	;	2.1	;	PaOrn Oligoribonuclease D11A mutant with RNA GU complex structure
7VA3	;	1.8	;	PaOrn Oligoribonuclease D11A mutant with substrate pGpG complex structure
7V9Z	;	1.85	;	PaOrn Oligoribonuclease native structure
8A8K	;	3.1	;	PAP phosphatase from Methanothermococcus thermolithotrophicus refined to 3.1 A
2MG0	;		;	PAP262-270 in SDS micelles
6AEF	;	2.16	;	PapA2 acyl transferase
6TCX	;	1.65	;	Papain bound to a natural cysteine protease inhibitor from Streptomyces mobaraensis
7SDR	;	2.72	;	Papain-Like Protease of SARS CoV-2 in Complex with Jun9-72-2 Inhibitor
7RZC	;	2.04	;	Papain-Like Protease of SARS CoV-2 in complex with Jun9-84-3 inhibitor
7SGW	;	1.95	;	Papain-Like Protease of SARS CoV-2 in complex with PLP_Snyder630 inhibitor
8G62	;	2.17	;	Papain-Like Protease of SARS CoV-2 in complex with remodilin NCGC 390004
7SQE	;	2.0	;	Papain-Like Protease of SARS CoV-2, C111S mutant, in complex with Jun9-84-3 inhibitor
7SGU	;	1.79	;	Papain-Like Protease of SARS CoV-2, C111S mutant, in complex with PLP_Snyder608 inhibitor
7SGV	;	2.0	;	Papain-Like Protease of SARS CoV-2, C111S mutant, in complex with PLP_Snyder630 inhibitor
6I5Z	;	3.0	;	Papaver somniferum O-methyltransferase
6I5Q	;	3.05	;	Papaver somniferum O-methyltransferase 1
6I6K	;	1.49	;	Papaver somniferum O-methyltransferase 1
6I6L	;	1.29	;	Papaver somniferum O-methyltransferase 1
6I6M	;	1.2	;	Papaver somniferum O-methyltransferase 1
6I6N	;	1.5	;	Papaver somniferum O-methyltransferase 1
5K93	;	2.7	;	PapD wild-type chaperone
1PDK	;	2.4	;	PAPD-PAPK CHAPERONE-PILUS SUBUNIT COMPLEX FROM E.COLI P PILUS
1J8S	;	2.1	;	PAPG ADHESIN RECEPTOR BINDING DOMAIN-UNBOUND FORM
8A7E	;	5.02	;	PAPP-A dimer in complex with its inhibitor STC2
8A8O	;	1.45	;	PAPS reductase from Methanothermococcus thermolithotrophicus refined to 1.45 A
2O8V	;	3.0	;	PAPS reductase in a covalent complex with thioredoxin C35A
1N4F	;	1.78	;	Para-Arsanilate Derivative of Hen Egg-White Lysozyme
6YOK	;	1.25	;	Para-Carborane di-propyl-sulfonamide in complex with CA IX mimic
6YO4	;	1.7	;	Para-Carborane propyl-sulfonamide in complex with CA IX mimic
7R6U	;	1.55	;	Paracoccidioides americana Pb03 Calcium Binding Protein 1 (Cbp1)
3C75	;	2.5	;	Paracoccus versutus methylamine dehydrogenase in complex with amicyanin
7R2X	;	3.35	;	Paradendryphiella salina PL8 mannuronate-specific alginate lyase
1HIQ	;		;	PARADOXICAL STRUCTURE AND FUNCTION IN A MUTANT HUMAN INSULIN ASSOCIATED WITH DIABETES MELLITUS
1Z4Y	;	2.6	;	Parainfluenza Virus 5 (SV5) Hemagglutinin-Neuraminidase (HN) (pH 8.0)
1Z4V	;	2.3	;	Parainfluenza Virus 5 (SV5) Hemagglutinin-Neuraminidase (HN) with ligand DANA (soaked with DANA, pH 7.0)
1Z4W	;	2.7	;	Parainfluenza Virus 5 (SV5) Hemagglutinin-Neuraminidase (HN) with ligand DANA (soaked with DANA, pH8.0)
1Z50	;	2.8	;	Parainfluenza Virus 5 (SV5) Hemagglutinin-Neuraminidase (HN) with ligand DANA (soaked with sialic acid, pH 8.0)
1Z4Z	;	2.5	;	Parainfluenza Virus 5 (SV5) Hemagglutinin-Neuraminidase (HN) with ligand DANA(soaked with sialic acid, pH7.0))
1Z4X	;	2.5	;	Parainfluenza Virus 5 (SV5) Hemagglutinin-Neuraminidase (HN) with ligand Sialyllactose (soaked with Sialyllactose, pH8.0)
6V85	;	4.38	;	Parainfluenza virus 5 L-P complex
6V86	;	4.63	;	Parainfluenza virus 5 L-P complex with an alternate conformation of the CD-MTase-CTD module
6YY4	;		;	Parallel 17-mer DNA G-quadruplex
272D	;	2.0	;	PARALLEL AND ANTIPARALLEL (G.GC)2 TRIPLE HELIX FRAGMENTS IN A CRYSTAL STRUCTURE
2CCE	;	1.9	;	Parallel Configuration of pLI E20S
7EUC	;		;	Parallel G-quadruplex structure
5XAX	;	2.903	;	Parallel homodimer structures of the extracellular domains of the voltage-gated sodium channel beta4 subunit explain its role in cell-cell adhesion
5XAW	;	2.101	;	Parallel homodimer structures of voltage-gated sodium channel beta4 for cell-cell adhesion
2M1G	;		;	Parallel human telomeric quadruplex containing 2'F-ANA substitutions
7PNE	;		;	Parallel Q-D hybrid with 3' duplex stem-loop as a lateral snapback loop
4AH9	;	1.7	;	Parallel screening of a low molecular weight compound library: do differences in methodology affect hit identification
4AHR	;	1.9	;	Parallel screening of a low molecular weight compound library: do differences in methodology affect hit identification
4AHS	;	1.75	;	Parallel screening of a low molecular weight compound library: do differences in methodology affect hit identification
4AHT	;	1.8	;	Parallel screening of a low molecular weight compound library: do differences in methodology affect hit identification
4AHU	;	1.9	;	Parallel screening of a low molecular weight compound library: do differences in methodology affect hit identification
4AHV	;	1.8	;	Parallel screening of a low molecular weight compound library: do differences in methodology affect hit identification
2MB2	;		;	parallel-stranded G-quadruplex in DNA poly-G stretches
2K9C	;		;	Paramagnetic shifts in solid-state NMR of Proteins to elicit structural information
2XY8	;		;	Paramagnetic-based NMR structure of the complex between the N- terminal epsilon domain and the theta domain of the DNA polymerase III
3QB8	;	1.5	;	Paramecium Chlorella Bursaria Virus1 Putative ORF A654L is a Polyamine Acetyltransferase
1SVF	;	1.4	;	PARAMYXOVIRUS SV5 FUSION PROTEIN CORE
8D52	;	2.02	;	Parathyroid hormone 1 receptor extracellular domain complexed with a peptide ligand containing (2-naphthyl)-beta-3-homoalanine
8D51	;	2.0	;	Parathyroid hormone 1 receptor extracellular domain complexed with a peptide ligand containing beta-3-homotryptophan
7UZO	;	1.3	;	Parathyroid hormone 1 receptor extracellular domain complexed with a peptide ligand containing one beta-amino acid
7UZP	;	2.29	;	parathyroid hormone 1 receptor extracellular domain complexed with a peptide ligand containing three beta-amino acids
8C24	;	2.1	;	ParDE1 toxin-antitoxin complex from Mycobacterium tuberculosis (rv1960c-rv1959c)
8C26	;	2.35	;	ParDE2 toxin-antitoxin complex from Mycobacterium tuberculosis (rv2142A-rv2142c)
7CMP	;	2.886	;	parE in complex with AMPPNP
2HU3	;	1.3	;	Parent Structure of Hen Egg White Lysozyme grown in acidic pH 4.8. Refinement for comparison with crosslinked molecules of lysozyme
4E07	;	2.9	;	ParF-AMPPCP-C2221 form
7PA3	;	1.42	;	PARK7 with covalent inhibitor JYQ-88
7PA2	;	1.21	;	PARK7 with inhibitor 8RK64
1ZGS	;	2.5	;	Parkia platycephala seed lectin in complex with 5-bromo-4-chloro-3-indolyl-a-D-mannose
5C23	;	2.37	;	Parkin (S65DUblR0RBR)
5C1Z	;	1.79	;	Parkin (UblR0RBR)
6HUE	;	2.85	;	ParkinS65N
7US2	;	2.76	;	PARL-cleaved Skd3 (human ClpB) E455Q Nucleotide Binding Domain hexamer bound to ATPgammaS, open conformation
5AI7	;		;	ParM doublet model
2ZHC	;	23.0	;	ParM filament
1MWM	;	2.0	;	ParM from plasmid R1 ADP form
1MWK	;	2.3	;	ParM from plasmid R1 APO form
4A61	;	2.0	;	ParM from plasmid R1 in complex with AMPPNP
4A62	;	2.2	;	ParM from R1 plasmid in complex with peptide from C-terminus of ParR
2ZGY	;	1.9	;	PARM with GDP
2ZGZ	;	2.25	;	PARM with GMPPNP
1A3M	;		;	PAROMOMYCIN BINDING INDUCES A LOCAL CONFORMATIONAL CHANGE IN THE A SITE OF 16S RRNA, NMR, 20 STRUCTURES
4ZC7	;	3.041	;	Paromomycin bound to a leishmanial ribosomal A-site
2LE0	;		;	PARP BRCT Domain
2RCW	;	2.8	;	PARP complexed with A620223
2RD6	;	2.3	;	PARP complexed with A861695
3GN7	;	2.5	;	PARP complexed with A861696
3L3L	;	2.5	;	PARP complexed with A906894
3L3M	;	2.5	;	PARP complexed with A927929
3GJW	;	2.3	;	PARP complexed with A968427
4L6S	;	2.2	;	PARP complexed with benzo[1,4]oxazin-3-one inhibitor
7ONR	;	2.05	;	PARP1 catalytic domain in complex with 8-chloroquinazolinone-based inhibitor (compound 9)
7ONT	;	1.853	;	PARP1 catalytic domain in complex with a selective pyridine carboxamide-based inhibitor (compound 22)
7ONS	;	1.97	;	PARP1 catalytic domain in complex with isoquinolone-based inhibitor (compound 16)
7R3L	;	2.0	;	PARP14 catalytic domain in complex with OUL40
5O2D	;	1.6	;	PARP14 Macrodomain 2 with inhibitor
7F41	;	1.39721	;	PARP15 catalytic domain in complex with 3-AMINOBENZAMIDE
6RY4	;	1.95	;	PARP15 catalytic domain in complex with 4-(3-carbamoylphenoxy)benzamide.
7F42	;	1.41	;	PARP15 catalytic domain in complex with Iniparib
7F43	;	1.62	;	PARP15 catalytic domain in complex with Niraparib
7OSP	;	1.44	;	PARP15 catalytic domain in complex with OUL113
7R4A	;	1.9	;	PARP15 catalytic domain in complex with OUL188
7OSS	;	1.5	;	PARP15 catalytic domain in complex with OUL194
7OSX	;	1.6	;	PARP15 catalytic domain in complex with OUL205
7Z1V	;	1.5	;	PARP15 catalytic domain in complex with OUL208
7Z41	;	2.1	;	PARP15 catalytic domain in complex with OUL209
7OTF	;	1.3	;	PARP15 catalytic domain in complex with OUL213
7Z2O	;	1.5	;	PARP15 catalytic domain in complex with OUL215
7PW3	;	1.4	;	PARP15 catalytic domain in complex with OUL217
7PWL	;	2.0	;	PARP15 catalytic domain in complex with OUL218
7OTH	;	1.7	;	PARP15 catalytic domain in complex with OUL219
7OUW	;	1.6	;	PARP15 catalytic domain in complex with OUL220
7PWP	;	2.1	;	PARP15 catalytic domain in complex with OUL221
7PWW	;	2.15	;	PARP15 catalytic domain in complex with OUL224
7OUX	;	1.95	;	PARP15 catalytic domain in complex with OUL228
7Z2Q	;	2.0	;	PARP15 catalytic domain in complex with OUL232
7R5D	;	2.15	;	PARP15 catalytic domain in complex with OUL234
7PWA	;	1.6	;	PARP15 catalytic domain in complex with OUL237
7PWC	;	1.5	;	PARP15 catalytic domain in complex with OUL238
7PWK	;	1.8	;	PARP15 catalytic domain in complex with OUL239
7PWQ	;	1.7	;	PARP15 catalytic domain in complex with OUL240
7PX6	;	1.65	;	PARP15 catalytic domain in complex with OUL241
7PX7	;	1.6	;	PARP15 catalytic domain in complex with OUL242
7Z1Y	;	1.75	;	PARP15 catalytic domain in complex with OUL245
7Z1W	;	1.9	;	PARP15 catalytic domain in complex with OUL246
7PWM	;	1.35	;	PARP15 catalytic domain in complex with OUL252
7PWR	;	1.6	;	PARP15 catalytic domain in complex with OUL254
7PWS	;	1.8	;	PARP15 catalytic domain in complex with OUL255
7PWU	;	1.9	;	PARP15 catalytic domain in complex with OUL256
7R3O	;	2.2	;	PARP15 catalytic domain in complex with OUL40
7OQQ	;	2.0	;	PARP15 catalytic domain in complex with TIQ-A
6EK3	;	1.6	;	PARP15 CATALYTIC DOMAIN MUTANT (Y598L) IN COMPLEX WITH OUL35
7R59	;	2.0	;	PARP2 catalytic domain in complex with OUL245
8SWZ	;	3.0	;	PARP4 ART domain bound to EB47
8SWY	;	2.55	;	PARP4 ART domain bound to NADH
8SX1	;	4.2	;	PARP4 catalytic domain
8SX2	;	2.95	;	PARP4 catalytic domain bound to EB47
2JD3	;	2.8	;	ParR from plasmid pB171
6D0H	;	1.5	;	ParT: Prs ADP-ribosylating toxin bound to cognate antitoxin ParS
6D0I	;	1.55	;	ParT: Prs ADP-ribosylating toxin bound to cognate antitoxin ParS. L48M ParT, SeMet-substituted complex.
2LJ9	;		;	Partial 3d structure of the c-terminal part of the free arabidopsis thaliana cp12-2 in its oxidized form
8G99	;	2.8	;	Partial auto-inhibitory complex of Xenopus laevis DNA polymerase alpha-primase
7N8X	;	3.4	;	Partial C. difficile TcdB and CSPG4 fragment
7KFT	;	3.4	;	Partial Cas6-RT-Cas1--Cas2 complex
7EPR	;	2.2	;	Partial Consensus L-threonine 3-dehydrogenase (C-Change)
7EPS	;	2.102	;	Partial Consensus L-threonine 3-dehydrogenase (E-change)
8A7D	;	3.06	;	Partial dimer complex of PAPP-A and its inhibitor STC2
8G9N	;	3.5	;	Partial DNA elongation subcomplex of Xenopus laevis DNA polymerase alpha-primase
8UCU	;	2.85	;	Partial DNA termination subcomplex of Xenopus laevis DNA polymerase alpha-primase
1QD7	;	5.5	;	PARTIAL MODEL FOR 30S RIBOSOMAL SUBUNIT
7K1V	;	4.6	;	Partial open state of Mycobacterium tuberculosis zinc metalloprotease 1
4N6V	;	1.8	;	Partial rotational order disorder structure of human stefin B
1DV4	;	4.5	;	PARTIAL STRUCTURE OF 16S RNA OF THE SMALL RIBOSOMAL SUBUNIT FROM THERMUS THERMOPHILUS
4KYD	;	2.21	;	Partial Structure of the C-terminal domain of the HPIV4B phosphoprotein, fused to MBP.
4KYE	;	2.6	;	Partial Structure of the C-terminal domain of the HPIV4B phosphoprotein, fused to MBP.
6ZZU	;	3.5	;	Partial structure of the substrate-free tyrosine hydroxylase (apo-TH).
6ZN2	;	4.3	;	Partial structure of tyrosine hydroxylase in complex with dopamine showing the catalytic domain and an alpha-helix from the regulatory domain involved in dopamine binding.
7PIM	;	4.6	;	Partial structure of tyrosine hydroxylase lacking the first 35 residues in complex with dopamine.
7VTB	;	2.0	;	Partially closed conformation of talaropentaene synthase cyclase domain
2J25	;	2.9	;	Partially deglycosylated glucoceramidase
8OR4	;	3.8	;	Partially dissociated CAND1-CUL1-RBX1-SKP1-SKP2-CKS1-CDK2
6ZOA	;	3.05	;	Partially induced AcrB T protomer and DDM binding to the TM8/PC2 pathway of AcrB L2 protomer
4JA3	;	3.8	;	Partially occluded inward open conformation of the xylose transporter XylE from E. coli
1ULX	;	2.0	;	Partially photolyzed structure of CO-bound heme-heme oxygenase complex
1YUZ	;	1.4	;	Partially Reduced State of Nigerythrin
1MFZ	;	2.8	;	Partially refined 2.8 A Crystal structure of GDP-mannose dehydrogenase from P. aeruginosa
6RGI	;	2.64	;	Partially unfolded cytochrome c in complex with sulfonatocalix[6]arene
8SR4	;	3.12	;	particulate methane monooxygeanse treated with potassium cyanide and copper reloaded
8SQW	;	2.16	;	particulate methane monooxygenase crosslinked with 2,2,2-trifluoroethanol bound
8SR1	;	2.18	;	particulate methane monooxygenase crosslinked with 4,4,4-trifluorobutanol bound
8SR2	;	2.36	;	particulate methane monooxygenase incubated with 4,4,4-trifluorobutanol
8SR5	;	3.22	;	particulate methane monooxygenase potassium cyanide treated
8OYI	;	2.19	;	particulate methane monooxygenase with 2,2,2-trifluoroethanol bound
3EZ9	;	2.8	;	Partition Protein
3EZF	;	2.8	;	Partition Protein
3EZ7	;	2.92	;	Partition Protein Apo form in space group I4122
3EZ2	;	2.05	;	Partition protein-ADP complex
1B8C	;	2.0	;	PARVALBUMIN
1B8R	;	1.9	;	PARVALBUMIN
1B9A	;	2.0	;	PARVALBUMIN (MUTATION;D51A, F102W)
1DNV	;	3.6	;	PARVOVIRUS (DENSOVIRUS) FROM GALLERIA MELLONELLA
4DPV	;	2.9	;	PARVOVIRUS/DNA COMPLEX
3A0S	;	1.47	;	PAS domain of histidine kinase ThkA (TM1359)
3A0V	;	1.7	;	PAS domain of histidine kinase ThkA (TM1359) (SeMet, F486M/F489M)
6TC7	;	2.13	;	PAS-GAF bidomain of Glycine max phytochromeA
4Y5F	;	1.7	;	PAS-GAF fragment from Deinococcus radiodurans BphP assembled with BV - Y307S, high dose
4Y3I	;	1.69	;	PAS-GAF fragment from Deinococcus radiodurans BphP assembled with BV - Y307S, low dose
6T3U	;	2.21	;	PAS-GAF fragment from Deinococcus radiodurans phytochrome 1ps after photoexcitation
6T3L	;	2.07	;	PAS-GAF fragment from Deinococcus radiodurans phytochrome in dark state
5NOD	;	1.9	;	PASTA subunit 4 of Streptococcus pneumoniae STKP crystallized with PEG and succinate
4UVQ	;	1.724	;	PatG Domain of Unknown Function
4AKS	;	2.19	;	PatG macrocyclase domain
4AKT	;	2.63	;	PatG macrocyclase in complex with peptide
8ACX	;	1.9	;	Pathogen effector of Zymoseptoria tritici: Zt-KP4
7XVI	;	3.11	;	pathogen effectors which are essential to cause plant disease by manipulating cellular processes in the host
7UQO	;	1.75	;	Pathogenesis related 10-10 (S)-tetrahydropapaverine complex
7UQL	;	1.9	;	Pathogenesis related 10-10 app from
7UQN	;	1.7	;	Pathogenesis related 10-10 noscapine complex
7UQM	;	1.8	;	Pathogenesis related 10-10 papaverine complex
1AUN	;	1.8	;	PATHOGENESIS-RELATED PROTEIN 5D FROM NICOTIANA TABACUM
8Q1S	;	3.23	;	Pathogenic mutations of human phosphorylation sites affect protein-protein interactions
6XSD	;	2.54	;	Patient-derived B2GPI
4MIX	;	1.8	;	PaToxG Glycosyltransferase
8BXL	;	2.4	;	Patulin Synthase from Penicillium expansum
5KN4	;	1.99	;	Pavine N-methyltransferase apoenzyme pH 6.0
5KPC	;	2.5	;	Pavine N-methyltransferase H206A mutant in complex with S-adenosylmethionine pH 6
5KPG	;	1.6	;	Pavine N-methyltransferase in complex with S-adenosylhomocysteine pH 7
5KOC	;	2.293	;	Pavine N-methyltransferase in complex with S-adenosylmethionine pH 7
5KOK	;	1.792	;	Pavine N-methyltransferase in complex with Tetrahydropapaverine and S-adenosylhomocysteine pH 7.25
6AZG	;		;	PawL-Derived Peptide PLP-10 (cis conformer)
6AZF	;		;	PawL-Derived Peptide PLP-10 (trans conformer)
6AWK	;		;	PawL-Derived Peptide PLP-12
6AXI	;		;	PawL-Derived Peptide PLP-2
6AWM	;		;	PawL-Derived Peptide PLP-4
1K78	;	2.25	;	Pax5(1-149)+Ets-1(331-440)+DNA
6EK4	;	2.8	;	PaxB from Photorhabdus luminescens
1OW8	;	2.85	;	Paxillin LD2 motif bound to the Focal Adhesion Targeting (FAT) domain of the Focal Adhesion Kinase
1OW6	;	2.35	;	Paxillin LD4 motif bound to the Focal Adhesion Targeting (FAT) domain of the Focal Adhesion Kinase
1OW7	;	2.6	;	Paxillin LD4 motif bound to the Focal Adhesion Targeting (FAT) domain of the Focal Adhesion Kinase
4NJ6	;	2.4	;	PB1 Domain of AtARF7
4NJ7	;	3.0	;	PB1 Domain of AtARF7 - SeMet Derivative
5JUN	;	2.69	;	PB2 bound to an azaindole inhibitor
5JUR	;	2.93	;	PB2 bound to an azaindole inhibitor
5LHX	;	1.53	;	PB3 Domain of Drosophila melanogaster PLK4 (Sak)
5LHY	;	3.31	;	PB3 Domain of Human PLK4 (apo)
5LHZ	;	2.51	;	PB3 Domain of Human PLK4 in Complex with Coiled-Coil Domain of STIL
1M4X	;	28.0	;	PBCV-1 virus capsid, quasi-atomic model
8CKD	;	1.6	;	PBP AccA from A. fabrum C58 in complex with agrocinopine D-like
8C6W	;	2.8	;	PBP AccA from A. tumefaciens Bo542 in apoform 1
8C6Y	;	1.901	;	PBP AccA from A. tumefaciens Bo542 in apoform 2
8C75	;	1.673	;	PBP AccA from A. tumefaciens Bo542 in apoform 3
8C6R	;	1.884	;	PBP AccA from A. tumefaciens Bo542 in apoform 4
8CAW	;	1.256	;	PBP AccA from A. tumefaciens Bo542 in complex with agrocin84
8CAY	;	1.626	;	PBP AccA from A. tumefaciens Bo542 in complex with Agrocinopine D-like
8CB9	;	1.79	;	PBP AccA from A. tumefaciens Bo542 in complex with D-Glucose-2-phosphate
4ZE8	;	1.72	;	PBP AccA from A. tumefaciens C58
4ZEC	;	2.15	;	PBP AccA from A. tumefaciens C58 in complex with agrocin 84
4ZEB	;	1.89	;	PBP AccA from A. tumefaciens C58 in complex with agrocinopine A
4ZED	;	1.75	;	PBP AccA from A. tumefaciens C58 in complex with agrocinopine-3'-O-benzoate
4RA1	;	1.75	;	PBP AccA from A. tumefaciens C58 in complex with D-Glucose-2-phosphate
4ZEK	;	2.09	;	PBP AccA from A. tumefaciens C58 in complex with L-arabinose-2-isopropylphosphate
4ZEI	;	2.3	;	PBP AccA from A. tumefaciens C58 in complex with L-arabinose-2-phosphate
8CJU	;	1.349	;	PBP AccA from A. vitis S4 in complex with agrocin84
8CH1	;	1.496	;	PBP AccA from A. vitis S4 in complex with Agrocinopine A
8CH3	;	1.398	;	PBP AccA from A. vitis S4 in complex with Agrocinopine C-like
8CHC	;	1.679	;	PBP AccA from A. vitis S4 in complex with Agrocinopine D-like
8CI6	;	1.199	;	PBP AccA from A. vitis S4 in complex with D-glucose-2-phosphate (G2P)
8CH2	;	1.404	;	PBP AccA from A. vitis S4 in complex with L-arabinose-2-phosphate (A2P)
8CKE	;	1.298	;	PBP AccA from A.tumefaciens C58 in complex with agrocinopine A in space group I222
8CKO	;	1.421	;	PBP AccA from A.tumefaciens C58 in complex with agrocinopine C-like
8CDO	;	1.32	;	PBP AccA-F144YG440Q from A. tumefaciens Bo542 in complex with agrocinopine C-like
8C6U	;	1.843	;	PBP AccA-G145YG440Q mutant from A. tumefaciens Bo542 in apoform 4
1K25	;	3.2	;	PBP2x from a Highly Penicillin-resistant Streptococcus pneumoniae Clinical Isolate
1RP5	;	3.0	;	PBP2x from Streptococcus pneumoniae strain 5259 with reduced susceptibility to beta-lactam antibiotics
7Y4L	;	3.3	;	PBS of PBS-PSII-PSI-LHCs from Porphyridium purpureum.
1B72	;	2.35	;	PBX1, HOMEOBOX PROTEIN HOX-B1/DNA TERNARY COMPLEX
4MGQ	;	1.68	;	PbXyn10C CBM APO
2KE3	;		;	PC1/3 DCSG sorting domain in CHAPS
2KDT	;		;	PC1/3 DCSG sorting domain structure in DPC
6IXW	;	3.253	;	pCBH ParM non-polymerisable quadruple mutant
2JZX	;		;	PCBP2 KH1-KH2 domains
7A67	;	3.18	;	Pcc1Pcc2 complex
7UQW	;	1.5	;	PCC6803 Cyanophycinase S132DAP covalently bound to cyanophycin dimer
4ZM7	;	0.701	;	PcCel45A N105D mutatnt at cryo condition
4G8Z	;	1.75	;	pcDHFR K37S/F69N double mutant TMP NADPH ternary complex
4IXG	;	1.7	;	pcDHFR-268-K37S-N69F variant
4IXF	;	1.7	;	pcDHFR-269 F69N variant
4IXE	;	1.54	;	pcDHFR-NADPH-270
6MEQ	;	2.9	;	PcdhgB3 EC1-4 in 50 mM HEPES
6MER	;	3.0	;	PcdhgB3 EC1-4 in 50 mM HEPES
1GY3	;	2.7	;	pCDK2/cyclin A in complex with MgADP, nitrate and peptide substrate
5M8Z	;	1.659	;	PCE reductive dehalogenase from S. multivorans in complex with 2,3-difluorophenol
5M8X	;	1.869	;	PCE reductive dehalogenase from S. multivorans in complex with 2,4,5-trichlorophenol
5M2G	;	1.8	;	PCE reductive dehalogenase from S. multivorans in complex with 2,4,6-tribromophenol
5MA1	;	2.498	;	PCE reductive dehalogenase from S. multivorans in complex with 2,4,6-trichlorophenol
5M92	;	1.785	;	PCE reductive dehalogenase from S. multivorans in complex with 2,4-dibromophenol
5M91	;	1.719	;	PCE reductive dehalogenase from S. multivorans in complex with 2,6-dibromophenol
5MA0	;	1.9	;	PCE reductive dehalogenase from S. multivorans in complex with 2,6-dichlorophenol
5M90	;	1.599	;	PCE reductive dehalogenase from S. multivorans in complex with 3,4,5-trifluorophenol
5MAA	;	1.686	;	PCE reductive dehalogenase from S. multivorans in complex with 3-bromophenol
5M8Y	;	1.857	;	PCE reductive dehalogenase from S. multivorans in complex with 3-chlorophenol
5M8U	;	1.9	;	PCE reductive dehalogenase from S. multivorans in complex with 4-bromophenol
5M8W	;	2.279	;	PCE reductive dehalogenase from S. multivorans in complex with 4-chlorophenol
5MA2	;	1.879	;	PCE reductive dehalogenase from S. multivorans in complex with 4-iodophenol
5OBI	;	1.599	;	PCE reductive dehalogenase from S. multivorans with 5-METHOXYBENZIMIDAZOLYL-NORCOBAMIDE cofactor
5OBP	;	1.593	;	PCE reductive dehalogenase from S. multivorans with 6-hydroxybenzimidazolyl norcobamide cofactor
4PZ7	;	2.109	;	PCE1 guanylyltransferase
4PZ6	;	2.406	;	PCE1 guanylyltransferase bound to SER2/SER5 phosphorylated RNA pol II CTD
4PZ8	;	3.1	;	PCE1 guanylyltransferase bound to SPT5 CTD
6QEQ	;	1.9	;	PcfF from Enterococcus faecalis pCF10
4HPL	;	2.0	;	PCGF1 Ub fold (RAWUL)/BCOR PUFD Complex
4HPM	;	1.85	;	PCGF1 Ub fold (RAWUL)/BCORL1 PUFD Complex
4S3O	;	2.0	;	PCGF5-RING1B-UbcH5c complex
3T5X	;	2.123	;	PCID2:DSS1 Structure
8A6U	;	1.65	;	PcIDS1 in complex with Mg2+
8A7A	;	1.6	;	PcIDS1 in complex with Mg2+ and 3-Br-GPP
8A70	;	2.1	;	PcIDS1 in complex with Mg2+ and GPP
8A6V	;	1.9	;	PcIDS1 in complex with Mg2+ and IPP
8A7L	;	1.85	;	PcIDS1 in complex with Mg2+, GPP, and ZOL
8A7C	;	1.2	;	PcIDS1 in complex with Mg2+, IPP, and ZOL
8A7K	;	1.3	;	PcIDS1 in complex with Mg2+/Mn2+, IPP, and ZOL
8A73	;	1.6	;	PcIDS1 in complex with Mn2+ and GPP
8A6Z	;	2.4	;	PcIDS1 in complex with Mn2+ and IPP
8A7J	;	1.2	;	PcIDS1 in complex with Mn2+, IPP, and ZOL
8A7B	;	1.65	;	PcIDS1_D319N in complex with Mg2+ and 3-Br-GPP
8A74	;	1.9	;	PcIDS1_F315A in complex with Mg2+ and GPP
8A78	;	1.6	;	PcIDS1_F315A in complex with Mg2+/Mn2+ and GPP
8A7U	;	1.55	;	PcIDS1_F315D in complex with Mg2+ and GPP
8A7R	;	2.0	;	PcIDS1_I420A in complex with Mg2+ and GPP
7KQ0	;	2.4	;	PCNA bound to peptide mimetic
7M5M	;	3.0	;	PCNA bound to peptide mimetic
7M5L	;	3.0	;	PCNA bound to peptide mimetic with linker
7M5N	;	3.11	;	PCNA bound to peptide mimetic with linker
7KQ1	;	3.3	;	PCNA bound to truncated peptide mimetic
6QCG	;	3.4	;	PCNA complex with Cdt1 N-terminal PIP-box peptide
6QC0	;	3.5	;	PCNA complex with Cdt2 C-terminal PIP-box peptide
8Q7I	;	1.95	;	PCNA from Chaetomium thermophilum in complex with Fen1 peptide
8P9O	;	2.45	;	PCNA from Chaetomium thermophilum in complex with PolD3 peptide
7O1F	;	2.45	;	PCNA from Chaetomium thermophilum in complex with PolD4 PIP peptide
7N5I	;	1.95	;	PCNA from Thermococcus gammatolerans: crystal I, collection 1, 1.95 A, 5.22 MGy
7N5J	;	2.82	;	PCNA from Thermococcus gammatolerans: crystal I, collection 5, 2.82 A, 89.1 MGy
7N5K	;	1.98	;	PCNA from Thermococcus gammatolerans: crystal II, collection 1, 1.98 A, 3.84 MGy
7N5L	;	3.07	;	PCNA from Thermococcus gammatolerans: crystal II, collection 20, 3.07 A, 77.0 MGy
7N5M	;	2.0	;	PCNA from Thermococcus gammatolerans: crystal III, collection 1, 2.00 A, 1.91 MGy
7N5N	;	2.2	;	PCNA from Thermococcus gammatolerans: crystal III, collection 15, 2.20 A, 28.7 MGy
6CBI	;	2.75	;	PCNA in complex with inhibitor
5V7K	;	3.05	;	PCNA mutant D41A/D42A Protein Defective in Gene Silencing
5V7M	;	1.93	;	PCNA mutant L126A/I128A Protein Defective in Gene Silencing
5V7L	;	3.201	;	PCNA mutant R61A/D63A Protein Defective in Gene Silencing
4RNS	;	2.7	;	PcpR inducer binding domain (apo-form)
4RPO	;	1.95	;	PcpR inducer binding domain (Complex with 2,4,6-trichlorophenol)
4RPN	;	2.272	;	PcpR inducer binding domain complex with pentachlorophenol
4NAE	;	2.0	;	PcrB from Geobacillus kaustophilus, with bound G1P
6CYF	;	2.78	;	PcrV fragment with bound Fab
5VL7	;	3.5	;	PCSK9 complex with Fab33
5VLP	;	2.9	;	PCSK9 complex with LDLR antagonist peptide and Fab7G7
7KEV	;	2.8	;	PCSK9 in complex with a cyclic peptide LDLR disruptor
6U36	;	2.7	;	PCSK9 in complex with a Fab and compound 14
6U38	;	2.73	;	PCSK9 in complex with a Fab and compound 8
6U26	;	1.53	;	PCSK9 in complex with compound 16
7S5G	;	2.041	;	PCSK9 in complex with compound 19
6U3X	;	2.64	;	PCSK9 in complex with compound 2
6U2N	;	2.15	;	PCSK9 in complex with compound 4
6U2P	;	2.04	;	PCSK9 in complex with compound 5
4NE9	;	2.6	;	PCSK9 in complex with LDLR peptide
7KFA	;	2.45	;	PCSK9 in complex with PCSK9i a 13mer cyclic peptide LDLR disruptor
3SQO	;	2.7	;	PCSK9 J16 Fab complex
6XIB	;	1.546	;	PCSK9(deltaCRD) in complex with cyclic peptide 30
7S5H	;	1.272	;	PCSK9(deltaCRD) in complex with cyclic peptide 35
6XIC	;	1.377	;	PCSK9(deltaCRD) in complex with cyclic peptide 40
6XID	;	1.482	;	PCSK9(deltaCRD) in complex with cyclic peptide 51
6XIE	;	1.43	;	PCSK9(deltaCRD) in complex with cyclic peptide 77
6XIF	;	1.774	;	PCSK9(deltaCRD) in complex with cyclic peptide 83
4NMX	;	1.85	;	PCSK9(deltaCRD) in complex with phage-derived inhibitory peptide 2-8
2W2P	;	2.62	;	PCSK9-deltaC D374A mutant bound to WT EGF-A of LDLR
2W2Q	;	2.33	;	PCSK9-deltaC D374H mutant bound to WT EGF-A of LDLR
2W2O	;	2.62	;	PCSK9-deltaC D374Y mutant bound to WT EGF-A of LDLR
6U2F	;	2.94	;	PCSK9-Fab 7G7 complex bound to cis-1-amino-4-phenylcyclohexaneacyl-WNLK(hR)IGLLR - NH2
3BPS	;	2.41	;	PCSK9:EGF-A complex
3GCX	;	2.7	;	PCSK9:EGFA (pH 7.4)
3GCW	;	2.7	;	PCSK9:EGFA(H306Y)
5OCA	;	2.3	;	PCSK9:Fab Complex with Dextran Sulfate
5UZW	;	2.82	;	PCY1 G696Insertion Variant in Complex with Follower Peptide and the Covalent Inhibitor ZPP
5UW5	;	2.94	;	PCY1 H695A Variant in Complex with Follower Peptide
5UW3	;	1.96	;	PCY1 in Complex with Follower Peptide
5UW6	;	3.3	;	PCY1 in Complex with Follower Peptide and Covalent Inhibitor ZPP
5UW7	;	2.37	;	PCY1 Y481F Variant in Complex with Follower Peptide
5C3T	;	1.8	;	PD-1 binding domain from human PD-L1
8AS0	;	3.5	;	PD-1 extracellular domain in complex with Fab fragment from D12 antibody
7WSL	;	1.534	;	PD-1 in complex with Dostarlimab
5GGR	;	3.3	;	PD-1 in complex with nivolumab Fab
5GGS	;	1.997	;	PD-1 in complex with pembrolizumab Fab
6NM7	;	2.426	;	PD-L1 IgV domain bound to fragment
6NNV	;	1.92	;	PD-L1 IgV domain complex with macro-cyclic peptide
6NOJ	;	2.33	;	PD-L1 IgV domain V76T with fragment
6NOS	;	2.701	;	PD-L1 IgV domain V76T with fragment
6NP9	;	1.27	;	PD-L1 IgV domain V76T with fragment
5X8L	;	3.1	;	PD-L1 in complex with atezolizumab
5GGT	;	2.8	;	PD-L1 in complex with BMS-936559 Fab
5X8M	;	2.661	;	PD-L1 in complex with durvalumab
8EQ6	;	1.65	;	PD1 signaling receptor bound to FAB Complex
1PDT	;		;	PD235, PNA-DNA DUPLEX, NMR, 8 STRUCTURES
7WBN	;		;	PDB structure of RevCC
6E0H	;	4.05	;	PDB: afTMEM16 reconstituted in nanodiscs in the presence of Ca2+
5ZQ4	;	2.217	;	PDE-Ubi-ADPr
5ZQ3	;	2.182	;	PDE-Ubiquitin
5C1W	;	1.7	;	PDE10 complexed with 4,6-dichloro-2-cyclopropyl-5-methyl-pyrimidine
4ZO5	;	2.5	;	PDE10 complexed with 4-isopropoxy-2-(2-(3-(4-methoxyphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)isoindoline-1,3-dione
5DH4	;	2.2	;	PDE10 complexed with 5-chloro-N-[(2,4-dimethylthiazol-5-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine
5C29	;	2.05	;	PDE10 complexed with 6-chloro-2-cyclopropyl-5-methyl-N-propyl-pyrimidin-4-amine
5C28	;	1.56	;	PDE10 complexed with 6-chloro-2-cyclopropyl-5-methyl-pyrimidin-4-amine
5C2A	;	2.0	;	PDE10 complexed with 6-chloro-2-cyclopropyl-N-[(2,4-dimethylthiazol-5-yl)methyl]-5-methyl-pyrimidin-4-amine
5C2H	;	2.09	;	PDE10 complexed with 6-chloro-N-[(2,4-dimethylthiazol-5-yl)methyl]-5-methyl-2-[3-(2-quinolyl)propoxy]pyrimidin-4-amine
5DH5	;	2.0	;	PDE10 complexed with N-[(1-methylpyrazol-4-yl)methyl]-5-[[(1S,2S)-2-(2-pyridyl)cyclopropyl]methoxy]pyrazolo[1,5-a]pyrimidin-7-amine
5C2E	;	2.1	;	PDE10 complexed with6-chloro-N-[(2,4-dimethylthiazol-5-yl)methyl]-5-methyl-2-[2-(2-pyridyl)ethoxy]pyrimidin-4-amine
4DDL	;	2.07	;	PDE10a Crystal Structure Complexed with Novel Inhibitor
4AEL	;	2.2	;	PDE10A in complex with the inhibitor AZ5
5K9R	;	2.7	;	PDE10a with imidazopyrazine inhibitor
5W6E	;	1.9	;	PDE1b complexed with compound 3S
5U7D	;	1.75	;	PDE2 catalytic domain complexed with inhibitors
5U7I	;	2.0	;	PDE2 catalytic domain complexed with inhibitors
5U7J	;	1.9	;	PDE2 catalytic domain complexed with inhibitors
5U7K	;	2.06	;	PDE2 catalytic domain complexed with inhibitors
5U7L	;	2.38	;	PDE2 catalytic domain complexed with inhibitors
6BLF	;	2.11	;	PDE2 complexed with 2-[6-fluoro-8-methylsulfonyl-9-[(1R)-1-[4-(trifluoromethyl)phenyl]ethyl]-1,2,3,4-tetrahydrocarbazol-1-yl]acetic acid
6B98	;	1.97	;	PDE2 in complex with compound 1
6CYC	;	1.54	;	PDE2 in complex with compound 5
6CYB	;	1.62	;	PDE2 in complex with compound 7
6CYD	;	1.69	;	PDE2 in complex with compound 7
6EZF	;	1.5	;	PDE2 in complex with molecule 5
4D08	;	1.9	;	PDE2a catalytic domain in complex with a brain penetrant inhibitor
4D09	;	2.5	;	PDE2a catalytic domain in complex with a brain penetrant inhibitor
4NW7	;	2.15	;	PDE4 catalytic domain
4WCU	;	2.35	;	PDE4 complexed with inhibitor
5K1I	;	2.61	;	PDE4 crystal structure in complex with small molecule inhibitor
8OEG	;	1.89	;	PDE4B bound to MAPI compound 92a
3O0J	;	1.95	;	PDE4B In complex with ligand an2898
4W1O	;	2.2	;	PDE4D complexed with inhibitor
5K32	;	1.99	;	PDE4D crystal structure in complex with small molecule inhibitor
5JO3	;	1.49	;	PDE5A for NaV1.7
6X88	;	3.19974	;	PDE6 chicken GAF domain
4PM0	;	2.1	;	PDE7A catalytic domain in complex with 2-(Cyclopentylamino)thieno[3,2-d]pyrimidin-4(3H)-one derivative
3G3N	;	2.4	;	PDE7A catalytic domain in complex with 3-(2,6-difluorophenyl)-2-(methylthio)quinazolin-4(3H)-one
6VNA	;	2.2	;	Pden_1323
7QW4	;	3.1	;	Pden_5119 protein
1ICJ	;	1.9	;	PDF PROTEIN IS CRYSTALLIZED AS NI2+ CONTAINING FORM, COCRYSTALLIZED WITH INHIBITOR POLYETHYLENE GLYCOL (PEG)
4QCI	;	2.3	;	PDGF-B blocking antibody bound to PDGF-BB
2L6W	;		;	PDGFR beta-TM
6V0L	;		;	PDGFR-b Promoter Forms a G-Vacancy Quadruplex that Can be Complemented by dGMP: Molecular Structure and Recognition of Guanine Derivatives and Metabolites
8PQH	;	2.5	;	PDGFRA T674I mutant kinase domain in complex with avapritinib
8PQI	;	2.6	;	PDGFRA T674I mutant kinase domain in complex with avapritinib derivative 9
8PQJ	;	1.82	;	PDGFRA wild-type kinase domain
3IOP	;	2.2	;	PDK-1 in complex with the inhibitor Compound-8i
3ION	;	2.4	;	PDK1 in complex with Compound 8h
3QC4	;	1.8	;	PDK1 in complex with DFG-OUT inhibitor xxx
3NAY	;	2.6	;	PDK1 in complex with inhibitor MP6
3NAX	;	1.75	;	PDK1 in complex with inhibitor MP7
3ORZ	;	1.9995	;	PDK1 mutant bound to allosteric disulfide fragment activator 2A2
3OTU	;	2.1013	;	PDK1 mutant bound to allosteric disulfide fragment activator JS30
3ORX	;	2.2044	;	PDK1 mutant bound to allosteric disulfide fragment inhibitor 1F8
4Q2O	;	2.1	;	PDLIM4 PDZ in Complex with a Phage-Derived Peptide
3NGK	;	2.2608	;	PduA from Salmonella enterica Typhimurium
4RBV	;	3.1	;	PduA K26A S40GSG mutant, from Salmonella enterica serovar Typhimurium LT2
4RBT	;	2.3	;	PduA K26A S40L mutant, from Salmonella enterica serovar Typhimurium LT2
4RBU	;	2.79	;	PduA K26A S40Q mutant, from Salmonella enterica serovar Typhimurium LT2
4PPD	;	2.4	;	PduA K26A, crystal form 2
5D6V	;	1.5	;	PduJ K25A mutant, from Salmonella enterica serovar Typhimurium LT2, PduJ mutant
3N79	;	1.5	;	PduT C38S Mutant from Salmonella enterica Typhimurium
7LB6	;	3.16	;	PDX1.2/PDX1.3 co-expression complex
6HX3	;	2.0	;	PDX1.2/PDX1.3 complex
6HXG	;	1.9	;	PDX1.2/PDX1.3 complex (intermediate)
6HYE	;	2.53	;	PDX1.2/PDX1.3 complex (PDX1.3:K97A)
5K2Z	;	1.8	;	PDX1.3-adduct (Arabidopsis)
1R8K	;	2.1	;	PDXA PROTEIN; NAD-DEPENDENT DEHYDROGENASE/CARBOXYLASE; SUBUNIT OF PYRIDOXINE PHOSPHATE BIOSYNTHETIC PROTEIN PDXJ-PDXA [SALMONELLA TYPHIMURIUM]
4WXZ	;	2.7	;	PdxS (G. stearothermophilus) co-crystallized with R5P
4WY0	;	2.3	;	PdxS (G. stearothermophilus) co-crystallized with R5P in the presence of ammonia.
6X1X	;	1.198	;	PDZ domain from choanoflagellate GIPC (mbGIPC)
6X20	;	1.402	;	PDZ domain from choanoflagellate GIPC (mbGIPC) bound to B1AR peptide
6X22	;	1.402	;	PDZ domain from choanoflagellate GIPC (mbGIPC) bound to GAIP peptide
6X23	;	2.154	;	PDZ domain from choanoflagellate SHANK1 (mbSHANK1) bound to GIRK3 peptide
3PS4	;	1.85	;	PDZ domain from Human microtubule-associated serine/threonine-protein kinase 1
5OVP	;	1.5	;	PDZ domain from rat Shank3 bound to the C terminus of CIRL
5OVC	;	1.55	;	PDZ domain from rat Shank3 bound to the C terminus of GKAP
5OVV	;	1.4	;	PDZ domain from rat Shank3 bound to the C terminus of ProSAPiP1
6EXJ	;	1.8	;	PDZ domain from rat Shank3 bound to the C terminus of somatostatin receptor subtype 2
2LOB	;		;	PDZ Domain of CAL (Cystic Fibrosis Transmembrane Regulator-Associated Ligand)
2I4S	;	1.92	;	PDZ domain of EpsC from Vibrio cholerae, residues 204-305
2I6V	;	1.63	;	PDZ domain of EpsC from Vibrio cholerae, residues 219-305
1WFG	;		;	PDZ domain of human RIM2B
1ZOK	;		;	PDZ1 Domain Of Synapse Associated Protein 97
1KEF	;		;	PDZ1 of SAP90
1VJ6	;		;	PDZ2 from PTP-BL in complex with the C-terminal ligand from the APC protein
5E1Y	;	1.011	;	PDZ2 of LNX2 at 277K, model with alternate conformations
5E21	;	1.011	;	PDZ2 of LNX2 at 277K,single conformer model
7QCT	;	3.197	;	PDZ2 of LNX2 with SARS-CoV-2_E PBM complex
1TP3	;	1.99	;	PDZ3 domain of PSD-95 protein complexed with KKETPV peptide ligand
6EZI	;	1.50332	;	PDZK1 domain 4 in complex with C-terminal peptide of human PepT2.
4AF7	;	2.85	;	PEA FNR C266M MUTANT
4AF6	;	2.9	;	PEA FNR L268V MUTANT
1QFY	;	1.8	;	PEA FNR Y308S MUTANT IN COMPLEX WITH NADP+
1QFZ	;	1.7	;	PEA FNR Y308S MUTANT IN COMPLEX WITH NADPH
1QGA	;	2.0	;	PEA FNR Y308W MUTANT IN COMPLEX WITH NADP+
1OFS	;	1.8	;	Pea lectin-sucrose complex
2BHW	;	2.5	;	PEA LIGHT-HARVESTING COMPLEX II AT 2.5 ANGSTROM RESOLUTION
2PEL	;	2.25	;	PEANUT LECTIN
1V6O	;	3.0	;	Peanut lectin complexed with 10mer peptide (PVRIWSSATG)
1BZW	;	2.7	;	PEANUT LECTIN COMPLEXED WITH C-LACTOSE
6VAV	;	1.85	;	Peanut lectin complexed with divalent N-beta-D-galactopyranosyl-L-succinamoyl derivative (diNGS)
6V95	;	1.78	;	Peanut lectin complexed with divalent N-beta-D-galactopyranosyl-L-tartaramidoyl derivative (diNGT)
6VGF	;	1.83	;	Peanut lectin complexed with divalent S-beta-D-thiogalactopyranosyl beta-D-glucopyranoside derivative (diSTGD)
1QF3	;	2.8	;	PEANUT LECTIN COMPLEXED WITH METHYL-BETA-GALACTOSE
1CIW	;	2.7	;	PEANUT LECTIN COMPLEXED WITH N-ACETYLLACTOSAMINE
6VAW	;	1.75	;	Peanut lectin complexed with N-beta-D-galactopyranosyl-L-succinamoyl derivative (NGS)
6VC3	;	1.95	;	Peanut lectin complexed with S-beta-D-thiogalactopyranosyl 6-deoxy-6-S-propynyl-beta-D-glucopyranoside (STG)
6VC4	;	1.9	;	Peanut lectin complexed with S-beta-D-Thiogalactopyranosyl beta-D-glucopyranoside derivative (STGD)
2TEP	;	2.5	;	PEANUT LECTIN COMPLEXED WITH T-ANTIGENIC DISACCHARIDE
1V6M	;	2.7	;	Peanut Lectin with 9mer peptide (IWSSAGNVA)
1V6N	;	3.5	;	Peanut lectin with 9mer peptide (PVIWSSATG)
1V6J	;	2.9	;	peanut lectin-lactose complex crystallized in orthorhombic form at acidic pH
1V6I	;	2.15	;	Peanut lectin-lactose complex in acidic pH
1V6L	;	2.5	;	Peanut lectin-lactose complex in the presence of 9mer peptide (PVIWSSATG)
1V6K	;	2.4	;	Peanut lectin-lactose complex in the presence of peptide(IWSSAGNVA)
1CR7	;	2.6	;	PEANUT LECTIN-LACTOSE COMPLEX MONOCLINIC FORM
1CQ9	;	3.5	;	PEANUT LECTIN-TRICLINIC FORM
1SCH	;	2.56	;	PEANUT PEROXIDASE
8SY2	;	2.67	;	Peanut USP-type BURP Domain Peptide Cyclase
2QY1	;	1.9	;	pectate lyase A31G/R236F from Xanthomonas campestris
7BBV	;	1.2	;	Pectate lyase B from Verticillium dahliae
2O17	;	2.3	;	Pectate lyase bound to hexasaccharide
2O04	;	1.7	;	Pectate lyase bound to hexasaccharide compound II
2O0V	;	1.9	;	Pectate lyase bound to hexasaccharide compound III
2O0W	;	1.9	;	Pectate lyase bound to hexasaccharide compound IV
2O1D	;	2.0	;	Pectate lyase bound to trisaccharide
1AIR	;	2.2	;	PECTATE LYASE C FROM ERWINIA CHRYSANTHEMI (EC16) TO A RESOLUTION OF 2.2 ANGSTROMS WITH 128 WATERS
1O8E	;	2.2	;	Pectate Lyase C from Erwinia Chrysanthemi at pH 11.2 with 1mM Ca2+
1O88	;	2.2	;	Pectate Lyase C From Erwinia Chrysanthemi at pH 11.2 with 30mM Ca2+
1O8D	;	2.2	;	Pectate Lyase C from Erwinia Chrysanthemi at pH 11.2 with 5mM CA2+
1O8K	;	2.2	;	Pectate Lyase C from Erwinia Chrysanthemi at pH 4.5 with 20mM CA2+
1O8J	;	2.2	;	Pectate Lyase C from Erwinia Chrysanthemi at pH 4.5 with 30mM CA2+
1O8L	;	2.2	;	Pectate Lyase C from Erwinia Chrysanthemi at pH 4.5 with 5mM CA2+
1O8M	;	2.2	;	Pectate Lyase C from Erwinia Chrysanthemi at pH 4.5 with no Ca2+ Added
1O8H	;	2.2	;	Pectate Lyase C from Erwinia Chrysanthemi at pH 9.5 with 0.3mM Ca2+ Added
1O8F	;	2.2	;	Pectate Lyase C from Erwinia Chrysanthemi at pH 9.5 with 30mM Ca2+
1O8G	;	2.2	;	Pectate Lyase C from Erwinia Chrysanthemi at pH 9.5 with 5mM Ca2+
1O8I	;	2.2	;	Pectate Lyase C from Erwinia Chrysanthemi at pH 9.5 with no Ca2+ Added
1PLU	;	2.2	;	PECTATE LYASE C FROM ERWINIA CHRYSANTHEMI WITH 1 LU+3 ION IN THE PUTATIVE CALCIUM BINDING SITE
2QXZ	;	2.12	;	pectate lyase R236F from Xanthomonas campestris
1IDJ	;	2.4	;	PECTIN LYASE A
1IDK	;	1.93	;	PECTIN LYASE A
1QCX	;	1.7	;	PECTIN LYASE B
1GQ8	;	1.75	;	Pectin methylesterase from Carrot
3UW0	;	3.5	;	Pectin methylesterase from Yersinia enterocolitica
1QJV	;	2.37	;	Pectin methylesterase PemA from Erwinia chrysanthemi
7VJO	;	1.31	;	Pectobacterium phage ZF40 apo-Aca2
7VJQ	;	2.79	;	Pectobacterium phage ZF40 apo-aca2 complexed with 26bp DNA substrate
4AO8	;	1.61	;	PEG-bound complex of a novel cold-adapted esterase from an Arctic intertidal metagenomic library
7LGA	;	1.9	;	PEG10 CA-like C-terminal domain
7T2Q	;	1.95	;	PEGylated Calmodulin-1 (K148U)
6D9I	;	1.15	;	Pekin duck egg lysozyme isoform II (DEL-II)
5V94	;	1.65	;	Pekin duck egg lysozyme isoform III (DEL-III), cubic form
5V92	;	1.11	;	Pekin duck egg lysozyme isoform III (DEL-III), orthorhombic form
5VAS	;	1.4	;	Pekin duck egg lysozyme isoform III (DEL-III), orthorhombic form
5V8G	;	1.2	;	Pekin duck lysozyme isoform I (DEL-I)
5WFT	;	2.821	;	PelB 319-436 from Pseudomonas aeruginosa PAO1
5T10	;	2.4987	;	PelC dodecamer from Paraburkholderia phytofirmans, space group P6
5T0Z	;	2.255	;	PelC from Geobacter metallireducens
5T11	;	2.104	;	PelC L103M dodecamer from Paraburkholderia phytofirmans, space group C2
4DN0	;	2.3	;	PelD 156-455 from Pseudomonas aeruginosa PA14 in complex with c-di-GMP
4DMZ	;	2.102	;	PelD 156-455 from Pseudomonas aeruginosa PA14, apo form
1KPZ	;		;	PEMV-1 P1-P2 Frameshifting Pseudoknot Regularized Average Structure
1KPY	;		;	PEMV-1 P1-P2 Frameshifting Pseudoknot, 15 Lowest Energy Structures
4MBH	;	1.22	;	Penam sulfone PSR-3-226 bound to E166A variant of SHV-1 beta-lactamase
8UUK	;	2.5	;	Pendrin in apo
8SIE	;	2.7	;	Pendrin in complex with bicarbonate
8SGW	;	2.5	;	Pendrin in complex with chloride
8SH3	;	2.8	;	Pendrin in complex with iodide
8SHC	;	3.0	;	Pendrin in complex with Niflumic acid
1AJP	;	2.31	;	PENICILLIN ACYLASE COMPLEXED WITH 2,5-DIHYDROXYPHENYLACETIC ACID
1AI4	;	2.35	;	PENICILLIN ACYLASE COMPLEXED WITH 3,4-DIHYDROXYPHENYLACETIC ACID
1AI5	;	2.36	;	PENICILLIN ACYLASE COMPLEXED WITH M-NITROPHENYLACETIC ACID
1AJN	;	2.36	;	PENICILLIN ACYLASE COMPLEXED WITH P-NITROPHENYLACETIC ACID
1AI7	;	2.5	;	PENICILLIN ACYLASE COMPLEXED WITH PHENOL
1AJQ	;	2.05	;	PENICILLIN ACYLASE COMPLEXED WITH THIOPHENEACETIC ACID
1PNK	;	1.9	;	PENICILLIN ACYLASE HAS A SINGLE-AMINO-ACID CATALYTIC CENTRE
1PNL	;	2.5	;	PENICILLIN ACYLASE HAS A SINGLE-AMINO-ACID CATALYTIC CENTRE
1PNM	;	2.5	;	PENICILLIN ACYLASE HAS A SINGLE-AMINO-ACID CATALYTIC CENTRE
1FXV	;	2.25	;	PENICILLIN ACYLASE MUTANT IMPAIRED IN CATALYSIS WITH PENICILLIN G IN THE ACTIVE SITE
1KEC	;	2.3	;	PENICILLIN ACYLASE MUTANT WITH PHENYL PROPRIONIC ACID
1AI6	;	2.55	;	PENICILLIN ACYLASE WITH P-HYDROXYPHENYLACETIC ACID
1K7D	;	2.15	;	Penicillin Acylase with Phenyl Proprionic Acid
1JX9	;	2.28	;	Penicillin Acylase, mutant
1K5Q	;	2.34	;	PENICILLIN ACYLASE, MUTANT COMPLEXED WITH PAA
1K5S	;	2.43	;	PENICILLIN ACYLASE, MUTANT COMPLEXED WITH PPA
5OJ1	;	2.85	;	Penicillin Binding Protein 2x (PBP2x) from S.pneumoniae in complex with Oxacillin and a tetrasaccharide
5CED	;	2.02	;	Penicillin G Acylated Bd3459 Predatory Endopeptidase from Bdellovibrio bacteriovorus in complex with immunity protein Bd3460
3PVA	;	2.8	;	PENICILLIN V ACYLASE FROM B. SPHAERICUS
5LP4	;	3.03	;	Penicillin-Binding Protein (PBP2) from Helicobacter pylori
2ZC5	;	3.0	;	Penicillin-binding protein 1A (PBP 1A) acyl-enzyme complex (biapenem) from Streptococcus pneumoniae
2ZC6	;	2.7	;	Penicillin-binding protein 1A (PBP 1A) acyl-enzyme complex (tebipenem) from Streptococcus pneumoniae
2C5W	;	2.55	;	PENICILLIN-BINDING PROTEIN 1A (PBP-1A) ACYL-ENZYME COMPLEX (CEFOTAXIME) FROM STREPTOCOCCUS PNEUMONIAE
2C6W	;	2.61	;	PENICILLIN-BINDING PROTEIN 1A (PBP-1A) FROM STREPTOCOCCUS PNEUMONIAE
7ZUL	;	1.744	;	PENICILLIN-BINDING PROTEIN 1B (PBP-1B) in complex with 8Az lactone - Streptococcus pneumoniae R6
2Y2G	;	2.05	;	PENICILLIN-BINDING PROTEIN 1B (PBP-1B) IN COMPLEX WITH AN ALKYL BORONATE (A01)
2Y2L	;	2.07	;	PENICILLIN-BINDING PROTEIN 1B (PBP-1B) IN COMPLEX WITH AN ALKYL BORONATE (E06)
2Y2N	;	2.07	;	PENICILLIN-BINDING PROTEIN 1B (PBP-1B) IN COMPLEX WITH AN ALKYL BORONATE (E07)
2Y2M	;	1.62	;	PENICILLIN-BINDING PROTEIN 1B (PBP-1B) IN COMPLEX WITH AN ALKYL BORONATE (E08)
2Y2O	;	1.88	;	PENICILLIN-BINDING PROTEIN 1B (PBP-1B) IN COMPLEX WITH AN ALKYL BORONATE (EO9)
2Y2Q	;	2.15	;	PENICILLIN-BINDING PROTEIN 1B (PBP-1B) IN COMPLEX WITH AN ALKYL BORONATE (Z06)
2Y2P	;	1.62	;	Penicillin-binding protein 1b (pbp-1b) in complex with an alkyl boronate (z10)
2Y2H	;	1.96	;	PENICILLIN-BINDING PROTEIN 1B (PBP-1B) IN COMPLEX WITH AN ALKYL BORONATE (ZA2)
2Y2I	;	1.78	;	PENICILLIN-BINDING PROTEIN 1B (PBP-1B) IN COMPLEX WITH AN ALKYL BORONATE (ZA3)
2Y2J	;	2.06	;	PENICILLIN-BINDING PROTEIN 1B (PBP-1B) IN COMPLEX WITH AN ALKYL BORONATE (ZA4)
2Y2K	;	2.09	;	PENICILLIN-BINDING PROTEIN 1B (PBP-1B) IN COMPLEX WITH AN ALKYL BORONATE (ZA5)
7ZUI	;	1.57	;	PENICILLIN-BINDING PROTEIN 1B (PBP-1B) in complex with lactone 5Az - Streptococcus pneumoniae R6
7ZUJ	;	1.55	;	PENICILLIN-BINDING PROTEIN 1B (PBP-1B) in complex with lactone 6Az - Streptococcus pneumoniae R6
7ZUK	;	1.631	;	PENICILLIN-BINDING PROTEIN 1B (PBP-1B) in complex with lactone 7Az - Streptococcus pneumoniae R6
7ZUH	;	1.467	;	PENICILLIN-BINDING PROTEIN 1B (PBP-1B) Streptococcus pneumoniae R6
2WAD	;	2.18	;	PENICILLIN-BINDING PROTEIN 2B (PBP-2B) FROM STREPTOCOCCUS PNEUMONIAE (STRAIN 5204)
2WAE	;	2.26	;	PENICILLIN-BINDING PROTEIN 2B (PBP-2B) FROM STREPTOCOCCUS PNEUMONIAE (STRAIN 5204)
2WAF	;	3.29	;	PENICILLIN-BINDING PROTEIN 2B (PBP-2B) FROM STREPTOCOCCUS PNEUMONIAE (STRAIN R6)
2ZC3	;	2.5	;	Penicillin-binding protein 2X (PBP 2X) acyl-enzyme complex (biapenem) from Streptococcus pneumoniae
2ZC4	;	2.8	;	Penicillin-binding protein 2X (PBP 2X) acyl-enzyme complex (tebipenem) from Streptococcus pneumoniae
1PMD	;	3.5	;	PENICILLIN-BINDING PROTEIN 2X (PBP-2X)
1QME	;	2.4	;	PENICILLIN-BINDING PROTEIN 2X (PBP-2X)
1QMF	;	2.8	;	PENICILLIN-BINDING PROTEIN 2X (PBP-2X) ACYL-ENZYME COMPLEX
2Z2L	;	2.85	;	Penicillin-Binding Protein 2X (PBP2X) from Streptococcus pneumoniae
5OAU	;	2.67	;	Penicillin-Binding Protein 2X (PBP2X) from Streptococcus pneumoniae
5OJ0	;	2.66	;	Penicillin-Binding Protein 2X (PBP2X) from Streptococcus pneumoniae in complex with Cefepime
5OIZ	;	2.7	;	Penicillin-Binding Protein 2X (PBP2X) from Streptococcus pneumoniae in complex with oxacillin
4F8X	;	1.47	;	Penicillium canescens endo-1,4-beta-xylanase XylE
3J3I	;	4.1	;	Penicillium chrysogenum virus (PcV) capsid structure
2RI8	;	2.16	;	Penicillium citrinum alpha-1,2-mannosidase complex with glycerol
2RI9	;	1.95	;	Penicillium citrinum alpha-1,2-mannosidase in complex with a substrate analog
7ZTF	;	1.1	;	Penicillium expansum antifungal protein B
7ZVH	;	1.2	;	Penicillium expansum antifungal protein B
7ZW2	;	1.2	;	Penicillium expansum antifungal protein B
7ZTJ	;	1.3	;	Penicillium expansum antifungal protein chimera C-ter
7ZUT	;	1.1	;	Penicillium expansum chimera loop1
1PWC	;	1.1	;	penicilloyl acyl enzyme complex of the Streptomyces R61 DD-peptidase with penicillin G
7F8S	;	2.63	;	Pennisetum glaucum (Pearl millet) dehydroascorbate reductase (DHAR) with catalytic cysteine (Cy20) in sulphenic and sulfinic acid forms.
2XXJ	;	1.964	;	Penta mutant of lactate dehydrogenase from Thermus thermophilus, ternary complex
6J9S	;	2.0	;	Penta mutant of Lactobacillus casei lactate dehydrogenase
4UWP	;	1.7	;	Penta Zn1 coordination. Leu224 in VIM-26 from Klebsiella pneumoniae has implications for drug binding.
2XXB	;	2.15	;	Penta-mutant of Thermus thermophilus lactate dehydrogenase, complex with AMP
8CGI	;	1.89	;	Pentacycline TP038 bound to the 30S head
7VEA	;	3.7	;	Pentacylindrical allophycocyanin core from Thermosynechococcus vulcanus
6VE4	;	6.9	;	Pentadecameric PilQ from Pseudomonas aeruginosa
3P81	;	1.2	;	Pentaerythritol tetranitrate reductase co-crystal structure containing a bound (E)-1-(4'-hydroxyphenyl)-2-nitroethene molecule
3P80	;	1.2	;	Pentaerythritol tetranitrate reductase co-crystal structure containing bound (E)-1-(3'-hydroxyphenyl)-2-nitroethene
3P7Y	;	1.2	;	Pentaerythritol tetranitrate reductase co-crystal structure with bound (E)-1-(2'-hydroxyphenyl)-2-nitroethene
3DN0	;	1.8	;	Pentafluorobenzene binding in the hydrophobic cavity of T4 lysozyme L99A mutant
6HQV	;	3.0	;	Pentafunctional AROM Complex from Chaetomium thermophilum
2D52	;	1.6	;	Pentaketide chromone synthase (M207G mutant complexed with Coa)
2D51	;	1.6	;	Pentaketide chromone synthase (M207G mutant)
2D3M	;	1.6	;	Pentaketide chromone synthase complexed with coenzyme A
1PS1	;	2.6	;	PENTALENENE SYNTHASE
8HEE	;	3.2	;	Pentamer of FMDV (A/TUR/14/98)
8HEG	;	3.2	;	Pentamer of FMDV (A/TUR/14/98) in complex with M3F
4J4U	;	2.803	;	Pentamer SFTSVN
2R5K	;	3.2	;	Pentamer Structure of Major Capsid protein L1 of Human Papilloma Virus type 11
2R5H	;	3.7	;	Pentamer structure of Major Capsid Protein L1 of Human Papilloma Virus type 16
2R5I	;	3.4	;	Pentamer Structure of Major Capsid Protein L1 of Human Papilloma Virus type 18
2R5J	;	3.3	;	Pentamer Structure of Major Capsid protein L1 of Human Papilloma Virus Type 35
2A3Y	;	2.0	;	Pentameric crystal structure of human serum amyloid P-component bound to Bis-1,2-{[(Z)-2carboxy-2-methyl-1,3-dioxane]-5-yloxycarbamoyl}-ethane.
3KLY	;	2.1	;	Pentameric formate channel
3KLZ	;	2.5	;	Pentameric formate channel with formate bound
2YKS	;	3.3	;	PENTAMERIC LIGAND GATED ION CHANNEL ELIC MUTANT F246A
2XQ3	;	3.5	;	Pentameric ligand gated ion channel GLIC in complex with Br-lidocaine
2XQ7	;	3.4	;	Pentameric ligand gated ion channel GLIC in complex with cadmium ion (Cd2+)
2XQ6	;	3.7	;	Pentameric ligand gated ion channel GLIC in complex with cesium ion (Cs+)
2XQA	;	3.7	;	Pentameric ligand gated ion channel GLIC in complex with tetrabutylantimony (TBSb)
2XQ5	;	3.5	;	Pentameric ligand gated ion channel GLIC in complex with tetraethylarsonium (TEAs)
2XQ4	;	3.6	;	Pentameric ligand gated ion channel GLIC in complex with tetramethylarsonium (TMAs)
2XQ8	;	3.6	;	Pentameric ligand gated ion channel GLIC in complex with zinc ion (Zn2+)
2XQ9	;	3.2	;	Pentameric ligand gated ion channel GLIC mutant E221A in complex with tetraethylarsonium (TEAs)
2YN6	;	3.31	;	Pentameric Ligand-Gated Ion Channel ELIC in Complex with Barium
5HEU	;	3.2	;	Pentameric ligand-gated ion channel ELIC mutant A257Y
5HEJ	;	3.5	;	Pentameric ligand-gated ion channel ELIC mutant F116A
5HEO	;	3.3	;	Pentameric ligand-gated ion channel ELIC mutant P254G
5HEW	;	4.5	;	Pentameric ligand-gated ion channel ELIC mutant T28D
5HEH	;	3.3	;	Pentameric ligand-gated ion channel GLIC mutant P246A
5HEG	;	3.214	;	Pentameric ligand-gated ion channel GLIC mutant P246G
8ATG	;	2.9	;	Pentameric ligand-gated ion channel GLIC with bound lipids
7Q3G	;	3.5	;	Pentameric ligand-gated ion channel, DeCLIC at pH 7 with 10 mM Ca2+
7Q3H	;	3.2	;	Pentameric ligand-gated ion channel, DeCLIC at pH 7 with 10 mM EDTA
1FOQ	;	20.0	;	PENTAMERIC MODEL OF THE BACTERIOPHAGE PHI29 PROHEAD RNA
4J4V	;	2.303	;	Pentameric SFTSVN with suramin
7WHP	;	3.7	;	Pentameric turret of Bombyx mori cytoplasmic polyhedrosis virus after spike detaches.
6FLS	;	2.8	;	Pentapeptide repeat family protein from Clostridium botulinum
6ZT4	;	1.77	;	Pentapeptide repeat protein MfpA from Mycobacterium smegmatis
7TBA	;	3.5	;	Pentraxin - ligand complex
3M3L	;	1.85	;	PEPA bound to the ligand binding domain of GluA2 (flop form)
3M3F	;	2.5	;	PEPA bound to the ligand binding domain of GluA3 (flop form)
1KHG	;	2.34	;	PEPCK
1M51	;	2.25	;	PEPCK complex with a GTP-competitive inhibitor
1NHX	;	2.1	;	PEPCK COMPLEX WITH A GTP-COMPETITIVE INHIBITOR
2GMV	;	2.3	;	PEPCK complex with a GTP-competitive inhibitor
1KHE	;	2.4	;	PEPCK complex with nonhydrolyzable GTP analog, MAD data
1KHB	;	1.854	;	PEPCK complex with nonhydrolyzable GTP analog, native data
1KHF	;	2.02	;	PEPCK complex with PEP
7L3V	;	1.98	;	PEPCK MMQX structure 120ms post-mixing with oxaloacetic acid
7L3M	;	2.07	;	PEPCK MMQX structure 40ms post-mixing with oxaloacetic acid
7L36	;	1.84	;	PEPCK steady-state structure with Mn and GTP
6HVK	;		;	Pepducin UT-Pep2 a biased allosteric agonist of Urotensin-II receptor
5D6K	;	2.4	;	PepT - CIM
5MAS	;	0.84	;	Peptaibol Bergofungin A
4Z0W	;	1.1	;	Peptaibol gichigamin isolated from Tolypocladium sup_5
3PBC	;	1.38	;	Peptidase module of the peptidoglycan hydrolase RipA (Rv1477) from Mycobacterium tuberculosis at 1.38 resolution
3S0Q	;	1.45	;	Peptidase module of the peptidoglycan hydrolase RipA (Rv1477) from Mycobacterium tuberculosis, catalytic site mutant (Cys383Ala) at 1.45 resolution
1FNO	;	2.4	;	PEPTIDASE T (TRIPEPTIDASE)
8CV7	;	1.6	;	Peptide 2.2E in complex with BRD2-BD2
5V4C	;		;	Peptide 38136 modified from fragment 21-37 of Plasmodium falciparum Cell-Traversal Protein for Ookinetes and Sporozoites (CelTOS)
5VL6	;		;	Peptide 38138 modified from fragment 21-37 of Plasmodium falciparum Cell-Traversal Protein for Ookinetes and Sporozoite (Pf-CelTOS)
5VR5	;		;	Peptide 38142 modified from fragment 41-60 of Plasmodium falciparum Thrombospondin-Related Sporozoite Protein (TRSP)
5UY2	;		;	peptide 38146 derived from fragment 41-60 of Plasmodium falciparum Thrombospondin-Related Sporozoite Protein (TRSP)
5V2B	;		;	Peptide 38148 modified from fragment 41-60 of Plasmodium falciparum Thrombospondin-Related Sporozoite Protein (TRSP)
8CV5	;	1.47	;	Peptide 4.2B in complex with BRD3.2
8CV6	;	1.7	;	Peptide 4.2B in complex with BRD4.2
8CV4	;	1.93	;	Peptide 4.2C in complex with BRD4.2
7Q8G	;	2.06	;	Peptide ALAASS in complex with human cathepsin V C25S mutant
1IMW	;		;	Peptide Antagonist of IGFBP-1
1GJE	;		;	Peptide Antagonist of IGFBP-1, Minimized Average Structure
1IN2	;		;	Peptide Antagonist of IGFBP1, (i,i+7) Covalently Restrained Analog
1GJF	;		;	Peptide Antagonist of IGFBP1, (i,i+7) Covalently Restrained Analog, Minimized Average Structure
1IN3	;		;	Peptide Antagonist of IGFBP1, (i,i+8) Covalently Restrained Analog
1GJG	;		;	Peptide Antagonist of IGFBP1, (i,i+8) Covalently Restrained Analog, Minimized Average Structure
1DSR	;		;	Peptide antibiotic, NMR, 6 structures
8BRP	;	2.6	;	Peptide Arginase OspR from the cyanobacterium Kamptonema sp.
6IDV	;	2.4	;	Peptide Asparaginyl Ligases from Viola yedoensis
7Q8I	;	1.59	;	Peptide AVAEKQ in complex with human cathepsin V C25S mutant
7QFH	;	1.52	;	Peptide AYFKKVL in complex with human cathepsin V C25A mutant
2OL9	;	0.85	;	Peptide corresponding to residues 170-175 of human prion
1DFF	;	2.88	;	PEPTIDE DEFORMYLASE
4AL3	;	1.98	;	peptide deformylase (Co-form) with mercaptoethanol
4AL2	;	2.6	;	peptide deformylase (Ni-form) with hydrosulfide
1BSZ	;	1.9	;	PEPTIDE DEFORMYLASE AS FE2+ CONTAINING FORM (NATIVE) IN COMPLEX WITH INHIBITOR POLYETHYLENE GLYCOL
1BS7	;	2.5	;	PEPTIDE DEFORMYLASE AS NI2+ CONTAINING FORM
1BS6	;	2.1	;	PEPTIDE DEFORMYLASE AS NI2+ CONTAINING FORM IN COMPLEX WITH TRIPEPTIDE MET-ALA-SER
1BS5	;	2.5	;	PEPTIDE DEFORMYLASE AS ZN2+ CONTAINING FORM
1BS4	;	1.9	;	PEPTIDE DEFORMYLASE AS ZN2+ CONTAINING FORM (NATIVE) IN COMPLEX WITH INHIBITOR POLYETHYLENE GLYCOL
1BS8	;	2.2	;	PEPTIDE DEFORMYLASE AS ZN2+ CONTAINING FORM IN COMPLEX WITH TRIPEPTIDE MET-ALA-SER
2DEF	;		;	PEPTIDE DEFORMYLASE CATALYTIC CORE (RESIDUES 1-147), NMR, 20 STRUCTURES
1DEF	;		;	PEPTIDE DEFORMYLASE CATALYTIC CORE (RESIDUES 1-147), NMR, 9 STRUCTURES
3QU1	;	1.8	;	Peptide deformylase from Vibrio cholerae
7Q8H	;	1.75	;	Peptide EVCKKKK in complex with human cathepsin V C25A mutant
1PEF	;	1.5	;	PEPTIDE F (EQLLKALEFLLKELLEKL), AMPHIPHILIC OCTADECAPEPTIDE
1DU1	;		;	PEPTIDE FRAGMENT THR671-LEU690 OF THE RABBIT SKELETAL DIHYDROPYRIDINE RECEPTOR
4HH6	;	2.5	;	Peptide from EAEC T6SS Sci1 SciI protein
7K1M	;		;	Peptide from stony coral Heliofungia actiniformis: Hact-1
7QHJ	;	1.4	;	Peptide GAKSAA in complex with human cathepsin V C25A mutant
7QO2	;	1.77	;	Peptide GAKSAA in complex with human cathepsin V C25A mutant
7Q8F	;	1.49	;	Peptide GNYKEAKK in complex with human cathepsin V C25A mutant
7P3H	;	2.1	;	Peptide HC02 - Lanthanide Selectivity Engineered into Structurally Characterized Designed Coiled Coils
7Q8J	;	1.64	;	Peptide IILKEK in complex with human cathepsin V C25S mutant
8BV1	;	2.834	;	Peptide inhibitor P4 in complex with ASF1 histone chaperone
1SHD	;	2.0	;	PEPTIDE INHIBITORS OF SRC SH3-SH2-PHOSPHOPROTEIN INTERACTIONS
7Q8N	;	2.0	;	Peptide KKYDAFLA in complex with human cathepsin V C25A mutant
7Q8M	;	1.57	;	Peptide KPKKKTK in complex with human cathepsin V C25A mutant
4I4W	;	1.77	;	Peptide length determines the outcome of T cell receptor/peptide-MHCI engagement
2M3N	;		;	Peptide leucine arginine
7Q9H	;	1.4	;	Peptide LLKAVAEKQ in complex with human cathepsin V C25A mutant
7Q8K	;	1.74	;	Peptide LLKVAL in complex with human cathepsin V C25S mutant
7Q8P	;	1.71	;	Peptide LLKVAL in complex with human cathepsin V C25S mutant
7Q8O	;	1.9	;	Peptide LLSGKE in complex with human cathepsin V C25S mutant
2NBL	;		;	Peptide model of 4-stranded beta-arch
7CIS	;	2.1	;	Peptide modification of MHC class I molecules
1PNN	;	2.5	;	PEPTIDE NUCLEIC ACID (PNA) COMPLEXED WITH DNA
1ODQ	;		;	PEPTIDE OF HUMAN APOA-I RESIDUES 166-185. NMR, 5 STRUCTURES AT PH 3.7, 37 DEGREES CELSIUS AND PEPTIDE:SDS MOLE RATIO OF 1:40
1ODR	;		;	PEPTIDE OF HUMAN APOA-I RESIDUES 166-185. NMR, 5 STRUCTURES AT PH 6.0, 37 DEGREES CELSIUS AND PEPTIDE:DPC MOLE RATIO OF 1:40
1ODP	;		;	PEPTIDE OF HUMAN APOA-I RESIDUES 166-185. NMR, 5 STRUCTURES AT PH 6.6, 37 DEGREES CELSIUS AND PEPTIDE:SDS MOLE RATIO OF 1:40
1OEF	;		;	PEPTIDE OF HUMAN APOE RESIDUES 263-286, NMR, 5 STRUCTURES AT PH 4.8, 37 DEGREES CELSIUS AND PEPTIDE:SDS MOLE RATIO OF 1:90
1OEG	;		;	PEPTIDE OF HUMAN APOE RESIDUES 267-289, NMR, 5 STRUCTURES AT PH 6.0, 37 DEGREES CELSIUS AND PEPTIDE:SDS MOLE RATIO OF 1:90
1OPP	;		;	PEPTIDE OF HUMAN APOLIPOPROTEIN C-I RESIDUES 1-38, NMR, 28 STRUCTURES
1BY6	;		;	Peptide of human apolipoprotein C-II
6CFA	;		;	peptide PaAMP1R3
7CIR	;	1.81	;	Peptide phosphorylation modification of MHC class I molecules
7QHK	;	1.83	;	Peptide QLRQQE in complex with human cathepsin V C25A mutant
7Q9C	;	1.4	;	Peptide RLSAKP in complex with human cathepsin V C25A mutant
7Q8Q	;	2.13	;	Peptide RLSAKP in complex with human cathepsin V C25S mutant
4OWI	;	1.202	;	peptide structure
1XNS	;	2.8	;	Peptide trapped Holliday junction intermediate in Cre-loxP recombination
7Q8D	;	1.8	;	Peptide TRESEDLE in complex with human cathepsin V C25A mutant
7QFF	;	1.5	;	Peptide VACKSSQP in complex with human cathepsin V C25A mutant
7Q8L	;	1.8	;	Peptide VPCGTAHE in complex with human cathepsin V C25A mutant
7QNS	;	1.4	;	Peptide VYEKKP in complex with human cathepsin V C25S mutant
7RTB	;	2.14	;	Peptide-19 bound to the Glucagon-Like Peptide-1 Receptor (GLP-1R)
4O6W	;	1.448	;	Peptide-Based Inhibitors of Plk1 Polo-box Domain
2OP6	;	1.85	;	Peptide-binding domain of Heat shock 70 kDa protein D precursor from C.elegans
3DQG	;	1.72	;	Peptide-binding domain of heat shock 70 kDa protein F, mitochondrial precursor, from Caenorhabditis elegans.
3DOB	;	2.39	;	Peptide-binding domain of Heat shock 70 kDa protein F44E5.5 from C.elegans.
6W9Q	;	2.05	;	Peptide-bound SARS-CoV-2 Nsp9 RNA-replicase
6WC1	;	2.4	;	Peptide-bound SARS-CoV-2 Nsp9 RNA-replicase
5CH4	;	3.64	;	Peptide-Bound State of Thermus thermophilus SecYEG
6X5V	;	1.6	;	Peptide-bound structure of Marinomonas primoryensis peptide-binding domain
6X5W	;	1.8	;	Peptide-bound structure of Marinomonas primoryensis peptide-binding domain
6X6M	;	1.9	;	Peptide-bound structure of Marinomonas primoryensis peptide-binding domain
6X6Q	;	2.17	;	Peptide-bound structure of Marinomonas primoryensis peptide-binding domain
1C9I	;	2.9	;	PEPTIDE-IN-GROOVE INTERACTIONS LINK TARGET PROTEINS TO THE B-PROPELLER OF CLATHRIN
1C9L	;	2.9	;	PEPTIDE-IN-GROOVE INTERACTIONS LINK TARGET PROTEINS TO THE B-PROPELLER OF CLATHRIN
5MXL	;		;	Peptide-membrane interaction between targeting and lysis
5MXS	;		;	Peptide-membrane interaction between targeting and lysis
5MXT	;		;	Peptide-membrane interaction between targeting and lysis
6HNE	;		;	Peptide-membrane interaction between targeting and lysis
6HNG	;		;	Peptide-membrane interaction between targeting and lysis
6HNH	;		;	Peptide-membrane interaction between targeting and lysis
7N5Q	;	1.76	;	Peptide-MHC complex of mouse H2-Db presenting PA224 with E4C mutation
4K40	;	2.634	;	Peptidoglycan O-acetylesterase in action, 0 min
4K3U	;	2.158	;	Peptidoglycan O-acetylesterase in action, 30 min
4K7J	;	1.968	;	Peptidoglycan O-acetylesterase in action, 5 min
4K9S	;	2.334	;	Peptidoglycan O-acetylesterase in action, setmet
1OHT	;	2.0	;	Peptidoglycan recognition protein LB
7R7H	;	2.15	;	Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors
7CTQ	;	1.978	;	Peptidyl tryptophan dihydroxylase QhpG essential for tryptophylquinone cofactor biogenesis
1G63	;	2.5	;	PEPTIDYL-CYSTEINE DECARBOXYLASE EPID
1YW5	;	1.6	;	Peptidyl-prolyl isomerase ESS1 from Candida albicans
2PTH	;	1.2	;	PEPTIDYL-TRNA HYDROLASE FROM ESCHERICHIA COLI
3TD6	;	3.2	;	Peptidyl-tRNA hydrolase from Mycobacterium tuberculosis from trigonal partially dehydrated crystal
8DSJ	;	2.8	;	Peptidylglycine alpha hydroxylating monooxygenase anaerobic
8DSL	;	2.05	;	Peptidylglycine alpha hydroxylating monooxygenase, Q272E
8DSN	;	2.8	;	Peptidylglycine alpha hydroxylating monoxygenase, Q272A
1PHM	;	1.9	;	PEPTIDYLGLYCINE ALPHA-HYDROXYLATING MONOOXYGENASE (PHM) FROM RAT
2NUL	;	2.1	;	PEPTIDYLPROLYL ISOMERASE FROM E. COLI
1A33	;	2.15	;	PEPTIDYLPROLYL ISOMERASE, CYCLOPHILIN-LIKE DOMAIN FROM BRUGIA MALAYI
2MN9	;		;	peptoid analogue of maculatin G15 - peptoid trans-Nleu at position 13
6W47	;	1.15	;	Peptoid-Containing Collagen Peptide
5OXO	;	1.95	;	PepTSt apo structure
5OXK	;	2.38	;	PepTSt in complex with dipeptide Ala-Gln
5OXL	;	2.66	;	PepTSt in complex with dipeptide Ala-Leu
5OXM	;	2.295	;	PepTSt in complex with dipeptide Asp-Glu
5OXN	;	2.196	;	PepTSt in complex with dipeptide Phe-Ala
6EIA	;	2.0	;	PepTSt in complex with HEPES (100 mM)
5OXQ	;	2.195	;	PepTSt in complex with HEPES (300 mM)
6GHJ	;	2.26	;	PepTSt in complex with tripeptide Phe-Ala-Gln
5OXP	;	2.372	;	PepTSt in occluded conformation with phosphate ion bound
6DGU	;	2.691	;	PER-2 class A extended-spectrum beta-lactamase crystal structure at 2.69 Angstrom resolution
6D3G	;	2.398	;	PER-2 class A extended-spectrum beta-lactamase crystal structure in complex with avibactam at 2.4 Angstrom resolution
5EZT	;	1.54	;	Peracetylated Bovine Carbonic Anhydrase II
2QXW	;	0.8	;	Perdeuterated alr2 in complex with idd594
7ABX	;	1.2	;	Perdeuterated E65Q-TIM complexed with 2-PHOSPHOGLYCOLIC ACID
7AZ3	;	1.7	;	Perdeuterated E65Q-TIM complexed with 2-PHOSPHOGLYCOLIC ACID
7AZ3	;	1.15	;	Perdeuterated E65Q-TIM complexed with 2-PHOSPHOGLYCOLIC ACID
7AZ4	;	1.7	;	Perdeuterated E65Q-TIM complexed with 2-PHOSPHOGLYCOLIC ACID
7AZ4	;	1.15	;	Perdeuterated E65Q-TIM complexed with 2-PHOSPHOGLYCOLIC ACID
7AZ9	;	1.8	;	Perdeuterated E65Q-TIM complexed with PHOSPHOGLYCOLOHYDROXAMATE
7AZ9	;	1.1	;	Perdeuterated E65Q-TIM complexed with PHOSPHOGLYCOLOHYDROXAMATE
7AZA	;	1.8	;	Perdeuterated E65Q-TIM complexed with PHOSPHOGLYCOLOHYDROXAMATE
7AZA	;	1.1	;	Perdeuterated E65Q-TIM complexed with PHOSPHOGLYCOLOHYDROXAMATE
7AVG	;	1.0	;	Perdeuterated hen egg-white lysozyme at 100 K
6S2M	;	0.72	;	Perdeuterated human myelin protein P2 at 0.72-A resolution
5AE0	;	1.04	;	Perdeuterated mouse CNPase catalytic domain at atomic resolution
4CE8	;	0.9	;	Perdeuterated Pseudomonas aeruginosa Lectin II complex with hydrogenated L-Fucose and Calcium
7AVE	;	0.98	;	Perdeuterated refolded hen egg-white lysozyme at 100 K
6NV8	;	2.26	;	Perdeuterated tyrosine phenol-lyase from Citrobacter freundii complexed with an aminoacrylate intermediate formed from S-ethyl-L-cysteine and 4-hydroxypyridine
2KLF	;		;	PERE NMR structure of maltodextrin-binding protein
2KLG	;		;	PERE NMR structure of ubiquitin
3NXO	;	1.35	;	Perferential Selection of Isomer Binding from Chiral Mixtures: Alternate Binding Modes Observed for the E- and Z-isomers of a Series of 5-Substituted 2,4-Diaminofuro[2,3-d]pyrimidines as Ternary Complexes with NADPH and Human Dihydrofolate Reductase
3NXR	;	1.35	;	Perferential Selection of Isomer Binding from Chiral Mixtures: Alternate Binding Modes Observed for the E- and Z-isomers of a Series of 5-Substituted 2,4-Diaminofuro[2,3-d]pyrimidines as Ternary Complexes with NADPH and Human Dihydrofolate Reductase
5UG6	;	2.0	;	Perforin C2 Domain - T431D
1PFO	;	2.2	;	PERFRINGOLYSIN O
1M3I	;	2.9	;	Perfringolysin O, new crystal form
2C9E	;	2.1	;	Peridinin-chlorophyll a protein, high-salt form
1PPR	;	2.0	;	PERIDININ-CHLOROPHYLL-PROTEIN OF AMPHIDINIUM CARTERAE
6ZK9	;	2.3	;	Peripheral domain of open complex I during turnover
8AP8	;	3.7	;	Peripheral stalk of Trypanosoma brucei mitochondrial ATP synthase
8OQJ	;	1.64	;	Peripheral subunit binding domain of the E. coli Dihydrolipoamide Acetyltransferase (E2) of the pyruvate dehydrogenase complex
1W4G	;		;	Peripheral-subunit binding domains from mesophilic, thermophilic, and hyperthermophilic bacteria fold by ultrafast, apparently two-state folding transitions
1W4E	;		;	Peripheral-subunit binding domains from mesophilic, thermophilic, and hyperthermophilic bacteria fold by ultrafast, apparently two-state transitions
1W4I	;		;	Peripheral-subunit binding domains from mesophilic, thermophilic, and hyperthermophilic bacteria fold by ultrafast, apparently two-state transitions
1W4J	;		;	Peripheral-subunit binding domains from mesophilic, thermophilic, and hyperthermophilic bacteria fold by ultrafast, apparently two-state transitions
1W4K	;		;	Peripheral-subunit binding domains from mesophilic, thermophilic, and hyperthermophilic bacteria fold by ultrafast, apparently two-state transitions
2BTH	;		;	Peripheral-subunit binding domains from mesophilic, thermophilic, and hyperthermophilic bacteria fold by ultrafast, apparently two-state transitions
2BTG	;		;	peripheral-subunit binding domains from mesophilic,thermophilic, and hyperthermophilic bacteria fold by ultrafast, apparently two-state transitions
1W4F	;		;	Peripheral-subunit from mesophilic, thermophilic and hyperthermophilic bacteria fold by ultrafast, apparently two-state transitions
1W4H	;		;	Peripheral-subunit from mesophilic, thermophilic and hyperthermophilic bacteria fold by ultrafast, apparently two-state transitions
3ZKW	;	1.71	;	Periplasmic Binding Protein CeuE apo form
5OD5	;	1.9	;	Periplasmic binding protein CeuE complexed with a synthetic catalyst
5A1J	;	1.6	;	Periplasmic Binding Protein CeuE in complex with ferric 4-LICAM
2LIV	;	2.4	;	PERIPLASMIC BINDING PROTEIN STRUCTURE AND FUNCTION. REFINED X-RAY STRUCTURES OF THE LEUCINE/ISOLEUCINE/VALINE-BINDING PROTEIN AND ITS COMPLEX WITH LEUCINE
1BF8	;		;	PERIPLASMIC CHAPERONE FIMC, NMR, 20 STRUCTURES
6FUE	;	1.78	;	Periplasmic coiled coil domain of the FapF amyloid transporter
6EY4	;	2.0	;	Periplasmic domain (residues 36-513) of GldM
2W7V	;	2.3	;	periplasmic domain of EpsL from Vibrio parahaemolyticus
1UV7	;	1.7	;	periplasmic domain of EpsM from Vibrio cholerae
8UK7	;	1.8	;	Periplasmic domain of Escherichia coli CpxA
6F49	;	2.02	;	Periplasmic domain of LolC lacking the Hook.
5NHX	;	1.95	;	Periplasmic domain of Outer Membrane Protein A from Klebsiella pneumoniae
8HDJ	;	1.85	;	Periplasmic domain of RsgI2 of Clostridium thermocellum
4E29	;	1.6	;	Periplasmic domain of the chimeric WzzB chain length regulator protein
3GR5	;	2.05	;	Periplasmic domain of the outer membrane secretin EscC from enteropathogenic E.coli (EPEC)
3LR3	;	2.1	;	Periplasmic domain of the risS sensor protein from Burkholderia pesuromallei, low pH native structure
3LR4	;	1.9	;	Periplasmic domain of the risS sensor protein from Burkholderia pseudomallei, barium phased at low pH
3LR0	;	1.9	;	Periplasmic domain of the risS sensor protein from Burkholderia pseudomallei, iodide phased at low pH
3LR5	;	2.3	;	Periplasmic domain of the risS sensor protein from Burkholderia pseudomallei, iodide phased at neutral pH
3GR0	;	2.3	;	Periplasmic domain of the T3SS inner membrane protein PrgH from S.typhimurium (fragment 170-362)
3GR1	;	2.8	;	Periplasmic domain of the T3SS inner membrane protein PrgH from S.typhimurium (fragment 170-392)
7NN6	;		;	periplasmic domain of Vibrio cholerae ToxR
3V67	;	2.3	;	Periplasmic domain of Vibrio parahaemolyticus CpxA
6WM7	;	1.56	;	Periplasmic EDTA-binding protein EppA, orthorhombic
6WM6	;	1.42	;	Periplasmic EDTA-binding protein EppA, tetragonal
1EFD	;	1.9	;	PERIPLASMIC FERRIC SIDEROPHORE BINDING PROTEIN FHUD COMPLEXED WITH GALLICHROME
5GIZ	;	1.5	;	Periplasmic heme-binding protein BhuT in apo form
5Y89	;	2.4	;	Periplasmic heme-binding protein BhuT in complex with one heme (holo-1)
5Y8A	;	2.001	;	Periplasmic heme-binding protein BhuT in complex with two hemes (holo-2 form)
5Y8B	;	2.4	;	Periplasmic heme-binding protein RhuT from Roseiflexus sp. RS-1 in apo form
5GJ3	;	2.0	;	Periplasmic heme-binding protein RhuT from Roseiflexus sp. RS-1 in two-heme bound form (holo-2)
6RWX	;	3.55	;	Periplasmic inner membrane ring of the Shigella type 3 secretion system
3IX1	;	2.4	;	Periplasmic N-formyl-4-amino-5-aminomethyl-2-methylpyrimidine binding protein from Bacillus halodurans
3UB7	;	1.4	;	Periplasmic portion of the Helicobacter pylori chemoreceptor TlpB with acetamide bound
3UB8	;	1.42	;	Periplasmic portion of the Helicobacter pylori chemoreceptor TlpB with formamide bound
3UB9	;	1.42	;	Periplasmic portion of the Helicobacter pylori chemoreceptor TlpB with hydroxyurea bound
3UB6	;	1.38	;	Periplasmic portion of the Helicobacter pylori chemoreceptor TlpB with urea bound
4XJY	;	1.8	;	Periplasmic repressor protein YfiR
3B47	;	2.0	;	Periplasmic sensor domain of chemotaxis protein GSU0582
3B42	;	1.9	;	Periplasmic sensor domain of chemotaxis protein GSU0935
4K08	;	2.0	;	Periplasmic sensor domain of chemotaxis protein, Adeh_3718
4K0D	;	1.997	;	Periplasmic sensor domain of sensor histidine kinase, Adeh_2942
2QRY	;	2.25	;	Periplasmic thiamin binding protein
1TOA	;	1.8	;	PERIPLASMIC ZINC BINDING PROTEIN TROA FROM TREPONEMA PALLIDUM
4W70	;	2.28	;	Periplasmically Produced Monomeric Single Domain Antibody (sdAb) C22A/C99V variant against Staphylococcal enterotoxin B (SEB) at pH 7.0
4W81	;	2.25	;	Periplasmically Produced Monomeric Single Domain Antibody (sdAb) C22A/C99V variant against Staphylococcal enterotoxin B (SEB) at pH 8.0
7QSP	;	1.36	;	Permutated C-terminal lobe of the ribose binding protein from Thermotoga maritima
7QSQ	;	1.79	;	Permutated N-terminal lobe of the ribose binding protein from Thermotoga maritima
1U9P	;	1.9	;	Permuted single-chain Arc
1GZA	;	2.06	;	PEROXIDASE
1GZB	;	1.8	;	PEROXIDASE
6ERC	;	2.50002	;	Peroxidase A from Dictyostelium discoideum (DdPoxA)
5WBD	;	1.5	;	Peroxide Activation Regulated by Hydrogen Bonds within Artificial Cu Proteins - N49A
5WBB	;	1.5	;	Peroxide Activation Regulated by Hydrogen Bonds within Artificial Cu Proteins - S112A
5WBA	;	1.5	;	Peroxide Activation Regulated by Hydrogen Bonds within Artificial Cu Proteins - WT
6ANX	;	1.62	;	Peroxide Activation Regulated by Hydrogen Bonds within Artificial Cu Proteins - WT (low exposure)
3MPS	;	2.0	;	Peroxide Bound Oxidized Rubrerythrin from Pyrococcus furiosus
3I63	;	2.09	;	Peroxide Bound Toluene 4-Monooxygenase
7O9D	;	1.28	;	peroxide-bound diCo-sulerythrin
3A2V	;	1.65	;	Peroxiredoxin (C207S) from Aeropyrum pernix K1 complexed with hydrogen peroxide
3A2X	;	1.9	;	Peroxiredoxin (C50S) from Aeropyrum pernix K1 (acetate-bound form)
3A2W	;	2.3	;	Peroxiredoxin (C50S) from Aeropytum pernix K1 (peroxide-bound form)
3A5W	;	2.2	;	Peroxiredoxin (wild type) from Aeropyrum pernix K1 (reduced form)
5XBS	;	2.51	;	Peroxiredoxin from Aeropyrum pernix (6m mutant)
6KRM	;	1.8	;	Peroxiredoxin from Aeropyrum pernix K1 (ApPrx) 0Cys F46A mutant
6KRQ	;	2.1	;	Peroxiredoxin from Aeropyrum pernix K1 (ApPrx) 0Cys F80A mutant
6KRK	;	1.8	;	Peroxiredoxin from Aeropyrum pernix K1 (ApPrx) 0Cys mutant
6KRR	;	2.15	;	Peroxiredoxin from Aeropyrum pernix K1 (ApPrx) 0Cys W210A mutant
6KRS	;	2.3	;	Peroxiredoxin from Aeropyrum pernix K1 (ApPrx) 0Cys W211A mutant
6KRP	;	1.89	;	Peroxiredoxin from Aeropyrum pernix K1 (ApPrx) 0Cys W88A mutant
7C87	;	2.2	;	Peroxiredoxin from Aeropyrum pernix K1 (ApPrx) C50S/F80C/C207S/C213S mutant (ApPrx*F80C)
7C8A	;	2.1	;	Peroxiredoxin from Aeropyrum pernix K1 (ApPrx) C50S/F80C/C207S/C213S mutant modified with 2-(bromoacetyl)naphthalene(Naph@ApPrx*)
7C89	;	2.1	;	Peroxiredoxin from Aeropyrum pernix K1 (ApPrx) C50S/F80C/C207S/C213S mutant modified with 2-bromoacetophenone(Ph@ApPrx*)
7CQJ	;	2.9	;	Peroxiredoxin from Aeropyrum pernix K1 (ApPrx) C50S/K84A/C207S/C213S mutant (ApPrx*K84A)
5XBQ	;	2.25	;	Peroxiredoxin from Pyrococcus horikoshii (6m mutant)
5XBR	;	2.1	;	Peroxiredoxin from Pyrococcus horikoshii (sulfonic acid form)
6IU1	;	2.89	;	Peroxiredoxin from Pyrococcus horikoshii 0Cys mutant)
6ITZ	;	2.96	;	Peroxiredoxin from Thermococcus kodakaraensis
6IU0	;	2.38	;	Peroxiredoxin from Thermococcus kodakaraensis (0Cys mutant)
8HH0	;	2.35	;	Peroxiredoxin from Thermococcus kodakaraensis (TkPrx) F42C/C46S/C205S/C211S mutant modified with 2-(bromoacetyl)naphthalene (Naph@TkPrx*F42C)
4EO3	;	1.649	;	Peroxiredoxin Nitroreductase Fusion Enzyme
2Y6V	;	2.83	;	Peroxisomal alpha-beta-hydrolase Lpx1 (Yor084w) from Saccharomyces cerevisiae (crystal form I)
2Y6U	;	1.9	;	Peroxisomal alpha-beta-hydrolase Lpx1 (Yor084w) from Saccharomyces cerevisiae (crystal form II)
5VXV	;	1.55	;	Peroxisomal membrane protein PEX15
8DK4	;	2.6	;	Peroxisome proliferator-activated receptor gamma in complex with VSP-51-2
6MS7	;	1.43	;	Peroxisome proliferator-activated receptor gamma ligand binding domain in complex with a novel selective PPAR-gamma modulator VSP-77
5TWO	;	1.927	;	Peroxisome proliferator-activated receptor gamma ligand binding domain in complex with a novel selectively PPAR gamma-modulating ligand VSP-51
6R9N	;	2.074	;	Peroxy diiron species of chemotaxis sensor ODP
3AXF	;	2.0	;	Perrhenate binding to A11C/R153C ModA mutant
3R26	;	1.7	;	Perrhenate Binding to Molybdate Binding Protein
1L00	;	1.9	;	PERTURBATION OF TRP 138 IN T4 LYSOZYME BY MUTATIONS AT GLN 105 USED TO CORRELATE CHANGES IN STRUCTURE, STABILITY, SOLVATION, AND SPECTROSCOPIC PROPERTIES
1L98	;	1.8	;	PERTURBATION OF TRP 138 IN T4 LYSOZYME BY MUTATIONS AT GLN 105 USED TO CORRELATE CHANGES IN STRUCTURE, STABILITY, SOLVATION, AND SPECTROSCOPIC PROPERTIES
1L99	;	1.95	;	PERTURBATION OF TRP 138 IN T4 LYSOZYME BY MUTATIONS AT GLN 105 USED TO CORRELATE CHANGES IN STRUCTURE, STABILITY, SOLVATION, AND SPECTROSCOPIC PROPERTIES
7U6Z	;	1.30002	;	Pertussis toxin E129D NAD
7SKK	;	1.65001	;	pertussis toxin in complex with ADPR and Nicotinamide
7SKI	;	1.09912	;	Pertussis toxin in complex with PJ34
7SKY	;	1.37	;	Pertussis toxin S1 bound to NAD+
7SNE	;	1.00011	;	Pertussis toxin S1 subunit bound to BaAD
6EZ7	;	1.9	;	Pes4 RRM3 Structure
4CBG	;	2.82	;	Pestivirus NS3 helicase
4CBH	;	2.51	;	Pestivirus NS3 helicase
4CBI	;	3.0	;	Pestivirus NS3 helicase
4CBL	;	3.05	;	Pestivirus NS3 helicase
4CBM	;	3.27	;	Pestivirus NS3 helicase
7Z6B	;	1.4	;	PET hydrolase PET6 from halophilic organsim Vibrio gazogenes
1ZLP	;	2.7	;	Petal death protein PSR132 with cysteine-linked glutaraldehyde forming a thiohemiacetal adduct
8CRU	;	1.3	;	PETase Ancestral Sequence Reconstruction 008
6QGC	;	2.0	;	PETase from Ideonella sakaiensis without ligand
6GR0	;	2.5	;	Petrobactin-binding engineered lipocalin in complex with gallium-petrobactin
6GQZ	;	1.4	;	Petrobactin-binding engineered lipocalin without ligand
2IZ0	;	2.6	;	PEX inhibitor-home data
5NL8	;	2.2	;	Pex4 of Hansenula Polymorpha
4BWF	;	3.23	;	Pex4p-Pex22p disulphide bond mutant
2Y9P	;	3.25	;	Pex4p-Pex22p mutant II structure
2Y9M	;	2.6	;	Pex4p-Pex22p structure
7LCK	;	3.24	;	PF 06882961 bound to the glucagon-like peptide-1 receptor (GLP-1R)
7LCI	;	2.9	;	PF 06882961 bound to the glucagon-like peptide-1 receptor (GLP-1R):Gs complex
7LCJ	;	2.82	;	PF 06882961 bound to the glucagon-like peptide-1 receptor (GLP-1R):Gs complex
2IFM	;	3.3	;	PF1 FILAMENTOUS BACTERIOPHAGE: REFINEMENT OF A MOLECULAR MODEL BY SIMULATED ANNEALING USING 3.3 ANGSTROMS RESOLUTION X-RAY FIBRE DIFFRACTION DATA
2IFN	;	4.0	;	PF1 FILAMENTOUS BACTERIOPHAGE: REFINEMENT OF A MOLECULAR MODEL BY SIMULATED ANNEALING USING 3.3 ANGSTROMS RESOLUTION X-RAY FIBRE DIFFRACTION DATA
3IFM	;	3.3	;	PF1 FILAMENTOUS BACTERIOPHAGE: REFINEMENT OF A MOLECULAR MODEL BY SIMULATED ANNEALING USING 3.3 ANGSTROMS RESOLUTION X-RAY FIBRE DIFFRACTION DATA
4IFM	;	3.3	;	PF1 FILAMENTOUS BACTERIOPHAGE: REFINEMENT OF A MOLECULAR MODEL BY SIMULATED ANNEALING USING 3.3 ANGSTROMS RESOLUTION X-RAY FIBRE DIFFRACTION DATA
1PFI	;	3.0	;	PF1 VIRUS STRUCTURE: HELICAL COAT PROTEIN AND DNA WITH PARAXIAL PHOSPHATES
2HR5	;	2.7	;	PF1283- Rubrerythrin from Pyrococcus furiosus iron bound form
1PFM	;		;	PF4-M2 CHIMERIC MUTANT WITH THE FIRST 10 N-TERMINAL RESIDUES OF R-PF4 REPLACED BY THE N-TERMINAL RESIDUES OF THE IL8 SEQUENCE. MODELS 1-15 OF A 27-MODEL SET.
1PFN	;		;	PF4-M2 CHIMERIC MUTANT WITH THE FIRST 10 N-TERMINAL RESIDUES OF R-PF4 REPLACED BY THE N-TERMINAL RESIDUES OF THE IL8 SEQUENCE. MODELS 16-27 OF A 27-MODEL SET.
5EUO	;	2.1	;	PF6-M1-HLA-A2
2R0Z	;	2.096	;	PFA1 FAB complexed with GripI peptide fragment
2IPT	;	2.0	;	PFA1 Fab Fragment
2IPU	;	1.65	;	PFA1 Fab fragment complexed with Abeta 1-8 peptide
3EYS	;	1.95	;	PFA1 Fab fragment complexed with pyro-Glu3-A-Beta (3-8)
3EYU	;	2.71	;	PFA1 Fab fragment complexed with Ror2(518-525)
2R0W	;	2.503	;	PFA2 FAB complexed with Abeta1-8
2IQA	;	2.0	;	PFA2 FAB fragment, monoclinic apo form
2IQ9	;	2.3	;	PFA2 FAB fragment, triclinic apo form
6RIW	;	1.85	;	PfaC Keto synthase-Chain length factor
3SRJ	;	2.15	;	PfAMA1 in complex with invasion-inhibitory peptide R1
2LJ3	;		;	PFBD: High-throughput Strategy of Backbone fold Determination for small well-folded proteins in less than a day
7BK6	;	2.15	;	PfCopC mutant - D83A
7BK7	;	2.3	;	PfCopC mutant - D83N
7BK5	;	1.54	;	PfCopC mutant - E27A
7PI3	;	3.269	;	PfCyRPA bound to Fab fragments from monoclonal antibodies Cy.003, Cy.004 and Cy.007
7PI7	;	2.72	;	PfCyRPA bound to monoclonal antibody Cy.002 Fab fragment
7PI2	;	3.14	;	PfCyRPA bound to monoclonal antibody Cy.003 Fab fragment
7PHW	;	2.793	;	PfCyRPA bound to monoclonal antibody Cy.004 Fab fragment
7PHV	;	3.091	;	PfCyRPA bound to monoclonal antibody Cy.007 Fab fragment
8CDE	;	3.1	;	PfCyRPA-PfRIPR complex from Plasmodium falciparum bound to antibody Cy.003
7CF8	;	2.21	;	PfkB(Mycobacterium marinum)
7FCA	;	2.21	;	PfkB(Mycobacterium marinum)
2DWO	;	2.25	;	PFKFB3 in complex with ADP and PEP
3QPW	;	2.25	;	PFKFB3 in complex with Aluminum Tetrafluoride
3QPU	;	2.3	;	PFKFB3 in complex with PPi
3QPV	;	2.5	;	PFKFB3 trapped in a phospho-enzyme intermediate state
5IY0	;	3.0	;	PfMCM N-terminal domain double hexamer
4POF	;	2.648	;	PfMCM N-terminal domain without DNA
4R7Z	;	3.8	;	PfMCM-AAA double-octamer
6RCU	;	4.005	;	PfRH5 bound to monoclonal antibodies R5.004 and R5.016
6RCV	;	3.582	;	PfRH5 bound to monoclonal antibodies R5.011 and R5.016
7PHU	;	2.53	;	PfRH5 bound to monoclonal antibody R5.015 and R5.016 Fab fragments
6RCO	;	1.66	;	PfRH5-binding monoclonal antibody R5.004
6RCQ	;	2.28	;	PfRH5-binding monoclonal antibody R5.011
6RCS	;	2.1	;	PfRH5-binding monoclonal antibody R5.016
8CDD	;	3.0	;	PfRH5-PfCyRPA-PfRIPR complex from Plasmodium falciparum bound to antibody Cy.003
7UA2	;	2.19	;	Pfs230 D1 domain in complex with 230AL-18
7UA8	;	2.8	;	Pfs230 D1 domain in complex with 230AL-20
7U9E	;	2.39	;	Pfs230 D1 domain in complex with 230AL-26
7UCQ	;	2.5	;	Pfs230 D1 domain in complex with 230AS-18
7UBS	;	2.5	;	Pfs230 D1 domain in complex with 230AS-26
7UC8	;	2.9	;	Pfs230 D1 domain in complex with 230AS-73
7U9W	;	2.79	;	Pfs230 D1 domain in complex with 230AS-88
7JUM	;	1.998	;	Pfs230 D1 domain in complex with neutralizing antibody LMIV230-01
7UI1	;	3.3	;	Pfs230 D1D2 domain in complex with 230AL-37
7UFW	;	2.1	;	Pfs230 D1D2 in complex with LMIV230-01
7UVS	;	2.06	;	Pfs230 domain 1 bound by LMIV230-02 Fab
7UVH	;	2.59	;	Pfs230 domain 1 bound by RUPA-32 Fab
7UVO	;	2.09	;	Pfs230 domain 1 bound by RUPA-38 Fab
7UVI	;	2.92	;	Pfs230 domain 1 bound by RUPA-55 Fab
7UVQ	;	3.29	;	Pfs230 domain 1 bound by RUPA-97 and 15C5 Fabs
6PHB	;	2.0	;	Pfs25 in complex with the human transmission blocking antibody 2530
6PHC	;	2.9	;	Pfs25 in complex with the human transmission blocking antibody 2544
6PHD	;	3.1	;	Pfs25 in complex with the human transmission blocking antibody 2586
6PHF	;	3.1	;	Pfs25 in complex with the human transmission blocking antibody 2587
8EZK	;	2.3	;	Pfs25 in complex with transmission-reducing antibody AS01-04
8EZL	;	2.3	;	Pfs25 in complex with transmission-reducing antibody AS01-50
8EZM	;	2.1	;	Pfs25 in complex with transmission-reducing antibody AS01-63
7ZXG	;	4.2	;	Pfs48/45 bound to Fab fragment of monoclonal antibody 10D8
7ZXF	;	3.72	;	Pfs48/45 bound to monoclonal antibodies 10D8 and 85RF45.1
7ZWF	;	2.132	;	Pfs48/45 bound to scFv fragment of monoclonal antibody 32F3
7ZWI	;	1.9	;	Pfs48/45 C-terminal domain bound to fab fragment of monoclonal antibody 32F3
7ZWM	;	3.69	;	Pfs48/45 central and C-terminal domains bound to Fab fragments of monoclonal antibody 10D8 and 32F3
2LU1	;		;	pfsub2 solution NMR structure
7YNT	;	3.1	;	pFTAA-bound alpha-synuclein fibrils
2K3R	;		;	Pfu Rpp21 structure and assignments
6RNY	;	3.9	;	PFV intasome - nucleosome strand transfer complex
4E7I	;	2.5301	;	PFV intasome freeze-trapped prior to 3'-processing, Mn-bound form (UI-Mn)
4E7H	;	2.5701	;	PFV intasome prior to 3'-processing, Apo form (UI-Apo)
4IKF	;	3.4	;	PFV intasome with inhibitor MB-76
4BE0	;	2.68	;	PFV intasome with inhibitor XZ-115
4BE1	;	2.71	;	PFV intasome with inhibitor XZ-116
4BE2	;	2.38	;	PFV intasome with inhibitor XZ-259
4BDY	;	2.52	;	PFV intasome with inhibitor XZ-89
4BDZ	;	2.85	;	PFV intasome with inhibitor XZ-90
4E7L	;	3.0001	;	PFV integrase Strand Transfer Complex (STC-Mn*) following reaction in crystallo, at 3.0 A resolution.
4E7K	;	3.02	;	PFV integrase Target Capture Complex (TCC-Mn), freeze-trapped prior to strand transfer, at 3.0 A resolution
4E7J	;	3.1501	;	PFV integrase Target Capture Complex, Apo form (TCC-Apo), at 3.15 A resolution
3OS0	;	2.81	;	PFV strand transfer complex (STC) at 2.81 A resolution
3OS1	;	2.97	;	PFV target capture complex (TCC) at 2.97 A resolution
3OS2	;	3.32	;	PFV target capture complex (TCC) at 3.32 A resolution
5WHZ	;	3.549	;	PGDM1400-10E8v4 CODV Fab
8XJL	;	2.77	;	PGF2-alpha bound Prostaglandin F2-alpha receptor-Gq Protein Complex
8RDX	;	3.67	;	PGGtase I in complex with probe BAY-6092
5NP8	;	1.9	;	PGK1 in complex with CRT0063465 (3-[2-(4-bromophenyl)-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-6-yl]propanoic acid)
5TYH	;	2.1	;	PglD from Campylobacter jejuni NCTC 11168 in complex with 5-(2-furanyl)-1H-pyrazole-3-carboxylic acid
3BSY	;	1.8	;	PglD from Campylobacter jejuni, NCTC 11168, in complex with acetyl coenzyme A
3BSS	;	2.3	;	PglD from Campylobacter jejuni, NCTC 11168, with native substrate
3BSW	;	1.77	;	PglD-citrate complex, from Campylobacter jejuni NCTC 11168
2VHE	;	1.8	;	PglD-CoA complex: An acetyl transferase from Campylobacter jejuni
4ZTC	;	2.0	;	PglE Aminotransferase in complex with External Aldimine, Mutant K184A
5NBD	;	3.9	;	PglK flippase in complex with inhibitory nanobody
7D62	;	1.9	;	pGpG-specific phosphodiesterase - PggH from Vibrio cholrae
6NIJ	;	5.7	;	PGT145 Fab in complex with full length AMC011 HIV-1 Env
1QFX	;	2.4	;	PH 2.5 ACID PHOSPHATASE FROM ASPERGILLUS NIGER
7YQV	;	3.58	;	pH 5.5 SARS-CoV-2 BA.2.75 S Trimer (1 RBD Up)
1B17	;	1.7	;	PH AFFECTS GLU B13 SWITCHING AND SULFATE BINDING IN CUBIC INSULIN CRYSTALS (PH 5.00 COORDINATES)
1B18	;	1.8	;	PH AFFECTS GLU B13 SWITCHING AND SULFATE BINDING IN CUBIC INSULIN CRYSTALS (PH 5.53 COORDINATES)
1B19	;	1.8	;	PH AFFECTS GLU B13 SWITCHING AND SULFATE BINDING IN CUBIC INSULIN CRYSTALS (PH 5.80 COORDINATES)
1B2A	;	1.7	;	PH AFFECTS GLU B13 SWITCHING AND SULFATE BINDING IN CUBIC INSULIN CRYSTALS (PH 6.00 COORDINATES)
1B2B	;	1.8	;	PH AFFECTS GLU B13 SWITCHING AND SULFATE BINDING IN CUBIC INSULIN CRYSTALS (PH 6.16 COORDINATES)
1B2C	;	1.8	;	PH AFFECTS GLU B13 SWITCHING AND SULFATE BINDING IN CUBIC INSULIN CRYSTALS (PH 6.26 COORDINATES)
1B2D	;	1.7	;	PH AFFECTS GLU B13 SWITCHING AND SULFATE BINDING IN CUBIC INSULIN CRYSTALS (PH 6.35 COORDINATES)
1B2E	;	1.9	;	PH AFFECTS GLU B13 SWITCHING AND SULFATE BINDING IN CUBIC INSULIN CRYSTALS (PH 6.50 COORDINATES)
1B2F	;	1.9	;	PH AFFECTS GLU B13 SWITCHING AND SULFATE BINDING IN CUBIC INSULIN CRYSTALS (PH 6.98 COORDINATES)
1B2G	;	1.8	;	PH AFFECTS GLU B13 SWITCHING AND SULFATE BINDING IN CUBIC INSULIN CRYSTALS (PH 9.00 COORDINATES)
2KJO	;		;	pH dependent structures of LAH4 in micellar environment: mode of acting
2KJN	;		;	pH dependent structures of LAH4 in micellar environmnet:mode of acting
1BWN	;	2.1	;	PH DOMAIN AND BTK MOTIF FROM BRUTON'S TYROSINE KINASE MUTANT E41K IN COMPLEX WITH INS(1,3,4,5)P4
1BTK	;	1.6	;	PH DOMAIN AND BTK MOTIF FROM BRUTON'S TYROSINE KINASE MUTANT R28C
1B55	;	2.4	;	PH DOMAIN FROM BRUTON'S TYROSINE KINASE IN COMPLEX WITH INOSITOL 1,3,4,5-TETRAKISPHOSPHATE
6F24	;		;	PH domain from PfAPH
6F8E	;		;	PH domain from TgAPH
5C79	;	1.6	;	PH domain of ASAP1 in complex with diC4-PtdIns(4,5)P2
2A6U	;		;	pH evolution of tetragonal HEWL at 4 degrees Celcius.
5UKD	;	1.9	;	PH INFLUENCES FLUORIDE COORDINATION NUMBER OF THE ALFX PHOSPHORYL TRANSFER TRANSITION STATE ANALOG
1QF9	;	1.7	;	PH INFLUENCES FLUORIDE COORDINATION NUMBER OF THE ALFX PHOSPHORYL TRANSFER TRANSITION STATE ANALOG IN UMP/CMP KINASE
2X12	;	2.9	;	pH-induced modulation of Streptococcus parasanguinis adhesion by Fap1 fimbriae
6SU5	;	1.2	;	Ph2119 endolysin from Thermus scotoductus MAT2119 bacteriophage Ph2119
5IP0	;	3.0	;	PHA Binding Protein PhaP (Phasin)
4RGA	;	2.1	;	Phage 1358 receptor binding protein in complex with the trisaccharide GlcNAc-Galf-GlcOMe
8C7J	;	2.0	;	Phage display derived serum albumin binding knob domain engineered within a novel VH framework 3 bispecific antibody format
8C7V	;	1.61	;	Phage display derived serum albumin binding knob domain engineered within a novel VH framework 3 bispecific antibody format
1KF9	;	2.6	;	PHAGE DISPLAY DERIVED VARIANT OF HUMAN GROWTH HORMONE COMPLEXED WITH TWO COPIES OF THE EXTRACELLULAR DOMAIN OF ITS RECEPTOR
3ZF1	;	3.0	;	Phage dUTPases control transfer of virulence genes by a proto- oncogenic G protein-like mechanism. (Staphylococcus bacteriophage 80alpha dUTPase D81N mutant with dUpNHpp).
3ZF4	;	3.1	;	Phage dUTPases control transfer of virulence genes by a proto- oncogenic G protein-like mechanism. (Staphylococcus bacteriophage 80alpha dUTPase Y81A mutant with dUpNHpp).
3ZF2	;	2.9	;	Phage dUTPases control transfer of virulence genes by a proto- oncogenic G protein-like mechanism. (Staphylococcus bacteriophage 80alpha dUTPase).
3ZEZ	;	2.8	;	Phage dUTPases control transfer of virulence genes by a proto- oncogenic G protein-like mechanism.(Staphylococcus bacteriophage 80alpha dUTPase with dUPNHPP).
3ZF6	;	2.6	;	Phage dUTPases control transfer of virulence genes by a proto-oncogenic G protein-like mechanism. (Staphylococcus bacteriophage 80alpha dUTPase D81A D110C S168C mutant with dUpNHpp).
3ZF0	;	2.9	;	Phage dUTPases control transfer of virulence genes by a proto-oncogenic G protein-like mechanism. (Staphylococcus bacteriophage 80alpha dUTPase D81A mutant with dUpNHpp).
3ZF5	;	3.2	;	Phage dUTPases control transfer of virulence genes by a proto-oncogenic G protein-like mechanism. (Staphylococcus bacteriophage 80alpha dUTPase Y84F mutant with dUpNHpp).
3ZF3	;	3.1	;	Phage dUTPases control transfer of virulence genes by a proto-oncogenic G protein-like mechanism. (Staphylococcus bacteriophage 80alpha dUTPase Y84I mutant).
1FR5	;	3.5	;	PHAGE FR CAPSIDS WITH A FOUR RESIDUE DELETION IN THE COAT PROTEIN FG LOOP
6WKK	;	6.1	;	Phage G gp27 major capsid proteins and gp26 decoration proteins
2WCC	;		;	phage lambda IntDBD1-64 complex with p prime 2 DNA
8F72	;	2.7	;	Phage P32 gp64- RNA polymerase
2FIP	;	2.0	;	Phage phi29 transcription regulator p4
2FIO	;	2.7	;	Phage phi29 transcription regulator p4-DNA complex
4HIZ	;	1.601	;	Phage phi92 endosialidase
6ZNB	;	2.8	;	PHAGE SAM LYASE IN APO STATE
6ZMG	;	1.48	;	PHAGE SAM LYASE IN COMPLEX WITH S-ADENOSYL-L-HOMOCYSTEINE
6ZM9	;	1.45	;	PHAGE SAM LYASE IN COMPLEX WITH S-METHYL-5'-THIOADENOSINE
2HOT	;	2.19	;	Phage selected homeodomain bound to modified DNA
206L	;	1.75	;	PHAGE T4 LYSOZYME
2XVR	;	10.8	;	Phage T7 empty mature head shell
3U6X	;	2.6	;	Phage TP901-1 baseplate tripod
5UDN	;	1.971	;	Phage-associated cell wall hydrolase PlyPy from Streptococcus pyogenes, space group P3121
5UDM	;	2.64	;	Phage-associated cell wall hydrolase PlyPy from Streptococcus pyogenes, space group P6522
4KLK	;	1.93	;	Phage-related protein DUF2815 from Enterococcus faecalis
2HOS	;	1.9	;	Phage-Selected Homeodomain Bound to Unmodified DNA
1ZDA	;		;	PHAGE-SELECTED MINI PROTEIN A DOMAIN, Z38, NMR, 24 STRUCTURES
1ZDB	;		;	PHAGE-SELECTED MINI PROTEIN A DOMAIN, Z38, NMR, MINIMIZED MEAN STRUCTURE
7BTI	;	3.6	;	Phalloidin bound F-actin complex
4ZB7	;	2.4	;	Phanerochaete chrysosporium URE2P6 in apo form.
3QBL	;	2.2	;	Pharaonis halorhodopsin complexed with nitrate
4DO4	;	1.4	;	Pharmacological chaperones for human alpha-N-acetylgalactosaminidase
4DO5	;	1.51	;	Pharmacological chaperones for human alpha-N-acetylgalactosaminidase
4DO6	;	1.6	;	Pharmacological chaperones for human alpha-N-acetylgalactosaminidase
3S5Y	;	2.105	;	Pharmacological Chaperoning in Human alpha-Galactosidase
3S5Z	;	2.001	;	Pharmacological Chaperoning in Human alpha-Galactosidase
3TV8	;	2.639	;	Pharmacological Chaperoning in Human alpha-Galactosidase
6X8R	;		;	Pharmacological characterisation and NMR structure of the novel mu-conotoxin SxIIIC, a potent irreversible NaV channel inhibitor
5AFV	;	2.25	;	Pharmacophore-based virtual screening to discover new active compounds for human choline kinase alpha1.
6LPD	;	1.65	;	Phascolosoma esculenta
6LPE	;	1.99	;	Phascolosoma esculenta ferritin
2Z18	;	1.15	;	Phase transition of monoclinic lysozyme crystal soaked in a 10% NaCl solution
2Z19	;	1.15	;	Phase transition of monoclinic lysozyme crystal soaked in a saturated NaCl solution
2VTV	;	1.9	;	PhaZ7 depolymerase from Paucimonas lemoignei
2D81	;	1.66	;	PHB depolymerase (S39A) complexed with R3HB trimer
2M85	;		;	PHD Domain from Human SHPRH
2M1R	;		;	PHD domain of ING4 N214D mutant
3ZVZ	;	1.449	;	PHD finger of human UHRF1
3ZVY	;	1.95	;	PHD finger of human UHRF1 in complex with unmodified histone H3 N- terminal tail
8JWU	;	3.58	;	PHD Finger Protein 7 (PHF7) fused to UBE2D2 via a (GSGG)3 linker
8JWJ	;	2.96	;	PHD Finger Protein 7 (PHF7) in complex with UBE2D2
3O70	;	1.85	;	PHD-type zinc finger of human PHD finger protein 13
5OQD	;	2.447	;	PHD2 and winged-helix domain of Polycomblike
3OUJ	;	2.3	;	PHD2 with 2-Oxoglutarate
3OUH	;	2.51	;	PHD2-R127 with JNJ41536014
3OUI	;	1.7	;	PHD2-R717 with 40787422
3HQU	;	2.3	;	PHD2:Fe:UN9:partial HIF1-alpha substrate complex
3HQR	;	2.0	;	PHD2:Mn:NOG:HIF1-alpha substrate complex
6MLC	;	1.8	;	PHD6 domain of MLL3 in complex with histone H4
6DAQ	;	2.0	;	PhdJ bound to substrate intermediate
6DAN	;	2.047	;	PhdJ WT 2 Angstroms resolution
2SGF	;	1.75	;	PHE 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B
3ZJJ	;	2.0	;	Phe(93)E11Leu mutation of M.acetivorans protoglobin in complex with cyanide
1TTT	;	2.7	;	Phe-tRNA, elongation factoR EF-TU:GDPNP ternary complex
1CC4	;	2.0	;	PHE161 AND ARG166 VARIANTS OF P-HYDROXYBENZOATE HYDROXYLASE. IMPLICATIONS FOR NADPH RECOGNITION AND STRUCTURAL STABILITY.
1CC6	;	2.2	;	PHE161 AND ARG166 VARIANTS OF P-HYDROXYBENZOATE HYDROXYLASE. IMPLICATIONS FOR NADPH RECOGNITION AND STRUCTURAL STABILITY.
1JPI	;	2.3	;	Phe232Leu mutant of human UROD, human uroporphyrinogen III decarboxylase
3PGU	;	1.7	;	Phe3Glu mutant of EcFadL
3PGS	;	1.9	;	Phe3Gly mutant of EcFadL
1MTI	;	1.9	;	PHE46(CD4) ORIENTS THE DISTAL HISTIDINE FOR HYDROGEN BONDING TO BOUND LIGANDS IN SPERM WHALE MYOGLOBIN
1MTJ	;	1.7	;	PHE46(CD4) ORIENTS THE DISTAL HISTIDINE FOR HYDROGEN BONDING TO BOUND LIGANDS IN SPERM WHALE MYOGLOBIN
1MTK	;	1.8	;	PHE46(CD4) ORIENTS THE DISTAL HISTIDINE FOR HYDROGEN BONDING TO BOUND LIGANDS IN SPERM WHALE MYOGLOBIN
7Z9L	;		;	Phen-DC3 intercalation causes hybrid-to-antiparallel transformation of human telomeric DNA G-quadruplex
1A18	;	2.4	;	PHENANTHROLINE MODIFIED MURINE ADIPOCYTE LIPID BINDING PROTEIN
7SAB	;	4.3	;	Phencyclidine-bound GluN1a-GluN2B NMDA receptors
3SMB	;	1.6	;	Phenethylisothiocyanate Covalently Bound to Macrophage Migration Inhibitory Factor (MIF)
7VQF	;	2.3	;	Phenol binding protein, MopR
1FOH	;	2.4	;	PHENOL HYDROXYLASE FROM TRICHOSPORON CUTANEUM
1PN0	;	1.7	;	Phenol hydroxylase from Trichosporon cutaneum
5KGY	;		;	Phenol-soluble modulin Alpha 3
5KGZ	;		;	Phenol-soluble modulin Beta2
4YYL	;	1.905	;	Phenolic acid derivative bound to influenza strain H1N1 polymerase subunit PA endonuclease
1W4X	;	1.7	;	Phenylacetone Monooxygenase, a Baeyer-Villiger Monooxygenase
4OVI	;	1.87	;	Phenylacetone monooxygenase: oxidised enzyme in complex with APADP
4C77	;	2.7	;	Phenylacetone monooxygenase: oxidised R337K mutant in complex with APADP
4C74	;	1.97	;	Phenylacetone monooxygenase: Reduced enzyme in complex with APADP
1AMU	;	1.9	;	PHENYLALANINE ACTIVATING DOMAIN OF GRAMICIDIN SYNTHETASE 1 IN A COMPLEX WITH AMP AND PHENYLALANINE
1W27	;	1.7	;	Phenylalanine ammonia-lyase (PAL) from Petroselinum crispum
6F6T	;	1.89996	;	Phenylalanine ammonia-lyase (PAL) from Petroselinum crispum complexed with S-APPA
6AT7	;	2.493	;	Phenylalanine Ammonia-Lyase (PAL) from Sorghum bicolor
1BXG	;	2.3	;	PHENYLALANINE DEHYDROGENASE STRUCTURE IN TERNARY COMPLEX WITH NAD+ AND BETA-PHENYLPROPIONATE
1BW9	;	1.5	;	PHENYLALANINE DEHYDROGENASE STRUCTURE IN TERNARY COMPLEX WITH NAD+ AND PHENYLPYRUVATE
5JK6	;	2.072	;	Phenylalanine hydroxylase from dictyostelium - apo form
5JK5	;	2.071	;	Phenylalanine hydroxylase from dictyostelium - BH2 complex
5JK8	;	2.394	;	Phenylalanine hydroxylase from dictyostelium - BH2, norleucine complex
2RG5	;	2.4	;	Phenylalanine pyrrolotriazine p38 alpha map kinase inhibitor compound 11B
2RG6	;	1.72	;	Phenylalanine pyrrolotriazine p38 alpha map kinase inhibitor compound 11J
1Q2H	;	1.7	;	Phenylalanine Zipper Mediates APS Dimerization
1B70	;	2.7	;	PHENYLALANYL TRNA SYNTHETASE COMPLEXED WITH PHENYLALANINE
1B7Y	;	2.5	;	PHENYLALANYL TRNA SYNTHETASE COMPLEXED WITH PHENYLALANINYL-ADENYLATE
1PYS	;	2.9	;	PHENYLALANYL-TRNA SYNTHETASE FROM THERMUS THERMOPHILUS
2IY5	;	3.1	;	PHENYLALANYL-TRNA SYNTHETASE FROM THERMUS THERMOPHILUS complexed with tRNA and a phenylalanyl-adenylate analog
8FDK	;	1.89	;	Phenylhydroxylamine in Reaction with Human Hemoglobin
1MUP	;	2.4	;	PHEROMONE BINDING TO TWO RODENT URINARY PROTEINS REVEALED BY X-RAY CRYSTALLOGRAPHY
2ERL	;	1.0	;	PHEROMONE ER-1 FROM
1ERY	;		;	PHEROMONE ER-11, NMR
1HD6	;		;	PHEROMONE ER-22, NMR
1HA8	;		;	Pheromone Er-23 from Euplotes raikovi
6E6O	;	0.7	;	Pheromone from Euplotes raikovi, Er-1
6E6N	;	1.363	;	Pheromone from Euplotes raikovi, Er-13
2RHQ	;	2.2	;	PheRS from Staphylococcus haemolyticus- rational protein engineering and inhibitor studies
2RHS	;	2.2	;	PheRS from Staphylococcus haemolyticus- rational protein engineering and inhibitor studies
4P73	;	3.03	;	PheRS in complex with compound 1a
4P72	;	2.62	;	PheRS in complex with compound 2a
4P74	;	2.7	;	PheRS in complex with compound 3a
4P75	;	2.96	;	PheRS in complex with compound 4a
8OTJ	;	3.3	;	PHF tau filament from Kii ALS/PDC
8SEH	;	2.9	;	PHF Tau from Down Syndrome
4HCZ	;	1.85	;	PHF1 Tudor in complex with H3K36me3
4BD3	;		;	Phf19 links methylated lysine 36 of histone H3 to regulation of Polycomb activity
8F8Z	;	3.3	;	PHF2 (PHD+JMJ) in Complex with H3 Histone N-Terminal Peptide
8F8Y	;	3.06	;	PHF2 (PHD+JMJ) in Complex with VRK1 N-Terminal Peptide
3PTR	;	1.954	;	PHF2 Jumonji domain
3PU3	;	1.95	;	PHF2 Jumonji domain-NOG complex
3PU8	;	1.943	;	PHF2 Jumonji-NOG-Fe(II) complex
3PUA	;	1.89	;	PHF2 Jumonji-NOG-Ni(II)
3PUS	;	2.08	;	PHF2 Jumonji-NOG-Ni(II)
7M10	;	1.15	;	PHF2 PHD Domain Complexed with Peptide From N-terminus of VRK1
6L10	;	1.6	;	PHF20L1 Tudor1 - MES
6WXK	;	2.9	;	PHF23 PHD Domain Apo
7DKM	;	1.7	;	PHGDH covalently linked to oridonin
8F2O	;	3.0	;	Phi-29 expanded, DNA-packaged fiberless prohead
8F2N	;	3.0	;	Phi-29 partially-expanded fiberless prohead
8F2M	;	3.7	;	Phi-29 scaffolding protein bound to intermediate-state MCP
2PZS	;	2.6	;	Phi29 DNA polymerase complexed with primer-template DNA (post-translocation binary complex)
2PYJ	;	2.03	;	Phi29 DNA polymerase complexed with primer-template DNA and incoming nucleotide substrates (ternary complex)
2PYL	;	2.2	;	Phi29 DNA polymerase complexed with primer-template DNA and incoming nucleotide substrates (ternary complex)
2PY5	;	1.6	;	Phi29 DNA polymerase complexed with single-stranded DNA
1XI1	;	2.2	;	Phi29 DNA polymerase ssDNA complex, monoclinic crystal form
1XHX	;	2.35	;	Phi29 DNA Polymerase, orthorhombic crystal form
1XHZ	;	2.7	;	Phi29 DNA polymerase, orthorhombic crystal form, ssDNA complex
2KVN	;		;	Phi29 E-loop hairpin
7PV4	;	2.8	;	PhiCPV4 bacteriophage Portal Protein
8FNE	;	3.9	;	phiPA3 PhuN Tetramer, p2
8JFL	;	2.9	;	PhK holoenzyme in active state, muscle isoform
8JFK	;	2.9	;	PhK holoenzyme in inactive state, muscle isoform
4PVK	;	1.3	;	Phl p 4 I153V N158H variant, a glucose oxidase
4PWC	;	2.3	;	Phl p 4 I153V N158H variant, a glucose oxidase, 3.5 M NaBr soak
4PVJ	;	1.8	;	Phl p 4 I153V variant, a glucose oxidase
4PWB	;	1.9	;	Phl p 4 I153V variant, a glucose oxidase, pressurized with Xenon
4PVH	;	1.4	;	Phl p 4 N158H variant, a glucose dehydrogenase
6TRK	;	1.6	;	Phl p 6 fold stabilized mutant - S46Y
6MT7	;	1.78	;	Phlebotomus duboscqi salivary D7 protein, selenomethionine derivative
7VUB	;	1.2	;	Phloem lectin (PP2) complex with Nitrobenzene
7W4B	;	2.5	;	Phloem lectin (PP2) structure -complex with Chitotrise
7VWB	;	1.9	;	Phloem lectin (PP2) structure -complex with N-Acetyllactosamine (LacNAc)
7VS6	;	2.5	;	Phloem lectin (PP2) structure -native form
7YAQ	;	1.853	;	Phloem lectin (PP2)C34S mutant
2UXI	;	2.5	;	Phloretin in complex with TtgR
5G4K	;	1.74	;	Phloroglucinol reductase from Clostridium sp. apo-form
5G4L	;	1.8	;	Phloroglucinol reductase from Clostridium sp. with bound NADPH
8KI5	;	2.01	;	PhmA, a type I diterpene synthase without NST/DTE motif
8KIH	;	2.0	;	PhmA, a type I diterpene synthase without NST/DTE motif
1GXP	;	2.5	;	PhoB effector domain in complex with pho box DNA.
1B00	;	1.88	;	PHOB RECEIVER DOMAIN FROM ESCHERICHIA COLI
2JB9	;	1.7	;	PhoB response regulator receiver domain constitutively-active double mutant D10A and D53E.
2JBA	;	1.45	;	PhoB response regulator receiver domain constitutively-active double mutant D53A and Y102C.
3T72	;	4.33	;	PhoB(E)-Sigma70(4)-(RNAP-Betha-flap-tip-helix)-DNA Transcription Activation Sub-Complex
7PZG	;	1.44	;	Phocaeicola vulgatus sialic acid esterase at 1.44 Angstrom resolution
7PZH	;	2.06	;	Phocaeicola vulgatus sialic acid esterase at 2.06 Angstrom resolution
8FZZ	;	2.68	;	Phocaeicola vulgatus type VI secretion system Ntox15 effector and immunity Tde2/Tdi2
6A86	;	1.8	;	Pholiota squarrosa lectin
6A87	;	2.41	;	Pholiota squarrosa lectin (PhoSL) in complex with fucose(alpha1-6)GlcNAc
7VU9	;	2.154	;	Pholiota squarrosa lectin (PhoSL) in complex with fucose(alpha1-6)[GlcNAc(beta1-4)]GlcNAc
5XZK	;		;	Pholiota squarrosa lectin trimer
7CNO	;	2.5	;	Phomopsin A in complex with tubulin
6A8V	;	2.7	;	PhoQ sensor domain (D179R mutant): analysis of internal cavity
6A8U	;	1.848	;	PhoQ sensor domain (wild type): analysis of internal cavity
2TRC	;	2.4	;	PHOSDUCIN/TRANSDUCIN BETA-GAMMA COMPLEX
5HPE	;	2.27	;	Phosphatase domain of PP5 bound to a phosphomimetic Cdc37 substrate peptide
6IAH	;	1.75	;	Phosphatase Tt82 from Thermococcus thioreducens
6A1K	;	2.3	;	Phosphate acyltransferase PlsX from B.subtilis
4OMB	;	1.5	;	Phosphate binding protein
8JFS	;	1.0	;	Phosphate bound acylphosphatase from Deinococcus radiodurans at 1 Angstrom resolution
1IE7	;	1.85	;	PHOSPHATE INHIBITED BACILLUS PASTEURII UREASE CRYSTAL STRUCTURE
4S2E	;	2.35	;	Phosphate ion bound Crystal structure of thymidylate kinase (aq_969) from Aquifex Aeolicus VF5
3DFP	;	2.05	;	Phosphate ions in D33N mutant fructose-1,6-bisphosphate aldolase from rabbit muscle
3DFT	;	1.94	;	Phosphate ions in D33S mutant fructose-1,6-bisphosphate aldolase from rabbit muscle
2QUV	;	2.22	;	Phosphate ions in fructose-1,6-bisphosphate aldolase from rabbit muscle
1A0A	;	2.8	;	PHOSPHATE SYSTEM POSITIVE REGULATORY PROTEIN PHO4/DNA COMPLEX
1IXH	;	0.98	;	PHOSPHATE-BINDING PROTEIN (PBP) COMPLEXED WITH PHOSPHATE
8ODS	;	1.909	;	Phosphate-Binding Protein (PstS) from Xanthomonas citri pv. citri A306 bound to phosphate
2ABH	;	1.7	;	PHOSPHATE-BINDING PROTEIN (RE-REFINED)
5JK4	;	1.1	;	Phosphate-Binding Protein from Stenotrophomonas maltophilia.
1A55	;	2.4	;	PHOSPHATE-BINDING PROTEIN MUTANT A197C
1A54	;	1.6	;	PHOSPHATE-BINDING PROTEIN MUTANT A197C LABELLED WITH A COUMARIN FLUOROPHORE AND BOUND TO DIHYDROGENPHOSPHATE ION
1OIB	;	2.4	;	PHOSPHATE-BINDING PROTEIN MUTANT T141D
1QUK	;	1.7	;	PHOSPHATE-BINDING PROTEIN MUTANT WITH ASP 137 REPLACED BY ASN COMPLEX WITH PHOSPHATE
1QUI	;	1.9	;	PHOSPHATE-BINDING PROTEIN MUTANT WITH ASP 137 REPLACED BY GLY COMPLEX WITH BROMINE AND PHOSPHATE
1QUJ	;	1.9	;	PHOSPHATE-BINDING PROTEIN MUTANT WITH ASP 137 REPLACED BY GLY COMPLEX WITH CHLORINE AND PHOSPHATE
1QUL	;	1.7	;	PHOSPHATE-BINDING PROTEIN MUTANT WITH ASP 137 REPLACED BY THR COMPLEX WITH CHLORINE AND PHOSPHATE
1IXI	;	1.89	;	PHOSPHATE-BINDING PROTEIN MUTANT WITH ASP 56 REPLACED BY ASN COMPLEX WITH MONOBASIC PHOSPHATE ION
1IXG	;	1.05	;	PHOSPHATE-BINDING PROTEIN MUTANT WITH THR 141 REPLACED BY ASP (T141D), COMPLEXED WITH PHOSPATE
1A40	;	1.7	;	PHOSPHATE-BINDING PROTEIN WITH ALA 197 REPLACED WITH TRP
5LTD	;	2.5	;	Phosphate-bound Pichia angusta Atg18
1A44	;	1.84	;	PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN FROM CALF BRAIN
2GZQ	;	1.3	;	Phosphatidylethanolamine-binding protein from Plasmodium vivax
1PHT	;	2.0	;	PHOSPHATIDYLINOSITOL 3-KINASE P85-ALPHA SUBUNIT SH3 DOMAIN, RESIDUES 1-85
1H9O	;	1.79	;	PHOSPHATIDYLINOSITOL 3-KINASE, P85-ALPHA SUBUNIT: C-TERMINAL SH2 DOMAIN COMPLEXED WITH A TYR751 PHOSPHOPEPTIDE FROM THE PDGF RECEPTOR, CRYSTAL STRUCTURE AT 1.79 A
1PIC	;		;	PHOSPHATIDYLINOSITOL 3-KINASE, P85-ALPHA SUBUNIT: C-TERMINAL SH2 DOMAIN COMPLEXED WITH A TYR751 PHOSPHOPEPTIDE FROM THE PDGF RECEPTOR, NMR, MINIMIZED MEAN STRUCTURE
4WAE	;	3.318	;	Phosphatidylinositol 4-kinase III beta crystallized with ATP
4WAG	;	3.407	;	Phosphatidylinositol 4-kinase III beta crystallized with MI103 inhibitor
4D0M	;	6.0	;	Phosphatidylinositol 4-kinase III beta in a complex with Rab11a-GTP- gamma-S and the Rab-binding domain of FIP3
4D0L	;	2.94	;	Phosphatidylinositol 4-kinase III beta-PIK93 in a complex with Rab11a- GTP gammaS
1BO1	;	3.0	;	PHOSPHATIDYLINOSITOL PHOSPHATE KINASE TYPE II BETA
1AUA	;	2.5	;	PHOSPHATIDYLINOSITOL TRANSFER PROTEIN SEC14P FROM SACCHAROMYCES CEREVISIAE
1VFY	;	1.15	;	PHOSPHATIDYLINOSITOL-3-PHOSPHATE BINDING FYVE DOMAIN OF VPS27P PROTEIN FROM SACCHAROMYCES CEREVISIAE
1PTD	;	2.6	;	PHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE C
1AOD	;	2.6	;	PHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE C FROM LISTERIA MONOCYTOGENES
2PLC	;	2.0	;	PHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE C FROM LISTERIA MONOCYTOGENES
1GYM	;	2.2	;	PHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE C IN COMPLEX WITH GLUCOSAMINE-(ALPHA-1-6)-MYO-INOSITOL
1PTG	;	2.6	;	PHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE C IN COMPLEX WITH MYO-INOSITOL
2PTD	;	2.0	;	PHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE C MUTANT D198E
4PTD	;	2.3	;	PHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE C MUTANT D274N
3PTD	;	2.2	;	PHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE C MUTANT D274S
5PTD	;	2.7	;	PHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE C MUTANT H32A
6PTD	;	2.6	;	PHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE C MUTANT H32L
7PTD	;	2.6	;	PHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE C MUTANT R163K
8A6M	;		;	Phosphatidylserine-dependent synaptic vesicle membrane sculpting by synaptogyrin
6IH6	;	2.491	;	Phosphite Dehydrogenase mutant I151R/P176R/M207A from Ralstonia sp. 4506 in complex with non-natural cofactor Nicotinamide Cytosine dinucleotide
1SUR	;	2.0	;	PHOSPHO-ADENYLYL-SULFATE REDUCTASE
2HEG	;	1.5	;	Phospho-Aspartyl Intermediate Analogue of Apha class B acid phosphatase/phosphotransferase
1J97	;	1.5	;	Phospho-Aspartyl Intermediate Analogue of Phosphoserine phosphatase
1RLO	;	2.0	;	Phospho-aspartyl Intermediate Analogue of ybiV from E. coli K12
5V60	;	2.18	;	Phospho-ERK2 bound to AMP-PCP
5V61	;	2.2	;	Phospho-ERK2 bound to bivalent inhibitor SBP2
5V62	;	1.9	;	Phospho-ERK2 bound to bivalent inhibitor SBP3
7UQC	;	2.65	;	phospho-GlialCAM peptide AA370-389 with Fab MS39p2w174
4PYH	;	1.65	;	Phospho-glucan bound structure of starch phosphatase Starch EXcess4 reveals the mechanism for C6-specificty
5J19	;	2.0	;	phospho-Pon binding-induced Plk1 dimerization
7R4H	;	2.34	;	phospho-STING binding to adaptor protein complex-1
1MCP	;	2.7	;	PHOSPHOCHOLINE BINDING IMMUNOGLOBULIN FAB MC/PC603. AN X-RAY DIFFRACTION STUDY AT 2.7 ANGSTROMS
7PK5	;	4.4	;	Phosphodiesterase PdeL (EAL domain of crystals comprising full-length protein)
7F0I	;	2.70001	;	phosphodiesterase-9A in complex with inhibitor 4b
4QGE	;	2.0	;	phosphodiesterase-9A in complex with inhibitor WYQ-C36D
1AQ2	;	1.9	;	PHOSPHOENOLPYRUVATE CARBOXYKINASE
1AYL	;	1.8	;	PHOSPHOENOLPYRUVATE CARBOXYKINASE
1OEN	;	1.9	;	PHOSPHOENOLPYRUVATE CARBOXYKINASE
1K3D	;	2.0	;	Phosphoenolpyruvate carboxykinase in complex with ADP and AlF3
1K3C	;	2.0	;	Phosphoenolpyruvate carboxykinase in complex with ADP, AlF3 and Pyruvate
1PYM	;	1.8	;	PHOSPHOENOLPYRUVATE MUTASE FROM MOLLUSK IN WITH BOUND MG2-OXALATE
1BLE	;	2.9	;	PHOSPHOENOLPYRUVATE-DEPENDENT PHOSPHOTRANSFERASE SYSTEM
1PDO	;	1.7	;	PHOSPHOENOLPYRUVATE-DEPENDENT PHOSPHOTRANSFERASE SYSTEM
3UJ9	;	1.24	;	Phosphoethanolamine methyltransferase from Plasmodium falciparum in complex with phosphocholine
3UJA	;	1.466	;	Phosphoethanolamine methyltransferase from Plasmodium falciparum in complex with phosphoethanolamine
3UJB	;	1.521	;	Phosphoethanolamine methyltransferase from Plasmodium falciparum in complex with SAH and phosphoethanolamine
3UJ7	;	1.549	;	Phosphoethanolamine methyltransferase from Plasmodium falciparum in complex with SAM and PO4
3UJ8	;	1.351	;	Phosphoethanolamine methyltransferase from Plasmodium falciparum in complex with sinefungin and PO4
6WLF	;	2.05	;	Phosphoethanolamine Methyltransferase from the Pine Wilt Nematode Bursaphelenchus xylophilus
3UJC	;	1.19	;	Phosphoethanolamine methyltransferase mutant (H132A) from Plasmodium falciparum in complex with phosphocholine
3UJD	;	1.5	;	Phosphoethanolamine methyltransferase mutant (Y19F) from Plasmodium falciparum in complex with phosphocholine
6PFK	;	2.6	;	PHOSPHOFRUCTOKINASE, INHIBITED T-STATE
3PFK	;	2.4	;	PHOSPHOFRUCTOKINASE. STRUCTURE AND CONTROL
4PFK	;	2.4	;	PHOSPHOFRUCTOKINASE. STRUCTURE AND CONTROL
2FUV	;	2.0	;	Phosphoglucomutase from Salmonella typhimurium.
1C4G	;	2.7	;	PHOSPHOGLUCOMUTASE VANADATE BASED TRANSITION STATE ANALOG COMPLEX
7VSS	;	2.96	;	Phosphoglucomutase_tlr1976
7VST	;	2.74	;	Phosphoglucomutase_tlr1976
1T10	;	2.35	;	Phosphoglucose isomerase from Leishmania mexicana in complex with substrate D-fructose-6-phosphate
1Q50	;	2.6	;	Phosphoglucose isomerase from Leishmania mexicana.
7OYL	;	1.78	;	Phosphoglucose isomerase of Aspergillus fumigatus in complexed with Glucose-6-phosphate
16PK	;	1.6	;	PHOSPHOGLYCERATE KINASE FROM TRYPANOSOMA BRUCEI BISUBSTRATE ANALOG
5Y2I	;	1.917	;	Phosphoglycerate mutase 1 (PGAM1) complexed with its inhibitor PGMI-004A
8IT5	;	2.2	;	Phosphoglycerate mutase 1 complexed with a compound
8IT6	;	2.55	;	Phosphoglycerate mutase 1 complexed with a compound
8IT7	;	2.8	;	Phosphoglycerate mutase 1 complexed with a compound
8IT8	;	1.95	;	Phosphoglycerate mutase 1 complexed with a compound
8ITB	;	2.38	;	Phosphoglycerate mutase 1 complexed with a compound
8ITC	;	1.88	;	Phosphoglycerate mutase 1 complexed with a compound
8ITD	;	1.9	;	Phosphoglycerate mutase 1 complexed with a compound
7XB7	;	2.2	;	Phosphoglycerate mutase 1 complexed with a covalent inhibitor
7XB8	;	1.6	;	Phosphoglycerate mutase 1 complexed with a covalent inhibitor
7XB9	;	1.58	;	Phosphoglycerate mutase 1 complexed with a covalent inhibitor
8IT4	;	2.4	;	Phosphoglycerate mutase 1 complexed with a covalent inhibitor
6ISN	;	1.98	;	Phosphoglycerate mutase 1 complexed with a small molecule inhibitor
5ZRM	;	2.28	;	Phosphoglycerate mutase 1 complexed with a small molecule inhibitor In-AC
5Y35	;	1.994	;	Phosphoglycerate mutase 1 complexed with a small molecule inhibitor KH1
5Y65	;	2.554	;	Phosphoglycerate mutase 1 complexed with a small molecule inhibitor KH2
5Y64	;	2.149	;	Phosphoglycerate mutase 1 H11 phosphorylated form complexed with KH1
5U9Z	;	2.001	;	Phosphoglycerol transferase GacH from Streptococcus pyogenes
7PO7	;	2.31	;	Phosphoglycolate phosphatase from Mus musculus
7POE	;	3.16	;	Phosphoglycolate Phosphatase with Inhibitor CP1
8V4J	;	1.31	;	Phosphoheptose isomerase GMHA from Burkholderia pseudomallei bound to inhibitor Mut148233
8V2T	;	1.402	;	Phosphoheptose isomerase GMHA from Burkholderia pseudomallei bound to inhibitor Mut148591
7KKE	;	2.81	;	Phosphoinositide 3-Kinase gamma bound to a thiazole inhibitor
6C1S	;	2.31	;	Phosphoinositide 3-Kinase gamma bound to an pyrrolopyridinone Inhibitor
8SO9	;	3.03	;	Phosphoinositide phosphate 3 kinase gamma
8SOB	;	3.9	;	Phosphoinositide phosphate 3 kinase gamma bound with ADP
8SOC	;	3.5	;	Phosphoinositide phosphate 3 kinase gamma bound with ADP and Gbetagamma
8SOD	;	3.4	;	Phosphoinositide phosphate 3 kinase gamma bound with ADP and two Gbetagamma subunits in State 1
8SOE	;	3.6	;	Phosphoinositide phosphate 3 kinase gamma bound with ADP and two Gbetagamma subunits in State 2
8SOA	;	3.32	;	Phosphoinositide phosphate 3 kinase gamma bound with ATP
3QD0	;	1.99	;	Phosphoinositide-Dependent Kinase-1 (PDK1) kinase domain with (2R,5S)-1-[2-Amino-6-(3-amino-1H-indazol-6-yl)-4-pyrimidinyl]-6-methyl-N-phenyl-3-piperidinecarboxamide
3QD3	;	2.0	;	Phosphoinositide-Dependent Kinase-1 (PDK1) kinase domain with 1,1-Dimethylethyl {(3R,6S)-1-[2-amino-6-(3-amino-1H-indazol-6-yl)-4-pyrimidinyl]-6-methyl-3-piperidinyl}carbamate
3QD4	;	2.3	;	Phosphoinositide-Dependent Kinase-1 (PDK1) kinase domain with 1,1-Dimethylethyl{(3R,5R)-1-[2-amino-6-(3-amino-1H-indazol-6-yl)-4-pyrimidinyl]-5-methyl-3-piperidinyl}carbamate
3QCY	;	2.2	;	Phosphoinositide-Dependent Kinase-1 (PDK1) kinase domain with 4-[2-Amino-6-(3-amino-1H-indazol-6-yl)-4-pyrimidinyl]-N-phenyl-2-morpholinecarboxamide
3QCQ	;	2.501	;	Phosphoinositide-Dependent Kinase-1 (PDK1) kinase domain with 6-(3-Amino-1H-indazol-6-yl)-N4-ethyl-2,4-pyrimidinediamine
3QCS	;	2.487	;	Phosphoinositide-Dependent Kinase-1 (PDK1) kinase domain with 6-[2-Amino-6-(4-morpholinyl)-4-pyrimidinyl]-1H-indazol-3-amine
3QCX	;	2.3	;	Phosphoinositide-Dependent Kinase-1 (PDK1) kinase domain with 6-{2-Amino-6-[(3R)-3-methyl-4-morpholinyl]-4-pyrimidinyl}-1H-indazol-3-amine
3NUU	;	1.9803	;	phosphoinositide-dependent kinase-1 (PDK1) with fragment11
3NUY	;	2.1	;	phosphoinositide-dependent kinase-1 (PDK1) with fragment17
3NUS	;	2.75	;	phosphoinositide-dependent kinase-1 (PDK1) with fragment8
3NUN	;	2.2	;	phosphoinositide-dependent kinase-1 (PDK1) with lead compound
3H9O	;	2.3	;	Phosphoinositide-dependent protein kinase 1 (PDK-1) in complex with compound 9
2ISD	;	2.5	;	PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C-DELTA1 FROM RAT
1DJH	;	2.5	;	PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C-DELTA1 FROM RAT COMPLEXED WITH BARIUM
1DJI	;	2.5	;	PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C-DELTA1 FROM RAT COMPLEXED WITH CALCIUM
1DJX	;	2.3	;	PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C-DELTA1 FROM RAT COMPLEXED WITH INOSITOL-1,4,5-TRISPHOSPHATE
1DJY	;	2.8	;	PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C-DELTA1 FROM RAT COMPLEXED WITH INOSITOL-2,4,5-TRISPHOSPHATE
1DJW	;	2.45	;	PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C-DELTA1 FROM RAT COMPLEXED WITH INOSITOL-2-METHYLENE-1,2-CYCLIC-MONOPHOSPHONATE
1DJZ	;	2.95	;	PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C-DELTA1 FROM RAT COMPLEXED WITH INOSITOL-4,5-BISPHOSPHATE
1DJG	;	2.6	;	PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C-DELTA1 FROM RAT COMPLEXED WITH LANTHANUM
3AHD	;	1.9	;	Phosphoketolase from Bifidobacterium Breve complexed with 2-acetyl-thiamine diphosphate
3AHE	;	2.1	;	Phosphoketolase from Bifidobacterium Breve complexed with dihydroxyethyl thiamine diphosphate
3AHF	;	2.3	;	Phosphoketolase from Bifidobacterium Breve complexed with inorganic phosphate
1A3D	;	1.8	;	PHOSPHOLIPASE A2 (PLA2) FROM NAJA NAJA VENOM
1A3F	;	2.65	;	PHOSPHOLIPASE A2 (PLA2) FROM NAJA NAJA VENOM
1BPQ	;	1.8	;	PHOSPHOLIPASE A2 ENGINEERING. X-RAY STRUCTURAL AND FUNCTIONAL EVIDENCE FOR THE INTERACTION OF LYSINE-56 WITH SUBSTRATES
2BPP	;	1.8	;	PHOSPHOLIPASE A2 ENGINEERING. X-RAY STRUCTURAL AND FUNCTIONAL EVIDENCE FOR THE INTERACTION OF LYSINE-56 WITH SUBSTRATES
1RGB	;	3.3	;	Phospholipase A2 from Vipera ammodytes meridionalis
1VPI	;	1.76	;	PHOSPHOLIPASE A2 INHIBITOR FROM VIPOXIN
1BK9	;	2.0	;	PHOSPHOLIPASE A2 MODIFIED BY PBPB
3JQ5	;	2.03	;	Phospholipase A2 Prevents the Aggregation of Amyloid Beta Peptides: Crystal Structure of the Complex of Phospholipase A2 with Octapeptide Fragment of Amyloid Beta Peptide, Asp-Ala-Glu-Phe-Arg-His-Asp-Ser at 2 A Resolution
5VET	;	2.0	;	PHOSPHOLIPASE A2, RE-REFINEMENT OF THE PDB STRUCTURE 1JQ8 WITHOUT THE PUTATIVE COMPLEXED OLIGOPEPTIDE
3V9M	;	1.563	;	Phospholipase ACII4 from Australian King Brown Snake
8EMX	;	3.3	;	Phospholipase C beta 3 (PLCb3) in complex with Gbg on lipid nanodiscs
8EMW	;	3.5	;	Phospholipase C beta 3 (PLCb3) in complex with Gbg on liposomes
8EMV	;	3.6	;	Phospholipase C beta 3 (PLCb3) in solution
1AH7	;	1.501	;	PHOSPHOLIPASE C FROM BACILLUS CEREUS
5TNW	;	1.4	;	Phospholipase C gamma-1 C-terminal SH2 domain
5TQ1	;	1.485	;	Phospholipase C gamma-1 C-terminal SH2 domain bound to a phosphopeptide derived from the insulin receptor
5TQS	;	1.876	;	Phospholipase C gamma-1 C-terminal SH2 domain bound to a phosphopeptide derived from the receptor tyrosine kinase ErbB2
5TO4	;	1.7	;	Phospholipase C gamma-1 C-terminal SH2 domain, spacegroup P212121
1YWP	;	1.6	;	Phospholipase Cgamma1 SH3
1YWO	;	1.81	;	Phospholipase Cgamma1 SH3 in complex with a SLP-76 motif
7JRB	;	2.493	;	Phospholipase D engineered mutant
7JS7	;	2.3	;	Phospholipase D engineered mutant (TNYR) H442 covalent adduct with 1-inositol phosphate
7JS5	;	2.5	;	Phospholipase D engineered mutant (TNYR) inactive enzyme (H168A) bound to 1-inositol phosphate
7JRV	;	2.42	;	Phospholipase D engineered mutant bound to phosphatidic acid (30 minute soak)
7JRW	;	1.99	;	Phospholipase D engineered mutant bound to phosphatidic acid (5 day soak)
7JRU	;	2.21	;	Phospholipase D engineered mutant bound to phosphatidic acid (8 hour soak)
7JRC	;	2.01	;	Phospholipase D engineered mutant in complex with phosphate
1V0T	;	1.53	;	Phospholipase D from Streptomyces sp. strain PMF soaked with the product glycerophosphate
1V0U	;	1.42	;	Phospholipase D from Streptomyces sp. strain PMF soaked with the product glycerophosphate.
1V0V	;	1.7	;	Phospholipase D from Streptomyces sp. strain PMF soaked with the substrate dibutyrylphosphatidylcholine.
1V0W	;	1.35	;	Phospholipase D from Streptomyces sp. strain PMF soaked with the substrate dibutyrylphosphatidylcholine.
1V0Y	;	1.71	;	Phospholipase D from Streptomyces sp. strain PMF soaked with the substrate dibutyrylphosphatidylcholine.
6ZTH	;	2.3	;	Phospholipase PlaB from Legionella pneumophila
6ZTI	;	1.81	;	Phospholipase PlaB from Legionella pneumophila in complex with thio-NAD
5G4J	;	1.87	;	Phospholyase A1RDF1 from Arthrobacter in complex with phosphoethanolamine
2I54	;	2.1	;	Phosphomannomutase from Leishmania mexicana
2FKF	;	2.0	;	Phosphomannomutase/Phosphoglucomutase from Pseudomonas aeruginosa with alpha-D-glucose 1,6-bisphosphate bound
4BAY	;	3.1	;	Phosphomimetic mutant of LSD1-8a splicing variant in complex with CoREST
4UPK	;	2.24	;	Phosphonate monoester hydrolase SpPMH from Silicibacter pomeroyi
4K5L	;	1.91	;	Phosphonic Arginine Mimetics as Inhibitors of the M1 Aminopeptidases from Plasmodium falciparum
4K5M	;	1.75	;	Phosphonic Arginine Mimetics as Inhibitors of the M1 Aminopeptidases from Plasmodium falciparum
4K5N	;	1.91	;	Phosphonic Arginine Mimetics as Inhibitors of the M1 Aminopeptidases from Plasmodium falciparum
4K5O	;	1.9	;	Phosphonic Arginine Mimetics as Inhibitors of the M1 Aminopeptidases from Plasmodium falciparum
4K5P	;	1.85	;	Phosphonic Arginine Mimetics as Inhibitors of the M1 Aminopeptidases from Plasmodium falciparum
4K3N	;	2.0	;	Phosphonic Arginine Mimetics as Inhibitors of the M17 Aminopeptidases from Plasmodium falciparum
1RQN	;	2.8	;	Phosphonoacetaldehyde hydrolase complexed with magnesium
3NBA	;	2.68	;	Phosphopantetheine Adenylyltranferase from Mycobacterium tuberculosis in complex with adenosine-5'-[(alpha,beta)-methyleno]triphosphate (AMPCPP)
6CHO	;	1.85	;	Phosphopantetheine adenylyltransferase (CoaD) in complex with (R)-2-((1-(3-(4-methoxyphenoxy)phenyl)ethyl)amino)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one
6CKW	;	2.06	;	Phosphopantetheine adenylyltransferase (CoaD) in complex with (R)-3-((7-(((S)-2-amino-2-(2-methoxyphenyl)ethyl)amino)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)amino)-3-(3-chlorophenyl)propanenitrile
6CHL	;	2.2	;	Phosphopantetheine adenylyltransferase (CoaD) in complex with (R)-3-(3-chlorophenyl)-3-((5-methyl-7-oxo-4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)amino)propanenitrile
6CHQ	;	1.79	;	Phosphopantetheine adenylyltransferase (CoaD) in complex with 2-benzyl-N-(3-chloro-4-methylphenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
6CHP	;	1.94	;	Phosphopantetheine adenylyltransferase (CoaD) in complex with methyl (R)-4-(3-(2-cyano-1-((5-methyl-1H-imidazo[4,5-b]pyridin-2-yl)amino)ethyl)benzyl)piperidine-1-carboxylate
6CHN	;	2.03	;	Phosphopantetheine adenylyltransferase (CoaD) in complex with methyl (R)-4-(3-(2-cyano-1-((5-methyl-7-oxo-4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)amino)ethyl)phenoxy)piperidine-1-carboxylate
6CHM	;	2.28	;	Phosphopantetheine adenylyltransferase (CoaD) in complex with N-(2-(5-methoxy-1H-indol-3-yl)ethyl)pivalamide
1QJC	;	1.63	;	Phosphopantetheine Adenylyltransferase from Escherichia coli in complex with 4'-phosphopantetheine
1TFU	;	1.99	;	phosphopantetheine adenylyltransferase from Mycobacterium tuberculosis
3RFF	;	1.76	;	Phosphopantetheine adenylyltransferase from Mycobacterium Tuberculosis (1.76 A resolution)
4E1A	;	1.62	;	Phosphopantetheine adenylyltransferase from Mycobacterium tuberculosis at 1.62A resolution
3UC5	;	1.7	;	Phosphopantetheine adenylyltransferase from Mycobacterium tuberculosis complexed with ATP
3LCJ	;	2.1	;	Phosphopantetheine adenylyltransferase from Mycobacterium tuberculosis complexed with CoA
3RHS	;	1.59	;	Phosphopantetheine adenylyltransferase from Mycobacterium tuberculosis complexed with CoA
3RBA	;	1.59	;	Phosphopantetheine adenylyltransferase from Mycobacterium tuberculosis complexed with DPCoA
6QMI	;	1.781	;	Phosphopantetheine adenylyltransferase from Mycobacterium tuberculosis in complex with 3-(1H-indol-1-yl)propanoic acid at 1.7A resolution.
6QMH	;	1.837	;	Phosphopantetheine adenylyltransferase from Mycobacterium tuberculosis in complex with 3-(1H-indol-3-yl)propanoic acid at 1.6A resolution.
3NBK	;	1.58	;	Phosphopantetheine Adenylyltransferase from Mycobacterium tuberculosis in complex with 4'-phosphopantetheine
6G6V	;	1.942	;	Phosphopantetheine adenylyltransferase from Mycobacterium tuberculosis in complex with 4-(2-carboxybenzoyl)-2-nitrobenzoic acid at 1.9A resolution.
6QMG	;	1.65	;	Phosphopantetheine adenylyltransferase from Mycobacterium tuberculosis in complex with 5-methyl-1-phenyl-1H-pyrazole-4-carboxylic acid at 1.8A resolution.
6QMF	;	1.771	;	Phosphopantetheine adenylyltransferase from Mycobacterium tuberculosis in complex with 5-[3-(1H-indol-3-yl)propoxy]-1-phenyl-1H-pyrazole-4-carboxylic acid at 1.8A resolution.
3PNB	;	2.11	;	Phosphopantetheine Adenylyltransferase from Mycobacterium tuberculosis in complex with coenzyme A
3L92	;	1.89	;	Phosphopantetheine adenylyltransferase from Yersinia pestis complexed with coenzyme A.
3L93	;	2.16	;	Phosphopantetheine adenylyltransferase from Yersinia pestis.
1B6T	;	1.8	;	PHOSPHOPANTETHEINE ADENYLYLTRANSFERASE IN COMPLEX WITH 3'-DEPHOSPHO-COA FROM ESCHERICHIA COLI
1H1T	;	1.78	;	PHOSPHOPANTETHEINE ADENYLYLTRANSFERASE IN COMPLEX WITH Coenzyme A FROM ESCHERICHIA COLI
1GN8	;	1.83	;	PHOSPHOPANTETHEINE ADENYLYLTRANSFERASE IN COMPLEX WITH Mn2+ATP FROM ESCHERICHIA COLI
8GKF	;	2.45	;	Phosphopantetheinyl transferase PptT from Mycobacterium tuberculosis in complex with Raltitrexed.
1U7U	;	2.4	;	Phosphopantothenoylcysteine synthetase from E. coli
1U7Z	;	2.3	;	Phosphopantothenoylcysteine synthetase from E. coli, 4'-phosphopantothenoyl-CMP complex
1U80	;	2.85	;	Phosphopantothenoylcysteine synthetase from E. coli, CMP complex
1U7W	;	2.5	;	Phosphopantothenoylcysteine synthetase from E. coli, CTP-complex
4LRD	;	1.78	;	Phosphopentomutase 4H11 variant
3M8W	;	1.85	;	Phosphopentomutase from Bacillus cereus
3M8Y	;	2.1	;	Phosphopentomutase from Bacillus cereus after glucose-1,6-bisphosphate activation
3OT9	;	1.75	;	Phosphopentomutase from Bacillus cereus bound to glucose-1,6-bisphosphate
3M8Z	;	1.8	;	Phosphopentomutase from Bacillus cereus bound with ribose-5-phosphate
4LR7	;	2.1	;	Phosphopentomutase S154A variant
4LR9	;	2.1	;	Phosphopentomutase S154A variant soaked with 2,3-dideoxyribose 5-phosphate
4LR8	;	2.0	;	Phosphopentomutase S154A variant soaked with ribose 5-phosphate
4LRA	;	2.0	;	Phosphopentomutase S154G variant
4LRB	;	2.0	;	Phosphopentomutase S154G variant soaked with 2,3-dideoxyribose 5-phosphate
4LRF	;	2.0	;	Phosphopentomutase S154G variant soaked with ribose 5-phosphate
4LRE	;	2.1	;	Phosphopentomutase soaked with 2,3-dideoxyribose 5-phosphate
3UN2	;	1.8	;	Phosphopentomutase T85Q variant enzyme
3UN3	;	1.8	;	phosphopentomutase T85Q variant soaked with glucose 1,6-bisphosphate
4LRC	;	1.89	;	Phosphopentomutase V158L variant
7S8I	;	1.66	;	PHOSPHOPEPTIDE-SPECIFIC LC13 TCR, MONOCLINIC CRYSTAL FORM
7S8J	;	1.92	;	PHOSPHOPEPTIDE-SPECIFIC LC13 TCR, ORTHORHOMBIC CRYSTAL FORM
3QN3	;	2.13	;	Phosphopyruvate hydratase from Campylobacter jejuni.
5LHE	;	1.85	;	Phosphoribosyl anthranilate isomerase from Thermococcus kodakaraensis
5LHF	;	1.75	;	Phosphoribosyl anthranilate isomerase from Thermococcus kodakaraensis
3MJF	;	1.47	;	Phosphoribosylamine-glycine ligase from Yersinia pestis
3OPQ	;	2.0	;	Phosphoribosylaminoimidazole carboxylase with fructose-6-phosphate bound to the central channel of the octameric protein structure.
1IBS	;	2.8	;	PHOSPHORIBOSYLDIPHOSPHATE SYNTHETASE IN COMPLEX WITH CADMIUM IONS
3P4E	;	1.77	;	Phosphoribosylformylglycinamidine cyclo-ligase from Vibrio cholerae
1A7J	;	2.5	;	PHOSPHORIBULOKINASE FROM RHODOBACTER SPHEROIDES
1E4O	;	2.9	;	Phosphorylase recognition and phosphorolysis of its oligosaccharide substrate: answers to a long outstanding question
1QM5	;	2.0	;	Phosphorylase recognition and phosphorylysis of its oligosaccharide substrate: answers to a long outstanding question
1CNU	;	2.25	;	PHOSPHORYLATED ACTOPHORIN FROM ACANTAMOEBA POLYPHAGA
4ZMF	;	2.39	;	Phosphorylated Aspartate in the Crystal Structure of the Alpha-kinase domain of Myosin-II Heavy Chain Kinase A
1QMP	;	2.0	;	Phosphorylated aspartate in the crystal structure of the sporulation response regulator, Spo0A
3TWZ	;	1.75	;	Phosphorylated Bacillus cereus phosphopentomutase in space group P212121
3UO0	;	2.3	;	phosphorylated Bacillus cereus phosphopentomutase soaked with glucose 1,6-bisphosphate
7R1K	;	1.5	;	Phosphorylated Bacillus pumilus Lipase A
3JRW	;	2.6	;	Phosphorylated BC domain of ACC2
6H91	;	2.38	;	Phosphorylated beta-phosphoglucomutase from Lactococcus lactis in an open conformer to 2.4 A
6H92	;	2.6	;	Phosphorylated beta-phosphoglucomutase from Lactococcus lactis in an open conformer to 2.6 A
1QMZ	;	2.2	;	PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
2RLT	;		;	phosphorylated CPI-17 (22-120)
2DVJ	;		;	phosphorylated Crk-II
1JST	;	2.6	;	PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
1R0Z	;	2.35	;	Phosphorylated Cystic fibrosis transmembrane conductance regulator (CFTR) nucleotide-binding domain one (NBD1) with ATP
7OPM	;	2.45	;	Phosphorylated ERK2 in complex with ORF45
6OPG	;	2.9	;	phosphorylated ERK2 with AMP-PNP
6OPH	;	2.4	;	phosphorylated ERK2 with GDC-0994
6OPI	;	3.0	;	phosphorylated ERK2 with SCH-CPD336
6OPK	;	2.54	;	Phosphorylated ERK2 with Vertex-11e
6HU7	;	2.8	;	phosphorylated F97L Hepatitis B core protein capsid
1D5W	;	2.3	;	PHOSPHORYLATED FIXJ RECEIVER DOMAIN
1YGP	;	2.8	;	PHOSPHORYLATED FORM OF YEAST GLYCOGEN PHOSPHORYLASE WITH PHOSPHATE BOUND IN THE ACTIVE SITE.
7MST	;	1.61	;	Phosphorylated human E105Qa GTP-specific succinyl-CoA synthetase complexed with coenzyme A
2Z8C	;	3.25	;	Phosphorylated insulin receptor tyrosine kinase in complex with (4-{[5-carbamoyl-4-(3-methylanilino)pyrimidin-2-yl]amino}phenyl)acetic acid
1IR3	;	1.9	;	PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH PEPTIDE SUBSTRATE AND ATP ANALOG
3TUY	;	2.498	;	Phosphorylated Light Chain Domain of Scallop smooth Muscle Myosin
2ERK	;	2.4	;	PHOSPHORYLATED MAP KINASE ERK2
1CM8	;	2.4	;	PHOSPHORYLATED MAP KINASE P38-GAMMA
5JEK	;	2.4	;	Phosphorylated MAVS in complex with IRF-3
6TCA	;	3.7	;	Phosphorylated p38 and MAPKAPK2 complex with inhibitor
5JEO	;	1.719	;	Phosphorylated Rotavirus NSP1 in complex with IRF-3
6G76	;	3.0	;	Phosphorylated RSK4 N-terminal Kinase Domain in complex with AMP-PNP
5JEJ	;	2.0	;	Phosphorylated STING in complex with IRF-3 CTD
5JEL	;	1.6	;	Phosphorylated TRIF in complex with IRF-3
6TKO	;	3.3	;	Phosphorylated turkey beta1 adrenoceptor with bound agonist formoterol coupled to arrestin-2 in lipid nanodisc.
6MSM	;	3.2	;	Phosphorylated, ATP-bound human cystic fibrosis transmembrane conductance regulator (CFTR)
5W81	;	3.37	;	Phosphorylated, ATP-bound structure of zebrafish cystic fibrosis transmembrane conductance regulator (CFTR)
2O02	;	1.5	;	Phosphorylation independent interactions between 14-3-3 and Exoenzyme S: from structure to pathogenesis
7CIQ	;	1.59	;	Phosphorylation modification of MHC I polypeptide
2FWN	;	1.4	;	Phosphorylation of an active site serine in a ThDP-dependent enzyme by phosphonate inactivation
4MPJ	;	1.5	;	Phosphorylation of an active site threonine in the benzyolformate decarboxylase mutant S26T by phosphonate inactivation
2MZA	;		;	Phosphorylation of CB1 Cannabinoid Receptor Fourth Intracellular Loop pepducins: Effects on Structure and Function
2MZ3	;		;	Phosphorylation of CB1Cannabinoid Receptor Fourth Intracellular Loop Pepducins: Effects on Structure and Function
2MZ2	;		;	Phosphorylation of CB1Cannabinoid Receptor Fourth Intracellular Loop Peptides: Effects on Structure and Function
7DYN	;	2.0	;	Phosphorylation of MHC I peptide
3FQN	;	1.65	;	Phosphorylation of self-peptides alters Human Leukocyte Antigen Class I-restricted antigen presentation and generates tumor specific epitopes
3FQR	;	1.7	;	Phosphorylation of self-peptides alters Human Leukocyte Antigen Class I-restricted antigen presentation and generates tumor specific epitopes
3FQT	;	1.8	;	Phosphorylation of self-peptides alters Human Leukocyte Antigen Class I-restricted antigen presentation and generates tumor specific epitopes
3FQU	;	1.8	;	Phosphorylation of self-peptides alters Human Leukocyte Antigen Class I-restricted antigen presentation and generates tumor specific epitopes
3FQW	;	1.927	;	Phosphorylation of self-peptides alters Human Leukocyte Antigen Class I-restricted antigen presentation and generates tumor specific epitopes
3FQX	;	1.7	;	Phosphorylation of self-peptides alters Human Leukocyte Antigen Class I-restricted antigen presentation and generates tumor specific epitopes
2KQS	;		;	Phosphorylation of SUMO-interacting motif by CK2 enhances Daxx SUMO binding activity
2CEH	;		;	Phosphorylation of the Cytoplasmic Tail of Tissue Factor and its Role in Modulating Structure and Binding Affinity
2CEZ	;		;	Phosphorylation of the Cytoplasmic Tail of Tissue Factor and its Role in Modulating Structure and Binding Affinity
2CFJ	;		;	Phosphorylation of the Cytoplasmic Tail of Tissue Factor and its Role in Modulating Structure and Binding Affinity
2CEF	;		;	Phosphorylation of the Cytoplasmic Tail of Tissue Factor and its Role in Modulating Structure and Binding Affinity.
3S8E	;	2.88	;	Phosphorylation regulates assembly of the caspase-6 substrate-binding groove
3WP1	;	2.804	;	Phosphorylation-dependent interaction between tumor suppressors Dlg and Lgl
1BT4	;	2.3	;	PHOSPHOSERINE AMINOTRANSFERASE FROM BACILLUS CIRCULANS SUBSP. ALKALOPHILUS
6N14	;	1.52169	;	Phosphoserine BlaC, Class A serine beta-lactamase from Mycobacterium tuberculosis
1QZT	;	2.7	;	Phosphotransacetylase from Methanosarcina thermophila
2AF4	;	2.147	;	Phosphotransacetylase from Methanosarcina thermophila co-crystallized with coenzyme A
2AF3	;	2.6	;	Phosphotransacetylase from Methanosarcina thermophila soaked with Coenzyme A
1FYN	;	2.3	;	PHOSPHOTRANSFERASE
1ZIO	;	1.96	;	PHOSPHOTRANSFERASE
6JBC	;	2.7	;	Phosphotransferase related to CoA biosynthesis pathway
6JBD	;	2.5	;	Phosphotransferase-ATP complex related to CoA biosynthesis pathway
1PSC	;	2.0	;	PHOSPHOTRIESTERASE FROM PSEUDOMONAS DIMINUTA
1BF6	;	1.7	;	PHOSPHOTRIESTERASE HOMOLOGY PROTEIN FROM ESCHERICHIA COLI
6FS3	;	1.75	;	Phosphotriesterase PTE_A53_1
6FQE	;	1.75	;	Phosphotriesterase PTE_A53_4
6FFW	;	1.495	;	Phosphotriesterase PTE_A53_5
6FRZ	;	1.65	;	Phosphotriesterase PTE_A53_7
6G1J	;	2.1	;	Phosphotriesterase PTE_C23M_1
6G3M	;	1.665	;	Phosphotriesterase PTE_C23M_4
6FU6	;	1.95	;	Phosphotriesterase PTE_C23_2
6FWE	;	1.774	;	Phosphotriesterase PTE_C23_6
4XD6	;	1.75	;	Phosphotriesterase Variant E2a
4XD4	;	1.9	;	Phosphotriesterase variant E2b
4XD3	;	1.57	;	Phosphotriesterase variant E3
5WCR	;	1.75	;	Phosphotriesterase variant R0deltaL7
6BH7	;	1.4	;	Phosphotriesterase variant R18+254S
6BHK	;	1.4	;	Phosphotriesterase variant R18deltaL7
4XD5	;	1.85	;	Phosphotriesterase variant R2
4PCN	;	1.54	;	Phosphotriesterase variant R22
4PBF	;	1.9	;	Phosphotriesterase variant Rev12
4PBE	;	1.51	;	Phosphotriesterase Variant Rev6
5W6B	;	1.739	;	Phosphotriesterase variant S1
5WCQ	;	1.576	;	Phosphotriesterase variant S2
5WCW	;	1.457	;	Phosphotriesterase variant S3
5WIZ	;	1.96	;	Phosphotriesterase variant S5
6B2F	;	1.775	;	Phosphotriesterase variant S5 + TS analogue
5WJ0	;	1.65	;	Phosphotriesterase variant S5+254R
6BHL	;	1.4	;	Phosphotriesterase variant S5deltaL7
5WCP	;	1.5	;	Phosphotriesterase variant S7
5WMS	;	1.6	;	Phosphotriesterase variant S7
6AML	;	1.46	;	Phosphotriesterase variant S8
2MQ1	;		;	Phosphotyrosine binding domain
4G36	;	2.624	;	Photinus pyralis luciferase in the adenylate-forming conformation bound to DLSA
2CZ0	;	1.5	;	photo-activation state of Fe-type NHase in aerobic condition
2CYZ	;	1.55	;	photo-activation state of Fe-type NHase in anaerobic condition
2CZ1	;	1.39	;	photo-activation state of Fe-type NHase with n-BA in anaerobic condition
6FRY	;	1.7	;	Photo-Driven Hydrogen Evolution by an Artificial Hydrogenase Utilizing the Biotin-Streptavidin Technology
1S1Y	;	1.6	;	Photoactivated chromophore conformation in Photoactive Yellow Protein (E46Q mutant) from 10 microseconds to 3 milliseconds
1S1Z	;	1.6	;	Photoactivated chromophore conformation in Photoactive Yellow Protein (E46Q mutant) from 10 to 500 nanoseconds
3GJ2	;	1.9	;	Photoactivated state of PA-GFP
1ODV	;	1.14	;	Photoactive yellow protein 1-25 deletion mutant
6P4I	;	1.6	;	Photoactive Yellow Protein PYP 10ps
6P5D	;	1.6	;	Photoactive Yellow Protein PYP 30ps
6P5E	;	1.6	;	Photoactive Yellow Protein PYP 80ps
6P5G	;	1.6	;	Photoactive Yellow Protein PYP Dark Full
6P5F	;	1.7	;	Photoactive Yellow Protein PYP Pure Dark
6MMD	;	1.228	;	Photoactive Yellow Protein with 3,5-dichlorotyrosine substituted at position 42
6MKT	;	1.6	;	Photoactive Yellow Protein with 3-chlorotyrosine substituted at position 42
6MHI	;	1.35	;	Photoactive Yellow Protein with covalently bound 3,5-dichloro-4-hydroxycinnamic acid chromophore
6MHN	;	1.67	;	Photoactive Yellow Protein with covalently bound 3-chloro-4-hydroxycinnamic acid chromophore
2PYR	;	1.9	;	PHOTOACTIVE YELLOW PROTEIN, 1 NANOSECOND INTERMEDIATE (287K)
3PYP	;	0.85	;	PHOTOACTIVE YELLOW PROTEIN, CRYOTRAPPED EARLY LIGHT CYCLE INTERMEDIATE
2PHY	;	1.4	;	PHOTOACTIVE YELLOW PROTEIN, DARK STATE (UNBLEACHED)
3PHY	;		;	PHOTOACTIVE YELLOW PROTEIN, DARK STATE (UNBLEACHED), SOLUTION STRUCTURE, NMR, 26 STRUCTURES
2PYP	;	1.9	;	PHOTOACTIVE YELLOW PROTEIN, PHOTOSTATIONARY STATE, 50% GROUND STATE, 50% BLEACHED
7XC6	;	2.79	;	Photobacterium phosphoreum fatty acid reductase complex LuxC-LuxE
5HPJ	;	1.5	;	Photobacterium profundum alpha-carbonic anhydrase
1FT4	;	2.9	;	PHOTOCHEMICALLY-ENHANCED BINDING OF SMALL MOLECULES TO THE TUMOR NECROSIS FACTOR RECEPTOR-1
8ISI	;	3.77	;	Photochromobilin-free form of Arabidopsis thaliana phytochrome A - apo-AtphyA
7DNA	;	2.3	;	Photocleavable Fluorescent Protein in green and red form
7DMX	;	2.1	;	Photocleavable Fluorescent Protein in green form
6Y1G	;	2.3	;	Photoconverted HcRed in its optoacoustic state
5EXC	;	2.14	;	Photoconverted red fluorescent protein DendRFP
6PRU	;	1.539	;	Photoconvertible crystals of PixJ from Thermosynechococcus elongatus
6D38	;	2.8	;	Photodissociable dimeric Dronpa green fluorescent protein variant M (pdDronpaM)
6D39	;	2.83	;	Photodissociable dimeric Dronpa green fluorescent protein variant V (pdDronpaV)
1JNU	;	2.6	;	Photoexcited structure of the plant photoreceptor domain, phy3 LOV2
6KII	;	1.6	;	photolyase from Arthrospira platensis
1ABS	;	1.5	;	PHOTOLYSED CARBONMONOXY-MYOGLOBIN AT 20 K
1DWS	;	1.45	;	PHOTOLYZED CARBONMONOXY MYOGLOBIN (HORSE HEART)
1DXD	;	1.4	;	Photolyzed CO complex of Myoglobin Mb-YQR at 20K
2G0V	;	1.95	;	Photolyzed CO L29F Myoglobin: 100ps
2G0Z	;	1.95	;	Photolyzed CO L29F Myoglobin: 1ns
2G10	;	1.9	;	Photolyzed CO L29F Myoglobin: 3.16ns
2G14	;	1.9	;	Photolyzed CO L29F Myoglobin: 3.16us
2G11	;	1.9	;	Photolyzed CO L29F Myoglobin: 31.6ns
2G12	;	1.9	;	Photolyzed CO L29F Myoglobin: 316ns
2G0X	;	1.95	;	Photolyzed CO L29F Myoglobin: 316ps
1AJH	;	1.69	;	PHOTOPRODUCT OF CARBONMONOXY MYOGLOBIN AT 40 K
1HCJ	;	1.8	;	Photoproduct of the wild-type Aequorea victoria Green Fluorescent Protein
1W7U	;	1.85	;	Photoproduct of the Wild-Type Aequorea victoria Green Fluorescent Protein after structural annealing at 170K
1W7T	;	1.85	;	Photoproduct of the Wild-Type Aequorea victoria Green Fluorescent Protein at 100 K
1DWT	;	1.4	;	Photorelaxed horse heart MYOGLOBIN CO complex
5MXF	;	1.9	;	Photorhabdus asymbiotica lectin (PHL) in complex with alpha-methyl fucoside
5MXG	;	2.2	;	Photorhabdus asymbiotica lectin (PHL) in complex with blood group H trisaccharide
5MXH	;	1.95	;	Photorhabdus asymbiotica lectin (PHL) in complex with D-galactose
6F5W	;	1.91	;	Photorhabdus asymbiotica lectin (PHL) in complex with propargyl-fucoside
6FHX	;	2.34	;	Photorhabdus asymbiotica lectin (PHL) in complex with synthetic C-fucoside
6FHY	;	1.86	;	Photorhabdus asymbiotica lectin (PHL) in complex with synthetic C-fucoside
6FLU	;	1.78	;	Photorhabdus asymbiotica lectin (PHL) in complex with synthetic C-fucoside
5MXE	;	1.9	;	Photorhabdus asymbiotica lectin (PHL) in free form
6RGU	;	1.75	;	Photorhabdus asymbiotica lectin PHL in complex with 3-O-methyl-D-glucose
6RGJ	;	1.8	;	Photorhabdus asymbiotica lectin PHL in complex with D-glucose
6RGR	;	1.89	;	Photorhabdus asymbiotica lectin PHL in complex with L-rhamnose
6RGW	;	1.75	;	Photorhabdus asymbiotica lectin PHL in complex with O-methylated PGL-1-derived disaccharide
8R05	;	2.5	;	Photorhabdus lamondii ClpP in complex with the natural product beta-lactone inhibitor Cystargolide A at 2.5 A resolution
6RG2	;	1.12	;	Photorhabdus laumondii lectin PLL2 in complex with 3-O-methyl-D-glucose
6RFZ	;	1.8	;	Photorhabdus laumondii lectin PLL2 in complex with D-glucose
6RG1	;	1.7	;	Photorhabdus laumondii lectin PLL2 in complex with L-rhamnose
6RGG	;	2.2	;	Photorhabdus laumondii lectin PLL2 in complex with O-methylated PGL-1-derived disaccharide
6T96	;	1.65	;	Photorhabdus laumondii subsp. laumondii lectin PLL3
7PQ5	;	3.17	;	Photorhabdus laumondii T6SS-associated Rhs protein carrying the Tre23 toxin domain
8P52	;	3.6	;	Photorhabdus luminescens Makes caterpillars floppy (Mcf) toxin
8P51	;	3.55	;	Photorhabdus luminescens Makes caterpillars floppy (Mcf) toxin with the C-terminal deletion
8P50	;	4.04	;	Photorhabdus luminescens Makes caterpillars floppy (Mcf) toxin with the C-terminal deletion in complex with Arf3
8CQ2	;	3.6	;	Photorhabdus luminescens TcdA1 prepore-to-pore intermediate, C16S, C20S, C870S, T1279C mutant
8CPZ	;	2.9	;	Photorhabdus luminescens TcdA1 prepore-to-pore intermediate, K1179W mutant
8CQ0	;	3.2	;	Photorhabdus luminescens TcdA1 prepore-to-pore intermediate, K567W K2008W mutant
6P22	;	2.291	;	Photorhabdus Virulence Cassette (PVC) PAAR repeat protein Pvc10 in complex with a T4 gp5 beta-helix fragment modified to mimic Pvc8, the central spike protein of PVC
6TL4	;	2.9	;	Photosensory module (PAS-GAF-PHY) of Glycine max phyB
8BOR	;	2.3	;	Photosensory module from DrBphP without PHY tongue
5LLY	;	2.4	;	Photosensory Module of Bacteriophytochrome linked Diguanylyl Cyclase from Idiomarina species A28L
6J1C	;	2.09	;	Photoswitchable fluorescent protein Gamillus, N150C/T204V double mutant, off-state
6J1B	;	1.99	;	Photoswitchable fluorescent protein Gamillus, N150C/T204V double mutant, on-state
6J1A	;	1.96	;	Photoswitchable fluorescent protein Gamillus, off-state
6JXF	;	1.8	;	Photoswitchable fluorescent protein Gamillus, off-state (pH7.0)
2N9Q	;		;	Photoswitchable G-quadruplex
3CFH	;	1.75	;	Photoswitchable red fluorescent protein psRFP, off-state
3CFF	;	1.8	;	Photoswitchable red fluorescent protein psRFP, on-state
1K6L	;	3.1	;	Photosynethetic Reaction Center from Rhodobacter sphaeroides
7UEA	;	3.49	;	Photosynthetic assembly of Chlorobaculum tepidum (RC-FMO1)
7UEB	;	3.08	;	Photosynthetic assembly of Chlorobaculum tepidum (RC-FMO2)
8WDV	;	2.24	;	Photosynthetic LH1-RC complex from the purple sulfur bacterium Allochromatium vinosum purified by Ca2+-DEAE
8WDU	;	2.24	;	Photosynthetic LH1-RC complex from the purple sulfur bacterium Allochromatium vinosum purified by sucrose density
6MGI	;	2.986	;	Photosynthetic phosphoenolpyruvate carboxylase isoenzyme from maize complexed with the allosteric activator glucose-6-phosphate in its allosteric site
1C51	;	4.0	;	PHOTOSYNTHETIC REACTION CENTER AND CORE ANTENNA SYSTEM (TRIMERIC), ALPHA CARBON ONLY
2PPS	;	4.0	;	PHOTOSYNTHETIC REACTION CENTER AND CORE ANTENNA SYSTEM (TRIMERIC), ALPHA CARBON ONLY
1R2C	;	2.86	;	PHOTOSYNTHETIC REACTION CENTER BLASTOCHLORIS VIRIDIS (ATCC)
1VRN	;	2.2	;	PHOTOSYNTHETIC REACTION CENTER BLASTOCHLORIS VIRIDIS (ATCC)
1RVJ	;	2.75	;	PHOTOSYNTHETIC REACTION CENTER DOUBLE MUTANT FROM RHODOBACTER SPHAEROIDES WITH ASP L213 REPLACED WITH ASN AND ARG H177 REPLACED WITH HIS
1RZZ	;	2.4	;	PHOTOSYNTHETIC REACTION CENTER DOUBLE MUTANT FROM RHODOBACTER SPHAEROIDES WITH ASP L213 REPLACED WITH ASN AND ARG M233 REPLACED WITH CYS IN THE CHARGE-NEUTRAL DQAQB STATE (TETRAGONAL FORM)
1RZH	;	1.8	;	PHOTOSYNTHETIC REACTION CENTER DOUBLE MUTANT FROM RHODOBACTER SPHAEROIDES WITH ASP L213 REPLACED WITH ASN AND ARG M233 REPLACED WITH CYS IN THE CHARGE-NEUTRAL DQAQB STATE (TRIGONAL FORM)
1S00	;	2.6	;	PHOTOSYNTHETIC REACTION CENTER DOUBLE MUTANT FROM RHODOBACTER SPHAEROIDES WITH ASP L213 REPLACED WITH ASN AND ARG M233 REPLACED WITH CYS IN THE CHARGE-SEPARATED D+QAQB- STATE
2JBL	;	2.4	;	PHOTOSYNTHETIC REACTION CENTER FROM BLASTOCHLORIS VIRIDIS
4TQQ	;	2.499	;	Photosynthetic Reaction Center from R. sphaeroides Analyzed at Room Temperature on an X-ray Transparent Microfluidic Chip
1M3X	;	2.55	;	Photosynthetic Reaction Center From Rhodobacter Sphaeroides
1Z9J	;	4.5	;	Photosynthetic Reaction Center from Rhodobacter sphaeroides
1Z9K	;	4.6	;	Photosynthetic Reaction Center from Rhodobacter sphaeroides
3I4D	;	2.01	;	Photosynthetic reaction center from rhodobacter sphaeroides 2.4.1
1AIJ	;	2.2	;	PHOTOSYNTHETIC REACTION CENTER FROM RHODOBACTER SPHAEROIDES IN THE CHARGE-NEUTRAL DQAQB STATE
1DS8	;	2.5	;	PHOTOSYNTHETIC REACTION CENTER FROM RHODOBACTER SPHAEROIDES IN THE CHARGE-NEUTRAL DQAQB STATE WITH THE PROTON TRANSFER INHIBITOR CD2+
1DV6	;	2.5	;	PHOTOSYNTHETIC REACTION CENTER FROM RHODOBACTER SPHAEROIDES IN THE CHARGE-NEUTRAL DQAQB STATE WITH THE PROTON TRANSFER INHIBITOR ZN2+
1DV3	;	2.5	;	PHOTOSYNTHETIC REACTION CENTER FROM RHODOBACTER SPHAEROIDES IN THE CHARGE-SEPARATED D+QAQB-STATE WITH THE PROTON TRANSFER INHIBITOR CD2+
1AIG	;	2.6	;	PHOTOSYNTHETIC REACTION CENTER FROM RHODOBACTER SPHAEROIDES IN THE D+QB-CHARGE SEPARATED STATE
3V3Y	;	2.8	;	Photosynthetic Reaction Center From Rhodobacter Sphaeroides strain RV
6Z02	;	2.1	;	Photosynthetic Reaction Center From Rhodobacter Sphaeroides strain RV in surfo crystallization
6Z27	;	2.1	;	Photosynthetic Reaction Center From Rhodobacter Sphaeroides strain RV LCP crystallization
6Z1J	;	2.1	;	Photosynthetic Reaction Center From Rhodobacter Sphaeroides strain RV LSP co-crystallization with spheroidene
5PRC	;	2.35	;	PHOTOSYNTHETIC REACTION CENTER FROM RHODOPSEUDOMONAS VIRIDIS (ATRAZINE COMPLEX)
6PRC	;	2.3	;	PHOTOSYNTHETIC REACTION CENTER FROM RHODOPSEUDOMONAS VIRIDIS (DG-420314 (TRIAZINE) COMPLEX)
7PRC	;	2.65	;	PHOTOSYNTHETIC REACTION CENTER FROM RHODOPSEUDOMONAS VIRIDIS (DG-420315 (TRIAZINE) COMPLEX)
3PRC	;	2.4	;	PHOTOSYNTHETIC REACTION CENTER FROM RHODOPSEUDOMONAS VIRIDIS (QB-DEPLETED)
2PRC	;	2.45	;	PHOTOSYNTHETIC REACTION CENTER FROM RHODOPSEUDOMONAS VIRIDIS (UBIQUINONE-2 COMPLEX)
1DXR	;	2.0	;	Photosynthetic reaction center from Rhodopseudomonas viridis - His L168 Phe mutant (terbutryn complex)
2GMR	;	2.5	;	Photosynthetic reaction center mutant from Rhodobacter sphaeroides with Asp L210 replaced with Asn
1RY5	;	2.1	;	PHOTOSYNTHETIC REACTION CENTER MUTANT FROM RHODOBACTER SPHAEROIDES WITH ASP L213 REPLACED WITH ASN
2JIY	;	2.2	;	PHOTOSYNTHETIC REACTION CENTER MUTANT WITH ALA M149 REPLACED WITH TRP (CHAIN M, AM149W)
2JJ0	;	2.8	;	PHOTOSYNTHETIC REACTION CENTER MUTANT WITH ALA M248 REPLACED WITH TRP (CHAIN M, AM248W)
1QOV	;	2.1	;	PHOTOSYNTHETIC REACTION CENTER MUTANT WITH ALA M260 REPLACED WITH TRP (CHAIN M, A260W)
1UMX	;	2.8	;	PHOTOSYNTHETIC REACTION CENTER MUTANT WITH ARG M267 REPLACED WITH LEU (CHAIN M, R267L)
1JH0	;	3.5	;	Photosynthetic Reaction Center Mutant With Glu L 205 Replaced to Leu
5LSE	;	2.5	;	PHOTOSYNTHETIC REACTION CENTER MUTANT WITH Glu L212 replaced with Ala (CHAIN L, EL212W), Asp L213 replaced with ALA (Chain L, DL213A) AND LEU M215 REPLACED WITH ALA (CHAIN M, LM215A)
5LRI	;	2.4	;	PHOTOSYNTHETIC REACTION CENTER MUTANT WITH GLUL212 REPLACED WITH TRP (CHAIN L, EL212W)
2BOZ	;	2.4	;	Photosynthetic Reaction Center Mutant With Gly M203 Replaced With Leu
1MPS	;	2.55	;	PHOTOSYNTHETIC REACTION CENTER MUTANT WITH PHE M 197 REPLACED WITH ARG AND TYR M 177 REPLACED WITH PHE (CHAIN M, Y177F, F197R)
1E14	;	2.7	;	PHOTOSYNTHETIC REACTION CENTER MUTANT WITH PHE M197 REPLACED WITH ARG (CHAIN M, FM197R) AND GLY M203 REPLACED WITH ASP (CHAIN M, GM203D)
1JGX	;	3.01	;	Photosynthetic Reaction Center Mutant With Thr M 21 Replaced With Asp
1JGW	;	2.8	;	Photosynthetic Reaction Center Mutant With Thr M 21 Replaced With Leu
1E6D	;	2.3	;	PHOTOSYNTHETIC REACTION CENTER MUTANT WITH TRP M115 REPLACED WITH PHE (CHAIN M, WM115F) PHE M197 REPLACED WITH ARG (CHAIN M, FM197R)
1JGZ	;	2.7	;	Photosynthetic Reaction Center Mutant With Tyr M 76 Replaced With Lys
1JGY	;	2.7	;	Photosynthetic Reaction Center Mutant With Tyr M 76 Replaced With Phe
3ZUM	;	2.5	;	Photosynthetic Reaction Centre Mutant with Phe L146 replaced with Ala
3ZUW	;	2.31	;	Photosynthetic Reaction Centre Mutant with TYR L128 replaced with HIS
8BCV	;	2.2	;	Photosystem I assembly intermediate of Avena sativa
8BCW	;	2.11	;	Photosystem I assembly intermediate of Avena sativa
7DWQ	;	3.3	;	Photosystem I from a chlorophyll d-containing cyanobacterium Acaryochloris marina
7BGI	;	2.54	;	Photosystem I of a temperature sensitive mutant Chlamydomonas reinhardtii
7BLX	;	3.15	;	Photosystem I of a temperature sensitive mutant Chlamydomonas reinhardtii
6IJJ	;	2.89	;	Photosystem I of Chlamydomonas reinhardtii
6IJO	;	3.3	;	Photosystem I of Chlamydomonas reinhardtii
6ZOO	;	2.74	;	Photosystem I reduced Plastocyanin Complex
6TCL	;	3.2	;	Photosystem I tetramer
7D0J	;	3.42	;	Photosystem I-LHCI-LHCII of Chlamydomonas reinhardtii
1FC6	;	1.8	;	PHOTOSYSTEM II D1 C-TERMINAL PROCESSING PROTEASE
1FC7	;	2.0	;	PHOTOSYSTEM II D1 C-TERMINAL PROCESSING PROTEASE
1FC9	;	1.9	;	PHOTOSYSTEM II D1 C-TERMINAL PROCESSING PROTEASE
1FCF	;	2.1	;	PHOTOSYSTEM II D1 C-TERMINAL PROCESSING PROTEASE
5MX2	;	2.197	;	Photosystem II depleted of the Mn4CaO5 cluster at 2.55 A resolution
1W5C	;	3.2	;	Photosystem II from Thermosynechococcus elongatus
7CJI	;	2.35	;	Photosystem II structure in the S1 state
7CJJ	;	2.4	;	Photosystem II structure in the S2 state
4ZFS	;	2.01	;	Phototoxic Fluorescent Protein KillerOrange
4ZBL	;	1.57	;	Phototoxic fluorescent protein mKillerOrange
3GBF	;	1.92	;	Phpd with cadmium complexed with hydroethylphosphonate (HEP)
8CNI	;	3.35	;	PHT1 in the outward facing conformation, bound to Sb27
2PIA	;	2.0	;	PHTHALATE DIOXYGENASE REDUCTASE: A MODULAR STRUCTURE FOR ELECTRON TRANSFER FROM PYRIDINE NUCLEOTIDES TO [2FE-2S]
3J5V	;	7.1	;	PhuZ201 filament
7VEB	;	4.2	;	Phycocyanin rod structure of cyanobacterial phycobilisome
8FWA	;	2.0	;	Phycocyanin structure from a modular droplet injector for serial femtosecond crystallography
4Z8K	;	2.5	;	Phycocyanin structure from T. elongatus at 2.5-A from XFEL using a viscous delivery medium for serial femtosecond crystallography
6TBY	;	1.8	;	Phycocyanobilin-adducted PAS-GAF bidomain of Sorghum bicolor phyB
2C7J	;	3.0	;	Phycoerythrocyanin from Mastigocladus laminosus, 295 K, 3.0 A
2JQ0	;		;	Phylloseptin-1
2JPY	;		;	Phylloseptin-2
2JQ1	;		;	Phylloseptin-3
7R8R	;	1.8	;	Physachenolide C with Bromodomain (BRD3-BD1)
1E57	;	3.2	;	PHYSALIS MOTTLE VIRUS: EMPTY CAPSID
2WWS	;	3.9	;	Physalis Mottle Virus: Natural Empty Capsid
2BL0	;	1.75	;	Physarum polycephalum myosin II regulatory domain
6EO5	;	2.6	;	Physcomitrella patens BBE-like 1 variant D396N
6EO4	;	2.9	;	Physcomitrella patens BBE-like 1 wild-type
5W6Y	;	1.995	;	Physcomitrella patens Chorismate Mutase
5IZ1	;	3.0	;	Physcomitrella patens FBPase
4QDQ	;	1.95	;	Physical basis for Nrp2 ligand binding
4QDR	;	2.4	;	Physical basis for Nrp2 ligand binding
4QDS	;	2.4	;	Physical basis for Nrp2 ligand binding
1IVY	;	2.2	;	PHYSIOLOGICAL DIMER HPP PRECURSOR
6TC5	;	2.1	;	Phytochromobilin-adducted PAS-GAF bidomain of Sorghum bicolor phyB
1FAT	;	2.8	;	PHYTOHEMAGGLUTININ-L
7XP9	;	1.93	;	Phytophthora infesfans RxLR effector AVRvnt1
8BAU	;	1.6	;	Phytophthora nicotianae var. parasitica NADAR in complex with ADP-ribose
6J8L	;	2.3	;	Phytophthora sojae effector PsAvh240 inhibits a host aspartic protease secretion to promote infection
8DCP	;	2.41	;	PI 3-kinase alpha with nanobody 3-126
8DD4	;	3.1	;	PI 3-kinase alpha with nanobody 3-142
8DD8	;	3.4	;	PI 3-kinase alpha with nanobody 3-142, crosslinked with DSG
8DCX	;	2.8	;	PI 3-kinase alpha with nanobody 3-159
6S2A	;	2.7	;	PI PLC mutant H82A
2RAK	;	3.0	;	PI(3)P bound PX-BAR membrane remodeling unit of Sorting Nexin 9
6DMU	;	4.0	;	PI(4,5)P2 bound full-length rbTRPV5
5X1O	;	1.9	;	PI(4,5)P2 lipid binding induced a reorientation of FGF2 molecules near membrane surface to facilitate the unconventional oligomerization-dependent secretion process as revealed by a combined FTIR/NMR/X-ray study
1VDE	;	2.4	;	PI-SCEI, A HOMING ENDONUCLEASE WITH PROTEIN SPLICING ACTIVITY
1RXI	;	1.5	;	pI258 arsenate reductase (ArsC) triple mutant C10S/C15A/C82S
6HI1	;	2.07	;	PI3 Kinase Delta in complex with 3[6(morpholin4yl)pyridin2yl]phenol
6HI9	;	2.08	;	PI3 Kinase Delta in complex with 3[6(oxan4yl)pyridin2yl]phenol
6HI2	;	1.9	;	PI3 Kinase Delta in complex with 3{6[(1S,6R)3oxabicyclo[4.1.0]heptan6yl]pyridin2yl}phenol
6EYZ	;	2.2	;	PI3 kinase delta in complex with 4-Fluorophenyl 5-(4-(5-((4-isopropylpiperazin-1-yl)methyl)oxazol-2-yl)-1H-indazol-6-yl)-2-methoxynicotinate
7POS	;	2.493	;	PI3 kinase delta in complex with 5-(3,6-dihydro-2H-pyran-4-yl)-2-methoxy-N-(5-{3-[4-(propan-2-yl)piperazin-1-yl]prop-1-yn-1-yl}pyridin-3-yl)pyridine-3-sulfonamide
7POP	;	2.491	;	PI3 kinase delta in complex with 5-[3,6-dihydro-2H-pyran-4-yl]-2-methoxy-N-[2-methylpyridin-4-yl]pyridine-3-sulfonamide
6EZ6	;	2.04	;	PI3 kinase delta in complex with Methyl 5-(4-(5-((4-isopropylpiperazin-1-yl)methyl)oxazol-2-yl)-1H-indazol-6-yl)-2-methoxynicotinate
7POR	;	2.26	;	PI3 kinase delta in complex with N-[2-(2-fluoro-4-{[4-(propan-2-yl)piperazin-1-yl]methyl}phenyl)pyridin-4-yl]-2-methoxy-5-(morpholin-4-yl)pyridine-3-sulfonamide
7POT	;	2.391	;	PI3 kinase delta in complex with N-[5-(3,6-dihydro-2H-pyran-4-yl)-2-methoxypyridin-3-yl]benzenesulfonamide
5L72	;	3.06	;	PI3 kinase delta in complex with N-[6-(5-methanesulfonamido-6-methoxypyridin-3-yl)-1,3-dihydro-2-benzofuran-4-yl]-2-(morpholin-4-yl)acetamide
4FUL	;	2.47	;	PI3 Kinase Gamma bound to a pyrmidine inhibitor
3MJW	;	2.87	;	PI3 Kinase gamma with a benzofuranone inhibitor
3LJ3	;	2.43	;	PI3-kinase-gamma with a pyrrolopyridine-benzofuran inhibitor
7TZ7	;	2.41	;	PI3K alpha in complex with an inhibitor
4YKN	;	2.9	;	Pi3K alpha lipid kinase with Active Site Inhibitor
6Q74	;	2.48	;	PI3K delta in complex with 1benzylN[5(3,6dihydro2Hpyran4yl)2methoxypyridin3yl]2methyl1Himidazole4sulfonamide
6TNS	;	2.4	;	PI3K delta in complex with 2methoxyN[2methoxy5(7{[(2R)4(oxetan3 yl)morpholin2yl]methoxy}1,3dihydro2 benzofuran5yl)pyridin3yl]ethane1 sulfonamide
6ZAA	;	2.52	;	PI3K Delta in complex with methoxy(methylsulfamoyl)pyridinylN(methylpiperidinyl)dihydrobenzoxazinecarboxamide
6ZAD	;	2.24	;	PI3K Delta in complex with methoxymethyloxathiatetraazatetracyclodocosahexaenedione
6Q6Y	;	2.03	;	PI3K delta in complex with N(2chloro5phenylpyridin3yl)benzenesulfonamide
6Q73	;	2.21	;	PI3K delta in complex with N[2chloro5(3,6dihydro2Hpyran4yl)pyridin3yl]methanesulfonamide
6TNR	;	1.9	;	PI3K delta in complex with N[5(7{2[4(2hydroxypropan2yl)piperidin1 yl]ethoxy}1,3dihydro2benzofuran5yl)2 methoxypyridin3yl]methanesulfonamide
7R26	;	2.3	;	PI3K delta in complex with SD5
6ZAC	;	2.15	;	PI3K Delta in complex with [(dimethylamino)methyldihydrobenzoxazin2methoxypyridinyl]methanesulfonamide
5AUL	;	1.1	;	PI3K p85 C-terminal SH2 domain/CD28-derived peptide complex
5GJI	;	0.9	;	PI3K p85 N-terminal SH2 domain/CD28-derived peptide complex
3I5R	;	1.7	;	PI3K SH3 domain in complex with a peptide ligand
6AUD	;	2.015	;	PI3K-gamma K802T in complex with Cpd 8 10-((1-(tert-butyl)piperidin-4-yl)sulfinyl)-2-(1-isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine
8V8I	;	3.2	;	PI3Ka H1047R co-crystal structure with inhibitor in cryptic pocket (compound 5).
8V8U	;	2.93	;	PI3Ka H1047R co-crystal structure with inhibitor in cryptic pocket near H1047R (compound 12).
8V8H	;	3.58	;	PI3Ka H1047R co-crystal structure with inhibitor in cryptic pocket near H1047R (compound 4).
8V8V	;	2.61	;	PI3Ka H1047R co-crystal structure with inhibitor in cryptic pocket near H1047R (compound 7).
8V8J	;	3.35	;	PI3Ka H1047R co-crystal structure with inhibitors in two cryptic pockets (compounds 4 and 5).
7BI4	;	2.42	;	PI3KC2a core apo
7BI6	;	2.75	;	PI3KC2a core in complex with ATP
7BI9	;	2.65	;	PI3KC2a core in complex with PIK90
8A9I	;	2.87	;	PI3KC2a core in complex with PITCOIN1
7Z74	;	2.5	;	PI3KC2a core in complex with PITCOIN2
7Z75	;	2.59	;	PI3KC2a core in complex with PITCOIN3
7BI2	;	3.25	;	PI3KC2aDeltaN and DeltaC-C2
7R2B	;	2.7	;	PI3Kdelta in complex with an inhibitor
5T7F	;	2.6	;	PI3Kdelta in complex with the inhibitor GS-643624
5T8I	;	2.6	;	PI3Kdelta in complex with the inhibitor GS-9901
5T23	;	2.78	;	PI3Kg IN COMPLEX WITH 5d
4URK	;	2.9	;	PI3Kg in complex with AZD6482
6FH5	;	2.84	;	PI3Kg IN COMPLEX WITH Compound 7
6GQ7	;	2.84	;	PI3Kg IN COMPLEX WITH INH
6WHG	;	3.1	;	PI3P and calcium bound full-length TRPY1 in detergent
5I0N	;	2.28	;	PI4K IIalpha bound to calcium
5FBL	;	3.372	;	PI4KB in complex with Rab11 and the MI356 Inhibitor
5FBQ	;	3.789	;	PI4KB in complex with Rab11 and the MI358 Inhibitor
5FBR	;	3.28	;	PI4KB in complex with Rab11 and the MI359 Inhibitor
5FBV	;	3.285	;	PI4KB in complex with Rab11 and the MI364 Inhibitor
5FBW	;	3.487	;	PI4KB in complex with Rab11 and the MI369 Inhibitor
7YNO	;	2.8	;	PiB-bound alpha-synuclein fibrils conformation 1
7YNQ	;	2.8	;	PiB-bound alpha-synuclein fibrils conformation 2
8GXS	;	4.16	;	PIC-Mediator in complex with +1 nucleosome (T40N) in H-binding state
8GXQ	;	5.04	;	PIC-Mediator in complex with +1 nucleosome (T40N) in MH-binding state
3UPW	;	1.781	;	Pichia Stipitis OYE2.6 complexed with nicotinamide
6BJN	;	2.43	;	PICK1 PDZ domain in complex with the class I PDZ binding motif QSAV
6BJO	;	1.75	;	PICK1 PDZ domain in complex with the small molecule inhibitor BIO124.
5B19	;	1.851	;	Picrophilus torridus aspartate racemase
3L35	;	1.55	;	PIE12 D-peptide against HIV entry
3L36	;	1.45	;	PIE12 D-peptide against HIV entry
3L37	;	1.45	;	PIE12 D-peptide against HIV entry
6PSA	;	1.3	;	PIE12 D-PEPTIDE AGAINST HIV ENTRY (IN COMPLEX WITH IQN17 Q577R RESISTANCE MUTANT)
6E49	;	2.9	;	Pif1 peptide bound to PCNA trimer
1EKO	;	2.2	;	PIG ALDOSE REDUCTASE COMPLEXED WITH IDD384 INHIBITOR
1AH0	;	2.3	;	PIG ALDOSE REDUCTASE COMPLEXED WITH SORBINIL
1AH4	;	2.0	;	PIG ALDOSE REDUCTASE, HOLO FORM
1PIF	;	2.3	;	PIG ALPHA-AMYLASE
4ZSW	;	1.7	;	Pig Brain GABA-AT inactivated by (E)-(1S,3S)-3-Amino-4-fluoromethylenyl-1-cyclopentanoic acid
4ZSY	;	1.7	;	Pig Brain GABA-AT inactivated by (Z)-(1S,3S)-3-Amino-4-fluoromethylenyl-1-cyclopentanoic acid.
5Y0B	;	6.5	;	PIG GASTRIC H+,K+ - ATPASE IN COMPLEX with BYK99
3IXZ	;	6.5	;	Pig gastric H+/K+-ATPase complexed with aluminium fluoride
2XZB	;	7.0	;	Pig Gastric H,K-ATPase with bound BeF and SCH28080
5YTA	;	2.1	;	Pig Heart Lactate Dehydrogenase in complex with NADH and Oxamate
3HDH	;	2.8	;	PIG HEART SHORT CHAIN L-3-HYDROXYACYL COA DEHYDROGENASE REVISITED: SEQUENCE ANALYSIS AND CRYSTAL STRUCTURE DETERMINATION
5FV4	;	2.4	;	Pig liver esterase 5 (PLE5)
1HDI	;	1.8	;	Pig muscle 3-PHOSPHOGLYCERATE KINASE complexed with 3-PG and MgADP.
1PIG	;	2.2	;	PIG PANCREATIC ALPHA-AMYLASE COMPLEXED WITH THE OLIGOSACCHARIDE V-1532
1BVN	;	2.5	;	PIG PANCREATIC ALPHA-AMYLASE IN COMPLEX WITH THE PROTEINACEOUS INHIBITOR TENDAMISTAT
1UTE	;	1.55	;	PIG PURPLE ACID PHOSPHATASE COMPLEXED WITH PHOSPHATE
5UQ6	;	1.182	;	PIG PURPLE ACID PHOSPHATASE COMPLEXED WITH PHOSPHATE IN TWO COORDINATION MODES ALONG WITH A BRIDGING HYDROXIDE ION
6X34	;	4.7	;	Pig R615C RyR1 EGTA (all classes, open)
6X35	;	4.2	;	Pig R615C RyR1 in complex with CaM, EGTA (class 1, open)
6X36	;	4.7	;	Pig R615C RyR1 in complex with CaM, EGTA (class 3, closed)
6W1N	;	4.0	;	Pig Ryanodine Receptor (WT) in 5mM EGTA condition
5ZW8	;	1.689	;	PigA with FAD and proline
6AF6	;	1.62	;	PigA with FAD and proline
6PU0	;	1.8979	;	Pigeon Cryptochrome4 bound to flavin adenine dinucleotide
2R80	;	1.44	;	Pigeon Hemoglobin (OXY form)
7CLF	;	1.982	;	PigF with SAH
7CLU	;	1.9	;	PigF with SAH
5JDX	;		;	PigG holo
4CSE	;	3.3	;	PIH N-terminal domain
4CV4	;	1.902	;	PIH N-terminal domain
4CKT	;	3.0	;	PIH1 N-terminal domain
4PSF	;	1.578	;	PIH1D1 N-terminal domain
4PSI	;	2.45	;	PIH1D1/phospho-Tel2 complex
2PII	;	1.9	;	PII, GLNB PRODUCT
6T76	;	1.9	;	PII-like protein CutA from Nostoc sp. PCC 7120 in apo form
6T7E	;	2.45	;	PII-like protein CutA from Nostoc sp. PCC7120 in complex with MES
6N4A	;	2.3	;	PII-like SbtB from Cyanobium sp PCC 7001 (apo)
6NTB	;	1.9	;	PII-like SbtB from Cyanobium sp PCC 7001 bound to ATP
4B7D	;	1.89	;	PikC bound to the 10-DML analog with the 3-(N,N-dimethylamino) propanoate anchoring group
4B7S	;	1.84	;	PikC D50N mutant bound to the 10-DML analog with the 3-(N,N- dimethylamino)propanoate anchoring group
3ZK5	;	1.89	;	PikC D50N mutant bound to the 10-DML analog with the 3-(N,N-dimethylamino)ethanoate anchoring group
4BF4	;	2.7	;	PikC D50N mutant in complex with the engineered cycloalkane substrate mimic bearing a termianl N,N-dimethylamino group
4UMZ	;	2.32	;	PikC D50N mutant in complex with the engineered substrate mimic bearing a 2-dimethylaminomethylbenzoate group
3ZPI	;	1.63	;	PikC D50N mutant in P21 space group
2PVB	;	0.91	;	PIKE PARVALBUMIN (PI 4.10) AT LOW TEMPERATURE (100K) AND ATOMIC RESOLUTION (0.91 A).
7K1W	;	5.1	;	PIKfyve/Fig4/Vac14 complex centered on Fig4 - map3
7K2V	;	6.6	;	PIKfyve/Fig4/Vac14 complex centered on PIKfyve - map2
7K1Y	;	5.25	;	PIKfyve/Fig4/Vac14 complex centered on Vac14 - map1
2H7X	;	1.85	;	Pikromycin Thioesterase adduct with reduced triketide affinity label
2HFK	;	1.79	;	Pikromycin thioesterase in complex with product 10-deoxymethynolide
2H7Y	;	2.1	;	Pikromycin Thioesterase with covalent affinity label
2HFJ	;	1.95	;	Pikromycin thioesterase with covalent pentaketide affinity label
7O5Y	;	1.77	;	PilA minor pilin of Streptococcus sanguinis type IV pili
5TSG	;	3.4011	;	PilB from Geobacter metallireducens bound to ADP
5TSH	;	2.3	;	PilB from Geobacter metallireducens bound to AMP-PNP
7B7P	;	2.26	;	PilB minor pilin from Streptococcus sanguinis
7OA7	;	1.45	;	PilC minor pilin of Streptococcus sanguinis 2908 type IV pili
7OA8	;	1.6	;	PilC minor pilin of Streptococcus sanguinis SK36 type IV pili
2YCH	;	2.2	;	PilM-PilN type IV pilus biogenesis complex
6I2V	;	1.75	;	Pilotin from Vibrio vulnificus type 2 secretion system, EpsS.
4K0U	;	2.15	;	Pilotin/secretin peptide Complex
5FL3	;	2.52	;	PilT2 from Thermus thermophilus
6OJZ	;	3.027	;	PilT4 from Geobacter metallireducens bound to ADP with partial occupancy: C3ocococ conformation
6OK2	;	3.287	;	PilT4 from Geobacter metallireducens bound to ADP: C3ocococ conformation
6OKV	;	4.007	;	PilT4 from Geobacter metallireducens bound to AMP-PNP: C2ccocco conformation
6OJX	;	1.892	;	PilT4 from Geobacter metallireducens bound to ATP
4BUG	;	2.8	;	Pilus-presented adhesin, Spy0125 (Cpa), Cys426Ala mutant
2XI9	;	1.9	;	Pilus-presented adhesin, Spy0125 (Cpa), P1 form
2XID	;	2.65	;	Pilus-presented adhesin, Spy0125 (Cpa), P212121 form (DLS)
2XIC	;	2.9	;	Pilus-presented adhesin, Spy0125 (Cpa), P212121 form (ESRF data)
3O0P	;	1.3	;	Pilus-related Sortase C of Group B Streptococcus
4XRN	;	2.0	;	Pilz domain with c-di-gmp of a protein from Pseudomonas aeruginosa
5Y6G	;	2.3	;	PilZ domain with c-di-GMP of YcgR from Escherichia coli
3C4E	;	1.98	;	Pim-1 Kinase Domain in Complex with 3-aminophenyl-7-azaindole
5TEL	;	2.214	;	Pim-1 kinase in complex with a 7-azaindole
5TEX	;	2.149	;	Pim-1 kinase in complex with a 7-azaindole
5TOE	;	2.301	;	Pim-1 kinase in complex with a 7-azaindole
5TUR	;	2.948	;	Pim-1 kinase in complex with a 7-azaindole
5KCX	;	2.2	;	Pim-1 kinase in Complex with a Selective N-substituted 7-azaindole Inhibitor
3WE8	;	1.954	;	Pim-1 kinase in complex with Ruthenium-based inhibitor
6VRU	;	2.07	;	PIM-inhibitor complex 1
3T9I	;	2.6	;	Pim1 complexed with a novel 3,6-disubstituted indole at 2.6 Ang Resolution
4N6Y	;	2.6	;	Pim1 Complexed with a phenylcarboxamide
4N6Z	;	2.2	;	Pim1 Complexed with a pyridylcarboxamide
4N70	;	2.1	;	Pim1 Complexed with a pyridylcarboxamide
6AYD	;	3.0	;	Pim1 complexed with N-(6-(4-hydroxyphenyl)-1H-indazol-3-yl)cyclopropanecarboxamide
7QFM	;	1.95	;	Pim1 in complex with (E)-4-((2-oxoindolin-3-ylidene)methyl)benzoic acid and Pimtide
7QB2	;	2.53	;	Pim1 in complex with (E)-4-((6-amino-1-methyl-2-oxoindolin-3-ylidene)methyl)benzoic acid and Pimtide
7Z6U	;	2.28	;	Pim1 in complex with (E)-4-((6-amino-2-oxoindolin-3-ylidene)methyl)benzoic acid and Pimtide
8R18	;	1.89	;	Pim1 in complex with (E)-4-(4-hydroxystyryl)benzoic acid and Pimtide
8AFR	;	2.15	;	Pim1 in complex with 4-((6-hydroxybenzofuran-3-yl)methyl)benzoic acid and Pimtide
8R1T	;	2.0	;	Pim1 in complex with 4-(4-aminophenethyl)benzoic acid and Pimtide
8R1N	;	2.21	;	Pim1 in complex with 4-(4-hydroxyphenethyl)benzoic acid and Pimtide
8R10	;	2.2	;	Pim1 in complex with 4-(4-hydroxystyryl)benzoic acid and Pimtide
8R1P	;	2.45	;	Pim1 in complex with 6-bromobenzo[d]oxazol-2-amine and Pimtide
6NO9	;	1.712	;	PIM1 in complex with Cpd16 (5-amino-N-(5-((4R,5R)-4-amino-5-fluoroazepan-1-yl)-1-methyl-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)thiazole-4-carboxamide)
5DIA	;	1.964	;	PIM1 in complex with Cpd36 ((1S,3S)-N1-(6-(5-(pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)pyridin-2-yl)cyclohexane-1,3-diamine)
5DHJ	;	2.457	;	PIM1 in complex with Cpd4 (3-methyl-5-(pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine)
6NO8	;	2.377	;	PIM1 in complex with Cpd9 ((R)-5-amino-N-(3-(4-aminoazepan-1-yl)-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)thiazole-4-carboxamide)
5VUA	;	2.2	;	Pim1 Kinase in complex with a benzofuranone inhibitor
5VUB	;	2.0	;	Pim1 Kinase in complex with a benzofuranone inhibitor
5VUC	;	2.0	;	Pim1 Kinase in complex with a benzofuranone inhibitor
4XHK	;	1.9	;	PIM1 kinase in complex with Compound 1s
5V80	;	2.252	;	PIM1 kinase in complex with Cpd1 (1-methyl-4-(3-(6-(piperazin-1-yl)pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)piperazin-2-one)
5V82	;	1.888	;	PIM1 kinase in complex with Cpd17 (1-(6-(4,4-difluoropiperidin-3-yl)pyridin-2-yl)-6-(6-methylpyrazin-2-yl)-1H-pyrazolo[4,3-c]pyridine)
7VSY	;	2.141	;	Pim1 with N82K mutation
4X7Q	;	2.33	;	PIM2 kinase in complex with Compound 1s
7VO4	;	2.1	;	Pimaricin type I PKS thioesterase domain (apo Pim TE)
7VO5	;	2.4	;	Pimaricin type I PKS thioesterase domain (holo Pim TE)
1PIN	;	1.35	;	PIN1 PEPTIDYL-PROLYL CIS-TRANS ISOMERASE FROM HOMO SAPIENS
2N1O	;		;	PIN1 WW domain in complex with a phosphorylated CPEB1 derived peptide
6AND	;	1.75	;	Pinatuzumab Fab in complex with anti-Kappa VHH domain
6QY4	;	1.84	;	Pink beam serial crystallography: Lysozyme, 1 us exposure, 14793 patterns merged
6QY5	;	1.84	;	Pink beam serial crystallography: Lysozyme, 1 us exposure, 4448 patterns merged (1 chip)
6QXX	;	1.7	;	Pink beam serial crystallography: Lysozyme, 5 us exposure, 14793 patterns merged
6QY1	;	1.7	;	Pink beam serial crystallography: Lysozyme, 5 us exposure, 1500 patterns merged
6QXW	;	1.7	;	Pink beam serial crystallography: Lysozyme, 5 us exposure, 24344 patterns merged (3 chips)
6QY0	;	1.7	;	Pink beam serial crystallography: Lysozyme, 5 us exposure, 3000 patterns merged
6QY2	;	1.7	;	Pink beam serial crystallography: Lysozyme, 5 us exposure, 750 patterns merged
6QXY	;	1.7	;	Pink beam serial crystallography: Lysozyme, 5 us exposure, 8813 patterns merged (1 chip)
6QXV	;	1.94	;	Pink beam serial crystallography: Proteinase K, 1 us exposure, 1585 patterns merged (2 chips)
5OAT	;	2.78	;	PINK1 structure
6RTR	;	1.55	;	Piperideine-6-carboxylate dehydrogenase from Streptomyces clavuligerus
6RTU	;	1.9	;	Piperideine-6-carboxylate dehydrogenase from Streptomyces clavuligerus complexed with alpha-aminoadipic acid
6RTS	;	2.25	;	Piperideine-6-carboxylate dehydrogenase from Streptomyces clavuligerus complexed with NAD+
6RTT	;	1.65	;	Piperideine-6-carboxylate dehydrogenase from Streptomyces clavuligerus complexed with picolinic acid
8FVZ	;	3.1	;	PiPT Y150A
3LSF	;	1.851	;	Piracetam bound to the ligand binding domain of GluA2
3LSL	;	2.122	;	Piracetam bound to the ligand binding domain of GluA2 (flop form)
3LSX	;	2.006	;	Piracetam bound to the ligand binding domain of GluA3
5MIL	;	2.1	;	Pirating conserved phage mechanisms promotes promiscuous staphylococcal pathogenicity islands transfer.
1QLL	;	2.04	;	Piratoxin-II (Prtx-II) - a K49 PLA2 from Bothrops pirajai
6PGM	;	2.3	;	PirF geranyltransferase
5LOS	;	2.0	;	Piriformospora indica PIIN_05872
7UV3	;		;	Pis v 3.0101 Vicilin Leader Sequence Residues 5-52
7UV4	;		;	Pis v 3.0101 vicilin leader sequence residues 56-115
6UFK	;	3.2	;	Pistol ribozyme product crystal soaked in Mn2+
6UFJ	;	2.645	;	Pistol ribozyme product crystal structure
6UEY	;	2.8	;	Pistol ribozyme transition-state analog vanadate
6UF1	;	3.1	;	Pistol ribozyme transition-state analog vanadate
1AU7	;	2.3	;	PIT-1 MUTANT/DNA COMPLEX
7U38	;	2.49	;	Pixantrone tethered DNA duplex
2F7E	;	2.0	;	PKA complexed with (S)-2-(1H-Indol-3-yl)-1-(5-isoquinolin-6-yl-pyridin-3-yloxymethyl-etylamine
1Q62	;	2.3	;	PKA double mutant model of PKB
1Q24	;	2.6	;	PKA double mutant model of PKB in complex with MgATP
2GNH	;	2.05	;	PKA five fold mutant model of Rho-kinase with H1152P
2GNI	;	2.27	;	PKA fivefold mutant model of Rho-kinase with inhibitor Fasudil (HA1077)
5BX7	;	1.89	;	PKA in complex with a benzothiophene fragment compound.
5BX6	;	1.89	;	PKA in complex with a halogenated phthalazinone fragment compound.
6WJF	;	7.5	;	PKA RIIbeta holoenzyme with DnaJB1-PKAc fusion in fibrolamellar hepatoceullar carcinoma
6WJG	;	6.2	;	PKA RIIbeta holoenzyme with DnaJB1-PKAc fusion in fibrolamellar hepatoceullar carcinoma
2UZT	;	2.1	;	PKA structures of AKT, indazole-pyridine inhibitors
2UZU	;	2.4	;	PKA structures of indazole-pyridine series of AKT inhibitors
2UZV	;	2.5	;	PKA structures of indazole-pyridine series of AKT inhibitors
2UZW	;	2.2	;	PKA structures of indazole-pyridine series of AKT inhibitors
2GNJ	;	2.28	;	PKA three fold mutant model of Rho-kinase with Y-27632
2GNL	;	2.6	;	PKA threefold mutant model of Rho-kinase with inhibitor H-1152P
1Q61	;	2.1	;	PKA triple mutant model of PKB
6FRX	;	1.88	;	PKA variant as Aurora B mimic in complex with a dianilinopyrimidine inhibitor
4C33	;	1.7	;	PKA-S6K1 Chimera Apo
4C35	;	2.19	;	PKA-S6K1 Chimera with compound 1 (NU1085) bound
4C36	;	1.98	;	PKA-S6K1 Chimera with compound 15e (CCT147581) bound
4C37	;	1.7	;	PKA-S6K1 Chimera with compound 21a (CCT196539) bound
4C38	;	1.58	;	PKA-S6K1 Chimera with compound 21e (CCT239066) bound
4C34	;	1.78	;	PKA-S6K1 Chimera with Staurosporine bound
4Z84	;	1.554	;	PKAB3 in complex with pyrrolidine inhibitor 34a
4Z83	;	1.8	;	PKAB3 in complex with pyrrolidine inhibitor 47a
4GV1	;	1.49	;	PKB alpha in complex with AZD5363
3TXO	;	2.05	;	PKC eta kinase in complex with a naphthyridine
8FP3	;	2.3	;	PKCeta kinase domain in complex with compound 11
8FP1	;	1.85	;	PKCeta kinase domain in complex with compound 2
1KPB	;	2.0	;	PKCI-1-APO
1KPC	;	2.2	;	PKCI-1-APO+ZINC
1KPA	;	2.0	;	PKCI-1-ZINC
1AV5	;	2.0	;	PKCI-SUBSTRATE ANALOG
1KPF	;	1.5	;	PKCI-SUBSTRATE ANALOG
1KPE	;	1.8	;	PKCI-TRANSITION STATE ANALOG
1B4R	;		;	PKD DOMAIN 1 FROM HUMAN POLYCYSTEIN-1
4XED	;	1.23	;	PKD domain of M14-like peptidase from Thermoplasmatales archaeon SCGC AB-540-F20
5JD7	;	1.749	;	PKG I's Carboxyl Terminal Cyclic Nucleotide Binding Domain (CNB-B) in a complex with PET-cGMP
5L0N	;	1.285	;	PKG I's Carboxyl Terminal Cyclic Nucleotide Binding Domain (CNB-B) in a complex with RP-cGMP
5JAX	;	1.486	;	PKG I's Carboyl Terminal Cyclic Nucleotide Binding Domain (CNB-B) in a complex with 8-Br-cGMP
5J48	;	1.49	;	PKG I's Carboyl Terminal Cyclic Nucleotide Binding Domain (CNB-B) in a complex with 8-pCPT-cGMP
5C6C	;	2.05	;	PKG II's Amino Terminal Cyclic Nucleotide Binding Domain (CNB-A) in a complex with cAMP
5C8W	;	1.8	;	PKG II's Amino Terminal Cyclic Nucleotide Binding Domain (CNB-A) in a complex with cGMP
5JIX	;	1.47	;	PKG II's Carboxyl Terminal Cyclic Nucleotide Binding Domain (CNB-B) in a complex with 8-Br-cGMP
5JIZ	;	1.5	;	PKG II's Carboxyl Terminal Cyclic Nucleotide Binding Domain (CNB-B) in a complex with 8-pCPT-cGMP
5BV6	;	1.94	;	PKG II's Carboxyl Terminal Cyclic Nucleotide Binding Domain (CNB-B) in a complex with cGMP
8G2E	;	1.838	;	PKM2 bound to compound 2
4G1N	;	2.3	;	PKM2 in complex with an activator
6TTQ	;	2.7	;	PKM2 in complex with Compound 10
5X1V	;	2.1	;	PKM2 in complex with compound 2
5X1W	;	3.0	;	PKM2 in complex with compound 5
6TTF	;	3.2	;	PKM2 in complex with Compound 5
6TTI	;	2.5	;	PKM2 in complex with Compound 6
6TTH	;	2.6	;	PKM2 in complex with L-threonine
8WJY	;	1.88	;	PKMYT1_Cocrystal_Cpd 4
2KFU	;		;	PknB-phosphorylated Rv1827
8QEL	;	2.451	;	PKR kinase domain- eIF2alpha in complex with compound
2A19	;	2.5	;	PKR kinase domain- eIF2alpha- AMP-PNP complex.
2A1A	;	2.8	;	PKR kinase domain-eIF2alpha Complex
5XUO	;	2.586	;	Pks13 AT domain fragment from Mycobacterium tuberculosis
4YXQ	;	2.47	;	PksG, a HMG-CoA Synthase from Bacillus subtilis
4YXT	;	2.1	;	PksG, a HMG-CoA Synthase from Bacillus subtilus
4YXV	;	2.75	;	PksG, a HMG-CoA Synthase from Bacillus subtilus
6WKN	;	3.46	;	PL-bound rat TRPV2 in nanodiscs
7CZH	;	2.104	;	PL24 ulvan lyase-Uly1
6MQU	;	3.17	;	PL5, synthetic transmembrane domain variant of human phospholamban
7DMK	;	2.213	;	PL6 alginate lyase BcAlyPL6
1LD4	;	11.4	;	Placement of the Structural Proteins in Sindbis Virus
3MK2	;	1.89	;	Placental alkaline phosphatase complexed with Phe
6A66	;	1.4	;	Placental protein 13/galectin-13 variant R53H with Tris
6A63	;	1.63	;	Placental protein 13/galectin-13 variant R53HH57R with Lactose
6A62	;	2.03	;	Placental protein 13/galectin-13 variant R53HH57RD33G with Lactose
6A65	;	1.771	;	Placental protein 13/galectin-13 variant R53HR55N with Tris
6A64	;	1.63	;	Placental protein 13/galectin-13 variant R53HR55NH57RD33G with Lactose
2EC6	;	3.25	;	Placopecten Striated Muscle Myosin II
2K1J	;		;	Plan homeodomain finger of tumour supressor ING4
3A8T	;	2.37	;	Plant adenylate isopentenyltransferase in complex with ATP
2O7R	;	1.4	;	Plant carboxylesterase AeCXE1 from Actinidia eriantha with acyl adduct
6S0P	;	1.24	;	Plant Cysteine Oxidase PCO4 from Arabidopsis thaliana
6S7E	;	1.82	;	Plant Cysteine Oxidase PCO4 from Arabidopsis thaliana (using PEG 3350 and NaF as precipitants)
6SBP	;	1.91	;	Plant Cysteine Oxidase PCO5 from Arabidopsis thaliana
1W1S	;	2.0	;	Plant Cytokinin Dehydrogenase in Complex with Benzylaminopurine
1W1Q	;	1.8	;	Plant Cytokinin Dehydrogenase in Complex with Isopentenyladenine
1W1R	;	1.9	;	Plant Cytokinin Dehydrogenase in Complex with trans-Zeatin
2C7Y	;	2.1	;	plant enzyme
2C7Z	;	2.37	;	Plant enzyme crystal form II
6GMO	;	1.75	;	Plant glutamate cysteine ligase (GCL) in complex with non-reducing GSH (GSM)
7W0K	;	2.04	;	plant glycosyltransferase
7DXN	;	1.8	;	Plant growth-promoting factor YxaL from Bacillus velezensis
7EVF	;	1.5	;	Plant growth-promoting factor YxaL mutant from Bacillus velezensis - T175W/S213G/W215A
7EQ5	;	2.6	;	Plant growth-promoting factor YxaL mutant from Bacillus velezensis - T175W/W215G
7JRG	;	3.2	;	Plant Mitochondrial complex III2 from Vigna radiata
7JRO	;	3.8	;	Plant Mitochondrial complex IV from Vigna radiata
7JRP	;	3.8	;	Plant Mitochondrial complex SC III2+IV from Vigna radiata
7A23	;	3.7	;	Plant mitochondrial respiratory complex I
7Z1I	;	3.09	;	Plant myrosinase TGG1 from Arabidopsis thaliana
7ZGM	;	1.43	;	Plant N-glycan specific alpha-1,3-mannosidase
4KPN	;	3.35	;	Plant nucleoside hydrolase - PpNRh1 enzyme
6ZK1	;	1.99	;	Plant nucleoside hydrolase - ZmNRh2b enzyme
6ZK2	;	2.2	;	Plant nucleoside hydrolase - ZmNRh2b in complex with forodesine
6ZK3	;	1.75	;	Plant nucleoside hydrolase - ZmNRh2b in complex with ribose
6ZK4	;	1.95	;	Plant nucleoside hydrolase - ZmNRh2b with a bound adenine
4KPO	;	2.49	;	Plant nucleoside hydrolase - ZmNRh3 enzyme
6ZK5	;	1.9	;	Plant nucleoside hydrolase - ZmNRh3 enzyme in complex with forodesine
3CPM	;	2.4	;	plant peptide deformylase PDF1B crystal structure
7DAB	;		;	plant peptide hormone
7OGU	;	2.872	;	Plant peptide hormone receptor complex H1C9S1
7OGZ	;	2.7	;	Plant peptide hormone receptor complex H1L3S1
7ODV	;	2.31	;	Plant peptide hormone receptor complex H1LS1
7ODK	;	1.83	;	Plant peptide hormone receptor H1
7OGO	;	2.38	;	Plant peptide hormone receptor H1I1S1
7OGQ	;	2.2	;	Plant peptide hormone receptor H1I2S1
5HYX	;	2.596	;	Plant peptide hormone receptor RGFR1 in complex with RGF1
5HZ0	;	2.56	;	Plant peptide hormone receptor RGFR1 in complex with RGF2
5HZ1	;	2.59	;	Plant peptide hormone receptor RGFR1 in complex with RGF3
5HZ3	;	2.86	;	Plant peptide hormone receptor RGFR1 in complex with RGFR5
2LIY	;		;	Plant peptide hormone regulating stomatal density
8JEC	;	3.1	;	plant potassium channel SKOR mutant - L271P/D312N
6YAC	;	2.5	;	Plant PSI-ferredoxin supercomplex
6YEZ	;	2.7	;	Plant PSI-ferredoxin-plastocyanin supercomplex
5GYY	;	2.351	;	Plant receptor complex
5XJO	;	2.626	;	Plant receptor ERL1-TMM in complex with peptide EPF1
7W3V	;	3.11	;	Plant receptor like protein RXEG1 in complex with xyloglucanase XEG1
3RJ0	;	2.541	;	Plant steroid receptor BRI1 ectodomain in complex with brassinolide
4LSX	;	3.302	;	Plant steroid receptor ectodomain bound to brassinolide and SERK1 co-receptor ectodomain
3VHF	;	1.39	;	plant thaumatin I at pH 8.0
7ZGN	;	1.95	;	Plant/insect N-glycan active PNGase
5MLH	;	1.86	;	Plantago Major multifunctional oxidoreductase in complex with 8-oxogeranial and NADP+
6GSD	;	2.7	;	Plantago Major multifunctional oxidoreductase in complex with progesterone and NADP+
5MLR	;	1.46	;	Plantago Major multifunctional oxidoreductase V150M mutant in complex with citral and NADP+
5MLM	;	2.563	;	Plantago Major multifunctional oxidoreductase V150M mutant in complex with progesterone and NADP+
2KHF	;		;	Plantaricin J in DPC-micelles
2KHG	;		;	Plantaricin J in TFE
2KEH	;		;	Plantaricin K in TFE
6GNZ	;		;	Plantaricin S-a in 100 mM DPC micelles. This is the alpha part of the bacteriocin plantaricin S.
6GO0	;		;	PLANTARICIN S-B IN 100 MM DPC MICELLES. THIS IS THE BETA PART OF THE BACTERIOCIN PLANTARICIN S
3EBB	;	1.9	;	PLAP/P97 complex
1E05	;	2.62	;	PLASMA ALPHA ANTITHROMBIN-III
1E03	;	2.9	;	PLASMA ALPHA ANTITHROMBIN-III AND PENTASACCHARIDE
1E04	;	2.6	;	PLASMA BETA ANTITHROMBIN-III
5HS4	;	1.339	;	Plasmdoium Vivax Lactate dehydrogenase
2BJU	;	1.56	;	Plasmepsin II complexed with a highly active achiral inhibitor
1SME	;	2.7	;	PLASMEPSIN II, A HEMOGLOBIN-DEGRADING ENZYME FROM PLASMODIUM FALCIPARUM, IN COMPLEX WITH PEPSTATIN A
1W6I	;	2.7	;	plasmepsin II-pepstatin A complex
6C4G	;	2.39	;	Plasmepsin V from Plasmodium vivax bound to a transition state mimetic (WEHI-601)
4ZL4	;	2.37	;	Plasmepsin V from Plasmodium vivax bound to a transition state mimetic (WEHI-842)
1GKI	;	3.0	;	Plasmid coupling protein TrwB in complex with ADP and Mg2+.
1GL7	;	3.0	;	Plasmid coupling protein TrwB in complex with the non-hydrolisable ATP-analogue ADPNP.
1GL6	;	2.8	;	Plasmid coupling protein TrwB in complex with the non-hydrolysable GTP analogue GDPNP
6AHT	;	2.0	;	Plasmid partitioning protein TubR from Bacillus cereus
1BQY	;	2.5	;	Plasminogen activator (TSV-PA) from snake venom
4AQH	;	2.4	;	Plasminogen activator inhibitor type-1 in complex with the inhibitor AZ3976
1B3K	;	2.99	;	Plasminogen activator inhibitor-1
1C5G	;	2.6	;	PLASMINOGEN ACTIVATOR INHIBITOR-1
1OC0	;	2.28	;	plasminogen activator inhibitor-1 complex with somatomedin B domain of vitronectin
6OG4	;	1.7	;	plasminogen binding group A streptococcal M protein
8TVL	;	3.8	;	Plasminogen binding group A streptococcus M-like protein from AP53 bound to human plasminogen
4CIK	;	1.78	;	plasminogen kringle 1 in complex with inhibitor
6ZN3	;	2.51	;	Plasmodium facliparum glideosome trimeric sub-complex
6FQX	;	2.8	;	Plasmodium falciparum 6-phosphogluconate dehydrogenase in its apo form, in complex with its cofactor NADP+ and in complex with its substrate 6-phosphogluconate
6FQY	;	2.9	;	Plasmodium falciparum 6-phosphogluconate dehydrogenase in its apo form, in complex with its cofactor NADP+ and in complex with its substrate 6-phosphogluconate
6FQZ	;	1.9	;	Plasmodium falciparum 6-phosphogluconate dehydrogenase in its apo form, in complex with its cofactor NADP+ and in complex with its substrate 6-phosphogluconate
7SXL	;	2.7	;	Plasmodium falciparum apicoplast DNA polymerase (exo-minus) without affinity tag
7SXQ	;	2.5	;	Plasmodium falciparum apicoplast DNA polymerase (exo-minus) without affinity tag
4EOY	;	2.22	;	Plasmodium falciparum Atg8 in complex with Plasmodium falciparum Atg3 peptide
5ULC	;	2.4	;	PLASMODIUM FALCIPARUM BROMODOMAIN-CONTAINING PROTEIN PF10_0328
8OIL	;		;	Plasmodium falciparum circumsporozoite protein C-terminal domain
1QNH	;	2.1	;	Plasmodium falciparum Cyclophilin (double mutant) complexed with Cyclosporin A
1QNG	;	2.1	;	Plasmodium falciparum Cyclophilin complexed with Cyclosporin A
2FU0	;	1.8	;	Plasmodium falciparum cyclophilin PFE0505w putative cyclosporin-binding domain
7TXE	;	2.3	;	Plasmodium falciparum Cyt c2 DSD
7U2V	;	2.55	;	Plasmodium falciparum Cyt c2 DSD
7DPI	;	3.597	;	Plasmodium falciparum cytoplasmic Phenylalanyl-tRNA synthetase in complex with BRD7929
3QG2	;	2.3	;	Plasmodium falciparum DHFR-TS qradruple mutant (N51I+C59R+S108N+I164L, V1/S) pyrimethamine complex
6I4B	;	1.98	;	Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) co-crystallized with 3-Hydroxy-1-methyl-5-((3-(trifluoromethyl)phenoxy)methyl)-1H-pyrazole-4-carboxylic acid
6I55	;	1.98	;	Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) co-crystallized with N-(2,2-Diphenylethyl)-4-hydroxy-1,2,5-thiadiazole-3-carboxamide
4CQ8	;	1.98	;	Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) in complex with Genz-669178
4CQ9	;	2.72	;	Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) in complex with IDI-6253
4CQA	;	2.82	;	Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) in complex with IDI-6273
7WYF	;	3.3	;	Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) in complex with its inhibitor 50
3I65	;	2.0	;	Plasmodium falciparum dihydroorotate dehydrogenase bound with triazolopyrimidine-based inhibitor DSM1
3I68	;	2.4	;	Plasmodium falciparum dihydroorotate dehydrogenase bound with triazolopyrimidine-based inhibitor DSM2
3I6R	;	2.5	;	Plasmodium falciparum dihydroorotate dehydrogenase bound with triazolopyrimidine-based inhibitor DSM74
6E0B	;	2.099	;	Plasmodium falciparum dihydroorotate dehydrogenase C276F mutant bound with triazolopyrimidine-based inhibitor DSM1
6GJG	;	1.99	;	Plasmodium falciparum dihydroorotate dehydrogenase DHODH in complex with 3,6-dimethyl-N-(4-(trifluoromethyl)phenyl)-(1,2)oxazolo(5,4-d)pyrimidin-4-amine
1TV5	;	2.4	;	Plasmodium falciparum dihydroorotate dehydrogenase with a bound inhibitor
2Y8C	;	2.1	;	Plasmodium falciparum dUTPase in complex with a trityl ligand
6N7Q	;	2.1	;	Plasmodium falciparum FVO apical membrane antigen 1 (AMA1) bound to cyclised RON2 peptide
6N87	;	1.588	;	Plasmodium falciparum FVO apical membrane antigen 1 (AMA1) bound to MTSL spin-labelled cyclised RON2 peptide
7MYV	;	3.51	;	Plasmodium falciparum HAD5/PMM
7ZZI	;	2.8	;	Plasmodium falciparum hexokinase complexed with glucose and citrate
1SQ6	;	2.4	;	Plasmodium falciparum homolog of Uridine phosphorylase/Purine nucleoside phosphorylase
6S02	;	1.87	;	Plasmodium falciparum Hsp70-x chaperone nucleotide binding domain - ADP bound state
6RZQ	;	1.81	;	Plasmodium falciparum Hsp70-x chaperone nucleotide binding domain - ANP-PnP bound state
7OOH	;	2.36	;	Plasmodium falciparum Hsp70-x chaperone nucleotide binding domain in complex with NCL-00023818
7P31	;	2.36	;	Plasmodium falciparum Hsp70-x chaperone nucleotide binding domain in complex with NCL-00023818
7OOG	;	2.42	;	Plasmodium falciparum Hsp70-x chaperone nucleotide binding domain in complex with NCL-00023823
7NQS	;	2.56	;	Plasmodium falciparum Hsp70-x chaperone nucleotide binding domain in complex with Z1203107138
7NQZ	;	2.319	;	Plasmodium falciparum Hsp70-x chaperone nucleotide binding domain in complex with Z1827898537
7NQR	;	2.22	;	Plasmodium falciparum Hsp70-x chaperone nucleotide binding domain in complex with Z287256168
7OOE	;	2.369	;	Plasmodium falciparum Hsp70-x chaperone nucleotide binding domain in complex with Z321318226
7NQU	;	2.13	;	Plasmodium falciparum Hsp70-x chaperone nucleotide binding domain in complex with Z396380540
7NBA	;	4.0	;	Plasmodium falciparum kinesin-5 motor domain bound to AMPPNP, complexed with 14 protofilament microtubule.
7NB8	;	4.4	;	Plasmodium falciparum kinesin-5 motor domain without nucleotide, complexed with 14 protofilament microtubule.
4B7U	;	1.88	;	PLASMODIUM FALCIPARUM L-LACTATE DEHYDROGENASE COMPLEXED WITH BICINE
1LDG	;	1.74	;	PLASMODIUM FALCIPARUM L-LACTATE DEHYDROGENASE COMPLEXED WITH NADH AND OXAMATE
2X8L	;	1.6	;	Plasmodium falciparum lactate dehydrogenase apo structure
1U4O	;	1.7	;	Plasmodium falciparum lactate dehydrogenase complexed with 2,6-naphthalenedicarboxylic acid
1U4S	;	2.0	;	Plasmodium falciparum lactate dehydrogenase complexed with 2,6-naphthalenedisulphonic acid
1XIV	;	1.7	;	Plasmodium falciparum lactate dehydrogenase complexed with 2-({4-chloro-[hydroxy(methoxy)methyl]cyclohexyl}amino)ethane-1,1,2-triol
1U5A	;	1.8	;	Plasmodium falciparum lactate dehydrogenase complexed with 3,5-dihydroxy-2-naphthoic acid
1U5C	;	2.65	;	Plasmodium falciparum lactate dehydrogenase complexed with 3,7-dihydroxynaphthalene-2-carboxylic acid and NAD+
1T24	;	1.7	;	Plasmodium falciparum lactate dehydrogenase complexed with NAD+ and 4-hydroxy-1,2,5-oxadiazole-3-carboxylic acid
1T2D	;	1.1	;	Plasmodium falciparum lactate dehydrogenase complexed with NAD+ and oxalate
1T2C	;	2.01	;	Plasmodium falciparum lactate dehydrogenase complexed with NADH
1T25	;	1.9	;	Plasmodium falciparum lactate dehydrogenase complexed with NADH and 3-hydroxyisoxazole-4-carboxylic acid
1T26	;	1.8	;	Plasmodium falciparum lactate dehydrogenase complexed with NADH and 4-hydroxy-1,2,5-thiadiazole-3-carboxylic acid
1T2E	;	1.85	;	Plasmodium falciparum lactate dehydrogenase S245A, A327P mutant complexed with NADH and oxamate
6TLB	;	2.85	;	Plasmodium falciparum lipocalin (PF3D7_0925900)
8SLO	;	1.55	;	Plasmodium falciparum M1 aminopeptidase bound to selective inhibitor MIPS2673
8EYF	;	1.9	;	Plasmodium falciparum M1 in complex with inhibitor 15aa
8EZ2	;	1.83	;	Plasmodium falciparum M1 in complex with inhibitor 15ag
8EYD	;	1.83	;	Plasmodium falciparum M1 in complex with inhibitor 15ah
8EX3	;	1.6	;	Plasmodium falciparum M1 in complex with inhibitor 9aa
8EYE	;	1.83	;	Plasmodium falciparum M1 in complex with inhibitor 9aj
8EWZ	;	1.75	;	Plasmodium falciparum M1 in complex with inhibitor 9c
8EZ4	;	1.89	;	Plasmodium falciparum M17 in complex with inhibitor 9aa
7RIE	;	2.49	;	Plasmodium falciparum M17 in complex with inhibitor MIPS2571
6ZBJ	;	3.3	;	Plasmodium falciparum merozoite surface protein 1 dimer, conformation 1
6ZBL	;	3.6	;	Plasmodium falciparum merozoite surface protein 1 dimer, conformation 2
6YCZ	;	3.27	;	Plasmodium falciparum Myosin A delta-Nter, Post-Rigor state
6YCY	;	2.55	;	Plasmodium falciparum Myosin A full-length, post-rigor state
8A12	;	2.03	;	Plasmodium falciparum Myosin A full-length, post-rigor state complexed to Mg.ATP-gamma-S
8CDM	;	2.35	;	Plasmodium falciparum Myosin A full-length, post-rigor state complexed to the inhibitor KNX-002
8CDQ	;	2.21	;	Plasmodium falciparum Myosin A full-length, post-rigor state complexed to the inhibitor KNX-002 and Mg.ATP-gamma-S
6YCX	;	3.99	;	Plasmodium falciparum Myosin A full-length, pre-powerstroke state
6I7D	;	2.82	;	Plasmodium falciparum Myosin A, post-rigor and rigor-like states
6I7E	;	3.492	;	Plasmodium falciparum Myosin A, Pre-powerstroke
5LM3	;	2.5	;	Plasmodium falciparum nicotinic acid mononucleotide adenylyltransferase complexed with APC
5LLT	;	2.2	;	Plasmodium falciparum nicotinic acid mononucleotide adenylyltransferase complexed with NaAD
1XIQ	;	3.05	;	Plasmodium falciparum Nucleoside diphosphate kinase B
1RL4	;	2.18	;	Plasmodium falciparum peptide deformylase complex with inhibitor
6RZY	;	1.379	;	Plasmodium falciparum PFA0660w Hsp40 co-chaperone J-domain
6H5N	;	3.23	;	Plasmodium falciparum Pfs48/45 C-terminal domain bound to monoclonal antibody 85RF45.1
4R6W	;	1.5894	;	Plasmodium falciparum phosphoethanolamine methyltransferase D128A mutant in complex with S-adenosylhomocysteine and phosphocholine
4R6X	;	2.5534	;	Plasmodium falciparum phosphoethanolamine methyltransferase D128A mutant in complex with S-adenosylhomocysteine and phosphoethanolamine
2JKF	;	2.31	;	Plasmodium falciparum profilin
2JKG	;	1.89	;	Plasmodium falciparum profilin
7V9D	;	1.937	;	Plasmodium falciparum Prolyl-tRNA Synthetase (PfPRS) in Complex with inhibitor L95 and azetidine
7F96	;	2.577	;	Plasmodium falciparum Prolyl-tRNA Synthetase (PfPRS) in Complex with L-proline and compound L95
7F97	;	2.394	;	Plasmodium falciparum Prolyl-tRNA Synthetase (PfPRS) in Complex with L-proline and compound L97
7S7R	;	1.77	;	Plasmodium falciparum protein Pf12 bound to nanobody G7
7KJ7	;	2.8	;	Plasmodium falciparum protein Pf12p
7KJH	;	2.0	;	Plasmodium falciparum protein Pf12p bound to nanobody B9
7KJI	;	3.25	;	Plasmodium falciparum protein Pf12p bound to nanobody D9
7USV	;	2.1	;	Plasmodium falciparum protein Pfs230 D1 in complex with nanobody F10
7UST	;	1.7	;	Plasmodium falciparum protein Pfs230 D1 in complex with nanobody F5
7USR	;	1.93	;	Plasmodium falciparum protein Pfs230 D1D2 - Structure of the first two 6-cysteine domains
7USS	;	1.9	;	Plasmodium falciparum protein Pfs230 Pro-D1D2 - Structure of the first two 6-cysteine domains with N-terminal extension
5ZNI	;	2.3	;	Plasmodium falciparum purine nucleoside phosphorylase in complex with mefloquine
5ZNC	;	1.66	;	Plasmodium falciparum purine nucleoside phosphorylase in complex with quinine
2FBN	;	1.63	;	Plasmodium falciparum putative FK506-binding protein PFL2275c, C-terminal TPR-containing domain
7Z4M	;	1.9	;	Plasmodium falciparum pyruvate kinase complexed with Mg2+ and K+
7Z4N	;	1.8	;	Plasmodium falciparum pyruvate kinase complexed with pyruvate
7Z4R	;	2.0	;	Plasmodium falciparum pyruvate kinase mutant - C343A
7Z4Q	;	2.1	;	Plasmodium falciparum pyruvate kinase mutant - C49A
4U0Q	;	3.1	;	Plasmodium falciparum reticulocyte-binding protein homologue 5 (PfRH5) bound to basigin
4U0R	;	2.3	;	Plasmodium falciparum reticulocyte-binding protein homologue 5 (PfRH5) bound to monoclonal antibody 9AD4
4U1G	;	3.1	;	Plasmodium falciparum reticulocyte-binding protein homologue 5 (PfRH5) bound to monoclonal antibody QA1
7KIY	;	2.92	;	Plasmodium falciparum RhopH complex in soluble form
2MUJ	;		;	Plasmodium falciparum SERA protein peptide analogues having short helical regions induce protection against malaria
3U31	;	2.2	;	Plasmodium falciparum Sir2A preferentially hydrolyzes medium and long chain fatty acyl lysine
3U3D	;	2.4	;	Plasmodium falciparum Sir2A preferentially hydrolyzes medium and long chain fatty acyl lysine
6HY1	;	1.6	;	Plasmodium falciparum spermidine synthase in complex with 5'-methylthioadenosine and N,N'-Bis(3-aminopropyl)-1,4-cyclohexanediamine after catalysis in crystal
6I1N	;	1.85	;	Plasmodium falciparum spermidine synthase in complex with N-(3-aminopropyl)-trans-cyclohexane-1,4-diamine
3ULP	;	2.1	;	Plasmodium falciparum SSB complex with ssDNA
2YOG	;	1.5	;	Plasmodium falciparum thymidylate kinase in complex with a (thio)urea- alpha-deoxythymidine inhibitor
2YOF	;	1.82	;	Plasmodium falciparum thymidylate kinase in complex with a (thio)urea- beta-deoxythymidine inhibitor
2YOH	;	1.6	;	Plasmodium falciparum thymidylate kinase in complex with a urea-alpha- deoxythymidine inhibitor
2WWH	;	2.7	;	Plasmodium falciparum thymidylate kinase in complex with AP5dT
2WWI	;	2.99	;	Plasmodium falciparum thymidylate kinase in complex with AZTMP and ADP
2WWG	;	2.4	;	Plasmodium falciparum thymidylate kinase in complex with dGMP and ADP
2WWF	;	1.89	;	Plasmodium falciparum thymidylate kinase in complex with TMP and ADP
1O5X	;	1.1	;	Plasmodium falciparum TIM complexed to 2-phosphoglycerate
1M7O	;	2.4	;	Plasmodium Falciparum Triosephosphate isomerase (PfTIM) compled to substrate analog 3-phosphoglycerate (3PG)
1M7P	;	2.4	;	Plasmodium Falciparum Triosephosphate isomerase (PfTIM) compled to substrate analog glycerol-3-phosphate (G3P).
1LYX	;	1.9	;	Plasmodium Falciparum Triosephosphate Isomerase (PfTIM)-Phosphoglycolate complex
1LZO	;	2.8	;	Plasmodium Falciparum Triosephosphate Isomerase-Phosphoglycolate Complex
7ROS	;	2.15	;	Plasmodium falciparum tyrosyl-tRNA synthetase in complex with ML901-Tyr
7ROR	;	1.8	;	Plasmodium falciparum tyrosyl-tRNA synthetase in complex with tyrosine-AMP
7ROT	;	2.2	;	Plasmodium falciparum tyrosyl-tRNA synthetase, S234C mutant, in complex with ML901-Tyr
2ONU	;	2.38	;	Plasmodium falciparum ubiquitin conjugating enzyme PF10_0330, putative homologue of human UBE2H
3FOW	;	2.8	;	Plasmodium Purine Nucleoside Phosphorylase V66I-V73I-Y160F Mutant
3LX3	;	1.55	;	Plasmodium vivax 6-pyruvoyltetrahydropterin synthase (PTPS) in complex with xanthopterin
3M0N	;	1.9	;	Plasmodium vivax 6-pyruvoyltetrahydropterin synthase (PTPS), E37A catalytic residue mutant
3LZE	;	1.9	;	Plasmodium vivax 6-pyruvoyltetrahydropterin synthase (PTPS), E37C catalytic residue mutant
2QGA	;	2.01	;	Plasmodium vivax adenylosuccinate lyase Pv003765 with AMP bound
7BY6	;	2.997	;	Plasmodium vivax cytoplasmic Phenylalanyl-tRNA synthetase in complex with BRD1389
8A44	;	2.49	;	Plasmodium vivax Duffy binding protein region II bound the DARC ectodomain and monoclonal antibody DB1
2QG7	;	2.407	;	Plasmodium vivax ethanolamine kinase Pv091845
6BPD	;	2.32	;	Plasmodium vivax invasion blocking monoclonal antibody 10B12
6BPB	;	1.87	;	Plasmodium vivax invasion blocking monoclonal antibody 4F7
6WVV	;	2.33	;	Plasmodium vivax M17 leucyl aminopeptidase
7K5K	;	2.66	;	Plasmodium vivax M17 leucyl aminopeptidase Pv-M17
2YNE	;	1.72	;	Plasmodium vivax N-myristoyltransferase in complex with a benzothiophene inhibitor
4CAE	;	1.46	;	Plasmodium vivax N-myristoyltransferase in complex with a benzothiophene inhibitor (compound 20b)
4CAF	;	1.7	;	Plasmodium vivax N-myristoyltransferase in complex with a benzothiophene inhibitor (compound 34a)
4C68	;	1.38	;	Plasmodium vivax N-myristoyltransferase in complex with a peptidomimetic inhibitor
2YND	;	1.89	;	Plasmodium vivax N-myristoyltransferase in complex with a pyrazole sulphonamide inhibitor.
4UFV	;	1.75	;	Plasmodium vivax N-myristoyltransferase in complex with a pyridyl inhibitor (compound 18)
4UFX	;	1.49	;	Plasmodium vivax N-myristoyltransferase in complex with a pyridyl inhibitor (compound 19)
4UFW	;	1.5	;	Plasmodium vivax N-myristoyltransferase in complex with a pyridyl inhibitor (compound 22)
5G1Z	;	1.5	;	Plasmodium vivax N-myristoyltransferase in complex with a quinoline inhibitor (compound 1)
5G22	;	2.32	;	Plasmodium vivax N-myristoyltransferase in complex with a quinoline inhibitor (compound 26)
2YNC	;	1.75	;	Plasmodium vivax N-myristoyltransferase in complex with YnC12-CoA thioester.
4B11	;	1.59	;	Plasmodium vivax N-myristoyltransferase with a bound benzofuran inhibitor (compound 13)
4B12	;	1.79	;	Plasmodium vivax N-myristoyltransferase with a bound benzofuran inhibitor (compound 23)
4B13	;	1.58	;	Plasmodium vivax N-myristoyltransferase with a bound benzofuran inhibitor (compound 25)
4B14	;	1.5	;	Plasmodium vivax N-myristoyltransferase with a bound benzofuran inhibitor (compound 26)
4BBH	;	1.63	;	Plasmodium vivax N-myristoyltransferase with a bound benzothiophene inhibitor
4B10	;	1.56	;	Plasmodium vivax N-myristoyltransferase with a non-hydrolysable co- factor
6TW5	;	1.55	;	Plasmodium vivax N-myristoyltransferase with bound indazole inhibitor IMP-917
6TW6	;	1.7	;	Plasmodium vivax N-myristoyltransferase with bound indazole inhibitor IMP-923
4A95	;	1.55	;	Plasmodium vivax N-myristoyltransferase with quinoline inhibitor
8ARL	;	1.45	;	Plasmodium vivax PVP01_0000100 TRAg domain
6WM9	;	2.45	;	Plasmodium vivax reticulocyte binding protein 2b (PvRBP2b) bound to human monoclonal antibody 237235
6WN1	;	3.15	;	Plasmodium vivax reticulocyte binding protein 2b (PvRBP2b) bound to human monoclonal antibody 241242
6WNO	;	3.35	;	Plasmodium vivax reticulocyte binding protein 2b (PvRBP2b) bound to human monoclonal antibody 243244
6WOZ	;	2.9	;	Plasmodium vivax reticulocyte binding protein 2b (PvRBP2b) bound to human monoclonal antibody 251249
6WTY	;	3.481	;	Plasmodium vivax reticulocyte binding protein 2b (PvRBP2b) bound to human monoclonal antibody 253245
6WTV	;	3.05	;	Plasmodium vivax reticulocyte binding protein 2b (PvRBP2b) bound to human monoclonal antibody 258259
6WTU	;	2.55	;	Plasmodium vivax reticulocyte binding protein 2b (PvRBP2b) bound to human monoclonal antibody 273264
6WQO	;	3.15	;	Plasmodium vivax reticulocyte binding protein 2b (PvRBP2b) bound to human monoclonal antibody 283284
6BPA	;	2.53	;	Plasmodium vivax reticulocyte binding protein 2b (PvRBP2b) bound to monoclonal antibody 3E9
6BPC	;	2.66	;	Plasmodium vivax reticulocyte binding protein 2b (PvRBP2b) bound to monoclonal antibody 4F7
6BPE	;	3.34	;	Plasmodium vivax reticulocyte binding protein 2b (PvRBP2b) bound to monoclonal antibody 6H1
2O1Z	;	2.4	;	Plasmodium vivax Ribonucleotide Reductase Subunit R2 (Pv086155)
5GVL	;	2.5	;	Plasmodium vivax SHMT bound with PLP-glycine and GS182
5GVK	;	2.24	;	Plasmodium vivax SHMT bound with PLP-glycine and GS256
5XMV	;	2.16	;	Plasmodium vivax SHMT bound with PLP-glycine and GS362
5XMU	;	2.39	;	Plasmodium vivax SHMT bound with PLP-glycine and GS363
5XMT	;	2.55	;	Plasmodium vivax SHMT bound with PLP-glycine and GS380
5XMS	;	2.45	;	Plasmodium vivax SHMT bound with PLP-glycine and GS498
5GVM	;	2.24	;	Plasmodium vivax SHMT bound with PLP-glycine and GS557
5YFY	;	2.3	;	Plasmodium vivax SHMT bound with PLP-glycine and GS625
5GVN	;	2.3	;	Plasmodium vivax SHMT bound with PLP-glycine and GS653
5GVP	;	2.26	;	Plasmodium vivax SHMT bound with PLP-glycine and GS654
5YG0	;	2.33	;	Plasmodium vivax SHMT bound with PLP-glycine and GS657
5YG1	;	2.45	;	Plasmodium vivax SHMT bound with PLP-glycine and GS704
5YG2	;	2.2	;	Plasmodium vivax SHMT bound with PLP-glycine and GS705
5YFZ	;	2.16	;	Plasmodium vivax SHMT bound with PLP-glycine and S-GS626
5YG3	;	2.4	;	Plasmodium vivax SHMT bound with PLP-glycine and S-GS834
5YG4	;	2.3	;	Plasmodium vivax SHMT bound with PLP-glycine and S-GS849
5XMR	;	2.55	;	Plasmodium vivax SHMT(C346A) bound with PLP-glycine and GS395
5XMQ	;	2.2	;	Plasmodium vivax SHMT(C346A) bound with PLP-glycine and MF011
5XMP	;	2.4	;	Plasmodium vivax SHMT(C346A) bound with PLP-glycine and MF057
2FO3	;	1.86	;	Plasmodium vivax ubiquitin conjugating enzyme E2
2QG8	;	2.0	;	Plasmodium yoelii acyl carrier protein synthase PY06285 with ADP bound
2B71	;	2.5	;	Plasmodium yoelii cyclophilin-like protein
4L0W	;	2.29	;	Plasmodium yoelii Prx1a modified at the N-terminus forms an artifactual octamer
2P1I	;	2.7	;	Plasmodium yoelii Ribonucleotide Reductase Subunit R2 (PY03671)
6YJE	;	1.62	;	Plasmoodium vivax phosphoglycerate kinase bound to nitrofuran inhibitor from PEG3350 and ammonium acetate at pH 5.5
6YJF	;	1.85	;	Plasmoodium vivax phosphoglycerate kinase bound to nitrofuran inhibitor from PEGSmear at pH 6.5
7AOJ	;	1.63	;	Plasmoredoxin, a redox-active protein unique for malaria parasites
7AOO	;	1.6	;	Plasmoredoxin, a redox-active protein unique for malaria parasites
3TMS	;	2.1	;	PLASTIC ADAPTATION TOWARD MUTATIONS IN PROTEINS: STRUCTURAL COMPARISON OF THYMIDYLATE SYNTHASES
4TMS	;	2.35	;	PLASTIC ADAPTATION TOWARD MUTATIONS IN PROTEINS: STRUCTURAL COMPARISON OF THYMIDYLATE SYNTHASES
1QRB	;	2.0	;	PLASTICITY AND STERIC STRAIN IN A PARALLEL BETA-HELIX: RATIONAL MUTATIONS IN P22 TAILSPIKE PROTEIN
3QZW	;	2.798	;	Plasticity of human CD8 binding to peptide-HLA-A*2402
2W0N	;		;	Plasticity of PAS domain and potential role for signal transduction in the histidine-kinase DcuS
3IIN	;	4.18	;	Plasticity of the kink turn structural motif
4KX6	;	2.95	;	Plasticity of the quinone-binding site of the complex II homolog quinol:fumarate reductase
8R5O	;	2.49	;	Plastid-encoded RNA polymerase
8R6S	;	2.49	;	Plastid-encoded RNA polymerase (Integrated model)
8RAS	;	2.62	;	Plastid-encoded RNA polymerase transcription elongation complex
8RDJ	;	2.62	;	Plastid-encoded RNA polymerase transcription elongation complex (Integrated model)
8IA1	;	2.31	;	plastidial glycerol-3-phosphate acyltransferases (GPAT) from the green alga Myrmecia incisa
5LRB	;	2.9	;	Plastidial phosphorylase from Barley in complex with acarbose
5LRA	;	3.0	;	Plastidial phosphorylase PhoI from barley in complex with maltotetraose
1IUZ	;	1.6	;	PLASTOCYANIN
7ZQE	;	2.55	;	Plastocyanin bound to PSI of Chlamydomonas reinhardtii
1NIN	;		;	PLASTOCYANIN FROM ANABAENA VARIABILIS, NMR, 20 STRUCTURES
1BAW	;	2.8	;	PLASTOCYANIN FROM PHORMIDIUM LAMINOSUM
1AG6	;	1.6	;	PLASTOCYANIN FROM SPINACH
2W8C	;	1.8	;	Plastocyanin variant with N-terminal Methionine - closed structure
2W88	;	2.89	;	Plastocyanin variant with N-terminal Methionine - open structure
1M8O	;		;	Platelet integrin alfaIIb-beta3 cytoplasmic domain
2KNC	;		;	Platelet integrin ALFAIIB-BETA3 transmembrane-cytoplasmic heterocomplex
1WAB	;	1.7	;	PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE
8UQN	;	3.4	;	PLCb3-Gaq complex on membranes
8UQO	;	3.37	;	PLCb3-Gbg-Gaq complex on membranes
2W2W	;	2.8	;	PLCg2 Split Pleckstrin Homology (PH) Domain
1MPH	;		;	PLECKSTRIN HOMOLOGY DOMAIN FROM MOUSE BETA-SPECTRIN, NMR, 50 STRUCTURES
1PMS	;		;	PLECKSTRIN HOMOLOGY DOMAIN OF SON OF SEVENLESS 1 (SOS1) WITH GLYCINE-SERINE ADDED TO THE N-TERMINUS, NMR, 20 STRUCTURES
1ZFU	;		;	Plectasin:A peptide antibiotic with therapeutic potential from a saprophytic fungus
4ZDM	;	1.5	;	Pleurobrachia bachei iGluR3 LBD Glycine Complex
2LS9	;		;	Pleurocidin-NH2
6T0Q	;	2.05	;	Pleurotus Ostreatus Lectin (POL), apo form
6T1D	;	2.2	;	Pleurotus Ostreatus Lectin (POL), compelx with melibiose
6MYI	;	1.15	;	Pleurotus ostreatus OstreolysinA
6MYK	;	1.8	;	Pleurotus ostreatus OstreolysinA mutant E69A with Bis-Tris
6MYJ	;	1.33	;	Pleurotus ostreatus OstreolysinA plus sphingomyelin
5L7N	;	2.2	;	Plexin A1 extracellular fragment, domains 7-10 (IPT3-IPT6)
5L56	;	4.0	;	Plexin A1 full extracellular region, domains 1 to 10, to 4 angstrom
5L59	;	6.0	;	Plexin A1 full extracellular region, domains 1 to 10, to 6 angstrom, spacegroup P2(1)
5L5C	;	6.0	;	Plexin A1 full extracellular region, domains 1 to 10, to 6 angstrom, spacegroup P4(3)2(1)2
3AL8	;	3.6	;	Plexin A2 / Semaphorin 6A complex
5L74	;	1.36	;	Plexin A2 extracellular segment domains 4-5 (PSI2-IPT2), resolution 1.36 Angstrom
5L5G	;	10.0	;	Plexin A2 full extracellular region, domains 1 to 8 modeled, data to 10 angstrom
3OKY	;	2.195	;	Plexin A2 in complex with Semaphorin 6A
5L5K	;	7.501	;	Plexin A4 full extracellular region, domains 1 to 10, data to 7.5 angstrom, spacegroup P4(1)
5L5M	;	8.0	;	Plexin A4 full extracellular region, domains 1 to 7 modeled, data to 8 angstrom, spacegroup P4(3)2(1)2
5L5N	;	8.502	;	Plexin A4 full extracellular region, domains 1 to 7 modeled, data to 8.5 angstrom, spacegroup P4(3)22
5L5L	;	8.001	;	Plexin A4 full extracellular region, domains 1 to 8 modeled, data to 8 angstrom, spacegroup P2(1)
7VG7	;	2.5	;	Plexin B1 extracellular fragment in complex with lasso-grafted PB1m6A9 peptide
7VF3	;	2.29	;	Plexin B1 extracellular fragment in complex with lasso-grafted PB1m7 peptide
5E6P	;	3.215	;	PlexinB2 cytoplasmic region/PDZ-RhoGEF PDZ domain complex
2CCN	;	1.6	;	pLI E20C is antiparallel
2BNI	;	1.5	;	pLI mutant E20C L16G Y17H, antiparallel
7MX1	;	1.64	;	PLK-1 polo-box domain in complex with a high affinity macrocycle synthesized using a novel glutamic acid analog
4X9R	;	1.398	;	PLK-1 polo-box domain in complex with Bioactive Imidazolium-containing phosphopeptide macrocycle 3B
4X9V	;	1.429	;	PLK-1 polo-box domain in complex with Bioactive Imidazolium-containing phosphopeptide macrocycle 3C
4X9W	;	1.798	;	PLK-1 polo-box domain in complex with Bioactive Imidazolium-containing phosphopeptide macrocycle 4C
6AX4	;	1.45	;	Plk-1 polo-box domain in complex with histidine N(tau)-cyclized Macrocycle 5b.
3FC2	;	2.45	;	PLK1 in complex with BI6727
8JOQ	;	1.796	;	Plk1 polo-box domain bound to HPV18 L2 residues 209-215 with pThr213
8JOY	;	2.61	;	Plk1 polo-box domain bound to HPV4 L2 residues 251-257 with pThr255
7VVS	;	2.2	;	PLL9 induced TmFtn nanocage
5OFZ	;	1.75	;	PllA lectin, apo
5OFI	;	2.0	;	PllA lectin, Fluorophore carbohydrate complex
5ODU	;	1.56	;	PllA lectin, monosaccharide complex
5OFX	;	1.75	;	Plla lectin, trisaccharide complex
7WAY	;	2.9	;	PlmCasX-sgRNAv1-dsDNA ternary complex at nts loading state
7WB0	;	3.2	;	PlmCasX-sgRNAv1-dsDNA ternary complex at nts loading state with flexible H2 domain
7WAZ	;	3.4	;	PlmCasX-sgRNAv1-dsDNA ternary complex at ts loading state
7WB1	;	3.7	;	PlmCasX-sgRNAv2-dsDNA ternary complex at nts loading state
6SMD	;	3.3	;	PlMCAT:AntF (holo): type II PKS acyl-carrier protein in complex with its malonyl-transacylase
4HXY	;	1.68	;	PlmKR1-Ketoreductase from the first module of phoslactomycin biosynthesis in Streptomyces sp. HK803
5T4J	;	2.231	;	PLP and GABA Trigger GabR-Mediated Transcription Regulation in Bacillus subsidies via External Aldimine Formation
5T4K	;	2.245	;	PLP and GABA Trigger GabR-Mediated Transcription Regulation in Bacillus subsidies via External Aldimine Formation
5T4L	;	1.53	;	PLP and GABA Trigger GabR-Mediated Transcription Regulation in Bacillus subsidies via External Aldimine Formation
4E3R	;	1.9	;	PLP-bound aminotransferase mutant crystal structure from Vibrio fluvialis
6K1N	;	2.26	;	PLP-bound form of a putative cystathionine gamma-lyase
1BS0	;	1.65	;	PLP-DEPENDENT ACYL-COA SYNTHASE
3HQT	;	2.7	;	PLP-Dependent Acyl-CoA Transferase CqsA
3KKI	;	1.8	;	PLP-Dependent Acyl-CoA transferase CqsA
1WCB	;	2.5	;	PLP-DEPENDENT CATALYTIC ANTIBODY 15A9 IN COMPLEX WITH ITS HAPTEN
6C3C	;	1.5	;	PLP-dependent L-arginine hydroxylase RohP quinonoid I complex
5G4I	;	1.5	;	PLP-dependent phospholyase A1RDF1 from Arthrobacter aurescens TC1
6YVA	;	3.18	;	PLpro-C111S with mISG15
4WXY	;	2.7	;	PLPS (inactive glutaminase mutant) co-crystallized with glutamine and R5P.
7CQM	;	1.8	;	PlsY grown in LCP soaked with selenourea for 22 min
2N5H	;		;	PltL-holo
2N5I	;		;	PltL-pyrrolyl
8I8C	;	4.93	;	Plug structure of the Autographa californica multiple nucleopolyhedrovirus (AcMNPV)
6M60	;	2.17	;	Plumbagin in complex with CRM1#-Ran-RanBP1
5YSU	;	2.3	;	Plumbagin in complex with CRM1-RanM189D-RanBP1
5URP	;	1.65	;	Plx2a, an ADP-ribosyltransferase toxin from Paenibacillus larvae
4ZRZ	;	1.72	;	PlyCB mutant R66E
6H5Y	;	2.3	;	PM1 mutant, 7D5
6RAS	;	2.75	;	Pmar-Lig_Pre.
6RCE	;	1.946	;	Pmar-Lig_PreS3
6RAR	;	1.785	;	Pmar-Lig_PreS3-Mn
7OZH	;	3.02	;	PMCA-amplified alpha-synuclein fibril polymorph, Multiple System Atrophy patient-derived seeds
7OZG	;	3.3	;	PMCA-amplified alpha-synuclein fibril polymorph, Parkinson's Disease patient-derived seeds
8SZ6	;	1.65	;	PmHMGR bound to mevaldehyde and CoA
2FKM	;	1.9	;	PMM/PGM S108D mutant with alpha-d-glucose 1,6-bisphosphate bound
7YZY	;	4.8	;	pMMO structure from native membranes by cryoET and STA
5BRK	;	2.3	;	pMob1-Lats1 complex
4D9C	;	1.97	;	PMP bound form of Salmonella typhimurium D-Cysteine desulfhydrase obtained after co-crystallization with L-cycloserine
4E3Q	;	1.9	;	PMP-bound form of Aminotransferase crystal structure from Vibrio fluvialis
1AUR	;	2.5	;	PMSF-INHIBITED CARBOXYLESTERASE FROM PSEUDOMONAS FLUORESCENS
6XJI	;	4.0	;	PmtCD ABC exporter at C1 symmetry
6XJH	;	3.6	;	PmtCD ABC exporter without the basket domain at C2 symmetry
6U2D	;	2.11	;	PmtCD peptide exporter basket domain
6XFU	;	1.4	;	PmtCD peptide exporter basket domain
1QE3	;	1.5	;	PNB ESTERASE
1C7J	;	1.6	;	PNB ESTERASE 56C8
6CSL	;	1.921	;	Pneumococcal PhtD protein 269-339 fragment with bound Zn(II)
1PSZ	;	2.0	;	PNEUMOCOCCAL SURFACE ANTIGEN PSAA
4QJZ	;	1.61	;	Pneumocystis carinii dihydrofolate reductase ternary complex with NADPH and the inhibitor 24, (N~6~-METHYL-N~6~-(NAPHTHALEN-1-YL)PYRIDO[2,3-D]PYRIMIDINE-2,4,6-TRIAMINE)
1PNF	;	2.0	;	PNGASE F COMPLEX WITH DI-N-ACETYLCHITOBIOSE
5F9G	;	2.772	;	pnGFP1.5-Y.Cro: circularly permuted green fluorescent protein (with a tyrosine-derived chromophore)
1CI0	;	2.7	;	PNP OXIDASE FROM SACCHAROMYCES CEREVISIAE
6A4D	;	2.19	;	pNP-TMP bound Oligoribonuclease (ORN) from Colwellia psychrerythraea strain 34H
7DBW	;	2.5	;	PnpA1, the oxygenase component of a two-component para-nitrophenol hydroxylase from Rhodococcus imtechensis RKJ300
2FQW	;	1.71	;	PnrA from Treponema pallidum as purified from E. coli (bound to inosine)
2FQY	;	1.9	;	PnrA from Treponema pallidum complexed with adenosine.
2FQX	;	1.7	;	PnrA from Treponema pallidum complexed with guanosine
6PD1	;	2.72	;	PntC-AEPT: fusion protein of phosphonate-specific cytidylyltransferase and 2-aminoethylphosphonate (AEP) transaminase from Treponema denticola
6PD2	;	1.95	;	PntC-AEPT: fusion protein of phosphonate-specific cytidylyltransferase and 2-aminoethylphosphonate (AEP) transaminase from Treponema denticola in complex with cytidine monophosphate-AEP
6LFU	;	3.123	;	Poa1p F152A mutant in complex with ADP-ribose
6LFS	;	1.87	;	Poa1p H23A mutant in complex with ADP-ribose
6LFR	;	1.78	;	Poa1p in complex with ADP-ribose
6LFT	;	1.57	;	Poa1p S30A mutant in complex with ADP-ribose
5W1E	;	2.06	;	PobR in complex with PHB
3MKH	;	1.995	;	Podospora anserina Nitroalkane Oxidase
6NOG	;	3.9	;	Poised-state Dot1L bound to the H2B-Ubiquitinated nucleosome
1GIK	;	1.8	;	POKEWEED ANTIVIRAL PROTEIN FROM SEEDS
1J1S	;	2.0	;	Pokeweed Antiviral Protein from Seeds (PAP-S1) Complexed with Formycin
6VDC	;	2.402	;	POL domain of Pol1 from M. smegmatis
6VDD	;	1.9	;	POL domain of Pol1 from M. smegmatis complex with DNA primer-template and dNTP
8OO6	;	4.3	;	Pol I bound to extended and displaced DNA section - closed conformation
8OOY	;	4.0	;	Pol I bound to extended and displaced DNA section - open conformation
6BQF	;	3.35	;	Pol II elongation complex with 'dT-AP' at i+1, i-1 position
6BLO	;	3.401	;	Pol II elongation complex with an abasic lesion at i+1 position
6BLP	;	3.203	;	Pol II elongation complex with an abasic lesion at i+1 position, soaking AMPCPP
6BM2	;	3.403	;	Pol II elongation complex with an abasic lesion at i-1 position
6BM4	;	2.951	;	Pol II elongation complex with an abasic lesion at i-1 position,soaking UMPNPP
5W4U	;	3.6	;	Pol II elongation complex with an N6-methyladenine-containing template
5W51	;	3.404	;	Pol II elongation complex with an N6-methyladenine-containing template and a matched UMPNPP
7OPC	;	3.0	;	Pol II-CSB-CRL4CSA-UVSSA-SPT6-PAF (Structure 4)
7OPD	;	3.0	;	Pol II-CSB-CRL4CSA-UVSSA-SPT6-PAF (Structure 5)
8B3F	;	3.1	;	Pol II-CSB-CSA-DDB1-ELOF1
7OO3	;	2.8	;	Pol II-CSB-CSA-DDB1-UVSSA (Structure1)
7OOB	;	2.7	;	Pol II-CSB-CSA-DDB1-UVSSA-ADPBeF3 (Structure2)
7OOP	;	2.9	;	Pol II-CSB-CSA-DDB1-UVSSA-PAF-SPT6 (Structure 3)
7UNC	;	3.0	;	Pol II-DSIF-SPT6-PAF1c-TFIIS complex with rewrapped nucleosome
7UND	;	3.0	;	Pol II-DSIF-SPT6-PAF1c-TFIIS-nucleosome complex (stalled at +38)
3DKE	;	1.25	;	Polar and non-polar cavities in phage T4 lysozyme
6KNB	;	6.9	;	PolD-PCNA-DNA (form A)
6KNC	;	9.3	;	PolD-PCNA-DNA (form B)
6PSZ	;	3.2	;	Poliovirus (Type 1 Mahoney), heat-catalysed 135S particle
6P9W	;	3.2	;	Poliovirus (Type 1 Mahoney), receptor catalysed 135S particle map
6Q0B	;	3.4	;	Poliovirus (Type 1 Mahoney), receptor-catalysed 135S particle incubated with anti-VP1 mAb at RT for 1 hr
1VBD	;	2.9	;	POLIOVIRUS (TYPE 1, MAHONEY STRAIN) COMPLEXED WITH R78206
1PO2	;	2.9	;	POLIOVIRUS (TYPE 1, MAHONEY) IN COMPLEX WITH R77975, AN INHIBITOR OF VIRAL REPLICATION
1PO1	;	2.9	;	POLIOVIRUS (TYPE 1, MAHONEY) IN COMPLEX WITH R80633, AN INHIBITOR OF VIRAL REPLICATION
1VBC	;	2.8	;	POLIOVIRUS (TYPE 3, SABIN STRAIN) (P3/SABIN, P3/LEON/12A(1)B) COMPLEXED WITH R77975
1VBA	;	2.9	;	POLIOVIRUS (TYPE 3, SABIN STRAIN) (P3/SABIN, P3/LEON/12A(1)B) COMPLEXED WITH R78206
1VBB	;	2.8	;	POLIOVIRUS (TYPE 3, SABIN STRAIN) (P3/SABIN, P3/LEON/12A(1)B) COMPLEXED WITH R80633
1VBE	;	2.8	;	POLIOVIRUS (TYPE 3, SABIN STRAIN, MUTANT 242-H2) COMPLEXED WITH R78206
1XYR	;	11.0	;	Poliovirus 135S cell entry intermediate
6P9O	;	2.9	;	Poliovirus 135S-like expanded particle in complex with a monoclonal antibody directed against the N-terminal extension of capsid protein VP1
1L1N	;	2.1	;	POLIOVIRUS 3C PROTEINASE
1RDR	;	2.4	;	POLIOVIRUS 3D POLYMERASE
3J9F	;	9.0	;	Poliovirus complexed with soluble, deglycosylated poliovirus receptor (Pvr) at 4 degrees C
3IYB	;	10.0	;	Poliovirus early RNA-release intermediate
3IYC	;	10.0	;	Poliovirus late RNA-release intermediate
4NLY	;	2.3	;	Poliovirus Polymerase - C290E Loop Mutant
4NLQ	;	2.3	;	Poliovirus Polymerase - C290F Loop Mutant
4NLO	;	2.2	;	Poliovirus Polymerase - C290I Loop Mutant
4NLR	;	2.0	;	Poliovirus Polymerase - C290S Loop Mutant
4NLP	;	2.2	;	Poliovirus Polymerase - C290V Loop Mutant
4NLU	;	2.1	;	Poliovirus Polymerase - G289A Loop Mutant
4NLV	;	2.3	;	Poliovirus Polymerase - G289A/C290F Loop Mutant
4NLW	;	2.1	;	Poliovirus Polymerase - G289A/C290I Loop Mutant
4NLX	;	2.6	;	Poliovirus Polymerase - G289A/C290V Loop Mutant
4NLS	;	2.0	;	Poliovirus Polymerase - S288A Loop Mutant
4NLT	;	2.5	;	Poliovirus Polymerase - S291P Loop Mutant
3OL6	;	2.5	;	Poliovirus polymerase elongation complex
4K4S	;	2.4	;	Poliovirus polymerase elongation complex (r3_form)
4K4T	;	2.75	;	Poliovirus polymerase elongation complex (r4_form)
4K4V	;	2.63	;	Poliovirus polymerase elongation complex (r5+1_form)
4K4W	;	2.69	;	Poliovirus polymerase elongation complex (r5+2_form)
4K4U	;	2.85	;	Poliovirus polymerase elongation complex (r5_form)
3OLB	;	2.41	;	Poliovirus polymerase elongation complex with 2',3'-dideoxy-ctp
3OLA	;	2.55	;	Poliovirus polymerase elongation complex with 2'-deoxy-CTP
3OL9	;	2.25	;	Poliovirus polymerase elongation complex with 3'-deoxy-CTP
3OL7	;	2.7	;	Poliovirus polymerase elongation complex with CTP
3OL8	;	2.75	;	Poliovirus polymerase elongation complex with CTP-Mn
1RA6	;	2.0	;	Poliovirus Polymerase Full Length Apo Structure
1TQL	;	2.3	;	POLIOVIRUS POLYMERASE G1A MUTANT
1RAJ	;	2.5	;	Poliovirus Polymerase with a 68 residue N-terminal truncation
1RA7	;	2.35	;	Poliovirus Polymerase with GTP
3URO	;	3.5005	;	Poliovirus receptor CD155 D1D2
8AYZ	;	1.88	;	Poliovirus type 2 (strain MEF-1) virus-like particle in complex with capsid binder compound 17
6Z6W	;	3.0	;	Poliovirus type 3 (strain Saukett) stabilised virus-like particle (PV3 SC8) from a mammalian expression system.
8AYX	;	2.5	;	Poliovirus type 3 (strain Saukett) stabilised virus-like particle (PV3 SC8) in complex with GSH and GPP3
8AYY	;	2.6	;	Poliovirus type 3 (strain Saukett) stabilised virus-like particle (PV3 SC8) in complex with GSH and Pleconaril
8ANW	;	2.7	;	Poliovirus type 3 (strain Saukett) stabilised virus-like particle (PV3 SC8).
5O5B	;	3.6	;	Poliovirus type 3 (strain Saukett) stabilized virus-like particle
5O5P	;	4.1	;	Poliovirus type 3 (strain Saukett) stabilized virus-like particle in complex with the pocket factor compound GPP3
5DMV	;	2.499	;	Polo-box domain of Mouse Polo-like kinase 1 complexed with Emi2 (146-177)
3RQ7	;	1.55	;	Polo-like kinase 1 Polo box domain in complex with a C6H5(CH2)8-derivatized peptide inhibitor
3FVH	;	1.58	;	Polo-like kinase 1 Polo box domain in complex with Ac-LHSpTA-NH2 peptide
3C5L	;	2.33	;	Polo-like kinase 1 Polo box domain in complex with PPHSpT peptide
3P36	;	1.59	;	Polo-like kinase I Polo-box domain in complex with DPPLHSpTA phosphopeptide from PBIP1
3P37	;	2.38	;	Polo-like kinase I Polo-box domain in complex with FDPPLHSpTA phosphopeptide from PBIP1
3Q1I	;	1.4	;	Polo-like kinase I Polo-box domain in complex with FMPPPMSpSM phosphopeptide from TCERG1
3P35	;	2.09	;	Polo-like kinase I Polo-box domain in complex with MQSpSPL phosphopeptide
3P34	;	1.4	;	Polo-like kinase I Polo-box domain in complex with MQSpTPL phosphopeptide
3P2Z	;	1.79	;	Polo-like kinase I Polo-box domain in complex with PLHSpTA phosphopeptide from PBIP1
8ADK	;	2.474	;	Poly(ADP-ribose) glycohydrolase (PARG) from Drosophila melanogaster
8ADJ	;	2.508	;	Poly(ADP-ribose) glycohydrolase (PARG) from Drosophila melanogaster in complex with PARG inhibitor PDD00017272
8GU4	;	1.5	;	Poly(ethylene terephthalate) hydrolase (IsPETase)-linker
6ACS	;	1.81	;	poly-cis-prenyltransferase
6EOJ	;	3.55	;	PolyA polymerase module of the cleavage and polyadenylation factor (CPF) from Saccharomyces cerevisiae
6HMM	;	1.9	;	POLYADPRIBOSYL GLYCOHYDROLASE IN COMPLEX WITH PDD00013907
6HMK	;	2.06	;	POLYADPRIBOSYL GLYCOHYDROLASE IN COMPLEX WITH PDD00016690
6HMN	;	2.87	;	POLYADPRIBOSYL GLYCOSIDASE IN COMPLEX WITH PDD00014909
5LHB	;	2.23	;	POLYADPRIBOSYL GLYCOSIDASE IN COMPLEX WITH PDD00017262
6HML	;	2.25	;	POLYADPRIBOSYL GLYCOSIDASE IN COMPLEX WITH PDD00017299
6OEH	;	3.8	;	PolyAla Model of OMCC I-Layer
6OEF	;	3.8	;	PolyAla Model of the O-layer from the Type 4 Secretion System of H. pylori
6ODJ	;	3.5	;	PolyAla Model of the PRC from the Type 4 Secretion System of H. pylori
5LIJ	;	4.2	;	polyalanine chain built in bacteriophage phi812K1-420 cement protein density map
6GZ7	;		;	Polyamide - DNA complex NMR structure
3KWA	;	2.0	;	Polyamines inhibit carbonic anhydrases
2IE1	;	1.6	;	Polyamines stabilize left-handed Z-DNA. We found new type of polyamine which stabilize left-handed Z-DNA by X-ray crystallography
1PDQ	;	1.76	;	Polycomb chromodomain complexed with the histone H3 tail containing trimethyllysine 27.
5U8F	;	1.343	;	Polycomb protein EED in complex with inhibitor: (3R,4S)-1-[(1S)-7-fluoro-2,3-dihydro-1H-inden-1-yl]-N,N-dimethyl-4-(1-methyl-1H-indol-3-yl)pyrrolidin-3-amine
5U8A	;	1.45	;	Polycomb protein EED in complex with inhibitor: (3R,4S)-1-[(2-bromo-6-fluorophenyl)methyl]-N,N-dimethyl-4-(1-methyl-1H-indol-3-yl)pyrrolidin-3-amine
5U69	;	1.28	;	Polycomb protein EED in complex with inhibitor: (3R,4S)-1-[(2-methoxyphenyl)methyl]-N,N-dimethyl-4-(1-methylindol-3-yl)pyrrolidin-3-amine
5U6D	;	1.64	;	Polycomb protein EED in complex with inhibitor: 2-[4-(4-{(3S,4R)-4-(dimethylamino)-1-[(2-fluoro-6-methylphenyl)methyl]pyrrolidin-3-yl}phenyl)-1H-pyrazol-1-yl]acetamide
4IDW	;		;	Polycrystalline T6 Bovine Insulin: Anisotropic Lattice Evolution and Novel Structure Refinement Strategy
5MQ6	;	2.0	;	Polycyclic Ketone Monooxygenase from the Thermophilic Fungus Thermothelomyces thermophila
8BRB	;	1.7	;	Polyester Hydrolase Leipzig 7 (PHL7) bound to terephthalic acid (TPA)
8BRA	;	1.7	;	Polyester Hydrolase Leipzig 7 (PHL7) bound to terephthalic acid (TPA) and Mg2+
7NEI	;	1.3	;	Polyester Hydrolase Leipzig 7 (PHL7) in the unliganded state
6SBN	;	1.09	;	Polyester hydrolase PE-H of Pseudomonas aestusnigri
6SCD	;	1.35	;	Polyester hydrolase PE-H Y250S mutant of Pseudomonas aestusnigri
5DQN	;	2.262	;	Polyethylene 600-bound form of P450 CYP125A3 mutant from Myobacterium Smegmatis - W83Y
8PO9	;	2.2	;	Polyethylene oxidation hexamerin PEase Cibeles (XP_026756460) from Galleria mellonella
7EC8	;	1.35	;	Polyethylene terephthalate hydrolyzing lipase PET2 mutant - F105R-E110K
7ECB	;	1.83	;	Polyethylene terephthalate hydrolyzing lipase PET2 mutant - R47C-G89C-F105R-E110K-S156P-G180A-T297P
6LVW	;	2.493	;	Polyextremophilic Beta-galactosidase from the Antarctic haloarchaeon Halorubrum lacusprofundi
1IA5	;	2.0	;	POLYGALACTURONASE FROM ASPERGILLUS ACULEATUS
1BHE	;	1.9	;	POLYGALACTURONASE FROM ERWINIA CAROTOVORA SSP. CAROTOVORA
5X2I	;	2.05	;	Polygalacturonate Lyase by Fusing with a Self-assembling Amphipathic Peptide
1KW4	;	1.75	;	Polyhomeotic SAM domain structure
5B08	;	1.325	;	Polyketide cyclase OAC from Cannabis sativa
5B09	;	1.7	;	Polyketide cyclase OAC from Cannabis sativa bound with Olivetolic acid
5B0A	;	2.1	;	Polyketide cyclase OAC from Cannabis sativa, H5Q mutant
5B0G	;	1.4	;	Polyketide cyclase OAC from Cannabis sativa, H78S mutant
5B0B	;	2.187	;	Polyketide cyclase OAC from Cannabis sativa, I7F mutant
5B0E	;	1.603	;	Polyketide cyclase OAC from Cannabis sativa, V59M mutant
5B0C	;	1.602	;	Polyketide cyclase OAC from Cannabis sativa, Y27F mutant
5B0D	;	1.801	;	Polyketide cyclase OAC from Cannabis sativa, Y27W mutant
5B0F	;	1.6	;	Polyketide cyclase OAC from Cannabis sativa, Y72F mutant
7W6E	;	1.38	;	Polyketide cyclase OAC-F24I mutant from Cannabis sativa in complex with 6-heptylresorcylic acid
7W6F	;	1.58	;	Polyketide cyclase OAC-F24I mutant from Cannabis sativa in complex with 6-nonylresorcylic acid
7W6D	;	1.54	;	Polyketide cyclase OAC-F24I mutant from Cannabis sativa in complex with olivetolic acid
5L40	;	1.6	;	polyketide ketoreductase SimC7 - apo crystal form 1
5L45	;	1.9	;	polyketide ketoreductase SimC7 - apo crystal form 2
5L3Z	;	1.95	;	polyketide ketoreductase SimC7 - binary complex with NADP+
5L4L	;	1.2	;	polyketide ketoreductase SimC7 - ternary complex with NADP+ and 7-oxo-SD8
8IHA	;	1.56	;	Polyketone cyclase Rv2186c in Mycobacterium tuberculosis H37Rv
7V4V	;	2.3	;	polylysine induce assembly of Thermotoga maritima ferritin
1LCU	;	3.5	;	Polylysine Induces an Antiparallel Actin Dimer that Nucleates Filament Assembly: Crystal Structure at 3.5 A Resolution
4MKY	;	2.4	;	Polymerase Domain from Mycobacterium tuberculosis Ligase D in complex with an annealed double-strand DNA break.
2R9L	;	2.4	;	Polymerase Domain from Mycobacterium tuberculosis Ligase D in complex with DNA
3PKY	;	3.1	;	Polymerase Domain from Mycobacterium tuberculosis Ligase D in complex with DNA, UTP and Manganese.
6XBU	;	3.29	;	polymerase domain of polymerase-theta
6D0Z	;	1.75	;	Polymerase Eta cytarabine (AraC) extension ternary complex
6D0M	;	1.832	;	Polymerase Eta post-insertion binary complex with cytarabine (AraC)
6PZ3	;	2.395	;	Polymerase Eta-catalyzed insertion of correct G opposite template cytarabine (AraC) residue
6Q02	;	2.09	;	Polymerase Eta-catalyzed insertion of the mismatched A opposite template cytarabine (AraC) residue
2JW5	;		;	Polymerase Lambda BRCT domain
7ZGP	;	2.7	;	Polymerase module of CPF in complex with Mpe1 and a pre-cleaved CYC1 RNA
7ZGR	;	2.6	;	Polymerase module of yeast CPF in complex with Mpe1, the yPIM of Cft2 and the pre-cleaved CYC1 RNA
7ZGQ	;	2.8	;	Polymerase module of yeast CPF in complex with the yPIM of Cft2
2IHM	;	2.4	;	Polymerase mu in ternary complex with gapped 11mer DNA duplex and bound incoming nucleotide
4Q43	;	2.45	;	Polymerase-damaged DNA complex
4Q44	;	2.71	;	Polymerase-Damaged DNA Complex
4IR1	;	2.38	;	Polymerase-DNA Complex
4IR9	;	2.33	;	Polymerase-DNA complex
4IRC	;	2.67	;	Polymerase-DNA complex
5TXJ	;	1.13	;	Polymorphic form 1 of amyloid-beta derived peptide - IFAEDV
5TXH	;	1.45	;	Polymorphic form 2 of amyloid-beta derived peptide - IFAEDV
239D	;	2.05	;	POLYMORPHISM IN LEFT HANDED DNA: THE CRYSTAL STRUCTURE OF D(CCCGGG)2
8DI3	;	1.5	;	Polymorphism in SARS-CoV-2 Nsp5 main protease reveals differences in cleavage of viral and host substrates
8DJJ	;	2.51	;	Polymorphism in SARS-CoV-2 Nsp5 main protease reveals differences in cleavage of viral and host substrates
8DK8	;	2.6	;	Polymorphism in SARS-CoV-2 Nsp5 main protease reveals differences in cleavage of viral and host substrates
8DKH	;	1.95	;	Polymorphism in SARS-CoV-2 Nsp5 main protease reveals differences in cleavage of viral and host substrates
8DKJ	;	2.11	;	Polymorphism in SARS-CoV-2 Nsp5 main protease reveals differences in cleavage of viral and host substrates
8DKK	;	2.0	;	Polymorphism in SARS-CoV-2 Nsp5 main protease reveals differences in cleavage of viral and host substrates
8DKL	;	1.9	;	Polymorphism in SARS-CoV-2 Nsp5 main protease reveals differences in cleavage of viral and host substrates
8DKZ	;	3.0	;	Polymorphism in SARS-CoV-2 Nsp5 main protease reveals differences in cleavage of viral and host substrates
8DMN	;	2.3	;	Polymorphism in SARS-CoV-2 Nsp5 main protease reveals differences in cleavage of viral and host substrates
8EJ7	;	2.3	;	Polymorphism in SARS-CoV-2 Nsp5 main protease reveals differences in cleavage of viral and host substrates
8EJ9	;	2.5	;	Polymorphism in SARS-CoV-2 Nsp5 main protease reveals differences in cleavage of viral and host substrates
4GP6	;	2.1	;	Polynucleotide kinase
4GP7	;	2.0	;	Polynucleotide kinase
7LD5	;	3.07	;	polynucleotide phosphorylase
4FB3	;	3.79	;	Polyomavirus T-ag binds symmetrical repeats at the viral origin in an asymmetrical manner
1VPS	;	1.9	;	POLYOMAVIRUS VP1 PENTAMER COMPLEXED WITH A DISIALYLATED HEXASACCHARIDE
8PTE	;	1.797	;	Polyoxidovanadate interaction with proteins: crystal structure of lysozyme bound to octadecavanadate ion (structure B)
7ZU6	;	1.183	;	Polyoxidovanadate interaction with proteins: crystal structure of lysozyme bound to tetra-vanadate ion (structure 1)
1GQE	;	1.81	;	Polypeptide Chain Release Factor 2 (RF2) from Escherichia coli
6IC2	;	1.15	;	Polypharmacology of Epacadostat: a Potent and Selective Inhibitor of the Tumor Associated Carbonic Anhydrases IX and XII
1RKK	;		;	POLYPHEMUSIN I NMR SOLUTION STRUCTURE
6ENJ	;	3.7	;	Polyproline-stalled ribosome in the presence of A+P site tRNA and elongation-factor P (EF-P)
6ENU	;	3.1	;	Polyproline-stalled ribosome in the presence of elongation-factor P (EF-P)
7XFD	;	2.2	;	Polysaccharide export protein Wza
7XFF	;	2.3	;	Polysaccharide export protein Wza
5NO8	;	1.7	;	Polysaccharide Lyase BACCELL_00875
5NOA	;	1.26	;	Polysaccharide Lyase BACCELL_00875
5NOK	;	2.24	;	Polysaccharide Lyase BACCELL_00875
7SHG	;	2.5	;	Polysaccharide ribofuranosyl transferase from Thermobacillus composti
3K91	;	1.75	;	Polysulfane Bridge in Cu-Zn Superoxide Dismutase
2VPZ	;	2.4	;	Polysulfide reductase native structure
2VPW	;	3.1	;	Polysulfide reductase with bound menaquinone
2VPX	;	3.1	;	Polysulfide reductase with bound quinone (UQ1)
2VPY	;	2.5	;	Polysulfide reductase with bound quinone inhibitor, pentachlorophenol (PCP)
6F36	;	3.7	;	Polytomella Fo model
8T9L	;	7.0	;	Pom34-Pom152 membrane attachment site yeast NPC
8C50	;	7.6	;	Pontibacter korlensis curli subunit CsgA
1QR1	;	2.4	;	POOR BINDING OF A HER-2/NEU EPITOPE (GP2) TO HLA-A2.1 IS DUE TO A LACK OF INTERACTIONS IN THE CENTER OF THE PEPTIDE
8OZ4	;	3.1	;	Populus tremula stable protein 1 with an alternate crystal lattice
8OZO	;	2.4	;	Populus tremula stable protein 1 with N-terminal binding peptide extension
8OZS	;	2.4	;	Populus tremula stable protein 1 with N-terminal binding peptide extension with hemin
4USS	;	2.5	;	Populus trichocarpa glutathione transferase X1-1 (GHR1), complexed with glutathione
5NQ0	;	1.1	;	Porcine (Sus scrofa) Major Histocompatibility Complex, class I, presenting DFEREGYSL
5NPZ	;	1.43	;	Porcine (Sus scrofa) Major Histocompatibility Complex, class I, presenting EFEDLTFLA
5NQ1	;	2.14	;	Porcine (Sus scrofa) Major Histocompatibility Complex, class I, with human beta2 micro globulin, presenting DFEREGYSL
3FX4	;	1.99	;	Porcine aldehyde reductase in ternary complex with inhibitor
6ZMR	;	3.94	;	Porcine ATP synthase Fo domain
6ZNA	;	6.2	;	Porcine ATP synthase Fo domain
5BNI	;	2.5	;	Porcine CD38 complexed with complexed with a covalent intermediate, ribo-F-ribose-5'-phosphate
6WDZ	;	2.03	;	Porcine circovirus 2 Rep domain complexed with a single-stranded DNA 10-mer comprising the cleavage site
1SDB	;	1.65	;	PORCINE DESB1-2 DESPENTAPEPTIDE(B26-B30) INSULIN
7LJS	;	2.0	;	Porcine Dihydropyrimidine dehydrogenase (DPD) complexed with 5-Ethynyluracil (5EU) - Open Form
7LJU	;	1.87	;	Porcine Dihydropyrimidine Dehydrogenase (DPD) crosslinked with 5-Ethynyluracil (5EU)
7LJT	;	1.98	;	Porcine Dihydropyrimidine Dehydrogenase (DPD) soaked with 5-Ethynyluracil (5EU), NADPH - 20 minutes
2AJC	;	1.95	;	Porcine dipeptidyl peptidase IV (CD26) in complex with 4-(2-Aminoethyl)-benzene sulphonyl fluoride (AEBSF)
2AJ8	;	2.11	;	Porcine dipeptidyl peptidase IV (CD26) in complex with 7-Benzyl-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione (BDPX)
2AJD	;	2.56	;	Porcine dipeptidyl peptidase IV (CD26) in complex with L-Pro-boro-L-Pro (boroPro)
2AJB	;	2.75	;	Porcine dipeptidyl peptidase IV (CD26) in complex with the tripeptide tert-butyl-Gly-L-Pro-L-Ile (tBu-GPI)
5LLS	;	2.41	;	Porcine dipeptidyl peptidase IV in complex with 8-(3-aminopiperidin-1-yl)-7-[(2-bromophenyl)methyl]-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione
6IAL	;	1.45	;	Porcine E.coli heat-labile enterotoxin B-pentamer in complex with Lacto-N-neohexaose
1LVY	;	1.87	;	PORCINE ELASTASE
1C1M	;	2.2	;	PORCINE ELASTASE UNDER XENON PRESSURE (8 BAR)
8URB	;	3.4	;	Porcine epidemic diarrhea virus complete core polymerase complex
8G6R	;	3.3	;	Porcine epidemic diarrhea virus core polymerase complex
7F0U	;	2.2	;	porcine epidemic diarrhea virus papain-like protease 2 C44S mutant in complex with mono ubiquitin
1PFX	;	3.0	;	PORCINE FACTOR IXA
1X7A	;	2.9	;	Porcine Factor IXa Complexed to 1-{3-[amino(imino)methyl]phenyl}-N-[4-(1H-benzimidazol-1-yl)-2-fluorophenyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide
5LZI	;	1.6	;	Porcine heat-labile enterotoxin R13H in complex with inhibitor MM146
6Z7Z	;	2.4	;	Porcine insulin in complex with the analytical antibody OXI-005 Fab
1VE9	;	2.5	;	Porcine kidney D-amino acid oxidase
1LEV	;	2.15	;	PORCINE KIDNEY FRUCTOSE-1,6-BISPHOSPHATASE COMPLEXED WITH AN AMP-SITE INHIBITOR
2QVU	;	1.5	;	Porcine Liver Fructose-1,6-bisphosphatase cocrystallized with Fru-2,6-P2 and Mg2+, I(T)-state
2QVV	;	2.03	;	Porcine Liver Fructose-1,6-bisphosphatase cocrystallized with Fru-2,6-P2 and Zn2+, I(T)-state
1F8P	;		;	PORCINE NEUROPEPTIDE Y BOUND TO DPC MICELLES
1E00	;	1.83	;	Porcine Odorant Binding Protein Complexed with 2,6-dimethyl-7-octen-2-ol
1DZJ	;	2.0	;	Porcine Odorant Binding Protein Complexed with 2-amino-4-butyl-5-propylselenazole
1E06	;	2.12	;	Porcine Odorant Binding Protein Complexed with 5-methyl-2-(1-methylethyl)phenol
1DZM	;	1.93	;	Porcine Odorant Binding Protein Complexed with benzoic acid phenylmethylester
1DZP	;	1.83	;	Porcine Odorant Binding Protein Complexed with diphenylmethanone
1DZK	;	1.48	;	Porcine Odorant Binding Protein Complexed with pyrazine (2-isobutyl-3-metoxypyrazine)
1E02	;	2.15	;	Porcine Odorant Binding Protein Complexed with undecanal
1SFW	;		;	PORCINE PANCREAS PHOSPHOLIPASE A2, NMR, 18 STRUCTURES
1SFV	;		;	PORCINE PANCREAS PHOSPHOLIPASE A2, NMR, MINIMIZED AVERAGE STRUCTURE
1OSE	;	2.3	;	Porcine pancreatic alpha-amylase complexed with acarbose
4X0N	;	2.6001	;	Porcine pancreatic alpha-amylase in complex with helianthamide, a novel proteinaceous inhibitor
1GVK	;	0.94	;	Porcine pancreatic elastase acyl enzyme at 0.95 A resolution
1QGF	;	1.7	;	PORCINE PANCREATIC ELASTASE COMPLEXED WITH (3R, 4S)N-PARA-TOLUENESULPHONYL-3-ETHYL-4-(CARBOXYLIC ACID)PYRROLIDIN-2-ONE
1BTU	;	1.6	;	PORCINE PANCREATIC ELASTASE COMPLEXED WITH (3S, 4R)-1-TOLUENESULPHONYL-3-ETHYL-AZETIDIN-2-ONE-4-CARBOXYLIC ACID
1E34	;	1.8	;	PORCINE PANCREATIC ELASTASE COMPLEXED WITH (3S, 4S)N-PARA- TOLUENESULPHONYL-3-ETHYL-4-(CARBOXYLIC ACID) PYRROLIDIN-2-ONE SOAKED IN PH 9 BUFFER FOR ONE MINUTE
1E36	;	1.7	;	PORCINE PANCREATIC ELASTASE COMPLEXED WITH (3S, 4S)N-PARA-NITROBENZENESULPHONYL -3-ETHYL-4-(CARBOXYLIC ACID)PYRROLIDIN-2-ONE
1E37	;	1.75	;	PORCINE PANCREATIC ELASTASE COMPLEXED WITH (3S, 4S)N-PARA-NITROBENZENESULPHONYL -3-ETHYL-4-(CARBOXYLIC ACID)PYRROLIDIN-2-ONE SOAKED IN PH 9 BUFFER FOR 1 MINUTE
1E38	;	1.7	;	PORCINE PANCREATIC ELASTASE COMPLEXED WITH (3S, 4S)N-PARA-NITROBENZENESULPHONYL -3-ETHYL-4-(CARBOXYLIC ACID)PYRROLIDIN-2-ONE SOAKED IN PH 9 BUFFER FOR 2 MINUTES
1E35	;	1.9	;	PORCINE PANCREATIC ELASTASE COMPLEXED WITH (3S, 4S)N-PARA-TOLUENESULPHONYL -3-ETHYL-4-(CARBOXYLIC ACID)PYRROLIDIN-2-ONE SOAKED IN PH 9 BUFFER FOR TWO MINUTES
1MMJ	;	2.2	;	Porcine pancreatic elastase complexed with a potent peptidyl inhibitor, FR136706
1H9L	;	1.67	;	PORCINE PANCREATIC ELASTASE COMPLEXED WITH ACETYL-VAL-GLU-PRO-ILE-COOH
2BDB	;	1.7	;	Porcine pancreatic elastase complexed with Asn-Pro-Ile and Ala-Ala at pH 5.0
2BDC	;	1.8	;	Porcine pancreatic elastase complexed with Asn-Pro-Ile at pH 5.0
2BD2	;	1.7	;	Porcine pancreatic elastase complexed with beta-casomorphin-7 and Arg-Phe at pH 5.0
2BD7	;	1.6	;	Porcine pancreatic elastase complexed with beta-casomorphin-7 and Arg-Phe at pH 5.0 (50 min soak)
2BD9	;	1.9	;	Porcine pancreatic elastase complexed with beta-casomorphin-7 and Arg-Phe at pH 5.0 (50 min soak) and immersed in pH 9 buffer for 28 seconds (2nd pH jump)
2BD8	;	1.7	;	Porcine pancreatic elastase complexed with beta-casomorphin-7 and Arg-Phe at pH 5.0 (50 min soak) and immersed in pH 9 buffer for 30 seconds
2BB4	;	1.6	;	Porcine pancreatic elastase complexed with beta-casomorphin-7 and Asp-Phe at pH 5.0
2BD3	;	1.6	;	Porcine pancreatic elastase complexed with beta-casomorphin-7 and Lys-Ala-NH2 at pH 5.0
2BD5	;	1.8	;	Porcine pancreatic elastase complexed with beta-casomorphin-7 and Lys-Ser at pH 5 and immersed in pH 9 buffer for 30 seconds
2BD4	;	1.7	;	Porcine pancreatic elastase complexed with beta-casomorphin-7 and Lys-Ser at pH 5.0
1HV7	;	1.7	;	PORCINE PANCREATIC ELASTASE COMPLEXED WITH GW311616A
1QIX	;	1.9	;	Porcine pancreatic elastase complexed with human beta-casomorphin-7
2H1U	;	1.6	;	Porcine pancreatic elastase complexed with MetPheLeuGlu at pH 5.0
2BDA	;	1.8	;	Porcine pancreatic elastase complexed with N-acetyl-NPI and Ala-Ala at pH 5.0
2V35	;	1.67	;	Porcine Pancreatic Elastase in complex with inhibitor JM54
1LKA	;	1.7	;	Porcine Pancreatic Elastase/Ca-Complex
1LKB	;	1.7	;	Porcine Pancreatic Elastase/Na-Complex
1UO6	;	1.65	;	PORCINE PANCREATIC ELASTASE/Xe-COMPLEX
2PSP	;	1.95	;	Porcine pancreatic spasmolytic polypeptide
1K3V	;	3.5	;	Porcine Parvovirus Capsid
6XCT	;	1.99	;	Porcine pepsin in complex with amprenavir
6XD2	;	1.9	;	Porcine pepsin in complex with darunavir
6XCY	;	2.05	;	Porcine pepsin in complex with ritonavir
6XCZ	;	1.89	;	Porcine pepsin in complex with saquinavir
5I65	;		;	Porcine reproductive and respiratory syndrome virus nonstructural protein 7 alpha (nsp7 alpha)
2BNH	;	2.3	;	PORCINE RIBONUCLEASE INHIBITOR
1S83	;	1.25	;	PORCINE TRYPSIN COMPLEXED WITH 4-AMINO PROPANOL
1S82	;	1.85	;	PORCINE TRYPSIN COMPLEXED WITH BORATE AND ETHYLENE GLYCOL
1S5S	;	1.4	;	Porcine trypsin complexed with guanidine-3-propanol inhibitor
1S6H	;	1.45	;	PORCINE TRYPSIN COMPLEXED WITH GUANIDINE-3-PROPANOL INHIBITOR
1S85	;	2.2	;	PORCINE TRYPSIN COMPLEXED WITH P-HYDROXYMETHYL BENZAMIDINE AND BORATE
1S84	;	1.85	;	PORCINE TRYPSIN COVALENT COMPLEX WITH 4-AMINO BUTANOL, BORATE AND ETHYLENE GLYCOL
1S6F	;	1.8	;	PORCINE TRYPSIN COVALENT COMPLEX WITH BORATE AND GUANIDINE-3 INHIBITOR
1S81	;	1.7	;	PORCINE TRYPSIN WITH NO INHIBITOR BOUND
8JJ5	;	3.5	;	Porcine uroplakin complex
4I0N	;	1.8	;	Pore forming protein
4P24	;	3.1	;	pore forming toxin
6KLX	;	2.9	;	Pore structure of Iota toxin binding component (Ib)
7T4D	;	3.0	;	Pore structure of pore-forming toxin Epx4
3W9T	;	2.9	;	pore-forming CEL-III
4WX3	;	1.701	;	pore-forming thermostable direct hemolysin from Grimontia hollisae
4WX5	;	2.302	;	pore-forming thermostable direct hemolysin from Grimontia hollisae
6Q61	;	1.3	;	Pore-modulating toxins exploit inherent slow inactivation to block K+ channels
6Q6C	;	1.3	;	Pore-modulating toxins exploit inherent slow inactivation to block K+ channels
3POR	;	2.5	;	PORIN CONFORMATION IN THE ABSENCE OF CALCIUM; REFINED STRUCTURE AT 2.5 ANGSTROMS RESOLUTION
7TLS	;	0.73	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
7TLU	;	0.79	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
7TM1	;	1.1	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
7TM2	;	0.88	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
7TMA	;	1.0	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
7TME	;	0.8	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
7TMH	;	0.8	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
7TMI	;	0.8	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
7TMJ	;	1.0	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
7TMK	;	0.83	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
7TML	;	0.93	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
8GB9	;	1.0	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
8GBA	;	0.89	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
8GBH	;	1.02	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
8GBI	;	0.95	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
8GBM	;	1.04	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
8GBO	;	1.06	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
8GD6	;	0.91	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
8GD8	;	1.04	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
8GIV	;	0.99	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
8GJ7	;	1.19	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
8GK1	;	0.83	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
8GK2	;	0.89	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
8GK9	;	0.97	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
8GKB	;	0.95	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
8GKX	;	0.81	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
8GL0	;	1.02	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
8GL4	;	0.76	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
8GL5	;	1.02	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
8SW2	;	1.2	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
8SY4	;	0.95	;	Porous framework formed by assembly of a bipyridyl-conjugated helical peptide
4HTG	;	1.45	;	Porphobilinogen Deaminase from Arabidopsis Thaliana
5H6O	;	2.702	;	Porphobilinogen deaminase from Vibrio Cholerae
2WOQ	;	1.75	;	Porphobilinogen Synthase (HemB) in Complex with 5-acetamido-4- oxohexanoic acid (Alaremycin 2)
4RBM	;	1.75	;	Porphyromonas gingivalis gingipain K (Kgp) catalytic and immunoglobulin superfamily-like domains
6I9A	;	1.2	;	Porphyromonas gingivalis gingipain K (Kgp) in complex with inhibitor KYT-36
6I0X	;	1.6	;	Porphyromonas gingivalis peptidylarginine deminase (PPAD) mutant G231N/E232T/N235D in complex with Cl-amidine.
7EY8	;	3.4	;	portal
6IAC	;	3.9	;	Portal and tail of native bacteriophage P68
8FWB	;	3.14	;	Portal assembly of Agrobacterium phage Milano
8PHO	;	2.34	;	Portal from the Borrelia bacteriophage BB1 procapsid
8PHP	;	2.56	;	Portal from the Borrelia bacteriophage BB1 procapsid with bound scaffold protein
7Z44	;	3.6	;	Portal of bacteriophage SU10
2JES	;	3.4	;	Portal protein (gp6) from bacteriophage SPP1
7QOG	;	3.09	;	Portal protein assembly of the phicrAss001 virion with C12 symmetry imposed
8FQL	;	3.6	;	Portal vertex of HK97 phage
6UZC	;	4.5	;	Portal vertex structure of bacteriophage T4
8JOV	;	3.8	;	Portal-tail complex of phage GP4
8I4M	;	3.81	;	Portal-tail complex structure of the Cyanophage P-SCSP1u
6FDB	;	3.619	;	Positively supercharged variant of the computationally designed cage protein O3-33
3R0A	;	2.31	;	Possible transcriptional regulator from Methanosarcina mazei Go1 (gi 21227196)
6SA1	;	2.01	;	Post catalytic complex of Prim-PolC from Mycobacterium smegmatis with gapped DNA and 3'-dUTP
7COD	;	1.8	;	Post insertion complex of DNA polymerase Mu (K438A/Q441A) with 1-nt gapped DNA
7ST2	;	2.9	;	Post translocation, non-rotated 70S ribosome with EF-G dissociated (Structure VII)
7R6M	;	3.68	;	Post-2S intermediate of the Tetrahymena group I intron, symmetry-expanded monomer from a synthetic dimeric construct
6IPE	;	1.7	;	Post-catalytic Complex of Human DNA Polymerase Mu with Templating Adenine and Mg-8oxodGMP
6IPD	;	1.7	;	Post-catalytic Complex of Human DNA Polymerase Mu with Templating Adenine and Mn-8oxodGMP
6IPG	;	1.62	;	Post-catalytic Complex of Human DNA Polymerase Mu with Templating Cytosine and Mg-8oxodGMP
6IPF	;	1.77	;	Post-catalytic Complex of Human DNA Polymerase Mu with Templating Cytosine and Mn-8oxodGMP
5VZ9	;	1.65	;	Post-catalytic complex of human Polymerase Mu (G433A) mutant with incoming dTTP
5VZ8	;	1.601	;	Post-catalytic complex of human Polymerase Mu (G433A) mutant with incoming UTP
5VZC	;	1.552	;	Post-catalytic complex of human Polymerase Mu (G433S) mutant with incoming dTTP
5VZB	;	1.5	;	Post-catalytic complex of human Polymerase Mu (G433S) mutant with incoming UTP
5TWS	;	1.85	;	Post-catalytic complex of human Polymerase Mu (H329A) with newly incorporated UTP
5VZF	;	1.65	;	Post-catalytic complex of human Polymerase Mu (W434A) mutant with incoming dTTP
5VZE	;	1.506	;	Post-catalytic complex of human Polymerase Mu (W434A) mutant with incoming UTP
5VZI	;	1.5	;	Post-catalytic complex of human Polymerase Mu (W434H) mutant with incoming dTTP
5VZH	;	1.95	;	Post-catalytic complex of human Polymerase Mu (W434H) mutant with incoming UTP
7M08	;	1.7	;	Post-catalytic nicked complex of DNA Polymerase Lambda with bound 1-nt gapped SSB substrate and incoming dUMPNPP
7M0C	;	2.65	;	Post-catalytic nicked complex of DNA Polymerase Lambda with bound mismatched DSB substrate
6P1S	;	1.75	;	Post-catalytic nicked complex of human DNA Polymerase Mu with 1-nt gapped substrate containing template 8OG and newly incorporated AMP
6P1U	;	1.75	;	Post-catalytic nicked complex of human DNA Polymerase Mu with 1-nt gapped substrate containing template 8OG and newly incorporated CMP
6P1O	;	1.65	;	Post-catalytic nicked complex of human DNA Polymerase Mu with 1-nt gapped substrate containing template 8OG and newly incorporated dAMP
6P1Q	;	1.9	;	Post-catalytic nicked complex of human DNA Polymerase Mu with 1-nt gapped substrate containing template 8OG and newly incorporated dCMP
6WIE	;	1.5	;	Post-catalytic nicked complex of human Polymerase Mu on a complementary DNA double-strand break substrate
5TWQ	;	1.8	;	Post-catalytic nicked complex of human Polymerase Mu with newly incorporated UTP
6EXN	;	3.7	;	Post-catalytic P complex spliceosome with 3' splice site docked
2GCV	;	2.1	;	Post-cleavage state of the Thermoanaerobacter tengcongensis glmS ribozyme
2H0W	;	2.4	;	Post-cleavage state of the Thermoanaerobacter tengcongensis glmS ribozyme
2HO6	;	2.8	;	Post-cleavage state of the Thermoanaerobacter tengcongensis glmS ribozyme
6S8C	;	2.57	;	Post-fusion conformation of the envelope protein of tick-borne encephalitis virus with longer stem
7UHZ	;	3.3	;	Post-fusion ectodomain of HSV-1 gB in complex with BMPC-23 Fab
7UI0	;	3.4	;	Post-fusion ectodomain of HSV-1 gB in complex with HSV010-13 Fab
1WYY	;	2.2	;	Post-fusion hairpin conformation of the sars coronavirus spike glycoprotein
6M3W	;	3.9	;	Post-fusion structure of SARS-CoV spike glycoprotein
3BQ2	;	2.7	;	Post-insertion binary complex of Dbh DNA polymerase
2V4Q	;	2.6	;	Post-insertion complex of the Y-family DNA polymerase Dpo4 with M1dG containing template DNA
8K7B	;	3.9	;	post-occluded structure of human ABCB6 W546A mutant (ADP/VO4-bound)
2FLC	;	2.59	;	Post-Reactive Complex of Restriction Endonuclease HinP1I with Nicked Cognate DNA and Magnesium Ions
2LLT	;		;	Post-translational S-nitrosylation is an endogenous factor fine-tuning human S100A1 protein properties
2LLU	;		;	Post-translational S-nitrosylation is an endogenous factor fine-tuning human S100A1 protein properties
5TBA	;	2.49	;	Postcatalytic ternary complex of Human DNA Polymerase Beta with Gapped DNA substrate, incorporated (-)3TC and PPi.
5TBB	;	2.39	;	Postcatalytic ternary complex of Human DNA Polymerase Beta with Gapped DNA substrate, incorporated (-)FTC and PPi.
4W4G	;	3.3	;	Postcleavage state of 70S bound to HigB toxin and AAA (lysine) codon
8DMJ	;	3.2	;	Postfusion Nipah virus fusion protein in complex with Fab 1H1
5L1K	;	1.82	;	PostInsertion complex of Human DNA Polymerase Eta bypassing an O6-Methyl-2'-deoxyguanosine : dC site
5L1L	;	1.62	;	PostInsertion complex of Human DNA Polymerase Eta bypassing an O6-Methyl-2'-deoxyguanosine : dT site
6RAU	;	1.99	;	PostS3_Pmar_lig4_WT
3ZD8	;	2.0	;	Potassium bound structure of E. coli ExoIX in P1
3ZD9	;	2.0	;	Potassium bound structure of E. coli ExoIX in P21
8HK6	;	2.64	;	potassium channel
1BL8	;	3.2	;	POTASSIUM CHANNEL (KCSA) FROM STREPTOMYCES LIVIDANS
1F6G	;		;	POTASSIUM CHANNEL (KCSA) FULL-LENGTH FOLD
1JQ1	;		;	POTASSIUM CHANNEL (KCSA) OPEN GATE MODEL
1JQ2	;		;	POTASSIUM CHANNEL (KCSA) OPEN GATE MODEL
1AV3	;		;	POTASSIUM CHANNEL BLOCKER KAPPA CONOTOXIN PVIIA FROM C. PURPURASCENS, NMR, 20 STRUCTURES
2WLL	;	3.65	;	POTASSIUM CHANNEL FROM BURKHOLDERIA PSEUDOMALLEI
2WLH	;	3.28	;	POTASSIUM CHANNEL FROM MAGNETOSPIRILLUM MAGNETOTACTICUM
2WLI	;	3.09	;	POTASSIUM CHANNEL FROM MAGNETOSPIRILLUM MAGNETOTACTICUM
2WLJ	;	2.6	;	Potassium channel from Magnetospirillum magnetotacticum
2WLM	;	3.61	;	POTASSIUM CHANNEL FROM MAGNETOSPIRILLUM MAGNETOTACTICUM
2WLN	;	3.44	;	POTASSIUM CHANNEL FROM MAGNETOSPIRILLUM MAGNETOTACTICUM
2WLO	;	4.036	;	POTASSIUM CHANNEL FROM MAGNETOSPIRILLUM MAGNETOTACTICUM
2X6A	;	3.1	;	Potassium Channel from Magnetospirillum Magnetotacticum
2X6B	;	3.3	;	Potassium Channel from Magnetospirillum Magnetotacticum
2X6C	;	2.7	;	Potassium Channel from Magnetospirillum Magnetotacticum
2JK5	;	2.4	;	Potassium Channel KcsA in complex with Tetrabutylammonium in high K
2NLJ	;	2.52	;	Potassium Channel KcsA(M96V)-Fab complex in KCl
2ITD	;	2.7	;	Potassium Channel KcsA-Fab complex in Barium Chloride
1R3L	;	2.41	;	potassium channel KcsA-Fab complex in Cs+
1K4C	;	2.0	;	Potassium Channel KcsA-Fab complex in high concentration of K+
1R3J	;	1.9	;	potassium channel KcsA-Fab complex in high concentration of Tl+
3GB7	;	2.85	;	Potassium Channel KcsA-Fab complex in Li+
3IGA	;	2.75	;	Potassium Channel KcsA-Fab complex in Li+ and K+
1K4D	;	2.3	;	Potassium Channel KcsA-Fab complex in low concentration of K+
1R3K	;	2.8	;	potassium channel KcsA-Fab complex in low concentration of Tl+
1R3I	;	2.4	;	potassium channel KcsA-Fab complex in Rb+
2ITC	;	3.2	;	Potassium Channel KcsA-Fab complex in Sodium Chloride
2BOB	;	2.76	;	Potassium channel KcsA-Fab complex in thallium with tetrabutylammonium (TBA)
2BOC	;	3.01	;	Potassium channel KcsA-Fab complex in thallium with tetraethylarsonium (TEAs)
1S5H	;	2.2	;	Potassium Channel Kcsa-Fab Complex T75C mutant in K+
2HJF	;	2.9	;	Potassium channel kcsa-fab complex with tetrabutylammonium (TBA)
2W0F	;	2.4	;	Potassium Channel KcsA-Fab Complex with Tetraoctylammonium
4UUJ	;	2.4	;	POTASSIUM CHANNEL KCSA-FAB WITH TETRAHEXYLAMMONIUM
8HIR	;	3.18	;	potassium channels
1K4X	;		;	POTASSIUM FORM OF OXY-1.5 QUADRUPLEX DNA
3ZDE	;	2.45	;	Potassium free structure of E. coli ExoIX
8WTZ	;	3.1	;	potassium outward rectifier channel SKOR
8K1S	;	2.83	;	Potassium transporter KtrAB from Bacillus subtilis in ADP-bound state
8K1U	;	2.82	;	Potassium transporter KtrAB from Bacillus subtilis in ATP-bound state with addition of EDTA and EGTA
8XMI	;	3.0	;	Potassium transporter KtrAB from Bacillus subtilis in ATP-bound state with addition of EDTA and EGTA, C1 symmetry
8XMH	;	2.85	;	Potassium transporter KtrAB from Bacillus subtilis in ATP-bound state with addition of EDTA and EGTA, vertical C2 symmetry axis
8K1T	;	2.48	;	Potassium transporter KtrAB from Bacillus subtilis in ATP-bound state with addition of MgCl2
4G65	;	2.09	;	Potassium transporter peripheral membrane component (trkA) from Vibrio vulnificus
8HEW	;	2.59	;	Potato 14-3-3 St14f
6LX1	;	2.03	;	Potato D-enzyme complexed with Acarbose
6LX2	;	2.05	;	Potato D-enzyme complexed with CA26
7COV	;	2.0	;	Potato D-enzyme, native (substrate free)
7ULO	;	2.21	;	Potato leafroll virus N-terminal readthrough domain
6HXX	;	3.4	;	Potato virus Y
8B2N	;	1.85	;	Potempin A (PotA) from Tannerella forsythia in complex with the catalytic domain of human MMP-12
4GB9	;	2.438	;	Potent and Highly Selective Benzimidazole Inhibitors of PI3K-delta
6F2U	;	1.88	;	Potent and selective Aldo-Keto Reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a Bioisosteric Scaffold Hopping Approach to Flufenamic acid
6F78	;	1.3	;	Potent and selective Aldo-Keto Reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: Application of a Bioisosteric Scaffold Hopping Approach to Flufenamic acid
6BA5	;	1.62	;	Potent and Selective Antitumor Activity of a T-Cell Engaging Bispecific Antibody Targeting a Membrane-Proximal Epitope of ROR1
6BAN	;	1.95	;	Potent and Selective Antitumor Activity of a T-Cell Engaging Bispecific Antibody Targeting a Membrane-Proximal Epitope of ROR1
6OSH	;	1.117	;	Potent and Selective Antitumor Antibody Targeting a Membrane-Proximal Epitope of ROR2
6OSN	;	1.083	;	Potent and Selective Antitumor Antibody Targeting a Membrane-Proximal Epitope of ROR2
6OSV	;	1.34	;	Potent and Selective Antitumor Antibody Targeting a Membrane-Proximal Epitope of ROR2
3QN7	;	1.9	;	Potent and selective bicyclic peptide inhibitor (UK18) of human urokinase-type plasminogen activator(uPA)
5ANS	;	1.6	;	Potent and selective inhibitors of MTH1 probe its role in cancer cell survival
5ANT	;	2.0	;	Potent and selective inhibitors of MTH1 probe its role in cancer cell survival
4EZJ	;	2.67	;	Potent and Selective Inhibitors of PI3K-delta: Obtaining Isoform Selectivity from the Affinity Pocket and Tryptophan Shelf
4EZK	;	2.803	;	Potent and Selective Inhibitors of PI3K-delta: Obtaining Isoform Selectivity from the Affinity Pocket and Tryptophan Shelf
4EZL	;	2.94	;	Potent and Selective Inhibitors of PI3K-delta: Obtaining Isoform Selectivity from the Affinity Pocket and Tryptophan Shelf
2P83	;	2.5	;	Potent and selective isophthalamide S2 hydroxyethylamine inhibitor of BACE1
4FCB	;	2.1	;	Potent and Selective Phosphodiesterase 10A Inhibitors
4FCD	;	2.02	;	Potent and Selective Phosphodiesterase 10A Inhibitors
3I25	;	2.1	;	Potent Beta-Secretase 1 hydroxyethylene Inhibitor
3IXK	;	2.5	;	Potent beta-secretase 1 inhibitor
5TUS	;	2.66	;	Potent competitive inhibition of human ribonucleotide reductase by a novel non-nucleoside small molecule
1V2N	;	1.8	;	Potent factor XA inhibitor in complex with bovine trypsin variant X(99/175/190)bT
3W19	;	1.278	;	Potent HIV fusion inhibitor CP32M-2
1JLD	;	2.5	;	Potent hiv protease inhibitors containing a novel (hydroxyethyl)amide isostere
3U1Y	;	2.0	;	Potent Inhibitors of LpxC for the Treatment of Gram-Negative Infections
5NQR	;	2.2	;	Potent inhibitors of NUDT5 silence hormone signaling in breast cancer
5NWH	;	2.6	;	Potent inhibitors of NUDT5 silence hormone signaling in breast cancer
8FIU	;	1.56	;	Potent long-acting inhibitors targeting HIV-1 capsid based on a versatile quinazolin-4-one scaffold
3OWN	;	2.0	;	Potent macrocyclic renin inhibitors
7N9A	;	3.5	;	Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting novel and conserved epitopes-CovS RBD with NB21
7N9B	;	3.8	;	Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting novel and conserved epitopes-CovS with NB21
7N9E	;	3.52	;	Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting novel and conserved epitopes-CovS with NB34
7N9C	;	3.71	;	Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting novel and conserved epitopes-CovS with NB95
7KZA	;	1.69	;	Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1antibodies
7KZB	;	2.83	;	Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1antibodies
7KZC	;	2.3	;	Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1antibodies
5E7V	;	2.4	;	Potent Vitamin D Receptor Agonist
2ZEB	;	2.5	;	Potent, Nonpeptide Inhibitors of Human Mast Cell Tryptase
2ZEC	;	2.059	;	Potent, Nonpeptide Inhibitors of Human Mast Cell Tryptase
5JHU	;	1.8	;	Potent, Reversible MetAP2 Inhibitors via FBDD
5JI6	;	2.15	;	Potent, Reversible MetAP2 Inhibitors via FBDD
5JFR	;	1.6	;	Potent, Reversible MetAP2 Inhibitors via Fragment Based Drug Discovery
5A2S	;	2.65	;	Potent, selective and CNS-penetrant tetrasubstituted cyclopropane class IIa histone deacetylase (HDAC) inhibitors
1NZ7	;	2.4	;	POTENT, SELECTIVE INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B USING A SECOND PHOSPHOTYROSINE BINDING SITE, complexed with compound 19.
1NL9	;	2.4	;	Potent, Selective Protein Tyrosine Phosphatase 1B Inhibitor Compound 12 Using a Linked-Fragment Strategy
1NNY	;	2.4	;	Potent, Selective Protein Tyrosine Phosphatase 1B Inhibitor Compound 23 Using a Linked-Fragment Strategy
1NO6	;	2.4	;	Potent, Selective Protein Tyrosine Phosphatase 1B Inhibitor Compound 5 Using a Linked-Fragment Strategy
1NC6	;	1.9	;	Potent, small molecule inhibitors of human mast cell tryptase. Anti-asthmatic action of a dipeptide-based transition state analogue containing benzothiazole ketone
8AT0	;	2.0	;	PotF with mutation D247K
8ASZ	;	1.28	;	PotF with mutations S87Y and A182D in complex with Agmatine
3MC9	;	2.2	;	POTRA1-2 of the periplasmic domain of Omp85 from Anabaena
3MC8	;	2.59	;	POTRA1-3 of the periplasmic domain of Omp85 from Anabaena
6NFW	;		;	Potyvirus viral protein genome linked (VPg) emulates the m7G cap to recruit the eukaryotic translation initiation factor eIF4E
3L1P	;	2.8	;	POU protein:DNA complex
7KYL	;	2.0	;	Powassan virus Envelope protein DIII in complex with neutralizing Fab POWV-80
7P7R	;	2.9	;	PoxtA-EQ2 antibiotic resistance ABCF bound to E. faecalis 70S ribosome, state I
7P7S	;	3.0	;	PoxtA-EQ2 antibiotic resistance ABCF bound to E. faecalis 70S ribosome, state II
7P7T	;	2.9	;	PoxtA-EQ2 antibiotic resistance ABCF bound to E. faecalis 70S ribosome, state III
5C5J	;	2.1	;	Poymerase Nucleotide complex
6OBQ	;	1.84	;	PP1 H66K in complex with Microcystin LR
6OBR	;	1.5	;	PP1 Y134A in complex with Microcystin LR
6OBS	;	1.803	;	PP1 Y134K
6OBU	;	1.95	;	PP1 Y134K in complex with Microcystin LR
4I5J	;	2.091	;	PP2A PR70 Holoenzyme
4I5K	;	2.9	;	PP2A PR70 Holoenzyme model3_diCa_rcsb.pdb bppnat5_extend.mtz
3C5V	;	2.0	;	PP2A-specific methylesterase apo form (PME)
4RA2	;	1.94	;	PP2Ca
6R8I	;	1.517	;	PP4R3A EVH1 domain bound to FxxP motif
1WAO	;	2.9	;	PP5 structure
2QUD	;	1.6	;	PP7 Coat Protein Dimer
2QUX	;	2.44	;	PP7 coat protein dimer in complex with RNA hairpin
3OZ0	;	3.0	;	PPAR Delta in complex with azppard02
6FZP	;	2.3	;	PPAR gamma complex.
7SQB	;	2.6	;	PPAR gamma LBD bound to Inverse Agonist SR10221
7SQA	;	2.499	;	PPAR gamma LBD bound to SR10221 and SMRT corepressor motif
6D8X	;	1.9	;	PPAR gamma LBD complexed with the agonist GW1929
6TDC	;	2.328	;	PPAR gamma ligand binding domain in complex with MRL-871
6FZG	;	2.1	;	PPAR gamma mutant complex
6FZJ	;	2.011	;	PPAR gamma mutant complex
6FZY	;	3.1	;	PPAR mutant
6T1S	;	1.65	;	PPAR mutant
6FZF	;	1.95	;	PPAR mutant complex
3PEQ	;	2.4	;	PPARd complexed with a phenoxyacetic acid partial agonist
3DY6	;	2.9	;	PPARdelta complexed with an anthranilic acid partial agonist
8DSY	;	2.95	;	PPARg bound to inverse agonist H3B-343
8DKV	;	1.59	;	PPARg bound to JTP-426467 and Co-R peptide
8DSZ	;	2.5	;	PPARg bound to partial agonist H3B-487
8DKN	;	1.95	;	PPARg bound to T0070907 and Co-R peptide
6E5A	;	2.4	;	PPARg in complex with compound 4b
7QB1	;	2.2	;	PPARg in complex with inhibitor
6C5Q	;	2.404	;	PPARg LBD bound to SR10171
6C5T	;	2.75	;	PPARg LBD bound to SR11023
6D3E	;	2.395	;	PPARg LBD in Complex with SR1988
7WOX	;	3.2	;	PPARgamma antagonist (MMT-160)- PPARgamma LBD complex
5LSG	;	2.0	;	PPARgamma complex with the betulinic acid
1WM0	;	2.9	;	PPARgamma in complex with a 2-BABA compound
2POB	;	2.3	;	PPARgamma Ligand binding domain complexed with a farglitazar analogue gw4709
4XUM	;	2.4	;	PPARgamma ligand binding domain in complex with indomethacin
4XUH	;	2.22	;	PPARgamma ligand binding domain in complex with sulindac sulfide
5JI0	;	1.98	;	PPARgamma-RXRalpha(S427F) heterodimer in complex with SRC-1, rosiglitazone, and 9-cis-retanoic acid
1MVL	;	2.0	;	PPC decarboxylase mutant C175S
1MVN	;	2.21	;	PPC decarboxylase mutant C175S complexed with pantothenoylaminoethenethiol
3SJ1	;	1.9	;	PpcA M58D mutant
3SEL	;	2.1	;	PpcA M58N mutant
3SJ4	;	1.9	;	PpcA mutant M58K
3SJ0	;	2.0	;	PpcA mutant M58S
3BXU	;	1.35	;	PpcB, A Cytochrome c7 from Geobacter sulfurreducens
3H33	;	2.25	;	PpcC, A cytochrome c7 from Geobacter sulfurreducens
3H4N	;	1.35	;	PpcD, A cytochrome c7 from Geobacter sulfurreducens
3H34	;	1.6	;	PpcE, A cytochrome c7 from Geobacter sulfurreducens
6DMD	;	2.65	;	ppGpp Riboswitch bound to ppGpp, manganese chloride structure
6DMC	;	2.2	;	ppGpp Riboswitch bound to ppGpp, native structure
6DME	;	2.702	;	ppGpp Riboswitch bound to ppGpp, thallium acetate structure
1HXV	;		;	PPIASE DOMAIN OF THE MYCOPLASMA GENITALIUM TRIGGER FACTOR
4TYO	;	1.75	;	PPIase in complex with a non-phosphate small molecule inhibitor.
5X1T	;	1.55	;	PpkA-294
5X1R	;	1.6	;	PpkA-294 apo form
5X1S	;	1.45	;	PpkA-294 with Amppcp
5X1Q	;	1.602	;	PpkA-294 with ATP and MnCl2
5YRG	;	1.5	;	PPL3A-isomaltose complex
5YRF	;	1.7	;	PPL3A-trehalose complex
5YRJ	;	1.8	;	PPL3B-isomaltose complex
5YRI	;	1.65	;	PPL3B-trehalose complex
5YRM	;	1.5	;	PPL3C-isomaltose complex
5YRL	;	2.1	;	PPL3C-trehalose complex
1RKY	;	1.68	;	PPLO + Xe
1W7C	;	1.23	;	PPLO at 1.23 Angstroms
2OB2	;	1.92	;	ppm1 in the absence of 1,8-ANS (cf 1JD)
2OB1	;	1.9	;	ppm1 with 1,8-ANS
6JKV	;	2.1	;	PppA, a key regulatory component of T6SS in Pseudomonas aeruginosa
1HKQ	;	2.75	;	PPS10 plasmid DNA replication initiator protein RepA. Replication inactive, dimeric N-terminal domain.
8A8E	;	2.9	;	PPSA C terminal octahedral structure
6RN5	;	2.037	;	PptA from Streptomyces chartreusis
6CT5	;	1.75935	;	PptT PAP(CoA) 8918 complex
7N8M	;	1.57	;	PptT PAP(CoA) 8978B complex
7N8L	;	2.26	;	PptT PAP(CoA) 9016 complex
7N8E	;	1.74	;	PptT PAP(CoA) 9056 complex
7WMK	;	1.47	;	PQQ-dependent alcohol dehydrogenase complexed with PQQ
7WMD	;	2.0	;	PQQ-dependent alcohol dehydrogenase detoxifying DON
7CE9	;	2.2	;	PQQ-soaked Apo-methanol dehydrogenase (MDH) from Methylococcus capsulatus (Bath)
1OTV	;	2.1	;	PqqC, Pyrroloquinolinquinone Synthase C
5OQ4	;	2.7	;	PQR309 - a Potent, Brain-Penetrant, Orally Bioavailable, pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology
6OAC	;	3.15	;	PQR530 [(S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine] bound to the PI3Ka catalytic subunit p110alpha
6TPR	;	3.2	;	PqsR (MvfR) bound to inhibitory compound 40
6Z07	;	2.95	;	PqsR (MvfR) in complex with antagonist 12
6Z5K	;	3.201	;	PqsR (MvfR) in complex with antagonist 18
6YZ3	;	3.0	;	PqsR (MvfR) in complex with antagonist 19
7O2U	;	3.0	;	PqsR (MvfR) in complex with antagonist 40
6Z17	;	3.15	;	PqsR (MvfR) in complex with antagonist 6
7O2T	;	2.65	;	PqsR (MvfR) in complex with antagonist 61
8Q5L	;	2.9	;	PqsR coinducer binding domain of Pseudomonas aeruginosa with ligand 2f: 2-(4-(3-((6-chloro-1-isopropyl-1H-benzo[d]imidazol-2-yl)amino)-2-hydroxypropoxy)phenyl)acetonitrile
8Q5K	;	2.8	;	PqsR coinducer binding domain of Pseudomonas aeruginosa with ligand 2t : 2-(4-(3-((6-chloro-1-(2-methoxyethyl)-1H-benzo[d]imidazol-2-yl)amino)-2-hydroxypropoxy)phenyl)acetonitrile
8ISJ	;	3.0	;	Pr conformer of Arabidopsis thaliana phytochrome A - AtphyA-Pr
8ISK	;	3.3	;	Pr conformer of Zea mays phytochrome A1 - ZmphyA1-Pr
4A2J	;	2.0	;	PR X-Ray structures in agonist conformations reveal two different mechanisms for partial agonism in 11beta-substituted steroids
4APU	;	1.9	;	PR X-Ray structures in agonist conformations reveal two different mechanisms for partial agonism in 11beta-substituted steroids
1FUJ	;	2.2	;	PR3 (MYELOBLASTIN)
7DBC	;	2.4	;	PRA in complex with tubulin
7EK4	;	2.3	;	prawn ferritin to coordinate with heavy metal ions
7EK5	;	3.0	;	prawn ferritin to coordinate with heavy metal ions
7EK7	;	2.7	;	prawn ferritin to coordinate with heavy metal ions
6WKR	;	3.5	;	PRC2-AEBP2-JARID2 bound to H2AK119ub1 nucleosome
7KSR	;	4.1	;	PRC2:EZH1_A from a dimeric PRC2 bound to a nucleosome
7KTP	;	4.8	;	PRC2:EZH1_B from a dimeric PRC2 bound to a nucleosome
4NAF	;	1.9	;	PrcB from Geobacillus kaustophilus, apo structure
1H99	;	1.55	;	PRD of LicT antiterminator from Bacillus subtilis
8U0T	;	3.2	;	PRD-0038 RBD bound to Rhinolophus alcyone ACE2 (local refinement)
1YQ5	;	2.0	;	PRD1 vertex protein P5
1YQ6	;	2.4	;	PRD1 vertex protein P5
1YQ8	;	2.6	;	PRD1 vertex protein P5
5V3G	;	2.416	;	PRDM9-allele-C ZnF8-13
7SSO	;	3.2	;	Pre translocation 70S ribosome with A/A and P/E tRNA (Structure II-A)
7SSN	;	3.2	;	Pre translocation 70S ribosome with A/P* and P/E tRNA (Structure II-B)
7ST7	;	3.2	;	Pre translocation intermediate stalled with viomycin and bound with EF-G in a GDP and Pi state (Structure III-vio)
7SSL	;	3.8	;	Pre translocation intermediate with EF-G bound to GDP and Pi (Structure III)
7ST6	;	3.0	;	Pre translocation, non-rotated 70S ribosome (Structure I)
7BL5	;	3.3	;	pre-50S-ObgE particle
7BL2	;	3.7	;	pre-50S-ObgE particle state 1
7BL3	;	3.5	;	pre-50S-ObgE particle state 2
6YLX	;	3.9	;	pre-60S State NE1 (TAP-Flag-Nop53)
6YLY	;	3.8	;	pre-60S State NE2 (TAP-Flag-Nop53)
7PDU	;		;	Pre-catalytic complex of 10-23 DNAzyme with RNA target
7M09	;	1.65	;	Pre-catalytic quaternary complex of DNA Polymerase Lambda with blunt-ended DSB substrate and incoming dUMPNPP
7M0D	;	1.8	;	Pre-catalytic quaternary complex of DNA Polymerase Lambda with bound complementary DSB substrate and incoming dUMPNPP
7M0B	;	2.0	;	Pre-catalytic quaternary complex of DNA Polymerase Lambda with bound mismatched DSB and incoming dUMPNPP
6WIC	;	1.55	;	Pre-catalytic quaternary complex of human Polymerase Mu on a complementary DNA double-strand break substrate
7M0E	;	2.25	;	Pre-catalytic synaptic complex of DNA Polymerase Lambda with gapped DSB substrate and incoming dUMPNPP
7M07	;	1.57	;	Pre-catalytic ternary complex of DNA Polymerase Lambda with bound 1-nt gapped SSB substrate and incoming dUMPNPP
5U2S	;	2.3	;	Pre-catalytic ternary complex of Human DNA Polymerase Beta With Gapped DNA substrate incoming (-)3TC-TP and Ca2+.
5U2T	;	1.79	;	Pre-catalytic ternary complex of Human DNA Polymerase Beta With Gapped DNA substrate incoming (-)FTC-TP and Ca2+.
6P1T	;	1.7	;	Pre-catalytic ternary complex of human DNA Polymerase Mu with 1-nt gapped substrate containing template 8OG and bound CMPCPP
6P1R	;	1.701	;	Pre-catalytic ternary complex of human DNA Polymerase Mu with 1-nt gapped substrate containing template 8OG and bound incoming AMPNPP
6P1N	;	1.6	;	Pre-catalytic ternary complex of human DNA Polymerase Mu with 1-nt gapped substrate containing template 8OG and bound incoming dAMPNPP
6P1P	;	1.75	;	Pre-catalytic ternary complex of human DNA Polymerase Mu with 1-nt gapped substrate containing template 8OG and bound incoming dCMPNPP
6P1W	;	1.751	;	Pre-catalytic ternary complex of human DNA Polymerase Mu with 1-nt gapped substrate containing undamaged template dG and bound incoming CMPCPP
6P1V	;	1.95	;	Pre-catalytic ternary complex of human DNA Polymerase Mu with 1-nt gapped substrate containing undamaged template dG and bound incoming dCMPNPP
6AK8	;	1.74	;	Pre-catalytic Ternary Complex of Human DNA Polymerase Mu with Templating Adenine and Incoming Ca-8oxodGTP
6AKH	;	1.75	;	Pre-catalytic Ternary Complex of Human DNA Polymerase Mu with Templating Adenine and Incoming Mn-dUMPNPP
6AK9	;	1.91	;	Pre-catalytic Ternary Complex of Human DNA Polymerase Mu with Templating Cytosine and Incoming Ca-8oxodGTP
5VZ7	;	1.551	;	Pre-catalytic ternary complex of human Polymerase Mu (G433A) mutant with incoming nonhydrolyzable UMPNPP
5VZA	;	1.501	;	Pre-catalytic ternary complex of human Polymerase Mu (G433S) mutant with incoming nonhydrolyzable UMPNPP
5TWR	;	1.9	;	Pre-catalytic ternary complex of human Polymerase Mu (H329A) mutant with incoming nonhydrolyzable UMPNPP
5VZD	;	1.602	;	Pre-catalytic ternary complex of human Polymerase Mu (W434A) mutant with incoming nonhydrolyzable UMPNPP
5VZG	;	1.85	;	Pre-catalytic ternary complex of human Polymerase Mu (W434H) mutant with incoming nonhydrolyzable UMPNPP
5TWP	;	2.001	;	Pre-catalytic ternary complex of human Polymerase Mu with incoming nonhydrolyzable UMPNPP
2GCS	;	2.1	;	Pre-cleavage state of the Thermoanaerobacter tengcongensis glmS ribozyme
2H0S	;	2.35	;	Pre-cleavage state of the Thermoanaerobacter tengcongensis glmS ribozyme
2H0X	;	2.3	;	Pre-cleavage state of the Thermoanaerobacter tengcongensis glmS ribozyme
2H0Z	;	2.7	;	Pre-cleavage state of the Thermoanaerobacter tengcongensis glmS ribozyme bound to glucose-6-phosphate
2HO7	;	2.9	;	Pre-cleavage state of the Thermoanaerobacter tengcongensis glmS ribozyme bound to glucose-6-phosphate
3SLJ	;	2.481	;	Pre-cleavage Structure of the Autotransporter EspP - N1023A mutant
3SLO	;	2.52	;	Pre-cleavage Structure of the Autotransporter EspP - N1023D mutant
3SLT	;	2.46	;	Pre-cleavage Structure of the Autotransporter EspP - N1023S Mutant
6TR2	;		;	Pre-folded structures govern folding pathways of human telomeric G-quadruplexes
5XJX	;	3.055	;	Pre-formed plant receptor ERL1-TMM complex
2M8R	;		;	Pre-Fusion Solution NMR Structure of Neuronal SNARE Syntaxin 1A
7N6A	;	14.3	;	Pre-fusion state 1 of EEEV with localized reconstruction
7N69	;	14.1	;	Pre-fusion state 2 of EEEV with localized reconstruction
4CC8	;	6.0	;	Pre-fusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy
3BQ0	;	2.6	;	Pre-insertion binary complex of Dbh DNA polymerase
4RZ9	;	1.28	;	Pre-mRNA-splicing factor 38A AS 1-179
4RZA	;	1.9	;	Pre-mRNA-splicing factor 38A AS 1-205
7A4L	;		;	PRE-only solution structure of the Iron-Sulfur protein PioC from Rhodopseudomonas palustris TIE-1
2OR3	;	1.2	;	Pre-oxidation Complex of Human DJ-1
6CIL	;	4.15	;	PRE-REACTION COMPLEX, RAG1(E962Q)/2-INTACT/INTACT 12/23RSS COMPLEX IN MN2+
6CIK	;	3.15	;	Pre-Reaction Complex, RAG1(E962Q)/2-intact/nicked 12/23RSS complex in Mn2+
6CIM	;	3.6	;	Pre-Reaction Complex, RAG1(E962Q)/2-nicked/intact 12/23RSS complex in Mn2+
1CKQ	;	1.85	;	PRE-TRANSITION STATE ECO RI ENDONUCLEASE/COGNATE DNA (TCGCGAATTCGCG) COMPLEX
7K53	;	3.2	;	Pre-translocation +1-frameshifting(CCC-A) complex (Structure I-FS)
7OSA	;	3.0	;	Pre-translocation complex of 80 S.cerevisiae ribosome with eEF2 and ligands
7K50	;	3.4	;	Pre-translocation non-frameshifting(CCA-A) complex (Structure I)
7LV0	;	3.2	;	Pre-translocation rotated ribosome +1-frameshifting(CCC-A) complex (Structure Irot-FS)
5EJ1	;	3.4	;	Pre-translocation state of bacterial cellulose synthase
7K98	;	2.19	;	Preaminoacylation complex of M. tuberculosis PheRS with cognate precursor tRNA and 5'-O-(N-phenylalanyl)sulfamoyl-adenosine (F-AMS)
5TB8	;	2.0	;	Precatalytic ternary complex of Human DNA Polymerase Beta in closed conformation With Gapped DNA substrate incoming (-)3TC-TP and Mn2+.
5TB9	;	2.49	;	Precatalytic ternary complex of Human DNA Polymerase Beta in closed conformation With Gapped DNA substrate incoming (-)FTC-TP and Mn2+.
4RQ3	;	2.0	;	Precatalytic ternary complex of Human DNA Polymerase Beta With Gapped DNA Containing an 8-oxo-7,8-dihydro-Guanine (8-oxoG) and dATP in the presence of CaCl2
4RPX	;	1.9	;	Precatalytic ternary complex of Human DNA Polymerase Beta With Gapped DNA Containing an 8-oxo-7,8-dihydro-Guanine (8-oxoG) and dCTP in the presence of CaCl2
5U2R	;	1.8	;	PRECATALYTIC TERNARY COMPLEX OF HUMAN DNA POLYMERASE BETA WITH GAPPED DNA SUBSTARTE, INCOMING L-DCTP AND CA2+
5TBC	;	1.85	;	PRECATALYTIC TERNARY COMPLEX OF HUMAN DNA POLYMERASE BETA WITH GAPPED DNA SUBSTRATE, INCORPORATED (-)3TC-MP AND AN ANOTHER INCOMING (-)3TC-TP NUCLEOTIDE.
5AWW	;	2.724	;	Precise Resting State of Thermus thermophilus SecYEG
8EOV	;	1.59	;	Precisely patterned nanofibers made from extendable protein multiplexes
8EOX	;	3.3	;	Precisely patterned nanofibers made from extendable protein multiplexes
8EOZ	;	3.0	;	Precisely patterned nanofibers made from extendable protein multiplexes
8ERW	;	2.88	;	Precisely patterned nanofibers made from extendable protein multiplexes
4YPB	;	3.4	;	Precleavage 70S structure of the P. vulgaris HigB DeltaH92 toxin bound to the AAA codon
4YZV	;	3.1	;	Precleavage 70S structure of the P. vulgaris HigB deltaH92 toxin bound to the ACA codon
4B05	;	1.8	;	Preclinical characterization of AZD3839, a novel clinical candidate BACE1 inhibitor for the treatment of Alzheimer Disease
6VEB	;	2.55	;	Precorrin-2-bound S128A S. typhimurium siroheme synthase
4E16	;	2.49	;	Precorrin-4 C(11)-methyltransferase from Clostridium difficile
1OU0	;	2.1	;	precorrin-8X methylmutase related protein
3PDI	;	2.4	;	Precursor bound NifEN
2IWM	;	2.5	;	precursor mutant Cys1Ser of Penicillin V Acylase from Bacillus sphaericus
2VQX	;	1.821	;	Precursor of Protealysin, Metalloproteinase from Serratia proteamaculans.
9GAA	;	2.1	;	PRECURSOR OF THE T152A MUTANT GLYCOSYLASPARAGINASE FROM FLAVOBACTERIUM MENINGOSEPTICUM
9GAC	;	1.9	;	PRECURSOR OF THE T152C MUTANT GLYCOSYLASPARAGINASE FROM FLAVOBACTERIUM MENINGOSEPTICUM
9GAF	;	1.9	;	PRECURSOR OF THE W11F MUTANT GLYCOSYLASPARAGINASE FROM FLAVOBACTERIUM MENINGOSEPTICUM
6OF4	;	3.2	;	Precursor ribosomal RNA processing complex, apo-state.
6OF3	;	3.0	;	Precursor ribosomal RNA processing complex, State 1.
6OF2	;	2.9	;	Precursor ribosomal RNA processing complex, State 2.
1KEH	;	2.5	;	Precursor structure of cephalosporin acylase
6SJX	;		;	Precursor structure of the self-processing module of iron-regulated FrpC of N. Meningitidis with calcium ions
1YOZ	;	2.0	;	Predicted coding region AF0941 from Archaeoglobus fulgidus
1YOY	;	2.0	;	Predicted coding region AF1432 from Archaeoglobus Fulgidus
2B6C	;	2.1	;	Predicted DNA alkylation repair enzyme from Enterococcus faecalis.
6PHG	;	2.0	;	Predicted germline variant of human transmission blocking antibody 2544
3GO9	;	1.62	;	Predicted insulinase family protease from Yersinia pestis
3AUV	;	2.4	;	Predicting Amino Acid Preferences in the Complementarity Determining Regions of an Antibody-Antigen Recognition Interface
4NVA	;	1.57	;	Predicting protein conformational response in prospective ligand discovery
4NVC	;	1.6	;	Predicting protein conformational response in prospective ligand discovery
4NVE	;	1.54	;	Predicting protein conformational response in prospective ligand discovery
4NVF	;	1.49	;	Predicting protein conformational response in prospective ligand discovery
4NVG	;	1.742	;	Predicting protein conformational response in prospective ligand discovery
4NVH	;	1.24	;	Predicting protein conformational response in prospective ligand discovery
4NVM	;	1.51	;	Predicting protein conformational response in prospective ligand discovery
4NVN	;	1.47	;	Predicting protein conformational response in prospective ligand discovery
4NVO	;	1.71	;	Predicting protein conformational response in prospective ligand discovery
4NVB	;	1.17	;	Predicting protein conformational response in prospective ligand discovery.
4NVD	;	1.3	;	Predicting protein conformational response in prospective ligand discovery.
4NVI	;	1.51	;	Predicting protein conformational response in prospective ligand discovery.
4NVJ	;	1.813	;	Predicting protein conformational response in prospective ligand discovery.
4NVK	;	1.56	;	Predicting protein conformational response in prospective ligand discovery.
4NVL	;	1.432	;	Predicting protein conformational response in prospective ligand discovery.
4OQ7	;	1.89	;	Predicting protein conformational response in prospective ligand discovery.
6BL8	;	2.5	;	Predicting the Conformational Variability of Abl Tyrosine Kinase Using Molecular Dynamics Simulations and Markov State Models
1TNG	;	1.8	;	PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS
1TNH	;	1.8	;	PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS
1TNI	;	1.9	;	PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS
1TNJ	;	1.8	;	PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS
1TNK	;	1.8	;	PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS
1TNL	;	1.9	;	PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS
3NXY	;	1.9	;	Preferential Selection of Isomer Binding from Chiral Mixtures: Alernate Binding Modes Observed fro the E- and Z-isomers of a Series of 5-Substituted 2,4-Diaminofuro[2,3-d]pyrimidines as Ternary Complexes with NADPH and Human Dihydrofolate Reductase
3NXX	;	1.35	;	Preferential Selection of Isomer Binding from Chiral Mixtures: Alternate Binding Modes Observed for the E- and Z-isomers of a Series of 5-Substituted 2,4-Diaminofuro-2,3-d]pyrimidines as Ternary Complexes with NADPH and Human Dihydrofolate Reductase
3NXV	;	1.9	;	Preferential Selection of Isomer Binding from Chiral Mixtures: Alternate Binding Modes Observed for the E- and Z-isomers of a Series of 5-Substituted 2,4-Diaminofuro[2,3-d]pyrimidines as Ternary Complexes with NADPH and Human Dihydrofolate Reductase
3NXT	;	1.7	;	Preferential Selection of Isomer Binding from Chiral Mixtures: Alternate Binding Modes Observed for the E-and Z-isomers of a Series of 5-substituted 2,4-diaminofuro[2m,3-d]pyrimidines as Ternary Complexes with NADPH and Human Dihydrofolate Reductase
7WU7	;	3.85	;	Prefoldin-tubulin-TRiC complex
6VSB	;	3.46	;	Prefusion 2019-nCoV spike glycoprotein with a single receptor-binding domain up
5I2S	;	3.0	;	PREFUSION FORM OF THE VESICULAR STOMATITIS VIRUS GLYCOPROTEIN G ECTODOMAIN
6W52	;	3.74	;	Prefusion RSV F bound by neutralizing antibody RSB1
7KQD	;	2.94	;	Prefusion RSV F Bound to RV521
7LUE	;	2.9	;	Prefusion RSV F glycoprotein bound by neutralizing site V-directed antibody ADI-14442
6OE4	;	3.3	;	Prefusion RSV F monomer bound by neutralizing antibody CR9501
6X79	;	2.9	;	Prefusion SARS-CoV-2 S ectodomain trimer covalently stabilized in the closed conformation
5I08	;	4.04	;	Prefusion structure of a human coronavirus spike protein
5X5C	;	4.1	;	Prefusion structure of MERS-CoV spike glycoprotein, conformation 1
5X5F	;	4.2	;	Prefusion structure of MERS-CoV spike glycoprotein, conformation 2
5X59	;	3.7	;	Prefusion structure of MERS-CoV spike glycoprotein, three-fold symmetry
6U7K	;	3.14	;	Prefusion structure of PEDV spike
5X58	;	3.2	;	Prefusion structure of SARS-CoV spike glycoprotein, conformation 1
5X5B	;	3.7	;	Prefusion structure of SARS-CoV spike glycoprotein, conformation 2
8U29	;	2.8	;	Prefusion structure of the PRD-0038 spike glycoprotein ectodomain trimer
8DNR	;	2.8	;	Prefusion-stabilized Hendra virus fusion protein
8CW9	;	3.46	;	Prefusion-stabilized hMPV fusion protein bound to ADI-61026 and MPE8 Fabs
8U1R	;	3.6	;	Prefusion-stabilized Langya virus F protein, variant G99C/I109C
8DNG	;	3.0	;	Prefusion-stabilized Nipah virus fusion protein
7UPK	;	2.8	;	Prefusion-stabilized Nipah virus fusion protein complexed with Fab 1A9
7UPB	;	3.0	;	Prefusion-stabilized Nipah virus fusion protein complexed with Fab 1H1
7UPA	;	2.5	;	Prefusion-stabilized Nipah virus fusion protein complexed with Fab 1H8
7UPD	;	2.4	;	Prefusion-stabilized Nipah virus fusion protein complexed with Fab 2B12
7UP9	;	2.9	;	Prefusion-stabilized Nipah virus fusion protein complexed with Fab 2D3
7UOP	;	2.8	;	Prefusion-stabilized Nipah virus fusion protein complexed with Fab 4H3
8DO4	;	3.2	;	Prefusion-stabilized Nipah virus fusion protein, dimer of trimers
8U1G	;	3.2	;	Prefusion-stabilized SARS-CoV-2 S2 subunit
8FEZ	;	3.72	;	Prefusion-stabilized SARS-CoV-2 spike protein
8T08	;	3.0	;	Preholo-Proteasome from Pre1-1 Pre4-1 Double Mutant
8DPX	;		;	Preligand association structure of DR5
4IRF	;	1.65	;	Preliminary structural investigations of a malarial protein secretion system
4IOD	;	1.8	;	Preliminary structural investigations of a malarial protein secretion system.
1IYW	;	4.0	;	Preliminary Structure of Thermus thermophilus Ligand-Free Valyl-tRNA Synthetase
2VZ1	;	1.91	;	Premat-galactose oxidase
1MRC	;	2.4	;	PREPARATION, CHARACTERIZATION AND CRYSTALLIZATION OF AN ANTIBODY FAB FRAGMENT THAT RECOGNIZES RNA. CRYSTAL STRUCTURES OF NATIVE FAB AND THREE FAB-MONONUCLEOTIDE COMPLEXES
1MRD	;	2.3	;	PREPARATION, CHARACTERIZATION AND CRYSTALLIZATION OF AN ANTIBODY FAB FRAGMENT THAT RECOGNIZES RNA. CRYSTAL STRUCTURES OF NATIVE FAB AND THREE FAB-MONONUCLEOTIDE COMPLEXES
1MRE	;	2.3	;	PREPARATION, CHARACTERIZATION AND CRYSTALLIZATION OF AN ANTIBODY FAB FRAGMENT THAT RECOGNIZES RNA. CRYSTAL STRUCTURES OF NATIVE FAB AND THREE FAB-MONONUCLEOTIDE COMPLEXES
1MRF	;	2.4	;	PREPARATION, CHARACTERIZATION AND CRYSTALLIZATION OF AN ANTIBODY FAB FRAGMENT THAT RECOGNIZES RNA. CRYSTAL STRUCTURES OF NATIVE FAB AND THREE FAB-MONONUCLEOTIDE COMPLEXES
5WHX	;	1.69	;	PREPHENATE DEHYDROGENASE FROM SOYBEAN
5T95	;	1.689	;	Prephenate Dehydrogenase M219T, N222D mutant from Soybean
5T9F	;	1.994	;	Prephenate Dehydrogenase N222D mutant from Soybean
7T4E	;	2.87	;	Prepore structure of pore-forming toxin Epx1
7REX	;	2.6	;	PreQ1-1 (type-1) riboswitch in complex with tandem stacked metabolites
8FB3	;	3.0	;	PreQ1-1 (type-1) riboswitch with stacked metabolites and a C10-G34 base pair in the expression platform
5D5L	;	2.5	;	PreQ1-II riboswitch with an engineered G-U wobble pair bound to Cs+
4JFD	;	2.46	;	Preservation of peptide specificity during TCR-MHC contact dominated affinity enhancement of a melanoma-specific TCR
4JFE	;	2.7	;	Preservation of peptide specificity during TCR-MHC contact dominated affinity enhancement of a melanoma-specific TCR
4JFF	;	2.43	;	Preservation of peptide specificity during TCR-MHC contact dominated affinity enhancement of a melanoma-specific TCR
5G3C	;	1.75	;	Preserving Metallic sites affected by radiation damage the CuT2 case in thermus termophilus multicopper oxidase
5G3E	;	1.78	;	Preserving Metallic Sites Affected by Radiation DAmage the CuT2 CAse in THermus Thermophilus Multicopper Oxidase
5G3F	;	1.82	;	Preserving Metallic Sites Affected by Radiation Damage the CuT2 CAse in Thermus Thermophilus Multicopper Oxidase
5G3G	;	1.84	;	Preserving MEtallic Sites Affected by Radiation Damage the CuT2 case in Thermus Thermophilus multicopper Oxidase
5G3H	;	1.93	;	Preserving Metallic Sites Affected by Radiation Damage the CuT2 Case in Thermus Thermophilus Multicopper oxidase
5G3D	;	1.78	;	preserving Metallic Sites Affected by Radiation Damage the CuT2 cCase in Thermus Thermophilus Multicopper Oxidase
5G3B	;	1.69	;	Preserving metallic sites affected by radiation damage: the CuT2 case in Thermus thermophilus multicopper oxidase
6G90	;	4.0	;	Prespliceosome structure provides insight into spliceosome assembly and regulation (map A2)
7AET	;	2.53	;	Pressure wave-exposed human hemoglobin: probe only data (3500 indexed images)
7AEU	;	2.54	;	Pressure wave-exposed human hemoglobin: probe only data (5500 indexed images)
7AEV	;	2.77	;	Pressure wave-exposed human hemoglobin: pump/probe data (3500 indexed images)
6WL2	;	3.3	;	preTCRbeta-pMHC complex crystal structure
6WL3	;	3.45	;	preTCRbeta-pMHC complex crystal structure
6WL4	;	3.6	;	preTCRbeta-pMHC complex crystal structure
4NGK	;	1.5	;	Previously de-ionized HEW lysozyme batch crystallized in 0.2 M CoCl2
4NEB	;	1.48	;	Previously de-ionized HEW lysozyme batch crystallized in 0.5 M MnCl2
4NGV	;	1.64	;	Previously de-ionized HEW lysozyme batch crystallized in 0.5 M YbCl3
4NGL	;	1.52	;	Previously de-ionized HEW lysozyme batch crystallized in 0.6 M CoCl2
4NGO	;	1.58	;	Previously de-ionized HEW lysozyme batch crystallized in 1.0 M CoCl2
4NFV	;	1.63	;	Previously de-ionized HEW lysozyme batch crystallized in 1.1 M MnCl2
4NG1	;	1.82	;	Previously de-ionized HEW lysozyme batch crystallized in 1.9 M CsCl
4NGZ	;	1.7	;	Previously de-ionized HEW lysozyme crystallized in 0.5 M YbCl3/30% (v/v) glycerol and collected at 125K
4NGI	;	1.7	;	Previously de-ionized HEW lysozyme crystallized in 1.0 M RbCl and collected at 125K
2BEO	;	2.7	;	PrfA, Transcriptional Regulator In Listeria Monocytogenes
2BGC	;	2.3	;	PrfA-G145S, a constitutive active mutant of the Transcriptional Regulator In L.monocytogenes
3ZQB	;	2.4	;	PrgI-SipD from Salmonella typhimurium
3ZQE	;	2.19	;	PrgI-SipD from Salmonella typhimurium in complex with deoxycholate
6LXD	;	3.9	;	Pri-miRNA bound DROSHA-DGCR8 complex
4NL4	;	2.65	;	PriA Helicase Bound to ADP
6DGD	;	2.823	;	PriA helicase bound to dsDNA of a DNA replication fork
4NL8	;	4.08	;	PriA Helicase Bound to SSB C-terminal Tail Peptide
8C9F	;	3.1	;	Priestia megaterium inactive HIGH motif mutant of type1 isoleucyl-tRNA synthetase complexed with an isoleucyl-adenylate analogue.
8C8W	;	2.29	;	Priestia megaterium mupirocin hyper-resistant HIGH motif mutant of type 2 isoleucyl-tRNA synthetase complexed with an isoleucyl-adenylate analogue
8C8U	;	1.901	;	Priestia megaterium mupirocin-resistant isoleucyl-tRNA synthetase 2 complexed with mupirocin
8C8V	;	2.2	;	Priestia megaterium mupirocin-resistant isoleucyl-tRNA synthetase 2 with a fully-resolved C-terminal tRNA-binding domain complexed with an isoleucyl-adenylate analogue
8C9E	;	2.9	;	Priestia megaterium mupirocin-sensitive isoleucyl-tRNA synthetase 1 complexed with an isoleucyl-adenylate analogue
8C9G	;	2.8	;	Priestia megaterium mupirocin-sensitive isoleucyl-tRNA synthetase 1 complexed with mupirocin
8C9D	;	2.3	;	Priestia megaterium W130Q mutant of type 2 isoleucyl-tRNA synthetase complexed with an isoleucyl-adenylate analogue
7NQD	;	2.97	;	Prim-Pol Domain of CRISPR-associated Prim-Pol (CAPP) from Marinitoga sp. 1137
7P9J	;	1.9	;	Prim-Pol Domain of CRISPR-associated Prim-Pol (CAPP) from Marinitoga sp. 1137 - Primer Initiation Complex
7QAZ	;	2.11	;	Prim-Pol Domain of CRISPR-associated Prim-Pol (CAPP) from Marinitoga sp. 1137 - Primer Initiation Complex
7NQE	;	1.28	;	Prim-Pol Domain of CRISPR-associated Prim-Pol (CAPP) from Marinitoga sp. 1137 with dGTP
7NQF	;	2.02	;	Prim-Pol Domain of CRISPR-associated Prim-Pol (CAPP) from Marinitoga sp. 1137 with dsDNA
1A56	;		;	PRIMARY SEQUENCE AND SOLUTION CONFORMATION OF FERRICYTOCHROME C-552 FROM NITROSOMONAS EUROPAEA, NMR, MEAN STRUCTURE REFINED WITH EXPLICIT HYDROGEN BOND CONSTRAINTS
1A8C	;		;	PRIMARY SEQUENCE AND SOLUTION CONFORMATION OF FERROCYTOCHROME C-552 FROM NITROSOMONAS EUROPAEA, NMR, MEAN STRUCTURE REFINED WITHOUT HYDROGEN BOND CONSTRAINTS
1SMV	;	3.0	;	PRIMARY STRUCTURE OF SESBANIA MOSAIC VIRUS COAT PROTEIN: ITS IMPLICATIONS TO THE ASSEMBLY AND ARCHITECTURE OF THE VIRUS
2DLA	;	2.9	;	Primase large subunit amino terminal domain from Pyrococcus horikoshii
8DWJ	;	3.9	;	Primase of mutant bacteriophage T4 primosome with single strand DNA/RNA primer hybrid in primer exiting state
4KI1	;	3.2	;	Primitive triclinic crystal form of the human IgE-Fc(epsilon)3-4 bound to its B cell receptor derCD23
3QIJ	;	1.8	;	Primitive-monoclinic crystal structure of the FERM domain of protein 4.1R
1MCB	;	2.7	;	PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCC	;	2.7	;	PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCD	;		;	PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCE	;	2.7	;	PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCF	;	2.7	;	PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCH	;	2.7	;	PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCI	;	2.7	;	PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCJ	;	2.7	;	PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCK	;	2.7	;	PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCL	;	2.7	;	PRINCIPLES AND PITFALLS in DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCN	;	2.7	;	PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCQ	;	2.7	;	PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCR	;	2.7	;	PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCS	;	2.7	;	PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
5NB5	;	3.0	;	Principles for computational design of antibodies
5NBI	;	2.1	;	Principles for computational design of antibodies
2ETW	;	1.67	;	Principles of protein-DNA recognition revealed in the structural analysis of Ndt80-MSE DNA complexes
2EUV	;	1.94	;	Principles of protein-DNA recognition revealed in the structural analysis of Ndt80-MSE DNA complexes
7ELJ	;		;	Prion Derived Tetrapeptide Stabilizes Thermolabile Insulin via Conformational Trapping
6HEQ	;	1.23	;	Prion nanobody 484
3MD4	;	1.15	;	Prion peptide
3MD5	;	1.4	;	Prion peptide
4WBU	;	1.15	;	prion peptide
1AG2	;		;	PRION PROTEIN DOMAIN PRP(121-231) FROM MOUSE, NMR, 2 MINIMIZED AVERAGE STRUCTURE
2XKS	;		;	Prion-like conversion during amyloid formation at atomic resolution
2XKU	;		;	Prion-like conversion during amyloid formation at atomic resolution
1B82	;	1.8	;	PRISTINE RECOMB. LIGNIN PEROXIDASE H8
1X24	;	3.2	;	Prl-1 (ptp4a)
1ZCL	;	2.9	;	prl-1 c104s mutant in complex with sulfate
6IZQ	;	2.449	;	PRMT4 bound with a bicyclic compound
6V0N	;	2.11	;	PRMT5 bound to PBM peptide from Riok1
6V0O	;	2.86	;	PRMT5 bound to the PBM peptide from pICln
6V0P	;	1.88	;	PRMT5 complex bound to covalent PBM inhibitor BRD6711
7MXG	;	2.395	;	PRMT5(M420T mutant):MEP50 complexed with inhibitor PF-06855800
7MXN	;	2.55	;	PRMT5(M420T mutant):MEP50 complexed with inhibitor PF-06939999
7L1G	;	2.47	;	PRMT5-MEP50 Complexed with SAM
7S1R	;	2.1	;	PRMT5/MEP50 crystal structure with MTA and a phthalazinone inhibitor bound (compound (M)-31)
7S1Q	;	2.78	;	PRMT5/MEP50 crystal structure with MTA and a phthalazinone inhibitor bound (Compound 9)
7UOH	;	2.7	;	PRMT5/MEP50 crystal structure with MTA and an achiral, class 1, non-atropisomeric inhibitor bound
7S1S	;	2.62	;	PRMT5/MEP50 crystal structure with MTA and MRTX-1719 bound
7S0U	;	2.01	;	PRMT5/MEP50 crystal structure with MTA and phthalazinone fragment bound
7S1P	;	2.21	;	PRMT5/MEP50 crystal structure with sinefungin bound
7SES	;	2.5	;	PRMT5/MEP50 with compound 29 bound
7SER	;	2.14	;	PRMT5/MEP50 with compound 30 bound
7KIC	;	2.43	;	PRMT5:MEP50 Complexed with 5,5-Bicyclic Inhibitor Compound 34
7KIB	;	2.52	;	PRMT5:MEP50 Complexed with 5,5-Bicyclic Inhibitor Compound 4
7KID	;	2.5	;	PRMT5:MEP50 Complexed with 5,5-Bicyclic Inhibitor Compound 72
7MXC	;	2.41	;	PRMT5:MEP50 complexed with adenosine
6UXX	;	2.69	;	PRMT5:MEP50 Complexed with Allosteric Inhibitor Compound 1a
6UXY	;	2.57	;	PRMT5:MEP50 Complexed with Allosteric Inhibitor Compound 8
7U30	;	2.6	;	PRMT5:MEP50 Complexed with Cyclonucleoside Compound 1
7MXA	;	2.713	;	PRMT5:MEP50 complexed with inhibitor PF-06855800
7MX7	;	2.49	;	PRMT5:MEP50 complexed with inhibitor PF-06939999
2V7M	;	2.0	;	PrnB 7-Cl-D-tryptophan complex
2V7L	;	2.4	;	PrnB 7Cl-L-tryptophan complex
2V7K	;	1.7	;	PrnB D-tryptophan complex
2V7J	;	2.0	;	PrnB L-tryptophan complex
2V7I	;	1.75	;	PrnB native
2SGP	;	1.8	;	PRO 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 6.5
1BOQ	;	2.1	;	PRO REGION C-TERMINUS: PROTEASE ACTIVE SITE INTERACTIONS ARE CRITICAL IN CATALYZING THE FOLDING OF ALPHA-LYTIC PROTEASE
2PRO	;	3.0	;	PRO REGION OF ALPHA-LYTIC PROTEASE
8JBQ	;	2.0	;	Pro-alpha-hemolysin of Vibrio campbellii
4YCG	;	3.3	;	Pro-bone morphogenetic protein 9
4P10	;	2.0	;	pro-carboxypeptidase U In Complex With 5-(3-aminopropyl)-1-propyl-6,7-dihydro-4H-benzimidazole-5-carboxylic acid
6XT6	;	2.103	;	pro-concanavalin A: Precursor of circularly permuted concanavalin A
6AGW	;	2.093	;	Pro-domain of Caspase-8
8G32	;	1.85	;	Pro-form of a CDCL short from E. anophelis
3S1E	;	1.9	;	Pro427Gln mutant of maize cytokinin oxidase/dehydrogenase complexed with N6-isopentenyladenine
2IH6	;		;	Pro6 variant of CMrVIA conotoxin
2FLY	;		;	Proadrenomedullin N-Terminal 20 Peptide
1PRE	;	2.8	;	PROAEROLYSIN
1Z52	;	2.38	;	Proaerolysin Mutant W373L
5GAI	;	10.5	;	Probabilistic Structural Models of Mature P22 Bacteriophage Portal, Hub, and Tailspike proteins
5BQF	;	1.45	;	Probable 2-hydroxyacid dehydrogenase from Rhizobium etli CFN 42 in complex with NADP, HEPES and L(+)-tartaric acid
4XCV	;	1.4	;	Probable 2-hydroxyacid dehydrogenase from Rhizobium etli CFN 42 in complex with NADPH
2OSU	;	2.29	;	Probable glutaminase from Bacillus subtilis complexed with 6-diazo-5-oxo-L-norleucine
2PBY	;	2.07	;	Probable Glutaminase from Geobacillus kaustophilus HTA426
2DOU	;	2.3	;	probable N-succinyldiaminopimelate aminotransferase (TTHA0342) from Thermus thermophilus HB8
2OER	;	2.0	;	Probable Transcriptional Regulator from Pseudomonas aeruginosa
7ZJG	;	3.49	;	Probenecid
4H9G	;	1.93	;	Probing EF-Tu with a very small brominated fragment library identifies the CCA pocket
6VI7	;	2.617	;	Probing extradiol dioxygenase mechanism in NAD(+) biosynthesis by viewing reaction cycle intermediates - a substrate bidentately bound structure
3QPK	;	1.9	;	Probing oxygen channels in Melanocarpus albomyces laccase
2DRI	;	1.6	;	PROBING PROTEIN-PROTEIN INTERACTIONS: THE RIBOSE BINDING PROTEIN IN BACTERIAL TRANSPORT AND CHEMOTAXIS
1DRJ	;	2.5	;	PROBING PROTEIN-PROTEIN INTERACTIONS: THE RIBOSE-BINDING PROTEIN IN BACTERIAL TRANSPORT AND CHEMOTAXIS
1DRK	;	2.0	;	PROBING PROTEIN-PROTEIN INTERACTIONS: THE RIBOSE-BINDING PROTEIN IN BACTERIAL TRANSPORT AND CHEMOTAXIS
4B2Y	;	1.9	;	Probing the active center of catalase-phenol oxidase from Scytalidium thermophilum
4B31	;	2.25	;	Probing the active center of catalase-phenol oxidase from Scytalidium thermophilum
4B40	;	1.93	;	Probing the active center of catalase-phenol oxidase from Scytalidium thermophilum
4B5K	;	1.7	;	Probing the active center of catalase-phenol oxidase from Scytalidium thermophilum
4B7A	;	1.95	;	Probing the active center of catalase-phenol oxidase from Scytalidium thermophilum
5ZZ1	;	1.91	;	Probing the active center of catalase-phenol oxidase from Scytalidium thermophilum
2XHZ	;	2.6	;	Probing the active site of the sugar isomerase domain from E. coli arabinose-5-phosphate isomerase via X-ray crystallography
8T5X	;	1.63	;	Probing the dissociation pathway of a kinetically labile transthyretin mutant (A25T)
3EEE	;	2.12	;	Probing the function of heme distortion in the H-NOX family
4KML	;	1.5	;	Probing the N-terminal beta-sheet conversion in the crystal structure of the full-length human prion protein bound to a Nanobody
4N9O	;	1.5	;	Probing the N-terminal beta-sheet conversion in the crystal structure of the human prion protein bound to a Nanobody
1MFU	;	2.0	;	Probing the role of a mobile loop in human salivary amylase: Structural studies on the loop-deleted mutant
1MFV	;	2.0	;	Probing the role of a mobile loop in human slaivary amylase: Structural studies on the loop-deleted enzyme
3DHP	;	1.5	;	Probing the role of aromatic residues at the secondary saccharide binding sites of human salivary alpha-amylase in substrate hydrolysis and bacterial binding
1RM9	;	2.9	;	Probing the Role of Tryptophans in Aequorea Victoria Green Fluorescent Proteins with an Expanded Genetic Code
1RMM	;	1.9	;	Probing the Role of Tryptophans in Aequorea Victoria Green Fluorescent Proteins with an Expanded Genetic Code
1RMO	;	1.8	;	Probing the Role of Tryptophans in Aequorea Victoria Green Fluorescent Proteins with an Expanded Genetic Code
1RMP	;	3.0	;	Probing the Role of Tryptophans in Aequorea Victoria Green Fluorescent Proteins with an Expanded Genetic Code
5CE5	;	2.0	;	Probing the roles of two tryptophans surrounding the unique zinc coordination site in lipase family I.5
1A2F	;	2.1	;	PROBING THE STRENGTH AND CHARACTER OF AN ASP-HIS-X HYDROGEN BOND BY INTRODUCING BURIED CHARGES
1A2G	;	2.1	;	PROBING THE STRENGTH AND CHARACTER OF AN ASP-HIS-X HYDROGEN BOND BY INTRODUCING BURIED CHARGES
1CCL	;	2.0	;	PROBING THE STRENGTH AND CHARACTER OF AN ASP-HIS-X HYDROGEN BOND BY INTRODUCING BURIED CHARGES
5C51	;	3.426	;	Probing the Structural and Molecular Basis of Nucleotide Selectivity by Human Mitochondrial DNA Polymerase gamma
5C52	;	3.637	;	Probing the Structural and Molecular Basis of Nucleotide Selectivity by Human Mitochondrial DNA Polymerase gamma
5C53	;	3.567	;	Probing the Structural and Molecular Basis of Nucleotide Selectivity by Human Mitochondrial DNA Polymerase gamma
4U10	;	2.05	;	Probing the structure and mechanism of de-N-acetylase from aggregatibacter actinomycetemcomitans
1BWP	;	2.1	;	PROBING THE SUBSTRATE SPECIFICITY OF THE INTRACELLULAR BRAIN PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE
1BWQ	;	2.3	;	PROBING THE SUBSTRATE SPECIFICITY OF THE INTRACELLULAR BRAIN PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE
1BWR	;	2.4	;	PROBING THE SUBSTRATE SPECIFICITY OF THE INTRACELLULAR BRAIN PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE
1AL0	;	3.5	;	PROCAPSID OF BACTERIOPHAGE PHIX174
1CD3	;	3.5	;	PROCAPSID OF BACTERIOPHAGE PHIX174
1KBC	;	1.8	;	PROCARBOXYPEPTIDASE TERNARY COMPLEX
1PCI	;	3.2	;	PROCARICAIN
3E4C	;	2.05	;	Procaspase-1 zymogen domain crystal structure
5FPW	;	2.1	;	proCathepsin B S9 from Trypanosoma congolense
3TM7	;	1.7	;	Processed Aspartate Decarboxylase Mutant with Asn72 mutated to Ala
1PYU	;	1.9	;	Processed Aspartate Decarboxylase Mutant with Ser25 mutated to Cys
2XRM	;	2.6	;	Processed Intracellular subtilisin from B. clausii
7FIE	;	2.36	;	Processive cleavage of substrate at individual proteolytic active sites of the Lon protease complex (conformation 2)
7FIZ	;	3.28	;	Processive cleavage of substrate at individual proteolytic active sites of the Lon protease complex (conformation 3)
7FID	;	2.44	;	Processive cleavage of substrate at individual proteolytic active sites of the Lon proteasecomplex (conformation 1)
1FCE	;	2.0	;	PROCESSIVE ENDOCELLULASE CELF OF CLOSTRIDIUM CELLULOLYTICUM
6TNY	;	3.08	;	Processive human polymerase delta holoenzyme
1GQ6	;	1.75	;	PROCLAVAMINATE AMIDINO HYDROLASE FROM STREPTOMYCES CLAVULIGERUS
1GQ7	;	2.45	;	PROCLAVAMINATE AMIDINO HYDROLASE FROM STREPTOMYCES CLAVULIGERUS
7POI	;	2.9	;	Prodomain bound BMP10 crystal form 1
7POJ	;	3.5	;	Prodomain bound BMP10 crystal form 2
6L1O	;	1.9	;	Product bound BacF structure from Bacillus subtillis
2QXF	;	1.5	;	Product bound structure of exonuclease I at 1.5 angstrom resolution
6YO9	;	2.4	;	Product bound structure of the Ectoine utilization protein EutD (DoeA) from Halomonas elongata
6TWM	;	2.5	;	Product bound structure of the Ectoine utilization protein EutE (DoeB) from Ruegeria pomeroyi
2YA1	;	2.25	;	Product complex of a multi-modular glycogen-degrading pneumococcal virulence factor SpuA
3N10	;	1.6	;	Product complex of adenylate cyclase class IV
4KQ6	;	2.24	;	Product complex of lumazine synthase from candida glabrata
4O21	;	1.95	;	Product complex of metal-free PKAc, ATP-gamma-S and SP20.
4B5I	;	2.555	;	Product complex of Neisseria AP endonuclease in presence of metal ions
4H45	;	3.1	;	Product Complexes of Porcine Liver Fructose-1,6-bisphosphatase with Mutation E192Q
4GX3	;	2.25	;	Product Complexes of Porcine Liver Fructose-1,6-bisphosphatase with mutation R22M Reveal a T-state Conformation
7U87	;	1.701	;	Product of 13mer primer with activated G monomer diastereomer 1
7U88	;	2.14	;	Product of 13mer primer with activated G monomer diastereomer 2
7U8B	;	1.73	;	Product of 14mer primer with activated asymmetric GA dimer diastereomer 1
7U89	;	1.65	;	Product of 14mer primer with activated G monomer diastereomer 1
7U8A	;	2.1	;	Product of 14mer primer with activated G monomer diastereomer 2
5A0R	;	1.251	;	Product peptide-bound structure of metalloprotease Zmp1 variant E143A from Clostridium difficile
2IYP	;	2.79	;	product rup
2CWV	;	1.85	;	Product schiff-base intermediate of copper amine oxidase from arthrobacter globiformis
3JVI	;	1.8	;	Product state mimic crystal structure of protein tyrosine phosphatase from Entamoeba histolytica
6NP1	;	1.6	;	Product state mimicry leads to aminoglycoside discrimination in an antibiotic acetyltransferase
7JOY	;	2.0	;	Product structure of SARS-CoV-2 Mpro C145A mutant in complex with its C-terminal autoprocessing sequence.
8DRX	;	1.5	;	Product structure of SARS-CoV-2 Mpro C145A mutant in complex with nsp10-nsp11 (C10) cut site sequence (form 2)
8DRY	;	2.49	;	Product structure of SARS-CoV-2 Mpro C145A mutant in complex with nsp12-nsp13 (C12) cut site sequence
8DRZ	;	1.98	;	Product structure of SARS-CoV-2 Mpro C145A mutant in complex with nsp13-nsp14 (C13) cut site sequence
8DS0	;	2.2	;	Product structure of SARS-CoV-2 Mpro C145A mutant in complex with nsp14-nsp15 (C14) cut site sequence (form 2)
8DRR	;	2.0	;	Product structure of SARS-CoV-2 Mpro C145A mutant in complex with nsp4-nsp5 (C4) cut site sequence
8DRS	;	1.8	;	Product structure of SARS-CoV-2 Mpro C145A mutant in complex with nsp6-nsp7 (C6) cut site sequence
8DRT	;	1.5	;	Product structure of SARS-CoV-2 Mpro C145A mutant in complex with nsp6-nsp7 (C6) cut site sequence (form 2)
8DRU	;	2.31	;	Product structure of SARS-CoV-2 Mpro C145A mutant in complex with nsp7-nsp8 (C7) cut site sequence
8DRV	;	2.4	;	Product structure of SARS-CoV-2 Mpro C145A mutant in complex with nsp8-nsp9 (C8) cut site sequence
8DRW	;	2.67	;	Product structure of SARS-CoV-2 Mpro C145A mutant in complex with nsp9-nsp10 (C9) cut site sequence
5MHB	;	2.1	;	Product-Complex of E.coli 5-Amino Laevulinic Acid Dehydratase
2AX2	;	1.5	;	Production and X-ray crystallographic analysis of fully deuterated human carbonic anhydrase II
8C6D	;	2.4	;	Production of antigenically stable enterovirus A71 virus-like particles in Pichia pastoris as a vaccine candidate.
2N8R	;		;	Productive complex between MMP-12 and synthetic triple-helical collagen, revealed through paramagnetic NMR
1R0C	;	2.37	;	Products in the T State of Aspartate Transcarbamylase: Crystal Structure of the Phosphate and N-carbamyl-L-aspartate Ligated Enzyme
1FDP	;	2.1	;	PROENZYME OF HUMAN COMPLEMENT FACTOR D, RECOMBINANT PROFACTOR D
1CJF	;	2.3	;	PROFILIN BINDS PROLINE-RICH LIGANDS IN TWO DISTINCT AMIDE BACKBONE ORIENTATIONS
1A0K	;	2.2	;	PROFILIN I FROM ARABIDOPSIS THALIANA
3NUL	;	1.6	;	Profilin I from Arabidopsis thaliana
3UB5	;	2.2	;	Profilin:actin with a wide open nucleotide cleft
3HQ5	;	2.1	;	Progesterone Receptor bound to an Alkylpyrrolidine ligand.
3KBA	;	2.0	;	Progesterone receptor bound to sulfonamide pyrrolidine partial agonist
1SR7	;	1.46	;	Progesterone Receptor Hormone Binding Domain with Bound Mometasone Furoate
1ZUC	;	2.0	;	Progesterone receptor ligand binding domain in complex with the nonsteroidal agonist tanaproget
1SQN	;	1.451	;	Progesterone Receptor Ligand Binding Domain with bound Norethindrone
2OVM	;	2.6	;	Progesterone Receptor with Bound Asoprisnil and a Peptide from the Co-Repressor NCoR
2OVH	;	2.0	;	Progesterone Receptor with Bound Asoprisnil and a Peptide from the Co-Repressor SMRT
3G8O	;	1.9	;	Progesterone Receptor with bound Pyrrolidine 1
4OAR	;	2.41	;	Progesterone receptor with bound ulipristal acetate and a peptide from the co-repressor SMRT
7P65	;	2.7	;	Progressive supranuclear palsy tau filament
6OKB	;	6.7	;	Prohead 2 of the phage T5
8XOT	;	3.51	;	Prohead portal of bacteriophage lambda
8XOU	;	5.58	;	Prohead portal vertex of bacteriophage lambda
3R4F	;	3.5	;	Prohead RNA
6UCK	;		;	proIAPP in DPC Micelles - Two-Conformer Ensemble Refinement, Bent Conformer
6UCJ	;		;	proIAPP in DPC Micelles - Two-Conformer Ensemble Refinement, Open Conformer
2PN0	;	1.7	;	Prokaryotic transcription elongation factor GreA/GreB from Nitrosomonas europaea
3NPZ	;	3.35	;	Prolactin Receptor (PRLR) Complexed with the Natural Hormone (PRL)
1PV9	;	2.0	;	Prolidase from Pyrococcus furiosus
1GE8	;	2.1	;	PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) HOMOLOG FROM PYROCOCCUS FURIOSUS
5DAI	;	2.0	;	Proliferating cell nuclear antigen homolog 1 bound to FEN-1 peptide
5A6D	;	2.8	;	Proliferating Cell Nuclear Antigen, PCNA, from Thermococcus gammatolerans
6WM8	;	2.6	;	Proliferation-Associated protein 2G4 (PA2G4)
1E5S	;	2.4	;	Proline 3-hydroxylase (type II) - Iron form
1E5R	;	2.3	;	Proline 3-hydroxylase (type II) -apo form
8P5O	;	2.6	;	Proline activating adenylation domain of gramicidin S synthetase 2 - GrsB1-Acore
4PV4	;	1.76	;	Proline aminopeptidase P II from Yersinia pestis
4ICB	;	1.6	;	PROLINE CIS-TRANS ISOMERS IN CALBINDIN D9K OBSERVED BY X-RAY CRYSTALLOGRAPHY
5CDL	;	1.8	;	Proline dipeptidase from Deinococcus radiodurans (selenomethionine derivative)
5CDV	;	1.45	;	Proline dipeptidase from Deinococcus radiodurans R1
7DT0	;	2.43	;	Proline hydroxylase H11-N101I mutant
5YHP	;	2.393	;	Proline iminopeptidase from Psychrophilic yeast glaciozyma antarctica
1AZW	;	2.7	;	PROLINE IMINOPEPTIDASE FROM XANTHOMONAS CAMPESTRIS PV. CITRI
8A4R	;	3.59	;	Proline Racemase (ProR) from the Gram-positive bacterium Acetoanaerobium sticklandii from isotropic orthorhombic data at 3.59 A
8A3F	;	3.15	;	Proline Racemase (ProR) from the Gram-positive bacterium Acetoanaerobium sticklandii from isotropic tetragonal data at 3.15 A
1W61	;	2.1	;	proline racemase in complex with 2 molecules of pyrrole-2-carboxylic acid (holo form)
1W62	;	2.5	;	proline racemase in complex with one molecule of pyrrole-2-carboxylic acid (hemi form)
5V7Y	;	2.05	;	Prolyl 4-Hydroxylase Interacts with and Modifies Elongation Factor Tu
6T8M	;	2.02	;	Prolyl Hydroxylase (PHD) involved in hypoxia sensing by Dictyostelium discoideum
6EY1	;	1.199	;	prolyl hydroxylase from Trichoplax adhaerens
6F0W	;	1.301	;	prolyl hydroxylase in complex with hypoxia inducible factor oxygen degradation domain peptide fragment from Trichoplax adhaerens
5UY9	;	1.85	;	Prolyl isomerase Pin1 R14A mutant bound with Brd4 peptide
5N4F	;	2.4	;	Prolyl oligopeptidase B from Galerina marginata - apo protein
5N4D	;	1.62	;	Prolyl oligopeptidase B from Galerina marginata bound to 25mer macrocyclization substrate - D661A mutant
5N4B	;	1.44	;	Prolyl oligopeptidase B from Galerina marginata bound to 25mer macrocyclization substrate - S577A mutant
5N4E	;	2.9	;	Prolyl oligopeptidase B from Galerina marginata bound to 35mer hydrolysis and macrocyclization substrate - H698A mutant
5N4C	;	2.19	;	Prolyl oligopeptidase B from Galerina marginata bound to 35mer hydrolysis and macrocyclization substrate - S577A mutant
3EQ7	;	2.89	;	Prolyl oligopeptidase complexed with R-Pro-(decarboxy-Pro)-Type inhibitors
3EQ8	;	2.73	;	Prolyl oligopeptidase complexed with R-Pro-(decarboxy-Pro)-Type inhibitors
3EQ9	;	2.47	;	Prolyl oligopeptidase complexed with R-Pro-(decarboxy-Pro)-Type inhibitors
1H2W	;	1.39	;	PROLYL OLIGOPEPTIDASE FROM PORCINE BRAIN
4AMY	;	2.0	;	PROLYL OLIGOPEPTIDASE FROM PORCINE BRAIN WITH A COVALENTLY BOUND INHIBITOR IC-1
4AMZ	;	2.0	;	PROLYL OLIGOPEPTIDASE FROM PORCINE BRAIN WITH A COVALENTLY BOUND INHIBITOR IC-2
4AN0	;	2.2	;	PROLYL OLIGOPEPTIDASE FROM PORCINE BRAIN WITH A COVALENTLY BOUND INHIBITOR IC-3
4AN1	;	1.9	;	PROLYL OLIGOPEPTIDASE FROM PORCINE BRAIN WITH A COVALENTLY BOUND INHIBITOR IC-4
4BCB	;	1.7	;	PROLYL OLIGOPEPTIDASE FROM PORCINE BRAIN WITH A COVALENTLY BOUND P2- substituted N-acyl-prolylpyrrolidine inhibitor
4BCC	;	1.65	;	PROLYL OLIGOPEPTIDASE FROM PORCINE BRAIN WITH A COVALENTLY BOUND P2- substituted N-acyl-prolylpyrrolidine inhibitor
4BCD	;	1.5	;	PROLYL OLIGOPEPTIDASE FROM PORCINE BRAIN WITH A NON-COVALENTLY BOUND P2-substituted N-acyl-prolylpyrrolidine inhibitor
1O6F	;	1.6	;	PROLYL OLIGOPEPTIDASE FROM PORCINE BRAIN, D641A MUTANT WITH BOUND PEPTIDE LIGAND SUC-GLY-PRO
1O6G	;	1.4	;	PROLYL OLIGOPEPTIDASE FROM PORCINE BRAIN, D641N MUTANT WITH BOUND PEPTIDE LIGAND SUC-GLY-PRO
4AX4	;	1.6	;	PROLYL OLIGOPEPTIDASE FROM PORCINE BRAIN, H680A MUTANT
1E5T	;	1.7	;	PROLYL OLIGOPEPTIDASE FROM PORCINE BRAIN, MUTANT
1E8M	;	1.5	;	PROLYL OLIGOPEPTIDASE FROM PORCINE BRAIN, MUTANT, COMPLEXED WITH INHIBITOR
1E8N	;	1.5	;	PROLYL OLIGOPEPTIDASE FROM PORCINE BRAIN, MUTANT, COMPLEXED WITH PEPTIDE
1UOQ	;	2.1	;	PROLYL OLIGOPEPTIDASE FROM PORCINE BRAIN, S554A MUTANT WITH BOUND PEPTIDE LIGAND GLU-PHE-SER-PRO
1UOO	;	2.35	;	Prolyl oligopeptidase from porcine brain, S554A mutant with bound peptide ligand GLY-PHE-ARG-PRO
1UOP	;	1.85	;	PROLYL OLIGOPEPTIDASE FROM PORCINE BRAIN, S554A MUTANT WITH BOUND PEPTIDE LIGAND GLY-PHE-GLU-PRO
1H2Z	;	1.65	;	PROLYL OLIGOPEPTIDASE FROM PORCINE BRAIN, S554A MUTANT WITH BOUND PEPTIDE LIGAND SUC-GLY-PRO
1VZ3	;	1.6	;	PROLYL OLIGOPEPTIDASE FROM PORCINE BRAIN, T597C MUTANT
1H2X	;	1.49	;	PROLYL OLIGOPEPTIDASE FROM PORCINE BRAIN, Y473F MUTANT
1H2Y	;	1.78	;	PROLYL OLIGOPEPTIDASE FROM PORCINE BRAIN, Y473F MUTANT WITH COVALENTLY BOUND INHIBITOR Z-PRO-PROLINAL
1VZ2	;	2.2	;	PROLYL OLIGOPEPTIDASE FROM PORCINE BRAIN, Y73C/V427C/C255T MUTANT
1QFM	;	1.4	;	PROLYL OLIGOPEPTIDASE FROM PORCINE MUSCLE
1QFS	;	2.0	;	PROLYL OLIGOPEPTIDASE FROM PORCINE MUSCLE WITH COVALENTLY BOUND INHIBITOR Z-PRO-PROLINAL
5T88	;	1.902	;	Prolyl oligopeptidase from Pyrococcus furiosus
6CAN	;	2.2	;	Prolyl oligopeptidase mutant S477C from Pyrococcus furiosus
3DDU	;	1.56	;	Prolyl Oligopeptidase with GSK552
2EEP	;	2.2	;	Prolyl Tripeptidyl Aminopeptidase Complexed with an Inhibitor
2Z3W	;	2.0	;	Prolyl tripeptidyl aminopeptidase mutant E636A
2Z3Z	;	1.95	;	Prolyl tripeptidyl aminopeptidase mutant E636A complexd with an inhibitor
2J3L	;	2.3	;	Prolyl-tRNA synthetase from Enterococcus faecalis complexed with a prolyl-adenylate analogue ('5'-O-(N-(L-PROLYL)-SULFAMOYL)ADENOSINE)
2J3M	;	2.3	;	PROLYL-TRNA SYNTHETASE FROM ENTEROCOCCUS FAECALIS COMPLEXED WITH ATP, manganese and prolinol
1HC7	;	2.43	;	Prolyl-tRNA synthetase from Thermus thermophilus
1H4T	;	2.9	;	Prolyl-tRNA synthetase from Thermus thermophilus complexed with L-proline
1H4S	;	2.85	;	Prolyl-tRNA synthetase from Thermus thermophilus complexed with tRNApro(CGG) and a prolyl-adenylate analogue
1H4Q	;	3.0	;	Prolyl-tRNA synthetase from Thermus thermophilus complexed with tRNApro(CGG), ATP and prolinol
6T2N	;	2.7	;	Prominent members of the human gut microbiota express endo-acting O-glycanases to initiate mucin breakdown
6T2O	;	2.05	;	Prominent members of the human gut microbiota express endo-acting O-glycanases to initiate mucin breakdown
6T2P	;	2.1	;	Prominent members of the human gut microbiota express endo-acting O-glycanases to initiate mucin breakdown
6T2Q	;	2.0	;	Prominent members of the human gut microbiota express endo-acting O-glycanases to initiate mucin breakdown
6T2R	;	2.1	;	Prominent members of the human gut microbiota express endo-acting O-glycanases to initiate mucin breakdown
6T2S	;	3.3	;	Prominent members of the human gut microbiota express endo-acting O-glycanases to initiate mucin breakdown
3A5U	;	2.8	;	Promiscuity and specificity in DNA binding to SSB: Insights from the structure of the Mycobacterium smegmatis SSB-ssDNA complex
8SF6	;	1.702	;	Promiscuous amino acid gamma synthase from Caldicellulosiruptor hydrothermalis in closed conformation
8SF5	;	2.3	;	Promiscuous amino acid gamma synthase from Caldicellulosiruptor hydrothermalis in open conformation
4V6U	;	6.6	;	Promiscuous behavior of proteins in archaeal ribosomes revealed by cryo-EM: implications for evolution of eukaryotic ribosomes
2L4S	;		;	Promiscuous Binding at the Crossroads of Numerous Cancer Pathways: Insight from the Binding of GIP with Glutaminase L
5NPO	;	1.95	;	Promiscuous Protein Self-Assembly as a Function of Protein Stability
6YPZ	;	1.08	;	Promiscuous Reductase LugOII Catalyzes Keto-reduction at C1 during Lugdunomycin Biosynthesis
6YQ0	;	1.08	;	Promiscuous Reductase LugOII Catalyzes Keto-reduction at C1 during Lugdunomycin Biosynthesis
6YQ3	;	1.57	;	Promiscuous Reductase LugOII Catalyzes Keto-reduction at C1 during Lugdunomycin Biosynthesis
6YQ6	;	2.08	;	Promiscuous Reductase LugOII Catalyzes Keto-reduction at C1 during Lugdunomycin Biosynthesis
3GTY	;	3.4	;	Promiscuous Substrate Recognition in Folding and Assembly Activities of the Trigger Factor Chaperone
3GU0	;	3.5	;	Promiscuous Substrate Recognition in Folding and Assembly Activities of the Trigger Factor Chaperone
1GXD	;	3.1	;	proMMP-2/TIMP-2 complex
5UE5	;		;	proMMP-7 with heparin octasaccharide bound to the catalytic domain
5UE2	;		;	proMMP-7 with heparin octasaccharide bridging between domains
5UE3	;	1.599	;	proMMP-9desFnII
5UE4	;	1.8	;	proMMP-9desFnII complexed to JNJ0966 INHIBITOR
5O3O	;	3.5	;	Pronase-treated paired helical filament in Alzheimer's disease brain
2NTX	;	2.2	;	Prone8
1JMW	;	1.9	;	Propagating Conformational Changes Over Long (And Short) Distances
1DC9	;	2.1	;	PROPERTIES AND CRYSTAL STRUCTURE OF A BETA-BARREL FOLDING MUTANT, V60N INTESTINAL FATTY ACID BINDING PROTEIN (IFABP)
3APT	;	1.85	;	properties and crystal structure of methylenetetrahydrofolate reductase from Thermus thermophilus HB8
3APY	;	2.8	;	Properties and crystal structure of methylenetetrahydrofolate reductase from Thermus thermophilus HB8
2WBA	;	2.3	;	Properties of Trypanothione Reductase From T. brucei
1HN4	;	1.5	;	PROPHOSPHOLIPASE A2 DIMER COMPLEXED WITH MJ33, SULFATE, AND CALCIUM
8E1U	;	2.65	;	Propionibacterium freudenreichii PPi-dependent PEPCK in complex with malate
1RQB	;	1.9	;	Propionibacterium shermanii transcarboxylase 5S subunit
1S3H	;	2.5	;	Propionibacterium shermanii transcarboxylase 5S subunit A59T
1RR2	;	2.0	;	Propionibacterium shermanii transcarboxylase 5S subunit bound to 2-ketobutyric acid
1RQE	;	2.5	;	Propionibacterium shermanii transcarboxylase 5S subunit bound to oxaloacetate
1RQH	;	2.0	;	Propionibacterium shermanii transcarboxylase 5S subunit bound to pyruvic acid
1U5J	;	2.8	;	Propionibacterium shermanii transcarboxylase 5S subunit, Met186Ile
3IBB	;	3.5	;	Propionyl-CoA Carboxylase Beta Subunit, D422A
3IB9	;	2.0	;	Propionyl-CoA Carboxylase Beta Subunit, D422L
3IAV	;	1.75	;	Propionyl-CoA Carboxylase Beta Subunit, D422V
6YBP	;	3.48	;	Propionyl-CoA carboxylase of Methylorubrum extorquens with bound CoA
5WGC	;	2.15	;	propionyl-DpsC in complex with oxetane-bearing probe
1PFZ	;	1.85	;	PROPLASMEPSIN II FROM PLASMODIUM FALCIPARUM
1IWD	;	1.63	;	Proposed Amino Acid Sequence and the 1.63 Angstrom X-ray Crystal Structure of a Plant Cysteine Protease Ervatamin B: Insight into the Structural Basis of its Stability and Substrate Specificity.
5CTS	;	1.9	;	PROPOSED MECHANISM FOR THE CONDENSATION REACTION OF CITRATE SYNTHASE. 1.9-ANGSTROMS STRUCTURE OF THE TERNARY COMPLEX WITH OXALOACETATE AND CARBOXYMETHYL COENZYME A
6CTS	;	2.5	;	PROPOSED MECHANISM FOR THE CONDENSATION REACTION OF CITRATE SYNTHASE. 1.9-ANGSTROMS STRUCTURE OF THE TERNARY COMPLEX WITH OXALOACETATE AND CARBOXYMETHYL COENZYME A
7R3I	;	3.1	;	PROSS optimitzed variant of RhlR (61 mutations) in complex with the synthetic antagonist mBTL
7R3H	;	3.49	;	PROSS optimitzed variant of RhlR (75 mutations) in complex with native autoinducer C4-HSL
7R3G	;	2.15	;	PROSS optimitzed variant of RhlR (75 mutations) in complex with the synthetic antagonist mBTL
8D1D	;	1.42	;	PROSS PETase
1RY8	;	1.69	;	Prostaglandin F synthase complexed with NADPH and rutin
1CQE	;	3.1	;	PROSTAGLANDIN H2 SYNTHASE-1 COMPLEX WITH FLURBIPROFEN
1PGF	;	4.5	;	PROSTAGLANDIN H2 SYNTHASE-1 COMPLEXED WITH 1-(4-IODOBENZOYL)-5-METHOXY-2-METHYLINDOLE-3-ACETIC ACID (IODOINDOMETHACIN), CIS MODEL
1PGG	;	4.5	;	PROSTAGLANDIN H2 SYNTHASE-1 COMPLEXED WITH 1-(4-IODOBENZOYL)-5-METHOXY-2-METHYLINDOLE-3-ACETIC ACID (IODOINDOMETHACIN), TRANS MODEL
1PGE	;	3.5	;	PROSTAGLANDIN H2 SYNTHASE-1 COMPLEXED WITH P-(2'-IODO-5'-THENOYL)HYDROTROPIC ACID (IODOSUPROFEN)
1GVZ	;	1.42	;	Prostate Specific Antigen (PSA) from stallion seminal plasma
7ZZV	;		;	Prostatic acid phosphatase (PAP) fragment (85-120)
3CNQ	;	1.71	;	Prosubtilisin Substrate Complex of Subtilisin SUBT_BACAM
8QU8	;	3.5	;	PROTAC-mediated complex of KRAS with VHL/Elongin-B/Elongin-C/Cullin-2/Rbx1
6ZHC	;	1.92	;	PROTAC6 mediated complex of VHL:EloB:EloC and Bcl-xL
2R0K	;	3.51	;	Protease domain of HGFA with inhibitor Fab58
1YBW	;	2.7	;	Protease domain of HGFA with no inhibitor
5LKQ	;	2.498	;	Protease domain of RadA
5KR0	;	1.8	;	Protease E35D-APV
5KQZ	;	1.7	;	Protease E35D-CaP2
5KQY	;	1.65	;	Protease E35D-DRV
5KQX	;	2.4	;	Protease E35D-SQV
1SKZ	;	1.9	;	PROTEASE INHIBITOR
5UGD	;	1.38	;	Protease Inhibitor
5UGG	;	1.2	;	Protease Inhibitor
1ECY	;	2.19	;	PROTEASE INHIBITOR ECOTIN
1ECZ	;	2.68	;	PROTEASE INHIBITOR ECOTIN
7SGQ	;	2.09	;	Protease inhibitors variant, CTI-homolog pacifastin
7SLT	;	2.0	;	Protease inhibitors variant, CTI-homolog pacifastin
5KR1	;	1.6	;	Protease PR5-DRV
5KR2	;	1.78	;	Protease PR5-SQV
7AGE	;	1.3	;	Protease Sapp1p from Candida parapsilosis in complex with KB32
7AGB	;	1.7	;	Protease Sapp1p from Candida parapsilosis in complex with KB70
7AGC	;	1.35	;	Protease Sapp1p from Candida parapsilosis in complex with KB74
7AGD	;	1.8	;	Protease Sapp1p from Candida parapsilosis in complex with KB75
6D3Z	;	2.0	;	Protease SFTI complex
7EOX	;	1.7	;	Protease structure from Euphorbia resinifera
3ICU	;	2.1	;	Protease-associated domain of the E3 ligase grail
4BR1	;	1.9	;	Protease-induced heterodimer of human triosephosphate isomerase.
1SI5	;	2.53	;	Protease-like domain from 2-chain hepatocyte growth factor
3VKM	;	2.98	;	Protease-resistant mutant form of Human Galectin-8 in complex with sialyllactose and lactose
3VKL	;	2.55	;	Protease-resistant mutant form of human Galectin-8 in complex with two lactose molecules
5YL7	;	1.4	;	Proteases from Pseudoalteromonas arctica PAMC 21717 (Pro21717)
3H4P	;	4.1	;	Proteasome 20S core particle from Methanocaldococcus jannaschii
8T0M	;	2.4	;	Proteasome 20S core particle from Pre1-1 Pre4-1 Double mutant
6SJ9	;	2.2	;	Proteasome accessory factor B/C (PafBC) of Arthrobacter aurescens
4V7O	;	3.005	;	Proteasome Activator Complex
1AVO	;	2.8	;	PROTEASOME ACTIVATOR REG(ALPHA)
2JAY	;	1.99	;	Proteasome beta subunit PrcB from Mycobacterium tuberculosis
1PMA	;	3.4	;	PROTEASOME FROM THERMOPLASMA ACIDOPHILUM
3SHJ	;	2.8	;	Proteasome in complex with hydroxyurea derivative HU10
3D29	;	2.6	;	Proteasome Inhibition by Fellutamide B
2WG5	;	2.1	;	Proteasome-Activating Nucleotidase (PAN) N-domain (57-134) from Archaeoglobus fulgidus fused to GCN4
2WG6	;	2.5	;	Proteasome-Activating Nucleotidase (PAN) N-domain (57-134) from Archaeoglobus fulgidus fused to GCN4, P61A Mutant
7QXN	;	3.7	;	Proteasome-ZFAND5 Complex Z+A state
7QXP	;	3.6	;	Proteasome-ZFAND5 Complex Z+B state
7QXU	;	4.3	;	Proteasome-ZFAND5 Complex Z+C state
7QXW	;	4.1	;	Proteasome-ZFAND5 Complex Z+D state
7QXX	;	4.4	;	Proteasome-ZFAND5 Complex Z+E state
7QY7	;	4.7	;	Proteasome-ZFAND5 Complex Z-A state
7QYA	;	4.8	;	Proteasome-ZFAND5 Complex Z-B state
7QYB	;	4.1	;	Proteasome-ZFAND5 Complex Z-C state
2MTX	;		;	Protection against experimental P. falciparum malaria is associated with short AMA-1 peptide analogue alpha-helical structures
8DOZ	;	1.7	;	Protective antibody against gonococcal lipooligosaccharide
8DUZ	;	1.65	;	Protective antibody against gonococcal lipooligosaccharide bound to peptide mimetic
7KXR	;	3.3	;	Protective antigen pore translocating lethal factor N-terminal domain
2MUG	;		;	Protective cellular immunity against P. falciparum malaria merozoite is associated with a different P7 and P8 residue orientation in the MHC-peptide-TCR complex
1PG1	;		;	PROTEGRIN 1 (PG1) FROM PORCINE LEUKOCYTES, NMR, 20 STRUCTURES
5UWZ	;	1.25	;	Protein 12 with aldehyde deformylating oxygenase activity from Gloeobacter violaceus
5UX2	;	1.99	;	Protein 19 with aldehyde deformylating oxidase activity from Synechococcus
8FHB	;	1.95	;	Protein 32 with aldehyde deformylating oxidase activity from Synechococcus sp.
5UXI	;	2.0	;	Protein 4 with aldehyde deformylating oxygenase activity from Nostoc puntiforme
7UZS	;	2.2	;	Protein 4.2 (local refinement from consensus reconstruction of ankyrin complex classes)
8FHC	;	2.097	;	Protein 41 with aldehyde deformylating oxidase activity from Gamma proteobacterium
5UX1	;	1.5	;	Protein 43 with aldehyde deformylating oxygenase activity from Synechococcus
6D9F	;	2.03	;	Protein 60 with aldehyde deformylating oxidase activity from Kitasatospora setae
5UXG	;	1.72	;	Protein 84 with aldehyde deformylating oxygenase activity from Sulfolobus tokodaii (monoclinic)
5V4T	;	1.7	;	Protein 84 with aldehyde deformylating oxygenase activity from Sulfolobus tokodaii (orthorhombic form)
2JWD	;		;	protein A
5C6N	;	3.0	;	protein A
6OOM	;	2.2	;	PROTEIN A
6VRZ	;	2.0	;	protein A
2M5A	;		;	Protein A binding by an engineered Affibody molecule
1CQM	;	1.65	;	PROTEIN AGGREGATION AND ALZHEIMER'S DISEASE: CRYSTALLOGRAPHIC ANALYSIS OF THE PHENOMENON. ENGINEERED VERSION OF THE RIBOSOMAL PROTEIN S6 USED AS A STABLE SCAFFOLD TO STUDY OLIGOMERIZATION.
1CQN	;	2.1	;	PROTEIN AGGREGATION AND ALZHEIMER'S DISEASE: CRYSTALLOGRAPHIC ANALYSIS OF THE PHENOMENON. ENGINEERED VERSION OF THE RIBOSOMAL PROTEIN S6 USED AS A STABLE SCAFFOLD TO STUDY OLIGOMERIZATION.
1QJH	;	2.2	;	Protein Aggregation and Alzheimer's Disease: Crystallographic Analysis of the Phenomenon. Engineered version of the ribosomal protein S6 used as a stable scaffold to study oligomerization.
6SVC	;		;	Protein allostery of the WW domain at atomic resolution: apo structure
6SVH	;		;	Protein allostery of the WW domain at atomic resolution: FFpSPR bound structure
6SVE	;		;	Protein allostery of the WW domain at atomic resolution: pCdc25C bound structure
2L61	;		;	Protein and metal cluster structure of the wheat metallothionein domain g-Ec-1. The second part of the puzzle.
2L62	;		;	Protein and metal cluster structure of the wheat metallothionein domain g-Ec-1. The second part of the puzzle.
6FH2	;	2.7	;	Protein arginine kinase McsB in the AMP-PN-bound state
6FH1	;	1.7	;	Protein arginine kinase McsB in the apo state
6FH3	;	1.85	;	Protein arginine kinase McsB in the pArg-bound state
4QQN	;	2.08	;	Protein arginine methyltransferase 3 in complex with compound MTV044246
5C6O	;	3.0	;	protein B
6OOP	;	2.8	;	protein B
6VS0	;	2.1	;	protein B
5C6P	;	3.0	;	protein C
6OOQ	;	3.0	;	protein C
6VS1	;	3.0	;	protein C
2PD0	;	2.3	;	Protein cgd2_2020 from Cryptosporidium parvum
7Q5S	;	4.47	;	Protein community member fatty acid synthase complex from C. thermophilum
7Q5Q	;	4.38	;	Protein community member oxoglutarate dehydrogenase complex E2 core from C. thermophilum
7Q5R	;	3.84	;	Protein community member pyruvate dehydrogenase complex E2 core from C. thermophilum
4GG6	;	3.2	;	Protein complex
7F7X	;		;	Protein complex between phosphorylated ubiquitin and Ubqln2 UBA
4OI4	;	2.4	;	Protein complex of Clp1 bound to ATP and Mg2+ with Pcf11deltaN454deltaC563 of S. cerevisiae
1Z3D	;	2.5	;	Protein crystal growth improvement leading to the 2.5A crystallographic structure of ubiquitin-conjugating enzyme (ubc-1) from Caenorhabditis elegans
4NN2	;	1.472	;	Protein Crystal Structure of Human Borjeson-Forssman-Lehmann Syndrome Associated Protein PHF6
4BQQ	;	2.15	;	Protein crystal structure of the N-terminal and recombinase domains of the Streptomyces temperate phage serine recombinase, fC31 integrase.
3RDK	;	1.49	;	Protein crystal structure of xylanase A1 of Paenibacillus sp. JDR-2
4A8I	;	0.95	;	Protein crystallization and microgravity: glucose isomerase crystals grown during the PCDF-PROTEIN mission
4A8L	;	1.35	;	Protein crystallization and microgravity: glucose isomerase crystals grown during the PCDF-PROTEIN mission
4A8N	;	1.2	;	Protein crystallization and microgravity: glucose isomerase crystals grown during the PCDF-PROTEIN mission
4A8R	;	1.42	;	Protein crystallization and microgravity: glucose isomerase crystals grown during the PCDF-PROTEIN mission
6QUK	;	1.58	;	Protein crystallization by ionic liquid hydrogel support: glucose isomerase grown by using ionic liquid hydrogel
6QUF	;	1.19	;	Protein crystallization by ionic liquid hydrogel support: reference crystal of glucose isomerase grown on standard silanized glass
6VS2	;	3.0	;	protein D
2BJX	;		;	PROTEIN DISULFIDE ISOMERASE
1A8L	;	1.9	;	PROTEIN DISULFIDE OXIDOREDUCTASE FROM ARCHAEON PYROCOCCUS FURIOSUS
4QGU	;	2.545	;	protein domain complex with ssDNA
3ZN2	;	1.8	;	protein engineering of halohydrin dehalogenase
1XIN	;	2.4	;	PROTEIN ENGINEERING OF XYLOSE (GLUCOSE) ISOMERASE FROM ACTINOPLANES MISSOURIENSIS. 1. CRYSTALLOGRAPHY AND SITE-DIRECTED MUTAGENESIS OF METAL BINDING SITES
2XIN	;	2.3	;	PROTEIN ENGINEERING OF XYLOSE (GLUCOSE) ISOMERASE FROM ACTINOPLANES MISSOURIENSIS. 1. CRYSTALLOGRAPHY AND SITE-DIRECTED MUTAGENESIS OF METAL BINDING SITES
3XIN	;	2.3	;	PROTEIN ENGINEERING OF XYLOSE (GLUCOSE) ISOMERASE FROM ACTINOPLANES MISSOURIENSIS. 1. CRYSTALLOGRAPHY AND SITE-DIRECTED MUTAGENESIS OF METAL BINDING SITES
4XIM	;	2.3	;	PROTEIN ENGINEERING OF XYLOSE (GLUCOSE) ISOMERASE FROM ACTINOPLANES MISSOURIENSIS. 1. CRYSTALLOGRAPHY AND SITE-DIRECTED MUTAGENESIS OF METAL BINDING SITES
5XIM	;	2.6	;	PROTEIN ENGINEERING OF XYLOSE (GLUCOSE) ISOMERASE FROM ACTINOPLANES MISSOURIENSIS. 1. CRYSTALLOGRAPHY AND SITE-DIRECTED MUTAGENESIS OF METAL BINDING SITES
5XIN	;	2.3	;	PROTEIN ENGINEERING OF XYLOSE (GLUCOSE) ISOMERASE FROM ACTINOPLANES MISSOURIENSIS. 1. CRYSTALLOGRAPHY AND SITE-DIRECTED MUTAGENESIS OF METAL BINDING SITES
6XIM	;	2.5	;	PROTEIN ENGINEERING OF XYLOSE (GLUCOSE) ISOMERASE FROM ACTINOPLANES MISSOURIENSIS. 1. CRYSTALLOGRAPHY AND SITE-DIRECTED MUTAGENESIS OF METAL BINDING SITES
7XIM	;	2.4	;	PROTEIN ENGINEERING OF XYLOSE (GLUCOSE) ISOMERASE FROM ACTINOPLANES MISSOURIENSIS. 1. CRYSTALLOGRAPHY AND SITE-DIRECTED MUTAGENESIS OF METAL BINDING SITES
8XIM	;	2.4	;	PROTEIN ENGINEERING OF XYLOSE (GLUCOSE) ISOMERASE FROM ACTINOPLANES MISSOURIENSIS. 1. CRYSTALLOGRAPHY AND SITE-DIRECTED MUTAGENESIS OF METAL BINDING SITES
9XIM	;	2.4	;	PROTEIN ENGINEERING OF XYLOSE (GLUCOSE) ISOMERASE FROM ACTINOPLANES MISSOURIENSIS. 1. CRYSTALLOGRAPHY AND SITE-DIRECTED MUTAGENESIS OF METAL BINDING SITES
1ML1	;	2.6	;	PROTEIN ENGINEERING WITH MONOMERIC TRIOSEPHOSPHATE ISOMERASE: THE MODELLING AND STRUCTURE VERIFICATION OF A SEVEN RESIDUE LOOP
6FVC	;		;	Protein environment affects the water-tryptophan binding mode. Molecular dynamics simulations of Engrailed homeodomain mutants
1FPP	;	2.75	;	PROTEIN FARNESYLTRANSFERASE COMPLEX WITH FARNESYL DIPHOSPHATE
2H6F	;	1.5	;	Protein Farnesyltransferase Complexed with a Farnesylated DDPTASACVLS Peptide Product at 1.5A Resolution
1KZP	;	2.1	;	PROTEIN FARNESYLTRANSFERASE COMPLEXED WITH A FARNESYLATED K-RAS4B PEPTIDE PRODUCT
1TN8	;	2.25	;	Protein Farnesyltransferase Complexed with a H-Ras Peptide Substrate and a FPP Analog at 2.25A Resolution
1TN6	;	1.8	;	Protein Farnesyltransferase Complexed with a Rap2a Peptide Substrate and a FPP Analog at 1.8A Resolution
1TN7	;	2.3	;	Protein Farnesyltransferase Complexed with a TC21 Peptide Substrate and a FPP Analog at 2.3A Resolution
3E37	;	1.8	;	Protein farnesyltransferase complexed with bisubstrate ethylenediamine scaffold inhibitor 5
1KZO	;	2.2	;	PROTEIN FARNESYLTRANSFERASE COMPLEXED WITH FARNESYLATED K-RAS4B PEPTIDE PRODUCT AND FARNESYL DIPHOSPHATE SUBSTRATE BOUND SIMULTANEOUSLY
3DPY	;	2.7	;	Protein farnesyltransferase complexed with FPP and caged TKCVIM substrate
3E30	;	2.45	;	Protein farnesyltransferase complexed with FPP and ethylene diamine inhibitor 4
3E32	;	2.45	;	Protein farnesyltransferase complexed with FPP and ethylenediamine scaffold inhibitor 2
3E33	;	1.9	;	Protein farnesyltransferase complexed with FPP and ethylenediamine scaffold inhibitor 7
3E34	;	2.05	;	Protein farnesyltransferase complexed with FPP and ethylenediamine-scaffold inhibitor 10
2KIB	;		;	Protein Fibril
167L	;	2.2	;	PROTEIN FLEXIBILITY AND ADAPTABILITY SEEN IN 25 CRYSTAL FORMS OF T4 LYSOZYME
168L	;	2.9	;	PROTEIN FLEXIBILITY AND ADAPTABILITY SEEN IN 25 CRYSTAL FORMS OF T4 LYSOZYME
169L	;	3.0	;	PROTEIN FLEXIBILITY AND ADAPTABILITY SEEN IN 25 CRYSTAL FORMS OF T4 LYSOZYME
170L	;	2.6	;	PROTEIN FLEXIBILITY AND ADAPTABILITY SEEN IN 25 CRYSTAL FORMS OF T4 LYSOZYME
171L	;	2.5	;	PROTEIN FLEXIBILITY AND ADAPTABILITY SEEN IN 25 CRYSTAL FORMS OF T4 LYSOZYME
172L	;	1.9	;	PROTEIN FLEXIBILITY AND ADAPTABILITY SEEN IN 25 CRYSTAL FORMS OF T4 LYSOZYME
173L	;	1.7	;	PROTEIN FLEXIBILITY AND ADAPTABILITY SEEN IN 25 CRYSTAL FORMS OF T4 LYSOZYME
174L	;	2.3	;	PROTEIN FLEXIBILITY AND ADAPTABILITY SEEN IN 25 CRYSTAL FORMS OF T4 LYSOZYME
175L	;	2.1	;	PROTEIN FLEXIBILITY AND ADAPTABILITY SEEN IN 25 CRYSTAL FORMS OF T4 LYSOZYME
176L	;	2.2	;	PROTEIN FLEXIBILITY AND ADAPTABILITY SEEN IN 25 CRYSTAL FORMS OF T4 LYSOZYME
177L	;	2.5	;	Protein flexibility and adaptability seen in 25 crystal forms of T4 LYSOZYME
178L	;	2.71	;	Protein flexibility and adaptability seen in 25 crystal forms of T4 LYSOZYME
180L	;	1.75	;	PROTEIN FLEXIBILITY AND ADAPTABILITY SEEN IN 25 CRYSTAL FORMS OF T4 LYSOZYME
2K6R	;		;	Protein folding on a highly rugged landscape: Experimental observation of glassy dynamics and structural frustration
4WH4	;	2.2	;	Protein GB1 Quadruple Mutant I6H/N8H/K28H/Q32H
1N4R	;	2.8	;	Protein Geranylgeranyltransferase type-I Complexed with a Geranylgeranylated KKKSKTKCVIL Peptide Product
1N4Q	;	2.4	;	Protein Geranylgeranyltransferase type-I Complexed with a GGPP Analog and a KKKSKTKCVIL Peptide
1N4P	;	2.65	;	Protein Geranylgeranyltransferase type-I Complexed with Geranylgeranyl Diphosphate
1N4S	;	2.6	;	Protein Geranylgeranyltransferase type-I Complexed with GGPP and a Geranylgeranylated KKKSKTKCVIL Peptide Product
4INN	;	2.6	;	Protein HP1028 from the human pathogen Helicobacter pylori belongs to the lipocalin family
1LMA	;	1.75	;	PROTEIN HYDRATION AND WATER STRUCTURE: X-RAY ANALYSIS OF A CLOSELY PACKED PROTEIN CRYSTAL WITH VERY LOW SOLVENT CONTENT
3MYZ	;	1.6	;	Protein induced photophysical changes to the amyloid indicator dye, thioflavin T
2F7Z	;	3.0	;	Protein Kinase A bound to (R)-1-(1H-Indol-3-ylmethyl)-2-(2-pyridin-4-yl-[1,7]naphtyridin-5-yloxy)-ehylamine
2F7X	;	1.9	;	Protein Kinase A bound to (S)-2-(1H-Indol-3-yl)-1-[5-((E)-2-pyridin-4-yl-vinyl)-pyridin-3-yloxymethyl]-ethylamine
7PID	;	1.496	;	Protein kinase A catalytic subunit in complex with PKI5-24 and EN060
7PIE	;	1.427	;	Protein kinase A catalytic subunit in complex with PKI5-24 and EN068
7PNS	;	1.855	;	Protein kinase A catalytic subunit in complex with PKI5-24 and EN081
7PIF	;	1.395	;	Protein kinase A catalytic subunit in complex with PKI5-24 and EN086
7PIG	;	1.553	;	Protein kinase A catalytic subunit in complex with PKI5-24 and EN088
7PIH	;	1.374	;	Protein kinase A catalytic subunit in complex with PKI5-24 and EN093
2GNG	;	1.87	;	Protein kinase A fivefold mutant model of Rho-kinase
2GNF	;	2.28	;	Protein kinase A fivefold mutant model of Rho-kinase with Y-27632
4UJ1	;	1.768	;	Protein Kinase A in complex with an Inhibitor
4UJ2	;	2.019	;	Protein Kinase A in complex with an Inhibitor
4UJ9	;	1.87	;	Protein Kinase A in complex with an Inhibitor
4UJA	;	1.93	;	Protein Kinase A in complex with an Inhibitor
4UJB	;	1.949	;	Protein Kinase A in complex with an Inhibitor
5N23	;	2.088	;	Protein kinase A mutants as surrogate model for Aurora B with AT9283 inhibitor
3AMA	;	1.75	;	Protein kinase A sixfold mutant model of Aurora B with inhibitor JNJ-7706621
3AMB	;	2.25	;	Protein kinase A sixfold mutant model of Aurora B with inhibitor VX-680
1SMH	;	2.044	;	Protein kinase A variant complex with completely ordered N-terminal helix
1PTQ	;	1.95	;	PROTEIN KINASE C DELTA CYS2 DOMAIN
1PTR	;	2.2	;	PROTEIN KINASE C DELTA CYS2 DOMAIN COMPLEXED WITH PHORBOL-13-ACETATE
2QC6	;	1.85	;	Protein kinase CK2 in complex with DBC
2OXX	;	2.3	;	Protein kinase CK2 in complex with tetrabromobenzoimidazole derivatives K17, K22 and K32
2OXY	;	1.812	;	Protein kinase CK2 in complex with tetrabromobenzoimidazole derivatives K17, K22 and K32
2OXD	;	2.3	;	Protein kinase CK2 in complex with tetrabromobenzoimidazole K17, K22 and K32 inhibitors
3FL5	;	2.3	;	Protein kinase CK2 in complex with the inhibitor Quinalizarin
2H6D	;	1.85	;	Protein Kinase Domain of the Human 5'-AMP-activated protein kinase catalytic subunit alpha-2 (AMPK alpha-2 chain)
2JBO	;	3.1	;	Protein kinase MK2 in complex with an inhibitor (crystal form-1, soaking)
2JBP	;	3.31	;	Protein kinase MK2 in complex with an inhibitor (crystal form-2, co- crystallization)
7OVK	;	2.05	;	Protein kinase MKK7 in complex with 5-bromo-2-hydroxyphenyl-substituted pyrazolopyrimidine
7OVM	;	2.9	;	Protein kinase MKK7 in complex with cyclobutyl-substituted indazole
7OVJ	;	2.35	;	Protein kinase MKK7 in complex with difluoro-phenethyltriazole-substituted pyrazolopyrimidine
7OVL	;	2.9	;	Protein kinase MKK7 in complex with methoxycyclohexyl-substituted indazole
7OVI	;	1.95	;	Protein kinase MKK7 in complex with phenethyltriazole-substituted pyrazolopyrimidine
7OVN	;	2.9	;	Protein kinase MKK7 in complex with tolyl-substituted indazole
2XIX	;	2.4	;	Protein kinase Pim-1 in complex with fragment-1 from crystallographic fragment screen
2XIY	;	2.2	;	Protein kinase Pim-1 in complex with fragment-2 from crystallographic fragment screen
2XIZ	;	2.21	;	Protein kinase Pim-1 in complex with fragment-3 from crystallographic fragment screen
2XJ0	;	3.1	;	Protein kinase Pim-1 in complex with fragment-4 from crystallographic fragment screen
2XJ2	;	2.2	;	Protein kinase Pim-1 in complex with small molecule inhibitor
2XJ1	;	2.13	;	Protein kinase Pim-1 in complex with small molecule inibitor
2UGI	;	2.2	;	PROTEIN MIMICRY OF DNA FROM CRYSTAL STRUCTURES OF THE URACIL GLYCOSYLASE INHIBITOR PROTEIN AND ITS COMPLEX WITH ESCHERICHIA COLI URACIL-DNA GLYCOSYLASE
7LYZ	;	2.5	;	PROTEIN MODEL BUILDING BY THE USE OF A CONSTRAINED-RESTRAINED LEAST-SQUARES PROCEDURE
1JHS	;	1.9	;	Protein Mog1 E65A mutant
5GZA	;	2.0	;	protein O-mannose kinase
2O35	;	2.12	;	Protein of Unknown Function (DUF1244) from Sinorhizobium meliloti
2OEZ	;	1.97	;	Protein of Unknown Function (DUF1342) from Vibrio parahaemolyticus
2OEQ	;	2.9	;	Protein of Unknown Function (DUF964) from Bacillus stearothermophilus
2GBO	;	2.2	;	Protein of Unknown Function EF2458 from Enterococcus faecalis
2DDZ	;	2.24	;	Protein of Unknown Function from Pyrococcus horikoshi
2GKP	;	1.35	;	Protein of Unknown Function NMB0488 from Neisseria meningitidis
8PW4	;	2.3	;	Protein p6 from bacteriophage phi29, C-terminal delta20 truncated version
8PW2	;	1.59	;	Protein p6 from bacteriophage phi29, C-terminal delta31 truncated version
6QWN	;	3.892	;	Protein peptide complex
6QXP	;	3.201	;	Protein peptide complex
6ZK6	;	1.9	;	Protein Phosphatase 1 (PP1) T320E mutant
6NTS	;	3.63	;	Protein Phosphatase 2A (Aalpha-B56alpha-Calpha) holoenzyme in complex with a Small Molecule Activator of PP2A (SMAP)
3K7V	;	2.85	;	Protein phosphatase 2A core complex bound to dinophysistoxin-1
3K7W	;	2.96	;	Protein phosphatase 2A core complex bound to dinophysistoxin-2
3QC1	;	2.35	;	Protein Phosphatase Subunit: Alpha4
2UZQ	;	2.38	;	Protein Phosphatase, New Crystal Form
2MP0	;		;	Protein Phosphorylation upon a Fleeting Encounter
6ZNV	;	1.14	;	Protein polybromo-1 (PB1 BD2) Bound To DP28
6ZN6	;	2.02	;	Protein polybromo-1 (PB1 BD2) Bound To MW278
1XSM	;	2.3	;	PROTEIN R2 OF RIBONUCLEOTIDE REDUCTASE FROM MOUSE
4G9J	;	3.1	;	Protein Ser/Thr phosphatase-1 in complex with cell-permeable peptide
1FJM	;	2.1	;	Protein serine/threonine phosphatase-1 (alpha isoform, type 1) complexed with microcystin-LR toxin
1SNO	;	1.7	;	PROTEIN STABILITY IN STAPHYLOCOCCAL NUCLEASE
1SNP	;	1.95	;	PROTEIN STABILITY IN STAPHYLOCOCCAL NUCLEASE
1SNQ	;	1.7	;	PROTEIN STABILITY IN STAPHYLOCOCCAL NUCLEASE
5O4W	;	2.11	;	Protein structure determination by electron diffraction using a single three-dimensional nanocrystal
5O4X	;	2.11	;	Protein structure determination by electron diffraction using a single three-dimensional nanocrystal
2M3W	;		;	Protein structure determination from a set of 4D NOESY
3M8E	;	2.0	;	Protein structure of Type III plasmid segregation TubR
3M9A	;	2.5	;	Protein structure of type III plasmid segregation TubR
3M8F	;	2.8	;	Protein structure of type III plasmid segregation TubR mutant
3M8K	;	2.3	;	Protein structure of type III plasmid segregation TubZ
3OH3	;	2.03	;	Protein structure of USP from L. major bound to URIDINE-5'-DIPHOSPHATE -Arabinose
3OH4	;	2.21	;	Protein structure of USP from L. major bound to URIDINE-5'-DIPHOSPHATE Glucose
3OH2	;	2.14	;	Protein structure of USP from L. major bound to URIDINE-5'-DIPHOSPHATE-GALACTOSE
3OH1	;	2.18	;	Protein structure of USP from L. major bound to URIDINE-5'-DIPHOSPHATE-Galacturonic acid
3OH0	;	2.15	;	Protein structure of USP from L. major bound to URIDINE-5'-TRIPHOSPHATE
3OGZ	;	2.03	;	Protein structure of USP from L. major in Apo-form
209L	;	2.7	;	PROTEIN STRUCTURE PLASTICITY EXEMPLIFIED BY INSERTION AND DELETION MUTANTS IN T4 LYSOZYME
210L	;	1.89	;	PROTEIN STRUCTURE PLASTICITY EXEMPLIFIED BY INSERTION AND DELETION MUTANTS IN T4 LYSOZYME
211L	;	1.7	;	PROTEIN STRUCTURE PLASTICITY EXEMPLIFIED BY INSERTION AND DELETION MUTANTS IN T4 LYSOZYME
212L	;	1.76	;	PROTEIN STRUCTURE PLASTICITY EXEMPLIFIED BY INSERTION AND DELETION MUTANTS IN T4 LYSOZYME
213L	;	2.13	;	PROTEIN STRUCTURE PLASTICITY EXEMPLIFIED BY INSERTION AND DELETION MUTANTS IN T4 LYSOZYME
214L	;	1.89	;	PROTEIN STRUCTURE PLASTICITY EXEMPLIFIED BY INSERTION AND DELETION MUTANTS IN T4 LYSOZYME
215L	;	1.96	;	PROTEIN STRUCTURE PLASTICITY EXEMPLIFIED BY INSERTION AND DELETION MUTANTS IN T4 LYSOZYME
218L	;	2.05	;	PROTEIN STRUCTURE PLASTICITY EXEMPLIFIED BY INSERTION AND DELETION MUTANTS IN T4 LYSOZYME
219L	;	1.66	;	PROTEIN STRUCTURE PLASTICITY EXEMPLIFIED BY INSERTION AND DELETION MUTANTS IN T4 LYSOZYME
7E15	;	2.45	;	Protein ternary complex working for DNA replication initiation
7CK6	;	3.4	;	Protein translocase of mitochondria
3S4O	;	2.3	;	Protein Tyrosine Phosphatase (putative) from Leishmania major
7LFO	;	1.94	;	Protein Tyrosine Phosphatase 1B
5K9W	;	2.01	;	Protein Tyrosine Phosphatase 1B (1-301) in complex with TCS401, closed state
6OL4	;	2.15	;	Protein Tyrosine Phosphatase 1B (1-301), F182A mutant, apo state
6PHA	;	2.299	;	Protein Tyrosine Phosphatase 1B (1-301), F182A mutant, vanadate bound state
5K9V	;	1.898	;	Protein Tyrosine Phosphatase 1B (1-301), open state
6OMY	;	2.1	;	Protein Tyrosine Phosphatase 1B (1-301), P180A mutant, apo state
6PM8	;	2.06	;	Protein Tyrosine Phosphatase 1B (1-301), P180A mutant, vanadate bound state
6OLV	;	2.1	;	Protein Tyrosine Phosphatase 1B (1-301), P185A mutant, apo state
6PHS	;	2.129	;	Protein Tyrosine Phosphatase 1B (1-301), P185A mutant, vanadate bound state
6OLQ	;	2.1	;	Protein Tyrosine Phosphatase 1B (1-301), P188A mutant, apo state
6PG0	;	2.1	;	Protein Tyrosine Phosphatase 1B (1-301), P188A mutant, vanadate bound state
6PFW	;	2.34	;	Protein Tyrosine Phosphatase 1B (1-301), T177A mutant, apo state
6PGT	;	2.2	;	Protein Tyrosine Phosphatase 1B (1-301), T177A mutant, vanadate bound state
3QKP	;	2.05	;	Protein Tyrosine Phosphatase 1B - Apo W179F mutant with open WPD-loop
7S4F	;	1.65	;	Protein Tyrosine Phosphatase 1B - F182Q mutant bound with Hepes
3I7Z	;	2.3	;	Protein Tyrosine Phosphatase 1B - Transition state analog for the first catalytic step
3I80	;	2.25	;	Protein Tyrosine Phosphatase 1B - Transition state analog for the second catalytic step
3QKQ	;	2.2	;	Protein Tyrosine Phosphatase 1B - W179F mutant bound with vanadate
6CWV	;	1.98002	;	Protein Tyrosine Phosphatase 1B A122S mutant
6W30	;	2.1	;	Protein Tyrosine Phosphatase 1B Bound to Amorphadiene
1A5Y	;	2.5	;	PROTEIN TYROSINE PHOSPHATASE 1B CYSTEINYL-PHOSPHATE INTERMEDIATE
5KA1	;	1.84	;	Protein Tyrosine Phosphatase 1B Delta helix 7 mutant in complex with TCS401, closed state
5KA0	;	1.991	;	Protein Tyrosine Phosphatase 1B Delta helix 7, open state
5KAB	;	1.968	;	Protein Tyrosine Phosphatase 1B Delta helix 7, P185G mutant in complex with TCS401, open state
5KAA	;	1.968	;	Protein Tyrosine Phosphatase 1B Delta helix 7, P185G mutant, open state
6CWU	;	2.08	;	Protein Tyrosine Phosphatase 1B F135Y mutant
5KA9	;	2.07	;	Protein Tyrosine Phosphatase 1B L192A mutant in complex with TCS401, open state
5KA8	;	1.971	;	Protein Tyrosine Phosphatase 1B L192A mutant, open state
5KAD	;	1.9	;	Protein Tyrosine Phosphatase 1B N193A mutant in complex with TCS401, closed state
5KAC	;	1.9	;	Protein Tyrosine Phosphatase 1B P185G mutant, open state
5KA7	;	2.061	;	Protein Tyrosine Phosphatase 1B T178A mutant in complex with TCS401, closed state
5KA4	;	2.185	;	Protein Tyrosine Phosphatase 1B T178A mutant, open state
1WAX	;	2.2	;	Protein tyrosine phosphatase 1B with active site inhibitor
7KLX	;	1.839	;	Protein Tyrosine Phosphatase 1B with inhibitor
2F6T	;	1.7	;	Protein tyrosine phosphatase 1B with sulfamic acid inhibitors
2F6V	;	1.7	;	Protein tyrosine phosphatase 1B with sulfamic acid inhibitors
2F6W	;	2.2	;	Protein tyrosine phosphatase 1B with sulfamic acid inhibitors
2F6Y	;	2.15	;	Protein tyrosine phosphatase 1B with sulfamic acid inhibitors
2F6Z	;	1.7	;	Protein tyrosine phosphatase 1B with sulfamic acid inhibitors
2F70	;	2.12	;	Protein tyrosine phosphatase 1B with sulfamic acid inhibitors
2F71	;	1.55	;	Protein tyrosine phosphatase 1B with sulfamic acid inhibitors
5KA3	;	2.141	;	Protein Tyrosine Phosphatase 1B YAYA (Y152A, Y153A) mutant in complex with TCS401, closed state
5KA2	;	2.071	;	Protein Tyrosine Phosphatase 1B YAYA (Y152A, Y153A) mutant, open state
7KEY	;	1.771	;	Protein Tyrosine Phosphatase 1B, Apo
7KEN	;	1.8	;	Protein Tyrosine Phosphatase 1B, D289A mutant, apo state
3BRH	;	2.2	;	Protein Tyrosine Phosphatase PTPN-22 (Lyp) bound to the mono-Phosphorylated Lck active site peptide
2JJD	;	3.2	;	Protein Tyrosine Phosphatase, Receptor Type, E isoform
1LP1	;	2.3	;	Protein Z in complex with an in vitro selected affibody
6HZX	;	2.91	;	Protein-aromatic foldamer complex crystal structure
6Q3O	;	2.23	;	PROTEIN-AROMATIC FOLDAMER COMPLEX CRYSTAL STRUCTURE
6Q9T	;	2.68	;	Protein-aromatic foldamer complex crystal structure
4QCB	;	2.89	;	Protein-DNA complex of Vaccinia virus D4 with double-stranded non-specific DNA
4CRO	;	3.9	;	PROTEIN-DNA CONFORMATIONAL CHANGES IN THE CRYSTAL STRUCTURE OF A LAMBDA CRO-OPERATOR COMPLEX
1O3Q	;	3.0	;	PROTEIN-DNA RECOGNITION AND DNA DEFORMATION REVEALED IN CRYSTAL STRUCTURES OF CAP-DNA COMPLEXES
1O3R	;	3.0	;	PROTEIN-DNA RECOGNITION AND DNA DEFORMATION REVEALED IN CRYSTAL STRUCTURES OF CAP-DNA COMPLEXES
1O3S	;	3.0	;	PROTEIN-DNA RECOGNITION AND DNA DEFORMATION REVEALED IN CRYSTAL STRUCTURES OF CAP-DNA COMPLEXES
1O3T	;	2.8	;	PROTEIN-DNA RECOGNITION AND DNA DEFORMATION REVEALED IN CRYSTAL STRUCTURES OF CAP-DNA COMPLEXES
3W1W	;	2.006	;	Protein-drug complex
2VQA	;	2.95	;	Protein-folding location can regulate Mn versus Cu- or Zn-binding. Crystal Structure of MncA.
3MZT	;	2.7	;	Protein-induced photophysical changes to the amyloid indicator dye, thioflavin T
1DL5	;	1.8	;	PROTEIN-L-ISOASPARTATE O-METHYLTRANSFERASE
4O29	;	2.9	;	PROTEIN-L-ISOASPARTATE O-METHYLTRANSFERASE from Pyrobaculum aerophilum in COMPLEX WITH S-ADENOSYL-L-HOMOCYSTEINE
2XNI	;	3.3	;	Protein-ligand complex of a novel macrocyclic HCV NS3 protease inhibitor derived from amino cyclic boronates
3S8L	;	1.71	;	Protein-Ligand Interactions: Thermodynamic Effects Associated with Increasing Hydrophobic Surface Area
2AN6	;	3.0	;	Protein-peptide complex
5U4P	;	2.5	;	Protein-protein complex between 26S proteasome regulatory subunit RPN8, RPN11, and Ubiquitin S31
3RPF	;	1.9	;	Protein-protein complex of subunit 1 and 2 of Molybdopterin-converting factor from Helicobacter pylori 26695
5B6G	;	1.99	;	Protein-protein interaction
5IZ6	;	2.15	;	Protein-protein interaction
5IZ8	;	3.06	;	Protein-protein interaction
5IZ9	;	2.93	;	Protein-protein interaction
5IZA	;	1.5	;	Protein-protein interaction
6FW4	;		;	Protein-protein interactions and conformational changes : Importance of the hydrophobic cavity of TolA C-terminal domain
2AOS	;	2.9	;	Protein-protein Interactions of protective signalling factor: Crystal structure of ternary complex involving signalling protein from goat (SPG-40), tetrasaccharide and a tripeptide Trp-pro-Trp at 2.9 A resolution
1BRS	;	2.0	;	PROTEIN-PROTEIN RECOGNITION: CRYSTAL STRUCTURAL ANALYSIS OF A BARNASE-BARSTAR COMPLEX AT 2.0-A RESOLUTION
2PY9	;	2.56	;	Protein-RNA Interaction involving KH1 domain from Human Poly(C)-Binding Protein-2
1BMV	;	3.0	;	PROTEIN-RNA INTERACTIONS IN AN ICOSAHEDRAL VIRUS AT 3.0 ANGSTROMS RESOLUTION
1EGP	;	2.0	;	PROTEINASE INHIBITOR EGLIN C WITH HYDROLYSED REACTIVE CENTER
3N0K	;	1.8	;	Proteinase inhibitor from Coprinopsis cinerea
1DEM	;		;	PROTEINASE INHIBITOR HOMOLOGUES AS POTASSIUM CHANNEL BLOCKERS
1DEN	;		;	PROTEINASE INHIBITOR HOMOLOGUES AS POTASSIUM CHANNEL BLOCKERS
1PMC	;		;	PROTEINASE INHIBITOR PMP-C (NMR, 36 STRUCTURES)
3SSI	;	2.3	;	PROTEINASE INHIBITOR SSI (STREPTOMYCES SUBTILISIN, INHIBITOR) FROM STREPTOMYCES ALBOGRISEOLUS
8F07	;	1.05	;	Proteinase K Anomalous Dataset at 273 K and 12 keV
8F05	;	1.8	;	Proteinase K Anomalous Dataset at 293 K and 7.1 keV
8F06	;	1.8	;	Proteinase K Anomalous Dataset at 310 K and 7.1 keV
3DWE	;	0.99	;	Proteinase K by Classical hanging drop method after high X-Ray dose on ESRF ID14-2 beamline
3I30	;	0.992	;	Proteinase K by Classical hanging drop Method after high X-Ray dose on ID14-2 Beamline at ESRF
3DE4	;	1.8	;	Proteinase K by Classical hanging drop method after the first step of high X-Ray dose on ESRF ID23-1 beamline
3DE7	;	2.3	;	Proteinase K by Classical hanging drop method after the fourth step of high X-Ray dose on ESRF ID23-1 beamline
3DE6	;	2.2	;	Proteinase K by Classical hanging drop method after the third step of high X-Ray dose on ESRF ID23-1 beamline
3DW3	;	0.99	;	Proteinase K by Classical hanging drop method before high X Ray dose on ESRF ID 14-2 beamline
3DE3	;	1.43	;	Proteinase K by Classical hanging drop method before high X-Ray dose on ESRF ID23-1 beamline
3I2Y	;	0.995	;	Proteinase K by Classical hanging drop Method before high X-Ray dose on ID14-2 Beamline at ESRF
4DJ5	;	1.8	;	Proteinase K by Langmuir-Blodgett Hanging Drop Method at 1.8A resolution for Unique Water Distribution
3I34	;	1.0	;	Proteinase K by LB Nanotemplate Method after high X-Ray dose on ID14-2 Beamline at ESRF
3DVR	;	1.02	;	Proteinase K by LB nanotemplate method after the first step of high X-Ray dose on ESRF ID14-2 beamline
3DDZ	;	1.7	;	Proteinase K by LB nanotemplate method after the first step of high X-Ray dose on ESRF ID23-1 beamline
3DE2	;	2.1	;	Proteinase K by LB nanotemplate method after the fourth step of high X-Ray dose on ESRF ID23-1 beamline
3DE0	;	1.9	;	Proteinase K by LB nanotemplate method after the second step of high X-Ray dose on ESRF ID23-1 beamline
3DW1	;	1.03	;	Proteinase K by LB nanotemplate method after the third step high X-Ray dose on ESRF ID14-2 beamline
3DE1	;	2.0	;	Proteinase K by LB nanotemplate method after the third step of high X-Ray dose on ESRF ID23-1 beamline
3DVQ	;	1.02	;	Proteinase K by LB nanotemplate method before high X-Ray dose on ESRF ID14-2 beamline
3D9Q	;	1.43	;	Proteinase K by LB nanotemplate method before high X-Ray dose on ESRF ID23-1 beamline
3I37	;	0.995	;	Proteinase K by LB Nanotemplate Method before high X-Ray dose on ID14-2 Beamline at ESRF
3DVS	;	1.02	;	Proteinase K by LB nanotmplate method after the second step of high dose on ESRF ID14-2 beamline
5CW1	;	1.45	;	Proteinase K complexed with 4-iodopyrazole
7A68	;	2.55	;	proteinase K crystallized from 0.5 M NaNO3
6V8R	;	1.6	;	Proteinase K Determined by MicroED Phased by ARCIMBOLDO_SHREDDER
6J43	;	1.85	;	Proteinase K determined by PAL-XFEL
7NJJ	;	1.65	;	Proteinase K grown inside HARE serial crystallography chip
6TXG	;	1.372	;	Proteinase K in complex with a ""half sandwich""-type Ru(II) coordination compound
8SOG	;	1.13	;	Proteinase K Multiconformer Model at 313K
8SQV	;	1.22	;	Proteinase K Multiconformer Model at 333K
8SPL	;	1.21	;	Proteinase K Multiconformer Model at 343K
8SOV	;	1.291	;	Proteinase K Multiconformer Model at 353K
8SOU	;	1.54	;	Proteinase K Multiconformer Model at 363K
7JSY	;	1.78	;	Proteinase K soaked with I3C determined by MicroED from a single milled microcrystal
7NUZ	;	1.09	;	Proteinase K structure at atomic resolution from crystals grown in agarose gel
3DYB	;	1.32	;	proteinase K- digalacturonic acid complex
4WOC	;	1.601	;	Proteinase-K Post-Surface Acoustic Waves
4WOB	;	1.9	;	Proteinase-K Pre-Surface Acoustic Wave
6FJS	;	1.9	;	Proteinase~K SIRAS phased structure of room-temperature, serially collected synchrotron data
8X34	;	2.8	;	ProteinMY
4E0Y	;	2.4	;	Protelomerase tela covalently complexed with mutated substrate DNA
4E0P	;	2.2	;	Protelomerase tela covalently complexed with substrate DNA
4F43	;	2.354	;	Protelomerase TelA mutant R255A complexed with CAAG hairpin DNA
4F41	;	2.5	;	Protelomerase TelA mutant R255A complexed with CTTG hairpin DNA
4E0Z	;	2.42	;	Protelomerase tela R205A covalently complexed with substrate DNA
4E0J	;	2.3	;	Protelomerase tela R255A mutant complexed with DNA hairpin product
4E10	;	2.506	;	Protelomerase tela Y201A covalently complexed with substrate DNA
4E0G	;	2.2	;	Protelomerase tela/DNA hairpin product/vanadate complex
2V6E	;	3.2	;	protelomerase TelK complexed with substrate DNA
5ZTZ	;	2.8	;	Proteobacterial origin of protein arginine methylation and regulation of Complex I assembly by MidA
5ZU0	;	2.76	;	Proteobacterial origin of protein arginine methylation and regulation of Complex I assembly by MidA
5ZZW	;	2.6	;	Proteobacterial origin of protein arginine methylation and regulation of Complex I assembly by MidA
4NJP	;	2.4	;	Proteolysis inside the membrane is a rate-governed reaction not Driven by substrate affinity
1W9C	;	2.3	;	Proteolytic fragment of CRM1 spanning six C-terminal HEAT repeats
7LY5	;	2.5	;	Proteolyzed crystal structure of the bacillamide NRPS, BmdB, in complex with the oxidase BmdC
6ESP	;		;	Proteome-wide analysis of phospho-regulated PDZ domain interactions
6H1Q	;	1.58	;	Proteus mirabilis Ambient Temperature Fimbriae adhesin AtfE
1NM0	;	2.3	;	Proteus mirabilis catalase in complex with formiate
6JD9	;	1.58	;	Proteus mirabilis lipase mutant - I118V/E130G
6H4E	;	1.561	;	Proteus mirabilis N-acetylneuraminate lyase
6MHH	;	2.083	;	Proteus mirabilis ScsC linker (residues 39-49) deletion and N6K mutant
6CHV	;	2.9	;	Proteus vulgaris HigA antitoxin bound to DNA
6CF1	;	1.9	;	Proteus vulgaris HigA antitoxin structure
8V9P	;	1.85	;	Proteus vulgaris tryptophan indole-lyase complexed with (3S)-dioxindolyl-L-alanine
8V6P	;	1.74	;	Proteus vulgaris tryptophan indole-lyase complexed with 7-aza-L-tryptophan
8V2K	;	1.81	;	Proteus vulgaris tryptophan indole-lyase complexed with L-alanine
8V4A	;	1.96	;	Proteus vulgaris tryptophan indole-lyase complexed with L-ethionine
5DZW	;	2.43	;	Protocadherin alpha 4 extracellular cadherin domains 1-4
5DZV	;	3.6	;	Protocadherin alpha 7 extracellular cadherin domains 1-5
5DZX	;	2.879	;	Protocadherin beta 6 extracellular cadherin domains 1-4
5DZY	;	2.9	;	Protocadherin beta 8 extracellular cadherin domains 1-4
5SZL	;	4.2	;	Protocadherin gamma A1 extracellular cadherin domains 1-4
5SZQ	;	2.608	;	Protocadherin Gamma A4 extracellular cadherin domains 3-6
5SZM	;	3.6	;	Protocadherin gamma A8 extracellular cadherin domains 1-4
5SZN	;	2.944	;	Protocadherin gamma A9 extracellular cadherin domains 1-5
5T9T	;	3.5	;	Protocadherin Gamma B2 extracellular cadherin domains 1-5
5SZR	;	2.3	;	Protocadherin Gamma B2 extracellular cadherin domains 3-6
5SZP	;	3.1	;	Protocadherin Gamma B7 extracellular cadherin domains 1-4 P21 crystal form
5SZO	;	3.612	;	Protocadherin Gamma B7 extracellular cadherin domains 1-4 P41212 crystal form
5V5X	;	3.5	;	Protocadherin gammaB7 EC3-6 cis-dimer structure
7JGZ	;	3.51	;	Protocadherin gammaC4 EC1-4 crystal structure
7RGF	;	2.4	;	Protocadherin gammaC4 EC1-4 crystal structure disrupted trans interface
1YKK	;	2.06	;	Protocatechuate 3,4-Dioxygenase Y408C Mutant
1YKL	;	2.25	;	Protocatechuate 3,4-Dioxygenase Y408C mutant bound to DHB
1YKM	;	2.22	;	Protocatechuate 3,4-Dioxygenase Y408E mutant
1YKN	;	2.06	;	Protocatechuate 3,4-dioxygenase Y408E mutant bound to DHB
1YKO	;	2.54	;	Protocatechuate 3,4-Dioxygenase Y408H mutant
1YKP	;	2.41	;	Protocatechuate 3,4-Dioxygenase Y408H mutant bound to DHB
3PCD	;	2.1	;	PROTOCATECHUATE 3,4-DIOXYGENASE Y447H MUTANT
1B4U	;	2.2	;	PROTOCATECHUATE 4,5-DIOXYGENASE (LIGAB) IN COMPLEX WITH PROTOCATECHUATE (PCA)
8JQQ	;	2.06	;	Protocatecuate hydroxylase from Xylophilus ampelinus C347T mutant
8JQP	;	1.65	;	Protocatecuate hydroxylase from Xylophilus ampelinus complexed with 3,4-dihydroxybenzoate
8JQO	;	1.6	;	Protocatecuate hydroxylase from Xylophilus ampelinus complexed with imidazole
3ZBQ	;	1.7	;	Protofilament of TubZ from Bacteriophage PhiKZ
6U0U	;	4.16	;	Protofilament Ribbon Flagellar Proteins Rib43a-L
6U0T	;	4.16	;	Protofilament Ribbon Flagellar Proteins Rib43a-S
7N32	;	4.5	;	protofilaments of microtubule doublets bound to outer-arm dynein
8IJ1	;	4.2	;	Protomer 1 and 2 of the asymmetry trimer of the Cul2-Rbx1-EloBC-FEM1B ubiquitin ligase complex
7V2W	;	3.2	;	protomer structure from the dimer of yeast THO complex
7ZF2	;	3.86	;	Protomeric substructure from an octameric assembly of M. tuberculosis RNA polymerase in complex with sigma-b initiation factor
2RLF	;		;	Proton Channel M2 from Influenza A in complex with inhibitor rimantadine
1RTN	;		;	PROTON NMR ASSIGNMENTS AND SOLUTION CONFORMATION OF RANTES, A CHEMOKINE OF THE CC TYPE
1RTO	;		;	PROTON NMR ASSIGNMENTS AND SOLUTION CONFORMATION OF RANTES, A CHEMOKINE OF THE CC TYPE
1VNA	;		;	PROTON NUCLEAR MAGNETIC RESONANCE AND DISTANCE GEOMETRY(SLASH)SIMULATED ANNEALING STUDIES ON THE VARIANT-1 NEUROTOXIN FROM THE NEW WORLD SCORPION CENTRUROIDES SCULPTURATUS EWING
1VNB	;		;	PROTON NUCLEAR MAGNETIC RESONANCE AND DISTANCE GEOMETRY(SLASH)SIMULATED ANNEALING STUDIES ON THE VARIANT-1 NEUROTOXIN FROM THE NEW WORLD SCORPION CENTRUROIDES SCULPTURATUS EWING
6AFX	;	2.301	;	Proton pyrophosphatase - E225A
6AFT	;	2.492	;	Proton pyrophosphatase - E301Q
6AFS	;	2.299	;	Proton pyrophosphatase - two phosphates-bound
6AFZ	;	2.483	;	Proton pyrophosphatase-E225H mutant
6AFY	;	2.401	;	Proton pyrophosphatase-E225S mutant
6AFV	;	2.701	;	Proton pyrophosphatase-L555K mutant
6AFU	;	2.798	;	Proton pyrophosphatase-L555M mutant
6AFW	;	2.185	;	Proton pyrophosphatase-T228D mutant
3X2N	;	1.2	;	Proton relay pathway in inverting cellulase
1YO0	;	1.8	;	Proton Transfer from His200 in Human Carbonic Anhydrase II
1YO1	;	1.7	;	Proton Transfer from His200 in Human Carbonic Anhydrase II
1YO2	;	1.8	;	Proton Transfer from His200 in Human Carbonic Anhydrase II
2L3Z	;		;	Proton-Detected 4D DREAM Solid-State NMR Structure of Ubiquitin
6WP8	;	2.5	;	Proton-pumping mutant of Mastigocladopsis repens rhodopsin chloride pump
2G7O	;	1.4	;	Protonation-mediated structural flexibility in the F conjugation regulatory protein, TraM
2G9E	;	1.8	;	Protonation-mediated structural flexibility in the F conjugation regulatory protein, TRAM
4BAC	;	3.263	;	prototype foamy virus strand transfer complexes on product DNA
1E0M	;		;	PROTOTYPE WW domain
7TGY	;	3.0	;	Prototypic SARS-CoV-2 G614 spike (closed form)
7TGX	;	3.2	;	Prototypic SARS-CoV-2 G614 spike (open form)
8UUL	;	3.2	;	Prototypic SARS-CoV-2 spike (containing K417) in the closed conformation
8UUM	;	3.9	;	Prototypic SARS-CoV-2 spike (containing K417) in the open conformation
8UUN	;	3.8	;	Prototypic SARS-CoV-2 spike (containing V417) in the closed conformation
8UUO	;	3.9	;	Prototypic SARS-CoV-2 spike (containing V417) in the open conformation
5KLT	;	2.6	;	Prototypical P4[M]cNLS
5KLR	;	2.2	;	Prototypical P4[R]cNLS
5N7M	;	1.73	;	Protruding domain of GI.1 norovirus in complex with 2-fucosyllactose (2FL)
5F4O	;	1.59	;	Protruding domain of GII.17 norovirus Kawasaki308
5LKG	;	1.51	;	Protruding domain of GII.17 norovirus Kawasaki308 in complex with 2-fucosyllactose (2'FL)
5LKK	;	1.49	;	Protruding domain of GII.17 norovirus Kawasaki308 in complex with 3-fucosyllactose (3FL)
5LKC	;	1.81	;	Protruding domain of GII.17 norovirus Kawasaki308 in complex with HBGA type A (triglycan)
5F4M	;	2.27	;	Protruding domain of GII.17 norovirus Kawasaki323
5F4J	;	1.933	;	Protruding domain of GII.17 norovirus Saitama/T87
5IYN	;	1.56	;	Protruding domain of GII.4 human norovirus CHDC2094
5IYR	;	1.54	;	Protruding domain of GII.4 human norovirus CHDC2094 in complex with 2-fucosyllactose (2'FL)
5IYW	;	1.41	;	Protruding domain of GII.4 human norovirus CHDC2094 in complex with 3-fucosyllactose (3FL)
5IYP	;	1.27	;	Protruding domain of GII.4 human norovirus CHDC2094 in complex with HBGA type A (triglycan)
5IYQ	;	1.41	;	Protruding domain of GII.4 human norovirus CHDC2094 in complex with HBGA type B (triglycan)
5KON	;	1.51	;	Protruding domain of GII.4 human norovirus isolate 08-14
5LFE	;	2.3	;	Protruding domain of GII.4 human norovirus isolate 8-14 in complex with HBGA type B (triglycan)
5J35	;	1.47	;	Protruding domain of GII.4 human norovirus NSW0514 in complex with 2-fucosyllactose (2'FL)
5J3O	;	1.47	;	Protruding domain of GII.4 human norovirus NSW0514 in complex with 3-fucosyllactose (3FL)
7CZ6	;	4.1	;	Protrusion structure of Omono River virus
8CDB	;	4.5	;	Proulilysin E229A structure
7P9B	;	2.45	;	Providencia stuartii Arginine decarboxylase (Adc), decamer structure
7PK6	;	2.15	;	Providencia stuartii Arginine decarboxylase (Adc), stack structure
2WSD	;	1.6	;	Proximal mutations at the type 1 Cu site of CotA-laccase: I494A mutant
4W5M	;	1.2	;	Prp peptide
4W5P	;	1.151	;	Prp peptide
5L6R	;		;	PrP226* - Solution-state NMR structure of truncated human prion protein
2KFD	;		;	Prp40 FF4 domain
6NQI	;	2.75	;	Prp8 RH domain from C. merolae
5BYT	;	2.0	;	PRPP complexed with a single Mg in the active site of Mycobacterium tuberculosis anthranilate phosphoribosyltransferase (AnPRT; trpD)
5C7S	;	2.1	;	PRPP complexed with two Mn2+ in the active site of Mycobacterium tuberculosis anthranilate phosphoribosyltransferase (AnPRT; trpD)
6DLR	;	2.656	;	PRPP Riboswitch bound to PRPP, iridium-hexamine soaked structure
6DNR	;	2.896	;	PRPP Riboswitch bound to PRPP, ligand-free structure
6DLQ	;	2.8	;	PRPP Riboswitch bound to PRPP, manganese chloride soaked structure
6DLT	;	2.9	;	PRPP Riboswitch bound to PRPP, native structure
6DLS	;	2.885	;	PRPP Riboswitch bound to PRPP, thallium acetate soaked structure
6CK5	;	2.49	;	PRPP riboswitch from T. mathranii bound to PRPP
5Y4L	;	2.198	;	PRRSV nsp4
8EHN	;	2.3	;	PRRSV-1 PLP2 domain
8EHO	;	2.85	;	PRRSV-1 PLP2 domain bound to ubiquitin
1K7G	;	2.0	;	PrtC from Erwinia chrysanthemi
1K7Q	;	1.8	;	PrtC from Erwinia chrysanthemi: E189A mutant
1K7I	;	1.59	;	PrtC from Erwinia chrysanthemi: Y228F mutant
3HBV	;	1.95	;	PrtC methionine mutants: M226A in-house
3HDA	;	2.131	;	PrtC methionine mutants: M226A_DESY
3HBU	;	1.77	;	PrtC methionine mutants: M226H DESY
3HB2	;	1.75	;	PrtC methionine mutants: M226I
5L22	;	3.15	;	PrtD T1SS ABC transporter
2OK9	;	2.34	;	PrTX-I-BPB
4Z3U	;	2.706	;	PRV nuclear egress complex
5J2Z	;	2.5	;	PRV UL37 N-terminal half (R2 mutant)
1TP9	;	1.62	;	PRX D (type II) from Populus tremula
7N1N	;	1.6	;	Prx in complex with ComR DNA-binding domain
3KB5	;	1.5	;	PRY-SPRY domain of human TRIM72
4B8E	;	1.779	;	PRY-SPRY domain of Trim25
5JYS	;	1.901	;	Pry1 CAP domain
8SPX	;	2.95	;	PS3 F1 Rotorless, high ATP
8SPW	;	3.5	;	PS3 F1 Rotorless, low ATP
8SPV	;	3.06	;	PS3 F1 Rotorless, no ATP
7L1Q	;	3.4	;	PS3 F1-ATPase Binding/TS Dwell
7L1R	;	3.1	;	PS3 F1-ATPase Hydrolysis Dwell
7L1S	;	3.6	;	PS3 F1-ATPase Pi-bound Dwell
7KYO	;	2.85	;	PsaBC from Streptococcus pneumoniae in complex with Fab
7KYP	;	2.9	;	PsaBC from Streptococcus pneumoniae in complex with Fab
1GXI	;		;	PsaE Subunit of the Photosystem I of the Cyanobacterium Synechocystis sp. PCC 6803
1W2Z	;	2.24	;	PSAO and Xenon
2KND	;		;	Psb27 structure from Synechocystis
8JNL	;	3.2	;	Psb34 from red algal Porphyridium purpureum.
5G3A	;	1.224	;	PsbO subunit of Photosystem II, beta barrel domain at 100K, pH 10
5G38	;	1.15	;	PsbO subunit of Photosystem II, beta barrel domain at 100K, pH 6
5G39	;	1.5	;	PsbO subunit of Photosystem II, beta barrel domain at 297K, pH 6
8JNM	;	3.2	;	PsbW from red algal Porphyridium purpureum.
5JXB	;	2.9	;	PSD-95 extended PDZ3 in complex with SynGAP PBM
1G6A	;	1.75	;	PSE-4 CARBENICILLINASE, R234K MUTANT
1G68	;	1.95	;	PSE-4 CARBENICILLINASE, WILD TYPE
2FNI	;	3.0	;	PseC aminotransferase involved in pseudoaminic acid biosynthesis
2FNU	;	1.5	;	PseC aminotransferase with external aldimine
5KHZ	;	1.49	;	PSEUDO T4 LYSOZYME
5KI1	;	1.46	;	PSEUDO T4 LYSOZYME MUTANT - Y18F
5KI3	;	1.65	;	PSEUDO T4 LYSOZYME MUTANT - Y18PHE-BR
5KIO	;	1.63	;	PSEUDO T4 LYSOZYME MUTANT - Y18PHE-I
5KI2	;	1.5	;	PSEUDO T4 LYSOZYME MUTANT - Y18PHE-METHYL
5KIG	;	1.5	;	PSEUDO T4 LYSOZYME MUTANT - Y88F
5KI8	;	1.55	;	PSEUDO T4 LYSOZYME MUTANT - Y88PHE-BR
5KIM	;	1.5	;	PSEUDO T4 LYSOZYME MUTANT - Y88PHE-I
5KII	;	1.56	;	PSEUDO T4 LYSOZYME MUTANT - Y88PHE-METHYL
5T0N	;	3.004	;	Pseudo-apo structure of Sestrin2 at 3.0 angstrom resolution
6SIT	;	4.5	;	Pseudo-atomic crystal structure of the desmoglein 2 - human adenovirus serotype 3 fibre knob complex
7OA6	;	7.8	;	Pseudo-atomic model for Hsp26 residues 63 to 214. Please be advised that the target map is not of sufficient resolution to unambiguously position backbone or side chain atoms. This model represents a likely fit.
6T1R	;	9.8	;	Pseudo-atomic model of a 16-mer assembly of reduced recombinant human alphaA-crystallin (non domain swapped configuration)
1YXN	;	7.9	;	Pseudo-atomic model of a fiberless isometric variant of bacteriophage phi29
1IF0	;	12.0	;	PSEUDO-ATOMIC MODEL OF BACTERIOPHAGE HK97 PROCAPSID (PROHEAD II)
3J6P	;	8.2	;	Pseudo-atomic model of dynein microtubule binding domain-tubulin complex based on a cryoEM map
4CK7	;	9.2	;	Pseudo-atomic model of microtubule-bound human kinesin-5 motor domain in presence of adp.alfx (NECK-LINKER IN ITS DISCONNECTED CONFORMATION, based on cryo-electron microscopy experiment
4CK5	;	10.0	;	Pseudo-atomic model of microtubule-bound human kinesin-5 motor domain in the ADP state, based on cryo-electron microscopy experiment.
4CK6	;	9.2	;	Pseudo-atomic model of microtubule-bound human kinesin-5 motor domain in the ADP.AlFx state, based on cryo-electron microscopy experiment.
5M5L	;	9.3	;	Pseudo-atomic model of microtubule-bound S. pombe kinesin-5 motor domain in the AMPPNP state (based on cryo-electron microscopy experiment): the N-terminus adopts multiple conformations
5M5M	;	9.3	;	Pseudo-atomic model of microtubule-bound S.pombe kinesin-5 motor domain in the AMPPNP state (based on cryo-electron microscopy experiment): the N-terminus adopts multiple conformations.
5M5N	;	9.3	;	Pseudo-atomic model of microtubule-bound S.pombe kinesin-5 motor domain in the AMPPNP state (based on cryo-electron microscopy experiment): the N-terminus adopts multiple conformations.
5M5O	;	9.3	;	Pseudo-atomic model of microtubule-bound S.pombe kinesin-5 motor domain in the AMPPNP state (based on cryo-electron microscopy experiment): the N-terminus adopts multiple conformations.
5M5I	;	9.3	;	Pseudo-atomic model of microtubule-bound S.pombe kinesin-5 motor domain in the AMPPNP state (based on cryo-electron microscopy experiment): the N-terminus conformation allows formation of a cover neck bundle.
3J4Q	;	35.0	;	Pseudo-atomic model of the AKAP18-PKA complex in a bent conformation derived from electron microscopy
3J4R	;	35.0	;	Pseudo-atomic model of the AKAP18-PKA Complex in a linear conformation derived from electron microscopy
3J41	;	25.0	;	Pseudo-atomic model of the Aquaporin-0/Calmodulin complex derived from electron microscopy
5U6Y	;	20.0	;	Pseudo-atomic model of the CaMKIIa holoenzyme.
3DIK	;	9.0	;	Pseudo-atomic model of the HIV-1 CA hexameric lattice
5VM7	;	5.7	;	Pseudo-atomic model of the MurA-A2 complex
5MS0	;	9.8	;	pseudo-atomic model of the RNA polymerase lambda-based antitermination complex solved by cryo-EM
3TIR	;	4.1	;	Pseudo-atomic model of the Rous Sarcoma Virus capsid hexamer
7PE3	;	6.49	;	Pseudo-atomic model of the tetrahedral 24mer of Hsp17 from Caenorhabditis elegans
6H60	;	6.0	;	pseudo-atomic structural model of the E3BP component of the human pyruvate dehydrogenase multienzyme complex
5JB1	;	6.0	;	Pseudo-atomic structure of Human Papillomavirus Type 59 L1 Virus-like Particle
3MUW	;	9.0	;	Pseudo-atomic structure of the E2-E1 protein shell in Sindbis virus
2LP9	;		;	Pseudo-triloop from the sub-genomic promoter of Brome Mosaic Virus
8RJK	;	5.91	;	Pseudoatomic model of a second-order Sierpinski triangle formed by the citrate synthase from Synechococcus elongatus
6Z9M	;	9.1	;	Pseudoatomic model of the pre-fusion conformation of glycoprotein B of Herpes simplex virus 1
1ADW	;	2.5	;	PSEUDOAZURIN
5X31	;	2.6	;	Pseudoazurin from Alcaligenes faecalis (space group P65)
2JKW	;	1.6	;	Pseudoazurin M16F
2UXF	;	2.0	;	Pseudoazurin with engineered amicyanin ligand loop, oxidized form, pH 5.5
2UX6	;	1.3	;	Pseudoazurin with engineered amicyanin ligand loop, oxidized form, pH 7.5
2UXG	;	1.99	;	Pseudoazurin with engineered amicyanin ligand loop, reduced form, pH 5.5
2UX7	;	1.3	;	Pseudoazurin with engineered amicyanin ligand loop, reduced form, pH 7.5
7UQV	;	2.4	;	Pseudobacteroides cellulosolvens pseudo-CphB
6A5I	;		;	Pseudocerastes Persicus Trypsin Inhibitor
5U4U	;	1.9	;	pseudoGTPase domain (pG1) of p190RhoGAP-A
5U4V	;	2.6	;	pseudoGTPase domain (pG1) of p190RhoGAP-B
7QP3	;	1.85	;	Pseudogymnoascus pannorum M36 protease without the propeptide
5CEM	;	2.1	;	Pseudokinase and C-terminal extension of Human Tribbles Homolog 1
6RUU	;	2.95	;	Pseudokinase domain of human IRAK3
5CEK	;	2.8	;	Pseudokinase domain of Human Tribbles Homolog 1
5KNJ	;	2.88	;	Pseudokinase Domain of MLKL bound to Compound 1.
5KO1	;	2.16	;	Pseudokinase Domain of MLKL bound to Compound 4.
1XK9	;	2.1	;	Pseudomanas exotoxin A in complex with the PJ34 inhibitor
8IXH	;	1.95	;	Pseudomoans aeruginosa Wildtype Ketopantoate Reductase With 3-Methyl-2-oxovalerate at substrate site
8IWQ	;	2.191	;	Pseudomoans Aerugiona Native Ketopantoate Reductase with glycerol
8IWG	;	2.15	;	Pseudomoans Aerugiona Wildtype Ketopantoate Reductase native structure
8IXM	;	1.96	;	Pseudomoans Aerugiona Wildtype Ketopantoate Reductase ternary complex with NADP+ and alpha-Ketoisocaproic acid
8IX9	;	2.198	;	Pseudomoans Aerugiona Wildtype Ketopantoate Reductase with NADPH
6SPE	;	3.6	;	Pseudomonas aeruginosa 30s ribosome from a clinical isolate
6SPC	;	2.95	;	Pseudomonas aeruginosa 30s ribosome from an aminoglycoside resistant clinical isolate
6LCH	;	1.899	;	Pseudomonas aeruginosa 5086 (PA5086)
6SPD	;	3.28	;	Pseudomonas aeruginosa 50s ribosome from a clinical isolate
6SPB	;	2.82	;	Pseudomonas aeruginosa 50s ribosome from a clinical isolate with a mutation in uL6
2OBA	;	2.33	;	Pseudomonas aeruginosa 6-pyruvoyl tetrahydrobiopterin synthase
6SPG	;	3.34	;	Pseudomonas aeruginosa 70s ribosome from a clinical isolate
6SPF	;	2.89	;	Pseudomonas aeruginosa 70s ribosome from an aminoglycoside resistant clinical isolate
7UNR	;	2.9	;	Pseudomonas aeruginosa 70S ribosome initiation complex bound to compact IF2-GDP (composite structure I-A)
7UNU	;	2.9	;	Pseudomonas aeruginosa 70S ribosome initiation complex bound to compact IF2-GDP (composite structure I-B)
7UNV	;	2.7	;	Pseudomonas aeruginosa 70S ribosome initiation complex bound to IF2-GDPCP (structure II-A)
7UNW	;	2.6	;	Pseudomonas aeruginosa 70S ribosome initiation complex bound to IF2-GDPCP (structure II-B)
7CSV	;	1.71	;	Pseudomonas aeruginosa antitoxin HigA
7CSY	;	2.29	;	Pseudomonas aeruginosa antitoxin HigA with higBA promoter
7CSW	;	1.97	;	Pseudomonas aeruginosa antitoxin HigA with pa2440 promoter
4ZU2	;	2.15	;	Pseudomonas aeruginosa AtuE
1JZJ	;	1.8	;	Pseudomonas aeruginosa Azurin Os(bpy)2(im)(His83)
1JZI	;	1.62	;	Pseudomonas aeruginosa Azurin Re(phen)(CO)3(His83)
1JZE	;	1.6	;	Pseudomonas aeruginosa Azurin Ru(bpy)2(im)(His83)
1JZH	;	1.7	;	Pseudomonas aeruginosa Azurin Ru(tpy)(bpy)(His83)
3FSZ	;	2.0	;	Pseudomonas aeruginosa Azurin with mutated metal-binding loop sequence (CAAAAHAAAAM)
3FT0	;	1.8	;	Pseudomonas aeruginosa Azurin with mutated metal-binding loop sequence (CAAAAHAAAAM), chemically reduced
2XV3	;	2.3	;	Pseudomonas aeruginosa Azurin with mutated metal-binding loop sequence (CAAAAHAAAAM), chemically reduced, pH5.3
3FSW	;	2.0	;	Pseudomonas aeruginosa Azurin with mutated metal-binding loop sequence (CAAAAHAAAM)
3FSV	;	2.3	;	Pseudomonas aeruginosa Azurin with mutated metal-binding loop sequence (CAAAHAAAM)
3FS9	;	1.05	;	Pseudomonas aeruginosa Azurin with mutated metal-binding loop sequence (CAAHAAM)
2XV2	;	1.6	;	Pseudomonas aeruginosa Azurin with mutated metal-binding loop sequence (CAAHAAM), chemically reduced, pH4.2
2XV0	;	1.6	;	Pseudomonas aeruginosa Azurin with mutated metal-binding loop sequence (CAAHAAM), chemically reduced, pH4.8
3FSA	;	0.98	;	Pseudomonas aeruginosa Azurin with mutated metal-binding loop sequence (CAAHAAM); chemically reduced.
4BQ0	;	1.77	;	Pseudomonas aeruginosa beta-alanine:pyruvate aminotransferase holoenzyme without divalent cations on dimer-dimer interface
1GJQ	;	2.7	;	Pseudomonas aeruginosa cd1 nitrite reductase reduced cyanide complex
3R5D	;	1.8	;	Pseudomonas aeruginosa DapD (PA3666) apoprotein
3R5C	;	2.4	;	Pseudomonas aeruginosa DapD (PA3666) in complex with CoA and succinate
3R5A	;	1.89	;	Pseudomonas aeruginosa DapD (PA3666) in complex with D-2-aminopimelate
3R5B	;	2.51	;	Pseudomonas aeruginosa DapD (PA3666) in complex with L-2-aminopimelate
7PTG	;	2.2	;	Pseudomonas aeruginosa DNA gyrase B 24kDa ATPase subdomain complexed with EBL2888
8BN6	;	1.6	;	Pseudomonas aeruginosa DNA gyrase B 24kDa ATPase subdomain complexed with EBL3021
7PTF	;	1.32	;	Pseudomonas aeruginosa DNA gyrase B 24kDa ATPase subdomain complexed with novobiocin
2FNW	;	1.4	;	Pseudomonas aeruginosa E2Q/H83Q/M109H-azurin RE(PHEN)(CO)3
3IBO	;	1.45	;	Pseudomonas aeruginosa E2Q/H83Q/T126H-azurin RE(PHEN)(CO)3
7Z68	;	1.5	;	Pseudomonas aeruginosa Elastase in complex with a Thiol based inhibitor (R-and S-configured)
3DBK	;	1.4	;	Pseudomonas aeruginosa elastase with phosphoramidon
1IKP	;	1.45	;	Pseudomonas Aeruginosa Exotoxin A, P201Q, W281A mutant
1IKQ	;	1.62	;	Pseudomonas Aeruginosa Exotoxin A, wild type
8R0I	;	1.51	;	Pseudomonas aeruginosa FabF C164A in complex with 3-amino-N-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)benzamide
8QER	;	1.95	;	Pseudomonas aeruginosa FabF C164A in complex with 4-(1H-pyrazole-3-carbonylamino)pentanoic acid
8R1V	;	2.087	;	Pseudomonas aeruginosa FabF C164A in complex with N-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-2-(4-methoxyphenoxy)acetamide
8PJ0	;	1.7	;	Pseudomonas aeruginosa FabF C164A mutant in complex with N-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-3-methylbutanamide
8PD1	;	1.87	;	Pseudomonas aeruginosa FabF C164A mutant in complex with N-isopropyl-1H-imidazole-4-carboxamide
8PFZ	;	1.78	;	Pseudomonas aeruginosa FabF C164A mutant in complex with(S)-2-(1H-pyrazole-3-carboxamido)butanoic acid
7DEK	;	2.9	;	Pseudomonas aeruginosa FK506-binding protein PaFkbA
2J5O	;		;	Pseudomonas aeruginosa FtsK gamma domain
6URB	;	2.096	;	Pseudomonas aeruginosa HasA mutant - H32A
6U87	;	1.3	;	Pseudomonas aeruginosa HasA mutant - Y75H
5G13	;	1.99	;	Pseudomonas aeruginosa HDAH (H143A) unliganded.
5G12	;	2.02	;	Pseudomonas aeruginosa HDAH (Y313F) unliganded.
5G10	;	1.71	;	Pseudomonas aeruginosa HDAH bound to 9,9,9 trifluoro-8,8-dihydroy-N-phenylnonanamide
5G0X	;	1.7	;	Pseudomonas aeruginosa HDAH bound to acetate.
5G11	;	2.48	;	Pseudomonas aeruginosa HDAH bound to PFSAHA.
5G0Y	;	2.29	;	Pseudomonas aeruginosa HDAH unliganded.
2WGN	;		;	Pseudomonas aeruginosa ICP
1GZT	;	1.3	;	Pseudomonas aeruginosa lectin II (PA-IIL) together with fucose
1W8F	;	1.05	;	PSEUDOMONAS AERUGINOSA LECTIN II (PA-IIL)COMPLEXED WITH LACTO-N-NEO- FUCOPENTAOSE V(LNPFV)
6UEE	;	2.1	;	Pseudomonas aeruginosa LpxA Complex Structure with Ligand
6UEG	;	2.0	;	Pseudomonas aeruginosa LpxA Complex Structure with Ligand
4J3D	;	2.0	;	Pseudomonas aeruginosa LpxC in complex with a hydroxamate inhibitor
5U39	;	1.75	;	Pseudomonas aeruginosa LpxC in complex with CHIR-090
5U3B	;	2.0	;	Pseudomonas aeruginosa LpxC in complex with NVS-LPXC-01
6UEC	;	2.6	;	Pseudomonas aeruginosa LpxD Complex Structure with Ligand
4JUQ	;	2.2	;	Pseudomonas aeruginosa MetAP T2N mutant, in Mn form
4FO8	;	1.9	;	Pseudomonas aeruginosa MetAP with Met, in Mn form
4FO7	;	1.8	;	Pseudomonas aeruginosa MetAP, in Mn form
6X9N	;	2.25	;	Pseudomonas aeruginosa MurC with AZ5595
6X9F	;	2.35	;	Pseudomonas aeruginosa MurC with AZ8074
8DOF	;	2.6	;	Pseudomonas aeruginosa MurC with WYH9-2-P - OSA_001044
8GXJ	;	2.18	;	Pseudomonas aeruginosa N-acetyltransferase domain-containing protein PA3270
7QVS	;	2.3	;	Pseudomonas aeruginosa nicotinamide adenine dinucleotide kinase (NADK) structure in complex with NADP
1JZF	;	1.5	;	Pseudomonas aeruginosa Oxidized Azurin(Cu2+) Ru(tpy)(phen)(His83)
1K0L	;	2.0	;	Pseudomonas aeruginosa phbh R220Q free of p-OHB
1K0I	;	1.8	;	Pseudomonas aeruginosa phbh R220Q in complex with 100mM PHB
1K0J	;	2.2	;	Pseudomonas aeruginosa phbh R220Q in complex with NADPH and free of p-OHB
4AS2	;	2.12	;	Pseudomonas Aeruginosa Phosphorylcholine Phosphatase. Monoclinic form
4AS3	;	2.4	;	Pseudomonas Aeruginosa Phosphorylcholine Phosphatase. Orthorhombic form
5EOX	;	2.4	;	Pseudomonas aeruginosa PilM bound to ADP
5EQ6	;	3.5	;	Pseudomonas aeruginosa PilM bound to AMP-PNP
5EOU	;	2.4	;	Pseudomonas aeruginosa PilM:PilN1-12 bound to ATP
1JZG	;	1.4	;	Pseudomonas aeruginosa Reduced Azurin (Cu1+) Ru(tpy)(phen)(His83)
2B4Q	;	2.3	;	Pseudomonas aeruginosa RhlG/NADP active-site complex
3ZLK	;	1.952	;	Pseudomonas aeruginosa RmlA in complex with allosteric inhibitor
3ZLL	;	2.0	;	Pseudomonas aeruginosa RmlA in complex with allosteric inhibitor
4ARW	;	2.204	;	Pseudomonas aeruginosa RmlA in complex with allosteric inhibitor
4ASJ	;	2.25	;	Pseudomonas aeruginosa RmlA in complex with allosteric inhibitor
4ASY	;	2.3	;	Pseudomonas aeruginosa RmlA in complex with allosteric inhibitor
4B2W	;	2.36	;	Pseudomonas aeruginosa RmlA in complex with allosteric inhibitor
4B2X	;	1.7	;	Pseudomonas aeruginosa RmlA in complex with allosteric inhibitor
4B3U	;	1.8	;	Pseudomonas aeruginosa RmlA in complex with allosteric inhibitor
4B42	;	2.505	;	Pseudomonas aeruginosa RmlA in complex with allosteric inhibitor
4B4B	;	2.1	;	Pseudomonas aeruginosa RmlA in complex with allosteric inhibitor
4B4G	;	2.5	;	Pseudomonas aeruginosa RmlA in complex with allosteric inhibitor
4B4M	;	2.35	;	Pseudomonas aeruginosa RmlA in complex with allosteric inhibitor
4B5B	;	2.055	;	Pseudomonas aeruginosa RmlA in complex with allosteric inhibitor
5FTS	;	2.2	;	Pseudomonas aeruginosa RmlA in complex with allosteric inhibitor
5FTV	;	2.213	;	Pseudomonas aeruginosa RmlA in complex with allosteric inhibitor
5FU0	;	1.9	;	Pseudomonas aeruginosa RmlA in complex with allosteric inhibitor
5FU8	;	2.2	;	Pseudomonas aeruginosa RmlA in complex with allosteric inhibitor
5FUH	;	1.6	;	Pseudomonas aeruginosa RmlA in complex with allosteric inhibitor
5FYE	;	2.4	;	Pseudomonas aeruginosa RmlA in complex with allosteric inhibitor
6T37	;	2.079	;	Pseudomonas aeruginosa RmlA in complex with allosteric inhibitor
6T38	;	2.15	;	Pseudomonas aeruginosa RmlA in complex with allosteric inhibitor
6TQG	;	2.45	;	Pseudomonas aeruginosa RmlA in complex with allosteric inhibitor
5EOY	;	2.5	;	Pseudomonas aeruginosa SeMet-PilM bound to ADP
6HE3	;	2.16	;	Pseudomonas aeruginosa Seryl-tRNA Synthetase in Complex with 5'-O-(N-(L-seryl)-sulfamoyl)cytidine
6HE1	;	2.22	;	Pseudomonas aeruginosa Seryl-tRNA Synthetase in Complex with 5'-O-(N-(L-seryl)-sulfamoyl)N3-methyluridine
6HDZ	;	2.06	;	Pseudomonas aeruginosa Seryl-tRNA Synthetase in Complex with 5'-O-(N-(L-seryl)-Sulfamoyl)uridine
2FHX	;	1.9	;	Pseudomonas aeruginosa SPM-1 metallo-beta-lactamase
7DRG	;	1.6	;	Pseudomonas aeruginosa T6SS protein PA0821
1LR0	;	1.914	;	Pseudomonas aeruginosa TolA Domain III, Seleno-methionine Derivative
7DYM	;	3.1	;	Pseudomonas aeruginosa TseT-TsiT complex
7FF0	;	2.6	;	Pseudomonas aeruginosa Virulence Factor Regulator with cAMP ligand and auranofin
7FEW	;	1.75	;	Pseudomonas aeruginosa Virulence Factor Regulator with cAMP ligand and auranofin gold analogues
7FF8	;	2.8	;	Pseudomonas aeruginosa Virulence Factor Regulator with cAMP ligand and Cl(triethylphosphine)gold(I)
7FF9	;	2.4	;	Pseudomonas aeruginosa Virulence Factor Regulator with cAMP ligand and Cl(triethylphosphine)gold(I)
1R1C	;	1.9	;	PSEUDOMONAS AERUGINOSA W48F/Y72F/H83Q/Y108W-AZURIN RE(PHEN)(CO)3(HIS107)
1H41	;	1.5	;	Pseudomonas cellulosa E292A alpha-D-glucuronidase mutant complexed with aldotriuronic acid
1HQD	;	2.3	;	PSEUDOMONAS CEPACIA LIPASE COMPLEXED WITH TRANSITION STATE ANALOGUE OF 1-PHENOXY-2-ACETOXY BUTANE
6EDG	;	1.47	;	Pseudomonas exotoxin A domain III T18H477L
8GXF	;	3.04	;	Pseudomonas flexibilis GCN5 family acetyltransferase
5VI0	;	2.396	;	Pseudomonas fluorescens alkylpurine DNA glycosylase AlkC bound to DNA containing an abasic site analog
5VHV	;	1.799	;	Pseudomonas fluorescens alkylpurine DNA glycosylase AlkC bound to DNA containing an oxocarbenium-intermediate analog
1VA4	;	1.804	;	Pseudomonas fluorescens aryl esterase
3IA2	;	1.65	;	Pseudomonas fluorescens esterase complexed to the R-enantiomer of a sulfonate transition state analog
7L9Z	;	1.3	;	Pseudomonas fluorescens G150A isocyanide hydratase (G150A-1) at 274K, Refmac5-refined
7LA0	;	1.25	;	Pseudomonas fluorescens G150A isocyanide hydratase (G150A-2) at 274K, Refmac5-refined
7LA3	;	1.349	;	Pseudomonas fluorescens G150A isocyanide hydratase (G150A-3) at 274K, Refmac5-refined
7LAV	;	1.149	;	Pseudomonas fluorescens G150T isocyanide hydratase (G150T-1) at 274K, Refmac5-refined
7LAX	;	1.198	;	Pseudomonas fluorescens G150T isocyanide hydratase (G150T-2) at 274K, Refmac5-refined
7LB9	;	1.101	;	Pseudomonas fluorescens G150T isocyanide hydratase (G150T-3) at 274K, Refmac5-refined
8TSX	;	1.0	;	Pseudomonas fluorescens G150T isocyanide hydratase at 100 K
8VPW	;	1.3	;	Pseudomonas fluorescens G150T isocyanide hydratase at 298 K XFEL data, free enzyme
8VQ1	;	1.3	;	Pseudomonas fluorescens G150T isocyanide hydratase at 298 K XFEL data, thioimidate intermediate
8TSU	;	1.15	;	Pseudomonas fluorescens G150T-1 isocyanide hydratase at 274 K
8TSY	;	1.2	;	Pseudomonas fluorescens G150T-2 isocyanide hydratase at 274 K
8TSZ	;	1.1	;	Pseudomonas fluorescens G150T-3 isocyanide hydratase at 274 K
6NIA	;	1.05	;	Pseudomonas fluorescens isocyanide hydratase at 100 K helical disorder model
6NI6	;	1.201	;	Pseudomonas fluorescens isocyanide hydratase at 274 K
6NI5	;	1.3	;	Pseudomonas fluorescens isocyanide hydratase at 274 K G150A mutant
6NI9	;	1.201	;	Pseudomonas fluorescens isocyanide hydratase at 274 K qFit multiconformer model
6NI7	;	1.15	;	Pseudomonas fluorescens isocyanide hydratase at 277 K
6NI4	;	1.1	;	Pseudomonas fluorescens isocyanide hydratase at 277 K G150T mutant
6NPQ	;	1.55	;	Pseudomonas fluorescens isocyanide hydratase at 298 K XFEL data
8TT0	;	1.5	;	Pseudomonas fluorescens isocyanide hydratase pH=4.2
8TT1	;	1.45	;	Pseudomonas fluorescens isocyanide hydratase pH=5.0
8TT2	;	1.33	;	Pseudomonas fluorescens isocyanide hydratase pH=5.4
8TT4	;	1.2	;	Pseudomonas fluorescens isocyanide hydratase pH=6.0
8TT5	;	1.02	;	Pseudomonas fluorescens isocyanide hydratase pH=8.3
6UNF	;	1.55	;	Pseudomonas fluorescens isocyanide hydratase post-catalysis at 298 K XFEL data
6NI8	;	1.45	;	Pseudomonas fluorescens isocyanide hydratase rotating anode 298K
6UND	;	1.55	;	Pseudomonas fluorescens isocyanide hydratase thioimidate intermediate at 298 K XFEL data
5NA5	;	1.94	;	Pseudomonas fluorescens kynurenine 3-monooxygenase (KMO) apo structure
5N7T	;	1.81	;	Pseudomonas fluorescens kynurenine 3-monooxygenase (KMO) in complex with 3-(5,6-dichloro-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)propanoic acid
5MZI	;	1.71	;	Pseudomonas fluorescens kynurenine 3-monooxygenase (KMO) in complex with 3-(5-chloro-6-cyclopropoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)propanoic acid
5MZC	;	1.82	;	Pseudomonas fluorescens kynurenine 3-monooxygenase (KMO) in complex with 3-(5-chloro-6-ethoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)propanoic acid
5NAB	;	1.63	;	Pseudomonas fluorescens kynurenine 3-monooxygenase (KMO) in complex with 3-(5-chloro-6-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)propanoic acid
5MZK	;	1.82	;	Pseudomonas fluorescens kynurenine 3-monooxygenase (KMO) in complex with 3-[5-chloro-6-(cyclobutylmethoxy)-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl]propanoic acid
5NAE	;	1.76	;	Pseudomonas fluorescens kynurenine 3-monooxygenase (KMO) in complex with 3-{5-chloro-2-oxo-6-[(1R)-1-(pyridin-2-yl)ethoxy]-2,3-dihydro-1,3-benzoxazol-3-yl}propanoic acid
5NAH	;	1.75	;	Pseudomonas fluorescens kynurenine 3-monooxygenase (KMO) in complex with 3-{5-chloro-6-[(1R)-1-(6-methylpyridazin-3-yl)ethoxy]-1,2-benzoxazol-3-yl}propanoic acid
5NAG	;	1.68	;	Pseudomonas fluorescens kynurenine 3-monooxygenase (KMO) in complex with 3-{5-chloro-6-[(1R)-1-(pyridin-2-yl)ethoxy]-1,2-benzoxazol-3-yl}propanoic acid
5NAK	;	1.5	;	Pseudomonas fluorescens kynurenine 3-monooxygenase (KMO) in complex with the enzyme substrate L-kynurenine
1M2W	;	1.8	;	Pseudomonas fluorescens mannitol 2-dehydrogenase ternary complex with NAD and D-mannitol
6QSI	;	1.69	;	Pseudomonas fluorescens Pf-5 thiamine diphosphate-dependent 4-hydroxybenzoylformate decarboxylase
4A9V	;	1.1	;	Pseudomonas fluorescens PhoX
4ALF	;	1.25	;	Pseudomonas fluorescens PhoX in complex with phosphate
4A9X	;	1.79	;	Pseudomonas fluorescens PhoX in complex with the substrate analogue AppCp
4AMF	;	1.52	;	Pseudomonas fluorescens PhoX in complex with the substrate analogue AppCp
3ZWU	;	1.39	;	Pseudomonas fluorescens PhoX in complex with vanadate, a transition state analogue
8GXK	;	1.78	;	Pseudomonas jinjuensis N-acetyltransferase
5LIP	;	2.9	;	PSEUDOMONAS LIPASE COMPLEXED WITH RC-(RP, SP)-1,2-DIOCTYLCARBAMOYLGLYCERO-3-O-OCTYLPHOSPHONATE
4LIP	;	1.75	;	PSEUDOMONAS LIPASE COMPLEXED WITH RC-(RP, SP)-DIBUTYLCARBAMOYLGLYCERO-3-O-BUTYLPHOSPHONATE
2LIP	;	2.1	;	PSEUDOMONAS LIPASE OPEN CONFORMATION
8E4A	;	2.034	;	Pseudomonas LpxC in complex with LPC-233
2FX5	;	1.8	;	Pseudomonas mendocina lipase
8FRS	;	3.96	;	Pseudomonas phage E217 5-fold vertex (capsid and decorating proteins)
8EON	;	3.6	;	Pseudomonas phage E217 baseplate complex
8FVG	;	3.1	;	Pseudomonas phage E217 contracted sheath
8FUV	;	3.1	;	Pseudomonas phage E217 extended sheath and tail tube
8FVH	;	3.1	;	Pseudomonas phage E217 neck (portal, head-to-tail connector, collar and gateway proteins)
7UXE	;	3.38	;	Pseudomonas phage E217 small terminase (TerS)
6ICK	;	1.952	;	Pseudomonas putida CBB5 NdmA
6ICP	;	2.2	;	Pseudomonas putida CBB5 NdmA QL mutant with caffeine
6ICQ	;	1.9	;	Pseudomonas putida CBB5 NdmA QL mutant with theobromine
6ICN	;	1.65	;	Pseudomonas putida CBB5 NdmA with caffeine
6ICM	;	2.961	;	Pseudomonas putida CBB5 NdmA with ferredoxin domain of NdmD
6ICO	;	1.85	;	Pseudomonas putida CBB5 NdmA with theophylline
6ICL	;	2.1	;	Pseudomonas putida CBB5 NdmB
6E13	;	2.349	;	Pseudomonas putida PqqB with a non-physiological zinc at the active site binds the substrate mimic, 5-cysteinyl-3,4-dihydroxyphenylalanine (5-Cys-DOPA), non-specifically but supports the proposed function of the enzyme in pyrroloquinoline quinone biosynthesis.
1NLU	;	1.3	;	Pseudomonas sedolisin (serine-carboxyl proteinase) complexed with two molecules of pseudo-iodotyrostatin
6M8W	;	1.1	;	PSEUDOMONAS SERINE-CARBOXYL PROTEINASE (SEDOLISIN) COMPLEXED WITH THE INHIBITOR AIAF
6M8Y	;	1.1	;	PSEUDOMONAS SERINE-CARBOXYL PROTEINASE (SEDOLISIN) COMPLEXED WITH THE INHIBITOR AIPF
6M9D	;	2.0	;	PSEUDOMONAS SERINE-CARBOXYL PROTEINASE (SEDOLISIN) COMPLEXED WITH THE INHIBITOR Chymostatin
6M9C	;	1.8	;	PSEUDOMONAS SERINE-CARBOXYL PROTEINASE (SEDOLISIN) COMPLEXED WITH THE INHIBITOR Pseudotyrostatin
6M9F	;	1.3	;	PSEUDOMONAS SERINE-CARBOXYL PROTEINASE (SEDOLISIN) COMPLEXED WITH THE INHIBITOR Tyrostatin
7APY	;	1.778	;	Pseudomonas stutzeri nitrous oxide reductase mutant, D576A
7AQ0	;	1.584	;	Pseudomonas stutzeri nitrous oxide reductase mutant, D576A/S550A
6Y6Y	;	1.67	;	Pseudomonas stutzeri nitrous oxide reductase mutant, H129A
6Y71	;	1.64	;	Pseudomonas stutzeri nitrous oxide reductase mutant, H130A
6Y72	;	1.55	;	Pseudomonas stutzeri nitrous oxide reductase mutant, H178A
6Y77	;	1.49	;	Pseudomonas stutzeri nitrous oxide reductase mutant, H326A
7AQA	;	1.497	;	Pseudomonas stutzeri nitrous oxide reductase mutant, H382A
6Y7D	;	1.6	;	Pseudomonas stutzeri nitrous oxide reductase mutant, H433A
6Y7E	;	1.6	;	Pseudomonas stutzeri nitrous oxide reductase mutant, H494A
7AQ2	;	1.683	;	Pseudomonas stutzeri nitrous oxide reductase mutant, H583A
7AQ3	;	1.639	;	Pseudomonas stutzeri nitrous oxide reductase mutant, H583D
7AQ4	;	1.708	;	Pseudomonas stutzeri nitrous oxide reductase mutant, H583E
7AQ6	;	1.514	;	Pseudomonas stutzeri nitrous oxide reductase mutant, H583F
7AQ5	;	1.7	;	Pseudomonas stutzeri nitrous oxide reductase mutant, H583N
7AQ9	;	1.585	;	Pseudomonas stutzeri nitrous oxide reductase mutant, H583W
7AQ7	;	1.608	;	Pseudomonas stutzeri nitrous oxide reductase mutant, H583Y
7AQ8	;	1.791	;	Pseudomonas stutzeri nitrous oxide reductase mutant, H583Y/D576A
3SBP	;	2.1	;	Pseudomonas stutzeri nitrous oxide reductase, P1 crystal form
3SBR	;	2.24	;	Pseudomonas stutzeri nitrous oxide reductase, P1 crystal form with substrate
3SBQ	;	1.7	;	Pseudomonas stutzeri nitrous oxide reductase, P65 crystal form
5O37	;	1.37	;	Pseudomonas stutzeri PtxB in complex with methylphosphonate (MPn) to 1.37 A resolution
5O2J	;	1.52	;	Pseudomonas stutzeri PtxB in complex with phosphite to 1.52 A resolution
6EAC	;	2.269	;	Pseudomonas syringae SelO
8DKR	;	2.05	;	Pseudomonas-phage E217 TerL nuclease domain
7U6L	;	2.6	;	Pseudooxynicotine amine oxidase
6C4N	;	1.95	;	Pseudopaline dehydrogenase (PaODH) - NADP+ bound
6PBN	;	1.65	;	Pseudopaline Dehydrogenase with (R)-Pseudopaline Soaked 1 hour
6PBT	;	2.18	;	Pseudopaline Dehydrogenase with (R)-Pseudopaline Soaked 2 hours
6PBP	;	1.64	;	Pseudopaline Dehydrogenase with (S)-Pseudopaline Soaked 1 hour
6PBM	;	1.57	;	Pseudopaline Dehydrogenase with NADP+ bound
5FKI	;	35.0	;	Pseudorabies virus (PrV) nuclear egress complex proteins fitted as a hexameric lattice into a sub-tomogram average derived from focused- ion beam milled lamellae electron cryo-microscopic data
5E8C	;	2.9	;	pseudorabies virus nuclear egress complex, pUL31, pUL34
1EA2	;	1.8	;	Pseudoreversion of the Catalytic Activity of Y14F by the Additional Tyrosine-to-Phenylalanine Substitution(s) in the Hydrogen Bond Network of Delta-5-3-Ketosteroid Isomerase from Pheudomonas putida Biotype B
7C1Y	;	2.08343	;	Pseudouridine and ADP bound structure of Pseudouridine kinase (PUKI) from Arabidopsis thaliana
7VVA	;	2.75029	;	Pseudouridine bound structure of Pseudouridine kinase (PUKI) from Escherichia coli strain B
7VTG	;	1.89859	;	Pseudouridine bound structure of Pseudouridine kinase (PUKI) S30A mutant from Escherichia coli strain B
5U5G	;	2.048	;	Psf3 in complex with NADP+ and 2-OPP
5U58	;	2.7	;	Psf4 in complex with Fe2+ and (R)-2-HPP
5U57	;	2.73	;	Psf4 in complex with Fe2+ and (S)-2-HPP
5U5D	;	2.49	;	Psf4 in complex with Mn2+ and (R)-2-HPP
5U55	;	2.45	;	Psf4 in complex with Mn2+ and (S)-2-HPP
8JW0	;	2.9	;	PSI-AcpPCI supercomplex from Amphidinium carterae
8JZE	;	2.99	;	PSI-AcpPCI supercomplex from Symbiodinium
8JZF	;	2.7	;	PSI-AcpPCI supercomplex from Symbiodinium
7WZN	;	4.9	;	PSI-LHCI from Chlamydomonas reinhardtii with bound ferredoxin
8WEY	;	1.92	;	PSI-LHCI of the red alga Cyanidium caldarium RK-1 (NIES-2137)
6L35	;	3.23	;	PSI-LHCI Supercomplex from Physcometrella patens
7XQP	;	2.68	;	PSI-LHCI-LHCII-Lhcb9 supercomplex of Physcomitrella patens
7F9O	;	4.5	;	PSI-NDH supercomplex of Barley
1E29	;	1.21	;	PSII associated cytochrome C549 from Synechocystis sp.
7DXA	;	3.14	;	PSII intermediate Psb28-RC47
6YP7	;	3.8	;	PSII-LHCII C2S2 supercomplex from Pisum sativum grown in high light conditions
7YMI	;	3.3	;	PSII-Pcb Dimer of Acaryochloris Marina
7YMM	;	3.6	;	PSII-Pcb Tetramer of Acaryochloris Marina
8PB8	;	2.531	;	PsiM in complex with SAH
8PB6	;	0.93	;	PsiM in complex with SAH and baeocystin
8PB3	;	1.18	;	PsiM in complex with SAH and norbaeocystin, monoclinic crystal form
8PB4	;	0.91	;	PsiM in complex with SAH and norbaeocystin, orthorhombic crystal form
8QXQ	;	0.94	;	PsiM in complex with SAH and psilocybin
8PB7	;	0.92	;	PsiM in complex with sinefungin and baeocystin
8PB5	;	0.89	;	PsiM in complex with sinefungin and norbaeocystin
1U83	;	2.2	;	PSL synthase from Bacillus subtilis
5MUA	;	1.49	;	PSL1a-E64 complex
7UIH	;	3.1	;	PSMD2 Structure
7UJD	;	2.5	;	PSMD2 Structure bound to MC1 and Fab8/14
1FHY	;	2.2	;	PSORALEN CROSS-LINKED D(CCGCTAGCGG) FORMS HOLLIDAY JUNCTION
1FHZ	;	2.2	;	PSORALEN CROSS-LINKED D(CCGGTACCGG) FORMS HOLLIDAY JUNCTION
4ZK0	;	2.15	;	Psoriasis pathogenesis - Pso p27 constitute a compact structure forming large aggregates. High pH structure
4ZK3	;	2.0	;	Psoriasis pathogenesis - Pso p27 constitute a compact structure forming large aggregates. Low pH structure
2BJW	;	1.75	;	PspF AAA domain
2VII	;	2.85	;	PspF1-275-Mg-AMP
6HYJ	;	1.929	;	PSPH Human phosphoserine phosphatase
6R02	;	2.65	;	Psychrobacter arcticus ATP phosphoribosyltransferase bound to histidine and PRPP
7Z6R	;	2.55	;	Psychrobacter arcticus ATPPRT (HisGZ) R56A mutant bound to ATP and PRPP
4XG1	;	2.5	;	Psychromonas ingrahamii diaminopimelate decarboxylase with LLP
4RKC	;	2.19	;	Psychrophilic aromatic amino acids aminotransferase from Psychrobacter sp. B6
4RKD	;	2.76	;	Psychrophilic aromatic amino acids aminotransferase from Psychrobacter sp. B6 cocrystalized with aspartic acid
6ZUP	;	2.5	;	Psychrophilic aromatic amino acids aminotransferase from Psychrobacter sp. B6 cocrystalized with substrate analog - L-(-)-3-phenyllactic acid
6ZVG	;	2.59	;	Psychrophilic aromatic amino acids aminotransferase from Psychrobacter sp. B6 cocrystalized with substrate analog - L-indole-3-lactic acid
6ZUR	;	2.31	;	Psychrophilic aromatic amino acids aminotransferase from Psychrobacter sp. B6 cocrystalized with substrate analog - L-p-hydroxyphenyllactic acid
6T3V	;	1.62	;	Psychrophilic aromatic amino acids aminotransferase from Psychrobacter sp. B6 cocrystalized with substrate analog - malic acid
1H71	;	2.1	;	Psychrophilic Protease from Pseudoalteromonas 'TAC II 18'
5T7L	;	2.83	;	Pt(II)-mediated copper-dependent interactions between ATOX1 and MNK1
2WB7	;	2.6	;	pT26-6p
2M38	;		;	PTB domain of AIDA1
5NJJ	;	2.7	;	PTB domain of human Numb isoform-1
5NJK	;	3.13	;	PTB domain of human Numb isoform-1
8BWF	;	2.9	;	PTBP1 RRM1 bound to an allosteric inhibitor
4OWH	;	1.484	;	PtBr6 binding to HEWL
6H6E	;	3.95	;	PTC3 holotoxin complex from Photorhabdus luminecens in prepore state (TcdA1, TcdB2, TccC3)
6H6F	;	3.72	;	PTC3 holotoxin complex from Photorhabdus luminiscens - Mutant TcC-D651A
4OWE	;	1.41	;	PtCl6 binding to HEWL
2VZ0	;	1.9	;	Pteridine Reductase 1 (PTR1) from Trypanosoma Brucei in complex with NADP and DDD00066641
2WD7	;	1.9	;	PTERIDINE REDUCTASE 1 (PTR1) FROM TRYPANOSOMA BRUCEI IN COMPLEX WITH NADP AND DDD00066750
2WD8	;	2.1	;	PTERIDINE REDUCTASE 1 (PTR1) FROM TRYPANOSOMA BRUCEI IN COMPLEX WITH NADP AND DDD00071204
1E92	;	2.2	;	Pteridine reductase 1 from Leishmania major complexed with NADP+ and dihydrobiopterin
1P33	;	2.86	;	Pteridine reductase from Leishmania tarentolae complex with NADPH and MTX
1N3O	;	2.0	;	Pterocarcpus angolensis lectin in complex with alpha-methyl glucose
1UKG	;	1.7	;	Pterocarps angolensis lectin PAL in complex with methyl-alpha-mannose
2PHT	;	2.1	;	Pterocarpus angolensis lectin (P L) in complex with Man-7D3
2ARE	;	1.8	;	Pterocarpus angolensis Lectin (PAL) In Complex With D-Mannose (anomeric mixture)
2PHX	;	1.8	;	Pterocarpus angolensis lectin (PAL) in complex with Man-5
2PHR	;	1.9	;	Pterocarpus angolensis lectin (PAL) in complex with Man-7D1
2PHW	;	1.8	;	Pterocarpus angolensis lectin (PAL) in complex with Man-9
1Q8Q	;	2.05	;	Pterocarpus angolensis lectin (PAL) in complex with the dimannoside Man(alpha1-4)Man
1Q8S	;	2.05	;	Pterocarpus angolensis lectin (PAL) in complex with the dimannoside Man(alpha1-6)Man
2ARB	;	1.8	;	Pterocarpus angolensis Lectin (PAL) In Complex With The GlcNAc(beta1-2)Man Disaccharide
2AR6	;	1.8	;	Pterocarpus angolensis Lectin (PAL) In Complex With The Pentasaccharide M592
1Q8V	;	1.85	;	Pterocarpus angolensis lectin (PAL) in complex with the trimannoside [Man(Alpha1-3)]Man(alpha1-6)Man
2PHF	;	2.1	;	Pterocarpus angolensis lectin complexed with Man-6
1N3Q	;	2.2	;	Pterocarpus angolensis lectin complexed with turanose
2PHU	;	2.2	;	Pterocarpus angolensis lectin in complex with Man-8D1D3
1N3P	;	2.1	;	Pterocarpus angolensis lectin in complex with sucrose
2AUY	;	1.95	;	Pterocarpus angolensis lectin in complex with the trisaccharide GlcNAc(b1-2)Man(a1-3)Man
1Q8P	;	1.75	;	Pterocarpus angolensis lectin PAL in complex with the dimannoside Man(alpha1-3)Man
1S1A	;	1.8	;	Pterocarpus angolensis seed lectin (PAL) with one binding site free and one binding site containing the disaccharide Man(a1-3)ManMe
2ARX	;	2.0	;	Pterocarpus angolensis seed lectin in complex with the decasaccharide NA2F
1Q8O	;	2.2	;	Pterocartpus angolensis lectin PAL in complex with the dimmanoside Man(alpha1-2)Man
6E10	;	4.16	;	PTEX Core Complex in the Engaged (Extended) State
6E11	;	4.23	;	PTEX Core Complex in the Resetting (Compact) State
1BL1	;		;	PTH RECEPTOR N-TERMINUS FRAGMENT, NMR, 1 STRUCTURE
7VVK	;	3.3	;	PTH-bound human PTH1R in complex with Gs (class1)
7VVL	;	2.8	;	PTH-bound human PTH1R in complex with Gs (class2)
7VVM	;	3.2	;	PTH-bound human PTH1R in complex with Gs (class3)
7VVN	;	3.8	;	PTH-bound human PTH1R in complex with Gs (class4)
7VVO	;	4.1	;	PTH-bound human PTH1R in complex with Gs (class5)
7VVJ	;	3.2	;	PTHrP-bound human PTH1R in complex with Gs
8HAF	;	3.25	;	PTHrP-PTH1R-Gs complex
4OWC	;	1.62	;	PtI6 binding to HEWL
7MN9	;	1.24	;	PTP1B 1-284 F225Y-R199N
7MNA	;	1.47	;	PTP1B 1-284 F225Y-R199N in complex with TCS401
7MOV	;	1.65	;	PTP1B 1-301 F225Y-R199N mutations
1XBO	;	2.5	;	PTP1B complexed with Isoxazole Carboxylic Acid
6NTP	;	1.89	;	PTP1B Domain of PTP1B-LOV2 Chimera
7MOW	;	1.8	;	PTP1B F225I in complex with TCS401
7MN7	;	1.95	;	PTP1B F225Y in complex with TCS401
7MKZ	;	1.4	;	PTP1B F225Y mutant, open state
7MOU	;	1.48	;	PTP1B F225Y-R199N-L195R
7MNB	;	2.2	;	PTP1B F225Y-R199N-L195R in complex with TCS401
8SKL	;	1.55	;	PTP1B in complex with 182
3CWE	;	1.6	;	PTP1B in complex with a phosphonic acid inhibitor
7MM1	;	1.85	;	PTP1B in complex with TCS401 by Native S-SAD at Room Temperature
7MNC	;	1.85	;	PTP1B L204A
7MND	;	2.29	;	PTP1B L204A in complex with TCS401
7MNF	;	1.7	;	PTP1B P206G in complex with TCS401
7MNE	;	1.6	;	PTP1B P206G mutation, open state
1NWE	;	3.1	;	Ptp1B R47C Modified at C47 with N-[4-(2-{2-[3-(2-Bromo-acetylamino)-propionylamino]-3-hydroxy-propionylamino}-ethyl)-phenyl]-oxalamic acid
1OEM	;	1.8	;	PTP1B with the catalytic cysteine oxidized to a sulfenyl-amide bond
1OEO	;	2.15	;	PTP1B with the catalytic cysteine oxidized to sulfonic acid
4ZRT	;	1.74	;	PTP1BC215S bound to Nephrin peptide substrate
4GFV	;	2.095	;	PTPN18 in complex with HER2-pY1196 phosphor-peptides
4GFU	;	2.0	;	PTPN18 in complex with HER2-pY1248 phosphor-peptides
8GVL	;	2.1	;	PTPN21 FERM
8GXE	;	3.0	;	PTPN21 FERM PTP complex
8GVV	;	1.8	;	PTPN21 PTP domain C1108S mutant
8GWH	;	2.0	;	PTPN21 PTP domain C1108S mutant in complex with SRC pTyr530 peptide
3OLR	;	2.5	;	PTPN22 in complex with consensus phospho-tyrosine peptide 1
3KLD	;	1.999	;	PTPRG CNTN4 complex
3S97	;	2.2971	;	PTPRZ CNTN1 complex
7ZL1	;	2.5	;	PTX3 Pentraxin Domain
2J17	;	2.84	;	pTyr bound form of SDP-1
1PUE	;	2.1	;	PU.1 ETS DOMAIN-DNA COMPLEX
7ZCU	;	2.7	;	PucA-LH2 complex from Rps. palustris
7ZDI	;	2.9	;	PucB-LH2 complex from Rps. palustris
7ZE3	;	2.7	;	PucD-LH2 complex from Rps. palustris
7ZE8	;	3.6	;	PucE-LH2 complex from Rps. palustris
3K4E	;	3.2	;	Puf3 RNA binding domain bound to Cox17 RNA 3' UTR recognition sequence site A
3K49	;	2.5	;	Puf3 RNA binding domain bound to Cox17 RNA 3' UTR recognition sequence site B
3BX2	;	2.84	;	Puf4 RNA binding domain bound to HO endonuclease RNA 3' UTR recognition sequence
3BX3	;	3.0	;	Puf4 T650C/C724R Mutant bound to Cox17 RNA 3' UTR recognition sequence
2WAN	;	1.65	;	Pullulanase from Bacillus acidopullulyticus
2YJ1	;	2.24	;	Puma BH3 foldamer in complex with Bcl-xL
1U11	;	1.55	;	PurE (N5-carboxyaminoimidazole Ribonucleotide Mutase) from the acidophile Acetobacter aceti
8GYG	;	2.0	;	Purification ,Crystallization and X-ray Diffraction analysis of a novel arysulfatase from Pseudoalteromonas atlantica T6c
2YYF	;		;	Purification and structural characterization of a D-amino acid containing conopeptide, marmophine, from Conus marmoreus
8E2X	;	3.3	;	Purification of Enterovirus A71, strain 4643, WT capsid
8E2Y	;	8.0	;	Purification of Enterovirus A71, strain 4643, WT capsid
8E31	;	14.0	;	Purification of Enterovirus A71, strain 4643, WT capsid
8E38	;	4.2	;	Purification of Enterovirus A71, strain 4643, WT capsid
8E39	;	3.1	;	Purification of Enterovirus A71, strain 4643, WT capsid
8E3A	;	7.4	;	Purification of Enterovirus A71, strain 4643, WT capsid
8E3B	;	5.9	;	Purification of Enterovirus A71, strain 4643, WT capsid
8E3C	;	7.1	;	Purification of Enterovirus A71, strain 4643, WT capsid
3WX8	;	1.952	;	Purification, characterization and structure of nucleoside diphosphate kinase from Drosophila S2 cells
7BX9	;	1.38	;	Purification, characterization and X-ray structure of YhdA-type azoreductase from Bacillus velezensis
1OFN	;	1.5	;	Purification, crystallisation and preliminary structural studies of dTDP-4-keto-6-deoxy-glucose-5-epimerase (EvaD) from Amycolatopsis orientalis; the fourth enzyme in the dTDP-L-epivancosamine biosynthetic pathway.
5XYJ	;	1.93	;	Purification,crystallization and structural analysis of cytoplastic acetoacetyl-CoA thiolase from Saccharomyces cerevisiae
5XZ5	;	2.2	;	Purification,crystallization and structural analysis of cytoplastic acetoacetyl-CoA thiolase from Saccharomyces cerevisiae
1S2D	;	2.1	;	Purine 2'-Deoxyribosyl complex with arabinoside: Ribosylated Intermediate (AraA)
1S3F	;	2.2	;	Purine 2'-deoxyribosyltransferase + selenoinosine
1S2G	;	2.1	;	Purine 2'deoxyribosyltransferase + 2'-deoxyadenosine
1S2I	;	2.24	;	Purine 2'deoxyribosyltransferase + bromopurine
1S2L	;	2.1	;	Purine 2'deoxyribosyltransferase native structure
1MAS	;	2.5	;	PURINE NUCLEOSIDE HYDROLASE
2MAS	;	2.3	;	PURINE NUCLEOSIDE HYDROLASE WITH A TRANSITION STATE INHIBITOR
1B8N	;	2.0	;	PURINE NUCLEOSIDE PHOSPHORYLASE
1B8O	;	1.5	;	PURINE NUCLEOSIDE PHOSPHORYLASE
1ECP	;	2.0	;	PURINE NUCLEOSIDE PHOSPHORYLASE
1PBN	;	2.0	;	PURINE NUCLEOSIDE PHOSPHORYLASE
1VFN	;	2.15	;	PURINE NUCLEOSIDE PHOSPHORYLASE
5IFK	;	1.967	;	Purine nucleoside phosphorylase
2AI1	;	2.0	;	Purine nucleoside phosphorylase from calf spleen
2AI2	;	1.7	;	Purine nucleoside phosphorylase from calf spleen
2AI3	;	1.7	;	Purine nucleoside phosphorylase from calf spleen
1FXU	;	2.2	;	PURINE NUCLEOSIDE PHOSPHORYLASE FROM CALF SPLEEN IN COMPLEX WITH N(7)-ACYCLOGUANOSINE INHIBITOR AND A PHOSPHATE ION
1C3X	;	2.4	;	PURINE NUCLEOSIDE PHOSPHORYLASE FROM CELLULOMONAS SP. IN COMPLEX WITH 8-IODO-GUANINE
1QE5	;	2.2	;	PURINE NUCLEOSIDE PHOSPHORYLASE FROM CELLULOMONAS SP. IN COMPLEX WITH PHOSPHATE
1K9S	;	2.0	;	PURINE NUCLEOSIDE PHOSPHORYLASE FROM E. COLI IN COMPLEX WITH FORMYCIN A DERIVATIVE AND PHOSPHATE
1ODI	;	2.4	;	Purine nucleoside phosphorylase from Thermus Thermophilus
1ODJ	;	2.4	;	PURINE NUCLEOSIDE PHOSPHORYLASE FROM THERMUS THERMOPHILUS
1ODK	;	1.9	;	PURINE NUCLEOSIDE PHOSPHORYLASE FROM THERMUS THERMOPHILUS
1ODL	;	2.1	;	PURINE NUCLEOSIDE PHOSPHORYLASE FROM THERMUS THERMOPHILUS
1A69	;	2.1	;	PURINE NUCLEOSIDE PHOSPHORYLASE IN COMPLEX WITH FORMYCIN B AND SULPHATE (PHOSPHATE)
8C25	;	1.56	;	purine nucleoside phosphorylase in complex with JS-375
7ZSR	;	1.97	;	purine nucleoside phosphorylase in complex with JS-379
8W7H	;	1.85	;	Purine Nucleoside Phosphorylase in complex with MMV000848
1OTX	;	2.7	;	Purine Nucleoside Phosphorylase M64V mutant
7OP9	;	1.5	;	Purine nucleoside phosphorylase(DeoD-type) from H. pylori with 2,6-dichloropurine
7OOZ	;	1.7	;	Purine nucleoside phosphorylase(DeoD-type) from H. pylori with 6-benzyloxo-2-chloropurine
7OOY	;	1.9	;	Purine nucleoside phosphorylase(DeoD-type) from H. pylori with 6-benzylthio-2-chloropurine
7OPA	;	2.0	;	Purine nucleoside phosphorylase(DeoD-type) from H. pylori with 6-benzylthiopurine
1PRU	;		;	PURINE REPRESSOR DNA-BINDING DOMAIN DNA BINDING
1PRV	;		;	PURINE REPRESSOR DNA-BINDING DOMAIN DNA BINDING
1JHZ	;	2.4	;	Purine Repressor Mutant Corepressor Binding Domain Structure
1BDH	;	2.7	;	PURINE REPRESSOR MUTANT-HYPOXANTHINE-PALINDROMIC OPERATOR COMPLEX
1BDI	;	3.0	;	PURINE REPRESSOR MUTANT-HYPOXANTHINE-PALINDROMIC OPERATOR COMPLEX
1QP7	;	2.9	;	PURINE REPRESSOR MUTANT-HYPOXANTHINE-PALINDROMIC OPERATOR COMPLEX
1QQA	;	3.0	;	PURINE REPRESSOR MUTANT-HYPOXANTHINE-PALINDROMIC OPERATOR COMPLEX
1QQB	;	2.7	;	PURINE REPRESSOR MUTANT-HYPOXANTHINE-PALINDROMIC OPERATOR COMPLEX
1JFS	;	2.9	;	PURINE REPRESSOR MUTANT-HYPOXANTHINE-PURF OPERATOR COMPLEX
1JFT	;	2.5	;	PURINE REPRESSOR MUTANT-HYPOXANTHINE-PURF OPERATOR COMPLEX
1JH9	;	2.55	;	PURINE REPRESSOR MUTANT-HYPOXANTHINE-PURF OPERATOR COMPLEX
1ZAY	;	2.7	;	PURINE REPRESSOR-HYPOXANTHINE-MODIFIED-PURF-OPERATOR COMPLEX
1QP0	;	2.9	;	PURINE REPRESSOR-HYPOXANTHINE-PALINDROMIC OPERATOR COMPLEX
1QP4	;	3.0	;	PURINE REPRESSOR-HYPOXANTHINE-PALINDROMIC OPERATOR COMPLEX
1QPZ	;	2.5	;	PURINE REPRESSOR-HYPOXANTHINE-PALINDROMIC OPERATOR COMPLEX
1PNR	;	2.7	;	PURINE REPRESSOR-HYPOXANTHINE-PURF-OPERATOR COMPLEX
6TK9	;	2.5	;	Purine-nucleoside phosphorylase from Thermus thermophilus
6BA1	;	2.9	;	Purine-Preferring Ribonucleoside Hydrolase from Gardnerella vaginalis
7K09	;	2.313	;	Puromycin N-acetyltransferase in complex with acetyl-CoA
7K0A	;	2.0	;	Puromycin N-acetyltransferase in complex with acetylated puromycin and CoA
8SW0	;	2.301	;	Puromycin sensitive aminopeptidase
8SW1	;	3.65	;	Puromycin-sensitive aminopeptidase with bound peptide
2MZG	;		;	Purotoxin-2 NMR structure in DPC micelles
2MZF	;		;	Purotoxin-2 NMR structure in water
1QHW	;	2.2	;	PURPLE ACID PHOSPHATASE FROM RAT BONE
6GJ2	;	1.68	;	PURPLE ACID PHYTASE FROM WHEAT ISOFORM B2 - COMPLEX WITH INOSITOL HEXASULPHATE
6GJA	;	1.5	;	PURPLE ACID PHYTASE FROM WHEAT ISOFORM B2 - H229A MUTANT
6GIT	;	1.418	;	PURPLE ACID PHYTASE FROM WHEAT ISOFORM B2 - PRODUCT COMPLEX
6GJ9	;	1.76	;	PURPLE ACID PHYTASE FROM WHEAT ISOFORM B2 - REGENERATION COMPLEX
6GIZ	;	1.54	;	PURPLE ACID PHYTASE FROM WHEAT ISOFORM B2 - SUBSTRATE COMPLEX
1CC3	;	1.65	;	PURPLE CUA CENTER
3CFD	;	2.5	;	Purple-fluorescent antibody EP2-25C10 in complex with its stilbene hapten
3OMS	;	1.9	;	Putative 3-demethylubiquinone-9 3-methyltransferase, PhnB protein, from Bacillus cereus.
2JZ4	;		;	Putative 32 kDa myrosinase binding protein At3g16450.1 from Arabidopsis thaliana
3IVE	;	1.7	;	Putative 5'-Nucleotidase (c4898) from Escherichia Coli in complex with Cytidine
3IVD	;	1.9	;	Putative 5'-Nucleotidase (c4898) from Escherichia Coli in complex with Uridine
3E6Q	;	1.75	;	Putative 5-carboxymethyl-2-hydroxymuconate isomerase from Pseudomonas aeruginosa.
4GB7	;	1.6	;	Putative 6-aminohexanoate-dimer hydrolase from Bacillus anthracis
1SGW	;	1.7	;	Putative ABC transporter (ATP-binding protein) from Pyrococcus furiosus Pfu-867808-001
1VKC	;	1.89	;	Putative acetyl transferase from Pyrococcus furiosus
2DXQ	;	1.8	;	Putative acetyltransferase from Agrobacterium tumefaciens str. C58
3EY5	;	2.15	;	Putative acetyltransferase from GNAT family from Bacteroides thetaiotaomicron.
5OEK	;		;	Putative active dimeric state of GHR transmembrane domain
5GJ7	;	1.95	;	putative Acyl-CoA dehydrogenase
6YP4	;	1.94541	;	Putative adenylyl cyclase HpAC1 from Hippeastrum reveals a dominant triphophatase activity
4EXB	;	2.75	;	Putative aldo-keto reductase from Pseudomona aeruginosa
5MG9	;	1.801	;	Putative Ancestral Mamba toxin 1 (AncTx1-W28R/I38S)
1CE3	;		;	PUTATIVE ANCESTRAL PROTEIN ENCODED BY A SINGLE SEQUENCE REPEAT OF THE MULTIDOMAIN PROTEINASE INHIBITOR FROM NICOTIANA ALATA
7KB2	;	1.6	;	Putative ankyrin repeat domain-containing protein from Enterobacter cloacae
2OMO	;	1.83	;	Putative antibiotic biosynthesis monooxygenase from Nitrosomonas europaea
3OMT	;	1.65	;	Putative antitoxin component, CHU_2935 protein, from Xre family from Prevotella buccae.
6U0I	;	1.9	;	Putative Antitoxin HicB3 from Escherichia coli str. K-12 substr. DH10B
4IP2	;	1.95	;	Putative Aromatic Acid Decarboxylase
4IWS	;	2.3	;	Putative Aromatic Acid Decarboxylase
3RDW	;	2.2	;	Putative arsenate reductase from Yersinia pestis
3QWU	;	2.35	;	Putative ATP-dependent DNA ligase from Aquifex aeolicus.
3DV9	;	1.72	;	Putative beta-phosphoglucomutase from Bacteroides vulgatus.
3LUY	;	2.0	;	Putative chorismate mutase from Bifidobacterium adolescentis
1S4K	;	1.9	;	Putative cytoplasmic protein from Salmonella typhimurium
1RYQ	;	1.38	;	Putative DNA-directed RNA polymerase, subunit e'' from Pyrococcus Furiosus Pfu-263306-001
1PQW	;	2.66	;	Putative enoyl reductase domain of polyketide synthase
4NEK	;	2.3	;	Putative enoyl-CoA hydratase/carnithine racemase from Magnetospirillum magneticum AMB-1
7KRM	;	1.9	;	Putative FabG bound to NADH from Acinetobacter baumannii
7KRK	;	1.4	;	Putative FabG from Acinetobacter baumannii
3FDX	;	1.58	;	Putative filament protein / universal stress protein F from Klebsiella pneumoniae.
1US4	;	1.75	;	PUTATIVE GLUR0 LIGAND BINDING CORE WITH L-GLUTAMATE
1US5	;	1.5	;	PUTATIVE GLUR0 LIGAND BINDING CORE WITH L-GLUTAMATE
7NIE	;	35.0	;	putative glycerol kinase-like proteins anchored on an array of voltage dependent anion channels in the outer mitochondrial membrane of pig sperm mitochondria
3JUW	;	2.11	;	Putative GnaT-family acetyltransferase from Bordetella pertussis.
3HP7	;	1.53	;	Putative hemolysin from Streptococcus thermophilus.
2QM2	;	2.09	;	Putative HopJ type III effector protein from Vibrio parahaemolyticus
5OHD	;		;	Putative inactive (dormant) dimeric state of GHR transmembrane domain
6W0P	;	2.23	;	Putative kojibiose phosphorylase from human microbiome
4GVO	;	1.448	;	Putative L-Cystine ABC transporter from Listeria monocytogenes
7EME	;	1.78	;	Putative Leptospira interrogans recombinant L-amino acid oxidase
1X9G	;	2.41	;	PUTATIVE MAR1 RIBONUCLEASE FROM LEISHMANIA DONOVANI
1XN4	;	3.8	;	PUTATIVE MAR1 RIBONUCLEASE FROM LEISHMANIA MAJOR
6QEK	;	1.95	;	Putative membrane tansporter, magnetosome protein MamM CTD [Desulfamplus magnetovallimortis BW-1]
2FPO	;	2.05	;	Putative methyltransferase yhhF from Escherichia coli.
3SQN	;	2.31	;	Putative Mga family transcriptional regulator from Enterococcus faecalis
2G2C	;	1.5	;	Putative molybdenum cofactor biosynthesis protein from Corynebacterium diphtheriae.
1VJK	;	1.51	;	Putative molybdopterin converting factor, subunit 1 from Pyrococcus furiosus, Pfu-562899-001
3E8X	;	2.1	;	Putative NAD-dependent epimerase/dehydratase from Bacillus halodurans.
1PW5	;	2.8	;	putative nagD protein
4DM5	;	1.5	;	Putative Osmotically inducible lipoprotein OsmE characterization by Xray crystallography
6OZ7	;	1.36	;	Putative oxidoreductase from Escherichia coli str. K-12
1DZ9	;	1.9	;	Putative oxo complex of P450cam from Pseudomonas putida
2M6I	;		;	Putative pentameric open-channel structure of full-length transmembrane domains of human glycine receptor alpha1 subunit
6WBU	;		;	Putative Peptidyl Prolyl cis-trans Isomerase FKBP12 from Mycobacterium tuberculosis
7UQ0	;	2.0	;	Putative periplasmic iron siderophore binding protein FecB (Rv3044) from Mycobacterium tuberculosis
7Z3M	;	2.001	;	Putative Phage Recombinase RecA
1TE2	;	1.76	;	Putative Phosphatase Ynic from Escherichia coli K12
5F64	;	2.71	;	Putative positive transcription regulator (sensor EvgS) from Shigella flexneri
2ODK	;	1.4	;	Putative prevent-host-death protein from Nitrosomonas europaea
1T6T	;	1.8	;	putative protein from Aquifex aeolicus
5GYQ	;	2.1	;	Putative receptor-binding domain of bat-derived coronavirus HKU9 spike protein
4JOQ	;	1.9	;	Putative ribose ABC transporter, periplasmic solute-binding protein from Rhodobacter sphaeroides
3N4J	;	1.47	;	Putative RNA methyltransferase from Yersinia pestis
3N4K	;	1.76	;	Putative RNA methyltransferase from Yersinia pestis in complex with S-ADENOSYL-L-HOMOCYSTEINE.
6PZM	;	2.1	;	Putative SDR from Acinetobacter baumannii Crystal Form 1
6PZN	;	2.0	;	Putative SDR from Acinetobacter baumannii Crystal Form 2
6NRP	;	1.9	;	Putative short-chain dehydrogenase/reductase (SDR) from Acinetobacter baumannii
3RY3	;	2.43	;	Putative solute-binding protein from Yersinia pestis.
1MJF	;	1.798	;	PUTATIVE SPERMIDINE SYNTHETASE FROM PYROCOCCUS FURIOSUS PFU-132382
4GL0	;	1.92	;	Putative spermidine/putrescine ABC transporter from Listeria monocytogenes
1USC	;	1.24	;	PUTATIVE STYRENE MONOOXYGENASE SMALL COMPONENT
1USF	;	1.3	;	PUTATIVE STYRENE MONOOXYGENASE SMALL COMPONENT WITH BOUND NADP+
6EWJ	;	1.9	;	Putative sugar aminotransferase Spr1654 from Streptococcus pneumoniae, apo-form
6EWQ	;	2.2	;	Putative sugar aminotransferase Spr1654 from Streptococcus pneumoniae, PLP-form
6EWR	;	2.4	;	Putative sugar aminotransferase Spr1654 from Streptococcus pneumoniae, PMP-form
5HTR	;	2.0	;	Putative sugar kinases from Arabidopsis thaliana in apo form
5HTX	;	1.492	;	Putative sugar kinases from Arabidopsis thaliana in complex with ADP
5HTV	;	1.78	;	Putative sugar kinases from Arabidopsis thaliana in complex with AMPPNP
5HUX	;	1.96	;	Putative sugar kinases from Synechococcus elongatus PCC7942 in complex with ADP
5HTP	;	2.3	;	Putative sugar kinases from Synechococcus elongatus PCC7942 in complex with AMPPNP
5HV7	;	2.35	;	Putative sugar kinases from Synechococcus elongatus PCC7942 in complex with D-ribulose
5HTN	;	2.301	;	putative sugar kinases from Synechococcus elongatus PCC7942-apo form
5HTJ	;	2.001	;	Putative sugar kinases from Synechococcus elongatus PCC7942-D8A
2R5F	;	2.1	;	Putative sugar-binding domain of transcriptional regulator DeoR from Pseudomonas syringae pv. tomato
2I10	;	2.05	;	Putative TetR transcriptional regulator from Rhodococcus sp. RHA1
3FFY	;	2.0	;	Putative tetrapyrrole (corrin/porphyrin) methyltransferase from Bacteroides fragilis.
3QDN	;	2.09	;	Putative thioredoxin protein from Salmonella typhimurium
2WLR	;	1.45	;	Putative thiosulfate sulfurtransferase YnjE
2WLX	;	1.9	;	Putative thiosulfate sulfurtransferase YnjE
3MLF	;	2.6	;	Putative transcriptional regulator from Staphylococcus aureus.
1YYV	;	2.35	;	Putative transcriptional regulator ytfH from Salmonella typhimurium
7NHR	;	2.85	;	Putative transmembrane protein Wzc K540M C1
2O38	;	1.83	;	Putative XRE Family Transcriptional Regulator
1PDX	;		;	PUTIDAREDOXIN
1R7S	;	1.91	;	PUTIDAREDOXIN (Fe2S2 ferredoxin), C73G mutant
1IWI	;	2.0	;	Putidaredoxin-Binding Stablilizes an Active Conformer of Cytochrome P450cam in its Reduced State; Crystal Structure of Cytochrome P450cam
1IWJ	;	2.0	;	Putidaredoxin-Binding Stablilizes an Active Conformer of Cytochrome P450cam in its Reduced State; Crystal Structure of Mutant(109K) Cytochrome P450cam
1IWK	;	2.0	;	Putidaredoxin-Binding Stablilizes an Active Conformer of Cytochrome P450cam in its Reduced State; Crystal Structure of Mutant(112K) Cytochrome P450cam
1A99	;	2.2	;	PUTRESCINE RECEPTOR (POTF) FROM E. COLI
6HX9	;	2.05	;	Putrescine transaminase from Pseudomonas putida
7B09	;	13.4	;	Puumala virus glycoprotein (Gc) in complex with fab fragment P-4G2.
7B0A	;	13.9	;	Puumala virus-like particle glycoprotein spike and lattice contacts model.
1EAH	;	2.9	;	PV2L COMPLEXED WITH ANTIVIRAL AGENT SCH48973
1X7K	;		;	PV5 nmr solution structure
2B5K	;		;	PV5 NMR solution structure in DPC micelles
2XF2	;	1.8	;	PVC-AT
6CUL	;	2.3	;	PvdF of pyoverdin biosynthesis is a structurally unique N10-formyltetrahydrofolate-dependent formyltransferase
4B95	;	2.8	;	pVHL-EloB-EloB-EloC complex_(2S,4R)-1-(2-chlorophenyl)carbonyl-N-[(4-chlorophenyl)methyl]-4-oxidanyl-pyrrolidine-2-carboxamide bound
4B9K	;	2.0	;	pVHL-ELOB-ELOC complex_(2S,4R)-1-(3-amino-2-methylbenzoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide bound
3ZRC	;	2.9	;	pVHL54-213-EloB-EloC complex (4R)-4-HYDROXY-1-[(3-METHYLISOXAZOL-5-YL)ACETYL]-N-[4-(1,3-OXAZOL-5-YL)BENZYL]-L-PROLINAMIDE bound
3ZTC	;	2.65	;	pVHL54-213-EloB-EloC complex _ (2S,4R)-N-((1,1'-biphenyl)-4-ylmethyl)- 4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2- carboxamide
3ZTD	;	2.79	;	pVHL54-213-EloB-EloC complex _ methyl 4-(((2S,4R)-4-hydroxy-1-(2-(3- methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxamido)methyl)benzoate
3ZUN	;	2.5	;	pVHL54-213-EloB-EloC complex_(2S,4R)-4-hydroxy-1-(2-(3-methylisoxazol- 5-yl)acetyl)-N-(4-nitrobenzyl)pyrrolidine-2-carboxamide bound
3ZRF	;	2.8	;	pVHL54-213-EloB-EloC complex_apo
4AWJ	;	2.5	;	pVHL:EloB:EloC complex, in complex with capped Hydroxyproline
4W9I	;	2.4	;	pVHL:EloB:EloC in complex with (2S,4R)-1-((2S,4R)-1-acetyl-4-hydroxypyrrolidine-2-carbonyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (ligand 10)
4W9L	;	2.2	;	pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-((S)-2-acetamido-3,3-dimethylbutanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (ligand 15)
4W9K	;	2.1	;	pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-((S)-2-acetamido-3-phenylpropanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (ligand 14)
4W9J	;	2.2	;	pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-((S)-2-acetamido-4-methylpentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (ligand 13)
5NW0	;	2.3	;	pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-(1-acetamidocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (ligand 17)
5NVZ	;	2.7	;	pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-(1-acetylcyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (ligand 16)
8CQK	;	2.62	;	pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-(1-Fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(2-methyl-4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 30)
8CQE	;	2.85	;	pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-(1-Fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(2-methyl-4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 37)
5NVX	;	2.2	;	pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-(1-fluorocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (ligand 10)
5NW1	;	2.1	;	pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-(cyclobutanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (ligand 18)
5NVW	;	2.2	;	pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-(cyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (ligand 6)
4W9H	;	2.1	;	pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-acetamido-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (ligand 7)
6FMJ	;	2.45	;	pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-Acetamidopropanethioyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl) benzyl)pyrrolidine-2-carboxamide (ligand 3)
5NVY	;	2.9	;	pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-acetamidopropanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl) pyrrolidine-2-carboxamide (ligand 11)
5NW2	;	2.2	;	pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-3,3-dimethyl-2-(oxetane-3-carboxamido)butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (ligand 19)
4W9G	;	2.7	;	pVHL:EloB:EloC in complex with (2S,4R)-1-(3,3-dimethylbutanoyl)-4-hydroxy-N-(3-methyl-4-(thiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (ligand 6)
4W9D	;	2.2	;	pVHL:EloB:EloC in complex with (2S,4R)-1-(3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methyloxazol-5-yl)benzyl)pyrrolidine-2-carboxamide (ligand 3)
4W9F	;	2.1	;	pVHL:EloB:EloC in complex with (2S,4R)-1-(3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (ligand 5)
4W9C	;	2.2	;	pVHL:EloB:EloC in complex with (2S,4R)-1-(3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(oxazol-5-yl)benzyl)pyrrolidine-2-carboxamide (ligand 2)
4W9E	;	2.6	;	pVHL:EloB:EloC in complex with (2S,4R)-1-(3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(thiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (ligand 4)
5NVV	;	2.1	;	pVHL:EloB:EloC in complex with (2S,4R)-4-hydroxy-1-((S)-2-(2-hydroxyacetamido)-3,3-dimethylbutanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (ligand 3)
8CQL	;	2.38	;	pVHL:EloB:EloC in complex with (2S,4R)-N-((S)-1-(5-Fluoro-2-methoxy-4-(4-methylthiazol-5-yl)phenyl)ethyl)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (Compound 33)
6GMQ	;	2.755	;	pVHL:EloB:EloC in complex with (4-(1H-pyrrol-1-yl)phenyl)methanol
6GMR	;	1.75	;	pVHL:EloB:EloC in complex with (4-(1H-pyrrol-1-yl)phenyl)methanol
6GMX	;	2.533	;	pVHL:EloB:EloC in complex with 6-chlorothiochroman-4-one
6GMN	;	1.94	;	pVHL:EloB:EloC in complex with methyl 4H-furo[3,2-b]pyrrole-5-carboxylate
6GFX	;	1.83	;	pVHL:EloB:EloC in complex with modified HIF-1a CODD peptide containing (3R,4S)-3-fluoro-4-hydroxyproline (ligand 13a)
6GFY	;	2.7	;	pVHL:EloB:EloC in complex with modified VH032 containing (3R,4S)-3-fluoro-4-hydroxyproline (ligand 14a)
6GFZ	;	2.3	;	pVHL:EloB:EloC in complex with modified VH032 containing (3S,4S)-3-fluoro-4-hydroxyproline (ligand 14b)
6FMI	;	2.8	;	pVHL:EloB:EloC in complex with N-((S)-1-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamothioyl) pyrrolidin-1-yl)-1-oxopropan-2-yl)acetamide (ligand 2)
6FMK	;	2.75	;	pVHL:EloB:EloC in complex with N-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamothioyl) pyrrolidin-1-yl)-1-thioxopropan-2-yl)acetamide (ligand 4)
5LLI	;	2.4	;	pVHL:EloB:EloC in complex with VH298
8QKG	;	1.538	;	PvSub1 Catalytic Domain in Complex with Peptidomimetic Inhibitor (MAM-125)
8QKJ	;	1.767	;	PvSub1 Catalytic Domain in Complex with Peptidomimetic Inhibitor (MAM-133)
8QKE	;	1.504	;	PvSub1 Catalytic Domain in Complex with Peptidomimetic Inhibitor (MH-13)
1BOO	;	2.8	;	PVUII DNA METHYLTRANSFERASE (CYTOSINE-N4-SPECIFIC)
2PVI	;	1.76	;	PVUII ENDONUCLEASE COMPLEXED TO AN IODINATED COGNATE DNA
1F0O	;	2.5	;	PVUII ENDONUCLEASE/COGNATE DNA COMPLEX (GLUTARALDEHYDE-CROSSLINKED CRYSTAL) AT PH 7.5 WITH TWO CALCIUM IONS AT EACH ACTIVE SITE
4RVQ	;	1.135	;	PWI-like domain of Chaetomium thermophilum Brr2
3L42	;	1.3	;	PWWP domain of human bromodomain and PHD finger containing protein 1
3MO8	;	1.69	;	PWWP Domain of Human Bromodomain and PHD finger-containing protein 1 In Complex with Trimethylated H3K36 Peptide
3PFS	;	1.9	;	PWWP Domain of Human Bromodomain and PHD finger-containing protein 3
3LYI	;	2.1	;	PWWP Domain of Human Bromodomain-Containing Protein 1
3EAE	;	2.24	;	PWWP domain of human hepatoma-derived growth factor 2 (HDGF2)
3PMI	;	2.82	;	PWWP Domain of Human Mutated Melanoma-Associated Antigen 1
4LD6	;	1.7	;	PWWP domain of human PWWP Domain-Containing Protein 2B
6UE6	;	2.4	;	PWWP1 domain of NSD2 in complex with MR837
6HTY	;	2.22	;	PXR in complex with P2X4 inhibitor compound 25
6TFI	;	1.85	;	PXR IN COMPLEX WITH THROMBIN INHIBITOR COMPOUND 17
2H01	;	2.3	;	PY00414- Plasmodium yoelii thioredoxin peroxidase I
7FEA	;	1.4	;	PY14 in complex with Col-D
8E94	;	3.72	;	PYD-106-bound Human GluN1a-GluN2C NMDA receptor in intact conformation
8E97	;	4.19	;	PYD-106-bound Human GluN1a-GluN2C NMDA receptor in splayed conformation
4XEF	;	2.5	;	Pyk2-FAT complexed with Leupaxin LD motif LD1
4XEK	;	1.793	;	Pyk2-FAT domain in complex with leupaxin LD4 motif
6NWC	;	2.35	;	PYL10 bound to the ABA pan-agonist 3CB
7MLC	;	1.77	;	PYL10 bound to the ABA pan-antagonist 4a
7MLD	;	1.8	;	PYL10 bound to the ABA pan-antagonist antabactin
6NWB	;	2.003	;	PYL10 bound to the selective agonist hexabactin
4FFN	;	2.4	;	PylC in complex with D-ornithine and AMPPNP
4FFL	;	1.5	;	PylC in complex with L-lysine
4FFP	;	2.0	;	PylC in complex with L-lysine-Ne-D-ornithine (cocrystallized with L-lysine and D-ornithine)
4FFM	;	1.91	;	PylC in complex with L-lysine-Ne-D-ornithine (cocrystallized with L-lysine-Ne-D-ornithine)
4FFO	;	2.0	;	PylC in complex with phosphorylated D-ornithine
4Q3A	;	2.2	;	PylD cocrystallized with L-Lysine-Ne-3S-methyl-L-ornithine and NAD+
4Q3B	;	1.9	;	PylD cocrystallized with L-Lysine-Ne-D-lysine and NAD+
4Q3C	;	2.1	;	PylD cocrystallized with L-Lysine-Ne-L-lysine and NAD+
4Q3E	;	2.2	;	PylD cocrystallized with L-Ornithine-Nd-D-lysine and NAD+
4Q3D	;	2.2	;	PylD cocrystallized with L-Ornithine-Nd-D-ornithine and NAD+
4J43	;	2.2	;	PylD holoenzyme
4JK3	;	2.5	;	PylD holoenzyme (SeMet)
4J49	;	2.2	;	PylD holoenzyme soaked with L-lysine-Ne-D-ornithine
4J4B	;	1.9	;	PylD in complex with L-lysine-Ne-D-ornithine and NADH
4J4H	;	1.8	;	PylD in complex with pyrroline-carboxy-lysine and NADH
4Q39	;	2.2	;	PylD in complex with pyrrolysine and NADH
6LY7	;	2.09447	;	PylRS C-terminus domain mutant bound with 1-Formyl-L-tryptophan and AMPNP
6LYA	;	1.5907	;	PylRS C-terminus domain mutant bound with 1-Methyl-L-tryptophan and AMPNP
6LY6	;	2.50013	;	PylRS C-terminus domain mutant bound with 3-(1-Naphthyl)-L-alanine and AMPNP
6LY3	;	1.8959	;	PylRS C-terminus domain mutant bound with 3-Benzothienyl-L-alanine and AMPNP
8KE4	;	1.75051	;	PylRS C-terminus domain mutant bound with D-3-bromophenylalanine and AMPNP
8KE5	;	1.90007	;	PylRS C-terminus domain mutant bound with D-3-chlorophenylalanine and AMPNP
8KE3	;	1.89981	;	PylRS C-terminus domain mutant bound with D-3-trifluoromethylphenylalanine and AMPNP
8KE1	;	2.50082	;	PylRS C-terminus domain mutant bound with L-3-bromophenylalanine and AMPNP
8KE6	;	1.89571	;	PylRS C-terminus domain mutant bound with L-3-chlorophenylalanine and AMPNP
8KE2	;	2.1964	;	PylRS C-terminus domain mutant bound with L-3-trifluoromethylphenylalanine and AMPNP
6LYB	;	1.90366	;	PylRS C-terminus domain mutant in complex with 3-Benzothienyl-D-alanine and AMPNP
4BWA	;	2.45	;	PylRS Y306G, Y384F, I405R mutant in complex with adenylated norbornene
4BW9	;	2.35	;	PylRS Y306G, Y384F, I405R mutant in complex with AMP-PNP
6O5D	;	2.4	;	PYOCHELIN
1XKW	;	2.0	;	Pyochelin outer membrane receptor FptA from Pseudomonas aeruginosa
7EMY	;	2.97	;	Pyochelin synthetase, a dimeric nonribosomal peptide synthetase elongation module
7EN1	;	3.47	;	Pyochelin synthetase, a dimeric nonribosomal peptide synthetase elongation module-after-condensation
7EN2	;	3.78	;	Pyochelin synthetase, a dimeric nonribosomal peptide synthetase elongation module-after-condensation, condensation
5K21	;	1.8	;	Pyocyanin demethylase
1XKH	;	3.6	;	Pyoverdine outer membrane receptor FpvA from Pseudomonas aeruginosa PAO1 bound to pyoverdine
5GX9	;	1.493	;	PYP mutant - E46Q
2QJ5	;	1.2	;	PYP ultra-high resolution of a bacterial photoreceptor
2QJ7	;	1.05	;	PYP ultra-high resolution of a bacterial photoreceptor
1NWZ	;	0.82	;	PYP Ultra-high resolution structure of a Bacterial Photoreceptor
5UR5	;	1.93	;	PYR1 bound to the rationally designed agonist 4m
5UR6	;	1.631	;	PYR1 bound to the rationally designed agonist cyanabactin
3NEG	;	2.801	;	Pyrabactin-bound PYL1 structure in the open and close forms
3NR4	;	2.006	;	Pyrabactin-bound PYL2
6B2V	;	1.55	;	Pyran synthase domain from module nine of the sorangicin pathway
3K4N	;	2.75	;	Pyranose 2-oxidase F454A/S455A/Y456A mutant
3K4K	;	1.6	;	Pyranose 2-oxidase F454N mutant
3K4L	;	1.75	;	Pyranose 2-oxidase F454N mutant in complex with 2FG
4MIH	;	2.4	;	Pyranose 2-oxidase from Phanerochaete chrysosporium, recombinant H158A mutant
4MIG	;	1.8	;	Pyranose 2-oxidase from Phanerochaete chrysosporium, recombinant wild type
4MIF	;	1.8	;	Pyranose 2-oxidase from Phanerochaete chrysosporium, wild type from natural source
3BG6	;	1.7	;	Pyranose 2-oxidase from Trametes multicolor, E542K mutant
3BLY	;	1.9	;	Pyranose 2-oxidase from Trametes multicolor, E542K/L537W
3BG7	;	2.1	;	Pyranose 2-oxidase from Trametes multicolor, L537G mutant
3PL8	;	1.35	;	Pyranose 2-oxidase H167A complex with 3-deoxy-3-fluoro-beta-D-glucose
4MOK	;	1.9	;	Pyranose 2-oxidase H167A mutant soaked with 3-fluorinated galactose (not bound)
4MOL	;	2.0	;	Pyranose 2-oxidase H167A mutant with 2-fluorinated galactose
3LSM	;	1.7	;	Pyranose 2-oxidase H167A mutant with flavin N(5) sulfite adduct
3K4C	;	1.7	;	Pyranose 2-oxidase H167A/T169G mutant
4MOO	;	1.65	;	Pyranose 2-oxidase H450G mutant with 2-fluorinated galactose
4MOF	;	1.85	;	Pyranose 2-oxidase H450G mutant with 2-fluorinated glucose
4MOM	;	1.9	;	Pyranose 2-oxidase H450G mutant with 3-fluorinated galactose
4MOE	;	2.0	;	Pyranose 2-oxidase H450G mutant with 3-fluorinated glucose
4MOS	;	1.8	;	Pyranose 2-oxidase H450G/V546C double mutant with 2-fluorinated galactose
4MOJ	;	2.0	;	Pyranose 2-oxidase H450G/V546C double mutant with 2-fluorinated glucose
4MOR	;	1.5	;	Pyranose 2-oxidase H450G/V546C double mutant with 3-fluorinated galactose
4MOI	;	1.9	;	Pyranose 2-oxidase H450G/V546C double mutant with 3-fluorinated glucose
3K4J	;	2.0	;	Pyranose 2-oxidase H450Q mutant
3LSH	;	1.9	;	Pyranose 2-oxidase T169A, monoclinic
3LSI	;	1.9	;	Pyranose 2-oxidase T169A, tetragonal
3LSK	;	1.95	;	Pyranose 2-oxidase T169S acetate complex
3K4B	;	1.9	;	Pyranose 2-oxidase T169S mutant
3FDY	;	1.55	;	Pyranose 2-oxidase thermostable triple mutant, T169G/E542K/V546C
4MOQ	;	1.6	;	Pyranose 2-oxidase V546C mutant with 2-fluorinated galactose
4MOH	;	2.1	;	Pyranose 2-oxidase V546C mutant with 2-fluorinated glucose
4MOP	;	2.3	;	Pyranose 2-oxidase V546C mutant with 3-fluorinated galactose
4MOG	;	2.0	;	Pyranose 2-oxidase V546C mutant with 3-fluorinated glucose
3K4M	;	2.2	;	Pyranose 2-oxidase Y456W mutant in complex with 2FG
7P58	;	1.886	;	Pyrazole Carboxylic Acid Inhibitors of KEAP1:NRF2 interaction
7P5E	;	1.874	;	Pyrazole Carboxylic Acid Inhibitors of KEAP1:NRF2 interaction
7P5F	;	1.88	;	Pyrazole Carboxylic Acid Inhibitors of KEAP1:NRF2 interaction
7P5I	;	1.86	;	Pyrazole Carboxylic Acid Inhibitors of KEAP1:NRF2 interaction
7P5K	;	1.79	;	Pyrazole Carboxylic Acid Inhibitors of KEAP1:NRF2 interaction
7P5N	;	1.89	;	Pyrazole Carboxylic Acid Inhibitors of KEAP1:NRF2 interaction
7P5P	;	1.85	;	Pyrazole Carboxylic Acid Inhibitors of KEAP1:NRF2 interaction
3IEJ	;	2.18	;	Pyrazole-based Cathepsin S Inhibitors with Arylalkynes as P1 Binding Elements
3D4Q	;	2.8	;	Pyrazole-based inhibitors of B-Raf kinase
2G01	;	3.5	;	Pyrazoloquinolones as Novel, Selective JNK1 inhibitors
3S7L	;	2.162	;	Pyrazolyl and Thienyl Aminohydantoins as Potent BACE1 Inhibitors
3S7M	;	2.2	;	Pyrazolyl and Thienyl Aminohydantoins as Potent BACE1 Inhibitors
7DVK	;	2.6	;	PyrI4 in complex with intermolecular Diels-Alder product
6S15	;	1.7	;	Pyridine derivative of the natural alkaloid Berberine as Human Telomeric G-quadruplex Binder
3CGB	;	1.9	;	Pyridine Nucleotide Complexes with Bacillus anthracis Coenzyme A-Disulfide Reductase: A Structural Analysis of Dual NAD(P)H Specificity
3CGC	;	2.3	;	Pyridine Nucleotide Complexes with Bacillus anthracis Coenzyme A-Disulfide Reductase: A Structural Analysis of Dual NAD(P)H Specificity
3CGD	;	2.25	;	Pyridine Nucleotide Complexes with Bacillus anthracis Coenzyme A-Disulfide Reductase: A Structural Analysis of Dual NAD(P)H Specificity
3CGE	;	2.262	;	Pyridine Nucleotide Complexes with Bacillus anthracis Coenzyme A-Disulfide Reductase: A Structural Analysis of Dual NAD(P)H Specificity
5W98	;	1.23	;	Pyridine synthase, PbtD, from GE2270 biosynthesis
5W99	;	1.59	;	Pyridine synthase, PbtD, from GE2270 biosynthesis bound to TSP
5WA3	;	2.8	;	Pyridine synthase, TbtD, from thiomuracin biosynthesis
5WA4	;	2.646	;	Pyridine synthase, TbtD, from thiomuracin biosynthesis bound to an N-terminal leader peptide fragment
4HXX	;	2.09	;	Pyridinylpyrimidines selectively inhibit human methionine aminopeptidase-1
4Y46	;	2.04	;	Pyridopyrimidinone Derivatives as Potent and Selective c-Jun N-Terminal Kinase (JNK) inhibitors
4Y5H	;	2.055	;	Pyridopyrimidinone Derivatives as Potent and Selective c-Jun N-Terminal Kinase (JNK) inhibitors
7LB5	;	3.16	;	Pyridoxal 5'-phosphate synthase-like subunit PDX1.2 (Arabidopsis thaliana)
6K8Z	;	1.9	;	Pyridoxal Kinase from Leishmania donovani in complex with ADP
6K92	;	1.85	;	Pyridoxal Kinase from Leishmania donovani in complex with ADP and Ginkgotoxin
6K90	;	1.9	;	Pyridoxal Kinase from Leishmania donovani in complex with ADP and Pyridoxamine
6K91	;	2.0	;	Pyridoxal Kinase from Leishmania donovani in complex with ADP and Pyridoxine
4S1H	;	1.6	;	Pyridoxal kinase of Entamoeba histolytica with ADP
4S1I	;	1.6	;	Pyridoxal Kinase of Entamoeba histolytica with PLP
3O6C	;	1.87	;	Pyridoxal phosphate biosynthetic protein PdxJ from Campylobacter jejuni
3O6D	;	1.95	;	Pyridoxal phosphate biosynthetic protein PdxJ from Campylobacter jejuni in complex with pyridoxine-5'-phosphate
2SKC	;	2.4	;	PYRIDOXAL PHOSPHORYLASE B IN COMPLEX WITH FLUOROPHOSPHATE, GLUCOSE AND INOSINE-5'-MONOPHOSPHATE
2SKD	;	2.4	;	PYRIDOXAL PHOSPHORYLASE B IN COMPLEX WITH PHOSPHATE, GLUCOSE AND INOSINE-5'-MONOPHOSPHATE
2SKE	;	2.46	;	PYRIDOXAL PHOSPHORYLASE B IN COMPLEX WITH PHOSPHITE, GLUCOSE AND INOSINE-5'-MONOPHOSPHATE
4D9B	;	1.67	;	Pyridoxamine 5' phosphate (PMP) bound form of Salmonella typhimurium D-Cysteine desulfhydrase obtained after co-crystallization with D-cycloserine
1A2D	;	2.4	;	PYRIDOXAMINE MODIFIED MURINE ADIPOCYTE LIPID BINDING PROTEIN
8XV5	;	3.7	;	Pyridoxamine-bound human SLC19A3
6BA0	;	2.03	;	Pyrimidine-specific Ribonucleoside Hydrolase from Gardnerella vaginalis
2WL1	;	1.35	;	Pyrin PrySpry domain
2ZYZ	;	1.7	;	Pyrobaculum aerophilum splicing endonuclease
5LZL	;	3.47	;	Pyrobaculum calidifontis 5-aminolaevulinic acid dehydratase
2YH2	;	2.2	;	Pyrobaculum calidifontis esterase monoclinic form
4FM2	;	2.9	;	Pyrococcus abyssi B family DNA polymerase (triple mutant) bound to a dsDNA, in edition mode
4FLT	;	2.9	;	Pyrococcus abyssi B family DNA polymerase bound to a dsDNA, in edition mode
4FLU	;	3.1	;	Pyrococcus abyssi B family DNA polymerase bound to a dsDNA, in edition mode
4FLV	;	2.7	;	Pyrococcus abyssi B family DNA polymerase bound to a dsDNA, in edition mode
4FLW	;	2.15	;	Pyrococcus abyssi B family DNA polymerase bound to a dsDNA, in edition mode
4FLX	;	2.9	;	Pyrococcus abyssi B family DNA polymerase bound to a dsDNA, in edition mode
4FLY	;	2.3	;	Pyrococcus abyssi B family DNA polymerase bound to a dsDNA, in edition mode
4FLZ	;	3.2	;	Pyrococcus abyssi B family DNA polymerase bound to a dsDNA, in edition mode
4FM0	;	3.12	;	Pyrococcus abyssi B family DNA polymerase bound to a dsDNA, in edition mode
4FM1	;	3.0	;	Pyrococcus abyssi B family DNA polymerase bound to a dsDNA, in edition mode
8PPT	;	2.9	;	Pyrococcus abyssi DNA polymerase D (PolD) in its editing mode bound to a primer/template substrate containing a mismatch
8PPU	;	3.02	;	Pyrococcus abyssi DNA polymerase D (PolD) in its editing mode bound to a primer/template substrate containing three consecutive mismatches
5WT3	;	3.204	;	Pyrococcus abyssi methyltransferase PaTrm5a bound by MTA and cognate tRNA
5WT1	;	2.598	;	Pyrococcus abyssi methyltransferase PaTrm5a bound by SAH and cognate tRNA
1YK5	;	1.79	;	Pyrococcus abyssi rubredoxin
1S4E	;	2.9	;	Pyrococcus furiosus galactokinase in complex with galactose, ADP and magnesium
4YWM	;	3.2	;	Pyrococcus furiosus MCM N-terminal domain beta-turn triple mutant pentameric ring
4YWL	;	3.2	;	Pyrococcus furiosus MCM N-terminal domain F179A point mutant pentameric ring
4YWK	;	1.55	;	Pyrococcus furiosus MCM N-terminal domain with Zinc-binding subdomain B deleted
1ISQ	;	2.3	;	Pyrococcus furiosus PCNA complexed with RFCL PIP-box peptide
1IZ5	;	1.8	;	Pyrococcus furiosus PCNA mutant (Met73Leu, Asp143Ala, Asp147Ala): orthorhombic form
1IZ4	;	2.0	;	Pyrococcus furiosus PCNA mutant (Met73Leu/Asp143Ala): tetragonal form
5AUJ	;	2.5	;	Pyrococcus furiosus proliferating cell nuclear antigen (PCNA) SeMet derivative
6ZFF	;	3.0	;	Pyrococcus furiosus Rad50 coiled coils in rod configuration
5X4I	;	2.092	;	Pyrococcus furiosus RecJ (D83A, Mn-soaking)
4RSJ	;	3.5	;	Pyrococcus furiosus Smc hinge domain with an extended coiled coil
4HXG	;	2.7	;	Pyrococcus horikoshii acylaminoacyl peptidase (orthorhombic crystal form)
4HXE	;	1.91	;	Pyrococcus horikoshii acylaminoacyl peptidase (uncomplexed)
5L1N	;	3.6	;	Pyrococcus horikoshii CoA Disulfide Reductase Quadruple Mutant
1G8A	;	1.4	;	PYROCOCCUS HORIKOSHII FIBRILLARIN PRE-RRNA PROCESSING PROTEIN
3GQU	;	2.5	;	Pyrococcus Horikoshii NOP5 RNA Binding Domain
3GQX	;	2.5	;	Pyrococcus Horikoshii NOP5 RNA Binding Domain from a twinned crystal form
2CF4	;	3.08	;	Pyrococcus horikoshii TET1 peptidase can assemble into a tetrahedron or a large octahedral shell
7LFQ	;	2.7	;	Pyrococcus RNA ligase
1QLV	;	2.1	;	Pyrone synthase (PYS) from Gerbera hybrida
6K21	;	2.0	;	Pyrophosphatase from Acinetobacter baumannii
6KI8	;	1.79	;	Pyrophosphatase mutant K149R from Acinetobacter baumannii
6KI7	;	2.75	;	Pyrophosphatase mutant K30R from Acinetobacter baumannii
6K27	;	1.86	;	Pyrophosphatase with PPi from Acinetobacter baumannii
5YSP	;	1.7	;	Pyrophosphate-dependent kinase in the ribokinase family complexed with a pyrophosphate analog and myo-inositol
1W30	;	1.9	;	PyrR of Mycobacterium Tuberculosis as a potential drug target
1A3C	;	1.6	;	PYRR, THE BACILLUS SUBTILIS PYRIMIDINE BIOSYNTHETIC OPERON REPRESSOR, DIMERIC FORM
1A4X	;	2.3	;	PYRR, THE BACILLUS SUBTILIS PYRIMIDINE BIOSYNTHETIC OPERON REPRESSOR, HEXAMERIC FORM
1NON	;	2.4	;	PyrR, the regulator of the pyrimidine biosynthetic operon in Bacillus caldolyticus
1XZ8	;	2.8	;	Pyrr, The Regulator Of The Pyrimidine Biosynthetic Operon In Bacillus caldolyticus, Nucleotide-bound form
1XZN	;	2.27	;	PYRR, THE REGULATOR OF THE PYRIMIDINE BIOSYNTHETIC OPERON IN BACILLUS CALDOLYTICUS, sulfate-bound form
4D0W	;	1.77	;	Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors
4D0X	;	1.82	;	Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors
4D1S	;	1.66	;	Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors
8C70	;	1.65	;	Pyrrolidine fragment 1 bound to endothiapepsin
8C72	;	1.2	;	Pyrrolidine fragment 10b bound to endothiapepsin
8C74	;	1.15	;	Pyrrolidine fragment 10d bound to endothiapepsin
8C71	;	1.1	;	Pyrrolidine fragment 5b bound to endothiapepsin
1A2Z	;	1.73	;	PYRROLIDONE CARBOXYL PEPTIDASE FROM THERMOCOCCUS LITORALIS
4GFN	;	1.9	;	Pyrrolopyrimidine inhibitors of dna gyrase b and topoisomerase iv, part i: structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic
4GGL	;	1.69	;	Pyrrolopyrimidine inhibitors of dna gyrase b and topoisomerase iv, part i: structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity
4HZ5	;	2.7	;	Pyrrolopyrimidine inhibitors of dna gyrase b and topoisomerase iv, part i: structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity
4GEE	;	1.7	;	Pyrrolopyrimidine inhibitors of DNA gyrase B and topoisomerase IV, part I: structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity.
4HXW	;	1.69	;	Pyrrolopyrimidine inhibitors of dna gyrase b and topoisomerase iv, part i: structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity.
4HXZ	;	2.7	;	Pyrrolopyrimidine inhibitors of dna gyrase b and topoisomerase iv, part i: structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity.
4HY1	;	1.9	;	Pyrrolopyrimidine inhibitors of dna gyrase b and topoisomerase iv, part i: structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity.
4HYM	;	1.9	;	Pyrrolopyrimidine inhibitors of dna gyrase b and topoisomerase iv, part i: structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity.
4HYP	;	2.6	;	Pyrrolopyrimidine inhibitors of dna gyrase b and topoisomerase iv, part i: structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity.
4HZ0	;	2.2	;	Pyrrolopyrimidine inhibitors of dna gyrase b and topoisomerase iv, part i: structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity.
2Q7G	;	1.9	;	Pyrrolysine tRNA Synthetase bound to a pyrrolysine analogue (cyc) and ATP
2Q7H	;	2.1	;	Pyrrolysyl-tRNA synthetase bound to adenylated pyrrolysine and pyrophosphate
2ZIM	;	2.1	;	Pyrrolysyl-tRNA synthetase bound to adenylated pyrrolysine and pyrophosphate
6EZD	;	2.4	;	Pyrrolysyl-tRNA synthetase from Canditatus Methanomethylophilus alvus (MmaPylRS)
7R6O	;	2.2	;	Pyrrolysyl-tRNA synthetase from methanogenic archaeon ISO4-G1 (G1PylRS)
8GMK	;	1.81	;	Pyruvate bound structure of Citrate Synthase (CitA) in Mycobacterium Tuberculosis
6EFG	;	2.04	;	Pyruvate decarboxylase from Kluyveromyces lactis
2VJY	;	2.3	;	Pyruvate decarboxylase from Kluyveromyces lactis in complex with the substrate analogue methyl acetylphosphonate
6EFH	;	2.99	;	Pyruvate decarboxylase from Kluyveromyces lactis soaked with pyruvamide
5EUJ	;	2.15	;	PYRUVATE DECARBOXYLASE FROM ZYMOBACTER PALMAE
1ZPD	;	1.86	;	PYRUVATE DECARBOXYLASE FROM ZYMOMONAS MOBILIS
3OE1	;	1.985	;	Pyruvate decarboxylase variant Glu473Asp from Z. mobilis in complex with reaction intermediate 2-lactyl-ThDP
1QPB	;	2.4	;	PYRUVATE DECARBOYXLASE FROM YEAST (FORM B) COMPLEXED WITH PYRUVAMIDE
2Q8I	;	2.6	;	Pyruvate dehydrogenase kinase isoform 3 in complex with antitumor drug radicicol
1JM6	;	2.5	;	Pyruvate dehydrogenase kinase, isozyme 2, containing ADP
1H17	;	1.75	;	Pyruvate Formate-Lyase (E.coli) in complex with CoA and the substrate analog oxamate
1H18	;	2.3	;	Pyruvate Formate-Lyase (E.coli) in complex with Pyruvate
1H16	;	1.53	;	Pyruvate Formate-Lyase (E.coli) in complex with Pyruvate and CoA
5WS8	;	2.62	;	Pyruvate kinase (PYK) from Mycobacterium tuberculosis in complex with Oxalate
5WSA	;	2.85	;	Pyruvate kinase (PYK) from Mycobacterium tuberculosis in complex with Oxalate and allosteric activator Glucose 6-Phosphate
5WSB	;	2.25	;	Pyruvate kinase (PYK) from Mycobacterium tuberculosis in complex with Oxalate, allosteric activators AMP and Glucose 6-Phosphate
5WS9	;	1.9	;	Pyruvate kinase (PYK) from Mycobacterium tuberculosis in complex with Oxalate, ATP and allosteric activator AMP
4HYW	;	2.35	;	Pyruvate kinase (PYK) from Trypanosoma brucei in the presence of Magnesium and F26BP
4HYV	;	2.3	;	Pyruvate kinase (PYK) from Trypanosoma brucei in the presence of Magnesium, PEP and F26BP
4KCV	;	2.18	;	Pyruvate kinase (PYK) from Trypanosoma brucei soaked with 2-oxoglutaric acid
4KCU	;	2.35	;	Pyruvate kinase (PYK) from Trypanosoma brucei soaked with D-Malate
4KCW	;	2.5	;	Pyruvate kinase (PYK) from Trypanosoma brucei soaked with oxalate
4KCT	;	1.95	;	Pyruvate kinase (PYK) from Trypanosoma brucei soaked with Oxaloacetate
4KS0	;	2.8	;	Pyruvate kinase (PYK) from Trypanosoma cruzi in the presence of Magnesium, oxalate and F26BP
1A5U	;	2.35	;	PYRUVATE KINASE COMPLEX WITH BIS MG-ATP-NA-OXALATE
1PKY	;	2.5	;	PYRUVATE KINASE FROM E. COLI IN THE T-STATE
1AQF	;	2.7	;	PYRUVATE KINASE FROM RABBIT MUSCLE WITH MG, K, AND L-PHOSPHOLACTATE
1A3W	;	3.0	;	PYRUVATE KINASE FROM SACCHAROMYCES CEREVISIAE COMPLEXED WITH FBP, PG, MN2+ AND K+
1A3X	;	3.0	;	PYRUVATE KINASE FROM SACCHAROMYCES CEREVISIAE COMPLEXED WITH PG, MN2+ AND K+
7UEH	;	2.4	;	Pyruvate kinase from Zymomonas mobilis
6ECK	;	2.36	;	Pyruvate Kinase Isoform L-type with phosphorylated Ser113 (pS113) in complex with FBP
6ECH	;	2.19	;	Pyruvate Kinase Isoform L-type with phosphorylated Ser12 (pS12) in complex with FBP
3BJF	;	2.03	;	Pyruvate kinase M2 is a phosphotyrosine binding protein
3BJT	;	2.5	;	Pyruvate kinase M2 is a phosphotyrosine binding protein
6B6U	;	1.35	;	Pyruvate Kinase M2 mutant - S437Y
6NU5	;	1.6	;	Pyruvate Kinase M2 Mutant - S437Y in Complex with L-cysteine
6NUB	;	1.7	;	Pyruvate Kinase M2 Mutant - S437Y in Complex with L-serine
6WP3	;	1.84	;	Pyruvate Kinase M2 Mutant-K433Q
7L21	;	2.29	;	Pyruvate Kinase M2 mutant-N70D
6WP5	;	2.17	;	Pyruvate Kinase M2 mutant-S37D
6WP4	;	1.9	;	Pyruvate Kinase M2 mutant-S37E
6WP6	;	2.45	;	Pyruvate Kinase M2 mutant-S37E K433E
6HAF	;	1.3	;	Pyruvate oxidase variant E59Q from L. plantarum in complex with phosphate
2EZ4	;	2.03	;	Pyruvate oxidase variant F479W
2EZU	;	2.16	;	Pyruvate oxidase variant F479W in complex with reaction intermediate 2-acetyl-thiamin diphosphate
2EZT	;	2.29	;	Pyruvate oxidase variant F479W in complex with reaction intermediate 2-hydroxyethyl-thiamin diphosphate
2EZ8	;	1.963	;	Pyruvate oxidase variant F479W in complex with reaction intermediate 2-lactyl-thiamin diphosphate
2EZ9	;	1.6	;	Pyruvate oxidase variant F479W in complex with reaction intermediate analogue 2-phosphonolactyl-thiamin diphosphate
1Y9D	;	2.2	;	Pyruvate Oxidase variant V265A from Lactobacillus plantarum
1DIK	;	2.3	;	PYRUVATE PHOSPHATE DIKINASE
1KBL	;	1.94	;	PYRUVATE PHOSPHATE DIKINASE
2R82	;	3.6	;	Pyruvate phosphate dikinase (PPDK) triple mutant R219E/E271R/S262D adapts a second conformational state
1VBG	;	2.3	;	Pyruvate Phosphate Dikinase from Maize
1VBH	;	2.3	;	Pyruvate Phosphate Dikinase with bound Mg-PEP from Maize
1KC7	;	2.2	;	Pyruvate Phosphate Dikinase with Bound Mg-phosphonopyruvate
2H9D	;	1.95	;	Pyruvate-Bound Structure of the Isochorismate-Pyruvate Lyase from Pseudomonas aerugionsa
6CIP	;	3.189	;	Pyruvate:ferredoxin oxidoreductase from Moorella thermoacetica with acetyl-TPP bound
6CIQ	;	3.302	;	Pyruvate:ferredoxin oxidoreductase from Moorella thermoacetica with coenzyme A bound
6CIO	;	3.003	;	Pyruvate:ferredoxin oxidoreductase from Moorella thermoacetica with lactyl-TPP bound
1AW8	;	2.2	;	PYRUVOYL DEPENDENT ASPARTATE DECARBOXYLASE
5YHS	;	2.5	;	Pyruvylated beta-D-galactosidase from Bacillus sp. HMA207, apo form
5YIF	;	2.45	;	Pyruvylated beta-D-galactosidase from Bacillus sp. HMA207, E163A mutant pyruvylated beta-D-galactose complex
3AHM	;	2.0	;	Pz peptidase a
3AHN	;	1.8	;	PZ PEPTIDASE A with Inhibitor 1
3AHO	;	1.88	;	PZ PEPTIDASE A with inhibitor 2
7SBF	;	2.9	;	PZM21 bound Mu Opioid Receptor-Gi Protein Complex
8EFO	;	2.8	;	PZM21-bound mu-opioid receptor-Gi complex
4WBA	;	1.799	;	Q/E mutant SA11 NSP4_CCD
6VVR	;	1.8	;	Q0 fused 4-OT wild type symmetric trimer
8DB2	;	1.5	;	Q108K:K40L:T51C:T53A:R58L:Q38F mutant of hCRBPII bound to synthetic fluorophore CM1V
8D6L	;	1.69	;	Q108K:K40L:T51C:T53A:R58L:Q38F:Q4F mutant of hCRBPII bound to synthetic fluorophore CM1V
8D6H	;	1.6	;	Q108K:K40L:T51C:T53A:R58L:Q38F:Q4F mutant of hCRBPII bound to synthetic fluorophore CM1V after UV irradiation
8DN1	;	1.32	;	Q108K:K40L:T51C:T53A:R58L:Q38F:Q4F mutant of hCRBPII bound to synthetic fluorophore CM1V at pH 7.2
8W02	;	1.499	;	Q108K:K40L:T51V:T53S:R58W mutant of hCRBPII bound to synthetic fluorophore TD-1V
8VZY	;	1.34	;	Q108K:K40L:T51V:T53S:R58Y mutant of hCRBPII bound to synthetic fluorophore TD-1V
8VZZ	;	1.22	;	Q108K:K40L:T51V:T53S:Y19W:R58W mutant of hCRBPII bound to synthetic fluorophore TD-1V
8W00	;	1.23	;	Q108K:K40L:T51V:T53S:Y19W:R58W:L117E mutant of hCRBPII bound to synthetic fluorophore TD-1V
8VZX	;	1.47	;	Q108K:K40L:T53A:R58F mutant of hCRBPII bound to synthetic fluorophore TD-1V
8D6N	;	1.42	;	Q108K:K40L:T53A:R58L:Q38F:Q4F mutant of hCRBPII bound to synthetic fluorophore CM1V
3NJN	;	1.25	;	Q118A mutant of SO1698 protein, an aspartic peptidase from Shewanella oneidensis
4AHD	;	2.47	;	Q12L - Angiogenin mutants and amyotrophic lateral sclerosis - a biochemical and biological analysis
1AW7	;	1.95	;	Q136A MUTANT OF TOXIC SHOCK SYNDROME TOXIN-1 FROM S. AUREUS
3E44	;	2.52	;	Q138F HincII bound to cleaved DNA (GTT | AAC) and Mn2+
2GIH	;	2.5	;	Q138F HincII bound to cognate DNA GTCGAC and Ca2+
2GII	;	2.3	;	Q138F HincII bound to cognate DNA GTTAAC
2GIJ	;	1.93	;	Q138F HincII bound to cognate DNA GTTAAC and Ca2+
3E41	;	2.73	;	Q138F HincII bound to GTCGAC and 5 mM Ca2+
3E42	;	2.68	;	Q138F HincII bound to GTCGAC and Ca2+ (cocrystallized)
3E43	;	2.73	;	Q138F HincII bound to GTTAAC and cocrystallized with 2.5 mM MgCl2
3E3Y	;	2.13	;	Q138F HincII bound to GTTAAC and cocrystallized with 5 mM Ca2+
3E40	;	2.1	;	Q138F HincII bound to GTTAAC and cocrystallized with 5 mM Ca2+
3E45	;	2.78	;	Q138F HincII bound to Noncognate DNA (GTGCAC) and Ca2+
1TS4	;	3.4	;	Q139K MUTANT OF TOXIC SHOCK SYNDROME TOXIN-1 FROM S. AUREUS
4AX0	;	1.74	;	Q157A mutant. Crystal Structure of the Mobile Metallo-beta-Lactamase AIM-1 from Pseudomonas aeruginosa: Insights into Antibiotic Binding and the role of Gln157
4AX1	;	1.4	;	Q157N mutant. Crystal Structure of the Mobile Metallo-beta-Lactamase AIM-1 from Pseudomonas aeruginosa: Insights into Antibiotic Binding and the role of Gln157
1E2Z	;	2.5	;	Q158L mutant of cytochrome f from Chlamydomonas reinhardtii
3FTN	;	2.192	;	Q165E/S254K Double Mutant Chimera of alcohol dehydrogenase by exchange of the cofactor binding domain res 153-295 of T. brockii ADH by C. beijerinckii ADH
7RVH	;	0.9	;	Q172E mutant of the bank vole prion protein 168-176 QYNNENNFV
4Y6C	;	1.772	;	Q17M crystal structure of Podosopora anserina putative kinesin light chain nearly identical TPR-like repeats
3B8J	;	2.507	;	Q191A mutant of DegS-deltaPDZ
3LH1	;	2.507	;	Q191A mutant of the DegS-deltaPDZ
6P19	;	3.8	;	Q21 transcription antitermination complex: loaded complex
6P18	;	3.5	;	Q21 transcription antitermination complex: loading complex
3NBF	;	1.9	;	Q28E mutant of hera helicase N-terminal domain bound to 8-oxo-ADP
3MWL	;	1.6	;	Q28E mutant of HERA N-terminal RecA-like domain in complex with 8-OXOADENOSINE
3MWJ	;	1.4	;	Q28E mutant of HERA N-terminal RecA-like domain, apo form
3MWK	;	1.45	;	Q28E mutant of HERA N-terminal RecA-like domain, complex with 8-oxo-AMP
3NEJ	;	2.57	;	Q28E mutant of Hera RNA helicase N-terminal domain - perfectly twinned hexagonal form
1EFQ	;	1.6	;	Q38D mutant of LEN
3B0N	;	2.0	;	Q448K mutant of assimilatory nitrite reductase (Nii3) from tobbaco leaf
2I3Q	;	2.3	;	Q44V mutant of Homing Endonuclease I-CreI
2BKB	;	1.7	;	q69e-FeSOD
1ZA5	;	1.8	;	Q69H-FeSOD
3PKQ	;	2.4	;	Q83D Variant of S. Enterica RmlA with dGTP
3PKP	;	2.6	;	Q83S Variant of S. Enterica RmlA with dATP
4MMK	;	2.156	;	Q8A Hfq from Pseudomonas aeruginosa
7OGW	;	1.09	;	Q9A mutant of Hfq protein from Neisseria meningitidis
7Y7T	;	2.5	;	QDE-1 in complex with 12nt DNA template, ATP and 3'-dGTP
7Y7R	;	2.1	;	QDE-1 in complex with DNA template, RNA primer and 3'-dGTP
7Y7S	;	2.7	;	QDE-1 in complex with DNA template, RNA primer and AMPNPP
7Y7Q	;	2.05	;	QDE-1 in complex with RNA template, RNA primer and 3'-dGTP
7Y7P	;	2.7	;	QDE-1 in complex with RNA template, RNA primer and AMPNPP
1A1H	;	1.6	;	QGSR (ZIF268 VARIANT) ZINC FINGER-DNA COMPLEX (GCAC SITE)
2HZ8	;		;	QM/MM structure refined from NMR-structure of a single chain diiron protein
2JBM	;	2.0	;	QPRTASE STRUCTURE FROM HUMAN
1MZH	;	2.0	;	QR15, an Aldolase
7O4D	;	2.249	;	QR2 inhibitor from a novel sulfanamide series to tackle age related oxidative stress and cognitive decline
6NBJ	;	2.94	;	Qri7
3WUH	;	2.937	;	Qri7 and AMP complex
3QCP	;	2.3	;	QSOX from Trypanosoma brucei
6H62	;	2.684	;	QTRT1, the catalytic subunit of murine tRNA-Guanine Transglycosylase
6FV5	;	2.179	;	QTRT2, the non-catalytic subunit of murine tRNA-Guanine Transglycosylase
6KOT	;	2.149	;	Quadruple mutant (N51I+C59R+S108N+I164L) plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) complexed with B12128 and NADPH
6KP7	;	1.97	;	Quadruple mutant (N51I+C59R+S108N+I164L) plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) complexed with B12154
6KPR	;	2.1	;	Quadruple mutant (N51I+C59R+S108N+I164L) plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) complexed with B12155 inhibitor
6LHJ	;	2.4	;	Quadruple mutant (N51I+C59R+S108N+I164L) plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) complexed with C452 (compound 16) and NADPH
6LHI	;	2.59	;	Quadruple mutant (N51I+C59R+S108N+I164L) plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) complexed with C466 (compound 42) and NADPH
6LEU	;	2.59	;	Quadruple mutant (N51I+C59R+S108N+I164L) plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) complexed with compound 42 and NADPH
6LEV	;	2.644	;	Quadruple mutant (N51I+C59R+S108N+I164L) plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) complexed with compound 46 and NADPH
6LEZ	;	2.644	;	Quadruple mutant (N51I+C59R+S108N+I164L) plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) complexed with compound 46 and NADPH
6LH9	;	2.644	;	Quadruple mutant (N51I+C59R+S108N+I164L) plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) complexed with compound 46 and NADPH
4DP3	;	2.4	;	Quadruple mutant (N51I+C59R+S108N+I164L) plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) complexed with P218 and NADPH
4DPH	;	2.38	;	Quadruple mutant (N51I+C59R+S108N+I164L) Plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) complexed with P65 and NADPH
3DG8	;	2.58	;	Quadruple mutant (N51I+C59R+S108N+I164L) Plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) complexed with RJF670, NADPH, and dUMP
1J3K	;	2.1	;	Quadruple mutant (N51I+C59R+S108N+I164L) Plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) complexed with WR99210, NADPH, and dUMP
7B2E	;	2.8	;	quadruple mutant of oxalyl-CoA decarboxylase from Methylorubrum extorquens with bound TPP and ADP
6KP2	;	1.973	;	Quadruple mutant plasmodium falciparum dihydrofolate reductase complexed with B10042
1QCA	;	2.2	;	QUADRUPLE MUTANT Q92C, N146F, Y168F, I172V TYPE III CAT COMPLEXED WITH FUSIDIC ACID. CRYSTALS GROWN AT PH 6.3. X-RAY DATA COLLECTED AT ROOM TEMPERATURE
3JSU	;	2.7	;	Quadruple mutant(N51I+C59R+S108N+I164L) plasmodium falciparum dihydrofolate reductase-thymidylate synthase(PFDHFR-TS) complexed with QN254, NADPH, and dUMP
5LDZ	;	2.2	;	Quadruple space group ambiguity due to rotational and translational non-crystallographic symmetry in human liver fructose-1,6-bisphosphatase
2RQJ	;		;	Quadruplex structure of an RNA aptamer against bovine prion protein
5MBR	;		;	Quadruplex with flipped tetrad formed by a human telomeric sequence
5MCR	;		;	Quadruplex with flipped tetrad formed by an artificial sequence
6ERL	;		;	Quadruplex with flipped tetrad formed by the c-myc promoter sequence
7CV3	;		;	Quadruplex-duplex hybrid structure in the PIM1 gene, Form 1
7CV4	;		;	Quadruplex-duplex hybrid structure in the PIM1 gene, Form 2
1IBI	;		;	QUAIL CYSTEINE AND GLYCINE-RICH PROTEIN, NMR, 15 MINIMIZED MODEL STRUCTURES
1QLI	;		;	QUAIL CYSTEINE AND GLYCINE-RICH PROTEIN, NMR, MINIMIZED AVERAGE STRUCTURE
7LX0	;	2.96	;	Quantitative assessment of chlorophyll types in cryo-EM maps of photosystem I acclimated to far-red light
5I1R	;		;	Quantitative characterization of configurational space sampled by HIV-1 nucleocapsid using solution NMR and X-ray scattering
5IFS	;	2.46	;	Quantitative interaction mapping reveals an extended ubiquitin regulatory domain in ASPL that disrupts functional p97 hexamers and induces cell death
5IFW	;	3.4	;	Quantitative interaction mapping reveals an extended ubiquitin regulatory domain in ASPL that disrupts functional p97 hexamers and induces cell death
5I5A	;	1.2	;	quasi racemic structure of allo-Ile7-ShK and D-ShK
5I5B	;	0.9	;	quasi racemic structure of allo-Thr13-ShK and D-ShK
1GW7	;	13.5	;	QUASI-ATOMIC RESOLUTION MODEL OF BACTERIOPHAGE PRD1 CAPSID, OBTAINED BY COMBINED CRYO-EM AND X-RAY CRYSTALLOGRAPHY.
1HB5	;	12.0	;	quasi-atomic resolution model of bacteriophage PRD1 P3-shell, obtained by combined cryo-EM and X-ray crystallography.
1HB7	;	14.0	;	quasi-atomic resolution model of bacteriophage PRD1 sus1 mutant, obtained by combined cryo-EM and X-ray crystallography.
1GW8	;	13.3	;	quasi-atomic resolution model of bacteriophage PRD1 sus607 mutant, obtained by combined cryo-EM and X-ray crystallography.
1HB9	;	25.0	;	quasi-atomic resolution model of bacteriophage PRD1 wild type virion, obtained by combined cryo-EM and X-ray crystallography.
7KZU	;	2.15	;	Quasi-intermediate state (Q) of a truncated Hsp70 DnaK fused with a substrate peptide
8DDF	;	1.1	;	Quasi-racemic mixture of L-FWF and D-FYF peptide reveals rippled beta-sheet
5E5T	;	1.572	;	Quasi-racemic snakin-1 in P1 after radiation damage
5E5Y	;	1.506	;	Quasi-racemic snakin-1 in P1 before radiation damage
4TTN	;	1.2507	;	Quasi-racemic structure of [G6A]kalata B1
4TTO	;	2.3002	;	Quasi-racemic structure of [V25A] kalata B1
3VCA	;	1.59	;	Quaternary Ammonium Oxidative Demethylation: X-ray Crystallographic, Resonance Raman and UV-visible Spectroscopic Analysis of a Rieske-type Demethylase
5NCO	;	4.8	;	Quaternary complex between SRP, SR, and SecYEG bound to the translating ribosome
5Y7R	;	1.96	;	Quaternary complex of AsqJ-Fe3+-2OG-cyclopeptin
5Y7T	;	2.05	;	Quaternary complex of AsqJ-Fe3+-2OG-D-cyclopeptin
6VND	;	1.97	;	Quaternary Complex of human dihydroorotate dehydrogenase (DHODH) with flavin mononucleotide (FMN), orotic acid and AG-636
7Q2J	;	2.5	;	Quaternary Complex of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC Homer
5ON3	;	3.1	;	Quaternary complex of mutant T252A of E. coli leucyl-tRNA synthetase with tRNA(leu), leucyl-adenylate analogue, and post-transfer editing analogue of leucine in the aminoacylation conformation
5ON2	;	3.1	;	Quaternary complex of mutant T252A of E. coli leucyl-tRNA synthetase with tRNA(leu), leucyl-adenylate analogue, and post-transfer editing analogue of norvaline in the aminoacylation conformation
5ONH	;	3.1	;	Quaternary complex of wild type E. coli leucyl-tRNA synthetase with tRNA(leu), leucyl-adenylate analogue, and post-transfer editing analogue of norvaline in the aminoacylation conformation
3O03	;	1.9	;	Quaternary complex structure of gluconate 5-dehydrogenase from streptococcus suis type 2
1ACJ	;	2.8	;	QUATERNARY LIGAND BINDING TO AROMATIC RESIDUES IN THE ACTIVE-SITE GORGE OF ACETYLCHOLINESTERASE
1ACL	;	2.8	;	QUATERNARY LIGAND BINDING TO AROMATIC RESIDUES IN THE ACTIVE-SITE GORGE OF ACETYLCHOLINESTERASE
4NI1	;	1.9	;	Quaternary R CO-liganded hemoglobin structure in complex with a thiol containing compound
4NI0	;	2.15	;	Quaternary R3 CO-liganded hemoglobin structure in complex with a thiol containing compound
3FM7	;	3.5	;	Quaternary Structure of Drosophila melanogaster IC/Tctex-1/LC8; Allosteric Interactions of Dynein Light Chains with Dynein Intermediate Chain
3GLW	;	3.15	;	Quaternary Structure of Drosophila melanogaster IC/Tctex-1/LC8; Allosteric Interactions of Dynein Light Chains with Dynein Intermediate Chain
4NTK	;	1.6	;	QueD from E. coli
4NTM	;	2.05	;	QueD soaked with sepiapterin (selenomethionine substituted protein)
1GQG	;	1.7	;	Quercetin 2,3-dioxygenase in complex with the inhibitor diethyldithiocarbamate
1GQH	;	2.15	;	Quercetin 2,3-dioxygenase in complex with the inhibitor kojic acid
6P78	;	1.726	;	queuine lyase from Clostridium spiroforme bound to SAM and queuine
4P2L	;	2.9	;	Quiescin Sulfhydryl Oxidase from Rattus norvegicus
3JYO	;	1.0	;	Quinate dehydrogenase from Corynebacterium glutamicum in complex with NAD
3JYP	;	1.16	;	Quinate dehydrogenase from Corynebacterium glutamicum in complex with quinate and NADH
3JYQ	;	1.16	;	Quinate dehydrogenase from Corynebacterium glutamicum in complex with shikimate and NADH
1O9B	;	2.5	;	QUINATE/SHIKIMATE DEHYDROGENASE YDIB COMPLEXED WITH NADH
4Z4Q	;	3.04	;	Quinazolinedione(PD 0305970)-DNA cleavage complex of topoisomerase IV from S. pneumoniae
3RAF	;	3.24	;	Quinazolinedione-DNA cleavage complex of type IV topoisomerase from S. pneumoniae
3PRE	;	2.91	;	Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors.
3PRZ	;	2.6	;	Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors.
3PS6	;	2.6	;	Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors.
2L7V	;		;	Quindoline/G-quadruplex complex
1CYX	;	2.3	;	QUINOL OXIDASE (PERIPLASMIC FRAGMENT OF SUBUNIT II WITH ENGINEERED CU-A BINDING SITE)(CYOA)
1CYW	;	2.5	;	QUINOL OXIDASE (PERIPLASMIC FRAGMENT OF SUBUNIT II) (CYOA)
6L1X	;	3.15	;	Quinol-dependent nitric oxide reductase (qNOR) from Neisseria meningitidis in the monomeric oxidized state with zinc complex.
1L0V	;	3.3	;	Quinol-Fumarate Reductase with Menaquinol Molecules
1KFY	;	3.6	;	QUINOL-FUMARATE REDUCTASE WITH QUINOL INHIBITOR 2-[1-(4-CHLORO-PHENYL)-ETHYL]-4,6-DINITRO-PHENOL
1E7P	;	3.1	;	QUINOL:FUMARATE REDUCTASE FROM WOLINELLA SUCCINOGENES
2BS2	;	1.78	;	QUINOL:FUMARATE REDUCTASE FROM WOLINELLA SUCCINOGENES
5O7A	;	2.495	;	Quinolin-6-yloxyacetamides are microtubule destabilizing agents that bind to the colchicine site of tubulin
1QPO	;	2.4	;	Quinolinate Phosphoribosyl Transferase (QAPRTase) Apo-Enzyme from Mycobacterium Tuberculosis
7XGL	;	2.11	;	Quinolinate Phosphoribosyl Transferase (QAPRTase) from Streptomyces pyridomyceticus NRRL B-2517 in Apo form
7XGN	;	2.6	;	Quinolinate Phosphoribosyl Transferase (QAPRTase) from Streptomyces pyridomyceticus NRRL B-2517 in complex with Nicotinic Acid (NA)
7XGM	;	2.85	;	Quinolinate Phosphoribosyl Transferase (QAPRTase) from Streptomyces pyridomyceticus NRRL B-2517 in complex with Quinolinic Acid (QA)
1QPN	;	2.6	;	Quinolinate Phosphoribosyl Transferase from Mycobacterium Tuberculosis in Complex with NCNN
1QPR	;	2.45	;	QUINOLINATE PHOSPHORIBOSYLTRANSFERASE (QAPRTASE) FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH PHTHALATE AND PRPCP
4HHE	;	2.797	;	Quinolinate synthase from Pyrococcus furiosus
1QAP	;	2.8	;	QUINOLINIC ACID PHOSPHORIBOSYLTRANSFERASE WITH BOUND QUINOLINIC ACID
6L73	;	2.0	;	Quinolone synthase (AmQNS) from Aegle marmelos Correa
6L78	;	1.55	;	Quinolone synthase (QNS) from Aegle marmelos
6L7J	;	1.8	;	Quinolone synthase (QNS) from Aegle marmelos Correa., complexed with Coenzyme A
6L5U	;	1.85	;	Quinolone synthase from Aegle marmelos Correa
7CCT	;	2.35	;	Quinolone synthase from Aegle marmelos Correa complexed with N-Methylanthraniloyl-CoA
6L61	;	1.4	;	Quinolone synthase from Aegle marmelos Correa, Dimer
3RAD	;	3.35	;	Quinolone(Clinafloxacin)-DNA cleavage complex of type IV topoisomerase from S. pneumoniae
4Z2D	;	3.38	;	Quinolone(Levofloxacin)-DNA cleavage complex of gyrase from S. pneumoniae
3RAE	;	2.9	;	Quinolone(Levofloxacin)-DNA cleavage complex of type IV topoisomerase from S. pneumoniae
4Z2C	;	3.19	;	Quinolone(Moxifloxacin)-DNA cleavage complex of gyrase from S. pneumoniae
4Z3O	;	3.44	;	Quinolone(Moxifloxacin)-DNA cleavage complex of topoisomerase IV from S. pneumoniae
4Z2E	;	3.46	;	Quinolone(Trovafloxacin)-DNA cleavage complex of gyrase from S. pneumoniae
4Z53	;	3.26	;	Quinolone(Trovafloxacin)-DNA cleavage complex of topoisomerase IV from S. pneumoniae
4KOE	;	3.02	;	Quinolone(Trovafloxacin)-DNA cleavage complex of type IV topoisomerase from S. pneumoniae
5EIX	;	3.35	;	QUINOLONE-STABILIZED CLEAVAGE COMPLEX OF TOPOISOMERASE IV FROM KLEBSIELLA PNEUMONIAE
3TZB	;	2.1901	;	Quinone Oxidoreductase (NQ02) bound to NSC13000
3TE7	;	1.7	;	Quinone Oxidoreductase (NQ02) bound to the imidazoacridin-6-one 5a1
3TEM	;	1.45	;	Quinone Oxidoreductase (NQ02) bound to the imidazoacridin-6-one 6a1
3FW1	;	1.75	;	Quinone Reductase 2
2QMY	;	2.5	;	Quinone Reductase 2 in complex with adrenochrome
1XI2	;	1.5	;	Quinone Reductase 2 in Complex with Cancer Prodrug CB1954
2QMZ	;	2.1	;	Quinone Reductase 2 in Complex with Dopamine
1QRD	;	2.4	;	QUINONE REDUCTASE/FAD/CIBACRON BLUE/DUROQUINONE COMPLEX
2VLF	;	1.89	;	Quinonoid intermediate of Citrobacter freundii tyrosine phenol-lyase formed with alanine
2VLH	;	1.95	;	Quinonoid intermediate of Citrobacter freundii tyrosine phenol-lyase formed with methionine
8TAO	;	2.9	;	Quis and CDPPB bound active mGlu5
8T7H	;	3.3	;	Quis-bound intermediate mGlu5
8T8M	;	3.0	;	Quis-bound intermediate mGlu5
4F2O	;	1.912	;	Quisqualate bound to the D655A mutant of the ligand binding domain of GluA3
4F2Q	;	2.202	;	Quisqualate bound to the D655A mutant of the ligand binding domain of GluA3
4F29	;	1.749	;	Quisqualate bound to the ligand binding domain of GluA3i
3SZT	;	2.55	;	Quorum Sensing Control Repressor, QscR, Bound to N-3-oxo-dodecanoyl-L-Homoserine Lactone
8DQ0	;	3.74	;	Quorum-sensing receptor RhlR bound to PqsE
8DQ1	;	4.1	;	Quorum-sensing receptor RhlR bound to PqsE
5EP1	;	1.5	;	Quorum-Sensing Signal Integrator LuxO - Catalytic Domain
5EP3	;	1.8	;	Quorum-Sensing Signal Integrator LuxO - Catalytic Domain Bound to CV-133 Inhibitor
5EP2	;	1.421	;	Quorum-Sensing Signal Integrator LuxO - Catalytic Domain in Complex with AzaU Inhibitor
5EP0	;	1.6	;	Quorum-Sensing Signal Integrator LuxO - Receiver+Catalytic Domains
1RVW	;	2.5	;	R STATE HUMAN HEMOGLOBIN [ALPHA V96W], CARBONMONOXY
2LPF	;		;	R state structure of monomeric phospholamban (C36A, C41F, C46A)
2L8W	;		;	r(CCGCUGCGG)2 UU Internal Loop Found in Myotonic Dystrophy Type 1 - UU pair with two hydrogen bond pairs
7BPV	;	1.781	;	r(GUGGGCCGAC)/d(GTCGGCCCAC) hybrid duplex structure
7T7Q	;	2.2	;	R-27 In Complex with S. aureus DHFR and alpha-NADPH - Remediated for comparison with tNADPH
7T7S	;	2.2	;	R-27 in Complex with S. aureus DHFR and tricyclic-NADPH (tNADPH)
5CPG	;	1.694	;	R-Hydratase PhaJ1 from Pseudomonas aeruginosa in the unliganded form
3ZHB	;	2.73	;	R-imine reductase from Streptomyces kanamyceticus in complex with NADP.
3OZ4	;	1.59	;	R-Methyl Carbocyclic LNA
1YXI	;	2.0	;	R-State AMP Complex Reveals Initial Steps of the Quaternary Transition of Fructose-1,6-bisphosphatase
1YYZ	;	1.85	;	R-State AMP Complex Reveals Initial Steps of the Quaternary Transition of Fructose-1,6-bisphosphatase
1YZ0	;	2.07	;	R-State AMP Complex Reveals Initial Steps of the Quaternary Transition of Fructose-1,6-bisphosphatase
1HBR	;	2.3	;	R-STATE FORM OF CHICKEN HEMOGLOBIN D
1AJ9	;	2.2	;	R-STATE HUMAN CARBONMONOXYHEMOGLOBIN ALPHA-A53S
3OO5	;	2.1	;	R-state human hemoglobin: nitriheme modified
3OO4	;	1.9	;	R-state human hemoglobin: nitriheme modified at alpha
7NGL	;	3.8	;	R-state of wild type human mitochondrial LONP1 protease bound to endogenous ADP
2ZQZ	;	2.5	;	R-state structure of allosteric L-lactate dehydrogenase from Lactobacillus casei
1RDX	;	2.75	;	R-STATE STRUCTURE OF THE ARG 243 TO ALA MUTANT OF PIG KIDNEY FRUCTOSE 1,6-BISPHOSPHATASE EXPRESSED IN E. COLI
2OWZ	;	2.18	;	R-state, citrate and Fru-6-P-bound Escherichia coli fructose-1,6-bisphosphatase
2OX3	;	2.18	;	R-state, PEP and Fru-6-P-bound, Escherichia coli fructose-1,6-bisphosphatase
1UCU	;	4.0	;	R-type straight flagellar filament made of full-length flagellin
6XKW	;	5.2	;	R. capsulatus CIII2CIV bipartite super-complex (SC-2A) with CcoH/cy
6XKX	;	6.1	;	R. capsulatus CIII2CIV tripartite super-complex, conformation A (SC-1A)
6XKZ	;	7.2	;	R. capsulatus CIII2CIV tripartite super-complex, conformation B (SC-1B)
6XI0	;	3.3	;	R. capsulatus cyt bc1 (CIII2) at 3.3A
6XKV	;	3.5	;	R. capsulatus cyt bc1 with both FeS proteins in b position (CIII2 b-b)
6XKT	;	3.75	;	R. capsulatus cyt bc1 with both FeS proteins in c position (CIII2 c-c)
6XKU	;	4.2	;	R. capsulatus cyt bc1 with one FeS protein in b position and one in c position (CIII2 b-c)
5M2O	;	1.26	;	R. flavefaciens' third ScaB cohesin in complex with a group 1 dockerin
5M2S	;	1.7	;	R. flavefaciens' third ScaB cohesin in complex with a group 1 dockerin
8GET	;	2.9	;	R. hominis 2 beta-glucuronidase bound to norquetiapine-glucuronide
8GES	;	2.7	;	R. hominis 2 beta-glucuronidase bound to UNC10201652-glucuronide
5OKU	;	2.07	;	R. palustris Rpa4515 with adipate
5OEI	;	1.78	;	R. palustris Rpa4515 with oxoadipate
1NM5	;	2.4	;	R. rubrum transhydrogenase (dI.Q132N)2(dIII)1 asymmetric complex
1U28	;	2.3	;	R. rubrum transhydrogenase asymmetric complex (dI.NAD+)2(dIII.NADP+)1
5V33	;	3.487	;	R. sphaeroides photosythetic reaction center mutant - Residue L223, Ser to Trp - Room Temperature Structure Solved on X-ray Transparent Microfluidic Chip
3D1K	;	1.25	;	R/T intermediate quaternary structure of an antarctic fish hemoglobin in an alpha(CO)-beta(pentacoordinate) state
4I1N	;	1.888	;	R104A-ca1697 nanobody binding to the binary DHFR.folate complex
1T96	;	1.85	;	r106g kdo8ps with pep
1T8X	;	1.8	;	r106g kdo8ps with pep and a5p
1T99	;	1.85	;	r106g kdo8ps without substrates
4I88	;	2.85	;	R107G HSP16.5
1CO7	;	1.9	;	R117H mutant rat anionic trypsin complexed with bovine pancreatic trypsin inhibitor (BPTI)
8AIB	;	2.2	;	R11A variant of glutathione transferase Chi 1 from Synechocystis sp. PCC 6803 in complex with glutathione
4AHN	;	2.977	;	R121H - Angiogenin mutants and amyotrophic lateral sclerosis - a biochemical and biological analysis
7PDJ	;	4.2	;	R12E vFLIP mutant
4JF1	;	1.28	;	R144Q mutant of N-acetylornithine aminotransferase
8GLL	;	2.65	;	R149E variant of Citrate Synthase (CitA) in Mycobacterium tuberculosis
8GMF	;	2.96	;	R153M variant of Citrate Synthase (CitA) in Mycobacterium tuberculosis
2J6W	;	2.6	;	R164N mutant of the RUNX1 Runt domain
8ECP	;	1.5	;	R16A PA0709 with BME modifications
3LGY	;	2.7	;	R178A mutant of the DegS-deltaPDZ protease
7OH8	;	1.7	;	R17A mutant of Hfq protein from Neisseria meningitidis
7T3N	;	3.0	;	R184Q/E191Q mutant of rat vesicular glutamate transporter 2 (VGLUT2)
5WK9	;	1.983	;	R186AP450cam with CN and camphor
5C5H	;	2.401	;	R195K E. coli MenE with bound OSB-AMS
6A42	;	1.7	;	R1EN(5-223)-ubiquitin fusion
6A43	;	2.4	;	R1EN(5-225)-ubiquitin fusion
6A44	;	2.4	;	R1EN(5-227)-ubiquitin fusion
4AC8	;	2.75	;	R2-like ligand binding Mn-Fe oxidase from M. tuberculosis with an organized C-terminal helix
3EE4	;	1.9	;	R2-like ligand binding Mn/Fe oxidase from M. tuberculosis
6F65	;	1.948	;	R2-like ligand-binding oxidase A171F mutant with aerobically reconstituted Mn/Fe cofactor
6F6B	;	2.009	;	R2-like ligand-binding oxidase A171F mutant with anaerobically reconstituted Mn/Fe cofactor
6QJV	;	1.905	;	R2-like ligand-binding oxidase E69D mutant with aerobically reconstituted Mn/Fe cofactor
6QK0	;	2.091	;	R2-like ligand-binding oxidase E69D mutant with anaerobically reconstituted Mn/Fe cofactor
6I90	;	1.803	;	R2-like ligand-binding oxidase G68F mutant with aerobically reconstituted Mn/Fe cofactor
6I92	;	1.849	;	R2-like ligand-binding oxidase G68F mutant with anaerobically reconstituted Mn/Fe cofactor
6I93	;	2.101	;	R2-like ligand-binding oxidase G68L mutant with aerobically reconstituted Fe/Fe cofactor
6I95	;	1.646	;	R2-like ligand-binding oxidase G68L mutant with anaerobically reconstituted Mn/Fe cofactor
6I94	;	1.703	;	R2-like ligand-binding oxidase G68L mutant with non-activated Mn/Mn cofactor (after aerobic reconstitution with Mn and Fe)
6F6C	;	1.766	;	R2-like ligand-binding oxidase V72A mutant with aerobically reconstituted Mn/Fe cofactor
6F6E	;	1.627	;	R2-like ligand-binding oxidase V72A mutant with anaerobically reconstituted Mn/Fe cofactor
6F6F	;	1.788	;	R2-like ligand-binding oxidase V72I mutant with aerobically reconstituted Mn/Fe cofactor
6F6G	;	1.991	;	R2-like ligand-binding oxidase V72I mutant with anaerobically reconstituted Mn/Fe cofactor
6F6H	;	1.764	;	R2-like ligand-binding oxidase V72L mutant with aerobically reconstituted Mn/Fe cofactor
6F6K	;	1.982	;	R2-like ligand-binding oxidase V72L mutant with anaerobically reconstituted Mn/Fe cofactor
4XB9	;	1.798	;	R2-like ligand-binding oxidase with aerobically reconstituted diiron cofactor
5DCO	;	2.326	;	R2-like ligand-binding oxidase with aerobically reconstituted diiron cofactor (short soak)
4XBW	;	1.991	;	R2-like ligand-binding oxidase with aerobically reconstituted dimanganese cofactor
4HR0	;	1.896	;	R2-like ligand-binding oxidase with aerobically reconstituted metal cofactor
5OMJ	;	2.005	;	R2-like ligand-binding oxidase with aerobically reconstituted metal cofactor after photoconversion
5OMK	;	1.704	;	R2-like ligand-binding oxidase with aerobically reconstituted metal cofactor before photoconversion
5DCS	;	2.006	;	R2-like ligand-binding oxidase with aerobically reconstituted Mn/Fe cofactor (long soak)
5EKB	;	2.074	;	R2-like ligand-binding oxidase with aerobically reconstituted Mn/Fe cofactor (reconstituted in solution)
5DCR	;	2.108	;	R2-like ligand-binding oxidase with aerobically reconstituted Mn/Fe cofactor (short soak)
4XBV	;	1.799	;	R2-like ligand-binding oxidase with anaerobically reconstituted diiron cofactor
4HR4	;	1.901	;	R2-like ligand-binding oxidase with anaerobically reconstituted metal cofactor
4HR5	;	2.291	;	R2-like ligand-binding oxidase without metal cofactor
6F6L	;	1.904	;	R2-like ligand-binding oxidase Y162F mutant with aerobically reconstituted Mn/Fe cofactor
6F6M	;	1.393	;	R2-like ligand-binding oxidase Y162F mutant with anaerobically reconstituted Mn/Fe cofactor
6QK1	;	1.754	;	R2-like ligand-binding oxidase Y175F mutant with aerobically reconstituted Mn/Fe cofactor
6QK2	;	1.596	;	R2-like ligand-binding oxidase Y715F mutant with anaerobically reconstituted Mn/Fe cofactor
6A8Q	;	2.0	;	R207A mutant of highly active EfBSH
2X0R	;	2.915	;	R207S, R292S Mutant of Malate Dehydrogenase from the Halophilic Archeon Haloarcula marismortui (HoloForm)
1H43	;	2.2	;	R210E N-TERMINAL LOBE HUMAN LACTOFERRIN
1H45	;	1.95	;	R210G N-TERMINAL LOBE HUMAN LACTOFERRIN
1EH3	;	2.0	;	R210K N-TERMINAL LOBE HUMAN LACTOFERRIN
1H44	;	2.0	;	R210L N-TERMINAL LOBE HUMAN LACTOFERRIN
2JM9	;		;	R21A Spc-SH3 bound
2JM8	;		;	R21A Spc-SH3 free
2JMA	;		;	R21A Spc-SH3:P41 complex
8GK8	;	2.68	;	R21A Staphylococcus aureus pyruvate carboxylase
3GU9	;	2.06	;	R228A mutation in organophosphorus hydrolase from Deinococcus radiodurans
1ESI	;	1.8	;	R248L MUTANT OF STREPTOMYCES K15 DD-TRANSPEPTIDASE
6PR1	;	1.82	;	R260A/S128A S. typhimurium siroheme synthase
6PR2	;	2.16	;	R261A/S128A S. typhimurium siroheme synthase
3AIM	;	2.3	;	R267E mutant of a HSL-like carboxylesterase from Sulfolobus tokodaii
3AIN	;	1.65	;	R267G mutant of a HSL-like carboxylesterase from Sulfolobus tokodaii
3AIO	;	1.7	;	R267K mutant of a HSL-like carboxylesterase from Sulfolobus tokodaii
4GXI	;	1.949	;	R283K DNA polymerase beta binary complex with a templating 8OG
4GXK	;	1.998	;	R283K DNA polymerase beta ternary complex with a templating 8OG and incoming dATP analog
4GXJ	;	2.2	;	R283K DNA polymerase beta ternary complex with a templating 8OG and incoming dCTP analog
1E0T	;	1.8	;	R292D mutant of E. coli pyruvate kinase
2L38	;		;	R29Q Sticholysin II mutant
1KGP	;	2.0	;	R2F from Corynebacterium Ammoniagenes in its Mn substituted form
1KGN	;	1.85	;	R2F from Corynebacterium Ammoniagenes in its oxidised, Fe containing, form
1KGO	;	2.25	;	R2F from Corynebacterium Ammoniagenes in its reduced, Fe containing, form
2K1V	;		;	R3/I5 relaxin chimera
2AEK	;	2.9	;	R304K trichodiene synthase
2AEL	;	2.5	;	R304K Trichodiene Synthase: Complex With Mg, Pyrophosphate, and (4R)-7-Azabisabolene
2AET	;	2.75	;	R304K trichodiene synthase: Complex with Mg, pyrophosphate, and (4S)-7-azabisabolene
1HQX	;	3.0	;	R308K ARGINASE VARIANT
4AHH	;	2.498	;	R31K - Angiogenin mutants and amyotrophic lateral sclerosis - a biochemical and biological analysis
1GYG	;	1.9	;	R32 CLOSED FORM OF ALPHA-TOXIN FROM CLOSTRIDIUM PERFRINGENS STRAIN CER89L43
2DIK	;	2.5	;	R337A MUTANT OF PYRUVATE PHOSPHATE DIKINASE
5CDE	;	1.85	;	R372A mutant of Xaa-Pro dipeptidase from Xanthomonas campestris
2B7S	;	2.12	;	R381K mutant of flavocytochrome c3
4BEN	;	2.15	;	R39-imipenem Acyl-enzyme crystal structure
7QVW	;	1.922	;	R396W mutant of the vanadium-dependent bromoperoxidase from Corallina pilulifera
7QW3	;	1.78	;	R396W mutant of the vanadium-dependent bromoperoxidase from Corallina pilulifera in complex with Br ion.
7ZJF	;	1.3	;	R399E, a mutated form of GDF5, for disease modification of osteoarthritis
3ZDP	;	2.69	;	R416A Monomeric nucleoprotein of influenza A virus
2ZY5	;	2.65	;	R487A mutant of L-aspartate beta-decarboxylase
6HDK	;	1.24	;	R49A variant of beta-phosphoglucomutase from Lactococcus lactis complexed with aluminium tetrafluoride and beta-G6P to 1.2 A.
6HDM	;	1.3	;	R49A variant of beta-phosphoglucomutase from Lactococcus lactis complexed with magnesium trifluoride and beta-G6P to 1.3 A.
6HDI	;	2.03	;	R49A variant of beta-phosphoglucomutase from Lactococcus lactis in an open conformer to 2.0 A.
6HDJ	;	1.16	;	R49K variant of beta-phosphoglucomutase from Lactococcus lactis complexed aluminium tetrafluoride and beta-G6P to 1.2 A.
6HDL	;	1.16	;	R49K variant of beta-phosphoglucomutase from Lactococcus lactis complexed with magnesium trifluoride and beta-G6P to 1.2 A.
6HDH	;	1.62	;	R49K variant of beta-phosphoglucomutase from Lactococcus lactis in an open conformer to 1.6 A.
2D02	;	1.42	;	R52Q Mutant of Photoactive Yellow Protein, P65 Form
2VLP	;	2.0	;	R54A mutant of E9 DNase domain in complex with Im9
1AI0	;		;	R6 HUMAN INSULIN HEXAMER (NON-SYMMETRIC), NMR, 10 STRUCTURES
4AIY	;		;	R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, 'GREEN' SUBSTATE, AVERAGE STRUCTURE
5AIY	;		;	R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, 'RED' SUBSTATE, AVERAGE STRUCTURE
1AIY	;		;	R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, 10 STRUCTURES
2AIY	;		;	R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, 20 STRUCTURES
3AIY	;		;	R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, REFINED AVERAGE STRUCTURE
6SE7	;	1.87	;	R600A mutant from Mycoplasma genitalium P110 Adhesin at 1.87 Angstroms resolution
4UZE	;	2.34	;	R66A mutant of FAD synthetase from Corynebacterium ammoniagenes
4UZF	;	2.52	;	R66E mutant of FAD synthetase from Corynebacterium ammoniagenes
6VVM	;	1.83	;	R7 fused 4-OT wild type asymmetric trimer
6QA2	;	2.2	;	R80A MUTANT OF NUCLEOSIDE DIPHOSPHATE KINASE FROM MYCOBACTERIUM TUBERCULOSIS
6W9W	;	2.65	;	R80A PCNA mutant defective in BIR
4ANE	;	1.9	;	R80N MUTANT OF NUCLEOSIDE DIPHOSPHATE KINASE FROM MYCOBACTERIUM TUBERCULOSIS
2UY8	;	2.8	;	R92A mutant of Bacillus subtilis Oxalate Decarboxylase OxdC
3CDR	;	1.7	;	R96Q Mutant of wildtype phage T4 lysozyme at 298 K
1WGY	;		;	RA domain of guanine nucleotide exchange factor for Rap1
1RAX	;		;	RA-DOMAIN OF RAL GUANOSINE-NUCLEOTIDE DISSOCIATION STIMULATOR
2P5S	;	2.15	;	RAB domain of human RASEF in complex with GDP
8BUX	;	1.86	;	Rab-binding domain of human MiniBAR
5JCZ	;	2.056	;	Rab11 bound to MyoVa-GTD
7OPQ	;	2.23	;	Rab27a fusion with Slp2a-RBDa1 effector covalent adduct with CA1 in C188
7OPR	;	2.32	;	Rab27a fusion with Slp2a-RBDa1 effector covalent adduct with CB1 in C123
6HH2	;	1.449	;	Rab29 small GTPase bound to GDP
3BBP	;	3.0	;	Rab6-GTP:GCC185 Rab binding domain complex
5LEF	;	2.088	;	Rab6A:Kif20A complex
4KZY	;	7.01	;	Rabbit 40S ribosomal subunit in complex with eIF1 and eIF1A.
4KZX	;	7.809	;	Rabbit 40S ribosomal subunit in complex with eIF1.
4KZZ	;	7.0305	;	Rabbit 40S ribosomal subunit in complex with mRNA, initiator tRNA and eIF1A
7ZJW	;	2.8	;	Rabbit 80S ribosome as it decodes the Sec-UGA codon
7O81	;	3.1	;	Rabbit 80S ribosome colliding in another ribosome stalled by the SARS-CoV-2 pseudoknot
7O80	;	2.9	;	Rabbit 80S ribosome in complex with eRF1 and ABCE1 stalled at the STOP codon in the mutated SARS-CoV-2 slippery site
7ZJX	;	3.1	;	Rabbit 80S ribosome programmed with SECIS and SBP2
7O7Z	;	2.4	;	Rabbit 80S ribosome stalled close to the mutated SARS-CoV-2 slippery site by a pseudoknot (classified for pseudoknot)
7O7Y	;	2.2	;	Rabbit 80S ribosome stalled close to the mutated SARS-CoV-2 slippery site by a pseudoknot (high resolution)
6SGC	;	2.8	;	Rabbit 80S ribosome stalled on a poly(A) tail
6MTE	;	3.4	;	Rabbit 80S ribosome with eEF2 and SERBP1 (rotated state)
6MTD	;	3.3	;	Rabbit 80S ribosome with eEF2 and SERBP1 (unrotated state with 40S head swivel)
6MTB	;	3.6	;	Rabbit 80S ribosome with P- and Z-site tRNAs (unrotated state)
6MTC	;	3.4	;	Rabbit 80S ribosome with Z-site tRNA and IFRD2 (unrotated state)
5W7B	;	1.9	;	Rabbit acyloxyacyl hydrolase (AOAH), proteolytically processed, S262A mutant, with LPS
5W7A	;	2.3	;	Rabbit acyloxyacyl hydrolase (AOAH), proteolytically processed, S262A mutant, with LPS (low quality saposin domain)
7JPV	;	3.4	;	Rabbit Cav1.1 in the presence of 1 micromolar (S)-(-)-Bay K8644 in nanodiscs at 3.4 Angstrom resolution
7JPL	;	3.4	;	Rabbit Cav1.1 in the presence of 10 micromolar (S)-(-)-Bay K8644 in nanodiscs at 3.4 Angstrom resolution
7JPW	;	3.2	;	Rabbit Cav1.1 in the presence of 100 micromolar (R)-(+)-Bay K8644 in nanodiscs at 3.2 Angstrom resolution
7JPK	;	3.0	;	Rabbit Cav1.1 in the presence of 100 micromolar (S)-(-)-Bay K8644 in nanodiscs at 3.0 Angstrom resolution
7JPX	;	2.9	;	Rabbit Cav1.1 in the presence of 100 micromolar amlodipine in nanodiscs at 2.9 Angstrom resolution
6JP8	;	2.7	;	Rabbit Cav1.1-Bay K8644 Complex
6JPB	;	2.9	;	Rabbit Cav1.1-Diltiazem Complex
6JP5	;	2.9	;	Rabbit Cav1.1-Nifedipine Complex
6JPA	;	2.6	;	Rabbit Cav1.1-Verapamil Complex
7NMN	;	3.6	;	Rabbit HCN4 stabilised in amphipol A8-35
3ZUE	;	10.3	;	Rabbit Hemorrhagic Disease Virus (RHDV)capsid protein
8E58	;	3.0	;	Rabbit L-type voltage-gated calcium channel Cav1.1 in the presence of Amiodarone and 1 mM MNI-1 at 3.0 Angstrom resolution
8E57	;	2.8	;	Rabbit L-type voltage-gated calcium channel Cav1.1 in the presence of Amiodarone and 100 microM MNI-1 at 2.8 Angstrom resolution
8E56	;	2.8	;	Rabbit L-type voltage-gated calcium channel Cav1.1 in the presence of Amiodarone at 2.8 Angstrom resolution
6YP9	;	2.564	;	Rabbit muscle actin in complex with ADF-H and ATP-ATTO-488
6ALD	;	2.3	;	RABBIT MUSCLE ALDOLASE A/FRUCTOSE-1,6-BISPHOSPHATE COMPLEX
6V20	;	2.13	;	Rabbit muscle aldolase determined using single-particle cryo-EM at 200 keV
8EHG	;	2.24	;	Rabbit muscle aldolase determined using single-particle cryo-EM with Apollo camera.
5VY5	;	2.6	;	Rabbit muscle aldolase using 200keV
3ZCP	;	1.83	;	Rabbit muscle glycogen phosphorylase b in complex with N- cyclohexancarbonyl-N-beta-D-glucopyranosyl urea determined at 1.83 A resolution
3ZCS	;	2.03	;	Rabbit muscle glycogen phosphorylase b in complex with N-(1-naphthoyl) -N-beta-D-glucopyranosyl urea determined at 2.07 A resolution
3ZCT	;	2.0	;	Rabbit muscle glycogen phosphorylase b in complex with N-(2-naphthoyl) -N-beta-D-glucopyranosyl urea determined at 2.0 A resolution
3ZCQ	;	2.15	;	Rabbit muscle glycogen phosphorylase b in complex with N-(4- trifluoromethyl-benzoyl)-N-beta-D-glucopyranosyl urea determined at 2. 15 A resolution
3ZCR	;	2.07	;	Rabbit muscle glycogen phosphorylase b in complex with N-(4-tert- butyl-benzoyl)-N-beta-D-glucopyranosyl urea determined at 2.07 A resolution
3ZCV	;	1.83	;	Rabbit muscle glycogen phosphorylase b in complex with N-(indol-2- carbonyl)-N-beta-D-glucopyranosyl urea determined at 1.8 A resolution
3ZCU	;	2.05	;	Rabbit muscle glycogen phosphorylase b in complex with N-(pyridyl-2- carbonyl)-N-beta-D-glucopyranosyl urea determined at 2.05 A resolution
7P7D	;	1.45	;	Rabbit muscle Glycogen Phosphorylase T state
7P4G	;	2.6	;	Rabbit Muscle L-lactate dehydrogenase in complex with citrate
5NQB	;	1.58	;	Rabbit Muscle L-lactate dehydrogenase in complex with malonate
5NQQ	;	1.872	;	Rabbit Muscle L-lactate dehydrogenase in complex with NADH and oxaloacetate
3H3F	;	2.38	;	Rabbit muscle L-lactate dehydrogenase in complex with NADH and oxamate
1JDY	;	2.7	;	RABBIT MUSCLE PHOSPHOGLUCOMUTASE
1VKL	;	2.7	;	RABBIT MUSCLE PHOSPHOGLUCOMUTASE
6H26	;	1.288	;	Rabbit muscle phosphoglycerate mutase
8F5U	;	2.3	;	Rabbit muscle pyruvate kinase in complex with magnesium, potassium and pyruvate
8F5T	;	2.41	;	Rabbit muscle pyruvate kinase in complex with sodium and magnesium
6DY0	;	3.014	;	Rabbit N-acylethanolamine-hydrolyzing acid amidase (NAAA) covalently bound to beta-lactam inhibitor ARN726, in presence of Triton X-100
6DXZ	;	2.7	;	Rabbit N-acylethanolamine-hydrolyzing acid amidase (NAAA) in complex with non-covalent benzothiazole-piperazine inhibitor ARN19702, in presence of Triton X-100
6DY1	;	2.998	;	Rabbit N-acylethanolamine-hydrolyzing acid amidase (NAAA) with fatty acid (myristate), in presence of Triton X-100
1LOX	;	2.4	;	RABBIT RETICULOCYTE 15-LIPOXYGENASE
7T64	;	4.0	;	Rabbit RyR1 disease mutant Y523S in complex with FKBP12.6 embedded in lipidic nanodisc in the closed state
7T65	;	4.05	;	Rabbit RyR1 disease mutant Y523S in complex with FKBP12.6 embedded in lipidic nanodisc in the open state
7TDJ	;	3.7	;	Rabbit RyR1 with AMP-PCP and high Ca2+ embedded in nanodisc in closed-inactivated conformation class 1(Dataset-A)
7TDI	;	3.3	;	Rabbit RyR1 with AMP-PCP and high Ca2+ embedded in nanodisc in closed-inactivated conformation class 2 (Dataset-A)
7TDK	;	3.8	;	Rabbit RyR1 with AMP-PCP and high Ca2+ embedded in nanodisc in closed-inactivated conformation class 3 (Dataset-A)
7TDG	;	3.8	;	Rabbit RyR1 with AMP-PCP and high Ca2+ embedded in nanodisc in inactivated conformation (Dataset-A)
7TDH	;	4.0	;	Rabbit RyR1 with AMP-PCP and high Ca2+ embedded in nanodisc in open conformation
1JNF	;	2.6	;	Rabbit serum transferrin at 2.6 A resolution.
2VYP	;	2.35	;	Rabbit-muscle G-actin in complex with myxobacterial rhizopodin
6D0S	;	2.3	;	RabGAP domain of human TBC1D22B
4EHM	;	2.2	;	RabGGTase in complex with covalently bound Psoromic acid
8A1E	;	2.83	;	Rabies virus glycoprotein in complex with Fab fragments of 17C7 and 1112-1 neutralizing antibodies
6TOU	;	2.587	;	Rabies virus glycoprotein PH domain in complex with the scFv fragment of broadly neutralizing human antibody RVC20
7U9G	;	3.39	;	Rabies virus glycoprotein pre-fusion trimer in complex with neutralizing antibody RVA122
8BUY	;	1.6	;	Rac-binding domain of human MiniBAR
6M7M	;	1.101	;	rac-GSTSTA from degenerate octameric repeats in InaZ, residues 707-712
2P2L	;	1.9	;	Rac1-GDP-Zinc Complex
1HH4	;	2.7	;	Rac1-RhoGDI complex involved in NADPH oxidase activation
2RMK	;		;	Rac1/PRK1 Complex
2W2T	;	1.95	;	Rac2 (G12V) in complex with GDP
2W2V	;	2.0	;	Rac2 (G12V) in complex with GTPgS
6ZPF	;	1.442	;	Racemic compound of RNA duplexes.
6ZQ9	;	1.5	;	Racemic compound of RNA duplexes.
6ZR1	;	1.528	;	Racemic compound of RNA duplexes.
6ZRL	;	1.53	;	Racemic compound of RNA duplexes.
6ZRS	;	1.52	;	Racemic compound of RNA duplexes.
6ZW3	;	1.522	;	Racemic compound of RNA duplexes.
6ZWU	;	1.527	;	Racemic compound of RNA duplexes.
6ZX5	;	1.523	;	Racemic compound of RNA duplexes.
6ZX8	;	1.981	;	Racemic compound of RNA duplexes.
7A9L	;	1.98	;	Racemic compound of RNA duplexes.
7A9N	;	1.602	;	Racemic compound of RNA duplexes.
7A9O	;	1.601	;	Racemic compound of RNA duplexes.
7A9P	;	1.985	;	Racemic compound of RNA duplexes.
7A9Q	;	2.185	;	Racemic compound of RNA duplexes.
7A9R	;	2.455	;	Racemic compound of RNA duplexes.
7A9S	;	2.29	;	Racemic compound of RNA duplexes.
7A9T	;	1.7	;	Racemic compound of RNA duplexes.
4R45	;	1.9	;	Racemic crystal structure of a bimolecular DNA G-quadruplex (P-1)
4R47	;	1.85	;	Racemic crystal structure of a bimolecular DNA G-quadruplex (P21/n)
4R49	;	1.28	;	Racemic crystal structure of a calcium-bound B-DNA duplex
4R48	;	2.33	;	Racemic crystal structure of a calcium-bound DNA four-way junction
4R4A	;	1.49	;	Racemic crystal structure of a cobalt-bound B-DNA duplex
4R4D	;	1.29	;	Racemic crystal structure of a magnesium-bound B-DNA duplex
4R44	;	2.695	;	Racemic crystal structure of a tetramolecular DNA G-quadruplex
6GN3	;	2.8	;	Racemic crystal structure of A-DNA duplex formed from d(CCCGGG) in space group P21/n
6GN2	;	2.48	;	Racemic crystal structure of A-DNA duplex formed from d(CCCGGG) in space group R3
4WSP	;	1.65	;	Racemic crystal structure of Rv1738 from Mycobacterium tuberculosis (Form-I)
4WPY	;	1.5	;	Racemic crystal structure of Rv1738 from Mycobacterium tuberculosis (Form-II)
5EWB	;	1.694	;	Racemic crystal structures of Pribnow box consensus promoter sequence (P21/c)
5ET9	;	1.83	;	Racemic crystal structures of Pribnow box consensus promoter sequence (P21/n)
5EZF	;	1.65	;	Racemic crystal structures of Pribnow box consensus promoter sequence (Pbca)
5EYQ	;	2.3	;	Racemic crystal structures of Pribnow box consensus promoter sequence (Pnna)
4RWB	;	2.0	;	Racemic influenza M2-TM crystallized from monoolein lipidic cubic phase
4RWC	;	1.05	;	Racemic M2-TM crystallized from racemic detergent
6MPL	;	1.55	;	Racemic M2-TM I39A crystallized from racemic detergent
6MPM	;	1.4	;	Racemic M2-TM I42A crystallized from racemic detergent
6MPN	;	1.4	;	Racemic M2-TM I42E crystallized from racemic detergent
6O4M	;	1.27	;	Racemic melittin
8T86	;	1.102	;	Racemic mixture of amylin segment 25-AILSS-29 forms heterochiral rippled beta-sheet
8T89	;	1.5	;	Racemic mixture of amyloid beta segment 16-KLVFFA-21 forms heterochiral rippled beta-sheet
8T84	;	1.101	;	Racemic mixture of amyloid beta segment 35-MVGGVV-40 forms heterochiral rippled beta-sheet, includes hexafluoroisopropanol
8T82	;	1.1	;	Racemic mixture of amyloid beta segment 35-MVGGVV-40 forms heterochiral rippled beta-sheet, includes pentafluoropropionic acid
8DDH	;	1.1	;	Racemic mixture of FYF peptide reveals rippled beta-sheet
6NIV	;	1.45	;	Racemic Phenol-Soluble Modulin Alpha 3 Peptide
8AVU	;	0.89	;	Racemic protein crystal structure of aureocin A53 from Staphylococcus aureus in the dimeric state
8AVS	;	1.21	;	Racemic protein crystal structure of aureocin A53 from Staphylococcus aureus in the presence of citrate and acetate
8AVT	;	1.2	;	Racemic protein crystal structure of aureocin A53 from Staphylococcus aureus in the presence of glycerol 3-phosphate
8AVR	;	1.13	;	Racemic protein crystal structure of aureocin A53 from Staphylococcus aureus in the presence of sulfate
7P5R	;	0.96	;	Racemic protein crystal structure of lacticin Q from Lactococcus lactis
5E5Q	;	1.6	;	Racemic snakin-1 in P21/c
5INZ	;	1.447	;	Racemic structure of baboon theta defensin-2
4TTL	;	1.7004	;	Racemic structure of cyclic Vc1.1 (cVc1.1-1)
6DL1	;	1.029	;	Racemic structure of jatrophidin, an orbitide from Jatropha curcas
4TTM	;	1.9001	;	Racemic structure of kalata B1 (kB1)
7QDJ	;	1.44	;	Racemic structure of PK-10 and PK-11
8BFD	;	2.0	;	Racemic structure of PK-7 (310HD-U2U5)
6DKZ	;	0.99	;	Racemic structure of ribifolin, an orbitide from Jatropha ribifolia
4TTK	;	1.2502	;	Racemic structure of Sunflower Trypsin Inhibitor-1 (SFTI-1)
7MMY	;	1.464	;	Racemic structure of the cyclic plant peptide PDP-23
8P6Q	;	1.4	;	Racemic structure of TNFR1 cysteine-rich domain
5YV7	;	2.395	;	Racemic X-ray Structure of Calcicludine
6KZF	;	2.52	;	Racemic X-ray Structure of Calcicludine
6M9J	;	0.9	;	Racemic-GSTSTA from degenerate octameric repeats in InaZ, residues 707-712
4JD8	;	1.16	;	Racemic-[Ru(phen)2(dppz)]2+] bound to synthetic DNA at high resolution
2Y43	;	1.8	;	Rad18 ubiquitin ligase RING domain structure
7STE	;	2.73	;	Rad24-RFC ADP state
3QKT	;	1.9	;	Rad50 ABC-ATPase with adjacent coiled-coil region in complex with AMP-PNP
1L8D	;	2.2	;	Rad50 coiled-coil Zn hook
1B22	;		;	RAD51 (N-TERMINAL DOMAIN)
1PZN	;	2.85	;	Rad51 (RadA)
8PBD	;	2.83	;	RAD51 filament on dsDNA bound by the BRCA2 c-terminus
8PBC	;	2.61	;	RAD51 filament on ssDNA bound by the BRCA2 c-terminus
8GJ8	;	2.3	;	RAD51C C-terminal domain
8GJ9	;	1.6	;	RAD51C N-terminal domain
8GJA	;	2.6	;	RAD51C-XRCC3 structure
5JRB	;	2.405	;	Rad52(1-212) K102A/K133A/E202A mutant
7UVC	;	3.05	;	Rad6(P43L)-Bre1 Complex
7UV8	;	2.7	;	Rad6-Bre1 Complex
3RCZ	;	1.9	;	Rad60 SLD2 Ubc9 Complex
5LKM	;	3.5	;	RadA bound to dTDP
4A6P	;	1.498	;	RadA C-terminal ATPase domain from Pyrococcus furiosus
4UQO	;	1.88	;	RADA C-TERMINAL ATPASE DOMAIN FROM PYROCOCCUS FURIOSUS BOUND TO ADP
4D6P	;	1.482	;	RADA C-TERMINAL ATPASE DOMAIN FROM PYROCOCCUS FURIOSUS BOUND TO AMPPNP
4A6X	;	1.548	;	RadA C-terminal ATPase domain from Pyrococcus furiosus bound to ATP
4B2P	;	1.6	;	RadA C-terminal ATPase domain from Pyrococcus furiosus bound to GTP
4QKQ	;	2.0	;	RadA from Methanococcus Voltae in complex with copper phthalocyanine tetrasulfonate inhibitor
3NTU	;	1.9	;	RADA RECOMBINASE D302K MUTANT IN COMPLEX with AMP-PNP
3ETL	;	2.4	;	RadA recombinase from Methanococcus maripaludis in complex with AMPPNP
3EWA	;	2.0	;	RADA recombinase from METHANOCOCCUS MARIPALUDIS in complex with AMPPNP and ammonium ions
3EW9	;	2.4	;	RADA recombinase from METHANOCOCCUS MARIPALUDIS in complex with AMPPNP and potassium ions
2FPK	;	2.1	;	RadA recombinase in complex with ADP
2FPM	;	2.0	;	RadA recombinase in complex with AMP-PNP and high concentration of K+
2FPL	;	2.3	;	RadA recombinase in complex with AMP-PNP and low concentration of K+
2B21	;	2.4	;	RADA Recombinase in complex with AMPPNP at pH 6.0
2I1Q	;	1.9	;	RadA Recombinase in complex with Calcium
7JTK	;	3.2	;	Radial spoke 1 isolated from Chlamydomonas reinhardtii
7JU4	;	3.4	;	Radial spoke 2 stalk, IDAc, and N-DRC attached with doublet microtubule
8X2U	;	3.57	;	Radial spoke head-neck dimer
6JUB	;	1.54	;	Radiation damage in Aspergillus oryzae pro-tyrosinase oxygen-bound C92A mutant
6JUD	;	1.56	;	Radiation damage in Aspergillus oryzae pro-tyrosinase oxygen-bound C92A/H103F mutant
4H94	;	1.2	;	Radiation damage in lysozyme - 0.56 MGy
2BHX	;	1.68	;	Radiation damage of the Schiff base in phosphoserine aminotransferase (structure A)
2BI1	;	1.69	;	Radiation damage of the Schiff base in phosphoserine aminotransferase (structure B)
2BI2	;	1.69	;	Radiation damage of the Schiff base in phosphoserine aminotransferase (structure C)
2BI3	;	1.69	;	Radiation damage of the Schiff base in phosphoserine aminotransferase (structure D)
2BI5	;	1.73	;	Radiation damage of the Schiff base in phosphoserine aminotransferase (structure E)
2BI9	;	1.73	;	Radiation damage of the Schiff base in phosphoserine aminotransferase (structure F)
2BIA	;	1.77	;	Radiation damage of the Schiff base in phosphoserine aminotransferase (structure G)
2BIE	;	1.3	;	Radiation damage of the Schiff base in phosphoserine aminotransferase (structure H)
2BIG	;	1.3	;	Radiation damage of the Schiff base in phosphoserine aminotransferase (structure I)
4M4F	;	1.9	;	Radiation damage study of Cu T6-insulin - 0.01 MGy
4M4H	;	1.9	;	Radiation damage study of Cu T6-insulin - 0.06 MGy
4M4I	;	1.9	;	Radiation damage study of Cu T6-insulin - 0.12 MGy
4M4J	;	1.9	;	Radiation damage study of Cu T6-insulin - 0.30 MGy
4H8X	;	1.1998	;	Radiation damage study of lysozyme - 0.07 MGy
4H8Z	;	1.1998	;	Radiation damage study of lysozyme - 0.21 MGy
4H90	;	1.1999	;	Radiation damage study of lysozyme - 0.28 MGy
4H91	;	1.2002	;	Radiation damage study of lysozyme - 0.35 MGy
4H93	;	1.2003	;	Radiation damage study of lysozyme - 0.49 MGy
4H9A	;	1.1997	;	Radiation damage study of lysozyme - 0.63 MGy
4H9B	;	1.1998	;	Radiation damage study of lysozyme - 0.70 MGy
4H9C	;	1.1998	;	Radiation damage study of lysozyme - 0.77 MGy
4H9E	;	1.1998	;	Radiation damage study of lysozyme - 0.84 MGy
4H9F	;	1.2003	;	Radiation damage study of lysozyme - 0.91 MGy
4H9H	;	1.2002	;	Radiation damage study of lysozyme - 0.98 MGy
4H9I	;	1.2002	;	Radiation damage study of lysozyme - 1.05 MGy
4H8Y	;	1.1998	;	Radiation damage study of lysozyme- 0.14 MGy
4H92	;	1.2002	;	Radiation damage study of lysozyme- 0.42 MGy
3P7P	;	2.2	;	Radiation damage study of thermolysin - 100K structure A (0.1 MGy)
3P7Q	;	2.2	;	Radiation damage study of thermolysin - 100K structure B (2.5 MGy)
3P7R	;	2.2	;	Radiation damage study of thermolysin - 100K structure C (4.9 MGy)
3P7S	;	2.2	;	Radiation damage study of thermolysin - 100K structure D (7.2 MGy)
3P7T	;	2.2	;	Radiation damage study of thermolysin - 160K structure A (0.1 MGy)
3P7U	;	2.2	;	Radiation damage study of thermolysin - 160K structure B (2.4 MGy)
3P7V	;	2.2	;	Radiation damage study of thermolysin - 160K structure C (4.8 MGy)
3P7W	;	2.2	;	Radiation damage study of thermolysin - 160K structure D (7.1 MGy)
6QT1	;	1.8	;	Radiation damage study on a 16mer DNA segment, structure at 0.48 MGy dose
6QT3	;	1.8	;	Radiation damage study on a 16mer DNA segment, structure at 12.0 MGy dose
6QT4	;	1.8	;	Radiation damage study on a 16mer DNA segment, structure at 17.7 MGy dose
6QT6	;	1.8	;	Radiation damage study on a 16mer DNA segment, structure at 29.2 MGy dose
6QT2	;	1.8	;	Radiation damage study on a 16mer DNA segment, structure at 6.2 MGy dose
6QT5	;	1.8	;	Radiation damage study on a 16mer DNA segment, structure at 63.7 MGy dose
6UPP	;	1.56	;	Radiation Damage Test of PixJ Pb state crystals
5MCC	;	2.0	;	Radiation damage to GH7 Family Cellobiohydrolase from Daphnia pulex: Dose (DWD) 1.11 MGy
5MCI	;	2.0	;	Radiation damage to GH7 Family Cellobiohydrolase from Daphnia pulex: Dose (DWD) 11.9 MGy
5MCJ	;	2.0	;	Radiation damage to GH7 Family Cellobiohydrolase from Daphnia pulex: Dose (DWD) 14.1 MGy
5MCK	;	2.0	;	Radiation damage to GH7 Family Cellobiohydrolase from Daphnia pulex: Dose (DWD) 16.2 MGy
5MCL	;	2.0	;	Radiation damage to GH7 Family Cellobiohydrolase from Daphnia pulex: Dose (DWD) 18.4 MGy
5MCM	;	2.0	;	Radiation damage to GH7 Family Cellobiohydrolase from Daphnia pulex: Dose (DWD) 20.6 MGy
5MCN	;	2.0	;	Radiation damage to GH7 Family Cellobiohydrolase from Daphnia pulex: Dose (DWD) 22.7 MGy
5MCD	;	2.0	;	Radiation damage to GH7 Family Cellobiohydrolase from Daphnia pulex: Dose (DWD) 3.27 MGy
5MCE	;	2.0	;	Radiation damage to GH7 Family Cellobiohydrolase from Daphnia pulex: Dose (DWD) 5.43 MGy
5MCF	;	2.0	;	Radiation damage to GH7 Family Cellobiohydrolase from Daphnia pulex: Dose (DWD) 7.59 MGy
5MCH	;	2.0	;	Radiation damage to GH7 Family Cellobiohydrolase from Daphnia pulex: Dose (DWD) 9.75 MGy
4X4D	;	2.8	;	RADIATION DAMAGE TO THE NUCLEOPROTEIN COMPLEX C.Esp1396I: DOSE (DWD) 10.3 MGy
4X4E	;	2.8	;	RADIATION DAMAGE TO THE NUCLEOPROTEIN COMPLEX C.Esp1396I: DOSE (DWD) 14.4 MGy
4X4B	;	2.8	;	RADIATION DAMAGE TO THE NUCLEOPROTEIN COMPLEX C.Esp1396I: DOSE (DWD) 2.1 MGy
4X4F	;	2.8	;	RADIATION DAMAGE TO THE NUCLEOPROTEIN COMPLEX C.Esp1396I: DOSE (DWD) 20.6 MGy
4X4G	;	2.8	;	RADIATION DAMAGE TO THE NUCLEOPROTEIN COMPLEX C.Esp1396I: DOSE (DWD) 26.8 MGy
4X4H	;	2.8	;	RADIATION DAMAGE TO THE NUCLEOPROTEIN COMPLEX C.Esp1396I: DOSE (DWD) 35.7 MGy
4X4I	;	2.8	;	RADIATION DAMAGE TO THE NUCLEOPROTEIN COMPLEX C.Esp1396I: DOSE (DWD) 44.6 MGy
4X4C	;	2.8	;	RADIATION DAMAGE TO THE NUCLEOPROTEIN COMPLEX C.Esp1396I: DOSE (DWD) 6.2 MGy
5EEU	;	1.98	;	RADIATION DAMAGE TO THE TRAP-RNA COMPLEX: DOSE (DWD) 1.31 MGy
5EEY	;	1.98	;	RADIATION DAMAGE TO THE TRAP-RNA COMPLEX: DOSE (DWD) 11.6 MGy
5EEZ	;	1.98	;	RADIATION DAMAGE TO THE TRAP-RNA COMPLEX: DOSE (DWD) 14.2 MGy
5EF0	;	1.98	;	RADIATION DAMAGE TO THE TRAP-RNA COMPLEX: DOSE (DWD) 16.7 MGy
5EF1	;	1.98	;	RADIATION DAMAGE TO THE TRAP-RNA COMPLEX: DOSE (DWD) 19.3 MGy
5EF2	;	1.98	;	RADIATION DAMAGE TO THE TRAP-RNA COMPLEX: DOSE (DWD) 21.9 MGy
5EF3	;	1.98	;	RADIATION DAMAGE TO THE TRAP-RNA COMPLEX: DOSE (DWD) 25.0 MGy
5EEV	;	1.98	;	RADIATION DAMAGE TO THE TRAP-RNA COMPLEX: DOSE (DWD) 3.88 MGy
5EEW	;	1.98	;	RADIATION DAMAGE TO THE TRAP-RNA COMPLEX: DOSE (DWD) 6.45 MGy
5EEX	;	1.98	;	RADIATION DAMAGE TO THE TRAP-RNA COMPLEX: DOSE (DWD) 9.02 MGy
1O7U	;	1.5	;	Radiation induced tryparedoxin-I
1O85	;	1.5	;	Radiation-reduced Tryparedoxin-I
1O8W	;	1.7	;	Radiation-reduced Tryparedoxin-I
6FD2	;	2.55	;	Radical SAM 1,2-diol dehydratase AprD4 in complex with its substrate paromamine
2IWS	;	2.7	;	Radicicol analogues bound to the ATP site of HSP90
1BGQ	;	2.5	;	RADICICOL BOUND TO THE ATP BINDING SITE OF THE N-TERMINAL DOMAIN OF THE YEAST HSP90 CHAPERONE
3X23	;	2.396	;	Radixin complex
1A1K	;	1.9	;	RADR (ZIF268 VARIANT) ZINC FINGER-DNA COMPLEX (GACC SITE)
1A1I	;	1.6	;	RADR (ZIF268 VARIANT) ZINC FINGER-DNA COMPLEX (GCAC SITE)
1A1J	;	2.0	;	RADR (ZIF268 VARIANT) ZINC FINGER-DNA COMPLEX (GCGT SITE)
1FAQ	;		;	RAF-1 CYSTEINE RICH DOMAIN, NMR, 27 STRUCTURES
1FAR	;		;	RAF-1 CYSTEINE RICH DOMAIN, NMR, MINIMIZED AVERAGE STRUCTURE
4ZZE	;	1.76	;	Raffinose and panose binding protein from Bifidobacterium animalis subsp. lactis Bl-04, bound with panose
4ZS9	;	1.37	;	Raffinose and panose binding protein from Bifidobacterium animalis subsp. lactis Bl-04, bound with raffinose
4ZZA	;	2.02	;	Raffinose and panose binding protein from Bifidobacterium animalis subsp. lactis Bl-04, bound with raffinose, selenomethionine derivative
1RMD	;	2.1	;	RAG1 DIMERIZATION DOMAIN
8T4R	;	1.2	;	RAG2-PHD finger in complex with H3K4tBuNle peptide
4OI8	;	3.101	;	RAGE is a nucleic acid receptor that promotes inflammatory responses to DNA.
4OI7	;	3.104	;	RAGE recognizes nucleic acids and promotes inflammatory responses to DNA
2LE9	;		;	RAGEC2-S100A13 tetrameric complex
2BBG	;		;	RAGWEED POLLEN ALLERGEN FROM AMBROSIA TRIFIDA V, NMR, 30 STRUCTURES
1BBG	;		;	RAGWEED POLLEN ALLERGEN FROM AMBROSIA TRIFIDA V, NMR, MINIMIZED AVERAGE STRUCTURE
1HK6	;		;	Ral binding domain from Sec5
2KWH	;		;	Ral binding domain of RLIP76 (RalBP1)
2KWI	;		;	RalB-RLIP76 (RalBP1) complex
8G63	;	2.5	;	Ralimetinib (LY2228820) in complex with wild type EGFR
8JLP	;	3.23	;	Ralmitaront(RO-6889450)-bound hTAAR1-Gs protein complex
7UJC	;	1.78	;	Raloxifene in Complex with Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutation
2CHH	;	1.0	;	RALSTONIA SOLANACEARUM HIGH-AFFINITY MANNOSE-BINDING LECTIN
1UQX	;	1.7	;	Ralstonia solanacearum lectin (RS-IIL) in complex with alpha-methylmannoside
2XBS	;	1.37	;	Raman crystallography of Hen White Egg Lysozyme - High X-ray dose (16 MGy)
2XBR	;	1.29	;	Raman crystallography of Hen White Egg Lysozyme - Low X-ray dose (0.2 MGy)
7CGT	;	3.0	;	RAMEB COMPLEX OF CYCLODEXTRIN GLYCOSYLTRANSFERASE MUTANT
6IE9	;	1.78	;	RamR in complex with chenodeoxycholic acid
6IE8	;	2.0	;	RamR in complex with cholic acid
5CIT	;	1.75	;	Ran GDP wild type monoclinic crystal form
5CIQ	;	1.65	;	Ran GDP wild type tetragonal crystal form
5CIW	;	1.75	;	Ran GDP Y39A mutant monoclinic crystal form
5CJ2	;	1.75	;	Ran GDP Y39A mutant triclinic crystal form
5CLQ	;	3.2	;	Ran Y39A in complex with GPPNHP and RanBD1
1I2M	;	1.76	;	RAN-RCC1-SO4 COMPLEX
8D6P	;	2.6	;	Rana catesbeiana saxiphilin mutant - Y558A
8D6S	;	2.6	;	Rana catesbeiana saxiphilin mutant - Y558A:STX (co-crystal)
8D6Q	;	2.7	;	Rana catesbeiana saxiphilin mutant - Y558I
8D6T	;	2.15	;	Rana catesbeiana saxiphilin mutant - Y558I:STX (co-crystal)
8D6U	;	2.65	;	Rana catesbeiana saxiphilin:F-STX (soaked)
2VH3	;	1.16	;	ranasmurfin
5YRO	;	2.396	;	RanL182A in complex with RanBP1-CRM1
5YST	;	2.04	;	RanM189D in complex with RanBP1-CRM1
5YTB	;	2.3	;	RanY197A in complex with RanBP1-CRM1
4GFB	;	2.99	;	Rap1/DNA complex
3ZFI	;	1.98	;	Rap1a protein (SMA2260) from Serratia marcescens
3ZIB	;	1.9	;	Rap2a protein (SMA2265) from Serratia marcescens
4A5G	;	2.05	;	Raphanus sativus anionic peroxidase.
4M3B	;	2.001	;	Rapid and efficient design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging and linking approaches
4M3D	;	1.9	;	Rapid and efficient design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging and linking approaches
4M3E	;	2.109	;	Rapid and efficient design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging and linking approaches
4M3F	;	2.0	;	Rapid and efficient design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging and linking approaches
4M3G	;	2.3	;	Rapid and efficient design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging and linking approaches
6LNG	;	1.8	;	Rapid crystallization of streptavidin using charged peptides
138L	;	1.7	;	RAPID CRYSTALLIZATION OF T4 LYSOZYME BY INTERMOLECULAR DISULFIDE CROSSLINKING
139L	;	1.7	;	RAPID CRYSTALLIZATION OF T4 LYSOZYME BY INTERMOLECULAR DISULFIDE CROSSLINKING
7LQP	;	2.07	;	Rapid development of potent inhibitors of the HIV integrase-LEDGF interaction by fragment-linking using off-rate screening
4YZU	;	1.41	;	Rapid development of two Factor IXa inhibitors from Hit to Lead
4Z0K	;	1.41	;	Rapid development of two Factor IXa inhibitors from Hit to Lead
5EH0	;	2.18	;	Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle kinase 1 (MPS1) Using a Structure-Based Hydridization Approach
5EHL	;	2.66	;	Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle kinase 1 (MPS1) Using a Structure-Based Hydridization Approach
5EHO	;	2.18	;	Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle kinase 1 (MPS1) Using a Structure-Based Hydridization Approach
5EHY	;	2.26	;	Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle kinase 1 (MPS1) Using a Structure-Based Hydridization Approach
5EI2	;	2.67	;	Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle kinase 1 (MPS1) Using a Structure-Based Hydridization Approach
5EI6	;	2.01	;	Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle kinase 1 (MPS1) Using a Structure-Based Hydridization Approach
5EI8	;	2.17	;	Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle kinase 1 (MPS1) Using a Structure-Based Hydridization Approach
2P1H	;	1.59	;	Rapid Folding and Unfolding of Apaf-1 CARD
6TMP	;	2.076	;	Rapid optimisation of fragments and hits to lead compounds from screening of crude reaction mixtures
6TMQ	;	2.112	;	Rapid optimisation of fragments and hits to lead compounds from screening of crude reaction mixtures
6TMZ	;	2.71	;	Rapid optimisation of fragments and hits to lead compounds from screening of crude reaction mixtures
6TN0	;	1.905	;	Rapid optimisation of fragments and hits to lead compounds from screening of crude reaction mixtures
6TN2	;	1.768	;	Rapid optimisation of fragments and hits to lead compounds from screening of crude reaction mixtures
6TN4	;	1.274	;	Rapid optimisation of fragments and hits to lead compounds from screening of crude reaction mixtures
6TN5	;	1.165	;	Rapid optimisation of fragments and hits to lead compounds from screening of crude reaction mixtures
3RCJ	;	1.7	;	Rapid preparation of triazolyl substituted NH-heterocyclic kinase inhibitors via one-pot Sonogashira coupling TMS-deprotection CuAAC sequence
1XRJ	;	2.0	;	Rapid structure determination of human uridine-cytidine kinase 2 using a conventional laboratory X-ray source and a single samarium derivative
6U62	;	3.18	;	Raptor-Rag-Ragulator complex
5M24	;	1.69	;	RARg mutant-S371E
1HE8	;	3.0	;	Ras G12V - PI 3-kinase gamma complex
6EPL	;	2.55	;	Ras guanine exchange factor SOS1 (Rem-cdc25) in complex with KRAS(G12C)
6EPN	;	2.5	;	Ras guanine exchange factor SOS1 (Rem-cdc25) in complex with KRAS(G12C) and fragment screening hit F2
6EPO	;	2.4	;	RAS GUANINE EXCHANGE FACTOR SOS1 (REM-CDC25) IN COMPLEX WITH KRAS(G12C) AND FRAGMENT SCREENING HIT F3
6EPP	;	2.4	;	RAS GUANINE EXCHANGE FACTOR SOS1 (REM-CDC25) IN COMPLEX WITH KRAS(G12C) AND FRAGMENT SCREENING HIT F4
6EPM	;	2.5	;	Ras guanine nucleotide exchange factor SOS1 (Rem-cdc25) in complex with KRAS(G12C) and fragment screening hit F1
5OVI	;	2.2	;	Ras guanine nucleotide exchange factor SOS1 (Rem-cdc25) in complex with small molecule inhibitor BAY-293 (compound 23)
5OVE	;	1.85	;	Ras guanine nucleotide exchange factor SOS1 (Rem-cdc25) in complex with small molecule inhibitor compound 1
5OVF	;	2.01	;	Ras guanine nucleotide exchange factor SOS1 (Rem-cdc25) in complex with small molecule inhibitor compound 17
5OVG	;	2.3	;	Ras guanine nucleotide exchange factor SOS1 (Rem-cdc25) in complex with small molecule inhibitor compound 18
5OVH	;	2.3	;	Ras guanine nucleotide exchange factor SOS1 (Rem-cdc25) in complex with small molecule inhibitor compound 21
5OVD	;	1.9	;	Ras guanine nucleotide exchange factor SOS1 (Rem-cdc25) in new crystal form
6EIE	;	2.72	;	Ras guanine nucleotide exchange factor SOS2 (Rem-cdc25), with surface mutations
2KMD	;		;	Ras signaling requires dynamic properties of Ets1 for phosphorylation-enhanced binding to co-activator CBP
3LBH	;	1.85	;	Ras soaked in Calcium Acetate
3LBN	;	1.862	;	Ras soaked in Magnesium Acetate
3LBI	;	2.087	;	Ras soaked in Magnesium Acetate and back soaked in Calcium Acetate
1WER	;	1.6	;	RAS-GTPASE-ACTIVATING DOMAIN OF HUMAN P120GAP
1WQ1	;	2.5	;	RAS-RASGAP COMPLEX
3X1W	;	1.2	;	Ras-related protein Rap1B with GDP
3X1X	;	1.0	;	Ras-related protein Rap1B with GppNHp
3X1Y	;	1.168	;	Ras-related protein Rap1B(L9V) with GppNHp
3X1Z	;	1.25	;	Ras-related protein Rap1B(T65A) with GppNHp
7NZZ	;	2.45	;	Ras1 guanine nucleotide exchange factor Cdc25 (REM and catalytic domains)
6BVI	;	1.746	;	Ras:SOS:Ras in complex with a small molecule activator
6BVJ	;	1.747	;	Ras:SOS:Ras in complex with a small molecule activator
6BVK	;	1.799	;	Ras:SOS:Ras in complex with a small molecule activator
6BVL	;	1.748	;	Ras:SOS:Ras in complex with a small molecule activator
6BVM	;	1.796	;	Ras:SOS:Ras in complex with a small molecule activator
6CUO	;	1.73	;	Ras:SOS:Ras in complex with a small molecule activator
6CUP	;	1.833	;	Ras:SOS:Ras in complex with a small molecule activator
6CUR	;	1.73	;	Ras:SOS:Ras in complex with a small molecule activator
6D55	;	1.68	;	Ras:SOS:Ras in complex with a small molecule activator
6D56	;	1.68	;	Ras:SOS:Ras in complex with a small molecule activator
6D59	;	1.7	;	Ras:SOS:Ras in complex with a small molecule activator
6D5E	;	1.75	;	Ras:SOS:Ras in complex with a small molecule activator
6D5G	;	1.92	;	Ras:SOS:Ras in complex with a small molecule activator
6D5H	;	1.8	;	Ras:SOS:Ras in complex with a small molecule activator
6D5J	;	1.751	;	Ras:SOS:Ras in complex with a small molecule activator
6D5L	;	1.7	;	Ras:SOS:Ras in complex with a small molecule activator
6D5M	;	2.081	;	Ras:SOS:Ras in complex with a small molecule activator
6D5V	;	2.04	;	Ras:SOS:Ras in complex with a small molecule activator
6D5W	;	2.478	;	Ras:SOS:Ras in complex with a small molecule activator
2XFQ	;	2.2	;	Rasagiline-inhibited human monoamine oxidase B in complex with 2-(2- benzofuranyl)-2-imidazoline
5KHQ	;	2.8	;	Rasip1 RA domain
5KHO	;	2.78	;	Rasip1 RA domain in complex with Rap1B
4WL6	;	1.85	;	Raster-scanning protein crystallography using micro and nano-focused synchrotron beams
6TU3	;	2.7	;	Rat 20S proteasome
2WJ5	;	1.12	;	Rat alpha crystallin domain
1SLU	;	1.8	;	RAT ANIONIC N143H, E151H TRYPSIN COMPLEXED TO A86H ECOTIN
1SLV	;	2.3	;	RAT ANIONIC N143H, E151H TRYPSIN COMPLEXED TO A86H ECOTIN; COPPER-BOUND
1SLW	;	2.0	;	RAT ANIONIC N143H, E151H TRYPSIN COMPLEXED TO A86H ECOTIN; NICKEL-BOUND
1SLX	;	2.2	;	RAT ANIONIC N143H, E151H TRYPSIN COMPLEXED TO A86H ECOTIN; ZINC-BOUND
1A8B	;	1.9	;	RAT ANNEXIN V COMPLEXED WITH GLYCEROPHOSPHOETHANOLAMINE
1A8A	;	1.9	;	RAT ANNEXIN V COMPLEXED WITH GLYCEROPHOSPHOSERINE
2RAN	;	1.89	;	RAT ANNEXIN V CRYSTAL STRUCTURE: CA2+-INDUCED CONFORMATIONAL CHANGES
4P7J	;	1.45	;	Rat apo-COMT sulfate bound
4P7G	;	2.58	;	Rat apo-COMT, phosphate bound
1AF3	;	2.5	;	RAT BCL-XL AN APOPTOSIS INHIBITORY PROTEIN
8DC0	;	1.93	;	Rat Betaglycan Zona Pellucida Domain (ZPC) in complex with mini monomer TGFb2 (mmTGF-b2-7M2R)
1E3S	;	2.0	;	Rat brain 3-hydroxyacyl-CoA dehydrogenase binary complex with NADH
1E3W	;	2.0	;	Rat brain 3-hydroxyacyl-CoA dehydrogenase binary complex with NADH and 3-keto butyrate
1E6W	;	1.7	;	Rat brain 3-hydroxyacyl-CoA dehydrogenase binary complex with NADH and estradiol
1BG3	;	2.8	;	RAT BRAIN HEXOKINASE TYPE I COMPLEX WITH GLUCOSE AND INHIBITOR GLUCOSE-6-PHOSPHATE
8F4Q	;	2.151	;	rat branched chain ketoacid dehydrogenase kinase in complex with inhibtors
8F6P	;	3.2	;	Rat Cardiac Sodium Channel with Ranolazine Bound
5LQA	;	1.2	;	rat catechol O-methyltransferase at high pH in complex with a bisubstrate inhibitor
5P9W	;	1.43	;	rat catechol O-methyltransferase in complex with 4'-fluoro-4,5-dihydroxy-N-{[(1R,2R)-2-{(2S,4R,5R)-4-hydroxy-5-[6-(methylamino)-9H-purin-9-yl]oxolan-2-yl}cyclopropyl]methyl}[1,1'-biphenyl]-3-carboxamide
5P98	;	1.2	;	rat catechol O-methyltransferase in complex with 5-(4-fluorophenyl)-2,3-dihydroxy-N-(2-hydroxyethyl)benzamide at 1.20A
5P9D	;	1.42	;	rat catechol O-methyltransferase in complex with 5-(4-fluorophenyl)-2,3-dihydroxy-N-(5-imidazol-1-ylpentyl)benzamide at 1.42A
5P9C	;	1.7	;	rat catechol O-methyltransferase in complex with 5-(4-fluorophenyl)-2,3-dihydroxy-N-(5-pyrrolo[3,2-c]pyridin-1-ylpentyl)benzamide at 1.70A
5P97	;	1.3	;	rat catechol O-methyltransferase in complex with 5-(4-fluorophenyl)-2,3-dihydroxy-N-[(1-methylimidazol-4-yl)methyl]benzamide at 1.30A
3OZT	;	1.48	;	Rat catechol O-methyltransferase in complex with a catechol-type, 4-oxo-pyridinyl-containing inhibitor - humanized form
3OZR	;	1.73	;	Rat catechol O-methyltransferase in complex with a catechol-type, bisubstrate inhibitor, no substituent in the adenine site - humanized form
3HVI	;	1.2	;	Rat catechol O-methyltransferase in complex with a catechol-type, N6-ethyladenine-containing bisubstrate inhibitor
3HVH	;	1.3	;	Rat catechol O-methyltransferase in complex with a catechol-type, N6-methyladenine-containing bisubstrate inhibitor
3HVJ	;	1.79	;	Rat catechol O-methyltransferase in complex with a catechol-type, N6-propyladenine-containing bisubstrate inhibitor
3HVK	;	1.3	;	Rat catechol O-methyltransferase in complex with a catechol-type, purine-containing bisubstrate inhibitor - humanized form
3OE4	;	1.49	;	Rat catechol O-methyltransferase in complex with a catechol-type, purine-containing bisubstrate inhibitor - humanized form
3OE5	;	1.52	;	Rat catechol O-methyltransferase in complex with a catechol-type, pyridylsulfanyl-containing inhibitor - humanized form
3OZS	;	1.44	;	Rat catechol O-methyltransferase in complex with a catechol-type, trifluoromethyl-imidazolyl-containing inhibitor - humanized form
5P9E	;	1.5	;	rat catechol O-methyltransferase in complex with N-[2-(5-benzyl-1H-1,2,4-triazol-3-yl)ethyl]-5-(4-fluorophenyl)-2,3-dihydroxybenzamide at 1.50A
5P99	;	1.2	;	rat catechol O-methyltransferase in complex with N-[2-[2-(3,4-dihydroxyphenyl)-2-oxoethyl]sulfanylethyl]-5-(4-fluorophenyl)-2,3-dihydroxybenzamide at 1.20A
5P9A	;	1.91	;	rat catechol O-methyltransferase in complex with N-[2-[2-(6-aminopurin-9-yl)ethoxy]ethyl]-5-(4-fluorophenyl)-2,3-dihydroxybenzamide at 1.91A
5P9B	;	1.45	;	rat catechol O-methyltransferase in complex with N-[2-[[5-(4-fluorophenyl)-2,3-dihydroxybenzoyl]amino]ethyl]-6-hydroxypyrimidine-4-carboxamide at 1.45A
5P96	;	1.4	;	rat catechol O-methyltransferase in complex with N-[5-(2-aminopurin-9-yl)pentyl]-5-(4-fluorophenyl)-2,3-dihydroxybenzamide at 1.40A
5P95	;	1.3	;	rat catechol O-methyltransferase in complex with N-[5-(6-aminopurin-9-yl)pentyl]-5-(4-fluorophenyl)-2,3-dihydroxybenzamide at 1.30A
5PA1	;	1.24	;	rat catechol O-methyltransferase in complex with SAH and 6-(4-fluorophenyl)quinolin-8-ol
3R6T	;	1.2	;	Rat catechol o-methyltransferase in complex with the bisubstrate inhibitor 4'-fluoro-4,5-dihydroxy-biphenyl-3-carboxylic acid {(E)-3-[(2S,4R,5R)-4-hydroxy-5-(6-methyl-purin-9-yl)-tetrahydro-furan-2-yl]-allyl}-amide
5N0K	;	2.3	;	Rat ceruloplasmin orthorhombic form
5N4L	;	3.2	;	Rat ceruloplasmin trigonal form
3NWB	;	1.3	;	Rat COMT in complex with a fluorinated desoxyribose-containing bisubstrate inhibitor avoids hydroxyl group
3NWE	;	1.5	;	Rat COMT in complex with a methylated desoxyribose bisubstrate-containing inhibitor avoids hydroxyl group
3NW9	;	1.65	;	Rat COMT in complex with a methylpurin-containing bisubstrate inhibitor
6GY1	;	2.1	;	rat COMT in complex with inhibitor
3S68	;	1.85	;	Rat COMT in complex with SAM and Tolcapone at 1.85A, P3221, Rfree=22.0
4P7K	;	1.22	;	Rat COMT in complex with sinefungin
5URG	;	2.3	;	rat CYPOR D632F mutant
4Y9R	;	2.4	;	rat CYPOR mutant - G141del
4Y7C	;	2.2	;	rat CYPOR mutant - G141del/E142N
4Y9U	;	1.95	;	rat CYPOR mutant - G143del
4YAF	;	1.91	;	rat CYPOR with 2'-AMP
5URI	;	2.7	;	Rat CYPOR/D632A with 2'-AMP
4KWL	;	1.63	;	Rat cysteine dioxygenase with 3-mercaptopropionic acid persulfide bound
4KWK	;	1.95	;	Rat cysteine dioxygenase with cysteine persulfide bound to active site iron
2QEY	;	1.9	;	Rat cytosolic PEPCK in complex with GTP
2QF2	;	1.65	;	Rat cytosolic PEPCK in complex with oxaloacetic acid and GDP.
2QF1	;	1.8	;	Rat cytosolic PEPCK in complex with oxaloacetic acid.
2QEW	;	1.8	;	Rat cytosolic PEPCK, in complex with manganese ion.
1UUM	;	2.3	;	Rat dihydroorotate dehydrogenase (DHOD)in complex with atovaquone
1UUO	;	2.44	;	Rat dihydroorotate dehydrogenase (DHOD)in complex with brequinar
4ORI	;	1.5	;	Rat dihydroorotate dehydrogenase bound with DSM338 (N-[3,5-difluoro-4-(trifluoromethyl)phenyl]-5-methyl-2-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine)
2GBF	;	3.1	;	rat dpp-IV with alkynyl cyanopyrrolidine #1
2GBG	;	3.0	;	rat DPP-IV with alkynyl cyanopyrrolidine #2
2GBI	;	3.3	;	rat DPP-IV with xanthine inhibitor 4
2I3Z	;	2.9	;	rat DPP-IV with xanthine mimetic inhibitor #7
2C08	;	2.9	;	Rat endophilin A1 BAR domain
6OT6	;	1.65	;	Rat ERK2 D319N
6OTS	;	2.1	;	Rat ERK2 E320K
1B5A	;		;	RAT FERROCYTOCHROME B5 A CONFORMATION, NMR, 1 STRUCTURE
1B5B	;		;	RAT FERROCYTOCHROME B5 B CONFORMATION, NMR, 1 STRUCTURE
5JPG	;	1.9	;	Rat Galectin 5 with lactose
3M2M	;	2.95	;	Rat galectin-1 complex with lactose
6KSS	;	8.1	;	Rat GluD1 receptor(compact conformation) in complex with 7-CKA and Calcium ions
6KSP	;	8.1	;	Rat GluD1 receptor(splayed conformation) in complex with 7-CKA and Calcium ions
4YBQ	;	3.27	;	Rat GLUT5 with Fv in the outward-open form
1EV9	;	2.2	;	RAT GLUTATHIONE S-TRANSFERASE A1-1 MUTANT W21F WITH GSO3 BOUND
1EV4	;	2.2	;	RAT GLUTATHIONE S-TRANSFERASE A1-1: MUTANT W21F/F220Y WITH GSO3 BOUND
1FI8	;	2.2	;	RAT GRANZYME B [N66Q] COMPLEXED TO ECOTIN [81-84 IEPD]
4G99	;	2.3	;	Rat Heme Oxygenase-1 in complex with Heme and CO at 100 K after warming to 160 K
4G98	;	2.3	;	Rat Heme Oxygenase-1 in complex with Heme and CO at 100K
4G7P	;	1.9	;	Rat Heme Oxygenase-1 in complex with Heme and CO with 1 hr Illumination at 100 K: Laser off
4G7T	;	1.9	;	Rat Heme Oxygenase-1 in complex with Heme and CO with 1 hr Illumination: Laser on
4G7U	;	1.9	;	Rat Heme Oxygenase-1 in complex with Heme and CO with 16 hr Illumination: Laser off
4G8P	;	1.9	;	Rat Heme Oxygenase-1 in complex with Heme and CO with 16 hr Illumination: Laser on
4G8U	;	2.1	;	Rat Heme Oxygenase-1 in complex with Heme and O2 with 13 hr illumination: Laser off
4G8W	;	2.4	;	Rat Heme Oxygenase-1 in complex with Heme and O2 with 13 hr illumination: Laser on
7OST	;	1.4	;	Rat HIP1R ANTH domain
6N69	;	2.0	;	rat hPGDS complexed with a quinoline
3P7L	;	2.0776	;	Rat Insulin Degrading Enzyme (Insulysin)
3P7O	;	2.1423	;	Rat Insulin Degrading Enzyme (Insulysin) E111F mutant with two bound peptides
6LU9	;	8.8	;	Rat ionotropic Glutamate Delta-2 receptor in complex with 7-CKA and Calcium
7UZG	;	3.7	;	Rat Kidney V-ATPase lacking subunit H, with SidK and NCOA7B, State 1
7UZI	;	3.9	;	Rat Kidney V-ATPase lacking subunit H, with SidK and NCOA7B, State 2
7UZF	;	3.8	;	Rat Kidney V-ATPase with SidK, State 1
7UZH	;	3.8	;	Rat Kidney V-ATPase with SidK, State 2
7UZK	;	3.0	;	Rat Kidney V1 complex lacking subunit H with SidK and NCOA7B, State 1
7UZJ	;	3.3	;	Rat Kidney V1 complex with SidK and NCOA7B, State 1
8I5M	;	2.85	;	Rat Kir4.1 in complex with PIP2
8I5N	;	2.85	;	Rat Kir4.1 in complex with PIP2 and Lys05
4AJI	;	1.93	;	rat LDHA in complex with 2-((3,4-dimethoxyphenyl)methyl))propanedioic acid
4AJJ	;	1.75	;	rat LDHA in complex with 2-((3,4-dimethoxyphenyl)methyl))propanedioic acid and N-(2-methyl-1,3-benzothiazol-6-yl)-3-ureido-propanamide
4AJN	;	2.1	;	rat LDHA in complex with 2-((4-(2-((3-((2-methyl-1,3-benzothiazol-6- yl)amino)-3-oxo-propyl)carbamoylamino)ethyl)phenyl)methyl) propanedioic acid
4AL4	;	1.78	;	rat LDHA in complex with 2-((4-(2-((3-((2-methyl-1,3-benzothiazol-6- yl)amino)3-oxo-propyl)carbamoylamino)ethoxy)phenyl)methylpropanedioic acid
4AJO	;	1.96	;	rat LDHA in complex with 2-((4-(4-((3-((2-methyl-1,3-benzothiazol-6yl) amino)-3-oxo-propyl)amino)-4-oxo-butyl)phenyl)methyl)propanedioic acid
4AJE	;	2.35	;	rat LDHA in complex with 2-(4-bromophenoxy)propanedioic acid
4AJL	;	1.77	;	rat LDHA in complex with 3-(ethylcarbamoylamino)-N-(2-methyl-1,3- benzothiazol-6-yl)propanamide
4AJ4	;	1.9	;	rat LDHA in complex with 4-((2-allylsulfanyl-1,3-benzothizol-6-yl) amino)-4-oxo-butanoic acid
4AJ2	;	1.75	;	rat LDHA in complex with 5-(2-chlorophenyl)-1H-tetrazole
4AJ1	;	1.87	;	rat LDHA in complex with N-(2-(methylamino)-1,3-benzothiazol-6-yl) acetamide
4AJK	;	2.03	;	rat LDHA in complex with N-(2-(methylamino)-1,3-benzothiazol-6-yl) acetamide
4AJH	;	1.93	;	rat LDHA in complex with N-(2-methyl-1,3-benzothiazol-6-yl)-3-ureido- propanamide and 2-(4-bromophenoxy)propanedioic acid
1MAB	;	2.8	;	RAT LIVER F1-ATPASE
2F43	;	3.0	;	Rat liver F1-ATPase
1PWE	;	2.8	;	Rat Liver L-Serine Dehydratase Apo Enzyme
1PWH	;	2.6	;	Rat Liver L-Serine Dehydratase- Complex with PYRIDOXYL-(O-METHYL-SERINE)-5-MONOPHOSPHATE
1B3R	;	2.8	;	RAT LIVER S-ADENOSYLHOMOCYSTEIN HYDROLASE
1KWT	;	1.95	;	Rat mannose binding protein A (native, MPD)
1KWV	;	2.0	;	Rat mannose binding protein A complexed with a-Me-GlcNAc
1KWU	;	1.95	;	Rat mannose binding protein A complexed with a-Me-Man
1KX0	;	2.0	;	Rat mannose protein A (H189V I207V) complexed with man-a13-man
1KWZ	;	1.9	;	Rat mannose protein A (H189V) complexed with Man-a13-Man
1KWW	;	1.9	;	Rat mannose protein A complexed with a-Me-Fuc.
1KWX	;	2.0	;	Rat mannose protein A complexed with b-Me-Fuc.
1KWY	;	2.0	;	Rat mannose protein A complexed with man-a13-man.
1KX1	;	2.8	;	Rat mannose protein A complexed with Man6-GlcNAc2-Asn
3RL3	;	1.42	;	Rat metallophosphodiesterase MPPED2
3RL4	;	1.29	;	Rat metallophosphodiesterase MPPED2 G252H Mutant
3RL5	;	1.26	;	Rat metallophosphodiesterase MPPED2 H67R Mutant
1ZVI	;	2.0	;	Rat Neuronal Nitric Oxide Synthase Oxygenase Domain
1ZVL	;	2.5	;	Rat Neuronal Nitric Oxide Synthase Oxygenase Domain complexed with natural substrate L-Arg.
1QW6	;	2.1	;	Rat neuronal nitric oxide synthase oxygenase domain in complex with N-omega-propyl-L-Arg.
1QWC	;	2.3	;	Rat neuronal nitric oxide synthase oxygenase domain in complex with W1400 inhibitor.
1P6K	;	1.78	;	Rat neuronal NOS D597N mutant heme domain with L-N(omega)-nitroarginine-2,4-L-diaminobutyric amide bound
1P6I	;	1.9	;	Rat neuronal NOS heme domain with (4S)-N-(4-amino-5-[aminoethyl]aminopentyl)-N'-nitroguanidine bound
1RS6	;	1.95	;	Rat neuronal NOS heme domain with D-lysine-D-nitroarginine amide bound
1RS7	;	1.95	;	Rat neuronal NOS heme domain with D-phenylalanine-D-nitroarginine amide bound
1P6J	;	2.0	;	Rat neuronal NOS heme domain with L-N(omega)-nitroarginine-(4R)-amino-L-proline amide bound
1P6H	;	1.98	;	Rat neuronal NOS heme domain with L-N(omega)-nitroarginine-2,4-L-diaminobutyric amide bound
1M00	;	2.05	;	Rat neuronal NOS heme domain with N-butyl-N'-hydroxyguanidine bound
1LZZ	;	2.05	;	Rat neuronal NOS heme domain with N-isopropyl-N'-hydroxyguanidine bound
1LZX	;	2.0	;	Rat neuronal NOS heme domain with NG-hydroxy-L-arginine bound
1MMV	;	2.0	;	Rat neuronal NOS heme domain with NG-propyl-L-arginine bound
1MMW	;	2.0	;	Rat neuronal NOS heme domain with vinyl-L-NIO bound
1ZZQ	;	1.9	;	Rat nNOS D597N mutant with L-N(omega)-Nitroarginine-(4R)-amino-L-proline amide bound
1ZZR	;	2.05	;	Rat nNOS D597N/M336V double mutant with L-N(omega)-Nitroarginine-(4R)-amino-L-proline amide bound
1ZZU	;	1.9	;	Rat nNOS D597N/M336V double mutant with L-N(omega)-Nitroarginine-2,4-L-Diaminobutyric Amide Bound
2HX3	;	2.0	;	Rat nNOS heme domain complexed with (4S)-N-{4-Amino-5-[(2-aminoethyl)-hydroxyamino]-pentyl}-N'-nitroguanidine
2HX4	;	2.15	;	Rat nNOS heme domain complexed with 4-N-(Nw-nitro-L-argininyl)-trans-4-hydroxyamino-L-proline amide
4BR0	;	2.05	;	rat NTPDase2 in complex with Ca AMPNP
4BR2	;	2.0	;	rat NTPDase2 in complex with Ca UMPPNP
4BQZ	;	2.05	;	Rat NTPDase2 in complex with Mg GMPPNP
4BR5	;	1.75	;	Rat NTPDase2 in complex with Zn AMPPNP
1QKN	;	2.25	;	RAT OESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH ANTAGONIST RALOXIFENE
1HJ1	;	2.3	;	RAT OESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH PURE ANTIOESTROGEN ICI164,384
1AWP	;	2.0	;	RAT OUTER MITOCHONDRIAL MEMBRANE CYTOCHROME B5
1B5M	;	2.7	;	RAT OUTER MITOCHONDRIAL MEMBRANE CYTOCHROME B5
1EUE	;	1.8	;	RAT OUTER MITOCHONDRIAL MEMBRANE CYTOCHROME B5
1ICC	;	2.0	;	RAT OUTER MITOCHONDRIAL MEMBRANE CYTOCHROME B5
1BU8	;	1.8	;	RAT PANCREATIC LIPASE RELATED PROTEIN 2
2IQY	;	1.4	;	Rat Phosphatidylethanolamine-Binding Protein
2IQX	;	2.2	;	Rat Phosphatidylethanolamine-Binding Protein Containing the S153E Mutation in the Complex with o-Phosphorylethanolamine
2A1L	;	2.18	;	Rat PITP-Beta Complexed to Phosphatidylcholine
3RDJ	;	1.9	;	Rat PKC C2 domain Apo
4L1L	;	1.6	;	Rat PKC C2 domain bound to CD
3TWY	;	1.5	;	RAT PKC C2 DOMAIN BOUND TO PB
2O8G	;	2.5	;	Rat pp1c gamma complexed with mouse inhibitor-2
2O8A	;	2.61	;	rat PP1cgamma complexed with mouse inhibitor-2
4JA9	;	2.3	;	Rat PP5 apo
4JA7	;	2.0	;	Rat PP5 co-crystallized with P5SA-2
5EUS	;	1.833	;	Rat prestin STAS domain in complex with bromide
5EUU	;	1.87	;	Rat prestin STAS domain in complex with chloride
5EUZ	;	2.403	;	Rat prestin STAS domain in complex with iodide
5EUW	;	1.81	;	Rat prestin STAS domain in complex with nitrate
5EUX	;	2.038	;	Rat prestin STAS domain in complex with thiocyanate
1MIR	;	2.8	;	RAT PROCATHEPSIN B
1SA5	;	2.6	;	Rat protein farnesyltransferase complexed with FPP and BMS-214662
8E9E	;	2.844	;	Rat protein farnesyltransferase in complex with FPP and inhibitor 2f
1TNY	;	2.7	;	Rat Protein Geranylgeranyltransferase Type-I Complexed with a GGPP analog and a FREKKFFCAIL Peptide Derived from the Heterotrimeric G Protein Gamma-2 Subunit
1TNU	;	2.7	;	Rat Protein Geranylgeranyltransferase Type-I Complexed with a GGPP analog and a GCINCCKVL Peptide Derived from RhoB
1TNO	;	2.7	;	Rat Protein Geranylgeranyltransferase Type-I Complexed with a GGPP analog and a KKKSKTKCVIM Peptide Derived from K-Ras4B
1TNZ	;	2.9	;	Rat Protein Geranylgeranyltransferase Type-I Complexed with a GGPP analog and a RRCVLL Peptide Derived from Cdc42 splice isoform-2
1TNB	;	2.85	;	Rat Protein Geranylgeranyltransferase Type-I Complexed with a GGPP analog and a substrate KKSKTKCVIF Peptide Derived from TC21
1S64	;	2.55	;	Rat protein geranylgeranyltransferase type-I complexed with L-778,123 and a sulfate anion
6J6U	;	3.32	;	Rat PTPRZ D1-D2 domain
7Y4O	;	3.0	;	Rat Semaphorin 6D extracellular region
2YJZ	;	2.2	;	Rat STEAP4 oxidoreductase domain complexed with NADP
1TON	;	1.8	;	RAT SUBMAXILLARY GLAND SERINE PROTEASE, TONIN. STRUCTURE SOLUTION AND REFINEMENT AT 1.8 ANGSTROMS RESOLUTION
1W16	;	2.3	;	rat synaptotagmin 4 C2B domain in the absence of calcium
1W15	;	1.93	;	rat synaptotagmin 4 C2B domain in the presence of calcium
1GKE	;	2.5	;	RAT TRANSTHYRETIN
1KGJ	;	2.3	;	Rat transthyretin (also called prealbumin) complex with 3',5'-dibromoflavone (EMD21388)
1KGI	;	1.8	;	Rat transthyretin (also called prealbumin) complex with 3,3',5,5'-tetraiodothyroacetic acid (t4ac)
1IE4	;	2.5	;	RAT TRANSTHYRETIN COMPLEX WITH THYROXINE (T4)
8SLX	;	3.23	;	Rat TRPV2 bound with 1 CBD ligand in nanodiscs
8SLY	;	3.32	;	Rat TRPV2 bound with 2 CBD ligands in nanodiscs
8EKS	;	3.1	;	rat TRPV2 in nanodiscs in the presence of weak acid at pH 5
1F7Z	;	1.55	;	RAT TRYPSINOGEN K15A COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR
1F5R	;	1.65	;	RAT TRYPSINOGEN MUTANT COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR
1AB8	;	2.2	;	RAT TYPE II ADENYLYL CYCLASE C2 DOMAIN/FORSKOLIN COMPLEX
4V2B	;	2.0	;	rat Unc5D Ig domain 1
7T3O	;	3.3	;	Rat vesicular glutamate transporter 2 (VGLUT2) in low Cl condition
6AJU	;	1.94	;	Rat Xanthine oxidoreductase
4YRW	;	1.99	;	rat xanthine oxidoreductase, C-terminal deletion protein variant
4YTZ	;	2.3	;	Rat xanthine oxidoreductase, C-terminal deletion protein variant, crystal grown without dithiothreitol
6A7X	;	2.15	;	Rat Xanthine oxidoreductase, D428A variant, NAD bound form
6AD4	;	1.8	;	Rat Xanthine oxidoreductase, D428A variant, NADH bound form
6ADJ	;	2.18	;	Rat Xanthine oxidoreductase, D428E variant
6AC4	;	2.19	;	Rat Xanthine oxidoreductase, D428N variant
6ABU	;	1.77	;	Rat Xanthine oxidoreductase, NAD bound form
6AC1	;	1.77	;	Rat Xanthine oxidoreductase, NADH bound form
6LFE	;	1.6	;	Rat-COMT, Nitecapone,SAM and Mg bond
7XJB	;	2.6	;	Rat-COMT, opicapone,SAM and Mg bond
4KJD	;	2.21	;	RatIntestinal AP expressed in E. coli
2J5C	;	1.95	;	Rational conversion of substrate and product specificity in a monoterpene synthase. Structural insights into the molecular basis of rapid evolution.
4F5J	;	1.954	;	Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.
4F5G	;	1.67	;	Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.
3U6A	;	2.199	;	Rational Design and Synthesis of Aminopiperazinones as Beta Secretase (BACE) Inhibitors
1T6W	;		;	RATIONAL DESIGN OF A CALCIUM-BINDING ADHESION PROTEIN NMR, 20 STRUCTURES
8ADT	;	1.4	;	Rational design of a calcium-independent trypsin variant
1USB	;	2.07	;	Rational design of a novel enzyme - efficient thioester hydrolysis enabled by the incorporation of a single His residue into human glutathione transferase A1-1
3K9Z	;	1.72	;	Rational Design of a Structural and Functional Nitric Oxide Reductase
4R6B	;	2.0	;	Rational Design of Enhanced Photoresistance in a Photoswitchable Fluorescent Protein
3T8M	;	2.5	;	Rational Design of PI3K-alpha Inhibitors that Exhibit Selectivity Over the PI3K-beta Isoform
1HVR	;	1.8	;	RATIONAL DESIGN OF POTENT, BIOAVAILABLE, NONPEPTIDE CYCLIC UREAS AS HIV PROTEASE INHIBITORS
1HPS	;	2.3	;	RATIONAL DESIGN, SYNTHESIS AND CRYSTALLOGRAPHIC ANALYSIS OF A HYDROXYETHYLENE-BASED HIV-1 PROTEASE INHIBITOR CONTAINING A HETEROCYCLIC P1'-P2' AMIDE BOND ISOSTERE
3GJE	;	2.3	;	Rational development of high-affinity T-cell receptor-like antibodies
3GJF	;	1.9	;	Rational development of high-affinity T-cell receptor-like antibodies
3HAE	;	2.9	;	Rational development of high-affinity T-cell receptor-like antibodies
6A9O	;	2.5	;	Rational discovery of a SOD1 tryptophan oxidation inhibitor with therapeutic potential for amyotrophic lateral sclerosis
6WS0	;	2.24	;	Rational drug design of phenazopyridine derivatives as novel inhibitors of Rev1-CT
6WS5	;	2.472	;	Rational drug design of phenazopyridine derivatives as novel inhibitors of Rev1-CT
5A25	;	1.9	;	Rational engineering of a mesophilic carbonic anhydrase to an extreme halotolerant biocatalyst
6DI4	;	1.9	;	Rational Modification of Vanillin Derivatives to Stereospecifically Destabilize Sickle Hemoglobin Polymer Formation
2GX6	;	1.97	;	Rational stabilization of E. coli ribose binding protein
7UVJ	;	1.99	;	Rationally Designed ED1 Epitope-Scaffold Immunogen for SARS-CoV-2
8HU2	;	1.6	;	Rattus Syntenin-1 PDZ domain with inhibitor
8WKL	;	2.67	;	Rauvolfia serpentina strictosidine synthase (RsSTR) in complex with a non-reactive tryptamine substitute crystallized in P1211 space group
3VF0	;	2.54	;	Raver1 in complex with metavinculin L954 deletion mutant
5KS2	;	2.18	;	RAWV_CTD (Helix form) of 16S/23S 2'-O-methyltransferase TlyA
5KYG	;	1.9	;	RAWV_CTD (Loop Structure) of 16S/23S 2'-O-methyltransferase TlyA
1GUX	;	1.85	;	RB POCKET BOUND TO E7 LXCXE MOTIF
2HFE	;	2.25	;	Rb+ complex of a K channel with an amide to ester substitution in the selectivity filter
6JXJ	;	2.5	;	Rb+-bound E2-AlF state of the gastric proton pump (Tyr799Trp)
6JXI	;	2.6	;	Rb+-bound E2-MgF state of the gastric proton pump (Tyr799Trp)
6JXK	;	4.3	;	Rb+-bound E2-MgF state of the gastric proton pump (Wild-type)
7NNP	;	3.2	;	Rb-loaded cryo-EM structure of the E1-ATP KdpFABC complex.
3QER	;	1.96	;	RB69 DNA Polymerase (L561A/S565G/Y567A) Ternary Complex with dATP Opposite Difluorotoluene Nucleoside
3SNN	;	2.0	;	RB69 DNA Polymerase (L561A/S565G/Y567A) Ternary Complex with dCTP Opposite dG in the presence of Mg2+
3QEI	;	2.178	;	RB69 DNA Polymerase (L561A/S565G/Y567A) Ternary Complex with dCTP Opposite Difluorotoluene Nucleoside
3QEV	;	1.77	;	RB69 DNA Polymerase (L561A/S565G/Y567A) Ternary Complex with dCTP Opposite dT
3QEW	;	1.84	;	RB69 DNA Polymerase (L561A/S565G/Y567A) Ternary Complex with dDTP Opposite dT
3QES	;	1.98	;	RB69 DNA Polymerase (L561A/S565G/Y567A) Ternary Complex with dGTP Opposite Difluorotoluene Nucleoside
3QEX	;	1.73	;	RB69 DNA Polymerase (L561A/S565G/Y567A) Ternary Complex with dGTP Opposite dT
3QEP	;	1.8	;	RB69 DNA Polymerase (L561A/S565G/Y567A) Ternary Complex with dTTP Opposite Difluorotoluene Nucleoside
3QET	;	2.08	;	RB69 DNA Polymerase (L561A/S565G/Y567A) Ternary Complex with dTTP Opposite dT
3NE6	;	2.001	;	RB69 DNA Polymerase (S565G/Y567A) Ternary Complex with dCTP Opposite dG
3NHG	;	2.5	;	RB69 DNA Polymerase (S565G/Y567A) Ternary Complex with dTTP Opposite dG
3QNO	;	1.88	;	RB69 DNA Polymerase (Y567A) Ternary Complex with dATP Opposite 3tCo
3LZI	;	2.3	;	RB69 DNA Polymerase (Y567A) ternary complex with dATP Opposite 7,8-dihydro-8-oxoguanine
3RWU	;	2.33	;	RB69 DNA Polymerase (Y567A) Ternary Complex with dATP Opposite Difluorotoluene Nucleoside
3NAE	;	2.003	;	RB69 DNA Polymerase (Y567A) Ternary Complex with dATP Opposite Guanidinohydantoin
3SUQ	;	3.15	;	RB69 DNA Polymerase (Y567A) Ternary Complex with dCTP Opposite 2AP (AT rich sequence)
3SUP	;	2.32	;	RB69 DNA Polymerase (Y567A) Ternary Complex with dCTP Opposite 2AP (GC rich sequence)
3LZJ	;	2.05	;	RB69 DNA Polymerase (Y567A) ternary complex with dCTP Opposite 7,8-Dihydro-8-oxoguanine
3NDK	;	2.0	;	RB69 DNA Polymerase (Y567A) Ternary Complex with dCTP Opposite dG
3QNN	;	1.92	;	RB69 DNA Polymerase (Y567A) Ternary Complex with dGT Opposite 3tCo
3SUN	;	2.42	;	RB69 DNA Polymerase (Y567A) Ternary Complex with dTTP Opposite 2AP (AT rich sequence)
3SUO	;	2.23	;	RB69 DNA Polymerase (Y567A) Ternary Complex with dTTP Opposite 2AP (GC rich sequence)
3NGI	;	1.886	;	RB69 DNA Polymerase (Y567A) Ternary Complex with dTTP Opposite dG
4J2A	;	1.8	;	RB69 DNA Polymerase L415A Ternary Complex
4J2B	;	2.04	;	RB69 DNA Polymerase L415G Ternary Complex
4J2D	;	1.76	;	RB69 DNA Polymerase L415K Ternary Complex
4J2E	;	2.02	;	RB69 DNA Polymerase L415M Ternary Complex
3UIQ	;	1.879	;	RB69 DNA Polymerase Ternary Complex containing dUpNpp
4DTN	;	1.96	;	RB69 DNA Polymerase Ternary Complex with dATP Opposite an Abasic Site and ddA/dT as the Penultimate Base-pair
4DTR	;	2.04	;	RB69 DNA Polymerase Ternary Complex with dATP Opposite an Abasic Site and ddC/dG as the Penultimate Base-pair
4DU1	;	2.15	;	RB69 DNA Polymerase Ternary Complex with dATP Opposite dT
4DU4	;	2.28	;	RB69 DNA Polymerase Ternary Complex with dATP Opposite dT with 3-Deaza-adenine at the N-3 Position of Primer Strand
4FJK	;	2.0	;	RB69 DNA polymerase ternary complex with dATP/dA
4FJG	;	2.02	;	RB69 DNA polymerase ternary complex with dATP/dC
4FJX	;	2.11	;	RB69 DNA polymerase ternary complex with dATP/dG
4FJ5	;	2.05	;	RB69 DNA polymerase ternary complex with dATP/dT
4DTO	;	2.05	;	RB69 DNA Polymerase Ternary Complex with dCTP Opposite an Abasic Site and ddA/dT as the Penultimate Base-pair
4DTS	;	1.96	;	RB69 DNA Polymerase Ternary Complex with dCTP Opposite an Abasic Site and ddC/dG as the Penultimate Base-pair
4DTM	;	1.95	;	RB69 DNA Polymerase Ternary Complex with dCTP Opposite an Abasic Site and ddG/dC as the Penultimate Base-pair
3NCI	;	1.79	;	RB69 DNA Polymerase Ternary Complex with dCTP Opposite dG at 1.8 angstrom resolution
4FJM	;	2.02	;	RB69 DNA polymerase ternary complex with dCTP/dA
4FJI	;	2.2	;	RB69 DNA polymerase ternary complex with dcTP/dC
4FK0	;	2.18	;	RB69 DNA polymerase ternary complex with dCTP/dG
4FJ8	;	2.19	;	RB69 DNA polymerase ternary complex with dCTP/dT
4DU3	;	2.02	;	RB69 DNA Polymerase Ternary Complex with dDTP Opposite dT with 3-Deaza-adenine at the N-1 Position of Template Strand
4M3Y	;	1.86	;	RB69 DNA polymerase ternary complex with dG/dT at position n-1 of primer/template duplex
4M3Z	;	1.84	;	RB69 DNA polymerase ternary complex with dG/dT at position n-2 of primer/tempLate duplex
4M41	;	2.15	;	RB69 DNA polymerase ternary complex with dG/dT at position n-3 of primer/tempLate duplex
4M42	;	2.04	;	RB69 DNA polymerase ternary complex with dG/dT at position n-4 of primer/tempLate duplex
4M45	;	1.89	;	RB69 DNA polymerase ternary complex with dG/dT at position n-5 of primer/template duplex
4DTP	;	2.05	;	RB69 DNA Polymerase Ternary Complex with dGTP Opposite an Abasic Site and ddA/dT as the Penultimate Base-pair
4DTU	;	1.86	;	RB69 DNA Polymerase Ternary Complex with dGTP Opposite an Abasic Site and ddC/dG as the Penultimate Base-pair
4FJL	;	1.87	;	RB69 DNA polymerase ternary complex with dGTP/dA
4FJH	;	2.11	;	RB69 DNA polymerase ternary complex with dGTP/dC
4FK4	;	1.9	;	RB69 DNA polymerase ternary complex with dGTP/dG
4FJ7	;	1.9	;	RB69 DNA polymerase ternary complex with dGTP/dT
4E3S	;	2.04	;	RB69 DNA Polymerase Ternary Complex with dQTP Opposite dT
4M3R	;	2.07	;	RB69 DNA polymerase ternary complex with dT/dG at position n-1 of primer/template duplex
4M3T	;	1.9	;	RB69 DNA polymerase ternary complex with dT/dG at position n-2 of primer/template duplex
4M3U	;	2.07	;	RB69 DNA polymerase ternary complex with dT/dG at position n-3 of primer/template duplex
4M3W	;	2.1	;	RB69 DNA polymerase ternary complex with dT/dG at position n-4 of primer/template duplex
4M3X	;	2.2	;	RB69 DNA polymerase ternary complex with dT/dG at position n-5 of primer/template duplex
3SQ2	;	2.1	;	RB69 DNA Polymerase Ternary Complex with dTTP Opposite 2AP (AT rich sequence)
3SQ4	;	2.23	;	RB69 DNA Polymerase Ternary Complex with dTTP Opposite 2AP (GC rich sequence)
4DTX	;	1.84	;	RB69 DNA Polymerase Ternary Complex with dTTP Opposite an Abasic Site and ddC/dG as the Penultimate Base-pair
4DTJ	;	1.9	;	RB69 DNA Polymerase Ternary Complex with dTTP Opposite an Abasic Site and ddT/dA as the Penultimate Base-pair
4FJN	;	1.98	;	RB69 DNA polymerase ternary complex with dTTP/dA
4FJJ	;	1.99	;	RB69 DNA polymerase ternary complex with dTTP/dC
4FK2	;	1.98	;	RB69 DNA polymerase ternary complex with dTTP/dG
4FJ9	;	1.97	;	RB69 DNA polymerase ternary complex with dTTP/dT
3SQ1	;	1.82	;	RB69 DNA Polymerase Ternary Complex with dUpCpp Opposite dA
3SI6	;	1.85	;	RB69 DNA Polymerase Triple Mutant (L561A/S565G/Y567A) Ternary Complex with dUpNpp and a Deoxy-terminated Primer in the presence of Mg2+
3SJJ	;	2.38	;	RB69 DNA Polymerase Triple Mutant (L561A/S565G/Y567A) Ternary Complex with dUpNpp and a Deoxy-terminated Primer in the presence of Mn2+
3SCX	;	2.35	;	RB69 DNA Polymerase Triple Mutant(L561A/S565G/Y567A) Ternary Complex with dUpNpp and a Deoxy-terminated Primer in the Presence of Ca2+
3S9H	;	1.95	;	RB69 DNA Polymerase Triple Mutant(L561A/S565G/Y567A) ternary complex with dUpNpp and a dideoxy-terminated primer in the presence of Ca2+
3SPY	;	2.14	;	RB69 DNA Polymerase(L415A/L561A/S565G/Y567A) Ternary Complex with dUpCpp Opposite dA
2A1K	;	2.0	;	RB69 single-stranded DNA binding protein core domain
2ATQ	;	3.2	;	RB69 single-stranded DNA binding protein-DNA polymerase fusion
7VOY	;	4.2	;	Rba sphaeroides PufX-KO RC-LH1
7VA9	;	3.08	;	Rba sphaeroides PufY-KO RC-LH1 dimer type-1
7VB9	;	3.45	;	Rba sphaeroides PufY-KO RC-LH1 dimer type-2
7VNM	;	2.86	;	Rba sphaeroides PufY-KO RC-LH1 monomer
7VNY	;	2.79	;	Rba sphaeroides WT RC-LH1 monomer
6ZZ3	;	2.095	;	RBcel1 cellulase variant Y201F with cellotriose covalently bound
6MR1	;	1.35	;	RbcS-like subdomain of CcmM
2PY8	;	2.45	;	RbcX
7PV5	;	1.6	;	RBD domain of D. melanogaster tRNA (uracil-5-)-methyltransferase homolog A (TRMT2A)
7NKT	;	2.3	;	RBD domain of SARS-CoV2 in complex with neutralizing nanobody NM1226
7B27	;	2.902	;	RBD domain SARS-CoV2 in complex with neutralizing nanobody NM1230
7XXL	;	7.3	;	RBD in complex with Fab14
2RGF	;		;	RBD OF RAL GUANOSINE-NUCLEOTIDE EXCHANGE FACTOR (PROTEIN), NMR, 10 STRUCTURES
8CYJ	;	3.6	;	RBD of SARS-CoV-2 Spike protein in complex with pan-sarbecovirus nanobodies 2-10, 2-67, 2-62 and 1-25
8JJE	;	3.4	;	RBD of SARS-CoV2 spike protein with ACE2 decoy
7WCR	;	3.5	;	RBD-1 of SARS-CoV-2 Beta spike in complex with S5D2 Fab
7V27	;	4.18	;	RBD/XG005 local refinement
6PPK	;	4.4	;	RbgA+45SRbgA complex
1QSD	;	2.2	;	RBL2P, BETA-TUBULIN BINDING POST-CHAPERONIN COFACTOR
5ZSW	;		;	RBM10-RRM2 domain and its lung cancer related mutant
5ZSY	;		;	RBM10-RRM2 domain and its lung cancer related mutant
5MFY	;		;	RBM5 OCRE domain
2M9K	;		;	RBPMS2-Nter
2LGV	;		;	Rbx1
6Z5S	;	2.65	;	RC-LH1(14)-W complex from Rhodopseudomonas palustris
6Z5R	;	2.8	;	RC-LH1(16) complex from Rhodopseudomonas palustris
4V9G	;	7.78	;	RC-LH1-PufX dimer complex from Rhodobacter sphaeroides
8ASL	;	3.15	;	RCII/PSI complex, class 2
8AM5	;	3.1	;	RCII/PSI complex, class 3
8ASP	;	2.9	;	RCII/PSI complex, focused refinement of PSI
4YS2	;	1.968	;	RCK domain with CDA
7B5U	;	1.2	;	RCK_C domain dimer of S.agalactiae BusR in complex with c-di-AMP
7B5W	;	1.0	;	RCK_C domain of S.agalactiae BusR in ligand-free state
8ODN	;	2.7	;	RcpA-TadD with C13 symmetry from the Pseudomonas aeruginosa Tight Adherence Secretion System
6T7F	;	2.58	;	RCR E3 ligase E2-Ubiquitin transthiolation intermediate
5E9D	;	2.51	;	RD-1 Mart-1 High bound to Mart-1 decameric peptide (ELA) in complex with HLA-A2
6W3G	;	1.62	;	Rd1NTF2_04 with long sheet
6W3D	;	1.38	;	Rd1NTF2_05 with long sheet
6W3F	;	1.83	;	Rd1NTF2_05_I64F_A80G_T94P_D101K_L106W
7EIK	;	1.7	;	RD4-BD1 in complex with LT-872-297
2KYD	;		;	RDC and RCSA refinement of an A-form RNA: Improvements in Major Groove Width
2KRO	;		;	RDC refined high resolution structure of the third SH3 domain of CD2AP
2MEY	;		;	RDC refined solution structure of Blo t 5.
2LUP	;		;	RDC refined solution structure of double-stranded RNA binding domain of S. cerevisiae RNase III (rnt1p) in complex with the terminal RNA hairpin of snr47 precursor
1XXE	;		;	RDC refined solution structure of the AaLpxC/TU-514 complex
2KRM	;		;	RDC refined solution structure of the first SH3 domain of CD2AP
6URP	;		;	RDC refined solution structure of the insecticidal toxin Ta1a
2L1G	;		;	RDC refined solution structure of the THAP zinc finger of THAP1 in complex with its 16bp RRM1 DNA target
1RO4	;		;	RDC-derived models of the zinc ribbon domain of human general transcription factor TFIIB (zinc free structures)
1RLY	;		;	RDC-derived models of the zinc ribbon domain of human general transcription TFIIB (zinc bound structures)
8CH7	;		;	RDC-refined Interleukin-4 (wild type) pH 5.6
1NTI	;		;	RDC-refined NMR structure of bovine Acyl-coenzyme A Binding Protein, ACBP
1NVL	;		;	RDC-refined NMR structure of bovine Acyl-coenzyme A Binding Protein, ACBP, in complex with palmitoyl-coenzyme A
1YJJ	;		;	RDC-refined Solution NMR structure of oxidized putidaredoxin
6NS8	;		;	RDC-refined SOLUTION NMR STRUCTURE OF PROTEIN PF2048.1
1YJI	;		;	RDC-refined Solution NMR structure of reduced putidaredoxin
2RO3	;		;	RDC-refined Solution Structure of the N-terminal DNA Recognition Domain of the Bacillus subtilis Transition-state Regulator Abh
2RO4	;		;	RDC-refined Solution Structure of the N-terminal DNA Recognition Domain of the Bacillus subtilis Transition-state Regulator AbrB
2RO5	;		;	RDC-refined solution structure of the N-terminal DNA recognition domain of the Bacillus subtilis transition-state regulator SpoVT
7ACZ	;	3.5	;	RdeltaD2 H/L (LMW SLP/HMW SLP) complex from C. difficile SlpA (R20291 strain)
6D0O	;	2.3	;	rdpA dioxygenase holoenzyme
6K32	;	3.2	;	RdRp complex
4MTP	;	3.65	;	RdRp from Japanesese Encephalitis Virus
5HMV	;	0.98	;	Re refinement of 4mwk.
5I5Q	;	1.42	;	Re refinement of 4mwn.
1I53	;	1.8	;	RE(I)-TRICARBONYL DIIMINE (Q107H)) AZURIN
1HYT	;	1.7	;	RE-DETERMINATION AND REFINEMENT OF THE COMPLEX OF BENZYLSUCCINIC ACID WITH THERMOLYSIN AND ITS RELATION TO THE COMPLEX WITH CARBOXYPEPTIDASE A
2DJG	;	2.05	;	Re-determination of the native structure of human dipeptidyl peptidase I (cathepsin C)
7P75	;	1.23	;	Re-engineered 2-deoxy-D-ribose-5-phosphate aldolase catalysing asymmetric Michael addition reactions in substrate-free state
7P76	;	1.9	;	Re-engineered 2-deoxy-D-ribose-5-phosphate aldolase catalysing asymmetric Michael addition reactions, Schiff base complex with cinnamaldehyde
1YO7	;	2.8	;	Re-engineering topology of the homodimeric ROP protein into a single-chain 4-helix bundle
1ZLZ	;	1.55	;	Re-Evaluation of the Low-Temperature Azide in Mn-Dependent Superoxide Dismutase
6W1I	;	1.8	;	Re-interpretation of ppGpp (G4P) electron density in the deposited crystal structure of Xanthine phosphoribosyltransferase (XPRT) (1Y0B).
3QGZ	;	1.1	;	Re-investigated high resolution crystal structure of histidine triad nucleotide-binding protein 1 (HINT1) from rabbit complexed with adenosine
4RR0	;	3.054	;	re-refined 1vcw, CRYSTAL STRUCTURE OF DEGS AFTER BACKSOAKING THE ACTIVATING PEPTIDE
3OU0	;	3.0	;	re-refined 3CS0
5UWB	;	2.604	;	Re-refined 4FCZ: lipid-bound crystal structure of toluene-tolerance protein from Pseudomonas putida
3SYU	;	1.95	;	Re-refined coordinates for pdb entry 1det - ribonuclease T1 carboxymethylated at GLU 58 in complex with 2'GMP
3QL3	;	1.8	;	Re-refined coordinates for PDB entry 1RX2
6TW2	;	1.8	;	Re-refined crystal structure of di-phosphorylated human CLK1 in complex with a novel substituted indole inhibitor
7K17	;	4.3	;	Re-refined crystal structure of DNA-dependent protein kinase catalytic subunit complexed with Ku80 C-terminal helix
4R1F	;	2.51	;	Re-refined Human DNA topoisomerase IIa (ATPase and transducer domains) in complex with ADP and SO4
8E0G	;	2.1	;	Re-refined model of active mu-opioid receptor (PDB 5c1m) as an adduct with BU72
4RQY	;	2.204	;	RE-REFINED STRUCTURE OF 1TE0 - STRUCTURAL ANALYSIS of DEGS, A STRESS SENSOR OF THE BACTERIAL PERIPLASM
7Q3V	;	1.9	;	Re-refined structure of a type III antifreeze protein isoform HPLC 12
6JML	;	2.3	;	Re-refined structure of R-state L-lactate dehydrogenase fromLactobacillus casei
5LYE	;	1.9	;	Re-refined structure of the bacteriophage T4 short tail fibre PDB entry 1H6W containing 71 additionally identified residues
3ZGO	;	1.63	;	Re-refined structure of the human Sirt2 apoform
4RQZ	;	2.4	;	re-refinement of 1soz, Crystal Structure of DegS protease in complex with an activating peptide
5L3H	;	1.7	;	Re-refinement of 4dd4; cisplatin coordination chemistry determination at hen egg white lysozyme His15 with standard uncertainties
5L3I	;	1.7	;	Re-refinement of 4dd6; cisplatin coordination chemistry determination at hen egg white lysozyme His15
5HLL	;	1.7	;	Re-refinement of 4g4a: room-temperature X-ray diffraction study of cisplatin and its binding to His15 of HEWL after 14 months chemical exposure in the presence of DMSO.
5HMJ	;	1.2999	;	Re-refinement of 4xan: hen lysozyme with carboplatin in sodium bromide solution
6QE4	;	2.3	;	Re-refinement of 5OLI human IBA57-I3C
6QE3	;	1.75	;	Re-refinement of 6ESR human IBA57 at 1.75 A resolution
4G1M	;	2.9	;	Re-refinement of alpha V beta 3 structure
4NX4	;	1.5	;	Re-refinement of CAP-1 HIV-CA complex
8EGK	;	1.98	;	Re-refinement of Crystal Structure of NosGet3d, the All4481 protein from Nostoc sp. PCC 7120
5V2C	;	1.9	;	RE-REFINEMENT OF CRYSTAL STRUCTURE OF PHOTOSYSTEM II COMPLEX
7Y44	;	1.9	;	Re-refinement of damage free X-ray structure of bovine cytochrome c oxidase at 1.9 angstrom resolution
4RR1	;	2.3	;	re-refinement of entry 1sot, Crystal Structure of the DegS stress sensor
2VDK	;	2.8	;	Re-refinement of Integrin AlphaIIbBeta3 Headpiece
2VDL	;	2.75	;	Re-refinement of Integrin AlphaIIbBeta3 Headpiece
2VDN	;	2.9	;	Re-refinement of Integrin AlphaIIbBeta3 Headpiece Bound to Antagonist Eptifibatide
2VC2	;	3.1	;	Re-refinement of Integrin AlphaIIbBeta3 Headpiece Bound to Antagonist L-739758
2VDM	;	2.9	;	Re-refinement of Integrin AlphaIIbBeta3 Headpiece Bound to Antagonist Tirofiban
5ES4	;	3.3	;	RE-REFINEMENT OF INTEGRIN ALPHAXBETA2 ECTODOMAIN IN THE CLOSED/BENT CONFORMATION
7NRY	;	3.8	;	Re-refinement of MAPKAP kinase-2/inhibitor complex 3fyj
2V4D	;	3.2	;	Re-refinement of MexA adaptor protein
7NRB	;	1.9	;	Re-refinement of MK3-inhibitor complex
6DSQ	;	2.7	;	Re-refinement of P. falciparum orotidine 5'-monophosphate decarboxylase
6DSR	;	2.597	;	Re-refinement of P. falciparum orotidine 5'-monophosphate decarboxylase
6DSS	;	2.599	;	Re-refinement of P. falciparum orotidine 5'-monophosphate decarboxylase
3V56	;	3.0	;	Re-refinement of PDB entry 1OSG - Complex between BAFF and a BR3 derived peptide presented in a beta-hairpin scaffold - reveals an additonal copy of the peptide.
4E1B	;	1.8	;	Re-refinement of PDB entry 2EQA - SUA5 protein from Sulfolobus tokodaii with bound threonylcarbamoyladenylate
3URP	;	3.19	;	Re-refinement of PDB entry 5RNT - ribonuclease T1 with guanosine-3',5'-diphosphate and phosphate ion bound
7F8T	;	1.5	;	Re-refinement of the 2XRY X-ray structure of archaeal class II CPD photolyase from Methanosarcina mazei
9BNA	;	1.9	;	RE-REFINEMENT OF THE B-DODECAMER D(CGCGAATTCGCG) WITH A COMPARATIVE ANALYSIS OF THE SOLVENT IN IT AND IN THE Z-HEXAMER D(5BRCG5BRCG5BRCG)
3PUK	;	3.054	;	Re-refinement of the crystal structure of Munc18-3 and Syntaxin4 N-peptide complex
5E6V	;	1.8	;	Re-refinement of the Crystal Structure of the Plexin-Semaphorin-Integrin Domain/Hybrid Domain/I-EGF1 Segment from the Human Integrin b2 Subunit
5E6W	;	2.2	;	Re-refinement of the Crystal Structure of the Plexin-Semaphorin-Integrin Domain/Hybrid Domain/I-EGF1 Segment from the Human Integrin b2 Subunit
5E6X	;	1.75	;	Re-refinement of the Crystal Structure of the Plexin-Semaphorin-Integrin Domain/Hybrid Domain/I-EGF1 Segment from the Human Integrin b2 Subunit
6EYC	;	3.8	;	Re-refinement of the MCM2-7 double hexamer using ISOLDE
5VEH	;	1.55	;	Re-refinement OF THE PDB STRUCTURE 1yiz of Aedes aegypti kynurenine aminotransferase
5W5E	;	3.5	;	Re-refinement of the pyocin tube structure
1IZ7	;	1.58	;	Re-refinement of the structure of hydrolytic haloalkane dehalogenase linb from sphingomonas paucimobilis UT26 AT 1.6 A resolution
1IZ8	;	2.0	;	Re-refinement of the structure of hydrolytic haloalkane dehalogenase linb from sphingomonas paucimobilis UT26 with 1,3-propanediol, a product of debromidation of dibrompropane, at 2.0A resolution
4HL8	;	3.5	;	Re-refinement of the vault ribonucleoprotein particle
5TMF	;	3.0	;	Re-refinement of thermus thermophilus RNA polymerase
5TMC	;	2.71	;	Re-refinement of Thermus thermopiles DNA-directed RNA polymerase structure
3F9Q	;	1.9	;	Re-refinement of uncomplexed plasmepsin II from Plasmodium falciparum.
4XHQ	;	1.948	;	Re-refinement the crystal structure of Dscam1 isoform 1.34, N-terminal four Ig domains
2JYJ	;		;	Re-refining the tetraloop-receptor RNA-RNA complex using NMR-derived restraints and Xplor-nih (2.18)
6I27	;	7.8	;	Rea1 AAA2L-H2alpha deletion mutant in AMPPNP State
6HYP	;	4.4	;	Rea1 Wild type ADP state (AAA+ ring part)
6HYD	;	3.9	;	Rea1 Wild type ADP state (tail part)
6I26	;	4.3	;	Rea1 Wild type AMPPNP state
2HG3	;	2.7	;	Reaction centre from Rhodobacter sphaeroides strain R-26.1 complexed with brominated phosphatidylcholine
2HH1	;	2.55	;	Reaction centre from Rhodobacter sphaeroides strain R-26.1 complexed with dibrominated phosphatidylcholine
2HIT	;	2.75	;	Reaction centre from Rhodobacter sphaeroides strain R-26.1 complexed with dibrominated phosphatidylethanolamine
2HHK	;	2.5	;	Reaction centre from Rhodobacter sphaeroides strain R-26.1 complexed with dibrominated phosphatidylglycerol
2HJ6	;	3.0	;	Reaction centre from Rhodobacter sphaeroides strain R-26.1 complexed with dibrominated phosphatidylserine
2HG9	;	2.45	;	Reaction centre from Rhodobacter sphaeroides strain R-26.1 complexed with tetrabrominated phosphatidylcholine
6ET5	;	2.87	;	Reaction centre light harvesting complex 1 from Blc. virids
4GST	;	1.9	;	REACTION COORDINATE MOTION IN AN SNAR REACTION CATALYZED BY GLUTATHIONE TRANSFERASE
5GST	;	2.0	;	REACTION COORDINATE MOTION IN AN SNAR REACTION CATALYZED BY GLUTATHIONE TRANSFERASE
2F5V	;	1.41	;	Reaction geometry and thermostability mutant of pyranose 2-oxidase from the white-rot fungus Peniophora sp.
2F6C	;	1.84	;	Reaction geometry and thermostability of pyranose 2-oxidase from the white-rot fungus Peniophora sp., Thermostability mutant E542K
1S4S	;	1.9	;	Reaction Intermediate in the Photocycle of PYP, intermediate occupied between 100 micro-seconds to 5 milli-seconds
3AEP	;	2.28	;	Reaction intermediate structure of Entamoeba histolytica methionine gamma-lyase 1 containing alpha-amino-alpha, beta-butenoic acid-pyridoxal-5'-phosphate
3AEO	;	2.15	;	Reaction intermediate structure of Entamoeba histolytica methionine gamma-lyase 1 containing methionine alpha, beta-enamine-pyridoxamine-5'-phosphate
3AEL	;	2.0	;	Reaction intermediate structure of Entamoeba histolytica methionine gamma-lyase 1 containing methionine imine-pyridoxamine-5'-phosphate and alpha-amino-alpha, beta-butenoic acid-pyridoxal-5'-phosphate
3AEN	;	2.0	;	Reaction intermediate structure of Entamoeba histolytica methionine gamma-lyase 1 containing Michaelis complex and alpha-amino-alpha, beta-butenoic acid-pyridoxal-5'-phosphate
3AEM	;	2.2	;	Reaction intermediate structure of Entamoeba histolytica methionine gamma-lyase 1 containing Michaelis complex and methionine imine-pyridoxamine-5'-phosphate
3AEJ	;	2.59	;	Reaction intermediate structure of Entamoeba histolytica methionine gamma-lyase 1 tetramer containing Michaelis complex and methionine-pyridoxal-5'-phosphate
1ALK	;	2.0	;	REACTION MECHANISM OF ALKALINE PHOSPHATASE BASED ON CRYSTAL STRUCTURES. TWO METAL ION CATALYSIS
5D2C	;	2.06	;	Reaction of phosphorylated CheY with imidazole 1 of 3
5DGC	;	1.94	;	Reaction of phosphorylated CheY with imidazole 2 of 3
5DKF	;	1.94	;	Reaction of phosphorylated CheY with imidazole 3 of 3
8EST	;	1.78	;	REACTION OF PORCINE PANCREATIC ELASTASE WITH 7-SUBSTITUTED 3-ALKOXY-4-CHLOROISOCOUMARINS: DESIGN OF POTENT INHIBITORS USING THE CRYSTAL STRUCTURE OF THE COMPLEX FORMED WITH 4-CHLORO-3-ETHOXY-7-GUANIDINO-ISOCOUMARIN
3C6B	;	2.17	;	Reaction product of paraoxon and S-formylglutathione hydrolase W197I mutant
4TKU	;	1.43	;	Reactivated Nitrogenase MoFe-protein from A. vinelandii
6EUC	;	2.21999	;	Reactivating oxime bound to Tc AChE's catalytic gorge.
8QBC	;	1.23	;	Reactive amide intermediate in sperm whale myoglobin mutant H64V V68A
6EE5	;	2.48	;	Reactive centre loop dynamics and serpin specificity
4C49	;	2.7	;	Reactive loop cleaved human CBG in complex with cortisol
1PI2	;	2.5	;	REACTIVE SITES OF AN ANTICARCINOGENIC BOWMAN-BIRK PROTEINASE INHIBITOR ARE SIMILAR TO OTHER TRYPSIN INHIBITORS
1WCI	;	1.84	;	Reactivity modulation of human branched-chain alpha-ketoacid dehydrogenase by an internal molecular switch
2BEU	;	1.89	;	Reactivity modulation of human branched-chain alpha-ketoacid dehydrogenase by an internal molecular switch
2BEV	;	1.8	;	Reactivity modulation of human branched-chain alpha-ketoacid dehydrogenase by an internal molecular switch
2BEW	;	1.79	;	Reactivity modulation of human branched-chain alpha-ketoacid dehydrogenase by an internal molecular switch
2BFB	;	1.77	;	Reactivity modulation of human branched-chain alpha-ketoacid dehydrogenase by an internal molecular switch
2BFC	;	1.64	;	Reactivity modulation of human branched-chain alpha-ketoacid dehydrogenase by an internal molecular switch
2BFD	;	1.39	;	Reactivity modulation of human branched-chain alpha-ketoacid dehydrogenase by an internal molecular switch
2BFE	;	1.69	;	Reactivity modulation of human branched-chain alpha-ketoacid dehydrogenase by an internal molecular switch
2BFF	;	1.46	;	Reactivity modulation of human branched-chain alpha-ketoacid dehydrogenase by an internal molecular switch
4V47	;	12.3	;	Real space refined coordinates of the 30S and 50S subunits fitted into the low resolution cryo-EM map of the EF-G.GTP state of E. coli 70S ribosome
4V48	;	11.5	;	Real space refined coordinates of the 30S and 50S subunits fitted into the low resolution cryo-EM map of the initiation-like state of E. coli 70S ribosome
7JR5	;	2.4	;	Real Time Reaction Intermediates in Stigmatella Bacteriophytochrome P2
1LYZ	;	2.0	;	Real-space refinement of the structure of hen egg-white lysozyme
2LYZ	;	2.0	;	Real-space refinement of the structure of hen egg-white lysozyme
3LYZ	;	2.0	;	Real-space refinement of the structure of hen egg-white lysozyme
4LYZ	;	2.0	;	Real-space refinement of the structure of hen egg-white lysozyme
5LYZ	;	2.0	;	Real-space refinement of the structure of hen egg-white lysozyme
6LYZ	;	2.0	;	Real-space refinement of the structure of hen egg-white lysozyme
2XFG	;	1.679	;	Reassembly and co-crystallization of a family 9 processive endoglucanase from separately expressed GH9 and CBM3c modules
7JU0	;	2.602	;	RebH Variant 0S, Tryptamine 7-halogenase with bound tryptamine
6P2V	;	2.553	;	RebH Variant 10S, Tryptamine 5-halogenase
6P00	;	2.249	;	RebH Variant 8F, Tryptamine 6-halogenase
2OAL	;	2.1	;	RebH with bound FAD
2E4G	;	2.08	;	RebH with bound L-Trp
5MJV	;	3.09	;	Rebuild and re-refined model for Human Parechovirus 1
6H86	;	1.901	;	Rebuilt and re-refined PDB entry 4R3Q: Crystal structure of SYCE3
7AER	;	3.0	;	Rebuilt and re-refined PDB entry 5yep: tri-AMPylated Shewanella oneidensis HEPN toxin in complex with MNT antitoxin
1B80	;	1.73	;	REC. LIGNIN PEROXIDASE H8 OXIDATIVELY PROCESSED
8SCA	;	1.67	;	Rec3 Domain from S. pyogenes Cas9
2REC	;		;	RECA HEXAMER MODEL, ELECTRON MICROSCOPY
5I0A	;	1.5	;	RecA mini intein in complex with cisplatin
5K08	;	1.401	;	RecA mini intein-Zeise's salt complex
1EW1	;		;	RECA PROTEIN-BOUND SINGLE-STRANDED DNA
1MO3	;	3.1	;	RECA-ADP COMPLEX
1G18	;	3.8	;	RECA-ADP-ALF4 COMPLEX
1MO4	;	3.2	;	RECA-ATP-GAMMA-S COMPLEX
1MO5	;	3.25	;	RECA-ATP-GAMMA-S-MG COMPLEX
1MO6	;	3.2	;	RECA-DATP-MG COMPLEX
8B1R	;	3.2	;	RecBCD in complex with the phage protein gp5.9
8B1T	;	3.4	;	RecBCD-DNA in complex with the phage protein Abc2
8B1U	;	3.8	;	RecBCD-DNA in complex with the phage protein Abc2 and host PpiB
1W36	;	3.1	;	RecBCD:DNA complex
2GKG	;	1.0	;	Receiver domain from Myxococcus xanthus social motility protein FrzS
2I6F	;	1.9	;	Receiver domain from Myxococcus xanthus social motility protein FrzS
2NT4	;	1.02	;	Receiver domain from Myxococcus xanthus social motility protein FrzS (H92F mutant)
2NT3	;	1.3	;	Receiver domain from Myxococcus xanthus social motility protein FrzS (Y102A Mutant)
7L9C	;	1.85	;	Receiver Domain of RssB
7LCM	;	1.91	;	Receiver Domain of RssB bound to beryllofluoride
5WQ0	;	2.604	;	Receiver domain of Spo0A from Paenisporosarcina sp. TG-14
1LRE	;		;	RECEPTOR ASSOCIATED PROTEIN (RAP) DOMAIN 1, NMR, 20 STRUCTURES
1NRE	;		;	RECEPTOR ASSOCIATED PROTEIN (RAP) DOMAIN 1, NMR, MINIMIZED AVERAGE STRUCTURE
4ZS6	;	3.166	;	Receptor binding domain and Fab complex
5VID	;	2.75	;	Receptor binding domain of BoNT/B in complex with mini-protein binder Bot.0671.2
5VMR	;	1.95	;	Receptor binding domain of BoNT/B in complex with mini-protein binder Bot.2110.4
5JLV	;	2.0	;	Receptor binding domain of Botulinum neurotoxin A in complex with human glycosylated SV2C
5JMC	;	2.64	;	Receptor binding domain of Botulinum neurotoxin A in complex with rat SV2C
1AYO	;	1.9	;	RECEPTOR BINDING DOMAIN OF BOVINE ALPHA-2-MACROGLOBULIN
6THB	;	2.78	;	Receptor binding domain of the Cedar Virus attachment glycoprotein (G)
1HIT	;		;	Receptor binding redefined by a structural switch in a mutant Human Insulin
1BV8	;		;	RECEPTOR DOMAIN FROM ALPHA-2-MACROGLOBULIN
2MOV	;		;	Receptor for Advanced Glycation End Products (RAGE) Specifically Recognizes Methylglyoxal Derived AGEs.
6XQ3	;	1.71	;	Receptor for Advanced Glycation End Products VC1 domain in complex with 3-(3-(((3-(4-Carboxyphenoxy)benzyl)oxy)methyl)phenyl)-1H-indole-2-carboxylic acid
7LML	;	2.15	;	Receptor for Advanced Glycation End Products VC1 domain in complex with 3-(3-(((3-(4-Carboxyphenoxy)benzyl)oxy)methyl)phenyl)-1H-indole-2-carboxylic acid
6XQ1	;	1.51	;	Receptor for Advanced Glycation End Products VC1 domain in complex with 3-(3-((4-(4-carboxyphenoxy)benzyl)oxy)phenyl)-1H-indole-2-carboxylic acid
7LMW	;	2.5	;	Receptor for Advanced Glycation End Products VC1 domain in complex with 3-(3-((4-(4-carboxyphenoxy)benzyl)oxy)phenyl)-1H-indole-2-carboxylic acid
6XQ5	;	1.8	;	Receptor for Advanced Glycation End Products VC1 domain in complex with Fragment 1
6XQ6	;	1.9	;	Receptor for Advanced Glycation End Products VC1 domain in complex with Fragment 11
6XQ7	;	1.8	;	Receptor for Advanced Glycation End Products VC1 domain in complex with Fragment 5
6XQ8	;	1.82	;	Receptor for Advanced Glycation End Products VC1 domain in complex with Fragments 1 & 11
6XQ9	;	2.3	;	Receptor for Advanced Glycation End Products VC1 domain in complex with Fragments 1 & 13
5LS2	;	2.3	;	Receptor mediated chitin perception in legumes is functionally seperable from Nod factor perception
1YFO	;	2.25	;	RECEPTOR PROTEIN TYROSINE PHOSPHATASE ALPHA, DOMAIN 1 FROM MOUSE
8DVC	;	2.638	;	Receptor ShHTL5 from Striga hermonthica in complex with strigolactone agonist GR24
7P8I	;	4.5	;	Receptor-binding domain (RBD) of the spike protein of the bat coronavirus RaTG13 virus in complex with the extracellular domain of human angiotensin-converting enzyme 2 (ACE2) - Crystal form 1
7P8J	;	6.585	;	Receptor-binding domain (RBD) of the spike protein of the bat coronavirus RaTG13 virus in complex with the extracellular domain of human angiotensin-converting enzyme 2 (ACE2) - Crystal form 2
1LCS	;	2.5	;	RECEPTOR-BINDING DOMAIN FROM SUBGROUP B FELINE LEUKEMIA VIRUS
6H1X	;	1.7	;	Receptor-binding domain of Proteus mirabilis Uroepithelial Cell Adhesin UcaD21-211
6H2L	;	1.5	;	Receptor-binding domain of Proteus mirabilis Uroepithelial Cell Adhesin UcaD21-217
7QLR	;	2.462	;	Receptor-binding protein of Clostridium difficile phage CDHS-1
1GEA	;		;	RECEPTOR-BOUND CONFORMATION OF PACAP21
6H3E	;		;	Receptor-bound Ghrelin conformation
5VZ4	;	2.2	;	Receptor-growth factor crystal structure at 2.20 Angstrom resolution
3OL2	;	2.99	;	Receptor-ligand structure of Human Semaphorin 4D with Plexin B1.
7YOQ	;	2.265	;	Recj2 and CMP complex from Methanocaldococcus jannaschii
7YOR	;	2.53	;	Recj2 and dCMP complex from Methanocaldococcus jannaschii
7YOS	;	2.17	;	Recj2 and Mn complex from Methanocaldococcus jannaschii
2RPF	;		;	RecO-bound ssDNA
4ILL	;	2.484	;	Recognition and Cleavage of a non-structured CRISPR RNA by its Processing Endoribonuclease Cas6
4ILR	;	3.088	;	Recognition and Cleavage of a non-structured CRISPR RNA by its Processing Endoribonuclease Cas6
6SEH	;	3.15	;	Recognition and processing of branched DNA substrates by Slx1-Slx4 nuclease
6SEI	;	2.69	;	Recognition and processing of branched DNA substrates by Slx1-Slx4 nuclease
5KP0	;		;	Recognition and targeting mechanisms by chaperones in flagella assembly and operation
5KRW	;		;	Recognition and targeting mechanisms by chaperones in flagella assembly and operation
5KS6	;		;	Recognition and targeting mechanisms by chaperones in flagella assembly and operation
1BGS	;	2.6	;	RECOGNITION BETWEEN A BACTERIAL RIBONUCLEASE, BARNASE, AND ITS NATURAL INHIBITOR, BARSTAR
1AN2	;	2.9	;	RECOGNITION BY MAX OF ITS COGNATE DNA THROUGH A DIMERIC B/HLH/Z DOMAIN
2MND	;		;	Recognition complex of DNA d(CGACGCGTCG)2 with thiazotropsin B
2MNE	;		;	Recognition complex of DNA d(CGACTAGTCG)2 with thiazotropsin analogue AIK-18/51
2K39	;		;	Recognition dynamics up to microseconds revealed from RDC derived ubiquitin ensemble in solution
1MFE	;	2.0	;	RECOGNITION OF A CELL-SURFACE OLIGO-SACCHARIDE OF PATHOGENIC SALMONELLA BY AN ANTIBODY FAB FRAGMENT
2OR1	;	2.5	;	RECOGNITION OF A DNA OPERATOR BY THE REPRESSOR OF PHAGE 434. A VIEW AT HIGH RESOLUTION
3O9W	;	2.8	;	Recognition of a Glycolipid Antigen by the iNKT Cell TCR
3KL4	;	3.5	;	Recognition of a signal peptide by the signal recognition particle
2WH0	;	2.25	;	Recognition of an intrachain tandem 14-3-3 binding site within protein kinase C epsilon
3FDQ	;	1.75	;	Recognition of AT-rich DNA binding sites by the MogR Repressor
6Q6R	;	1.5	;	Recognition of different base tetrads by RHAU: X-ray crystal structure of G4 recognition motif bound to the 3-end tetrad of a DNA G-quadruplex
1LJ2	;	2.38	;	Recognition of eIF4G by Rotavirus NSP3 reveals a basis for mRNA circularization
3O8X	;	2.74	;	Recognition of Glycolipid Antigen by iNKT Cell TCR
2KX5	;		;	Recognition of HIV TAR RNA by peptide mimetic of Tat protein
6MWR	;	3.3	;	Recognition of MHC-like molecule
1ZB5	;	2.45	;	Recognition of peptide ligands by signalling protein from porcine mammary gland (SPP-40): Crystal structure of the complex of SPP-40 with a peptide Trp-Pro-Trp at 2.45A resolution
3NFN	;	2.392	;	Recognition of peptide-MHC by a V-delta/V-beta TCR
1ZBK	;	2.9	;	Recognition of specific peptide sequences by signalling protein from sheep mammary gland (SPS-40): Crystal structure of the complex of SPS-40 with a peptide Trp-Pro-Trp at 2.9A resolution
7QXD	;	1.649	;	Recognition of Staphylococcus aureus wall teichoic acid analogue SA475 (compound 2) by Fab4497
7QXC	;	1.452	;	Recognition of Staphylococcus aureus wall teichoic acid analogue SA533 (compound 1) by Fab4461
7QXE	;	1.84	;	Recognition of Staphylococcus aureus wall teichoic acid analogue TB87 (compound 3) by Fab4497
4V7P	;	3.62	;	Recognition of the amber stop codon by release factor RF1.
6IYC	;	2.6	;	Recognition of the Amyloid Precursor Protein by Human gamma-secretase
4K5U	;	1.698	;	Recognition of the BG-H Antigen by a Lamprey Variable Lymphocyte Receptor
3QIS	;	2.3	;	Recognition of the F&H motif by the Lowe Syndrome protein OCRL
3QSY	;	3.2	;	Recognition of the methionylated initiator tRNA by the translation initiation factor 2 in Archaea
5J6G	;	3.3	;	Recognition of the MHC class Ib molecule H2-Q10 by the natural killer cell receptor Ly49C
5J6H	;	2.3	;	Recognition of the MHC class Ib molecule H2-Q10 by the natural killer cell receptor Ly49C
1KNZ	;	2.45	;	Recognition of the rotavirus mRNA 3' consensus by an asymmetric NSP3 homodimer
4K79	;	2.2	;	Recognition of the Thomsen-Friedenreich Antigen by a Lamprey Variable Lymphocyte Receptor
1AHQ	;	2.3	;	RECOMBINANT ACTOPHORIN
7EPP	;	2.4	;	Recombinant Alfalfa Mosaic virus coat protein virus-like particle (rAMV-CP VLP)
8VY8	;	2.4	;	Recombinant alpha bungarotoxin complexed with HAP peptide
7ULG	;	1.57	;	recombinant alpha cobra toxin
1VNS	;	1.66	;	RECOMBINANT APO-CHLOROPEROXIDASE FROM CURVULARIA INAEQUALIS
1RAV	;	2.2	;	RECOMBINANT AVIDIN
7KG4	;	3.3	;	Recombinant Beta-2-Glycoprotein I antibody recognition loop mutant
6XST	;	2.92	;	Recombinant Beta-2-Glycoprotein I with putative membrane insertion loop
1BFA	;	2.2	;	RECOMBINANT BIFUNCTIONAL HAGEMAN FACTOR/AMYLASE INHIBITOR FROM MAIZE
5HTE	;	2.4	;	Recombinant bovine beta-lactoglobulin variant L1A/I2S (sBlgB#2)
5HTD	;	2.5	;	Recombinant bovine beta-lactoglobulin variant L1A/I2S with endogenous ligand (sBlgB#1)
5K06	;	2.5	;	Recombinant bovine beta-lactoglobulin with uncleaved N-terminal methionine (rBlgB)
5KN1	;	2.137	;	Recombinant bovine skeletal calsequestrin, high-Ca2+ form
5KN3	;	1.849	;	Recombinant bovine skeletal calsequestrin, low-Ca2+ form
3FUC	;	1.45	;	Recombinant calf purine nucleoside phosphorylase in a binary complex with multisubstrate analogue inhibitor 9-(5',5'-difluoro-5'-phosphonopentyl)-9-deazaguanine structure in a new space group with one full trimer in the asymmetric unit
1CKI	;	2.3	;	RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
1MIT	;		;	RECOMBINANT CUCURBITA MAXIMA TRYPSIN INHIBITOR V (RCMTI-V) (NMR, MINIMIZED AVERAGE STRUCTURE)
1RMH	;	2.4	;	RECOMBINANT CYCLOPHILIN A FROM HUMAN T CELL
5T8A	;		;	Recombinant cytotoxin-I from the venom of cobra N. oxiana
8PDZ	;	3.32	;	Recombinant Ena3A L-Type endospore appendages
3ERA	;	1.7	;	RECOMBINANT ERABUTOXIN A (S8T MUTANT)
2ERA	;	1.81	;	RECOMBINANT ERABUTOXIN A, S8G MUTANT
5AX8	;	2.989	;	Recombinant expression, purification and preliminary crystallographic studies of the mature form of human mitochondrial aspartate aminotransferase
1HMK	;	2.0	;	RECOMBINANT GOAT ALPHA-LACTALBUMIN
1FKV	;	2.0	;	RECOMBINANT GOAT ALPHA-LACTALBUMIN T29I
1FKQ	;	1.8	;	RECOMBINANT GOAT ALPHA-LACTALBUMIN T29V
7ULQ	;	2.2	;	Recombinant Hannalgesin
7EGY	;	4.201	;	Recombinant head-to-tail dimeric E2 protein
5LDU	;	2.3	;	Recombinant high-redox potential laccase from Basidiomycete Trametes hirsuta
2ZA6	;	1.75	;	recombinant horse L-chain apoferritin
2ZA7	;	1.4	;	recombinant horse L-chain apoferritin N-terminal deletion mutant (residues 1-4)
2ZA8	;	1.4	;	recombinant horse L-chain apoferritin N-terminal deletion mutant (residues 1-8)
6ATJ	;	2.0	;	RECOMBINANT HORSERADISH PEROXIDASE C COMPLEX WITH FERULIC ACID
1ATJ	;	2.15	;	RECOMBINANT HORSERADISH PEROXIDASE C1A
1GWU	;	1.31	;	RECOMBINANT HORSERADISH PEROXIDASE C1A ALA140GLY
1GWO	;	2.07	;	Recombinant horseradish peroxidase C1A ALA170GLN
7ATJ	;	1.47	;	RECOMBINANT HORSERADISH PEROXIDASE C1A COMPLEX WITH CYANIDE AND FERULIC ACID
1GWT	;	1.7	;	RECOMBINANT HORSERADISH PEROXIDASE C1A PHE221MET
1GW2	;	2.15	;	RECOMBINANT HORSERADISH PEROXIDASE C1A THR171SER IN COMPLEX WITH FERULIC ACID
2ATJ	;	2.0	;	RECOMBINANT HORSERADISH PEROXIDASE COMPLEX WITH BENZHYDROXAMIC ACID
1GX2	;	2.2	;	Recombinant horseradish peroxidase Phe209Ser complex with benzhydroxamic acid
3LII	;	3.2	;	Recombinant human acetylcholinesterase
6XTA	;	2.5	;	Recombinant human butyrylcholinesterase in complex with (2S)-N-[2-(1-benzylazepan-4-yl)ethyl]-2-(butylamino)-3-(1H-indol-3-yl)propanamide
4AB1	;	2.2	;	Recombinant Human Carboxylesterase 1 from whole Cabbage Loopers
1F13	;	2.1	;	RECOMBINANT HUMAN CELLULAR COAGULATION FACTOR XIII
1FIE	;	2.5	;	RECOMBINANT HUMAN COAGULATION FACTOR XIII
1B0L	;	2.2	;	RECOMBINANT HUMAN DIFERRIC LACTOFERRIN
1QMT	;	2.4	;	Recombinant Human Eosinophil Cationic Protein
7QU4	;	1.66	;	Recombinant Human Fetal Hemoglobin mutant - alpha subunit mutations K11E,K56E,N78D,K90E
1FIB	;	2.1	;	RECOMBINANT HUMAN GAMMA-FIBRINOGEN CARBOXYL TERMINAL FRAGMENT (RESIDUES 143-411) BOUND TO CALCIUM AT PH 6.0
3FIB	;	2.1	;	RECOMBINANT HUMAN GAMMA-FIBRINOGEN CARBOXYL TERMINAL FRAGMENT (RESIDUES 143-411) BOUND TO CALCIUM AT PH 6.0: A FURTHER REFINEMENT OF PDB ENTRY 1FIB, AND DIFFERS FROM 1FIB BY THE MODELLING OF A CIS PEPTIDE BOND BETWEEN RESIDUES K338 AND C339
2FIB	;	2.01	;	RECOMBINANT HUMAN GAMMA-FIBRINOGEN CARBOXYL TERMINAL FRAGMENT (RESIDUES 143-411) COMPLEXED TO THE PEPTIDE GLY-PRO-ARG-PRO AT PH 6.0
7AS4	;	4.13	;	Recombinant human gTuRC
2CLU	;	2.1	;	Recombinant human H ferritin, K86Q and E107D mutant
2CN6	;	2.2	;	Recombinant human H ferritin, K86Q and E107D mutant, soaked with Zn ions
2CHI	;	1.6	;	Recombinant human H ferritin, K86Q and E27D mutant
2CIH	;	1.5	;	Recombinant human H ferritin, K86Q and E27D mutant, soaked with Zn
2CEI	;	1.8	;	Recombinant human H ferritin, K86Q mutant, soaked with Zn
2CN7	;	1.75	;	Recombinant human H ferritin, K86Q, E27D and E107D mutant
2IU2	;	1.8	;	Recombinant human H ferritin, K86Q, E27D and E107D mutant, soaked with Zn ions
1U31	;	2.2	;	recombinant human heart transhydrogenase dIII bound with NADPH
1HKC	;	2.8	;	RECOMBINANT HUMAN HEXOKINASE TYPE I COMPLEXED WITH GLUCOSE AND PHOSPHATE
6O17	;	1.58	;	Recombinant Human Insulin
1RH2	;	2.9	;	RECOMBINANT HUMAN INTERFERON-ALPHA 2B
1WAR	;	2.22	;	Recombinant Human Purple Acid Phosphatase expressed in Pichia Pastoris
3SQJ	;	2.05	;	Recombinant human serum albumin from transgenic plant
4BKE	;	2.35	;	Recombinant human serum albumin with palmitic acid. Synthetic cationic antimicrobial peptides bind with their hydrophobic parts to drug site II of human serum albumin
1INO	;	2.2	;	RECOMBINANT INORGANIC PYROPHOSPHATASE FROM ESCHERICHIA COLI
5C5V	;	2.35	;	Recombinant Inorganic Pyrophosphatase from T brucei brucei
7ULR	;	1.8	;	recombinant kappa-bungarotoxin
1KIV	;	2.1	;	RECOMBINANT KRINGLE IV-10/M66 VARIANT OF HUMAN APOLIPOPROTEIN(A)
3KIV	;	1.8	;	RECOMBINANT KRINGLE IV-10/M66 VARIANT OF HUMAN APOLIPOPROTEIN(A)
4KIV	;	2.2	;	RECOMBINANT KRINGLE IV-10/W72R MUTANT OF HUMAN APOLIPOPROTEIN(A)
2LVE	;	2.7	;	RECOMBINANT LEN
1ZIS	;	2.9	;	Recombinant Lumazine synthase (hexagonal form)
6BP8	;	4.9	;	Recombinant major vault protein [Rattus norvegicus] structure in solution: conformation 1
6BP7	;	4.9	;	Recombinant major vault protein [Rattus norvegicus] structure in solution: conformation 2
7ULB	;	2.49	;	recombinant Mambalgin-1
3VM5	;	2.85	;	Recombinant medaka fish alpha-amylase expressed in yeast Pichia pastoris
6DST	;		;	Recombinant melittin
1H96	;	1.6	;	recombinant mouse L-chain ferritin
5LSD	;		;	recombinant mouse Nerve Growth Factor
8DTY	;	3.5	;	Recombinant mouse RyR2 triple phosphomimetic mutant S2807D/S2813D/S2030D in complex with FKBP12.6 and nanodisc under closed-state conditions
8DVV	;	3.68	;	Recombinant mouse RyR2 triple phosphomimetic mutant S2807D/S2813D/S2030D in complex with FKBP12.6 and nanodisc under open-state conditions
8DTZ	;	3.6	;	Recombinant mouse RyR2 triple phosphonull mutant S2807A/S2813A/S2030A in complex with FKBP12.6 and nanodisc under closed-state conditions
1J4B	;	2.5	;	Recombinant Mouse-Muscle Adenylosuccinate Synthetase
7ULS	;	1.8	;	Recombinant muscarinic toxin alpha
1A90	;		;	RECOMBINANT MUTANT CHICKEN EGG WHITE CYSTATIN, NMR, 31 STRUCTURES
3ZQV	;	0.84	;	RECOMBINANT NATIVE CYTOCHROME C PRIME FROM ALCALIGENES XYLOSOXIDANS AT 0.84 A RESOLUTION: NON-RESTRAINED REFINEMENT
2YKZ	;	0.84	;	RECOMBINANT NATIVE CYTOCHROME C PRIME FROM ALCALIGENES XYLOSOXIDANS AT 0.84 A RESOLUTION: RESTRAINED REFINEMENT
2YLI	;	1.45	;	RECOMBINANT NATIVE CYTOCHROME C PRIME FROM ALCALIGENES XYLOSOXIDANS IN ITS FERROUS FORM AT 1.45 A
2YLD	;	1.25	;	RECOMBINANT NATIVE CYTOCHROME C PRIME FROM ALCALIGENES XYLOSOXIDANS: CARBON MONOOXIDE BOUND AT 1.25 A
3ZWI	;	1.25	;	RECOMBINANT NATIVE CYTOCHROME C PRIME FROM ALCALIGENES XYLOSOXIDANS: CARBON MONOOXIDE BOUND AT 1.25 A:UNRESTRAINT REFINEMENT
2ETE	;	1.75	;	Recombinant oxalate oxidase in complex with glycolate
3PMS	;	1.57	;	Recombinant peptide: N-glycanase F (PNGase F)
2E9Q	;	2.2	;	Recombinant pro-11S globulin of pumpkin
4FKC	;	2.6	;	Recombinant prolidase from Thermococcus sibiricus
6RL0	;	1.78	;	Recombinant Pseudomonas stutzeri nitrous oxide reductase, form I
6RKZ	;	1.601	;	Recombinant Pseudomonas stutzeri nitrous oxide reductase, form II
1F3W	;	3.0	;	RECOMBINANT RABBIT MUSCLE PYRUVATE KINASE
3US3	;	1.738	;	Recombinant rabbit skeletal calsequestrin-MPD complex
1BC1	;	2.05	;	RECOMBINANT RAT ANNEXIN V, QUADRUPLE MUTANT (T72K, S144K, S228K, S303K)
1BCW	;	2.1	;	RECOMBINANT RAT ANNEXIN V, T72A MUTANT
1BCY	;	1.95	;	RECOMBINANT RAT ANNEXIN V, T72K MUTANT
1BCZ	;	2.2	;	RECOMBINANT RAT ANNEXIN V, T72S MUTANT
1BC3	;	1.95	;	RECOMBINANT RAT ANNEXIN V, TRIPLE MUTANT (T72K, S144K, S228K)
1BC0	;	2.0	;	RECOMBINANT RAT ANNEXIN V, W185A MUTANT
1AFS	;	2.5	;	RECOMBINANT RAT LIVER 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE (3-ALPHA-HSD) COMPLEXED WITH NADP AND TESTOSTERONE
1RNW	;	1.8	;	RECOMBINANT RIBONUCLEASE A CRYSTALLIZED FROM 80% AMMONIUM SULPHATE
1BJ4	;	2.65	;	RECOMBINANT SERINE HYDROXYMETHYLTRANSFERASE (HUMAN)
1EJI	;	2.9	;	RECOMBINANT SERINE HYDROXYMETHYLTRANSFERASE (MOUSE)
2MBW	;	1.5	;	RECOMBINANT SPERM WHALE MYOGLOBIN (MET)
1OBM	;	1.85	;	RECOMBINANT SPERM WHALE MYOGLOBIN 29F/64Q/68F/122N MUTANT (MET)
1LTW	;	1.7	;	RECOMBINANT SPERM WHALE MYOGLOBIN 29W MUTANT (OXY)
1OFK	;	1.8	;	RECOMBINANT SPERM WHALE MYOGLOBIN F43H, H64L MUTANT (MET)
1LUE	;	1.7	;	RECOMBINANT SPERM WHALE MYOGLOBIN H64D/V68A/D122N MUTANT (MET)
1O16	;	1.95	;	RECOMBINANT SPERM WHALE MYOGLOBIN H64D/V68S/D122N MUTANT (MET)
1DTI	;	1.7	;	Recombinant sperm whale myoglobin h97d, d122n mutant (met)
1CH7	;	1.9	;	RECOMBINANT SPERM WHALE MYOGLOBIN H97F MUTANT (MET)
1CH9	;	1.8	;	RECOMBINANT SPERM WHALE MYOGLOBIN H97Q MUTANT (MET)
1CH5	;	2.1	;	RECOMBINANT SPERM WHALE MYOGLOBIN H97V MUTANT (MET)
1CIK	;	1.7	;	RECOMBINANT SPERM WHALE MYOGLOBIN I99A MUTANT (MET)
1CIO	;	1.6	;	RECOMBINANT SPERM WHALE MYOGLOBIN I99V MUTANT (MET)
1J52	;	1.9	;	Recombinant sperm whale myoglobin in the presence of 7atm xenon
1CO8	;	1.8	;	RECOMBINANT SPERM WHALE MYOGLOBIN L104A MUTANT (MET)
1CP5	;	2.1	;	RECOMBINANT SPERM WHALE MYOGLOBIN L104F MUTANT (MET)
1CP0	;	2.0	;	RECOMBINANT SPERM WHALE MYOGLOBIN L104N MUTANT (MET)
1CO9	;	1.6	;	RECOMBINANT SPERM WHALE MYOGLOBIN L104V MUTANT (MET)
1CPW	;	2.2	;	RECOMBINANT SPERM WHALE MYOGLOBIN L104W MUTANT (MET)
1OFJ	;	1.8	;	RECOMBINANT SPERM WHALE MYOGLOBIN L29H/H64L/D122N MUTANT (WITH INITIATOR MET)
1CH2	;	1.8	;	RECOMBINANT SPERM WHALE MYOGLOBIN L89F MUTANT (MET)
1CH1	;	1.9	;	Recombinant sperm whale myoglobin L89G mutatnt (MET)
1CH3	;	2.0	;	RECOMBINANT SPERM WHALE MYOGLOBIN L89W MUTANT (MET)
4PNJ	;	1.36	;	Recombinant Sperm Whale P6 Myoglobin Solved with Single Pulse Free Electron Laser Data
6U7D	;	3.0	;	Recombinant stem bromelain precursor
1OS8	;	1.55	;	RECOMBINANT STREPTOMYCES GRISEUS TRYPSIN
1X35	;	4.1	;	Recombinant T=3 capsid of a site specific mutant of SeMV CP
6L55	;	1.78305	;	Recombinant Tegillarca granosa ferritin
3VJQ	;	1.0	;	Recombinant thaumatin at pH 8.0 with hydrogen atoms
5X9L	;	0.9	;	Recombinant thaumatin I at 0.9 Angstrom
3AL7	;	1.1	;	Recombinant thaumatin I at 1.1 A
3VHG	;	1.0	;	Recombinant thaumatin I at PH 8.0
3X3O	;	1.48	;	Recombinant thaumatin in the presence of 0.5M PST at 298K
3X3P	;	1.48	;	Recombinant thaumatin in the presence of 0.75M PST at 293K
3X3R	;	1.52	;	Recombinant thaumatin in the presence of 1.0M PST and soaked 1 hr at 293K
3X3S	;	1.46	;	Recombinant thaumatin in the presence of 1.5M PST at 293K
3X3T	;	1.501	;	Recombinant thaumatin in the presence of 1.5M PST at 293K
4XVB	;	1.52	;	Recombinant thaumatin in the presence of 1.5M PST at 293K
2GHO	;	5.0	;	Recombinant Thermus aquaticus RNA polymerase for Structural Studies
2DXB	;	2.25	;	Recombinant thiocyanate hydrolase comprising partially-modified cobalt centers
2ZZD	;	1.78	;	Recombinant thiocyanate hydrolase, air-oxidized form of holo-enzyme
2DXC	;	1.9	;	Recombinant thiocyanate hydrolase, fully-matured form
8BCK	;	1.96	;	Recombinant Tipula oleracea Nudivirus polyhedrin
8BC5	;	1.91	;	Recombinant Tipula oleracea Nudivirus Polyhedrin - Selenomethionine
8BCL	;	2.8	;	Recombinant Tipula oleracea Nudivirus polyhedrin Expanded unit cell
1UP8	;	2.2	;	Recombinant vanadium-dependent bromoperoxidase from red algae Corallina pilulifera
2V02	;	2.2	;	Recombinant vertebrate calmodulin complexed with Ba
2V01	;	2.15	;	Recombinant vertebrate calmodulin complexed with Pb
4JCG	;	1.63	;	Recombinant wild type Nitrosomonas europaea cytochrome c552
1YFM	;	2.6	;	RECOMBINANT YEAST FUMARASE
8P8Q	;	1.792	;	Recombinant Ym1 crystal structure
8P8S	;	1.17	;	Recombinant Ym2 crystal structure
6ELV	;	1.05	;	Recombinantly expressed C-terminal domain of MdPPO1 (Csole-domain)
4Z14	;	2.53	;	Recombinantly expressed latent aurone synthase (polyphenol oxidase)
4Z12	;	1.85	;	Recombinantly expressed latent aurone synthase (polyphenol oxidase) co-crystallized with hexatungstotellurate(VI)
4Z13	;	1.78	;	Recombinantly expressed latent aurone synthase (polyphenol oxidase) co-crystallized with hexatungstotellurate(VI) and soaked in H2O2
6R6O	;	1.9	;	Recombinantly produced Kusta0087/Kusta0088 Complex, C32G/wt mutant
6R6N	;	2.0	;	Recombinantly produced Kusta0087/Kusta0088 Complex, C32M/C101M mutant
2F1J	;	2.3	;	Recombinase in Complex with ADP
3FYH	;	1.9	;	Recombinase in complex with ADP and metatungstate
2F1I	;	2.9	;	Recombinase in Complex with AMP-PNP
2F1H	;	2.7	;	RECOMBINASE IN COMPLEX WITH AMP-PNP and Potassium
2O5V	;	1.61	;	Recombination mediator RecF
192D	;	1.92	;	RECOMBINATION-LIKE STRUCTURE OF D(CCGCGG)
1U5K	;	2.0	;	Recombinational repair protein RecO
1ZXI	;	1.7	;	Reconstituted CO dehydrogenase from Oligotropha carboxidovorans
6OBP	;	2.7	;	Reconstituted PP1 holoenzyme
6J5T	;	3.4	;	Reconstitution and structure of a plant NLR resistosome conferring immunity
6J6I	;	3.7	;	Reconstitution and structure of a plant NLR resistosome conferring immunity
7FC0	;	2.643	;	Reconstitution of MbnABC complex from Rugamonas rubra ATCC-43154 (GroupIII)
7KCN	;	1.46	;	Reconstructed ancestor of HIUases and Transthyretins
7KJJ	;	1.55	;	Reconstructed ancestor of HIUases and Transthyretins
4UUP	;	1.543	;	Reconstructed ancestral trichomonad malate dehydrogenase in complex with NADH, SO4, and PO4
6TH8	;		;	Reconstructing the Origins of the HemD-like fold
7SYF	;	4.2	;	Reconstruction of full-length Prex-1 (PtdIns(3,4,5)P3-dependent Rac Exchanger 1)
7F6D	;	3.85	;	Reconstruction of the HerA-NurA complex from Deinococcus radiodurans
7MUQ	;	4.6	;	Reconstruction of the Legionella pneumophila Dot/Icm T4SS 3DVA Map 1
7MUS	;	4.6	;	Reconstruction of the Legionella pneumophila Dot/Icm T4SS 3DVA Map 2
7MUV	;	4.6	;	Reconstruction of the Legionella pneumophila Dot/Icm T4SS 3DVA Map 3
7MUW	;	4.6	;	Reconstruction of the Legionella pneumophila Dot/Icm T4SS 3DVA Map 4
7MUY	;	4.6	;	Reconstruction of the Legionella pneumophila Dot/Icm T4SS 3DVA Map 5
3J5R	;	4.2	;	Reconstruction of TRPV1 ion channel in complex with capsaicin by single particle cryo-microscopy
2KMU	;		;	RecQL4 Amino-terminal Domain
1C1N	;	1.4	;	RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C1O	;	1.4	;	RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C1P	;	1.37	;	RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C1Q	;	1.37	;	RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C1R	;	1.37	;	RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C1S	;	1.63	;	RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C1T	;	1.37	;	RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C1U	;	1.75	;	RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C1V	;	1.98	;	RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C1W	;	1.9	;	RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2D	;	1.65	;	RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2E	;	1.65	;	RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2F	;	1.7	;	RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2G	;	1.65	;	RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2H	;	1.4	;	RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2I	;	1.47	;	RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2J	;	1.4	;	RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2K	;	1.65	;	RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2L	;	1.5	;	RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2M	;	1.4	;	RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
2RPH	;		;	RecT-bound ssDNA
2HMS	;	2.7	;	Rectangular-shaped octameric ring structure of an RCK domain with NADH bound
5UTG	;		;	Red abalone lysin F104A
7BLZ	;	3.1	;	Red alga C.merolae Photosystem I
6MRM	;	2.9	;	Red Clover Necrotic Mosaic Virus
1IBY	;	1.65	;	RED COPPER PROTEIN NITROSOCYANIN FROM NITROSOMONAS EUROPAEA
1IBZ	;	2.3	;	RED COPPER PROTEIN NITROSOCYANIN FROM NITROSOMONAS EUROPAEA
1IC0	;	2.1	;	RED COPPER PROTEIN NITROSOCYANIN FROM NITROSOMONAS EUROPAEA
1GGX	;	1.9	;	RED FLUORESCENT PROTEIN (FP583 OR DSRED(CLONTECH)) FROM DISCOSOMA SP.
7X2B	;	1.63	;	Red fluorescent protein from Diadumene lineata
3IR8	;	1.63	;	Red fluorescent protein mKeima at pH 7.0
2ICR	;	1.51	;	Red fluorescent protein zRFP574 from Zoanthus sp.
6G46	;	2.4	;	Red kidney bean purple acid phosphatase in complex with 2-(Naphthalen-1-yl)thiazole-4-carboxylic acid
6HWR	;	1.95	;	Red kidney bean purple acid phosphatase in complex with adenosine divanadate
6BHN	;		;	Red Light-Absorbing State of NpR6012g4, a Red/Green Cyanobacteriochrome
7QUU	;		;	Red1-Iss10 complex
4BAA	;	2.5	;	Redesign of a Phenylalanine Aminomutase into a beta-Phenylalanine Ammonia Lyase
4BAB	;	2.56	;	Redesign of a Phenylalanine Aminomutase into a beta-Phenylalanine Ammonia Lyase
1CVC	;	2.3	;	REDESIGNING THE ZINC BINDING SITE OF HUMAN CARBONIC ANHYDRASE II: STRUCTURE OF A HIS2ASP-ZN2+ METAL COORDINATION POLYHEDRON
3QMW	;	2.5	;	RedJ with PEG molecule bound in the active site
3QMV	;	2.12	;	RedJ-Thioesterase from the Prodiginine biosynthetic pathway in Streptomyces coelicolor
3CYT	;	1.8	;	REDOX CONFORMATION CHANGES IN REFINED TUNA CYTOCHROME C
2KSU	;		;	Redox linked conformational changes in cytochrome C3 from Desulfovibrio desulfuricans ATCC 27774
8DIK	;	2.4	;	Redox properties and PAS domain structure of the E. coli Energy Sensor Aer indicate a multi-state sensing mechanism
5E37	;	1.6	;	Redox protein from Chlamydomonas reinhardtii
6J13	;	2.4	;	Redox protein from Chlamydomonas reinhardtii
6OID	;	2.365	;	Redox Regulation of FN3K from Arabidopsis thaliana
3NTJ	;	3.0	;	Redox regulation of Plasmodium falciparum ornithine delta-aminotransferase
4A5M	;	3.0	;	Redox regulator HypR in its oxidized form
1DCU	;	2.2	;	REDOX SIGNALING IN THE CHLOROPLAST: STRUCTURE OF OXIDIZED PEA FRUCTOSE-1,6-BISPHOSPHATE PHOSPHATASE
5ZZ5	;	2.0	;	Redox-sensing transcriptional repressor Rex
5ZZ6	;	2.2	;	Redox-sensing transcriptional repressor Rex
5ZZ7	;	2.45	;	Redox-sensing transcriptional repressor Rex
4A5N	;	1.81	;	Redoxregulator HypR in its reduced form
2FKZ	;	2.0	;	Reduced (All Ferrous) form of the Azotobacter vinelandii bacterioferritin
3PHM	;	2.1	;	REDUCED (CU+) PEPTIDYLGLYCINE ALPHA-HYDROXYLATING MONOOXYGENASE (PHM)
3MLL	;	3.25	;	Reduced (Cu+) peptidylglycine alpha-hydroxylating monooxygenase (PHM) with bound azide
3MLJ	;	2.15	;	Reduced (Cu+) peptidylglycine alpha-hydroxylating monooxygenase (PHM) with bound carbon monooxide (CO)
3MLK	;	3.1	;	Reduced (Cu+) peptidylglycine alpha-hydroxylating monooxygenase (PHM) with bound nitrite
1SDW	;	1.85	;	Reduced (Cu+) peptidylglycine alpha-hydroxylating monooxygenase with bound peptide and dioxygen
2B08	;	1.9	;	Reduced acetamide-bound M150G Nitrite Reductase from Alcaligenes faecalis
3WFD	;	2.3	;	Reduced and acetaldoxime-bound cytochrome c-dependent nitric oxide reductase (cNOR) from Pseudomonas aeruginosa in complex with antibody fragment
3WFC	;	2.5	;	Reduced and carbonmonoxide-bound cytochrome c-dependent nitric oxide reductase (cNOR) from Pseudomonas aeruginosa in complex with antibody fragment
2L8M	;		;	Reduced and CO-bound cytochrome P450cam (CYP101A1)
2LQD	;		;	Reduced and CO-bound cytochrome P450cam (CYP101A1)
3WFE	;	2.49	;	Reduced and cyanide-bound cytochrome c-dependent nitric oxide reductase (cNOR) from Pseudomonas aeruginosa in complex with antibody fragment
1DZ0	;	1.75	;	REDUCED AZURIN II FROM ALCALIGENES XYLOSOXIDANS
1FOL	;	2.2	;	REDUCED BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH L-ARG(H4B-FREE)
1SXN	;	1.9	;	REDUCED BOVINE SUPEROXIDE DISMUTASE AT PH 5.0
1SXZ	;	2.05	;	Reduced bovine superoxide dismutase at pH 5.0 complexed with azide
1SXS	;	2.0	;	Reduced bovine superoxide dismutase at pH 5.0 complexed with thiocyanate
1JCV	;	1.55	;	REDUCED BRIDGE-BROKEN YEAST CU/ZN SUPEROXIDE DISMUTASE LOW TEMPERATURE (-180C) STRUCTURE
2JCW	;	1.7	;	REDUCED BRIDGE-BROKEN YEAST CU/ZN SUPEROXIDE DISMUTASE ROOM TEMPERATURE (298K) STRUCTURE
3VMG	;	1.95	;	Reduced carbazole-bound complex between oxygenase and ferredoxin in carbazole 1,9a-dioxygenase
6GT2	;	1.6	;	Reduced copper nitrite reductase from Achromobacter cycloclastes determined by serial femtosecond rotation crystallography
4KNS	;	2.2	;	Reduced crystal structure of the Nitrosomonas europaea copper nitrite reductase at pH 6.5
2GBA	;	0.92	;	Reduced Cu(I) form at pH 4 of P52G mutant of amicyanin
4YAW	;	2.0	;	Reduced CYPOR mutant - G141del
4YAU	;	2.2	;	Reduced CYPOR mutant - G141del/E142N
4YAO	;	2.5	;	Reduced CYPOR mutant - G143del
4YAL	;	1.88	;	Reduced CYPOR with 2'-AMP
3WFB	;	2.7	;	Reduced cytochrome c-dependent nitric oxide reductase (cNOR) from Pseudomonas aeruginosa in complex with antibody fragment
1DDO	;	3.1	;	REDUCED D-AMINO ACID OXIDASE FROM PIG KIDNEY IN COMPLEX WITH IMINO-TRP
4DMR	;	1.9	;	REDUCED DMSO REDUCTASE FROM RHODOBACTER CAPSULATUS WITH BOUND DMSO SUBSTRATE
1A2L	;	2.7	;	REDUCED DSBA AT 2.7 ANGSTROMS RESOLUTION
3WU5	;	2.07	;	Reduced E.coli Lon Proteolytic domain
2FZU	;	1.25	;	Reduced enolate chromophore intermediate for GFP variant
2FWQ	;	1.4	;	Reduced enolate chromophore intermediate for Y66H GFP variant
7VKD	;	1.58	;	Reduced enzyme of FAD-dpendent Glucose Dehydrogenase at pH6.5
7VKF	;	1.6	;	Reduced enzyme of FAD-dpendent Glucose Dehydrogenase complex with D-glucono-1,5-lactone at pH8.5
1UWM	;	2.0	;	reduced ferredoxin 6 from Rhodobacter capsulatus
7BUH	;	1.79	;	Reduced ferredoxin of carbazole 1,9a-dioxygenase
1RZ1	;	2.1	;	Reduced flavin reductase PheA2 in complex with NAD
1YPN	;	2.3	;	REDUCED FORM HYDROXYMETHYLBILANE SYNTHASE (K59Q MUTANT) CRYSTAL STRUCTURE AFTER 2 HOURS IN A FLOW CELL DETERMINED BY TIME-RESOLVED LAUE DIFFRACTION
2GTJ	;		;	Reduced form of ADAP hSH3-N-domain
4Y2K	;	1.7	;	reduced form of apo-GolB
4IHU	;	1.896	;	Reduced form of disulfide bond oxdioreductase (DsbG) from Mycobacterium tuberculosis
1AA6	;	2.3	;	REDUCED FORM OF FORMATE DEHYDROGENASE H FROM E. COLI
3S61	;	3.03	;	Reduced Form of Ornithine Hydroxylase (PvdA) from Pseudomonas aeruginosa
1KDI	;	1.8	;	REDUCED FORM OF PLASTOCYANIN FROM DRYOPTERIS CRASSIRHIZOMA
5X0V	;	1.6	;	Reduced form of regulatory domain of OxyR2 from Vibrio vulnificus
7PXZ	;	1.75	;	Reduced form of SARS-CoV-2 Main Protease determined by XFEL radiation
1DXM	;	2.6	;	Reduced form of the H protein from glycine decarboxylase complex
5HS7	;	1.7	;	Reduced form of the transcriptional regulator YodB from B. subtilis
1AH5	;	2.4	;	REDUCED FORM SELENOMETHIONINE-LABELLED HYDROXYMETHYLBILANE SYNTHASE DETERMINED BY MAD
2PPE	;	1.75	;	Reduced H145A mutant of AfNiR exposed to NO
3WSE	;	2.5	;	Reduced HcgD from Methanocaldococcus jannaschii
3WSG	;	1.996	;	Reduced HcgD from Methanocaldococcus jannaschii with citrate
4OOI	;	2.2	;	Reduced HlyU from Vibrio cholerae N16961
1LT8	;	2.05	;	Reduced Homo sapiens Betaine-Homocysteine S-Methyltransferase in Complex with S-(delta-carboxybutyl)-L-Homocysteine
7KIZ	;	1.7	;	reduced human peroxiredoxin 2
1OA1	;	1.55	;	REDUCED HYBRID CLUSTER PROTEIN (HCP) FROM DESULFOVIBRIO VULGARIS HILDENBOROUGH STRUCTURE AT 1.55A RESOLUTION USING SYNCHROTRON RADIATION.
1OA0	;	1.25	;	REDUCED HYBRID CLUSTER PROTEIN FROM DESULFOVIBRIO DESULFURICANS X-RAY STRUCTURE AT 1.25A RESOLUTION
2PPF	;	1.65	;	Reduced mutant D98N of AfNiR exposed to nitric oxide
5PAZ	;	1.76	;	REDUCED MUTANT P80A PSEUDOAZURIN FROM A. FAECALIS
7PAZ	;	2.0	;	REDUCED MUTANT P80I PSEUDOAZURIN FROM A. FAECALIS
3QQX	;	1.5	;	Reduced Native Intermediate of the Multicopper Oxidase CueO
3PAZ	;	1.73	;	REDUCED NATIVE PSEUDOAZURIN FROM A. FAECALIS
7BUG	;	1.6	;	Reduced oxygenase of carbazole 1,9a-dioxygenase
1M1R	;	1.02	;	Reduced p222 crystal structure of the tetraheme cytochrome c of Shewanella oneidensis MR1
1YJK	;	2.0	;	Reduced Peptidylglycine Alpha-Hydroxylating Monooxygenase (PHM) in a New Crystal Form
1YJL	;	2.4	;	Reduced Peptidylglycine alpha-Hydroxylating Monooxygenase in a new crystal form
6KEV	;	2.50614	;	Reduced phosphoribulokinase from Synechococcus elongatus PCC 7942 complexed with adenosine diphosphate and glucose 6-phosphate
1BXV	;	1.8	;	REDUCED PLASTOCYANIN FROM SYNECHOCOCCUS SP.
1H6A	;	2.5	;	Reduced Precursor Form of Glucose-Fructose Oxidoreductase from Zymomonas mobilis
1H6B	;	2.6	;	Reduced Precursor Form of Glucose-Fructose Oxidoreductase from Zymomonas mobilis complexed with glycerol
1BQR	;	1.6	;	REDUCED PSEUDOAZURIN
1ZIB	;	2.0	;	REDUCED PSEUDOAZURIN
4ZVN	;	1.866	;	Reduced quinone reductase 2 in complex with acridine orange
4FGL	;	1.2	;	Reduced quinone reductase 2 in complex with chloroquine
4U7F	;	1.8	;	Reduced quinone reductase 2 in complex with CK2 inhibitor DMAT
4ZVK	;	1.867	;	Reduced quinone reductase 2 in complex with ethidium
1A3Z	;	1.9	;	REDUCED RUSTICYANIN AT 1.9 ANGSTROMS
1CUR	;		;	REDUCED RUSTICYANIN, NMR
1H32	;	1.5	;	Reduced SoxAX complex from Rhodovulum sulfidophilum
1SFH	;	1.05	;	Reduced state of amicyanin mutant P94F
1FT6	;	1.8	;	REDUCED STATE OF CYTOCHROME C554 FROM NITROSOMONAS EUROPAEA
1GMB	;	2.0	;	Reduced structure of CYTOCHROME C3 FROM DESULFOVIBRIO DESULFURICANS ATCC 27774 at pH 7.6
1UP9	;	1.35	;	REDUCED STRUCTURE OF CYTOCHROME C3 FROM DESULFOVIBRIO DESULFURICANS ATCC 27774 AT PH 7.6
2XLH	;	1.14	;	REDUCED STRUCTURE OF R124A MUTANT OF CYTOCHROME C' FROM ALCALIGENES XYLOSOXIDANS
2XL8	;	1.14	;	REDUCED STRUCTURE OF R124F MUTANT OF CYTOCHROME C' FROM ALCALIGENES XYLOSOXIDANS
7TXN	;	1.95	;	Reduced Structure of RexT
3CAR	;	1.9	;	REDUCED STRUCTURE OF THE ACIDIC CYTOCHROME C3 FROM DESULFOVIBRIO AFRICANUS
2W3F	;	1.6	;	Reduced structure of the first GAF domain of Mycobacterium tuberculosis DosS
1SU9	;	1.95	;	Reduced structure of the soluble domain of ResA
3PXM	;	1.8	;	Reduced sweetness of a monellin (MNEI) mutant results from increased protein flexibility and disruption of a distant poly-(L-proline) II helix
3PYJ	;	2.0	;	Reduced sweetness of a monellin (MNEI) mutant results from increased protein flexibility and disruption of a distant poly-(L-proline) II helix
3Q2P	;	2.341	;	Reduced sweetness of a monellin (MNEI) mutant results from increased protein flexibility and disruption of a distant poly-(L-proline) II helix
2XPD	;	2.0	;	Reduced Thiol peroxidase (Tpx) from yersinia Pseudotuberculosis
3ZRE	;	2.35	;	Reduced Thiol peroxidase (Tpx) from yersinia Pseudotuberculosis
6MVE	;	2.55	;	Reduced X-ray crystal structure of Bacillus subtilis ribonucleotide reductase NrdE alpha subunit with TTP, ATP, and ADP
2MJE	;		;	Reduced Yeast Adrenodoxin Homolog 1
3WU3	;	1.82	;	Reduced-form structure of E.coli Lon Proteolytic domain
8AEP	;	2.3	;	Reductase domain of the carboxylate reductase of Neurospora crassa
3ZYY	;	2.2	;	Reductive activator for corrinoid,iron-sulfur protein
6EOH	;	1.85	;	Reductive Aminase from Aspergillus terreus in complex with NADPH and ethyl levulinate
6EOI	;	1.76	;	Reductive Aminase from Aspergillus terreus in complex with NADPH and ethyl-5-oxohexanoate
6H7P	;	1.79	;	Reductive Aminase from Aspergillus terreus in complex with NADPH4, cyclohexanone and allyl amine
4RAS	;	2.3	;	Reductive dehalogenase structure suggests a mechanism for B12-dependent dehalogenation
8G21	;		;	Reelin C-Terminal Region
7LYU	;	3.0	;	Reelin repeat 8
3PLW	;	1.4	;	Ref protein from P1 bacteriophage
6JNL	;	2.15	;	REF6 ZnF2-4-NAC004 complex
6JNN	;	2.6	;	REF6 ZnF2-4-NAC004-mC1 complex
6JNM	;	2.05	;	REF6 ZnF2-4-NAC004-mC3 complex
6SVN	;	1.16	;	Reference structure of bovine trypsin (even frames of crystal x28)
6SVU	;	1.15	;	Reference structure of bovine trypsin (even frames of crystal x30)
6SVW	;	1.16	;	Reference structure of bovine trypsin (even frames of crystal x33)
6SVZ	;	1.15	;	Reference structure of bovine trypsin (even frames of crystal x34)
6SVR	;	1.16	;	Reference structure of bovine trypsin (odd frames of crystal x28)
6SVV	;	1.15	;	Reference structure of bovine trypsin (odd frames of crystal x30)
6SVX	;	1.16	;	Reference structure of bovine trypsin (odd frames of crystal x33)
6SW0	;	1.15	;	Reference structure of bovine trypsin (odd frames of crystal x34)
2ILI	;	1.05	;	Refine atomic structure of human carbonic anhydrase II
1LMB	;	1.8	;	REFINED 1.8 ANGSTROM CRYSTAL STRUCTURE OF THE LAMBDA REPRESSOR-OPERATOR COMPLEX
1EPT	;	1.8	;	REFINED 1.8 ANGSTROMS RESOLUTION CRYSTAL STRUCTURE OF PORCINE EPSILON-TRYPSIN
1MAR	;	1.8	;	REFINED 1.8 ANGSTROMS STRUCTURE OF HUMAN ALDOSE REDUCTASE COMPLEXED WITH THE POTENT INHIBITOR ZOPOLRESTAT
1DMB	;	1.8	;	REFINED 1.8 ANGSTROMS STRUCTURE REVEALS THE MECHANISM OF BINDING OF A CYCLIC SUGAR, BETA-CYCLODEXTRIN, TO THE MALTODEXTRIN BINDING PROTEIN
1IAD	;	2.3	;	REFINED 1.8 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF ASTACIN, A ZINC-ENDOPEPTIDASE FROM THE CRAYFISH ASTACUS ASTACUS L. STRUCTURE DETERMINATION, REFINEMENT, MOLECULAR STRUCTURE AND COMPARISON TO THERMOLYSIN
1IAC	;	2.1	;	REFINED 1.8 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF ASTACIN, A ZINC-ENDOPEPTIDASE FROM THE CRAYFISH ASTACUS ASTACUS L. STRUCTURE DETERMINATION, REFINEMENT, MOLECULAR STRUCTURE AND COMPARISON WITH THERMOLYSIN
5TIM	;	1.83	;	REFINED 1.83 ANGSTROMS STRUCTURE OF TRYPANOSOMAL TRIOSEPHOSPHATE ISOMERASE, CRYSTALLIZED IN THE PRESENCE OF 2.4 M-AMMONIUM SULPHATE. A COMPARISON WITH THE STRUCTURE OF THE TRYPANOSOMAL TRIOSEPHOSPHATE ISOMERASE-GLYCEROL-3-PHOSPHATE COMPLEX
1HSL	;	1.89	;	REFINED 1.89 ANGSTROMS STRUCTURE OF THE HISTIDINE-BINDING PROTEIN COMPLEXED WITH HISTIDINE AND ITS RELATIONSHIP WITH MANY OTHER ACTIVE TRANSPORT(SLASH)CHEMOSENSORY RECEPTORS
6I2I	;	3.6	;	Refined 13pf Hela Cell Tubulin microtubule (EML4-NTD decorated)
2PKA	;	2.05	;	REFINED 2 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF PORCINE PANCREATIC KALLIKREIN A, A SPECIFIC TRYPSIN-LIKE SERINE PROTEINASE. CRYSTALLIZATION, STRUCTURE DETERMINATION, CRYSTALLOGRAPHIC REFINEMENT, STRUCTURE AND ITS COMPARISON WITH BOVINE TRYPSIN
1ETR	;	2.2	;	REFINED 2.3 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF BOVINE THROMBIN COMPLEXES FORMED WITH THE BENZAMIDINE AND ARGININE-BASED THROMBIN INHIBITORS NAPAP, 4-TAPAP AND MQPA: A STARTING POINT FOR IMPROVING ANTITHROMBOTICS
1ETS	;	2.3	;	REFINED 2.3 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF BOVINE THROMBIN COMPLEXES FORMED WITH THE BENZAMIDINE AND ARGININE-BASED THROMBIN INHIBITORS NAPAP, 4-TAPAP AND MQPA: A STARTING POINT FOR IMPROVING ANTITHROMBOTICS
1ETT	;	2.5	;	REFINED 2.3 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF BOVINE THROMBIN COMPLEXES FORMED WITH THE BENZAMIDINE AND ARGININE-BASED THROMBIN INHIBITORS NAPAP, 4-TAPAP AND MQPA: A STARTING POINT FOR IMPROVING ANTITHROMBOTICS
2KAI	;	2.5	;	REFINED 2.5 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF THE COMPLEX FORMED BY PORCINE KALLIKREIN A AND THE BOVINE PANCREATIC TRYPSIN INHIBITOR. CRYSTALLIZATION, PATTERSON SEARCH, STRUCTURE DETERMINATION, REFINEMENT, STRUCTURE AND COMPARISON WITH ITS COMPONENTS AND WITH THE BOVINE TRYPSIN-PANCREATIC TRYPSIN INHIBITOR COMPLEX
2JNC	;		;	Refined 3D NMR structure of ECD1 of mCRF-R2beta at pH 5
5LAM	;		;	Refined 3D NMR structure of the cytoplasmic rhodanese domain of the inner membrane protein YgaP from Escherichia coli
1IFB	;	1.96	;	REFINED APOPROTEIN STRUCTURE OF RAT INTESTINAL FATTY ACID BINDING PROTEIN PRODUCED IN ESCHERICHIA COLI
2GLS	;	3.5	;	REFINED ATOMIC MODEL OF GLUTAMINE SYNTHETASE AT 3.5 ANGSTROMS RESOLUTION
3SC2	;	2.2	;	REFINED ATOMIC MODEL OF WHEAT SERINE CARBOXYPEPTIDASE II AT 2.2-ANGSTROMS RESOLUTION
3NN9	;	2.3	;	REFINED ATOMIC STRUCTURES OF N9 SUBTYPE INFLUENZA VIRUS NEURAMINIDASE AND ESCAPE MUTANTS
4NN9	;	2.3	;	REFINED ATOMIC STRUCTURES OF N9 SUBTYPE INFLUENZA VIRUS NEURAMINIDASE AND ESCAPE MUTANTS
5NN9	;	2.3	;	REFINED ATOMIC STRUCTURES OF N9 SUBTYPE INFLUENZA VIRUS NEURAMINIDASE AND ESCAPE MUTANTS
6NN9	;	2.3	;	REFINED ATOMIC STRUCTURES OF N9 SUBTYPE INFLUENZA VIRUS NEURAMINIDASE AND ESCAPE MUTANTS
7TAU	;	3.38	;	Refined capsid structure of human adenovirus D26 at 3.4 A resolution
2WBC	;	2.3	;	REFINED CRYSTAL STRUCTURE (2.3 ANGSTROM) OF A WINGED BEAN CHYMOTRYPSIN INHIBITOR AND LOCATION OF ITS SECOND REACTIVE SITE
1GCD	;	1.9	;	REFINED CRYSTAL STRUCTURE OF ""AGED"" AND ""NON-AGED"" ORGANOPHOSPHORYL CONJUGATES OF GAMMA-CHYMOTRYPSIN
1GMH	;	2.1	;	REFINED CRYSTAL STRUCTURE OF ""AGED"" AND ""NON-AGED"" ORGANOPHOSPHORYL CONJUGATES OF GAMMA-CHYMOTRYPSIN
2IMM	;	2.0	;	Refined crystal structure of a recombinant immunoglobulin domain and a complementarity-determining region 1-grafted mutant
2IMN	;	1.97	;	Refined crystal structure of a recombinant immunoglobulin domain and a complementarity-determining region 1-grafted mutant
1AGX	;	2.9	;	REFINED CRYSTAL STRUCTURE OF ACINETOBACTER GLUTAMINASIFICANS GLUTAMINASE-ASPARAGINASE
1JUY	;	2.5	;	REFINED CRYSTAL STRUCTURE OF ADENYLOSUCCINATE SYNTHETASE FROM ESCHERICHIA COLI COMPLEXED WITH HYDANTOCIDIN 5'-PHOSPHATE GDP, HPO4(2-), MG2+, AND HADACIDIN
1D92	;	2.25	;	REFINED CRYSTAL STRUCTURE OF AN OCTANUCLEOTIDE DUPLEX WITH G.T MISMATCHED BASE-PAIRS
1D90	;	1.7	;	REFINED CRYSTAL STRUCTURE OF AN OCTANUCLEOTIDE DUPLEX WITH I.T MISMATCHED BASE PAIRS
1AOZ	;	1.9	;	REFINED CRYSTAL STRUCTURE OF ASCORBATE OXIDASE AT 1.9 ANGSTROMS RESOLUTION
1FR1	;	2.0	;	REFINED CRYSTAL STRUCTURE OF BETA-LACTAMASE FROM CITROBACTER FREUNDII INDICATES A MECHANISM FOR BETA-LACTAM HYDROLYSIS
1FR6	;	2.5	;	REFINED CRYSTAL STRUCTURE OF BETA-LACTAMASE FROM CITROBACTER FREUNDII INDICATES A MECHANISM FOR BETA-LACTAM HYDROLYSIS
3BLM	;	2.0	;	REFINED CRYSTAL STRUCTURE OF BETA-LACTAMASE FROM STAPHYLOCOCCUS AUREUS PC1 AT 2.0
1BU3	;	1.65	;	REFINED CRYSTAL STRUCTURE OF CALCIUM-BOUND SILVER HAKE (PI 4.2) PARVALBUMIN AT 1.65 A.
4CPV	;	1.5	;	REFINED CRYSTAL STRUCTURE OF CALCIUM-LIGANDED CARP PARVALBUMIN 4.25 AT 1.5-ANGSTROMS RESOLUTION
1DGR	;	2.6	;	Refined crystal structure of canavalin from jack bean
5CPA	;	1.54	;	REFINED CRYSTAL STRUCTURE OF CARBOXYPEPTIDASE A AT 1.54 ANGSTROMS RESOLUTION.
2OXI	;	2.1	;	REFINED CRYSTAL STRUCTURE OF CU-SUBSTITUTED ALCOHOL DEHYDROGENASE AT 2.1 ANGSTROMS RESOLUTION
1HH7	;	1.4	;	REFINED CRYSTAL STRUCTURE OF CYTOCHROME C2 FROM RHODOPSEUDOMONAS PALUSTRIS AT 1.4 ANGSTROM RESOLUTION
4MDH	;	2.5	;	REFINED CRYSTAL STRUCTURE OF CYTOPLASMIC MALATE DEHYDROGENASE AT 2.5-ANGSTROMS RESOLUTION
1HBS	;	3.0	;	REFINED CRYSTAL STRUCTURE OF DEOXYHEMOGLOBIN S. I. RESTRAINED LEAST-SQUARES REFINEMENT AT 3.0-ANGSTROMS RESOLUTION
1LDM	;	2.1	;	Refined crystal structure of dogfish M4 apo-lactate dehydrogenase
6LDH	;	2.0	;	REFINED CRYSTAL STRUCTURE OF DOGFISH M4 APO-LACTATE DEHYDROGENASE
8LDH	;	2.8	;	REFINED CRYSTAL STRUCTURE OF DOGFISH M4 APO-LACTATE DEHYDROGENASE
1FXD	;	1.7	;	REFINED CRYSTAL STRUCTURE OF FERREDOXIN II FROM DESULFOVIBRIO GIGAS AT 1.7 ANGSTROMS
2GCH	;	1.9	;	REFINED CRYSTAL STRUCTURE OF GAMMA-CHYMOTRYPSIN AT 1.9 ANGSTROMS RESOLUTION
3PBH	;	2.5	;	REFINED CRYSTAL STRUCTURE OF HUMAN PROCATHEPSIN B AT 2.5 ANGSTROM RESOLUTION
1C8M	;	2.8	;	REFINED CRYSTAL STRUCTURE OF HUMAN RHINOVIRUS 16 COMPLEXED WITH VP63843 (PLECONARIL), AN ANTI-PICORNAVIRAL DRUG CURRENTLY IN CLINICAL TRIALS
1GPR	;	1.9	;	REFINED CRYSTAL STRUCTURE OF IIA DOMAIN OF THE GLUCOSE PERMEASE OF BACILLUS SUBTILIS AT 1.9 ANGSTROMS RESOLUTION
3LAD	;	2.2	;	REFINED CRYSTAL STRUCTURE OF LIPOAMIDE DEHYDROGENASE FROM AZOTOBACTER VINELANDII AT 2.2 ANGSTROMS RESOLUTION. A COMPARISON WITH THE STRUCTURE OF GLUTATHIONE REDUCTASE
2OHX	;	1.8	;	REFINED CRYSTAL STRUCTURE OF LIVER ALCOHOL DEHYDROGENASE-NADH COMPLEX AT 1.8 ANGSTROMS RESOLUTION
1PMY	;	1.5	;	REFINED CRYSTAL STRUCTURE OF PSEUDOAZURIN FROM METHYLOBACTERIUM EXTORQUENS AM1 AT 1.5 ANGSTROMS RESOLUTION
1FNB	;	1.7	;	REFINED CRYSTAL STRUCTURE OF SPINACH FERREDOXIN REDUCTASE AT 1.7 ANGSTROMS RESOLUTION: OXIDIZED, REDUCED, AND 2'-PHOSPHO-5'-AMP BOUND STATES
1FNC	;	2.0	;	REFINED CRYSTAL STRUCTURE OF SPINACH FERREDOXIN REDUCTASE AT 1.7 ANGSTROMS RESOLUTION: OXIDIZED, REDUCED, AND 2'-PHOSPHO-5'-AMP BOUND STATES
1FND	;	1.7	;	REFINED CRYSTAL STRUCTURE OF SPINACH FERREDOXIN REDUCTASE AT 1.7 ANGSTROMS RESOLUTION: OXIDIZED, REDUCED, AND 2'-PHOSPHO-5'-AMP BOUND STATES
1SGT	;	1.7	;	REFINED CRYSTAL STRUCTURE OF STREPTOMYCES GRISEUS TRYPSIN AT 1.7 ANGSTROMS RESOLUTION
1FDN	;	1.84	;	REFINED CRYSTAL STRUCTURE OF THE 2[4FE-4S] FERREDOXIN FROM CLOSTRIDIUM ACIDURICI AT 1.84 ANGSTROMS RESOLUTION
2SIC	;	1.8	;	REFINED CRYSTAL STRUCTURE OF THE COMPLEX OF SUBTILISIN BPN' AND STREPTOMYCES SUBTILISIN INHIBITOR AT 1.8 ANGSTROMS RESOLUTION
2FBJ	;	1.95	;	REFINED CRYSTAL STRUCTURE OF THE GALACTAN-BINDING IMMUNOGLOBULIN FAB J539 AT 1.95-ANGSTROMS RESOLUTION
1S72	;	2.4	;	REFINED CRYSTAL STRUCTURE OF THE HALOARCULA MARISMORTUI LARGE RIBOSOMAL SUBUNIT AT 2.4 ANGSTROM RESOLUTION
4BV6	;	1.8	;	Refined crystal structure of the human Apoptosis inducing factor
1NCA	;	2.5	;	REFINED CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS N9 NEURAMINIDASE-NC41 FAB COMPLEX
1NCD	;	2.9	;	REFINED CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS N9 NEURAMINIDASE-NC41 FAB COMPLEX
2MCP	;	3.1	;	REFINED CRYSTAL STRUCTURE OF THE MC/PC603 FAB-PHOSPHOCHOLINE COMPLEX AT 3.1 ANGSTROMS RESOLUTION
6GPB	;	2.86	;	REFINED CRYSTAL STRUCTURE OF THE PHOSPHORYLASE-HEPTULOSE 2-PHOSPHATE-OLIGOSACCHARIDE-AMP COMPLEX
4CPA	;	2.5	;	REFINED CRYSTAL STRUCTURE OF THE POTATO INHIBITOR COMPLEX OF CARBOXYPEPTIDASE A AT 2.5 ANGSTROMS RESOLUTION
1SRY	;	2.5	;	REFINED CRYSTAL STRUCTURE OF THE SERYL-TRNA SYNTHETASE FROM THERMUS THERMOPHILUS AT 2.5 ANGSTROMS RESOLUTION
5P21	;	1.35	;	REFINED CRYSTAL STRUCTURE OF THE TRIPHOSPHATE CONFORMATION OF H-RAS P21 AT 1.35 ANGSTROMS RESOLUTION: IMPLICATIONS FOR THE MECHANISM OF GTP HYDROLYSIS
5TNC	;	2.0	;	REFINED CRYSTAL STRUCTURE OF TROPONIN C FROM TURKEY SKELETAL MUSCLE AT 2.0 ANGSTROMS RESOLUTION
3CLA	;	1.75	;	REFINED CRYSTAL STRUCTURE OF TYPE III CHLORAMPHENICOL ACETYLTRANSFERASE AT 1.75 ANGSTROMS RESOLUTION
8DFR	;	1.7	;	REFINED CRYSTAL STRUCTURES OF CHICKEN LIVER DIHYDROFOLATE REDUCTASE. 3 ANGSTROMS APO-ENZYME AND 1.7 ANGSTROMS NADPH HOLO-ENZYME COMPLEX
1GLM	;	2.4	;	REFINED CRYSTAL STRUCTURES OF GLUCOAMYLASE FROM ASPERGILLUS AWAMORI VAR. X100
3GLY	;	2.2	;	REFINED CRYSTAL STRUCTURES OF GLUCOAMYLASE FROM ASPERGILLUS AWAMORI VAR. X100
1SBN	;	2.1	;	REFINED CRYSTAL STRUCTURES OF SUBTILISIN NOVO IN COMPLEX WITH WILD-TYPE AND TWO MUTANT EGLINS. COMPARISON WITH OTHER SERINE PROTEINASE INHIBITOR COMPLEXES
1SIB	;	2.4	;	REFINED CRYSTAL STRUCTURES OF SUBTILISIN NOVO IN COMPLEX WITH WILD-TYPE AND TWO MUTANT EGLINS. COMPARISON WITH OTHER SERINE PROTEINASE INHIBITOR COMPLEXES
1OVT	;	2.4	;	REFINED CRYSTALLOGRAPHIC STRUCTURE OF HEN OVOTRANSFERRIN AT 2.4 ANGSTROMS RESOLUTION
3EOH	;	3.125	;	Refined group II intron structure
6UT8	;	3.68	;	Refined half-complex from tetradecameric assembly of Thermococcus gammatolerans McrB AAA+ hexamers with bound McrC
2LOY	;		;	Refined Miminal Constraint Solution NMR Structure of Translationally-controlled tumor protein (TCTP) from Caenorhabditis elegans, Northeast Structural Genomics Consortium Target WR73
2ZJR	;	2.91	;	Refined native structure of the large ribosomal subunit (50S) from Deinococcus radiodurans
2M54	;		;	Refined NMR solution structure of metal-modified DNA
1DV0	;		;	Refined NMR solution structure of the C-terminal UBA domain of the human homologue of RAD23A (HHR23A)
2HID	;		;	REFINED NMR STRUCTURE OF PHOSPHOCARRIER HISTIDINE CONTAINING PROTEIN FROM BACILLUS SUBTILIS
1J4O	;		;	REFINED NMR STRUCTURE OF THE FHA1 DOMAIN OF YEAST RAD53
1K3J	;		;	Refined NMR Structure of the FHA1 Domain of Yeast Rad53
1Y1V	;	3.8	;	Refined RNA Polymerase II-TFIIS complex
6TIQ	;		;	Refined solution NMR structure of hVDAC-1 in detergent micelles
2M6Q	;		;	Refined Solution NMR Structure of Staphylococcus aureus protein SAV1430. Northeast Strucutral Genomics Consortium Target ZR18
2LP6	;		;	Refined Solution NMR Structure of the 50S ribosomal protein L35Ae from Pyrococcus furiosus, Northeast Structural Genomics Consortium Target (NESG) PfR48
1Q2N	;		;	REFINED Solution NMR structure of the Z domain of STAPHYLOCOCCAL PROTEIN A
2LZJ	;		;	Refined solution structure and dynamics of First Catalytic Cysteine Half-domain from mouse E1 enzyme
1PDC	;		;	REFINED SOLUTION STRUCTURE AND LIGAND-BINDING PROPERTIES OF PDC-109 DOMAIN B. A COLLAGEN-BINDING TYPE II DOMAIN
1F3C	;		;	REFINED SOLUTION STRUCTURE OF 8KDA DYNEIN LIGHT CHAIN (DLC8)
2KOI	;		;	Refined solution structure of a cyanobacterial phytochrome GAF domain in the red light-absorbing ground state
2LB9	;		;	Refined solution structure of a cyanobacterial phytochrome gaf domain in the red light-absorbing ground state (corrected pyrrole ring planarity)
2KEI	;		;	Refined Solution Structure of a Dimer of LAC repressor DNA-Binding domain complexed to its natural operator O1
1F71	;		;	REFINED SOLUTION STRUCTURE OF CALMODULIN C-TERMINAL DOMAIN
1F70	;		;	REFINED SOLUTION STRUCTURE OF CALMODULIN N-TERMINAL DOMAIN
1WRF	;		;	Refined solution structure of Der f 2, The Major Mite Allergen from Dermatophagoides farinae
2KGQ	;		;	Refined solution structure of des-pyro Glu brazzein
1KA5	;		;	Refined Solution Structure of Histidine Containing Phosphocarrier Protein from Staphyloccocus aureus
2M6Z	;		;	Refined solution structure of Human Adult Hemoglobin in the Carbonmonoxy Form
1GD3	;		;	refined solution structure of human cystatin A
1PFL	;		;	REFINED SOLUTION STRUCTURE OF HUMAN PROFILIN I
1CW6	;		;	REFINED SOLUTION STRUCTURE OF LEUCOCIN A
2KHL	;		;	Refined solution structure of Methanosarcina thermophila protein MC1
5X3Y	;		;	Refined solution structure of musashi1 RBD2
2RLK	;		;	Refined solution structure of porcine peptide YY (PYY)
2LY5	;		;	Refined solution structure of recombinant brazzein
2LY6	;		;	Refined solution structure of recombinant brazzein at low temperature
2RVK	;		;	Refined solution structure of Schizosaccharomyces pombe Sin1 CRIM domain
1FMF	;		;	REFINED SOLUTION STRUCTURE OF THE (13C,15N-LABELED) B12-BINDING SUBUNIT OF GLUTAMATE MUTASE FROM CLOSTRIDIUM TETANOMORPHUM
2DMO	;		;	Refined solution structure of the 1st SH3 domain from human Neutrophil cytosol factor 2 (NCF-2)
156D	;		;	REFINED SOLUTION STRUCTURE OF THE DIMERIC QUADRUPLEX FORMED FROM THE OXYTRICHA TELOMERIC OLIGONUCLEOTIDE D(GGGGTTTTGGGG)
1FHQ	;		;	REFINED SOLUTION STRUCTURE OF THE FHA2 DOMAIN OF RAD53
2RUG	;		;	Refined solution structure of the first RNA recognition motif domain in CPEB3
1GDC	;		;	REFINED SOLUTION STRUCTURE OF THE GLUCOCORTICOID RECEPTOR DNA-BINDING DOMAIN
2GDA	;		;	REFINED SOLUTION STRUCTURE OF THE GLUCOCORTICOID RECEPTOR DNA-BINDING DOMAIN
1O7B	;		;	Refined solution structure of the human TSG-6 Link module
1DK2	;		;	REFINED SOLUTION STRUCTURE OF THE N-TERMINAL DOMAIN OF DNA POLYMERASE BETA
1DK3	;		;	REFINED SOLUTION STRUCTURE OF THE N-TERMINAL DOMAIN OF DNA POLYMERASE BETA
2RP0	;		;	Refined solution structure of the PEMV-1 mRNA pseudoknot, 28 lowest energy structures
2RP1	;		;	Refined solution structure of the PEMV-1 mRNA pseudoknot, regularized average structure
1SY4	;		;	Refined solution structure of the S. cerevisiae U6 INTRAMOLECULAR STEM LOOP (ISL) RNA USING RESIDUAL DIPOLAR COUPLINGS (RDCS)
2GVA	;		;	REFINED SOLUTION STRUCTURE OF THE TYR 41--> HIS MUTANT OF THE M13 GENE V PROTEIN. A COMPARISON WITH THE CRYSTAL STRUCTURE
2GVB	;		;	REFINED SOLUTION STRUCTURE OF THE TYR 41--> HIS MUTANT OF THE M13 GENE V PROTEIN. A COMPARISON WITH THE CRYSTAL STRUCTURE
2LB5	;		;	Refined Structural Basis for the Photoconversion of A Phytochrome to the Activated FAR-RED LIGHT-ABSORBING Form
1JJZ	;		;	REFINED STRUCTURE AND DISULFIDE PAIRING OF THE KALATA B1 PEPTIDE
1K48	;		;	REFINED STRUCTURE AND DISULFIDE PAIRING OF THE KALATA B1 PEPTIDE
1DOG	;	2.3	;	REFINED STRUCTURE FOR THE COMPLEX OF 1-DEOXYNOJIRIMYCIN WITH GLUCOAMYLASE FROM (ASPERGILLUS AWAMORI) VAR. X100 TO 2.4 ANGSTROMS RESOLUTION
1AGM	;	2.3	;	Refined structure for the complex of acarbose with glucoamylase from Aspergillus awamori var. x100 to 2.4 angstroms resolution
1SHI	;		;	REFINED STRUCTURE IN SOLUTION OF THE SEA ANEMONE NEUROTOXIN SHI
1JFF	;	3.5	;	Refined structure of alpha-beta tubulin from zinc-induced sheets stabilized with taxol
2ALP	;	1.7	;	REFINED STRUCTURE OF ALPHA-LYTIC PROTEASE AT 1.7 ANGSTROMS RESOLUTION. ANALYSIS OF HYDROGEN BONDING AND SOLVENT STRUCTURE
1ALC	;	1.7	;	REFINED STRUCTURE OF BABOON ALPHA-LACTALBUMIN AT 1.7 ANGSTROMS RESOLUTION. COMPARISON WITH C-TYPE LYSOZYME
4TNC	;	2.0	;	REFINED STRUCTURE OF CHICKEN SKELETAL MUSCLE TROPONIN C IN THE TWO-CALCIUM STATE AT 2-ANGSTROMS RESOLUTION
5CNA	;	2.0	;	REFINED STRUCTURE OF CONCANAVALIN A COMPLEXED WITH ALPHA-METHYL-D-MANNOPYRANOSIDE AT 2.0 ANGSTROMS RESOLUTION AND COMPARISON WITH THE SACCHARIDE-FREE STRUCTURE
5CRO	;	2.3	;	REFINED STRUCTURE OF CRO REPRESSOR PROTEIN FROM BACTERIOPHAGE LAMBDA
2CDV	;	1.8	;	REFINED STRUCTURE OF CYTOCHROME C3 AT 1.8 ANGSTROMS RESOLUTION
5NPN	;		;	Refined structure of cytotoxin I
1LTS	;	1.95	;	REFINED STRUCTURE OF E. COLI HEAT LABILE ENTEROTOXIN, A CLOSE RELATIVE OF CHOLERA TOXIN
2RC5	;	2.431	;	Refined structure of FNR from Leptospira interrogans
2RC6	;	2.7	;	Refined structure of FNR from Leptospira interrogans bound to NADP+
3GRS	;	1.54	;	REFINED STRUCTURE OF GLUTATHIONE REDUCTASE AT 1.54 ANGSTROMS RESOLUTION
2KPE	;		;	Refined structure of Glycophorin A transmembrane segment dimer in DPC micelles
1CA2	;	2.0	;	REFINED STRUCTURE OF HUMAN CARBONIC ANHYDRASE II AT 2.0 ANGSTROMS RESOLUTION
4CAC	;	2.2	;	REFINED STRUCTURE OF HUMAN CARBONIC ANHYDRASE II AT 2.0 ANGSTROMS RESOLUTION
5CAC	;	2.2	;	REFINED STRUCTURE OF HUMAN CARBONIC ANHYDRASE II AT 2.0 ANGSTROMS RESOLUTION
1N4Y	;		;	REFINED STRUCTURE OF KISTRIN
1MLD	;	1.83	;	REFINED STRUCTURE OF MITOCHONDRIAL MALATE DEHYDROGENASE FROM PORCINE HEART AND THE CONSENSUS STRUCTURE FOR DICARBOXYLIC ACID OXIDOREDUCTASES
2MNH	;		;	Refined structure of outer membrane protein x in nanodisc by measuring residual dipolar couplings
1R9U	;		;	Refined structure of peptaibol zervamicin IIB in methanol solution from trans-hydrogen bond J couplings
3AV8	;	1.46	;	Refined Structure of Plant-type [2Fe-2S] Ferredoxin I from Aphanothece sacrum at 1.46 A Resolution
3ADK	;	2.1	;	REFINED STRUCTURE OF PORCINE CYTOSOLIC ADENYLATE KINASE AT 2.1 ANGSTROMS RESOLUTION
2PSG	;	1.8	;	REFINED STRUCTURE OF PORCINE PEPSINOGEN AT 1.8 ANGSTROMS RESOLUTION
1PRN	;	1.96	;	REFINED STRUCTURE OF PORIN FROM RHODOPSEUDOMONAS BLASTICA AND COMPARISON WITH THE PORIN FROM RHODOBACTER CAPSULATUS
1PVV	;	1.87	;	Refined Structure of Pyrococcus furiosus Ornithine Carbamoyltransferase at 1.87 A
1CCD	;	3.0	;	REFINED STRUCTURE OF RAT CLARA CELL 17 KDA PROTEIN AT 3.0 ANGSTROMS RESOLUTION
2RU7	;		;	Refined structure of RNA aptamer in complex with the partial binding peptide of prion protein
1NO3	;	2.15	;	REFINED STRUCTURE OF SOYBEAN LIPOXYGENASE-3 WITH 4-NITROCATECHOL AT 2.15 ANGSTROM RESOLUTION
1GOX	;	2.0	;	REFINED STRUCTURE OF SPINACH GLYCOLATE OXIDASE AT 2 ANGSTROMS RESOLUTION
2VIL	;		;	REFINED STRUCTURE OF THE ACTIN-SEVERING DOMAIN VILLIN 14T, DETERMINED BY SOLUTION NMR, 11 STRUCTURES
2VIK	;		;	REFINED STRUCTURE OF THE ACTIN-SEVERING DOMAIN VILLIN 14T, DETERMINED BY SOLUTION NMR, MINIMIZED AVERAGE STRUCTURE
7JSQ	;		;	Refined structure of the C-terminal domain of DNAJB6b
1GKY	;	2.0	;	REFINED STRUCTURE OF THE COMPLEX BETWEEN GUANYLATE KINASE AND ITS SUBSTRATE GMP AT 2.0 ANGSTROMS RESOLUTION
1EYF	;		;	REFINED STRUCTURE OF THE DNA METHYL PHOSPHOTRIESTER REPAIR DOMAIN OF E. COLI ADA
3QJO	;	4.0	;	Refined Structure of the functional unit (KLH1-H) of keyhole limpet hemocyanin
2GN5	;	2.3	;	REFINED STRUCTURE OF THE GENE 5 DNA BINDING PROTEIN FROM BACTERIOPHAGE FD
5JJ3	;	7.0	;	Refined Structure of the Mature Virion Conformation of P22 Portal Protein
2BG9	;	4.0	;	REFINED STRUCTURE OF THE NICOTINIC ACETYLCHOLINE RECEPTOR AT 4A RESOLUTION.
1COL	;	2.4	;	REFINED STRUCTURE OF THE PORE-FORMING DOMAIN OF COLICIN A AT 2.4 ANGSTROMS RESOLUTION
1PYA	;	2.5	;	REFINED STRUCTURE OF THE PYRUVOYL-DEPENDENT HISTIDINE DECARBOXYLASE FROM LACTOBACILLUS 30A
7QBY	;		;	Refined structure of the T193A mutant in the C-terminal domain of DNAJB6b
1TRK	;	2.0	;	REFINED STRUCTURE OF TRANSKETOLASE FROM SACCHAROMYCES CEREVISIAE AT 2.0 ANGSTROMS RESOLUTION
3ENL	;	2.25	;	REFINED STRUCTURE OF YEAST APO-ENOLASE AT 2.25 ANGSTROMS RESOLUTION
2XOK	;	3.01	;	Refined structure of yeast F1c10 ATPase complex to 3 A resolution
1HUJ	;	2.1	;	REFINED STRUCTURE OF YEAST INORGANIC PYROPHOSPHATASE AND ITS K61R MUTANT
1HUK	;	2.2	;	REFINED STRUCTURE OF YEAST INORGANIC PYROPHOSPHATASE AND ITS K61R MUTANT
1HPC	;	2.0	;	REFINED STRUCTURES AT 2 ANGSTROMS AND 2.2 ANGSTROMS OF THE TWO FORMS OF THE H-PROTEIN, A LIPOAMIDE-CONTAINING PROTEIN OF THE GLYCINE DECARBOXYLASE
1HTP	;	2.2	;	REFINED STRUCTURES AT 2 ANGSTROMS AND 2.2 ANGSTROMS OF THE TWO FORMS OF THE H-PROTEIN, A LIPOAMIDE-CONTAINING PROTEIN OF THE GLYCINE DECARBOXYLASE COMPLEX
1CZN	;	1.7	;	REFINED STRUCTURES OF OXIDIZED FLAVODOXIN FROM ANACYSTIS NIDULANS
1CZU	;	2.0	;	REFINED STRUCTURES OF OXIDIZED FLAVODOXIN FROM ANACYSTIS NIDULANS
1D03	;	1.85	;	REFINED STRUCTURES OF OXIDIZED FLAVODOXIN FROM ANACYSTIS NIDULANS
1THY	;	2.9	;	REFINED STRUCTURES OF SUBSTRATE-BOUND AND PHOSPHATE-BOUND THYMIDYLATE SYNTHASE FROM LACTOBACILLUS CASEI
1SPH	;	2.0	;	REFINED STRUCTURES OF THE ACTIVE S83C AND IMPAIRED S46D HPRS: EVIDENCE THAT PHOSPHORYLATION DOES NOT REQUIRE A BACKBONE CONFORMATIONAL TRANSITION
1MDP	;	2.3	;	REFINED STRUCTURES OF TWO INSERTION(SLASH)DELETION MUTANTS PROBE FUNCTION OF THE MALTODEXTRIN BINDING PROTEIN
1MDQ	;	1.9	;	REFINED STRUCTURES OF TWO INSERTION(SLASH)DELETION MUTANTS PROBE FUNCTION OF THE MALTODEXTRIN BINDING PROTEIN
1CXN	;		;	REFINED THREE-DIMENSIONAL SOLUTION STRUCTURE OF A SNAKE CARDIOTOXIN: ANALYSIS OF THE SIDE-CHAIN ORGANISATION SUGGESTS THE EXISTENCE OF A POSSIBLE PHOSPHOLIPID BINDING SITE
1CXO	;		;	REFINED THREE-DIMENSIONAL SOLUTION STRUCTURE OF A SNAKE CARDIOTOXIN: ANALYSIS OF THE SIDE-CHAIN ORGANISATION SUGGESTS THE EXISTENCE OF A POSSIBLE PHOSPHOLIPID BINDING SITE
1ICA	;		;	REFINED THREE-DIMENSIONAL STRUCTURE OF INSECT DEFENSIN A
1GIG	;	2.3	;	REFINED THREE-DIMENSIONAL STRUCTURE OF THE FAB FRAGMENT OF A MURINE IGG1, LAMBDA ANTIBODY
3OVO	;	1.55	;	REFINED X-RAY CRYSTAL STRUCTURES OF THE REACTIVE SITE MODIFIED OVOMUCOID INHIBITOR THIRD DOMAINS FROM SILVER PHEASANT (OMSVP3(ASTERISK)) AND FROM JAPANESE QUAIL (OMJPQ3(ASTERISK))
4OVO	;	2.5	;	REFINED X-RAY CRYSTAL STRUCTURES OF THE REACTIVE SITE MODIFIED OVOMUCOID INHIBITOR THIRD DOMAINS FROM SILVER PHEASANT (OMSVP3(ASTERISK)) AND FROM JAPANESE QUAIL (OMJPQ3(ASTERISK))
1NPK	;	1.8	;	REFINED X-RAY STRUCTURE OF DICTYOSTELIUM NUCLEOSIDE DIPHOSPHATE KINASE AT 1,8 ANGSTROMS RESOLUTION
1PE6	;	2.1	;	REFINED X-RAY STRUCTURE OF PAPAIN(DOT)E-64-C COMPLEX AT 2.1-ANGSTROMS RESOLUTION
1RTP	;	2.0	;	REFINED X-RAY STRUCTURE OF RAT PARVALBUMIN, A MAMMALIAN ALPHA-LINEAGE PARVALBUMIN, AT 2.0 A RESOLUTION
1EDE	;	1.9	;	REFINED X-RAY STRUCTURES OF HALOALKANE DEHALOGENASE AT PH 6.2 AND PH 8.2 AND IMPLICATIONS FOR THE REACTION MECHANISM
3CD4	;	2.2	;	REFINEMENT AND ANALYSIS OF THE FIRST TWO DOMAINS OF HUMAN CD4
1AJR	;	1.74	;	REFINEMENT AND COMPARISON OF THE CRYSTAL STRUCTURES OF PIG CYTOSOLIC ASPARTATE AMINOTRANSFERASE AND ITS COMPLEX WITH 2-METHYLASPARTATE
1AJS	;	1.6	;	REFINEMENT AND COMPARISON OF THE CRYSTAL STRUCTURES OF PIG CYTOSOLIC ASPARTATE AMINOTRANSFERASE AND ITS COMPLEX WITH 2-METHYLASPARTATE
3EBX	;	1.4	;	REFINEMENT AT 1.4 ANGSTROMS RESOLUTION OF A MODEL OF ERABUTOXIN B. TREATMENT OF ORDERED SOLVENT AND DISCRETE DISORDER
1I1P	;	1.63	;	REFINEMENT INCLUDING EXPERIMENTAL MAD PHASES ALLOWS AN EXHAUSTIVE STUDY OF ORDERED SOLVENT MOLECULES FOR A PLATINATED DECANUCLEOTIDE
2LHB	;	2.0	;	REFINEMENT OF A MOLECULAR MODEL FOR LAMPREY HEMOGLOBIN FROM PETROMYZON MARINUS
1THB	;	1.5	;	REFINEMENT OF A PARTIALLY OXYGENATED T STATE HAEMOGLOBIN AT 1.5 ANGSTROMS RESOLUTION
1P2Z	;	2.2	;	Refinement of Adenovirus Type 2 Hexon with CNS
1P30	;	2.5	;	Refinement of Adenovirus Type 5 Hexon with CNS
1HEW	;	1.75	;	REFINEMENT OF AN ENZYME COMPLEX WITH INHIBITOR BOUND AT PARTIAL OCCUPANCY. HEN EGG-WHITE LYSOZYME AND TRI-N-ACETYLCHITOTRIOSE AT 1.75 ANGSTROMS RESOLUTION
1LXI	;	2.0	;	Refinement of BMP7 crystal structure
1PQT	;		;	REFINEMENT OF d(GCGAAGC) HAIRPIN STRUCTURE USING ONE- AND TWO-BOND RESIDUAL DIPOLAR COUPLINGS
1KR8	;		;	Refinement of d(GCGAAGC) Hairpin Structure Using One-and Two-Bonds Residual Dipolar Couplings
2RSL	;	2.3	;	REFINEMENT OF GAMMA DELTA RESOLVASE REVEALS A STRIKINGLY FLEXIBLE MOLECULE
6XIA	;	1.65	;	REFINEMENT OF GLUCOSE ISOMERASE FROM STREPTOMYCES ALBUS AT 1.65 ANGSTROMS WITH DATA FROM AN IMAGING PLATE
1GQZ	;	1.75	;	Refinement of Haemophilus influenzae Diaminopimelate epimerase at 1.7A
1LZ1	;	1.5	;	REFINEMENT OF HUMAN LYSOZYME AT 1.5 ANGSTROMS RESOLUTION. ANALYSIS OF NON-BONDED AND HYDROGEN-BOND INTERACTIONS
4MBN	;	2.0	;	REFINEMENT OF MYOGLOBIN AND CYTOCHROME C
5CYT	;	1.5	;	REFINEMENT OF MYOGLOBIN AND CYTOCHROME C
5MBN	;	2.0	;	REFINEMENT OF MYOGLOBIN AND CYTOCHROME C
101D	;	2.25	;	REFINEMENT OF NETROPSIN BOUND TO DNA: BIAS AND FEEDBACK IN ELECTRON DENSITY MAP INTERPRETATION
2CD1	;		;	Refinement of P4 stemloop structure using residual dipolar coupling data
1XX2	;	1.88	;	Refinement of P99 beta-lactamase from Enterobacter cloacae
3MK0	;	1.9	;	Refinement of placental alkaline phosphatase complexed with nitrophenyl
3MK1	;	1.57	;	Refinement of placental alkaline phosphatase complexed with nitrophenyl
4OFV	;	3.1	;	Refinement of RAGE-DNA complex in 3S58 without DNA
4OF5	;	2.803	;	Refinement of RAGE-DNA complex in 3S59 without DNA
1RRO	;	1.3	;	REFINEMENT OF RECOMBINANT ONCOMODULIN AT 1.30 ANGSTROMS RESOLUTION
2RQ4	;		;	Refinement of RNA binding domain 3 in CUG triplet repeat RNA-binding protein 1
2RRB	;		;	Refinement of RNA binding domain in human Tra2 beta protein
2CD3	;		;	Refinement of RNase P P4 stemloop structure using residual dipolar coupling data - C70U mutant
2CD6	;		;	Refinement of RNase P P4 stemloop structure using residual dipolar coupling data, C70U mutant cobalt(III) hexammine complex
2CD5	;		;	Refinement of RNase P P4 stemloop structure using residual dipolar couplings - cobalt(III) hexammine complex structure
8RXN	;	1.0	;	REFINEMENT OF RUBREDOXIN FROM DESULFOVIBRIO VULGARIS AT 1.0 ANGSTROMS WITH AND WITHOUT RESTRAINTS
1UTG	;	1.34	;	REFINEMENT OF THE C2221 CRYSTAL FORM OF OXIDIZED UTEROGLOBIN AT 1.34 ANGSTROMS RESOLUTION
2C2C	;	2.0	;	REFINEMENT OF THE CRYSTAL STRUCTURE OF OXIDIZED RHODOSPIRILLUM RUBRUM CYTOCHROME C2
3C2C	;	1.68	;	REFINEMENT OF THE CRYSTAL STRUCTURE OF OXIDIZED RHODOSPIRILLUM RUBRUM CYTOCHROME C2
1RNU	;	1.6	;	REFINEMENT OF THE CRYSTAL STRUCTURE OF RIBONUCLEASE S. COMPARISON WITH AND BETWEEN THE VARIOUS RIBONUCLEASE A STRUCTURES
1RNV	;	1.6	;	REFINEMENT OF THE CRYSTAL STRUCTURE OF RIBONUCLEASE S. COMPARISON WITH AND BETWEEN THE VARIOUS RIBONUCLEASE A STRUCTURES
2RNS	;	1.6	;	REFINEMENT OF THE CRYSTAL STRUCTURE OF RIBONUCLEASE S. COMPARISON WITH AND BETWEEN THE VARIOUS RIBONUCLEASE A STRUCTURES
2HMG	;	3.0	;	REFINEMENT OF THE INFLUENZA VIRUS HEMAGGLUTININ BY SIMULATED ANNEALING
3HMG	;	2.9	;	REFINEMENT OF THE INFLUENZA VIRUS HEMAGGLUTININ BY SIMULATED ANNEALING
4HMG	;	3.0	;	REFINEMENT OF THE INFLUENZA VIRUS HEMAGGLUTININ BY SIMULATED ANNEALING
5HMG	;	3.2	;	REFINEMENT OF THE INFLUENZA VIRUS HEMAGGLUTININ BY SIMULATED ANNEALING
2ABK	;	1.85	;	REFINEMENT OF THE NATIVE STRUCTURE OF ENDONUCLEASE III TO A RESOLUTION OF 1.85 ANGSTROM
1ACP	;		;	REFINEMENT OF THE NMR STRUCTURES FOR ACYL CARRIER PROTEIN WITH SCALAR COUPLING DATA
1PVC	;	2.4	;	REFINEMENT OF THE SABIN STRAIN OF TYPE 3 POLIOVIRUS AT 2.4 ANGSTROMS AND THE CRYSTAL STRUCTURES OF ITS VARIANTS AT 2.9 ANGSTROMS RESOLUTION
1GRM	;		;	REFINEMENT OF THE SPATIAL STRUCTURE OF THE GRAMICIDIN A TRANSMEMBRANE ION-CHANNEL (RUSSIAN)
1FGA	;	2.2	;	REFINEMENT OF THE STRUCTURE OF HUMAN BASIC FIBROBLAST GROWTH FACTOR AT 1.6 ANGSTROMS RESOLUTION AND ANALYSIS OF PRESUMED HEPARIN BINDING SITES BY SELENATE SUBSTITUTION
4FGF	;	1.6	;	REFINEMENT OF THE STRUCTURE OF HUMAN BASIC FIBROBLAST GROWTH FACTOR AT 1.6 ANGSTROMS RESOLUTION AND ANALYSIS OF PRESUMED HEPARIN BINDING SITES BY SELENATE SUBSTITUTION
1PAZ	;	1.55	;	REFINEMENT OF THE STRUCTURE OF PSEUDOAZURIN FROM ALCALIGENES FAECALIS S-6 AT 1.55 ANGSTROMS RESOLUTION
1IFC	;	1.19	;	REFINEMENT OF THE STRUCTURE OF RECOMBINANT RAT INTESTINAL FATTY ACID-BINDING APOPROTEIN AT 1.2 ANGSTROMS RESOLUTION
3CI2	;		;	REFINEMENT OF THE THREE-DIMENSIONAL SOLUTION STRUCTURE OF BARLEY SERINE PROTEINASE INHIBITOR 2 AND COMPARISON WITH THE STRUCTURES IN CRYSTALS
1LZT	;	1.97	;	REFINEMENT OF TRICLINIC LYSOZYME
3LZT	;	0.925	;	REFINEMENT OF TRICLINIC LYSOZYME AT ATOMIC RESOLUTION
2LZT	;	1.97	;	REFINEMENT OF TRICLINIC LYSOZYME. II. THE METHOD OF STEREOCHEMICALLY RESTRAINED LEAST-SQUARES
1LEN	;	1.8	;	REFINEMENT OF TWO CRYSTAL FORMS OF LENTIL LECTIN AT 1.8 ANGSTROMS RESOLUTION
5L6Q	;	1.4	;	Refolded AL protein from cardiac amyloidosis
1CPI	;	2.05	;	REGIOSELECTIVE STRUCTURAL AND FUNCTIONAL MIMICRY OF PEPTIDES. DESIGN OF HYDROLYTICALLY STABLE CYCLIC PEPTIDOMIMETIC INHIBITORS OF HIV-1 PROTEASE
7JKM	;	1.78	;	REGN1 Human Fab in complex with anti-Kappa VHH domain
2N5L	;		;	Regnase-1 C-terminal domain
2N5J	;		;	Regnase-1 N-terminal domain
2N5K	;		;	Regnase-1 Zinc finger domain
2NUU	;	2.5	;	Regulating the Escherichia coli ammonia channel: the crystal structure of the AmtB-GlnK complex
5ICD	;	2.5	;	REGULATION OF AN ENZYME BY PHOSPHORYLATION AT THE ACTIVE SITE
6ICD	;	2.8	;	REGULATION OF AN ENZYME BY PHOSPHORYLATION AT THE ACTIVE SITE
7ICD	;	2.4	;	REGULATION OF AN ENZYME BY PHOSPHORYLATION AT THE ACTIVE SITE
8ICD	;	2.5	;	REGULATION OF AN ENZYME BY PHOSPHORYLATION AT THE ACTIVE SITE
1UTX	;	1.9	;	Regulation of Cytolysin Expression by Enterococcus faecalis: Role of CylR2
1LX8	;		;	Regulation of directionality in bacteriophage lambda site-specific recombination: structure of the Xis protein
4ICD	;	2.5	;	REGULATION OF ISOCITRATE DEHYDROGENASE BY PHOSPHORYLATION INVOLVES NO LONG-RANGE CONFORMATIONAL CHANGE IN THE FREE ENZYME
1OYO	;	2.02	;	Regulation of protease activity by melanin: Crystal structure of the complex formed between proteinase K and melanin monomers at 2.0 resolution
3CVB	;	1.4	;	Regulation of Protein Function: Crystal Packing Interfaces and Conformational Dimerization
3CVC	;	1.72	;	Regulation of Protein Function: Crystal Packing Interfaces and Conformational Dimerization
3CVD	;	1.5	;	Regulation of Protein Function: Crystal Packing Interfaces and Conformational Dimerization
5TWF	;	3.136	;	Regulation of protein interactions by MOB1 phosphorylation
1ZVD	;	2.1	;	Regulation of Smurf2 Ubiquitin Ligase Activity by Anchoring the E2 to the HECT domain
2IU6	;	2.0	;	REGULATION OF THE DHA OPERON OF LACTOCOCCUS LACTIS
4CXG	;	8.7	;	Regulation of the mammalian elongation cycle by 40S subunit rolling: a eukaryotic-specific ribosome rearrangement
4CXH	;	8.9	;	Regulation of the mammalian elongation cycle by 40S subunit rolling: a eukaryotic-specific ribosome rearrangement
4UJE	;	6.9	;	Regulation of the mammalian elongation cycle by 40S subunit rolling: a eukaryotic-specific ribosome rearrangement
1B9M	;	1.75	;	REGULATOR FROM ESCHERICHIA COLI
1B9N	;	2.09	;	REGULATOR FROM ESCHERICHIA COLI
1A12	;	1.7	;	REGULATOR OF CHROMOSOME CONDENSATION (RCC1) OF HUMAN
6AM3	;	1.53	;	Regulator of G protein signaling (RGS) 17 in complex with Ca2+
2BV1	;	2.0	;	Regulator of G-protein Signalling 1 (Human)
1GRO	;	2.5	;	REGULATORY AND CATALYTIC MECHANISMS IN ESCHERICHIA COLI ISOCITRATE DEHYDROGENASE: MULTIPLE ROLES FOR N115
1GRP	;	2.5	;	REGULATORY AND CATALYTIC MECHANISMS IN ESCHERICHIA COLI ISOCITRATE DEHYDROGENASE: MULTIPLE ROLES FOR N115
2AAO	;	2.0	;	Regulatory apparatus of Calcium Dependent protein kinase from Arabidopsis thaliana
1C7Z	;	2.6	;	REGULATORY COMPLEX OF FRUCTOSE-2,6-BISPHOSPHATASE
1C80	;	2.2	;	REGULATORY COMPLEX OF FRUCTOSE-2,6-BISPHOSPHATASE
3T9O	;	2.2	;	Regulatory CZB domain of DgcZ
7QRI	;		;	Regulatory domain dimer of tryptophan hydroxylase 2 in complex with L-Phe
5FHK	;	1.905	;	Regulatory domain of AphB in Vibrio vulnificus
5X0O	;	2.402	;	Regulatory domain of AphB treated with Cumene hydroperoxide from Vibrio vulnificus
1SPY	;		;	REGULATORY DOMAIN OF HUMAN CARDIAC TROPONIN C IN THE CALCIUM-FREE STATE, NMR, 40 STRUCTURES
1AP4	;		;	REGULATORY DOMAIN OF HUMAN CARDIAC TROPONIN C IN THE CALCIUM-SATURATED STATE, NMR, 40 STRUCTURES
5YDO	;	2.0	;	Regulatory domain of HypT from Salmonella typhimurium (apo-form)
5YER	;	2.301	;	Regulatory domain of HypT from Salmonella typhimurium (Bromide ion-bound)
5YDV	;	1.752	;	Regulatory domain of HypT from Salmonella typhimurium complexed with HOCl (HOCl-bound form)
5YEZ	;	2.6	;	Regulatory domain of HypT M206Q mutant from Salmonella typhimurium
5X0N	;	2.993	;	Regulatory domain of variant C227S AphB from Vibrio vulnificus
4AB5	;	2.51	;	Regulatory domain structure of NMB2055 (MetR) a LysR family regulator from N. meningitidis
4AB6	;	2.8	;	Regulatory domain structure of NMB2055 (MetR), C103S C106S mutant, a LysR family regulator from N. meningitidis
1QAW	;	2.5	;	Regulatory Features of the TRP Operon and the Crystal Structure of the TRP RNA-Binding Attenuation Protein from Bacillus Stearothermophilus.
3MEI	;	1.968	;	Regulatory motif from the thymidylate synthase mRNA
1MC0	;	2.86	;	Regulatory Segment of Mouse 3',5'-Cyclic Nucleotide Phosphodiesterase 2A, Containing the GAF A and GAF B Domains
6FLO	;	2.13869	;	Regulatory subunit of a cAMP-independent protein kinase A from Trypanosoma brucei at 2.1 Angstrom resolution
6H4G	;	2.14352	;	Regulatory subunit of a cAMP-independent protein kinase A from Trypanosoma brucei: E311A, T318R, V319A mutant bound to cAMP in the A site
6FTF	;	1.09152	;	Regulatory subunit of a cAMP-independent protein kinase A from Trypanosoma cruzi at 1.09 A resolution
6HYI	;	1.39945	;	Regulatory subunit of a cAMP-independent protein kinase A from Trypanosoma cruzi at 1.4 A resolution in complex with inosine
6HYQ	;	2.08	;	Regulatory subunit of a cAMP-independent protein kinase A from Trypanosoma cruzi bound to guanosine
1RGS	;	2.8	;	REGULATORY SUBUNIT OF CAMP DEPENDENT PROTEIN KINASE
6RSX	;	1.6	;	Regulatory Subunit of cAMP-dependant Protein Kinase A from Euglena gracilis at 1.6 A resolution
1YUP	;	2.1	;	Reindeer beta-lactoglobulin
2IV2	;	2.27	;	Reinterpretation of reduced form of formate dehydrogenase H from E. coli
3QBA	;	1.4	;	Reintroducing Electrostatics into Macromolecular Crystallographic Refinement: Z-DNA (X-ray)
3QBA	;	1.53	;	Reintroducing Electrostatics into Macromolecular Crystallographic Refinement: Z-DNA (X-ray)
1KSB	;		;	Relationship of Solution and Protein-Bound Structures of DNA Duplexes with the Major Intrastrand Cross-Link Lesions Formed on Cisplatin Binding to DNA
3CTI	;		;	RELAXATION MATRIX REFINEMENT OF THE SOLUTION STRUCTURE OF SQUASH TRYPSIN INHIBITOR
1ARQ	;		;	RELAXATION MATRIX REFINEMENT OF THE SOLUTION STRUCTURE OF THE ARC REPRESSOR
1ARR	;		;	RELAXATION MATRIX REFINEMENT OF THE SOLUTION STRUCTURE OF THE ARC REPRESSOR
1M9L	;		;	Relaxation-based Refined Structure Of Chlamydomonas Outer Arm Dynein Light Chain 1
5XK5	;		;	Relaxed state of S65-phosphorylated ubiquitin
6KOX	;		;	Relaxed state of S65/T66 double-phosphorylated ubiquitin
8G8Q	;	2.6	;	RelB NLS in complex with Importin alpha 2
8G8R	;	2.6	;	RelB NLS in complex with Importin alpha 2
6ORE	;	2.9	;	Release complex 70S
6SZS	;	3.06	;	Release factor-dependent ribosome rescue by BrfA in the Gram-positive bacterium Bacillus subtilis
482D	;	1.54	;	RELEASE OF THE CYANO MOIETY IN THE CRYSTAL STRUCTURE OF N-CYANOMETHYL-N-(2-METHOXYETHYL)-DAUNOMYCIN COMPLEXED WITH D(CGATCG)
1BRA	;	2.2	;	RELOCATING A NEGATIVE CHARGE IN THE BINDING POCKET OF TRYPSIN
1BRC	;	2.5	;	RELOCATING A NEGATIVE CHARGE IN THE BINDING POCKET OF TRYPSIN
3AH6	;	2.4	;	Remarkable improvement of the heat stability of CutA1 from E.coli by rational protein designing
6OBI	;		;	Remarkable rigidity of the single alpha-helical domain of myosin-VI revealed by NMR spectroscopy
6DFY	;	2.623	;	Remodeled crystal structure of DNA-bound DUX4-HD2
5YDT	;	4.5	;	Remodeled Utp30 in 90S pre-ribosome (Mtr4-depleted, Enp1-TAP)
3J0S	;	9.0	;	Remodeling of actin filaments by ADF cofilin proteins
8E4G	;	3.2	;	Remodeling of the bacteriophage T7 during initial infection
2WQY	;	2.1	;	Remodelling of carboxin binding to the Q-site of avian respiratory complex II
3K0V	;	1.91	;	Removal of sugars and sugars-like molecules from the solution by C-lobe of lactoferrin: Crystal structure of the complex of C-lobe with beta-D-glucopyranosyl-(1->4)-beta-D-galactopyranosyl-(1->4)-alpha-D-glucopyranose at 1.9 A resolution
4ZCD	;	1.6605	;	Renalase in complex with NAD+
4ZCC	;	1.997	;	Renalase in complex with NADH
5KRQ	;	2.086	;	Renalase in complex with NADPH
4XX4	;	2.4	;	Renin in complex with (4S)-4-isopropyl-4-methyl-6-oxo-1-(3-(2-oxo-4-phenylpyrrolidin-1-yl)benzyl)tetrahydropyrimidin-2(1H)-iminium
4XX3	;	2.4	;	Renin in complex with (S)-1-(3-(benzylcarbamoyl)benzyl)-4-isopropyl-4-methyl-6-oxotetrahydropyrimidin-2(1H)-iminium
4S1G	;	2.1	;	Renin in complex with (S)-1-(3-fluoro-5-(((S)-1-phenylethyl)carbamoyl)benzyl)-4-isopropyl-4-methyl-6-oxotetrahydropyrimidin-2(1H)-iminium
4RZ1	;	2.6	;	RENIN IN COMPLEXED WITH (3S,4S)-4-({[4-methoxy-3-(3-methoxypropoxy)benzoyl](propan-2-yl)amino}methyl)pyrrolidin-3-yl benzylcarbamate INHIBITOR
4RYC	;	2.45	;	RENIN IN COMPLEXED WITH 4-methoxy-3-(3-methoxypropoxy)-N-{[(3S,4S)-4-{[(4-methylphenyl)sulfonyl]amino}pyrrolidin-3-yl]methyl}-N-(propan-2-yl)benzamide INHIBITOR
4RYG	;	2.65	;	RENIN IN COMPLEXED WITH N-({(3S,4S)-4-[(benzylsulfonyl)amino]pyrrolidin-3-yl}methyl)-4-methoxy-3-(3-methoxypropoxy)-N-(propan-2-yl)benzamide INHIBITOR
6TIF	;	1.6	;	ReoM- Listeria monocytogenes
1EJ6	;	3.6	;	Reovirus core
1MUK	;	2.5	;	reovirus lambda3 native structure
1UON	;	7.6	;	REOVIRUS POLYMERASE LAMBDA-3 LOCALIZED BY ELECTRON CRYOMICROSCOPY OF VIRIONS AT 7.6-A RESOLUTION
1MWH	;	2.5	;	REOVIRUS POLYMERASE LAMBDA3 BOUND TO MRNA CAP ANALOG
1N38	;	2.8	;	reovirus polymerase lambda3 elongation complex with one phosphodiester bond formed
6ROR	;	2.601	;	REP related 18-mer DNA
6ROS	;	2.7	;	REP related 18-mer DNA
6ROU	;	2.902	;	REP related 18-mer DNA
7Z7L	;	2.5	;	REP-related Chom18 variant with double AC mismatch
7Z82	;	3.2	;	REP-related Chom18 variant with double AG mismatch
7Z7K	;	2.7	;	REP-related Chom18 variant with double AT base pairing
7Z7M	;	2.6	;	REP-related Chom18 variant with double CC mismatch
7Z7U	;	2.75	;	REP-related Chom18 variant with double CG base pair
7Z7W	;	2.75	;	REP-related Chom18 variant with double GC base pairing
7Z7Y	;	2.7	;	REP-related Chom18 variant with double GT mismatch
7Z7Z	;	2.9	;	REP-related Chom18 variant with double TA base pair
7Z81	;	2.75	;	REP-related Chom18 variant with double TC mismatch
3PPT	;	1.28	;	REP1-NXSQ fatty acid transporter
3PP6	;	1.9	;	REP1-NXSQ fatty acid transporter Y128F mutant
3URE	;	1.49	;	Repack mutant (T181I, W199L, Q210I) of alpha-Lytic Protease
1PQK	;	2.0	;	Repacking of the Core of T4 Lysozyme by Automated Design
8AMV	;	2.77	;	RepB pMV158 hexamer
8AMU	;	3.0	;	RepB pMV158 OBD domain bound to DDR region
4NI6	;	1.1	;	Repeat domain 1 of Clostridium perfringens CPE0147
4MKM	;	1.75	;	Repeat domains 1 & 2 of Clostridium perfringens Cpe0147
6GBJ	;	1.63	;	Repertoires of functionally diverse enzymes through computational design at epistatic active-site positions
6GBK	;	1.9	;	Repertoires of functionally diverse enzymes through computational design at epistatic active-site positions
6GBL	;	1.95	;	Repertoires of functionally diverse enzymes through computational design at epistatic active-site positions
2LYI	;		;	Repetitive domain (RP) of aciniform spidroin 1 from Nephila antipodiana
2UUE	;	2.06	;	REPLACE: A strategy for Iterative Design of Cyclin Binding Groove Inhibitors
2V22	;	2.6	;	REPLACE: A strategy for Iterative Design of Cyclin Binding Groove Inhibitors
1DUR	;	2.0	;	Replacement for 1FDX 2(4FE4S) ferredoxin from (NOW) Peptostreptococcus asaccharolyticus
1CIA	;	2.5	;	REPLACEMENT OF CATALYTIC HISTIDINE-195 OF CHLORAMPHENICOL ACETYLTRANSFERASE: EVIDENCE FOR A GENERAL BASE ROLE FOR GLUTAMATE
3EAW	;	1.86	;	Replacement of Val3 in Human Thymidylate Synthase Affects Its Kinetic Properties and Intracellular Stability
3EBU	;	2.05	;	Replacement of Val3 in Human Thymidylate Synthase Affects Its Kinetic Properties and Intracellular Stability
3ED7	;	1.56	;	Replacement of Val3 in Human Thymidylate Synthase Affects Its Kinetic Properties and Intracellular Stability
3EDW	;	1.75	;	Replacement of Val3 in Human Thymidylate Synthase Affects Its Kinetic Properties and Intracellular Stability
3EF9	;	3.2	;	Replacement of Val3 in Human Thymidylate Synthase Affects Its Kinetic Properties and Intracellular Stability
3EJL	;	3.2	;	Replacement of Val3 in Human Thymidylate Synthase Affects Its Kinetic Properties and Intracellular Stability
3GG5	;	2.77	;	Replacement of Val3 in Human Thymidylate Synthase Affects Its Kinetic Properties and Intracellular Stability
3GH0	;	1.56	;	Replacement of Val3 in Human Thymidylate Synthase Affects Its Kinetic Properties and Intracellular Stability
3GH2	;	1.75	;	Replacement of Val3 in Human Thymidylate Synthase Affects Its Kinetic Properties and Intracellular Stability
1CSU	;	1.81	;	REPLACEMENTS IN A CONSERVED LEUCINE CLUSTER IN THE HYDROPHOBIC HEME POCKET OF CYTOCHROME C
1CSV	;	1.9	;	REPLACEMENTS IN A CONSERVED LEUCINE CLUSTER IN THE HYDROPHOBIC HEME POCKET OF CYTOCHROME C
1CSW	;	1.9	;	REPLACEMENTS IN A CONSERVED LEUCINE CLUSTER IN THE HYDROPHOBIC HEME POCKET OF CYTOCHROME C
1CSX	;	1.9	;	REPLACEMENTS IN A CONSERVED LEUCINE CLUSTER IN THE HYDROPHOBIC HEME POCKET OF CYTOCHROME C
1L25	;	1.8	;	REPLACEMENTS OF PRO86 IN PHAGE T4 LYSOZYME EXTEND AN ALPHA-HELIX BUT DO NOT ALTER PROTEIN STABILITY
1L26	;	1.7	;	REPLACEMENTS OF PRO86 IN PHAGE T4 LYSOZYME EXTEND AN ALPHA-HELIX BUT DO NOT ALTER PROTEIN STABILITY
1L27	;	1.8	;	REPLACEMENTS OF PRO86 IN PHAGE T4 LYSOZYME EXTEND AN ALPHA-HELIX BUT DO NOT ALTER PROTEIN STABILITY
1L28	;	1.9	;	REPLACEMENTS OF PRO86 IN PHAGE T4 LYSOZYME EXTEND AN ALPHA-HELIX BUT DO NOT ALTER PROTEIN STABILITY
1L29	;	1.7	;	REPLACEMENTS OF PRO86 IN PHAGE T4 LYSOZYME EXTEND AN ALPHA-HELIX BUT DO NOT ALTER PROTEIN STABILITY
1L30	;	1.7	;	REPLACEMENTS OF PRO86 IN PHAGE T4 LYSOZYME EXTEND AN ALPHA-HELIX BUT DO NOT ALTER PROTEIN STABILITY
1L31	;	1.8	;	REPLACEMENTS OF PRO86 IN PHAGE T4 LYSOZYME EXTEND AN ALPHA-HELIX BUT DO NOT ALTER PROTEIN STABILITY
1L32	;	1.7	;	REPLACEMENTS OF PRO86 IN PHAGE T4 LYSOZYME EXTEND AN ALPHA-HELIX BUT DO NOT ALTER PROTEIN STABILITY
2CHQ	;	3.5	;	Replication Factor C ADPNP complex
2CHV	;	4.0	;	Replication Factor C ADPNP complex
2CHG	;	2.1	;	Replication Factor C domains 1 and 2
3R8F	;	3.366	;	Replication initiator DnaA bound to AMPPCP and single-stranded DNA
7SGC	;	2.7	;	Replication Initiator Protein REPE54 and cognate DNA sequence with terminal five prime phosphates.
7SPM	;	3.28	;	Replication Initiator Protein REPE54 and cognate DNA sequence with terminal three prime phosphates chemically crosslinked (30 mg/mL EDC, 12 hours, 2 doses).
7SOZ	;	3.14	;	Replication Initiator Protein REPE54 and cognate DNA sequence with terminal three prime phosphates chemically crosslinked (5 mg/mL EDC, 12 hours).
7SDP	;	3.01	;	Replication Initiator Protein REPE54 and cognate DNA sequence with terminal three prime phosphates.
1RYR	;	2.28	;	REPLICATION OF A CIS-SYN THYMINE DIMER AT ATOMIC RESOLUTION
1RYS	;	2.03	;	REPLICATION OF A CIS-SYN THYMINE DIMER AT ATOMIC RESOLUTION
3V6H	;	2.3	;	Replication of N2,3-Ethenoguanine by DNA Polymerases
3V6J	;	2.3	;	Replication of N2,3-Ethenoguanine by DNA Polymerases
3V6K	;	3.6	;	Replication of N2,3-Ethenoguanine by DNA Polymerases
1BM9	;	2.0	;	REPLICATION TERMINATOR PROTEIN FROM BACILLUS SUBTILIS
5IOH	;	2.566	;	RepoMan-PP1a (protein phosphatase 1, alpha isoform) holoenzyme complex
5INB	;	1.3	;	RepoMan-PP1g (protein phosphatase 1, gamma isoform) holoenzyme complex
8FV5	;	4.21	;	Representation of 16-mer phiPA3 PhuN Lattice, p2
5UJL	;		;	Representative 1-conformer ensembles of K27-linked Ub2 from RDC data
5UJN	;		;	Representative 2-conformer ensembles of K27-linked Ub2 from RDC data
1R9K	;		;	Representative solution structure of the catalytic domain of SopE2
7SQ2	;	2.6	;	Reprocessed and refined structure of Phospholipase C-beta and Gq signaling complex
6Z3G	;	2.78	;	Repulsive Guidance Molecule A (RGMA) in complex with Growth Differentiation Factor 5 (GDF5)
6Z3J	;	1.65	;	Repulsive Guidance Molecule B (RGMB) in complex with Growth Differentiation Factor 5 (GDF5) (crystal form 1)
6Z3H	;	3.158	;	Repulsive Guidance Molecule B (RGMB) in complex with Growth Differentiation Factor 5 (GDF5) (crystal form 2)
6Z3M	;	5.501	;	Repulsive Guidance Molecule B (RGMB) in complex with Growth Differentiation Factor 5 (GDF5) and Neogenin 1 (NEO1).
6Z3L	;	2.513	;	Repulsive Guidance Molecule C (RGMC, Hemojuvelin, HJV, HFE2) in complex with Growth Differentiation Factor 5 (GDF5)
6NR7	;	3.0	;	Rerefinement of chicken vinculin
2H1A	;	2.4	;	ResA C74A Variant
2H1G	;	3.1	;	ResA C74A/C77A
2H1B	;	1.95	;	ResA E80Q
2H1D	;	2.6	;	ResA pH 9.25
1ZRR	;		;	Residual Dipolar Coupling Refinement of Acireductone Dioxygenase from Klebsiella
1GFY	;	2.13	;	RESIDUE 259 IS A KEY DETERMINANT OF SUBSTRATE SPECIFICITY OF PROTEIN-TYROSINE PHOSPHATASE 1B AND ALPHA
6BYO	;	3.6	;	Residue assignment correction to the voltage gated calcium Cav1.1 rabbit alpha 1 subunit PDB entries 3JBR & 5GJV
2AUP	;	1.8	;	Residue F4 plays a key role in modulating oxygen affinity and cooperativity in Scapharca dimeric hemoglobin
2AUO	;	1.53	;	Residue F4 plays a key role in modulating the oxygen affinity and cooperatrivity in Scapharca dimeric hemoglobin
7W91	;	3.292	;	Residues 440-490 of centrosomal protein 63
2MU8	;		;	Residues belonging the n-terminal region derived of merozoite surface protein-2 of plasmodium falciparum
1M07	;	1.8	;	RESIDUES INVOLVED IN THE CATALYSIS AND BASE SPECIFICITY OF CYTOTOXIC RIBONUCLEASE FROM BULLFROG (RANA CATESBEIANA)
6N86	;	3.9	;	Resistance to inhibitors of cholinesterase 8A (Ric8A) protein
6N85	;	2.5	;	Resistance to inhibitors of cholinesterase 8A (Ric8A) protein in complex with MBP-tagged transducin-alpha residues 327-350
1Z3Q	;	1.7	;	Resolution of the structure of the allergenic and antifungal banana fruit thaumatin-like protein at 1.7A
4MAB	;	1.9	;	Resolving Cys to Ala variant of Salmonella Alkyl Hydroperoxide Reductase C in its substrate-ready conformation
4BXC	;	2.86	;	Resolving the activation site of positive regulators in plant phosphoenolpyruvate carboxylase
4BXH	;	2.24	;	Resolving the activation site of positive regulators in plant phosphoenolpyruvate carboxylase
2MH9	;		;	Resonance assignment of RQC domain of human Bloom syndrome protein
5I1X	;		;	Resonance assignments and NMR structure determination of tarantula toxin, F8A mutant of beta-TRTX-Pre1a
5I2P	;		;	Resonance assignments and NMR structure determination of tarantula toxin- W7A mutant of mu-TRTX-Pre1a (W6A in native sequence numbering)
2MZV	;		;	Resonance assignments and secondary structure of a phytocystatin from Sesamum indicum
1SXL	;		;	RESONANCE ASSIGNMENTS AND SOLUTION STRUCTURE OF THE SECOND RNA-BINDING DOMAIN OF SEX-LETHAL DETERMINED BY MULTIDIMENSIONAL HETERONUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
2NBC	;		;	Resonance assignments and structure determination of poneritoxin, omega-PONTX-Ae1a, from Anochetus emarginatus
4TVW	;	3.505	;	Resorufin ligase with bound resorufin-AMP analog
2IX9	;	1.7	;	Respective role of protein folding and glycosylation in the thermal stability of recombinant Feruloyl Esterase A
6ADQ	;	3.5	;	Respiratory Complex CIII2CIV2SOD2 from Mycobacterium smegmatis
7NYR	;	3.3	;	Respiratory complex I from Escherichia coli - conformation 1
7NYU	;	3.8	;	Respiratory complex I from Escherichia coli - conformation 2
7NYV	;	3.7	;	Respiratory complex I from Escherichia coli - conformation 3
7NZ1	;	2.1	;	Respiratory complex I from Escherichia coli - focused refinement of cytoplasmic arm
7NYH	;	3.6	;	Respiratory complex I from Escherichia coli - focused refinement of membrane arm
6Y11	;	3.109	;	Respiratory complex I from Thermus thermophilus
6Q8W	;	3.4	;	Respiratory complex I from Thermus thermophilus with bound Aureothin.
6I0D	;	3.6	;	Respiratory complex I from Thermus thermophilus with bound Decyl-Ubiquinone
6I1P	;	3.207	;	Respiratory complex I from Thermus thermophilus with bound NADH
6Q8O	;	3.605	;	Respiratory complex I from Thermus thermophilus with bound Piericidin A
6Q8X	;	3.508	;	Respiratory complex I from Thermus thermophilus with bound Pyridaben.
6ZJL	;	4.3	;	Respiratory complex I from Thermus thermophilus, NAD+ dataset, major state
6ZJY	;	5.5	;	Respiratory complex I from Thermus thermophilus, NAD+ dataset, minor state
6ZIY	;	4.25	;	Respiratory complex I from Thermus thermophilus, NADH dataset, major state
6ZJN	;	6.1	;	Respiratory complex I from Thermus thermophilus, NADH dataset, minor state
1QLB	;	2.33	;	respiratory complex II-like fumarate reductase from Wolinella succinogenes
2WJ8	;	3.29	;	Respiratory Syncitial Virus RiboNucleoProtein
6OJ7	;	1.45	;	Respiratory syncytial virus fusion glycoprotein N-terminal heptad repeat domain+VIQKI I456F
6NTX	;	2.2	;	Respiratory syncytial virus fusion protein N-terminal heptad repeat domain+VIQKI
8IUO	;	3.96	;	respiratory syncytial virus nucleocapsid-like assembly
1BN9	;		;	RESPONSE ELEMENT OF THE ORPHAN NUCLEAR RECEPTOR REV-ERB BETA
1I3C	;	1.9	;	RESPONSE REGULATOR FOR CYANOBACTERIAL PHYTOCHROME, RCP1
1W25	;	2.7	;	Response regulator PleD in complex with c-diGMP
3AHC	;	1.7	;	Resting form of Phosphoketolase from Bifidobacterium Breve
2IWF	;	1.86	;	Resting form of pink nitrous oxide reductase from Achromobacter Cycloclastes
4WHP	;	1.541	;	Resting Protocatechuate 3,4-dioxygenase (pseudomonas putida) at pH 6.5
4WHO	;	1.83	;	Resting Protocatechuate 3,4-dioxygenase (pseudomonas putida) at pH 8.5
5ONX	;	1.6	;	Resting state copper nitrite reductase determined by serial femtosecond rotation crystallography
7OCA	;	3.4	;	Resting state full-length GluA1/A2 heterotertramer in complex with TARP gamma 8 and CNIH2
7OCE	;	3.1	;	Resting state GluA1/A2 AMPA receptor in complex with TARP gamma 8 and CNIH2 (LBD-TMD)
8AYM	;	3.3	;	Resting state GluA1/A2 AMPA receptor in complex with TARP gamma 8 and ligand JNJ-55511118
8AYL	;	3.2	;	Resting state GluA1/A2 AMPA receptor in complex with TARP gamma 8 and ligand JNJ-61432059
8AYN	;	2.8	;	Resting state GluA1/A2 AMPA receptor in complex with TARP gamma 8 and ligand LY3130481
7OCD	;	3.5	;	Resting state GluA1/A2 heterotetramer in complex with auxiliary subunit TARP gamma 8 (LBD-TMD)
8C1Q	;	2.82	;	Resting state homomeric GluA1 AMPA receptor in complex with TARP gamma 3
8C1R	;	3.2	;	Resting state homomeric GluA2 F231A mutant AMPA receptor in complex with TARP gamma-2
4AQ2	;	1.95	;	resting state of homogentisate 1,2-dioxygenase
4KWJ	;	1.75	;	Resting state of rat cysteine dioxygenase
4YYO	;	1.77	;	Resting state of rat cysteine dioxygenase C164S variant
4UBG	;	1.9	;	Resting state of rat cysteine dioxygenase C93G variant
4YSF	;	1.94	;	Resting state of rat cysteine dioxygenase H155N variant
5EFU	;	2.8	;	Resting state of rat cysteine dioxygenase H155Q variant
6U1M	;	1.61	;	Resting state of rat cysteine dioxygenase R60E variant
4UBH	;	1.81	;	Resting state of rat cysteine dioxygenase Y157F variant
6S6V	;	3.5	;	Resting state of the E. coli Mre11-Rad50 (SbcCD) head complex bound to ATPgS
5F7B	;	1.56	;	Resting state structure of CuNiR form Alcaligenes faecalis determined at 293 K
6ZWZ	;	1.2	;	Resting state structure of the OMPD-domain of human UMPS variant (K314AcK) at 1.2 Angstroms resolution
1RPO	;	1.4	;	RESTORED HEPTAD PATTERN CONTINUITY DOES NOT ALTER THE FOLDING OF A 4-ALPHA-HELICAL BUNDLE
2M8W	;		;	Restrained CS-Rosetta Solution NMR Structure of Staphylococcus aureus protein SAV1430. Northeast Structural Genomics Target ZR18. Structure determination
2M8X	;		;	Restrained CS-Rosetta Solution NMR structure of the CARDB domain of PF1109 from Pyrococcus furiosus. Northeast Structural Genomics Consortium target PfR193A
3AIT	;		;	RESTRAINED ENERGY REFINEMENT WITH TWO DIFFERENT ALGORITHMS AND FORCE FIELDS OF THE STRUCTURE OF THE ALPHA-AMYLASE INHIBITOR TENDAMISTAT DETERMINED BY NMR IN SOLUTION
4AIT	;		;	RESTRAINED ENERGY REFINEMENT WITH TWO DIFFERENT ALGORITHMS AND FORCE FIELDS OF THE STRUCTURE OF THE ALPHA-AMYLASE INHIBITOR TENDAMISTAT DETERMINED BY NMR IN SOLUTION
1CDP	;	1.6	;	RESTRAINED LEAST SQUARES REFINEMENT OF NATIVE (CALCIUM) AND CADMIUM-SUBSTITUTED CARP PARVALBUMIN USING X-RAY CRYSTALLOGRAPHIC DATA AT 1.6-ANGSTROMS RESOLUTION
5CPV	;	1.6	;	RESTRAINED LEAST SQUARES REFINEMENT OF NATIVE (CALCIUM) AND CADMIUM-SUBSTITUTED CARP PARVALBUMIN USING X-RAY CRYSTALLOGRAPHIC DATA AT 1.6-ANGSTROMS RESOLUTION
1RNT	;	1.9	;	RESTRAINED LEAST-SQUARES REFINEMENT OF THE CRYSTAL STRUCTURE OF THE RIBONUCLEASE T1(ASTERISK)2(PRIME)-GUANYLIC ACID COMPLEX AT 1.9 ANGSTROMS RESOLUTION
1PPD	;	2.0	;	RESTRAINED LEAST-SQUARES REFINEMENT OF THE SULFHYDRYL PROTEASE PAPAIN TO 2.0 ANGSTROMS
1TRA	;	3.0	;	RESTRAINED REFINEMENT OF THE MONOCLINIC FORM OF YEAST PHENYLALANINE TRANSFER RNA. TEMPERATURE FACTORS AND DYNAMICS, COORDINATED WATERS, AND BASE-PAIR PROPELLER TWIST ANGLES
2TRA	;	3.0	;	RESTRAINED REFINEMENT OF TWO CRYSTALLINE FORMS OF YEAST ASPARTIC ACID AND PHENYLALANINE TRANSFER RNA CRYSTALS
3TRA	;	3.0	;	RESTRAINED REFINEMENT OF TWO CRYSTALLINE FORMS OF YEAST ASPARTIC ACID AND PHENYLALANINE TRANSFER RNA CRYSTALS
4TRA	;	3.0	;	RESTRAINED REFINEMENT OF TWO CRYSTALLINE FORMS OF YEAST ASPARTIC ACID AND PHENYLALANINE TRANSFER RNA CRYSTALS
7KRT	;	2.79	;	Restraining state of a truncated Hsp70 DnaK
7KO2	;	2.64	;	Restraining state of near full-length Hsp70 DnaK
4JKP	;	2.82	;	Restricting HIV-1 Pathways for Escape using Rationally-Designed Anti-HIV-1 Antibodies
1ESG	;	1.9	;	RESTRICTION ENDONUCLEASE BAMHI BOUND TO A NON-SPECIFIC DNA.
1BHM	;	2.2	;	RESTRICTION ENDONUCLEASE BAMHI COMPLEX WITH DNA
2BAM	;	2.0	;	RESTRICTION ENDONUCLEASE BAMHI COMPLEX WITH DNA AND CALCIUM IONS (PRE-REACTIVE COMPLEX).
3BAM	;	1.8	;	RESTRICTION ENDONUCLEASE BAMHI COMPLEX WITH DNA AND MANGANESE IONS (POST-REACTIVE COMPLEX)
2Q10	;	1.75	;	RESTRICTION ENDONUCLEASE BcnI (WILD TYPE)-COGNATE DNA SUBSTRATE COMPLEX
2ODH	;	1.6	;	Restriction Endonuclease BCNI in the Absence of DNA
2ODI	;	1.45	;	Restriction Endonuclease BCNI-Cognate DNA Substrate Complex
4ESJ	;	2.05	;	RESTRICTION ENDONUCLEASE DpnI IN COMPLEX WITH TARGET DNA
4KYW	;	2.35	;	Restriction endonuclease DPNI in complex with two DNA molecules
1B94	;	1.9	;	RESTRICTION ENDONUCLEASE ECORV WITH CALCIUM
3OR3	;	1.95	;	Restriction endonuclease HPY188I in complex with product DNA
3OQG	;	1.75	;	Restriction endonuclease HPY188I in complex with substrate DNA
3NDH	;	1.3	;	Restriction endonuclease in complex with substrate DNA
2OA9	;	1.5	;	Restriction endonuclease MvaI in the absence of DNA
2OAA	;	1.5	;	Restriction endonuclease MvaI-cognate DNA substrate complex
3BM3	;	1.7	;	Restriction endonuclease PspGI-substrate DNA complex
1DC1	;	1.7	;	RESTRICTION ENZYME BSOBI/DNA COMPLEX STRUCTURE: ENCIRCLEMENT OF THE DNA AND HISTIDINE-CATALYZED HYDROLYSIS WITHIN A CANONICAL RESTRICTION ENZYME FOLD
5TGQ	;	1.88	;	Restriction-modification system Type II R.SwaI, DNA free
5TGX	;	2.3	;	Restriction/modification system-Type II R-SwaI complexed with partially cleaved DNA
5TH3	;	2.33	;	Restriction/modification system-Type II R.SwaI cleaved DNA complex
7BWU	;	1.87	;	Restructuring hemagglutinin-neuraminidase (HN) of Newcastle disease virus produced from Oryza sativa
6UR5	;	4.0	;	Resurfaced influenza hemagglutinin in complex with a broadly neutralizing antibody
5TDX	;	1.96	;	Resurrected Ancestral Hydroxynitrile Lyase from Flowering Plants
3Q8G	;	1.8	;	Resurrection of a functional phosphatidylinositol transfer protein from a pseudo-Sec14 scaffold by directed evolution
7YS5	;		;	RET G-quadruplex in 10mM Na+
7YS7	;		;	RET oncogene primer G4-DNA in 100mMNa+
4UX8	;	24.0	;	RET recognition of GDNF-GFRalpha1 ligand by a composite binding site promotes membrane-proximal self-association
7AML	;	3.5	;	RET/GDNF/GFRa1 extracellular complex Cryo-EM structure
8CEU	;	1.83	;	Retapamulin and Capreomycin bound to the 50S subunit
1BI9	;	2.7	;	RETINAL DEHYDROGENASE TYPE TWO WITH NAD BOUND
6G7K	;	1.9	;	Retinal isomerization in bacteriorhodopsin revealed by a femtosecond X-ray laser: 10 ps state structure
6G7J	;	1.9	;	Retinal isomerization in bacteriorhodopsin revealed by a femtosecond X-ray laser: 457-646 fs state structure
6G7I	;	1.9	;	Retinal isomerization in bacteriorhodopsin revealed by a femtosecond X-ray laser: 49-406 fs state structure
6G7L	;	1.9	;	Retinal isomerization in bacteriorhodopsin revealed by a femtosecond X-ray laser: 8.3 ms state structure
6G7H	;	1.5	;	Retinal isomerization in bacteriorhodopsin revealed by a femtosecond X-ray laser: resting state structure
1GH6	;	3.2	;	RETINOBLASTOMA POCKET COMPLEXED WITH SV40 LARGE T ANTIGEN
2VE3	;	2.1	;	Retinoic acid bound cyanobacterial CYP120A1
4OC7	;	2.5	;	Retinoic acid receptor alpha in complex with (E)-3-(3'-allyl-6-hydroxy-[1,1'-biphenyl]-3-yl)acrylic acid and a fragment of the coactivator TIF2
5EC9	;	2.3	;	Retinoic acid receptor alpha in complex with chiral dihydrobenzofuran benzoic acid 9a and a fragment of the coactivator TIF2
7WQQ	;	1.9	;	Retinoic acid receptor alpha mutant - N299H
6UCG	;	2.87	;	Retinoic acid receptor-related orphan receptor (ROR) gamma in complex with allosteric compound 28
2NLL	;	1.9	;	RETINOID X RECEPTOR-THYROID HORMONE RECEPTOR DNA-BINDING DOMAIN HETERODIMER BOUND TO THYROID RESPONSE ELEMENT DNA
1RLB	;	3.1	;	RETINOL BINDING PROTEIN COMPLEXED WITH TRANSTHYRETIN
1AQB	;	1.65	;	RETINOL-BINDING PROTEIN (RBP) FROM PIG PLASMA
5N6W	;	4.2	;	Retinoschisin R141H Mutant
5XK4	;		;	Retracted state of S65-phosphorylated ubiquitin
6KOW	;		;	Retracted state of S65/T66 double-phosphorylated ubiquitin
2LUF	;		;	Retro Trp-cage peptide
1LO2	;	2.0	;	Retro-Diels-Alderase Catalytic Antibody
1LO4	;	2.4	;	Retro-Diels-Alderase Catalytic antibody 9D9
1LO3	;	2.3	;	Retro-Diels-Alderase Catalytic Antibody: Product Analogue
1BFW	;		;	RETRO-INVERSO ANALOGUE OF THE G-H LOOP OF VP1 IN FOOT-AND-MOUTH-DISEASE (FMD) VIRUS, NMR, 10 STRUCTURES
6DN0	;	2.0	;	Retrofitted antibodies with stabilizing mutations: Herceptin scFv mutant with VH K30D and VL S52D.
4X4X	;	2.25	;	Retrofitting antibodies with stabilizing mutations. Herceptin scFv mutant.
4X4Z	;	1.8	;	Retrofitting antibodies with stabilizing mutations. Herceptin VL mutant F53D.
6DK7	;	2.6	;	RetS histidine kinase region with cobalt
6DK8	;	3.8	;	RetS kinase region without cobalt
1ETG	;		;	REV RESPONSE ELEMENT (RRE) RNA COMPLEXED WITH REV PEPTIDE, NMR, 19 STRUCTURES
1ETF	;		;	REV RESPONSE ELEMENT (RRE) RNA COMPLEXED WITH REV PEPTIDE, NMR, MINIMIZED AVERAGE STRUCTURE
6X76	;	2.53	;	Rev1 L325G Mn2+-facilitated Product Complex with second dCTP bound
6X71	;	1.78	;	Rev1 Mg2+-facilitated Intermediate complex with reactant dCTP and product dCMP
6X74	;	1.69	;	Rev1 Mg2+-facilitated Product Complex with no monophosphates
6X73	;	2.05	;	Rev1 Mg2+-facilitated Product Complex with one monophosphate
6X72	;	2.19	;	Rev1 Mg2+-facilitated Product Complex with two monophosphates
6X75	;	1.95	;	Rev1 Mn2+-facilitated Product Complex with second dCTP bound
6X77	;	1.64	;	Rev1 R518A Ternary Complex with dCTP and Ca2+
7T1A	;	1.81	;	Rev1 Ternary Complex with dATP and Ca2+
6X6Z	;	1.4	;	Rev1 Ternary Complex with dCTP and Ca2+
7T19	;	2.01	;	Rev1 Ternary Complex with dGTP and Ca2+
7T18	;	1.7	;	Rev1 Ternary Complex with dTTP and Ca2+
7T1B	;	1.75	;	Rev1 Ternary Complex with rCTP and Ca2+
6ASR	;	2.356	;	REV1 UBM2 domain complex with ubiquitin
6X70	;	2.05	;	Rev1-DNA Binary Complex
4DQM	;	2.75	;	Revealing a marine natural product as a novel agonist for retinoic acid receptors with a unique binding mode and antitumor activity
3QT0	;	2.496	;	Revealing a steroid receptor ligand as a unique PPARgamma agonist
5C7R	;	1.94	;	Revealing surface waters on an antifreeze protein by fusion protein crystallography
4REU	;	2.5	;	Revelation of Endogenously bound Fe2+ ions in the Crystal Structure of Ferritin from Escherichia coli
1A6Y	;	2.3	;	REVERBA ORPHAN NUCLEAR RECEPTOR/DNA COMPLEX
4YGV	;	1.76	;	Reversal Agent for Dabigatran
4YHI	;	1.9	;	Reversal Agent for Dabigatran
4YHK	;	2.21	;	Reversal Agent for Dabigatran
4YHL	;	2.09	;	Reversal Agent for Dabigatran
4YHM	;	2.16	;	Reversal Agent for Dabigatran
4YHO	;	1.82	;	Reversal Agent for Dabigatran
3PLF	;	1.92	;	Reverse Binding Mode of MetRD peptide complexed with c-Cbl TKB domain
1GKU	;	2.7	;	Reverse gyrase from Archaeoglobus fulgidus
4MLB	;	2.349	;	Reverse polarity of binding pocket suggests different function of a MOP superfamily transporter from Pyrococcus furiosus Vc1 (DSM3638)
1P43	;	1.8	;	REVERSE PROTONATION IS THE KEY TO GENERAL ACID-BASE CATALYSIS IN ENOLASE
1P48	;	2.0	;	REVERSE PROTONATION IS THE KEY TO GENERAL ACID-BASE CATALYSIS IN ENOLASE
6VUN	;	1.4	;	Reverse Transcriptase Diabody with R83C Mutation
7KBM	;	2.0	;	Reverse Transcriptase Diabody with R83C Mutation Crystallized in C2
6VRP	;	1.6	;	Reverse Transcriptase Diabody with R83T Mutation
6VUP	;	1.4	;	Reverse Transcriptase Diabody with R83T/E85C Mutations
7KBO	;	2.2	;	Reverse Transcriptase Diabody with S82bC, R83T Mutations Crystallized in C2
6VUO	;	1.449	;	Reverse Transcriptase Diabody with S82bC/R83T Mutation
5HHL	;	2.1	;	Reverse transcriptase domain of group II intron maturase from Eubacterium rectale in P21 space group
5IRF	;	1.6	;	Reverse transcriptase domain of group II intron maturase from Roseburia intestinalis in P1 space group
5HHJ	;	1.2	;	Reverse transcriptase domain of group II intron maturase from Roseburia intestinalis in P21 space group
5HHK	;	1.4	;	Reverse transcriptase domain of group II intron maturase from Roseburia intestinalis in P21 space group (Se-MET)
5IRG	;	2.3	;	Reverse transcriptase domain of group II intron maturase from Roseburia intestinalis in P212121 space group
3BNA	;	3.0	;	REVERSIBLE BENDING AND HELIX GEOMETRY IN A B-DNA DODECAMER: CGCGAATTBRCGCG
4BNA	;	2.3	;	REVERSIBLE BENDING AND HELIX GEOMETRY IN A B-DNA DODECAMER: CGCGAATTBRCGCG
6CYM	;	2.9	;	Reversible Covalent Direct Thrombin Inhibitors
7FIC	;	2.32	;	Reversible lysine-targeted probes reveal residence time-based kinase selectivity in vivo
4WKX	;	1.94	;	Reversible S-Nitrosylation in an Engineered Mutant of Pseudomonas aeruginosa Azurin with Red Copper Site
7O76	;	1.131	;	Reversible supramolecular assembly of the anti-microbial peptide plectasin
3A3K	;	2.5	;	Reversibly bound chloride in the atrial natriuretic peptide receptor hormone-binding domain
5EXU	;	1.65	;	Reversibly photoswitching protein Dathail, Ensemble refinement
1C94	;	2.08	;	REVERSING THE SEQUENCE OF THE GCN4 LEUCINE ZIPPER DOES NOT AFFECT ITS FOLD.
3PEP	;	2.3	;	REVISED 2.3 ANGSTROMS STRUCTURE OF PORCINE PEPSIN. EVIDENCE FOR A FLEXIBLE SUBDOMAIN
2C7E	;	14.9	;	REVISED ATOMIC STRUCTURE FITTING INTO A GROEL(D398A)-ATP7 CRYO-EM MAP (EMD 1047)
6RVD	;	3.5	;	Revised cryo-EM structure of the human 2:1 Ptch1-Shh complex
4K6A	;	1.8	;	Revised Crystal Structure of apo-form of Triosephosphate Isomerase (tpiA) from Escherichia coli at 1.8 Angstrom Resolution.
6CGV	;	3.8	;	Revised crystal structure of human adenovirus
5LXG	;	2.73	;	Revised crystal structure of the human adiponectin receptor 1 in an open conformation
5LWY	;	2.4	;	Revised crystal structure of the human adiponectin receptor 2 in complex with a C18 free fatty acid
5WFN	;	3.0	;	Revised model of leiomodin 2-mediated actin regulation (alternate refinement of PDB 4RWT)
1ZUE	;		;	Revised Solution Structure of DLP-2
4MZ9	;	2.2	;	Revised structure of E. coli SSB
2P0M	;	2.4	;	Revised structure of rabbit reticulocyte 15S-lipoxygenase
3C98	;	2.601	;	Revised structure of the munc18a-syntaxin1 complex
8FFR	;	3.49	;	Revised structure of the rabies virus nucleoprotein-RNA complex
4EXO	;	1.9	;	Revised, rerefined crystal structure of PDB entry 2QHK, methyl accepting chemotaxis protein
5FL2	;	6.2	;	Revisited cryo-EM structure of Inducible lysine decarboxylase complexed with LARA domain of RavA ATPase
2XB6	;	2.6	;	Revisited crystal structure of Neurexin1beta-Neuroligin4 complex
6RH8	;	1.9	;	Revisiting pH-gated conformational switch. Complex HK853 mutant H260A -RR468 mutant D53A pH 5.3
6RH7	;	2.0	;	Revisiting pH-gated conformational switch. Complex HK853 mutant H260A -RR468 mutant D53A pH 7.5
6RH2	;	2.0	;	Revisiting pH-gated conformational switch. Complex HK853-RR468 D53A pH 5.3
6RH1	;	2.0	;	Revisiting pH-gated conformational switch. Complex HK853-RR468 D53A pH 7
6RH0	;	2.87	;	Revisiting pH-gated conformational switch. Complex HK853-RR468 pH 5.5
6RGZ	;	2.35	;	Revisiting pH-gated conformational switch. Complex HK853-RR468 pH 6.5
6RFV	;	2.83	;	Revisiting pH-gated conformational switch. Complex HK853-RR468 pH 7
6RGY	;	2.2	;	Revisiting pH-gated conformational switch. Complex HK853-RR468 pH 7.5
6OSK	;	3.6	;	RF1 accommodated 70S complex at 60 ms
6OSQ	;	3.5	;	RF1 accommodated state bound Release complex 70S at long incubation time point
6ORL	;	3.5	;	RF1 pre-accommodated 70S complex at 24 ms
6OUO	;	3.7	;	RF2 accommodated state bound 70S complex at long incubation time
6OT3	;	3.9	;	RF2 accommodated state bound Release complex 70S at 24 ms
2IHR	;	2.5	;	RF2 of Thermus thermophilus
6OST	;	4.2	;	RF2 pre-accommodated state bound Release complex 70S at 24ms
8B4J	;	1.58	;	Rfa1-N-terminal domain in complex with phosphorylated Ddc2
8B4K	;	1.55	;	Rfa1-N-terminal domain in complex with phosphorylated Ddc2
5OND	;	2.1	;	RfaH from Escherichia coli in complex with ops DNA
7U1P	;	3.0	;	RFC:PCNA bound to DNA with a ssDNA gap of five nucleotides
7U1A	;	3.3	;	RFC:PCNA bound to dsDNA with a ssDNA gap of six nucleotides
7U19	;	3.7	;	RFC:PCNA bound to nicked DNA
7KWO	;	2.9	;	rFVIIIFc-VWF-XTEN (BIVV001)
6MEW	;	1.78	;	RFXANK ankyrin repeats in complex with a RFX7 peptide
7ZCV	;	1.9	;	Rgg144 of Streptococcus pneumoniae
6K88	;	1.788	;	RGLG1 MIDAS binds calcium ion
6K82	;	1.402	;	RGLG1 mutant-D338A E378A
6K8A	;	2.4	;	RGLG1 VWA domain with MIDAS is occupied by water
1FQI	;	1.94	;	RGS9 RGS DOMAIN
2O1I	;	1.1	;	RH(BPY)2CHRYSI complexed to mismatched DNA
1TGG	;	2.0	;	RH3 DESIGNED RIGHT-HANDED COILED COIL TRIMER
1RH4	;	1.9	;	RH4 DESIGNED RIGHT-HANDED COILED COIL TETRAMER
2O6N	;	1.1	;	RH4B: designed right-handed coiled coil tetramer with all biological amino acids
1DEO	;	1.55	;	RHAMNOGALACTURONAN ACETYLESTERASE FROM ASPERGILLUS ACULEATUS AT 1.55 A RESOLUTION WITH SO4 IN THE ACTIVE SITE
1DEX	;	1.9	;	RHAMNOGALACTURONAN ACETYLESTERASE FROM ASPERGILLUS ACULEATUS AT 1.9 A RESOLUTION
1K7C	;	1.12	;	Rhamnogalacturonan acetylesterase with seven N-linked carbohydrate residues distributed at two N-glycosylation sites refined at 1.12 A resolution
5OLQ	;	1.48	;	Rhamnogalacturonan lyase
5OLR	;	1.07	;	Rhamnogalacturonan lyase
5OLS	;	2.2	;	Rhamnogalacturonan lyase
1NKG	;	1.5	;	Rhamnogalacturonan lyase from Aspergillus aculeatus
2XHN	;	1.52	;	Rhamnogalacturonan lyase from Aspergillus aculeatus K150A active site mutant
3NJV	;	2.4	;	Rhamnogalacturonan lyase from Aspergillus aculeatus K150A substrate complex
3NJX	;	1.94	;	Rhamnogalacturonan Lyase from Aspergillus aculeatus mutant H210A
1RMG	;	2.0	;	RHAMNOGALACTURONASE A FROM ASPERGILLUS ACULEATUS
2ZX0	;	1.9	;	Rhamnose-binding lectin CSL3
2ZX1	;	1.9	;	Rhamnose-binding lectin CSL3
2ZX2	;	1.8	;	Rhamnose-binding lectin CSL3
2ZX3	;	2.1	;	Rhamnose-binding lectin CSL3
2ZX4	;	2.7	;	Rhamnose-binding lectin CSL3
4XHC	;	2.7	;	rhamnosidase from Klebsiella oxytoca with rhamnose bound
1YBK	;	1.45	;	RHCC cocrystallized with CAPB
5JR5	;	1.9	;	RHCC in Complex with Elemental Sulfur
5VKF	;	2.752	;	RHCC in complex with Naphthalene
7R6H	;	2.2	;	RHCC in complex with o-carborane
5VH0	;	2.055	;	RHCC in complex with pyrene
6BRI	;	3.266	;	RHCC with unreduced and reduced Mercury complexes
6MNQ	;	1.804	;	Rhesus macaque anti-HIV V3 antibody DH727.2 with gp120 V3 ZAM18 peptide
6MNR	;	2.201	;	Rhesus macaque anti-HIV V3 antibody DH753 with gp120 V3 ZAM18 peptide
6MNS	;	2.7	;	Rhesus macaque anti-HIV V3 antibody DH753 with gp120 V3 ZAM18 peptide
3RWE	;	2.4	;	rhesus macaque MHC class I molecule Mamu-B*17-FW9
3RWI	;	2.009	;	Rhesus macaque MHC class I molecule Mamu-B*17-GW10
3RWJ	;	2.7	;	Rhesus macaque MHC class I molecule Mamu-B*17-HW8
3RWD	;	2.602	;	rhesus macaque MHC class I molecule Mamu-B*17-IW11
3RWH	;	2.6	;	Rhesus macaque MHC class I molecule Mamu-B*17-MF8
3RWG	;	2.1	;	Rhesus macaque MHC class I molecule Mamu-B*17-MW9
3RWF	;	2.6	;	Rhesus macaque MHC class I molecule Mamu-B*17-QW9
5K3Q	;	1.8	;	Rhesus macaques Trim5alpha Bbox2 domain
7N0X	;	2.0	;	Rhesusized RV144 DH827 Fab bound to HIV-1 Env V2 peptide
7N8Q	;	2.9	;	Rhesusized RV305 DH677.3 Fab bound to Clade A/E 93TH057 HIV-1 gp120 core.
1RUF	;	2.9	;	RHINOVIRUS 14 (HRV14) (MUTANT WITH ASN 1 219 REPLACED BY ALA (N219A IN CHAIN 1)
7NUO	;	3.9	;	Rhinovirus 14 empty particle at pH 6.2
7NUN	;	3.6	;	Rhinovirus 14 ICAM-1 virion-like particle at pH 6.2
1RUC	;	3.1	;	RHINOVIRUS 14 MUTANT N1105S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035
1RUD	;	2.9	;	RHINOVIRUS 14 MUTANT N1105S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084
1RUG	;	3.0	;	RHINOVIRUS 14 MUTANT N1219S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035
1RUH	;	3.0	;	RHINOVIRUS 14 MUTANT N1219S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084
1RUI	;	3.0	;	RHINOVIRUS 14 MUTANT S1223G COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084
1RUJ	;	3.0	;	RHINOVIRUS 14 MUTANT WITH SER 1 223 REPLACED BY GLY (S1223G)
1RUE	;	2.9	;	RHINOVIRUS 14 SITE DIRECTED MUTANT N1219A COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035
7NUQ	;	2.8	;	Rhinovirus 14 virion-like at pH 6.2
4K50	;	2.93	;	Rhinovirus 16 polymerase elongation complex (r1_form)
7ARA	;	2.243	;	Rhinovirus A2 2A protease in complex with zVAM.fmk
6PPO	;	3.2	;	Rhinovirus C15 complexed with domain I of receptor CDHR3
6PSF	;	3.5	;	Rhinovirus C15 complexed with domains I and II of receptor CDHR3
7NUL	;	4.0	;	Rhinovirus-14 ICAM-1 activated particle at pH 6.2
7NUM	;	3.9	;	Rhinovirus-14 ICAM-1 empty particle at pH 6.2
5VJV	;	1.95	;	Rhizobiales-like phosphatase 2
6QPP	;	1.49	;	Rhizomucor miehei lipase propeptide complex, native
6QPR	;	1.45	;	Rhizomucor miehei lipase propeptide complex, Ser95/Ile96 deletion mutant
8IK2	;	2.151	;	RhlA exhibits dual thioesterase and acyltransferase activities during rhamnolipid biosynthesis
5JJK	;	3.15	;	Rho transcription termination factor bound to rA7 and 6 ADP-BeF3 molecules
3ICE	;	2.8	;	Rho transcription termination factor bound to RNA and ADP-BeF3
5JJI	;	2.601	;	Rho transcription termination factor bound to rU7 and 6 ADP-BeF3 molecules
5JJL	;	3.2	;	Rho transcription termination factor bound to rU8 and 5 ADP-BeF3 molecules
2A8V	;	2.4	;	RHO TRANSCRIPTION TERMINATION FACTOR/RNA COMPLEX
5HVU	;	2.8	;	Rho-associated protein kinase 1 (ROCK 1) in complex with a pyridine thiazole piperidine inhibitor
3TWJ	;	2.9	;	Rho-associated protein kinase 1 (ROCK 1) IN COMPLEX WITH RKI1447
1TX4	;	1.65	;	RHO/RHOGAP/GDP(DOT)ALF4 COMPLEX
5C4M	;	1.3	;	RhoA GDP with novel switch II conformation
5ENS	;	2.8	;	Rhodamine bound structure of bacterial efflux pump.
2ORA	;	1.99	;	RHODANESE (THIOSULFATE: CYANIDE SULFURTRANSFERASE)
2JTQ	;		;	Rhodanese from E.coli
2JTR	;		;	rhodanese persulfide from E. coli
2JTS	;		;	rhodanese with anions from E. coli
1ZRT	;	3.51	;	Rhodobacter capsulatus cytochrome bc1 complex with stigmatellin bound
5AWH	;	2.0	;	Rhodobacter sphaeroides Argonaute in complex with guide RNA/target DNA heteroduplex
6NHH	;	3.0	;	Rhodobacter sphaeroides bc1 with azoxystrobin
5KKZ	;	2.97	;	Rhodobacter sphaeroides bc1 with famoxadone
6NIN	;	3.6	;	Rhodobacter sphaeroides bc1 with STIGMATELLIN A
5KLI	;	2.996	;	Rhodobacter sphaeroides bc1 with stigmatellin and antimycin
1JO5	;		;	Rhodobacter sphaeroides Light Harvesting 1 beta Subunit in Detergent Micelles
6NHG	;	2.8	;	Rhodobacter sphaeroides Mitochondrial respiratory chain complex
7TLJ	;	2.91	;	Rhodobacter sphaeroides Mitochondrial respiratory chain complex
5THP	;	3.006	;	Rhodocetin in complex with the integrin alpha2-A domain
6ND8	;	2.9	;	RHODOCETIN IN COMPLEX WITH THE INTEGRIN ALPHA2-A DOMAIN AND BARIUM
6NDA	;	3.15	;	RHODOCETIN IN COMPLEX WITH THE INTEGRIN ALPHA2-A DOMAIN AND CADMIUM
6NDB	;	3.2	;	RHODOCETIN IN COMPLEX WITH THE INTEGRIN ALPHA2-A DOMAIN AND COBALT
6NDH	;	2.9	;	RHODOCETIN IN COMPLEX WITH THE INTEGRIN ALPHA2-A DOMAIN AND ZINC
6ND9	;	2.9	;	RHODOCETIN IN COMPLEX WITH THE INTEGRIN ALPHA2-A DOMAIN WITH CALCIUM
6NDC	;	3.35	;	RHODOCETIN IN COMPLEX WITH THE INTEGRIN ALPHA2-A DOMAIN WITH CHROMIUM BOUND
6NDD	;	3.05	;	RHODOCETIN IN COMPLEX WITH THE INTEGRIN ALPHA2-A DOMAIN WITH MANGANESE BOUND
6NDE	;	3.5	;	RHODOCETIN IN COMPLEX WITH THE INTEGRIN ALPHA2-A DOMAIN WITH PRASEDYMIUM
6NDF	;	3.05	;	RHODOCETIN IN COMPLEX WITH THE INTEGRIN ALPHA2-A DOMAIN WITH STRONTIUM
6NDG	;	3.15	;	RHODOCETIN IN COMPLEX WITH THE INTEGRIN ALPHA2-A DOMAIN WITH YTTRIUM BOUND
3VEC	;	2.6	;	Rhodococcus jostii RHA1 DypB D153A variant in complex with heme
3VED	;	2.5	;	Rhodococcus jostii RHA1 DypB D153H variant in complex with heme
3VEE	;	2.4	;	Rhodococcus jostii RHA1 DypB N246A variant in complex with heme
3VEF	;	2.64	;	Rhodococcus jostii RHA1 DypB N246H variant in complex with heme
3VEG	;	2.35	;	Rhodococcus jostii RHA1 DypB R244L variant in complex with heme
7ORX	;	2.6	;	Rhodococcus jostii RHA1 thiamine diphosphate-dependent 4-hydroxybenzoylformate decarboxylase
2PRN	;	1.93	;	RHODOPSEUDOMONAS BLASTICA PORIN, TRIPLE MUTANT E1M, E99W, A116W
4JB2	;	2.1	;	Rhodopseudomonas palustris (strain CGA009) Rp1789
4JB0	;	1.91	;	Rhodopseudomonas palustris (strain CGA009) Rp1789 transport protein
1I8O	;	1.15	;	RHODOPSEUDOMONAS PALUSTRIS CYT C2 AMMONIA COMPLEX AT 1.15 ANGSTROM RESOLUTION
2I4L	;	2.0	;	Rhodopseudomonas palustris prolyl-tRNA synthetase
2I4O	;	2.4	;	Rhodopseudomonas palustris prolyl-tRNA synthetase in complex with ATP
2I4N	;	2.85	;	Rhodopseudomonas palustris prolyl-tRNA synthetase in complex with CysAMS
2I4M	;	2.8	;	Rhodopseudomonas palustris prolyl-tRNA synthetase in complex with ProAMS
7MT9	;	7.0	;	Rhodopsin kinase (GRK1) in complex with rhodopsin
3T8O	;	2.5	;	Rhodopsin kinase (GRK1) L166K mutant at 2.5A resolution
7MT8	;	5.8	;	Rhodopsin kinase (GRK1)-S5E/S488E/T489E in complex with rhodopsin
7MTA	;	4.1	;	Rhodopsin kinase (GRK1)-S5E/S488E/T489E in complex with rhodopsin and Fab1
7MTB	;	4.0	;	Rhodopsin kinase (GRK1)-S5E/S488E/T489E in complex with rhodopsin and Fab6
6CMO	;	4.5	;	Rhodopsin-Gi complex
6QNO	;	4.38	;	Rhodopsin-Gi protein complex
6Y8V	;		;	Rhodospirillum rubrum oxidized CooT solution structure
6Y8W	;		;	Rhodospirillum rubrum reduced CooT solution structure
8XX9	;	1.55	;	Rhodothermus marinus alpha-amylase RmGH13_47A CBM48-A-B-C domains
8XXA	;	1.55	;	Rhodothermus marinus alpha-amylase RmGH13_47A CBM48-A-B-C domains in complex with branched pentasaccharide
4CSW	;	2.821	;	Rhodothermus marinus YCFD-like ribosomal protein L16 Arginyl hydroxylase
4CUG	;	2.96	;	Rhodothermus marinus YCFD-like ribosomal protein L16 Arginyl hydroxylase in complex substrate fragment
5JCP	;	2.1	;	RhoGAP domain of ARAP3 in complex with RhoA in the transition state
5T81	;	2.604	;	Rhombohedral crystal form of the EpoB NRPS cyclization-docking bidomain from Sorangium cellulosum
6XTD	;	1.3	;	Rhs1-CT in complex with cognate immunity protein RhsI1
6O6H	;	2.5	;	RIAM cc-RA-PH structure in the P21212 space group
6OLU	;	1.9	;	RIAM RA-PH core structure in the P212121 space group
7UF1	;	1.95	;	RibB from Vibrio cholera bound with D-Ribose-5-phosphate (D-R5P) and manganese
7UF0	;	1.8	;	RibB from Vibrio cholera bound with D-ribulose-5-phosphate (D-Ru5P)
7UF2	;	2.0	;	RibB from Vibrio cholera bound with D-xylulose-5-phosphate (D-Xy5P) and manganese
7UF4	;	2.2	;	RibB from Vibrio cholera bound with intermediate 1 of the reaction cycle and D-ribulose-5-phosphate (D-Ru5P)
7UF5	;	2.1	;	RibB from Vibrio cholera bound with intermediate 2 in the reaction cycle and the products DHBP and formate
7UF3	;	2.0	;	RibB from Vibrio cholera bound with L-xylulose-5-phosphate (L-Xy5P) and manganese
1RMV	;	2.9	;	RIBGRASS MOSAIC VIRUS, FIBER DIFFRACTION
2VBU	;	1.7	;	Riboflavin kinase Mj0056 from Methanocaldococcus jannaschii in complex with CDP
2VBV	;	2.4	;	Riboflavin kinase Mj0056 from Methanocaldococcus jannaschii in complex with CDP and FMN
2VBT	;	2.7	;	Riboflavin kinase Mj0056 from Methanocaldococcus jannaschii in complex with CDP and PO4
2VBS	;	3.0	;	Riboflavin kinase Mj0056 from Methanocaldococcus jannaschii in complex with PO4
1KZL	;	2.1	;	Riboflavin Synthase from S.pombe bound to Carboxyethyllumazine
5ZWY	;	1.95	;	Ribokinase from Leishmania donovani
6A8C	;	1.98	;	Ribokinase from Leishmania donovani with ADP
6A8B	;	2.01	;	Ribokinase from Leishmania donovani with AMPPCP
6A8A	;	1.8	;	Ribokinase from Leishmania donovani with ATP
8CQX	;	2.27	;	Ribokinase from T.sp mutant A92G
6ZNX	;	2.4	;	Ribokinase from Thermus Species
1RSN	;	2.0	;	RIBONUCLEASE (RNASE SA) (E.C.3.1.4.8) COMPLEXED WITH EXO-2',3'-CYCLOPHOSPHOROTHIOATE
1BU4	;	1.9	;	RIBONUCLEASE 1 COMPLEX WITH 2'GMP
1E21	;	1.9	;	Ribonuclease 1 des1-7 Crystal Structure at 1.9A
1RBX	;	1.69	;	RIBONUCLEASE A (E.C.3.1.27.5) CONTROL
1RBW	;	1.69	;	RIBONUCLEASE A (E.C.3.1.27.5) WITH GUANIDINIUM
3I6J	;	1.3	;	Ribonuclease A by Classical hanging drop method after high X-Ray dose on ESRF ID14-2 beamline
3I6F	;	1.3	;	Ribonuclease A by Classical hanging drop method before high X-Ray dose on ESRF ID14-2 beamline
3I67	;	1.3	;	Ribonuclease A by LB nanotemplate method after high X-Ray dose on ESRF ID14-2 beamline
3I6H	;	1.3	;	Ribonuclease A by LB nanotemplate method before high X-Ray dose on ESRF ID14-2 beamline
1RNM	;	2.0	;	RIBONUCLEASE A COMPLEX WITH CYTIDYLIC ACID (5'CMP) CRYSTALLIZED FROM 80% AMMONIUM SULPHATE
1RNN	;	1.8	;	RIBONUCLEASE A COMPLEX WITH CYTIDYLIC ACID (5'CMP) CRYSTALLIZED FROM 8M SODIUM FORMATE
1AQP	;	2.0	;	RIBONUCLEASE A COPPER COMPLEX
1RNZ	;	1.9	;	RIBONUCLEASE A CRYSTALLIZED FROM 2.5M SODIUM CHLORIDE, 3.3M SODIUM FORMATE
1RNY	;	2.0	;	RIBONUCLEASE A CRYSTALLIZED FROM 3M CESIUM CHLORIDE, 30% AMMONIUM SULFATE
1RNX	;	1.9	;	RIBONUCLEASE A CRYSTALLIZED FROM 3M SODIUM CHLORIDE, 30% AMMONIUM SULFATE
1RNO	;	1.9	;	RIBONUCLEASE A CRYSTALLIZED FROM 80% AMMONIUM SULPHATE
1RNQ	;	2.0	;	RIBONUCLEASE A CRYSTALLIZED FROM 8M SODIUM FORMATE
1RRA	;	2.5	;	RIBONUCLEASE A FROM RATTUS NORVEGICUS (COMMON RAT)
1O0H	;	1.2	;	Ribonuclease A in complex with 5'-ADP
1AFL	;	1.7	;	RIBONUCLEASE A IN COMPLEX WITH 5'-DIPHOSPHOADENOSINE 2'-PHOSPHATE AT 1.7 ANGSTROM RESOLUTION
1O0O	;	1.2	;	Ribonuclease A in complex with adenosine-2',5'-diphosphate
1O0M	;	1.5	;	Ribonuclease A in complex with uridine-2'-phosphate
1O0N	;	1.5	;	Ribonuclease A in complex with uridine-3'-phosphate
3DXH	;	1.4	;	Ribonuclease A uridine 5' diphosphate complex
1LSQ	;	1.9	;	RIBONUCLEASE A WITH ASN 67 REPLACED BY A BETA-ASPARTYL RESIDUE
1Z6S	;	1.5	;	Ribonuclease A- AMP complex
1Z6D	;	1.54	;	Ribonuclease A- IMP complex
3DXG	;	1.39	;	Ribonuclease A- uridine 5' phosphate complex
1RUV	;	1.25	;	RIBONUCLEASE A-URIDINE VANADATE COMPLEX: HIGH RESOLUTION RESOLUTION X-RAY STRUCTURE (1.3 A)
1RBJ	;	2.7	;	RIBONUCLEASE B COMPLEX WITH D(TETRA-(DEOXY-ADENYLATE))
1GOV	;	2.0	;	RIBONUCLEASE BI(G SPECIFIC ENDONUCLEASE) COMPLEXED WITH SULFATE IONS
1GOU	;	1.65	;	Ribonuclease Binase (G Specific Endonuclease) Unliganded Form
1E44	;	2.4	;	ribonuclease domain of colicin E3 in complex with its immunity protein
1TFO	;	2.3	;	Ribonuclease from Escherichia coli complexed with its inhibitor protein
1TFK	;	2.1	;	Ribonuclease from Escherichia coli complexed with its inhibtor protein
5GY6	;	1.5	;	Ribonuclease from Hericium erinaceus (RNase He1)
6LS1	;	1.58	;	Ribonuclease from Hericium erinaceus active and GMP binding form
1DFJ	;	2.5	;	RIBONUCLEASE INHIBITOR COMPLEXED WITH RIBONUCLEASE A
1A4Y	;	2.0	;	RIBONUCLEASE INHIBITOR-ANGIOGENIN COMPLEX
1BK7	;	1.75	;	RIBONUCLEASE MC1 FROM THE SEEDS OF BITTER GOURD
1VD3	;	1.8	;	Ribonuclease NT in complex with 2'-UMP
1AY7	;	1.7	;	RIBONUCLEASE SA COMPLEX WITH BARSTAR
5HOH	;	2.0	;	RIBONUCLEASE T1 (ASN9ALA/THR93ALA DOUBLEMUTANT) COMPLEXED WITH 2'GMP
2HOH	;	1.9	;	RIBONUCLEASE T1 (N9A MUTANT) COMPLEXED WITH 2'GMP
4HOH	;	2.05	;	RIBONUCLEASE T1 (THR93ALA MUTANT) COMPLEXED WITH 2'GMP
3HOH	;	1.95	;	RIBONUCLEASE T1 (THR93GLN MUTANT) COMPLEXED WITH 2'GMP
1BVI	;	1.9	;	RIBONUCLEASE T1 (WILDTYPE) COMPLEXED WITH 2'GMP
1DET	;	1.8	;	RIBONUCLEASE T1 CARBOXYMETHYLATED AT GLU 58 IN COMPLEX WITH 2'GMP
2BU4	;	1.95	;	RIBONUCLEASE T1 COMPLEX WITH 2'GMP
3BU4	;	1.77	;	RIBONUCLEASE T1 COMPLEX WITH 2'GMP
4BU4	;	1.8	;	RIBONUCLEASE T1 COMPLEX WITH 2'GMP
5BU4	;	1.77	;	RIBONUCLEASE T1 COMPLEX WITH 2'GMP
3GSP	;	1.9	;	RIBONUCLEASE T1 COMPLEXED WITH 2',3'-CGPS + 3'-GMP, 4 DAYS
4GSP	;	1.65	;	RIBONUCLEASE T1 COMPLEXED WITH 2',3'-CGPS + 3'-GMP, 7 DAYS
1GSP	;	2.2	;	RIBONUCLEASE T1 COMPLEXED WITH 2',3'-CGPS, 1 DAY
1RHL	;	1.95	;	RIBONUCLEASE T1 COMPLEXED WITH 2'GMP/G23A MUTANT
1I0V	;	1.234	;	Ribonuclease T1 in complex with 2'GMP (form I crystal)
1I0X	;	1.65	;	RIBONUCLEASE T1 IN COMPLEX WITH 2'GMP (FORM II CRYSTAL)
1HZ1	;	1.8	;	RIBONUCLEASE T1 V16A MUTANT IN COMPLEX WITH MG2+
1HYF	;	1.7	;	RIBONUCLEASE T1 V16A MUTANT IN COMPLEX WITH SR2+
1I2E	;	1.8	;	Ribonuclease T1 V16A mutant, form I
1I2F	;	1.95	;	Ribonuclease T1 V16A mutant, form II
1FYS	;	2.0	;	Ribonuclease T1 V16C mutant
1G02	;	1.86	;	Ribonuclease T1 V16S mutant
1I2G	;	1.85	;	Ribonuclease T1 V16T mutant
1I3I	;	1.76	;	Ribonuclease T1 V78T mutant
1I3F	;	2.35	;	Ribonuclease T1 V89S mutant
9RNT	;	1.5	;	RIBONUCLEASE T1 WITH FREE RECOGNITION AND CATALYTIC SITE: CRYSTAL STRUCTURE ANALYSIS AT 1.5 ANGSTROMS RESOLUTION
1BIR	;	1.8	;	RIBONUCLEASE T1, PHE 100 TO ALA MUTANT COMPLEXED WITH 2' GMP
2GSP	;	1.8	;	RIBONUCLEASE T1/2',3'-CGPS AND 3'-GMP, 2 DAYS
7GSP	;	2.0	;	RIBONUCLEASE T1/2',3'-CGPS, NON-PRODUCTIVE
6GSP	;	2.2	;	RIBONUCLEASE T1/3'-GMP, 15 WEEKS
5GSP	;	1.8	;	RIBONUCLEASE T1/3'-GMP, 9 WEEKS
4BIR	;	1.7	;	RIBONUCLEASE T1: FREE HIS92GLN MUTANT
1PFR	;	2.2	;	RIBONUCLEOSIDE-DIPHOSPHATE REDUCTASE 1 BETA CHAIN
1XIK	;	1.7	;	RIBONUCLEOSIDE-DIPHOSPHATE REDUCTASE 1 BETA CHAIN
1BIQ	;	2.05	;	RIBONUCLEOSIDE-DIPHOSPHATE REDUCTASE 1 BETA CHAIN MUTANT E238A
2L7D	;		;	Ribonucleotide Perturbation of DNA Structure: Solution Structure of [d(CGC)r(G)d(AATTCGCG)]2
7Q3C	;	2.15	;	Ribonucleotide Reductase AaR2 protein from Aquifex aeolicus
5CI4	;	2.05	;	Ribonucleotide reductase beta subunit
2BQ1	;	3.99	;	Ribonucleotide reductase class 1b holocomplex R1E,R2F from Salmonella typhimurium
8BT3	;	1.5	;	Ribonucleotide Reductase class Ie R2 from Mesoplasma florum, catalytically active radical state solved by XFEL
6GP2	;	1.48	;	Ribonucleotide Reductase class Ie R2 from Mesoplasma florum, DOPA-active form
6GP3	;	1.23	;	Ribonucleotide Reductase class Ie R2 from Mesoplasma florum, inactive form
8BT4	;	1.35	;	Ribonucleotide Reductase class Ie R2 from Mesoplasma florum, radical-lost ground state
3N37	;	1.65	;	Ribonucleotide Reductase Dimanganese(II)-NrdF from Escherichia coli
3N39	;	2.5	;	Ribonucleotide Reductase Dimanganese(II)-NrdF from Escherichia coli in Complex with NrdI
3N3A	;	1.99	;	Ribonucleotide Reductase Dimanganese(II)-NrdF from Escherichia coli in Complex with Reduced NrdI
3N3B	;	2.36	;	Ribonucleotide Reductase Dimanganese(II)-NrdF from Escherichia coli in Complex with Reduced NrdI with a Trapped Peroxide
5R1R	;	3.1	;	RIBONUCLEOTIDE REDUCTASE E441A MUTANT R1 PROTEIN FROM ESCHERICHIA COLI
6R1R	;	3.1	;	RIBONUCLEOTIDE REDUCTASE E441D MUTANT R1 PROTEIN FROM ESCHERICHIA COLI
7R1R	;	3.1	;	RIBONUCLEOTIDE REDUCTASE E441Q MUTANT R1 PROTEIN FROM ESCHERICHIA COLI
3N38	;	1.9	;	Ribonucleotide Reductase NrdF from Escherichia coli Soaked with Ferrous Ions
1PEM	;	2.99	;	Ribonucleotide Reductase Protein R1E from Salmonella typhimurium
1PEO	;	3.0	;	Ribonucleotide Reductase Protein R1E from Salmonella typhimurium
1PEQ	;	2.8	;	Ribonucleotide Reductase Protein R1E from Salmonella typhimurium
1PEU	;	3.2	;	Ribonucleotide Reductase Protein R1E from Salmonella typhimurium
7AGJ	;	2.7	;	Ribonucleotide Reductase R1 protein from Aquifex aeolicus
1R1R	;	2.9	;	RIBONUCLEOTIDE REDUCTASE R1 PROTEIN MUTANT Y730F WITH A REDUCED ACTIVE SITE FROM ESCHERICHIA COLI
3R1R	;	3.0	;	RIBONUCLEOTIDE REDUCTASE R1 PROTEIN WITH AMPPNP OCCUPYING THE ACTIVITY SITE FROM ESCHERICHIA COLI
2R1R	;	3.0	;	RIBONUCLEOTIDE REDUCTASE R1 PROTEIN WITH DTTP OCCUPYING THE SPECIFICITY SITE FROM ESCHERICHIA COLI
4R1R	;	3.2	;	RIBONUCLEOTIDE REDUCTASE R1 PROTEIN WITH SUBSTRATE, GDP AND EFFECTOR DTTP FROM ESCHERICHIA COLI
2X0X	;	2.3	;	Ribonucleotide reductase R1 subunit of E. coli to 2.3 A resolution
1PIZ	;	1.9	;	RIBONUCLEOTIDE REDUCTASE R2 D84E MUTANT SOAKED WITH FERROUS IONS AT NEUTRAL PH
2ALX	;	2.6	;	Ribonucleotide Reductase R2 from Escherichia coli in space group P6(1)22
7AIK	;	2.1	;	Ribonucleotide Reductase R2 protein from Aquifex aeolicus
1PIY	;	1.68	;	RIBONUCLEOTIDE REDUCTASE R2 SOAKED WITH FERROUS ION AT NEUTRAL PH
6ZJK	;	2.0	;	Ribonucleotide reductase R2 subunit from Clostridium botulinum
1AV8	;	2.8	;	RIBONUCLEOTIDE REDUCTASE R2 SUBUNIT FROM E. COLI
1PJ0	;	1.9	;	RIBONUCLEOTIDE REDUCTASE R2-D84E/W48F MUTANT SOAKED WITH FERROUS IONS AT NEUTRAL PH
1PJ1	;	1.95	;	RIBONUCLEOTIDE REDUCTASE R2-D84E/W48F SOAKED WITH FERROUS IONS AT PH 5
1R2F	;	2.1	;	RIBONUCLEOTIDE REDUCTASE R2F PROTEIN FROM SALMONELLA TYPHIMURIUM
2R2F	;	2.25	;	RIBONUCLEOTIDE REDUCTASE R2F PROTEIN FROM SALMONELLA TYPHIMURIUM (OXIDIZED)
7AIL	;	1.73	;	Ribonucleotide Reductase R2m protein from Aquifex aeolicus
7Q39	;	2.1	;	Ribonucleotide Reductase R2_genomic protein from Aquifex aeolicus
5CI3	;	2.401	;	Ribonucleotide reductase Y122 2,3,5-F3Y variant
5CI2	;	2.25	;	Ribonucleotide reductase Y122 2,3,6-F3Y variant
5CI1	;	1.95	;	Ribonucleotide reductase Y122 2,3-F2Y variant
5CI0	;	2.25	;	Ribonucleotide reductase Y122 3,5-F2Y variant
2XOF	;	2.2	;	Ribonucleotide reductase Y122NO2Y modified R2 subunit of E. coli
1JK0	;	2.8	;	Ribonucleotide reductase Y2Y4 heterodimer
2XO4	;	2.5	;	RIBONUCLEOTIDE REDUCTASE Y730NH2Y MODIFIED R1 SUBUNIT OF E. COLI
2XAY	;	2.65	;	Ribonucleotide reductase Y730NO2Y and C439A modified R1 subunit of E. coli
2XAZ	;	2.6	;	Ribonucleotide reductase Y730NO2Y and C439S modified R1 subunit of E. coli
2XAX	;	2.75	;	Ribonucleotide reductase Y730NO2Y and Y731A modified R1 subunit of E. coli
2XAW	;	3.1	;	Ribonucleotide reductase Y730NO2Y and Y731F modified R1 subunit of E. coli
2XAK	;	2.8	;	Ribonucleotide reductase Y730NO2Y modified R1 subunit of E. coli
2XO5	;	2.7	;	RIBONUCLEOTIDE REDUCTASE Y731NH2Y MODIFIED R1 SUBUNIT OF E. COLI
2XAV	;	2.8	;	Ribonucleotide reductase Y731NO2Y and Y730F modified R1 subunit of E. coli
2XAP	;	2.1	;	Ribonucleotide reductase Y731NO2Y modified R1 subunit of E. coli to 2. 1 A resolution
2F8M	;	2.087	;	Ribose 5-phosphate isomerase from Plasmodium falciparum
6X8Y	;	1.0	;	Ribose-bound structure of Marinomonas primoryensis PA14 carbohydrate-binding domain
1DGZ	;		;	RIBOSMAL PROTEIN L36 FROM THERMUS THERMOPHILUS: NMR STRUCTURE ENSEMBLE
2BM1	;	2.6	;	Ribosomal elongation factor G (EF-G) Fusidic acid resistant mutant G16V
2BM0	;	2.4	;	Ribosomal elongation factor G (EF-G) Fusidic acid resistant mutant T84A
1W3E	;	1.77	;	Ribosomal L30e of Thermococcus celer, P59A mutant
1S7N	;	2.1	;	Ribosomal L7/L12 alpha-N-protein acetyltransferase in complex with Coenzyme A (CoA free sulfhydryl)
7O5H	;	3.1	;	Ribosomal methyltransferase KsgA bound to small ribosomal subunit
1DWU	;	2.8	;	Ribosomal protein L1
4F9T	;	1.46	;	Ribosomal protein L1 from Thermus thermophilus with substitution Thr217Ala
1AD2	;	1.9	;	RIBOSOMAL PROTEIN L1 MUTANT WITH SERINE 179 REPLACED BY CYSTEINE
1ZAV	;	1.9	;	Ribosomal Protein L10-L12(NTD) Complex, Space Group P21
1ZAW	;	2.3	;	Ribosomal Protein L10-L12(NTD) Complex, Space Group P212121, Form A
1ZAX	;	2.1	;	Ribosomal Protein L10-L12(NTD) Complex, Space Group P212121, Form B
5COL	;	2.25	;	RIBOSOMAL PROTEIN L11 FROM METHANOCOCCUS JANNASCHII
2K3F	;		;	Ribosomal protein L11 from Thermotoga maritima
3CJT	;	2.3	;	Ribosomal protein L11 methyltransferase (PrmA) in complex with dimethylated ribosomal protein L11
3CJQ	;	2.7	;	Ribosomal protein L11 methyltransferase (PrmA) in complex with dimethylated ribosomal protein L11 in space group P212121
3CJR	;	2.05	;	Ribosomal protein L11 methyltransferase (PrmA) in complex with ribosomal protein L11 (K39A) and inhibitor Sinefungin.
3EGV	;	1.75	;	Ribosomal protein L11 methyltransferase (PrmA) in complex with trimethylated ribosomal protein L11
1WHI	;	1.5	;	RIBOSOMAL PROTEIN L14
1RL2	;	2.3	;	RIBOSOMAL PROTEIN L2 RNA-BINDING DOMAIN FROM BACILLUS STEAROTHERMOPHILUS
1BXE	;	1.9	;	RIBOSOMAL PROTEIN L22 FROM THERMUS THERMOPHILUS
1H7M	;	1.96	;	Ribosomal Protein L30e from Thermococcus celer
1RL6	;	2.0	;	RIBOSOMAL PROTEIN L6
1DIV	;	2.6	;	RIBOSOMAL PROTEIN L9
6I7V	;	2.9	;	Ribosomal protein paralogs bL31 and bL36
1A32	;	2.1	;	RIBOSOMAL PROTEIN S15 FROM BACILLUS STEAROTHERMOPHILUS
2FKX	;		;	Ribosomal protein s15 from thermus thermophilus, nmr recalculated structure
1AB3	;		;	RIBOSOMAL PROTEIN S15 FROM THERMUS THERMOPHILUS, NMR, 26 STRUCTURES
1RIP	;		;	RIBOSOMAL PROTEIN S17: CHARACTERIZATION OF THE THREE-DIMENSIONAL STRUCTURE BY 1H-AND 15N-NMR
1LOU	;	1.95	;	RIBOSOMAL PROTEIN S6
1HUS	;	2.5	;	RIBOSOMAL PROTEIN S7
6JMK	;	1.8	;	Ribosomal protein S7 from Mycobacterium tuberculosis
1RSS	;	1.9	;	RIBOSOMAL PROTEIN S7 FROM THERMUS THERMOPHILUS
1AN7	;	2.9	;	RIBOSOMAL PROTEIN S8 FROM THERMUS THERMOPHILUS
4WCW	;	2.1	;	Ribosomal silencing factor during starvation or stationary phase (RsfS) from Mycobacterium tuberculosis
5SUM	;	2.8	;	Ribosome assembly factor NSA1
5SUI	;	1.3	;	Ribosome assembly factor NSA1: C-terminal truncation
7AFQ	;		;	Ribosome binding factor A (RbfA)
1JOS	;	1.7	;	Ribosome Binding Factor A(rbfA)
1P9Y	;	2.15	;	Ribosome binding of E. coli Trigger Factor mutant F44L.
2B7U	;	1.6	;	Ribosome inactivating protein type 1 from Charybdis maritima AGG
8BDV	;		;	Ribosome maturation factor P (RimP) from Staphylococcus aureus
7AFR	;		;	Ribosome maturation factor RimP (apo)
6S0K	;	3.1	;	Ribosome nascent chain in complex with SecA
1EH1	;	2.6	;	RIBOSOME RECYCLING FACTOR FROM THERMUS THERMOPHILUS
5ZLU	;	3.6	;	Ribosome Structure bound to ABC-F protein.
4GMQ	;	1.3	;	Ribosome-binding domain of Zuo1
6R7L	;	6.0	;	Ribosome-bound SecYEG translocon in a nanodisc
5M5H	;	4.5	;	RIBOSOME-BOUND YIDC INSERTASE
3BO0	;	9.6	;	Ribosome-SecY complex
3BO1	;	9.6	;	Ribosome-SecY complex
4V7I	;	9.6	;	Ribosome-SecY complex.
8BDB	;	1.7	;	Ribulose-1,5-bisphosphate carboxylase/oxygenase from Griffithsia monilis
8I3X	;	1.78	;	Rice APIP6-RING homodimer
2RGL	;	2.2	;	Rice BGlu1 beta-glucosidase, a plant exoglucanase/beta-glucosidase
2RGM	;	1.55	;	Rice BGlu1 beta-glucosidase, a plant exoglucanase/beta-glucosidase
4BQK	;	1.997	;	rice importin_alpha : VirD2NLS complex
4BPL	;	2.3	;	rice importin_alpha in complex with nucleoplasmin NLS
3FR8	;	2.8	;	rice Ketolacid reductoisomerase in complex with Mg2+-NADPH
7EZI	;	1.2	;	Rice L-galactose dehydrogenase (apo form)
7EZL	;	1.8	;	Rice L-galactose dehydrogenase (holo form)
1RZL	;	1.6	;	RICE NONSPECIFIC LIPID TRANSFER PROTEIN
3WBE	;	1.97	;	Rice Os3BGlu6 Beta-Glucosidase E178Q mutant in a covalent complex with Glc from GA4GE.
3WBA	;	1.9	;	Rice Os3BGlu6 E178Q with Covalent Glucosyl Moiety from p-nitrophenyl glucopyranoside.
6KYI	;	1.75	;	Rice Rubisco in complex with sulfate ions
6IR8	;	2.3	;	Rice WRKY/DNA complex
1F2N	;	2.8	;	RICE YELLOW MOTTLE VIRUS
6K9N	;	2.27	;	Rice_OTUB_like_catalytic domain
1BR5	;	2.5	;	RICIN A CHAIN (RECOMBINANT) COMPLEX WITH NEOPTERIN
1BR6	;	2.3	;	RICIN A CHAIN (RECOMBINANT) COMPLEX WITH PTEROIC ACID
6OBC	;	1.762	;	Ricin A chain bound to camelid
4LGP	;	2.4	;	Ricin A chain bound to camelid nanobody (VHH1)
4Z9K	;	1.5	;	Ricin A chain bound to camelid nanobody (VHH2)(F5)
4LGR	;	1.65	;	Ricin A chain bound to camelid nanobody (VHH3)
4LGS	;	2.7	;	Ricin A chain bound to camelid nanobody (VHH4)
4LHJ	;	1.8	;	Ricin A chain bound to camelid nanobody (VHH5)
4LHQ	;	2.3	;	Ricin A chain bound to camelid nanobody (VHH8)
5BOZ	;	3.1	;	Ricin A chain bound to camelid nanobody (VHH9)(E1)
6OCA	;	2.113	;	Ricin A chain bound to VHH antibody V2G10
6OBO	;	1.9	;	Ricin A chain bound to VHH antibody V6A6
6OBM	;	2.495	;	Ricin A chain bound to VHH antibody V6A7
6OCD	;	2.103	;	Ricin A chain bound to VHH antibody V6D4
6OBE	;	1.732	;	Ricin A chain bound to VHH antibody V6H8
6OBG	;	1.996	;	Ricin A chain bound to VHH antibody V8E6
1IFT	;	1.8	;	RICIN A-CHAIN (RECOMBINANT)
1J1M	;	1.5	;	Ricin A-Chain (Recombinant) at 100K
2R3D	;	2.09	;	Ricin A-chain (recombinant) complex with Acetamide
2P8N	;	1.94	;	Ricin a-chain (recombinant) complex with adenine
1IFS	;	2.0	;	RICIN A-CHAIN (RECOMBINANT) COMPLEX WITH ADENOSINE (ADENOSINE BECOMES ADENINE IN THE COMPLEX)
1IFU	;	2.4	;	RICIN A-CHAIN (RECOMBINANT) COMPLEX WITH FORMYCIN
2PJO	;	1.8	;	Ricin a-chain (recombinant) complex with n-methylurea
2R2X	;	2.4	;	Ricin A-chain (recombinant) complex with Urea
2VC4	;	1.39	;	Ricin A-Chain (Recombinant) E177D Mutant
2VC3	;	1.6	;	Ricin A-Chain (Recombinant) E177D Mutant with a bound acetate
1UQ5	;	1.4	;	RICIN A-CHAIN (RECOMBINANT) N122A MUTANT
1UQ4	;	1.9	;	RICIN A-CHAIN (RECOMBINANT) R213D MUTANT
3LC9	;	2.28	;	Ricin A-chain variant 1-33/44-198 with engineered disulfide bond
4IMV	;	2.25	;	Ricin A-chain variant 1-33/44-198 with engineered disulfide bond, R48C/T77C/D75N
7KD2	;	2.55	;	Ricin bound to VHH antibody V11B2
7KD0	;	2.768	;	Ricin bound to VHH antibody V2C11
7KBI	;	3.049	;	Ricin bound to VHH antibody V5E1
7KDU	;	2.809	;	Ricin bound to VHH antibody V5E4
7KC9	;	2.301	;	Ricin bound to VHH antibody V5G1
7KDM	;	2.301	;	Ricin bound to VHH antibody V5G6
7KBK	;	2.091	;	Ricin bound to VHH antibody V6E11
6CWG	;	2.6	;	Ricin catalytic subunit bound go A9 VHH antibody
5E1H	;	2.032	;	Ricin toxin in complex with neutralizing single chain monoclonal antibodies (VHHs)
4LQ8	;	2.2	;	Rickettsia rickettsii cell surface antigen 4 (sca4) head domain (residues 21-360)
7QWT	;	3.712	;	Rieske non-heme iron monooxygenase for guaiacol O-demethylation
1RFS	;	1.83	;	RIESKE SOLUBLE FRAGMENT FROM SPINACH
5HV2	;	2.912	;	Rifampin phosphotransferase G527Y mutant from Listeria monocytogenes
5HV3	;	3.118	;	Rifampin phosphotransferase G527Y mutant in complex with AMPPNP from Listeria monocytogenes
5HV1	;	3.103	;	Rifampin phosphotransferase in complex with AMPPNP and rifampin from Listeria monocytogenes
6ZDX	;	3.0	;	RIFIN variable region bound to LILRB1 ectodomain
3VN9	;	2.6	;	Rifined Crystal structure of non-phosphorylated MAP2K6 in a putative auto-inhibition state
3FLA	;	1.8	;	RifR - Type II thioesterase from Rifamycin NRPS/PKS biosynthetic pathway - Form 1
3FLB	;	1.8	;	RifR - Type II thioesterase from Rifamycin NRPS/PKS biosynthetic pathway - Form 2
6I9I	;	1.98	;	Rift valley fever virus Gn in complex with a neutralizing antibody fragment
7WFE	;	3.25	;	Right PSI in the cyclic electron transfer supercomplex NDH-PSI from Arabidopsis
8PDR	;	4.0	;	Rigid body fit of assembled HMPV N-RNA spiral bound to the C-terminal region of P
8VRD	;	7.0	;	Rigid body fitted model for free recombinant gamma tubulin ring complex.
8VRJ	;	7.7	;	Rigid body fitted model for gamma tubulin ring complex capped microtubule
8VRK	;	8.5	;	Rigid body fitted model for refined density map of gamma tubulin ring complex capped microtubule
6PWB	;	9.83	;	Rigid body fitting of flagellin FlaB, and flagellar coiling proteins, FcpA and FcpB, into a 10 Angstrom structure of the asymmetric flagellar filament purified from Leptospira biflexa Patoc WT cells resolved via subtomogram averaging
2JYH	;		;	Rigid-body refinement of the tetraloop-receptor RNA complex
7N0W	;	2.46	;	Rigidity of loop 1 contributes to equipotency of globular and ribbon isomers of alpha-conotoxin AusIA
7N0Y	;	2.58	;	Rigidity of loop 1 contributes to equipotency of globular and ribbon isomers of alpha-conotoxin AusIA
4ATX	;	8.2	;	Rigor kinesin motor domain with an ordered neck-linker, docked on tubulin dimer, modelled into the 8A cryo-EM map of doublecortin- microtubules decorated with kinesin
5KG8	;	9.1	;	Rigor myosin X co-complexed with an actin filament
2OS8	;	3.27	;	Rigor-like structures of muscle myosins reveal key mechanical elements in the transduction pathways of this allosteric motor
2OTG	;	3.12	;	Rigor-like structures of muscle myosins reveal key mechanical elements in the transduction pathways of this allosteric motor
2V9U	;	2.59	;	Rim domain of main porin from Mycobacteria smegmatis
2CNM	;	2.6	;	RimI - Ribosomal S18 N-alpha-protein acetyltransferase in complex with a bisubstrate inhibitor (Cterm-Arg-Arg-Phe-Tyr-Arg-Ala-N-alpha- acetyl-S-CoA).
2CNS	;	2.5	;	RimI - Ribosomal S18 N-alpha-protein acetyltransferase in complex with acetylCoA.
2CNT	;	2.4	;	RimI - Ribosomal S18 N-alpha-protein acetyltransferase in complex with CoenzymeA.
4IWX	;	2.854	;	Rimk structure at 2.85A
1S7K	;	1.8	;	RimL- Ribosomal L7/L12 alpha-N-protein acetyltransferase crystal form 2 (apo)
1S7F	;	2.0	;	RimL- Ribosomal L7/L12 alpha-N-protein acetyltransferase crystal form I (apo)
1S7L	;	2.3	;	RimL- Ribosomal L7/L12 alpha-N-protein acetyltransferase in complex with Coenzyme A (CoA-Cys134 Disulfide)
4B8J	;	2.001	;	rImp_alpha1a
4B8P	;	2.3	;	rImp_alpha_A89NLS
2YNS	;	2.1	;	rImp_alpha_B54NLS
4B8O	;	2.084	;	rImp_alpha_SV40TAgNLS
4J3H	;	1.5002	;	Ring cycle for dilating and constricting the nuclear pore: structure of a Nup54 homo-tetramer.
2XEU	;	1.5	;	Ring domain
8A38	;	2.196	;	RING domain of human TRIM2
6Y5N	;	1.88	;	RING-DTC domain of Deltex1
6Y5P	;	1.74	;	RING-DTC domain of Deltex1 bound to NAD
6Y3J	;	2.6	;	RING-DTC domains of Deltex 2, bound to ADP-ribose
6Y22	;	2.069	;	RING-DTC domains of Deltex 2, Form 1
6Y2X	;	1.77	;	RING-DTC domains of Deltex 2, Form 2
1IYM	;		;	RING-H2 finger domain of EL5
6SA8	;	2.4	;	ring-like DARPin-Armadillo fusion H83_D01
4JV0	;	2.95	;	Ring-Opening of the -OH-PdG Adduct in Ternary Complexes with the Sulfolobus solfataricus DNA polymerase Dpo4
3GS2	;	1.699	;	Ring1B C-terminal domain/Cbx7 Cbox Complex
3IXS	;	1.7	;	Ring1B C-terminal domain/RYBP C-terminal domain Complex
2CKL	;	2.0	;	Ring1b-Bmi1 E3 catalytic domain structure
6WI7	;	1.702	;	RING1B-BMI1 fusion in closed conformation
4ZQY	;	2.9515	;	Ringhalexin from hemachatus haemachatus: A novel inhibitor of extrinsic tenase complex
6FDN	;	2.9	;	Rio2 structure
6FDO	;	2.6	;	Rio2 structure
1N6X	;	1.4	;	RIP-phasing on Bovine Trypsin
1N6Y	;	1.4	;	RIP-phasing on Bovine Trypsin
1N7A	;	1.2	;	RIP-Radiation-damage Induced Phasing
1N7B	;	1.4	;	RIP-Radiation-damage Induced Phasing
5TX5	;	2.56	;	Rip1 Kinase ( flag 1-294, C34A, C127A, C233A, C240A) with GSK772
5AR2	;	2.44	;	RIP2 Kinase Catalytic Domain (1 - 310)
5AR3	;	3.23	;	RIP2 Kinase Catalytic Domain (1 - 310) complex with AMP-PCP
5AR5	;	2.66	;	RIP2 Kinase Catalytic Domain (1 - 310) complex with Benzimidazole
5AR7	;	2.71	;	RIP2 Kinase Catalytic Domain (1 - 310) complex with Biaryl Urea
5AR8	;	2.79	;	RIP2 Kinase Catalytic Domain (1 - 310) complex with Biphenylsulfonamide
5AR4	;	2.7	;	RIP2 Kinase Catalytic Domain (1 - 310) complex with SB-203580
6UL8	;	2.68	;	RIP2 kinase catalytic domain complex with (5S,6S,8R)-2-(benzo[d]thiazol-5-yl)-6-hydroxy-4,5,6,7,8,9-hexahydro-5,8-methanopyrazolo[1,5-a][1,3]diazocine-3-carboxamide
6RN8	;	2.69	;	RIP2 Kinase Catalytic Domain complex with 2(4[(1,3benzothiazol5yl)amino]6(2methylpropane2sulfonyl)quinazolin7yl)oxy)ethyl phosphate
6RNA	;	2.62	;	RIP2 Kinase Catalytic Domain complex with 2({4[(1,3benzothiazol5yl)amino]6(2methylpropane2sulfonyl)quinazolin7yl}oxy)ethan1ol
6SZE	;	2.94	;	RIP2 Kinase Catalytic Domain complex with 5-Amino-1-Phenylpyrazole-4-Carboxamide.
6SZJ	;	2.53	;	RIP2 Kinase Catalytic Domain complex with 5amino1tertbutyl3(3methoxyphenyl)1H pyrazole4carboxamide.
6HMX	;	2.53	;	RIP2 Kinase Catalytic Domain complex with N(4,5dimethyl1Hpyrazol3yl)7methoxy6(2methylpropane2sulfonyl)quinolin4amine
6EWY	;	2.2	;	RipA Peptidoglycan hydrolase (Rv1477, Mycobacterium tuberculosis) N-terminal domain
4LJ1	;	1.17	;	RipD (Rv1566c) from Mycobacterium tuberculosis: a non-catalytic NlpC/p60 domain protein with two penta-peptide repeat units (PVQQA-PVQPA)
4JXB	;	1.56	;	RipD (Rv1566c) from Mycobacterium tuberculosis: a non-catalytic NlpC/p60 domain protein, adaptation to peptidoglycan-binding function
5VFA	;	1.452	;	RitR Mutant - C128D
5U8K	;	1.69	;	RitR mutant - C128S
6EUE	;	2.0	;	Rivastigmine analogue bound to Tc ACHE.
6YLG	;	3.0	;	Rix1-Rea1 pre-60S particle - 60S core, body 1 (rigid body refinement)
6YLH	;	3.1	;	Rix1-Rea1 pre-60S particle - full composite structure
6YLF	;	4.2	;	Rix1-Rea1 pre-60S particle - Rea1, body 3 (rigid body refinement, composite structure of Rea1 ring and tail)
6YLE	;	3.3	;	Rix1-Rea1 pre-60S particle - Rix1-subcomplex, body 3 (rigid body refinement)
6KGI	;	1.04	;	RLGS-yUbr1 Ubr box
6LHN	;	2.5	;	RLGSGG-AtPRT6 UBR box
7Y6Y	;	1.543	;	RLGSGG-AtPRT6 UBR box (C121)
7XWF	;	1.451	;	RLGSGG-AtPRT6 UBR box (highest resolution)
7Y6Z	;	1.598	;	RLGSGG-AtPRT6 UBR box (I222)
7Y70	;	1.801	;	RLGSGG-AtPRT6 UBR box (P4332)
2MBG	;		;	Rlip76 (gap-gbd)
5IQK	;	1.75	;	Rm3 metallo-beta-lactamase
8ERA	;	2.86	;	RMC-5552 in complex with mTORC1 and FKBP12
1RTV	;	2.5	;	RmlC (dTDP-6-deoxy-D-xylo-4-hexulose 3,5-epimerase) crystal structure from Pseudomonas aeruginosa, apo structure
1PM7	;	2.2	;	RmlC (dTDP-6-DEOXY-D-XYLO-4-HEXULOSE 3,5-EPIMERASE)STRUCTURE FROM MYCOBACTERIUM TUBERCULOSIS AND INHIBITOR DESIGN. THE APO STRUCTURE.
1DZR	;	2.17	;	RmlC from Salmonella typhimurium
1DZT	;	2.2	;	RMLC FROM SALMONELLA TYPHIMURIUM
2IXC	;	1.79	;	RmlC M. tuberculosis with dTDP-rhamnose
2IXJ	;	2.54	;	RmlC P aeruginosa native
2IXK	;	1.7	;	RmlC P aeruginosa with dTDP-4-keto rhamnnose (the product of the reaction)
2IXH	;	2.0	;	RmlC P aeruginosa with dTDP-rhamnose
2IXI	;	1.8	;	RmlC P aeruginosa with dTDP-xylose
2IXL	;	1.6	;	RmlC S. suis with dTDP-rhamnose
6CI9	;	1.9	;	RMM microcompartment-associated aminopropanol dehydrogenase NADP + aminoacetone holo-structure
2RMP	;	2.7	;	RMP-pepstatin A complex
8JKM	;	3.98	;	RN-1747 bound state of mTRPV4
4MSR	;	1.2	;	RNA 10mer duplex with six 2'-5'-linkages
4MSB	;	1.55	;	RNA 10mer duplex with two 2'-5'-linkages
5KRG	;	1.6	;	RNA 15mer duplex binding with PZG monomer
4IQS	;	2.6	;	RNA 8mer duplex modified with 4-Se-Uridine
2RSK	;		;	RNA aptamer against prion protein in complex with the partial binding peptide
1KOC	;		;	RNA APTAMER COMPLEXED WITH ARGININE, NMR
1KOD	;		;	RNA APTAMER COMPLEXED WITH CITRULLINE, NMR
1ULL	;		;	RNA APTAMER COMPLEXED WITH HIV-1 REV PEPTIDE, NMR, 7 STRUCTURES
2LUN	;		;	RNA Aptamer for B. anthracis Ribosomal Protein S8
1ZDI	;	2.7	;	RNA BACTERIOPHAGE MS2 COAT PROTEIN/RNA COMPLEX
2U1A	;		;	RNA BINDING DOMAIN 2 OF HUMAN U1A PROTEIN, NMR, 20 STRUCTURES
4OZS	;	2.17	;	RNA binding protein
4B8T	;		;	RNA BINDING PROTEIN Solution structure of the third KH domain of KSRP in complex with the G-rich target sequence.
2NCI	;		;	RNA Bulge Loop that Specifically Binds Metal Ions
7EEM	;	2.593	;	RNA bulged-G motif
7M3V	;	2.19	;	RNA bulged-G motif
6WLH	;		;	RNA complex of WT1 zinc finger transcription factor
3S49	;	2.3	;	RNA crystal structure with 2-Se-uridine modification
5TDK	;	1.43	;	RNA decamer duplex with eight 2'-5'-linkages
5TDJ	;	1.5	;	RNA decamer duplex with four 2'-5'-linkages
5H0R	;	3.9	;	RNA dependent RNA polymerase ,vp4,dsRNA
1HHS	;	2.0	;	RNA dependent RNA polymerase from dsRNA bacteriophage phi6
1HI8	;	2.5	;	RNA dependent RNA polymerase from dsRNA bacteriophage phi6
1HI1	;	3.0	;	RNA dependent RNA polymerase from dsRNA bacteriophage phi6 plus bound NTP
1HI0	;	3.0	;	RNA dependent RNA polymerase from dsRNA bacteriophage phi6 plus initiation complex
1HHT	;	2.9	;	RNA dependent RNA polymerase from dsRNA bacteriophage phi6 plus template
5FSW	;	3.19	;	RNA dependent RNA polymerase QDE-1 from Thielavia terrestris
7LO9	;	1.78	;	RNA dodecamer containing a GNA A residue
6XUR	;	1.1	;	RNA dodecamer with a 6-hydrazino-2-aminopurine modified base
6XUS	;	1.1	;	RNA dodecamer with a 6-hydrazino-2-aminopurine modified base
8SX6	;	1.45	;	RNA duplex bound with GMP and AMP monomers
8SWG	;	1.5	;	RNA duplex bound with GpppA dinucleotide ligand
8SY1	;	1.76	;	RNA duplex bound with imidazolium bridged GA dinucleotide
6U8U	;	2.4	;	RNA duplex bound with TNA 3'-3' imidazolium dimer
1RRR	;		;	RNA DUPLEX CONTAINING A PURINE-RICH STRAND, NMR, 10 STRUCTURES
7ECM	;	1.51	;	RNA duplex containing C-A base pair
7ECJ	;	3.1	;	RNA duplex containing C-A base pairs
7ECL	;	3.01	;	RNA duplex containing C-Ag-A and U-Ag-A base pair
7ECK	;	2.79	;	RNA duplex containing C-Ag-A and U-Ag-A base pairs
7ECN	;	1.6	;	RNA duplex containing C-Ag-A base pairs
7ECP	;	2.91	;	RNA duplex containing C-Ag-U
7EDU	;	2.3	;	RNA duplex containing C-Au-C base pair
7EDT	;	1.2	;	RNA duplex containing CC mispairs
6N8H	;		;	RNA Duplex containing the internal loop 5'-GCAU/3'-UACG
6N8F	;		;	RNA Duplex containing the internal loop 5'-GCUU/3'-UUCG
6N8I	;		;	RNA Duplex containing the internal loop 5'-UUCG/3'-GCUU
7ECO	;	1.81	;	RNA duplex containing U-Ag-U base pairs
4U38	;	1.8	;	RNA duplex containing UU mispair
5LQO	;	1.87	;	RNA duplex has central consecutive GA pairs flanked by G-C basepairs
5LQT	;	1.5	;	RNA duplex has central consecutive GA pairs flanked by G-C basepairs
5LR3	;	1.65	;	RNA duplex has central consecutive GA pairs flanked by G-U basepairs
5LR4	;	1.8	;	RNA duplex has central consecutive GA pairs flanked by G-U basepairs with a methyl group on the adenine N6
5V0J	;	1.5	;	RNA duplex with 2-MeImpG analogue bound-2 binding sites
5V0K	;	1.6	;	RNA duplex with 2-MeImpG analogue bound-3 binding sites
5V0H	;	1.9	;	RNA duplex with 2-MeImpG analogue bound-one binding site
7A3Y	;		;	RNA duplex with a cytosine bulge in complex with berberine
6U89	;	2.36	;	RNA duplex, bound with TNA monomer
2LA5	;		;	RNA Duplex-Quadruplex Junction Complex with FMRP RGG peptide
5HZD	;	1.6	;	RNA Editing TUTase 1 from Trypanosoma brucei
5IDO	;	2.2	;	RNA Editing TUTase 1 from Trypanosoma brucei in complex with UTP
5I49	;	1.8	;	RNA Editing TUTase 1 from Trypanosoma brucei in complex with UTP analog UMPNPP
8Q4O	;		;	RNA G-quadruplex from the 5'-UTR of human tyrosine kinase 2 (TYK2)
6AZ4	;	2.98	;	RNA hairpin complex with guanosine dinucleotide ligand G(5')ppp(5')G
6BMD	;	3.0	;	RNA hairpin containing GpppG-oligo to mimic intermediate formed by activated monomer and activated downstream helper
5UZ6	;	2.1	;	RNA hairpin structure containing 2-MeImp-oligo analogue
5V0O	;	2.7	;	RNA hairpin structure containing 2-MeImpG analogue bound
5V9Z	;	2.51	;	RNA hairpin structure containing 2-MeImpG analogue bound
5UX3	;	2.5	;	RNA hairpin structure containing 2-MeImpG monomer analogue and 2-MeImp-oligomer analogue
6U7Z	;	2.71	;	RNA hairpin structure containing one TNA nucleotide as primer
6U7Y	;	2.95	;	RNA hairpin structure containing one TNA nucleotide as template
5VGW	;	2.42	;	RNA hairpin structure containing tetraloop/receptor motif
5VCF	;	2.8	;	RNA hairpin structure containing tetraloop/receptor motif, complexed with 2-MeImpG analogue
5VCI	;	2.6	;	RNA hairpin structure containing tetraloop/receptor motif, complexed with 2-MeImpG analogue
6U8F	;	2.81	;	RNA hairpin, bound with TNA monomer
5TKO	;	1.52	;	RNA heptamer duplex with one 2'-5'-linkage
259D	;	1.46	;	RNA HYDRATION: A DETAILED LOOK
7EFG	;	2.6	;	RNA kink-turn motif
7EFH	;	2.7	;	RNA kink-turn motif
7EFI	;	2.9	;	RNA kink-turn motif composed of RNA, DNA and 2'-O-methyl RNA
7EI7	;	3.2	;	RNA kink-turn motif with 2-aminopurine
7EI8	;	3.1	;	RNA kink-turn motif with 2-aminopurine
7F8Z	;	3.0	;	RNA kink-turn motif with 2-aminopurine
7EI9	;	2.7	;	RNA kink-turn motif with pyrrolo cytosine
7EIA	;	3.0	;	RNA kink-turn motif with pyrrolo cytosine
8DCA	;	2.43	;	RNA ligase RtcB from Pyrococcus horikoshii in complex with Co2+ and GTP
8DCF	;	2.42	;	RNA ligase RtcB from Pyrococcus horikoshii in complex with Cu2+ and GTP
8DC9	;	2.47	;	RNA ligase RtcB from Pyrococcus horikoshii in complex with Mn2+ and GTP
8DCB	;	2.6	;	RNA ligase RtcB from Pyrococcus horikoshii in complex with Ni2+ and GTP
8DCD	;	2.22	;	RNA ligase RtcB from Pyrococcus horikoshii in complex with Zn2+ and GTP
4ISZ	;	2.303	;	RNA ligase RtcB in complex with GTP alphaS and Mn(II)
4ISJ	;	2.344	;	RNA Ligase RtcB in complex with Mn(II)
4DWQ	;	2.25	;	RNA ligase RtcB-GMP/Mn(2+) complex
4DWR	;	1.48	;	RNA ligase RtcB/Mn2+ complex
1BJ2	;		;	RNA LOOP-LOOP COMPLEX: THE COLE1 INVERTED LOOP SEQUENCE, NMR, 8 STRUCTURES
2BJ2	;		;	RNA LOOP-LOOP COMPLEX: THE COLE1 INVERTED LOOP SEQUENCE, NMR, MINIMIZED AVERAGE STRUCTURE
7CV6	;	3.01	;	RNA methyltransferase METTL4
7CV7	;	2.3	;	RNA methyltransferase METTL4
7CV8	;	2.37	;	RNA methyltransferase METTL4
7CV9	;	2.455	;	RNA methyltransferase METTL4
7CVA	;	2.5	;	RNA methyltransferase METTL4
7DPE	;	2.751	;	RNA methyltransferase METTL4
6YU8	;	1.841	;	RNA Methyltransferase of Sudan Ebola Virus
5D8T	;	1.2	;	RNA octamer containing (S)-5' methyl, 2'-F U.
6CXZ	;	1.5	;	RNA octamer containing 2'-F, 4'-Calpha-Me U.
6CY0	;	2.398	;	RNA octamer containing 2'-F, 4'-Cbeta-OMe U.
5VR4	;	1.5	;	RNA octamer containing 2'-F-4'-OMe U.
6CY4	;	1.851	;	RNA octamer containing 2'-OMe, 4'- Cbeta-OMe U.
6CY2	;	1.4	;	RNA octamer containing 2'-OMe, 4'Calpha-OMe U.
5DEK	;	1.993	;	RNA octamer containing dT
5V2H	;	1.08001	;	RNA octamer containing glycol nucleic acid, SgnT
1G2J	;	1.97	;	RNA OCTAMER R(CCCP*GGGG) CONTAINING PHENYL RIBONUCLEOTIDE
5DER	;	1.8	;	RNA oligonucleotide containing (R)-C5'-ME-2'F U
8SKQ	;	1.35	;	RNA oligonucleotide containing an alpha-(L)-threofuranosyl nucleic acid (TNA)
6OWL	;	2.0	;	RNA oligonucleotides with 3'-arabino guanosine co-crystallized with GMP
8TVZ	;	5.94	;	RNA origami 3-helix tile Traptamer
7PTQ	;	4.08	;	RNA origami 5-helix tile
7PTS	;	5.71	;	RNA origami 5-helix tile
5VVS	;	6.4	;	RNA pol II elongation complex
6DRD	;	3.9	;	RNA Pol II(G)
3N97	;	3.252	;	RNA polymerase alpha C-terminal domain (E. coli) and sigma region 4 (T. aq. mutant) bound to (UP,-35 element) DNA
8AC1	;	4.06	;	RNA polymerase at U-rich pause bound to non-regulatory RNA - inactive, open clamp state
8ABZ	;	3.4	;	RNA polymerase at U-rich pause bound to non-regulatory RNA - pause prone, closed clamp state
8AC0	;	4.1	;	RNA polymerase at U-rich pause bound to regulatory RNA putL - active, closed clamp state
8ACP	;	4.5	;	RNA polymerase at U-rich pause bound to regulatory RNA putL - inactive, open clamp state
8AD1	;	4.1	;	RNA polymerase at U-rich pause bound to RNA putL triple mutant - pause prone, closed clamp state
8ABY	;	3.7	;	RNA polymerase bound to purified in vitro transcribed regulatory RNA putL - pause prone, closed clamp state
7Q0K	;	4.0	;	RNA polymerase elongation complex in less-swiveled conformation
7Q0J	;	4.3	;	RNA polymerase elongation complex in more-swiveled conformation
6RQH	;	3.7	;	RNA Polymerase I Closed Conformation 1 (CC1)
6RQL	;	2.9	;	RNA Polymerase I Closed Conformation 2 (CC2)
5M5X	;	4.0	;	RNA Polymerase I elongation complex 1
5M5Y	;	4.0	;	RNA Polymerase I elongation complex 2
5M64	;	4.6	;	RNA Polymerase I elongation complex with A49 tandem winged helix domain
5W5Y	;	3.8	;	RNA polymerase I Initial Transcribing Complex
5W64	;	4.2	;	RNA Polymerase I Initial Transcribing Complex State 1
5W65	;	4.3	;	RNA polymerase I Initial Transcribing Complex State 2
5W66	;	3.9	;	RNA polymerase I Initial Transcribing Complex State 3
5N61	;	3.4	;	RNA polymerase I initially transcribing complex
5M5W	;	3.8	;	RNA Polymerase I open complex
6RUO	;	3.5	;	RNA Polymerase I Open Complex conformation 1
6RWE	;	3.0	;	RNA Polymerase I Open Complex conformation 2
5OA1	;	4.4	;	RNA polymerase I pre-initiation complex
6RRD	;	3.1	;	RNA Polymerase I Pre-initiation complex DNA opening intermediate 1
6RUI	;	2.7	;	RNA Polymerase I Pre-initiation complex DNA opening intermediate 2
4YM7	;	5.5	;	RNA polymerase I structure with an alternative dimer hinge
5G5L	;	4.8	;	RNA polymerase I-Rrn3 complex at 4.8 A resolution
6RQT	;	4.0	;	RNA Polymerase I-tWH-Rrn3-DNA
4A3I	;	3.8	;	RNA Polymerase II binary complex with DNA
1TWH	;	3.4	;	RNA polymerase II complexed with 2'dATP
1TWA	;	3.2	;	RNA polymerase II complexed with ATP
1TWG	;	3.3	;	RNA polymerase II complexed with CTP
1TWC	;	3.0	;	RNA polymerase II complexed with GTP
1TWF	;	2.3	;	RNA polymerase II complexed with UTP at 2.3 A resolution
8S5N	;	3.4	;	RNA polymerase II core initially transcribing complex with an ordered RNA of 12 nt
7NVT	;	2.9	;	RNA polymerase II core pre-initiation complex with closed promoter DNA in distal position
7NVS	;	2.8	;	RNA polymerase II core pre-initiation complex with closed promoter DNA in proximal position
7NVU	;	2.5	;	RNA polymerase II core pre-initiation complex with open promoter DNA
8BZ1	;	3.8	;	RNA polymerase II core pre-initiation complex with the proximal +1 nucleosome (cPIC-Nuc10W)
1I3Q	;	3.1	;	RNA POLYMERASE II CRYSTAL FORM I AT 3.1 A RESOLUTION
1I50	;	2.8	;	RNA POLYMERASE II CRYSTAL FORM II AT 2.8 A RESOLUTION
7OZN	;	3.5	;	RNA Polymerase II dimer (Class 1)
7OZO	;	3.8	;	RNA Polymerase II dimer (Class 2)
7OZP	;	3.8	;	RNA Polymerase II dimer (Class 3)
1I6H	;	3.3	;	RNA POLYMERASE II ELONGATION COMPLEX
6O6C	;	3.1	;	RNA polymerase II elongation complex arrested at a CPD lesion
2E2H	;	3.95	;	RNA polymerase II elongation complex at 5 mM Mg2+ with GTP
3M4O	;	3.57	;	RNA polymerase II elongation complex B
6IR9	;	3.8	;	RNA polymerase II elongation complex bound with Elf1 and Spt4/5, stalled at SHL(-1) of the nucleosome
6J4X	;	4.3	;	RNA polymerase II elongation complex bound with Elf1 and Spt4/5, stalled at SHL(-1) of the nucleosome (+1A)
6J4Y	;	4.3	;	RNA polymerase II elongation complex bound with Elf1 and Spt4/5, stalled at SHL(-1) of the nucleosome (+1B)
7WBX	;	4.0	;	RNA polymerase II elongation complex bound with Elf1 and Spt4/5, stalled at SHL(-3) of the nucleosome
7WBW	;	7.1	;	RNA polymerase II elongation complex bound with Elf1 and Spt4/5, stalled at SHL(-3.5) of the nucleosome
7WBV	;	4.1	;	RNA polymerase II elongation complex bound with Elf1 and Spt4/5, stalled at SHL(-4) of the nucleosome
6J4W	;	7.9	;	RNA polymerase II elongation complex bound with Elf1 and Spt4/5, stalled at SHL(-5) of the nucleosome
8JH2	;	5.7	;	RNA polymerase II elongation complex bound with Elf1, Spt4/5 and foreign DNA, stalled at SHL(-1) of the nucleosome
8HE5	;	6.95	;	RNA polymerase II elongation complex bound with Rad26 and Elf1, stalled at SHL(-3.5) of the nucleosome
6J4Z	;	4.1	;	RNA polymerase II elongation complex bound with Spt4/5 and foreign DNA, stalled at SHL(-1) of the nucleosome
6J50	;	4.7	;	RNA polymerase II elongation complex bound with Spt4/5 and foreign DNA, stalled at SHL(-1) of the nucleosome (tilted conformation)
6J51	;	4.2	;	RNA polymerase II elongation complex bound with Spt4/5 and foreign DNA, stalled at SHL(-1) of the nucleosome, weak Elf1 (+1 position)
5XON	;	3.83	;	RNA Polymerase II elongation complex bound with Spt4/5 and TFIIS
5XOG	;	3.0	;	RNA Polymerase II elongation complex bound with Spt5 KOW5 and Elf1
3M3Y	;	3.18	;	RNA polymerase II elongation complex C
8JH3	;	3.7	;	RNA polymerase II elongation complex containing 40 bp upstream DNA loop, stalled at SHL(-1) of the nucleosome
8JH4	;	3.2	;	RNA polymerase II elongation complex containing 60 bp upstream DNA loop, stalled at SHL(-1) of the nucleosome
4A93	;	3.4	;	RNA Polymerase II elongation complex containing a CPD Lesion
7XN7	;	3.1	;	RNA polymerase II elongation complex containing Spt4/5, Elf1, Spt6, Spn1 and Paf1C
2NVQ	;	2.9	;	RNA Polymerase II Elongation Complex in 150 mM Mg+2 with 2'dUTP
2NVT	;	3.36	;	RNA Polymerase II Elongation Complex in 150 mM Mg+2 with GMPCPP
2YU9	;	3.4	;	RNA polymerase II elongation complex in 150 mm MG+2 with UTP
2E2I	;	3.41	;	RNA polymerase II elongation complex in 5 mM Mg+2 with 2'-dGTP
2NVX	;	3.6	;	RNA polymerase II elongation complex in 5 mM Mg+2 with 2'-dUTP
2E2J	;	3.5	;	RNA polymerase II elongation complex in 5 mM Mg+2 with GMPCPP
5OT2	;	3.2	;	RNA polymerase II elongation complex in the presence of 3d-Napht-A
7RIQ	;	3.0	;	RNA polymerase II elongation complex scaffold 1 without polyamide
7RIW	;	3.2	;	RNA polymerase II elongation complex scaffold 2, without polyamide
6A5T	;	6.7	;	RNA polymerase II elongation complex stalled at SHL(-1) of the nucleosome
6A5L	;	5.6	;	RNA polymerase II elongation complex stalled at SHL(-1) of the nucleosome, with foreign DNA
6INQ	;	6.9	;	RNA polymerase II elongation complex stalled at SHL(-1) of the nucleosome, with foreign DNA (+1 position)
6A5U	;	7.6	;	RNA polymerase II elongation complex stalled at SHL(-1) of the nucleosome, with foreign DNA, tilt conformation
6A5R	;	8.7	;	RNA polymerase II elongation complex stalled at SHL(-2) of the nucleosome
6A5P	;	7.0	;	RNA polymerase II elongation complex stalled at SHL(-5) of the nucleosome
6A5O	;	9.9	;	RNA polymerase II elongation complex stalled at SHL(-6) of the nucleosome
7XSZ	;	3.4	;	RNA polymerase II elongation complex transcribing a nucleosome (EC115)
7XSE	;	3.6	;	RNA polymerase II elongation complex transcribing a nucleosome (EC42)
7XSX	;	3.8	;	RNA polymerase II elongation complex transcribing a nucleosome (EC49)
7XT7	;	4.2	;	RNA polymerase II elongation complex transcribing a nucleosome (EC49B)
7XTI	;	3.9	;	RNA polymerase II elongation complex transcribing a nucleosome (EC58hex)
7XTD	;	3.9	;	RNA polymerase II elongation complex transcribing a nucleosome (EC58oct)
6UPX	;	3.4	;	RNA polymerase II elongation complex with 5-guanidinohydantoin lesion in state 1
6UPY	;	3.4	;	RNA polymerase II elongation complex with 5-guanidinohydantoin lesion in state 2E
6UPZ	;	3.1	;	RNA polymerase II elongation complex with 5-guanidinohydantoin lesion in state 3
6UQ0	;	3.56	;	RNA polymerase II elongation complex with 5-guanidinohydantoin lesion in state 4
6UQ3	;	3.47	;	RNA polymerase II elongation complex with 5-guanidinohydantoin lesion in state 5
6UQ1	;	3.6	;	RNA polymerase II elongation complex with 5-guanidinohydantoin lesion in state 6
6UQ2	;	3.2	;	RNA polymerase II elongation complex with dG in state 1
7RIM	;	2.9	;	RNA polymerase II elongation complex with hairpin polyamide Py-Im 1, scaffold 1
7RIP	;	3.3	;	RNA polymerase II elongation complex with hairpin polyamide Py-Im 1, scaffold 1 soaked with CTP
7RIX	;	3.4	;	RNA polymerase II elongation complex with hairpin polyamide Py-Im 1, scaffold 2
7RIY	;	3.7	;	RNA polymerase II elongation complex with hairpin polyamide Py-Im 1, scaffold 2 soaked with UTP
7KED	;	3.6	;	RNA polymerase II elongation complex with unnatural base dTPT3
7KEF	;	3.89	;	RNA polymerase II elongation complex with unnatural base dTPT3, rNaM in swing state
7KEE	;	3.45	;	RNA polymerase II elongation complex with unnatural base dTPT3, rNaMTP bound to E-site
2NVZ	;	4.3	;	RNA Polymerase II elongation complex with UTP, updated 11/2006
2NVY	;	3.4	;	RNA Polymerase II form II in 150 mM Mn+2
5X4Z	;	7.8	;	RNA Polymerase II from Komagataella Pastoris (Type-1 crystal)
5X50	;	4.293	;	RNA Polymerase II from Komagataella Pastoris (Type-2 crystal)
5X51	;	6.996	;	RNA Polymerase II from Komagataella Pastoris (Type-3 crystal)
3H0G	;	3.65	;	RNA Polymerase II from Schizosaccharomyces pombe
4A3G	;	3.5	;	RNA Polymerase II initial transcribing complex with a 2nt DNA-RNA hybrid
4A3J	;	3.7	;	RNA Polymerase II initial transcribing complex with a 2nt DNA-RNA hybrid and soaked with GMPCPP
4A3B	;	3.5	;	RNA Polymerase II initial transcribing complex with a 4nt DNA-RNA hybrid
4A3M	;	3.9	;	RNA Polymerase II initial transcribing complex with a 4nt DNA-RNA hybrid and soaked with AMPCPP
4A3C	;	3.5	;	RNA Polymerase II initial transcribing complex with a 5nt DNA-RNA hybrid
4A3E	;	3.4	;	RNA Polymerase II initial transcribing complex with a 5nt DNA-RNA hybrid and soaked with AMPCPP
4A3D	;	3.4	;	RNA Polymerase II initial transcribing complex with a 6nt DNA-RNA hybrid
4A3F	;	3.5	;	RNA Polymerase II initial transcribing complex with a 6nt DNA-RNA hybrid and soaked with AMPCPP
4A3K	;	3.5	;	RNA Polymerase II initial transcribing complex with a 7nt DNA-RNA hybrid
4A3L	;	3.5	;	RNA Polymerase II initial transcribing complex with a 7nt DNA-RNA hybrid and soaked with AMPCPP
7ML4	;	3.1	;	RNA polymerase II initially transcribing complex (ITC)
3RZO	;	3.0	;	RNA Polymerase II Initiation Complex with a 4-nt RNA
3S1Q	;	3.3	;	RNA Polymerase II Initiation Complex with a 5-nt 3'-deoxy RNA soaked with ATP
3S1R	;	3.2	;	RNA Polymerase II Initiation Complex with a 5-nt 3'-deoxy RNA soaked with GTP
3RZD	;	3.3	;	RNA Polymerase II Initiation Complex with a 5-nt RNA
3S1M	;	3.13	;	RNA Polymerase II Initiation Complex with a 5-nt RNA (variant 1)
3S1N	;	3.1	;	RNA Polymerase II Initiation Complex with a 5-nt RNA (variant 2)
3S2D	;	3.2	;	RNA Polymerase II Initiation Complex with a 5-nt RNA containing a 5Br-U
3S14	;	2.85	;	RNA Polymerase II Initiation Complex with a 6-nt RNA
3S2H	;	3.3	;	RNA Polymerase II Initiation Complex with a 6-nt RNA containing a 2[prime]-iodo ATP
3S15	;	3.3	;	RNA Polymerase II Initiation Complex with a 7-nt RNA
3S17	;	3.2	;	RNA Polymerase II Initiation Complex with a 9-nt RNA
3S16	;	3.241	;	RNA Polymerase II Initiation Complex with an 8-nt RNA
7ML0	;	3.0	;	RNA polymerase II pre-initiation complex (PIC1)
7ML1	;	4.0	;	RNA polymerase II pre-initiation complex (PIC2)
7ML2	;	3.4	;	RNA polymerase II pre-initiation complex (PIC3)
7NVZ	;	7.2	;	RNA polymerase II pre-initiation complex with closed promoter DNA in distal position
7NVY	;	7.3	;	RNA polymerase II pre-initiation complex with closed promoter DNA in proximal position
7NW0	;	6.6	;	RNA polymerase II pre-initiation complex with open promoter DNA
8BVW	;	4.0	;	RNA polymerase II pre-initiation complex with the distal +1 nucleosome (PIC-Nuc18W)
8BYQ	;	4.1	;	RNA polymerase II pre-initiation complex with the proximal +1 nucleosome (PIC-Nuc10W)
1SFO	;	3.61	;	RNA POLYMERASE II STRAND SEPARATED ELONGATION COMPLEX
1R9S	;	4.25	;	RNA POLYMERASE II STRAND SEPARATED ELONGATION COMPLEX, MATCHED NUCLEOTIDE
1R9T	;	3.5	;	RNA POLYMERASE II STRAND SEPARATED ELONGATION COMPLEX, MISMATCHED NUCLEOTIDE
1R5U	;	4.5	;	RNA POLYMERASE II TFIIB COMPLEX
8H0V	;	3.8	;	RNA polymerase II transcribing a chromatosome (type I)
8H0W	;	4.6	;	RNA polymerase II transcribing a chromatosome (type II)
3QT1	;	4.3	;	RNA polymerase II variant containing A Chimeric RPB9-C11 subunit
4BXZ	;	4.8	;	RNA Polymerase II-Bye1 complex
7NKX	;	2.9	;	RNA polymerase II-Spt4/5-nucleosome-Chd1 structure
7NKY	;	3.2	;	RNA Polymerase II-Spt4/5-nucleosome-FACT structure
1PQV	;	3.8	;	RNA polymerase II-TFIIS complex
1Y1Y	;	4.0	;	RNA Polymerase II-TFIIS-DNA/RNA complex
6EU1	;	3.4	;	RNA Polymerase III - open DNA complex (OC-POL3).
6F42	;	5.5	;	RNA Polymerase III closed complex CC1.
6F44	;	4.2	;	RNA Polymerase III closed complex CC2.
7DU2	;	3.35	;	RNA polymerase III EC complex in post-translocation state
6F41	;	4.3	;	RNA Polymerase III initially transcribing complex
6F40	;	3.7	;	RNA Polymerase III open complex
6EU0	;	4.0	;	RNA Polymerase III open pre-initiation complex (OC-PIC)
8IUE	;	4.1	;	RNA polymerase III pre-initiation complex melting complex 1
8IUH	;	3.4	;	RNA polymerase III pre-initiation complex open complex 1
4NJC	;	2.3	;	RNA Polymerase interacting protein YkzG from Geobacillus stearothermophilus
5EZK	;	8.5	;	RNA polymerase model placed by Molecular replacement into X-ray diffraction map of DNA-bound RNA Polymerase-Sigma 54 holoenzyme complex.
8AC2	;	3.7	;	RNA polymerase- post-terminated, open clamp state
3AOH	;	4.1	;	RNA polymerase-Gfh1 complex (Crystal type 1)
3AOI	;	4.3	;	RNA polymerase-Gfh1 complex (Crystal type 2)
3WOD	;	3.6	;	RNA polymerase-gp39 complex
5HBW	;	1.9	;	RNA primer-template complex with 2-methylimidazole-activated monomer analogue
5HBX	;	1.7	;	RNA primer-template complex with 2-methylimidazole-activated monomer analogue-2 binding sites
5HBY	;	1.18	;	RNA primer-template complex with 2-methylimidazole-activated monomer analogue-3 binding sites
5UEG	;	2.6	;	RNA primer-template complex with guanosine dinucleotide G(5')pppp(5')G ligand
5UED	;	1.5	;	RNA primer-template complex with guanosine dinucleotide ligand G(5')pp(5')G
5UEE	;	1.9	;	RNA primer-template complex with guanosine dinucleotide ligand G(5')ppp(5')G
5UEF	;	2.1	;	RNA primer-template complex with guanosine dinucleotide p(5')G(3')p(5')G ligand
387D	;	3.1	;	RNA Pseudoknot with 3D Domain Swapping
2GJW	;	2.85	;	RNA Recognition and Cleavage by an Splicing Endonuclease
2B6G	;		;	RNA recognition by the Vts1 SAM domain
2B2E	;	3.15	;	RNA stemloop from bacteriophage MS2 complexed with an N87S,E89K mutant MS2 capsid
1ZSE	;	3.0	;	RNA stemloop from bacteriophage Qbeta complexed with an N87S mutant MS2 Capsid
2B2D	;	2.9	;	RNA stemloop operator from bacteriophage QBETA complexed with an N87S,E89K mutant MS2 capsid
2LRX	;		;	RNA structural dynamics are modulated through anti-folding by chaperones
4GXY	;	3.05	;	RNA structure
2G3S	;	1.499	;	RNA structure containing GU base pairs
2N0R	;		;	RNA structure determination by solid-state NMR spectroscopy
8PFK	;	1.321	;	RNA structure with 1-methylpseudoridine, C2 space group
8PFQ	;	1.01	;	RNA structure with 1-methylpseudoridine, P1 space group
4JIY	;	1.91	;	RNA three-way junction stabilized by a supramolecular di-iron(II) cylinder drug
8SXL	;	1.9	;	RNA UU template binding to AMP monomer
6C8J	;	1.5	;	RNA-activated 2-AIpG monomer complex, 15 min soaking
6C8L	;	2.25	;	RNA-activated 2-AIpG monomer complex, 1h soaking
6C8N	;	1.9	;	RNA-activated 2-AIpG monomer complex, 2h soaking
6C8K	;	2.259	;	RNA-activated 2-AIpG monomer complex, 30 min soaking
6C8I	;	1.77	;	RNA-activated 2-AIpG monomer complex, 5 min soaking
6C8M	;	2.4	;	RNA-activated 2-AIpG monomer, 1.5h soaking
6C8O	;	1.85	;	RNA-activated 2-AIpG monomer, 3h soaking
2GUN	;	2.8	;	RNA-Binding Affinities and Crystal Structure of Oligonucleotides containing Five-Atom Amide-Based Backbone Structures
1NS1	;		;	RNA-BINDING DOMAIN OF NON-STRUCTURAL PROTEIN 1 FROM INFLUENZA VIRUS, NMR, 16 STRUCTURES
6TGJ	;	1.5	;	RNA-binding domain of RNase M5
1FHT	;		;	RNA-BINDING DOMAIN OF THE U1A SPLICEOSOMAL PROTEIN U1A117, NMR, 43 STRUCTURES
2LHN	;		;	RNA-binding zinc finger protein
7QDY	;	3.1	;	RNA-bound human SKI complex
2EC0	;	2.75	;	RNA-dependent RNA polymerase of foot-and-mouth disease virus in complex with a template-primer RNA and ATP
3JA4	;	4.8	;	RNA-dependent RNA polymerases of transcribing cypoviruses
6C8D	;	1.92	;	RNA-dGMP complex with Mg ion
6CAB	;	2.5	;	RNA-dGMP complex with Sr ion
5U0Q	;	1.43	;	RNA-DNA heptamer duplex with one 2'-5'-linkage
8E27	;	3.4	;	RNA-free Human Dis3L2
7OG5	;	3.37	;	RNA-free Ribonuclease P from Halorhodospira halophila
6C8E	;	1.8	;	RNA-imidazolium-bridged intermediate complex, 4h soaking
7SP1	;	3.4	;	RNA-induced tau amyloid fibril
6U6J	;	1.6	;	RNA-monomer complex containing pyrophosphate linkage
1I6U	;	2.6	;	RNA-PROTEIN INTERACTIONS: THE CRYSTAL STRUCTURE OF RIBOSOMAL PROTEIN S8/RRNA COMPLEX FROM METHANOCOCCUS JANNASCHII
6DBP	;	1.603	;	RNA-recognition motif 1 of human MSI2
5NEW	;	2.511	;	RNA-RNA base stacking in the crystal structure of an Hfq6:RNA dimer
1OKA	;		;	RNA/DNA CHIMERA, NMR
1DNX	;	1.7	;	RNA/DNA DODECAMER R(G)D(CGTATACGC) WITH MAGNESIUM BINDING SITES
1DNT	;	1.7	;	RNA/DNA DODECAMER R(GC)D(GTATACGC) WITH MAGNESIUM BINDING SITES
1G4Q	;	1.15	;	RNA/DNA HYBRID DECAMER OF CAAAGAAAAG/CTTTTCTTTG
1PJG	;	1.15	;	RNA/DNA Hybrid Decamer of CAAAGAAAAG/CTTTTCTTTG
4AYB	;	3.202	;	RNAP at 3.2Ang
6YMT	;	1.58	;	RNASE 3/1 version1
6YBE	;	1.14	;	RNASE 3/1 version2
6YBC	;	1.49	;	RNASE 3/1 version2 phosphate complex
6SSN	;	1.511	;	RNASE 3/1 version3
1O0F	;	1.5	;	RNASE A in complex with 3',5'-ADP
6PVW	;	1.6	;	RNase A in complex with cp4pA
6PVU	;	1.49	;	RNase A in complex with hexametaphosphate
6PVV	;	1.65	;	RNase A in complex with p5A
6PVX	;	1.55	;	RNase A in complex with p5U
3D6P	;	1.6	;	RNase A- 5'-Deoxy-5'-N-morpholinouridine complex
3D8Y	;	1.72	;	RNase A- 5'-Deoxy-5'-N-piperidinothymidine complex
3D8Z	;	1.98	;	RNase A- 5'-Deoxy-5'-N-pyrrolidinothymidine complex
2W5G	;	1.7	;	RNASE A-5'-ATP COMPLEX
8S96	;	1.68	;	RNase A-Adenosine 5'-Heptaphosphate (RNaseA.p7A)
8GGG	;	1.86	;	RNase A-Adenosine 5'-Hexaphosphate (RNaseA.p6A)
2W5I	;	2.4	;	RNASE A-AP3A COMPLEX
2W5L	;	1.7	;	RNASE A-NADP COMPLEX
2W5K	;	1.7	;	RNASE A-NADPH COMPLEX
2W5M	;	1.8	;	RNASE A-PYROPHOSPHATE ION COMPLEX
8GC9	;	1.85	;	RNase A-Uridine 5'-Heptaphosphate (RNase A.p7U)
8FHM	;	1.79	;	RNase A-Uridine 5'-Hexaphosphate (RNaseA.p6U)
2BLZ	;	1.4	;	RNAse after a high dose X-ray ""burn""
2BLP	;	1.4	;	RNase before unattenuated X-RAY burn
3MZQ	;	1.5	;	RNase crystals grown by the hanging drop method
3MZR	;	1.5	;	RNase crystals grown in loops/micromounts
6G63	;	3.95	;	RNase E in complex with sRNA RrpA
1TFR	;	2.06	;	RNASE H FROM BACTERIOPHAGE T4
4Z0U	;	2.0	;	RNase HI/SSB-Ct complex
1I39	;	1.95	;	RNASE HII FROM ARCHAEOGLOBUS FULGIDUS
1I3A	;	2.15	;	RNASE HII FROM ARCHAEOGLOBUS FULGIDUS WITH COBALT HEXAMMINE CHLORIDE
2IX0	;	2.44	;	RNase II
2IX1	;	2.74	;	RNase II D209N mutant
7WNT	;	2.44	;	RNase J from Mycobacterium tuberculosis
6TPQ	;	3.07	;	RNase M5 bound to 50S ribosome with precursor 5S rRNA
1A6F	;	2.6	;	RNASE P PROTEIN FROM BACILLUS SUBTILIS
1D6T	;		;	RNASE P PROTEIN FROM STAPHYLOCOCCUS AUREUS
1NZ0	;	1.2	;	RNASE P PROTEIN FROM THERMOTOGA MARITIMA
6CQC	;	1.54	;	RNase P protein from Thermotoga maritima in complex with 1-(4-Fluorophenyl)-2-thiourea
2BR2	;	2.8	;	RNase PH core of the archaeal exosome
2C38	;	3.1	;	RNase PH core of the archaeal exosome in complex with A5 RNA
2C39	;	3.3	;	RNase PH core of the archaeal exosome in complex with ADP
2C37	;	2.8	;	RNASE PH CORE OF THE ARCHAEAL EXOSOME IN COMPLEX WITH U8 RNA
3WR2	;	1.75	;	RNase Po1 complexed with 3'GMP
8CDU	;	3.1	;	Rnase R bound to a 30S degradation intermediate (main state)
8CEC	;	3.57	;	Rnase R bound to a 30S degradation intermediate (State I - head-turning)
8CED	;	4.15	;	Rnase R bound to a 30S degradation intermediate (State I - head-turning)
8CEE	;	3.7	;	Rnase R bound to a 30S degradation intermediate (State I - head-turning)
8CDV	;	4.73	;	Rnase R bound to a 30S degradation intermediate (state II)
4OKF	;	1.54	;	RNase S in complex with an artificial peptide
4YGW	;	2.18	;	RNase S in complex with stabilized S peptide
1D5H	;	2.25	;	Rnase s(f8a). mutant ribonucleasE S.
1RGK	;	1.87	;	RNASE T1 MUTANT GLU46GLN BINDS THE INHIBITORS 2'GMP AND 2'AMP AT THE 3' SUBSITE
1RGL	;	2.0	;	RNASE T1 MUTANT GLU46GLN BINDS THE INHIBITORS 2'GMP AND 2'AMP AT THE 3' SUBSITE
1FZU	;	1.8	;	RNAse T1 V78A mutant
1Q9E	;	1.7	;	RNase T1 variant with adenine specificity
1CH0	;	2.3	;	RNASE T1 VARIANT WITH ALTERED GUANINE BINDING SEGMENT
2VQ8	;	1.35	;	RNASE ZF-1A
2VQ9	;	1.85	;	RNASE ZF-3E
1YQT	;	1.9	;	RNase-L Inhibitor
1JY5	;	2.05	;	RNase-related protein from Calystegia sepium
5GAE	;	3.33	;	RNC in complex with a translocating SecYEG
5GAF	;	4.3	;	RNC in complex with SRP
5GAH	;	3.8	;	RNC in complex with SRP with detached NG domain
5GAG	;	3.8	;	RNC in complex with SRP-SR in the closed state
7OBR	;	2.8	;	RNC-SRP early complex
5GAD	;	3.7	;	RNC-SRP-SR complex early state
7YLE	;	2.052	;	RnDmpX in complex with DMSP
6W9D	;	3.19	;	RNF12 RING domain in complex with a Ube2d2~Ub conjugate
6W7Z	;	1.8	;	RNF12 RING domain in complex with Ube2d2
6W9A	;	2.3	;	RNF12 RING domain in complex with Ube2e2
6CF6	;	1.93	;	RNF146 TBM-Tankyrase ARC2-3 complex
8IEJ	;	3.12	;	RNF20-RNF40/hRad6A-Ub/nucleosome complex
8EB0	;	3.03	;	RNF216/E2-Ub/Ub transthiolation complex
4V3L	;	1.53	;	RNF38-UB-UbcH5B-Ub complex
4V3K	;	2.04	;	RNF38-UbcH5B-UB complex
4AP4	;	2.21	;	Rnf4 - ubch5a - ubiquitin heterotrimeric complex
4AYC	;	1.9	;	RNF8 RING domain structure
4CD1	;	2.0	;	RnNTPDase2 in complex with PSB-071
4CD3	;	2.19	;	RnNTPDase2 X4 variant in complex with PSB-071
1YVR	;	1.95	;	Ro autoantigen
1YVP	;	2.2	;	Ro autoantigen complexed with RNAs
7YH1	;	2.69	;	Roadblock from Candidatus Prometheoarchaeum syntrophicum strain MK-D1
7F8F	;	1.83	;	Roadblock from Odinarchaeota LCB_4
7F8M	;	2.14	;	Roadblock from Thorarchaeota SMTZ1-45
6F1Z	;	3.4	;	Roadblock-1 region of the dynein tail/dynactin/BICDR1 complex
5O5G	;	3.03	;	Robo1 Ig1 to 4 crystal form 1
5OPE	;	2.54	;	Robo1 Ig1-4 crystals form 2
5O5I	;	3.01	;	Robo1 Ig5
2J9N	;	1.5	;	Robotically harvested Trypsin complexed with Benzamidine containing polypeptide mediated crystal contacts
3NXF	;	2.4	;	Robust computational design, optimization, and structural characterization of retroaldol enzymes
3O6Y	;	2.091	;	Robust computational design, optimization, and structural characterization of retroaldol enzymes
8J0A	;	3.0	;	Robust design of effective allosteric activator UbV R4 for Rsp5 E3 ligase using the machine-learning tool ProteinMPNN
3DPU	;	2.9	;	RocCOR domain tandem of Rab family protein (Roco)
5BML	;	2.95	;	ROCK 1 bound to a pyridine thiazole inhibitor
5KKS	;	3.3	;	ROCK 1 bound to azaindole thiazole inhibitor
5KKT	;	2.8	;	ROCK 1 bound to azaindole thiazole piperazine inhibitor
4YVE	;	3.4	;	ROCK 1 bound to methoxyphenyl thiazole inhibitor
4YVC	;	3.2	;	ROCK 1 bound to thiazole inhibitor
7S25	;	2.337	;	ROCK1 IN COMPLEX WITH LIGAND G4998
7S26	;	2.744	;	ROCK1 IN COMPLEX WITH LIGAND G5018
4WOT	;	2.93	;	ROCK2 IN COMPLEX WITH 1426382-07-1
4L6Q	;	2.79	;	ROCK2 in complex with benzoxaborole
7P6N	;	3.0	;	ROCK2 IN COMPLEX WITH COMPOUND 12
6LS0	;	1.87	;	rod-shaped crystal of TmFtn mutant-T4FY stimulited by PLL15
2AH8	;	2.24	;	roGFP1-R7. Cystal structure analysis of a rate-enhanced variant of redox-sensitive green fluorescent protein in the oxidized form.
5F7P	;	2.84	;	Rok Repressor Lmo0178 from Listeria monocytogenes
5F7R	;	1.85	;	ROK repressor Lmo0178 from Listeria monocytogenes bound to inducer
5F7Q	;	2.4	;	ROK repressor Lmo0178 from Listeria monocytogenes bound to operator
1POV	;	2.8	;	ROLE AND MECHANISM OF THE MATURATION CLEAVAGE OF VP0 IN POLIOVIRUS ASSEMBLY: STRUCTURE OF THE EMPTY CAPSID ASSEMBLY INTERMEDIATE AT 2.9 ANGSTROMS RESOLUTION
3C3S	;	2.5	;	Role of a Glutamate Bridge Spanning the Dimeric Interface of Human Manganese Superoxide Dismutase
3C3T	;	2.2	;	Role of a Glutamate Bridge Spanning the Dimeric Interface of Human Manganese Superoxide Dismutase
1HHQ	;	2.1	;	Role of active site resiude Lys16 in Nucleoside Diphosphate Kinase
1DI3	;	1.8	;	ROLE OF AMINO ACID RESIDUES AT TURNS IN THE CONFORMATIONAL STABILITY AND FOLDING OF HUMAN LYSOZYME
1DI4	;	2.0	;	ROLE OF AMINO ACID RESIDUES AT TURNS IN THE CONFORMATIONAL STABILITY AND FOLDING OF HUMAN LYSOZYME
1DI5	;	2.2	;	ROLE OF AMINO ACID RESIDUES AT TURNS IN THE CONFORMATIONAL STABILITY AND FOLDING OF HUMAN LYSOZYME
133L	;	1.77	;	ROLE OF ARG 115 IN THE CATALYTIC ACTION OF HUMAN LYSOZYME. X-RAY STRUCTURE OF HIS 115 AND GLU 115 MUTANTS
134L	;	1.77	;	ROLE OF ARG 115 IN THE CATALYTIC ACTION OF HUMAN LYSOZYME. X-RAY STRUCTURE OF HIS 115 AND GLU 115 MUTANTS
3BLP	;	1.6	;	Role of aromatic residues in human salivary alpha-amylase
3BLK	;	2.0	;	Role of aromatic residues in starch binding
1SPA	;	2.0	;	ROLE OF ASP222 IN THE CATALYTIC MECHANISM OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE: THE AMINO ACID RESIDUE WHICH ENHANCES THE FUNCTION OF THE ENZYME-BOUND COENZYME PYRIDOXAL 5'-PHOSPHATE
1IZA	;	2.5	;	ROLE OF B13 GLU IN INSULIN ASSEMBLY: THE HEXAMER STRUCTURE OF RECOMBINANT MUTANT (B13 GLU-> GLN) INSULIN
1IZB	;	2.0	;	ROLE OF B13 GLU IN INSULIN ASSEMBLY: THE HEXAMER STRUCTURE OF RECOMBINANT MUTANT (B13 GLU-> GLN) INSULIN
140L	;	2.1	;	ROLE OF BACKBONE FLEXIBILITY IN THE ACCOMMODATION OF VARIANTS THAT REPACK THE CORE OF T4 LYSOZYME
141L	;	2.0	;	ROLE OF BACKBONE FLEXIBILITY IN THE ACCOMMODATION OF VARIANTS THAT REPACK THE CORE OF T4 LYSOZYME
142L	;	2.0	;	ROLE OF BACKBONE FLEXIBILITY IN THE ACCOMMODATION OF VARIANTS THAT REPACK THE CORE OF T4 LYSOZYME
143L	;	2.0	;	ROLE OF BACKBONE FLEXIBILITY IN THE ACCOMMODATION OF VARIANTS THAT REPACK THE CORE OF T4 LYSOZYME
144L	;	2.1	;	ROLE OF BACKBONE FLEXIBILITY IN THE ACCOMMODATION OF VARIANTS THAT REPACK THE CORE OF T4 LYSOZYME
145L	;	2.0	;	ROLE OF BACKBONE FLEXIBILITY IN THE ACCOMMODATION OF VARIANTS THAT REPACK THE CORE OF T4 LYSOZYME
146L	;	1.85	;	ROLE OF BACKBONE FLEXIBILITY IN THE ACCOMMODATION OF VARIANTS THAT REPACK THE CORE OF T4 LYSOZYME
147L	;	2.0	;	ROLE OF BACKBONE FLEXIBILITY IN THE ACCOMMODATION OF VARIANTS THAT REPACK THE CORE OF T4 LYSOZYME
6UBF	;	4.597	;	Role of Beta-hairpin motifs in the DNA duplex opening by the Rad4/XPC nucleotide excision repair complex
6UIN	;	3.348	;	Role of Beta-hairpin motifs in the DNA duplex opening by the Rad4/XPC nucleotide excision repair complex
1NUF	;	2.7	;	Role of Calcium Ions in the Activation and Activity of the Transglutaminase 3 Enzyme
1NUG	;	2.4	;	Role of Calcium Ions in the Activation and Activity of the Transglutaminase 3 Enzyme (2 calciums, 1 Mg, inactive form)
1NUD	;	2.7	;	Role of Calcium Ions in the Activation and Activity of the Transglutaminase 3 Enzyme (3 calciums, active form)
6NQB	;	3.8	;	Role of Era in Assembly and Homeostasis of the Ribosomal Small Subunit
1JXK	;	1.9	;	Role of ethe mobile loop in the mehanism of human salivary amylase
1L9C	;	1.9	;	Role of Histidine 269 in Catalysis by Monomeric Sarcosine Oxidase
1L9D	;	1.95	;	Role of Histidine 269 in Catalysis by Monomeric Sarcosine Oxidase
1L9E	;	1.85	;	Role of Histidine 269 in Catalysis by Monomeric Sarcosine Oxidase
1SZX	;	1.95	;	Role Of Hydrogen Bonding In The Active Site Of Human Manganese Superoxide Dismutase
3DV7	;	1.7	;	Role of Hydrophilic Residues in Proton Transfer During Catalysis by Human Carbonic Anhydrase II (N62A)
2CEP	;	2.2	;	ROLE OF MET-230 IN INTRAMOLECULAR ELECTRON TRANSFER BETWEEN THE OXYFERRYL HEME AND TRP 191 IN CYTOCHROME C PEROXIDASE COMPOUND II
1JXJ	;	1.99	;	Role of mobile loop in the mechanism of human salivary amylase
3PRJ	;	3.1	;	Role of Packing Defects in the Evolution of Allostery and Induced Fit in Human UDP-Glucose Dehydrogenase.
3PTZ	;	2.5	;	Role of Packing Defects in the Evolution of Allostery and Induced Fit in Human UDP-Glucose Dehydrogenase.
1LHH	;	1.8	;	ROLE OF PROLINE RESIDUES IN HUMAN LYSOZYME STABILITY: A SCANNING CALORIMETRIC STUDY COMBINED WITH X-RAY STRUCTURE ANALYSIS OF PROLINE MUTANTS
1LHI	;	1.8	;	ROLE OF PROLINE RESIDUES IN HUMAN LYSOZYME STABILITY: A SCANNING CALORIMETRIC STUDY COMBINED WITH X-RAY STRUCTURE ANALYSIS OF PROLINE MUTANTS
1LHJ	;	1.8	;	ROLE OF PROLINE RESIDUES IN HUMAN LYSOZYME STABILITY: A SCANNING CALORIMETRIC STUDY COMBINED WITH X-RAY STRUCTURE ANALYSIS OF PROLINE MUTANTS
1LHK	;	1.8	;	ROLE OF PROLINE RESIDUES IN HUMAN LYSOZYME STABILITY: A SCANNING CALORIMETRIC STUDY COMBINED WITH X-RAY STRUCTURE ANALYSIS OF PROLINE MUTANTS
1LHL	;	1.8	;	ROLE OF PROLINE RESIDUES IN HUMAN LYSOZYME STABILITY: A SCANNING CALORIMETRIC STUDY COMBINED WITH X-RAY STRUCTURE ANALYSIS OF PROLINE MUTANTS
1A3P	;		;	ROLE OF THE 6-20 DISULFIDE BRIDGE IN THE STRUCTURE AND ACTIVITY OF EPIDERMAL GROWTH FACTOR, NMR, 20 STRUCTURES
1R68	;	1.2	;	Role of the amino sugar in DNA binding of disaccharide anthracyclines: crystal structure of MAR70/d(CGATCG) complex
4GXF	;	2.734	;	Role of the biradical intermediate observed during the turnover of SLAC: A two-domain laccase from Streptomyces coelicolor
4GY4	;	2.67	;	Role of the biradical intermediate observed during the turnover of SLAC: A two-domain laccase from Streptomyces coelicolor
6KBB	;	2.365	;	Role of the DEF/Y motif of Swc5 in histone H2A.Z deposition
6M7W	;	1.98	;	Role of the highly conserved G68 residue in the yeast phosphorelay protein Ypd1: implications for interactions between histidine phosphotransfer (HPt) and response regulator proteins
4KU1	;	1.9	;	Role of the hinge and C-gamma-2/C-gamma-3 interface in immunoglobin G1 Fc domain motions: implications for Fc engineering
3BP2	;	2.1	;	ROLE OF THE N-TERMINUS IN THE INTERACTION OF PANCREATIC PHOSPHOLIPASE A2 WITH AGGREGATED SUBSTRATES. PROPERTIES AND CRYSTAL STRUCTURE OF TRANSAMINATED PHOSPHOLIPASE A2
1VZU	;	1.97	;	Roles of active site tryptophans in substrate binding and catalysis by ALPHA-1,3 GALACTOSYLTRANSFERASE
1VZX	;	1.97	;	Roles of active site tryptophans in substrate binding and catalysis by ALPHA-1,3 GALACTOSYLTRANSFERASE
1OLS	;	1.85	;	Roles of His291-alpha and His146-beta' in the reductive acylation reaction catalyzed by human branched-chain alpha-ketoacid dehydrogenase
1OLU	;	1.9	;	Roles of His291-alpha and His146-beta' in the reductive acylation reaction catalyzed by human branched-chain alpha-ketoacid dehydrogenase
1OLX	;	2.25	;	Roles of His291-alpha and His146-beta' in the reductive acylation reaction catalyzed by human branched-chain alpha-ketoacid dehydrogenase
1O7O	;	1.97	;	Roles of Individual Residues of Alpha-1,3 Galactosyltransferases in Substrate Binding and Catalysis
1O7Q	;	1.3	;	Roles of Individual Residues of Alpha-1,3 Galactosyltransferases in Substrate Binding and Catalysis
1VZT	;	2.0	;	ROLES OF INDIVIDUAL RESIDUES OF ALPHA-1,3 GALACTOSYLTRANSFERASES IN SUBSTRATE BINDING AND CATALYSIS
5NJN	;	1.6	;	Roll out the beta-barrel: structure and mechanism of Pac13, a unique nucleoside dehydratase
5NJO	;	1.55	;	Roll out the beta-barrel: structure and mechanism of Pac13, a unique nucleoside dehydratase
3PLS	;	2.24	;	RON in complex with ligand AMP-PNP
4Z5R	;	3.0	;	Rontalizumab Fab bound to Interferon-a2
7DTB	;	1.65	;	Room tempeature structure of lysozyme by fixed-target serial crystallography
5V5D	;	2.104	;	Room temperature (280K) crystal structure of Kaposi's sarcoma-associated herpesvirus protease in complex with allosteric inhibitor (compound 250)
5V5E	;	2.299	;	Room temperature (280K) crystal structure of Kaposi's sarcoma-associated herpesvirus protease in complex with allosteric inhibitor (compound 733)
1I1O	;	2.0	;	ROOM TEMPERATURE CRYSTAL STRUCTURE FLAVODOXIN D. VULGARIS MUTANT Y98H AT 2.0 ANG. RESOLUTION
8CTS	;	1.6	;	Room temperature crystal structure of a K+ selective NaK mutant (NaK2K)
4J5O	;	1.11	;	Room temperature crystal structure of a RNA binding motif protein 39 (Rbm39) from Mus musculus at 1.11 A resolution
8BRL	;	1.88	;	Room temperature crystal structure of cytochrome c' from Hydrogenophilus thermoluteolus
8BRK	;	1.75	;	Room temperature crystal structure of cytochrome c' from Thermus thermophilus
2WT4	;	1.8	;	Room temperature crystal structure of Helicobacter pylori L- asparaginase at 1.8 A resolution
4N0X	;	1.63	;	Room temperature crystal structure of human carbonic anhydrase II in complex with thiophene-2-sulfonamide
4WG1	;	1.7	;	Room temperature crystal structure of lysozyme determined by serial synchrotron crystallography (micro focused beam - crystFEL)
7JIB	;	2.65	;	Room Temperature Crystal Structure of Nsp10/Nsp16 from SARS-CoV-2 with Substrates and Products of 2'-O-methylation of the Cap-1
7ZCK	;	1.8	;	Room temperature crystal structure of PhnD from Synechococcus MITS9220 in complex with phosphate
4OP8	;	1.95	;	Room temperature crystal structure of stabilized TEM-1 beta-lactamase variant v.13 carrying G238S mutation
4OPY	;	1.75	;	Room temperature crystal structure of stabilized TEM-1 beta-lactamase variant v.13 carrying R164S mutation
4OPQ	;	1.7	;	Room temperature crystal structure of stabilized TEM-1 beta-lactamase variant v.13 carrying R164S/G238S mutations
1LR4	;	2.0	;	Room Temperature Crystal Structure of the Apo-form of the catalytic subunit of protein kinase CK2 from Zea mays
8A97	;	2.897	;	ROOM TEMPERATURE CRYSTAL STRUCTURE OF THE COFACTOR-DEVOID 1-H-3-HYDROXY-4- OXOQUINALDINE 2,4-DIOXYGENASE (HOD) UNDER XENON PRESSURE (30 bar)
4UTS	;	2.03	;	Room temperature crystal structure of the fast switching M159T mutant of fluorescent protein Dronpa
8QFI	;	1.9	;	Room temperature crystal structure of the Photoactivated Adenylate Cyclase OaPAC after blue light excitation at 1.8 us delay
8QFJ	;	1.9	;	Room temperature crystal structure of the Photoactivated Adenylate Cyclase OaPAC after blue light excitation at 2.3 us delay
8QFH	;	1.8	;	Room temperature crystal structure of the Photoactivated Adenylate Cyclase OaPAC with ATP bound
6RHL	;	1.299	;	Room temperature data of Galectin-3C in complex with a pair of enantiomeric ligands: R enantiomer
6RHM	;	1.596	;	Room temperature data of Galectin-3C in complex with a pair of enantiomeric ligands: S enantiomer
7UD0	;	3.5	;	Room Temperature Drosophila Cryptochrome
3TGP	;	1.3075	;	Room temperature H-ras
7QT8	;	2.01	;	Room temperature In-situ SARS-CoV-2 MPRO with bound ABT-957
7QT6	;	2.11	;	Room temperature In-situ SARS-CoV-2 MPRO with bound Z1367324110
7QT5	;	2.26	;	Room temperature In-situ SARS-CoV-2 MPRO with bound Z31792168
7QT7	;	2.25	;	Room temperature In-situ SARS-CoV-2 MPRO with bound Z4439011520
7QT9	;	2.43	;	Room temperature In-situ SARS-CoV-2 MPRO with bound Z4439011584
5NE0	;	1.57	;	Room temperature in-situ structure of hen egg-white lysozyme from crystals enclosed between ultrathin silicon nitride membranes
4O34	;	2.09	;	Room temperature macromolecular serial crystallography using synchrotron radiation
4KJL	;	1.38	;	Room Temperature N23PPS148A DHFR
4Q49	;	1.8	;	Room temperature neutron crystal structure of apo human carbonic anhydrase at pH 7.5
8DYK	;	2.1	;	Room temperature neutron structure of a fluorescent Ag8 cluster templated by a multistranded DNA scaffold
3KCJ	;	1.8	;	Room temperature neutron structure of apo-D-Xylose Isomerase (refined jointly with X-ray structure 3KBJ)
3KCJ	;	2.0	;	Room temperature neutron structure of apo-D-Xylose Isomerase (refined jointly with X-ray structure 3KBJ)
3KCL	;	2.0	;	Room temperature neutron structure of D-Xylose Isomerase in complex with two Cd2+ cations and d12-D-alpha-glucose in the ring form (refined jointly with X-ray structure 3KBM)
3KCL	;	2.0	;	Room temperature neutron structure of D-Xylose Isomerase in complex with two Cd2+ cations and d12-D-alpha-glucose in the ring form (refined jointly with X-ray structure 3KBM)
3KCO	;	1.8	;	Room temperature neutron structure of D-Xylose Isomerase in complex with two Ni2+ cations and d12-D-glucose in the linear form (refined jointly with X-ray structure 3KBN)
3KCO	;	1.53	;	Room temperature neutron structure of D-Xylose Isomerase in complex with two Ni2+ cations and d12-D-glucose in the linear form (refined jointly with X-ray structure 3KBN)
6BBR	;	2.3	;	Room temperature neutron/X-ray structure of AAC-VIa
6BBR	;	2.002	;	Room temperature neutron/X-ray structure of AAC-VIa
6BBZ	;	2.2	;	Room temperature neutron/X-ray structure of sisomicin bound AAC-VIa
6BBZ	;	1.9	;	Room temperature neutron/X-ray structure of sisomicin bound AAC-VIa
7KFM	;	1.75	;	Room temperature oxyferrous Dehaloperoxidase B
8A7V	;	1.46	;	Room temperature rsEGFP2 in its OFF-state obtained with SFX
8A6S	;	1.63	;	Room temperature rsEGFP2 with a chlorinated chromophore 1 microsecond after Photoexcitation
8A6R	;	1.63	;	Room temperature rsEGFP2 with a chlorinated chromophore 100 ps after Photoexcitation
8A6N	;	1.63	;	Room temperature rsEGFP2 with a chlorinated chromophore 300 fs after Photoexcitation
8A6Q	;	1.63	;	Room temperature rsEGFP2 with a chlorinated chromophore 5 ps after photoexcitation
8A6O	;	1.63	;	Room temperature rsEGFP2 with a chlorinated chromophore 600 fs after Photoexcitation
8A6P	;	1.63	;	Room temperature rsEGFP2 with a chlorinated chromophore 900 fs after photoexcitation
8A6G	;	1.63	;	Room temperature rsEGFP2 with a chlorinated chromophore in the non-fluorescent OFF-state
7TSU	;	1.75	;	Room temperature rsEospa Cis-state structure at pH 5.5
7TSR	;	1.75	;	Room temperature rsEospa Cis-state structure at pH 8.4
7TSV	;	1.75	;	Room temperature rsEospa Trans-state structure at pH 5.5
7TSS	;	1.75	;	Room temperature rsEospa Trans-state structure at pH 8.4
7RGG	;	3.0	;	Room temperature serial crystal structure of Glutaminase C in complex with inhibitor BPTES
7REN	;	2.8	;	Room temperature serial crystal structure of Glutaminase C in complex with inhibitor UPGL-00004
7ZPV	;	1.4	;	Room temperature SSX crystal structure of CTX-M-14
8AF7	;	1.55	;	Room temperature SSX crystal structure of CTX-M-14 (10K dataset)
8AF8	;	1.55	;	Room temperature SSX crystal structure of CTX-M-14 (5K dataset)
7ZQ0	;	1.9	;	Room temperature SSX structure of GH11 xylanase from Nectria haematococca (1000 frames)
8AF5	;	1.63	;	Room temperature SSX structure of GH11 xylanase from Nectria haematococca (10000 frames)
8AF6	;	1.7	;	Room temperature SSX structure of GH11 xylanase from Nectria haematococca (4000 frames)
8AF4	;	1.51	;	Room temperature SSX structure of GH11 xylanase from Nectria haematococca (40000 frames)
5TRX	;	2.38	;	Room temperature structure of an extradiol ring-cleaving dioxygenase from B.fuscum determined using serial femtosecond crystallography
7PXR	;	1.8	;	Room temperature structure of an LPMO.
7ZY3	;	1.8	;	Room temperature structure of Archaerhodopsin-3 obtained 110 ns after photoexcitation
6GUY	;	2.2	;	Room temperature structure of Archaerhodopsin-3 via LCP extruder using synchrotron radiation
8A4E	;	1.96	;	Room temperature structure of AtPhot2LOV2 in a photostationary equilibrium
7F8K	;	2.2	;	Room temperature structure of bacterial copper amine oxidase determined by serial femtosecond crystallography
4X31	;	2.4	;	Room temperature structure of bacteriorhodopsin from lipidic cubic phase obtained with serial millisecond crystallography using synchrotron radiation
6O52	;	3.2	;	Room temperature structure of binary complex of native hAChE with BW284c51
6O5R	;	2.8	;	Room temperature structure of binary complex of native hAChE with oxime reactivator RS-170B
6QQK	;	2.4	;	Room temperature structure of blue light-irradiated AtPhot2LOV2 recorded after an accumulated dose of 34 kGy
1QGL	;	2.66	;	Room temperature structure of concanavalin A complexed to bivalent ligand
4YSD	;	1.35	;	Room temperature structure of copper nitrite reductase from Geobacillus thermodenitrificans
3K0N	;	1.391	;	Room temperature structure of CypA
3K0O	;	1.55	;	Room temperature structure of CypA mutant Ser99Thr
3KBV	;	1.8	;	Room temperature structure of D-Xylose Isomerase in complex with 2Ni(2+) co-factors
3KBN	;	1.53	;	Room temperature structure of D-Xylose Isomerase in complex with 2Ni(2+) co-factors and d12-D-glucose in the linear form
7FAG	;	1.3	;	Room temperature structure of elastase with high-strength agarose hydrogel
8IH1	;	1.75	;	Room temperature structure of GH11 from Thermoanaerobacterium saccharolyticum by serial crystallography
7E03	;	1.6	;	Room temperature structure of glucose isomerase delivered in beef tallow by serial millisecond crystallography
6KD2	;	1.7	;	Room temperature structure of glucose isomerase delivered in gelatin by serial millisecond crystallography
7CK0	;	1.8	;	Room temperature structure of glucose isomerase delivered in lard by serial millisecond crystallography
6KCA	;	1.9	;	Room temperature structure of glucose isomerase delivered in shortening A by serial millisecond crystallography
6KCC	;	2.0	;	Room temperature structure of glucose isomerase delivered in shortening B by serial millisecond crystallography
7RB5	;	2.8	;	Room temperature structure of hAChE in complex with substrate analog 4K-TMA
7RB7	;	2.6	;	Room temperature structure of hAChE in complex with substrate analog 4K-TMA and MMB4 oxime
6QQF	;	1.95	;	Room temperature structure of Hen Egg White Lysozyme recorded after an accumulated dose of 100 kGy
6QQE	;	1.37	;	Room temperature structure of Hen Egg White Lysozyme recorded after an accumulated dose of 20 kGy
6JCG	;	2.5	;	Room temperature structure of HIV-1 Integrase catalytic core domain by serial femtosecond crystallography.
6YXD	;	2.9	;	Room temperature structure of human adiponectin receptor 2 (ADIPOR2) at 2.9 A resolution determined by Serial Crystallography (SSX) using CrystalDirect
5LG1	;	2.7	;	Room temperature structure of human IgG4-Fc from crystals analysed in situ
5FVF	;	2.75	;	Room temperature structure of IrisFP determined by serial femtosecond crystallography.
6HW1	;	2.5	;	ROOM TEMPERATURE STRUCTURE OF LIPASE FROM T. LANUGINOSA AT 2.5 A RESOLUTION IN CHIPX MICROFLUIDIC DEVICE
7DTF	;	1.85	;	Room temperature structure of lysozyme by serial millisecond crystallography
6KD1	;	1.85	;	Room temperature structure of lysozyme delivered in agarose by serial millisecond crystallography
7E02	;	1.55	;	Room temperature structure of lysozyme delivered in beef tallow by serial millisecond crystallography
7CJZ	;	1.75	;	Room temperature structure of lysozyme delivered in lard by serial millisecond crystallography
6JXP	;	1.56	;	Room temperature structure of lysozyme delivered in LCP by serial millisecond crystallography
6JXQ	;	1.76	;	Room temperature structure of lysozyme delivered in polyacrylamide by serial millisecond crystallography
6KCB	;	1.8	;	Room temperature structure of lysozyme delivered in shortening A by serial millisecond crystallography
6KCD	;	1.5	;	Room temperature structure of lysozyme delivered in shortening B by serial millisecond crystallography
7WKR	;	1.6	;	Room temperature structure of lysozyme solved by serial synchrotron crystallography
7K9P	;	2.6	;	Room temperature structure of NSP15 Endoribonuclease from SARS CoV-2 solved using SFX.
5BN2	;	1.3	;	Room Temperature Structure of Pichia pastoris aquaporin at 1.3 A
7Q79	;	1.55	;	Room temperature structure of RNase A at 100 MPa helium gas pressure in a sapphire capillary
7Q7A	;	1.56	;	Room temperature structure of RNase A at 120 MPa helium gas pressure in a sapphire capillary
7Q76	;	1.48	;	Room temperature structure of RNase A at 22 MPa helium gas pressure in a sapphire capillary
7Q77	;	1.6	;	Room temperature structure of RNase A at 50 MPa helium gas pressure in a sapphire capillary
7Q78	;	1.52	;	Room temperature structure of RNase A at 72 MPa helium gas pressure in a sapphire capillary
7Q75	;	1.64	;	Room temperature structure of RNase A at atmospheric pressure
7Q7B	;	1.78	;	Room temperature structure of RNase A at atmospheric pressure in a sapphire capillary after high helium gas pressure release
7KOA	;	2.4	;	Room Temperature Structure of SARS-CoV-2 Nsp10/16 Methyltransferase in a Complex with Cap-0 and SAM Determined by Pink-Beam Serial Crystallography
7JHE	;	2.25	;	Room Temperature Structure of SARS-CoV-2 Nsp10/Nsp16 Methyltransferase in a Complex with 2'-O-methylated m7GpppA Cap-1 and SAH Determined by Fixed-Target Serial Crystallography
7JPE	;	2.18	;	Room Temperature Structure of SARS-CoV-2 Nsp10/Nsp16 Methyltransferase in a Complex with m7GpppA Cap-0 and SAM Determined by Fixed-Target Serial Crystallography
6XKM	;	2.25	;	Room Temperature Structure of SARS-CoV-2 NSP10/NSP16 Methyltransferase in a Complex with SAM Determined by Fixed-Target Serial Crystallography
1TR5	;	2.1	;	Room temperature structure of Staphylococcal nuclease variant truncated Delta+PHS I92E
6HEF	;	3.538	;	Room temperature structure of the (SR)Ca2+-ATPase Ca2-E1-CaAMPPCP form
6S45	;	2.2	;	Room temperature structure of the dark state of the LOV2 domain of phototropin-2 from Arabidopsis thaliana determined with a serial crystallography approach
6QQB	;	2.45	;	Room temperature structure of the fluorescent protein Cerulean recorded after an accumulated dose of 147 kGy
6QQA	;	1.66	;	Room temperature structure of the fluorescent protein Cerulean recorded after an accumulated dose of 21 kGy
8A2W	;	2.04	;	Room temperature structure of the ground state of AtPhot2LOV2 in space group P212121, as recovered 1620 seconds after light irradiation
8A2V	;	1.59	;	Room temperature structure of the ground state of AtPhot2LOV2 in space group P43212
6QQJ	;	2.08	;	Room temperature structure of the ground state of AtPhot2LOV2 recorded after an accumulated dose of 354 kGy
7FG5	;	1.3	;	Room temperature structure of the human heart fatty acid-binding protein complexed with capric acid
7FCX	;	1.15	;	Room temperature structure of the human heart fatty acid-binding protein complexed with hexanoic acid
7Q7C	;	2.85	;	Room temperature structure of the human Serine/Threonine Kinase 17B (STK17B/DRAK2) in complex with ADP at atmospheric pressure
7Q7D	;	2.6	;	Room temperature structure of the human Serine/Threonine Kinase 17B (STK17B/DRAK2) in complex with ATP/ADP at 111 MPa helium gas pressure in a sapphire capillary
7Q7E	;	2.85	;	Room temperature structure of the human Serine/Threonine Kinase 17B (STK17B/DRAK2) in complex with ATP/ADP at atmospheric pressure in a sapphire capillary after high helium gas pressure release
6S46	;	2.75	;	Room temperature structure of the LOV2 domain of phototropin-2 from Arabidopsis thaliana 4158 ms after initiation of illumination, determined with a serial crystallography approach
7Q7M	;	2.55	;	Room temperature structure of the Rhodobacter Sphaeroides Photosynthetic Reaction Center F(M197)H mutant at 100 MPa helium gas pressure in a sapphire capillary
7Q7N	;	2.87	;	Room temperature structure of the Rhodobacter Sphaeroides Photosynthetic Reaction Center F(M197)H mutant at 120 MPa helium gas pressure in a sapphire capillary
7Q7G	;	2.69	;	Room temperature structure of the Rhodobacter Sphaeroides Photosynthetic Reaction Center F(M197)H mutant at 30 MPa helium gas pressure in a sapphire capillary
7Q7H	;	2.49	;	Room temperature structure of the Rhodobacter Sphaeroides Photosynthetic Reaction Center F(M197)H mutant at 51 MPa helium gas pressure in a sapphire capillary
7Q7J	;	2.69	;	Room temperature structure of the Rhodobacter Sphaeroides Photosynthetic Reaction Center F(M197)H mutant at 75 MPa helium gas pressure in a sapphire capillary
7Q7F	;	2.75	;	Room temperature structure of the Rhodobacter Sphaeroides Photosynthetic Reaction Center F(M197)H mutant at atmospheric pressure
7Q7O	;	2.65	;	Room temperature structure of the Rhodobacter Sphaeroides Photosynthetic Reaction Center F(M197)H mutant at atmospheric pressure after high helium gas pressure release
8YEA	;	2.85	;	Room temperature structure of TsaGH11 determined by macromolecular crystallography
8YPX	;	2.7	;	Room temperature structure of TsaGH11 determined by MX
5TOF	;	1.12	;	Room temperature structure of ubiquitin variant u7ub25
5TOG	;	1.08	;	Room temperature structure of ubiquitin variant u7ub25.2540
6O5S	;	2.801	;	Room temperature structure of VX-phosphonylated hAChE in complex with oxime reactivator RS-170B
8YJI	;	2.1	;	Room temperature structure of xylanase from Trichoderma longibrachiatum
3KMF	;	2.0	;	Room Temperature Time-of-Flight Neutron Diffraction Study of Deoxy Human Normal Adult Hemoglobin
3U7T	;	0.85	;	Room temperature ultra-high resolution time-of-flight neutron and X-ray diffraction studies of H/D exchanged crambin
4KJK	;	1.351	;	Room Temperature WT DHFR
8V2Y	;	2.86	;	Room temperature X-ray Crystal Structure of FMN-bound long-chain flavodoxin from Rhodopseudomonas palustris
5VG0	;	1.1	;	Room temperature X-ray crystallographic structure of a Jonesia denitrificans lytic polysaccharide monooxygenase at 1.1 angstrom resolution.
6XB0	;	1.8	;	Room temperature X-ray crystallography reveals catalytic cysteine in the SARS-CoV-2 3CL Mpro is highly reactive: Insights for enzyme mechanism and drug design
6XB1	;	1.8	;	Room temperature X-ray crystallography reveals catalytic cysteine in the SARS-CoV-2 3CL Mpro is highly reactive: Insights for enzyme mechanism and drug design
6XB2	;	2.1	;	Room temperature X-ray crystallography reveals catalytic cysteine in the SARS-CoV-2 3CL Mpro is highly reactive: Insights for enzyme mechanism and drug design
6XHU	;	1.8	;	Room temperature X-ray crystallography reveals oxidation and reactivity of cysteine residues in SARS-CoV-2 3CL Mpro: Insights for enzyme mechanism and drug design
4G49	;	2.4	;	Room temperature X-ray diffraction of cisplatin binding to HEWL in aqueous media after 15 months of crystal storage
5LAF	;	1.5	;	Room temperature X-ray diffraction of tetragonal HEWL with 1M of uridine. First data set (0.31 MGy)
5LAG	;	1.6	;	Room temperature X-ray diffraction of tetragonal HEWL with 1M of uridine. Second data set (0.62 MGy)
5LAN	;	1.65	;	Room temperature X-ray diffraction of tetragonal HEWL with 1M of uridine. Third data set (0.93 MGy)
5L9J	;	1.5	;	Room temperature X-ray diffraction of tetragonal HEWL. First data set (0.31 MGy)
5LA5	;	1.7	;	Room temperature X-ray diffraction of tetragonal HEWL. Second data set (0.62 MGy)
5LA8	;	2.0	;	Room temperature X-ray diffraction of tetragonal HEWL. Third data set (0.93 MGy)
4YEN	;	2.0	;	Room temperature X-ray diffraction studies of cisplatin binding to HEWL in DMSO media after 14 months of crystal storage - new refinement
4GCC	;	2.0	;	Room temperature X-ray diffraction study of a 6-fold molar excess of a cisplatin/carboplatin mixture binding to HEWL, Dataset 1
4GCD	;	2.8	;	Room temperature X-ray diffraction study of a 6-fold molar excess of a cisplatin/carboplatin mixture binding to HEWL, Dataset 2
4GCE	;	2.9	;	Room temperature X-ray diffraction study of a 6-fold molar excess of a cisplatin/carboplatin mixture binding to HEWL, Dataset 3
4GCF	;	3.5	;	Room temperature X-ray diffraction study of a 6-fold molar excess of a cisplatin/carboplatin mixture binding to HEWL, Dataset 4
4G4C	;	2.0	;	Room temperature X-ray diffraction study of carboplatin binding to HEWL in DMSO media after 13 months of crystal storage
4G4B	;	2.1	;	Room temperature X-ray diffraction study of cisplatin binding to HEWL in DMSO media with NAG after 7 months of crystal storage
3KBW	;	1.6	;	Room temperature X-ray mixed-metal structure of D-Xylose Isomerase in complex with Ni(2+) and Mg(2+) co-factors
3KBJ	;	2.0	;	Room temperature X-ray structure of apo-D-Xylose Isomerase
4DH5	;	2.2	;	Room temperature X-ray structure of cAMP dependent Protein Kinase A catalytic subunit with high Mg2+, ADP, Phosphate, and IP20
4DH8	;	2.3	;	Room temperature X-ray structure of cAMP dependent Protein Kinase A catalytic subunit with high Mg2+, AMP-PNP and IP20
4IAF	;	2.2	;	Room temperature X-ray Structure OF cAMP dependent protein kinase A in complex with high Mg2+ concentration, ADP and phosphorylated peptide pSP20
4IAY	;	2.0	;	Room temperature X-ray Structure of cAMP dependent protein kinase A in complex with high Sr2+ concentration, ADP and phosphorylated peptide pSP20
3KBM	;	2.0	;	Room Temperature X-ray structure of D-Xylose Isomerase complexed with 2Cd(2+) co-factors and d12-D-alpha-glucose in the cyclic form
3QYS	;	1.85	;	Room Temperature X-ray Structure of D-Xylose Isomerase in complex with 0.6Ni2+ cation bound in M2 metal binding site at pH=5.8
3KBS	;	1.8	;	Room Temperature X-ray structure of D-Xylose Isomerase in complex with 2Cd(2+) co-factors
4QE1	;	1.55	;	Room temperature X-ray structure of D-xylose isomerase in complex with two Cd2+ ions and L-ribulose
4QEH	;	1.55	;	Room temperature X-ray structure of D-xylose isomerase in complex with two Mg2+ ions and L-ribose
4QE5	;	1.56	;	Room temperature X-ray structure of D-xylose isomerase in complex with two Mg2+ ions and L-ribulose
4QEE	;	1.6	;	Room temperature X-ray structure of D-xylose isomerase in complex with two Ni2+ ions and L-ribose
4QE4	;	1.7	;	Room temperature X-ray structure of D-xylose isomerase in complex with two Ni2+ ions and L-ribulose
7B7F	;	1.6	;	Room temperature X-ray structure of H/D-exchanged PLL lectin in complex with L-fucose
6PU8	;	1.8	;	Room temperature X-ray structure of HIV-1 protease triple mutant (V32I,I47V,V82I) with tetrahedral intermediate of keto-darunavir
7PXS	;	1.9	;	Room temperature X-ray structure of LPMO at 1.91x10^3 Gy
7B7E	;	1.6	;	Room temperature X-ray structure of perdeuterated PLL lectin
7B7C	;	1.55	;	Room temperature X-ray structure of perdeuterated PLL lectin in complex with L-fucose
7TEH	;	1.8	;	Room temperature X-ray structure of SARS-CoV-2 main protease (3CL Mpro) in complex with BBH-2
7TFR	;	1.8	;	Room temperature X-ray structure of SARS-CoV-2 main protease (3CL Mpro) in complex with NBH-2
7RNH	;	2.0	;	Room temperature X-ray structure of SARS-CoV-2 main protease (Mpro) in complex with HL-3-45
7RME	;	2.0	;	Room temperature X-ray structure of SARS-CoV-2 main protease (Mpro) in complex with HL-3-52
7RMZ	;	2.1	;	Room temperature X-ray structure of SARS-CoV-2 main protease (Mpro) in complex with HL-3-63
7RLS	;	2.0	;	Room temperature X-ray structure of SARS-CoV-2 main protease (Mpro) in complex with HL-3-68
7RN4	;	1.85	;	Room temperature X-ray structure of SARS-CoV-2 main protease (Mpro) in complex with HL-3-69
7RMT	;	2.0	;	Room temperature X-ray structure of SARS-CoV-2 main protease (Mpro) in complex with HL-3-70
7RNK	;	2.1	;	Room temperature X-ray structure of SARS-CoV-2 main protease (Mpro) in complex with HL-3-71
7RMB	;	2.0	;	Room temperature X-ray structure of SARS-CoV-2 main protease (Mpro) in complex with HL-3-78
7RM2	;	2.0	;	Room temperature X-ray structure of SARS-CoV-2 main protease (Mpro) in complex with Mcule-CSR-494190-S1
7SI9	;	2.0	;	Room temperature X-ray structure of SARS-CoV-2 main protease (Mpro) in complex with PF-07321332
7S3K	;	1.9	;	Room temperature X-ray structure of SARS-CoV-2 main protease in complex with compound Z1530718726
7S3S	;	2.0	;	Room temperature X-ray structure of SARS-CoV-2 main protease in complex with compound Z1530724813
7S4B	;	2.0	;	Room temperature X-ray structure of SARS-CoV-2 main protease in complex with compound Z1530724963
8DL9	;	1.9	;	Room temperature X-ray structure of SARS-CoV-2 main protease in complex with compound Z199538122
8DLB	;	1.9	;	Room temperature X-ray structure of SARS-CoV-2 main protease in complex with compound Z2799209083
8DMD	;	2.0	;	Room temperature X-ray structure of SARS-CoV-2 main protease in complex with compound ZZ4461624291
2XR0	;	2.2	;	Room temperature X-ray structure of the perdeuterated Toho-1 R274N R276N double mutant beta-lactamase
8GFK	;	2.0	;	Room temperature X-ray structure of truncated SARS-CoV-2 main protease C145A mutant, residues 1-304
8GFN	;	1.8	;	Room temperature X-ray structure of truncated SARS-CoV-2 main protease C145A mutant, residues 1-304, in complex with BBH1
8GFO	;	2.0	;	Room temperature X-ray structure of truncated SARS-CoV-2 main protease C145A mutant, residues 1-304, in complex with GC373
8GFR	;	2.0	;	Room temperature X-ray structure of truncated SARS-CoV-2 main protease C145A mutant, residues 1-304, in complex with NBH2
8GFU	;	1.8	;	Room temperature X-ray structure of truncated SARS-CoV-2 main protease C145A mutant, residues 1-304, in complex with nirmatrelvir (NMV)
7M75	;	2.75	;	Room Temperature XFEL Crystallography reveals asymmetry in the vicinity of the two phylloquinones in Photosystem I
7M76	;	3.0	;	Room Temperature XFEL Crystallography reveals asymmetry in the vicinity of the two phylloquinones in Photosystem I
7M78	;	3.0	;	Room Temperature XFEL Crystallography reveals asymmetry in the vicinity of the two phylloquinones in Photosystem I
6ZAF	;	1.4001	;	Room temperature XFEL Isopenicillin N synthase structure in complex with Fe and ACV after exposure to dioxygen for 400ms.
6ZAL	;	1.83	;	Room temperature XFEL Isopenicillin N synthase structure in complex with Fe and ACV after exposure to dioxygen for 500ms without glycerol.
6ZAG	;	1.4001	;	Room temperature XFEL Isopenicillin N synthase structure in complex with Fe and ACV after exposure to dioxygen for 500ms.
6ZAH	;	1.43	;	Room temperature XFEL Isopenicillin N synthase structure in complex with Fe and ACV after exposure to dioxygen for 800ms.
6ZAE	;	1.4	;	Room temperature XFEL Isopenicillin N synthase structure in complex with Fe and ACV under anaerobic conditions.
6ZAQ	;	1.6	;	Room temperature XFEL Isopenicillin N synthase structure in complex with Fe and IPN after dioxygen exposure
6ZAI	;	1.5501	;	Room temperature XFEL Isopenicillin N synthase structure in complex with Fe, O2 and ACV after exposure to dioxygen for 1600ms.
6ZAJ	;	1.5301	;	Room temperature XFEL Isopenicillin N synthase structure in complex with Fe, O2 and ACV after exposure to dioxygen for 3000ms.
6ZAK	;	1.54	;	Room temperature XFEL Isopenicillin N synthase structure in complex with the Fe(IV)=O mimic VO and ACV.
5TIS	;	2.25	;	Room temperature XFEL structure of the native, doubly-illuminated photosystem II complex
7BH6	;	1.65	;	Room temperature, serial X-ray structure of CTX-M-15 collected on fixed target chips at Diamond Light Source I24
7BH7	;	1.65	;	Room temperature, serial X-ray structure of the ertapenem-derived acylenzyme of CTX-M-15 (10 min soak) collected on fixed target chips at Diamond Light Source I24
3BDQ	;	2.0	;	Room Tempreture Crystal Structure of Sterol Carrier Protein-2 Like-2
7S8Z	;	1.64	;	Room-temperature apo Human Hsp90a-NTD
4WL7	;	1.95	;	Room-temperature crystal structure of lysozyme determined by serial synchrotron crystallography using a micro focused beam (Conventional resolution cut-off)
4WG7	;	1.7	;	Room-temperature crystal structure of lysozyme determined by serial synchrotron crystallography using a nano focused beam.
7S95	;	1.71	;	Room-temperature Human Hsp90a-NTD bound to adenine
7S9G	;	1.79	;	Room-temperature Human Hsp90a-NTD bound to BIIB021
7S9I	;	1.75	;	Room-temperature Human Hsp90a-NTD bound to EC144
7S99	;	1.52	;	Room-temperature Human Hsp90a-NTD bound to N6M
4DVO	;	2.0	;	Room-temperature joint X-ray/neutron structure of D-xylose isomerase in complex with 2Ni2+ and per-deuterated D-sorbitol at pH 5.9
5FB6	;	1.901	;	Room-temperature macromolecular crystallography using a micro-patterned silicon chip with minimal background scattering
8DU7	;	2.4	;	Room-temperature serial synchrotron crystallography (SSX) structure of apo PTP1B
6MYB	;	1.899	;	Room-temperature structure of deuterated Tetdron (isomorph 1)
6MYC	;	2.396	;	Room-temperature structure of deuterated Tetdron (isomorph 2)
6MXW	;	2.049	;	Room-temperature structure of hydrogenated Tetdron (isomorph 1)
8H8W	;	1.7	;	Room-temperature structure of lysozyme by pink-beam serial crystallography (100 ms, center)
8H8V	;	1.7	;	Room-temperature structure of lysozyme by pink-beam serial crystallography (100 ms, edge)
8H8U	;	1.7	;	Room-temperature structure of lysozyme by pink-beam serial crystallography (50 ms, center)
8H8T	;	1.7	;	Room-temperature structure of lysozyme by pink-beam serial crystallography (50 ms, edge)
7WUC	;	2.1	;	Room-temperature structure of lysozyme by serial femtosecond crystallography (BITS)
8BRZ	;	1.7	;	Room-temperature structure of Pedobacter heparinus N-acetylglucosamine 2-epimerase at 52 MPa helium gas pressure in a sapphire capillary
8BS0	;	1.7	;	Room-temperature structure of Pedobacter heparinus N-acetylglucosamine 2-epimerase at 80 MPa helium gas pressure in a sapphire capillary
8BRY	;	1.5	;	Room-temperature structure of Pedobacter heparinus N-acetylglucosamine 2-epimerase at atmospheric pressure
8BS2	;	2.35	;	Room-temperature structure of SARS-CoV-2 Main protease at 104 MPa helium gas pressure in a sapphire capillary
8BS1	;	2.05	;	Room-temperature structure of SARS-CoV-2 Main protease at atmospheric pressure
8A2P	;	3.5	;	Room-temperature structure of the stabilised A2A-LUAA47070 complex determined by synchrotron serial crystallography
8A2O	;	3.45	;	Room-temperature structure of the stabilised A2A-Theophylline complex determined by synchrotron serial crystallography
4P3Q	;	1.351	;	Room-temperature WT DHFR, time-averaged ensemble
6XQU	;	2.2	;	Room-temperature X-ray Crystal structure of SARS-CoV-2 main protease in complex with Boceprevir
6XCH	;	2.2	;	Room-temperature X-ray Crystal structure of SARS-CoV-2 main protease in complex with Leupeptin
6XQT	;	2.3	;	Room-temperature X-ray Crystal structure of SARS-CoV-2 main protease in complex with Narlaprevir
6XQS	;	1.9	;	Room-temperature X-ray Crystal structure of SARS-CoV-2 main protease in complex with Telaprevir
4DUO	;	2.0	;	Room-temperature X-ray structure of D-Xylose Isomerase in complex with 2Mg2+ ions and xylitol at pH 7.7
8SSJ	;	2.5	;	Room-temperature X-ray structure of human mitochondrial serine hydroxymethyltransferase (hSHMT2)
7UJG	;	1.8	;	Room-temperature X-ray structure of monomeric SARS-CoV-2 main protease catalytic domain (MPro1-196) in complex with GC-376
7UJU	;	1.85	;	Room-temperature X-ray structure of monomeric SARS-CoV-2 main protease catalytic domain (MPro1-196) in complex with nirmatrelvir
7UJ9	;	2.25	;	Room-temperature X-ray structure of monomeric SARS-CoV-2 main protease catalytic domain (MPro1-199)
7LTJ	;	1.8	;	Room-temperature X-ray structure of SARS-CoV-2 main protease (3CL Mpro) in complex with a non-covalent inhibitor Mcule-5948770040
7N89	;	2.0	;	Room-temperature X-ray structure of SARS-CoV-2 main protease C145A mutant in complex with substrate Ac-SAVLQSGF-CONH2
8FIG	;	1.75	;	Room-temperature X-ray structure of SARS-CoV-2 main protease double mutant E290A/R298A in complex with GC373
8E4J	;	1.9	;	Room-temperature X-ray structure of SARS-CoV-2 main protease H41A miniprecursor mutant
8E4R	;	1.8	;	Room-temperature X-ray structure of SARS-CoV-2 main protease H41A miniprecursor mutant in complex with GC373
7UKK	;	2.0	;	Room-temperature X-ray structure of SARS-CoV-2 main protease in complex with GC-376
8SSY	;	1.8	;	Room-temperature X-ray structure of Thermus thermophilus serine hydroxymethyltransferase (SHMT) bound with D-Ser in a pseudo-Michaelis complex
7CWJ	;	1.61	;	Root induced Secreted protein Tsp1 from Biocontrol fungi Trichoderma virens
7CWP	;	2.1	;	Root induced Secreted protein Tsp1 from Biocontrol fungi Trichoderma virens
7ESW	;	1.25	;	Root induced Secreted protein Tsp1 from Biocontrol fungi Trichoderma virens
7KAE	;	1.6	;	Rop protein variant with a buried tryptophan
4JRN	;	2.71	;	ROP18 kinase domain in complex with AMP-PNP and sucrose
2W1Z	;	1.97	;	ROP2 from Toxoplasma gondii: A virulence factor with a protein- kinase fold and no enzymatic activity.
2NTY	;	3.1	;	Rop4-GDP-PRONE8
7KCO	;	1.86	;	ROR gamma in complex with SCR2 and compound 3
6T4T	;	1.62	;	ROR(gamma)t ligand binding domain in complex with 20-alpha-hydroxycholesterol and allosteric ligand FM26
6T4W	;	1.71	;	ROR(gamma)t ligand binding domain in complex with 20-alpha-hydroxycholesterol and allosteric ligand Glenmark
6T4U	;	2.0	;	ROR(gamma)t ligand binding domain in complex with 20-alpha-hydroxycholesterol and allosteric ligand MRL871
6T4X	;	1.48	;	ROR(gamma)t ligand binding domain in complex with 25-hydroxycholesterol and allosteric ligand FM26
6T50	;	1.87	;	ROR(gamma)t ligand binding domain in complex with 25-hydroxycholesterol and allosteric ligand Glenmark
6T4Y	;	1.95	;	ROR(gamma)t ligand binding domain in complex with 25-hydroxycholesterol and allosteric ligand MRL871
6TLM	;	2.321	;	ROR(gamma)t ligand binding domain in complex with allosteric ligand compound 13 (Glenmark)
7NPC	;	1.47	;	ROR(gamma)t ligand binding domain in complex with allosteric ligand FM156
7NP5	;	1.55	;	ROR(gamma)t ligand binding domain in complex with allosteric ligand FM216
7NEC	;	1.95	;	ROR(gamma)t ligand binding domain in complex with allosteric ligand FM217
7NP6	;	1.84	;	ROR(gamma)t ligand binding domain in complex with allosteric ligand FM257
6SAL	;	1.61	;	ROR(gamma)t ligand binding domain in complex with allosteric ligand FM26
6T4G	;	1.93	;	ROR(gamma)t ligand binding domain in complex with cholesterol and allosteric ligand FM26
6TLQ	;	1.761	;	ROR(gamma)t ligand binding domain in complex with cholesterol and allosteric ligand Glenmark
6T4I	;	1.84	;	ROR(gamma)t ligand binding domain in complex with cholesterol and allosteric ligand MRL871
6T4J	;	1.79	;	ROR(gamma)t ligand binding domain in complex with desmosterol and allosteric ligand FM26
6TLT	;	2.11	;	ROR(gamma)t ligand binding domain in complex with desmosterol and allosteric ligand Glenmark
6T4K	;	1.89	;	ROR(gamma)t ligand binding domain in complex with desmosterol and allosteric ligand MRL871
6CN6	;	2.45	;	RORC2 LBD complexed with compound 34
6Q6M	;	2.35	;	RORCVAR2 (RORGT, 264-499) IN COMPLEX WITH COMPOUND 1: Identification of N-aryl imidazoles as potent and selective RORgt inhibitors
6Q6O	;	2.3	;	RORCVAR2 (RORGT, 264-499) IN COMPLEX WITH COMPOUND 2 AT 2.3A: Identification of N-aryl imidazoles as potent and selective RORgt inhibitors
6Q7A	;	2.2	;	RORCVAR2 (RORGT, 264-499) IN COMPLEX WITH COMPOUND 4 AT 2.2A: Identification of N-aryl imidazoles as potent and selective RORgt inhibitors
6Q7H	;	2.3	;	RORCVAR2 (RORGT, 264-499) IN COMPLEX WITH COMPOUND 9 AT 2.3A: Identification of N-aryl imidazoles as potent and selective RORgt inhibitors
4XT9	;	2.25	;	RORgamma (263-509) complexed with GSK2435341A and SRC2
5YP6	;	2.2	;	RORgamma (263-509) complexed with SRC2 and Compound 6
5IZ0	;	2.635	;	RORgamma in complex with agonist BIO592 and Coactivator EBI96
4ZJW	;	2.5	;	RORgamma in complex with inverse agonist 16
4ZJR	;	2.702	;	RORgamma in complex with inverse agonist 48
4ZOM	;	2.27	;	RORgamma in complex with inverse agonist 4j.
5IXK	;	2.35	;	RORgamma in complex with inverse agonist BIO399.
7E3M	;	2.8	;	RORgamma LBD complexed with Panaxatriol and SRC2.2
6NWS	;	2.44	;	RORgamma Ligand Binding Domain
6NWT	;	2.35	;	RORgamma Ligand Binding Domain
6NWU	;	3.2	;	RORgamma Ligand Binding Domain
6J3N	;	1.99	;	RORgammat LBD complexed with Ursonic Acid and SRC2.2
6G05	;	1.9	;	RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST ""CPD-2"" AND RIP140 PEPTIDE AT 1.90A
6G07	;	1.66	;	RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST ""CPD-9"" AND RIP140 PEPTIDE AT 1.66A
6FZU	;	1.8	;	RORGT (264-518;C455S) IN COMPLEX WITH THE FRAGMENT (""CPD-1"") AND RIP140 PEPTIDE AT 1.80A
5ETH	;	2.803	;	RORy in complex with inverse agonist 3.
5EJV	;	2.58	;	RORy in complex with T090131718 and Coactivator peptide EBI96
7Z5W	;	2.254	;	ROS1 with AstraZeneca ligand 1
7Z5X	;	2.035	;	ROS1 with AstraZeneca ligand 2
8B59	;	3.3	;	Rosellinia necatrix megabirnavirus 1-W779 Crown protein
8B4Z	;	3.2	;	Rosellinia necatrix megabirnavirus 1-W779 full capsid
5X4V	;	2.0	;	Roseoflavin substituted OaPAC
1C3T	;		;	ROTAMER STRAIN AS A DETERMINANT OF PROTEIN STRUCTURAL SPECIFICITY
7JT3	;	3.7	;	Rotated 70S ribosome stalled on long mRNA with ArfB-1 and ArfB-2 bound in the A site (+9-IV)
1T34	;	2.95	;	ROTATION MECHANISM FOR TRANSMEMBRANE SIGNALING BY THE ATRIAL NATRIURETIC PEPTIDE RECEPTOR
1N6M	;	2.5	;	Rotation of the stalk/neck and one head in a new crystal structure of the kinesin motor protein, Ncd
4KPI	;	1.58	;	Rotational order-disorder structure of reversibly photoswitchable red fluorescent protein rsTagRFP
8APA	;	3.7	;	rotational state 1a of the Trypanosoma brucei mitochondrial ATP synthase dimer
8APB	;	3.8	;	rotational state 1b of the Trypanosoma brucei mitochondrial ATP synthase dimer
8APC	;	3.5	;	rotational state 1c of the Trypanosoma brucei mitochondrial ATP synthase dimer
8APD	;	3.7	;	rotational state 1d of the Trypanosoma brucei mitochondrial ATP synthase dimer
8APE	;	3.7	;	rotational state 1e of the Trypanosoma brucei mitochondrial ATP synthase dimer
8APF	;	4.3	;	rotational state 2a of the Trypanosoma brucei mitochondrial ATP synthase dimer
8APG	;	3.5	;	rotational state 2b of the Trypanosoma brucei mitochondrial ATP synthase dimer
8APH	;	3.8	;	rotational state 2c of the Trypanosoma brucei mitochondrial ATP synthase dimer
8APJ	;	3.8	;	rotational state 2d of Trypanosoma brucei mitochondrial ATP synthase
8APK	;	3.7	;	rotational state 3 of the Trypanosoma brucei mitochondrial ATP synthase dimer
6O6B	;	2.7	;	Rotavirus A-VP3 (RVA-VP3)
6CYA	;	2.6	;	Rotavirus SA11 NSP2 S313A mutant
3DE5	;	2.1	;	roteinase K by Classical hanging drop method after the second step of high X-Ray dose on ESRF ID23-1 beamline
3ZRY	;	6.5	;	Rotor architecture in the F(1)-c(10)-ring complex of the yeast F-ATP synthase
8AP9	;	3.7	;	rotor of the Trypanosoma brucei mitochondrial ATP synthase dimer
8UQW	;	1.5	;	Round 18 Arylesterase Variant of Apo-Phosphotriesterase Measured at 13 keV
8UQX	;	1.52	;	Round 18 Arylesterase Variant of Apo-Phosphotriesterase Measured at 9.5 keV
4GY0	;	1.85	;	Round 18 Arylesterase Variant of Phosphotriesterase
8UQY	;	1.78	;	Round 18 Arylesterase Variant of Phosphotriesterase Bound to Europium(III) Measured at 9.5 keV
8UQZ	;	1.61	;	Round 18 Arylesterase Variant of Phosphotriesterase Bound to Gadolinium(III) Measured at 9.5 keV
4GY1	;	1.5	;	Round 18 Arylesterase Variant of Phosphotriesterase with Bound Cacodylate
4E3T	;	1.65	;	Round 18 Arylesterase Variant of Phosphotriesterase with Bound Transition State Analog
8CEP	;	2.04	;	Round2 30S head (no antibiotic)
1EOQ	;		;	ROUS SARCOMA VIRUS CAPSID PROTEIN: C-TERMINAL DOMAIN
1EM9	;	2.05	;	ROUS SARCOMA VIRUS CAPSID PROTEIN: N-TERMINAL DOMAIN
1FIG	;	3.0	;	ROUTES TO CATALYSIS: STRUCTURE OF A CATALYTIC ANTIBODY AND COMPARISON WITH ITS NATURAL COUNTERPART
6XZ5	;	2.3	;	RovC - regulator of virulence interconnected with the Csr system
1GPL	;	2.01	;	RP2 LIPASE
8C5Y	;	3.35	;	RPA tetrameric supercomplex from Pyrococcus abyssi
8C5Z	;	3.8	;	RPA tetrameric supercomplex with AROD-OB-1
8JZV	;	1.5	;	RPA70N-ETAA1 fusion
8K00	;	1.4	;	RPA70N-MRE11 fusion
8JZY	;	1.5	;	RPA70N-RAD9 fusion
6FM8	;	1.78	;	RPAP3 c-terminus
1DZF	;	1.9	;	RPB5 from S.cerevisiae
4E04	;	1.79	;	RpBphP2 chromophore-binding domain crystallized by homologue-directed mutagenesis.
8TOF	;	2.8	;	Rpd3S bound to an H3K36Cme3 modified nucleosome
8IHT	;	3.72	;	Rpd3S bound to the nucleosome
8KC7	;	3.46	;	Rpd3S histone deacetylase complex
8KD2	;	3.02	;	Rpd3S in complex with 187bp nucleosome
8KD7	;	3.09	;	Rpd3S in complex with nucleosome with H3K36MLA modification and 167bp DNA
8KD4	;	2.93	;	Rpd3S in complex with nucleosome with H3K36MLA modification and 187bp DNA, class1
8KD5	;	2.9	;	Rpd3S in complex with nucleosome with H3K36MLA modification and 187bp DNA, class2
8KD6	;	3.07	;	Rpd3S in complex with nucleosome with H3K36MLA modification and 187bp DNA, class3
8KD3	;	2.9	;	Rpd3S in complex with nucleosome with H3K36MLA modification, H3K9Q mutation and 187bp DNA
3UK0	;	1.49	;	RPD_1889 protein, an extracellular ligand-binding receptor from Rhodopseudomonas palustris.
6FJU	;	1.65	;	Rpn11 homolog from Caldiarchaeum Subterraneum
6FJV	;	1.35	;	Rpn11 homolog from Caldiarchaeum Subterraneum, truncated
6OI4	;	1.76	;	RPN13 (19-132)-RPN2 (940-952) pY950-Ub complex
5W83	;	1.554	;	Rpn8/Rpn11 dimer complex
6AX5	;		;	RPT1 region of INI1/SNF5/SMARCB1_HUMAN - SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1.
7OPE	;	3.2	;	RqcH DR variant bound to 50S-peptidyl-tRNA-RqcP RQC complex (rigid body refinement)
6N4P	;	1.851	;	RQEFEV, crystal structure of the N-terminal segment RQEFEV from protein tau
7LQ4	;	2.9	;	Rr (RsiG)2-(c-di-GMP)2-WhiG complex
8FFN	;	2.96	;	RR-bound wildtype rabbit TRPV5 in nanodiscs
2A9R	;	2.342	;	RR02-Rec Phosphate in the active site
1Y69	;	3.33	;	RRF domain I in complex with the 50S ribosomal subunit from Deinococcus radiodurans
7XWE	;	1.598	;	RRGSGG-AtPRT6 UBR box
7Y6W	;	1.95	;	RRGSGG-AtPRT6 UBR box (I222)
7Y6X	;	2.196	;	RRGSGG-AtPRT6 UBR box (P32)
4CH0	;		;	RRM domain from C. elegans SUP-12
4CH1	;		;	RRM domain from C. elegans SUP-12 bound to GGTGTGC DNA
4CIO	;		;	RRM domain from C. elegans SUP-12 bound to GGUGUGC RNA
2M8H	;		;	RRM domain of human RBM7
2KT5	;		;	RRM domain of mRNA export adaptor REF2-I bound to HSV-1 ICP27 peptide
2YKA	;		;	RRM domain of mRNA export adaptor REF2-I bound to HVS ORF57 peptide
2GO9	;		;	RRM domains 1 and 2 of Prp24 from S. cerevisiae
5B88	;		;	RRM-like domain of DEAD-box protein, CsdA
4UQT	;		;	RRM-peptide structure in RES complex
6TQO	;	3.8	;	rrn anti-termination complex
6TQN	;	3.8	;	rrn anti-termination complex without S4
1O9G	;	1.5	;	rRNA methyltransferase aviRa from Streptomyces viridochromogenes at 1.5A
1O9H	;	2.4	;	rRNA methyltransferase aviRa from Streptomyces viridochromogenes at 2.4A
5GU4	;	1.55	;	rRNA N-glycosylase RTA
5NLG	;	2.35	;	RRP5 C-terminal domain
8WZB	;	3.28	;	RS head-neck monomer
8IMM	;	2.76	;	Rs2'I-Rs2'II, Rs1'I-Rs1'II, Rb'I-Rb'II cylinder in cyanobacterial phycobilisome from Anthocerotibacter panamensis (Cluster E)
8IML	;	2.74	;	Rs2I-Rs2II, Rs1I-Rs1II, RbI-RbII cylinder in cyanobacterial phycobilisome from Anthocerotibacter panamensis (Cluster D)
6D8A	;	2.251	;	RsAgo Ternary Complex with guide RNA and Target DNA Containing A-A Bulge Within the Seed Segment of the Target Strand
6D8F	;	2.15	;	RsAgo Ternary Complex with Guide RNA and Target DNA Containing T-T Bulge Within the Seed Segment
6V8O	;	3.07	;	RSC core
6K15	;	3.4	;	RSC substrate-recruitment module
6V92	;	20.0	;	RSC-NCP
7A7L	;	1.3	;	rsEGFP in the green-off state
7A7K	;	1.55	;	rsEGFP in the green-on state
8AHA	;	2.38	;	rsEGFP2 photoswitched to its off-state at 100K
8AHB	;	1.79	;	rsEGFP2 photoswitched to its off-state at room temperature and back-switched to its on-state at 100K
6PFR	;	1.51	;	rsEGFP2 with a chlorinated chromophore in the fluorescent on-state
6PFS	;	1.759	;	rsEGFP2 with a chlorinated chromophore in the fluorescent on-state in a contracted unit cell
8A83	;	1.81	;	rsEGFP2 with a chlorinated chromophore in the fluorescent ON-state in a crystal dehydrated after illumination
6PFT	;	1.45	;	rsEGFP2 with a chlorinated chromophore in the non-fluorescent off-state
6PFU	;	1.619	;	rsEGFP2 with a chlorinated chromophore in the non-fluorescent off-state in a contracted unit cell
5NO4	;	5.16	;	RsgA-GDPNP bound to the 30S ribosomal subunit (RsgA assembly intermediate with uS3)
5NO3	;	5.16	;	RsgA-GDPNP bound to the 30S ribosomal subunit (RsgA assembly intermediate without uS3)
5NO2	;	5.16	;	RsgA-GDPNP bound to the 30S ribosomal subunit (RsgA assembly intermediate)
7A7X	;	1.85	;	rsGreen0.7-F145M in the green-off state
7A7W	;	1.3	;	rsGreen0.7-F145M partially in the green-on state
7A7Y	;	0.97	;	rsGreen0.7-F145Q in the green-on state
7A7O	;	1.8	;	rsGreen0.7-K206A in the green-on state
7A7P	;	1.48	;	rsGreen0.7-K206A partially in the green-off state
7A7Z	;	1.1	;	rsGreen0.7-K206A-E222G in the green-on state
7A80	;	2.05	;	rsGreen0.7-K206A-E222V in the green-on state
7A82	;	1.9	;	rsGreen0.7-K206A-F145A partially in the green-off state
7A81	;	1.7	;	rsGreen0.7-K206A-F145A partially in the green-on state
7A83	;	1.73	;	rsGreen0.7-K206A-F145H in the green-on-state
7A84	;	2.1	;	rsGreen0.7-K206A-F145H partially in the green-off state
7A85	;	1.52	;	rsGreen0.7-K206A-F145L in the green-on state
7A86	;	1.9	;	rsGreen0.7-K206A-F145L partially in the green-off state
7A88	;	1.95	;	rsGreen0.7-K206A-F145M in the green-off state
7A87	;	1.75	;	rsGreen0.7-K206A-F145M in the green-on state
7A89	;	2.5	;	rsGreen0.7-K206A-F145Q in the green-on state
7A8A	;	1.93	;	rsGreen0.7-K206A-F145Q partially in the green-off state
7A8C	;	2.13	;	rsGreen0.7-K206A-F145S in the green-off state
7A8B	;	1.55	;	rsGreen0.7-K206A-F145S partially in the green-on state
7A8F	;	2.27	;	rsGreen0.7-K206A-F165L in the green-on state
7A8E	;	2.2	;	rsGreen0.7-K206A-F165W partially in the green-off state
7A8D	;	1.65	;	rsGreen0.7-K206A-F165W partially in the green-on state
7A8G	;	2.0	;	rsGreen0.7-K206A-H148G in the green-on state
7A8H	;	1.7	;	rsGreen0.7-K206A-H148S in the green-on state
7A8I	;	2.0	;	rsGreen0.7-K206A-H148S partially in the green-off state
7A8J	;	1.85	;	rsGreen0.7-K206A-H148V in the green-on state
7A8K	;	2.25	;	rsGreen0.7-K206A-H148V partially in the green-off state
7A8L	;	1.75	;	rsGreen0.7-K206A-N205C in the green-on state
7A8M	;	1.6	;	rsGreen0.7-K206A-N205G in the green-on state
7A8N	;	2.1	;	rsGreen0.7-K206A-N205L in the green-on state
7A8O	;	1.6	;	rsGreen0.7-K206A-N205S in the green-on state
7A7N	;	1.2	;	rsGreen0.7b in the green-off state
7A7M	;	1.6	;	rsGreen0.7b in the green-on state
7A7U	;	2.15	;	rsGreen1 in the green-on state
7A7V	;	2.0	;	rsGreen1-K206A partially in the green-off state
7A7S	;	1.73	;	rsGreenF in the green-on state
7A7T	;	1.58	;	rsGreenF partially in the green-off state
7A7R	;	2.35	;	rsGreenF-K206A in the green-off state
7A7Q	;	2.0	;	rsGreenF-K206A in the green-on state
7XWG	;	1.832	;	RSGSGG-AtPRT6 UBR box
4D9T	;	2.4	;	Rsk2 C-terminal Kinase Domain with inhibitor (E)-methyl 3-(4-amino-7-(3-hydroxypropyl)-5-p-tolyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-2-cyanoacrylate
4D9U	;	2.4	;	Rsk2 C-terminal Kinase Domain, (E)-tert-butyl 3-(4-amino-7-(3-hydroxypropyl)-5-p-tolyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-2-cyanoacrylate
4JG6	;	2.6	;	RSK2 CTD bound to 2-cyano-3-(1H-indazol-5-yl)acrylamide
7OPO	;	2.75	;	RSK2 N-terminal kinase domain in complex with ORF45
4NW6	;	1.74	;	Rsk2 N-terminal kinase in complex with 2-amino-7-substituted benzoxazole compound 27
4NW5	;	1.94	;	Rsk2 N-terminal kinase in complex with 2-amino-7-substituted benzoxazole compound 8
5D9K	;	2.55	;	Rsk2 N-terminal Kinase in Complex with BI-D1870
5D9L	;	2.15	;	Rsk2 N-terminal Kinase in Complex with bis-phenol pyrazole
4NUS	;	2.39	;	Rsk2 N-terminal kinase in complex with LJH685
4M8T	;	3.0	;	RSK2 T493M C-Terminal Kinase Domain in complex with 3-(3-(1H-pyrazol-4-yl)phenyl)-2-cyanoacrylamide
4MAO	;	2.6	;	RSK2 T493M C-Terminal Kinase Domain in Complex with RMM58
6G77	;	2.499	;	RSK4 N-terminal Kinase Domain in complex with AMP-PNP
6G78	;	2.5	;	RSK4 N-terminal Kinase Domain S232E in complex with AMP-PNP
7QLO	;	1.31	;	rsKiiro pump dump probe structure by TR-SFX
7QLN	;	1.5	;	rsKiiro pump probe structure by TR-SFX
7QLL	;	1.324	;	rsKiiro Thermal annealing at 290K of 200K Cis intermediate
7QLM	;	1.3	;	rsKiiro trans chromophore dark structure by SFX
8E7X	;	2.1	;	RsTSPO A138F with one Heme bound
8E7Y	;	2.3	;	RsTSPO A138F with two heme bound
8E7W	;	2.1	;	RsTSPO A139T with Heme
8E7Z	;	2.6	;	RsTSPO mutant -A138F
8DZW	;	2.46	;	RSV F trimer bound to RSV-199 Fab
6BLH	;	2.0	;	RSV G central conserved region bound to Fab CB017.5
6BLI	;	2.12	;	RSV G peptide bound to Fab CB002.5
4D4T	;	1.9	;	RSV Matrix protein
4V23	;	1.7	;	RSV Matrix protein
6DC3	;	3.501	;	RSV prefusion F bound to RSD5 Fab
6DC5	;	3.5	;	RSV prefusion F in complex with AM22 Fab
6DC4	;	1.7	;	RSV-neutralizing human antibody AM22
4IXQ	;	5.7	;	RT fs X-ray diffraction of Photosystem II, dark state
4IXR	;	5.9	;	RT fs X-ray diffraction of Photosystem II, first illuminated state
6YBO	;	1.06	;	RT structure of Glucose Isomerase obtained at 1.06 A resolution from crystal grown in a Kapton microchip.
6YBR	;	1.2	;	RT structure of Glucose Isomerase obtained at 1.20 A resolution from crystal grown in a Mylar microchip.
6YBI	;	1.12	;	RT structure of HEW Lysozyme obtained at 1.12 A resolution from crystal grown in a Mylar microchip.
6YBF	;	1.13	;	RT structure of HEW Lysozyme obtained at 1.13 A resolution from crystal grown in a Kapton microchip.
6Q88	;	1.74007	;	RT structure of HEWL at 5 kGy
6YBX	;	1.14	;	RT structure of Thaumatin obtained at 1.14 A resolution from crystal grown in a Mylar microchip.
6YC5	;	1.35	;	RT structure of Thaumatin obtained at 1.35 A resolution from crystal grown in a Kapton microchip.
6U5E	;	1.56	;	RT XFEL structure of CypA solved using celloluse carrier media
6U5D	;	1.65	;	RT XFEL structure of CypA solved using LCP injection system
6U5C	;	1.62	;	RT XFEL structure of CypA solved using MESH injection system
7RF2	;	2.08	;	RT XFEL structure of dark-stable state of Photosystem II (0F, S1 rich) at 2.08 Angstrom
8F4H	;	2.1	;	RT XFEL structure of Photosystem II 1200 microseconds after the third illumination at 2.10 Angstrom resolution
6W1R	;	2.23	;	RT XFEL structure of Photosystem II 150 microseconds after the second illumination at 2.23 Angstrom resolution
7RF5	;	2.23	;	RT XFEL structure of Photosystem II 150 microseconds after the second illumination at 2.23 Angstrom resolution
6DHG	;	2.5	;	RT XFEL structure of Photosystem II 150 microseconds after the second illumination at 2.5 Angstrom resolution
8F4I	;	2.0	;	RT XFEL structure of Photosystem II 2000 microseconds after the third illumination at 2.00 Angstrom resolution
4TNK	;	5.2	;	RT XFEL structure of Photosystem II 250 microsec after the third illumination at 5.2 A resolution
6W1T	;	2.01	;	RT XFEL structure of Photosystem II 250 microseconds after the second illumination at 2.01 Angstrom resolution
7RF6	;	2.01	;	RT XFEL structure of Photosystem II 250 microseconds after the second illumination at 2.01 Angstrom resolution
8F4E	;	2.09	;	RT XFEL structure of Photosystem II 250 microseconds after the third illumination at 2.09 Angstrom resolution
6W1U	;	2.09	;	RT XFEL structure of Photosystem II 400 microseconds after the second illumination at 2.09 Angstrom resolution
7RF7	;	2.09	;	RT XFEL structure of Photosystem II 400 microseconds after the second illumination at 2.09 Angstrom resolution
6DHH	;	2.2	;	RT XFEL structure of Photosystem II 400 microseconds after the second illumination at 2.2 Angstrom resolution
8F4J	;	2.0	;	RT XFEL structure of Photosystem II 4000 microseconds after the third illumination at 2.00 Angstrom resolution
6W1Q	;	2.27	;	RT XFEL structure of Photosystem II 50 microseconds after the second illumination at 2.27 Angstrom resolution
7RF4	;	2.27	;	RT XFEL structure of Photosystem II 50 microseconds after the second illumination at 2.27 Angstrom resolution
8F4D	;	2.15	;	RT XFEL structure of Photosystem II 50 microseconds after the third illumination at 2.15 Angstrom resolution
8F4F	;	2.03	;	RT XFEL structure of Photosystem II 500 microseconds after the third illumination at 2.03 Angstrom resolution
4TNJ	;	4.5	;	RT XFEL structure of Photosystem II 500 ms after the 2nd illumination (2F) at 4.5 A resolution
4TNI	;	4.6	;	RT XFEL structure of Photosystem II 500 ms after the third illumination at 4.6 A resolution
8F4G	;	2.03	;	RT XFEL structure of Photosystem II 730 microseconds after the third illumination at 2.03 Angstrom resolution
7RF1	;	1.89	;	RT XFEL structure of Photosystem II averaged across all S-states at 1.89 Angstrom resolution
5KAF	;	3.00001	;	RT XFEL structure of Photosystem II in the dark state at 3.0 A resolution
4TNH	;	4.90001	;	RT XFEL structure of Photosystem II in the dark state at 4.9 A resolution
6DHE	;	2.05	;	RT XFEL structure of the dark-stable state of Photosystem II (0F, S1-rich) at 2.05 Angstrom resolution
6W1O	;	2.08	;	RT XFEL structure of the dark-stable state of Photosystem II (0F, S1-rich) at 2.08 Angstrom resolution
6DHF	;	2.08	;	RT XFEL structure of the one-flash state of Photosystem II (1F, S2-rich) at 2.08 Angstrom resolution
6W1P	;	2.26	;	RT XFEL structure of the one-flash state of Photosystem II (1F, S2-rich) at 2.26 Angstrom resolution
7RF3	;	2.26	;	RT XFEL structure of the one-flash state of Photosystem II (1F, S2-rich) at 2.26 Angstrom resolution
6DHP	;	2.04	;	RT XFEL structure of the three-flash state of Photosystem II (3F, S0-rich) at 2.04 Angstrom resolution
8F4K	;	2.16	;	RT XFEL structure of the three-flash state of Photosystem II (3F, S0-rich) at 2.16 Angstrom resolution
8F4C	;	2.0	;	RT XFEL structure of the two-flash state of Photosystem II (2F, S3-rich) at 2.00 Angstrom resolution
6DHO	;	2.07	;	RT XFEL structure of the two-flash state of Photosystem II (2F, S3-rich) at 2.07 Angstrom resolution
6W1V	;	2.09	;	RT XFEL structure of the two-flash state of Photosystem II (2F, S3-rich) at 2.09 Angstrom resolution
7RF8	;	2.09	;	RT XFEL structure of the two-flash state of Photosystem II (2F, S3-rich) at 2.09 Angstrom resolution
8EZ5	;	2.09	;	RT XFEL structure of the two-flash state of Photosystem II (2F, S3-rich) at 2.09 Angstrom resolution
8IMO	;	3.08	;	Rt1'I-Rt1'II, Rt2I-Rt2II, Rt3'I-Rt3'II cylinder in cyanobacterial phycobilisome from Anthocerotibacter panamensis (Cluster G)
8IMN	;	3.07	;	Rt1I-Rt1II, Rt2'I-Rt2'II, Rt3I-Rt3II cylinder in cyanobacterial phycobilisome from Anthocerotibacter panamensis (Cluster F)
2FJV	;	2.05	;	RT29 Bound to D(CTTAATTCGAATTAAG) in complex with MMLV RT Catalytic Fragment
2FJX	;	1.8	;	RT29 bound to D(CTTGAATGCATTCAAG) in complex with MMLV RT catalytic fragment
3PX8	;	1.29	;	RTA in complex with 7-carboxy-pterin
3PX9	;	1.89	;	RTA in complex with N-(furanylmethyl)-7-carbamoyl-pterin
5J56	;	1.8	;	RTA-V1C7
5U4M	;	2.5	;	RTA-V1C7-G29R-no_salt
5U4L	;	2.5	;	RTA-V1C7_G29R-high-salt
5SV3	;	2.73	;	RTA1-33/44-198 (RVEC) bound to Single Domain Antibody A3C8
6TT9	;	1.9	;	rTBL Recombinant Lectin From Tepary Bean
1HVZ	;		;	RTD-1, A CYCLIC ANTIMICROBIAL DEFENSIN FROM RHESUS MACAQUE LEUKOCYTES
3GYP	;	2.406	;	Rtt106p
8GQ3	;	1.767	;	RTT109 mutant from Candida albicans
6F0Y	;		;	Rtt109 peptide bound to Asf1
6WYA	;	2.41	;	RTX (Reverse Transcription Xenopolymerase) in complex with a DNA duplex and dAMPNPP
6WYB	;	2.5	;	RTX (Reverse Transcription Xenopolymerase) in complex with an RNA/DNA hybrid
2BT6	;	1.5	;	Ru(bpy)2(mbpy)-Modified Bovine Adrenodoxin
3M0B	;	2.0	;	Ru-Porphyrin Protein Scaffolds for Sensing O2
2W8Y	;	1.8	;	RU486 bound to the progesterone receptor in a destabilized agonistic conformation
8P0C	;	1.72	;	Rubella virus p150 macro domain (apo)
8P0E	;	1.59	;	Rubella virus p150 macro domain in complex with ADP-ribose
4IBL	;	1.8	;	Rubidium Sites in Blood Coagulation Factor VIIa
6UEW	;	2.4	;	Rubisco / CsoS2 N-peptide complex responsible for alpha-carboxysome cargo loading
4W5W	;	2.9	;	Rubisco activase from Arabidopsis thaliana
5IU0	;	1.499	;	Rubisco from Arabidopsis thaliana
1GK8	;	1.4	;	Rubisco from Chlamydomonas reinhardtii
1IWA	;	2.6	;	RUBISCO FROM GALDIERIA PARTITA
7YK5	;	2.0	;	Rubisco from Phaeodactylum tricornutum bound to PYCO1(452-592)
6FTL	;	2.6	;	Rubisco from Skeletonema marinoi
5MZ2	;	1.9	;	Rubisco from Thalassiosira antarctica
5N9Z	;	1.899	;	Rubisco from Thalassiosira hyalina
7JN4	;	2.68	;	Rubisco in the apo state
1BQ9	;	1.2	;	Rubredoxin (Formyl Methionine Mutant) from Pyrococcus Furiosus
1BQ8	;	1.1	;	Rubredoxin (Methionine Mutant) from Pyrococcus Furiosus
1IRO	;	1.1	;	RUBREDOXIN (OXIDIZED, FE(III)) AT 1.1 ANGSTROMS RESOLUTION
1BRF	;	0.95	;	Rubredoxin (Wild Type) from Pyrococcus Furiosus
1IRN	;	1.2	;	RUBREDOXIN (ZN-SUBSTITUTED) AT 1.2 ANGSTROMS RESOLUTION
1S24	;		;	Rubredoxin domain II from Pseudomonas oleovorans
1RDG	;	1.4	;	RUBREDOXIN FROM DESULFOVIBRIO GIGAS. A MOLECULAR MODEL OF THE OXIDIZED FORM AT 1.4 ANGSTROMS RESOLUTION
2RDV	;	1.9	;	RUBREDOXIN FROM DESULFOVIBRIO VULGARIS MIYAZAKI F, MONOCLINIC CRYSTAL FORM
1RDV	;	2.0	;	RUBREDOXIN FROM DESULFOVIBRIO VULGARIS MIYAZAKI F, TRIGONAL CRYSTAL FORM
1RB9	;	0.92	;	RUBREDOXIN FROM DESULFOVIBRIO VULGARIS REFINED ANISOTROPICALLY AT 0.92 ANGSTROMS RESOLUTION
1DX8	;		;	Rubredoxin from Guillardia theta
1H7V	;		;	Rubredoxin from Guillardia Theta
1E5D	;	2.5	;	RUBREDOXIN OXYGEN:OXIDOREDUCTASE (ROO) FROM ANAEROBE DESULFOVIBRIO GIGAS
2M4Y	;		;	Rubredoxin type protein from Mycobacterium ulcerans
1C09	;	1.6	;	RUBREDOXIN V44A CP
1QCV	;		;	RUBREDOXIN VARIANT (PFRD-XC4) FOLDS WITHOUT IRON
1B71	;	1.9	;	RUBRERYTHRIN
1DVB	;	1.9	;	RUBRERYTHRIN
1RYT	;	2.1	;	RUBRERYTHRIN
8FUH	;	1.852	;	Rubrerythrin from B. pseudomallei: apo form
8FVV	;	1.93	;	Rubrerythrin from B. pseudomallei: iron-bound
8FXD	;	1.58	;	Rubrerythrin from B. pseudomallei: manganese-bound
1NNQ	;	2.35	;	rubrerythrin from Pyrococcus furiosus Pfu-1210814
7MN1	;		;	Rules for designing protein fold switches and their implications for the folding code
7MN2	;		;	Rules for designing protein fold switches and their implications for the folding code
7MP7	;		;	Rules for designing protein fold switches and their implications for the folding code
7MQ4	;		;	Rules for designing protein fold switches and their implications for the folding code
7LSA	;	1.76	;	Ruminococcus bromii Amy12 with maltoheptaose
7LSU	;	1.95	;	Ruminococcus bromii Amy12-D392A with 63-a-D-glucosyl-maltotriose
7LST	;	2.05	;	Ruminococcus bromii Amy12-D392A with 63-a-D-glucosyl-maltotriosyl-maltotriose
7LSR	;	2.42	;	Ruminococcus bromii Amy12-D392A with maltoheptaose
7JJT	;	1.66	;	Ruminococcus bromii amylase Amy5 (RBR_07800)
8AJY	;	1.71	;	Ruminococcus flavefaciens Cohesin-Dockerin structure: dockerin from ScaH adaptor scaffoldin in complex with the cohesin from ScaE anchoring scaffoldin
7PMO	;	2.1	;	Ruminococcus gnavus ATC29149 endo-beta-1,4-galactosidase (RgGH98)
7Q1W	;	1.65	;	Ruminococcus gnavus ATC29149 endo-beta-1,4-galactosidase (RgGH98) E411A in complex with blood group A (BgA II) tetrasaccharide
7Q20	;	1.95	;	Ruminococcus gnavus ATC29149 endo-beta-1,4-galactosidase (RgGH98) in complex with blood group A trisaccharide
6EC6	;	2.85	;	Ruminococcus gnavus Beta-glucuronidase
6TR4	;	1.45	;	Ruminococcus gnavus GH29 fucosidase E1_10125 D221A mutant in complex with fucose
6TR3	;	1.7	;	Ruminococcus gnavus GH29 fucosidase E1_10125 in complex with fucose
6ER2	;	1.73	;	Ruminococcus gnavus IT-sialidase CBM40
6ER3	;	1.37	;	Ruminococcus gnavus IT-sialidase CBM40 bound to alpha2,3 sialyllactose
6ER4	;	1.3	;	Ruminococcus gnavus IT-sialidase CBM40 bound to alpha2,6 sialyllactose
6RB7	;	1.6	;	Ruminococcus gnavus sialic acid aldolase catalytic lysine mutant
6RD1	;	1.892	;	Ruminococcus gnavus sialic acid aldolase catalytic lysine mutant in complex with sialic acid
6RAB	;	1.96	;	Ruminococcus gnavus sialic acid aldolase Wild Type
4OBV	;	2.84	;	Ruminococcus gnavus tryptophan decarboxylase RUMGNA_01526 (alpha-FMT)
4OBU	;	2.804	;	Ruminococcus gnavus tryptophan decarboxylase RUMGNA_01526 (apo)
2CXF	;	3.07	;	RUN domain of Rap2 interacting protein x, crystallized in C2 space group
2CXL	;	3.2	;	RUN domain of Rap2 interacting protein x, crystallized in I422 space group
2DWG	;	3.22	;	RUN domain of Rap2 interacting protein x, crystallized in P2(1)2(1)2(1) space group
3S9A	;	1.9	;	Russell's viper venom serine proteinase, RVV-V (closed-form)
3S9B	;	1.9	;	Russell's viper venom serine proteinase, RVV-V (open-form)
3SBK	;	2.55	;	Russell's viper venom serine proteinase, RVV-V (PPACK-bound form)
3S9C	;	1.8	;	Russell's viper venom serine proteinase, RVV-V in complex with the fragment (residues 1533-1546) of human factor V
1RCY	;	1.9	;	RUSTICYANIN (RC) FROM THIOBACILLUS FERROOXIDANS
8BYW	;	1.59	;	Rut B structure
2HTO	;	1.54	;	Ruthenium hexammine ion interactions with Z-DNA
2HTT	;	2.6	;	Ruthenium Hexammine ion interactions with Z-DNA
7OTB	;	1.6	;	Ruthenium polypridyl complex bound to a unimolecular chair-form G-quadruplex
8CMM	;	0.9	;	ruthenium polypyridyl complexes bound to DNA mismatch oligonucleotide
5V4H	;	1.22	;	Ruthenium(II)(cymene)(chlorido)2-lysozyme adduct formed when ruthenium(II)(cymene)(bromido)2 underwent ligand exchange, resulting in one binding site
5V4G	;	1.2	;	Ruthenium(II)(cymene)(chlorido)2-lysozyme adduct with two binding sites
7OA5	;	2.378	;	RUVA COMPLEXED TO A HOLLIDAY JUNCTION.
2H5X	;	2.7	;	RuvA from Mycobacterium tuberculosis
8GH8	;	4.3	;	RuvA Holliday junction DNA complex
1IXR	;	3.3	;	RuvA-RuvB complex
7PBU	;	3.3	;	RuvAB branch migration motor complexed to the Holliday junction - RuvA-HJ core [t2 dataset]
7PBS	;	3.3	;	RuvAB branch migration motor complexed to the Holliday junction - RuvB AAA+ state s0+A [t1 dataset]
7PBQ	;	3.1	;	RuvAB branch migration motor complexed to the Holliday junction - RuvB AAA+ state s0+A [t2 dataset]
7PBR	;	3.0	;	RuvAB branch migration motor complexed to the Holliday junction - RuvB AAA+ state s0-A [t2 dataset]
7PBT	;	3.3	;	RuvAB branch migration motor complexed to the Holliday junction - RuvB AAA+ state s1 [t1 dataset]
7PBL	;	3.2	;	RuvAB branch migration motor complexed to the Holliday junction - RuvB AAA+ state s1 [t2 dataset]
7PBM	;	3.2	;	RuvAB branch migration motor complexed to the Holliday junction - RuvB AAA+ state s2 [t2 dataset]
7PBN	;	3.2	;	RuvAB branch migration motor complexed to the Holliday junction - RuvB AAA+ state s3 [t2 dataset]
7PBO	;	2.9	;	RuvAB branch migration motor complexed to the Holliday junction - RuvB AAA+ state s4 [t2 dataset]
7PBP	;	3.2	;	RuvAB branch migration motor complexed to the Holliday junction - RuvB AAA+ state s5 [t2 dataset]
7AHO	;	4.18	;	RUVBL1-RUVBL2 heterohexameric ring after binding of RNA helicase DHX34
6K0R	;	2.502	;	Ruvbl1-Ruvbl2 with truncated domain II in complex with phosphorylated Cordycepin
2LC1	;		;	Rv0020c_FHA Structure
2LC0	;		;	Rv0020c_Nter structure
3B18	;	2.75	;	Rv0098 of Mycobacterium tuberculosis with ordered loop between beta-4 and beta-5
2BI0	;	1.9	;	RV0216, A conserved hypothetical protein from Mycobacterium tuberculosis that is essential for bacterial survival during infection, has a double hotdogfold
3H87	;	1.49	;	Rv0301 Rv0300 Toxin Antitoxin Complex from Mycobacterium tuberculosis
3HZO	;	2.6	;	Rv0554 from Mycobacterium tuberculosis - the structure solved from the tetragonal crystal form
2L26	;		;	Rv0899 from Mycobacterium tuberculosis contains two separated domains
2VG0	;	1.7	;	Rv1086 citronellyl pyrophosphate complex
2VG1	;	1.7	;	Rv1086 E,E-farnesyl diphosphate complex
2VFW	;	2.3	;	Rv1086 native
8IHE	;	2.74	;	Rv1122(gnd2) in Mycobacterium tuberculosis
1Q7T	;	1.9	;	Rv1170 (MshB) from Mycobacterium tuberculosis
2K3M	;		;	Rv1761c
1NFQ	;	2.4	;	Rv2002 gene product from Mycobacterium tuberculosis
1NFR	;	2.1	;	Rv2002 gene product from Mycobacterium tuberculosis
5F8E	;	2.9	;	Rv2258c-SAH
5F8F	;	1.9	;	Rv2258c-SFG
5F8C	;	1.83	;	Rv2258c-unbound
2VG4	;	2.6	;	Rv2361 native
2VG3	;	1.8	;	Rv2361 with citronellyl pyrophosphate
2VG2	;	1.95	;	Rv2361 with IPP
6IME	;	1.55	;	Rv2361c complex with substrate analogues
4L69	;	2.9	;	Rv2372c of Mycobacterium tuberculosis is RsmE like methyltransferse
4NXI	;	1.698	;	Rv2466c Mediates the Activation of TP053 To Kill Replicating and Non-replicating Mycobacterium tuberculosis
3P9N	;	1.9	;	Rv2966c of M. tuberculosis is a RsmD-like methyltransferase
7F72	;	1.64	;	Rv3094c in complex with FAD and ETH.
7F74	;	2.0	;	Rv3094c in complex with FMN.
7JLS	;	1.52	;	RV3666c bound to tripeptide
5C6U	;	1.83	;	Rv3722c aminotransferase from Mycobacterium tuberculosis
6U78	;	2.6	;	Rv3722c in complex with glutamic acid
6U7A	;	2.22	;	Rv3722c in complex with kynurenine
4O6G	;	1.55	;	Rv3902c from M. tuberculosis
6JTQ	;	2.48	;	RVD HA specifically contacts 5mC through van der Waals interactions
6JVZ	;	2.48	;	RVD HA specifically contacts 5mC through van der Waals interactions
6LEW	;	2.48	;	RVD HA specifically contacts 5mC through van der Waals interactions
6JW5	;	2.99	;	RVD Q* recognizes 5hmC through water-mediated H bonds
5Y0Y	;	3.398	;	RVFV GN-AU
8AWM	;	3.5	;	RVFV GnH with Fab268 bound
7R4E	;	3.00001	;	RVX-inhibited acetylcholinesterase in complex with 2-((hydroxyimino)methyl)-1-(5-(4-methyl-3-nitrobenzamido)pentyl)pyridinium
6RQS	;		;	RW16 peptide
2M7P	;		;	RXFP1 utilises hydrophobic moieties on a signalling surface of the LDLa module to mediate receptor activation
4ZSH	;	1.8	;	RXR LBD in complex with 9-cis-13,14-dihydroretinoic acid
6JNO	;	2.65	;	RXRa structure complexed with CU-6PMN
6JNR	;	2.3	;	RXRa structure complexed with CU-6PMN and SRC1 peptide.
6FEZ	;	2.3	;	Ryegrass mottle virus protease domain
6FF0	;	2.1	;	Ryegrass mottle virus serine protease domain fused with VPg domain
7YZV	;	1.6	;	Ryegrass mottle virus serine protease domain S159A mutant
8DVE	;	3.84	;	RyR1 in presence of IpCa-T26E phosphomimetic and activating ligands
8E77	;	1.0	;	rystal structure of Pcryo_0616, the aminotransferase required to synthesize UDP-N-acetyl-3-amino-D-glucosaminuronic acid (UDP-GlcNAc3NA), incomplete with its external aldimine reaction intermediate
7DBA	;	2.461	;	RYX in complex with tubulin
7WWM	;	2.8	;	S protein of Delta variant in complex with ZWC6
7WWL	;	3.0	;	S protein of Delta variant in complex with ZWD12
7DX3	;	3.5	;	S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 1 (1 up RBD and no PD bound)
7DX5	;	3.3	;	S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 2 (1 up RBD and 1 PD bound)
7DX6	;	3.0	;	S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 3 (2 up RBD and 1 PD bound)
7DX1	;	3.1	;	S protein of SARS-CoV-2 D614G mutant
7C2L	;	3.1	;	S protein of SARS-CoV-2 in complex bound with 4A8
7D00	;	3.0	;	S protein of SARS-CoV-2 in complex bound with FabP5A-1B8
7D03	;	3.2	;	S protein of SARS-CoV-2 in complex bound with FabP5A-2G7
7CZP	;	3.0	;	S protein of SARS-CoV-2 in complex bound with P2B-1A1
7CZQ	;	2.8	;	S protein of SARS-CoV-2 in complex bound with P2B-1A10
7FAF	;	3.69	;	S protein of SARS-CoV-2 in complex bound with P36-5D2 (state1)
7FAE	;	3.65	;	S protein of SARS-CoV-2 in complex bound with P36-5D2(state2)
7CZU	;	3.4	;	S protein of SARS-CoV-2 in complex bound with P5A-1B6_2B
7CZV	;	3.3	;	S protein of SARS-CoV-2 in complex bound with P5A-1B6_3B
7CZR	;	3.5	;	S protein of SARS-CoV-2 in complex bound with P5A-1B8_2B
7CZS	;	3.6	;	S protein of SARS-CoV-2 in complex bound with P5A-1B8_3B
7CZX	;	2.8	;	S protein of SARS-CoV-2 in complex bound with P5A-1B9
7CZY	;	3.3	;	S protein of SARS-CoV-2 in complex bound with P5A-2F11_2B
7CZZ	;	3.2	;	S protein of SARS-CoV-2 in complex bound with P5A-2F11_3B
7CZW	;	2.8	;	S protein of SARS-CoV-2 in complex bound with P5A-2G7
7CZT	;	2.7	;	S protein of SARS-CoV-2 in complex bound with P5A-2G9
7D0C	;	3.4	;	S protein of SARS-CoV-2 in complex bound with P5A-3A1
7D0B	;	3.9	;	S protein of SARS-CoV-2 in complex bound with P5A-3C12_1B
7D0D	;	3.8	;	S protein of SARS-CoV-2 in complex bound with P5A-3C12_2B
7CT5	;	4.0	;	S protein of SARS-CoV-2 in complex bound with T-ACE2
7X08	;	2.7	;	S protein of SARS-CoV-2 in complex with 2G1
7EPX	;	3.0	;	S protein of SARS-CoV-2 in complex with GW01
7DWZ	;	3.3	;	S protein of SARS-CoV-2 in the active conformation
7DWY	;	2.7	;	S protein of SARS-CoV-2 in the locked conformation
7W7H	;	2.6	;	S Suis FakA-FakB2 complex structure
7SAC	;	3.69	;	S-(+)-ketamine bound GluN1a-GluN2B NMDA receptors at 3.69 Angstrom resolution
7DK5	;	13.5	;	S-2H2-F1 structure, one RBD is up and two RBDs are down, only up RBD binds with a 2H2 Fab
7DK6	;	4.3	;	S-2H2-F2 structure, two RBDs are up and one RBD is down, each up RBD binds with a 2H2 Fab.
7DK4	;	3.8	;	S-2H2-F3a structure, two RBDs are up and one RBD is down, each RBD binds with a 2H2 Fab.
7DK7	;	9.7	;	S-2H2-F3b structure, three RBDs are up and each RBD binds with a 2H2 Fab.
7DD8	;	7.5	;	S-3C1-F1 structure, one RBD is up and two RBDs are down, the up RBD binds with a 3C1 fab
7DD2	;	5.6	;	S-3C1-F2 structure, two RBDs are up and one RBD is down, the two up RBD bind with a 3C1 fab.
7DCX	;	5.9	;	S-3C1-F3a structure, two RBDs are up and one RBD is down, each RBD binds with a 3C1 fab.
7DCC	;	4.3	;	S-3C1-F3b structure, all the three RBDs are in the up conformation and each of them associates with a 3C1 Fab
3H9U	;	1.9	;	S-adenosyl homocysteine hydrolase (SAHH) from Trypanosoma brucei
7LOO	;	1.95	;	S-adenosyl methionine transferase cocrystallized with ATP
5M5K	;	1.84	;	S-adenosyl-L-homocysteine hydrolase from Bradyrhizobium elkanii in complex with adenosine and cordycepin
2Z6A	;	2.88	;	S-Adenosyl-L-methionine-Dependent Methyl Transfer: Observable Precatalytic Intermediates during DNA Cytosine Methylation
2H5L	;	2.8	;	S-Adenosylhomocysteine hydrolase containing NAD and 3-deaza-D-eritadenine
1KY4	;	2.8	;	S-Adenosylhomocysteine hydrolase refined with noncrystallographic restraints
7YRI	;	2.61	;	S-adenosylmethionine sensor upstream of mTORC1
7YRJ	;	2.35	;	S-adenosylmethionine sensor upstream of mTORC1
1FUG	;	3.2	;	S-ADENOSYLMETHIONINE SYNTHETASE
7LOW	;	2.39	;	S-adenosylmethionine synthetase
7LOZ	;	2.25	;	S-adenosylmethionine synthetase
1XRB	;	3.0	;	S-adenosylmethionine synthetase (MAT, ATP: L-methionine S-adenosyltransferase, E.C.2.5.1.6) in which MET residues are replaced with selenomethionine residues (MSE)
7LL3	;	2.24	;	S-adenosylmethionine synthetase co-crystallized with UppNHp
7LNH	;	2.5	;	S-adenosylmethionine synthetase co-crystallized with UppNHp
7LO2	;	1.89	;	S-adenosylmethionine synthetase cocrystallized with CTP
1P7L	;	2.5	;	S-Adenosylmethionine synthetase complexed with AMPPNP and Met.
1RG9	;	2.5	;	S-Adenosylmethionine synthetase complexed with SAM and PPNP
7R3B	;	2.82	;	S-adenosylmethionine synthetase from Lactobacillus plantarum complexed with AMPPNP, methionine and SAM
1MXC	;	3.0	;	S-ADENOSYLMETHIONINE SYNTHETASE WITH 8-BR-ADP
1MXB	;	2.8	;	S-ADENOSYLMETHIONINE SYNTHETASE WITH ADP
1MXA	;	2.8	;	S-ADENOSYLMETHIONINE SYNTHETASE WITH PPI
1C53	;	1.8	;	S-CLASS CYTOCHROMES C HAVE A VARIETY OF FOLDING PATTERNS: STRUCTURE OF CYTOCHROME C-553 FROM DESULFOVIBRIO VULGARIS DETERMINED BY THE MULTI-WAVELENGTH ANOMALOUS DISPERSION METHOD
7Y1Y	;	3.3	;	S-ECD (Omicron BA.2) in complex with PD of ACE2
8I9B	;	3.5	;	S-ECD (Omicron BA.2.75) in complex with PD of ACE2
7Y1Z	;	3.4	;	S-ECD (Omicron BA.3) in complex with three PD of ACE2
7Y20	;	3.8	;	S-ECD (Omicron BA.3) in complex with two PD of ACE2
7Y21	;	2.8	;	S-ECD (Omicron BA.5) in complex with PD of ACE2
8I9C	;	3.85	;	S-ECD (Omicron BF.7) in complex with PD of ACE2
8I9D	;	3.95	;	S-ECD (Omicron XBB.1) in complex with PD of ACE2
7XID	;	3.3	;	S-ECD (Omicron) in complex with PD of ACE2
7XIC	;	3.3	;	S-ECD (Omicron) in complex with STS165
6SMT	;	1.55	;	S-enantioselective imine reductase from Mycobacterium smegmatis
8ILJ	;	1.73	;	S-formylglutathione hydrolase (BuSFGH) from Burkholderiaceae sp.
7YVT	;	2.38	;	S-formylglutathione hydrolase from Variovorax sp. PAMC 28711
6JZL	;	2.32	;	S-formylglutathione hydrolase homolog from a psychrophilic bacterium of Shewanella frigidimarina
4FOL	;	2.07	;	S-formylglutathione hydrolase Variant H160I
4FLM	;	2.41	;	S-formylglutathione Hydrolase W197I Variant containing Copper
4MA4	;	2.23	;	S-glutathionylated PFKFB3
7ZGX	;	2.88	;	S-layer Deinoxanthin Binding Complex, C1 symmetry
7ZGY	;	2.54	;	S-layer Deinoxanthin Binding Complex, C3 symmetry
8ACQ	;	2.54	;	S-layer Deinoxanthin-Binding Complex (SDBC), subunit DR_2577 assembled with its SOD DR_0644
5N8P	;	2.7	;	S-layer protein RsaA from C. crescentus
8AN2	;	3.2	;	S-layer protein SlaA from Sulfolobus acidocaldarius at pH 10.0
7ZCX	;	3.1	;	S-layer protein SlaA from Sulfolobus acidocaldarius at pH 4.0
8AN3	;	3.9	;	S-layer protein SlaA from Sulfolobus acidocaldarius at pH 7.0
8Q1O	;	3.401	;	S-layer protein SlpA from Lactobacillus amylovorus, domain I (aa 32-209), important for Self-assembly
3OZ5	;	1.36	;	S-Methyl Carbocyclic LNA
8Q9V	;	2.2	;	S-methylthiourocanate hydratase from Variovorax sp. RA8 in complex with NAD+ and imidazolone propionate
8Q9U	;	2.0	;	S-methylthiourocanate hydratase, variant R450A, from Variovorax sp. RA8 in complex with NAD+
3QJ5	;	1.9	;	S-nitrosoglutathione reductase (GSNOR) in complex with N6022
5LAO	;		;	S-nitrosylated 3D NMR structure of the cytoplasmic rhodanese domain of the inner membrane protein YgaP from Escherichia coli
2NRM	;	1.09	;	S-nitrosylated blackfin tuna myoglobin
2Y33	;	2.0	;	S-nitrosylated PHD2 (GSNO soaked) in complex with Zn(II) and UN9
2Y34	;	2.01	;	S-nitrosylated PHD2 (NO exposed) in complex with Fe(II) and UN9
8I9F	;	2.9	;	S-RBD (Omicron BA.2.75) in complex with PD of ACE2
8I9G	;	3.2	;	S-RBD (Omicron BF.7) in complex with PD of ACE2
8I9H	;	3.6	;	S-RBD (Omicron XBB.1) in complex with PD of ACE2
8I9E	;	3.2	;	S-RBD(Omicron BA.3) in complex with PD of ACE2
4XCH	;	2.2	;	S-ribosylhomocysteinase from Streptococcus suis
1Q5C	;	30.0	;	S-S-lambda-shaped TRANS and CIS interactions of cadherins model based on fitting C-cadherin (1L3W) to 3D map of desmosomes obtained by electron tomography
4R8U	;	2.3	;	S-SAD structure of DINB-DNA Complex
3WWO	;	2.55	;	S-selective hydroxynitrile lyase from Baliospermum montanum (apo1)
3WWP	;	1.9	;	S-selective hydroxynitrile lyase from Baliospermum montanum (apo2)
1Q5A	;	30.0	;	S-shaped trans interactions of cadherins model based on fitting C-cadherin (1L3W) to 3D map of desmosomes obtained by electron tomography
7OZ3	;	4.46	;	S. agalactiae BusR in complex with its busA-promotor DNA
7B5Y	;	7.1	;	S. agalactiae BusR in complex with its busAB-promotor DNA
7B5T	;	2.8	;	S. agalactiae BusR transcription factor
1W9B	;	1.7	;	S. alba myrosinase in complex with carba-glucotropaeolin
1W9D	;	1.6	;	S. alba myrosinase in complex with S-ethyl phenylacetothiohydroximate- O-sulfate
5ETR	;	1.32	;	S. aureus 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase complexed with AMPCPP and inhibitor at 1.32 angstrom resolution
5ETT	;	1.55	;	S. aureus 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase complexed with AMPCPP and inhibitor at 1.55 angstrom resolution
5ETV	;	1.72	;	S. aureus 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase complexed with AMPCPP and inhibitor at 1.72 angstrom resolution
5ETS	;	1.95	;	S. aureus 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase complexed with AMPCPP and inhibitor at 1.95 angstrom resolution
5ETQ	;	1.96	;	S. aureus 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase complexed with AMPCPP and inhibitor at 1.96 angstrom resolution
6N80	;	1.96	;	S. aureus ClpP bound to anti-4a
4NAU	;	2.33	;	S. aureus CoaD with Inhibitor
3FRD	;	2.1	;	S. aureus DHFR complexed with NADPH and folate
3FRF	;	2.2	;	S. aureus DHFR complexed with NADPH and iclaprim
3FRE	;	2.2	;	S. aureus DHFR complexed with NADPH and TMP
6PR8	;	2.01	;	S. aureus dihydrofoate reductase co-crystallized with 3,5-dimethylphenyl-dihydropthalazine inhibitor and NADP(H)
6PR9	;	2.01	;	S. aureus dihydrofolate reductase co-crystallized with 1-ethylpropyl-dihydropthalazine inhibitor and NADP(H)
6PR7	;	2.01	;	S. aureus dihydrofolate reductase co-crystallized with benzyl-dihydropthalazine inhibitor and NADP(H)
6PRB	;	2.0	;	S. aureus dihydrofolate reductase co-crystallized with cyclopropyl-dimethyoxydihydropthalazine inhibitor and NADP(H)
4FGH	;	2.5	;	S. aureus dihydrofolate reductase co-crystallized with ethyl-DAP isobutenyl-dihydrophthalazine inhibitor
6PRD	;	2.01	;	S. aureus dihydrofolate reductase co-crystallized with para-methoxyphenyl-dimethyoxydihydropthalazine inhibitor and NADP(H)
6PR6	;	2.01	;	S. aureus dihydrofolate reductase co-crystallized with para-tolyl-dihydropthalazine inhibitor and NADP(H)
4FGG	;	2.3	;	S. aureus dihydrofolate reductase co-crystallized with propyl-DAP isobutenyl-dihydrophthalazine inhibitor
3SQY	;	1.5	;	S. aureus Dihydrofolate Reductase complexed with novel 7-aryl-2,4-diaminoquinazolines
3SR5	;	1.68	;	S. aureus Dihydrofolate Reductase complexed with novel 7-aryl-2,4-diaminoquinazolines
3SRQ	;	1.69	;	S. aureus Dihydrofolate Reductase complexed with novel 7-aryl-2,4-diaminoquinazolines
3SRR	;	1.7	;	S. aureus Dihydrofolate Reductase complexed with novel 7-aryl-2,4-diaminoquinazolines
3SRS	;	1.7	;	S. aureus Dihydrofolate Reductase complexed with novel 7-aryl-2,4-diaminoquinazolines
3SRU	;	1.7	;	S. aureus Dihydrofolate Reductase complexed with novel 7-aryl-2,4-diaminoquinazolines
3SRW	;	1.7	;	S. aureus Dihydrofolate Reductase complexed with novel 7-aryl-2,4-diaminoquinazolines
6PRA	;	2.01	;	S. aureus dihydrofolate reductase with NADP(H) and empty folate pocket
3FRB	;	2.0	;	S. aureus F98Y DHFR complexed with TMP
5MN6	;	3.2	;	S. aureus FtsZ 12-316 F138A GDP Closed form (3FCm)
5MN4	;	1.5	;	S. aureus FtsZ 12-316 F138A GDP Open form (1FOf)
5MN7	;	3.3	;	S. aureus FtsZ 12-316 F138A GTP Closed form (3FCm)
5MN8	;	3.5	;	S. aureus FtsZ 12-316 F138A GTP Closed form (5FCm)
5MN5	;	2.802	;	S. aureus FtsZ 12-316 T66W GTP Closed form (2TCm)
6KVP	;	1.4	;	S. aureus FtsZ in complex with 3-(1-(5-bromo-4-(4-(trifluoromethyl)phenyl)oxazol-2-yl)ethoxy)-2,6-difluorobenzamide (compound 2)
6KVQ	;	1.6	;	S. aureus FtsZ in complex with BOFP (compound 3)
7TF7	;	2.13	;	S. aureus GS(12) - apo
7TF6	;	2.15	;	S. aureus GS(12)-Q-GlnR peptide
4P8O	;	2.4	;	S. aureus gyrase bound to an aminobenzimidazole urea inhibitor
3U2K	;	1.64	;	S. aureus GyrB ATPase domain in complex with a small molecule inhibitor
3U2D	;	1.85	;	S. aureus GyrB ATPase domain in complex with small molecule inhibitor
5DLO	;	1.401	;	S. aureus MazF in complex with substrate analogue
5FFZ	;	2.585	;	S. aureus MepR bound to ethidium bromide
5FB2	;	1.8	;	S. aureus MepR F27L Mutant bound to oligodeoxyribonucleotide
5FFX	;	1.47	;	S. aureus MepR G34K Mutant
5F6F	;	1.751	;	S. aureus MepR G34R Mutant
5ENZ	;	1.91	;	S. aureus MnaA-UDP co-structure
3HZS	;	2.1	;	S. aureus monofunctional glycosyltransferase (MtgA)in complex with moenomycin
4B19	;		;	S. aureus pepA1 NMR structure
7NS1	;		;	S. aureus pepG1 NMR solution structure
7D8J	;	2.88	;	S. aureus SsbB with 5-FU
7DEP	;	3.094	;	S. aureus SsbB with 5-FU
8VA1	;	3.4	;	S. aureus TarL H300N in complex with CDP-ribitol (single tetramer)
2O7K	;	2.2	;	S. aureus thioredoxin
2O87	;	2.4	;	S. aureus thioredoxin P31S mutant
2O85	;	2.2	;	S. Aureus thioredoxin P31T mutant
2O89	;	2.55	;	S. aureus thioredoxin P31T/C32S mutant
8QEC	;	3.3	;	S. cerevisia Niemann-Pick type C protein NCR1 in GDN at pH 5.5
8QEB	;	3.3	;	S. cerevisia Niemann-Pick type C protein NCR1 in GDN at pH 7.5
8QED	;	3.27	;	S. cerevisia Niemann-Pick type C protein NCR1 in LMNG at pH 5.5
8QEE	;	2.43	;	S. cerevisia Niemann-Pick type C protein NCR1 in Peptidisc at pH 7.5
3J6Y	;	6.1	;	S. cerevisiae 80S ribosome bound with Taura syndrome virus (TSV) IRES, 2 degree rotation (Class I)
3J6X	;	6.1	;	S. cerevisiae 80S ribosome bound with Taura syndrome virus (TSV) IRES, 5 degree rotation (Class II)
8A3T	;	3.5	;	S. cerevisiae APC/C-Cdh1 complex
8A61	;	5.4	;	S. cerevisiae apo phosphorylated APC/C
8A5Y	;	4.9	;	S. cerevisiae apo unphosphorylated APC/C.
7PSL	;	3.3	;	S. cerevisiae Atm1 in MSP1D1 nanodiscs in nucleotide-free state
7PSM	;	3.4	;	S. cerevisiae Atm1 in MSP1D1 nanodiscs with bound AMP-PNP and Mg2+
7PSN	;	2.9	;	S. cerevisiae Atm1 in MSP1E3D1 nanodiscs with bound AMP-PNP and Mg2+
8K3Q	;	2.6	;	S. cerevisiae Chs1 in apo state
8K3R	;	3.51	;	S. cerevisiae Chs1 in apo state incubated with GlcNAc
8K3X	;	2.86	;	S. cerevisiae Chs1 in complex with Nikkomycin Z
8K3P	;	3.64	;	S. cerevisiae Chs1 in complex with polyoxin B
8K3T	;	3.57	;	S. cerevisiae Chs1 in complex with UDP
8K3U	;	3.06	;	S. cerevisiae Chs1 in complex with UDP and GlcNAc
8K3V	;	3.1	;	S. cerevisiae Chs1 in complex with UDP-GlcNAc
8K3W	;	2.91	;	S. cerevisiae Chs1 in complex with UDP-GlcNAc and GlcNAc
6HV9	;	4.98	;	S. cerevisiae CMG-Pol epsilon-DNA
7Z13	;	3.4	;	S. cerevisiae CMGE dimer nucleating origin DNA melting
7QHS	;	3.3	;	S. cerevisiae CMGE nucleating origin DNA melting
8DL4	;	1.91	;	S. CEREVISIAE CYP51 COMPLEXED WITH Courmarin-containing INHIBITOR
4WMZ	;	2.05	;	S. cerevisiae CYP51 complexed with fluconazole in the active site
6E8Q	;	2.2	;	S. CEREVISIAE CYP51 COMPLEXED WITH Posaconazole
7RYX	;	2.1	;	S. CEREVISIAE CYP51 COMPLEXED WITH VT-1129
5UL0	;	2.2	;	S. CEREVISIAE CYP51 COMPLEXED WITH VT-1161
7RYA	;	2.1	;	S. CEREVISIAE CYP51 I471T MUTANT COMPLEXED WITH ITRACONAZOLE
7RY9	;	2.4	;	S. CEREVISIAE CYP51 I471T mutant COMPLEXED WITH Voriconazole
7RY8	;	1.98	;	S. CEREVISIAE CYP51 Y140H mutant COMPLEXED WITH Voriconazole
7RYB	;	2.9	;	S. CEREVISIAE CYP51 Y140H/I471T - double mutant COMPLEXED WITH Voriconazole
3PEY	;	1.401	;	S. cerevisiae Dbp5 bound to RNA and ADP BeF3
5ELX	;	1.81	;	S. cerevisiae Dbp5 bound to RNA and mant-ADP BeF3
3RRN	;	4.001	;	S. cerevisiae dbp5 l327v bound to gle1 h337r and ip6
3RRM	;	2.9	;	S. cerevisiae dbp5 l327v bound to nup159, gle1 h337r, ip6 and adp
3PEW	;	1.501	;	S. cerevisiae Dbp5 L327V bound to RNA and ADP BeF3
3PEV	;	2.499	;	S. cerevisiae Dbp5 L327V C-terminal domain bound to Gle1 and IP6
3PEU	;	2.6	;	S. cerevisiae Dbp5 L327V C-terminal domain bound to Gle1 H337R and IP6
2PFV	;	2.1	;	S. cerevisiae Exo70 with additional residues to 2.1 Angrstrom resolution
2Z50	;	2.01	;	S. cerevisiae geranylgeranyl pyrophosphate synthase in complex with BPH-28
2E93	;	2.12	;	S. cerevisiae geranylgeranyl pyrophosphate synthase in complex with BPH-629
2ZEU	;	2.0	;	S. Cerevisiae Geranylgeranyl Pyrophosphate Synthase in Complex with BPH-715
2Z78	;	2.1	;	S. cerevisiae geranylgeranyl pyrophosphate synthase in complex with BPH-806
2Z7H	;	2.08	;	S. cerevisiae geranylgeranyl pyrophosphate synthase in complex with inhibitor BPH-210
2Z7I	;	2.1	;	S. cerevisiae geranylgeranyl pyrophosphate synthase in complex with inhibitor BPH-742
2Z52	;	2.13	;	S. cerevisiae geranylgeranyl pyrophosphate synthase in complex with magnesium and BPH-23
2Z4Y	;	2.1	;	S. cerevisiae geranylgeranyl pyrophosphate synthase in complex with magnesium and BPH-252
2Z4X	;	1.9	;	S. cerevisiae geranylgeranyl pyrophosphate synthase in complex with magnesium and BPH-252 (P21)
2E92	;	2.31	;	S. cerevisiae geranylgeranyl pyrophosphate synthase in complex with magnesium and BPH-261
2E94	;	2.18	;	S. cerevisiae geranylgeranyl pyrophosphate synthase in complex with magnesium and BPH-364
2E95	;	2.2	;	S. cerevisiae geranylgeranyl pyrophosphate synthase in complex with magnesium and BPH-675
2Z4W	;	2.45	;	S. cerevisiae geranylgeranyl pyrophosphate synthase in complex with magnesium and BPH-749
2E91	;	2.14	;	S. cerevisiae geranylgeranyl pyrophosphate synthase in complex with magnesium and BPH-91
2Z4Z	;	2.09	;	S. cerevisiae geranylgeranyl pyrophosphate synthase in complex with magnesium and BPH-sc01
2Z4V	;	1.86	;	S. cerevisiae geranylgeranyl pyrophosphate synthase in complex with magnesium and GGPP (inhibitory site)
2E8X	;	2.04	;	S. cerevisiae geranylgeranyl pyrophosphate synthase in complex with magnesium and GPP
2E8W	;	2.35	;	S. cerevisiae geranylgeranyl pyrophosphate synthase in complex with magnesium and IPP
2E8U	;	2.08	;	S. cerevisiae geranylgeranyl pyrophosphate synthase in complex with magnesium and IPP (P21)
2E8T	;	2.13	;	S. cerevisiae geranylgeranyl pyrophosphate synthase in complex with magnesium, FsPP and IPP
2ZEV	;	2.23	;	S. Cerevisiae Geranylgeranyl Pyrophosphate Synthase in Complex with Magnesium, IPP and BPH-715
2E90	;	2.55	;	S. cerevisiae geranylgeranyl pyrophosphate synthase in complex with magnesium, pyrophosphate and FPP
2E8V	;	1.8	;	S. cerevisiae geranylgeranyl pyrophosphate synthase in complex with product GGPP (P21)
3ZS8	;	3.0	;	S. cerevisiae Get3 complexed with a cytosolic Get1 fragment
3ZS9	;	2.095	;	S. cerevisiae Get3-ADP-AlF4- complex with a cytosolic Get2 fragment
1C3G	;	2.7	;	S. CEREVISIAE HEAT SHOCK PROTEIN 40 SIS1
5VY8	;	5.6	;	S. cerevisiae Hsp104-ADP complex
5VYA	;	4.0	;	S. cerevisiae Hsp104:casein complex, Extended Conformation
5VY9	;	6.7	;	S. cerevisiae Hsp104:casein complex, Middle Domain Conformation
6F0L	;	4.77	;	S. cerevisiae MCM double hexamer bound to duplex DNA
7TJF	;	2.6	;	S. cerevisiae ORC bound to 84 bp ARS1 DNA
7TJJ	;	2.7	;	S. cerevisiae ORC bound to 84 bp ARS1 DNA and Cdc6 (state 1) with docked Orc6 N-terminal domain
7TJH	;	2.5	;	S. cerevisiae ORC bound to 84 bp ARS1 DNA and Cdc6 (state 1) with flexible Orc6 N-terminal domain
7TJK	;	2.7	;	S. cerevisiae ORC bound to 84 bp ARS1 DNA and Cdc6 (state 2) with docked Orc6 N-terminal domain
7TJI	;	2.7	;	S. cerevisiae ORC bound to 84 bp ARS1 DNA and Cdc6 (state 2) with flexible Orc6 N-terminal domain
2PRZ	;	1.895	;	S. cerevisiae orotate phosphoribosyltransferase complexed with OMP
2PS1	;	1.75	;	S. cerevisiae orotate phosphoribosyltransferase complexed with orotic acid and PRPP
8U0V	;	3.89	;	S. cerevisiae Pex1/Pex6 with 1 mM ATP
8B9C	;	4.6	;	S. cerevisiae pol alpha - replisome complex
5I8Q	;	4.2	;	S. cerevisiae Prp43 in complex with RNA and ADPNP
8B9A	;	3.5	;	S. cerevisiae replisome + Ctf4, bound by pol alpha primase. Complex engaged with a fork DNA substrate containing a 60 nucleotide lagging strand.
8B9B	;	3.5	;	S. cerevisiae replisome + Ctf4, bound by pol alpha. Complex engaged with a fork DNA substrate containing a 60 nucleotide lagging strand.
7PMK	;	3.2	;	S. cerevisiae replisome-SCF(Dia2) complex bound to double-stranded DNA (conformation I)
7PMN	;	3.2	;	S. cerevisiae replisome-SCF(Dia2) complex bound to double-stranded DNA (conformation II)
1Z1A	;	2.5	;	S. cerevisiae Sir1 ORC-interaction domain
2FL7	;	1.85	;	S. cerevisiae Sir3 BAH domain
6N7P	;	3.6	;	S. cerevisiae spliceosomal E complex (UBC4)
5M5P	;	4.2	;	S. cerevisiae spliceosomal helicase Brr2 (271-end) in complex with the Jab/MPN domain of S. cerevisiae Prp8
6BK8	;	3.3	;	S. cerevisiae spliceosomal post-catalytic P complex
6BL7	;	2.5	;	S. cerevisiae stu2 coiled coil domain
1SW6	;	2.1	;	S. CEREVISIAE SWI6 ANKYRIN-REPEAT FRAGMENT
7NLH	;	2.8	;	S. cerevisiae Ty1 p22 restriction factor, Gag CA-CTD, AUG1 variant
7NLI	;	3.119	;	S. cerevisiae Ty1 p22 restriction factor, Gag CA-CTD, AUG2 variant
7NLG	;	3.528	;	S. cerevisiae Ty1 p22 restriction factor, Gag CA-CTD, AUG2 variant A273V mutant
6N7X	;	3.6	;	S. cerevisiae U1 snRNP
3O2U	;	2.003	;	S. cerevisiae Ubc12
5OJW	;	2.0	;	S. cerevisiae UBC13 - MMs2 complex
4FH1	;	2.61	;	S. cerevisiae Ubc13-N79A
5L6U	;	1.6	;	S. ENTERICA HISA MUTANT - D10G, DUP13-15, Q24L, G102A
5L9F	;	2.594	;	S. enterica HisA mutant - D10G, G11D, dup13-15, G44E, G102A
5G5I	;	2.001	;	S. enterica HisA mutant D10G
5G4E	;	2.65	;	S. enterica HisA mutant D10G, Dup13-15, Q24L, G102A, V106L
5G1Y	;	1.798	;	S. enterica HisA mutant D10G, dup13-15,V14:2M, Q24L, G102
5G2W	;	2.099	;	S. enterica HisA mutant D10G, G102A
5G4W	;	2.3	;	S. enterica HisA mutant D7N, D10G, Dup13-15 (VVR) with substrate ProFAR
5G2I	;	1.601	;	S. enterica HisA mutant Dup13-15(VVR)
5G1T	;	1.7	;	S. enterica HisA mutant dup13-15, D10G
5G2H	;	1.9	;	S. enterica HisA with mutation L169R
5AC8	;	1.699	;	S. enterica HisA with mutations D10G, dup13-15, G102A
5AC7	;	1.904	;	S. enterica HisA with mutations D7N, D10G, dup13-15
8T53	;	4.1	;	S. enterica WbaP in a styrene maleic acid liponanoparticle
5DJ7	;	0.87	;	S. erythraea trypsin acyl-enzyme
5KWM	;	0.777	;	S. erythraea trypsin long construct apoenzyme
5DKM	;	0.92	;	S. erythraea trypsin Michaelis-Menten complex
5DK1	;	0.938	;	S. erythraea trypsin mixed catalytic intermediate
5BQS	;	1.9	;	S. Pneumoniae Fabh with small molecule inhibitor 4
4HSB	;	1.9	;	S. pombe 3-methyladenine DNA glycosylase-like protein Mag2 bound to damaged DNA
4X01	;	2.201	;	S. pombe Ctp1 tetramerization domain
5MJS	;	4.6	;	S. pombe microtubule copolymerized with GTP and Mal3-143
6S8M	;	4.5	;	S. pombe microtubule decorated with Cut7 motor domain in the AMPPNP state
4GQ2	;	2.4	;	S. pombe Nup120-Nup37 complex
6OP8	;	1.703	;	S. pombe Ubc7/U7BR complex
6O82	;	2.604	;	S. pombe ubiquitin E1 complex with a ubiquitin-AMP mimic
6O83	;	3.153	;	S. pombe ubiquitin E1~ubiquitin-AMP tetrahedral intermediate mimic
5LW7	;	17.0	;	S. solfataricus ABCE1 post-splitting state
5TNU	;	3.05	;	S. tokodaii XPB II crystal structure at 3.0 Angstrom resolution
7KGN	;	3.6	;	S. Typhi YcbB - ertapenem complex
4IDJ	;	3.36	;	S.Aureus a-hemolysin monomer in complex with Fab
6EM9	;	8.4	;	S.aureus ClpC resting state, asymmetric map
6EM8	;	8.4	;	S.aureus ClpC resting state, C2 symmetrised
5Z9N	;	2.54	;	S.aureus GyrB ATPase domain in complex with 4,6-dichloro-2-(methylthio)pyrimidine
2AI9	;	2.5	;	S.aureus Polypeptide Deformylase
4QG7	;	1.67	;	S.aureus TMK in complex with a potent inhibitor compound 18, 2-(3-CHLOROPHENOXY)-3-METHOXY-4-{[(3S)-3-(5-METHYL-2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)PIPERIDIN-1-YL]METHYL}BENZOIC ACID
4QGA	;	1.94	;	S.aureus TMK in complex with potent inhibitor compound 19, 2-(3-CHLOROPHENOXY)-3-FLUORO-4-{[(3S)-3-(5-METHYL-2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)PIPERIDIN-1-YL]METHYL}BENZOIC ACID
4QGH	;	1.78	;	S.aureus TMK in complex with potent inhibitor compound 47
4QGF	;	1.83	;	S.aureus TMK in complex with the potent inhibitor compound 38, 2-(3-CHLOROPHENOXY)-3-METHOXY-4-{(1R)-1-[(3S)-3-(5-METHYL-2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)PIPERIDIN-1-YL]PROPYL}BENZOIC ACID
7QEN	;	3.46	;	S.c. Condensin core in DNA- and ATP-bound state
7QFW	;	3.86	;	S.c. Condensin peripheral Ycg1 subcomplex bound to DNA
6TRQ	;	2.944	;	S.c. Scavenger Decapping Enzyme DcpS in complex with the capped RNA dinucleotide m7G-GU
5AC6	;	1.993	;	S.enterica HisA mutant D10G, dup13-15, Q24L, G102A
5AB3	;	1.803	;	S.enterica HisA mutant D7N, D10G, dup13-15, Q24L, G102A
5ABT	;	1.65	;	S.enterica HisA mutant D7N, G102A, V106M, D176A
5G5Y	;	1.73	;	S.pneumoniae ABC-transporter substrate binding protein FusA apo structure
5G62	;	1.99	;	S.pneumoniae ABC-transporter substrate binding protein FusA EF-hand mutant in complex with fructo-nystose
5G61	;	2.4	;	S.pneumoniae ABC-transporter substrate binding protein FusA in complex with fructo-nystose
5G5Z	;	2.01	;	S.pneumoniae ABC-transporter substrate binding protein FusA in complex with kestose
5G60	;	1.99	;	S.pneumoniae ABC-transporter substrate binding protein FusA in complex with nystose
1G97	;	1.96	;	S.PNEUMONIAE GLMU COMPLEXED WITH UDP-N-ACETYLGLUCOSAMINE AND MG2+
4AAW	;	2.2	;	S.pneumoniae GlmU in complex with an antibacterial inhibitor
4AC3	;	2.1	;	S.pneumoniae GlmU in complex with an antibacterial inhibitor
2AIA	;	1.7	;	S.pneumoniae PDF complexed with SB-543668
2AI7	;	2.0	;	S.pneumoniae Polypeptide Deformylase complexed with SB-485345
2AIE	;	1.7	;	S.pneumoniae polypeptide deformylase complexed with SB-505684
4FCX	;	3.0	;	S.pombe Mre11 apoenzym
5FBC	;	1.75	;	S1 nuclease from Aspergillus oryzae in complex with 2'-deoxyadenosine-5'-thio-monophosphate (5'dAMP(S)).
7QTB	;	1.04	;	S1 nuclease from Aspergillus oryzae in complex with cytidine-5'-monophosphate
5FBA	;	1.8	;	S1 nuclease from Aspergillus oryzae in complex with phosphate
5FBD	;	1.75	;	S1 nuclease from Aspergillus oryzae in complex with phosphate and 2'-deoxycytidine
5FBB	;	1.75	;	S1 nuclease from Aspergillus oryzae in complex with phosphate and adenosine 5'-monophosphate
5FBF	;	1.04	;	S1 nuclease from Aspergillus oryzae in complex with two molecules of 2'-deoxycytidine-5'-monophosphate
7QTA	;	1.06	;	S1 nuclease from Aspergillus oryzae in complex with uridine
5FB9	;	1.5	;	S1 nuclease from Aspergillus oryzae with unoccupied active site
5FBG	;	1.97	;	S1 nuclease from Aspergillus oryzae, mutant D65N, in complex with phosphate, 2'-deoxycytidine and 2'-deoxyguanosine.
1SRO	;		;	S1 RNA BINDING DOMAIN, NMR, 20 STRUCTURES
7VHK	;	3.6	;	S1-S2 deletion S-2P trimer(3 down)
2WC8	;	1.88	;	S100A12 complex with zinc in the absence of calcium
2WCB	;	1.73	;	S100A12 complex with zinc in the absence of calcium
2K8M	;		;	S100A13-C2A binary complex structure
1CFP	;		;	S100B (S100BETA) NMR DATA WAS COLLECTED FROM A SAMPLE OF CALCIUM FREE PROTEIN AT PH 6.3 AND A TEMPERATURE OF 311 K AND 1.7-6.9 MM CONCENTRATION, 25 STRUCTURES
5CSF	;	2.4	;	S100B-RSK1 crystal structure A
5CSI	;	2.13	;	S100B-RSK1 crystal structure A'
5CSJ	;	2.7	;	S100B-RSK1 crystal structure B
5CSN	;	2.95	;	S100B-RSK1 crystal structure C
1QLS	;	2.3	;	S100C (S100A11),OR CALGIZZARIN, IN COMPLEX WITH ANNEXIN I N-TERMINUS
2Y5I	;	2.03	;	S100Z from zebrafish in complex with calcium
6LQ9	;	2.5	;	S109 in complex with CRM1-Ran-RanBP1
8AI9	;	1.7	;	S10T variant of glutathione transferase Chi 1 from Synechocystis sp. PCC 6803 in complex with glutathione
3NJI	;	1.8	;	S114A mutant of SO1698 protein, an aspartic peptidase from Shewanella oneidensis.
2HVE	;	2.402	;	S120G mutant of human nucleoside diphosphate kinase A complexed with ADP
1GN2	;	3.4	;	S123C mutant of the iron-superoxide dismutase from Mycobacterium tuberculosis.
8SOQ	;	3.1	;	S127A variant of LarB, a carboxylase/hydrolase involved in synthesis of the cofactor for lactate racemase, in complex with authentic substrate NaAD
8STD	;	2.65	;	S127A variant of LarB, a carboxylase/hydrolase involved in synthesis of the cofactor for lactate racemase, in complex with authentic substrate NaAD and soaked with CS2
4Z7U	;	2.7	;	S13 complex
1GT6	;	2.2	;	S146A mutant of Thermomyces (Humicola) lanuginosa lipase complex with oleic acid
8AAB	;	1.6	;	S148F mutant of blue-to-red fluorescent timer mRubyFT
1Q5P	;	1.6	;	S156E/S166D variant of Bacillus lentus subtilisin
4OZH	;	2.8	;	S16 protein complex
2UYB	;	2.1	;	S161A mutant of Bacillus subtilis Oxalate Decarboxylase OxdC
4IST	;	2.6	;	S177A Kluyveromyces lactis Allophanate Hydrolase
6CX2	;	3.101	;	S177G Mutant of Yeast PCNA
6CX3	;	3.101	;	S179T Mutant of Yeast PCNA
3UB4	;	3.1	;	S180L variant of TIR domain of Mal/TIRAP
3TGJ	;	2.2	;	S195A TRYPSINOGEN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI)
4MK4	;	2.5	;	S197C variant of human ferrochelatase.
4PEL	;	2.8	;	S1C mutant of Penicillin G acylase from Kluyvera citrophila
5EUD	;	2.24	;	S1P Lyase Bacterial Surrogate bound to N-(1-(4-(3-hydroxyprop-1-yn-1-yl)phenyl)-2-((4-methoxy-2,5-dimethylbenzyl)amino)ethyl)-5-methylisoxazole-3-carboxamide
5EUE	;	2.83	;	S1P Lyase Bacterial Surrogate bound to N-(2-((4-methoxy-2,5-dimethylbenzyl)amino)-1-phenylethyl)-5-methylisoxazole-3-carboxamide
7YUB	;	3.22	;	S1P-bound human SPNS2
2DCO	;		;	S1P4 First Extracellular Loop Peptidomimetic
8UDG	;	4.98	;	S1V2-72 Fab bound to EHA2 from influenza B/Malaysia/2506/2004
4OZI	;	3.2	;	S2 protein complex
6UCX	;	0.85	;	S2 symmetric peptide design number 1, Wednesday
6UD9	;	1.1	;	S2 symmetric peptide design number 2, Morticia
6UDR	;	1.0	;	S2 symmetric peptide design number 3 crystal form 1, Lurch
6UDW	;	1.1	;	S2 symmetric peptide design number 3 crystal form 2, Lurch
6UDZ	;	1.1	;	S2 symmetric peptide design number 4 crystal form 1, Pugsley
6UF4	;	1.1	;	S2 symmetric peptide design number 4 crystal form 2, Pugsley
6UF7	;	0.8	;	S2 symmetric peptide design number 5, Uncle Fester
6UF8	;	0.8	;	S2 symmetric peptide design number 6, London Bridge
1ES5	;	1.4	;	S216A MUTANT OF STREPTOMYCES K15 DD-TRANSPEPTIDASE
3ZGJ	;	1.95	;	S221M V223F Y359A mutant of 4-Hydroxymandelate synthase from Streptomyces coelicolor
1ESU	;	2.0	;	S235A MUTANT OF TEM1 BETA-LACTAMASE
1Q9K	;	1.96	;	S25-2 Fab Unliganded 1
1Q9L	;	2.28	;	S25-2 Fab Unliganded 2
3T77	;	1.739	;	S25-2- A(2-4)KDO disaccharide complex
3SY0	;	1.489	;	S25-2- A(2-8)-A(2-4)KDO trisaccharide complex
3T65	;	1.45	;	S25-2- A(2-8)KDO disaccharide complex
3T4Y	;	1.73	;	S25-2- KDO monosaccharide complex
6C5J	;	2.29	;	S25-23 Fab in complex with Chlamydiaceae LPS (Crystal form 1)
6C5K	;	1.75	;	S25-23 Fab in complex with Chlamydiaceae LPS (Crystal form 2)
6C5H	;	1.99	;	S25-5 Fab in complex with Chlamydiaceae-specific LPS antigen
1PQE	;	1.95	;	S25A mutant of pyruvoyl dependent aspartate decarboxylase
3WZX	;	1.9	;	S266A mutant 3-isopropylmalate dehydrogenase from Shewanella oneidensis MR-1 at 0.1MPa - complex with IPM and Mg
3WZY	;	1.55	;	S266A mutant 3-isopropylmalate dehydrogenase from Shewanella oneidensis MR-1 at 580MPa - complex with IPM and Mg
4JCF	;	2.2	;	S268F Variant of JC Polyomavirus Major Capsid Protein VP1 in Complex with LSTc
4JCD	;	2.0	;	S268Y Variant of JC Polyomavirus Major Capsid Protein VP1
4AHG	;	2.448	;	S28N - Angiogenin mutants and amyotrophic lateral sclerosis - a biochemical and biological analysis
8U8P	;	2.2	;	S292F Streptomyces coelicolor Laccase
7RNJ	;	2.67	;	S2P6 Fab fragment bound to the SARS-CoV/SARS-CoV-2 spike stem helix peptide
2KIH	;		;	S31N mutant of M2 proton channel
5L02	;	1.9	;	S324T variant of B. pseudomallei KatG
2KZQ	;		;	s34r Structure
1XT6	;	1.8	;	S35C Flavodoxin Mutant in the semiquinone state
6UF9	;	1.1	;	S4 symmetric peptide design number 1, Tim apo form
6UFA	;	0.77	;	S4 symmetric peptide design number 1, Tim zinc-bound form
1F3X	;	2.8	;	S402P MUTANT OF RABBIT MUSCLE PYRUVATE KINASE
7X26	;	3.685	;	S41 neutralizing antibody Fab(MERS-CoV)
2GKO	;	1.4	;	S41 Psychrophilic Protease
5CC1	;	2.302	;	S425G Glucocorticoid receptor DNA binding domain - (+)GRE complex
3G2G	;	2.0	;	S437Y Mutant of human muscle pyruvate kinase, isoform M2
1Q9W	;	1.75	;	S45-18 Fab pentasaccharide bisphosphate complex
1Q9O	;	1.79	;	S45-18 Fab Unliganded
1DF8	;	1.51	;	S45A MUTANT OF STREPTAVIDIN IN COMPLEX WITH BIOTIN
7U9N	;	2.2	;	S48A Horse Liver Alcohol Dehydrogenase in Complex with NADH and N-Cyclohexylformamide
7UQ9	;	1.4	;	S48T Horse Liver Alcohol Dehydrogenase in Complex with NADH and N-Cyclohexylformamide
1G88	;	3.0	;	S4AFL3ARG515 MUTANT
2LXE	;		;	S4wyild
7ZB1	;	2.0	;	S580A with 18mer
4B2V	;		;	S64, a spider venom toxin peptide from Sicarius dolichocephalus
1C96	;	1.81	;	S642A:CITRATE COMPLEX OF ACONITASE
1B0K	;	2.5	;	S642A:FLUOROCITRATE COMPLEX OF ACONITASE
1C97	;	1.98	;	S642A:ISOCITRATE COMPLEX OF ACONITASE
5N38	;	2.6	;	S65DParkin and pUB complex
1Q4B	;	1.48	;	S65T Q80R Green Fluorescent Protein (GFP) pH 5.5
1Q4A	;	1.45	;	S65T Q80R Green Fluorescent Protein (GFP) pH 8.5
1Q4D	;	1.58	;	S65T Q80R T203C Green Fluorescent Protein (GFP) pH 5.5
1Q4C	;	1.55	;	S65T Q80R T203C Green Fluorescent Protein (GFP) pH 8.5
1Q4E	;	1.38	;	S65T Q80R Y145C Green Fluorescent Protein (GFP) pH 8.5
1Q73	;	1.6	;	S65T Q80R Y145C T203C Green Fluorescent Protein (GFP) pH 8.5
3V92	;	2.74	;	S663A Stable-5-LOX
3V98	;	2.07	;	S663D Stable-5-LOX
3V99	;	2.252	;	S663D Stable-5-LOX in complex with Arachidonic Acid
4B2U	;		;	S67, A spider venom toxin peptide from Sicarius dolichocephalus
8D0Z	;	3.7	;	S728-1157 IgG in complex with SARS-CoV-2-6P-Mut7 Spike protein (focused refinement)
2GC6	;	1.9	;	S73A mutant of L. casei FPGS
3QEN	;	1.997	;	S74E dCK in complex with 5-bromodeoxycytidine and UDP
3QEJ	;	2.49	;	S74E-dCK mutant in complex with UDP
3QEO	;	1.897	;	S74E-R104M-D133A dCK variant in complex with L-deoxythymidine and UDP
6OC9	;		;	S8 phosphorylated beta amyloid 40 fibrils
1BGZ	;		;	S8 RRNA BINDING SITE FROM E. COLI, NMR, 6 STRUCTURES
6KYW	;	2.60113	;	S8-mSRK-S8-SP11 complex
1GKL	;	1.4	;	S954A mutant of the feruloyl esterase module from clostridium thermocellum complexed with ferulic acid
1WB4	;	1.4	;	S954A mutant of the feruloyl esterase module from clostridium thermocellum complexed with sinapinate
1WB5	;	1.4	;	S954A mutant of the feruloyl esterase module from clostridium thermocellum complexed with syringate
1WB6	;	1.4	;	S954A mutant of the feruloyl esterase module from clostridium thermocellum complexed with vanillate
1ES2	;	1.55	;	S96A mutant of streptomyces K15 DD-transpeptidase
1TPU	;	1.9	;	S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE
1TPV	;	1.9	;	S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE
6WJD	;	4.8	;	SA-like state of human 26S Proteasome with non-cleavable M1-linked hexaubiquitin and E3 ubiquitin ligase E6AP/UBE3A
6CY9	;	2.615	;	SA11 Rotavirus NSP2 with disulfide bridge
2H5S	;	1.28	;	SA2-13 penam sulfone complexed to wt SHV-1 beta-lactamase
7U97	;	2.66	;	SAAV pH 4.0 capsid structure
7U96	;	2.14	;	SAAV pH 5.5 capsid structure
7U95	;	2.73	;	SAAV pH 6.0 capsid structure
7U94	;	3.25	;	SAAV pH 7.4 capsid structure
3FWB	;	2.5	;	Sac3:Sus1:Cdc31 complex
3FWC	;	2.7	;	Sac3:Sus1:Cdc31 complex
4MBE	;	2.612	;	Sac3:Sus1:Cdc31:Nup1 complex
3T5V	;	2.9	;	Sac3:Thp1:Sem1 complex
4X2H	;	1.8	;	Sac3N peptide bound to Mex67:Mtr2
4X2O	;	1.85	;	Sac3N peptide bound to Mex67:Mtr2
5LSF	;	2.1	;	Sacbrood honeybee virus
5OYP	;	3.22	;	Sacbrood virus of honeybee
6EGV	;	3.18	;	Sacbrood virus of honeybee
6EGX	;	4.06	;	Sacbrood virus of honeybee - expansion state I
6EH1	;	7.25	;	Sacbrood virus of honeybee - expansion state II
6EIW	;	3.87	;	Sacbrood virus of honeybee empty particle
1TOB	;		;	SACCHARIDE-RNA RECOGNITION IN AN AMINOGLYCOSIDE ANTIBIOTIC-RNA APTAMER COMPLEX, NMR, 7 STRUCTURES
1NEM	;		;	Saccharide-RNA recognition in the neomycin B / RNA aptamer complex
1YPR	;	2.3	;	SACCHAROMYCES CEREVISIAE (YEAST) PROFILIN
6S47	;	3.28	;	Saccharomyces cerevisiae 80S ribosome bound with ABCF protein New1
5JUO	;	4.0	;	Saccharomyces cerevisiae 80S ribosome bound with elongation factor eEF2-GDP-sordarin and Taura Syndrome Virus IRES, Structure I (fully rotated 40S subunit)
5JUP	;	3.5	;	Saccharomyces cerevisiae 80S ribosome bound with elongation factor eEF2-GDP-sordarin and Taura Syndrome Virus IRES, Structure II (mid-rotated 40S subunit)
5JUS	;	4.2	;	Saccharomyces cerevisiae 80S ribosome bound with elongation factor eEF2-GDP-sordarin and Taura Syndrome Virus IRES, Structure III (mid-rotated 40S subunit)
5JUT	;	4.0	;	Saccharomyces cerevisiae 80S ribosome bound with elongation factor eEF2-GDP-sordarin and Taura Syndrome Virus IRES, Structure IV (almost non-rotated 40S subunit)
5JUU	;	4.0	;	Saccharomyces cerevisiae 80S ribosome bound with elongation factor eEF2-GDP-sordarin and Taura Syndrome Virus IRES, Structure V (least rotated 40S subunit)
5IMS	;	1.984	;	Saccharomyces cerevisiae acetohydroxyacid synthase
6BD3	;	2.28	;	Saccharomyces cerevisiae acetohydroxyacid synthase
6BD9	;	1.982	;	Saccharomyces cerevisiae acetohydroxyacid synthase
6U9D	;	3.194	;	Saccharomyces cerevisiae acetohydroxyacid synthase
5FEM	;	2.168	;	Saccharomyces cerevisiae Acetohydroxyacid Synthase in complex with bensulfuron methyl
5WKC	;	2.334	;	Saccharomyces cerevisiae acetohydroxyacid synthase in complex with the herbicide penoxsulam
1MR3	;	1.6	;	Saccharomyces cerevisiae ADP-ribosylation Factor 2 (ScArf2) complexed with GDP-3'P at 1.6A resolution
3KYH	;	3.0	;	Saccharomyces cerevisiae Cet1-Ceg1 capping apparatus
5HS1	;	2.1	;	Saccharomyces cerevisiae CYP51 (Lanosterol 14-alpha demethylase) complexed with Voriconazole
5ESJ	;	2.15	;	Saccharomyces cerevisiae CYP51 (Lanosterol 14-alpha demethylase) G464S mutant complexed with fluconazole
5ESK	;	2.24	;	Saccharomyces cerevisiae CYP51 (Lanosterol 14-alpha demethylase) G464S mutant complexed with itraconazole
5ESF	;	2.25	;	Saccharomyces cerevisiae CYP51 (Lanosterol 14-alpha demethylase) G73E mutant complexed with fluconazole
5ESG	;	1.981	;	Saccharomyces cerevisiae CYP51 (Lanosterol 14-alpha demethylase) G73E mutant complexed with itraconazole
5ESE	;	2.2	;	Saccharomyces cerevisiae CYP51 (Lanosterol 14-alpha demethylase) G73R mutant complexed with fluconazole
5ESI	;	2.1	;	Saccharomyces cerevisiae CYP51 (Lanosterol 14-alpha demethylase) G73W mutant
5ESH	;	2.15	;	Saccharomyces cerevisiae CYP51 (Lanosterol 14-alpha demethylase) G73W mutant in complex with itraconazole
5ESM	;	2.0	;	Saccharomyces cerevisiae CYP51 (Lanosterol 14-alpha demethylase) T322I mutant complexed with fluconazole
5ESL	;	2.35	;	Saccharomyces cerevisiae CYP51 (Lanosterol 14-alpha demethylase) T322I mutant complexed with itraconazole
5ESN	;	2.35	;	Saccharomyces cerevisiae CYP51 (Lanosterol 14-alpha demethylase) T322I mutant structure
4ZDZ	;	2.3	;	Saccharomyces cerevisiae CYP51 (Lanosterol 14-alpha demethylase) Y140F mutant complexed with fluconazole
4ZDY	;	2.02	;	Saccharomyces cerevisiae CYP51 (Lanosterol 14-alpha demethylase) Y140F mutant complexed with itraconazole
4ZE0	;	2.2	;	Saccharomyces cerevisiae CYP51 (Lanosterol 14-alpha demethylase) Y140F mutant complexed with Voriconazole
4ZE3	;	2.2	;	Saccharomyces cerevisiae CYP51 (Lanosterol 14-alpha demethylase) Y140H mutant complexed with fluconazole
4ZE2	;	2.3	;	Saccharomyces cerevisiae CYP51 (Lanosterol 14-alpha demethylase) Y140H mutant complexed with itraconazole
5EAH	;	2.541	;	Saccharomyces cerevisiae CYP51 complexed with the plant pathogen inhibitor Difenoconazole
5EAF	;	2.65	;	Saccharomyces cerevisiae CYP51 complexed with the plant pathogen inhibitor Fluquinconazole
5EAG	;	2.4	;	Saccharomyces cerevisiae CYP51 complexed with the plant pathogen inhibitor Prochloraz
5EAE	;	2.11	;	Saccharomyces cerevisiae CYP51 complexed with the plant pathogen inhibitor R-desthio-prothioconazole
5EAC	;	2.26	;	Saccharomyces cerevisiae CYP51 complexed with the plant pathogen inhibitor R-tebuconazole
5EAD	;	2.0	;	Saccharomyces cerevisiae CYP51 complexed with the plant pathogen inhibitor S-desthio-prothioconazole
5EAB	;	2.6	;	Saccharomyces cerevisiae CYP51 complexed with the plant pathogen inhibitor S-tebuconazole
4ZE1	;	2.05	;	Saccharomyces cerevisiae CYP51 Y140F mutant complexed with posaconazole in the active site
2QB8	;	1.9	;	Saccharomyces cerevisiae cytosolic exopolyphosphatase, ATP complex
2QB7	;	1.6	;	Saccharomyces cerevisiae cytosolic exopolyphosphatase, phosphate complex
2QB6	;	1.8	;	Saccharomyces cerevisiae cytosolic exopolyphosphatase, sulfate complex
3HMJ	;	4.0	;	Saccharomyces cerevisiae FAS type I
5FIH	;	1.8	;	SACCHAROMYCES CEREVISIAE GAS2P (E176Q MUTANT) IN COMPLEX WITH LAMINARITETRAOSE AND LAMINARIPENTAOSE
2W61	;	1.62	;	Saccharomyces cerevisiae Gas2p apostructure (E176Q mutant)
2W62	;	1.85	;	Saccharomyces cerevisiae Gas2p in complex with laminaripentaose
2W63	;	1.9	;	SACCHAROMYCES CEREVISIAE GAS2P IN COMPLEX WITH LAMINARITRIOSE AND LAMINARITETRAOSE
3IG5	;	2.1	;	Saccharomyces cerevisiae glutamate cysteine ligase in complex with Mg2+ and L-glutamate
3IG8	;	2.69	;	Saccharomyces cerevisiae glutamate cysteine ligase in complex with Mg2+, L-glutamate and ADP
2JKZ	;	3.45	;	SACCHAROMYCES CEREVISIAE HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE IN COMPLEX WITH GMP (GUANOSINE 5'- MONOPHOSPHATE) (ORTHORHOMBIC CRYSTAL FORM)
2JKY	;	2.3	;	SACCHAROMYCES CEREVISIAE HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE IN COMPLEX WITH GMP (GUANOSINE 5'- MONOPHOSPHATE) (TETRAGONAL CRYSTAL FORM)
2XBU	;	1.8	;	Saccharomyces cerevisiae hypoxanthine-guanine phosphoribosyltransferase in complex with GMP (monoclinic crystal form)
7ZTS	;	16.0	;	Saccharomyces cerevisiae L-BC virus, open particle, asymmetric reconstruction
7ZUF	;	10.0	;	Saccharomyces cerevisiae L-BC virus, open particle, C5 reconstruction
4LXJ	;	1.9	;	Saccharomyces cerevisiae lanosterol 14-alpha demethylase with lanosterol bound
3B54	;	3.1	;	Saccharomyces cerevisiae nucleoside diphosphate kinase
5V4V	;	1.798	;	Saccharomyces cerevisiae Old Yellow Enzyme 3
5ZR1	;	3.0	;	Saccharomyces Cerevisiae Origin Recognition Complex Bound to a 72-bp Origin DNA containing ACS and B1 element
5V4P	;	1.88	;	Saccharomyces cerevisiae OYE 3 soaked with p-hydroxybenzaldehyde
7T9X	;	1.52	;	Saccharomyces cerevisiae Pex12 RING domain
4PGM	;	2.3	;	SACCHAROMYCES CEREVISIAE PHOSPHOGLYCERATE MUTASE
5PGM	;	2.12	;	SACCHAROMYCES CEREVISIAE PHOSPHOGLYCERATE MUTASE
1BQ4	;	2.5	;	SACCHAROMYCES CEREVISIAE PHOSPHOGLYCERATE MUTASE IN COMPLEX WITH BENZENE HEXACARBOXYLATE
1BQ3	;	2.7	;	SACCHAROMYCES CEREVISIAE PHOSPHOGLYCERATE MUTASE IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
6GIQ	;	3.23	;	Saccharomyces cerevisiae respiratory supercomplex III2IV
6N7R	;	3.2	;	Saccharomyces cerevisiae spliceosomal E complex (ACT1)
7OQE	;	5.9	;	Saccharomyces cerevisiae spliceosomal pre-A complex (delta BS-A ACT1)
3FPZ	;	1.82	;	Saccharomyces cerevisiae THI4p is a suicide thiamin thiazole synthase
8DAW	;	3.6	;	Saccharomyces cerevisiae Ufd1/Npl4/Cdc48 complex bound to three ubiquitin moieties and one unfolded ubiquitin in presence of SUMO-ubiquitin(K48polyUb)-mEOS and ATP, state 2 (uD)
8DAT	;	3.8	;	Saccharomyces cerevisiae Ufd1/Npl4/Cdc48 complex bound to three ubiquitin moieties in presence of SUMO-ubiquitin(K48polyUb)-mEOS and ATP, state 1 (intB)
8DAU	;	3.7	;	Saccharomyces cerevisiae Ufd1/Npl4/Cdc48 complex bound to two folded ubiquitin moieties and one unfolded ubiquitin in presence of SUMO-ubiquitin(K48polyUb)-mEOS and ATP, state 1 (uA)
8DAV	;	3.5	;	Saccharomyces cerevisiae Ufd1/Npl4/Cdc48 complex bound to two ubiquitin moieties and one unfolded ubiquitin in presence of SUMO-ubiquitin(K48polyUb)-mEOS and ATP, state 2 (uC)
8DAS	;	3.5	;	Saccharomyces cerevisiae Ufd1/Npl4/Cdc48 complex bound to two ubiquitin moieties in presence of SUMO-ubiquitin(K48polyUb)-mEOS and ATP, state 1 (intA)
8DAR	;	3.0	;	Saccharomyces cerevisiae Ufd1/Npl4/Cdc48 complex unbound but in the presence of SUMO-ubiquitin(K48polyUb)-mEOS and ATP
6O7V	;	6.6	;	Saccharomyces cerevisiae V-ATPase Stv1-V1VO State 1
6O7W	;	7.0	;	Saccharomyces cerevisiae V-ATPase Stv1-V1VO State 2
6O7X	;	8.7	;	Saccharomyces cerevisiae V-ATPase Stv1-V1VO State 3
6O7U	;	3.1	;	Saccharomyces cerevisiae V-ATPase Stv1-VO
6O7T	;	3.2	;	Saccharomyces cerevisiae V-ATPase Vph1-VO
8J2W	;	1.7	;	Saccharothrix syringae photocobilins protein, dark state
8J2X	;	1.98	;	Saccharothrix syringae photocobilins protein, light state
3UL5	;	2.3	;	Saccharum officinarum canecystatin-1 in space group C2221
3UL6	;	2.63	;	Saccharum officinarum canecystatin-1 in space group P6422
4GLE	;	2.7	;	SacUVDE in complex with 6-4PP-containing DNA
6H6S	;	1.45	;	Sad phasing on nickel-substituted human carbonic anhydrase II
2FPD	;	2.05	;	Sad structure determination: crystal structure of the intrinsic dimerization sh3 domain of the ib1 scaffold protein
6SIJ	;	1.61018	;	SAD structure of Hen Egg White Lysozyme recovered by continuous rotation data collection and multivariate analysis of Friedel pairs
6SIK	;	1.61007	;	SAD structure of Hen Egg White Lysozyme recovered by continuous rotation data collection and univariate analysis
6SIL	;	1.61018	;	SAD structure of Hen Egg White Lysozyme recovered by inverse beam geometry data collection and multivariate analysis of Friedel pairs
6SIM	;	1.61018	;	SAD structure of Hen Egg White Lysozyme recovered by inverse beam geometry data collection and univariate analysis
6SHO	;	3.20008	;	SAD structure of Human Survivin recovered by continuous rotation data collection and multivariate analysis of Friedel pairs
5A3Y	;	1.27	;	SAD structure of Thermolysin obtained by multi crystal data collection
3L1K	;	1.55	;	SAD structure solution of proteinase K grown in potassium tellurate solution
2V8B	;	0.94	;	SAD Structure solution of Proteinase K grown in selenate solution
2V0B	;	1.65	;	SAD Structure solution porcine pancreatic elastase from a Selenate derivative
4WXO	;	2.805	;	SadC (300-487) from Pseudomonas aeruginosa PAO1
4WXW	;	1.8	;	SadC (323-487) from Pseudomonas aeruginosa PAO1
6EN8	;	3.29	;	SaFadR in complex with dsDNA
6EL2	;	1.9	;	SaFadR_lauroyl_CoA complex
7ON4	;	1.79	;	SaFtsZ complexed with GDP (co-crystalization with 1mM EDTA)
7OI2	;	1.9	;	SaFtsz complexed with GDP (NaCl purification)
7ON3	;	2.32	;	SaFtsZ complexed with GDP (soak 10 mM EGTA)
7ON2	;	1.69	;	SaFtsZ complexed with GDP (soaking in 10 mM CyDTA)
7OHH	;	1.45	;	SaFtsZ complexed with GDP and BeF3-
7OHN	;	1.62	;	SaFtsZ complexed with GDP, AlF4- and Mg2+
7OHK	;	1.75	;	SaFtsZ complexed with GDP, BeF3- and Mg2+
7OHL	;	1.75	;	SaFtsZ complexed with GDP, BeF3- and Mn2+
7OMJ	;	1.57	;	SaFtsZ complexed with GDPPCP
7OMP	;	1.52	;	SaFtsZ complexed with GDPPCP and Mg2+
7OMQ	;	1.45	;	SaFtsZ complexed with GDPPCP and Mn2+
7OJZ	;	1.65	;	SaFtsZ complexed with GMPCP
7OJA	;	2.22	;	SaFtsZ(D210N) complexed with GDP
7OJD	;	1.82	;	SaFtsZ(D46A) complexed with GDP
7OJC	;	1.95	;	SaFtsZ(Q48A) complexed with GDP
7OJB	;	1.7	;	SaFtsZ(R143K) complexed with GDP
6YD1	;	1.7	;	SaFtsZ-DFMBA
6RVQ	;	1.136	;	SaFtsz-GDP-EthGLy
6RVP	;	1.16	;	SaFtsz-GDP-MetPyr
6YD5	;	1.55	;	SaFtsZ-UCM151 (comp. 18)
6YD6	;	1.7	;	SaFtsZ-UCM152 (comp.20)
6T9K	;	3.3	;	SAGA Core module
6T9L	;	3.6	;	SAGA DUB module bound to a ubiqitinated nucleosome
6AQR	;	2.1	;	SAGA DUB module Ubp8(C146A)/Sgf11/Sus1/Sgf73 bound to monoubiquitin
4ZUX	;	3.82	;	SAGA DUB module Ubp8/Sgf11/Sus1/Sgf73 bound to ubiqitinated nucleosome
6T9J	;	3.4	;	SAGA Tra1 module
5FAD	;	1.87	;	SAH complex with aKMT from the hyperthermophilic archaeon Sulfolobus islandicus
8HAR	;	2.12	;	SAH-bound C-Methyltransferase Fur6 from Streptomyces sp. KO-3988
1A48	;	1.9	;	SAICAR SYNTHASE
4O81	;	2.1	;	SAICAR synthetase (Type-1) in complex with ADP AND AMP
4O82	;	2.16	;	SAICAR synthetase (Type-1) in complex with ADP AND AMP in both chains
4O83	;	2.05	;	SAICAR synthetase (Type-1) in complex with ADP/AMP
4O84	;	2.09	;	SAICAR synthetase (Type-1) in complex with GMP
4O7L	;	2.1	;	SAICAR synthetase (Type-2) in complex with ADP
4O7N	;	2.16	;	SAICAR synthetase (Type-2) in complex with ADP
4O86	;	2.2	;	SAICAR synthetase (Type-2) in complex with ADP and CDP
4O7V	;	2.3	;	SAICAR synthetase (Type-2) in complex with ADP and UDP/UMP
4O7T	;	2.1	;	SAICAR synthetase (Type-2) in complex with ADP, ASP and TMP
4O7W	;	2.2	;	SAICAR synthetase (Type-2) in complex with ATP and TDP
4O7Y	;	2.0	;	SAICAR synthetase (Type-2) in complex with CMP
4O7Z	;	2.3	;	SAICAR synthetase (Type-2) in complex with GMP
4O7S	;	2.24	;	SAICAR synthetase (Type-2) in complex with TMP/TDP
4O7R	;	2.35	;	SAICAR synthetase (Type-2) in complex with UMP/UDP
2GQR	;	2.0	;	SAICAR Synthetase Complexed with ADP-Mg2+
2GQS	;	2.05	;	SAICAR Synthetase Complexed with CAIR-Mg2+ and ADP
1OBD	;	1.4	;	SAICAR-synthase complexed with ATP
1OBG	;	2.05	;	SAICAR-synthase complexed with ATP
2CNV	;	2.0	;	SAICAR-synthase from Saccharomyces cerevisiae complexed SAICAR
7CYB	;	1.6	;	Saimiri boliviensis boliviensis galectin-13 with glycerol
7CYA	;	1.71	;	Saimiri boliviensis boliviensis galectin-13 with lactose
1OHM	;		;	Sakacin P variant that is structurally stabilized by an inserted C-terminal disulfide bridge.
8F9Y	;	2.6	;	SAL1 from Arabidopsis thaliana
8S9R	;	2.6	;	SAL2, Staphylococcus aureus lipase 2 (geh, lip2), apo form
7TZ4	;	1.69	;	Salicylate Adenylate PchD from Pseudomonas aeruginosa containing 4-cyanosalicyl-AMS
7TYB	;	2.11	;	Salicylate Adenylate PchD from Pseudomonas aeruginosa containing salicyl-AMS
3RET	;	1.79	;	Salicylate and Pyruvate Bound Structure of the Isochorismate-Pyruvate Lyase K42E Mutant from Pseudomonas aerugionsa
5EVY	;	2.47	;	Salicylate hydroxylase substrate complex
3SKV	;	2.49	;	Salicylyl-Acyltransferase SsfX3 from a Tetracycline Biosynthetic Pathway
5ODN	;	2.598	;	Salinibacter ruber Single-Strand Binding protein
5ODP	;	2.535	;	Salinibacter ruber Single-Strand Binding protein D17K D71K mutant
7KC8	;	2.3	;	Salivary protein from Culex quinquefasciatus that belongs to the Cysteins and Tryptophan-Rich (CWRC) family
7KCG	;	1.87	;	Salivary protein from Culex quiquefasciatus that belongs to the Cysteine and Tryptophan-Rich (CWRC) family
3Q6K	;	2.52	;	Salivary protein from Lutzomyia longipalpis
3Q6T	;	2.93	;	Salivary protein from Lutzomyia longipalpis, Ligand free
3Q6P	;	2.75	;	Salivary protein from Lutzomyia longipalpis. Selenomethionine derivative
2Q6L	;	2.72	;	SalL double mutant Y70T/G131S with CLDA and L-MET
2Q6K	;	1.55	;	SalL with adenosine
6RZ2	;	1.77	;	SalL with Chloroadenosine
2Q6I	;	2.6	;	salL with ClDA and LMet
6RYZ	;	1.5	;	SalL with S-adenosyl methionine
2Q6O	;	2.0	;	SalL-Y70T with SAM and Cl
6Z12	;	4.6	;	Salmonella AcrB solubilised in the SMA copolymer
8GJH	;	3.6	;	Salmonella ArnA
6RAD	;	2.796	;	Salmonella ATPase InvC with ADP
6SDX	;	2.645	;	Salmonella ATPase InvC with ATP gamma S
5LQ7	;	1.6	;	Salmonella effector SpvD - G161 variant
5LQ6	;	1.48	;	Salmonella effector SpvD - R161 variant
6AYH	;	2.05	;	Salmonella enterica GusR
7ZHL	;	2.2	;	Salmonella enterica Rhs1 C-terminal toxin TreTu
7ZHM	;	2.7	;	Salmonella enterica Rhs1 C-terminal toxin TreTu complex with TriTu immunity protein
2YO1	;	3.1	;	Salmonella enterica SadA 1049-1304 fused to GCN4 adaptors (SadAK9- cfII)
2YO0	;	2.8	;	Salmonella enterica SadA 1049-1304 fused to GCN4 adaptors (SadAK9-cfI)
2YO3	;	2.0	;	Salmonella enterica SadA 1185-1386 fused to GCN4 adaptors (SadAK14)
2YNY	;	1.35	;	Salmonella enterica SadA 255-302 fused to GCN4 adaptors (SadAK1)
2YO2	;	2.0	;	Salmonella enterica SadA 255-358 fused to GCN4 adaptors (SadAK12)
3ZMF	;	1.85	;	Salmonella enterica SadA 303-358 fused to GCN4 adaptors (SadAK2)
2WPQ	;	1.85	;	Salmonella enterica SadA 479-519 fused to GCN4 adaptors (SadAK3, in- register fusion)
2WPR	;	2.65	;	Salmonella enterica SadA 483-523 fused to GCN4 adaptors (SadAK3b-V1, out-of-register fusion)
2WPS	;	2.6	;	Salmonella enterica SadA 483-523 fused to GCN4 adaptors (SadAK3b-V2, out-of-register fusion)
2YNZ	;	1.4	;	Salmonella enterica SadA 823-947 fused to a GCN4 adaptor (SadAK5)
2CO4	;	1.85	;	Salmonella enterica SafA pilin in complex with a 19-residue SafA Nte peptide
2CO1	;	2.4	;	Salmonella enterica SafA pilin in complex with a 19-residue SafA Nte peptide (F17A mutant)
2CO2	;	2.3	;	Salmonella enterica SafA pilin in complex with a 19-residue SafA Nte peptide (F3A mutant)
2CNY	;	1.9	;	Salmonella enterica SafA pilin in complex with a 19-residue SafA Nte peptide (I15A mutant)
2CNZ	;	1.8	;	Salmonella enterica SafA pilin in complex with a 19-residue SafA Nte peptide (V13A mutant)
2CO6	;	2.0	;	Salmonella enterica SafA pilin in complex with the SafB chaperone (Type I)
2CO7	;	1.8	;	Salmonella enterica SafA pilin in complex with the SafB chaperone (Type II)
2CO3	;	1.78	;	Salmonella enterica SafA pilin, head-to-tail swapped dimer of Ntd1 mutant
4C47	;	2.448	;	Salmonella enterica trimeric lipoprotein SadB
8VL8	;	2.5	;	Salmonella enterica Typhimurium taxis to serine and repellents (Tsr) ligand-binding domain with L-Ser, pH 7
7BIN	;	3.2	;	Salmonella export gate and rod refined in focussed C1 map
7BJ2	;	3.0	;	Salmonella flagellar basal body assembly intermediate - P ring alone structure
7NVG	;	3.7	;	Salmonella flagellar basal body refined in C1 map
7BK0	;	3.8	;	Salmonella FliF ring (34mer) in intact basal body - C1
5I5F	;	1.84	;	Salmonella global domain 191
5I5D	;	1.64	;	Salmonella global domain 245
6K3I	;	2.86	;	Salmonella hook in curved state - 66 subunit models
7BGL	;	2.2	;	Salmonella LP ring 26 mer refined in C26 map
4KR4	;	3.8	;	Salmonella typhi OmpF complex with Ampicillin
4KRA	;	3.32	;	Salmonella typhi OmpF complex with Ciprofloxacin
4KR8	;	3.1	;	Salmonella typhi OmpF complex with Daunomycin
3UU2	;	3.59	;	Salmonella typhi osmoporin(OmpC):an Outer Membrane Protein
6P4P	;	2.0	;	Salmonella typhi PltB Homopentamer N29K Mutant
6P4Q	;	1.77	;	Salmonella typhi PltB Homopentamer N29K Mutant with Neu5Ac-alpha-2-3-Gal-beta-1-4-GlcNAc Glycans
6P4R	;	1.87	;	Salmonella typhi PltB Homopentamer N29K Mutant with Neu5Ac-alpha-2-6-Gal-beta-1-4-GlcNAc glycans
6P4S	;	2.0	;	Salmonella typhi PltB Homopentamer T65I Mutant
6P4T	;	2.17	;	Salmonella typhi PltB Homopentamer T65I Mutant with Neu5Ac-alpha-2-3-Gal-beta-1-4-GlcNAc Glycans
6TYO	;	2.04	;	Salmonella Typhi PltB Homopentamer with Neu-5NAc-4OAc-alpha-2-3-Gal-beta-1-4-GlcNAc Glycans
6TYN	;	2.33	;	Salmonella Typhi PltB Homopentamer with Neu-5NAc-9OAc-alpha-2-3-Gal-beta-1-4-GlcNAc Glycans
6TYQ	;	1.88	;	Salmonella Typhi PltB Homopentamer with Neu-5NAc-9OAc-alpha-2-6-Gal-beta-1-4-GlcNAc Glycans
6P4M	;	1.802	;	Salmonella typhi PltB Homopentamer with Neu5Ac-alpha-2-3-Gal-beta-1-4-GlcNAc Glycans
6P4N	;	1.7	;	Salmonella typhi PltB Homopentamer with Neu5Ac-alpha-2-6-Gal-beta-1-4-GlcNAc Glycans
6A02	;	1.4	;	Salmonella Typhi YfdX in the F222 space group at 1.4 A resolution
6A07	;	1.501	;	Salmonella Typhi YfdX in the F222 space group at 1.5 A resolution
6A09	;	2.293	;	Salmonella Typhi YfdX in the P222 space group
4XS4	;	2.65	;	Salmonella typhimurium AhpC C165S mutant
5UKA	;	1.9	;	Salmonella typhimurium AhpC E49Q mutant
4XTS	;	2.704	;	Salmonella typhimurium AhpC T43A mutant
4XRA	;	1.75	;	Salmonella typhimurium AhpC T43S mutant
4XS1	;	2.1	;	Salmonella typhimurium AhpC T43V mutant
4XRD	;	2.3	;	Salmonella typhimurium AhpC W169F mutant
4XS6	;	3.35	;	Salmonella typhimurium AhpC W81F mutant
8T0J	;	2.59	;	Salmonella Typhimurium ArnD
4D92	;	2.22	;	Salmonella typhimurium D-Cysteine desulfhydrase soaked with beta-chloro-D-alanine shows pyruvate bound 4 A away from active site
4D8W	;	2.01	;	Salmonella typhimurium D-Cysteine desulfhydrase soaked with D-cys shows pyruvate bound 4 A away from active site
4D97	;	1.77	;	Salmonella typhimurium D-Cysteine desulfhydrase with D-ser bound at active site
4D99	;	2.01	;	Salmonella typhimurium D-Cysteine desulfhydrase with L-ser bound non-covalently at the active site
8EWH	;	2.33	;	Salmonella typhimurium GTPase BIPA
2I8A	;	1.64	;	Salmonella typhimurium liganded by phosphate ion at 1.64A resolution
6TVI	;	1.0	;	Salmonella typhimurium mutant neuraminidase (D100S)+ DANA
7AEY	;	0.919	;	Salmonella typhimurium neuraminidase in complex with isocarba-DANA.
6TRG	;	1.0	;	Salmonella typhimurium neuraminidase mutant (D100S)
7AF2	;	0.792	;	Salmonella typhimurium neuraminidase mutant (D62G)
6XE3	;	1.55	;	Salmonella typhimurium Tryptophan Synthase beta-S377A mutant in complex with inhibitor F9 at the enzyme alpha-site, cesium ion at the metal coordination site and carbanion III E(C3) at the enzyme beta-site.
6XOY	;	1.64	;	Salmonella typhimurium tryptophan synthase complexed with D-tryptophan and D-glycerol-3-phosphate
6XT0	;	1.37	;	Salmonella typhimurium tryptophan synthase complexed with dioxindolyl-L-alanine and D-glycerol-3-phosphate
6XNC	;	2.11	;	Salmonella typhimurium tryptophan synthase complexed with L-tryptophan and D-glycerol-3-phosphate
6XRH	;	1.44	;	Salmonella typhimurium tryptophan synthase complexed with oxindolyl-L-alanine and D-glycerol-3-phosphate
5IHF	;	1.576	;	Salmonella Typhimurium VirG-like (STV) protein
5IO8	;	2.192	;	Salmonella Typhimurium VirG-like (STV) protein at 2.19 Angstrom resolution solved by Iodine SAD.
6SA4	;	1.77	;	SALSA / DMBT1 / GP340 SRCR domain 1
6SA5	;	1.29	;	SALSA / DMBT1 / GP340 SRCR domain 8
6SAN	;	1.36	;	SALSA / DMBT1 / GP340 SRCR domain 8 soaked in calcium and magnesium
8R4O	;	2.725	;	Salt inducible kinase 3 in complex with inhibitor
8R4Q	;	2.838	;	Salt inducible kinase 3 in complex with inhibitor
8OKU	;	3.1	;	Salt-Inducible Kinase 3 in complex with an inhibitor
6BN1	;	2.6	;	Salvador Hippo SARAH domain complex
7X2Q	;	3.68	;	Salvia miltiorrhiza CYP76AH3
5FA8	;	1.3	;	SAM complex with aKMT from the hyperthermophilic archaeon Sulfolobus islandicu
1UQV	;		;	SAM domain from Ste50p
3BQ7	;	2.9	;	SAM domain of Diacylglycerol Kinase delta1 (E35G)
3HIL	;	2.0	;	SAM Domain of Human Ephrin Type-A Receptor 1 (EphA1)
3H8M	;	2.1	;	SAM domain of human ephrin type-a receptor 7 (EPHA7)
5D4U	;	2.0	;	SAM-bound HcgC from Methanocaldococcus jannaschii
6UET	;	4.1	;	SAM-bound SAM-IV riboswitch
8TJK	;	1.85	;	SAM-dependent methyltransferase RedM bound to SAH
8TJJ	;	1.82	;	SAM-dependent methyltransferase RedM bound to SAM
8TJI	;	1.73	;	SAM-dependent methyltransferase RedM, apo
4B5R	;	2.95	;	SAM-I riboswitch bearing the H. marismortui K-t-7
5FK5	;	3.315	;	SAM-I riboswitch bearing the H. marismortui Kt-7 variant 3bn is AA
5FK6	;	2.5	;	SAM-I riboswitch bearing the H. marismortui Kt-7 variant 3bn is CA
5FK3	;	2.5	;	SAM-I riboswitch bearing the H. marismortui Kt-7 variant 3bn is CC
5FKG	;	2.95	;	SAM-I riboswitch bearing the H. marismortui Kt-7 variant 3bn is CG
5FKH	;	2.65	;	SAM-I riboswitch bearing the H. marismortui Kt-7 variant 3bn is CU
5FK2	;	2.6	;	SAM-I riboswitch bearing the H. marismortui Kt-7 variant 3bn is GG
5FKE	;	2.8	;	SAM-I riboswitch bearing the H. marismortui Kt-7 variant 3bn is GU
5FKD	;	3.0	;	SAM-I riboswitch bearing the H. marismortui Kt-7 variant 3bn is UA
5FKF	;	2.8	;	SAM-I riboswitch bearing the H. marismortui Kt-7 variant 3bn is UC
5FK1	;	2.5	;	SAM-I riboswitch bearing the H. marismortui Kt-7 variant 3bn is UG
5FK4	;	2.43	;	SAM-I riboswitch bearing the H. marismortui Kt-7 variant 3bn is UU
5FJC	;	1.71	;	SAM-I riboswitch bearing the H. marismortui Kt-7 variant C-2bU
4AOB	;	2.95	;	SAM-I riboswitch containing the T. solenopsae Kt-23 in complex with S- adenosyl methionine
3IQP	;	2.9	;	SAM-I riboswitch from T. tencongensis variant A94G apo form
3IQR	;	2.55	;	SAM-I riboswitch from T. tencongensis variant A94G bound with SAM
2YGH	;	2.6	;	SAM-I riboswitch with a G2nA mutation in the Kink turn in complex with S-adenosylmethionine
2QWY	;	2.8	;	SAM-II riboswitch bound to S-adenosylmethionine
6C27	;	3.601	;	SAM-III riboswitch ON-state
6WLR	;	4.8	;	SAM-IV riboswitch with SAM models, 4.8 Angstrom resolution
7Z89	;	2.76	;	Sam68
7Z8A	;	2.06	;	Sam68
7Z9A	;	2.57	;	Sam68
7Z9B	;	3.333	;	Sam68
7ZAB	;	2.46	;	Sam68
7ZAC	;	2.08	;	Sam68
7ZAF	;	2.71	;	Sam68
7ZAM	;	2.79	;	Sam68
3CA0	;	1.95	;	Sambucus nigra agglutinin II (SNA-II), hexagonal crystal form
3C9Z	;	1.35	;	Sambucus nigra agglutinin II (SNA-II), tetragonal crystal form
3CA1	;	1.55	;	Sambucus nigra agglutinin II (SNA-II)- tetragonal crystal form- complexed to galactose
3CA6	;	1.4	;	Sambucus nigra agglutinin II (SNA-II)- tetragonal crystal form- complexed to Tn antigen
3CA4	;	1.55	;	Sambucus nigra agglutinin II, tetragonal crystal form- complexed to lactose
3CAH	;	1.55	;	Sambucus nigra aggutinin II. tetragonal crystal form- complexed to fucose
6DW4	;	1.99	;	SAMHD1 Bound to Cladribine-TP in the Catalytic Pocket and Allosteric Pocket
6DWD	;	1.7	;	SAMHD1 Bound to Clofarabine-TP in the Catalytic Pocket and Allosteric Pocket
6DW3	;	2.2	;	SAMHD1 Bound to Cytarabine-TP in the Catalytic Pocket
6DWK	;	2.3	;	SAMHD1 Bound to Fludarabine-TP in the Catalytic Pocket
6DW5	;	1.93	;	SAMHD1 Bound to Gemcitabine-TP in the Catalytic Pocket
6DWJ	;	2.5	;	SAMHD1 Bound to Vidarabine-TP in the Catalytic Pocket
7S2Y	;	2.8	;	SAMHD1 HD domain bound to CNDAC
6CM2	;	2.14	;	SAMHD1 HD domain bound to decitabine triphosphate
6DW7	;	2.5	;	SAMHD1 without Catalytic Nucleotides
7LTT	;	1.9	;	SAMHD1(113-626) H206R D207N R366C
7LU5	;	3.57	;	SAMHD1(113-626) H206R D207N R366H
8D94	;	2.44	;	SAMHD1-DNA complex
8D9J	;	2.82	;	SAMHD1-DNA complex
7TJQ	;	3.13	;	SAN27-14 bound to a antigenic site V on prefusion-stabilized hMPV F
5EZ2	;	1.849	;	Sandercyanin Fluorescent Protein (SFP)
7YX1	;	2.65	;	Sandercyanin fluorescent protein - Y142A variant bound to BV
5F6Z	;	2.248	;	Sandercyanin Fluorescent Protein purified from Sander vitreus
7O2Y	;	2.5	;	Sandercyanin Fluorescent Protein variant V71E bound to biliverdin IX-alpha
7VNS	;	1.95	;	Sandercyanin mutant E79A-Biliverdin complex
7VNL	;	1.93	;	Sandercyanin mutant-F55A-Biliverdin complex
1MJ0	;	2.031	;	SANK E3_5: an artificial Ankyrin repeat protein
3HM5	;	1.8	;	SANT domain of human DNA methyltransferase 1 associated protein 1
2NOG	;	2.0	;	SANT Domain Structure of Xenopus Remodeling Factor ISWI
2WQG	;		;	SAP domain from Tho1: L31W (fluorophore) mutant
1KA6	;		;	SAP/SH2D1A bound to peptide n-pY
1KA7	;		;	SAP/SH2D1A bound to peptide n-Y-c
8VD4	;	3.1	;	SaPI1 mature capsid structure containing DNA
8VD5	;	3.2	;	SaPI1 mature capsid structure without DNA
8VD8	;	3.2	;	SaPI1 portal structure in mature capsids containing DNA
8VDC	;	3.5	;	SaPI1 portal structure in mature capsids without DNA
8VDE	;	3.4	;	SaPI1 portal-capsid interface in mature capsids with DNA
7RWZ	;	4.0	;	SaPIbov5 procapsid structure including size redirecting protein Ccm
3S64	;	2.301	;	Saposin-like protein Ac-SLP-1
3S63	;	2.7	;	Saposin-like protein Na-SLP-1
3TYQ	;	1.6	;	SAR development and discovery of potent indole-based inhibitors of the hepatitis c virus NS5B polymerase
3TYV	;	1.65	;	SAR development and discovery of potent indole-based inhibitors of the hepatitis C virus NS5B polymerase
4UYN	;	1.9	;	SAR156497 an exquisitely selective inhibitor of Aurora kinases
4UZD	;	3.2	;	SAR156497 an exquisitely selective inhibitor of Aurora kinases
4UZH	;	2.0	;	SAR156497 an exquisitely selective inhibitor of Aurora kinases
8ULD	;	1.8	;	SARA CoV-2 3C-like protease in complex with GSK3487016A
6Y0T	;	1.393	;	Sarcin Ricin Loop, mutant C2666A U2653G C2667A
6Y0Y	;	0.95	;	Sarcin Ricin Loop, mutant C2666U
6ZXZ	;	2.44	;	Sarcin-Ricin Loop RNA from Ecoli with a A2670-2'-OCF3 modification
6ZYB	;	0.9	;	Sarcin-Ricin Loop RNA from Ecoli with a C2667-2'-OCF3 modification
7JJE	;	1.25	;	Sarcin-ricin loop with guanosine dithiophosphate residue.
7JJD	;	1.21	;	Sarcin-ricin loop with guanosine monothiophosphate residue.
7JJF	;	1.2	;	Sarcin-ricin loop with modified residue.
8BFA	;	3.0	;	Sarkosyl-extracted AppNL-G-F Abeta42 fibril structure
8BFB	;	3.2	;	Sarkosyl-extracted AppNL-G-F Abeta42 fibril structure (Methoxy-X04-labelled mice)
6WPK	;	3.3	;	SARM1 Autoinhibited Conformation
7KNQ	;	3.4	;	SARM1 Octamer
6QWV	;	2.47	;	SARM1 SAM1-2 domains
6ZG0	;	7.7	;	SARM1 SAM1-2 domains
6ZG1	;	3.77	;	SARM1 SAM1-2 domains
1HSJ	;	2.3	;	SARR MBP FUSION STRUCTURE
2FE8	;	1.85	;	SARS coronavirus papain-like protease: structure of a viral deubiquitinating enzyme
7MPB	;	2.3	;	SARS Coronavirus-2 Main Protease 3CL-pro binding Ascorbate
2KQV	;		;	SARS coronavirus-unique domain (SUD): Three-domain molecular architecture in solution and RNA binding. I: Structure of the SUD-M domain of SUD-MC
2KQW	;		;	SARS coronavirus-unique domain (SUD): Three-domain molecular architecture in solution and RNA binding. II: Structure of the SUD-C domain of SUD-MC
7ZH2	;	2.71	;	SARS CoV Spike protein, Closed C1 conformation
7ZH1	;	2.48	;	SARS CoV Spike protein, Closed C3 conformation
7ZH5	;	3.3	;	SARS CoV Spike protein, Open conformation
7JVZ	;	2.5	;	SARS CoV-2 MAIN PROTEASE 3CLpro, ROOM TEMPERATURE, DAMAGE FREE XFEL MONOCLINIC STRUCTURE
8GWJ	;	2.9	;	SARS CoV-2 Mpro 1-302 C145A in complex with peptide 7
8GVY	;	2.5	;	SARS CoV-2 Mpro in complex with D-3-149
7CJM	;	3.2	;	SARS CoV-2 PLpro in complex with GRL0617
7TZJ	;	2.66	;	SARS CoV-2 PLpro in complex with inhibitor 3k
6XA9	;	2.9	;	SARS CoV-2 PLpro in complex with ISG15 C-terminal domain propargylamide
6XAA	;	2.7	;	SARS CoV-2 PLpro in complex with ubiquitin propargylamide
7ODL	;	3.03	;	SARS CoV-2 Spike protein, Bristol UK Deletion variant, Closed conformation, C1 symmetry
7OD3	;	2.8	;	SARS CoV-2 Spike protein, Bristol UK Deletion variant, Closed conformation, C3 symmetry
6ZB4	;	3.03	;	SARS CoV-2 Spike protein, Closed conformation, C1 symmetry
6ZB5	;	2.85	;	SARS CoV-2 Spike protein, Closed conformation, C3 symmetry
7T2V	;	2.47	;	SARS CoV2 Mpro C145S mutant
7JWB	;	3.2	;	SARS CoV2 Spike ectodomain with engineered trimerized VH binder
8A99	;	2.5	;	SARS Cov2 Spike in 1-up conformation complex with Fab47
8A94	;	2.4	;	SARS CoV2 Spike in the 2-up state in complex with Fab47.
8A95	;	2.64	;	SARS Cov2 Spike RBD in complex with Fab47
8A96	;	2.7	;	SARS Cov2 Spike RBD in complex with Fab47
6CS2	;	4.4	;	SARS Spike Glycoprotein - human ACE2 complex, Stabilized variant, all ACE2-bound particles
6CRV	;	3.2	;	SARS Spike Glycoprotein, Stabilized variant, C3 symmetry
6CRW	;	3.9	;	SARS Spike Glycoprotein, Stabilized variant, single upwards S1 CTD conformation
6CRX	;	3.9	;	SARS Spike Glycoprotein, Stabilized variant, two S1 CTDs in the upwards conformation
6CRZ	;	3.3	;	SARS Spike Glycoprotein, Trypsin-cleaved, Stabilized variant, C3 symmetry
6CS0	;	3.8	;	SARS Spike Glycoprotein, Trypsin-cleaved, Stabilized variant, one S1 CTD in an upwards conformation
6CS1	;	4.6	;	SARS Spike Glycoprotein, Trypsin-cleaved, Stabilized variant, two S1 CTDs in an upwards conformation
6NUR	;	3.1	;	SARS-Coronavirus NSP12 bound to NSP7 and NSP8 co-factors
6NUS	;	3.5	;	SARS-Coronavirus NSP12 bound to NSP8 co-factor
7L3N	;	3.27	;	SARS-CoV 2 Spike Protein bound to LY-CoV555
6NB6	;	4.2	;	SARS-CoV complex with human neutralizing S230 antibody Fab fragment (state 1)
6NB7	;	4.5	;	SARS-CoV complex with human neutralizing S230 antibody Fab fragment (state 2)
8CB3	;	1.572	;	SARS-CoV Macro domain complexed with 3-(N-morpholino)propanesulfonic acid
3M3T	;	2.9	;	SARS-CoV main protease monomeric Arg298Ala mutant with N-terminal additional residues (Gly-Ser)
3M3V	;	2.7	;	SARS-CoV main protease triple mutant STI/A with two N-terminal additional residue (Gly-Ser)
5NFY	;	3.382	;	SARS-CoV nsp10/nsp14 dynamic complex
8C0G	;	1.88	;	SARS-CoV nsp16-nsp10 complexed with N7-GTP
5WRG	;	4.3	;	SARS-CoV spike glycoprotein
7LMJ	;	1.686	;	SARS-CoV-1 3CLPro in complex with 2-(1H-benzo[d][1,2,3]triazol-1-yl)-N-(3-chlorobenzyl)-N-(4-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)acetamide
7LMH	;	1.85	;	SARS-CoV-1 3CLPro in complex with 2-(1H-benzo[d][1,2,3]triazol-1-yl)-N-(4-(pyridin-3-yl)phenyl)-N-(thiophen-3-ylmethyl)acetamide
7LMG	;	1.6	;	SARS-CoV-1 3CLPro in complex with N-(4-(1H-imidazol-4-yl)phenyl)-2-(1H-benzo[d][1,2,3]triazol-1-yl)-N-(thiophen-3-ylmethyl)acetamide
7LMI	;	1.707	;	SARS-CoV-1 3CLPro in complex with N-(4-(1H-pyrazol-4-yl)phenyl)-2-(1H-benzo[d][1,2,3]triazol-1-yl)-N-(thiophen-3-ylmethyl)acetamide
8UYP	;	7.1	;	SARS-CoV-1 5' proximal stem-loop 5
7WZ2	;	2.7	;	SARS-CoV-2 (D614G) Spike trimer
6M2Q	;	1.7	;	SARS-CoV-2 3CL protease (3CL pro) apo structure (space group C21)
6M2N	;	2.198	;	SARS-CoV-2 3CL protease (3CL pro) in complex with a novel inhibitor
7DPV	;	2.35	;	SARS-CoV-2 3CL protease (3CLpro) in complex with 7-O-methyl-dihydromyricetin
7DPU	;	1.75	;	SARS-CoV-2 3CL protease (3CLpro) in complex with 7-O-methyl-myricetin
7VVT	;	2.51	;	SARS-CoV-2 3CL protease (3CLpro) in complex with a covalent inhibitor
8IFP	;	1.78	;	SARS-CoV-2 3CL protease (3CLpro) in complex with compound 1
8IFT	;	1.8	;	SARS-CoV-2 3CL protease (3CLpro) in complex with compound 10
8IFQ	;	1.96	;	SARS-CoV-2 3CL protease (3CLpro) in complex with compound 2
8IFR	;	1.66	;	SARS-CoV-2 3CL protease (3CLpro) in complex with compound 3
8HTV	;	2.04	;	SARS-CoV-2 3CL protease (3CLpro) in complex with compound 3a
7X6J	;	1.5	;	SARS-CoV-2 3CL protease (3CLpro) in complex with compound 3af
7X6K	;	2.34	;	SARS-CoV-2 3CL protease (3CLpro) in complex with compound 3w
8IFS	;	2.46	;	SARS-CoV-2 3CL protease (3CLpro) in complex with compound 7
8IGX	;	1.9	;	SARS-CoV-2 3CL protease (3CLpro) in complex with compound 9 (simnotrelvir, SIM0417, SSD8432)
8GTV	;	1.8	;	SARS-CoV-2 3CL protease (3CLpro) in complex with compound JZD-07
8GTW	;	1.85	;	SARS-CoV-2 3CL protease (3CLpro) in complex with compound JZD-26
7DPP	;	2.1	;	SARS-CoV-2 3CL protease (3CLpro) in complex with myricetin
8IGY	;	1.96	;	SARS-CoV-2 3CL protease (3CLpro) in complex with nirmatrelvir
8HI9	;	2.28	;	SARS-CoV-2 3CL protease (3CLpro) in complex with Robinetin
7JR3	;	1.55	;	SARS-CoV-2 3CL protease crystallized under reducing conditions
7JR4	;	1.55	;	SARS-CoV-2 3CL protease with alternative conformation of the active site promoted by methylene-bridged cysteine and lysine residues
7WO3	;	2.01	;	SARS-CoV-2 3CLpro
7WOF	;	1.72	;	SARS-CoV-2 3CLpro
7WOH	;	1.72	;	SARS-CoV-2 3CLpro
8GZB	;	2.7	;	SARS-CoV-2 3CLpro
7LMF	;	2.2	;	SARS-CoV-2 3CLPro in complex with 2-(benzotriazol-1-yl)-N-[4-(1H-imidazol-4-yl)phenyl]-N-(3-thienylmethyl)acetamide
7LMD	;	1.96	;	SARS-CoV-2 3CLPro in complex with 2-(benzotriazol-1-yl)-N-[4-(1H-pyrazol-4-yl)phenyl]-N-(3-thienylmethyl)acetamide
7TEL	;	2.4	;	SARS-CoV-2 3CLPro in complex with N-(4-(1H-imidazol-4-yl)phenyl)-N-(3-chloro-5-fluorobenzyl)-2-(isoquinolin-4-yl)acetamide
7TEK	;	2.2	;	SARS-CoV-2 3CLPro in complex with N-(4-(1H-pyrazol-4-yl)phenyl)-N-(3-chlorobenzyl)-2-(pyridin-3-yl)acetamide
7LME	;	2.1	;	SARS-CoV-2 3CLPro in complex with N-[4-[[2-(benzotriazol-1-yl)acetyl]-(3-thienylmethyl)amino]phenyl]cyclopropanecarboxamide
7WO2	;	1.96	;	SARS-CoV-2 3CLPro Peptidomimetic Inhibitor TPM5
8UYS	;	4.7	;	SARS-CoV-2 5' proximal stem-loop 5
7FEM	;	4.1	;	SARS-CoV-2 B.1.1.7 S-ACE2 complex
7FET	;	3.7	;	SARS-CoV-2 B.1.1.7 Spike Glycoprotein trimer
7YBL	;	3.6	;	SARS-CoV-2 B.1.620 variant spike (close state)
7YBK	;	3.9	;	SARS-CoV-2 B.1.620 variant spike (open state)
8ERQ	;	3.3	;	SARS-CoV-2 BA.1 spike ectodomain trimer in complex with the S2X324 neutralizing antibody Fab fragment (local refinement of the RBD and S2X324)
8GSB	;	3.99	;	SARS-COV-2 BA.1 Spike incomplex with VacBB-665
7XJ6	;	3.29	;	SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab and 58G6 Fab in the class 1 conformation
7XJ8	;	3.3	;	SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab and 58G6 Fab in the class 2 conformation
7WWI	;	3.5	;	SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab in the class 1 conformation
7WWJ	;	3.5	;	SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab in the class 2 conformation
8H08	;	3.2	;	SARS-CoV-2 BA.1 variants S ectodomain trimer in complex with neutralizing antibody 10-5B and 6-2C
8GS9	;	2.66	;	SARS-CoV-2 BA.2 spike RBD in complex bound with VacBB-551
7X6A	;	3.5	;	SARS-CoV-2 BA.2 variant spike protein in complex with Fab BD55-5840
8BH5	;	2.38	;	SARS-CoV-2 BA.2.12.1 RBD in complex with Beta-27 Fab and C1 nanobody
7YQT	;	3.45	;	SARS-CoV-2 BA.2.75 S Trimer (1 RBD Up)
7YQU	;	3.19	;	SARS-CoV-2 BA.2.75 S Trimer (3 RBD Down)
7YQW	;	3.51	;	SARS-CoV-2 BA.2.75 S Trimer (3 RBD Down)
7YR4	;	4.12	;	SARS-CoV-2 BA.2.75 S Trimer in complex with ACE2(interface)
7YR2	;	3.3	;	SARS-CoV-2 BA.2.75 S Trimer in complex with ACE2(state1)
7YR3	;	3.52	;	SARS-CoV-2 BA.2.75 S Trimer in complex with ACE2(state2)
7YR0	;	3.98	;	SARS-CoV-2 BA.2.75 S Trimer in complex with S309 (interface)
7YQX	;	3.72	;	SARS-CoV-2 BA.2.75 S Trimer in complex with S309 (state1)
7YQY	;	3.74	;	SARS-CoV-2 BA.2.75 S Trimer in complex with S309 (state2)
7YQZ	;	3.84	;	SARS-CoV-2 BA.2.75 S Trimer in complex with S309 (state3)
7YR1	;	3.62	;	SARS-CoV-2 BA.2.75 S Trimer in complex with XG2v024
8H07	;	2.9	;	SARS-CoV-2 BA.4 variants S ectodomain trimer in complex with neutralizing antibody 10-5B and 6-2C
8DF5	;	2.7	;	SARS-CoV-2 Beta RBD in complex with human ACE2 and S304 Fab and S309 Fab
7ZFC	;	3.24	;	SARS-CoV-2 Beta RBD in complex with nanobody C1, Omi-18 and Omi-31 Fabs
7WCZ	;	3.5	;	SARS-CoV-2 Beta spike in complex with one S5D2 Fab
7WD9	;	3.7	;	SARS-CoV-2 Beta spike in complex with three S3H3 Fabs
7WD7	;	3.5	;	SARS-CoV-2 Beta spike in complex with three S5D2 Fabs
7WDF	;	3.9	;	SARS-CoV-2 Beta spike in complex with two S3H3 Fabs
7WD0	;	3.3	;	SARS-CoV-2 Beta spike in complex with two S5D2 Fabs
7WD8	;	4.3	;	SARS-CoV-2 Beta spike SD1 in complex with S3H3 Fab
7VX1	;	3.5	;	SARS-CoV-2 Beta variant spike protein in open state
7WEV	;	3.6	;	SARS-COV-2 BETA VARIANT SPIKE PROTEIN IN TRANSITION STATE
8S9G	;	3.0	;	SARS-CoV-2 BN.1 spike RBD bound to the human ACE2 ectodomain and the S309 neutralizing antibody Fab fragment
8FXC	;	3.2	;	SARS-CoV-2 BQ.1.1 spike RBD bound to the human ACE2 ectodomain and the S309 neutralizing antibody Fab fragment
7YBM	;	3.45	;	SARS-CoV-2 C.1.2 variant spike (Close state)
7YBN	;	3.82	;	SARS-CoV-2 C.1.2 variant spike (Open state)
7KDL	;	2.96	;	SARS-CoV-2 D614G 1-RBD up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-D614G)
7KDJ	;	3.49	;	SARS-CoV-2 D614G 1-RBD-up Spike Protein Trimer fully cleaved by furin without the P986-P987 stabilizing mutations (S-RRAR-D614G)
7KEA	;	3.33	;	SARS-CoV-2 D614G 1-RBD-up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-D614G sub classification)
7KE9	;	3.08	;	SARS-CoV-2 D614G 1-RBD-up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-D614G sub-classification)
7KEC	;	3.84	;	SARS-CoV-2 D614G 1-RBD-up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-D614G Sub-Classification)
7KEB	;	3.48	;	SARS-CoV-2 D614G 1RBD up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-D614G sub-classification)
7KDI	;	3.26	;	SARS-CoV-2 D614G 3 RBD down Spike Protein Trimer fully cleaved by furin without the P986-P987 stabilizing mutations (S-RRAR-D614G)
7KE4	;	3.21	;	SARS-CoV-2 D614G 3 RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-D614G Sub-class)
7KE6	;	3.1	;	SARS-CoV-2 D614G 3 RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-D614G sub-classification)
7KE8	;	3.26	;	SARS-CoV-2 D614G 3 RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-D614G sub-classification)
7KDK	;	2.8	;	SARS-CoV-2 D614G 3 RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-D614G)
7KE7	;	3.32	;	SARS-CoV-2 D614G 3-RBD-down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-D614G Sub-Classification)
7X7D	;	2.92	;	SARS-CoV-2 Delta RBD and Nb22
8QZR	;	3.77	;	SARS-CoV-2 delta RBD complexed with BA.4/5-9 Fab
7W9E	;	3.1	;	SARS-CoV-2 Delta S-8D3
7W98	;	3.6	;	SARS-CoV-2 Delta S-ACE2-C1
7W99	;	3.4	;	SARS-CoV-2 Delta S-ACE2-C2a
7W9B	;	3.4	;	SARS-CoV-2 Delta S-ACE2-C2b
7W9C	;	3.2	;	SARS-CoV-2 Delta S-ACE2-C3
7W9F	;	3.6	;	SARS-CoV-2 Delta S-RBD-8D3
7W9I	;	3.4	;	SARS-CoV-2 Delta S-RBD-ACE2
8HRL	;	2.8	;	SARS-CoV-2 Delta S-RBD-ACE2
8HRK	;	3.3	;	SARS-CoV-2 Delta S-RBD-ACE2 complex
8HHX	;	3.62	;	SARS-CoV-2 Delta Spike in complex with FP-12A
8HHY	;	2.77	;	SARS-CoV-2 Delta Spike in complex with IS-9A
8HRI	;	2.9	;	SARS-CoV-2 Delta variant spike protein
8HRJ	;	3.1	;	SARS-CoV-2 Delta variant spike protein
8BBN	;	3.58	;	SARS-CoV-2 Delta-RBD complexed with BA.2-10 and EY6A Fabs
8C3V	;	2.74	;	SARS-CoV-2 Delta-RBD complexed with BA.2-13 Fab and C1 nanobody
8BBO	;	2.75	;	SARS-CoV-2 Delta-RBD complexed with BA.2-36 Fab
8CBD	;	3.52	;	SARS-CoV-2 Delta-RBD complexed with BA.4/5-1 and EY6A Fabs
8CBE	;	3.16	;	SARS-CoV-2 Delta-RBD complexed with BA.4/5-2 and Beta-49 Fabs
8CMA	;	3.29	;	SARS-CoV-2 Delta-RBD complexed with BA.4/5-35 Fab
8BCZ	;	2.9	;	SARS-CoV-2 Delta-RBD complexed with Fabs BA.2-36, BA.2-23, EY6A and COVOX-45
8CBF	;	2.33	;	SARS-CoV-2 Delta-RBD complexed with Omi-42 and Beta-49 Fabs
8GWM	;	2.64	;	SARS-CoV-2 E-RTC bound with MMP-nsp9 and GMPPNP
8GWB	;	2.75	;	SARS-CoV-2 E-RTC complex with RNA-nsp9
8GWE	;	2.66	;	SARS-CoV-2 E-RTC complex with RNA-nsp9 and GMPPNP
7TPK	;	3.4	;	SARS-CoV-2 E406W mutant RBD - Local Refinement
7TPI	;	2.3	;	SARS-CoV-2 E406W mutant Spike ectodomain
7TJ2	;	3.2	;	SARS-CoV-2 endoribonuclease Nsp15 bound to dsRNA
7TQV	;	3.43	;	SARS-CoV-2 endoribonuclease Nsp15 bound to dsRNA
8U1T	;		;	SARS-CoV-2 Envelope Protein Transmembrane Domain: Dimeric Structure Determined by Solid-State NMR
7K3G	;		;	SARS-CoV-2 Envelope Protein Transmembrane Domain: Pentameric Structure Determined by Solid-State NMR
8VCI	;	6.1	;	SARS-CoV-2 Frameshift Stimulatory Element with Upstream Multibranch Loop
7LYJ	;	2.11	;	SARS-CoV-2 frameshifting pseudoknot RNA
7MKY	;	1.31	;	SARS-CoV-2 frameshifting pseudoknot RNA
8FDO	;	2.2	;	SARS-CoV-2 fusion peptide epitope scaffold FP15 bound to DH1058
6XKL	;	3.21	;	SARS-CoV-2 HexaPro S One RBD up
7VXB	;	3.9	;	SARS-CoV-2 Kappa variant spike protein in C2b state
7VXC	;	3.9	;	SARS-CoV-2 Kappa variant spike protein in C3 state
7VXA	;	3.9	;	SARS-CoV-2 Kappa variant spike protein in complex with ACE2, state C2a
7VX9	;	4.0	;	SARS-CoV-2 Kappa variant spike protein in complex wth ACE2, state C1
7VXE	;	3.2	;	SARS-CoV-2 Kappa variant spike protein in open state
7VXI	;	3.4	;	SARS-CoV-2 Kappa variant spike protein in transition state
7YBH	;	3.5	;	SARS-CoV-2 lambda variant spike
7VGR	;	2.7	;	SARS-CoV-2 M protein dimer (long form) in complex with YN7756_1 Fab
7VGS	;	2.8	;	SARS-CoV-2 M protein dimer (short form) in complex with YN7717_9 Fab
6Z6I	;	2.0	;	SARS-CoV-2 Macrodomain in complex with ADP-HPD
6Z72	;	2.3	;	SARS-CoV-2 Macrodomain in complex with ADP-HPM
6Z5T	;	1.571	;	SARS-CoV-2 Macrodomain in complex with ADP-ribose
7QG7	;	1.72	;	SARS-CoV-2 macrodomain Nsp3b bound to the remdesivir nucleoside GS-441524
7CAM	;	2.85	;	SARS-CoV-2 main protease (Mpro) apo structure (space group P212121)
7MB9	;	1.81	;	SARS-CoV-2 Main Protease (Mpro) C145A in Complex with Cleavage Site Nsp10/11 (P6-P1)
7MB4	;	1.83	;	SARS-CoV-2 Main Protease (Mpro) C145A in Complex with Cleavage Site Nsp4/5 (P6-P1)
7MB5	;	1.6	;	SARS-CoV-2 Main Protease (Mpro) C145A in Complex with Cleavage Site Nsp5/6 (P6-P1)
7MB6	;	2.21	;	SARS-CoV-2 Main Protease (Mpro) C145A in Complex with Cleavage Site Nsp6/7 (P6-P1)
7MB7	;	2.02	;	SARS-CoV-2 Main Protease (Mpro) C145A in Complex with Cleavage Site Nsp7/8 (P6-P1)
7MB8	;	1.62	;	SARS-CoV-2 Main Protease (Mpro) C145A in Complex with Cleavage Site Nsp8/9 (P6-P1)
8UAB	;	1.781	;	SARS-CoV-2 main protease (Mpro) complex with AC1115
7Z59	;	2.0	;	SARS-CoV-2 main protease (Mpro) covalently modified with a penicillin derivative
8DDL	;	1.95	;	SARS-CoV-2 Main Protease (Mpro) H163A Mutant Apo Structure
8DD6	;	2.3	;	SARS-CoV-2 Main Protease (Mpro) H163A Mutant in Complex with GC376
8SG6	;	2.49	;	SARS-CoV-2 Main Protease (Mpro) H163A Mutant Reduced with 20mM TCEP
8DD1	;	2.03	;	SARS-CoV-2 Main Protease (Mpro) H164N Mutant in Complex with Inhibitor GC376
7NIJ	;	1.58	;	SARS-CoV-2 main protease (Mpro) in a novel conformational state.
7MAV	;	1.91	;	SARS-CoV-2 Main Protease (Mpro) in Complex with Covalent Inhibitor dFFCit-yne
7MAT	;	2.74	;	SARS-CoV-2 Main Protease (Mpro) in Complex with Covalent Inhibitor dFFR
7MAU	;	1.95	;	SARS-CoV-2 Main Protease (Mpro) in Complex with Covalent Inhibitor dFFR-yne
7MAW	;	2.07	;	SARS-CoV-2 Main Protease (Mpro) in Complex with Covalent Inhibitor SM129
7MAX	;	1.98	;	SARS-CoV-2 Main Protease (Mpro) in Complex with Covalent Inhibitor SM137
7MAZ	;	1.7	;	SARS-CoV-2 Main Protease (Mpro) in Complex with Covalent Inhibitor SM139
7MB0	;	1.54	;	SARS-CoV-2 Main Protease (Mpro) in Complex with Covalent Inhibitor SM141
7MB1	;	1.43	;	SARS-CoV-2 Main Protease (Mpro) in Complex with Covalent Inhibitor SM143
7MB2	;	1.89	;	SARS-CoV-2 Main Protease (Mpro) in Complex with Covalent Inhibitor SM144
7MB3	;	1.81	;	SARS-CoV-2 Main Protease (Mpro) in Complex with Covalent Inhibitor SM145
7SET	;	1.7	;	SARS-CoV-2 Main Protease (Mpro) in Complex with ML1000
7SF1	;	1.85	;	SARS-CoV-2 Main Protease (Mpro) in Complex with ML1001
7U92	;	1.8	;	SARS-CoV-2 Main Protease (Mpro) in Complex with ML1006a
7SF3	;	1.75	;	SARS-CoV-2 Main Protease (Mpro) in Complex with ML1006m
7SFB	;	1.9	;	SARS-CoV-2 Main Protease (Mpro) in Complex with ML101
7SFH	;	1.4	;	SARS-CoV-2 Main Protease (Mpro) in Complex with ML102
7SFI	;	1.95	;	SARS-CoV-2 Main Protease (Mpro) in Complex with ML104
7SGH	;	1.85	;	SARS-CoV-2 Main Protease (Mpro) in Complex with ML124N
7L0D	;	2.39	;	SARS-CoV-2 Main Protease (Mpro) in Complex with ML188
8EZV	;	1.8	;	SARS-CoV-2 Main Protease (Mpro) in Complex with ML2006a
8EZZ	;	1.85	;	SARS-CoV-2 Main Protease (Mpro) in Complex with ML2006a2
8F02	;	2.0	;	SARS-CoV-2 Main Protease (Mpro) in Complex with ML2006a4
8F2C	;	1.95	;	SARS-CoV-2 Main Protease (Mpro) in Complex with ML3006a
8F2D	;	1.95	;	SARS-CoV-2 Main Protease (Mpro) in Complex with ML4006a
8B2T	;	1.893	;	SARS-CoV-2 Main Protease (Mpro) in complex with nirmatrelvir alkyne
7L8I	;	2.1	;	SARS-CoV-2 Main Protease (Mpro) in Complex with Rupintrivir (P21)
7L8J	;	2.45	;	SARS-CoV-2 Main Protease (Mpro) in Complex with Rupintrivir (P21212)
8B0S	;	2.42	;	SARS-COV-2 Main Protease adduct with Au(NHC)Cl
8B0T	;	2.4	;	SARS-CoV-2 Main Protease adduct with Au(PEt3)Br
7N5Z	;	1.76	;	SARS-CoV-2 Main protease C145S mutant
7N6N	;	2.8	;	SARS-CoV-2 Main protease C145S mutant in complex with N and C-terminal residues
7K6D	;	1.48	;	SARS-CoV-2 Main Protease Co-Crystal Structure with Telaprevir Determined from Crystals Grown with 40 nL Acoustically Ejected Mpro Droplets at 1.48 A Resolution (Cryo-protected)
7K6E	;	1.63	;	SARS-CoV-2 Main Protease Co-Crystal Structure with Telaprevir Determined from Crystals Grown with 40 nL Acoustically Ejected Mpro Droplets at 1.63 A Resolution (Direct Vitrification)
8AEB	;	1.83	;	SARS-CoV-2 Main Protease complexed with N-(pyridin-3-ylmethyl)thioformamide
7KFI	;	1.6	;	SARS-CoV-2 Main protease immature form - apo structure
7LFE	;	2.79	;	SARS-CoV-2 Main protease immature form - F2X Entry Library E03 fragment
7LDX	;	2.23	;	SARS-CoV-2 Main protease immature form - F2X Entry Library E06 fragment
7LFP	;	2.2	;	SARS-CoV-2 Main protease immature form - F2X Entry Library G05 fragment
7KVL	;	2.09	;	SARS-CoV-2 Main protease immature form - FMAX Library E01 fragment
7KVR	;	2.12	;	SARS-CoV-2 Main protease immature form - FMAX Library E09 fragment
7AEH	;	1.3	;	SARS-CoV-2 main protease in a covalent complex with a pyridine derivative of ABT-957, compound 1
7AEG	;	1.7	;	SARS-CoV-2 main protease in a covalent complex with SDZ 224015 derivative, compound 5
7RNW	;	2.35	;	SARS-CoV-2 Main Protease in complex with a cyclic peptide inhibitor
8FY6	;	2.0	;	SARS-CoV-2 main protease in complex with covalent inhibitor
8FY7	;	1.94	;	SARS-CoV-2 main protease in complex with covalent inhibitor
7MGS	;	1.84	;	SARS-CoV-2 main protease in complex with N-terminal autoprocessing substrate
7MGR	;	1.94	;	SARS-CoV-2 main protease in complex with nsp8/9 substrate peptide
7WQA	;	1.8	;	SARS-CoV-2 main protease in complex with Z-VAD-FMK
7KPH	;	1.46	;	SARS-CoV-2 Main Protease in mature form
7MBG	;	1.86	;	SARS-CoV-2 Main protease in orthorhombic space group
7WQB	;	1.87	;	SARS-CoV-2 main protease mutant (P168A) in complex with MG-132
7UUG	;	2.0	;	SARS-CoV-2 Main Protease S144A (Mpro S144A) in Complex with ML1006a
7UUP	;	2.0	;	SARS-CoV-2 Main Protease S144A (Mpro S144A) in Complex with Nirmatrelvir (PF-07321332)
8VSG	;	2.071	;	SARS-CoV-2 main protease with covalent inhibitor
6Y84	;	1.39	;	SARS-CoV-2 main protease with unliganded active site (2019-nCoV, coronavirus disease 2019, COVID-19)
6YB7	;	1.25	;	SARS-CoV-2 main protease with unliganded active site (2019-nCoV, coronavirus disease 2019, COVID-19).
7EIN	;	1.7	;	SARS-CoV-2 main proteinase complex with microbial metabolite leupeptin
9EML	;	2.4	;	SARS-CoV-2 methyltransferase nsp10-16 in complex with SAM and m7GpppA (Cap0-analog)/m7GpppAm (Cap1-analog)
9EMJ	;	1.79	;	SARS-CoV-2 methyltransferase nsp10-16 in complex with Toyocamycin and m7GpppA (Cap0-analog)
8R19	;	1.91	;	SARS-CoV-2 Mpro (Omicron, P132H) free enzyme
8R0V	;	2.48	;	SARS-CoV-2 Mpro (Omicron, P132H) in complex with alpha-ketoamide 13b-K at pH 6.5
8GWS	;	2.9	;	SARS-CoV-2 Mpro 1-302 c145a in complex with peptide 4
8GW4	;	2.9	;	SARS-CoV-2 Mpro 1-302/C145A in complex with peptide 8-1
8H7K	;	1.45	;	SARS-CoV-2 Mpro Double Mutant (H41A and T21I) in complex with nsp4/5 peptidyl substrate
8GVD	;	2.0	;	SARS-CoV-2 Mpro in complex with D-4-38
8JPQ	;	2.7	;	SARS-CoV-2 Mpro in complex with D-5-96
7DW0	;	1.81	;	SARS-CoV-2 Mpro mutant (H41A) in complex with nsp14|15 peptidyl substrate
7DW6	;	1.7	;	SARS-CoV-2 Mpro mutant (H41A) in complex with nsp15|16 peptidyl substrate
7DVP	;	1.69	;	SARS-CoV-2 Mpro mutant (H41A) in complex with nsp4|5 peptidyl substrate
7DVW	;	1.49	;	SARS-CoV-2 Mpro mutant (H41A) in complex with nsp5|6 peptidyl substrate
7DVX	;	1.8	;	SARS-CoV-2 Mpro mutant (H41A) in complex with nsp6|7 peptidyl substrate
7DVY	;	1.8	;	SARS-CoV-2 Mpro mutant (H41A) in complex with nsp9|10 peptidyl substrate
7YBI	;	4.1	;	SARS-CoV-2 Mu variant spike (open state)
7YBJ	;	3.73	;	SARS-CoV-2 Mu variant spike(close state)
8BZN	;	2.19	;	SARS-CoV-2 non-structural protein 10 (nsp10) variant T102I
8AZ8	;	1.18	;	SARS-CoV-2 non-structural protein-1 (nsp1) in complex with 2-(benzylamino)ethan-1-ol
8AYS	;	1.37	;	SARS-CoV-2 non-structural protein-1 (nsp1) in complex with 4-(2-aminothiazol-4-yl)phenol
8A4Y	;	1.099	;	SARS-CoV-2 non-structural protein-1 (nsp1) in complex with N-(2,3-dihydro-1H-inden-5-yl)acetamide
7JQB	;	2.7	;	SARS-CoV-2 Nsp1 and rabbit 40S ribosome complex
6ZON	;	3.0	;	SARS-CoV-2 Nsp1 bound to a human 43S preinitiation ribosome complex - state 1
6ZP4	;	2.9	;	SARS-CoV-2 Nsp1 bound to a human 43S preinitiation ribosome complex - state 2
6ZMT	;	3.0	;	SARS-CoV-2 Nsp1 bound to a pre-40S-like ribosome complex
6ZN5	;	3.2	;	SARS-CoV-2 Nsp1 bound to a pre-40S-like ribosome complex - state 2
6ZLW	;	2.6	;	SARS-CoV-2 Nsp1 bound to the human 40S ribosomal subunit
6ZM7	;	2.7	;	SARS-CoV-2 Nsp1 bound to the human CCDC124-80S-EBP1 ribosome complex
6ZME	;	3.0	;	SARS-CoV-2 Nsp1 bound to the human CCDC124-80S-eERF1 ribosome complex
6ZMI	;	2.6	;	SARS-CoV-2 Nsp1 bound to the human LYAR-80S ribosome complex
6ZMO	;	3.1	;	SARS-CoV-2 Nsp1 bound to the human LYAR-80S-eEF1a ribosome complex
7K5I	;	2.9	;	SARS-COV-2 nsp1 in complex with human 40S ribosome
7JQC	;	3.3	;	SARS-CoV-2 Nsp1, CrPV IRES and rabbit 40S ribosome complex
8OV3	;	1.82	;	SARS-CoV-2 nsp10-16 methyltransferase in complex with 5-Iodotubercidin
8BZV	;	1.8	;	SARS-CoV-2 nsp10-16 methyltransferase in complex with adenosine
8OV1	;	1.67	;	SARS-CoV-2 nsp10-16 methyltransferase in complex with ADP
8OTO	;	1.8	;	SARS-CoV-2 nsp10-16 methyltransferase in complex with AMP
8OSX	;	1.83	;	SARS-CoV-2 nsp10-16 methyltransferase in complex with ATP
8C5M	;	1.9	;	SARS-CoV-2 nsp10-16 methyltransferase in complex with MTA
8OT0	;	2.21	;	SARS-CoV-2 nsp10-16 methyltransferase in complex with MTA and glycine
8OTR	;	1.77	;	SARS-CoV-2 nsp10-16 methyltransferase in complex with SAM analog BDH 33959089
8OV2	;	1.86	;	SARS-CoV-2 nsp10-16 methyltransferase in complex with Sangivamycin
9EMV	;	2.34	;	SARS-CoV-2 nsp10-16 methyltransferase in complex with Sangivamycin and m7GpppA (Cap0-analog)/m7GpppAm (Cap1-analog)
8S8W	;	2.1	;	SARS-CoV-2 nsp10-16 methyltransferase in complex with Sangivamycin and m7GpppA-RNA (Cap0-RNA)
8OV4	;	1.93	;	SARS-CoV-2 nsp10-16 methyltransferase in complex with Toyocamycin
8S8X	;	1.99	;	SARS-CoV-2 nsp10-16 methyltransferase in complex with Toyocamycin and m7GpppA-RNA (Cap0-RNA)
8BSD	;	1.95	;	SARS-CoV-2 nsp10-16 methyltransferase in complex with tubercidin
7THM	;	3.18	;	SARS-CoV-2 nsp12/7/8 complex with a native N-terminus nsp9
7N06	;	2.2	;	SARS-CoV-2 Nsp15 endoribonuclease post-cleavage state
7N33	;	2.5	;	SARS-CoV-2 Nsp15 endoribonuclease pre-cleavage state
8RV5	;	2.05	;	SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 1
8RZE	;	2.0	;	SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 10
8RZC	;	2.35	;	SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 11
8RV4	;	2.35	;	SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 2
8RV6	;	2.25	;	SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 2
8RV7	;	1.9	;	SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 4
8RV8	;	1.7	;	SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 5
8RV9	;	1.9	;	SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 6
8RVA	;	1.8	;	SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 7
8RVB	;	1.95	;	SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 8
8RZD	;	2.1	;	SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 9
7MSX	;	3.15	;	SARS-CoV-2 Nsp2
8C19	;	1.95	;	SARS-CoV-2 NSP3 macrodomain in complex with 1-methyl-4-[5-(morpholin-4-ylcarbonyl)-2-furyl]-1H-pyrrolo[2,3-b]pyridine
8C1A	;	1.9	;	SARS-CoV-2 NSP3 macrodomain in complex with aztreonam
6WXD	;	2.0	;	SARS-CoV-2 Nsp9 RNA-replicase
7E8F	;	3.18	;	SARS-CoV-2 NTD in complex with N9 Fab
8FG2	;	6.0	;	SARS-CoV-2 Nucleocapsid dimer structure determined from COVID-19 patients
7SD4	;		;	SARS-CoV-2 Nucleocapsid N-terminal domain (N-NTD) protein
7QIK	;	2.01	;	SARS-CoV-2 Nucleocapsid phosphopeptide 193-200 bound to human 14-3-3 sigma
7QIP	;	2.65	;	SARS-CoV-2 Nucleocapsid phosphopeptide 201-210 bound to human 14-3-3 sigma
7F2E	;	3.1	;	SARS-CoV-2 nucleocapsid protein C-terminal domain (dodecamer)
7TGE	;	3.68	;	SARS-CoV-2 Omicron 1-RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-Omicron)
7TEI	;	3.4	;	SARS-CoV-2 Omicron 1-RBD up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-Omicron)
7TL9	;	3.5	;	SARS-CoV-2 Omicron 1-RBD up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-Omicron)
7YCY	;	3.74	;	SARS-CoV-2 Omicron 1-RBD up Spike trimer complexed with three XG005 molecules
7YD0	;	3.58	;	SARS-CoV-2 Omicron 1-RBD up spike trimer complexed with two XG005 Fab
7YCZ	;	3.24	;	SARS-CoV-2 Omicron 2-RBD up Spike trimer complexed with three XG005 molecules
7TF8	;	3.36	;	SARS-CoV-2 Omicron 3-RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-Omicron)
7TL1	;	3.5	;	SARS-CoV-2 Omicron 3-RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-Omicron)
8ERR	;	3.1	;	SARS-CoV-2 Omicron BA.1 spike ectodomain trimer in complex with the S2X324 neutralizing antibody Fab fragment
8H01	;	3.7	;	SARS-CoV-2 Omicron BA.1 Spike glycoprotein in complex with rabbit monoclonal antibody 1H1 Fab in class 2 conformation
8H00	;	3.41	;	SARS-CoV-2 Omicron BA.1 Spike glycoprotein in complex with rabbit monoclonal antibody 1H1 Fab in the class 1 conformation
8ITU	;	3.68	;	SARS-CoV-2 Omicron BA.1 Spike glycoprotein in complex with rabbit monoclonal antibody 1H1 IgG.
8HHZ	;	4.28	;	SARS-CoV-2 Omicron BA.1 Spike in complex with IY-2A
8HFY	;	3.21	;	SARS-CoV-2 Omicron BA.1 spike protein receptor-binding domain in complex with white-tailed deer ACE2
8HC7	;	4.54	;	SARS-CoV-2 Omicron BA.1 spike trimer (6P) complex with YB9-258 Fab, focused refinement of RBD-dimer region
8HC2	;	6.21	;	SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 1 YB9-258 Fab (1 RBD up)
8HC3	;	4.35	;	SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 2 YB9-258 Fabs (2 RBD up)
8HCA	;	4.35	;	SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 3 YB13-292 Fabs (1 RBD up)
8HCB	;	4.18	;	SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 3 YB13-292 Fabs (2 RBD up)
8HC9	;	6.03	;	SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 3 YB13-292 Fabs (3 RBD down)
8HC8	;	3.95	;	SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with YB13-292 Fab, focused refinement of Fab region
8HC6	;	4.69	;	SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with YB9-258 Fab, focused refinement of Fab region
7XO6	;	2.6	;	SARS-CoV-2 Omicron BA.1 Variant RBD with mouse ACE2 Bound
7XO5	;	3.13	;	SARS-CoV-2 Omicron BA.1 Variant Spike Trimer with one mouse ACE2 Bound
7XO4	;	3.24	;	SARS-CoV-2 Omicron BA.1 Variant Spike Trimer with two mouse ACE2 Bound
8HWT	;	2.91	;	SARS-CoV-2 Omicron BA.2 RBD complexed with BD-604 and S304 Fab
7ZF7	;	3.46	;	SARS-CoV-2 Omicron BA.2 RBD in complex with ACE2
7ZF8	;	2.95	;	SARS-CoV-2 Omicron BA.2 RBD in complex with COVOX-150 Fab
7ZF9	;	3.25	;	SARS-CoV-2 Omicron BA.2 RBD in complex with COVOX-150 Fab (P21)
7XO9	;	3.0	;	SARS-CoV-2 Omicron BA.2 Variant RBD complexed with human ACE2
7XOC	;	3.0	;	SARS-CoV-2 Omicron BA.2 Variant RBD complexed with mouse ACE2
7XIW	;	3.62	;	SARS-CoV-2 Omicron BA.2 variant spike (state 1)
7XIX	;	3.25	;	SARS-CoV-2 Omicron BA.2 variant spike (state 2)
7XOA	;	3.2	;	SARS-CoV-2 Omicron BA.2 Variant Spike Trimer with one mouse ACE2 Bound
7XO8	;	3.48	;	SARS-CoV-2 Omicron BA.2 Variant Spike Trimer with three human ACE2 Bound
7XOD	;	3.27	;	SARS-CoV-2 Omicron BA.2 Variant Spike Trimer with three JMB2002 Fab Bound
7XO7	;	3.38	;	SARS-CoV-2 Omicron BA.2 Variant Spike Trimer with two human ACE2 Bound
7XOB	;	3.3	;	SARS-CoV-2 Omicron BA.2 Variant Spike Trimer with two mouse ACE2 Bound
7XNR	;	3.49	;	SARS-CoV-2 Omicron BA.2.13 variant spike
8ASY	;	2.85	;	SARS-CoV-2 Omicron BA.2.75 RBD in complex with ACE2
7XIY	;	3.07	;	SARS-CoV-2 Omicron BA.3 variant spike
7XIZ	;	3.74	;	SARS-CoV-2 Omicron BA.3 variant spike (local)
7XNQ	;	3.52	;	SARS-CoV-2 Omicron BA.4 variant spike
7XNS	;	3.48	;	SARS-CoV-2 Omicron BA.4 variant spike
7ZXU	;	1.89	;	SARS-CoV-2 Omicron BA.4/5 RBD in complex with Beta-27 Fab and C1 nanobody
7WKA	;	3.64	;	SARS-CoV-2 Omicron closed state spike protein in complex with S3H3 Fab
7WK9	;	3.48	;	SARS-CoV-2 Omicron open state spike protein in complex with S3H3 Fab
7TN0	;	2.85	;	SARS-CoV-2 Omicron RBD in complex with human ACE2 and S304 Fab and S309 Fab
7ZFB	;	3.08	;	SARS-CoV-2 Omicron RBD in complex with nanobody C1, Omi-18 and Omi-31 Fabs
7ZF5	;	5.32	;	SARS-CoV-2 Omicron RBD in complex with Omi-12 and Beta-54 Fabs
7ZFD	;	3.39	;	SARS-CoV-2 Omicron RBD in complex with Omi-25 Fab
7ZF3	;	3.15	;	SARS-CoV-2 Omicron RBD in complex with Omi-3 and EY6A Fabs
7ZFE	;	3.25	;	SARS-CoV-2 Omicron RBD in complex with Omi-32 Fab and nanobody C1
7ZFA	;	4.24	;	SARS-CoV-2 Omicron RBD in complex with Omi-6 and COVOX-150 Fabs
7ZF4	;	4.18	;	SARS-CoV-2 Omicron RBD in complex with Omi-9 Fab and nanobody F2
7WOG	;	4.06	;	SARS-CoV-2 Omicron S monomer complexed with 553-49
7WK2	;	3.1	;	SARS-CoV-2 Omicron S-close
7WK3	;	3.4	;	SARS-CoV-2 Omicron S-open
7WVN	;	3.4	;	SARS-CoV-2 Omicron S-open
7WVO	;	3.41	;	SARS-CoV-2 Omicron S-open-2
7WK8	;	3.61	;	SARS-CoV-2 Omicron spike protein SD1 in complex with S3H3 Fab
7WZ1	;	3.4	;	SARS-CoV-2 Omicron Spike trimer
7WPB	;	2.79	;	SARS-CoV-2 Omicron Variant RBD complexed with ACE2
7WPD	;	3.18	;	SARS-CoV-2 Omicron Variant S Trimer complexed with one JMB2002 Fab
7WPF	;	2.92	;	SARS-CoV-2 Omicron Variant S Trimer complexed with three JMB2002 Fab
7WPE	;	2.69	;	SARS-CoV-2 Omicron Variant S Trimer complexed with two JMB2002 Fab
7WT7	;	3.4	;	SARS-CoV-2 Omicron variant spike in complex with Fab 9A8 (State 1)
7WT8	;	3.6	;	SARS-CoV-2 Omicron variant spike in complex with Fab 9A8 (State 2)
7WTF	;	3.0	;	SARS-CoV-2 Omicron variant spike in complex with Fab XGv051
7WTI	;	3.8	;	SARS-CoV-2 Omicron variant spike in complex with Fab XGv264
7WTK	;	3.6	;	SARS-CoV-2 Omicron variant spike in complex with Fab XGv286
7WI0	;	3.82	;	SARS-CoV-2 Omicron variant spike in complex with three human neutralizing antibodies
7WE8	;	3.5	;	SARS-CoV-2 Omicron variant spike protein in complex with Fab XGv265
7WE7	;	3.8	;	SARS-CoV-2 Omicron variant spike protein in complex with Fab XGv282
7WE9	;	3.6	;	SARS-CoV-2 Omicron variant spike protein in complex with Fab XGv289
7WEA	;	3.3	;	SARS-CoV-2 Omicron variant spike protein in complex with two XGv347 binding to one close state RBD and one open state RBD
7WEC	;	3.3	;	SARS-CoV-2 Omicron variant spike protein with three XGv347 Fabs binding to three closed state RBDs
7WEB	;	3.7	;	SARS-CoV-2 Omicron variant spike protein with two XGv347 binding to two open state RBDs
7WT9	;	4.3	;	SARS-CoV-2 Omicron variant spike RBD in complex with Fab 9A8
7WTG	;	3.8	;	SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv051
7WTH	;	4.3	;	SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv264
7WEE	;	4.0	;	SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv265
7WLC	;	4.0	;	SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv282
7WTJ	;	4.2	;	SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv286
7WEF	;	3.8	;	SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv289
7WED	;	3.5	;	SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv347
7WPA	;	2.77	;	SARS-CoV-2 Omicron Variant SPIKE trimer complexed with ACE2
7WP9	;	2.56	;	SARS-CoV-2 Omicron Variant SPIKE trimer, all RBDs down
7UB0	;	3.31	;	SARS-CoV-2 Omicron-BA.2 3-RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-Omicron-BA.2)
7UB5	;	3.35	;	SARS-CoV-2 Omicron-BA.2 3-RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-Omicron-BA.2)
7UB6	;	3.52	;	SARS-CoV-2 Omicron-BA.2 3-RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-Omicron-BA.2)
8T5Q	;	1.9	;	SARS-CoV-2 ORF3a peptide in complex with TRAF2 TRAF domain
8T5P	;	2.5	;	SARS-CoV-2 ORF3a peptide in complex with TRAF3 TRAF domain
7F5F	;	1.62	;	SARS-CoV-2 ORF8 S84
7LBS	;	2.8	;	SARS-CoV-2 papain-like protease (PLpro) bound to inhibitor XR8-24
7LOS	;	2.9	;	SARS-CoV-2 papain-like protease (PLpro) bound to inhibitor XR8-65
7LLZ	;	2.9	;	SARS-CoV-2 papain-like protease (PLpro) bound to inhibitor XR8-69
7LLF	;	2.3	;	SARS-CoV-2 papain-like protease (PLpro) bound to inhibitor XR8-83
7LBR	;	2.2	;	SARS-CoV-2 papain-like protease (PLpro) bound to inhibitor XR8-89
8UVM	;	2.85	;	SARS-CoV-2 papain-like protease (PLpro) complex with covalent inhibitor Jun11313
8UUY	;	3.05	;	SARS-CoV-2 papain-like protease (PLpro) complex with inhibitor Jun12129
8UUF	;	2.84	;	SARS-CoV-2 papain-like protease (PLpro) with inhibitor Jun11941
8UUW	;	3.2	;	SARS-CoV-2 papain-like protease (PLpro) with inhibitor Jun12145
8UUU	;	3.01	;	SARS-Cov-2 papain-like protease (PLpro) with inhibitor Jun12162
8UUV	;	3.01	;	SARS-CoV-2 papain-like protease (PLpro) with inhibitor Jun12197
8UUH	;	2.8	;	SARS-CoV-2 papain-like protease (PLpro) with inhibitor Jun12199
8UUG	;	2.74	;	SARS-CoV-2 papain-like protease (PLpro) with inhibitor Jun12303
8UOB	;	2.52	;	SARS-CoV-2 Papain-like protease (PLpro) with Inhibitor Jun12682
8EIR	;	2.49	;	SARS-CoV-2 polyprotein substrate regulates the stepwise Mpro cleavage reaction
7MLX	;	2.09	;	SARS-CoV-2 programmed -1 frameshifting element three stem H-type pseudoknot
7X7E	;	2.67	;	SARS-CoV-2 RBD and Nb22
8EL2	;	2.89	;	SARS-CoV-2 RBD bound to neutralizing antibody Fab ICO-hu23
7KDG	;	3.01	;	SARS-CoV-2 RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS)
7Y7K	;	4.4	;	SARS-CoV-2 RBD in complex with 1F Fab
8BE1	;	1.98	;	SARS-CoV-2 RBD in complex with a Fab fragment of a neutralising antibody mRBD2
7F3Q	;	3.3	;	SARS-CoV-2 RBD in complex with A5-10 Fab and A34-2 Fab
7KLG	;	3.2	;	SARS-CoV-2 RBD in complex with Fab 15033
7KLH	;	3.0	;	SARS-CoV-2 RBD in complex with Fab 15033-7
8E1G	;	2.57	;	SARS-CoV-2 RBD in complex with Omicron-neutralizing antibody 2A10
7KDH	;	3.33	;	SARS-CoV-2 RBD up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS)
7BH9	;	2.9	;	SARS-CoV-2 RBD-62 in complex with ACE2 peptidase domain
7DTE	;	3.0	;	SARS-CoV-2 RdRP catalytic complex with T33-1 RNA
7L1F	;	3.89	;	SARS-CoV-2 RdRp in complex with 4 Remdesivir monophosphate
7OZU	;	3.3	;	SARS-CoV-2 RdRp with Molnupiravir/ NHC in the template strand base-paired with A
7OZV	;	3.2	;	SARS-CoV-2 RdRp with Molnupiravir/ NHC in the template strand base-paired with G
6XQB	;	3.4	;	SARS-CoV-2 RdRp/RNA complex
7MZL	;	3.7	;	SARS-CoV-2 receptor binding domain bound to Fab PDI 210
7MZM	;	2.3	;	SARS-CoV-2 receptor binding domain bound to Fab PDI 215
7RR0	;	3.12	;	SARS-CoV-2 receptor binding domain bound to Fab PDI 222
7MZN	;	3.1	;	SARS-CoV-2 receptor binding domain bound to Fab PDI 231
7MZF	;	2.493	;	SARS-CoV-2 receptor binding domain bound to Fab PDI 37
7MZG	;	2.0	;	SARS-CoV-2 receptor binding domain bound to Fab PDI 42
7MZH	;	2.1	;	SARS-CoV-2 receptor binding domain bound to Fab WCSL 119
7MZI	;	1.85	;	SARS-CoV-2 receptor binding domain bound to Fab WCSL 129
7MZJ	;	2.4	;	SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 and Fab PDI 93
7MZK	;	2.25	;	SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 and Fab PDI 96
7TE1	;	3.5	;	SARS-CoV-2 Receptor Binding Domain in Complex with Ab17
8DAD	;	3.85	;	SARS-CoV-2 receptor binding domain in complex with AZ090 Fab
7LDJ	;	2.36	;	SARS-CoV-2 receptor binding domain in complex with WNb-2
8DCE	;	2.0	;	SARS-CoV-2 Receptor-Binding Domain SPEEDesign Immunogen 1 Bound to C144 scFv
8DCC	;	2.6	;	SARS-CoV-2 Receptor-Binding Domain SPEEDesign Immunogen 3 Bound to P2B-2F6 Fab
7UO7	;	3.09	;	SARS-CoV-2 replication-transcription complex bound to ATP, in a pre-catalytic state
7UOE	;	2.67	;	SARS-CoV-2 replication-transcription complex bound to CTP, in a pre-catalytic state
7UOB	;	2.68	;	SARS-CoV-2 replication-transcription complex bound to GTP, in a pre-catalytic state
7RE2	;	3.17	;	SARS-CoV-2 replication-transcription complex bound to nsp13 helicase - nsp13(1)-RTC
7RE1	;	2.91	;	SARS-CoV-2 replication-transcription complex bound to nsp13 helicase - nsp13(2)-RTC (composite)
7RDZ	;	3.6	;	SARS-CoV-2 replication-transcription complex bound to nsp13 helicase - nsp13(2)-RTC - apo class
7RDY	;	3.1	;	SARS-CoV-2 replication-transcription complex bound to nsp13 helicase - nsp13(2)-RTC - engaged class
7RDX	;	3.1	;	SARS-CoV-2 replication-transcription complex bound to nsp13 helicase - nsp13(2)-RTC - open class
7RE0	;	3.5	;	SARS-CoV-2 replication-transcription complex bound to nsp13 helicase - nsp13(2)-RTC - swiveled class
7RE3	;	3.33	;	SARS-CoV-2 replication-transcription complex bound to nsp13 helicase - nsp13(2)-RTC dimer
8SQ9	;	2.9	;	SARS-CoV-2 replication-transcription complex bound to nsp9 and UMPCPP, as a pre-catalytic NMPylation intermediate
7UO4	;	3.38	;	SARS-CoV-2 replication-transcription complex bound to Remdesivir triphosphate, in a pre-catalytic state
8SQK	;	3.01	;	SARS-CoV-2 replication-transcription complex bound to RNA-nsp9 and GDP-betaS, as a pre-catalytic deRNAylation/mRNA capping intermediate
8SQJ	;	3.06	;	SARS-CoV-2 replication-transcription complex bound to RNA-nsp9, as a noncatalytic RNA-nsp9 binding mode
7UO9	;	3.13	;	SARS-CoV-2 replication-transcription complex bound to UTP, in a pre-catalytic state
7N1B	;	2.81	;	SARS-CoV-2 RLQ peptide binds to HLA-A2
7N1C	;	1.881	;	SARS-CoV-2 RLQ peptide-specific TCR pRLQ3
7N1E	;	2.3	;	SARS-CoV-2 RLQ peptide-specific TCR pRLQ3 binds to RLQ-HLA-A2
8GWK	;	2.72	;	SARS-CoV-2 RNA E-RTC complex with RMP-nsp9 and GMPPNP
6M71	;	2.9	;	SARS-Cov-2 RNA-dependent RNA polymerase in complex with cofactors
7BTF	;	2.95	;	SARS-CoV-2 RNA-dependent RNA polymerase in complex with cofactors in reduced condition
6X29	;	2.7	;	SARS-CoV-2 rS2d Down State Spike Protein Trimer
7N8I	;	3.0	;	SARS-CoV-2 S (B.1.429 / epsilon variant) + S2M11 + S2L20 (Local Refinement of the NTD/S2L20)
7N8H	;	2.3	;	SARS-CoV-2 S (B.1.429 / epsilon variant) + S2M11 + S2L20 Global Refinement
8VYE	;	2.7	;	SARS-CoV-2 S (C.37 Lambda variant) plus S309, S2L20, and S2X303 Fabs
7T67	;	3.0	;	SARS-CoV-2 S (Spike Glycoprotein) D614G with One(1) RBD Up
7T3M	;	3.0	;	SARS-CoV-2 S (Spike Glycoprotein) D614G with Three (3) RBDs Up, Bound to Antibody 2-7 scFv, composite map
7TLY	;	3.0	;	SARS-CoV-2 S B.1.1.529 Omicron variant (RBD + S309 Local Refinement)
7TM0	;	3.1	;	SARS-CoV-2 S B.1.1.529 Omicron variant + S309 + S2L20 Global Refinement
7SOE	;	2.8	;	SARS-CoV-2 S B.1.617.1 kappa variant + S2X303 Global Refinement
7SOB	;	2.4	;	SARS-CoV-2 S B.1.617.1 kappa variant + S309 + S2L20 Global Refinement
7SO9	;	2.4	;	SARS-CoV-2 S B.1.617.2 delta variant + S2M11 + S2L20 Global Refinement
7RAL	;		;	SARS-CoV-2 S bound to S2X259 Fab (local refinement of the RBD/S2X259 variable domains)
7XD2	;	3.3	;	SARS-CoV-2 S ectodomain trimer in complex with neutralizing antibody 10-5B
7RA8	;	3.1	;	SARS-CoV-2 S glycoprotein in complex with S2X259 Fab
8VYF	;	3.2	;	SARS-CoV-2 S NTD (C.37 Lambda variant) plus S2L20 and S2X303 Fabs, local refinement
7TLZ	;	3.3	;	SARS-CoV-2 S NTD B.1.1.529 Omicron variant + S309 Local Refinement
7SOD	;	3.2	;	SARS-CoV-2 S NTD B.1.617.1 kappa variant S2L20 Local Refinement
7SOF	;	3.6	;	SARS-CoV-2 S NTD B.1.617.1 kappa variant S2X303 Local Refinement
7SOA	;	3.1	;	SARS-CoV-2 S NTD B.1.617.2 delta variant + S2L20 Local Refinement
7QO7	;	3.02	;	SARS-CoV-2 S Omicron Spike B.1.1.529
7QTI	;	3.04	;	SARS-CoV-2 S Omicron Spike B.1.1.529 - 3-P2G3 and 1-P5C3 Fabs (Global)
7QO9	;	3.88	;	SARS-CoV-2 S Omicron Spike B.1.1.529 - RBD and NTD (Local)
7QTK	;	3.84	;	SARS-CoV-2 S Omicron Spike B.1.1.529 - RBD down - 1-P2G3 Fab (Local)
7QTJ	;	4.01	;	SARS-CoV-2 S Omicron Spike B.1.1.529 - RBD up - 1-P2G3 and 1-P5C3 Fabs (Local)
8QPR	;	3.8	;	SARS-CoV-2 S protein bound to human neutralising antibody UZGENT_G5
8QQ0	;	3.5	;	SARS-CoV-2 S protein bound to neutralising antibody UZGENT_A3
8BG6	;	4.11	;	SARS-CoV-2 S protein in complex with pT1644 Fab
8BG8	;	3.64	;	SARS-CoV-2 S protein in complex with pT1696 Fab
7F7E	;	2.49	;	SARS-CoV-2 S protein RBD in complex with A5-10 Fab
7F7H	;	3.19	;	SARS-CoV-2 S protein RBD in complex with A8-1 Fab
7QDG	;	3.4	;	SARS-CoV-2 S protein S:A222V + S:D614G mutant 1-up
7QDH	;	4.2	;	SARS-CoV-2 S protein S:D614G mutant 1-up
8P9Y	;	4.3	;	SARS-CoV-2 S protein S:D614G mutant in 3-down with binding site of an entry inhibitor
8VYG	;	3.1	;	SARS-CoV-2 S RBD (C.37 Lambda variant) plus S309 Fab, local refinement
7SOC	;	3.3	;	SARS-CoV-2 S RBD B.1.617.1 kappa variant S309 Local Refinement
7S3N	;	1.9	;	SARS-CoV-2 S stem helix peptide bound to Fab22
7Y7J	;	3.8	;	SARS-CoV-2 S trimer in complex with 1F Fab
7E5S	;	3.6	;	SARS-CoV-2 S trimer with four-antibody cocktail complex
7CAC	;	3.55	;	SARS-CoV-2 S trimer with one RBD in the open state and complexed with one H014 Fab.
7CAK	;	3.58	;	SARS-CoV-2 S trimer with three RBD in the open state and complexed with three H014 Fab
7E5R	;	3.6	;	SARS-CoV-2 S trimer with three-antibody cocktail complex
7CAI	;	3.49	;	SARS-CoV-2 S trimer with two RBDs in the open state and complexed with two H014 Fab
7DF3	;	2.7	;	SARS-CoV-2 S trimer, S-closed
7DK3	;	6.0	;	SARS-CoV-2 S trimer, S-open
7E8C	;	3.16	;	SARS-CoV-2 S-6P in complex with 9 Fabs
7DF4	;	3.8	;	SARS-CoV-2 S-ACE2 complex
7M8J	;	3.48	;	SARS-CoV-2 S-NTD + Fab CM25
8P99	;	3.4	;	SARS-CoV-2 S-protein:D614G mutant in 1-up conformation
7T01	;	2.69	;	SARS-CoV-2 S-RBD + Fab 54042-4
8C1V	;	2.9	;	SARS-CoV-2 S-trimer (3 RBDs up) bound to TriSb92, fitted into cryo-EM map
7LXZ	;	2.6	;	SARS-CoV-2 S/S2M11/S2L28 Global Refinement
7LXX	;	3.0	;	SARS-CoV-2 S/S2M11/S2L28 Local Refinement
7LY2	;	2.5	;	SARS-CoV-2 S/S2M11/S2M28 Global Refinement
7LY0	;	2.6	;	SARS-CoV-2 S/S2M11/S2M28 Local Refinement
7LXY	;	2.2	;	SARS-CoV-2 S/S2M11/S2X333 Global Refinement
7LXW	;	2.8	;	SARS-CoV-2 S/S2M11/S2X333 Local Refinement
8F5H	;	2.3	;	SARS-CoV-2 S2 helix epitope scaffold
8F5I	;	1.9	;	SARS-CoV-2 S2 helix epitope scaffold bound by antibody DH1057.1
8GOP	;	2.8	;	SARS-CoV-2 specific private TCR RLQ7
8GOM	;	2.783	;	SARS-CoV-2 specific private TCR RLQ7 in complex with RLQ-HLA-A2
8GON	;	2.601	;	SARS-CoV-2 specific private TCR RLQ7 in complex with RLQ-T1006I-HLA-A2
8DNT	;	3.18	;	SARS-CoV-2 specific T cell receptor
7N62	;	4.0	;	SARS-CoV-2 Spike (2P) in complex with C12C9 Fab (NTD local reconstruction)
7N64	;	4.2	;	SARS-CoV-2 Spike (2P) in complex with G32R7 Fab (RBD and NTD local reconstruction)
7YDY	;	4.75	;	SARS-CoV-2 Spike (6P) in complex with 1 R1-32 Fab
7YE5	;	6.75	;	SARS-CoV-2 Spike (6P) in complex with 2 R1-32 Fabs
7YE9	;	4.17	;	SARS-CoV-2 Spike (6P) in complex with 3 R1-32 Fabs
7YEG	;	3.73	;	SARS-CoV-2 Spike (6P) in complex with 3 R1-32 Fabs and 3 ACE2
7YDI	;	3.98	;	SARS-CoV-2 Spike (6P) in complex with 3 R1-32 Fabs and 3 ACE2, focused refinement of RBD region
7NS6	;	3.18	;	SARS-CoV-2 Spike (dimers) in complex with six Fu2 nanobodies
6XS6	;	3.7	;	SARS-CoV-2 Spike D614G variant, minus RBD
6VYB	;	3.2	;	SARS-CoV-2 spike ectodomain structure (open state)
7Q0A	;	4.8	;	SARS-CoV-2 Spike ectodomain with Fab FI3A
6ZDH	;	3.7	;	SARS-CoV-2 Spike glycoprotein in complex with a neutralizing antibody EY6A Fab
8ELJ	;	3.6	;	SARS-CoV-2 spike glycoprotein in complex with the ICO-hu23 neutralizing antibody Fab fragment
7Y71	;	3.12	;	SARS-CoV-2 spike glycoprotein trimer complexed with Fab fragment of anti-RBD antibody E7
7Y72	;	4.03	;	SARS-CoV-2 spike glycoprotein trimer complexed with Fab fragment of anti-RBD antibody E7 (focused refinement on Fab-RBD interface)
7WGV	;	3.2	;	SARS-CoV-2 spike glycoprotein trimer in closed state
7WGX	;	3.5	;	SARS-CoV-2 spike glycoprotein trimer in closed state after treatment with Cathepsin L
7WGY	;	4.0	;	SARS-CoV-2 spike glycoprotein trimer in Intermediate state
7WGZ	;	4.5	;	SARS-CoV-2 spike glycoprotein trimer in open state
7A94	;	3.9	;	SARS-CoV-2 Spike Glycoprotein with 1 ACE2 Bound
7A96	;	4.8	;	SARS-CoV-2 Spike Glycoprotein with 1 ACE2 Bound and 1 RBD Erect in Anticlockwise Direction
7A95	;	4.3	;	SARS-CoV-2 Spike Glycoprotein with 1 ACE2 Bound and 1 RBD Erect in Clockwise Direction
7A97	;	4.4	;	SARS-CoV-2 Spike Glycoprotein with 2 ACE2 Bound
7A93	;	5.9	;	SARS-CoV-2 Spike Glycoprotein with 2 RBDs Erect
7A98	;	5.4	;	SARS-CoV-2 Spike Glycoprotein with 3 ACE2 Bound
7KJ2	;	3.6	;	SARS-CoV-2 Spike Glycoprotein with one ACE2 Bound
7KJ4	;	3.4	;	SARS-CoV-2 Spike Glycoprotein with three ACE2 Bound
7KJ3	;	3.7	;	SARS-CoV-2 Spike Glycoprotein with two ACE2 Bound
7KJ5	;	3.6	;	SARS-CoV-2 Spike Glycoprotein, prefusion with one RBD up conformation
7KQE	;	2.88	;	SARS-CoV-2 spike glycoprotein:Fab 3D11 complex
7KQB	;	2.42	;	SARS-CoV-2 spike glycoprotein:Fab 5A6 complex I
8GB0	;	4.1	;	SARS-CoV-2 Spike H655Y variant, One RBD Open
7UHC	;	3.1	;	SARS-CoV-2 spike in complex with AHB2-2GS-SB175
7UHB	;	3.0	;	SARS-CoV-2 spike in complex with AHB2-2GS-SB175 (local refinement of the RBD and AHB2)
7WUH	;	4.7	;	SARS-CoV-2 Spike in complex with Fab of m31A7
7WO4	;	4.47	;	SARS-CoV-2 Spike in complex with IgG 553-15 (S-553-15 dimer trimer )
7WO5	;	3.45	;	SARS-CoV-2 Spike in complex with IgG 553-15 (S-553-15 trimer)
7WOA	;	3.25	;	SARS-CoV-2 Spike in complex with IgG 553-60 (1-up trimer)
7WOB	;	3.25	;	SARS-CoV-2 Spike in complex with IgG 553-60 (2-up trimer)
7JZL	;	2.7	;	SARS-CoV-2 spike in complex with LCB1 (2RBDs open)
7JZU	;	3.1	;	SARS-CoV-2 spike in complex with LCB1 (local refinement of the RBD and LCB1)
7JZN	;	3.1	;	SARS-CoV-2 spike in complex with LCB3 (2RBDs open)
7JZM	;	3.5	;	SARS-CoV-2 spike in complex with LCB3 (local refinement of the RBD and LCB3)
7KSG	;	3.33	;	SARS-CoV-2 spike in complex with nanobodies E
8HGL	;	2.9	;	SARS-CoV-2 spike in complex with neutralizing antibody NIV-11
7YH7	;	3.3	;	SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 (state 2)
7K9H	;	3.2	;	SARS-CoV-2 Spike in complex with neutralizing Fab 2B04 (one up, two down conformation)
7K9J	;	3.0	;	SARS-CoV-2 Spike in complex with neutralizing Fab 2H04 (three down conformation)
7MKL	;	3.2	;	SARS-CoV-2 Spike in complex with neutralizing Fab SARS2-38 (three down conformation)
7SWX	;	3.13	;	SARS-CoV-2 Spike in complex with neutralizing Fab SARS2-57 (three down conformation)
7KKL	;	2.85	;	SARS-CoV-2 Spike in complex with neutralizing nanobody mNb6
7KKK	;	3.03	;	SARS-CoV-2 Spike in complex with neutralizing nanobody Nb6
7RBU	;	3.7	;	SARS-CoV-2 Spike in complex with PVI.V6-14 Fab
7RBV	;	3.6	;	SARS-CoV-2 Spike in complex with PVI.V6-14 Fab
8C89	;	4.41	;	SARS-CoV-2 spike in complex with the 17T2 neutralizing antibody Fab fragment (local refinement of RBD and Fab)
7E3C	;	4.2	;	SARS-CoV-2 spike in complex with the Ab1 neutralizing antibody (focused refinement on Fab-RBD)
7E39	;	3.7	;	SARS-CoV-2 spike in complex with the Ab4 neutralizing antibody (State 3)
7E3B	;	4.2	;	SARS-Cov-2 spike in complex with the Ab5 neutralizing antibody (focused refinement on Fab-RBD)
7E23	;	3.3	;	SARS-CoV-2 spike in complex with the CA521 neutralizing antibody Fab (focused refinement on Fab-RBD)
7JVC	;	3.3	;	SARS-CoV-2 spike in complex with the S2A4 neutralizing antibody Fab fragment
7JVA	;	3.6	;	SARS-CoV-2 spike in complex with the S2A4 neutralizing antibody Fab fragment (local refinement of the receptor-binding domain and Fab variable domains)
7R7N	;	3.95	;	SARS-CoV-2 spike in complex with the S2D106 neutralizing antibody Fab fragment (local refinement of the RBD and S2D106)
7K4N	;	3.3	;	SARS-CoV-2 spike in complex with the S2E12 neutralizing antibody Fab fragment
7K45	;	3.7	;	SARS-CoV-2 spike in complex with the S2E12 neutralizing antibody Fab fragment (local refinement of the RBD and Fab variable domains)
7JV6	;	3.0	;	SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody (closed conformation)
7JV4	;	3.4	;	SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody (one RBD open)
7JV2	;	3.5	;	SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody Fab fragment (local refinement of the receptor-binding motif and Fab variable domains)
7TAS	;	3.2	;	SARS-CoV-2 spike in complex with the S2K146 neutralizing antibody Fab fragment (local refinement of the RBD and S2K146)
7TAT	;	3.2	;	SARS-CoV-2 spike in complex with the S2K146 neutralizing antibody Fab fragment (two receptor-binding domains open)
7K43	;	2.6	;	SARS-CoV-2 spike in complex with the S2M11 neutralizing antibody Fab fragment
7JW0	;	4.3	;	SARS-CoV-2 spike in complex with the S304 neutralizing antibody Fab fragment
7WHD	;	2.65	;	SARS-CoV-2 spike in complex with the ZB8 neutralizing antibody Fab (2u1d)
7WHB	;	2.67	;	SARS-CoV-2 spike in complex with the ZB8 neutralizing antibody Fab (3U)
7WH8	;	3.11	;	SARS-CoV-2 spike in complex with the ZB8 neutralizing antibody Fab (focused refinement on Fab-RBD)
6ZOW	;	3.0	;	SARS-CoV-2 spike in prefusion state
6ZP5	;	3.1	;	SARS-CoV-2 spike in prefusion state (flexibility analysis, 1-up closed conformation)
6ZP7	;	3.3	;	SARS-CoV-2 spike in prefusion state (flexibility analysis, 1-up open conformation)
7SWW	;	3.13	;	SARS-CoV-2 Spike NTD in complex with neutralizing Fab SARS2-57 (local refinement)
7CWL	;	3.8	;	SARS-CoV-2 spike protein and P17 fab complex with one RBD in close state
8EYH	;	3.75	;	SARS-CoV-2 spike protein bound with a nanobody
8EYG	;	3.73	;	SARS-CoV-2 spike protein complexed with two nanobodies
7FB0	;	3.4	;	SARS-CoV-2 spike protein in closed state
8CXQ	;	2.3	;	SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 1-22
8CY9	;	2.9	;	SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 1-23
8CYB	;	2.7	;	SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 1-8
8CY7	;	2.9	;	SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-34
8CYC	;	2.9	;	SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-34
8CYD	;	2.6	;	SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-45
8CXN	;	2.9	;	SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-57
8CY6	;	3.2	;	SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-65
8CYA	;	2.7	;	SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-67
7VXD	;	4.0	;	SARS-CoV-2 spike protein in complex with ACE2, Beta variant, C1 state
7VXK	;	3.7	;	SARS-CoV-2 spike protein in complex with ACE2, Beta variant, C2A state
7VXF	;	3.6	;	SARS-CoV-2 spike protein in complex with ACE2, Beta variant, C2B state
7VXM	;	3.6	;	SARS-CoV-2 spike protein in complex with ACE2, Beta variant, C3 state
7KXK	;	5.0	;	SARS-CoV-2 spike protein in complex with Fab 15033-7, 2-""up""-1-""down"" conformation
7KXJ	;	6.4	;	SARS-CoV-2 spike protein in complex with Fab 15033-7, 3-""up"", asymmetric
7CWT	;	3.7	;	SARS-CoV-2 Spike protein in complex with hb27 and fc05 Fab cocktail
7P7B	;	3.13	;	SARS-CoV-2 spike protein in complex with sybody no68 in a 1up/2down conformation
7P78	;	3.32	;	SARS-CoV-2 spike protein in complex with sybody#15 and sybody#68 in a 1up/1up-out/1down conformation
7P77	;	2.98	;	SARS-CoV-2 spike protein in complex with sybody#15 and sybody#68 in a 3up conformation
7P7A	;	4.76	;	SARS-CoV-2 spike protein in complex with sybody#68 in a 2up/1flexible conformation
7P79	;	4.0	;	SARS-CoV-2 spike protein in complex with sybodyb#15 in a 1up/1up-out/1down conformation.
7ZCE	;	3.5	;	SARS-CoV-2 Spike protein in complex with the single chain fragment scFv76
7WHZ	;	3.42	;	SARS-CoV-2 spike protein in complex with three human neutralizing antibodies
7FB1	;	3.7	;	SARS-CoV-2 spike protein in one-RBD open state
7FB3	;	3.1	;	SARS-CoV-2 spike protein in one-RBD weak state after CTSL-treatment
7FB4	;	3.4	;	SARS-CoV-2 spike protein in two-RBD weak state after CTSL-treatment
7E7X	;	2.78	;	SARS-CoV-2 Spike Protein N terminal domain in Complex with N11 Fab
7CWO	;	3.9	;	SARS-CoV-2 spike protein RBD and P17 fab complex
7LC8	;		;	SARS-CoV-2 spike Protein TM domain
8F4P	;	3.7	;	SARS-CoV-2 spike protein trimer (down conformation) bound with a nanobody
7LJR	;	3.66	;	SARS-CoV-2 Spike Protein Trimer bound to DH1043 fab
7CWS	;	3.4	;	SARS-CoV-2 Spike Proteins Trimer in Complex with FC05 and H014 Fabs Cocktail
7CWU	;	3.5	;	SARS-CoV-2 spike proteins trimer in complex with P17 and FC05 Fabs cocktail
7NLL	;	2.89	;	SARS-CoV-2 Spike RBD (dimer) in complex with two Fu2 nanobodies
8D8R	;	4.1	;	SARS-CoV-2 Spike RBD in complex with DMAb 2196
8D8Q	;	4.2	;	SARS-CoV-2 Spike RBD in complex with DMAbs 2130 and 2196
7X7O	;	3.75	;	SARS-CoV-2 spike RBD in complex with neutralizing antibody UT28K
7K9I	;	3.3	;	SARS-CoV-2 Spike RBD in complex with neutralizing Fab 2B04 (local refinement)
7K9K	;	3.14	;	SARS-CoV-2 Spike RBD in complex with neutralizing Fab 2H04 (local refinement)
7MKM	;	3.16	;	SARS-CoV-2 Spike RBD in complex with neutralizing Fab SARS2-38 (local refinement)
7ZCF	;	4.0	;	SARS-CoV-2 Spike RBD in complex with the single chain fragment scFv76 (Focused Refinement)
7FDH	;	3.72	;	SARS-COV-2 Spike RBDMACSp25 binding to hACE2
7FDI	;	3.12	;	SARS-COV-2 Spike RBDMACSp36 binding to hACE2
7FDK	;	3.69	;	SARS-COV-2 Spike RBDMACSp36 binding to mACE2
7FDG	;	3.69	;	SARS-COV-2 Spike RBDMACSp6 binding to hACE2
7R6X	;	2.95	;	SARS-CoV-2 spike receptor-binding domain (RBD) in complex with S2E12 Fab, S309 Fab, and S304 Fab
7R6W	;	1.83	;	SARS-CoV-2 spike receptor-binding domain (RBD) in complex with S2X35 Fab and S309 Fab
7LO4	;	2.465	;	SARS-CoV-2 spike receptor-binding domain with a G485R mutation in complex with human ACE2
8HEB	;	3.53	;	SARS-CoV-2 Spike trimer in complex with RmAb 9H1 Fab in the class 1 conformation
8HEC	;	3.5	;	SARS-CoV-2 Spike trimer in complex with RmAb 9H1 Fab in the class 2 conformation
7V2A	;	3.4	;	SARS-CoV-2 Spike trimer in complex with XG014 Fab
7U9P	;	3.5	;	SARS-CoV-2 spike trimer RBD in complex with Fab NA8
7U9O	;	3.4	;	SARS-CoV-2 spike trimer RBD in complex with Fab NE12
7QUR	;	2.27	;	SARS-CoV-2 Spike with ethylbenzamide-tri-iodo Siallyllactose, C3 symmetry
7QUS	;	2.39	;	SARS-CoV-2 Spike, C3 symmetry
7SA2	;	1.85	;	SARS-CoV-2 spike-derived peptide S1060-1068 (VVFLHVTYV) presented by HLA-A*02:01
7U1R	;	1.8	;	SARS-CoV-2 Spike-derived peptide S1185-1193 K1191N mutant (RLNEVANNL) presented by HLA-A*02:01
7UR1	;	2.17	;	SARS-CoV-2 Spike-derived peptide S1215-1224 (YIWLGFIAGL) presented by HLA-A*02:01
7RTD	;	2.05	;	SARS-CoV-2 Spike-derived peptide S269-277 (YLQPRTFLL) presented by HLA-A*02:01
7UM2	;	1.63	;	SARS-CoV-2 Spike-derived peptide S417-425 K417T mutant (TIADYNYKL) presented by HLA-A*02:01
7TLT	;	2.3	;	SARS-CoV-2 Spike-derived peptide S489-497 (YFPLQSYGF) presented by HLA-A*29:02
7SIS	;	1.9	;	SARS-CoV-2 Spike-derived peptide S976-984 (VLNDILSRL) presented by HLA-A*02:01
8G70	;	3.4	;	SARS-CoV-2 spike/nanobody mixture complex
8G72	;	5.6	;	SARS-CoV-2 spike/Nb2 complex with 1 RBD up (local refinement at 5.6 A)
8G74	;	2.5	;	SARS-CoV-2 spike/Nb3 complex with 1 RBD up and 2 Nb3
8G7B	;	3.2	;	SARS-CoV-2 spike/Nb3 complex with 1 RBD up and 2 Nb3 (local refinement)
8G7A	;	3.3	;	SARS-CoV-2 spike/Nb3 complex with 2 RBDs up and 3 Nb3 (local refinement)
8G73	;	2.5	;	SARS-CoV-2 spike/Nb3 complex with 2 RBDs up and 3 Nb3 bound at 2.5 A
8G75	;	3.4	;	SARS-CoV-2 spike/Nb4 complex with 2 RBDs up and 3 Nb4 bound
8G76	;	3.8	;	SARS-CoV-2 spike/Nb5 complex
8G77	;	2.8	;	SARS-CoV-2 spike/Nb6 complex
7M71	;	2.66	;	SARS-CoV-2 Spike:5A6 Fab complex I focused refinement
7M7B	;	2.95	;	SARS-CoV-2 Spike:Fab 3D11 complex focused refinement
6X2A	;	3.3	;	SARS-CoV-2 u1S2q 1-RBD Up Spike Protein Trimer
6X2B	;	3.6	;	SARS-CoV-2 u1S2q 2-RBD Up Spike Protein Trimer
6X2C	;	3.2	;	SARS-CoV-2 u1S2q All Down RBD State Spike Protein Trimer
7M0J	;	3.52	;	SARS-CoV-2 u1S2q All Down RBD State Spike Protein Trimer - asymmetric refinement
8HC5	;	3.43	;	SARS-CoV-2 wildtype S1 in complex with YB9-258 Fab and R1-32 Fab
8HC4	;	3.54	;	SARS-CoV-2 wildtype spike trimer (6P) in complex with 3 YB9-258 Fabs and 3 R1-32 Fabs (3 RBD up)
7Y0N	;	3.8	;	SARS-CoV-2 WT Spike in complex with R15 Fab and P14 Nanobody
8DV2	;	3.5	;	SARS-CoV-2 Wuhan-hu-1-Spike-RBD bound to computationally engineered ACE2 mimetic CVD293
8DV1	;	3.4	;	SARS-CoV-2 Wuhan-hu-1-Spike-RBD bound to linker variant of affinity matured ACE2 mimetic CVD432
8PSD	;	2.9	;	SARS-CoV-2 XBB 1.0 closed conformation.
8FXB	;	3.1	;	SARS-CoV-2 XBB.1 spike RBD bound to the human ACE2 ectodomain and the S309 neutralizing antibody Fab fragment
8WRH	;	3.08	;	SARS-CoV-2 XBB.1.5.70 in complex with ACE2
7N1A	;	2.065	;	SARS-CoV-2 YLQ peptide binds to HLA-A2
7N1D	;	2.35	;	SARS-CoV-2 YLQ peptide-specific TCR pYLQ7
7N1F	;	2.393	;	SARS-CoV-2 YLQ peptide-specific TCR pYLQ7 binds to YLQ-HLA-A2
7S6I	;	3.2	;	SARS-CoV-2-6P-Mut2 S protein
7RU2	;	3.0	;	SARS-CoV-2-6P-Mut7 S protein (asymmetric)
7RU1	;	2.8	;	SARS-CoV-2-6P-Mut7 S protein (C3 symmetry)
7XIL	;	2.91	;	SARS-CoV-2-Beta-RBD and B38-GWP/P-VK antibody complex
7X63	;	2.24	;	SARS-CoV-2-Beta-RBD and BD-236-GWP/P-VK antibody complex
7XEG	;	2.69	;	SARS-CoV-2-Beta-RBD and CB6-092-Fab complex
6ZOJ	;	2.8	;	SARS-CoV-2-Nsp1-40S complex, composite map
6ZOK	;	2.8	;	SARS-CoV-2-Nsp1-40S complex, focused on body
6ZOL	;	2.8	;	SARS-CoV-2-Nsp1-40S complex, focused on head
7XIK	;	2.89	;	SARS-CoV-2-Omicron-RBD and B38-GWP/P-VK antibody complex
7X66	;	2.4	;	SARS-CoV-2-Omicron-RBD and BD-236-GWP/P-VK antibody complex
7XEI	;	2.76	;	SARS-CoV-2-prototyped-RBD and CB6-092-Fab complex
7B18	;	2.62	;	SARS-CoV-spike bound to two neutralising nanobodies
7B17	;	4.01	;	SARS-CoV-spike RBD bound to two neutralising nanobodies.
7T2U	;	2.1	;	SARS-CoV2 3C-Like protease complexed with Nemo peptide
7URB	;	2.14	;	Sars-Cov2 Main Protease in complex with CDD-1733
7US4	;	2.07	;	Sars-Cov2 Main Protease in complex with CDD-1819
7UR9	;	2.16	;	SARS-Cov2 Main protease in complex with inhibitor CDD-1845
7Z0P	;	2.52	;	SARS-COV2 Main Protease in complex with inhibitor MG-131
7QL8	;	1.807	;	SARS-COV2 Main Protease in complex with inhibitor MG78
7T2T	;	1.45	;	SARS-CoV2 Mpro native form
8OKC	;	2.0	;	SARS-CoV2 NSP5 in complex with a GC-376 based peptidomimetic PROTAC
8OKB	;	2.31	;	SARS-CoV2 NSP5 in complex with a peptidomimetic ligand
7NWX	;	1.8	;	SARS-COV2 NSP5 in the presence of Zn2+
7UPL	;	4.1	;	SARS-Cov2 Omicron varient S protein structure in complex with neutralizing monoclonal antibody 002-S21F2
7WPH	;	2.89	;	SARS-CoV2 RBD bound to Fab06
7DDD	;	3.0	;	SARS-Cov2 S protein at close state
7DDN	;	6.3	;	SARS-Cov2 S protein at open state
7U0Q	;	3.86	;	SARS-Cov2 S protein structure in complex with neutralizing monoclonal antibody 002-02
7U0X	;	3.82	;	SARS-Cov2 S protein structure in complex with neutralizing monoclonal antibody 002-13
8GDR	;	3.6	;	SARS-Cov2 S protein structure in complex with neutralizing monoclonal antibody 002-S21B10
7U0P	;	3.76	;	SARS-Cov2 S protein structure in complex with neutralizing monoclonal antibody 002-S21F2
7UOW	;	4.4	;	SARS-Cov2 S protein structure in complex with neutralizing monoclonal antibody 034_32
6X45	;	2.2	;	SARS-CoV2 spike glycoprotein N-terminal heptad repeat domain + SARS-CoV2(QEYKKEKE)
5UTV	;		;	SARS-unique fold in the Rousettus Bat Coronavirus HKU9
4BY2	;	2.57	;	SAS-4 (dCPAP) TCP domain in complex with a Proline Rich Motif of Ana2 (dSTIL) of Drosophila Melanogaster
7UWW	;	1.61	;	Sas6 with alpha-cyclodextrin
1STM	;	1.9	;	SATELLITE PANICUM MOSAIC VIRUS
7JW1	;	4.19	;	Satellite phage P4 procapsid including size determination (Sid) protein
4NIA	;	1.82	;	Satellite Tobacco Mosaic Virus Refined at room temperature to 1.8 A Resolution using NCS Restraints
4OQ8	;	1.45	;	Satellite Tobacco Mosaic Virus Refined to 1.4 A Resolution using icosahedral constraints
4OQ9	;	1.45	;	Satellite Tobacco Mosaic Virus Refined to 1.4 A Resolution using non-crystallographic symmetry restraints
1A34	;	1.81	;	SATELLITE TOBACCO MOSAIC VIRUS/RNA COMPLEX
2BUK	;	2.45	;	SATELLITE TOBACCO NECROSIS VIRUS
4BCU	;	2.29	;	Satellite Tobacco Necrosis Virus (STNV) virus like particle in complex with the B3 aptamer
2QUE	;	2.25	;	Saturation of substrate-binding site using two natural ligands: Crystal structure of a ternary complex of phospholipase A2 with anisic acid and ajmaline at 2.25 A resolution
7ALX	;	1.8	;	Sav-SOD: Chimeric Streptavidin-cSOD as Host for Artificial Metalloenzymes
5XR2	;	2.6	;	SAV0551
5XR3	;	3.01	;	SAV0551 with glyoxylate
4Y0N	;	2.1	;	SAV1875
4Y1E	;	1.8	;	SAV1875-C105D
4Y1R	;	1.65	;	SAV1875-cysteinesulfonic acid
4Y1F	;	1.8	;	SAV1875-E17D
4Y1G	;	1.9	;	SAV1875-E17N
1SVN	;	1.4	;	SAVINASE
4CFY	;	1.17	;	SAVINASE CRYSTAL STRUCTURES FOR COMBINED SINGLE CRYSTAL DIFFRACTION AND POWDER DIFFRACTION ANALYSIS
4CFZ	;	1.57	;	SAVINASE CRYSTAL STRUCTURES FOR COMBINED SINGLE CRYSTAL DIFFRACTION AND POWDER DIFFRACTION ANALYSIS
4CG0	;	1.36	;	Savinase crystal structures for combined single crystal diffraction and powder diffraction analysis
6O0D	;	2.5	;	Saxiphilin Apo structure
6O0F	;	2.12	;	Saxiphilin:STX complex, co-crystal
6O0E	;	2.5	;	Saxiphilin:STX complex, soaking
8I0D	;	1.43	;	Sb3GT1 375S/Q377H mutant complex with UDP-Glc
8I0E	;	1.9	;	Sb3GT1 complex with UDP
4KEC	;	2.4	;	SbHCT-complex form
5UJD	;	2.1	;	SbnI from Staphylococcus pseudintermedius
5UJE	;	2.5	;	SbnI with C-terminal truncation from Staphylococcus aureus
6PQL	;	2.65	;	SBP RafE in complex with raffinose
6PRG	;	2.35	;	SBP RafE in complex with stachyose
6PRE	;	2.4	;	SBP RafE in complex with verbascose
7WAR	;	2.101	;	SbSOMT in complex with pinostilbene and nicotinamide adenine dinucleotide(NAD+)
7WAS	;	2.401	;	SbSOMT in complex with pterostilbene and nicotinamide adenine dinucleotide(NAD+)
7WAQ	;	2.56	;	SbSOMT in complex with resveratrol
7VB8	;	1.72	;	SbSOMT in complex with resveratrol and nicotinamide adenine dinucleotide(NAD+)
1W1W	;	2.9	;	Sc Smc1hd:Scc1-C complex, ATPgS
6R8E	;		;	SC14 G-hairpin
6VPA	;	1.5	;	Scabin (N110A) toxin from Streptomyces scabies
6VUV	;	1.55	;	Scabin (S117A) toxin from Streptomyces scabies
6VV4	;	1.7	;	Scabin (V109G) toxin from Streptomyces scabies
6APY	;	1.5	;	Scabin (W128Y) toxin from Streptomyces scabies
5UVQ	;	1.6	;	Scabin (W155A) toxin from Streptomyces scabies
6VVF	;	1.75	;	Scabin (Y129H) toxin from Streptomyces scabies
5EWY	;	1.4	;	Scabin toxin from Streptomyces Scabies in complex with inhibitor P6E
5EWK	;	1.6	;	Scabin toxin from Streptomyces Scabies in complex with inhibitor PJ34
5TLB	;	1.7	;	Scabin toxin from Streptomyces scabies in complex with NADH
4BHZ	;	2.85	;	Scaffold Focused Virtual Screening: Prospective Application to the Discovery of TTK Inhibitor
4BI0	;	2.84	;	Scaffold Focused Virtual Screening: Prospective Application to the Discovery of TTK Inhibitor
4BI1	;	2.7	;	Scaffold Focused Virtual Screening: Prospective Application to the Discovery of TTK Inhibitor
4BI2	;	3.11	;	Scaffold Focused Virtual Screening: Prospective Application to the Discovery of TTK Inhibitor
8D95	;	2.166	;	Scaffold Hopping via Ring Opening Enables Identification of Acyclic Compounds as New Complement Factor D Inhibitors
8DEA	;	2.214	;	Scaffold Hopping via Ring Opening Enables Identification of Acyclic Compounds as New Complement Factor D Inhibitors
8DG6	;	1.986	;	Scaffold Hopping via Ring Opening Enables Identification of Acyclic Compounds as New Complement Factor D Inhibitors
8PHT	;	6.37	;	Scaffold rings inside the Borrelia bacteriophage BB1 procapsid
3V1S	;	2.328	;	Scaffold tailoring by a newly detected Pictet-Spenglerase ac-tivity of strictosidine synthase (STR1): from the common tryp-toline skeleton to the rare piperazino-indole framework
6Y3E	;	1.45	;	Scaffold-ligand complex with ligand unmodelled
6YBM	;	1.41	;	Scaffold-ligand complex with ligand unmodelled.
4FL4	;	2.8	;	Scaffoldin conformation and dynamics revealed by a ternary complex from the Clostridium thermocellum cellulosome
8DT0	;	2.46	;	Scaffolding protein functional sites using deep learning
8E1E	;	4.27	;	Scaffolding protein functional sites using deep learning
8AYI	;	2.2	;	Scalindua brodae amxFabZ H48N mutant
8AYC	;	1.75	;	Scalindua brodae amxFabZ, I69G mutant
1KK8	;	2.3	;	SCALLOP MYOSIN (S1-ADP-BeFx) IN THE ACTIN-DETACHED CONFORMATION
1KK7	;	3.2	;	SCALLOP MYOSIN IN THE NEAR RIGOR CONFORMATION
1WDC	;	2.0	;	SCALLOP MYOSIN REGULATORY DOMAIN
1DFL	;	4.2	;	SCALLOP MYOSIN S1 COMPLEXED WITH MGADP:VANADATE-TRANSITION STATE
1L2O	;	2.8	;	SCALLOP MYOSIN S1-ADP-p-PDM IN THE ACTIN-DETACHED CONFORMATION
1KQM	;	3.0	;	SCALLOP MYOSIN S1-AMPPNP IN THE ACTIN-DETACHED CONFORMATION
1KWO	;	3.8	;	SCALLOP MYOSIN S1-ATPgammaS-p-PDM IN THE ACTIN-DETACHED CONFORMATION
5HBI	;	1.6	;	SCAPHARCA DIMERIC HEMOGLOBIN, MUTANT T72I, CO-LIGANDED FORM
4HBI	;	1.6	;	SCAPHARCA DIMERIC HEMOGLOBIN, MUTANT T72I, DEOXY FORM
7HBI	;	1.6	;	SCAPHARCA DIMERIC HEMOGLOBIN, MUTANT T72V, CO-LIGANDED FORM
6HBI	;	1.8	;	SCAPHARCA DIMERIC HEMOGLOBIN, MUTANT T72V, DEOXY FORM
4HRR	;	1.25	;	Scapharca tetrameric hemoglobin, CO-state
4HRT	;	1.46	;	Scapharca tetrameric hemoglobin, unliganded
5DGK	;	2.895	;	SCCmec type IV Cch - active helicase
6BTC	;	2.17741	;	SCCmec type IV LP1413 - nucleic acids binding protein
4TXE	;	1.8	;	ScCTS1 in complex with compound 5
2UY3	;	1.9	;	ScCTS1_8-chlorotheophylline crystal structure
2UY4	;	1.75	;	ScCTS1_acetazolamide crystal structure
2UY2	;	1.6	;	ScCTS1_apo crystal structure
2UY5	;	1.6	;	ScCTS1_kinetin crystal structure
7JIZ	;	1.85	;	ScDLH
6S50	;	2.0	;	scdSav(SARK)mv2 - Engineering Single-Chain Dimeric Streptavidin as Host for Artificial Metalloenzymes
6S4Q	;	1.85	;	scdSav(SASK) - Engineering Single-Chain Dimeric Streptavidin as Host for Artificial Metalloenzymes
5I4F	;	1.549	;	scFv 2D10 complexed with alpha 1,6 mannobiose
5VF2	;	1.55	;	scFv 2D10 re-refined as a complex with trehalose replacing the original alpha-1,6-mannobiose
6EHV	;	2.54	;	scFv AbVance: increasing our knowledge of antibody structural space to enable faster and better decision making in drug discovery
6EHW	;	2.19	;	scFv AbVance: increasing our knowledge of antibody structural space to enable faster and better decision making in drug discovery
6EHX	;	2.2	;	scFv AbVance: increasing our knowledge of antibody structural space to enable faster and better decision making in drug discovery
6EHY	;	2.25	;	scFv AbVance: increasing our knowledge of antibody structural space to enable faster and better decision making in drug discovery
4KV5	;	3.0	;	scFv GC1009 in complex with TGF-beta1.
6TGG	;	2.0	;	scFv-1SM3 in complex with glycopeptide containing an sp2-imino sugar
3UMT	;	1.798	;	scFv12, Anti-BclA antibody single chain variable fragment
1EUA	;	1.95	;	SCHIFF BASE INTERMEDIATE IN KDPG ALDOLASE FROM ESCHERICHIA COLI
1H7P	;	1.64	;	SCHIFF-BASE COMPLEX OF YEAST 5-AMINOLAEVULINIC ACID DEHYDRATASE WITH 4-KETO-5-AMINO-HEXANOIC (KAH) AT 1.64 A RESOLUTION
1GJP	;	1.8	;	SCHIFF-BASE COMPLEX OF YEAST 5-AMINOLAEVULINIC ACID DEHYDRATASE WITH 4-OXOSEBACIC ACID
1H7O	;	1.75	;	SCHIFF-BASE COMPLEX OF YEAST 5-AMINOLAEVULINIC ACID DEHYDRATASE WITH 5-AMINOLAEVULINIC ACID AT 1.7 A RESOLUTION
1YLV	;	2.15	;	SCHIFF-BASE COMPLEX OF YEAST 5-AMINOLAEVULINIC ACID DEHYDRATASE WITH LAEVULINIC ACID
1H7N	;	1.6	;	SCHIFF-BASE COMPLEX OF YEAST 5-AMINOLAEVULINIC ACID DEHYDRATASE WITH LAEVULINIC ACID AT 1.6 A RESOLUTION
1H7R	;	2.0	;	SCHIFF-BASE COMPLEX OF YEAST 5-AMINOLAEVULINIC ACID DEHYDRATASE WITH SUCCINYLACETONE AT 2.0 A RESOLUTION.
5TIV	;	1.43	;	Schistosoma haematobium (Blood Fluke) Sulfotransferase
6B53	;	1.6	;	Schistosoma haematobium (Blood Fluke) Sulfotransferase, S166T Mutant
6B51	;	2.05	;	Schistosoma haematobium (Blood Fluke) Sulfotransferase, Y54F Mutant
6UUY	;	1.37	;	Schistosoma haematobium (Blood Fluke) Sulfotransferase/Hycanthone Complex
6B54	;	1.8	;	Schistosoma haematobium (Blood Fluke) Sulfotransferase/Oxamniquine Complex, S166T Mutant
6B52	;	1.8	;	Schistosoma haematobium (Blood Fluke) Sulfotransferase/Oxamniquine Complex, Y54F Mutant
5TIX	;	1.78	;	Schistosoma haematobium (Blood Fluke) Sulfotransferase/R-oxamniquine Complex
5TIW	;	1.66	;	Schistosoma haematobium (Blood Fluke) Sulfotransferase/Racemic Oxamniquine Complex
5TIY	;	1.76	;	Schistosoma haematobium (Blood Fluke) Sulfotransferase/S-oxamniquine Complex
5TIZ	;	2.87	;	Schistosoma japonicum (Blood Fluke) Sulfotransferase
4MUA	;	1.95	;	Schistosoma mansoni (Blood Fluke) Sulfotransferase
6B4X	;	1.46	;	Schistosoma mansoni (Blood Fluke) Sulfotransferase, F39Y Mutant
6B4Z	;	1.74	;	Schistosoma mansoni (Blood Fluke) Sulfotransferase, T157S Mutant
6BDP	;	1.43	;	Schistosoma mansoni (Blood Fluke) Sulfotransferase/CIDD-0000071 (Compound 9c) Complex
6BDQ	;	1.83	;	Schistosoma mansoni (Blood Fluke) Sulfotransferase/CIDD-0000074 (Compound 10a) Complex
6BDS	;	1.53	;	Schistosoma mansoni (Blood Fluke) Sulfotransferase/CIDD-0000204 (Compound 11f) Complex
6BDR	;	1.66	;	Schistosoma mansoni (Blood Fluke) Sulfotransferase/CIDD-0000206 (Compound 9f) Complex
6MFE	;	1.444	;	Schistosoma mansoni (Blood Fluke) Sulfotransferase/CIDD-0000773 (Compound 11g) Complex
8E5Q	;	1.33	;	Schistosoma mansoni (Blood Fluke) Sulfotransferase/CIDD-0150303 Complex
8E5R	;	1.4	;	Schistosoma mansoni (Blood Fluke) Sulfotransferase/CIDD-0150610 Complex
6UUX	;	1.5	;	Schistosoma mansoni (Blood Fluke) Sulfotransferase/Hycanthone Complex
4MUB	;	1.75	;	Schistosoma mansoni (Blood Fluke) Sulfotransferase/Oxamniquine Complex
6B4Y	;	1.95	;	Schistosoma mansoni (Blood Fluke) Sulfotransferase/Oxamniquine Complex, F39Y Mutant
6B50	;	1.87	;	Schistosoma mansoni (Blood Fluke) Sulfotransferase/Oxamniquine Complex, T157S Mutant
5BYJ	;	1.8	;	Schistosoma mansoni (Blood Fluke) Sulfotransferase/R-oxamniquine Complex
5BYK	;	1.28	;	Schistosoma mansoni (Blood Fluke) Sulfotransferase/S-oxamniquine Complex
3UMF	;	2.047	;	Schistosoma mansoni adenylate kinase
7YZH	;	1.79	;	Schistosoma Mansoni Carbonic Anhydrase in complex with 4-oxo-N-(4-sulfamoylphenethyl)-1,3,4,6,7,11b-hexahydro-2H-pyrazino[2,1-a]isoquinoline-2-carbothioamide
3VCO	;	1.946	;	Schistosoma mansoni Dihydrofolate reductase
1VYG	;	2.4	;	schistosoma mansoni fatty acid binding protein in complex with arachidonic acid
1VYF	;	1.85	;	schistosoma mansoni fatty acid binding protein in complex with oleic acid
6EZU	;	2.04	;	Schistosoma mansoni Phosphodiesterase 4A
6FG5	;	2.35	;	Schistosoma mansoni Phosphodiesterase 4A
2POA	;		;	Schistosoma mansoni Sm14 Fatty Acid-Binding Protein: improvement of protein stability by substitution of the single Cys62 residue
3IEX	;	2.05	;	Schistosoma Purine nucleoside phosphorylase in complex with guanosine
3S6I	;	2.28	;	Schizosaccaromyces pombe 3-methyladenine DNA glycosylase (Mag1) in complex with abasic-DNA.
6O2D	;	2.52	;	Schizosaccharomyces pombe Cnp3 Cupin Domain
4QYT	;	1.05	;	Schizosaccharomyces pombe DJ-1
4GE0	;	1.45	;	Schizosaccharomyces pombe DJ-1 T114P mutant
4GE3	;	1.5	;	Schizosaccharomyces pombe DJ-1 T114V mutant
3DAV	;	2.2	;	Schizosaccharomyces Pombe Profilin crystallized from Sodium formate
7AOD	;	4.5	;	Schizosaccharomyces pombe RNA polymerase I (dimer)
7AOE	;	3.9	;	Schizosaccharomyces pombe RNA polymerase I (elongation complex)
7AOC	;	3.84	;	Schizosaccharomyces pombe RNA polymerase I (monomer)
7A56	;	1.85	;	Schmallenberg Virus Envelope Glycoprotein Gc Fusion Domains in Postfusion Conformation
6H3T	;	2.836	;	Schmallenberg Virus Glycoprotein Gc Head Domain in Complex with scFv 1C11
6H3U	;	3.168	;	Schmallenberg Virus Glycoprotein Gc Head Domain in Complex with scFv 4B6
6H3S	;	2.023	;	Schmallenberg Virus Glycoprotein Gc Head/Stalk Domains
4JNG	;	2.12	;	Schmallenberg virus nucleoprotein-RNA complex
4Z2F	;	2.5	;	Sclerotium Rolfsii lectin variant (SSR2) with fine carbohydrate specificity
1PK3	;	1.85	;	Scm SAM domain
4I52	;	2.35	;	scMenB im complex with 1-hydroxy-2-naphthoyl-CoA
7MEL	;	1.75	;	Sco GlgEI-V279S in complex with 4-alpha-glucoside of validamine
7MGY	;	1.83	;	Sco GlgEI-V279S in complex with 4-alpha-glucoside of valienamine
5VSJ	;	2.456	;	Sco GlgEI-V279S in complex with a pyrolidene-based ethyl-phosphonate compound
5VT4	;	3.205	;	Sco GlgEI-V279S in complex with a pyrolidene-based methyl-phosphonate compound
7UVD	;	2.73	;	Sco GlgEI-V279S in complex with cyclohexyl carbasugar
8D6K	;	2.73	;	Sco GlgEI-V279S in complex with cyclohexyl carbasugar
4U31	;	1.849	;	Sco GlgEI-V279S in Complex with maltose-C-phosphonate
4U2Y	;	2.483	;	Sco GlgEI-V279S in Complex with Reaction Intermediate Azasugar
7PT0	;	1.89	;	SCO3201 with putative ligand
3D7J	;	1.45	;	SCO6650, a 6-pyruvoyltetrahydropterin synthase homolog from Streptomyces coelicolor
6XO3	;	1.85	;	ScoE with alpha-ketoglutarate in an off-site
6XPA	;	2.1	;	ScoE with oxovanadium and the CABA substrate bound and His299 and Arg157 flipped out
6XOJ	;	1.45	;	ScoE with the CABA substrate bound and alpha-ketoglutarate in an off-site
6XN6	;	1.7	;	ScoE with the CABA substrate bound and His299 and Arg157 flipped out
3IXW	;	8.0	;	Scorpion Hemocyanin activated state pseudo atomic model built based on cryo-EM density map
3IXV	;	6.8	;	Scorpion Hemocyanin resting state pseudo atomic model built based on cryo-EM density map
1WMT	;		;	Scorpion toxin (IsTX) from Opisthacanthus madagascariensis
1TXM	;		;	SCORPION TOXIN (MAUROTOXIN) FROM SCORPIO MAURUS, NMR, 35 STRUCTURES
1SXM	;		;	SCORPION TOXIN (NOXIUSTOXIN) WITH HIGH AFFINITY FOR VOLTAGE DEPENDENT POTASSIUM CHANNEL AND LOW AFFINITY FOR CALCIUM DEPENDENT POTASSIUM CHANNEL (NMR AT 20 DEGREES, PH3.5, 39 STRUCTURES)
1SCO	;		;	SCORPION TOXIN (OSK1 TOXIN) WITH HIGH AFFINITY FOR SMALL CONDUCTANCE CA(2+)-ACTIVATED K+ CHANNEL IN NEUROBLASTOMA-X-GLUOMA NG 108-15 HYBRID CELLS, NMR, 30 STRUCTURES
1TSK	;		;	SCORPION TOXIN (TS KAPPA) FROM TITYUS SERRULATUS ACTIVE ON SMALL CONDUCTANCE POTASSIUM CHANNEL, NMR, 30 STRUCTURES
1BCG	;	2.1	;	SCORPION TOXIN BJXTR-IT
1BIG	;		;	SCORPION TOXIN BMTX1 FROM BUTHUS MARTENSII KARSCH, NMR, 25 STRUCTURES
2BMT	;		;	SCORPION TOXIN BMTX2 FROM BUTHUS MARTENSII KARSCH, NMR, 25 STRUCTURES
2ASC	;	1.1	;	Scorpion toxin LQH-alpha-IT
6NEI	;	1.85	;	Scoulerine 9-O-methyltransferase from Thalictrum flavum
6NEJ	;	1.6	;	scoulerine 9-O-methyltransferase from Thalictrum flavum complexed (13aS)-3,10-dimethoxy-5,8,13,13a-tetrahydro-6H-isoquino[3,2-a]isoquinoline-2,9-diol and with S-ADENOSYL-L-HOMOCYSTEINE
7EGD	;	6.75	;	SCP promoter-bound TFIID-TFIIA in initial TBP-loading state
7EGJ	;	8.64	;	SCP promoter-bound TFIID-TFIIA in post TBP-loading state
7YZX	;	1.9	;	ScpA from Streptococcus pyogenes, D783A mutant.
7BJ3	;	2.6	;	ScpA from Streptococcus pyogenes, S512A active site mutant
2QZF	;	14.0	;	SCR1 of DAF from 1ojv fitted into cryoEM density
2QZH	;	14.0	;	SCR2/3 of DAF from the NMR structure 1nwv fitted into a cryoEM reconstruction of CVB3-RD complexed with DAF
2VXL	;	2.7	;	Screening a Limited Structure-based Library Identifies UDP-GalNAc- Specific Mutants of alpha-1,3 Galactosyltransferase
2VXM	;	2.82	;	Screening a Limited Structure-based Library Identifies UDP-GalNAc- Specific Mutants of alpha-1,3 Galactosyltransferase
1WCC	;	2.2	;	screening for fragment binding by X-ray crystallography
2X0Y	;	2.25	;	Screening-based discovery of drug-like O-GlcNAcase inhibitor scaffolds
8HOA	;	1.676	;	ScRIPK mutant K124R
8HOD	;	1.95	;	ScRIPK MUTANT-S253A, T254A
8HO6	;	2.1	;	ScRIPK WT
4NPA	;	2.1	;	Scrystal structure of protein with unknown function from Vibrio cholerae at P22121 spacegroup
7AWA	;	3.5	;	SctV (SsaV) cytoplasmic domain
7TUS	;	2.4	;	Sculpting a uniquely reactive cysteine residue for site-specific antibody conjugation
3STD	;	1.65	;	SCYTALONE DEHYDRATASE AND CYANOCINNOLINE INHIBITOR
2STD	;	2.1	;	SCYTALONE DEHYDRATASE COMPLEXED WITH TIGHT-BINDING INHIBITOR CARPROPAMID
5STD	;	1.95	;	SCYTALONE DEHYDRATASE PLUS INHIBITOR 2
6STD	;	1.8	;	SCYTALONE DEHYDRATASE PLUS INHIBITOR 3
7STD	;	1.8	;	SCYTALONE DEHYDRATASE PLUS INHIBITOR 4
7PLH	;	3.57	;	Scytonema hofmannii TnsC bound to AMPPNP and DNA
6WJN	;	5.7	;	SD-like state of human 26S Proteasome with non-cleavable M1-linked hexaubiquitin and E3 ubiquitin ligase E6AP/UBE3A
8R1C	;	2.2	;	SD1-2 Fab in complex with SARS-CoV-2 BA.2.12.1 Spike Glycoprotein
8R1D	;	2.37	;	SD1-3 Fab in complex with SARS-CoV-2 BA.2.12.1 Spike Glycoprotein
8D48	;	3.7	;	sd1.040 Fab in complex with SARS-CoV-2 Spike 2P glycoprotein
8ACA	;	2.54	;	SDBC DR_0644 subunit, only-Cu Superoxide Dismutase
6CP0	;	3.01	;	SdcA in complex with the E2, UbcH5C
7FT8	;	2.4	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with NCL-00024671
7FT6	;	1.85	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with POB0008
7FT5	;	1.77	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with POB0093
7FSY	;	2.8	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z1148165337
7FTB	;	2.22	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z1198269757
7FSX	;	1.91	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z1328078283
7FSQ	;	2.07	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z1429867185
7FSV	;	2.25	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z1454310449
7FTC	;	1.87	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z1509711879
7FSP	;	1.86	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z1650168321
7FSW	;	2.14	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z169675004
7FSI	;	2.31	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z18197050
7FSK	;	2.4	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z1954800564
7FSO	;	1.9	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z198195770
7FT1	;	2.11	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z2204875953
7FTA	;	2.03	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z228589380
7FT2	;	2.04	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z235449082
7FSN	;	2.4	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z254580486
7FST	;	1.98	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z26968795
7FTD	;	1.8	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z27782662
7FT3	;	2.05	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z291279160
7FSZ	;	2.05	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z3006151474
7FSH	;	2.11	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z32367954
7FT9	;	1.77	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z45636695
7FT4	;	2.17	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z48847594
7FSR	;	2.29	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z54615640
7FT0	;	2.45	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z56767614
7FSG	;	2.02	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z56772132
7FT7	;	1.78	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z57127349
7FSJ	;	1.97	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z57744712
7FSU	;	1.97	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z729726784
7FSL	;	2.38	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z730649594
7FSM	;	2.1	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z763030030
7FSS	;	2.11	;	SDCBP PanDDA analysis group deposition -- The PDZ domans of SDCBP in complex with Z839706072
7N99	;		;	SDE2 SAP domain apo structure
6WTG	;	2.63	;	SdeA DUB Domain in complex with Ubiquitin
5YSK	;	2.403	;	SdeA mART-C domain EE/AA apo
5YSI	;	1.546	;	SdeA mART-C domain EE/AA NCA complex
5YSJ	;	2.059	;	SdeA mART-C domain WT apo
1A15	;	2.2	;	SDF-1ALPHA
6C12	;	2.15	;	SDHA-SDHE complex
4Y15	;	2.835	;	SdiA in complex with 3-oxo-C6-homoserine lactone
4Y17	;	2.84	;	SdiA in complex with 3-oxo-C8-homoserine lactone
4Y13	;	3.096	;	SdiA in complex with octanoyl-rac-glycerol
7XSI	;	2.7	;	SdnG, a Diels Alderase catalyzed the formation of norbornene skeleton in Sordarin biosynthetic pathway
7BSX	;	2.0	;	SDR protein NapW-NADP
7BTM	;	2.08312	;	SDR protein/resistance protein NapW
5AJL	;	3.45	;	Sdsa sulfatase tetragonal
5A23	;	2.41	;	SdsA sulfatase triclinic form
7MY6	;	2.02	;	Se-CrtE C-term His-tag with IPP added
7MY7	;	2.36	;	Se-CrtE N-term His-tag structure
7E1D	;	2.002	;	Se-DBD
8K5U	;	2.15	;	Se-glycosyltransferase RsSenB
7QE3	;	2.2	;	Se-M variant of B-trefoil lectin from Salpingoeca rosetta in complex with GalNAc
7QOC	;	2.3	;	Se-Met derivative structure of a small alarmone hydrolase (RelH) from Corynebacterium glutamicum
4A7P	;	3.403	;	Se-Met derivatized UgdG, UDP-glucose dehydrogenase from Sphingomonas elodea
2Y3G	;	1.91	;	Se-Met form of Cupriavidus metallidurans CH34 CnrXs
6IQO	;	2.11	;	Se-Met L45M Programmed Cell Death 5 protein from Sulfolobus solfataricus
8Q28	;	1.8	;	Se-Met labelled TtX122A - A domain of unknown function from the Teredinibacter turnerae protein TERTU_3803
3GYO	;	3.1	;	Se-Met Rtt106p
6OI7	;	2.9	;	Se-Met structure of apo- Escherichia coli dGTPase
4ZE9	;	2.65	;	Se-PBP AccA from A. tumefaciens C58 in complex with agrocinopine A
5OQ2	;	2.3	;	Se-SAD structure of the functional region of Cwp19 from Clostridium difficile
1BGK	;		;	SEA ANEMONE TOXIN (BGK) WITH HIGH AFFINITY FOR VOLTAGE DEPENDENT POTASSIUM CHANNEL, NMR, 15 STRUCTURES
7MI2	;	1.4	;	Seb1-G476S RNA binding domain
3JRP	;	2.6	;	SEC13 with NUP145C (AA109-179) insertion blade
3MZK	;	2.69	;	Sec13/Sec16 complex, S.cerevisiae
3MZL	;	2.8	;	Sec13/Sec31 edge element, loop deletion mutant
2E2X	;	2.5	;	Sec14 Homology Module of Neurofibromin in complex with phosphatitylethanolamine
1IFQ	;	2.4	;	Sec22b N-terminal domain
3DKN	;	8.7	;	Sec61 in the Canine ribosome-channel complex from the endoplasmic reticulum
4JMI	;	1.5	;	Sec7 domain of ARNO, an exchange factor, at 1.5 Angstrom resolution
1R8M	;	1.7	;	SEC7 DOMAIN OF THE ARF EXCHANGE FACTOR ARNO WITH BREFELDIN A-SENSITIZING MUTATIONS
1PBV	;	2.0	;	SEC7 DOMAIN OF THE EXCHANGE FACTOR ARNO
6GOX	;	3.5	;	SecA
5K9T	;	2.6	;	SecA-N68, a C-terminal truncation of the SecA ATPase from E. coli
2CG6	;	1.55	;	Second and third fibronectin type I module pair (crystal form I).
2CG7	;	1.2	;	SECOND AND THIRD FIBRONECTIN TYPE I MODULE PAIR (CRYSTAL FORM II).
1VRY	;		;	Second and Third Transmembrane Domains of the Alpha-1 Subunit of Human Glycine Receptor
1QI6	;	2.5	;	SECOND APO FORM OF AN NADP DEPENDENT ALDEHYDE DEHYDROGENASE WITH GLU250 SITUATED 3.7 A FROM CYS284
2K2W	;		;	Second BRCT domain of NBS1
5N18	;	1.45	;	Second Bromodomain (BD2) from Candida albicans Bdf1 bound to an imidazopyridine (compound 2)
5N13	;	1.2	;	Second Bromodomain (BD2) from Candida albicans Bdf1 in the unbound form
5TCK	;	1.95	;	Second Bromodomain from Leishmania donovani LdBPK.091320 complexed with Bromosporine
7UG5	;	1.8	;	Second bromodomain of BRD3 liganded with BMS-536924
5U9N	;	2.4	;	Second Bromodomain of cdg4_1340 from Cryptosporidium parvum, complexed with bromosporine
6DBC	;	1.05	;	Second bromodomain of Human BRD2 with a Tetrahydroquinoline analogue
5I1Q	;	1.5	;	Second bromodomain of TAF1 bound to a pyrrolopyridone compound
2KLT	;		;	Second Ca2+ binding domain of NCX1.3
2FWU	;		;	Second Ca2+ binding domain of the Na,Ca-exchanger (NCX1)
1BHD	;	2.0	;	SECOND CALPONIN HOMOLOGY DOMAIN FROM UTROPHIN
7URP	;	1.03	;	Second cohesin module from Sca5 of Ruminococcus bromii
7ZVC	;	1.85	;	Second crystal form of the mature glutamic-class prolyl-endopeptidase neprosin at 1.85 A resolution.
6YET	;		;	Second EH domain of AtEH1/Pan1
6YEU	;		;	Second EH domain of AtEH1/Pan1
2V9S	;	2.0	;	Second LRR domain of human Slit2
1Q8L	;		;	Second Metal Binding Domain of the Menkes ATPase
1CX1	;		;	SECOND N-TERMINAL CELLULOSE-BINDING DOMAIN FROM CELLULOMONAS FIMI BETA-1,4-GLUCANASE C, NMR, 22 STRUCTURES
4E4P	;	1.92	;	Second native structure of Xylanase A1 from Paenibacillus sp. JDR-2
6GVK	;	1.55	;	Second pair of Fibronectin type III domains of integrin beta4 (T1663R mutant) bound to the bullous pemphigoid antigen BP230 (BPAG1e)
6GVL	;	2.05	;	Second pair of Fibronectin type III domains of integrin beta4 bound to the bullous pemphigoid antigen BP230 (BPAG1e)
2KQC	;		;	Second PBZ domain of human APLF protein
2KQE	;		;	Second PBZ domain of human APLF protein in complex with ribofuranosyladenosine
1GM1	;		;	Second PDZ Domain (PDZ2) of PTP-BL
3LNX	;	1.642	;	Second PDZ domain from human PTP1E
3LNY	;	1.3	;	Second PDZ domain from human PTP1E in complex with RA-GEF2 peptide
5E11	;	1.8	;	Second PDZ domain of Ligand of Numb protein X 2 by Laue crystallography (no electric field)
1QG9	;		;	SECOND REPEAT (IS2MIC) FROM VOLTAGE-GATED SODIUM CHANNEL
1LDR	;		;	SECOND REPEAT OF THE LDL RECEPTOR LIGAND-BINDING DOMAIN
7RCD	;	2.448	;	Second stage reengineered variant of I-OnuI targeting human PD1 gene with activity enhancing substitutions
4CGW	;	3.001	;	Second TPR of Spaghetti (RPAP3) bound to HSP90 peptide SRMEEVD
5M9Z	;		;	Second zinc-binding domain from yeast Pcf11
2XPC	;	1.49	;	Second-generation sulfonamide inhibitors of MurD: Activity optimisation with conformationally rigid analogues of D-glutamic acid
4PZY	;	1.88	;	Second-site screening of K-Ras in the presence of covalently attached first-site ligands
4PZZ	;	1.403	;	Second-site screening of K-Ras in the presence of covalently attached first-site ligands
4Q01	;	1.291	;	Second-site screening of K-Ras in the presence of covalently attached first-site ligands
4Q02	;	1.702	;	Second-site screening of K-Ras in the presence of covalently attached first-site ligands
4Q03	;	1.201	;	Second-site screening of K-Ras in the presence of covalently attached first-site ligands
1CNW	;	2.0	;	SECONDARY INTERACTIONS SIGNIFICANTLY REMOVED FROM THE SULFONAMIDE BINDING POCKET OF CARBONIC ANHYDRASE II INFLUENCE BINDING CONSTANTS
1CNX	;	1.9	;	SECONDARY INTERACTIONS SIGNIFICANTLY REMOVED FROM THE SULFONAMIDE BINDING POCKET OF CARBONIC ANHYDRASE II INFLUENCE BINDING CONSTANTS
1CNY	;	2.3	;	SECONDARY INTERACTIONS SIGNIFICANTLY REMOVED FROM THE SULFONAMIDE BINDING POCKET OF CARBONIC ANHYDRASE II INFLUENCE BINDING CONSTANTS
1NTX	;		;	SECONDARY STRUCTURE DETERMINATION FOR ALPHA-NEUROTOXIN FROM DENDROASPIS POLYLEPIS POLYLEPIS BASED ON SEQUENCE SPECIFIC PROTON NUCLEAR MAGNETIC RESONANCE ASSIGNMENTS
8BAV	;	2.3	;	Secretagogin (human) in complex with its target peptide from SNAP-25
8BAN	;	2.35	;	Secretagogin (mouse) in complex with its target peptide from SNAP-25
8BBJ	;	2.65	;	Secretagogin (mouse) in complex with its target peptide from Syntaxin-4
3FV3	;	1.85	;	Secreted aspartic protease 1 from Candida parapsilosis in complex with pepstatin A
3PVK	;	1.27	;	Secreted aspartic protease 2 in complex with benzamidine
1ZAP	;	2.5	;	SECRETED ASPARTIC PROTEASE FROM C. ALBICANS
3Q70	;	1.4	;	Secreted aspartic protease in complex with ritonavir
2QZW	;	2.05	;	Secreted aspartic proteinase (Sap) 1 from Candida albicans
2H6S	;	2.2	;	Secreted aspartic proteinase (Sap) 3 from Candida albicans
2H6T	;	1.9	;	Secreted aspartic proteinase (Sap) 3 from Candida albicans complexed with pepstatin A
2QZX	;	2.5	;	Secreted aspartic proteinase (Sap) 5 from Candida albicans
1EAG	;	2.1	;	Secreted aspartic proteinase (SAP2) from Candida albicans complexed with A70450
4JDN	;	2.0	;	Secreted Chlamydial Protein PGP3, C-terminal Domain
4JDO	;	2.3	;	Secreted chlamydial protein pgp3, coiled-coil deletion
4JDM	;	3.1	;	Secreted Chlamydial Protein PGP3, full-length
2FP1	;	1.55	;	Secreted Chorismate Mutase from Mycobacterium tuberculosis
2FP2	;	1.64	;	Secreted Chorismate Mutase from Mycobacterium tuberculosis
7VS2	;	2.5	;	secreted fungal effector protein MoErs1
5HZL	;	2.75	;	Secreted Internalin-like protein Lmo2445 from Listeria monocytogenes
6G5J	;	1.85	;	Secreted phospholipase A2 type X in complex with ligand
3HE1	;	2.098	;	Secreted protein Hcp3 from Pseudomonas aeruginosa.
6BQM	;	2.2	;	Secreted serine protease VesC from Vibrio cholerae
6I1M	;	1.6	;	Secreted type 1 cystatin from Fasciola hepatica
7JG2	;	3.3	;	Secretory Immunoglobin A (SIgA)
1AWT	;	2.55	;	SECYPA COMPLEXED WITH HAGPIA
1AWS	;	2.55	;	SECYPA COMPLEXED WITH HAGPIA (PSEUDO-SYMMETRIC MONOMER)
6CQS	;	1.7	;	Sediminispirochaeta smaragdinae SPS-1 metallo-beta-lactamase
5BY2	;	2.8	;	Sedoheptulose 7-phosphate isomerase from Colwellia psychrerythraea strain 34H
8OT4	;	2.97	;	seeded Abeta(1-40) amyloid fibril (morphology I)
2K3B	;		;	Seeing the Invisible: Structures of Excited Protein States by Relaxation Dispersion NMR
6N3B	;	3.8	;	SegA-asym, conformation of TDP-43 low complexity domain segment A asym
6N3A	;	3.3	;	SegA-long, conformation of TDP-43 low complexity domain segment A long
6N37	;	3.8	;	SegA-sym, conformation of TDP-43 low complexity domain segment A sym
6N3C	;	3.3	;	SegB, conformation of TDP-43 low complexity domain segment A
6CB9	;	1.1	;	Segment AALQSS from the low complexity domain of TDP-43, residues 328-333
6CEW	;	1.2	;	Segment AMMAAA from the low complexity domain of TDP-43, residues 321-326
6AXZ	;	0.75	;	Segment from bank vole prion protein 168-176 QYNNQNNFV
6BTK	;	1.1	;	Segment from bank vole prion protein 168-176 QYNNQNNFV
7RVI	;	1.05	;	Segment from naked mole rat (elk T174S) prion protein 168-176 QYNNQNSFV
7RVG	;	1.0	;	Segment from rabbit/pig prion protein 168-176 QYSNQNSFV
7RVC	;	1.002	;	Segment from the human prion protein 168-176 EYSNQNNFV
7RVJ	;	1.0	;	Segment from the human prion protein 169-175 YSNQNNF
7RVD	;	1.003	;	Segment from the mouse/cow prion protein 168-176 QYSNQNNFV
7RVE	;	0.85	;	Segment from the S170N mutant of the human prion protein 168-176 EYNNQNNFV
7RVF	;	1.0	;	Segment from the Y169F mutant of the bank vole prion protein 168-176 QFNNQNNFV
7RVL	;	1.0	;	Segment from the Y169F mutant of the human prion protein 168-176 EFSNQNNFV
7RVK	;	1.0	;	Segment from Y169G mutant of the human prion protein 169-175 GSNQNNF
6CF4	;	0.75	;	Segment NFGTFS, with familial mutation A315T and phosphorylated threonine, from the low complexity domain of TDP-43, residues 312-317
6QY3	;	9.1	;	Segment of the Cas1-Cas2-Csn2-DNA filament complex from the Type II-A CRISPR-Cas system
3DG1	;	1.66	;	Segment SSTNVG derived from IAPP
2JVO	;		;	Segmental isotope labeling of Npl3
2JVR	;		;	Segmental Isotope Labeling of Npl3p
3RN3	;	1.45	;	SEGMENTED ANISOTROPIC REFINEMENT OF BOVINE RIBONUCLEASE A BY THE APPLICATION OF THE RIGID-BODY TLS MODEL
7RSL	;	3.45	;	Seipin forms a flexible cage at lipid droplet formation sites
8PC2	;	2.8	;	SelDeg51 in complex with FKBP51FK1 domain and pVHL:EloB:EloC
1KMB	;	2.1	;	SELECTIN-LIKE MUTANT OF MANNOSE-BINDING PROTEIN A
3L9J	;	2.1	;	Selection of a novel highly specific TNFalpha antagonist: Insight from the crystal structure of the antagonist-TNFalpha complex
4X0M	;	1.68	;	Selection of fragments for kinase inhibitor design: decoration is key
4X2F	;	1.49	;	Selection of fragments for kinase inhibitor design: decoration is key
4X2G	;	1.51	;	Selection of fragments for kinase inhibitor design: decoration is key
4X2J	;	1.69	;	Selection of fragments for kinase inhibitor design: decoration is key
4X2K	;	1.69	;	Selection of fragments for kinase inhibitor design: decoration is key
4X2N	;	1.8	;	Selection of fragments for kinase inhibitor design: decoration is key
4X3J	;	2.5	;	Selection of fragments for kinase inhibitor design: decoration is key
4JW2	;	1.9	;	Selection of specific protein binders for pre-defined targets from an optimized library of artificial helicoidal repeat proteins (alphaRep)
4JW3	;	2.6	;	Selection of specific protein binders for pre-defined targets from an optimized library of artificial helicoidal repeat proteins (alphaRep)
4I5M	;	1.801	;	Selective & Brain-Permeable Polo-like Kinase-2 (Plk-2) Inhibitors that Reduce -Synuclein Phosphorylation in Rat Brain
4I5P	;	1.738	;	Selective & Brain-Permeable Polo-like Kinase-2 (Plk-2) Inhibitors that Reduce -Synuclein Phosphorylation in Rat Brain
4I6B	;	1.8	;	Selective & Brain-Permeable Polo-like Kinase-2 (Plk-2) Inhibitors that Reduce -Synuclein Phosphorylation in Rat Brain
4I6F	;	2.9	;	Selective & Brain-Permeable Polo-like Kinase-2 (Plk-2) Inhibitors that Reduce -Synuclein Phosphorylation in Rat Brain
4I6H	;	1.91	;	Selective & Brain-Permeable Polo-like Kinase-2 (Plk-2) Inhibitors that Reduce alpha-Synuclein Phosphorylation in Rat Brain
4MGI	;	2.8	;	Selective activation of Epac1 and Epac2
4MGK	;	2.7	;	Selective activation of Epac1 and Epac2
4MGY	;	2.6	;	Selective activation of Epac1 and Epac2
4MGZ	;	3.0	;	Selective activation of Epac1 and Epac2
4MH0	;	2.4	;	Selective activation of Epac1 and Epac2
6ST2	;	1.79	;	Selective Affimers Recognize BCL-2 Family Proteins Through Non-Canonical Structural Motifs
6STJ	;	2.2	;	Selective Affimers Recognize BCL-2 Family Proteins Through Non-Canonical Structural Motifs
2GMX	;	3.5	;	Selective Aminopyridine-Based C-Jun N-terminal Kinase inhibitors with cellular activity
2UWL	;	1.9	;	Selective and Dual Action Orally Active Inhibitors of Thrombin and Factor Xa
2UWO	;	1.75	;	Selective and Dual Action Orally Active Inhibitors of Thrombin and Factor Xa
5KEZ	;	1.83	;	Selective and potent inhibition of the glycosidase human amylase by the short and extremely compact peptide piHA from mRNA display
3LC5	;	2.62	;	Selective Benzothiophine Inhibitors of Factor IXa
5FQP	;	1.88	;	Selective estrogen receptor downregulator antagonists: Tetrahydroisoquinoline phenols 1.
5FQR	;	1.88	;	Selective estrogen receptor downregulator antagonists: Tetrahydroisoquinoline phenols 2.
5FQS	;	1.94	;	Selective estrogen receptor downregulator antagonists: Tetrahydroisoquinoline phenols 3.
5FQT	;	1.99	;	Selective estrogen receptor downregulator antagonists: Tetrahydroisoquinoline phenols 4.
5FQV	;	1.74	;	Selective estrogen receptor downregulator antagonists: Tetrahydroisoquinoline phenols 5.
6I1J	;	2.35	;	Selective formation of trinuclear transition metal centers in a trimeric helical peptide
5KXA	;	2.59	;	Selective Inhibition of Autotaxin is Effective in Mouse Models of Liver Fibrosis
6NLV	;	1.794	;	Selective inhibition of carbonic anhydrase IX activity, using compound SLC-149, displays limited anticancer effects in breast cancer cell lines
6NM0	;	1.44	;	Selective inhibition of carbonic anhydrase IX activity, using compound SLC-149, displays limited anticancer effects in breast cancer cell lines
4MYQ	;	1.9	;	Selective Inhibition of the Catalytic Domain Of Human Phosphodiesterase 4B With A-33
1WO9	;		;	Selective inhibition of trypsins by insect peptides: role of P6-P10 loop
4C1I	;	2.4	;	Selective Inhibitors of PDE2, PDE9, and PDE10: Modulators of Activity of the Central Nervous System
1C4U	;	2.1	;	SELECTIVE NON ELECTROPHILIC THROMBIN INHIBITORS WITH CYCLOHEXYL MOIETIES.
1C4V	;	2.1	;	SELECTIVE NON ELECTROPHILIC THROMBIN INHIBITORS WITH CYCLOHEXYL MOIETIES.
1C4Y	;	2.7	;	SELECTIVE NON-ELECTROPHILIC THROMBIN INHIBITORS
2WHW	;	2.2	;	Selective oxidation of carbolide C-H bonds by engineered macrolide P450 monooxygenase
2WI9	;	2.0	;	Selective oxidation of carbolide C-H bonds by engineered macrolide P450 monooxygenase
5CFW	;	1.15	;	Selective pharmacological inhibition of the CREB binding protein bromodomain regulates inflammatory cytokines in macrophages and RGS4 in neurons
5CGP	;	1.96	;	Selective pharmacological inhibition of the CREB binding protein bromodomain regulates inflammatory cytokines in macrophages and RGS4 in neurons
6DGT	;	2.601	;	Selective PI3K beta inhibitor bound to PI3K delta
3H4V	;	2.4	;	Selective screening and design to identify inhibitors of leishmania major pteridine reductase 1
5C45	;	2.93	;	Selective Small Molecule Inhibition of the FMN Riboswitch
5KX9	;	2.9	;	Selective Small Molecule Inhibition of the FMN Riboswitch
4AOF	;	3.3	;	Selective small molecule inhibitor discovered by chemoproteomic assay platform reveals regulation of Th17 cell differentiation by PI3Kgamma
3TC5	;	1.4	;	Selective targeting of disease-relevant protein binding domains by O-phosphorylated natural product derivatives
8GT9	;	2.0	;	Selective targeting of the Beclin 2-Atg14L coiled coil complex by stapled peptides promotes autophagy and endolysosomal trafficking of GPCRs
8GU7	;	2.6	;	Selective targeting of the Beclin 2-Atg14L coiled coil complex by stapled peptides promotes autophagy and endolysosomal trafficking of GPCRs
1GJ4	;	1.81	;	SELECTIVITY AT S1, H2O DISPLACEMENT, UPA, TPA, SER190/ALA190 PROTEASE, STRUCTURE-BASED DRUG DESIGN
1GJ5	;	1.73	;	SELECTIVITY AT S1, H2O DISPLACEMENT, UPA, TPA, SER190/ALA190 PROTEASE, STRUCTURE-BASED DRUG DESIGN
4TPG	;	3.91	;	Selectivity mechanism of a bacterial homologue of the human drug peptide transporters PepT1 and PepT2
4TPH	;	3.155	;	Selectivity mechanism of a bacterial homologue of the human drug peptide transporters PepT1 and PepT2
4TPJ	;	3.201	;	Selectivity mechanism of a bacterial homologue of the human drug peptide transporters PepT1 and PepT2
316D	;	3.0	;	Selectivity of F8-actinomycin D for RNA:DNA hybrids and its anti-leukemia activity
2R8G	;	2.7	;	Selectivity of Nucleoside Triphosphate Incorporation Opposite 1,N2-Propanodeoxyguanosine (PdG) by the Sulfolobus solfataricus DNA Polymerase Dpo4 Polymerase
2R8H	;	2.48	;	Selectivity of Nucleoside Triphosphate Incorporation Opposite 1,N2-Propanodeoxyguanosine (PdG) by the Sulfolobus solfataricus DNA Polymerase Dpo4 Polymerase
2R8I	;	2.38	;	Selectivity of Nucleoside Triphosphate Incorporation Opposite 1,N2-Propanodeoxyguanosine (PdG) by the Sulfolobus solfataricus DNA Polymerase Dpo4 Polymerase
5TO8	;	1.9849	;	Selectivity switch between FAK and Pyk2: Macrocyclization of FAK inhibitors improves Pyk2 potency
5TOB	;	2.117	;	Selectivity switch between FAK and Pyk2: Macrocyclization of FAK inhibitors improves Pyk2 potency
3TWH	;	1.79	;	Selenium Derivatized RNA/DNA Hybrid in complex with RNase H Catalytic Domain D132N Mutant
2R7Y	;	1.8	;	Selenium Derivatized RNA/DNA Hybrid in complex with RNase H CATALYTIC DOMAIN MUTANT D132N
6OP2	;	1.9	;	Selenium incorporated FeMo-cofactor of nitrogenase from azotobacter vinelandii at high concentration of selenium
6OP3	;	1.6	;	Selenium incorporated FeMo-cofactor of nitrogenase from Azotobacter vinelandii with low concentration of selenium
5BVG	;	1.6	;	Selenium incorporated nitrogenase MoFe-protein (Av1-Se2B) from A. vinelandii
6OP1	;	1.7	;	Selenium incorporated, carbon monoxide inhibited FeMo-cofactor of azotobacter vinelandii
3QMP	;	1.1	;	Selenium SAD structure solution of proteinase K grown in SO4-less solution and soaked in selenate.
3U5S	;	1.5	;	Selenium Substituted Human Augmenter of Liver Regeneration
1VRO	;	1.1	;	Selenium-Assisted Nucleic Acid Crystallography: Use of Phosphoroselenoates for MAD Phasing of a DNA Structure
7TPW	;	1.18	;	Selenium-free nitrogenase Fe protein (Av2) from A. vinelandii
7TPX	;	1.35	;	Selenium-free nitrogenase Fe protein (Av2) from A. vinelandii
7TPV	;	1.49	;	Selenium-free nitrogenase Fe protein (Av2) from A. vinelandii (5mM KSeCN Soaked)
7TPY	;	1.48	;	Selenium-free nitrogenase Fe protein (Av2) from A. vinelandii (nucleotide control)
7TPZ	;	1.71	;	Selenium-free nitrogenase Fe protein (Av2) from A. vinelandii (nucleotide control)
7TQJ	;	1.48	;	Selenium-incorporated nitrogenase Fe protein (Av2-Se) from A. vinelandii (1 mM KSeCN)
7TQK	;	1.48	;	Selenium-incorporated nitrogenase Fe protein (Av2-Se) from A. vinelandii (1 mM KSeCN)
7TPN	;	1.38	;	Selenium-incorporated nitrogenase Fe protein (Av2-Se) from A. vinelandii (11 mM KSeCN)
7TQH	;	1.49	;	Selenium-incorporated nitrogenase Fe protein (Av2-Se) from A. vinelandii (11 mM KSeCN)
7TQI	;	1.47	;	Selenium-incorporated nitrogenase Fe protein (Av2-Se) from A. vinelandii (11 mM KSeCN)
7TNE	;	1.39	;	Selenium-incorporated nitrogenase Fe protein (Av2-Se) from A. vinelandii (22 mM KSeCN)
7TQC	;	1.53	;	Selenium-incorporated nitrogenase Fe protein (Av2-Se) from A. vinelandii (22 mM KSeCN)
7TQE	;	1.59	;	Selenium-incorporated nitrogenase Fe protein (Av2-Se) from A. vinelandii (22 mM KSeCN)
7TQF	;	1.45	;	Selenium-incorporated nitrogenase Fe protein (Av2-Se) from A. vinelandii (22 mM KSeCN)
7T4H	;	1.51	;	Selenium-incorporated nitrogenase Fe protein (Av2-Se) from A. vinelandii (22 mM KSeCN, with Av1)
7TQ0	;	1.81	;	Selenium-incorporated nitrogenase Fe protein (Av2-Se) from A. vinelandii (22 mM KSeCN, with Av1)
7TQ9	;	1.6	;	Selenium-incorporated nitrogenase Fe protein (Av2-Se) from A. vinelandii (22 mM KSeCN, with Av1)
7TPO	;	1.35	;	Selenium-incorporated nitrogenase Fe-protein (Av2-Se) from A. vinelandii (1 mM KSeCN)
6OP4	;	2.3	;	Selenium-incorporated, carbon monoxide-inhibited, reactivated FeMo-cofactor of nitrogenase from Azotobacter vinelandii
6JKW	;	2.29	;	Seleno-methionine PNGM-1 from deep-sea sediment metagenome
5T9E	;	2.03	;	Seleno-methionine Prephenate Dehydrogenase from Soybean
4EM2	;	2.08	;	seleno-methionine staphylococcus aureus MarR in complex with salicylate
7QBH	;	1.223	;	Selenocarbamates as a novel prodrug-based approach towards Carbonic Anhydrase inhibition (hCA II)
6SWM	;	2.77	;	selenol bound carbonic anhydrase I
6HWZ	;	1.64	;	Selenols: a new class of Carbonic Anhydrase inhibitors
6HX5	;	1.44	;	Selenols: a new class of Carbonic Anhydrase inhibitors
7ENM	;	1.696	;	Selenomethionine anti-Cas protein
5CK1	;	1.835	;	selenomethionine BT4246
5E1N	;	1.0	;	Selenomethionine Ca2+-Calmodulin from Paramecium tetraurelia qFit disorder model
5E1K	;	1.0	;	Selenomethionine Ca2+-Calmodulin from Paramecium tetraurelia SAD data
7OC6	;	2.01	;	Selenomethionine derivative of alpha-humulene synthase AsR6 from Sarocladium schorii
6Y8G	;	1.8	;	selenomethionine derivative of ferulic acid esterase (FAE)
2GUX	;	2.0	;	Selenomethionine derivative of griffithsin
6HNL	;	2.2	;	Selenomethionine derivative of IdmH 96-104 loop truncation variant
3BU9	;	1.4	;	Selenomethionine derivative of monomine L57,63,87,146M mutant
4ACY	;	1.69	;	Selenomethionine derivative of the GH99 endo-alpha-mannosidase from Bacteroides thetaiotaomicron
6SWF	;	2.601	;	Selenomethionine derivative of the REC domain of AraT, a response regulator from Geobacillus stearothermophilus
4WMO	;	2.3	;	Selenomethionine derivative of Xenopus laevis embryonic epidermal lectin carbohydrate-binding domain
6E9C	;	3.2	;	Selenomethionine Derivative Structure of A Bacterial Homolog to Human Lysosomal Transporter, Spinster
8GLB	;	2.1	;	Selenomethionine Derivatized Citrate Synthase (CitA) in Mycobacterium tuberculosis with Pyruvate
4N7D	;	2.1	;	Selenomethionine incorporated Bla g 4
7EEH	;	2.0	;	Selenomethionine labeled Fe(II)/(alpha)ketoglutarate-dependent dioxygenase TqaL
7TXO	;	2.5	;	Selenomethionine Labeled Structure of RexT
5NYF	;	2.2	;	Selenomethionine labelled Anbu (Gly-1) mutant from Hyphomicrobium sp. strain MC1
6CHE	;	1.1	;	Selenomethionine mutant (A34Sem) of protein GB1 examined by X-ray diffraction
6CPZ	;	1.12	;	Selenomethionine mutant (I6Sem) of protein GB1 examined by X-ray diffraction
7V9F	;	2.5	;	Selenomethionine mutant (L740Sem) of BEN4 domain of protein Bend3 with DNA
6C9O	;	1.2	;	Selenomethionine mutant (V29Sem) of protein GB1 examined by X-ray diffraction
6CT8	;	2.62	;	Selenomethionine structure of N-truncated R2-type pyocin tail fiber at 2.6 angstrom resolution
1GSJ	;	1.85	;	Selenomethionine substituted N-acetyl-L-glutamate kinase from Escherichia coli complexed with its substrate n-acetyl-L-glutamate and its substrate analog AMPPNP
4PHS	;	1.54	;	Selenomethionine substituted structure of domain of unknown function 1792 (DUF1792)
1JJK	;	3.0	;	Selenomethionine Substitution of Orotidine-5'-monophosphate Decarboxylase from E. coli Causes a Change in Crystal Contacts and Space Group
6CNE	;	1.2	;	Selenomethionine variant (V29SeM) of protein GB1
6R7U	;	1.6	;	Selenomethionine variant of Tannerella forsythia promirolysin mutant E225A
5XMW	;	3.0	;	Selenomethionine-derivated ZHD
7VJP	;	1.594	;	Selenomethionine-derived Pectobacterium phage ZF40 apo-Aca2
7FA3	;	1.847	;	Selenomethionine-derived structure of Aca1 in Pseudomonas phage JBD30
8HN2	;	2.3	;	Selenomethionine-labelled soluble domain of Rieske iron-sulfur protein from chlorobaculum tepidum
6TVH	;	2.651	;	Selenomethionine-substituted HPF1 from Nematostella vectensis
7EWF	;	2.85	;	Selenomethionine-substituted structure of S. cerevisiae Csn12 in complex with Thp3 and Sem1
6CCR	;	1.6	;	Selenomethionyl derivative of a GID4 fragment
1UBN	;	2.4	;	SELENOSUBTILISIN BPN
8FBX	;	2.25	;	Selenosugar synthase SenB from Variovorax paradoxus
2ZFN	;	1.9	;	Self-acetylation mediated histone H3 lysine 56 acetylation by rtt109
7R96	;	5.68	;	Self-Assembled 3D DNA Hexagonal Tensegrity Triangle
5MUE	;	2.397	;	Self-assembled alpha-Tocopherol Transfer Protein Nanoparticles Promote Vitamin E Delivery Across an Endothelial Barrier
5MUG	;	2.42	;	Self-assembled alpha-Tocopherol Transfer Protein Nanoparticles Promote Vitamin E Delivery Across an Endothelial Barrier
7OPU	;	1.7	;	Self-assembled crystal structure of the computationally designed SAKe6BE-3HH protein
5LVS	;	1.42	;	Self-assembled protein-aromatic foldamer complexes with 2:3 and 2:2:1 stoichiometries
7URK	;	3.12	;	Self-assembling DNA tensegrity triangle motif with intercalating internal Cy3 modification
6WSQ	;	2.807	;	Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J10 immobile Holliday junction
6WSR	;	2.85	;	Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J10 immobile Holliday junction
6WSS	;	3.001	;	Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J15 immobile Holliday junction
6WST	;	3.055	;	Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J16 immobile Holliday junction
6WSU	;	2.756	;	Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J19 immobile Holliday junction
6WSV	;	3.101	;	Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J20 immobile Holliday junction
6WSW	;	3.12	;	Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J21 immobile Holliday junction
6WSX	;	3.122	;	Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J22 immobile Holliday junction
6WSY	;	3.053	;	Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J23 immobile Holliday junction
6WSZ	;	3.053	;	Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J24 immobile Holliday junction
6WT0	;	3.106	;	Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J25 immobile Holliday junction
6WRJ	;	3.129	;	Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J26 immobile Holliday junction
6WRI	;	3.057	;	Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J28 immobile Holliday junction
6WT1	;	3.11	;	Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J29 immobile Holliday junction
6WQG	;	3.003	;	Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J3 immobile Holliday junction
6WRC	;	3.178	;	Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J31 immobile Holliday junction
6WR9	;	3.071	;	Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J32 immobile Holliday junction
6WR7	;	3.11	;	Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J33 immobile Holliday junction
6WRA	;	3.0	;	Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J34 immobile Holliday junction
6WR5	;	3.063	;	Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J35 immobile Holliday junction
6WR3	;	3.173	;	Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J36 immobile Holliday junction
6WRB	;	3.15	;	Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J5 immobile Holliday junction
6X8B	;	2.899	;	Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J6 immobile Holliday junction
6WSN	;	3.052	;	Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J7 immobile Holliday junction
6WSO	;	3.106	;	Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J8 immobile Holliday junction
6WSP	;	3.049	;	Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J9 immobile Holliday junction
6X8C	;	3.098	;	Self-assembly of a 3D DNA crystal lattice (4x5 junction version) containing the J1 immobile Holliday junction
6XEJ	;	2.807	;	Self-assembly of a 3D DNA crystal lattice (4x5 junction version) containing the J10 immobile Holliday junction
6XEK	;	2.85	;	Self-assembly of a 3D DNA crystal lattice (4x5 junction version) containing the J14 immobile Holliday junction
6XEL	;	3.001	;	Self-assembly of a 3D DNA crystal lattice (4x5 junction version) containing the J15 immobile Holliday junction
6XEM	;	3.055	;	Self-assembly of a 3D DNA crystal lattice (4x5 junction version) containing the J16 immobile Holliday junction
6XFC	;	2.756	;	Self-assembly of a 3D DNA crystal lattice (4x5 junction version) containing the J19 immobile Holliday junction
6XFD	;	3.101	;	Self-assembly of a 3D DNA crystal lattice (4x5 junction version) containing the J20 immobile Holliday junction
6XFE	;	3.12	;	Self-assembly of a 3D DNA crystal lattice (4x5 junction version) containing the J21 immobile Holliday junction
6XFF	;	3.122	;	Self-assembly of a 3D DNA crystal lattice (4x5 junction version) containing the J22 immobile Holliday junction
6XFG	;	3.053	;	Self-assembly of a 3D DNA crystal lattice (4x5 junction version) containing the J23 immobile Holliday junction
6XFW	;	3.053	;	Self-assembly of a 3D DNA crystal lattice (4x5 junction version) containing the J24 immobile Holliday junction
6XGM	;	3.11	;	Self-assembly of a 3D DNA crystal lattice (4x5 junction version) containing the J25 immobile Holliday junction
6XFX	;	3.129	;	Self-assembly of a 3D DNA crystal lattice (4x5 junction version) containing the J26 immobile Holliday junction
6XFY	;	3.057	;	Self-assembly of a 3D DNA crystal lattice (4x5 junction version) containing the J28 immobile Holliday junction
6XFZ	;	3.113	;	Self-assembly of a 3D DNA crystal lattice (4x5 junction version) containing the J29 immobile Holliday junction
6XDV	;	3.003	;	Self-assembly of a 3D DNA crystal lattice (4x5 junction version) containing the J3 immobile Holliday junction
6XG0	;	3.178	;	Self-assembly of a 3D DNA crystal lattice (4x5 junction version) containing the J31 immobile Holliday junction
6XGJ	;	3.071	;	Self-assembly of a 3D DNA crystal lattice (4x5 junction version) containing the J32 immobile Holliday junction
6XGN	;	3.12	;	Self-assembly of a 3D DNA crystal lattice (4x5 junction version) containing the J33 immobile Holliday junction
6XGO	;	3.0	;	Self-assembly of a 3D DNA crystal lattice (4x5 junction version) containing the J34 immobile Holliday junction
6XGK	;	3.063	;	Self-assembly of a 3D DNA crystal lattice (4x5 junction version) containing the J35 immobile Holliday junction
6XGL	;	3.173	;	Self-assembly of a 3D DNA crystal lattice (4x5 junction version) containing the J36 immobile Holliday junction
6XDW	;	3.148	;	Self-assembly of a 3D DNA crystal lattice (4x5 junction version) containing the J5 immobile Holliday junction
6XDX	;	2.899	;	Self-assembly of a 3D DNA crystal lattice (4x5 junction version) containing the J6 immobile Holliday junction
6XDY	;	3.06	;	Self-assembly of a 3D DNA crystal lattice (4x5 junction version) containing the J7 immobile Holliday junction
6XDZ	;	3.106	;	Self-assembly of a 3D DNA crystal lattice (4x5 junction version) containing the J8 immobile Holliday junction
6XEI	;	3.049	;	Self-assembly of a 3D DNA crystal lattice (4x5 junction version) containing the J9 immobile Holliday junction
7JP8	;	3.103	;	Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J10 immobile Holliday junction
7JP7	;	3.207	;	Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J16 immobile Holliday junction
7JPB	;	3.158	;	Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J2 immobile Holliday junction
7JP6	;	3.087	;	Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J20 immobile Holliday junction
7JP5	;	3.094	;	Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J22 immobile Holliday junction
7JON	;	3.107	;	Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J23 immobile Holliday junction
7JOL	;	3.114	;	Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J24 immobile Holliday junction
7JOK	;	3.11	;	Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J26 immobile Holliday junction
7JOJ	;	3.108	;	Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J28 immobile Holliday junction
7JOI	;	3.148	;	Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J30 immobile Holliday junction
7JOH	;	4.195	;	Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J31 immobile Holliday junction
7JS0	;	3.19	;	Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J31 immobile Holliday junction with R3 symmetry
7JOG	;	3.101	;	Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J33 immobile Holliday junction
7JS1	;	3.152	;	Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J33 immobile Holliday junction with R3 symmetry
7JS2	;	3.058	;	Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J36 immobile Holliday junction with R3 symmetry
7JRY	;	3.158	;	Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J4 immobile Holliday junction with R3 symmetry
7JPA	;	3.164	;	Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J5 immobile Holliday junction
7JRZ	;	3.096	;	Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J5 immobile Holliday junction with R3 symmetry
7JPC	;	3.1	;	Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J7 immobile Holliday junction
7JP9	;	3.157	;	Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J8 immobile Holliday junction
6XNA	;	3.05	;	Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J1 immobile Holliday junction
7JFW	;	3.012	;	Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J10 immobile Holliday junction
7JFX	;	3.21	;	Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J16 immobile Holliday junction
7JFT	;	3.158	;	Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J2 immobile Holliday junction
7JH8	;	3.087	;	Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J20 immobile Holliday junction
7JH9	;	3.094	;	Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J22 immobile Holliday junction
7JHA	;	3.107	;	Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J23 immobile Holliday junction
7JHB	;	3.114	;	Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J24 immobile Holliday junction
7JHC	;	3.11	;	Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J26 immobile Holliday junction
6XO6	;	3.108	;	Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J28 immobile Holliday junction
6XO7	;	3.105	;	Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J30 immobile Holliday junction
6XO8	;	4.195	;	Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J31 immobile Holliday junction
7JHT	;	3.19	;	Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J31 immobile Holliday junction with R3 symmetry
6XO9	;	3.103	;	Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J33 immobile Holliday junction
7JHU	;	3.152	;	Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J33 immobile Holliday junction with R3 symmetry
7JHV	;	3.058	;	Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J36 immobile Holliday junction with R3 symmetry
7JHR	;	3.158	;	Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J4 immobile Holliday junction with R3 symmetry
7JFU	;	3.164	;	Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J5 immobile Holliday junction
7JHS	;	3.096	;	Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J5 immobile Holliday junction with R3 symmetry
7JFV	;	3.1	;	Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J7 immobile Holliday junction
6XO5	;	3.157	;	Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J8 immobile Holliday junction
7JKD	;	3.058	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J1 immobile Holliday junction
7JKK	;	2.794	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J10 immobile Holliday junction with R3 symmetry
7JL9	;	3.022	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J14 immobile Holliday junction with R3 symmetry
7JLA	;	3.0	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J16 immobile Holliday junction with R3 symmetry
7JLB	;	3.007	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J19 immobile Holliday junction with R3 symmetry
7JKE	;	3.068	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J2 immobile Holliday junction
7JLC	;	3.06	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J21 immobile Holliday junction with R3 symmetry
7JLD	;	3.163	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J22 immobile Holliday junction with R3 symmetry
7JLE	;	3.017	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J23 immobile Holliday junction with R3 symmetry
7JLF	;	2.909	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J24 immobile Holliday junction with R3 symmetry
7JNJ	;	3.015	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J26 immobile Holliday junction with R3 symmetry
7JKG	;	2.851	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J3 immobile Holliday junction with R3 symmetry
7JSB	;	3.103	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J30 immobile Holliday junction with R3 symmetry
7JSC	;	2.95	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J31 immobile Holliday junction with R3 symmetry
7JNK	;	3.105	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J33 immobile Holliday junction with R3 symmetry
7JNL	;	3.005	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J34 immobile Holliday junction with R3 symmetry
7JNM	;	2.702	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J36 immobile Holliday junction with R3 symmetry
7JKH	;	3.107	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J5 immobile Holliday junction with R3 symmetry
7JKI	;	3.019	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J7 immobile Holliday junction with R3 symmetry
7JKJ	;	3.077	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J8 immobile Holliday junction with R3 symmetry
7JK0	;	3.058	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J1 immobile Holliday junction
7JJ5	;	2.794	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J10 immobile Holliday junction with R3 symmetry
7JJ4	;	3.022	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J14 immobile Holliday junction with R3 symmetry
7JJ3	;	2.987	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J16 immobile Holliday junction with R3 symmetry
7JJ2	;	3.007	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J19 immobile Holliday junction with R3 symmetry
7JJZ	;	3.068	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J2 immobile Holliday junction
7JIQ	;	3.06	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J21 immobile Holliday junction with R3 symmetry
7JIP	;	3.163	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J22 immobile Holliday junction with R3 symmetry
7JIO	;	3.02	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J23 immobile Holliday junction with R3 symmetry
7JIN	;	2.909	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J24 immobile Holliday junction with R3 symmetry
7JIM	;	3.015	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J26 immobile Holliday junction with R3 symmetry
7JJY	;	2.851	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J3 immobile Holliday junction with R3 symmetry
7JI9	;	3.103	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J30 immobile Holliday junction with R3 symmetry
7JI8	;	2.95	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J31 immobile Holliday junction with R3 symmetry
7JI7	;	3.105	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J33 immobile Holliday junction with R3 symmetry
7JI6	;	3.005	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J34 immobile Holliday junction with R3 symmetry
7JI5	;	2.702	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J36 immobile Holliday junction with R3 symmetry
7JJX	;	3.107	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J5 immobile Holliday junction with R3 symmetry
7JJW	;	3.019	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J7 immobile Holliday junction with R3 symmetry
7JJ6	;	3.077	;	Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J8 immobile Holliday junction with R3 symmetry
2NRN	;	1.4	;	Self-assembly of coiled-coil tetramers in the 1.40 A structure of a leucine-zipper mutant
3LR2	;	1.7	;	Self-assembly of spider silk proteins is controlled by a pH-sensitive relay
3LR6	;	2.2	;	Self-assembly of spider silk proteins is controlled by a pH-sensitive relay
3LR8	;	2.3	;	Self-assembly of spider silk proteins is controlled by a pH-sensitive relay
3LRD	;	2.15	;	Self-assembly of spider silk proteins is controlled by a pH-sensitive relay
1BKL	;	2.1	;	SELF-ASSOCIATED APO SRC SH2 DOMAIN
184D	;	1.8	;	SELF-ASSOCIATION OF A DNA LOOP CREATES A QUADRUPLEX: CRYSTAL STRUCTURE OF D(GCATGCT) AT 1.8 ANGSTROMS RESOLUTION
1HVV	;	2.4	;	SELF-ASSOCIATION OF THE H3 REGION OF SYNTAXIN 1A: IMPLICATIONS FOR SNARE COMPLEX ASSEMBLY
1BUF	;		;	SELF-COMPLEMENTARY DNA 5'-D(CAATTG)2, NMR, MINIMIZED AVERAGE STRUCTURE
1UQC	;		;	SELF-COMPLEMENTARY DNA 5'-D(CACGTG)2, NMR, MINIMIZED AVERAGE STRUCTURE
1UQB	;		;	SELF-COMPLEMENTARY DNA 5'-D(CAGCTG)2, NMR, MINIMIZED AVERAGE STRUCTURE
1UQA	;		;	SELF-COMPLEMENTARY DNA 5'-D(CATATG)2, NMR, MINIMIZED AVERAGE STRUCTURE
1UQD	;		;	SELF-COMPLEMENTARY DNA 5'-D(CGATCG)2, NMR, MINIMIZED AVERAGE STRUCTURE
1UQG	;		;	SELF-COMPLEMENTARY DNA 5'-D(CGCGCG)2, NMR, MINIMIZED AVERAGE STRUCTURE
1UQF	;		;	SELF-COMPLEMENTARY DNA 5'-D(CGGCCG)2, NMR, MINIMIZED AVERAGE STRUCTURE
1UQE	;		;	SELF-COMPLEMENTARY DNA 5'-D(CGTACG)2, NMR, MINIMIZED AVERAGE STRUCTURE
6S7D	;	1.45	;	Self-complementary duplex DNA containing an internucleoside phosphoroselenolate
6ERJ	;	1.69	;	Self-complemented FimA subunit from Salmonella enterica
2JTY	;		;	Self-complemented variant of FimA, the main subunit of type 1 pilus
5L00	;	1.25	;	Self-complimentary RNA 15mer binding with GMP monomers
4OKM	;	2.1	;	Selinadiene Synthase apo and in complex with diphosphate
4OKZ	;	1.9	;	Selinadiene Synthase in complex with dihydrofarnesyl pyrophosphate
2SEM	;	2.2	;	SEM5 SH3 DOMAIN COMPLEXED WITH PEPTOID INHIBITOR
3SEM	;	2.2	;	SEM5 SH3 DOMAIN COMPLEXED WITH PEPTOID INHIBITOR
7KI0	;	2.5	;	Semaglutide-bound Glucagon-Like Peptide-1 (GLP-1) Receptor in Complex with Gs protein
7Y4Q	;	4.7	;	Semaphorin 6D in complex with Plexin A1
8CKM	;	2.72	;	Semaphorin-5A TSR 3-4 domains
8CKK	;	1.56	;	Semaphorin-5A TSR 3-4 domains in complex with nitrate
8CKL	;	2.56	;	Semaphorin-5A TSR 3-4 domains in complex with sucrose octasulfate (SOS)
8CKG	;	1.714	;	Semaphorin-5A TSR 3-4 domains in complex with sulfate
1USZ	;	3.28	;	SeMet AfaE-3 adhesin from Escherichia Coli
7LNI	;	2.68	;	SeMet CamA Adenine Methyltransferase Complexed to Cognate Substrate DNA
6LIY	;	1.761	;	SeMet CRL Protein of Arabidopsis
5FRK	;	2.12	;	SeMet crystal structure of Erwinia amylovora AmyR amylovoran repressor, a member of the YbjN protein family
5V0M	;	1.407	;	SeMet crystal structure of the Neisseria meningitidis non-core minor pilin PilV in the monoclinic form
5V23	;	1.956	;	SeMet crystal structure of the Neisseria meningitidis non-core minor pilin PilV in the orthorhombic form
1W3Z	;	3.2	;	SeMet derivative of BbCRASP-1 from Borrelia Burgdorferi
3OUV	;	2.004	;	SeMet Derivative of L512M mutant of PASTA domain 3 of Mycobacterium tuberculosis PknB
1E3H	;	2.6	;	SeMet derivative of Streptomyces antibioticus PNPase/GPSI enzyme
7F91	;	1.401	;	SeMet derivative of Thrombocorticin
4KRG	;	1.68	;	SeMet Haemonchus contortus Phosphoethanolamine N-methyltransferase 1 in complex with phosphoethanolamine and S-adenosylhomocysteine
4KRH	;	3.0	;	SeMet Haemonchus contortus Phosphoethanolamine N-methyltransferase 2 in complex with S-adenosyl-L-methionine
5LAC	;	1.94	;	SeMet Labeled Derivative of Cavally Virus 3CL Protease
3JYY	;	2.1	;	SeMet LinB complexed with PPi
3UJ6	;	1.974	;	SeMet Phosphoethanolamine methyltransferase from Plasmodium falciparum in complex with SAM and PO4
4DWP	;	2.35	;	SeMet protelomerase tela covalently complexed with substrate DNA
5FHP	;	2.65	;	SeMet regulator of nicotine degradation
4V18	;	2.28	;	SeMet structure of a novel carbohydrate binding module from glycoside hydrolase family 5 glucanase from Ruminococcus flavefaciens FD-1
4V1K	;	1.6	;	SeMet structure of a novel carbohydrate binding module from glycoside hydrolase family 9 (Cel9A) from Ruminococcus flavefaciens FD-1
4D3L	;	2.0	;	SeMet structure of a novel carbohydrate binding module from glycoside hydrolase family 9 (Cel9A) from Ruminococcus flavefaciens FD-1 in the orthorhombic form
2JAA	;	3.1	;	SeMet substituted Shigella Flexneri Ipad
6ECU	;	1.96	;	SeMet substituted StiD O-MT residues 976-1266
7RFO	;	3.02	;	SeMet Tailspike protein 4 (TSP4) phage CBA120, residues 1-335, obtained in the presence of LiSO4
4EBF	;	2.3	;	SeMet thermostable phosphite dehydrogenase Glu175-Ala mutant
4AY8	;	2.1	;	SeMet-derivative of a methyltransferase from M. mazei
8AQQ	;	1.68	;	SeMet-derived crystal structure of the N-terminal beta-hairpin docking (bHD) domain of the AerJ halogenase, from the aeruginosin biosynthetic assembly line
4FFR	;	1.8	;	SeMet-labeled PylC (remote)
5D5T	;	2.4	;	SeMet-labelled HcgC from Methanocaldococcus jannaschii in P1 space group
5D4T	;	2.9	;	SeMet-labelled HcgC from Methanocaldococcus jannaschii in space group P212121
3WVA	;	1.4	;	SeMet-labelled HcgF from Methanocaldococcus jannaschii
4YT8	;	1.902	;	SeMet-labelled HmdII from Methanocaldococcus jannaschii
6XIV	;	2.8	;	SeMet-Rns, in complex with potential inhibitor
2Q6U	;	1.75	;	SeMet-substituted form of NikD
4ISS	;	2.5	;	SeMet-substituted Kluyveromyces lactis Allophanate Hydrolase
4IWY	;	2.9	;	SeMet-substituted RimK structure
3AHV	;	1.89	;	Semi-active E176Q mutant of rice bglu1 covalent complex with 2-deoxy-2-fluoroglucoside
3F4V	;	1.65	;	Semi-active E176Q mutant of rice BGlu1, a plant exoglucanase/beta-glucosidase
3F5J	;	1.95	;	Semi-active E176Q mutant of rice BGlu1, a plant exoglucanase/beta-glucosidase
3F5K	;	1.8	;	Semi-active E176Q mutant of rice BGlu1, a plant exoglucanase/beta-glucosidase
3F5L	;	1.37	;	Semi-active E176Q mutant of rice BGlu1, a plant exoglucanase/beta-glucosidase
1I8X	;		;	SEMI-AUTOMATIC STRUCTURE DETERMINATION OF THE CG1 1-30 PEPTIDE BASED ON ARIA
1I8Y	;		;	SEMI-AUTOMATIC STRUCTURE DETERMINATION OF THE CG1 3-30 PEPTIDE BASED ON ARIA
1ZVO	;		;	Semi-extended solution structure of human myeloma immunoglobulin D determined by constrained X-ray scattering
6J1Y	;	2.55	;	Semi-open conformation E3 ligase
1XSS	;	1.6	;	Semi-rational engineering of a green-emitting coral fluorescent protein into an efficient highlighter.
1JH6	;	1.8	;	Semi-reduced Cyclic Nucleotide Phosphodiesterase from Arabidopsis thaliana
1JH7	;	2.4	;	Semi-reduced Inhibitor-bound Cyclic Nucleotide Phosphodiesterase from Arabidopsis thaliana
2WRX	;	1.5	;	Semi-synthetic analogue of human insulin NMeAlaB26-insulin at pH 3.0
2WS0	;	2.1	;	Semi-synthetic analogue of human insulin NMeAlaB26-insulin at pH 7.5
2WS6	;	1.5	;	Semi-synthetic analogue of human insulin NMeTyrB26-insulin in hexamer form
2WS1	;	1.6	;	Semi-synthetic analogue of human insulin NMeTyrB26-insulin in monomer form
2WS7	;	2.59	;	Semi-synthetic analogue of human insulin ProB26-DTI
2WS4	;	1.9	;	Semi-synthetic analogue of human insulin ProB26-DTI in monomer form
8G0L	;	3.39	;	Semi-synthetic CoA-alpha-Synuclein Constructs Trap N-terminal Acetyltransferase NatB for Binding Mechanism Studies
2WRW	;	2.41	;	Semi-synthetic highly active analogue of human insulin D-ProB26-DTI- NH2
2WRU	;	1.57	;	Semi-synthetic highly active analogue of human insulin NMeAlaB26-DTI- NH2
2WRV	;	2.15	;	Semi-synthetic highly active analogue of human insulin NMeHisB26-DTI- NH2
3OR0	;	2.3	;	Semi-synthetic ribonuclease S: cyanylated homocysteine at position 13
3OQZ	;	2.5	;	Semi-synthetic ribonuclease S: meta-cyano-phenylalanine at position 8
3OQY	;	1.494	;	Semi-synthetic ribonuclease S: para-cyano-phenylalanine at position 8
4O37	;	1.4	;	seminsynthetic RNase S1-15-3Pl-7/11
4O36	;	1.22	;	Semisynthetic RNase S1-15-H7/11-Q10
6H63	;	2.08	;	Semisynthetic [FeFe]-hydrogenase CpI with ethanedithiolate [2Fe] cofactor
5BYQ	;	1.73	;	Semisynthetic [FeFe]-hydrogenase CpI with oxodithiolato-bridged [2Fe] cofactor
5BYR	;	1.82	;	Semisynthetic [FeFe]-hydrogenase CpI with propane-dithiolato-bridged [2Fe] cofactor
5BYS	;	1.93	;	Semisynthetic [FeFe]-hydrogenase CpI with sulfur-dithiolato-bridged [2Fe] cofactor
1VCP	;	3.0	;	SEMLIKI FOREST VIRUS CAPSID PROTEIN (CRYSTAL FORM I)
1VCQ	;	3.1	;	SEMLIKI FOREST VIRUS CAPSID PROTEIN (CRYSTAL FORM II)
8JBF	;	3.0	;	Senktide bound to active human neurokinin 3 receptor in complex with Gq
2IY1	;	2.46	;	SENP1 (mutant) full length SUMO1
2IY0	;	2.77	;	SENP1 (mutant) SUMO1 RanGAP
2IYD	;	3.2	;	SENP1 covalent complex with SUMO-2
2IYC	;	2.45	;	SENP1 native structure
2CKH	;	3.2	;	SENP1-SUMO2 complex
2V09	;	1.8	;	SENS161-164DSSN mutant of Bacillus subtilis Oxalate Decarboxylase OxdC
3QYL	;	1.79	;	Sensitivity of receptor internal motions to ligand binding affinity and kinetic off-rate
3QYO	;	2.09	;	Sensitivity of receptor internal motions to ligand binding affinity and kinetic off-rate
6EU6	;	1.98	;	Sensor Amt Protein
1P0Z	;	1.6	;	Sensor Kinase CitA binding domain
2YKF	;	2.0	;	Sensor region of a sensor histidine kinase
2YKH	;	2.78	;	Sensor region of a sensor histidine kinase
1OJG	;		;	Sensory domain of the membraneous two-component fumarate sensor DcuS of E. coli
1GU8	;	2.27	;	SENSORY RHODOPSIN II
1GUE	;	2.27	;	SENSORY RHODOPSIN II
1H68	;	2.1	;	sensory rhodopsin II
1LU3	;	16.8	;	Separate Fitting of the Anticodon Loop Region of tRNA (nucleotide 26-42) in the Low Resolution Cryo-EM Map of an EF-Tu Ternary Complex (GDP and Kirromycin) Bound to E. coli 70S Ribosome
6A4F	;	2.21	;	Separated uridine bound Oligoribonuclease (ORN) from Colwellia psychrerythraea strain 34H
2XHI	;	1.55	;	Separation-of-function mutants unravel the dual reaction mode of human 8-oxoguanine DNA glycosylase
5GVB	;	2.75	;	SepB domain of human AND-1
3ZIE	;	2.0	;	SepF-like protein from Archaeoglobus fulgidus
3ZIG	;	2.5	;	SepF-like protein from Pyrococcus furiosus
1NAS	;	2.1	;	SEPIAPTERIN REDUCTASE COMPLEXED WITH N-ACETYL SEROTONIN
6I6F	;	1.94	;	SEPIAPTERIN REDUCTASE IN COMPLEX WITH COMPOUND 1
6I6C	;	1.72	;	SEPIAPTERIN REDUCTASE IN COMPLEX WITH COMPOUND 2
6I6P	;	1.62	;	SEPIAPTERIN REDUCTASE IN COMPLEX WITH COMPOUND 3
6I79	;	1.63	;	SEPIAPTERIN REDUCTASE IN COMPLEX WITH COMPOUND 4
6I6T	;	1.79	;	SEPIAPTERIN REDUCTASE IN COMPLEX WITH COMPOUND 5
6I6V	;	1.43	;	SEPIAPTERIN REDUCTASE IN COMPLEX WITH COMPOUND 6
5C9E	;	3.21	;	SepL
1FE5	;	2.45	;	SEQUENCE AND CRYSTAL STRUCTURE OF A BASIC PHOSPHOLIPASE A2 FROM COMMON KRAIT (BUNGARUS CAERULEUS) AT 2.4 RESOLUTION: IDENTIFICATION AND CHARACTERIZATION OF ITS PHARMACOLOGICAL SITES.
4RNK	;	2.08	;	Sequence and structure of a self-assembled 3-D DNA crystal: D(GGAAAATTTGGAG)
4RO4	;	2.04	;	Sequence and structure of a self-assembled 3-D DNA crystal: D(GGAAACGTTGGAG)
4RO7	;	2.03	;	Sequence and structure of a self-assembled 3-D DNA crystal: D(GGAAAGCTTGGAG)
4RO8	;	2.08	;	Sequence and structure of a self-assembled 3-D DNA crystal: D(GGAATCGATGGAG)
4ROG	;	2.08	;	Sequence and structure of a self-assembled 3-D DNA crystal: D(GGACACGTGGGAG)
4ROK	;	2.16	;	Sequence and structure of a self-assembled 3-D DNA crystal: D(GGACAGCTGGGAG)
4RON	;	2.39	;	Sequence and structure of a self-assembled 3-D DNA crystal: D(GGACCATGGGGAG)
4ROO	;	2.37	;	Sequence and structure of a self-assembled 3-D DNA crystal: D(GGACCGCGGGGAG)
4ROY	;	2.09	;	Sequence and structure of a self-assembled 3-D DNA crystal: D(GGACGATCGGGAG)
4ROZ	;	2.08	;	Sequence and structure of a self-assembled 3-D DNA crystal: D(GGACGGCCGGGAG)
4RP0	;	2.19	;	Sequence and structure of a self-assembled 3-D DNA crystal: D(GGATAATTAGGAG)
4RP1	;	2.27	;	Sequence and structure of a self-assembled 3-D DNA crystal: D(GGATACGTAGGAG)
4RP2	;	2.32	;	Sequence and structure of a self-assembled 3-D DNA crystal: D(GGATAGCTAGGAG)
2R2V	;	1.9	;	Sequence Determinants of the Topology of the Lac Repressor Tetrameric Coiled Coil
5APU	;	1.35	;	Sequence IANKEDKAD inserted between GCN4 adaptors - Structure A9b black
5APV	;	2.0	;	Sequence IANKEDKAD inserted between GCN4 adaptors - Structure A9b grey
5APQ	;	2.1	;	Sequence IENKAD inserted between GCN4 adaptors - Structure A6
5APT	;	1.8	;	Sequence IENKADKAD inserted between GCN4 adaptors - Structure A9
5APS	;	1.37	;	Sequence IENKKAD inserted between GCN4 adaptors - Structure A7
6UG1	;	2.833	;	Sequence impact in DNA duplex opening by the Rad4/XPC nucleotide excision repair complex
1G2X	;	2.5	;	Sequence induced trimerization of krait PLA2: crystal structure of the trimeric form of krait PLA2
5APW	;	1.6	;	Sequence MATKDD inserted between GCN4 adaptors - Structure T6
5APX	;	1.8	;	Sequence MATKDDIAN inserted between GCN4 adaptors - Structure T9(6)
5APY	;	2.0	;	Sequence MATKDDIAN inserted between GCN4 adaptors - Structure T9(9)
6DNW	;	2.849	;	Sequence Requirements of the Listeria innocua prophage attP site
8TC6	;	2.45	;	Sequence specific (AATT and TGTCA) orientation of netropsin and ImPyPy molecules at two unique minor groove binding sites within a self-assembled 3D DNA lattice (4x5)
8TB3	;	3.0	;	Sequence specific (AATT) orientation of DAPI molecules at a unique minor groove binding site (position1) within a self-assembled 3D DNA lattice (4x5)
8TA9	;	2.8	;	Sequence specific (AATT) orientation of DAPI molecules at a unique minor groove binding site (position1) within a self-assembled 3D DNA lattice (4x6)
8TB4	;	3.11	;	Sequence specific (AATT) orientation of DAPI molecules at a unique minor groove binding site (position2) within a self-assembled 3D DNA lattice (4x5)
8TDT	;	3.007	;	Sequence specific (AATT) orientation of DAPI molecules at a unique minor groove binding site (position2) within a self-assembled 3D DNA lattice (4x6)
8T7X	;	3.07	;	Sequence specific (AATT) orientation of DAPI molecules at two unique minor groove binding sites within a self-assembled 3D DNA lattice (4x5)
8TB8	;	2.95	;	Sequence specific (AATT) orientation of Hoechst molecules at a unique minor groove binding site (position1) within a self-assembled 3D DNA lattice (4x5)
8TBD	;	3.0	;	Sequence specific (AATT) orientation of Hoechst molecules at a unique minor groove binding site (position2) within a self-assembled 3D DNA lattice (4x5)
8TAQ	;	2.951	;	Sequence specific (AATT) orientation of Hoechst molecules at a unique minor groove binding site (position2) within a self-assembled 3D DNA lattice (4x6)
8T80	;	2.91	;	Sequence specific (AATT) orientation of Hoechst molecules at two unique minor groove binding sites within a self-assembled 3D DNA lattice (4x5)
8TAM	;	2.95	;	Sequence specific (AATT) orientation of Hoechst molecules at two unique minor groove binding sites within a self-assembled 3D DNA lattice (4x6)
8TBO	;	2.599	;	Sequence specific (AATT) orientation of netropsin molecules at a unique minor groove binding site (position1) within a self-assembled 3D DNA lattice (4x5)
8TAJ	;	2.9	;	Sequence specific (AATT) orientation of netropsin molecules at a unique minor groove binding site (position1) within a self-assembled 3D DNA lattice (4x6)
8T7B	;	3.05	;	Sequence specific (AATT) orientation of netropsin molecules at a unique minor groove binding site (position2) within a self-assembled 3D DNA lattice (4x5)
8TAP	;	3.11	;	Sequence specific (AATT) orientation of netropsin molecules at a unique minor groove binding site (position2) within a self-assembled 3D DNA lattice (4x6)
8TC2	;	3.05	;	Sequence specific (AATT) orientation of netropsin molecules at two unique minor groove binding sites within a self-assembled 3D DNA lattice (4x5)
8TA8	;	3.05	;	Sequence specific (AATT) orientation of netropsin molecules at two unique minor groove binding sites within a self-assembled 3D DNA lattice (4x6)
8TC4	;	3.06	;	Sequence specific (TGTCA) orientation of ImPyPy molecules at a unique minor groove binding site within a self-assembled 3D DNA lattice (4x5)
2F8K	;	2.0	;	Sequence specific recognition of RNA hairpins by the SAM domain of Vts1
185D	;		;	SEQUENCE SPECIFICITY OF QUINOXALINE ANTIBIOTICS. 1. SOLUTION STRUCTURE OF A 1:1 COMPLEX BETWEEN TRIOSTIN A AND [D(GACGTC)]2 AND COMPARISON WITH THE SOLUTION STRUCTURE OF THE [N-MECYS3, N-MECYS7]TANDEM-[D(GATATC)]2 COMPLEX
1VJ4	;	1.8	;	SEQUENCE-DEPENDENT CONFORMATION OF AN A-DNA DOUBLE HELIX: THE CRYSTAL STRUCTURE OF THE OCTAMER D(G-G-T-A-T-A-C-C)
102D	;	2.2	;	SEQUENCE-DEPENDENT DRUG BINDING TO THE MINOR GROOVE OF DNA: THE CRYSTAL STRUCTURE OF THE DNA DODECAMER D(CGCAAATTTGCG)2 COMPLEXED WITH PROPAMIDINE
296D	;	2.25	;	SEQUENCE-DEPENDENT EFFECTS IN DRUG-DNA INTERACTION: THE CRYSTAL STRUCTURE OF HOECHST 33258 BOUND TO THE D(CGCAAATTTGCG)2 DUPLEX
180D	;	2.5	;	SEQUENCE-DEPENDENT MICROHETEROGENEITY OF Z-DNA: THE CRYSTAL AND MOLECULAR STRUCTURES OF D(CACGCG).D(CGCGTG) AND D(CGCACG).D(CGTGCG)
181D	;	1.6	;	SEQUENCE-DEPENDENT MICROHETEROGENEITY OF Z-DNA: THE CRYSTAL AND MOLECULAR STRUCTURES OF D(CACGCG).D(CGCGTG) AND D(CGCACG).D(CGTGCG)
3GPX	;	1.78	;	Sequence-matched MutM Interrogation Complex 4 (IC4)
3GQ5	;	1.9	;	Sequence-matched MutM Interrogation Complex 5 (IC5)
3GPY	;	1.85	;	Sequence-matched MutM Lesion Recognition Complex 3 (LRC3)
3GQ4	;	1.7	;	Sequence-matched MutM Lesion Recognition Complex 5 (LRC5)
1EGR	;		;	SEQUENCE-SPECIFIC 1H N.M.R. ASSIGNMENTS AND DETERMINATION OF THE THREE-DIMENSIONAL STRUCTURE OF REDUCED ESCHERICHIA COLI GLUTAREDOXIN
1BBA	;		;	SEQUENCE-SPECIFIC 1H NMR ASSIGNMENTS AND SOLUTION STRUCTURE OF BOVINE PANCREATIC POLYPEPTIDE
2YHX	;	2.1	;	SEQUENCING A PROTEIN BY X-RAY CRYSTALLOGRAPHY. II. REFINEMENT OF YEAST HEXOKINASE B CO-ORDINATES AND SEQUENCE AT 2.1 ANGSTROMS RESOLUTION
1KDU	;		;	SEQUENTIAL 1H NMR ASSIGNMENTS AND SECONDARY STRUCTURE OF THE KRINGLE DOMAIN FROM UROKINASE
1AKP	;		;	SEQUENTIAL 1H,13C AND 15N NMR ASSIGNMENTS AND SOLUTION CONFORMATION OF APOKEDARCIDIN
1OMA	;		;	SEQUENTIAL ASSIGNMENT AND STRUCTURE DETERMINATION OF SPIDER TOXIN OMEGA-AGA-IVB
1OMB	;		;	SEQUENTIAL ASSIGNMENT AND STRUCTURE DETERMINATION OF SPIDER TOXIN OMEGA-AGA-IVB
2B7X	;	3.0	;	Sequential reorganization of beta-sheet topology by insertion of a single strand
3JR6	;	3.0	;	Sequential reorganization of beta-sheet topology by insertion of a single strand
1L7Q	;	1.76	;	Ser117Ala Mutant of Bacterial Cocaine Esterase cocE
1ZDG	;	2.3	;	Ser159 mutant of glycogenin complexed with UDP-glucose and manganese
1ZDF	;	2.45	;	Ser162 mutant of glycogenin complexed with UDP-glucose and manganese
1DM4	;	2.5	;	SER195ALA MUTANT OF HUMAN THROMBIN COMPLEXED WITH FIBRINOPEPTIDE A (7-16)
5K9P	;	1.55	;	Ser20 phosphorylated ubiquitin
5J85	;	2.6	;	Ser480Ala mutant of L-arabinonate dehydratase
4WZP	;	1.9	;	Ser65 phosphorylated ubiquitin, major conformation
4BEW	;	2.5	;	SERCA bound to phosphate analogue
3B9R	;	3.0	;	SERCA Ca2+-ATPase E2 aluminium fluoride complex without thapsigargin
2YFY	;	3.1	;	SERCA in the HnE2 State Complexed With Debutanoyl Thapsigargin
5MPM	;	3.3	;	SERCA2a from pig heart
6HXB	;	4.0	;	SERCA2a from pig heart
1FYL	;	2.1	;	SERENDIPITOUS CRYSTAL STRUCTURE CONTAINING THE HEAT SHOCK TRANSCRIPTION FACTOR'S DNA BINDING DOMAIN AND COGNATE DNA IN A HEAD-TO-HEAD ORIENTATION
1FYM	;	2.2	;	SERENDIPITOUS CRYSTAL STRUCTURE CONTAINING THE HEAT SHOCK TRANSCRIPTION FACTOR'S DNA BINDING DOMAIN AND COGNATE DNA IN A TAIL-TO-TAIL ORIENTATION
1FYK	;	2.5	;	SERENDIPITOUS CRYSTAL STRUCTURE CONTAINING THE HEAT SHOCK TRANSCRIPTION FACTOR'S DNA BINDING DOMAIN AND COGNATE DNA THAT IS TRANSLATIONALLY DISORDERED
8C7E	;	2.8	;	Serendipitous cyanase structure from Serratia-like contamination
2V3Q	;	1.89	;	Serendipitous discovery and X-ray structure of a human phosphate binding apolipoprotein
6UQS	;	1.37	;	Serendipitous Discovery of Aryl Boronic Acids as beta-Lactamase Inhibitors
6UQT	;	1.25	;	Serendipitous Discovery of Aryl Boronic Acids as beta-Lactamase Inhibitors
6UQU	;	1.0902	;	Serendipitous Discovery of Aryl Boronic Acids as beta-Lactamase Inhibitors
6UR3	;	1.423	;	Serendipitous Discovery of Aryl Boronic Acids as beta-Lactamase Inhibitors
8C7L	;	3.52	;	Serendipitous structure of OmpF contaminant in space group P21.
7QAR	;	2.3	;	Serial crystallography structure of cofactor-free urate oxidase in complex with the 5-peroxo derivative of 9-methyl uric acid at room temperature
5N8I	;	1.4	;	Serial Cu nitrite reductase structures at elevated cryogenic temperature, 100K reference dataset.
5N8F	;	1.38	;	Serial Cu nitrite reductase structures at elevated cryogenic temperature, 240K. Dataset 1.
5N8G	;	1.47	;	Serial Cu nitrite reductase structures at elevated cryogenic temperature, 240K. Dataset 2.
5N8H	;	1.65	;	Serial Cu nitrite reductase structures at elevated cryogenic temperature, 240K. Dataset 3.
5B35	;	2.35	;	Serial Femtosecond Crystallography (SFX) of Ground State Bacteriorhodopsin Crystallized from Bicelles Determined Using 7-keV X-ray Free Electron Laser (XFEL) at SACLA
7VSO	;	2.35	;	Serial Femtosecond Crystallography (SFX) of Ground State Bacteriorhodopsin Crystallized from Bicelles in Complex with HAD16 Determined Using 7-keV X-ray Free Electron Laser (XFEL) at SACLA
5B34	;	2.1	;	Serial Femtosecond Crystallography (SFX) of Ground State Bacteriorhodopsin Crystallized from Bicelles in Complex with Iodine-labeled Detergent HAD13a Determined Using 7-keV X-ray Free Electron Laser (XFEL) at SACLA
6FTR	;	1.76	;	Serial Femtosecond Crystallography at Megahertz pulse rates
6GTH	;	1.69	;	Serial Femtosecond Crystallography at Megahertz pulse rates
4ZIZ	;	1.75	;	Serial Femtosecond Crystallography of Soluble Proteins in Lipidic Cubic Phase (C-Phycocyanin from T. elongatus)
4CAS	;	3.5	;	Serial femtosecond crystallography structure of a photosynthetic reaction center
8AJZ	;	2.0	;	Serial femtosecond crystallography structure of CO bound ba3- type cytochrome c oxidase at 2 milliseconds after irradiation by a 532 nm laser
8K65	;	2.0	;	Serial femtosecond crystallography structure of CO bound ba3- type cytochrome c oxidase without pump laser irradiation
6QWG	;	1.9	;	Serial Femtosecond Crystallography Structure of Cu Nitrite Reductase from Achromobacter cycloclastes: Nitrite complex at Room Temperature
8K6Y	;	2.0	;	Serial femtosecond crystallography structure of photo dissociated CO from ba3- type cytochrome c oxidase determined by extrapolation method
6CAS	;	3.5	;	Serial Femtosecond X-ray Crystal Structure of 30S ribosomal subunit from Thermus thermophilus in complex with N1MS
6CAR	;	3.4	;	Serial Femtosecond X-ray Crystal Structure of 30S ribosomal subunit from Thermus thermophilus in complex with Sisomicin
6NA6	;	2.1	;	Serial Femtosecond X-ray Crystallography Structure of ECR in complex with NADPH
5XFC	;	1.4	;	Serial femtosecond X-ray structure of a stem domain of human O-mannose beta-1,2-N-acetylglucosaminyltransferase solved by Se-SAD using XFEL (refined against 13,000 patterns)
5XFD	;	1.5	;	Serial femtosecond X-ray structure of Agrocybe cylindracea galectin with lactose solved by Se-SAD using XFEL (refined against 60,000 patterns)
8K6U	;	1.9	;	Serial Femtosecond X-ray structure of E.coli Cyanase with un-modeled density at active site
3WXQ	;	1.6	;	Serial femtosecond X-ray structure of human fatty acid-binding protein type-3 (FABP3) in complex with stearic acid (C18:0) determined using X-ray free-electron laser at SACLA
7ADQ	;	2.01	;	Serial Laue crystallography structure of dehaloperoxidase B from Amphitrite ornata
7S4R	;	2.1	;	Serial Macromolecular Crystallography at ALBA Synchrotron Light Source - alpha Spectrin-SH3 domain
7S4Y	;	1.71	;	Serial Macromolecular Crystallography at ALBA Synchrotron Light Source - Insulin
7S4W	;	2.1	;	Serial Macromolecular Crystallography at ALBA Synchrotron Light Source - Lysozyme
7S50	;	2.1	;	Serial Macromolecular Crystallography at ALBA Synchrotron Light Source - Phycocyanin
7S4Z	;	1.9	;	Serial Macromolecular Crystallography at ALBA Synchrotron Light Source - Proteinase K
5UVI	;	3.2	;	Serial Millisecond Crystallography of Membrane and Soluble Protein Micro-crystals using Synchrotron Radiation
5UVJ	;	2.05	;	Serial Millisecond Crystallography of Membrane and Soluble Protein Micro-crystals using Synchrotron Radiation
5UVK	;	3.1	;	Serial Millisecond Crystallography of Membrane and Soluble Protein Micro-crystals using Synchrotron Radiation
5UVL	;	2.65	;	Serial Millisecond Crystallography of Membrane and Soluble Protein Micro-crystals using Synchrotron Radiation
7QUT	;	2.24	;	serial synchrotron crystallographic structure of Drosophila Melanogaster (6-4) photolyase
8HUA	;	2.12	;	Serial synchrotron crystallography structure of ba3-type cytochrome c oxidase from Thermus thermophilus using a goniometer compatible flow-cell
8RGS	;	1.79	;	Serial synchrotron in plate room temperature structure of Dye Type Peroxidase Aa
8RGW	;	1.88	;	Serial synchrotron in plate room temperature structure of Dye Type Peroxidase Aa, 12 drops merged
8RGY	;	2.07	;	Serial synchrotron in plate room temperature structure of Dye Type Peroxidase Aa, 8 drops merged
8RGE	;	1.88	;	Serial synchrotron in plate room temperature structure of Lysozyme.
7ACP	;	1.45	;	Serial synchrotron structure of dehaloperoxidase B
4RVY	;	5.5	;	Serial Time resolved crystallography of Photosystem II using a femtosecond X-ray laser. The S state after two flashes (S3)
4PBU	;	5.0	;	Serial Time-resolved crystallography of Photosystem II using a femtosecond X-ray laser The S1 state
2M3B	;		;	Serine 16 phosphorylated phospholamban pentamer, Hybrid solution and solid-state NMR structural ensemble
1PQH	;	1.29	;	Serine 25 to Threonine mutation of aspartate decarboxylase
1SSM	;	2.15	;	Serine Acetyltransferase- Apoenzyme (truncated)
1SST	;	2.0	;	Serine Acetyltransferase- Complex with CoA
1SSQ	;	1.85	;	Serine Acetyltransferase- Complex with Cysteine
6JN3	;	2.216	;	Serine Beta-Lactamase KPC-2 in Complex with Dual MBL/SBL Inhibitor MS05
6JN5	;	1.97	;	Serine Beta-Lactamase KPC-2 in Complex with Dual MBL/SBL Inhibitor MS23
6J8Q	;	1.787	;	Serine Beta-Lactamase KPC-2 in Complex with Dual MBL/SBL Inhibitor WL-001
6JN4	;	1.9	;	Serine Beta-Lactamase KPC-2 in Complex with Dual MBL/SBL Inhibitor WL-001
7V1Y	;	2.82	;	Serine beta-lactamase-like protein LACTB in complex with inhibitor
2RKB	;	2.8	;	Serine dehydratase like-1 from human cancer cells
3GBX	;	1.8	;	Serine hydroxymethyltransferase from Salmonella typhimurium
3PGY	;	1.92	;	Serine hydroxymethyltransferase from Staphylococcus aureus, S95P mutant.
3G8M	;	3.3	;	Serine Hydroxymethyltransferase Y55F Mutant
8H1W	;	1.4	;	Serine Palmitoyltransferase from Sphingobacterium multivorum
8H20	;	1.45	;	Serine Palmitoyltransferase from Sphingobacterium multivorum complexed with Glycine
8H21	;	1.54	;	Serine Palmitoyltransferase from Sphingobacterium multivorum complexed with L-alanine
8H1Y	;	1.55	;	Serine Palmitoyltransferase from Sphingobacterium multivorum complexed with L-homoserine
8H1Q	;	1.5	;	Serine Palmitoyltransferase from Sphingobacterium multivorum complexed with L-serine
8H29	;	1.45	;	Serine Palmitoyltransferase from Sphingobacterium multivorum complexed with L-threonine
8GUH	;	1.65	;	Serine Palmitoyltransferase from Sphingobacterium multivorum complexed with Tris
4BMK	;	1.62	;	Serine Palmitoyltransferase K265A from S. paucimobilis with bound PLP- Myriocin Aldimine
1HXE	;	2.1	;	SERINE PROTEASE
4RI0	;	3.272	;	Serine Protease HtrA3, mutationally inactivated
1P01	;	2.0	;	Serine protease mechanism. structure of an inhibitory complex oF ALPHA-LYTIC Protease and a tightly bound peptide boronic acid
1AH2	;		;	SERINE PROTEASE PB92 FROM BACILLUS ALCALOPHILUS, NMR, 18 STRUCTURES
2VID	;	1.8	;	Serine protease SplB from Staphylococcus aureus at 1.8A resolution
2SFA	;	1.6	;	SERINE PROTEINASE FROM STREPTOMYCES FRADIAE ATCC 14544
5JPF	;	2.3993	;	Serine/Threonine phosphatase Z1 (Candida albicans) binds to inhibitor microcystin-LR
5L2Q	;	2.53	;	Serine/threonine-protein kinase 40 (STK40) kinase homology domain
4ZLO	;	2.5	;	Serine/threonine-protein kinase PAK1 complexed with a dibenzodiazepine: identification of an allosteric site on PAK1
5C1Q	;	3.0	;	Serine/threonine-protein kinase pim-1
7E32	;	2.9	;	Serotonin 1D (5-HT1D) receptor-Gi protein complex
7E33	;	2.9	;	Serotonin 1E (5-HT1E) receptor-Gi protein complex
7XTA	;	3.2	;	Serotonin 4 (5-HT4) receptor-Gi-scFv16 complex
7XT9	;	3.2	;	Serotonin 4 (5-HT4) receptor-Gs complex
7XT8	;	3.1	;	Serotonin 4 (5-HT4) receptor-Gs-Nb35 complex
7X5H	;	3.1	;	Serotonin 5A (5-HT5A) receptor-Gi protein complex
7XTB	;	3.3	;	Serotonin 6 (5-HT6) receptor-Gs-Nb35 complex
7XTC	;	3.2	;	Serotonin 7 (5-HT7) receptor-Gs-Nb35 complex
1CJW	;	1.8	;	SEROTONIN N-ACETYLTRANSFERASE COMPLEXED WITH A BISUBSTRATE ANALOG
6Y5A	;	2.8	;	Serotonin-bound 5-HT3A receptor in Salipro
7E2Y	;	3.0	;	Serotonin-bound Serotonin 1A (5-HT1A) receptor-Gi protein complex
3STO	;	2.41	;	Serpin from the trematode Schistosoma Haematobium
1YXA	;	2.1	;	Serpina3n, a murine orthologue of human antichymotrypsin
3WD2	;	2.2	;	Serratia marcescens Chitinase B complexed with azide inhibitor
3WD3	;	2.2	;	Serratia marcescens Chitinase B complexed with azide inhibitor
3WD4	;	2.0	;	Serratia marcescens Chitinase B complexed with azide inhibitor and quinoline compound
4Z2G	;	2.6	;	Serratia marcescens Chitinase B complexed with macrolide inhibitor 26
4Z2H	;	2.35	;	Serratia marcescens Chitinase B complexed with macrolide inhibitor 29
4Z2I	;	2.0	;	Serratia marcescens Chitinase B complexed with macrolide inhibitor 30
4Z2J	;	2.6	;	Serratia marcescens Chitinase B complexed with macrolide inhibitor 31
4Z2K	;	2.3	;	Serratia marcescens Chitinase B complexed with macrolide inhibitor 32
4Z2L	;	2.3	;	Serratia marcescens Chitinase B complexed with macrolide inhibitor 33
3WD1	;	2.3	;	Serratia marcescens Chitinase B complexed with syn-triazole inhibitor
3WD0	;	1.7	;	Serratia marcescens Chitinase B, tetragonal form
5WUL	;	1.87	;	Serratia marcescens short-chain dehydrogenase/reductase F98A/F202L
5WUW	;	1.9	;	Serratia marcescens short-chain dehydrogenase/reductase F98L/F202L mutant
5WVA	;	1.47	;	Serratia marcescens short-chain dehydrogenase/reductase F98Y/F202Y mutant
7ZGW	;	1.83	;	Serratia NucC apo form
7ZGV	;	1.48	;	Serratia NucC bound to cA3
1AF0	;	1.8	;	SERRATIA PROTEASE IN COMPLEX WITH INHIBITOR
6TV0	;	1.96	;	Serratia spp. cyanase hydratase
1GYK	;	2.2	;	Serum Amyloid P Component co-crystallised with MOBDG at neutral pH
1V04	;	2.2	;	serum paraoxonase by directed evolution
3SRE	;	1.99	;	Serum paraoxonase-1 by directed evolution at pH 6.5
3SRG	;	2.19	;	Serum paraoxonase-1 by directed evolution at pH 6.5 in complex with 2-hydroxyquinoline
4HHQ	;	2.3	;	Serum paraoxonase-1 by directed evolution with the H115Q and H134Q mutations
4HHO	;	2.1	;	Serum paraoxonase-1 by directed evolution with the H115W mutation
4Q1U	;	2.302	;	Serum paraoxonase-1 by directed evolution with the K192Q mutation
6H0A	;	2.1	;	Serum paraoxonase-1 by directed evolution with the L69G/H115W/H134R/F222S/T332S mutations
6GMU	;	2.7	;	Serum paraoxonase-1 by directed evolution with the L69G/H134R/F222S/T332S mutations
6G82	;	2.401	;	Serum paraoxonase-1 by directed evolution with the L69S/H115W/F222S mutations
1SRS	;	3.2	;	SERUM RESPONSE FACTOR (SRF) CORE COMPLEXED WITH SPECIFIC SRE DNA
1BC7	;	2.01	;	SERUM RESPONSE FACTOR ACCESSORY PROTEIN 1A (SAP-1)/DNA COMPLEX
2WLP	;	2.65	;	Sesbania mosaic virus capsid protein dimer mutant (rCP-DEL-N65-W170K)
4DLY	;	1.57	;	Set 1 CaCl2/DTT, ordered off
5WCG	;	2.02	;	SET and MYND Domain Containing protein 2
2JV0	;		;	SET domain of RIZ1 tumor suppressor (PRDM2)
6NZO	;	3.8	;	Set2 bound to nucleosome
6PX1	;	3.3	;	Set2 bound to nucleosome
6PX3	;	4.1	;	Set2 bound to nucleosome
5TDR	;	1.42	;	Set3 PHD finger in complex with histone H3K4me2
5TDW	;	1.7	;	Set3 PHD finger in complex with histone H3K4me3
4E47	;	2.0	;	SET7/9 in complex with inhibitor (R)-(3-(3-cyanophenyl)-1-oxo-1-(pyrrolidin-1-yl)propan-2-yl)-1,2,3,4-tetrahydroisoquinoline-6- sulfonamide and S-adenosylmethionine
3M53	;	1.85	;	SET7/9 in complex with TAF10 peptide and AdoHcy
4J8O	;	1.63	;	SET7/9 in complex with TAF10K189A peptide and AdoHcy
4J83	;	1.7	;	SET7/9 in complex with TAF10K189A peptide and AdoMet
5EG2	;	1.55	;	SET7/9 N265A in complex with AdoHcy and TAF10 peptide
3M57	;	1.7	;	SET7/9 Y245A in complex with TAF10 peptide and AdoHcy
3M58	;	1.4	;	SET7/9 Y245A in complex with TAF10-K189me1 peptide and AdoHcy
3M59	;	1.7	;	SET7/9 Y245A in complex with TAF10-K189me2 peptide and AdoHcy
3M5A	;	1.75	;	SET7/9 Y245A in complex with TAF10-K189me3 peptide and AdoHcy
3M54	;	1.6	;	SET7/9 Y305F in complex with TAF10 peptide and AdoHcy
3M55	;	1.55	;	SET7/9 Y305F in complex with TAF10-K189me1 peptide and AdoHcy
3M56	;	1.65	;	SET7/9 Y305F in complex with TAF10-K189me2 peptide and AdoHcy
3OS5	;	1.69	;	SET7/9-Dnmt1 K142me1 complex
3CBO	;	1.65	;	SET7/9-ER-AdoHcy complex
3CBM	;	1.69	;	SET7/9-ER-AdoMet complex
3CBP	;	1.42	;	Set7/9-ER-Sinefungin complex
4J7I	;	2.56	;	SET7/9Y335F in complex with TAF10 peptide and AdoHcy
4J7F	;	1.59	;	SET7/9Y335pAF in complex with TAF10 peptide and AdoHcy
6VDB	;	2.3	;	SETD2 in complex with a H3-variant super-substrate peptide
6V62	;	2.36	;	SETD3 double mutant (N255F/W273A) in Complex with an Actin Peptide with His73 Replaced with Lysine
6OX3	;	1.785	;	SETD3 in Complex with an Actin Peptide with His73 Replaced with Lysine
6WK1	;	1.89	;	SETD3 in Complex with an Actin Peptide with His73 Replaced with Methionine
6OX0	;	1.755	;	SETD3 in Complex with an Actin Peptide with Sinefungin Replacing SAH as Cofactor
6OX1	;	1.949	;	SETD3 in Complex with an Actin Peptide with Target Histidine Partially Methylated
6WK2	;	1.76	;	SETD3 mutant (N255V) in Complex with an Actin Peptide with His73 Replaced with Methionine
6V63	;	2.02	;	SETD3 WT in Complex with an Actin Peptide with His73 Replaced with Glutamine
6MBK	;	1.69	;	SETD3, a Histidine Methyltransferase, in Complex with an Actin Peptide and SAH, First P212121 Crystal Form
6MBJ	;	1.78	;	SETD3, a Histidine Methyltransferase, in Complex with an Actin Peptide and SAH, P21 Crystal Form
6MBL	;	2.197	;	SETD3, a Histidine Methyltransferase, in Complex with an Actin Peptide and SAH, Second P212121 Crystal Form
6OX2	;	2.089	;	SETD3in Complex with an Actin Peptide with the Target Histidine Fully Methylated
4JLG	;	1.896	;	SETD7 in complex with inhibitor (R)-PFI-2 and S-adenosyl-methionine
4JDS	;	1.7	;	SETD7 in complex with inhibitor PF-5426 and S-adenosyl-methionine
5W1Y	;	1.7	;	SETD8 in complex with a covalent inhibitor
5KH6	;	2.05	;	SETDB1 in complex with a fragment candidate
5KCO	;	1.47	;	SETDB1 in complex with an early stage, low affinity fragment candidate modelled at reduced occupancy
5KCH	;	1.7	;	SETDB1 in complex with an early stage, low affinity fragment candidate modelled at reduced occupancy into weak electron density
8FTM	;	3.01	;	Setx-ssRNA-ADP-SO4 complex
487D	;	7.5	;	SEVEN RIBOSOMAL PROTEINS FITTED TO A CRYO-ELECTRON MICROSCOPIC MAP OF THE LARGE 50S SUBUNIT AT 7.5 ANGSTROMS RESOLUTION
1B1Y	;	2.5	;	SEVENFOLD MUTANT OF BARLEY BETA-AMYLASE
3V3M	;	1.96	;	Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease in Complex with N-[(1R)-2-(tert-butylamino)-2-oxo-1-(pyridin-3-yl)ethyl]-N-(4-tert-butylphenyl)furan-2-carboxamide inhibitor.
3MJ5	;	2.63	;	Severe Acute Respiratory Syndrome-Coronavirus Papain-Like Protease Inhibitors: Design, Synthesis, Protein-Ligand X-ray Structure and Biological Evaluation
7ALP	;	3.4	;	Severe fever with thrombocytopenia syndrome virus (Phenuiviridae) L protein
1SVY	;	1.75	;	SEVERIN DOMAIN 2, 1.75 ANGSTROM CRYSTAL STRUCTURE
6LF2	;	1.6	;	SeviL bound to asialo-GM1 saccharide
6LF1	;	1.7	;	SeviL, a GM1b/asialo-GM1 binding lectin
6ULB	;	1.75	;	Sex Hormone-binding globulin mutant E176K in complex with Danazol
6PYB	;	1.8	;	Sex Hormone-binding globulin mutant E176K in complex with DVT
6PYF	;	1.73	;	Sex Hormone-binding globulin mutant E176K in complex with Estradiol
6PYA	;	1.71	;	Sex Hormone-binding globulin mutant E176K in complex with IPI
2SXL	;		;	SEX-LETHAL RBD1, NMR, MINIMIZED AVERAGE STRUCTURE
3SXL	;	2.7	;	SEX-LETHAL RNA RECOGNITION DOMAINS 1 AND 2 FROM DROSOPHILA MELANOGASTER
3FLE	;	2.009	;	SE_1780 protein of unknown function from Staphylococcus epidermidis.
8SEI	;	2.9	;	SF Tau from Down Syndrome
3F7D	;	2.2	;	SF-1 LBD bound by phosphatidylcholine
5Y5H	;	1.5	;	SF-ROX structure of cytochrome P450nor (NO-bound state) determined at SACLA
6EN4	;	3.08	;	SF3b core in complex with a splicing modulator
5ZYA	;	3.95	;	SF3b spliceosomal complex bound to E7107
5HY7	;	2.9	;	SF3B10-SF3B130 from Chaetomium thermophilum
6MPO	;		;	Sf6 coat protein I-domain
8SMA	;	2.18	;	SfbO with di-Manganese cofactor
4BJI	;	1.45	;	Sfc1-DBD
4BJJ	;	2.4	;	Sfc1-Sfc7 dimerization module
5NI3	;	1.28	;	sfGFP 204-204 mutant dimer
8BXP	;	1.79	;	SfGFP C148 F206 mutant
8C1X	;	1.89	;	sfGFP C148 F206 mutant
6DQ0	;	2.048	;	sfGFP D133 mutated to 4-nitro-L-phenylalanine
5DPI	;	2.54	;	sfGFP double mutant - 133/149 p-cyano-L-phenylalanine
5DPJ	;	2.5	;	sfGFP double mutant - 133/149 p-ethynyl-L-phenylalanine
5DPG	;	1.85	;	sfGFP mutant - 133 p-cyano-L-phenylalanine
5DPH	;	1.42	;	sfGFP mutant - 149 p-cyano-L-phenylalanine
5EHU	;	1.45	;	sfGFP mutant with unnatural amino acid 4-azidoethoxy-L-phenylalanine incorporated at the 149 site
6DQ1	;	1.598	;	sfGFP N149 mutated to 4-nitro-L-phenylalanine
6GU1	;	1.7	;	SFI3 effector protein from the oomycete plant pathogen Phytophthora infestans
7UN9	;	3.3	;	SfSTING with c-di-GMP double fiber
7UN8	;	3.3	;	SfSTING with c-di-GMP single fiber
7UNA	;	4.0	;	SfSTING with cGAMP (masked)
6BVU	;		;	SFTI-HFRW-1
6BVX	;		;	SFTI-HFRW-2
6BVW	;		;	SFTI-HFRW-3
6BVY	;		;	SFTI-HFRW-4
7X6W	;	5.18	;	SFTSV 2 fold hexamer
7X6U	;	4.5	;	SFTSV 3 fold hexmer
7X72	;	7.2	;	SFTSV 5 fold pentamer
5Y10	;	2.6	;	SFTSV Gn head domain
5Y11	;	2.1	;	SFTSV GN with neutralizing antibody MAb4-5
6NTV	;	2.4	;	SFTSV L endonuclease domain
7VJ7	;	2.3	;	SFX structure of archaeal class II CPD photolyase from Methanosarcina mazei in the fully reduced state
7VJ8	;	2.1	;	SFX structure of archaeal class II CPD photolyase from Methanosarcina mazei in the oxidized state
7VJ6	;	2.1	;	SFX structure of archaeal class II CPD photolyase from Methanosarcina mazei in the semiquinone state
5JD2	;	1.9	;	SFX structure of corestreptavidin-selenobiotin complex
5MND	;	2.56	;	SFX structure of Cydia pomonella granulovirus using a double flow-focusing nozzle
5Y5M	;	2.1	;	SFX structure of cytochrome P450nor: a complete dark data without pump laser (resting state)
8C1U	;	1.7	;	SFX structure of D.m(6-4)photolyase
6I43	;	1.88	;	SFX Structure of Damage Free Ferric State of Dye Type Peroxidase Aa from Streptomyces lividans
7ADF	;	1.85	;	SFX structure of dehaloperoxidase B in the ferric form
7ADX	;	1.85	;	SFX structure of dehaloperoxidase B in the oxyferrous form
7QZH	;	1.92	;	SFX structure of dye-type peroxidase DtpB D152A variant in the ferric state
7QZE	;	1.9	;	SFX structure of dye-type peroxidase DtpB D152A variant in the ferryl state
7QZF	;	2.2	;	SFX structure of dye-type peroxidase DtpB D152A/N245A variant in the ferric state
6YRJ	;	1.85	;	SFX structure of dye-type peroxidase DtpB in the ferric state
6YRD	;	1.75	;	SFX structure of dye-type peroxidase DtpB in the ferryl state
7QZG	;	2.1	;	SFX structure of dye-type peroxidase DtpB N245A variant in the ferric state
7ZMJ	;	2.0	;	SFX structure of dye-type peroxidase DtpB R243A variant in the ferric state
8OEI	;	1.65	;	SFX structure of FutA after an accumulated dose of 350 kGy
8C4Y	;	1.6	;	SFX structure of FutA bound to Fe(III)
8GCQ	;	2.38	;	SFX structure of oxidized cytochrome c oxidase at 2.38 Angstrom resolution
6NMP	;	2.9	;	SFX structure of oxidized cytochrome c oxidase at room temperature
6NMF	;	2.8	;	SFX structure of reduced cytochrome c oxidase at room temperature
8OET	;	2.11	;	SFX structure of the class II photolyase complexed with a thymine dimer
7L6W	;	2.3	;	SFX structure of the MyD88 TIR domain higher-order assembly
7BER	;	2.3	;	SFX structure of the MyD88 TIR domain higher-order assembly (solved, rebuilt and refined using an identical protocol to the MicroED structure of the MyD88 TIR domain higher-order assembly)
5DLH	;	2.2501	;	SFX structure of thermolysin
8TDQ	;	1.65	;	SFX-XFEL structure of CYP121 cocrystallized with substrate cYY
7K44	;	1.45	;	SGBP-B from a complex xyloglucan utilization locus in Bacteroides uniformis
3KIK	;	2.1	;	Sgf11:Sus1 complex
3KJL	;	2.7	;	Sgf11:Sus1 complex
8BBL	;	2.711	;	SGL a GH20 family sulfoglycosidase
7K3X	;	1.705	;	SGMGCIT segment 58-64 from Keratin-8 with G62C mutation
7K3C	;	1.1	;	SGMGGIT segment 58-64 from Keratin-8
3N7B	;	2.65	;	SgrAI bound to secondary site DNA and Ca(II)
3N78	;	2.95	;	SgrAI bound to Secondary Site DNA and Mg(II)
3MQY	;	2.0	;	SgrAI with cleaved DNA and Magnesium bound
3DVO	;	1.892	;	SgrAI with cognate DNA and calcium bound
3DW9	;	2.2	;	SgrAI with cognate DNA and manganese bound
3DPG	;	1.91	;	SgrAI with noncognate DNA bound
2RJS	;	2.4	;	SgTAM bound to substrate mimic
2MF3	;		;	SGTX-Sf1a
8FTV	;	2.04	;	SgvM methyltransferase triple variant (M144V/F329V/T331A) with SAH and 2-oxo-4-phenylbutanoic acid
8FTR	;	2.13	;	SgvM methyltransferase with MTA and alpha-ketoleucine
8FTS	;	2.2	;	SgvM methyltransferase with SAH and alpha-ketoleucine
1LCJ	;	1.8	;	SH2 (SRC HOMOLOGY-2) DOMAIN OF HUMAN P56-LCK TYROSINE KINASE COMPLEXED WITH THE 11 RESIDUE PHOSPHOTYROSYL PEPTIDE EPQPYEEIPIYL
2EYV	;		;	SH2 domain of CT10-Regulated Kinase
7RNV	;	2.15	;	SH2 domain of guanine nucleotide exchange factor Vav2 in complex with an actin peptide with phosphorylated tyrosine 53
2CI8	;	1.8	;	sh2 domain of human nck1 adaptor protein - uncomplexed
5W3R	;	1.386	;	SH2B1 SH2 Domain
4M4Z	;	2.1	;	SH3 and SH2 domains of human Src-like adaptor protein 2 (SLAP2)
1AWW	;		;	SH3 DOMAIN FROM BRUTON'S TYROSINE KINASE, NMR, 42 STRUCTURES
1AWX	;		;	SH3 DOMAIN FROM BRUTON'S TYROSINE KINASE, NMR, MINIMIZED AVERAGE STRUCTURE
1ARK	;		;	SH3 DOMAIN FROM HUMAN NEBULIN, NMR, 15 STRUCTURES
1NEB	;		;	SH3 DOMAIN FROM HUMAN NEBULIN, NMR, MINIMIZED AVERAGE STRUCTURE
5NVJ	;	1.18	;	SH3 domain from Mouse cortactin (C 1 2 1 crystal form)
5NV1	;	1.51	;	SH3 domain from Mouse cortactin (C 2 2 21 crystal form)
5NXJ	;	2.282	;	SH3 domain from Mouse cortactin (P 1 21 1 crystal form)
2IIM	;	1.0	;	SH3 Domain of Human Lck
1H92	;		;	SH3 domain of human Lck tyrosine kinase
1W1F	;		;	SH3 DOMAIN OF HUMAN LYN TYROSINE KINASE
1WA7	;		;	SH3 DOMAIN OF HUMAN LYN TYROSINE KINASE IN COMPLEX WITH A HERPESVIRAL LIGAND
1S1N	;		;	SH3 domain of human nephrocystin
1UG1	;		;	SH3 domain of Hypothetical protein BAA76854.1
7NYK	;	1.45	;	SH3 domain of JNK-interacting Protein 1 (JIP1)
1KIK	;		;	SH3 Domain of Lymphocyte Specific Kinase (LCK)
7CFZ	;	1.89	;	SH3 domain of NADPH oxidase activator 1
1W70	;	1.46	;	SH3 domain of p40phox complexed with C-terminal polyProline region of p47phox
1W6X	;	2.0	;	SH3 domain of p40phox, component of the NADPH oxidase
1YN8	;	1.7	;	SH3 domain of yeast NBP2
1YNZ	;	2.2	;	SH3 domain of yeast Pin3
8CF4	;		;	SH3 domain solved by the exact solid-state method from the Bruker Dynamics Center using the combined correction method with PDB 2NUZ
8CHG	;		;	SH3 domain solved by the exact solid-state method from the Bruker Dynamics Center using the correction for dipolar truncation with PDB 2NUZ
8CHH	;		;	SH3 domain solved by the exact solid-state method from the Bruker Dynamics Center using the correction method for spin-diffusion with PDB 2NUZ as reference
1KJW	;	1.8	;	SH3-Guanylate Kinase Module from PSD-95
4Z89	;	2.64	;	SH3-II of Drosophila Rim-binding protein bound to a Cacophony derived peptide
4Z88	;	2.09	;	SH3-II of Drosophila Rim-binding protein with Aplip1 peptide
4Z8A	;	1.759	;	SH3-III of Drosophila Rim-binding protein bound to a Cacophony derived peptide
8B2F	;	1.183	;	SH3-like cell wall binding domain of the GH24 family muramidase from Trichophaea saccata in complex with triglycine
8B2G	;	1.5	;	SH3-like domain from Penicillium virgatum muramidase
2ABL	;	2.5	;	SH3-SH2 DOMAIN FRAGMENT OF HUMAN BCR-ABL TYROSINE KINASE
1LCK	;	2.5	;	SH3-SH2 DOMAIN FRAGMENT OF HUMAN P56-LCK TYROSINE KINASE COMPLEXED WITH THE 10 RESIDUE SYNTHETIC PHOSPHOTYROSYL PEPTIDE TEGQPYQPQPA
6SCW	;		;	SH3-subunit of chicken alpha spectrin solved by NMR
2R9R	;	2.4	;	Shaker family voltage dependent potassium channel (kv1.2-kv2.1 paddle chimera channel) in association with beta subunit
8TEO	;	2.39	;	Shaker in low K+ (4mM K+)
4MWL	;	1.8	;	Shanghai N9
4MWY	;	1.8	;	Shanghai N9-laninamivir
4MWW	;	1.9	;	Shanghai N9-oseltamivir carboxylate
4MX0	;	2.101	;	Shanghai N9-peramivir
4MWX	;	1.801	;	Shanghai N9-zanamivir
4HGK	;	3.04	;	Shark IgNAR variable domain
4HGM	;	2.34	;	Shark IgNAR Variable Domain
2LNY	;		;	ShB peptide structure bound to negatively charged lipid-bilayer after Molecular Dynamics refinement
1SHC	;		;	SHC PTB DOMAIN COMPLEXED WITH A TRKA RECEPTOR PHOSPHOPEPTIDE, NMR, MINIMIZED AVERAGE STRUCTURE
2L1C	;		;	Shc-PTB:biphosphorylated integrin beta3 cytoplasmic tail complex (1:1)
1MUV	;		;	Sheared A(anti)-A(anti) Base Pairs in a Destabilizing 2x2 Internal Loop: The NMR Structure of 5'(rGGCAAGCCU)2
1P0U	;		;	Sheared G/C Base Pair
5ABM	;	1.7	;	Sheep aldehyde dehydrogenase 1A1
5AC1	;	2.08	;	Sheep aldehyde dehydrogenase 1A1 with duocarmycin analog inhibitor
7JKC	;	1.9	;	Sheep Connexin-46 at 1.9 angstroms resolution by CryoEM
7JMD	;	2.5	;	Sheep Connexin-46 at 2.5 angstroms resolution, Lipid Class 1
7JN0	;	2.5	;	Sheep Connexin-46 at 2.5 angstroms resolution, Lipid Class 2
7JN1	;	2.5	;	Sheep Connexin-46 at 2.5 angstroms resolution, Lipid Class 3
7JJP	;	1.94	;	Sheep Connexin-50 at 1.9 angstroms resolution by CryoEM
7JM9	;	2.5	;	Sheep Connexin-50 at 2.5 angstroms reoslution, Lipid Class 2
7JLW	;	2.5	;	Sheep Connexin-50 at 2.5 angstroms resolution, Lipid Class 1
7JMC	;	2.5	;	Sheep Connexin-50 at 2.5 angstroms resolution, Lipid Class 3
6N3R	;	2.397	;	Sheep Galectin-11 (LGALS11) complex with galactose
6N44	;	2.0	;	Sheep Galectin-11 (LGALS11) complex with glycerol
1BXS	;	2.35	;	SHEEP LIVER CLASS 1 ALDEHYDE DEHYDROGENASE WITH NAD BOUND
3QE3	;	1.9	;	Sheep liver sorbitol dehydrogenase
7B6S	;	1.923	;	Sheep Polyomavirus VP1 in complex with 10 mM Forssman antigen pentaose
7B6T	;	1.701	;	Sheep Polyomavirus VP1 in complex with 10 mM globo-N-tetraose
7B6V	;	1.798	;	Sheep Polyomavirus VP1 in complex with 5 mM Forssman antigen pentaose and 20 mM 3'-sialyllactosamine
7B6U	;	1.901	;	Sheep Polyomavirus VP1 in complex with 5 mM Forssman antigen pentaose and 20 mM 6'-sialyllactosamine
4S1P	;	1.45	;	Shel_16390 protein, a putative SGNH hydrolase from Slackia heliotrinireducens
4PFM	;	2.327	;	SHEWANELLA BENTHICA DHDPS WITH LYSINE AND PYRUVATE
5NC8	;	3.09	;	Shewanella denitrificans Kef CTD in AMP bound form
5I5I	;	2.14	;	Shewanella denitrificans nitrous oxide reductase, app form
5I5M	;	1.37	;	Shewanella denitrificans nitrous oxide reductase, Ca2+-reconstituted form
5I5J	;	2.55	;	Shewanella denitrificans nitrous oxide reductase, reduced apo form
6BG8	;	1.59713	;	Shewanella frigidimarina ice-binding protein_1 DUF3494 Domain
4PU4	;	3.786	;	Shewanella oneidensis MR-1 Toxin Antitoxin System HipA, HipB and its operator DNA complex (space group P21)
4PU3	;	3.39	;	Shewanella oneidensis MR-1 Toxin Antitoxin System HipA, HipB and its operator DNA complex (space group P212121)
4PU7	;	1.85	;	Shewanella oneidensis Toxin Antitoxin System Antitoxin Protein HipB Resolution 1.85
4PU8	;	2.35	;	Shewanella oneidensis Toxin Antitoxin System Antitoxin Protein HipB Resolution 2.35
4PU5	;	1.834	;	Shewanella oneidensis Toxin Antitoxin System Toxin Protein HipA Bound with AMPPNP and Mg
2MUA	;		;	Shifting the Polarity of some Critical Residues in Malarial Peptides Binding to Host Cells is a Key Factor in Breaking Conserved Antigens
1DM0	;	2.5	;	SHIGA TOXIN
1R4Q	;	2.5	;	Shiga toxin
1R4P	;	1.77	;	Shiga toxin type 2
2C5C	;	2.94	;	Shiga-like toxin 1 B subunit complexed with a bivalent inhibitor
1BOS	;	2.8	;	SHIGA-LIKE TOXIN COMPLEXED WITH ITS RECEPTOR
1QNU	;	2.23	;	Shiga-Like Toxin I B Subunit Complexed with the Bridged-Starfish Inhibitor
4Q5H	;	1.999	;	Shigella Effector Kinase OspG bound to AMPPNP and E2-Ub UbcH7-Ub Conjugate
4Q5E	;	1.869	;	Shigella Effector Kinase OspG bound to E2-Ub UbcH7-Ub Conjugate
5KH1	;	3.4	;	Shigella flexneri Effector IpaH1880
4XZX	;	2.2	;	Shigella flexneri effector OspI C62S mutant
2J0O	;	3.0	;	Shigella Flexneri IpaD
4ZM5	;	2.47	;	Shigella flexneri lipopolysaccharide O-antigen chain-length regulator WzzBSF - A107P mutant
4ZM1	;	2.55	;	Shigella flexneri lipopolysaccharide O-antigen chain-length regulator WzzBSF - wild type
2VJ5	;	3.0	;	Shigella flexneri MxiC
3RF3	;	1.61	;	Shigella IpaA-VBS3 in complex with human vinculin
5NL1	;	2.5	;	Shigella IpaA-VBS3/TBS in complex with the Talin VBS1 domain 488-512
3LXR	;	1.68	;	Shigella IpgB2 in complex with human RhoA and GDP (complex C)
3LW8	;	1.85	;	Shigella IpgB2 in complex with human RhoA, GDP and Mg2+ (complex A)
3LWN	;	2.28	;	Shigella IpgB2 in complex with human RhoA, GDP and Mg2+ (complex B)
3PHJ	;	2.3	;	Shikimate 5-Dehydrogenase (aroE) from Helicobacter pylori in complex with 3-Dehydroshikimate
3PHH	;	1.42	;	Shikimate 5-Dehydrogenase (aroE) from Helicobacter pylori in complex with Shikimate
3PHI	;	2.04	;	Shikimate 5-Dehydrogenase (aroE) from Helicobacter pylori in complex with Shikimate and NADPH
1NYT	;	1.5	;	SHIKIMATE DEHYDROGENASE AroE COMPLEXED WITH NADP+
4Y0A	;	1.911	;	Shikimate kinase from Acinetobacter baumannii in complex with shikimate
3MUF	;	2.3	;	Shikimate kinase from Helicobacter pylori in complex with shikimate-3-phosphate and ADP
2IYU	;	1.85	;	Shikimate kinase from Mycobacterium tuberculosis in complex with ADP, open LID (conf. A)
2IYV	;	1.35	;	Shikimate kinase from Mycobacterium tuberculosis in complex with ADP, open LID (conf. B)
2IYW	;	1.85	;	Shikimate kinase from Mycobacterium tuberculosis in complex with MgATP, open LID (conf. B)
2IYR	;	1.98	;	Shikimate kinase from Mycobacterium tuberculosis in complex with shikimate
2IYQ	;	1.8	;	Shikimate kinase from Mycobacterium tuberculosis in complex with shikimate and ADP
2IYX	;	1.49	;	Shikimate kinase from Mycobacterium tuberculosis in complex with shikimate and SO4
2IYS	;	1.4	;	Shikimate kinase from Mycobacterium tuberculosis in complex with shikimate, open LID (conf. A)
2IYZ	;	2.3	;	Shikimate kinase from Mycobacterium tuberculosis in complex with shikimate-3-phosphate and ADP
2IYY	;	1.62	;	Shikimate kinase from Mycobacterium tuberculosis in complex with shikimate-3-phosphate and SO4
2IYT	;	1.47	;	Shikimate kinase from Mycobacterium tuberculosis in unliganded state, open LID (conf. A)
1BEI	;		;	Shk-dnp22: A Potent Kv1.3-specific immunosuppressive polypeptide, NMR, 20 structures
6YRW	;	2.5	;	SHMT from Streptococcus thermophilus Tyr55Ser variant as internal aldimine and as non-covalent complex with D-Ser
6TI4	;	1.93	;	SHMT from Streptococcus thermophilus Tyr55Ser variant in complex with PLP/D-Serine/Lys230 gem diamine complex
6TI1	;	2.0	;	SHMT from Streptococcus thermophilus Tyr55Ser variant in complex with PLP/L-Threonine/Lys230 gem diamine complex
6TGH	;	2.12	;	SHMT from Streptococcus thermophilus Tyr55Thr variant in complex with D-Serine both as external aldimine and as non-covalent complex
8J84	;	3.3	;	Short ago complexed with TIR-APAZ
4BMS	;	2.89	;	Short chain alcohol dehydrogenase from Ralstonia sp. DSM 6428 in complex with NADPH
7VYQ	;	3.13	;	Short chain dehydrogenase (SCR) cryoEM structure with NADP and ethyl 4-chloroacetoacetate
7DLM	;	1.59	;	Short chain dehydrogenase (SCR) crystal structure with NADPH
7DMG	;	1.79	;	Short chain dehydrogenase 2 (SCR2) crystal structure with NADP
7DLL	;	1.89	;	Short chain dehydrogenase 2 (SCR2) crystal structure with NADPH
2NWQ	;	2.3	;	Short chain dehydrogenase from Pseudomonas aeruginosa
3T4X	;	2.8	;	Short chain dehydrogenase/reductase family oxidoreductase from Bacillus anthracis str. Ames Ancestor
5T2U	;	2.2	;	short chain dehydrogenase/reductase family protein
2IX6	;	3.9	;	SHORT CHAIN SPECIFIC ACYL-COA OXIDASE FROM ARABIDOPSIS THALIANA, ACX4
2IX5	;	2.7	;	Short chain specific acyl-CoA oxidase from Arabidopsis thaliana, ACX4 in complex with acetoacetyl-CoA
1YGC	;	2.0	;	Short Factor VIIa with a small molecule inhibitor
7TVC	;	1.19	;	Short form D7 protein from Aedes aegypti
7TVY	;	1.98	;	Short form D7 protein from Culex quinquefasciatus
1YC0	;	2.6	;	short form HGFA with first Kunitz domain from HAI-1
2R0L	;	2.2	;	Short Form HGFA with Inhibitory Fab75
5LUV	;	2.5	;	Short LOV protein W619_1 in apo-state
5VLA	;	2.4	;	Short PCSK9 delta-P' complex with Fusion2 peptide
5VLH	;	2.86	;	Short PCSK9 delta-P' complex with peptide Pep1
5VLL	;	2.37	;	Short PCSK9 delta-P' complex with peptide Pep3
5VLK	;	2.2	;	Short PCSK9 delta-P' complex with shrunken peptide bearing homo-Arginine
3VU6	;	2.324	;	Short peptide HIV entry inhibitor MT-SC22EK with a M-T hook
3VU5	;	2.087	;	Short peptide HIV entry Inhibitor SC22EK
8PXS	;		;	Short RNA binding to peptide amyloids
7XGS	;	2.21	;	Short vegetative phase protein
7P8Y	;	2.18	;	Short wilavidin apo form
7P8Z	;	1.67	;	Short wilavidin biotin complex
4BMV	;	2.5	;	Short-chain dehydrogenase from Sphingobium yanoikuyae in complex with NADPH
8EH2	;	2.4	;	Short-chain dehydrogenase/reductase (SDR) from Acinetobacter baumannii
8GBB	;	2.4	;	Short-chain dehydrogenase/reductase (SDR) from multi-drug resistant Acinetobacter baumannii
4ZGW	;	1.47	;	Short-chain dehydrogenase/reductase from Serratia marcescens BCRC 10948
4FN4	;	1.75	;	short-chain NAD(H)-dependent dehydrogenase/reductase from Sulfolobus acidocaldarius
2MU7	;		;	Shortening and modifying the 1513 MSP-1 peptide's alpha-helical region induces protection against malaria
4UZM	;		;	Shotgun proteolysis: A practical application
4HJQ	;	1.8013	;	SHP-1 catalytic domain WPD loop closed
4HJP	;	1.3994	;	SHP-1 catalytic domain WPD loop open
7PPN	;	1.9	;	SHP2 catalytic domain in complex with CD28 (183-198) phosphopeptide (pTyr-191, p-Thr-195)
7PPL	;	1.53	;	SHP2 catalytic domain in complex with IRS1 (625-639) phosphopeptide (pTyr-632, pSer-636)
7PPM	;	1.48	;	SHP2 catalytic domain in complex with IRS1 (889-901) phosphopeptide (pSer-892, pTyr-896)
8CBH	;	2.24	;	SHP2 in complex with a novel allosteric inhibitor
8B5Y	;	1.83	;	SHP2 in complex with allosteric imidazopyrazine inhibitor
4QSY	;	2.1	;	SHP2 SH2 domain in complex with GAB1 peptide
7DLV	;	2.525	;	shrimp dUTPase in complex with Stl
6LBD	;	1.386	;	shrimp ferritin T158R G159R
6LBC	;	1.801	;	shrimp ferritin-T158R
6KCU	;	1.65	;	Shuguo PWWP domain
6KD6	;	1.58	;	Shuguo PWWP domain
6KCO	;	2.4	;	Shuguo PWWP in complex with ssDNA
6KCP	;	1.8	;	Shuguo PWWP in complex with ssDNA
3MXR	;	1.3	;	SHV-1 beta-lactamase complex with compound 1
3MXS	;	1.24	;	SHV-1 beta-lactamase complex with compound 2
3MKF	;	1.33	;	SHV-1 beta-lactamase complex with GB0301
3D4F	;	1.55	;	SHV-1 beta-lactamase complex with LN1-255
3MKE	;	1.75	;	SHV-1 beta-lactamase complex with LP06
4GD6	;	1.53	;	SHV-1 beta-lactamase in complex with penam sulfone SA1-204
4GD8	;	1.6	;	SHV-1 beta-lactamase in complex with penam sulfone SA3-53
1ONG	;	1.1	;	SHV-1 beta-lactamase with a penem inhibitor
2ZD8	;	1.05	;	SHV-1 class A beta-lactamase complexed with meropenem
1Q2P	;	2.0	;	SHV-1 class A beta-lactamase complexed with penem WAY185229
4GDB	;	1.84	;	SHV-1 in complex with 4H-pyrazolo[1,5-c][1,3]thiazole containing penem inhibitor
6U2A	;	2.3	;	ShyA endopeptidase from Vibrio cholera (open form)
6UE4	;	2.08	;	ShyA Endopeptidase from Vibrio cholerae (Closed form)
1AB1	;	0.89	;	SI FORM CRAMBIN
6K4E	;	2.094	;	SiaA-PP2C domain of Pseudomonas aeruginosa
6K4F	;	1.735	;	SiaC of Pseudomonas aeruginosa
1K2F	;	2.6	;	siah, Seven In Absentia Homolog
4I7B	;	3.0	;	Siah1 bound to synthetic peptide (ACE)KLRPV(ABA)MVRPTVR
4I7D	;	2.4	;	Siah1 bound to synthetic peptide (ACE)KLRPVAMVRP(PRK)VR
4I7C	;	2.8	;	Siah1 mutant bound to synthetic peptide (ACE)KLRPV(23P)MVRPWVR
6VS7	;	2.0	;	Sialic acid binding region of Streptococcus Sanguinis SK1 adhesin
6VU6	;	2.1	;	Sialic acid binding region of Streptococcus Sanguinis SK1 adhesin bound to 3'sLn
6VT2	;	1.52	;	Sialic acid binding region of Streptococcus sanguinis SK1 adhesin bound to sTa
1EUR	;	1.82	;	SIALIDASE
5MQR	;	2.2	;	Sialidase BT_1020
5MQS	;	3.0	;	Sialidase BT_1020
1EUS	;	2.0	;	SIALIDASE COMPLEXED WITH 2-DEOXY-2,3-DEHYDRO-N-ACETYLNEURAMINIC ACID
3SIL	;	1.05	;	SIALIDASE FROM SALMONELLA TYPHIMURIUM
1DIL	;	1.9	;	SIALIDASE FROM SALMONELLA TYPHIMURIUM COMPLEXED WITH APANA AND EPANA INHIBITORS
1DIM	;	1.6	;	SIALIDASE FROM SALMONELLA TYPHIMURIUM COMPLEXED WITH EPANA INHIBITOR
1SLL	;	2.0	;	SIALIDASE L FROM LEECH MACROBDELLA DECORA
1EUU	;	2.5	;	SIALIDASE OR NEURAMINIDASE, LARGE 68KD FORM
1EUT	;	2.5	;	SIALIDASE, LARGE 68KD FORM, COMPLEXED WITH GALACTOSE
7MHU	;	2.0	;	Sialidase24 apo
6MRX	;	2.0	;	Sialidase26 apo
6MRV	;	1.8	;	Sialidase26 co-crystallized with DANA
6MYV	;	2.2	;	Sialidase26 co-crystallized with DANA-Gc
8AXI	;	1.25	;	Sialidases and Fucosidases of Akkermansia muciniphila are key for rapid growth on colonic mucin and nutrient sharing amongst mucin-associated human gut microbiota
8AXS	;	1.3	;	Sialidases and Fucosidases of Akkermansia muciniphila are key for rapid growth on colonic mucin and nutrient sharing amongst mucin-associated human gut microbiota
8AXT	;	1.59	;	Sialidases and Fucosidases of Akkermansia muciniphila are key for rapid growth on colonic mucin and nutrient sharing amongst mucin-associated human gut microbiota
8AYR	;	2.7	;	Sialidases and Fucosidases of Akkermansia muciniphila are key for rapid growth on colonic mucin and nutrient sharing amongst mucin-associated human gut microbiota
6H75	;	1.45	;	SiaP A11N in complex with Neu5Ac (RT)
2XWV	;	1.05	;	SiaP complex
2XXK	;	1.48	;	SiaP complex
6H76	;	1.5	;	SiaP in complex with Neu5Ac (RT)
2WYK	;	1.5	;	SiaP in complex with Neu5Gc
2XWK	;	1.49	;	SiaP R147A mutant in complex with Neu5Ac
2XWO	;	1.54	;	SiaP R147E mutant in complex with sialylamide
2XWI	;	2.195	;	SiaP R147K mutant in complex with Neu5Ac
7EAU	;		;	SIB1, an effector of Colletotrichum orbiculare
5CIV	;	1.384	;	Sibling Lethal Factor Precursor - DfsB
6QWT	;	2.3	;	Sicinivirus 3Dpol RNA dependent RNA polymerase
4ZUZ	;	2.86	;	SidC 1-871
6CP2	;	2.9	;	SidC in complex with UbcH7~Ub
6RRE	;	3.586	;	SidD, deAMPylase from Legionella pneumophila
5ZQ2	;	2.704	;	SidE apo form
159D	;	1.8	;	SIDE BY SIDE BINDING OF TWO DISTAMYCIN A DRUGS IN THE MINOR GROOVE OF AN ALTERNATING B-DNA DUPLEX
304D	;	1.9	;	SIDE-BY-SIDE BINDING OF DISTAMYCIN MOLECULES TO D(ICATATIC) IN THE MONOCLINIC FORM
305D	;	2.17	;	SIDE-BY-SIDE BINDING OF DISTAMYCIN MOLECULES TO D(ICATATIC) IN THE TETRAGONAL FORM
306D	;	1.6	;	SIDE-BY-SIDE BINDING OF DISTAMYCIN MOLECULES TO D(ICITACIC)
3DR1	;	2.7	;	Side-chain fluorine atoms of non-steroidal vitamin D3 analogs stabilize helix 12 of vitamin D receptor
3AT5	;	2.2	;	Side-necked turtle (Pleurodira, Chelonia, REPTILIA) hemoglobin: cDNA-derived primary structures and X-ray crystal structures of Hb A
3AT6	;	2.35	;	Side-necked turtle (Pleurodira, Chelonia, REPTILIA) hemoglobin: cDNA-derived primary structures and X-ray crystal structures of Hb A
5ZQ5	;	2.487	;	SidE-Ubi
5ZQ6	;	3.009	;	SidE-Ubi-ADPr
5ZQ7	;	2.847	;	SidE-Ubi-NAD
2N7J	;		;	Sidechain chi1 distribution in B3 domain of protein G from extensive sets of residual dipolar couplings
5K6Z	;	2.7	;	Sidekick chimera containing sidekick-2 immunoglobulin domains 1-2 and sidekick-1 immunoglobulin domains 3-4
5K6U	;	2.201	;	Sidekick-1 immunoglobulin domains 1-4, crystal form 1
5K6V	;	3.208	;	Sidekick-1 immunoglobulin domains 1-4, crystal form 2
5K6W	;	3.5	;	Sidekick-1 immunoglobulin domains 1-5
5K70	;	2.7	;	Sidekick-2 immunoglobulin domains 1-4 H18R/N22S mutant
5K6X	;	2.7	;	Sidekick-2 immunoglobulin domains 1-4, crystal form 1
5K6Y	;	3.2	;	Sidekick-2 immunoglobulin domains 1-4, crystal form 2
2LBV	;		;	Siderocalin Q83 reveals a dual ligand binding mode
3PEC	;	2.19	;	Siderocalin Recognitin of Carboxymycobactins: Interference by the immune system in intracellular iron acquisition by Mycobacteria tuberculosis
3PED	;	2.3	;	Siderocalin Recognitin of Carboxymycobactins: Interference by the immune system in intracellular iron acquisition by Mycobacteria tuberculosis
4ZFX	;	2.55	;	Siderocalin-mediated recognition and cellular uptake of actinides
4ZHC	;	2.04	;	Siderocalin-mediated recognition and cellular uptake of actinides
4ZHD	;	2.05	;	Siderocalin-mediated recognition and cellular uptake of actinides
4ZHF	;	2.45	;	Siderocalin-mediated recognition and cellular uptake of actinides
4ZHG	;	2.05	;	Siderocalin-mediated recognition and cellular uptake of actinides
4ZHH	;	2.04	;	Siderocalin-mediated recognition and cellular uptake of actinides
6GUO	;	1.75	;	Siderophore hydrolase EstA from Aspergillus nidulans
6GUD	;	1.7	;	Siderophore hydrolase EstB from Aspergillus fumigatus
6GUP	;	1.85	;	Siderophore hydrolase EstB from Aspergillus fumigatus
6GUR	;	2.1	;	Siderophore hydrolase EstB from Aspergillus fumigatus in complex with TAFC
6GUN	;	2.0	;	Siderophore hydrolase EstB from Aspergillus nidulans
6GUL	;	2.3	;	Siderophore hydrolase EstB mutant E211Q from Aspergillus fumigatus
6GUI	;	1.7	;	Siderophore hydrolase EstB mutant H267N from Aspergillus fumigatus
6GUG	;	1.45	;	Siderophore hydrolase EstB mutant S148A from Aspergillus fumigatus
7Y68	;	2.87	;	SIDT2-pH5.5 plus miRNA
8B3Z	;	2.38	;	SigE N-terminal Domain
2HRL	;	1.85	;	Siglec-7 in complex with GT1b
7QUH	;	2.867	;	Siglec-8 in complex with therapeutic Fab AK002.
6PMI	;	3.86	;	Sigm28-transcription initiation complex with specific promoter at the state 1
6PMJ	;	3.91	;	Sigm28-transcription initiation complex with specific promoter at the state 2
1SC5	;	3.26	;	Sigma-28(FliA)/FlgM complex
5MWW	;		;	Sigma1.1 domain of sigmaA from Bacillus subtilis
5IPL	;	3.6	;	SigmaS-transcription initiation complex with 4-nt nascent RNA
5IPM	;	4.2	;	SigmaS-transcription initiation complex with 4-nt nascent RNA
5IPN	;	4.61	;	SigmaS-transcription initiation complex with 4-nt nascent RNA
8F1K	;	2.8	;	SigN RNA polymerase early-melted intermediate bound to full duplex DNA fragment dhsU36 (-12T)
8F1J	;	2.6	;	SigN RNA polymerase early-melted intermediate bound to mismatch DNA fragment dhsU36mm2 (-12A)
8F1I	;	3.0	;	SigN RNA polymerase early-melted intermediate bound to mismatch fragment dhsU36mm1 (-12T)
7ZL3	;	3.2	;	Signal peptide mimicry primes Sec61 for client-selective inhibition
1914	;	2.53	;	SIGNAL RECOGNITION PARTICLE ALU RNA BINDING HETERODIMER, SRP9/14
1J8M	;	2.0	;	Signal Recognition Particle conserved GTPase domain from A. ambivalens
1J8Y	;	2.0	;	Signal Recognition Particle conserved GTPase domain from A. ambivalens T112A mutant
1NRJ	;	1.7	;	Signal Recognition Particle Receptor Beta-Subunit in Complex with the SRX Domain from the Alpha-Subunit
2GED	;	2.2	;	Signal Recognition Particle Receptor Beta-Subunit in nucleotide-free dimerized form
1FTS	;	2.2	;	SIGNAL RECOGNITION PARTICLE RECEPTOR FROM E. COLI
5CK4	;	1.89	;	Signal recognition particle receptor SRb-GDP from Chaetomium thermophilum
5CK5	;	2.4	;	Signal recognition particle receptor SRb-GDP-Mg from Chaetomium thermophilum
5CK3	;	3.2	;	Signal recognition particle receptor SRb-GTP/SRX complex from Chaetomium thermophilum
5NIY	;	1.7	;	Signal recognition particle-docking protein FtsY
6L7I	;	2.9	;	Signal substraction of TcdB1-TccC2 and part of TcdA1
6Y5L	;	3.6	;	Signal Subtracted Extended Intermediate form of X-31 Influenza Haemagglutinin at pH 5 (State IV)
7MI3	;	3.5	;	Signal subtracted reconstruction of AAA2, AAA3, and AAA4 domains of dynein in the presence of a pyrazolo-pyrimidinone-based compound, Model 4
7MI8	;	3.7	;	Signal subtracted reconstruction of AAA5 and AAA6 domains of dynein in the presence of a pyrazolo-pyrimidinone-based compound, Model 5
1TZE	;	2.1	;	SIGNAL TRANSDUCTION ADAPTOR GROWTH FACTOR, GRB2 SH2 DOMAIN COMPLEXED WITH PHOSPHOTYROSYL HEPTAPEPTIDE LYS-PRO-PHE-PTYR-VAL-ASN-VAL-NH2 (KFPPYVNC-NH2)
1BAK	;		;	SIGNAL TRANSDUCTION PLECKSTRIN HOMOLOGY DOMAIN OF G-PROTEIN COUPLED RECEPTOR KINASE 2 (BETA-ADRENERGIC RECEPTOR KINASE 1), C-TERMINAL EXTENDED, NMR, 20 STRUCTURES
1YMU	;	2.3	;	SIGNAL TRANSDUCTION PROTEIN CHEY MUTANT WITH MET 17 REPLACED BY GLY (M17G)
1YMV	;	1.9	;	SIGNAL TRANSDUCTION PROTEIN CHEY MUTANT WITH PHE 14 REPLACED BY GLY, SER 15 REPLACED BY GLY, AND MET 17 REPLACED BY GLY
4XCO	;	2.9	;	Signal-sequence induced conformational changes in the signal recognition particle
2KX6	;		;	Signaling state of Photoactive Yellow Protein
7YNS	;	3.0	;	SIL5-bound alpha-synuclein fibrils
7DKI	;	2.0	;	Silk worm FKBP, isoform-1
6VM7	;	2.41	;	SILv44 T cell receptor bound to HLA-A2 presenting gp100 peptide (ITDQVPFSV)
6VM8	;	2.41	;	SILv44 T cell receptor bound to HLA-A2 presenting gp100T2M peptide (IMDQVPFSV)
3NSD	;	2.0	;	Silver bound to the multicopper oxidase CueO (untagged)
8C2Q	;		;	Silver ion-bound structure of the silver specific chaperone SilF needed for bacterial silver resistance
3RU5	;	1.35	;	Silver Metallated Hen Egg White Lysozyme at 1.35 A
3UGE	;	1.7	;	Silver Metallated Pseudomonas aeruginosa Azurin at 1.70 A
7CGC	;	2.548	;	Silver-bound E. coli Malate dehydrogenase (C113 and C251)
6KA0	;	2.22	;	Silver-bound E.coli Malate dehydrogenase
7CGD	;	2.06	;	Silver-bound E.coli malate dehydrogenase
6IO4	;	3.1	;	Silver-bound Glyceraldehyde-3-phosphate dehydrogenase A
6IO6	;	2.64	;	Silver-bound Glyceraldehyde-3-phosphate dehydrogenase A at non-catalytic site
1SVA	;	3.1	;	SIMIAN VIRUS 40
1L85	;	2.0	;	SIMILAR HYDROPHOBIC REPLACEMENTS OF LEU 99 AND PHE 153 WITHIN THE CORE OF T4 LYSOZYME HAVE DIFFERENT STRUCTURAL AND THERMODYNAMIC CONSEQUENCES
1L86	;	1.8	;	SIMILAR HYDROPHOBIC REPLACEMENTS OF LEU 99 AND PHE 153 WITHIN THE CORE OF T4 LYSOZYME HAVE DIFFERENT STRUCTURAL AND THERMODYNAMIC CONSEQUENCES
1L87	;	1.8	;	SIMILAR HYDROPHOBIC REPLACEMENTS OF LEU 99 AND PHE 153 WITHIN THE CORE OF T4 LYSOZYME HAVE DIFFERENT STRUCTURAL AND THERMODYNAMIC CONSEQUENCES
1L88	;	1.85	;	SIMILAR HYDROPHOBIC REPLACEMENTS OF LEU 99 AND PHE 153 WITHIN THE CORE OF T4 LYSOZYME HAVE DIFFERENT STRUCTURAL AND THERMODYNAMIC CONSEQUENCES
1L89	;	1.9	;	SIMILAR HYDROPHOBIC REPLACEMENTS OF LEU 99 AND PHE 153 WITHIN THE CORE OF T4 LYSOZYME HAVE DIFFERENT STRUCTURAL AND THERMODYNAMIC CONSEQUENCES
1L90	;	1.75	;	SIMILAR HYDROPHOBIC REPLACEMENTS OF LEU 99 AND PHE 153 WITHIN THE CORE OF T4 LYSOZYME HAVE DIFFERENT STRUCTURAL AND THERMODYNAMIC CONSEQUENCES
1L91	;	1.8	;	SIMILAR HYDROPHOBIC REPLACEMENTS OF LEU 99 AND PHE 153 WITHIN THE CORE OF T4 LYSOZYME HAVE DIFFERENT STRUCTURAL AND THERMODYNAMIC CONSEQUENCES
1L92	;	1.7	;	SIMILAR HYDROPHOBIC REPLACEMENTS OF LEU 99 AND PHE 153 WITHIN THE CORE OF T4 LYSOZYME HAVE DIFFERENT STRUCTURAL AND THERMODYNAMIC CONSEQUENCES
1L93	;	1.8	;	SIMILAR HYDROPHOBIC REPLACEMENTS OF LEU 99 AND PHE 153 WITHIN THE CORE OF T4 LYSOZYME HAVE DIFFERENT STRUCTURAL AND THERMODYNAMIC CONSEQUENCES
1L94	;	1.8	;	SIMILAR HYDROPHOBIC REPLACEMENTS OF LEU 99 AND PHE 153 WITHIN THE CORE OF T4 LYSOZYME HAVE DIFFERENT STRUCTURAL AND THERMODYNAMIC CONSEQUENCES
1L95	;	2.0	;	SIMILAR HYDROPHOBIC REPLACEMENTS OF LEU 99 AND PHE 153 WITHIN THE CORE OF T4 LYSOZYME HAVE DIFFERENT STRUCTURAL AND THERMODYNAMIC CONSEQUENCES
2CPL	;	1.63	;	SIMILARITIES AND DIFFERENCES BETWEEN HUMAN CYCLOPHILIN A AND OTHER BETA-BARREL STRUCTURES. STRUCTURAL REFINEMENT AT 1.63 ANGSTROMS RESOLUTION
2Y31	;	2.3	;	Simocyclinone C4 bound form of TetR-like repressor SimR
2Y30	;	2.3	;	Simocyclinone D8 bound form of TetR-like repressor SimR
1EQV	;	1.94	;	SIMPLIFICATION OF A PROTEIN LOOP IN STAPHYLOCOCCAL NUCLEASE
1F2M	;	2.0	;	SIMPLIFICATION OF A PROTEIN LOOP IN STAPHYLOCOCCAL NUCLEASE
1F2Y	;	2.0	;	SIMPLIFICATION OF A PROTEIN LOOP IN STAPHYLOCOCCAL NUCLEASE
1F2Z	;	1.8	;	SIMPLIFICATION OF A PROTEIN LOOP IN STAPHYLOCOCCAL NUCLEASE
7CKB	;	3.24	;	Simplified Alpha-Carboxysome, T=3
7CKC	;	2.9	;	Simplified Alpha-Carboxysome, T=4
3AUD	;	1.943	;	Simplified BPTI variant with poly Asn amino acid tag (C5N) at the C-terminus
1XQQ	;		;	Simultaneous determination of protein structure and dynamics
2NMQ	;		;	Simultaneous determination of protein structure and dynamics using rdcs
3FO7	;	1.4	;	Simultaneous inhibition of anti-coagulation and inflammation: Crystal structure of phospholipase A2 complexed with indomethacin at 1.4 A resolution reveals the presence of the new common ligand binding site
3H1X	;	1.4	;	Simultaneous inhibition of anti-coagulation and inflammation: Crystal structure of phospholipase A2 complexed with indomethacin at 1.4 A resolution reveals the presence of the new common ligand binding site
2KDQ	;		;	Simultaneous recognition of HIV-1 TAR RNA bulge and loop sequences by cyclic peptide mimic of Tat protein
3HLC	;	2.0	;	Simvastatin Synthase (LovD) from Aspergillus terreus, S5 mutant, unliganded
3HL9	;	3.4	;	Simvastatin Synthase (LovD) from Aspergillus terreus, unliganded
3HLB	;	2.5	;	Simvastatin Synthase (LovD) from Aspergillus terreus, unliganded, selenomethionyl derivative
4LCL	;	1.8	;	Simvastatin Synthase (LOVD), from Aspergillus Terreus, LovD6 mutant (simh6208)
4LCM	;	3.19	;	Simvastatin Synthase (LOVD), from Aspergillus Terreus, LovD9 mutant (simh9014)
3HLD	;	2.0	;	Simvastatin Synthase (LovD), from Aspergillus terreus, S5 mutant complex with monacolin J acid
3HLG	;	2.01	;	Simvastatin Synthase (LovD), from Aspergillus terreus, S5 mutant, S76A mutant, complex with lovastatin
3HLE	;	2.06	;	Simvastatin Synthase (LovD), from Aspergillus terreus, S5 mutant, S76A mutant, complex with monacolin J acid
3HLF	;	2.0	;	Simvastatin Synthase (LovD), from Aspergillus terreus, S5 mutant, S76A mutant, complex with simvastatin
8AHN	;	1.8	;	Sin Nombre virus Gn in complex with Fab SNV-42
1YQX	;	2.5	;	Sinapyl Alcohol Dehydrogenase at 2.5 Angstrom Resolution
1YQD	;	1.65	;	Sinapyl Alcohol Dehydrogenase complexed with NADP+
3J0F	;	7.0	;	Sindbis virion
1KXC	;	3.1	;	SINDBIS VIRUS CAPSID (N190K MUTANT), TETRAGONAL CRYSTAL FORM
1KXD	;	3.0	;	SINDBIS VIRUS CAPSID (N222L MUTANT), TETRAGONAL CRYSTAL FORM
1KXB	;	2.9	;	SINDBIS VIRUS CAPSID (S215A MUTANT), TETRAGONAL CRYSTAL FORM
1KXE	;	3.2	;	SINDBIS VIRUS CAPSID (Y180S, E183G DOUBLE MUTANT), TETRAGONAL CRYSTAL FORM
1SVP	;	2.0	;	SINDBIS VIRUS CAPSID PROTEIN
1WYK	;	2.0	;	SINDBIS VIRUS CAPSID PROTEIN (114-264)
2SNW	;	2.7	;	SINDBIS VIRUS CAPSID PROTEIN, TYPE3 CRYSTAL FORM
1KXF	;	2.38	;	SINDBIS VIRUS CAPSID, (WILD-TYPE) RESIDUES 1-264, TETRAGONAL CRYSTAL FORM (FORM II)
1KXA	;	3.1	;	SINDBIS VIRUS CAPSID, (WILD-TYPE) RESIDUES 106-264, TETRAGONAL CRYSTAL FORM
5LSN	;		;	SINEB2 element of the long non-coding RNA activator of translation AS Uchl1
5MPR	;	1.6	;	Single Amino Acid Variant of Human Mitochondrial Branched Chain Amino Acid Aminotransferase 2
1AP2	;	2.36	;	SINGLE CHAIN FV OF C219
1MVU	;	1.78	;	SINGLE CHAIN FV OF C219 HEAVY CHAIN V101L MUTANT IN COMPLEX WITH SYNTHETIC EPITOPE PEPTIDE
2AP2	;	2.4	;	SINGLE CHAIN FV OF C219 IN COMPLEX WITH SYNTHETIC EPITOPE PEPTIDE
2IIF	;	2.72	;	single chain Integration Host Factor mutant protein (scIHF2-K45aE) in complex with DNA
2IIE	;	2.41	;	single chain Integration Host Factor protein (scIHF2) in complex with DNA
5HKJ	;	1.35	;	Single Chain Recombinant Globular Head of the Complement System Protein C1q
5HZF	;	1.55	;	Single Chain Recombinant Globular Head of the Complement System Protein C1q in complex with magnesium
7SR0	;	2.54	;	Single chain trimer HLA-A*02:01 (H98L, Y108C) with HPV.16 E7 peptide YMLDLQPET
7SR3	;	2.49	;	Single chain trimer HLA-A*02:01 (H98L, Y108C) with HPV.16 E7 peptide YMLDLQPETTDL
7SR4	;	2.59	;	Single chain trimer HLA-A*02:01 (H98L, Y108C) with HPV.16 E7 peptide YMLDLQPETTDLYC
7SSH	;	2.73	;	Single chain trimer HLA-A*02:01 (Y108A) with HPV.16 E7 peptide YMLDLQPETTDLYC
7SQP	;	2.53	;	Single chain trimer HLA-A*02:01 (Y108C) with HPV.16 E7 peptide YMLDLQPETTDL
7SR5	;	2.35	;	Single chain trimer HLA-A*02:01 (Y108C, A163C) with Wilms tumor protein peptide RMFPNAPYL
7SRK	;	2.5	;	Single chain trimer HLA-A*24:02 (Y108C, A163C) with 8mer peptide YPPVPETF
1AOH	;	1.7	;	SINGLE COHESIN DOMAIN FROM THE SCAFFOLDING PROTEIN CIPA OF THE CLOSTRIDIUM THERMOCELLUM CELLULOSOME
4NX7	;	1.15	;	single cryogenic temperature model of DHFR
251D	;	1.9	;	SINGLE CRYSTAL AND MOLECULAR STRUCTURE OF D(CTCGAG)
6RHR	;	1.06	;	Single crystal serial study of the inhibition of laccases from Steccherinum murashkinskyi by chloride anions at sub-atomic resolution. First structure of the series with 15 KGy dose.
6RI0	;	1.0	;	Single crystal serial study of the inhibition of laccases from Steccherinum murashkinskyi by chloride anions at sub-atomic resolution. Ninth structure of the series with 1215 KGy dose.
6RHU	;	0.96	;	Single crystal serial study of the inhibition of laccases from Steccherinum murashkinskyi by chloride anions at sub-atomic resolution. Second structure of the series with 165 KGy dose.
6RHX	;	0.96	;	Single crystal serial study of the inhibition of laccases from Steccherinum murashkinskyi by chloride anions at sub-atomic resolution. Third structure of the series with 315 KGy dose.
6RI2	;	1.09	;	Single crystal serial study of the inhibition of laccases from Steccherinum murashkinskyi by chloride anions at sub-atomic resolution. Twentieth structure of the series with 4065 KGy dose.
6RI4	;	1.08	;	Single crystal serial study of the inhibition of laccases from Steccherinum murashkinskyi by fluoride anions at sub-atomic resolution. First structure of the series with 13 KGy dose.
6RIL	;	1.34	;	Single crystal serial study of the inhibition of laccases from Steccherinum murashkinskyi by fluoride anions at sub-atomic resolution. Fourteenth structure of the series with 5600 KGy dose (data was collected after refreezing).
6RII	;	0.97	;	Single crystal serial study of the inhibition of laccases from Steccherinum murashkinskyi by fluoride anions at sub-atomic resolution. Fourth structure of the series with 1200 KGy dose.
6RI6	;	0.93	;	Single crystal serial study of the inhibition of laccases from Steccherinum murashkinskyi by fluoride anions at sub-atomic resolution. Second structure of the series with 400 KGy dose.
6RI8	;	0.95	;	Single crystal serial study of the inhibition of laccases from Steccherinum murashkinskyi by fluoride anions at sub-atomic resolution. Third structure of the series with 800 KGy dose.
6RIK	;	1.2	;	Single crystal serial study of the inhibition of laccases from Steccherinum murashkinskyi by fluoride anions at sub-atomic resolution. Thirteenth structure of the series with 5200 KGy dose.
6RGH	;	1.08	;	Single crystal serial study of the X-ray induced enzymatic reduction of molecular oxygen to water for laccase from Steccherinum murashkinskyi at sub-atomic resolution. First structure of the series with 15 KGy dose.
6RHI	;	1.01	;	Single crystal serial study of the X-ray induced enzymatic reduction of molecular oxygen to water for laccase from Steccherinum murashkinskyi at sub-atomic resolution. Ninth structure of the series with 1215 KGy dose.
6RGP	;	0.97	;	Single crystal serial study of the X-ray induced enzymatic reduction of molecular oxygen to water for laccase from Steccherinum murashkinskyi at sub-atomic resolution. Second structure of the series with 165 KGy dose.
6RHH	;	0.97	;	Single crystal serial study of the X-ray induced enzymatic reduction of molecular oxygen to water for laccase from Steccherinum murashkinskyi at sub-atomic resolution. Third structure of the series with 315 KGy dose.
6RHO	;	1.07	;	Single crystal serial study of the X-ray induced enzymatic reduction of molecular oxygen to water for laccase from Steccherinum murashkinskyi at sub-atomic resolution. Twentieth structure of the series with 4065 KGy dose.
6RHP	;	1.6	;	Single crystal serial study of the X-ray induced enzymatic reduction of molecular oxygen to water for laccase from Steccherinum murashkinskyi at sub-atomic resolution. Twenty first structure of the series with 4415 KGy dose (collected after refreezing).
1EDG	;	1.6	;	SINGLE CRYSTAL STRUCTURE DETERMINATION OF THE CATALYTIC DOMAIN OF CELCCA CARRIED OUT AT 15 DEGREE C
1H2A	;	1.8	;	SINGLE CRYSTALS OF HYDROGENASE FROM DESULFOVIBRIO VULGARIS
2M4W	;		;	single G-bulge in a conserved regulatory region of the HEV genome
3G93	;	3.2	;	Single ligand occupancy crystal structure of cytochrome P450 2B4 in complex with the inhibitor 1-biphenyl-4-methyl-1H-imidazole
7B71	;		;	Single modified phosphoryl guanidine DNA duplex, Sp diastereomer
2UYF	;	2.2	;	Single mutant F111L DntR from Burkholderia sp. strain DNT in complex with thiocyanate
2XKY	;	17.2	;	Single particle analysis of Kir2.1NC_4 in negative stain
2XKX	;	22.9	;	Single particle analysis of PSD-95 in negative stain
6FBV	;	3.52	;	Single particle cryo em structure of Mycobacterium tuberculosis RNA polymerase in complex with Fidaxomicin
8P1I	;	2.97	;	Single particle cryo-EM co-structure of Klebsiella pneumoniae AcrB with the BDM91288 efflux pump inhibitor at 2.97 Angstrom resolution
6GSR	;	5.5	;	Single Particle Cryo-EM map of human Transferrin receptor 1 - H-Ferritin complex at 5.5 Angstrom resolution.
6H5I	;	3.9	;	Single Particle Cryo-EM map of human Transferrin receptor 1 - H-Ferritin complex.
8A9B	;	4.0	;	Single Particle cryo-EM of the empty lipid binding protein P116 (MPN213) from Mycoplasma pneumoniae at 4 Angstrom resolution
8A9A	;	3.3	;	Single Particle cryo-EM of the lipid binding protein P116 (MPN213) from Mycoplasma pneumoniae at 3.3 Angstrom resolution.
8PBX	;	3.3	;	Single particle cryo-EM of the P140-P110 heterodimer of Mycoplasma genitalium at 3.3 Angstrom resolution.
8PBY	;	3.7	;	Single particle cryo-EM of the P140-P110 heterodimer with an alternative conformation in the P140 stalk of Mycoplasma genitalium at a resolution of 3.7 Angstrom.
6B9Q	;	3.17	;	Single particle cryo-EM structure determination of the LuIII capsid protein
8P5W	;	2.26	;	Single particle cryo-EM structure of homohexameric 2-oxoglutarate dehydrogenase OdhA from Corynebacterium glutamicum following reaction with the 2-oxoglutarate analogue succinyl phosphonate
8P5V	;	2.07	;	Single particle cryo-EM structure of homohexameric 2-oxoglutarate dehydrogenase OdhA from Corynebacterium glutamicum in complex with the product succinyl-CoA
8P5U	;	2.17	;	Single particle cryo-EM structure of homohexameric 2-oxoglutarate dehydrogenase OdhA from Corynebacterium glutamicum with Coenzyme A bound to the E2o domain
6UWM	;	5.9	;	Single particle cryo-EM structure of KvAP
7Q57	;	13.0	;	Single Particle Cryo-EM structure of photosynthetic A10B10 glyceraldehyde-3-phospahte dehydrogenase from Spinacia oleracea.
7Q53	;	6.3	;	Single Particle Cryo-EM structure of photosynthetic A2B2 glyceraldehyde 3-phosphate dehydrogenase from Spinacia oleracia
7Q54	;	8.9	;	Single Particle Cryo-EM structure of photosynthetic A4B4-glyceraldehyde 3-phosphate dehydrogenase from Spinacia oleracia.
7Q56	;	7.1	;	Single Particle Cryo-EM structure of photosynthetic A8B8 glyceraldehyde-3-phosphate dehydrogenase (minor conformer) from Spinacia oleracea.
7Q55	;	5.7	;	Single Particle Cryo-EM structure of photosynthetic A8B8 glyceraldehyde-3-phosphate dehydrogenase hexadecamer (major conformer) from Spinacia oleracia.
3J9S	;	2.6	;	Single particle cryo-EM structure of rotavirus VP6 at 2.6 Angstrom resolution
7MVY	;	2.39	;	Single particle cryo-EM structure of the Chaetomium thermophilum Nup188-Nic96 complex (Nup188 residues 1-1858; Nic96 residues 240-301)
7MVZ	;	2.81	;	Single particle cryo-EM structure of the Chaetomium thermophilum Nup188-Nic96-Nup145N complex (Nup188 residues 1-1858; Nic96 residues 240-301; Nup145N residues 640-732)
7MVU	;	3.77	;	Single particle cryo-EM structure of the Chaetomium thermophilum Nup192-Nic96 complex (Nup192 residues 1-1756; Nic96 residues 240-301)
7MVV	;	3.22	;	Single particle cryo-EM structure of the Chaetomium thermophilum Nup192-Nic96-Nup53-Nup145N complex (Nup192 residues 1-1756; Nic96 residues 240-301; Nup53 31-67; Nup145N 616-683)
8P5X	;	2.29	;	Single particle cryo-EM structure of the complex between Corynebacterium glutamicum homohexameric 2-oxoglutarate dehydrogenase OdhA and the FHA-protein inhibitor OdhI
8P5T	;	2.17	;	Single particle cryo-EM structure of the homohexameric 2-oxoglutarate dehydrogenase OdhA from Corynebacterium glutamicum
6PBY	;	3.67	;	Single particle cryo-EM structure of the voltage-gated K+ channel Eag1 3-13 deletion mutant bound to calmodulin (conformation 1)
6PBX	;	4.0	;	Single particle cryo-EM structure of the voltage-gated K+ channel Eag1 3-13 deletion mutant bound to calmodulin (conformation 2)
5K7L	;	3.78	;	Single particle cryo-EM structure of the voltage-gated K+ channel Eag1 bound to the channel inhibitor calmodulin
6MWQ	;	3.0	;	Single particle cryoEM structure of a DARPin-aldolase platform in complex with GFP
6W6M	;	2.7	;	Single particle cryoEM structure of V. cholerae Type IV competence pilus secretin PilQ
4AV2	;	26.0	;	Single particle electron microscopy of PilQ dodecameric complexes from Neisseria meningitidis.
6NHV	;	3.5	;	Single particle reconstruction of DARPin and its bound GFP on a symmetric scaffold
6VRS	;	2.7	;	Single particle reconstruction of glucose isomerase from Streptomyces rubiginosus based on data acquired in the presence of substantial aberrations
6VSA	;	2.32	;	Single particle reconstruction of HemQ from Geobacillus based on data acquired in the presence of substantial aberrations
6VSC	;	2.6	;	Single particle reconstruction of HemQ from Geobacillus based on data acquired in the presence of substantial aberrations
6PCV	;	3.2	;	Single Particle Reconstruction of Phosphatidylinositol (3,4,5) trisphosphate-dependent Rac exchanger 1 bound to G protein beta gamma subunits
5LK8	;	3.42	;	single particle reconstruction of slow bee paralysis virus empty particle
5LK7	;	3.42	;	Single particle reconstruction of slow bee paralysis virus virion at pH 5.5
6NHT	;	2.9	;	Single particle reconstruction of the symmetric core an engineered protein scaffold
8AFX	;	4.8	;	Single particle structure of Atg18-WT
6CSX	;	3.0	;	Single particles Cryo-EM structure of AcrB D407A associated with lipid bilayer at 3.0 Angstrom
4A73	;	3.001	;	SINGLE POINT MUTANT OF THERMUS THERMOPHILUS LACTATE DEHYDROGENASE
4NX6	;	1.35	;	single room temperature model of DHFR
8BZ0	;	1.2	;	single soak stabilizer for ERa - 14-3-3 interaction (AZ275)
8BZ9	;	1.3	;	single soak stabilizer for ERa - 14-3-3 interaction (AZ354)
8BZA	;	1.25	;	single soak stabilizer for ERa - 14-3-3 interaction (AZ555)
1EQQ	;	3.2	;	SINGLE STRANDED DNA BINDING PROTEIN AND SSDNA COMPLEX
2VW9	;	2.3	;	Single stranded DNA binding protein complex from Helicobacter pylori
7R4W	;	2.3	;	Single stranded DNA binding protein SSB M5 from Fervidobacterium gondwanense
1JMC	;	2.4	;	SINGLE STRANDED DNA-BINDING DOMAIN OF HUMAN REPLICATION PROTEIN A BOUND TO SINGLE STRANDED DNA, RPA70 SUBUNIT, RESIDUES 183-420
1URJ	;	3.0	;	Single stranded DNA-binding protein(ICP8) from Herpes simplex virus-1
4WBB	;	2.8	;	Single Turnover Autophosphorylation Cycle of the PKA RIIb Holoenzyme
6K4Z	;	1.65	;	Single-chain Fv antibody of C6 COMPLEXED WITH 2-(4-HYDROXY-3-NITROPHENYL)ACETIC ACID
4ZCH	;	2.43	;	Single-chain human APRIL-BAFF-BAFF Heterotrimer
7U23	;	4.6	;	Single-chain LCDV-1 viral insulin-like peptide bound to IGF-1R ectodomain, leucine-zippered form
3GVW	;	2.8	;	Single-chain UROD F217Y (YF) mutation
3GVR	;	2.2	;	Single-chain UROD Y164G (GY) mutation
3GVV	;	2.8	;	Single-chain UROD Y164G (GY) mutation
7YD3	;	2.16	;	Single-chain variable fragment of app 3D1 antibody
6EGC	;	1.74	;	Single-chain version of 2L4HC2_23 (PDB 5J0K)
7TGI	;	2.104	;	Single-domain VHH intrabodies neutralize ricin toxin
7TH2	;	1.838	;	Single-domain VHH intrabodies neutralize ricin toxin
7TH3	;	2.292	;	Single-domain VHH intrabodies neutralize ricin toxin
7TGF	;	1.347	;	Single-domain VHH intrabodies neutralize ricin toxin.
5A7U	;	4.8	;	Single-particle cryo-EM of co-translational folded adr1 domain inside the E. coli ribosome exit tunnel.
6W98	;	2.9	;	Single-Particle Cryo-EM Structure of Arabinofuranosyltransferase AftD from Mycobacteria
6WBX	;	3.5	;	Single-Particle Cryo-EM Structure of Arabinofuranosyltransferase AftD from Mycobacteria, Mutant R1389S Class 1
6WBY	;	3.4	;	Single-Particle Cryo-EM Structure of Arabinofuranosyltransferase AftD from Mycobacteria, Mutant R1389S Class 2
6X0O	;	3.3	;	Single-Particle Cryo-EM Structure of Arabinosyltransferase EmbB from Mycobacterium smegmatis
7TPT	;	3.9	;	Single-particle Cryo-EM structure of Arp2/3 complex at branched-actin junction.
7MJS	;	3.03	;	Single-Particle Cryo-EM Structure of Major Facilitator Superfamily Domain containing 2A in complex with LPC-18:3
8J5A	;	1.19	;	Single-particle cryo-EM structure of mouse apoferritin at 1.19 Angstrom resolution (Dataset A)
6UKJ	;	3.3	;	Single-Particle Cryo-EM Structure of Plasmodium falciparum Chloroquine Resistance Transporter (PfCRT) 7G8 Isoform
7TPJ	;	3.46	;	Single-Particle Cryo-EM Structure of the WaaL O-antigen ligase in its apo state
7TPG	;	3.23	;	Single-Particle Cryo-EM Structure of the WaaL O-antigen ligase in its ligand bound state
5M3L	;	3.8	;	Single-particle cryo-EM using alignment by classification (ABC): the structure of Lumbricus terrestris hemoglobin
6C9K	;	3.49	;	Single-Particle reconstruction of DARP14 - A designed protein scaffold displaying ~17kDa DARPin proteins
6C9I	;	3.09	;	Single-Particle reconstruction of DARP14 - A designed protein scaffold displaying ~17kDa DARPin proteins - Scaffold
5MJJ	;	1.75009	;	Single-shot pink beam serial crystallography: Lysozyme
5MJM	;	2.302	;	Single-shot pink beam serial crystallography: Phycocyanin (Five chips merged)
5MJQ	;	2.7	;	Single-shot pink beam serial crystallography: Phycocyanin (One chip)
5O7M	;	2.46	;	Single-shot pink beam serial crystallography: Phycocyanin (One chip, chip_1)
5MJL	;	2.21014	;	Single-shot pink beam serial crystallography: Proteinase K
5MJG	;	2.1	;	Single-shot pink beam serial crystallography: Thaumatin
6BY4	;		;	Single-State 14-mer UUCG Tetraloop calculated from Exact NOEs
7WCG	;		;	Single-Stranded DNA binding protein of Sulfolobus Solfataricus structure at high-temperature
5ODJ	;	1.5	;	Single-stranded DNA-binding protein from bacteriophage Enc34
5ODL	;	1.56	;	Single-stranded DNA-binding protein from bacteriophage Enc34 in complex with ssDNA
5ODK	;	1.34	;	Single-stranded DNA-binding protein from bacteriophage Enc34, C-terminal truncation
2FXQ	;	1.85	;	Single-stranded DNA-binding protein from Thermus aquaticus
8BTZ	;	5.39	;	Single-stranded Paranemic Crossover RNA Triangle (PXT)
6VHA	;	4.3	;	Singlet Tau Fibril from Corticobasal Degeneration Human Brain Tissue
6BGO	;	4.2	;	Singly PafE-capped 20S CP in Mycobacterium tuberculosis
5CVU	;	1.8	;	sinpyl alcohol bound monolignol 4-O-methyltransferase 5
1B0N	;	1.9	;	SINR PROTEIN/SINI PROTEIN COMPLEX
2YAL	;	2.27	;	SinR, Master Regulator of biofilm formation in Bacillus subtilis
8QXI	;		;	SipA solution structure
2YM9	;	3.0	;	SipD from Salmonella typhimurium
3RIQ	;	1.5	;	Siphovirus 9NA tailspike receptor binding domain
3JR3	;	1.5	;	Sir2 bound to acetylated peptide
4BUZ	;	1.9	;	SIR2 COMPLEX STRUCTURE MIXTURE OF EX-527 INHIBITOR AND REACTION PRODUCTS OR OF REACTION SUBSTRATES P53 PEPTIDE AND NAD
2H59	;	1.9	;	Sir2 H116A-deacetylated p53 peptide-3'-o-acetyl ADP ribose
2H4H	;	1.99	;	Sir2 H116Y mutant-p53 peptide-NAD
1M2K	;	1.47	;	Sir2 homologue F159A mutant-ADP ribose complex
1M2J	;	1.7	;	Sir2 homologue H80N mutant-ADP ribose complex
1M2H	;	1.8	;	Sir2 homologue S24A mutant-ADP ribose complex
1M2G	;	1.7	;	Sir2 homologue-ADP ribose complex
1M2N	;	2.6	;	Sir2 homologues (D102G/F159A/R170A) mutant-2'-O-acetyl ADP ribose complex
2H4J	;	2.1	;	Sir2-deacetylated peptide (from enzymatic turnover in crystal)
2H4F	;	2.0	;	Sir2-p53 peptide-NAD+
1YC5	;	1.4	;	Sir2-p53 peptide-nicotinamide
3D81	;	2.5	;	Sir2-S-alkylamidate complex crystal structure
1YC2	;	2.4	;	Sir2Af2-NAD-ADPribose-nicotinamide
2CGI	;	1.35	;	Siras structure of tetragonal lysozyme using derivative data collected at the high energy remote Holmium Kedge
5ZT8	;	2.0	;	SirB from Bacillus subtilis
5ZT7	;	2.94	;	SirB from Bacillus subtilis with Co2+
5ZTA	;	3.07	;	SirB from Bacillus subtilis with Fe3+
5ZT9	;	2.8	;	SirB from Bacillus subtilis with Ni2+
3DFZ	;	2.3	;	SirC, precorrin-2 dehydrogenase
4CZD	;	2.23	;	Sirohaem decarboxylase AhbA/B - an enzyme with structural homology to the Lrp/AsnC transcription factor family that is part of the alternative haem biosynthesis pathway.
4UN1	;	1.97	;	Sirohaem decarboxylase AhbA/B - an enzyme with structural homology to the Lrp/AsnC transcription factor family that is part of the alternative haem biosynthesis pathway.
6M28	;	3.0	;	Sirohydrochlorin nickelochelatase CfbA in complex with Co2+
6M29	;	2.9	;	Sirohydrochlorin nickelochelatase CfbA in complex with Co2+ and formate
6M2G	;	2.8	;	Sirohydrochlorin nickelochelatase CfbA in complex with cobalt-sirohydrochlorin
6M27	;	2.6	;	Sirohydrochlorin nickelochelatase CfbA in complex with Ni2+
6M2F	;	2.4	;	Sirohydrochlorin nickelochelatase CfbA in complex with nickel-sirohydrochlorin
6M2E	;	2.6	;	Sirohydrochlorin nickelochelatase CfbA in complex with sirohydrochlorin
6M26	;	2.61	;	Sirohydrochlorin nickelochelatase CfbA in P212121 space group
6M25	;	2.5	;	Sirohydrochlorin nickelochelatase CfbA in P41 space group
6P5X	;	1.97	;	Sirohydrochlorin-bound S. typhimurium siroheme synthase
6BIT	;	2.191	;	SIRPalpha antibody complex
4ZZH	;	3.1001	;	SIRT1/Activator Complex
4ZZI	;	2.7346	;	SIRT1/Activator/Inhibitor Complex
4ZZJ	;	2.7403	;	SIRT1/Activator/Substrate Complex
5FYQ	;	3.0	;	Sirt2 in complex with a 13-mer trifluoroacetylated Ran peptide
4X3O	;	1.5	;	Sirt2 in complex with a myristoyl peptide
4X3P	;	1.8	;	Sirt2 in complex with a myristoyl peptide
6NR0	;	2.45	;	SIRT2(56-356) with covalent intermediate between mechanism-based inhibitor Glucose-TM-1beta and 1'-SH ADP-ribose
3RIG	;	2.0	;	Sirt5 is an NAD-dependent protein lysine demalonylase and desuccinylase
3RIY	;	1.55	;	Sirt5 is an NAD-dependent protein lysine demalonylase and desuccinylase
5X16	;	1.97	;	Sirt6 apo structure
8F86	;	3.1	;	SIRT6 bound to an H3K9Ac nucleosome
6L72	;	2.501	;	Sirtuin 2 demyristoylation native final product
6L71	;	2.109	;	Sirtuin 2 demyristoylation native intermediate I & II mixture
6L65	;	1.8	;	Sirtuin 2 protein with H3K18 myristoylated peptide
6L66	;	2.169	;	Sirtuin 2 protein with H3K18 myristoylated peptide and intact NAD molecule
5OJN	;	1.8	;	Sirtuin 4 from Xenopus tropicalis in complex with thioacetyl-ADP-ribose
5OJ7	;	1.58	;	Sirtuin 4 orthologue from Xenopus Tropicalis in complex with ADP-ribose
5OJO	;	3.1	;	Sirtuin 5 from Danio rerio in complex with 3-hydroxy-3-methylglutaryl-CPS1 peptide
7Y4G	;	1.97	;	sit-bound btDPP4
7Y75	;	3.1	;	SIT1-ACE2-BA.2 RBD
7Y76	;	3.2	;	SIT1-ACE2-BA.5 RBD
8DI2	;		;	Site 2 insulin receptor binding peptide IM459N21
2IU7	;	1.91	;	Site directed mutagenesis of key residues involved in the catalytic mechanism of Cyanase
2IUO	;	1.9	;	Site Directed Mutagenesis of Key Residues Involved in the Catalytic Mechanism of Cyanase
2IV1	;	1.88	;	SITE DIRECTED MUTAGENESIS OF KEY RESIDUES INVOLVED IN THE CATALYTIC MECHANISM OF CYANASE
2IVB	;	1.95	;	SITE DIRECTED MUTAGENESIS OF KEY RESIDUES INVOLVED IN THE CATALYTIC MECHANISM OF CYANASE
2IVG	;	1.87	;	SITE DIRECTED MUTAGENESIS OF KEY RESIDUES INVOLVED IN THE CATALYTIC MECHANISM OF CYANASE
2IVQ	;	2.1	;	SITE DIRECTED MUTAGENESIS OF KEY RESIDUES INVOLVED IN THE CATALYTIC MECHANISM OF CYANASE
1CGV	;	2.5	;	SITE DIRECTED MUTATIONS OF THE ACTIVE SITE RESIDUE TYROSINE 195 OF CYCLODEXTRIN GLYCOSYLTRANSFERASE FROM BACILLUS CIRCULANS STRAIN 251 AFFECTING ACTIVITY AND PRODUCT SPECIFICITY
1CGW	;	2.5	;	SITE DIRECTED MUTATIONS OF THE ACTIVE SITE RESIDUE TYROSINE 195 OF CYCLODEXTRIN GLYCOSYLTRANSFERASE FROM BACILLUS CIRCULANS STRAIN 251 AFFECTING ACTIVITY AND PRODUCT SPECIFICITY
1CGX	;	2.5	;	SITE DIRECTED MUTATIONS OF THE ACTIVE SITE RESIDUE TYROSINE 195 OF CYCLODEXTRIN GLYXOSYLTRANSFERASE FROM BACILLUS CIRCULANS STRAIN 251 AFFECTING ACTIVITY AND PRODUCT SPECIFICITY
1CGY	;	2.5	;	SITE DIRECTED MUTATIONS OF THE ACTIVE SITE RESIDUE TYROSINE 195 OF CYCLODEXTRIN GLYXOSYLTRANSFERASE FROM BACILLUS CIRCULANS STRAIN 251 AFFECTING ACTIVITY AND PRODUCT SPECIFICITY
1PON	;		;	SITE III-SITE IV TROPONIN C HETERODIMER, NMR
1MOO	;	1.05	;	Site Specific Mutant (H64A) of Human Carbonic Anhydrase II at high resolution
3B4R	;	3.3	;	Site-2 Protease from Methanocaldococcus jannaschii
1FD2	;	1.9	;	SITE-DIRECTED MUTAGENESIS OF AZOTOBACTER VINELANDII FERREDOXIN I. (FE-S) CLUSTER-DRIVEN PROTEIN REARRANGEMENT
1UI7	;	2.0	;	Site-directed mutagenesis of His433 involved in binding of copper ion in Arthrobacter globiformis amine oxidase
1UI8	;	1.8	;	Site-directed mutagenesis of His592 involved in binding of copper ion in Arthrobacter globiformis amine oxidase
2VKA	;	2.0	;	Site-Directed Mutagenesis of the Catalytic Tryptophan Environment in Pleurotus eryngii Versatile Peroxidase
1CPY	;	2.6	;	SITE-DIRECTED MUTAGENESIS ON (SERINE) CARBOXYPEPTIDASE Y FROM YEAST. THE SIGNIFICANCE OF THR 60 AND MET 398 IN HYDROLYSIS AND AMINOLYSIS REACTIONS
3CIU	;	3.5	;	Site-Selective Glycosylation of Cysteine-93 beta on the Surface of Bovine Hemoglobin and its Application as a Novel Oxygen Therapeutic
3PI8	;	2.2	;	Site-specific Glycosylation of Hemoglobin Utilizing Oxime Ligation Chemistry as a Viable Alternative to PEGylation
3PI9	;	2.9	;	Site-specific Glycosylation of Hemoglobin Utilizing Oxime Ligation Chemistry as a Viable Alternative to PEGylation
3PIA	;	2.1	;	Site-specific Glycosylation of Hemoglobin Utilizing Oxime Ligation Chemistry as a Viable Alternative to PEGylation
6U85	;	2.78	;	Site-specific lysine arylation as an alternative bioconjugation strategy for chemically programmed antibodies and antibody-drug conjugates
1G0F	;	1.6	;	SITE-SPECIFIC MUTANT (HIS64 REPLACED WITH ALA) OF HUMAN CARBONIC ANHYDRASE II
1G0E	;	1.6	;	SITE-SPECIFIC MUTANT (HIS64 REPLACED WITH ALA) OF HUMAN CARBONIC ANHYDRASE II COMPLEXED WITH 4-METHYLIMIDAZOLE
1LZV	;	2.3	;	Site-Specific Mutant (Tyr7 replaced with His) of Human Carbonic Anhydrase II
1A0P	;	2.5	;	SITE-SPECIFIC RECOMBINASE, XERD
1PB3	;	1.7	;	Sites of binding and orientation in a four location model for protein stereospecificity.
8DUA	;	4.32	;	SIV E660.CR54 SOS-2P Env Trimer with ITS92.02
2SIV	;	2.2	;	SIV GP41 CORE STRUCTURE
1C6V	;	3.0	;	SIV INTEGRASE (CATALYTIC DOMAIN + DNA BIDING DOMAIN COMPRISING RESIDUES 50-293) MUTANT WITH PHE 185 REPLACED BY HIS (F185H)
1TCW	;	2.4	;	SIV PROTEASE COMPLEXED WITH INHIBITOR SB203386
1YTG	;	2.3	;	SIV PROTEASE CRYSTALLIZED WITH PEPTIDE PRODUCT
1YTH	;	2.2	;	SIV PROTEASE CRYSTALLIZED WITH PEPTIDE PRODUCT
1YTI	;	2.2	;	SIV PROTEASE CRYSTALLIZED WITH PEPTIDE PRODUCT
1YTJ	;	2.5	;	SIV PROTEASE CRYSTALLIZED WITH PEPTIDE PRODUCT
4HTW	;	2.9	;	SIVmac239 capsid N-terminal domain
3IOZ	;	3.699	;	SIVmac239 Nef in complex with a TCR zeta polypeptide DP1 (L51-D93)
3IK5	;	2.05	;	SIVmac239 Nef in complex with TCR zeta ITAM 1 polypeptide (A63-R80)
6RWL	;	3.36	;	SIVrcm intasome
6RWO	;	3.05	;	SIVrcm intasome (Q148H/G140S) in complex with bictegravir
6RWM	;	2.81	;	SIVrcm intasome in complex with bictegravir
6RWN	;	3.1	;	SIVrcm intasome in complex with dolutegravir
3F3M	;	2.4	;	Six Crystal Structures of Two Phosphopantetheine Adenylyltransferases Reveal an Alternative Ligand Binding Mode and an Associated Structural Change
7YWI	;	8.0	;	Six DNA duplex bundle nanopore - State 2
7YWH	;	8.0	;	Six DNA Helix Bundle nanopore - State 1
7YWL	;	8.0	;	Six DNA Helix Bundle nanopore - State 3
7YWN	;	8.0	;	Six DNA Helix Bundle nanopore - State 4
7YWO	;	8.0	;	Six DNA Helix Bundle nanopore - State 5
2LLF	;		;	Sixth Gelsolin-like domain of villin in 5 mM CaCl2
6I36	;	1.59	;	SIXTY MINUTES IRON LOADED FROG M FERRITIN
4MJY	;	1.4	;	Sixty minutes iron loaded frog M ferritin mutant H54Q
5JAC	;	1.18	;	Sixty minutes iron loaded Rana Catesbeiana H' ferritin variant E57A/E136A/D140A
6IAJ	;	1.62	;	Sixty minutes iron loaded Rana Catesbeiana H' ferritin variant H54N
7URX	;	3.4	;	SJ25C1 Fab in complex with soluble CD19
6HCZ	;	2.3	;	Sjoegren syndrome/scleroderma autoantigen 1 (SSSCA1)
6EFI	;	1.715	;	SK678 binding region (Siglec + Unique)
7TTS	;	2.9	;	Skd3, hexamer, filtered
7TTR	;	2.96	;	Skd3_ATPyS_FITC-casein Hexamer, AAA+ only
4V10	;		;	Skelemin Association with alpha2b,beta3 Integrin: A Structural Model
2JTD	;		;	Skelemin Immunoglobulin C2 like domain 4
6YSY	;	3.246	;	Skeletal Myosin bound to MPH-220, MgADP-VO4
5C4V	;	2.6	;	Ski-like protein
4NLH	;	1.9	;	SKICH domain of human TAX1BP1
3VVV	;	1.35	;	Skich domain of NDP52
8WUI	;	3.4	;	SKOR D312N L271P double mutation
5IBK	;	2.503	;	Skp1-F-box in complex with a ubiquitin variant
2JD5	;	2.5	;	Sky1p bound to Npl3p-derived substrate peptide
1BN0	;		;	SL3 HAIRPIN FROM THE PACKAGING SIGNAL OF HIV-1, NMR, 11 STRUCTURES
2KKW	;		;	SLAS-micelle bound alpha-synuclein
8JZX	;	2.5	;	SLC15A4 inhibitor complex
8JZU	;	3.05	;	SLC15A4_TASL complex
6URS	;		;	Sleeping Beauty transposase PAI subdomain mutant - H19Y
8DKD	;	3.2	;	Sliding clamp from M. thermoresistibile
1B8H	;	3.0	;	SLIDING CLAMP, DNA POLYMERASE
1LT1	;	1.91	;	SLIDING HELIX INDUCED CHANGE OF COORDINATION GEOMETRY IN A MODEL DI-MN(II) PROTEIN
8DK9	;	2.5	;	Sliding-clamp-DinX peptide
8DJQ	;	2.8	;	Sliding-clamp-DnaE1 peptide
8DJ6	;	2.5	;	Sliding-clamp-ImuB peptide
5X4A	;	3.4	;	SLL-2-Forssman antigen tetrasaccharides complex
8C7A	;		;	Slow cation movements within tetramolecular G-quadruplex: vacant cation binding sites in addition to all syn G-quartet
8C7B	;		;	Slow cation movements within tetramolecular G-quadruplex: vacant cation binding sites in addition to all syn G-quartet
1SHH	;	1.55	;	Slow form of Thrombin Bound with PPACK
4TMN	;	1.7	;	SLOW-AND FAST-BINDING INHIBITORS OF THERMOLYSIN DISPLAY DIFFERENT MODES OF BINDING. CRYSTALLOGRAPHIC ANALYSIS OF EXTENDED PHOSPHONAMIDATE TRANSITION-STATE ANALOGUES
5TMN	;	1.6	;	Slow-and fast-binding inhibitors of thermolysin display different modes of binding. crystallographic analysis of extended phosphonamidate transition-state analogues
6XF7	;	6.6	;	SLP
7ACV	;	2.4	;	SLPL/HID (LMW SLP complex with HMW SLP interacting domain - HID) from C. difficile (R7404 strain)
1G8T	;	1.1	;	SM ENDONUCLEASE FROM SERATIA MARCENSCENS AT 1.1 A RESOLUTION
1QL0	;	1.1	;	Sm Endonuclease from Seratia marcenscens at atomic resolution
6XM1	;	2.8	;	SM Protein Vps45 in Complex with Qa SNARE Tlg2
6XMD	;	3.9	;	SM Protein Vps45 in Complex with Qa SNARE Tlg2 (1-310)
5H3U	;	2.499	;	Sm RNA bound to GEMIN5-WD
2OPY	;	2.8	;	Smac mimic bound to BIR3-XIAP
1KHU	;	2.5	;	Smad1 crystal structure reveals the details of BMP signaling pathway
1MK2	;	2.74	;	SMAD3 SBD complex
7RAZ	;	3.4	;	Small conductance mechanosensitive channel MscS
7A46	;	3.0	;	small conductance mechanosensitive channel YbiO
6NUE	;	3.3	;	Small conformation of apo CRISPR_Csm complex
6NUD	;	3.5	;	Small conformation of ssRNA-bound CRISPR_Csm complex
8GRT	;	2.59	;	Small Dipeptide Analogues developed by Co-crystal Structure of Stenotrophomonas maltophilia Dipeptidyl Peptidase 7
1E0S	;	2.28	;	small G protein Arf6-GDP
1MH1	;	1.38	;	SMALL G-PROTEIN
4ZJ9	;	2.0	;	Small heat shock protein AgsA from Salmonella typhimurium: Alpha crystallin domain
4ZJA	;	4.101	;	Small heat shock protein AgsA from Salmonella typhimurium: C-terminal truncated construct
4ZJD	;	7.5	;	Small heat shock protein AgsA from Salmonella typhimurium: Truncations at N- and C- termini
5ZS3	;	2.001	;	Small heat shock protein from M. marinum:Form-1
1SHS	;	2.9	;	SMALL HEAT SHOCK PROTEIN FROM METHANOCOCCUS JANNASCHII
5ZUL	;	3.75	;	Small heat shock protein from Mycobacterium marinum M : Form-3
3VQL	;	1.9	;	Small heat shock protein hsp14.0 of C-terminal deletion variant
3VQM	;	2.55	;	Small heat shock protein hsp14.0 of C-terminal deletion variant with C-terminal peptide
3VQK	;	4.5	;	Small heat shock protein hsp14.0 of wild type
3AAB	;	1.851	;	Small heat shock protein hsp14.0 with the mutations of I120F and I122F in the form I crystal
3AAC	;	2.4	;	Small heat shock protein hsp14.0 with the mutations of I120F and I122F in the form II crystal
7TUK	;	6.3	;	Small hepatitis B virus surface protein without cytosolic and antigenic loops
3T9W	;	1.5	;	Small laccase from Amycolatopsis sp. ATCC 39116
3TA4	;	2.35	;	Small laccase from Amycolatopsis sp. ATCC 39116 complexed with 1-(3,4-dimethoxyphenyl)-2-(2-methoxyphenoxy)-1,3-dihydroxypropane
3TAS	;	2.3	;	Small laccase from Streptomyces viridosporus T7A
3TBC	;	2.7	;	Small laccase from Streptomyces viridosporus T7A; alternate crystal form complexed with acetovanillone.
3TBB	;	2.3	;	Small laccase from Streptomyces viridosporus T7A; alternate crystal form.
4NEJ	;	1.919	;	Small molecular fragment bound to crystal contact interface of Interleukin-2
4NEM	;	1.934	;	Small molecular fragment bound to crystal contact interface of Interleukin-2
8ATR	;	1.7	;	Small molecular stabilizer for C-RAF (pS259) and 14-3-3 (1075297)
8ATS	;	1.4	;	Small molecular stabilizer for C-RAF (pS259) and 14-3-3 (1075306)
8AV7	;	1.4	;	Small molecular stabilizer for ERalpha and 14-3-3 (1074202 - non covalent)
8AV3	;	1.8	;	Small molecular stabilizer for ERalpha and 14-3-3 (1075299)
8AV8	;	1.8	;	Small molecular stabilizer for ERalpha and 14-3-3 (1075300)
8AV4	;	1.6	;	Small molecular stabilizer for ERalpha and 14-3-3 (1075305)
8ALW	;	1.5	;	Small molecular stabilizer for ERalpha and 14-3-3 (1075310)
8ALT	;	1.4	;	Small molecular stabilizer for ERalpha and 14-3-3 (1075311)
8ARR	;	1.35	;	Small molecular stabilizer for ERalpha and 14-3-3 (1076394)
8AM7	;	1.5	;	Small molecular stabilizer for ERalpha and 14-3-3 (1076397)
8AS1	;	1.5	;	Small molecular stabilizer for ERalpha and 14-3-3 (1076398)
8ARW	;	1.5	;	Small molecular stabilizer for ERalpha and 14-3-3 (1076402)
8ALV	;	1.6	;	Small molecular stabilizer for ERalpha and 14-3-3 (1076403)
8ARG	;	1.5	;	Small molecular stabilizer for ERalpha and 14-3-3 (1076405)
8AR5	;	1.4	;	Small molecular stabilizer for ERalpha and 14-3-3 (1080265)
8ARQ	;	1.4	;	Small molecular stabilizer for ERalpha and 14-3-3 (1080266)
8AQZ	;	1.4	;	Small molecular stabilizer for ERalpha and 14-3-3 (1080267)
8ALR	;	1.4	;	Small molecular stabilizer for ERalpha and 14-3-3 (1080272)
8ARY	;	1.45	;	Small molecular stabilizer for ERalpha and 14-3-3 (1080273)
8ARO	;	1.6	;	Small molecular stabilizer for ERalpha and 14-3-3 (1080291)
8AU2	;	1.6	;	Small molecular stabilizer for ERalpha and 14-3-3 (1080293)
8AQC	;	1.5	;	Small molecular stabilizer for ERalpha and 14-3-3 (1080294)
8AQE	;	1.6	;	Small molecular stabilizer for ERalpha and 14-3-3 (1080295)
8AUS	;	1.4	;	Small molecular stabilizer for ERalpha and 14-3-3 (1080297)
8B39	;	1.4	;	Small molecular stabilizer for ERalpha and 14-3-3 (1080299)
8AR4	;	1.5	;	Small molecular stabilizer for ERalpha and 14-3-3 (1080300)
8APS	;	1.2	;	Small molecular stabilizer for ERalpha and 14-3-3 (1083744)
8ARX	;	1.4	;	Small molecular stabilizer for ERalpha and 14-3-3sigma (1074378)
8AI0	;	1.6	;	Small molecular stabilizer for ERalpha and 14-3-3sigma (1080268)
8JR9	;	2.57	;	Small molecule agonist (PCO371) bound to human parathyroid hormone receptor type 1 (PTH1R)
3C6N	;	2.6	;	Small molecule agonists and antagonists of F-box protein-substrate interactions in auxin perception and signaling
3C6O	;	2.7	;	Small molecule agonists and antagonists of F-box protein-substrate interactions in auxin perception and signaling
3C6P	;	2.7	;	Small molecule agonists and antagonists of F-box protein-substrate interactions in auxin perception and signaling
8C4F	;	1.4	;	Small molecule amidine soak in 14-3-3/ERa (AZ037)
8C4G	;	1.46	;	Small molecule amidine soak in 14-3-3/ERa (AZ132)
1CMP	;	1.9	;	SMALL MOLECULE BINDING TO AN ARTIFICIALLY CREATED CAVITY AT THE ACTIVE SITE OF CYTOCHROME C PEROXIDASE
1CMQ	;	2.3	;	SMALL MOLECULE BINDING TO AN ARTIFICIALLY CREATED CAVITY AT THE ACTIVE SITE OF CYTOCHROME C PEROXIDASE
3LKJ	;	2.5	;	Small Molecule Inhibition of the TNF Family Cyokine CD40 Ligand Through a Subunit Fracture Mechanism
5V8P	;	2.501	;	Small Molecule Inhibitor ABS-143 Bound to the Botulinum Neurotoxin Serotype A Light Chain
5V8R	;	1.9	;	Small Molecule Inhibitor ABS-143 Bound to the Botulinum Neurotoxin Serotype A Light Chain
5V8U	;	2.05	;	Small Molecule Inhibitor ABS-143 Bound to the Botulinum Neurotoxin Serotype A Light Chain
6QMC	;	1.77	;	Small molecule inhibitor of the KEAP1-NRF2 protein-protein interaction
6QMD	;	1.94	;	Small molecule inhibitor of the KEAP1-NRF2 protein-protein interaction
6QME	;	1.81	;	Small molecule inhibitor of the KEAP1-NRF2 protein-protein interaction
6QMJ	;	1.86	;	Small molecule inhibitor of the KEAP1-NRF2 protein-protein interaction
6QMK	;	1.72	;	Small molecule inhibitor of the KEAP1-NRF2 protein-protein interaction
5M6E	;	2.32	;	Small Molecule inhibitors of IAP
5M6F	;	2.39	;	Small Molecule inhibitors of IAP
5M6H	;	2.5	;	Small Molecule inhibitors of IAP
5M6L	;	2.61	;	Small Molecule inhibitors of IAP
5M6M	;	2.37	;	Small Molecule inhibitors of IAP
5M6N	;	1.8	;	Small Molecule inhibitors of IAP
3ZCM	;	1.8	;	Small molecule inhibitors of the LEDGF site of HIV integrase identified by fragment screening and structure based design.
3ZSO	;	1.75	;	Small molecule inhibitors of the LEDGF site of HIV type 1 integrase identified by fragment screening and structure based design
3ZSQ	;	1.7	;	Small molecule inhibitors of the LEDGF site of HIV type 1 integrase identified by fragment screening and structure based drug design
3ZSR	;	1.7	;	Small molecule inhibitors of the LEDGF site of HIV type 1 integrase identified by fragment screening and structure based drug design
3ZSV	;	1.75	;	Small molecule inhibitors of the LEDGF site of HIV type 1 integrase identified by fragment screening and structure based drug design
3ZSW	;	1.8	;	Small molecule inhibitors of the LEDGF site of HIV type 1 integrase identified by fragment screening and structure based drug design
3ZSX	;	1.95	;	Small molecule inhibitors of the LEDGF site of HIV type 1 integrase identified by fragment screening and structure based drug design
3ZSY	;	2.2	;	Small molecule inhibitors of the LEDGF site of HIV type 1 integrase identified by fragment screening and structure based drug design
3ZSZ	;	2.0	;	Small molecule inhibitors of the LEDGF site of HIV type 1 integrase identified by fragment screening and structure based drug design
3ZT0	;	1.95	;	Small molecule inhibitors of the LEDGF site of HIV type 1 integrase identified by fragment screening and structure based drug design
3ZT1	;	1.75	;	Small molecule inhibitors of the LEDGF site of HIV type 1 integrase identified by fragment screening and structure based drug design
3ZT2	;	1.7	;	Small molecule inhibitors of the LEDGF site of HIV type 1 integrase identified by fragment screening and structure based drug design
3ZT3	;	1.95	;	Small molecule inhibitors of the LEDGF site of HIV type 1 integrase identified by fragment screening and structure based drug design
3ZT4	;	2.2	;	Small molecule inhibitors of the LEDGF site of HIV type 1 integrase identified by fragment screening and structure based drug design
8ATP	;	1.4	;	Small molecule stabilizer (1075481) for ERalpha and 14-3-3
8AV0	;	1.5	;	small molecule stabilizer (compound 1) for C-RAF pS259 and 14-3-3
8AFN	;	1.36	;	Small molecule stabilizer (compound 1) for ERalpha and 14-3-3
8A62	;	1.6	;	Small molecule stabilizer (compound 2) for FOXO1 and 14-3-3
8A65	;	1.6	;	Small molecule stabilizer (compound 3) for FOXO1 and 14-3-3
8A68	;	1.6	;	Small molecule stabilizer (compound 5) for C-RAF(pS259) and 14-3-3
8A6H	;	1.6	;	Small molecule stabilizer (compound 7) for C-RAF and 14-3-3
8A6F	;	1.6	;	Small molecule stabilizer (compound 8) for C-RAF and 14-3-3
8AWG	;	1.8	;	small molecule stabilizer for ERalpha and 14-3-3 (1074202)
8AXE	;	1.8	;	Small molecule stabilizer for ERalpha and 14-3-3 (1074210)
8ANF	;	1.4	;	Small molecule stabilizer for ERalpha and 14-3-3 (1074359)
8AXU	;	1.6	;	Small molecule stabilizer for ERalpha and 14-3-3 (1075297)
8AZE	;	1.6	;	Small molecule stabilizer for ERalpha and 14-3-3 (1075306)
8AOY	;	1.4	;	Small molecule stabilizer for ERalpha and 14-3-3 (1075478)
8ARZ	;	1.5	;	Small molecule stabilizer for ERalpha and 14-3-3 (1076406)
8AT9	;	1.4	;	Small molecule stabilizer for ERalpha and 14-3-3 (1080269)
8AUY	;	1.5	;	Small molecule stabilizer for ERalpha and 14-3-3 (1080298)
8AQ1	;	1.4	;	small molecule stabilizer for ERalpha and 14-3-3 (1083743)
3IGE	;	2.254	;	Small outer capsid protein (Soc) from bacteriophage RB69
3IG9	;	1.9	;	Small outer capsid protein (SOC) of bacteriophage RB69
8HDG	;	1.73	;	Small peptide enhances the binding of nutline-3a to MdmX
8IA5	;	1.93	;	Small peptide enhances the binding of nutline-3a to N-terminal domain of MdmX
4ANG	;	3.5	;	Small RNA phage PRR1 in complex with an RNA operator fragment
3MJO	;	1.36	;	Small subunit (R2F) of native ribonucleotide reductase from Corynebacterium ammoniagenes
1AFT	;		;	SMALL SUBUNIT C-TERMINAL INHIBITORY PEPTIDE OF MOUSE RIBONUCLEOTIDE REDUCTASE AS BOUND TO THE LARGE SUBUNIT, NMR, 26 STRUCTURES
5XYU	;	3.45	;	Small subunit of Mycobacterium smegmatis ribosome
7PKQ	;	4.2	;	Small subunit of the Chlamydomonas reinhardtii mitoribosome
5XXU	;	3.35	;	Small subunit of Toxoplasma gondii ribosome
5XYI	;	3.35	;	Small subunit of Trichomonas vaginalis ribosome
8OM3	;	2.87	;	Small subunit of yeast mitochondrial ribosome in complex with IF3/Aim23.
8OM2	;	2.57	;	Small subunit of yeast mitochondrial ribosome in complex with METTL17/Rsm22.
8OM4	;	2.32	;	Small subunit of yeast mitochondrial ribosome.
6EE7	;	1.394	;	Small tetraheme cytochrome c from Shewanella oneidensis
8WP9	;	2.49	;	Small-heat shock protein from Methanocaldococcus jannaschii, Hsp16.5
7XHQ	;	2.2	;	Small-molecule Allosteric Regulation Mechanism of SHP2
8GWW	;	3.0	;	Small-molecule Allosteric Regulation Mechanism of SHP2
5NDF	;	2.3	;	Small-molecule inhibition of ppGalNAc-Ts selectively reduces mucin-type O-glycosylation
6YE9	;	1.8	;	Small-molecule inhibitor of 14-3-3 protein-protein interactions
3T0L	;	1.6	;	Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening
3T0M	;	1.62	;	Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening
4DHM	;	1.7	;	Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening
4DHN	;	1.8	;	Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening
4DHO	;	1.7	;	Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening
4DHP	;	1.75	;	Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening
4DHQ	;	1.75	;	Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening
4DHR	;	1.4	;	Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening
4DHS	;	1.74	;	Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening
4DHT	;	1.8	;	Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening
4DHU	;	1.67	;	Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening
6ZBQ	;	1.43	;	Small-molecule inhibitors of the PDZ domain of Dishevelled proteins interrupt Wnt signalling
6ZBZ	;	1.6	;	Small-molecule inhibitors of the PDZ domain of Dishevelled proteins interrupt Wnt signalling
6ZC3	;	1.67	;	Small-molecule inhibitors of the PDZ domain of Dishevelled proteins interrupt Wnt signalling
6ZC4	;	1.85	;	Small-molecule inhibitors of the PDZ domain of Dishevelled proteins interrupt Wnt signalling
6ZC6	;	1.58	;	Small-molecule inhibitors of the PDZ domain of Dishevelled proteins interrupt Wnt signalling
6ZC7	;	1.48	;	Small-molecule inhibitors of the PDZ domain of Dishevelled proteins interrupt Wnt signalling
6ZC8	;	2.76	;	Small-molecule inhibitors of the PDZ domain of Dishevelled proteins interrupt Wnt signalling
4DSN	;	2.03	;	Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity
4DSO	;	1.85	;	Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity
4DST	;	2.3	;	Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity
4DSU	;	1.7	;	Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity
5EWZ	;	2.34	;	Small-molecule stabilization of the 14-3-3/Gab2 PPI interface
5EXA	;	1.95	;	Small-molecule stabilization of the 14-3-3/Gab2 PPI interface
6YGJ	;	2.07	;	small-molecule stabilizer of 14-3-3 and the Carbohydrate Response Element Binding Protein (ChREBP) protein-protein interaction
3IGC	;	2.1	;	Smallpox virus topoisomerase-DNA transition state
8HXS	;	1.35	;	Small_spotted catshark CD8alpha
6UCH	;		;	SMARCB1 nucleosome-interacting C-terminal alpha helix
6K4W	;		;	smart chimeric peptide SCP-A6
7AMC	;	1.22	;	SmBRD3(2), Bromodomain 2 of the Bromodomain 3 protein from Schistosoma mansoni in complex with iBET726
7AMH	;	1.863	;	SmBRD3(2), Second Bromodomain of Bromodomain 3 from Schistosoma mansoni in complex with DM-A-33, an iBET726 analogue
4IPZ	;	1.67	;	SmBz bound to Cyclophilin A
1E69	;	3.1	;	SMC head domain from Thermotoga maritima
1GXJ	;	2.0	;	SMC hinge domain from T. maritima w/o coiled coil
1GXK	;	3.0	;	SMC hinge domain from T. maritima w/o coiled coil, P212121 crystal form
1GXL	;	3.0	;	SMC hinge domain from T. maritima with coiled coil
2WD5	;	2.7	;	SMC hinge heterodimer (Mouse)
8T8F	;	4.8	;	Smc5/6 8mer
5Z7M	;	2.0	;	SmChiA sliding-intermediate with chitohexaose
5Z7N	;	1.7	;	SmChiA sliding-intermediate with chitopentaose
5Z7O	;	2.0	;	SmChiA sliding-intermediate with chitotetraose
5Z7P	;	2.0	;	SmChiA sliding-intermediate with chitotriose
3P9T	;	2.02	;	SmeT-Triclosan complex
5NKM	;	2.493	;	SMG8-SMG9 complex
5NKK	;	2.64	;	SMG8-SMG9 complex GDP bound
1BR2	;	2.9	;	SMOOTH MUSCLE MYOSIN MOTOR DOMAIN COMPLEXED WITH MGADP.ALF4
1BR1	;	3.5	;	SMOOTH MUSCLE MYOSIN MOTOR DOMAIN-ESSENTIAL LIGHT CHAIN COMPLEX WITH MGADP.ALF4 BOUND AT THE ACTIVE SITE
1BR4	;	3.62	;	SMOOTH MUSCLE MYOSIN MOTOR DOMAIN-ESSENTIAL LIGHT CHAIN COMPLEX WITH MGADP.BEF3 BOUND AT THE ACTIVE SITE
6Z47	;	6.3	;	Smooth muscle myosin shutdown state heads region
1L2N	;		;	Smt3 Solution Structure
1SMT	;	2.2	;	SMTB REPRESSOR FROM SYNECHOCOCCUS PCC7942
2LTX	;		;	Smurf1 WW2 domain in complex with a Smad7 derived peptide
2LTZ	;		;	Smurf2 WW3 domain in complex with a Smad7 derived peptide
6FZO	;	2.3	;	SMURFP-Y56F mutant
6FZN	;	2.5	;	SMURFP-Y56R mutant in complex with biliverdin
5KJK	;	1.93	;	SMYD2 in complex with AZ370
5KJL	;	2.7	;	SMYD2 in complex with AZ378
5KJN	;	2.72	;	SMYD2 in complex with AZ506
5KJM	;	2.19	;	SMYD2 in complex with AZ931
5ARG	;	1.99	;	SMYD2 in complex with SGC probe BAY-598
5ARF	;	1.92	;	SMYD2 in complex with small molecule inhibitor compound-2
8OWO	;	1.8	;	SMYD3 in complex with fragment FL01507
7QNR	;	1.57	;	SMYD3 in complex with fragment FL01791
7QLB	;	1.8	;	SMYD3 in complex with fragment FL06268
7QNU	;	1.64	;	SMYD3 in complex with fragment FL08619
8HRH	;	2.07	;	SN-131/1B2 anti-MUC1 antibody with a glycopeptide
7M17	;	3.65	;	SN-407-LRRC8A in MSP1E3D1 lipid nanodiscs (Pose-1)
7M19	;	3.69	;	SN-407-LRRC8A in MSP1E3D1 lipid nanodiscs (Pose-2)
6X84	;	1.25	;	Sn-glycerol-3-phosphate binding periplasmic protein UgpB from Escherichia coli - W169S, W172S
2SOB	;		;	SN-OB, OB-FOLD SUB-DOMAIN OF STAPHYLOCOCCAL NUCLEASE, NMR, 10 STRUCTURES
7QEE	;	2.374	;	SN243 mutant D415N bound to para-nitrophenyl-Beta-D-glucuronide
1NHL	;	2.3	;	SNAP-23N Structure
3ZD6	;	2.8	;	Snapshot 1 of RIG-I scanning on RNA duplex
3ZD7	;	2.5	;	Snapshot 3 of RIG-I scanning on RNA duplex
3OJU	;	2.0	;	Snapshot of the large fragment of DNA polymerase I from Thermus Aquaticus processing c5 modified thymidies
4ELT	;	2.2	;	Snapshot of the large fragment of DNA polymerase I from Thermus Aquaticus processing modified pyrimidines
4ELU	;	1.8	;	Snapshot of the large fragment of DNA polymerase I from Thermus Aquaticus processing modified pyrimidines
4ELV	;	1.9	;	Snapshot of the large fragment of DNA polymerase I from Thermus Aquaticus processing modified pyrimidines
2ZZ1	;	1.57	;	Snapshot of the reaction from 6-CN-UMP to BMP catalyzed by Orotidine Monophosphate Deacarboxylase from M. thermoautotrophicum
2RDI	;	1.92	;	Snapshots of a Y-family DNA polymerase in replication: Dpo4 in apo and binary/ternary complex forms
2RDJ	;	2.2	;	Snapshots of a Y-family DNA polymerase in replication: Dpo4 in apo and binary/ternary complex forms
3DUF	;	2.5	;	Snapshots of catalysis in the E1 subunit of the pyruvate dehydrogenase multi-enzyme complex
3DV0	;	2.5	;	Snapshots of catalysis in the E1 subunit of the pyruvate dehydrogenase multi-enzyme complex
3DVA	;	2.35	;	Snapshots of catalysis in the E1 subunit of the pyruvate dehydrogenase multi-enzyme complex
2YLW	;	2.9	;	SNAPSHOTS OF ENZYMATIC BAEYER-VILLIGER CATALYSIS: OXYGEN ACTIVATION AND INTERMEDIATE STABILIZATION: Arg337Lys MUTANT IN COMPLEX WITH MES
2YM1	;	2.28	;	SNAPSHOTS OF ENZYMATIC BAEYER-VILLIGER CATALYSIS: OXYGEN ACTIVATION AND INTERMEDIATE STABILIZATION: Arg337Lys MUTANT IN COMPLEX WITH NADP
2YM2	;	2.7	;	SNAPSHOTS OF ENZYMATIC BAEYER-VILLIGER CATALYSIS: OXYGEN ACTIVATION AND INTERMEDIATE STABILIZATION: Arg337Lys MUTANT REDUCED STATE WITH NADP
2YLX	;	2.2	;	SNAPSHOTS OF ENZYMATIC BAEYER-VILLIGER CATALYSIS: OXYGEN ACTIVATION AND INTERMEDIATE STABILIZATION: Asp66Ala MUTANT IN COMPLEX WITH NADP AND MES
2YLR	;	2.26	;	SNAPSHOTS OF ENZYMATIC BAEYER-VILLIGER CATALYSIS: OXYGEN ACTIVATION AND INTERMEDIATE STABILIZATION: COMPLEX WITH NADP
2YLT	;	2.65	;	SNAPSHOTS OF ENZYMATIC BAEYER-VILLIGER CATALYSIS: OXYGEN ACTIVATION AND INTERMEDIATE STABILIZATION: COMPLEX WITH NADP and MES
2YLZ	;	2.0	;	SNAPSHOTS OF ENZYMATIC BAEYER-VILLIGER CATALYSIS: OXYGEN ACTIVATION AND INTERMEDIATE STABILIZATION: Met446Gly MUTANT
2YLS	;	2.26	;	SNAPSHOTS OF ENZYMATIC BAEYER-VILLIGER CATALYSIS: OXYGEN ACTIVATION AND INTERMEDIATE STABILIZATION: REDUCED ENZYME BOUND TO NADP
3DKR	;	1.6	;	Snapshots of esterase D from lactobacillus rhamnosus: Insights into a rotation driven catalytic mechanism
3DLT	;	1.9	;	Snapshots of esterase D from lactobacillus rhamnosus: Insights into a rotation driven catalytic mechanism
3DYI	;	1.72	;	Snapshots of esterase D from lactobacillus rhamnosus: Insights into a rotation driven catalytic mechanism
3DYV	;	1.81	;	Snapshots of esterase D from lactobacillus rhamnosus: Insights into a rotation driven catalytic mechanism
3E1G	;	2.2	;	Snapshots of esterase D from lactobacillus rhamnosus: Insights into a rotation driven catalytic mechanism
7VXV	;	2.23	;	Snapshots of Human PSMD10(Gankyrin) unfolding by urea: 0 hours incubation / Native
7VXW	;	2.22	;	Snapshots of Human PSMD10(Gankyrin) unfolding by urea: 1 hour incubation
7VY4	;	2.22	;	Snapshots of Human PSMD10(Gankyrin) unfolding by urea: 2 hours incubation
7VY7	;	2.23	;	Snapshots of Human PSMD10(Gankyrin) unfolding by urea: 3 hours incubation
1S0N	;	2.8	;	Snapshots of replication through an abasic lesion: structural basis for base substitution and frameshift
1S0O	;	2.1	;	Snapshots of replication through an abasic lesion: structural basis for base substitution and frameshift
1S10	;	2.1	;	Snapshots of replication through an abasic lesion: structural basis for base substitution and frameshift
1HAX	;	1.6	;	Snapshots of serine protease catalysis: (A) acyl-enzyme intermediate between porcine pancreatic elastase and human beta-casomorphin-7 at pH 5
1HAY	;	1.7	;	Snapshots of serine protease catalysis: (B) acyl-enzyme intermediate between porcine pancreatic elastase and human beta-casomorphin-7 jumped to pH 10 for 10 seconds
1HAZ	;	1.4	;	Snapshots of serine protease catalysis: (C) acyl-enzyme intermediate between porcine pancreatic elastase and human beta-casomorphin-7 jumped to pH 9 for 1 minute
1HB0	;	2.05	;	Snapshots of serine protease catalysis: (D) acyl-enzyme intermediate between porcine pancreatic elastase and human beta-casomorphin-7 jumped to pH 10 for 2 minutes
3OJS	;	1.9	;	Snapshots of the large fragment of DNA polymerase I from Thermus Aquaticus processing C5 modified thymidines
3D9I	;	1.907	;	Snapshots of the RNA processing factor SCAF8 bound to different phosphorylated forms of the Carboxy-Terminal Domain of RNA-Polymerase II
3D9J	;	1.6	;	Snapshots of the RNA processing factor SCAF8 bound to different phosphorylated forms of the Carboxy-Terminal Domain of RNA-Polymerase II
3D9K	;	2.2	;	Snapshots of the RNA processing factor SCAF8 bound to different phosphorylated forms of the Carboxy-Terminal Domain of RNA-Polymerase II
3D9L	;	2.2	;	Snapshots of the RNA processing factor SCAF8 bound to different phosphorylated forms of the Carboxy-Terminal Domain of RNA-Polymerase II
3D9M	;	1.75	;	Snapshots of the RNA processing factor SCAF8 bound to different phosphorylated forms of the Carboxy-Terminal Domain of RNA-Polymerase II
3D9N	;	1.6	;	Snapshots of the RNA processing factor SCAF8 bound to different phosphorylated forms of the Carboxy-Terminal Domain of RNA-Polymerase II
3D9O	;	2.0	;	Snapshots of the RNA processing factor SCAF8 bound to different phosphorylated forms of the Carboxy-Terminal Domain of RNA-Polymerase II
3D9P	;	2.1	;	Snapshots of the RNA processing factor SCAF8 bound to different phosphorylated forms of the Carboxy-Terminal Domain of RNA-Polymerase II
7EG6	;	3.1	;	Snf5 Finger Helix bound to the nucleosome
6ISK	;	1.77	;	SnoaL-like cyclase XimE
6ISL	;	1.77	;	SnoaL-like cyclase XimE with its product xiamenmycin B
7E85	;	2.424	;	SnoaL-like domain-containing protein
3BOG	;	1.2	;	Snow Flea Antifreeze Protein Quasi-racemate
3BOI	;	1.0	;	Snow Flea Antifreeze Protein Racemate
2MY2	;		;	Snu17p-Bud13p structure intermediate during RES complex assembly
2MY3	;		;	Snu17p-Pml1p structure intermediate during RES complex assembly
3N55	;	1.57	;	SO1698 protein, an aspartic peptidase from Shewanella oneidensis.
2RAJ	;	2.45	;	SO4 bound PX-BAR membrane remodeling unit of Sorting Nexin 9
6ZLR	;	3.1	;	Soaking competent crystal form of the SARS-CoV-2 Receptor Binding Domain (RBD):CR3022 complex.
2JZ3	;		;	SOCS box elonginBC ternary complex
5AG2	;	1.77	;	SOD-3 azide complex
5O40	;	1.5	;	SOD1 bound to Ebselen
5O3Y	;	1.3	;	SOD1 bound to Ebsulfur
1BYY	;		;	SODIUM CHANNEL IIA INACTIVATION GATE
2FMQ	;	2.2	;	Sodium in active site of DNA Polymerase Beta
1PLY	;	3.2	;	SODIUM IONS AND WATER MOLECULES IN THE STRUCTURE OF POLY D(A)(DOT)POLY D(T)
8A1T	;	3.37	;	Sodium pumping NADH-quinone oxidoreductase
8A1X	;	3.2	;	Sodium pumping NADH-quinone oxidoreductase with inhibitor DQA
8A1Y	;	3.3	;	Sodium pumping NADH-quinone oxidoreductase with inhibitor HQNO
8A1W	;	2.56	;	Sodium pumping NADH-quinone oxidoreductase with substrate Q1
8A1V	;	2.73	;	Sodium pumping NADH-quinone oxidoreductase with substrate Q2
8A1U	;	2.86	;	Sodium pumping NADH-quinone oxidoreductase with substrates NADH and Q2
3BJH	;	1.6	;	Soft-SAD crystal structure of a pheromone binding protein from the honeybee Apis mellifera L.
7XJI	;	3.9	;	Solabegron-activated dog beta3 adrenergic receptor
1ZN5	;		;	Solid State NMR Structure of the low-temperature form of the Pf1 Major Coat Protein in Magnetically Aligned Bacteriophage
2L0J	;		;	Solid State NMR structure of the M2 proton channel from Influenza A Virus in hydrated lipid bilayer
1PJF	;		;	Solid State NMR structure of the Pf1 Major Coat Protein in Magnetically Aligned Bacteriophage
5JZR	;		;	Solid-state MAS NMR structure of Acinetobacter phage 205 (AP205) coat protein in assembled capsid particles
5JXV	;		;	Solid-state MAS NMR structure of immunoglobulin beta 1 binding domain of protein G (GB1)
1M8M	;		;	SOLID-STATE MAS NMR STRUCTURE OF THE A-SPECTRIN SH3 DOMAIN
2RLZ	;		;	Solid-State MAS NMR structure of the dimer Crh
6EKA	;		;	Solid-state MAS NMR structure of the HELLF prion amyloid fibrils
8ACZ	;		;	Solid-State NMR Atomic-Resolution Structure of the Protein Encoded by Gene V of fd Bacteriophage in Complex with Viral ssDNA
8H1D	;		;	Solid-state NMR Structure of Aquaporin Z in its Native Cellular Membranes
2JZZ	;		;	Solid-State NMR Structure of Microcrystalline Ubiquitin
6QWR	;		;	Solid-state NMR structure of outer membrane protein AlkL in DMPC lipid bilayers
5MWV	;		;	Solid-state NMR Structure of outer membrane protein G in lipid bilayers
2MCV	;		;	Solid-state NMR structure of piscidin 1 in aligned 1:1 phosphatidylethanolamine/phosphoglycerol lipid bilayers
2MCU	;		;	Solid-state NMR structure of piscidin 1 in aligned 3:1 phosphatidylcholine/phosphoglycerol lipid bilayers
6PF0	;		;	SOLID-STATE NMR STRUCTURE OF PISCIDIN 1 IN ALIGNED 4:1 PHOSPHATIDYLCHOLINE/CHOLESTEROL LIPID BILAYERS
2MCX	;		;	Solid-state NMR structure of piscidin 3 in aligned 1:1 phosphatidylethanolamine/phosphoglycerol lipid bilayers
2MCW	;		;	Solid-state NMR structure of piscidin 3 in aligned 3:1 phosphatidylcholine/phosphoglycerol lipid bilayers
6PEZ	;		;	SOLID-STATE NMR STRUCTURE OF PISCIDIN 3 IN ALIGNED 4:1 PHOSPHATIDYLCHOLINE/CHOLESTEROL LIPID BILAYERS
7QGV	;		;	Solid-state NMR structure of Teixobactin-Lipid II.
7WEM	;		;	Solid-state NMR Structure of TFo c-Subunit Ring
2KLR	;		;	Solid-state NMR structure of the alpha-crystallin domain in alphaB-crystallin oligomers
6YFY	;		;	Solid-state NMR structure of the D-Arg4,L10-teixobactin - Lipid II complex in lipid bilayers.
2KQT	;		;	Solid-state NMR structure of the M2 transmembrane peptide of the influenza A virus in DMPC lipid bilayers bound to deuterated amantadine
2LME	;		;	Solid-state NMR structure of the membrane anchor domain of the trimeric autotransporter YadA
2MSG	;		;	Solid-state NMR structure of ubiquitin
2N28	;		;	Solid-state NMR structure of Vpu
1RLD	;	2.5	;	SOLID-STATE PHASE TRANSITION IN THE CRYSTAL STRUCTURE OF RIBULOSE 1,5-BIPHOSPHATE CARBOXYLASE(SLASH)OXYGENASE
2JU6	;		;	Solid-State Protein Structure Determination with Proton-Detected Triple Resonance 3D Magic-Angle Spinning NMR Spectroscopy
8P1O	;	2.17	;	Solubilizer tag effect on PD-L1/inhibitor binding properties for m-terphenyl derivatives
1WC0	;	2.4	;	Soluble adenylyl cyclase CyaC from S. platensis in complex with alpha, beta-methylene-ATP
1WC4	;	3.0	;	Soluble adenylyl cyclase CyaC from S. platensis in complex with alpha, beta-methylene-ATP and Europium
1WC3	;	1.9	;	Soluble adenylyl cyclase CyaC from S. platensis in complex with alpha, beta-methylene-ATP and Strontium
1WC5	;	2.3	;	Soluble adenylyl cyclase CyaC from S. platensis in complex with alpha, beta-methylene-ATP in presence of bicarbonate
1WC1	;	1.93	;	Soluble adenylyl cyclase CyaC from S. platensis in complex with Rp- ATPalphaS
1WC6	;	2.51	;	Soluble adenylyl cyclase CyaC from S. platensis in complex with Rp- ATPalphaS in presence of bicarbonate
4Z7E	;	1.5	;	Soluble binding domain of Lmo1422 ABC-transporter
7BWH	;	1.4	;	Soluble cytochrome b5 from Ramazzottius varieornatus
8HN3	;	1.65	;	Soluble domain of cytochrome c-556 from Chlorobaculum tepidum
2NVE	;	1.5	;	Soluble domain of Rieske Iron Sulfur Protein
2NWF	;	1.1	;	Soluble domain of Rieske Iron Sulfur Protein
2NVG	;	1.35	;	Soluble domain of Rieske Iron Sulfur protein.
2NUM	;	1.5	;	Soluble domain of Rieske Iron-Sulfur Protein
2NVF	;	1.5	;	Soluble domain of Rieske Iron-Sulfur protein.
2NUK	;	1.2	;	Soluble Domain of the Rieske Iron-Sulfur Protein from Rhodobacter sphaeroides
4JNC	;	1.96	;	Soluble Epoxide Hydrolase complexed with a carboxamide inhibitor
6HGX	;	2.16	;	Soluble epoxide hydrolase in complex with 1-(4-((4-(tert-butyl)morpholin-2-yl)methoxy)phenyl)-3-cyclohexylurea
6HGW	;	2.407	;	Soluble epoxide hydrolase in complex with 2-(4-fluorophenyl)-N-(4-phenoxybenzyl)ethanamine
6YL4	;	2.001	;	Soluble epoxide hydrolase in complex with 3-((R)-3-(1-hydroxyureido)but-1-yn-1-yl)-N-((S)-3-phenyl-3-(4-trifluoromethoxy)phenyl)propyl)benzamide
8QZD	;	1.3	;	Soluble epoxide hydrolase in complex with Epoxykinin
7P4K	;	2.15	;	Soluble epoxide hydrolase in complex with FL217
6FR2	;	2.262	;	Soluble epoxide hydrolase in complex with LK864
3OTQ	;	3.0	;	Soluble Epoxide Hydrolase in complex with pyrazole antagonist
8QN0	;	1.49	;	Soluble epoxide hydrolase in complex with RK3
8QMZ	;	1.47	;	Soluble epoxide hydrolase in complex with RK4
6HGV	;	2.0	;	Soluble epoxide hydrolase in complex with talinolol
7A7G	;	2.4	;	Soluble epoxide hydrolase in complex with TK90
1XU5	;	1.96	;	Soluble methane monooxygenase hydroxylase-phenol soaked
1XU3	;	2.3	;	Soluble methane monooxygenase hydroxylase-soaked with bromophenol
1XVE	;	2.4	;	soluble methane monooxygenase hydroxylase: 3-bromo-3-butenol soaked structure
1XVD	;	2.3	;	Soluble methane monooxygenase hydroxylase: 4-fluorophenol soaked structure
1XVB	;	1.8	;	soluble methane monooxygenase hydroxylase: 6-bromohexanol soaked structure
1XVC	;	2.0	;	soluble methane monooxygenase hydroxylase: 8-bromooctanol soaked structure
1XVG	;	1.96	;	soluble methane monooxygenase hydroxylase: bromoethanol soaked structure
1XVF	;	2.0	;	soluble methane monooxygenase hydroxylase: chloropropanol soaked structure
6L2U	;	1.5	;	Soluble methane monooxygenase reductase FAD-binding domain from Methylosinus sporium.
6PTT	;	1.84	;	Soluble model of Arabidopsis thaliana CuA (Tt3LAt)
6PTY	;	1.98	;	Soluble model of human CuA (Tt3Lh)
4XA7	;	1.56	;	Soluble part of holo NqrC from V. harveyi
1F97	;	2.5	;	SOLUBLE PART OF THE JUNCTION ADHESION MOLECULE FROM MOUSE
1QBI	;	1.72	;	SOLUBLE QUINOPROTEIN GLUCOSE DEHYDROGENASE FROM ACINETOBACTER CALCOACETICUS
1CRU	;	1.5	;	SOLUBLE QUINOPROTEIN GLUCOSE DEHYDROGENASE FROM ACINETOBACTER CALCOACETICUS IN COMPLEX WITH PQQ AND METHYLHYDRAZINE
1CQ1	;	1.9	;	Soluble Quinoprotein Glucose Dehydrogenase from Acinetobacter Calcoaceticus in Complex with PQQH2 and Glucose
4XBH	;	2.114	;	Soluble rabbit neprilysin
4ZR5	;	2.8016	;	Soluble rabbit neprilysin in complex with phosphoramidon
5V48	;	2.9965	;	Soluble rabbit neprilysin in complex with thiorphan
1WJZ	;		;	Soluiotn structure of J-domain of mouse DnaJ like protein
2DIG	;		;	Solusion structure of the Todor domain of human Lamin-B receptor
7ZZY	;	3.3	;	Solution BcsD structure
226D	;		;	SOLUTION CONFORMATION OF A BIZELESIN A-TRACT DUPLEX ADDUCT, NMR, 1 STRUCTURE
2JXZ	;		;	Solution Conformation of A Non-Amyloidogenic Analogue of Human Calcitonin in Sodium Dodecyl Sulfate Micelles
1DG2	;		;	SOLUTION CONFORMATION OF A-CONOTOXIN AUIB
1WZ4	;		;	Solution Conformation of adr subtype HBV Pre-S2 Epitope
1UL2	;		;	Solution Conformation of alpha-Conotoxin GIC
1ZLC	;		;	Solution Conformation of alpha-conotoxin PIA
1PQR	;		;	Solution Conformation of alphaA-Conotoxin EIVA
1ANP	;		;	SOLUTION CONFORMATION OF AN ATRIAL NATRIURETIC PEPTIDE VARIANT SELECTIVE FOR THE TYPE-A RECEPTOR
1COD	;		;	SOLUTION CONFORMATION OF COBROTOXIN: A NUCLEAR MAGNETIC RESONANCE AND HYBRID DISTANCE GEOMETRY-DYNAMICAL SIMULATED ANNEALING STUDY
1COE	;		;	SOLUTION CONFORMATION OF COBROTOXIN: A NUCLEAR MAGNETIC RESONANCE AND HYBRID DISTANCE GEOMETRY-DYNAMICAL SIMULATED ANNEALING STUDY
5UHU	;		;	Solution conformation of cytochrome P450 MycG with mycinamicin IV bound
1BUS	;		;	SOLUTION CONFORMATION OF PROTEINASE INHIBITOR IIA FROM BULL SEMINAL PLASMA BY 1H NUCLEAR MAGNETIC RESONANCE AND DISTANCE GEOMETRY
2BUS	;		;	SOLUTION CONFORMATION OF PROTEINASE INHIBITOR IIA FROM BULL SEMINAL PLASMA BY 1H NUCLEAR MAGNETIC RESONANCE AND DISTANCE GEOMETRY
1D18	;		;	SOLUTION CONFORMATION OF PURINE-PYRIMIDINE DNA OCTAMERS USING NUCLEAR MAGNETIC RESONANCE, RESTRAINED MOLECULAR DYNAMICS AND NOE-BASED REFINEMENT
1D19	;		;	SOLUTION CONFORMATION OF PURINE-PYRIMIDINE DNA OCTAMERS USING NUCLEAR MAGNETIC RESONANCE, RESTRAINED MOLECULAR DYNAMICS AND NOE-BASED REFINEMENT
2JX2	;		;	Solution conformation of RNA-bound NELF-E RRM
2GLH	;		;	Solution Conformation of Salmon Calcitonin in Sodium Dodecyl Sulfate Micelles
2KS9	;		;	Solution conformation of substance P in water complexed with NK1R
1CR3	;		;	SOLUTION CONFORMATION OF THE (+)TRANS-ANTI-BENZO[G]CHRYSENE-DA ADDUCT OPPOSITE DT IN A DNA DUPLEX
1AXL	;		;	SOLUTION CONFORMATION OF THE (-)-TRANS-ANTI-[BP]DG ADDUCT OPPOSITE A DELETION SITE IN DNA DUPLEX D(CCATC-[BP]G-CTACC)D(GGTAG--GATGG), NMR, 6 STRUCTURES
2I8F	;		;	Solution Conformation of the H47A Mutant of Pseudomonas stutzeri ZoBell Ferrocytochrome c-551
1I34	;		;	SOLUTION DNA QUADRUPLEX WITH DOUBLE CHAIN REVERSAL LOOP AND TWO DIAGONAL LOOPS CONNECTING GGGG TETRADS FLANKED BY G-(T-T) TRIAD AND T-T-T TRIPLE
1D6D	;		;	SOLUTION DNA STRUCTURE CONTAINING (A-A)-T TRIADS INTERDIGITATED BETWEEN A-T BASE PAIRS AND GGGG TETRADS; NMR, 8 STRUCT.
1MZI	;		;	Solution ensemble structures of HIV-1 gp41 2F5 mAb epitope
2K7Y	;		;	Solution fold of HIV-1 Virus protein U cytoplasmic domain in the presence of DPC micelles
2JQR	;		;	Solution model of crosslinked complex of cytochrome c and adrenodoxin
2M0Q	;		;	Solution NMR analysis of intact KCNE2 in detergent micelles demonstrate a straight transmembrane helix
6XMN	;		;	Solution NMR CXCL8-CXCR1 N-domain complex structure
6QH2	;		;	Solution NMR ensemble for a chimeric KH-S1 domain construct of exosomal polynucleotide phosphrylase at 298K compiled using the CoMAND method
6QF8	;		;	Solution NMR ensemble for human ubiquitin at 298K compiled using the CoMAND method
6QFP	;		;	Solution NMR ensemble for MlbQ at 298K compiled using the CoMAND method
6VHJ	;		;	Solution NMR of Prochlorosin 1.1 produced by Prochlorococcus MIT 9313
6VLJ	;		;	Solution NMR of Prochlorosin 2.8 produced by Prochlorococcus MIT 9313
2KVV	;		;	Solution NMR of Putative excisionase from Klebsiella pneumoniae, Northeast Structural Genomics Consortium Target Target KpR49
6QYU	;		;	Solution NMR of synthetic analogues of nisin and mutacin ring A and ring B - Mutacin I Ring A
6QYV	;		;	Solution NMR of synthetic analogues of nisin and mutacin ring A and ring B - Mutacin I Ring A (Ser2, Ala5, Ala8) analogue
6QYT	;		;	Solution NMR of synthetic analogues of nisin and mutacin ring A and ring B - Mutacin I Ring A truncated analogue
6QTF	;		;	Solution NMR of synthetic analogues of nisin and mutacin ring A and ring B - Mutacin I Ring B, major conformer
6QYR	;		;	Solution NMR of synthetic analogues of nisin and mutacin ring A and ring B - Mutacin I Ring B, minor conformer
6QYW	;		;	Solution NMR of synthetic analogues of nisin and mutacin ring A and ring B - nisin ring A
6QYS	;		;	Solution NMR of synthetic analogues of nisin and mutacin ring A and ring B - Nisin Ring B
6QM1	;		;	Solution NMR of synthetic analogues of nisin and mutacin ring A and ring B - Nisin Ring B (Lan8,11) analogue
2KW2	;		;	Solution NMR of the specialized acyl carrier protein (RPA2022) from Rhodopseudomonas palustris, Northeast Structural Genomics Consortium Target RpR324
2LPK	;		;	Solution NMR of the specialized apo-acyl carrier protein (RPA2022) from Rhodopseudomonas palustris, Northeast Structural Genomics Consortium Target RpR324
7TZD	;		;	Solution NMR of the specialized apo-acyl carrier protein (RPA2022) from Rhodopseudomonas palustris, refined without RDCs. Northeast Structural Genomics Consortium Target RpR324
2M30	;		;	Solution NMR refinement of a metal ion bound protein using quantum mechanical/molecular mechanical and molecular dynamics methods
7RY6	;		;	Solution NMR structural bundle of the first cyclization domain from yersiniabactin synthetase (Cy1) impacted by dynamics
5YQ3	;		;	Solution NMR Structure and Backbone Dynamics of the Partially Disordered Arabidopsis thaliana Phloem Protein 16-1, A Putative mRNA Transporter
7JYZ	;		;	Solution NMR structure and dynamics of human Brd3 ET in complex with MLV IN CTD
1SX0	;		;	Solution NMR Structure and X-Ray Absorption Analysis of the C-Terminal Zinc-Binding Domain of the SecA ATPase
1SX1	;		;	Solution NMR Structure and X-ray Absorption Analysis of the C-Terminal Zinc-Binding Domain of the SecA ATPase
6LMS	;		;	Solution NMR structure cold shock domain of YB1 from Homo sapiens
2M5O	;		;	Solution NMR Structure CTD domain of NFU1 Iron-Sulfur Cluster Scaffold Homolog from Homo sapiens, Northeast Structural Genomics Consortium (NESG) Target HR2876C
2LVB	;		;	Solution NMR Structure DE NOVO DESIGNED PFK fold PROTEIN, Northeast Structural Genomics Consortium (NESG) Target OR250
2LV8	;		;	Solution NMR Structure de novo designed rossmann 2x2 fold protein, Northeast Structural Genomics Consortium (NESG) Target OR16
6CMY	;		;	Solution NMR Structure Determination of Mouse Melanoregulin
2MPE	;		;	Solution NMR structure for B. pseudomallei BPSL1050
6BR0	;		;	Solution NMR structure for CcoTx-I
6NU0	;		;	Solution NMR structure of 1918 NS1 effector domain
2KRK	;		;	Solution NMR Structure of 26S protease regulatory subunit 8 from H.sapiens, Northeast Structural Genomics Consortium Target Target HR3102A
6U79	;		;	Solution NMR structure of 5' UTR stem loop B from West Nile Virus
6W3M	;		;	Solution NMR Structure of 5'UTR Stem Loop B in DENV4 Flavivirus.
7UBF	;		;	Solution NMR structure of 8-residue Rosetta-designed cyclic peptide D8.21 in 50% d6-DMSO and 50% water with cis/trans switching (CC conformation, 50%)
8CUN	;		;	Solution NMR structure of 8-residue Rosetta-designed cyclic peptide D8.21 in 50% d6-DMSO and 50% water with cis/trans switching (CC conformation, 50%)
8CWA	;		;	Solution NMR structure of 8-residue Rosetta-designed cyclic peptide D8.21 in CDCl3 with cis/trans switching (TC conformation, 53%)
7UBI	;		;	Solution NMR structure of 8-residue Rosetta-designed cyclic peptide D8.21 in CDCl3 with cis/trans switching (TT conformation, 47%)
7UBE	;		;	Solution NMR structure of 8-residue Rosetta-designed cyclic peptide D8.21 in d6-DMSO with cis/trans switching
7UBH	;		;	Solution NMR structure of 8-residue Rosetta-designed cyclic peptide D8.31 in CDCl3 with cis/trans switching
7UBD	;		;	Solution NMR structure of 8-residue Rosetta-designed cyclic peptide D8.31 in d6-DMSO with cis/trans switching (A-CC conformation)
8CTO	;		;	Solution NMR structure of 8-residue Rosetta-designed cyclic peptide D8.31 in d6-DMSO with cis/trans switching (B-CT conformation)
7UBG	;		;	Solution NMR structure of 9-residue Rosetta-designed cyclic peptide D9.16 in CDCl3 with cis/trans switching (A-TT conformation)
7UZL	;		;	Solution NMR structure of 9-residue Rosetta-designed cyclic peptide D9.16 in CDCl3 with cis/trans switching (B-TC conformation)
7UBC	;		;	Solution NMR structure of 9-residue Rosetta-designed cyclic peptide D9.16 in d6-DMSO with cis/trans switching
5ZLD	;		;	SOLUTION NMR STRUCTURE OF A 14-MER DOUBLE STRANDED DNA DUPLEX CGCGAAATTTCGCG
6IJV	;		;	Solution NMR structure of a 14-mer dsDNA complexed with a novel NIR fluorescent probe QCy-DT
5B81	;		;	Solution NMR structure of a 16-mer DNA duplex containing quadruple GC mismatches showing staggered base pairing, and consequent rescue of canonical double helical characteristics
2KPN	;		;	Solution NMR structure of a Bacterial Ig-like (Big_3) domain from Bacillus cereus. Northeast Structural Genomics Consortium target BcR147A
6E98	;		;	Solution NMR Structure of a Class I Hydrophobin from Phanerochaete carnosa
5W0Y	;		;	Solution NMR Structure of a Class I Hydrophobin from Serpula lacrymans
6E9M	;		;	Solution NMR Structure of a Class I Hydrophobin from Wallemia ichthyophaga
8EP5	;		;	Solution NMR structure of a computationally designed mastoparan-like peptide, mastoparan-R1
8ERU	;		;	Solution NMR structure of a computationally designed mastoparan-like peptide, mastoparan-R4
2KRT	;		;	Solution NMR Structure of a Conserved Hypothetical Membrane Lipoprotein Obtained from Ureaplasma parvum: Northeast Structural Genomics Consortium Target UuR17A (139-239)
6E5C	;		;	Solution NMR structure of a de novo designed double-stranded beta-helix
2KKE	;		;	Solution NMR Structure of a dimeric protein of unknown function from Methanobacterium thermoautotrophicum, Northeast Structural Genomics Consortium Target TR5
2LIA	;		;	Solution NMR structure of a DNA dodecamer containing the 7-aminomethyl-7-deaza-2'-deoxyguanosine adduct
8X4F	;		;	Solution NMR structure of a DNA hairpin formed by pure CTG repeats
6IJW	;		;	SOLUTION NMR STRUCTURE OF A DODECAMERIC dsDNA COMPLEXED WITH A NIR FLUORESCENT PROBE QCy-DT
2KEY	;		;	Solution NMR structure of a domain from a putative phage integrase protein BF2284 from Bacteroides fragilis, Northeast Structural Genomics Consortium Target BfR257C
2KJ5	;		;	Solution NMR structure of a domain from a putative phage integrase protein Nmul_A0064 from Nitrosospira multiformis, Northeast Structural Genomics Consortium Target NmR46C
2KQ8	;		;	Solution NMR structure of a domain from BT9727_4915 from Bacillus thuringiensis, Northeast Structural Genomics Consortium Target BuR95A
2KYW	;		;	Solution NMR Structure of a domain of adhesion exoprotein from Pediococcus pentosaceus, Northeast Structural Genomics Consortium Target PtR41O
2KTA	;		;	Solution NMR structure of a domain of protein A6KY75 from Bacteroides vulgatus, Northeast Structural Genomics target BvR106A
2LGO	;		;	Solution NMR structure of a FKBP-type peptidyl-prolyl cis-trans isomerase from Giardia lamblia, Seattle Structural Genomics Center for Infectious Disease target GilaA.00840.a
2LC3	;		;	Solution NMR structure of a helical bundle domain from human E3 ligase HECTD1. Northeast structural genomics consortium (NESG) target HT6305A
1W6B	;		;	Solution NMR Structure of a Long Neurotoxin from the Venom of the Asian Cobra, 20 Structures
2MJX	;		;	Solution NMR structure of a mismatch DNA
2LFI	;		;	Solution NMR structure of a MucBP domain (fragment 187-294) of the protein LBA1460 from Lactobacillus acidophilus, Northeast structural genomics consortium target LaR80A
6QJY	;		;	Solution NMR structure of a mutant major ampullate spidroin 1 N-terminal domain
5ZCN	;		;	Solution NMR structure of a new lasso peptide brevunsin
6AK0	;		;	Solution NMR structure of a new lasso peptide specialicin
5GVO	;		;	Solution NMR structure of a new lasso peptide sphaericin
5XM4	;		;	Solution NMR structure of a new lasso peptide subterisin
2LS6	;		;	Solution NMR Structure of a Non-canonical galactose-binding CBM32 from Clostridium perfringens
2MW7	;		;	Solution NMR structure of a novel cysteine framework containing Conus peptide Mo3964
2KHQ	;		;	Solution NMR structure of a phage integrase SSP1947 fragment 59-159 from Staphylococcus saprophyticus, Northeast Structural Genomics Consortium Target SyR103B
2LXF	;		;	Solution NMR structure of a potential acylphosphatase from Giardia lamblia, Seattle Structural Genomics Center for Infectious Disease target GilaA.01396.a
2MIY	;		;	Solution NMR structure of a preQ1 Class II riboswitch from Streptococcus pneumoniae
2LCH	;		;	Solution NMR Structure of a Protein With a Redesigned Hydrophobic Core, Northeast Structural Genomics Consortium Target OR38
6ALI	;		;	Solution NMR structure of a putative thioredoxin (ECH_0218) in the oxidized state from Ehrlichia chaffeensis, the etiological agent responsible for human monocytic ehrlichiosis. Seattle Structural Genomics Center for Infectious Disease target EhchA.00546.a
6AMR	;		;	Solution NMR structure of a putative thioredoxin (ECH_0218) in the reduced state from Ehrlichia chaffeensis, the etiological agent responsible for human monocytic ehrlichiosis. Seattle Structural Genomics Center for Infectious Disease target EhchA.00546.a
6MZA	;		;	Solution NMR structure of a putative thioredoxin (trxA) in the reduced state from Rickettsia prowazekii, the etiological agent responsible for typhus. Seattle Structural Genomics Center for Infectious Disease target RiprA.00029.a
2L3F	;		;	Solution NMR Structure of a putative Uracil DNA glycosylase from Methanosarcina acetivorans, Northeast Structural Genomics Consortium Target MvR76
6OQH	;		;	Solution NMR structure of a quiet outer membrane protein G Nanopore (OmpG mutant: Delta-L6-D215)
8TB1	;		;	Solution NMR structure of a RiPP proteusin precursor protein
2LUG	;		;	Solution NMR structure of a S72-S107 peptide of 18.5kDa murine myelin basic protein (MBP) in association with dodecylphosphocholine micelles
2KQ5	;		;	Solution NMR structure of a section of the repeat domain of the type III effector protein PthA
2A9L	;		;	SOLUTION NMR STRUCTURE OF A SUBSTRATE FOR THE ARCHAEAL PRE-TRNA SPLICING ENDONUCLEASES: THE BULGE-HELIX-BULGE MOTIF, MINIMIZED AVERAGE STRUCTURE
2LEK	;		;	Solution NMR structure of a Thiamine Biosynthesis (ThiS) Protein RPA3574 from Rhodopseudomonas palustris refined with NH RDCs. Northeast Structural Genomics Consortium target RpR325
2NEO	;		;	SOLUTION NMR STRUCTURE OF A TWO-BASE DNA BULGE COMPLEXED WITH AN ENEDIYNE CLEAVING ANALOG, 11 STRUCTURES
1YFC	;		;	Solution nmr structure of a yeast iso-1-ferrocytochrome C
2KZX	;		;	Solution NMR Structure of A3DHT5 from Clostridium thermocellum, Northeast Structural Genomics Consortium Target CmR116
8AHK	;		;	Solution NMR structure of AG41, a 41-amino acid insecticidal protein extracted from Medicago truncatula
1MR0	;		;	SOLUTION NMR STRUCTURE OF AGRP(87-120; C105A)
2K4Z	;		;	Solution NMR Structure of Allochromatium vinosum DsrR: Northeast Structural Genomics Consortium Target OP5
8OJR	;		;	Solution NMR Structure of Alpha-Synuclein 1-25 Peptide in 50% TFE.
2MI7	;		;	Solution NMR structure of alpha3Y
2LJW	;		;	Solution NMR structure of Alr2454 protein from Nostoc sp. strain PCC 7120, Northeast Structural Genomics Consortium Target NsR264
1BJB	;		;	SOLUTION NMR STRUCTURE OF AMYLOID BETA[E16], RESIDUES 1-28, 14 STRUCTURES
1BJC	;		;	SOLUTION NMR STRUCTURE OF AMYLOID BETA[F16], RESIDUES 1-28, 15 STRUCTURES
1AFZ	;		;	SOLUTION NMR STRUCTURE OF AN 11 BASE-PAIR OLIGONUCLEOTIDE FROM THE HUMAN N-RAS PROTOONCOGENE ENCODING FOR AMINO ACIDS 11-13 OF P21, MINIMIZED AVERAGE STRUCTURE
1KOS	;		;	SOLUTION NMR STRUCTURE OF AN ANALOG OF THE YEAST TRNA PHE T STEM LOOP CONTAINING RIBOTHYMIDINE AT ITS NATURALLY OCCURRING POSITION
7LZL	;		;	Solution NMR structure of an avian defensin, AvBD3, from mallard
2KKV	;		;	Solution NMR structure of an integrase domain from protein SPA4288 from Salmonella enterica, Northeast Structural Genomics Consortium Target SlR105H
2KIF	;		;	Solution NMR structure of an O6-methylguanine DNA methyltransferase family protein from Vibrio parahaemolyticus. Northeast Structural Genomics Consortium target VpR247.
1GUC	;		;	SOLUTION NMR STRUCTURE OF AN RNA WITH TANDEM, SYMMETRIC GU MISMATCHES, 30 STRUCTURES
2N9B	;		;	Solution NMR Structure of Antiparallel Myosin-10:GCN4 Tandem Coiled-Coil
2KSH	;		;	Solution NMR structure of apo Sterol Carrier Protein - 2 from Aedes aegypti (AeSCP-2)
2LTD	;		;	Solution NMR Structure of apo YdbC from Lactococcus lactis, Northeast Structural Genomics Consortium (NESG) Target KR150
2L53	;		;	Solution NMR Structure of apo-calmodulin in complex with the IQ motif of Human Cardiac Sodium Channel NaV1.5
6YHI	;		;	Solution NMR Structure of APP G38L mutant TMD
6YHO	;		;	Solution NMR Structure of APP G38P mutant TM
6YHX	;		;	Solution NMR Structure of APP I45T mutant TMD
6YHF	;		;	Solution NMR Structure of APP TMD
6YHP	;		;	Solution NMR Structure of APP V44M mutant TMD
7P2K	;		;	Solution NMR Structure of Arginine to Cysteine mutant of Arkadia RING domain.
2KRX	;		;	Solution NMR Structure of asl3597 from Nostoc sp. PCC7120. Northeast Structural Genomics Consortium Target ID Nsr244.
2LQA	;		;	Solution NMR structure of Asteropsin A from marine sponge Asteropus sp.
2LZX	;		;	Solution NMR structure of Asteropsin B from a marine sponge Asteropus sp.
2LZY	;		;	Solution NMR structure of asteropsin c from a marine sponge asteropus sp.
2N2G	;		;	SOLUTION NMR STRUCTURE of ASTEROPSIN F FROM MARINE SPONGE ASTEROPUS
2N3P	;		;	SOLUTION NMR STRUCTURE of ASTEROPSIN G from MARINE SPONGE ASTEROPUS
1YDU	;		;	Solution NMR structure of At5g01610, an Arabidopsis thaliana protein containing DUF538 domain
1AX3	;		;	SOLUTION NMR STRUCTURE OF B. SUBTILIS IIAGLC, 16 STRUCTURES
2KC7	;		;	Solution NMR structure of Bacteroides fragilis protein BF1650. Northeast Structural Genomics Consortium target BfR218
7SAG	;		;	Solution NMR structure of barrettide C
2KN1	;		;	Solution NMR Structure of BCMA
6B7G	;		;	Solution NMR structure of BCoR in complex with AF9 (BCoR-AF9)
2MJ7	;		;	Solution NMR structure of beta-adaptin appendage domain of human adaptor protein complex 4 subunit beta, Northeast Structural Genomics Consortium (NESG) Target HR8998C
2LIO	;		;	Solution NMR Structure of BfR322 from Bacteroides fragilis, Northeast Structural Genomics Consortium Target BfR322
2JZ8	;		;	Solution NMR structure of BH09830 from Bartonella henselae modeled with one Zn+2 bound. Northeast Structural Genomics Consortium target BnR55
2KA1	;		;	Solution NMR structure of BNIP3 transmembrane peptide dimer in detergent micelles
2KA2	;		;	Solution NMR structure of BNIP3 transmembrane peptide dimer in detergent micelles with His173-Ser172 intermonomer hydrogen bond restraints
2JS4	;		;	Solution NMR Structure of Bordetella bronchiseptica protein BB2007. Northeast Structural Genomics Consortium target BoR54
2K2E	;		;	Solution NMR structure of Bordetella pertussis protein BP2786, a Mth938-like domain. Northeast Structural Genomics Consortium target BeR31
1BVM	;		;	SOLUTION NMR STRUCTURE OF BOVINE PANCREATIC PHOSPHOLIPASE A2, 20 STRUCTURES
1L7B	;		;	Solution NMR Structure of BRCT Domain of T. Thermophilus: Northeast Structural Genomics Consortium Target WR64TT
6BGH	;		;	Solution NMR structure of Brd3 ET domain bound to Brg1 peptide
2L5Q	;		;	Solution NMR Structure of BVU_3817 from Bacteroides vulgatus, Northeast Structural Genomics Consortium Target BvR159
2K2D	;		;	Solution NMR structure of C-terminal domain of human pirh2. Northeast Structural Genomics Consortium (NESG) target HT2C
2LLL	;		;	Solution NMR structure of C-terminal globular domain of human Lamin-B2, Northeast Structural Genomics Consortium target HR8546A
1L7Y	;		;	Solution NMR Structure of C. elegans Protein ZK652.3. NORTHEAST STRUCTURAL GENOMICS CONSORTIUM TARGET WR41.
2LV2	;		;	Solution NMR structure of C2H2-type Zinc-fingers 4 and 5 from human Insulinoma-associated protein 1 (fragment 424-497), Northeast Structural Genomics Consortium Target HR7614B
1MUX	;		;	SOLUTION NMR STRUCTURE OF CALMODULIN/W-7 COMPLEX: THE BASIS OF DIVERSITY IN MOLECULAR RECOGNITION, 30 STRUCTURES
2LUZ	;		;	Solution NMR Structure of CalU16 from Micromonospora echinospora, Northeast Structural Genomics Consortium (NESG) Target MiR12
2LL6	;		;	Solution NMR structure of CaM bound to iNOS CaM binding domain peptide
2LL7	;		;	Solution NMR structure of CaM bound to the eNOS CaM binding domain peptide
2JRS	;		;	Solution NMR Structure of CAPER RRM2 Domain. Northeast Structural Genomics Target HR4730A
2LR8	;		;	Solution NMR Structure of CASP8-associated protein 2 from Homo sapiens, Northeast Structural Genomics Consortium (NESG) Target HR8150A
6FFQ	;		;	Solution NMR structure of CBM64 from S.thermophila
6FFU	;		;	Solution NMR structure of CBM64 from S.thermophila using 20% 13C, 100% 15N
2N4Q	;		;	Solution NMR structure of CBX8 in complex with AF9 (CBX8-AF9)
2JQN	;		;	Solution NMR structure of CC0527 from Caulobacter crescentus. Northeast Structural Genomics Target CCR55
7KNV	;		;	Solution NMR structure of CDHR3 extracellular domain EC1
8X3A	;		;	Solution NMR structure of cellulosomal double-dockerin module of Clo1313_0689 from Clostridium thermocellum
2K8Y	;		;	Solution NMR Structure of Cgi121 from Methanococcus jannaschii. Northeast Structural Genomics Consortium Target MJ0187
2L3G	;		;	Solution NMR Structure of CH domain of Rho guanine nucleotide exchange factor 7 from Homo sapiens, Northeast Structural Genomics Consortium Target HR4495E
2MF6	;		;	Solution NMR structure of Chimeric Avidin, ChiAVD(I117Y), in the biotin bound form
8K3N	;		;	Solution NMR structure of cis X-Pro peptide bond conformer of a single disulfide conopeptide Mo1853
2KOB	;		;	Solution NMR structure of CLOLEP_01837 (fragment 61-160) from Clostridium leptum. Northeast Structural Genomics Consortium Target QlR8A
1IIY	;		;	Solution NMR Structure of Complex of 1:2 Cyanovirin-N:Man-Alpha1,2-Man-Alpha Restrained Regularized Mean Coordinates
2L7Q	;		;	Solution NMR structure of conjugate transposon protein BVU_1572(27-141) from Bacteroides Vulgatus, Northeast Structural Genomics Consortium Target BvR155
6CEI	;		;	Solution NMR Structure of Conotoxin GXIA from Conus geographus
2HGA	;		;	Solution NMR Structure of Conserved protein MTH1368, Northeast Structural Genomics Consortium Target TT821A
2N24	;		;	Solution NMR structure of Contryphan-Vc1
2KZV	;		;	Solution NMR structure of CV_0373(175-257) protein from Chromobacterium violaceum, Northeast Structural Genomics Consortium Target CvR118A
2EZN	;		;	SOLUTION NMR STRUCTURE OF CYANOVIRIN-N ENSEMBLE OF 40 SIMULATED ANNEALING STRUCTURES
2EZM	;		;	SOLUTION NMR STRUCTURE OF CYANOVIRIN-N, RESTRAINED REGULARIZED MEAN COORDINATES
2KW6	;		;	Solution NMR Structure of Cyclin-dependent kinase 2-associated protein 1 (CDK2-associated protein 1; oral cancer suppressor Deleted in oral cancer 1, DOC-1) from H.sapiens, Northeast Structural Genomics Consortium Target Target HR3057H
2M1L	;		;	Solution NMR Structure of Cyclin-dependent kinase 2-associated protein 2 (CDK2AP2, DOC-1R) from Homo sapiens, Northeast Structural Genomics Consortium (NESG) Target HR8910C
5WOV	;		;	Solution NMR structure of cyclotide MCoTI-I
5WOW	;		;	Solution NMR structure of cyclotide MCoTI-I
6BYV	;		;	Solution NMR structure of cysteine-rich calcium bound domains of very low density lipoprotein receptor
6NJF	;		;	Solution NMR Structure of DANCER3-F34A, a rigid and natively folded single mutant of the dynamic protein DANCER-3
2N2U	;		;	Solution NMR Structure of DE NOVO DESIGNED Ferredoxin Fold PROTEIN sfr3, Northeast Structural Genomics Consortium (NESG) Target OR358
2KL8	;		;	Solution NMR Structure of de novo designed ferredoxin-like fold protein, Northeast Structural Genomics Consortium Target OR15
2LSE	;		;	Solution NMR Structure of De Novo Designed Four Helix Bundle Protein, Northeast Structural Genomics Consortium (NESG) Target OR188
2MTL	;		;	Solution NMR Structure of De novo designed FR55, Northeast Structural Genomics Consortium (NESG) Target OR109
5GAJ	;		;	Solution NMR structure of De novo designed PLOOP2X3_50 fold protein, Northeast Structural Genomics Consortium (NESG) target OR258
2N2T	;		;	Solution NMR Structure of DE NOVO DESIGNED PROTEIN (FDA_60), Northeast Structural Genomics Consortium (NESG) Target OR303
7M5T	;		;	Solution NMR structure of de novo designed protein 0515
2MQ8	;		;	Solution NMR Structure of De novo designed protein LFR1 1 with ferredoxin fold, Northeast Structural Genomics Consortium (NESG) Target OR414
2N76	;		;	Solution NMR Structure of De novo designed protein LFR1 1 with ferredoxin fold, Northeast Structural Genomics Consortium (NESG) Target OR414
2N41	;		;	Solution NMR Structure of DE NOVO DESIGNED PROTEIN Top7NNSTYCC, Northeast Structural Genomics Consortium (NESG) Target OR34
2N4E	;		;	Solution NMR Structure of DE NOVO DESIGNED PROTEIN Top7NNSTYCC, Northeast Structural Genomics Consortium (NESG) Target OR34
2LN3	;		;	Solution NMR Structure of DE NOVO DESIGNED PROTEIN, IF3-like fold, Northeast Structural Genomics Consortium Target OR135 (CASD target)
2MR5	;		;	Solution NMR Structure of De novo designed Protein, Northeast Structural Genomics Consortium (NESG) Target OR457
2MRA	;		;	Solution NMR Structure of De novo designed protein, Northeast Structural Genomics Consortium (NESG) Target OR459
2MR6	;		;	Solution NMR Structure of De novo designed protein, Northeast Structural Genomics Consortium (NESG) Target OR462
2LR0	;		;	Solution NMR structure of de novo designed protein, p-loop ntpase fold, northeast structural genomics consortium target or136
2LRH	;		;	Solution NMR structure of de novo designed protein, p-loop ntpase fold, Northeast Structural Genomics Consortium target or137
2L69	;		;	Solution NMR Structure of de novo designed protein, P-loop NTPase fold, Northeast Structural Genomics Consortium Target OR28
2L82	;		;	Solution NMR Structure of de novo designed protein, P-loop NTPase fold, Northeast Structural Genomics Consortium Target OR32
2LCI	;		;	Solution NMR Structure of DE NOVO DESIGNED PROTEIN, P-LOOP NTPASE FOLD, Northeast Structural Genomics Consortium Target OR36 (CASD Target)
2LND	;		;	Solution NMR Structure of DE NOVO DESIGNED PROTEIN, PFK fold, Northeast Structural Genomics Consortium Target OR134
2LTA	;		;	Solution NMR structure of De novo designed protein, rossmann 3x1 fold, Northeast Structural Genomics Consortium target OR157
2N3Z	;		;	Solution NMR Structure of de novo designed protein, Rossmann2x2 Fold, Northeast Structural Genomics Consortium (NESG) Target OR446
2N75	;		;	Solution NMR Structure of De novo designed protein, Rossmann2x2 Fold, Northeast Structural Genomics Consortium (NESG) Target OR446
2KPO	;		;	Solution NMR structure of de novo designed rossmann 2x2 fold protein, Northeast Structural Genomics Consortium target OR16
6XEH	;		;	Solution NMR Structure of DE NOVO DESIGNED Rossmann 2x3 Fold Protein r2x3_168, Northeast Structural Genomics Consortium (NESG) Target OR386
7KBQ	;		;	Solution NMR Structure of DE NOVO DESIGNED Rossmann 3x3 Fold Protein r3x3_bp3, Northeast Structural Genomics Consortium (NESG) Target OR689
6X1K	;		;	Solution NMR structure of de novo designed TMB2.3
2MBL	;		;	Solution NMR Structure of De novo designed Top7 Fold Protein Top7m13, Northeast Structural Genomics Consortium (NESG) Target OR33
2MBM	;		;	Solution NMR Structure of De novo designed Top7 Fold Protein Top7m13, Northeast Structural Genomics Consortium (NESG) Target OR33
6LLQ	;		;	Solution NMR structure of de novo Rossmann2x2 fold with most of the core mutated to valine, R2x2_VAL88
5KPH	;		;	Solution NMR Structure of Denovo Beta Sheet Design Protein, Northeast Structural Genomics Consortium (NESG) Target OR485
5KPE	;		;	Solution NMR Structure of Denovo Beta Sheet Design Protein, Northeast Structural Genomics Consortium (NESG) Target OR664
7JS6	;		;	Solution NMR structure of des-citrulassin F
8T62	;		;	Solution NMR structure of designed peptide BH21 (TMIEDPEAGHFHTSSA)
8TXS	;		;	Solution NMR structure of designed peptide BH26 (RGVTVPHNGESKDYSV)
8T61	;		;	Solution NMR structure of designed peptide BH33 (RHYYKFNSTGRHYHYY)
8T63	;		;	Solution NMR structure of designed peptide PH1 (WHMWNTVPNAKQVIAA)
2N8I	;		;	Solution NMR Structure of Designed Protein DA05, Northeast Structural Genomics Consortium (NESG) Target OR626
2N8W	;		;	Solution NMR Structure of Designed Protein DA05R1, Northeast Structural Genomics Consortium (NESG) Target OR690
6V88	;		;	Solution NMR structure of Dictyostelium discoideum Skp1A (truncated) dimer
2LFD	;		;	Solution NMR structure of Diiron protein in presence of 2 eq Zn2+, Northeast Structural Genomics Consortium Target OR21
2K8S	;		;	Solution NMR structure of dimeric thioredoxin-like protein NE0084 from Nitrosomonas europea: Northeast Structural Genomics Target NeT6
2MO2	;		;	Solution NMR structure of DNA dodecamer containing the 5-hydroxycytosine
2MO7	;		;	Solution NMR structure of DNA dodecamer with A:C mismatch
5X1X	;		;	Solution NMR Structure of DNA Mismatch Repair Protein MutT (Family Nudix Hydrolase) from Methicillin Resistant Staphylococcus aureus 252
8XEQ	;		;	Solution NMR structure of DNA sequence d(CGATCG)2
7CFV	;		;	Solution NMR structure of DnaX mini intein from Spirulina platensis
1OP1	;		;	Solution NMR structure of domain 1 of receptor associated protein
2F88	;		;	Solution NMR structure of domain 5 from the Pyaiella littoralis (PL) group II intron
2MV7	;		;	Solution NMR structure of DOT1L in complex with AF9 (DOT1L-AF9)
2L33	;		;	Solution NMR Structure of DRBM 2 domain of Interleukin enhancer-binding factor 3 from Homo sapiens, Northeast Structural Genomics Consortium Target HR4527E
5OAP	;		;	Solution NMR structure of DREB2A(255-272) bound to RCD1-RST
2K74	;		;	Solution NMR structure of DsbB-ubiquinone complex
2KYI	;		;	Solution NMR structure of Dsy0195(21-82) protein from Desulfitobacterium Hafniense. Northeast Structural Genomics Consortium Target DhR8C
2N2F	;		;	Solution NMR structure of Dynorphin 1-13 bound to Kappa Opioid Receptor
2L5T	;		;	Solution NMR structure of E2 lipoyl domain from Thermoplasma acidophilum
2M9A	;		;	Solution NMR Structure of E3 ubiquitin-protein ligase ZFP91 from Homo sapiens, Northeast Structural Genomics Consortium (NESG) Target HR7784A
6EVI	;		;	solution NMR structure of EB1 C terminus (191-260)
6EVQ	;		;	solution NMR structure of EB1 C terminus (191-260) with a small molecule bound into the SxIP binding site
2EZP	;		;	SOLUTION NMR STRUCTURE OF ECTODOMAIN OF SIV GP41, MODELS 1-10 OF AN ENSEMBLE OF 40 SIMULATED ANNEALING STRUCTURES
2EZQ	;		;	SOLUTION NMR STRUCTURE OF ECTODOMAIN OF SIV GP41, MODELS 11-20 OF AN ENSEMBLE OF 40 SIMULATED ANNEALING STRUCTURES
2EZR	;		;	SOLUTION NMR STRUCTURE OF ECTODOMAIN OF SIV GP41, MODELS 21-30 OF AN ENSEMBLE OF 40 SIMULATED ANNEALING STRUCTURES
2EZS	;		;	SOLUTION NMR STRUCTURE OF ECTODOMAIN OF SIV GP41, MODELS 31-40 OF AN ENSEMBLE OF 40 SIMULATED ANNEALING STRUCTURES
2EZO	;		;	SOLUTION NMR STRUCTURE OF ECTODOMAIN OF SIV GP41, RESTRAINED REGULARIZED MEAN STRUCTURE
1QCE	;		;	SOLUTION NMR STRUCTURE OF ECTODOMAIN OF SIV GP41, RESTRAINED REGULARIZED MEAN STRUCTURE PLUS 29 SIMULATED ANNEALING STRUCTURES
2M7T	;		;	Solution NMR Structure of Engineered Cystine Knot Protein 2.5D
6MM4	;		;	Solution NMR Structure of Engineered Cystine Knot Protein 2.5F
6VGT	;		;	Solution NMR structure of enterococcal cytolysin L (CylLL"") produced by Enterococcus faecalis
6VE9	;		;	Solution NMR structure of enterococcal cytolysin S (CylLS"") produced by Enterococcus faecalis
2KB5	;		;	Solution NMR Structure of Eosinophil Cationic Protein/RNase 3
1EOT	;		;	SOLUTION NMR STRUCTURE OF EOTAXIN, MINIMIZED AVERAGE STRUCTURE
2N9U	;		;	Solution NMR structure of Erythrobacter litoralis PhyR response regulator REC domain
7VQH	;		;	Solution NMR structure of Escherichia coli Total Lipid Extract Bicelle bound VR18 Antimicrobial Peptide
2KD7	;		;	Solution NMR structure of F5/8 type C-terminal domain of a putative chitobiase from Bacteroides thetaiotaomicron. Northeast Structural Genomics Consortium target BtR324B
5LNF	;		;	Solution NMR structure of farnesylated PEX19, C-terminal domain
2L8E	;		;	Solution NMR structure of FCS domain of Human Polyhomeotic Homolog 1 (HPH1)
2K5F	;		;	Solution NMR structure of FeoA protein from Chlorobium tepidum. Northeast Structural Genomics Consortium target CtR121
2KKL	;		;	Solution NMR structure of FHA domain of Mb1858 from Mycobacterium bovis. Northeast Structural Genomics Consortium Target MbR243C (24-155).
2AAV	;		;	Solution NMR structure of Filamin A domain 17
7BQM	;		;	Solution NMR structure of fold-0 Chantal; de novo designed protein with an asymmetric all-alpha topology
7BQN	;		;	Solution NMR structure of fold-C Rei; de novo designed protein with an asymmetric all-alpha topology
7BQR	;		;	Solution NMR structure of fold-K Mussoc; de novo designed protein with an asymmetric all-alpha topology
7BQS	;		;	Solution NMR structure of fold-U Nomur; de novo designed protein with an asymmetric all-alpha topology
7BQQ	;		;	Solution NMR structure of fold-Z Gogy; de novo designed protein with an asymmetric all-alpha topology
8AOU	;		;	Solution NMR structure of full-length Nsp1 from SARS-CoV-2.
2M33	;		;	Solution NMR structure of full-length oxidized microsomal rabbit cytochrome b5
2LFC	;		;	Solution NMR Structure of Fumarate reductase flavoprotein subunit from Lactobacillus plantarum, Northeast Structural Genomics Consortium Target LpR145J
5TLR	;		;	Solution NMR structure of gHwTx-IV
2LXN	;		;	Solution NMR structure of glutamine amido transferase subunit of gaunosine monophosphate synthetase from Methanocaldococcus jannaschii
2MK3	;		;	Solution NMR structure of gp41 ectodomain monomer on a DPC micelle
2KTM	;		;	Solution NMR structure of H2H3 domain of ovine prion protein (residues 167-234)
7QIL	;		;	Solution NMR structure of halophilic DnaE intein
2JY0	;		;	Solution NMR structure of HCV NS2 protein, membrane segment (1-27)
7MLA	;		;	Solution NMR structure of HDMX in complex with Zn and MCo-52-2
2LDU	;		;	Solution NMR Structure of Heat shock factor protein 1 DNA binding domain from homo sapiens, Northeast Structural Genomics Consortium Target HR3023C
7UQT	;		;	Solution NMR structure of hexahistidine tagged QseM (6H-QseM)
2JUZ	;		;	Solution NMR structure of HI0947 from Haemophilus influenzae, Northeast Structural Genomics Consortium Target IR123
5VEY	;		;	Solution NMR structure of histone H2A-H2B mono-ubiquitylated at H2A Lys15 in complex with RNF169 (653-708)
5MPG	;		;	Solution NMR structure of hnRNP A1 RRM1 in complex with 5'-UUAGGUC-3' RNA
2LML	;		;	Solution NMR structure of holo acyl carrier protein from geobacter Metallireducens refined with nh rdcs, Northeast Structural Genomics consortium target gmr141
2LKI	;		;	Solution NMR structure of holo acyl carrier protein NE2163 from nitrosomonas europaea. Northeast structural genomics consortium target NET1.
2LY9	;		;	Solution NMR Structure of Homeobox 2 Domain from Human ZHX1 repressor, Northeast Structural Genomics Consortium (NESG) Target HR7907F
2LK2	;		;	Solution NMR structure of homeobox domain (171-248) of human homeobox protein TGIF1, Northeast Structural Genomics Consortium Target HR4411B
2L9R	;		;	Solution NMR Structure of Homeobox domain of Homeobox protein Nkx-3.1 from homo sapiens, Northeast Structural Genomics Consortium Target HR6470A
2M0C	;		;	Solution NMR Structure of Homeobox Domain of Human ALX4, Northeast Structural Genomics Consortium (NESG) Target HR4490C
2JR2	;		;	Solution NMR structure of homodimer CPS_2611 from Colwellia psychrerythraea. Northeast Structural Genomics Consortium target CsR4.
2L3A	;		;	Solution NMR structure of homodimer protein SP_0782 (7-79) from Streptococcus pneumoniae Northeast Structural Genomics Consortium Target SpR104 .
2JPQ	;		;	Solution NMR structure of homodimer VP2129 from Vibrio parahaemolyticus. Northeast Structural Genomics Consortium target VpR61.
2LF6	;		;	Solution NMR structure of HopABPph1448_220_320 from Pseudomonas syringae pv. phaseolicola str. 1448A, Midwest Center for Structural Genomics target APC40132.4 and Northeast Structural Genomics Consortium target PsT3A
2LF3	;		;	Solution NMR structure of HopPmaL_281_385 from Pseudomonas syringae pv. maculicola str. ES4326, Midwest Center for Structural Genomics target APC40104.5 and Northeast Structural Genomics Consortium target PsT2A
2K9Q	;		;	Solution NMR structure of HTH_XRE family transcriptional regulator BT_p548217 from Bacteroides thetaiotaomicron. Northeast Structural Genomics Consortium Target BtR244.
2L86	;		;	Solution NMR structure of human amylin in SDS micelles at pH 7.3
6CKV	;		;	Solution NMR structure of human BOK
7JYN	;		;	Solution NMR structure of human Brd3 ET complexed with NSD3(148-184) peptide
7JMY	;		;	Solution NMR structure of human Brd3 ET domain
7JQ8	;		;	Solution NMR structure of human Brd3 ET domain
8V9U	;		;	Solution NMR structure of human DNMT1 N-terminal alpha-helical domain
2K07	;		;	Solution NMR structure of human E2-like ubiquitin-fold modifier conjugating enzyme 1 (UFC1). Northeast Structural Genomics Consortium target HR41
5O9B	;		;	Solution NMR structure of human GATA2 C-terminal zinc finger domain
6ZFV	;		;	Solution NMR structure of human GATA2 N-terminal zinc finger domain
5KNW	;		;	Solution NMR structure of human LARP7 xRRM2
2JS7	;		;	Solution NMR structure of human myeloid differentiation primary response (MyD88). Northeast Structural Genomics target HR2869A
2L76	;		;	Solution NMR structure of human NFATC2IP ubiquitin-like domain, NFATC2IP_244_338, NESG target HT65A/OCSP target hs00387_244_338/SGC-toronto
2L0F	;		;	Solution NMR structure of human polymerase iota UBM2 (P692A mutant) in complex with ubiquitin
2KTF	;		;	Solution NMR structure of human polymerase iota UBM2 in complex with ubiquitin
2KEO	;		;	Solution NMR structure of human protein HS00059, cytochrome-b5-like domain of the HERC2 E3 ligase. Northeast structural genomics consortium (NESG) target ht98a
1XPW	;		;	Solution NMR Structure of human protein HSPCO34. Northeast Structural Genomics Target HR1958
5VF0	;		;	Solution NMR structure of human RAD18 (198-240) in complex with ubiquitin
2MV1	;		;	Solution NMR structure of Human Relaxin-2
5VZM	;		;	Solution NMR structure of human Rev1 (932-1039) in complex with ubiquitin
1DVD	;		;	SOLUTION NMR STRUCTURE OF HUMAN STEFIN A AT PH 5.5 AND 308K, NMR, 17 STRUCTURES
1DVC	;		;	SOLUTION NMR STRUCTURE OF HUMAN STEFIN A AT PH 5.5 AND 308K, NMR, MINIMIZED AVERAGE STRUCTURE
2LW4	;		;	Solution NMR Structure of Human Transcription Elongation Factor A protein 2, Central Domain, Northeast Structural Genomics Consortium (NESG) Target HR8682B
2L2D	;		;	Solution NMR Structure of human UBA-like domain of OTUD7A_11_83, NESG target HT6304A/OCSP target OTUD7A_11_83/SGC-Toronto
2KVR	;		;	Solution NMR structure of human ubiquitin specific protease Usp7 UBL domain (residues 537-664). NESG target hr4395c/ SGC-Toronto
5GIW	;		;	Solution NMR structure of Humanin containing a D-isomerized serine residue
1PAV	;		;	SOLUTION NMR STRUCTURE OF HYPOTHETICAL PROTEIN TA1414 OF THERMOPLASMA ACIDOPHILUM
2LU7	;		;	Solution NMR Structure of Ig like domain (1277-1357) of Obscurin-like protein 1 from Homo sapiens, Northeast Structural Genomics Consortium (NESG) Target HR8578D
2LVC	;		;	Solution NMR Structure of Ig like domain (805-892) of Obscurin-like protein 1 from Homo sapiens, Northeast Structural Genomics Consortium (NESG) Target HR8578K
7SJL	;		;	Solution NMR Structure of Immunoglobulin-like Domain of Human Neuregulin-1
2K73	;		;	Solution NMR structure of integral membrane protein DsbB
6CGW	;		;	Solution NMR structure of JzTx-V, a Nav 1.7 inhibitory peptide
5ZYX	;		;	Solution NMR structure of K30 peptide in 10 mM dioctanoyl phosphatidylglycerol (D8PG)
8UBH	;		;	Solution NMR structure of KaiB variant from Thermosynechococcus elongatus vestitus (KaiBTV-4)
2LT7	;		;	Solution NMR structure of Kaiso zinc finger DNA binding domain in complex with Kaiso binding site DNA
2KCX	;		;	Solution NMR Structure of Kazal-1 Domain of Human Follistatin-related protein 3 (FSTL-3). Northeast Structural Genomics Target HR6186A.
5UI6	;		;	Solution NMR Structure of Lasso Peptide Acinetodin
5UI7	;		;	Solution NMR Structure of Lasso Peptide Klebsidin
2NBM	;		;	Solution NMR structure of ligand free sterol carrier protein 2 like 2 from Aedes aegypti
2KPP	;		;	Solution NMR structure of Lin0431 protein from Listeria innocua. Northeast Structural Genomics Consortium Target LkR112
2MFN	;		;	SOLUTION NMR STRUCTURE OF LINKED CELL ATTACHMENT MODULES OF MOUSE FIBRONECTIN CONTAINING THE RGD AND SYNERGY REGIONS, 10 STRUCTURES
1MFN	;		;	SOLUTION NMR STRUCTURE OF LINKED CELL ATTACHMENT MODULES OF MOUSE FIBRONECTIN CONTAINING THE RGD AND SYNERGY REGIONS, 20 STRUCTURES
2K1G	;		;	Solution NMR structure of lipoprotein spr from Escherichia coli K12. Northeast Structural Genomics target ER541-37-162
2LM1	;		;	Solution NMR Structure of Lysine-specific demethylase lid from Drosophila melanogaster, Northeast Structural Genomics Consortium Target FR824D
2K4M	;		;	Solution NMR Structure of M. thermoautotrophicum protein MTH_1000, Northeast Structural Genomics Consortium Target TR8
2MV0	;		;	Solution NMR Structure of Maltose-binding protein from Escherichia coli, Northeast Structural Genomics Consortium (NESG) Target ER690
2MS8	;		;	Solution NMR structure of MAVS CARD
7OVZ	;		;	SOLUTION NMR STRUCTURE OF MAXIMIN 1 IN 50% TRIFLUOROETHANOL
6HZ2	;		;	SOLUTION NMR STRUCTURE OF MAXIMIN 3 IN 50% TRIFLUOROETHANOL
2L6U	;		;	Solution NMR Structure of Med25(391-543) Comprising the Activator-Interacting Domain (ACID) of Human Mediator Subuniti 25. Northeast Structural Genomics Consortium Target HR6188A
2M9X	;		;	Solution NMR Structure of Microtubule-associated serine/threonine-protein kinase 1 from Homo sapiens, Northeast Structural Genomics Consortium (NESG) Target HR9151A
2LM4	;		;	Solution NMR Structure of mitochondrial succinate dehydrogenase assembly factor 2 from Saccharomyces cerevisiae, Northeast Structural Genomics Consortium Target YT682A
2LAH	;		;	Solution NMR Structure of Mitotic checkpoint serine/threonine-protein kinase BUB1 N-terminal domain from Homo sapiens, Northeast Structural Genomics Consortium Target HR5460A (Methods Development)
2RVF	;		;	Solution NMR structure of Monosiga brevicollis CRK/CRKL homolog (crka1) SH2 domain
2KZ8	;		;	Solution NMR structure of MqsA, a protein from E. coli, containing a Zinc finger, N-terminal and a Helix Turn-Helix C-terminal domain
2KT7	;		;	Solution NMR structure of mucin-binding domain of protein lmo0835 from Listeria monocytogenes, Northeast Structural Genomics Consortium Target LmR64A
2L2E	;		;	Solution NMR structure of myristoylated NCS1p in apo form
7Z0B	;		;	Solution NMR structure of N-acetylglucosaminyltransferase V (GnTV) G22L and G26L double mutant TMD
7Z08	;		;	Solution NMR structure of N-acetylglucosaminyltransferase V (GnTV) G22L mutant TMD
7Z07	;		;	Solution NMR structure of N-acetylglucosaminyltransferase V (GnTV) G26P mutant TMD
7YYI	;		;	Solution NMR structure of N-acetylglucosaminyltransferase V (GnTV) TMD
2LNB	;		;	Solution NMR structure of N-terminal domain (6-74) of human ZBP1 protein, Northeast Structural Genomics Consortium Target HR8174A.
2MK2	;		;	Solution NMR structure of N-terminal domain (SH2 domain) of human Inositol polyphosphate phosphatase-like protein 1 (INPPL1) (fragment 20-117), Northeast Structural Genomics Consortium Target HR9134A
2LFE	;		;	Solution NMR structure of N-terminal domain of human E3 ubiquitin-protein ligase HECW2, Northeast structural genomics consortium (NESG) target ht6306A
2K2C	;		;	Solution NMR structure of N-terminal domain of human pirh2. Northeast Structural Genomics Consortium (NESG) target HT2A
2LEZ	;		;	Solution NMR structure of N-terminal domain of Salmonella effector protein PipB2. Northeast structural genomics consortium (NESG) target stt318a
8GS7	;		;	SOLUTION NMR STRUCTURE OF N-TERMINAL DOMAIN OF TRICONEPHILA CLAVIPES MAJOR AMPULLATE SPIDROIN 2
2L7R	;		;	Solution NMR structure of N-terminal Ubiquitin-like domain of FUBI, a ribosomal protein S30 precursor from Homo sapiens. NorthEast Structural Genomics consortium (NESG) target HR6166
5UB0	;		;	Solution NMR Structure of NERD-C, a natively folded tetramutant of the B1 domain of streptococcal protein G (GB1)
5UBS	;		;	Solution NMR Structure of NERD-S, a natively folded pentamutant of the B1 domain of streptococcal protein G (GB1) with a solvent-exposed Trp43
7JGX	;		;	Solution NMR structure of neuroVAL, a derived peptide from wasp
7BPL	;		;	Solution NMR structure of NF1; de novo designed protein with a novel fold
7BPM	;		;	Solution NMR structure of NF2; de novo designed protein with a novel fold
7BQE	;		;	Solution NMR structure of NF3; de novo designed protein with a novel fold
7BQC	;		;	Solution NMR structure of NF4; de novo designed protein with a novel fold
7BPP	;		;	Solution NMR structure of NF5; de novo designed protein with a novel fold
7BQB	;		;	Solution NMR structure of NF6; de novo designed protein with a novel fold
7BPN	;		;	Solution NMR structure of NF7; de novo designed protein with a novel fold
7BQD	;		;	Solution NMR structure of NF8 (knot fold); de novo designed protein with a novel fold
2LTM	;		;	Solution NMR Structure of NFU1 Iron-Sulfur Cluster Scaffold Homolog from Homo sapiens, Northeast Structural Genomics Consortium (NESG) Target HR2876B
2LTL	;		;	Solution NMR Structure of NifU-like protein from Saccharomyces cerevisiae, Northeast Structural Genomics Consortium (NESG) Target YR313A
2JZA	;		;	Solution NMR structure of nitrite reductase [NAD(P)H] small subunit from Erwinia carotovora. Northeast Structural Genomics Consortium target EwR120
2L08	;		;	Solution NMR Structure of Nonsense mRNA reducing factor 3A from H. Sapiens, Northeast Structural Genomics Consortium Target HR4714B
2LNC	;		;	Solution NMR structure of Norwalk virus protease
8ORZ	;		;	Solution NMR structure of Notch1 G1740-1743 TMD
8ORY	;		;	Solution NMR structure of Notch1 L1740-1743 TMD
8OR5	;		;	Solution NMR structure of Notch1 TMD
8OS0	;		;	Solution NMR structure of Notch3 WT TMD
2N5Y	;		;	Solution NMR structure of octyl-tridecaptin A1 in DPC micelles containing Gram-negative lipid II
2KF2	;		;	Solution NMR structure of of Streptomyces coelicolor polyketide cyclase SCO5315. Northeast Structural Genomics Consortium target RR365
6QAM	;		;	Solution NMR structure of outer membrane protein AlkL
2N6L	;		;	Solution NMR structure of Outer Membrane Protein G from Pseudomonas aeruginosa
2N6P	;		;	Solution NMR structure of Outer Membrane Protein G P92A mutant from Pseudomonas aeruginosa
1ACW	;		;	SOLUTION NMR STRUCTURE OF P01, A NATURAL SCORPION PEPTIDE STRUCTURALLY ANALOGOUS TO SCORPION TOXINS SPECIFIC FOR APAMIN-SENSITIVE POTASSIUM CHANNEL, 25 STRUCTURES
2LCJ	;		;	Solution NMR structure of Pab PolII Intein
2NBN	;		;	Solution NMR structure of palmitated SCP2L2 from Aedes aegypti
7P4X	;		;	SOLUTION NMR STRUCTURE OF PALUSTRIN-CA IN 50% TRIFLUOROETHANOL
2L79	;		;	Solution NMR structure of PAP248-286 in 30% TFE
2L77	;		;	Solution NMR structure of PAP248-286 in 50% TFE
5WE3	;		;	Solution NMR structure of PaurTx-3
7M25	;		;	Solution NMR Structure of PawL-Derived Peptide PLP-13
7M27	;		;	Solution NMR Structure of PawL-Derived Peptide PLP-16
7M28	;		;	Solution NMR Structure of PawL-Derived Peptide PLP-22
7M29	;		;	Solution NMR Structure of PawL-Derived Peptide PLP-29
7M2A	;		;	Solution NMR Structure of PawL-Derived Peptide PLP-38
7M2B	;		;	Solution NMR Structure of PawL-Derived Peptide PLP-42
7M2C	;		;	Solution NMR Structure of PawL-Derived Peptide PLP-46
7M3U	;		;	Solution NMR Structure of PawS-Derived Peptide PDP-24
2MZ0	;		;	Solution NMR Structure of PDFL2.1 from Arabidopsis thaliana
7RM8	;		;	Solution NMR structure of PDLIM7 PDZ bound to SNX17 peptide
2JT1	;		;	Solution NMR structure of PefI (Plasmid-Encoded Fimbriae Regulatory) protein from Salmonella typhimurium. Northeast Structural Genomics target StR82
7N87	;		;	Solution NMR structure of peptidase domain from Clostridium thermocellum PCAT1
2MOA	;		;	Solution NMR structure of peptide ImI1 (peak 2)
2KZN	;		;	Solution NMR Structure of Peptide methionine sulfoxide reductase msrB from Bacillus subtilis, Northeast Structural Genomics Consortium Target SR10
6M56	;		;	Solution NMR Structure of Peptide P9R
5X0S	;		;	Solution NMR structure of peptide toxin SsTx from Scolopendra subspinipes mutilans
2LUL	;		;	Solution NMR Structure of PH Domain of Tyrosine-protein kinase Tec from Homo sapiens, Northeast Structural Genomics Consortium (NESG) Target HR3504C
2HG7	;		;	Solution NMR structure of Phage-like element PBSX protein xkdW, Northeast Structural Genomics Consortium Target SR355
2MIQ	;		;	Solution NMR Structure of PHD Type 1 Zinc Finger Domain 1 of Lysine-specific Demethylase Lid from Drosophila melanogaster, Northeast Structural Genomics Consortium (NESG) Target FR824J
2MA5	;		;	Solution NMR structure of PHD type Zinc finger domain of Lysine-specific demethylase 5B (PLU-1/JARID1B) from Homo sapiens, Northeast Structural Genomics Consortium (NESG) Target HR7375C
5TBN	;		;	Solution NMR structure of PHF20 PHD domain in complex with a histone H3K4me2 peptide
1N7L	;		;	Solution NMR structure of phospholamban in detergent micelles
2KVO	;		;	Solution NMR structure of Photosystem II reaction center Psb28 protein from Synechocystis sp.(strain PCC 6803), Northeast Structural Genomics Consortium Target SgR171
6I2O	;		;	Solution NMR structure of PilE1 from Streptococcus sanguinis
2RQX	;		;	Solution NMR structure of PMRD from klebsiella pneumoniae
2KT9	;		;	Solution NMR Structure of Probable 30S Ribosomal Protein PSRP-3 (Ycf65-like protein) from Synechocystis sp. (strain PCC 6803), Northeast Structural Genomics Consortium Target Target SgR46
6VJQ	;		;	Solution NMR structure of Prochlorosin 2.1 produced by Prochlorococcus MIT 9313
7JVF	;		;	Solution NMR structure of Prochlorosin 2.10 produced by Prochlorococcus MIT 9313
7JU9	;		;	Solution NMR structure of Prochlorosin 2.11 (Pcn2.11) produced by Prochlorococcus MIT 9313
2LDK	;		;	Solution NMR Structure of Protein AAur_3427 from Arthrobacter aurescens, Northeast Structural Genomics Consortium Target AaR96
2KK4	;		;	Solution NMR structure of protein AF2094 from Archaeoglobus fulgidus. Northeast Structural Genomics Consotium (NESG) target GT2
1NWB	;		;	Solution NMR Structure of Protein AQ_1857 from Aquifex aeolicus: Northeast Structural Genomics Consortium Target QR6.
2L09	;		;	Solution NMR Structure of Protein asr4154 from Nostoc sp. PCC7120 Northeast Structural Genomics Consortium target ID NsR143
2KJZ	;		;	Solution NMR structure of protein ATC0852 from Agrobacterium tumefaciens. Northeast Structural Genomics Consortium (NESG) target AtT2.
2K7I	;		;	Solution NMR structure of protein ATU0232 from AGROBACTERIUM TUMEFACIENS. Northeast Structural Genomics Consortium (NESG) target AtT3. Ontario Center for Structural Proteomics target ATC0223.
2K54	;		;	Solution NMR structure of protein Atu0742 from Agrobacterium Tumefaciens. Northeast Structural Genomics Consortium (NESG0) target AtT8. Ontario Center for Structural Proteomics target ATC0727 .
2K2P	;		;	Solution NMR structure of protein Atu1203 from Agrobacterium tumefaciens. Northeast Structural Genomics Consortium (NESG) target AtT10, Ontario Center for Structural Proteomics target ATC1183
2K0S	;		;	Solution NMR structure of protein BC066483
2L02	;		;	Solution NMR Structure of protein BT2368 from Bacteroides thetaiotaomicron, Northeast Structural Genomics Consortium Target BtR375
2L01	;		;	Solution NMR Structure of protein BVU3908 from Bacteroides vulgatus, Northeast Structural Genomics Consortium Target BvR153
2L7K	;		;	Solution NMR Structure of protein CD1104.2 from Clostridium difficile, Northeast Structural Genomics Consortium Target CfR130
2JN6	;		;	Solution NMR structure of Protein Cgl2762 from Corynebacterium Glutamicum: Northeast Structural Genomics Consortium Target CgR3
2KP6	;		;	Solution NMR structure of protein CV0237 from Chromobacterium violaceum. Northeast Structural Genomics Consortium (NESG) target CvT1
2B95	;		;	Solution NMR structure of protein dynein light chain 2A, cytoplasmic; Northeast structural genomics consortium TARGET HR2106
2K5G	;		;	Solution NMR structure of protein encoded by gene BPP1335 from Bordetella parapertussis: Northeast Structural Genomics Target BpR195
2K5H	;		;	Solution NMR structure of protein encoded by MTH693 from Methanobacterium thermoautotrophicum: Northeast Structural Genomics Consortium target tt824a
2K5L	;		;	Solution NMR Structure of Protein FeoA from Clostridium thermocellum, Northeast Structural Genomics Consortium Target CmR17
2K0Z	;		;	Solution NMR structure of protein hp1203 from Helicobacter pylori 26695. Northeast Structural Genomics Consortium (NESG) target PT1/Ontario Center for Structural Proteomics target hp1203
2L5P	;		;	Solution NMR structure of protein lipocalin 12 from rat epididymis
1RYJ	;		;	Solution NMR Structure of Protein Mth1743 from Methanobacterium thermoautotrophicum. Ontario Centre for Structural Proteomics target MTH1743_1_70; Northeast Structural Genomics Consortium Target TT526.
2FGX	;		;	Solution NMR Structure of Protein Ne2328 from Nitrosomonas europaea. Northeast Structural Genomics Consortium Target NeT3.
1PUZ	;		;	Solution NMR Structure of Protein NMA1147 from Neisseria meningitidis. Northeast Structural Genomics Consortium Target MR19
2KHV	;		;	Solution NMR structure of protein Nmul_A0922 from Nitrosospira multiformis. Northeast Structural Genomics Consortium target NmR38B.
2K8E	;		;	Solution NMR Structure of protein of unknown function yegP from E. coli. Ontario Center for Structural Proteomics target EC0640_1_123 Northeast Structural Genomics Consortium Target ET102.
2HG6	;		;	Solution NMR Structure of Protein PA1123 from Pseudomonas aeruginosa. Northeast Structural Genomics Consortium Target PaT4; Ontario Centre for Structural Proteomics Target PA1123.
2GPF	;		;	Solution NMR Structure of Protein PA22412 from Pseudomonas aeruginosa. Northeast Structural Genomics Consortium Target PaT86, Ontario Centre for Structural Proteomics Target PA2412.
2H3J	;		;	Solution NMR Structure of Protein PA4359 from Pseudomonas aeruginosa: Northeast Structural Genomics Consortium Target PaT89
1S04	;		;	Solution NMR Structure of Protein PF0455 from Pyrococcus furiosus. Northeast Structural Genomics Consortium Target PfR13
2GMG	;		;	Solution NMR Structure of protein PF0610 from Pyrococcus furiosus, Northeast Structural Genomics Consortium Target PfG3
6E4J	;		;	Solution NMR Structure of Protein PF2048.1
2LCG	;		;	Solution NMR structure of protein Rmet_5065 from Ralstonia metallidurans, Northeast Structural Genomics Consortium Target CrR115
2JN4	;		;	Solution NMR Structure of Protein RP4601 from Rhodopseudomonas palustris. Northeast Structural Genomics Consortium Target RpT2; Ontario Center for Structural Proteomics Target RP4601.
2HFV	;		;	Solution NMR Structure of Protein RPA1041 from Pseudomonas aeruginosa. Northeast Structural Genomics Consortium Target PaT90.
2IDA	;		;	Solution NMR Structure of Protein RPA1320 from Rhodopseudomonas Palustris. Northeast Structural Genomics Consortium Target RpT3; Ontario Center for Structural Proteomics Target RP1313.
2L0C	;		;	Solution NMR Structure of protein STY4237 (residues 36-120) from Salmonella enterica, Northeast Structural Genomics Consortium Target SlR115
1X9B	;		;	Solution NMR Structure of Protein Ta0354 from Thermoplasma acidophilum. Ontario Center for Structural Proteomics target TA0354_69_121; Northeast Structural Genomics Consortium Target TaT38.
1X9A	;		;	Solution NMR Structure of Protein Tm0979 from Thermotoga maritima. Ontario Center for Structural Proteomics Target TM0979_1_87; Northeast Structural Genomics Consortium Target VT98.
1LKN	;		;	Solution NMR Structure of Protein TM_1112 from Thermotoga maritima. Ontario Centre for Structural Proteomics Target TM1112_1_89; Northeast Structural Genomics Consortium Target VT74.
2JNY	;		;	Solution NMR structure of protein Uncharacterized BCR, Northeast Structural Genomics Consortium target CgR1
2JRX	;		;	Solution NMR structure of protein YejL from E. coli. Northeast Structural Genomics target ER309
1N91	;		;	Solution NMR Structure of Protein yggU from Escherichia coli. Northeast Structural Genomics Consortium Target ER14.
1YH5	;		;	Solution NMR Structure of Protein yggU from Escherichia coli. Northeast Structural Genomics Consortium Target ER14.
1NYN	;		;	Solution NMR Structure of Protein YHR087W from Saccharomyces cerevisiae. Northeast Structural Genomics Consortium Target YTYST425.
2K3I	;		;	Solution NMR structure of protein yiiS from Shigella flexneri. Northeast Structural Genomics Consortium target SfR90
2HJJ	;		;	Solution NMR structure of protein ykfF from Escherichia coli. Northeast Structural Genomics target ER397.
1WPI	;		;	Solution NMR Structure of Protein YKR049C from Saccharomyces cerevisiae. Ontario Centre for Structural Proteomics target YST0250_1_133; Northeast Structural Genomics Consortium YTYst250
1N6Z	;		;	Solution NMR Structure of Protein YML108W from Saccharomyces cerevisiae. A novel member of the split bab fold. Northeast Structural Genomics Consortium Target YT601.
2GRG	;		;	Solution NMR Structure of Protein YNR034W-A from Saccharomyces cerevisiae. Northeast Structural Genomics Consortium Target YT727; Ontario Center for Structural Proteomics Target yst6499.
1NEI	;		;	Solution NMR Structure of Protein yoaG from Escherichia coli. Ontario Centre for Structural Proteomics Target EC0264_1_60; Northeast Structural Genomics Consortium Target ET94.
2HFI	;		;	Solution NMR Structure of Protein yppE from Bacillus subtilis. Northeast Structural Genomics Consortium Target SR213
2HGK	;		;	Solution NMR Structure of protein YqcC from E. coli: Northeast Structural Genomics Consortium target ER225
1TE7	;		;	Solution NMR Structure of Protein yqfB from Escherichia coli. Northeast Structural Genomics Consortium Target ET99
1XHS	;		;	Solution NMR Structure of Protein ytfP from Escherichia coli. Northeast Structural Genomics Consortium Target ER111.
2KL5	;		;	Solution NMR Structure of protein yutD from B.subtilis, Northeast Structural Genomics Consortium Target SR232
2HC5	;		;	Solution NMR Structure of Protein yvyC from Bacillus subtilis. Northeast Structural Genomics Consortium Target SR482.
2JOZ	;		;	Solution NMR structure of protein yxeF, Northeast Structural Genomics Consortium target Sr500a
2L6X	;		;	Solution NMR Structure of Proteorhodopsin.
7JGY	;		;	Solution NMR structure of protonectin, a peptide from wasp
7JHF	;		;	Solution NMR structure of protonectin-F, a derived peptide from wasp
7VQI	;		;	Solution NMR structure of Pseudomonas aeruginosa Lipopolysaccharide (LPS) Bicelle bound VR18 Antimicrobial Peptide
1YWU	;		;	Solution NMR structure of Pseudomonas Aeruginosa protein PA4608. Northeast Structural Genomics target PaT7
6FIP	;		;	Solution NMR structure of Pseudomonas aeruginosa TonB CTD
2KFP	;		;	Solution NMR structure of PSPTO_3016 from Pseudomonas syringae. Northeast Structural Genomics Consortium target PsR293.
5J3G	;		;	Solution NMR structure of PT-free dsDNA from Streptomyces lividans
8J3N	;		;	Solution NMR structure of purS subunit of phosphoribosylformylglycinamidine synthase enzyme from Staphylococcus aureus
2L0D	;		;	Solution NMR Structure of putative cell surface protein MA_4588 (272-376 domain) from Methanosarcina acetivorans, Northeast Structural Genomics Consortium Target MvR254A
2K5W	;		;	Solution NMR Structure of Putative Lipoprotein from Bacillus cereus Ordered Locus BC_2438. Northeast Structural Genomics Target BcR103A.
2K57	;		;	Solution NMR Structure of Putative Lipoprotein from Pseudomonas syringae Gene Locus PSPTO2350. Northeast Structural Genomics Target PsR76A.
2K5T	;		;	Solution NMR Structure of Putative N-Acetyl Transferase YhhK from E. coli Bound to Coenzyme A: Northeast Structural Genomics Consortium Target ET106
2L9P	;		;	Solution NMR Structure of Q5HLI9 from Staphylococcus epidermidis, Northeast Structural Genomics Consortium Target SeR147
2JRR	;		;	Solution NMR Structure of Q5LLS5 from Silicibacter pomeroyi. Northeast Structural Genomics Consortium target SiR90
2KZW	;		;	Solution NMR Structure of Q8PSA4 from Methanosarcina mazei, Northeast Structural Genomics Consortium Target MaR143A
2GZP	;		;	Solution NMR structure of Q8ZP25 from Salmonella typhimurium LT2; Northeast Structural Genomics Consortium Target STR70
2JZT	;		;	Solution NMR structure of Q8ZP25_SALTY from Salmonella typhimurium. Northeast Structural Genomics Consortium target StR70
2JN8	;		;	Solution NMR structure of Q8ZRJ2 from Salmonella typhimurium. Northeast Structural Genomics target StR65.
2MFU	;		;	Solution NMR structure of quadruplex d(TGGGTTTGGGTTGGGTTTGGG) in sodium conditions
6XN9	;		;	Solution NMR structure of recifin, a cysteine-rich tyrosyl-DNA Phosphodiesterase I modulatory peptide from the marine sponge Axinella sp.
1CYU	;		;	SOLUTION NMR STRUCTURE OF RECOMBINANT HUMAN CYSTATIN A UNDER THE CONDITION OF PH 3.8 AND 310K
1CYV	;		;	SOLUTION NMR STRUCTURE OF RECOMBINANT HUMAN CYSTATIN A UNDER THE CONDITION OF PH 3.8 AND 310K
1JIC	;		;	SOLUTION NMR STRUCTURE OF RECOMBINANT SSO7D WITH RNASE ACTIVITY, MINIMIZED AVERAGE STRUCTURE
1B10	;		;	SOLUTION NMR STRUCTURE OF RECOMBINANT SYRIAN HAMSTER PRION PROTEIN RPRP(90-231) , 25 STRUCTURES
1A24	;		;	SOLUTION NMR STRUCTURE OF REDUCED DSBA FROM ESCHERICHIA COLI, FAMILY OF 20 STRUCTURES
1A23	;		;	SOLUTION NMR STRUCTURE OF REDUCED DSBA FROM ESCHERICHIA COLI, MINIMIZED AVERAGE STRUCTURE
2JVM	;		;	Solution NMR structure of Rhodobacter sphaeroides protein RHOS4_26430. Northeast Structural Genomics Consortium target RhR95
1RCH	;		;	SOLUTION NMR STRUCTURE OF RIBONUCLEASE HI FROM ESCHERICHIA COLI, 8 STRUCTURES
2KCO	;		;	Solution NMR structure of ribosomal protein sso0164 from Sulfolobus solfataricus. Northeast Structural Genomics Consortium (NESG) target SsT4.
2JRM	;		;	Solution NMR structure of ribosome modulation factor VP1593 from Vibrio parahaemolyticus. Northeast Structural Genomics target VpR55
6KRA	;		;	Solution NMR Structure of RMAD4 alpha Defensin
1XV0	;		;	Solution NMR structure of RNA internal loop with three consecutive sheared GA pairs in 5'GGUGGAGGCU/3'PCCGAAGCCG
2LA6	;		;	Solution NMR Structure of RRM domain of RNA-binding protein FUS from homo sapiens, Northeast Structural Genomics Consortium Target HR6430A
1MWN	;		;	Solution NMR structure of S100B bound to the high-affinity target peptide TRTK-12
5TVZ	;		;	Solution NMR structure of Saccharomyces cerevisiae Pom152 Ig-like repeat, residues 718-820
2M46	;		;	Solution NMR structure of SACOL0876 from Staphylococcus aureus COL, NESG target ZR353 and CSGID target IDP00841
2K5D	;		;	SOLUTION NMR STRUCTURE OF SAG0934 from Streptococcus agalactiae. NORTHEAST STRUCTURAL GENOMICS TARGET SaR32[1-108].
2MA8	;		;	Solution NMR Structure of Salmonella typhimurium LT2 Secreted Protein SrfN: Northeast Structural Genomics Consortium Target StR109
2JNA	;		;	Solution NMR Structure of Salmonella typhimurium LT2 Secreted Protein STM0082: Northeast Structural Genomics Consortium Target StR109
2MZ8	;		;	Solution NMR structure of Salmonella Typhimurium transcriptional regulator protein Crl
2KW9	;		;	Solution NMR Structure of SAP domain of MKL/myocardin-like protein 1 from H.sapiens, Northeast Structural Genomics Consortium Target HR4547E
2KVU	;		;	Solution NMR Structure of SAP domain of MKL/myocardin-like protein 1 from H.sapiens, Northeast Structural Genomics Consortium Target Target HR4547E
2JZ7	;		;	Solution NMR structure of selenium-binding protein from Methanococcus Vannielii
1HZ2	;		;	SOLUTION NMR STRUCTURE OF SELF-COMPLEMENTARY DUPLEX 5'-D(AGGCG*CCT)2 CONTAINING A TRIMETHYLENE CROSSLINK AT THE N2 POSITION OF G*. MODEL OF A MALONDIALDEHYDE CROSSLINK
1LUH	;		;	SOLUTION NMR STRUCTURE OF SELF-COMPLIMENTARY DUPLEX 5'-D(TCCG*CGGA)2 CONTAINING A TRIMETHYLENE CROSSLINK AT THE N2 POSITION OF G*
2KSY	;		;	Solution nmr structure of sensory rhodopsin II
2K1H	;		;	Solution NMR structure of SeR13 from Staphylococcus epidermidis. Northeast Structural Genomics Consortium target SeR13
2MIO	;		;	Solution NMR Structure of SH3 Domain 1 of Rho GTPase-activating Protein 10 from Homo sapiens, Northeast Structural Genomics Consortium (NESG) Target HR9129A
2KRS	;		;	Solution NMR structure of SH3 domain from CPF_0587 (fragment 415-479) from Clostridium perfringens. Northeast Structural Genomics Consortium (NESG) Target CpR74A.
2LX7	;		;	Solution NMR structure of SH3 domain of growth arrest-specific protein 7 (GAS7) (fragment 1-60) from Homo sapiens, Northeast Structural Genomics Consortium (NESG) Target HR8574A
5WAH	;		;	SOLUTION NMR STRUCTURE OF SIGLEC-5 BINDING DOMAIN FROM STREPTOCOCCAL BETA PROTEIN
2L0A	;		;	Solution NMR Structure of Signal transducing adapter molecule 1 STAM-1 from Homo sapiens, Northeast Structural Genomics Consortium Target HR4479E
2MEM	;		;	Solution NMR structure of SLED domain of Scml2
6A5J	;		;	solution NMR Structure of small peptide
2JRO	;		;	Solution NMR Structure of SO0334 from Shewanella oneidensis. Northeast Structural Genomics Target SoR75
6MK4	;		;	Solution NMR structure of spider toxin analogue [E17K]ProTx-II
6MK5	;		;	Solution NMR structure of spider toxin analogue [F5A,M6F,T26L,K28R]GpTx-1
2JZ2	;		;	Solution NMR structure of Ssl0352 protein from Synechocystis sp. PCC 6803. Northeast Structural Genomics Consortium target SgR42
2KCD	;		;	Solution NMR structure of SSP0047 from Staphylococcus saprophyticus. Northeast Structural Genomics Consortium Target SyR6.
1PQX	;		;	Solution NMR Structure of Staphylococcus aureus protein SAV1430. Northeast Structural Genomics Consortium Target ZR18.
2KSI	;		;	Solution NMR structure of Sterol Carrier Protein - 2 from Aedes aegypti (AeSCP-2) complex with C16 fatty acid (palmitate)
2KPI	;		;	Solution NMR structure of Streptomyces coelicolor SCO3027 modeled with Zn+2 bound, Northeast Structural Genomics Consortium Target RR58
2LNI	;		;	Solution NMR Structure of Stress-induced-phosphoprotein 1 STI1 from Homo sapiens, Northeast Structural Genomics Consortium Target HR4403E
2SDF	;		;	SOLUTION NMR STRUCTURE OF STROMAL CELL-DERIVED FACTOR-1 (SDF-1), 30 STRUCTURES
7S5J	;		;	Solution NMR structure of substrate bound peptidase domain from PCAT1
1KMR	;		;	Solution NMR Structure of Surfactant Protein B (11-25) (SP-B11-25)
2LQ3	;		;	Solution NMR Structure of syc0711_d from Synechococcus sp., Northeast Structural Genomics Consortium (NESG) Target SnR212
5KMZ	;		;	Solution NMR structure of Tetrahymena telomerase RNA pseudoknot
2KCL	;		;	Solution NMR structure of tetratricopeptide repeat domain protein SrU_0103 from Salinibacter ruber, Northeast Structural Genomics Consortium (NESG) Target SrR115C
2KCV	;		;	Solution nmr structure of tetratricopeptide repeat domain protein sru_0103 from salinibacter ruber, northeast structural genomics consortium (nesg) target srr115c
2LE1	;		;	Solution NMR Structure of Tfu_2981 from Thermobifida fusca, Northeast Structural Genomics Consortium Target TfR85A
2N0J	;		;	Solution NMR Structure of the 27 nucleotide engineered neomycin sensing riboswitch RNA-ribostamycin complex
2KXM	;		;	Solution NMR Structure of the 27 nucleotide engineered neomycin sensing riboswitch RNA-ribostmycin complex
1QSX	;		;	SOLUTION NMR STRUCTURE OF THE 2:1 HOECHST 33258-D(CTTTTGCAAAAG)2 COMPLEX
2LT1	;		;	Solution NMR structure of the 72-residue N-terminal domain of Myxococcus xanthus CarD
2KO1	;		;	Solution NMR structure of the ACT domain from GTP pyrophosphokinase of Chlorobium tepidum. Northeast Structural Genomics Consortium Target CtR148A
2LGH	;		;	Solution NMR structure of the AHSA1-like protein AHA_2358 from Aeromonas hydrophila refined with NH RDCs, Northeast Structural Genomics Consortium Target AhR99.
2LF2	;		;	Solution NMR structure of the AHSA1-like protein CHU_1110 from Cytophaga hutchinsonii, Northeast Structural Genomics Consortium Target ChR152
2LAK	;		;	Solution NMR structure of the AHSA1-like protein RHE_CH02687 (1-152) from Rhizobium etli, Northeast Structural Genomics Consortium Target ReR242
2KQ2	;		;	Solution NMR structure of the apo form of a ribonuclease H domain of protein DSY1790 from Desulfitobacterium hafniense, Northeast Structural Genomics target DhR1A
2LU3	;		;	Solution NMR structure of the apo-form of the beta2 carbohydrate module of AMP-activated protein kinase
2HPU	;		;	Solution NMR structure of the apo-NosL protein from Achromobacter cycloclastes
2HQ3	;		;	Solution NMR structure of the apo-NosL protein from Achromobacter cycloclastes
2KXI	;		;	Solution NMR structure of the apoform of NarE (NMB1343)
2LU4	;		;	Solution NMR structure of the beta2 carbohydrate module of AMP-activated protein kinase bound to glucosyl-cyclodextrin
5VX7	;		;	Solution NMR structure of the BRCT domain of S. cerevisiae Rev1
2L3B	;		;	Solution NMR structure of the BT_0084 lipoprotein from Bacteroides thetaiotaomicron, Northeast Structural Genomics Consortium Target BtR376
6YJL	;		;	Solution NMR structure of the C-terminal arm of RSV nucleoprotein
2M9U	;		;	Solution NMR structure of the C-terminal domain (CTD) of Moloney murine leukemia virus integrase, Northeast Structural Genomics Target OR41A
2LT3	;		;	Solution NMR structure of the C-terminal domain of CdnL from Myxococcus xanthus
3GAT	;		;	SOLUTION NMR STRUCTURE OF THE C-TERMINAL DOMAIN OF CHICKEN GATA-1 BOUND TO DNA, 34 STRUCTURES
5NOC	;		;	Solution NMR Structure of the C-terminal domain of ParB (Spo0J)
2KCZ	;		;	Solution NMR structure of the C-terminal domain of protein DR_A0006 from Deinococcus radiodurans. Northeast Structural Genomics Consortium Target DrR147D
2HJ8	;		;	Solution NMR structure of the C-terminal domain of the interferon alpha-inducible ISG15 protein from Homo sapiens. Northeast Structural Genomics target HR2873B
2KBI	;		;	Solution NMR structure of the C-terminal EF-hand domain of human cardiac sodium channel NaV1.5
2YOM	;		;	Solution NMR structure of the C-terminal extension of two bacterial light, oxygen, voltage (LOV) photoreceptor proteins from Pseudomonas putida
2YON	;		;	Solution NMR structure of the C-terminal extension of two bacterial light, oxygen, voltage (LOV) photoreceptor proteins from Pseudomonas putida
5VNT	;		;	Solution NMR Structure of the C-terminal Headpiece Domain of Villin 4 from A.thaliana, the First Non-Vertebrate Headpiece Structure
2MFS	;		;	Solution NMR structure of the cactus-derived antimicrobial peptide Ep-AMP1
2KL6	;		;	Solution NMR structure of the CARDB domain of PF1109 from Pyrococcus furiosus. Northeast Structural Genomics Consortium target PfR193A
2L11	;		;	Solution NMR structure of the Cbx3 in complex with H3K9me3 peptide
1L4T	;		;	SOLUTION NMR STRUCTURE OF THE CCK2E3
2KXO	;		;	Solution NMR structure of the cell division regulator MinE protein from Neisseria gonorrhoeae
2K28	;		;	Solution NMR structure of the chromo domain of the chromobox protein homolog 4
2K1B	;		;	Solution NMR structure of the chromo domain of the chromobox protein homolog 7
2L12	;		;	Solution NMR structure of the chromobox protein 7 with H3K9me3
2L1B	;		;	Solution NMR structure of the chromobox protein Cbx7 with H3K27me3
7K3S	;		;	Solution NMR Structure of the Coiled-coil BRCA1-PALB2 Heterodimer
1G6P	;		;	SOLUTION NMR STRUCTURE OF THE COLD SHOCK PROTEIN FROM THE HYPERTHERMOPHILIC BACTERIUM THERMOTOGA MARITIMA
6E4H	;		;	Solution NMR Structure of the Colied-coil PALB2 Homodimer
1BXP	;		;	SOLUTION NMR STRUCTURE OF THE COMPLEX OF ALPHA-BUNGAROTOXIN WITH A LIBRARY DERIVED PEPTIDE, 20 STRUCTURES
2BTX	;		;	SOLUTION NMR STRUCTURE OF THE COMPLEX OF ALPHA-BUNGAROTOXIN WITH A LIBRARY DERIVED PEPTIDE, NMR, MINIMIZED AVERAGE STRUCTURE
1GCC	;		;	SOLUTION NMR STRUCTURE OF THE COMPLEX OF GCC-BOX BINDING DOMAIN OF ATERF1 AND GCC-BOX DNA, MINIMIZED AVERAGE STRUCTURE
1A66	;		;	SOLUTION NMR STRUCTURE OF THE CORE NFATC1/DNA COMPLEX, 18 STRUCTURES
2KT8	;		;	Solution NMR structure of the CPE1231(468-535) protein from Clostridium perfringens, Northeast Structural Genomics Consortium Target CpR82B
7L55	;		;	Solution NMR structure of the cyclic plant protein PDP-23 in DPC micelles
7L54	;		;	Solution NMR structure of the cyclic plant protein PDP-23 in SDS micelles
2M6W	;		;	Solution NMR structure of the d(GGGGTTGGGGTTTTGGGGAAGGGG) quadruplex in sodium conditions
2M6V	;		;	Solution NMR structure of the d(GGGTTGGGTTTTGGGTGGG) quadruplex in sodium conditions
2MFT	;		;	Solution NMR structure of the d(GGGTTTTGGGTGGGTTTTGGG) quadruplex in sodium conditions
5UYO	;		;	Solution NMR structure of the de novo mini protein HEEH_rd4_0097
6U6R	;		;	Solution NMR Structure Of The delta30-ngMinE Protein From Neisseria gonorrheae
7L51	;		;	Solution NMR structure of the dimeric form of the cyclic plant protein PDP-23 in H2O
1HBW	;		;	Solution nmr structure of the dimerization domain of the yeast transcriptional activator Gal4 (residues 50-106)
2LZ1	;		;	Solution NMR Structure of the DNA-Binding Domain of Human NF-E2-Related Factor 2, Northeast Structural Genomics Consortium (NESG) Target HR3520O
6U3S	;		;	Solution NMR structure of the DNAJB6b deltaST variant (Aligned on the CTD domain)
6U3R	;		;	Solution NMR structure of the DNAJB6b deltaST variant (Aligned on the J domain)
2KIW	;		;	Solution NMR structure of the domain N-terminal to the integrase domain of SH1003 from Staphylococcus haemolyticus. Northeast Structural Genomics Consortium Target ShR105F (64-166).
2C7H	;		;	Solution NMR structure of the DWNN domain from human RBBP6
2KL7	;		;	Solution NMR Structure of the EGF-like 1 Domain of Human Fibulin-4. Northeast Structural Genomics Target HR6275
2L2T	;		;	Solution NMR structure of the ErbB4 dimeric membrane domain
2LXU	;		;	Solution NMR Structure of the eukaryotic RNA recognition motif, RRM1, from the heterogeneous nuclear ribonucleoprotein H from Homo sapiens, Northeast Structural Genomics Consortium (NESG) Target HR8614A
2K9U	;		;	Solution NMR structure of the Filamin-migfilin complex
2OPU	;		;	Solution NMR Structure of the First Domain of KSRP
2K3D	;		;	Solution NMR structure of the folded 79 residue fragment of Lin0334 from Listeria innocua. Northeast Structural Genomics Consortium target LkR15
2K1S	;		;	Solution NMR structure of the folded C-terminal fragment of YiaD from Escherichia coli. Northeast Structural Genomics Consortium target ER553.
2JVD	;		;	Solution NMR structure of the folded N-terminal fragment of UPF0291 protein ynzC from Bacillus subtilis. Northeast Structural Genomics target SR384-1-46
6U6P	;		;	Solution NMR Structure Of The Full Length Latent Form MinE Protein From Neisseria gonorrheae
6WA5	;		;	Solution NMR Structure of the G4L/Q5K/G6S (NOS) Unmyristoylated Feline Immunodeficiency Virus Matrix Protein
1YUJ	;		;	SOLUTION NMR STRUCTURE OF THE GAGA FACTOR/DNA COMPLEX, 50 STRUCTURES
1YUI	;		;	SOLUTION NMR STRUCTURE OF THE GAGA FACTOR/DNA COMPLEX, REGULARIZED MEAN STRUCTURE
2LSO	;		;	Solution NMR Structure of the Globular Domain of Human Histone H1x, Northeast Structural Genomics Consortium (NESG) Target HR7057A
2FN2	;		;	SOLUTION NMR STRUCTURE OF THE GLYCOSYLATED SECOND TYPE TWO MODULE OF FIBRONECTIN, 20 STRUCTURES
2GBQ	;		;	SOLUTION NMR STRUCTURE OF THE GRB2 N-TERMINAL SH3 DOMAIN COMPLEXED WITH A TEN-RESIDUE PEPTIDE DERIVED FROM SOS DIRECT REFINEMENT AGAINST NOES, J-COUPLINGS, AND 1H AND 13C CHEMICAL SHIFTS, 15 STRUCTURES
4GBQ	;		;	SOLUTION NMR STRUCTURE OF THE GRB2 N-TERMINAL SH3 DOMAIN COMPLEXED WITH A TEN-RESIDUE PEPTIDE DERIVED FROM SOS DIRECT REFINEMENT AGAINST NOES, J-COUPLINGS, AND 1H AND 13C CHEMICAL SHIFTS, 15 STRUCTURES
1GBQ	;		;	SOLUTION NMR STRUCTURE OF THE GRB2 N-TERMINAL SH3 DOMAIN COMPLEXED WITH A TEN-RESIDUE PEPTIDE DERIVED FROM SOS DIRECT REFINEMENT AGAINST NOES, J-COUPLINGS, AND 1H AND 13C CHEMICAL SHIFTS, MINIMIZED AVERAGE STRUCTURE
3GBQ	;		;	SOLUTION NMR STRUCTURE OF THE GRB2 N-TERMINAL SH3 DOMAIN COMPLEXED WITH A TEN-RESIDUE PEPTIDE DERIVED FROM SOS DIRECT REFINEMENT AGAINST NOES, J-COUPLINGS, AND 1H AND 13C CHEMICAL SHIFTS, MINIMIZED AVERAGE STRUCTURE
5LWJ	;		;	Solution NMR structure of the GTP binding Class II RNA aptamer-ligand-complex containing a protonated adenine nucleotide with a highly shifted pKa.
1R9P	;		;	Solution NMR Structure Of The Haemophilus Influenzae Iron-Sulfur Cluster Assembly Protein U (IscU) with Zinc Bound at the Active Site. Northeast Structural Genomics Consortium Target IR24.
1Q48	;		;	Solution NMR Structure of The Haemophilus Influenzae Iron-Sulfur Cluster Assembly Protein U (IscU) with Zinc Bound at the Active Site. Northeast Structural Genomics Consortium Target IR24. This protein is not apo, it is a model without zinc binding constraints.
2LFH	;		;	Solution NMR Structure of the Helix-loop-Helix Domain of Human ID3 Protein, Northeast Structural Genomics Consortium Target HR3111A
4C26	;		;	Solution NMR structure of the HicA toxin from Burkholderia pseudomallei
2LDL	;		;	Solution NMR Structure of the HIV-1 Exon Splicing Silencer 3
5VWE	;		;	Solution NMR structure of the HMG domain of human FACT complex subunit SSRP1
2KW4	;		;	Solution NMR Structure of the Holo Form of a Ribonuclease H domain from D.hafniense, Northeast Structural Genomics Consortium Target DhR1A
2JS1	;		;	Solution NMR structure of the homodimer protein YVFG from Bacillus subtilis, Northeast Structural Genomics Consortium Target SR478
2KKO	;		;	Solution NMR structure of the homodimeric winged helix-turn-helix DNA-binding domain (fragment 1-100) Mb0332 from Mycobacterium bovis, a possible ArsR-family transcriptional regulator. Northeast Structural Genomics Consortium Target MbR242E.
7ZBS	;		;	Solution NMR structure of the HTH_8cm consensus miniprotein in 30% TFE at 278K
2STT	;		;	SOLUTION NMR STRUCTURE OF THE HUMAN ETS1/DNA COMPLEX, 25 STRUCTURES
2STW	;		;	SOLUTION NMR STRUCTURE OF THE HUMAN ETS1/DNA COMPLEX, RESTRAINED REGULARIZED MEAN STRUCTURE
1HPJ	;		;	SOLUTION NMR STRUCTURE OF THE HUMAN PLASMINOGEN KRINGLE 1 DOMAIN COMPLEXED WITH 6-AMINOHEXANOIC ACID AT PH 5.3, 310K, DERIVED FROM RANDOMLY GENERATED STRUCTURES USING SIMULATED ANNEALING, 12 STRUCTURES
1HPK	;		;	SOLUTION NMR STRUCTURE OF THE HUMAN PLASMINOGEN KRINGLE 1 DOMAIN COMPLEXED WITH 6-AMINOHEXANOIC ACID AT PH 5.3, 310K, DERIVED FROM RANDOMLY GENERATED STRUCTURES USING SIMULATED ANNEALING, MINIMIZED AVERAGE STRUCTURE
6U6S	;		;	Solution NMR Structure Of The I24N-delta10-ngMinE Protein From Neisseria gonorrheae
2EZL	;		;	SOLUTION NMR STRUCTURE OF THE IBETA SUBDOMAIN OF THE MU END DNA BINDING DOMAIN OF PHAGE MU TRANSPOSASE, 29 STRUCTURES
2EZK	;		;	SOLUTION NMR STRUCTURE OF THE IBETA SUBDOMAIN OF THE MU END DNA BINDING DOMAIN OF PHAGE MU TRANSPOSASE, REGULARIZED MEAN STRUCTURE
2KKQ	;		;	Solution NMR Structure of the Ig-like C2-type 2 Domain of Human Myotilin. Northeast Structural Genomics Target HR3158.
2EZI	;		;	SOLUTION NMR STRUCTURE OF THE IGAMMA SUBDOMAIN OF THE MU END DNA BINDING DOMAIN OF MU PHAGE TRANSPOSASE, 30 STRUCTURES
2EZH	;		;	SOLUTION NMR STRUCTURE OF THE IGAMMA SUBDOMAIN OF THE MU END DNA BINDING DOMAIN OF MU PHAGE TRANSPOSASE, MINIMIZED AVERAGE STRUCTURE
1BRV	;		;	SOLUTION NMR STRUCTURE OF THE IMMUNODOMINANT REGION OF PROTEIN G OF BOVINE RESPIRATORY SYNCYTIAL VIRUS, 48 STRUCTURES
2LY0	;		;	Solution NMR structure of the influenza A virus S31N mutant (19-49) in presence of drug M2WJ332
2KD1	;		;	Solution NMR structure of the integrase-like domain from Bacillus cereus ordered locus BC_1272. Northeast Structural Genomics Consortium Target BcR268F
6YTC	;		;	Solution NMR structure of the isolated NTE domain of BT1762-63 levan transporter
6MIE	;		;	Solution NMR structure of the KCNQ1 voltage-sensing domain
2LPE	;		;	Solution NMR Structure of the KSR1 CA1-CA1a domain
7GAT	;		;	SOLUTION NMR STRUCTURE OF THE L22V MUTANT DNA BINDING DOMAIN OF AREA COMPLEXED TO A 13 BP DNA CONTAINING A TGATA SITE, 34 STRUCTURES
6GAT	;		;	SOLUTION NMR STRUCTURE OF THE L22V MUTANT DNA BINDING DOMAIN OF AREA COMPLEXED TO A 13 BP DNA CONTAINING A TGATA SITE, REGULARIZED MEAN STRUCTURE
2N5C	;		;	Solution NMR structure of the lasso peptide chaxapeptin
2MW3	;		;	Solution NMR structure of the lasso peptide streptomonomicin
2K13	;		;	Solution NMR Structure of the Leech Protein Saratin, a Novel Inhibitor of Haemostasis
2L2J	;		;	Solution NMR structure of the lower part of the R/G stem loop RNA
5UCE	;		;	Solution NMR structure of the major species of DANCER-2, a dynamic and natively folded pentamutant of the B1 domain of streptococcal protein G (GB1)
6GMS	;		;	Solution NMR structure of the major type IV pilin PpdD from enterohemorrhagic Escherichia coli (EHEC)
5VWL	;		;	Solution NMR Structure of the Membrane Associated Segment of HIV-1 gp41 Cytoplasmic Tail
5VKV	;		;	Solution NMR structure of the membrane electron transporter CcdA
2N9V	;		;	Solution NMR Structure of the membrane localization domain from Pasteurella multocida toxin
2N9W	;		;	Solution NMR Structure of the membrane localization domain from the Ras/Rap1-specific endopeptidase (RRSP) of the Vibrio vulnificus multifunctional autoprocessing repeats-in-toxins (MARTX) toxin
1ZZA	;		;	Solution NMR Structure of the Membrane Protein Stannin
2BAU	;		;	Solution NMR structure of the micelle-bound myristoylated N-terminal Arf6
2NBA	;		;	Solution NMR structure of the minor DNA-uptake pilin ComP from Neisseri subflava
2LNA	;		;	Solution NMR Structure of the mitochondrial inner membrane domain (residues 164-251), FtsH_ext, from the paraplegin-like protein AFG3L2 from Homo sapiens, Northeast Structural Genomics Consortium Target HR6741A
1OM2	;		;	SOLUTION NMR STRUCTURE OF THE MITOCHONDRIAL PROTEIN IMPORT RECEPTOR TOM20 FROM RAT IN A COMPLEX WITH A PRESEQUENCE PEPTIDE DERIVED FROM RAT ALDEHYDE DEHYDROGENASE (ALDH)
7L53	;		;	Solution NMR structure of the monomeric form of the cyclic plant protein PDP-23 in CD3CN/H2O
2KKZ	;		;	Solution NMR structure of the monomeric W187R mutant of A/Udorn NS1 effector domain. Northeast Structural Genomics target OR8C[W187R].
2KP7	;		;	Solution NMR structure of the Mus81 N-terminal HhH. Northeast Structural Genomics Consortium target MmT1A
6WA3	;		;	Solution NMR structure of the myristoylated feline immunodeficiency virus matrix protein
2BAO	;		;	Solution NMR structure of the myristoylated N-terminal fragment of Arf6
7NWJ	;		;	Solution NMR structure of the N-terminal domain of CEP164 (1-109)
2KPT	;		;	Solution NMR structure of the N-terminal domain of cg2496 protein from Corynebacterium glutamicum. Northeast Structural Genomics Consortium Target CgR26A
2K5N	;		;	Solution NMR Structure of the N-Terminal Domain of Protein ECA1580 from Erwinia carotovora, Northeast Structural Genomics Consortium Target EwR156A
2KW7	;		;	Solution NMR Structure of the N-terminal domain of protein PG_0361 from P.gingivalis, Northeast Structural Genomics Consortium Target PgR37A
2KYY	;		;	Solution NMR Structure of the N-terminal Domain of Putative ATP-dependent DNA Helicase RecG-related Protein from Nitrosomonas europaea, Northeast Structural Genomics Consortium Target NeR70A
2M2J	;		;	Solution NMR structure of the N-terminal domain of STM1478 from Salmonella typhimurium LT2: Target STR147A of the Northeast Structural Genomics consortium (NESG), and APC101565 of the Midwest Center for Structural Genomics (MCSG).
6VTI	;		;	Solution NMR structure of the N-terminal domain of the Serine/threonine-protein phosphatase 1 regulatory subunit 10, PPP1R10
7N45	;		;	Solution NMR structure of the N-terminal globular domain of the endemic HKU1 coronavirus nucleocapsid protein
2L1A	;		;	Solution NMR structure of the N-terminal GTPase-like domain of dictyostelium discoideum Fomin C
6L7Z	;		;	Solution NMR structure of the N-terminal immunoglobulin variable domain of BTNL2
2LLK	;		;	Solution NMR structure of the N-terminal myb-like 1 domain of the human cyclin-D-binding transcription factor 1 (hDMP1), Northeast Structural Genomics Consortium (NESG) target ID hr8011a
2KCM	;		;	Solution NMR structure of the N-terminal OB-domain of SO_1732 from Shewanella oneidensis. Northeast Structural Genomics Consortium Target SoR210A.
2L0W	;		;	Solution NMR structure of the N-terminal PAS domain of HERG potassium channel
2KJR	;		;	Solution NMR structure of the N-terminal Ubiquitin-like Domain from Tubulin-binding Cofactor B, CG11242, from Drosophila melanogaster. Northeast Structural Genomics Consortium Target FR629A (residues 8-92)
6XXU	;		;	Solution NMR structure of the native form of UbcH7 (UBE2L3)
7O7B	;		;	Solution NMR Structure of the Neh1 Domain of Human Nuclear factor erythroid 2-related factor 2 (NRF2)
6U6G	;		;	Solution NMR structure of the nodule-specific cysteine-rich peptide NCR044 from Medicago truncatula
2JZO	;		;	Solution NMR structure of the non-productive complex between IIAMannose and IIBMannose of the mannose transporter of the E. coli phosphotransferase system
2LMZ	;		;	Solution NMR structure of the novel conotoxin im23a from Conus imperialis
2KBN	;		;	Solution NMR structure of the OB domain (residues 67-166) of MM0293 from Methanosarcina mazei. Northeast Structural Genomics Consortium target MaR214a.
2KEN	;		;	Solution NMR structure of the OB domain (residues 67-166) of MM0293 from Methanosarcina mazei. Northeast Structural Genomics Consortium target MaR214a.
2K75	;		;	Solution NMR structure of the OB domain of Ta0387 from Thermoplasma acidophilum. Northeast Structural Genomics Consortium target TaR80b.
2KCT	;		;	Solution nmr structure of the ob-fold domain of heme chaperone ccme from desulfovibrio vulgaris. northeast structural genomics target dvr115g.
2MXW	;		;	Solution NMR Structure of the OCRE Domain of RBM10
6YP5	;		;	Solution NMR structure of the oligomerization domain of respiratory syncytial virus phosphoprotein
6CEG	;		;	Solution NMR structure of the omega conotoxin MoVIB from Conus moncuri
6WPV	;		;	Solution NMR structure of the orbitide xanthoxycyclin D
1MM4	;		;	Solution NMR structure of the outer membrane enzyme PagP in DPC micelles
1MM5	;		;	Solution NMR structure of the outer membrane enzyme PagP in OG micelles
2MH0	;		;	Solution NMR structure of the p300 Taz2:ETAD1 complex
2KNB	;		;	Solution NMR structure of the parkin Ubl domain in complex with the endophilin-A1 SH3 domain
6U6Q	;		;	Solution NMR Structure Of The Partially Activated MTS Deleted Form MinE Protein (delta10-ngMinE) From Neisseria gonorrheae
2KY4	;		;	Solution NMR structure of the PBS linker domain of phycobilisome linker polypeptide from Anabaena sp. Northeast Structural Genomics Consortium Target NsR123E
2L3W	;		;	Solution NMR Structure of the PBS linker domain of phycobilisome rod linker polypeptide from Synechococcus elongatus, Northeast Structural Genomics Consortium Target SnR168A
7TZ8	;		;	Solution NMR structure of the PBS linker polypeptide domain (fragment 254-400) of phycobilisome linker protein ApcE from Synechocystis sp. PCC 6803 refined with NH RDCs. Northeast Structural Genomics Consortium Target SgR209C
2L06	;		;	Solution NMR structure of the PBS linker polypeptide domain (fragment 254-400) of phycobilisome linker protein ApcE from Synechocystis sp. PCC 6803. Northeast Structural Genomics Consortium Target SgR209C
2KRU	;		;	Solution NMR structure of the PCP_red domain of light-independent protochlorophyllide reductase subunit B from Chlorobium tepidum. Northeast Structural Genomics Consortium Target CtR69A
6RSM	;		;	Solution NMR structure of the peptide 12530 from medicinal leech Hirudo medicinalis in dodecylphosphocholine micelles
6RRL	;		;	Solution NMR structure of the peptide 3967 from medicinal leech Hirudo medicinalis in dodecylphosphocholine micelles
6RRO	;		;	Solution NMR structure of the peptide 536_2 from medicinal leech Hirudo medicinalis in dodecylphosphocholine micelles
1ZZV	;		;	Solution NMR Structure of the Periplasmic Signaling Domain of the Outer Membrane Iron Transporter FecA from Escherichia coli.
2A02	;		;	Solution NMR Structure of the Periplasmic Signaling Domain of the Outer Membrane Iron Transporter PupA from Pseudomonas putida.
2KKP	;		;	Solution NMR structure of the phage integrase SAM-like Domain from Moth 1796 from Moorella thermoacetica. Northeast Structural Genomics Consortium Target MtR39K (residues 64-171).
2LV9	;		;	Solution NMR structure of the PHD domain of human MLL5, Northeast structural genomics consortium target HR6512A
2L8V	;		;	Solution NMR structure of the phycobilisome linker polypeptide domain of CpcC (20-153) from Thermosynechococcus elongatus, Northeast Structural Genomics Consortium Target TeR219A
1ZU2	;		;	Solution NMR structure of the plant Tom20 mitochondrial import receptor from Arabidopsis thaliana
7LQT	;		;	Solution NMR structure of the PNUTS amino-terminal Domain fused to Myc Homology Box 0
2M47	;		;	Solution NMR structure of the Polyketide_cyc-like protein Cgl2372 from Corynebacterium glutamicum, Northeast Structural Genomics Consortium Target CgR160
1VSQ	;		;	Solution NMR structure of the productive complex between IIAMannose and IIBMannose of the mannose transporter of the E. coli phosphotransferase system
2JZN	;		;	Solution NMR structure of the productive complex between IIAMannose and IIBMannose of the mannose transporter of the E. coli phosphotransferase system
2JWN	;		;	Solution NMR structure of the protease-resistent domain of Xenopus laevis ePABP2
1YWL	;		;	Solution NMR structure of the protein EF2693 from E. faecalis: Northeast Structural Genomics Consortium target EFR36
2L1N	;		;	Solution NMR structure of the protein YP_399305.1
2KZC	;		;	Solution NMR structure of the protein YP_510488.1
2G7J	;		;	Solution NMR structure of the putative cytoplasmic protein ygaC from Salmonella typhimurium. Northeast Structural Genomics target StR72.
2KS0	;		;	Solution NMR structure of the Q251Q8_DESHY(21-82) protein from Desulfitobacterium Hafniense, Northeast Structural Genomics Consortium Target DhR8C
2L2K	;		;	Solution NMR structure of the R/G STEM LOOP RNA-ADAR2 DSRBM2 Complex
2K9N	;		;	Solution NMR structure of the R2R3 DNA binding domain of Myb1 protein from protozoan parasite Trichomonas vaginalis
2L05	;		;	Solution NMR Structure of the Ras-binding domain of Serine/threonine-protein kinase B-raf from Homo sapiens, Northeast Structural Genomics Consortium Target HR4694F
2MNS	;		;	Solution NMR structure of the reovirus p15 fusion-associated small transmembrane (FAST) protein fusion-inducing lipid packing sensor (FLiPS) motif in dodecyl phosphocholine (DPC) micelles
2K50	;		;	Solution NMR Structure of the replication Factor A Related Protein from Methanobacterium thermoautotrophicum. Northeast Structural Genomics Target TR91A.
2KL3	;		;	Solution NMR structure of the Rhodanese-like domain from Anabaena sp Alr3790 protein. Northeast Structural Genomics Consortium Target NsR437A
2MA6	;		;	Solution NMR Structure of the RING finger domain from the Kip1 ubiquitination-promoting E3 complex protein 1 (KPC1/RNF123) from Homo sapiens, Northeast Structural Genomics Consortium (NESG) Target HR8700A
7EB1	;		;	Solution NMR structure of the RRM domain of RNA binding protein RBM3 from homo sapiens
2M96	;		;	Solution NMR structure of the RXFP2 LDLa module
6XWI	;		;	Solution NMR structure of the S0_2.126 designed protein
2LE7	;		;	Solution nmr structure of the S4S5 linker of herg potassium channel
2M2E	;		;	Solution NMR structure of the SANT domain of human DNAJC2, Northeast structural genomics consortium target HR8254a
2JVZ	;		;	Solution NMR Structure of the Second and Third KH Domains of KSRP
2OPV	;		;	Solution NMR Structure of the Second Domain of KSRP
2K5V	;		;	SOLUTION NMR STRUCTURE OF the second OB-fold domain of replication protein A from Methanococcus maripaludis. NORTHEAST STRUCTURAL GENOMICS TARGET MrR110B.
2L81	;		;	Solution NMR Structure of the serine-rich domain of hEF1 (Enhancer of filamentation 1) from Homo sapiens, Northeast Structural Genomics Consortium Target HR5554A
2KT1	;		;	Solution NMR Structure of the SH3 Domain from the p85beta subunit of Phosphatidylinositol 3-kinase from H.sapiens, Northeast Structural Genomics Consortium Target HR5531E
7ATY	;		;	Solution NMR structure of the SH3 domain of human Caskin1
1TCE	;		;	SOLUTION NMR STRUCTURE OF THE SHC SH2 DOMAIN COMPLEXED WITH A TYROSINE-PHOSPHORYLATED PEPTIDE FROM THE T-CELL RECEPTOR, MINIMIZED AVERAGE STRUCTURE
8B1X	;		;	Solution NMR structure of the single alpha helix peptide (P3-7)2
1PFS	;		;	SOLUTION NMR STRUCTURE OF THE SINGLE-STRANDED DNA BINDING PROTEIN OF THE FILAMENTOUS PSEUDOMONAS PHAGE PF3, MINIMIZED AVERAGE STRUCTURE
2KW5	;		;	Solution NMR Structure of the Slr1183 protein from Synechocystis sp. PCC 6803, Northeast Structural Genomics Consortium Target SgR145
2LTE	;		;	Solution NMR structure of the specialized acyl carrier protein PA3334 (apo) from Pseudomonas aeruginosa, Northeast Structural Genomics Consortium Target PaT415
2LL8	;		;	Solution NMR structure of the specialized holo-acyl carrier protein RPA2022 from Rhodopseudomonas palustris refined with NH RDCs, Northeast Structural Genomics Consortium Target RpR324
2BRZ	;		;	SOLUTION NMR STRUCTURE OF THE SWEET PROTEIN BRAZZEIN, MINIMIZED AVERAGE STRUCTURE
2MM3	;		;	Solution NMR structure of the ternary complex of human ileal bile acid-binding protein with glycocholate and glycochenodeoxycholate
6GZK	;		;	Solution NMR structure of the tetramethylrhodamine (TMR) aptamer 3 in complex with 5-TAMRA
6GZR	;		;	Solution NMR structure of the tetramethylrhodamine (TMR) aptamer 3 in complex with 5-TAMRA
2KMM	;		;	Solution NMR structure of the TGS domain of PG1808 from Porphyromonas gingivalis. Northeast Structural Genomics Consortium Target PgR122A (418-481)
2KZF	;		;	Solution NMR structure of the thermotoga maritima protein TM0855 a putative ribosome binding factor A
2MQT	;		;	Solution NMR structure of the U5-primer binding site (U5-PBS) domain of murine leukemia virus RNA genome
2MQV	;		;	Solution NMR structure of the U5-primer binding site (U5-PBS) domain of murine leukemia virus RNA genome bound to the retroviral nucleocapsid protein
2LNU	;		;	Solution NMR Structure of the uncharacterized protein from gene locus rrnAC0354 of Haloarcula marismortui, Northeast Structural Genomics Consortium Target HmR11
2LOK	;		;	Solution NMR Structure of the uncharacterized protein from gene locus VNG_0733H of Halobacterium salinarium, Northeast Structural Genomics Consortium Target HsR50
2K0M	;		;	Solution NMR structure of the uncharacterized protein from Rhodospirillum rubrum gene locus Rru_A0810. Northeast Structural Genomics Target RrR43
6WA4	;		;	Solution NMR structure of the unmyristoylated feline immunodeficiency virus matrix protein
1ZG2	;		;	Solution NMR structure of the UPF0213 protein BH0048 from Bacillus halodurans. Northeast Structural Genomics target BhR2.
2HEP	;		;	Solution NMR structure of the UPF0291 protein ynzC from Bacillus subtilis. Northeast Structural Genomics target SR384.
2FJ6	;		;	Solution NMR structure of the UPF0346 protein yozE from Bacillus subtilis. Northeast Structural Genomics target SR391.
2M8T	;		;	Solution NMR structure of the V209M variant of the human prion protein (residues 90-231)
5GAT	;		;	SOLUTION NMR STRUCTURE OF THE WILD TYPE DNA BINDING DOMAIN OF AREA COMPLEXED TO A 13BP DNA CONTAINING A CGATA SITE, 35 STRUCTURES
4GAT	;		;	SOLUTION NMR STRUCTURE OF THE WILD TYPE DNA BINDING DOMAIN OF AREA COMPLEXED TO A 13BP DNA CONTAINING A CGATA SITE, REGULARIZED MEAN STRUCTURE
5LXJ	;		;	Solution NMR structure of the X domain of Peste des Petits Ruminants phosphoprotein
7MU9	;		;	Solution NMR structure of the XVIPCD region from the T4SS effector X-Tfe(XAC2609) from Xanthomonas citri
2HH8	;		;	Solution NMR structure of the ydfO protein from Escherichia coli. Northeast Structural Genomics target ER251.
2JN0	;		;	Solution NMR structure of the ygdR protein from Escherichia coli. Northeast Structural Genomics target ER382A.
2HGC	;		;	Solution NMR structure of the YjcQ protein from Bacillus subtilis. Northeast Structural Genomics target SR346.
2KZY	;		;	Solution NMR structure of the ZNF216 A20 zinc finger
1AXU	;		;	SOLUTION NMR STRUCTURE OF THE [AP]DG ADDUCT OPPOSITE DA IN A DNA DUPLEX, NMR, 9 STRUCTURES
1AXV	;		;	SOLUTION NMR STRUCTURE OF THE [BP]DA ADDUCT OPPOSITE DT IN A DNA DUPLEX, 6 STRUCTURES
2KKN	;		;	Solution NMR structure of Themotoga maritima protein TM1076: Northeast Structural Genomics Consortium target VT57
2RQ8	;		;	Solution NMR structure of titin I27 domain mutant
6YJ0	;		;	Solution NMR structure of titin N2A region Ig domain I83
6S3W	;		;	Solution NMR Structure of TolAIII Bound to a Peptide Derived from the N-terminus of TolB
1TXB	;		;	SOLUTION NMR STRUCTURE OF TOXIN B, A LONG NEUROTOXIN FROM THE VENOM OF THE KING COBRA, 10 STRUCTURES
1TXA	;		;	SOLUTION NMR STRUCTURE OF TOXIN B, A LONG NEUROTOXIN FROM THE VENOM OF THE KING COBRA, MINIMIZED AVERAGE STRUCTURE
2K72	;		;	Solution NMR structure of toxin-like potassium channel blocking domain in MMP23
8K3M	;		;	Solution NMR structure of trans X-Pro peptide bond conformer of a single disulfide conopeptide Mo1853
2K8T	;		;	Solution NMR structure of trans-4-hydroxynonenal derived dG adduct of (6R,8S,11R)-configuration opposite dC
2K8U	;		;	Solution NMR structure of trans-4-hydroxynonenal derived dG adduct of (6S,8R,11S)-configuration matched with dC
2M9W	;		;	Solution NMR Structure of Transcription Factor GATA-4 from Homo sapiens, Northeast Structural Genomics Consortium (NESG) Target HR4783B
2KZ5	;		;	Solution NMR Structure of Transcription factor NF-E2 subunit's DNA binding domain from Homo sapiens, Northeast Structural Genomics Consortium Target HR4653B
2L8S	;		;	Solution NMR Structure of Transmembrane and Cytosolic Regions of Integrin Alpha1 in Detergent Micelles
2LZ4	;		;	Solution NMR structure of transmembrane domain of amyloid precursor protein V44M
2LZ3	;		;	Solution NMR structure of transmembrane domain of amyloid precursor protein WT
2MS1	;		;	Solution NMR structure of tRNApro:MLV Nucleocapsid Protein (1:1) Complex
5OQK	;		;	Solution NMR structure of truncated, human Hv1/VSOP (Voltage-gated proton channel)
5LG0	;		;	Solution NMR structure of Tryptophan to Alanine mutant of Arkadia RING domain.
5LG7	;		;	Solution NMR structure of Tryptophan to Arginine mutant of Arkadia RING domain
2LOJ	;		;	Solution NMR structure of TSTM1273 from Salmonella typhimurium LT2, NESG target STT322, CSGID target IDP01027 and OCSP target TSTM1273
2JRF	;		;	Solution NMR structure of Tubulin polymerization-promoting protein family member 3 from Homo sapiens. Northeast Structural Genomics target HR387.
1A5E	;		;	SOLUTION NMR STRUCTURE OF TUMOR SUPPRESSOR P16INK4A, 18 STRUCTURES
1DC2	;		;	SOLUTION NMR STRUCTURE OF TUMOR SUPPRESSOR P16INK4A, 20 STRUCTURES
2A5E	;		;	SOLUTION NMR STRUCTURE OF TUMOR SUPPRESSOR P16INK4A, RESTRAINED MINIMIZED MEAN STRUCTURE
2KI8	;		;	Solution NMR structure of tungsten formylmethanofuran dehydrogenase subunit D from Archaeoglobus fulgidus, Northeast Structural Genomics Consortium target AtT7
6YTS	;		;	Solution NMR structure of type-I ribosome-inactivating protein trichobakin (TBK)
2MJB	;		;	Solution nmr structure of ubiquitin refined against dipolar couplings in 4 media
2KZR	;		;	Solution NMR Structure of Ubiquitin thioesterase OTU1 (EC 3.1.2.-) from Mus musculus, Northeast Structural Genomics Consortium Target MmT2A
2L0G	;		;	Solution NMR structure of ubiquitin-binding motif (UBM2) of human polymerase iota
2KAN	;		;	Solution NMR structure of ubiquitin-like domain of Arabidopsis thaliana protein At2g32350. Northeast Structural Genomics Consortium target AR3433A
6B9K	;		;	Solution NMR Structure of Unbound P18-I10
2JXP	;		;	Solution NMR structure of uncharacterized lipoprotein B from Nitrosomonas europaea. Northeast Structural Genomics target NeR45A
2JWY	;		;	Solution NMR structure of uncharacterized lipoprotein yajI from Escherichia coli. Northeast Structural Genomics target ER540
2X8N	;		;	Solution NMR structure of uncharacterized protein CV0863 from Chromobacterium violaceum. NORTHEAST STRUCTURAL GENOMICS TARGET (NESG) target CvT3. OCSP target CV0863.
2KPM	;		;	Solution NMR Structure of uncharacterized protein from gene locus NE0665 of Nitrosomonas europaea. Northeast Structural Genomics Target NeR103A
2JVW	;		;	Solution NMR structure of uncharacterized protein Q5E7H1 from Vibrio fischeri. Northeast Structural Genomics target VfR117
6BI6	;		;	Solution NMR structure of uncharacterized protein YejG
7S3E	;		;	Solution NMR structure of uperin 3.5 in SDS micelles
2HI6	;		;	Solution NMR structure of UPF0107 protein AF_0055, Northeast Structural Genomics Consortium Target GR101
2K49	;		;	Solution NMR structure of UPF0339 protein SO3888 from Shewanella oneidensis. Northeast Structural Genomics Consortium target SoR190
2KXP	;		;	Solution NMR structure of V-1 bound to capping protein (CP)
8GQO	;		;	Solution NMR structure of vaccinia virus protein A28: an entry-fusion complex component
2KHD	;		;	Solution NMR structure of VC_A0919 from Vibrio cholerae. Northeast Structural Genomics Consortium Target VcR52
4ULL	;		;	SOLUTION NMR STRUCTURE OF VEROTOXIN-1 B-SUBUNIT FROM E. COLI, 5 STRUCTURES
7U37	;		;	Solution NMR structure of Vibrio cholerae ferrous iron transport protein C (FeoC)
2M4E	;		;	Solution NMR structure of VV2_0175 from Vibrio vulnificus, NESG target VnR1 and CSGID target IDP91333
2KN0	;		;	Solution NMR Structure of xenopus Fn14
2K5R	;		;	Solution NMR Structure of XF2673 from Xylella fastidiosa. Northeast Structural Genomics Consortium Target XfR39
2MA4	;		;	Solution NMR Structure of yahO protein from Salmonella typhimurium, Northeast Structural Genomics Consortium (NESG) Target StR106
2KVT	;		;	solution NMR structure of yaiA from Escherichia Eoli. Northeast Structural Genomics Target ER244
2LTT	;		;	Solution NMR Structure of YdbC:dT19G1 complex. Northeast Structural Genomics Consortium (NESG) Target KR150
2KY9	;		;	Solution NMR Structure of ydhK C-terminal Domain from B.subtilis, Northeast Structural Genomics Consortium Target Target SR518
2KKM	;		;	Solution NMR structure of yeast protein YOR252W [residues 38-178]: Northeast Structural Genomics Consortium target YT654
2E2Z	;		;	Solution NMR structure of yeast Tim15, co-chaperone of mitochondrial Hsp70
2JRP	;		;	Solution NMR Structure of YfgJ from Salmonella typhimurium Modeled with Two Zn+2 Bound, Northeast Structural Genomics Consortium Target StR86
2KR1	;		;	Solution NMR structure of zinc binding N-terminal domain of ubiquitin-protein ligase E3A from Homo Sapiens. Northeast Structural Genomics Consortium (NESG) target HR3662
2L0B	;		;	Solution NMR structure of zinc finger domain of E3 ubiquitin-protein ligase praja-1 from Homo sapiens, Northeast Structural Genomics Consortium (NESG) target HR4710B
2MDG	;		;	Solution NMR Structure of Zinc finger protein 423 from Homo sapiens, Northeast Structural Genomics Consortium (NESG) Target HR7298F
2MA7	;		;	Solution NMR Structure of Zinc finger protein Eos from Homo sapiens, Northeast Structural Genomics Consortium (NESG) Target HR7992A
1LV3	;		;	Solution NMR Structure of Zinc Finger Protein yacG from Escherichia coli. Northeast Structural Genomics Consortium Target ET92.
2KGO	;		;	Solution NMR structure of Zn finger protein YBIL from Escherichia coli. NESG target ET107, OCSP target EC0402
7RC7	;		;	Solution NMR Structure of [Ala19]Crp4
7RC8	;		;	Solution NMR Structure of [D-Ala19]Crp4
2MS0	;		;	Solution NMR structure pf tRNApro:MLV-Nucleocapsid (1:2) Complex
2N03	;		;	Solution NMR Structure plectin repeat domain 6 (4403-4606) of Plectin from Homo sapiens, Northeast Structural Genomics Consortium (NESG) Target HR6354E
1RYK	;		;	Solution NMR Structure Protein yjbJ from Escherichia coli. Northeast Structural Genomics Consortium Target ET93; Ontario Centre for Structural Proteomics target EC0298_1_69;
2OA4	;		;	Solution NMR Structure: Northeast Structural Genomics Consortium Target SiR5
6BTV	;		;	Solution NMR structures for CcoTx-II
2NDF	;		;	Solution NMR structures of AF9 yeats domain in complex with histon H3 acetylation at K18
2NDG	;		;	Solution NMR structures of AF9 yeats domain in complex with histone H3 crotonylation at K18
2NCZ	;		;	Solution NMR structures of BRD4 ET domain in complex with NSD3_1 peptide
2ND1	;		;	Solution NMR structures of BRD4 ET domain in complex with NSD3_3 peptide
6BNH	;		;	Solution NMR structures of BRD4 ET domain with JMJD6 peptide
2ND0	;		;	Solution NMR structures of BRD4 ET domain with LANA peptide
5Z9C	;		;	Solution NMR structures of BRD4 first bromodomain with small compound MMQO
2L84	;		;	Solution NMR structures of CBP bromodomain with small molecule j28
2L85	;		;	Solution NMR structures of CBP bromodomain with small molecule of HBS
6M0C	;		;	Solution NMR Structures of DNA minidumbbell formed by 5'-CTTG CATG-3'.
6M0B	;		;	Solution NMR structures of DNA minidumbbell formed by 5'-CTTG CGTG-3'.
7VM9	;		;	Solution NMR structures of DNA minidumbbell formed with two regular CTTTG pentaloops
2KEF	;		;	Solution NMR structures of human hepcidin at 325K
6BGG	;		;	Solution NMR structures of the BRD3 ET domain in complex with a CHD4 peptide
2CPB	;		;	SOLUTION NMR STRUCTURES OF THE MAJOR COAT PROTEIN OF FILAMENTOUS BACTERIOPHAGE M13 SOLUBILIZED IN DODECYLPHOSPHOCHOLINE MICELLES, 25 LOWEST ENERGY STRUCTURES
2CPS	;		;	SOLUTION NMR STRUCTURES OF THE MAJOR COAT PROTEIN OF FILAMENTOUS BACTERIOPHAGE M13 SOLUBILIZED IN SODIUM DODECYL SULPHATE MICELLES, 25 LOWEST ENERGY STRUCTURES
5TM0	;		;	Solution NMR structures of two alternative conformations of E. coli tryptophan repressor in dynamic equilibrium
2JWS	;		;	Solution NMR structures of two designed proteins with 88% sequence identity but different fold and function
2JWU	;		;	Solution NMR structures of two designed proteins with 88% sequence identity but different fold and function
2LVW	;		;	Solution NMR studies of the dimeric regulatory subunit IlvN of the E.coli Acetohydroxyacid synthase I (AHAS I)
2LD5	;		;	Solution NMR-derived complex structure of Hoxa13 DNA binding domain bound to DNA
1Y8B	;		;	Solution NMR-Derived Global Fold of Malate Synthase G from E.coli
5UCF	;		;	Solution NMR-derived model of the minor species of DANCER-2, a dynamic and natively folded pentamutant of the B1 domain of streptococcal protein G (GB1)
5T0X	;		;	Solution NMR-derived structure of calmodulin bound with ER alpha peptides
2LLQ	;		;	Solution nmr-derived structure of calmodulin c-lobe bound with er alpha peptide
2LLO	;		;	Solution NMR-derived structure of calmodulin N-lobe bound with ER alpha peptide
2MXS	;		;	Solution NMR-structure of the neomycin sensing riboswitch RNA bound to paromomycin
1LMR	;		;	Solution of ADO1, a Toxin from the Assassin Bugs Agriosphodrus dohrni that Blocks the Voltage Sensitive Calcium Channel L-type
5DOW	;	1.7	;	Solution of the Variably-Twinned Structure of a Novel Calmodulin-Peptide Complex in a Novel Configuration
2D1A	;		;	Solution RNA structure model of the HIV-1 dimerization initiation site in the extended-duplex dimer
2D1B	;		;	Solution RNA structure model of the HIV-1 dimerization initiation site in the kissing-loop dimer
2D18	;		;	Solution RNA structure of loop region of the HIV-1 dimerization initiation site in the extended-duplex dimer
2D19	;		;	Solution RNA structure of loop region of the HIV-1 dimerization initiation site in the kissing-loop dimer
2D17	;		;	Solution RNA structure of stem-bulge-stem region of the HIV-1 dimerization initiation site
6Q2I	;		;	Solution state NMR structures of the RNA recognition motif (RRM) domain of human CstF-64
2MHO	;		;	Solution State Structure PSD-95 PDZ1 with 5HT2C Receptor peptide
7CNF	;		;	Solution strcture of HsTFIIS LW domain
1WFH	;		;	Solution structrue of the zf-AN1 domain from Arabidopsis thaliana At2g36320 protein
8EF4	;		;	Solution structural bundle of bivalirudin - a bivalent hirudin based thrombin inhibitor
2MZB	;		;	Solution structural studies of GTP:adenosylcobinamide-phosphate guanylyltransferase (CobY) from Methanocaldococcus jannaschii
1OWA	;		;	Solution Structural Studies on Human Erythrocyte Alpha Spectrin N Terminal Tetramerization Domain
1DK9	;		;	SOLUTION STRUCTURE ANALYSIS OF THE DNA DUPLEX D(CATGAGTAC)D(GTACTCATG)
2LIX	;		;	Solution structure Analysis of the ImKTx104
1D7N	;		;	SOLUTION STRUCTURE ANALYSIS OF THE MASTOPARAN WITH DETERGENTS
2HX6	;		;	Solution structure analysis of the phage T4 endoribonuclease RegB
2K23	;		;	Solution Structure Analysis of the rLcn2
1XS3	;		;	Solution Structure Analysis of the XC975 protein
6RH5	;		;	Solution structure and 1H, 13C and 15N chemical shift assignments for NECAP1 PHear domain
6RH6	;		;	Solution structure and 1H, 13C and 15N chemical shift assignments for the complex of NECAP1 PHear domain with phosphorylated AP2 mu2 148-163
6TL0	;		;	Solution structure and 1H, 13C and 15N chemical shift assignments for the complex of VPS29 with VARP 687-747
1FJN	;		;	SOLUTION STRUCTURE AND ACTIVITY OF THE FOUR DISULFIDE BOND MEDITERRANEAN MUSSEL DEFENSIN MGD-1
2M8V	;		;	Solution Structure and Activity Study of Bovicin HJ50, a Particular Type AII Lantibiotic
2GX1	;		;	Solution structure and alanine scan of a spider toxin that affects the activation of mammalian sodium channels
1HZ8	;		;	SOLUTION STRUCTURE AND BACKBONE DYNAMICS OF A CONCATEMER OF EGF-HOMOLOGY MODULES OF THE HUMAN LOW DENSITY LIPOPROTEIN RECEPTOR
1I0U	;		;	SOLUTION STRUCTURE AND BACKBONE DYNAMICS OF A CONCATEMER OF EGF-HOMOLOGY MODULES OF THE HUMAN LOW DENSITY LIPOPROTEIN RECEPTOR
1FUW	;		;	SOLUTION STRUCTURE AND BACKBONE DYNAMICS OF A DOUBLE MUTANT SINGLE-CHAIN MONELLIN(SCM) DETERMINED BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
2AL3	;		;	Solution structure and backbone dynamics of an N-terminal ubiquitin-like domain in the GLUT4-tethering protein, TUG
1KRW	;		;	SOLUTION STRUCTURE AND BACKBONE DYNAMICS OF BERYLLOFLUORIDE-ACTIVATED NTRC RECEIVER DOMAIN
1KLV	;		;	Solution Structure and Backbone Dynamics of GABARAP, GABAA Receptor associated protein
1KM7	;		;	Solution Structure and Backbone Dynamics of GABARAP, GABAA Receptor Associated Protein
3LRI	;		;	Solution structure and backbone dynamics of long-[Arg(3)]insulin-like growth factor-I
1S6O	;		;	Solution structure and backbone dynamics of the apo-form of the second metal-binding domain of the Menkes protein ATP7A
1S6U	;		;	Solution structure and backbone dynamics of the Cu(I) form of the second metal-binding domain of the Menkes protein ATP7A
1J7Q	;		;	Solution structure and backbone dynamics of the defunct EF-hand domain of Calcium Vector Protein
1J7R	;		;	Solution structure and backbone dynamics of the defunct EF-hand domain of Calcium Vector Protein
2KIU	;		;	Solution structure and backbone dynamics of the DNA-binding domain of FOXP1: Insight into its domain swapping
1RJA	;		;	Solution Structure and Backbone Dynamics of the Nonreceptor Tyrosine Kinase PTK6/Brk SH2 Domain
2KJW	;		;	Solution structure and backbone dynamics of the permutant P54-55
2KJV	;		;	Solution structure and backbone dynamics of the ribosomal protein S6wt
1P7M	;		;	SOLUTION STRUCTURE AND BASE PERTURBATION STUDIES REVEAL A NOVEL MODE OF ALKYLATED BASE RECOGNITION BY 3-METHYLADENINE DNA GLYCOSYLASE I
2OSG	;		;	Solution Structure and Binding Property of the Domain-swapped Dimer of ZO2PDZ2
2LK0	;		;	Solution structure and binding studies of the RanBP2-type zinc finger of RBM5
2LK1	;		;	Solution structure and binding studies of the RanBP2-type zinc finger of RBM5
2E6W	;		;	Solution structure and calcium binding properties of EF-hands 3 and 4 of calsenilin
2OJM	;		;	Solution structure and cell selectivity of Piscidin 1 and its analogues
2OJN	;		;	Solution structure and cell selectivity of Piscidin 1 and its analogues
2OJO	;		;	Solution structure and cell selectivity of Piscidin 1 and its analogues
1J6Q	;		;	Solution structure and characterization of the heme chaperone CcmE
1LM0	;		;	Solution structure and characterization of the heme chaperone CcmE
2MSK	;		;	Solution Structure and Chemical Shift Assignments for BeF3 activated Receiver Domain of Nitrogen Regulatory Protein C (NtrC) at 35C
2MSL	;		;	Solution Structure and Chemical Shift Assignments for the Apo form of the Receiver Domain of Nitrogen Regulatory Protein C (NTRC) at 35C
2JTZ	;		;	Solution structure and chemical shift assignments of the F104-to-5-flurotryptophan mutant of cardiac troponin C
1UMQ	;		;	solution structure and DNA binding of the effector domain from the global regulator PrrA(RegA) from R. sphaeroides: Insights into DNA binding specificity
1SSO	;		;	SOLUTION STRUCTURE AND DNA-BINDING PROPERTIES OF A THERMOSTABLE PROTEIN FROM THE ARCHAEON SULFOLOBUS SOLFATARICUS
2LJ6	;		;	Solution Structure and DNA-binding Properties of the Phosphoesterase Domain of DNA Ligase D
2KY8	;		;	Solution structure and dynamic analysis of chicken MBD2 methyl binding domain bound to a target methylated DNA sequence
2L72	;		;	Solution structure and dynamics of ADF from Toxoplasma gondii (TgADF)
1FZT	;		;	SOLUTION STRUCTURE AND DYNAMICS OF AN OPEN B-SHEET, GLYCOLYTIC ENZYME-MONOMERIC 23.7 KDA PHOSPHOGLYCERATE MUTASE FROM SCHIZOSACCHAROMYCES POMBE
5WBT	;		;	Solution Structure and Dynamics of an Ultra-Stable Single-Chain Insulin Analog STUDIES OF AN ENGINEERED MONOMER AND IMPLICATIONS FOR RECEPTOR BINDING
2A3S	;		;	Solution structure and Dynamics of DNA-Binding Domain of Myocyte Nuclear Factor
2LP2	;		;	Solution structure and dynamics of human S100A1 protein modified at cysteine 85 with homocysteine disulfide bond formation in calcium saturated form
2M0R	;		;	Solution structure and dynamics of human S100A14
1Y6D	;		;	Solution structure and dynamics of LuxU from Vibrio harveyi, a phosphotransferase protein involved in bacterial quorum sensing
2RQY	;		;	Solution structure and dynamics of mouse ARMET
1Q80	;		;	Solution structure and dynamics of Nereis sarcoplasmic calcium binding protein
1PCE	;		;	SOLUTION STRUCTURE AND DYNAMICS OF PEC-60, A PROTEIN OF THE KAZAL TYPE INHIBITOR FAMILY, DETERMINED BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
2KAX	;		;	Solution structure and dynamics of S100A5 in the apo and Ca2+ -bound states
2KAY	;		;	Solution structure and dynamics of S100A5 in the Ca2+ -bound states
2K5Z	;		;	Solution structure and dynamics of the apical stem-loop of Duck hepatitis B virus
2D2W	;		;	Solution structure and Dynamics of the DNA-Binding Domain of Myocyte Nuclear Factor
1P9J	;		;	Solution structure and dynamics of the EGF/TGF-alpha chimera T1E
1M7T	;		;	Solution Structure and Dynamics of the Human-Escherichia coli Thioredoxin Chimera: Insights into Thermodynamic Stability
5MCS	;		;	Solution structure and dynamics of the outer membrane cytochrome OmcF from Geobacter sulfurreducens
2GT3	;		;	Solution structure and dynamics of the reduced form of Methionine Sulfoxide Reductase A from Escherichia coli, a 23 kDa protein
2KE5	;		;	Solution structure and dynamics of the small GTPase Ralb in its active conformation: significance for effector protein binding
6YDH	;		;	Solution structure and dynamics of Zn-Finger HVO_2753 protein
1IB8	;		;	SOLUTION STRUCTURE AND FUNCTION OF A CONSERVED PROTEIN SP14.3 ENCODED BY AN ESSENTIAL STREPTOCOCCUS PNEUMONIAE GENE
1Q3T	;		;	Solution structure and function of an essential CMP kinase of Streptococcus pneumoniae
2KNF	;		;	Solution structure and functional characterization of human plasminogen kringle 5
177D	;		;	SOLUTION STRUCTURE AND HYDRATION PATTERNS OF A PYRIMIDINE(DOT)PURINE(DOT)PYRIMIDINE DNA TRIPLEX CONTAINING A NOVEL T(DOT)CG TRIPLE
2BN8	;		;	Solution Structure and interactions of the E .coli Cell Division Activator Protein CedA
1GFC	;		;	SOLUTION STRUCTURE AND LIGAND-BINDING SITE OF THE C-TERMINAL SH3 DOMAIN OF GRB2
1GFD	;		;	SOLUTION STRUCTURE AND LIGAND-BINDING SITE OF THE C-TERMINAL SH3 DOMAIN OF GRB2
1PNJ	;		;	SOLUTION STRUCTURE AND LIGAND-BINDING SITE OF THE SH3 DOMAIN OF THE P85ALPHA SUBUNIT OF PHOSPHATIDYLINOSITOL 3-KINASE
2PNI	;		;	SOLUTION STRUCTURE AND LIGAND-BINDING SITE OF THE SH3 DOMAIN OF THE P85ALPHA SUBUNIT OF PHOSPHATIDYLINOSITOL 3-KINASE
2MOQ	;		;	Solution Structure and Molecular determinants of Hemoglobin Binding of the first NEAT Domain of IsdB in Staphylococcus aureus
1G9E	;		;	SOLUTION STRUCTURE AND RELAXATION MEASUREMENTS OF AN ANTIGEN-FREE HEAVY CHAIN VARIABLE DOMAIN (VHH) FROM LLAMA
2JP2	;		;	Solution structure and resonance assignment of the N-terminal EVH1 domain from the human Spred2 protein (Sprouty-related protein with EVH1 domain isoform 2)
2J76	;		;	Solution structure and RNA interactions of the RNA recognition motif from eukaryotic translation initiation factor 4B
2RSM	;		;	Solution structure and siRNA-mediated knockdown analysis of the mitochondrial disease-related protein C12orf65 (ICT2)
2KD4	;		;	Solution structure and thermodynamics of 2',5' RNA intercalation
2JQV	;		;	Solution structure At3g28950.1 from Arabidopsis thaliana
1V90	;		;	Solution structure by NMR means of delta-paluIT1-NH2
1EQX	;		;	SOLUTION STRUCTURE DETERMINATION AND MUTATIONAL ANALYSIS OF THE PAPILLOMAVIRUS E6-INTERACTING PEPTIDE OF E6AP
1A1U	;		;	SOLUTION STRUCTURE DETERMINATION OF A P53 MUTANT DIMERIZATION DOMAIN, NMR, MINIMIZED AVERAGE STRUCTURE
1L3O	;		;	SOLUTION STRUCTURE DETERMINATION OF THE FULLY OXIDIZED DOUBLE MUTANT K9-10A CYTOCHROME C7 FROM DESULFUROMONAS ACETOXIDANS, ENSEMBLE OF 35 STRUCTURES
1KWJ	;		;	solution structure determination of the fully oxidized double mutant K9-10A cytochrome c7 from Desulfuromonas acetoxidans, minimized average structure
4A5V	;		;	Solution structure ensemble of the two N-terminal apple domains (residues 58-231) of Toxoplasma gondii microneme protein 4
8TZM	;		;	Solution structure for a putative Type I site-specific deoxyribonuclease from Neisseria gonorrhoeae (NCCP11945). Seattle Structural Genomics Center for Infectious Disease target NegoA.19201.a
7TXX	;		;	Solution structure for Bartonella henselae BamE, a component of the beta-barrel assembly machinery complex. Seattle Structural Genomics Center for Infectious Disease target BaheA.17605.a
2MVZ	;		;	Solution Structure for Cyclophilin A from Geobacillus Kaustophilus
6AAS	;		;	Solution Structure for helix 45 in 3' end of 12S rRNA
5XI9	;		;	Solution structure for human HSP70 substrate binding domain
5XIR	;		;	Solution structure for human HSP70 substrate binding domain L542Y mutant
6AAU	;		;	Solution Structure for m62A helix 45 in 3' end of 12S rRNA
2AKL	;		;	Solution structure for phn-A like protein PA0128 from Pseudomonas aeruginosa
2N6C	;		;	Solution structure for quercetin complexed with c-myc G-quadruplex DNA
5Z80	;		;	Solution structure for the 1:1 complex of a platinum(II)-based tripod bound to a hybrid-1 human telomeric G-quadruplex
1PUL	;		;	Solution structure for the 21KDa caenorhabditis elegans protein CE32E8.3. NORTHEAST STRUCTURAL GENOMICS CONSORTIUM TARGET WR33
2EXN	;		;	Solution structure for the protein coded by gene locus BB0938 of Bordetella bronchiseptica. Northeast Structural Genomics target BoR11.
5Z8F	;		;	Solution structure for the unique dimeric 4:2 complex of a platinum(II)-based tripod bound to a hybrid-1 human telomeric G-quadruplex
2MPF	;		;	Solution structure human HCN2 CNBD in the cAMP-unbound state
2MT8	;		;	Solution structure MTAbl13, a grafted MCoTI-II
1CDN	;		;	Solution structure of (CD2+)1-calbindin D9K reveals details of the stepwise structural changes along the apo--> (CA2+)II1--> (CA2+)I,II2 binding pathway
2M9N	;		;	Solution Structure of (HhH)2 domain of human FAAP24
2LEY	;		;	Solution structure of (R7G)-Crp4
2F3W	;		;	solution structure of 1-110 fragment of staphylococcal nuclease in 2M TMAO
1RKN	;		;	Solution structure of 1-110 fragment of Staphylococcal Nuclease with G88W mutation
2F3V	;		;	Solution structure of 1-110 fragment of staphylococcal nuclease with V66W mutation
2K6B	;		;	Solution structure of 1-112 fragment of human programmed cell death 5 protein
1YYB	;		;	Solution structure of 1-26 fragment of human programmed cell death 5 protein
7PNG	;		;	Solution structure of 1:1 complex of an indoloquinoline derivative SYUIQ-5 to parallel quadruplex-duplex (Q-D) hybrid
2LSC	;		;	Solution structure of 2'F-ANA and ANA self-complementary duplex
1I5V	;		;	SOLUTION STRUCTURE OF 2-(PYRIDO[1,2-E]PURIN-4-YL)AMINO-ETHANOL INTERCALATED IN THE DNA DUPLEX D(CGATCG)2
7CK5	;		;	Solution structure of 28 amino acid polypeptide (354-381) in Plantago asiatica mosaic virus replicase bound to SDS micelle
2CKU	;		;	Solution structure of 2F13F1 from human fibronectin
2YUW	;		;	Solution Structure of 2nd Fibronectin Domain of Slow Type Myosin-Binding Protein C
2YUV	;		;	Solution Structure of 2nd Immunoglobulin Domain of Slow Type Myosin-Binding Protein C
1EDV	;		;	SOLUTION STRUCTURE OF 2ND INTRADISKAL LOOP OF BOVINE RHODOPSIN (RESIDUES 172-205)
1IEZ	;		;	Solution Structure of 3,4-Dihydroxy-2-Butanone 4-Phosphate Synthase of Riboflavin Biosynthesis
1LMZ	;		;	Solution Structure of 3-Methyladenine DNA Glycosylase I (TAG)
2K4X	;		;	Solution structure of 30S ribosomal protein S27A from Thermoplasma acidophilum
1QXF	;		;	SOLUTION STRUCTURE OF 30S RIBOSOMAL PROTEIN S27E FROM ARCHAEOGLOBUS FULGIDUS: GR2, A NESG TARGET PROTEIN
2KCP	;		;	SOLUTION STRUCTURE OF 30S RIBOSOMAL PROTEIN S8E; FROM Methanothermobacter thermautotrophicus, NORTHEASTSTRUCTURAL GENOMICS CONSORTIUM (NESG) TARGET Tr71d
2YUX	;		;	Solution Structure of 3rd Fibronectin type three Domain of slow type Myosin-Binding Protein C
2DJ7	;		;	Solution Structure of 3rd LIM Domain of Actin-binding LIM Protein 3
2YUZ	;		;	Solution Structure of 4th Immunoglobulin Domain of Slow Type Myosin-Binding Protein C
2JZ6	;		;	Solution structure of 50S ribosomal protein L28 from Thermotoga maritima. Northeast Structural Genomics Consortium target VR97
2AYJ	;		;	Solution structure of 50S ribosomal protein L40e from Sulfolobus solfataricus
2JXT	;		;	Solution structure of 50S ribosomal protein LX from Methanobacterium thermoautotrophicum. Northeast Structural Genomics Consortium (NESG) target TR80
2MWO	;		;	Solution structure of 53BP1 tandem Tudor domains in complex with a p53K370me2 peptide
2MWP	;		;	Solution structure of 53BP1 tandem Tudor domains in complex with a p53K382me2 peptide
2FXY	;		;	Solution structure of 55-72 segment of staphylococcal nuclease
1EQ0	;		;	SOLUTION STRUCTURE OF 6-HYDROXYMETHYL-7,8-DIHYDROPTERIN PYROPHOSPHOKINASE COMPLEXED WITH MGAMPPCP
2MKW	;		;	Solution Structure of 6aJl2 and 6aJL2-R24G Amyloidogenics Light Chain Proteins
1E88	;		;	Solution structure of 6F11F22F2, a compact three-module fragment of the gelatin-binding domain of human fibronectin
1E8B	;		;	Solution structure of 6F11F22F2, a compact three-module fragment of the gelatin-binding domain of human fibronectin
8OQB	;		;	Solution structure of 6xHIS-tagged wild-type Gaussia luciferase
6MCI	;		;	Solution structure of 7SK stem-loop 1
7T1N	;		;	Solution structure of 7SK stem-loop 1 with HEXIM Arginine Rich Motif
7T1P	;		;	Solution structure of 7SK stem-loop 1 with HIV-1 Tat Finland Arginine Rich Motif
6MCF	;		;	Solution structure of 7SK stem-loop 1 with HIV-1 Tat RNA Binding Domain
7T1O	;		;	Solution structure of 7SK stem-loop 1 with HIV-1 Tat Subtype G Arginine Rich Motif
1N2W	;		;	Solution Structure of 8OG:G mismatch containing duplex
2FXZ	;		;	Solution structure of 97-109 segment of staphylococcal nuclease
6CEJ	;		;	Solution structure of a 14mer fragment of the p21 protein
1KBD	;		;	SOLUTION STRUCTURE OF A 16 BASE-PAIR DNA RELATED TO THE HIV-1 KAPPA B SITE
1F9L	;		;	Solution Structure of a 22-Nucleotide Hairpin Similar to the P5ABC Region of a Group I Ribozyme with Cobalt(III)hexammine Complexed to the GAAA Tetraloop
2K4L	;		;	Solution structure of a 2:1C2-(2-naphthyl)pyrrolo[2,1-c][1,4]benzodiazepine (PBD) DNA adduct: molecular basis for unexpectedly high DNA helix stabilization.
1GH9	;		;	SOLUTION STRUCTURE OF A 8.3 KDA PROTEIN (GENE MTH1184) FROM METHANOBACTERIUM THERMOAUTOTROPHICUM
2VAI	;		;	Solution structure of a B-DNA hairpin at high pressure
2VAH	;		;	Solution structure of a B-DNA hairpin at low pressure.
2HNA	;		;	Solution Structure of a bacterial apo-flavodoxin
2MYJ	;		;	Solution structure of a bacterial chaperone
2K0G	;		;	Solution Structure of a Bacterial Cyclic Nucleotide-Activated K+ Channel Binding Domain in Complex with cAMP
2KXL	;		;	Solution structure of a bacterial cyclic nucleotide-activated K+ channel binding domain in the unliganded state
2HNB	;		;	Solution Structure of a bacterial holo-flavodoxin
2MQG	;		;	Solution structure of a bacterial immunoglobulin-like domain form a surface protein of Leptospira
1QBH	;		;	SOLUTION STRUCTURE OF A BACULOVIRAL INHIBITOR OF APOPTOSIS (IAP) REPEAT
1K3K	;		;	Solution Structure of a Bcl-2 Homolog from Kaposi's Sarcoma Virus
6BF2	;		;	Solution structure of a Bcl-xL S62E mutant
2M7J	;		;	Solution Structure of a Beta-Hairpin Peptidomimetic antibiotic that target LptD in Pseudomonas sp.
2M7I	;		;	Solution structure of a Beta-Hairpin Peptidomimetic antibiotic that targets LptD in Pseudomonas sp.
2NS4	;		;	Solution structure of a Beta-Hairpin Peptidomimetic Inhibitor of the BIV Tat-Tar Interaction
1B3C	;		;	SOLUTION STRUCTURE OF A BETA-NEUROTOXIN FROM THE NEW WORLD SCORPION CENTRUROIDES SCULPTURATUS EWING
2B3C	;		;	SOLUTION STRUCTURE OF A BETA-NEUROTOXIN FROM THE NEW WORLD SCORPION CENTRUROIDES SCULPTURATUS EWING
8QKX	;		;	Solution structure of a bimolecular quadruplex-duplex hybrid containing a V-shaped loop
2ERM	;		;	Solution structure of a biologically active human FGF-1 monomer, complexed to a hexasaccharide heparin-analogue
1HT4	;		;	SOLUTION STRUCTURE OF A BISTRAND ABASIC SITE LESION STAGGERED IN A 3'-ORIENTATION.
2KZ0	;		;	Solution structure of a BolA protein (ECH_0303) from Ehrlichia chaffeensis. Seattle Structural Genomics Center for Infectious Disease target EhchA.10365.a
1V9J	;		;	Solution structure of a BolA-like protein from Mus musculus
2G4A	;		;	Solution structure of a Bromodomain from RING3 protein
2MJU	;		;	Solution structure of a C terminal fragment of the neuronal isoform of the polypyrimidine tract binding protein (nPTB)
6MXQ	;		;	Solution structure of a c-JUN 5' UTR stem-loop associated with specialized cap-dependent translation initiation
1TIZ	;		;	Solution Structure of a Calmodulin-Like Calcium-Binding Domain from Arabidopsis thaliana
2BBM	;		;	SOLUTION STRUCTURE OF A CALMODULIN-TARGET PEPTIDE COMPLEX BY MULTIDIMENSIONAL NMR
2BBN	;		;	SOLUTION STRUCTURE OF A CALMODULIN-TARGET PEPTIDE COMPLEX BY MULTIDIMENSIONAL NMR
1HOV	;		;	SOLUTION STRUCTURE OF A CATALYTIC DOMAIN OF MMP-2 COMPLEXED WITH SC-74020
1M36	;		;	Solution Structure of a CCHC Zinc Finger from MOZ
1JN7	;		;	Solution Structure of a CCHH mutant of the ninth CCHC Zinc Finger of U-shaped
1PXE	;		;	Solution Structure of a CCHHC Domain of Neural Zinc Finger Factor-1
1EXG	;		;	SOLUTION STRUCTURE OF A CELLULOSE BINDING DOMAIN FROM CELLULOMONAS FIMI BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
1EXH	;		;	SOLUTION STRUCTURE OF A CELLULOSE BINDING DOMAIN FROM CELLULOMONAS FIMI BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
2M1N	;		;	Solution structure of a chaperone in type III secretion system
2M62	;		;	Solution Structure of a Chi/Lambda Conotoxin fron Conus araneosus
1UUC	;		;	solution structure of a chimeric LEKTI-domain
8P25	;		;	Solution structure of a chimeric U2AF2 RRM2 / FUBP1 N-Box
1ON5	;		;	SOLUTION STRUCTURE OF A CHOLIC ACID-CAPPED DNA DUPLEX
2M99	;		;	Solution structure of a chymotrypsin inhibitor from the Taiwan cobra
1M3B	;		;	Solution structure of a circular form of the N-terminal SH3 domain (A134C, E135G, R191G mutant) from oncogene protein c-Crk.
1M3C	;		;	Solution structure of a circular form of the N-terminal SH3 domain (E132C, E133G, R191G mutant) from oncogene protein c-Crk
1M3A	;		;	Solution structure of a circular form of the truncated N-terminal SH3 domain from oncogene protein c-Crk.
1N02	;		;	Solution Structure of a Circular-Permuted Variant of the Potent HIV-inactivating Protein Cyanovirin-N
1N8C	;		;	Solution Structure of a Cis-Opened (10R)-N6-Deoxyadenosine Adduct of (9S,10R)-(9,10)-Epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene in a DNA Duplex
1DDP	;		;	Solution structure of a CISPLATIN-INDUCED [CATAGCTATG]2 Interstrand cross-link
2DA8	;		;	SOLUTION STRUCTURE OF A COMPLEX BETWEEN (N-MECYS3,N-MECYS7)TANDEM AND (D(GATATC))2
1CX3	;		;	SOLUTION STRUCTURE OF A COMPLEX BETWEEN D(ATGCAT)2 AND THE ANTITUMOR BISNAPHTHALIMIDE LU-79553
2M3M	;		;	Solution structure of a complex consisting of hDlg/SAP-97 residues 318-406 and HPV51 oncoprotein E6 residues 141-151
2EZE	;		;	SOLUTION STRUCTURE OF A COMPLEX OF THE SECOND DNA BINDING DOMAIN OF HUMAN HMG-I(Y) BOUND TO DNA DODECAMER CONTAINING THE PRDII SITE OF THE INTERFERON-BETA PROMOTER, NMR, 35 STRUCTURES
2EZD	;		;	SOLUTION STRUCTURE OF A COMPLEX OF THE SECOND DNA BINDING DOMAIN OF HUMAN HMG-I(Y) BOUND TO DNA DODECAMER CONTAINING THE PRDII SITE OF THE INTERFERON-BETA PROMOTER, NMR, MINIMIZED AVERAGE STRUCTURE
2EZG	;		;	SOLUTION STRUCTURE OF A COMPLEX OF THE THIRD DNA BINDING DOMAIN OF HUMAN HMG-I(Y) BOUND TO DNA DODECAMER CONTAINING THE PRDII SITE OF THE INTERFERON-BETA PROMOTER, NMR, 35 STRUCTURES
2EZF	;		;	SOLUTION STRUCTURE OF A COMPLEX OF THE THIRD DNA BINDING DOMAIN OF HUMAN HMG-I(Y) BOUND TO DNA DODECAMER CONTAINING THE PRDII SITE OF THE INTERFERON-BETA PROMOTER, NMR, MINIMIZED AVERAGE STRUCTURE
2LUD	;		;	Solution structure of a conformational mutant of the adhesion protein delta-Bd37 from Babesia divergens
140D	;		;	SOLUTION STRUCTURE OF A CONSERVED DNA SEQUENCE FROM THE HIV-1 GENOME: RESTRAINED MOLECULAR DYNAMICS SIMULATION WITH DISTANCE AND TORSION ANGLE RESTRAINTS DERIVED FROM TWO-DIMENSIONAL NMR SPECTRA
141D	;		;	SOLUTION STRUCTURE OF A CONSERVED DNA SEQUENCE FROM THE HIV-1 GENOME: RESTRAINED MOLECULAR DYNAMICS SIMULATION WITH DISTANCE AND TORSION ANGLE RESTRAINTS DERIVED FROM TWO-DIMENSIONAL NMR SPECTRA
142D	;		;	SOLUTION STRUCTURE OF A CONSERVED DNA SEQUENCE FROM THE HIV-1 GENOME: RESTRAINED MOLECULAR DYNAMICS SIMULATION WITH DISTANCE AND TORSION ANGLE RESTRAINTS DERIVED FROM TWO-DIMENSIONAL NMR SPECTRA
2FDT	;		;	Solution structure of a conserved RNA hairpin of eel LINE UnaL2
2GQB	;		;	Solution Structure of a conserved unknown protein RPA2825 from Rhodopseudomonas palustris; (Northeast Structural Genomics Consortium Target RpT4; Ontario Centre for Structural Proteomics Target rp2812 )
2L8Q	;		;	Solution Structure of a control DNA Duplex
2KTT	;		;	Solution Structure of a Covalently Bound Pyrrolo[2,1-c][1,4]benzodiazepine-Benzimidazole Hybrid to a 10mer DNA Duplex
1OTR	;		;	Solution Structure of a CUE-Ubiquitin Complex
1SB6	;		;	Solution structure of a cyanobacterial copper metallochaperone, ScAtx1
2K2N	;		;	Solution structure of a cyanobacterial phytochrome GAF domain in the red light-absorbing ground state
7V5F	;		;	Solution structure of a Cysteine rich peptide from Withania somnifera (Indian ginseng)
2MTQ	;		;	Solution Structure of a De Novo Designed Peptide that Sequesters Toxic Heavy Metals
2A3D	;		;	SOLUTION STRUCTURE OF A DE NOVO DESIGNED SINGLE CHAIN THREE-HELIX BUNDLE (A3D)
2OEY	;		;	Solution Structure of a Designed Spirocyclic Helical Ligand Binding at a Two-Base Bulge Site in DNA
2KIR	;		;	Solution structure of a designer toxin, mokatoxin-1
1U7J	;		;	Solution structure of a diiron protein model
1U7M	;		;	Solution structure of a diiron protein model: Due Ferri(II) turn mutant
1L1M	;		;	SOLUTION STRUCTURE OF A DIMER OF LAC REPRESSOR DNA-BINDING DOMAIN COMPLEXED TO ITS NATURAL OPERATOR O1
2KEJ	;		;	Solution structure of a dimer of LAC repressor DNA-binding domain complexed to its natural operator O2
2KEK	;		;	Solution structure of a dimer of LAC repressor DNA-binding domain complexed to its natural operator O3
1OSL	;		;	Solution structure of a dimeric lactose DNA-binding domain complexed to a nonspecific DNA sequence
1GJZ	;		;	Solution structure of a dimeric N-terminal fragment of human ubiquitin
2N54	;		;	Solution structure of a disulfide stabilized XCL1 dimer
2KUA	;		;	Solution structure of a divergent Bcl-2 protein
7BZH	;		;	Solution structure of a DNA binding protein from Sulfolobus islandicus
2LL9	;		;	Solution structure of a DNA containing a thymime-thymine mismatch
1AC9	;		;	SOLUTION STRUCTURE OF A DNA DECAMER CONTAINING THE ANTIVIRAL DRUG GANCICLOVIR: COMBINED USE OF NMR, RESTRAINED MOLECULAR DYNAMICS, AND FULL RELAXATION REFINEMENT, 6 STRUCTURES
1BJD	;		;	SOLUTION STRUCTURE OF A DNA DODECAMER CONTAINING SINGLE G*T MISMATCHES USING RELAXATION MATRIX ANALYSIS AND RESTRAINED MOLECULAR DYNAMICS, NMR, 1 STRUCTURE
170D	;		;	SOLUTION STRUCTURE OF A DNA DODECAMER CONTAINING THE ANTI-NEOPLASTIC AGENT ARABINOSYLCYTOSINE: COMBINED USE OF NMR, RESTRAINED MOLECULAR DYNAMICS AND FULL RELAXATION MATRIX REFINEMENT
171D	;		;	SOLUTION STRUCTURE OF A DNA DODECAMER CONTAINING THE ANTI-NEOPLASTIC AGENT ARABINOSYLCYTOSINE: COMBINED USE OF NMR, RESTRAINED MOLECULAR DYNAMICS AND FULL RELAXATION MATRIX REFINEMENT
6ALU	;		;	Solution structure of a DNA dodecamer with 5-methylcytosine at the 3rd and 8-oxoguanine at the 4th position
6ALT	;		;	Solution structure of a DNA dodecamer with 5-methylcytosine at the 3rd and 9th position
5UZ2	;		;	Solution Structure of a DNA Dodecamer with 5-methylcytosine at the 3rd and 9th position and 8-oxoguanine at the 10th position
6ALS	;		;	Solution structure of a DNA dodecamer with 5-methylcytosine at the 3rd and 9th position and 8-oxoguanine at the 4th position
5L06	;		;	Solution Structure of a DNA Dodecamer with 5-methylcytosine at the 3rd Position
5UZ1	;		;	Solution Structure of a DNA Dodecamer with 5-methylcytosine at the 3rd position and 8-oxoguanine at the 10th position
5L2G	;		;	Solution Structure of a DNA Dodecamer with 5-methylcytosine at the 9th Position
5UZ3	;		;	Solution Structure of a DNA Dodecamer with 5-methylcytosine at the 9th position and 8-oxoguanine at the 10th position
5TRN	;		;	Solution Structure of a DNA Dodecamer with 8-oxoguanine at the 4th position and 5-methylcytosine at the 9th position
1BW7	;		;	SOLUTION STRUCTURE OF A DNA DUPLEX CONTAINING A REPLICABLE DIFLUOROTOLUENE-ADENINE PAIR
1ONM	;		;	Solution Structure of a DNA duplex containing A:G mismatch. d(GCTTCAGTCGT):d(ACGACGGAAGC)
1S0T	;		;	Solution structure of a DNA duplex containing an alpha-anomeric adenosine: insights into substrate recognition by endonuclease IV
1S74	;		;	SOLUTION STRUCTURE OF A DNA DUPLEX CONTAINING AN ALPHA-ANOMERIC ADENOSINE: INSIGHTS INTO SUBSTRATE RECOGNITION BY ENDONUCLEASE IV
1S75	;		;	SOLUTION STRUCTURE OF A DNA DUPLEX CONTAINING AN ALPHA-ANOMERIC ADENOSINE: INSIGHTS INTO SUBSTRATE RECOGNITION BY ENDONUCLEASE IV
2LHO	;		;	Solution Structure of a DNA duplex Containing an Unnatural, Hydrophobic Base Pair
1K29	;		;	Solution Structure of a DNA Duplex Containing M1G Opposite a 2 Base Pair Deletion
1DA4	;		;	Solution structure of a DNA duplex containing the CIS-PT(NH3)2[D(-GTG-)-N7-(G)-N7(G)N7(G)]Adduct as determined with high field NMR and molecular mechanics/dynamics
1DA5	;		;	Solution structure of a DNA Duplex containing the CIS-PT(NH3)2[D(-GTG-)-N7-(G)-N7(G)N7(G)]Adduct as determined with high field NMR And molecular mechanics/dynamics
2L8P	;		;	Solution Structure of a DNA Duplex Containing the Potent Anti-Poxvirus Agent Cidofovir
2O4Y	;		;	Solution structure of a DNA duplex containing the universal base 5-nitroindole-3-carboxamide
2F1Q	;		;	Solution structure of a DNA Holliday Junction
1D70	;		;	SOLUTION STRUCTURE OF A DNA OCTAMER CONTAINING THE PRIBNOW BOX VIA RESTRAINED MOLECULAR DYNAMICS SIMULATION WITH DISTANCE AND TORSION ANGLE CONSTRAINTS DERIVED FROM TWO-DIMENSIONAL NUCLEAR MAGNETIC RESONANCE SPECTRAL FITTING
1EZN	;		;	SOLUTION STRUCTURE OF A DNA THREE-WAY JUNCTION
1C2Q	;		;	SOLUTION STRUCTURE OF A DNA.RNA HYBRID CONTAINING AN ALPHAT-ANOMERIC THYMIDINE AND POLARITY REVERSALS
2JNK	;		;	Solution structure of a dockerin-containing modular pair from a family 84 glycoside hydrolase
2JN5	;		;	Solution Structure of a Dodecapeptide from Alpha-Synuclein Bound with Synphilin-1
2N2P	;		;	Solution structure of a double base-pair inversion mutant of murine tumour necrosis factor alpha CDE-23 RNA
2JYL	;		;	Solution Structure of A Double Mutant of The Carboxy-terminal Dimerization Domain of The HIV-1 Capsid Protein
2M0N	;		;	Solution structure of a DUF3349 annotated protein from Mycobacterium abscessus, MAB_3403c. Seattle Structural Genomics Center for Infectious Disease target MyabA.17112.a.A2
1DSI	;		;	Solution structure of a duocarmycin sa-indole-alkylated dna dupleX
7VF1	;		;	Solution structure of a duplex-quadruplex hybrid formed by d[G4C2] repeats
2MHH	;		;	Solution structure of a EF-hand domain from sea urchin polycystin-2
2LVZ	;		;	Solution structure of a Eosinophil Cationic Protein-trisaccharide heparin mimetic complex
2JNW	;		;	Solution structure of a ERCC1-XPA heterodimer
1NVO	;		;	Solution structure of a four-helix bundle model, apo-DF1
2KWG	;		;	Solution structure of a fully modified 2'-F/2'-OMe siRNA construct
1NWV	;		;	SOLUTION STRUCTURE OF A FUNCTIONALLY ACTIVE COMPONENT OF DECAY ACCELERATING FACTOR
2MS9	;		;	Solution structure of a G-quadruplex
2MGN	;		;	Solution structure of a G-quadruplex bound to the bisquinolinium compound Phen-DC3
2KBP	;		;	Solution structure of a G-quadruplex of human telomeric RNA
2F87	;		;	Solution structure of a GAAG tetraloop in SRP RNA from Pyrococcus furiosus
6U46	;		;	Solution Structure of a Heat-Resistant Long-Acting Insulin Analog
1JHI	;		;	Solution Structure of a Hedamycin-DNA complex
7DO1	;		;	Solution structure of a heteromolecular telomeric (3+1) G-quadruplex containing right loop progression
1EC4	;		;	SOLUTION STRUCTURE OF A HEXITOL NUCLEIC ACID DUPLEX WITH FOUR CONSECUTIVE T:T BASE PAIRS
1AUL	;		;	SOLUTION STRUCTURE OF A HIGHLY STABLE DNA DUPLEX CONJUGATED TO A MINOR GROOVE BINDER, NMR, MINIMIZED AVERAGE STRUCTURE
5WQZ	;		;	Solution structure of a histone binding domain
1EJZ	;		;	SOLUTION STRUCTURE OF A HNA-RNA HYBRID
1RJJ	;		;	Solution structure of a homodimeric hypothetical protein, At5g22580, a structural genomics target from Arabidopsis thaliana
1ZR9	;		;	Solution Structure of a Human C2H2-type Zinc Finger Protein
2I3B	;		;	Solution Structure of a Human Cancer-Related Nucleoside Triphosphatase
5MVB	;		;	Solution structure of a human G-Quadruplex hybrid-2 form in complex with a Gold-ligand.
1CQ0	;		;	SOLUTION STRUCTURE OF A HUMAN HYPOCRETIN-2/OREXIN-B'SOLUTION STRUCTURE OF A HUMAN HYPOCRETIN-2/OREXIN-B '
2LAT	;		;	Solution structure of a Human minimembrane protein OST4
1ZKH	;		;	Solution structure of a human ubiquitin-like domain in SF3A1
1J5B	;		;	Solution structure of a hydrophobic analogue of the winter flounder antifreeze protein
1MY9	;		;	Solution structure of a K+ cation stabilized dimeric RNA quadruplex containing two G:G(:A):G:G(:A) hexads, G:G:G:G tetrads and UUUU loops
1JLZ	;		;	Solution Structure of a K+-Channel Blocker from the Scorpion Toxin of Tityus cambridgei
2K44	;		;	Solution structure of a K+-channel voltage-sensor paddle domain
2JMZ	;		;	Solution structure of a KlbA intein precursor from Methanococcus jannaschii
2JNQ	;		;	Solution Structure of a KlbA Intein Precursor from Methanococcus jannaschii
1J9V	;		;	Solution structure of a lactam analogue (DabD) of HIV gp41 600-612 loop.
7QB3	;		;	Solution structure of a lanthanide-binding DNA aptamer
6FE6	;		;	Solution structure of a last generation P2-P4 macrocyclic inhibitor
2JXV	;		;	Solution structure of a let-7 miRNA:lin-41 mRNA complex from C. elegans
1N89	;		;	Solution structure of a liganded type 2 wheat non-specific Lipid Transfer Protein
2IT8	;		;	Solution structure of a linear analog of the cyclic squash trypsin inhibitor MCoTI-II
1KQE	;		;	Solution structure of a linked shortened gramicidin A in benzene/acetone 10:1
1TKQ	;		;	SOLUTION STRUCTURE OF A LINKED UNSYMMETRIC GRAMICIDIN IN A MEMBRANE-ISOELECTRICAL SOLVENTS MIXTURE IN THE PRESENCE OF CsCl
1SPW	;		;	Solution Structure of a Loop Truncated Mutant from D. gigas Rubredoxin, NMR
1BVH	;		;	SOLUTION STRUCTURE OF A LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE
1ZGG	;		;	Solution structure of a low molecular weight protein tyrosine phosphatase from Bacillus subtilis
2LPD	;		;	Solution structure of a MbtH-like protein from Burkholderia pseudomallei, the etiological agent responsible for melioidosis, Seattle Structural Genomics Center for Infectious Disease target BupsA.13472.b
1VM3	;		;	Solution structure of a membrane-targeting peptide designed based on the N-terminal sequence of E. coli enzyme IIA (Glucose)
2LSX	;		;	Solution structure of a mini i-motif
1D5Q	;		;	SOLUTION STRUCTURE OF A MINI-PROTEIN REPRODUCING THE CORE OF THE CD4 SURFACE INTERACTING WITH THE HIV-1 ENVELOPE GLYCOPROTEIN
2LC9	;		;	Solution Structure of a Minor and Transiently Formed State of a T4 Lysozyme Mutant
2LCB	;		;	Solution Structure of a Minor and Transiently Formed State of a T4 Lysozyme Mutant
8DOA	;		;	Solution structure of a model HEEH mini-protein (HEEH_TK_rd5_0958)
1G22	;		;	SOLUTION STRUCTURE OF A MODIFIED HUMAN CENTROMERIC FRAGMENT
1EL2	;		;	SOLUTION STRUCTURE OF A MODIFIED HUMAN TELOMERE FRAGMENT (STRUCTURE ""A"")
1ELN	;		;	SOLUTION STRUCTURE OF A MODIFIED HUMAN TELOMERE FRAGMENT (STRUCTURE ""S"")
2LTK	;		;	Solution structure of a monomeric truncated mutant of Trypanosoma brucei 1-C-Grx1
1Y4O	;		;	Solution structure of a mouse cytoplasmic Roadblock/LC7 dynein light chain
2AXL	;		;	Solution structure of a multifunctional DNA- and protein-binding domain of human Werner syndrome protein
1UGJ	;		;	Solution structure of a murine hypothetical protein from RIKEN cDNA 2310057J16
2LZZ	;		;	Solution structure of a mutant of the triheme cytochrome PpcA from Geobacter sulfurreducens sheds light on the role of the conserved aromatic residue F15
1EXE	;		;	SOLUTION STRUCTURE OF A MUTANT OF TRANSCRIPTION FACTOR 1.
1V6E	;		;	Solution Structure of a N-terminal Ubiquitin-like Domain in Mouse Tubulin-specific Chaperone B
1A8N	;		;	SOLUTION STRUCTURE OF A NA+ CATION STABILIZED DNA QUADRUPLEX CONTAINING G.G.G.G AND G.C.G.C TETRADS FORMED BY G-G-G-C REPEATS OBSERVED IN AAV AND HUMAN CHROMOSOME 19, NMR, 8 STRUCTURES
1T12	;		;	Solution Structure of a new LTP1
1M2S	;		;	Solution Structure of A New Potassium Channels Blocker from the Venom of Chinese Scorpion Buthus martensi Karsch
2P0X	;		;	solution structure of a non-biological ATP-binding protein
7B2B	;		;	Solution structure of a non-covalent extended docking domain complex of the Pax NRPS: PaxA T1-CDD/PaxB NDD
2L6K	;		;	Solution Structure of a Nonphosphorylated Peptide Recognizing Domain
1EEK	;		;	SOLUTION STRUCTURE OF A NONPOLAR, NON HYDROGEN BONDED BASE PAIR SURROGATE IN DNA.
2LZ5	;		;	Solution structure of a Novel Alpha-Conotoxin TxIB
5X3L	;		;	Solution structure of a novel antimicrobial peptide, P1, from jumper ant Myrmecia pilosula
1WF9	;		;	Solution structure of a novel beta-grasp fold like domain of Hypothetical protein (Arabidopsis thaliana)
2BEY	;		;	Solution Structure of a Novel C2 Symmetrical Bifunctional Bicyclic Inhibitor Based on SFTI-1
1J5I	;		;	Solution Structure of a Novel Chromoprotein Derived from Apo-Neocarzinostatin and a Synthetic Chromophore
2JQB	;		;	Solution structure of a novel D-amiNo acid containing conopeptide, conomarphin at pH 5
2KTC	;		;	Solution Structure of a Novel hKv1.1 inhibiting scorpion toxin from Mesibuthus tamulus
2RPS	;		;	Solution structure of a novel insect chemokine isolated from integument
1X22	;		;	Solution structure of a novel moricin analogue, an antibacterial peptide from a lepidopteran insect, Spodoptera litura
2K89	;		;	Solution structure of a novel Ubiquitin-binding domain from Human PLAA (PFUC, Gly76-Pro77 cis isomer)
2K8A	;		;	Solution structure of a novel Ubiquitin-binding domain from Human PLAA (PFUC, Gly76-Pro77 trans isomer)
1HFH	;		;	SOLUTION STRUCTURE OF A PAIR OF COMPLEMENT MODULES BY NUCLEAR MAGNETIC RESONANCE
1HFI	;		;	SOLUTION STRUCTURE OF A PAIR OF COMPLEMENT MODULES BY NUCLEAR MAGNETIC RESONANCE
1QO6	;		;	Solution structure of a pair of modules from the gelatin-binding domain of fibronectin
1HKY	;		;	Solution structure of a PAN module from Eimeria tenella
139D	;		;	SOLUTION STRUCTURE OF A PARALLEL-STRANDED G-QUADRUPLEX DNA
2LUJ	;		;	Solution structure of a parallel-stranded oligoisoguanine DNA pentaplex formed by d(T(iG)4T) in the presence of Cs ions
2K76	;		;	Solution structure of a paralog-specific Mena binder by NMR
2KHA	;		;	Solution Structure of a Pathogen Recognition Domain from a Lepidopteran Insect, Plodia interpunctella
2KG2	;		;	Solution structure of a PDZ protein
2B0Y	;		;	Solution Structure of a peptide mimetic of the fourth cytoplasmic loop of the G-protein coupled CB1 cannabinoid receptor
2K4G	;		;	Solution Structure of a Peptide Nucleic Acid Duplex, 10 structures
1KAT	;		;	Solution Structure of a Phage-Derived Peptide Antagonist in Complex with Vascular Endothelial Growth Factor
8ABN	;		;	Solution structure of a phenyl-indoloquinoline intercalating into a quadruplex-duplex hybrid
6C2U	;		;	Solution structure of a phosphate-loop protein
6C2V	;		;	Solution structure of a phosphate-loop protein
1D0T	;		;	SOLUTION STRUCTURE OF A PHOSPHOROTHIOATE MODIFIED RNA BINDING SITE FOR PHAGE MS2 COAT PROTEIN
1XRW	;		;	Solution Structure of a Platinum-Acridine Modified Octamer
1PLS	;		;	SOLUTION STRUCTURE OF A PLECKSTRIN HOMOLOGY DOMAIN
1PSM	;		;	SOLUTION STRUCTURE OF A POLYPEPTIDE CONTAINING FOUR HEPTAD REPEATS FROM A MEROZOITE SURFACE ANTIGEN OF PLASMODIUM FALCIPARUM
2GIP	;		;	Solution structure of a portion of the 5'UTR of HspA mRNA from Bradyrhizobium janponicum having deleted G83
2GIO	;		;	Solution Structure of a portion of the 5'UTR of HspA mRNA of Bradyrhizobium japonicum
1HDP	;		;	SOLUTION STRUCTURE OF A POU-SPECIFIC HOMEODOMAIN: 3D-NMR STUDIES OF HUMAN B-CELL TRANSCRIPTION FACTOR OCT-2
2L1V	;		;	Solution structure of a preQ1 riboswitch (Class I) aptamer bound to preQ1
1F16	;		;	SOLUTION STRUCTURE OF A PRO-APOPTOTIC PROTEIN BAX
2MRI	;		;	Solution structure of a proteasome related subunit C terminal domain
2MQW	;		;	Solution structure of a proteasome related subunit N terminal domain
2MKZ	;		;	solution structure of a protein C-terminal domain
2MK5	;		;	Solution structure of a protein domain
2GVO	;		;	Solution structure of a purine rich hexaloop hairpin belonging to PGY/MDR1 mRNA and targeted by antisense oligonucleotides
134D	;		;	SOLUTION STRUCTURE OF A PURINE(DOT)PURINE(DOT)PYRIMIDINE DNA TRIPLEX CONTAINING G(DOT)GC AND T(DOT)AT TRIPLES
135D	;		;	SOLUTION STRUCTURE OF A PURINE(DOT)PURINE(DOT)PYRIMIDINE DNA TRIPLEX CONTAINING G(DOT)GC AND T(DOT)AT TRIPLES
136D	;		;	SOLUTION STRUCTURE OF A PURINE(DOT)PURINE(DOT)PYRIMIDINE DNA TRIPLEX CONTAINING G(DOT)GC AND T(DOT)AT TRIPLES
2ENK	;		;	Solution structure of a putativ DNA-binding domain of the humansolute carrier family 30 (zinc transporter) protein
2L4B	;		;	Solution structure of a putative acyl carrier protein from Anaplasma phagocytophilum. Seattle Structural Genomics Center for Infectious Disease target AnphA.01018.a
2MU0	;		;	Solution structure of a putative arsenate reductase from Brucella melitensis. Seattle Structural Genomics Center for Infectious Disease target BrabA.00073.a
2KUC	;		;	Solution Structure of a putative disulphide-isomerase from Bacteroides thetaiotaomicron
1YYC	;		;	Solution Structure of a putative late embryogenesis abundant (LEA) protein At2g46140.1
1J26	;		;	Solution structure of a putative peptidyl-tRNA hydrolase domain in a mouse hypothetical protein
2LS5	;		;	Solution structure of a putative protein disulfide isomerase from Bacteroides thetaiotaomicron
1PA4	;		;	Solution structure of a putative ribosome-binding factor from Mycoplasma pneumoniae (MPN156)
1J03	;		;	Solution structure of a putative steroid-binding protein from Arabidopsis
2L7Y	;		;	Solution structure of a putative surface protein
2LJA	;		;	Solution Structure of a putative thiol-disulfide oxidoreductase from Bacteroides vulgatus
2L5O	;		;	Solution Structure of a Putative Thioredoxin from Neisseria meningitidis
2NAS	;		;	Solution structure of a PWWP doamin from Trypanosoma brucei
1H3Z	;		;	Solution structure of a PWWP domain from Schizosaccharomyces Pombe
2M1H	;		;	Solution structure of a PWWP domain from Trypanosoma brucei
149D	;		;	SOLUTION STRUCTURE OF A PYRIMIDINE(DOT)PURINE(DOT) PYRIMIDINE DNA TRIPLEX CONTAINING T(DOT)AT, C+(DOT)GC AND G(DOT)TA TRIPLES
1C38	;		;	SOLUTION STRUCTURE OF A QUADRUPLEX FORMING DNA AND ITS INTERMEDIATE
1C32	;		;	SOLUTION STRUCTURE OF A QUADRUPLEX FORMING DNA AND ITS INTERMIDIATE
1C34	;		;	SOLUTION STRUCTURE OF A QUADRUPLEX FORMING DNA AND ITS INTERMIDIATE
1C35	;		;	SOLUTION STRUCTURE OF A QUADRUPLEX FORMING DNA AND ITS INTERMIDIATE
1KSE	;		;	Solution Structure of a quinolone-capped DNA duplex
193D	;		;	SOLUTION STRUCTURE OF A QUINOMYCIN BISINTERCALATOR-DNA COMPLEX
1DF3	;		;	SOLUTION STRUCTURE OF A RECOMBINANT MOUSE MAJOR URINARY PROTEIN
1Y03	;		;	Solution structure of a recombinant type I sculpin antifreeze protein
1Y04	;		;	Solution structure of a recombinant type I sculpin antifreeze protein
7JH1	;		;	Solution structure of a reconstructed XCL1 ancestor
2RT9	;		;	Solution structure of a regulatory domain of meiosis inhibitor
5KIZ	;		;	Solution Structure of a repacked version of HIF-2 alpha PAS-B
1XSF	;		;	Solution structure of a resuscitation promoting factor domain from Mycobacterium tuberculosis
2RVO	;		;	Solution structure of a reverse transcriptase recognition site of a LINE RNA from zebrafish
2MMP	;		;	Solution structure of a ribosomal protein
2LVY	;		;	Solution Structure of a RNA Duplex Containing a 2'-O-Pivaloyloxymethyl Modification
6J9P	;		;	Solution structure of a salt-resistant antimicrobial peptide, RR12
2KH2	;		;	Solution structure of a scFv-IL-1B complex
2N4J	;		;	Solution structure of a self complementary Xylonucleic Acid duplex
1ZXF	;		;	Solution structure of a self-sacrificing resistance protein, CalC from Micromonospora echinospora
1CFA	;		;	SOLUTION STRUCTURE OF A SEMI-SYNTHETIC C5A RECEPTOR ANTAGONIST AT PH 5.2, 303K, NMR, 20 STRUCTURES
2LDS	;		;	Solution Structure of a Short-chain LaIT1 from the Venom of Scorpion Liocheles australasiae
2LI4	;		;	Solution structure of a shortened antiterminator hairpin from a Mg2+ riboswitch
1IEH	;		;	SOLUTION STRUCTURE OF A SOLUBLE SINGLE-DOMAIN ANTIBODY WITH HYDROPHOBIC RESIDUES TYPICAL OF A VL/VH INTERFACE
1MSE	;		;	SOLUTION STRUCTURE OF A SPECIFIC DNA COMPLEX OF THE MYB DNA-BINDING DOMAIN WITH COOPERATIVE RECOGNITION HELICES
1MSF	;		;	SOLUTION STRUCTURE OF A SPECIFIC DNA COMPLEX OF THE MYB DNA-BINDING DOMAIN WITH COOPERATIVE RECOGNITION HELICES
2A63	;		;	Solution structure of a stably monomeric mutant of lambda Cro produced by substitutions in the ball-and-socket interface
2MB4	;		;	Solution structure of a stacked dimeric G-quadruplex formed by a segment of the human CEB1 minisatellite
1A9L	;		;	SOLUTION STRUCTURE OF A SUBSTRATE FOR THE ARCHAEAL PRE-TRNA SPLICING ENDONUCLEASES: THE BULGE-HELIX-BULGE MOTIF, NMR, 12 STRUCTURES
2F3I	;		;	Solution Structure of a Subunit of RNA Polymerase II
2RPQ	;		;	Solution Structure of a SUMO-interacting motif of MBD1-containing chromatin-associated factor 1 bound to SUMO-3
1POQ	;		;	Solution Structure of a Superantigen from Yersinia pseudotuberculosis
1TBA	;		;	SOLUTION STRUCTURE OF A TBP-TAFII230 COMPLEX: PROTEIN MIMICRY OF THE MINOR GROOVE SURFACE OF THE TATA BOX UNWOUND BY TBP, NMR, 25 STRUCTURES
2K3V	;		;	Solution Structure of a Tetrahaem Cytochrome from Shewanella Frigidimarina
2LRN	;		;	Solution structure of a thiol:disulfide interchange protein from Bacteroides sp.
2LST	;		;	Solution structure of a thioredoxin from Thermus thermophilus
2B5Y	;		;	Solution Structure of a Thioredoxin-like Protein in the Oxidized Form
2B5X	;		;	Solution Structure of a Thioredoxin-like Protein in the Reduced Form
2LLP	;		;	Solution structure of a THP type 1 alpha 1 collagen fragment (772-786)
1J1H	;		;	Solution structure of a tmRNA-binding protein, SmpB, from Thermus thermophilus
1LUP	;		;	Solution structure of a toxin (GsMTx2) from the tarantula, Grammostola spatulata, which inhibits mechanosensitive ion channels
1HP2	;		;	SOLUTION STRUCTURE OF A TOXIN FROM THE SCORPION TITYUS SERRULATUS (TSTX-K ALPHA) DETERMINED BY NMR.
1TYK	;		;	SOLUTION STRUCTURE OF A TOXIN FROM THE TARANTULA, GRAMMOSTOLA SPATULATA, WHICH INHIBITS MECHANOSENSITIVE ION CHANNELS
1JDG	;		;	Solution Structure of a Trans-Opened (10S)-dA Adduct of (+)-(7S,8R,9S,10R)-7,8-Dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene in a fully Complementary DNA Duplex
1PCP	;		;	SOLUTION STRUCTURE OF A TREFOIL-MOTIF-CONTAINING CELL GROWTH FACTOR, PORCINE SPASMOLYTIC PROTEIN
5T3M	;		;	Solution structure of a triple mutant of HwTx-IV - a potent blocker of Nav1.7
4CRP	;		;	Solution structure of a TrkAIg2 domain construct for use in drug discovery
1UUB	;		;	Solution structure of a truncated bovine pancreatic trypsin inhibitor mutant, 3-58 BPTI (K15R, R17A, R42S)
1UUA	;		;	Solution structure of a truncated bovine pancreatic trypsin inhibitor, 3-58 BPTI.
1Y7X	;		;	Solution structure of a two-repeat fragment of major vault protein
1T0Y	;		;	Solution Structure of a Ubiquitin-Like Domain from Tubulin-binding Cofactor B
2LRW	;		;	Solution structure of a ubiquitin-like protein from Trypanosoma brucei
2KDI	;		;	Solution structure of a Ubiquitin/UIM fusion protein
6D2U	;		;	Solution structure of a ultra-high affinity macrocycle bound to HIV-1 TAR RNA
1DGO	;		;	SOLUTION STRUCTURE OF A URACIL CONTAINING HAIRPIN DNA
1QE7	;		;	SOLUTION STRUCTURE OF A URACIL CONTAINING HAIRPIN DNA
1P96	;		;	Solution Structure of a Wedge-Shaped Synthetic Molecule at a Two-Base Bulge Site in DNA
7D11	;		;	Solution structure of a WKRY DNA-binding domain
1ZW8	;		;	Solution structure of a ZAP1 zinc-responsive domain provides insights into metalloregulatory transcriptional repression in Saccharomyces cerevisiae
1CO4	;		;	SOLUTION STRUCTURE OF A ZINC DOMAIN CONSERVED IN YEAST COPPER-REGULATED TRANSCRIPTION FACTORS
2L0Z	;		;	Solution structure of a zinc-binding domain from the Junin virus envelope glycoprotein
2K8D	;		;	Solution structure of a zinc-binding methionine sulfoxide reductase
2FJ4	;		;	SOLUTION STRUCTURE OF a-domain of HUMAN Metallothionein-3 (MT-3)
7B7O	;		;	Solution structure of A. thaliana core TatA in DHPC micelles
1ZXG	;		;	Solution structure of A219
1JEX	;		;	SOLUTION STRUCTURE OF A67V MUTANT OF RAT FERRO CYTOCHROME B5
6NK9	;		;	Solution structure of AcaTx1, a potassium channel inhibitor from the sea anemone Antopleura cascaia
1XWU	;		;	Solution structure of ACAUAGA loop
2MWR	;		;	Solution Structure of Acidocin B, a Circular Bacteriocin from Lactobacillus acidophilus M46
7D37	;		;	Solution structure of Acm2-precursor peptide of Heat-stable enterotoxin produced by Enterotoxigenic Escherichia coli
1VDJ	;		;	Solution structure of actin-binding domain of troponin in Ca2+-bound state
1VDI	;		;	Solution structure of actin-binding domain of troponin in Ca2+-free state
2RU0	;		;	Solution structure of actinomycesin
2JU1	;		;	Solution structure of acyl carrier protein domain from module 2 of 6-deoxyerythronolide B synthase (DEBS)
2KWL	;		;	Solution Structure of acyl carrier protein from Borrelia burgdorferi
2N98	;		;	Solution structure of acyl carrier protein LipD from Actinoplanes friuliensis
2LBB	;		;	Solution structure of acyl CoA binding protein from Babesia bovis T2Bo
1ST7	;		;	Solution structure of Acyl Coenzyme A Binding Protein from yeast
2L3C	;		;	Solution structure of ADAR2 dsRBM1 bound to LSL RNA
2MP4	;		;	Solution Structure of ADF like UNC-60A Protein of Caenorhabditis elegans
2KVK	;		;	Solution structure of ADF/cofilin (LDCOF) from Leishmania donovani
2LJ8	;		;	Solution structure of ADF/Cofilin from trypanosoma brucei
2MMF	;		;	Solution structure of AGA modified
2E2S	;		;	Solution structure of agelenin, an insecticidal peptide from the venom of Agelena opulenta
6BZJ	;		;	Solution structure of AGL55
6UZ4	;		;	Solution structure of AGL55-Kringle 2 complex
2LNS	;		;	Solution structure of AGR2 residues 41-175
2MMQ	;		;	Solution structure of AGT FAPY Modified duplex
2M8B	;		;	Solution structure of AhPDF1 from Arabidopsis halleri
1IJP	;		;	Solution Structure of Ala20Pro/Pro64Ala substituted subunit c of Escherichia coli ATP synthase
1GV6	;		;	Solution structure of alfa-L-LNA:DNA duplex
2ML1	;		;	Solution Structure of AlgE6R1 subunit from the Azotobacter vinelandii Mannuronan C5-epimerase
2ML2	;		;	Solution Structure of AlgE6R2 subunit from the Azotobacter vinelandii Mannuronan C5-epimerase
2ML3	;		;	Solution Structure of AlgE6R3 subunit from the Azotobacter vinelandii Mannuronan C5-epimerase
2L88	;		;	Solution structure of all parallel G-quadruplex formed by the oncogene RET promoter sequence
2MI9	;		;	Solution structure of allatide C4, conformation 1
2MIA	;		;	Solution structure of allatide C4, conformation 2
1Q3J	;		;	Solution structure of ALO3: a new knottin-type antifungal peptide from the insect Acrocinus longimanus
2MM6	;		;	solution structure of alpha amylase inhibitor peptide aS1 from Allatide scholaris
1Q8K	;		;	Solution structure of alpha subunit of human eIF2
2MM5	;		;	solution structure of alpha-amylase inhibitor peptide aS4 from Allatide scholaris
2MAU	;		;	Solution structure of alpha-amylase inhibitor wrightide R1 (wR1) peptide from Wrightia religiosa
1KFH	;		;	Solution Structure of alpha-Bungarotoxin by NMR Spectroscopy
1LXH	;		;	Solution structure of alpha-cobratoxin complexed with a cognate peptide (minimized average structure)
1LXG	;		;	Solution structure of alpha-cobratoxin complexed with a cognate peptide (structure ensemble)
1MXN	;		;	Solution structure of alpha-conotoxin AuIB
2I28	;		;	Solution Structure of alpha-Conotoxin BuIA
1IMI	;		;	SOLUTION STRUCTURE OF ALPHA-CONOTOXIN IM1
1MII	;		;	SOLUTION STRUCTURE OF ALPHA-CONOTOXIN MII
2GCZ	;		;	Solution Structure of alpha-Conotoxin OmIA
1QMW	;		;	Solution structure of alpha-conotoxin SI
2H8S	;		;	Solution structure of alpha-conotoxin Vc1.1
6MZT	;		;	Solution structure of alpha-KTx-6.21 (UroTx) from Urodacus yaschenkoi
2KZB	;		;	Solution structure of alpha-mannosidase binding domain of Atg19
2KZK	;		;	Solution structure of alpha-mannosidase binding domain of Atg34
2RMO	;		;	Solution structure of alpha-spectrin_SH3-bergerac from Chicken
1QP6	;		;	SOLUTION STRUCTURE OF ALPHA2D
2M0W	;		;	Solution structure of ALPS-23 peptide in SDS micelles
1YZ2	;		;	Solution structure of Am2766
6CJZ	;		;	Solution Structure of Amebosin
1EDX	;		;	SOLUTION STRUCTURE OF AMINO TERMINUS OF BOVINE RHODOPSIN (RESIDUES 1-40)
2KBE	;		;	solution structure of amino-terminal domain of Dbp5p
2V6Z	;		;	Solution Structure of Amino-Terminal Domain of Human DNA Polymerase Epsilon Subunit B
2GFR	;		;	Solution structure of Amphibian tachykinin Uperolein bound to DPC micelles
1KB1	;		;	SOLUTION STRUCTURE OF AN 11-MER DNA DUPLEX CONTAINING 6-THIOGUANINE OPPOSITE CYTOSINE
1KBM	;		;	SOLUTION STRUCTURE OF AN 11-MER DNA DUPLEX CONTAINING 6-THIOGUANINE OPPOSITE THYMINE
2KLW	;		;	Solution structure of an abc collagen heterotrimer reveals a single-register helix stabilized by electrostatic interactions
2MD9	;		;	Solution Structure of an Active Site Mutant Pepitdyl Carrier Protein
1JBN	;		;	Solution structure of an acyclic permutant of SFTI-1, A trypsin inhibitor from sunflower seeds
2KR5	;		;	Solution Structure of an Acyl Carrier Protein Domain from Fungal Type I Polyketide Synthase
7X31	;		;	solution structure of an anti-CRISPR protein
1VM4	;		;	Solution structure of an antibacterial and antitumor peptide designed based on the N-terminal membrane anchor of E. coli enzyme IIA (Glucose)
1VM2	;		;	Solution structure of an anticancer peptide designed based on the N-terminal sequence of E. coli enzyme IIA (Glucose)
2JOB	;		;	Solution structure of an antilipopolysaccharide factor from shrimp and its possible Lipid A binding site
2LP8	;		;	SOLUTION STRUCTURE OF AN APOPTOSIS ACTIVATING PHOTOSWITCHABLE BAK PEPTIDE BOUND to BCL-XL
5VFK	;		;	Solution structure of an archaeal DUF61 family protein SSO0941
2KJG	;		;	Solution structure of an archaeal protein SSO6904 from hyperthermophilic Sulfolobus solfataricus
2KOK	;		;	Solution structure of an arsenate reductase (ArsC) related protein from Brucella melitensis. Seattle Structural Genomics Center for Infectious Disease target BrabA.00007.a.
2LW6	;		;	Solution structure of an avirulence protein AvrPiz-t from pathogen Magnaportheoryzae
1W86	;		;	Solution structure of an dsDNA:LNA triplex
1CEJ	;		;	SOLUTION STRUCTURE OF AN EGF MODULE PAIR FROM THE PLASMODIUM FALCIPARUM MEROZOITE SURFACE PROTEIN 1
1Z6C	;		;	Solution structure of an EGF pair (EGF34) from vitamin K-dependent protein S
2FLG	;		;	Solution structure of an EGF-LIKE domain from the Plasmodium falciparum merozoite surface protein 1
2KML	;		;	Solution structure of an endopeptidase from Escherichia coli
2I8L	;		;	Solution Structure of an endopeptidase HycI from Escherichia coli
1JR6	;		;	Solution Structure of an Engineered Arginine-rich Subdomain 2 of the Hepatitis C Virus NS3 RNA Helicase
1ONB	;		;	Solution structure of an engineered arginine-rich subdomain 2 of the hepatitis C virus NS3 RNA helicase
2V9H	;		;	Solution Structure of an Escherichia coli YaeT tandem POTRA domain
1ALG	;		;	SOLUTION STRUCTURE OF AN HGR INHIBITOR, NMR, 10 STRUCTURES
1IE2	;		;	Solution Structure of an In Vitro Selected RNA which is Sequence Specifically Recognized by RBD12 of Hamster Nucleolin.sNRE (anti)
6A7Y	;		;	Solution structure of an intermolecular leaped V-shape G-quadruplex
2MB3	;		;	Solution structure of an intramolecular (3+1) human telomeric G-quadruplex bound to a telomestatin derivative
7CLS	;		;	Solution structure of an intramolecular G-quadruplex containing a duplex bulge
2M4P	;		;	Solution structure of an intramolecular propeller-type G-quadruplex containing a single bulge
7QA2	;		;	Solution structure of an intramolecular RNA G-quadruplex formed by the 6A mutant from a 22mer guanine-rich sequence within the 5'UTR of BCL-2 proto-oncogene
7Q6L	;		;	Solution structure of an intramolecular RNA G-quadruplex formed by the 6A8A17U mutant from a 22mer guanine-rich sequence within the 5'UTR of BCL-2 proto-oncogene
7Q48	;		;	Solution structure of an intramolecular RNA G-quadruplex formed by the 6A8U17U mutant from a 22mer guanine-rich sequence within the 5'UTR of BCL-2 proto onco-gene
1MAJ	;		;	SOLUTION STRUCTURE OF AN ISOLATED ANTIBODY VL DOMAIN
1MAK	;		;	SOLUTION STRUCTURE OF AN ISOLATED ANTIBODY VL DOMAIN
2WCN	;		;	Solution structure of an LNA-modified quadruplex
2EFZ	;		;	Solution Structure of an M-1 Conotoxin with a novel disulfide linkage
2N6G	;		;	Solution structure of an MbtH-like protein from Mycobacterium avium, Seattle Structural Genomics Center for Infectious Disease target MyavA.01649.c
2MYY	;		;	Solution structure of an MbtH-like protein from Mycobacterium marinum, Seattle Structural Genomics Center for Infectious Disease target MymaA.01649.c
2K33	;		;	Solution structure of an N-glycosylated protein using in vitro glycosylation
1PYJ	;		;	Solution Structure of an O6-[4-oxo-4-(3-pyridyl)butyl]guanine adduct in an 11mer DNA duplex
5HV8	;		;	Solution structure of an octanoyl- loaded acyl carrier protein domain from module MLSA2 of the mycolactone polyketide synthase.
1NRA	;		;	SOLUTION STRUCTURE OF AN OLD WORLD-LIKE NEUROTOXIN FROM THE VENOM OF THE NEW WORLD SCORPION CENTRUROIDES SCULPTURATUS EWING
1NRB	;		;	SOLUTION STRUCTURE OF AN OLD WORLD-LIKE NEUROTOXIN FROM THE VENOM OF THE NEW WORLD SCORPION CENTRUROIDES SCULPTURATUS EWING
1U6N	;		;	Solution Structure of an Oligodeoxynucleotide Containing a Butadiene Derived N1 b-Hydroxyalkyl Adduct on Deoxyinosine in the Human N-ras Codon 61 Sequence
6UHW	;		;	Solution structure of an organic hydroperoxide resistance protein from Burkholderia pseudomallei. Seattle Structural Genomics Center for Infectious Disease target BupsA.00074.a.
2IEM	;		;	Solution structure of an oxidized form (Cys51-Cys198) of E. coli Methionine Sulfoxide Reductase A (MsrA)
2MP9	;		;	Solution structure of an potent antifungal peptide Cm-p5 derived from C. muricatus
1FUV	;		;	SOLUTION STRUCTURE OF AN RGD PEPTIDE ISOMER-A
1FUL	;		;	SOLUTION STRUCTURE OF AN RGD PEPTIDE ISOMER-B
1NAO	;		;	SOLUTION STRUCTURE OF AN RNA 2'-O-METHYLATED RNA DUPLEX CONTAINING AN RNA/DNA HYBRID SEGMENT AT THE CENTER, NMR, MINIMIZED AVERAGE STRUCTURE
1D0U	;		;	SOLUTION STRUCTURE OF AN RNA BINDING SITE FOR PHAGE MS2 COAT PROTEIN
7DD4	;		;	Solution structure of an RNA derived from the joint region of the TAR and PolyA stems of HIV-1 genomic RNA
1C4L	;		;	SOLUTION STRUCTURE OF AN RNA DUPLEX INCLUDING A C-U BASE-PAIR
1IK1	;		;	Solution Structure of an RNA Hairpin from HRV-14
1WKS	;		;	Solution structure of an RNA stem-loop derived from the 3' conserved region of eel LINE UnaL2
1AC3	;		;	SOLUTION STRUCTURE OF AN RNA-DNA HYBRID DUPLEX CONTAINING A 3'-THIOFORMACETAL LINKER AND AN RNA A-TRACT, NMR, 8 STRUCTURES
1YUB	;		;	SOLUTION STRUCTURE OF AN RRNA METHYLTRANSFERASE (ERMAM) THAT CONFERS MACROLIDE-LINCOSAMIDE-STREPTOGRAMIN ANTIBIOTIC RESISTANCE, NMR, MINIMIZED AVERAGE STRUCTURE
2PCV	;		;	Solution Structure of an rRNA Substrate Bound to the Pseudouridylation Pocket of a Box H/ACA snoRNA
2PCW	;		;	Solution Structure of an rRNA Substrate Bound to the Pseudouridylation Pocket of a Box H/ACA snoRNA
2L57	;		;	Solution Structure of an Uncharacterized Thioredoin-like Protein from Clostridium perfringens
1RAU	;		;	SOLUTION STRUCTURE OF AN UNUSUALLY STABLE RNA TETRAPLEX CONTAINING G-AND U-QUARTET STRUCTURES
5IJ4	;		;	Solution structure of AN1-type zinc finger domain from Cuz1 (Cdc48 associated ubiquitin-like/zinc-finger protein-1)
1CZ6	;		;	SOLUTION STRUCTURE OF ANDROCTONIN
1Y1B	;		;	Solution structure of Anemonia elastase inhibitor
1Y1C	;		;	Solution structure of Anemonia elastase inhibitor analogue
2MAR	;		;	Solution structure of Ani s 5 Anisakis simplex allergen
2KCR	;		;	Solution structure of anntoxin
1QWV	;		;	Solution structure of Antheraea polyphemus pheromone binding protein (ApolPBP)
6M3N	;		;	Solution structure of anti-CRISPR AcrIF7
2LW5	;		;	Solution structure of anti-CRISPR protein Acr30-35 from Pseudomonas aeruginosa Phage JBD30
6LKF	;		;	Solution structure of Anti-CRISPR protein AcrIIA5
1GQ0	;		;	Solution structure of Antiamoebin I, a membrane channel-forming polypeptide; NMR, 20 structures
1KV4	;		;	Solution structure of antibacterial peptide (Moricin)
5KQJ	;		;	Solution Structure of Antibiotic-Resistance Factor ANT(2'')-Ia Reveals Substrate-Regulated Conformation Dynamics
1V95	;		;	Solution Structure of Anticodon Binding Domain from Nuclear Receptor Coactivator 5 (Human KIAA1637 Protein)
1IYC	;		;	Solution structure of antifungal peptide, scarabaecin
6VPN	;		;	Solution structure of antifungal plant defensin PvD1
5OQS	;		;	Solution structure of antifungal protein NFAP
1XV7	;		;	Solution structure of antimicrobial and endotoxin-neutralizing peptide Lf11 in DPC micelles
1XV4	;		;	Solution structure of antimicrobial and endotoxin-neutralizing peptide Lf11 in SDS micelles
7OSC	;		;	Solution structure of antimicrobial peptide cathelicidin-1 PcDode from sperm whale Physeter catodon
2HFR	;		;	solution structure of antimicrobial peptide Fowlicidin 3
6TWG	;		;	Solution structure of antimicrobial peptide, crabrolin Plus in the presence of Lipopolysaccharide
2CK4	;		;	Solution Structure of aOSK1
1C15	;		;	SOLUTION STRUCTURE OF APAF-1 CARD
2F1E	;		;	Solution structure of ApaG protein
1WQK	;		;	Solution structure of APETx1, a specific peptide inhibitor of human Ether-a-go-go-related gene potassium channels from the venom of the sea anemone Anthopleura elegantissima: a new fold for an HERG toxin
1WXN	;		;	Solution structure of APETx2, a specific peptide inhibitor of ASIC3 proton-gated channels
5TTB	;		;	Solution structure of apo ArCP from yersiniabactin synthetase
1RK7	;		;	Solution structure of apo Cu,Zn Superoxide Dismutase: role of metal ions in protein folding
1GR5	;	7.9	;	Solution Structure of apo GroEL by Cryo-Electron microscopy
2GT5	;		;	Solution structure of apo Human Sco1
1SKT	;		;	SOLUTION STRUCTURE OF APO N-DOMAIN OF TROPONIN C, NMR, 40 STRUCTURES
5U3H	;		;	Solution structure of apo PCP1 from yersiniabactin synthetase
2L50	;		;	Solution structure of apo S100A16
1U97	;		;	Solution Structure of Apo Yeast Cox17
1Z2G	;		;	Solution structure of apo, oxidized yeast Cox17
3BDO	;		;	SOLUTION STRUCTURE OF APO-BIOTINYL DOMAIN FROM ACETYL COENZYME A CARBOXYLASE OF ESCHERICHIA COLI DETERMINED BY TRIPLE-RESONANCE NMR SPECTROSCOPY
1YG0	;		;	Solution structure of apo-CopP from Helicobacter pylori
2JQA	;		;	Solution structure of apo-DR1885 from Deinococcus radiodurans
2KCW	;		;	Solution structure of Apo-form YjaB from Escherichia coli
2KQK	;		;	Solution structure of apo-IscU(D39A)
2L4X	;		;	Solution Structure of apo-IscU(WT)
1J5H	;		;	Solution Structure of Apo-Neocarzinostatin
2LKP	;		;	solution structure of apo-NmtR
2LVI	;		;	Solution structure of apo-Phl p 7
1YUS	;		;	Solution structure of apo-S100A13
1YUR	;		;	Solution structure of apo-S100A13 (minimized mean structure)
1IT5	;		;	Solution structure of apo-type PLA2 from Streptomyces violaceruber A-2688.
7F7N	;		;	Solution structure of apo-WhiB4 from Mycobacterium tuberculosis
6K3J	;		;	Solution structure of APOBEC3G-CD2 with ssDNA, Product A
6K3K	;		;	Solution structure of APOBEC3G-CD2 with ssDNA, Product B
2AJ0	;		;	Solution structure of apoCadA
2AJ1	;		;	Solution structure of apoCadA
1M42	;		;	Solution structure of apoCopC from Pseudomonas syringae
1SP0	;		;	Solution Structure of apoCox11
1SO9	;		;	Solution Structure of apoCox11, 30 structures
1APC	;		;	SOLUTION STRUCTURE OF APOCYTOCHROME B562
1TL5	;		;	Solution structure of apoHAH1
2EW9	;		;	Solution structure of apoWLN5-6
2MTB	;		;	Solution structure of apo_FldB
5SYQ	;		;	Solution structure of Aquifex aeolicus Aq1974
2LOW	;		;	Solution structure of AR55 in 50% HFIP
2I9Y	;		;	Solution structure of Arabidopsis thaliana protein At1g70830, a member of the major latex protein family
1Y9X	;		;	Solution structure of Archaeon DNA-binding protein ssh10b
2JSB	;		;	Solution structure of arenicin-1
5Y0I	;		;	Solution structure of arenicin-3 derivative N1
5Y0J	;		;	Solution structure of arenicin-3 derivative N2
5Y0H	;		;	Solution structure of arenicin-3 derivative N6
5V11	;		;	Solution structure of arenicin-3 synthetic analog.
5V0Y	;		;	Solution structure of arenicin-3.
2CRR	;		;	Solution structure of ArfGap domain from human SMAP1
1KN5	;		;	SOLUTION STRUCTURE OF ARID DOMAIN OF ADR6 FROM SACCHAROMYCES CEREVISIAE
7DM4	;		;	Solution structure of ARID4B Tudor domain
2KIZ	;		;	Solution structure of Arkadia RING-H2 finger domain
1IRZ	;		;	Solution structure of ARR10-B belonging to the GARP family of plant Myb-related DNA binding motifs of the Arabidopsis response regulators
6I9F	;		;	Solution structure of As-p18 reveals that nematode fatty acid binding proteins exhibit unusual structural features
2L9G	;		;	Solution structure of AS1p-Tar in 10% negatively charged bicelles
2D56	;		;	Solution Structure of ASABF, Antibacterial Peptide Isolated from a Nematode, Ascaris Suum
2HM2	;		;	Solution structure of ASC2
1IW4	;		;	Solution structure of ascidian trypsin inhibitor
2KZA	;		;	Solution structure of ASIP(80-132, P103A, P105A, Q115Y, S124Y)
2AFD	;		;	Solution Structure of Asl1650, an Acyl Carrier Protein from Anabaena sp. PCC 7120 with a Variant Phosphopantetheinylation-Site Sequence
2AFE	;		;	Solution Structure of Asl1650, an Acyl Carrier Protein from Anabaena sp. PCC 7120 with a Variant Phosphopantetheinylation-Site Sequence
2UWQ	;		;	Solution structure of ASPP2 N-terminus
1XO8	;		;	Solution structure of AT1g01470 from Arabidopsis Thaliana
2KMW	;		;	Solution structure of At3g03773.1 protein from Arabidopsis thaliana
1XOY	;		;	Solution structure of At3g04780.1, an Arabidopsis ortholog of the C-terminal domain of human thioredoxin-like protein
2G0Q	;		;	Solution structure of At5g39720.1 from Arabidopsis thaliana
1TQ1	;		;	Solution structure of At5g66040, a putative protein from Arabidosis Thaliana
7DHT	;		;	Solution structure of ATG8f of Arabidopsis thaliana
8IEX	;		;	Solution structure of AtWRKY11-DBD
2Y95	;		;	Solution structure of AUCG tetraloop hairpin found in human Xist RNA A-repeats essential for X-inactivation
1XWP	;		;	Solution structure of AUCGCA loop
2LTU	;		;	Solution Structure of autoinhibitory domain of human AMP-activated protein kinase catalytic subunit
6M5C	;		;	Solution structure of avenatide aV1
2KQY	;		;	Solution structure of Avian Thymic Hormone
2N37	;		;	Solution structure of AVR-Pia
2NAR	;		;	Solution structure of AVR3a_60-147 from Phytophthora infestans
2CQY	;		;	Solution structure of B domain from human propionyl-CoA carboxylase alpha subunit
1HY8	;		;	SOLUTION STRUCTURE OF B. SUBTILIS ACYL CARRIER PROTEIN
5N7Y	;		;	Solution structure of B. subtilis Sigma G inhibitor CsfB
1N53	;		;	SOLUTION STRUCTURE OF B. SUBTILIS T BOX ANTITERMINATOR RNA
2MPI	;		;	Solution structure of B24G insulin
2KGK	;		;	Solution structure of Bacillus anthracis dihydrofolate reductase
2KW8	;		;	Solution Structure of Bacillus anthracis Sortase A (SrtA) Transpeptidase
1XN5	;		;	Solution Structure of Bacillus halodurans Protein BH1534: The Northeast Structural Genomics Consortium Target BhR29
2FHM	;		;	Solution Structure of Bacillus subtilis Acylphosphatase
2HLT	;		;	Solution Structure of Bacillus subtilis Acylphosphatase
2HLU	;		;	Solution Structure of Bacillus subtilis Acylphosphatase
1Z2E	;		;	Solution Structure of Bacillus subtilis ArsC in oxidized state
1Z2D	;		;	Solution Structure of Bacillus subtilis ArsC in reduced state
2B8F	;		;	solution structure of Bacillus subtilis BLAP Apo form (energy minimized mean structure)
1Z7T	;		;	Solution structure of Bacillus subtilis BLAP apo-form
1Z6H	;		;	Solution Structure of Bacillus subtilis BLAP biotinylated-form
2B8G	;		;	solution structure of Bacillus subtilis BLAP biotinylated-form (energy minimized mean structure)
2M4I	;		;	Solution structure of Bacillus subtilis MinC N-terminal domain
1ZTS	;		;	Solution Structure of Bacillus Subtilis Protein YQBG: Northeast Structural Genomics Consortium Target SR215
1XN8	;		;	Solution Structure of Bacillus subtilis Protein yqbG: The Northeast Structural Genomics Consortium Target SR215
1YX0	;		;	Solution Structure of Bacillus subtilis Protein ysnE: The Northeast Structural Genomics Consortium Target SR220
2L16	;		;	Solution structure of Bacillus subtilits TatAd protein in DPC micelles
2LWY	;		;	Solution Structure of Bacterial Intein-Like domain from Clostridium thermocellum
1E68	;		;	Solution structure of bacteriocin AS-48
1K0H	;		;	Solution structure of bacteriophage lambda gpFII
2KX4	;		;	Solution structure of Bacteriophage Lambda gpFII
1HYW	;		;	SOLUTION STRUCTURE OF BACTERIOPHAGE LAMBDA GPW
1L0M	;		;	Solution structure of Bacteriorhodopsin
2KM7	;		;	Solution Structure of BamE, a component of the outer membrane protein assembly machinery in Escherichia coli
2K18	;		;	Solution structure of bb' domains of human protein disulfide isomerase
2GOW	;		;	Solution structure of BC059385 from Homo sapiens
6IJQ	;		;	Solution structure of BCL-XL bound to P73-TAD peptide
2ME9	;		;	Solution structure of BCL-xL containing the alpha1-alpha2 disordered loop determined with selective isotope labelling of I,L,V sidechains
2M03	;		;	Solution structure of BCL-xL determined with selective isotope labelling of I,L,V sidechains
2M04	;		;	Solution structure of BCL-xL in complex with PUMA BH3 peptide
2ME8	;		;	Solution Structure of BCL-xL in its p53-bound conformation determined with selective isotope labelling of I,L,V sidechains
7OXF	;		;	Solution structure of bee apamin
1DJM	;		;	SOLUTION STRUCTURE OF BEF3-ACTIVATED CHEY FROM ESCHERICHIA COLI
2KFK	;		;	Solution structure of Bem1p PB1 domain complexed with Cdc24p PB1 domain
2RQW	;		;	Solution structure of Bem1p SH3CI domain complexed with Ste20p-PRR peptide
7MSV	;		;	Solution Structure of Berberine Bound to a dGMP Fill-in G-Quadruplex in the PDGFR-b Promoter
1KRX	;		;	SOLUTION STRUCTURE OF BERYLLOFLUORIDE-ACTIVATED NTRC RECEIVER DOMAIN: MODEL STRUCTURES INCORPORATING ACTIVE SITE CONTACTS
1J8Z	;		;	Solution structure of beta3 analogue peptide (HCYS) of HIV gp41 600-612 loop.
1J8N	;		;	Solution structure of beta3-analogue peptide corresponding to the gp41 600-612 loop of HIV.
1K09	;		;	Solution structure of BetaCore, A Designed Water Soluble Four-Stranded Antiparallel b-sheet Protein
6IMG	;		;	Solution Structure of Bicyclic Peptide pb-13
6IMH	;		;	Solution Structure of Bicyclic Peptide pb-18
2RNG	;		;	Solution structure of big defensin
2KCC	;		;	Solution Structure of biotinoyl domain from human acetyl-CoA carboxylase 2
6R3C	;		;	Solution structure of birch pollen allergen Bet v 1a
1ZBN	;		;	Solution structure of BIV TAR hairpin complexed to JDV Tat arginine-rich motif
2MFJ	;		;	Solution structure of Blo t 19, a minor dust mite allergen from Blomia tropicalis
5VTO	;		;	Solution Structure of BlsM
2KET	;		;	solution structure of BMAP-27
2NDC	;		;	Solution Structure of BMAP-28(1-18)
1Q2K	;		;	Solution structure of BmBKTx1 a new potassium channel blocker from the Chinese Scorpion Buthus martensi Karsch
2KBK	;		;	Solution Structure of BmK-M10
2E0H	;		;	Solution Structure of BmKalphaIT01, an alpha-insect toxin from the Venom of the Chinese Scorpion Buthus martensi Karsch
2KBH	;		;	solution structure of BmKalphaTx11 (major conformation)
2KBJ	;		;	solution structure of BmKalphaTx11 (minor conformation)
1S8K	;		;	Solution Structure of BmKK4, A Novel Potassium Channel Blocker from Scorpion Buthus martensii Karsch, 25 structures
2MLA	;		;	Solution structure of BmKTX-D19K
2MLD	;		;	Solution structure of BmKTX-D19K/K6D
1RJI	;		;	Solution Structure of BmKX, a novel potassium channel blocker from the Chinese Scorpion Buthus martensi Karsch
1WM7	;		;	Solution Structure of BmP01 from the Venom of Scorpion Buthus martensii Karsch, 9 structures
1DU9	;		;	SOLUTION STRUCTURE OF BMP02, A NATURAL SCORPION TOXIN WHICH BLOCKS APAMIN-SENSITIVE CALCIUM-ACTIVATED POTASSIUM CHANNELS, 25 STRUCTURES
1WM8	;		;	Solution Structure of BmP03 from the Venom of Scorpion Buthus martensii Karsch, 10 structures
1PVZ	;		;	Solution Structure of BmP07, A Novel Potassium Channel Blocker from Scorpion Buthus martensi Karsch, 15 structures
1WT8	;		;	Solution Structure of BmP08 from the Venom of Scorpion Buthus martensii Karsch, 20 structures
5LCI	;		;	Solution structure of BOLA1 from Homo sapiens
1V60	;		;	Solution structure of BolA1 protein from Mus musculus
2NCL	;		;	Solution structure of BOLA3 from Homo sapiens
2AP7	;		;	Solution structure of bombinin H2 in DPC micelles
2AP8	;		;	Solution structure of bombinin H4 in DPC micelles
7NY0	;		;	Solution structure of Boskar4; a de novo designed G-CSF agonist
2N3F	;		;	Solution structure of both dsRBDs of DRB4 along with linker (viz. DRB4(1-153))
6KH9	;		;	Solution structure of bovine insulin amyloid intermediate-1
6KHA	;		;	Solution structure of bovine insulin amyloid intermediate-2
1BNB	;		;	SOLUTION STRUCTURE OF BOVINE NEUTROPHIL BETA-DEFENSIN 12: THE PEPTIDE FOLD OF THE BETA-DEFENSINS IS IDENTICAL TO THAT OF THE CLASSICAL DEFENSINS
2KGH	;		;	Solution structure of Brachyperma ruhnaui toxin 2
2HDL	;		;	Solution structure of Brak/CXCL14
8R63	;		;	Solution structure of branaplam bound to the RNA duplex formed upon 5'-splice site recognition
2DUN	;		;	Solution structure of BRCT domain of DNA polymerase mu
2COK	;		;	Solution structure of BRCT domain of poly(ADP-ribose) polymerase-1
2COE	;		;	Solution structure of BRCT domain of terminal deoxynucleotidyltransferase
2KU3	;		;	Solution structure of BRD1 PHD1 finger
2LQ6	;		;	Solution structure of BRD1 PHD2 finger
1HX2	;		;	SOLUTION STRUCTURE OF BSTI, A TRYPSIN INHIBITOR FROM BOMBINA BOMBINA.
1IJC	;		;	Solution Structure of Bucandin, a Neurotoxin from the Venom of the Malayan Krait
2MY1	;		;	Solution structure of Bud31p
1JC6	;		;	SOLUTION STRUCTURE OF BUNGARUS FACIATUS IX, A KUNITZ-TYPE CHYMOTRYPSIN INHIBITOR
1WT7	;		;	Solution structure of BuTX-MTX: a butantoxin-maurotoxin chimera
2KRA	;		;	Solution structure of Bv8
2KNG	;		;	Solution structure of C-domain of Lsr2
2FCE	;		;	Solution structure of C-lobe Myosin Light Chain from Saccharomices cerevisiae
2HD7	;		;	Solution structure of C-teminal domain of twinfilin-1.
2MJG	;		;	Solution Structure of C-terminal AbrB
1NMR	;		;	Solution Structure of C-terminal Domain from Trypanosoma cruzi Poly(A)-Binding Protein
2JYW	;		;	Solution structure of C-terminal domain of APOBEC3G
2JO8	;		;	Solution structure of C-terminal domain of human mammalian sterile 20-like kinase 1 (MST1)
2CRV	;		;	Solution structure of C-terminal domain of mitochondrial translational initiationfactor 2
1TH5	;		;	Solution structure of C-terminal domain of NifU-like protein from Oryza sativa
2JNV	;		;	Solution structure of C-terminal domain of NifU-like protein from Oryza sativa
2KKY	;		;	Solution Structure of C-terminal domain of oxidized NleG2-3 (residue 90-191) from Pathogenic E. coli O157:H7. Northeast Structural Genomics Consortium and Midwest Center for Structural Genomics target ET109A
1IFW	;		;	SOLUTION STRUCTURE OF C-TERMINAL DOMAIN OF POLY(A) BINDING PROTEIN FROM SACCHAROMYCES CEREVISIAE
2KKX	;		;	Solution Structure of C-terminal domain of reduced NleG2-3 (residues 90-191) from Pathogenic E. coli O157:H7. Northeast Structural Genomics Consortium and Midwest Center for Structural Genomics target ET109A
2CRQ	;		;	Solution structure of C-terminal domain of RIKEN cDNA 2810012L14
2K7X	;		;	solution structure of C-terminal domain of SARS-CoV main protease
5XME	;		;	Solution structure of C-terminal domain of TRADD
2KK1	;		;	Solution structure of C-terminal Domain of Tyrosine-protein kinase ABL2 from Homo sapiens, Northeast Structural Genomics Consortium (NESG) target HR5537A
1F7W	;		;	SOLUTION STRUCTURE OF C-TERMINAL DOMAIN ZIPA
1F7X	;		;	SOLUTION STRUCTURE OF C-TERMINAL DOMAIN ZIPA
2JZY	;		;	Solution structure of C-terminal effector domain of putative two-component-system response regulator involved in copper resistance from Klebsiella pneumoniae
2NB8	;		;	Solution structure of C-terminal extramembrane domain of SH protein
1WFT	;		;	Solution structure of C-terminal fibronectin type III domain of mouse 1700129L13Rik protein
2LMB	;		;	Solution Structure of C-terminal RAGE (ctRAGE)
7BBB	;		;	Solution structure of C-terminal RecA and RRM domains of the DEAD box helicase DbpA
1KFZ	;		;	Solution Structure of C-terminal Sem-5 SH3 Domain (Ensemble of 16 Structures)
1WH3	;		;	Solution structure of C-terminal ubiquitin like domain of human 2'-5'-oligoadenylate synthetase-like protain (p59 OASL)
2RU3	;		;	Solution structure of c.elegans SUP-12 RRM in complex with RNA
1FYB	;		;	SOLUTION STRUCTURE OF C1-T1, A TWO-DOMAIN PROTEINASE INHIBITOR DERIVED FROM THE CIRCULAR PRECURSOR PROTEIN NA-PROPI FROM NICOTIANA ALATA
5W4S	;		;	Solution structure of C2 domain from protein kinase C alpha in ternary complex with calcium and V5-pHM peptide
5MYE	;		;	Solution structure of C20S variant of Dehydroascorbate reductase 3A from Populus trichocarpa in complex with dehydroascorbic acid.
2LHA	;		;	Solution structure of C2B with IP6
2YSV	;		;	Solution structure of C2H2 type Zinc finger domain 17 in Zinc finger protein 473
2YTA	;		;	Solution structure of C2H2 type Zinc finger domain 3 in Zinc finger protein 32
2YT9	;		;	Solution structure of C2H2 type Zinc finger domain 345 in Zinc finger protein 278
2YTB	;		;	Solution structure of C2H2 type Zinc finger domain 5 in Zinc finger protein 32
2JYY	;		;	Solution structure of C8A/C37A-T1 from Nicotiana alata
1QLK	;		;	SOLUTION STRUCTURE OF CA(2+)-LOADED RAT S100B (BETABETA) NMR, 20 STRUCTURES
2LVK	;		;	Solution structure of Ca-bound Phl p 7
2LNK	;		;	Solution structure of Ca-bound S100A4 in complex with non-muscle myosin IIA
2KYC	;		;	solution structure of Ca-free chicken parvalbumin 3 (CPV3)
2KIS	;		;	Solution structure of CA150 FF1 domain and FF1-FF2 interdomain linker
2NCE	;		;	Solution Structure of Ca2+-bound C2 domain from Protein Kinase C alpha in the form of complex with V5-pHM peptide
2LV7	;		;	Solution structure of Ca2+-bound CaBP7 N-terminal doman
2B1O	;		;	Solution Structure of Ca2+-bound DdCAD-1
1I56	;		;	SOLUTION STRUCTURE OF CA2+-BOUND STATE OF CANINE MILK LYSOZYME
2LHH	;		;	Solution structure of Ca2+-bound yCaM
2LM5	;		;	Solution structure of Ca2+-CIB1 in complex with the cytoplasmic domain of the integrin aIIb subunit
1YHP	;		;	Solution Structure of Ca2+-free DdCAD-1
2K2F	;		;	Solution structure of Ca2+-S100A1-RyRP12
1NWD	;		;	Solution Structure of Ca2+/Calmodulin bound to the C-terminal Domain of Petunia Glutamate Decarboxylase
2L7L	;		;	Solution structure of Ca2+/calmodulin complexed with a peptide representing the calmodulin-binding domain of calmodulin kinase I
2LGF	;		;	Solution structure of Ca2+/calmodulin complexed with a peptide representing the calmodulin-binding domain of L-selectin
2LHI	;		;	Solution structure of Ca2+/CNA1 peptide-bound yCaM
6KG8	;		;	Solution structure of CaCohA2 from Clostridium acetobutylicum
6KG9	;		;	Solution structure of CaDoc0917 from Clostridium acetobutylicum
2JSA	;		;	Solution structure of Caenopore-5 (81 Pro Trans confomer)
2L51	;		;	Solution structure of calcium bound S100A16
2RO9	;		;	Solution structure of calcium bound soybean calmodulin isoform 1 C-terminal domain
2RO8	;		;	Solution structure of calcium bound soybean calmodulin isoform 1 N-terminal domain
2ROB	;		;	Solution structure of calcium bound soybean calmodulin isoform 4 C-terminal domain
2ROA	;		;	Solution structure of calcium bound soybean calmodulin isoform 4 N-terminal domain
1J7P	;		;	Solution structure of Calcium calmodulin C-terminal domain
5T7C	;		;	Solution structure of calcium free, myristoylated visinin-like protein 3
2JTT	;		;	Solution structure of calcium loaded S100A6 bound to C-terminal Siah-1 interacting protein
1PSB	;		;	Solution structure of calcium loaded S100B complexed to a peptide from N-Terminal regulatory domain of NDR kinase.
1LA0	;		;	Solution Structure of Calcium Saturated Cardiac Troponin C in the Troponin C-Troponin I Complex
2KYF	;		;	solution structure of calcium-bound CPV3
2M9G	;		;	Solution structure of calcium-bound human S100A12
1J7O	;		;	Solution structure of Calcium-calmodulin N-terminal domain
2NLN	;		;	Solution Structure of Calcium-free Rat Beta-parvalbumin
1YUU	;		;	Solution structure of Calcium-S100A13
1YUT	;		;	Solution structure of Calcium-S100A13 (minimized mean structure)
2MG5	;		;	Solution Structure of Calmodulin bound to the target peptide of Endothelial Nitrogen Oxide Synthase phosphorylated at Thr495
2B1U	;		;	Solution structure of Calmodulin-like Skin Protein C terminal domain
2DK9	;		;	Solution structure of Calponin Homology domain of Human MICAL-1
2RR8	;		;	Solution structure of calponin homology domain of IQGAP1
1K9C	;		;	Solution Structure of Calreticulin P-domain subdomain (residues 189-261)
1K91	;		;	Solution Structure of Calreticulin P-domain subdomain (residues 221-256)
2K61	;		;	Solution structure of CaM complexed to DAPk peptide
2K0J	;		;	Solution structure of CaM complexed to DRP1p
6FEG	;		;	Solution Structure of CaM/Kv7.2-hAB Complex
6FEH	;		;	Solution Structure of CaM/Kv7.2-hAB Complex
6K2I	;		;	Solution structure of camelid nanobody Nb11 against aflatoxin B1
6IYN	;		;	Solution structure of camelid nanobody Nb26 against aflatoxin B1
1JGK	;		;	SOLUTION STRUCTURE OF CANDOXIN
1TKN	;		;	Solution structure of CAPPD*, an independently folded extracellular domain of human Amyloid-beta Precursor Protein
1MYF	;		;	SOLUTION STRUCTURE OF CARBONMONOXY MYOGLOBIN DETERMINED FROM NMR DISTANCE AND CHEMICAL SHIFT CONSTRAINTS
2KBF	;		;	solution structure of carboxyl-terminal domain of Dbp5p
2JXL	;		;	Solution structure of cardiac N-domain troponin C mutant F77W-V82A
1KBS	;		;	SOLUTION STRUCTURE OF CARDIOTOXIN IV, NMR, 1 STRUCTURE
1KBT	;		;	SOLUTION STRUCTURE OF CARDIOTOXIN IV, NMR, 12 STRUCTURES
1CW5	;		;	SOLUTION STRUCTURE OF CARNOBACTERIOCIN B2
8C18	;		;	Solution structure of carotenoid-binding protein AstaPo1 in complex with astaxanthin
2I3E	;		;	Solution structure of catalytic domain of goldfish RICH protein
2ILX	;		;	Solution structure of catalytic domain of rat 2',3'-cyclic-nucleotide 3'-phosphodiesterase (CNP) protein
2JVB	;		;	Solution Structure of Catalytic Domain of yDcp2
2IGR	;		;	Solution structure of CB1a, a novel anticancer peptide derived from natural antimicrobial peptide cecropin B
1V46	;		;	Solution Structure of CCAP (Crustacean Cardioactive Peptide) from Drosophila melanogaster
1Y49	;		;	Solution Structure of CCAP (Crustacean Cardioactive Peptide) from Drosophila melanogaster
2D9N	;		;	Solution structure of CCCH type zinc-finger domain 2 in Cleavage and polyadenylation specificity factor
2D9M	;		;	Solution structure of CCCH type zinc-finger domain 3 in zinc finger CCCH-type domain containing 7A
2LIQ	;		;	Solution structure of CCL2 in complex with glycan
4B2R	;		;	Solution structure of CCP modules 10-11 of complement factor H
4B2S	;		;	Solution structure of CCP modules 11-12 of complement factor H
2LMA	;		;	Solution structure of CD4+ T cell derived peptide Thp5
1CEE	;		;	SOLUTION STRUCTURE OF CDC42 IN COMPLEX WITH THE GTPASE BINDING DOMAIN OF WASP
1EES	;		;	SOLUTION STRUCTURE OF CDC42HS COMPLEXED WITH A PEPTIDE DERIVED FROM P-21 ACTIVATED KINASE, NMR, 20 STRUCTURES
2MJ8	;		;	Solution structure of CDYL2 chromodomain
1D9L	;		;	SOLUTION STRUCTURE OF CECROPIN A(1-8)-MAGAININ 2 HYBRID PEPTIDE ANALOGUE(P1)
1D9M	;		;	SOLUTION STRUCTURE OF CECROPIN A(1-8)-MAGAININ 2 HYBRID PEPTIDE ANALOGUE(P2)
1D9J	;		;	SOLUTION STRUCTURE OF CECROPIN A(1-8)-MAGAININ 2(1-12) HYBRID PEPTIDE
1D9O	;		;	SOLUTION STRUCTURE OF CECROPIN A(1-8)-MAGAININ 2(1-12) HYBRID PEPTIDE ANALOGUE(P3)
1D9P	;		;	SOLUTION STRUCTURE OF CECROPIN A(1-8)-MAGAININ 2(1-12) HYBRID PEPTIDE ANALOGUE(P4)
7DEH	;		;	Solution structure of cecropin P1 in dodecylphosphocholine micelles
2N92	;		;	Solution structure of cecropin P1 with LPS
7VOZ	;		;	Solution structure of cecropin P1(1-29) in dodecylphosphocholine micelles
2D35	;		;	Solution structure of Cell Division Reactivation Factor, CedA
2L2Q	;		;	Solution Structure of cellobiose-specific phosphotransferase IIB component protein from Borrelia burgdorferi
1KGL	;		;	Solution structure of cellular retinol binding protein type-I in complex with all-trans-retinol
1JBH	;		;	Solution structure of cellular retinol binding protein type-I in the ligand-free state
1E5G	;		;	Solution structure of central CP module pair of a pox virus complement inhibitor
5ZOR	;		;	Solution structure of centrin4 from Trypanosoma brucei
4BIT	;		;	solution structure of cerebral dopamine neurotrophic factor (CDNF)
1Z2F	;		;	solution structure of CfAFP-501
1CS9	;		;	SOLUTION STRUCTURE OF CGGIRGERA IN CONTACT WITH THE MONOCLONAL ANTIBODY MAB 4X11, NMR, 7 STRUCTURES
1CT6	;		;	SOLUTION STRUCTURE OF CGGIRGERG IN CONTACT WITH THE MONOCLONAL ANTIBODY MAB 4X11, NMR, 11 STRUCTURES
2K31	;		;	Solution Structure of cGMP-binding GAF domain of Phosphodiesterase 5
2LQL	;		;	Solution structure of CHCH5
2LQT	;		;	Solution structure of CHCHD7
2L75	;		;	Solution structure of CHD4-PHD2 in complex with H3K9me3
2HO9	;		;	Solution Structure of chemotaxi protein CheW from Escherichia coli
1TVJ	;		;	Solution Structure of chick cofilin
3ZOB	;		;	Solution structure of chicken Engrailed 2 homeodomain
2LBA	;		;	Solution structure of chicken ileal BABP in complex with glycochenodeoxycholic acid
2JM0	;		;	Solution structure of chicken villin headpiece subdomain containing a fluorinated side chain in the core
2RV9	;		;	Solution structure of chitosan-binding module 1 derived from chitosanase/glucanase from Paenibacillus sp. IK-5
2RVA	;		;	Solution structure of chitosan-binding module 2 derived from chitosanase/glucanase from Paenibacillus sp. IK-5
1DS9	;		;	SOLUTION STRUCTURE OF CHLAMYDOMONAS OUTER ARM DYNEIN LIGHT CHAIN 1
1W9R	;		;	Solution Structure of Choline Binding Protein A, Domain R2, the Major Adhesin of Streptococcus pneumoniae
2L8O	;		;	Solution structure of Chr148 from Cytophaga hutchinsonii, Northeast Structural Genomics Consortium Target Chr148
2EPB	;		;	Solution structure of chromo domain 2 in Chromodomain-helicase-DNA-binding protein 6
2KVB	;		;	Solution structure of CI-MPR domain 5 bound to N-acetylglucosaminyl 6-phosphomethylmannoside
2KVA	;		;	SOLUTION STRUCTURE OF CI-MPR ligand-free domain 5
2ERI	;		;	Solution structure of circulin B
2M6G	;		;	Solution structure of cis(C2-P3) trans (D5-P6) form of lO959 in water
2KH5	;		;	Solution Structure of cis-5R,6S-thymine glycol opposite complementary adenine in duplex DNA
2KH6	;		;	Solution Structure of cis-5R,6S-thymine glycol opposite complementary adenine in duplex DNA
2KH7	;		;	Solution Structure of cis-5R,6S-thymine glycol opposite complementary guanine in duplex DNA
2KH8	;		;	Solution Structure of cis-5R,6S-thymine glycol opposite complementary guanine in duplex DNA
1J3G	;		;	Solution structure of Citrobacter Freundii AmpD
2JMY	;		;	Solution structure of CM15 in DPC micelles
6NW8	;		;	SOLUTION STRUCTURE OF CN29, A TOXIN FROM CENTRUROIDES NOXIUS SCORPION VENOM
1UDM	;		;	Solution structure of Coactosin-like protein (Cofilin family) from Mus Musculus
2LXX	;		;	Solution structure of cofilin like UNC-60B protein from Caenorhabditis elegans
5HUZ	;		;	Solution structure of coiled coil domain of myosin binding subunit of myosin light chain phosphatase
6LMR	;		;	Solution structure of cold shock domain and ssDNA complex
2L15	;		;	Solution Structure of Cold Shock Protein CspA Using Combined NMR and CS-Rosetta method
2F52	;		;	Solution structure of cold shock protein CspB from Bacillus subtilis in complex with heptathymidine
5XV9	;		;	Solution Structure of Cold Shock Protein from Colwellia psychrerythraea
6Y6M	;		;	solution structure of cold-shock domain 1 and 2 of drosophila Upstream of N-Ras (Unr)
6Y4H	;		;	Solution structure of cold-shock domain 7 and 8 of drosophila Upstream of N-Ras (Unr)
6Y96	;		;	solution structure of cold-shock domain 9 of drosophila Upstream of N-Ras (Unr)
5NCA	;		;	Solution structure of ComGC from Streptococcus pneumoniae
2KNX	;		;	Solution Structure of complement repeat CR17 from LRP-1
2N21	;		;	Solution structure of complex between DNA G-quadruplex and G-quadruplex recognition domain of RHAU
1VRE	;		;	SOLUTION STRUCTURE OF COMPONENT IV GLYCERA DIBRANCHIATA MONOMERIC HEMOGLOBIN-CO
1VRF	;		;	SOLUTION STRUCTURE OF COMPONENT IV GLYCERA DIBRANCHIATA MONOMERIC HEMOGLOBIN-CO
6PPC	;		;	Solution structure of conotoxin MiXXVIIA
1RMK	;		;	Solution structure of conotoxin MrVIB
2FQC	;		;	Solution structure of conotoxin pl14a
6BX9	;		;	Solution structure of conotoxin reg3b
1EYO	;		;	SOLUTION STRUCTURE OF CONOTOXIN TVIIA FROM CONUS TULIPA
1AS5	;		;	SOLUTION STRUCTURE OF CONOTOXIN Y-PIIIE FROM CONUS PURPURASCENS, NMR, 14 STRUCTURES
1K6G	;		;	Solution Structure of Conserved AGNN Tetraloops: Insights into Rnt1p RNA Processing
1K6H	;		;	Solution Structure of Conserved AGNN Tetraloops: Insights into Rnt1p RNA processing
2OTR	;		;	Solution Structure of Conserved Hypothetical Protein HP0892 from Helicobacter pylori
1RWU	;		;	Solution structure of conserved protein YbeD from E. coli
1NXN	;		;	SOLUTION STRUCTURE OF CONTRYPHAN-VN
2K0Q	;		;	Solution structure of CopK, a periplasmic protein involved in copper resistance in Cupriavidus metallidurans CH34
1OQ6	;		;	solution structure of Copper-S46V CopA from Bacillus subtilis
2L6I	;		;	Solution structure of coronaviral stem-loop 2 (SL2)
1V5A	;		;	Solution Structure of Covalitoxin I
2MKE	;		;	Solution structure of CPEB1 ZZ domain in the free state
1J2M	;		;	Solution structure of CPI-17(22-120)
1J2N	;		;	Solution structure of CPI-17(22-120) T38D
2KYB	;		;	Solution structure of CpR82G from Clostridium perfringens. North East Structural Genomics Consortium Target CpR82g
1W2R	;		;	Solution structure of CR2 SCR 1-2 by X-ray scattering
1W2S	;		;	Solution structure of CR2 SCR 1-2 in its complex with C3d by X-ray scattering
1YV8	;		;	Solution structure of crambin in acetone/water mixed solvent
2MYI	;		;	Solution Structure of Crc from P. syringae Lz4W
1K1C	;		;	Solution Structure of Crh, the Bacillus subtilis Catabolite Repression HPr
2LQN	;		;	Solution structure of CRKL
1Z99	;		;	Solution structure of Crotamine, a myotoxin from Crotalus durissus terrificus
1H5O	;		;	Solution structure of Crotamine, a neurotoxin from Crotalus durissus terrificus
2HLI	;		;	Solution structure of Crotonaldehyde-Derived N2-[3-Oxo-1(S)-methyl-propyl]-dG DNA Adduct in the 5'-CpG-3' Sequence
5XS1	;		;	Solution structure of Crustacean Hyperglycemic Hormone-like (CHH-L) from the Scylla Olivacea
1TV0	;		;	Solution structure of cryptdin-4, the most potent alpha-defensin from mouse Paneth cells
2HUA	;		;	Solution Structure of CSFV IRES Domain IIa
5M1U	;		;	Solution structure of CsgF in DHPC micelles
2A1C	;		;	Solution structure of CSP1
1T3O	;		;	Solution structure of CsrA, a bacterial carbon storage regulatory protein
2LI7	;		;	Solution Structure of CssII
2LJM	;		;	Solution Structure of CssII
2KW1	;		;	Solution structure of CTD
1TL4	;		;	Solution structure of Cu(I) HAH1
2RLI	;		;	Solution structure of Cu(I) human Sco2
2HRF	;		;	Solution Structure of Cu(I) P174L HSco1
2HRN	;		;	Solution Structure of Cu(I) P174L-HSco1
1NM4	;		;	Solution structure of Cu(I)-CopC from Pseudomonas syringae
1OT4	;		;	Solution structure of Cu(II)-CopC from Pseudomonas syringae
1WGL	;		;	Solution Structure of CUE domain in the C-terminal of Human Toll-interacting Protein (Tollip)
5M8I	;		;	Solution structure of CUG-BP2 RRM3 in complex with 5'-UUUAA-3' RNA
1X9L	;		;	Solution structure of CuI-DR1885 from Deinococcus Radiodurans
2LUA	;		;	Solution structure of CXC domain of MSL2
2MGS	;		;	Solution structure of CXCL5
2LNJ	;		;	Solution Structure of Cyanobacterial PsbP (CyanoP) from Synechocystis sp. PCC 6803
1I5T	;		;	SOLUTION STRUCTURE OF CYANOFERRICYTOCHROME C
2RP3	;		;	Solution Structure of Cyanovirin-N Domain B Mutant
2JRW	;		;	Solution structure of Cyclic extended Pep1(Cyc.ext.Pep.1) for autoimmune myasthenia gravis
1XWN	;		;	solution structure of cyclophilin like 1(PPIL1) and insights into its interaction with SKIP
2KCG	;		;	Solution structure of cycloviolacin O2
2N5Q	;		;	Solution structure of cystein-rich peptide jS1 from Jasminum sambac
8HJC	;		;	Solution structure of cysteine-rich peptide Bidentatide (Achyranthes bidentata peptide)
8HJD	;		;	Solution structure of cysteine-rich peptide Bidentatide (Achyranthes bidentata peptide) with glycation
1I5U	;		;	SOLUTION STRUCTURE OF CYTOCHROME B5 TRIPLE MUTANT (E48A/E56A/D60A)
2MHM	;		;	Solution structure of cytochrome c Y67H
1AYG	;		;	SOLUTION STRUCTURE OF CYTOCHROME C-552, NMR, 20 STRUCTURES
2AI5	;		;	Solution Structure of Cytochrome C552, determined by Distributed Computing Implementation for NMR data
2E4H	;		;	Solution structure of cytoskeletal protein in complex with tubulin tail
2MVL	;		;	Solution structure of cytosolic part of Trop2
1M58	;		;	Solution Structure of Cytotoxic RC-RNase2
1KVZ	;		;	Solution Structure of Cytotoxic RC-RNase4
2L95	;		;	Solution Structure of Cytotoxic T-Lymphocyte Antigent-2(Ctla protein), Crammer at pH 6.0
2KJB	;		;	Solution structure of CzrA in the DNA bound state
2KJC	;		;	Solution structure of CzrA in the Zn(II) state
1Q2T	;		;	Solution structure of d(5mCCTCTCC)4
8XGW	;		;	Solution structure of d(CGATCG)2-Baicalein complex
1JRV	;		;	SOLUTION STRUCTURE OF DAATAA DNA BULGE
1JRW	;		;	Solution Structure of dAATAA DNA Bulge
1JS5	;		;	Solution Structure of dAAUAA DNA Bulge
1JS7	;		;	Solution Structure of dAAUAA DNA Bulge
1V5N	;		;	Solution Structure of DC1 Domain of PDI-like Hypothetical Protein from Arabidopsis thaliana
2LQ0	;		;	Solution structure of de novo designed antifreeze peptide 1m
2LQ1	;		;	Solution structure of de novo designed antifreeze peptide 3
2LQ2	;		;	Solution structure of de novo designed peptide 4m
6BEQ	;		;	Solution structure of de novo macrocycle design10.1
6BER	;		;	Solution structure of de novo macrocycle design10.2
6BES	;		;	Solution structure of de novo macrocycle design11_ss
6BET	;		;	Solution structure of de novo macrocycle design12_ss
6BEU	;		;	Solution structure of de novo macrocycle design14_ss
6BE9	;		;	Solution structure of de novo macrocycle design7.1
6BEW	;		;	Solution structure of de novo macrocycle design7.2
6BF3	;		;	Solution structure of de novo macrocycle design7.3a
6BF5	;		;	Solution structure of de novo macrocycle design7.3a
6BE7	;		;	Solution structure of de novo macrocycle Design8.1
6BEN	;		;	Solution structure of de novo macrocycle design8.2
6BEO	;		;	Solution structure of de novo macrocycle design9.1
2KK0	;		;	Solution structure of dead ringer-like protein 1 (at-rich interactive domain-containing protein 3a) from homo sapiens, northeast structural genomics consortium (NESG) target hr4394c
2MVG	;		;	Solution structure of decorin binding protein B from Borrelia burgdorferi
1D6B	;		;	SOLUTION STRUCTURE OF DEFENSIN-LIKE PEPTIDE-2 (DLP-2) FROM PLATYPUS VENOM
2CK5	;		;	Solution structure of Delta 1-7 aOSK1
1BUQ	;		;	SOLUTION STRUCTURE OF DELTA-5-3-KETOSTEROID ISOMERASE COMPLEXED WITH THE STEROID 19-NORTESTOSTERONE-HEMISUCCINATE
6V6T	;		;	Solution structure of delta-theraphotoxin-Hm1b from Heteroscodra maculata
1R6R	;		;	Solution Structure of Dengue Virus Capsid Protein Reveals a New Fold
2A0A	;		;	Solution Structure of Der f 13, Group 13 Allergen from House Dust Mites
2DD6	;		;	Solution structure of Dermaseptin antimicrobial peptide truncated, mutated analog, K4-S4(1-13)a
2KSG	;		;	Solution structure of dermcidin-1L, a human antibiotic peptide
1ICO	;		;	SOLUTION STRUCTURE OF DESIGNED BETA-SHEET MINI-PROTEIN TH10BOX
1ICL	;		;	SOLUTION STRUCTURE OF DESIGNED BETA-SHEET MINI-PROTEIN TH1OX
1WO5	;		;	Solution structure of Designed Functional Finger 2 (DFF2): Designed mutant based on non-native CHANCE domain
1WO6	;		;	Solution structure of Designed Functional Finger 5 (DFF5): Designed mutant based on non-native CHANCE domain
1WO7	;		;	Solution structure of Designed Functional Finger 7 (DFF7): Designed mutant based on non-native CHANCE domain
2L6C	;		;	Solution structure of desulfothioredoxin from Desulfovibrio vulgaris Hildenborough in its oxidized form
2L6D	;		;	Solution structure of desulfothioredoxin from Desulfovibrio vulgaris Hildenborough in its reduced form
1QN1	;		;	SOLUTION STRUCTURE OF DESULFOVIBRIO GIGAS FERRICYTOCHROME C3, NMR, 15 STRUCTURES
1QN0	;		;	SOLUTION STRUCTURE OF DESULFOVIBRIO GIGAS FERROCYTOCHROME C3, NMR, 20 STRUCTURES
1E8J	;		;	SOLUTION STRUCTURE OF DESULFOVIBRIO GIGAS ZINC RUBREDOXIN, NMR, 20 STRUCTURES
2BPN	;		;	SOLUTION STRUCTURE OF DESULFOVIBRIO VULGARIS (HILDENBOROUGH) FERRICYTOCHROME C3, NMR, 20 STRUCTURES
1A2I	;		;	SOLUTION STRUCTURE OF DESULFOVIBRIO VULGARIS (HILDENBOROUGH) FERROCYTOCHROME C3, NMR, 20 STRUCTURES
5NF8	;		;	Solution structure of detergent-solubilized Rcf1, a yeast mitochondrial inner membrane protein involved in respiratory Complex III/IV supercomplex formation
1LUD	;		;	SOLUTION STRUCTURE OF DIHYDROFOLATE REDUCTASE COMPLEXED WITH TRIMETHOPRIM AND NADPH, 24 STRUCTURES
2HM9	;		;	Solution structure of dihydrofolate reductase complexed with trimethoprim, 33 structures
2LFF	;		;	Solution structure of Diiron protein in presence of 8 eq Zn2+, Northeast Structural Genomics consortium target OR21
1W0R	;		;	Solution structure of dimeric form of properdin by X-ray solution scattering and analytical ultracentrifugation
1MNT	;		;	SOLUTION STRUCTURE OF DIMERIC MNT REPRESSOR (1-76)
1X9X	;		;	Solution Structure of Dimeric SAM Domain from MAPKKK Ste11
2MN6	;		;	Solution structure of dimeric TatA of twin-arginine translocation system from E. coli
1GHH	;		;	SOLUTION STRUCTURE OF DINI
6IRR	;		;	Solution structure of DISC1/ATF4 complex
2AXK	;		;	Solution structure of discrepin, a scorpion venom toxin blocking K+ channels.
2JVU	;		;	Solution Structure of Dispersin from Enteroaggregative Escherichia coli
6M6F	;		;	Solution structure of disulfide bond mutaion of the core domain of Fibroblast growth factor 21 (FGF21)
2AF2	;		;	Solution structure of disulfide reduced and copper depleted Human Superoxide Dismutase
2KAP	;		;	Solution structure of DLC1-SAM
1ZUF	;		;	Solution Structure of DLP-4
1YNX	;		;	Solution structure of DNA binding domain A (DBD-A) of S.cerevisiae Replication Protein A (RPA)
2K9S	;		;	Solution structure of dna binding domain of E. coli arac
2JUH	;		;	Solution structure of DNA binding domain of ngTRF1
2JXH	;		;	Solution Structure of DNA binding domain of Proline Utilization A (PutA) for Psuedomonas putida
2KD9	;		;	Solution Structure of DNA Containing Alpha-OH-PdG: the Mutagenic Adduct Produced by Acrolein
2KDA	;		;	Solution Structure of DNA Containing Alpha-OH-PdG: the Mutagenic Adduct Produced by Acrolein
1PIB	;		;	Solution structure of DNA containing CPD opposited by GA
2RVP	;		;	Solution structure of DNA Containing Metallo-Base-Pair
1AU6	;		;	SOLUTION STRUCTURE OF DNA D(CATGCATG) INTERSTRAND-CROSSLINKED BY BISPLATIN COMPOUND (1,1/T,T), NMR, MINIMIZED AVERAGE STRUCTURE
5IZP	;		;	Solution Structure of DNA Dodecamer with 8-oxoguanine at 10th Position
5IV1	;		;	Solution Structure of DNA Dodecamer with 8-oxoguanine at 4th Position
7NBK	;		;	Solution structure of DNA duplex containing a 2'-deoxy-2'2'-difluorodeoxycytidine (gemcitabine) modification
7NBP	;		;	Solution structure of DNA duplex containing a 7,8-dihydro-8-oxo-1,N6-ethenoadenine base modification that induces exclusively A->T transversions in Escherichia coli
2MH6	;		;	Solution structure of DNA duplex containing N3T-ethylene-N1I interstrand cross-link
1JAJ	;		;	Solution Structure of DNA Polymerase X from the African Swine Fever Virus
1NYD	;		;	Solution structure of DNA quadruplex GCGGTGGAT
1F3S	;		;	Solution Structure of DNA Sequence GGGTTCAGG Forms GGGG Tetrade and G(C-A) Triad.
1K9L	;		;	Solution Structure of DNA TATGAGCGCTCATA
1HG9	;		;	Solution structure of DNA:RNA hybrid
7NBL	;		;	Solution structure of DNA:RNA hybrid containing a 2'-deoxy-2'2'-difluorodeoxycytidine (gemcitabine) modification
7NEJ	;		;	Solution structure of DNA:RNA hybrid duplex
2KEQ	;		;	Solution structure of DnaE intein from Nostoc punctiforme
2KQ9	;		;	Solution structure of DnaK suppressor protein from Agrobacterium tumefaciens C58. Northeast Structural Genomics Consortium target AtT12/Ontario Center for Structural Proteomics Target atc0888
2MTE	;		;	Solution structure of Doc48S
6TRP	;		;	Solution Structure of Docking Domain Complex of Pax NRPS: PaxC NDD - PaxB CDD
6EWV	;		;	Solution Structure of Docking Domain Complex of RXP NRPS: Kj12C NDD - Kj12B CDD
1YSX	;		;	Solution structure of domain 3 from human serum albumin complexed to an anti-apoptotic ligand directed against Bcl-xL and Bcl-2
2FTU	;		;	solution structure of domain 3 of RAP
1R2P	;		;	Solution structure of domain 5 from the ai5(gamma) group II intron
2AHT	;		;	Solution structure of domain 6 from the ai5(gamma)group II intron
2O2O	;		;	Solution structure of domain B from human CIN85 PROTEIN
2RO2	;		;	Solution structure of domain I of the negative polarity CChMVd hammerhead ribozyme
2RPK	;		;	Solution Structure of Domain II of the Positive Polarity CCHMVD Hammerhead Ribozyme
5OMZ	;		;	Solution structure of domain III (DIII)of Zika virus Envelope protein
2L3U	;		;	Solution Structure of Domain IV from the YbbR family protein of Desulfitobacterium hafniense: Northeast Structural Genomics Consortium target DhR29A
2MJA	;		;	Solution Structure of Domain-Swapped GLPG
2ROP	;		;	Solution structure of domains 3 and 4 of human ATP7B
6CUC	;		;	Solution structure of double knot toxin (DkTx)
3K2S	;		;	Solution structure of double super helix model
2LBS	;		;	Solution structure of double-stranded RNA binding domain of S. cerevisiae RNase III (Rnt1p) in complex with AAGU tetraloop hairpin
1T4L	;		;	Solution structure of double-stranded RNA binding domain of S. cerevisiae RNase III (Rnt1p) in complex with the 5' terminal RNA hairpin of snR47 precursor
2LUQ	;		;	Solution structure of double-stranded RNA binding domain of S.cerevisiae RNase III (rnt1p)
2N3G	;		;	Solution structure of DRB4 dsRBD1 (viz. DRB4(1-72))
2N3H	;		;	Solution structure of DRB4 dsRBD2 (viz. DRB4(81-151))
1MYN	;		;	SOLUTION STRUCTURE OF DROSOMYCIN, THE FIRST INDUCIBLE ANTIFUNGAL PROTEIN FROM INSECTS, NMR, 15 STRUCTURES
5NPG	;		;	Solution structure of Drosophila melanogaster Loquacious dsRBD1
5NPA	;		;	Solution structure of Drosophila melanogaster Loquacious dsRBD2
2K3K	;		;	Solution structure of Drosophila melanogaster SNF RBD1
2AYM	;		;	Solution Structure of Drosophila melanogaster SNF RBD2
2B0G	;		;	Solution Structure of Drosophila melanogaster SNF RBD2
2E2F	;		;	Solution structure of DSP
1X47	;		;	Solution structure of DSRM domain in DGCR8 protein
2DMY	;		;	Solution structure of DSRM domain in Spermatid perinuclear RNA-bind protein
1UHZ	;		;	Solution structure of dsRNA binding domain in Staufen homolog 2
2M2C	;		;	Solution structure of Duplex DNA
2LWM	;		;	Solution Structure of Duplex DNA Containing a b-Carba-Fapy-dG Lesion
2LWN	;		;	Solution Structure of Duplex DNA Containing a b-Carba-Fapy-dG Lesion
2LWO	;		;	Solution Structure of Duplex DNA Containing a b-Carba-Fapy-dG Lesion
2K1Y	;		;	Solution Structure of Duplex DNA Containing the Mutagenic Lesion: 1,N2-Etheno-2'-deoxyguanine
2E8J	;		;	Solution structure of dynein light chain 2A
1F95	;		;	SOLUTION STRUCTURE OF DYNEIN LIGHT CHAIN 8 (DLC8) AND BIM PEPTIDE COMPLEX
1F96	;		;	SOLUTION STRUCTURE OF DYNEIN LIGHT CHAIN 8 (DLC8) AND NNOS PEPTIDE COMPLEX
2AVX	;		;	solution structure of E coli SdiA1-171
2JVV	;		;	Solution Structure of E. coli NusG carboxyterminal domain
2KNQ	;		;	Solution structure of E.Coli GspH
5WYO	;		;	Solution structure of E.coli HdeA
1XN7	;		;	Solution Structure of E.Coli Protein yhgG: The Northeast Structural Genomics Consortium Target ET95
1XSG	;		;	Solution structure of E.coli RNase P RNA P4 stem oligoribonucleotide, U69A mutation
1XSH	;		;	Solution structure of E.coli RNase P RNA P4 stem oligoribonucleotide, U69C/C70U mutation
1XST	;		;	Solution structure of E.coli RNase P RNA P4 stem, U69A mutation, complexed with cobalt (III) hexammine.
1XSU	;		;	Solution structure of E.coli RNase P RNA P4 stem, U69C/C70U mutation, complexed with cobalt (III) hexammine.
2K8I	;		;	Solution structure of E.Coli SlyD
1ECU	;		;	SOLUTION STRUCTURE OF E2F BINDING DNA FRAGMENT GCGCGAAAC-T-GTTTCGCGC
2KRE	;		;	Solution structure of E4B/UFD2A U-Box domain
2MQ9	;		;	Solution structure of E55Q mutant of eRF1 N-domain
2LNT	;		;	Solution structure of E60A mutant AGR2
2K3X	;		;	Solution structure of EAF3 chromo barrel domain
2K3Y	;		;	Solution structure of EAF3 chromo barrel domain bound to histone h3 with a dimethyllysine analog H3K36ME2
2K6A	;		;	Solution structure of EAS D15 truncation mutant
1JE3	;		;	Solution Structure of EC005 from Escherichia coli
2G3Q	;		;	Solution Structure of Ede1 UBA-ubiquitin complex
2MVM	;		;	Solution structure of eEF1Bdelta CAR domain
2MVN	;		;	Solution structure of eEF1Bdelta CAR domain in TCTP-bound state
2KRB	;		;	Solution structure of EIF3B-RRM bound to EIF3J peptide
4B6U	;		;	Solution structure of eIF4E3 in complex with m7GDP
6JPP	;		;	Solution structure of ELMO1 RBD
1V6R	;		;	Solution Structure of Endothelin-1 with its C-terminal Folding
1ZTR	;		;	Solution structure of Engrailed homeodomain L16A mutant
2JWT	;		;	Solution structure of Engrailed homeodomain WT
2M2L	;		;	Solution structure of Entamoeba histolytica HP1 chromodomain
2N4K	;		;	Solution Structure of Enterocin HF, an Antilisterial Bacteriocin Produced by Enterococcus faecium M3K31
2KYR	;		;	Solution structure of Enzyme IIB subunit of PTS system from Escherichia coli K12. Northeast Structural Genomics Consortium target ER315/Ontario Center for Structural Proteomics target ec0544
2EOT	;		;	SOLUTION STRUCTURE OF EOTAXIN, AN ENSEMBLE OF 32 NMR SOLUTION STRUCTURES
1G2S	;		;	SOLUTION STRUCTURE OF EOTAXIN-3
1G2T	;		;	SOLUTION STRUCTURE OF EOTAXIN-3
2M9M	;		;	Solution Structure of ERCC4 domain of human FAAP24
2LX9	;		;	Solution Structure of Escherichia coli Ferrous Iron transport protein A (FeoA)
1EY1	;		;	SOLUTION STRUCTURE OF ESCHERICHIA COLI NUSB
2MQE	;		;	Solution structure of Escherichia coli Outer membrane protein A C-terminal domain
1XX3	;		;	Solution Structure of Escherichia coli TonB-CTD
1E52	;		;	Solution structure of Escherichia coli UvrB C-terminal domain
2RU1	;		;	Solution structure of esf3
2LEO	;		;	Solution structure of esophageal cancer-related gene 2
2PP4	;		;	Solution Structure of ETO-TAFH refined in explicit solvent
2DAO	;		;	Solution structure of ETS domain Transcriptional factor ETV6 protein
5W3G	;		;	Solution Structure of ETS Transcription Factor PU.1
7MLL	;		;	Solution structure of Exenatide (exendin-4) in 30-vol% trifluoroethanol using CS-Rosetta
1JRJ	;		;	Solution structure of exendin-4 in 30-vol% trifluoroethanol
1R4T	;		;	Solution structure of exoenzyme S
2KJD	;		;	Solution structure of extended PDZ2 domain from NHERF1 (150-270)
2JT0	;		;	Solution structure of F104W cardiac troponin C
2JT3	;		;	Solution Structure of F153W cardiac troponin C
1IB7	;		;	SOLUTION STRUCTURE OF F35Y MUTANT OF RAT FERRO CYTOCHROME B5, A CONFORMATION, ENSEMBLE OF 20 STRUCTURES
2MWJ	;		;	Solution structure of Family 1 Carbohydrate-Binding Module from Trichoderma reesei Cel7A with O-mannose residues at Thr1 and Ser3
2KCJ	;		;	solution structure of FAPP1 PH domain
1KTM	;		;	SOLUTION STRUCTURE OF FAT DOMAIN OF FOCAL ADHESION KINASE
2PAC	;		;	SOLUTION STRUCTURE OF FE(II) CYTOCHROME C551 FROM PSEUDOMONAS AERUGINOSA AS DETERMINED BY TWO-DIMENSIONAL 1H NMR
2E45	;		;	Solution structure of Fe65 WW domain
2GCX	;		;	Solution Structure of Ferrous Iron Transport Protein A (FeoA) of Klebsiella pneumoniae
2B9Z	;		;	Solution structure of FHV B2, a viral suppressor of RNAi
1WK0	;		;	Solution structure of Fibronectin type III domain derived from human KIAA0970 protein
1WFU	;		;	Solution structure of fibronectin type III domain of mouse hypothetical protein
2M5G	;		;	Solution structure of FimA wt
2DAR	;		;	Solution structure of first LIM domain of Enigma-like PDZ and LIM domains protein
2EEH	;		;	Solution Structure of First PDZ domain of PDZ Domain Containing Protein 7
2JS2	;		;	Solution structure of first SH3 domain of adaptor Nck
2OFN	;		;	Solution structure of FK506-binding domain (FKBD)of FKBP35 from Plasmodium falciparum
1FKR	;		;	SOLUTION STRUCTURE OF FKBP, A ROTAMASE ENZYME AND RECEPTOR FOR FK506 AND RAPAMYCIN
1FKS	;		;	SOLUTION STRUCTURE OF FKBP, A ROTAMASE ENZYME AND RECEPTOR FOR FK506 AND RAPAMYCIN
1FKT	;		;	SOLUTION STRUCTURE OF FKBP, A ROTAMASE ENZYME AND RECEPTOR FOR FK506 AND RAPAMYCIN
1F40	;		;	SOLUTION STRUCTURE OF FKBP12 COMPLEXED WITH GPI-1046, A NEUROTROPHIC LIGAND
2LPV	;		;	Solution Structure of FKBP12 from Aedes aegypti
2JNF	;		;	Solution structure of fly troponin C, isoform F1
1VD7	;		;	Solution structure of FMBP-1 tandem repeat 1
1VD8	;		;	Solution structure of FMBP-1 tandem repeat 2
1VD9	;		;	Solution structure of FMBP-1 tandem repeat 3
1VDA	;		;	Solution structure of FMBP-1 tandem repeat 4
1FMN	;		;	SOLUTION STRUCTURE OF FMN-RNA APTAMER COMPLEX, NMR, 5 STRUCTURES
2RPJ	;		;	Solution structure of Fn14 CRD domain
1UG7	;		;	Solution structure of four helical up-and-down bundle domain of the hypothetical protein 2610208M17Rik similar to the protein FLJ12806
2EEJ	;		;	Solution Structure of Fourth PDZ domain of PDZ Domain Containing Protein 1
2AMN	;		;	Solution structure of Fowlicidin-1, a novel Cathelicidin antimicrobial peptide from chicken
2K86	;		;	Solution Structure of FOXO3a Forkhead domain
1QYT	;		;	Solution structure of fragment (25-35) of beta amyloid peptide in SDS micellar solution
1EMZ	;		;	SOLUTION STRUCTURE OF FRAGMENT (350-370) OF THE TRANSMEMBRANE DOMAIN OF HEPATITIS C ENVELOPE GLYCOPROTEIN E1
2F05	;		;	Solution structure of free PAH2 domain of mSin3B
8HWU	;		;	Solution structure of frog peptide LL-TIL
1FME	;		;	SOLUTION STRUCTURE OF FSD-EY, A NOVEL PEPTIDE ASSUMING A BETA-BETA-ALPHA FOLD
6BUT	;		;	Solution structure of full-length apo mammalian calmodulin bound to the IQ motif of the human voltage-gated sodium channel NaV1.2
1PM6	;		;	Solution Structure of Full-Length Excisionase (Xis) from Bacteriophage HK022
2KFW	;		;	Solution structure of full-length SlyD from E.coli
2RMQ	;		;	Solution structure of fully modified 4'-thioDNA with the sequence of d(CGCGAATTCGCG)
6GBM	;		;	Solution structure of FUS-RRM bound to stem-loop RNA
6G99	;		;	Solution structure of FUS-ZnF bound to UGGUG
2LCW	;		;	solution structure of FUS/TLS RRM domain
2RUM	;		;	Solution structure of Fusion peptide
5ZEV	;		;	Solution structure of G-quadruplex formed in vegfr-2 proximal promoter sequence
2N16	;		;	Solution structure of G-quadruplex recognition domain of RHAU
1HU6	;		;	SOLUTION STRUCTURE OF G10 NOVISPIRIN
1M9G	;		;	Solution structure of G16A-MNEI, a structural mutant of single chain monellin MNEI
5Z2O	;		;	solution structure of G2,7,13A SMAP-18 analogue
1CMZ	;		;	SOLUTION STRUCTURE OF GAIP (GALPHA INTERACTING PROTEIN): A REGULATOR OF G PROTEIN SIGNALING
1GPS	;		;	SOLUTION STRUCTURE OF GAMMA 1-H AND GAMMA 1-P THIONINS FROM BARLEY AND WHEAT ENDOSPERM DETERMINED BY 1H-NMR: A STRUCTURAL MOTIF COMMON TO TOXIC ARTHROPOD PROTEINS
1GPT	;		;	SOLUTION STRUCTURE OF GAMMA 1-H AND GAMMA 1-P THIONINS FROM BARLEY AND WHEAT ENDOSPERM DETERMINED BY 1H-NMR: A STRUCTURAL MOTIF COMMON TO TOXIC ARTHROPOD PROTEINS
1MR6	;		;	Solution Structure of gamma-Bungarotoxin:Implication for the role of the Residues Adjacent to RGD in Integrin Binding
2KLJ	;		;	Solution Structure of gammaD-Crystallin with RDC and SAXS
2M3C	;		;	Solution Structure of gammaM7-Crystallin
7D2O	;		;	Solution structure of Gaussia Luciferase by NMR
2RMM	;		;	Solution structure of GB1 A34F mutant
2KLK	;		;	Solution structure of GB1 A34F mutant with RDC and SAXS
2J52	;		;	Solution Structure of GB1 domain Protein G and low and high pressure.
2J53	;		;	Solution Structure of GB1 domain Protein G and low and high pressure.
2RPV	;		;	Solution Structure of GB1 with LBT probe
2L5M	;		;	Solution structure of GF-17 in complex with micelles
2OBU	;		;	Solution structure of GIP in TFE/water
1T5Q	;		;	Solution Structure of GIP(1-30)amide in TFE/Water
1RRZ	;		;	Solution structure of GlgS protein from E. coli
5YNR	;		;	Solution Structure of glia maturation factor from Caenorhabditis elegans
1V6F	;		;	Solution Structure of Glia Maturation Factor-beta from Mus Musculus
1WFS	;		;	Solution Structure of Glia Maturation Factor-gamma from Mus Musculus
2B5Q	;		;	Solution structure of globular conformation of CMrVIA lambda conotoxin
1D0R	;		;	SOLUTION STRUCTURE OF GLUCAGON-LIKE PEPTIDE-1-(7-36)-AMIDE IN TRIFLUOROETHANOL/WATER
2B4N	;		;	Solution Structure of Glucose-Dependent Insulinotropic Polypeptide
2KLX	;		;	Solution structure of glutaredoxin from Bartonella henselae str. Houston
2KHP	;		;	Solution structure of Glutaredoxin from Brucella melitensis
2KUT	;		;	Solution Structure of GmR58A from Geobacter metallireducens. Northeast Structural Genomics Consortium Target GmR58A
6MY1	;		;	Solution structure of gomesin at 278 K
6MY2	;		;	Solution structure of gomesin at 298 K
6MY3	;		;	Solution structure of gomesin at 310K
2WNM	;		;	Solution structure of Gp2
2LSM	;		;	Solution structure of gpFI C-terminal domain
2LCF	;		;	Solution structure of GppNHp-bound H-RasT35S mutant protein
1MSG	;		;	SOLUTION STRUCTURE OF GRO(SLASH)MELANOMA GROWTH STIMULATORY ACTIVITY DETERMINED BY 1H NMR SPECTROSCOPY
1MSH	;		;	SOLUTION STRUCTURE OF GRO(SLASH)MELANOMA GROWTH STIMULATORY ACTIVITY DETERMINED BY 1H NMR SPECTROSCOPY
1GRU	;	12.5	;	SOLUTION STRUCTURE OF GROES-ADP7-GROEL-ATP7 COMPLEX BY CRYO-EM
2EQH	;		;	Solution structure of growth-blocking peptide of the armyworm, Pseudaletia separata
2EQQ	;		;	Solution structure of growth-blocking peptide of the armyworm, Pseudaletia separata
2DJ9	;		;	Solution structure of growth-blocking peptide of the cabbage armyworm, Mamestra brassicae
2DJC	;		;	Solution structure of growth-blocking peptide of the tobacco cutworm, Spodoptera litura
1YKA	;		;	Solution structure of Grx4, a monothiol glutaredoxin from E. coli.
2KY3	;		;	Solution structure of GS-alfa-Ktx5.4 synthetic scorpion like
1LU8	;		;	Solution structure of GsMTx-4
2K4K	;		;	Solution structure of GSP13 from Bacillus subtilis
2LNV	;		;	Solution structure of GspC-HR of typeII secretion system
2KL1	;		;	Solution structure of GtR34C from Geobacillus thermodenitrificans. Northeast Structural Genomics Consortium Target GtR34C
2WH9	;		;	Solution structure of GxTX-1E
5ZC6	;		;	Solution structure of H-RasT35S mutant protein in complex with KBFM123
2LWI	;		;	Solution structure of H-RasT35S mutant protein in complex with Kobe2601
1WJF	;		;	SOLUTION STRUCTURE OF H12C MUTANT OF THE N-TERMINAL ZN BINDING DOMAIN OF HIV-1 INTEGRASE COMPLEXED TO CADMIUM, NMR, 40 STRUCTURES
1WJE	;		;	SOLUTION STRUCTURE OF H12C MUTANT OF THE N-TERMINAL ZN BINDING DOMAIN OF HIV-1 INTEGRASE COMPLEXED TO CADMIUM, NMR, MINIMIZED AVERAGE STRUCTURE
1D1H	;		;	SOLUTION STRUCTURE OF HANATOXIN 1
2KBQ	;		;	Solution structure of harmonin N terminal domain
2LSR	;		;	Solution structure of harmonin N terminal domain in complex with a exon68 encoded peptide of cadherin23
2KBR	;		;	Solution structure of harmonin N terminal domain in complex with a internal peptide of cadherin23
2KBS	;		;	Solution structure of harmonin PDZ2 in complex with the carboxyl tail peptide of cadherin23
5Y7L	;		;	Solution structure of Hbeta4 extracellular loop of BK potassium channel
1S5R	;		;	Solution Structure of HBP1 SID-mSin3A PAH2 Complex
1UFZ	;		;	Solution structure of HBS1-like domain in hypothetical protein BAB28515
1P5O	;		;	Solution Structure of HCV IRES Domain II
1P5P	;		;	Solution Structure of HCV IRES Domain II (minimized average structure)
1P5M	;		;	Solution Structure of HCV IRES Domain IIa
1P5N	;		;	Solution Structure of HCV IRES Domain IIb
1F84	;		;	SOLUTION STRUCTURE OF HCV IRES RNA DOMAIN IIID
1F85	;		;	SOLUTION STRUCTURE OF HCV IRES RNA DOMAIN IIIE
2KDR	;		;	Solution structure of HCV NS4B(227-254)
2K8J	;		;	Solution structure of HCV p7 tm2
2HDP	;		;	Solution Structure of Hdm2 RING Finger Domain
2M86	;		;	Solution structure of Hdm2 with engineered cyclotide
2KR7	;		;	solution structure of Helicobacter pylori SlyD
1JUR	;		;	Solution Structure of Helix III in Xenopus Oocyte 5S rRNA.
2LV0	;		;	Solution Structure of Helix-35 Stem-loop from E. coli 23S rRNA
2LDR	;		;	Solution structure of Helix-RING domain of Cbl-b in the Tyr363 phosphorylated form
2LVJ	;		;	solution structure of hemi-Mg-bound Phl p 7
1JW2	;		;	SOLUTION STRUCTURE OF HEMOLYSIN EXPRESSION MODULATING PROTEIN Hha FROM ESCHERICHIA COLI. Ontario Centre for Structural Proteomics target EC0308_1_72; Northeast Structural Genomics Target ET88
3IRI	;		;	Solution Structure of Heparin dp18
3IRJ	;		;	Solution Structure of Heparin dp24
3IRK	;		;	Solution Structure of Heparin dp30
3IRL	;		;	Solution Structure of Heparin dp36
1M4E	;		;	Solution Structure of Hepcidin-20
1M4F	;		;	Solution Structure of Hepcidin-25
1NE5	;		;	Solution Structure of HERG Specific Scorpion Toxin CnErg1
1J5J	;		;	Solution structure of HERG-specific scorpion toxin BeKm-1
1LGL	;		;	Solution structure of HERG-specific scorpion toxin BeKm-1
5X9X	;		;	Solution structure of heterodimeric coiled-coil domain of Drosophila GABAB receptor 1 and 2
5GWM	;		;	Solution structure of heterodimeric coiled-coil domain of Drosophila GABAB receptor 1 and 3
5IPO	;		;	Solution Structure of Hge36: Scorpine-like Peptide from Hadrurus Gertschi
5JYH	;		;	Solution Structure of Hge36: Scorpine-like Peptide from Hadrurus Gertschi
1IMU	;		;	Solution Structure of HI0257, a Ribosome Binding Protein
1J7H	;		;	Solution Structure of HI0719, a Hypothetical Protein From Haemophilus Influenzae
2OUT	;		;	Solution Structure of HI1506, a Novel Two Domain Protein from Haemophilus influenzae
6L7K	;		;	solution structure of hIFABP V60C/Y70C variant.
2KAA	;		;	Solution Structure of Hirsutellin A from Hirsutella thompsonii
1QR5	;		;	SOLUTION STRUCTURE OF HISTIDINE CONTAINING PROTEIN (HPR) FROM STAPHYLOCOCCUS CARNOSUS
2LD6	;		;	Solution Structure of Histidine Phosphotransfer Domain of CheA
2PJV	;		;	solution structure of hiv-1 gp41 fusion domain bound to DPC micelle
6B3U	;		;	Solution Structure of HIV-1 GP41 Transmembrane Domain in Bicelles
2H3Q	;		;	Solution structure of HIV-1 myrMA bound to di-C4-phosphatidylinositol-(4,5)-bisphosphate
484D	;		;	SOLUTION STRUCTURE OF HIV-1 REV PEPTIDE-RNA APTAMER COMPLEX
1N8X	;		;	Solution structure of HIV-1 Stem Loop SL1
6MCE	;		;	Solution structure of HIV-1 TAR with Tat RNA Binding Domain
1FI0	;		;	SOLUTION STRUCTURE OF HIV-1 VPR (13-33) PEPTIDE IN MICELLS
1JTJ	;		;	Solution structure of HIV-1Lai mutated SL1 hairpin
2K4I	;		;	Solution structure of HIV-2 myrMA bound to di-C4-PI(4,5)P2
1L8Y	;		;	Solution structure of HMG box 5 in human upstream binding factor
1L8Z	;		;	Solution structure of HMG box 5 in human upstream binding factor
2AUV	;		;	Solution Structure of HndAc : A Thioredoxin-like [2Fe-2S] Ferredoxin Involved in the NADP-reducing Hydrogenase Complex
1S7E	;		;	Solution structure of HNF-6
2MXY	;		;	Solution structure of hnRNP C RRM in complex with 5'-AUUUUUC-3' RNA
2MZ1	;		;	Solution structure of hnRNP C RRM in complex with 5'-UUUUC-3' RNA
2MB0	;		;	Solution structure of hnRNP G RRM in complex with the RNA 5'-AUCAAA-3'
8GSA	;		;	Solution structure of holo acyl carrier protein A from Enterococcus faecalis
6LVT	;		;	Solution structure of holo acyl carrier protein from Thermotoga maritima
2N6Y	;		;	Solution structure of holo ArCP from yersiniabactin synthetase
2M5R	;		;	Solution structure of holo-acyl carrier protein of Leishmania major
2BDO	;		;	SOLUTION STRUCTURE OF HOLO-BIOTINYL DOMAIN FROM ACETYL COENZYME A CARBOXYLASE OF ESCHERICHIA COLI DETERMINED BY TRIPLE-RESONANCE NMR SPECTROSCOPY
1O5P	;		;	Solution Structure of holo-Neocarzinostatin
2MT9	;		;	Solution structure of holo_FldB
1WH7	;		;	Solution structure of homeobox domain of Arabidopsis thaliana hypothetical protein F22K18.140
1WH5	;		;	Solution structure of homeobox domain of Arabidopsisthaliana zinc finger homeobox family protein
7YB4	;		;	Solution structure of homeodomain of EXTRADENTICLE
7YWQ	;		;	Solution structure of homodimeric Capsid protein (residues 17-95) of Tick-borne encephalitis virus (d16-TBEVC)
1HLY	;		;	SOLUTION STRUCTURE OF HONGOTOXIN 1
2MSY	;		;	Solution structure of Hox homeodomain
2MX0	;		;	Solution structure of HP0268 from Helicobacter pylori
1ZHC	;		;	Solution structure of HP1242 from Helicobacter pylori
2LXR	;		;	Solution structure of HP1264 from Helicobacter pylori
2EVQ	;		;	Solution structure of HP7, a 12-residue beta hairpin
2JX8	;		;	Solution structure of hPCIF1 WW domain
2F65	;		;	Solution structure of HPPK in complex with inhibitor analog AMPCPP
2F63	;		;	Solution structure of HPPK in complex with inhibitor analogs AMPCPP and HP-1
1EMX	;		;	SOLUTION STRUCTURE OF HPTX2, A TOXIN FROM HETEROPODA VENATORIA SPIDER VENOM THAT BLOCKS KV4.2 POTASSIUM CHANNEL
2MA1	;		;	Solution structure of HRDC1 domain of RecQ helicase from Deinococcus radiodurans
1Y2P	;		;	Solution structure of Hstx3P
1EXY	;		;	SOLUTION STRUCTURE OF HTLV-1 PEPTIDE BOUND TO ITS RNA APTAMER TARGET
1QRJ	;		;	Solution structure of htlv-i capsid protein
2L97	;		;	Solution structure of HtrA PDZ domain from Streptococcus pneumoniae
2LVM	;		;	Solution structure of human 53BP1 tandem Tudor domains in complex with a histone H4K20me2 peptide
2RQ9	;		;	Solution structure of human acidic fibroblast growth factor (aFGF) in the presence of a protein stabilizer NDSB-new
2K8R	;		;	Solution structure of human acidic fibroblast growth factor in complex with anti-angiogenic drug inositol hexaphosphate (IP6)
7X7S	;		;	Solution structure of human adenylate kinase 1 (hAK1)
7DME	;		;	Solution structure of human Aha1
7DMD	;		;	Solution structure of human Aha1 N-terminal domain
1RK9	;		;	Solution Structure of Human alpha-Parvalbumin (Minimized Average Structure)
1RJV	;		;	Solution Structure of Human alpha-Parvalbumin refined with a paramagnetism-based strategy
2L67	;		;	Solution Structure of Human Apo L-FABP
2GVP	;		;	Solution structure of Human apo Sco1
2LLS	;		;	solution structure of human apo-S100A1 C85M
2L0P	;		;	Solution structure of human apo-S100A1 protein by NMR spectroscopy
8BFG	;		;	Solution structure of human apo/Calmodulin G113R (G114R)
2RN9	;		;	Solution structure of human apoCox17
1JFN	;		;	SOLUTION STRUCTURE OF HUMAN APOLIPOPROTEIN(A) KRINGLE IV TYPE 6
2EZZ	;		;	SOLUTION STRUCTURE OF HUMAN BARRIER-TO-AUTOINTEGRATION FACTOR BAF NMR, ENSEMBLE OF 20 SIMULATED ANNEALING STRUCTURES
2EZY	;		;	SOLUTION STRUCTURE OF HUMAN BARRIER-TO-AUTOINTEGRATION FACTOR BAF, NMR, ENSEMBLE OF 20 SIMULATED ANNEALING STRUCTURES
2EZX	;		;	SOLUTION STRUCTURE OF HUMAN BARRIER-TO-AUTOINTEGRATION FACTOR BAF, NMR, REGULARIZED MEAN STRUCTURE
1QCK	;		;	SOLUTION STRUCTURE OF HUMAN BARRIER-TO-AUTOINTEGRATION FACTOR BAF, NMR, REGULARIZED MEAN STRUCTURE PLUS 20 INDIVIDUAL SIMULATED ANNEALING STRUCTURES
1MK3	;		;	SOLUTION STRUCTURE OF HUMAN BCL-W PROTEIN
1TTX	;		;	Solution Structure of human beta parvalbumin (oncomodulin) refined with a paramagnetism based strategy
1KJ5	;		;	Solution Structure of Human beta-defensin 1
1KJ6	;		;	Solution Structure of Human beta-Defensin 3
1FQQ	;		;	SOLUTION STRUCTURE OF HUMAN BETA-DEFENSIN-2
2IZ3	;		;	Solution structure of human beta-microseminoprotein
2H60	;		;	Solution Structure of Human Brg1 Bromodomain
2LS8	;		;	Solution structure of human C-type lectin domain family 4 member D
2MRD	;		;	Solution structure of human Ca2+-loaded S100A4 cys-free mutant
5I8N	;		;	Solution Structure of human calcium-binding S100A9 (C3S) protein
6NL3	;		;	Solution structure of human Coa6
1TMW	;		;	Solution structure of Human Coactosin Like Protein D123N
3GAV	;		;	Solution structure of Human Complement Factor H in 137 mM NaCl buffer
3GAW	;		;	Solution structure of Human Complement Factor H in 250 mM NaCl buffer
3GAU	;		;	Solution structure of Human Complement Factor H in 50 mM NaCl buffer
2GT6	;		;	Solution structure of Human Cu(I) Sco1
2GQM	;		;	Solution structure of Human Cu(I)-Sco1
2RNB	;		;	Solution structure of human Cu(I)Cox17
2JR7	;		;	Solution structure of human DESR1
1YHO	;		;	Solution structure of human dihydrofolate reductase complexed with trimethoprim and nadph, 25 structures
2QTJ	;		;	Solution structure of human dimeric immunoglobulin A
5MS9	;		;	Solution structure of Human Fibrillin-1 EGF2-EGF3-Hybrid1-cbEGF1 four domain fragment
2MPH	;		;	Solution Structure of human FK506 binding Protein 25
2RSV	;		;	Solution structure of human full-length vaccinia related kinase 1 (VRK1)
1KOT	;		;	Solution Structure of Human GABA Receptor Associated Protein GABARAP
5H3M	;		;	Solution structure of human Gelsolin protein domain 1 at pH 5.0
5H3N	;		;	Solution structure of human Gelsolin protein domain 1 at pH 7.3
1G5W	;		;	SOLUTION STRUCTURE OF HUMAN HEART-TYPE FATTY ACID BINDING PROTEIN
2L68	;		;	Solution Structure of Human Holo L-FABP
2MBC	;		;	Solution Structure of human holo-PRL-3 in complex with vanadate
2L2O	;		;	Solution structure of human HSPC280 protein
1IJZ	;		;	Solution Structure of Human IL-13
1IK0	;		;	Solution Structure of Human IL-13
2EC7	;		;	Solution Structure of Human Immunodificiency Virus Type-2 Nucleocapsid Protein
2RCJ	;		;	Solution structure of human Immunoglobulin M
2MVC	;		;	Solution structure of human insulin at pH 1.9
2GF1	;		;	SOLUTION STRUCTURE OF HUMAN INSULIN-LIKE GROWTH FACTOR 1: A NUCLEAR MAGNETIC RESONANCE AND RESTRAINED MOLECULAR DYNAMICS STUDY
3GF1	;		;	SOLUTION STRUCTURE OF HUMAN INSULIN-LIKE GROWTH FACTOR 1: A NUCLEAR MAGNETIC RESONANCE AND RESTRAINED MOLECULAR DYNAMICS STUDY
1IGL	;		;	SOLUTION STRUCTURE OF HUMAN INSULIN-LIKE GROWTH FACTOR II RELATIONSHIP TO RECEPTOR AND BINDING PROTEIN INTERACTIONS
2KBC	;		;	Solution structure of human insulin-like peptide 5 (INSL5)
2KKI	;		;	Solution structure of human Interleukin 1a
1IRP	;		;	SOLUTION STRUCTURE OF HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST PROTEIN
2OQP	;		;	Solution structure of human interleukin-21
2KLL	;		;	Solution structure of human interleukin-33
7OX6	;		;	Solution structure of human interleukin-9
1KZW	;		;	Solution structure of Human Intestinal Fatty acid binding protein
1KZX	;		;	Solution structure of human intestinal fatty acid binding protein with a naturally-occurring single amino acid substitution (A54T)
2L6L	;		;	Solution structure of human J-protein co-chaperone, Dph4
1R21	;		;	Solution Structure of human Ki67 FHA Domain
2L1Q	;		;	Solution structure of human Liver Expressed Antimicrobial Peptide 2
2PY1	;		;	Solution structure of human liver fatty acid binding protein
2LMF	;		;	Solution structure of human LL-23 bound to membrane-mimetic micelles
1J8I	;		;	Solution Structure of Human Lymphotactin
1J9O	;		;	SOLUTION STRUCTURE OF HUMAN LYMPHOTACTIN
2Z2D	;		;	Solution structure of human macrophage elastase (MMP-12) catalytic domain complexed with a gamma-keto butanoic acid inhibitor
4D4W	;		;	Solution structure of human MBD1 CXXC1 domain
2KBW	;		;	Solution Structure of human Mcl-1 complexed with human Bid_BH3 peptide
2PPH	;		;	solution structure of human MEKK3 PB1 domain
2JRH	;		;	Solution structure of human MEKK3 PB1 domain cis isomer
1PC2	;		;	Solution structure of human mitochondria fission protein Fis1
5YFG	;		;	SOLUTION STRUCTURE OF HUMAN MOG1
1FWQ	;		;	SOLUTION STRUCTURE OF HUMAN MSS4, A GUANINE NUCLEOTIDE EXCHANGE FACTOR FOR RAB PROTEINS
6O6W	;		;	Solution structure of human myeloid-derived growth factor
6E5N	;		;	Solution structure of human Myosin VI isoform 3 (1050-1131) in complex with Clathrin light chain a (46-61)
2N12	;		;	Solution structure of human Myosin VI isoform3 (1050-1131)
2N11	;		;	Solution structure of human Myosin VI isoform3 (998-1071)
2JVX	;		;	Solution Structure of human NEMO zinc finger
2GQK	;		;	Solution structure of Human Ni(II)-Sco1
2GQL	;		;	Solution structure of Human Ni(II)-Sco1
2H35	;		;	Solution structure of Human normal adult hemoglobin
2MWC	;		;	Solution structure of human obscurin Ig58
1TR4	;		;	Solution structure of human oncogenic protein gankyrin
1R02	;		;	Solution structure of Human Orexin-A:Regulator of Appetite and Wakefulness
1V66	;		;	Solution structure of human p53 binding domain of PIAS-1
2FEJ	;		;	Solution structure of human p53 DNA binding domain.
2HP8	;		;	SOLUTION STRUCTURE OF HUMAN P8-MTCP1, A CYSTEINE-RICH PROTEIN ENCODED BY THE MTCP1 ONCOGENE,REVEALS A NEW ALPHA-HELICAL ASSEMBLY MOTIF, NMR, 30 STRUCTURES
1HP8	;		;	SOLUTION STRUCTURE OF HUMAN P8-MTCP1, A CYSTEINE-RICH PROTEIN ENCODED BY THE MTCP1 ONCOGENE,REVEALS A NEW ALPHA-HELICAL ASSEMBLY MOTIF, NMR, MINIMIZED AVERAGE STRUCTURE
2K11	;		;	Solution structure of human pancreatic ribonuclease
2K27	;		;	Solution structure of Human Pax8 Paired Box Domain
2LDM	;		;	Solution structure of human PHF20 Tudor2 domain bound to a p53 segment containing a dimethyllysine analog p53K370me2
2AI6	;		;	Solution structure of human phosphohistidine phosphatase 1
2OZX	;		;	Solution structure of human phosphohistidine phosphatase 1 in phosphate free form
2OZW	;		;	Solution structure of human phosphohistidine phosphatase 1 with phosphate ligand
1NMV	;		;	Solution structure of human Pin1
2RUR	;		;	Solution structure of Human Pin1 PPIase C113S mutant
2RUQ	;		;	solution structure of human Pin1 PPIase mutant C113A
2L0S	;		;	Solution Structure of Human Plasminogen Kringle 3
1R6H	;		;	Solution Structure of human PRL-3
1O8R	;		;	Solution structure of human proguanylin
1T0C	;		;	Solution Structure of Human Proinsulin C-Peptide
1RW5	;		;	Solution structure of human prolactin
2L8R	;		;	Solution structure of human protein C6orf130 in complex with ADP-ribose
2LGR	;		;	Solution structure of human protein C6orf130, a putative macro domain
2DF0	;		;	Solution structure of human PYY3-36
2FHW	;		;	Solution structure of human relaxin-3
4BEH	;		;	Solution structure of human ribosomal protein P1.P2 heterodimer
7VB2	;		;	Solution structure of human ribosomal protein uL11
2LUC	;		;	Solution Structure of human S100 calcium-binding protein A11
2HDE	;		;	Solution Structure of Human SAP18
2KOL	;		;	Solution structure of human SDF1-alpha H25R
2OCW	;		;	Solution structure of human secretory component
3CHN	;		;	Solution structure of human secretory IgA1
1RL1	;		;	Solution structure of human Sgt1 CS domain
3CM9	;		;	Solution Structure of Human SIgA2
2AWT	;		;	Solution Structure of Human Small Ubiquitin-Like Modifier Protein Isoform 2 (SUMO-2)
2KRG	;		;	Solution Structure of human sodium/ hydrogen exchange regulatory factor 1(150-358)
2ETT	;		;	Solution Structure of Human Sorting Nexin 22 PX Domain
2LEA	;		;	Solution structure of human SRSF2 (SC35) RRM
2LEB	;		;	Solution structure of human SRSF2 (SC35) RRM in complex with 5'-UCCAGU-3'
2LEC	;		;	Solution structure of human SRSF2 (SC35) RRM in complex with 5'-UGGAGU-3'
2KT0	;		;	Solution structure of human stem cell transcription factor Nanog homeodomain fragment
7WH3	;		;	Solution structure of human stomatin SPFH domain in a phosphate buffer
1YZS	;		;	Solution structure of human sulfiredoxin (srx)
2B6F	;		;	Solution structure of human sulfiredoxin (SRX)
1WZ0	;		;	Solution Structure of Human SUMO-2 (SMT3B), a Ubiquitin-like Protein
1U4A	;		;	Solution structure of human SUMO-3 C47S
2N1V	;		;	Solution structure of human SUMO1
2N1W	;		;	Solution structure of human SUMO2
2K6M	;		;	Solution Structure of Human Supervillin Headpiece
2K6N	;		;	Solution Structure of Human Supervillin Headpiece, Minimized Average
1XOX	;		;	SOLUTION STRUCTURE OF HUMAN SURVIVIN
1DL6	;		;	SOLUTION STRUCTURE OF HUMAN TFIIB N-TERMINAL DOMAIN
1B4Q	;		;	Solution structure of human thioltransferase complex with glutathione
2HR9	;		;	Solution structure of human translationally controlled tumor protein
1VF9	;		;	Solution Structure Of Human Trf2
2Y4W	;		;	Solution structure of human ubiquitin conjugating enzyme Rad6b
2KLY	;		;	Solution structure of human ubiquitin conjugating enzyme Ube2g2
2YUJ	;		;	Solution structure of human ubiquitin fusion degradation protein 1 homolog UFD1
5ZD0	;		;	Solution structure of human ubiquitin with three alanine mutations in living eukaryotic cells by in-cell NMR spectroscopy
2KDB	;		;	Solution Structure of human ubiquitin-like domain of Herpud2_9_85, Northeast Structural Genomics Consortium (NESG) target HT53A
2KUL	;		;	Solution structure of human vaccinia related kinase 1(VRK1)
2KTY	;		;	Solution Structure of human Vaccinia Related Kinase-1
2K4T	;		;	Solution structure of human VDAC-1 in LDAO micelles
2HF6	;		;	Solution structure of human zeta-COP
2KOM	;		;	Solution structure of humar Par-3b PDZ2 (residues 451-549)
1QK6	;		;	Solution structure of huwentoxin-I by NMR
2KC5	;		;	Solution Structure of HybE from Escherichia coli
1S6W	;		;	Solution Structure of hybrid white striped bass hepcidin
2KDX	;		;	Solution structure of HypA protein
2OT2	;		;	Solution Structure of HypC
1Q53	;		;	SOLUTION STRUCTURE OF HYPOTHETICAL ARABIDOPSIS THALIANA PROTEIN AT3G17210. CENTER FOR EUKARYOTIC STRUCTURAL GENOMICS TARGET 13081
1WJK	;		;	Solution structure of hypothetical protein C330018D20Rik from Mus musculus
1WJJ	;		;	Solution structure of hypothetical protein F20O9.120 from Arabidopsis thaliana
1EO1	;		;	Solution structure of hypothetical protein MTH1175 from Methanobacterium thermoautotrophicum
1EIW	;		;	Solution structure of hypothetical protein MTH538 from Methanobacterium thermoautotrophicum
2H9Z	;		;	Solution structure of hypothetical protein, HP0495 from Helicobacter pylori
2K6P	;		;	Solution Structure of hypothetical protein, HP1423
2M48	;		;	Solution Structure of IBR-RING2 Tandem Domain from Parkin
1DGN	;		;	SOLUTION STRUCTURE OF ICEBERG, AN INHIBITOR OF INTERLEUKIN-1BETA GENERATION
1ZYI	;		;	Solution structure of ICLN, a multifunctional protein involved in regulatory mechanisms as different as cell volume regulation and rna splicing
6JHD	;		;	Solution structure of IFN alpha8
2K3T	;		;	Solution Structure of IG-Like Domain 23 from Human Filamin A
1ZFL	;		;	Solution structure of III-A, the major intermediate in the oxidative folding of leech carboxypeptidase inhibitor
2L5X	;		;	Solution structure of IL1A-S100A13 complex
2KBX	;		;	Solution structure of ILK-PINCH complex
1UFG	;		;	Solution structure of immunoglobulin like domain of mouse nuclear lamin
1IE6	;		;	SOLUTION STRUCTURE OF IMPERATOXIN A
2LA8	;		;	Solution structure of INAD PDZ5 complexed with Kon-tiki peptide
1MFY	;		;	SOLUTION STRUCTURE OF INFLUENZA A VIRUS C4 PROMOTER
1JO7	;		;	Solution Structure of Influenza A Virus Promoter
1V91	;		;	Solution structure of insectidal toxin delta-paluIT2-NH2
2H8B	;		;	Solution structure of INSL3
2K8O	;		;	Solution structure of integrin Alpha L
5ZAZ	;		;	Solution structure of integrin b2 monomer tranmembrane domain in bicelle
2KMQ	;		;	Solution structure of intermediate IIb of Leech-derived tryptase inhibitor, LDTI.
2KMR	;		;	Solution structure of intermediate IIc of Leech-derived tryptase inhibitor, LDTI.
2KMP	;		;	Solution structure of intermeidate IIa of Leeck-derived tryptase inhibitor, LDTI.
2RUO	;		;	Solution Structure of Internal Fusion Peptide
1EDS	;		;	SOLUTION STRUCTURE OF INTRADISKAL LOOP 1 OF BOVINE RHODOPSIN (RHODOPSIN RESIDUES 92-123)
1AU5	;		;	SOLUTION STRUCTURE OF INTRASTRAND CISPLATIN-CROSSLINKED DNA OCTAMER D(CCTG*G*TCC):D(GGACCAGG), NMR, MINIMIZED AVERAGE STRUCTURE
2JUB	;		;	Solution structure of IPI*
2K5I	;		;	SOLUTION STRUCTURE OF IRON(II) TRANSPORT PROTEIN A FROM CLOSTRIDIUM THERMOCELLUM , NORTHEAST STRUCTURAL GENOMICS CONSORTIUM (NESG) TARGET VR131
1XJS	;		;	Solution structure of Iron-Sulfur cluster assembly protein IscU from Bacillus subtilis, with Zinc bound at the active site. Northeast Structural Genomics Consortium Target SR17
2AZH	;		;	Solution structure of iron-sulfur cluster assembly protein SUFU from Bacillus subtilis, with zinc bound at the active site. Northeast Structural Genomics Consortium target SR17
1WFZ	;		;	Solution structure of Iron-sulfur cluster protein U (IscU)
2RSX	;		;	Solution structure of IseA, an inhibitor protein of DL-endopeptidases from Bacillus subtilis
5M0A	;		;	Solution structure of isolated 15th Fibronectin III domain from human fibronectin
7PJ1	;		;	Solution structure of isolated Drosophila histone H2A-H2B heterodimer
1X4T	;		;	Solution structure of Isy1 domain in hypothetical protein
1SZY	;		;	Solution structure of ITALY1 (""Initiator tRNA Anticodon Loop from Yeast""), an unmodified 21-nt RNA with the sequence of the anticodon stem-loop of yeast initiator tRNA
2CTP	;		;	Solution structure of J-domain from human DnaJ subfamily B menber 12
2CTR	;		;	Solution structure of J-domain from human DnaJ subfamily B menber 9
2CTQ	;		;	Solution structure of J-domain from human DnaJ subfamily C menber 12
2CTW	;		;	Solution structure of J-domain from mouse DnaJ subfamily C menber 5
2DN9	;		;	Solution structure of J-domain from the DnaJ homolog, human Tid1 protein
8S9E	;		;	Solution structure of jarastatin (rJast), a disintegrin from Bothrops jararaca
2KGG	;		;	Solution Structure of JARID1A C-terminal PHD finger
2KGI	;		;	Solution structure of JARID1A C-terminal PHD finger in complex with H3(1-9)K4me3
2W9O	;		;	Solution structure of jerdostatin from Trimeresurus jerdonii
2W9V	;		;	Solution structure of jerdostatin from Trimeresurus jerdonii with end C-terminal residues N45G46 deleted
2W9U	;		;	Solution structure of jerdostatin mutant R24K from Trimeresurus jerdonii
2W9W	;		;	Solution structure of jerdostatin mutant R24K from Trimeresurus jerdonii with end C-terminal residues N45G46 deleted
2I1T	;		;	Solution structure of Jingzhaotoxin-III, a novel toxin inhibiting both Nav and Kv channels
1ZJQ	;		;	Solution structure of Jingzhaotoxin-VII
2AAP	;		;	Solution structure of jingzhaotoxin-vii
2RQF	;		;	Solution structure of juvenile hormone binding protein from silkworm in complex with JH III
2N9Z	;		;	Solution structure of K1 lobe of double-knot toxin
2KE6	;		;	Solution Structure of K10 TLS RNA
2KUW	;		;	Solution Structure of K10 TLS RNA (A-form mutant in lower helix)
2KUR	;		;	Solution Structure of K10 TLS RNA (AU mutant in upper helix)
2KUV	;		;	Solution Structure of K10 TLS RNA (GC mutant in lower helix)
2KUU	;		;	Solution Structure of K10 TLS RNA (GC mutant in upper helix)
2NAJ	;		;	Solution structure of K2 lobe of double-knot toxin
2KVX	;		;	Solution structure of kalata B12
2MN1	;		;	Solution Structure of kalata B1[W23WW]
2M9O	;		;	Solution structure of kalata B7
2B38	;		;	Solution structure of kalata B8
5WLX	;		;	Solution structure of kappa-theraphotoxin-Aa1a
1X4M	;		;	Solution structure of KH domain in Far upstream element binding protein 1
1X4N	;		;	Solution structure of KH domain in FUSE binding protein 1
1WE8	;		;	Solution structure of KH domain in protein BAB28342
1UL7	;		;	Solution structure of kinase associated domain 1 of mouse MAP/microtubule affinity-regulating kinase 3
1V5S	;		;	Solution structure of kinase associated domain 1 of mouse MAP/microtubule affinity-regulating kinase 3
2LIF	;		;	Solution Structure of KKGF
1Z09	;		;	Solution structure of km23
2MY5	;		;	Solution Structure of KstB-PCP in kosinostatin biosynthesis
5WPX	;		;	Solution Structure of KstB-PCP loaded with nicotinic acid in kosinostatin biosynthesis
5WPY	;		;	Solution Structure of KstB-PCP loaded with nicotinic acid in kosinostatin biosynthesis
6BZK	;		;	Solution structure of KTI55
6UZ5	;		;	Solution structure of KTI55-Kringle 2 complex
2M01	;		;	Solution structure of Kunitz-type neurotoxin LmKKT-1a from scorpion venom
1T1T	;		;	Solution Structure of Kurtoxin
2NAU	;		;	Solution structure of KYE28A in lipopolysachharide
2LF1	;		;	Solution structure of L. casei dihydrofolate reductase complexed with NADPH, 30 structures
2HQP	;		;	Solution structure of L.casei dihydrofolate reductase complexed with NADPH, 32 structures
2KLM	;		;	Solution Structure of L11 with SAXS and RDC
2NV3	;		;	Solution structure of L8A mutant of HIV-1 myristoylated matrix protein
2LGP	;		;	Solution structure of LA45 from LDLR
1JAA	;		;	Solution structure of lactam analogue (DapE) of HIV gp41 600-612 loop.
1JAR	;		;	Solution structure of lactam analogue (DDab)of HIV gp41 600-612 loop.
1JC8	;		;	Solution structure of lactam analogue (DDap) of gp41 600-612 loop of HIV
1JDK	;		;	solution structure of lactam analogue (EDap) of HIV gp41 600-612 loop.
1JD8	;		;	Solution structure of lactam analogue DapD of HIV gp41 600-612 loop
1D0W	;		;	SOLUTION STRUCTURE OF LACTAM-BRIDGED C-TERMINAL ANALOGUE-I OF NEUROPEPTIDE Y
1D1E	;		;	SOLUTION STRUCTURE OF LACTAM-BRIDGED C-TERMINAL ANALOGUE-II OF NEUROPEPTIDE Y
1D1F	;		;	SOLUTION STRUCTURE OF LACTAM-BRIDGED C-TERMINAL ANALOGUE-III OF NEUROPEPTIDE Y
2N8P	;		;	Solution Structure of Lacticin Q
2L28	;		;	Solution structure of lactobacillus casei dihydrofolate reductase apo-form, 25 conformers
2MK1	;		;	Solution structure of Lactodifucotetraose (LDFT) beta anomer
2L99	;		;	Solution structure of LAK160-P10
2L9A	;		;	Solution structure of LAK160-P12
2L96	;		;	Solution structure of LAK160-P7
7K1Q	;		;	Solution structure of lantibiotic from Paenibacillus sp.
2OMJ	;		;	solution structure of LARG PDZ domain
2OS6	;		;	Solution structure of LARG PDZ domain in complex with C-terminal octa-peptide of Plexin B1
3ZPM	;		;	Solution structure of latherin
2N93	;		;	Solution structure of lcFABP
2B9K	;		;	Solution structure of LCI, an AMP from Bacillus subtilis
1WK1	;		;	Solution structure of Lectin C-type domain derived from a hypothetical protein from C. elegans
2MSR	;		;	Solution structure of LEDGF/p75 IBD in complex with MLL1 peptide (140-160)
2N3A	;		;	Solution structure of LEDGF/p75 IBD in complex with POGZ peptide (1389-1404)
1JU8	;		;	Solution structure of Leginsulin, a plant hormon
7OIO	;		;	Solution structure of Legionella pneumophila LspC
7PMP	;		;	Solution structure of Legionella pneumophila LspD
6XTT	;		;	Solution structure of Legionella pneumophila NttA
2N7S	;		;	Solution Structure of Leptospiral LigA4 Big Domain
2RQA	;		;	Solution structure of LGP2 CTD
1X4L	;		;	Solution structure of LIM domain in Four and a half LIM domains protein 2
1X4K	;		;	Solution structure of LIM domain in LIM-protein 3
2LZU	;		;	Solution structure of LIMD2
2KHB	;		;	Solution structure of linear kalata B1 (loop 6)
1DWM	;		;	Solution structure of Linum usitatissinum trypsin inhibitor (LUTI)
5OVM	;		;	Solution structure of lipase binding domain LID1 of foldase from Pseudomonas aeruginosa
6GSF	;		;	Solution structure of lipase binding domain LID1 of foldase from Pseudomonas aeruginosa
2MAL	;		;	Solution structure of Lipid Transfer Protein from Lentil Lens Culinaris
2N81	;		;	Solution Structure of Lipid Transfer Protein From Pea Pisum Sativum
2M5Q	;		;	Solution structure of lipidated glucagon analog in d-TFE
2M5P	;		;	Solution structure of lipidated glucagon analog in water
8J3Q	;		;	Solution structure of LL-TILmut1
1HHW	;		;	Solution structure of LNA1:RNA hybrid
1HHX	;		;	Solution structure of LNA3:RNA hybrid
6PK9	;		;	Solution Structure of lncRNA (LINK-A) 20-nt Hexaloop Hairpin
2N8X	;		;	Solution structure of LptE from Pseudomonas Aerigunosa
8BO0	;		;	Solution structure of Lqq4 toxin from Leiurus quinquestriatus quinquestriatus
5GHC	;		;	SOLUTION STRUCTURE OF LYS33 ACETYLATED HUMAN SUMO2
5B7A	;		;	SOLUTION STRUCTURE OF LYS37 ACETYLATED HUMAN SUMO1
5GHD	;		;	SOLUTION STRUCTURE OF LYS39 ACETYLATED HUMAN SUMO1
5GHB	;		;	SOLUTION STRUCTURE OF LYS42 ACETYLATED HUMAN SUMO2
2MI8	;		;	Solution structure of lysine-free (K0) ubiquitin
5YZ6	;		;	Solution structure of LysM domain from a chitinase derived from Volvox carteri
5YZK	;		;	Solution structure of LysM domain from a chitinase derived from Volvox carteri
2MKX	;		;	Solution structure of LysM the peptidoglycan binding domain of autolysin AtlA from Enterococcus faecalis
1GXV	;		;	Solution structure of lysozyme at low and high pressure
1GXX	;		;	Solution structure of lysozyme at low and high pressure
2MYW	;		;	Solution structure of M. oryzae protein AVR-PIA
2MYV	;		;	Solution structure of M. oryzae protein AVR1-CO39
2JVF	;		;	Solution structure of M7, a computationally-designed artificial protein
6TG5	;		;	Solution structure of MacpD, a acyl carrier protein, from Pseudomonas fluorescens involved in Mupirocin biosynthesis.
1S5Q	;		;	Solution Structure of Mad1 SID-mSin3A PAH2 Complex
6AX2	;		;	Solution structure of Magi3 a specific insect toxin from the spider Macrothele gigas
2ROO	;		;	Solution structure of Magi4, a spider toxin from Macrothele gigas
2RRT	;		;	Solution structure of Magnesium-bound form of calmodulin C-domain E104D/E140D mutant
2FQ0	;		;	Solution structure of major conformation of holo-acyl carrier protein from malaria parasite plasmodium falciparum
2JQX	;		;	Solution structure of Malate Synthase G from joint refinement against NMR and SAXS data
2H25	;		;	Solution Structure of Maltose Binding Protein complexed with beta-cyclodextrin
2B19	;		;	Solution Structure of mammalian tachykinin peptide, Neuropeptide K
2JR8	;		;	Solution structure of Manduca sexta moricin
2ND9	;		;	Solution structure of MapZ extracellular domain first subdomain
2NDA	;		;	Solution structure of MapZ extracellular domain second subdomain
2M3J	;		;	Solution Structure of Marine Sponge-Derived Asteropsin E Which is Highly Resistant to Gastrointestinal Proteases
1IXU	;		;	Solution structure of marinostatin, a protease inhibitor, containing two ester linkages
2RTZ	;		;	Solution structure of MarkTX-7
2KYL	;		;	Solution structure of MAST2-PDZ complexed with the C-terminus of PTEN
2KQF	;		;	Solution structure of MAST205-PDZ complexed with the C-terminus of a rabies virus G protein
2DDY	;		;	Solution Structure of Matrilysin (MMP-7) Complexed to Constraint Conformational Sulfonamide Inhibitor
1YCM	;		;	Solution Structure of matrix metalloproteinase 12 (MMP12) in the presence of N-Isobutyl-N-[4-methoxyphenylsulfonyl]glycyl hydroxamic acid (NNGH)
2JT6	;		;	Solution structure of matrix metalloproteinase 3 (MMP-3) in the presence of 3-4'-cyanobyphenyl-4-yloxy)-n-hdydroxypropionamide (MMP-3 inhibitor VII)
2JT5	;		;	solution structure of matrix metalloproteinase 3 (MMP-3) in the presence of n-hydroxy-2-[n-(2-hydroxyethyl)biphenyl-4-sulfonamide] hydroxamic acid (MLC88)
2JNP	;		;	Solution structure of matrix metalloproteinase 3 (MMP-3) in the presence of N-isobutyl-N-[4-methoxyphenylsulfonyl]glycyl hydroxamic acid (NNGH)
1R05	;		;	Solution Structure of Max B-HLH-LZ
2MB7	;		;	Solution structure of MBD3 methylcytosine binding domain
2MOE	;		;	Solution structure of MBD4 methyl-cytosine binding domain bound to methylated DNA
2M2Q	;		;	Solution structure of MCh-1: A novel inhibitor cystine knot peptide from Momordica charantia
2M2R	;		;	Solution structure of MCh-2: A novel inhibitor cystine knot peptide from Momordica charantia
2MRW	;		;	Solution Structure of MciZ from Bacillus subtilis
1WSX	;		;	Solution structure of MCL-1
2ROD	;		;	Solution Structure of MCL-1 Complexed with NoxaA
2JM6	;		;	Solution structure of MCL-1 complexed with NOXAB
2ROC	;		;	Solution structure of Mcl-1 Complexed with Puma
1IB9	;		;	SOLUTION STRUCTURE OF MCOTI-II, A MACROCYCLIC TRYPSIN INHIBITOR
2LJS	;		;	Solution structure of MCoTI-V
2RQB	;		;	Solution structure of MDA5 CTD
6LCI	;		;	Solution structure of mdaA-1 domain
1MC7	;		;	Solution Structure of mDvl1 PDZ domain
6H0I	;		;	Solution structure of Melampsora larici-populina MlpP4.1
1K0X	;		;	Solution Structure of Melanoma Inhibitory Activity Protein
1FW5	;		;	SOLUTION STRUCTURE OF MEMBRANE BINDING PEPTIDE OF SEMLIKI FOREST VIRUS MRNA CAPPING ENZYME NSP1
1S6L	;		;	Solution structure of MerB, the Organomercurial Lyase involved in the bacterial mercury resistance system
1JW3	;		;	Solution Structure of Methanobacterium Thermoautotrophicum Protein 1598. Ontario Centre for Structural Proteomics target MTH1598_1_140; Northeast Structural Genomics Target TT6
1YWX	;		;	Solution Structure of Methanococcus maripaludis Protein MMP0443: The Northeast Structural Genomics Consortium Target MrR16
1XN9	;		;	Solution Structure of Methanosarcina mazei Protein RPS24E: The Northeast Structural Genomics Consortium Target MaR11
1E8E	;		;	Solution Structure of Methylophilus methylotrophus Cytochrome c''. Insights into the Structural Basis of Haem-Ligand Detachment
8BVC	;		;	Solution structure of Metridium senile toxin Ms13-1 with the unique fold
2KFE	;		;	Solution structure of meucin-24
6THI	;		;	Solution structure of MeuNaTxalpha-1 toxin from Mesobuthus Eupeus
2M0A	;		;	Solution structure of MHV nsp3a
1C01	;		;	SOLUTION STRUCTURE OF MIAMP1, A PLANT ANTIMICROBIAL PROTEIN
2DK3	;		;	Solution structure of Mib-herc2 domain in HECT domain containing protein 1
5YAM	;		;	Solution structure of mice Met-CCL5/RANTES
1VM5	;		;	Solution structure of micelle-bound aurein 1.2, an antimicrobial and anticancer peptide from an Australian frog
2ARI	;		;	Solution structure of micelle-bound fusion domain of HIV-1 gp41
2KCH	;		;	Solution structure of micelle-bound kalata B2
2N7X	;		;	Solution structure of microRNA 20b pre-element
1V49	;		;	Solution structure of microtubule-associated protein light chain-3
1WO3	;		;	Solution structure of Minimal Mutant 1 (MM1): Multiple alanine mutant of non-native CHANCE domain
1WO4	;		;	Solution structure of Minimal Mutant 2 (MM2): Multiple alanine mutant of non-native CHANCE domain
2FQ2	;		;	Solution structure of minor conformation of holo-acyl carrier protein from malaria parasite plasmodium falciparum
2CPT	;		;	Solution structure of MIT domain from human SKD1
2CRB	;		;	Solution structure of MIT domain from mouse NRBF-2
207D	;		;	SOLUTION STRUCTURE OF MITHRAMYCIN DIMERS BOUND TO PARTIALLY OVERLAPPING SITES ON DNA
7CLV	;		;	Solution structure of mitochondrial Tim23 channel in complex with a signaling peptide
2LVU	;		;	Solution structure of Miz-1 zinc finger 10
7MC1	;		;	Solution structure of Miz-1 Zinc finger 10
7MC2	;		;	Solution structure of Miz-1 Zinc finger 11 H586Y
7MC3	;		;	Solution structure of Miz-1 zinc finger 12
5ION	;		;	Solution Structure of Miz-1 Zinc Finger 13
2N25	;		;	Solution structure of Miz-1 zinc finger 2
2M0D	;		;	Solution Structure of Miz-1 zinc finger 5
2M0E	;		;	Solution Structure of Miz-1 zinc finger 6
2M0F	;		;	Solution Structure of Miz-1 zinc finger 7
2LVR	;		;	Solution structure of Miz-1 zinc finger 8
2LVT	;		;	Solution structure of Miz-1 zinc finger 9
2N26	;		;	Solution structure of Miz-1 zinc fingers 3 and 4
2P3M	;		;	Solution structure of Mj0056
1Y74	;		;	Solution Structure of mLin-2/mLin-7 L27 Domain Complex
6ZPR	;		;	Solution structure of MLKL executioner domain in complex with a covalent inhibitor
7NM2	;		;	Solution structure of MLKL executioner domain in complex with a fragment
7NM4	;		;	Solution structure of MLKL executioner domain in complex with a fragment
7NM5	;		;	Solution structure of MLKL executioner domain in complex with a fragment
2JYI	;		;	Solution structure of MLL CXXC domain
2KKF	;		;	Solution structure of MLL CXXC domain in complex with palindromic CPG DNA
2MTN	;		;	Solution structure of MLL-IBD complex
2KU7	;		;	Solution structure of MLL1 PHD3-Cyp33 RRM chimeric protein
6O7G	;		;	Solution structure of MLL4 PHD6 domain in complex with histone H4K16ac peptide
1S9S	;		;	SOLUTION STRUCTURE OF MLV PSI SITE
1Z3J	;		;	Solution Structure of MMP12 in the presence of N-isobutyl-N-4-methoxyphenylsulfonyl]glycyl hydroxamic acid (NNGH)
2JSD	;		;	Solution structure of MMP20 complexed with NNGH
1FA3	;		;	SOLUTION STRUCTURE OF MNEI, A SWEET PROTEIN
5ZKV	;		;	Solution structure of molten globule state of L94G mutant of horse cytochrome-c
2G0U	;		;	Solution Structure of Monomeric BsaL, the Type III Secretion Needle Protein of Burkholderia pseudomallei
7CJW	;		;	Solution structure of monomeric superoxide dismutase 1 with an additional mutation H46W in a crowded environment
7CJV	;		;	Solution structure of monomeric superoxide dismutase 1 with an additional mutation H46W in a dilute environment
2MN7	;		;	Solution structure of monomeric TatA of twin-arginine translocation system from E. coli
1WLM	;		;	Solution structure of mouse CGI-38 protein
1WM4	;		;	Solution structure of mouse coactosin, an actin filament binding protein
1WWQ	;		;	Solution Structure of Mouse ER
2YUG	;		;	Solution structure of mouse FRG1 protein
1UHS	;		;	Solution structure of mouse homeodomain-only protein HOP
1J0G	;		;	Solution Structure of Mouse Hypothetical 9.1 kDa Protein, A Ubiquitin-like Fold
1UG2	;		;	Solution Structure of Mouse Hypothetical Gene (2610100B20Rik) Product Homologous to Myb DNA-binding Domain
1V2Y	;		;	Solution Structure of Mouse Hypothetical Gene (RIKEN cDNA 3300001G02) Product Homologous to Ubiquitin Fold
1WGK	;		;	Solution Structure of Mouse Hypothetical Protein 2900073H19RIK
1WIA	;		;	Solution structure of mouse hypothetical ubiquitin-like protein BAB25500
2L3Y	;		;	Solution structure of mouse IL-6
2E4J	;		;	Solution Structure of mouse Lipocalin-type Prostaglandin D Synthase
2KTD	;		;	Solution structure of mouse lipocalin-type prostaglandin D synthase / substrate analog (U-46619) complex
2RQ0	;		;	Solution Structure of Mouse Lipocalin-type Prostaglandin D Synthase Possessing the Intrinsic Disulfide Bond
1IVM	;		;	Solution structure of mouse lysozyme M
1WFD	;		;	Solution structure of mouse MIT domain
2KOJ	;		;	Solution structure of mouse Par-3 PDZ2 (residues 450-558)
2LMK	;		;	Solution Structure of Mouse Pheromone ESP1
1WYJ	;		;	Solution structure of mouse protocadherin beta 14 (26-137)
1V9W	;		;	Solution structure of mouse putative 42-9-9 protein
2BBU	;		;	solution structure of mouse socs3 in complex with a phosphopeptide from the gp130 receptor
2YRU	;		;	Solution structure of mouse Steroid receptor RNA activator 1 (SRA1) protein
1WGH	;		;	Solution Structure of Mouse Ubiquitin-like 3 Protein
2EW4	;		;	Solution structure of MrIA
1IEO	;		;	SOLUTION STRUCTURE OF MRIB-NH2
2L36	;		;	Solution structure of MSI-594 derived mutant peptide MSI594F5A in Lipopolysaccharide Micelles
2RMR	;		;	Solution structure of mSin3A PAH1 domain
2LKY	;		;	Solution structure of MSMEG_1053, the second DUF3349 annotated protein in the genome of Mycobacterium smegmatis, Seattle Structural Genomics Center for Infectious Disease target MysmA.17112.b
2LGJ	;		;	Solution structure of MsPTH
1Z9V	;		;	Solution Structure of MTH0776 from Methanobacterium thermoautotrophicum (strain H)
1JCU	;		;	Solution Structure of MTH1692 Protein from Methanobacterium thermoautotrophicum
1TE4	;		;	Solution structure of MTH187. Ontario Centre for Structural Proteomics target MTH0187_1_111; Northeast Structural Genomics Target TT740
1IQO	;		;	Solution structure of MTH1880 from methanobacterium thermoautotrophicum
2RUJ	;		;	Solution structure of MTSL spin-labeled Schizosaccharomyces pombe Sin1 CRIM domain
2MZ4	;		;	Solution Structure of mu-SLPTX-Ssm6a
2MUN	;		;	Solution structure of mu-SLPTX3-Ssm6a
8FD4	;		;	Solution structure of mu-theraphotoxin Cg4a from Chinese tarantula Chilobrachys jingzhao
8CM3	;		;	Solution structure of Mu3.1 from Conus mucronatus
6K2K	;		;	Solution structure of MUL1-RING domain
6FNV	;		;	Solution structure of mule deer prion protein with polymorphism S138
1FYJ	;		;	SOLUTION STRUCTURE OF MULTI-FUNCTIONAL PEPTIDE MOTIF-1 PRESENT IN HUMAN GLUTAMYL-PROLYL TRNA SYNTHETASE (EPRS).
1EGF	;		;	SOLUTION STRUCTURE OF MURINE EPIDERMAL GROWTH FACTOR DETERMINED BY NMR SPECTROSCOPY AND REFINED BY ENERGY MINIMIZATION WITH RESTRAINTS
3EGF	;		;	SOLUTION STRUCTURE OF MURINE EPIDERMAL GROWTH FACTOR DETERMINED BY NMR SPECTROSCOPY AND REFINED BY ENERGY MINIMIZATION WITH RESTRAINTS
2L3O	;		;	Solution structure of murine interleukin 3
1MI2	;		;	SOLUTION STRUCTURE OF MURINE MACROPHAGE INFLAMMATORY PROTEIN-2, NMR, 20 STRUCTURES
2L90	;		;	Solution structure of murine myristoylated msrA
2GOV	;		;	Solution structure of Murine p22HBP
5X3Z	;		;	Solution structure of musashi1 RBD2 in complex with RNA
6C8U	;		;	Solution structure of Musashi2 RRM1
2LWE	;		;	Solution structure of mutant (T170E) second CARD of human RIG-I
2NDE	;		;	Solution Structure of Mutant of BMAP-28(1-18)
6A4C	;		;	Solution structure of MXAN_0049
1FEX	;		;	SOLUTION STRUCTURE OF MYB-DOMAIN OF HUMAN RAP1
1XG1	;		;	Solution structure of Myb-domain of human TRF2
1P4S	;		;	Solution structure of Mycobacterium tuberculosis adenylate kinase
1G91	;		;	SOLUTION STRUCTURE OF MYELOID PROGENITOR INHIBITORY FACTOR-1 (MPIF-1)
2K5U	;		;	Solution structure of myirstoylated yeast ARF1 protein, GDP-bound
2KIA	;		;	Solution structure of Myosin VI C-terminal cargo-binding domain
2LD3	;		;	Solution structure of myosin VI lever arm extension
1MYO	;		;	SOLUTION STRUCTURE OF MYOTROPHIN, NMR, 44 STRUCTURES
2MYO	;		;	SOLUTION STRUCTURE OF MYOTROPHIN, NMR, MINIMIZED AVERAGE STRUCTURE
2MV4	;		;	Solution structure of myristoylated Y28F/Y67F mutant of the Mason-Pfizer monkey virus matrix protein
2N0Z	;		;	Solution structure of MyUb (1080-1122) of human Myosin VI
2N10	;		;	Solution structure of MyUb (1080-1131) of human Myosin VI
1JJG	;		;	Solution Structure of Myxoma Virus Protein M156R
2MQK	;		;	Solution structure of N terminal domain of the MuB AAA+ ATPase
2NC3	;		;	Solution Structure of N-Allosylated Pin1 WW Domain
2NC4	;		;	Solution Structure of N-Galactosylated Pin1 WW Domain
2NC6	;		;	Solution Structure of N-L-idosylated Pin1 WW Domain
2FCD	;		;	Solution structure of N-lobe Myosin Light Chain from Saccharomices cerevisiae
2LEP	;		;	Solution Structure of N-terminal Cytosolic Domain of Rhomboid Intramembrane Protease from Escherichia Coli
7WJ0	;		;	Solution structure of N-terminal domain (nMazE6) of mycobacterial antitoxin MazE6 from MazEF6 TA system
2KW0	;		;	Solution structure of N-terminal domain of CcmH from Escherichia.coli
2CS4	;		;	Solution structure of N-terminal domain of chromosome 12 open reading frame 2
2LPN	;		;	Solution Structure of N-Terminal domain of human Conserved Dopamine Neurotrophic Factor (CDNF)
2MY9	;		;	Solution structure of N-terminal domain of human TIG3
2LKT	;		;	Solution structure of N-terminal domain of human TIG3 in 2 M UREA
2CR2	;		;	Solution structure of N-terminal domain of speckle-type POZ protein
2NB7	;		;	Solution structure of N-terminal extramembrane domain of SH protein
2CSJ	;		;	Solution structure of N-terminal PDZ domain from mouse TJP2
1M30	;		;	Solution structure of N-terminal SH3 domain from oncogene protein c-Crk
1K1Z	;		;	Solution structure of N-terminal SH3 domain mutant(P33G) of murine Vav
2DJM	;		;	Solution structure of N-terminal starch-binding domain of glucoamylase from Rhizopus oryzae
1WJU	;		;	Solution structure of N-terminal ubiquitin-like domain of human NEDD8 ultimate buster-1
2NC5	;		;	Solution Structure of N-Xylosylated Pin1 WW Domain
1MR4	;		;	Solution Structure of NaD1 from Nicotiana alata
8AO1	;		;	solution structure of nanoFAST fluorogen-activating protein in the apo state
8AO0	;		;	Solution structure of nanoFAST/HBR-DOM2 complex
2KOZ	;		;	Solution structure of nasonin-1
2KP0	;		;	Solution structure of nasonin-1M
2KMO	;		;	Solution structure of native Leech-derived tryptase inhibitor, LDTI
2RTY	;		;	Solution structure of navitoxin
1UDK	;		;	Solution Structure of Nawaprin
1ESK	;		;	SOLUTION STRUCTURE OF NCP7 FROM HIV-1
7CKD	;		;	Solution structure of NCR169 oxidized form 1 from Medicago truncatula
7CKE	;		;	Solution structure of NCR169 oxidized form 2 from Medicago truncatula
2MXP	;		;	Solution structure of NDP52 ubiquitin-binding zinc finger
1TQZ	;		;	Solution structure of NECAP1 protein
5GO0	;		;	Solution structure of nedd8 from Trypanosoma brucei
2BZ2	;		;	Solution structure of NELF E RRM
2G0K	;		;	Solution Structure of Neocarzinostatin Apo-Protein
2G0L	;		;	Solution Structure of Neocarzinostatin Apo-Protein with bound Flavone
2JPU	;		;	solution structure of NESG target SsR10, Orf c02003 protein
2GLE	;		;	Solution structure of neurabin SAM domain
1OP4	;		;	Solution Structure of Neural Cadherin Prodomain
1C98	;		;	SOLUTION STRUCTURE OF NEUROMEDIN B
1C9A	;		;	SOLUTION STRUCTURE OF NEUROMEDIN B
1SH1	;		;	SOLUTION STRUCTURE OF NEUROTOXIN I FROM THE SEA ANEMONE STICHODACTYLA HELIANTHUS. A NUCLEAR MAGNETIC RESONANCE, DISTANCE GEOMETRY AND RESTRAINED MOLECULAR DYNAMICS STUDY
2SH1	;		;	SOLUTION STRUCTURE OF NEUROTOXIN I FROM THE SEA ANEMONE STICHODACTYLA HELIANTHUS. A NUCLEAR MAGNETIC RESONANCE, DISTANCE GEOMETRY AND RESTRAINED MOLECULAR DYNAMICS STUDY
1FMM	;		;	SOLUTION STRUCTURE OF NFGF-1
2NOR	;		;	Solution structure of NK1 agonist Phyllomedusin bound to DPC micelles
1XN6	;		;	Solution Structure of Northeast Structural Genomics Target Protein BcR68 encoded in gene Q816V6 of B. cereus
1XPV	;		;	Solution Structure of Northeast Structural Genomics Target Protein XcR50 from X. Campestris
1L3X	;		;	Solution Structure of Novel Disintegrin Salmosin
7UGA	;		;	Solution structure of NPSL2
2KWT	;		;	Solution structure of NS2 [27-59]
2KWZ	;		;	Solution structure of NS2 [60-99]
2CR0	;		;	Solution structure of nuclear move domain of nuclear distribution gene C
2DHS	;		;	Solution Structure of Nucleic Acid Binding Protein CUGBP1ab and its Binding Study with DNA and RNA
1FJ7	;		;	SOLUTION STRUCTURE OF NUCLEOLIN RBD1
1FJE	;		;	SOLUTION STRUCTURE OF NUCLEOLIN RBD12 IN COMPLEX WITH SNRE RNA
1FJC	;		;	SOLUTION STRUCTURE OF NUCLEOLIN RBD2
2JR0	;		;	Solution structure of NusB from Aquifex Aeolicus
2MEW	;		;	Solution Structure of NusE (S10) from Thermotoga maritima
2KVQ	;		;	Solution structure of NusE:NusG-CTD complex
7L7A	;		;	Solution Structure of NuxVA
7YHI	;		;	Solution structure of O-di-mannosylated carbohydrate binding module (CBM) of the glycoside hydrolase Family 7 cellobiohydrolase from Trichoderma reesei
1OCP	;		;	SOLUTION STRUCTURE OF OCT3 POU-HOMEODOMAIN
1SS3	;		;	Solution structure of Ole e 6, an allergen from olive tree pollen
1JYT	;		;	Solution structure of olfactory marker protein from rat
6PQG	;		;	Solution structure of OlvA(BC)
6PQF	;		;	Solution structure of OlvA(BCS)
1FYG	;		;	Solution structure of omega conotoxin SO3 determined by 1H-NMR
1OMC	;		;	SOLUTION STRUCTURE OF OMEGA-CONOTOXIN GVIA USING 2-D NMR SPECTROSCOPY AND RELAXATION MATRIX ANALYSIS
1FEO	;		;	Solution structure of omega-conotoxin MVIIA with C-terminal Gly
1OMN	;		;	SOLUTION STRUCTURE OF OMEGA-CONOTOXIN MVIIC, A HIGH AFFINITY OF P-TYPE CALCIUM CHANNELS, USING 1H NMR SPECTROSCOPY AND COMPLETE RELAXATION MATRIX ANALYSIS
1KOZ	;		;	SOLUTION STRUCTURE OF OMEGA-GRAMMOTOXIN SIA
2JPB	;		;	Solution Structure of OMPR-C DNA Binding Protein
1IY6	;		;	Solution structure of OMSVP3 variant, P14C/N39C
2KB6	;		;	Solution structure of onconase C87A/C104A
2MAF	;		;	Solution structure of opa60 from n. gonorrhoeae
2L2G	;		;	Solution structure of Opossum Domain 11
2MK4	;		;	Solution structure of ORF2
1EQK	;		;	SOLUTION STRUCTURE OF ORYZACYSTATIN-I, A CYSTEINE PROTEINASE INHIBITOR OF THE RICE, ORYZA SATIVA L. JAPONICA
2LHF	;		;	Solution structure of outer membrane protein H (OprH) from P. aeruginosa in DHPC micelles
2M4F	;		;	Solution Structure of Outer surface protein E
2N53	;		;	Solution structure of ovis aries prp
2MV8	;		;	Solution structure of Ovis Aries PrP with mutation delta190-197
2MV9	;		;	Solution structure of Ovis Aries PrP with mutation delta193-196
1HU5	;		;	SOLUTION STRUCTURE OF OVISPIRIN-1
1OMU	;		;	SOLUTION STRUCTURE OF OVOMUCOID (THIRD DOMAIN) FROM DOMESTIC TURKEY (298K, PH 4.1) (NMR, 50 STRUCTURES) (REFINED MODEL USING NETWORK EDITING ANALYSIS)
1OMT	;		;	SOLUTION STRUCTURE OF OVOMUCOID (THIRD DOMAIN) FROM DOMESTIC TURKEY (298K, PH 4.1) (NMR, 50 STRUCTURES) (STANDARD NOESY ANALYSIS)
2K8V	;		;	Solution structure of Oxidised ERp18
5FRH	;		;	Solution structure of oxidised RsrA
5MGQ	;		;	Solution structure of oxidized and amidated human IAPP (1-37), the diabetes II peptide.
1NX7	;		;	Solution Structure of Oxidized Bovine Microsomal Cytochrome B5
1F03	;		;	SOLUTION STRUCTURE OF OXIDIZED BOVINE MICROSOMAL CYTOCHROME B5 MUTANT (E44A, E48A, E56A, D60A) AND ITS INTERACTION WITH CYTOCHROME C
1F04	;		;	SOLUTION STRUCTURE OF OXIDIZED BOVINE MICROSOMAL CYTOCHROME B5 MUTANT (E44A, E48A, E56A, D60A) AND ITS INTERACTION WITH CYTOCHROME C
1SH4	;		;	Solution structure of oxidized bovine microsomal cytochrome B5 Mutant V45H
1J0Q	;		;	Solution Structure of Oxidized Bovine Microsomal Cytochrome b5 mutant V61H
7O9U	;		;	Solution structure of oxidized cytochrome c552 from Thioalkalivibrio paradoxus
2MIT	;		;	Solution structure of oxidized dimeric form of human defensin 5
1QPU	;		;	SOLUTION STRUCTURE OF OXIDIZED ESCHERICHIA COLI CYTOCHROME B562
1AKK	;		;	SOLUTION STRUCTURE OF OXIDIZED HORSE HEART CYTOCHROME C, NMR, MINIMIZED AVERAGE STRUCTURE
2N9J	;		;	Solution structure of oxidized human cytochrome c
2RTU	;		;	Solution structure of oxidized human HMGB1 A box
1DO9	;		;	SOLUTION STRUCTURE OF OXIDIZED MICROSOMAL RABBIT CYTOCHROME B5. FACTORS DETERMINING THE HETEROGENEOUS BINDING OF THE HEME.
1J5C	;		;	SOLUTION STRUCTURE OF OXIDIZED PARAMAGNETIC CU(II) PLASTOCYANIN FROM SYNECHOCYSTIS PCC6803
1J5D	;		;	SOLUTION STRUCTURE OF OXIDIZED PARAMAGNETIC CU(II) PLASTOCYANIN FROM SYNECHOCYSTIS PCC6803-MINIMIZED AVERAGE STRUCTURE
1BLV	;		;	SOLUTION STRUCTURE OF OXIDIZED RAT MICROSOMAL CYTOCHROME B5 IN THE PRESENCE OF 2 M GUANIDINIUM CHLORIDE: MONITORING THE EARLY STEPS IN PROTEIN UNFOLDING
2MZ9	;		;	Solution structure of oxidized triheme cytochrome PpcA from Geobacter sulfurreducens
2MH7	;		;	Solution structure of oxidized [2Fe-2S] ferredoxin PetF from Chlamydomonas reinhardtii
1NQ4	;		;	Solution Structure of Oxytetracycline Acyl Carrier Protein
2LP4	;		;	Solution structure of P1-CheY/P2 complex in bacterial chemotaxis
1BU9	;		;	SOLUTION STRUCTURE OF P18-INK4C, 21 STRUCTURES
1RZS	;		;	Solution structure of P22 Cro
1GD4	;		;	SOLUTION STRUCTURE OF P25S CYSTATIN A
2L3E	;		;	Solution structure of P2a-J2a/b-P2b of human telomerase RNA
5KQE	;		;	Solution structure of P2a-J2a/b-P2b of medaka telomerase RNA
6FGN	;		;	Solution Structure of p300Taz2-p63TA
6FGS	;		;	Solution structure of p300Taz2-p73TA1
2IB1	;		;	Solution structure of p45 Death Domain
5HOU	;		;	Solution Structure of p53TAD-TAZ1
1P8B	;		;	SOLUTION STRUCTURE OF PA1B, A 37-AMINO ACID INSECTICIDAL PROTEIN EXTRACTED FROM PEA SEEDS (PISUM SATIVUM)
1DKC	;		;	SOLUTION STRUCTURE OF PAFP-S, AN ANTIFUNGAL PEPTIDE FROM THE SEEDS OF PHYTOLACCA AMERICANA
2LA2	;		;	Solution structure of papiliocin isolated from the swallowtail butterfly, Papilio xuthus
2K1Z	;		;	Solution structure of Par-3 PDZ3
2K20	;		;	Solution structure of Par-3 PDZ3 in complex with PTEN peptide
2LC6	;		;	Solution structure of Par-6 Q144C/L164C
5TGG	;		;	Solution structure of parallel stranded adenosine duplex
1IRR	;		;	Solution structure of paralytic peptide of the silkworm, Bombyx mori
1V28	;		;	Solution structure of paralytic peptide of the wild Silkmoth, Antheraea yamamai
2KGJ	;		;	Solution structure of parvulin domain of PpiD from E.Coli
1Y76	;		;	Solution Structure of Patj/Pals1 L27 Domain Complex
7QB0	;		;	Solution structure of paxillin LIM2/3
6U4M	;		;	Solution structure of paxillin LIM4
6U4N	;		;	Solution structure of paxillin LIM4 in complex with kindlin-2 F0
1DNY	;		;	SOLUTION STRUCTURE OF PCP, A PROTOTYPE FOR THE PEPTIDYL CARRIER DOMAINS OF MODULAR PEPTIDE SYNTHETASES
6TVJ	;		;	Solution structure of PD-i3 peptide inhibitor of the human PD-1 extracellular domain
6TT6	;		;	Solution structure of PD-i6 peptide inhibitor of the human PD-1 extracellular domain
2L89	;		;	Solution structure of Pdp1 PWWP domain reveals its unique binding sites for methylated H4K20 and DNA
2DC2	;		;	Solution Structure of PDZ Domain
2N7P	;		;	Solution structure of PDZ domain
1WG6	;		;	Solution structure of PDZ domain in protein XP_110852
1V5L	;		;	Solution structure of PDZ domain of mouse Alpha-actinin-2 associated LIM protein
1WJL	;		;	Solution structure of PDZ domain of mouse Cypher protein
2EEG	;		;	Solution Structure of PDZ domain of PDZ and LIM domain protein
2CS5	;		;	Solution structure of PDZ domain of Protein tyrosine phosphatase, non-receptor type 4
2YUY	;		;	Solution Structure of PDZ domain of Rho GTPase Activating Protein 21
2MHV	;		;	Solution Structure of Penicillium Antifungal Protein PAF
5ZV6	;		;	Solution structure of peptide cQ2 from Chenopodium quinoa
2KMN	;		;	Solution structure of peptide deformylase complexed with actinonin
7R6P	;		;	Solution structure of peptide toxin MIITX2-Mg1a from the venom of the Australian giant red bull ant Myrmecia gulosa
2AIZ	;		;	Solution structure of peptidoglycan associated lipoprotein from Haemophilus influenza bound to UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine
2KE0	;		;	Solution structure of peptidyl-prolyl cis-trans isomerase from Burkholderia pseudomallei
2L2S	;		;	Solution structure of peptidyl-prolyl cis-trans isomerase from Burkholderia pseudomallei complexed with 1-{[(4-methylphenyl)thio]acetyl}piperidine
2KO7	;		;	Solution structure of peptidyl-prolyl cis-trans isomerase from Burkholderia pseudomallei complexed with Cycloheximide-N-ethylethanoate
5ZR0	;		;	Solution structure of peptidyl-prolyl cis/trans isomerase domain of Trigger Factor in complex with MBP
2NAF	;		;	Solution structure of peptidyl-tRNA hydrolase from Mycobacterium smegmatis
2JRC	;		;	Solution structure of Peptidyl-tRNA Hydrolase from Mycobacterium tuberculosis H37Rv.
2MJL	;		;	Solution structure of peptidyl-tRNA hyrolase from Vibrio cholerae
2JWL	;		;	Solution Structure of periplasmic domain of TolR from H. influenzae with SAXS data
2L9S	;		;	Solution structure of Pf1 SID1-mSin3A PAH2 Complex
2KDN	;		;	Solution structure of PFE0790c, a putative bolA-like protein from the protozoan parasite Plasmodium falciparum.
2LSN	;		;	Solution structure of PFV RNase H domain
2M3X	;		;	Solution structure of Ph1500: a homohexameric protein centered on a 12-bladed beta-propeller
5W96	;		;	Solution structure of phage derived peptide inhibitor of frizzled 7 receptor
1D20	;		;	SOLUTION STRUCTURE OF PHAGE LAMBDA HALF-OPERATOR DNA
1A4T	;		;	SOLUTION STRUCTURE OF PHAGE P22 N PEPTIDE-BOX B RNA COMPLEX, NMR, 20 STRUCTURES
2XC7	;		;	Solution Structure of PHAX-RBD in complex with ssRNA
1WEM	;		;	Solution structure of PHD domain in death inducer-obliterator 1(DIO-1)
1WEW	;		;	Solution structure of PHD domain in DNA-binding family protein AAM98074
1WEU	;		;	Solution structure of PHD domain in ING1-like protein BAC25009
1WEN	;		;	Solution structure of PHD domain in ING1-like protein BAC25079
1WES	;		;	Solution structure of PHD domain in inhibitor of growth family, member 1-like
1X4I	;		;	Solution structure of PHD domain in inhibitor of growth protein 3 (ING3)
1WE9	;		;	Solution structure of PHD domain in nucleic acid binding protein-like NP_197993
1WEE	;		;	Solution structure of PHD domain in PHD finger family protein
1WEQ	;		;	Solution structure of PHD domain in PHD finger protein 7
1WEP	;		;	Solution structure of PHD domain in PHF8
1WEV	;		;	Solution structure of PHD domain in protein NP_082203
8ABD	;		;	Solution structure of Phen-DC3 intercalating into a quadruplex-duplex hybrid
2JNZ	;		;	Solution structure of phl p 3, a major allergen from timothy grass pollen
2AKK	;		;	Solution structure of phnA-like protein rp4479 from Rhodopseudomonas palustris
1N3K	;		;	Solution structure of phosphoprotein enriched in astrocytes 15 kDa (PEA-15)
2LQW	;		;	Solution structure of phosphorylated CRKL
2MVK	;		;	Solution structure of phosphorylated cytosolic part of Trop2
1V50	;		;	Solution structure of phosphorylated N-terminal fragment of S100C/A11 protein
1WJ1	;		;	Solution structure of phosphotyrosine interaction domain of mouse Numb protein
1QP2	;		;	SOLUTION STRUCTURE OF PHOTOSYSTEM I ACCESSORY PROTEIN E FROM THE CYANOBACTERIUM NOSTOC SP. STRAIN PCC 8009
1QP3	;		;	SOLUTION STRUCTURE OF PHOTOSYSTEM I ACCESSORY PROTEIN E FROM THE CYANOBACTERIUM NOSTOC SP. STRAIN PCC 8009
1V7F	;		;	Solution structure of phrixotoxin 1
1WZ5	;		;	Solution structure of Pi1-3p
1N8M	;		;	Solution structure of Pi4, a four disulfide bridged scorpion toxin active on potassium channels
7ZRU	;		;	Solution structure of Pi6, a low affinity blocking kappa-K+-channel peptide from the scorpion Pandinus imperator
1QKY	;		;	Solution structure of PI7, a non toxic peptide isolated from the scorpion Pandinus Imperator.
2PKU	;		;	Solution structure of PICK1 PDZ in complex with the carboxyl tail peptide of GluR2
2LC4	;		;	Solution Structure of PilP from Pseudomonas aeruginosa
1I6C	;		;	SOLUTION STRUCTURE OF PIN1 WW DOMAIN
1I8G	;		;	SOLUTION STRUCTURE OF PIN1 WW DOMAIN COMPLEXED WITH CDC25 PHOSPHOTHREONINE PEPTIDE
1I8H	;		;	SOLUTION STRUCTURE OF PIN1 WW DOMAIN COMPLEXED WITH HUMAN TAU PHOSPHOTHREONINE PEPTIDE
1J6Y	;		;	Solution structure of Pin1At from Arabidopsis thaliana
2JOS	;		;	Solution structure of piscidin in presence of DPC micelles
2K8B	;		;	Solution structure of PLAA family ubiquitin binding domain (PFUC) cis isomer in complex with ubiquitin
2K8C	;		;	Solution structure of PLAA family ubiquitin binding domain (PFUC) trans isomer in complex with ubiquitin
1TI5	;		;	Solution structure of plant defensin
1L6H	;		;	Solution Structure of Plant nsLTP2 purified from Rice (oryza Sativa)
1HN6	;		;	SOLUTION STRUCTURE OF PLASMODIUM FALCIPARUM APICAL MEMBRANE ANTIGEN 1 (RESIDUES 436-545)
2N7C	;		;	Solution structure of Plasmodium falciparum SR1-RRM1 in complex with ACAUCA RNA
1WG7	;		;	Solution structure of pleckstrin homology domain from human KIAA1058 protein
1WJM	;		;	Solution structure of pleckstrin homology domain of human beta III spectrin.
6K51	;		;	Solution structure of plectasin derivative MP1102
6K50	;		;	Solution structure of plectasin derivative NZ2114
8FEY	;		;	Solution structure of Pmu1a
1PNH	;		;	SOLUTION STRUCTURE OF PO5-NH2, A SCORPION TOXIN ANALOG WITH HIGH AFFINITY FOR THE APAMIN-SENSITIVE POTASSIUM CHANNEL
1ITP	;		;	Solution Structure of POIA1
8TNS	;		;	Solution structure of poly(UG) RNA (GU)12 G-quadruplex
2LSI	;		;	Solution structure of polymerase-interacting domain of human Rev1 in complex with translesional synthesis polymerase kappa
2AD9	;		;	Solution structure of Polypyrimidine Tract Binding protein RBD1 complexed with CUCUCU RNA
2ADB	;		;	Solution structure of Polypyrimidine Tract Binding protein RBD2 complexed with CUCUCU RNA
2ADC	;		;	Solution structure of Polypyrimidine Tract Binding protein RBD34 complexed with CUCUCU RNA
2RQO	;		;	Solution structure of Polytheonamide B
1G92	;		;	SOLUTION STRUCTURE OF PONERATOXIN
1XHH	;		;	Solution Structure of porcine beta-microseminoprotein
2IZ4	;		;	Solution structure of porcine beta-microseminoprotein
5ID5	;		;	Solution structure of porcine lactoferricin
1PIR	;		;	SOLUTION STRUCTURE OF PORCINE PANCREATIC PHOSPHOLIPASE A2
1PIS	;		;	SOLUTION STRUCTURE OF PORCINE PANCREATIC PHOSPHOLIPASE A2
1PCN	;		;	SOLUTION STRUCTURE OF PORCINE PANCREATIC PROCOLIPASE AS DETERMINED FROM 1H HOMONUCLEAR TWO-AND THREE-DIMENSIONAL NMR
1PCO	;		;	SOLUTION STRUCTURE OF PORCINE PANCREATIC PROCOLIPASE AS DETERMINED FROM 1H HOMONUCLEAR TWO-AND THREE-DIMENSIONAL NMR
1RU5	;		;	Solution structure of porcine peptide YY (pPYY)
1RUU	;		;	Solution structure of porcine peptide YY (pPYY) bound to DPC micelles
6NZL	;		;	Solution structure of POS-1, a CCCH-type Tandem Zinc Finger protein from C. elegans
2RUN	;		;	Solution Structure of Pre Transmembrane domain
2KR6	;		;	Solution structure of presenilin-1 CTF subunit
2CRU	;		;	Solution structure of programmed cell death 5
2PQE	;		;	Solution structure of proline-free mutant of staphylococcal nuclease
2KKU	;		;	Solution structure of protein af2351 from Archaeoglobus fulgidus. Northeast Structural Genomics Consortium target AtT9/Ontario Center for Structural Proteomics Target af2351
6SFT	;		;	Solution structure of protein ARR_CleD in complex with c-di-GMP
2KNR	;		;	Solution structure of protein Atu0922 from A. tumefaciens. Northeast Structural Genomics Consortium target AtT13. Ontario Center for Structural Proteomics target ATC0905
2KQ1	;		;	Solution Structure Of Protein BH0266 From Bacillus halodurans. Northeast Structural Genomics Consortium Target BhR97a
2KAT	;		;	Solution structure of protein BPP2914 from Bordetella parapertussis. Northeast Structural Genomics Consortium target BpR206
2KZ6	;		;	Solution structure of protein CV0426 from Chromobacterium violaceum, Northeast structural genomics consortium (NESG) target CVT2
2KKS	;		;	Solution Structure Of Protein DSY2949 From Desulfitobacterium hafniense. Northeast Structural Genomics Consortium Target DhR27
2JOQ	;		;	Solution Structure of Protein HP0495 from H. pylori; Northeast structural genomics consortium target PT2; Ontario Centre for Structural Proteomics target HP0488
2KGR	;		;	Solution structure of protein ITSN1 from Homo sapiens. Northeast Structural Genomics Consortium target HR5524A
2JV8	;		;	Solution structure of protein NE1242 from Nitrosomonas europaea. Northeast Structural Genomics Consortium Target NeT4
2KJQ	;		;	Solution Structure Of Protein NMB1076 From Neisseria meningitidis. Northeast Structural Genomics Consortium Target MR101B.
2JTV	;		;	Solution Structure of protein RPA3401, Northeast Structural Genomics Consortium Target RpT7, Ontario Center for Structural Proteomics Target RP3384
2KZ4	;		;	Solution structure of protein SF1141 from Shigella flexneri 2a, Northeast structural genomics consortium (NESG) target SFT2
2KO6	;		;	Solution structure of protein sf3929 from Shigella flexneri 2a. Northeast Structural Genomics Consortium target SfR81/Ontario Center for Structural Proteomics Target sf3929
2KPJ	;		;	Solution Structure Of Protein SOS-response transcriptional repressor, LexA From Eubacterium rectale. Northeast Structural Genomics Consortium Target ErR9A
1KVV	;		;	Solution Structure Of Protein SRP19 Of The Archaeoglobus fulgidus Signal Recognition Particle, Minimized Average Structure
1KVN	;		;	Solution Structure Of Protein SRP19 Of The Arhaeoglobus fulgidus Signal Recognition Particle, 10 Structures
2KCQ	;		;	Solution structure of protein SRU_2040 from Salinibacter ruber (strain DSM 13855) . Northeast Structural Genomics Consortium target SrR106
2K5J	;		;	Solution structure of protein yiiF from Shigella flexneri serotype 5b (strain 8401) . Northeast Structural Genomics Consortium target sft1
2KJP	;		;	Solution structure of protein YlbL (BSU15050) from Bacillus subtilis, Northeast Structural Genomics Consortium target sr713a
1NY8	;		;	Solution structure of Protein yrbA from Escherichia Coli: Northeast Structural Genomics Consortium target ER115
2M9L	;		;	Solution structure of protoxin-1
2KMF	;		;	Solution Structure of Psb27 from cyanobacterial photosystem II
2MWQ	;		;	Solution structure of PsbQ from spinacia oleracea
2FS1	;		;	solution structure of PSD-1
2KA9	;		;	Solution structure of PSD-95 PDZ12 complexed with cypin peptide
2NCY	;		;	Solution structure of pseudin-2 analog (Ps-P)
2NCX	;		;	Solution structure of pseudin-2 isolated from the skin of paradoxical frog, Pseudis paradoxa
6VRJ	;		;	Solution structure of Pseudomonas aeruginosa IF3 C-terminal domain
1YWY	;		;	Solution Structure of Pseudomonas aeruginosa Protein PA2021. The Northeast Structural Genomics Consortium Target Pat85.
2AWQ	;		;	Solution Structure of pseudouridine-32 modified anticodon stem-loop of E. coli tRNAPhe
1LMM	;		;	Solution Structure of Psmalmotoxin 1, the First Characterized Specific Blocker of ASIC1a NA+ channel
1I26	;		;	SOLUTION STRUCTURE OF PTU-1, A TOXIN FROM THE ASSASSIN BUGS PEIRATES TURPIS THAT BLOCKS THE VOLTAGE SENSITIVE CALCIUM CHANNEL N-TYPE
2ITA	;		;	Solution structure of PufX from Rhodobacter sphaeroides
2NRG	;		;	Solution Structure of PufX from Rhodobacter Sphaeroides (minimised average)
1SBO	;		;	Solution Structure of putative anti sigma factor antagonist from Thermotoga maritima (TM1442)
2DUW	;		;	Solution structure of putative CoA-binding protein of Klebsiella pneumoniae
1V9V	;		;	Solution structure of putative domain of human KIAA0561 protein
2K02	;		;	Solution Structure of Putative Ferrous Iron Transport Protein C (FeoC) of Klebsiella pneumoniae
2LJU	;		;	Solution structure of putative oxidoreductase from Ehrlichia chaffeensis, Seattle Structural Genomics Center for Infectious Disease (SSGCID)
2NOC	;		;	Solution Structure of Putative periplasmic protein: Northest Structural Genomics Target StR106
2E7G	;		;	Solution structure of putative ribosome-binding factor A (RbfA) from human mutochondrial precursor
2K5E	;		;	SOLUTION STRUCTURE OF PUTATIVE UNCHARACTERIZED PROTEIN GSU1278 FROM METHANOCALDOCOCCUS JANNASCHII, NORTHEAST STRUCTURAL GENOMICS CONSORTIUM (NESG) TARGET GsR195
1X4Q	;		;	Solution structure of PWI domain in U4/U6 small nuclear ribonucleoprotein Prp3(hPrp3)
2CSK	;		;	Solution structure of PX domain from human SNX12
1JI8	;		;	Solution Structure of Pyrobaculum Aerophilum DsrC/gamma subunit of dissimilatory sulfite reductase
1XNE	;		;	Solution Structure of Pyrococcus furiosus Protein PF0470: The Northeast Structural Genomics Consortium Target PfR14
2NB4	;		;	Solution structure of Q388A3 PDZ domain
2REL	;		;	SOLUTION STRUCTURE OF R-ELAFIN, A SPECIFIC INHIBITOR OF ELASTASE, NMR, 11 STRUCTURES
1K5E	;		;	Solution Structure of R-styrene Adduct in the Ras61 Sequence
2N59	;		;	Solution Structure of R. palustris CsgH
1NSH	;		;	Solution Structure of Rabbit apo-S100A11 (19 models)
2L3N	;		;	Solution structure of Rap1-Taz1 fusion protein
6BA6	;		;	Solution structure of Rap1b/talin complex
5J17	;		;	Solution structure of Ras Binding Domain (RBD) of B-Raf
5J2R	;		;	Solution structure of Ras Binding Domain (RBD) of B-Raf
5J18	;		;	Solution structure of Ras Binding Domain (RBD) of B-Raf complexed with Rigosertib (Complex I)
1WXA	;		;	Solution Structure of Ras-binding Domain in Mouse AF-6 Protein
2MA2	;		;	Solution structure of RasGRP2 EF hands bound to calcium
1B4C	;		;	SOLUTION STRUCTURE OF RAT APO-S100B USING DIPOLAR COUPLINGS
1U3O	;		;	Solution structure of rat Kalirin N-terminal SH3 domain
2RUP	;		;	Solution structure of rat P2X4 receptor head domain
6GWM	;		;	Solution structure of rat RIP2 caspase recruitment domain
5GWG	;		;	Solution structure of rattusin
2LCC	;		;	Solution structure of RBBP1 chromobarrel domain
2MGZ	;		;	Solution structure of RBFOX family ASD-1 RRM and SUP-12 RRM in ternary complex with RNA
7VRL	;		;	Solution structure of Rbfox RRM bound to a non-cognate RNA
6DZ9	;		;	Solution structure of Rbfox2 RRM mimetic peptide CPfox2
6DZA	;		;	Solution structure of Rbfox2 RRM mimetic peptide CPfox4
6DZB	;		;	Solution structure of Rbfox2 RRM mimetic peptide CPfox5
6DZC	;		;	Solution structure of Rbfox2 RRM mimetic peptide CPfox6
6DZE	;		;	Solution structure of Rbfox2 RRM mimetic peptide CPfox7
7ZAP	;		;	Solution structure of RBM39 RRM1 bound to U1 snRNA stem loop 3
7Q33	;		;	Solution structure of RBM39 RRM2 bound to 5'-AGCUUUG-3
2KHZ	;		;	Solution Structure of RCL
2LTS	;		;	Solution structure of RDE-4(150-235)
2LTR	;		;	Solution structure of RDE-4(32-136)
1TUS	;		;	SOLUTION STRUCTURE OF REACTIVE-SITE HYDROLYZED TURKEY OVOMUCOID THIRD DOMAIN BY NUCLEAR MAGNETIC RESONANCE AND DISTANCE GEOMETRY METHODS
7BWI	;		;	Solution structure of recombinant APETx1
2HIR	;		;	SOLUTION STRUCTURE OF RECOMBINANT HIRUDIN AND THE LYS-47 (RIGHT ARROW) GLU MUTANT. A NUCLEAR MAGNETIC RESONANCE AND HYBRID DISTANCE GEOMETRY-DYNAMICAL SIMULATED ANNEALING STUDY
4HIR	;		;	SOLUTION STRUCTURE OF RECOMBINANT HIRUDIN AND THE LYS-47 (RIGHT ARROW) GLU MUTANT. A NUCLEAR MAGNETIC RESONANCE AND HYBRID DISTANCE GEOMETRY-DYNAMICAL SIMULATED ANNEALING STUDY
5HIR	;		;	SOLUTION STRUCTURE OF RECOMBINANT HIRUDIN AND THE LYS-47 (RIGHT ARROW) GLU MUTANT. A NUCLEAR MAGNETIC RESONANCE AND HYBRID DISTANCE GEOMETRY-DYNAMICAL SIMULATED ANNEALING STUDY
6HIR	;		;	SOLUTION STRUCTURE OF RECOMBINANT HIRUDIN AND THE LYS-47 (RIGHT ARROW) GLU MUTANT. A NUCLEAR MAGNETIC RESONANCE AND HYBRID DISTANCE GEOMETRY-DYNAMICAL SIMULATED ANNEALING STUDY
1JJX	;		;	Solution Structure of Recombinant Human Brain-type Fatty acid Binding Protein
1JJJ	;		;	SOLUTION STRUCTURE OF RECOMBINANT HUMAN EPIDERMAL-TYPE FATTY ACID BINDING PROTEIN
1LA3	;		;	Solution structure of recoverin mutant, E85Q
5FRF	;		;	Solution structure of reduced and zinc-bound RsrA
2MM9	;		;	Solution structure of reduced BolA2 from Arabidopsis thaliana
1BFY	;		;	SOLUTION STRUCTURE OF REDUCED CLOSTRIDIUM PASTEURIANUM RUBREDOXIN, NMR, 20 STRUCTURES
1JXD	;		;	SOLUTION STRUCTURE OF REDUCED CU(I) PLASTOCYANIN FROM SYNECHOCYSTIS PCC6803
1JXF	;		;	SOLUTION STRUCTURE OF REDUCED CU(I) PLASTOCYANIN FROM SYNECHOCYSTIS PCC6803
1Z7P	;		;	Solution structure of reduced glutaredoxin C1 from Populus tremula x tremuloides
1Z7R	;		;	Solution Structure of reduced glutaredoxin C1 from Populus tremula x tremuloides
1LC2	;		;	Solution Structure Of Reduced Horse Heart Cytochrome c in 30% Acetonitrile Solution, NMR 30 Structures
1LC1	;		;	Solution Structure Of Reduced Horse Heart Cytochrome c in 30% Acetonitrile Solution, NMR Minimized Average Structure
2GIW	;		;	SOLUTION STRUCTURE OF REDUCED HORSE HEART CYTOCHROME C, NMR, 40 STRUCTURES
1GIW	;		;	SOLUTION STRUCTURE OF REDUCED HORSE HEART CYTOCHROME C, NMR, MINIMIZED AVERAGE STRUCTURE
2N9I	;		;	Solution structure of reduced human cytochrome c
2HMR	;		;	Solution structure of reduced interstrand cross-link arising from S-alpha-methyl-gamma-OH-1,N2-propano-2'-deoxyguanosine in the 5'-CpG-3' DNA sequence
1AQA	;		;	SOLUTION STRUCTURE OF REDUCED MICROSOMAL RAT CYTOCHROME B5, NMR, MINIMIZED AVERAGE STRUCTURE
1FO5	;		;	SOLUTION STRUCTURE OF REDUCED MJ0307
2LKU	;		;	Solution structure of reduced poplar apo GrxS14
1J3S	;		;	Solution Structure of Reduced Recombinant Human Cytochrome c
1AMB	;		;	SOLUTION STRUCTURE OF RESIDUES 1-28 OF THE AMYLOID BETA-PEPTIDE
1AMC	;		;	SOLUTION STRUCTURE OF RESIDUES 1-28 OF THE AMYLOID BETA-PEPTIDE
1S34	;		;	Solution structure of residues 907-929 from Rous Sarcoma Virus
5T3Y	;		;	Solution structure of response regulator protein from Burkholderia multivorans
6TF4	;		;	Solution structure of RfaH C-terminal domain from Vibrio cholerae
2LCL	;		;	Solution Structure of RfaH carboxyterminal domain
2I59	;		;	Solution structure of RGS10
6EWS	;		;	Solution Structure of Rhabdopeptide NRPS Docking Domain Kj12A-NDD
6EWT	;		;	Solution Structure of Rhabdopeptide NRPS Docking Domain Kj12B-NDD
6EWU	;		;	Solution Structure of Rhabdopeptide NRPS Docking Domain Kj12C-NDD
2PJF	;		;	Solution structure of rhodostomin
2PJG	;		;	Solution structure of rhodostomin D51E mutant
2LJV	;		;	Solution structure of Rhodostomin G50L mutant
2PJI	;		;	Solution structure of rhodostomin P48A mutant
2K5K	;		;	Solution structure of RhR2 from Rhodobacter Sphaeroides. Northeast Structural Genomics Consortium
2NS3	;		;	Solution structure of ribbon BuIA
2B5P	;		;	Solution structure of ribbon isoform of CMrVIA lambda conotoxin
1C54	;		;	SOLUTION STRUCTURE OF RIBONUCLEASE SA
2H8W	;		;	Solution structure of ribosomal protein L11
1WKI	;		;	solution structure of ribosomal protein L16 from thermus thermophilus HB8
1OVY	;		;	Solution Structure of Ribosomal Protein L18 from Bacillus stearothermophilus
1ILY	;		;	Solution Structure of Ribosomal Protein L18 of Thermus thermophilus
1B75	;		;	SOLUTION STRUCTURE OF RIBOSOMAL PROTEIN L25 FROM ESCHERICHIA COLI
1RQ6	;		;	Solution structure of ribosomal protein S17E from Methanobacterium Thermoautotrophicum, Northeast Structural Genomics Consortium Target TT802 / Ontario Center for Structural Proteomics Target Mth0803
2G1D	;		;	Solution Structure of Ribosomal Protein S24E from Thermoplasma acidophilum
1NE3	;		;	Solution structure of ribosomal protein S28E from Methanobacterium Thermoautotrophicum. Ontario Centre for Structural Proteomics target MTH0256_1_68; Northeast Structural Genomics Target TT744
1C06	;		;	SOLUTION STRUCTURE OF RIBOSOMAL PROTEIN S4 DELTA 41, REFINED WITH DIPOLAR COUPLINGS (ENSEMBLE OF 16 STRUCTURES)
1C05	;		;	SOLUTION STRUCTURE OF RIBOSOMAL PROTEIN S4 DELTA 41, REFINED WITH DIPOLAR COUPLINGS (MINIMIZED AVERAGE STRUCTURE)
2KCY	;		;	SOLUTION STRUCTURE OF RIBOSOMAL PROTEIN S8E FROM Methanothermobacter thermautotrophicus, NORTHEASTSTRUCTURAL GENOMICS CONSORTIUM (NESG) TARGET TR71D
1L4S	;		;	Solution structure of ribosome associated factor Y
2RMJ	;		;	Solution structure of RIG-I C-terminal domain
2A20	;		;	Solution structure of Rim2 Zinc Finger Domain
2M6M	;		;	Solution structure of RING domain of E3 ubiquitin ligase Doa10
2EP4	;		;	solution structure of RING finger from human RING finger protein 24
1X4J	;		;	Solution structure of RING finger in RING finger protein 38
1WEO	;		;	Solution structure of RING-finger in the catalytic subunit (IRX3) of cellulose synthase
2LWR	;		;	Solution Structure of RING2 Domain from Parkin
2N7Z	;		;	Solution structure of RIP2 CARD
8R62	;		;	Solution structure of Risdiplam bound to the RNA duplex formed upon 5'-splice site recognition
2RRC	;		;	Solution Structure of RNA aptamer against AML1 Runt domain
2DNQ	;		;	Solution structure of RNA binding domain 1 in RNA-binding protein 30
2E5I	;		;	Solution structure of RNA binding domain 2 in Heterogeneous nuclear ribonucleoprotein L-like
2DNP	;		;	Solution structure of RNA binding domain 2 in RNA-binding protein 14
2CPZ	;		;	solution structure of RNA binding domain 3 in CUG triplet repeat RNA-binding protein 1
2CPY	;		;	solution structure of RNA binding domain 3 in RNA binding motif protein 12
2D9P	;		;	Solution structure of RNA binding domain 4 in Polyadenylation binding protein 3
1WG1	;		;	Solution structure of RNA binding domain in BAB13405(homolog EXC-7)
2DNK	;		;	Solution structure of RNA binding domain in Bruno-like 4 RNA binding protein
2DNH	;		;	Solution structure of RNA binding domain in Bruno-like 5 RNA binding protein
2DNL	;		;	Solution structure of RNA binding domain in Cytoplasmic polyadenylation element binding protein 3
2CQ0	;		;	solution structure of RNA binding domain in eukaryotic translation initiation factor 3 subunit 4
2DNG	;		;	Solution structure of RNA binding domain in Eukaryotic translation initiation factor 4H
2RRA	;		;	Solution structure of RNA binding domain in human Tra2 beta protein in complex with RNA (GAAGAA)
2D9O	;		;	Solution structure of RNA binding domain in Hypothetical protein FLJ10634
2CPX	;		;	solution structure of RNA binding domain in Hypothetical protein FLJ11016
2CQ2	;		;	solution structure of RNA binding domain in Hypothetical protein LOC91801
2E44	;		;	Solution structure of RNA binding domain in Insulin-like growth factor 2 mRNA binding protein 3
2E5J	;		;	Solution structure of RNA binding domain in Methenyltetrahydrofolate synthetase domain containing
1WEL	;		;	Solution structure of RNA binding domain in NP_006038
2YTC	;		;	Solution structure of RNA binding domain in Pre-mRNA-splicing factor RBM22
2CQ1	;		;	solution structure of RNA binding domain in PTB-like protein L
2E5G	;		;	Solution structure of RNA binding domain in RNA binding motif protein 21
2CQ4	;		;	solution structure of RNA binding domain in RNA binding motif protein 23
2CQ3	;		;	solution structure of RNA binding domain in RNA binding motif protein 9
2DNN	;		;	Solution structure of RNA binding domain in RNA-binding protein 12
2DNM	;		;	Solution structure of RNA binding domain in SRp46 splicing factor
2DNR	;		;	Solution structure of RNA binding domain in Synaptojanin 1
2DNO	;		;	Solution structure of RNA binding domain in Trinucleotide repeat containing 4 variant
2E5H	;		;	Solution structure of RNA binding domain in Zinc finger CCHC-type and RNA binding motif 1
1HS8	;		;	SOLUTION STRUCTURE OF RNA HAIRPIN LOOP UCAAUU AS PART OF HAIRPIN R(GCGUCAAUUCGCA)
1HS4	;		;	SOLUTION STRUCTURE OF RNA HAIRPIN LOOP UUAAAU AS PART OF HAIRPIN R(GCGUUAAAUCGCA)
1HS1	;		;	SOLUTION STRUCTURE OF RNA HAIRPIN LOOP UUAACU AS PART OF HAIRPIN R(GCGUUAACUCGCA)
1HS2	;		;	SOLUTION STRUCTURE OF RNA HAIRPIN LOOP UUAAGU AS PART OF HAIRPIN R(GCGUUAAGUCGCA)
1HS3	;		;	SOLUTION STRUCTURE OF RNA HAIRPIN LOOP UUAAUU AS PART OF HAIRPIN R(GCGUUAAUUCGCA)
1HMJ	;		;	SOLUTION STRUCTURE OF RNA POLYMERASE SUBUNIT H
1EIK	;		;	Solution Structure of RNA Polymerase Subunit RPB5 from Methanobacterium Thermoautotrophicum
2KDV	;		;	Solution structure of RNA Pyrophosphohydrolase RppH from Escherichia coli
2MYF	;		;	Solution structure of RNA recognition motif of a cyclophilin33-like protein from Plasmodium falciparum
2N3L	;		;	Solution structure of RNA recognition motif-1 of Plasmodium falciparum serine/arginine-rich protein 1.
2RQC	;		;	Solution Structure of RNA-binding domain 3 of CUGBP1 in complex with RNA (UG)3
2JNB	;		;	Solution Structure of RNA-binding protein 15.5K
1F79	;		;	SOLUTION STRUCTURE OF RNASE P RNA (M1 RNA) P4 STEM C70U MUTANT OLIGORIBONUCLEOTIDE COMPLEXED WITH COBALT(III) HEXAMMINE, NMR, MINIMIZED AVERAGE STRUCTURE
1F78	;		;	SOLUTION STRUCTURE OF RNASE P RNA (M1 RNA) P4 STEM OLIGORIBONUCLEOTIDE COMPLEXED WITH COBALT (III) HEXAMINE, NMR, MINIMIZED AVERAGE STRUCTURE
2N9O	;		;	Solution structure of RNF126 N-terminal zinc finger domain
2N9P	;		;	Solution structure of RNF126 N-terminal zinc finger domain in complex with BAG6 Ubiquitin-like domain
1UFW	;		;	Solution structure of RNP domain in Synaptojanin 2
1T4N	;		;	Solution structure of Rnt1p dsRBD
1QDP	;		;	SOLUTION STRUCTURE OF ROBUSTOXIN, THE LETHAL NEUROTOXIN FROM THE FUNNEL WEB SPIDER ATRAX ROBUSTUS, NMR, 20 STRUCTURES
7BCJ	;		;	Solution Structure of RoxP
1RPB	;		;	SOLUTION STRUCTURE OF RP 71955, A NEW 21 AMINO ACID TRICYCLIC PEPTIDE ACTIVE AGAINST HIV-1 VIRUS
1RPC	;		;	SOLUTION STRUCTURE OF RP 71955, A NEW 21 AMINO ACID TRICYCLIC PEPTIDE ACTIVE AGAINST HIV-1 VIRUS
2JQ5	;		;	Solution structure of RPA3114, a SEC-C motif containing protein from Rhodopseudomonas palustris; Northeast Structural Genomics Consortium target RpT5 / Ontario Center for Structural Proteomics target RP3097
7DTH	;		;	Solution structure of RPB6, common subunit of RNA polymerases I, II, and III
2DK8	;		;	Solution structure of rpc34 subunit in RNA polymerase III from mouse
2KDW	;		;	Solution structure of RppH mutant E53A from Escherichia coli
1X5S	;		;	Solution structure of RRM domain in A18 hnRNP
1WEY	;		;	Solution structure of RRM domain in calcipressin 1
1X4B	;		;	Solution structure of RRM domain in Heterogeneous nuclear ribonucleaoproteins A2/B1
1WEZ	;		;	Solution structure of RRM domain in heterogeneous nuclear ribonucleoprotein H'
2DK2	;		;	Solution structure of RRM domain in heterogeneous nuclear ribonucleoprotein R (hnRNP R)
1WF2	;		;	Solution structure of RRM domain in HNRPC protein
1X4D	;		;	Solution structure of RRM domain in Matrin 3
1X4G	;		;	Solution structure of RRM domain in Nucleolysin TIAR
1X5P	;		;	Solution structure of RRM domain in Parp14
1WEX	;		;	Solution structure of RRM domain in protein BAB28521
1WG4	;		;	Solution structure of RRM domain in protein BAB31986
1X5O	;		;	Solution structure of RRM domain in RNA binding motif, single-stranded interacting protein 1
1X4E	;		;	Solution structure of RRM domain in RNA binding motif, single-stranded interacting protein 2
1X4H	;		;	Solution structure of RRM domain in RNA-binding protein 28
1WF1	;		;	Solution structure of RRM domain in RNA-binding protein NP_057951
1X4C	;		;	Solution structure of RRM domain in splicing factor 2
1X4A	;		;	Solution structure of RRM domain in splicing factor SF2
1WF0	;		;	Solution structure of RRM domain in TAR DNA-binding protein-43
5ZUH	;		;	Solution structure of RRM domian of La protein from Trypanosoma brucei
7XX8	;		;	Solution structure of RRM1 of Human SART3
2K8G	;		;	Solution structure of RRM2 domain of PABP1
7XX9	;		;	Solution structure of RRM2 of Human SART3
1IYG	;		;	Solution structure of RSGI RUH-001, a Fis1p-like and CGI-135 homologous domain from a mouse cDNA
1UHC	;		;	Solution Structure of RSGI RUH-002, a SH3 Domain of KIAA1010 protein [Homo sapiens]
1UJD	;		;	Solution Structure of RSGI RUH-003, a PDZ domain of hypothetical KIAA0559 protein from human cDNA
1Q60	;		;	Solution Structure of RSGI RUH-004, a GTF2I domain in Mouse cDNA
1UHP	;		;	Solution structure of RSGI RUH-005, a PDZ domain in human cDNA, KIAA1095
1UIT	;		;	Solution structure of RSGI RUH-006, The third PDZ domain OF hDlg5 (KIAA0583) protein [Homo sapiens]
1UM1	;		;	Solution Structure of RSGI RUH-007, PDZ domain in Human cDNA
1V5J	;		;	Solution Structure of RSGI RUH-008, fn3 domain in Human cDNA
1VCS	;		;	Solution Structure of RSGI RUH-009, an N-Terminal Domain of Vti1a [Mus musculus]
1SPK	;		;	Solution Structure of RSGI RUH-010, an SH3 Domain from Mouse cDNA
1VEK	;		;	Solution Structure of RSGI RUH-011, a UBA Domain from Arabidopsis cDNA
1VEG	;		;	Solution Structure of RSGI RUH-012, a UBA Domain from Mouse cDNA
1VDL	;		;	Solution Structure of RSGI RUH-013, a UBA domain in Mouse cDNA
1VG5	;		;	Solution Structure of RSGI RUH-014, a UBA domain from Arabidopsis cDNA
1WJ7	;		;	Solution structure of RSGI RUH-015, a UBA domain from mouse cDNA
1VEJ	;		;	Solution Structure of RSGI RUH-016, a UBA Domain from mouse cDNA
1VEH	;		;	Solution structure of RSGI RUH-018, a NifU-like domain of hirip5 protein from mouse cDNA
1WIG	;		;	Solution structure of RSGI RUH-019, a LIM domain of actin binding LIM protein 2 (KIAA1808 protein) from human cDNA
1WIH	;		;	Solution structure of RSGI RUH-021, a domain II of ribosome recycling factor from mouse cDNA
1WGX	;		;	Solution structure of RSGI RUH-022, a myb DNA-binding domain in human cDNA
1WIV	;		;	solution structure of RSGI RUH-023, a UBA domain from Arabidopsis cDNA
1WJ6	;		;	Solution structure of RSGI RUH-024, a PB1 domain in human cDNA, KIAA0049
1WII	;		;	Solution structure of RSGI RUH-025, a DUF701 domain from mouse cDNA
1WHC	;		;	Solution Structure of RSGI RUH-027, a UBA domain from Mouse cDNA
2E1O	;		;	Solution structure of RSGI RUH-028, a homeobox domain from human cDNA
1WVO	;		;	Solution structure of RSGI RUH-029, an antifreeze protein like domain in human N-acetylneuraminic acid phosphate synthase gene.
2CPC	;		;	Solution structure of RSGI RUH-030, an Ig like domain from human cDNA
2CPW	;		;	Solution structure of RSGI RUH-031, a UBA domain from human cDNA
2CQ7	;		;	Solution structure of RSGI RUH-032, a cystein-rich domain of CRISP-2 from human cDNA
2CQ8	;		;	Solution structure of RSGI RUH-033, a pp-binding domain of 10-FTHFDH from human cDNA
2CQX	;		;	Solution structure of RSGI RUH-034, a homeodomain from mouse cDNA
2CON	;		;	Solution Structure of RSGI RUH-035, a Zn-ribbon module in Mouse cDNA
2CRE	;		;	Solution structure of RSGI RUH-036, an SH3 domain from human cDNA
2CQQ	;		;	Solution Structure of RSGI RUH-037, a myb DNA-binding domain in human cDNA
2COS	;		;	Solution structure of RSGI RUH-038, a UBA domain from Mouse LATS2 (Large Tumor Suppressor homolog 2)
2CQA	;		;	Solution structure of RSGI RUH-039, a fragment of C-terminal domain of RuvB-like 2 from human cDNA
2COP	;		;	Solution structure of RSGI RUH-040, an ACBP domain from human cDNA
2CQW	;		;	Solution structure of RSGI RUH-041, a SMB-like domain from mouse cDNA
2CP9	;		;	Solution structure of RSGI RUH-042, a UBA domain from human mitochondrial elongation factor Ts
2CQR	;		;	Solution structure of RSGI RUH-043, a myb DNA-binding domain in human cDNA
2CQ9	;		;	Solution structure of RSGI RUH-044, an N-terminal domain of Glutaredoxin 2 from human cDNA
2CQU	;		;	Solution Structure of RSGI RUH-045, a Human Acyl-CoA Binding Protein
2D99	;		;	Solution Structure of RSGI RUH-048, a GTF2I domain in human cDNA
2D9S	;		;	Solution structure of RSGI RUH-049, a UBA domain from mouse cDNA
2D9A	;		;	Solution Structure of RSGI RUH-050, a myb DNA-binding domain in mouse cDNA
2DB6	;		;	Solution structure of RSGI RUH-051, a C1 domain of STAC3 from human cDNA
2D9B	;		;	Solution Structure of RSGI RUH-052, a GTF2I domain in human cDNA
2DN8	;		;	Solution Structure of RSGI RUH-053, an Apo-Biotin Carboxy Carrier Protein from Human Transcarboxylase
2DNC	;		;	Solution Structure of RSGI RUH-054, a lipoyl domain from human 2-oxoacid dehydrogenase
2DNV	;		;	Solution Structure of RSGI RUH-055, a Chromo Domain from Mus musculus cDNA
2DNA	;		;	Solution Structure of RSGI RUH-056, a UBA domain from mouse cDNA
2DN5	;		;	Solution Structure of RSGI RUH-057, a GTF2I domain in human cDNA
2DNE	;		;	Solution Structure of RSGI RUH-058, a lipoyl domain of human 2-oxoacid dehydrogenase
2DNW	;		;	Solution structure of RSGI RUH-059, an ACP domain of acyl carrier protein, mitochondrial [Precursor] from human cDNA
2DN4	;		;	Solution Structure of RSGI RUH-060, a GTF2I domain in human cDNA
2DNU	;		;	Solution structure of RSGI RUH-061, a SH3 domain from human
2DNF	;		;	Solution structure of RSGI RUH-062, a DCX domain from human
2DNX	;		;	Solution structure of RSGI RUH-063, an N-terminal domain of Syntaxin 12 from human cDNA
2DNT	;		;	Solution Structure of RSGI RUH-064, a Chromo Domain from Human cDNA
2DO6	;		;	Solution structure of RSGI RUH-065, a UBA domain from human cDNA
2DZQ	;		;	Solution Structure of RSGI RUH-066, a GTF2I domain in human cDNA
2DZR	;		;	Solution Structure of RSGI RUH-067, a GTF2I domain in human cDNA
2E3L	;		;	Solution Structure of RSGI RUH-068, a GTF2I domain in human cDNA
2ED2	;		;	Solution Structure of RSGI RUH-069, a GTF2I domain in human cDNA
2EDU	;		;	Solution structure of RSGI RUH-070, a C-terminal domain of kinesin-like protein KIF22 from human cDNA
2EJE	;		;	Solution Structure of RSGI RUH-071, a GTF2I domain in human cDNA
2KM4	;		;	Solution structure of Rtt103 CTD interacting domain
2L0I	;		;	Solution structure of Rtt103 CTD-interacting domain bound to a Ser2 phosphorylated CTD peptide
5M9D	;		;	Solution structure of Rtt103 CTD-interacting domain bound to a Ser2Ser7 phosphorylated CTD peptide
5LVF	;		;	Solution structure of Rtt103 CTD-interacting domain bound to a Thr4 phosphorylated CTD peptide
2D9F	;		;	Solution structure of RUH-047, an FKBP domain from human cDNA
2EJM	;		;	Solution structure of RUH-072, an apo-biotnyl domain form human acetyl coenzyme A carboxylase
2EKO	;		;	Solution structure of RUH-073, a Pseudo Chromo Domain from Human cDNA
2EKK	;		;	Solution structure of RUH-074, a human UBA domain
2EKF	;		;	Solution structure of RUH-075, a human CUE domain
2EJS	;		;	Solution structure of RUH-076, a human CUE domain
2KGY	;		;	Solution structure of Rv0603 protein from Mycobacterium tuberculosis H37Rv
5IRD	;		;	Solution structure of Rv1466 from Mycobacterium tuberculosis, a protein associated with [Fe-S] complex assembly and repair - Seattle Structural Genomics Center for Infectious Disease target MytuD.17486.a
2KHR	;		;	Solution structure of Rv2377c, a MbtH-like protein from Mycobacterium tuberculosis
2YZ0	;		;	Solution Structure of RWD/GI domain of Saccharomyces cerevisiae GCN2
1P68	;		;	Solution structure of S-824, a de novo designed four helix bundle
7YHH	;		;	Solution structure of S-di-mannosylated S3C mutant of carbohydrate binding module (CBM) of the glycoside hydrolase Family 7 cellobiohydrolase from Trichoderma reesei
7YHG	;		;	Solution structure of S-mono-mannosylated S3C mutant of carbohydrate binding module (CBM) of the glycoside hydrolase Family 7 cellobiohydrolase from Trichoderma reesei
2LZN	;		;	Solution structure of S. aureus primase C-terminal domain
2JZV	;		;	Solution structure of S. aureus PrsA-PPIase
2JXN	;		;	Solution Structure of S. cerevisiae PDCD5-like Protein Ymr074cp
1ZFS	;		;	Solution structure of S100A1 bound to calcium
2LP3	;		;	Solution structure of S100A1 Ca2+
2KOT	;		;	Solution structure of S100A13 with a drug amlexanox
7YHF	;		;	Solution structure of S3C mutant of carbohydrate binding module (CBM) of the glycoside hydrolase Family 7 cellobiohydrolase from Trichoderma reesei
1YX5	;		;	Solution Structure of S5a UIM-1/Ubiquitin Complex
1YX6	;		;	Solution Structure of S5a UIM-2/Ubiquitin Complex
1UGL	;		;	Solution structure of S8-SP11
2JQQ	;		;	Solution structure of Saccharomyces cerevisiae conserved oligomeric Golgi subunit 2 protein (Cog2p)
1L4V	;		;	SOLUTION STRUCTURE OF SAPECIN
7LHQ	;		;	Solution structure of SARS-CoV-2 nonstructural protein 7 at pH 7.0
2MW8	;		;	Solution structure of SATB1 homeodomain
2KKR	;		;	Solution structure of SCA7 zinc finger domain from human ataxin-7 protein
2MVT	;		;	Solution structure of scoloptoxin SSD609 from Scolopendra mutilans
6OHX	;		;	Solution structure of scorpion Hottentotta jayakari venom toxin Hj1a
2JMV	;		;	Solution structure of scytovirin refined against residual dipolar couplings
5IEB	;		;	Solution structure of SdrG from Sphingomonas melonis Fr1
7SXI	;		;	Solution Structure of Sds3 Capped Tudor Domain
2N2H	;		;	Solution structure of Sds3 in complex with Sin3A
2RRN	;		;	Solution structure of SecDF periplasmic domain P4
2LWD	;		;	Solution structure of second CARD of human RIG-I
2CUQ	;		;	Solution Structure of Second Lim Domain from Human Skeletal Muscle Lim-Protein 2
2EEI	;		;	Solution Structure of Second PDZ domain of PDZ Domain Containing Protein 1
2DAQ	;		;	Solution structure of second PWWP domain of WHSC1L1 protein
2JS0	;		;	Solution structure of second SH3 domain of adaptor Nck
1QK7	;		;	Solution structure of Selenocosmia huwena lectin-I(SHL-I) by 2D-NMR
2A2P	;		;	Solution structure of SelM from Mus musculus
1SS6	;		;	Solution structure of SEP domain from human p47
2A4H	;		;	Solution structure of Sep15 from Drosophila melanogaster
5TR5	;		;	Solution structure of Serine 65 phosphorylated UBL domain from parkin
2LF0	;		;	Solution structure of sf3636, a two-domain unknown function protein from Shigella flexneri 2a, determined by joint refinement of NMR, residual dipolar couplings and small-angle X-ray scattering, NESG target SfR339/OCSP target sf3636
1O8Z	;		;	Solution structure of SFTI-1(6,5), an acyclic permutant of the proteinase inhibitor SFTI-1, cis-trans-trans conformer (ct-A)
1O8Y	;		;	Solution structure of SFTI-1(6,5), an acyclic permutant of the proteinase inhibitor SFTI-1, trans-trans-trans conformer (tt-A)
1JBL	;		;	Solution structure of SFTI-1, A cyclic trypsin inhibitor from sunflower seeds
6NOX	;		;	Solution structure of SFTI-KLK5 inhibitor
2LO2	;		;	Solution structure of Sgf11(63-99) zinc finger domain
2LO3	;		;	Solution structure of Sgf73(59-102) zinc finger domain
1LA4	;		;	Solution Structure of SGTx1
2KK6	;		;	Solution structure of sh2 domain of proto-oncogene tyrosine-protein kinase fer from homo sapiens, northeast structural genomics consortium (nesg) target hr3461d
6CPI	;		;	Solution structure of SH3 domain from Shank1
6CPJ	;		;	Solution structure of SH3 domain from Shank2
6CPK	;		;	Solution structure of SH3 domain from Shank3
1UJY	;		;	Solution structure of SH3 domain in Rac/Cdc42 guanine nucleotide exchange factor(GEF) 6
2EPD	;		;	Solution structure of SH3 domain in Rho-GTPase-activating protein 4
2E5K	;		;	Solution structure of SH3 domain in Suppressor of T-cell receptor signaling 1
1WFW	;		;	Solution structure of SH3 domain of mouse Kalirin-9a protein
1Z9Q	;		;	Solution structure of SH3 domain of p40phox
2KGT	;		;	Solution structure of SH3 domain of PTK6
2RQV	;		;	Solution structure of SH3CI domain of Bem1p
2KR3	;		;	Solution structure of SHA-D
2K4P	;		;	Solution Structure of Ship2-Sam
2MD0	;		;	Solution structure of ShK-like immunomodulatory peptide from Ancylostoma caninum (hookworm)
2MCR	;		;	Solution structure of ShK-like immunomodulatory peptide from Brugia malayi (filarial worm)
1TTY	;		;	Solution structure of sigma A region 4 from Thermotoga maritima
2JYS	;		;	Solution structure of Simian Foamy Virus (mac) protease
5TMX	;		;	Solution Structure of SinI, antagonist to the master biofilm-regulator SinR in Bacillus subtilis
2CUR	;		;	Solution structure of Skeletal muscle LIM-protein 1
5XYL	;		;	Solution Structure of Skp1 from Homo sapiens
2HBP	;		;	Solution Structure of Sla1 Homology Domain 1
2KJM	;		;	Solution structure of SLBP RNA binding domain fragment
2LWK	;		;	Solution structure of small molecule-influenza RNA complex
5Z26	;		;	solution structure of SMAP-18
4A4G	;		;	Solution structure of SMN Tudor domain in complex with asymmetrically dimethylated arginine
4A4E	;		;	Solution structure of SMN Tudor domain in complex with symmetrically dimethylated arginine
8R8P	;		;	Solution structure of SMN-CX bound to the RNA helix formed upon SMN2 exon7 5'-splice site recognition
2MAH	;		;	Solution structure of Smoothened
2KXQ	;		;	Solution Structure of Smurf2 WW2 and WW3 bound to Smad7 PY motif containing peptide
2DJY	;		;	Solution structure of Smurf2 WW3 domain-Smad7 PY peptide complex
2KHS	;		;	Solution structure of SNase121:SNase(111-143) complex
2KQ3	;		;	Solution structure of SNase140
2FJ5	;		;	SOLUTION STRUCTURE OF sole a-domain of HUMAN Metallothionein-3 (MT-3)
1ON4	;		;	Solution structure of soluble domain of Sco1 from Bacillus Subtilis
6R1V	;		;	Solution structure of sortase A from S. aureus in complex with 2-(aminomethyl)-3-hydroxy-4H-pyran-4-one based prodrug
2MLM	;		;	Solution structure of sortase A from S. aureus in complex with benzo[d]isothiazol-3-one based inhibitor
6LAG	;		;	Solution structure of SPA-2 SHD
4A4H	;		;	Solution structure of SPF30 Tudor domain in complex with asymmetrically dimethylated arginine
4A4F	;		;	Solution structure of SPF30 Tudor domain in complex with symmetrically dimethylated arginine
1UT3	;		;	Solution Structure of Spheniscin-2, a beta-Defensin from Penguin Stomach Preserving Food
7SKC	;		;	Solution structure of spider toxin Ssp1a
2MT7	;		;	Solution structure of spider-venom peptide Hs1a
1ZRW	;		;	solution structure of spinigerin in H20/TFE 10%
1ZRV	;		;	solution structure of spinigerin in H20/TFE 50%
2DK4	;		;	Solution structure of Splicing Factor Motif in Pre-mRNA splicing factor 18 (hPRP18)
1BUZ	;		;	SOLUTION STRUCTURE OF SPOIIAA, A PHOSPHORYLATABLE COMPONENT OF THE SYSTEM THAT REGULATES TRANSCRIPTION FACTOR SIGMA-F OF BACILLUS SUBTILIS NMR, MINIMIZED AVERAGE STRUCTURE
1AUZ	;		;	SOLUTION STRUCTURE OF SPOIIAA, A PHOSPHORYLATABLE COMPONENT OF THE SYSTEM THAT REGULATES TRANSCRIPTION FACTOR SIGMA-F OF BACILLUS SUBTILIS, NMR, 24 STRUCTURES
1EWW	;		;	SOLUTION STRUCTURE OF SPRUCE BUDWORM ANTIFREEZE PROTEIN AT 30 DEGREES CELSIUS
1N4I	;		;	Solution structure of spruce budworm antifreeze protein at 5 degrees celsius
1LWA	;		;	Solution Structure of SRY_DNA
1N2Y	;		;	SOLUTION STRUCTURE OF SS-CYCLIZED CATESTATIN FRAGMENT FROM CHROMOGRANIN A
2KI2	;		;	Solution Structure of ss-DNA Binding Protein 12RNP2 Precursor, HP0827(O25501_HELPY) form Helicobacter pylori
2JTM	;		;	Solution structure of Sso6901 from Sulfolobus solfataricus P2
1XXZ	;		;	Solution structure of sst1-selective somatostatin (SRIF) analog
1OH1	;		;	Solution structure of staphostatin A form Staphylococcus aureus confirms the discovery of a novel class of cysteine proteinase inhibitors.
2M00	;		;	Solution structure of staphylococcal nuclease E43S mutant in the presence of ssDNA and Cd2+
2LHR	;		;	Solution structure of Staphylococcus aureus IsdH linker domain
2MOU	;		;	Solution structure of StAR-related lipid transfer domain protein 6 (STARD6)
2KLN	;		;	Solution Structure of STAS domain of RV1739c from M. tuberculosis
6SDW	;		;	Solution structure of Staufen1 dsRBD3+4 - hARF1 SBS dsRNA complex.
6SDY	;		;	Solution structure of Staufen1 dsRBD4 - hARF1 SBS dsRNA complex.
2L4U	;		;	Solution structure of Ste5PM24 in the presence of SDS micelle
2KGN	;		;	Solution structure of Ste5PM24 in the zwitterionic DPC micelle
2AVA	;		;	Solution Structure of Stearoyl-Acyl Carrier Protein
2JYM	;		;	Solution structure of stem-loop alpha of the hepatitis B virus post-transcriptional regulatory element
1X02	;		;	Solution structure of stereo array isotope labeled (SAIL) calmodulin
2JW8	;		;	Solution structure of stereo-array isotope labelled (SAIL) C-terminal dimerization domain of SARS coronavirus nucleocapsid protein
2FF0	;		;	Solution Structure of Steroidogenic Factor 1 DNA Binding Domain Bound to its Target Sequence in the Inhibin alpha-subunit Promoter
1ZRX	;		;	solution structure of stomoxyn in H20/TFE 50%
2LPX	;		;	Solution Structure of Strawberry Allergen Fra a 1e
1V4R	;		;	Solution structure of Streptmycal repressor TraR
4CA3	;		;	SOLUTION STRUCTURE OF STREPTOMYCES VIRGINIAE VIRA ACP5B
1SDF	;		;	SOLUTION STRUCTURE OF STROMAL CELL-DERIVED FACTOR-1 (SDF-1), NMR, MINIMIZED AVERAGE STRUCTURE
2LGZ	;		;	Solution structure of STT3P
1WU0	;		;	Solution structure of subunit c of F1Fo-ATP synthase from the thermophilic bacillus PS3
7VIL	;		;	Solution structure of subunit epsilon of the Mycobacterium abscessus F-ATP synthase
7XKZ	;		;	Solution structure of subunit epsilon of the Mycobacterium abscessus F-ATP synthase
1VZS	;		;	Solution structure of subunit F6 from the peripheral stalk region of ATP synthase from bovine heart mitochondria
2KSK	;		;	Solution Structure of Sugarcane defensin 5
2MP2	;		;	Solution structure of SUMO dimer in complex with SIM2-3 from RNF4
5GJL	;		;	Solution structure of SUMO from Plasmodium falciparum
2K8H	;		;	Solution structure of SUMO from Trypanosoma brucei
2ASQ	;		;	Solution Structure of SUMO-1 in Complex with a SUMO-binding Motif (SBM)
2KXY	;		;	Solution structure of SuR18C from Streptococcus thermophilus. Northeast Structural Genomics Consortium Target SuR18C
1UG0	;		;	Solution structure of SURP domain in BAB30904
1X4P	;		;	Solution structure of SURP domain in SFRS14 protei
1X4O	;		;	Solution structure of SURP domain in splicing factor 4
2CUJ	;		;	Solution structure of SWIRM domain of mouse transcriptional adaptor 2-like
1NLA	;		;	Solution Structure of Switch Arc, a Mutant with 3(10) Helices Replacing a Wild-Type Beta-Ribbon
2KSC	;		;	Solution structure of Synechococcus sp. PCC 7002 hemoglobin
1S4T	;		;	Solution structure of synthetic 21mer peptide spanning region 135-155 (in human numbering) of sheep prion protein
2RMW	;		;	Solution structure of synthetic 26-mer peptide containing 142-166 sheep prion protein segment and C-terminal cysteine with R156A mutation
2RMV	;		;	Solution structure of synthetic 26-mer peptide containing 142-166 sheep prion protein segment and C-terminal cysteine with Y155A mutation
1G04	;		;	SOLUTION STRUCTURE OF SYNTHETIC 26-MER PEPTIDE CONTAINING 145-169 SHEEP PRION PROTEIN SEGMENT AND C-TERMINAL CYSTEINE
1IM7	;		;	Solution structure of synthetic cyclic peptide mimicking the loop of HIV-1 gp41 glycoprotein envelope
2MJY	;		;	Solution structure of synthetic Mamba-1 peptide
1ID7	;		;	SOLUTION STRUCTURE OF SYR6
1Q68	;		;	Solution structure of T-cell surface glycoprotein CD4 and Proto-oncogene tyrosine-protein kinase LCK fragments
1Q69	;		;	Solution structure of T-cell surface glycoprotein CD8 alpha chain and Proto-oncogene tyrosine-protein kinase LCK fragments
7XRW	;		;	Solution structure of T. brucei RAP1
1TKV	;		;	Solution Structure of T4 AsiA Dimer
2JPN	;		;	Solution Structure of T4 Bacteriophage Helicase Uvsw.1
1TL6	;		;	Solution structure of T4 bacteriphage AsiA monomer
1SJG	;		;	Solution Structure of T4moC, the Rieske Ferredoxin Component of the Toluene 4-Monooxygenase Complex
1HU7	;		;	SOLUTION STRUCTURE OF T7 NOVISPIRIN
2ABY	;		;	Solution structure of TA0743 from Thermoplasma acidophilum
2G1E	;		;	Solution Structure of TA0895
2JMK	;		;	Solution structure of ta0956
1DQC	;		;	SOLUTION STRUCTURE OF TACHYCITIN, AN ANTIMICROBIAL PROTEIN WITH CHITIN-BINDING FUNCTION
1WO0	;		;	Solution structure of tachyplesin I in H2O
1MA4	;		;	Solution Structure of Tachyplesin I Mutant TPY4 in water
1XUT	;		;	Solution structure of TACI-CRD2
6LQZ	;		;	Solution structure of Taf14ET-Sth1EBMC
2LY3	;		;	Solution structure of TamA POTRA domain I
2CS8	;		;	Solution structure of tandem repeat of the fifth and sixth zinc-finger C2HC domains from human ST18
2CSH	;		;	Solution structure of tandem repeat of the zf-C2H2 domains of human zinc finger protein 297B
2MKH	;		;	Solution structure of tandem RRM domains of cytoplasmic polyadenylation element binding protein 1 (CPEB1) in free state
2MKI	;		;	Solution structure of tandem RRM domains of cytoplasmic polyadenylation element binding protein 4 (CPEB4) in complex with RNA
2MKJ	;		;	Solution structure of tandem RRM domains of cytoplasmic polyadenylation element binding protein 4 (CPEB4) in free state
8B8S	;		;	Solution structure of tandem RRM1 and RRM2 domains of yeast NPL3
2L3T	;		;	Solution structure of tandem SH2 domain from Spt6
2MOX	;		;	solution structure of tandem SH3 domain of Sorbin and SH3 domain-containing protein 1
2LBC	;		;	solution structure of tandem UBA of USP13
1Q0V	;		;	Solution Structure of Tandem UIMs of Vps27
2RPP	;		;	Solution structure of Tandem zinc finger domain 12 in Muscleblind-like protein 2
7LVN	;		;	Solution structure of tarantula toxin omega-Avsp1a
2M7Q	;		;	Solution structure of TAX1BP1 UBZ1+2
5HP0	;		;	Solution Structure of TAZ2-p53AD2
5HPD	;		;	Solution Structure of TAZ2-p53TAD
5MRG	;		;	Solution structure of TDP-43 (residues 1-102)
2N3X	;		;	Solution Structure of TDP-43 Amyloidogenic Core Region
6B1G	;		;	Solution structure of TDP-43 N-terminal domain dimer.
7ELK	;		;	Solution structure of Terfa derived from Danio rerio
1MM0	;		;	Solution structure of termicin, an antimicrobial peptide from the termite Pseudacanthotermes spiniger
1TER	;		;	SOLUTION STRUCTURE OF TERTIAPIN DETERMINED USING NUCLEAR MAGNETIC RESONANCE AND DISTANCE GEOMETRY
7X5C	;		;	Solution structure of Tetrahymena p75OB1-p50PBM
1TLR	;		;	SOLUTION STRUCTURE OF TETRALOOP RECEPTOR RNA, NMR, 20 STRUCTURES
2MG8	;		;	Solution structure of TFF1 Estrogen Response Element complexed with DNA Bis-intercalating Anticancer Drug XR5944 (MLN944)
1KLC	;		;	SOLUTION STRUCTURE OF TGF-B1, NMR, MINIMIZED AVERAGE STRUCTURE
1KLA	;		;	SOLUTION STRUCTURE OF TGF-B1, NMR, MODELS 1-17 OF 33 STRUCTURES
1KLD	;		;	SOLUTION STRUCTURE OF TGF-B1, NMR, MODELS 18-33 OF 33 STRUCTURES
7DOJ	;		;	Solution structure of TGS domain of the Mycobacterium tuberculosis Rel protein
8ONU	;		;	Solution structure of thanatin analogue 7 in complex with LptAm(Ab)1.0
8BSS	;		;	Solution Structure of thanatin-like derivative 5 in complex with E. coli LptA mutant Q62L
7QS6	;		;	Solution structure of thanatin-like derivative 7 in complex with E.coli LptA
7ZED	;		;	Solution structure of thanatin-like derivative 7 in complex with E.coli LptA mutant Q62L
7ZAX	;		;	Solution structure of thanatin-like derivative 7 in complex with K. pneumoniae LptA
2EPY	;		;	Solution structure of the 10th C2H2 type zinc finger domain of Zinc finger protein 268
2ELM	;		;	Solution structure of the 10th C2H2 zinc finger of human Zinc finger protein 406
2DIA	;		;	Solution structure of the 10th filamin domain from human Filamin-B
2EQ4	;		;	Solution structure of the 11th C2H2 type zinc finger domain of Zinc finger protein 224
2ELN	;		;	Solution structure of the 11th C2H2 zinc finger of human Zinc finger protein 406
2DIB	;		;	Solution structure of the 11th filamin domain from human Filamin-B
2EC3	;		;	Solution structure of the 11th FN1 domain from human Fibronectin 1
2ELO	;		;	Solution structure of the 12th C2H2 zinc finger of human Zinc finger protein 406
2DIC	;		;	Solution structure of the 12th filamin domain from human Filamin-B
2CTK	;		;	Solution structure of the 12th KH type I domain from human Vigilin
2ELP	;		;	Solution structure of the 13th C2H2 zinc finger of human Zinc finger protein 406
2DJ4	;		;	Solution structure of the 13th filamin domain from human Filamin-B
2CTL	;		;	Solution structure of the 13th KH type I domain from human Vigilin
2ELQ	;		;	Solution structure of the 14th C2H2 zinc finger of human Zinc finger protein 406
2D7M	;		;	Solution structure of the 14th Filamin domain from human Filamin C
2E9J	;		;	Solution structure of the 14th filamin domain from human Filamin-B
2DM7	;		;	Solution structure of the 14th Ig-like domain of human KIAA1556 protein
2CTM	;		;	Solution structure of the 14th KH type I domain from human Vigilin
2ELR	;		;	Solution structure of the 15th C2H2 zinc finger of human Zinc finger protein 406
1UVG	;		;	Solution structure of the 15th Domain of LEKTI
2DMB	;		;	Solution structure of the 15th Filamin domain from human Filamin-B
2GQH	;		;	Solution structure of the 15th Ig-like domain of human KIAA1556 protein
2EL4	;		;	Solution structure of the 15th zf-C2H2 domain from human Zinc finger protein 268
2EQ2	;		;	Solution structure of the 16th C2H2 type zinc finger domain of Zinc finger protein 347
2D7N	;		;	Solution structure of the 16th Filamin domain from human Filamin C
2EE9	;		;	Solution structure of the 16th filamin domain from human Filamin-B
1IR5	;		;	Solution Structure of the 17mer TF1 Binding Site
2EQ3	;		;	Solution structure of the 17th C2H2 type zinc finger domain of Zinc finger protein 347
2D7O	;		;	Solution structure of the 17th Filamin domain from human Filamin C
2EEA	;		;	Solution structure of the 17th filamin domain from human Filamin-B
2ELZ	;		;	Solution structure of the 17th zf-C2H2 domain from human Zinc finger protein 224
1T17	;		;	Solution Structure of the 18 kDa Protein CC1736 from Caulobacter crescentus: The Northeast Structural Genomics Consortium Target CcR19
2DMC	;		;	Solution structure of the 18th Filamin domain from human Filamin-B
2EM0	;		;	Solution structure of the 18th zf-C2H2 domain from human Zinc finger protein 224
2EL5	;		;	Solution structure of the 18th zf-C2H2 domain from human Zinc finger protein 268
2DI8	;		;	Solution structure of the 19th filamin domain from human Filamin-B
2CP2	;		;	Solution structure of the 1st CAP-Gly domain in human CLIP-115/CYLN2
2CP0	;		;	Solution structure of the 1st CAP-Gly domain in human CLIP-170-related protein CLIPR59
2CP5	;		;	Solution structure of the 1st CAP-Gly domain in human CLIP-170/restin
1WHL	;		;	Solution structure of the 1st CAP-Gly domain in human cylindromatosis tumor suppressor CYLD
1WHJ	;		;	Solution structure of the 1st CAP-Gly domain in mouse 1700024K14Rik hypothetical protein
2CP7	;		;	Solution structure of the 1st CAP-Gly domain in mouse CLIP-170/restin
2KDG	;		;	Solution Structure of the 1st Ig domain of Myotilin
2CTE	;		;	Solution structure of the 1st KH type I domain from human Vigilin
2YRM	;		;	Solution structure of the 1st zf-C2H2 domain from Human B-cell lymphoma 6 protein
2FYH	;		;	Solution structure of the 2'-5' RNA ligase-like protein from Pyrococcus furiosus
2EPV	;		;	Solution structure of the 20th C2H2 type zinc finger domain of Zinc finger protein 268
2DLG	;		;	Solution structure of the 20th Filamin domain from human Filamin-B
2L0X	;		;	Solution structure of the 21 kDa GTPase RHEB bound to GDP
2EE6	;		;	Solution structure of the 21th filamin domain from human Filamin-B
2EL6	;		;	Solution structure of the 21th zf-C2H2 domain from human Zinc finger protein 268
2D7P	;		;	Solution structure of the 22th Filamin domain from human Filamin C
2EEB	;		;	Solution structure of the 22th filamin domain from human Filamin-B
2D7Q	;		;	Solution structure of the 23th Filamin domain from human Filamin C
2EEC	;		;	Solution structure of the 23th filamin domain from human Filamin-B
2EPW	;		;	Solution structure of the 24th C2H2 type zinc finger domain of Zinc finger protein 268
2EED	;		;	Solution structure of the 24th filamin domain from human Filamin-B
1H7J	;		;	Solution structure of the 26 aa presequence of 5-ALAS
2M5T	;		;	Solution structure of the 2A proteinase from a common cold agent, human rhinovirus RV-C02, strain W12
2ELS	;		;	Solution structure of the 2nd C2H2 zinc finger of human Zinc finger protein 406
2CP3	;		;	Solution structure of the 2nd CAP-Gly domain in human CLIP-115/CYLN2
2CP6	;		;	Solution structure of the 2nd CAP-Gly domain in human CLIP-170/restin
1WHM	;		;	Solution structure of the 2nd CAP-Gly domain in human cylindromatosis tumor suppressor CYLD
1WHH	;		;	Solution structure of the 2nd CAP-Gly domain in mouse CLIP170-related 59kDa protein CLIPR-59
1X4Z	;		;	Solution structure of the 2nd fibronectin type III domain from mouse biregional cell adhesion molecule-related/down-regulated oncogenes (Cdon) binding protein
1WJR	;		;	Solution structure of the 2nd mbt domain from human KIAA1617 protein
1MM2	;		;	Solution structure of the 2nd PHD domain from Mi2b
1MM3	;		;	Solution structure of the 2nd PHD domain from Mi2b with C-terminal loop replaced by corresponding loop from WSTF
1WFE	;		;	Solution structure of the 2nd zf-AN1 domain of mouse RIKEN cDNA 2310008M20 protein
2P89	;		;	Solution structure of the 3' pseudouridyation pocket of U65 snoRNA with bound substrate
1YBN	;		;	Solution structure of the 3'E topology of the i-motif tetramer of d(CCCCAA)
2MVU	;		;	Solution Structure of the 3,7-dioxo-octyl Actinorhodin Acyl Carrier Protein from Streptomyces coelicolor
1QXN	;		;	Solution Structure of the 30 kDa Polysulfide-sulfur Transferase Homodimer from Wolinella Succinogenes
2Q7Z	;		;	Solution Structure of the 30 SCR domains of human Complement Receptor 1
1NY4	;		;	Solution structure of the 30S ribosomal protein S28E from Pyrococcus horikoshii. Northeast Structural Genomics Consortium target JR19.
2CUH	;		;	Solution structure of the 31st fibronectin type III domain of the human tenascin X
2CUI	;		;	Solution structure of the 31st fibronectin type III domain of the human tenascin X
1N9J	;		;	Solution Structure of the 3D domain swapped dimer of Stefin A
2ELT	;		;	Solution structure of the 3rd C2H2 zinc finger of human Zinc finger protein 406
1WHK	;		;	Solution structure of the 3rd CAP-Gly domain in mouse 1700024K14Rik hypothetical protein
1X4Y	;		;	Solution structure of the 3rd fibronectin type III domain from mouse biregional cell adhesion molecule-related/down-regulated oncogenes (Cdon) binding protein
1V64	;		;	Solution structure of the 3rd HMG box of mouse UBF1
1V62	;		;	Solution structure of the 3rd PDZ domain of GRIP2
2RQ1	;		;	Solution structure of the 4.1R FERM alpha lobe domain
1H7D	;		;	Solution structure of the 49 aa presequence of 5-ALAS
2EPZ	;		;	Solution structure of the 4th C2H2 type zinc finger domain of Zinc finger protein 28 homolog
1WGF	;		;	Solution structure of the 4th HMG-box of mouse UBF1
2CTF	;		;	Solution structure of the 4th KH type I domain from human Vigilin
2EPS	;		;	Solution structure of the 4th zinc finger domain of Zinc finger protein 278
1YBR	;		;	Solution structure of the 5'E topology of the i-motif tetramer of d(CCCCAA)
2MVV	;		;	Solution Structure of the 5-phenyl-3-oxo-pentyl Actinorhodin Acyl Carrier Protein from Streptomyces coelicolor
1SQR	;		;	Solution Structure of the 50S Ribosomal Protein L35AE from Pyrococcus furiosus. Northeast Structural Genomics Consortium Target PfR48.
2ELU	;		;	Solution structure of the 5th C2H2 zinc finger of human Zinc finger protein 406
2ELW	;		;	Solution structure of the 5th C2H2 zinc finger of mouse Zinc finger protein 406
2EQW	;		;	Solution structure of the 6th C2H2 type zinc finger domain of Zinc finger protein 484
2ELV	;		;	Solution structure of the 6th C2H2 zinc finger of human Zinc finger protein 406
1X4X	;		;	Solution structure of the 6th fibronectin type III domain from human fibronectin type III domain containing protein 3
1V63	;		;	Solution structure of the 6th HMG box of mouse UBF1
2E7B	;		;	Solution structure of the 6th Ig-like domain from human KIAA1556
2E7C	;		;	Solution structure of the 6th Ig-like domain from human Myosin-binding protein C, fast-type
2EQF	;		;	Solution structure of the 7th A20-type zinc finger domain from human tumor necrosis factor, alpha-induced protein3
2DAZ	;		;	Solution structure of the 7th PDZ domain of InaD-like protein
1MK6	;		;	SOLUTION STRUCTURE OF THE 8,9-DIHYDRO-8-(N7-GUANYL)-9-HYDROXY-AFLATOXIN B1 ADDUCT MISPAIRED WITH DEOXYADENOSINE
8OR8	;		;	Solution structure of the 8-17 DNAzyme in presence of Zn2+
2EQ0	;		;	Solution structure of the 8th C2H2 type zinc finger domain of Zinc finger protein 347
2ELX	;		;	Solution structure of the 8th C2H2 zinc finger of mouse Zinc finger protein 406
2CTJ	;		;	Solution structure of the 8th KH type I domain from human Vigilin
2EQ1	;		;	Solution structure of the 9th C2H2 type zinc finger domain of Zinc finger protein 347
2DI9	;		;	Solution structure of the 9th filamin domain from human Filamin-B
2M71	;		;	Solution structure of the a C-terminal domain of translation initiation factor IF-3 from Campylobacter jejuni
1I3X	;		;	SOLUTION STRUCTURE OF THE A LOOP OF 23S RIBOSOMAL RNA
1I3Y	;		;	SOLUTION STRUCTURE OF THE A LOOP OF 23S RIBOSOMAL RNA.
2RUE	;		;	Solution structure of the a' domain of thermophilic fungal protein disulfide (oxidized form, 303K)
2RUF	;		;	Solution structure of the a' domain of thermophilic fungal protein disulfide (reduced form, 303K)
2DJJ	;		;	Solution structure of the a' domain of thermophilic fungal protein disulfide isomerase
2KP1	;		;	Solution structure of the a' domain of thermophilic fungal protein disulfide isomerase
1E9J	;		;	SOLUTION STRUCTURE OF THE A-SUBUNIT OF HUMAN CHORIONIC GONADOTROPIN [INCLUDING A SINGLE GLCNAC RESIDUE AT ASN52 AND ASN78]
1HD4	;		;	SOLUTION STRUCTURE OF THE A-SUBUNIT OF HUMAN CHORIONIC GONADOTROPIN [MODELED WITH DIANTENNARY GLYCAN AT ASN78]
1DZ7	;		;	Solution structure of the a-subunit of human chorionic gonadotropin [modeled without carbohydrate residues]
2N02	;		;	Solution structure of the A147T variant of the mitochondrial translocator protein (tspo) in complex with pk11195
2EEE	;		;	Solution structure of the A1pp domain from human protein C6orf130
2J8J	;		;	Solution Structure of the A4 Domain of Blood Coagulation Factor XI
1X26	;		;	Solution structure of the AA-mismatch DNA complexed with naphthyridine-azaquinolone
2N73	;		;	Solution structure of the ACBD3:PI4KB complex
2KG6	;		;	Solution Structure of the acetyl Actinorhodin Acyl Carrier Protein from Streptomyces coelicolor
1TJZ	;		;	Solution Structure of the Active Site Stem-Loop of the VS Ribozyme
1TXE	;		;	Solution structure of the active-centre mutant Ile14Ala of the histidine-containing phosphocarrier protein (HPr) from Staphylococcus carnosus
2KIJ	;		;	Solution structure of the Actuator domain of the copper-transporting ATPase ATP7A
1ORX	;		;	Solution Structure of the acyclic permutant des-(24-28)-kalata B1.
2LBM	;		;	Solution structure of the ADD domain of ATRX complexed with histone tail H3 1-15 K9me3
2JO7	;		;	Solution structure of the adhesion protein Bd37 from Babesia divergens
2AIN	;		;	Solution structure of the AF-6 PDZ domain complexed with the C-terminal peptide from the Bcr protein
2LM0	;		;	Solution structure of the AF4-AF9 complex
2M89	;		;	Solution structure of the Aha1 dimer from Colwellia psychrerythraea
2KQN	;		;	Solution structure of the AL-09 H87Y immunoglobulin light chain variable domain
1GJS	;		;	Solution structure of the Albumin binding domain of Streptococcal Protein G
1GJT	;		;	Solution structure of the Albumin binding domain of Streptococcal Protein G
2MUI	;		;	Solution structure of the AlgH protein from Pseudomonas aeruginosa, PA0405, UPF0301
2RN4	;		;	Solution structure of the alkaline proteinase inhibitor APRin from Pseudomonas aeruginosa
2JUE	;		;	Solution structure of the all-D kalata B1
2E9G	;		;	Solution structure of the alpha adaptinC2 domain from human Adapter-related protein complex 1 gamma 2 subunit
1M0G	;		;	Solution structure of the alpha domain of mt_nc
2KUB	;		;	Solution structure of the alpha subdomain of the major non-repeat unit of Fap1 fimbriae of Streptococcus parasanguis
7KNN	;		;	Solution structure of the alpha-conotoxin analogue [2-8]-alkyne Vc1.1
2N3J	;		;	Solution Structure of the alpha-crystallin domain from the redox-sensitive chaperone, HSPB1
2F5H	;		;	Solution structure of the alpha-domain of human Metallothionein-3
1DFS	;		;	SOLUTION STRUCTURE OF THE ALPHA-DOMAIN OF MOUSE METALLOTHIONEIN-1
1JI9	;		;	Solution structure of the alpha-domain of mouse metallothionein-3
1WHU	;		;	Solution structure of the alpha-helical domain from mouse hypothetical PNPase
2JP1	;		;	Solution structure of the alternative conformation of XCL1/Lymphotactin
1Q7X	;		;	Solution structure of the alternatively spliced PDZ2 domain (PDZ2b) of PTP-Bas (hPTP1E)
1IYT	;		;	Solution structure of the Alzheimer's disease amyloid beta-peptide (1-42)
1URK	;		;	SOLUTION STRUCTURE OF THE AMINO TERMINAL FRAGMENT OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
2KGS	;		;	Solution structure of the amino-terminal domain of OmpATb, a pore forming protein from Mycobacterium tuberculosis
1C95	;		;	Solution structure of the aminoacyl-capped oligodeoxyribonucleotide duplex TRP-D(TGCGCAC)2
2KWP	;		;	Solution structure of the aminoterminal domain of E. coli NusA
2K06	;		;	Solution structure of the aminoterminal domain of E. coli NusG
1KDL	;		;	Solution structure of the amphipathic domain of YopD from Yersinia
6SZF	;		;	Solution structure of the amyloid beta-peptide (1-42)
2MUB	;		;	Solution structure of the analgesic sea anemone peptide APETx2
1CW8	;		;	SOLUTION STRUCTURE OF THE ANALOGUE RETRO-INVERSO (mA-R)REGRIGGC IN CONTACT WITH THE MONOCLONAL ANTIBODY MAB 4X11, NMR, 6 STRUCTURES
1CWZ	;		;	Solution structure of the analogue retro-inverso (MA-S)REGRIGGC in contact with the monoclonal antibody MAB 4X11, NMR, 7 structures
1CVQ	;		;	SOLUTION STRUCTURE OF THE ANALOGUE RETRO-INVERSO MGREGRIGGC IN CONTACT WITH THE MONOCLONAL ANTIBODY MAB 4X11, NMR, 7 STRUCTURES
1YSW	;		;	Solution structure of the anti-apoptotic protein Bcl-2 complexed with an acyl-sulfonamide-based ligand
2O21	;		;	Solution structure of the anti-apoptotic protein Bcl-2 in complex with an acyl-sulfonamide-based ligand
2O22	;		;	Solution structure of the anti-apoptotic protein Bcl-2 in complex with an acyl-sulfonamide-based ligand
2O2F	;		;	Solution structure of the anti-apoptotic protein Bcl-2 in complex with an acyl-sulfonamide-based ligand
1YSN	;		;	Solution structure of the anti-apoptotic protein Bcl-xL complexed with an acyl-sulfonamide-based ligand
1YSG	;		;	Solution Structure of the Anti-apoptotic Protein Bcl-xL in Complex with ""SAR by NMR"" Ligands
1YSI	;		;	Solution structure of the anti-apoptotic protein Bcl-xL in complex with an acyl-sulfonamide-based ligand
2O1Y	;		;	Solution structure of the anti-apoptotic protein Bcl-xL in complex with an acyl-sulfonamide-based ligand
2O2M	;		;	Solution structure of the anti-apoptotic protein Bcl-xL in complex with an acyl-sulfonamide-based ligand
2O2N	;		;	Solution structure of the anti-apoptotic protein Bcl-xL in complex with an acyl-sulfonamide-based ligand
2LR3	;		;	Solution structure of the anti-fungal defensin DEF4 (MTR_8g070770) from Medicago truncatula (barrel clover)
1JR5	;		;	Solution Structure of the Anti-Sigma Factor AsiA Homodimer
1B03	;		;	SOLUTION STRUCTURE OF THE ANTIBODY-BOUND HIV-1IIIB V3 PEPTIDE
1KRS	;		;	SOLUTION STRUCTURE OF THE ANTICODON BINDING DOMAIN OF ESCHERICHIA COLI LYSYL-TRNA SYNTHETASE AND STUDIES OF ITS INTERACTIONS WITH TRNA-LYS
1KRT	;		;	SOLUTION STRUCTURE OF THE ANTICODON BINDING DOMAIN OF ESCHERICHIA COLI LYSYL-TRNA SYNTHETASE AND STUDIES OF ITS INTERACTIONS WITH TRNA-LYS
2G1G	;		;	Solution structure of the anticodon loop of S. Pombe tRNAi including the naturally occurring N6-threonyl adenine
1AFP	;		;	SOLUTION STRUCTURE OF THE ANTIFUNGAL PROTEIN FROM ASPERGILLUS GIGANTEUS. EVIDENCE FOR DISULPHIDE CONFIGURATIONAL ISOMERISM
2KCN	;		;	Solution structure of the antifungal protein PAF from Penicillium chrysogenum
6TRM	;		;	Solution structure of the antifungal protein PAFC
1YS5	;		;	Solution structure of the antigenic domain of GNA1870 of Neisseria meningitidis
1NYO	;		;	Solution structure of the antigenic TB protein MPT70/MPB70
1KFP	;		;	Solution structure of the antimicrobial 18-residue gomesin
2M2Y	;		;	Solution structure of the antimicrobial peptide Btd-2[3,4]
8HVS	;		;	Solution Structure of the Antimicrobial Peptide HT-2
2LXZ	;		;	Solution Structure of the Antimicrobial Peptide Human Defensin 5
2M2G	;		;	Solution structure of the antimicrobial peptide [Aba3,16]BTD-2
2M2X	;		;	Solution structure of the antimicrobial peptide [Aba3,5,7,12,14,16]BTD-2
2M2H	;		;	Solution structure of the antimicrobial peptide [Aba3,7,12,16]BTD-2
2M2S	;		;	Solution structure of the antimicrobial peptide [Aba5,7,12,14]BTD-2
2IXY	;		;	Solution structure of the apical stem-loop of the human hepatitis B virus encapsidation signal
2IXZ	;		;	Solution structure of the apical stem-loop of the human hepatitis B virus encapsidation signal
2K2A	;		;	Solution Structure of the Apo C terminal domain of Lethocerus troponin C isoform F1
5Y08	;		;	Solution structure of the apo doublet acyl carrier protein from prodigiosin biosynthesis
1QJT	;		;	SOLUTION STRUCTURE OF THE APO EH1 DOMAIN OF MOUSE EPIDERMAL GROWTH FACTOR RECEPTOR SUBSTRATE 15, EPS15
2MMZ	;		;	Solution structure of the apo form of human glutaredoxin 5
1Y3K	;		;	Solution structure of the apo form of the fifth domain of Menkes protein
1YJR	;		;	Solution structure of the apo form of the sixth soluble domain A69P mutant of Menkes protein
1YJU	;		;	Solution structure of the apo form of the sixth soluble domain of Menkes protein
2G9O	;		;	Solution structure of the apo form of the third metal-binding domain of ATP7A protein (Menkes Disease protein)
1FES	;		;	SOLUTION STRUCTURE OF THE APO FORM OF THE YEAST METALLOCHAPERONE, ATX1
1F54	;		;	SOLUTION STRUCTURE OF THE APO N-TERMINAL DOMAIN OF YEAST CALMODULIN
5HVC	;		;	Solution structure of the apo state of the acyl carrier protein from the MLSA2 subunit of the mycolactone polyketide synthase
2JT2	;		;	Solution Structure of the Aquifex aeolicus LpxC- CHIR-090 complex
6NU4	;		;	Solution structure of the Arabidopsis thaliana RALF8 peptide
2AJE	;		;	Solution structure of the Arabidopsis thaliana telomeric repeat-binding protein DNA binding domain
1GH8	;		;	SOLUTION STRUCTURE OF THE ARCHAEAL TRANSLATION ELONGATION FACTOR 1BETA FROM METHANOBACTERIUM THERMOAUTOTROPHICUM
2CRW	;		;	Solution structure of the ArfGap domain of ADP-ribosylation factor GTPaseactivating protein 3 (ArfGap 3)
2D9L	;		;	Solution structure of the ArfGap domain of human RIP
2EQY	;		;	Solution structure of the ARID domain of Jarid1b protein
2YQE	;		;	Solution structure of the ARID domain of JARID1D protein
6QXZ	;		;	Solution structure of the ASHH2 CW domain with the N-terminal histone H3 tail mimicking peptide monomethylated on lysine 4
2RQ5	;		;	Solution structure of the AT-rich interaction domain (ARID) of Jumonji/JARID2
2GGP	;		;	Solution structure of the Atx1-Cu(I)-Ccc2a complex
2JSN	;		;	Solution structure of the atypical PDZ-like domain of synbindin
1EJ5	;		;	SOLUTION STRUCTURE OF THE AUTOINHIBITED CONFORMATION OF WASP
2KQ7	;		;	Solution structure of the Autophagy-Related Protein Atg8
2NCN	;		;	Solution Structure of the Autophagy-Related Protein LC3C
2M41	;		;	Solution Structure of the AXH domain of Ataxin-1 in complex with ligand peptide from Capicua
2L4C	;		;	Solution Structure of the b domain of Human ERp27
2DJK	;		;	Solution structure of the b' domain of thermophilic fungal protein disulfide isomerase
2KP2	;		;	Solution structure of the b' domain of thermophilic fungal protein disulfide isomerase
2YRG	;		;	Solution structure of the B-box domain from tripartite motif-containing protein 5
2DJA	;		;	Solution structure of the B-box domain of the human Midline-2 protein
2D8U	;		;	Solution structure of the B-box domain of the human tripartite motif-containing 63 protein
2D8V	;		;	Solution structure of the B-box domain of the zinc finger FYVE domain-containing protein 19 from Mus musculus
1LAI	;		;	Solution Structure of the B-DNA Duplex CGCGGTGTCCGCG.
1LAQ	;		;	Solution Structure of the B-DNA Duplex CGCGGTXTCCGCG (X=PdG) Containing the 1,N2-propanodeoxyguanosine Adduct with the Deoxyribose at C20 Opposite PdG in the C2' Endo Conformation.
1LAS	;		;	Solution Structure of the B-DNA Duplex CGCGGTXTCCGCG (X=PdG) Containing the 1,N2-propanodeoxyguanosine Adduct with the Deoxyribose at C20 Opposite PdG in the C3' Endo Conformation.
2GDY	;		;	Solution structure of the B. brevis TycC3-PCP in A-state
2GDW	;		;	Solution structure of the B. brevis TycC3-PCP in A/H-state
2GDX	;		;	Solution structure of the B. brevis TycC3-PCP in H-state
5MSL	;		;	Solution structure of the B. subtilis anti-sigma-F factor, FIN
1WID	;		;	Solution Structure of the B3 DNA-Binding Domain of RAV1
2VKC	;		;	Solution structure of the B3BP Smr domain
2RUI	;		;	Solution Structure of the Bacillus anthracis Sortase A-substrate Complex
2M5C	;		;	Solution Structure of the Bacillus cereus Metallo-Beta-Lactamase BcII
2M5D	;		;	Solution Structure of the Bacillus cereus Metallo-Beta-Lactamase BcII in Complex with R-Thiomandelic Acid
2P7C	;		;	Solution structure of the bacillus licheniformis BlaI monomeric form in complex with the blaP half-operator.
2EQX	;		;	Solution structure of the BACK domain of Kelch repeat and BTB domain-containing protein 4
2AN7	;		;	Solution structure of the bacterial antidote ParD
2ADL	;		;	Solution structure of the bacterial antitoxin CcdA: Implications for DNA and toxin binding
2ADN	;		;	Solution structure of the bacterial antitoxin CcdA: Implications for DNA and toxin binding
1SOY	;		;	Solution structure of the bacterial frataxin orthologue, CyaY
5LBJ	;		;	Solution structure of the bacterial toxin LdrD in Tetrafluorethanol
2KHE	;		;	Solution Structure of the Bacterial Toxin Rele from Thermus Thermophilus HB8
1NYB	;		;	SOLUTION STRUCTURE OF THE BACTERIOPHAGE PHI21 N PEPTIDE-BOXB RNA COMPLEX
2D9D	;		;	Solution structure of the BAG domain (275-350) of BAG-family molecular chaperone regulator-5
1M62	;		;	Solution structure of the BAG domain from BAG4/SODD
1WIN	;		;	Solution Structure of the Band 7 Domain of the mouse Flotillin 2 Protein
8SQX	;		;	Solution structure of the basal pilin SpaB from Corynebacterium diphtheriae
2PON	;		;	Solution structure of the Bcl-xL/Beclin-1 complex
2N1L	;		;	Solution structure of the BCOR PUFD
5IEJ	;		;	Solution structure of the BeF3-activated conformation of SdrG from Pseudomonas melonis Fr1
2KYM	;		;	Solution structure of the Bem1p SH3-CI domain from L.elongisporus in complex with Ste20p peptide
2JRL	;		;	Solution structure of the beryllofluoride-activated NtrC4 receiver domain dimer
1M0J	;		;	solution structure of the beta domain of mt_nc
1DFT	;		;	SOLUTION STRUCTURE OF THE BETA-DOMAIN OF MOUSE METALLOTHIONEIN-1
2KAK	;		;	Solution structure of the beta-E-domain of wheat Ec-1 metallothionein
1Q59	;		;	Solution Structure of the BHRF1 Protein From Epstein-Barr Virus, a Homolog of Human Bcl-2
2MH4	;		;	Solution structure of the Big domain from Leptospira interrogans
2K79	;		;	Solution Structure of the binary complex between the SH3 and SH2 domain of interleukin-2 tyrosine kinase
1H4B	;		;	SOLUTION STRUCTURE OF THE BIRCH POLLEN ALLERGEN BET V 4
2JPW	;		;	Solution structure of the bisphosphorylated cardiac specific N-extension of cardiac troponin I
2BUN	;		;	Solution structure of the BLUF domain of AppA 5-125
2DHM	;		;	Solution structure of the BolA protein from Escherichia coli
2RSC	;		;	Solution Structure of the bombyx mori lysozyme
1XFR	;		;	Solution structure of the Bombyx mori pheromone-binding protein fragment BmPBP(1-128) at pH 6.5
2LVF	;		;	Solution structure of the Brazil Nut 2S albumin Ber e 1
1JM7	;		;	Solution structure of the BRCA1/BARD1 RING-domain heterodimer
2EBW	;		;	Solution structure of the BRCT domain from human DNA repair protein REV1
2EP8	;		;	Solution structure of the BRCT domain from human Pescadillo homolog 1
2EBU	;		;	Solution structure of the BRCT domain from human replication factor C large subunit 1
1OQA	;		;	Solution structure of the BRCT-c domain from human BRCA1
2JRZ	;		;	Solution structure of the Bright/ARID domain from the human JARID1C protein.
2GLO	;		;	Solution structure of the Brinker DNA binding domain in complex with the omb enhancer
2E7O	;		;	Solution structure of the Bromodomain from human Bromodomain adjacent to zinc finger domain 2B
2YW5	;		;	Solution structure of the bromodomain from human bromodomain containing protein 3
2I7K	;		;	Solution Structure of the Bromodomain of Human BRD7 Protein
2RS9	;		;	Solution structure of the bromodomain of human BRPF1 in complex with histone H4K5ac peptide
2DKW	;		;	Solution structure of the bromodomain of human protein KIAA1240
2DAT	;		;	Solution structure of the Bromodomain of human SWI/SNF related matrix associated actin dependent regulator of cromatin subfamily A member 2
2D9E	;		;	Solution structure of the Bromodomain of Peregrin
2N9G	;		;	Solution structure of the bromodomain of Trypanosoma brucei Bromodomain Factor 2(BDF2)
2JNS	;		;	Solution structure of the Bromodomain-containing protein 4 ET domain
1X3A	;		;	Solution structure of the BSD domain of human Synapse associated protein 1
2DII	;		;	Solution structure of the BSD domain of human TFIIH basal transcription factor complex p62 subunit
2YS2	;		;	Solution structure of the BTK motif of human Cytoplasmic tyrosine-protein kinase BMX
2E6I	;		;	Solution structure of the BTK motif of tyrosine-protein kinase ITK from human
6CKQ	;		;	Solution structure of the Burkholderia thailandensis transcription antitermination protein NusB (BTH_I1529) - Seattle Structural Genomics Center for Infectious Disease target ButhA.17903.a
2LCA	;		;	Solution structure of the C domain of RV0899 from mycobacterium tuberculosis
2LBT	;		;	Solution structure of the C domain of RV0899(D236A) from mycobacterium tuberculosis
1M8B	;		;	Solution structure of the C State of turkey ovomucoid at pH 2.5
7QA5	;		;	Solution structure of the C terminal domain of MgtC (PA4635) from Pseudomonas aeruginosa
1F6V	;		;	SOLUTION STRUCTURE OF THE C TERMINAL OF MU B TRANSPOSITION PROTEIN
7DTA	;		;	Solution structure of the C-clamp domain from human HDBP1 in complex with DNA
2AYA	;		;	Solution Structure of the C-Terminal 14 kDa Domain of the tau subunit from Escherichia coli DNA Polymerase III
2RNQ	;		;	Solution structure of the C-terminal acidic domain of TFIIE alpha
1R48	;		;	Solution structure of the C-terminal cytoplasmic domain residues 468-497 of Escherichia coli protein ProP
2LMG	;		;	Solution Structure of The C-terminal Domain (537-610) of Human Heat Shock Protein 70
2EWL	;		;	Solution structure of the C-terminal domain (monomer) of the HPV45 oncoprotein E7
2A4J	;		;	Solution structure of the C-terminal domain (T94-Y172) of the human centrin 2 in complex with a 17 residues peptide (P1-XPC) from xeroderma pigmentosum group C protein
2K3P	;		;	Solution structure of the C-terminal domain (TUSP1-C) of the egg case silk from Nephila antipodiana
2GAT	;		;	SOLUTION STRUCTURE OF THE C-TERMINAL DOMAIN OF CHICKEN GATA-1 BOUND TO DNA, NMR, REGULARIZED MEAN STRUCTURE
1QW1	;		;	Solution Structure of the C-Terminal Domain of DtxR residues 110-226
1Z00	;		;	Solution structure of the C-terminal domain of ERCC1 complexed with the C-terminal domain of XPF
2L92	;		;	Solution structure of the C-terminal domain of H-NS like protein Bv3F
2L5V	;		;	Solution structure of the C-terminal domain of hRpn13
1DPU	;		;	SOLUTION STRUCTURE OF THE C-TERMINAL DOMAIN OF HUMAN RPA32 COMPLEXED WITH UNG2(73-88)
2H7T	;		;	Solution Structure of the C-terminal Domain of Insulin-like Growth Factor Binding Protein 2 (IGFBP-2)
1WJW	;		;	Solution structure of the C-terminal domain of mouse phosphoacetylglucosamine mutase (PAGM)
2MXE	;		;	Solution structure of the C-terminal domain of MvaT
7CQ1	;		;	Solution structure of the C-terminal domain of Mycobacterium Tuberculosis ribosome maturation factor protein RimM
1RG6	;		;	Solution structure of the C-terminal domain of p63
2L9W	;		;	Solution Structure of the C-terminal domain of Prp24
2M5Y	;		;	Solution Structure of the C-terminal domain of RV0431
5NKO	;		;	Solution structure of the C-terminal domain of S. aureus Hibernating Promoting Factor (CTD-SaHPF)
2L93	;		;	Solution structure of the C-terminal domain of Salmonella H-NS
2L55	;		;	Solution structure of the C-terminal domain of SilB from Cupriavidus metallidurans
2KN2	;		;	Solution structure of the C-terminal domain of soybean calmodulin isoform 4 fused with the calmodulin-binding domain of NtMKP1
2LSL	;		;	Solution structure of the C-terminal domain of Tetrahymena telomerase protein p65
2RRL	;		;	Solution structure of the C-terminal domain of the FliK
1J3C	;		;	Solution structure of the C-terminal domain of the HMGB2
1J3D	;		;	Solution structure of the C-terminal domain of the HMGB2
1PBU	;		;	Solution structure of the C-terminal domain of the human eEF1Bgamma subunit
2LQJ	;		;	Solution structure of the C-terminal domain of the MgtC protein from Mycobacterium tuberculosis
6ZXP	;		;	Solution structure of the C-terminal domain of the vaccinia virus DNA polymerase processivity factor component A20 fused to a short peptide from the viral DNA polymerase E9.
6ZYC	;		;	Solution structure of the C-terminal domain of the vaccinia virus DNA polymerase processivity factor component A20.
1Q6A	;		;	Solution Structure of the C-terminal Domain of Thermosynechococcus elongatus KaiA (ThKaiA180C); Averaged Minimized Structure
1Q6B	;		;	Solution Structure of the C-terminal Domain of Thermosynechococcus elongatus KaiA (ThKaiA180C); Ensemble of 25 Structures
1KFT	;		;	Solution Structure of the C-Terminal domain of UvrC from E-coli
2JON	;		;	Solution structure of the C-terminal domain Ole e 9
1M39	;		;	Solution structure of the C-terminal fragment (F86-I165) of the human centrin 2 in calcium saturated form
2FCG	;		;	Solution structure of the C-terminal fragment of human LL-37
1X50	;		;	Solution structure of the C-terminal gal-bind lectin domain from human galectin-4
2YRO	;		;	Solution structure of the C-terminal Gal-bind lectin protein from Human Galectin-8
2O13	;		;	Solution structure of the C-terminal LIM domain of MLP/CRP3
2HM8	;		;	Solution Structure of the C-terminal MA-3 domain of Pdcd4
5TN2	;		;	Solution Structure of the C-terminal multimerization domain of the master biofilm-regulator SinR from Bacillus subtilis
2K47	;		;	Solution structure of the C-terminal N-RNA binding domain of the Vesicular Stomatitis Virus Phosphoprotein
1DT7	;		;	SOLUTION STRUCTURE OF THE C-TERMINAL NEGATIVE REGULATORY DOMAIN OF P53 IN A COMPLEX WITH CA2+-BOUND S100B(BB)
2LNM	;		;	Solution structure of the C-terminal NP-repeat domain of Tic40, a co-chaperone during protein import into chloroplasts
1PQS	;		;	Solution structure of the C-terminal OPCA domain of yCdc24p
1JH4	;		;	Solution structure of the C-terminal PABC domain of human poly(A)-binding protein in complex with the peptide from Paip1
1JGN	;		;	Solution structure of the C-terminal PABC domain of human poly(A)-binding protein in complex with the peptide from Paip2
2E6J	;		;	Solution structure of the C-terminal PapD-like domain from human HYDIN protein
2LWX	;		;	Solution structure of the C-terminal Pdr1-activating domain of the J-protein Zuo1
2COC	;		;	Solution structure of the C-terminal PH domain of FYVE, RhoGEF and PH domain containing protein 3 (FGD3) from human
1X05	;		;	Solution structure of the C-terminal PH domain of human pleckstrin
1X1G	;		;	Solution structure of the C-terminal PH domain of human pleckstrin 2
2COF	;		;	Solution structure of the C-terminal PH domain of hypothetical protein KIAA1914 from human
1WGU	;		;	Solution Structure of the C-terminal Phosphotyrosine Interaction Domain of APBB2 from Mouse
1V5U	;		;	Solution Structure of the C-terminal Pleckstrin Homology Domain of Sbf1 from Mouse
2YUH	;		;	Solution structure of the C-terminal region in human tubulin folding cofactor C
1WD2	;		;	Solution Structure of the C-terminal RING from a RING-IBR-RING (TRIAD) motif
2DH9	;		;	Solution structure of the C-terminal RNA binding domain in Heterogeneous nuclear ribonucleoprotein M
2DHG	;		;	Solution structure of the C-terminal RNA recognition motif in tRNA selenocysteine associated protein
2CPH	;		;	Solution structure of the C-terminal RNA recognition motif of hypothetical RNA-binding protein RBM19
1IQT	;		;	Solution structure of the C-terminal RNA-binding domain of heterogeneous nuclear ribonucleoprotein D0 (AUF1)
1UTA	;		;	Solution structure of the C-terminal RNP domain from the divisome protein FtsN
2AHQ	;		;	Solution Structure of the C-terminal RpoN Domain of Sigma-54 from Aquifex aeolicus
1OWX	;		;	Solution structure of the C-terminal RRM of human La (La225-334)
2E8N	;		;	Solution structure of the C-terminal SAM-domain of EphaA2: Ephrin type-A receptor 2 precursor (EC 2.7.10.1)
2E8M	;		;	Solution structure of the C-terminal SAM-domain of epidermal growth receptor pathway substrate 8
2EAO	;		;	Solution structure of the C-terminal SAM-domain of mouse ephrin type-B receptor 1 precursor (EC 2.7.1.112)
2QFH	;		;	Solution Structure of the C-terminal SCR-16/20 fragment of Complement Factor H.
1K76	;		;	Solution Structure of the C-terminal Sem-5 SH3 Domain (Minimized Average Structure)
1BFI	;		;	SOLUTION STRUCTURE OF THE C-TERMINAL SH2 DOMAIN OF THE P85ALPHA REGULATORY SUBUNIT OF PHOSPHOINOSITIDE 3-KINASE, NMR, 30 STRUCTURES
1BFJ	;		;	SOLUTION STRUCTURE OF THE C-TERMINAL SH2 DOMAIN OF THE P85ALPHA REGULATORY SUBUNIT OF PHOSPHOINOSITIDE 3-KINASE, NMR, MINIMIZED AVERAGE STRUCTURE
2GGR	;		;	Solution structure of the C-terminal SH3 domain of c-CrkII
1K4U	;		;	Solution structure of the C-terminal SH3 domain of p67phox complexed with the C-terminal tail region of p47phox
1X3U	;		;	Solution structure of the C-terminal transcriptional activator domain of FixJ from Sinorhizobium melilot
2DAH	;		;	Solution Structure of the C-terminal UBA Domain in the Human Ubiquilin 3
1WJN	;		;	Solution structure of the C-terminal ubiquitin-like domain of mouse tubulin-specific chaperone e
1WJ2	;		;	Solution Structure of the C-terminal WRKY Domain of AtWRKY4
2FK4	;		;	Solution structure of the C-terminal zinc binding domain of the HPV16 E6 oncoprotein
6PMG	;		;	Solution structure of the C-terminal zinc finger of the C. elegans protein MEX-5
2M3L	;		;	Solution structure of the C-terminal zinc-binding domain of HPV51 oncoprotein E6
2MFO	;		;	Solution structure of the C-terminally encoded peptide of the model plant host Medicago truncatula - CEP1
2MFM	;		;	Solution structure of the C-terminally encoded peptide of the plant parasitic nematode Meloidogyne hapla - CEP11
1RFH	;		;	Solution structure of the C1 domain of Nore1, a novel Ras effector
1R79	;		;	Solution Structure of The C1 Domain of The Human Diacylglycerol Kinase Delta
1Z9B	;		;	Solution structure of the C1-subdomain of Bacillus stearothermophilus translation initiation factor IF2
2K0R	;		;	Solution structure of the C103S mutant of the N-terminal Domain of DsbD from Neisseria meningitidis
2ENQ	;		;	Solution structure of the C2 domain from human PI3-kinase p110 subunit alpha
2ENJ	;		;	Solution structure of the C2 domain from human protein kinase C theta
2JQZ	;		;	Solution Structure of the C2 domain of human Smurf2
2AP0	;		;	Solution Structure of the C27A ScYLV P1-P2 Frameshifting Pseudoknot, 20 Lowest Energy Structures
2AP5	;		;	Solution Structure of the C27A ScYLV P1-P2 Frameshifting Pseudoknot, Average Structure
2EN8	;		;	Solution structure of the C2H2 type zinc finger (region 171-203) of human Zinc finger protein 224
2EM6	;		;	Solution structure of the C2H2 type zinc finger (region 199-231) of human Zinc finger protein 224
2YTT	;		;	Solution structure of the C2H2 type zinc finger (region 204-236) of human Zinc finger protein 473
2EOR	;		;	Solution structure of the C2H2 type zinc finger (region 255-287) of human Zinc finger protein 224
2EMX	;		;	Solution structure of the C2H2 type zinc finger (region 273-303) of human Zinc finger protein 268
2EOQ	;		;	Solution structure of the C2H2 type zinc finger (region 283-315) of human Zinc finger protein 224
2EN4	;		;	Solution structure of the C2H2 type zinc finger (region 284-316) of human Zinc finger protein 347
2EMW	;		;	Solution structure of the C2H2 type zinc finger (region 301-331) of human Zinc finger protein 268
2ENA	;		;	Solution structure of the C2H2 type zinc finger (region 311-343) of human Zinc finger protein 224
2EMA	;		;	Solution structure of the C2H2 type zinc finger (region 312-344) of human Zinc finger protein 347
2EOX	;		;	Solution structure of the C2H2 type zinc finger (region 315-345) of human Zinc finger protein 473
2EOI	;		;	Solution structure of the C2H2 type zinc finger (region 329-359) of human Zinc finger protein 268
2EM7	;		;	Solution structure of the C2H2 type zinc finger (region 339-371) of human Zinc finger protein 224
2ENF	;		;	Solution structure of the C2H2 type zinc finger (region 340-372) of human Zinc finger protein 347
2EOM	;		;	Solution structure of the C2H2 type zinc finger (region 341-373) of human Zinc finger protein 95 homolog
2EMB	;		;	Solution structure of the C2H2 type zinc finger (region 342-372) of human Zinc finger protein 473
2EOJ	;		;	Solution structure of the C2H2 type zinc finger (region 355-385) of human Zinc finger protein 268
2EM9	;		;	Solution structure of the C2H2 type zinc finger (region 367-399) of human Zinc finger protein 224
2EOW	;		;	Solution structure of the C2H2 type zinc finger (region 368-400) of human Zinc finger protein 347
2YTG	;		;	Solution structure of the C2H2 type zinc finger (region 369-401) of human Zinc finger protein 95 homolog
2EOU	;		;	Solution structure of the C2H2 type zinc finger (region 370-400) of human Zinc finger protein 473
2EMF	;		;	Solution structure of the C2H2 type zinc finger (region 379-411) of human Zinc finger protein 484
2EN0	;		;	Solution structure of the C2H2 type zinc finger (region 385-413) of human Zinc finger protein 268
2ENC	;		;	Solution structure of the C2H2 type zinc finger (region 395-427) of human Zinc finger protein 224
2YTK	;		;	Solution structure of the C2H2 type zinc finger (region 396-428) of human Zinc finger protein 347
2EON	;		;	Solution structure of the C2H2 type zinc finger (region 397-429) of human Zinc finger protein 95 homolog
2EOF	;		;	Solution structure of the C2H2 type zinc finger (region 411-441) of human Zinc finger protein 268
2EN9	;		;	Solution structure of the C2H2 type zinc finger (region 415-447) of human Zinc finger protein 28 homolog
2EM8	;		;	Solution structure of the C2H2 type zinc finger (region 423-455) of human Zinc finger protein 224
2EOO	;		;	Solution structure of the C2H2 type zinc finger (region 425-457) of human Zinc finger protein 95 homolog
2YTD	;		;	Solution structure of the C2H2 type zinc finger (region 426-458) of human Zinc finger protein 473
2EP1	;		;	Solution structure of the C2H2 type zinc finger (region 435-467) of human Zinc finger protein 484
2EOK	;		;	Solution structure of the C2H2 type zinc finger (region 441-469) of human Zinc finger protein 268
2EMG	;		;	Solution structure of the C2H2 type zinc finger (region 463-495) of human Zinc finger protein 484
2YTH	;		;	Solution structure of the C2H2 type zinc finger (region 479-511) of human Zinc finger protein 224
2YTE	;		;	Solution structure of the C2H2 type zinc finger (region 484-512) of human Zinc finger protein 473
2EMH	;		;	Solution structure of the C2H2 type zinc finger (region 491-523) of human Zinc finger protein 484
2EN7	;		;	Solution structure of the C2H2 type zinc finger (region 495-525) of human Zinc finger protein 268
2YSP	;		;	Solution structure of the C2H2 type zinc finger (region 507-539) of human Zinc finger protein 224
2EOE	;		;	Solution structure of the C2H2 type zinc finger (region 508-540) of human Zinc finger protein 347
2EOV	;		;	Solution structure of the C2H2 type zinc finger (region 519-551) of human Zinc finger protein 484
2EP0	;		;	Solution structure of the C2H2 type zinc finger (region 528-560) of human Zinc finger protein 28 homolog
2EMP	;		;	Solution structure of the C2H2 type zinc finger (region 536-568) of human Zinc finger protein 347
2EMM	;		;	Solution structure of the C2H2 type zinc finger (region 544-576) of human Zinc finger protein 95 homolog
2EMI	;		;	Solution structure of the C2H2 type zinc finger (region 547-579) of human Zinc finger protein 484
2EMY	;		;	Solution structure of the C2H2 type zinc finger (region 551-583) of human Zinc finger protein 268
2ENH	;		;	Solution structure of the C2H2 type zinc finger (region 556-588) of human Zinc finger protein 28 homolog
2EOY	;		;	Solution structure of the C2H2 type zinc finger (region 557-589) of human Zinc finger protein 473
2EN1	;		;	Solution structure of the C2H2 type zinc finger (region 563-595) of human Zinc finger protein 224
2YTI	;		;	Solution structure of the C2H2 type zinc finger (region 564-596) of human Zinc finger protein 347
2EOL	;		;	Solution structure of the C2H2 type zinc finger (region 581-609) of human Zinc finger protein 268
2EM2	;		;	Solution structure of the C2H2 type zinc finger (region 584-616) of human Zinc finger protein 28 homolog
2ENE	;		;	Solution structure of the C2H2 type zinc finger (region 592-624) of human Zinc finger protein 347
2EN2	;		;	Solution structure of the C2H2 type zinc finger (region 598-626) of human B-cell lymphoma 6 protein
2EP2	;		;	Solution structure of the C2H2 type zinc finger (region 603-635) of human Zinc finger protein 484
2YTF	;		;	Solution structure of the C2H2 type zinc finger (region 607-639) of human Zinc finger protein 268
2EMJ	;		;	Solution structure of the C2H2 type zinc finger (region 612-644) of human Zinc finger protein 28 homolog
2EOS	;		;	Solution structure of the C2H2 type zinc finger (region 626-654) of human B-cell lymphoma 6 protein
2EMZ	;		;	Solution structure of the C2H2 type zinc finger (region 628-660) of human Zinc finger protein 95 homolog
2EP3	;		;	Solution structure of the C2H2 type zinc finger (region 631-663) of human Zinc finger protein 484
2EM1	;		;	Solution structure of the C2H2 type zinc finger (region 637-667) of human Zinc finger protein 268
2EM3	;		;	Solution structure of the C2H2 type zinc finger (region 640-672) of human Zinc finger protein 28 homolog
2EMC	;		;	Solution structure of the C2H2 type zinc finger (region 641-673) of human Zinc finger protein 473
2YU8	;		;	Solution structure of the C2H2 type zinc finger (region 648-680) of human Zinc finger protein 347
2YSO	;		;	Solution structure of the C2H2 type zinc finger (region 656-688) of human Zinc finger protein 95 homolog
2YTO	;		;	Solution structure of the C2H2 type zinc finger (region 659-691) of human Zinc finger protein 484
2EMK	;		;	Solution structure of the C2H2 type zinc finger (region 668-700) of human Zinc finger protein 28 homolog
2YTP	;		;	Solution structure of the C2H2 type zinc finger (region 687-719) of human Zinc finger protein 484
2EOG	;		;	Solution structure of the C2H2 type zinc finger (region 693-723) of human Zinc finger protein 268
2YTM	;		;	Solution structure of the C2H2 type zinc finger (region 696-728) of human Zinc finger protein 28 homolog
2YTS	;		;	Solution structure of the C2H2 type zinc finger (region 715-747) of human Zinc finger protein 484
2EOP	;		;	Solution structure of the C2H2 type zinc finger (region 719-751) of human Zinc finger protein 268
2EM4	;		;	Solution structure of the C2H2 type zinc finger (region 724-756) of human Zinc finger protein 28 homolog
2EME	;		;	Solution structure of the C2H2 type zinc finger (region 725-757) of human Zinc finger protein 473
2YTN	;		;	Solution structure of the C2H2 type zinc finger (region 732-764) of human Zinc finger protein 347
2EML	;		;	Solution structure of the C2H2 type zinc finger (region 752-784) of human Zinc finger protein 28 homolog
2YTR	;		;	Solution structure of the C2H2 type zinc finger (region 760-792) of human Zinc finger protein 347
2EM5	;		;	Solution structure of the C2H2 type zinc finger (region 768-800) of human Zinc finger protein 95 homolog
2YTJ	;		;	Solution structure of the C2H2 type zinc finger (region 771-803) of human Zinc finger protein 484
2YTQ	;		;	Solution structure of the C2H2 type zinc finger (region 775-807) of human Zinc finger protein 268
2EOH	;		;	Solution structure of the C2H2 type zinc finger (region 780-812) of human Zinc finger protein 28 homolog
2EN3	;		;	Solution structure of the C2H2 type zinc finger (region 796-828) of human Zinc finger protein 95 homolog
2EOZ	;		;	Solution structure of the C2H2 type zinc finger (region 809-841) of human Zinc finger protein 473
2EMV	;		;	Solution structure of the C2H2 type zinc finger (region 859-889) of human Zinc finger protein 268
2EN6	;		;	Solution structure of the C2H2 type zinc finger (region 887-919) of human Zinc finger protein 268
1X3C	;		;	Solution structure of the C2H2 type zinc-binding domain of human zinc finger protein 292
1X5W	;		;	Solution structure of the C2H2 type zinc-binding domain of human zinc finger protein 64, isoforms 1 and 2
1WIR	;		;	Solution structure of the C2H2 zinc finger domain of the protein arginine N-methyltransferase 3 from Mus musculus
2YRH	;		;	Solution structure of the C2H2-type zinc finger domain (699-729) from zinc finger protein 473
2YRJ	;		;	Solution structure of the C2H2-type zinc finger domain (781-813) from zinc finger protein 473
2C6A	;		;	Solution structure of the C4 zinc-finger domain of HDM2
2C6B	;		;	Solution structure of the C4 zinc-finger domain of HDM2
2ENV	;		;	Solution structure of the C4-type zinc finger domain from human Peroxisome proliferator-activated receptor delta
1YTP	;		;	Solution structure of the C4A/C41A variant of the Nicotiana alata proteinase inhibitor T1
8HTA	;		;	Solution Structure of the C65A/C167A Mutant of Human Lipocalin-type Prostaglandin D Synthase
1J9W	;	2.6	;	Solution Structure of the CAI Michigan 1 Variant
2KLD	;		;	Solution Structure of the Calcium Binding Domain of the C-terminal Cytosolic Domain of Polycystin-2
1F55	;		;	SOLUTION STRUCTURE OF THE CALCIUM BOUND N-TERMINAL DOMAIN OF YEAST CALMODULIN
5TP5	;		;	Solution structure of the calcium deficient mutant calmodulin CaM1234
1BYN	;		;	SOLUTION STRUCTURE OF THE CALCIUM-BOUND FIRST C2-DOMAIN OF SYNAPTOTAGMIN I
2AMI	;		;	Solution Structure Of The Calcium-loaded N-Terminal Sensor Domain Of Centrin
1KKD	;		;	Solution structure of the calmodulin binding domain (CaMBD) of small conductance Ca2+-activated potassium channels (SK2)
2M7E	;		;	solution structure of the calmodulin-binding domain of plant calcium-ATPase ACA2
2M73	;		;	solution structure of the calmodulin-binding domain of plant calcium-ATPase ACA8
5TP6	;		;	Solution structure of the CaM34 with the iNOS CaM binding domain peptide
2ROK	;		;	Solution structure of the cap-binding domain of PARN complexed with the cap analog
1IXD	;		;	Solution structure of the CAP-GLY domain from human cylindromatosis tomour-suppressor CYLD
2COZ	;		;	Solution structure of the CAP-Gly domain in human centrosome-associated protein CAP350
2COY	;		;	Solution structure of the CAP-Gly domain in human Dynactin 1
2COW	;		;	Solution structure of the CAP-Gly domain in human Kinesin-like protein KIF13B
1WHG	;		;	Solution structure of the CAP-Gly domain in mouse tubulin specific chaperone B
6GSE	;		;	Solution structure of the capsid domain from the activity-regulated cytoskeleton-associated protein, Arc
2M83	;		;	Solution structure of the carbohydrate binding module of the muscle glycogen-targeting subunit of Protein Phosphatase-1
1Y00	;		;	Solution structure of the Carbon Storage Regulator protein CsrA
2MI6	;		;	Solution structure of the carboxy terminal domain of NusG from Mycobacterium tuberculosis
1Z60	;		;	Solution structure of the carboxy-terminal domain of human TFIIH P44 subunit
2KGW	;		;	Solution Structure of the carboxy-terminal domain of OmpATb, a pore forming protein from Mycobacterium tuberculosis
1UC6	;		;	Solution Structure of the Carboxyl Terminal Domain of the Ciliary Neurotrophic Factor Receptor
2DBH	;		;	Solution structure of the carboxyl-terminal CARD-like domain in human TNFR-related death receptor-6
1NHA	;		;	Solution Structure of the Carboxyl-Terminal Domain of RAP74 and NMR Characterization of the FCP-Binding Sites of RAP74 and CTD of RAP74, the subunit of Human TFIIF
1X0H	;		;	Solution structure of the carboxyl-terminal RGC domain in human IQGAP1
2DBD	;		;	Solution structure of the CARD domain in human caspase recruitment domain protein 4 (Nod1 protein)
2KZ7	;		;	Solution structure of the CARMIL CAH3a/b domain bound to capping protein (CP)
1CWW	;		;	SOLUTION STRUCTURE OF THE CASPASE RECRUITMENT DOMAIN (CARD) FROM APAF-1
1GHT	;		;	SOLUTION STRUCTURE OF THE CATALYTIC DOMAIN OF GAMMA DELTA RESOLVASE
1HX7	;		;	SOLUTION STRUCTURE OF THE CATALYTIC DOMAIN OF GAMMA DELTA RESOLVASE
2M9Y	;		;	Solution Structure of the Catalytic Domain of HHARI
1EUB	;		;	SOLUTION STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN COLLAGENASE-3 (MMP-13) COMPLEXED TO A POTENT NON-PEPTIDIC SULFONAMIDE INHIBITOR
1BM6	;		;	SOLUTION STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN STROMELYSIN-1 COMPLEXED TO A POTENT NON-PEPTIDIC INHIBITOR, NMR, 20 STRUCTURES
1M3G	;		;	SOLUTION STRUCTURE OF THE CATALYTIC DOMAIN OF MAPK PHOSPHATASE PAC-1: INSIGHTS INTO SUBSTRATE-INDUCED ENZYMATIC ACTIVATION
2K7Z	;		;	Solution Structure of the Catalytic Domain of Procaspase-8
1R6E	;		;	Solution structure of the catalytic domain of SopE2
5KVP	;		;	Solution structure of the catalytic domain of zoocin A
1FLS	;		;	SOLUTION STRUCTURE OF THE CATALYTIC FRAGMENT OF HUMAN COLLAGENASE-3 (MMP-13) COMPLEXED WITH A HYDROXAMIC ACID INHIBITOR
1FM1	;		;	SOLUTION STRUCTURE OF THE CATALYTIC FRAGMENT OF HUMAN COLLAGENASE-3 (MMP-13) COMPLEXED WITH A HYDROXAMIC ACID INHIBITOR
1N5P	;		;	Solution structure of the cathelin-like domain of protegrins (all amide bonds involving proline residues are in trans conformation)
1N5H	;		;	Solution structure of the cathelin-like domain of protegrins (the R87-P88 and D118-P119 amide bonds are in the cis conformation)
2EEF	;		;	Solution structure of the CBM_21 domain from human protein phosphatase 1, regulatory (inhibitor) subunit 3B
2KVM	;		;	Solution structure of the CBX7 chromodomain in complex with a H3K27me2 peptide
6QK6	;		;	Solution Structure of the Cd-loaded form of a Metallothionein from Helix Pomatia
1S40	;		;	SOLUTION STRUCTURE OF THE CDC13 DNA-BINDING DOMAIN COMPLEXED WITH A SINGLE-STRANDED TELOMERIC DNA 11-MER
1KXL	;		;	Solution Structure of the Cdc13 DNA-binding Domain in a Complex with Single-Stranded Telomeric DNA (DNA structure not modeled)
4BMF	;		;	Solution structure of the cellulose-binding domain of endoglucanase I from Trichoderma reesei and its interaction with cello- oligosaccharides
2ELH	;		;	Solution structure of the CENP-B N-terminal DNA-binding domain of fruit fly distal antenna CG11849-PA
1KWE	;		;	SOLUTION STRUCTURE OF THE CENTRAL CONSERVED REGION OF HUMAN RESPIRATORY SYNCYTIAL VIRUS ATTACHMENT GLYCOPROTEIN G
1KWD	;		;	SOLUTION STRUCTURE OF THE CENTRAL CONSERVED REGION OF HUMAN RESPIRATORY SYNCYTIAL VIRUS ATTACHMENT GLYCOPROTEIN G 187
1D8J	;		;	SOLUTION STRUCTURE OF THE CENTRAL CORE DOMAIN OF TFIIE BETA
1D8K	;		;	SOLUTION STRUCTURE OF THE CENTRAL CORE DOMAIN OF TFIIE BETA
1YSV	;		;	Solution structure of the central region of the human GluR-B R/G pre-mRNA
1S79	;		;	Solution structure of the central RRM of human La protein
2RSG	;		;	Solution structure of the CERT PH domain
1WA8	;		;	Solution Structure of the CFP-10.ESAT-6 Complex. Major Virulence Determinants of Pathogenic Mycobacteria
2D89	;		;	Solution structure of the CH domain from human EH domain binding protein 1
2E9K	;		;	Solution structure of the CH domain from human MICAL-2
2D88	;		;	Solution structure of the CH domain from human MICAL-3 protein
2YRN	;		;	Solution structure of the CH domain from Human Neuron navigator 2
2D87	;		;	Solution structure of the CH domain from human Smoothelin splice isoform L2
2EE7	;		;	Solution structure of the CH domain from human Sperm flagellar protein 1
2D86	;		;	Solution structure of the CH domain from human Vav-3 protein
1V5K	;		;	Solution structure of the CH domain from mouse EB-1
1UJO	;		;	Solution Structure of the CH domain from Mouse Trangelin
1WYP	;		;	Solution structure of the CH domain of human Calponin 1
1WYN	;		;	Solution structure of the CH domain of human calponin-2
1WYO	;		;	Solution structure of the CH domain of human microtubule-associated protein RP/EB family member 3
1WYL	;		;	Solution structure of the CH domain of human NEDD9 interacting protein with calponin homology and LIM domains
1WYR	;		;	Solution structure of the CH domain of human Rho guanine nucleotide exchange factor 6
1WYM	;		;	Solution structure of the CH domain of human transgelin-2
1DLZ	;		;	SOLUTION STRUCTURE OF THE CHANNEL-FORMER ZERVAMICIN IIB (PEPTAIBOL ANTIBIOTIC)
2L4N	;		;	Solution Structure of the Chemokine CCL21
1HUM	;		;	SOLUTION STRUCTURE OF THE CHEMOKINE HMIP-1BETA(SLASH)ACT-2 BY MULTI-DIMENSIONAL NMR: A NOVEL CHEMOKINE DIMER
1HUN	;		;	SOLUTION STRUCTURE OF THE CHEMOKINE HMIP-1BETA(SLASH)ACT-2 BY MULTI-DIMENSIONAL NMR: A NOVEL CHEMOKINE DIMER
1XEE	;		;	Solution structure of the Chemotaxis Inhibitory Protein of Staphylococcus aureus
1K0S	;		;	Solution structure of the chemotaxis protein CheW from the thermophilic organism Thermotoga maritima
1B8T	;		;	SOLUTION STRUCTURE OF THE CHICKEN CRP1
2YSZ	;		;	Solution structure of the chimera of the C-terminal PID domain of Fe65L and the C-terminal tail peptide of APP
2YT0	;		;	Solution structure of the chimera of the C-terminal tail peptide of APP and the C-terminal PID domain of Fe65L
2YT1	;		;	Solution structure of the chimera of the C-terminal tail peptide of APP and the C-terminal PID domain of Fe65L
2KUQ	;		;	Solution structure of the chimera of the PTB domain of SNT-2 and 19-residue peptide (aa 1571-1589) of HALK
2YT2	;		;	Solution structure of the chimera of the PTB domain of SNT-2 and 19-residue peptide (aa 1571-1589) of hALK
2LFR	;		;	Solution structure of the chimeric Af1503 HAMP- EnvZ DHp homodimer
2LFS	;		;	Solution structure of the chimeric Af1503 HAMP- EnvZ DHp homodimer; A219F variant
4BWH	;		;	Solution structure of the chimeric hydrophobin NChi2
1R4D	;		;	Solution structure of the chimeric L/D DNA oligonucleotide d(C8metGCGC(L)G(L)CGCG)2
7PRD	;		;	Solution structure of the chimeric Nrd1-Nab3 heterodimerization domains
7VH9	;		;	Solution structure of the chimeric peptide of the first SURP domain of Human SF3A1 and the interacting region of SF1.
1ED7	;		;	SOLUTION STRUCTURE OF THE CHITIN-BINDING DOMAIN OF BACILLUS CIRCULANS WL-12 CHITINASE A1
2RTT	;		;	Solution structure of the chitin-binding domain of Chi18aC from Streptomyces coelicolor
2CZN	;		;	Solution structure of the chitin-binding domain of hyperthermophilic chitinase from pyrococcus furiosus
2D49	;		;	Solution structure of the Chitin-Binding Domain of Streptomyces griseus Chitinase C
2MQH	;		;	Solution structure of the Chlamydomonas reinhardtii NAB1 cold shock domain, CSD1
7BGH	;		;	Solution structure of the chloroplast outer envelope channel OEP21
2YRT	;		;	Solution structure of the CHORD domain of human CHORD-containing protein 1
2D9U	;		;	Solution structure of the Chromo domain of chromobox homolog 2 from human
2EFI	;		;	Solution structure of the chromo domain of Mortality factor 4-like protein 1 from human
2RSN	;		;	Solution structure of the chromodomain of Chp1 in complex with H3K9me3 peptide
2RVN	;		;	Solution structure of the chromodomain of HP1a with the phosphorylated N-terminal tail complexed with H3K9me3 peptide
2RVL	;		;	Solution structure of the chromodomain of HP1alpha with the N-terminal tail
2RVM	;		;	Solution structure of the chromodomain of HP1alpha with the phosphorylated N-terminal tail
2RSO	;		;	Solution structure of the chromodomain of Swi6
6K5W	;		;	Solution structure of the chromodomain of yeast Eaf3
2M1B	;		;	Solution structure of the CHXR DNA-binding domain
2DKT	;		;	Solution structure of the CHY zinc finger domain of the RING finger and CHY zinc finger domain-containing protein 1 from Mus musculus
2EEL	;		;	Solution structure of the CIDE-N domain of human cell death activator CIDE-A
5MNW	;		;	Solution structure of the cinaciguat bound human beta1 H-NOX.
2MFP	;		;	Solution structure of the circular g-domain analog from the wheat metallothionein Ec-1
1W09	;		;	Solution structure of the cis form of the human alpha-hemoglobin stabilizing protein (AHSP)
1P4Q	;		;	Solution structure of the CITED2 transactivation domain in complex with the p300 CH1 domain
2LSH	;		;	Solution structure of the class I hydrophobin DewA
2FMC	;		;	Solution structure of the class I hydrophobin EAS
4AOG	;		;	Solution structure of the Class II hydrophobin NC2
2MID	;		;	Solution structure of the CLAVATA encoded peptide of Arabidopsis thaliana - AtCLE10
2MIE	;		;	Solution structure of the CLAVATA encoded peptide of Arabidopsis thaliana - AtCLE44
2MIF	;		;	Solution structure of the CLAVATA-like encoded peptide of Meloidogyne hapla - MhCLE4
2MIG	;		;	Solution structure of the CLAVATA-like encoded peptide of Meloidogyne hapla - MhCLE5
2MIH	;		;	Solution structure of the CLAVATA-like encoded peptide of Meloidogyne hapla - MhCLE6/7
2YH0	;		;	Solution structure of the closed conformation of human U2AF65 tandem RRM1 and RRM2 domains
1G6Z	;		;	SOLUTION STRUCTURE OF THE CLR4 CHROMO DOMAIN
1WGP	;		;	Solution structure of the cNMP-binding domain from Arabidopsis thaliana cyclic nucleotide-regulated ion channel
2D93	;		;	Solution structure of the cNMP_binding domain of human Rap guanine nucleotide exchange factor 6
1X67	;		;	Solution structure of the cofilin homology domain of HIP-55 (drebrin-like protein)
2L2L	;		;	Solution structure of the coiled-coil complex between MBD2 and p66alpha
1ZXA	;		;	Solution Structure of the Coiled-Coil Domain of cGMP-dependent Protein Kinase Ia
2KES	;		;	Solution Structure of the Coiled-coil Domain of Synphilin-1
1M7L	;		;	Solution Structure of the Coiled-Coil Trimerization Domain from Lung Surfactant Protein D
1M82	;		;	SOLUTION STRUCTURE OF THE COMPLEMENTARY RNA PROMOTER OF INFLUENZA A VIRUS
2GHF	;		;	Solution structure of the complete zinc-finger region of human zinc-fingers and homeoboxes 1 (ZHX1)
2MEJ	;		;	Solution Structure of the Complex Between BCL-xL and the p53 Core Domain determined with PRE restraints
5GOW	;		;	Solution structure of the complex between DP1 acidic region and TFIIH p62 PH domain
2JZB	;		;	Solution structure of the complex between E.coli NusA-AR2 and RNAP-aCTD
2RR3	;		;	Solution structure of the complex between human VAP-A MSP domain and human OSBP FFAT motif
5L85	;		;	Solution structure of the complex between human ZNHIT3 and NUFIP1 proteins
2ESG	;		;	Solution structure of the complex between immunoglobulin IgA1 and human serum albumin
2P80	;		;	Solution structure of the complex between nitrite reductase and pseudoazurin from A. faecalis
2RUK	;		;	Solution structure of the complex between p53 transactivation domain 2 and TFIIH p62 PH domain
7CSQ	;		;	Solution structure of the complex between p75NTR-DD and TRADD-DD
7QDW	;		;	Solution structure of the complex between plasmodial ZNHIT3 and NUFIP1 proteins
2FIN	;		;	Solution Structure of the complex between poxvirus-encoded CC chemokine inhibitor vCCI and human MIP-1beta, ensemble structure
2FFK	;		;	Solution structure of the complex between poxvirus-encoded CC chemokine inhibitor vCCI and human MIP-1beta, minimized average structure
7DTI	;		;	Solution structure of the complex between RNA polymerase subunit RPB6 and TFIIH p62 PH domain
2RNR	;		;	Solution structure of the complex between TFIIE alpha C-terminal acidic domain and TFIIH p62 PH domain
2RQU	;		;	Solution structure of the complex between the DDEF1 SH3 domain and the APC SAMP1 motif
2LXC	;		;	Solution structure of the complex between the Sgt2 homodimerization domain and the Get5 UBL domain
2MJF	;		;	Solution structure of the complex between the yeast Rsa1 and Hit1 proteins
5XV8	;		;	Solution structure of the complex between UVSSA acidic region and TFIIH p62 PH domain
2RVB	;		;	Solution structure of the complex between XPC acidic domain and TFIIH p62 PH domain
2GB8	;		;	Solution structure of the complex between yeast iso-1-cytochrome c and yeast cytochrome c peroxidase
1R4E	;		;	Solution structure of the Complex Formed between a Left-Handed Wedge-Shaped Spirocyclic Molecule and Bulged DNA
2MAP	;		;	Solution structure of the complex formed by the region 2 of E. coli sigmaE and its cognate -10 promoter element non template strand TGTCAAA.
1RKJ	;		;	Solution structure of the complex formed by the two N-terminal RNA-binding domains of nucleolin and a pre-rRNA target
1O9A	;		;	Solution structure of the complex of 1F12F1 from fibronectin with B3 from FnBB from S. dysgalactiae
2N82	;		;	solution structure of the complex of microRNA 20b pre-element with Rbfox RRM
6OQJ	;		;	SOLUTION STRUCTURE OF THE COMPLEX OF MUTANT VEK50[RH1/AA] AND PLASMINOGEN KRINGLE 2
6OQK	;		;	SOLUTION STRUCTURE OF THE COMPLEX OF MUTANT VEK50[RH2/AA] AND PLASMINOGEN KRINGLE 2
6IZP	;		;	Solution structure of the complex of naphthyridine carbamate dimer and an RNA with UGGAA-UGGAA pentad
2KUP	;		;	Solution structure of the complex of the PTB domain of SNT-2 and 19-residue peptide (aa 1571-1589) of HALK
2YS5	;		;	Solution structure of the complex of the PTB domain of SNT-2 and 19-residue peptide (aa 1571-1589) of hALK
5OEO	;		;	Solution structure of the complex of TRPV5(655-725) with a Calmodulin E32Q/E68Q double mutant
2L0T	;		;	Solution structure of the complex of ubiquitin and the VHS domain of Stam2
2JY6	;		;	Solution structure of the complex of ubiquitin and ubiquilin 1 UBA domain
2KJ4	;		;	Solution structure of the complex of VEK-30 and plasminogen kringle 2
5OAO	;		;	Solution structure of the complexed RCD1-RST
2KDD	;		;	Solution structure of the conserved C-terminal dimerization domain of Borealin
2A7Y	;		;	Solution Structure of the Conserved Hypothetical Protein Rv2302 from the Bacterium Mycobacterium tuberculosis
1WFR	;		;	Solution structure of the conserved hypothetical protein TT1886, possibly sterol carrier protein, from Thermus Thermophilus HB8
1Z8M	;		;	Solution structure of the conserved hypothtical protein HP0894 from Helicobacter pylori
1YEZ	;		;	Solution structure of the conserved protein from the gene locus MM1357 of Methanosarcina mazei. Northeast Structural Genomics target MaR30.
1YVC	;		;	Solution structure of the conserved protein from the gene locus MMP0076 of Methanococcus maripaludis. Northeast Structural Genomics target MrR5.
1DPQ	;		;	SOLUTION STRUCTURE OF THE CONSTITUTIVELY ACTIVE MUTANT OF THE INTEGRIN ALPHA IIB CYTOPLASMIC DOMAIN.
1Y3J	;		;	Solution structure of the copper(I) form of the fifth domain of Menkes protein
2GA7	;		;	Solution structure of the copper(I) form of the third metal-binding domain of ATP7A protein (menkes disease protein)
2M4H	;		;	Solution structure of the Core Domain (10-76) of the Feline Calicivirus VPg protein
2M4G	;		;	Solution structure of the Core Domain (11-85) of the Murine Norovirus VPg protein
1X5M	;		;	Solution structure of the core domain of calcyclin binding protein; siah-interacting protein (SIP)
6M6E	;		;	Solution structure of the core domain of Fibroblast growth factor 21 (FGF21)
2LEH	;		;	Solution structure of the core SMN-Gemin2 complex
7K7F	;		;	Solution Structure of the Corynebacterium diphtheriae SpaA Pilin-Signal Peptide Complex
107D	;		;	SOLUTION STRUCTURE OF THE COVALENT DUOCARMYCIN A-DNA DUPLEX COMPLEX
2MHI	;		;	Solution structure of the CR4/5 domain of medaka telomerase RNA
2QH2	;		;	Solution structure of the CR7 terminal hairpin loop from human telomerase RNA
6G8O	;		;	Solution structure of the cross-linked SAM domain dimer of murine SLy1
1WGV	;		;	Solution Structure of the CS Domain of Human KIAA1068 Protein
1WH0	;		;	Solution structure of the CS domain of human USP19
6K7W	;		;	Solution Structure of the CS1 Domain of USP19
6KHV	;		;	Solution Structure of the CS2 Domain of USP19
1KVJ	;		;	Solution Structure of the Cu(I) bound form of the first heavy metal binding motif of the Menkes protein
1YJT	;		;	Solution structure of the Cu(I) form of the sixth soluble domain A69P mutant of Menkes protein
1YJV	;		;	Solution structure of the Cu(I) form of the sixth soluble domain of Menkes protein
1FD8	;		;	SOLUTION STRUCTURE OF THE CU(I) FORM OF THE YEAST METALLOCHAPERONE, ATX1
2DI0	;		;	Solution Structure of the CUE Domain in the Human Activating Signal Cointegrator 1 Complex Subunit 2 (ASCC2)
2DHY	;		;	Solution Structure of the CUE Domain in the Human CUE Domain Containing Protein 1 (CUEDC1)
2JNG	;		;	Solution structure of the CUL7-CPH domain from Homo Sapiens; Northeast Structural Genomics Consortium target HT1.
1IUY	;		;	Solution structure of the cullin-3 homologue
1X2L	;		;	Solution structure of the CUT domain of human homeobox protein Cux-2 (Cut-like 2)
1RNG	;		;	SOLUTION STRUCTURE OF THE CUUG HAIRPIN: A NOVEL RNA TETRALOOP MOTIF
2E62	;		;	Solution structure of the cwf21 domain in protein AAK25922
1B2T	;		;	SOLUTION STRUCTURE OF THE CX3C CHEMOKINE DOMAIN OF FRACTALKINE
2N5U	;		;	Solution structure of the cyanobacterial cytochrome b6f complex subunit PetP
6UXS	;		;	Solution structure of the cyclic peptide 3.1B
6DNY	;		;	Solution structure of the cyclic tetrapeptide, PYPV
2MHF	;		;	Solution structure of the cyclic-nucleotide binding homology domain of a KCNH channel
2KNM	;		;	Solution structure of the cyclotide cycloviolacin O2
2KNN	;		;	Solution structure of the cyclotide cycloviolacin O2 with Glu6 methylated (cyO2Me)
2KUX	;		;	Solution structure of the cyclotide kalata B5 from Oldenlandia affinis
1R1F	;		;	Solution Structure of the Cyclotide Palicourein: Implications for the development of pharmaceutical and agricultural applications
7K7X	;		;	Solution structure of the cyclotide pase A
1YP8	;		;	Solution structure of the cyclotide tricyclon A
1KBE	;		;	Solution structure of the cysteine-rich C1 domain of Kinase Suppressor of Ras
1KBF	;		;	Solution Structure of the Cysteine-Rich C1 Domain of Kinase Suppressor of Ras
1EXK	;		;	SOLUTION STRUCTURE OF THE CYSTEINE-RICH DOMAIN OF THE ESCHERICHIA COLI CHAPERONE PROTEIN DNAJ.
2ORL	;		;	Solution structure of the cytochrome c- para-aminophenol adduct
1PLP	;		;	SOLUTION STRUCTURE OF THE CYTOPLASMIC DOMAIN OF PHOSPHOLAMBAN
1DPK	;		;	SOLUTION STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE INTEGRIN ALPHA-IIB SUBUNIT
1JO6	;		;	Solution structure of the cytoplasmic N-terminus of the BK beta-subunit KCNMB2
2E30	;		;	Solution structure of the cytoplasmic region of Na+/H+ exchanger 1 complexed with essential cofactor calcineurin B homologous protein 1
2L58	;		;	Solution structure of the cytosolic fragment 22-53 of Bcl-2 member Harakiri
1Z5F	;		;	Solution Structure of the Cytotoxic RC-RNase 3 with a Pyroglutamate Residue at the N-terminus
1DE3	;		;	SOLUTION STRUCTURE OF THE CYTOTOXIC RIBONUCLEASE ALPHA-SARCIN
179D	;		;	SOLUTION STRUCTURE OF THE D(T-C-G-A) DUPLEX AT ACIDIC PH: A PARALLEL-STRANDED HELIX CONTAINING C+.C, G.G AND A.A PAIRS
1WVZ	;		;	Solution Structure of the D2 Domain of the Fibroblast Growth Factor
5N6R	;		;	Solution structure of the Dbl-homology domain of Bcr-Abl
5UP1	;		;	Solution structure of the de novo mini protein EEHEE_rd3_1049
5UP5	;		;	Solution structure of the de novo mini protein EHEE_rd1_0284
5JI4	;		;	Solution structure of the de novo mini protein gEEHE_02
2ND3	;		;	Solution structure of the de novo mini protein gEEH_04
5JHI	;		;	Solution structure of the de novo mini protein gEHE_06
5W9F	;		;	Solution structure of the de novo mini protein gHEEE_02
2ND2	;		;	Solution structure of the de novo mini protein gHHH_06
5TX8	;		;	Solution structure of the de novo mini protein gHH_44
5UOI	;		;	Solution structure of the de novo mini protein HHH_rd1_0142
2CW1	;		;	Solution structure of the de novo-designed lambda Cro fold protein
1KQQ	;		;	Solution Structure of the Dead ringer ARID-DNA Complex
2JW6	;		;	Solution structure of the DEAF1 MYND domain
2DBF	;		;	Solution structure of the Death domain in human Nuclear factor NF-kappa-B p105 subunit
2YQF	;		;	Solution structure of the death domain of Ankyrin-1
1WH4	;		;	Solution structure of the DEATH domain of Interleukin-1 receptor-associated kinase4 (IRAK4) from Mus musculus
2D96	;		;	Solution structure of the Death domain of Nuclear factor NF-kappa-B p100
1WXP	;		;	Solution structure of the death domain of nuclear matrix protein p84
2N5F	;		;	Solution structure of the dehydroascorbate reductase 3A from Populus trichocarpa
1R4Y	;		;	SOLUTION STRUCTURE OF THE DELETION MUTANT DELTA(7-22) OF THE CYTOTOXIC RIBONUCLEASE ALPHA-SARCIN
2M4K	;		;	Solution structure of the delta subunit of RNA polymerase from Bacillus subtilis
2NC1	;		;	Solution structure of the delta-J-delta-K domain of EMCV IRES
1JUA	;		;	Solution Structure of the Deoxyribose HIV-1Lai Initiation Sequence Stable Dimer
2YSR	;		;	Solution structure of the DEP domain from human DEP domain-containing protein 1
2CSO	;		;	Solution structure of the DEP domain of human pleckstrin
1UHW	;		;	Solution structure of the DEP domain of mouse pleckstrin
1V3F	;		;	Solution structure of the DEP domain of mouse pleckstrin2
7R0R	;		;	Solution structure of the designed Armadillo repeat protein N(A4)M4C(AII) refined by pseudocontact shifts
1UD7	;		;	SOLUTION STRUCTURE OF THE DESIGNED HYDROPHOBIC CORE MUTANT OF UBIQUITIN, 1D7
2M8U	;		;	Solution structure of the Dictyostelium discodieum Myosin Light Chain, MlcC
2LBH	;		;	Solution Structure of the Dimeric Form of a Unliganded Bovine Neurophysin, Minimized Average Structure
2LBF	;		;	Solution structure of the dimerization domain of human ribosomal protein P1/P2 heterodimer
5YI4	;		;	Solution Structure of the DISC1/Ndel1 complex
2Z4F	;		;	Solution structure of the Discoidin Domain of DDR2
1PE3	;		;	Solution structure of the disulphide-linked dimer of human intestinal trefoil factor (TFF3)
2MYG	;		;	Solution structure of the dithiolic glutaredoxin 2-C-Grx1 from the pathogen Trypanosoma brucei brucei
1LAE	;		;	Solution Structure of the DNA 13-mer Hairpin CGCGGTXTCCGCG (X=PdG) Containing the 1,N2-propanodeoxyguanosine Adduct at the Seventh Position
1DB6	;		;	SOLUTION STRUCTURE OF THE DNA APTAMER 5'-CGACCAACGTGTCGCCTGGTCG-3' COMPLEXED WITH ARGININAMIDE
2K6G	;		;	Solution structure of the DNA binding BRCT domain from the large subunit of human Replication Factor C
2JR1	;		;	Solution structure of the DNA binding domain of a nucleoid-associated protein, H-NS, from the phytopathogen Xylella fastidiosa.
1IHW	;		;	SOLUTION STRUCTURE OF THE DNA BINDING DOMAIN OF HIV-1 INTEGRASE, NMR, 40 STRUCTURES
1IHV	;		;	SOLUTION STRUCTURE OF THE DNA BINDING DOMAIN OF HIV-1 INTEGRASE, NMR, MINIMIZED AVERAGE STRUCTURE
1ITY	;		;	Solution structure of the DNA binding domain of human TRF1
2JXG	;		;	Solution Structure of the DNA Binding domain of Proline Utilization A (PutA)
1E17	;		;	Solution structure of the DNA binding domain of the human Forkhead transcription factor AFX (FOXO4)
1P6R	;		;	Solution structure of the DNA binding domain of the repressor BlaI.
1DP3	;		;	SOLUTION STRUCTURE OF THE DNA BINDING DOMAIN OF THE TRAM PROTEIN
1I11	;		;	SOLUTION STRUCTURE OF THE DNA BINDING DOMAIN, SOX-5 HMG BOX FROM MOUSE
1IV6	;		;	Solution Structure of the DNA Complex of Human TRF1
1VFC	;		;	Solution Structure Of The DNA Complex Of Human Trf2
2Z33	;		;	Solution structure of the DNA complex of PhoB DNA-binding/transactivation Domain
5ZUX	;		;	Solution Structure of the DNA complex of the C-terminal Domain of Rok
1SNH	;		;	Solution structure of the DNA Decamer Duplex Containing Double TG Mismatches of Cis-syn Cyclobutane Pyrimidine Dimer
1RVI	;		;	SOLUTION STRUCTURE OF THE DNA DODECAMER CGTTTTAAAACG
1RVH	;		;	SOLUTION STRUCTURE OF THE DNA DODECAMER GCAAAATTTTGC
2BQ2	;		;	Solution Structure of the DNA Duplex ACGCGU-NA with a 2' Amido-Linked Nalidixic Acid Residue at the 3' Terminal Nucleotide
1IEY	;		;	SOLUTION STRUCTURE OF THE DNA DUPLEX D(CCACCGGAAC).(GTTCCGGTGG) WITH A CHIRAL ALKYL-PHOSPHONATE MOIETY (DIAESTEREOISOMER R)
1IEK	;		;	SOLUTION STRUCTURE OF THE DNA DUPLEX D(CCACCGGAAC).(GTTCCGGTGG) WITH A CHIRAL ALKYL-PHOSPHONATE MOIETY (DIAESTEREOISOMER S)
1X6W	;		;	Solution Structure of the DNA Duplex TGCGCA:TGCGCA Capped by Trimethoxystilbene Residues
1LA8	;		;	Solution structure of the DNA hairpin 13-mer CGCGGTGTCCGCG
1ADN	;		;	SOLUTION STRUCTURE OF THE DNA METHYLPHOSPHOTRIESTER REPAIR DOMAIN OF ESCHERICHIA COLI ADA
1SNJ	;		;	Solution structure of the DNA three-way junction with the A/C-stacked conformation
1XPA	;		;	SOLUTION STRUCTURE OF THE DNA-AND RPA-BINDING DOMAIN OF THE HUMAN REPAIR FACTOR XPA, NMR, 1 STRUCTURE
1QQI	;		;	SOLUTION STRUCTURE OF THE DNA-BINDING AND TRANSACTIVATION DOMAIN OF PHOB FROM ESCHERICHIA COLI
1C20	;		;	SOLUTION STRUCTURE OF THE DNA-BINDING DOMAIN FROM THE DEAD RINGER PROTEIN
1KKX	;		;	Solution structure of the DNA-binding domain of ADR6
1HKS	;		;	SOLUTION STRUCTURE OF THE DNA-BINDING DOMAIN OF DROSOPHILA HEAT SHOCK TRANSCRIPTION FACTOR
1HKT	;		;	SOLUTION STRUCTURE OF THE DNA-BINDING DOMAIN OF DROSOPHILA HEAT SHOCK TRANSCRIPTION FACTOR
1WIJ	;		;	Solution Structure of the DNA-Binding Domain of Ethylene-Insensitive3-Like3
1JXS	;		;	Solution Structure of the DNA-Binding Domain of Interleukin Enhancer Binding Factor
1K1V	;		;	Solution Structure of the DNA-Binding Domain of MafG
1NTC	;		;	SOLUTION STRUCTURE OF THE DNA-BINDING DOMAIN OF NTRC WITH THREE ALANINE SUBSTITUTIONS
2JXI	;		;	Solution structure of the DNA-binding domain of Pseudomonas putida Proline utilization A (putA) bound to GTTGCA DNA sequence
5ZUZ	;		;	Solution Structure of the DNA-Binding Domain of Rok
1WJ0	;		;	Solution Structure of the DNA-Binding Domain of Squamosa Promoter Binding Protein-Like 12 Lacking the Second Zinc-Binding Site
1UL4	;		;	Solution structure of the DNA-binding domain of squamosa promoter binding protein-like 4
1UL5	;		;	Solution structure of the DNA-binding domain of squamosa promoter binding protein-like 7
1P4W	;		;	Solution structure of the DNA-binding domain of the Erwinia amylovora RcsB protein
1G2H	;		;	SOLUTION STRUCTURE OF THE DNA-BINDING DOMAIN OF THE TYRR PROTEIN OF HAEMOPHILUS INFLUENZAE
7QYI	;		;	Solution structure of the DNA-binding minor pilin FimT from Legionella pneumophila
6TEY	;		;	Solution Structure of the DNA-binding TubR fragment from Clostridium Botulinum
1X95	;		;	Solution structure of the DNA-hexamer ATGCAT complexed with DNA Bis-intercalating Anticancer Drug XR5944 (MLN944)
2YUA	;		;	Solution structure of the DnaJ domain from human Williams-Beuren syndrome chromosome region 18 protein
2EJ7	;		;	Solution structure of the DnaJ domain of the human protein HCG3, a hypothetical protein tmp_locus_21
2YS8	;		;	Solution structure of the DnaJ-like domain from human ras-associated protein Rap1
2EZ5	;		;	Solution Structure of the dNedd4 WW3* Domain- Comm LPSY Peptide Complex
1L6E	;		;	Solution structure of the docking and dimerization domain of protein kinase A II-alpha (RIIalpha D/D). Alternatively called the N-terminal dimerization domain of the regulatory subunit of protein kinase A.
2EZW	;		;	Solution structure of the docking and dimerization domain of the type I alpha regulatory subunit of protein kinase A (RIalpha D/D)
1PJW	;		;	Solution Structure of the Domain III of the Japan Encephalitis Virus Envelope Protein
2YU3	;		;	Solution structure of the domain swapped WingedHelix in DNA-directed RNA polymerase III 39 kDa polypeptide
2K9D	;		;	Solution structure of the domain X of measle phosphoprotein
2KWN	;		;	Solution structure of the double PHD (plant homeodomain) fingers of human transcriptional protein DPF3b bound to a histone H4 peptide containing acetylation at Lysine 16
2KWO	;		;	Solution structure of the double PHD (plant homeodomain) fingers of human transcriptional protein DPF3b bound to a histone H4 peptide containing N-terminal acetylation at Serine 1
2DB2	;		;	Solution structure of the double-stranded RNA binding domain in KIAA0890 protein
1R4K	;		;	Solution Structure of the Drosophila Argonaute 1 PAZ Domain
1WHN	;		;	Solution structure of the dsRBD from hypothetical protein BAB26260
2DIX	;		;	Solution structure of the DSRM domain of Protein activator of the interferon-induced protein kinase
1WWY	;		;	Solution structure of the DUF1000 domain of a thioredoxin-like protein 1
2GE2	;		;	Solution structure of the Duplex DNA Containing the 3-(Deoxyguanosin-N2-yl)-2-Acetoaminofluorene
1W6V	;		;	Solution structure of the DUSP domain of hUSP15
7KRB	;		;	Solution Structure of the Dysferlin C2A Domain in its Calcium-bound State
7K6B	;		;	Solution Structure of the Dysferlin C2A Domain in its Calcium-free State
1Q75	;		;	Solution structure of the dyskeratosis congenita mutant P2b hairpin from human telomerase RNA
2KRW	;		;	Solution structure of the E coli tRNA-Arg1 (ACG) containing the 2-thiocytidine modification in position 32
1SE7	;		;	Solution structure of the E. coli bacteriophage P1 encoded HOT protein: a homologue of the theta subunit of E. coli DNA polymerase III
2RRK	;		;	Solution structure of the E. coli ORF135 protein
2L8Y	;		;	Solution structure of the E. coli outer membrane protein RcsF (periplasmatic domain)
2RQL	;		;	Solution structure of the E. coli ribosome hibernation promoting factor HPF
2JSX	;		;	Solution structure of the E. coli Tat proofreading chaperone protein NapD
2MI2	;		;	Solution structure of the E. coli TatB protein in DPC micelles
2KRV	;		;	Solution structure of the E. coli tRNA-Arg1 (ICG) ASL containing the 2-thiocytidine modification
2KRP	;		;	Solution structure of the E. coli tRNA-Arg2(acg) anticodon stem and loop
2AYY	;		;	Solution structure of the E.coli RcsC C-terminus (residues 700-816) containing linker region
2AYX	;		;	Solution structure of the E.coli RcsC C-terminus (residues 700-949) containing linker region and phosphoreceiver domain
2AYZ	;		;	Solution structure of the E.coli RcsC C-terminus (residues 817-949) containing phosphoreceiver domain
2KX7	;		;	Solution structure of the E.coli RcsD-ABL domain (residues 688-795)
2COO	;		;	Solution structure of the e3_binding domain of dihydrolipoamide branched chaintransacylase
2MKF	;		;	Solution structure of the E81 deletion mutant of the tandem UIMs of RAP80
2L1M	;		;	Solution structure of the eag domain of the hERG (Kv11.1) K+ channel
2N2J	;		;	Solution structure of the EBNA-2 N-terminal Dimerization (END) domain from the Epstein-barr virus
2JVY	;		;	Solution Structure of the EDA-ID-related C417F mutant of human NEMO zinc finger
1HYJ	;		;	SOLUTION STRUCTURE OF THE EEA1 FYVE DOMAIN
1HYI	;		;	SOLUTION STRUCTURE OF THE EEA1 FYVE DOMAIN COMPLEXED WITH INOSITOL 1,3-BISPHOSPHATE
2Y4Q	;		;	Solution structure of the EF-hand domain of Human Polycystin 2
2RNL	;		;	Solution structure of the EGF-like domain from human Amphiregulin
2E9H	;		;	Solution structure of the eIF-5_eIF-2B domain from human Eukaryotic translation initiation factor 5
2CQV	;		;	Solution structure of the eighth Ig-like domain of human myosin light chain kinase
2DM8	;		;	Solution structure of the eighth PDZ domain of human InaD-like protein
2E5N	;		;	Solution structure of the ELL_N2 domain of target of RNA polymerase II elongation factor ELL2
1EGX	;		;	SOLUTION STRUCTURE OF THE ENA-VASP HOMOLOGY 1 (EVH1) DOMAIN OF HUMAN VASODILATOR-STIMULATED PHOSPHOPROTEIN (VASP)
2LCQ	;		;	Solution structure of the endonuclease Nob1 from P.horikoshii
1RXL	;		;	Solution structure of the engineered protein Afae-dsc
2XDF	;		;	Solution Structure of the Enzyme I Dimer Complexed with HPr Using Residual Dipolar Couplings and Small Angle X-Ray Scattering
2KX9	;		;	Solution Structure of the Enzyme I dimer Using Residual Dipolar Couplings and Small Angle X-Ray Scattering
1HRE	;		;	SOLUTION STRUCTURE OF THE EPIDERMAL GROWTH FACTOR-LIKE DOMAIN OF HEREGULIN-ALPHA, A LIGAND FOR P180ERB4
1HRF	;		;	SOLUTION STRUCTURE OF THE EPIDERMAL GROWTH FACTOR-LIKE DOMAIN OF HEREGULIN-ALPHA, A LIGAND FOR P180ERB4
1IQ3	;		;	SOLUTION STRUCTURE OF THE EPS15 HOMOLOGY DOMAIN OF A HUMAN POB1
2RQ7	;		;	Solution structure of the epsilon subunit chimera combining the N-terminal beta-sandwich domain from T. Elongatus bp-1 f1 and the C-terminal alpha-helical domain from spinach chloroplast F1
2RQ6	;		;	Solution structure of the epsilon subunit of the F1-atpase from thermosynechococcus elongatus BP-1
1BSH	;		;	SOLUTION STRUCTURE OF THE EPSILON SUBUNIT OF THE F1-ATPSYNTHASE FROM ESCHERICHIA COLI AND ORIENTATION OF THE SUBUNIT RELATIVE TO THE BETA SUBUNITS OF THE COMPLEX
1BSN	;		;	SOLUTION STRUCTURE OF THE EPSILON SUBUNIT OF THE F1-ATPSYNTHASE FROM ESCHERICHIA COLI AND ORIENTATION OF THE SUBUNIT RELATIVE TO THE BETA SUBUNITS OF THE COMPLEX
1INZ	;		;	SOLUTION STRUCTURE OF THE EPSIN N-TERMINAL HOMOLOGY (ENTH) DOMAIN OF HUMAN EPSIN
2K84	;		;	Solution Structure of the equine infectious anemia virus p9 GAG protein
2JPD	;		;	Solution structure of the ERCC1 central domain
2EV8	;		;	Solution structure of the erythroid p55 PDZ domain
2M6K	;		;	Solution structure of the Escherichia coli apo ferric enterobactin binding protein
2M6L	;		;	Solution structure of the Escherichia coli holo ferric enterobactin binding protein
1S62	;		;	Solution structure of the Escherichia coli TolA C-terminal domain
1SR2	;		;	Solution structure of the Escherichia coli YojN Histidine-Phosphotransferase (HPt) domain
1EF4	;		;	SOLUTION STRUCTURE OF THE ESSENTIAL RNA POLYMERASE SUBUNIT RPB10 FROM METHANOBACTERIUM THERMOAUTOTROPHICUM
2LDC	;		;	Solution structure of the estrogen receptor-binding stapled peptide SP1 (Ac-HXILHXLLQDS-NH2)
2LDA	;		;	Solution structure of the estrogen receptor-binding stapled peptide SP2 (Ac-HKXLHQXLQDS-NH2)
2LDD	;		;	Solution structure of the estrogen receptor-binding stapled peptide SP6 (Ac-EKHKILXRLLXDS-NH2)
2H7B	;		;	Solution structure of the eTAFH domain from the human leukemia-associated fusion protein AML1-ETO
1WWX	;		;	Solution structure of the ETS-domain of the Ets domain transcription factor
2DGY	;		;	Solution structure of the eukaryotic initiation factor 1A in MGC11102 protein
1KD6	;		;	Solution structure of the eukaryotic pore-forming cytolysin equinatoxin II
1B8Q	;		;	SOLUTION STRUCTURE OF THE EXTENDED NEURONAL NITRIC OXIDE SYNTHASE PDZ DOMAIN COMPLEXED WITH AN ASSOCIATED PEPTIDE
1XHP	;		;	Solution Structure of the Extended U6 ISL as Observed in the U2/U6 complex from Saccharomyces cerevisiae
1OSX	;		;	Solution Structure of the Extracellular Domain of BLyS Receptor 3 (BR3)
2KJX	;		;	Solution structure of the extracellular domain of JTB
2JVE	;		;	Solution structure of the extracellular domain of Prod1, a protein implicated in proximodistal identity during amphibian limb regeneration
2L5S	;		;	Solution structure of the extracellular domain of the TGF-beta type I receptor
1ZLG	;		;	Solution structure of the extracellular matrix protein anosmin-1
2MJ6	;		;	Solution structure of the extracellular sensor domain of DraK histidine kinase
6CUI	;		;	Solution structure of the Extraterminal (ET) Domain of BRD2
1ZZP	;		;	Solution structure of the F-actin binding domain of Bcr-Abl/c-Abl
2JT8	;		;	Solution structure of the F153-to-5-flurotryptophan mutant of human cardiac troponin C
2MUT	;		;	Solution structure of the F231L mutant ERCC1-XPF dimerization region
2NBO	;		;	Solution structure of the F87M/L110M variant of transthyretin in the monomeric state
2KC0	;		;	Solution structure of the factor H binding protein
5X39	;		;	Solution structure of the Family 1 carbohydrate-binding module Q2A mutant with mannosylated Ser3
5X38	;		;	Solution structure of the Family 1 carbohydrate-binding module with glucosylated Ser3
5X37	;		;	Solution structure of the Family 1 carbohydrate-binding module with mannosylated Ser14
5X36	;		;	Solution structure of the Family 1 carbohydrate-binding module with mannosylated Ser3
5X35	;		;	Solution structure of the Family 1 carbohydrate-binding module with mannosylated Thr1
5X3C	;		;	Solution structure of the Family 1 carbohydrate-binding module Y5A mutant with mannosylated Ser3
5X34	;		;	Solution structure of the Family 1 carbohydrate-binding module, unglycosylated form
1X3B	;		;	Solution structure of the FAS1 domain of human transforming growth factor-beta induced protein IG-H3
1QVX	;		;	SOLUTION STRUCTURE OF THE FAT DOMAIN OF FOCAL ADHESION KINASE
2W0T	;		;	Solution structure of the FCS zinc finger domain of human LMBL2
2KIQ	;		;	Solution structure of the FF Domain 2 of human transcription elongation factor CA150
2CQN	;		;	Solution structure of the FF domain of human Formin-binding protein 3
2EH0	;		;	Solution structure of the FHA domain from human Kinesin-like protein KIF1B
1UHT	;		;	Solution Structure of The FHA Domain of Arabidopsis thaliana Hypothetical Protein
2CSW	;		;	Solution structure of the FHA domain of human ubiquitin ligase protein RNF8
1WLN	;		;	Solution structure of the FHA domain of mouse Afadin 6
2N84	;		;	Solution structure of the FHA domain of TbPar42
1J4L	;		;	SOLUTION STRUCTURE OF THE FHA2 DOMAIN OF RAD53 COMPLEXED WITH A PHOSPHOTHREONYL PEPTIDE DERIVED FROM RAD9
1K2N	;		;	Solution Structure of the FHA2 domain of Rad53 Complexed with a Phosphothreonyl Peptide Derived from Rad9
1FHR	;		;	SOLUTION STRUCTURE OF THE FHA2 DOMAIN OF RAD53 COMPLEXED WITH A PHOSPHOTYROSYL PEPTIDE
1J4K	;		;	SOLUTION STRUCTURE OF THE FHA2 DOMAIN OF RAD53 COMPLEXED WITH A PHOSPHOTYROSYL PEPTIDE DERIVED FROM RAD9
1K2M	;		;	Solution Structure of the FHA2 Domain of Rad53 Complexed with a Phosphotyrosyl Peptide Derived from Rad9
1TPM	;		;	SOLUTION STRUCTURE OF THE FIBRIN BINDING FINGER DOMAIN OF TISSUE-TYPE PLASMINOGEN ACTIVATOR DETERMINED BY 1H NUCLEAR MAGNETIC RESONANCE
1TPN	;		;	SOLUTION STRUCTURE OF THE FIBRIN BINDING FINGER DOMAIN OF TISSUE-TYPE PLASMINOGEN ACTIVATOR DETERMINED BY 1H NUCLEAR MAGNETIC RESONANCE
1K85	;		;	Solution structure of the fibronectin type III domain from Bacillus circulans WL-12 Chitinase A1.
2YRZ	;		;	Solution structure of the fibronectin type III domain of human Integrin beta-4
1X5X	;		;	Solution structure of the fibronectin type-III domain of human fibronectin type III domain containing protein 3
1X3D	;		;	Solution structure of the fibronectin type-III domain of human fibronectin type-III domain containing protein 3a
2DOC	;		;	Solution structure of the Fibronectin type-III domain of human Neural cell adhesion molecule 2
1X5Z	;		;	Solution structure of the fibronectin type-III domain of human protein tyrosine phosphatase, receptor type, D isoform 4 variant
1X5Y	;		;	Solution structure of the fibronectin type-III domain of mouse myosin-binding protein C, Fast-type homolog
2YQD	;		;	Solution structure of the fifth bromodomain from mouse polybromo-1
2YTV	;		;	Solution structure of the fifth cold-shock domain of the human KIAA0885 protein (unr protein)
2DAD	;		;	Solution structure of the fifth crystall domain of the non-lens protein, Absent in melanoma 1
2EDD	;		;	Solution structure of the fifth fibronectin type III domain of human Netrin receptor DCC
2RPR	;		;	Solution structure of the fifth FLYWCH domain of FLYWCH-type zinc finger-containing protein 1
1WIS	;		;	Solution structure of the fifth FNIII domain from human KIAA1514 protein
2CRZ	;		;	Solution structure of the fifth FNIII domain of human fibronectin type III domain containing protein 3a
2EO9	;		;	Solution structure of the fifth ig-like domain from human Roundabout homo1
2EDJ	;		;	Solution structure of the fifth ig-like domain from human Roundabout homolog 2
2CRY	;		;	Solution structure of the fifth ig-like domain of human kin of IRRE like 3
2E70	;		;	Solution structure of the fifth KOW motif of human transcription elongation factor SPT5
1WFV	;		;	Solution structure of the fifth PDZ domain of human membrane associated guanylate kinase inverted-2 (KIAA0705 protein)
2D92	;		;	Solution structure of the fifth PDZ domain of InaD-like protein
2EGC	;		;	Solution structure of the fifth SH3 domain from human KIAA0418 protein
2DI7	;		;	Solution structure of the filamin domain from human BK158_1 protein
2DS4	;		;	Solution structure of the filamin domain from human tripartite motif protein 45
3ZPD	;		;	Solution structure of the FimH adhesin carbohydrate-binding domain
2EQG	;		;	Solution structure of the first A20-type zinc finger domain from human tumor necrosis factor, alpha-induced protein3
2COT	;		;	Solution structure of the first and second zf-C2H2 domain of Zinc finger protein 435
2EPA	;		;	Solution structure of the first and second zf-C2H2 domains from human Krueppel-like factor 10
2DLK	;		;	Solution structure of the first and the second zf-C2H2 domains of zinc finger protein 692
2DMI	;		;	Solution structure of the first and the second zf-C2H2 like domains of human Teashirt homolog 3
2D8M	;		;	Solution structure of the first BRCT domain of DNA-repair protein XRCC1
2E2W	;		;	Solution structure of the first BRCT domain of human DNA ligase IV
2DL6	;		;	Solution structure of the first BRK domain from human chromodomain-helicase-DNA-binding protein 8
2ENN	;		;	Solution structure of the first C1 domain from human protein kinase C theta
2ENP	;		;	Solution structure of the first C2 domain from human B/K protein
2YRB	;		;	Solution structure of the first C2 domain from human KIAA1005 protein
2DMH	;		;	Solution structure of the first C2 domain of human myoferlin
1V27	;		;	Solution structure of the first C2 domain of RIM2
1UGK	;		;	Solution structure of the first C2 domain of synaptotagmin IV from human fetal brain (KIAA1342)
2D8K	;		;	Solution structure of the first C2 domain of synaptotagmin VII
2EPP	;		;	Solution structure of the first C2H2 type zinc finger domain of Zinc finger protein 278
2EPT	;		;	Solution structure of the first C2H2 type zinc finger domain of Zinc finger protein 32
2YQG	;		;	Solution structure of the first cadherin domain from human Desmoglein-2
2DY7	;		;	Solution structure of the first chromodomain of yeast Chd1
2IKD	;		;	Solution Structure of the first Clip domain in PAP2
1WFQ	;		;	Solution structure of the first cold-shock domain of the human KIAA0885 protein (UNR protein)
1WIZ	;		;	Solution structure of the first CUT domain of KIAA1034 protein
1X49	;		;	Solution structure of the first DSRM domain in Interferon-induced, double-stranded RNA-activated protein kinase
2DOD	;		;	Solution structure of the first FF domain of human transcription factor CA150
1UEY	;		;	Solution Structure of The First Fibronectin Type III Domain of Human KIAA0343 protein
1UEM	;		;	Solution Structure of the First Fibronectin Type III domain of human KIAA1568 Protein
2ED7	;		;	Solution structure of the first fibronectin type III domain of human Netrin receptor DCC
1WF5	;		;	Solution structure of the first Fn3 domain of Sidekick-2 protein
1K99	;		;	Solution Structure of the first HMG box in human Upstream binding factor
2EQZ	;		;	Solution structure of the first HMG-box domain from high mobility group protein B3
2DA1	;		;	Solution structure of the first homeobox domain of AT-binding transcription factor 1 (ATBF1)
2DM2	;		;	Solution structure of the first ig domain of human palladin
2EDO	;		;	Solution structure of the first ig-like domain from human CD48 antigen
2EDN	;		;	Solution structure of the first ig-like domain from human Myosin-binding protein C, fast-type
2DKS	;		;	Solution structure of the first IG-like domain of human carcinoembryonic antigen related cell adhesion molecule 8
2CR3	;		;	Solution structure of the first Ig-like domain of human fibroblast growth factor receptor 1
2DAV	;		;	Solution structure of the first ig-like domain of Myosin-binding protein C, slow-type
2D9C	;		;	Solution structure of the first ig-like domain of signal-regulatory protein beta-1 (SIRP-beta-1)
2EHE	;		;	Solution structure of the first LIM domain from human four and a half LIM domains protein 3
1X61	;		;	Solution structure of the first LIM domain of thyroid receptor interacting protein 6 (TRIP6)
1WJS	;		;	Solution structure of the first mbt domain from human KIAA1798 protein
1UGO	;		;	Solution structure of the first Murine BAG domain of Bcl2-associated athanogene 5
2H3K	;		;	Solution Structure of the first NEAT domain of IsdH
2CR7	;		;	Solution structure of the first PAH domain of the mouse transcriptional repressor SIN3B
1X45	;		;	Solution structure of the first PDZ domain of amyloid beta A4 precursor protein-binding family A, member 1
1UEQ	;		;	Solution Structure of The First PDZ domain of Human Atrophin-1 Interacting Protein 1 (KIAA0705 protein)
1UEZ	;		;	Solution structure of the first PDZ domain of human KIAA1526 protein
2DB5	;		;	Solution structure of the first PDZ domain of InaD-like protein
1X5Q	;		;	Solution structure of the first PDZ domain of scribble homolog protein (hScrib)
2YUU	;		;	Solution structure of the first Phorbol esters/diacylglycerol binding domain of human Protein kinase C, delta
7FBR	;		;	Solution structure of The first RNA binding domain of Matrin-3
1D8Z	;		;	SOLUTION STRUCTURE OF THE FIRST RNA-BINDING DOMAIN (RBD1) OF HU ANTIGEN C (HUC)
1U2F	;		;	SOLUTION STRUCTURE OF THE FIRST RNA-BINDING DOMAIN OF HU2AF65
1WG5	;		;	Solution structure of the first RRM domain in heterogeneous nuclear ribonucleoprotein H
5GVQ	;		;	Solution structure of the first RRM domain of human spliceosomal protein SF3b49
2LMR	;		;	Solution structure of the first sam domain of odin
2EQR	;		;	Solution structure of the first SANT domain from human nuclear receptor corepressor 1
2EGA	;		;	Solution structure of the first SH3 domain from human KIAA0418 protein
1UFF	;		;	Solution structure of the first SH3 domain of human intersectin2 (KIAA1256)
2DL5	;		;	Solution structure of the first SH3 domain of human KIAA0769 protein
2DL3	;		;	Solution structure of the first SH3 domain of human sorbin and Sh3 domain-containing protein 1
2DLM	;		;	Solution structure of the first SH3 domain of human vinexin
2NWM	;		;	Solution structure of the first SH3 domain of human Vinexin and its interaction with the peptides from Vinculin
1WIE	;		;	Solution structure of the first SH3 domain of KIAA0318 protein
2DL4	;		;	Solution structure of the first SH3 domain of Stac protein
2B86	;		;	Solution structure of the first Src homology 3 domain of Nck2
5WQ1	;		;	Solution Structure of the first stem-loop of Escherichia coli DsrA RNA
2DT6	;		;	Solution structure of the first SURP domain of human splicing factor SF3a120
2KXF	;		;	Solution structure of the first two RRM domains of FBP-interacting repressor (FIR)
2KXH	;		;	Solution structure of the first two RRM domains of FIR in the complex with FBP Nbox peptide
1OWW	;		;	Solution structure of the first type III module of human fibronectin determined by 1H, 15N NMR spectroscopy
2DAI	;		;	Solution Structure of the First UBA Domain in the Human Ubiquitin Associated Domain Containing 1 (UBADC1)
2DAG	;		;	Solution Structure of the First UBA Domain in the Human Ubiquitin Specific Protease 5 (Isopeptidase 5)
2YSD	;		;	Solution structure of the first WW domain from the human membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1. MAGI-1
2YSB	;		;	Solution structure of the first WW domain from the mouse salvador homolog 1 protein (SAV1)
2YSI	;		;	Solution structure of the first WW domain from the mouse transcription elongation regulator 1, transcription factor CA150
1ZR7	;		;	Solution structure of the first WW domain of FBP11
2DYF	;		;	Solution structure of the first WW domain of FBP11 / HYPA (FBP11 WW1) complexed with a PL (PPLP) motif peptide ligand
1WR3	;		;	Solution structure of the first WW domain of Nedd4-2
1WYS	;		;	Solution structure of the first zf-AN1 domain of mouse RIKEN cDNA 2310008M20 protein
2DMJ	;		;	Solution structure of the first zf-PARP domain of human Poly(ADP-ribose)polymerase-1
1FV5	;		;	SOLUTION STRUCTURE OF THE FIRST ZINC FINGER FROM THE DROSOPHILA U-SHAPED TRANSCRIPTION FACTOR
1N0Z	;		;	Solution structure of the first zinc-finger domain from ZNF265
1V9X	;		;	Solution structure of the first Zn-finger domain of poly(ADP-ribose) polymerase-1
2F2D	;		;	Solution structure of the FK506-binding domain of human FKBP38
2UZ5	;		;	Solution structure of the fkbp-domain of Legionella pneumophila Mip
2VCD	;		;	Solution structure of the FKBP-domain of Legionella pneumophila Mip in complex with rapamycin
1YKG	;		;	Solution structure of the flavodoxin-like domain from the Escherichia coli sulfite reductase
7AVA	;		;	Solution structure of the fluorogen-activating protein FAST in complex with the ligand N871b
7AVB	;		;	Solution structure of the fluorogen-activating protein FAST in the apo state
1D1N	;		;	SOLUTION STRUCTURE OF THE FMET-TRNAFMET BINDING DOMAIN OF BECILLUS STEAROTHERMOPHILLUS TRANSLATION INITIATION FACTOR IF2
2CSP	;		;	Solution structure of the FNIII domain of human RIM-binding protein 2
1R5E	;		;	Solution structure of the folded core of Pseudomonas syringae effector protein, AvrPto
2K2Y	;		;	Solution structure of the folded domain of intermediate IIIa of Tick Carboxypeptidase Inhibitor
2K2Z	;		;	Solution structure of the folded domain of intermediate IIIb of Tick Carboxypeptidase Inhibitor
2MBF	;		;	Solution structure of the forkhead domain of Brugia malayi DAF-16a
1D5V	;		;	SOLUTION STRUCTURE OF THE FORKHEAD DOMAIN OF THE ADIPOCYTE-TRANSCRIPTION FACTOR FREAC-11 (S12)
2D9H	;		;	Solution structure of the forth and fifth zf-C2H2 domains of zinc finger protein 692
1WJO	;		;	Solution structure of the forth CH domain from human plastin 3 T-isoform
2CRM	;		;	Solution structure of the forth FNIII domain of human
1UEW	;		;	Solution Structure of The forth PDZ Domain of Human Atrophin-1 Interacting Protein 1 (KIAA0705 Protein)
6CGH	;		;	Solution structure of the four-helix bundle region of human J-protein Zuotin, a component of ribosome-associated complex (RAC)
2EQE	;		;	Solution structure of the fourth A20-type zinc finger domain from human tumor necrosis factor, alpha-induced protein3
2D85	;		;	Solution structure of the fourth CH domain from human L-plastin
2YTY	;		;	Solution structure of the fourth cold-shock domain of the human KIAA0885 protein (UNR protein)
2MKL	;		;	Solution structure of the fourth constant immunoglobulin domain of nurse shark IgNAR
2DOF	;		;	Solution structure of the fourth FF domain of human transcription factor CA150
2EDB	;		;	Solution structure of the fourth fibronectin type III domain of human Netrin receptor DCC
2DLE	;		;	Solution structure of the fourth fn3 domain of human receptor-type tyrosine-protein phosphatase eta
1WJ3	;		;	Solution structure of the fourth fn3 domain of KIAA1496 protein
2YR3	;		;	Solution structure of the fourth Ig-like domain from myosin light chain kinase, smooth muscle
2HH2	;		;	Solution structure of the fourth KH domain of KSRP
2EGQ	;		;	Solution structure of the fourth LIM domain from human four and a half LIM domains 1
1X5R	;		;	Solution structure of the fourth PDZ domain of Glutamate receptor interacting protein 2
1UJU	;		;	Solution structure of the fourth PDZ domain of human scribble (KIAA0147 protein)
1WH1	;		;	Solution structure of the fourth PDZ domain of KIAA1095 protein
1UE9	;		;	Solution structure of the fourth SH3 domain of human intersectin 2 (KIAA1256)
2YSF	;		;	Solution structure of the fourth WW domain from the human E3 ubiquitin-protein ligase Itchy homolog, ITCH
6RSS	;		;	Solution structure of the fourth WW domain of WWP2 with GB1-tag
2EBR	;		;	Solution structure of the fourth zf-RanBP domain from human Nuclear pore complex protein Nup153
2JTP	;		;	Solution Structure of the Frameshift-Inducing RNA Stem-Loop in SIV
6QVW	;		;	Solution structure of the free FOXO1 DNA binding domain
2K16	;		;	Solution structure of the free TAF3 PHD domain
2MXC	;		;	Solution structure of the full length sorting nexin 3
1I6E	;		;	SOLUTION STRUCTURE OF THE FUNCTIONAL DOMAIN OF PARACOCCUS DENITRIFICANS CYTOCHROME C552 IN THE OXIDIZED STATE
1C7M	;		;	SOLUTION STRUCTURE OF THE FUNCTIONAL DOMAIN OF PARACOCCUS DENITRIFICANS CYTOCHROME C552 IN THE REDUCED STATE
1I6D	;		;	SOLUTION STRUCTURE OF THE FUNCTIONAL DOMAIN OF PARACOCCUS DENITRIFICANS CYTOCHROME C552 IN THE REDUCED STATE
1ZAE	;		;	Solution structure of the functional domain of phi29 replication organizer p16.7c
6SNJ	;		;	Solution structure of the FUS/TLS RNA recognition motif in complex with U1 snRNA stem loop III
1X4U	;		;	Solution structure of the FYVE domain from human FYVE domain containing 27 isoform b protein
2YQM	;		;	Solution structure of the FYVE domain in zinc finger FYVE domain-containing protein 12
6W9N	;		;	Solution structure of the FYVE domain of ALFY
2N4G	;		;	Solution Structure of the G335D Mutant of TDP-43 Amyloidogenic Core Region
2JX9	;		;	Solution structure of the Gal_lectin domain of mouse Latrophilin-1 GPCR
1V5R	;		;	Solution Structure of the Gas2 Domain of the Growth Arrest Specific 2 Protein
2N1H	;		;	Solution structure of the GBII-beta MRH domain W409A point mutant
3GCC	;		;	SOLUTION STRUCTURE OF THE GCC-BOX BINDING DOMAIN, NMR, 46 STRUCTURES
2GCC	;		;	SOLUTION STRUCTURE OF THE GCC-BOX BINDING DOMAIN, NMR, MINIMIZED MEAN STRUCTURE
2EDG	;		;	Solution structure of the GCV_H domain from mouse glycine
2F09	;		;	Solution Structure of the gene product of E. coli gene ydhA
2LO0	;		;	Solution structure of the Get5 carboxyl domain from A. fumigatus
2LNZ	;		;	Solution structure of the Get5 carboxyl domain from S. cerevisiae
2LXA	;		;	Solution structure of the Get5 ubiquitin-like domain
2RTX	;		;	Solution structure of the GGQ domain of YaeJ protein from Escherichia coli
2MJH	;		;	Solution structure of the GLD-1 RNA-binding domain in complex with RNA
6HQ1	;		;	Solution structure of the globular domain from human histone H1.0
1UHM	;		;	Solution structure of the globular domain of linker histone homolog Hho1p from S. cerevisiae
2K42	;		;	Solution Structure of the GTPase Binding Domain of WASP in Complex with EspFU, an EHEC Effector
1B64	;		;	SOLUTION STRUCTURE OF THE GUANINE NUCLEOTIDE EXCHANGE FACTOR DOMAIN FROM HUMAN ELONGATION FACTOR-ONE BETA, NMR, 20 STRUCTURES
2E29	;		;	Solution structure of the GUCT domain from human ATP-dependent RNA helicase DDX50, DEAD box protein 50
1WH2	;		;	Solution structure of the GYF domain of a hypothetical protein from Arabidopsis thaliana
6OCV	;		;	Solution structure of the H-NOX protein from Shewanella woodyi in the Fe(II)CO ligation state
2KYT	;		;	Solution structure of the H-REV107 N-terminal domain
2L5H	;		;	Solution Structure of the H189Q mutant of the Enzyme I dimer Using Residual Dipolar Couplings and Small Angle X-Ray Scattering
8DWQ	;		;	Solution Structure of the H3 protein
2HVA	;		;	Solution Structure of the haem-binding protein p22HBP
1B36	;		;	SOLUTION STRUCTURE OF THE HAIRPIN RIBOZYME LOOP B DOMAIN RNA, NMR, 10 STRUCTURES
2M19	;		;	Solution structure of the Haloferax volcanii HVO 2177 protein
6GQ9	;		;	Solution structure of the hazel allergen Cor a 1.0401
1QQV	;		;	SOLUTION STRUCTURE OF THE HEADPIECE DOMAIN OF CHICKEN VILLIN
2DOA	;		;	Solution structure of the helical domain in human Eleven-nineteen lysine-rich leukemia protein ELL
2DGZ	;		;	Solution structure of the Helicase and RNase D C-terminal domain in Werner syndrome ATP-dependent helicase
2HAJ	;		;	Solution structure of the helicase-binding domain of Escherichia coli primase
2M22	;		;	Solution structure of the helix II template boundary element from Tetrahymena telomerase RNA
1SR3	;		;	Solution structure of the heme chaperone CcmE of Escherichia coli
2JXY	;		;	Solution structure of the hemopexin-like domain of MMP12
1CWX	;		;	SOLUTION STRUCTURE OF THE HEPATITIS C VIRUS N-TERMINAL CAPSID PROTEIN 2-45 [C-HCV(2-45)]
1UJL	;		;	Solution Structure of the HERG K+ channel S5-P extracellular linker
1F4I	;		;	SOLUTION STRUCTURE OF THE HHR23A UBA(2) MUTANT P333E, DEFICIENT IN BINDING THE HIV-1 ACCESSORY PROTEIN VPR
2IC4	;		;	Solution structure of the His402 allotype of the Factor H SCR6-SCR7-SCR8 fragment
1FR0	;		;	SOLUTION STRUCTURE OF THE HISTIDINE-CONTAINING PHOSPHOTRANSFER DOMAIN OF ANAEROBIC SENSOR KINASE ARCB FROM ESCHERICHIA COLI.
1Z2J	;		;	Solution structure of the HIV-1 frameshift inducing element
1PJY	;		;	Solution structure of the HIV-1 frameshift inducing stem-loop RNA
1Z9E	;		;	Solution structure of the HIV-1 integrase-binding domain in LEDGF/p75
2N4L	;		;	Solution Structure of the HIV-1 Intron Splicing Silencer and its Interactions with the UP1 Domain of hnRNP A1
2H3F	;		;	Solution structure of the HIV-1 MA protein
2H3I	;		;	Solution structure of the HIV-1 myristoylated Matrix protein
2EXF	;		;	Solution structure of the HIV-1 nucleocapsid (NCp7(12-55)) complexed with the DNA (-) Primer Binding Site
7LVA	;		;	Solution structure of the HIV-1 PBS-segment
2K4H	;		;	Solution structure of the HIV-2 myristoylated Matrix protein
2K4E	;		;	Solution structure of the HIV-2 UNMYRISTOYLATED MATRIX PROTEIN
2LE4	;		;	Solution structure of the HMG box DNA-binding domain of human stem cell transcription factor Sox2
2E6O	;		;	Solution structure of the HMG box domain from human HMG-box transcription factor 1
2D7L	;		;	Solution structure of the HMG box domain from human WD repeat and HMG-box DNA binding protein 1
2CTO	;		;	Solution structure of the HMG box like domain from human hypothetical protein FLJ14904
2YUK	;		;	Solution structure of the HMG box of human Myeloid/lymphoid or mixed-lineage leukemia protein 3 homolog
2YUL	;		;	Solution structure of the HMG box of human Transcription factor SOX-17
2CS1	;		;	Solution structure of the HMG domain of human DNA mismatch repair protein
2CRJ	;		;	Solution structure of the HMG domain of mouse HMG domain protein HMGX2
1WXL	;		;	Solution Structure of the HMG-box domain in the SSRP1 subunit of FACT
1WZ6	;		;	Solution Structure of the HMG_box Domain of Murine Bobby Sox Homolog
2CO9	;		;	Solution structure of the HMG_box domain of thymus high mobility group box protein TOX from mouse
1IRY	;		;	Solution structure of the hMTH1, a nucleotide pool sanitization enzyme
1OR5	;		;	SOLUTION STRUCTURE OF THE HOLO-FORM OF THE FRENOLICIN ACYL CARRIER PROTEIN, MINIMIZED MEAN STRUCTURE
2E19	;		;	Solution structure of the homeobox domain from human NIL-2-A zinc finger protein, transcription factor 8
2DA6	;		;	Solution structure of the homeobox domain of Hepatocyte nuclear factor 1-beta (HNF-1beta)
2DMT	;		;	Solution structure of the homeobox domain of Homeobox protein BarH-like 1
2DMU	;		;	Solution structure of the homeobox domain of Homeobox protein goosecoid
2DMS	;		;	Solution structure of the homeobox domain of Homeobox protein OTX2
2CRA	;		;	Solution structure of the homeobox domain of human homeo box B13
1X2N	;		;	Solution structure of the homeobox domain of human homeobox protein PKNOX1
2DMQ	;		;	Solution structure of the homeobox domain of LIM/homeobox protein Lhx9
1X2M	;		;	Solution structure of the homeobox domain of mouse LAG1 longevity assurance homolog 6
2CUF	;		;	Solution structure of the homeobox domain of the human hypothetical protein FLJ21616
2CUE	;		;	Solution structure of the homeobox domain of the human paired box protein Pax-6
2DA4	;		;	Solution structure of the homeobox domain of the hypothetical protein, DKFZp686K21156
2DA7	;		;	Solution structure of the homeobox domain of Zinc finger homeobox protein 1b (Smad interacting protein 1)
1WI3	;		;	Solution structure of the homeodomain of KIAA1034 protein
2HI3	;		;	Solution structure of the homeodomain-only protein HOP
1JOY	;		;	SOLUTION STRUCTURE OF THE HOMODIMERIC DOMAIN OF ENVZ FROM ESCHERICHIA COLI BY MULTI-DIMENSIONAL NMR.
1TUJ	;		;	Solution structure of the honey bee general odorant binding protein ASP2 in complex with trimethylsilyl-d4 propionate
1NIQ	;		;	Solution Structure of the HOO-Bm bound BLMT, Transposon Tn5-encoding Bleomycin-binding Protein
2CPR	;		;	Solution structure of the HRDC domain of human Exosome component 10
6T3I	;		;	Solution structure of the HRP2 IBD
3ZEH	;		;	Solution structure of the Hs. PSIP1 PWWP domain
2A7O	;		;	Solution Structure of the hSet2/HYPB SRI domain
1FNX	;		;	SOLUTION STRUCTURE OF THE HUC RBD1-RBD2 COMPLEXED WITH THE AU-RICH ELEMENT
2ECD	;		;	Solution structure of the human ABL2 SH2 domain
1UND	;		;	Solution structure of the human advillin C-terminal headpiece subdomain
2LG1	;		;	Solution structure of the human AKAP13 PH domain and stabilizing DH helix
1W0B	;		;	Solution structure of the human alpha-hemoglobin stabilizing protein (AHSP) P30A mutant
1KUN	;		;	SOLUTION STRUCTURE OF THE HUMAN ALPHA3-CHAIN TYPE VI COLLAGEN C-TERMINAL KUNITZ DOMAIN, NMR, 20 STRUCTURES
2L9E	;		;	Solution Structure of the human Anti-codon Stem and loop(hASL) of transfer RNA Lysine 3 (tRNALys3)
2D46	;		;	Solution Structure of the Human Beta4a-A Domain
2KV2	;		;	Solution Structure of the human BLM HRDC domain
2EKX	;		;	Solution structure of the human BMX SH2 domain
1EL0	;		;	SOLUTION STRUCTURE OF THE HUMAN CC CHEMOKINE, I-309
1WBR	;		;	SOLUTION STRUCTURE OF THE HUMAN CD4 (403-419) RECEPTOR PEPTIDE, NMR, 32 STRUCTURES
2MP1	;		;	Solution structure of the human chemokine CCL19
2KUM	;		;	Solution structure of the human chemokine CCL27
1EIG	;		;	SOLUTION STRUCTURE OF THE HUMAN CHEMOKINE EOTAXIN-2
1EIH	;		;	SOLUTION STRUCTURE OF THE HUMAN CHEMOKINE EOTAXIN-2
2HCC	;		;	SOLUTION STRUCTURE OF THE HUMAN CHEMOKINE HCC-2, NMR, 30 STRUCTURES
2RQT	;		;	Solution structure of the human DDEF1 SH3 domain
1E4S	;		;	Solution structure of the human defensin hBD-1
1E4Q	;		;	Solution structure of the human defensin hBD-2
2MUQ	;		;	Solution Structure of the Human FAAP20 UBZ
2MUR	;		;	Solution Structure of the Human FAAP20 UBZ-Ubiquitin Complex
1WQU	;		;	Solution structure of the human FES SH2 domain
2JP3	;		;	Solution Structure of the human FXYD4 (CHIF) protein in SDS micelles
1MW4	;		;	Solution structure of the human Grb7-SH2 domain in complex with a 10 amino acid peptide pY1139
2AQ0	;		;	Solution structure of the human homodimeric dna repair protein XPF
2C55	;		;	Solution Structure of the Human Immunodeficiency Virus Type 1 p6 Protein
1J0S	;		;	Solution structure of the human interleukin-18
1IY4	;		;	Solution structure of the human lysozyme at 35 degree C
1IY3	;		;	Solution Structure of the Human lysozyme at 4 degree C
2CH0	;		;	Solution structure of the human MAN1 C-terminal domain (residues 655- 775)
2KRZ	;		;	Solution structure of the Human Mitochondrial tRNAMet
2KRY	;		;	Solution structure of the human mitochondrial tRNAMet ASL containing the 5-formylcytidine modification in position 34
1ZGU	;		;	Solution structure of the human Mms2-Ubiquitin complex
2JRJ	;		;	Solution structure of the human Pirh2 RING-H2 domain. Northeast Structural Genomics Consortium Target HT2B
2MBB	;		;	Solution Structure of the human Polymerase iota UBM1-Ubiquitin Complex
2KHW	;		;	Solution Structure of the human Polymerase iota UBM2-Ubiquitin Complex
2LFG	;		;	Solution structure of the human prolactin receptor ecd domain d2
2L7W	;		;	Solution structure of the human Raf-1 kinase inhibitor protein
7P08	;		;	Solution structure of the human SF3A1 ubiquitin-like domain
2YSX	;		;	Solution structure of the human SHIP SH2 domain
2N7A	;		;	Solution structure of the human Siglec-8 lectin domain
2N7B	;		;	Solution structure of the human Siglec-8 lectin domain in complex with 6'sulfo sialyl Lewisx
5L7B	;		;	Solution structure of the human SNF5/INI1 domain
1H5P	;		;	Solution structure of the human Sp100b SAND domain by heteronuclear NMR.
2EL8	;		;	Solution structure of the human STAP2 SH2 domain
143D	;		;	SOLUTION STRUCTURE OF THE HUMAN TELOMERIC REPEAT D(AG3[T2AG3]3) OF THE G-QUADRUPLEX
1O7C	;		;	Solution structure of the human TSG-6 Link module in the presence of a hyaluronan octasaccharide
2MT6	;		;	Solution structure of the human ubiquitin conjugating enzyme Ube2w
2HLW	;		;	Solution Structure of the Human Ubiquitin-conjugating Enzyme Variant Uev1a
1UNC	;		;	Solution structure of the human villin C-terminal headpiece subdomain
2KAV	;		;	Solution structure of the human Voltage-gated Sodium Channel, brain isoform (Nav1.2)
2MDX	;		;	Solution structure of the human wild type FAPP1-PH domain
1POZ	;		;	SOLUTION STRUCTURE OF THE HYALURONAN BINDING DOMAIN OF HUMAN CD44
2NBH	;		;	Solution structure of the HYD1 hydrophobin from Schizophyllum commune
2N4O	;		;	Solution structure of the hydrophobin MPG1 from the rice blast fungus Magnaporthe oryzae
1WJ5	;		;	Solution structure of the hypothetical domain of RIKEN cDNA 0610009H20
2NNZ	;		;	Solution structure of the hypothetical protein AF2241 from Archaeoglobus fulgidus
1WLO	;		;	Solution structure of the hypothetical protein from thermus thermophilus HB8
1PU1	;		;	Solution structure of the Hypothetical protein mth677 from Methanothermobacter Thermautotrophicus
1RQ8	;		;	Solution structure of the hypothetical protein SAV1595 from Staphylococcus aureus, a putative RNA binding protein
1OVQ	;		;	Solution structure of the hypothetical protein YqgF from Escherichia coli
2EDW	;		;	Solution structure of the I-set domain (3537-3630) of human obscurin
2CT7	;		;	Solution Structure of the IBR domain of the RING finger protein 31 protein
2M12	;		;	Solution structure of the ID3 stem loop of domain 1 of the ai5gamma group II intron
2CR6	;		;	Solution structure of the Ig domain (2998-3100) of human obscurin
2EO1	;		;	Solution structure of the ig domain of human OBSCN protein
2ENY	;		;	Solution structure of the ig-like domain (2735-2825) of human obscurin
2EDR	;		;	Solution structure of the ig-like domain (3361-3449) of human obscurin
2EDT	;		;	Solution structure of the ig-like domain (3449-3537) from human Obscurin
2EDQ	;		;	Solution structure of the ig-like domain (3713-3806) of human obscurin
2EDL	;		;	Solution structure of the ig-like domain (3801-3897) of human obscurin
2E6Q	;		;	Solution structure of the Ig-like domain (615-713) from human Obscurin-like protein 1
2E6P	;		;	Solution structure of the Ig-like domain (714-804) from human Obscurin-like protein 1
2DL9	;		;	Solution structure of the Ig-like domain of human Leucine-rich repeat-containing protein 4
2DLT	;		;	Solution structure of the Ig-like domain(433- 525) of murine myosin-binding protein C, fast-type
5XF0	;		;	Solution structure of the IgI domain of CD147
1FI7	;		;	Solution structure of the imidazole complex of cytochrome C
1FI9	;		;	SOLUTION STRUCTURE OF THE IMIDAZOLE COMPLEX OF CYTOCHROME C
1NMI	;		;	Solution structure of the imidazole complex of iso-1 cytochrome c
2MF7	;		;	Solution structure of the ims domain of the mitochondrial import protein TIM21 from S. cerevisiae
2K2O	;		;	Solution Structure of the inner DysF domain of human myoferlin
1G9P	;		;	SOLUTION STRUCTURE OF THE INSECTICIDAL CALCIUM CHANNEL BLOCKER OMEGA-ATRACOTOXIN-HV2A
1DL0	;		;	SOLUTION STRUCTURE OF THE INSECTICIDAL NEUROTOXIN J-ATRACOTOXIN-HV1C
2M36	;		;	Solution structure of the insecticidal spider-venom peptide Aps III
2EO2	;		;	Solution structure of the insertion region (510-573) of FTHFS domain from mouse methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like protein
2MAM	;		;	Solution structure of the interdigitated double Tudor domain of RBBP1
2ERS	;		;	Solution structure of the Interleukin-15 receptor sushi domain
6K8Q	;		;	Solution structure of the intermembrane space domain of the mitochondrial import protein Tim21 from S. cerevisiae
2MX7	;		;	Solution structure of the internal EH domain of gamma-synergin
2EUY	;		;	Solution structure of the internal loop of human U65 H/ACA snoRNA 3' hairpin
1IFY	;		;	Solution Structure of the Internal UBA Domain of HHR23A
5US5	;		;	Solution structure of the IreB homodimer
2DLL	;		;	Solution structure of the IRF domain of human interferon regulator factors 4
2DLW	;		;	Solution structure of the IRS domain of human docking protein 2, isoform a
2K78	;		;	Solution Structure of the IsdC NEAT domain bound to Zinc Protoporphyrin
2RVQ	;		;	Solution structure of the isolated histone H2A-H2B heterodimer
2LC7	;		;	Solution structure of the isolated Par-6 PDZ domain
6WQE	;		;	Solution Structure of the IWP-051-bound H-NOX from Shewanella woodyi in the Fe(II)CO ligation state
2DMX	;		;	Solution structure of the J domain of DnaJ homolog subfamily B member 8
2NBY	;		;	Solution structure of the J domain of EMCV IRES
2LGW	;		;	Solution Structure of the J Domain of HSJ1a
2CUG	;		;	Solution structure of the J domain of the pseudo DnaJ protein, mouse hypothetical mKIAA0962
6IWS	;		;	Solution structure of the J-domain of Tid1, a Mitochondrial Hsp40/DnaJ Protein
2NBX	;		;	Solution structure of the J-K region of EMCV IRES
2ADZ	;		;	solution structure of the joined PH domain of alpha1-syntrophin
1YZB	;		;	Solution structure of the Josephin domain of Ataxin-3
2JRI	;		;	Solution structure of the Josephin domain of Ataxin-3 in complex with ubiquitin molecule.
2NBZ	;		;	Solution structure of the K domain of EMCV IRES
1RQM	;		;	SOLUTION STRUCTURE OF THE K18G/R82E ALICYCLOBACILLUS ACIDOCALDARIUS THIOREDOXIN MUTANT
2LQ9	;		;	Solution structure of the K60A mutant of Atox1
2YQR	;		;	Solution structure of the KH domain in KIAA0907 protein
1WH9	;		;	Solution structure of the KH domain of human ribosomal protein S3
2BL5	;		;	Solution structure of the KH-QUA2 region of the Xenopus STAR-GSG Quaking protein.
2KQM	;		;	Solution structure of the KI O18/O8 Y87H immunoglobulin light chain variable domain
1F5U	;		;	SOLUTION STRUCTURE OF THE KISSING DIMER OF H3 GACG STEM-LOOP IN THE 5'-END DIMERIZATION SIGNAL OF MOLONEY MURINE LEUKEMIA VIRUS GENOMIC RNA
1SB0	;		;	Solution structure of the KIX domain of CBP bound to the transactivation domain of c-Myb
2RO0	;		;	Solution structure of the knotted tudor domain of the yeast histone acetyltransferase, Esa1
1V65	;		;	Solution structure of the Kruppel-associated box (KRAB) domain
1VYX	;		;	Solution structure of the KSHV K3 N-terminal domain
2CQK	;		;	Solution structure of the La domain of c-Mpl binding protein
2MTF	;		;	Solution structure of the La motif of human LARP6
1XFE	;		;	Solution structure of the LA7-EGFA pair from the LDL receptor
1JCP	;		;	Solution structure of the lactam analogue EDap of HIV gp41 600-612 loop.
1KJK	;		;	Solution structure of the lambda integrase amino-terminal domain
2MVO	;		;	Solution structure of the lantibiotic self-resistance lipoprotein MlbQ from Microbispora ATCC PTA-5024
6MK7	;		;	Solution structure of the large extracellular loop of FtsX in Streptococcus pneumoniae
1LDZ	;		;	SOLUTION STRUCTURE OF THE LEAD-DEPENDENT RIBOZYME, NMR, 25 STRUCTURES
2LDZ	;		;	SOLUTION STRUCTURE OF THE LEAD-DEPENDENT RIBOZYME, NMR, MINIMIZED AVERAGE STRUCTURE
2KYA	;		;	Solution structure of the leader sequence of the patellamide precursor peptide, PatE1-34
6EMR	;		;	Solution structure of the LEDGF/p75 IBD - IWS1 (aa 446-548) complex
6EMO	;		;	Solution structure of the LEDGF/p75 IBD - JPO2 (aa 1-32) complex
5YI9	;		;	Solution structure of the LEDGF/p75 IBD - JPO2 (aa 56-91) complex
6EMQ	;		;	Solution structure of the LEDGF/p75 IBD - MLL1 (aa 111-160) complex
6EMP	;		;	Solution structure of the LEDGF/p75 IBD - POGZ (aa 1370-1404) complex
1ZFI	;		;	Solution structure of the leech carboxypeptidase inhibitor
5YHN	;		;	Solution structure of the LEKTI Domain 4
2ELL	;		;	Solution structure of the Leucine Rich Repeat of human Acidic leucine-rich nuclear phosphoprotein 32 family member B
2RR6	;		;	Solution structure of the leucine rich repeat of human acidic leucine-rich nuclear phosphoprotein 32 family member B
1LEA	;		;	SOLUTION STRUCTURE OF THE LEXA REPRESSOR DNA BINDING DETERMINED BY 1H NMR SPECTROSCOPY
1LEB	;		;	SOLUTION STRUCTURE OF THE LEXA REPRESSOR DNA BINDING DETERMINED BY 1H NMR SPECTROSCOPY
1WYH	;		;	Solution structure of the LIM domain from human Skeletal muscle LIM-protein 2
1X64	;		;	Solution structure of the LIM domain of alpha-actinin-2 associated LIM protein
1X62	;		;	Solution structure of the LIM domain of carboxyl terminal LIM domain protein 1
2D8Y	;		;	Solution structure of the LIM domain of Epithelial protein lost in neoplasm
2CU8	;		;	Solution structure of the LIM domain of human Cysteine-rich protein 2
1X3H	;		;	Solution structure of the LIM domain of human Leupaxin
1V6G	;		;	Solution Structure of the LIM Domain of the Human Actin Binding LIM Protein 2
2N40	;		;	Solution structure of the link module of human tsg-6 in presence of a chondroitin 4-sulfate hexasaccharide
5A4H	;		;	Solution structure of the lipid droplet anchoring peptide of CGI-58 bound to DPC micelles
1K8M	;		;	Solution Structure of the Lipoic Acid-Bearing Domain of the E2 component of Human, Mitochondrial Branched-Chain alpha-Ketoacid Dehydrogenase
1K8O	;		;	Solution Structure of the Lipoic Acid-Bearing Domain of the E2 component of Human, Mitochondrial Branched-Chain alpha-Ketoacid Dehydrogenase
1GHK	;		;	SOLUTION STRUCTURE OF THE LIPOYL DOMAIN OF THE 2-OXOGLUTARATE DEHYDROGENASE COMPLEX FROM AZOTOBACTER VINELAND II, NMR, 25 STRUCTURES
1GHJ	;		;	SOLUTION STRUCTURE OF THE LIPOYL DOMAIN OF THE 2-OXOGLUTARATE DEHYDROGENASE COMPLEX FROM AZOTOBACTER VINELAND II, NMR, MINIMIZED AVERAGE STRUCTURE
1GJX	;		;	Solution structure of the lipoyl domain of the chimeric dihydrolipoyl dehydrogenase P64K from Neisseria meningitidis
2FBS	;		;	Solution structure of the LL-37 core peptide bound to detergent micelles
2F3A	;		;	Solution structure of the LL-37-derived aurein 1.2 analog (LLAA) in membrane-mimetic micelles
2LDE	;		;	Solution structure of the long sarafotoxin srtx-i3
2LDF	;		;	Solution structure of the long sarafotoxin srtx-m
2DMW	;		;	Solution structure of the LONGIN domain of Synaptobrevin-like protein 1
2KFJ	;		;	Solution structure of the loop deletion mutant of PB1 domain of Cdc24p
2GI4	;		;	Solution Structure of the Low Molecular Weight Protein Tyrosine Phosphatase from Campylobacter jejuni.
1P8A	;		;	Solution structure of the low molecular weight protein tyrosine phosphatase from Tritrichomonas foetus
2RM4	;		;	Solution Structure of the LSM Domain of Dm EDC3 (Enhancer of DECAPPING 3)
2VXE	;		;	SOLUTION STRUCTURE OF THE LSM DOMAIN OF DROSOPHILA MELANOGASTER TRAL (TRAILER HITCH)
2VXF	;		;	Solution structure of the LSm-domain of zebrafish RAP55
1NZP	;		;	Solution Structure of the Lyase Domain of Human DNA Polymerase Lambda
2MPW	;		;	Solution structure of the LysM region of the E. coli Intimin periplasmic domain
5LMY	;		;	Solution structure of the m-pmv myristoylated matrix protein
2F76	;		;	Solution structure of the M-PMV wild type matrix protein (p10)
1FI3	;		;	SOLUTION STRUCTURE OF THE M61H MUTANT OF PSEUDOMONAS STUTZERI SUBSTRAIN ZOBELL FERROCYTOCHROME C-551
2GGF	;		;	Solution structure of the MA3 domain of human Programmed cell death 4
1HTX	;		;	SOLUTION STRUCTURE OF THE MAIN ALPHA-AMYLASE INHIBITOR FROM AMARANTH SEEDS
2KPY	;		;	Solution Structure of the major allergen of Artemisia vulgaris (Art v 1)
1E09	;		;	Solution Structure of the Major Cherry Allergen Pru av 1
1H2O	;		;	SOLUTION STRUCTURE OF THE MAJOR CHERRY ALLERGEN PRU AV 1 MUTANT E45W
2MHP	;		;	Solution structure of the major factor VIII binding region on von Willebrand factor
2MHQ	;		;	Solution structure of the major factor VIII binding region on von Willebrand factor
5XND	;		;	Solution structure of the major fish allergen parvalbumin Sco j 1 derived from the Pacific mackerel
7KBX	;		;	Solution structure of the major MYC promoter G-quadruplex in complex with NSC85697, a quinoline derivative
7KBW	;		;	Solution structure of the major MYC promoter G-quadruplex with a wild-type flanking in complex with NSC85697, a quinoline derivative
7KBV	;		;	Solution structure of the major MYC promoter G-quadruplex with a wild-type flanking sequence
1Q8N	;		;	Solution Structure of the Malachite Green RNA Binding Aptamer
2OQ3	;		;	Solution Structure of the mannitol- specific cryptic phosphotransferase enzyme IIA CmtB from Escherichia coli
1YSE	;		;	Solution structure of the MAR-binding domain of SATB1
1F43	;		;	SOLUTION STRUCTURE OF THE MATA1 HOMEODOMAIN
1UB1	;		;	Solution structure of the matrix attachment region-binding domain of chicken MeCP2
2MMM	;		;	Solution structure of the mature form, GK cecropin-like peptide from Ae. aegypti mosquito
1Q9P	;		;	Solution structure of the mature HIV-1 protease monomer
4D7X	;		;	Solution Structure of the Mediator Gall11 KIX Domain of C. Glabrata
2N2Y	;		;	Solution structure of the meiosis-expressed gene 1 (Meig1)
1KUP	;		;	Solution Structure of the Membrane Proximal Regions of alpha-IIb and beta-3 Integrins
1KUZ	;		;	Solution Structure of the Membrane Proximal Regions of alpha-IIb and beta-3 Integrins
202D	;		;	SOLUTION STRUCTURE OF THE MENOGARIL-DNA COMPLEX
1IX5	;		;	Solution structure of the Methanococcus thermolithotrophicus FKBP
1BA6	;		;	SOLUTION STRUCTURE OF THE METHIONINE-OXIDIZED AMYLOID BETA-PEPTIDE (1-40). DOES OXIDATION AFFECT CONFORMATIONAL SWITCHING? NMR, 10 STRUCTURES
7D8K	;		;	Solution structure of the methyl-CpG binding domain of MBD6 from Arabidopsis thaliana
1IG4	;		;	Solution Structure of the Methyl-CpG-Binding Domain of Human MBD1 in Complex with Methylated DNA
1D9N	;		;	SOLUTION STRUCTURE OF THE METHYL-CPG-BINDING DOMAIN OF THE METHYLATION-DEPENDENT TRANSCRIPTIONAL REPRESSOR MBD1/PCM1
2L7T	;		;	Solution structure of the MFS-bound Sans CEN2 peptide
5IM8	;		;	Solution Structure of the Microtubule-Targeting COS Domain of MID1
2DQ5	;		;	solution structure of the Mid1 B Box2 Chc(D/C)C2H2 Zinc-Binding Domain: insights into an evolutionary conserved ring fold
2HST	;		;	Solution structure of the middle domain of human eukaryotic translation termination factor eRF1
1EV0	;		;	SOLUTION STRUCTURE OF THE MINE TOPOLOGICAL SPECIFICITY DOMAIN
2DL1	;		;	Solution structure of the MIT domain from human Spartin
146D	;		;	SOLUTION STRUCTURE OF THE MITHRAMYCIN DIMER-DNA COMPLEX
2CQM	;		;	Solution structure of the mitochondrial ribosomal protein L17 isolog
2MGY	;		;	Solution structure of the mitochondrial translocator protein (TSPO) in complex with its high-affinity ligand PK11195
2MSV	;		;	Solution structure of the MLKL N-terminal domain
2LC8	;		;	Solution structure of the MLV readthrough pseudoknot
2L9Y	;		;	Solution structure of the MoCVNH-LysM module from the rice blast fungus Magnaporthe oryzae protein (MGG_03307)
7T2F	;		;	Solution structure of the model HEEH mini protein homodimer HEEH_TK_rd5_0341
6TO6	;		;	Solution structure of the modulator of repression (MOR) of the temperate bacteriophage TP901-1 from Lactococcus lactis
1PT4	;		;	Solution structure of the Moebius cyclotide kalata B2
199D	;		;	Solution structure of the monoalkylated mitomycin c-DNA complex
1DON	;		;	SOLUTION STRUCTURE OF THE MONOCYTE CHEMOATTRACTANT PROTEIN-1 DIMER USING HETERONUCLEAR, NMR, 20 STRUCTURES
1DOM	;		;	SOLUTION STRUCTURE OF THE MONOCYTE CHEMOATTRACTANT PROTEIN-1 DIMER USING HETERONUCLEAR, NMR, MINIMIZED AVERAGE STRUCTURE
2LFJ	;		;	Solution structure of the monomeric derivative of BS-RNase
1L5C	;		;	Solution Structure of the Monomeric Form of a Mutant Unliganded Bovine Neurophysin, 20 Structures
1L5D	;		;	Solution Structure of the Monomeric Form of a Mutant Unliganded Bovine Neurophysin, Minimized Average Structure
2RPZ	;		;	Solution structure of the monomeric form of mouse APOBEC2
1QWQ	;		;	Solution structure of the monomeric N67D mutant of Bovine Seminal Ribonuclease
1JE4	;		;	Solution structure of the monomeric variant of the chemokine MIP-1beta
1JCO	;		;	Solution structure of the monomeric [Thr(B27)->Pro,Pro(B28)->Thr] insulin mutant (PT insulin)
1SSF	;		;	Solution structure of the mouse 53BP1 fragment (residues 1463-1617)
1E4T	;		;	Solution structure of the mouse defensin mBD-7
1E4R	;		;	Solution structure of the mouse defensin mBD-8
1WGE	;		;	Solution structure of the mouse DESR1
8IM5	;		;	Solution structure of the mouse HOIL1-L NZF domain in the free form
1KN6	;		;	Solution Structure of the Mouse Prohormone Convertase 1 Pro-Domain
2LSG	;		;	Solution structure of the mouse Rev1 C-terminal domain
2LSJ	;		;	Solution structure of the mouse Rev1 CTD in complex with the Rev1-interacting Region (RIR)of Pol Kappa
2N1D	;		;	Solution structure of the MRG15-MRGBP complex
6F99	;		;	Solution structure of the MRH domain of Yos9
6F9A	;		;	Solution structure of the MRH domain of Yos9 complexed with alpha3,alpha6-Man5
2RMS	;		;	Solution structure of the mSin3A PAH1-SAP25 SID complex
2LD7	;		;	Solution structure of the mSin3A PAH3-SAP30 SID complex
2CRI	;		;	Solution structure of the MSP domain of mouse VAMP-associated proteinA
1WIC	;		;	Solution structure of the MSP domain of RIKEN cDNA 6030424E15
1NEQ	;		;	SOLUTION STRUCTURE OF THE MU NER PROTEIN BY MULTIDIMENSIONAL NMR
1NER	;		;	SOLUTION STRUCTURE OF THE MU NER PROTEIN BY MULTIDIMENSIONAL NMR
1Y8F	;		;	Solution structure of the munc13-1 C1-domain
1UK5	;		;	Solution structure of the Murine BAG domain of Bcl2-associated athanogene 3
1UH6	;		;	Solution Structure of the murine ubiquitin-like 5 protein from RIKEN cDNA 0610031K06
1PPX	;		;	Solution Structure of the MutT Pyrophosphohydrolase Complexed with Mg(2+) and 8-oxo-dGMP, a Tightly-bound Product
1PUN	;		;	Solution Structure of the MutT Pyrophosphohydrolase Complexed with Mg(2+) and 8-oxo-dGMP, a Tightly-bound Product
1PUQ	;		;	Solution Structure of the MutT Pyrophosphohydrolase Complexed with Mg(2+) and 8-oxo-dGMP, a Tightly-bound Product
1PUS	;		;	Solution Structure of the MutT Pyrophosphohydrolase Complexed with Mg(2+) and 8-oxo-dGMP, a Tightly-bound Product
1X41	;		;	Solution structure of the Myb-like DNA binding domain of human Transcriptional adaptor 2-like, isoform B
2YUM	;		;	Solution structure of the Myb-like DNA-binding domain of human ZZZ3 protein
2CRG	;		;	Solution structure of the myb-like DNA-binding domain of mouse MTA3 protein
2DIM	;		;	Solution structure of the Myb_DNA-binding domain of human Cell division cycle 5-like protein
2DIN	;		;	Solution structure of the Myb_DNA-binding domain of human Cell division cycle 5-like protein
5W77	;		;	Solution structure of the MYC G-quadruplex bound to small molecule DC-34
7N7D	;		;	Solution structure of the MYC promoter G-quadruplex in complex with berberine: conformer A
7N7E	;		;	Solution structure of the MYC promoter G-quadruplex in complex with berberine: conformer B
2KVC	;		;	Solution structure of the Mycobacterium tuberculosis protein Rv0543c, a member of the DUF3349 superfamily. Seattle Structural Genomics Center for Infectious Disease target MytuD.17112.a
2ODD	;		;	Solution structure of the MYND domain from AML1-ETO complexed with SMRT, a corepressor
2OD1	;		;	Solution structure of the MYND domain from human AML1-ETO
2D8Q	;		;	Solution structure of the MYND domain of the human zinc finger MYND domain-containing protein 10
8IMH	;		;	Solution structure of the N terminal domain of MazE9 antitoxin (nMazE9) from Mycobacterium tuberculosis
1HN3	;		;	SOLUTION STRUCTURE OF THE N-TERMINAL 37 AMINO ACIDS OF THE MOUSE ARF TUMOR SUPPRESSOR PROTEIN
2DMD	;		;	Solution structure of the N-terminal C2H2 type zinc-binding domain of the Zinc finger protein 64, isoforms 1 and 2
2DAE	;		;	Solution Structure of the N-terminal CUE Domain in the Human Mitogen-activated Protein Kinase Kinase Kinase 7 Interacting Protein 2 (MAP3K7IP2)
1UF0	;		;	Solution structure of the N-terminal DCX domain of human doublecortin-like kinase
4ASV	;		;	Solution structure of the N-terminal dimerisation domain of Sgt2
2FY9	;		;	Solution Structure of the N-Terminal DNA Recognition Domain of the Bacillus Subtilis Transcription-State Regulator ABH
1Z0R	;		;	Solution Structure of the N-terminal DNA Recognition Domain of the Bacillus subtilis Transcription-State Regulator AbrB
5TN0	;		;	Solution Structure of the N-terminal DNA-binding domain of the master biofilm-regulator SinR from Bacillus subtilis
1ZMZ	;		;	Solution structure of the N-terminal domain (M1-S98) of human centrin 2
2KQR	;		;	Solution structure of the N-terminal domain (residues 1-111) of Brugia malayi asparaginyl-tRNA synthetase
2K3Q	;		;	Solution structure of the n-terminal domain (TUSP1-N) of the egg case silk from Nephila antipodiana
1WIB	;		;	Solution structure of the N-terminal domain from mouse hypothetical protein BAB22488
1WJT	;		;	Solution structure of the N-terminal Domain I of mouse transcription elongation factor S-II protein 3
2YUI	;		;	Solution structure of the N-terminal domain in human cytokine-induced apoptosis inhibitor anamorsin
1KQK	;		;	Solution Structure of the N-terminal Domain of a Potential Copper-translocating P-type ATPase from Bacillus subtilis in the Cu(I)loaded State
2KRC	;		;	Solution structure of the N-terminal domain of Bacillus subtilis delta subunit of RNA polymerase
2JML	;		;	Solution structure of the N-terminal domain of CarA repressor
2H2M	;		;	Solution Structure of the N-terminal domain of COMMD1 (Murr1)
2KSN	;		;	Solution Structure of the N-terminal Domain of DC-UbP/UBTD2
2LD4	;		;	Solution structure of the N-terminal domain of human anamorsin
2MF9	;		;	Solution structure of the N-terminal domain of human FKBP38 (FKBP38NTD)
1SW8	;		;	Solution structure of the N-terminal domain of Human N60D calmodulin refined with paramagnetism based strategy
2LLX	;		;	Solution structure of the N-terminal domain of human polypeptide chain release factor eRF1
2CQL	;		;	Solution structure of the N-terminal domain of human ribosomal protein L9
7OZ0	;		;	Solution structure of the N-terminal domain of human telomeric Repeat-binding factor 2-interacting protein 1 (hRap1): implication for Rap1-TRF2 interaction in Human.
2LD0	;		;	Solution structure of the N-terminal domain of huntingtin (htt17) in 50 % TFE
2LD2	;		;	Solution structure of the N-terminal domain of huntingtin (htt17) in presence of DPC micelles
2KMC	;		;	Solution Structure of the N-terminal domain of kindlin-1
1WGW	;		;	Solution Structure of the N-terminal Domain of Mouse Putative Signal Recognition Particle 54 (SRP54)
2L1T	;		;	Solution Structure of the N-terminal Domain of NP_954075.1
2MT4	;		;	Solution structure of the N-terminal domain of NUSA from B. Subtilis
5LGF	;		;	Solution structure of the N-terminal domain of Ogataea polymorpha telomerase reverse transcriptase
2JV2	;		;	Solution Structure of the N-terminal Domain of PH1500
1IWF	;		;	Solution structure of the N-terminal domain of pig gastric H/K-ATPase
2GQC	;		;	Solution structure of the N-terminal domain of Rhomboid Intramembrane Protease from P. aeruginosa
1HZE	;		;	SOLUTION STRUCTURE OF THE N-TERMINAL DOMAIN OF RIBOFLAVIN SYNTHASE FROM E. COLI
1I18	;		;	SOLUTION STRUCTURE OF THE N-TERMINAL DOMAIN OF RIBOFLAVIN SYNTHASE FROM E. COLI
1CQU	;		;	SOLUTION STRUCTURE OF THE N-TERMINAL DOMAIN OF RIBOSOMAL PROTEIN L9
2DOG	;		;	Solution structure of the N-terminal domain of RimM from Thermus thermophilus HB8
1M2E	;		;	Solution structure of the N-terminal domain of Synechococcus elongatus KaiA (KaiA135N); Average minimized structure.
1M2F	;		;	Solution structure of the N-terminal domain of Synechococcus elongatus KaiA (KaiA135N); Family of 25 structures
1T4Z	;		;	Solution structure of the N-terminal domain of Synechococcus elongatus SasA (25-structures ensemble)
1T4Y	;		;	Solution structure of the N-terminal domain of Synechococcus elongatus SasA (average minimized structure)
2N4P	;		;	Solution structure of the n-terminal domain of tdp-43
5X4F	;		;	Solution Structure of the N-terminal Domain of TDP-43
6IVS	;		;	Solution structure of the N-terminal domain of the anti-sigma factor RsgI1 from Clostridium thermocellum
2GCF	;		;	Solution structure of the N-terminal domain of the coppper(I) ATPase PacS in its apo form
6B3N	;		;	Solution structure of the N-terminal domain of the effector NleG5-1 from Escherichia coli O157:H7 str. Sakai
1J3X	;		;	Solution structure of the N-terminal domain of the HMGB2
1G25	;		;	SOLUTION STRUCTURE OF THE N-TERMINAL DOMAIN OF THE HUMAN TFIIH MAT1 SUBUNIT
2XXS	;		;	Solution structure of the N-terminal domain of the Shigella type III secretion protein MxiG
6QBZ	;		;	Solution structure of the N-terminal domain of the Staphylococcus aureus Hibernation Promoting Factor
1F2H	;		;	SOLUTION STRUCTURE OF THE N-TERMINAL DOMAIN OF THE TNFR1 ASSOCIATED PROTEIN, TRADD.
2KM1	;		;	Solution structure of the N-terminal domain of the yeast protein Dre2
5ZMR	;		;	Solution Structure of the N-terminal Domain of the Yeast Rpn5
2OFG	;		;	Solution structure of the n-terminal domain of the zinc(II) ATPase ziaa in its apo form
2OFH	;		;	Solution structure of the n-terminal domain of the zinc(II) ATPase ziaa in its apo form
1MWY	;		;	Solution structure of the N-terminal domain of ZntA in the apo-form
1MWZ	;		;	Solution structure of the N-terminal domain of ZntA in the Zn(II)-form
1WHQ	;		;	Solution structure of the N-terminal dsRBD from hypothetical protein BAB28848
2RS6	;		;	Solution structure of the N-terminal dsRBD from RNA helicase A
2E9I	;		;	Solution structure of the N-terminal extended 20th Filamin domain from human Filamin-B
6J3L	;		;	Solution structure of the N-terminal extended protuberant domain of eukaryotic ribosomal stalk protein P0
2V37	;		;	Solution structure of the N-terminal extracellular domain of human T- cadherin
2JOP	;		;	Solution structure of the N-terminal extracellular domain of the lymphocyte receptor CD5 (CD5 domain 1)
2JP0	;		;	Solution structure of the N-terminal extraceullular domain of the lymphocyte receptor CD5 calculated using inferential structure determination (ISD)
1QGB	;		;	SOLUTION STRUCTURE OF THE N-TERMINAL F1 MODULE PAIR FROM HUMAN FIBRONECTIN
2FBU	;		;	Solution structure of the N-terminal fragment of human LL-37
1V4Z	;		;	Solution structure of the N-terminal fragment of S100C/A11 protein
6VWB	;		;	Solution structure of the N-terminal helix-hairpin-helix domain of human MUS81
2CPQ	;		;	Solution structure of the N-terminal KH domain of human FXR1
2O10	;		;	Solution structure of the N-terminal LIM domain of MLP/CRP3
1O53	;		;	Solution structure of the N-terminal membrane anchor of E. coli enzyme IIA(Glucose)
2YS4	;		;	Solution structure of the N-terminal PapD-like domain of HYDIN protein from human
2COD	;		;	Solution structure of the N-terminal PH domain of ARAP2 protein from human
1PFJ	;		;	Solution structure of the N-terminal PH/PTB domain of the TFIIH P62 subunit
1V5P	;		;	Solution Structure of the N-terminal Pleckstrin Homology Domain Of TAPP2 from Mouse
2D5U	;		;	Solution structure of the N-terminal portion of the PUB domain of mouse peptide:N-glycanase
1WXM	;		;	Solution Structure of the N-terminal Ras-binding Domain (RBD) in Human a-Raf Kinase
1NTR	;		;	SOLUTION STRUCTURE OF THE N-TERMINAL RECEIVER DOMAIN OF NTRC
5O57	;		;	Solution Structure of the N-terminal Region of Dkk4
1WHW	;		;	Solution structure of the N-terminal RNA binding domain from hypothetical protein BAB23448
2DGP	;		;	Solution structure of the N-terminal RNA binding domain in Bruno-like 4 RNA-binding protein
2DGQ	;		;	Solution structure of the N-terminal RNA binding domain in Bruno-like 6 RNA-binding protein
2DH8	;		;	Solution structure of the N-terminal RNA binding domain in DAZ-associated protein 1
2CPJ	;		;	Solution structure of the N-terminal RNA recognition motif of NonO
2RS8	;		;	Solution structure of the N-terminal RNA recognition motif of NonO
1UAW	;		;	Solution structure of the N-terminal RNA-binding domain of mouse Musashi1
2EAM	;		;	Solution structure of the N-terminal SAM-domain of a human putative 47 kDa protein
2E8P	;		;	Solution structure of the N-terminal SAM-domain of E74-like factor 3
2EAN	;		;	Solution structure of the N-terminal SAM-domain of human KIAA0902 protein (connector enhancer of kinase suppressor of ras 2)
2EAP	;		;	Solution structure of the N-terminal SAM-domain of human lymphocyte cytosolic protein 2
2E8O	;		;	Solution structure of the N-terminal SAM-domain of the SAM domain and HD domain containing protein 1 (Dendritic cell-derived IFNG-induced protein) (DCIP) (Monocyte protein 5) (MOP-5)
2RNO	;		;	Solution Structure of the N-terminal SAP Domain of SUMO E3 Ligases from Oryza sativa
2RNN	;		;	Solution Structure of the N-terminal SAP Domain of SUMO E3 Ligases from Saccharomyces cerevisiae
2QFG	;		;	Solution Structure of the N-terminal SCR-1/5 fragment of Complement Factor H.
2A36	;		;	Solution structure of the N-terminal SH3 domain of DRK
2RML	;		;	Solution structure of the N-terminal soluble domains of Bacillus subtilis CopA
1ND9	;		;	Solution Structure of the N-terminal Subdomain of Translation Initiation Factor IF2
1WY8	;		;	Solution Structure of the N-terminal Ubiquitin-like Domain in Human Np95/ICBP90-like Ring Finger Protein (NIRF)
1X1M	;		;	Solution Structure of the N-terminal Ubiquitin-like Domain in Mouse Ubiquitin-like Protein SB132
1WX8	;		;	Solution Structure of the N-terminal Ubiquitin-like Domain in the 4931431F19Rik Protein
1WX9	;		;	Solution Structure of the N-terminal Ubiquitin-like Domain in the Human BAT3 Protein
1WX7	;		;	Solution Structure of the N-terminal Ubiquitin-like Domain in the Human Ubiquilin 3 (UBQLN3)
1WGG	;		;	Solution Structure of the N-terminal Ubiquitin-like Domain of Mouse Ubiquitin Specific Protease 14 (USP14)
1WJV	;		;	Solution structure of the N-terminal zinc finger domain of mouse cell growth regulating nucleolar protein LYAR
1GNF	;		;	SOLUTION STRUCTURE OF THE N-TERMINAL ZINC FINGER OF MURINE GATA-1, NMR, 25 STRUCTURES
1ZU1	;		;	Solution Structure of the N-terminal Zinc Fingers of the Xenopus laevis double stranded RNA binding protein ZFa
1WJB	;		;	SOLUTION STRUCTURE OF THE N-TERMINAL ZN BINDING DOMAIN OF HIV-1 INTEGRASE (D FORM), NMR, 40 STRUCTURES
1WJA	;		;	SOLUTION STRUCTURE OF THE N-TERMINAL ZN BINDING DOMAIN OF HIV-1 INTEGRASE (D FORM), NMR, REGULARIZED MEAN STRUCTURE
1WJD	;		;	SOLUTION STRUCTURE OF THE N-TERMINAL ZN BINDING DOMAIN OF HIV-1 INTEGRASE (E FORM), NMR, 38 STRUCTURES
1WJC	;		;	SOLUTION STRUCTURE OF THE N-TERMINAL ZN BINDING DOMAIN OF HIV-1 INTEGRASE (E FORM), NMR, REGULARIZED MEAN STRUCTURE
2EE5	;		;	Solution structure of the N-teruminus extended RhoGAP domain from human Rho GTPase activating protein 5 variant
1NZ9	;		;	Solution Structure of the N-utilization substance G (NusG) C-terminal (NGC) domain from Thermus thermophilus
1NZ8	;		;	Solution Structure of the N-utilization substance G (NusG) N-terminal (NGN) domain from Thermus thermophilus
1E3T	;		;	Solution Structure of the NADP(H) binding Component (dIII) of Proton-Translocating Transhydrogenase from Rhodospirillum rubrum
2EQN	;		;	Solution structure of the NAF1 domain of Hypothetical protein BC008207 [Homo sapiens]
1PX9	;		;	Solution structure of the native CnErg1 Ergtoxin, a highly specific inhibitor of HERG channel
1LWR	;		;	Solution structure of the NCAM fibronectin type III module 2
2YUF	;		;	Solution structure of the NCD2 domain in human transcriptional repressor Nab1 protein
2MXA	;		;	Solution structure of the NDH-1 complex subunit CupS from Thermosynechococcus elongatus
1IIJ	;		;	SOLUTION STRUCTURE OF THE NEU/ERBB-2 MEMBRANE SPANNING SEGMENT
1YN2	;		;	Solution structure of the Neurospora VS ribozyme stem-loop V in the presence of MgCl2 with modeling of bound manganese ions
8GDH	;		;	Solution structure of the Neutrophil Serine Protease Inhibitor, EapH1
8GDG	;		;	Solution structure of the Neutrophil Serine Protease Inhibitor, EapH2
2YUE	;		;	Solution structure of the NEUZ (NHR) domain in Neuralized from Drosophila melanogaster
2E63	;		;	Solution structure of the NEUZ domain in KIAA1787 protein
6G81	;		;	Solution structure of the Ni metallochaperone HypA from Helicobacter pylori
1FU9	;		;	SOLUTION STRUCTURE OF THE NINTH ZINC-FINGER DOMAIN OF THE U-SHAPED TRANSCRIPTION FACTOR
1S9N	;		;	Solution structure of the nitrous acid (G)-(G) cross-linked DNA dodecamer duplex GCATCC(G)GATGC
1S9O	;		;	Solution structure of the nitrous acid induced DNA interstrand cross-linked dodecamer duplex CGCTAC(G)TAGCG with the cross-linked guanines denoted (G)
2B1W	;		;	Solution structure of the NOD1 Caspase Activating and Recruitment Domain
2L00	;		;	Solution structure of the non-covalent complex of the ZNF216 A20 domain with ubiquitin
2N05	;		;	Solution Structure of the non-phosphorylated N-terminal region of Human Cysteine String Protein (CSP)
1J5N	;		;	Solution Structure of the Non-Sequence-Specific HMGB protein NHP6A in complex with SRY DNA
1JLO	;		;	Solution Structure of the Noncompetitive Skeletal Muscle Nicotinic Acetylcholine Receptor Antagonist Psi-conotoxin PIIIE
1JLP	;		;	Solution Structure of the Noncompetitive Skeletal Muscle Nicotinic Acetylcholine Receptor Antagonist Psi-conotoxin PIIIF
2J2S	;		;	Solution structure of the nonmethyl-CpG-binding CXXC domain of the leukaemia-associated MLL histone methyltransferase
2DAM	;		;	Solution Structure of the Novel Identified UBA-like Domain in the N-terminal of Human ETEA Protein
2DAL	;		;	Solution Structure of the Novel Identified UBA-like Domain in the N-terminal of Human Fas Associated Factor 1 Protein
2DAJ	;		;	Solution Structure of the Novel Identified Ubiquitin-like Domain in the Human COBL-like 1 Protein
2DAF	;		;	Solution Structure of the Novel Identified Ubiquitin-like Domain in the Human Hypothetical Protein FLJ35834
7PRE	;		;	Solution structure of the NRDI domain of Nab3
2CZY	;		;	Solution structure of the NRSF/REST-mSin3B PAH1 complex
4C7Q	;		;	Solution structure of the Nt. GR-RBP1 RRM domain
2KKJ	;		;	Solution structure of the Nuclear coactivator binding domain of CBP
1NO8	;		;	SOLUTION STRUCTURE OF THE NUCLEAR FACTOR ALY RBD DOMAIN
1J9N	;		;	Solution Structure of the Nucleopeptide [AC-LYS-TRP-LYS-HSE(p3*dGCATCG)-ALA]-[p5*dCGTAGC]
2KMX	;		;	Solution structure of the nucleotide binding domain of the human Menkes protein in the ATP-bound form
2KMV	;		;	Solution structure of the nucleotide binding domain of the human Menkes protein in the ATP-free form
1X51	;		;	Solution structure of the NUDIX domain from human A/G-specific adenine DNA glycosylase alpha-3 splice isoform
1JKN	;		;	Solution Structure of the Nudix Enzyme Diadenosine Tetraphosphate Hydrolase from Lupinus angustifolius Complexed with ATP
1F3Y	;		;	SOLUTION STRUCTURE OF THE NUDIX ENZYME DIADENOSINE TETRAPHOSPHATE HYDROLASE FROM LUPINUS ANGUSTIFOLIUS L.
1DDM	;		;	SOLUTION STRUCTURE OF THE NUMB PTB DOMAIN COMPLEXED TO A NAK PEPTIDE
1POG	;		;	SOLUTION STRUCTURE OF THE OCT-1 POU-HOMEO DOMAIN DETERMINED BY NMR AND RESTRAINED MOLECULAR DYNAMICS
2RP5	;		;	Solution structure of the oligomerization domain in CEP-1
2RP4	;		;	Solution Structure of the oligomerization domain in Dmp53
1LR1	;		;	Solution Structure of the Oligomerization Domain of the Bacterial Chromatin-Structuring Protein H-NS
1Z3R	;		;	Solution structure of the Omsk Hemhorraghic Fever Envelope Protein Domain III
2LJK	;		;	Solution structure of the oncogenic-potential MIEN1 protein
1QTT	;		;	SOLUTION STRUCTURE OF THE ONCOPROTEIN P13MTCP1
1QTU	;		;	SOLUTION STRUCTURE OF THE ONCOPROTEIN P13MTCP1
7C4O	;		;	Solution structure of the Orange domain from human protein HES1
1TBD	;		;	SOLUTION STRUCTURE OF THE ORIGIN DNA BINDING DOMAIN OF SV40 T-ANTIGEN, NMR, MINIMIZED AVERAGE STRUCTURE
1FVY	;		;	SOLUTION STRUCTURE OF THE OSTEOGENIC 1-31 FRAGMENT OF THE HUMAN PARATHYROID HORMONE
2MMO	;		;	Solution Structure of the oxidised Thioredoxin from Plasmodium falciparum
2JZR	;		;	Solution structure of the oxidized form (Cys67-Cys70) of the N-terminal domain of PilB from N. meningitidis.
1SSE	;		;	Solution structure of the oxidized form of the Yap1 redox domain
5UJ5	;		;	Solution structure of the oxidized iron-sulfur protein adrenodoxin from Encephalitozoon cuniculi. Seattle Structural Genomics Center for Infectious Disease target EncuA.00705.a
2I96	;		;	Solution structure of the oxidized microsomal human cytochrome b5
201D	;		;	SOLUTION STRUCTURE OF THE OXYTRICHA TELOMERIC REPEAT D[G4(T4G4)3] G-TETRAPLEX
1WLP	;		;	Solution Structure Of The P22Phox-P47Phox Complex
2MNW	;		;	Solution structure of the P22S mutant of N-terminal CS domain of human Shq1
1NA2	;		;	Solution structure of the p2b hairpin from human telomerase RNA
1YMO	;		;	Solution structure of the P2b-P3 pseudoknot from human telomerase RNA
1XZY	;		;	Solution structure of the P30-trans form of Alpha Hemoglobin Stabilizing Protein (AHSP)
1C0O	;		;	SOLUTION STRUCTURE OF THE P5 HAIRPIN FROM A GROUP I INTRON COMPLEXED WITH COBALT (III) HEXAMMINE, NMR, 19 CONVERGED STRUCTURES
2EJY	;		;	Solution structure of the p55 PDZ T85C domain complexed with the glycophorin C F127C peptide
1AJF	;		;	SOLUTION STRUCTURE OF THE P5B STEM LOOP FROM A GROUP I INTRON COMPLEXED WITH COBALT (III) HEXAMMINE, NMR, MINIMIZED AVERAGE STRUCTURE
2JNJ	;		;	Solution structure of the p8 TFIIH subunit
2DYD	;		;	Solution structure of the PABC domain from Triticum aevestium poly(A)-binding protein
1G9L	;		;	SOLUTION STRUCTURE OF THE PABC DOMAIN OF HUMAN POLY(A) BINDING PROTEIN
2KV5	;		;	Solution structure of the par toxin Fst in DPC micelles
7FHQ	;		;	Solution structure of the pathogenic mutant G131V of Human prion protein (91-231)
7B2F	;		;	Solution structure of the Pax NRPS docking domain PaxB NDD
1IP9	;		;	SOLUTION STRUCTURE OF THE PB1 DOMAIN OF BEM1P
1IPG	;		;	SOLUTION STRUCTURE OF THE PB1 DOMAIN OF BEM1P
1Q1O	;		;	Solution Structure of the PB1 Domain of Cdc24p (Long Form)
1TZ1	;		;	Solution structure of the PB1 domain of CDC24P (short form)
2CU1	;		;	Solution structure of the PB1 domain of human protein kinase MEKK2b
1WI0	;		;	Solution structure of the PB1 domain of mouse mitogen activated protein kinase kinase 5 (MAP2K5)
1VD2	;		;	Solution Structure of the PB1 domain of PKCiota
1UFM	;		;	Solution structure of the PCI domain
1WI9	;		;	Solution structure of the PCI domain from mouse hypothetical protein AAH51541
2EDH	;		;	Solution structure of the PDZ domain (3614- 3713 ) from human obscurin
2EDV	;		;	Solution structure of the PDZ domain from human FERM and PDZ domain containing 1
2DKR	;		;	Solution structure of the PDZ domain from human Lin-7 homolog B
2E7K	;		;	Solution structure of the PDZ domain from Human MAGUK p55 subfamily member 2
2EDP	;		;	Solution structure of the PDZ domain from human Shroom family member 4
2ENO	;		;	Solution structure of the PDZ domain from human Synaptojanin 2 binding protein
1V5Q	;		;	Solution Structure of the PDZ Domain from Mouse Glutamate Receptor Interacting Protein 1A-L (GRIP1) Homolog
2YUB	;		;	Solution structure of the PDZ domain from mouse LIM domain kinase
1WI2	;		;	Solution structure of the PDZ domain from RIKEN cDNA 2700099C19
1T2M	;		;	Solution Structure Of The Pdz Domain Of AF-6
1Z86	;		;	Solution structure of the PDZ domain of alpha-syntrophin
2YT7	;		;	Solution structure of the PDZ domain of Amyloid beta A4 precursor protein-binding family A member 3
2YT8	;		;	Solution structure of the PDZ domain of Amyloid beta A4 precursor protein-binding family A member 3 (Neuron- specific X11L2 protein) (Neuronal Munc18-1-interacting protein 3) (Mint-3) (Adapter protein X11gamma)
1WF7	;		;	Solution structure of the PDZ domain of Enigma homologue protein
2CSS	;		;	Solution structure of the PDZ domain of human KIAA0340 protein
2DLS	;		;	Solution structure of the PDZ domain of human Rho guanine nucleotide exchange factor 11
1VAE	;		;	Solution structure of the PDZ domain of mouse Rhophilin-2
1VA8	;		;	Solution structure of the PDZ domain of Pals1 protein
1VB7	;		;	Solution structure of the PDZ domain of PDZ and LIM domain 2
1WHD	;		;	Solution structure of the PDZ domain of RGS3
1WF8	;		;	Solution structure of the PDZ domain of Spinophilin/NeurabinII protein
1WI4	;		;	Solution structure of the PDZ domain of syntaxin binding protein 4
2D8I	;		;	Solution structure of the PDZ domain of T-cell lymphoma invasion and metastasis 1 varian
2YTW	;		;	Solution structure of the PDZ-domain of human protease HTRA 1 precursor
3PDZ	;		;	SOLUTION STRUCTURE OF THE PDZ2 DOMAIN FROM HUMAN PHOSPHATASE HPTP1E
1D5G	;		;	SOLUTION STRUCTURE OF THE PDZ2 DOMAIN FROM HUMAN PHOSPHATASE HPTP1E COMPLEXED WITH A PEPTIDE
2KY5	;		;	Solution structure of the PECAM-1 cytoplasmic tail with DPC
1YGO	;		;	Solution Structure of the pelle Death Domain
2CPF	;		;	Solution structure of the penultimate RNA recognition motif of hypothetical RNA-binding protein RBM19
8PWT	;		;	Solution structure of the peptide U11-MYRTX-Tb1a from the venom of the ant Tetramorium bicarinatum
1X60	;		;	Solution structure of the peptidoglycan binding domain of B. subtilis cell wall lytic enzyme CwlC
2RUD	;		;	Solution structure of the peptidyl prolyl cis-trans isomerase domain of C113D mutant human Pin1 with sulfate ion
2RUC	;		;	Solution structure of the peptidyl prolyl cis-trans isomerase domain of human Pin1 with sulfate ion
8HER	;		;	Solution structure of the periplasmic domain of RsgI6 from Clostridium thermocellum
8HEP	;		;	Solution structure of the periplasmic domain of the anti-sigma factor RsgI1 from Clostridium thermocellum
8HEQ	;		;	Solution structure of the periplasmic domain of the anti-sigma factor RsgI2 from Clostridium thermocellum
2JWK	;		;	Solution Structure of the periplasmic domain of TolR from Haemophilus influenzae
2D1U	;		;	Solution structure of the periplasmic signaling domain of FecA from Escherichia coli
2M5J	;		;	Solution structure of the periplasmic signaling domain of HasR, a TonB-dependent outer membrane heme transporter
1FHO	;		;	Solution Structure of the PH Domain from the C. Elegans Muscle Protein UNC-89
8I53	;		;	Solution structure of the PH domain from the Tfb1 subunit of fission yeast TFIIH
2D9W	;		;	Solution structure of the PH domain of Docking protein 2 from human
2YS1	;		;	Solution structure of the PH domain of Dynamin-2 from human
2DHI	;		;	Solution structure of the PH domain of Evectin-2 from mouse
1WI1	;		;	Solution structure of the PH domain of human calcium-dependent activator protein for secretion (CAPS)
1X1F	;		;	Solution structure of the PH domain of human Docking protein BRDG1
2DN6	;		;	Solution structure of the PH domain of KIAA0640 protein from human
2YS3	;		;	Solution structure of the PH domain of Kindlin-3 from human
2D9X	;		;	Solution structure of the PH domain of Oxysterol binding protein-related protein 11 from human
2D9Y	;		;	Solution structure of the PH domain of PEPP-3 from human
2DA0	;		;	Solution structure of the PH domain of PIP2-dependent ARF1 GTPase-activating protein from human
2YRY	;		;	Solution structure of the PH domain of Pleckstrin homology domain-containing family A member 6 from human
2DKP	;		;	Solution structure of the PH domain of pleckstrin homology domain-containing protein family A member 5 from human
2D9V	;		;	Solution structure of the PH domain of Pleckstrin homology domain-containing protein family B member 1 from mouse
2COA	;		;	Solution structure of the PH domain of protein kinase C, D2 type from human
2D9Z	;		;	Solution structure of the PH domain of Protein kinase C, nu type from human
2DHJ	;		;	Solution structure of the PH domain of Rho GTPase activating protein 21 from human
2DHK	;		;	Solution structure of the PH domain of TBC1 domain family member 2 protein from human
1FP0	;		;	SOLUTION STRUCTURE OF THE PHD DOMAIN FROM THE KAP-1 COREPRESSOR
2YQL	;		;	Solution structure of the PHD domain in PHD finger protein 21A
2E6S	;		;	Solution structure of the PHD domain in RING finger protein 107
2E6R	;		;	Solution structure of the PHD domain in SmcY protein
2YT5	;		;	Solution structure of the PHD domain of Metal-response element-binding transcription factor 2
2MUM	;		;	Solution structure of the PHD domain of Yeast YNG2
6VFO	;		;	Solution structure of the PHD of mouse UHRF1 (NP95)
7KLO	;		;	Solution structure of the PHD1 domain of histone demethylase KDM5A
7KLR	;		;	Solution structure of the PHD1 domain of histone demethylase KDM5A in complex with a histone H3(1-10) peptide
2JTF	;		;	Solution Structure of the PHF20L1 MBT domain
2RV8	;		;	Solution Structure of the PhoP DNA-Binding Domain from Mycobacterium tuberculosis
2E73	;		;	Solution structure of the phorbol esters/diacylglycerol binding domain of protein kinase C gamma
7TOD	;		;	Solution structure of the phosphatidylinositol 3-phosphate binding domain from the Legionella effector SetA
2N04	;		;	Solution Structure of the phosphorylated N-terminal region of Human Cysteine String Protein (CSP)
1WIK	;		;	Solution Structure of the PICOT homology 2 domain of the mouse PKC-interacting cousin of thioredoxin protein
2L74	;		;	Solution structure of the PilZ domain protein PA4608 complex with c-di-GMP identifies charge clustering as molecular readout
5GPH	;		;	Solution structure of the Pin1-PPIase (S138A) mutant
2L7F	;		;	Solution Structure of the Pitx2 Homeodomain
2L7M	;		;	Solution Structure of the Pitx2 Homeodomain R24H mutant
2E7M	;		;	Solution structure of the PKD domain (329-428) from human KIAA0319
1WGO	;		;	Solution structure of the PKD domain from human VPS10 domain-containing receptor SorCS2
2YRL	;		;	Solution structure of the PKD domain from KIAA 1837 protein
2RSD	;		;	Solution structure of the plant homeodomain (PHD) of the E3 SUMO ligase Siz1 from rice
1V61	;		;	Solution Structure of the Pleckstrin Homology Domain of alpha-Pix
1V89	;		;	Solution Structure of the Pleckstrin Homology Domain of Human KIAA0053 Protein
1P6S	;		;	Solution Structure of the Pleckstrin Homology Domain of Human Protein Kinase B beta (Pkb/Akt)
1V5M	;		;	Solution Structure of the Pleckstrin Homology Domain of Mouse APS
1WGQ	;		;	Solution Structure of the Pleckstrin Homology Domain of Mouse Ethanol Decreased 4 Protein
1V88	;		;	Solution Structure of the Pleckstrin Homology Domain of Oxysterol-Binding Protein-Related Protein 8 (KIAA1451 Protein)
2DB9	;		;	Solution structure of the plus-3 domain of human KIAA0252 protein
2L47	;		;	Solution structure of the PlyG catalytic domain
2L48	;		;	Solution structure of the PlyG cell wall binding domain
1SXD	;		;	Solution Structure of the Pointed (PNT) Domain from mGABPa
2GRW	;		;	Solution structure of the poliovirus 3'-UTR Y-stem
2GV4	;		;	Solution structure of the poliovirus 3'-UTR Y-stem
1OF9	;		;	Solution structure of the pore forming toxin of entamoeba histolytica (Amoebapore A)
5ID3	;		;	Solution structure of the pore-forming region of C. elegans Mitochondrial Calcium Uniporter (MCU)
1AGT	;		;	SOLUTION STRUCTURE OF THE POTASSIUM CHANNEL INHIBITOR AGITOXIN 2: CALIPER FOR PROBING CHANNEL GEOMETRY
1QUZ	;		;	Solution structure of the potassium channel scorpion toxin HSTX1
1H20	;		;	Solution structure of the potato carboxypeptidase inhibitor
2MDI	;		;	Solution structure of the PP2WW mutant (KPP2WW) of HYPB
1L1P	;		;	Solution Structure of the PPIase Domain from E. coli Trigger Factor
2LKN	;		;	Solution structure of the PPIase domain of human aryl-hydrocarbon receptor-interacting protein (AIP)
1NMW	;		;	Solution structure of the PPIase domain of human Pin1
2N87	;		;	Solution structure of the PPIase domain of TbPar42
2K7N	;		;	Solution structure of the PPIL1 bound to a fragment of SKIP
2MPL	;		;	Solution structure of the PR domain of FOG-1
2RNZ	;		;	Solution structure of the presumed chromodomain of the yeast histone acetyltransferase, Esa1
2NCJ	;		;	Solution Structure of the PriC DNA replication restart protein
2BZM	;		;	Solution structure of the primary host recognition region of complement factor H
1IT4	;		;	Solution structure of the prokaryotic Phospholipase A2 from Streptomyces violaceoruber
2KR0	;		;	Solution structure of the proteasome ubiquitin receptor Rpn13
2JMB	;		;	Solution structure of the protein Atu4866 from Agrobacterium tumefaciens
1NR3	;		;	SOLUTION STRUCTURE OF THE PROTEIN MTH0916: THE NORTHEAST STRUCTURAL GENOMICS CONSORTIUM TARGET TT212
2L9D	;		;	Solution structure of the protein YP_546394.1, the first structural representative of the pfam family PF12112
1O6W	;		;	Solution Structure of the Prp40 WW Domain Pair of the Yeast Splicing Factor Prp40
5WLP	;		;	Solution structure of the pseudo-receiver domain of Atg32
1E95	;		;	Solution structure of the pseudoknot of SRV-1 RNA, involved in ribosomal frameshifting
2KYE	;		;	Solution structure of the pseudouridine modified P6.1 hairpin of human telomerase RNA
1SSL	;		;	Solution structure of the PSI domain from the Met receptor
2M1M	;		;	Solution structure of the PsIAA4 oligomerization domain reveals interaction modes for transcription factors in early auxin response
2DKQ	;		;	Solution structure of the PTB domain of KIAA1075 protein from human
7ZE0	;		;	Solution structure of the PulM C-terminal domain from Klebsiella oxytoca
2L3M	;		;	Solution structure of the putative copper-ion-binding protein from Bacillus anthracis str. Ames
2M4N	;		;	Solution structure of the putative Ras interaction domain of AFD-1, isoform a from Caenorhabditis elegans
1MP1	;		;	Solution structure of the PWI motif from SRm160
1N27	;		;	Solution structure of the PWWP domain of mouse Hepatoma-derived growth factor, related protein 3
1GD5	;		;	SOLUTION STRUCTURE OF THE PX DOMAIN FROM HUMAN P47PHOX NADPH OXIDASE
2CZO	;		;	Solution Structure of the PX Domain of Bem1p
2I4K	;		;	Solution Structure of the PX domain of Sorting Nexin 1
2DBG	;		;	Solution structure of the Pyrin (PAAD-DAPIN) domain in human Myeloid cell nuclear differentiation antigen
2MPC	;		;	Solution structure of the pyrin domain of human Pyrin
2DO9	;		;	Solution structure of the Pyrin/PAAD-DAPIN domain in mouse NALP10 (NACHT, leucine rich repeat and PYD containing 10)
2N72	;		;	Solution structure of the Q domain from ACBD3
2N4H	;		;	Solution Structure of the Q343R Mutant of TDP-43 Amyloidogenic Core Region
2YMJ	;		;	Solution structure of the QUA1 dimerization domain of pXqua, the Xenopus ortholog of Quaking.
1DVV	;		;	SOLUTION STRUCTURE OF THE QUINTUPLE MUTANT OF CYTOCHROME C-551 FROM PSEUDOMONAS AERUGINOSA
6GE1	;		;	Solution structure of the r(UGGUGGU)4 RNA quadruplex
2AGM	;		;	Solution structure of the R-module from AlgE4
2LSS	;		;	Solution structure of the R. rickettsii cold shock-like protein
2KVP	;		;	Solution Structure of the R10 Domain of Talin
2JSW	;		;	Solution Structure of the R13 Domain of Talin
1SJ8	;	2.6	;	Solution Structure of the R1R2 Domains of Talin
7KWI	;		;	Solution Structure of the R2ab Repeat Domain from Staph. epidermidis Autolysin (AtlE)
2L7A	;		;	Solution Structure of the R3 Domain of Talin
1WHR	;		;	Solution structure of the R3H domain from human hypothetical protein BAA76846
1MSZ	;		;	Solution structure of the R3H domain from human Smubp-2
2LRR	;		;	Solution structure of the R3H domain from human Smubp-2 in complex with 2'-deoxyguanosine-5'-monophosphate
2CPM	;		;	Solution structure of the R3H domain of human sperm-associated antigen 7
2LQG	;		;	Solution Structure of the R4 domain of talin
2L7N	;		;	Solution Structure of the R5 Domain of Talin
2F77	;		;	Solution structure of the R55F mutant of M-PMV matrix protein (p10)
2L10	;		;	Solution Structure of the R6 Domain of Talin
2KBB	;		;	Solution Structure of the R9 Domain of Talin
2DHZ	;		;	Solution Structure of the RA Domain in the Human Link Guanine Nucleotide Exchange Factor II (Link-GEFII)
1WGR	;		;	Solution Structure of the RA Domain of Human Grb7 Protein
2NBU	;		;	Solution structure of the Rad23 ubiquitin-like (UBL) domain
2EC1	;		;	Solution structure of the RanBD1 domain from human Nucleoporin 50 kDa
2CRF	;		;	Solution structure of the Ran_BP1 domain of RAN-binding protein-3
1WFY	;		;	Solution structure of the Ras-binding domain of mouse RGS14
1EF5	;		;	SOLUTION STRUCTURE OF THE RAS-BINDING DOMAIN OF RGL
1I35	;		;	SOLUTION STRUCTURE OF THE RAS-BINDING DOMAIN OF THE PROTEIN KINASE BYR2 FROM SCHIZOSACCHAROMYCES POMBE
2B3A	;		;	Solution structure of the Ras-binding domain of the Ral Guanosine Dissociation Stimulator
1Y9J	;		;	Solution structure of the rat Sly1 N-terminal domain
6U19	;		;	Solution Structure of the RAZUL domain from 26S proteasome subunit hRpn10/S5a complexed with the AZUL domain from E3 ligase E6AP/UBE3A
2YRV	;		;	Solution structure of the RBB1NT domain of human RB(retinoblastoma)-binding protein 1
2FFW	;		;	Solution structure of the RBCC/TRIM B-box1 domain of human MID1: B-box with a RING
2KRR	;		;	Solution structure of the RBD1,2 domains from human nucleolin
5MF9	;		;	Solution structure of the RBM5 OCRE domain in complex with polyproline SmN peptide.
2K96	;		;	Solution structure of the RDC-refined P2B-P3 pseudoknot from human telomerase RNA (delta U177)
2B68	;		;	Solution structure of the recombinant Crassostrea gigas defensin
1MWB	;		;	Solution structure of the recombinant hemoglobin from the cyanobacterium Synechocystis sp. PCC 6803 in its hemichrome state
1SM7	;		;	Solution structure of the recombinant pronapin precursor, BnIb.
1KVI	;		;	Solution Structure of the Reduced Form of the First Heavy Metal Binding Motif of the Menkes Protein
2JZS	;		;	Solution structure of the reduced form of the N-terminal domain of PilB from N. meningitidis.
2MMN	;		;	Solution Structure of the Reduced Thioredoxin from Plasmodium falciparum
2V1N	;		;	SOLUTION STRUCTURE OF THE REGION 51-160 OF HUMAN KIN17 REVEALS A WINGED HELIX FOLD
2KRD	;		;	Solution Structure of the Regulatory Domain of Human Cardiac Troponin C in Complex with the Switch Region of cardiac Troponin I and W7
2K6T	;		;	Solution structure of the relaxin-like factor
1FI6	;		;	SOLUTION STRUCTURE OF THE REPS1 EH DOMAIN
3KPE	;	1.47	;	Solution structure of the respiratory syncytial virus (RSV)six-helix bundle complexed with TMC353121, a small-moleucule inhibitor of RSV
1UHU	;		;	Solution structure of the retroviral Gag MA-like domain of RIKEN cDNA 3110009E22
2EBZ	;		;	Solution structure of the RGS domain from human Regulator of G-protein signaling 12 (RGS12)
2JM5	;		;	Solution Structure of the RGS domain from human RGS18
2OWI	;		;	Solution structure of the RGS domain from human RGS18
2DLR	;		;	Solution structure of the RGS domain of human Regulator of G-protein signaling 10
2DLV	;		;	Solution structure of the RGS domain of human regulator of G-protein signaling 18
2JNU	;		;	Solution structure of the RGS domain of human RGS14
2D9J	;		;	Solution structure of the RGS domain of Regulator of G-protein signaling 7
2CRP	;		;	Solution structure of the RGS domain of regulator of G-protein signalling 5 (RGS 5)
2MRM	;		;	Solution structure of the rhodanese domain of YgaP from E. coli
1WHB	;		;	Solution structure of the Rhodanese-like domain in human ubiquitin specific protease 8 (UBP8)
2DW3	;		;	Solution structure of the Rhodobacter sphaeroides PufX membrane protein
2EE4	;		;	Solution structure of the RhoGAP domain from human Rho GTPase activating protein 5 variant
1MXP	;		;	Solution structure of the ribbon disulfide bond isomer of alpha-conotoxin AuIB
1EMW	;		;	SOLUTION STRUCTURE OF THE RIBOSOMAL PROTEIN S16 FROM THERMUS THERMOPHILUS
1QKF	;		;	SOLUTION STRUCTURE OF THE RIBOSOMAL PROTEIN S19 FROM THERMUS THERMOPHILUS
1QKH	;		;	SOLUTION STRUCTURE OF THE RIBOSOMAL PROTEIN S19 FROM THERMUS THERMOPHILUS
6RK3	;		;	Solution structure of the ribosome Elongation Factor P (EF-P) from Staphylococcus aureus
1GE9	;		;	SOLUTION STRUCTURE OF THE RIBOSOME RECYCLING FACTOR
1N3G	;		;	Solution structure of the ribosome-associated cold shock response protein Yfia of Escherichia coli
1ZUB	;		;	Solution Structure of the RIM1alpha PDZ Domain in Complex with an ELKS1b C-terminal Peptide
2YSJ	;		;	Solution structure of the RING domain (1-56) from tripartite motif-containing protein 31
2YSL	;		;	Solution structure of the RING domain (1-66) from tripartite motif-containing protein 31
2JMD	;		;	Solution Structure of the Ring Domain of Human TRAF6
2ECG	;		;	Solution structure of the ring domain of the Baculoviral IAP repeat-containing protein 4 from Homo sapiens
6F98	;		;	Solution structure of the RING domain of the E3 ubiquitin ligase HRD1
2EA5	;		;	Solution Structure of the RING domain of the human Cell growth regulator with RING finger domain 1 protein
2D8S	;		;	Solution structure of the RING domain of the human cellular modulator of immune recognition protein
2DJB	;		;	Solution structure of the RING domain of the human Polycomb group RING finger protein 6
2ECN	;		;	Solution structure of the RING domain of the human RING finger protein 141
2D8T	;		;	Solution structure of the RING domain of the human RING finger protein 146
2EA6	;		;	Solution Structure of the RING domain of the human ring finger protein 4
2ECL	;		;	Solution Structure of the RING domain of the human RING-box protein 2
2ECI	;		;	Solution structure of the RING domain of the human TNF receptor-associated factor 6 protein
2ECJ	;		;	Solution structure of the RING domain of the human tripartite motif-containing protein 39
2CT0	;		;	Solution structure of the RING domain of the Non-SMC element 1 protein
2ECM	;		;	Solution structure of the RING domain of the RING finger and CHY zinc finger domain-containing protein 1 from Mus musculus
2CSZ	;		;	Solution Structure of the RING domain of the Synaptotagmin-like protein 4
2CT2	;		;	Solution Structure of the RING domain of the Tripartite motif protein 32
2CSY	;		;	Solution structure of the RING domain of the Zinc finger protein 183-like 1
1WIL	;		;	Solution Structure of the RING Finger Domain of the Human KIAA1045 Protein
1WIM	;		;	Solution Structure of the RING finger Domain of the human UbcM4-interacting Protein 4
2YUR	;		;	Solution structure of the Ring finger of human Retinoblastoma-binding protein 6
3ZTG	;		;	Solution structure of the RING finger-like domain of Retinoblastoma Binding Protein-6 (RBBP6)
2EGP	;		;	Solution structure of the RING-finger domain from human Tripartite motif protein 34
1V87	;		;	Solution Structure of the Ring-H2 Finger Domain of Mouse Deltex Protein 2
2LDY	;		;	Solution structure of the RMM-CTD domains of human LINE-1 ORF1p
1WHV	;		;	Solution structure of the RNA binding domain from hypothetical protein BAB23382
1WI6	;		;	Solution structure of the RNA binding domain from mouse hypothetical protein BAB23670
2DGO	;		;	Solution structure of the RNA binding domain in cytotoxic granule-associated RNA binding protein 1
2DB1	;		;	Solution structure of the RNA binding domain in heterogeneous nuclear ribonucleoprotein F homolog
2DGV	;		;	Solution structure of the RNA binding domain in Heterogeneous nuclear ribonucleoprotein M
2DGU	;		;	Solution structure of the RNA binding domain in Heterogeneous nuclear ribonucleoprotein Q
1WI8	;		;	Solution structure of the RNA binding domain of eukaryotic initiation factor 4B
2DO0	;		;	Solution structure of the RNA binding domain of heterogeneous nuclear ribonucleoprotein M
2CQH	;		;	Solution structure of the RNA binding domain of IGF-II mRNA-binding protein 2
5O1T	;		;	Solution structure of the RNA binding domain of Nrd1
2CQI	;		;	Solution structure of the RNA binding domain of Nucleolysin TIAR
2CQP	;		;	Solution structure of the RNA binding domain of RNA-binding protein 12
2DO4	;		;	Solution structure of the RNA binding domain of squamous cell carcinoma antigen recognized by T cells 3
2CQG	;		;	Solution structure of the RNA binding domain of TAR DNA-binding protein-43
6HMI	;		;	Solution structure of the RNA duplex formed by the 5'-end of U1snRNA and the 5'-splice site of SMN2 exon7
6HMO	;		;	Solution structure of the RNA duplex formed by the 5'-end of U1snRNA and the 5'-splice site of SMN2 exon7 in complex with the SMN-C5 splicing modifier
6NOA	;		;	Solution Structure of the RNA element that recruits eIF3 to the 5'-UTR of c-Jun and regulates specialized translation initiation (apical loop)
8CF2	;		;	Solution structure of the RNA helix formed by the 5'-end of U1 snRNA and an A-1 bulged 5'-splice site in complex with SMN-CY
1WHY	;		;	Solution structure of the RNA recognition motif from hypothetical RNA binding protein BC052180
2CQC	;		;	Solution Structure of the RNA recognition motif in Arginine/serine-rich splicing factor 10
2DGX	;		;	Solution structure of the RNA recognition motif in KIAA0430 protein
2CQB	;		;	Solution Structure of the RNA recognition motif in Peptidyl-prolyl cis-trans isomerase E
2CQD	;		;	Solution Structure of the RNA recognition motif in RNA-binding region containing protein 1
2CPI	;		;	Solution structure of the RNA recognition motif of CNOT4
2CPE	;		;	Solution structure of the RNA recognition motif of Ewing Sarcoma(EWS) protein
2CPD	;		;	Solution structure of the RNA recognition motif of human APOBEC-1 complementation factor, ACF
2MMY	;		;	Solution structure of the RNA recognition motif of human TAF15
2N74	;		;	Solution Structure of the RNA-Binding domain of non-structural protein 1 from the 1918 H1N1 influenza virus
1AUU	;		;	SOLUTION STRUCTURE OF THE RNA-BINDING DOMAIN OF THE ANTITERMINATOR PROTEIN SACY, NMR, 10 STRUCTURES
1O1W	;		;	SOLUTION STRUCTURE OF THE RNASE H DOMAIN OF THE HIV-1 REVERSE TRANSCRIPTASE IN THE PRESENCE OF MAGNESIUM
1F6Z	;		;	SOLUTION STRUCTURE OF THE RNASE P RNA (M1 RNA) P4 STEM C70U MUTANT OLIGORIBONUCLEOTIDE
1F7I	;		;	SOLUTION STRUCTURE OF THE RNASE P RNA (M1 RNA) P4 STEM C70U MUTANT OLIGORIBONUCLEOTIDE COMPLEXED WITH COBALT (III) HEXAMINE ,NMR, ENSEMBLE OF 12 STRUCTURES
1F7G	;		;	SOLUTION STRUCTURE OF THE RNASE P RNA (M1 RNA) P4 STEM C70U MUTANT OLIGORIBONUCLEOTIDE, ENSEMBLE OF 17 STRUCTURES
1F6X	;		;	SOLUTION STRUCTURE OF THE RNASE P RNA (M1 RNA) P4 STEM OLIGORIBONUCLEOTIDE
1F7H	;		;	SOLUTION STRUCTURE OF THE RNASE P RNA (M1 RNA) P4 STEM OLIGORIBONUCLEOTIDE COMPLEXED WITH COBALT (III) HEXAMINE, NMR, ENSEMBLE OF 11 STRUCTURES
1F7F	;		;	SOLUTION STRUCTURE OF THE RNASE P RNA (M1 RNA) P4 STEM OLIGORIBONUCLEOTIDE, NMR, ENSEMBLE OF 9 STRUCTURES
2N8S	;		;	Solution Structure of the rNedd4 WW1 Domain by NMR
2N8U	;		;	Solution Structure of the rNedd4 WW2 Domain by NMR
2N8T	;		;	Solution Structure of the rNedd4 WW2 Domain-Cx43CT Peptide Complex by NMR
1I5H	;		;	SOLUTION STRUCTURE OF THE RNEDD4 WWIII DOMAIN-RENAL BP2 PEPTIDE COMPLEX
6GCJ	;		;	Solution structure of the RodA hydrophobin from Aspergillus fumigatus
2IHX	;		;	Solution Structure of the Rous Sarcoma Virus Nucleocapsid Protein:uPsi RNA Packaging Signal Complex
2N3T	;		;	Solution structure of the Rpn1 substrate receptor site toroid 1 (T1)
2N3U	;		;	Solution structure of the Rpn1 T1 site engaging two monoubiquitin molecules
2N3W	;		;	Solution structure of the Rpn1 T1 site with K48-linked diubiquitin in the contracted binding mode
2N3V	;		;	Solution structure of the Rpn1 T1 site with K48-linked diubiquitin in the extended binding mode
2NBW	;		;	Solution structure of the Rpn1 T1 site with the Rad23 UBL domain
2KQZ	;		;	Solution structure of the Rpn13 DEUBAD domain
2NBV	;		;	Solution structure of the Rpn13 Pru domain engaging the hPLIC2 UBL domain
2DIW	;		;	Solution structure of the RPR domain of Putative RNA-binding protein 16
2DHX	;		;	Solution Structure of the RRM Domain in the Human Poly (ADP-ribose) Polymerase Family, Member 10 Variant
2KYX	;		;	Solution structure of the RRM domain of CYP33
2NLW	;		;	Solution structure of the RRM domain of human eukaryotic initiation factor 3b
2DIU	;		;	Solution structure of the RRM domain of KIAA0430 protein
2HVZ	;		;	Solution structure of the RRM domain of SR rich factor 9G8
2M4M	;		;	Solution structure of the RRM domain of the hypothetical protein CAGL0M09691g from Candida glabrata
2DIV	;		;	Solution structure of the RRM domain of TRNA selenocysteine associated protein
2DIS	;		;	Solution structure of the RRM domain of unnamed protein product
2I38	;		;	Solution structure of the RRM of SRp20
2I2Y	;		;	Solution structure of the RRM of SRp20 bound to the RNA CAUC
2MTG	;		;	Solution structure of the RRM1 of human LARP6
2DIT	;		;	Solution structure of the RRM_1 domain of HIV TAT specific factor 1 variant
2FC8	;		;	Solution structure of the RRM_1 domain of NCL protein
2FC9	;		;	Solution structure of the RRM_1 domain of NCL protein
2CP8	;		;	Solution structure of the RSGI RUH-046, a UBA domain from human Next to BRCA1 gene 1 protein (KIAA0049 protein) R923H variant
2DAX	;		;	Solution structure of the RWD domain of human protein C21orf6
2DAY	;		;	Solution structure of the RWD domain of human ring finger protein 25
2EBM	;		;	Solution structure of the RWD domain of human RWD domain containing protein 1
2EBK	;		;	Solution structure of the RWD domain of human RWD domain containing protein 3
2DAW	;		;	Solution structure of the RWD domain of human RWD omain containing protein 2
1UKX	;		;	Solution structure of the RWD domain of mouse GCN2
2LC2	;		;	Solution structure of the RXLR effector P. capsici AVR3a4
1K5F	;		;	SOLUTION STRUCTURE OF THE S-STYRENE ADDUCT IN THE RAS61 SEQUENCE
2KID	;		;	Solution Structure of the S. Aureus Sortase A-substrate Complex
2LBX	;		;	Solution structure of the S. cerevisiae H/ACA RNP protein Nhp2p
2LBW	;		;	Solution structure of the S. cerevisiae H/ACA RNP protein Nhp2p-S82W mutant
1SYZ	;		;	Solution structure of the S. Cerevisiae U6 intramolecular stem loop (ISL) RNA at pH 5.7
1NZ1	;		;	Solution structure of the S. cerevisiae U6 Intramolecular stem-loop containing an SP phosphorothioate at nucleotide U80
1SLJ	;		;	Solution structure of the S1 domain of RNase E from E. coli
1WI5	;		;	Solution structure of the S1 RNA binding domain from human hypothetical protein BAA11502
2EQS	;		;	Solution structure of the S1 RNA binding domain of human ATP-dependent RNA helicase DHX8
2CQO	;		;	Solution structure of the S1 RNA binding domain of human hypothetical protein FLJ11067
2CQJ	;		;	Solution structure of the S4 domain of U3 small nucleolar ribonucleoprotein protein IMP3 homolog
2N6Z	;		;	Solution structure of the salicylate-loaded ArCP from yersiniabactin synthetase
2GYT	;		;	Solution structure of the SAM (sterile alpha motif) domain of DLC1 (deleted in liver cancer 1)
1X40	;		;	Solution structure of the SAM domain of human ARAP2
1WWV	;		;	Solution structure of the SAM domain of human connector enhancer of KSR-like protein CNK1
2D8C	;		;	Solution structure of the sam-domain of mouse phosphatidyl ceramidecholinephosphotransferase 1
2DKY	;		;	Solution structure of the SAM-domain of Rho-GTPase-activating protein 7
2DL0	;		;	Solution structure of the SAM-domain of the SAM and SH3 domain containing protein 1
1WWU	;		;	Solution structure of the SAM_PNT domain of human protein FLJ21935
2DKX	;		;	Solution structure of the SAM_PNT-domain of ETS transcription factor PDEF (Prostate ets)
1X66	;		;	Solution structure of the SAM_PNT-domain of the human friend LEUKEMIAINTEGRATION 1 transcription factor
2YTU	;		;	Solution structure of the SAM_PNT-domain of the human friend LEUKEMIAINTEGRATION 1 transcription factor
2DKZ	;		;	Solution structure of the SAM_PNT-domain of the hypothetical protein LOC64762
1UFN	;		;	Solution structure of the SAND domain of the putative nuclear protein homolog (5830484A20Rik)
2YQK	;		;	Solution structure of the SANT domain in Arginine-glutamic acid dipeptide (RE) repeats
2ELK	;		;	Solution structure of the SANT domain of fission yeast SPCC24B10.08c protein
2CU7	;		;	Solution structure of the SANT domain of human KIAA1915 protein
2YUS	;		;	Solution structure of the SANT domain of human SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily C member 1
2LTP	;		;	Solution structure of the SANT2 domain of the human nuclear receptor corepressor 2 (NCoR2), Northeast Structural Genomics Consortium (NESG) target ID HR4636E
1ZRJ	;		;	Solution structure of the SAP domain of human E1B-55kDa-associated protein 5 isoform c
2DO1	;		;	Solution structure of the SAP domain of human nuclear protein Hcc-1
2DO5	;		;	Solution structure of the SAP domain of human splicing factor 3B subunit 2
2KDP	;		;	Solution Structure of the SAP30 zinc finger motif
1YO4	;		;	Solution Structure of the SARS Coronavirus ORF 7a coded X4 protein
2FXP	;		;	Solution Structure of the SARS-Coronavirus HR2 Domain
2KAF	;		;	Solution structure of the SARS-unique domain-C from the nonstructural protein 3 (nsp3) of the severe acute respiratory syndrome coronavirus
5Z8Q	;		;	Solution structure of the SBDalpha domain of yeast Ssa1
5Z8I	;		;	Solution structure of the SBDbeta domain of yeast Ssa1
2KKT	;		;	Solution structure of the SCA7 domain of human Ataxin-7-L3 protein
2FI2	;		;	Solution structure of the SCAN homodimer from MZF-1/ZNF42
2K4U	;		;	Solution structure of the SCORPION TOXIN ADWX-1
1NM7	;		;	Solution structure of the ScPex13p SH3 domain
1YG3	;		;	Solution Structure of the ScYLV P1-P2 Frameshifting Pseudoknot, 20 Lowest Energy Structures
1YG4	;		;	Solution Structure of the ScYLV P1-P2 Frameshifting Pseudoknot, Regularized Average Structure
1IVZ	;		;	Solution structure of the SEA domain from murine hypothetical protein homologous to human mucin 16
2ACM	;		;	Solution structure of the SEA domain of human mucin 1 (MUC1)
2VDA	;		;	Solution structure of the SecA-signal peptide complex
2YSM	;		;	Solution structure of the second and third PHD domain from Histone-lysine N-methyltransferase 2C (KMT2C/MLL3)
2COU	;		;	Solution structure of the second BRCT domain of epithelial cell transforming 2
2E7N	;		;	Solution structure of the second Bromodomain from human Bromodomain-containing protein 3
2I8N	;		;	Solution structure of the second bromodomain of Brd4
2KTB	;		;	Solution Structure of the Second Bromodomain of Human Polybromo in complex with an acetylated peptide from Histone 3
2ENZ	;		;	Solution structure of the second C1 domain from human protein kinase C theta
2EP6	;		;	Solution structure of the second C2 domain from human MCTP2 protein
2ENT	;		;	Solution structure of the second C2H2-type zinc finger domain from human Krueppel-like factor 15
1WYQ	;		;	Solution structure of the second CH domain of human spectrin beta chain, brain 2
2DY8	;		;	Solution structure of the second chromodomain of yeast Chd1
2IKE	;		;	Solution Structure of the second Clip domain in PAP2
2YTX	;		;	Solution structure of the second cold-shock domain of the human KIAA0885 protein (UNR protein)
1SS2	;		;	Solution structure of the second complement control protein (CCP) module of the GABA(B)R1a receptor, Pro-119 cis conformer
1SRZ	;		;	Solution structure of the second complement control protein (CCP) module of the GABA(B)R1a receptor, Pro-119 trans conformer
1WH6	;		;	Solution structure of the second CUT domain of human Homeobox protein Cux-2
2CSF	;		;	Solution structure of the second CUT domain of human SATB2
2KJK	;		;	Solution structure of the second domain of the listeria protein Lin2157, Northeast Structural Genomics Consortium target Lkr136b
2RS7	;		;	Solution structure of the second dsRBD from RNA helicase A
2L2M	;		;	Solution structure of the second dsRBD of HYL1
2CPN	;		;	Solution structure of the second dsRBD of TAR RNA-binding protein 2
1X48	;		;	Solution structure of the second DSRM domain in Interferon-induced, double-stranded RNA-activated protein kinase
2E71	;		;	Solution structure of the second FF domain of human transcription factor CA150
1UJT	;		;	Solution structure of the second fibronectin Type III domain of human KIAA1568 protein
2ED8	;		;	Solution structure of the second fibronectin type III domain of human Netrin receptor DCC
2KBG	;		;	Solution structure of the second Fibronectin type-III module of NCAM2
2E7H	;		;	Solution structure of the second fn3 domain from human Ephrin type-B receptor 4
1X5L	;		;	Solution structure of the second fn3 domain of Eph receptor A8 protein
2DLH	;		;	Solution structure of the second fn3 domain of human receptor-type tyrosine-protein phosphatase delta
2DM4	;		;	Solution structure of the second fn3 domain of human sorLA/LR11
1VA9	;		;	Solution structure of the second FNIII domain of DSCAML1 protein
2YQI	;		;	Solution structure of the second HMG-box domain from high mobility group protein B3
2DA2	;		;	Solution structure of the second homeobox domain of AT-binding transcription factor 1 (ATBF1)
2ECC	;		;	Solution Structure of the second Homeobox Domain of Human Homeodomain Leucine Zipper-Encoding Gene (Homez)
2DN0	;		;	Solution structure of the second homeobox domain of human zinc fingers and homeoboxes protein 3
2DA5	;		;	Solution structure of the second homeobox domain of Zinc fingers and homeoboxes protein 3 (Triple homeobox 1 protein)
2DM3	;		;	Solution structure of the second ig domain of human palladin
2EDF	;		;	Solution structure of the second ig-like domain(2826-2915) from human Obscurin
2DGR	;		;	Solution structure of the second KH domain in ring finger and KH domain containing protein 1
2E6Z	;		;	Solution structure of the second KOW motif of human transcription elongation factor SPT5
2DLO	;		;	Solution structure of the second LIM domain of human Thyroid receptor-interacting protein 6
2D8X	;		;	Solution structure of the second LIM domain of particularly interesting new Cys-His protein (PINCH)
1X63	;		;	Solution structure of the second LIM domain of skeletal muscle LIM protein 1
2JWE	;		;	Solution structure of the second PDZ domain from human zonula occludens-1: A dimeric form with 3D domain swapping
1X5N	;		;	Solution structure of the second PDZ domain of harmonin protein
2DLU	;		;	Solution structure of the second PDZ domain of human InaD-like protein
1UF1	;		;	Solution structure of the second PDZ domain of human KIAA1526 protein
1UJV	;		;	Solution structure of the second PDZ domain of human membrane associated guanylate kinase inverted-2 (MAGI-2)
1WHA	;		;	Solution structure of the second PDZ domain of human scribble (KIAA0147 protein).
2OGP	;		;	Solution structure of the second PDZ domain of Par-3
1QLC	;		;	Solution structure of the second PDZ domain of Postsynaptic Density-95
1Y7N	;		;	Solution structure of the second PDZ domain of the human neuronal adaptor X11alpha
2ELI	;		;	Solution structure of the second Phorbol esters/diacylglycerol binding domain of human Protein kinase C alpha type
1XKE	;		;	Solution structure of the second Ran-binding domain from human RanBP2
1WHX	;		;	Solution structure of the second RNA binding domain from hypothetical protein BAB23448
2DGS	;		;	Solution structure of the second RNA binding domain in DAZ-associated protein 1
2DH7	;		;	Solution structure of the second RNA binding domain in Nucleolysin TIAR
2DGT	;		;	Solution structure of the second RNA binding domain in RNA-binding protein 30
2DNZ	;		;	Solution structure of the second RNA binding domain of RNA binding motif protein 23
2RNE	;		;	Solution structure of the second RNA recognition motif (RRM) of TIA-1
2DHA	;		;	Solution structure of the second RNA recognition motif in Hypothetical protein FLJ201171
2DGW	;		;	Solution structure of the second RNA recognition motif in RNA-binding protein 19
1D9A	;		;	SOLUTION STRUCTURE OF THE SECOND RNA-BINDING DOMAIN (RBD2) OF HU ANTIGEN C (HUC)
2U2F	;		;	SOLUTION STRUCTURE OF THE SECOND RNA-BINDING DOMAIN OF HU2AF65
1X4F	;		;	Solution structure of the second RRM domain in Matrin 3
1X5T	;		;	Solution structure of the second RRM domain in splicing factor = 3B
2RT3	;		;	Solution structure of the second RRM domain of Nrd1
2LKZ	;		;	Solution structure of the second RRM domain of RBM5
2EOB	;		;	Solution structure of the second SH2 domain from rat PLC gamma-2
2GSB	;		;	Solution structure of the second SH2 domain of human Ras GTPase-activating protein 1
2FRW	;		;	Solution structure of the second SH3 domain of human adaptor protein NCK2
2FEI	;		;	Solution structure of the second SH3 domain of Human CMS protein
1J3T	;		;	Solution structure of the second SH3 domain of human intersectin 2 (KIAA1256)
2DL7	;		;	Solution structure of the second SH3 domain of human KIAA0769 protein
2DM1	;		;	Solution structure of the second SH3 domain of human protein vav-2
2CSQ	;		;	Solution structure of the second SH3 domain of human RIM-binding protein 2
2YUP	;		;	Solution structure of the second SH3 domain of human Vinexin
2DT7	;		;	Solution structure of the second SURP domain of human splicing factor SF3a120 in complex with a fragment of human splicing factor SF3a60
2D8B	;		;	Solution structure of the second tandem cofilin-domain of mouse twinfilin
2H45	;		;	Solution structure of the second type III domain of human Fibronectin: ensemble of 25 structures
2H41	;		;	Solution structure of the second type III domain of human Fibronectin: minimized average structure
2DAK	;		;	Solution Structure of the Second UBA Domain in the Human Ubiquitin Specific Protease 5 (Isopeptidase 5)
2DWV	;		;	Solution structure of the second WW domain from mouse salvador homolog 1 protein (mWW45)
2YSE	;		;	Solution structure of the second WW domain from the human membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1. MAGI-1
2DMV	;		;	Solution structure of the second ww domain of Itchy homolog E3 ubiquitin protein ligase (Itch)
1WR4	;		;	Solution structure of the second WW domain of Nedd4-2
1WMV	;		;	Solution structure of the second WW domain of WWOX
2EBQ	;		;	Solution structure of the second zf-RanBP domain from human Nuclear pore complex protein Nup153
2K1P	;		;	Solution structure of the second zinc finger domain of ZRANB2/ZNF265
2CS2	;		;	Solution structure of the second Zn-finger domain of poly(ADP-ribose) polymerase-1
2EPU	;		;	Solution structure of the secound C2H2 type zinc finger domain of Zinc finger protein 32
2EPR	;		;	Solution structure of the secound zinc finger domain of Zinc finger protein 278
6WQL	;		;	Solution structure of the seed peptide C2 (VBP-1) from pumpkin
1R4G	;		;	Solution structure of the Sendai virus protein X C-subdomain
7CG1	;		;	Solution structure of the sensor domain of the anti-sigma factor RsgI4 in Pseudobacteroides cellulosolvens
1LWM	;		;	Solution Structure of the Sequence-Non-Specific HMGB protein NHP6A
2LAQ	;		;	Solution structure of the Sex Peptide from Drosophila melanogaster
2LXB	;		;	Solution structure of the Sgt2 homodimerization domain
4CPG	;		;	Solution structure of the SGTA N-terminal domain
2EO3	;		;	Solution structure of the SH2 domain from human Crk-like protein
2EO6	;		;	Solution structure of the SH2 domain from mouse B-cell linker protein BLNK
2RSY	;		;	Solution structure of the SH2 domain of Csk in complex with a phosphopeptide from Cbp
2CS0	;		;	Solution structure of the SH2 domain of human HSH2D protein
2DLZ	;		;	Solution structure of the SH2 domain of human protein vav-2
2CRH	;		;	Solution structure of the SH2 domain of human proto-oncogene protein VAV1
2CR4	;		;	Solution structure of the SH2 domain of human SH3BP2 protein
2DM0	;		;	Solution structure of the SH2 domain of human Tyrosine-protein kinase TXK
2DLY	;		;	Solution structure of the SH2 domain of murine Fyn-related kinase
1J0F	;		;	Solution Structure of the SH3 Domain Binding Glutamic Acid-rich Protein Like 3
1JEG	;		;	Solution structure of the SH3 domain from C-terminal Src Kinase complexed with a peptide from the tyrosine phosphatase PEP
1WXB	;		;	Solution structure of the SH3 domain from human epidermal growth factor receptor pathway substrate 8-like protein
2EBP	;		;	Solution structure of the SH3 domain from human SAM and SH3 domain containing protein 1
2ENM	;		;	Solution structure of the SH3 domain from mouse sorting nexin-9
2EQI	;		;	Solution structure of the SH3 domain from Phospholipase C, gamma 2
2YSQ	;		;	Solution structure of the SH3 domain from Rho guanine nucleotide exchange factor 9
2ED1	;		;	Solution structure of the SH3 domain of 130 kDa phosphatidylinositol 4,5-biphosphate-dependent ARF1 GTPase-activating protein
2ED0	;		;	Solution structure of the SH3 domain of Abl interactor 2 (Abelson interactor 2)
2M0Y	;		;	Solution structure of the SH3 domain of DOCK180
1X43	;		;	Solution structure of the SH3 domain of Endophilin B1 (Sh3g1b1)
2D8J	;		;	Solution structure of the SH3 domain of Fyn-related kinase
1WXT	;		;	Solution structure of the SH3 domain of human hypothetical protein FLJ21522
2DLP	;		;	Solution structure of the SH3 domain of human KIAA1783 protein
2YUN	;		;	Solution structure of the SH3 domain of human Nostrin
1UGV	;		;	Solution structure of the SH3 domain of human olygophrein-1 like protein (KIAA0621)
1X2K	;		;	Solution Structure of the SH3 Domain of Human osteoclast stimulating factor 1 (OSTF1)
2GQI	;		;	Solution structure of the SH3 domain of human Ras GTPase-activating protein 1
2EW3	;		;	Solution Structure Of The SH3 Domain Of Human SH3GL3
2DL8	;		;	Solution structure of the SH3 domain of human SLIT-ROBO Rho GTPase-activating protein 2
2YUQ	;		;	Solution structure of the SH3 domain of human Tyrosine-protein kinase ITK/TSK
2D8H	;		;	Solution structure of the SH3 domain of Hypothetical protein SH3YL1
1WXU	;		;	Solution structure of the SH3 domain of mouse peroxisomal biogenesis factor 13
2YUO	;		;	Solution structure of the SH3 domain of mouse RUN and TBC1 domain containing 3
1V1C	;		;	Solution Structure of the SH3 domain of Obscurin
1HSQ	;		;	SOLUTION STRUCTURE OF THE SH3 DOMAIN OF PHOSPHOLIPASE CGAMMA
2HSP	;		;	SOLUTION STRUCTURE OF THE SH3 DOMAIN OF PHOSPHOLIPASE CGAMMA
1WI7	;		;	Solution structure of the SH3 domain of SH3-domain kinase binding protein 1
2ECZ	;		;	Solution structure of the SH3 domain of Sorbin and SH3 domain-containing protein 1
2CUB	;		;	Solution structure of the SH3 domain of the human cytoplasmic protein Nck1
1WX6	;		;	Solution structure of the SH3 domain of the human cytoplasmic protein NCK2
2DIL	;		;	Solution structure of the SH3 domain of the human Proline-serine-threonine phosphatase-interacting protein 1
2CUD	;		;	Solution structure of the SH3 domain of the human SRC-like adopter protein (SLAP)
2CUC	;		;	Solution structure of the SH3 domain of the mouse hypothetical protein SH3RF2
1X2P	;		;	Solution structure of the SH3 domain of the Protein arginine N-methyltransferase 2
1X2Q	;		;	Solution structure of the SH3 domain of the Signal transducing adaptor molecule 2
2CT3	;		;	Solution Structure of the SH3 domain of the Vinexin protein
1WRY	;		;	Solution structure of the SH3 domain-binding glutamic acid-rich-like protein
2CT6	;		;	solution structure of the sh3 domain-binding glutamic acid-rich-like protein 2
2YT6	;		;	Solution structure of the SH3_1 domain of Yamaguchi sarcoma viral (v-yes) oncogene homolog 1
1XYU	;		;	Solution structure of the sheep prion protein with polymorphism H168
2ZAJ	;		;	Solution structure of the short-isoform of the second WW domain from the human membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 (MAGI-1)
2RMX	;		;	Solution structure of the SHP-1 C-terminal SH2 domain complexed with a tyrosine-phosphorylated peptide from NKG2A
2YU7	;		;	Solution structure of the SHP-1 C-terminal SH2 domain complexed with a tyrosine-phosphorylated peptide from NKG2A
6IVU	;		;	Solution structure of the Sigma-anti-sigma factor complex RsgI1N-SigI1C from Clostridium thermocellum
2RQE	;		;	Solution structure of the silkworm bGRP/GNBP3 N-terminal domain reveals the mechanism for b-1,3-glucan specific recognition
1H95	;		;	Solution structure of the single-stranded DNA-binding Cold Shock Domain (CSD) of human Y-box protein 1 (YB1) determined by NMR (10 lowest energy structures)
2EDE	;		;	Solution structure of the sixth fibronectin type III domain of human Netrin receptor DCC
2EHR	;		;	Solution structure of the sixth PDZ domain of human InaD-like protein
2YEN	;		;	Solution structure of the skeletal muscle and neuronal voltage gated sodium channel antagonist mu-conotoxin CnIIIC
2CUP	;		;	Solution structure of the Skeletal muscle LIM-protein 1
2JT4	;		;	Solution Structure of the Sla1 SH3-3-Ubiquitin Complex
2N99	;		;	Solution structure of the SLURP-2, a secreted isoform of Lynx1
2L52	;		;	Solution structure of the small archaeal modifier protein 1 (SAMP1) from Methanosarcina acetivorans
2M1U	;		;	Solution structure of the small dictyostelium discoideium myosin light chain mlcb provides insights into iq-motif recognition of class i myosin myo1b
1KGM	;		;	SOLUTION STRUCTURE OF THE SMALL SERINE PROTEASE INHIBITOR SGCI
1KIO	;		;	SOLUTION STRUCTURE OF THE SMALL SERINE PROTEASE INHIBITOR SGCI[L30R, K31M]
1KJ0	;		;	SOLUTION STRUCTURE OF THE SMALL SERINE PROTEASE INHIBITOR SGTI
5AJ1	;		;	Solution Structure of the Smarc Domain
2D9I	;		;	Solution structure of the SMR domain of NEDD4-binding protein 2
1XC5	;		;	Solution Structure of the SMRT Deacetylase Activation Domain
1M7K	;		;	Solution Structure of the SODD BAG Domain
2MPQ	;		;	Solution structure of the sodium channel toxin Hd1a
2LW3	;		;	Solution structure of the soluble domain of MmpS4 from Mycobacterium tuberculosis
2K14	;		;	Solution structure of the soluble domain of the NfeD protein YuaF from Bacillus subtilis
2JQ8	;		;	Solution structure of the Somatomedin B domain from vitronectin produced in Pichia pastoris
2YS0	;		;	Solution structure of the Somatomedin B domain of human Ectonucleotide pyrophosphatase/phosphodiesterase family member
3ZKT	;		;	SOLUTION STRUCTURE OF THE SOMATOSTATIN SST3 RECEPTOR ANTAGONIST TAU- CONOTOXIN CnVA
5WOE	;		;	Solution structure of the sorting nexin 25 phox-homology domain
2YU4	;		;	Solution structure of the SP-RING domain in non-SMC element 2 homolog (MMS21, S. cerevisiae)
1GAT	;		;	SOLUTION STRUCTURE OF THE SPECIFIC DNA COMPLEX OF THE ZINC CONTAINING DNA BINDING DOMAIN OF THE ERYTHROID TRANSCRIPTION FACTOR GATA-1 BY MULTIDIMENSIONAL NMR
1GAU	;		;	SOLUTION STRUCTURE OF THE SPECIFIC DNA COMPLEX OF THE ZINC CONTAINING DNA BINDING DOMAIN OF THE ERYTHROID TRANSCRIPTION FACTOR GATA-1 BY MULTIDIMENSIONAL NMR
1AJ3	;		;	SOLUTION STRUCTURE OF THE SPECTRIN REPEAT, NMR, 20 STRUCTURES
1DUJ	;		;	SOLUTION STRUCTURE OF THE SPINDLE ASSEMBLY CHECKPOINT PROTEIN HUMAN MAD2
2FJL	;		;	Solution Structure of the Split PH domain in Phospholipase C-gamma1
1Z87	;		;	solution structure of the split PH-PDZ Supramodule of alpha-Syntrophin
2LFV	;		;	Solution Structure of the SPOR domain from E. coli DamX
2IT7	;		;	Solution structure of the squash trypsin inhibitor EETI-II
1HA9	;		;	SOLUTION STRUCTURE OF THE SQUASH TRYPSIN INHIBITOR MCoTI-II, NMR, 30 STRUCTURES.
2NC0	;		;	Solution structure of the St domain of EMCV IRES
5IXF	;		;	Solution structure of the STAM2 SH3 with AMSH derived peptide complex
1XHJ	;		;	Solution Structure Of The Staphylococcus Epidermidis Protein SE0630. Northest Structural Genomics Consortium Target SeR8.
2KD8	;		;	Solution structure of the stem-loop IIId of GBV-B IRES
1V38	;		;	Solution structure of the Sterile Alpha Motif (SAM) domain of mouse SAMSN1
4UEI	;		;	Solution structure of the sterol carrier protein domain 2 of Helicoverpa armigera
2MAK	;		;	Solution structure of the STIM1 CC1-CC2 homodimer in complex with two Orai1 C-terminal domains.
2MAJ	;		;	Solution Structure of the STIM1 CC1-CC2 homodimer.
2EQP	;		;	Solution structure of the stn_TNFRSF12A_TNFR domain of Tumor necrosis factor receptor superfamily member 12A precursor
2EQO	;		;	Solution structure of the stn_TRAF3IP1_nd domain of interleukin 13 receptor alpha 1-binding protein-1 [Homo sapiens]
2L4O	;		;	Solution structure of the Streptococcus pneumoniae RrgB pilus backbone D1 domain
1UVF	;		;	Solution Structure of the structured part of the 15th Domain of LEKTI
2JMF	;		;	Solution structure of the Su(dx) WW4- Notch PY peptide complex
1ZWV	;		;	Solution Structure of the subunit binding domain (hbSBD) of the human mitochondrial branched-chain alpha-ketoacid dehydrogenase
1MHJ	;		;	SOLUTION STRUCTURE OF THE SUPERACTIVE MONOMERIC DES-[PHE(B25)] HUMAN INSULIN MUTANT. ELUCIDATION OF THE STRUCTURAL BASIS FOR THE MONOMERIZATION OF THE DES-[PHE(B25)] INSULIN AND THE DIMERIZATION OF NATIVE INSULIN
2E60	;		;	Solution structure of the surp1 domain in splicing factor, arginine/serine-rich 8
2E5Z	;		;	Solution structure of the surp2 domain in splicing factor, arginine/serine-rich 8
6HKC	;		;	Solution structure of the Sushi 1 domain of GABAbR1a
1BRZ	;		;	SOLUTION STRUCTURE OF THE SWEET PROTEIN BRAZZEIN, NMR, 43 STRUCTURES
1RYU	;		;	Solution Structure of the SWI1 ARID
1UHR	;		;	Solution structure of the SWIB domain of mouse BRG1-associated factor 60a
1V32	;		;	Solution structure of the SWIB/MDM2 domain of the hypothetical protein At5g08430 from Arabidopsis thaliana
1V31	;		;	Solution structure of the SWIB/MDM2 domain of the hypothetical protein At5g14170 from Arabidopsis thaliana
2ELJ	;		;	Solution structure of the SWIRM domain of baker's yeast Transcriptional adapter 2
2DCE	;		;	Solution structure of the SWIRM domain of human KIAA1915 protein
1EJP	;		;	SOLUTION STRUCTURE OF THE SYNDECAN-4 WHOLE CYTOPLASMIC DOMAIN
1EJQ	;		;	SOLUTION STRUCTURE OF THE SYNDECAN-4 WHOLE CYTOPLASMIC DOMAIN IN THE PRESENCE OF PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE
1J5M	;		;	SOLUTION STRUCTURE OF THE SYNTHETIC 113CD_3 BETA_N DOMAIN OF LOBSTER METALLOTHIONEIN-1
2EEM	;		;	Solution structure of the synthetic mytilin
2PDZ	;		;	SOLUTION STRUCTURE OF THE SYNTROPHIN PDZ DOMAIN IN COMPLEX WITH THE PEPTIDE GVKESLV, NMR, 15 STRUCTURES
1M8C	;		;	SOLUTION STRUCTURE OF THE T State OF TURKEY OVOMUCOID AT PH 2.5
5ZCZ	;		;	Solution structure of the T. Thermophilus HB8 TTHA1718 protein in living eukaryotic cells by in-cell NMR spectroscopy
2NBP	;		;	Solution structure of the T119M variant of transthyretin in its monomeric state
2AZV	;		;	Solution structure of the T22G mutant of N-terminal SH3 domain of DRK (calculated without NOEs)
2A37	;		;	Solution structure of the T22G mutant of N-terminal SH3 domain of DRK (DRKN SH3 DOMAIN)
1MXQ	;		;	Solution Structure of the Tachykinin Peptide Eledoisin
1N6T	;		;	Solution Structure of the Tachykinin Peptide Neurokinin A
2K17	;		;	Solution structure of the TAF3 PHD domain in complex with a H3K4me3 peptide
7AC1	;		;	Solution structure of the TAF4-RST domain
2H7D	;		;	Solution structure of the talin F3 domain in complex with a chimeric beta3 integrin-PIP kinase peptide
2H7E	;		;	Solution structure of the talin F3 domain in complex with a chimeric beta3 integrin-PIP kinase peptide- minimized average structure
2K00	;		;	Solution structure of the talin F3 in complex with layilin cytodomain
5AGQ	;		;	Solution structure of the TAM domain of human TIP5 BAZ2A involved in epigenetic regulation of rRNA genes
2DLQ	;		;	Solution structure of the tandem four zf-C2H2 domain repeats of murine GLI-Kruppel family member HKR3
2YRQ	;		;	Solution structure of the tandem HMG box domain from Human High mobility group protein B1
1KN7	;		;	Solution structure of the tandem inactivation domain (residues 1-75) of potassium channel RCK4 (Kv1.4)
7BUL	;		;	Solution structure of the tandem PH and BSD1 domains of TFIIH p62
6L87	;		;	Solution structure of the tandem PWWP-ARID domains of human RBBP1
2KLZ	;		;	Solution Structure of the Tandem UIM Domain of Ataxin-3 Complexed with Ubiquitin
2MKG	;		;	Solution structure of the tandem UIMs of RAP80
2L5F	;		;	Solution structure of the tandem WW domains from HYPA/FBP11
2JXW	;		;	Solution Structure of the Tandem WW Domains of FBP21
2RPC	;		;	Solution structure of the tandem zf-C2H2 domains from the human zinc finger protein ZIC 3
2LUY	;		;	Solution structure of the tandem zinc finger domain of fission yeast Stc1
2LS0	;		;	Solution Structure of the Target Recognition Domain of Zoocin A
6VA1	;		;	Solution Structure of the Tau pre-mRNA Exon 10 Splicing Regulatory Element
6VA2	;		;	Solution Structure of the Tau pre-mRNA Exon 10 Splicing Regulatory Element Bound to MH5
6VA4	;		;	Solution Structure of the Tau pre-mRNA Exon 10 Splicing Regulatory Element Bound to MIP
6VA3	;		;	Solution Structure of the Tau pre-mRNA Exon 10 Splicing Regulatory Element Bound to MQC
1F81	;		;	SOLUTION STRUCTURE OF THE TAZ2 DOMAIN OF THE TRANSCRIPTIONAL ADAPTOR PROTEIN CBP
2LJ4	;		;	Solution structure of the TbPIN1
1XDX	;		;	Solution Structure of the Tctex1 Light Chain From Chlamydomonas Inner Dynein Arm I1
1L1I	;		;	Solution Structure of the Tenebrio molitor Antifreeze Protein
2M0P	;		;	Solution structure of the tenth complement type repeat of human megalin
2MOG	;		;	Solution structure of the terminal Ig-like domain from Leptospira interrogans LigB
2M21	;		;	Solution structure of the Tetrahymena telomerase RNA stem IV terminal loop
186D	;		;	SOLUTION STRUCTURE OF THE TETRAHYMENA TELOMERIC REPEAT D(T2G4)4 G-TETRAPLEX
2DME	;		;	Solution structure of the TFIIS domain II of human PHD finger protein 3
1WWT	;		;	Solution structure of the TGS domain from human threonyl-tRNA synthetase
2JM3	;		;	Solution structure of the THAP domain from C. elegans C-terminal binding protein (CtBP)
2D8R	;		;	Solution structure of the thap domain of the human thap domain-containing protein 2
2KO0	;		;	Solution structure of the THAP zinc finger of THAP1 in complex with its DNA target
2LAU	;		;	Solution structure of the THAP-zinc finger domain 1-81 from the cell growth suppressor human THAP11 protein
2JTG	;		;	Solution structure of the THAP-zinc finger of THAP1
1DU2	;		;	SOLUTION STRUCTURE OF THE THETA SUBUNIT OF DNA POLYMERASE III
2AE9	;		;	Solution Structure of the theta subunit of DNA polymerase III from E. coli
2AXD	;		;	solution structure of the theta subunit of escherichia coli DNA polymerase III in complex with the epsilon subunit
2ROQ	;		;	Solution Structure of the thiolation-thioesterase di-domain of enterobactin synthetase component F
1QUW	;		;	SOLUTION STRUCTURE OF THE THIOREDOXIN FROM BACILLUS ACIDOCALDARIUS
1TI3	;		;	Solution structure of the Thioredoxin h1 from poplar, a CPPC active site variant
6NE8	;		;	Solution Structure of the Thioredoxin-like Domain of Arabidopsis NCP (NUCLEAR CONTROL OF PEP ACTIVITY)
2DBC	;		;	Solution structure of the Thioredoxin-like domain of Phosducin-like protein 2(PDCL2)
2DMG	;		;	Solution structure of the third C2 domain of KIAA1228 protein
2EPX	;		;	Solution structure of the third C2H2 type zinc finger domain of Zinc finger protein 28 homolog
2YST	;		;	Solution structure of the third cadherin domain from human protocadherin 7
1X65	;		;	Solution structure of the third cold-shock domain of the human KIAA0885 protein (UNR PROTEIN)
1WH8	;		;	Solution structure of the third CUT domain of human Homeobox protein Cux-2
2MDR	;		;	Solution structure of the third double-stranded RNA-binding domain (dsRBD3) of human adenosine-deaminase ADAR1
2DOE	;		;	Solution structure of the third FF domain of human transcription factor CA150
1UEN	;		;	Solution Structure of The Third Fibronectin III Domain of Human KIAA0343 Protein
2ED9	;		;	Solution structure of the third fibronectin type III domain of human Netrin receptor DCC
1KZ0	;		;	Solution structure of the third helix of Antennapedia homeodomain
1KZ2	;		;	Solution structure of the third helix of Antennapedia homeodomain derivative [W6F,W14F]
1KZ5	;		;	Solution structure of the third helix of Antennapedia homeodomain derivatives (RQIKIWFRKWKK)
2DA3	;		;	Solution structure of the third homeobox domain of AT-binding transcription factor 1 (ATBF1)
2DMP	;		;	Solution structure of the third homeobox domain of Zinc fingers and homeoboxes protein 2
2ENS	;		;	Solution structure of the third ig-like domain from human Advanced glycosylation end product-specific receptor
2EDK	;		;	Solution structure of the third ig-like domain from human Myosin-binding protein C, fast-type
2DKU	;		;	Solution structure of the third Ig-like domain of human KIAA1556 protein
1X44	;		;	Solution structure of the third ig-like domain of Myosin-dinding protein C, slow-type
2L7J	;		;	Solution structure of the third Immunoglobulin-like domain of nectin-1
2HH3	;		;	Solution structure of the third KH domain of KSRP
2DO3	;		;	Solution structure of the third KOW motif of transcription elongation factor SPT5
2D8Z	;		;	Solution structure of the third LIM domain of Four and a half LIM domains protein 2 (FHL-2)
2COR	;		;	Solution structure of the third LIM domain of particularly interesting new Cys-His protein
1WJQ	;		;	Solution structure of the third mbt domain from human KIAA1798 protein
1UEP	;		;	Solution Structure of The Third PDZ Domain of Human Atrophin-1 Interacting Protein 1 (KIAA0705 Protein)
2DMZ	;		;	Solution structure of the third PDZ domain of human InaD-like protein
1UFX	;		;	Solution structure of the third PDZ domain of human KIAA1526 protein
1V6B	;		;	Solution structure of the third PDZ domain of mouse harmonin
2D90	;		;	Solution structure of the third PDZ domain of PDZ domain containing protein 1
1UM7	;		;	Solution structure of the third PDZ domain of synapse-associated protein 102
2DNY	;		;	Solution structure of the third RNA binding domain of FBP-interacting repressor, SIAHBP1
1O0P	;		;	Solution Structure of the third RNA Recognition Motif (RRM) of U2AF65 in complex with an N-terminal SF1 peptide
1OPI	;		;	SOLUTION STRUCTURE OF THE THIRD RNA RECOGNITION MOTIF (RRM) OF U2AF65 IN COMPLEX WITH AN N-TERMINAL SF1 PEPTIDE
2EGE	;		;	Solution structure of the third SH3 domain from human KIAA1666 protein
1UHF	;		;	Solution Structure of the third SH3 domain of human intersectin 2(KIAA1256)
2FRY	;		;	Solution structure of the third SH3 domain of human NCK2 adaptor protein
2CSI	;		;	Solution structure of the third SH3 domain of human RIM-binding protein 2
2DA9	;		;	Solution structure of the third SH3 domain of SH3-domain kinase binding protein 1 (Regulator of ubiquitous kinase, Ruk)
2K9G	;		;	Solution structure of the third SH3 domain of the Cin85 adapter protein
1WLX	;		;	Solution structure of the third spectrin repeat of alpha-actinin-4
2EHF	;		;	Solution structure of the third Sushi domain from human CUB and sushi domain-containing protein 1
1WR7	;		;	Solution structure of the third WW domain of Nedd4-2
2ELY	;		;	Solution structure of the third zf-C2H2 domain from human Zinc finger protein 224
2EBV	;		;	Solution structure of the third zf-RanBP domain from human Nuclear pore complex protein Nup153
1SRK	;		;	Solution structure of the third zinc finger domain of FOG-1
2EPQ	;		;	Solution structure of the third zinc finger domain of Zinc finger protein 278
1P7A	;		;	Solution Structure of the Third Zinc Finger from BKLF
2DIR	;		;	Solution structure of the THUMP domain of THUMP domain-containing protein 1
2YRP	;		;	Solution structure of the TIG domain from Human Nuclear factor of activated T-cells, cytoplasmic 4
2Z5V	;		;	Solution structure of the TIR domain of human MyD88
1PK2	;		;	SOLUTION STRUCTURE OF THE TISSUE-TYPE PLASMINOGEN ACTIVATOR KRINGLE 2 DOMAIN COMPLEXED TO 6-AMINOHEXANOIC ACID AN ANTIFIBRINOLYTIC DRUG
132D	;		;	SOLUTION STRUCTURE OF THE TN AN DNA DUPLEX GCCGTTAACGGC CONTAINING THE HPA I RESTRICTION SITE
2TOB	;		;	SOLUTION STRUCTURE OF THE TOBRAMYCIN-RNA APTAMER COMPLEX, NMR, 13 STRUCTURES
7CSS	;		;	Solution structure of the topological isomer of Heat-stable enterotoxin produced by Enterotoxigenic Escherichia coli
2NDI	;		;	Solution structure of the toxin ISTX-I from Ixodes scapularis
2MVA	;		;	Solution structure of the toxin, RhTx
2BUG	;		;	Solution structure of the TPR domain from Protein phosphatase 5 in complex with Hsp90 derived peptide
6G5S	;		;	Solution structure of the TPR domain of the cell division coordinator, CpoB
1TRF	;		;	SOLUTION STRUCTURE OF THE TR1C FRAGMENT OF SKELETAL MUSCLE TROPONIN-C
2YUC	;		;	Solution structure of the TRAF-type zinc finger domains (102-164) from human TNF receptor associated factor 4
1W0A	;		;	Solution structure of the trans form of the human alpha-hemoglobin stabilizing protein (AHSP)
2GUT	;		;	Solution structure of the trans-activation domain of the human co-activator ARC105
2M0S	;		;	Solution Structure of the trans-membrane domain of the NS2A of dengue virus
1I1S	;		;	SOLUTION STRUCTURE OF THE TRANSCRIPTIONAL ACTIVATION DOMAIN OF THE BACTERIOPHAGE T4 PROTEIN MOTA
2MV6	;		;	Solution structure of the transmembrane domain and the juxta-membrane domain of the Erythropoietin Receptor in micelles
2L5B	;		;	Solution structure of the transmembrane domain of Bcl-2 member Harakiri in micelles
2MFR	;		;	Solution structure of the transmembrane domain of the insulin receptor in micelles
2KNU	;		;	Solution structure of the transmembrane proximal region of the hepatis C virus E1 glycoprotein
1MH6	;		;	Solution Structure of the Transposon Tn5-encoding Bleomycin-binding Protein, BLMT
2MVW	;		;	Solution structure of the TRIM19 B-box1 (B1) of human promyelocytic leukemia (PML)
5JPX	;		;	Solution structure of the TRIM21 B-box2 (B2)
2KRQ	;		;	Solution structure of the tRNA-Arg2 (ICG) ASL.
1DU6	;		;	SOLUTION STRUCTURE OF THE TRUNCATED PBX HOMEODOMAIN
2FO8	;		;	Solution structure of the Trypanosoma cruzi cysteine protease inhibitor chagasin
6VEE	;		;	Solution structure of the TTD and linker region of mouse UHRF1 (NP95)
6VED	;		;	Solution structure of the TTD and linker region of UHRF1
2XK0	;		;	Solution structure of the Tudor domain from Drosophila Polycomblike (Pcl)
1WGS	;		;	Solution Structure of the Tudor Domain from Mouse Hypothetical Protein Homologous to Histone Acetyltransferase
2EQJ	;		;	Solution structure of the TUDOR domain of Metal-response element-binding transcription factor 2
2E5P	;		;	Solution structure of the TUDOR domain of PHD finger protein 1 (PHF1 protein)
2E5Q	;		;	Solution structure of the TUDOR domain of PHD finger protein 19, isoform b [Homo sapiens]
2EQU	;		;	Solution structure of the tudor domain of PHD finger protein 20-like 1
2EQM	;		;	Solution structure of the TUDOR domain of PHD finger protein 20-like 1 [Homo sapiens]
6NNB	;		;	Solution structure of the Tudor domain of PSHCP
2E6N	;		;	Solution structure of the TUDOR domain of Staphylococcal nuclease domain-containing protein 1
1G5V	;		;	SOLUTION STRUCTURE OF THE TUDOR DOMAIN OF THE HUMAN SMN PROTEIN
2DIQ	;		;	Solution structure of the TUDOR domain of Tudor and KH domain containing protein
2D9T	;		;	Solution structure of the Tudor domain of Tudor domain containing protein 3 from mouse
2EQK	;		;	Solution structure of the TUDOR domain of Tudor domain-containing protein 4
1ICH	;		;	SOLUTION STRUCTURE OF THE TUMOR NECROSIS FACTOR RECEPTOR-1 DEATH DOMAIN
1U5L	;		;	Solution Structure of the turtle prion protein fragment (121-226)
2I1P	;		;	Solution structure of the twelfth cysteine-rich ligand-binding repeat in rat megalin
2A55	;		;	Solution structure of the two N-terminal CCP modules of C4b-binding protein (C4BP) alpha-chain.
2LYV	;		;	Solution structure of the two RRM domains of hnRNP A1 (UP1) using segmental isotope labeling
2GQJ	;		;	Solution structure of the two zf-C2H2 like domains(493-575) of human zinc finger protein KIAA1196
1ZDX	;		;	Solution Structure of the type 1 pilus assembly platform FimD(25-125)
1ZDV	;		;	Solution Structure of the type 1 pilus assembly platform FimD(25-139)
2K3N	;		;	Solution structure of the type 1 repetitive domain (TUSP1-RP1) of the egg case silk from Nephila Antipodiana
2K3O	;		;	Solution structure of the type 2 repetitive domain (TUSP1-RP2) of the egg case silk from Nephila Antipodiana
1DAV	;		;	SOLUTION STRUCTURE OF THE TYPE I DOCKERIN DOMAIN FROM THE CLOSTRIDIUM THERMOCELLUM CELLULOSOME (20 STRUCTURES)
1DAQ	;		;	SOLUTION STRUCTURE OF THE TYPE I DOCKERIN DOMAIN FROM THE CLOSTRIDIUM THERMOCELLUM CELLULOSOME (MINIMIZED AVERAGE STRUCTURE)
1WGM	;		;	Solution structure of the U-box in human ubiquitin conjugation factor E4A
1N87	;		;	Solution structure of the U-box of Prp19
1LC6	;		;	Solution Structure of the U6 Intramolecular Stem-loop RNA
2QH3	;		;	Solution structure of the U64 H/ACA snoRNA 3' terminal hairpin loop
2QH4	;		;	Solution structure of the U85 C/D-H/ACA scaRNA 5' terminal hairpin loop
2EC4	;		;	Solution structure of the UAS domain from human FAS-associated factor 1
2DLX	;		;	Solution structure of the UAS domain of human UBX domain-containing protein 7
2JUJ	;		;	Solution Structure of the UBA domain from c-Cbl
2JNH	;		;	Solution Structure of the UBA Domain from Cbl-b
1V92	;		;	Solution structure of the UBA domain from p47, a major cofactor of the AAA ATPase p97
2DZL	;		;	Solution Structure of the UBA domain in Human Protein FAM100B
1PGY	;		;	Solution structure of the UBA domain in Saccharomyces cerevisiae protein, Swa2p
2DKL	;		;	Solution Structure of the UBA Domain in the Human Trinucleotide Repeat Containing 6C Protein (hTNRC6C)
2MGW	;		;	Solution Structure of the UBA Domain of Human NBR1
1WJI	;		;	Solution Structure of the UBA Domain of Human Tudor Domain Containing Protein 3
2CRN	;		;	Solution structure of the UBA domain of human UBASH3A protein
2RRU	;		;	Solution structure of the UBA omain of p62 and its interaction with ubiquitin
2FUH	;		;	Solution Structure of the UbcH5c/Ub Non-covalent Complex
1V86	;		;	Solution structure of the ubiquitin domain from mouse D7Wsu128e protein
2JX5	;		;	Solution structure of the ubiquitin domain N-terminal to the S27a ribosomal subunit of Giardia lamblia
1WXV	;		;	Solution structure of the ubiquitin domain of BCL-2 binding athanogene-1
2CWB	;		;	Solution Structure of the Ubiquitin-Associated Domain of Human BMSC-UbP and its Complex with Ubiquitin
2DEN	;		;	Solution Structure of the Ubiquitin-Associated Domain of Human BMSC-UbP and its Complex with Ubiquitin
2KHU	;		;	Solution Structure of the Ubiquitin-Binding Motif of Human Polymerase Iota
2I5O	;		;	Solution Structure of the Ubiquitin-Binding Zinc Finger (UBZ) Domain of the Human DNA Y-Polymerase Eta
1V5O	;		;	Solution Structure of the Ubiquitin-like Domain from Mouse Hypothetical 1700011N24Rik Protein
1V5T	;		;	Solution Structure of the Ubiquitin-like Domain from Mouse Hypothetical 8430435I17Rik Protein
2DZM	;		;	Solution Structure of the Ubiquitin-like Domain in Human FAS-associated factor 1 (hFAF1)
1J8C	;		;	Solution Structure of the Ubiquitin-like Domain of hPLIC-2
1TTN	;		;	Solution structure of the ubiquitin-like domain of human DC-UBP from dendritic cells
2N7D	;		;	Solution structure of the UBL domain of human Ddi2
6KQV	;		;	Solution Structure of the UbL Domain of USP19
2N7E	;		;	Solution structure of the UBL domain of yeast Ddi1
1WGD	;		;	Solution structure of the Ubl-domain of Herp
2MUL	;		;	Solution Structure of the UBM1 domain of human HUWE1/ARF-BP1
2CR5	;		;	Solution structure of the UBX domain of D0H8S2298E protein
1WJ4	;		;	Solution structure of the UBX domain of KIAA0794 protein
1I4V	;		;	SOLUTION STRUCTURE OF THE UMUD' HOMODIMER
2LRT	;		;	Solution structure of the uncharacterized thioredoxin-like protein BVU_1432 from Bacteroides vulgatus
1N4B	;		;	Solution Structure of the undecamer CGAAAC*TTTCG
1J4Y	;		;	Solution Structure of the Unmodified Anticodon Stem-loop from E. coli tRNA(Phe)
1KKA	;		;	Solution Structure of the Unmodified Anticodon Stem-loop from E. coli tRNA(Phe)
1LMV	;		;	Solution structure of the unmodified U2 snRNA-intron branch site helix from S. cerevisiae
2EDI	;		;	Solution structure of the UQ_con domain from human NEDD8-conjugating enzyme NCE2
1KMD	;		;	SOLUTION STRUCTURE OF THE VAM7P PX DOMAIN
2LCT	;		;	Solution structure of the Vav1 SH2 domain complexed with a Syk-derived doubly phosphorylated peptide
2MC1	;		;	Solution structure of the Vav1 SH2 domain complexed with a Syk-derived singly phosphorylated peptide
2ROR	;		;	Solution structure of the VAV1 SH2 domain complexed with a tyrosine-phosphorylated peptide from SLP76
1UJS	;		;	Solution structure of the Villin headpiece domain of human actin-binding LIM protein homologue (KIAA0843 protein)
1JMN	;		;	Solution Structure of the Viscotoxin A2
1JMP	;		;	Solution Structure of the Viscotoxin B
2KYH	;		;	Solution structure of the voltage-sensing domain of KvAP
1YN1	;		;	Solution structure of the VS ribozyme stem-loop V in the presence of MgCl2
1HWQ	;		;	SOLUTION STRUCTURE OF THE VS RIBOZYME SUBSTRATE STEM-LOOP
2FE9	;		;	Solution structure of the Vts1 SAM domain in the presence of RNA
2JYG	;		;	Solution Structure of the W184A/M185A Mutant of the Carboxy-terminal Dimerization Domain of the HIV-1 Capsid Protein
1I87	;		;	SOLUTION STRUCTURE OF THE WATER-SOLUBLE FRAGMENT OF RAT HEPATIC APOCYTOCHROME B5
1I8C	;		;	SOLUTION STRUCTURE OF THE WATER-SOLUBLE FRAGMENT OF RAT HEPATIC APOCYTOCHROME B5
6IB6	;		;	Solution structure of the water-soluble LU-domain of human Lypd6 protein
6ZSO	;		;	Solution structure of the water-soluble LU-domain of human Lypd6b protein
2EOC	;		;	Solution structure of the WGR domain from human poly [ADP-ribose] polymerase-3
8E4V	;		;	Solution structure of the WH domain of MORF
2K2G	;		;	Solution structure of the wild-type catalytic domain of human matrix metalloproteinase 12 (MMP-12) in complex with a tight-binding inhibitor
2K95	;		;	Solution structure of the wild-type P2B-P3 pseudoknot of human telomerase RNA
2ARF	;		;	Solution structure of the Wilson ATPase N-domain in the presence of ATP
2DO7	;		;	Solution structure of the winged helix-turn-helix motif of human CUL-4B
1T84	;		;	Solution structure of the Wiskott-Aldrich Syndrome Protein (WASP) autoinhibited core domain complexed with (S)-wiskostatin, a small molecule inhibitor
2LRU	;		;	Solution Structure of the WNK1 Autoinhibitory Domain
2YSC	;		;	Solution structure of the WW domain from the human amyloid beta A4 precursor protein-binding family B member 3, APBB3
2YSH	;		;	Solution structure of the WW domain from the human growth-arrest-specific protein 7, GAS-7
2YSG	;		;	Solution structure of the WW domain from the human syntaxin-binding protein 4
2MDC	;		;	Solution structure of the WW domain of HYPB
1TP4	;		;	Solution structure of the XPC binding domain of hHR23A protein
1FVS	;		;	SOLUTION STRUCTURE OF THE YEAST COPPER TRANSPORTER DOMAIN CCC2A IN THE APO AND CU(I) LOAD STATES
1FVQ	;		;	SOLUTION STRUCTURE OF THE YEAST COPPER TRANSPORTER DOMAIN CCC2A IN THE APO AND CU(I) LOADED STATES
5KES	;		;	Solution structure of the yeast Ddi1 HDD domain
2JTI	;		;	Solution structure of the yeast iso-1-cytochrome c (T12A) : yeast cytochrome c peroxidase complex
1LPW	;		;	Solution structure of the yeast spliceosomal U2 snRNA-intron branch site helix featuring a conserved pseudouridine
2LLV	;		;	Solution structure of the yeast Sti1 DP1 domain
2LLW	;		;	Solution structure of the yeast Sti1 DP2 domain
1RF8	;		;	Solution structure of the yeast translation initiation factor eIF4E in complex with m7GDP and eIF4GI residues 393 to 490
1M94	;		;	Solution Structure of the Yeast Ubiquitin-Like Modifier Protein Hub1
1IV0	;		;	Solution structure of the YqgF-family protein (N-terminal fragment)
6LR2	;		;	SOLUTION STRUCTURE OF THE YTH DOMAIN IN YTH DOMAIN-2 CONTAINING PROTEIN 2
2YUD	;		;	Solution structure of the YTH domain in YTH domain-containing protein 1 (Putative splicing factor YT521)
2YU6	;		;	Solution structure of the YTH domain in YTH domain-containing protein 2
2MTV	;		;	Solution Structure of the YTH Domain of YT521-B in complex with N6-Methyladenosine containing RNA
1OYI	;		;	Solution structure of the Z-DNA binding domain of the vaccinia virus gene E3L
2L54	;		;	Solution structure of the Zalpha domain mutant of ADAR1 (N43A,Y47A)
2L4M	;		;	Solution structure of the Zbeta domain of human DAI and its binding modes to B- and Z-DNA
6CKU	;		;	Solution structure of the zebrafish granulin AaE
1WFP	;		;	Solution structure of the zf-AN1 domain from Arabiopsis thaliana F5O11.17 protein
1X4W	;		;	Solution structure of the zf-AN1 domain from human hypothetical protein FLJ13222
1X4V	;		;	Solution structure of the zf-AN1 domain from human hypothetical protein LOC130617
1WFF	;		;	Solution structure of the zf-AN1 domain from mouse RIKEN cDNA 2810002D23 protein
1WFL	;		;	Solution structure of the zf-AN1 domain from mouse zinc finger protein 216
2EGM	;		;	Solution structure of the zf-B_box domain from human Tripartite motif protein 41
2CSV	;		;	Solution structure of the zf-B_box type2 domain of human tripartite motif protein TRIM29 isoform alpha
2YU5	;		;	Solution structure of the zf-C2H2 domain (669-699AA) in zinc finger protein 473
2YRK	;		;	Solution structure of the zf-C2H2 domain in zinc finger homeodomain 4
2CS3	;		;	Solution structure of the zf-C3HC4 domain of human KIAA1865
2FC6	;		;	Solution structure of the zf-CCCH domain of target of EGR1, member 1 (Nuclear)
2E5S	;		;	Solution structure of the zf-CCCHx2 domain of muscleblind-like 2, isoform 1 [Homo sapiens]
2E61	;		;	Solution structure of the zf-CW domain in zinc finger CW-type PWWP domain protein 1
2YQP	;		;	Solution structure of the zf-HIT domain in DEAD (Asp-Glu-Ala-Asp) box polypeptide 59
2YQQ	;		;	Solution structure of the zf-HIT domain in zinc finger HIT domain-containing protein 3 (TRIP-3)
2CR8	;		;	Solution structure of the zf-RanBP domain of p53-binding protein Mdm4
2CRC	;		;	Solution structure of the zf-RanBP domain of the protein HBV associated factor
2D9G	;		;	Solution structure of the zf-RanBP domain of YY1-associated factor 2
2YRC	;		;	Solution structure of the zf-Sec23_Sec24 from human Sec23A
2YRD	;		;	Solution structure of the zf-Sec23_Sec24 from human Sec23A mutant V69A
2D9K	;		;	Solution structure of the zf-TRAF domain of FLN29 gene product
2KZI	;		;	Solution structure of the ZHER2 Affibody
2KZJ	;		;	Solution structure of the ZHER2 Affibody (alternative)
2LVH	;		;	Solution structure of the zinc finger AFV1p06 protein from the hyperthermophilic archaeal virus AFV1
2CT5	;		;	Solution Structure of the zinc finger BED domain of the zinc finger BED domain containing protein 1
2YSA	;		;	Solution structure of the zinc finger CCHC domain from the human retinoblastoma-binding protein 6 (Retinoblastoma-binding Q protein 1, RBQ-1)
2E72	;		;	Solution structure of the zinc finger domain of human KIAA0461
7SEK	;		;	Solution structure of the zinc finger domain of murine MetAP1, complexed with ZNG N-terminal peptide
1VD4	;		;	Solution structure of the zinc finger domain of TFIIE alpha
2CT1	;		;	Solution Structure of the zinc finger domain of Transcriptional repressor CTCF protein
2L80	;		;	Solution Structure of the Zinc Finger Domain of USP13
2YRA	;		;	Solution structure of the zinc finger domains (1-87) from human F-box only protein
2YRE	;		;	Solution structure of the zinc finger domains (1-87) from human F-box only protein
2ECT	;		;	Solution structure of the Zinc finger, C3HC4 type (RING finger) domain of RING finger protein 126
2ECV	;		;	Solution structure of the Zinc finger, C3HC4 type (RING finger) domain of Tripartite motif-containing protein 5
2ECW	;		;	Solution structure of the Zinc finger, C3HC4 type (RING finger) domain Tripartite motif protein 30
2ECY	;		;	Solution structure of the Zinc finger, C3HC4 type (RING finger)"" domain of TNF receptor-associated factor 3
2EBL	;		;	Solution structure of the Zinc finger, C4-type domain of human COUP transcription factor 1
5U6H	;		;	Solution structure of the zinc fingers 1 and 2 of MBNL1
5U9B	;		;	Solution structure of the zinc fingers 1 and 2 of MBNL1 in complex with human cardiac troponin T pre-mRNA
5U6L	;		;	Solution structure of the zinc fingers 3 and 4 of MBNL1
1UW0	;		;	Solution structure of the zinc-finger domain from DNA ligase IIIa
2CQE	;		;	Solution Structure of the Zinc-finger domain in KIAA1064 protein
2CQF	;		;	Solution Structure of the Zinc-finger domain in LIN-28
2BL6	;		;	Solution structure of the Zn complex of EIAV NCp11(22-58) peptide, including two CCHC Zn-binding motifs.
2IWJ	;		;	SOLUTION STRUCTURE OF THE ZN COMPLEX OF HIV-2 NCP(23-49) PEPTIDE, ENCOMPASSING PROTEIN CCHC-LINKER, DISTAL CCHC ZN-BINDING MOTIF AND C- TERMINAL TAIL.
2LK5	;		;	Solution structure of the Zn(II) form of Desulforedoxin
6QK5	;		;	Solution Structure of the Zn-loaded form of a Metallothionein from Helix Pomatia
6KCZ	;		;	Solution structure of the ZnF-UBP domain of USP20/VDU2
2E5R	;		;	Solution structure of the ZZ domain of Dystrobrevin alpha (Dystrobrevin-alpha)
2DIP	;		;	Solution structure of the ZZ domain of Zinc finger SWIM domain containing protein 2
2FC7	;		;	Solution structure of the ZZ domain of ZZZ3 protein
1AX6	;		;	SOLUTION STRUCTURE OF THE [AF]-C8-DG ADDUCT OPPOSITE A-2 DELETION SITE IN THE NARI HOT SPOT SEQUENCE CONTEXT; NMR, 6 STRUCTURES
1AX7	;		;	SOLUTION STRUCTURE OF THE [AF]-C8-DG ADDUCT POSITIONED AT A TEMPLATE-PRIMER JUNCTION, NMR, 6 STRUCTURES
1C0Y	;		;	SOLUTION STRUCTURE OF THE [AF]-C8-DG ADDUCT POSITIONED OPPOSITE DA AT A TEMPLATE-PRIMER JUNCTION
2MPG	;		;	Solution structure of the [AibB8,LysB28,ProB29]-insulin analogue
1UEO	;		;	Solution structure of the [T8A]-Penaeidin-3
1S7P	;		;	Solution structure of thermolysin digested microcin J25
2LLN	;		;	Solution structure of Thermus thermophilus apo-CuA
2ROG	;		;	Solution structure of Thermus thermophilus HB8 TTHA1718 protein in living E. coli cells
2ROE	;		;	Solution structure of thermus thermophilus HB8 TTHA1718 protein in vitro
1PJZ	;		;	Solution structure of thiopurine methyltransferase from Pseudomonas syringae
2HSY	;		;	Solution structure of Thioredoxin 2 from Saccharomyces cerevisiae
2L5L	;		;	Solution Structure of Thioredoxin from Bacteroides Vulgatus
1XFL	;		;	Solution Structure of Thioredoxin h1 from Arabidopsis Thaliana
1GL8	;		;	Solution structure of thioredoxin m from spinach, oxidized form
1WMJ	;		;	Solution structure of Thioredoxin type h from Oryza sativa
5ZPV	;		;	Solution Structure of Thioredoxin-Like Effector Protein (TRX3) from Edwardsiella piscicida
1EDW	;		;	SOLUTION STRUCTURE OF THIRD INTRADISKAL LOOP OF BOVINE RHODOPSIN (RESIDUES 268-293)
1F0Z	;		;	SOLUTION STRUCTURE OF THIS, THE SULFUR CARRIER PROTEIN IN E.COLI THIAMIN BIOSYNTHESIS
2EBT	;		;	Solution structure of three tandem repeats of zf-C2H2 domains from human Kruppel-like factor 5
2EE8	;		;	Solution structure of three zf-C2H2 domains from mouse protein odd-skipped-related 2 splicing isoform 2
7V3T	;		;	Solution structure of thrombin binding aptamer G-quadruplex bound a self-adaptive small molecule with rotated ligands
1IEN	;		;	SOLUTION STRUCTURE OF TIA
2JTO	;		;	Solution Structure of Tick Carboxypeptidase Inhibitor
2K2X	;		;	Solution Structure of Tick Carboxypeptidase Inhibitor at pH 3.5
5H2S	;		;	Solution structure of Tilapia Piscidin 4 (TP4) from Oreochromis niloticus
7QXJ	;		;	Solution structure of Tk-hefu-11
8AR0	;		;	Solution structure of TLR2 transmembrane and cytoplasmic juxtamembrane regions
8AR1	;		;	Solution structure of TLR3 transmembrane and cytoplasmic juxtamembrane regions
8AR2	;		;	Solution structure of TLR5 transmembrane and cytoplasmic juxtamembrane regions
8AR3	;		;	Solution structure of TLR9 transmembrane and cytoplasmic juxtamembrane regions
1JDQ	;		;	Solution Structure of TM006 Protein from Thermotoga maritima
1T6R	;		;	Solution structure of TM1442, a putative anti sigma factor antagonist in phosphorylated state
1R73	;		;	Solution Structure of TM1492, the L29 ribosomal protein from Thermotoga maritima
1TVI	;		;	Solution structure of TM1509 from Thermotoga maritima: VT1, a NESGC target protein
2JTW	;		;	Solution structure of TM7 bound to DPC micelles
7NT7	;		;	Solution structure of toll like receptor 1 (TLR1) TIR domain
1CN2	;		;	SOLUTION STRUCTURE OF TOXIN 2 FROM CENTRUROIDES NOXIUS HOFFMANN, A BETA SCORPION NEUROTOXIN ACTING ON SODIUM CHANNELS, NMR, 15 STRUCTURES
1PE4	;		;	SOLUTION STRUCTURE OF TOXIN CN12 FROM CENTRUROIDES NOXIUS ALFA SCORPION TOXIN ACTING ON SODIUM CHANNELS. NMR STRUCTURE
2MHJ	;		;	Solution structure of TpsB4 N-terminal POTRA domain from Pseudomonas aeruginosa
2JSY	;		;	Solution structure of Tpx in the oxidized state
2JSZ	;		;	Solution structure of Tpx in the reduced state
2EOD	;		;	Solution structure of TRAF-type zinc finger domains (190- 248) from human TNF receptor-associated factor 4
2M6H	;		;	Solution structure of trans(C2-P3) trans (D5-P6) of LO959 in methanol
1VA1	;		;	Solution Structure of Transcription Factor Sp1 DNA Binding Domain (Zinc Finger 1)
1VA2	;		;	Solution Structure of Transcription Factor Sp1 DNA Binding Domain (Zinc Finger 2)
1VA3	;		;	Solution Structure of Transcription Factor Sp1 DNA Binding Domain (Zinc Finger 3)
2N8N	;		;	Solution structure of translation initiation factor
6C00	;		;	Solution structure of translation initiation factor 1 from Clostridium difficile
2NCH	;		;	Solution structure of translation initiation factor IF1 from wolbachia endosymbiont strain TRS of Brugia malayi
6J2Y	;		;	Solution structure of translationally controlled tumor protein from photosynthetic microalga Nannochloropsis oceanica
2DAS	;		;	Solution structure of TRASH domain of zinc finger MYM-type protein 5
6D6S	;		;	Solution structure of Trigger Factor dimer
2LDO	;		;	Solution structure of triheme cytochrome PpcA from Geobacter sulfurreducens reveals the structural origin of the redox-Bohr effect
6I9H	;		;	Solution structure of TRIM28 RING domain
1W0S	;		;	Solution structure of trimeric form of properdin by X-ray solution scattering and analytical ultracentrifugation
2L5K	;		;	Solution structure of truncated 23-mer DNA MUC1 aptamer
6OKY	;		;	Solution structure of truncated peptide from PAMap53
5YOZ	;		;	Solution structure of truncated Rab5a from Leishmania donovani
2IPA	;		;	solution structure of Trx-ArsC complex
1TUR	;		;	SOLUTION STRUCTURE OF TURKEY OVOMUCOID THIRD DOMAIN AS DETERMINED FROM NUCLEAR MAGNETIC RESONANCE DATA
2MV2	;		;	Solution structure of Twinstar from Drosophila melanogastor
2CTD	;		;	Solution structure of two zf-C2H2 domains from human Zinc finger protein 512
2FZ5	;		;	Solution structure of two-electron reduced Megasphaera elsdenii flavodoxin
1E8R	;		;	SOLUTION STRUCTURE OF TYPE X CBD
1QLD	;		;	Solution structure of type X CBM
2M3V	;		;	Solution structure of tyrosine phosphatase related to biofilm formation A (TpbA) from Pseudomonas aeruginosa
1JH3	;		;	Solution structure of tyrosyl-tRNA synthetase C-terminal domain.
7AEP	;		;	Solution structure of U1-A RRM2 (190-282)
2M0X	;		;	Solution structure of U14Ub1, an engineered ubiquitin variant with increased affinity for USP14
2O32	;		;	Solution structure of U2 snRNA stem I from human, containing modified nucleotides
2O33	;		;	Solution structure of U2 snRNA stem I from S. cerevisiae
6TR0	;		;	Solution structure of U2AF2 RRM1,2
1WGN	;		;	Solution Structure of UBA domain of Human Ubiquitin Associated Protein 1 (UBAP1)
2KNA	;		;	Solution structure of UBA domain of XIAP
1XO3	;		;	Solution Structure of Ubiquitin like protein from Mus Musculus
8HW9	;		;	Solution structure of ubiquitin-like domain (UBL) of human ZFAND1
1WE7	;		;	Solution structure of Ubiquitin-like domain in SF3a120
1WE6	;		;	Solution structure of Ubiquitin-like domain in splicing factor AAL91182
1UEL	;		;	Solution structure of ubiquitin-like domain of hHR23B complexed with ubiquitin-interacting motif of proteasome subunit S5a
1IYF	;		;	Solution structure of ubiquitin-like domain of human parkin
2MQJ	;		;	Solution structure of ubiquitin-like protein from Caldiarchaeum subterraneum
2L32	;		;	solution structure of ubiquitin-like small archaeal modifier protein in Haloferax volcanii
1P0R	;		;	Solution Structure of UBL5 a human Ubiquitin-Like Protein
2KWV	;		;	Solution Structure of UBM1 of murine Polymerase iota in Complex with Ubiquitin
2KWU	;		;	Solution Structure of UBM2 of murine Polymerase iota in Complex with Ubiquitin
2I50	;		;	Solution Structure of Ubp-M Znf-UBP domain
2KXJ	;		;	Solution structure of UBX domain of human UBXD2 protein
2LEN	;		;	Solution structure of UCHL1 S18Y variant
6IZG	;		;	Solution structure of Ufm1 protein from Trypanosoma brucei
1WXS	;		;	Solution Structure of Ufm1, a ubiquitin-fold modifier
2M1Z	;		;	Solution structure of uncharacterized protein lmo0427
2K4V	;		;	Solution structure of uncharacterized protein PA1076 from Pseudomonas aeruginosa. Northeast Structural Genomics Consortium (NESG) target PaT3, Ontario Center for Structural Proteomics target PA1076 .
2M72	;		;	Solution structure of uncharacterized thioredoxin-like protein PG_2175 from Porphyromonas gingivalis
6ZLE	;		;	Solution structure of unliganded MLKL executioner domain
2DO8	;		;	Solution Structure of UPF0301 protein HD_1794
2JR5	;		;	Solution structure of UPF0350 protein VC_2471. Northeast Structural Genomics Target VcR36
2JR6	;		;	Solution structure of UPF0434 protein NMA0874. Northeast Structural Genomics Target MR32
2AX5	;		;	Solution Structure of Urm1 from Saccharomyces Cerevisiae
2K9X	;		;	Solution structure of Urm1 from Trypanosoma brucei
2HDM	;		;	Solution structure of V21C/V59C Lymphotactin/XCL1
2NBE	;		;	Solution structure of V26A mutant of Ubiquitin at pH 2.0
2NBD	;		;	Solution structure of V26A mutant of Ubiquitin at pH 6.0
2JMG	;		;	Solution structure of V7R mutant of HIV-1 myristoylated matrix protein
1VFI	;		;	Solution Structure of Vanabin2 (RUH-017), a Vanadium-binding Protein from Ascidia sydneiensis samea
2E5E	;		;	Solution Structure of Variable-type Domain of Human Receptor for Advanced Glycation Endproducts
2K7G	;		;	Solution Structure of varv F
2LNX	;		;	Solution structure of Vav2 SH2 domain
1U89	;		;	Solution structure of VBS2 fragment of talin
2B0H	;		;	Solution structure of VBS3 fragment of talin
6OKW	;		;	Solution structure of VEK50
6OQ9	;		;	Solution structure of VEK50 in the bound form with plasminogen kringle 2
6OKX	;		;	Solution structure of VEK50RH1/AA
6BZL	;		;	Solution structure of VEK75
2LHT	;		;	Solution structure of Venturia inaequalis cellophane-induced 1 protein (ViCin1) domains 1 and 2
2LUW	;		;	Solution structure of vEP C-ter 100
2N9N	;		;	solution structure of VG16KRKP in C.neoformans (conformation 1)
2KUK	;		;	Solution structure of vhl-2
1VB8	;		;	solution structure of vhr1, the first cyclotide from root tissue
1NXI	;		;	Solution structure of Vibrio cholerae protein VC0424
6WQJ	;		;	Solution structure of vicilin-buried peptide-10 from cucumber
1HHV	;		;	SOLUTION STRUCTURE OF VIRUS CHEMOKINE VMIP-II
5V4U	;		;	Solution structure of VKK38 bound to plasminogen kringle 2
2K9O	;		;	Solution structure of Vm24 synthetic scorpion toxin
2MXD	;		;	Solution structure of VPg of porcine sapovirus
1Q0W	;		;	Solution structure of Vps27 amino-terminal UIM-ubiquitin complex
1S6X	;		;	Solution structure of VSTx
2N1N	;		;	Solution structure of VSTx1
2VB5	;		;	Solution structure of W60G mutant of human beta2-microglobulin
2CR9	;		;	Solution structure of WGR domain of poly(ADP-ribose) polymerase-1
1CZ2	;		;	SOLUTION STRUCTURE OF WHEAT NS-LTP COMPLEXED WITH PROSTAGLANDIN B2.
1IY5	;		;	Solution structure of wild type OMSVP3
1KQ8	;		;	Solution Structure of Winged Helix Protein HFH-1
2DK5	;		;	Solution structure of Winged-Helix domain in RNA polymerase III 39KDa polypeptide
2DK7	;		;	Solution structure of WW domain in transcription elongation regulator 1
2DK1	;		;	Solution structure of WW domain in WW domain binding protein 4 (WBP-4)
2MDJ	;		;	Solution structure of WW domain with polyproline stretch (PP2WW) of HYPB
1UJR	;		;	Solution structure of WWE domain in BAB28015
1X4R	;		;	Solution structure of WWE domain in Parp14 protein
2DK6	;		;	Solution structure of WWE domain in poly (ADP-ribose) polymerase family, member 11 (PARP 11)
2KEP	;		;	Solution structure of XcpT, the main component of the type 2 secretion system of Pseudomonas aeruginosa
1R3B	;		;	Solution structure of xenopus laevis Mob1
1XU0	;		;	Solution structure of Xenopus leavis prion protein
1PVE	;		;	Solution structure of XPC binding domain of hHR23B
5W8Y	;		;	Solution Structure of XPH1, a Hybrid Sequence of Xfaso 1 and Pfl 6, Two Cro Proteins With Different Folds
5W8Z	;		;	Solution Structure of XPH2, a Hybrid Sequence of Xfaso 1 and Pfl 6, Two Cro Proteins With Different Folds
2ORU	;		;	Solution structure of xtz1-peptide, a beta-hairpin peptide with a structured extension
2MQ6	;		;	Solution structure of Y125F mutant of eRF1 N-domain
1SG5	;		;	Solution structure of Yaeo, a Rho-specific inhibitor of transcription termination
1YWS	;		;	Solution structure of YBL071w-A from Saccharomyces cerevisiae.
2ASY	;		;	Solution Structure of ydhR protein from Escherichia coli
1U96	;		;	Solution Structure of Yeast Cox17 with Copper Bound
2M80	;		;	Solution structure of yeast dithiol glutaredoxin Grx8
2OGH	;		;	Solution structure of yeast eIF1
1HV2	;		;	SOLUTION STRUCTURE OF YEAST ELONGIN C IN COMPLEX WITH A VON HIPPEL-LINDAU PEPTIDE
5Y4B	;		;	Solution structure of yeast Fra2
2K0N	;		;	Solution Structure of Yeast Gal11p kix domain
6ALY	;		;	Solution structure of yeast Med15 ABD2 residues 277-368
1Y8M	;		;	Solution Structure of Yeast Mitochondria Fission Protein Fis1
2KH9	;		;	Solution structure of yeast Prp24-RRM2 bound to a fragment of U6 RNA
1XS8	;		;	Solution Structure of YGGX protein of salmonella enterica
1DCJ	;		;	SOLUTION STRUCTURE OF YHHP, A NOVEL ESCHERICHIA COLI PROTEIN IMPLICATED IN THE CELL DIVISION
1H8M	;		;	Solution structure of ykt6
1IOU	;		;	SOLUTION STRUCTURE OF YKT6P (1-140)
2ML9	;		;	Solution structure of YSCUCN in a micellar complex with SDS
2RVC	;		;	Solution structure of Zalpha domain of goldfish ZBP-containing protein kinase
1RGW	;		;	Solution Structure of ZASP's PDZ domain
1WG2	;		;	Solution structure of zf-AN1 domain from Arabidopsis thaliana
1WJP	;		;	Solution structure of zf-C2H2 domains from human Zinc finger protein 295
2DJ8	;		;	Solution Structure of zf-MYND Domain of Protein CBFA2TI (Protein MTG8)
7YAB	;		;	Solution structure of zinc finger domain 1 of human ZFAND1
7Y7L	;		;	Solution structure of zinc finger domain 2 of human ZFAND1
2EPC	;		;	Solution structure of Zinc finger domain 7 in Zinc finger protein 32
2CTT	;		;	Solution structure of zinc finger domain from human DnaJ subfamily A menber 3
2CTU	;		;	Solution structure of zinc finger domain from human Zn finger protein 483
1X4S	;		;	Solution structure of zinc finger HIT domain in protein FON
1M60	;		;	Solution Structure of Zinc-substituted cytochrome c
2KN9	;		;	Solution structure of zinc-substituted rubredoxin B (Rv3250c) from Mycobacterium tuberculosis. Seattle Structural Genomics Center for Infectious Disease target MytuD.01635.a
8COO	;		;	Solution structure of Zipcode binding protein 1 (ZBP1) KH3(DD)KH4 domains in complex with N6-Methyladenosine containing RNA
2NB9	;		;	Solution structure of ZitP zinc finger
6DMZ	;		;	Solution structure of ZmD32
2N6J	;		;	Solution structure of Zmp1, a zinc-dependent metalloprotease secreted by Clostridium difficile
6KH8	;		;	Solution structure of Zn free Bovine Pancreatic Insulin in 20% acetic acid-d4 (pH 1.9)
2ODX	;		;	Solution structure of Zn(II)Cox4
6E83	;		;	Solution structure of ZZZ3 ZZ domain in complex with histone H3 tail
6E86	;		;	Solution structure of ZZZ3 ZZ domain in complex with histone H3K4ac peptide
1C2U	;		;	SOLUTION STRUCTURE OF [ABU3,35]SHK12-28,17-32
2N2V	;		;	Solution structure of [B26-B29 triazole cross-linked]-insulin analogue at pH 1.9
2N2W	;		;	Solution structure of [B26-B29 triazole cross-linked]-insulin analogue at pH 8.0
1D69	;		;	SOLUTION STRUCTURE OF [D(ATGAGCGAATA)]2: ADJACENT G:A MISMATCHES STABILIZED BY CROSS-STRAND BASE-STACKING AND BII PHOSPHATE GROUPS
1D68	;		;	SOLUTION STRUCTURE OF [D(GCGTATACGC)]2
1D42	;		;	SOLUTION STRUCTURE OF [D(GTATATAC)]2 VIA RESTRAINED MOLECULAR DYNAMICS SIMULATIONS WITH NUCLEAR MAGNETIC RESONANCE CONSTRAINTS DERIVED FROM RELAXATION MATRIX ANALYSIS OF TWO-DIMENSIONAL NUCLEAR OVERHAUSER EFFECT EXPERIMENTS
2MVD	;		;	Solution structure of [GlnB22]-insulin mutant at pH 1.9
2N2X	;		;	Solution structure of [GlyB24,B27-B29 triazole cross-linked]-insulin analogue at pH 1.9
2F2I	;		;	Solution structure of [P20D,V21K]-kalata B1
2BC7	;		;	Solution structure of [Sec2,8]-ImI
2F2J	;		;	Solution structure of [W19K, P20N, V21K]-kalata B1
2KV8	;		;	Solution structure ofRGS12 PDZ domain
1GK5	;		;	Solution Structure the mEGF/TGFalpha44-50 chimeric growth factor
2LRO	;		;	Solution structure, dynamics and binding studies of CtCBM11
2LRP	;		;	Solution structure, dynamics and binding studies of CtCBM11
2AB3	;		;	Solution structures and characterization of HIV RRE IIB RNA targeting zinc finger proteins
2AB7	;		;	Solution structures and characterization of HIV RRE IIB RNA targeting zinc finger proteins
7YRV	;		;	Solution structures of a disulfide-directed multicyclic peptide with affinity for FGFR1
7YRW	;		;	Solution structures of a disulfide-directed multicyclic peptide with affinity for HER2
7YRX	;		;	Solution structures of a disulfide-directed multicyclic peptide with affinity for HER3
7W8Z	;		;	Solution structures of a disulfide-rich peptide designed through sequence grafting
8GUC	;		;	Solution structures of a disulfide-rich peptide selected via Cellular Protein Quality Control
7WE3	;		;	Solution structures of a disulfide-rich peptide that can bind CD28
7WEI	;		;	Solution structures of a disulfide-rich peptide that can bind CD28
7W8T	;		;	Solution structures of a disulfide-rich peptide that can bind KEAP1
7W96	;		;	Solution structures of a disulfide-rich peptide that can bind KEAP1
7W8K	;		;	Solution structures of a disulfide-rich peptide that can bind mdm2
7W8O	;		;	Solution structures of a disulfide-rich peptide that can bind mdm2
7W8R	;		;	Solution structures of a disulfide-rich peptide that can bind mdm2
2NQ1	;		;	Solution Structures of a DNA Dodecamer Duplex
2NQ4	;		;	Solution Structures of a DNA Dodecamer Duplex
2NPW	;		;	Solution Structures of a DNA Dodecamer Duplex with a Cisplatin 1,2-d(GG) Intrastrand Cross-Link
2NQ0	;		;	Solution Structures of a DNA Dodecamer Duplex with a Cisplatin 1,2-d(GG) Intrastrand Cross-Link
2MM0	;		;	Solution Structures of active Ptr ToxB and its inactive homolog highlight protein dynamics as a modulator of toxin activity
2MM2	;		;	Solution Structures of Active Ptr ToxB and its inactive Homolog highlight Protein Dynamics as a Modulator of Toxin activity.
2K6Y	;		;	Solution structures of apo form PCuA (cis conformation of the peptide bond involving the nitrogen of P14)
2K6W	;		;	Solution structures of apo PCuA (trans conformation of the peptide bond involving the nitrogen of P14)
2K6V	;		;	Solution structures of apo Sco1 protein from Thermus Thermophilus
7Y0I	;		;	Solution structures of ASH1L PHD domain in complex with H3K4me2 peptide
5U5S	;		;	Solution structures of Brd2 second bromodomain in complex with stat3 peptide
2LSP	;		;	solution structures of BRD4 second bromodomain with NF-kB-K310ac peptide
1HZK	;		;	SOLUTION STRUCTURES OF C-1027 APOPROTEIN AND ITS COMPLEX WITH THE AROMATIZED CHROMOPHORE
1HZL	;		;	SOLUTION STRUCTURES OF C-1027 APOPROTEIN AND ITS COMPLEX WITH THE AROMATIZED CHROMOPHORE
2K70	;		;	Solution structures of copper loaded form PCuA (cis conformation of the peptide bond involving the nitrogen of P14)
2K6Z	;		;	Solution structures of copper loaded form PCuA (trans conformation of the peptide bond involving the nitrogen of P14)
1IT1	;		;	Solution structures of ferrocytochrome c3 from Desulfovibrio vulgaris Miyazaki F
7KYZ	;		;	Solution structures of full-length K-RAS bound to GDP
1R8T	;		;	Solution structures of high affinity miniprotein ligands to Streptavidin
7P3M	;		;	Solution structures of HIV-1 and SIVmac p6 and their interaction with accessory proteins Vpr and Vpx in the presence of DPC micelles
7P3O	;		;	Solution structures of HIV-1 and SIVmac p6 and their interaction with accessory proteins Vpr and Vpx in the presence of DPC micelles
7P3P	;		;	Solution structures of HIV-1 and SIVmac p6 and their interaction with accessory proteins Vpr and Vpx in the presence of DPC micelles
2L5C	;		;	Solution structures of human PIWI-like 1 PAZ domain
2L5D	;		;	Solution Structures of human PIWI-like 1 PAZ domain with ssRNA (5'-pUGACA)
4TGF	;		;	SOLUTION STRUCTURES OF HUMAN TRANSFORMING GROWTH FACTOR ALPHA DERIVED FROM 1*H NMR DATA
2LPU	;		;	Solution structures of KmAtg10
2G6U	;		;	Solution structures of MP-2: a high affinity miniprotein ligand to Streptavidin
2L4Q	;		;	Solution Structures of Oxidized and Reduced Thioredoxin C from M. tb
2L59	;		;	Solution Structures of Oxidized and Reduced Thioredoxin C from M. tb
2LQM	;		;	Solution Structures of RadA intein from Pyrococcus horikoshii
2MJV	;		;	Solution structures of second bromodomain of Brd4 with di-acetylated Twist peptide
1ID6	;		;	SOLUTION STRUCTURES OF SYR6
2DN7	;		;	Solution structures of the 6th fn3 domain of human receptor-type tyrosine-protein phosphatase F
5KH8	;		;	Solution structures of the apo state fluoride riboswitch
2CKA	;		;	Solution structures of the BRK domains of the human Chromo Helicase Domain 7 and 8, reveals structural similarity with GYF domain suggesting a role in protein interaction
2CKC	;		;	Solution structures of the BRK domains of the human Chromo Helicase Domain 7 and 8, reveals structural similarity with GYF domain suggesting a role in protein interaction
1BYM	;		;	SOLUTION STRUCTURES OF THE C-TERMINAL DOMAIN OF DIPHTHERIA TOXIN REPRESSOR
1X52	;		;	Solution structures of the C-terminal domain of the human Pelota homolog (CGI-17)
1X68	;		;	Solution structures of the C-terminal LIM domain of human FHL5 protein
1X6H	;		;	Solution structures of the C2H2 type zinc finger domain of human Transcriptional repressor CTCF
2DJR	;		;	Solution structures of the C2H2 type zinc finger domain of human zinc finger BED domain containing protein 2
1X6E	;		;	Solution structures of the C2H2 type zinc finger domain of human Zinc finger protein 24
1X6F	;		;	Solution structures of the C2H2 type zinc finger domain of human Zinc finger protein 462
2EE0	;		;	Solution structures of the CA domain of human protocadherin 9
2EE1	;		;	Solution structures of the Chromo domain of human chromodomain helicase-DNA-binding protein 4
2RUY	;		;	Solution structures of the DNA-binding domain (ZF10) of immune-related zinc-finger protein ZFAT
2RUZ	;		;	Solution structures of the DNA-binding domain (ZF11) of immune-related zinc-finger protein ZFAT
2RV0	;		;	Solution structures of the DNA-binding domain (ZF12) of immune-related zinc-finger protein ZFAT
2RV1	;		;	Solution structures of the DNA-binding domain (ZF13) of immune-related zinc-finger protein ZFAT
2RV2	;		;	Solution structures of the DNA-binding domain (ZF14) of immune-related zinc-finger protein ZFAT
2RV3	;		;	Solution structures of the DNA-binding domain (ZF15) of immune-related zinc-finger protein ZFAT
2RUT	;		;	Solution structures of the DNA-binding domain (ZF2) of immune-related zinc-finger protein ZFAT
2RUU	;		;	Solution structures of the DNA-binding domain (ZF3) of immune-related zinc-finger protein ZFAT
2RUV	;		;	Solution structures of the DNA-binding domain (ZF4) of immune-related zinc-finger protein ZFAT
2RUW	;		;	Solution structures of the DNA-binding domain (ZF5) of immune-related zinc-finger protein ZFAT
2RV4	;		;	Solution structures of the DNA-binding domain (ZF5) of mouse immune-related zinc-finger protein ZFAT
2RUX	;		;	Solution structures of the DNA-binding domain (ZF6) of immune-related zinc-finger protein ZFAT
2RV5	;		;	Solution structures of the DNA-binding domain (ZF8) of mouse immune-related zinc-finger protein ZFAT
2RV6	;		;	Solution structures of the DNA-binding domains (ZF2-ZF3-ZF4) of immune-related zinc-finger protein ZFAT
2RV7	;		;	Solution structures of the DNA-binding domains (ZF3-ZF4-ZF5) of immune-related zinc-finger protein ZFAT
2RSH	;		;	Solution structures of the DNA-binding domains of immune-related zinc-finger protein ZFAT
2RSI	;		;	Solution structures of the DNA-binding domains of immune-related zinc-finger protein ZFAT
2RSJ	;		;	Solution structures of the DNA-binding domains of immune-related zinc-finger protein ZFAT
2KWJ	;		;	Solution structures of the double PHD fingers of human transcriptional protein DPF3 bound to a histone peptide containing acetylation at lysine 14
2KWK	;		;	Solution structures of the double PHD fingers of human transcriptional protein DPF3b bound to a H3 peptide wild type
2JSF	;		;	Solution structures of the envelope protein domain III from the dengue-2 virus
2DKM	;		;	Solution structures of the fn3 domain of human collagen alpha-1(XX) chain
2EE3	;		;	Solution structures of the fn3 domain of human collagen alpha-1(XX) chain
2EKJ	;		;	Solution structures of the fn3 domain of human collagen alpha-1(XX) chain
2EE2	;		;	Solution structures of the fn3 domain of human contactin 1
2DJS	;		;	Solution structures of the fn3 domain of human ephrin type-B receptor 1
2DBJ	;		;	Solution structures of the fn3 domain of human Proto-oncogene tyrosine-protein kinase MER precursor
2DJU	;		;	Solution structures of the fn3 domain of human receptor-type tyrosine-protein phosphatase F
2EDX	;		;	Solution structures of the fn3 domain of human receptor-type tyrosine-protein phosphatase F
2EDY	;		;	Solution structures of the fn3 domain of human receptor-type tyrosine-protein phosphatase F
2DB8	;		;	Solution structures of the fn3 domain of human Tripartite motif protein 9
1X57	;		;	Solution structures of the HTH domain of human EDF-1 protein
2COB	;		;	Solution structures of the HTH domain of human LCoR protein
105D	;		;	SOLUTION STRUCTURES OF THE I-MOTIF TETRAMERS OF D(TCC), D(5MCCT) AND D(T5MCC). NOVEL NOE CONNECTIONS BETWEEN AMINO PROTONS AND SUGAR PROTONS
106D	;		;	Solution structures of the i-motif tetramers of D(TCC), D(5MCCT) and D(T5MCC). Novel NOE connections between amino protons and sugar protons
2LRK	;		;	Solution Structures of the IIA(Chitobiose)-HPr complex of the N,N'-Diacetylchitobiose
2LRL	;		;	Solution Structures of the IIA(Chitobiose)-HPr complex of the N,N'-Diacetylchitobiose Branch of the Escherichia coli Phosphotransferase System
2CO8	;		;	Solution structures of the LIM domain of human NEDD9 interacting protein with calponin homology and LIM domains
1X58	;		;	Solution structures of the myb-like DNA binding domain of 4930532D21Rik protein
2GZZ	;		;	solution structures of the oxidized form of thioredoxin from Bacillus subtilis
1VAZ	;		;	Solution structures of the p47 SEP domain
2YU0	;		;	Solution structures of the PAAD_DAPIN domain of mus musculus interferon-activatable protein 205
1X6D	;		;	Solution structures of the PDZ domain of human Interleukin-16
2DJT	;		;	Solution structures of the PDZ domain of human unnamed protein product
2EDZ	;		;	Solution structures of the PDZ domain of mus musculus PDZ domain-containing protein 1
2GZY	;		;	solution structures of the reduced form of thioredoxin from Bacillus subtilis
1X6A	;		;	Solution structures of the second LIM domain of human LIM-kinase 2 (LIMK2)
2GE9	;		;	Solution Structures of the SH2 domain of Bruton's Tyrosine Kinase
1X6C	;		;	Solution structures of the SH2 domain of human protein-tyrosine phosphatase SHP-1
2DBK	;		;	Solution structures of the SH3 domain of human Crk-like protein
2EKH	;		;	Solution structures of the SH3 domain of human KIAA0418
1X6G	;		;	Solution structures of the SH3 domain of human megakaryocyte-associated tyrosine-protein kinase.
1X6B	;		;	Solution structures of the SH3 domain of human rho guanine exchange factor (GEF) 16
2DBM	;		;	Solution structures of the SH3 domain of human SH3-containing GRB2-like protein 2
1X69	;		;	Solution structures of the SH3 domain of human Src substrate cortactin
2EKI	;		;	Solution structures of the TGS domain of human developmentally-regulated GTP-binding protein 1
1X59	;		;	Solution structures of the WHEP-TRS domain of human histidyl-tRNA synthetase
2DJV	;		;	Solution structures of the WHEP-TRS domain of human methionyl-tRNA synthetase
1V80	;		;	Solution structures of ubiquitin at 30 bar and 3 kbar
1V81	;		;	Solution structures of ubiquitin at 30 bar and 3 kbar
230D	;		;	SOLUTION STRUCTURES OF UNIMOLECULAR QUADRUPLEXES FORMED BY OLIGONUCLEOTIDES CONTAINING OXYTRICHA TELOMERE REPEATS
7E42	;		;	Solution strucutre of holo acyl carrier protein from Acinetobacter baumannii
2LAA	;		;	Solution Strucuture of the CBM25-1 of beta/alpha-amylase from Paenibacillus polymyxa
2LAB	;		;	Solution Strucuture of the CBM25-2 of beta/alpha-amylase from Paenibacillus polymyxa
2CT4	;		;	Solution Strutcure of the SH3 domain of the Cdc42-interacting protein 4
2N68	;		;	Solution study of Astexin1
2N6U	;		;	Solution study of Astexin2-dC4
2N6V	;		;	Solution study of Astexin3
2MSQ	;		;	Solution study of cBru9a
2MSO	;		;	Solution study of cGm9a
5T1O	;		;	Solution-state NMR and SAXS structural ensemble of NPr (1-85) in complex with EIN-Ntr (170-424)
6UD0	;		;	Solution-state NMR structural ensemble of human Tsg101 UEV in complex with K63-linked diubiquitin
5VKG	;		;	Solution-state NMR structural ensemble of human Tsg101 UEV in complex with tenatoprazole
5T1N	;		;	Solution-state NMR structural ensemble of NPr (1-85) refined with RDCs and PCS
2M3U	;		;	Solution-state NMR structure of cataract-related human gamma(S)-crystallin point variant G18V
6IF9	;		;	Solution-state NMR structure of G57W human gammaS crystallin
2LV1	;		;	Solution-state NMR structure of prion protein mutant V210I at neutral pH
2LSB	;		;	Solution-state NMR structure of the human prion protein
2N29	;		;	Solution-state NMR structure of Vpu cytoplasmic domain
2M3T	;		;	Solution-state NMR structure of wild-type human gamma(S)-crystallin
2JU3	;		;	Solution-state NMR structures of apo-LFABP (Liver Fatty Acid-Binding Protein)
1ZRP	;		;	SOLUTION-STATE STRUCTURE BY NMR OF ZINC-SUBSTITUTED RUBREDOXIN FROM THE MARINE HYPERTHERMOPHILIC ARCHAEBACTERIUM PYROCOCCUS FURIOSUS
1TTD	;		;	SOLUTION-STATE STRUCTURE OF A DNA DODECAMER DUPLEX CONTAINING A CIS-SYN THYMINE CYCLOBUTANE DIMER
1COC	;		;	SOLUTION-STATE STRUCTURE OF A DNA DODECAMER DUPLEX CONTAINING A CIS-SYN THYMINE CYCLOBUTANE DIMER.
2LOD	;		;	Solution-state structure of an intramolecular G-quadruplex with propeller, diagonal and edgewise loops
2JU8	;		;	Solution-State Structures of Oleate-Liganded LFABP, Major Form of 1:2 Protein-Ligand Complex
2JU7	;		;	Solution-State Structures of Oleate-Liganded LFABP, Protein Only
1B1G	;		;	SOLVATED REFINEMENT OF CA-LOADED CALBINDIN D9K
2I08	;	2.0	;	Solvation effect in conformational changes of EF-hand proteins: X-ray structure of Ca2+-saturated double mutant Q41L-K75I of N-domain of calmodulin
1DN4	;	1.6	;	SOLVATION OF THE LEFT-HANDED HEXAMER D(5BRC-G-5BRC-G-5BRC-G) IN CRYSTALS GROWN AT TWO TEMPERATURES
1DN5	;	1.4	;	SOLVATION OF THE LEFT-HANDED HEXAMER D(5BRC-G-5BRC-G-5BRC-G) IN CRYSTALS GROWN AT TWO TEMPERATURES
2BCN	;	1.7	;	Solvent isotope effects on interfacial protein electron transfer between cytochrome c and cytochrome c peroxidase
1ENN	;	0.89	;	SOLVENT ORGANIZATION IN AN OLIGONUCLEOTIDE CRYSTAL: THE STRUCTURE OF D(GCGAATTCG)2 AT ATOMIC RESOLUTION
3JS8	;	1.54	;	Solvent-stable cholesterol oxidase
1FHA	;	2.4	;	SOLVING THE STRUCTURE OF HUMAN H FERRITIN BY GENETICALLY ENGINEERING INTERMOLECULAR CRYSTAL CONTACTS
1S4G	;		;	Somatomedin-B Domain of human plasma vitronectin.
2MI1	;		;	Somatostatin-14 solution structure in 5% D-mannitol
7BWT	;	2.3	;	SopD-Rab8 complex structure
5HIW	;	1.85	;	Sorangium cellulosum So Ce56 cytochrome P450 260B1
3WSZ	;	3.201	;	SorLA Vps10p domain in complex with Abeta-derived peptide
3WSY	;	3.11	;	SorLA Vps10p domain in complex with its own propeptide fragment
3WSX	;	2.35	;	SorLA Vps10p domain in ligand-free form
6WTB	;	2.58	;	Sort-Tagged Drosophila Cryptochrome
5K9A	;	2.1	;	Sortase A from Corynebacterium diphtheriae
6BWE	;	1.85	;	Sortase A from Corynebacterium diphtheriae, lid mutant
7S54	;	1.794	;	Sortase A from Streptococcus agalactiae with the deltaN188 b7-b8 loop sequence from Staphylococcus aureus Sortase A
7S56	;	1.4	;	Sortase A from Streptococcus agalactiae, residues 79-247
5JCV	;	2.23	;	Sortase B from Listeria monocytogenes.
4G1J	;	1.75	;	Sortase C1 of GBS Pilus Island 1
6X48	;	2.9	;	Sortilin-Progranulin Interaction With Compound 17
6X3L	;	2.7	;	Sortilin-Progranulin Interaction With Compound 2
6X4H	;	2.9	;	Sortilin-Progranulin Interaction With Compound 24
6SCM	;	1.866	;	SOS1 in Complex with Inhibitor BI-3406
6SFR	;	1.917	;	SOS1 in Complex with Inhibitor BI-68BS
8UH0	;	2.73	;	SOS2 co-crystal structure with fragment bound (compound 10)
8T5G	;	1.92	;	SOS2 co-crystal structure with fragment bound (compound 12)
8UC9	;	2.44	;	SOS2 co-crystal structure with fragment bound (compound 9)
8T5R	;	2.12	;	SOS2 crystal structure with fragment bound (compound 13)
8T5M	;	1.79	;	SOS2 crystal structure with fragment bound (compound 14)
6RSN	;	1.7	;	SOSEKI polymerising domain (SOK4 D85A mutant)
7LYN	;	3.32	;	South African (B.1.351) SARS-CoV-2 spike protein variant (S-GSAS-B.1.351) in the 1-RBD-up conformation
7LYO	;	3.32	;	South African (B.1.351) SARS-CoV-2 spike protein variant (S-GSAS-B.1.351) in the 1-RBD-up conformation
7LYP	;	4.05	;	South African (B.1.351) SARS-CoV-2 spike protein variant (S-GSAS-B.1.351) in the 1-RBD-up conformation
7LYQ	;	3.34	;	South African (B.1.351) SARS-CoV-2 spike protein variant (S-GSAS-B.1.351) in the 1-RBD-up conformation
7LYK	;	3.65	;	South African (B.1.351) SARS-CoV-2 spike protein variant (S-GSAS-B.1.351) in the 2-RBD-up conformation
7LYL	;	3.72	;	South African (B.1.351) SARS-CoV-2 spike protein variant (S-GSAS-B.1.351) in the RBD-down conformation
7LYM	;	3.57	;	South African (B.1.351) SARS-CoV-2 spike protein variant (S-GSAS-B.1.351) in the RBD-down conformation
1VKA	;	1.6	;	Southeast Collaboratory for Structural Genomics: Hypothetical Human Protein Q15691 N-Terminal Fragment
2JQE	;		;	Soution Structure of Af54 M-domain
6WX7	;	2.7	;	SOX2 bound to Importin-alpha 2
6WX8	;	2.3	;	SOX2 bound to Importin-alpha 3
6WX9	;	2.8	;	SOX2 bound to Importin-alpha 5
1SBF	;	2.43	;	SOYBEAN AGGLUTININ
1SBD	;	2.52	;	SOYBEAN AGGLUTININ COMPLEXED WITH 2,4-PENTASACCHARIDE
2SBA	;	2.6	;	SOYBEAN AGGLUTININ COMPLEXED WITH 2,6-PENTASACCHARIDE
1SBE	;	2.8	;	SOYBEAN AGGLUTININ FROM GLYCINE MAX
4D69	;	2.7	;	SOYBEAN AGGLUTININ FROM GLYCINE MAX IN COMPLEX WITH THE ANTIGEN Tn
4MAF	;	2.48	;	Soybean ATP Sulfurylase
1RRL	;	2.09	;	Soybean Lipoxygenase (LOX-3) at 93K at 2.0 A resolution
1RRH	;	2.0	;	Soybean Lipoxygenase (LOX-3) at ambient temperatures at 2.0 A resolution
5EEO	;	2.1	;	soybean lipoxygenase(L1)-T756R
3PZW	;	1.4	;	Soybean lipoxygenase-1 - re-refinement
6J4J	;	2.101	;	soybean seed H-2 ferritin
4N6A	;	1.75	;	Soybean Serine Acetyltransferase Apoenzyme
4N6B	;	3.005	;	Soybean Serine Acetyltransferase Complexed with CoA
4N69	;	1.8	;	Soybean Serine Acetyltransferase Complexed with Serine
1BA7	;	2.5	;	SOYBEAN TRYPSIN INHIBITOR
2AM1	;	2.5	;	sp protein ligand 1
2AM2	;	2.8	;	sp protein ligand 2
5T3N	;	2.4	;	Sp-2Cl-cAMPS bound to PKAR CBD2
2M1T	;		;	SP-B C-terminal (residues 59-80) peptide in DPC micelles
2M0H	;		;	SP-B C-terminal (residues 59-80) peptide in methanol
1RG4	;		;	SP-B C-terminal peptide in organic solvent (HFIP)
1RG3	;		;	SP-B C-terminal peptide in SDS micelles
6G8R	;	2.74	;	SP140 PHD-Bromodomain complex with scFv
4L37	;	2.9	;	SP2-SP3 - a complex of two storage proteins from Bombyx mori hemolymph
2BLC	;	2.25	;	SP21 double mutant P. vivax Dihydrofolate reductase in complex with des-chloropyrimethamine
2BLA	;	2.5	;	SP21 double mutant P. vivax Dihydrofolate reductase in complex with pyrimethamine
7RMI	;	3.2	;	SP6-11 biased agonist bound to active human neurokinin 1 receptor in complex with miniGs/q70
8BP8	;	2.7	;	SPA of Trypsin untreated Rotavirus TLP spike
1RY9	;	1.82	;	Spa15, a Type III Secretion Chaperone from Shigella flexneri
6PHY	;	2.0	;	SpAga D472N structure in complex alpha 1,3 galactobiose
6PHW	;	2.2	;	SpAga D472N structure in complex with melibiose
6PHX	;	2.0	;	SpAga D472N structure in complex with raffinose
6PHV	;	2.1	;	SpAga galactose product complex structure
6PHU	;	2.2	;	SpAga wild type apo structure
4YX5	;	2.9001	;	SpaO(SPOA1,2)
4YX1	;	1.35	;	SpaO(SPOA2)
2K2B	;		;	Sparse-constraint solution NMR structure of micelle-solublized cytosolic amino terminal domain of C. elegans mechanosensory ion channel subunit MEC-4. New York Consortium on Membrane Protein Structure (NYCOMPS)
5TTT	;		;	Sparse-restraint solution NMR structure of micelle-solubilized cytosolic amino terminal domain of C. elegans mechanosensory ion channel MEC-4 refined by restrained Rosetta
8J9P	;	3.4	;	SPARTA dimer bound with guide-target
8J8H	;	3.4	;	SPARTA monomer bound with guide-target, state 2
3B9P	;	2.7	;	Spastin
5Z6R	;	3.0	;	SPASTIN AAA WITH ATP
6P07	;	3.2	;	Spastin hexamer in complex with substrate
1RQV	;		;	Spatial model of L7 dimer from E.coli with one hinge region in helical state
2PCO	;		;	Spatial Structure and Membrane Permeabilization for Latarcin-1, a Spider Antimicrobial Peptide
8BVZ	;		;	Spatial structure of amyloidogenic SEM1(49-67) peptide
5M9U	;		;	Spatial structure of antimicrobial peptide arenicin-1 mutant V8R
2L8X	;		;	Spatial structure of antimicrobial peptide Arenicin-2 dimer in DPC micelles
2JNI	;		;	Spatial structure of antimicrobial peptide arenicin-2 in aqueous solution
2KUS	;		;	Spatial structure of Antimicrobial Peptide Sm-AMP-1.1a
2N1S	;		;	Spatial Structure of Antimicrobial Peptide SmAMP2-2c from Seeds of Stellaria media
2L9U	;		;	Spatial structure of dimeric ErbB3 transmembrane domain
2M59	;		;	Spatial structure of dimeric VEGFR2 membrane domain in DPC micelles
2N5S	;		;	Spatial structure of EGFR transmembrane and juxtamembrane domains in DPC micelles
2N2A	;		;	Spatial structure of HER2/ErbB2 dimeric transmembrane domain in the presence of cytoplasmic juxtamembrane domains
2MQU	;		;	Spatial structure of Hm-3, a membrane-active spider toxin affecting sodium channels
1SIS	;		;	SPATIAL STRUCTURE OF INSECTOTOXIN I5A BUTHUS EUPEUS BY 1H NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY (RUSSIAN)
8C5J	;		;	Spatial structure of Lch-alpha peptide from two-component lantibiotic system Lichenicidin VK21
2KTO	;		;	Spatial structure of Lch-beta peptide from two-component lantibiotic Lichenicidin VK21
2MJ0	;		;	Spatial structure of P33A mutant of non-conventional toxin WTX from Naja kaouthia
2LZO	;		;	Spatial structure of Pi-AnmTX Ugr 9a-1
2KGU	;		;	Spatial structure of purotoxin-1 in water
2KPF	;		;	Spatial structure of the dimeric transmembrane domain of glycophorin A in bicelles soluton
2MK9	;		;	Spatial structure of the dimeric transmembrane domain of Toll-like receptor 3
2LCX	;		;	Spatial Structure of the ErbB4 dimeric TM domain
5LQV	;		;	Spatial structure of the lentil lipid transfer protein in complex with anionic lysolipid LPPG
4MN0	;	1.9	;	Spatial structure of the novel light-sensitive photoprotein berovin from the ctenophore Beroe abyssicola in the Ca2+-loaded apoprotein conformation state
2MKA	;		;	Spatial structure of the Toll-like receptor 3 transmembrane domain in the trimeric state
2L03	;		;	Spatial structure of water-soluble Lynx1
8BOO	;		;	Spatials structure of amyloidogenic SEM1(45-67) peptide
7ZRF	;		;	Spatials structure of amyloidogenic SEM1(68-85) peptide
3WPL	;	2.0	;	SPATIOTEMPORAL DEVELOPMENT of SOAKED PROTEIN CRYSTAL; 2510 SEC
3WPK	;	2.0	;	SPATIOTEMPORAL DEVELOPMENT of SOAKED PROTEIN CRYSTAL; 750 SEC
3WU8	;	2.0	;	Spatiotemporal development of soaked protein crystal; derivative 1080 sec
3WU9	;	2.0	;	Spatiotemporal development of soaked protein crystal; derivative 1580 sec
3WU7	;	2.0	;	Spatiotemporal development of soaked protein crystal; derivative 250 sec
3WUA	;	2.0	;	Spatiotemporal development of soaked protein crystal; derivative 3610 sec
3WPJ	;	2.0	;	SPATIOTEMPORAL DEVELOPMENT of SOAKED PROTEIN CRYSTAL; NATIVE
7Z4K	;	3.81	;	SpCas9 bound to 10-nucleotide complementary DNA substrate
7Z4G	;	3.64	;	SpCas9 bound to 12-nucleotide complementary DNA substrate
7Z4H	;	3.49	;	SpCas9 bound to 14-nucleotide complementary DNA substrate
7Z4I	;	3.12	;	SpCas9 bound to 16-nucleotide complementary DNA substrate
7Z4J	;	2.99	;	SpCas9 bound to 18-nucleotide complementary DNA substrate in the catalytic state
7Z4L	;	2.54	;	SpCas9 bound to 18-nucleotide complementary DNA substrate in the checkpoint state
7Z4C	;	3.87	;	SpCas9 bound to 6 nucleotide complementary DNA substrate
7Z4E	;	4.14	;	SpCas9 bound to 8-nucleotide complementary DNA substrate
7QQO	;	3.0	;	SpCas9 bound to AAVS1 off-target1 DNA substrate
7QR7	;	3.0	;	SpCas9 bound to AAVS1 off-target2 DNA substrate
7QQP	;	2.6	;	SpCas9 bound to AAVS1 off-target3 DNA substrate
7QQQ	;	2.65	;	SpCas9 bound to AAVS1 off-target4 DNA substrate
7QQR	;	2.75	;	SpCas9 bound to AAVS1 off-target5 DNA substrate
7ZO1	;	2.4	;	SpCas9 bound to CD34 off-target9 DNA substrate
7QQT	;	2.5	;	SpCas9 bound to FANCF off-target1 DNA substrate
7QQU	;	2.45	;	SpCas9 bound to FANCF off-target2 DNA substrate
7QQV	;	2.25	;	SpCas9 bound to FANCF off-target3 DNA substrate
7QQW	;	3.1	;	SpCas9 bound to FANCF off-target4 DNA substrate
7QQX	;	2.4	;	SpCas9 bound to FANCF off-target5 DNA substrate
7QR5	;	3.3	;	SpCas9 bound to FANCF off-target6 DNA substrate
7QQZ	;	2.25	;	SpCas9 bound to FANCF off-target7 DNA substrate
7QQS	;	2.4	;	SpCas9 bound to FANCF on-target DNA substrate
7QR8	;	2.75	;	SpCas9 bound to PTPRC off-target1 DNA substrate
7QR0	;	2.3	;	SpCas9 bound to TRAC off-target1 DNA substrate
7QR1	;	2.6	;	SpCas9 bound to TRAC off-target2 DNA substrate
8FZT	;	3.03	;	SpCas9 with dual-guide RNA and target DNA
8G1I	;	3.12	;	SpCas9 with sgRNA and target DNA
5ZY5	;	2.295	;	spCOMT apo structure
7D9I	;	2.1	;	SpdH Spermidine dehydrogenase D282A mutant
7D9H	;	2.31	;	SpdH Spermidine dehydrogenase N33 truncation structure
7D9G	;	2.4	;	SpdH Spermidine dehydrogenase native structure
7D9F	;	1.85	;	SpdH Spermidine dehydrogenase SeMet Structure
7D9J	;	2.19	;	SpdH Spermidine dehydrogenase Y443A mutant
2BJM	;	2.15	;	SPE7:Anthrone Complex
4P8Z	;	3.85	;	Speciation of a group I intron into a lariat capping ribozyme
4P9R	;	2.703	;	Speciation of a group I intron into a lariat capping ribozyme (Heavy atom derivative)
2B17	;	2.71	;	Specific binding of non-steroidal anti-inflammatory drugs (NSAIDs) to phospholipase A2: Crystal structure of the complex formed between phospholipase A2 and diclofenac at 2.7 A resolution:
1QID	;	2.05	;	SPECIFIC CHEMICAL AND STRUCTURAL DAMAGE AT NINE TIME POINTS (POINT A) CAUSED BY INTENSE SYNCHROTRON RADIATION TO TORPEDO CALIFORNICA ACETYLCHOLINESTERASE
1QIE	;	2.1	;	SPECIFIC CHEMICAL AND STRUCTURAL DAMAGE AT NINE TIME POINTS (POINT B) CAUSED BY INTENSE SYNCHROTRON RADIATION TO TORPEDO CALIFORNICA ACETYLCHOLINESTERASE
1QIF	;	2.1	;	SPECIFIC CHEMICAL AND STRUCTURAL DAMAGE AT NINE TIME POINTS (POINT C) CAUSED BY INTENSE SYNCHROTRON RADIATION TO TORPEDO CALIFORNICA ACETYLCHOLINESTERASE
1QIG	;	2.3	;	SPECIFIC CHEMICAL AND STRUCTURAL DAMAGE AT NINE TIME POINTS (POINT D) CAUSED BY INTENSE SYNCHROTRON RADIATION TO TORPEDO CALIFORNICA ACETYLCHOLINESTERASE
1QIH	;	2.5	;	SPECIFIC CHEMICAL AND STRUCTURAL DAMAGE AT NINE TIME POINTS (POINT E) CAUSED BY INTENSE SYNCHROTRON RADIATION TO TORPEDO CALIFORNICA ACETYLCHOLINESTERASE
1QII	;	2.65	;	SPECIFIC CHEMICAL AND STRUCTURAL DAMAGE AT NINE TIME POINTS (POINT F) CAUSED BY INTENSE SYNCHROTRON RADIATION TO TORPEDO CALIFORNICA ACETYLCHOLINESTERASE
1QIJ	;	2.8	;	SPECIFIC CHEMICAL AND STRUCTURAL DAMAGE AT NINE TIME POINTS (POINT G) CAUSED BY INTENSE SYNCHROTRON RADIATION TO TORPEDO CALIFORNICA ACETYLCHOLINESTERASE
1QIK	;	2.9	;	SPECIFIC CHEMICAL AND STRUCTURAL DAMAGE AT NINE TIME POINTS (POINT H) CAUSED BY INTENSE SYNCHROTRON RADIATION TO TORPEDO CALIFORNICA ACETYLCHOLINESTERASE
1QIM	;	3.0	;	SPECIFIC CHEMICAL AND STRUCTURAL DAMAGE AT NINE TIME POINTS (POINT I) CAUSED BY INTENSE SYNCHROTRON RADIATION TO TORPEDO CALIFORNICA ACETYLCHOLINESTERASE
1QIO	;	1.2	;	SPECIFIC CHEMICAL AND STRUCTURAL DAMAGE CAUSED BY INTENSE SYNCHROTRON RADIATION TO HEN EGG WHITE LYSOZYME
8AO2	;	1.796	;	Specific covalent inhibitor (3) of ERK2
8AO4	;	1.825	;	Specific covalent inhibitor (5) of ERK2
8AO5	;	1.595	;	Specific covalent inhibitor (6) of ERK2
8AO7	;	1.61	;	Specific covalent inhibitor (8) of ERK2
8AO3	;	1.778	;	Specific covalent inhibitor of ERK2
8AOC	;	1.62	;	Specific covalent inhibitor of ERK2
8AOJ	;	1.12	;	Specific covalent inhibitor of ERK2
8AO9	;	1.624	;	Specific covalent inhibitor(10) of ERK2
8AOB	;	1.623	;	Specific covalent inhibitor(12) of ERK2
8AOD	;	1.62	;	Specific covalent inhibitor(14) of ERK2
8AOE	;	1.687	;	Specific covalent inhibitor(15) of ERK2
8AOF	;	1.615	;	Specific covalent inhibitor(16) of ERK2
8AOH	;	1.6	;	Specific covalent inhibitor(18) of ERK2
8AOI	;	1.602	;	Specific covalent inhibitor(19) of ERK2
8AO8	;	1.697	;	Specific covalent inhibitor(9) of ERK2
6SX0	;	1.75	;	Specific dsRNA recognition by wild type H7N1 NS1 RNA-binding domain
7QIZ	;	2.38	;	Specific features and methylation sites of a plant 80S ribosome
7QIX	;	2.53	;	Specific features and methylation sites of a plant ribosome. 40S body ribosomal subunit.
7QIY	;	2.58	;	Specific features and methylation sites of a plant ribosome. 40S head ribosomal subunit.
7QIW	;	2.35	;	Specific features and methylation sites of a plant ribosome. 60S ribosomal subunit.
7LMV	;	1.9	;	SPECIFIC INHIBITOR OF INTEGRIN ALPHA-V BETA-6
2KPA	;		;	Specific motifs of the V-ATPase a2-subunit isoform interact with catalytic and regulatory domains of ARNO
2KPB	;		;	Specific motifs of the V-ATPase a2-subunit isoform interact with catalytic and regulatory domains of ARNO
1G0Z	;	2.18	;	SPECIFIC MUTATIONS IN KRAIT PLA2 LEAD TO DIMERIZATION OF PROTEIN MOLECULES: CRYSTAL STRUCTURE OF KRAIT PLA2 AT 2.1 RESOLUTION
6EZ0	;		;	Specific phosphorothioate substitution within domain 6 of a group II intron ribozyme leads to changes in local structure and metal ion binding
5E08	;	2.38	;	Specific Recognition of a Single-stranded RNA Sequence by an Engineered Synthetic Antibody Fragment
3RU7	;	2.6	;	Specific recognition of N-acetylated substrates and domain flexibility in WbgU: a UDP-GalNAc 4-epimerase
3RU9	;	2.21	;	Specific recognition of N-acetylated substrates and domain flexibility in WbgU: a UDP-GalNAc 4-epimerase
3RUA	;	2.1	;	Specific recognition of N-acetylated substrates and domain flexibility in WbgU: a UDP-GalNAc 4-epimerase
3RUC	;	2.1	;	Specific recognition of N-acetylated substrates and domain flexibility in WbgU: a UDP-GalNAc 4-epimerase
5LME	;		;	Specific-DNA binding activity of the cross-brace zinc finger motif of the piggyBac transposase
1W9V	;	2.0	;	Specificity and affinity of natural product cyclopentapeptide argifin against Aspergillus fumigatus
1WAW	;	1.75	;	Specificity and affinity of natural product cyclopentapeptide inhibitor Argadin against human chitinase
1WB0	;	1.65	;	specificity and affinity of natural product cyclopentapeptide inhibitor Argifin against human chitinase
1W9P	;	1.7	;	Specificity and affinity of natural product cyclopentapeptide inhibitors against Aspergillus fumigatus, human and bacterial chitinaseFra
1W9U	;	1.85	;	Specificity and affnity of natural product cyclopentapeptide inhibitor Argadin against Aspergillus fumigatus chitinase
2Q8E	;	2.05	;	Specificity and Mechanism of JMJD2A, a Trimethyllysine-Specific Histone Demethylase
1OJO	;	1.75	;	SPECIFICITY AND MECHANISM OF STREPTOCOCCUS PNEUMONIAE HYALURONATE LYASE: COMPLEX OF THE TYR408PHE MUTANT WITH 4-SULPHATED CHONDROITIN DISACCHARIDE
1OJN	;	1.6	;	SPECIFICITY AND MECHANISM OF STREPTOCOCCUS PNEUMONIAE HYALURONATE LYASE: COMPLEX OF THE TYR408PHE MUTANT WITH 6-SULPHATED CHONDROITIN DISACCHARIDE
1OJP	;	1.9	;	SPECIFICITY AND MECHANISM OF STREPTOCOCCUS PNEUMONIAE HYALURONATE LYASE: COMPLEX WITH 6-SULPHATED CHONDROITIN DISACCHARIDE
1OJM	;	1.78	;	SPECIFICITY AND MECHANISM OF STREPTOCOCCUS PNEUMONIAE HYALURONATE LYASE: COMPLEX WITH UNSULPHATED CHONDROITIN DISACCHARIDE
4FAO	;	3.357	;	Specificity and Structure of a high affinity Activin-like 1 (ALK1) signaling complex
1TKA	;	2.7	;	SPECIFICITY OF COENZYME BINDING IN THIAMIN DIPHOSPHATE DEPENDENT ENZYMES: CRYSTAL STRUCTURES OF YEAST TRANSKETOLASE IN COMPLEX WITH ANALOGS OF THIAMIN DIPHOSPHATE
1TKB	;	2.3	;	SPECIFICITY OF COENZYME BINDING IN THIAMIN DIPHOSPHATE DEPENDENT ENZYMES: CRYSTAL STRUCTURES OF YEAST TRANSKETOLASE IN COMPLEX WITH ANALOGS OF THIAMIN DIPHOSPHATE
1TKC	;	2.7	;	SPECIFICITY OF COENZYME BINDING IN THIAMIN DIPHOSPHATE DEPENDENT ENZYMES: CRYSTAL STRUCTURES OF YEAST TRANSKETOLASE IN COMPLEX WITH ANALOGS OF THIAMIN DIPHOSPHATE
181L	;	1.8	;	SPECIFICITY OF LIGAND BINDING IN A BURIED NON-POLAR CAVITY OF T4 LYSOZYME: LINKAGE OF DYNAMICS AND STRUCTURAL PLASTICITY
182L	;	1.8	;	SPECIFICITY OF LIGAND BINDING IN A BURIED NON-POLAR CAVITY OF T4 LYSOZYME: LINKAGE OF DYNAMICS AND STRUCTURAL PLASTICITY
183L	;	1.8	;	SPECIFICITY OF LIGAND BINDING IN A BURIED NON-POLAR CAVITY OF T4 LYSOZYME: LINKAGE OF DYNAMICS AND STRUCTURAL PLASTICITY
184L	;	1.8	;	SPECIFICITY OF LIGAND BINDING IN A BURIED NON-POLAR CAVITY OF T4 LYSOZYME: LINKAGE OF DYNAMICS AND STRUCTURAL PLASTICITY
185L	;	1.8	;	SPECIFICITY OF LIGAND BINDING IN A BURIED NON-POLAR CAVITY OF T4 LYSOZYME: LINKAGE OF DYNAMICS AND STRUCTURAL PLASTICITY
186L	;	1.8	;	SPECIFICITY OF LIGAND BINDING IN A BURIED NON-POLAR CAVITY OF T4 LYSOZYME: LINKAGE OF DYNAMICS AND STRUCTURAL PLASTICITY
187L	;	1.8	;	SPECIFICITY OF LIGAND BINDING IN A BURIED NON-POLAR CAVITY OF T4 LYSOZYME: LINKAGE OF DYNAMICS AND STRUCTURAL PLASTICITY
188L	;	1.8	;	SPECIFICITY OF LIGAND BINDING IN A BURIED NON-POLAR CAVITY OF T4 LYSOZYME: LINKAGE OF DYNAMICS AND STRUCTURAL PLASTICITY
1NHB	;	1.8	;	Specificity of ligand binding in a buried non-polar cavity of t4 lysozyme: linkage of dynamics and structural plasticity
1AA4	;	2.1	;	SPECIFICITY OF LIGAND BINDING IN A BURIED POLAR CAVITY OF CYTOCHROME C PEROXIDASE
1AEU	;	2.1	;	SPECIFICITY OF LIGAND BINDING IN A POLAR CAVITY OF CYTOCHROME C PEROXIDASE (2-METHYLIMIDAZOLE)
1AEJ	;	2.1	;	SPECIFICITY OF LIGAND BINDING TO A BURIED POLAR CAVITY AT THE ACTIVE SITE OF CYTOCHROME C PEROXIDASE (1-VINYLIMIDAZOLE)
1AEH	;	2.1	;	SPECIFICITY OF LIGAND BINDING TO A BURIED POLAR CAVITY AT THE ACTIVE SITE OF CYTOCHROME C PEROXIDASE (2-AMINO-4-METHYLTHIAZOLE)
1AEN	;	2.1	;	SPECIFICITY OF LIGAND BINDING TO A BURIED POLAR CAVITY AT THE ACTIVE SITE OF CYTOCHROME C PEROXIDASE (2-AMINO-5-METHYLTHIAZOLE)
1AEO	;	2.1	;	SPECIFICITY OF LIGAND BINDING TO A BURIED POLAR CAVITY AT THE ACTIVE SITE OF CYTOCHROME C PEROXIDASE (2-AMINOPYRIDINE)
1AED	;	2.1	;	SPECIFICITY OF LIGAND BINDING TO A BURIED POLAR CAVITY AT THE ACTIVE SITE OF CYTOCHROME C PEROXIDASE (3,4-DIMETHYLTHIAZOLE)
1AEF	;	2.1	;	SPECIFICITY OF LIGAND BINDING TO A BURIED POLAR CAVITY AT THE ACTIVE SITE OF CYTOCHROME C PEROXIDASE (3-AMINOPYRIDINE)
1AEB	;	2.1	;	SPECIFICITY OF LIGAND BINDING TO A BURIED POLAR CAVITY AT THE ACTIVE SITE OF CYTOCHROME C PEROXIDASE (3-METHYLTHIAZOLE)
1AEG	;	2.1	;	SPECIFICITY OF LIGAND BINDING TO A BURIED POLAR CAVITY AT THE ACTIVE SITE OF CYTOCHROME C PEROXIDASE (4-AMINOPYRIDINE)
1AEE	;	2.1	;	SPECIFICITY OF LIGAND BINDING TO A BURIED POLAR CAVITY AT THE ACTIVE SITE OF CYTOCHROME C PEROXIDASE (ANILINE)
1AES	;	2.1	;	SPECIFICITY OF LIGAND BINDING TO A BURIED POLAR CAVITY AT THE ACTIVE SITE OF CYTOCHROME C PEROXIDASE (IMIDAZOLE)
1AEM	;	2.1	;	SPECIFICITY OF LIGAND BINDING TO A BURIED POLAR CAVITY AT THE ACTIVE SITE OF CYTOCHROME C PEROXIDASE (IMIDAZO[1,2-A]PYRIDINE)
1AEK	;	2.1	;	SPECIFICITY OF LIGAND BINDING TO A BURIED POLAR CAVITY AT THE ACTIVE SITE OF CYTOCHROME C PEROXIDASE (INDOLINE)
2C21	;	2.0	;	Specificity of the Trypanothione-dependednt Leishmania major Glyoxalase I: Structure and biochemical comparison with the human enzyme
2HLA	;	2.6	;	SPECIFICITY POCKETS FOR THE SIDE CHAINS OF PEPTIDE ANTIGENS IN HLA-AW68
2KZL	;		;	Specifier domain and GA motif region of B. subtilis tyrS T box leader RNA
2KHY	;		;	Specifier Domain of B. subtilis tyrS T box leader RNA
1VR1	;	1.9	;	Specifity for Plasminogen Activator Inhibitor-1
6UC3	;	1.84	;	Spectroscopic and structural characterization of a genetically encoded direct sensor for protein-ligand interactions
6UD1	;	1.55	;	Spectroscopic and structural characterization of a genetically encoded direct sensor for protein-ligand interactions
6UD6	;	1.502	;	Spectroscopic and structural characterization of a genetically encoded direct sensor for protein-ligand interactions
6UDB	;	1.55	;	Spectroscopic and structural characterization of a genetically encoded direct sensor for protein-ligand interactions
6UDC	;	2.1	;	Spectroscopic and structural characterization of a genetically encoded direct sensor for protein-ligand interactions
6FLL	;	1.79	;	SPECTROSCOPIC AND STRUCTURAL STUDY OF QW, A EGFP MUTANT SHOWING PHOTOSWITCHING PROPERTIES
2H6V	;	1.47	;	Spectroscopic and structural study of the heterotropic linkage between halide and proton ion binding to GFP proteins- E2(GFP) APO FORM
2O29	;	1.8	;	Spectroscopic and Structural Study of the Heterotropic Linkage between Halide and Proton Ion Binding to Gfp Proteins: E2(GFP)-BR Complex
2O24	;	1.45	;	Spectroscopic and Structural Study of the Heterotropic Linkage between Halide and Proton Ion Binding to Gfp Proteins: E2(GFP)-Cl Complex
2O2B	;	1.94	;	Spectroscopic and Structural Study of the Heterotropic Linkage between Halide and Proton Ion Binding to Gfp Proteins: E2(GFP)-I Complex
4CJG	;	1.26	;	Spectroscopically validated structure of the 5 coordinate proximal NO adduct of cytochrome c prime from Alcaligenes xylosoxidans
4CDV	;	1.17	;	Spectroscopically-validated structure of cytochrome c prime from Alcaligenes xylosoxidans, reduced by X-ray irradiation at 100K
4CDY	;	1.77	;	Spectroscopically-validated structure of cytochrome c prime from Alcaligenes xylosoxidans, reduced by X-ray irradiation at 160K
6YRC	;	1.99	;	Spectroscopically-validated structure of DtpB from Streptomyces lividans in the ferric state
4CDA	;	1.3	;	Spectroscopically-validated structure of ferric cytochrome c prime from Alcaligenes xylosoxidans
4CJO	;	1.55	;	Spectroscopically-validated structure of ferrous cytochrome c prime from Alcaligenes xylosoxidans, reduced at 180K using X-rays
4CIP	;	1.22	;	Spectroscopically-validated structure of ferrous cytochrome c prime from Alcaligenes xylosoxidans, reduced using ascorbate
7KX3	;	2.67	;	SpeG Spermidine N-acetyltransferase F149G mutant from Vibrio cholerae
8FV0	;	2.65	;	SpeG spermidine N-acetyltransferase from Staphylococcus aureus in complex with spermine
8FV1	;	2.95	;	SpeG spermidine N-acetyltransferase from Staphylococcus aureus in complex with spermine
1JP9	;	1.7	;	Sperm Whale met-Myoglobin (low temperature; high pressure)
1JPB	;	1.7	;	Sperm Whale met-Myoglobin (low temperature; high pressure)
1JP8	;	2.3	;	Sperm Whale met-Myoglobin (room temperature; high pressure)
1JP6	;	2.3	;	Sperm Whale met-Myoglobin (room temperature; room pressure)
1EBC	;	1.8	;	SPERM WHALE MET-MYOGLOBIN:CYANIDE COMPLEX
1DUO	;	2.0	;	SPERM WHALE METAQUOMYOGLOBIN PROXIMAL HISTIDINE MUTANT H93G WITH 1-METHYLIMIDAZOLE AS PROXIMAL LIGAND.
8QBA	;	1.39	;	Sperm whale myoblogin mutant H64V V68A in complex with glycine ethyl ester
1HJT	;	1.7	;	SPERM WHALE MYOGLOBIN (FERROUS, NITRIC OXIDE BOUND)
1JDO	;	1.9	;	SPERM WHALE MYOGLOBIN (FERROUS, NITRIC OXIDE BOUND)
1MCY	;	1.7	;	SPERM WHALE MYOGLOBIN (MUTANT WITH INITIATOR MET AND WITH HIS 64 REPLACED BY GLN, LEU 29 REPLACED BY PHE
6E04	;	2.0	;	sperm whale myoglobin 1-nitrosopropane
109M	;	1.83	;	SPERM WHALE MYOGLOBIN D122N ETHYL ISOCYANIDE AT PH 9.0
110M	;	1.77	;	SPERM WHALE MYOGLOBIN D122N METHYL ISOCYANIDE AT PH 9.0
111M	;	1.88	;	SPERM WHALE MYOGLOBIN D122N N-BUTYL ISOCYANIDE AT PH 9.0
112M	;	2.34	;	SPERM WHALE MYOGLOBIN D122N N-PROPYL ISOCYANIDE AT PH 9.0
101M	;	2.07	;	SPERM WHALE MYOGLOBIN F46V N-BUTYL ISOCYANIDE AT PH 9.0
102M	;	1.84	;	SPERM WHALE MYOGLOBIN H64A AQUOMET AT PH 9.0
103M	;	2.07	;	SPERM WHALE MYOGLOBIN H64A N-BUTYL ISOCYANIDE AT PH 9.0
5VZO	;	1.78	;	Sperm whale myoglobin H64A with nitric oxide
5UT9	;	1.85	;	Sperm whale myoglobin H64A with nitrite
5KD1	;	1.7	;	Sperm whale myoglobin H64A with nitrosoamphetamine
5VZP	;	1.78	;	Sperm whale myoglobin H64Q with nitric oxide
5UTA	;	1.81	;	Sperm whale myoglobin H64Q with nitrite
6CF0	;	1.64	;	Sperm Whale Myoglobin H64V Mutant with Nitrite
6Z4T	;	1.23	;	sperm whale myoglobin mutant (H64V V64A) bearing the non-canonical amino acid 2-Amino-3-(thiazol-5-yl)propanoic acid as axial heme ligand
6Z4R	;	1.96	;	sperm whale myoglobin mutant (H64V V64A) bearing the non-canonical amino acid 3-thienylalanine as axial heme ligand
3NML	;	1.68	;	Sperm whale myoglobin mutant H64W carbonmonoxy-form
3OGB	;	1.6	;	Sperm whale myoglobin mutant H64W deoxy-form
8EKO	;	1.34	;	Sperm whale myoglobin mutant L29H F33W F43H (F33W CuBMb)
5HAV	;	1.268	;	Sperm whale myoglobin mutant L29H F33Y F43H (F33Y CuBMb) with oxygen bound
1H1X	;	1.4	;	Sperm whale Myoglobin mutant T67R S92D
104M	;	1.71	;	SPERM WHALE MYOGLOBIN N-BUTYL ISOCYANIDE AT PH 7.0
105M	;	2.02	;	SPERM WHALE MYOGLOBIN N-BUTYL ISOCYANIDE AT PH 9.0
6E03	;	1.76	;	sperm whale myoglobin nitrosoethane adduct
5YCE	;	0.77	;	Sperm whale myoglobin swMb
4NXC	;	1.55	;	SPERM WHALE MYOGLOBIN UNDER 30 BAR NITROUS Oxide
4NXA	;	1.6	;	SPERM WHALE MYOGLOBIN UNDER XENON PRESSURE 30 Bar
5VZQ	;	1.79	;	Sperm whale myoglobin V68A/I107Y with nitric oxide
5UTD	;	1.78	;	Sperm whale myoglobin V68A/I107Y with nitrite
106M	;	1.99	;	SPERM WHALE MYOGLOBIN V68F ETHYL ISOCYANIDE AT PH 9.0
108M	;	2.67	;	SPERM WHALE MYOGLOBIN V68F N-BUTYL ISOCYANIDE AT PH 7.0
107M	;	2.09	;	SPERM WHALE MYOGLOBIN V68F N-BUTYL ISOCYANIDE AT PH 9.0
1SPE	;	2.0	;	SPERM WHALE NATIVE CO MYOGLOBIN AT PH 4.0, TEMP 4C
4NCZ	;	1.89	;	Spermidine N-acetyltransferase from Vibrio cholerae in complex with 2-[n-cyclohexylamino]ethane sulfonate.
7KX2	;	2.6	;	Spermidine N-acetyltransferase SpeG F149A mutant from Vibrio cholerae
7KWJ	;	2.58	;	Spermidine N-acetyltransferase SpeG K23-Q34 chimera from Vibrio cholerae and hSSAT
7KWH	;	2.9	;	Spermidine N-acetyltransferase SpeG K23-Y30 chimera from Vibrio cholerae and hSSAT
7KWX	;	2.42	;	Spermidine N-acetyltransferase SpeG N152L mutant from Vibrio cholerae
7KWQ	;	2.3	;	Spermidine N-acetyltransferase SpeG R149-K152 chimera from Vibrio cholerae and hSSAT
8IYI	;	1.9	;	Spermidine synthase from Kluyveromyces lactis
1POY	;	2.5	;	SPERMIDINE/PUTRESCINE-BINDING PROTEIN COMPLEXED WITH SPERMIDINE (DIMER FORM)
1POT	;	1.8	;	SPERMIDINE/PUTRESCINE-BINDING PROTEIN COMPLEXED WITH SPERMIDINE (MONOMER FORM)
2B3V	;	1.95	;	Spermine spermidine acetyltransferase in complex with acetylcoa, K26R mutant
3BJ7	;	2.2	;	Spermine/spermidine N1-acetyltransferase from mouse: Crystal structure of a ternary complex reveals solvent-mediated spermine binding
3BJ8	;	2.3	;	Spermine/spermidine N1-acetyltransferase from mouse: Crystal structure of a ternary complex reveals solvent-mediated spermine binding
4FVF	;	2.46	;	SPFH domain of mouse stomatin (Crystal form 1)
4FVG	;	1.8	;	SPFH domain of mouse stomatin (Crystal form 3)
8GN9	;	2.5	;	SPFH domain of Pyrococcus horikoshii stomatin
4FVJ	;	2.69	;	SPFH domain of the mouse stomatin (Crystal form 2)
1EA7	;	0.93	;	Sphericase
2IXT	;	0.8	;	SPHERICASE
6GSB	;	1.45	;	Sphingobacterium sp. T2 manganese superoxide dismutase catalyses the oxidative demethylation of polymeric lignin via generation of hydroxyl radical
6GSC	;	1.32	;	Sphingobacterium sp. T2 manganese superoxide dismutase catalyses the oxidative demethylation of polymeric lignin via generation of hydroxyl radical
2X8U	;	2.1	;	Sphingomonas wittichii Serine palmitoyltransferase
2I7F	;	1.9	;	Sphingomonas yanoikuyae B1 ferredoxin
4V24	;	1.8	;	Sphingosine kinase 1 in complex with PF-543
7TD3	;	3.0	;	Sphingosine-1-phosphate receptor 1-Gi complex bound to S1P
7TD4	;	2.6	;	Sphingosine-1-phosphate receptor 1-Gi complex bound to Siponimod
7C4S	;	3.2	;	Sphingosine-1-phosphate receptor 3 with a natural ligand.
8BWB	;		;	Spider toxin Pha1b (PnTx3-6) from Phoneutria nigriventer targeting CaV2.x calcium channels and TRPA1 channel
2MU3	;		;	Spider wrapping silk fibre architecture arising from its modular soluble protein precursor
7VHN	;	3.8	;	Spike of SARS-CoV-2 spike protein(1 up)
7DZY	;	3.6	;	Spike protein from SARS-CoV2 with Fab fragment of enhancing antibody 2490
7DZX	;	3.53	;	Spike protein from SARS-CoV2 with Fab fragment of enhancing antibody 8D2
6ZGF	;	3.1	;	Spike Protein of RaTG13 Bat Coronavirus in Closed Conformation
8G71	;	2.1	;	Spike/Nb2 complex with 1 RBD up
7PSW	;	1.21	;	Spin labeled IPNS S55C variant in complex with Fe and ACV under anaerobic conditions
7POY	;	1.75	;	Spin labeled IPNS S55C variant in complex with Fe, ACV and NO
6NJR	;	2.7	;	Spin-Labeled T177C/A637C Mutant of Rat CYPOR
6V51	;	1.5	;	Spin-labeled T4 Lysozyme (9/131FnbY)-(4-Amino-TEMPO)
5JGV	;	1.732	;	Spin-Labeled T4 Lysozyme Construct A73V1
5JGN	;	1.534	;	Spin-Labeled T4 Lysozyme Construct I9V1
5KGR	;	1.473	;	Spin-Labeled T4 Lysozyme Construct I9V1/V131V1 (30 days)
5JGR	;	1.46	;	Spin-Labeled T4 Lysozyme Construct K43V1
5JGU	;	1.468	;	Spin-Labeled T4 Lysozyme Construct R119V1
5JGZ	;	1.534	;	Spin-Labeled T4 Lysozyme Construct T151V1
5JGX	;	1.533	;	Spin-Labeled T4 Lysozyme Construct V131V1
8AMZ	;	3.3	;	Spinach 19S proteasome
7QVE	;	3.3	;	Spinach 20S proteasome
1A70	;	1.7	;	SPINACH FERREDOXIN
1F56	;	2.05	;	SPINACH PLANTACYANIN
1UPP	;	2.3	;	SPINACH RUBISCO IN COMPLEX WITH 2-CARBOXYARABINITOL 2 BISPHOSPHATE and Calcium.
1RBO	;	2.3	;	SPINACH RUBISCO IN COMPLEX WITH THE INHIBITOR 2-CARBOXYARABINITOL-1,5-DIPHOSPHATE
1RCO	;	2.3	;	SPINACH RUBISCO IN COMPLEX WITH THE INHIBITOR D-XYLULOSE-2,2-DIOL-1,5-BISPHOSPHATE
7L0Z	;	2.1	;	Spinach variant bound to DFHBI-1T
2G5M	;		;	Spinophilin PDZ domain
4LDP	;	2.5	;	Spinosyn Forosaminyltransferase SpnP
4LEI	;	3.15	;	Spinosyn Forosaminyltransferase SpnP
3TSA	;	1.7	;	Spinosyn Rhamnosyltransferase SpnG
3UYK	;	1.7	;	Spinosyn Rhamnosyltransferase SpnG complexed with spinosyn aglycone
3UYL	;	1.85	;	Spinosyn Rhamnosyltransferase SpnG complexed with thymidine diphosphate
5JCY	;	1.8	;	Spir2-GTBM bound to MyoVa-GTD
7YPI	;	3.8	;	Spiral hexamer of the substrate-free Lon protease with a Y224S mutation
8PDN	;	4.7	;	Spiral of assembled human metapneumovirus (HMPV) N-RNA
7YPJ	;	3.8	;	Spiral pentamer of the substrate-free Lon protease with a S678A mutation
6Q7L	;	7.6	;	Spiral structure of E. coli RavA in the RavA-LdcI cage-like complex
6Q7M	;	7.8	;	Spiral structure of E. coli RavA in the RavA-LdcI cage-like complex
5E9O	;	2.1	;	Spirochaeta thermophila X module - CBM64 - mutant G504A
5E9P	;	1.2	;	Spirochaeta thermophila X module - CBM64 - wildtype
3QKK	;	2.3	;	Spirochromane Akt Inhibitors
3QKL	;	1.9	;	Spirochromane Akt Inhibitors
4JOO	;	1.8	;	Spirocyclic Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors
4JP9	;	1.8	;	Spirocyclic Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors
4JPC	;	1.8	;	Spirocyclic Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors
4JPE	;	1.8	;	Spirocyclic Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors
3QKM	;	2.2	;	Spirocyclic sulfonamides as AKT inhibitors
1A8I	;	1.78	;	SPIROHYDANTOIN INHIBITOR OF GLYCOGEN PHOSPHORYLASE
7YSZ	;	2.30004	;	Spiroplasma melliferum FtsZ bound to GDP
7YOP	;	2.20003	;	Spiroplasma melliferum FtsZ bound to GMPPNP
8GRW	;	2.40005	;	Spiroplasma melliferum FtsZ F224M bound to GDP
6M5M	;	1.7	;	SPL-1 - GlcNAc complex
2W7S	;	1.8	;	SplA serine protease of Staphylococcus aureus (1.8A)
2W7U	;	2.43	;	SplA serine protease of Staphylococcus aureus (2.4A)
2P5H	;		;	sPLA2 inhibitor 9
2P5J	;		;	sPLA2 inhibitor pip 17
6OE5	;	4.1	;	Splayed open prefusion RSV F captured by CR9501 and motavizumab Fabs
4WZJ	;	3.6	;	Spliceosomal U4 snRNP core domain
4ZB4	;	2.3	;	Spliceosome component
5M88	;	2.8	;	Spliceosome component
5M89	;	1.605	;	Spliceosome component
5M8C	;	2.3	;	Spliceosome component
3AJV	;	1.7	;	Splicing endonuclease from Aeropyrum pernix
6YAK	;	1.34	;	Split gene transketolase, active alpha2beta2 heterotetramer
6YAJ	;	1.9	;	Split gene transketolase, inactive beta4 tetramer
2RLO	;		;	Split PH domain of PI3-kinase enhancer
8IA9	;	2.5	;	SpnK Methyltransferase from the Spinosyn Biosynthetic Pathway in Complex with Mg
8IAA	;	2.1	;	SpnK Methyltransferase from the Spinosyn Biosynthetic Pathway in Complex with SAH
6L6V	;		;	SPO1 Gp44 N-terminal region (1-55)
3DNX	;	1.94	;	SPO1766 protein of unknown function from Silicibacter pomeroyi.
5HY6	;	2.186	;	Spodoptera frugiperda eukaryotic translation initiation factor EIF5A
5WC3	;	3.5	;	SpoIIIAG
4O1V	;	2.0	;	SPOP Promotes Tumorigenesis by Acting as a Key Regulatory Hub in Kidney Cancer
8DWU	;	3.4	;	SPOP W22R Form 1
8DWT	;	6.2	;	SPOP W22R Form 2
6ZTG	;		;	Spor protein DedD
4FHC	;	2.2	;	Spore photoproduct lyase
4FHE	;	2.0	;	Spore photoproduct lyase C140A mutant
4FHF	;	2.3	;	Spore photoproduct lyase C140A mutant with dinucleoside spore photoproduct
4RH0	;	2.1	;	Spore photoproduct lyase C140A/S76C mutant with bound AdoMet
4RH1	;	2.6	;	Spore photoproduct lyase C140A/S76C mutant with bound AdoMet and dinucleoside spore photoproduct
4FHG	;	2.0	;	Spore photoproduct lyase C140S mutant
4FHD	;	2.0	;	Spore photoproduct lyase complexed with dinucleoside spore photoproduct
4K9R	;	2.3	;	Spore photoproduct lyase Y98F mutant
7ZCY	;	1.54	;	Sporosarcina pasteurii urease (SPU) co-crystallized in the presence of an Ebselen-derivative and bound to Se atoms
6G48	;	1.91	;	Sporosarcina pasteurii urease inhibited by silver
4U5A	;	2.75	;	Sporozoite Protein for Cell Traversal
4TPS	;	1.65	;	Sporulation Inhibitor of DNA Replication, SirA, in complex with Domain I of DnaA
4I0I	;	2.2	;	SPR and structural analysis yield insight towards mechanism of inhibition of BACE inhibitors
4I0J	;	1.99	;	SPR and structural analysis yield insight towards mechanism of inhibition of BACE inhibitors
4I0H	;	2.2	;	SPR and structural analysis yield insight towards mechanism of inhibition of BACE inhibitors.
7QCA	;	2.79	;	Spraguea lophii ribosome
8P60	;	14.3	;	Spraguea lophii ribosome dimer
8P5D	;	10.8	;	Spraguea lophii ribosome in the closed conformation by cryo sub tomogram averaging
2AFJ	;		;	SPRY domain-containing SOCS box protein 2 (SSB-2)
6DN8	;	1.75	;	SPRY domain-containing SOCS box protein 2 complexed with (GZJ)VDINNN(CY3) Cyclic peptide inhibitor
6DN6	;	1.59	;	SPRY domain-containing SOCS box protein 2 complexed with INNN(ABU) cyclic peptide inhibitor
6DN5	;	2.4	;	SPRY domain-containing SOCS box protein 2 complexed with WDINNN(BAL) cyclic peptide inhibitor
6DN7	;	1.4	;	SPRY domain-containing SOCS box protein 2 complexed with WDINNN(BAL) Cyclic peptide inhibitor
3EK9	;	2.6	;	SPRY Domain-containing SOCS Box Protein 2: Crystal Structure and Residues Critical for Protein Binding
2W8T	;	1.25	;	SPT with PLP, N100C
2W8V	;	1.43	;	SPT with PLP, N100W
2W8U	;	1.5	;	SPT with PLP, N100Y
2W8J	;	1.5	;	SPT with PLP-ser
4WNN	;	1.8	;	SPT16-H2A-H2B FACT HISTONE Complex
5VKO	;	1.8	;	SPT6 tSH2-RPB1 1468-1500 pT1471, pS1493
5VKL	;	2.198	;	SPT6 tSH2-RPB1 1476-1500 pS1493
7FCB	;	1.4	;	SptF 9 residues truncated mutant
7D53	;	1.6	;	SpuA mutant - H221N with Glu
7D50	;	1.77	;	SpuA mutant - H221N with glutamyl-thioester
7D4R	;	1.6	;	SpuA native structure
2GWJ	;	1.9	;	SpvB ADP-ribosylated actin: hexagonal crystal form
2GWK	;	2.0	;	SpvB ADP-ribosylated actin: orthorhombic crystal form
6OWY	;	2.07	;	Spy H96L:Im7 K20pI-Phe complex; multiple anomalous datasets contained herein for element identification
6OWX	;	2.06	;	Spy H96L:Im7 L18pI-Phe complex; multiple anomalous datasets contained herein for element identification
6OWZ	;	2.05	;	Spy H96L:Im7 L19pI-Phe complex; multiple anomalous datasets contained herein for element identification
1H3B	;	2.8	;	Squalene-Hopene Cyclase
1O6H	;	2.8	;	Squalene-Hopene Cyclase
3SQC	;	2.8	;	SQUALENE-HOPENE CYCLASE
2SQC	;	2.0	;	SQUALENE-HOPENE CYCLASE FROM ALICYCLOBACILLUS ACIDOCALDARIUS
1SQC	;	2.85	;	SQUALENE-HOPENE-CYCLASE FROM ALICYCLOBACILLUS ACIDOCALDARIUS
6S5D	;	3.393	;	Square conformation of KtrA R16A mutant ring with bound ATP
6S2J	;	2.67	;	Square conformation of KtrA R16K mutant ring with bound ATP
6S5C	;	3.0	;	Square conformation of KtrA WT ring with bound ATP and calcium
2HMW	;	3.0	;	Square-shaped octameric ring structure of an RCK domain with ATP bound
4J90	;	3.24	;	Square-shaped octameric structure of KtrA with ATP bound
8OWA	;	2.85	;	SR Ca(2+)-ATPase in the E2 state complexed with the photoswitch-thapsigargin derivative AzTG-4
8OWL	;	3.02	;	SR Ca(2+)-ATPase in the E2 state complexed with the photoswitch-thapsigargin derivative AzTG-6
3NAN	;	3.1	;	SR Ca(2+)-ATPase in the HnE2 state complexed with a Thapsigargin derivative Boc-(phi)Tg
2BY4	;	3.3	;	SR Ca(2+)-ATPase in the HnE2 state complexed with the thapsigargin derivative Boc-12ADT.
3NAM	;	3.1	;	SR Ca(2+)-ATPase in the HnE2 state complexed with the Thapsigargin derivative dOTg
3NAL	;	2.65	;	SR Ca(2+)-ATPase in the HnE2 state complexed with the Thapsigargin derivative DTB
6FAD	;	2.801	;	SR protein kinase 1 (SRPK1) in complex with the RGG-box of HSV1 ICP27
8EFL	;	3.2	;	SR17018-bound mu-opioid receptor-Gi complex
6VCS	;	1.7	;	SRA domain of UHRF1 in complex with DNA
1BU1	;	2.6	;	SRC FAMILY KINASE HCK SH3 DOMAIN
2C0I	;	2.3	;	Src family kinase Hck with bound inhibitor A-420983
2C0T	;	2.15	;	Src family kinase Hck with bound inhibitor A-641359
2C0O	;	2.85	;	Src family kinase Hck with bound inhibitor A-770041
1AD5	;	2.6	;	SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
2HCK	;	3.0	;	SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
3U51	;	2.241	;	Src in complex with DNA-templated macrocyclic inhibitor MC1
5BMM	;	2.5	;	Src in complex with DNA-templated macrocyclic inhibitor MC25b
3U4W	;	1.9	;	Src in complex with DNA-templated macrocyclic inhibitor MC4b
6ATE	;	2.402	;	SRC kinase bound to covalent inhibitor
7NG7	;	1.5	;	Src kinase bound to eCF506 trapped in inactive conformation
7OTE	;	2.49	;	Src Kinase Domain in complex with ponatinib
2H8H	;	2.2	;	Src kinase in complex with a quinazoline inhibitor
5J5S	;	2.153	;	Src kinase in complex with a sulfonamide inhibitor
2BDF	;	2.1	;	Src kinase in complex with inhibitor AP23451
2BDJ	;	2.5	;	Src kinase in complex with inhibitor AP23464
4MXY	;	2.582	;	Src M314L T338M double mutant bound to kinase inhibitor bosutinib
4MXZ	;	2.582	;	Src M314L T338M double mutant bound to kinase inhibitor bosutinib
1F2F	;	1.7	;	SRC SH2 THREF1TRP MUTANT
1F1W	;	2.1	;	SRC SH2 THREF1TRP MUTANT COMPLEXED WITH THE PHOSPHOPEPTIDE S(PTR)VNVQN
3G6H	;	2.35	;	Src Thr338Ile inhibited in the DFG-Asp-Out conformation
3ZMQ	;	3.3	;	Src-derived mutant peptide inhibitor complex of PTP1B
3ZMP	;	2.619	;	Src-derived peptide inhibitor complex of PTP1B
3LQX	;	1.93	;	SRP ribonucleoprotein core complexed with cobalt hexammine
7OBQ	;	3.9	;	SRP-SR at the distal site conformation
5IJ3	;	1.7	;	SrpA adhesin in complex with sialyl T antigen
5IJ2	;	1.683	;	SrpA adhesin in complex with sialyllactosamine
5IJ1	;	1.8	;	SrpA adhesin in complex with sialyllactose
5IIY	;	1.888	;	SrpA adhesin in complex with the Neu5Ac-galactoside disaccharide
5KIQ	;	1.638	;	SrpA with sialyl LewisX
1WBP	;	2.4	;	SRPK1 bound to 9mer docking motif peptide
5XV7	;	2.32	;	SRPK1 in complex with Alectinib
7ZKS	;	2.28	;	SRPK1 IN COMPLEX WITH INHIBITOR
7PQS	;	2.2	;	SRPK1 in complex with MSC2711186
7ZKX	;	2.06	;	SRPK2 IN COMPLEX WITH INHIBITOR
5UTT	;	1.7	;	SrtA sortase from Actinomyces oris
5UUS	;	2.02	;	SrtF sortase from Corynebacterium diphtheriae
5HP5	;	3.198	;	Srtucture of human peptidylarginine deiminase type I (PAD1)
2B58	;	1.95	;	SSAT with coa_sp, spermine disordered, K26R mutant
2B4B	;	2.0	;	SSAT+COA+BE-3-3-3, K26R mutant
2B4D	;	2.0	;	SSAT+COA+SP- SP disordered
5YWL	;	2.098	;	SsCR_L211H
5YWN	;	2.039	;	SsCR_L211H-NADP+
1FGU	;	2.5	;	SSDNA-BINDING DOMAIN OF THE LARGE SUBUNIT OF REPLICATION PROTEIN A
7DBB	;	2.805	;	SSE in complex with tubulin
2MUZ	;		;	ssNMR structure of a designed rocker protein
5V7Z	;		;	SSNMR Structure of the Human RIP1/RIP3 Necrosome
2XVO	;	2.08	;	SSO1725, a protein involved in the CRISPR/Cas pathway
1BNZ	;	2.0	;	SSO7D HYPERTHERMOPHILE PROTEIN/DNA COMPLEX
8BMW	;	3.5	;	SsoCsm
8EAF	;	2.62	;	SsoMCM hexamer bound to Mg/ADP-BeFx and 12-mer oligo-dT. Class 1
8EAG	;	3.01	;	SsoMCM hexamer bound to Mg/ADP-BeFx and 12-mer oligo-dT. Class 2
8EAH	;	2.48	;	SsoMCM hexamer bound to Mg/ADP-BeFx and 16-mer oligo-dT. Class 1
8EAI	;	2.76	;	SsoMCM hexamer bound to Mg/ADP-BeFx and 16-mer oligo-dT. Class 2
8EAJ	;	2.45	;	SsoMCM hexamer bound to Mg/ADP-BeFx and 46-mer DNA strand. Class 1
8EAK	;	2.67	;	SsoMCM hexamer bound to Mg/ADP-BeFx and 46-mer DNA strand. Class 2
8EAL	;	2.34	;	SsoMCM hexamer bound to Mg/ADP-BeFx and DNA. Class 1. Merged particles from datasets with 3 different DNA entities
8EAM	;	2.59	;	SsoMCM hexamer bound to Mg/ADP-BeFx and DNA. Class 2. Merged particles from datasets with 3 different DNA entities
6M4J	;	1.8	;	SspA in complex with cysteine
6JUF	;	1.587	;	SspB crystal structure
1TWB	;	1.9	;	SspB disulfide crosslinked to an ssrA degradation tag
6JIV	;	3.31	;	SspE crystal structure
2JPC	;		;	SSRB DNA Binding Protein
8TDV	;	3.44	;	ssRNA bound SAMHD1 T closed
8TDW	;	3.04	;	ssRNA bound SAMHD1 T open
6NPW	;	2.486	;	SSu72/Sympk in complex with Ser2/Ser5 phosphorylated peptide
3VCF	;	2.7	;	SSV1 integrase C-terminal catalytic domain (174-335aa)
8S2X	;	2.5	;	SSX structure of Arabidopsis thaliana Pdx1.3 grown in microfluidic droplets
8S2W	;	2.5	;	SSX structure of Arabidopsis thaliana Pdx1.3 grown in seeded batch conditions
8S2U	;	1.8	;	SSX structure of Lysozyme grown in batch conditions
8S2V	;	1.8	;	SSX structure of Lysozyme grown in microfluidic droplets
6H79	;	2.1	;	SSX structure of Lysozyme in flow - metal-kapton microfluidic device
7UHT	;	2.2	;	SSX Structure of Metallo Beta-Lactamase L1 with One Zinc in the Active Site
7UHS	;	2.2	;	SSX Structure of Metallo Beta-Lactamase L1 with Two Water Molecules in the Active Site
1CPR	;	2.1	;	ST. LOUIS CYTOCHROME C' FROM THE PURPLE PHOTOTROPIC BACTERIUM, RHODOBACTER CAPSULATUS
5Z0A	;	2.09	;	ST0452(Y97N)-GlcNAc binding form
5Z09	;	2.91	;	ST0452(Y97N)-UTP binding form
8JLZ	;	3.09	;	ST1936-5HT6R complex
6GWX	;		;	Stabilising and Understanding a Miniprotein by Rational Design.
1N0C	;		;	Stability of cyclic beta-hairpins: Asymmetric contibutions from side chains of hydrogen bonded cross-strand residue pair
1N0D	;		;	Stability of cyclic beta-hairpins: Asymmetric contibutions from side chains of hydrogen bonded cross-strand residue pair
3AKY	;	2.23	;	STABILITY, ACTIVITY AND STRUCTURE OF ADENYLATE KINASE MUTANTS
1KDA	;	1.9	;	STABILIZATION OF A STRAINED PROTEIN LOOP CONFORMATION THROUGH PROTEIN ENGINEERING
1KDB	;	1.9	;	STABILIZATION OF A STRAINED PROTEIN LOOP CONFORMATION THROUGH PROTEIN ENGINEERING
1KDC	;	2.0	;	STABILIZATION OF A STRAINED PROTEIN LOOP CONFORMATION THROUGH PROTEIN ENGINEERING
1UR5	;	1.75	;	Stabilization of a Tetrameric Malate Dehydrogenase by Introduction of a Disulfide Bridge at the Dimer/Dimer Interface
1LAV	;	1.8	;	STABILIZATION OF ESCHERICHIA COLI RIBONUCLEASE HI BY CAVITY-FILLING MUTATIONS WITHIN A HYDROPHOBIC CORE
1LAW	;	1.8	;	STABILIZATION OF ESCHERICHIA COLI RIBONUCLEASE HI BY CAVITY-FILLING MUTATIONS WITHIN A HYDROPHOBIC CORE
1IOQ	;	1.79	;	STABILIZATION OF HEN EGG WHITE LYSOZYME BY A CAVITY-FILLING MUTATION
1IOR	;	1.76	;	STABILIZATION OF HEN EGG WHITE LYSOZYME BY A CAVITY-FILLING MUTATION
1IOS	;	1.76	;	STABILIZATION OF HEN EGG WHITE LYSOZYME BY A CAVITY-FILLING MUTATION
1IOT	;	1.75	;	STABILIZATION OF HEN EGG WHITE LYSOZYME BY A CAVITY-FILLING MUTATION
1BZU	;		;	STABILIZATION OF THE ANTICODON STEM-LOOP OF TRNALYS, 3 BY AN A+C BASE PAIR AND BY PSEUDOURIDINE, NMR, 1 STRUCTURE
1BZ2	;		;	STABILIZATION OF THE ANTICODON STEM-LOOP OF TRNALYS,3 BY AN A+C BASE PAIR AND BY PSEUDOURIDINE, NMR, 1 STRUCTURE
1BZ3	;		;	STABILIZATION OF THE ANTICODON STEM-LOOP OF TRNALYS,3 BY AN A+C BASE PAIR AND BY PSEUDOURIDINE, NMR, 1 STRUCTURE
1BZT	;		;	STABILIZATION OF THE ANTICODON STEM-LOOP OF TRNALYS,3 BY AN A+C BASE PAIR AND BY PSEUDOURIDINE, NMR, 1 STRUCTURE
1JCI	;	1.9	;	Stabilization of the Engineered Cation-binding Loop in Cytochrome c Peroxidase (CcP)
1D41	;	1.3	;	STABILIZATION OF Z-DNA BY DEMETHYLATION OF THYMINE BASES: 1.3 ANGSTROMS SINGLE-CRYSTAL STRUCTURE OF D(M5CGUAM5CG)
6NI2	;	4.0	;	Stabilized beta-arrestin 1-V2T subcomplex of a GPCR-G protein-beta-arrestin mega-complex
3MK9	;	2.08	;	Stabilized Ricin Immunogen 1-33/44-198
1KNI	;	1.7	;	Stabilizing Disulfide Bridge Mutant of T4 Lysozyme
168D	;	2.0	;	STABILIZING EFFECTS OF THE RNA 2'-SUBSTITUENT: CRYSTAL STRUCTURE OF AN OLIGODEOXYNUCLEOTIDE DUPLEX CONTAINING 2'-O-METHYLATED ADENOSINES
1U0P	;		;	Stable A-state hairpin of T4 fibritin foldon
7LUR	;	1.95	;	Stable Effector Functionless 2 (SEFL2) IgG1 Fc Scaffold Bound to a Minimized Version of the B-domain (Mini-Z) from Protein A Called Z34C
200D	;	1.85	;	STABLE LOOP IN THE CRYSTAL STRUCTURE OF THE INTERCALATED FOUR-STRANDED CYTOSINE-RICH METAZOAN TELOMERE
5HQ3	;	2.6	;	Stable, high-expression variant of human acetylcholinesterase
3O8Y	;	2.389	;	Stable-5-Lipoxygenase
7TTK	;	1.98	;	Stable-5-LOX
7TTJ	;	2.1	;	Stable-5-LOX elongated Ha2
7TTL	;	2.43	;	Stable-5-LOX elongated Ha2 (4 copies ASU)
7PIN	;	3.6	;	Stacked compact Dunaliella PSII
7PIW	;	4.0	;	Stacked stretched Dunaliella PSII
8OP2	;	2.8	;	Stacks of nucleocapsid rings of the N1-370 mutant of the human Respiratory Syncytial Virus
6BS9	;	2.32	;	Stage III sporulation protein AB (SpoIIIAB)
6DCS	;	2.7	;	Stage III sporulation protein AF (SpoIIIAF)
2EH1	;	2.25	;	Stage V Sporolation Protein S (SpoVS) from Thermus thermophilus
2EK0	;	1.9	;	Stage V Sporolation Protein S (SPOVS) from Thermus thermophilus Zinc form
7CG3	;	5.1	;	Staggered ring conformation of CtHsp104 (Hsp104 from Chaetomium Thermophilum)
7O3V	;	3.7	;	Stalk complex structure (TrwJ/VirB5-TrwI/VirB6) from the fully-assembled R388 type IV secretion system determined by cryo-EM.
7JTS	;	6.1	;	Stalk of radial spoke 1 attached with doublet microtubule from Chlamydomonas reinhardtii
6T8G	;	4.34	;	Stalled FtsK motor domain bound to dsDNA
6T8O	;	3.99	;	Stalled FtsK motor domain bound to dsDNA end
3FYW	;	2.1	;	Staph. aureus DHFR complexed with NADPH and AR-101
3FYV	;	2.2	;	Staph. aureus DHFR complexed with NADPH and AR-102
3FY9	;	2.25	;	Staph. aureus DHFR F98Y complexed with AR-102
3NUC	;	1.9	;	STAPHLOCOCCAL NUCLEASE, 1-N-PROPANE THIOL DISULFIDE TO V23C VARIANT
2NUC	;	2.0	;	STAPHLOCOCCAL NUCLEASE, ETHANE THIOL DISULFIDE TO V23C VARIANT
1CV8	;	1.75	;	STAPHOPAIN, CYSTEINE PROTEINASE FROM STAPHYLOCOCCUS AUREUS V8
1NYC	;	1.4	;	Staphostatins resemble lipocalins, not cystatins in fold.
2A1D	;	3.5	;	Staphylocoagulase bound to bovine thrombin
1NU9	;	2.2	;	Staphylocoagulase-Prethrombin-2 complex
1NU7	;	2.2	;	Staphylocoagulase-Thrombin Complex
4YHD	;	2.801	;	Staphylococcal alpha-hemolysin H35A mutant monomer
4DXD	;	2.01	;	Staphylococcal Aureus FtsZ in complex with 723
3NMS	;	4.1	;	Staphylococcal Complement Inhibitor (SCIN) in complex with Human Complement C3c
3L5N	;	7.536	;	Staphylococcal Complement Inhibitor (SCIN) in complex with Human Complement Component C3b
3L3O	;	3.405	;	Staphylococcal Complement Inhibitor (SCIN) in complex with Human Complement Component C3c
1ESF	;	1.9	;	STAPHYLOCOCCAL ENTEROTOXIN A
1DYQ	;	1.5	;	STAPHYLOCOCCAL ENTEROTOXIN A MUTANT VACCINE
3SEB	;	1.48	;	STAPHYLOCOCCAL ENTEROTOXIN B
5XZ0	;	3.002	;	Staphylococcal Enterotoxin B (SEB) mutant S19 - N23A, Y90A, R110A and F177A
1SE3	;	2.3	;	STAPHYLOCOCCAL ENTEROTOXIN B COMPLEXED WITH GM3 TRISACCHARIDE
1SE4	;	1.9	;	STAPHYLOCOCCAL ENTEROTOXIN B COMPLEXED WITH LACTOSE
3GP7	;	1.9	;	Staphylococcal Enterotoxin B mutant N23YK97SK98S
1STE	;	2.0	;	STAPHYLOCOCCAL ENTEROTOXIN C2 FROM STAPHYLOCOCCUS AUREUS
1SE2	;	2.7	;	STAPHYLOCOCCAL ENTEROTOXIN C2, MONOCLINIC FORM
1I4X	;	2.4	;	STAPHYLOCOCCAL ENTEROTOXIN C2, MONOCLINIC FORM CRYSTALLIZED AT PH 8.0
1F77	;	2.4	;	STAPHYLOCOCCAL ENTEROTOXIN H DETERMINED TO 2.4 A RESOLUTION
1SXT	;	2.7	;	STAPHYLOCOCCAL ENTEROTOXIN TYPE A (SEA) CO-CRYSTALLISED WITH ZINC
1SND	;	1.84	;	STAPHYLOCOCCAL NUCLEASE DIMER CONTAINING A DELETION OF RESIDUES 114-119 COMPLEXED WITH CALCIUM CHLORIDE AND THE COMPETITIVE INHIBITOR DEOXYTHYMIDINE-3',5'-DIPHOSPHATE
4G57	;	1.81	;	Staphylococcal Nuclease double mutant I72L, I92L
4WOR	;	1.596	;	Staphylococcal nuclease in complex with Ca2+ and thymidine-3'-5'-diphosphate (pdTp) at room temperature
2LKV	;		;	Staphylococcal Nuclease PHS variant
5NUC	;	2.1	;	STAPHYLOCOCCAL NUCLEASE, 1-N-PENTANE THIOL DISULFIDE TO V23C VARIANT
1A2T	;	1.96	;	STAPHYLOCOCCAL NUCLEASE, B-MERCAPTOETHANOL DISULFIDE TO V23C VARIANT
1A3U	;	2.05	;	STAPHYLOCOCCAL NUCLEASE, CYCLOHEXANE THIOL DISULFIDE TO V23C VARIANT
1A3V	;	2.2	;	STAPHYLOCOCCAL NUCLEASE, CYCLOPENTANE THIOL DISULFIDE TO V23C VARIANT
1AEX	;	2.1	;	STAPHYLOCOCCAL NUCLEASE, METHANE THIOL DISULFIDE TO V23C VARIANT
1NUC	;	1.9	;	STAPHYLOCOCCAL NUCLEASE, V23C VARIANT
1A2U	;	2.0	;	STAPHYLOCOCCAL NUCLEASE, V23C VARIANT, COMPLEX WITH 1-N-BUTANE THIOL AND 3',5'-THYMIDINE DIPHOSPHATE
1A3T	;	2.1	;	STAPHYLOCOCCAL NUCLEASE, V23C VARIANT, COMPLEX WITH 2-FLUOROETHANE THIOL AND 3',5'-THYMIDINE DIPHOSPHATE
2SNS	;	1.5	;	STAPHYLOCOCCAL NUCLEASE. PROPOSED MECHANISM OF ACTION BASED ON STRUCTURE OF ENZYME-THYMIDINE 3(PRIME),5(PRIME)-BIPHOSPHATE-CALCIUM ION COMPLEX AT 1.5-ANGSTROMS RESOLUTION
1EDL	;		;	STAPHYLOCOCCAL PROTEIN A E-DOMAIN (-60), NMR, 22 STRUCTURES
1EDK	;		;	STAPHYLOCOCCAL PROTEIN A E-DOMAIN (-60), NMR, MINIMIZED AVERAGE STRUCTURE
1EDJ	;		;	STAPHYLOCOCCAL PROTEIN A E-DOMAIN (180), NMR, 20 STRUCTURES
1EDI	;		;	STAPHYLOCOCCAL PROTEIN A E-DOMAIN (180), NMR, MINIMIZED AVERAGE STRUCTURE
1SS1	;		;	STAPHYLOCOCCAL PROTEIN A, B-DOMAIN, Y15W MUTANT, NMR, 25 STRUCTURES
2SPZ	;		;	STAPHYLOCOCCAL PROTEIN A, Z-DOMAIN, NMR, 10 STRUCTURES
1V1O	;	2.75	;	staphylococcal superantigen-like protein 7
1TXT	;	2.501	;	Staphylococcus aureus 3-hydroxy-3-methylglutaryl-CoA synthase
7KWG	;	3.75	;	Staphylococcus aureus 30S ribosomal subunit in presence of spermidine
7BGD	;	3.2	;	Staphylococcus aureus 30S ribosomal subunit in presence of spermidine (body only)
7BGE	;	3.6	;	Staphylococcus aureus 30S ribosomal subunit in presence of spermidine (head only)
7ASN	;	2.73	;	Staphylococcus aureus 50S after 30 minutes incubation a 37C
7ASM	;	2.48	;	Staphylococcus aureus 50S after 30 minutes incubation at 37C
4CYU	;	2.7	;	Staphylococcus aureus 7,8-Dihydro-6-hydroxymethylpterin- pyrophosphokinase in complex with AMPCPP
4CRJ	;	2.0	;	Staphylococcus aureus 7,8-Dihydro-6-hydroxymethylpterin- pyrophosphokinase in complex with AMPCPP and an inhibitor
4CWB	;	1.56	;	Staphylococcus aureus 7,8-Dihydro-6-hydroxymethylpterin- pyrophosphokinase in complex with AMPCPP and an inhibitor
7ASO	;	3.11	;	Staphylococcus aureus 70S after 30 minutes incubation at 37C
7ASP	;	2.86	;	Staphylococcus aureus 70S after 50 minutes incubation at 37C
2X75	;	2.5	;	Staphylococcus aureus adenylosuccinate lyase
6M3A	;		;	Staphylococcus aureus Bap-C1
5N57	;	2.3	;	Staphylococcus aureus cambialistic superoxide dismutase SodM
6EX4	;	2.4	;	Staphylococcus aureus cambialistic superoxide dismutase SodM
5W18	;	2.44	;	Staphylococcus aureus ClpP in complex with (S)-N-((2R,6S,8aS,14aS,20S,23aS)-2,6-dimethyl-5,8,14,19,23-pentaoxooctadecahydro-1H,5H,14H,19H-pyrido[2,1-i]dipyrrolo[2,1-c:2',1'-l][1]oxa[4,7,10,13]tetraazacyclohexadecin-20-yl)-3-phenyl-2-(3-phenylureido)propanamide
8E7P	;	1.68	;	Staphylococcus aureus ClpP in complex with compound 3421
8E71	;	1.57	;	Staphylococcus aureus ClpP in complex with compound 3471
8R03	;	2.0	;	Staphylococcus aureus ClpP in complex with the natural product beta-lactone inhibitor Cystargolide A at 2.0 A resolution
8OLL	;	2.7	;	Staphylococcus aureus ClpP in complex with the natural product beta-lactone inhibitor Cystargolide A at 2.7 A resolution
5C90	;	1.75	;	Staphylococcus aureus ClpP mutant - Y63A
8EF8	;	2.17	;	Staphylococcus aureus ClpP Y63W in complex with compound 3471
2WY8	;	1.7	;	Staphylococcus aureus complement subversion protein Sbi-IV in complex with complement fragment C3d
2WY7	;	1.7	;	Staphylococcus aureus complement subversion protein Sbi-IV in complex with complement fragment C3d revealing an alternative binding mode
7U9K	;	2.0	;	Staphylococcus aureus D-alanine-D-alanine ligase in complex with ATP, D-ala-D-ala, Mg2+ and K+
5JG0	;	1.879	;	Staphylococcus aureus Dihydrofolate Reductase complexed with beta-NADPH and UCP1191
5HF0	;	2.245	;	Staphylococcus aureus Dihydrofolate Reductase complexed with beta-NADPH, cyclic alpha-NADPH anomer and 3'-(3-(2,4-diamino-6-ethylpyrimidin-5-yl)prop-2-yn-1-yl)-4'-methoxy-[1,1'-biphenyl]-4-carboxylic acid (UCP1106)
5IST	;	1.723	;	Staphylococcus aureus Dihydrofolate Reductase complexed with beta-NADPH, cyclic alpha-NADPH anomer and 3'-(3-(2,4-diamino-6-ethylpyrimidin-5-yl)prop-2-yn-1-yl)-4'-methoxy-[1,1'-biphenyl]-4-carboxylic acid (UCP1106)
5HF2	;	1.81	;	Staphylococcus aureus Dihydrofolate Reductase complexed with cyclized alpha-NADPH anomer and 3'-(3-(2,4-diamino-6-ethylpyrimidin-5-yl)prop-2-yn-1-yl)-5'-methoxy-[1,1'-biphenyl]-4-carboxylic acid (UCP1175)
3FQ0	;	1.69	;	Staphylococcus aureus dihydrofolate reductase complexed with NADPH and 2,4-diamino-5-(3-(2,5-dimethoxyphenyl)prop-1-ynyl)-6-ethylpyrimidine (UCP120B)
3FQC	;	2.35	;	Staphylococcus aureus dihydrofolate reductase complexed with NADPH and 2,4-diamino-5-[3-(3,4,5-trimethoxyphenyl)pent-1-ynyl]-6-methylpyrimidine (UCP115A)
3FQZ	;	1.72	;	Staphylococcus aureus dihydrofolate reductase complexed with NADPH and 2,4-diamino-5-[3-(3-methoxy-4-phenylphenyl)but-1-ynyl]-6-methylpyrimidine
3F0Q	;	2.08	;	Staphylococcus aureus dihydrofolate reductase complexed with NADPH and 2,4-Diamino-5-[3-(3-methoxy-5-(2,6-dimethylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
3F0S	;	2.7	;	Staphylococcus aureus dihydrofolate reductase complexed with NADPH and 2,4-Diamino-5-[3-(3-methoxy-5-(3,5-dimethylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
3F0B	;	2.1	;	Staphylococcus aureus dihydrofolate reductase complexed with NADPH and 2,4-Diamino-5-[3-(3-methoxy-5-phenylphenyl)but-1-ynyl]-6-methylpyrimidine
3SH2	;	2.999	;	Staphylococcus aureus Dihydrofolate Reductase complexed with NADPH and 6-ethyl-5-(3-(4-methoxybiphenyl-3-yl)prop-1-ynyl)pyrimidine-2,4-diamine (UCP120J)
6ND2	;	2.243	;	Staphylococcus aureus Dihydrofolate Reductase complexed with NADPH and 6-ETHYL-5-[(3R)-3-[2-METHOXY-5-(PYRIDIN-4-YL)PHENYL]BUT-1-YN-1-YL]PYRIMIDINE-2,4-DIAMINE (UCP1063)
4XE6	;	2.692	;	Staphylococcus aureus Dihydrofolate Reductase complexed with NADPH and 6-ETHYL-5-[(3R)-3-[3-METHOXY-5-(PYRIDIN-4-YL)PHENYL]BUT-1-YN-1-YL]PYRIMIDINE-2,4-DIAMINE (UCP1061)
4XEC	;	2.692	;	Staphylococcus aureus Dihydrofolate Reductase complexed with NADPH and 6-ETHYL-5-[(3R)-3-[3-METHOXY-5-(PYRIDIN-4-YL)PHENYL]BUT-1-YN-1-YL]PYRIMIDINE-2,4-DIAMINE (UCP1061)
3SGY	;	2.598	;	Staphylococcus aureus Dihydrofolate Reductase complexed with NADPH and 6-ETHYL-5-[(3S)-3-[3-METHOXY-5-(PYRIDIN-4-YL)PHENYL]BUT-1-YN-1-YL]PYRIMIDINE-2,4-DIAMINE (UCP1006)
4TU5	;	2.161	;	Staphylococcus aureus Dihydrofolate Reductase complexed with NADPH and 6-ETHYL-5-[(3S)-3-[3-METHOXY-5-(PYRIDIN-4-YL)PHENYL]BUT-1-YN-1-YL]PYRIMIDINE-2,4-DIAMINE (UCP1062)
6P9Z	;	1.86	;	Staphylococcus aureus Dihydrofolate reductase in complex with NADPH and Methotrexate
6PBO	;	1.649	;	Staphylococcus aureus Dihydrofolate reductase in complex with NADPH and UCP1232
6CLU	;	1.95	;	Staphylococcus aureus Dihydropteroate Synthase (saDHPS) F17L E208K double mutant structure
6CLV	;	2.3	;	Staphylococcus aureus Dihydropteroate Synthase (saDHPS) F17L E208K double mutant structure
8AXY	;	1.05	;	Staphylococcus aureus endonuclease IV orthorhombic crystal form
8EDD	;	1.5	;	Staphylococcus aureus endonuclease IV Y33F mutant
3FRA	;	2.35	;	Staphylococcus aureus F98Y DHFR complexed with iclaprim
5ISP	;	1.84	;	Staphylococcus aureus F98Y Dihydrofolate Reductase mutant complexed with beta-NADPH and 3'-(3-(2,4-diamino-6-ethylpyrimidin-5-yl)prop-2-yn-1-yl)-4'-methoxy-[1,1'-biphenyl]-4-carboxylic acid (UCP1106)
4Q67	;	2.04	;	Staphylococcus aureus F98Y mutant dihydrofolate reductase complexed with NADPH
3FQO	;	2.09	;	Staphylococcus aureus F98Y mutant dihydrofolate reductase complexed with NADPH and 2,4-diamino-5-[3-(2,5-dimethoxyphenyl)prop-1-ynyl]-6-ethylpyrimidine (UCP120B)
3FQF	;	1.77	;	Staphylococcus aureus F98Y mutant dihydrofolate reductase complexed with NADPH and 2,4-diamino-5-[3-(3,4,5-trimethoxyphenyl)pent-1-ynyl]-6-methylpyrimidine (UCP115A)
3FQV	;	1.85	;	Staphylococcus aureus F98Y mutant dihydrofolate reductase complexed with NADPH and 2,4-diamino-5-[3-(3-methoxy-4-phenylphenyl)but-1-ynyl]-6-methylpyrimidine
3F0V	;	2.35	;	Staphylococcus aureus F98Y mutant dihydrofolate reductase complexed with NADPH and 2,4-Diamino-5-[3-(3-methoxy-5-(2,6-dimethylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
3F0X	;	2.6	;	Staphylococcus aureus F98Y mutant dihydrofolate reductase complexed with NADPH and 2,4-Diamino-5-[3-(3-methoxy-5-(3,5-dimethylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
3F0U	;	1.6	;	Staphylococcus aureus F98Y mutant dihydrofolate reductase complexed with NADPH and 2,4-Diamino-5-[3-(3-methoxy-5-phenylphenyl)but-1-ynyl]-6-methylpyrimidine
6KVS	;	2.3	;	Staphylococcus aureus FabH with covalent inhibitor Oxa1
3WQT	;	2.2	;	Staphylococcus aureus FtsA complexed with AMPPNP
3WQU	;	2.8	;	Staphylococcus aureus FtsA complexed with ATP
5XDU	;	2.0	;	Staphylococcus aureus FtsZ 12-316 complexed with TXA6101
5XDT	;	1.3	;	Staphylococcus aureus FtsZ 12-316 complexed with TXA707
8HTB	;	1.3	;	Staphylococcus aureus FtsZ 12-316 complexed with TXH9179
5XDW	;	2.0	;	Staphylococcus aureus FtsZ 12-316 G196S
5XDV	;	1.7	;	Staphylococcus aureus FtsZ 12-316 G196S complexed with TXA6101
3VOA	;	1.73	;	Staphylococcus aureus FtsZ 12-316 GDP-form
3VPA	;	2.487	;	Staphylococcus aureus FtsZ apo-form
3VO9	;	2.706	;	Staphylococcus aureus FtsZ apo-form (SeMet)
3WGN	;	2.606	;	STAPHYLOCOCCUS AUREUS FTSZ bound with GTP-gamma-S
3VO8	;	2.255	;	Staphylococcus aureus FtsZ GDP-form
3WGJ	;	2.179	;	STAPHYLOCOCCUS AUREUS FTSZ T7 chimera mutant, T7Bs
3WGK	;	2.799	;	STAPHYLOCOCCUS AUREUS FTSZ T7 mutant substituted for GAG, DeltaT7GAG-GDP
3WGL	;	3.066	;	STAPHYLOCOCCUS AUREUS FTSZ T7 mutant substituted for GAN bound with GDP, DeltaT7GAN-GDP
3WGM	;	2.091	;	STAPHYLOCOCCUS AUREUS FTSZ T7 mutant substituted for GAN bound with GTP, DeltaT7GAN-GTP
3VOB	;	2.703	;	Staphylococcus aureus FtsZ with PC190723
5H5G	;	2.2	;	Staphylococcus aureus FtsZ-GDP in T and R states
5H5I	;	1.9	;	Staphylococcus aureus FtsZ-GDP R29A mutant in R state
5H5H	;	1.7	;	Staphylococcus aureus FtsZ-GDP R29A mutant in T state
2MZW	;		;	Staphylococcus aureus FusB:EF-GC3 complex
3G7B	;	2.3	;	Staphylococcus aureus Gyrase B co-complex with METHYL ({5-[4-(4-HYDROXYPIPERIDIN-1-YL)-2-PHENYL-1,3-THIAZOL-5-YL]-1H-PYRAZOL-3-YL}METHYL)CARBAMATE inhibitor
3I8A	;	2.41	;	Staphylococcus aureus H30N, F98Y Dihydrofolate Reductase complexed with NADPH and 2,4-diamino-5-(3-(2,5-dimethoxyphenyl)prop-1-ynyl)-6-ethylpyrimidine (UCP120B)
5ISQ	;	1.9	;	Staphylococcus aureus H30N, F98Y Dihydrofolate Reductase mutant complexed with beta-NADPH and 3'-(3-(2,4-diamino-6-ethylpyrimidin-5-yl)prop-2-yn-1-yl)-4'-methoxy-[1,1'-biphenyl]-4-carboxylic acid (UCP1106)
3RTL	;	1.453	;	Staphylococcus aureus heme-bound IsdB-N2
3RUR	;	1.7	;	Staphylococcus aureus heme-bound selenomethionine-labeled IsdB-N2
3QZM	;	1.25	;	Staphylococcus aureus IsdA NEAT domain H83A variant in complex with heme
3QZP	;	1.9	;	Staphylococcus aureus IsdA NEAT domain in complex with cobalt-protoporphyrin IX
3QZO	;	1.952	;	Staphylococcus aureus IsdA NEAT domain in complex with heme, reduced crystal
3QZL	;	1.3	;	Staphylococcus aureus IsdA NEAT domain K75A variant in complex with heme
3QZN	;	2.0	;	Staphylococcus aureus IsdA NEAT domain Y166A variant in complex with heme
5VMM	;	3.6	;	Staphylococcus aureus IsdB bound to human hemoglobin
6KSI	;	2.08	;	Staphylococcus aureus lipase - native
6KSL	;	2.59	;	Staphylococcus aureus lipase - S116A inactive mutant
6KSM	;	2.23	;	Staphylococcus aureus lipase -Orlistat complex
4EM0	;	2.9	;	staphylococcus aureus MarR in complex with salicylate and kanamycin
4EM1	;	3.0	;	staphylococcus aureus MarR native
5N56	;	2.07	;	Staphylococcus aureus Mn-dependent superoxide dismutase SodA
2QIE	;	2.5	;	Staphylococcus aureus molybdopterin synthase in complex with precursor Z
6FTB	;	2.1	;	Staphylococcus aureus monofunctional glycosyltransferase in complex with moenomycin
7CTO	;	3.47	;	Staphylococcus aureus MsrB
5IIP	;	2.5	;	Staphylococcus aureus OpuCA
2L8T	;		;	Staphylococcus aureus pathogenicity island 1 protein gp6, an internal scaffold in size determination
3HL6	;	2.5	;	Staphylococcus aureus pathogenicity island 3 ORF9 protein
2CD7	;	1.5	;	Staphylococcus aureus pI258 arsenate reductase (ArsC) H62Q mutant
1BDC	;		;	STAPHYLOCOCCUS AUREUS PROTEIN A, IMMUNOGLOBULIN-BINDING B DOMAIN, NMR, 10 STRUCTURES
1BDD	;		;	STAPHYLOCOCCUS AUREUS PROTEIN A, IMMUNOGLOBULIN-BINDING B DOMAIN, NMR, MINIMIZED AVERAGE STRUCTURE
7P48	;	2.9	;	Staphylococcus aureus ribosome in complex with Sal(B)
5Y9P	;	2.2	;	Staphylococcus aureus RNase HII
2W9T	;	2.35	;	Staphylococcus aureus S1:DHFR
2W9S	;	1.8	;	Staphylococcus aureus S1:DHFR in complex with trimethoprim
4LFD	;	2.49	;	Staphylococcus aureus sortase B-substrate complex
6EX3	;	2.2	;	Staphylococcus aureus superoxide dismutase SodA
6QV9	;	1.8	;	Staphylococcus aureus superoxide dismutase SodA double mutant
6QV8	;	1.5	;	Staphylococcus aureus superoxide dismutase SodM double mutant
6LEB	;	1.54	;	Staphylococcus aureus surface protein SdrC mutant-P366H
6LXH	;	2.07	;	Staphylococcus aureus surface protein-sdrc
6EX5	;	1.75	;	Staphylococcus aureus triple mutant of superoxide dismutase SodM
4M7X	;	1.42	;	Staphylococcus aureus Type II pantothenate kinase in complex with a pantothenate analog
4M7Y	;	1.8	;	Staphylococcus aureus Type II pantothenate kinase in complex with a pantothenate analog
5ELZ	;	1.8	;	Staphylococcus aureus Type II pantothenate kinase in complex with a pantothenate analog
5JIC	;	1.4	;	Staphylococcus aureus Type II pantothenate kinase in complex with a pantothenate analog
6AWJ	;	2.5	;	Staphylococcus aureus Type II pantothenate kinase in complex with ADP and pantothenate analog Deoxy-MeO-N5Pan with pantothenate present in reaction
6AWI	;	1.8	;	Staphylococcus aureus Type II pantothenate kinase in complex with ADP and pantothenate analog Deoxy-N5Pan
6EBV	;	3.0	;	Staphylococcus aureus Type II pantothenate kinase in complex with ADP and pantothenate analog Deoxy-N7-Pan
6AVP	;	2.3	;	Staphylococcus aureus Type II pantothenate kinase in complex with ADP and pantothenate analog Phosphate-MeO-N5Pan
6AWH	;	1.9	;	Staphylococcus aureus Type II pantothenate kinase in complex with ATP and pantothenate analog Deoxy-MeO-N5Pan
6AWG	;	2.4	;	Staphylococcus aureus Type II pantothenate kinase in complex with nucleotides and pantothenate analog Deoxy-N190Pan
3WDF	;	1.48	;	Staphylococcus aureus UDG
3WDG	;	2.2	;	Staphylococcus aureus UDG / UGI complex
4Q6A	;	2.099	;	Staphylococcus aureus V31L, F98Y Mutant Dihydrofolate Reductase Complexed with NADPH
3LG4	;	3.15	;	Staphylococcus aureus V31Y, F92I mutant dihydrofolate reductase complexed with NADPH and 5-[(3S)-3-(5-methoxy-2',6'-dimethylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
5CCT	;	2.4	;	Staphylococcus bacteriophage 80alpha dUTPase G164S mutant with dUpNHpp.
5CCO	;	2.33	;	Staphylococcus bacteriophage 80alpha dUTPase with dUMP.
5M95	;	3.4	;	STAPHYLOCOCCUS CAPITIS DIVALENT METAL ION TRANSPORTER (DMT) IN COMPLEX WITH MANGANESE
3KP3	;	3.2	;	Staphylococcus epidermidis in complex with ampicillin
7UZY	;	4.05	;	Staphylococcus epidermidis RP62A CRISPR effector complex with non-self target RNA 2
7UZW	;	3.55	;	Staphylococcus epidermidis RP62a CRISPR effector subcomplex
7UZX	;	3.49	;	Staphylococcus epidermidis RP62a CRISPR effector subcomplex with non-self target RNA bound
7V02	;	4.97	;	Staphylococcus epidermidis RP62A CRISPR short effector complex
7V01	;	3.67	;	Staphylococcus epidermidis RP62a CRISPR short effector complex with self RNA target and ATP
7UZZ	;	4.45	;	Staphylococcus epidermidis RP62a CRISPR tall effector complex
7V00	;	3.87	;	Staphylococcus epidermidis RP62a CRISPR tall effector complex with bound ATP
3KP7	;	2.3	;	Staphylococcus epidermidis TcaR (apo form)
4EJU	;	2.4	;	Staphylococcus epidermidis TcaR full length
4EJV	;	2.9	;	Staphylococcus epidermidis TcaR in complex with chloramphenicol
3KP5	;	3.0	;	Staphylococcus epidermidis TcaR in complex with kanamycin
3KP4	;	2.84	;	Staphylococcus epidermidis TcaR in complex with methicillin
3KP2	;	2.55	;	Staphylococcus epidermidis TcaR in complex with penicillin G
4EJT	;	3.0	;	Staphylococcus epidermidis TcaR in complex with RNA
3KP6	;	2.45	;	Staphylococcus epidermidis TcaR in complex with salicylate
4EJW	;	2.8	;	Staphylococcus epidermidis TcaR in complex with streptomycin
6E0U	;	2.75	;	Staphylococcus pseudintermedius exfoliative toxin EXI
5D85	;	1.92	;	Staphyloferrin B precursor biosynthetic enzyme SbnA bound to aminoacrylate intermediate
5D84	;	1.45	;	Staphyloferrin B precursor biosynthetic enzyme SbnA bound to PLP
5D86	;	1.5	;	Staphyloferrin B precursor biosynthetic enzyme SbnA Y152F variant
5D87	;	1.5	;	Staphyloferrin B precursor biosynthetic enzyme SbnA Y152F/S185G variant
4MPD	;	2.101	;	Staphyloferrin B precursor biosynthetic enzyme SbnB bound a-ketoglutarate and NAD+
4MP6	;	2.1	;	Staphyloferrin B precursor biosynthetic enzyme SbnB bound to citrate and NAD+
4MP8	;	1.85	;	Staphyloferrin B precursor biosynthetic enzyme SbnB bound to malonate and NAD+
4MP3	;	2.11	;	Staphyloferrin B precursor biosynthetic enzyme selenomethionine-labeled SbnB
1C77	;	2.3	;	STAPHYLOKINASE (SAK) DIMER
1C78	;	2.3	;	STAPHYLOKINASE (SAK) DIMER
1C79	;	2.3	;	STAPHYLOKINASE (SAK) DIMER
1C76	;	2.25	;	STAPHYLOKINASE (SAK) MONOMER
2SAK	;	1.8	;	STAPHYLOKINASE (SAKSTAR VARIANT)
1SSN	;		;	STAPHYLOKINASE, SAKSTAR VARIANT, NMR, 20 STRUCTURES
6C4R	;	2.288	;	Staphylopine dehydrogenase (SaODH) - Apo
6C4T	;	2.49	;	Staphylopine dehydrogenase (SaODH) - NADP+ bound
6GMZ	;	2.22	;	Staphylopine dehydrogenase in complex with Histidine tag and citrate
6H3F	;	2.21	;	Staphylopine dehydrogenase in complex with staphylopine and NADP+
6H3D	;	2.05	;	Staphylopine dehydrogenase in complex with xNA
6H31	;	2.3	;	Staphylopine dehydrogenase in the apo state
7E1Y	;	2.9	;	Staphylothermus marinus amylopullulanase -SmApu
8GJS	;	1.75	;	Stapled Peptide ALRN-6924 Bound to MDMX
2YJD	;	1.93	;	Stapled peptide bound to Estrogen Receptor Beta
7F7I	;	2.595	;	Stapled Peptide Inhibitor in complex with PSD95 GK domain
8C3J	;	3.02	;	Stapled peptide SP2 in complex with humanised RadA mutant HumRadA22
8BR9	;	1.63	;	Stapled peptide SP24 in complex with humanised RadA mutant HumRadA22
8C3N	;	1.21	;	Stapled peptide SP30 in complex with humanised RadA mutant HumRadA22
2YJA	;	1.82	;	Stapled Peptides binding to Estrogen Receptor alpha.
7V1A	;	1.845	;	Stapled TBS peptide from RIAM bound to talin R7R8 domains
5ZJY	;	1.59	;	Stapled-peptides tailored against initiation of translation
5ZJZ	;	1.67	;	Stapled-peptides tailored against initiation of translation
5ZK5	;	2.25	;	Stapled-peptides tailored against initiation of translation
5ZK7	;	2.12	;	Stapled-peptides tailored against initiation of translation
5ZK9	;	1.76	;	Stapled-peptides tailored against initiation of translation
5ZML	;	1.8	;	Stapled-peptides tailored against initiation of translation
4MCV	;	2.73	;	Star 12 bound to analog-sensitive Src kinase
1EM2	;	2.2	;	Star-related lipid transport domain of MLN64
7UWU	;	2.19	;	Starch adherence system protein 6 (Sas6)
1CQY	;	1.95	;	STARCH BINDING DOMAIN OF BACILLUS CEREUS BETA-AMYLASE
5TD4	;	2.3	;	Starch binding sites on the Human pancreatic alpha amylase D300N variant complexed with an octaose substrate.
2C4M	;	1.9	;	Starch phosphorylase: structural studies explain oxyanion-dependent kinetic stability and regulatory control.
3NY7	;	1.922	;	STAS domain of YchM bound to ACP
1BGF	;	1.45	;	STAT-4 N-DOMAIN
6NJS	;	2.7	;	Stat3 Core in complex with compound SD36
6NUQ	;	3.15	;	Stat3 Core in complex with compound SI109
7TVA	;	2.835	;	Stat5a Core in complex with AK2292
7TVB	;	2.653	;	Stat5A Core in Complex with AK305
7UC6	;	3.101	;	Stat5a Core in complex with Compound 12
7UC7	;	3.102	;	Stat5a Core in complex with Compound 17
7UBT	;	2.352	;	Stat5a Core in complex with Compound 18
7N95	;	4.1	;	state 1 of TcdB and FZD2 at pH5
6RBD	;	3.47	;	State 1 of yeast Tsr1-TAP Rps20-Deltaloop pre-40S particles
7N97	;	5.1	;	State 2 of TcdB and FZD2 at pH5
6RBE	;	3.8	;	State 2 of yeast Tsr1-TAP Rps20-Deltaloop pre-40S particles
7N9Q	;	4.6	;	State 3 of TcdB and FZD2 at pH5
7N9R	;	5.9	;	state 4 of TcdB and FZD2 at pH5
6EM3	;	3.2	;	State A architectural model (Nsa1-TAP Flag-Ytm1) - Visualizing the assembly pathway of nucleolar pre-60S ribosomes
7ODR	;	2.9	;	State A of the human mitoribosomal large subunit assembly intermediate
6YXX	;	3.9	;	State A of the Trypanosoma brucei mitoribosomal large subunit assembly intermediate
6EM4	;	4.1	;	State B architectural model (Nsa1-TAP Flag-Ytm1) - Visualizing the assembly pathway of nucleolar pre-60S ribosomes
7ODS	;	3.1	;	State B of the human mitoribosomal large subunit assembly intermediate
6YXY	;	3.1	;	State B of the Trypanosoma brucei mitoribosomal large subunit assembly intermediate
6EM1	;	3.6	;	State C (Nsa1-TAP Flag-Ytm1) - Visualizing the assembly pathway of nucleolar pre-60S ribosomes
7ODT	;	3.1	;	State C of the human mitoribosomal large subunit assembly intermediate
6EM5	;	4.3	;	State D architectural model (Nsa1-TAP Flag-Ytm1) - Visualizing the assembly pathway of nucleolar pre-60S ribosomes
6ELZ	;	3.3	;	State E (TAP-Flag-Ytm1 E80A) - Visualizing the assembly pathway of nucleolar pre-60S ribosomes
7R7A	;	3.04	;	State E1 nucleolar 60S ribosome biogenesis intermediate - Composite model
7R72	;	3.07	;	State E1 nucleolar 60S ribosome biogenesis intermediate - Spb4 local model
7NAC	;	3.04	;	State E2 nucleolar 60S ribosomal biogenesis intermediate - Composite model
7R7C	;	3.71	;	State E2 nucleolar 60S ribosomal biogenesis intermediate - L1 stalk local model
7NAF	;	3.13	;	State E2 nucleolar 60S ribosomal biogenesis intermediate - Spb1-MTD local model
7NAD	;	3.04	;	State E2 nucleolar 60S ribosomal biogenesis intermediate - Spb4 local refinement model
7R6K	;	3.17	;	State E2 nucleolar 60S ribosomal intermediate - Model for Noc2/Noc3 region
7R6Q	;	2.98	;	State E2 nucleolar 60S ribosome biogenesis intermediate - Foot region model
7U0H	;	2.76	;	State NE1 nucleolar 60S ribosome biogenesis intermediate - Overall model
7DZ7	;	2.84	;	State transition supercomplex PSI-LHCI-LHCII from double phosphatase mutant pph1;pbcp of green alga Chlamydomonas reinhardtii
7DZ8	;	3.16	;	State transition supercomplex PSI-LHCI-LHCII from the LhcbM1 lacking mutant of Chlamydomonas reinhardtii
5KSQ	;	2.63	;	Stationary phase survival protein E (SurE) from Xylella fastidiosa
5KSS	;	2.82	;	Stationary phase survival protein E (SurE) from Xylella fastidiosa - XFSurE-Ds (Dimer Smaller)
5KSR	;	1.96	;	Stationary phase survival protein E (SurE) from Xylella fastidiosa - XFSurE-TB (Tetramer Bigger).
5KST	;	2.759	;	Stationary phase Survival protein E (SurE) from Xylella fastidiosa- XfSurE-TSAmp (Tetramer Smaller - crystallization with 3'AMP).
4WLI	;	1.76	;	Stationary Phase Survival Protein YuiC from B.subtilis
4WJT	;	1.21	;	Stationary Phase Survival Protein YuiC from B.subtilis complexed with NAG
4WLK	;	2.03	;	Stationary Phase Survival Protein YuiC from B.subtilis complexed with reaction product
8BEM	;	2.6	;	STE20-like serine/threonine-protein kinase (SLK) in complex with Tivozanib
6RQO	;	2.0	;	Steady-state-SMX activated state structure of bacteriorhodopsin
6RQP	;	1.8	;	Steady-state-SMX dark state structure of bacteriorhodopsin
1AFR	;	2.4	;	STEAROYL-ACYL CARRIER PROTEIN DESATURASE FROM CASTOR SEEDS
8JBI	;	2.356	;	SteC 202-375 mutant- C276S
5E9N	;	0.95	;	Steccherinum murashkinskyi laccase at 0.95 resolution
2OCT	;	1.4	;	Stefin B (Cystatin B) tetramer
2U2A	;		;	STEM LOOP IIA FROM U2 SNRNA OF SACCHAROMYCES CEREVISIAE, NMR, MINIMIZED AVERAGE STRUCTURE
1U2A	;		;	STEM LOOP IIA FROM U2SNRNA OF SACCHAROMYCES CEREVISIAE, NMR, MINIMIZED AVERAGE STRUCTURE
8CQ1	;		;	Stem-Loop 4 of the 5'-UTR of the SARS-CoV2 genomic RNA
1TXS	;		;	STEM-LOOP D OF THE CLOVERLEAF DOMAIN OF ENTEROVIRAL 5'UTR RNA
7DKD	;	1.92	;	Stenotrophomonas maltophilia DPP7 in complex with Asn-Tyr
7DKE	;	1.91	;	Stenotrophomonas maltophilia DPP7 in complex with Phe-Tyr
7DKC	;	1.86	;	Stenotrophomonas maltophilia DPP7 in complex with Tyr-Tyr
7DKB	;	2.03	;	Stenotrophomonas maltophilia DPP7 in complex with Val-Tyr
8GMM	;	1.8	;	Stenotrophomonas maltophilia Holo HphA
2QJS	;	2.25	;	Stenotrophomonas maltophilia L1 metallo-beta-lactamase Asp-120 Asn mutant
2QIN	;	1.76	;	Stenotrophomonas maltophilia L1 Metallo-beta-Lactamase Asp-120 Cys mutant
1W54	;	2.2	;	Stepwise introduction of a zinc binding site into Porphobilinogen synthase from Pseudomonas aeruginosa (mutation D139C)
1W56	;	1.7	;	Stepwise introduction of zinc binding site into porphobilinogen synthase of Pseudomonas aeruginosa (mutations A129C and D131C)
1W5M	;	1.6	;	Stepwise introduction of zinc binding site into porphobilinogen synthase of Pseudomonas aeruginosa (mutations A129C and D139C)
1W5O	;	1.85	;	Stepwise introduction of zinc binding site into porphobilinogen synthase of Pseudomonas aeruginosa (mutations A129C, D131C and D139C)
1W5P	;	1.55	;	Stepwise introduction of zinc binding site into porphobilinogen synthase of Pseudomonas aeruginosa (mutations A129C, D131C, D139C, P132E)
1W5Q	;	1.4	;	Stepwise introduction of zinc binding site into porphobilinogen synthase of Pseudomonas aeruginosa (mutations A129C, D131C, D139C, P132E, K229R)
1W5N	;	1.65	;	Stepwise introduction of zinc binding site into porphobilinogen synthase of Pseudomonas aeruginosa (mutations D131C and D139C)
3LX4	;	1.97	;	Stepwise [FeFe]-hydrogenase H-cluster assembly revealed in the structure of HydA(deltaEFG)
2HMD	;		;	Stereochemistry Modulates Stability of Reduced Inter-Strand Cross-Links Arising From R- and S-alpha-methyl-gamma-OH-1,N2-propano-2'-Deoxyguanine in the 5'-CpG-3' DNA Sequence
5C1R	;	1.802	;	Stereoisomer of PRPP bound in the active site of Mycobacterium tuberculosis anthranilate phosphoribosyl (AnPRT; trpD)
4A4Q	;	1.8	;	Stereoselective Synthesis, X-ray Analysis, and Biological Evaluation of a New Class of Lactam Based HIV-1 Protease Inhibitors
4A6B	;	1.8	;	Stereoselective Synthesis, X-ray Analysis, and Biological Evaluation of a New Class of Lactam Based HIV-1 Protease Inhibitors
4A6C	;	1.5	;	Stereoselective Synthesis, X-ray Analysis, and Biological Evaluation of a New Class of Lactam Based HIV-1 Protease Inhibitors
2ROU	;		;	Stereospecific Conformations of N2-dG 1R-trans-anti-Benzo[c]phenanthrene DNA Adducts: 3'-Intercalation of the 1R Adduct and 5'-Minor Groove Orientation of the 1S Adduct in an Iterated (CG)3 Repeat
1JIM	;	2.31	;	STEREOSPECIFIC REACTION OF 3-METHOXY-4-CHLORO-7-AMINOISOCOUMARIN WITH CRYSTALLINE PORCINE PANCREATIC ELASTASE
1AMI	;	2.0	;	STERIC AND CONFORMATIONAL FEATURES OF THE ACONITASE MECHANISM
1AMJ	;	2.0	;	STERIC AND CONFORMATIONAL FEATURES OF THE ACONITASE MECHANISM
1UCV	;		;	Sterile alpha motif (SAM) domain of ephrin type-A receptor 8
1V85	;		;	Sterile alpha motif (SAM) domain of mouse bifunctional apoptosis regulator
8E1F	;	2.16	;	Sterile Alpha Motif Domain of Human Translocation ETS Leukemia, Non-Polymer Crystal Form
8FZ3	;	2.784	;	Sterile Alpha Motif of Human Translocation ETS Leukemia, Non-Polymer Crystal Form
6V0M	;	1.8	;	Sterile alpha-motif from apoptosis signal-regulating kinase 3
4NZ6	;	2.0	;	Steroid receptor RNA Activator (SRA) modification by the human Pseudouridine Synthase 1 (hPus1p): RNA binding, activity, and atomic model
4NZ7	;	2.7	;	Steroid receptor RNA Activator (SRA) modification by the human Pseudouridine Synthase 1 (hPus1p): RNA binding, activity, and atomic model
1ESS	;		;	STEROID TETHERED DNA, NMR, MINIMIZED AVERAGE STRUCTURE
3ZG2	;	2.8	;	Sterol 14 alpha-demethylase (CYP51) from Trypanosoma cruzi in complex with the pyridine inhibitor (S)-2-(4-chlorophenyl)-2-(pyridin-3-yl)-1- (4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)ethanone (EPL-BS1246,UDO)
3TIK	;	2.05	;	Sterol 14-alpha demethylase (CYP51) from Trypanosoma brucei in complex with the tipifarnib derivative 6-((4-chlorophenyl)(methoxy)(1-methyl-1H-imidazol-5-yl)methyl)-4-(2,6-difluorophenyl)-1-methylquinolin-2(1H)-one
4G3J	;	1.83	;	Sterol 14-alpha demethylase (CYP51) from Trypanosoma brucei in complex with the VNI derivative (R)-N-(1-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide [R-VNI-triazole (VNT)]
4G7G	;	2.05	;	Sterol 14-alpha demethylase (CYP51) from Trypanosoma brucei in complex with the VNI derivative (R)-N-(1-(3,4'-difluorobiphenyl-4-yl)-2-(1H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide [VNI/VNF (VFV)]
5AJR	;	2.75	;	Sterol 14-alpha demethylase (CYP51) from Trypanosoma cruzi in complex with the 1-tetrazole derivative VT-1161 ((R)-2-(2,4-Difluorophenyl)-1, 1-difluoro-3-(1H-tetrazol-1-yl)-1-(5-(4-(2,2,2-trifluoroethoxy)phenyl) pyridin-2-yl)propan-2-ol)
4CK8	;	2.62	;	STEROL 14-ALPHA DEMETHYLASE (CYP51)FROM TRYPANOSOMA CRUZI IN COMPLEX WITH (R)-1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethyl 4-(4-(3,4- dichlorophenyl)piperazin-1-yl)phenylcarbamate (LFD)
4CK9	;	2.74	;	STEROL 14-ALPHA DEMETHYLASE (CYP51)FROM TRYPANOSOMA CRUZI IN COMPLEX WITH (S)-1-(4-chlorophenyl)-2-(1H-imidazol-1-yl)ethyl 4- isopropylphenylcarbamate (LFT)
4CKA	;	2.7	;	STEROL 14-ALPHA DEMETHYLASE (CYP51)FROM TRYPANOSOMA CRUZI IN COMPLEX WITH (S)-1-(4-fluorophenyl)-2-(1H-imidazol-1-yl)ethyl 4- isopropylphenylcarbamate (LFS)
4H6O	;	2.8	;	Sterol 14-alpha demethylase (CYP51)from Trypanosoma cruzi in complex with the inhibitor NEU321 (1-(3-(4-chloro-3,5-dimethylphenoxy)benzyl)-1H-imidazole
3ZG3	;	2.9	;	STEROL 14-ALPHA DEMETHYLASE (CYP51)FROM TRYPANOSOMA CRUZI IN COMPLEX WITH THE PYRIDINE INHIBITOR N-(1-(5-(trifluoromethyl)(pyridin-2-yl)) piperidin-4yl)-N-(4-(trifluoromethyl)phenyl)pyridin-3-amine (EPL- BS967, UDD)
7RTQ	;	2.11	;	Sterol 14alpha demethylase (CYP51) from Naegleria fowleri in complex with an inhibitor R)-N-(1-(3,4'-difluorobiphenyl-4-yl)-2-(1H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide
3P99	;	3.0	;	Sterol 14alpha-demethylase (CYP51) from Trypanosoma brucei in complex with delta7-14alpha-methylene-cyclopropyl-dihydrolanosterol
5XVM	;	2.77	;	Sterol 3-beta-glucosyltransferase (ugt51) from Saccharomyces cerevisiae (strain ATCC 204508 / S288c)
5GL5	;	1.9	;	Sterol 3-beta-glucosyltransferase (ugt51) from Saccharomyces cerevisiae (strain ATCC 204508 / S288c): UDPG complex
1C44	;	1.8	;	STEROL CARRIER PROTEIN 2 (SCP2) FROM RABBIT
6OVP	;	1.991	;	Sterol Carrier Protein 2 from Yarrowia Lipolytica (apo form)
8AF3	;	1.52	;	Sterol carrier protein Artifical metalloenzyme incorporating Q111C mutation coupled to 2,2'-bipyridine
1QND	;		;	STEROL CARRIER PROTEIN-2, NMR, 20 STRUCTURES
2MLG	;		;	Stf76 from the Sulfolobus islandicus plasmid-virus pSSVx
6BZP	;	1.1	;	STGGYG from low-complexity domain of FUS, residues 77-82
7TKT	;	3.6	;	SthK closed state, cAMP-bound in the presence of detergent
7TJ5	;	2.41	;	SthK closed state, cAMP-bound in the presence of POPA
7TJ6	;	2.9	;	SthK open state, cAMP-bound in the presence of POPA
6VY0	;	6.68	;	SthK P300A cyclic nucleotide-gated potassium channel in a putative active state, in complex with cAMP
6VXZ	;	3.42	;	SthK P300A cyclic nucleotide-gated potassium channel in the closed state, in complex with cAMP
7RTF	;	2.9	;	SthK R120A Closed State
7RU0	;	4.3	;	SthK R120A Open State 1
7RYS	;	3.7	;	SthK R120A Open State 2
7RYR	;	3.6	;	SthK R120A Open State 3
7RTJ	;	3.8	;	SthK Y26F Activated State
7RSH	;	3.0	;	SthK Y26F Closed State
6ECW	;	1.7	;	StiD O-MT residues 956-1266
6ECV	;	1.798	;	StiD O-MT residues 976-1266
6ECX	;	1.9	;	StiE O-MT residues 942-1257
6ECT	;	1.42	;	StiE O-MT residues 961-1257
7KDQ	;		;	StigA15
6BAY	;	3.15	;	Stigmatella aurantiaca bacterial phytochrome P1, PAS-GAF-PHY T289H mutant, room temperature structure
6BAP	;	2.65	;	Stigmatella aurantiaca bacterial phytochrome PAS-GAF-PHY, T289H mutant
6BAO	;	2.18	;	Stigmatella aurantiaca phytochrome photosensory core module, wild type
3BCC	;	3.7	;	STIGMATELLIN AND ANTIMYCIN BOUND CYTOCHROME BC1 COMPLEX FROM CHICKEN
3H1I	;	3.53	;	Stigmatellin and antimycin bound cytochrome bc1 complex from chicken
2BCC	;	3.5	;	STIGMATELLIN-BOUND CYTOCHROME BC1 COMPLEX FROM CHICKEN
3H1J	;	3.0	;	Stigmatellin-bound cytochrome bc1 complex from chicken
6VL2	;		;	Stigmurin
2N19	;		;	STIL binding to the Polo-box domain 3 of PLK4 regulates centriole duplication
7QR6	;	2.9	;	Stilbene dioxygenase (NOV1) from Novosphingobium aromaticivorans: Ser283Phe mutant
7OSU	;	1.37	;	sTIM11noCys-SB, a de novo designed TIM barrel with a salt-bridge cluster (crystal form 1)
7OT7	;	1.51	;	sTIM11noCys-SB, a de novo designed TIM barrel with a salt-bridge cluster (crystal form 2)
7KRU	;	1.82	;	Stimulating state of a truncated Hsp70 DnaK fused with a substrate peptide
7KRV	;	1.92	;	Stimulating state of disulfide-bridged Hsp70 DnaK
7KRW	;	7.7	;	Stimulating state of near full-length Hsp70 DnaK fused with a substrate peptide
3KJT	;	1.5	;	Stimulation of the maltose transporter by a mutant sucrose binding protein gives insights into ABC transporter coupling
6CFF	;	2.396	;	Stimulator of Interferon Genes Human
6Z80	;	3.0	;	stimulatory human GTP cyclohydrolase I - GFRP complex
7LLI	;	3.2	;	Stimulatory immune receptor protein complex
6UKW	;	1.97	;	STING C-terminal Domain Complexed with Non-cyclic Dinucleotide Compound 10
6UKX	;	1.93	;	STING C-terminal Domain Complexed with Non-cyclic Dinucleotide Compound 11
6UKY	;	1.95	;	STING C-terminal Domain Complexed with Non-cyclic Dinucleotide Compound 12
6UKU	;	1.68	;	STING C-terminal Domain Complexed with Non-cyclic Dinucleotide Compound 3
6UL0	;	1.76	;	STING C-terminal Domain Complexed with Non-cyclic Dinucleotide Compound 4
6UKZ	;	1.52	;	STING C-terminal Domain Complexed with Non-cyclic Dinucleotide Compound 6
6UKV	;	1.83	;	STING C-terminal Domain Complexed with Non-cyclic Dinucleotide Compound 9
6UKM	;	1.74	;	STING C-terminal Domain Complexed with Non-cyclic Dinucleotide Compound MSA-2
7QGP	;	1.9	;	STK10 (LOK) bound to Macrocycle CKJB51
8TUQ	;	2.0	;	STL Polyomavirus LTA NLS bound to importin alpha 2
7OUG	;	3.1	;	STLV-1 intasome:B56 in complex with the strand-transfer inhibitor raltegravir
7MPI	;	3.05	;	Stm1 bound vacant 80S structure isolated from cbf5-D95A
7MPJ	;	2.7	;	Stm1 bound vacant 80S structure isolated from wild-type
5HXG	;	1.998	;	STM1697-FlhD complex
6IAI	;	2.54	;	StoD is a novel Salmonella Typhi type III secretion system E3 ubiquitin ligase effector
1JXE	;	2.85	;	STOFFEL FRAGMENT OF TAQ DNA POLYMERASE I
4WVM	;	3.1	;	Stonustoxin structure
1MZ9	;	1.7	;	Storage function of COMP:the crystal structure of the coiled-coil domain in complex with vitamin D3
2V6X	;	1.98	;	Stractural insight into the interaction between ESCRT-III and Vps4
8UZ0	;	2.8	;	Straight actin filament from Arp2/3 branch junction sample (ADP)
8UZ1	;	3.6	;	Straight actin filament from Arp2/3 branch junction sample (ADP-BeFx)
8D17	;	3.69	;	Straight ADP-F-actin 1
8D18	;	3.66	;	Straight ADP-F-actin 2
8HRE	;	5.5	;	Straight fiber of DT57C bacteriophage in the full state
6VI3	;	3.3	;	Straight Filament from Alzheimer's Disease Human Brain Tissue
7NRX	;	3.55	;	Straight filament from Alzheimer's disease with PET ligand APN-1607
6HRF	;	3.3	;	Straight filament from sporadic Alzheimer's disease brain
5O3T	;	3.4	;	Straight filament in Alzheimer's disease brain
7MKG	;	3.07	;	Straight tau filament extracted from PrP-CAA Patient brain tissue | tau filament | SF Tau
7SVW	;	3.69	;	Strand-transfer complex of TnsB from ShCAST
7CC2	;	2.723	;	Strategic design of catalytic lysine-targeting reversible covalent BCR-ABL Inhibitors
7DT2	;	2.3	;	Strategic design of catalytic lysine-targeting reversible covalent BCR-ABL Inhibitors
1PFG	;	2.5	;	Strategy to design inhibitors: Structure of a complex of Proteinase K with a designed octapeptide inhibitor N-Ac-Pro-Ala-Pro-Phe-DAla-Ala-Ala-Ala-NH2 at 2.5A resolution
2PJH	;		;	Strctural Model of the p97 N domain- npl4 UBD complex
2G6N	;	1.9	;	Strcture of rat nNOS heme domain (BH2 bound) complexed with CO
2MTD	;		;	Strcucture of Decorin Binding Protein A from strain PBr of Borrelia garinii
5Y2V	;	2.6	;	Strcutrue of the full-length CcmR complexed with 2-OG from Synechocystis PCC6803
3SW8	;	1.702	;	Strep Peptide Deformylase with a time dependent dichlorobenzamide-reverse hydroxamic acid
3SVJ	;	1.55	;	Strep Peptide Deformylase with a time dependent thiazolidine amide
3STR	;	1.75	;	Strep Peptide Deformylase with a time dependent thiazolidine hydroxamic acid
7R4V	;	1.3	;	Strep-tag FtrA-P19 from Rubrivivax gelatinosus in complex with an endogenous CU1
7R5P	;	1.68	;	Strep-tag FtrA-P19 from Rubrivivax gelatinosus in complex with copper and iron
7R4Z	;	2.75	;	Strep-tag FtrA-P19 from Rubrivivax gelatinosus in complex with iron and copper
1MC9	;	1.7	;	STREPROMYCES LIVIDANS XYLAN BINDING DOMAIN CBM13 IN COMPLEX WITH XYLOPENTAOSE
4EKV	;	2.0	;	Streptavidin 8-aa-loop H127C mutein with reversible biotin binding
4CPI	;	1.54	;	streptavidin A86D mutant with love-hate ligand 4
6AVK	;	1.4	;	Streptavidin bound to peptide-like compound KPM-6
4JO6	;	1.75	;	Streptavidin complex with SBP-Tag
1VWP	;	1.75	;	STREPTAVIDIN COMPLEXED WITH CYCLO-AC-[CHPQGPPC]-NH2 MONOMER, PH 2.5
1VWO	;	1.65	;	STREPTAVIDIN COMPLEXED WITH CYCLO-AC-[CHPQGPPC]-NH2 MONOMER, PH 2.85
1VWF	;	1.92	;	STREPTAVIDIN COMPLEXED WITH CYCLO-AC-[CHPQGPPC]-NH2 MONOMER, PH 3.67
1VWG	;	1.46	;	STREPTAVIDIN COMPLEXED WITH THE HEAD-TO-TAIL DISULFIDE-BONDED PEPTIDE DIMER OF CYCLO-AC-[CHPQGPPC]-NH2, PH 2.5
1VWH	;	1.48	;	STREPTAVIDIN COMPLEXED WITH THE HEAD-TO-TAIL DISULFIDE-BONDED PEPTIDE DIMER OF CYCLO-AC-[CHPQGPPC]-NH2, PH 3.5
1STR	;	1.8	;	STREPTAVIDIN DIMERIZED BY DISULFIDE-BONDED PEPTIDE AC-CHPQNT-NH2 DIMER
1STS	;	1.95	;	STREPTAVIDIN DIMERIZED BY DISULFIDE-BONDED PEPTIDE FCHPQNT-NH2 DIMER
2G5L	;	1.15	;	Streptavidin in complex with Nanotag
7ZOF	;	1.74	;	Streptavidin Iron-Porphyrin
6VJL	;	1.3	;	Streptavidin mutant M112 (G26C/A46C)
6VJK	;	1.6	;	Streptavidin mutant M88 (N49C/A86C)
1N4J	;	2.18	;	STREPTAVIDIN MUTANT N23A AT 2.18A
1N43	;	1.89	;	Streptavidin Mutant N23A with biotin at 1.89A
1N7Y	;	1.96	;	STREPTAVIDIN MUTANT N23E AT 1.96A
8AQY	;	1.65	;	streptavidin mutant S112A with an iridium catalyst for CH activation
8BY0	;	2.1	;	streptavidin mutant S112I K121R with an iridium catalyst for CH activation
8AQX	;	1.85	;	streptavidin mutant S112I with an iridium catalyst for CH activation
6Y2M	;	1.95	;	Streptavidin mutant S112R with a biotC4-1 cofactor - an artificial iron hydroxylase
6Y33	;	1.49	;	Streptavidin mutant S112R with a biotC5-1 cofactor - an artificial iron hydroxylase
6Y25	;	1.95	;	Streptavidin mutant S112R,K121E with a biotC4-1 cofactor - an artificial iron hydroxylase
6Y3Q	;	1.95	;	Streptavidin mutant S112R_K121E with a biotC5-1 cofactor - an artificial iron hydroxylase
1N9Y	;	1.53	;	Streptavidin Mutant S27A at 1.5A Resolution
1N9M	;	1.6	;	Streptavidin Mutant S27A with Biotin at 1.6A Resolution
1MM9	;	1.66	;	Streptavidin Mutant with Insertion of Fibronectin Hexapeptide, including RGD
1MOY	;	1.55	;	Streptavidin Mutant with Osteopontin Hexapeptide Insertion Including RGD
1NBX	;	1.7	;	Streptavidin Mutant Y43A at 1.70A Resolution
1NC9	;	1.8	;	STREPTAVIDIN MUTANT Y43A WITH IMINOBIOTIN AT 1.8A RESOLUTION
1SWU	;	1.14	;	STREPTAVIDIN MUTANT Y43F
1NDJ	;	1.81	;	Streptavidin Mutant Y43F with Biotin at 1.81A Resolution
8CRN	;	2.0	;	Streptavidin S112Y Co-TAML artificial metalloenzyme
8OJX	;	1.6	;	Streptavidin S112YK121E artificial metalloenzyme for carboamination
6T1E	;	1.3	;	Streptavidin variants harbouring an artificial organocatalyst based cofactor
6T1G	;	1.9	;	Streptavidin variants harbouring an artificial organocatalyst based cofactor
6T1K	;	1.2	;	Streptavidin variants harbouring an artificial organocatalyst based cofactor
6T2L	;	1.0	;	Streptavidin variants harbouring an artificial organocatalyst based cofactor
6T2Y	;	1.8	;	Streptavidin variants harbouring an artificial organocatalyst based cofactor
6T2Z	;	1.35	;	Streptavidin variants harbouring an artificial organocatalyst based cofactor
6T30	;	1.8	;	Streptavidin variants harbouring an artificial organocatalyst based cofactor
6T31	;	1.35	;	Streptavidin variants harbouring an artificial organocatalyst based cofactor
6T32	;	1.75	;	Streptavidin variants harbouring an artificial organocatalyst based cofactor
6Y2T	;	1.55	;	Streptavidin wildtype with a biotC4-1 cofactor - an artificial iron hydroxylase
6Y34	;	1.307	;	Streptavidin wildtype with a biotC5-1 cofactor - an artificial iron hydroxylase
8AQO	;	1.9	;	Streptavidin with a bisbiothinilated Fe4S4 cluster
7ZX9	;	1.546	;	Streptavidin with a fluorescent substrate
8QQ3	;	1.6	;	Streptavidin with a Ni-cofactor
8BY1	;	1.486	;	streptavidin with an iridium catalyst for CH activation
8OJW	;	1.484	;	Streptavidin WT artificial metalloenzyme for carboamination
8CRP	;	2.0	;	Streptavidin WT Co-TAML artificial metalloenzyme
1SLE	;	2.0	;	STREPTAVIDIN, PH 5.0, BOUND TO CYCLIC PEPTIDE AC-CHPQGPPC-NH2
1SLG	;	1.76	;	STREPTAVIDIN, PH 5.6, BOUND TO PEPTIDE FCHPQNT
1SLD	;	2.5	;	STREPTAVIDIN, PH 7.5, BOUND TO CYCLIC DISULFIDE-BONDED PEPTIDE LIGAND AC-CHPQFC-NH2
2RTN	;	1.8	;	STREPTAVIDIN-2-IMINOBIOTIN COMPLEX, PH 2.0, SPACE GROUP I222
2RTO	;	1.58	;	STREPTAVIDIN-2-IMINOBIOTIN COMPLEX, PH 2.6, SPACE GROUP I222
2RTP	;	1.5	;	STREPTAVIDIN-2-IMINOBIOTIN COMPLEX, PH 3.25, SPACE GROUP I222
2RTQ	;	1.39	;	STREPTAVIDIN-2-IMINOBIOTIN COMPLEX, PH 3.25, SPACE GROUP I222, CRYSTALLIZED FROM 4.3 M AMMONIUM SULFATE
2RTR	;	1.62	;	STREPTAVIDIN-2-IMINOBIOTIN COMPLEX, PH 4.0, SPACE GROUP I222
2IZL	;	1.48	;	STREPTAVIDIN-2-IMINOBIOTIN PH 7.3 I222 COMPLEX
2RTL	;	1.41	;	STREPTAVIDIN-2-IMINOBIOTIN-SULFATE COMPLEX, PH 2.50, SPACE GROUP I4122
2RTM	;	1.3	;	STREPTAVIDIN-2-IMINOBIOTIN-SULFATE COMPLEX, PH 3.50, SPACE GROUP I4122
1LCZ	;	1.95	;	streptavidin-BCAP complex
2RTD	;	1.65	;	STREPTAVIDIN-BIOTIN COMPLEX, PH 1.39, SPACE GROUP I222
2RTE	;	1.5	;	STREPTAVIDIN-BIOTIN COMPLEX, PH 1.90, SPACE GROUP I222
2RTF	;	1.47	;	STREPTAVIDIN-BIOTIN COMPLEX, PH 2.00, SPACE GROUP I222
2RTG	;	1.39	;	STREPTAVIDIN-BIOTIN COMPLEX, PH 2.40, SPACE GROUP I222
2IZH	;	1.36	;	STREPTAVIDIN-BIOTIN PH 10.44 I222 COMPLEX
2IZG	;	1.36	;	STREPTAVIDIN-BIOTIN PH 2.0 I222 COMPLEX
2IZI	;	1.5	;	STREPTAVIDIN-BIOTIN PH 2.53 I4122 STRUCTURE
2IZJ	;	1.3	;	STREPTAVIDIN-BIOTIN PH 3.50 I4122 STRUCTURE
2IZF	;	1.58	;	STREPTAVIDIN-BIOTIN PH 4.0 I222 COMPLEX
1VWB	;	1.82	;	STREPTAVIDIN-CYCLO-AC-[CHPQFC]-NH2, PH 11.8
1VWC	;	1.86	;	STREPTAVIDIN-CYCLO-AC-[CHPQFC]-NH2, PH 2.0
1VWD	;	1.87	;	STREPTAVIDIN-CYCLO-AC-[CHPQFC]-NH2, PH 3.0
1VWE	;	1.5	;	STREPTAVIDIN-CYCLO-AC-[CHPQFC]-NH2, PH 3.6
1VWM	;	1.6	;	STREPTAVIDIN-CYCLO-AC-[CHPQFC]-NH2, PH 4.2
1VWN	;	1.85	;	STREPTAVIDIN-CYCLO-AC-[CHPQFC]-NH2, PH 4.8
1VWK	;	1.45	;	STREPTAVIDIN-CYCLO-[5-S-VALERAMIDE-HPQGPPC]K-NH2
1VWI	;	1.5	;	STREPTAVIDIN-CYCLO-[5-S-VALERAMIDE-HPQGPPC]K-NH2, PH 1.5, I222 COMPLEX
1VWJ	;	1.45	;	STREPTAVIDIN-CYCLO-[5-S-VALERAMIDE-HPQGPPC]K-NH2, PH 2.5, I222 COMPLEX
1VWQ	;	1.7	;	STREPTAVIDIN-CYCLO-[5-S-VALERAMIDE-HPQGPPC]K-NH2, PH 2.5, I4122 COMPLEX
1VWL	;	1.45	;	STREPTAVIDIN-CYCLO-[5-S-VALERAMIDE-HPQGPPC]K-NH2, PH 3.5, I222 COMPLEX
1VWR	;	1.5	;	STREPTAVIDIN-CYCLO-[5-S-VALERAMIDE-HPQGPPC]K-NH2, PH 3.5, I4122 COMPLEX
1VWA	;	1.85	;	STREPTAVIDIN-FSHPQNT
2RTH	;	1.56	;	STREPTAVIDIN-GLYCOLURIL COMPLEX, PH 2.50, SPACE GROUP I222
2RTI	;	1.4	;	STREPTAVIDIN-GLYCOLURIL COMPLEX, PH 2.50, SPACE GROUP I222
2RTJ	;	1.4	;	STREPTAVIDIN-GLYCOLURIL COMPLEX, PH 2.50, SPACE GROUP I4122
2RTK	;	1.82	;	STREPTAVIDIN-GLYCOLURIL COMPLEX, PH 2.58, SPACE GROUP I4122 PREPARED FROM AN APOSTREPTAVIDIN CRYSTAL
2IZK	;	1.3	;	STREPTAVIDIN-GLYCOLURIL PH 2.58 I4122 COMPLEX
1LCW	;	2.2	;	streptavidin-homobiotin complex
4GJS	;	1.85	;	Streptavidin-K121H
1LCV	;	2.3	;	streptavidin-norbiotin complex
4GJV	;	2.4	;	Streptavidin-S112H
5CSE	;	1.792	;	Streptavidin-S112Y-K121E Complexed with Palladium-Containing Biotin Ligand
7AVK	;	0.82	;	Streptococcal High Identity Repeats in Tandem (SHIRT) domain 10 from cell surface protein SGO_0707
7AVJ	;	0.95	;	Streptococcal High Identity Repeats in Tandem (SHIRT) domain 2 from cell surface protein SGO_0707
7AVH	;	1.35	;	Streptococcal High Identity Repeats in Tandem (SHIRT) domains 3-4 from cell surface protein SGO_0707
1B1Z	;	2.57	;	STREPTOCOCCAL PYROGENIC EXOTOXIN A1
1BXT	;	1.85	;	STREPTOCOCCAL SUPERANTIGEN (SSA) FROM STREPTOCOCCUS PYOGENES
5L2D	;	2.66	;	Streptococcal surface adhesin - CshA NR2
6YZG	;	1.4	;	Streptococcal surface adhesin - CshB NR2
5DZA	;	2.19	;	Streptococcus agalactiae AgI/II polypeptide BspA C terminal domain (WT)
5DZ9	;	1.89	;	Streptococcus agalactiae AgI/II polypeptide BspA C-terminal domain (Mut)
5DZ8	;	2.41	;	Streptococcus agalactiae AgI/II polypeptide BspA variable (V) domain
6AZ6	;	1.909	;	Streptococcus agalactiae GntR
2J4X	;	1.95	;	Streptococcus dysgalactiae-derived mitogen (SDM)
7L0O	;	2.7	;	Streptococcus gordonii C123 Domain(s)-Structural and Functional Analysis
6M9M	;	1.401	;	Streptococcus mutans AlkD2 bound to inosine-5'-monophosphate
7WJG	;	2.42	;	Streptococcus mutans BusR transcriptional factor
7LGR	;	1.6	;	Streptococcus mutans Collagen binding Protein CNM - N2 Domain
1I74	;	2.2	;	STREPTOCOCCUS MUTANS INORGANIC PYROPHOSPHATASE
5LJI	;	2.07	;	Streptococcus pneumonia TIGR4 flavodoxin: structural and biophysical characterization of a novel drug target
5LJL	;	1.6	;	Streptococcus pneumonia TIGR4 flavodoxin: structural and biophysical characterization of a novel drug target
8OFH	;	1.64	;	Streptococcus pneumoniae CdaA
8OFG	;	2.4	;	Streptococcus pneumoniae CdaA in complex with c-di-amp
7PAF	;	3.75	;	Streptococcus pneumoniae choline importer LicB in lipid nanodiscs
5M6D	;	2.0	;	Streptococcus pneumoniae Glyceraldehyde-3-Phosphate Dehydrogenase (SpGAPDH) crystal structure
1N7O	;	1.5	;	Streptococcus pneumoniae Hyaluronate Lyase F343V Mutant
1LOH	;	2.0	;	Streptococcus pneumoniae Hyaluronate Lyase in Complex with Hexasaccharide Hyaluronan Substrate
1LXK	;	1.53	;	Streptococcus pneumoniae Hyaluronate Lyase in Complex with Tetrasaccharide Hyaluronan Substrate
1N7Q	;	2.3	;	Streptococcus pneumoniae Hyaluronate Lyase W291A/W292A Double Mutant complex with hyaluronan hexasacchride
1N7R	;	2.2	;	Streptococcus pneumoniae Hyaluronate Lyase W291A/W292A/F343V Mutant complex with hexasaccharide hyaluronan
1N7N	;	1.55	;	Streptococcus pneumoniae Hyaluronate Lyase W292A Mutant
1N7P	;	1.55	;	Streptococcus pneumoniae Hyaluronate Lyase W292A/F343V Double Mutant
6XJA	;	4.0	;	Streptococcus Pneumoniae IgA1 Protease with IgA1 substrate
2OI2	;	2.5	;	Streptococcus pneumoniae Mevalonate Kinase in Complex with Diphosphomevalonate
3GON	;	1.9	;	Streptococcus pneumoniae Phosphomevalonate Kinase in Complex with Phosphomevalonate and AMPPNP
4YW4	;	2.2	;	Streptococcus pneumoniae sialidase NanC
7PKJ	;	1.989	;	Streptococcus pyogenes apo GapN
7PKC	;	1.5	;	Streptococcus pyogenes Apo-GapN C284S variant
6DQ3	;	1.78	;	Streptococcus pyogenes deacetylase PplD in complex with acetate
2WLA	;	2.0	;	Streptococcus pyogenes Dpr
6DGM	;	1.49	;	Streptococcus pyogenes phosphoglycerol transferase GacH in complex with sn-glycerol-1-phosphate
5WCX	;	2.0	;	Streptococcus pyogenes phosphoglycerol transferase GacH in complex with sn-glycerol-1-phosphate, crystal form 1
8SNQ	;	1.5	;	Streptococcus pyogenes Sortase A (SrtA) with the F145E mutation
6YRO	;	2.05	;	Streptococcus suis SadP mutant - N285D
8HI1	;	3.09	;	Streptococcus thermophilus Cas1-Cas2- prespacer ternary complex
6FJW	;	2.7	;	Streptococcus thermophilus Cas6
2QC5	;	1.8	;	Streptogramin B lyase structure
4OPE	;	2.58	;	Streptomcyes albus JA3453 oxazolomycin ketosynthase domain OzmH KS7
4OPF	;	2.12	;	Streptomcyes albus JA3453 oxazolomycin ketosynthase domain OzmH KS8
4WKY	;	2.0	;	Streptomcyes albus JA3453 oxazolomycin ketosynthase domain OzmN KS2
4OQJ	;	1.904	;	Streptomcyes albus JA3453 oxazolomycin ketosynthase domain OzmQ KS1
6B9R	;	1.802	;	Streptomyces albus HEPD with substrate 2-hydroxyethylphosphonate (2-HEP) and Fe(II) bound
4OQZ	;	1.96	;	Streptomyces aurantiacus imine reductase
4ZBO	;	1.4	;	Streptomyces bingchenggensis acetoacetate decarboxylase in non-covalent complex with potassium formate
6EEJ	;	1.892	;	Streptomyces bingchenggensis Aldolase-Dehydratase in covalent complex with dienone product.
4ZBT	;	1.8	;	Streptomyces bingchenggensis aldolase-dehydratase in Schiff base complex with pyruvate
7P37	;	2.96	;	Streptomyces coelicolor ATP-loaded NrdR
7P3F	;	3.31	;	Streptomyces coelicolor dATP/ATP-loaded NrdR in complex with its cognate DNA
7P3Q	;	3.12	;	Streptomyces coelicolor dATP/ATP-loaded NrdR octamer
6WF6	;	1.39	;	Streptomyces coelicolor methylmalonyl-CoA epimerase
6XBR	;	1.55	;	Streptomyces coelicolor methylmalonyl-CoA epimerase (E43L) in complex with 2-nitronate-propionyl-CoA
6XBS	;	1.5	;	Streptomyces coelicolor methylmalonyl-CoA epimerase (E43Q) in complex with 2-nitronate-propionyl-CoA
6XBT	;	1.49	;	Streptomyces coelicolor methylmalonyl-CoA epimerase (Q60A) in complex with 2-nitronate-propionyl-CoA
6XBV	;	1.5	;	Streptomyces coelicolor methylmalonyl-CoA epimerase (S115T) in complex with 2-nitronate-propionyl-CoA
6XBQ	;	1.64	;	Streptomyces coelicolor methylmalonyl-CoA epimerase in complex with carboxy-carba(dethia)-CoA
6WFH	;	1.84	;	Streptomyces coelicolor methylmalonyl-CoA epimerase substrate complex
5FGM	;	2.6	;	Streptomyces coelicolor SigR region 4
7VO9	;	3.8	;	Streptomyces coelicolor zinc uptake regulator complexed with zinc and DNA (dimer of dimers)
7VO0	;	3.4	;	Streptomyces coelicolor zinc uptake regulator complexed with zinc and DNA (trimer of dimers)
4M7G	;	0.81	;	Streptomyces Erythraeus Trypsin
4I4K	;	1.7	;	Streptomyces globisporus C-1027 9-membered enediyne conserved protein SgcE6
4OO2	;	2.63	;	Streptomyces globisporus C-1027 FAD dependent (S)-3-chloro-&#946;-tyrosine-S-SgcC2 C-5 hydroxylase SgcC apo form
4HX6	;	1.89	;	Streptomyces globisporus C-1027 NADH:FAD oxidoreductase SgcE6
4R82	;	1.659	;	Streptomyces globisporus C-1027 NADH:FAD oxidoreductase SgcE6 in complex with NAD and FAD fragments
1TKJ	;	1.15	;	Streptomyces griseus aminopeptidase complexed with D-Methionine
1TKH	;	1.25	;	Streptomyces griseus aminopeptidase complexed with D-Phenylalanine
1TKF	;	1.2	;	Streptomyces griseus aminopeptidase complexed with D-tryptophan
1TF8	;	1.3	;	Streptomyces griseus aminopeptidase complexed with L-tryptophan
1QQ9	;	1.53	;	STREPTOMYCES GRISEUS AMINOPEPTIDASE COMPLEXED WITH METHIONINE
1XBU	;	1.2	;	Streptomyces griseus aminopeptidase complexed with p-iodo-D-phenylalanine
1TF9	;	1.3	;	Streptomyces griseus aminopeptidase complexed with P-Iodo-L-Phenylalanine
6R01	;	1.18	;	Streptomyces lividans Ccsp mutant - H107A/H111A
6QYB	;	1.18	;	Streptomyces lividans Ccsp mutant - H111A
6QVH	;	1.28	;	Streptomyces lividans Ccsp mutant - H113A
2NLR	;	1.2	;	STREPTOMYCES LIVIDANS ENDOGLUCANASE (EC: 3.2.1.4) COMPLEX WITH MODIFIED GLUCOSE TRIMER
1KNL	;	1.2	;	Streptomyces lividans Xylan Binding Domain cbm13
1KNM	;	1.2	;	Streptomyces lividans Xylan Binding Domain cbm13 in Complex with Lactose
1CHK	;	2.4	;	STREPTOMYCES N174 CHITOSANASE PH5.5 298K
5OO8	;	1.78	;	Streptomyces PAC13 (H42Q) with uridine
5OO9	;	1.59	;	Streptomyces PAC13 (Y55F) with uridine
5OOA	;	1.6	;	Streptomyces PAC13 (Y89F) with uridine
5OO4	;	1.6	;	Streptomyces PAC13 with uridine
5OO5	;	1.78	;	Streptomyces PAC13 with uridine uronic acid
5NTB	;	1.5	;	Streptomyces papain inhibitor (SPI)
5IT1	;	2.1	;	Streptomyces peucetius CYP105P2 complex with biphenyl compound
4ZXV	;	3.0	;	Streptomyces peucetius nitrososynthase DnmZ in ligand-free state
4ZYJ	;	2.736	;	Streptomyces peucetius nitrososynthase dnmZ in TDP-bound state
4QYR	;	2.902	;	Streptomyces platensis isomigrastatin ketosynthase domain MgsE KS3
4ZDN	;	2.509	;	Streptomyces platensis isomigrastatin ketosynthase domain MgsF KS4
4TKT	;	2.4289	;	Streptomyces platensis isomigrastatin ketosynthase domain MgsF KS6
1HP5	;	2.1	;	STREPTOMYCES PLICATUS BETA-N-ACETYLHEXOSAMINIDASE COMPLEXED WITH INTERMEDIATE ANALOUGE NAG-THIAZOLINE
1JAK	;	1.75	;	Streptomyces plicatus beta-N-acetylhexosaminidase in Complex with (2R,3R,4S,5R)-2-acetamido-3,4-dihydroxy-5-hydroxymethyl-piperidinium chloride (IFG)
5FD0	;	2.0	;	Streptomyces plicatus N-acetyl-beta-hexosaminidase in complex with NAGlucal
5FCZ	;	2.45	;	Streptomyces plicatus N-acetyl-beta-hexosaminidase in complex with Thio-NAglucal (TNX)
5UUJ	;	2.299	;	Streptomyces sahachiroi DNA glycosylase AlkZ
4OQY	;	1.9	;	Streptomyces sp. GF3546 imine reductase
5MGZ	;	1.9	;	Streptomyces Spheroides NovO (8-demethylnovbiocic acid methyltransferase) with SAH
8DY7	;	3.18	;	Streptomyces venezuelae RNAP transcription open promoter complex with WhiA and WhiB transcription factors
8DY9	;	3.12	;	Streptomyces venezuelae RNAP unconstrained open promoter complex with WhiA and WhiB transcription factors
8CAI	;	2.08	;	Streptomycin and Hygromycin B bound to the 30S body
8CGJ	;	1.79	;	Streptomycin bound to the 30S body
1KAA	;	1.9	;	STRESS AND STRAIN IN STAPHYLOCOCCAL NUCLEASE
1KAB	;	1.8	;	STRESS AND STRAIN IN STAPHYLOCOCCAL NUCLEASE
7XNJ	;	2.1	;	Stress Response Facilitator A SrfA
4YDZ	;	3.6	;	Stress-induced protein 1 from Caenorhabditis elegans
4YE0	;	2.1	;	Stress-induced protein 1 truncation mutant (43 - 140) from Caenorhabditis elegans
2RME	;		;	Stressin
7B0U	;	3.86	;	Stressosome complex from Listeria innocua
6ZEA	;	1.54	;	Strictosidine Synthase from Catharanthus roseus in complex with racemic 1-methyl-2,3,4,9-tetrahydro-1H-beta-carboline
6S5J	;	2.42	;	Strictosidine Synthase from Ophiorrhiza pumila in complex with (S)-1-Ethyl-2,3,4,9-tetrahydro-1H-beta-carboline
6S5Q	;	2.01	;	Strictosidine Synthase from Ophiorrhiza pumila in complex with (S)-1-isobutyl-2,3,4,9-tetrahydro-1H-beta-carboline
6S5M	;	1.9	;	Strictosidine Synthase from Ophiorrhiza pumila in complex with (S)-1-n-propyl-2,3,4,9-tetrahydro-1H-beta-carboline
6S5U	;	2.03	;	Strictosidine Synthase from Ophiorrhiza pumila in complex with N-[2-(1H-Indol-3-yl)ethyl]-3-methyl-1-butanamine
7WA8	;	2.33	;	Strigolactone receptors in Striga ShHTL7
6HTQ	;	4.5	;	Stringent response control by a bifunctional RelA enzyme in the presence and absence of the ribosome
1QG7	;	2.0	;	STROMA CELL-DERIVED FACTOR-1ALPHA (SDF-1ALPHA)
1VMC	;		;	STROMA CELL-DERIVED FACTOR-1ALPHA (SDF-1ALPHA)
6YEL	;		;	Stromal interaction molecule 1 coiled-coil 1 fragment
1B3D	;	2.3	;	STROMELYSIN-1
2D1O	;	2.02	;	Stromelysin-1 (MMP-3) complexed to a hydroxamic acid inhibitor
1UMT	;		;	Stromelysin-1 catalytic domain with hydrophobic inhibitor bound, ph 7.0, 32oc, 20 mm cacl2, 15% acetonitrile; nmr average of 20 structures minimized with restraints
1UMS	;		;	STROMELYSIN-1 CATALYTIC DOMAIN WITH HYDROPHOBIC INHIBITOR BOUND, PH 7.0, 32OC, 20 MM CACL2, 15% ACETONITRILE; NMR ENSEMBLE OF 20 STRUCTURES
1M6F	;	1.78	;	Strong Binding in the DNA Minor Groove by an Aromatic Diamidine With a Shape That Does Not Match the Curvature of the Groove
1OTD	;	1.25	;	STRONG HYDROGEN BONDS IN PHOTOACTIVE YELLOW PROTEIN AND THEIR ROLE IN ITS PHOTOCYCLE
1ZND	;	1.6	;	Strong Solute-Solute Dispersive Interactions in a Protein-Ligand Complex
1ZNE	;	2.0	;	Strong Solute-Solute Dispersive Interactions in a Protein-Ligand Complex
1ZNG	;	1.6	;	Strong Solute-Solute Dispersive Interactions in a Protein-Ligand Complex
1ZNH	;	2.1	;	Strong Solute-Solute Dispersive Interactions in a Protein-Ligand Complex
1ZNK	;	1.6	;	Strong Solute-Solute Dispersive Interactions in a Protein-Ligand Complex
1ZNL	;	1.7	;	Strong Solute-Solute Dispersive Interactions in a Protein-Ligand Complex
3GOO	;	2.5	;	Strontium bound to the Holliday junction sequence d(TCGGCGCCGA)4
1NVY	;	1.5	;	Strontium bound to the Holliday junction sequence d(TCGGTACCGA)4
3PBX	;	1.879	;	Strontium bound to the sequence d(CCGGCGCCGG)
2WOH	;	2.7	;	Strontium soaked E. coli copper amine oxidase
1U2D	;	3.0	;	Structre of transhydrogenaes (dI.NADH)2(dIII.NADPH)1 asymmetric complex
5D8W	;	2.86	;	Structrue of a lucidum protein
5D8Z	;	2.7	;	Structrue of a lucidum protein
1QX4	;	1.8	;	Structrue of S127P mutant of cytochrome b5 reductase
3W30	;	2.99	;	Structual basis for the recognition of Ubc13 by the Shigella flexneri effector OspI
3W31	;	2.96	;	Structual basis for the recognition of Ubc13 by the Shigella flexneri effector OspI
2YXN	;	1.8	;	Structual basis of azido-tyrosine recognition by engineered bacterial Tyrosyl-tRNA synthetase
2ZP1	;	1.7	;	Structual basis of iodo-tyrosine recognition by engineered archeal tyrosyl-tRNA synthetase
1QY6	;	1.9	;	Structue of V8 Protease from Staphylococcus aureus
3TP0	;	1.9	;	Structural activation of the transcriptional repressor EthR from M. tuberculosis by single amino-acid change mimicking natural and synthetic ligands
3CCO	;	2.2	;	Structural adaptation and conservation in quadruplex-drug recognition
3CDM	;	2.1	;	Structural adaptation and conservation in quadruplex-drug recognition
2PU3	;	1.5	;	Structural adaptation of endonuclease I from the cold-adapted and halophilic bacterium Vibrio salmonicida
1AXO	;		;	STRUCTURAL ALIGNMENT OF THE (+)-TRANS-ANTI-[BP]DG ADDUCT POSITIONED OPPOSITE DC AT A DNA TEMPLATE-PRIMER JUNCTION, NMR, 6 STRUCTURES
3UD6	;	2.091	;	Structural analyses of covalent enzyme-substrate analogue complexes reveal strengths and limitations of de novo enzyme design
2DQP	;	2.1	;	Structural analyses of DNA:DNA and RNA:DNA duplexes containing 5-(N-aminohexyl)carbamoyl modified uridines
1DNU	;	1.85	;	STRUCTURAL ANALYSES OF HUMAN MYELOPEROXIDASE-THIOCYANATE COMPLEX
4A5K	;	1.76	;	Structural analyses of Slm1-PH domain demonstrate ligand binding in the non-canonical site
5LGA	;	2.5	;	Structural analysis and biological activities of BXL0124, a Gemini analog of Vitamin D
5I97	;	2.441	;	Structural analysis and inhibition of TraE from the pKM101 type IV secretion system
4JHO	;	2.21	;	Structural analysis and insights into glycon specificity of the rice GH1 Os7BGlu26 beta-D-mannosidase
4JIE	;	2.45	;	Structural analysis and insights into glycon specificity of the rice GH1 Os7BGlu26 beta-D-mannosidase
8A5K	;	2.3	;	Structural analysis of 1-deoxy-D-xylulose 5-phosphate synthase from Pseudomonas aeruginosa and Klebsiella pneumoniae reveals conformational changes upon cofactor binding
8A45	;	2.0	;	Structural analysis of 1-deoxy-D-xylulose 5-phosphate synthase from Pseudomonas aeruginosa with 2-acetyl thiamine diphosphate
3WDP	;	1.7	;	Structural analysis of a beta-glucosidase mutant derived from a hyperthermophilic tetrameric structure
2LHK	;		;	Structural analysis of a chaperone in type III secretion system
3Q50	;	2.75	;	Structural analysis of a class I PreQ1 riboswitch aptamer in the metabolite-bound state
3Q51	;	2.85	;	Structural analysis of a class I PreQ1 riboswitch aptamer in the metabolite-free state.
2PG1	;	2.8	;	Structural analysis of a cytoplasmic dynein Light Chain-Intermediate Chain complex
3D84	;	1.9	;	Structural Analysis of a Holo Enzyme Complex of Mouse Dihydrofolate Reductase with NADPH and a Ternary Complex with the Potent and Selective Inhibitor 2.4-Diamino-6-(-2'-hydroxydibenz[b,f]azepin-5-yl)methylpteridine
3D80	;	1.4	;	Structural Analysis of a Holo Enzyme Complex of Mouse Dihydrofolate Reductase with NADPH and a Ternary Complex wtih the Potent and Selective Inhibitor 2,4-Diamino-6-(2'-hydroxydibenz[b,f]azepin-5-yl)methylpteridine
1Y1X	;	1.95	;	Structural analysis of a homolog of programmed cell death 6 protein from Leishmania major Friedlin
3POT	;	1.2	;	Structural analysis of a Ni(III)-methyl species in methyl-coenzyme M reductase from Methanothermobacter marburgensis
6NZJ	;	2.4	;	Structural Analysis of a Nitrogenase Iron Protein from Methanosarcina acetivorans: Implications for CO2 Capture by a Surface-Exposed [Fe4S4] Cluster
4L4L	;	2.122	;	Structural Analysis of a Phosphoribosylated Inhibitor in Complex with Human Nicotinamide Phosphoribosyltransferase
4L4M	;	2.445	;	Structural Analysis of a Phosphoribosylated Inhibitor in Complex with Human Nicotinamide Phosphoribosyltransferase
1TC5	;	1.93	;	Structural Analysis of a probable eukaryotic D-amino acid tRNA deacylase
1TYA	;	2.8	;	STRUCTURAL ANALYSIS OF A SERIES OF MUTANTS OF TYROSYL-TRNA SYNTHETASE: ENHANCEMENT OF CATALYSIS BY HYDROPHOBIC INTERACTIONS
1TYB	;	2.5	;	STRUCTURAL ANALYSIS OF A SERIES OF MUTANTS OF TYROSYL-TRNA SYNTHETASE: ENHANCEMENT OF CATALYSIS BY HYDROPHOBIC INTERACTIONS
1TYC	;	2.5	;	STRUCTURAL ANALYSIS OF A SERIES OF MUTANTS OF TYROSYL-TRNA SYNTHETASE: ENHANCEMENT OF CATALYSIS BY HYDROPHOBIC INTERACTIONS
5IC0	;	1.97	;	Structural analysis of a talin triple domain module
5IC1	;	2.2	;	Structural analysis of a talin triple domain module, E1794Y, E1797Y, Q1801Y mutant
2A9M	;	2.1	;	Structural Analysis of a Tight-binding Fluorescein-scFv; apo form
6JSJ	;	3.2	;	Structural analysis of a trimeric assembly of the mitochondrial dynamin-like GTPase Mgm1
3PRM	;	2.3	;	Structural analysis of a viral OTU domain protease from the Crimean-Congo Hemorrhagic Fever virus in complex with human ubiquitin
3PRP	;	1.699	;	Structural analysis of a viral OTU domain protease from the Crimean-Congo Hemorrhagic Fever virus in complex with human ubiquitin
1FX2	;	1.46	;	STRUCTURAL ANALYSIS OF ADENYLATE CYCLASES FROM TRYPANOSOMA BRUCEI IN THEIR MONOMERIC STATE
3TVY	;	2.0	;	Structural Analysis of Adhesive Tip pilin, GBS104 from Group B Streptococcus agalactiae
3TW0	;	2.0	;	Structural Analysis of Adhesive Tip pilin, GBS104 from Group B Streptococcus agalactiae
3TXA	;	2.619	;	Structural Analysis of Adhesive Tip pilin, GBS104 from Group B Streptococcus agalactiae
6JPV	;	2.15001	;	Structural analysis of AIMP2-DX2 and HSP70 interaction
6K39	;	1.39814	;	Structural analysis of AIMP2-DX2 and HSP70 interaction
3R07	;	2.7	;	Structural analysis of an archaeal lipoylation system. A bi-partite lipoate protein ligase and its E2 lipoyl domain from Thermoplasma acidophilum
3VWX	;	1.8	;	Structural analysis of an epsilon-class glutathione S-transferase from housefly, Musca domestica
4BQ2	;	1.9	;	Structural analysis of an exo-beta-agarase
4BQ3	;	2.1	;	Structural analysis of an exo-beta-agarase
4BQ4	;	2.05	;	Structural analysis of an exo-beta-agarase
4BQ5	;	2.3	;	Structural analysis of an exo-beta-agarase
1R08	;	3.0	;	STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES
2R04	;	3.0	;	STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES
2R06	;	3.0	;	STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES
2R07	;	3.0	;	STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES
2RM2	;	3.0	;	STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES
2RR1	;	3.0	;	STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES
2RS1	;	3.0	;	STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES
2RS3	;	3.0	;	STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES
2RS5	;	3.0	;	STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES
2FLE	;	1.9	;	Structural analysis of asymmetric inhibitor bound to the HIV-1 Protease V82A mutant
4PD4	;	3.04	;	Structural analysis of atovaquone-inhibited cytochrome bc1 complex reveals the molecular basis of antimalarial drug action
4WU0	;	1.6	;	Structural Analysis of C. acetobutylicum ATCC 824 Glycoside Hydrolase From Family 105
2XK9	;	2.35	;	Structural analysis of checkpoint kinase 2 (Chk2) in complex with inhibitor PV1533
2YIQ	;	1.89	;	Structural analysis of checkpoint kinase 2 in complex with inhibitor PV1322
2YIR	;	2.1	;	Structural analysis of checkpoint kinase 2 in complex with inhibitor PV1352
2YIT	;	2.2	;	Structural analysis of checkpoint kinase 2 in complex with PV1162, a novel inhibitor
5HV0	;	1.63	;	Structural Analysis of Cofactor Binding of a Prolyl 4-Hydroxylase from the Pathogenic Bacterium Bacillus anthracis
1TE0	;	2.2	;	Structural analysis of DegS, a stress sensor of the bacterial periplasm
3KF4	;	1.9	;	Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template
3KFA	;	1.22	;	Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template
1ZFN	;	2.75	;	Structural Analysis of Escherichia coli ThiF
1ZKM	;	2.95	;	Structural Analysis of Escherichia Coli ThiF
5DU2	;	2.7	;	Structural analysis of EspG2 glycosyltransferase
5GP9	;	1.755	;	Structural analysis of fatty acid degradation regulator FadR from Bacillus halodurans
5GPA	;	2.051	;	Structural analysis of fatty acid degradation regulator FadR from Bacillus halodurans
5GPC	;	2.8	;	Structural analysis of fatty acid degradation regulator FadR from Bacillus halodurans
5UC1	;	2.351	;	Structural Analysis of Glucocorticoid Receptor beta Ligand Binding Domain Complexed with Glucocorticoid Antagonist RU-486: Implication of Helix 12 in Antagonism
1DC3	;	2.5	;	STRUCTURAL ANALYSIS OF GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASE FROM ESCHERICHIA COLI: DIRECT EVIDENCE FOR SUBSTRATE BINDING AND COFACTOR-INDUCED CONFORMATIONAL CHANGES
1DC4	;	2.5	;	STRUCTURAL ANALYSIS OF GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASE FROM ESCHERICHIA COLI: DIRECT EVIDENCE FOR SUBSTRATE BINDING AND COFACTOR-INDUCED CONFORMATIONAL CHANGES
1DC5	;	2.0	;	STRUCTURAL ANALYSIS OF GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASE FROM ESCHERICHIA COLI: DIRECT EVIDENCE FOR SUBSTRATE BINDING AND COFACTOR-INDUCED CONFORMATIONAL CHANGES
1DC6	;	2.0	;	STRUCTURAL ANALYSIS OF GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASE FROM ESCHERICHIA COLI: DIRECT EVIDENCE FOR SUBSTRATE BINDING AND COFACTOR-INDUCED CONFORMATIONAL CHANGES.
2VRZ	;	1.9	;	Structural analysis of homodimeric staphylococcal aureus EsxA
2VS0	;	1.4	;	Structural analysis of homodimeric staphylococcal aureus virulence factor EsxA
4GGA	;	2.044	;	Structural Analysis of Human Cdc20 Supports Multi-site Degron Recognition by APC/C
4GGC	;	1.35	;	Structural Analysis of Human Cdc20 Supports Multi-site Degron Recognition by APC/C
4GGD	;	2.435	;	Structural analysis of human Cdc20 supports multisite degron recognition by APC/C.
1H3W	;	2.85	;	Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity
8COK	;	2.91	;	Structural analysis of ING3 protein and its binding to histone H3
1IMA	;	2.3	;	STRUCTURAL ANALYSIS OF INOSITOL MONOPHOSPHATASE COMPLEXES WITH SUBSTRATES
1IMB	;	2.2	;	STRUCTURAL ANALYSIS OF INOSITOL MONOPHOSPHATASE COMPLEXES WITH SUBSTRATES
1Q7I	;		;	Structural Analysis of Integrin alpha IIb beta 3- Disintegrin with the AKGDWN Motif
1Q7J	;		;	Structural Analysis of Integrin alpha IIb beta 3- Disintegrin with the AKGDWN Motif
5H38	;	1.7	;	Structural analysis of KSHV thymidylate synthase
5H39	;	2.0	;	Structural analysis of KSHV thymidylate synthase
5H3A	;	2.4	;	Structural analysis of KSHV thymidylate synthase
1X6O	;	1.6	;	Structural Analysis of Leishmania braziliensis eukaryotic initiation factor 5a
1XTP	;	1.94	;	Structural Analysis of Leishmania major LMAJ004091AAA, a SAM-dependent methyltransferase of the DUF858/Pfam05891 family
1YF9	;	2.0	;	Structural analysis of Leishmania major ubiquitin conjugating enzyme E2
1XTD	;	2.7	;	Structural Analysis of Leishmania mexicana eukaryotic initiation factor 5a
2CZP	;		;	Structural analysis of membrane-bound mastoparan-X by solid-state NMR
6JBZ	;	2.603	;	Structural analysis of molybdopterin synthases from two mycobacteria pathogens
6JC0	;	2.1	;	Structural analysis of molybdopterin synthases from two mycobacteria pathogens
1HLB	;	2.5	;	Structural analysis of monomeric hemichrome and dimeric cyanomet hemoglobins from Caudina arenicola
5AIR	;	2.53	;	Structural analysis of mouse GSK3beta fused with LRP6 peptide.
4Y7T	;	1.8	;	Structural analysis of MurU
4Y7U	;	1.7	;	Structural analysis of MurU
4Y7V	;	1.8	;	Structural analysis of MurU
3DTF	;	2.2	;	Structural analysis of mycobacterial branched chain aminotransferase- implications for inhibitor design
3DTG	;	1.9	;	Structural analysis of mycobacterial branched chain aminotransferase- implications for inhibitor design
1R1H	;	1.95	;	STRUCTURAL ANALYSIS OF NEPRILYSIN WITH VARIOUS SPECIFIC AND POTENT INHIBITORS
1R1I	;	2.6	;	STRUCTURAL ANALYSIS OF NEPRILYSIN WITH VARIOUS SPECIFIC AND POTENT INHIBITORS
1R1J	;	2.35	;	STRUCTURAL ANALYSIS OF NEPRILYSIN WITH VARIOUS SPECIFIC AND POTENT INHIBITORS
2B94	;	1.85	;	Structural analysis of P knowlesi homolog of P falciparum PNP
2YYR	;	2.5	;	Structural analysis of PHD domain of Pygopus complexed with trimethylated histone H3 peptide
1B9X	;	3.0	;	STRUCTURAL ANALYSIS OF PHOSDUCIN AND ITS PHOSPHORYLATION-REGULATED INTERACTION WITH TRANSDUCIN
1B9Y	;	3.0	;	STRUCTURAL ANALYSIS OF PHOSDUCIN AND ITS PHOSPHORYLATION-REGULATED INTERACTION WITH TRANSDUCIN BETA-GAMMA
2R9B	;	2.8	;	Structural Analysis of Plasmepsin 2 from Plasmodium falciparum complexed with a peptide-based inhibitor
1Y13	;	2.2	;	Structural Analysis of Plasmodium falciparum 6-pyruvoyl tetrahydropterin synthase (PTPS)
8Q1K	;	1.51	;	Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5' exonuclease-mediated nucleic acid degradation
8Q1X	;	1.85	;	Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5' exonuclease-mediated nucleic acid degradation
3NZD	;	1.8	;	Structural Analysis of Pneumocystis carinii and Human DHFR Complexes with NADPH and a Series of Five 5-(omega-carboxy(alkyloxy(pyrido[2,3-d]pyrimidine Derivatives
3NZC	;	2.0	;	Structural Analysis of Pneumocystis carinii and Human DHFR Complexes with NADPH and a Series of Five Potent 5-(omega-carboxy(alkyloxy)pyrido[2,3-d]pyridine Derivativea
3NZ6	;	2.0	;	Structural Analysis of Pneumocystis carinii and Human DHFR Complexes with NADPH and a Series of Five Potent 5-(omega-Carboxy(alkyloxy)Pyrido[2,3-d]pyrimidine Derivatives
3NZ9	;	1.8	;	Structural Analysis of Pneumocystis carinii and Human DHFR Complexes with NADPH and a Series of Five Potent 5-(omega-Carboxy(alkyloxy)Pyrido[2,3-d]pyrimidine Derivatives
3NZA	;	1.9	;	Structural Analysis of Pneumocystis carinii and Human DHFR Complexes with NADPH and a Series of Five Potent 5-(omega-Carboxy(alkyloxy)pyrido[2,3-d]pyrimidine Derivatives
3NZB	;	1.45	;	Structural Analysis of Pneumocystis carinii and Human DHFR Complexes with NADPH and a Series of Potent 5-(omega-carboxyl(alkyloxy)pyrido[2,-d]pyrimidine Derivatives
3TD8	;	1.8	;	Structural Analysis of Pneumocystis carinii Dihydrofolate Reductase Complex with NADPH and 2,4-diamino-5-methyl-6-[2'-(4-carboxy-1-pentynyl)-5'-methoxybenzyl]pyrido[2,3-d]pyrimidine
1W8X	;	4.2	;	Structural analysis of PRD1
3PR9	;	1.95	;	Structural analysis of protein folding by the Methanococcus jannaschii chaperone FKBP26
3PRA	;	2.4	;	Structural analysis of protein folding by the Methanococcus jannaschii chaperone FKBP26
3PRB	;	2.2	;	Structural analysis of protein folding by the Methanococcus jannaschii chaperone FKBP26
3PRD	;	3.3	;	Structural analysis of protein folding by the Methanococcus jannaschii chaperone FKBP26
1LA2	;	2.65	;	Structural analysis of Saccharomyces cerevisiae myo-inositol phosphate synthase
1SRP	;	2.0	;	STRUCTURAL ANALYSIS OF SERRATIA PROTEASE
4EQM	;	3.0	;	Structural analysis of Staphylococcus aureus serine/threonine kinase PknB
2BC1	;	2.15	;	Structural Analysis of Streptococcus pyogenes NADH oxidase: C44S Nox
2BCP	;	2.1	;	Structural Analysis of Streptococcus pyogenes NADH oxidase: C44S Nox with Azide
2BC0	;	2.0	;	Structural Analysis of Streptococcus pyogenes NADH oxidase: Wild-type Nox
4RZQ	;	1.98	;	Structural Analysis of Substrate, Reaction Intermediate and Product Binding in Haemophilus influenzae Biotin Carboxylase
4UMA	;	1.76	;	Structural analysis of substrate-mimicking inhibitors in complex with Neisseria meningitidis 3 deoxy D arabino heptulosonate 7 phosphate synthase the importance of accommodating the active site water
4UMB	;	2.17	;	Structural analysis of substrate-mimicking inhibitors in complex with Neisseria meningitidis 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase - the importance of accommodating the active site water
4UMC	;	2.34	;	Structural analysis of substrate-mimicking inhibitors in complex with Neisseria meningitidis 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase - the importance of accommodating the active site water
1ELD	;	2.0	;	Structural analysis of the active site of porcine pancreatic elastase based on the x-ray crystal structures of complexes with trifluoroacetyl-dipeptide-anilide inhibitors
1ELE	;	2.0	;	STRUCTURAL ANALYSIS OF THE ACTIVE SITE OF PORCINE PANCREATIC ELASTASE BASED ON THE X-RAY CRYSTAL STRUCTURES OF COMPLEXES WITH TRIFLUOROACETYL-DIPEPTIDE-ANILIDE INHIBITORS
4Q6M	;	1.6	;	Structural analysis of the apo-form of Helicobacter pylori Csd4, a D,L-carboxypeptidase
3EWI	;	1.9	;	Structural analysis of the C-terminal domain of murine CMP-Sialic acid Synthetase
1YVG	;	2.6	;	Structural analysis of the catalytic domain of tetanus neurotoxin
3HCQ	;	2.89	;	Structural analysis of the choline binding protein ChoX in a semi-closed and ligand-free conformation
1MKY	;	1.9	;	Structural Analysis of the Domain Interactions in Der, a Switch Protein Containing Two GTPase Domains
5UQZ	;	1.149	;	Structural Analysis of the Glucan Binding Protein C of Streptococcus mutans Provides Evidence that it Mediates both Sucrose-Independent and -Dependent Adherence
4TYI	;	3.4	;	Structural analysis of the human Fibroblast Growth Factor Receptor 4
4TYE	;	2.8	;	Structural analysis of the human Fibroblast Growth Factor Receptor 4 Kinase
4TYG	;	2.4	;	Structural analysis of the human Fibroblast Growth Factor Receptor 4 Kinase
4TYJ	;	2.45	;	Structural analysis of the human Fibroblast Growth Factor Receptor 4 Kinase
7TLN	;	2.3	;	STRUCTURAL ANALYSIS OF THE INHIBITION OF THERMOLYSIN BY AN ACTIVE-SITE-DIRECTED IRREVERSIBLE INHIBITOR
1QPC	;	1.6	;	STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
1QPD	;	2.0	;	STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
1QPE	;	2.0	;	STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
4Q6O	;	1.41	;	Structural analysis of the mDAP-bound form of Helicobacter pylori Csd4, a D,L-carboxypeptidase
4LD1	;	1.44	;	Structural analysis of the microcephaly protein CPAP G-box domain suggests a role in centriole elongation.
4LD3	;	2.44	;	Structural analysis of the microcephaly protein CPAP G-box domain suggests a role in centriole elongation.
2CMM	;	1.8	;	STRUCTURAL ANALYSIS OF THE MYOGLOBIN RECONSTITUTED WITH IRON PORPHINE
2J82	;	1.28	;	Structural analysis of the PP2C Family Phosphatase tPphA from Thermosynechococcus elongatus
2J86	;	3.05	;	Structural analysis of the PP2C Family Phosphatase tPphA of Thermosynechococcus elongatus
6RAE	;	2.049	;	Structural analysis of the Salmonella type III secretion system ATPase InvC
1RO7	;	1.8	;	Structural analysis of the sialyltransferase CstII from Campylobacter jejuni in complex with a substrate analogue, CMP-3FNeuAc.
1RO8	;	2.05	;	Structural analysis of the sialyltransferase CstII from Campylobacter jejuni in complex with a substrate analogue, cytidine-5'-monophosphate
1KVP	;	27.0	;	STRUCTURAL ANALYSIS OF THE SPIROPLASMA VIRUS, SPV4, IMPLICATIONS FOR EVOLUTIONARY VARIATION TO OBTAIN HOST DIVERSITY AMONG THE MICROVIRIDAE, ELECTRON MICROSCOPY, ALPHA CARBONS ONLY
2VL6	;	2.8	;	STRUCTURAL ANALYSIS OF THE SULFOLOBUS SOLFATARICUS MCM PROTEIN N- TERMINAL DOMAIN
1L16	;	1.7	;	STRUCTURAL ANALYSIS OF THE TEMPERATURE-SENSITIVE MUTANT OF BACTERIOPHAGE T4 LYSOZYME, GLYCINE 156 (RIGHT ARROW) ASPARTIC ACID
6GHD	;	2.1	;	Structural analysis of the ternary complex between lamin A/C, BAF and emerin identifies an interface disrupted in autosomal recessive progeroid diseases
4Q6N	;	1.55	;	Structural analysis of the tripeptide-bound form of Helicobacter pylori Csd4, a D,L-carboxypeptidase
2R8N	;	1.2	;	Structural Analysis of the Unbound Form of HIV-1 Subtype C Protease
4RIR	;	2.5	;	Structural Analysis of the Unmutated Ancestor of the HIV-1 Envelope V2 Region Antibody CH58 Isolated From an RV144 HIV-1 Vaccine Efficacy Trial Vaccinee and Associated with Decreased Transmission Risk
4RIS	;	2.3	;	Structural Analysis of the Unmutated Ancestor of the HIV-1 Envelope V2 Region Antibody CH58 Isolated From an RV144 HIV-1 Vaccine Efficacy Trial Vaccinee and Associated with Decreased Transmission Risk
1T3S	;	2.3	;	Structural Analysis of the Voltage-Dependent Calcium Channel Beta Subunit Functional Core
1T3L	;	2.2	;	Structural Analysis of the Voltage-Dependent Calcium Channel Beta Subunit Functional Core in Complex with Alpha1 Interaction Domain
1JO8	;	1.3	;	Structural analysis of the yeast actin binding protein Abp1 SH3 domain
1CAI	;	1.8	;	STRUCTURAL ANALYSIS OF THE ZINC HYDROXIDE-THR 199-GLU 106 HYDROGEN BONDING NETWORK IN HUMAN CARBONIC ANHYDRASE II
1CAJ	;	1.9	;	STRUCTURAL ANALYSIS OF THE ZINC HYDROXIDE-THR 199-GLU 106 HYDROGEN BONDING NETWORK IN HUMAN CARBONIC ANHYDRASE II
1CAK	;	1.9	;	STRUCTURAL ANALYSIS OF THE ZINC HYDROXIDE-THR 199-GLU 106 HYDROGEN BONDING NETWORK IN HUMAN CARBONIC ANHYDRASE II
1CAL	;	2.2	;	STRUCTURAL ANALYSIS OF THE ZINC HYDROXIDE-THR 199-GLU 106 HYDROGEN BONDING NETWORK IN HUMAN CARBONIC ANHYDRASE II
1CAM	;	1.7	;	STRUCTURAL ANALYSIS OF THE ZINC HYDROXIDE-THR 199-GLU 106 HYDROGEN BONDING NETWORK IN HUMAN CARBONIC ANHYDRASE II
4Q6P	;	2.62	;	Structural analysis of the Zn-form I of Helicobacter pylori Csd4, a D,L-carboxypeptidase
4Q6Q	;	2.4	;	Structural analysis of the Zn-form II of Helicobacter pylori Csd4, a D,L-carboxypeptidase
3T8I	;	1.8	;	Structural analysis of thermostable S. solfataricus purine-specific nucleoside hydrolase
3T8J	;	1.6	;	Structural analysis of thermostable S. solfataricus pyrimidine-specific nucleoside hydrolase
4WY5	;	2.43	;	Structural analysis of two fungal esterases from Rhizomucor miehei explaining their substrate specificity
4WY8	;	2.27	;	Structural analysis of two fungal esterases from Rhizomucor miehei explaining their substrate specificity
2OIV	;	1.95	;	Structural Analysis of Xanthomonas XopD Provides Insights Into Substrate Specificity of Ubiquitin-like Protein Proteases
1WG3	;	3.0	;	Structural analysis of yeast nucleosome-assembly factor CIA1p
5T9P	;	2.0	;	Structural analysis reveals the flexible C-terminus of Nop15 undergoes rearrangement to recognize a pre-ribosomal RNA folding intermediate
2F6B	;	2.8	;	Structural and active site modification studies implicate Glu, Trp and Arg in the activity of xylanase from alkalophilic Bacillus sp. (NCL 87-6-10).
4O0Z	;	2.049	;	Structural and Biochemical Analyses of the Catalysis and Potency Impact of Inhibitor Phosphoribosylation by Human Nicotinamide Phosphoribosyltransferase
4O10	;	1.55	;	Structural and Biochemical Analyses of the Catalysis and Potency Impact of Inhibitor Phosphoribosylation by Human Nicotinamide Phosphoribosyltransferase
4O12	;	2.498	;	Structural and Biochemical Analyses of the Catalysis and Potency Impact of Inhibitor Phosphoribosylation by Human Nicotinamide Phosphoribosyltransferase
2OBL	;	1.8	;	Structural and biochemical analysis of a prototypical ATPase from the type III secretion system of pathogenic bacteria
2OBM	;	2.25	;	Structural and biochemical analysis of a prototypical ATPase from the type III secretion system of pathogenic bacteria
2W5E	;	2.0	;	Structural and biochemical analysis of human pathogenic astrovirus serine protease at 2.0 Angstrom resolution
1YEP	;	2.5	;	Structural and biochemical analysis of the link between enzymatic activity and olgomerization in AhpC, a bacterial peroxiredoxin.
1YEX	;	2.3	;	Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.
1YF0	;	2.5	;	Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.
1YF1	;	2.6	;	Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.
4MMN	;	2.6	;	Structural and biochemical analysis of type II free methionine-R-sulfoxide reductase from Thermoplasma acidophilum
4MN7	;	2.0	;	Structural and biochemical analysis of type II free methionine-R-sulfoxide reductase from Thermoplasma acidophilum
1ZGY	;	1.8	;	Structural and Biochemical Basis for Selective Repression of the Orphan Nuclear Receptor LRH-1 by SHP
1ZH7	;	2.5	;	Structural and Biochemical Basis for Selective Repression of the Orphan Nuclear Receptor LRH-1 by SHP
3CS8	;	2.3	;	Structural and Biochemical Basis for the Binding Selectivity of PPARg to PGC-1a
4M6R	;	2.0	;	Structural and biochemical basis for the inhibition of cell death by APIP, a methionine salvage enzyme
4HY7	;	1.2	;	Structural and biochemical characterization of a cytosolic wheat cyclophilin TaCypA-1
1H56	;	3.0	;	Structural and biochemical characterization of a new magnesium ion binding site near Tyr94 in the restriction endonuclease PvuII
5BK6	;	1.59	;	Structural and biochemical characterization of a non-canonical biuret hydrolase (BiuH) from the cyanuric acid catabolism pathway of Rhizobium leguminasorum bv. viciae 3841
6AZN	;	1.75	;	Structural and biochemical characterization of a non-canonical biuret hydrolase (BiuH) from the cyanuric acid catabolism pathway of Rhizobium leguminasorum bv. viciae 3841
6AZO	;	2.46	;	Structural and biochemical characterization of a non-canonical biuret hydrolase (BiuH) from the cyanuric acid catabolism pathway of Rhizobium leguminasorum bv. viciae 3841
6AZQ	;	2.22	;	Structural and biochemical characterization of a non-canonical biuret hydrolase (BiuH) from the cyanuric acid catabolism pathway of Rhizobium leguminasorum bv. viciae 3841
6AZS	;	1.59	;	Structural and biochemical characterization of a non-canonical biuret hydrolase (BiuH) from the cyanuric acid catabolism pathway of Rhizobium leguminasorum bv. viciae 3841
4Z7A	;	1.98	;	Structural and biochemical characterization of a non-functionally redundant M. tuberculosis (3,3) L,D-Transpeptidase, LdtMt5.
4AEK	;	1.75	;	Structural and biochemical characterization of a novel Carbohydrate Binding Module of endoglucanase Cel5A from Eubacterium cellulosolvens
4AEM	;	2.1	;	Structural and biochemical characterization of a novel Carbohydrate Binding Module of endoglucanase Cel5A from Eubacterium cellulosolvens
4AFD	;	1.34	;	Structural and biochemical characterization of a novel Carbohydrate Binding Module of endoglucanase Cel5A from Eubacterium cellulosolvens with a partially bound cellotetraose moeity.
4AFM	;	1.25	;	Structural and biochemical characterization of a novel Carbohydrate Binding Module of endoglucanase Cel5A from Eubacterium cellulosolvens.
3ASW	;	2.6	;	Structural and biochemical characterization of ClfB:ligand interactions
3AT0	;	2.5	;	Structural and biochemical characterization of ClfB:ligand interactions
3AU0	;	2.45	;	Structural and biochemical characterization of ClfB:ligand interactions
5YVD	;	2.7	;	Structural and biochemical characterization of endoribonuclease Nsp15 encoded by Middle East Respiratory Syndrome Coronavirus
2VR3	;	1.95	;	Structural and Biochemical Characterization of Fibrinogen binding to ClfA from Staphylocccus aureus
2KI3	;		;	Structural and biochemical characterization of FK506 binding domain from Plasmodium vivax
3UI3	;	2.8	;	Structural and Biochemical Characterization of HP0315 from Helicobacter pylori as a VapD Protein with an Endoribonuclease Activity
4FFX	;	2.7	;	Structural and Biochemical Characterization of Human Adenylosuccinate Lyase (ADSL) and the R303C ADSL Deficiency Associated Mutation
4FLC	;	2.6	;	Structural and Biochemical Characterization of Human Adenylosuccinate Lyase (ADSL) and the R303C ADSL Deficiency Associated Mutation
2MM8	;		;	Structural and biochemical characterization of Jaburetox
8DC1	;	1.62	;	Structural and biochemical characterization of L. interrogans Lsa45 reveals a penicillin-binding protein with esterase activity
1DJQ	;	2.2	;	STRUCTURAL AND BIOCHEMICAL CHARACTERIZATION OF RECOMBINANT C30A MUTANT OF TRIMETHYLAMINE DEHYDROGENASE FROM METHYLOPHILUS METHYLOTROPHUS (SP. W3A1)
1DJN	;	2.2	;	STRUCTURAL AND BIOCHEMICAL CHARACTERIZATION OF RECOMBINANT WILD TYPE TRIMETHYLAMINE DEHYDROGENASE FROM METHYLOPHILUS METHYLOTROPHUS (SP. W3A1)
5EO2	;	2.5	;	Structural and biochemical characterization of the hypothetical protein SAV2348 from Staphylococcus aureus in complex with CoA.
5EO4	;	2.0	;	Structural and biochemical characterization of the hypothetical protein SAV2348 from Staphylococcus aureus.
4UTU	;	1.45	;	Structural and biochemical characterization of the N- acetylmannosamine-6-phosphate 2-epimerase from Clostridium perfringens
3RSE	;	2.65	;	Structural and biochemical characterization of two binding sites for nucleation promoting factor WASp-VCA on Arp2/3 complex
3GX8	;	1.673	;	Structural and biochemical characterization of yeast monothiol glutaredoxin Grx5
1SU1	;	2.25	;	Structural and biochemical characterization of Yfce, a phosphoesterase from E. coli
2VJX	;	1.85	;	Structural and biochemical evidence for a boat-like transition state in beta-mannosidases
2VL4	;	1.9	;	Structural and biochemical evidence for a boat-like transition state in beta-mannosidases
2VMF	;	2.1	;	Structural and biochemical evidence for a boat-like transition state in beta-mannosidases
2VO5	;	2.3	;	Structural and biochemical evidence for a boat-like transition state in beta-mannosidases
2VOT	;	1.95	;	Structural and biochemical evidence for a boat-like transition state in beta-mannosidases
2VQT	;	2.1	;	Structural and biochemical evidence for a boat-like transition state in beta-mannosidases
2VQU	;	1.9	;	Structural and biochemical evidence for a boat-like transition state in beta-mannosidases
1SSU	;		;	Structural and biochemical evidence for disulfide bond heterogeneity in active forms of the somatomedin B domain of human vitronectin
3JYI	;	2.703	;	Structural and biochemical evidence that a TEM-1 {beta}-lactamase Asn170Gly active site mutant acts via substrate-assisted catalysis
1N39	;	2.2	;	Structural and biochemical exploration of a critical amino acid in human 8-oxoguanine glycosylase
1N3A	;	2.2	;	Structural and biochemical exploration of a critical amino acid in human 8-oxoguanine glycosylase
1N3C	;	2.7	;	Structural and biochemical exploration of a critical amino acid in human 8-oxoguanine glycosylase
1XDQ	;	2.55	;	Structural and Biochemical Identification of a Novel Bacterial Oxidoreductase
1XDY	;	2.2	;	Structural and Biochemical Identification of a Novel Bacterial Oxidoreductase, W-containing cofactor
7LW0	;	2.32	;	Structural and Biochemical Insight into Assembly of Molecular Motors Involved in Viral DNA Packaging
7LWR	;	2.35	;	Structural and Biochemical Insight into Assembly of Molecular Motors Involved in Viral DNA Packaging
7LXS	;	2.21	;	Structural and Biochemical Insight into Assembly of Molecular Motors Involved in Viral DNA Packaging
5FYD	;	1.6	;	Structural and biochemical insights into 7beta-hydroxysteroid dehydrogenase stereoselectivity
3P4F	;	2.35	;	Structural and biochemical insights into MLL1 core complex assembly and regulation.
8USP	;	3.3	;	Structural and biochemical investigations of a HEAT-repeat protein involved in the cytosolic iron-sulfur cluster assembly pathway
8USQ	;	12.77	;	Structural and biochemical investigations of a HEAT-repeat protein involved in the cytosolic iron-sulfur cluster assembly pathway
2A3I	;	1.95	;	Structural and Biochemical Mechanisms for the Specificity of Hormone Binding and Coactivator Assembly by Mineralocorticoid Receptor
8TYL	;	2.85	;	Structural and biochemical rationale for Beta variant protein booster vaccine broad cross-neutralization of SARS-CoV-2
8TYO	;	2.75	;	Structural and biochemical rationale for Beta variant protein booster vaccine broad cross-neutralization of SARS-CoV-2
1Y7H	;	2.52	;	Structural and biochemical studies identify tobacco SABP2 as a methylsalicylate esterase and further implicate it in plant innate immunity, Northeast Structural Genomics Target AR2241
1Y7I	;	2.1	;	Structural and biochemical studies identify tobacco SABP2 as a methylsalicylate esterase and further implicate it in plant innate immunity, Northeast Structural Genomics Target AR2241
4RG8	;	2.12	;	Structural and biochemical studies of a moderately thermophilic Exonuclease I from Methylocaldum szegediense
1VYJ	;	2.8	;	Structural and biochemical studies of human PCNA complexes provide the basis for association with CDK/cyclin and rationale for inhibitor design
3G5C	;	2.36	;	Structural and biochemical studies on the ectodomain of human ADAM22
3WVT	;	1.601	;	Structural and biochemical study of equine lentivirus receptor 1
4I1L	;	2.1	;	Structural and Biological Features of FOXP3 Dimerization Relevant to Regulatory T Cell Function
5BTS	;	1.77	;	Structural and biophysical characterization of a covalent insulin dimer formed during storage of neutral formulation of human insulin
2HLE	;	2.05	;	Structural and biophysical characterization of the EPHB4-EPHRINB2 protein protein interaction and receptor specificity.
2MF2	;		;	Structural and biophysical characterization of the mRNA interferase SaMazF from Staphylococcus aureus.
4FL1	;	1.79	;	Structural and Biophysical Characterization of the Syk Activation Switch
4FL2	;	2.19	;	Structural and Biophysical Characterization of the Syk Activation Switch
4FL3	;	1.9	;	Structural and Biophysical Characterization of the Syk Activation Switch
3GQF	;	2.2	;	Structural and Biophysical Properties of the Pathogenic SOD1 Variant H46R/H48Q
6K5G	;	1.574	;	Structural and catalytic analysis of two diverse uridine phosphorylases in the oomycete Phytophthora capsici
6K5H	;	2.503	;	Structural and catalytic analysis of two diverse uridine phosphorylases in the oomycete Phytophthora capsici.
6K5K	;	2.097	;	Structural and catalytic analysis of two diverse uridine phosphorylases in the oomycete Phytophthora capsici.
6K8P	;	1.965	;	Structural and catalytic analysis of two diverse uridine phosphorylases in the oomycete Phytophthora capsici.
6KD3	;	2.764	;	Structural and catalytic analysis of two diverse uridine phosphorylases in the oomycete Phytophthora capsici.
4HBA	;	1.762	;	Structural and Catalytic Characterization of a Thermal and Acid Stable Variant of Human Carbonic Anhydrase II Containing an Engineered Disulfide Bond
4UB9	;	2.27	;	Structural and catalytic characterization of molinate hydrolase
4QK2	;	1.519	;	Structural and Catalytic Effects of Proline Substitution and Surface Loop Deletion in the Extended Active Site of Human Carbonic Anhydrase II - E234P
4QK1	;	1.599	;	Structural and Catalytic Effects of Proline Substitution and Surface Loop Deletion in the Extended Active Site of Human Carbonic Anhydrase II - K170P
4QK3	;	1.345	;	Structural and Catalytic Effects of Proline Substitution and Surface Loop Deletion in the Extended Active Site of Human Carbonic Anhydrase II - [delta]230-240
6W6C	;	2.38	;	Structural and catalytic roles of human 18S rRNA methyltransferases DIMT1 in ribosome assembly and translation
6W6F	;	3.2	;	Structural and catalytic roles of human 18S rRNA methyltransferases DIMT1 in ribosome assembly and translation
6TOB	;		;	Structural and DNA Binding Properties of Mycobacterial Integration Host Factor mIHF
6YJ2	;	2.0	;	Structural and DNA binding studies of the transcriptional repressor Rv2506 (BkaR) from Mycobacterium tuberculosis supports a role in L-Leucine catabolism
6YL2	;	3.15	;	Structural and DNA binding studies of the transcriptional repressor Rv2506 (BkaR) from Mycobacterium tuberculosis supports a role in L-Leucine catabolism
5DDO	;	3.1	;	Structural and Dynamic Basis for Low Affinity-High Selectivity Binding of L-glutamine by the Gln-riboswitch
6S0M	;	2.0	;	Structural and dynamic studies provide insights into specificity and allosteric regulation of Ribonuclease AS, a key enzyme in mycobacterial virulence
2I7U	;		;	Structural and Dynamical Analysis of a Four-Alpha-Helix Bundle with Designed Anesthetic Binding Pockets
1YBJ	;		;	Structural and Dynamics studies of both apo and holo forms of the hemophore HasA
5H58	;	3.991	;	Structural and dynamics studies of the TetR family protein, CprB from Streptomyces coelicolor in complex with its biological operator sequence
1HVD	;	2.0	;	STRUCTURAL AND ELECTROPHYSIOLOGICAL ANALYSIS OF ANNEXIN V MUTANTS. MUTAGENESIS OF HUMAN ANNEXIN V, AN IN VITRO VOLTAGE-GATED CALCIUM CHANNEL, PROVIDES INFORMATION ABOUT THE STRUCTURAL FEATURES OF THE ION PATHWAY, THE VOLTAGE SENSOR AND THE ION SELECTIVITY FILTER
1HVE	;	2.3	;	STRUCTURAL AND ELECTROPHYSIOLOGICAL ANALYSIS OF ANNEXIN V MUTANTS. MUTAGENESIS OF HUMAN ANNEXIN V, AN IN VITRO VOLTAGE-GATED CALCIUM CHANNEL, PROVIDES INFORMATION ABOUT THE STRUCTURAL FEATURES OF THE ION PATHWAY, THE VOLTAGE SENSOR AND THE ION SELECTIVITY FILTER
1HVF	;	2.0	;	STRUCTURAL AND ELECTROPHYSIOLOGICAL ANALYSIS OF ANNEXIN V MUTANTS. MUTAGENESIS OF HUMAN ANNEXIN V, AN IN VITRO VOLTAGE-GATED CALCIUM CHANNEL, PROVIDES INFORMATION ABOUT THE STRUCTURAL FEATURES OF THE ION PATHWAY, THE VOLTAGE SENSOR AND THE ION SELECTIVITY FILTER
1HVG	;	3.0	;	STRUCTURAL AND ELECTROPHYSIOLOGICAL ANALYSIS OF ANNEXIN V MUTANTS. MUTAGENESIS OF HUMAN ANNEXIN V, AN IN VITRO VOLTAGE-GATED CALCIUM CHANNEL, PROVIDES INFORMATION ABOUT THE STRUCTURAL FEATURES OF THE ION PATHWAY, THE VOLTAGE SENSOR AND THE ION SELECTIVITY FILTER
1HQ1	;	1.52	;	STRUCTURAL AND ENERGETIC ANALYSIS OF RNA RECOGNITION BY A UNIVERSALLY CONSERVED PROTEIN FROM THE SIGNAL RECOGNITION PARTICLE
3FIL	;	0.88	;	Structural and energetic determinants for hyperstable variants of GB1 obtained from in-vitro evolution
1BSU	;	2.0	;	STRUCTURAL AND ENERGETIC ORIGINS OF INDIRECT READOUT IN SITE-SPECIFIC DNA CLEAVAGE BY A RESTRICTION ENDONUCLEASE
1BUA	;	2.15	;	STRUCTURAL AND ENERGETIC ORIGINS OF INDIRECT READOUT IN SITE-SPECIFIC DNA CLEAVAGE BY A RESTRICTION ENDONUCLEASE
6EB3	;	2.35	;	Structural and enzymatic characterization of an esterase from a metagenomic library
1MPF	;	3.0	;	STRUCTURAL AND FUNCTIONAL ALTERATIONS OF A COLICIN RESISTANT MUTANT OF OMPF-PORIN FROM ESCHERICHIA COLI
3LKZ	;	2.0	;	Structural and functional analyses of a conserved hydrophobic pocket of flavivirus methyltransferase
1LZ5	;	1.8	;	STRUCTURAL AND FUNCTIONAL ANALYSES OF THE ARG-GLY-ASP SEQUENCE INTRODUCED INTO HUMAN LYSOZYME
1LZ6	;	1.8	;	STRUCTURAL AND FUNCTIONAL ANALYSES OF THE ARG-GLY-ASP SEQUENCE INTRODUCED INTO HUMAN LYSOZYME
3ZXP	;	2.495	;	Structural and Functional Analyses of the Bro1 Domain Protein BROX
3DR2	;	1.67	;	Structural and Functional Analyses of XC5397 from Xanthomonas campestris: A Gluconolactonase Important in Glucose Secondary Metabolic Pathways
3FAK	;	1.9	;	Structural and Functional Analysis of a Hormone-Sensitive Lipase like EstE5 from a Metagenome Library
4RL1	;	2.0	;	Structural and functional analysis of a loading acyltransferase from the avermectin modular polyketide synthase
4RGY	;	1.4	;	Structural and functional analysis of a low-temperature-active alkaline esterase from South China Sea marine sediment microbial metagenomic library
5FJQ	;	1.85	;	Structural and functional analysis of a lytic polysaccharide monooxygenase important for efficient utilization of chitin in Cellvibrio japonicus
2LI3	;		;	Structural and functional analysis of a novel potassium toxin argentinean scorpion Tityus trivittatus reveals a new kappa sub-family
6WS6	;	3.3	;	Structural and functional analysis of a potent sarbecovirus neutralizing antibody
4KY9	;	2.23	;	Structural and Functional Analysis of a Putative Substrate Access Tunnel in the Cytosolic Domain of Human Anion Exchanger 1
2AQE	;		;	Structural and functional analysis of ada2 alpha swirm domain
2AQF	;		;	Structural and functional analysis of ADA2 alpha swirm domain
3PTJ	;	2.6	;	Structural and functional Analysis of Arabidopsis thaliana thylakoid lumen protein AtTLP18.3
3PVH	;	1.6	;	Structural and Functional Analysis of Arabidopsis thaliana thylakoid lumen protein AtTLP18.3
3PW9	;	2.1	;	Structural and functional Analysis of Arabidopsis thaliana thylakoid lumen protein AtTLP18.3
2GIZ	;	1.68	;	Structural and functional analysis of Natrin, a member of crisp-3 family blocks a variety of ion channels
3PO8	;	1.5	;	Structural and functional analysis of phosphothreonine-dependent FHA domain interactions
3POA	;	2.01	;	Structural and functional analysis of phosphothreonine-dependent FHA domain interactions
3V3V	;	2.7	;	Structural and functional analysis of quercetagetin, a natural JNK1 inhibitor
2HJN	;	2.0	;	Structural and functional analysis of Saccharomyces cerevisiae Mob1
7CK4	;	7.0	;	Structural and functional analysis of small heat shock protein from Synechococcus phage S-ShM2
3DWH	;	1.95	;	Structural and Functional Analysis of SRA domain
1TUW	;	1.9	;	Structural and Functional Analysis of Tetracenomycin F2 Cyclase from Streptomyces glaucescens: A Type-II Polyketide Cyclase
4A24	;		;	Structural and functional analysis of the DEAF-1 and BS69 MYND domains
5E1L	;	2.15	;	Structural and functional analysis of the E. coli FtsZ interacting protein, ZapC, reveals insight into molecular properties of a novel Z ring stabilizing protein
3D3B	;	1.3	;	Structural and functional analysis of the E. coli NusB-S10 transcription antitermination complex.
3D3C	;	2.6	;	Structural and functional analysis of the E. coli NusB-S10 transcription antitermination complex.
2MPU	;		;	Structural and Functional analysis of the Hordeum vulgare L. HvGR-RBP1 protein, a glycine-rich RNA binding protein implicated in the regulation of barley leaf senescence and environmental adaptation
3MMY	;	1.65	;	Structural and functional analysis of the interaction between the nucleoporin Nup98 and the mRNA export factor Rae1
7PB3	;	2.841	;	Structural and Functional analysis of the Proline Racemase (ProR) from the Gram-positive bacterium Acetoanaerobium sticklandii
8CIB	;	1.78	;	Structural and functional analysis of the Pseudomonas aeruginosa PA1677 protein
2L0E	;		;	Structural and functional analysis of tm vi of the nhe1 isoform of the na+/h+ exchanger
2KBV	;		;	Structural and functional analysis of TM XI of the NHE1 isoform of thE NA+/H+ exchanger
2M7X	;		;	Structural and Functional Analysis of Transmembrane Segment IV of the Salt Tolerance Protein Sod2
5CFI	;	2.6	;	Structural and functional attributes of malaria parasite Ap4A hydrolase
5CFJ	;	1.25	;	Structural and functional attributes of malaria parasite Ap4A hydrolase
6K60	;	3.149	;	Structural and functional basis for HLA-G isoform recognition of immune checkpoint receptor LILRBs
6EVG	;	1.1	;	Structural and Functional Characterisation of a Bacterial Laccase-like Multi-copper Oxidase CueO from Lignin-Degrading Bacterium Ochrobactrum sp. with Oxidase Activity towards Lignin Model Compounds and Lignosulfonate
6FCO	;	2.03	;	Structural and functional characterisation of Frataxin (FXN) like protein from Chaetomium thermophilum
2J6Y	;	1.85	;	Structural and Functional Characterisation of partner switching regulating the environmental stress response in Bacillus subtilis
2J6Z	;	1.95	;	Structural and functional characterisation of partner-switching regulating the environmental stress response in B. subtilis
2J70	;	1.95	;	Structural and functional characterisation of partner-switching regulating the environmental stress response in B. subtilis
4BBK	;	2.1	;	Structural and functional characterisation of the kindlin-1 pleckstrin homology domain
6SAO	;	1.2	;	Structural and functional characterisation of three novel fungal amylases with enhanced stability and pH tolerance
6SAV	;	1.4	;	Structural and functional characterisation of three novel fungal amylases with enhanced stability and pH tolerance
6SAU	;	1.35	;	Structural and functional characterisation of three novel fungal amylases with enhanced stability and pH tolerance.
8SEM	;		;	Structural and functional characterisation of Tst2, a novel TRPV1 inhibitory peptide from the Australian sea anemone Telmatactis stephensoni
4O7I	;	2.11	;	Structural and functional characterization of 3'(2'),5'-bisphosphate nucleotidase1 from Entamoeba histolytica
1U3F	;	2.5	;	Structural and Functional Characterization of a 5,10-Methenyltetrahydrofolate Synthetase from Mycoplasma pneumoniae (GI: 13508087)
1U3G	;	2.5	;	Structural and Functional Characterization of a 5,10-Methenyltetrahydrofolate Synthetase from Mycoplasma pneumoniae (GI: 13508087)
5CBF	;	3.61	;	Structural and Functional Characterization of a Calcium-activated Cation channel from Tsukamurella Paurometabola
5CBH	;	3.37	;	Structural and Functional Characterization of a Calcium-activated Cation channel from Tsukamurella Paurometabola
5AA7	;	1.55	;	Structural and functional characterization of a chitin-active 15.5 kDa lytic polysaccharide monooxygenase domain from a modular chitinase from Jonesia denitrificans
4KUJ	;	1.99	;	Structural and functional characterization of a novel Alpha Kinase from Entamoeba histolytica
4NL0	;	2.41	;	Structural and functional characterization of a novel Alpha Kinase in complex with ADP from Entamoeba histolytica
1S3L	;	2.4	;	Structural and Functional Characterization of a Novel Archaeal Phosphodiesterase
1S3M	;	2.5	;	Structural and Functional Characterization of a Novel Archaeal Phosphodiesterase
1S3N	;	2.5	;	Structural and Functional Characterization of a Novel Archaeal Phosphodiesterase
3RJ2	;	2.2	;	Structural and functional characterization of a novel histone H3 binding protein ORF158L from the Singapore grouper iridovirus (SGIV)
3HH7	;	1.55	;	Structural and Functional Characterization of a Novel Homodimeric Three-finger Neurotoxin from the Venom of Ophiophagus hannah (King Cobra)
4V00	;	1.82	;	Structural and functional characterization of a novel monotreme- specific protein from the milk of the platypus
4V3J	;	1.97	;	Structural and functional characterization of a novel monotreme- specific protein from the milk of the platypus
1NHO	;		;	Structural and Functional characterization of a Thioredoxin-like Protein from Methanobacterium thermoautotrophicum
3SKJ	;	2.5	;	Structural And Functional Characterization of an Agonistic Anti-Human EphA2 Monoclonal Antibody
3UGD	;	1.45	;	Structural and functional characterization of an anesthetic binding site in the second cysteine-rich domain of protein kinase C delta
3UGI	;	1.361	;	Structural and functional characterization of an anesthetic binding site in the second cysteine-rich domain of protein kinase C delta
3UGL	;	1.357	;	Structural and functional characterization of an anesthetic binding site in the second cysteine-rich domain of protein kinase C delta
3UEJ	;	1.301	;	Structural and functional characterization of an anesthetic binding site in the second cysteine-rich domain of protein kinase Cdelta
3UEY	;	1.301	;	Structural and functional characterization of an anesthetic binding site in the second cysteine-rich domain of protein kinase Cdelta
3UFF	;	1.3	;	Structural and functional characterization of an anesthetic binding site in the second cysteine-rich domain of protein kinase Cdelta
7F0H	;	1.695	;	Structural and functional characterization of bovine G1P[5] rotavirus VP8* protein
2Q8R	;	1.82	;	Structural and Functional Characterization of CC Chemokine CCL14
3TDG	;	2.1	;	Structural and functional characterization of Helicobacter pylori DsbG
7C8P	;	2.6	;	Structural and functional characterization of human group A rotavirus P[25] VP8*
4FVK	;	2.198	;	Structural and functional characterization of neuraminidase-like molecule N10 derived from bat influenza A virus
5MNV	;	2.97	;	Structural and functional characterization of OleP in complex with 6DEB in PEG
5MNS	;	2.62	;	Structural and functional characterization of OleP in complex with 6DEB in sodium formate
5DWZ	;	2.04	;	Structural and functional characterization of PqsBC, a condensing enzyme in the biosynthesis of the Pseudomonas aeruginosa quinolone signal
4KNC	;	2.141	;	Structural and functional characterization of Pseudomonas aeruginosa AlgX
7ZJB	;	1.37	;	Structural and functional characterization of the bacterial lytic polysaccharide Monooxygenase ScLPMO10D
8BPD	;	1.8	;	Structural and Functional Characterization of the Novel Endo-alpha(1,4)-Fucoidanase Mef1 from the Marine Bacterium Muricauda eckloniae
2JP6	;		;	Structural and functional characterization of the recombinant form of the Kv1.3 channel blocker Tc32
3RKG	;	1.28	;	Structural and Functional Characterization of the Yeast Mg2+ Channel Mrs2
2K3C	;		;	Structural and Functional Characterization of TM IX of the NHE1 Isoform of the Na+/H+ Exchanger
2HTG	;		;	Structural and functional characterization of TM VII of the NHE1 isoform of the Na+/H+ exchanger
3FOT	;	1.75	;	Structural and Functional Characterization of TRI3 Trichothecene 15-O-acetyltransferase from Fusarium sporotrichioides
3FP0	;	1.9	;	Structural and Functional Characterization of TRI3 Trichothecene 15-O-acetyltransferase from Fusarium sporotrichioides
4FYB	;	2.2	;	Structural and functional characterizations of a thioredoxin-fold protein from Helicobacter pylori
4FYC	;	2.31	;	Structural and functional characterizations of a thioredoxin-fold protein from Helicobacter pylori
1BSQ	;	2.22	;	STRUCTURAL AND FUNCTIONAL CONSEQUENCES OF POINT MUTATIONS OF VARIANTS A AND B OF BOVINE BETA-LACTOGLOBULIN
1C49	;		;	STRUCTURAL AND FUNCTIONAL DIFFERENCES OF TWO TOXINS FROM THE SCORPION PANDINUS IMPERATOR
1MLF	;	2.0	;	STRUCTURAL AND FUNCTIONAL EFFECTS OF APOLAR MUTATIONS OF VAL68(E11) IN MYOGLOBIN
1MLG	;	2.0	;	STRUCTURAL AND FUNCTIONAL EFFECTS OF APOLAR MUTATIONS OF VAL68(E11) IN MYOGLOBIN
1MLH	;	2.0	;	STRUCTURAL AND FUNCTIONAL EFFECTS OF APOLAR MUTATIONS OF VAL68(E11) IN MYOGLOBIN
1MLJ	;	2.0	;	STRUCTURAL AND FUNCTIONAL EFFECTS OF APOLAR MUTATIONS OF VAL68(E11) IN MYOGLOBIN
1MLK	;	1.8	;	STRUCTURAL AND FUNCTIONAL EFFECTS OF APOLAR MUTATIONS OF VAL68(E11) IN MYOGLOBIN
1MLL	;	1.7	;	STRUCTURAL AND FUNCTIONAL EFFECTS OF APOLAR MUTATIONS OF VAL68(E11) IN MYOGLOBIN
1MLM	;	1.8	;	STRUCTURAL AND FUNCTIONAL EFFECTS OF APOLAR MUTATIONS OF VAL68(E11) IN MYOGLOBIN
1MLN	;	2.0	;	STRUCTURAL AND FUNCTIONAL EFFECTS OF APOLAR MUTATIONS OF VAL68(E11) IN MYOGLOBIN
1MLO	;	1.8	;	STRUCTURAL AND FUNCTIONAL EFFECTS OF APOLAR MUTATIONS OF VAL68(E11) IN MYOGLOBIN
1MLQ	;	2.0	;	STRUCTURAL AND FUNCTIONAL EFFECTS OF APOLAR MUTATIONS OF VAL68(E11) IN MYOGLOBIN
1MLR	;	2.0	;	STRUCTURAL AND FUNCTIONAL EFFECTS OF APOLAR MUTATIONS OF VAL68(E11) IN MYOGLOBIN
1MLS	;	1.7	;	Structural and functional effects of apolar mutations of val68(e11) in myoglobin
1CIE	;	1.8	;	STRUCTURAL AND FUNCTIONAL EFFECTS OF MULTIPLE MUTATIONS AT DISTAL SITES IN CYTOCHROME C
1CIF	;	1.9	;	STRUCTURAL AND FUNCTIONAL EFFECTS OF MULTIPLE MUTATIONS AT DISTAL SITES IN CYTOCHROME C
1CIG	;	1.8	;	STRUCTURAL AND FUNCTIONAL EFFECTS OF MULTIPLE MUTATIONS AT DISTAL SITES IN CYTOCHROME C
1CIH	;	1.8	;	STRUCTURAL AND FUNCTIONAL EFFECTS OF MULTIPLE MUTATIONS AT DISTAL SITES IN CYTOCHROME C
3OLY	;	2.05	;	Structural and functional effects of substitution at position T+1 in CheY: CheYA88M-BeF3-Mn complex
3OLX	;	2.1	;	Structural and functional effects of substitution at position T+1 in CheY: CheYA88S-BeF3-Mn complex
3OLW	;	2.304	;	Structural and functional effects of substitution at position T+1 in CheY: CheYA88T-BeF3-Mn complex
3OLV	;	1.697	;	Structural and functional effects of substitution at position T+1 in CheY: CheYA88V-BeF3-Mg complex
7TNW	;	3.1	;	Structural and functional impact by SARS-CoV-2 Omicron spike mutations
7TO4	;	3.4	;	Structural and functional impact by SARS-CoV-2 Omicron spike mutations
1CVA	;	2.25	;	STRUCTURAL AND FUNCTIONAL IMPORTANCE OF A CONSERVED HYDROGEN BOND NETWORK IN HUMAN CARBONIC ANHYDRASE II
1CVB	;	2.4	;	STRUCTURAL AND FUNCTIONAL IMPORTANCE OF A CONSERVED HYDROGEN BOND NETWORK IN HUMAN CARBONIC ANHYDRASE II
1P8Q	;	2.95	;	Structural and Functional Importance of First-Shell Metal Ligands in the Binuclear Cluster of Arginase I.
1P8M	;	2.84	;	Structural and Functional Importance of First-Shell Metal Ligands in the Binuclear Manganese Cluster of Arginase I.
1P8N	;	2.9	;	Structural and Functional Importance of First-Shell Metal Ligands in the Binuclear Manganese Cluster of Arginase I.
1P8O	;	2.96	;	Structural and Functional Importance of First-Shell Metal Ligands in the Binuclear Manganese Cluster of Arginase I.
1P8P	;	2.5	;	Structural and Functional Importance of First-Shell Metal Ligands in the Binuclear Manganese Cluster of Arginase I.
1P8R	;	2.5	;	Structural and Functional Importance of First-Shell Metal Ligands in the Binuclear Manganese Cluster of Arginase I.
1P8S	;	3.2	;	Structural and Functional Importance of First-Shell Metal Ligands in the Binuclear Manganese Cluster of Arginase I.
6M31	;	2.3	;	Structural and Functional Insights into an Archaeal Lipid Synthase
6M34	;	2.9	;	Structural and functional insights into an Archaeal synthase
5WOS	;	2.45	;	Structural and functional insights into Canarypox Virus CNP058 regulation of apoptosis
2JK0	;	2.5	;	Structural and functional insights into Erwinia carotovora L- asparaginase
7EKZ	;	1.43	;	Structural and functional insights into Hydra Actinoporin-Like Toxin 1 (HALT-1)
6LKV	;	2.2	;	Structural and functional insights into macrophage migration inhibitory factor from Oncomelania hupensis, the intermediate host of Schistosoma japonicum
6LKW	;	3.2	;	Structural and functional insights into macrophage migration inhibitory factor from Oncomelania hupensis, the intermediate host of Schistosoma japonicum
6LR3	;	1.77	;	Structural and functional insights into macrophage migration inhibitory factor from Oncomelania hupensis, the intermediate host of Schistosoma japonicum
3NCU	;	2.55	;	Structural and functional insights into pattern recognition by the innate immune receptor RIG-I
4ZG5	;	1.9	;	Structural and functional insights into Survival endonuclease, an important virulence factor of Brucella abortus
6Q6E	;		;	Structural and functional insights into the condensin ATPase cycle
2GJK	;	2.6	;	Structural and functional insights into the human Upf1 helicase core
2GK6	;	2.4	;	Structural and Functional insights into the human Upf1 helicase core
2GK7	;	2.8	;	Structural and Functional insights into the human Upf1 helicase core
3EYB	;	2.79	;	Structural and functional insights into the ligand binding domain of a non-duplicated RXR from the invertebrate chordate amphioxus
3OOB	;	1.89	;	Structural and functional insights of directly targeting Pin1 by Epigallocatechin-3-gallate
2YEU	;	2.0	;	Structural and functional insights of DR2231 protein, the MazG-like nucleoside triphosphate pyrophosphohydrolase from Deinococcus radiodurans, complex with Gd
2YFD	;	1.767	;	STRUCTURAL AND FUNCTIONAL INSIGHTS OF DR2231 PROTEIN, THE MAZG-LIKE NUCLEOSIDE TRIPHOSPHATE PYROPHOSPHOHYDROLASE FROM DEINOCOCCUS RADIODURANS, COMPLEXED WITH Mg and dUMP
2YFC	;	2.01	;	STRUCTURAL AND FUNCTIONAL INSIGHTS OF DR2231 PROTEIN, THE MAZG-LIKE NUCLEOSIDE TRIPHOSPHATE PYROPHOSPHOHYDROLASE FROM DEINOCOCCUS RADIODURANS, COMPLEXED WITH Mn and dUMP
2YF9	;	1.899	;	STRUCTURAL AND FUNCTIONAL INSIGHTS OF DR2231 PROTEIN, THE MAZG-LIKE NUCLEOSIDE TRIPHOSPHATE PYROPHOSPHOHYDROLASE FROM DEINOCOCCUS RADIODURANS, NATIVE FORM
5M11	;	2.9	;	Structural and functional probing of PorZ, an essential bacterial surface component of the type-IX secretion system of human oral-microbiomic Porphyromonas gingivalis.
3RG0	;	2.57	;	Structural and functional relationships between the lectin and arm domains of calreticulin
8YE5	;	1.49	;	Structural and functional research of Reductive Dehalogenases TmrC using a cell-free expression system for heterologous expression
7M1D	;		;	Structural and functional studies about scorpine showed the presence of blocking channel and cytolytic activities as well as two different structural domains
7M1E	;		;	Structural and functional studies about scorpine showed the presence of blocking channel and cytolytic activities as well as two different structural domains
4X4J	;	2.65	;	Structural and Functional Studies of BexE: Insights into Oxidation During BE-7585A Biosynthesis
3PBK	;	3.0	;	Structural and Functional Studies of Fatty Acyl-Adenylate Ligases from E. coli and L. pneumophila
5JU6	;	2.2	;	Structural and Functional Studies of Glycoside Hydrolase Family 3 beta-Glucosidase Cel3A from the Moderately Thermophilic Fungus Rasamsonia emersonii
3OTW	;	1.8	;	Structural and Functional Studies of Helicobacter pylori Wild-Type and Mutated Proteins Phosphopantetheine adenylyltransferase
4DVC	;	1.2	;	Structural and functional studies of TcpG, the Vibrio cholerae DsbA disulfide-forming protein required for pilus and cholera toxin production
2VXW	;	1.7	;	Structural and Functional Studies of the Potent Anti-HIV Chemokine Variant P2-RANTES
4D8P	;	3.05	;	Structural and functional studies of the trans-encoded HLA-DQ2.3 (DQA1*03:01/DQB1*02:01) molecule
3HGQ	;	3.0	;	Structural and functional studies of the yeast class II Hda1 HDAC complex
3HGT	;	2.2	;	Structural and functional studies of the yeast class II Hda1 HDAC complex
4CG1	;	1.4	;	Structural and functional studies on a thermostable polyethylene terephthalate degrading hydrolase from Thermobifida fusca
4CG2	;	1.437	;	Structural and functional studies on a thermostable polyethylene terephthalate degrading hydrolase from Thermobifida fusca
4CG3	;	1.55	;	Structural and functional studies on a thermostable polyethylene therephtalate degrading hydrolase from Thermobifida fusca
4O6P	;	3.0	;	Structural and functional studies the characterization of C58G/C70G mutant in Cys4 Zinc-finger motif in the recombination mediator protein RecR
4O6O	;	3.0	;	Structural and functional studies the characterization of Cys4 Zinc-finger motif in the recombination mediator protein RecR
5GUY	;	2.399	;	Structural and functional study of chuY from E. coli CFT073 strain
4ADB	;	2.2	;	Structural and functional study of succinyl-ornithine transaminase from E. coli
4ADC	;	2.3	;	Structural and functional study of succinyl-ornithine transaminase from E. coli
4ADD	;	2.45	;	Structural and functional study of succinyl-ornithine transaminase from E. coli
4ADE	;	2.75	;	Structural and functional study of succinyl-ornithine transaminase from E. coli
2MSA	;		;	Structural and immunological analysis of circumsporozoite protein peptides: a further step in the identification of potential components of a minimal subunit-based, chemically synthesised antimalarial vaccine.
6FRR	;	1.948	;	Structural and immunological properties of the allergen Art v 3
8C4A	;	2.675	;	Structural and interactional insights into the glideosome-associated connector from Toxoplasma gondii
1DAZ	;	1.55	;	Structural and kinetic analysis of drug resistant mutants of HIV-1 protease
1DW6	;	1.88	;	Structural and kinetic analysis of drug resistant mutants of HIV-1 protease
1EBK	;	2.06	;	Structural and kinetic analysis of drug resistant mutants of HIV-1 protease
2HFW	;	2.5	;	Structural and kinetic analysis of proton shuttle residues in the active site of human carbonic anhydrase III
3RGP	;	1.88	;	Structural and Kinetic Analysis of the Beef liver Catalase complexed with Nitric Oxide
3RE8	;	1.9	;	Structural and Kinetic Analysis of the Beef liver Catalase interacting with Nitric Oxide
3RGS	;	1.99	;	Structural and kinetic analysis of the beef liver catalase with the ammonia as a ligand
3WT4	;	2.3	;	Structural and kinetic bases for the metal preference of the M18 aminopeptidase from Pseudomonas aeruginosa
4NJQ	;	2.702	;	Structural and kinetic bases for the metal preference of the M18 aminopeptidase from Pseudomonas aeruginosa
4NJR	;	2.3	;	Structural and kinetic bases for the metal preference of the M18 aminopeptidase from Pseudomonas aeruginosa
4OID	;	2.3	;	Structural and kinetic bases for the metal preference of the M18 aminopeptidase from Pseudomonas aeruginosa
4OIW	;	2.44	;	Structural and kinetic bases for the metal preference of the M18 aminopeptidase from Pseudomonas aeruginosa
2BNQ	;	1.7	;	Structural and kinetic basis for heightened immunogenicity of T cell vaccines
2BNR	;	1.9	;	Structural and kinetic basis for heightened immunogenicity of T cell vaccines
2BNU	;	1.4	;	Structural and kinetic basis for heightened immunogenicity of T cell vaccines
7CJE	;	1.95001	;	Structural and kinetic characterization of Porphyromonas gingivalis glutaminyl cyclase
7CJG	;	2.0	;	Structural and kinetic characterization of Porphyromonas gingivalis glutaminyl cyclase
3OAF	;	1.7	;	Structural and Kinetic Data for Antifolate Interactions Against Pneumocystis jirovecii, Pneumocystis carinii and Human Dihydrofolate Reductase and Thier Active Site Mutants
2NWO	;	1.7	;	Structural and kinetic effect of hydrophobic mutations in the active site of human carbonic anhydrase II
2NWP	;	1.8	;	Structural and kinetic effects of hydrophobic mutations in the active site of human carbonic anhydrase II
2NXS	;	1.8	;	Structural and kinetic effects of hydrophobic mutations in the active site of human carbonic anhydrase II
2NXT	;	1.15	;	Structural and kinetic effects of hydrophobic mutations in the active site of human carbonic anhydrase II
2NWY	;	1.65	;	Structural and kinetic effects of hydrophobic mutations on the active site of human carbonic anhydrase II
2NWZ	;	1.8	;	Structural and kinetic effects of hydrophobic mutations on the active site of human carbonic anhydrase II
6Y4I	;	1.16	;	Structural and Kinetic Evaluation of Phosphoramidate Inhibitors on Thermolysin
6YI6	;	1.44	;	Structural and Kinetic Evaluation of Phosphoramidate Inhibitors on Thermolysin
6YMR	;	1.6	;	Structural and Kinetic Evaluation of Phosphoramidate Inhibitors on Thermolysin
6YMS	;	1.32	;	Structural and Kinetic Evaluation of Phosphoramidate Inhibitors on Thermolysin
3CKY	;	2.3	;	Structural and Kinetic Properties of a beta-hydroxyacid dehydrogenase involved in nicotinate fermentation
4ILZ	;	1.91	;	Structural and kinetic study of an internal substrate binding site of dehaloperoxidase-hemoglobin A from Amphitrite ornata
3E4D	;	2.01	;	Structural and Kinetic Study of an S-Formylglutathione Hydrolase from Agrobacterium tumefaciens
2QKA	;	2.2	;	Structural and Kinetic Study of the Differences between Human and E.coli Manganese Superoxide Dismutases
2QKC	;	2.3	;	Structural and Kinetic Study of the Differences between Human and E.coli Manganese Superoxide Dismutases
4IY0	;	1.9	;	Structural and ligand binding properties of the Bateman domain of human magnesium transporters CNNM2 and CNNM4
4IY2	;	3.6	;	Structural and ligand binding properties of the Bateman domain of human magnesium transporters CNNM2 and CNNM4
4IY4	;	2.9	;	Structural and ligand binding properties of the Bateman domain of human magnesium transporters CNNM2 and CNNM4
4IYS	;	1.8	;	Structural and ligand binding properties of the Bateman domain of human magnesium transporters CNNM2 and CNNM4
7WZF	;	1.4	;	Structural and mechanism analysis of YunM
5YEU	;	3.001	;	Structural and mechanistic analyses reveal a unique Cas4-like protein in the mimivirus virophage resistance element system
5K9N	;	2.3	;	Structural and Mechanistic Analysis of Drosophila melanogaster Polyamine N acetyltransferase, an enzyme that Catalyzes the Formation of N acetylagmatine
2XLQ	;	2.22	;	Structural and Mechanistic Analysis of the Magnesium-Independent Aromatic Prenyltransferase CloQ from the Clorobiocin Biosynthetic Pathway
2XLY	;	3.1	;	Structural and Mechanistic Analysis of the Magnesium-Independent Aromatic Prenyltransferase CloQ from the Clorobiocin Biosynthetic Pathway
2XM5	;	1.85	;	Structural and Mechanistic Analysis of the Magnesium-Independent Aromatic Prenyltransferase CloQ from the Clorobiocin Biosynthetic Pathway
2XM7	;	2.22	;	Structural and Mechanistic Analysis of the Magnesium-Independent Aromatic Prenyltransferase CloQ from the Clorobiocin Biosynthetic Pathway
3EJ3	;	1.7	;	Structural and mechanistic analysis of trans-3-chloroacrylic acid dehalogenase activity
3EJ7	;	1.9	;	Structural and mechanistic analysis of trans-3-chloroacrylic acid dehalogenase activity
3EJ9	;	1.5	;	Structural and mechanistic analysis of trans-3-chloroacrylic acid dehalogenase activity
1YR2	;	1.8	;	Structural and Mechanistic Analysis of Two Prolyl Endopeptidases: Role of Inter-Domain Dynamics in Catalysis and Specificity
2BKL	;	1.5	;	Structural and Mechanistic Analysis of Two Prolyl Endopeptidases: Role of Inter-Domain Dynamics in Catalysis and Specificity
4V43	;	3.52	;	Structural and mechanistic basis for allostery in the bacterial chaperonin GroEL
2JCH	;	2.4	;	Structural and mechanistic basis of penicillin binding protein inhibition by lactivicins
2JE5	;	2.6	;	STRUCTURAL AND MECHANISTIC BASIS OF PENICILLIN BINDING PROTEIN INHIBITION BY LACTIVICINS
4G1P	;	2.547	;	Structural and Mechanistic Basis of Substrate Recognition by Novel Di-peptidase Dug1p From Saccharomyces cerevisiae
2EF9	;	2.0	;	Structural and mechanistic changes along an engineered path from metallo to non-metallo KDO8P synthase
2NWS	;	1.8	;	Structural and mechanistic changes along an engineered path from metallo to non-metallo KDO8P synthase
2NX1	;	1.8	;	Structural and mechanistic changes along an engineered path from metallo to non-metallo KDO8P synthase
2NX3	;	2.1	;	Structural and mechanistic changes along an engineered path from metallo to non-metallo KDO8P synthase
2NXG	;	1.95	;	Structural and mechanistic changes along an engineered path from metallo to non-metallo KDO8P synthase.
2NXH	;	2.11	;	Structural and mechanistic changes along an engineered path from metallo to non-metallo KDO8P synthase.
2NXI	;	2.3	;	Structural and mechanistic changes along an engineered path from metallo to non-metallo KDO8P synthase.
8J5Y	;	3.07	;	Structural and mechanistic insight into ribosomal ITS2 RNA processing by nuclease-kinase machinery
8J60	;	3.39	;	Structural and mechanistic insight into ribosomal ITS2 RNA processing by nuclease-kinase machinery
6O0B	;	1.6	;	Structural and Mechanistic Insights into CO2 Activation by Nitrogenase Iron Protein
2WVB	;	1.9	;	Structural and mechanistic insights into Helicobacter pylori NikR function
2WVC	;	2.1	;	Structural and mechanistic insights into Helicobacter pylori NikR function
2WVD	;	2.65	;	Structural and mechanistic insights into Helicobacter pylori NikR function
2WVE	;	2.3	;	Structural and mechanistic insights into Helicobacter pylori NikR function
2WVF	;	1.6	;	Structural and mechanistic insights into Helicobacter pylori NikR function
5UCU	;	1.797	;	STRUCTURAL AND MECHANISTIC INSIGHTS INTO HEMOGLOBIN-CATALYZED HYDROGEN SULFIDE OXIDATION AND THE FATE OF POLYSULFIDE PRODUCTS
4RL0	;	1.3	;	Structural and mechanistic insights into NDM-1 catalyzed hydrolysis of cephalosporins
4RL2	;	2.008	;	Structural and mechanistic insights into NDM-1 catalyzed hydrolysis of cephalosporins
4RM5	;	2.1	;	Structural and mechanistic insights into NDM-1 catalyzed hydrolysis of cephalosporins
5GTU	;	1.5	;	Structural and mechanistic insights into regulation of the retromer coat by TBC1d5
7BPU	;	3.32	;	Structural and mechanistic insights into the biosynthesis of Digeranylgeranylglyceryl phosphate synthase in membranes
2LK4	;		;	Structural and mechanistic insights into the interaction between PAT Pyk2 and Paxillin LD motif
7EQK	;	2.04001	;	Structural and mechanistic studies of a novel non-heme iron epimerase/lyase and its utilization in chemoselective synthesis.
7EU6	;	2.05011	;	Structural and mechanistic studies of a novel non-heme iron epimerase/lyase and its utilization in chemoselective synthesis.
7EUE	;	2.08757	;	Structural and mechanistic studies of a novel non-heme iron epimerase/lyase and its utilization in chemoselective synthesis.
7EUP	;	2.11043	;	Structural and mechanistic studies of a novel non-heme iron epimerase/lyase and its utilization in chemoselective synthesis.
7EUZ	;	1.91028	;	Structural and mechanistic studies of a novel non-heme iron epimerase/lyase and its utilization in chemoselective synthesis.
7F6X	;	2.16	;	Structural and mechanistic studies of a novel non-heme iron epimerase/lyase and its utilization in chemoselective synthesis.
3V5O	;	2.5	;	Structural and Mechanistic Studies of Catalysis and Sulfa Drug Resistance in Dihydropteroate Synthase
2XEP	;	1.5	;	Structural and mechanistic studies on a cephalosporin esterase from the clavulanic acid biosynthesis pathway
2XF3	;	1.55	;	Structural and mechanistic studies on a cephalosporin esterase from the clavulanic acid biosynthesis pathway
2XFS	;	1.8	;	Structural and mechanistic studies on a cephalosporin esterase from the clavulanic acid biosynthesis pathway
2XFT	;	1.8	;	Structural and mechanistic studies on a cephalosporin esterase from the clavulanic acid biosynthesis pathway
2XGN	;	1.7	;	Structural and mechanistic studies on a cephalosporin esterase from the clavulanic acid biosynthesis pathway
2XH9	;	1.8	;	Structural and mechanistic studies on a cephalosporin esterase from the clavulanic acid biosynthesis pathway
5H43	;	2.3	;	Structural and mechanistical studies of the nuclear import by Importin-alpha
2OHE	;	2.7	;	Structural and mutational analysis of tRNA-Intron splicing endonuclease from Thermoplasma acidophilum DSM 1728
2OHC	;	2.5	;	structural and mutational analysis of tRNA-intron splicing endonuclease from Thermoplasma acidophilum DSM1728
4CB8	;	2.9	;	Structural and mutational analysis reveals that CTNNBL1 binds NLSs in a manner distinct from that of its closest armadillo-relative, karyopherin alpha
1S5O	;	1.8	;	Structural and Mutational Characterization of L-carnitine Binding to Human carnitine Acetyltransferase
2A8K	;	1.5	;	Structural and Mutational Studies of the Catalytic Domain of Colicin E5a tRNA-Specific Ribonuclease
3UE4	;	2.424	;	Structural and spectroscopic analysis of the kinase inhibitor bosutinib binding to the Abl tyrosine kinase domain
2VZX	;	2.0	;	Structural and spectroscopic characterization of photoconverting fluorescent protein Dendra2
2ET7	;	1.7	;	Structural and spectroscopic insights into the mechanism of oxalate oxidase
3GUZ	;	1.67	;	Structural and substrate-binding studies of pantothenate synthenate (PS)provide insights into homotropic inhibition by pantoate in PS's
1AZY	;	3.0	;	STRUCTURAL AND THEORETICAL STUDIES SUGGEST DOMAIN MOVEMENT PRODUCES AN ACTIVE CONFORMATION OF THYMIDINE PHOSPHORYLASE
1OTP	;	2.8	;	STRUCTURAL AND THEORETICAL STUDIES SUGGEST DOMAIN MOVEMENT PRODUCES AN ACTIVE CONFORMATION OF THYMIDINE PHOSPHORYLASE
2TPT	;	2.6	;	STRUCTURAL AND THEORETICAL STUDIES SUGGEST DOMAIN MOVEMENT PRODUCES AN ACTIVE CONFORMATION OF THYMIDINE PHOSPHORYLASE
2YV0	;	1.4	;	Structural and Thermodynamic Analyses of E. coli ribonuclease HI Variant with Quintuple Thermostabilizing Mutations
1HEL	;	1.7	;	STRUCTURAL AND THERMODYNAMIC ANALYSIS OF COMPENSATING MUTATIONS WITHIN THE CORE OF CHICKEN EGG WHITE LYSOZYME
1HEM	;	1.8	;	STRUCTURAL AND THERMODYNAMIC ANALYSIS OF COMPENSATING MUTATIONS WITHIN THE CORE OF CHICKEN EGG WHITE LYSOZYME
1HEN	;	1.8	;	STRUCTURAL AND THERMODYNAMIC ANALYSIS OF COMPENSATING MUTATIONS WITHIN THE CORE OF CHICKEN EGG WHITE LYSOZYME
1HEO	;	1.8	;	STRUCTURAL AND THERMODYNAMIC ANALYSIS OF COMPENSATING MUTATIONS WITHIN THE CORE OF CHICKEN EGG WHITE LYSOZYME
1HEP	;	1.8	;	STRUCTURAL AND THERMODYNAMIC ANALYSIS OF COMPENSATING MUTATIONS WITHIN THE CORE OF CHICKEN EGG WHITE LYSOZYME
1HEQ	;	1.8	;	STRUCTURAL AND THERMODYNAMIC ANALYSIS OF COMPENSATING MUTATIONS WITHIN THE CORE OF CHICKEN EGG WHITE LYSOZYME
1HER	;	1.8	;	STRUCTURAL AND THERMODYNAMIC ANALYSIS OF COMPENSATING MUTATIONS WITHIN THE CORE OF CHICKEN EGG WHITE LYSOZYME
1L48	;	1.7	;	STRUCTURAL AND THERMODYNAMIC ANALYSIS OF THE PACKING OF TWO ALPHA-HELICES IN BACTERIOPHAGE T4 LYSOZYME
1L49	;	1.8	;	STRUCTURAL AND THERMODYNAMIC ANALYSIS OF THE PACKING OF TWO ALPHA-HELICES IN BACTERIOPHAGE T4 LYSOZYME
1L50	;	1.85	;	STRUCTURAL AND THERMODYNAMIC ANALYSIS OF THE PACKING OF TWO ALPHA-HELICES IN BACTERIOPHAGE T4 LYSOZYME
1L51	;	1.9	;	STRUCTURAL AND THERMODYNAMIC ANALYSIS OF THE PACKING OF TWO ALPHA-HELICES IN BACTERIOPHAGE T4 LYSOZYME
1L52	;	1.7	;	STRUCTURAL AND THERMODYNAMIC ANALYSIS OF THE PACKING OF TWO ALPHA-HELICES IN BACTERIOPHAGE T4 LYSOZYME
1L53	;	1.85	;	STRUCTURAL AND THERMODYNAMIC ANALYSIS OF THE PACKING OF TWO ALPHA-HELICES IN BACTERIOPHAGE T4 LYSOZYME
4ONS	;	2.8	;	Structural and thermodynamic characterization of cadherin-beta-catenin-alpha-catenin complex formation
3LXK	;	2.0	;	Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6
3LXL	;	1.74	;	Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6
3LXN	;	2.5	;	Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6
3LXP	;	1.65	;	Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6
2WMA	;	2.8	;	Structural and thermodynamic consequences of cyclization of peptide ligands for the recruitment site of cyclin A
2WMB	;	2.6	;	Structural and thermodynamic consequences of cyclization of peptide ligands for the recruitment site of cyclin A
1OH4	;	1.35	;	Structural and thermodynamic dissection of specific mannan recognition by a carbohydrate-binding module
1OF3	;	2.0	;	Structural and thermodynamic dissection of specific mannan recognition by a carbohydrate-binding module, TmCBM27
1OF4	;	1.6	;	Structural and thermodynamic dissection of specific mannan recognition by a carbohydrate-binding module, TmCBM27
4BPT	;	2.5	;	Structural and thermodynamic insight into phenylalanine hydroxylase from the human pathogen Legionella pneumophila
6HM1	;	1.54	;	Structural and thermodynamic signatures of ligand binding to an enigmatic chitinase-D from Serratia proteamaculans
4QC8	;	3.2	;	Structural annotation of pathogenic bovine Parvovirus-1
6YP6	;	0.97	;	Structural annotation of the conserved carbohydrate esterase vb_24B_21 from Shiga toxin-encoding bacteriophage phi24B
8TN9	;	3.05	;	Structural architecture of the acidic region of the B domain of coagulation factor V
1TLM	;	1.9	;	STRUCTURAL ASPECTS OF INOTROPIC BIPYRIDINE BINDING: CRYSTAL STRUCTURE DETERMINATION TO 1.9 ANGSTROMS OF THE HUMAN SERUM TRANSTHYRETIN-MILRINONE COMPLEX
1FPD	;	2.1	;	STRUCTURAL ASPECTS OF THE ALLOSTERIC INHIBITION OF FRUCTOSE-1,6-BISPHOSPHATASE BY AMP: THE BINDING OF BOTH THE SUBSTRATE ANALOGUE 2,5-ANHYDRO-D-GLUCITOL-1,6-BISPHOSPHATE AND CATALYTIC METAL IONS MONITORED BY X-RAY CRYSTALLOGRAPHY
1FPE	;	2.2	;	STRUCTURAL ASPECTS OF THE ALLOSTERIC INHIBITION OF FRUCTOSE-1,6-BISPHOSPHATASE BY AMP: THE BINDING OF BOTH THE SUBSTRATE ANALOGUE 2,5-ANHYDRO-D-GLUCITOL-1,6-BISPHOSPHATE AND CATALYTIC METAL IONS MONITORED BY X-RAY CRYSTALLOGRAPHY
1FPF	;	2.1	;	STRUCTURAL ASPECTS OF THE ALLOSTERIC INHIBITION OF FRUCTOSE-1,6-BISPHOSPHATASE BY AMP: THE BINDING OF BOTH THE SUBSTRATE ANALOGUE 2,5-ANHYDRO-D-GLUCITOL-1,6-BISPHOSPHATE AND CATALYTIC METAL IONS MONITORED BY X-RAY CRYSTALLOGRAPHY
1FPG	;	2.3	;	STRUCTURAL ASPECTS OF THE ALLOSTERIC INHIBITION OF FRUCTOSE-1,6-BISPHOSPHATASE BY AMP: THE BINDING OF BOTH THE SUBSTRATE ANALOGUE 2,5-ANHYDRO-D-GLUCITOL-1,6-BISPHOSPHATE AND CATALYTIC METAL IONS MONITORED BY X-RAY CRYSTALLOGRAPHY
3EDD	;	2.65	;	Structural base for cyclodextrin hydrolysis
3EDE	;	1.71	;	Structural base for cyclodextrin hydrolysis
3EDF	;	1.65	;	Structural base for cyclodextrin hydrolysis
3EDJ	;	1.69	;	Structural base for cyclodextrin hydrolysis
3EDK	;	1.77	;	Structural base for cyclodextrin hydrolysis
1LAF	;	2.06	;	STRUCTURAL BASES FOR MULTIPLE LIGAND SPECIFICITY OF THE PERIPLASMIC LYSINE-, ARGININE-, ORNITHINE-BINDING PROTEIN
1LAG	;	2.06	;	STRUCTURAL BASES FOR MULTIPLE LIGAND SPECIFICITY OF THE PERIPLASMIC LYSINE-, ARGININE-, ORNITHINE-BINDING PROTEIN
1LAH	;	2.06	;	STRUCTURAL BASES FOR MULTIPLE LIGAND SPECIFICITY OF THE PERIPLASMIC LYSINE-, ARGININE-, ORNITHINE-BINDING PROTEIN
6LP3	;	3.547	;	Structural basis and functional analysis epo1-bem3p complex for bud growth
6LP4	;	2.049	;	Structural basis and functional analysis epo1-bem3p complex for bud growth
4HYF	;	2.8	;	Structural basis and SAR for OD 270, a lead stage 1,2,4-triazole based specific Tankyrase1/2 inhibitor
6P2H	;	2.803	;	Structural basis for 2'-deoxyguanosine recognition by the 2'-dG-II class of riboswitches
1T2R	;		;	Structural basis for 3' end recognition of nucleic acids by the Drosophila Argonaute 2 PAZ domain
1T2S	;		;	Structural basis for 3' end recognition of nucleic acids by the Drosophila Argonaute 2 PAZ domain
1OT7	;	2.9	;	Structural Basis for 3-deoxy-CDCA Binding and Activation of FXR
1YTU	;	2.5	;	Structural basis for 5'-end-specific recognition of the guide RNA strand by the A. fulgidus PIWI protein
7KFV	;	2.102	;	Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-B12 Fab)
7KFW	;	2.792	;	Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-B3 Fab)
7KFX	;	2.226	;	Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-C2 Fab)
7KFY	;	2.157	;	Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-F10 Fab)
2CJS	;	1.78	;	Structural Basis for a Munc13-1 Homodimer - Munc13-1 - RIM Heterodimer Switch: C2-domains as Versatile Protein-Protein Interaction Modules
2CJT	;	1.44	;	Structural Basis for a Munc13-1 Homodimer - Munc13-1 - RIM Heterodimer Switch: C2-domains as Versatile Protein-Protein Interaction Modules
3NF6	;	1.9	;	Structural basis for a new mechanism of inhibition of HIV integrase identified by fragment screening and structure based design
3NF7	;	1.8	;	Structural basis for a new mechanism of inhibition of HIV integrase identified by fragment screening and structure based design
3NF8	;	1.9	;	Structural basis for a new mechanism of inhibition of HIV integrase identified by fragment screening and structure based design
3NF9	;	1.95	;	Structural basis for a new mechanism of inhibition of HIV integrase identified by fragment screening and structure based design
3NFA	;	1.95	;	Structural basis for a new mechanism of inhibition of HIV integrase identified by fragment screening and structure based design
5D46	;	2.8	;	Structural Basis for a New Templated Activity by Terminal Deoxynucleotidyl Transferase: Implications for V(D)J Recombination
5D49	;	1.99	;	Structural Basis for a New Templated Activity by Terminal Deoxynucleotidyl Transferase: Implications for V(D)J Recombination
5D4B	;	2.66	;	Structural Basis for a New Templated Activity by Terminal Deoxynucleotidyl Transferase: Implications for V(D)J Recombination
2XYO	;	3.0	;	Structural basis for a new tetracycline resistance mechanism relying on the TetX monooxygenase
2P4R	;	2.001	;	Structural basis for a novel interaction between AIP4 and beta-PIX
1U9L	;	1.9	;	Structural basis for a NusA- protein N interaction
5WZX	;	2.95	;	Structural basis for a pentacyclic oleanane-type triterpenoid as a ligand of FXR
5VBS	;	1.749	;	Structural basis for a six letter alphabet including GATCKX
5ZY9	;	2.5	;	Structural basis for a tRNA synthetase
5BN5	;	2.997	;	Structural basis for a unique ATP synthase core complex from Nanoarcheaum equitans
2QKW	;	3.2	;	Structural basis for activation of plant immunity by bacterial effector protein AvrPto
4K2R	;	3.0	;	Structural basis for activation of ZAP-70 by phosphorylation of the SH2-kinase linker
6IYZ	;	2.2	;	Structural basis for activity of TRIC counter-ion channels in calcium release
6IZ3	;	3.791	;	Structural basis for activity of TRIC counter-ion channels in calcium release
6IZF	;	2.0	;	Structural basis for activity of TRIC counter-ion channels in calcium release
5INF	;	2.751	;	Structural basis for acyl-CoA carboxylase-mediated assembly of unusual polyketide synthase extender units incorporated into the stambomycin antibiotics
5INI	;	2.85	;	Structural basis for acyl-CoA carboxylase-mediated assembly of unusual polyketide synthase extender units incorporated into the stambomycin antibiotics
3KTA	;	1.627	;	Structural Basis for Adenylate Kinase Activity in ABC ATPases
3ZR7	;	1.65	;	Structural basis for agonism and antagonism for a set of chemically related progesterone receptor modulators
3ZRA	;	1.9	;	Structural basis for agonism and antagonism for a set of chemically related progesterone receptor modulators
3ZRB	;	1.8	;	Structural basis for agonism and antagonism for a set of chemically related progesterone receptor modulators
4H6B	;	1.35	;	Structural basis for allene oxide cyclization in moss
1UXN	;	2.3	;	Structural basis for allosteric regulation and substrate specificity of the non-phosphorylating glyceraldehyde-3-phosphate dehydrogenase (GAPN) from Thermoproteus tenax
1UXP	;	2.55	;	Structural basis for allosteric regulation and substrate specificity of the non-phosphorylating glyceraldehyde-3-phosphate dehydrogenase (GAPN) from Thermoproteus tenax
1UXQ	;	2.4	;	Structural basis for allosteric regulation and substrate specificity of the non-phosphorylating glyceraldehyde-3-phosphate dehydrogenase (GAPN) from Thermoproteus tenax
1UXR	;	2.3	;	Structural basis for allosteric regulation and substrate specificity of the non-phosphorylating glyceraldehyde-3-phosphate dehydrogenase (GAPN) from Thermoproteus tenax
1UXT	;	2.2	;	Structural basis for allosteric regulation and substrate specificity of the non-phosphorylating glyceraldehyde-3-phosphate dehydrogenase (GAPN) from Thermoproteus tenax
1UXU	;	2.25	;	Structural basis for allosteric regulation and substrate specificity of the non-phosphorylating glyceraldehyde-3-phosphate dehydrogenase (GAPN) from Thermoproteus tenax
1UXV	;	2.35	;	Structural basis for allosteric regulation and substrate specificity of the non-phosphorylating glyceraldehyde-3-phosphate dehydrogenase (GAPN) from Thermoproteus tenax
1H7B	;	2.45	;	Structural basis for allosteric substrate specificity regulation in class III ribonucleotide reductases, native NRDD
1H7A	;	2.75	;	Structural basis for allosteric substrate specificity regulation in class III ribonucleotide reductases: NRDD in complex with dATP
1H78	;	2.5	;	STRUCTURAL BASIS FOR ALLOSTERIC SUBSTRATE SPECIFICITY REGULATION IN CLASS III RIBONUCLEOTIDE REDUCTASES: NRDD IN COMPLEX WITH DCTP.
1HK8	;	2.45	;	STRUCTURAL BASIS FOR ALLOSTERIC SUBSTRATE SPECIFICITY REGULATION IN CLASS III RIBONUCLEOTIDE REDUCTASES: NRDD IN COMPLEX WITH DGTP
1H79	;	2.9	;	STRUCTURAL BASIS FOR ALLOSTERIC SUBSTRATE SPECIFICITY REGULATION IN CLASS III RIBONUCLEOTIDE REDUCTASES: NRDD IN COMPLEX WITH DTTP
1TYE	;	2.9	;	Structural basis for allostery in integrins and binding of ligand-mimetic therapeutics to the platelet receptor for fibrinogen
1WZE	;	2.0	;	Structural basis for alteration of cofactor specificity of Malate dehydrogenase from Thermus flavus
1WZI	;	2.0	;	Structural basis for alteration of cofactor specificity of Malate dehydrogenase from Thermus flavus
1LE2	;	3.0	;	STRUCTURAL BASIS FOR ALTERED FUNCTION IN THE COMMON MUTANTS OF HUMAN APOLIPOPROTEIN-E
1LE4	;	2.5	;	STRUCTURAL BASIS FOR ALTERED FUNCTION IN THE COMMON MUTANTS OF HUMAN APOLIPOPROTEIN-E
2XZE	;	1.75	;	Structural basis for AMSH-ESCRT-III CHMP3 interaction
5ZMA	;	3.175	;	Structural basis for an allosteric Eya2 phosphatase inhibitor
4JYO	;	2.5	;	Structural basis for angiopoietin-1 mediated signaling initiation
4K0V	;	4.51	;	Structural basis for angiopoietin-1 mediated signaling initiation
5U68	;	3.083	;	Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus
5VK2	;	3.201	;	Structural basis for antibody-mediated neutralization of Lassa virus
5MGP	;	3.1	;	Structural basis for ArfA-RF2 mediated translation termination on stop-codon lacking mRNAs
5NJ8	;	3.3	;	Structural basis for aryl hydrocarbon receptor mediated gene activation
3LRA	;	2.95	;	Structural Basis for Assembling a Human Tripartite Complex Dlg1-MPP7-Mals3
4LG4	;	2.42	;	Structural Basis for Autoactivation of Human Mst2 Kinase and Its Regulation by RASSF5
4LGD	;	3.05	;	Structural Basis for Autoactivation of Human Mst2 Kinase and Its Regulation by RASSF5
4BHW	;	2.799	;	Structural basis for autoinhibition of the acetyltransferase activity of p300
2LO8	;		;	Structural Basis for Bifunctional Zn(II) Macrocyclic Complex Recognition of Thymine Bulges in DNA
2LOA	;		;	Structural Basis for Bifunctional Zn(II) Macrocyclic Complex Recognition of Thymine Bulges in DNA
2LO5	;		;	Structural Basis for Bifunctional Zn(II) Macrocyclic Complex Recognition of Thymine Bulges in DNA, Structure of a Thymine bulge
1OSV	;	2.5	;	STRUCTURAL BASIS FOR BILE ACID BINDING AND ACTIVATION OF THE NUCLEAR RECEPTOR FXR
4CYK	;		;	Structural basis for binding of Pan3 to Pan2 and its function in mRNA recruitment and deadenylation
7N09	;	2.0	;	Structural basis for branched substrate selectivity in a ketoreductase from Ascaris suum
3V7A	;	3.297	;	Structural basis for broad detection of genogroup II noroviruses by a monoclonal antibody that binds to a site occluded in the viral particle
2A3V	;	2.8	;	Structural basis for broad DNA-specificity in integron recombination
6EAY	;	3.72	;	Structural Basis for Broad Neutralization of Ebolaviruses by an Antibody Targeting the Glycoprotein Fusion Loop
2LPR	;	2.25	;	STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS
3LPR	;	2.15	;	STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS
5LPR	;	2.13	;	STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS
6LPR	;	2.1	;	STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS
7LPR	;	2.05	;	STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS
8LPR	;	2.25	;	STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS
9LPR	;	2.2	;	STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS
2GD5	;	2.8	;	Structural basis for budding by the ESCRTIII factor CHMP3
4MTG	;	3.296	;	Structural Basis for Ca2+ Selectivity of a Voltage-gated Calcium Channel
4MTO	;	3.402	;	Structural Basis for Ca2+ Selectivity of a Voltage-gated Calcium Channel
4MVM	;	3.1997	;	Structural Basis for Ca2+ Selectivity of a Voltage-gated Calcium Channel
4MVO	;	3.296	;	Structural Basis for Ca2+ Selectivity of a Voltage-gated Calcium Channel
4MVQ	;	3.4	;	Structural Basis for Ca2+ Selectivity of a Voltage-gated Calcium Channel
4MVR	;	3.196	;	Structural Basis for Ca2+ Selectivity of a Voltage-gated Calcium Channel
4MVS	;	3.299	;	Structural Basis for Ca2+ Selectivity of a Voltage-gated Calcium Channel
4MVU	;	3.198	;	Structural Basis for Ca2+ Selectivity of a Voltage-gated Calcium Channel
4MVZ	;	3.3	;	Structural Basis for Ca2+ Selectivity of a Voltage-gated Calcium Channel
4MW3	;	3.2997	;	Structural Basis for Ca2+ Selectivity of a Voltage-gated Calcium Channel
4MW8	;	3.256	;	Structural Basis for Ca2+ Selectivity of a Voltage-gated Calcium Channel
4Y1S	;	1.611	;	Structural basis for Ca2+-mediated interaction of the perforin C2 domain with lipid membranes
4Y1T	;	2.666	;	Structural basis for Ca2+-mediated interaction of the perforin C2 domain with lipid membranes
3Q6J	;	1.92	;	Structural basis for carbon dioxide binding by 2-ketopropyl coenzyme M Oxidoreductase/Carboxylase
5G4Y	;	2.0	;	Structural basis for carboxylic acid recognition by a Cache chemosensory domain.
5G4Z	;	1.98	;	Structural basis for carboxylic acid recognition by a Cache chemosensory domain.
3PKZ	;	1.8	;	Structural basis for catalytic activation of a serine recombinase
1XPY	;	2.3	;	Structural Basis for Catalytic Racemization and Substrate Specificity of an N-Acylamino Acid Racemase Homologue from Deinococcus radiodurans
1XS2	;	2.3	;	Structural Basis for Catalytic Racemization and Substrate Specificity of an N-Acylamino Acid Racemase Homologue from Deinococcus radiodurans
7UPZ	;	2.487	;	Structural basis for cell type specific DNA binding of C/EBPbeta: the case of cell cycle inhibitor p15INK4b promoter
6MG8	;	3.6	;	Structural basis for cholesterol transport-like activity of the Hedgehog receptor Patched
6PPT	;		;	Structural Basis for Client Recognition and Activity of Hsp40 Chaperones
6PQ2	;		;	Structural Basis for Client Recognition and Activity of Hsp40 Chaperones
6PQE	;		;	Structural Basis for Client Recognition and Activity of Hsp40 Chaperones
6PQM	;		;	Structural Basis for Client Recognition and Activity of Hsp40 Chaperones
6PRI	;		;	Structural Basis for Client Recognition and Activity of Hsp40 Chaperones
6PRJ	;		;	Structural Basis for Client Recognition and Activity of Hsp40 Chaperones
6PRP	;		;	Structural Basis for Client Recognition and Activity of Hsp40 Chaperones
6PRQ	;		;	Structural Basis for Client Recognition and Activity of Hsp40 Chaperones
6PSI	;		;	Structural Basis for Client Recognition and Activity of Hsp40 Chaperones
5WUC	;	1.6	;	Structural basis for conductance through TRIC cation channels
5WUD	;	1.9	;	Structural basis for conductance through TRIC cation channels
5WUE	;	2.4	;	Structural basis for conductance through TRIC cation channels
5WUF	;	2.401	;	Structural basis for conductance through TRIC cation channels
6SRN	;	1.5	;	Structural basis for control of antibiotic production by bacterial hormones
2PJY	;	3.0	;	Structural basis for cooperative assembly of the TGF-beta signaling complex
6PW2	;	3.01	;	Structural Basis for Cooperative Binding of EBNA1 to the Epstein-Barr Virus Dyad Symmetry Minimal Origin of Replication
2BNW	;	2.45	;	Structural basis for cooperative binding of Ribbon-Helix-Helix Omega repressor to direct DNA heptad repeats
2BNZ	;	2.6	;	Structural basis for cooperative binding of Ribbon-Helix-Helix Omega repressor to inverted DNA heptad repeats
2CAX	;	2.9	;	STRUCTURAL BASIS FOR COOPERATIVE BINDING OF RIBBON-HELIX-HELIX REPRESSOR OMEGA TO MUTATED DIRECT DNA HEPTAD REPEATS
2AGH	;		;	Structural basis for cooperative transcription factor binding to the CBP coactivator
2IW5	;	2.57	;	Structural Basis for CoREST-Dependent Demethylation of Nucleosomes by the Human LSD1 Histone Demethylase
7C8J	;	3.18	;	Structural basis for cross-species recognition of COVID-19 virus spike receptor binding domain to bat ACE2
7C8K	;	3.2	;	Structural basis for cross-species recognition of COVID-19 virus spike receptor binding domain to bat ACE2
7ML7	;	3.17	;	Structural basis for CSPG4 as a receptor for TcdB and a therapeutic target in Clostridioides difficile infection
3OMJ	;	0.95	;	Structural Basis for Cyclic Py-Im Polyamide Allosteric Inhibition of Nuclear Receptor Binding
4IG8	;	2.7	;	Structural basis for cytosolic double-stranded RNA surveillance by human OAS1
1T21	;	2.19	;	Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, variant SL9, monoclinic crystal
1T22	;	2.2	;	Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, variant SL9, orthorhombic crystal
1S8D	;	2.2	;	Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, variant SL9-3A
1T1W	;	2.2	;	Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, variant SL9-3F6I8V
1T1X	;	2.2	;	Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, variant SL9-4L
1T1Y	;	2.0	;	Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, variant SL9-5V
1T1Z	;	1.9	;	Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, variant SL9-6A
1T20	;	2.2	;	Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, variant SL9-6I
1R1P	;	1.8	;	Structural Basis for Differential Recognition of Tyrosine Phosphorylated Sites in the Linker for Activation of T cells (LAT) by the Adaptor Protein Gads
1R1Q	;	1.8	;	Structural Basis for Differential Recognition of Tyrosine Phosphorylated Sites in the Linker for Activation of T cells (LAT) by the Adaptor Protein Gads
1R1S	;	1.9	;	Structural Basis for Differential Recognition of Tyrosine Phosphorylated Sites in the Linker for Activation of T cells (LAT) by the Adaptor Protein Gads
3COQ	;	2.4	;	Structural Basis for Dimerization in DNA Recognition by Gal4
5H31	;	3.16954	;	Structural basis for dimerization of the death effector domains of Caspase-8
5H33	;	3.60014	;	Structural basis for dimerization of the death effector domains of Caspase-8
3TVT	;	1.6	;	Structural basis for Discs Large interaction with Pins
1JGU	;	1.8	;	STRUCTURAL BASIS FOR DISFAVORED ELIMINATION REACTION IN CATALYTIC ANTIBODY 1D4
1JGV	;	1.85	;	STRUCTURAL BASIS FOR DISFAVORED ELIMINATION REACTION IN CATALYTIC ANTIBODY 1D4
2BZF	;	2.87	;	Structural basis for DNA bridging by barrier-to-autointegration factor (BAF)
3QSV	;	2.708	;	Structural basis for DNA recognition by constitutive Smad4 MH1 dimers
7XVN	;	2.302	;	Structural basis for DNA recognition feature of retinoid-related orphan receptors
5A9K	;	19.0	;	Structural basis for DNA strand separation by a hexameric replicative helicase
6L3G	;	3.3	;	Structural Basis for DNA Unwinding at Forked dsDNA by two coordinating Pif1 helicases
3GOD	;	2.17	;	Structural basis for DNase activity of a conserved protein implicated in CRISPR-mediated antiviral defense
6KDU	;	2.2	;	Structural basis for domain rotation during adenylation of active site K123 and fragment library screening against NAD+ -dependent DNA ligase from Mycobacterium tuberculosis
6KJM	;	2.2	;	Structural basis for domain rotation during adenylation of active site K123 and fragment library screening against NAD+ -dependent DNA ligase from Mycobacterium tuberculosis
6KKV	;	2.56	;	Structural basis for domain rotation during adenylation of active site K123 and fragment library screening against NAD+ -dependent DNA ligase from Mycobacterium tuberculosis
6KRH	;	2.6	;	Structural basis for domain rotation during adenylation of active site K123 and fragment library screening against NAD+ -dependent DNA ligase from Mycobacterium tuberculosis
6KSC	;	2.4	;	Structural basis for domain rotation during adenylation of active site K123 and fragment library screening against NAD+ -dependent DNA ligase from Mycobacterium tuberculosis
6KSD	;	2.5	;	Structural basis for domain rotation during adenylation of active site K123 and fragment library screening against NAD+ -dependent DNA ligase from Mycobacterium tuberculosis
6LW8	;	2.401	;	Structural basis for domain rotation during adenylation of active site K123 and fragment library screening against NAD+ -dependent DNA ligase from Mycobacterium tuberculosis
2V5M	;	1.95	;	Structural basis for Dscam isoform specificity
2V5R	;	3.0	;	Structural basis for Dscam isoform specificity
2V5S	;	2.3	;	Structural basis for Dscam isoform specificity
4GL2	;	3.557	;	Structural Basis for dsRNA duplex backbone recognition by MDA5
2ZKO	;	1.7	;	Structural basis for dsRNA recognition by NS1 protein of human influenza virus A
3QTL	;	2.6	;	Structural Basis for Dual-inhibition Mechanism of a Non-classical Kazal-type Serine Protease Inhibitor from Horseshoe Crab in Complex with Subtilisin
5T0C	;	3.8	;	Structural basis for dynamic regulation of the human 26S proteasome
5T0G	;	4.4	;	Structural basis for dynamic regulation of the human 26S proteasome
5T0H	;	6.8	;	Structural basis for dynamic regulation of the human 26S proteasome
5T0I	;	8.0	;	Structural basis for dynamic regulation of the human 26S proteasome
5T0J	;	8.0	;	Structural basis for dynamic regulation of the human 26S proteasome
1KPS	;	2.5	;	Structural Basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin conjugating enzyme Ubc9 and RanGAP1
5NV8	;	2.294	;	Structural basis for EarP-mediated arginine glycosylation of translation elongation factor EF-P
4HRL	;	2.55	;	Structural Basis for Eliciting a Cytotoxic Effect in HER2-Overexpressing Cancer Cells via Binding to the Extracellular Domain of HER2
4HRM	;	3.2	;	Structural Basis for Eliciting a Cytotoxic Effect in HER2-Overexpressing Cancer Cells via Binding to the Extracellular Domain of HER2
4HRN	;	2.65	;	Structural Basis for Eliciting a Cytotoxic Effect in HER2-Overexpressing Cancer Cells via Binding to the Extracellular Domain of HER2
7N1Q	;	2.9	;	Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants
7N1T	;	3.11	;	Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants
7N1U	;	3.14	;	Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants
7N1V	;	3.21	;	Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants
7N1W	;	3.33	;	Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants
7N1X	;	4.0	;	Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants
7N1Y	;	4.3	;	Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants
2O3Q	;	1.98	;	Structural Basis for Formation and Hydrolysis of Calcium Messenger Cyclic ADP-ribose by Human CD38
2O3R	;	1.75	;	Structural Basis for Formation and Hydrolysis of Calcium Messenger Cyclic ADP-ribose by Human CD38
2O3S	;	1.5	;	Structural Basis for Formation and Hydrolysis of Calcium Messenger Cyclic ADP-ribose by Human CD38
2O3T	;	1.68	;	Structural Basis for Formation and Hydrolysis of Calcium Messenger Cyclic ADP-ribose by Human CD38
2O3U	;	2.11	;	Structural Basis for Formation and Hydrolysis of Calcium Messenger Cyclic ADP-ribose by Human CD38
4P3N	;	2.6	;	Structural Basis for Full-Spectrum Inhibition of Threonyl-tRNA Synthetase by Borrelidin 1
4P3O	;	2.505	;	Structural Basis for Full-Spectrum Inhibition of Threonyl-tRNA Synthetase by Borrelidin 2
4P3P	;	2.1	;	Structural Basis for Full-Spectrum Inhibition of Threonyl-tRNA Synthetase by Borrelidin 3
365D	;	2.0	;	STRUCTURAL BASIS FOR G C RECOGNITION IN THE DNA MINOR GROOVE
5T15	;	3.6	;	Structural basis for gating and activation of RyR1 (30 uM Ca2+ dataset, all particles)
7XDT	;	3.31	;	Structural basis for Gemin5 decamer-mediated mRNA binding
4CI4	;	2.302	;	Structural basis for GL479 a dual Peroxisome Proliferator-Activated Receptor alpha agonist
4CI5	;	1.77	;	Structural basis for GL479 a dual Peroxisome Proliferator-Activated Receptor gamma agonist
2OHV	;	2.5	;	Structural Basis for Glutamate Racemase Inhibition
2OHO	;	2.25	;	Structural Basis for Glutamate Racemase Inhibitor
2OHG	;	2.5	;	Structural Basis for Glutamte Racemase Inhibition
1KP8	;	2.0	;	Structural Basis for GroEL-assisted Protein Folding from the Crystal Structure of (GroEL-KMgATP)14 at 2.0 A Resolution
5YEW	;	3.2	;	Structural basis for GTP hydrolysis and conformational change of mitofusin 1 in mediating mitochondrial fusion
8I17	;	1.98	;	Structural basis for H2A-H2B recognitions by human Spt16
1TFZ	;	1.8	;	Structural basis for herbicidal inhibitor selectivity revealed by comparison of crystal structures of plant and mammalian 4-hydroxyphenylpyruvate dioxygenases
1L8C	;		;	STRUCTURAL BASIS FOR HIF-1ALPHA/CBP RECOGNITION IN THE CELLULAR HYPOXIC RESPONSE
2Y7I	;	1.9	;	Structural basis for high arginine specificity in Salmonella typhimurium periplasmic binding protein STM4351.
2L43	;		;	Structural basis for histone code recognition by BRPF2-PHD1 finger
2XA6	;		;	Structural basis for homodimerization of the Src-associated during mitosis, 68 kD protein (Sam68) Qua1 domain
4K12	;	1.079	;	Structural Basis for Host Specificity of Factor H Binding by Streptococcus pneumoniae
6NZK	;	2.8	;	Structural basis for human coronavirus attachment to sialic acid receptors
6OHW	;	2.9	;	Structural basis for human coronavirus attachment to sialic acid receptors. Apo-HCoV-OC43 S
3SP6	;	2.21	;	Structural basis for iloprost as a dual PPARalpha/delta agonist
3SP9	;	2.3	;	Structural basis for iloprost as a dual PPARalpha/delta agonist
3RKI	;	3.2	;	Structural basis for immunization with post-fusion RSV F to elicit high neutralizing antibody titers
2H9V	;	3.1	;	Structural basis for induced-fit binding of Rho-kinase to the inhibitor Y27632
4QOK	;	3.0	;	Structural basis for ineffective T-cell responses to MHC anchor residue improved heteroclitic peptides
3BA9	;	1.9	;	Structural Basis for Inhbition of NAD-Dependent Ligase
5TIH	;	2.44	;	Structural basis for inhibition of erythrocyte invasion by antibodies to Plasmodium falciparum protein CyRPA
5TIK	;	3.09	;	Structural basis for inhibition of erythrocyte invasion by antibodies to Plasmodium falciparum protein CyRPA
4ZG6	;	1.8	;	Structural basis for inhibition of human autotaxin by four novel compounds
4ZG7	;	1.75	;	Structural basis for inhibition of human autotaxin by four novel compounds
4ZG9	;	2.95	;	Structural basis for inhibition of human autotaxin by four novel compounds
4ZGA	;	2.6	;	Structural basis for inhibition of human autotaxin by four novel compounds
2CM7	;	2.1	;	Structural Basis for Inhibition of Protein Tyrosine Phosphatase 1B by Isothiazolidinone Heterocyclic Phosphonate Mimetics
2CM8	;	2.1	;	Structural Basis for Inhibition of Protein Tyrosine Phosphatase 1B by Isothiazolidinone Heterocyclic Phosphonate Mimetics
2CMA	;	2.3	;	Structural Basis for Inhibition of Protein Tyrosine Phosphatase 1B by Isothiazolidinone Heterocyclic Phosphonate Mimetics
2CMB	;	1.7	;	Structural Basis for Inhibition of Protein Tyrosine Phosphatase 1B by Isothiazolidinone Heterocyclic Phosphonate Mimetics
2CMC	;	2.2	;	Structural Basis for Inhibition of Protein Tyrosine Phosphatase 1B by Isothiazolidinone Heterocyclic Phosphonate Mimetics
1SQD	;	1.8	;	Structural basis for inhibitor selectivity revealed by crystal structures of plant and mammalian 4-hydroxyphenylpyruvate dioxygenases
1SQI	;	2.15	;	Structural basis for inhibitor selectivity revealed by crystal structures of plant and mammalian 4-hydroxyphenylpyruvate dioxygenases
5HOT	;	4.4	;	Structural Basis for Inhibitor-Induced Aggregation of HIV-1 Integrase
2OM7	;	7.3	;	Structural Basis for Interaction of the Ribosome with the Switch Regions of GTP-bound Elongation Factors
1XX1	;	1.75	;	Structural basis for ion-coordination and the catalytic mechanism of sphingomyelinases D
3OF9	;	1.761	;	Structural Basis for Irreversible Inhibition of Human Cathepsin L by a Diazomethylketone Inhibitor
6B5C	;	2.4	;	Structural Basis for Katanin Self-Assembly
6B5D	;	3.1	;	Structural Basis for Katanin Self-Assembly
2NDJ	;		;	Structural Basis for KCNE3 and Estrogen Modulation of the KCNQ1 Channel
3ZS5	;	1.6	;	Structural basis for kinase selectivity of three clinical p38alpha inhibitors
2ORX	;	2.4	;	Structural Basis for Ligand Binding and Heparin Mediated Activation of Neuropilin
2ORZ	;	2.15	;	Structural Basis for Ligand Binding and Heparin Mediated Activation of Neuropilin
7DPT	;	2.48	;	Structural basis for ligand binding modes of CTP synthase
7DPW	;	2.65	;	Structural basis for ligand binding modes of CTP synthase
7WIZ	;	3.2	;	Structural basis for ligand binding modes of CTP synthase
7WJ4	;	3.15	;	Structural basis for ligand binding modes of CTP synthase
3QG6	;	2.5	;	Structural Basis for Ligand Recognition and Discrimination of a Quorum Quenching Antibody
3QG7	;	2.78	;	Structural Basis for Ligand Recognition and Discrimination of a Quorum Quenching Antibody
7MDH	;	2.4	;	STRUCTURAL BASIS FOR LIGHT ACITVATION OF A CHLOROPLAST ENZYME. THE STRUCTURE OF SORGHUM NADP-MALATE DEHYDROGENASE IN ITS OXIDIZED FORM
2PR5	;	1.45	;	Structural Basis for Light-dependent Signaling in the Dimeric LOV Photosensor YtvA (Dark Structure)
2PR6	;	1.95	;	Structural Basis for Light-dependent Signaling in the Dimeric LOV Photosensor YtvA (Light Structure)
5NUO	;	3.2	;	Structural basis for maintenance of bacterial outer membrane lipid asymmetry
5NUP	;	2.9	;	Structural basis for maintenance of bacterial outer membrane lipid asymmetry
5NUQ	;	3.2	;	Structural basis for maintenance of bacterial outer membrane lipid asymmetry
5NUR	;	3.29	;	Structural basis for maintenance of bacterial outer membrane lipid asymmetry
4GHL	;	2.02	;	Structural Basis for Marburg virus VP35 mediate immune evasion mechanisms
3EY9	;	2.9	;	Structural basis for membrane binding and catalytic activation of the peripheral membrane enzyme pyruvate oxidase from Escherichia coli
3EYA	;	2.5	;	Structural basis for membrane binding and catalytic activation of the peripheral membrane enzyme pyruvate oxidase from Escherichia coli
1A2O	;	2.4	;	STRUCTURAL BASIS FOR METHYLESTERASE CHEB REGULATION BY A PHOSPHORYLATION-ACTIVATED DOMAIN
5BRM	;	2.651	;	Structural basis for Mob1-dependent activation of the core Mst-Lats kinase cascade in Hippo signaling
2LKM	;		;	Structural Basis for Molecular Interactions Involving MRG Domains: Implications in Chromatin Biology
2B87	;		;	Structural basis for molecular recognition in an affibody:affibody complex
2B88	;		;	Structural basis for molecular recognition in an affibody:affibody complex
2B89	;		;	Structural basis for molecular recognition in an affibody:affibody complex
3VIB	;	2.4	;	Structural basis for multidrug recognition and antimicrobial resistance by MTRR, an efflux pump regulator from Neisseria Gonorrhoeae
6OF0	;	2.0	;	Structural basis for multidrug recognition and antimicrobial resistance by MTRR, an efflux pump regulator from Neisseria Gonorrhoeae
4X1L	;	2.16	;	Structural basis for mutation-induced destabilization of Profilin 1 in ALS
4X1M	;	2.17	;	Structural basis for mutation-induced destabilization of Profilin 1 in ALS
4X25	;	2.23	;	Structural basis for mutation-induced destabilization of Profilin 1 in ALS
2VC5	;	2.6	;	Structural basis for natural lactonase and promiscuous phosphotriesterase activities
2VC7	;	2.05	;	Structural basis for natural lactonase and promiscuous phosphotriesterase activities
8BOB	;	2.94	;	Structural basis for negative regulation of the maltose system
7CAB	;	3.52	;	Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
1SZC	;	1.75	;	Structural basis for nicotinamide cleavage and ADP-ribose transfer by NAD+-dependent Sir2 histone/protein deacetylases
1SZD	;	1.5	;	Structural basis for nicotinamide cleavage and ADP-ribose transfer by NAD+-dependent Sir2 histone/protein deacetylases
2OD9	;	2.05	;	Structural Basis for Nicotinamide Inhibition and Base Exchange in Sir2 Enzymes
1WK9	;	1.75	;	Structural basis for non-cognate amino acid discrimination by the valyl-tRNA synthetase editing domain
1WKA	;	1.7	;	Structural basis for non-cognate amino acid discrimination by the valyl-tRNA synthetase editing domain
2J0F	;	2.31	;	Structural basis for non-competitive product inhibition in human thymidine phosphorylase: implication for drug design
3RY8	;	1.4	;	Structural basis for norovirus inhibition and fucose mimicry by citrate
5KW9	;	2.3	;	Structural Basis for Norovirus Neutralization by a HBGA Blocking Human IgA Antibody
1SK7	;	1.6	;	Structural Basis for Novel Delta-Regioselective Heme Oxygenation in the Opportunistic Pathogen Pseudomonas aeruginosa
2H3A	;		;	Structural basis for nucleic acid and toxin recognition of the bacterial antitoxin CcdA
2H3C	;		;	Structural basis for nucleic acid and toxin recognition of the bacterial antitoxin CcdA
5OFT	;	3.2	;	Structural basis for OXA-48 dimerization
6GOA	;	2.55	;	Structural basis for OXA-48 dimerization - R189A mutant
4I7H	;	2.0	;	Structural basis for peroxide sensing and gene regulation by PerR from Streptococcus pyogenes
1Y19	;	2.6	;	Structural basis for phosphatidylinositol phosphate kinase type I-gamma binding to talin at focal adhesions
4MXP	;	1.83	;	Structural Basis for PI(4)P-Specific Membrane Recruitment of the Legionella pneumophila Effector DrrA/SidM
1IDX	;		;	Structural Basis for Poor Excision from Hairpin DNA: NMR Study
1II1	;		;	Structural Basis for Poor Uracil Excision from Hairpin DNA: NMR Study
6C6K	;	2.54	;	Structural basis for preferential recognition of cap 0 RNA by a human IFIT1-IFIT3 protein complex
4ZTU	;	3.299	;	Structural basis for processivity and antiviral drug toxicity in human mitochondrial DNA replicase
4ZTZ	;	3.442	;	Structural basis for processivity and antiviral drug toxicity in human mitochondrial DNA replicase
3NGD	;	2.8	;	Structural Basis for Proficient Incorporation of dTTP Opposite O6-methylguanine by Human DNA Polymerase Iota
3OSN	;	1.9	;	Structural Basis for Proficient Incorporation of dTTP Opposite O6-Methylguanine by Human DNA Polymerase Iota
3AKA	;	1.8	;	Structural basis for prokaryotic calcium-mediated regulation by a Streptomyces coelicolor calcium-binding protein
3AKB	;	1.5	;	Structural basis for prokaryotic calcium-mediated regulation by a Streptomyces coelicolor calcium-binding protein
6DB8	;	1.86541	;	Structural basis for promiscuous binding and activation of fluorogenic dyes by DIR2s RNA aptamer
6DB9	;	2.025	;	Structural basis for promiscuous binding and activation of fluorogenic dyes by DIR2s RNA aptamer
2XU7	;	1.9	;	Structural basis for RbAp48 binding to FOG-1
5ZMC	;	2.99	;	Structural Basis for Reactivation of -146C>T Mutant TERT Promoter by cooperative binding of p52 and ETS1/2
1PKH	;	1.42	;	STRUCTURAL BASIS FOR RECOGNITION AND CATALYSIS BY THE BIFUNCTIONAL DCTP DEAMINASE AND DUTPASE FROM METHANOCOCCUS JANNASCHII
1PKJ	;	2.1	;	Structural basis for recognition and catalysis by the bifunctional dCTP deaminase and dUTPase from Methanococcus jannaschii
1PKK	;	1.77	;	Structural basis for recognition and catalysis by the bifunctional dCTP deaminase and dUTPase from Methanococcus jannaschii
6RA2	;	2.3	;	Structural basis for recognition and ring-cleavage of the Pseudomonas quinolone signal (PQS) by AqDC
6RA3	;	2.0	;	Structural basis for recognition and ring-cleavage of the Pseudomonas quinolone signal (PQS) by AqDC in complex with its product
6RB3	;	2.3	;	Structural basis for recognition and ring-cleavage of the Pseudomonas quinolone signal (PQS) by AqdC variant in complex with its substrate
407D	;	2.2	;	STRUCTURAL BASIS FOR RECOGNITION OF A-T AND T-A BASE PAIRS IN THE MINOR GROOVE OF B-DNA
408D	;	2.1	;	STRUCTURAL BASIS FOR RECOGNITION OF A-T AND T-A BASE PAIRS IN THE MINOR GROOVE OF B-DNA
5W6Q	;	2.66	;	Structural basis for recognition of artificial DNA by an evolved KlenTaq variant
2L5A	;		;	Structural basis for recognition of centromere specific histone H3 variant by nonhistone Scm3
6C0B	;	2.5	;	Structural basis for recognition of frizzled proteins by Clostridium difficile toxin B
5YU0	;	1.92	;	Structural basis for recognition of L-lysine, L-ornithine, and L-2,4-diamino butyric acid by lysine cyclodeaminase
5YU1	;	1.923	;	Structural basis for recognition of L-lysine, L-ornithine, and L-2,4-diamino butyric acid by lysine cyclodeaminase
5YU3	;	1.79	;	Structural basis for recognition of L-lysine, L-ornithine, and L-2,4-diamino butyric acid by lysine cyclodeaminase
5YU4	;	2.144	;	Structural basis for recognition of L-lysine, L-ornithine, and L-2,4-diamino butyric acid by lysine cyclodeaminase
2IAL	;	1.92	;	Structural basis for recognition of mutant self by a tumor-specific, MHC class II-restricted TCR
2IAM	;	2.8	;	Structural basis for recognition of mutant self by a tumor-specific, MHC class II-restricted TCR
2IAN	;	2.8	;	Structural basis for recognition of mutant self by a tumor-specific, MHC class II-restricted TCR
2BBQ	;	2.3	;	STRUCTURAL BASIS FOR RECOGNITION OF POLYGLUTAMYL FOLATES BY THYMIDYLATE SYNTHASE
1K1G	;		;	STRUCTURAL BASIS FOR RECOGNITION OF THE INTRON BRANCH SITE RNA BY SPLICING FACTOR 1
1RGO	;		;	Structural Basis for Recognition of the mRNA Class II AU-Rich Element by the Tandem Zinc Finger Domain of TIS11d
1EI2	;		;	STRUCTURAL BASIS FOR RECOGNITION OF THE RNA MAJOR GROOVE IN THE TAU EXON 10 SPLICING REGULATORY ELEMENT BY AMINOGLYCOSIDE ANTIBIOTICS
1YTY	;	2.29	;	Structural basis for recognition of UUUOH 3'-terminii of nascent RNA pol III transcripts by La autoantigen
1ZH5	;	1.85	;	Structural basis for recognition of UUUOH 3'-terminii of nascent RNA pol III transcripts by La autoantigen
4HMY	;	7.0	;	Structural basis for recruitment and activation of the AP-1 clathrin adaptor complex by Arf1
1Y8X	;	2.4	;	Structural basis for recruitment of Ubc12 by an E2-binding domain in NEDD8's E1
4LC9	;	3.4	;	Structural Basis for Regulation of Human Glucokinase by Glucokinase Regulatory Protein
4O14	;	1.871	;	Structural Basis for Resistance to Diverse Classes of NAMPT Inhibitors
4O16	;	1.783	;	Structural Basis for Resistance to Diverse Classes of NAMPT Inhibitors
4O17	;	1.82	;	Structural Basis for Resistance to Diverse Classes of NAMPT Inhibitors
4O18	;	1.92	;	Structural Basis for Resistance to Diverse Classes of NAMPT Inhibitors
4O1D	;	1.705	;	Structural Basis for Resistance to Diverse Classes of NAMPT Inhibitors
4O28	;	2.0	;	Structural Basis for Resistance to Diverse Classes of NAMPT Inhibitors
3OF8	;	2.2	;	Structural Basis for Reversible and Irreversible Inhibition of Human Cathepsin L by their Respective Dipeptidyl Glyoxal and Diazomethylketone Inhibitors
5E3H	;	2.7	;	Structural Basis for RNA Recognition and Activation of RIG-I
2DB3	;	2.2	;	Structural basis for RNA unwinding by the DEAD-box protein Drosophila Vasa
7M4R	;	3.65	;	Structural basis for SARS-CoV-2 envelope protein in recognition of human cell junction protein PALS1
6H8Q	;	3.631	;	Structural basis for Scc3-dependent cohesin recruitment to chromatin
2E31	;	2.4	;	Structural basis for selection of glycosylated substrate by SCFFbs1 ubiquitin ligase
2E32	;	3.52	;	Structural basis for selection of glycosylated substrate by SCFFbs1 ubiquitin ligase
2E33	;	2.7	;	Structural basis for selection of glycosylated substrate by SCFFbs1 ubiquitin ligase
1C5L	;	1.47	;	STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5M	;	1.95	;	STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5N	;	1.5	;	STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5O	;	1.9	;	STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5P	;	1.43	;	STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5Q	;	1.43	;	STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5R	;	1.47	;	STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5S	;	1.36	;	STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5T	;	1.37	;	STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5U	;	1.37	;	STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5V	;	1.48	;	STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5W	;	1.94	;	STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5X	;	1.75	;	STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5Y	;	1.65	;	STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5Z	;	1.85	;	STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
5WE0	;	2.3	;	Structural Basis for Shelterin Bridge Assembly
5WE1	;	3.202	;	Structural Basis for Shelterin Bridge Assembly
1ZUH	;	1.8	;	Structural Basis for Shikimate-binding Specificity of Helicobacter pylori Shikimate Kinase
1ZUI	;	2.3	;	Structural Basis for Shikimate-binding Specificity of Helicobacter pylori Shikimate Kinase
4XW2	;	2.001	;	Structural basis for simvastatin competitive antagonism of complement receptor 3
4OIV	;	1.7	;	Structural basis for small molecule NDB as a selective antagonist of FXR
1PFB	;	1.4	;	Structural Basis for specific binding of polycomb chromodomain to histone H3 methylated at K27
6UMX	;	2.79	;	Structural basis for specific inhibition of extracellular activation of pro/latent myostatin by SRK-015
5Z82	;	1.694	;	Structural basis for specific inhibition of highly sensitive ShHTL7 receptor
5Z89	;	1.42	;	Structural basis for specific inhibition of highly sensitive ShHTL7 receptor
5Z8P	;	1.35	;	Structural basis for specific inhibition of highly sensitive ShHTL7 receptor
5Z95	;	1.2	;	Structural basis for specific inhibition of highly sensitive ShHTL7 receptor
1H3H	;		;	Structural Basis for Specific Recognition of an RxxK-containing SLP-76 peptide by the Gads C-terminal SH3 domain
3A7Q	;	2.6	;	Structural basis for specific recognition of reelin by its receptors
5EFT	;	2.5	;	Structural Basis for Specific Recognition of ssDNA by SRBSDV P9-1 Octamers
3DEO	;	1.5	;	Structural basis for specific substrate recognition by the chloroplast signal recognition particle protein cpSRP43
3DEP	;	2.7	;	Structural basis for specific substrate recognition by the chloroplast signal recognition particle protein cpSRP43
1A94	;	2.0	;	STRUCTURAL BASIS FOR SPECIFICITY OF RETROVIRAL PROTEASES
2KGP	;		;	Structural basis for stabilization of the tau pre-mRNA splicing regulatory element by Novantrone (Mitoxantrone)
2CFC	;	1.8	;	structural basis for stereo selectivity in the (R)- and (S)- hydroxypropylethane thiosulfonate dehydrogenases
3B96	;	1.91	;	Structural Basis for Substrate Fatty-Acyl Chain Specificity: Crystal Structure of Human Very-Long-Chain Acyl-CoA Dehydrogenase
3NVK	;	3.209	;	Structural basis for substrate placement by an archaeal box C/D ribonucleoprotein particle
3NVM	;	3.408	;	Structural basis for substrate placement by an archaeal box C/D ribonucleoprotein particle
4ICQ	;	2.25	;	Structural basis for substrate recognition and reaction mechanism of bacterial aminopeptidase peps
4ICR	;	2.17	;	Structural basis for substrate recognition and reaction mechanism of bacterial aminopeptidase peps
4FYF	;	2.424	;	Structural basis for substrate recognition by a novel Legionella phosphoinositide phosphatase
4FYG	;	2.822	;	Structural basis for substrate recognition by a novel Legionella phosphoinositide phosphatase
2Y24	;	1.39	;	STRUCTURAL BASIS FOR SUBSTRATE RECOGNITION BY ERWINIA CHRYSANTHEMI GH5 GLUCURONOXYLANASE
2WN4	;	1.85	;	Structural Basis for Substrate Recognition in the Enzymatic Component of ADP-ribosyltransferase Toxin CDTa from Clostridium difficile
2WN5	;	1.9	;	Structural Basis for Substrate Recognition in the Enzymatic Component of ADP-ribosyltransferase Toxin CDTa from Clostridium difficile
2WN6	;	1.96	;	Structural Basis for Substrate Recognition in the Enzymatic Component of ADP-ribosyltransferase Toxin CDTa from Clostridium difficile
2WN7	;	2.25	;	Structural Basis for Substrate Recognition in the Enzymatic Component of ADP-ribosyltransferase Toxin CDTa from Clostridium difficile
2WN8	;	2.0	;	Structural Basis for Substrate Recognition in the Enzymatic Component of ADP-ribosyltransferase Toxin CDTa from Clostridium difficile
1S0V	;	3.2	;	Structural basis for substrate selection by T7 RNA polymerase
4EIR	;	1.1	;	Structural basis for substrate targeting and catalysis by fungal polysaccharide monooxygenases (PMO-2)
4EIS	;	1.37	;	Structural basis for substrate targeting and catalysis by fungal polysaccharide monooxygenases (PMO-3)
1MAL	;	3.1	;	STRUCTURAL BASIS FOR SUGAR TRANSLOCATION THROUGH MALTOPORIN CHANNELS AT 3.1 ANGSTROMS RESOLUTION
7OAS	;	1.819	;	Structural basis for targeted p97 remodeling by ASPL as prerequisite for p97 trimethylation by METTL21D
7OAT	;	2.995	;	Structural basis for targeted p97 remodelling by ASPL as prerequisite for p97 trimethylation by METTL21D
4UE4	;	7.0	;	Structural basis for targeting and elongation arrest of Bacillus signal recognition particle
4UE5	;	9.0	;	Structural basis for targeting and elongation arrest of Bacillus signal recognition particle
4NNG	;	2.02	;	Structural basis for targeting the ribosomal protein S1 of Mycobacterium tuberculosis by pyrazinamide
4NNH	;	2.3	;	Structural basis for targeting the ribosomal protein S1 of Mycobacterium tuberculosis by pyrazinamide
4NNI	;	2.64	;	Structural basis for targeting the ribosomal protein S1 of Mycobacterium tuberculosis by pyrazinamide
4NNK	;	2.31	;	Structural basis for targeting the ribosomal protein S1 of Mycobacterium tuberculosis by pyrazinamide
5WE2	;	2.5	;	Structural Basis for Telomere Length Regulation by the Shelterin Bridge
3J25	;	7.2	;	Structural basis for TetM-mediated tetracycline resistance
1Q2J	;		;	Structural basis for tetrodotoxin-resistant sodium channel binding by mu-conotoxin SmIIIA
6UML	;	3.58	;	Structural Basis for Thalidomide Teratogenicity Revealed by the Cereblon-DDB1-SALL4-Pomalidomide Complex
1K2G	;		;	Structural basis for the 3'-terminal guanosine recognition by the group I intron
4G1D	;	2.9	;	Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear Receptor
4G1Y	;	2.85	;	Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear Receptor
4G1Z	;	2.5	;	Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear Receptor
4G20	;	2.9	;	Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear Receptor
4G21	;	2.9	;	Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear Receptor
4G2H	;	2.5	;	Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear Receptor
4G2I	;	1.8	;	Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear Receptor
2A5D	;	1.8	;	Structural basis for the activation of cholera toxin by human ARF6-GTP
1PYG	;	2.87	;	STRUCTURAL BASIS FOR THE ACTIVATION OF GLYCOGEN PHOSPHORYLASE B BY ADENOSINE MONOPHOSPHATE
6PBC	;	2.46	;	Structural basis for the activation of PLC-gamma isozymes by phosphorylation and cancer-associated mutations
4E7X	;	3.2	;	Structural Basis for the Activity of a Cytoplasmic RNA Terminal U-transferase
4E80	;	3.02	;	Structural Basis for the Activity of a Cytoplasmic RNA Terminal U-transferase
4E8F	;	2.6	;	Structural Basis for the Activity of a Cytoplasmic RNA Terminal U-transferase
2QIA	;	1.74	;	Structural basis for the acyl chain selectivity and mechanism of UDP-N-acetylglucosamine Acyltransferase
2QIV	;	1.85	;	Structural basis for the acyl chain selectivity and mechanism of UDP-N-acetylglucosamine acyltransferase
2Y0R	;	2.85	;	Structural basis for the allosteric interference of myosin function by mutants G680A and G680V of Dictyostelium myosin-2
2Y8I	;	3.132	;	Structural basis for the allosteric interference of myosin function by mutants G680A and G680V of Dictyostelium myosin-2
2Y9E	;	3.397	;	Structural basis for the allosteric interference of myosin function by mutants G680A and G680V of Dictyostelium myosin-2
1GOZ	;	2.0	;	Structural basis for the altered T-cell receptor binding specificty in a superantigenic staphylococcus aureus Enterotoxin-B mutant
3UYU	;	1.57	;	Structural basis for the antifreeze activity of an ice-binding protein (LeIBP) from Arctic yeast
4PXT	;	2.9	;	Structural basis for the assembly of the mitotic motor kinesin-5 into bipolar tetramers
4PXU	;	2.601	;	Structural basis for the assembly of the mitotic motor kinesin-5 into bipolar tetramers
4QQB	;	2.8	;	Structural basis for the assembly of the SXL-UNR translation regulatory complex
1OPJ	;	1.75	;	Structural basis for the auto-inhibition of c-Abl tyrosine kinase
1OPK	;	1.8	;	Structural basis for the auto-inhibition of c-Abl tyrosine kinase
1OPL	;	3.42	;	Structural basis for the auto-inhibition of c-Abl tyrosine kinase
1T45	;	1.9	;	STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C-KIT TYROSINE KINASE
1T46	;	1.6	;	STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C-KIT TYROSINE KINASE
3H90	;	2.9	;	Structural basis for the autoregulation of the zinc transporter YiiP
5GP7	;	1.502	;	Structural basis for the binding between Tankyrase-1 and USP25
1FV1	;	1.9	;	STRUCTURAL BASIS FOR THE BINDING OF AN IMMUNODOMINANT PEPTIDE FROM MYELIN BASIC PROTEIN IN DIFFERENT REGISTERS BY TWO HLA-DR2 ALLELES
6WN4	;	2.8	;	Structural basis for the binding of monoclonal antibody 5D2 to the tryptophan-rich lipid-binding loop in lipoprotein lipase
6WT3	;	2.85	;	Structural basis for the binding of monoclonal antibody 5D2 to the tryptophan-rich lipid-binding loop in lipoprotein lipase
3IE3	;	1.8	;	Structural basis for the binding of the anti-cancer compound 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) to human glutathione S-transferases
2QDT	;	2.0	;	Structural Basis for the Broad-Spectrum Inhibition of Metallo-{Beta}-Lactamases: L1- IS38 Complex
3OTF	;	2.4	;	Structural basis for the cAMP-dependent gating in human HCN4 channel
1AKA	;	2.1	;	STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING ITS PYRIDOXAL-5'-PHOSPHATE-BINDING LYSINE RESIDUE
1AKB	;	2.3	;	STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING ITS PYRIDOXAL-5'-PHOSPHATE-BINDING LYSINE RESIDUE
1AKC	;	2.3	;	Structural basis for the catalytic activity of aspartate aminotransferase K258H lacking its pyridoxal-5'-phosphate-binding lysine residue
1AIA	;	2.2	;	STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE
1AIB	;	2.8	;	STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE
1AIC	;	2.4	;	STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE
5JXU	;	1.751	;	Structural basis for the catalytic activity of Thermomonospora curvata heme-containing DyP-type peroxidase.
2Z8M	;	2.0	;	Structural basis for the catalytic mechanism of phosphothreonine lyase
2Z8N	;	1.8	;	Structural basis for the catalytic mechanism of phosphothreonine lyase
2Z8O	;	2.4	;	Structural basis for the catalytic mechanism of phosphothreonine lyase
2Z8P	;	1.8	;	Structural basis for the catalytic mechanism of phosphothreonine lyase
3GEQ	;	2.2	;	Structural basis for the chemical rescue of Src kinase activity
7V1M	;	2.834	;	Structural basis for the co-chaperone relationship of sNASP and ASF1b
4A5T	;	3.49	;	STRUCTURAL BASIS FOR THE CONFORMATIONAL MODULATION
1JMK	;	1.71	;	Structural Basis for the Cyclization of the Lipopeptide Antibiotic Surfactin by the Thioesterase Domain SrfTE
1X2J	;	1.6	;	Structural basis for the defects of human lung cancer somatic mutations in the repression activity of Keap1 on Nrf2
1X2R	;	1.7	;	Structural basis for the defects of human lung cancer somatic mutations in the repression activity of Keap1 on Nrf2
4FVU	;	2.91	;	Structural basis for the dsRNA specificity of the Lassa virus NP exonuclease
5ZWQ	;	1.797	;	Structural Basis for the Enantioselectivity of Est-Y29 toward (S)-ketoprofen
5ZWR	;	1.69	;	Structural Basis for the Enantioselectivity of Est-Y29 toward (S)-ketoprofen
5ZWV	;	2.099	;	Structural Basis for the Enantioselectivity of Est-Y29 toward (S)-ketoprofen
4OW5	;	1.9	;	Structural basis for the enhancement of virulence by entomopoxvirus fusolin and its in vivo crystallization into viral spindles
4X27	;	2.4	;	Structural basis for the enhancement of virulence by entomopoxvirus fusolin and its in vivo crystallization into viral spindles (complex with Copper)
4X29	;	2.405	;	Structural basis for the enhancement of virulence by entomopoxvirus fusolin and its in vivo crystallization into viral spindles (complex with Zinc)
1RQ5	;	2.4	;	Structural Basis for the Exocellulase Activity of the Cellobiohydrolase CbhA from C. thermocellum
1UT9	;	2.1	;	Structural Basis for the Exocellulase Activity of the Cellobiohydrolase CbhA from C. thermocellum
1ZKJ	;	1.55	;	Structural Basis for the Extended Substrate Spectrum of CMY-10, a Plasmid-Encoded Class C beta-lactamase
1ESM	;	2.5	;	STRUCTURAL BASIS FOR THE FEEDBACK REGULATION OF ESCHERICHIA COLI PANTOTHENATE KINASE BY COENZYME A
1ESN	;	2.6	;	STRUCTURAL BASIS FOR THE FEEDBACK REGULATION OF ESCHERICHIA COLI PANTOTHENATE KINASE BY COENZYME A
3QLE	;	1.831	;	Structural Basis for the Function of Tim50 in the Mitochondrial Presequence Translocase
3S35	;	2.2	;	Structural basis for the function of two anti-VEGF receptor antibodies
3S36	;	3.2	;	Structural basis for the function of two anti-VEGF receptor antibodies
3S37	;	2.7	;	Structural basis for the function of two anti-VEGF receptor antibodies
1GS4	;	1.95	;	Structural basis for the glucocorticoid response in a mutant human androgen receptor (ARccr) derived from an androgen-independent prostate cancer
2ZS0	;	1.6	;	Structural Basis for the Heterotropic and Homotropic Interactions of Invertebrate Giant Hemoglobin
2ZS1	;	1.7	;	Structural Basis for the Heterotropic and Homotropic Interactions of Invertebrate Giant Hemoglobin
5JH5	;	2.55	;	Structural Basis for the Hierarchical Assembly of the Core of PRC1.1
3UIM	;	2.2	;	Structural basis for the impact of phosphorylation on plant receptor-like kinase BAK1 activation
1BLP	;	2.3	;	STRUCTURAL BASIS FOR THE INACTIVATION OF THE P54 MUTANT OF BETA-LACTAMASE FROM STAPHYLOCOCCUS AUREUS PC1
5DIN	;	1.864	;	Structural Basis for the Indispensable Role of a Unique Zinc Finger Motif in LNX2 Ubiquitination
2NP8	;	2.25	;	Structural Basis for the Inhibition of Aurora A Kinase by a Novel Class of High Affinity Disubstituted Pyrimidine Inhibitors
3W9H	;	3.05	;	Structural basis for the inhibition of bacterial multidrug exporters
3W9I	;	2.71	;	Structural basis for the inhibition of bacterial multidrug exporters
3W9J	;	3.15	;	Structural basis for the inhibition of bacterial multidrug exporters
3BA8	;	1.9	;	Structural Basis for the Inhibition of Bacterial NAD+ Dependent DNA Ligase
3BAA	;	1.9	;	Structural Basis for the Inhibition of Bacterial NAD+ Dependent DNA Ligase
3BAB	;	2.5	;	Structural Basis for the Inhibition of Bacterial NAD+ Dependent DNA Ligase
3BAC	;	3.0	;	Structural Basis for the Inhibition of Bacterial NAD+ Dependent DNA Ligase
6G9F	;	2.35	;	Structural basis for the inhibition of E. coli PBP2
6G9P	;	2.101	;	Structural basis for the inhibition of E. coli PBP2
6G9S	;	2.001	;	Structural basis for the inhibition of E. coli PBP2
2DSP	;	2.5	;	Structural Basis for the Inhibition of Insulin-like Growth Factors by IGF Binding Proteins
2DSQ	;	2.8	;	Structural Basis for the Inhibition of Insulin-like Growth Factors by IGF Binding Proteins
2DSR	;	2.1	;	Structural Basis for the Inhibition of Insulin-like Growth Factors by IGF Binding Proteins
1U0H	;	2.9	;	STRUCTURAL BASIS FOR THE INHIBITION OF MAMMALIAN ADENYLYL CYCLASE BY MANT-GTP
4GSQ	;	1.8	;	Structural basis for the inhibition of Mycobacterium tuberculosis L,D-transpeptidase by meropenem, a drug effective against extensively drug-resistant strains
4GSR	;	1.79	;	Structural basis for the inhibition of Mycobacterium tuberculosis L,D-transpeptidase by meropenem, a drug effective against extensively drug-resistant strains
4GSU	;	2.0	;	Structural basis for the inhibition of Mycobacterium tuberculosis L,D-transpeptidase by meropenem, a drug effective against extensively drug-resistant strains
2N8H	;		;	Structural basis for the inhibition of voltage-gated sodium channels with conotoxin-muOxi-GVIIJ
3ITF	;	1.45	;	Structural basis for the inhibitory function of the CPXP adaptor protein
5SXP	;	1.65	;	STRUCTURAL BASIS FOR THE INTERACTION BETWEEN ITCH PRR AND BETA-PIX
5WFU	;	1.97	;	Structural basis for the interaction of 14-3-3beta with Tricarboxylic Acid Cycle intermediate Malate
5WFX	;	1.651	;	Structural basis for the interaction of 14-3-3beta with Tricarboxylic Acid Cycle intermediate Malate
1J5A	;	3.5	;	STRUCTURAL BASIS FOR THE INTERACTION OF ANTIBIOTICS WITH THE PEPTIDYL TRANSFERASE CENTER IN EUBACTERIA
1JZX	;	3.1	;	Structural Basis for the Interaction of Antibiotics with the Peptidyl Transferase Center in Eubacteria
1JZY	;	3.5	;	Structural Basis for the Interaction of Antibiotics with the Peptidyl Transferase Center in Eubacteria
1JZZ	;	3.8	;	Structural Basis for the Interaction of Antibiotics with the Peptidyl Transferase Center in Eubacteria
1K01	;	3.5	;	Structural Basis for the Interaction of Antibiotics with the Peptidyl Transferase Center in Eubacteria
2LWL	;		;	Structural Basis for the Interaction of Human &#946;-Defensin 6 and Its Putative Chemokine Receptor CCR2 and Breast Cancer Microvesicles
2X71	;	2.1	;	Structural basis for the interaction of lactivicins with serine beta- lactamases
3U3F	;	3.101	;	Structural basis for the interaction of Pyk2 PAT domain with paxillin LD motifs
2EVA	;	2.0	;	Structural Basis for the Interaction of TAK1 Kinase with its Activating Protein TAB1
1TDQ	;	2.6	;	Structural basis for the interactions between tenascins and the C-type lectin domains from lecticans: evidence for a cross-linking role for tenascins
4ANI	;	4.094	;	Structural basis for the intermolecular communication between DnaK and GrpE in the DnaK chaperone system from Geobacillus kaustophilus HTA426
3BVE	;	1.8	;	Structural basis for the iron uptake mechanism of Helicobacter pylori ferritin
3BVF	;	1.5	;	Structural basis for the iron uptake mechanism of Helicobacter pylori ferritin
3BVI	;	2.0	;	Structural basis for the iron uptake mechanism of Helicobacter pylori ferritin
3BVK	;	1.5	;	Structural basis for the iron uptake mechanism of Helicobacter pylori ferritin
3BVL	;	1.8	;	Structural basis for the iron uptake mechanism of Helicobacter pylori ferritin
5JT8	;	2.1	;	Structural basis for the limited antibody cross reactivity between the mite allergens Blo t 1 and Der p 1
1S7G	;	2.3	;	Structural Basis for the Mechanism and Regulation of Sir2 Enzymes
2I65	;	1.9	;	Structural Basis for the Mechanistic Understanding Human CD38 Controlled Multiple Catalysis
2I66	;	1.7	;	Structural Basis for the Mechanistic Understanding Human CD38 Controlled Multiple Catalysis
2I67	;	1.71	;	Structural Basis for the Mechanistic Understanding Human CD38 Controlled Multiple Catalysis
4C9Y	;	2.01	;	Structural Basis for the microtubule binding of the human kinetochore Ska complex
4CA0	;	2.259	;	Structural Basis for the microtubule binding of the human kinetochore Ska complex
4MN4	;	2.3	;	Structural Basis for the MukB-topoisomerase IV Interaction
3M4W	;	2.3	;	Structural basis for the negative regulation of bacterial stress response by RseB
1F8A	;	1.84	;	STRUCTURAL BASIS FOR THE PHOSPHOSERINE-PROLINE RECOGNITION BY GROUP IV WW DOMAINS
2KLI	;		;	Structural Basis for the Photoconversion of A Phytochrome to the Activated FAR-RED LIGHT-ABSORBING Form
1QXD	;	2.25	;	Structural Basis for the Potent Antisickling Effect of a Novel Class of 5-Membered Heterocyclic Aldehydic Compounds
1QXE	;	1.85	;	Structural Basis for the Potent Antisickling Effect of a Novel Class of 5-Membered Heterocyclic Aldehydic Compounds
1PEG	;	2.59	;	Structural basis for the product specificity of histone lysine methyltransferases
2C26	;	2.1	;	Structural basis for the promiscuous specificity of the carbohydrate- binding modules from the beta-sandwich super family
2C4X	;	2.0	;	Structural basis for the promiscuous specificity of the carbohydrate- binding modules from the beta-sandwich super family
2B4J	;	2.02	;	Structural basis for the recognition between HIV-1 integrase and LEDGF/p75
1JN5	;	2.8	;	Structural basis for the recognition of a nucleoporin FG-repeat by the NTF2-like domain of TAP-p15 mRNA export factor
1JKG	;	1.9	;	Structural basis for the recognition of a nucleoporin FG-repeat by the NTF2-like domain of TAP-p15 mRNA nuclear export factor
3RMP	;	2.21	;	Structural basis for the recognition of attP substrates by P4-like integrases
3D7T	;	2.899	;	Structural basis for the recognition of c-Src by its inactivator Csk
3D7U	;	4.111	;	Structural basis for the recognition of c-Src by its inactivator Csk
4OT1	;	2.11	;	Structural Basis for the Recognition of Human Cytomegalovirus Glycoprotein B by the Neutralizing Human Antibody SM5-1
2DOS	;		;	Structural basis for the recognition of Lys48-linked polyubiquitin chain by the Josephin domain of ataxin-3, a putative deubiquitinating enzyme
4E41	;	2.6	;	Structural basis for the recognition of mutant self by a tumor-specific, MHC class II-restricted T cell receptor G4
4E42	;	2.7	;	Structural basis for the recognition of mutant self by a tumor-specific, MHC class II-restricted T cell receptor G4
4QLB	;	2.6	;	Structural Basis for the Recruitment of Glycogen Synthase by Glycogenin
6KEY	;	1.24	;	Structural basis for the regulation of inducible nitric oxide synthase (iNOS) by the SPRY domain-containing SOCS box protein 2 (SPSB2)
1WQJ	;	1.6	;	Structural Basis for the Regulation of Insulin-Like Growth Factors (IGFs) by IGF Binding Proteins (IGFBPs)
2RD5	;	2.51	;	Structural basis for the regulation of N-acetylglutamate kinase by PII in Arabidopsis thaliana
2K8F	;		;	Structural Basis for the Regulation of p53 Function by p300
2FCI	;		;	Structural basis for the requirement of two phosphotyrosines in signaling mediated by Syk tyrosine kinase
1UKH	;	2.35	;	Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125
1UKI	;	2.7	;	Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125
5CM8	;	2.6	;	Structural Basis for the Selectivity of Guanine Nucleotide Exchange Factors for the small G-protein Ral
5CM9	;	2.6	;	Structural Basis for the Selectivity of Guanine Nucleotide Exchange Factors for the small G-protein Ral
3EYY	;	2.4	;	Structural basis for the specialization of Nur, a nickel-specific Fur homologue, in metal sensing and DNA recognition
1CKA	;	1.5	;	STRUCTURAL BASIS FOR THE SPECIFIC INTERACTION OF LYSINE-CONTAINING PROLINE-RICH PEPTIDES WITH THE N-TERMINAL SH3 DOMAIN OF C-CRK
1CKB	;	1.9	;	STRUCTURAL BASIS FOR THE SPECIFIC INTERACTION OF LYSINE-CONTAINING PROLINE-RICH PEPTIDES WITH THE N-TERMINAL SH3 DOMAIN OF C-CRK
2G99	;	1.9	;	Structural basis for the specific recognition of methylated histone H3 lysine 4 by the WD-40 protein WDR5
2G9A	;	2.7	;	Structural basis for the specific recognition of methylated histone H3 lysine 4 by the WD-40 protein WDR5
1CMX	;	2.25	;	STRUCTURAL BASIS FOR THE SPECIFICITY OF UBIQUITIN C-TERMINAL HYDROLASES
2HWQ	;	1.97	;	Structural basis for the structure-activity relationships of Peroxisome Proliferator-Activated Receptor agonists
2HWR	;	2.34	;	Structural basis for the structure-activity relationships of Peroxisome Proliferator-Activated Receptor agonists
1JT2	;	1.8	;	STRUCTURAL BASIS FOR THE SUBSTRATE SPECIFICITY OF THE FERUL DOMAIN OF THE CELLULOSOMAL XYLANASE Z FROM C. THERMOCELLUM
1JJF	;	1.75	;	STRUCTURAL BASIS FOR THE SUBSTRATE SPECIFICITY OF THE FERULOYL ESTERASE DOMAIN OF THE CELLULOSOMAL XYLANASE Z OF CLOSTRIDIUM THERMOCELLUM
3HSQ	;	2.1	;	Structural Basis for the Sugar Nucleotide and Acyl Chain Selectivity of Leptospira interrogans LpxA
3I3A	;	2.12	;	Structural Basis for the Sugar Nucleotide and Acyl Chain Selectivity of Leptospira interrogans LpxA
3I3X	;	2.1	;	Structural Basis for the Sugar Nucleotide and Acyl Chain Selectivity of Leptospira interrogans LpxA
6J4K	;	1.58	;	Structural basis for the target DNA recognition and binding by the MYB domain of phosphate starvation response 1
6J4R	;	2.8	;	Structural basis for the target DNA recognition and binding by the MYB domain of phosphate starvation response regulator 1
6J5B	;	2.7	;	Structural basis for the target DNA recognition and binding by the MYB domain of phosphate starvation response regulator 1
7EPT	;	3.0	;	Structural basis for the tethered peptide activation of adhesion GPCRs
1H75	;	1.7	;	Structural basis for the thioredoxin-like activity profile of the glutaredoxin-like protein NrdH-redoxin from Escherichia coli.
1MSW	;	2.1	;	Structural basis for the transition from initiation to elongation transcription in T7 RNA polymerase
3KWV	;	3.101	;	Structural basis for the unfolding of anthrax lethal factor by protective antigen oligomers
5IEC	;		;	Structural basis for therapeutic inhibition of complement C5
1GUY	;	2.2	;	Structural Basis for Thermophilic Protein Stability: Structures of Thermophilic and Mesophilic Malate Dehydrogenases
1GUZ	;	2.0	;	Structural Basis for Thermophilic Protein Stability: Structures of Thermophilic and Mesophilic Malate Dehydrogenases
1GV0	;	2.5	;	Structural Basis for Thermophilic Protein Stability: Structures of Thermophilic and Mesophilic Malate Dehydrogenases
1GV1	;	2.5	;	Structural Basis for Thermophilic Protein Stability: Structures of Thermophilic and Mesophilic Malate Dehydrogenases
4OFA	;	1.55	;	Structural basis for thymine glycosylase activity on T:O6-methylG mismatch by methyl-CpG binding domain protein 4: Implications for roles of Arg468 in mismatch recognition and catalysis
4OFE	;	2.15	;	Structural basis for thymine glycosylase activity on T:O6-methylG mismatch by methyl-CpG binding domain protein 4: Implications for roles of Arg468 in mismatch recognition and catalysis
4OFH	;	2.22	;	Structural basis for thymine glycosylase activity on T:O6-methylG mismatch by methyl-CpG binding domain protein 4: Implications for roles of Arg468 in mismatch recognition and catalysis
4S20	;	4.7	;	Structural basis for transcription reactivation by RapA
1SMY	;	2.7	;	Structural basis for transcription regulation by alarmone ppGpp
1GTS	;	2.8	;	STRUCTURAL BASIS FOR TRANSFER RNA AMINOACEYLATION BY ESCHERICHIA COLI GLUTAMINYL-TRNA SYNTHETASE
4V63	;	3.207	;	Structural basis for translation termination on the 70S ribosome.
5J13	;	2.298	;	Structural basis for TSLP antagonism by the therapeutic antibody Tezepelumab (MEDI9929 / AMG-157)
2HTH	;	2.7	;	Structural basis for ubiquitin recognition by the human EAP45/ESCRT-II GLUE domain
5XDA	;	3.285	;	Structural basis for Ufm1 recognition by UfSP
2B4V	;	1.8	;	Structural Basis for UTP Specificity of RNA Editing TUTases From Trypanosoma Brucei
2B51	;	2.05	;	Structural Basis for UTP Specificity of RNA Editing TUTases from Trypanosoma Brucei
2B56	;	1.97	;	Structural Basis for UTP Specificity of RNA Editing TUTases From Trypanosoma Brucei
1P69	;	3.1	;	STRUCTURAL BASIS FOR VARIATION IN ADENOVIRUS AFFINITY FOR THE CELLULAR RECEPTOR CAR (P417S MUTANT)
1P6A	;	2.9	;	STRUCTURAL BASIS FOR VARIATION IN ADENOVIRUS AFFINITY FOR THE CELLULAR RECEPTOR CAR (S489Y MUTANT)
3K8P	;	2.6	;	Structural basis for vesicle tethering by the Dsl1 complex
7O3W	;	4.9	;	Structural basis for VIPP1 oligomerization and maintenance of thylakoid membrane integrity
7O3X	;	3.9	;	Structural basis for VIPP1 oligomerization and maintenance of thylakoid membrane integrity
7O3Y	;	3.8	;	Structural basis for VIPP1 oligomerization and maintenance of thylakoid membrane integrity
7O3Z	;	5.0	;	Structural basis for VIPP1 oligomerization and maintenance of thylakoid membrane integrity
7O40	;	4.3	;	Structural basis for VIPP1 oligomerization and maintenance of thylakoid membrane integrity
4FUM	;	2.4	;	Structural basis for Zn2+-dependent intercellular adhesion in staphylococcal biofilms
4FUN	;	2.31	;	Structural basis for Zn2+-dependent intercellular adhesion in staphylococcal biofilms
4FUO	;	1.97	;	Structural basis for Zn2+-dependent intercellular adhesion in staphylococcal biofilms
4FUP	;	2.51	;	Structural basis for Zn2+-dependent intercellular adhesion in staphylococcal biofilms
3IU0	;	1.9	;	Structural basis for zymogen activation and substrate binding of transglutaminase from Streptomyces mobaraense
2X2V	;	2.5	;	Structural basis of a novel proton-coordination type in an F1Fo-ATP synthase rotor ring
4R4Y	;	2.1	;	Structural basis of a point mutation that causes the genetic disease Aspartylglucosaminuria
4JAS	;	3.0	;	Structural basis of a rationally rewired protein-protein interface (HK853mutant A268V, A271G, T275M, V294T and D297E and RR468mutant V13P, L14I, I17M and N21V)
4JAU	;	2.7	;	Structural basis of a rationally rewired protein-protein interface (HK853mutant A268V, A271G, T275M, V294T and D297E)
4JAV	;	3.1	;	Structural basis of a rationally rewired protein-protein interface (HK853wt and RR468mutant V13P, L14I, I17M and N21V)
4JA2	;	1.79	;	Structural basis of a rationally rewired protein-protein interface (RR468mutant V13P, L14I, I17M and N21V)
7YPP	;	2.2	;	Structural basis of a superoxide dismutase from a tardigrade, Ramazzottius varieornatus strain YOKOZUNA-1.
7YPR	;	2.101	;	Structural basis of a superoxide dismutase from a tardigrade, Ramazzottius varieornatus strain YOKOZUNA-1.
2MC0	;		;	Structural Basis of a Thiopeptide Antibiotic Multidrug Resistance System from Streptomyces lividans:Nosiheptide in Complex with TipAS
2MBZ	;		;	Structural Basis of a Thiopeptide Antibiotic Multidrug Resistance System from Streptomyces lividans:Promothiocin A in Complex with TipAS
1T44	;	2.0	;	Structural basis of actin sequestration by thymosin-B4: Implications for arp2/3 activation
5DZ7	;	2.5	;	STRUCTURAL BASIS OF ACYL TRANSFER IN A TRANS-AT POLYKETIDE SYNTHASE
8P66	;		;	Structural basis of aggregate binding/recognition by the AAA+ disaggregase ClpG
6IM4	;	1.93	;	Structural basis of AimP signaling molecule recognition by AimR in Spbeta group of bacteriophages
107L	;	1.8	;	STRUCTURAL BASIS OF ALPHA-HELIX PROPENSITY AT TWO SITES IN T4 LYSOZYME
108L	;	1.8	;	STRUCTURAL BASIS OF ALPHA-HELIX PROPENSITY AT TWO SITES IN T4 LYSOZYME
109L	;	1.85	;	STRUCTURAL BASIS OF ALPHA-HELIX PROPENSITY AT TWO SITES IN T4 LYSOZYME
110L	;	1.7	;	STRUCTURAL BASIS OF ALPHA-HELIX PROPENSITY AT TWO SITES IN T4 LYSOZYME
111L	;	1.8	;	STRUCTURAL BASIS OF ALPHA-HELIX PROPENSITY AT TWO SITES IN T4 LYSOZYME
112L	;	1.8	;	STRUCTURAL BASIS OF ALPHA-HELIX PROPENSITY AT TWO SITES IN T4 LYSOZYME
113L	;	1.8	;	STRUCTURAL BASIS OF ALPHA-HELIX PROPENSITY AT TWO SITES IN T4 LYSOZYME
114L	;	1.8	;	STRUCTURAL BASIS OF ALPHA-HELIX PROPENSITY AT TWO SITES IN T4 LYSOZYME
115L	;	1.8	;	STRUCTURAL BASIS OF ALPHA-HELIX PROPENSITY AT TWO SITES IN T4 LYSOZYME
216L	;	2.1	;	STRUCTURAL BASIS OF ALPHA-HELIX PROPENSITY AT TWO SITES IN T4 LYSOZYME
217L	;	1.7	;	STRUCTURAL BASIS OF ALPHA-HELIX PROPENSITY AT TWO SITES IN T4 LYSOZYME
6WVT	;	3.56	;	Structural basis of alphaE-catenin - F-actin catch bond behavior
137L	;	1.85	;	STRUCTURAL BASIS OF AMINO ACID ALPHA HELIX PROPENSITY
1GTR	;	2.5	;	STRUCTURAL BASIS OF ANTICODON LOOP RECOGNITION BY GLUTAMINYL-TRNA SYNTHETASE
2AAB	;	2.5	;	Structural basis of antigen mimicry in a clinically relevant melanoma antigen system
4ZCF	;	2.6	;	Structural basis of asymmetric DNA methylation and ATP-triggered long-range diffusion by EcoP15I
3HVT	;	2.9	;	STRUCTURAL BASIS OF ASYMMETRY IN THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REVERSE TRANSCRIPTASE HETERODIMER
3KTR	;	1.7	;	Structural basis of ataxin-2 recognition by poly(A)-binding protein
3OPE	;	2.9	;	Structural Basis of Auto-inhibitory mechanism of Histone methyltransferase
4LOO	;	1.95	;	Structural basis of autoactivation of p38 alpha induced by TAB1 (Monoclinic crystal form)
4LOQ	;	2.319	;	Structural basis of autoactivation of p38 alpha induced by TAB1 (Tetragonal crystal form with bound sulphate)
4LOP	;	2.049	;	Structural basis of autoactivation of p38 alpha induced by TAB1 (Tetragonal crystal form)
5HLE	;	2.9	;	Structural basis of backwards motion in kinesin-14: minus-end directed nKn664 in the ADP state
5HNW	;	6.6	;	Structural basis of backwards motion in kinesin-14: minus-end directed nKn664 in the AMPPNP state
5HNX	;	6.6	;	Structural basis of backwards motion in kinesin-14: minus-end directed nKn664 in the nucleotide-free state
5HNY	;	6.3	;	Structural basis of backwards motion in kinesin-14: plus-end directed nKn669 in the AMPPNP state
5HNZ	;	5.8	;	Structural basis of backwards motion in kinesin-14: plus-end directed nKn669 in the nucleotide-free state
4N75	;	2.604	;	Structural Basis of BamA-mediate Outer Membrane Protein Biogenesis
4MS2	;	2.75	;	Structural basis of Ca2+ selectivity of a voltage-gated calcium channel
4MTF	;	3.2	;	Structural Basis of Ca2+ Selectivity of a Voltage-gated Calcium Channel
2FMD	;	1.9	;	Structural basis of carbohydrate recognition by Bowringia milbraedii seed agglutinin
3O0W	;	1.95	;	Structural basis of carbohydrate recognition by calreticulin
3O0X	;	2.01	;	Structural basis of carbohydrate recognition by calreticulin
2GTX	;	2.0	;	Structural Basis of Catalysis by Mononuclear Methionine Aminopeptidase
1NCG	;	2.1	;	STRUCTURAL BASIS OF CELL-CELL ADHESION BY CADHERINS
1NCH	;	2.1	;	STRUCTURAL BASIS OF CELL-CELL ADHESION BY CADHERINS
1NCI	;	2.1	;	STRUCTURAL BASIS OF CELL-CELL ADHESION BY CADHERINS
4TNY	;	2.6	;	Structural basis of cellular dNTP regulation, SAMHD1-dGTP-dATP-dGTP complex
4TO3	;	2.2	;	Structural basis of cellular dNTP regulation, SAMHD1-dGTP-dGTP-dCTP complex
4TNP	;	2.0	;	Structural basis of cellular dNTP regulation, SAMHD1-GTP-dCTP-cCTP complex
4TNQ	;	2.55	;	Structural basis of cellular dNTP regulation, SAMHD1-GTP-dTTP-dTTP complex
7ZJS	;	3.24	;	Structural basis of centromeric cohesion protection by SGO1
4P4K	;	2.8	;	Structural Basis of Chronic Beryllium Disease: Bridging the Gap Between allergic hypersensitivity and auto immunity
4P4R	;	3.0	;	Structural Basis of Chronic Beryllium Disease: Bridging the Gap Between Allergic Hypersensitivity and Autoimmunity
4P5M	;	1.7	;	Structural Basis of Chronic Beryllium Disease: Bridging the Gap Between Allergic Hypersensitivity and Autoimmunity
4P5K	;	2.59	;	Structural Basis of Chronic Beryllium Disease: Bridging the Gap Between Allergy and Autoimmunity
1LZW	;	2.5	;	Structural basis of ClpS-mediated switch in ClpA substrate recognition
5U4I	;	3.5	;	Structural Basis of Co-translational Quality Control by ArfA and RF2 Bound to Ribosome
5U4J	;	3.7	;	Structural Basis of Co-translational Quality Control by ArfA and RF2 Bound to Ribosome
5FC3	;	3.1	;	Structural basis of cohesin cleavage by separase
6QPW	;	3.3	;	Structural basis of cohesin ring opening
1G9W	;	1.3	;	STRUCTURAL BASIS OF COLLAGEN STABILIZATION INDUCED BY PROLINE HYDROXYLATION
6UGM	;	3.7	;	Structural basis of COMPASS eCM recognition of an unmodified nucleosome
6UH5	;	3.5	;	Structural basis of COMPASS eCM recognition of the H2Bub nucleosome
3IXE	;	1.9	;	Structural basis of competition between PINCH1 and PINCH2 for binding to the ankyrin repeat domain of integrin-linked kinase
4N19	;	1.2	;	Structural basis of conformational transitions in the active site and 80 s loop in the FK506 binding protein FKBP12
6MEO	;	3.9	;	Structural basis of coreceptor recognition by HIV-1 envelope spike
6MET	;	4.5	;	Structural basis of coreceptor recognition by HIV-1 envelope spike
6R6H	;	8.4	;	Structural basis of Cullin-2 RING E3 ligase regulation by the COP9 signalosome
6R7F	;	8.2	;	Structural basis of Cullin-2 RING E3 ligase regulation by the COP9 signalosome
6R7H	;	8.8	;	Structural basis of Cullin-2 RING E3 ligase regulation by the COP9 signalosome
6R7I	;	5.9	;	Structural basis of Cullin-2 RING E3 ligase regulation by the COP9 signalosome
6R7N	;	6.5	;	Structural basis of Cullin-2 RING E3 ligase regulation by the COP9 signalosome
3RLN	;	2.251	;	Structural Basis of Cytosolic DNA Recognition by Innate Immune Receptors
3RN2	;	2.55	;	Structural Basis of Cytosolic DNA Recognition by Innate Immune Receptors
3RN5	;	2.5	;	Structural basis of cytosolic DNA recognition by innate immune receptors
3RLO	;	1.8	;	Structural Basis of Cytosolic DNA Recognition by Innate Receptors
3RNU	;	2.502	;	Structural Basis of Cytosolic DNA Sensing by Innate Immune Receptors
1D06	;	1.4	;	STRUCTURAL BASIS OF DIMERIZATION AND SENSORY MECHANISMS OF OXYGEN-SENSING DOMAIN OF RHIZOBIUM MELILOTI FIXL DETERMINED AT 1.4A RESOLUTION
2FDC	;	3.3	;	Structural Basis of DNA Damage Recognition and Processing by UvrB: crystal structure of a UvrB/DNA complex
1AW4	;		;	STRUCTURAL BASIS OF DNA FOLDING AND RECOGNITION IN AMP-DNA APTAMER COMPLEX, NMR, 7 STRUCTURES
4B20	;	2.75	;	Structural basis of DNA loop recognition by Endonuclease V
2AC0	;	1.8	;	Structural Basis of DNA Recognition by p53 Tetramers (complex I)
2ATA	;	2.2	;	Structural Basis of DNA Recognition by p53 Tetramers (complex II)
2AHI	;	1.85	;	Structural Basis of DNA Recognition by p53 Tetramers (complex III)
2ADY	;	2.5	;	Structural Basis of DNA Recognition by p53 Tetramers (complex IV)
2M87	;		;	Structural Basis of DNA Recognition by the Effector Domain of Klebsiella pneumoniae PmrA
1CF7	;	2.6	;	STRUCTURAL BASIS OF DNA RECOGNITION BY THE HETERODIMERIC CELL CYCLE TRANSCRIPTION FACTOR E2F-DP
1HVS	;	2.25	;	STRUCTURAL BASIS OF DRUG RESISTANCE FOR THE V82A MUTANT OF HIV-1 PROTEASE: BACKBONE FLEXIBILITY AND SUBSITE REPACKING
1T3E	;	3.25	;	Structural basis of dynamic glycine receptor clustering
5F18	;	2.0	;	Structural basis of Ebola virus entry: viral glycoprotein bound to its endosomal receptor Niemann-Pick C1
5F1B	;	2.3	;	Structural basis of Ebola virus entry: viral glycoprotein bound to its endosomal receptor Niemann-Pick C1
4O6F	;	2.822	;	Structural Basis of Estrogen Receptor Alpha Methylation Mediated by Histone Methyltransferase SmyD2
2QXV	;	1.82	;	Structural basis of EZH2 recognition by EED
6O3T	;	3.06	;	Structural basis of FOXC2 and DNA interactions
6LDM	;	2.4	;	Structural basis of G-quadruplex DNA recognition by the yeast telomeric protein Rap1
1AFA	;	2.0	;	STRUCTURAL BASIS OF GALACTOSE RECOGNITION IN C-TYPE ANIMAL LECTINS
1AFB	;	1.9	;	STRUCTURAL BASIS OF GALACTOSE RECOGNITION IN C-TYPE ANIMAL LECTINS
1AFD	;	2.0	;	STRUCTURAL BASIS OF GALACTOSE RECOGNITION IN C-TYPE ANIMAL LECTINS
3HYT	;	2.74	;	Structural Basis of GDP Release and Gating in G Protein Coupled Fe2+ Transport
2XG8	;	3.2	;	Structural basis of gene regulation by protein PII: The crystal complex of PII and PipX from Synechococcus elongatus PCC 7942
5MPF	;	2.918	;	Structural Basis of Gene Regulation by the Grainyhead Transcription Factor Superfamily
5MPH	;	2.337	;	Structural Basis of Gene Regulation by the Grainyhead Transcription Factor Superfamily
5MPI	;	2.345	;	Structural Basis of Gene Regulation by the Grainyhead Transcription Factor Superfamily
2ZSH	;	1.8	;	Structural basis of gibberellin(GA3)-induced DELLA recognition by the gibberellin receptor
2ZSI	;	1.8	;	Structural basis of gibberellin(GA4)-induced DELLA recognition by the gibberellin receptor
6K2N	;	1.8	;	Structural basis of glycan recognition in globally predominant human P[8] rotavirus
6K2O	;	2.296	;	Structural basis of glycan recognition in globally predominant human P[8] rotavirus
4YFW	;	1.66	;	Structural basis of glycan recognition in neonate-specific rotaviruses
4YFZ	;	1.5	;	Structural basis of glycan recognition in neonate-specific rotaviruses
4YG0	;	1.285	;	Structural basis of glycan recognition in neonate-specific rotaviruses
4YG3	;	2.285	;	Structural basis of glycan recognition in neonate-specific rotaviruses
4YG6	;	1.46	;	Structural basis of glycan recognition in neonate-specific rotaviruses
5YMS	;	2.1	;	Structural basis of glycan specificity and identification of a novel glycan binding cavity in human P[19] rotavirus
3AJN	;	1.05	;	Structural basis of glycine amide on suppression of protein aggregation by high resolution X-ray analysis
3KTP	;	1.5	;	Structural basis of GW182 recognition by poly(A)-binding protein
5CHL	;	1.892	;	Structural basis of H2A.Z recognition by YL1 histone chaperone component of SRCAP/SWR1 chromatin remodeling complex
2HAN	;	1.95	;	Structural basis of heterodimeric ecdysteroid receptor interaction with natural response element hsp27 gene promoter
2UXN	;	2.72	;	Structural Basis of Histone Demethylation by LSD1 Revealed by Suicide Inactivation
4KHA	;	2.35	;	Structural basis of histone H2A-H2B recognition by the essential chaperone FACT
3C99	;	2.9	;	Structural Basis of Histone H4 Recognition by p55
3C9C	;	3.2	;	Structural Basis of Histone H4 Recognition by p55
4WYM	;	2.6	;	Structural basis of HIV-1 capsid recognition by CPSF6
2X7A	;	2.77	;	Structural basis of HIV-1 tethering to membranes by the Bst2-tetherin ectodomain
7E9B	;	1.78	;	Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy
6GIS	;	2.82	;	Structural basis of human clamp sliding on DNA
4UDF	;	20.0	;	STRUCTURAL BASIS OF HUMAN PARECHOVIRUS NEUTRALIZATION BY HUMAN MONOCLONAL ANTIBODIES
7YK1	;	3.08	;	Structural basis of human PRPS2 filaments
2JK2	;	1.7	;	STRUCTURAL BASIS OF HUMAN TRIOSEPHOSPHATE ISOMERASE DEFICIENCY. CRYSTAL STRUCTURE OF THE WILD TYPE ENZYME.
2VOM	;	1.85	;	Structural basis of human triosephosphate isomerase deficiency. Mutation E104D and correlation to solvent perturbation.
1T0P	;	1.66	;	Structural Basis of ICAM recognition by integrin alpahLbeta2 revealed in the complex structure of binding domains of ICAM-3 and alphaLbeta2 at 1.65 A
6MNX	;	2.2	;	Structural basis of impaired hydrolysis in KRAS Q61H mutant
1YDA	;	2.1	;	STRUCTURAL BASIS OF INHIBITOR AFFINITY TO VARIANTS OF HUMAN CARBONIC ANHYDRASE II
1YDB	;	1.9	;	STRUCTURAL BASIS OF INHIBITOR AFFINITY TO VARIANTS OF HUMAN CARBONIC ANHYDRASE II
1YDC	;	1.95	;	STRUCTURAL BASIS OF INHIBITOR AFFINITY TO VARIANTS OF HUMAN CARBONIC ANHYDRASE II
1YDD	;	2.1	;	STRUCTURAL BASIS OF INHIBITOR AFFINITY TO VARIANTS OF HUMAN CARBONIC ANHYDRASE II
7PKS	;	3.6	;	Structural basis of Integrator-mediated transcription regulation
7WG3	;	2.19	;	Structural basis of interleukin-17B receptor in complex with a neutralizing antibody D9 for guiding humanization and affinity maturation for cancer therapy
7R0G	;	4.01	;	STRUCTURAL BASIS OF ION UPTAKE IN COPPER-TRANSPORTING P1B-TYPE ATPASES
7R0H	;	3.31	;	STRUCTURAL BASIS OF ION UPTAKE IN COPPER-TRANSPORTING P1B-TYPE ATPASES
7R0I	;	2.7	;	STRUCTURAL BASIS OF ION UPTAKE IN COPPER-TRANSPORTING P1B-TYPE ATPASES
3EGM	;	2.1	;	Structural basis of iron transport gating in Helicobacter pylori ferritin
3UGC	;	1.34	;	Structural basis of Jak2 inhibition by the type II inhibtor NVP-BBT594
3DD4	;	3.0	;	Structural Basis of KChIP4a Modulation of Kv4.3 Slow Inactivation
5XPY	;	2.099	;	Structural basis of kindlin-mediated integrin recognition and activation
5XPZ	;	2.601	;	Structural basis of kindlin-mediated integrin recognition and activation
5XQ0	;	2.75	;	Structural basis of kindlin-mediated integrin recognition and activation
5XQ1	;	2.954	;	Structural basis of kindlin-mediated integrin recognition and activation
4PGZ	;	2.4	;	Structural basis of KIT activation by oncogenic mutations in the extracellular region reveals a zipper-like mechanism for ligand-dependent or oncogenic receptor tyrosine kinase activation
4AZJ	;	1.5	;	Structural basis of L-phosphoserine binding to Bacillus alcalophilus phosphoserine aminotransferase
4AZK	;	1.595	;	Structural basis of L-phosphoserine binding to Bacillus alcalophilus phosphoserine aminotransferase
5FQD	;	2.45	;	Structural basis of Lenalidomide induced CK1a degradation by the crl4crbn ubiquitin ligase
4ZH7	;	2.12	;	Structural basis of Lewisb antigen binding by the Helicobacter pylori adhesin BabA
7DTY	;	2.98	;	Structural basis of ligand selectivity conferred by the human glucose-dependent insulinotropic polypeptide receptor
2V1D	;	3.1	;	Structural basis of LSD1-CoREST selectivity in histone H3 recognition
5E38	;	3.0	;	Structural basis of mapping the spontaneous mutations with 5-flourouracil in uracil phosphoribosyltransferase from Mycobacterium tuberculosis
5V8F	;	3.9	;	Structural basis of MCM2-7 replicative helicase loading by ORC-Cdc6 and Cdt1
3L4C	;	2.37	;	Structural basis of membrane-targeting by Dock180
8DGI	;	3.94	;	Structural Basis of MicroRNA Biogenesis by Dicer-1 and Its Partner Protein Loqs-PB - complex Ia
8DGJ	;	4.02	;	Structural Basis of MicroRNA Biogenesis by Dicer-1 and Its Partner Protein Loqs-PB - complex Ib
8DFV	;	3.06	;	Structural Basis of MicroRNA Biogenesis by Dicer-1 and Its Partner Protein Loqs-PB - complex IIa
8DG5	;	3.26	;	Structural Basis of MicroRNA Biogenesis by Dicer-1 and Its Partner Protein Loqs-PB - complex IIb
8DG7	;	3.32	;	Structural Basis of MicroRNA Biogenesis by Dicer-1 and Its Partner Protein Loqs-PB - complex III
8DGA	;	3.73	;	Structural Basis of MicroRNA Biogenesis by Dicer-1 and Its Partner Protein Loqs-PB - complex IV
2QJX	;	1.9	;	Structural Basis of Microtubule Plus End Tracking by XMAP215, CLIP-170 and EB1
2QJZ	;	1.25	;	Structural Basis of Microtubule Plus End Tracking by XMAP215, CLIP-170 and EB1
2QK0	;	2.0	;	Structural Basis of Microtubule Plus End Tracking by XMAP215, CLIP-170 and EB1
2QK1	;	1.7	;	Structural Basis of Microtubule Plus End Tracking by XMAP215, CLIP-170 and EB1
2QK2	;	2.1	;	Structural Basis of Microtubule Plus End Tracking by XMAP215, CLIP-170 and EB1
5WP9	;	4.22	;	Structural Basis of Mitochondrial Receptor Binding and Constriction by Dynamin-Related Protein 1
2X43	;		;	STRUCTURAL BASIS OF MOLECULAR RECOGNITION BY SHERP AT MEMBRANE SURFACES
1T9T	;	3.23	;	Structural Basis of Multidrug transport by the AcrB Multidrug Efflux Pump
1T9U	;	3.11	;	Structural Basis of Multidrug Transport by the AcrB Multidrug Efflux Pump
1T9V	;	3.8	;	Structural Basis of Multidrug Transport by the AcrB Multidrug Efflux Pump
1T9W	;	3.23	;	Structural Basis of Multidrug Transport by the AcrB Multidrug Efflux Pump
1T9X	;	3.08	;	Structural Basis of Multidrug Transport by the AcrB Multidrug Efflux Pump
1T9Y	;	3.64	;	Structural Basis of Multidrug Transport by the AcrB Multidrug Efflux Pump
1OYD	;	3.8	;	Structural Basis of Multiple Binding Capacity of the AcrB multidrug Efflux Pump
1OYE	;	3.48	;	Structural Basis of Multiple Binding Capacity of the AcrB multidrug Efflux Pump
1OY8	;	3.63	;	Structural Basis of Multiple Drug Binding Capacity of the AcrB Multidrug Efflux Pump
1OY9	;	3.8	;	Structural Basis of Multiple Drug Binding Capacity of the AcrB Multidrug Efflux Pump
1WDW	;	3.0	;	Structural basis of mutual activation of the tryptophan synthase a2b2 complex from a hyperthermophile, Pyrococcus furiosus
2W9R	;	1.7	;	Structural basis of N-end rule substrate recognition in Escherichia coli by the ClpAP adaptor protein ClpS
2WA8	;	2.15	;	Structural basis of N-end rule substrate recognition in Escherichia coli by the ClpAP adaptor protein ClpS - The Phe peptide structure
2WA9	;	2.9	;	Structural basis of N-end rule substrate recognition in Escherichia coli by the ClpAP adaptor protein ClpS - Trp peptide structure
2OCV	;	2.2	;	Structural basis of Na+ activation mimicry in murine thrombin
6N4I	;	3.541	;	Structural basis of Nav1.7 inhibition by a gating-modifier spider toxin
5AOQ	;	2.7	;	Structural basis of neurohormone perception by the receptor tyrosine kinase Torso
1FK6	;	1.9	;	STRUCTURAL BASIS OF NON-SPECIFIC LIPID BINDING IN MAIZE LIPID-TRANSFER PROTEIN COMPLEXES WITH ALPHA-LINOLENIC ACID REVEALED BY HIGH-RESOLUTION X-RAY CRYSTALLOGRAPHY
1FK0	;	1.8	;	STRUCTURAL BASIS OF NON-SPECIFIC LIPID BINDING IN MAIZE LIPID-TRANSFER PROTEIN COMPLEXES WITH CAPRIC ACID REVEALED BY HIGH-RESOLUTION X-RAY CRYSTALLOGRAPHY
1FK1	;	1.8	;	STRUCTURAL BASIS OF NON-SPECIFIC LIPID BINDING IN MAIZE LIPID-TRANSFER PROTEIN COMPLEXES WITH LAURIC ACID REVEALED BY HIGH-RESOLUTION X-RAY CRYSTALLOGRAPHY
1FK2	;	1.8	;	STRUCTURAL BASIS OF NON-SPECIFIC LIPID BINDING IN MAIZE LIPID-TRANSFER PROTEIN COMPLEXES WITH MYRISTIC ACID REVEALED BY HIGH-RESOLUTION X-RAY CRYSTALLOGRAPHY
1FK5	;	1.3	;	STRUCTURAL BASIS OF NON-SPECIFIC LIPID BINDING IN MAIZE LIPID-TRANSFER PROTEIN COMPLEXES WITH OLEIC ACID REVEALED BY HIGH-RESOLUTION X-RAY CRYSTALLOGRAPHY
1FK3	;	1.8	;	STRUCTURAL BASIS OF NON-SPECIFIC LIPID BINDING IN MAIZE LIPID-TRANSFER PROTEIN COMPLEXES WITH PALMITOLEIC ACID REVEALED BY HIGH-RESOLUTION X-RAY CRYSTALLOGRAPHY
1FK7	;	1.9	;	STRUCTURAL BASIS OF NON-SPECIFIC LIPID BINDING IN MAIZE LIPID-TRANSFER PROTEIN COMPLEXES WITH RICINOLEIC ACID REVEALED BY HIGH-RESOLUTION X-RAY CRYSTALLOGRAPHY
1FK4	;	1.8	;	STRUCTURAL BASIS OF NON-SPECIFIC LIPID BINDING IN MAIZE LIPID-TRANSFER PROTEIN COMPLEXES WITH STEARIC ACID REVEALED BY HIGH-RESOLUTION X-RAY CRYSTALLOGRAPHY
6LC1	;	3.12	;	Structural basis of NR4A1 bound to the human pituitary proopiomelanocortin gene promoter
6L6L	;	2.781	;	Structural basis of NR4A2 homodimers binding to selective Nur-responsive elements
6L6Q	;	2.601	;	Structural basis of NR4A2 homodimers binding to selective Nur-responsive elements
3UVU	;	2.38	;	Structural basis of nuclear import of Flap endonuclease 1 (FEN1)
2QHS	;	1.5	;	Structural Basis of Octanoic Acid Recognition by Lipoate-Protein Ligase B
2QHT	;	1.5	;	Structural Basis of Octanoic Acid Recognition by Lipoate-Protein Ligase B
2QHU	;	1.9	;	Structural Basis of Octanoic Acid Recognition by Lipoate-Protein Ligase B
2QHV	;	1.6	;	Structural Basis of Octanoic Acid Recognition by Lipoate-Protein Ligase B
3LJB	;	2.4	;	Structural basis of oligomerisation in the MxA stalk
7YJ0	;	2.43	;	Structural basis of oxepinone formation by a flavin-monooxygenase VibO
2Y9T	;		;	Structural basis of p63a SAM domain mutants involved in AEC syndrome
2Y9U	;	1.6	;	Structural basis of p63a SAM domain mutants involved in AEC syndrome
1PZ5	;	1.8	;	Structural basis of peptide-carbohydrate mimicry in an antibody combining site
8TJ3	;	3.2	;	Structural basis of peptidoglycan synthesis by E. coli RodA-PBP2 complex
1T2V	;	3.3	;	Structural basis of phospho-peptide recognition by the BRCT domain of BRCA1, structure with phosphopeptide
2LKO	;		;	Structural Basis of Phosphoinositide Binding to Kindlin-2 Pleckstrin Homology Domain in Regulating Integrin Activation
1T2U	;	2.8	;	Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1: structure of BRCA1 missense variant V1809F
6X24	;	3.25	;	Structural basis of plant blue light photoreceptor
3FGA	;	2.7	;	Structural Basis of PP2A and Sgo interaction
3BJI	;	2.6	;	Structural Basis of Promiscuous Guanine Nucleotide Exchange by the T-Cell Essential Vav1
1XPX	;	2.8	;	Structural basis of prospero-DNA interaction; implications for transcription regulation in developing cells
4NND	;	2.502	;	Structural basis of PTPN18 fingerprint on distinct HER2 tyrosine phosphorylation sites
2K2M	;		;	Structural Basis of PxxDY Motif Recognition in SH3 Binding
2ROL	;		;	Structural Basis of PxxDY motif recognition in SH3 binding
1ZBD	;	2.6	;	STRUCTURAL BASIS OF RAB EFFECTOR SPECIFICITY: CRYSTAL STRUCTURE OF THE SMALL G PROTEIN RAB3A COMPLEXED WITH THE EFFECTOR DOMAIN OF RABPHILIN-3A
7CWH	;		;	Structural basis of RACK7 PHD to read a pediatric glioblastoma-associated histone mutation H3.3G34R
7B4B	;	1.76	;	Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ). Human p53DBD-R273C mutant bound to MQ: R273C-MQ (I)
7B4C	;	1.71	;	Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ). Human p53DBD-R273C mutant bound to MQ: R273C-MQ (II)
7B4D	;	1.85	;	Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ). Human p53DBD-R273C/S240R double mutant bound to DNA and MQ: R273C/S240R-DNA-MQ
7B49	;	1.42	;	Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ). Human p53DBD-R273H mutant bound to DNA and MQ: R273H-DNA-MQ
7B4A	;	1.9	;	Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ). Human p53DBD-R273H mutant bound to DNA: R273H-DNA
7B47	;	1.8	;	Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ). Human p53DBD-R273H mutant bound to MQ: R273H-MQ (I)
7B48	;	2.05	;	Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ). Human p53DBD-R273H mutant bound to MQ: R273H-MQ (II)
7B4E	;	1.58	;	Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ). Human p53DBD-R282W mutant bound to DNA and MQ: R282W-DNA-MQ
7B4F	;	1.78	;	Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ). Human p53DBD-R282W mutant bound to DNA: R282W-MQ (I)
7B4G	;	1.86	;	Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ). Human p53DBD-R282W mutant bound to DNA: R282W-MQ (II)
6ZNC	;	1.64	;	Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ). Human wild-type p53DBD bound to DNA and MQ: wt-DNA-MQ (I)
7B4N	;	1.32	;	Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ). Human wild-type p53DBD bound to DNA and MQ: wt-DNA-MQ (II)
7B4H	;	1.39	;	Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ). Human wild-type p53DBD bound to DNA and MQ: wt-DNA-MQ (III)
7B46	;	2.02	;	Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ). Human wild-type p53DBD bound to DNA and MQ: wt-DNA-MQ (P1)
2MPM	;		;	Structural Basis of Receptor Sulfotyrosine Recognition by a CC Chemokine: the N-terminal Region of CCR3 Bound to CCL11/Eotaxin-1
3RT4	;	1.7	;	Structural Basis of Recognition of Pathogen-associated Molecular Patterns and Inhibition of Proinflammatory Cytokines by Camel Peptidoglycan Recognition Protein
4GMN	;	2.95	;	Structural basis of Rpl5 recognition by Syo1
2JPP	;		;	Structural basis of RsmA/CsrA RNA recognition: Structure of RsmE bound to the Shine-Dalgarno sequence of hcnA mRNA
6WPG	;	2.283	;	Structural Basis of Salicylic Acid Perception by Arabidopsis NPR Proteins
6TL8	;	2.8	;	Structural basis of SALM3 dimerization and adhesion complex formation with the presynaptic receptor protein tyrosine phosphatases
3FHV	;	1.9	;	Structural basis of Salmonella typhi type IVb PilS and cystic fibrosis transmembrane conductance regulator (CFTR) interaction
7DRV	;	3.09	;	Structural basis of SARS-CoV-2-closely-related bat coronavirus RaTG13 to hACE2
3QMI	;	2.1	;	Structural Basis of Selective Binding of Non-Methylated CpG islands (DNA-ACGT) by the CXXC Domain of CFP1
3QMH	;	2.5	;	Structural Basis of Selective Binding of Non-Methylated CpG islands (DNA-TCGA) by the CXXC Domain of CFP1
3QMG	;	2.3	;	Structural Basis of Selective Binding of Non-Methylated CpG islands by the CXXC Domain of CFP1
3QMB	;	2.06	;	Structural Basis of Selective Binding of Nonmethylated CpG Islands by the CXXC Domain of CFP1
3QMC	;	2.1	;	Structural Basis of Selective Binding of Nonmethylated CpG Islands by the CXXC Domain of CFP1
3QMD	;	1.9	;	Structural Basis of Selective Binding of Nonmethylated CpG Islands by the CXXC Domain of CFP1
1N6J	;	2.2	;	Structural basis of sequence-specific recruitment of histone deacetylases by Myocyte Enhancer Factor-2
3ZN8	;	12.0	;	Structural Basis of Signal Sequence Surveillance and Selection by the SRP-SR Complex
1XR0	;		;	Structural Basis of SNT PTB Domain Interactions with Distinct Neurotrophic Receptors
4OWT	;	2.0	;	Structural basis of SOSS1 complex assembly
4OWX	;	2.3	;	Structural basis of SOSS1 in complex with a 12nt ssDNA
4OWW	;	2.3	;	Structural basis of SOSS1 in complex with a 35nt ssDNA
4TQJ	;	2.0	;	Structural basis of specific recognition of non-reducing terminal N-acetylglucosamine by an Agrocybe aegerita lection
4TQK	;	2.1	;	Structural basis of specific recognition of non-reducing terminal N-acetylglucosamine by an Agrocybe aegerita lection
4TQM	;	2.0	;	Structural basis of specific recognition of non-reducing terminal N-acetylglucosamine by an Agrocybe aegerita lection
3S7B	;	2.42	;	Structural Basis of Substrate Methylation and Inhibition of SMYD2
3S7D	;	2.3	;	Structural Basis of Substrate Methylation and Inhibition of SMYD2
3S7F	;	2.85	;	Structural Basis of Substrate Methylation and Inhibition of SMYD2
3S7J	;	3.04	;	Structural Basis of Substrate Methylation and Inhibition of SMYD2
4IMQ	;	1.5	;	Structural Basis of Substrate Specificity and Protease Inhibition in Norwalk Virus
4IMZ	;	1.7	;	Structural Basis of Substrate Specificity and Protease Inhibition in Norwalk Virus
4IN1	;	2.05	;	Structural Basis of Substrate Specificity and Protease Inhibition in Norwalk Virus
4IN2	;	2.401	;	Structural Basis of Substrate Specificity and Protease Inhibition in Norwalk Virus
4INH	;	1.7	;	Structural Basis of Substrate Specificity and Protease Inhibition in Norwalk Virus
4LC5	;	1.97	;	Structural basis of substrate specificity of CDA superfamily guanine deaminase
4BWG	;	2.6	;	Structural basis of subtilase cytotoxin SubAB assembly
1UMH	;	2.0	;	Structural basis of sugar-recognizing ubiquitin ligase
1UMI	;	2.4	;	Structural basis of sugar-recognizing ubiquitin ligase
2AKR	;	1.9	;	Structural basis of sulfatide presentation by mouse CD1d
2IJ0	;	2.25	;	Structural basis of T cell specificity and activation by the bacterial superantigen toxic shock syndrome toxin-1
5C9H	;	3.0	;	Structural Basis of Template Boundary Definition in Tetrahymena Telomerase
1NGA	;	2.18	;	STRUCTURAL BASIS OF THE 70-KILODALTON HEAT SHOCK COGNATE PROTEIN ATP HYDROLYTIC ACTIVITY, II. STRUCTURE OF THE ACTIVE SITE WITH ADP OR ATP BOUND TO WILD TYPE AND MUTANT ATPASE FRAGMENT
1NGB	;	2.18	;	STRUCTURAL BASIS OF THE 70-KILODALTON HEAT SHOCK COGNATE PROTEIN ATP HYDROLYTIC ACTIVITY, II. STRUCTURE OF THE ACTIVE SITE WITH ADP OR ATP BOUND TO WILD TYPE AND MUTANT ATPASE FRAGMENT
1NGC	;	2.2	;	STRUCTURAL BASIS OF THE 70-KILODALTON HEAT SHOCK COGNATE PROTEIN ATP HYDROLYTIC ACTIVITY, II. STRUCTURE OF THE ACTIVE SITE WITH ADP OR ATP BOUND TO WILD TYPE AND MUTANT ATPASE FRAGMENT
1NGD	;	2.18	;	STRUCTURAL BASIS OF THE 70-KILODALTON HEAT SHOCK COGNATE PROTEIN ATP HYDROLYTIC ACTIVITY, II. STRUCTURE OF THE ACTIVE SITE WITH ADP OR ATP BOUND TO WILD TYPE AND MUTANT ATPASE FRAGMENT
1NGE	;	2.05	;	STRUCTURAL BASIS OF THE 70-KILODALTON HEAT SHOCK COGNATE PROTEIN ATP HYDROLYTIC ACTIVITY, II. STRUCTURE OF THE ACTIVE SITE WITH ADP OR ATP BOUND TO WILD TYPE AND MUTANT ATPASE FRAGMENT
1NGF	;	2.17	;	STRUCTURAL BASIS OF THE 70-KILODALTON HEAT SHOCK COGNATE PROTEIN ATP HYDROLYTIC ACTIVITY, II. STRUCTURE OF THE ACTIVE SITE WITH ADP OR ATP BOUND TO WILD TYPE AND MUTANT ATPASE FRAGMENT
1NGG	;	2.19	;	STRUCTURAL BASIS OF THE 70-KILODALTON HEAT SHOCK COGNATE PROTEIN ATP HYDROLYTIC ACTIVITY, II. STRUCTURE OF THE ACTIVE SITE WITH ADP OR ATP BOUND TO WILD TYPE AND MUTANT ATPASE FRAGMENT
1NGH	;	2.23	;	STRUCTURAL BASIS OF THE 70-KILODALTON HEAT SHOCK COGNATE PROTEIN ATP HYDROLYTIC ACTIVITY, II. STRUCTURE OF THE ACTIVE SITE WITH ADP OR ATP BOUND TO WILD TYPE AND MUTANT ATPASE FRAGMENT
1NGI	;	2.15	;	STRUCTURAL BASIS OF THE 70-KILODALTON HEAT SHOCK COGNATE PROTEIN ATP HYDROLYTIC ACTIVITY, II. STRUCTURE OF THE ACTIVE SITE WITH ADP OR ATP BOUND TO WILD TYPE AND MUTANT ATPASE FRAGMENT
1NGJ	;	2.1	;	STRUCTURAL BASIS OF THE 70-KILODALTON HEAT SHOCK COGNATE PROTEIN ATP HYDROLYTIC ACTIVITY, II. STRUCTURE OF THE ACTIVE SITE WITH ADP OR ATP BOUND TO WILD TYPE AND MUTANT ATPASE FRAGMENT
7JJO	;	2.6	;	Structural Basis of the Activation of Heterotrimeric Gs-protein by Isoproterenol-bound Beta1-Adrenergic Receptor
7O7F	;	3.15	;	Structural basis of the activation of the CC chemokine receptor 5 by a chemokine agonist
3KX7	;	1.7	;	Structural basis of the activity and substrate specificity of the fluoroacetyl-CoA FlK - apo wild type FlK
3KVU	;	2.0	;	Structural basis of the activity and substrate specificity of the fluoroacetyl-CoA FlK - T42S mutant in complex with Acetyl-CoA
3KW1	;	1.9	;	Structural basis of the activity and substrate specificity of the fluoroacetyl-CoA FlK - Wild type FlK in complex with FAcOPan
3KVZ	;	2.1	;	Structural basis of the activity and substrate specificity of the fluoroacetyl-CoA thiesterase FlK - wild type FlK in complex with FAcCPan
3KX8	;	2.35	;	Structural basis of the activity and substrate specificity of the fluoroacetyl-CoA thioesterase FlK
3KVI	;	1.76	;	Structural basis of the activity and substrate specificity of the fluoroacetyl-CoA thioesterase FlK - T42A mutant in complex with fluoro-acetate
3KUV	;	1.5	;	Structural basis of the activity and substrate specificity of the fluoroacetyl-CoA thioesterase FlK - T42S mutant in complex with acetate.
3KV7	;	1.56	;	Structural basis of the activity and substrate specificity of the fluoroacetyl-CoA thioesterase FlK - wild type FlK in complex with acetate
3KV8	;	1.85	;	Structural basis of the activity and substrate specificity of the fluoroacetyl-CoA thioesterase FlK - Wild type FlK in complex with fluoro-acetate
3KUW	;	1.9	;	Structural basis of the activity ans substrate specificity of the fluoroacetyl-CoA thioesterase FlK - T42S mutant in complex with Fluoro-acetate
4A53	;		;	Structural basis of the Dcp1:Dcp2 mRNA decapping complex activation by Edc3 and Scd6
4A54	;		;	Structural basis of the Dcp1:Dcp2 mRNA decapping complex activation by Edc3 and Scd6
8HBM	;	3.3	;	Structural basis of the farnesoid X receptor/retinoid X receptor heterodimer on inverted repeat DNA
5H7R	;	1.7	;	Structural basis of the flanking zinc-finger motifs crucial for the E3 ligase activity of the LNX1 RING domain
5H7S	;	3.49	;	Structural basis of the flanking zinc-finger motifs crucial for the E3 ligase activity of the LNX1 RING domain
5Z1P	;	1.89	;	Structural basis of the improved sweetness and stability of the single-chain sweet-tasting protein monellin (MNEI)
3SVL	;	2.2	;	Structural basis of the improvement of ChrR - a multi-purpose enzyme
3CFS	;	2.4	;	Structural basis of the interaction of RbAp46/RbAp48 with histone H4
3CFV	;	2.6	;	Structural basis of the interaction of RbAp46/RbAp48 with histone H4
1H0J	;	1.9	;	Structural Basis of the Membrane-induced Cardiotoxin A3 Oligomerization
1OY6	;	3.68	;	Structural Basis of the Multiple Binding Capacity of the AcrB Multidrug Efflux Pump
2KDU	;		;	Structural basis of the Munc13-1/Ca2+-Calmodulin interaction: A novel 1-26 calmodulin binding motif with a bipartite binding mode
1I92	;	1.7	;	STRUCTURAL BASIS OF THE NHERF PDZ1-CFTR INTERACTION
2MF0	;		;	Structural basis of the non-coding RNA RsmZ acting as protein sponge: Conformer L of RsmZ(1-72)/RsmE(dimer) 1to3 complex
2MF1	;		;	Structural basis of the non-coding RNA RsmZ acting as protein sponge: Conformer R of RsmZ(1-72)/RsmE(dimer) 1to3 complex
2C96	;	1.8	;	Structural basis of the nucleotide driven conformational changes in the AAA domain of transcription activator PspF
2C98	;	1.9	;	Structural basis of the nucleotide driven conformational changes in the AAA domain of transcription activator PspF
2C99	;	1.9	;	Structural basis of the nucleotide driven conformational changes in the AAA domain of transcription activator PspF
2C9C	;	2.1	;	Structural basis of the nucleotide driven conformational changes in the AAA domain of transcription activator PspF
3IB0	;	1.4	;	Structural basis of the prevention of NSAID-induced damage of the gastrointestinal tract by C-terminal half (C-lobe) of bovine colostrum protein lactoferrin: Binding and structural studies of C-lobe complex with diclofenac
3IB1	;	2.2	;	Structural basis of the prevention of NSAID-induced damage of the gastrointestinal tract by C-terminal half (C-lobe) of bovine colostrum protein lactoferrin: Binding and structural studies of C-lobe complex with indomethacin
3IAZ	;	2.0	;	Structural basis of the prevention of NSAID-induced damage of the gastrointestinal tract by C-terminal half (C-lobe) of bovine colostrum protein lactoferrin: Binding and structural studies of the C-lobe complex with aspirin
5CIU	;	2.24	;	Structural basis of the recognition of H3K36me3 by DNMT3B PWWP domain
5CIY	;	1.594	;	Structural basis of the recognition of H3K36me3 by DNMT3B PWWP domain
1FSH	;		;	STRUCTURAL BASIS OF THE RECOGNITION OF THE DISHEVELLED DEP DOMAIN IN THE WNT SIGNALING PATHWAY
7DEE	;		;	Structural Basis of the regulation of DISC Assembly by the interaction of c-FLIPs with Procaspase-8
2C1C	;	2.3	;	Structural basis of the resistance of an insect carboxypeptidase to plant protease inhibitors
5GT5	;	1.449	;	Structural basis of the specific activity and thermostability of pectate lyase (pelN) from Paenibacillus sp. 0602
8IQK	;	2.879	;	Structural basis of the specificity and interaction mechanism of Bmf binding to pro-survival proteins
8IQL	;	2.9577	;	Structural basis of the specificity and interaction mechanism of Bmf binding to pro-survival proteins
8IQM	;	1.967	;	Structural basis of the specificity and interaction mechanism of Bmf binding to pro-survival proteins
3BLG	;	2.56	;	STRUCTURAL BASIS OF THE TANFORD TRANSITION OF BOVINE BETA-LACTOGLOBULIN FROM CRYSTAL STRUCTURES AT THREE PH VALUES; PH 6.2
1BSY	;	2.24	;	STRUCTURAL BASIS OF THE TANFORD TRANSITION OF BOVINE BETA-LACTOGLOBULIN FROM CRYSTAL STRUCTURES AT THREE PH VALUES; PH 7.1
2BLG	;	2.46	;	STRUCTURAL BASIS OF THE TANFORD TRANSITION OF BOVINE BETA-LACTOGLOBULIN FROM CRYSTAL STRUCTURES AT THREE PH VALUES; PH 8.2
5YKJ	;	1.53	;	Structural basis of the thiol resolving mechanism in yeast mitochondrial 1-Cys peroxiredoxin via glutathione/thioredoxin systems
5YKW	;	2.08	;	Structural basis of the thiol resolving mechanism in yeast mitochondrial 1-Cys peroxiredoxin via glutathione/thioredoxin systems
3D2G	;	2.25	;	Structural basis of thiamine pyrophosphate analogues binding to the eukaryotic riboswitch
3P6Z	;	1.7	;	Structural basis of thrombin mediated factor V activation: essential role of the hirudin-like sequence Glu666-Glu672 for processing at the heavy chain-B domain junction
3P70	;	2.55	;	Structural basis of thrombin-mediated factor V activation: essential role of the hirudin-like sequence Glu666-Glu672 for processing at the heavy chain-B domain junction
2MPO	;		;	Structural basis of Toxoplasma gondii MIC2-Associated Protein interaction with MIC2
2W2H	;	3.25	;	Structural basis of transcription activation by the Cyclin T1-Tat-TAR RNA complex from EIAV
6R9G	;	3.7	;	Structural basis of transcription inhibition by the DNA mimic Ocr protein of bacteriophage T7
8JO2	;	2.74	;	Structural basis of transcriptional activation by the OmpR/PhoB-family response regulator PmrA
3VEM	;	3.2	;	Structural basis of transcriptional gene silencing mediated by Arabidopsis MOM1
8WKP	;	4.62	;	Structural basis of translation inhibition by a valine tRNA-derived fragment
8WQ2	;	4.1	;	Structural basis of translation inhibition by a valine tRNA-derived fragment
8WQ4	;	4.53	;	Structural basis of translation inhibition by a valine tRNA-derived fragment
2XL1	;		;	Structural basis of translational stalling by human cytomegalovirus (hCMV) and fungal arginine attenuator peptide (AAP)
7D42	;	2.697	;	Structural basis of tropifexor as a potent and selective agonist for farnesoid X receptor
6JZC	;	2.201	;	Structural basis of tubulin detyrosination
6J4O	;	2.3	;	Structural basis of tubulin detyrosination by vasohibins-SVBP enzyme complex and functional implications
6J4P	;	1.599	;	Structural basis of tubulin detyrosination by vasohibins-SVBP enzyme complex and functional implications
6J4Q	;	2.7	;	Structural basis of tubulin detyrosination by vasohibins-SVBP enzyme complex and functional implications
6J4S	;	2.8	;	Structural basis of tubulin detyrosination by vasohibins-SVBP enzyme complex and functional implications
6J4U	;	1.998	;	Structural basis of tubulin detyrosination by vasohibins-SVBP enzyme complex and functional implications
6J4V	;	2.1	;	Structural basis of tubulin detyrosination by vasohibins-SVBP enzyme complex and functional implications
6MZE	;	3.6	;	Structural Basis of Tubulin Recruitment and Assembly by Microtubule Polymerases with Tumor Overexpressed Gene (TOG) Domain Arrays
6MZF	;	4.4	;	Structural Basis of Tubulin Recruitment and Assembly by Microtubule Polymerases with Tumor Overexpressed Gene (TOG) Domain Arrays
6MZG	;	3.208	;	Structural Basis of Tubulin Recruitment and Assembly by Microtubule Polymerases with Tumor Overexpressed Gene (TOG) Domain Arrays
3OQ3	;	2.1	;	Structural Basis of Type-I Interferon Sequestration by a Poxvirus Decoy Receptor
7YTW	;	3.2	;	Structural basis of vitamin C recognition and transport by mammalian SVCT1 transporter
3EMH	;	1.37	;	Structural basis of WDR5-MLL interaction
3S2K	;	2.8	;	Structural basis of Wnt signaling inhibition by Dickkopf binding to LRP5/6.
3JUA	;	3.0	;	Structural basis of YAP recognition by TEAD4 in the Hippo pathway
2HRK	;	2.05	;	Structural basis of yeast aminoacyl-tRNA synthetase complex formation revealed by crystal structures of two binary sub-complexes
2HSM	;	3.0	;	Structural basis of yeast aminoacyl-tRNA synthetase complex formation revealed by crystal structures of two binary sub-complexes
2HSN	;	2.2	;	Structural basis of yeast aminoacyl-tRNA synthetase complex formation revealed by crystal structures of two binary sub-complexes
5LBS	;	2.41	;	structural basis of Zika and Dengue virus potent antibody cross-neutralization
5LBV	;	2.2	;	Structural basis of zika and dengue virus potent antibody cross-neutralization
5LCV	;	2.64	;	Structural basis of Zika and Dengue virus potent antibody cross-neutralization
5MRK	;	1.9	;	Structural basis of Zika virus methyltransferase inhibition by sinefungin
3WR5	;	2.142	;	Structural basis on the efficient CO2 reduction of acidophilic formate dehydrogenase
7QS9	;	1.8	;	Structural basis on the interaction of Scribble PDZ domains with the Tick Born encephalitis virus (TBEV) NS5 protein
7QSA	;	2.02	;	Structural basis on the interaction of Scribble PDZ domains with the Tick Born encephalitis virus (TBEV) NS5 protein
7QSB	;	1.84	;	Structural basis on the interaction of Scribble PDZ domains with the Tick Born encephalitis virus (TBEV) NS5 protein
5YBB	;	3.2	;	Structural basis underlying complex assembly andconformational transition of the type I R-M system
4WUJ	;	2.23	;	Structural Biochemistry of a Fungal LOV Domain Photoreceptor Reveals an Evolutionarily Conserved Pathway Integrating Blue-Light and Oxidative Stress
1XEW	;	2.0	;	Structural biochemistry of ATP-driven dimerization and DNA stimulated activation of SMC ATPases.
1XEX	;	2.5	;	Structural biochemistry of ATP-driven dimerization and DNA stimulated activation of SMC ATPases.
7QTO	;	3.5	;	Structural biology of the NS1 avian influenza protein subversion on the Scribble cell polarity module
7QTP	;	1.9	;	Structural biology of the NS1 avian influenza protein subversion on the Scribble cell polarity module
7QTU	;	2.84	;	Structural biology of the NS1 avian influenza protein subversion on the Scribble cell polarity module
1DV9	;		;	STRUCTURAL CHANGES ACCOMPANYING PH-INDUCED DISSOCIATION OF THE B-LACTOGLOBULIN DIMER
4LW2	;	1.8	;	Structural changes during cysteine desulfurase CsdA and sulfur-acceptor CsdE interactions provide insight into the trans-persulfuration
4LW4	;	2.01	;	Structural changes during cysteine desulfurase CsdA and sulfur-acceptor CsdE interactions provide insight into the trans-persulfuration
2JPT	;		;	Structural changes induced in apo-s100a1 protein by the disulphide formation between its CYS85 residue and b-mercaptoethanol
1LZR	;	1.5	;	STRUCTURAL CHANGES OF THE ACTIVE SITE CLEFT AND DIFFERENT SACCHARIDE BINDING MODES IN HUMAN LYSOZYME CO-CRYSTALLIZED WITH HEXA-N-ACETYL-CHITOHEXAOSE AT PH 4.0
1LZS	;	1.6	;	STRUCTURAL CHANGES OF THE ACTIVE SITE CLEFT AND DIFFERENT SACCHARIDE BINDING MODES IN HUMAN LYSOZYME CO-CRYSTALLIZED WITH HEXA-N-ACETYL-CHITOHEXAOSE AT PH 4.0
3SRN	;	2.0	;	STRUCTURAL CHANGES THAT ACCOMPANY THE REDUCED CATALYTIC EFFICIENCY OF TWO SEMISYNTHETIC RIBONUCLEASE ANALOGS
4SRN	;	2.0	;	STRUCTURAL CHANGES THAT ACCOMPANY THE REDUCED CATALYTIC EFFICIENCY OF TWO SEMISYNTHETIC RIBONUCLEASE ANALOGS
1H3P	;	2.6	;	STRUCTURAL CHARACTERISATION OF A MONOCLONAL ANTIBODY SPECIFIC FOR THE PRES1 REGION OF THE HEPATITIS B VIRUS
261L	;	2.5	;	STRUCTURAL CHARACTERISATION OF AN ENGINEERED TANDEM REPEAT CONTRASTS THE IMPORTANCE OF CONTEXT AND SEQUENCE IN PROTEIN FOLDING
262L	;	2.5	;	STRUCTURAL CHARACTERISATION OF AN ENGINEERED TANDEM REPEAT CONTRASTS THE IMPORTANCE OF CONTEXT AND SEQUENCE IN PROTEIN FOLDING
2J66	;	1.65	;	Structural characterisation of BtrK decarboxylase from butirosin biosynthesis
5K3W	;	2.503	;	Structural characterisation of fold IV-transaminase, CpuTA1, from Curtobacterium pusillum
5T02	;	2.8	;	Structural characterisation of mutant Asp39Ala of thioesterase (NmACH) from Neisseria meningitidis
4UTT	;	1.71	;	Structural characterisation of NanE, ManNac6P C2 epimerase, from Clostridium perfingens
4UTW	;	1.9	;	Structural characterisation of NanE, ManNac6P C2 epimerase, from Clostridium perfingens
3RKW	;	2.5	;	Structural characterisation of staphylococcus aureus biotin protein ligase
3RKX	;	2.1	;	Structural characterisation of staphylococcus aureus biotin protein ligase
3RKY	;	3.232	;	Structural characterisation of staphylococcus aureus biotin protein ligase
4L4R	;	2.1	;	Structural Characterisation of the Apo-form of Human Lactate Dehydrogenase M Isozyme
1DA1	;	2.25	;	STRUCTURAL CHARACTERISATION OF THE BROMOURACIL-GUANINE BASE PAIR MISMATCH IN A Z-DNA FRAGMENT
1NVN	;	1.8	;	Structural Characterisation of the Holliday junction formed by the sequence CCGGTACCGG at 1.8 A
1NT8	;	2.0	;	Structural Characterisation of the Holliday junction formed by the sequence CCGGTACCGG at 2.00 A
1NQS	;	1.97	;	Structural Characterisation of the Holliday Junction formed by the sequence d(TCGGTACCGA) at 1.97 A
1M6G	;	1.652	;	Structural Characterisation of the Holliday Junction TCGGTACCGA
4L4S	;	2.9	;	Structural characterisation of the NADH binary complex of human lactate dehydrogenase M isozyme
7AXS	;	1.88	;	Structural characterisation of WDR5:CS-VIP8 interaction in cis state 1
7AXP	;	2.432	;	Structural characterisation of WDR5:CS-VIP8 interaction in cis state 2
1ETL	;	0.89	;	STRUCTURAL CHARACTERISTICS FOR BIOLOGICAL ACTIVITY OF HEAT-STABLE ENTEROTOXIN PRODUCED BY ENTEROTOXIGENIC ESCHERICHIA COLI: X-RAY CRYSTALLOGRAPHY OF WEAKLY TOXIC AND NONTOXIC ANALOGS
1ETM	;	0.89	;	STRUCTURAL CHARACTERISTICS FOR BIOLOGICAL ACTIVITY OF HEAT-STABLE ENTEROTOXIN PRODUCED BY ENTEROTOXIGENIC ESCHERICHIA COLI: X-RAY CRYSTALLOGRAPHY OF WEAKLY TOXIC AND NONTOXIC ANALOGS
3WBH	;	2.1	;	Structural characteristics of alkaline phosphatase from a moderately halophilic bacteria Halomonas sp.593
1VTU	;	2.2	;	Structural characteristics of enantiomorphic DNA: Crystal analysis of racemates of the D(CGCGCG) duplex
3HU7	;	2.0	;	Structural characterization and binding studies of a plant pathogenesis related protein heamanthin from haemanthus multiflorus reveal its dual inhibitory effects against xylanase and alpha-amylase
5BWJ	;	2.054	;	Structural characterization and modeling of the Borrelia burgdorferi hybrid histidine kinase Hk1 periplasmic sensor
2HN8	;		;	Structural characterization and oligomerization of PB1-F2, a pro-apoptotic influenza A virus protein
3IKJ	;	2.4	;	Structural characterization for the nucleotide binding ability of subunit A mutant S238A of the A1AO ATP synthase
3ND8	;	2.4	;	Structural characterization for the nucleotide binding ability of subunit A of the A1AO ATP synthase
3ND9	;	3.1	;	Structural characterization for the nucleotide binding ability of subunit A of the A1AO ATP synthase
3I73	;	2.4	;	Structural characterization for the nucleotide binding ability of subunit A with ADP of the A1AO ATP synthase
3I4L	;	2.4	;	Structural characterization for the nucleotide binding ability of subunit A with AMP-PNP of the A1AO ATP synthase
3I72	;	2.47	;	Structural characterization for the nucleotide binding ability of subunit A with SO4 of the A1AO ATP synthase
2YI0	;	1.6	;	Structural characterization of 5-Aryl-4-(5-substituted-2-4- dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors.
2YI5	;	2.5	;	Structural characterization of 5-Aryl-4-(5-substituted-2-4- dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors.
2YI6	;	1.8	;	Structural characterization of 5-Aryl-4-(5-substituted-2-4- dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors.
2YI7	;	1.4	;	Structural characterization of 5-Aryl-4-(5-substituted-2-4- dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors.
1NCP	;		;	STRUCTURAL CHARACTERIZATION OF A 39 RESIDUE SYNTHETIC PEPTIDE CONTAINING THE TWO ZINC BINDING DOMAINS FROM THE HIV-1 P7 NUCLEOCAPSID PROTEIN BY CD AND NMR SPECTROSCOPY
2IYO	;	2.4	;	Structural characterization of a bacterial 6PDH reveals aspects of specificity, mechanism and mode of inhibition
2IB5	;	1.8	;	Structural characterization of a blue chromoprotein and its yellow mutant from the sea anemone cnidopus japonicus
2IB6	;	2.0	;	Structural characterization of a blue chromoprotein and its yellow mutant from the sea anemone cnidopus japonicus
5MLT	;	1.61	;	Structural characterization of a carbohydrate substrate binding protein from Streptococcus pneumoniae
2MKR	;		;	Structural Characterization of a Complex Between the Acidic Transactivation Domain of EBNA2 and the Tfb1/p62 subunit of TFIIH.
3SJP	;	2.004	;	Structural characterization of a GII.4 2004 norovirus variant (TCH05)
3SKB	;	3.22	;	Structural characterization of a GII.4 2004 norovirus variant (TCH05)
3SLD	;	2.679	;	Structural characterization of a GII.4 2004 norovirus variant (TCH05) bound to A trisaccharide
3SLN	;	2.841	;	Structural characterization of a GII.4 2004 norovirus variant (TCH05) bound to H pentasaccharide
3SEJ	;	3.041	;	Structural characterization of a GII.4 2004 norovirus variant (TCH05) bound to Secretor Lewis HBGA (LeB)
3C2S	;	2.3	;	Structural Characterization of a Human Fc Fragment Engineered for Lack of Effector Functions
6QPS	;	1.287	;	Structural characterization of a mannuronic acid specific polysaccharide family 6 lyase enzyme from human gut microbiota
2QL1	;	2.534	;	Structural Characterization of a Mutated, ADCC-Enhanced Human Fc Fragment
5C3C	;	2.8	;	Structural characterization of a newly identified component of alpha-carboxysomes: The AAA+ domain Protein cso-CbbQ
6B4M	;	2.5	;	Structural characterization of a novel monotreme-specific protein from the milk of the platypus
3CSX	;	1.84	;	Structural characterization of a protein in the DUF683 family- crystal structure of cce_0567 from the cyanobacterium Cyanothece 51142.
3E3K	;	2.8	;	Structural characterization of a putative endogenous metal chelator in the periplasmic nickel transporter NikA (butane-1,2,4-tricarboxylate without nickel form)
3DP8	;	2.5	;	Structural characterization of a putative endogenous metal chelator in the periplasmic nickel transporter NikA (nickel butane-1,2,4-tricarboxylate form)
2YJL	;	1.81	;	Structural characterization of a secretin pilot protein from the type III secretion system (T3SS) of Pseudomonas aeruginosa
4YEB	;	3.19	;	Structural characterization of a synaptic adhesion complex
3UX1	;	2.8	;	Structural Characterization of Adeno-Associated Virus Serotype 9
3CRT	;	1.9	;	Structural characterization of an engineered allosteric protein
3CRU	;	2.3	;	Structural characterization of an engineered allosteric protein
2LQ4	;		;	Structural Characterization of an LPA1 Second Extracellular Loop Mimetic with a Self-Assembling Coiled-Coil Folding Constraint
2YDM	;	2.44	;	Structural characterization of angiotensin-I converting enzyme in complex with a selenium analogue of captopril
2G15	;	2.15	;	Structural Characterization of autoinhibited c-Met kinase
6PMU	;	2.1	;	Structural Characterization of Beta Cyanoalanine Synthase from Tetranychus Urticae
7MFJ	;	2.351	;	Structural Characterization of Beta Cyanoalanine Synthase from Tetranychus Urticae
6XO2	;	1.6	;	Structural Characterization of Beta Cyanoalanine Synthase from Tetranychus Urticae (two-spotted spider mite)
8QME	;	2.25	;	Structural characterization of beta-xyloxidase XynB2 from Geobacillus stearothermophilus CECT43
1K2L	;	2.4	;	STRUCTURAL CHARACTERIZATION OF BISINTERCALATION IN HIGHER-ORDER DNA AT A JUNCTION-LIKE QUADRUPLEX
4E8E	;	2.51	;	Structural characterization of Bombyx mori glutathione transferase BmGSTD1
3WYW	;	1.7	;	Structural characterization of catalytic site of a Nilaparvata lugens delta-class glutathione transferase
6HVM	;	2.0	;	Structural characterization of CdaA-APO
5HDI	;	1.54	;	Structural characterization of CYP144A1, a Mycobacterium tuberculosis cytochrome P450
3II1	;	2.25	;	Structural characterization of difunctional glucanase-xylanse CelM2
6JZB	;	2.754	;	Structural characterization of DnaJ from Streptococcus pneumonia presents a new tetramer of Hsp40 family
3VP6	;	2.1	;	Structural characterization of Glutamic Acid Decarboxylase; insights into the mechanism of autoinactivation
4G0R	;	2.7	;	Structural characterization of H-1 Parvovirus: comparison of infectious virions to replication defective particles
4GBT	;	3.2	;	Structural characterization of H-1 Parvovirus: comparison of infectious virions to replication defective particles
3KWQ	;	3.5	;	Structural characterization of H3K56Q nucleosomes and nucleosomal arrays
3KXB	;	3.2	;	Structural characterization of H3K56Q nucleosomes and nucleosomal arrays
1YMA	;	2.0	;	STRUCTURAL CHARACTERIZATION OF HEME LIGATION IN THE HIS64-->TYR VARIANT OF MYOGLOBIN
4JS9	;	2.784	;	Structural Characterization of Inducible Nitric Oxide Synthase Substituted With Mesoheme
2MKN	;		;	Structural Characterization of Interactions between the Double-Stranded RNA-Binding Zinc Finger Protein JAZ and dsRNA
5DZZ	;	2.6	;	Structural characterization of intermediate filaments binding domain of desmoplakin
5EK5	;	2.26	;	STRUCTURAL CHARACTERIZATION OF IRMA FROM ESCHERICHIA COLI
7A6G	;	1.95	;	Structural characterization of L-proline amide hydrolase from Pseudomonas syringae
2M0M	;		;	Structural Characterization of Minor Ampullate Spidroin Domains and their Distinct Roles in Fibroin Solubility and Fiber Formation
4V6N	;	12.1	;	Structural characterization of mRNA-tRNA translocation intermediates (50S ribosome of class2 of the six classes)
4V6S	;	13.1	;	Structural characterization of mRNA-tRNA translocation intermediates (class 3 of the six classes)
4V6O	;	14.7	;	Structural characterization of mRNA-tRNA translocation intermediates (class 4a of the six classes)
4V6P	;	13.5	;	Structural characterization of mRNA-tRNA translocation intermediates (class 4b of the six classes)
4V6Q	;	11.5	;	Structural characterization of mRNA-tRNA translocation intermediates (class 5 of the six classes)
4V6R	;	11.5	;	Structural characterization of mRNA-tRNA translocation intermediates (class 6 of the six classes)
5Y05	;	2.799	;	Structural characterization of msmeg_4306 from Mycobacterium smegmatis
5Y06	;	2.606	;	Structural characterization of msmeg_4306 from Mycobacterium smegmatis
6IZJ	;	2.1	;	Structural characterization of mutated NreA protein in nitrate binding site from Staphylococcus aureus
6IZK	;	2.29	;	Structural characterization of mutated NreA protein in nitrate binding site from Staphylococcus aureus
6K2H	;	1.8	;	structural characterization of mutated NreA protein in nitrate binding site from staphylococcus aureus.
1GEI	;	1.6	;	STRUCTURAL CHARACTERIZATION OF N-BUTYL-ISOCYANIDE COMPLEXES OF CYTOCHROMES P450NOR AND P450CAM
1GEJ	;	1.5	;	STRUCTURAL CHARACTERIZATION OF N-BUTYL-ISOCYANIDE COMPLEXES OF CYTOCHROMES P450NOR AND P450CAM
1GEK	;	1.7	;	STRUCTURAL CHARACTERIZATION OF N-BUTYL-ISOCYANIDE COMPLEXES OF CYTOCHROMES P450NOR AND P450CAM
1GEM	;	2.0	;	STRUCTURAL CHARACTERIZATION OF N-BUTYL-ISOCYANIDE COMPLEXES OF CYTOCHROMES P450NOR AND P450CAM
1Y2Y	;		;	Structural Characterization of Nop10p using Nuclear Magnetic Resonance Spectroscopy
6VY7	;		;	Structural characterization of novel conotoxin MIIIB derived from Conus magus
3PGA	;	2.0	;	STRUCTURAL CHARACTERIZATION OF PSEUDOMONAS 7A GLUTAMINASE-ASPARAGINASE
2L9Q	;		;	Structural Characterization of small heat shock protein (Hsp12)
3IJT	;	2.377	;	Structural Characterization of SMU.440, a Hypothetical Protein from Streptococcus mutans
3EKL	;	1.51	;	Structural Characterization of tetrameric Mycobacterium tuberculosis fructose 1,6-bisphosphate aldolase - substrate binding and catalysis mechanism of a class IIa bacterial aldolase
3EKZ	;	2.07	;	Structural Characterization of tetrameric Mycobacterium tuberculosis fructose 1,6-bisphosphate aldolase - substrate binding and catalysis mechanism of a class IIa bacterial aldolase
3ELF	;	1.31	;	Structural Characterization of tetrameric Mycobacterium tuberculosis fructose 1,6-bisphosphate aldolase - substrate binding and catalysis mechanism of a class IIa bacterial aldolase
7TB9	;		;	Structural characterization of the biological synthetic peptide pCEMP1
3PM0	;	2.7	;	Structural Characterization of the Complex between Alpha-Naphthoflavone and Human Cytochrome P450 1B1 (CYP1B1)
1I9F	;		;	STRUCTURAL CHARACTERIZATION OF THE COMPLEX OF THE REV RESPONSE ELEMENT RNA WITH A SELECTED PEPTIDE
6AD3	;	1.79	;	Structural characterization of the condensation domain from Monacolin K polyketide synthase MokA
3OAH	;	3.0	;	Structural Characterization of the Dual Glycan Binding Adeno-Associated Virus Serotype 6
2M0T	;		;	Structural characterization of the extended PDZ1 domain from NHERF1
5O3X	;	2.55	;	Structural characterization of the fast and promiscuous macrocyclase from plant - apo PCY1
5O3W	;	2.0	;	Structural characterization of the fast and promiscuous macrocyclase from plant - PCY1-S562A bound to Presegetalin A1
5O3V	;	2.17	;	Structural characterization of the fast and promiscuous macrocyclase from plant - PCY1-S562A bound to Presegetalin B1
5O3U	;	1.86	;	Structural characterization of the fast and promiscuous macrocyclase from plant - PCY1-S562A bound to Presegetalin F1
4ZMR	;	2.001	;	Structural characterization of the full-length response regulator spr1814 in complex with a phosphate analogue reveals a novel conformational plasticity of the linker region
5ZHY	;	2.441	;	Structural characterization of the HCoV-229E fusion core
8OUP	;	1.7	;	Structural characterization of the hexa-coordinated globin from Spisula solidissima
3QDR	;	2.65	;	Structural characterization of the interaction of colicin A, colicin N, and TolB with the TolAIII translocon
3QDP	;	2.15	;	Structural characterization of the interaction of colicin A, colicin N, and TolB with TolAIII translocon
4WAI	;	2.427	;	Structural characterization of the late competence protein ComFB from Bacillus subtilis.
2MMG	;		;	Structural Characterization of the Mengovirus Leader Protein Bound to Ran GTPase by Nuclear Magnetic Resonance
1WR0	;		;	Structural characterization of the MIT domain from human Vps4b
6F2X	;		;	Structural characterization of the Mycobacterium tuberculosis Protein Tyrosine Kinase A (PtkA)
1DLP	;	3.3	;	STRUCTURAL CHARACTERIZATION OF THE NATIVE FETUIN-BINDING PROTEIN SCILLA CAMPANULATA AGGLUTININ (SCAFET): A NOVEL TWO-DOMAIN LECTIN
1T6C	;	1.53	;	Structural characterization of the Ppx/GppA protein family: crystal structure of the Aquifex aeolicus family member
3MFY	;	2.35	;	Structural characterization of the subunit A mutant F236A of the A-ATP synthase from Pyrococcus horikoshii
3SDZ	;	2.53	;	Structural characterization of the subunit A mutant F427W of the A-ATP synthase from Pyrococcus horikoshii
3SE0	;	2.62	;	Structural characterization of the subunit A mutant F508W of the A-ATP synthase from Pyrococcus horikoshii
3M4Y	;	2.38	;	Structural characterization of the subunit A mutant P235A of the A-ATP synthase
2EJN	;	1.64	;	Structural characterization of the tetrameric form of the major cat allergen fel D 1
5JO9	;	2.894	;	Structural characterization of the thermostable Bradyrhizobium japonicum d-sorbitol dehydrogenase
2JW1	;		;	Structural characterization of the type III pilotin-secretin interaction in Shigella flexneri by NMR spectroscopy
6XFL	;		;	Structural characterization of the type III secretion system pilotin-secretin complex InvH-InvG by NMR spectroscopy
2F5U	;	2.1	;	Structural Characterization of the UL25 DNA Packaging Protein from Herpes Simplex Virus Type 1
4FN6	;	2.69	;	Structural Characterization of Thiaminase type II TenA from Staphylococcus aureus
7PBH	;		;	Structural characterization of Thorarchaeota profilin indicates a eukaryotic-like fold but with an extended N-terminus
7LGL	;		;	Structural characterization of two b-KTx scorpion toxins. One of them blocks human KCNQ1 potassium channels
6PNT	;	1.85	;	Structural Characterization of UDP-glycosyltransferase from Tetranychus Urticae
4BYZ	;	1.55	;	Structural characterization using Sulfur-SAD of the cytoplasmic domain of Burkholderia pseudomallei PilO2Bp, an actin-like protein component of a Type IVb R64-derivative pilus machinery.
4BZ0	;	1.76	;	Structural characterization using Sulfur-SAD of the cytoplasmic domain of Burkholderia pseudomallei PilO2Bp, an actin-like protein component of a Type IVb R64-derivative pilus machinery.
3D0Z	;	2.5	;	Structural charcaterization of an engineered allosteric protein
2VXK	;	1.8	;	Structural comparison between Aspergillus fumigatus and human GNA1
249D	;	2.25	;	STRUCTURAL COMPARISON BETWEEN THE D(CTAG) SEQUENCE IN OLIGONUCLEOTIDES AND TRP AND MET REPRESSOR-OPERATOR COMPLEXES
250D	;	2.47	;	STRUCTURAL COMPARISON BETWEEN THE D(CTAG) SEQUENCE IN OLIGONUCLEOTIDES AND TRP AND MET REPRESSOR-OPERATOR COMPLEXES
1B0W	;	1.8	;	Structural comparison of amyloidogenic light chain dimer in two crystal forms with nonamyloidogenic counterparts
1D10	;	1.5	;	STRUCTURAL COMPARISON OF ANTICANCER DRUG-DNA COMPLEXES. ADRIAMYCIN AND DAUNOMYCIN
1D12	;	1.7	;	STRUCTURAL COMPARISON OF ANTICANCER DRUG-DNA COMPLEXES. ADRIAMYCIN AND DAUNOMYCIN
7A9Y	;	1.64	;	Structural comparison of cellular retinoic acid binding protein I and II in the presence and absence of natural and synthetic ligands
7A9Z	;	2.41	;	Structural comparison of cellular retinoic acid binding protein I and II in the presence and absence of natural and synthetic ligands
7AA0	;	1.82	;	Structural comparison of cellular retinoic acid binding protein I and II in the presence and absence of natural and synthetic ligands
7AA1	;	1.71	;	Structural comparison of cellular retinoic acid binding proteins I and II in the presence and absence of natural and synthetic ligands
1WG0	;	2.53	;	Structural comparison of Nas6p protein structures in two different crystal forms
1CPS	;	2.25	;	STRUCTURAL COMPARISON OF SULFODIIMINE AND SULFONAMIDE INHIBITORS IN THEIR COMPLEXES WITH ZINC ENZYMES
2GC4	;	1.9	;	Structural comparison of the oxidized ternary electron transfer complex of methylamine dehydrogenase, amicyanin and cytochrome c551i from Paracoccus denitrificans with the substrate-reduced, copper free complex at 1.9 A resolution.
1ENX	;	1.5	;	STRUCTURAL COMPARISON OF TWO MAJOR ENDO-1,4-BETA-XYLANASES FROM TRICHODREMA REESEI
1XYN	;	2.0	;	STRUCTURAL COMPARISON OF TWO MAJOR ENDO-1,4-BETA-XYLANASES FROM TRICHODREMA REESEI
1XYO	;	1.5	;	STRUCTURAL COMPARISON OF TWO MAJOR ENDO-1,4-BETA-XYLANASES FROM TRICHODREMA REESEI
1XYP	;	1.5	;	STRUCTURAL COMPARISON OF TWO MAJOR ENDO-1,4-BETA-XYLANASES FROM TRICHODREMA REESEI
2SEC	;	1.8	;	STRUCTURAL COMPARISON OF TWO SERINE PROTEINASE-PROTEIN INHIBITOR COMPLEXES. EGLIN-C-SUBTILISIN CARLSBERG AND CI-2-SUBTILISIN NOVO
2SNI	;	2.1	;	STRUCTURAL COMPARISON OF TWO SERINE PROTEINASE-PROTEIN INHIBITOR COMPLEXES. EGLIN-C-SUBTILISIN CARLSBERG AND CI-2-SUBTILISIN NOVO
1ZWZ	;	1.9	;	Structural comparison of Yeast snoRNP and splicesomal protein snu13p with its homologs
8TLN	;	1.6	;	STRUCTURAL COMPARISON SUGGESTS THAT THERMOLYSIN AND RELATED NEUTRAL PROTEASES UNDERGO HINGE-BENDING MOTION DURING CATALYSIS
4ZS3	;	2.45	;	Structural complex of 5-aminofluorescein bound to the FTO protein
7CKK	;	2.35	;	Structural complex of FTO bound with Dac51
4ZS2	;	2.16	;	Structural complex of FTO/fluorescein
1N5O	;	2.8	;	Structural consequences of a cancer-causing BRCA1-BRCT missense mutation
1D85	;	2.5	;	STRUCTURAL CONSEQUENCES OF A CARCINOGENIC ALKYLATION LESION ON DNA: EFFECT OF O6-ETHYL-GUANINE ON THE MOLECULAR STRUCTURE OF D(CGC[E6G]AATTCGCG)-NETROPSIN COMPLEX
1D86	;	2.2	;	STRUCTURAL CONSEQUENCES OF A CARCINOGENIC ALKYLATION LESION ON DNA: EFFECT OF O6-ETHYL-GUANINE ON THE MOLECULAR STRUCTURE OF D(CGC[E6G]AATTCGCG)-NETROPSIN COMPLEX
3ICV	;	1.49	;	Structural Consequences of a Circular Permutation on Lipase B from Candida Antartica
1EI8	;	2.0	;	STRUCTURAL CONSEQUENCES OF A DISCONTINUITY IN THE REPEATING TRIPEPTIDE SEQUENCE OF A COLLAGEN-LIKE TRIPLE-HELICAL PEPTIDE
1P2I	;	1.65	;	Structural consequences of accommodation of four non-cognate amino-acid residues in the S1 pocket of bovine trypsin and chymotrypsin
1P2J	;	1.35	;	Structural consequences of accommodation of four non-cognate amino-acid residues in the S1 pocket of bovine trypsin and chymotrypsin
1P2K	;	1.6	;	Structural consequences of accommodation of four non-cognate amino-acid residues in the S1 pocket of bovine trypsin and chymotrypsin
1P2M	;	1.75	;	Structural consequences of accommodation of four non-cognate amino-acid residues in the S1 pocket of bovine trypsin and chymotrypsin
1P2N	;	1.8	;	Structural consequences of accommodation of four non-cognate amino-acid residues in the S1 pocket of bovine trypsin and chymotrypsin
1P2O	;	2.0	;	Structural consequences of accommodation of four non-cognate amino-acid residues in the S1 pocket of bovine trypsin and chymotrypsin
1P2Q	;	1.8	;	Structural consequences of accommodation of four non-cognate amino-acid residues in the S1 pocket of bovine trypsin and chymotrypsin
4AT1	;	2.6	;	STRUCTURAL CONSEQUENCES OF EFFECTOR BINDING TO THE T STATE OF ASPARTATE CARBAMOYLTRANSFERASE. CRYSTAL STRUCTURES OF THE UNLIGATED AND ATP-, AND CTP-COMPLEXED ENZYMES AT 2.6-ANGSTROMS RESOLUTION
5AT1	;	2.6	;	STRUCTURAL CONSEQUENCES OF EFFECTOR BINDING TO THE T STATE OF ASPARTATE CARBAMOYLTRANSFERASE. CRYSTAL STRUCTURES OF THE UNLIGATED AND ATP-, AND CTP-COMPLEXED ENZYMES AT 2.6-ANGSTROMS RESOLUTION
6AT1	;	2.6	;	STRUCTURAL CONSEQUENCES OF EFFECTOR BINDING TO THE T STATE OF ASPARTATE CARBAMOYLTRANSFERASE. CRYSTAL STRUCTURES OF THE UNLIGATED AND ATP-, AND CTP-COMPLEXED ENZYMES AT 2.6-ANGSTROMS RESOLUTION
1HEB	;	2.0	;	STRUCTURAL CONSEQUENCES OF HYDROPHILIC AMINO-ACID SUBSTITUTIONS IN THE HYDROPHOBIC POCKET OF HUMAN CARBONIC ANHYDRASE II
1HEC	;	2.0	;	STRUCTURAL CONSEQUENCES OF HYDROPHILIC AMINO-ACID SUBSTITUTIONS IN THE HYDROPHOBIC POCKET OF HUMAN CARBONIC ANHYDRASE II
1HED	;	2.0	;	STRUCTURAL CONSEQUENCES OF HYDROPHILIC AMINO-ACID SUBSTITUTIONS IN THE HYDROPHOBIC POCKET OF HUMAN CARBONIC ANHYDRASE II
1CVD	;	2.2	;	STRUCTURAL CONSEQUENCES OF REDESIGNING A PROTEIN-ZINC BINDING SITE
1CVE	;	2.25	;	STRUCTURAL CONSEQUENCES OF REDESIGNING A PROTEIN-ZINC BINDING SITE
1CVF	;	2.25	;	STRUCTURAL CONSEQUENCES OF REDESIGNING A PROTEIN-ZINC BINDING SITE
1CVH	;	2.3	;	STRUCTURAL CONSEQUENCES OF REDESIGNING A PROTEIN-ZINC BINDING SITE
132L	;	1.8	;	STRUCTURAL CONSEQUENCES OF REDUCTIVE METHYLATION OF LYSINE RESIDUES IN HEN EGG WHITE LYSOZYME: AN X-RAY ANALYSIS AT 1.8 ANGSTROMS RESOLUTION
6PL5	;	3.5	;	Structural coordination of polymerization and crosslinking by a peptidoglycan synthase complex
6PL6	;	3.3	;	Structural coordination of polymerization and crosslinking by a peptidoglycan synthase complex
3F91	;	1.9	;	Structural Data for Human Active Site Mutant Enzyme Complexes
5YY5	;	2.8	;	Structural definition of a unique neutralization epitope on the receptor-binding domain of MERS-CoV spike glycoprotein
5ZXV	;	4.482	;	Structural definition of a unique neutralization epitope on the receptor-binding domain of MERS-CoV spike glycoprotein
6XRQ	;	1.21	;	Structural descriptions of ligand interactions to DNA and RNA quadruplexes folded from the non-coding region of Pseudorabies virus
2RN2	;	1.48	;	STRUCTURAL DETAILS OF RIBONUCLEASE H FROM ESCHERICHIA COLI AS REFINED TO AN ATOMIC RESOLUTION
1ETU	;	2.9	;	STRUCTURAL DETAILS OF THE BINDING OF GUANOSINE DIPHOSPHATE TO ELONGATION FACTOR TU FROM E. COLI AS STUDIED BY X-RAY CRYSTALLOGRAPHY
5B6C	;	1.55	;	Structural Details of Ufd1 binding to p97
1TAG	;	1.8	;	STRUCTURAL DETERMINANTS FOR ACTIVATION OF THE ALPHA-SUBUNIT OF A HETEROTRIMERIC G PROTEIN
2K3H	;		;	Structural determinants for Ca2+ and PIP2 binding by the C2A domain of rabphilin-3A
2XEE	;	2.1	;	Structural Determinants for Improved Thermal Stability of Designed Ankyrin Repeat Proteins With a Redesigned C-capping Module.
2XEH	;	1.81	;	Structural Determinants for Improved Thermal Stability of Designed Ankyrin Repeat Proteins With a Redesigned C-capping Module.
2XEN	;	2.2	;	Structural Determinants for Improved Thermal Stability of Designed Ankyrin Repeat Proteins With a Redesigned C-capping Module.
6DRX	;	3.1	;	Structural Determinants of Activation and Biased Agonism at the 5-HT2B Receptor
6DRY	;	2.918	;	Structural Determinants of Activation and Biased Agonism at the 5-HT2B Receptor
6DRZ	;	3.102	;	Structural Determinants of Activation and Biased Agonism at the 5-HT2B Receptor
6DS0	;	3.188	;	Structural Determinants of Activation and Biased Agonism at the 5-HT2B Receptor
1MYM	;	1.7	;	STRUCTURAL DETERMINANTS OF CO STRETCHING VIBRATION FREQUENCIES IN MYOGLOBIN
4BHT	;	2.5	;	Structural Determinants of Cofactor Specificity and Domain Flexibility in Bacterial Glutamate Dehydrogenases
8PUO	;	1.8	;	Structural determinants of cold-activity and glucose tolerance of a family 1 glycoside hydrolase (GH1) from Antarctic Marinomonas Ef 1
1SEM	;	2.0	;	STRUCTURAL DETERMINANTS OF PEPTIDE-BINDING ORIENTATION AND OF SEQUENCE SPECIFICITY IN SH3 DOMAINS
2W07	;	2.2	;	Structural determinants of polymerization reactivity of the P pilus adaptor subunit PapF
2YKU	;	1.9	;	Structural Determinants of the Beta-Selectivity of a Bacterial Aminotransferase
2YKV	;	1.9	;	Structural Determinants of the Beta-Selectivity of a Bacterial Aminotransferase
2YKX	;	1.85	;	Structural Determinants of the Beta-Selectivity of a Bacterial Aminotransferase
2YKY	;	1.69	;	Structural Determinants of the Beta-Selectivity of a Bacterial Aminotransferase
4AO4	;	1.95	;	Structural Determinants of the beta-Selectivity of a Bacterial Aminotransferase
1GQ5	;	2.2	;	Structural Determinants of the NHERF Interaction with beta2-AR and PDGFR
1GQ4	;	1.9	;	STRUCTURAL DETERMINANTS OF THE NHERF INTERACTION WITH BETA2AR AND PDGFR
1Z14	;	3.25	;	Structural Determinants of Tissue Tropism and In Vivo Pathogenicity for the Parvovirus Minute Virus of Mice
1Z1C	;	3.5	;	Structural Determinants of Tissue Tropism and In Vivo Pathogenicity for the Parvovirus Minute virus of Mice
3U91	;	1.45	;	Structural Determinants of Trimerization Specificity in HIV-1 gp41 Protein
3UIA	;	2.0	;	Structural Determinants of Trimerization Specificity in HIV-1 gp41 Protein
4HLR	;	1.57	;	Structural Determinants of Trimerization Specificity in HIV-1 gp41 Protein
7A6P	;	1.93	;	Structural determinants underlying the adduct lifetime in a short LOV protein PpSB2-LOV
5EII	;	2.44	;	Structural determination of an protein complex of a Fab with increased solubility
4M1B	;	1.99	;	Structural Determination of BA0150, a Polysaccharide Deacetylase from Bacillus anthracis
4JAD	;	1.9	;	STRUCTURAL DETERMINATION OF THE A50T:S279G:S280K:V281K:K282E:H283N VARIANT OF CITRATE SYNTHASE from E. COLI
4JAF	;	2.3	;	STRUCTURAL DETERMINATION OF THE A50T:S279G:S280K:V281K:K282E:H283N VARIANT OF CITRATE SYNTHASE FROM E. COLI COMPLEXED with NADH
4JAG	;	2.1	;	STRUCTURAL DETERMINATION OF THE A50T:S279G:S280K:V281K:K282E:H283N VARIANT OF CITRATE SYNTHASE FROM E. COLI COMPLEXED WITH oxaloacetate
4JAE	;	2.7	;	STRUCTURAL DETERMINATION OF THE A50T:S279G:S280K:V281K:K282E:H283N VARIANT OF CITRATE SYNTHASE FROM E. COLI complexed WITH S-CARBOXYMETHYL-COA
6NZY	;	1.9	;	Structural Determination of the Carboxy-terminal portion of ATP-citrate lyase
2M70	;		;	Structural determination of the Citrus sinensis Poly(A)-Binding Protein CsPABP1
1T4W	;	2.1	;	Structural Differences in the DNA Binding Domains of Human p53 and its C. elegans Ortholog Cep-1: Structure of C. elegans Cep-1
1SKX	;	2.8	;	Structural Disorder in the Complex of Human PXR and the Macrolide Antibiotic Rifampicin
3DBH	;	2.85	;	Structural Dissection of a Gating Mechanism Preventing Misactivation of Ubiquitin by NEDD8's E1 (APPBP1-UBA3Arg190Ala-NEDD8Ala72Arg)
3DBR	;	3.05	;	Structural Dissection of a Gating Mechanism Preventing Misactivation of Ubiquitin by NEDD8's E1 (APPBP1-UBA3Arg190Gln-NEDD8Ala72Arg)
3DBL	;	2.9	;	Structural Dissection of a Gating Mechanism Preventing Misactivation of Ubiquitin by NEDD8's E1 (APPBP1-UBA3Arg190wt-NEDD8Ala72Gln)
2ZOQ	;	2.39	;	Structural dissection of human mitogen-activated kinase ERK1
2B2B	;	1.5	;	Structural distortions in psoralen cross-linked DNA
2C52	;		;	Structural diversity in CBP p160 complexes
3G51	;	1.8	;	Structural diversity of the active conformation of the N-terminal kinase domain of p90 ribosomal S6 kinase 2
2O6Q	;	2.5	;	Structural diversity of the hagfish Variable Lymphocyte Receptors A29
2O6S	;	1.5	;	Structural diversity of the hagfish Variable Lymphocyte Receptors B59
2O6R	;	2.3	;	Structural diversity of the hagfish Variable Lymphocyte Receptors B61
6FHN	;	2.0	;	Structural dynamics and catalytic properties of a multi-modular xanthanase (Pt derivative)
6FHJ	;	2.04	;	Structural dynamics and catalytic properties of a multi-modular xanthanase, native.
2MS5	;		;	Structural dynamics of double-helical RNA having CAG motif
3J3R	;	9.4	;	Structural dynamics of the MecA-ClpC complex revealed by cryo-EM
3J3S	;	11.0	;	Structural dynamics of the MecA-ClpC complex revealed by cryo-EM
3J3T	;	9.0	;	Structural dynamics of the MecA-ClpC complex revealed by cryo-EM
3J3U	;	10.0	;	Structural dynamics of the MecA-ClpC complex revealed by cryo-EM
3CNZ	;	2.9	;	Structural dynamics of the microtubule binding and regulatory elements in the kinesin-like calmodulin binding protein
3COB	;	2.2	;	Structural Dynamics of the Microtubule binding and regulatory elements in the Kinesin-like Calmodulin binding protein
1HKG	;	3.5	;	STRUCTURAL DYNAMICS OF YEAST HEXOKINASE DURING CATALYSIS
1AAL	;	1.6	;	STRUCTURAL EFFECTS INDUCED BY MUTAGENESIS AFFECTED BY CRYSTAL PACKING FACTORS: THE STRUCTURE OF A 30-51 DISULFIDE MUTANT OF BASIC PANCREATIC TRYPSIN INHIBITOR
7PTI	;	1.6	;	STRUCTURAL EFFECTS INDUCED BY REMOVAL OF A DISULFIDE BRIDGE. THE X-RAY STRUCTURE OF THE C30A(SLASH)C51A MUTANT OF BASIC PANCREATIC TRYPSIN INHIBITOR AT 1.6 ANGSTROMS
2NXR	;	1.7	;	Structural effects of hydrophobic mutations on the active site of human carbonic anhydrase II
7POF	;		;	Structural effects of m6A modification of the Xist A repeat AUCG tetraloop and its recognition by YTHDC1
1B0D	;	1.84	;	Structural effects of monovalent anions on polymorphic lysozyme crystals
1B2K	;	1.6	;	Structural effects of monovalent anions on polymorphic lysozyme crystals
1HF4	;	1.45	;	STRUCTURAL EFFECTS OF MONOVALENT ANIONS ON POLYMORPHIC LYSOZYME CRYSTALS
3U6M	;	2.1	;	Structural effects of sequence context on lesion recognition by MutM
6V7O	;	2.9	;	Structural Elucidation of Peptide Binding to KLHL-12, a Substrate Specific Adapter Protein in a Cul3-Ring E3 Ligase Complex
6OOL	;	2.8	;	Structural elucidation of the Ectodomain of mouse UNC5H2
2N6M	;		;	Structural elucidation of the frog skin-derived peptide Esculentin-1a[Esc(1-21)NH2] inLipopolysaccharide and correlation with their function
2N0T	;		;	Structural ensemble of the enzyme cyclophilin reveals an orchestrated mode of action at atomic resolution
4M4U	;	1.84	;	Structural evaluation D84A mutant of the aspergillus fumigatus kdnase (sialidase)
4M4V	;	1.84	;	Structural evaluation R171L mutant of the aspergillus fumigatus kdnase (sialidase)
4M4N	;	1.84	;	Structural evaluation the Y358H mutant of the aspergillus fumigatus kdnase (sialidase)
2JHF	;	1.0	;	Structural evidence for a ligand coordination switch in liver alcohol dehydrogenase
2JHG	;	1.2	;	Structural evidence for a ligand coordination switch in liver alcohol dehydrogenase
1NNT	;	2.3	;	STRUCTURAL EVIDENCE FOR A PH-SENSITIVE DI-LYSINE TRIGGER IN THE HEN OVOTRANSFERRIN N-LOBE: IMPLICATIONS FOR TRANSFERRIN IRON RELEASE
1K9V	;	2.4	;	Structural evidence for ammonia tunelling across the (beta-alpha)8-barrel of the imidazole glycerol phosphate synthase bienzyme complex
3ZR4	;	2.41	;	STRUCTURAL EVIDENCE FOR AMMONIA TUNNELING ACROSS THE (BETA-ALPHA)8 BARREL OF THE IMIDAZOLE GLYCEROL PHOSPHATE SYNTHASE BIENZYME COMPLEX
1GPW	;	2.4	;	Structural evidence for ammonia tunneling across the (beta/alpha)8 barrel of the imidazole glycerol phosphate synthase bienzyme complex.
4N1C	;	1.7	;	Structural evidence for antigen receptor evolution
4N1E	;	2.23	;	Structural evidence for antigen receptor evolution
1NVU	;	2.2	;	Structural evidence for feedback activation by RasGTP of the Ras-specific nucleotide exchange factor SOS
1NVV	;	2.18	;	Structural evidence for feedback activation by RasGTP of the Ras-specific nucleotide exchange factor SOS
1NVW	;	2.7	;	Structural evidence for feedback activation by RasGTP of the Ras-specific nucleotide exchange factor SOS
1NVX	;	3.2	;	Structural evidence for feedback activation by RasGTP of the Ras-specific nucleotide exchange factor SOS
1HIM	;	2.9	;	STRUCTURAL EVIDENCE FOR INDUCED FIT AS A MECHANISM FOR ANTIBODY-ANTIGEN RECOGNITION
1HIN	;	3.1	;	STRUCTURAL EVIDENCE FOR INDUCED FIT AS A MECHANISM FOR ANTIBODY-ANTIGEN RECOGNITION
1HIL	;	2.0	;	STRUCTURAL EVIDENCE FOR INDUCED FIT AS A MECHANISM FOR ANTIGEN-ANTIBODY RECOGNITION
3ORD	;	2.22	;	Structural Evidence for Stabilization of Inhibitor Binding by a Protein Cavity in the Dehaloperoxidase-Hemoglobin from Amphitrite ornata
1PCH	;	1.8	;	STRUCTURAL EVIDENCE FOR THE EVOLUTIONARY DIVERGENCE OF MYCOPLASMA FROM GRAM-POSITIVE BACTERIA: THE HISTIDINE-CONTAINING PHOSPHOCARRIER PROTEIN
7AAF	;		;	Structural evolution of the tissue-specific U2AF2 paralog and alternative splicing factor LS2
7AAO	;		;	Structural evolution of the tissue-specific U2AF2 paralog and alternative splicing factor LS2
2JL9	;	3.2	;	Structural explanation for the role of Mn in the activity of phi6 RNA- dependent RNA polymerase
2JLF	;	3.2	;	STRUCTURAL EXPLANATION FOR THE ROLE OF MN IN THE ACTIVITY OF PHI6 RNA- DEPENDENT RNA POLYMERASE
2JLG	;	2.8	;	STRUCTURAL EXPLANATION FOR THE ROLE OF MN IN THE ACTIVITY OF PHI6 RNA-DEPENDENT RNA POLYMERASE
2PLV	;	2.88	;	STRUCTURAL FACTORS THAT CONTROL CONFORMATIONAL TRANSITIONS AND SEROTYPE SPECIFICITY IN TYPE 3 POLIOVIRUS
1D99	;	2.5	;	STRUCTURAL FEATURES AND HYDRATION OF A DODECAMER DUPLEX CONTAINING TWO C.A MISPAIRS
2MXL	;		;	Structural features of a 3' splice site in influenza A: 39-nt hairpin
2MXJ	;		;	Structural features of a 3' splice site influenza A: 11-nt hairpin
2MXK	;		;	Structural features of a 3' splice site influenza A: 19-nt duplex
1HA5	;	2.82	;	Structural features of a zinc-binding site in the superantigen streptococcal pyrogenic exotoxin A (SpeA1): implications for MHC class II recognition.
1AZU	;	2.7	;	STRUCTURAL FEATURES OF AZURIN AT 2.7 ANGSTROMS RESOLUTION
2WK5	;	2.99	;	Structural features of native human thymidine phosphorylase and in complex with 5-iodouracil
2WK6	;	2.5	;	Structural features of native human thymidine phosphorylase and in complex with 5-iodouracil
4AGH	;	1.787	;	Structural features of ssDNA binding protein MoSub1 from Magnaporthe oryzae
2K9F	;		;	Structural features of the complex between the DsbD N-terminal and the PilB N-terminal domains from Neisseria meningitidis
1AC7	;		;	STRUCTURAL FEATURES OF THE DNA HAIRPIN D(ATCCTAGTTATAGGAT): THE FORMATION OF A G-A BASE PAIR IN THE LOOP, NMR, 10 STRUCTURES
1HLP	;	3.2	;	STRUCTURAL FEATURES STABILIZING HALOPHILIC MALATE DEHYDROGENASE FROM AN ARCHAEBACTERIUM
2YPK	;	1.95	;	Structural features underlying T-cell receptor sensitivity to concealed MHC class I micropolymorphisms
2YPL	;	2.4	;	Structural features underlying T-cell receptor sensitivity to concealed MHC class I micropolymorphisms
3O2R	;	1.251	;	Structural flexibility in region involved in dimer formation of nuclease domain of Ribonuclase III (rnc) from Campylobacter jejuni
8RCQ	;	3.8	;	Structural flexibility of Nucleoprotein of the Toscana virus in the presence of a nanobody.
3QJM	;	2.311	;	Structural flexibility of Shank PDZ domain is important for its binding to different ligands
3QJN	;	2.71	;	Structural flexibility of Shank PDZ domain is important for its binding to different ligands
1ML8	;	2.6	;	structural genomics
1R9H	;	1.8	;	Structural Genomics of C.elegans: FKBP-type Peptidylprolyl Isomerase
1OOJ	;	2.11	;	Structural genomics of Caenorhabditis elegans : Calmodulin
1OOE	;	1.65	;	Structural Genomics of Caenorhabditis elegans : Dihydropteridine reductase
1YIS	;	2.4	;	Structural genomics of Caenorhabditis elegans: adenylosuccinate lyase
1LPL	;	1.77	;	Structural Genomics of Caenorhabditis elegans: CAP-Gly domain of F53F4.3
1TOV	;	1.77	;	Structural genomics of Caenorhabditis elegans: CAP-GLY domain of F53F4.3
1YQ1	;	3.0	;	Structural Genomics Of Caenorhabditis Elegans: glutathione S-Transferase
1QWK	;	1.6	;	Structural genomics of Caenorhabditis Elegans: Hypothetical 35.2 kDa protein (aldose reductase family member)
1T9F	;	2.0	;	Structural genomics of Caenorhabditis elegans: Structure of a protein with unknown function
1T7S	;	2.8	;	Structural Genomics of Caenorhabditis elegans: Structure of BAG-1 protein
1MO0	;	1.7	;	Structural Genomics Of Caenorhabditis Elegans: Triose Phosphate Isomerase
1PGV	;	1.8	;	Structural Genomics of Caenorhabditis elegans: tropomodulin C-terminal domain
1Y9W	;	1.9	;	Structural Genomics, 1.9A crystal structure of an acetyltransferase from Bacillus cereus ATCC 14579
1SR8	;	1.9	;	Structural Genomics, 1.9A crystal structure of cobalamin biosynthesis protein (cbiD) from Archaeoglobus fulgidus
1S7H	;	2.2	;	Structural Genomics, 2.2A crystal structure of protein YKOF from Bacillus subtilis
1RLJ	;	2.0	;	Structural Genomics, a Flavoprotein NrdI from Bacillus subtilis
1T5B	;	1.4	;	Structural genomics, A protein from Salmonella typhimurium similar to E. coli acyl carrier protein phosphodiesterase
1NQK	;	2.2	;	Structural Genomics, Crystal structure of Alkanesulfonate monooxygenase
1L7A	;	1.5	;	structural Genomics, crystal structure of Cephalosporin C deacetylase
1T8Q	;	2.0	;	Structural genomics, Crystal structure of Glycerophosphoryl diester phosphodiesterase from E. coli
1SQU	;	2.4	;	Structural Genomics, Crystal structure of the CheX protein from Thermotoga maritima
1I60	;	1.6	;	Structural genomics, IOLI protein
1PC6	;	2.51	;	Structural Genomics, NinB
1KTN	;	1.4	;	Structural Genomics, Protein EC1535
1K4N	;	1.6	;	Structural Genomics, Protein EC4020
1OTK	;	2.0	;	Structural Genomics, Protein paaC
1K7J	;	1.4	;	Structural Genomics, protein TF1
1KUT	;	2.2	;	Structural Genomics, Protein TM1243, (SAICAR synthetase)
1NMO	;	2.2	;	Structural genomics, protein ybgI, unknown function
1Q8B	;	1.9	;	Structural Genomics, protein YJCS
1PF5	;	2.5	;	Structural Genomics, Protein YJGH
1NN4	;	2.2	;	Structural Genomics, RpiB/AlsB
2O3G	;	2.55	;	Structural Genomics, the crystal structure of a conserved putative domain from Neisseria meningitidis MC58
2P0T	;	2.19	;	Structural Genomics, the crystal structure of a conserved putative protein from Pseudomonas syringae pv. tomato str. DC3000
2AO9	;	1.9	;	Structural Genomics, The crystal structure of a Phage protein (phBC6A51) from Bacillus cereus ATCC 14579
2GEN	;	1.7	;	Structural Genomics, the crystal structure of a probable transcriptional regulator from Pseudomonas aeruginosa PAO1
2PMA	;	1.89	;	Structural Genomics, the crystal structure of a protein Lpg0085 with unknown function (DUF785) from Legionella pneumophila subsp. pneumophila str. Philadelphia 1.
2P0S	;	1.6	;	Structural Genomics, the crystal structure of a putative ABC transporter domain from Porphyromonas gingivalis W83
2OR0	;	2.1	;	Structural Genomics, the crystal structure of a putative hydroxylase from Rhodococcus sp. RHA1
2AN1	;	2.0	;	Structural Genomics, The crystal structure of a putative kinase from Salmonella typhimurim LT2
2OQT	;	2.41	;	Structural Genomics, the crystal structure of a putative PTS IIA domain from Streptococcus pyogenes M1 GAS
2HKU	;	2.0	;	Structural Genomics, the crystal structure of a putative transcriptional regulator from Rhodococcus sp. RHA1
2HXI	;	1.7	;	Structural Genomics, the crystal structure of a putative transcriptional regulator from Streptomyces coelicolor A3(2)
2HS5	;	2.2	;	Structural Genomics, the crystal structure of a putative transcriptional regulator GntR from Rhodococcus sp. RHA1
1T33	;	2.2	;	Structural Genomics, The crystal structure of a putative transcriptional repressor (TetR/AcrR family) from Salmonella typhimurim LT2
2GUP	;	2.01	;	Structural Genomics, the crystal structure of a ROK family protein from Streptococcus pneumoniae TIGR4 in complex with sucrose
2OF7	;	2.3	;	Structural Genomics, the crystal structure of a tetR-family transcriptional regulator from Streptomyces coelicolor A3
2GNP	;	1.65	;	Structural Genomics, the crystal structure of a transcriptional regulator from Streptococcus pneumoniae TIGR4
1XIZ	;	2.0	;	Structural Genomics, The crystal structure of domain IIA of putative phosphotransferase system specific for mannitol/fructose from Salmonella typhimurium
2I9Z	;	2.3	;	Structural Genomics, the Crystal structure of full-length SpoVG from Staphylococcus epidermidis ATCC 12228
2NR7	;	1.3	;	Structural Genomics, the crystal structure of putative secretion activator protein from Porphyromonas gingivalis W83
2I9X	;	1.8	;	Structural Genomics, the crystal structure of SpoVG conserved domain from Staphylococcus epidermidis ATCC 12228
2IA9	;	3.0	;	Structural Genomics, the crystal structure of SpoVG from Bacillus subtilis subsp. subtilis str. 168
1Z9U	;	2.2	;	Structural Genomics, The crystal structure of the acetyl transferase, modifies N-terminal serine of 50S ribosomal subunit protein L7/L12 from Salmonella typhimurium
2PKH	;	1.95	;	Structural Genomics, the crystal structure of the C-terminal domain of histidine utilization repressor from Pseudomonas syringae pv. tomato str. DC3000
2IKK	;	1.8	;	Structural Genomics, the crystal structure of the C-terminal domain of Yurk from Bacillus subtilis subsp. subtilis str. 168
2PLS	;	2.15	;	Structural Genomics, the crystal structure of the CorC/HlyC transporter associated domain of a CBS domain protein from Chlorobium tepidum TLS
2PQQ	;	2.0	;	Structural Genomics, the crystal structure of the N-terminal domain of a transcriptional regulator from Streptomyces coelicolor A3(2)
2O3F	;	1.75	;	Structural Genomics, the crystal structure of the N-terminal domain of the putative transcriptional regulator ybbH from Bacillus subtilis subsp. subtilis str. 168.
1OJ7	;	2.0	;	STRUCTURAL GENOMICS, UNKNOWN FUNCTION CRYSTAL STRUCTURE OF E. COLI K-12 YQHD
1NMP	;	2.2	;	Structural genomics, ybgI protein, unknown function
2FB5	;	1.99	;	Structural Genomics; The crystal structure of the hypothetical membrane spanning protein from Bacillus cereus
2KT6	;		;	Structural homology between the C-terminal domain of the PapC usher and its plug
1PZD	;	2.31	;	Structural Identification of a conserved appendage domain in the carboxyl-terminus of the COPI gamma-subunit.
4UUY	;	2.14	;	Structural Identification of the Vps18 beta-propeller reveals a critical role in the HOPS complex stability and function.
5KGV	;		;	Structural impact of single ribonucleotides in DNA
5KI4	;		;	Structural impact of single ribonucleotides in DNA
5KI5	;		;	Structural impact of single ribonucleotides in DNA
5KI7	;		;	Structural impact of single ribonucleotides in DNA
5KIB	;		;	Structural impact of single ribonucleotides in DNA
5KIE	;		;	Structural impact of single ribonucleotides in DNA
5KIF	;		;	Structural impact of single ribonucleotides in DNA
5KIH	;		;	Structural impact of single ribonucleotides in DNA
7KRQ	;	3.4	;	Structural impact on SARS-CoV-2 spike protein by D614G substitution
7KRR	;	3.5	;	Structural impact on SARS-CoV-2 spike protein by D614G substitution
7KRS	;	3.2	;	Structural impact on SARS-CoV-2 spike protein by D614G substitution
1FFF	;	1.9	;	STRUCTURAL IMPLICATIONS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE : HIGH RESOLUTION CRYSTAL STRUCTURES OF THE MUTANT PROTEASE/SUBSTRATE ANALOG COMPLEXES.
1FEJ	;	1.78	;	STRUCTURAL IMPLICATIONS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE: HIGH RESOLUTION CRYSTAL STRUCTURES OF THE MUTANT PROTEASE/SUBSTRATE ANALOG COMPLEXES
1FFI	;	1.7	;	STRUCTURAL IMPLICATIONS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE: HIGH RESOLUTION CRYSTAL STRUCTURES OF THE MUTANT PROTEASE/SUBSTRATE ANALOG COMPLEXES
1FG6	;	1.8	;	STRUCTURAL IMPLICATIONS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE: HIGH RESOLUTION CRYSTAL STRUCTURES OF THE MUTANT PROTEASE/SUBSTRATE ANALOG COMPLEXES
1FG8	;	1.85	;	STRUCTURAL IMPLICATIONS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE: HIGH RESOLUTION CRYSTAL STRUCTURES OF THE MUTANT PROTEASE/SUBSTRATE ANALOG COMPLEXES
1FGC	;	1.9	;	STRUCTURAL IMPLICATIONS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE: HIGH RESOLUTION CRYSTAL STRUCTURES OF THE MUTANT PROTEASE/SUBSTRATE ANALOG COMPLEXES
1FF0	;	1.85	;	STRUCTURAL IMPLICATIONS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE: HIGH RESOLUTION CRYSTAL STRUCTURES OF THE MUTANT PROTEASE/SUBSTRATE ANALOG COMPLEXES.
5CV2	;	2.693	;	Structural implications of homo-pyrimidine base pairs on the parallel-stranded d(GAY) motif
4ZYM	;	2.53	;	Structural implications of homo-pyrimidine base pairs on the parallel-stranded d(GAY) motif.
4L5W	;	1.7	;	Structural implications of the secondary CO2 binding pocket in human carbonic anhydrase II
2NCR	;		;	Structural insight for dynamics of r(CGG) motif RNA found in Fragile X syndrome/ Fragile X tremor ataxia at 25 degree C
7YUA	;	2.5	;	Structural Insight into a Metal-Dependent Mutase MtdL Revealing an Arginine Residue Covalently Mediated Interconversion between Nucleotide-Based furanose and pyranose
7YV0	;	2.34	;	Structural Insight into a Metal-Dependent Mutase MtdL Revealing an Arginine Residue Covalently Mediated Interconversion between Nucleotide-Based furanose and pyranose
6EHN	;	1.9	;	Structural insight into a promiscuous CE15 esterase from the marine bacterial metagenome
7YEQ	;	2.32	;	Structural insight into African Swine Fever Virus CP312R protein reveals it as a single-stranded DNA binding protein
2MVF	;		;	Structural insight into an essential assembly factor network on the pre-ribosome
5GUF	;	2.397	;	Structural insight into an intramembrane enzyme for archaeal membrane lipids biosynthesis
2JL1	;	1.96	;	Structural insight into bioremediation of triphenylmethane dyes by Citrobacter sp. triphenylmethane reductase
4M7E	;	3.602	;	Structural insight into BL-induced activation of the BRI1-BAK1 complex
3RGX	;	2.47	;	Structural insight into brassinosteroid perception by BRI1
3RGZ	;	2.281	;	Structural insight into brassinosteroid perception by BRI1
7E8I	;	3.1	;	Structural insight into BRCA1-BARD1 complex recruitment to damaged chromatin
5GVX	;	2.596	;	Structural insight into dephosphorylation by Trehalose 6-phosphate Phosphatase (OtsB2) from Mycobacterium Tuberculosis
4MZ7	;	1.8	;	Structural insight into dGTP-dependent activation of tetrameric SAMHD1 deoxynucleoside triphosphate triphosphohydrolase
4YW6	;	1.4	;	Structural Insight into Divalent Galactoside Binding to Pseudomonas aeruginosa lectin LecA
4YW7	;	1.82	;	Structural Insight into Divalent Galactoside Binding to Pseudomonas aeruginosa lectin LecA
4YWA	;	1.192	;	Structural Insight into Divalent Galactoside Binding to Pseudomonas aeruginosa lectin LecA
3HYR	;	2.2	;	Structural Insight into G Protein Coupling and Regulation of Fe2+ Membrane Transport
4KFV	;	2.2	;	Structural insight into Golgi membrane stacking by GRASP65 and GRASP55
4KFW	;	2.7	;	Structural insight into Golgi membrane stacking by GRASP65 and GRASP55
5IRB	;	2.0	;	Structural insight into host cell surface retention of a 1.5-MDa bacterial ice-binding adhesin
2MPV	;		;	Structural insight into host recognition and biofilm formation by aggregative adherence fimbriae of enteroaggregative Esherichia coli
3M1V	;	1.45	;	Structural Insight into Methyl-Coenzyme M Reductase Chemistry using Coenzyme B Analogues
3M2R	;	1.3	;	Structural Insight into Methyl-Coenzyme M Reductase Chemistry using Coenzyme B Analogues
3M2U	;	1.4	;	Structural Insight into Methyl-Coenzyme M Reductase Chemistry using Coenzyme B Analogues
3M2V	;	1.8	;	Structural Insight into Methyl-Coenzyme M Reductase Chemistry using Coenzyme B Analogues
3M30	;	1.45	;	Structural Insight into Methyl-Coenzyme M Reductase Chemistry using Coenzyme B Analogues
3M32	;	1.35	;	Structural Insight into Methyl-Coenzyme M Reductase Chemistry using Coenzyme B Analogues
4QQR	;	2.7	;	Structural insight into nucleotide rhamnose synthase/epimerase-reductase from Arabidopsis thaliana
6IWM	;	1.98	;	Structural insight into probable lipid transfer mechanism of non-specific lipid transfer protein via intermediate structures in Solanum melongena
6IWN	;	2.408	;	Structural insight into probable lipid transfer mechanism of non-specific lipid transfer protein via intermediate structures in Solanum melongena
6IWO	;	2.35	;	Structural insight into probable lipid transfer mechanism of non-specific lipid transfer protein via intermediate structures in Solanum melongena
6IWP	;	2.4	;	Structural insight into probable lipid transfer mechanism of non-specific lipid transfer protein via intermediate structures in Solanum melongena
3FDS	;	2.05	;	Structural insight into recruitment of translesion DNA polymerase Dpo4 to sliding clamp PCNA
4LMZ	;	2.78	;	Structural insight into RNA recognition by RRM1+2 domain of human ETR-3 protein
2GKD	;		;	Structural insight into self-sacrifice mechanism of enediyne resistance
6XY4	;	2.04623	;	Structural insight into sheep-pox virus mediated inhibition of apoptosis
6XY6	;	2.91415	;	Structural insight into sheep-pox virus mediated inhibition of apoptosis
6TQP	;	1.84941	;	Structural insight into tanapoxvirus mediated inhibition of apoptosis
6TQQ	;	3.0018	;	Structural insight into tanapoxvirus mediated inhibition of apoptosis
6TRR	;	2.12007	;	Structural insight into tanapoxvirus mediated inhibition of apoptosis
5YJ7	;	1.61	;	Structural insight into the beta-GH1 glucosidase BGLN1 from oleaginous microalgae Nannochloropsis
1Z3K	;		;	Structural Insight into the Binding Diversity between the Tyr-Phosphorylated Human EphrinBs and Nck2 SH2 Domain
6LYW	;	1.7	;	Structural insight into the biological functions of Arabidopsis thaliana ACHT1
5EC3	;	2.1	;	Structural insight into the catalyitc mechanism of human 4-Hydroxyphenylpyruvate dioxygenase
2Q8Y	;	2.0	;	Structural insight into the enzymatic mechanism of the phophothreonine lyase
2J9W	;	1.3	;	Structural insight into the ESCRT-I-II link and its role in MVB trafficking
4PJ3	;	2.3	;	Structural insight into the function and evolution of the spliceosomal helicase Aquarius, Structure of Aquarius in complex with AMPPNP
2YN3	;	2.12	;	Structural insight into the giant calcium-binding adhesin SiiE: implications for the adhesion of Salmonella enterica to polarized epithelial cells
2YN5	;	1.85	;	Structural insight into the giant calcium-binding adhesin SiiE: implications for the adhesion of Salmonella enterica to polarized epithelial cells
2W2U	;	2.2	;	STRUCTURAL INSIGHT INTO THE INTERACTION BETWEEN ARCHAEAL ESCRT-III AND AAA-ATPASE
5Y3D	;	3.14	;	Structural insight into the interaction between RNA polymerase and VPg for norovirus replication
7XIV	;	2.498	;	Structural insight into the interactions between Lloviu virus VP30 and nucleoprotein
3C7U	;	2.2	;	Structural Insight into the Kinetics and Cp of interactions between TEM-1-Lactamase and BLIP
3C7V	;	2.07	;	Structural Insight into the Kinetics and Delta-Cp of interactions between TEM-1 Beta-Lactamase and BLIP
3A36	;	2.8	;	Structural insight into the membrane insertion of tail-anchored proteins by Get3
3A37	;	3.0	;	Structural insight into the membrane insertion of tail-anchored proteins by Get3
3FOE	;	4.001	;	Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases
3FOF	;	4.0	;	Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases
8K1C	;	1.894	;	Structural insight into the role of acetyl-CoA acetyltransferase from Fusobacterium nucleatum
7QRS	;	1.77	;	Structural insight into the Scribble PDZ domains interaction with the oncogenic Human T-cell lymphotrophic virus-1 (HTLV-1) Tax1
7QRT	;	1.9	;	Structural insight into the Scribble PDZ domains interaction with the oncogenic Human T-cell lymphotrophic virus-1 (HTLV-1) Tax1
7QS8	;	1.85	;	Structural insight into the Scribble PDZ domains interaction with the oncogenic Human T-cell lymphotrophic virus-1 (HTLV-1) Tax1
3LEL	;	2.95	;	Structural Insight into the Sequence-Dependence of Nucleosome Positioning
4YWU	;	2.4	;	Structural insight into the substrate inhibition mechanism of NADP+-dependent succinic semialdehyde dehydrogenase from Streptococcus pyogenes
4YWV	;	2.4	;	Structural insight into the substrate inhibition mechanism of NADP+-dependent succinic semialdehyde dehydrogenase from Streptococcus pyogenes
2OLU	;	2.9	;	Structural Insight Into the Transglycosylation Step Of Bacterial Cell Wall Biosynthesis : Apoenzyme
2OLV	;	2.8	;	Structural Insight Into the Transglycosylation Step Of Bacterial Cell Wall Biosynthesis : Donor Ligand Complex
2LHU	;		;	Structural Insight into the Unique Cardiac Myosin Binding Protein-C Motif: A Partially Folded Domain
5Z0R	;	2.05	;	Structural insight into the Zika virus capsid encapsulating the viral genome
5Z0V	;	2.913	;	Structural insight into the Zika virus capsid encapsulating the viral genome
5MUN	;	1.8	;	Structural insight into zymogenic latency of gingipain K from Porphyromonas gingivalis.
5E09	;	2.347	;	Structural Insight of a Trimodular Halophilic Cellulase with a Family 46 Carbohydrate-Binding Module
5E0C	;	2.351	;	Structural Insight of a Trimodular Halophilic Cellulase with a Family 46 Carbohydrate-Binding Module
5XI1	;		;	Structural Insight of Flavonoids binding to CAG repeat RNA that causes Huntington's Disease (HD) and Spinocerebellar Ataxia (SCAs)
7VUE	;	2.601	;	Structural insight of the molecular mechanism of cilofexor bound to FXR
3QDK	;	2.31	;	Structural insight on mechanism and diverse substrate selection strategy of ribulokinase
4YN6	;	2.301	;	Structural Insight reveals dynamics in repeating r(CAG) transcript found in Huntington's disease (HD) and Spinocerebellar ataxias (SCAs)
1T1U	;	1.55	;	Structural Insights and Functional Implications of Choline Acetyltransferase
1XXS	;	1.8	;	Structural insights for fatty acid binding in a Lys49 phospholipase A2: crystal structure of myotoxin II from Bothrops moojeni complexed with stearic acid
3QO2	;	2.49	;	Structural insights for MPP8 chromodomain interaction with histone H3 lysine 9
6AGS	;	2.31	;	Structural insights for non-natural cofactor binding by the L310R/Q401C mutant of malic enzyme from Escherichia coli
4REB	;	4.2	;	Structural Insights into 5' Flap DNA Unwinding and Incision by the Human FAN1 Dimer
7E43	;	2.2	;	Structural insights into a bifunctional peptide methionine sulfoxide reductase MsrA/B fusion protein from Helicobacter pylori
7CZL	;	3.78	;	Structural insights into a dimeric Psb27-photosystem II complex from a cyanobacterium Thermosynechococcus vulcanus
5JVK	;	2.5	;	Structural insights into a family 39 glycoside hydrolase from the gut symbiont Bacteroides cellulosilyticus WH2.
3UX9	;	2.8	;	Structural insights into a human anti-IFN antibody exerting therapeutic potential for systemic lupus erythematosus
6INX	;	1.429	;	Structural insights into a novel glycoside hydrolase family 18 N-acetylglucosaminidase from Paenibacillus barengoltzii
6GIG	;		;	Structural insights into AapA1 toxin
2MJW	;		;	Structural Insights into Calcium Bound S100P - V Domain of the receptor for advanced glycation end products (RAGE) Complex
3OWV	;	1.75	;	Structural insights into catalytic and substrate binding mechanisms of the strategic EndA nuclease from Streptococcus pneumoniae
2XNQ	;	1.3	;	Structural insights into cis element recognition of non- polyadenylated RNAs by the Nab3-RRM
2XNR	;	1.6	;	Structural insights into cis element recognition of non- polyadenylated RNAs by the Nab3-RRM
3VZ0	;	2.3	;	Structural insights into cofactor and substrate selection by Gox0499
4V6K	;	8.25	;	Structural insights into cognate vs. near-cognate discrimination during decoding.
4V6L	;	13.2	;	Structural insights into cognate vs. near-cognate discrimination during decoding.
6TXR	;	2.5	;	Structural insights into cubane-modified aptamer recognition of a malaria biomarker
2Z7J	;	2.4	;	Structural insights into de multifunctional VP3 protein of birnaviruses:gold derivative
6OBT	;	1.8	;	Structural insights into dehydratase substrate selection for the borrelidin and fluvirucin polyketide synthases
6OBV	;	2.01	;	Structural insights into dehydratase substrate selection for the borrelidin and fluvirucin polyketide synthases
6JTG	;	2.4	;	Structural insights into G domain dimerization and pathogenic mutations of OPA1
4P7T	;	1.72	;	Structural insights into higher-order assembly and function of the bacterial microcompartment protein PduA
4P7V	;	1.93	;	Structural insights into higher-order assembly and function of the bacterial microcompartment protein PduA
7XOU	;	3.2	;	Structural insights into human brain gut peptide cholecystokinin receptors
7XOV	;	3.0	;	Structural insights into human brain gut peptide cholecystokinin receptors
7XOW	;	3.1	;	Structural insights into human brain gut peptide cholecystokinin receptors
8IA7	;	3.1	;	Structural insights into human brain gut peptide cholecystokinin receptors
8P4A	;	3.6	;	Structural insights into human co-transcriptional capping - structure 1
8P4B	;	3.2	;	Structural insights into human co-transcriptional capping - structure 2
8P4C	;	3.8	;	Structural insights into human co-transcriptional capping - structure 3
8P4D	;	3.6	;	Structural insights into human co-transcriptional capping - structure 4
8P4E	;	3.9	;	Structural insights into human co-transcriptional capping - structure 5
8P4F	;	4.0	;	Structural insights into human co-transcriptional capping - structure 6
2M49	;		;	Structural Insights into Human S100B and Basic Fibroblast Growth Factor (FGF2) Interaction
8CLL	;	3.4	;	Structural insights into human TFIIIC promoter recognition
5UC6	;	2.1	;	Structural insights into IL-1 alpha recognition by a naphthyl-modified aptamer that mimics IL-1RI Domain III
4GPQ	;	1.46	;	Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia
2NAT	;		;	Structural insights into interaction of KYE28 and lipopolysachharide
5VRG	;	2.518	;	Structural insights into lipoprotein N-acylation by Escherichia coli apolipoprotein N-acyltransferase
3F9Z	;	1.6	;	Structural Insights into Lysine Multiple Methylation by SET Domain Methyltransferases, SET8-Y245F / H4-Lys20 / AdoHcy
3F9W	;	1.6	;	Structural Insights into Lysine Multiple Methylation by SET Domain Methyltransferases, SET8-Y334F / H4-Lys20 / AdoHcy
3F9Y	;	1.5	;	Structural Insights into Lysine Multiple Methylation by SET Domain Methyltransferases, SET8-Y334F / H4-Lys20me1 / AdoHcy
3F9X	;	1.25	;	Structural Insights into Lysine Multiple Methylation by SET Domain Methyltransferases, SET8-Y334F / H4-Lys20me2 / AdoHcy
7D6D	;	9.0	;	Structural insights into membrane remodeling by SNX1
7D6E	;	10.0	;	Structural insights into membrane remodeling by SNX1
6IW7	;	2.69212	;	structural insights into Mycobacterium tuberculosis ClpP1P2 inhibition by Cediranib: implications for developing antimicrobial agents targeting Clp protease
7X8X	;	3.24	;	structural insights into Mycobacterium tuberculosis ClpP1P2 inhibition by Cediranib: implications for developing antimicrobial agents targeting Clp protease
3DQV	;	3.0	;	Structural Insights into NEDD8 Activation of Cullin-RING Ligases: Conformational Control of Conjugation
3DPL	;	2.6	;	Structural Insights into NEDD8 Activation of Cullin-RING Ligases: Conformational Control of Conjugation.
7CXW	;	2.2	;	Structural insights into novel mechanisms of inhibition of the major b-carbonic anhydrase CafB from the pathogenic fungus Aspergillus fumigatus (C116 flipped form)
7CXX	;	2.0	;	Structural insights into novel mechanisms of inhibition of the major b-carbonic anhydrase CafB from the pathogenic fungus Aspergillus fumigatus (disulfide-bonded form)
7CXY	;	2.2	;	Structural insights into novel mechanisms of inhibition of the major b-carbonic anhydrase CafB from the pathogenic fungus Aspergillus fumigatus (zinc-bound form)
7BP4	;	2.1	;	Structural insights into nucleosome reorganization by NAP1-RELATED PROTEIN 1 (NRP1)
7BP5	;	1.9	;	Structural insights into nucleosome reorganization by NAP1-RELATED PROTEIN 1 (NRP1)
7BP6	;	1.58	;	Structural insights into nucleosome reorganization by NAP1-RELATED PROTEIN 1 (NRP1)
7C7X	;	3.0	;	Structural insights into nucleosome reorganization by NAP1-RELATED PROTEIN 1 (NRP1)
4IS0	;	1.721	;	Structural Insights into Omega-Class Glutathione Transferases: A Snapshot of Enzyme Reduction and Identification of the Non-Catalytic Ligandin Site.
5YJG	;	2.399	;	Structural insights into periostin functions
5YJH	;	2.957	;	Structural insights into periostin functions
1E8X	;	2.2	;	STRUCTURAL INSIGHTS INTO PHOSHOINOSITIDE 3-KINASE ENZYMATIC MECHANISM AND SIGNALLING
3L4Q	;	2.3	;	Structural insights into phosphoinositide 3-kinase activation by the influenza A virus NS1 protein
8J5K	;	2.93	;	Structural insights into photosystem II supercomplex and trimeric FCP antennae of a centric diatom Cyclotella meneghiniana
6TE4	;	2.29	;	Structural insights into Pseudomonas aeruginosa Type six secretion system exported effector 8: Tse8 in complex with a peptide
6YHV	;	1.893	;	Structural insights into Pseudomonas aeruginosa Type six secretion system exported effector 8: unliganded Tse8
4FDF	;	2.202	;	Structural insights into putative molybdenum cofactor biosynthesis protein C (MoaC2) from Mycobacterium tuberculosis H37Rv
3VYX	;	2.29	;	Structural insights into RISC assembly facilitated by dsRNA binding domains of human RNA helicase (DHX9)
3VYY	;	2.9	;	Structural insights into RISC assembly facilitated by dsRNA binding domains of human RNA helicase A (DHX9)
2YKG	;	2.5	;	Structural insights into RNA recognition by RIG-I
4BPB	;	2.584	;	STRUCTURAL INSIGHTS INTO RNA RECOGNITION BY RIG-I
3VNB	;	1.5	;	Structural insights into small RNA sorting and mRNA binding by Arabidopsis Ago domains
3VNA	;	2.0	;	Structural insights into small RNA sorting and mRNA binding by Arabidopsis Ago Mid domains
3VZ2	;	2.5	;	Structural insights into substrate and cofactor selection by sp2771
3VZ3	;	1.69	;	Structural insights into substrate and cofactor selection by sp2771
3VZ1	;	2.1	;	Structural insights into substrate and cofactor selelction by sp2771
5WMV	;	2.6	;	Structural Insights into Substrate and Inhibitor Binding Sites in Human Indoleamine 2,3-Dioxygenase 1
5WMW	;	3.03	;	Structural Insights into Substrate and Inhibitor Binding Sites in Human Indoleamine 2,3-Dioxygenase 1
5WMX	;	2.69	;	Structural Insights into Substrate and Inhibitor Binding Sites in Human Indoleamine 2,3-Dioxygenase 1
5WN8	;	2.5	;	Structural Insights into Substrate and Inhibitor Binding Sites in Human Indoleamine 2,3-Dioxygenase 1
5WMU	;	2.4	;	Structural Insights into Substrate and Inhibitor Binding Sites in Human Indoleamine 2,3-Dioxygenase I
4RW3	;	1.72	;	Structural insights into substrate binding of brown spider venom class II phospholipases D
4RW5	;	1.64	;	Structural insights into substrate binding of brown spider venom class II phospholipases D
4LEP	;	3.2	;	Structural insights into substrate recognition in proton dependent oligopeptide transporters
3KRG	;	1.9	;	Structural insights into substrate specificity and the anti beta-elimination mechanism of pectate lyase
6KKS	;	2.15	;	Structural insights into target DNA recognition by R2R3-type MYB transcription factor
5CO4	;	1.7	;	Structural insights into the 2-OH methylation of C/U34 on tRNA
3M4F	;	1.89	;	Structural insights into the acidophilic pH adaptation of a novel endo-1,4-beta-xylanase from Scytalidium acidophilum
7E6T	;	3.0	;	Structural insights into the activation of human calcium-sensing receptor
4DKI	;	2.9	;	Structural Insights into the Anti- Methicillin-Resistant Staphylococcus aureus (MRSA) Activity of Ceftobiprole
8A3L	;	3.42	;	Structural insights into the binding of bS1 to the ribosome
2XAC	;	2.71	;	Structural Insights into the Binding of VEGF-B by VEGFR-1D2: Recognition and Specificity
5ZRC	;	1.1	;	Structural insights into the catalysis mechanism of M. smegmatis antimutator protein MutT2
2XD5	;	2.5	;	Structural insights into the catalytic mechanism and the role of Streptococcus pneumoniae PBP1b
3P5S	;	1.95	;	Structural insights into the catalytic mechanism of CD38: Evidence for a conformationally flexible covalent enzyme-substrate complex
3GC6	;	1.51	;	Structural insights into the catalytic mechanism of CD38: Evidence for a conformationally flexible covalent enzyme-substrate complex.
3GH3	;	1.8	;	Structural insights into the catalytic mechanism of CD38: Evidence for a conformationally flexible covalent enzyme-substrate complex.
3GHH	;	1.94	;	Structural insights into the catalytic mechanism of CD38: Evidence for a conformationally flexible covalent enzyme-substrate complex.
3KOU	;	1.78	;	Structural insights into the catalytic mechanism of CD38: Evidence for a conformationally flexible covalent enzyme-substrate complex.
5YJD	;	2.26	;	Structural insights into the CRISPR-Cas-associated ribonuclease activity of Staphylococcus epidermidis Csm3
5YJC	;	2.007	;	Structural insights into the CRISPR-Cas-associated ribonuclease activity of Staphylococcus epidermidis Csm6
2D7D	;	2.1	;	Structural insights into the cryptic DNA dependent ATP-ase activity of UvrB
2L4L	;		;	Structural insights into the cTAR DNA recognition by the HIV-1 Nucleocapsid protein: role of sugar deoxyriboses in the binding polarity of NC
2CNE	;	1.8	;	Structural Insights into the Design of Nonpeptidic Isothiazolidinone- Containing Inhibitors of Protein Tyrosine Phosphatase 1B
2CNF	;	2.2	;	Structural Insights into the Design of Nonpeptidic Isothiazolidinone- Containing Inhibitors of Protein Tyrosine Phosphatase 1B
2CNG	;	1.9	;	Structural Insights into the Design of Nonpeptidic Isothiazolidinone- Containing Inhibitors of Protein Tyrosine Phosphatase 1B
2CNH	;	1.8	;	Structural Insights into the Design of Nonpeptidic Isothiazolidinone- Containing Inhibitors of Protein Tyrosine Phosphatase 1B
2CNI	;	2.0	;	Structural Insights into the Design of Nonpeptidic Isothiazolidinone- Containing Inhibitors of Protein Tyrosine Phosphatase 1B
2MH2	;		;	Structural insights into the DNA recognition and protein interaction domains reveal fundamental homologous DNA pairing properties of HOP2
4GF9	;	2.8	;	Structural insights into the dual strategy of recognition of peptidoglycan recognition protein, PGRP-S: ternary complex of PGRP-S with LPS and fatty acid
5X9R	;	3.98	;	Structural insights into the elevator-like mechanism of the sodium/citrate symporter CitS
5XAR	;	3.62	;	Structural insights into the elevator-like mechanism of the sodium/citrate symporter CitS
5XAS	;	3.47	;	Structural insights into the elevator-like mechanism of the sodium/citrate symporter CitS
5XAT	;	3.76	;	Structural insights into the elevator-like mechanism of the sodium/citrate symporter CitS
2P05	;	2.8	;	Structural Insights into the Evolution of a Non-Biological Protein
2P09	;	1.65	;	Structural Insights into the Evolution of a Non-Biological Protein
5TUD	;	3.0	;	Structural Insights into the Extracellular Recognition of the Human Serotonin 2B Receptor by an Antibody
6B0T	;	2.8	;	Structural Insights into the Induced-fit Inhibition of Fascin by a Small Molecule
1P1D	;		;	Structural Insights into the Inter-domain Chaperoning of Tandem PDZ Domains in Glutamate Receptor Interacting Proteins
1P1E	;		;	Structural Insights into the Inter-domain Chaperoning of Tandem PDZ Domains in Glutamate Receptor Interacting Proteins
5GLF	;	2.25	;	Structural insights into the interaction of p97 N-terminal domain and SHP motif in Derlin-1 rhomboid pseudoprotease
5EPP	;	1.88	;	Structural Insights into the Interaction of p97 N-terminus Domain and VBM Motif in Rhomboid Protease, RHBDL4
5AMV	;	1.57	;	Structural insights into the loss of catalytic competence in pectate lyase at low pH
5CB3	;	1.8	;	Structural Insights into the Mechanism of Escherichia coli Ymdb
5CB5	;	2.8	;	Structural Insights into the Mechanism of Escherichia coli Ymdb
5CMS	;	2.98	;	Structural Insights into the Mechanism of Escherichia coli Ymdb
7VHP	;	3.27	;	Structural insights into the membrane microdomain organization by SPFH family proteins
7VHQ	;	3.27	;	Structural insights into the membrane microdomain organization by SPFH family proteins
3LAH	;	2.0	;	Structural insights into the molecular mechanism of H-NOX activation
3LAI	;	2.144	;	Structural insights into the molecular mechanism of H-NOX activation
3CVZ	;	2.4	;	Structural insights into the molecular organization of the S-layer from Clostridium difficile
2R18	;	2.3	;	Structural insights into the multifunctional protein VP3 of Birnaviruses
4CID	;	3.0	;	Structural insights into the N-terminus of the EHD2 ATPase
4YPG	;	3.0	;	Structural Insights Into the Neutralization Properties of a Human Anti-Interferon Monoclonal Antibody
5O7J	;		;	Structural insights into the periplasmic sensor domain of the GacS histidine kinase controlling biofilm formation in Pseudomonas aeruginosa
5WBX	;	1.9	;	Structural insights into the potency of SK/IK channel positive modulators
5WC5	;	2.3	;	Structural insights into the potency of SK/IK channel positive modulators
2WVA	;	2.2	;	Structural insights into the pre-reaction state of pyruvate decarboxylase from Zymomonas mobilis
2WVG	;	1.75	;	Structural insights into the pre-reaction state of pyruvate decarboxylase from Zymomonas mobilis
2WVH	;	2.3	;	Structural insights into the pre-reaction state of pyruvate decarboxylase from Zymomonas mobilis
1NHC	;	1.7	;	Structural insights into the processivity of endopolygalacturonase I from Aspergillus niger
2ZKS	;	2.7	;	Structural insights into the proteolytic machinery of apoptosis-inducing Granzyme M
5DWX	;	2.71	;	Structural Insights into the Quadruplex-Duplex 3' Interface formed from a Telomeric Repeat - TLOOP
5DWW	;	2.79	;	Structural Insights into the Quadruplex-Duplex 3' Interface formed from a Telomeric Repeat - TTLOOP
5A3D	;	1.8	;	Structural insights into the recognition of cisplatin and AAF-dG lesions by Rad14 (XPA)
2V3S	;	1.7	;	Structural insights into the recognition of substrates and activators by the OSR1 kinase
2RT5	;		;	Structural insights into the recruitment of SMRT by the co-repressor SHARP under phosphorylative regulation
5C8B	;	2.7	;	Structural insights into the redesign of a sucrose phosphorylase by induced loop repositioning
4HA7	;	2.1	;	Structural insights into the reduction mechanism of Saccharomyces cerevisia Riboflavin Biosynthesis Reductase Rib7
4HA9	;	2.35	;	Structural insights into the reduction mechanism of Saccharomyces cerevisia Riboflavin Biosynthesis Reductase Rib7
5C6G	;	2.6	;	Structural Insights into the Scc2-Scc4 Cohesin Loader
2L9C	;		;	Structural insights into the specificity of darcin, an atypical major urinary protein.
7V58	;	1.84	;	Structural insights into the substrate selectivity of acyl-CoA transferase
7V5I	;	3.08	;	Structural insights into the substrate selectivity of acyl-CoA transferase
7EE2	;	1.37012	;	Structural insights into the substrate-binding mechanism of a glycoside hydrolase family 12 beta-1,3-1,4-glucanase from Chaetomium sp.CQ31
6AID	;	1.3	;	Structural insights into the unique polylactate degrading mechanism of Thermobifida alba cutinase
4LJK	;	2.354	;	Structural insights into the unique single-stranded DNA binding mode of DNA processing protein A from Helicobacter pylori
4LJL	;	2.2	;	Structural insights into the unique single-stranded DNA binding mode of DNA processing protein A from Helicobacter pylori
4LJR	;	1.8	;	Structural insights into the unique single-stranded DNA binding mode of DNA processing protein A from Helicobacter pylori
5WGG	;	2.036	;	Structural Insights into Thioether Bond Formation in the Biosynthesis of Sactipeptides
5WHY	;	2.692	;	Structural Insights into Thioether Bond Formation in the Biosynthesis of Sactipeptides
3SF8	;	1.56	;	Structural insights into thiol stabilization of DJ-1
3UL3	;	2.905	;	Structural insights into thioredoxin-2: a component of malaria parasite protein secretion machinery
4CSF	;	2.598	;	Structural insights into Toscana virus RNA encapsidation
4CSG	;	3.32	;	Structural insights into Toscana virus RNA encapsidation
6NU2	;	3.9	;	Structural insights into unique features of the human mitochondrial ribosome recycling
6NU3	;	4.4	;	Structural insights into unique features of the human mitochondrial ribosome recycling
7DOP	;	2.38	;	Structural insights into viral RNA capping and plasma membrane targeting by Chikungunya virus nonstructural protein 1
4BQO	;	1.56	;	Structural insights into WcbI, a novel polysaccharide biosynthesis enzyme. Native protein without disulfide bond between COA and Cys14.
4BQN	;	1.38	;	Structural insights into WcbI, a novel polysaccharide biosynthesis enzyme. Native protein.
4NQ0	;	2.1	;	Structural insights into yeast histone chaperone Hif1: a scaffold protein recruiting protein complexes to core histones
4HGD	;	2.04	;	Structural insights into yeast Nit2: C169S mutant of yeast Nit2 in complex with an endogenous peptide-like ligand
4H5U	;	1.92	;	Structural insights into yeast Nit2: wild-type yeast Nit2
4HG3	;	1.93	;	Structural insights into yeast Nit2: wild-type yeast Nit2 in complex with alpha-ketoglutarate
4HG5	;	1.91	;	Structural insights into yeast Nit2: wild-type yeast Nit2 in complex with oxaloacetate
3NTT	;	3.45	;	Structural insights of Adeno-Associated virus 5. A gene therapy Vector for Cystic Fibrosis
6IOZ	;	3.1	;	Structural insights of idursulfase beta
5E9H	;	2.3	;	Structural insights of isocitrate lyases from Fusarium graminearum
5E9F	;	2.8	;	Structural insights of isocitrate lyases from Magnaporthe oryzae
5E9G	;	2.1	;	Structural insights of isocitrate lyases from Magnaporthe oryzae
4KTV	;	3.3	;	Structural insights of MAT enzymes: MATa2b complexed with adenosine and pyrophosphate
4KTT	;	2.59	;	Structural insights of MAT enzymes: MATa2b complexed with SAM
4NDN	;	2.34	;	Structural insights of MAT enzymes: MATa2b complexed with SAM and PPNP
2NCQ	;		;	Structural insights of r(CGG) motif found in Fragile X Syndrome and Fragile-X associated tremor/ataxia syndrome (FXTAS) at 45 degree C
3EKI	;	1.6	;	Structural insights of the Mycoplasma hyorhinis protein Mh-p37: A putative thiamine pyrophosphate transporter
5IUY	;	2.29	;	Structural insights of the outer-membrane channel OprN
2MOF	;		;	Structural insights of TM domain of LAMP-2A in DPC micelles
2MOM	;		;	Structural insights of TM domain of LAMP-2A in DPC micelles
2PFF	;	4.0	;	Structural Insights of Yeast Fatty Acid Synthase
6O9N	;	2.598	;	Structural insights on a new fungal aryl-alcohol oxidase
8AU4	;		;	Structural insights reveal a heterotetramer between oncogenic K-Ras4BG12V and Rgl2, a RalA/B activator
4DEN	;	1.6	;	Structural insightsinto potent, specific anti-HIV property of actinohivin; Crystal structure of actinohivin in complex with alpha(1-2) mannobiose moiety of high-mannose type glycan of gp120
3AJF	;	2.0	;	Structural insigths into dsRNA binding and RNA silencing suppression by NS3 protein of rice hoja blanca tenuivirus
1ATL	;	1.8	;	Structural interaction of natural and synthetic inhibitors with the VENOM METALLOPROTEINASE, ATROLYSIN C (FORM-D)
1HTD	;	2.1	;	STRUCTURAL INTERACTION OF NATURAL AND SYNTHETIC INHIBITORS WITH THE VENOM METALLOPROTEINASE, ATROLYSIN C (HT-D)
5MDM	;	2.998	;	Structural intermediates in the fusion associated transition of vesiculovirus glycoprotein
4DQJ	;	1.23	;	Structural Investigation of Bacteriophage Phi6 Lysin (in complex with chitotetraose)
4DQ7	;	1.4	;	Structural Investigation of Bacteriophage Phi6 Lysin (V207F mutant)
4DQ5	;	1.395	;	Structural Investigation of Bacteriophage Phi6 Lysin (WT)
2MQL	;		;	Structural Investigation of hnRNP L
2MQM	;		;	Structural Investigation of hnRNP L
2MQN	;		;	Structural Investigation of hnRNP L
4QPT	;	1.351	;	Structural Investigation of hnRNP L
2MQO	;		;	Structural Investigation of hnRNP L bound to RNA
2MQP	;		;	Structural Investigation of hnRNP L bound to RNA
2MQQ	;		;	Structural Investigation of hnRNP L bound to RNA
1JH8	;	1.8	;	Structural Investigation of the Biosynthesis of Alternative Lower Ligands for Cobamides by Nicotinate Mononucleotide:5,6-Dimethylbenzimidazole Phosphoribosyltransferase (CobT) from Salmonella enterica
1JHA	;	2.0	;	Structural Investigation of the Biosynthesis of Alternative Lower Ligands for Cobamides by Nicotinate Mononucleotide:5,6-Dimethylbenzimidazole Phosphoribosyltransferase (CobT) from Salmonella enterica
2NZ4	;	2.498	;	Structural investigation of the GlmS ribozyme bound to its catalytic cofactor
6HQC	;	1.28	;	Structural investigation of the TasA anchoring protein TapA from Bacillus subtilis
6QAY	;		;	Structural investigation of the TasA anchoring protein TapA from Bacillus subtilis
4C5R	;	2.14	;	Structural Investigations into the Stereochemistry and Activity of a Phenylalanine-2,3-Aminomutase from Taxus chinensis
4C5S	;	1.85	;	Structural Investigations into the Stereochemistry and Activity of a Phenylalanine-2,3-Aminomutase from Taxus chinensis
4C5U	;	2.19	;	Structural Investigations into the Stereochemistry and Activity of a Phenylalanine-2,3-Aminomutase from Taxus chinensis
4C6G	;	2.1	;	Structural Investigations into the Stereochemistry and Activity of a Phenylalanine-2,3-Aminomutase from Taxus chinensis
4CQ5	;	1.9	;	Structural Investigations into the Stereochemistry and Activity of a Phenylalanine-2,3-Aminomutase from Taxus chinensis
7OBN	;	2.45	;	Structural investigations of a new L3 DNA ligase: structure-function analysis
5VVO	;	2.6	;	Structural Investigations of the Substrate Specificity of Human O-GlcNAcase
5VVT	;	2.8	;	Structural Investigations of the Substrate Specificity of Human O-GlcNAcase
5VVU	;	2.7	;	Structural Investigations of the Substrate Specificity of Human O-GlcNAcase
5VVV	;	2.8	;	Structural Investigations of the Substrate Specificity of Human O-GlcNAcase
5VVX	;	2.9	;	Structural Investigations of the Substrate Specificity of Human O-GlcNAcase
4WI2	;	1.9	;	Structural mapping of the human IgG1 binding site for FcRn: hu3S193 Fc (wild-type)
4WI5	;	2.8	;	Structural mapping of the human IgG1 binding site for FcRn: hu3S193 Fc mutation H310A
4WI7	;	1.9	;	Structural mapping of the human IgG1 binding site for FcRn: hu3S193 Fc mutation H435A
4WI3	;	2.703	;	Structural mapping of the human IgG1 binding site for FcRn: hu3S193 Fc mutation I253A
4WI9	;	2.65	;	Structural mapping of the human IgG1 binding site for FcRn: hu3S193 Fc mutation I253A/H310A
4WI6	;	2.201	;	Structural mapping of the human IgG1 binding site for FcRn: hu3S193 Fc mutation N434A
4WI4	;	2.8	;	Structural mapping of the human IgG1 binding site for FcRn: hu3S193 Fc mutation S254A
4WI8	;	2.8	;	Structural mapping of the human IgG1 binding site for FcRn: hu3S193 Fc mutation Y436A
7BP2	;	1.58	;	Structural mechanism directing nucleosome reorganization by NAP1-RELATED PROTEIN 1 (NRP1)
2LR1	;		;	Structural Mechanism for Bax Inhibition by Cytomegalovirus Protein vMIA
1GPA	;	2.9	;	STRUCTURAL MECHANISM FOR GLYCOGEN PHOSPHORYLASE CONTROL BY PHOSPHORYLATION AND AMP
7GPB	;	2.9	;	STRUCTURAL MECHANISM FOR GLYCOGEN PHOSPHORYLASE CONTROL BY PHOSPHORYLATION AND AMP
8GPB	;	2.2	;	STRUCTURAL MECHANISM FOR GLYCOGEN PHOSPHORYLASE CONTROL BY PHOSPHORYLATION AND AMP
2NZU	;	2.5	;	Structural mechanism for the fine-tuning of CcpA function by the small molecule effectors G6P and FBP
2NZV	;	3.0	;	Structural mechanism for the fine-tuning of CcpA function by the small molecule effectors G6P and FBP
2OEN	;	3.17	;	Structural mechanism for the fine-tuning of CcpA function by the small molecule effectors glucose-6-phosphate and fructose-1,6-bisphosphate
1UNL	;	2.2	;	Structural mechanism for the inhibition of CD5-p25 from the roscovitine, aloisine and indirubin.
1UNG	;	2.3	;	Structural mechanism for the inhibition of CDK5-p25 by roscovitine, aloisine and indirubin.
1UNH	;	2.35	;	Structural mechanism for the inhibition of CDK5-p25 by roscovitine, aloisine and indirubin.
1XJF	;	2.4	;	Structural mechanism of allosteric substrate specificity in a ribonucleotide reductase: dATP complex
1XJN	;	2.25	;	Structural mechanism of allosteric substrate specificity in a ribonucleotide reductase: dATP-CDP complex
1XJG	;	2.5	;	Structural mechanism of allosteric substrate specificity in a ribonucleotide reductase: dATP-UDP complex
1XJJ	;	1.86	;	Structural mechanism of allosteric substrate specificity in a ribonucleotide reductase: dGTP complex
1XJK	;	2.12	;	Structural mechanism of allosteric substrate specificity in a ribonucleotide reductase: dGTP-ADP complex
1XJM	;	2.4	;	Structural mechanism of allosteric substrate specificity in a ribonucleotide reductase: dTTP complex
1XJE	;	1.9	;	Structural mechanism of allosteric substrate specificity in a ribonucleotide reductase: dTTP-GDP complex
1J04	;	2.6	;	Structural mechanism of enzyme mistargeting in hereditary kidney stone disease in vitro
4U6P	;	2.593	;	Structural mechanism of error-free bypass of major benzo[a]pyrene adduct by human polymerase kappa
4YIA	;	1.58	;	Structural mechanism of hormone release in thyroxine binding globulin
1XPU	;	3.05	;	Structural mechanism of inhibition of the Rho transcription termination factor by the antibiotic 5a-(3-formylphenylsulfanyl)-dihydrobicyclomycin (FPDB)
1XPR	;	3.15	;	Structural mechanism of inhibition of the Rho transcription termination factor by the antibiotic 5a-formylbicyclomycin (FB)
1XPO	;	3.15	;	Structural mechanism of inhibition of the Rho transcription termination factor by the antibiotic bicyclomycin
5DE2	;	2.78	;	Structural mechanism of Nek7 activation by Nek9-induced dimerisation
6M4D	;	4.4	;	Structural mechanism of nucleosome dynamics governed by human histone variants H2A.B and H2A.Z.2.2
6M4G	;	2.8	;	Structural mechanism of nucleosome dynamics governed by human histone variants H2A.B and H2A.Z.2.2
6M4H	;	3.9	;	Structural mechanism of nucleosome dynamics governed by human histone variants H2A.B and H2A.Z.2.2
6THK	;	2.2	;	Structural mechanism of pyocin S5 import into Pseudomonas aeruginosa
3J67	;	34.0	;	Structural mechanism of the dynein powerstroke (post-powerstroke state)
3J68	;	30.0	;	Structural mechanism of the dynein powerstroke (pre-powerstroke state)
4I5L	;	2.43	;	Structural mechanism of trimeric PP2A holoenzyme involving PR70: insight for Cdc6 dephosphorylation
4I5N	;	2.8	;	Structural mechanism of trimeric PP2A holoenzyme involving PR70: insight for Cdc6 dephosphorylation
5T90	;	2.8	;	Structural mechanisms for alpha-conotoxin selectivity at the human alpha3beta4 nicotinic acetylcholine receptor
1RR8	;	2.6	;	Structural Mechanisms of Camptothecin Resistance by Mutations in Human Topoisomerase I
1RRJ	;	2.3	;	Structural Mechanisms of Camptothecin Resistance by Mutations in Human Topoisomerase I
5JDH	;	2.203	;	Structural mechanisms of extracellular ion exchange and induced binding-site occlusion in the sodium-calcium exchanger NCX_Mj soaked with 10 mM Na+ and 10mM Ca2+
5JDN	;	2.3	;	Structural mechanisms of extracellular ion exchange and induced binding-site occlusion in the sodium-calcium exchanger NCX_Mj soaked with 10 mM Na+ and 10mM Sr2+
5HWY	;	2.098	;	Structural mechanisms of extracellular ion exchange and induced binding-site occlusion in the sodium-calcium exchanger NCX_Mj soaked with 10 mM Na+ and zero Ca2+
5JDQ	;	2.5	;	Structural mechanisms of extracellular ion exchange and induced binding-site occlusion in the sodium-calcium exchanger NCX_Mj soaked with 100 mM Na+ and 10mM Sr2+
5HXE	;	2.288	;	Structural mechanisms of extracellular ion exchange and induced binding-site occlusion in the sodium-calcium exchanger NCX_Mj soaked with 100 mM Na+ and zero Ca2+
5JDG	;	2.407	;	Structural mechanisms of extracellular ion exchange and induced binding-site occlusion in the sodium-calcium exchanger NCX_Mj soaked with 2.5 mM Na+ and 0.1mM Ca2+
5JDM	;	2.558	;	Structural mechanisms of extracellular ion exchange and induced binding-site occlusion in the sodium-calcium exchanger NCX_Mj soaked with 2.5 mM Na+ and 0.1mM Sr2+
5HXR	;	2.463	;	Structural mechanisms of extracellular ion exchange and induced binding-site occlusion in the sodium-calcium exchanger NCX_Mj soaked with 2.5 mM Na+ and 10mM Ca2+
5HXS	;	2.789	;	Structural mechanisms of extracellular ion exchange and induced binding-site occlusion in the sodium-calcium exchanger NCX_Mj soaked with 2.5 mM Na+ and 10mM Sr2+
5JDF	;	2.65	;	Structural mechanisms of extracellular ion exchange and induced binding-site occlusion in the sodium-calcium exchanger NCX_Mj soaked with 2.5 mM Na+ and 1mM Ca2+
5JDL	;	2.904	;	Structural mechanisms of extracellular ion exchange and induced binding-site occlusion in the sodium-calcium exchanger NCX_Mj soaked with 2.5 mM Na+ and 1mM Sr2+
5HWX	;	2.4	;	Structural mechanisms of extracellular ion exchange and induced binding-site occlusion in the sodium-calcium exchanger NCX_Mj soaked with 2.5 mM Na+ and zero Ca2+
5HXC	;	2.101	;	Structural mechanisms of extracellular ion exchange and induced binding-site occlusion in the sodium-calcium exchanger NCX_Mj soaked with 20 mM Na+ and zero Ca2+
5HXH	;	2.804	;	Structural mechanisms of extracellular ion exchange and induced binding-site occlusion in the sodium-calcium exchanger NCX_Mj soaked with zero Na+ and Ca2+
5HYA	;	1.897	;	Structural mechanisms of extracellular ion exchange and induced binding-site occlusion in the sodium-calcium exchangerNCX_Mj soaked with 150 mM Na+ and nominal Ca2+
4JBJ	;	2.692	;	Structural mimicry for functional antagonism
4ZS7	;	2.93	;	Structural mimicry of receptor interaction by antagonistic IL-6 antibodies
5XAJ	;	2.5	;	Structural mimicry of the dengue virus envelope glycoprotein revealed by the crystallographic study of an idiotype-anti-idiotype Fab complex.
2LMQ	;		;	Structural Model for a 40-residue Beta-Amyloid Fibril with Three-Fold Symmetry, Negative Stagger
2LMP	;		;	Structural Model for a 40-residue Beta-Amyloid Fibril with Three-Fold Symmetry, Positive Stagger
2LMO	;		;	Structural Model for a 40-Residue Beta-Amyloid Fibril with Two-Fold Symmetry, Negative Stagger
2LMN	;		;	Structural Model for a 40-Residue Beta-Amyloid Fibril with Two-Fold Symmetry, Positive Stagger
1LMS	;		;	Structural model for an alkaline form of ferricytochrome c
7JXG	;		;	Structural model for Fe-containing human acireductone dioxygenase
2VER	;		;	Structural model for the complex between the Dr adhesins and carcinoembryonic antigen (CEA)
2HJI	;		;	Structural model for the Fe-containing isoform of acireductone dioxygenase
1Z1D	;		;	Structural Model for the interaction between RPA32 C-terminal domain and SV40 T antigen origin binding domain.
2FTC	;	12.1	;	Structural Model for the Large Subunit of the Mammalian Mitochondrial Ribosome
8IS3	;		;	Structural model for the micelle-bound indolicidin-like peptide in solution
2NCA	;		;	Structural Model for the N-terminal Domain of Human Cdc37
5KGF	;	4.54	;	Structural model of 53BP1 bound to a ubiquitylated and methylated nucleosome, at 4.5 A resolution
5JS7	;		;	Structural model of a apo G-protein alpha subunit determined with NMR residual dipolar couplings and SAXS
5JS8	;		;	Structural Model of a Protein alpha subunit in complex with GDP obtained with SAXS and NMR residual couplings
2LWB	;		;	Structural model of BAD-1 repeat loop by NMR
1ZY3	;		;	Structural model of complex of Bcl-w protein with Bid BH3-peptide
1M11	;	16.0	;	structural model of human decay-accelerating factor bound to echovirus 7 from cryo-electron microscopy
4A6J	;	7.2	;	Structural model of ParM filament based on CryoEM map
3IKU	;	18.0	;	Structural model of ParM filament in closed state from cryo-EM
3IKY	;	18.0	;	Structural model of ParM filament in the open state by cryo-EM
5HQ2	;	4.5	;	Structural model of Set8 histone H4 Lys20 methyltransferase bound to nucleosome core particle
2MKK	;		;	Structural model of tandem RRM domains of cytoplasmic polyadenylation element binding protein 1 (CPEB1) in complex with RNA
1E08	;		;	Structural model of the [Fe]-Hydrogenase/cytochrome c553 complex combining NMR and soft-docking
2K92	;		;	Structural modification of acyl carrier protein by butyryl group
2K93	;		;	Structural modification of acyl carrier protein by butyryl group
2K94	;		;	Structural modification of acyl carrier protein by butyryl group
2MUD	;		;	Structural modifications to a high-activity binding peptide located whitin the PfEMP1 NTS domain induce protection against P. falciparum malaria in Aotus monkeys
5Z87	;	2.3	;	Structural of a novel b-glucosidase EmGH1 at 2.3 angstrom from Erythrobacter marinus
2J5S	;	1.57	;	Structural of ABDH, a beta-diketone hydrolase from the Cyanobacterium Anabaena sp. PCC 7120 bound to (S)-3-oxocyclohexyl acetic acid
4BMA	;	2.08	;	structural of Aspergillus fumigatus UDP-N-acetylglucosamine pyrophosphorylase
4E8H	;	2.12	;	Structural of Bombyx mori glutathione transferase BmGSTD1 complex with GTT
4CBA	;	3.1	;	Structural of delta 1-76 CTNNBL1 in space group I222
8T9Z	;	2.995	;	Structural of M8C10 Fab in complex human metapneumovirus fusion protein
2FYZ	;	2.2	;	Structural of Mumps virus fusion protein core
5WYD	;	2.101	;	Structural of Pseudomonas aeruginosa DspI
5YLO	;	2.39	;	Structural of Pseudomonas aeruginosa PA4980
5Z8O	;	1.95	;	Structural of START superfamily protein MSMEG_0129 from Mycobacterium smegmatis
7W85	;	2.94	;	Structural of the filamentous Escherichia coli glutamine synthetase
5YBH	;	2.5	;	Structural of the highly conserved ATPase from type III secretion system of bacterial pathogens
3L1A	;	2.69	;	Structural ordering of disordered ligand binding loops of biotin protein ligase into active conformations as a consequence of dehydration
7QTT	;	3.1	;	Structural organization of a late activated human spliceosome (Baqr, core region)
4IFF	;	2.3	;	Structural organization of FtsB, a transmembrane protein of the bacterial divisome
1STP	;	2.6	;	STRUCTURAL ORIGINS OF HIGH-AFFINITY BIOTIN BINDING TO STREPTAVIDIN
2HPA	;	2.9	;	STRUCTURAL ORIGINS OF L(+)-TARTRATE INHIBITION OF HUMAN PROSTATIC ACID PHOSPHATASE
1D9H	;	1.6	;	Structural origins of the exonuclease resistance of a zwitterionic RNA
337D	;	1.85	;	STRUCTURAL PARAMETERS FROM SINGLE-CRYSTAL STRUCTURES FOR ACCURATE MODELS OF A-DNA
338D	;	1.85	;	STRUCTURAL PARAMETERS FROM SINGLE-CRYSTAL STRUCTURES FOR ACCURATE MODELS OF A-DNA
339D	;	2.2	;	STRUCTURAL PARAMETERS FROM SINGLE-CRYSTAL STRUCTURES FOR ACCURATE MODELS OF A-DNA
340D	;	1.6	;	STRUCTURAL PARAMETERS FROM SINGLE-CRYSTAL STRUCTURES FOR ACCURATE MODELS OF A-DNA
341D	;	1.75	;	STRUCTURAL PARAMETERS FROM SINGLE-CRYSTAL STRUCTURES FOR ACCURATE MODELS OF A-DNA
342D	;	2.1	;	STRUCTURAL PARAMETERS FROM SINGLE-CRYSTAL STRUCTURES FOR ACCURATE MODELS OF A-DNA
343D	;	2.1	;	STRUCTURAL PARAMETERS FROM SINGLE-CRYSTAL STRUCTURES FOR ACCURATE MODELS OF A-DNA
345D	;	1.85	;	STRUCTURAL PARAMETERS FROM SINGLE-CRYSTAL STRUCTURES FOR ACCURATE MODELS OF A-DNA
346D	;	2.1	;	STRUCTURAL PARAMETERS FROM SINGLE-CRYSTAL STRUCTURES FOR ACCURATE MODELS OF A-DNA
1P09	;	2.2	;	STRUCTURAL PLASTICITY AS A DETERMINANT OF ENZYME SPECIFICITY. CREATING BROADLY SPECIFIC PROTEASES
1P10	;	2.25	;	STRUCTURAL PLASTICITY AS A DETERMINANT OF ENZYME SPECIFICITY. CREATING BROADLY SPECIFIC PROTEASES
1AXI	;	2.1	;	STRUCTURAL PLASTICITY AT THE HGH:HGHBP INTERFACE
2OZ4	;	2.7	;	Structural Plasticity in IgSF Domain 4 of ICAM-1 Mediates Cell Surface Dimerization
1KFR	;	1.85	;	Structural plasticity in the eight-helix fold of a trematode hemoglobin
4UD4	;	1.74	;	Structural Plasticity of Cid1 Provides a Basis for its RNA Terminal Uridylyl Transferase Activity
4UD5	;	2.52	;	Structural Plasticity of Cid1 Provides a Basis for its RNA Terminal Uridylyl Transferase Activity
3J89	;	3.6	;	Structural Plasticity of Helical Nanotubes Based on Coiled-Coil Assemblies
2LEW	;		;	Structural Plasticity of Paneth cell alpha-Defensins: Characterization of Salt-Bridge Deficient Analogues of Mouse Cryptdin-4
4DDQ	;	3.3	;	Structural plasticity of the Bacillus subtilis GyrA homodimer
6WQF	;	2.3	;	Structural Plasticity of the SARS-CoV-2 3CL Mpro Active Site Cavity Revealed by Room Temperature X-ray Crystallography
4N8M	;	1.802	;	Structural polymorphism in the N-terminal oligomerization domain of NPM1
1W8P	;	2.08	;	Structural properties of the B25Tyr-NMe-B26Phe insulin mutant.
4Q2R	;	1.65	;	Structural Proteomics From Crude Native Rod Outer Segments
1XUW	;	1.25	;	Structural rationalization of a large difference in RNA affinity despite a small difference in chemistry between two 2'-O-modified nucleic acid analogs
1XUX	;	1.3	;	Structural rationalization of a large difference in RNA affinity despite a small difference in chemistry between two 2'-O-modified nucleic acid analogs
4N7C	;	1.75	;	Structural re-examination of native Bla g 4
1TA8	;	1.8	;	Structural rearrangement accompanying NAD+ synthesis within a bacterial DNA ligase crystal
1TAE	;	2.7	;	Structural rearrangement accompanying NAD+ synthesis within a bacterial DNA ligase crystal
3D5O	;	2.8	;	Structural recognition and functional activation of FcrR by innate pentraxins
2MEV	;	3.0	;	STRUCTURAL REFINEMENT AND ANALYSIS OF MENGO VIRUS
6POJ	;		;	STRUCTURAL REFINEMENT OF AQUAPORIN 1 VIA SSNMR
1REW	;	1.863	;	Structural refinement of the complex of bone morphogenetic protein 2 and its type IA receptor
1NFP	;	1.6	;	STRUCTURAL REFINEMENT OF THE NON-FLUORESCENT FLAVOPROTEIN FROM PHOTOBACTERIUM LEIOGNATHI AT 1.60 ANGSTROMS RESOLUTION
2KHH	;		;	Structural requirements for the UBA domain of the mRNA export factor Mex67 to bind its specific targets, the transcription elongation Tho complex component Hpr1 and nucleoporin FxFG repeats
1B27	;	2.1	;	STRUCTURAL RESPONSE TO MUTATION AT A PROTEIN-PROTEIN INTERFACE
1B2S	;	1.82	;	STRUCTURAL RESPONSE TO MUTATION AT A PROTEIN-PROTEIN INTERFACE
1B2U	;	2.1	;	STRUCTURAL RESPONSE TO MUTATION AT A PROTEIN-PROTEIN INTERFACE
1B3S	;	2.39	;	STRUCTURAL RESPONSE TO MUTATION AT A PROTEIN-PROTEIN INTERFACE
1R63	;		;	STRUCTURAL ROLE OF A BURIED SALT BRIDGE IN THE 434 REPRESSOR DNA-BINDING DOMAIN, NMR, 20 STRUCTURES
2R63	;		;	STRUCTURAL ROLE OF A BURIED SALT BRIDGE IN THE 434 REPRESSOR DNA-BINDING DOMAIN, NMR, 20 STRUCTURES
2I9V	;	2.2	;	Structural role of Y98 in PYP: effects on fluorescence, gateway and photocycle recovery
6QUP	;	1.871	;	Structural signatures in EPR3 define a unique class of plant carbohydrate receptors
5H4P	;	3.07	;	Structural snapshot of cytoplasmic pre-60S ribosomal particles bound with Nmd3, Lsg1, Tif6 and Reh1
4AOH	;	1.041	;	Structural snapshots and functional analysis of human angiogenin variants associated with Amyotrophic Lateral Sclerosis (ALS)
7M2H	;	2.642	;	Structural Snapshots of Intermediates in the Gating of a K+ Channel
7M2I	;	2.695	;	Structural Snapshots of Intermediates in the Gating of a K+ Channel
7M2J	;	3.201	;	Structural Snapshots of Intermediates in the Gating of a K+ Channel
7RP0	;	2.48	;	Structural Snapshots of Intermediates in the Gating of a K+ Channel
6H3I	;	3.5	;	Structural snapshots of the Type 9 protein translocon
6H3J	;	3.7	;	Structural snapshots of the Type 9 protein translocon Plug-complex
5NTI	;	2.4	;	Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds
5NTK	;	1.9	;	Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds
5NTN	;	1.9	;	Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds
5NTP	;	1.7	;	Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds
5NTQ	;	2.26	;	Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds
5NTW	;	1.64	;	Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds
5NU1	;	1.85	;	Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds
7LUW	;		;	Structural studies about ScnTx neurotoxin using Solution NMR 2D and 3D
4FRF	;	2.9	;	Structural Studies and Protein Engineering of Inositol Phosphate Multikinase
2FFZ	;	2.05	;	Structural Studies Examining the Substrate Specificity Profiles of PC-PLCBc Protein Variants
2FGN	;	2.04	;	Structural Studies Examining the Substrate Specificity Profiles of PC-PLCBc Protein Variants
2HUC	;	1.9	;	Structural Studies Examining the Substrate Specificity Profiles of PC-PLCBc Protein Variants
1EZE	;		;	STRUCTURAL STUDIES OF A BABOON (PAPIO SP.) PLASMA PROTEIN INHIBITOR OF CHOLESTERYL ESTER TRANSFERASE.
5NBS	;	2.25	;	Structural studies of a Glycoside Hydrolase Family 3 beta-glucosidase from the Model Fungus Neurospora crassa
1BE5	;		;	STRUCTURAL STUDIES OF A STABLE PARALLEL-STRANDED DNA DUPLEX INCORPORATING ISOGUANINE:CYTOSINE AND ISOCYTOSINE:GUANINE BASE PAIRS BY NMR, MINIMIZED AVERAGE STRUCTURE
4UHD	;	1.07	;	Structural studies of a thermophilic esterase from Thermogutta terrifontis (acetate bound)
4UHH	;	1.06	;	Structural studies of a thermophilic esterase from Thermogutta terrifontis (cacodylate complex)
4UHF	;	1.08	;	Structural studies of a thermophilic esterase from Thermogutta terrifontis (L37A mutant with butyrate bound)
4UHE	;	1.16	;	Structural studies of a thermophilic esterase from Thermogutta terrifontis (malate bound)
4UHC	;	1.03	;	Structural studies of a thermophilic esterase from Thermogutta terrifontis (Native)
5DCX	;	2.6	;	Structural studies of AAV2 Rep68 reveal a partially structured linker and compact domain conformation
3RA2	;	2.7	;	Structural studies of AAV8 capsid transitions associated with endosomal trafficking
3RA4	;	2.7	;	Structural studies of AAV8 capsid transitions associated with endosomal trafficking
3RA8	;	2.7	;	Structural studies of AAV8 capsid transitions associated with endosomal trafficking
3RA9	;	2.7	;	Structural studies of AAV8 capsid transitions associated with endosomal trafficking
3RAA	;	3.2	;	Structural studies of AAV8 capsid transitions associated with endosomal trafficking
3BGT	;	2.1	;	Structural Studies of Acetoacetate Decarboxylase
3BH2	;	2.4	;	Structural Studies of Acetoacetate Decarboxylase
1F1O	;	3.25	;	STRUCTURAL STUDIES OF ADENYLOSUCCINATE LYASES
7UIJ	;	2.701	;	Structural studies of B5-OspC complex
1M0F	;	16.0	;	Structural Studies of Bacteriophage alpha3 Assembly, Cryo-electron microscopy
1M06	;	3.5	;	Structural Studies of Bacteriophage alpha3 Assembly, X-Ray Crystallography
1BNS	;	2.05	;	STRUCTURAL STUDIES OF BARNASE MUTANTS
4QO6	;	2.26	;	Structural studies of CdsD, a structural protein of the Type III secretion system (TTSS) of Chlamydia trachomatis
1I9A	;	2.5	;	STRUCTURAL STUDIES OF CHOLESTEROL BIOSYNTHESIS: MEVALONATE 5-DIPHOSPHATE DECARBOXYLASE AND ISOPENTENYL DIPHOSPHATE ISOMERASE
1UGT	;		;	Structural Studies of Cu(I)-Bleomycin
1BH1	;		;	STRUCTURAL STUDIES OF D-PRO MELITTIN, NMR, 20 STRUCTURES
1Y47	;	2.7	;	Structural studies of designed alpha-helical hairpins
6GP9	;	3.1	;	Structural studies of hepatitis C virus non-structural protein-5b of genotype 4a
5FIV	;	1.9	;	STRUCTURAL STUDIES OF HIV AND FIV PROTEASES COMPLEXED WITH AN EFFICIENT INHIBITOR OF FIV PR
6FIV	;	1.9	;	STRUCTURAL STUDIES OF HIV AND FIV PROTEASES COMPLEXED WITH AN EFFICIENT INHIBITOR OF FIV PR
3TLH	;	2.0	;	STRUCTURAL STUDIES OF HIV AND FIV PROTEASES COMPLEXED WITHAN EFFICIENT INHIBITOR OF FIV PR
1TIV	;		;	STRUCTURAL STUDIES OF HIV-1 TAT PROTEIN
7VCE	;	2.6	;	Structural studies of human inositol monophosphatase-1 inhibition by ebselen
8Q3F	;	3.77	;	Structural studies of human serum albumin using cryo-EM up to 0.38 nm resolution
5WSL	;	1.5	;	Structural studies of keratinase from Meiothermus taiwanensis WR-220
1IMC	;	2.6	;	STRUCTURAL STUDIES OF METAL BINDING BY INOSITOL MONOPHOSPHATASE: EVIDENCE FOR TWO-METAL ION CATALYSIS
1IMD	;	2.6	;	STRUCTURAL STUDIES OF METAL BINDING BY INOSITOL MONOPHOSPHATASE: EVIDENCE FOR TWO-METAL ION CATALYSIS
1IME	;	2.25	;	STRUCTURAL STUDIES OF METAL BINDING BY INOSITOL MONOPHOSPHATASE: EVIDENCE FOR TWO-METAL ION CATALYSIS
1IMF	;	2.5	;	STRUCTURAL STUDIES OF METAL BINDING BY INOSITOL MONOPHOSPHATASE: EVIDENCE FOR TWO-METAL ION CATALYSIS
3LZM	;	1.7	;	STRUCTURAL STUDIES OF MUTANTS OF T4 LYSOZYME THAT ALTER HYDROPHOBIC STABILIZATION
1L01	;	1.7	;	STRUCTURAL STUDIES OF MUTANTS OF THE LYSOZYME OF BACTERIOPHAGE T4. THE TEMPERATURE-SENSITIVE MUTANT PROTEIN THR157 (RIGHT ARROW) ILE
1L10	;	1.7	;	STRUCTURAL STUDIES OF MUTANTS OF THE LYSOZYME OF BACTERIOPHAGE T4. THE TEMPERATURE-SENSITIVE MUTANT PROTEIN THR157 (RIGHT ARROW) ILE
2YW6	;	2.53	;	Structural studies of N terminal deletion mutant of Dps from Mycobacterium smegmatis
2JJ8	;	2.8	;	Structural Studies of Nucleoside Analog and Feedback Inhibitor Binding to Drosophila Melanogaster Multisubstrate Deoxyribonucleoside Kinase
2VP0	;	2.2	;	Structural Studies of Nucleoside Analog and Feedback Inhibitor Binding to Drosophila Melanogaster Multisubstrate Deoxyribonucleoside Kinase
2VP2	;	2.5	;	Structural Studies of Nucleoside Analog and Feedback Inhibitor Binding to Drosophila Melanogaster Multisubstrate Deoxyribonucleoside Kinase
2VP4	;	2.2	;	Structural Studies of Nucleoside Analog and Feedback Inhibitor Binding to Drosophila Melanogaster Multisubstrate Deoxyribonucleoside Kinase
2VP5	;	2.3	;	Structural Studies of Nucleoside Analog and Feedback Inhibitor Binding to Drosophila Melanogaster Multisubstrate Deoxyribonucleoside Kinase
2VP6	;	3.0	;	Structural Studies of Nucleoside Analog and Feedback Inhibitor Binding to Drosophila Melanogaster Multisubstrate Deoxyribonucleoside Kinase
2VP9	;	2.9	;	Structural Studies of Nucleoside Analog and Feedback Inhibitor Binding to Drosophila Melanogaster Multisubstrate Deoxyribonucleoside Kinase
2VQS	;	2.9	;	Structural Studies of Nucleoside Analog and Feedback Inhibitor Binding to Drosophila Melanogaster Multisubstrate Deoxyribonucleoside Kinase
1Q4N	;	2.07	;	Structural studies of Phe256Trp of human salivary alpha-amylase: implications for the role of a conserved water molecule and its associated chain in enzyme activity
2WU8	;	2.25	;	Structural studies of phosphoglucose isomerase from Mycobacterium tuberculosis H37Rv
4XTT	;	2.708	;	Structural Studies of Potassium Transport Protein KtrA Regulator of Conductance of K+ (RCK) C domain in Complex with Cyclic Diadenosine Monophosphate (c-di-AMP)
2I4H	;	2.15	;	Structural studies of protein tyrosine phosphatase beta catalytic domain co-crystallized with a sulfamic acid inhibitor
2I4G	;	1.65	;	Structural studies of protein tyrosine phosphatase beta catalytic domain in complex with a sulfamic acid (soaking experiment)
2H02	;	2.3	;	Structural studies of protein tyrosine phosphatase beta catalytic domain in complex with inhibitors
2H03	;	1.65	;	Structural studies of protein tyrosine phosphatase beta catalytic domain in complex with inhibitors
2H04	;	2.3	;	Structural studies of protein tyrosine phosphatase beta catalytic domain in complex with inhibitors
2I3U	;	1.85	;	Structural studies of protein tyrosine phosphatase beta catalytic domain in complex with inhibitors
2I4E	;	1.75	;	Structural studies of protein tyrosine phosphatase beta catalytic domain in complex with inhibitors
3H21	;	2.32	;	Structural Studies of Pterin-Based Inhibitors of Dihydropteroate Synthase
3H22	;	2.4	;	Structural Studies of Pterin-Based Inhibitors of Dihydropteroate Synthase
3H23	;	2.2	;	Structural Studies of Pterin-Based Inhibitors of Dihydropteroate Synthase
3H24	;	2.5	;	Structural Studies of Pterin-Based Inhibitors of Dihydropteroate Synthase
3H26	;	2.5	;	Structural Studies of Pterin-Based Inhibitors of Dihydropteroate Synthase
3H2A	;	2.4	;	Structural Studies of Pterin-Based Inhibitors of Dihydropteroate Synthase
3H2C	;	2.6	;	Structural Studies of Pterin-Based Inhibitors of Dihydropteroate Synthase
3H2E	;	2.0	;	Structural Studies of Pterin-Based Inhibitors of Dihydropteroate Synthase
3H2F	;	2.2	;	Structural Studies of Pterin-Based Inhibitors of Dihydropteroate Synthase
3H2M	;	2.31	;	Structural Studies of Pterin-Based Inhibitors of Dihydropteroate Synthase
3H2N	;	2.4	;	Structural Studies of Pterin-Based Inhibitors of Dihydropteroate Synthase
3H2O	;	2.7	;	Structural Studies of Pterin-Based Inhibitors of Dihydropteroate Synthase
4CWE	;	3.0	;	Structural studies of rolling circle replication initiation protein from Staphylococcus aureus
1RF6	;	1.9	;	Structural Studies of Streptococcus pneumoniae EPSP Synthase in S3P-GLP Bound State
1RF5	;	2.3	;	Structural Studies of Streptococcus pneumoniae EPSP Synthase in Unliganded State
1RF4	;	2.2	;	Structural Studies of Streptococcus pneumoniae EPSP Synthase, Tetrahedral intermediate Bound State
5LVY	;		;	Structural studies of the Aggregative Adherence Fimbriae of Enteroaggregative Escherichia coli
1AFC	;	2.7	;	STRUCTURAL STUDIES OF THE BINDING OF THE ANTI-ULCER DRUG SUCROSE OCTASULFATE TO ACIDIC FIBROBLAST GROWTH FACTOR
1ENH	;	2.1	;	STRUCTURAL STUDIES OF THE ENGRAILED HOMEODOMAIN
1MVP	;	2.2	;	STRUCTURAL STUDIES OF THE RETROVIRAL PROTEINASE FROM AVIAN MYELOBLASTOSIS ASSOCIATED VIRUS
1CHH	;	1.97	;	STRUCTURAL STUDIES OF THE ROLES OF RESIDUES 82 AND 85 AT THE INTERACTIVE FACE OF CYTOCHROME C
1CHI	;	2.0	;	STRUCTURAL STUDIES OF THE ROLES OF RESIDUES 82 AND 85 AT THE INTERACTIVE FACE OF CYTOCHROME C
1CHJ	;	1.9	;	STRUCTURAL STUDIES OF THE ROLES OF RESIDUES 82 AND 85 AT THE INTERACTIVE FACE OF CYTOCHROME C
4EIX	;	2.9	;	Structural Studies of the ternary complex of Phaspholipase A2 with nimesulide and indomethacin
5KBD	;	2.8	;	Structural Studies of Transcription Factor p73 DNA Binding Domain Bound to PA26 20-mer Response Element
4ZFY	;	2.42	;	Structural studies on a non-toxic homologue of type II RIPs from Momordica charantia (bitter gourd) in complex with ALPHA-METHYL-D-GALACTOSIDE
4ZBV	;	2.0	;	Structural studies on a non-toxic homologue of type II RIPs from Momordica charantia (bitter gourd) in complex with benzyl T-antigen
4ZFW	;	2.54	;	Structural studies on a non-toxic homologue of type II RIPs from Momordica charantia (bitter gourd) in complex with galactose.
4ZLB	;	2.55	;	Structural studies on a non-toxic homologue of type II RIPs from Momordica charantia (bitter gourd) in complex with lactose
4ZFU	;	2.53	;	Structural studies on a non-toxic homologue of type II RIPs from Momordica charantia (bitter gourd) in complex with N-acetyl D galactosamine
4ZGR	;	1.97	;	Structural studies on a non-toxic homologue of type II RIPs from Momordica charantia (bitter gourd) in complex with T-Antigen.
4Z8S	;	2.36	;	Structural studies on a non-toxic homologue of type II RIPs from Momordica charantia (bitter gourd)-Native-1
4Z9W	;	1.77	;	Structural studies on a non-toxic homologue of type II RIPs from Momordica charantia (bitter gourd)-Native-2
4ZA3	;	1.67	;	Structural studies on a non-toxic homologue of type II RIPs from Momordica charantia (bitter gourd)-Native-3
1IDT	;	2.0	;	STRUCTURAL STUDIES ON A PRODRUG-ACTIVATING SYSTEM-CB1954 AND FMN-DEPENDENT NITROREDUCTASE
1VJ3	;	2.1	;	STRUCTURAL STUDIES ON BIO-ACTIVE COMPOUNDS. CRYSTAL STRUCTURE AND MOLECULAR MODELING STUDIES ON THE PNEUMOCYSTIS CARINII DIHYDROFOLATE REDUCTASE COFACTOR COMPLEX WITH TAB, A HIGHLY SELECTIVE ANTIFOLATE.
1CNE	;	3.0	;	STRUCTURAL STUDIES ON CORN NITRATE REDUCTASE: REFINED STRUCTURE OF THE CYTOCHROME B REDUCTASE FRAGMENT AT 2.5 ANGSTROMS, ITS ADP COMPLEX AND AN ACTIVE SITE MUTANT AND MODELING OF THE CYTOCHROME B DOMAIN
1CNF	;	2.7	;	STRUCTURAL STUDIES ON CORN NITRATE REDUCTASE: REFINED STRUCTURE OF THE CYTOCHROME B REDUCTASE FRAGMENT AT 2.5 ANGSTROMS, ITS ADP COMPLEX AND AN ACTIVE SITE MUTANT AND MODELING OF THE CYTOCHROME B DOMAIN
2CND	;	2.5	;	STRUCTURAL STUDIES ON CORN NITRATE REDUCTASE: REFINED STRUCTURE OF THE CYTOCHROME B REDUCTASE FRAGMENT AT 2.5 ANGSTROMS, ITS ADP COMPLEX AND AN ACTIVE SITE MUTANT AND MODELING OF THE CYTOCHROME B DOMAIN
1PJH	;	2.1	;	Structural studies on delta3-delta2-enoyl-CoA isomerase: the variable mode of assembly of the trimeric disks of the crotonase superfamily
2MCC	;		;	Structural studies on dinuclear ruthenium(II) complexes that bind diastereoselectively to an anti-parallel folded human telomere sequence
2MCO	;		;	Structural studies on dinuclear ruthenium(II) complexes that bind diastereoselectively to an anti-parallel folded human telomere sequence
265D	;	2.01	;	STRUCTURAL STUDIES ON NUCLEIC ACIDS
266D	;	2.03	;	STRUCTURAL STUDIES ON NUCLEIC ACIDS
267D	;	2.0	;	STRUCTURAL STUDIES ON NUCLEIC ACIDS
268D	;	2.02	;	STRUCTURAL STUDIES ON NUCLEIC ACIDS
269D	;	2.15	;	STRUCTURAL STUDIES ON NUCLEIC ACIDS
270D	;	2.01	;	STRUCTURAL STUDIES ON NUCLEIC ACIDS
271D	;	2.02	;	STRUCTURAL STUDIES ON NUCLEIC ACIDS
2NPR	;		;	Structural Studies on Plasmodium vivax Merozoite Surface Protein-1
1SXG	;	2.75	;	Structural studies on the apo transcription factor form B. megaterium
1BNX	;		;	STRUCTURAL STUDIES ON THE EFFECTS OF THE DELETION IN THE RED CELL ANION EXCHANGER (BAND3, AE1) ASSOCIATED WITH SOUTH EAST ASIAN OVALOCYTOSIS.
1BZK	;		;	STRUCTURAL STUDIES ON THE EFFECTS OF THE DELETION IN THE RED CELL ANION EXCHANGER (BAND3, AE1) ASSOCIATED WITH SOUTH EAST ASIAN OVALOCYTOSIS.
2CNR	;		;	Structural studies on the interaction of ScFAS ACP with ACPS
1K6A	;	1.14	;	Structural studies on the mobility in the active site of the Thermoascus aurantiacus xylanase I
1LLW	;	2.7	;	Structural studies on the synchronization of catalytic centers in glutamate synthase: complex with 2-oxoglutarate
1LM1	;	2.8	;	Structural studies on the synchronization of catalytic centers in glutamate synthase: native enzyme
1LLZ	;	3.0	;	Structural studies on the synchronization of catalytic centers in glutamate synthase: reduced enzyme
2QBT	;	1.75	;	Structural Studies Reveal The Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 8.0)
2QA3	;	1.75	;	Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms (at pH6.5)
2QB3	;	1.45	;	Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5)
2QB2	;	1.7	;	Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (s)-4,5-dihydro-2thiophenecarboylic acid (SADTA) via two mechanisms (at pH 7.0).
2Q7W	;	1.4	;	Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0
4JOU	;	2.7	;	Structural study of Bacillus subtilis HmoB in complex with heme
3HE8	;	1.9	;	Structural study of Clostridium thermocellum Ribose-5-Phosphate Isomerase B
3HEE	;	2.0	;	Structural study of Clostridium thermocellum Ribose-5-Phosphate Isomerase B and ribose-5-phosphate
1OSR	;		;	Structural study of dna duplex containaing a n-(2-deoxy-beta-erytho-pentofuranosyl) formamide frameshift by nmr and restrained molecular dynamics
8IZN	;	6.67	;	Structural study of Interferon-induced, double-stranded RNA-activated protein kinase (PKR) and Non-structural protein 1 (NS1) complex
7UPS	;	2.43	;	Structural study of Legionella pneumophila effector DotY (Lpg0294)
1RBR	;	1.8	;	STRUCTURAL STUDY OF MUTANTS OF ESCHERICHIA COLI RIBONUCLEASE HI WITH ENHANCED THERMOSTABILITY
1RBS	;	1.8	;	STRUCTURAL STUDY OF MUTANTS OF ESCHERICHIA COLI RIBONUCLEASE HI WITH ENHANCED THERMOSTABILITY
1RBT	;	1.8	;	STRUCTURAL STUDY OF MUTANTS OF ESCHERICHIA COLI RIBONUCLEASE HI WITH ENHANCED THERMOSTABILITY
1RBU	;	1.8	;	STRUCTURAL STUDY OF MUTANTS OF ESCHERICHIA COLI RIBONUCLEASE HI WITH ENHANCED THERMOSTABILITY
1RBV	;	1.8	;	STRUCTURAL STUDY OF MUTANTS OF ESCHERICHIA COLI RIBONUCLEASE HI WITH ENHANCED THERMOSTABILITY
9EST	;	1.9	;	STRUCTURAL STUDY OF PORCINE PANCREATIC ELASTASE COMPLEXED WITH 7-AMINO-3-(2-BROMOETHOXY)-4-CHLOROISOCOUMARIN AS A NONREACTIVATABLE DOUBLY COVALENT ENZYME-INHIBITOR COMPLEX
2EP7	;	2.3	;	Structural study of Project ID aq_1065 from Aquifex aeolicus VF5
2EKC	;	2.0	;	Structural study of Project ID aq_1548 from Aquifex aeolicus VF5
2EKD	;	2.3	;	Structural study of Project ID PH0250 from Pyrococcus horikoshii OT3
1WNG	;	2.1	;	Structural study of project ID PH0725 from Pyrococcus horikoshii OT3
2E8R	;	2.0	;	Structural study of Project ID PH0725 from Pyrococcus horikoshii OT3
2E8S	;	2.5	;	Structural study of Project ID PH0725 from Pyrococcus horikoshii OT3
2EK2	;	2.2	;	Structural study of Project ID PH0725 from Pyrococcus horikoshii OT3 (E140M)
2E8Q	;	2.5	;	Structural study of Project ID PH0725 from Pyrococcus horikoshii OT3 (K19M)
2EK7	;	2.0	;	Structural study of Project ID PH0725 from Pyrococcus horikoshii OT3 (L163M)
2EL2	;	2.3	;	Structural study of Project ID PH0725 from Pyrococcus horikoshii OT3 (L185M)
2EKA	;	2.3	;	Structural study of Project ID PH0725 from Pyrococcus horikoshii OT3 (L202M)
2EL0	;	2.4	;	Structural study of Project ID PH0725 from Pyrococcus horikoshii OT3 (L21M)
2EL3	;	2.4	;	Structural study of Project ID PH0725 from Pyrococcus horikoshii OT3 (L242M)
2EK3	;	2.8	;	Structural study of Project ID PH0725 from Pyrococcus horikoshii OT3 (L3M)
2EL1	;	2.2	;	Structural study of Project ID PH0725 from Pyrococcus horikoshii OT3 (L44M)
2EK4	;	2.2	;	Structural study of Project ID PH0725 from Pyrococcus horikoshii OT3 (L8M)
2EJZ	;	1.85	;	Structural study of Project ID PH0725 from Pyrococcus horikoshii OT3 (Y11M)
2EP5	;	2.4	;	Structural study of Project ID ST1242 from Sulfolobus tokodaii strain7
2EER	;	2.1	;	Structural study of Project ID ST2577 from Sulfolobus tokodaii strain7
2EKB	;	1.7	;	Structural study of Project ID TTHB049 from Thermus thermophilus HB8 (L19M)
2EKZ	;	1.85	;	Structural study of Project ID TTHB049 from Thermus thermophilus HB8 (L52M)
2EOA	;	1.75	;	Structural study of Project ID TTHB049 from Thermus thermophilus HB8 (W85H)
2J4R	;	2.71	;	Structural Study of the Aquifex aeolicus PPX-GPPA enzyme
7WUZ	;	1.93	;	Structural study of the complex of cblC methylmalonic aciduria and homocysteinuria-related protein MMACHC with cyanocobalamin
5MEJ	;	1.5	;	Structural study of the X-ray induced enzymatic reduction of molecular oxygen to water for laccase from Steccherinum murashkinskyi. First structure of the series with 3 min total X-ray exposition time.
2D3K	;	1.9	;	Structural study on Project ID PH1539 from Pyrococcus horikoshii OT3
2D29	;	1.65	;	Structural study on project ID TT0172 from Thermus thermophilus HB8
1T5N	;		;	Structural transitions as determinants of calcium-dependent antibiotic daptomycin
1T5M	;		;	Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin
5M4R	;	3.1	;	Structural tuning of CD81LEL (space group C2)
5M33	;	1.28	;	Structural tuning of CD81LEL (space group P21)
5M3D	;	2.38	;	Structural tuning of CD81LEL (space group P31)
5M2C	;	1.961	;	Structural tuning of CD81LEL (space group P32 1 2)
5M3T	;	2.021	;	Structural tuning of CD81LEL (space group P64)
390D	;	2.0	;	STRUCTURAL VARIABILITY AND NEW INTERMOLECULAR INTERACTIONS OF Z-DNA IN CRYSTALS OF D(PCPGPCPGPCPG)
391D	;	2.75	;	STRUCTURAL VARIABILITY AND NEW INTERMOLECULAR INTERACTIONS OF Z-DNA IN CRYSTALS OF D(PCPGPCPGPCPG)
392D	;	3.0	;	STRUCTURAL VARIABILITY AND NEW INTERMOLECULAR INTERACTIONS OF Z-DNA IN CRYSTALS OF D(PCPGPCPGPCPG)
368D	;	1.6	;	STRUCTURAL VARIABILITY OF A-DNA IN CRYSTALS OF THE OCTAMER D(PCPCPCPGPCPGPGPG)
369D	;	1.9	;	STRUCTURAL VARIABILITY OF A-DNA IN CRYSTALS OF THE OCTAMER D(PCPCPCPGPCPGPGPG)
370D	;	1.67	;	STRUCTURAL VARIABILITY OF A-DNA IN CRYSTALS OF THE OCTAMER D(PCPCPCPGPCPGPGPG)
371D	;	1.9	;	STRUCTURAL VARIABILITY OF A-DNA IN CRYSTALS OF THE OCTAMER D(PCPCPCPGPCPGPGPG)
372D	;	2.6	;	STRUCTURAL VARIABILITY OF A-DNA IN CRYSTALS OF THE OCTAMER D(PCPCPCPGPCPGPGPG)
1D93	;	2.15	;	STRUCTURAL VARIATION IN D(CTCTAGAG). IMPLICATIONS FOR PROTEIN-DNA INTERACTIONS
4RJ1	;	0.92	;	Structural variations and solvent structure of UGGGGU quadruplexes stabilized by Sr2+ ions
4RKV	;	0.88	;	Structural variations and solvent structure of UGGGGU quadruplexes stabilized by Sr2+ ions
4RNE	;	1.01	;	Structural variations and solvent structure of UGGGGU quadruplexes stabilized by Sr2+ ions
4X2Z	;	2.15	;	Structural view and substrate specificity of papain-like protease from Avian Infectious Bronchitis Virus
1O9C	;	2.6	;	Structural view of a fungal toxin acting on a 14-3-3 regulatory complex
1O9D	;	2.3	;	Structural view of a fungal toxin acting on a 14-3-3 regulatory complex
1O9E	;	2.6	;	Structural view of a fungal toxin acting on a 14-3-3 regulatory complex
1O9F	;	2.7	;	Structural view of a fungal toxin acting on a 14-3-3 regulatory complex
3UT4	;	2.03	;	Structural view of a non Pfam singleton and crystal packing analysis
3UT7	;	3.01	;	Structural view of a non Pfam singleton and crystal packing analysis
3UT8	;	2.168	;	Structural view of a non Pfam singleton and crystal packing analysis
4D70	;	1.99	;	Structural, biophysical and biochemical analyses of a Clostridium perfringens Sortase D5 transpeptidase
3L3R	;	2.0	;	Structural, Computational and Kinetic Data for Antifolate Interactions Against Pneumocystis jirovecii, Pneumocystis carinii and Human Dihydrofolate Reductase and Their Active Site Mutants
5GO1	;	2.5	;	Structural, Functional characterization and discovery of novel inhibitors of Leishmania amazonensis Nucleoside Diphosphatase Kinase (NDK)
7TVK	;	2.35	;	Structural, Kinetic, and Mechanistic Analysis of the Wild-Type and Inactivated Malonate Semialdehyde Decarboxylase: A Structural Basis for the Decarboxylase and Hydratase Activities
2D55	;	3.0	;	Structural, physical and biological characteristics of RNA.DNA binding agent N8-actinomycin D
209D	;	3.0	;	Structural, physical and biological characteristics of RNA:DNA binding agent N8-actinomycin D
3QHY	;	2.06	;	Structural, thermodynamic and kinetic analysis of the picomolar binding affinity interaction of the beta-lactamase inhibitor protein-II (BLIP-II) with class A beta-lactamases
3QI0	;	2.8	;	Structural, thermodynamic and kinetic analysis of the picomolar binding affinity interaction of the beta-lactamase inhibitor protein-II (BLIP-II) with class A beta-lactamases
4OKA	;	2.505	;	Structural-, Kinetic- and Docking Studies of Artificial Imine Reductases Based on the Biotin-Streptavidin Technology: An Induced Lock-and-Key Hypothesis
1RF3	;	3.5	;	Structurally Distinct Recognition Motifs in Lymphotoxin-B Receptor and CD40 for TRAF-mediated Signaling
8HKP	;	3.6	;	Structurally hetero-junctional human Cx36/GJD2 gap junction channel in detergents (C6 symmetry)
7XNV	;	3.4	;	Structurally hetero-junctional human Cx36/GJD2 gap junction channel in soybean lipids (C6 symmetry)
2G8G	;	3.2	;	Structurally mapping the diverse phenotype of Adeno-Associated Virus serotype 4
6NQ6	;	1.5	;	Structure & function of a new Aspartylglucosaminuria variant
1X6Z	;	0.78	;	Structure 1: cryocooled crystal structure of the truncated pak pilin from Pseudomonas aeruginosa at 0.78A resolution
1X6X	;	0.96	;	Structure 2: cryocolled crystal structure of the truncated pak pilin from Pseudomonas aeruginosa at 0.95A resolution
1X6Q	;	1.51	;	Structure 3: cryocooled crystal structure of the truncated pak pilin from Pseudomonas aeruginosa at 1.51A resolution
1X6P	;	1.63	;	Structure 4; room temperature crystal structure of truncated pak pilin from Pseudomonas aeruginosa at 1.63A resolution
1X6R	;	1.82	;	Structure 5: room temperature crystal structure of the truncated pak pilin from Pseudomonas aeruginosa at 1.80A resolution
1X6Y	;	1.55	;	Structure 6: room temperature crystal structure of the truncated pak pilin from Pseudomonas aeruginosa at 1.80A resolution
4G79	;	1.8	;	Structure a C. elegans SAS-6 variant
8P37	;	1.219	;	Structure a catalytically inactive mutant of the IMP dehydrogenase related protein GUAB3 from Synechocystis PCC 6803
2Y9H	;	2.5	;	Structure A of CRISPR endoribonuclease Cse3 bound to 19 nt RNA
5G2X	;	3.8	;	Structure a of Group II Intron Complexed with its Reverse Transcriptase
5G2Y	;	4.5	;	Structure a of Group II Intron Complexed with its Reverse Transcriptase
4ZUL	;	1.76	;	Structure ALDH7A1 complexed with alpha-aminoadipate
4ZUK	;	2.001	;	Structure ALDH7A1 complexed with NAD+
4X0U	;	1.95	;	Structure ALDH7A1 inactivated by 4-diethylaminobenzaldehyde
4X0T	;	2.4	;	Structure ALDH7A1 inactivated by 4-diethylaminobenzaldehyde and complexed with NAD+
1KWH	;	2.0	;	Structure Analysis AlgQ2, a Macromolecule(alginate)-Binding Periplasmic Protein of Sphingomonas sp. A1.
2DRX	;	1.4	;	Structure Analysis of (POG)4-(LOG)2-(POG)4
2DRT	;	1.6	;	Structure Analysis of (POG)4-LOG-(POG)5
3U1R	;	2.0	;	Structure Analysis of A New Psychrophilic Marine Protease
3R50	;	2.27	;	Structure analysis of a wound-inducible lectin ipomoelin from sweet potato
3R51	;	2.1	;	Structure analysis of a wound-inducible lectin ipomoelin from sweet potato
3R52	;	2.1	;	Structure analysis of a wound-inducible lectin ipomoelin from sweet potato
4DDN	;	1.9	;	Structure analysis of a wound-inducible lectin ipomoelin from sweet potato
3KL5	;	2.59	;	Structure Analysis of a Xylanase From Glycosyl Hydrolase Family Thirty: Carbohydrate Ligand Complexes Reveal this Family of Enzymes Unique Mechanism of Substrate Specificity and Recognition
1FX4	;	1.9	;	STRUCTURE ANALYSIS OF ADENYLATE CYCLASES FROM TRYPANOSOMA BRUCEI IN THEIR MONOMERIC STATE
1J1N	;	1.6	;	Structure Analysis of AlgQ2, A Macromolecule(Alginate)-Binding Periplasmic Protein Of Sphingomonas Sp. A1., Complexed with an Alginate Tetrasaccharide
4GS8	;	2.99	;	Structure analysis of cysteine free insulin degrading enzyme (ide) with compound bdm43079 [{[(s)-2-(1h-imidazol-4-yl)-1-methylcarbamoyl-ethylcarbamoyl]-methyl}-(3-phenyl-propyl)-amino]-acetic acid
3QV2	;	2.15	;	Structure Analysis of Entamoeba histolytica methyltransferase EhMeth
6UKO	;	4.4	;	Structure analysis of full-length mouse bcs1 complex
5B4N	;	2.3	;	Structure analysis of function associated loop mutant of substrate recognition domain of Fbs1 ubiquitin ligase
4F85	;	2.2	;	Structure analysis of Geranyl diphosphate methyltransferase
4F86	;	3.0	;	Structure analysis of Geranyl diphosphate methyltransferase in complex with GPP and sinefungin
4F84	;	2.2	;	Structure analysis of Geranyl diphosphate methyltransferase in complex with SAM
4GSC	;	2.81	;	Structure analysis of insulin degrading enzyme with compound bdm41559 ((s)-2-[2-(carboxymethyl-phenethyl-amino)-acetylamino]-3-(1h-imidazol-4-yl)-propionic acid methyl ester)
4KMC	;	2.15	;	Structure analysis of M. Tuberculosis rRNA transcriptional regulator CarD and its interaction with T. Aquaticus RNA polymerase-BETA1 domain
3TN2	;	1.6	;	structure analysis of MIP1-beta P8A
1WS0	;	1.7	;	Structure analysis of peptide deformylase from Bacillus cereus
1WS1	;	2.0	;	Structure analysis of peptide deformylase from Bacillus cereus
1R9L	;	1.59	;	structure analysis of ProX in complex with glycine betaine
1R9Q	;	2.05	;	structure analysis of ProX in complex with proline betaine
4V8D	;	3.0	;	Structure analysis of ribosomal decoding (cognate tRNA-tyr complex).
1P02	;	2.0	;	STRUCTURE ANALYSIS OF SPECIFICITY. ALPHA-LYTIC PROTEASE COMPLEXES WITH ANALOGUES OF REACTION INTERMEDIATES
1P03	;	2.15	;	STRUCTURE ANALYSIS OF SPECIFICITY. ALPHA-LYTIC PROTEASE COMPLEXES WITH ANALOGUES OF REACTION INTERMEDIATES
1P04	;	2.55	;	STRUCTURE ANALYSIS OF SPECIFICITY. ALPHA-LYTIC PROTEASE COMPLEXES WITH ANALOGUES OF REACTION INTERMEDIATES
1P05	;	2.1	;	STRUCTURE ANALYSIS OF SPECIFICITY. ALPHA-LYTIC PROTEASE COMPLEXES WITH ANALOGUES OF REACTION INTERMEDIATES
1P06	;	2.34	;	STRUCTURE ANALYSIS OF SPECIFICITY. ALPHA-LYTIC PROTEASE COMPLEXES WITH ANALOGUES OF REACTION INTERMEDIATES
1V8L	;	2.1	;	Structure Analysis of the ADP-ribose pyrophosphatase complexed with ADP-ribose
4F1R	;	2.201	;	Structure analysis of the global metabolic regulator Crc from Pseudomonas aeruginos
4RA8	;	2.6	;	Structure analysis of the Mip1a P8A mutant
2N9D	;		;	Structure analysis of the Tom1 GAT domain reveals distinct ligand-specific conformational states
3L8Q	;	1.57	;	Structure analysis of the type II cohesin dyad from the adaptor ScaA scaffoldin of Acetivibrio cellulolyticus
2BKN	;	2.6	;	STRUCTURE ANALYSIS OF UNKNOWN FUNCTION PROTEIN
2BKO	;	1.9	;	STRUCTURE ANALYSIS OF UNKNOWN FUNCTION PROTEIN
2BKP	;	2.2	;	STRUCTURE ANALYSIS OF UNKNOWN FUNCTION PROTEIN
2N8J	;		;	Structure and 15N relaxation data of Calmodulin bound to the endothelial Nitric Oxide Synthase Calmodulin Binding Domain Peptide at Physiological Calcium Concentration
1U7H	;	1.8	;	Structure and a Proposed Mechanism for Ornithine Cyclodeaminase from Pseudomonas putida
3E1T	;	2.05	;	Structure and action of the myxobacterial chondrochloren halogenase CndH, a new variant of FAD-dependent halogenases
3I6U	;	3.0	;	Structure and Activation Mechanism of the CHK2 DNA-Damage Checkpoint Kinase
3I6W	;	3.25	;	Structure and Activation Mechanism of the CHK2 DNA-Damage Checkpoint Kinase
3P43	;	2.1	;	Structure and Activities of Archaeal Members of the LigD 3' Phosphoesterase DNA Repair Enzyme Superfamily
2C9Z	;	2.1	;	Structure and activity of a flavonoid 3-0 glucosyltransferase reveals the basis for plant natural product modification
2C1X	;	1.9	;	Structure and activity of a flavonoid 3-O glucosyltransferase reveals the basis for plant natural product modification
2C1Z	;	1.9	;	Structure and activity of a flavonoid 3-O glucosyltransferase reveals the basis for plant natural product modification
4D05	;	1.65	;	Structure and activity of a minimal-type ATP-dependent DNA ligase from a psychrotolerant bacterium
4GLK	;	2.16	;	Structure and activity of AbiQ, a lactococcal anti-phage endoribonuclease belonging to the type-III toxin-antitoxin system
2W7O	;	3.16	;	Structure and Activity of Bypass Synthesis by Human DNA Polymerase Kappa Opposite the 7,8-Dihydro-8-oxodeoxyguanosine Adduct
2W7P	;	3.71	;	Structure and Activity of Bypass Synthesis by Human DNA Polymerase Kappa Opposite the 7,8-Dihydro-8-oxodeoxyguanosine Adduct
3G5K	;	1.7	;	Structure and activity of human mitochondrial peptide deformylase, a novel cancer target
3G5P	;	1.7	;	Structure and activity of human mitochondrial peptide deformylase, a novel cancer target
7EN0	;	2.97	;	Structure and Activity of SLAC1 Channels for Stomatal Signaling in Leaves
4N31	;	2.2	;	Structure and activity of Streptococcus pyogenes SipA: a signal peptidase homologue essential for pilus polymerisation
4C7D	;	1.85	;	Structure and activity of the GH20 beta-N-acetylhexosaminidase from Streptomyces coelicolor A3(2)
4C7F	;	2.0	;	Structure and activity of the GH20 beta-N-acetylhexosaminidase from Streptomyces coelicolor A3(2)
4C7G	;	1.8	;	Structure and activity of the GH20 beta-N-acetylhexosaminidase from Streptomyces coelicolor A3(2)
6YXZ	;	1.75	;	Structure and activity of the GH20 beta-N-beta-N-acetylhexosaminidase from Bifidobacterium bifidum
2WFW	;	1.6	;	Structure and activity of the N-terminal substrate recognition domains in proteasomal ATPases - The Arc domain structure
4GCH	;	1.9	;	STRUCTURE AND ACTIVITY OF TWO PHOTOREVERSIBLE CINNAMATES BOUND TO CHYMOTRYPSIN
8J6H	;	2.44074	;	Structure and allosteric regulation of the inosine 5'-monophosphate-specific phosphatase ISN1 from Saccharomyces cerevisiae
8JB3	;	1.77382	;	Structure and allosteric regulation of the inosine 5'-monophosphate-specific phosphatase ISN1 from Saccharomyces cerevisiae
3NWY	;	2.54	;	Structure and allosteric regulation of the uridine monophosphate kinase from Mycobacterium tuberculosis
4BV4	;	2.35	;	Structure and allostery in Toll-Spatzle recognition
3TNP	;	2.3	;	Structure and Allostery of the PKA RIIb Tetrameric Holoenzyme
3TNQ	;	3.097	;	Structure and Allostery of the PKA RIIb Tetrameric Holoenzyme
5K79	;	1.6	;	Structure and anti-HIV activity of CYT-CVNH, a new cyanovirin-n homolog
5T5H	;	2.54	;	Structure and assembly model for the Trypanosoma cruzi 60S ribosomal subunit
2YMS	;	2.101	;	Structure and assembly of a b-propeller with nine blades and a new conserved repetitive sequence motif
2N1F	;	4.0	;	Structure and assembly of the mouse ASC filament by combined NMR spectroscopy and cryo-electron microscopy
3ZXA	;	3.2	;	Structure and Assembly of Turnip Crinkle Virus I. X-ray Crystallographic Structure Analysis at 3.2 A Resolution
3J92	;	3.6	;	Structure and assembly pathway of the ribosome quality control complex
4NFW	;	2.3	;	Structure and atypical hydrolysis mechanism of the Nudix hydrolase Orf153 (YmfB) from Escherichia coli
4NFX	;	2.69	;	Structure and atypical hydrolysis mechanism of the Nudix hydrolase Orf153 (YmfB) from Escherichia coli
1Q14	;	2.5	;	Structure and autoregulation of the yeast Hst2 homolog of Sir2
1I5K	;	2.7	;	STRUCTURE AND BINDING DETERMINANTS OF THE RECOMBINANT KRINGLE-2 DOMAIN OF HUMAN PLASMINOGEN TO AN INTERNAL PEPTIDE FROM A GROUP A STREPTOCOCCAL SURFACE PROTEIN
2LUV	;		;	Structure and Binding Interface of the Cytosolic Tails of aXb2 Integrin
2CDE	;	3.5	;	Structure and binding kinetics of three different human CD1d-alpha- Galactosylceramide specific T cell receptors - iNKT-TCR
2CDG	;	2.6	;	Structure and binding kinetics of three different human CD1d-alpha- Galactosylceramide-specific T cell receptors (TCR 5B)
2CDF	;	2.25	;	Structure and binding kinetics of three different human CD1d-alpha- Galactosylceramide-specific T cell receptors (TCR 5E)
3PVS	;	2.5	;	Structure and biochemical activities of Escherichia coli MgsA
3VDP	;	2.451	;	Structure and biochemical studies of the recombination mediator protein RecR in RecFOR pathway
8DAJ	;	1.2	;	Structure and Biochemistry of a Promiscuous Thermophilic Polyhydroxybutyrate Depolymerase from Lihuaxuella thermophilia
3O4G	;	2.5	;	Structure and Catalysis of Acylaminoacyl Peptidase
3O4H	;	1.82	;	Structure and Catalysis of Acylaminoacyl Peptidase
3O4I	;	2.7	;	Structure and Catalysis of Acylaminoacyl Peptidase
3O4J	;	2.5	;	Structure and Catalysis of Acylaminoacyl Peptidase
1MLV	;	2.6	;	Structure and Catalytic Mechanism of a SET Domain Protein Methyltransferase
3OT4	;	2.4	;	Structure and Catalytic Mechanism of Bordetella bronchiseptica nicF
1DEA	;	2.1	;	STRUCTURE AND CATALYTIC MECHANISM OF GLUCOSAMINE 6-PHOSPHATE DEAMINASE FROM ESCHERICHIA COLI AT 2.1 ANGSTROMS RESOLUTION
1HOR	;	2.4	;	STRUCTURE AND CATALYTIC MECHANISM OF GLUCOSAMINE 6-PHOSPHATE DEAMINASE FROM ESCHERICHIA COLI AT 2.1 ANGSTROMS RESOLUTION
5JCI	;	1.7	;	Structure and catalytic mechanism of monodehydroascorbate reductase, MDHAR, from Oryza sativa L. japonica
5JCK	;	2.0	;	Structure and catalytic mechanism of monodehydroascorbate reductase, MDHAR, from Oryza sativa L. japonica
5JCL	;	1.8	;	Structure and catalytic mechanism of monodehydroascorbate reductase, MDHAR, from Oryza sativa L. japonica
5JCM	;	1.9	;	Structure and catalytic mechanism of monodehydroascorbate reductase, MDHAR, from Oryza sativa L. japonica
5JCN	;	2.29	;	Structure and catalytic mechanism of monodehydroascorbate reductase, MDHAR, from Oryza sativa L. japonica
3UAO	;	2.399	;	Structure and Catalytic Mechanism of the Vitamin B3 Degradative Enzyme Maleamate Amidohydrolase from Bordetalla bronchiseptica RB50
8IWH	;	2.68	;	Structure and characteristics of a photosystem II supercomplex containing monomeric LHCX and dimeric FCPII antennae from the diatom Thalassiosira pseudonana
1CXY	;	1.65	;	STRUCTURE AND CHARACTERIZATION OF ECTOTHIORHODOSPIRA VACUOLATA CYTOCHROME B558, A PROKARYOTIC HOMOLOGUE OF CYTOCHROME B5
2LU5	;		;	Structure and chemical shifts of Cu(I),Zn(II) superoxide dismutase by solid-state NMR
4GOP	;	3.1	;	Structure and Conformational Change of a Replication Protein A Heterotrimer Bound to ssDNA
5TF6	;	2.3	;	Structure and conformational plasticity of the U6 small nuclear ribonucleoprotein core
4V8V	;	20.0	;	Structure and conformational variability of the Mycobacterium tuberculosis fatty acid synthase multienzyme complex
4V8W	;	17.5	;	Structure and conformational variability of the Mycobacterium tuberculosis fatty acid synthase multienzyme complex
3P8C	;	2.29	;	Structure and Control of the Actin Regulatory WAVE Complex
2XJH	;	0.92	;	Structure and Copper-binding Properties of Methanobactins from Methylosinus trichosporium OB3b
2XJI	;	1.0	;	Structure and Copper-binding Properties of Methanobactins from Methylosinus trichosporium OB3b
2C5Z	;		;	Structure and CTD binding of the Set2 SRI domain
3QBC	;	1.65	;	Structure and design of a new pterin site inhibitor of S. aureus HPPK
2FH9	;	2.8	;	Structure and dimerization of the kinase domain from yeast Snf1
4M4X	;	2.551	;	Structure and Dimerization Properties of the Aryl Hydrocarbon Receptor (AHR) PAS-A Domain
6ES5	;		;	Structure and dynamics conspire in the evolution of affinity between intrinsically disordered proteins
6ES6	;		;	Structure and dynamics conspire in the evolution of affinity between intrinsically disordered proteins
6ES7	;		;	Structure and dynamics conspire in the evolution of affinity between intrinsically disordered proteins
2K71	;		;	Structure and dynamics of a DNA GNRA hairpin solved vy high-sensitivity NMR with two independent converging methods, simulated annealing (DYANA) and mesoscopic molecular modelling (BCE/AMBER)
2M3O	;		;	Structure and dynamics of a human Nedd4 WW domain-ENaC complex
1HIS	;		;	Structure and dynamics of des-pentapeptide-insulin in solution: the molten-globule hypothesis.
1DVH	;		;	STRUCTURE AND DYNAMICS OF FERROCYTOCHROME C553 FROM DESULFOVIBRIO VULGARIS STUDIED BY NMR SPECTROSCOPY AND RESTRAINED MOLECULAR DYNAMICS
2JQ3	;		;	Structure and Dynamics of Human Apolipoprotein C-III
1N9C	;		;	Structure and dynamics of reduced Bacillus pasteurii cytochrome c: oxidation state dependent properties and implications for electron transfer processes
5VH7	;		;	Structure and dynamics of RNA repeat expansions that cause Huntington's Disease and myotonic dystrophy type 1
5VH8	;		;	Structure and dynamics of RNA repeat expansions that cause Huntington's Disease and myotonic dystrophy type 1
5JCO	;	4.0	;	Structure and dynamics of single-isoform recombinant neuronal human tubulin
2NPV	;		;	Structure and dynamics of surfactin studied by NMR in micellar media
2MZP	;		;	Structure and dynamics of the acidosis-resistant a162H mutant of the switch region of troponin I bound to the regulatory domain of troponin C
1GNC	;		;	STRUCTURE AND DYNAMICS OF THE HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR DETERMINED BY NMR SPECTROSCOPY. LOOP MOBILITY IN A FOUR-HELIX-BUNDLE PROTEIN
2KSJ	;		;	Structure and Dynamics of the Membrane-bound form of Pf1 Coat Protein: Implications for Structural Rearrangement During Virus Assembly
6FWN	;		;	Structure and dynamics of the platelet integrin-binding C4 domain of von Willebrand factor
1N17	;		;	Structure and Dynamics of Thioguanine-modified Duplex DNA
1N14	;		;	Structure and Dynamics of Thioguanine-modified Duplex DNA in Comparison with Unmodified DNA; Structure of Unmodified Duplex DNA
1MUA	;	1.7	;	STRUCTURE AND ENERGETICS OF A NON-PROLINE CIS-PEPTIDYL LINKAGE IN AN ENGINEERED PROTEIN
2KG7	;		;	Structure and features of the complex formed by the tuberculosis virulence factors Rv0287 and Rv0288
7OSR	;		;	Structure and folding of a 600-million-year-old nuclear coactivator binding domain suggest conservation of dynamic properties
7OSW	;		;	Structure and folding of a 600-million-year-old nuclear coactivator binding domain suggest conservation of dynamic properties
4V14	;	2.42	;	Structure and function analysis of MutT from the psychrofile fish pathogen Aliivibrio salmonicida and the mesophile Vibrio cholerae
1OXN	;	2.2	;	Structure and Function Analysis of Peptide Antagonists of Melanoma Inhibitor of Apoptosis (ML-IAP)
1OXQ	;	2.3	;	Structure and Function Analysis of Peptide Antagonists of Melanoma Inhibitor of Apoptosis (ML-IAP)
1OY7	;	2.7	;	Structure and Function Analysis of Peptide Antagonists of Melanoma Inhibitor of Apoptosis (ML-IAP)
5FMG	;	3.6	;	Structure and function based design of Plasmodium-selective proteasome inhibitors
3AQO	;	2.6	;	Structure and function of a membrane component SecDF that enhances protein export
5YQW	;	1.36	;	Structure and function of a novel periplasmic chitooligosaccharide-binding protein from marine Vibrio bacteria
4RCN	;	3.01	;	Structure and function of a single-chain, multi-domain long-chain acyl-coa carboxylase
3OLM	;	2.495	;	Structure and Function of a Ubiquitin Binding Site within the Catalytic Domain of a HECT Ubiquitin Ligase
1KPT	;	1.75	;	STRUCTURE AND FUNCTION OF A VIRALLY ENCODED FUNGAL TOXIN FROM USTILAGO MAYDIS: A FUNGAL AND MAMMALIAN CALCIUM CHANNEL INHIBITOR
6FJX	;	2.25	;	Structure and function of aldehyde dehydrogenase from Thermus thermophilus: An enzyme with an evolutionarily-distinct C-terminal arm (Native protein)
6FK3	;	2.3	;	Structure and function of aldehyde dehydrogenase from Thermus thermophilus: An enzyme with an evolutionarily-distinct C-terminal arm (Recombinant full-length protein in complex with propanal)
6FKV	;	2.9	;	Structure and function of aldehyde dehydrogenase from Thermus thermophilus: An enzyme with an evolutionarily-distinct C-terminal arm (Recombinant protein with shortened C-terminal, ADH508)
6FKU	;	2.4	;	Structure and function of aldehyde dehydrogenase from Thermus thermophilus: An enzyme with an evolutionarily-distinct C-terminal arm (Recombinant protein with shortened C-terminal, in complex with NADP)
4BI3	;	1.85	;	Structure and function of amidase toxin - antitoxin combinations associated with the type VI secretion system of Serratia marcescens.
4BI4	;	2.21	;	Structure and function of amidase toxin - antitoxin combinations associated with the type VI secretion system of Serratia marcescens.
4C3O	;	3.2	;	Structure and function of an oxygen tolerant NiFe hydrogenase from Salmonella
4HV0	;	2.6	;	Structure and Function of AvtR, a Novel Transcriptional Regulator from a Hyperthermophilic Archaeal Lipothrixvirus
1CRM	;	2.0	;	STRUCTURE AND FUNCTION OF CARBONIC ANHYDRASES
3FEW	;	2.45	;	Structure and Function of Colicin S4, a colicin with a duplicated receptor binding domain
2GUI	;	1.6	;	Structure and Function of Cyclized Versions of the Proofreading Exonuclease Subunit of E. coli DNA Polymerase III
1PJQ	;	2.21	;	Structure and function of CysG, the multifunctional methyltransferase/dehydrogenase/ferrochelatase for siroheme synthesis
7DFX	;	2.996	;	Structure and function of Diadenylate cyclase DacM in Mycoplasma ovipneumoniae
7DG0	;	1.895	;	Structure and function of Diadenylate cyclase DacM in Mycoplasma ovipneumoniae
5YB1	;	2.616	;	Structure and function of human serum albumin-metal agent complex
8CHX	;	1.8	;	Structure and function of LolA from Vibrio cholerae
4R1I	;	3.959	;	Structure and Function of Neisseria gonorrhoeae MtrF Illuminates a Class of Antimetabolite Efflux Pumps
1U1V	;	1.7	;	Structure and function of phenazine-biosynthesis protein PhzF from Pseudomonas fluorescens 2-79
1U1W	;	1.35	;	Structure and function of phenazine-biosynthesis protein PhzF from Pseudomonas fluorescens 2-79
1U1X	;	1.88	;	Structure and function of phenazine-biosynthesis protein PhzF from Pseudomonas fluorescens 2-79
6QVV	;	2.4	;	Structure and function of phenuiviridae cap snatching endonucleases
2C2I	;	1.8	;	Structure and function of Rv0130, a conserved hypothetical protein from M.tuberculosis
4I5S	;	3.3	;	Structure and function of sensor histidine kinase
1NXB	;	1.38	;	STRUCTURE AND FUNCTION OF SNAKE VENOM CURARIMIMETIC NEUROTOXINS
1AN4	;	2.9	;	STRUCTURE AND FUNCTION OF THE B/HLH/Z DOMAIN OF USF
1P5S	;	2.22	;	STRUCTURE AND FUNCTION OF THE CALPONIN-HOMOLOGY DOMAIN OF AN IQGAP PROTEIN FROM SCHIZOSACCHAROMYCES POMBE
1CEH	;	1.9	;	STRUCTURE AND FUNCTION OF THE CATALYTIC SITE MUTANT ASP99ASN OF PHOSPHOLIPASE A2: ABSENCE OF CONSERVED STRUCTURAL WATER
5UL7	;	2.8	;	Structure and function of the divalent anion/Na+ symporter from Vibrio cholerae and a humanized variant
5UL9	;	2.78	;	Structure and function of the divalent anion/Na+ symporter from Vibrio cholerae and a humanized variant
5ULD	;	2.78	;	Structure and function of the divalent anion/Na+ symporter from Vibrio cholerae and a humanized variant
5ULE	;	2.8	;	Structure and function of the divalent anion/Na+ symporter from Vibrio cholerae and a humanized variant
2OXL	;	1.8	;	Structure and Function of the E. coli Protein YmgB: a Protein Critical for Biofilm Formation and Acid Resistance
1RIB	;	2.2	;	STRUCTURE AND FUNCTION OF THE ESCHERICHIA COLI RIBONUCLEOTIDE REDUCTASE PROTEIN R2
5BY4	;	1.702	;	Structure and function of the Escherichia coli Tol-Pal stator protein TolR
2WJG	;	2.2	;	Structure and function of the FeoB G-domain from Methanococcus jannaschii
2WJH	;	2.1	;	Structure and function of the FeoB G-domain from Methanococcus jannaschii
2WJI	;	1.903	;	Structure and function of the FeoB G-domain from Methanococcus jannaschii
2WJJ	;	2.405	;	Structure and function of the FeoB G-domain from Methanococcus jannaschii
4AE9	;	2.3	;	Structure and function of the Human Sperm-Specific Isoform of Protein Kinase A (PKA) Catalytic Subunit C alpha 2
4AE6	;	2.1	;	Structure and Function of the Human Sperm-Specific Isoform of Protein Kinase A (PKA) Catalytic Subunit Calpha 2
4YHJ	;	2.6	;	Structure and Function of the Hypertension Variant A486V of G Protein-coupled Receptor Kinase 4 (GRK4)
2RRE	;		;	Structure and function of the N-terminal nucleolin binding domain of nuclear valocine containing protein like 2 (NVL2) harboring a nucleolar localization signal
1XUA	;	1.9	;	Structure and function of the phenazine biosynthetic protein PhzF from Pseudomonas fluorescens
1XUB	;	1.3	;	Structure and function of the phenazine biosynthetic protein PhzF from Pseudomonas fluorescens
3NYB	;	2.7007	;	Structure and function of the polymerase core of TRAMP, a RNA surveillance complex
4AUI	;	3.2	;	STRUCTURE AND FUNCTION OF THE PORB PORIN FROM DISSEMINATING N. GONORRHOEAE
2XNH	;	2.8	;	Structure and function of the Rad9-binding region of the DNA damage checkpoint adaptor TopBP1
2XNK	;	2.6	;	Structure and function of the Rad9-binding region of the DNA damage checkpoint adaptor TopBP1
2FQ3	;	1.4	;	Structure and function of the SWIRM domain, a conserved protein module found in chromatin regulatory complexes
6QW5	;	1.988	;	Structure and function of the toscana virus cap snatching endonuclease
5XI8	;	1.7	;	Structure and function of the TPR domain
6QW0	;	1.5	;	Structure and function of toscana virus cap snatching endonucleases
1R8G	;	2.15	;	Structure and function of YbdK
2NZ5	;	2.35	;	Structure and Function Studies of Cytochrome P450 158A1 from Streptomyces coelicolor A3(2)
2NZA	;	2.9	;	Structure and Function Studies of Cytochrome P450 158A1 from Streptomyces coelicolor A3(2)
2QN4	;	1.8	;	Structure and function study of rice bifunctional alpha-amylase/subtilisin inhibitor from Oryza sativa
3RHZ	;	1.898	;	Structure and functional analysis of a new subfamily of glycosyltransferases required for glycosylation of serine-rich streptococcal adhesions
4DTD	;	2.5	;	Structure and functional characterization of a Vibrio cholerae toxin from the MARTX/VgrG family.
3MME	;	3.97	;	Structure and functional dissection of PG16, an antibody with broad and potent neutralization of HIV-1
2VT2	;	2.3	;	Structure and functional properties of the Bacillus subtilis transcriptional repressor Rex
2VT3	;	2.0	;	Structure and functional properties of the Bacillus subtilis transcriptional repressor Rex
3NE0	;	1.0	;	Structure and functional regulation of RipA, a mycobacterial enzyme essential for daughter cell separation
5A8F	;	10.6	;	Structure and genome release mechanism of human cardiovirus Saffold virus-3
4LOW	;	1.3	;	Structure and identification of a pterin dehydratase-like protein as a RuBisCO assembly factor in the alpha-carboxysome
2KUO	;		;	Structure and identification of ADP-ribose recognition motifs of APLF and role in the DNA damage response
2ESY	;		;	Structure and influence on stability and activity of the N-terminal propetide part of lung surfactant protein C
2ZCG	;	2.223	;	Structure and inhibition of orotidine 5'-phosphate decarboxylase from plasmodium falciparum
2W3N	;	2.05	;	Structure and inhibition of the CO2-sensing carbonic anhydrase Can2 from the pathogenic fungus Cryptococcus neoformans
2W3Q	;	1.34	;	Structure and inhibition of the CO2-sensing carbonic anhydrase Can2 from the pathogenic fungus Cryptococcus neoformans
1YXE	;		;	Structure and inter-domain interactions of domain II from the blood stage malarial protein, apical membrane antigen 1
1BLQ	;		;	STRUCTURE AND INTERACTION SITE OF THE REGULATORY DOMAIN OF TROPONIN-C WHEN COMPLEXED WITH THE 96-148 REGION OF TROPONIN-I, NMR, 29 STRUCTURES
7LXC	;		;	Structure and Interactions of DED1 of human cFLIP
1LL8	;		;	Structure and interactions of PAS kinase N-terminal PAS domain: Model for intramolecular kinase regulation
4GZK	;	1.69	;	Structure and interactions of the RNA-dependent RNA polymerase from bacteriophage phi12
4IEG	;	2.1	;	Structure and interactions of the RNA-dependent RNA polymerase from bacteriophage phi12 (P1 crystal form)
4JGT	;	2.161	;	Structure and kinetic analysis of H2S production by human Mercaptopyruvate Sulfurtransferase
2BKV	;	1.5	;	Structure and kinetics of a monomeric glucosamine-6-phosphate deaminase: missing link of the NagB superfamily
2BKX	;	1.4	;	Structure and kinetics of a monomeric glucosamine-6-phosphate deaminase: missing link of the NagB superfamily
5SVG	;	2.5	;	Structure and kinetics of the LOV domain of ZEITLUPE determine its circadian function in Arabidopsis
5SVU	;	2.601	;	Structure and kinetics of the LOV domain of ZEITLUPE determine its circadian function in Arabidopsis
5SVV	;	2.101	;	Structure and kinetics of the LOV domain of ZEITLUPE determine its circadian function in Arabidopsis
5HPG	;	1.66	;	STRUCTURE AND LIGAND DETERMINANTS OF THE RECOMBINANT KRINGLE 5 DOMAIN OF HUMAN PLASMINOGEN
1N72	;		;	Structure and Ligand of a Histone Acetyltransferase Bromodomain
2OLP	;	1.932	;	Structure and ligand selection of hemoglobin II from Lucina pectinata
1N7Z	;	2.0	;	Structure and location of gene product 8 in the bacteriophage T4 baseplate
5IAO	;	2.598	;	Structure and mapping of spontaneous mutational sites of PyrR from Mycobacterium tuberculosis
3OTK	;	2.3	;	Structure and mechanisim of core 2 beta1,6-n-acetylglucosaminyltransferase: a Metal-ion independent gt-a glycosyltransferase
4Q1G	;	2.1	;	Structure and mechanism of a dehydratase/decarboxylase enzyme couple involved in polyketide beta-branching
4Q1H	;	1.93	;	Structure and mechanism of a dehydratase/decarboxylase enzyme couple involved in polyketide beta-branching
4Q1I	;	2.1	;	Structure and mechanism of a dehydratase/decarboxylase enzyme couple involved in polyketide beta-branching
4Q1J	;	2.17	;	Structure and mechanism of a dehydratase/decarboxylase enzyme couple involved in polyketide beta-branching
4Q1K	;	1.75	;	Structure and mechanism of a dehydratase/decarboxylase enzyme couple involved in polyketide beta-branching
5COT	;	1.69	;	Structure and mechanism of a eukaryal nick-sealing RNA ligase
5COU	;	1.9	;	Structure and mechanism of a eukaryal nick-sealing RNA ligase K170M+ATP
5COV	;	2.2	;	Structure and mechanism of a eukaryal nick-sealing RNA ligase K170M+Mn
7XBK	;	3.7	;	Structure and mechanism of a mitochondrial AAA+ disaggregase CLPB
6O07	;	2.702	;	Structure and mechanism of acetylation by the N-terminal dual enzyme NatA/Naa50 complex
1OW2	;	2.0	;	STRUCTURE AND MECHANISM OF ACTION OF ISOPENTENYLPYROPHOSPHATE-DIMETHYLALLYLPYROPHOSPHATE ISOMERASE: COMPLEX OF C67A MUTANT WITH EIPP
1NFZ	;	1.97	;	STRUCTURE AND MECHANISM OF ACTION OF ISOPENTENYLPYROPHOSPHATE-DIMETHYLALLYLPYROPHOSPHATE ISOMERASE: COMPLEX WITH EIPP
1NFS	;	1.96	;	STRUCTURE AND MECHANISM OF ACTION OF ISOPENTENYLPYROPHOSPHATE-DIMETHYLALLYLPYROPHOSPHATE ISOMERASE: COMPLEX WITH NIPP
1Q54	;	1.93	;	STRUCTURE AND MECHANISM OF ACTION OF ISOPENTENYLPYROPHOSPHATE-DIMETHYLALLYLPYROPHOSPHATE ISOMERASE: COMPLEX WITH THE BROMOHYDRINE OF IPP
4OR1	;	3.0	;	Structure and mechanism of fibronectin binding and biofilm formation of enteroaggregative Escherischia coli AAF fimbriae
1B4Y	;		;	STRUCTURE AND MECHANISM OF FORMATION OF THE H-Y5 ISOMER OF AN INTRAMOLECULAR DNA TRIPLE HELIX.
1ICE	;	2.6	;	STRUCTURE AND MECHANISM OF INTERLEUKIN-1BETA CONVERTING ENZYME
2OJT	;	1.95	;	Structure and mechanism of kainate receptor modulation by anions
2EUA	;	2.5	;	Structure and Mechanism of MenF, the Menaquinone-Specific Isochorismate Synthase from Escherichia Coli
1RI1	;	2.5	;	Structure and mechanism of mRNA cap (guanine N-7) methyltransferase
1RI2	;	2.7	;	Structure and mechanism of mRNA cap (guanine N-7) methyltransferase
1RI3	;	2.5	;	Structure and mechanism of mRNA cap (guanine N-7) methyltransferase
1RI4	;	2.4	;	Structure and mechanism of mRNA cap (guanine N-7) methyltransferase
1RI5	;	2.1	;	Structure and mechanism of mRNA cap (guanine N-7) methyltransferase
2I6Y	;	2.5	;	Structure and Mechanism of Mycobacterium tuberculosis Salicylate Synthase, MbtI
1S68	;	1.9	;	Structure and Mechanism of RNA Ligase
6BZ5	;	2.006	;	Structure and mechanism of salicylate hydroxylase from Pseudomonas putida G7
1LY1	;	2.0	;	Structure and Mechanism of T4 Polynucleotide Kinase
4AXH	;	2.7	;	Structure and mechanism of the first inverting alkylsulfatase specific for secondary alkylsulfatases
3KSO	;	4.367	;	Structure and Mechanism of the Heavy Metal Transporter CusA
3KSS	;	3.88	;	Structure and Mechanism of the Heavy Metal Transporter CusA
1BY4	;	2.1	;	STRUCTURE AND MECHANISM OF THE HOMODIMERIC ASSEMBLY OF THE RXR ON DNA
3P5N	;	3.6	;	Structure and mechanism of the S component of a bacterial ECF transporter
2K9B	;		;	Structure and membrane interactions of the antibiotic peptide dermadistinctin K by multidimensional solution and oriented 15N and 31P solid-state NMR spectroscopy
2JX6	;		;	Structure and membrane interactions of the antibiotic peptide dermadistinctin k by solution and oriented 15N and 31P solid-state NMR spectroscopy
2PRS	;	1.7	;	Structure and metal binding properties of ZnuA, a periplasmic zinc transporter from Escherichia coli
2PS0	;	2.0	;	Structure and metal binding properties of ZnuA, a periplasmic zinc transporter from Escherichia coli
2PS3	;	2.47	;	Structure and metal binding properties of ZnuA, a periplasmic zinc transporter from Escherichia coli
2PS9	;	2.15	;	Structure and metal binding properties of ZnuA, a periplasmic zinc transporter from Escherichia coli
2XLF	;	2.3	;	Structure and metal-loading of a soluble periplasm cupro-protein: apo- CucA-closed (SeMet)
2XLA	;	1.93	;	Structure and metal-loading of a soluble periplasm cupro-protein: Cu- CucA-closed
2XL7	;	2.4	;	Structure and metal-loading of a soluble periplasm cupro-protein: Cu- CucA-closed (SeMet)
2XLG	;	1.8	;	Structure and metal-loading of a soluble periplasm cupro-protein: Cu- CucA-open
2XL9	;	2.06	;	Structure and metal-loading of a soluble periplasm cupro-protein: Zn- CucA-closed (SeMet)
1AJY	;		;	STRUCTURE AND MOBILITY OF THE PUT3 DIMER: A DNA PINCER, NMR, 13 STRUCTURES
2VSA	;	2.89	;	Structure and mode of action of a mosquitocidal holotoxin
2VSE	;	2.5	;	Structure and mode of action of a mosquitocidal holotoxin
4FAJ	;	1.9	;	Structure and mode of peptide binding of pheromone receptor PrgZ
6TAA	;	2.1	;	STRUCTURE AND MOLECULAR MODEL REFINEMENT OF ASPERGILLUS ORYZAE (TAKA) ALPHA-AMYLASE: AN APPLICATION OF THE SIMULATED-ANNEALING METHOD
3TGL	;	1.9	;	STRUCTURE AND MOLECULAR MODEL REFINEMENT OF RHIZOMUCOR MIEHEI TRIACYLGLYCERIDE LIPASE: A CASE STUDY OF THE USE OF SIMULATED ANNEALING IN PARTIAL MODEL REFINEMENT
7ESO	;	2.45	;	Structure and mutation analysis of the hexameric P4 from Pseudomonas aeruginosa phage phiYY
7ESP	;	2.43	;	Structure and mutation analysis of the hexameric P4 from Pseudomonas aeruginosa phage phiYY
7ESQ	;	1.85	;	Structure and mutation analysis of the hexameric P4 from Pseudomonas aeruginosa phage phiYY
7ESV	;	2.18	;	Structure and mutation analysis of the hexameric P4 from Pseudomonas aeruginosa phage phiYY
1W7W	;	2.8	;	Structure and mutational analysis of a plant mitochondrial nucleoside diphosphate kinase: identification of residues involved in serine phosphorylation and oligomerization.
2MH5	;		;	Structure and NMR assignments of lantibiotic NAI-107 in DPC micelles
2MDL	;		;	Structure and NMR assignments of Scylla Serrata anti lipopolysaccharide Factor-24 (SsALF-24)
1VYN	;		;	STRUCTURE AND NUCLEIC ACID BINDING OF THE DROSOPHILA ARGONAUTE2 PAZ DOMAIN
2LQY	;		;	Structure and orientation of the gH625-644 membrane interacting region of herpes simplex virus type 1 in a membrane mimetic system.
1KF1	;	2.1	;	Structure and Packing of Human Telomeric DNA
2TAA	;	3.0	;	STRUCTURE AND POSSIBLE CATALYTIC RESIDUES OF TAKA-AMYLASE A
2N4Y	;		;	Structure and possible function of a G-quadruplex in the long terminal repeat of the proviral HIV-1 genome
1FRX	;	2.5	;	STRUCTURE AND PROPERTIES OF C20S FDI MUTANT
4ALO	;	2.37	;	STRUCTURE AND PROPERTIES OF H1 CRUSTACYANIN FROM LOBSTER HOMARUS AMERICANUS
1NRG	;	1.95	;	Structure and Properties of Recombinant Human Pyridoxine-5'-Phosphate Oxidase
1MA1	;	2.6	;	Structure and properties of the atypical iron superoxide dismutase from Methanobacterium thermoautotrophicum
2Y7Z	;	1.84	;	Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs
2Y80	;	1.9	;	Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs
2Y81	;	1.7	;	Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs
2Y82	;	2.2	;	Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs
2VH6	;	1.95	;	Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs
2WYG	;	1.88	;	Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs
2WYJ	;	2.38	;	Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs
2VH0	;	1.7	;	Structure and property based design of factor Xa inhibitors:biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifs
1S18	;	1.7	;	Structure and protein design of human apyrase
1S1D	;	1.6	;	Structure and protein design of human apyrase
6GEH	;	1.15	;	Structure and reactivity of a siderophore-interacting protein from the marine bacterium Shewanella reveals unanticipated functional versatility.
2PTM	;	1.93	;	Structure and rearrangements in the carboxy-terminal region of SpIH channels
2Q0A	;	2.25	;	Structure and rearrangements in the carboxy-terminal region of SpIH channels
4WE7	;	2.5	;	Structure and receptor binding preferences of recombinant human A(H3N2) virus hemagglutinins
4WEA	;	2.2	;	Structure and receptor binding prefereneces of recombinant human A(H3N2) virus hemagglutinins
4KPQ	;	2.502	;	Structure and receptor binding specificity of the hemagglutinin H13 from avian influenza A virus H13N6
4KPS	;	2.587	;	Structure and receptor binding specificity of the hemagglutinin H13 from avian influenza A virus H13N6
2APR	;	1.8	;	STRUCTURE AND REFINEMENT AT 1.8 ANGSTROMS RESOLUTION OF THE ASPARTIC PROTEINASE FROM RHIZOPUS CHINENSIS
1MBO	;	1.6	;	Structure and refinement of oxymyoglobin at 1.6 angstroms resolution
3APP	;	1.8	;	STRUCTURE AND REFINEMENT OF PENICILLOPEPSIN AT 1.8 ANGSTROMS RESOLUTION
2UTG	;	1.64	;	STRUCTURE AND REFINEMENT OF THE OXIDIZED P21 FORM OF UTEROGLOBIN AT 1.64 ANGSTROMS RESOLUTION
1H4L	;	2.65	;	Structure and regulation of the CDK5-p25(nck5a) complex
3GVO	;	1.6	;	Structure and RNA binding of the mouse Pumilio-2 Puf Domain
3GVT	;	2.8	;	Structure and RNA binding of the mouse Pumilio-2 Puf Domain
1F5V	;	1.7	;	STRUCTURE AND SITE-DIRECTED MUTAGENESIS OF A FLAVOPROTEIN FROM ESCHERICHIA COLI THAT REDUCES NITROCOMPOUNDS. ALTERATION OF PYRIDINE NUCLEOTIDE BINDING BY A SINGLE AMINO ACID SUBSTITUTION
2JRY	;		;	Structure and Sodium Channel Activity of an Excitatory I1-Superfamily Conotoxin
2P4L	;		;	Structure and sodium channel activity of an excitatory I1-superfamily conotoxin
4QR7	;	2.303	;	Structure and specificity of L-D-Transpeptidase from Mycobacterium tuberculosis and antibiotic resistance: Calcium binding promotes dimer formation
4QRA	;	2.29	;	Structure and specificity of L-D-Transpeptidase from Mycobacterium tuberculosis and antibiotic resistance: Calcium binding promotes dimer formation
4QRB	;	1.64	;	Structure and specificity of L-D-Transpeptidase from Mycobacterium tuberculosis and antibiotic resistance: Calcium binding promotes dimer formation
4QTF	;	2.0	;	Structure and specificity of L-D-Transpeptidase from Mycobacterium tuberculosis and antibiotic resistance: Calcium binding promotes dimer formation
1BSX	;	3.7	;	STRUCTURE AND SPECIFICITY OF NUCLEAR RECEPTOR-COACTIVATOR INTERACTIONS
1IBG	;	2.7	;	STRUCTURE AND SPECIFICITY OF THE ANTI-DIGOXIN ANTIBODY 40-50
2LSF	;		;	Structure and Stability of Duplex DNA Containing (5'S) 5',8-Cyclo-2'-Deoxyadenosine: An Oxidative Lesion Repair by NER
2MVY	;		;	Structure and Stability of RNAs Containing N6-Methyl-adenosine
1S5P	;	1.96	;	Structure and substrate binding properties of cobB, a Sir2 homolog protein deacetylase from Eschericia coli.
4BPQ	;	6.0	;	Structure and substrate induced conformational changes of the secondary citrate-sodium symporter CitS revealed by electron crystallography
1N3J	;		;	Structure and Substrate of a Histone H3 Lysine Methyltransferase from Paramecium Bursaria Chlorella Virus 1
4R8Q	;	2.31	;	Structure and substrate recruitment of the human spindle checkpoint kinase bub1
145D	;	1.25	;	Structure and thermodynamics of nonalternating C/G base pairs in Z-DNA: the 1.3 angstroms crystal structure of the asymmetric hexanucleotide D(M(5)CGGGM(5) CG)/D(M(5)CGCCM(5)CG)
2VSN	;	2.75	;	Structure and topological arrangement of an O-GlcNAc transferase homolog: insight into molecular control of intracellular glycosylation
1EPS	;	3.0	;	STRUCTURE AND TOPOLOGICAL SYMMETRY OF THE GLYPHOSPHATE 5-ENOL-PYRUVYLSHIKIMATE-3-PHOSPHATE SYNTHASE: A DISTINCTIVE PROTEIN FOLD
1PJD	;		;	Structure and Topology of a Peptide Segment of the 6th Transmembrane Domain of the Saccharomyces cerevisiae alpha-Factor Receptor in Phospholipid Bilayers
7MPA	;		;	Structure and topology of DWORF in bicelles by oriented solid-state NMR
1NJ3	;		;	Structure and Ubiquitin Interactions of the Conserved NZF Domain of Npl4
6LDY	;	1.77	;	Structure antibody D6 in complex with methylated peptide
6LDX	;	1.8	;	Structure antibody E6 in complex with methylated peptide
6LDV	;	1.9	;	Structure antibody F9 in complex with methylated peptide
5EPQ	;	1.752	;	Structure at 1.75 A resolution of a glycosylated, lipid-binding, lipocalin-like protein
1KV9	;	1.9	;	Structure at 1.9 A Resolution of a Quinohemoprotein Alcohol Dehydrogenase from Pseudomonas putida HK5
4MTY	;	1.0	;	Structure at 1A resolution of a helical aromatic foldamer-protein complex.
5CDF	;	2.3	;	Structure at 2.3 A of the alpha/beta monomer of the F-ATPase from Paracoccus denitrificans
8HVP	;	2.5	;	STRUCTURE AT 2.5-ANGSTROMS RESOLUTION OF CHEMICALLY SYNTHESIZED HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE COMPLEXED WITH A HYDROXYETHYLENE*-BASED INHIBITOR
1AR1	;	2.7	;	Structure at 2.7 Angstrom Resolution of the Paracoccus Denitrificans two-subunit Cytochrome C Oxidase Complexed with an Antibody Fv Fragment
1FER	;	2.3	;	STRUCTURE AT PH 6.5 OF FERREDOXIN I FROM AZOTOBACTER VINELANDII AT 2.3 ANGSTROMS RESOLUTION
5G15	;	2.06	;	Structure Aurora A (122-403) bound to activating monobody Mb1 and AMPPCP
2Y8Y	;	1.44	;	Structure B of CRISPR endoribonuclease Cse3 bound to 19 nt RNA
6C4D	;	2.52	;	Structure based design of RIP1 kinase inhibitors
4GQP	;	2.0	;	Structure based design of sub-nanomolar affinity anti-methamphetamine single chain antibodies.
3QBH	;	2.24	;	Structure based design, synthesis and SAR of cyclic hydroxyethylamine (HEA) BACE-1 inhibitors
1UNT	;	2.07	;	Structure Based Engineering of Internal Molecular Surfaces Of Four Helix Bundles
1UNU	;	2.07	;	Structure Based Engineering of Internal Molecular Surfaces Of Four Helix Bundles
1UNV	;	2.14	;	Structure Based Engineering of Internal Molecular Surfaces Of Four Helix Bundles
1UNW	;	2.2	;	Structure Based Engineering of Internal Molecular Surfaces Of Four Helix Bundles
1UNX	;	2.4	;	Structure Based Engineering of Internal Molecular Surfaces Of Four Helix Bundles
1UNY	;	2.3	;	Structure Based Engineering of Internal Molecular Surfaces Of Four Helix Bundles
1UNZ	;	2.3	;	Structure Based Engineering of Internal Molecular Surfaces Of Four Helix Bundles
1UO0	;	2.4	;	Structure Based Engineering of Internal Molecular Surfaces Of Four Helix Bundles
1UO1	;	2.5	;	Structure Based Engineering of Internal Molecular Surfaces Of Four Helix Bundles
1UO2	;	1.99	;	Structure Based Engineering of Internal Molecular Surfaces Of Four Helix Bundles
1UO3	;	1.92	;	Structure Based Engineering of Internal Molecular Surfaces Of Four Helix Bundles
1UO4	;	1.7	;	Structure Based Engineering of Internal Molecular Surfaces Of Four Helix Bundles
1UO5	;	2.07	;	Structure Based Engineering of Internal Molecular Surfaces Of Four Helix Bundles
4JNJ	;	1.902	;	Structure based engineering of streptavidin monomer with a reduced biotin dissociation rate
5HXL	;	1.97	;	Structure based function annotation of a hypothetical protein MGG_01005 related to the development of rice blast fungus
5HYC	;	2.4	;	Structure based function annotation of a hypothetical protein MGG_01005 related to the development of rice blast fungus
6RSB	;	1.8	;	Structure based optimization of JAK1-ATP binding pocket Inhibitors in the aminopyrazole class
6RSC	;	1.85	;	Structure based optimization of JAK1-ATP binding pocket Inhibitors in the aminopyrazole class
6RSD	;	1.76	;	Structure based optimization of JAK1-ATP binding pocket Inhibitors in the aminopyrazole class
6RSE	;	1.8	;	Structure based optimization of JAK1-ATP binding pocket Inhibitors in the aminopyrazole class
6RSH	;	1.71	;	Structure based optimization of JAK1-ATP binding pocket Inhibitors in the aminopyrazole class
8GSQ	;	2.1	;	Structure based studies reveal an atypical antipsychotic drug candidate - Paliperidone as a potent hSOD1 modulator with implications in ALS treatment.
6KEB	;	3.2	;	Structure basis for Diltiazem block of a voltage-gated calcium channel
1ZB1	;	1.95	;	Structure basis for endosomal targeting by the Bro1 domain
4FF5	;	1.86	;	Structure basis of a novel virulence factor GHIP a glycosyl hydrolase 25 of Streptococcus pneumoniae participating in host cell invasion
3R1G	;	2.8	;	Structure Basis of Allosteric Inhibition of BACE1 by an Exosite-Binding Antibody
4TO6	;	2.33	;	Structure basis of cellular dNTP regulation, SAMHD1-dGTP-dATP-dTTP/dGTP complex
4TO2	;	2.27	;	Structure basis of cellular dNTP regulation, SAMHD1-dGTP-dGTP-dGTP/dTTP complex
4TNR	;	2.75	;	Structure basis of cellular dNTP regulation, SAMHD1-GTP-dATP-dATP complex
4TO0	;	2.3	;	Structure basis of cellular dNTP regulation, SAMHD1-GTP-dATP-dCTP complex
4TNZ	;	2.38	;	Structure basis of cellular dNTP regulation, SAMHD1-GTP-dATP-dTTP complex
4TO1	;	2.55	;	Structure basis of cellular dNTP regulation, SAMHD1-GTP-dATP/dCTP-dCTP complex
4TNX	;	2.31	;	Structure basis of cellular dNTP regulation, SAMHD1-GTP-dGTP complex
4TO4	;	2.1	;	Structure basis of cellular dNTP regulation, SAMHD1-GTP-dGTP-dCTP complex
4TO5	;	2.8	;	Structure basis of cellular dNTP regulation, SAMHD1-GTP-dTTP-dCTP complex
3WUT	;	2.301	;	Structure basis of inactivating cell abscission
3WUU	;	2.904	;	Structure basis of inactivating cell abscission with chimera peptide 1
3WUV	;	2.79	;	Structure basis of inactivating cell abscission with chimera peptide 2
4N4R	;	2.8	;	Structure basis of lipopolysaccharide biogenesis
1YHN	;	3.0	;	Structure basis of RILP recruitment by Rab7
1XT3	;	2.4	;	Structure Basis of Venom Citrate-Dependent Heparin Sulfate-Mediated Cell Surface Retention of Cobra Cardiotoxin A3
1U2N	;		;	Structure CBP TAZ1 Domain
4ZGN	;	2.9	;	Structure Cdc123 complexed with the C-terminal domain of eIF2gamma
4ALE	;	1.48	;	Structure changes of Polysaccharide monooxygenase CBM33A from Enterococcus faecalis by X-ray induced photoreduction.
2JV4	;		;	Structure Characterisation of PINA WW Domain and Comparison with other Group IV WW Domains, PIN1 and ESS1
1P6T	;		;	Structure characterization of the water soluble region of P-type ATPase CopA from Bacillus subtilis
4G2V	;	2.4	;	Structure complex of LGN binding with FRMPD1
2W44	;	2.0	;	Structure DeltaA1-A4 insulin
1E7U	;	2.0	;	Structure determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin and staurosporine
1E7V	;	2.4	;	Structure determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin and staurosporine
1E8W	;	2.5	;	Structure determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin and staurosporine
1E8Y	;	2.0	;	Structure determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin and staurosporine
1E8Z	;	2.4	;	Structure determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin and staurosporine
1E90	;	2.7	;	Structure determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin and staurosporine
1EB8	;	2.1	;	Structure Determinants of Substrate Specificity of Hydroxynitrile Lyase from Manihot esculenta
1EB9	;	2.1	;	Structure Determinants of Substrate Specificity of Hydroxynitrile Lyase from Manihot esculenta
1YEA	;	1.9	;	STRUCTURE DETERMINATION AND ANALYSIS OF YEAST ISO-2-CYTOCHROME C AND A COMPOSITE MUTANT PROTEIN
1YEB	;	1.95	;	STRUCTURE DETERMINATION AND ANALYSIS OF YEAST ISO-2-CYTOCHROME C AND A COMPOSITE MUTANT PROTEIN
1GKG	;		;	Structure Determination and Rational Mutagenesis reveal binding surface of immune adherence receptor, CR1 (CD35)
1GKN	;		;	Structure Determination and Rational Mutagenesis reveal binding surface of immune adherence receptor, CR1 (CD35)
1X1N	;	1.8	;	Structure determination and refinement at 1.8 A resolution of Disproportionating Enzyme from Potato
1TJ7	;	2.44	;	Structure determination and refinement at 2.44 A resolution of Argininosuccinate lyase from E. coli
1LDB	;	2.8	;	STRUCTURE DETERMINATION AND REFINEMENT OF BACILLUS STEAROTHERMOPHILUS LACTATE DEHYDROGENASE
2LDB	;	3.0	;	STRUCTURE DETERMINATION AND REFINEMENT OF BACILLUS STEAROTHERMOPHILUS LACTATE DEHYDROGENASE
1ITH	;	2.5	;	STRUCTURE DETERMINATION AND REFINEMENT OF HOMOTETRAMERIC HEMOGLOBIN FROM URECHIS CAUPO AT 2.5 ANGSTROMS RESOLUTION
1GUH	;	2.6	;	Structure determination and refinement of human alpha class glutathione transferase A1-1, and a comparison with the MU and PI class enzymes
1RBL	;	2.2	;	STRUCTURE DETERMINATION AND REFINEMENT OF RIBULOSE 1,5 BISPHOSPHATE CARBOXYLASE(SLASH)OXYGENASE FROM SYNECHOCOCCUS PCC6301
1OMS	;	2.3	;	Structure determination by MAD: E.coli Trigger Factor binding at the ribosomal exit tunnel.
2N6N	;		;	Structure Determination for spider toxin, U4-agatoxin-Ao1a
1A8Z	;	2.1	;	STRUCTURE DETERMINATION OF A 16.8KDA COPPER PROTEIN RUSTICYANIN AT 2.1A RESOLUTION USING ANOMALOUS SCATTERING DATA WITH DIRECT METHODS
6EBX	;	1.7	;	STRUCTURE DETERMINATION OF A DIMERIC FORM OF ERABUTOXIN B, CRYSTALLIZED FROM THIOCYANATE SOLUTION
5TH6	;	1.7	;	Structure determination of a potent, selective antibody inhibitor of human MMP9 (apo MMP9)
5TH9	;	2.999	;	Structure determination of a potent, selective antibody inhibitor of human MMP9 (GS-5745 bound to MMP-9)
5KEK	;	3.098	;	Structure Determination of a Self-Assembling DNA Crystal
5KEO	;	3.15	;	Structure Determination of a Self-Assembling DNA Crystal
6BO3	;	1.83	;	Structure Determination of A223, a turret protein in Sulfolobus turreted icosahedral virus, using an iterative hybrid approach
6TMO	;	2.1	;	Structure determination of an enhanced affinity TCR, a24b17, in complex with HLA-A*02:01 presenting a MART-1 peptide, EAAGIGILTV
1FOR	;	2.75	;	STRUCTURE DETERMINATION OF AN FAB FRAGMENT THAT NEUTRALIZES HUMAN RHINOVIRUS AND ANALYSIS OF THE FAB-VIRUS COMPLEX
4BPD	;	3.3	;	Structure determination of an integral membrane kinase
4YCR	;	2.3	;	Structure determination of an integral membrane protein at room temperature from crystals in situ
1HRI	;	3.0	;	STRUCTURE DETERMINATION OF ANTIVIRAL COMPOUND SCH 38057 COMPLEXED WITH HUMAN RHINOVIRUS 14
2PGH	;	2.8	;	STRUCTURE DETERMINATION OF AQUOMET PORCINE HEMOGLOBIN AT 2.8 ANGSTROM RESOLUTION
2W1C	;	3.24	;	Structure determination of Aurora Kinase in complex with inhibitor
2W1D	;	2.97	;	Structure determination of Aurora Kinase in complex with inhibitor
2W1E	;	2.93	;	Structure determination of Aurora Kinase in complex with inhibitor
2W1F	;	2.85	;	Structure determination of Aurora Kinase in complex with inhibitor
2W1G	;	2.71	;	Structure determination of Aurora Kinase in complex with inhibitor
2W1I	;	2.6	;	Structure determination of Aurora Kinase in complex with inhibitor
6JLC	;	1.847	;	Structure determination of CAMP factor of Mobiluncus curtisii and insight into structural dynamics
1CGM	;	3.4	;	STRUCTURE DETERMINATION OF CUCUMBER GREEN MOTTLE MOSAIC VIRUS BY X-RAY FIBER DIFFRACTION. SIGNIFICANCE FOR THE EVOLUTION OF TOBAMOVIRUSES
4L0O	;	2.76	;	Structure determination of cystathionine gamma-synthase from Helicobacter pylori
3H8O	;	2.0	;	Structure determination of DNA methylation lesions N1-meA and N3-meC in duplex DNA using a cross-linked host-guest system
3H8R	;	1.77	;	Structure determination of DNA methylation lesions N1-meA and N3-meC in duplex DNA using a cross-linked host-guest system
3H8X	;	1.95	;	Structure determination of DNA methylation lesions N1-meA and N3-meC in duplex DNA using a cross-linked host-guest system
3ZYT	;	2.45	;	Structure Determination of EstA from Arthrobacter nitroguajacolicus Rue61a
1FPV	;	3.3	;	STRUCTURE DETERMINATION OF FELINE PANLEUKOPENIA VIRUS EMPTY PARTICLES
1PRY	;	1.97	;	Structure Determination of Fibrillarin Homologue From Hyperthermophilic Archaeon Pyrococcus furiosus (Pfu-65527)
1DXI	;	2.6	;	STRUCTURE DETERMINATION OF GLUCOSE ISOMERASE FROM STREPTOMYCES MURINUS AT 2.6 ANGSTROMS RESOLUTION
1S0H	;	3.0	;	Structure determination of haemoglobin from Donkey(equus asinus) at 3.0 Angstrom resolution
2QMB	;	2.8	;	Structure determination of haemoglobin from Turkey(meleagris gallopavo) at 2.8 Angstrom resolution
6QAN	;		;	Structure determination of N-terminal fragment of UL49.5 protein from bovine herpesvirus 1 by NMR spectroscopy and molecular dynamics
2PLT	;	1.5	;	STRUCTURE DETERMINATION OF PLASTOCYANIN FROM A CRYSTAL SPECIMEN WITH HEMIHEDRAL TWINNING FRACTION OF ONE-HALF
2MVH	;		;	Structure determination of Stage V sporulation protein M (SpoVM)
2MK6	;		;	Structure determination of substrate binding domain of MecA
1S3W	;	1.9	;	Structure Determination of Tetrahydroquinazoline Antifoaltes in Complex with Human and Pneumocystis carinii Dihydrofolate Reductase: Correlations of Enzyme Selectivity and Stereochemistry
1S3U	;	2.5	;	Structure Determination of Tetrahydroquinazoline Antifolates in Complex with Human and Pneumocystis carinii Dihydrofolate Reductase: Correlations of Enzyme Selectivity and Stereochemistry
1S3V	;	1.8	;	Structure Determination of Tetrahydroquinazoline Antifolates in Complex with Human and Pneumocystis carinii Dihydrofolate Reductase: Correlations of Enzyme Selectivity and Stereochemistry
1S3Y	;	2.25	;	Structure Determination of Tetrahydroquinazoline Antifolates in Complex with Human and Pneumocystis carinii Dihydrofolate Reductase: Correlations of Enzyme Selectivity and Stereochemistry
1LLC	;	3.0	;	STRUCTURE DETERMINATION OF THE ALLOSTERIC L-LACTATE DEHYDROGENASE FROM LACTOBACILLUS CASEI AT 3.0 ANGSTROMS RESOLUTION
2HOA	;		;	STRUCTURE DETERMINATION OF THE ANTP(C39->S) HOMEODOMAIN FROM NUCLEAR MAGNETIC RESONANCE DATA IN SOLUTION USING A NOVEL STRATEGY FOR THE STRUCTURE CALCULATION WITH THE PROGRAMS DIANA, CALIBA, HABAS AND GLOMSA
3E78	;	1.9	;	Structure determination of the cancer-associated Mycoplasma hyorhinis protein Mh-p37
3E79	;	1.9	;	Structure determination of the cancer-associated Mycoplasma hyorhinis protein Mh-p37
1CEI	;	1.8	;	STRUCTURE DETERMINATION OF THE COLICIN E7 IMMUNITY PROTEIN (IMME7) THAT BINDS SPECIFICALLY TO THE DNASE-TYPE COLICIN E7 AND INHIBITS ITS BACTERIOCIDAL ACTIVITY
1R11	;	2.7	;	Structure Determination of the Dimeric Endonuclease in a Pseudo-face-centerd P21 space group
1R0V	;	2.0	;	Structure Determination of the Dimeric Endonuclease in a Pseudo-face-centerd P21212 space group
4AV7	;	3.0	;	Structure determination of the double mutant S233Y F250G from the sec- alkyl sulfatase PisA1
1FJ0	;	1.7	;	STRUCTURE DETERMINATION OF THE FERRICYTOCHROME C2 FROM RHODOPSEUDOMONAS PALUSTRIS
1I8P	;	1.95	;	STRUCTURE DETERMINATION OF THE FERROCYTOCHROME C2 FROM RHODOPSEUDOMONAS PALUSTRIS
7FAU	;	2.08	;	Structure Determination of the NB1B11-RBD Complex
1RLF	;		;	STRUCTURE DETERMINATION OF THE RAS-BINDING DOMAIN OF THE RAL-SPECIFIC GUANINE NUCLEOTIDE EXCHANGE FACTOR RLF, NMR, 10 STRUCTURES
7FAT	;	1.99	;	Structure Determination of the RBD-NB1A7
2MHY	;		;	Structure determination of the salamander courtship pheromone Plethodontid Modulating Factor
1A5R	;		;	STRUCTURE DETERMINATION OF THE SMALL UBIQUITIN-RELATED MODIFIER SUMO-1, NMR, 10 STRUCTURES
2YHE	;	2.7	;	Structure determination of the stereoselective inverting sec- alkylsulfatase Pisa1 from Pseudomonas sp.
6R8N	;	4.1	;	STRUCTURE DETERMINATION OF THE TETRAHEDRAL AMINOPEPTIDASE TET2 FROM P. HORIKOSHII BY USE OF COMBINED SOLID-STATE NMR, SOLUTION-STATE NMR AND EM DATA 4.1 A, FOLLOWED BY REAL_SPACE_REFINEMENT AT 4.1 A
1OI6	;	1.4	;	Structure determination of the TMP-complex of EvaD
2KPC	;		;	Structure determination of the top-loop of the conserved 3 terminal secondary structure in the genome of YFV
2KPD	;		;	Structure determination of the top-loop of the conserved 3 terminal secondary structure in the genome of YFV-mutant
6T58	;	3.1	;	Structure determination of the transactivation domain of p53 in complex with S100A4 using annexin A2 as a crystallization chaperone
6QBJ	;		;	Structure determination of transmembrane- C-terminal fragment of UL49.5 protein from bovine herpesvirus 1 by NMR spectroscopy and molecular dynamics
3LZ2	;	2.5	;	STRUCTURE DETERMINATION OF TURKEY EGG WHITE LYSOZYME USING LAUE DIFFRACTION
1UMU	;	2.5	;	STRUCTURE DETERMINATION OF UMUD' BY MAD PHASING OF THE SELENOMETHIONYL PROTEIN
5UF3	;		;	Structure Effects of the Four-Adenine Loop of the Coliphage GA Replicase RNA Operator
5XPX	;	2.77	;	Structure elucidation of truncated AMS3 lipase from an Antarctic Pseudomonas
5MWJ	;	2.04	;	Structure Enabled Discovery of a Stapled Peptide Inhibitor to Target the Oncogenic Transcriptional Repressor TLE1
2K36	;		;	Structure ensemble Backbone and side-chain 1H, 13C, and 15N Chemical Shift Assignments, 1H-15N RDCs and 1H-1H nOe restraints for protein K7 from the Vaccinia virus
2HOU	;		;	Structure ensembles of duplex DNA containing a 4'-oxidized abasic site.
1XGP	;	2.1	;	Structure for antibody HyHEL-63 Y33A mutant complexed with hen egg lysozyme
1XGU	;	2.1	;	Structure for antibody HyHEL-63 Y33F mutant complexed with hen egg lysozyme
1XGR	;	2.1	;	Structure for antibody HyHEL-63 Y33I mutant complexed with hen egg lysozyme
1XGT	;	2.1	;	Structure for antibody HyHEL-63 Y33L mutant complexed with hen egg lysozyme
1XGQ	;	2.1	;	Structure for antibody HyHEL-63 Y33V mutant complexed with hen egg lysozyme
2JMP	;		;	Structure for the N-terminus of chromosomal replication initiation protein dnaA from M. genitalium
5YJ4	;		;	structure for the protective mutant G127V of Human prion protein
5YJ5	;		;	structure for wildtype Human prion protein (M129)
3FUY	;	2.0	;	Structure from the mobile metagenome of Cole Harbour Salt Marsh: Integron Cassette Protein HFX_CASS1
3IF4	;	2.181	;	Structure from the mobile metagenome of North West Arm Sewage Outfall: Integron Cassette Protein Hfx_Cass5
3EY7	;	1.6	;	Structure from the mobile metagenome of V. Cholerae. Integron cassette protein VCH_CASS1
3FY6	;	2.1	;	Structure from the mobile metagenome of V. Cholerae. Integron cassette protein VCH_CASS3
3JRT	;	2.3	;	Structure from the mobile metagenome of V. paracholerae: Integron cassette protein Vpc_cass2
3EY8	;	1.6	;	Structure from the mobile metagenome of V. Pseudocholerae. VPC_CASS1
3I9S	;	2.2	;	Structure from the mobile metagenome of V.cholerae. Integron cassette protein VCH_CASS6
3IMO	;	1.8	;	Structure from the mobile metagenome of Vibrio cholerae. Integron cassette protein VCH_CASS14
3G1J	;	1.7	;	Structure from the mobile metagenome of Vibrio cholerae. Integron cassette protein VCH_CASS4.
5HJX	;	1.799	;	Structure function studies of R. palustris RubisCO (A47V mutant; CABP-bound)
5HK4	;	2.15	;	Structure function studies of R. palustris RubisCO (A47V-M331A mutant)
5HQL	;	2.53	;	Structure function studies of R. palustris RubisCO (A47V-M331A mutant; CABP-bound; no expression tag)
5HJY	;	2.3	;	Structure function studies of R. palustris RubisCO (I165T mutant; CABP-bound)
5KOZ	;	2.3	;	Structure function studies of R. palustris RubisCO (K192C mutant; CABP-bound)
5HAO	;	2.182	;	Structure function studies of R. palustris RubisCO (M331A mutant; CABP-bound)
5HQM	;	1.95	;	Structure function studies of R. palustris RubisCO (R. palustris/R. rubrum chimera)
5HAN	;	2.04	;	Structure function studies of R. palustris RubisCO (S59F mutant; CABP-bound)
5HAT	;	2.0	;	Structure function studies of R. palustris RubisCO (S59F/M331A mutant; CABP-bound)
3KEA	;	2.3	;	Structure function studies of vaccinia virus host-range protein K1 reveal a novel ankyrin repeat interaction surface for K1s function
1KR4	;	1.4	;	Structure Genomics, Protein TM1056, cutA
5G5W	;	2.2	;	Structure guided design and discovery of Indazole ethers as highly potent, non-steroidal Glucocorticoid receptor modulators
6HY2	;	1.6	;	Structure guided design of an antibacterial peptide that targets UDP-N-acetylglucosamine acyltransferase
3UWK	;	1.91	;	Structure Guided Development of Novel Thymidine Mimetics targeting Pseudomonas aeruginosa Thymidylate Kinase: from Hit to Lead Generation
3UWO	;	1.7	;	Structure Guided Development of Novel Thymidine Mimetics targeting Pseudomonas aeruginosa Thymidylate Kinase: from Hit to Lead Generation
3UXM	;	1.95	;	Structure Guided Development of Novel Thymidine Mimetics targeting Pseudomonas aeruginosa Thymidylate Kinase: from Hit to Lead Generation
5EV1	;	2.037	;	Structure I of Intact U2AF65 Recognizing a 3' Splice Site Signal
5EV2	;	1.86	;	Structure II of Intact U2AF65 Recognizing the 3' Splice Site Signal
5EV3	;	1.5	;	Structure III of Intact U2AF65 Recognizing the 3' Splice Site Signal
2MUE	;		;	Structure Immunogenicity and Protectivity Relationship for the 1585 Malarial Peptide and Its Substitution Analogues
6HLZ	;	1.89	;	Structure in C2 form of the PBP AgtB from A.tumefacien R10 in complex with agropinic acid
6HM2	;	1.74	;	Structure in P1 form of the PBP AgtB in complex with agropinic acid from A.tumefacien R10
6TFX	;	1.56	;	Structure in P21 form of the PBP/SBP MoaA in complex with mannopinic acid from A.tumefacien R10
6HLY	;	1.4	;	Structure in P212121 form of the PBP AgtB in complex with agropinic acid from A.tumefacien R10
6TFS	;	2.0	;	Structure in P3212 form of the PBP/SBP MoaA in complex with glucopinic acid from A.tumefacien R10
6TFQ	;	2.05	;	Structure in P3212 form of the PBP/SBP MoaA in complex with mannopinic acid from A.tumefacien R10
1S6D	;		;	Structure in solution of a methionine-rich 2S Albumin protein from Sunflower Seed
6HNF	;		;	Structure in solution of human fibronectin type III-domain 14
7R3M	;		;	Structure in solution of the TANGO1 cargo-binding domain (21-131)
6AE8	;	1.65	;	Structure insight into histone chaperone Chz1-mediated H2A.Z recognition and replacement
8IY8	;	1.5	;	Structure insight into substrate recognition and catalysis by feruloyl esterase from Aspergillus sydowii
8IYB	;	1.5	;	Structure insight into substrate recognition and catalysis by feruloyl esterase from Aspergillus sydowii
8IYC	;	1.55	;	Structure insight into substrate recognition and catalysis by feruloyl esterase from Aspergillus sydowii
3T0H	;	1.2	;	Structure insights into mechanisms of ATP hydrolysis and the activation of human Hsp90
8J6E	;	2.05	;	Structure insights into the NADPH quinone oxidoreductase from Leishmania donovani
6QKF	;		;	Structure investigations of Protegrin-4 by High resolution NMR spectroscopy
5EV4	;	1.57	;	Structure IV of Intact U2AF65 Recognizing the 3' Splice Site Signal
5YYR	;	1.07	;	Structure K106A thaumatin
5YYP	;	1.01	;	Structure K137A thaumatin
5YYQ	;	1.07	;	Structure K78A thaumatin
4KZT	;	2.8	;	Structure mmNAGS bound with L-arginine
5B7J	;		;	Structure model of Sap1-DNA complex
1OC6	;	1.5	;	structure native of the D405N mutant of the CELLOBIOHYDROLASE CEL6A FROM HUMICOLA INSOLENS at 1.5 angstrom resolution
8BZ3	;	1.31	;	Structure od the carbohydrate reconition domain of Gal3 in comples with SAF-2-010
6RQY	;	1.9	;	Structure of % reduced KpDyP
3KDI	;	2.379	;	Structure of (+)-ABA bound PYL2
6BG3	;	1.05	;	Structure of (3S,4S)-1-benzyl-4-(3-(3-(trifluoromethyl)phenyl)ureido)piperidin-3-yl acetate bound to DCN1
1YFV	;		;	STRUCTURE OF (5'-R(GP*GP*CP*GP*AP*GP*CP*C)-3')2 BY 2-D NMR, 1 STRUCTURE
3DNF	;	1.65	;	Structure of (E)-4-Hydroxy-3-methyl-but-2-enyl Diphosphate Reductase, the Terminal Enzyme of the Non-Mevalonate Pathway
3A08	;	1.22	;	Structure of (PPG)4-OOG-(PPG)4, monoclinic, twinned crystal
3A19	;	1.55	;	Structure of (PPG)4-OOG-(PPG)4_H monoclinic, twinned crystal
3A0A	;	1.36	;	Structure of (PPG)4-OPG-(PPG)4, monoclinic, twinned crystal
3A0M	;	1.02	;	Structure of (PPG)4-OVG-(PPG)4, monoclinic, twinned crystal
3RR3	;	2.842	;	Structure of (R)-flurbiprofen bound to mCOX-2
3Q7D	;	2.4	;	Structure of (R)-naproxen bound to mCOX-2.
2C9M	;	3.0	;	Structure of (SR) Calcium-ATPase in the Ca2E1 state solved in a P1 crystal form.
2MT3	;		;	Structure of -24 DNA binding domain of sigma 54 from E.coli
5LON	;	3.5	;	Structure of /K. lactis/ Dcp1-Dcp2 decapping complex.
1G42	;	1.8	;	STRUCTURE OF 1,3,4,6-TETRACHLORO-1,4-CYCLOHEXADIENE HYDROLASE (LINB) FROM SPHINGOMONAS PAUCIMOBILIS COMPLEXED WITH 1,2-DICHLOROPROPANE
6BG5	;	1.1	;	Structure of 1-(benzo[d][1,3]dioxol-5-ylmethyl)-1-(1-propylpiperidin-4-yl)-3-(3-(trifluoromethyl)phenyl)urea bound to DCN1
3D2A	;	1.73	;	Structure of 1-17A4, a thermostable mutant of Bacillus subtilis lipase obtained through directed evolution
5KHD	;	1.7501	;	Structure of 1.75 A BldD C-domain-c-di-GMP complex
6RR1	;	1.9	;	Structure of 10% reduced KpDyP
6RR6	;	1.9	;	Structure of 100% reduced KpDyP
6RR8	;	1.9	;	Structure of 100% reduced KpDyP (final wedges)
7X4E	;	2.32	;	Structure of 10635-DndE
2FVE	;		;	Structure of 10:0-ACP (protein alone)
2FVF	;		;	Structure of 10:0-ACP (protein with docked fatty acid)
1D14	;	1.5	;	STRUCTURE OF 11-DEOXYDAUNOMYCIN BOUND TO DNA CONTAINING A PHOSPHOROTHIOATE
6A5Q	;	2.0	;	Structure of 14-3-3 beta in complex with TFEB 14-3-3 binding motif
6BYK	;	3.0	;	Structure of 14-3-3 beta/alpha bound to O-ClcNAc peptide
7NMZ	;	2.303	;	Structure of 14-3-3 eta in complex with Nedd4-2(335-455) containing two 14-3-3 binding motifs Ser342 and Ser448
6BYL	;	3.35	;	Structure of 14-3-3 gamma bound to O-GlcNAcylated thr peptide
6FEL	;	2.84	;	Structure of 14-3-3 gamma in complex with CaMKK2 14-3-3 binding motif Ser511
6GKF	;	2.598	;	Structure of 14-3-3 gamma in complex with caspase-2 14-3-3 binding motif Ser139
6GKG	;	2.847	;	Structure of 14-3-3 gamma in complex with caspase-2 14-3-3 binding motif Ser164
6S9K	;	1.6	;	Structure of 14-3-3 gamma in complex with caspase-2 peptide containing 14-3-3 binding motif Ser139 and NLS
7A6R	;	2.7	;	Structure of 14-3-3 gamma in complex with DAPK2 peptide containing the 14-3-3 binding motif
7A6Y	;	2.5	;	Structure of 14-3-3 gamma in complex with DAPK2 peptide stabilized by FC-A
6SAD	;	2.753	;	Structure of 14-3-3 gamma in complex with double phosphorylated caspase-2 peptide on Ser139 and Ser164
6ZBT	;	1.79949	;	Structure of 14-3-3 gamma in complex with Nedd4-2 14-3-3 binding motif Ser342
6ZC9	;	1.89896	;	Structure of 14-3-3 gamma in complex with Nedd4-2 14-3-3 binding motif Ser448
6A5S	;	2.099	;	Structure of 14-3-3 gamma in complex with TFEB 14-3-3 binding motif
6BZD	;	2.67	;	Structure of 14-3-3 gamma R57E mutant bound to GlcNAcylated peptide
3E6Y	;	2.5	;	Structure of 14-3-3 in complex with the differentiation-inducing agent Cotylenin A
3O8I	;	2.0	;	Structure of 14-3-3 isoform sigma in complex with a C-Raf1 peptide and a stabilizing small molecule fragment
8C2F	;	2.3	;	Structure of 14-3-3 sigma delta C with electrophilic peptide 3MHR-5
8C2E	;	2.2	;	Structure of 14-3-3 sigma delta C with electrophilic peptide 4IEA-5
4DAU	;	2.0	;	Structure of 14-3-3 sigma in complex with PADI6 14-3-3 binding motif I
4DAT	;	1.4	;	Structure of 14-3-3 sigma in complex with PADI6 14-3-3 binding motif II
6EJL	;	2.382	;	Structure of 14-3-3 zeta in complex with ASK1 14-3-3 binding motif
6EWW	;	2.679	;	Structure of 14-3-3 zeta in complex with CaMKK2 14-3-3 binding motif
4C3I	;	3.0	;	Structure of 14-subunit RNA polymerase I at 3.0 A resolution, crystal form C2-100
4C3H	;	3.27	;	Structure of 14-subunit RNA polymerase I at 3.27 A resolution, crystal form C2-93
4C3J	;	3.35	;	Structure of 14-subunit RNA polymerase I at 3.35 A resolution, crystal form C2-90
2X9O	;	1.55	;	STRUCTURE OF 15, 16- DIHYDROBILIVERDIN:FERREDOXIN OXIDOREDUCTASE (PebA)
7U0J	;	2.7	;	Structure of 162bp LIN28b nucleosome
1PBR	;		;	STRUCTURE OF 16S RIBOSOMAL RNA, NMR, MINIMIZED AVERAGE STRUCTURE
1EMI	;	7.5	;	STRUCTURE OF 16S RRNA IN THE REGION AROUND RIBOSOMAL PROTEIN S8.
2J7Y	;	1.8	;	STRUCTURE OF 17-EPIESTRIOL-BOUND ESTROGEN RECEPTOR BETA LBD IN COMPLEX WITH LXXLL MOTIF FROM NCOA5
2LB6	;		;	Structure of 18694Da MUP, typical to the major urinary protein family: MUP9, MUP11, MUP15, MUP18 & MUP19
8DK5	;	2.71	;	Structure of 187bp LIN28b nucleosome with site 0 mutation
2FVA	;		;	Structure of 18:0-ACP with docked fatty acid
7Y5N	;	3.45	;	Structure of 1:1 PAPP-A.ProMBP complex(half map)
7Y5Q	;	3.8	;	Structure of 1:1 PAPP-A.STC2 complex(half map)
6OOR	;	2.45	;	Structure of 1B1 bound to mouse CD1d
8EZ7	;	2.6	;	Structure of 1F04 Fab in complex with A/Moscow/10/1999 (H3N2) influenza virus neuraminidase
3IBT	;	2.6	;	Structure of 1H-3-hydroxy-4-oxoquinoline 2,4-dioxygenase (QDO)
7ZK3	;	2.85	;	Structure of 1PBC- and calcium-bound mTMEM16A(ac) chloride channel at 2.85 A resolution
2M58	;		;	Structure of 2'-5' AG1 lariat forming ribozyme in its inactive state
2KP4	;		;	Structure of 2'F-ANA/RNA hybrid duplex
2M84	;		;	Structure of 2'F-RNA/2'F-ANA chimeric duplex
360D	;	1.85	;	STRUCTURE OF 2,5-BIS{[4-(N-ETHYLAMIDINO)PHENYL]}FURAN COMPLEXED TO 5'-D(CPGPCPGPAPAPTPTPCPGPCPG)-3'. A MINOR GROOVE DRUG COMPLEX, SHOWING PATTERNS OF GROOVE HYDRATION
7CUP	;	2.0	;	Structure of 2,5-dihydroxypridine Dioxygenase from Pseudomonas putida KT2440
7CNT	;	2.28	;	Structure of 2,5-dihydroxypridine Dioxygenase from Pseudomonas putida KT2440 in complex with product N-formylmaleamic acid formed via in crystallo reaction with 2,5-dihydroxypridine
2VOU	;	2.6	;	Structure of 2,6-dihydroxypyridine-3-hydroxylase from Arthrobacter nicotinovorans
6BNG	;	2.2	;	Structure of 2-dehydro-3-deoxyphosphooctonate aldolase from Acinetobacter baumannii
1VCV	;	2.0	;	Structure of 2-deoxyribose-5-phosphate aldolase from Pyrobaculum aerophilum
8EA2	;	2.394	;	Structure of 2-hydroxyisoflavanone dehydratase from Pueraria lobate
8E83	;	2.0	;	Structure of 2-hydroxyisoflavanone synthase from Medicago truncatula
1KGA	;	3.5	;	STRUCTURE OF 2-KETO-3-DEOXY-6-PHOSPHOGLUCONATE ALDOLASE AT 2.8 ANGSTROMS RESOLUTION
1EUN	;	2.0	;	STRUCTURE OF 2-KETO-3-DEOXY-6-PHOSPHOGLUCONATE ALDOLASE FROM ESCHERICHIA COLI
4BVL	;	2.002	;	Structure of 202-208 deletion mutant of PhaZ7 PHB depolymerase
5N9I	;	1.91	;	STRUCTURE OF 206-GVVTSE-211, THE STERIC ZIPPER THAT SUPPORTS THE SELF-ASSOCIATION OF P. STUARTII OMP-PST1 INTO DIMERS OF TRIMERS
1L8F	;	1.8	;	Structure of 20K-endoglucanase from Melanocarpus albomyces at 1.8 A
4E48	;	2.5	;	Structure of 20mer double-helical RNA composed of CUG/CUG-repeats
3J96	;	7.6	;	Structure of 20S supercomplex determined by single particle cryoelectron microscopy (State I)
3J97	;	7.8	;	Structure of 20S supercomplex determined by single particle cryoelectron microscopy (State II)
3J98	;	8.4	;	Structure of 20S supercomplex determined by single particle cryoelectron microscopy (State IIIa)
3J99	;	8.2	;	Structure of 20S supercomplex determined by single particle cryoelectron microscopy (State IIIb)
1MT4	;		;	Structure of 23S ribosomal RNA hairpin 35
2O43	;	3.6	;	Structure of 23S rRNA of the large ribosomal subunit from Deinococcus radiodurans in complex with the macrolide erythromycylamine
2O44	;	3.3	;	Structure of 23S rRNA of the large ribosomal subunit from Deinococcus radiodurans in complex with the macrolide josamycin
6RR4	;	1.9	;	Structure of 25% reduced KpDyP
5N9H	;	0.997	;	STRUCTURE OF 283-LGNY-286, THE STERIC ZIPPER THAT SUPPORTS THE SELF-ASSOCIATION OF P. STUARTII OMP-PST2 INTO DIMERS OF TRIMERS
6QP4	;	2.5	;	Structure of 299-452 fragment of the UspA1 protein from Moraxella catarrhalis
6E1H	;	3.5	;	Structure of 2:1 human Ptch1-Shh-N complex
8HGG	;	3.64	;	Structure of 2:2 PAPP-A.ProMBP complex
8HGH	;	4.16	;	Structure of 2:2 PAPP-A.STC2 complex
7BNY	;	2.62	;	Structure of 2A protein from encephalomyocarditis virus (EMCV)
7NBV	;	1.87	;	Structure of 2A protein from Theilers murine encephalomyelitis virus (TMEV)
2AMT	;	2.3	;	Structure of 2C-Methyl-D-Erythritol 2,4-Clycodiphosphate Synthase complexed with a CDP derived fluorescent inhibitor
2GZL	;	2.5	;	Structure of 2C-methyl-D-erythritol 2,4-clycodiphosphate synthase complexed with a CDP derived fluorescent inhibitor
1JN1	;	2.9	;	Structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Haemophilus influenzae (HI0671)
2PMP	;	2.3	;	Structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from the isoprenoid biosynthetic pathway of Arabidopsis thaliana
1GX1	;	1.8	;	Structure of 2C-Methyl-D-erythritol-2,4-cyclodiphosphate Synthase
1IV1	;	1.65	;	Structure of 2C-Methyl-D-erythritol-2,4-cyclodiphosphate Synthase
1IV2	;	1.55	;	Structure of 2C-Methyl-D-erythritol-2,4-cyclodiphosphate Synthase (bound form CDP)
1IV3	;	1.52	;	Structure of 2C-Methyl-D-erythritol-2,4-cyclodiphosphate Synthase (bound form MG atoms)
1IV4	;	1.55	;	Structure of 2C-Methyl-D-erythritol-2,4-cyclodiphosphate Synthase (bound form Substrate)
3D2B	;	1.95	;	Structure of 2D9, a thermostable mutant of Bacillus subtilis lipase obtained through directed evolution
4NHH	;	6.5	;	Structure of 2G12 IgG Dimer
7KGU	;	2.4	;	Structure of 2Q1-Fab, an antibody selective for IDH2R140Q-HLA-B*07:02
6IX1	;	1.28	;	Structure of 2S albumin seed protein from Dolichos
6FK5	;	2.02	;	Structure of 3' phosphatase NExo (D146N) from Neisseria bound to DNA substrate in presence of magnesium ion
6FKE	;	2.151	;	Structure of 3' phosphatase NExo (D146N) from Neisseria bound to product DNA hairpin
6FK4	;	2.297	;	Structure of 3' phosphatase NExo (WT) from Neisseria bound to DNA substrate
4F2Y	;	1.59	;	Structure of 3'-Fluoro Cyclohexenyl Nucleic Acid Decamer
4F2X	;	1.57	;	Structure of 3'-Fluoro Cyclohexenyl Nucleic Acid Heptamer
1DIC	;	1.8	;	STRUCTURE OF 3,4-DICHLOROISOCOUMARIN-INHIBITED FACTOR D
6J75	;	2.695	;	Structure of 3,6-anhydro-L-galactose Dehydrogenase
6J76	;	2.368	;	Structure of 3,6-anhydro-L-galactose Dehydrogenase in Complex with NAP
4PH6	;	2.2	;	Structure of 3-Dehydroquinate Dehydratase from Enterococcus faecalis
5EKS	;	1.85	;	Structure of 3-dehydroquinate synthase from Acinetobacter baumannii in complex with NAD
3ZOK	;	2.4	;	Structure of 3-Dehydroquinate Synthase from Actinidia chinensis in complex with NAD
3PFP	;	2.35	;	Structure of 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase from Mycobacterium tuberculosis in complex with an active site inhibitor
1OSI	;	3.0	;	STRUCTURE OF 3-ISOPROPYLMALATE DEHYDROGENASE
1OSJ	;	2.35	;	STRUCTURE OF 3-ISOPROPYLMALATE DEHYDROGENASE
1HEX	;	2.5	;	STRUCTURE OF 3-ISOPROPYLMALATE DEHYDROGENASE IN COMPLEX WITH NAD+: LIGAND-INDUCED LOOP-CLOSING AND MECHANISM FOR COFACTOR SPECIFICITY
2ZTW	;	2.79	;	Structure of 3-isopropylmalate dehydrogenase in complex with the inhibitor and NAD+
3R8W	;	2.25	;	Structure of 3-isopropylmalate dehydrogenase isoform 2 from Arabidopsis thaliana at 2.2 angstrom resolution
1V7L	;	1.98	;	Structure of 3-isopropylmalate isomerase small subunit from Pyrococcus horikoshii
1XBX	;	1.81	;	Structure of 3-keto-L-gulonate 6-phosphate decarboxylase E112D/R139V/T169A mutant with bound D-ribulose 5-phosphate
1XBY	;	1.58	;	Structure of 3-keto-L-gulonate 6-phosphate decarboxylase E112D/T169A mutant with bound D-ribulose 5-phosphate
1Q6O	;	1.202	;	Structure of 3-keto-L-gulonate 6-phosphate decarboxylase with bound L-gulonaet 6-phosphate
1Q6L	;	1.8	;	Structure of 3-keto-L-gulonate 6-phosphate decarboxylase with bound L-threonohydroxamate 4-phosphate
1Q6R	;	1.76	;	Structure of 3-keto-L-gulonate 6-phosphate decarboxylase with bound L-xylulose 5-phosphate
1Q6Q	;	1.695	;	Structure of 3-keto-L-gulonate 6-phosphate decarboxylase with bound xylitol 5-phosphate
3RSH	;	1.95	;	Structure of 3-ketoacyl-(acyl-carrier-protein)reductase (FabG) from Vibrio cholerae O1 complexed with NADP+ (space group P62)
6IJB	;	2.111	;	Structure of 3-methylmercaptopropionate CoA ligase mutant K523A in complex with AMP and MMPA
3LYL	;	1.95	;	Structure of 3-oxoacyl-acylcarrier protein reductase, FabG from Francisella tularensis
7P97	;	2.35	;	Structure of 3-phospho-D-glycerate guanylyltransferase with product 3-GPPG bound
6AWD	;	8.1	;	Structure of 30S (S1 depleted) ribosomal subunit and RNA polymerase complex
1SEI	;	1.9	;	STRUCTURE OF 30S RIBOSOMAL PROTEIN S8
6AWB	;	6.7	;	Structure of 30S ribosomal subunit and RNA polymerase complex in non-rotated state
6AWC	;	7.9	;	Structure of 30S ribosomal subunit and RNA polymerase complex in rotated state
4TOY	;	1.551	;	Structure of 35O22 Fab, a HIV-1 neutralizing antibody
8EZ3	;	2.5	;	Structure of 3A10 Fab in complex with A/Moscow/10/1999 (H3N2) influenza virus neuraminidase
8EZ8	;	2.78	;	Structure of 3C08 Fab in complex with A/Moscow/10/1999 (H3N2) influenza virus neuraminidase
6PYD	;	2.0	;	Structure of 3E9 antibody Fab bound to marinobufagenin
4LGG	;	2.41	;	Structure of 3MB-PP1 bound to analog-sensitive Src kinase
2XH5	;	2.72	;	Structure of 4-(4-tert-Butylbenzyl)-1-(7H-pyrrolo(2,3-d)pyrimidin-4- yl)piperidin-4-amine bound to PKB
2X39	;	1.93	;	Structure of 4-Amino-N-(4-chlorobenzyl)-1-(7H-pyrrolo(2,3-d)pyrimidin- 4-yl)piperidine-4-carboxamide bound to PKB
1H3M	;	2.4	;	Structure of 4-diphosphocytidyl-2C-methyl-D-erythritol synthetase
3M6Y	;	1.45	;	Structure of 4-hydroxy-2-oxoglutarate aldolase from bacillus cereus at 1.45 a resolution.
5TJY	;	2.4	;	Structure of 4-Hydroxy-tetrahydrodipicolinate Reductase from Mycobacterium tuberculosis with 2,6 Pyridine Dicarboxylic Acid and NADH
5TEJ	;	2.5	;	Structure of 4-Hydroxy-tetrahydrodipicolinate Reductase from Vibrio vulnificus with 2,5 Furan Dicarboxylic and NADH
5TEN	;	2.45	;	Structure of 4-Hydroxy-tetrahydrodipicolinate Reductase from Vibrio vulnificus with 2,5 Furan Dicarboxylic and NADH with Intact Polyhistidine Tag
5TEM	;	2.2	;	Structure of 4-Hydroxy-tetrahydrodipicolinate Reductase from Vibrio vulnificus with 2,6 Pyridine Dicarboxylic and NADH
1RM6	;	1.6	;	Structure of 4-hydroxybenzoyl-CoA reductase from Thauera aromatica
1SB3	;	2.2	;	Structure of 4-hydroxybenzoyl-CoA reductase from Thauera aromatica
6EB0	;	2.37	;	STRUCTURE OF 4-HYDROXYPHENYLACETATE 3-MONOOXYGENASE (HPAB), OXYGENASE COMPONENT FROM ESCHERICHIA COLI
6B1B	;	1.944	;	STRUCTURE OF 4-HYDROXYPHENYLACETATE 3-MONOOXYGENASE (HPAB), OXYGENASE COMPONENT FROM ESCHERICHIA COLI MUTANT XS6 (APO Enzyme)
5TJZ	;	1.5	;	Structure of 4-Hydroxytetrahydrodipicolinate Reductase from Mycobacterium tuberculosis with NADPH and 2,6 Pyridine Dicarboxylic Acid
5D6C	;	1.72	;	Structure of 4497 Fab bound to synthetic wall teichoic acid fragment
3RVU	;	2.5	;	Structure of 4C1 Fab in C2221 space group
3RVT	;	2.05	;	Structure of 4C1 Fab in P212121 space group
3D2C	;	2.18	;	Structure of 4D3, a thermostable mutant of Bacillus subtilis lipase obtained through directed evolution
6RPE	;	1.8	;	Structure of 5% reduced KpDyP in complex with cyanide
1VTF	;	2.0	;	STRUCTURE OF 5'-D(*(BRO)CP*GP*(BRO)CP*G)-3' IN COMPLEX WITH PROFLAVINE
1V4N	;	2.45	;	Structure of 5'-deoxy-5'-methylthioadenosine phosphorylase homologue from Sulfolobus tokodaii
1ZOS	;	1.6	;	Structure of 5'-methylthionadenosine/S-Adenosylhomocysteine nucleosidase from S. pneumoniae with a transition-state inhibitor MT-ImmA
4HTU	;	1.489	;	Structure of 5-chlorouracil modified A:U base pair
4HUF	;	1.69	;	Structure of 5-chlorouracil modified A:U base pair
4HUG	;	1.64	;	Structure of 5-chlorouracil modified A:U base pairs
4HUE	;	1.561	;	Structure of 5-chlorouracil modified G:U base pair
6RR5	;	1.9	;	Structure of 50% reduced KpDyP
6MXX	;	2.298	;	Structure of 53BP1 tandem Tudor domains in complex with small molecule UNC2991
6MXY	;	1.624	;	Structure of 53BP1 tandem Tudor domains in complex with small molecule UNC3351
6MY0	;	2.2	;	Structure of 53BP1 Tandem Tudor domains with E1549P and D1550N mutations
6MXZ	;	2.5	;	Structure of 53BP1 Tudor domains in complex with small molecule UNC3474
2IG0	;	1.7	;	Structure of 53BP1/methylated histone peptide complex
4CKL	;	2.05	;	Structure of 55 kDa N-terminal domain of E. coli DNA gyrase A subunit with simocyclinone D8 bound
8P8A	;	3.2	;	Structure of 5D3-Fab and nanobody(Nb17)-bound ABCG2
8P7W	;	3.04	;	Structure of 5D3-Fab and nanobody(Nb8)-bound ABCG2
8P8J	;	3.49	;	Structure of 5D3-Fab and nanobody(Nb96)-bound ABCG2
6D7G	;	2.75	;	Structure of 5F3 TCR in complex with HLA-A2/MART-1
2A59	;	2.7	;	Structure of 6,7-Dimethyl-8-ribityllumazine synthase from Schizosaccharomyces pombe mutant W27Y with bound ligand 5-nitroso-6-ribitylamino-2,4(1H,3H)-pyrimidinedione
2A58	;	2.8	;	Structure of 6,7-Dimethyl-8-ribityllumazine synthase from Schizosaccharomyces pombe mutant W27Y with bound riboflavin
2A57	;	2.75	;	Structure of 6,7-Dimthyl-8-ribityllumazine synthase from Schizosaccharomyces pombe mutant W27Y with bound ligand 6-carboxyethyl-7-oxo-8-ribityllumazine
3A2P	;	1.9	;	Structure of 6-aminohexanoate cyclic dimer hydrolase
3A2Q	;	1.8	;	Structure of 6-aminohexanoate cyclic dimer hydrolase complexed with substrate
1WYB	;	1.8	;	Structure of 6-aminohexanoate-dimer hydrolase
2ZM2	;	1.55	;	Structure of 6-aminohexanoate-dimer hydrolase, A61V/A124V/R187S/F264C/G291R/G338A/D370Y mutant (Hyb-S4M94)
2ZM9	;	1.5	;	Structure of 6-Aminohexanoate-dimer Hydrolase, A61V/S112A/A124V/R187S/F264C/G291R/G338A/D370Y mutant (Hyb-S4M94) with Substrate
2E8I	;	1.45	;	Structure of 6-aminohexanoate-dimer hydrolase, D1 mutant
2ZLY	;	1.58	;	Structure of 6-aminohexanoate-dimer hydrolase, D370Y mutant
1WYC	;	1.58	;	Structure of 6-aminohexanoate-dimer hydrolase, DN mutant
2ZM0	;	1.5	;	Structure of 6-aminohexanoate-dimer hydrolase, G181D/H266N/D370Y mutant
2ZM8	;	1.55	;	Structure of 6-Aminohexanoate-dimer Hydrolase, S112A/D370Y Mutant Complexed with 6-Aminohexanoate-dimer
2ZM7	;	1.6	;	Structure of 6-Aminohexanoate-dimer Hydrolase, S112A/G181D Mutant Complexed with 6-Aminohexanoate-dimer
3AXG	;	2.0	;	Structure of 6-aminohexanoate-oligomer hydrolase
5XYG	;	1.6	;	Structure of 6-aminohexanoate-oligomer hydrolase from Arthrobacter sp. KI72.
5XYO	;	2.0	;	Structure of 6-aminohexanoate-oligomer hydrolase from Arthrobacter sp. KI72., D122G mutant
5Y0L	;	1.385	;	Structure of 6-aminohexanoate-oligomer hydrolase from Arthrobacter sp. KI72., D122G/H130Y mutant
5XYQ	;	1.1	;	Structure of 6-aminohexanoate-oligomer hydrolase from Arthrobacter sp. KI72., D122K mutant
5XYP	;	1.2	;	Structure of 6-aminohexanoate-oligomer hydrolase from Arthrobacter sp. KI72., D122R mutant
5XYS	;	1.05	;	Structure of 6-aminohexanoate-oligomer hydrolase from Arthrobacter sp. KI72., D122V mutant
5Y0M	;	1.03	;	Structure of 6-aminohexanoate-oligomer hydrolase from Arthrobacter sp. KI72., D36A/D122G/H130Y/E263Q mutant
5XYT	;	1.9	;	Structure of 6-aminohexanoate-oligomer hydrolase from Arthrobacter sp. KI72., H130Y mutant
7YU1	;	1.13	;	Structure of 6-aminohexanoate-oligomer hydrolase NylC precursor, D122G/H130Y/T267C mutant
7YU0	;	1.35	;	Structure of 6-aminohexanoate-oligomer hydrolase NylC precursor, H130Y/N266A/T267A mutant
7YU2	;	1.21	;	Structure of 6-aminohexanoate-oligomer hydrolase NylC, D122G/H130Y/T267C mutant, hydroxylamine-treated
7V0F	;	2.35	;	Structure of 6-carboxy-5,6,7,8-tetrahydropterin synthase paralog QueD2 from Acinetobacter baumannii
7DA9	;	2.108	;	Structure of 6-hydroxy-3-succinoyl-pyridine 3-monooxygenase (HspB) from Pseudomonas putida S16
6L6J	;	2.6	;	Structure of 6-hydroxypseudooxynicotine (6-HPON) amine oxidase (HisD) from Pseudomonas geniculata N1
3NTB	;	2.27	;	Structure of 6-methylthio naproxen analog bound to mCOX-2.
3QN0	;	2.34	;	Structure of 6-pyruvoyltetrahydropterin synthase
7ZS5	;	3.2	;	Structure of 60S ribosomal subunit from S. cerevisiae with eIF6 and tRNA
3QMM	;	1.89	;	Structure of 6B, a thermostable mutant of Bacillus subtilis lipase obtained through directed evolution
5MYJ	;	5.6	;	Structure of 70S ribosome from Lactococcus lactis
5XK0	;	1.451	;	Structure of 8-mer DNA2
5XK1	;	1.501	;	Structure of 8-mer DNA3
8V8B	;	2.4	;	Structure of 80alpha portal protein expressed in E. coli
6ISH	;	3.3	;	Structure of 9N-I DNA polymerase incorporation with 3'-AL in the active site
6ISI	;	3.2	;	Structure of 9N-I DNA polymerase incorporation with 3'-CL in the active site
6IS7	;	2.8	;	Structure of 9N-I DNA polymerase incorporation with dA in the active site
6ISG	;	3.401	;	Structure of 9N-I DNA polymerase incorporation with dG in the active site
6ISF	;	2.8	;	Structure of 9N-I DNA polymerase incorporation with dT in the active site
1KG9	;	1.81	;	Structure of a ""mock-trapped"" early-M intermediate of bacteriorhosopsin
2KZD	;		;	Structure of a (3+1) G-quadruplex formed by hTERT promoter sequence
6AC7	;		;	Structure of a (3+1) hybrid G-quadruplex in the PARP1 promoter
1MXD	;	2.0	;	Structure of a (Ca,Zn)-dependent alpha-amylase from the hyperthermophilic archaeon Pyrococcus woesei
7JY7	;	2.9	;	Structure of a 12 base pair RecA-D loop complex
5C0W	;	4.6	;	Structure of a 12-subunit nuclear exosome complex bound to single-stranded RNA substrates
5C0X	;	3.812	;	Structure of a 12-subunit nuclear exosome complex bound to structured RNA
8F0U	;	3.1	;	Structure of a 12mer DegP cage bound to the client protein hTRF1
3VDX	;	3.002	;	Structure of a 16 nm protein cage designed by fusing symmetric oligomeric domains
4D9J	;	3.92	;	Structure of a 16 nm protein cage designed by fusing symmetric oligomeric domains
4QES	;	4.193	;	Structure of a 16 nm protein cage designed by fusing symmetric oligomeric domains, quadruple mutant, I222 form
4QF0	;	6.494	;	Structure of a 16 nm protein cage designed by fusing symmetric oligomeric domains, quadruple mutant, P21212 form
4QFF	;	7.811	;	Structure of a 16 nm protein cage designed by fusing symmetric oligomeric domains, quadruple mutant, P212121 form
4IVJ	;	7.351	;	Structure of a 16 nm protein cage designed by fusing symmetric oligomeric domains, triple mutant, I222 form
4IQ4	;	3.495	;	Structure of a 16 nm protein cage designed by fusing symmetric oligomeric domains, triple mutant, P21212 form
4ITV	;	3.598	;	Structure of a 16 nm protein cage designed by fusing symmetric oligomeric domains, triple mutant, P212121 form
5GOU	;	2.91	;	Structure of a 16-mer protein nanocage fabricated from its 24-mer analogue by subunit interface redesign
405D	;	2.5	;	STRUCTURE OF A 16-MER RNA DUPLEX R(GCAGACUUAAAUCUGC)2 WITH WOBBLE LIKE A.C MISMATCHES
3TK8	;	1.8	;	Structure of a 2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-succinyltransferase from Burkholderia pseudomallei
8F1U	;	13.8	;	Structure of a 24mer DegP cage bound to the client protein hTRF1
3TR1	;	2.0	;	Structure of a 3-phosphoshikimate 1-carboxyvinyltransferase (aroA) from Coxiella burnetii
8F21	;	14.1	;	Structure of a 30mer DegP cage bound to the client protein hTRF1
4IXT	;	2.49	;	Structure of a 37-fold mutant of halohydrin dehalogenase (HheC) bound to ethyl (R)-4-cyano-3-hydroxybutyrate
4IY1	;	2.1	;	Structure of a 37-fold mutant of halohydrin dehalogenase (HheC) with chloride bound
5GN8	;	2.805	;	Structure of a 48-mer protein nanocage fabricated from its 24-mer analogue by subunit interface redesign
2L8F	;		;	Structure of a 4X4 Nucleotide RNA Internal Loop from an R2 Retrotransposon
3TY2	;	1.885	;	Structure of a 5'-nucleotidase (surE) from Coxiella burnetii
5KPY	;	2.0	;	Structure of a 5-hydroxytryptophan aptamer
1PY2	;	2.8	;	Structure of a 60 nM Small Molecule Bound to a Hot Spot on IL-2
8F26	;	9.7	;	Structure of a 60mer DegP cage bound to the client protein hTRF1
7JY9	;	2.7	;	Structure of a 9 base pair RecA-D loop complex
2JE6	;	1.6	;	Structure of a 9-subunit archaeal exosome
2JEB	;	2.4	;	Structure of a 9-subunit archaeal exosome bound to Mn ions
2JEA	;	2.33	;	Structure of a 9-subunit archaeal exosome bound to RNA
3TQW	;	2.0	;	Structure of a ABC transporter, periplasmic substrate-binding protein from Coxiella burnetii
2HQN	;		;	Structure of a Atypical Orphan Response Regulator Protein Revealed a New Phosphorylation-Independent Regulatory Mechanism
2HQO	;		;	Structure of a Atypical Orphan Response Regulator Protein Revealed a New Phosphorylation-Independent Regulatory Mechanism
2HQR	;		;	Structure of a Atypical Orphan Response Regulator Protein Revealed a New Phosphorylation-Independent Regulatory Mechanism
2BNA	;	2.7	;	STRUCTURE OF A B-DNA DODECAMER AT 16 KELVIN
1BNA	;	1.9	;	STRUCTURE OF A B-DNA DODECAMER. CONFORMATION AND DYNAMICS
8F2W	;	1.3	;	Structure of a B-Form Dodecamer: 5'-CGCGAATTCGCG-3
7BIZ	;	1.53	;	Structure of a B12 binding lipoprotein from Bacteroides thetaiotaomicron
6CSJ	;	2.395	;	Structure of a Bacillus coagulans polyol dehydrogenase double mutant with an acquired D-lactate dehydrogenase activity
5NNV	;	3.295	;	Structure of a Bacillus subtilis Smc coiled coil middle fragment
7YLR	;	1.68	;	Structure of a bacteria protein
7YLT	;	2.3	;	Structure of a bacteria protein
7YLS	;	1.8	;	Structure of a bacteria protein complex
6QUL	;	3.0	;	Structure of a bacterial 50S ribosomal subunit in complex with the novel quinoxolidinone antibiotic cadazolid
6MVR	;	1.95	;	Structure of a bacterial ALDH16
6MVU	;	1.488	;	Structure of a bacterial ALDH16 active site mutant C295A complexed with p-nitrophenylacetate
6MVS	;	1.65	;	Structure of a bacterial ALDH16 complexed with NAD
6MVT	;	2.3	;	Structure of a bacterial ALDH16 complexed with NADH
6VQU	;	3.88	;	Structure of a bacterial Atm1-family ABC exporter
6PAN	;	3.4	;	Structure of a bacterial Atm1-family ABC exporter with ATP bound
6PAO	;	3.65	;	Structure of a bacterial Atm1-family ABC exporter with ATP bound
6PAQ	;	3.301	;	Structure of a bacterial Atm1-family ABC exporter with ATP bound
6VQT	;	3.03	;	Structure of a bacterial Atm1-family ABC exporter with MgADPVO4 bound
6PAR	;	3.35	;	Structure of a bacterial Atm1-family ABC exporter with MgAMPPNP bound
4MRN	;	2.5	;	Structure of a bacterial Atm1-family ABC transporter
4MRP	;	2.5	;	Structure of a bacterial Atm1-family ABC transporter
4MRR	;	2.97	;	Structure of a bacterial Atm1-family ABC transporter
4MRS	;	2.35	;	Structure of a bacterial Atm1-family ABC transporter
4MRV	;	2.5	;	Structure of a bacterial Atm1-family ABC transporter
6PAM	;	3.7	;	Structure of a bacterial Atm1-family ABC transporter with MgADP bound
4B7G	;	1.9	;	Structure of a bacterial catalase
3BEH	;	3.1	;	Structure of a Bacterial Cyclic Nucleotide Regulated Ion Channel
2ZD9	;	4.0	;	Structure of a Bacterial Cyclic-Nucleotide Regulated Ion Channel
8SS1	;	1.88	;	Structure of a bacterial death-like domain from Azospirillum sp.
8SRZ	;	1.25	;	Structure of a bacterial death-like domain from Lysobacter enzymogenes
3C23	;	2.5	;	Structure of a bacterial DNA damage sensor protein with non-reactive Ligand
3C21	;	2.7	;	Structure of a bacterial DNA damage sensor protein with reaction product
4HZU	;	3.53	;	Structure of a bacterial energy-coupling factor transporter
3ICD	;	2.5	;	STRUCTURE OF A BACTERIAL ENZYME REGULATED BY PHOSPHORYLATION, ISOCITRATE DEHYDROGENASE
7SZO	;	2.8	;	Structure of a bacterial fimbrial tip containing FocH
7N50	;	1.5	;	Structure of a bacterial gasdermin from Bradyrhizobium tropiciagri
7N52	;	2.9	;	Structure of a bacterial gasdermin from Runella zeae
7N51	;	1.67	;	Structure of a bacterial gasdermin from Vitiosangium sp.
8SL0	;	3.3	;	Structure of a bacterial gasdermin slinky-like oligomer
3KP9	;	3.6	;	Structure of a bacterial homolog of vitamin K epoxide reductase
5MBG	;	2.3	;	Structure of a bacterial light-regulated adenylyl cyclase
5MBH	;	2.4	;	Structure of a bacterial light-regulated adenylyl cyclase
5MBJ	;	2.3	;	Structure of a bacterial light-regulated adenylyl cyclase
5M27	;	2.0	;	Structure of a bacterial light-regulated adenylyl cylcase
5M2A	;	1.8	;	Structure of a bacterial light-regulated adenylyl cylcase
5MBB	;	3.1	;	Structure of a bacterial light-regulated adenylyl cylcase
5MBC	;	1.8	;	Structure of a bacterial light-regulated adenylyl cylcase
5MBD	;	2.25	;	Structure of a bacterial light-regulated adenylyl cylcase
5MBE	;	2.4	;	Structure of a bacterial light-regulated adenylyl cylcase
5MBK	;	2.4	;	Structure of a bacterial light-regulated adenylyl cylcase
5NBY	;	2.5	;	Structure of a bacterial light-regulated adenylyl cylcase
6BTX	;	3.2	;	Structure of a bacterial metal transporter
2J62	;	2.26	;	Structure of a bacterial O-glcnacase in complex with glcnacstatin
2AW6	;	3.0	;	Structure of a bacterial peptide pheromone/receptor complex and its mechanism of gene regulation
5WC6	;	2.2	;	Structure of a bacterial polysialyltransferase at 2.2 Angstrom resolution
5WC8	;	2.75	;	Structure of a bacterial polysialyltransferase at 2.75 Angstrom resolution
5WCN	;	3.0	;	Structure of a bacterial polysialyltransferase in complex with CDP
5WD7	;	3.1	;	Structure of a bacterial polysialyltransferase in complex with fondaparinux
3Q1Q	;	3.8	;	Structure of a Bacterial Ribonuclease P Holoenzyme in Complex with tRNA
4KH3	;	2.5	;	Structure of a bacterial self-associating protein
8GXV	;	2.2	;	Structure of a bacterial serpin Choloropin derived from Cholorobium limicola
6WT5	;	2.8	;	Structure of a bacterial STING receptor from Capnocytophaga granulosa
6WT4	;	1.78	;	Structure of a bacterial STING receptor from Flavobacteriaceae sp. in complex with 3',3'-cGAMP
4GW9	;	2.9	;	Structure of a bacteriophytochrome and light-stimulated protomer swapping with a gene repressor
7PZJ	;	2.1	;	Structure of a bacteroidetal polyethylene terephthalate (PET) esterase
7RI5	;	4.0	;	Structure of a BAM in MSP1E3D1 nanodiscs at 4 Angstrom resolution
7RI4	;	3.4	;	Structure of a BAM/EspP(beta9-12) hybrid-barrel intermediate
1JIA	;	2.13	;	STRUCTURE OF A BASIC PHOSPHOLIPASE A2 FROM AGKISTRODON HALYS PALLAS AT 2.13A RESOLUTION
2Y6W	;	2.0	;	Structure of a Bcl-w dimer
5JAW	;	1.6	;	Structure of a beta galactosidase with inhibitor
6TBF	;	1.5	;	Structure of a beta galactosidase with inhibitor
6TBG	;	1.5	;	Structure of a beta galactosidase with inhibitor
6TBH	;	1.5	;	Structure of a beta galactosidase with inhibitor
6TBI	;	1.46	;	Structure of a beta galactosidase with inhibitor
6TBJ	;	1.5	;	Structure of a beta galactosidase with inhibitor
6TBK	;	1.6	;	Structure of a beta galactosidase with inhibitor
1W9S	;	1.59	;	Structure of a beta-1,3-glucan binding CBM6 from Bacillus halodurans
1W9W	;	2.1	;	Structure of a beta-1,3-glucan binding CBM6 from Bacillus halodurans in complex with laminarihexaose
1W9T	;	1.62	;	Structure of a beta-1,3-glucan binding CBM6 from Bacillus halodurans in complex with xylobiose
5JU9	;	1.18	;	Structure of a beta-1,4-mannanase, SsGH134, in complex with Man3.
5JTS	;	1.09	;	Structure of a beta-1,4-mannanase, SsGH134.
6VU4	;	2.077	;	Structure of a beta-hairpin peptide mimic derived from Abeta 14-36
4HES	;	1.9	;	Structure of a Beta-Lactamase Class A-like Protein from Veillonella parvula.
2JE8	;	1.7	;	Structure of a beta-mannosidase from Bacteroides thetaiotaomicron
1P22	;	2.95	;	Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity on the SCFbeta-TrCP1 ubiquitin ligase
4MLX	;	1.65	;	Structure of a bidentate 3-hydroxy-4H-pyran-4-thione ligand bound to hCAII
1BVD	;	1.4	;	STRUCTURE OF A BILIVERDIN APOMYOGLOBIN COMPLEX (FORM B) AT 98 K
1BVC	;	1.5	;	STRUCTURE OF A BILIVERDIN APOMYOGLOBIN COMPLEX (FORM D) AT 118 K
4M3C	;	2.5	;	Structure of a binary complex between homologous tetrameric legume lectins from Butea monosperma and Spatholobus parviflorus seeds
3C5F	;	2.25	;	Structure of a binary complex of the R517A Pol lambda mutant
3MBU	;	1.05	;	Structure of a bipyridine-modified PNA duplex
2LLJ	;		;	Structure of a bis-naphthalene bound to a thymine-thymine DNA mismatch
4GCZ	;	2.3	;	Structure of a blue-light photoreceptor
6AAA	;	1.9	;	Structure of a blue-shifted Luciferase from Amydetes vivianii
2H0D	;	2.5	;	Structure of a Bmi-1-Ring1B Polycomb group ubiquitin ligase complex
3TR3	;	2.456	;	Structure of a bolA protein homologue from Coxiella burnetii
6YIE	;	3.49	;	Structure of a Borealin-INCENP-Survivin complex
7TWK	;	1.79	;	Structure of a borosin methyltransferase from Mycena rosella with native peptide (MroMA1) in complex with SAH
7TWL	;	1.86	;	Structure of a borosin methyltransferase from Mycena rosella with peptide A2 (MroMA2) in complex with SAH
7TWM	;	1.93	;	Structure of a borosin methyltransferase from Mycena rosella with peptide CspL(MroMCspL) in complex with SAH
2ZVX	;	1.09	;	Structure of a BPTI-[5,55] variant containing Gly/Val at the 14/38th positions
1IYJ	;	3.4	;	STRUCTURE OF A BRCA2-DSS1 COMPLEX
1MIU	;	3.1	;	Structure of a BRCA2-DSS1 complex
1MJE	;	3.5	;	STRUCTURE OF A BRCA2-DSS1-SSDNA COMPLEX
3IRW	;	2.7	;	Structure of a c-di-GMP riboswitch from V. cholerae
3Q3Z	;	2.51	;	Structure of a c-di-GMP-II riboswitch from C. acetobutylicum bound to c-di-GMP
1PKG	;	2.9	;	Structure of a c-Kit Kinase Product Complex
3U9C	;	3.2	;	Structure of a C-terminal deletion mutant of human protein kinase CK2 catalytic subunit with the ATP-competitive inhibitor resorufin
2ZK7	;	2.71	;	Structure of a C-terminal deletion mutant of Thermoplasma acidophilum aldohexose dehydrogenase (AldT)
3GAJ	;	1.38	;	Structure of a C-terminal deletion variant of a PduO-type ATP:corrinoid adenosyltransferase from Lactobacillus reuteri complexed with cobalamin and ATP
5MUZ	;	1.776	;	Structure of a C-terminal domain of a reptarenavirus L protein
5MUY	;	1.99	;	Structure of a C-terminal domain of a reptarenavirus L protein with m7GTP
3NS4	;	2.9	;	Structure of a C-terminal fragment of its Vps53 subunit suggests similarity of GARP to a family of tethering complexes
5KE1	;	1.9	;	Structure of a C-terminal fragment of the IcsA/VirG passenger-domain
5ZA3	;	1.5	;	Structure of a C-terminal S. mutans response regulator VicR domain
1L2G	;	2.85	;	Structure of a C-terminally truncated form of glycoprotein D from HSV-1
5DN5	;	2.15	;	Structure of a C-terminally truncated glycoside hydrolase domain from Salmonella typhimurium FlgJ
1EGG	;	2.3	;	STRUCTURE OF A C-TYPE CARBOHYDRATE-RECOGNITION DOMAIN (CRD-4) FROM THE MACROPHAGE MANNOSE RECEPTOR
1EGI	;	2.3	;	STRUCTURE OF A C-TYPE CARBOHYDRATE-RECOGNITION DOMAIN (CRD-4) FROM THE MACROPHAGE MANNOSE RECEPTOR
2MSB	;	1.7	;	STRUCTURE OF A C-TYPE MANNOSE-BINDING PROTEIN COMPLEXED WITH AN OLIGOSACCHARIDE
4JND	;	1.652	;	Structure of a C.elegans sex determining protein
3W56	;	1.6	;	Structure of a C2 domain
3W57	;	1.662	;	Structure of a C2 domain
5DBV	;	1.77	;	Structure of a C269A mutant of propionaldehyde dehydrogenase from the Clostridium phytofermentans fucose utilisation bacterial microcompartment
3H4W	;	1.5	;	Structure of a Ca+2 dependent Phosphatidylinositol-specific phospholipase C (PI-PLC) Enzyme from Streptomyces antibioticus
3H4X	;	1.23	;	Structure of a Ca+2 dependent Phosphatidylinositol-specific phospholipase C (PI-PLC) Enzyme from Streptomyces antibioticus
3VF1	;	2.473	;	Structure of a calcium-dependent 11R-lipoxygenase suggests a mechanism for Ca-regulation
3BYA	;	1.85	;	Structure of a Calmodulin Complex
4PTC	;	2.711	;	Structure of a carboxamide compound (3) (2-{2-[(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~,3-THIAZOLE-5-CARBOXAMIDE) to GSK3b
4PTG	;	2.361	;	Structure of a carboxamine compound (26) (2-{2-[(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) to GSK3b
1R1D	;	2.0	;	Structure of a Carboxylesterase from Bacillus stearothermophilus
3R9S	;	2.2	;	Structure of a carnitinyl-CoA dehydratase from Mycobacterium avium 104
4PTE	;	2.033	;	Structure of a carvoxamide compound (15) (N-[4-(ISOQUINOLIN-7-YL)PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) to GSK3b
1YEC	;	1.9	;	STRUCTURE OF A CATALYTIC ANTIBODY IGG2A FAB FRAGMENT (D2.3)
1YED	;	3.1	;	STRUCTURE OF A CATALYTIC ANTIBODY IGG2A FAB FRAGMENT (D2.4)
1YEE	;	2.2	;	STRUCTURE OF A CATALYTIC ANTIBODY, IGG2A FAB FRAGMENT (D2.5)
1RTD	;	3.2	;	STRUCTURE OF A CATALYTIC COMPLEX OF HIV-1 REVERSE TRANSCRIPTASE: IMPLICATIONS FOR NUCLEOSIDE ANALOG DRUG RESISTANCE
6A7W	;	2.988	;	Structure of a catalytic domain of the colistin resistance enzyme
1N31	;	2.2	;	Structure of A Catalytically Inactive Mutant (K223A) of C-DES with a Substrate (Cystine) Linked to the Co-Factor
4L2H	;	1.46	;	Structure of a catalytically inactive PARG in complex with a poly-ADP-ribose fragment
3MKT	;	3.65	;	Structure of a Cation-bound Multidrug and Toxin Compound Extrusion (MATE) transporter
3MKU	;	4.2	;	Structure of a Cation-bound Multidrug and Toxin Compound Extrusion (MATE) transporter
2IWE	;	2.83	;	Structure of a cavity mutant (H117G) of Pseudomonas aeruginosa azurin
5X40	;	1.45	;	Structure of a CbiO dimer bound with AMPPCP
1FBV	;	2.9	;	STRUCTURE OF A CBL-UBCH7 COMPLEX: RING DOMAIN FUNCTION IN UBIQUITIN-PROTEIN LIGASES
2CDP	;	1.59	;	Structure of a CBM6 in complex with neoagarohexaose
5OCD	;	3.06	;	structure of a CDPS from Fluoribacter dumoffii
5CXX	;	1.55	;	Structure of a CE1 ferulic acid esterase, AmCE1/Fae1A, from Anaeromyces mucronatus in complex with Ferulic acid
2A5Y	;	2.6	;	Structure of a CED-4/CED-9 complex
1RJ4	;	2.0	;	Structure of a Cell Wall Invertase Inhibitor from Tobacco in Complex with Cd2+
7S78	;	3.72	;	Structure of a cell-entry defective human adenovirus provides insights into precursor proteins and capsid maturation
4HG6	;	3.25	;	Structure of a cellulose synthase - cellulose translocation intermediate
3R45	;	2.6	;	Structure of a CENP-A-Histone H4 Heterodimer in complex with chaperone HJURP
5W2L	;	1.86	;	Structure of a central domain of human Ctc1
8GJW	;	1.93	;	Structure of a cGAS-like receptor Cv-cGLR1 from C. virginica
8GJY	;	1.5	;	Structure of a cGAS-like receptor Sp-cGLR1 from S. pistillata
8RW2	;		;	Structure of a chair-type antiparallel quadruplex-duplex hybrid at pH 6
7FBS	;	3.4	;	structure of a channel
6O38	;	2.595	;	Structure of a chaperone-substrate complex
5FLU	;	3.8	;	Structure of a Chaperone-Usher pilus reveals the molecular basis of rod uncoilin
5OJM	;	3.3	;	Structure of a chimaeric beta3-alpha5 GABAA receptor in complex with nanobody Nb25
5O8F	;	3.2	;	Structure of a chimaeric beta3-alpha5 GABAA receptor in complex with nanobody Nb25 and pregnanolone
3U87	;	2.9	;	Structure of a chimeric construct of human CK2alpha and human CK2alpha' in complex with a non-hydrolysable ATP-analogue
2YFH	;	2.695	;	Structure of a Chimeric Glutamate Dehydrogenase
3BQL	;	2.0	;	Structure of a chondroitin sulphate binding DBL3X domain from a var2csa encoded PfEMP1 protein
3BQI	;	2.2	;	Structure of a chondroitin sulphate binding DBL3X from a var2csa encoded PfEMP1 protein
3BQK	;	1.8	;	Structure of a chondroitin sulphate binding DBL3X from a var2csa encoded PfEMP1 protein in complex with sulphate
1U5M	;		;	Structure of a Chordin-like Cysteine-rich Repeat (VWC module) from Collagen IIA
3P28	;	1.8	;	Structure of a Circular Permutant of Green Fluorescent Protein
3ICW	;	1.69	;	Structure of a Circular Permutation on Lipase B from Candida Antartica with Bound Suicide Inhibitor
1KH8	;	2.0	;	Structure of a cis-proline (P114) to glycine variant of Ribonuclease A
4MYY	;	1.68	;	Structure of a class 2 docking domain complex from modules CurG and CurH of the curacin A polyketide synthase
4MYZ	;	1.5	;	Structure of a class 2 docking domain complex from modules CurK and CurL of the curacin A polyketide synthase
8U1U	;	3.1	;	Structure of a class A GPCR/agonist complex
8TLM	;	2.9	;	Structure of a class A GPCR/Fab complex
3TV2	;	2.1	;	Structure of a class II fumarate hydratase from Burkholderia pseudomallei
4JF2	;	2.28	;	Structure of a class II preQ1 riboswitch reveals ligand recognition by a new fold
2O26	;	2.5	;	Structure of a class III RTK signaling assembly
2O27	;	2.2	;	Structure of a class III RTK signaling assembly
4UX7	;	2.55	;	Structure of a Clostridium difficile sortase
7B4Q	;	1.61	;	Structure of a cold active HSL family esterase reveals mechanisms of low temperature adaptation and substrate specificity
1H12	;	1.2	;	Structure of a cold-adapted family 8 xylanase
1H13	;	1.3	;	Structure of a cold-adapted family 8 xylanase
1H14	;	1.5	;	Structure of a cold-adapted family 8 xylanase
1XW2	;	1.76	;	Structure Of A Cold-Adapted Family 8 Xylanase
1XWQ	;	1.88	;	Structure Of A Cold-Adapted Family 8 Xylanase
1XWT	;	1.3	;	Structure Of A Cold-Adapted Family 8 Xylanase
2A8Z	;	3.2	;	Structure Of A Cold-Adapted Family 8 Xylanase
2B4F	;	1.95	;	Structure Of A Cold-Adapted Family 8 Xylanase in complex with substrate
7AKK	;	3.395	;	Structure of a complement factor-receptor complex
4AYE	;	2.8	;	Structure of a complex between CCPs 6 and 7 of Human Complement Factor H and Neisseria meningitidis FHbp Variant 1 E283AE304A mutant
4AYD	;	2.4	;	Structure of a complex between CCPs 6 and 7 of Human Complement Factor H and Neisseria meningitidis FHbp Variant 1 R106A mutant
4AYM	;	3.0	;	Structure of a complex between CCPs 6 and 7 of Human Complement Factor H and Neisseria meningitidis FHbp Variant 3 P106A mutant
4AYI	;	2.31	;	Structure of a complex between CCPs 6 and 7 of Human Complement Factor H and Neisseria meningitidis FHbp Variant 3 Wild type
2KRI	;		;	Structure of a complex between domain V of beta2-glycoprotein I and the fourth ligand-binding module from LDLR determined with Haddock
4RT6	;	2.8	;	Structure of a complex between hemopexin and hemopexin binding protein
2W80	;	2.35	;	Structure of a complex between Neisseria meningitidis factor H binding protein and CCPs 6-7 of human complement factor H
2W81	;	2.35	;	Structure of a complex between Neisseria meningitidis factor H binding protein and CCPs 6-7 of human complement factor H
5KTB	;	3.05	;	Structure of a complex between S. cerevisiae Csm1 and Mam1
6C6W	;	2.23	;	Structure of a Complex Between Thaumatin and Thioflavin T
2PKG	;	3.3	;	Structure of a complex between the A subunit of protein phosphatase 2A and the small t antigen of SV40
1EEL	;	2.4	;	STRUCTURE OF A COMPLEX BETWEEN THE DNA SEQUENCE DCGCGAATTCGCG AND BIS[PIPERIDINO-ETHYL]-FURAMIDINE
1EFX	;	3.0	;	STRUCTURE OF A COMPLEX BETWEEN THE HUMAN NATURAL KILLER CELL RECEPTOR KIR2DL2 AND A CLASS I MHC LIGAND HLA-CW3
2FCW	;	1.26	;	Structure of a Complex Between the Pair of the LDL Receptor Ligand-Binding Modules 3-4 and the Receptor Associated Protein (RAP).
1P7V	;	1.08	;	Structure of a complex formed between Proteinase K and a designed heptapeptide inhibitor Pro-Ala-Pro-Phe-Ala-Ala-Ala at atomic resolution
8AW4	;	2.21	;	Structure of a complex of biosynthetic proteins bB-E3 and bGFPD-YY
2O1L	;	1.97	;	Structure of a complex of C-terminal lobe of bovine lactoferrin with disaccharide at 1.97 A resolution
4GRW	;	2.55	;	Structure of a complex of human IL-23 with 3 Nanobodies (Llama vHHs)
6IB8	;	1.646	;	Structure of a complex of SuhB and NusA AR2 domain
2GZK	;		;	Structure of a complex of tandem HMG boxes and DNA
1UPT	;	1.7	;	Structure of a complex of the golgin-245 GRIP domain with Arl1
2D2O	;	2.1	;	Structure of a complex of Thermoactinomyces vulgaris R-47 alpha-amylase 2 with maltohexaose demonstrates the important role of aromatic residues at the reducing end of the substrate binding cleft
5IER	;	2.005	;	Structure of a computationally designed 17-OHP binder
5IF6	;	2.501	;	Structure of a computationally designed 17-OHP binder
1LMT	;	1.6	;	STRUCTURE OF A CONFORMATIONALLY CONSTRAINED ARG-GLY-ASP SEQUENCE INSERTED INTO HUMAN LYSOZYME
1FXT	;		;	STRUCTURE OF A CONJUGATING ENZYME-UBIQUITIN THIOLESTER COMPLEX
5ZXE	;	1.3	;	Structure of a consensus sequence derived from the FGF family
2VT8	;	2.6	;	Structure of a conserved dimerisation domain within Fbox7 and PI31
2AU5	;	2.1	;	Structure of a conserved domain from locus EF2947 from Enterococcus faecalis V583
2MM4	;		;	Structure of a Conserved Golgi Complex-targeting Signal in Coronavirus Envelope Proteins
1RLH	;	1.8	;	Structure of a conserved protein from Thermoplasma acidophilum
2IJC	;	2.05	;	Structure of a Conserved Protein of Unknown Function PA0269 from Pseudomonas aeruginosa
1Q7H	;	2.1	;	Structure of a Conserved PUA Domain Protein from Thermoplasma acidophilum
2L1F	;		;	Structure of a conserved retroviral RNA packaging element by NMR spectroscopy and cryo-electron tomography
6TWR	;		;	Structure of a constitutively active CAT-PRD1 mutant of the antiterminator LicT protein.
5KO3	;	1.949	;	Structure of a Core Papain-like Protease of MERS Coronavirus with utility for structure-based drug design
1Y80	;	1.7	;	Structure of a corrinoid (factor IIIm)-binding protein from Moorella thermoacetica
6HAA	;	1.7	;	Structure of a covalent complex of endo-Xyloglucanase from Cellvibrio japonicus after reacting with XXXG(2F)-beta-DNP
2OWC	;	2.05	;	Structure of a covalent intermediate in Thermus thermophilus amylomaltase
6VZX	;	1.37	;	Structure of a Covalently Captured Collagen Triple Helix using Lysine-Glutamate Pairs
3OQ2	;	1.35	;	Structure of a CRISPR associated protein Cas2 from Desulfovibrio vulgaris
7A1G	;	3.0	;	Structure of a crosslinked yeast ABCE1-bound 43S pre-initiation complex
3ODQ	;	3.1	;	Structure of a Crystal Form of Human Methemoglobin Indicative of Fiber Formation
4QCC	;	7.078	;	Structure of a cube-shaped, highly porous protein cage designed by fusing symmetric oligomeric domains
3ETI	;	2.2	;	Structure of a cubic crystal form of X (ADRP) domain from FCoV
3JZT	;	3.91	;	Structure of a cubic crystal form of X (ADRP) domain from FCoV with ADP-ribose
3RPJ	;	1.9	;	Structure of a curlin genes transcriptional regulator protein from Proteus mirabilis HI4320.
1X0P	;	2.0	;	Structure of a cyanobacterial BLUF protein, Tll0078
8BI8	;	1.59	;	Structure of a cyclic beta-hairpin peptide derived from neuronal nitric oxide synthase
8BI9	;	1.44	;	Structure of a cyclic beta-hairpin peptide derived from neuronal nitric oxide synthase (T112W/T116E variant)
1QX9	;		;	Structure of a cyclic indolicidin peptide derivative with higher charge
4JJM	;	2.09	;	Structure of a cyclophilin from Citrus sinensis (CsCyp) in complex with cyclosporin A
4OQR	;	1.81	;	Structure of a CYP105AS1 mutant in complex with compactin
1G2D	;	2.2	;	STRUCTURE OF A CYS2HIS2 ZINC FINGER/TATA BOX COMPLEX (CLONE #2)
1G2F	;	2.0	;	STRUCTURE OF A CYS2HIS2 ZINC FINGER/TATA BOX COMPLEX (TATAZF;CLONE #6)
5HA8	;	2.054	;	Structure of a cysteine hydrolase
5HWG	;	1.99	;	Structure of a cysteine hydrolase with a negative substrate
5HWH	;	1.79	;	Structure of a cysteine hydrolase with a positive substrate
3RR2	;	1.95	;	Structure of a Cysteine synthase (O-Acetylserine Sulfhydrylase (OASS)) from Mycobacterium marinum ATCC BAA-535 / M
6OEW	;	1.85	;	Structure of a Cytidylyltransferase from Leptospira borgpetersenii serovar Hardjo-bovis (strain JB197)
3OZZ	;	1.7	;	Structure of a cytochrome b5 core-swap mutant
1S6V	;	1.88	;	Structure of a cytochrome c peroxidase-cytochrome c site specific cross-link
3QT2	;	2.55	;	Structure of a cytokine ligand-receptor complex
4NKQ	;	3.301	;	Structure of a Cytokine Receptor Complex
5JEA	;	2.65	;	Structure of a cytoplasmic 11-subunit RNA exosome complex including Ski7, bound to RNA
3LW9	;	1.85	;	Structure of a Cytoplasmic Domain of Salmonella InvA
7R0U	;	2.5	;	Structure of a cytosolic sulfotransferase of Anopheles gambiae (AGAP001425) in complex with 3'-phosphoadenosine 5-phosphate and vanillin.
7R0S	;	2.1	;	Structure of a cytosolic sulfotransferase of Anopheles gambiae (AGAP001425) in complex with vanillin
7R0O	;	2.0	;	Structure of a cytosolic sulfotransferase of Anopheles gambiae (AGAP001425).
328D	;	2.6	;	STRUCTURE OF A D(CGCGAATTCGCG)2-SN7167 COMPLEX
6VMS	;	3.8	;	Structure of a D2 dopamine receptor-G-protein complex in a lipid membrane
2R6X	;	2.61	;	Structure of a D35N variant PduO-type ATP:co(I)rrinoid adenosyltransferase from Lactobacillus reuteri complexed with ATP
6GHV	;	2.1	;	Structure of a DC-SIGN CRD in complex with high affinity glycomimetic.
6DG6	;	1.999	;	Structure of a de novo designed Interleukin-2/Interleukin-15 mimetic
6DG5	;	2.516	;	Structure of a de novo designed Interleukin-2/Interleukin-15 mimetic complex with IL-2Rb and IL-2Rg
6JCC	;	1.45	;	structure of a de novo protein D_1CY5_M1
1QVF	;	3.1	;	Structure of a deacylated tRNA minihelix bound to the E site of the large ribosomal subunit of Haloarcula marismortui
3R5Y	;	1.801	;	Structure of a Deazaflavin-dependent nitroreductase from Nocardia farcinica, with co-factor F420
3R5Z	;	1.503	;	Structure of a Deazaflavin-dependent reductase from Nocardia farcinica, with co-factor F420
7A7E	;	2.8	;	Structure of a delta-N mutant - E232start - of PA1120 (TpbB or YfiN) from Pseudomonas aeruginosa (PAO1) comprising only the GGDEF domain
3TQZ	;	1.75	;	Structure of a deoxyuridine 5'-triphosphate nucleotidohydrolase (dut) from Coxiella burnetii
2Y7S	;	1.9	;	Structure of a designed meningococcal antigen (factor H binding protein, mutant G1) inducing broad protective immunity
4D2C	;	2.47	;	Structure of a di peptide bound POT family peptide transporter
5HA4	;	1.85	;	Structure of a diaminopimelate epimerase from Acinetobacter baumannii
1LEX	;	2.25	;	STRUCTURE OF A DICATIONIC MONOIMIDAZOLE LEXITROPSIN BOUND TO DNA (ORIENTATION 1)
1LEY	;	2.25	;	STRUCTURE OF A DICATIONIC MONOIMIDAZOLE LEXITROPSIN BOUND TO DNA (ORIENTATION 2)
3TR9	;	1.895	;	Structure of a dihydropteroate synthase (folP) in complex with pteroic acid from Coxiella burnetii
4QAG	;	1.712	;	Structure of a dihydroxycoumarin active-site inhibitor in complex with the RNASE H domain of HIV-1 reverse transcriptase
6WNZ	;	2.0	;	Structure of a dimer of the Sulfolobus solfataricus MCM N-terminal domain reveals potential role in MCM ring opening
2LE6	;		;	Structure of a dimeric all-parallel-stranded G-quadruplex stacked via the 5'-to-5' interface
3QYC	;	1.6	;	Structure of a dimeric anti-HER2 single domain antibody
3P3W	;	4.2	;	Structure of a dimeric GluA3 N-terminal domain (NTD) at 4.2 A resolution
1JYE	;	1.7	;	Structure of a Dimeric Lac Repressor with C-terminal Deletion and K84L Substitution
2AK7	;	2.0	;	structure of a dimeric P-Ser-Crh
7VW0	;	1.447	;	Structure of a dimeric periplasmic protein
7VW2	;	2.186	;	Structure of a dimeric periplasmic protein bound with cupric ions
7VW1	;	2.494	;	Structure of a dimeric periplasmic protein bound with cuprous ions
8EQM	;	2.6	;	Structure of a dimeric photosystem II complex acclimated to far-red light
4D60	;	3.3	;	Structure of a dimeric Plasmodium falciparum profilin mutant
6E7L	;	2.59	;	Structure of a dimerized UUCG motif
4BIK	;	3.494	;	Structure of a disulfide locked mutant of Intermedilysin with human CD59
1AAR	;	2.3	;	STRUCTURE OF A DIUBIQUITIN CONJUGATE AND A MODEL FOR INTERACTION WITH UBIQUITIN CONJUGATING ENZYME (E2)
307D	;	1.85	;	Structure of a DNA analog of the primer for HIV-1 RT second strand synthesis
2VQC	;	2.3	;	Structure of a DNA binding winged-helix protein, F-112, from Sulfolobus Spindle-shaped Virus 1.
1HT7	;		;	STRUCTURE OF A DNA DUPLEX CONTAINING A BISTRAND ABASIC SITE LESION STAGGERED IN A 5'-ORIENTATION.
401D	;	2.2	;	STRUCTURE OF A DNA IN LOW SALT CONDITIONS D(GACCGCGGTC)
6D0Q	;	2.80051	;	Structure of a DNA retention-prone PCNA variant
6D0R	;	2.85857	;	Structure of a DNA retention-prone PCNA variant
1AGL	;	2.2	;	STRUCTURE OF A DNA-BISDAUNOMYCIN COMPLEX
6OBJ	;	3.5	;	Structure of a DNA-bound dimer extracted from filamentous SgrAI endonuclease in its activated form
7P5Z	;	3.3	;	Structure of a DNA-loaded MCM double hexamer engaged with the Dbf4-dependent kinase
231D	;	2.4	;	STRUCTURE OF A DNA-PORPHYRIN COMPLEX
124D	;		;	STRUCTURE OF A DNA:RNA HYBRID DUPLEX: WHY RNASE H DOES NOT CLEAVE PURE RNA
8FDR	;	1.55	;	Structure of a dodecamer complex: 5'-CGCGAAAAGCCG-3-DB1476
4ZC0	;	6.7	;	Structure of a dodecameric bacterial helicase
2Y4Y	;	1.7	;	Structure of a domain from the type IV pilus biogenesis lipoprotein PilP, from Pseudomonas aeruginosa
2Y4X	;	1.7	;	Structure of a domain from the type IV pilus biogenesis lipoprotein PilP, from Pseudomonas aeruginosa PA01
2P3P	;	1.76	;	Structure of a domain of an uncharacterized protein PG_1388 from Porphyromonas gingivalis W83
3QRF	;	2.8	;	Structure of a domain-swapped FOXP3 dimer
3CUS	;	2.2	;	Structure of a double ILE/PHE mutant of NI-FE hydrogenase refined at 2.2 angstrom resolution
3CUR	;	2.4	;	Structure of a double methionine mutant of NI-FE hydrogenase
5LUK	;	1.45	;	Structure of a double variant of cutinase 2 from Thermobifida cellulosilytica
6XA1	;	2.8	;	Structure of a drug-like compound stalled human translation termination complex
7LT2	;	1.58	;	Structure of a dsRNA-sensing cGAS-like receptor from the beetle Tribolium castaneum
6BQO	;	2.8	;	Structure of a dual topology fluoride channel with monobody S8
2H1Z	;		;	Structure of a dual-target spider toxin
3AXB	;	1.92	;	Structure of a dye-linked L-proline dehydrogenase from the aerobic hyperthermophilic archaeon, Aeropyrum pernix
3VQR	;	2.01	;	Structure of a dye-linked L-proline dehydrogenase mutant from the aerobic hyperthermophilic archaeon, Aeropyrum pernix
1EG3	;	2.0	;	STRUCTURE OF A DYSTROPHIN WW DOMAIN FRAGMENT IN COMPLEX WITH A BETA-DYSTROGLYCAN PEPTIDE
1EG4	;	2.0	;	STRUCTURE OF A DYSTROPHIN WW DOMAIN FRAGMENT IN COMPLEX WITH A BETA-DYSTROGLYCAN PEPTIDE
2X9K	;	2.18	;	Structure of a E.coli porin
5H3O	;	3.5	;	Structure of a eukaryotic cyclic nucleotide-gated channel
6FAI	;	3.4	;	Structure of a eukaryotic cytoplasmic pre-40S ribosomal subunit
4U04	;	2.48	;	Structure of a eukaryotic fic domain containing protein
4HCW	;	2.705	;	Structure of a eukaryotic thiaminase-I
4HCY	;	2.75	;	Structure of a eukaryotic thiaminase-I bound to the thiamin analogue 3-deazathiamin
5X0M	;	3.8	;	Structure of a eukaryotic voltage-gated sodium channel at near atomic resolution
3GAI	;	1.48	;	Structure of a F112A variant PduO-type ATP:corrinoid adenosyltransferase from Lactobacillus reuteri complexed with cobalamin and ATP
3GAH	;	1.17	;	Structure of a F112H variant PduO-type ATP:corrinoid adenosyltransferase from Lactobacillus reuteri complexed with cobalamin and ATP
8BF0	;	1.75	;	Structure of a Fab portion from TKH2
2V8I	;	1.5	;	Structure of a Family 2 Pectate Lyase in a Native Form
2V8J	;	2.01	;	Structure of a Family 2 Pectate Lyase in Complex with a Transition Metal
2V8K	;	2.1	;	Structure of a Family 2 Pectate Lyase in Complex with Trigalacturonic Acid
2V3G	;	1.2	;	Structure of a family 26 lichenase in complex with noeuromycin
1XSI	;	2.2	;	Structure of a Family 31 alpha glycosidase
1XSJ	;	2.1	;	Structure of a Family 31 alpha glycosidase
1XSK	;	2.2	;	Structure of a Family 31 alpha glycosidase glycosyl-enzyme intermediate
2W3J	;	1.7	;	Structure of a family 35 carbohydrate binding module from an environmental isolate
2J13	;	1.7	;	Structure of a family 4 carbohydrate esterase from Bacillus anthracis
2V5D	;	3.3	;	Structure of a Family 84 Glycoside Hydrolase and a Family 32 Carbohydrate-Binding Module in Tandem from Clostridium perfringens.
2JKP	;	1.99	;	Structure of a family 97 alpha-glucosidase from Bacteroides thetaiotaomicron in complex with castanospermine
2JKE	;	1.7	;	Structure of a family 97 alpha-glucosidase from Bacteroides thetaiotaomicron in complex with deoxynojirimycin
2WAA	;	1.8	;	Structure of a family two carbohydrate esterase from Cellvibrio japonicus
2WAO	;	1.8	;	Structure of a family two carbohydrate esterase from Clostridium thermocellum in complex with cellohexaose
6HRK	;	2.52	;	Structure of a far-red fluorescent biliprotein derived from a far-red induced allophycocyanin F subunit from a thermophilic cyanobacterium Chroococcidiopsis thermalis
8OR7	;	2.8	;	Structure of a far-red induced allophycocyanin from Chroococcidiopsis thermalis sp. PCC 7203
1GOJ	;	2.3	;	Structure of a fast kinesin: Implications for ATPase mechanism and interactions with microtubules
5TPS	;	2.7	;	Structure of a Fc heterodimer
6F2Z	;	2.3	;	Structure of a Fc mutant
7LB8	;	3.4	;	Structure of a ferrichrome importer FhuCDB from E. coli
5NQX	;	3.66	;	Structure of a fHbp(V1.1):PorA(P1.16) chimera. Fusion at fHbp position 294.
5NQZ	;	1.63	;	Structure of a fHbp(V1.1):PorA(P1.16) chimera. Fusion at fHbp position 309.
5NQP	;	2.86	;	Structure of a fHbp(V1.4):PorA(P1.16) chimera. Fusion at fHbp position 151.
5NQY	;	2.6	;	Structure of a fHbp(V1.4):PorA(P1.16) chimera. Fusion at fHbp position 309.
1TEN	;	1.8	;	STRUCTURE OF A FIBRONECTIN TYPE III DOMAIN FROM TENASCIN PHASED BY MAD ANALYSIS OF THE SELENOMETHIONYL PROTEIN
7CB8	;	2.6	;	Structure of a FIC-domain protein from Mycobacterium marinum in complex with CDP
8AN1	;	3.93	;	Structure of a first level Sierpinski triangle formed by a citrate synthase
8RJL	;	3.34	;	Structure of a first order Sierpinski triangle formed by the H369R mutant of the citrate synthase from Synechococcus elongatus
5B3D	;	2.3	;	Structure of a flagellar type III secretion chaperone, FlgN
6JSX	;	2.7	;	Structure of a flagellin protein, HpFlaG
1G28	;	2.73	;	STRUCTURE OF A FLAVIN-BINDING DOMAIN, LOV2, FROM THE CHIMERIC PHYTOCHROME/PHOTOTROPIN PHOTORECEPTOR PHY3
2ARK	;	2.4	;	Structure of a flavodoxin from Aquifex aeolicus
5WID	;	1.681	;	Structure of a flavodoxin from the domain Archaea
1DCW	;	2.1	;	STRUCTURE OF A FOUR-WAY JUNCTION IN AN INVERTED REPEAT SEQUENCE.
6R6K	;	2.1	;	Structure of a FpvC mutant from pseudomonas aeruginosa
6XAY	;	2.48	;	Structure of a fragment of human fibronectin containing the 10th, 11th and 12th type III domains
6XAX	;	2.4	;	Structure of a fragment of human fibronectin containing the 11th type III domain, extra domain A, and the 12th type III domain
4QJ3	;	3.0	;	Structure of a fragment of human phospholipase C-beta3 delta472-559, in complex with Galphaq
4QJ4	;	3.3	;	Structure of a fragment of human phospholipase C-beta3 delta472-569, bound to IP3 and in complex with Galphaq
4QJ5	;	3.41	;	Structure of a fragment of human phospholipase C-beta3 delta472-581, bound to IP3 and in complex with Galphaq
4GDO	;	1.7	;	Structure of a fragment of the rod domain of plectin
6HTN	;	1.55	;	Structure of a fucose lectin from Kordia zhangzhouensis in complex with methyl-fucoside
3SW1	;	2.63	;	Structure of a full-length bacterial LOV protein
2IG9	;	1.9	;	Structure of a full-length Homoprotocatechuate 2,3-Dioxygenase from B. fuscum in a new spacegroup.
7PHR	;	3.08	;	Structure of a fully assembled T-cell receptor engaging a tumor-associated peptide-MHC I
7SHQ	;	2.34	;	Structure of a functional construct of eukaryotic elongation factor 2 kinase in complex with calmodulin.
2XHL	;	2.8	;	Structure of a functional derivative of Clostridium botulinum neurotoxin type B
6SEJ	;	3.501	;	Structure of a functional monomeric properdin lacking TSR3
6HWH	;	3.3	;	Structure of a functional obligate respiratory supercomplex from Mycobacterium smegmatis
6RUS	;	2.8	;	Structure of a functional properdin monomer
3HJW	;	2.35	;	Structure of a functional ribonucleoprotein pseudouridine synthase bound to a substrate RNA
3HJY	;	3.65	;	Structure of a functional ribonucleoprotein pseudouridine synthase bound to a substrate RNA
1JS8	;	2.3	;	Structure of a Functional Unit from Octopus Hemocyanin
8JZN	;	2.47	;	Structure of a fungal 1,3-beta-glucan synthase
8B4G	;	1.496	;	Structure of a fungal LPMO bound to ligands
4FPQ	;	2.3	;	Structure of a fungal protein
4FPR	;	2.402	;	Structure of a fungal protein
7PUO	;	2.35	;	Structure of a fused 4-OT variant engineered for asymmetric Michael addition reactions
4ZSV	;	4.2	;	Structure of a fusion protein with a helix linker, 2ARH-3-3KAW-1.0
4ZSX	;	2.19	;	Structure of a fusion protein with a helix linker, 2ARH-3-3KAW-2.0
4ZSZ	;	4.251	;	Structure of a fusion protein with a helix linker, 2ARH-3-3KAW-3.0
3ONW	;	2.38	;	Structure of a G-alpha-i1 mutant with enhanced affinity for the RGS14 GoLoco motif.
2MAY	;		;	Structure of a G-quadruplex containing a single LNA modification
5V2R	;		;	Structure of a GA Rich 8x8 Nucleotide RNA Internal Loop
1G8X	;	2.8	;	STRUCTURE OF A GENETICALLY ENGINEERED MOLECULAR MOTOR
8OS6	;	2.66	;	Structure of a GFRA1/GDNF LICAM complex
7CUK	;		;	Structure of a GG mismatch-containing duplex formed by G4C2 repeats
7AYP	;	1.70001	;	Structure of a GH11 domain refined from the X-ray diffraction data of a GH11-CBM36-1 crystal.
5K6M	;	2.17	;	Structure of a GH3 b-glIcosidase from cow rumen metagenome in complex with glucose
5K6N	;	2.08	;	Structure of a GH3 b-glicosidase from cow rumen metagenome in complexed with xylose
5K6L	;	1.83	;	Structure of a GH3 b-glucosidase from cow rumen metagenome
5K6O	;	2.29	;	Structure of a GH3 b-glucosidase from cow rumen metagenome in complex with galactose
4M29	;	2.1	;	Structure of a GH39 Beta-xylosidase from Caulobacter crescentus
4X0V	;	2.798	;	Structure of a GH5 family lichenase from Caldicellulosiruptor sp. F32
4F52	;	3.0	;	Structure of a Glomulin-RBX1-CUL1 complex
1BH0	;	3.0	;	STRUCTURE OF A GLUCAGON ANALOG
7XHP	;	2.78	;	Structure of a Glucose 6-Phosphate Dehydrogenase from Zymomonas mobilis
3WIE	;	2.33	;	Structure of a glucose dehydrogenase T277F mutant in complex with D-glucose and NAADP
3WID	;	2.25	;	Structure of a glucose dehydrogenase T277F mutant in complex with NADP
7DMM	;	0.99	;	Structure of a glucose isomerase crystal grown in an aqueous glycerol solution without any precipitants
4QFH	;	1.8	;	Structure of a glucose-6-phosphate isomerase from Trypanosoma cruzi
1GR2	;	1.9	;	STRUCTURE OF A GLUTAMATE RECEPTOR LIGAND BINDING CORE (GLUR2) COMPLEXED WITH KAINATE
6GMG	;	2.25	;	Structure of a glutamine donor mimicking inhibitory peptide shaped by the catalytic cleft of microbial transglutaminase
2H8N	;	2.6	;	Structure of a glutamine-rich domain from histone deacetylase 4
6K5J	;	1.903	;	Structure of a glycoside hydrolase family 3 beta-N-acetylglucosaminidase from Paenibacillus sp. str. FPU-7
4P8R	;	2.2	;	Structure of a glycosomal glyceraldehyde 3-phosphate dehydrogenase from Trypanosoma brucei
2JWG	;		;	Structure of a Glycosylphosphatidylinositol-anchored Domain from a Trypanosome Variant Surface Glycoprotein
2JWH	;		;	Structure of a Glycosylphosphatidylinositol-anchored Domain from a Trypanosome Variant Surface Glycoprotein
6EJI	;	2.3	;	Structure of a glycosyltransferase
6EJK	;	3.3	;	Structure of a glycosyltransferase
6EJJ	;	2.7	;	Structure of a glycosyltransferase / state 2
6P61	;	1.95	;	Structure of a Glycosyltransferase from Leptospira borgpetersenii serovar Hardjo-bovis (strain JB197)
5CXY	;	2.15	;	Structure of a Glycosyltransferase in Complex with Inhibitor
5JQ4	;	1.8	;	Structure of a GNAT acetyltransferase SACOL1063 from Staphylococcus aureus
5JPH	;	1.46	;	Structure of a GNAT acetyltransferase SACOL1063 from Staphylococcus aureus in complex with CoA
6EDV	;	1.35	;	Structure of a GNAT superfamily acetyltransferase PA3944 in complex with CoA
7KPS	;	1.8	;	Structure of a GNAT superfamily PA3944 acetyltransferase in complex with AcCoA
7KYE	;	1.93	;	Structure of a GNAT superfamily PA3944 acetyltransferase in complex with CHES
7KYJ	;	2.0	;	Structure of a GNAT superfamily PA3944 acetyltransferase in complex with zinc
8HQC	;	3.89	;	Structure of a GPCR-G protein in complex with a natural peptide agonist
3BJX	;	2.3	;	Structure of a Group I haloacid dehalogenase from Pseudomonas putida strain PP3
6MEC	;	3.6	;	Structure of a group II intron retroelement after DNA integration
6ME0	;	3.6	;	Structure of a group II intron retroelement prior to DNA integration
8T2T	;	3.0	;	Structure of a group II intron ribonucleoprotein in the post-ligation (post-2F) state
8T2S	;	3.0	;	Structure of a group II intron ribonucleoprotein in the pre-branching (pre-1F) state
8T2R	;	3.1	;	Structure of a group II intron ribonucleoprotein in the pre-ligation (pre-2F) state
3MJK	;	2.4	;	Structure of a growth factor precursor
2BE3	;	2.4	;	Structure of a GTP Pyrophosphokinase Family Protein from Streptococcus pneumoniae
2ZCI	;	2.3	;	Structure of a GTP-dependent bacterial PEP-carboxykinase from Corynebacterium glutamicum
5T83	;	2.71	;	Structure of a guanidine-I riboswitch from S. acidophilus
2GJE	;	3.37	;	Structure of a guideRNA-binding protein complex bound to a gRNA
2PAE	;	2.5	;	Structure of a H49N mutant dTDP-4-keto-6-deoxy-D-glucose-3,4-ketoisomerase from Aneurinibacillus thermoaerophilus in complex with TDP
2PAM	;	2.5	;	Structure of a H49N, H51N double mutant dTDP-4-keto-6-deoxy-D-glucose-3,4-ketoisomerase from Aneurinibacillus thermoaerophilus complexed with TDP
2PAK	;	2.4	;	Structure of a H51N mutant dTDP-4-keto-6-deoxy-D-glucose-3,4-ketoisomerase from Aneurinibacillus thermoaerophilus complexed with TDP
6OM5	;	1.6	;	Structure of a haemophore from Haemophilus haemolyticus
2AZ1	;	2.35	;	Structure of a halophilic nucleoside diphosphate kinase from Halobacterium salinarum
2AZ3	;	2.2	;	Structure of a halophilic nucleoside diphosphate kinase from Halobacterium salinarum in complex with CDP
3TQU	;	1.9	;	Structure of a HAM1 protein from Coxiella burnetii
2HAP	;	2.5	;	STRUCTURE OF A HAP1-18/DNA COMPLEX REVEALS THAT PROTEIN/DNA INTERACTIONS CAN HAVE DIRECT ALLOSTERIC EFFECTS ON TRANSCRIPTIONAL ACTIVATION
1HWT	;	2.5	;	STRUCTURE OF A HAP1/DNA COMPLEX REVEALS DRAMATICALLY ASYMMETRIC DNA BINDING BY A HOMODIMERIC PROTEIN
1RI9	;		;	Structure of a helically extended SH3 domain of the T cell adapter protein ADAP
1Y12	;	1.95	;	Structure of a hemolysin-coregulated protein from Pseudomonas aeruginosa
1QA9	;	3.2	;	Structure of a Heterophilic Adhesion Complex Between the Human CD2 and CD58(LFA-3) Counter-Receptors
8PFB	;	3.67	;	Structure of a heteropolymeric type 4 pilus from a monoderm bacterium
2OT4	;	1.5	;	Structure of a hexameric multiheme c nitrite reductase from the extremophile bacterium Thiolkalivibrio nitratireducens
3SXQ	;	1.9	;	Structure of a hexameric multiheme c nitrite reductase from the extremophile bacterium Thiolkalivibrio paradoxus
1U7K	;	1.85	;	Structure of a hexameric N-terminal domain from murine leukemia virus capsid
4Q79	;	3.1	;	Structure of a HG-derivative CsgG
6H4N	;	3.0	;	Structure of a hibernating 100S ribosome reveals an inactive conformation of the ribosomal protein S1 - 70S Hibernating E. coli Ribosome
6H58	;	7.9	;	Structure of a hibernating 100S ribosome reveals an inactive conformation of the ribosomal protein S1 - Full 100S Hibernating E. coli Ribosome
1LM8	;	1.85	;	Structure of a HIF-1a-pVHL-ElonginB-ElonginC Complex
2JWV	;		;	Structure of a high affinity anti-NFkB RNA aptamer
2E7L	;	2.5	;	Structure of a high-affinity mutant of the 2C TCR in complex with Ld/QL9
1XC9	;	1.9	;	Structure of a high-fidelity polymerase bound to a benzo[a]pyrene adduct that blocks replication
4B7H	;	1.39	;	Structure of a highdose liganded bacterial catalase
1Z5L	;	2.2	;	Structure of a highly potent short-chain galactosyl ceramide agonist bound to CD1D
2YMU	;	1.794	;	Structure of a highly repetitive propeller structure
1L96	;	2.0	;	STRUCTURE OF A HINGE-BENDING BACTERIOPHAGE T4 LYSOZYME MUTANT, ILE3-> PRO
1L97	;	2.0	;	STRUCTURE OF A HINGE-BENDING BACTERIOPHAGE T4 LYSOZYME MUTANT, ILE3-> PRO
3DGE	;	2.8	;	Structure of a histidine kinase-response regulator complex reveals insights into Two-component signaling and a novel cis-autophosphorylation mechanism
3DGF	;	2.0	;	Structure of a histidine kinase-response regulator complex reveals insights into Two-component signaling and a novel cis-autophosphorylation mechanism
1PAA	;		;	STRUCTURE OF A HISTIDINE-X4-HISTIDINE ZINC FINGER DOMAIN: INSIGHTS INTO ADR1-UAS1 PROTEIN-DNA RECOGNITION
7K7L	;	2.539	;	Structure of a hit for G Protein Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure
7K7Z	;	2.60609	;	Structure of a hit for G Protein Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure
3CMY	;	1.95	;	Structure of a homeodomain in complex with DNA
2QS6	;	3.08	;	Structure of a Hoogsteen antiparallel duplex with extra-helical thymines
3SIV	;	3.304	;	Structure of a hPrp31-15.5K-U4atac 5' stem loop complex, dimeric form
3SIU	;	2.626	;	Structure of a hPrp31-15.5K-U4atac 5' stem loop complex, monomeric form
2BRC	;	1.6	;	Structure of a Hsp90 Inhibitor bound to the N-terminus of Yeast Hsp90.
2BRE	;	2.0	;	STRUCTURE OF A HSP90 INHIBITOR BOUND TO THE N-TERMINUS OF YEAST HSP90.
8OZ0	;	3.5	;	Structure of a human 48S translation initiation complex with eIF4F and eIF4A
6ZMW	;	3.7	;	Structure of a human 48S translational initiation complex
6YBW	;	3.1	;	Structure of a human 48S translational initiation complex - 40S body
6YBV	;	3.8	;	Structure of a human 48S translational initiation complex - eIF2-TC
6YBD	;	3.3	;	Structure of a human 48S translational initiation complex - eIF3
6YBT	;	6.0	;	Structure of a human 48S translational initiation complex - eIF3bgi
6YBS	;	3.1	;	Structure of a human 48S translational initiation complex - head
5ANR	;	2.102	;	Structure of a human 4E-T - DDX6 - CNOT1 complex
1XFD	;	3.0	;	Structure of a human A-type Potassium Channel Accelerating factor DPPX, a member of the dipeptidyl aminopeptidase family
6ZVJ	;	3.8	;	Structure of a human ABCE1-bound 43S pre-initiation complex - State II
7A09	;	3.5	;	Structure of a human ABCE1-bound 43S pre-initiation complex - State III
2I32	;	2.7	;	Structure of a human ASF1a-HIRA complex and insights into specificity of histone chaperone complex assembly
5FII	;	1.8	;	Structure of a human aspartate kinase, chorismate mutase and TyrA domain.
1LGV	;	1.95	;	Structure of a Human Bence-Jones Dimer Crystallized in U.S. Space Shuttle Mission STS-95: 100K
1LHZ	;	2.3	;	Structure of a Human Bence-Jones Dimer Crystallized in U.S. Space Shuttle Mission STS-95: 293K
4OGW	;	2.05	;	Structure of a human CD38 mutant complexed with NMN
3OFM	;	2.0	;	Structure of a human CK2alpha prime, the paralog isoform of the catalytic subunit of protein kinase CK2 from Homo sapiens
8EOI	;	3.4	;	Structure of a human EMC:human Cav1.2 channel complex in GDN detergent
4DGJ	;	1.9	;	Structure of a human enteropeptidase light chain variant
6QX9	;	3.28	;	Structure of a human fully-assembled precatalytic spliceosome (pre-B complex).
7W72	;	3.1	;	Structure of a human glycosylphosphatidylinositol (GPI) transamidase
7OF2	;	2.7	;	Structure of a human mitochondrial ribosome large subunit assembly intermediate in complex with GTPBP6.
7OF0	;	2.2	;	Structure of a human mitochondrial ribosome large subunit assembly intermediate in complex with MTERF4-NSUN4 (dataset1).
7OF3	;	2.7	;	Structure of a human mitochondrial ribosome large subunit assembly intermediate in complex with MTERF4-NSUN4 (dataset2).
7OF7	;	2.5	;	Structure of a human mitochondrial ribosome large subunit assembly intermediate in complex with MTERF4-NSUN4 and GTPBP5 (dataset1).
7OF5	;	2.9	;	Structure of a human mitochondrial ribosome large subunit assembly intermediate in complex with MTERF4-NSUN4 and GTPBP5 (dataset2).
1DFB	;	2.7	;	STRUCTURE OF A HUMAN MONOCLONAL ANTIBODY FAB FRAGMENT AGAINST GP41 OF HUMAN IMMUNODEFICIENCY VIRUS TYPE I
7DSV	;	3.4	;	Structure of a human NHE1-CHP1 complex under pH 6.5
7DSW	;	3.3	;	Structure of a human NHE1-CHP1 complex under pH 7.5
7DSX	;	3.5	;	Structure of a human NHE1-CHP1 complex under pH 7.5, bound by cariporide
7X2U	;	3.2	;	Structure of a human NHE3-CHP1 complex in the autoinhibited state
6T79	;	3.2	;	Structure of a human nucleosome at 3.2 A resolution
2RD0	;	3.05	;	Structure of a human p110alpha/p85alpha complex
1UMW	;	1.9	;	Structure of a human Plk1 Polo-box domain/phosphopeptide complex
2OZB	;	2.6	;	Structure of a human Prp31-15.5K-U4 snRNA complex
1JL0	;	1.5	;	Structure of a Human S-Adenosylmethionine Decarboxylase Self-processing Ester Intermediate and Mechanism of Putrescine Stimulation of Processing as Revealed by the H243A Mutant
5GWI	;	2.737	;	Structure of a Human topoisomerase IIbeta fragment in complex with DNA and E7873R
5GWJ	;	2.566	;	Structure of a Human topoisomerase IIbeta fragment in complex with DNA and E7873S
4U3X	;	2.26	;	Structure of a human VH antibody domain binding to the cleft of hen egg lysozyme
7ZEK	;		;	Structure of a hybrid-type G-quadruplex with a snapback loop (hybrid 1R')
7ZEO	;		;	Structure of a hybrid-type G-quadruplex with a snapback loop and an all-syn G-column (hybrid-1R)
5FKY	;	1.8	;	Structure of a hydrolase bound with an inhibitor
5FL0	;	1.95	;	Structure of a hydrolase with an inhibitor
5FL1	;	1.95	;	Structure of a hydrolase with an inhibitor
2HNF	;	1.8	;	Structure of a Hyper-cleavable Monomeric Fragment of Phage lambda Repressor Containing the Cleavage Site Region
2HO0	;	2.5	;	Structure of a Hyper-cleavable Monomeric Fragment of Phage Lambda Repressor Containing the Cleavage Site Region
1AOR	;	2.3	;	STRUCTURE OF A HYPERTHERMOPHILIC TUNGSTOPTERIN ENZYME, ALDEHYDE FERREDOXIN OXIDOREDUCTASE
6EKI	;	2.555	;	Structure of a hyperthermostable carbonic anhydrase identified from an active hydrothermal vent chimney
6J8O	;	1.855	;	Structure of a hypothetical protease
6J91	;	3.5	;	Structure of a hypothetical protease
1P9Q	;	2.0	;	Structure of a hypothetical protein AF0491 from Archaeoglobus fulgidus
2H8P	;	2.25	;	Structure of a K channel with an amide to ester substitution in the selectivity filter
3OUF	;	1.55	;	Structure of a K+ selective NaK mutant
8CU2	;	2.01	;	Structure of a K+ selective NaK mutant (NaK2K, Laue diffraction) in the presence of an electric field of ~0.8MV/cm along the crystallographic z axis, 100ns, with eightfold extrapolation of structure factor differences
8CU4	;	2.01	;	Structure of a K+ selective NaK mutant (NaK2K, Laue diffraction) in the presence of an electric field of ~0.8MV/cm along the crystallographic z axis, 1us, with eightfold extrapolation of structure factor differences
8CU3	;	2.01	;	Structure of a K+ selective NaK mutant (NaK2K, Laue diffraction) in the presence of an electric field of ~0.8MV/cm along the crystallographic z axis, 200ns, with eightfold extrapolation of structure factor differences
8CU1	;	2.01	;	Structure of a K+ selective NaK mutant (NaK2K, Laue diffraction) in the presence of an electric field of ~0.8MV/cm along the crystallographic z axis, 500ns, with eightfold extrapolation of structure factor differences
8CTN	;	2.01	;	Structure of a K+ selective NaK mutant (NaK2K, Laue diffraction, no electric field)
6LDR	;	1.79	;	Structure of a K245A mutant of a Group II PLP dependent decarboxylase from Methanocaldococcus jannaschii, in complex with PLP
6LDS	;	1.8	;	Structure of a K245A mutant of L-tyrosine decarboxylase from Methanocaldococcus jannaschii complexed with L-Tyr: External aldimine form
4MZ0	;	2.8	;	Structure of a ketosynthase-acyltransferase di-domain from module CurL of the curacin A polyketide synthase
7QHY	;	2.45	;	Structure of a Kluyveromyces lactis protein involved in RNA decay
5NXN	;	3.12	;	Structure of a L5-deletion mutant of Providencia stuartii Omp-Pst1
3G39	;	1.55	;	Structure of a lamprey variable lymphocyte receptor
3G3A	;	2.2	;	Structure of a lamprey variable lymphocyte receptor in complex with a protein antigen
3G3B	;	2.4	;	Structure of a lamprey variable lymphocyte receptor mutant in complex with a protein antigen
5DCM	;	1.6	;	Structure of a lantibiotic response regulator: C-terminal domain of the nisin resistance regulator NsrR
5DCL	;	1.41	;	Structure of a lantibiotic response regulator: N terminal domain of the nisin resistance regulator NsrR
5OWF	;	1.91	;	Structure of a LAO-binding protein mutant with glutamine
8CH6	;	5.9	;	Structure of a late-stage activated spliceosome (BAqr) arrested with a dominant-negative Aquarius mutant (state B complex).
8JMP	;	1.9	;	Structure of a leaf-branch compost cutinase, ICCG in complex with 1,4-butanediol terephthalate
8JMO	;	1.95	;	Structure of a leaf-branch compost cutinase, ICCG in complex with 4-((4-Hydroxybutoxy)carbonyl)benzoic acid
4U2A	;	1.74	;	Structure of a lectin from the seeds of Vatairea macrocarpa complexed with GalNAc
4U5M	;	1.5	;	Structure of a left-handed DNA G-quadruplex
6GZ6	;	2.006	;	Structure of a left-handed G-quadruplex
5YIM	;	3.394	;	Structure of a Legionella effector
5YIK	;	3.102	;	Structure of a Legionella effector with its substrate
5YIJ	;	3.18	;	Structure of a Legionella effector with substrates
1LTE	;	2.0	;	STRUCTURE OF A LEGUME LECTIN WITH AN ORDERED N-LINKED CARBOHYDRATE IN COMPLEX WITH LACTOSE
8A19	;	2.358	;	Structure of a leucinostatin derivative determined by host lattice display : L1E4V1 construct
8A1A	;	2.05	;	Structure of a leucinostatin derivative determined by host lattice display : L1F11V1 construct
4D2B	;	2.35	;	Structure of a ligand free POT family peptide transporter
4B7F	;	1.76	;	Structure of a liganded bacterial catalase
1HA7	;	2.2	;	STRUCTURE OF A LIGHT-HARVESTING PHYCOBILIPROTEIN, C-PHYCOCYANIN FROM SPIRULINA PLATENSIS AT 2.2A RESOLUTION
2IYI	;	2.95	;	structure of a light-induced intermediate of the BLUF domain of the rhodobacterial protein AppA
1W66	;	1.08	;	Structure of a lipoate-protein ligase b from Mycobacterium tuberculosis
5CYB	;	2.1	;	Structure of a lipocalin lipoprotein affecting virulence in Streptococcus pneumoniae
4Y68	;	2.21	;	Structure of a lipoprotein from Streptococcus agalactiae
4R96	;	3.31	;	Structure of a Llama Glama Fab 48A2 against human cMet
1U0Q	;	1.6	;	Structure of a Llama VHH domain raised against a carbazole molecule
2K01	;		;	Structure of a locked SDF1 dimer
3CP1	;	2.0	;	Structure of a longer thermalstable core domain of HIV-1 gp41 containing the enfuvirtide resistance mutation N43D
3CYO	;	2.1	;	Structure of a longer thermalstable core domain of HIV-1 GP41 containing the enfuvirtide resistance mutation N43D and complementary mutation E137K
3M3N	;	7.0	;	Structure of a Longitudinal Actin Dimer Assembled by Tandem W Domains
2VH4	;	2.45	;	Structure of a loop C-sheet serpin polymer
1WOB	;	2.8	;	Structure of a loop6 hinge mutant of Plasmodium falciparum Triosephosphate Isomerase, W168F, complexed to sulfate
4G22	;	1.7	;	Structure of a Lys-HCT mutant from Coffea canephora (Crystal form 1)
4G2M	;	2.5	;	Structure of a Lys-HCT mutant from Coffea canephora (Crystal form 2)
4TSB	;	1.95	;	Structure of a lysozyme antibody complex
4TSC	;	1.92	;	Structure of a lysozyme antibody complex
4TTD	;	2.15	;	Structure of a lysozyme antibody complex
4TSA	;	2.27	;	Structure of a lysozyme FAb complex
3VEH	;	2.0	;	Structure of a M. tuberculosis salicylate synthase, MbtI, in complex with an inhibitor methylAMT
3RV8	;	2.29	;	Structure of a M. tuberculosis Salicylate Synthase, MbtI, in Complex with an Inhibitor with Cyclopropyl R-Group
3RV9	;	2.14	;	Structure of a M. tuberculosis Salicylate Synthase, MbtI, in Complex with an Inhibitor with Ethyl R-Group
3RV7	;	2.5	;	Structure of a M. tuberculosis Salicylate Synthase, MbtI, in Complex with an Inhibitor with Isopropyl R-Group
3RV6	;	2.04	;	Structure of a M. tuberculosis Salicylate Synthase, MbtI, in Complex with an Inhibitor with Phenyl R-Group
3ST6	;	1.75	;	Structure of a M. tuberculosis Synthase, MbtI, in Complex with an Isochorismate Analogue Inhibitor
2QP2	;	2.0	;	Structure of a MACPF/perforin-like protein
1FOD	;	2.6	;	STRUCTURE OF A MAJOR IMMUNOGENIC SITE ON FOOT-AND-MOUTH DISEASE VIRUS
4AE5	;	1.85	;	STRUCTURE OF A MAJOR REGULATOR OF STAPHYLOCOCCAL PATHOGENESIS
4O2X	;	2.7	;	Structure of a malarial protein
4O32	;	2.196	;	Structure of a malarial protein
4XBI	;	2.013	;	Structure Of A Malarial Protein Involved in Proteostasis
6P5N	;	3.2	;	Structure of a mammalian 80S ribosome in complex with a single translocated Israeli Acute Paralysis Virus IRES and eRF1
6P5I	;	3.1	;	Structure of a mammalian 80S ribosome in complex with the Israeli Acute Paralysis Virus IRES (Class 1)
6P5J	;	3.1	;	Structure of a mammalian 80S ribosome in complex with the Israeli Acute Paralysis Virus IRES (Class 2)
6P5K	;	3.1	;	Structure of a mammalian 80S ribosome in complex with the Israeli Acute Paralysis Virus IRES (Class 3)
4V5Z	;	8.7	;	Structure of a mammalian 80S ribosome obtained by docking homology models of the RNA and proteins into an 8.7 A cryo-EM map
3JAG	;	3.65	;	Structure of a mammalian ribosomal termination complex with ABCE1, eRF1(AAQ), and the UAA stop codon
3JAH	;	3.45	;	Structure of a mammalian ribosomal termination complex with ABCE1, eRF1(AAQ), and the UAG stop codon
3JAI	;	3.65	;	Structure of a mammalian ribosomal termination complex with ABCE1, eRF1(AAQ), and the UGA stop codon
6P4G	;	3.1	;	Structure of a mammalian small ribosomal subunit in complex with the Israeli Acute Paralysis Virus IRES (Class 1)
6P4H	;	3.2	;	Structure of a mammalian small ribosomal subunit in complex with the Israeli Acute Paralysis Virus IRES (Class 2)
6FUV	;	2.001	;	Structure of a manno-oligosaccharide specific solute binding protein, BlMnBP2 from Bifidobacterium animalis subsp. lactis ATCC 27673 in complex with mannotriose
1XXQ	;	1.8	;	Structure of a mannose-specific jacalin-related lectin from Morus nigra
1XXR	;	2.0	;	Structure of a mannose-specific jacalin-related lectin from Morus Nigra in complex with mannose
6NYB	;	4.1	;	Structure of a MAPK pathway complex
6Q0J	;	4.9	;	Structure of a MAPK pathway complex
6Q0K	;	6.8	;	Structure of a MAPK pathway complex
6Q0T	;	5.7	;	Structure of a MAPK pathway complex
6SHL	;	3.1	;	Structure of a marine algae virus of the order Picornavirales
5UJB	;	2.7	;	Structure of a Mcl-1 Inhibitor Binding to Site 3 of Human Serum Albumin
5VKQ	;	3.55	;	Structure of a mechanotransduction ion channel Drosophila NOMPC in nanodisc
5AYW	;	3.555	;	Structure of a membrane complex
4NYK	;	3.0	;	Structure of a membrane protein
4Q35	;	2.393	;	Structure of a membrane protein
4U9L	;	2.3	;	Structure of a membrane protein
4U9N	;	2.2	;	Structure of a membrane protein
7WSO	;	3.03	;	Structure of a membrane protein G
7WSP	;	4.09	;	Structure of a membrane protein M
7XT6	;	3.63	;	Structure of a membrane protein M3
7XE4	;	3.4	;	structure of a membrane-bound glycosyltransferase
7XS7	;	3.2	;	structure of a membrane-integrated glycosyltransferase
7XS6	;	2.9	;	structure of a membrane-integrated glycosyltransferase with inhibitor
3WYB	;	2.4	;	Structure of a meso-diaminopimelate dehydrogenase
3WYC	;	2.07	;	Structure of a meso-diaminopimelate dehydrogenase in complex with NADP
2WYM	;	2.6	;	Structure of a metallo-b-lactamase
4TYF	;	1.1	;	Structure of a Metallo-beta-lactamase
6WT6	;	2.41	;	Structure of a metazoan TIR-STING receptor from C. gigas
6WT7	;	2.9	;	Structure of a metazoan TIR-STING receptor from C. gigas in complex with 2',3'-cGAMP
8DOT	;	3.05	;	Structure of a methane clathrate binding protein
5Y4R	;	2.298	;	Structure of a methyltransferase complex
5Y4S	;	3.405	;	Structure of a methyltransferase complex
4O1E	;	1.61	;	Structure of a methyltransferase component in complex with MTHF involved in O-demethylation
4O1F	;	1.8	;	Structure of a methyltransferase component in complex with THF involved in O-demethylation
7QNG	;	2.7	;	Structure of a MHC I-Tapasin-ERp57 complex
2FIK	;	1.8	;	Structure of a microbial glycosphingolipid bound to mouse CD1d
5NUS	;	2.2	;	Structure of a minimal complex between p44 and p34 from Chaetomium thermophilum
2C5D	;	3.3	;	Structure of a minimal Gas6-Axl complex
7O1V	;	4.31	;	Structure of a Minimal Photosystem I
6RHZ	;	3.2	;	Structure of a minimal photosystem I from a green alga
7B91	;	3.0	;	Structure of a minimal SF3B core in complex with pladienolide D (form I)
7B9C	;	2.4	;	Structure of a minimal SF3B core in complex with spliceostatin A (form I)
7B0I	;	3.0	;	Structure of a minimal SF3B core in complex with spliceostatin A (form II)
7OMF	;	3.0	;	Structure of a minimal SF3B core in complex with sudemycin D6 (form I)
7B92	;	3.0	;	Structure of a minimal SF3B core in complex with sudemycin D6 (form II)
7OPI	;	3.1	;	Structure of a minimal SF3B core in complex with the inactive modulator spliceostatin E (form I)
4EU1	;	2.3	;	Structure of a mitochondrial aspartate aminotransferase from Trypanosoma brucei
4W5K	;	1.7	;	Structure of a mitochondrial aspartate aminotransferase from Trypanosoma brucei, K237A mutant
6XQN	;	3.3	;	Structure of a mitochondrial calcium uniporter holocomplex (MICU1, MICU2, MCU, EMRE) in low Ca2+
2PWJ	;	2.8	;	Structure of a mitochondrial type II peroxiredoxin from Pisum sativum
4UBU	;	3.0	;	Structure of a modified C93S variant of the 3-ketoacyl-CoA thiolase FadA5 from M. tuberculosis in complex with CoA
5OBB	;	2.65	;	Structure of a modified mouse H chain ferritin with a lanthanide binding motif in complex with Terbium
5OBA	;	2.85	;	Structure of a modified mouse H-chain ferritin with a lanthanide binding motif
6FHK	;	1.657	;	Structure of a modified protein containing a genetically encoded phosphoserine
1UUX	;	1.6	;	Structure of a molybdopterin-bound cnx1g domain links molybdenum and copper metabolism
1UUY	;	1.45	;	Structure of a molybdopterin-bound cnx1g domain links molybdenum and copper metabolism
2B3Y	;	1.85	;	Structure of a monoclinic crystal form of human cytosolic aconitase (IRP1)
3UO1	;	1.641	;	Structure of a monoclonal antibody complexed with its MHC-I antigen
3UYR	;	1.7	;	Structure of a monoclonal antibody complexed with its MHC-I antigen
3V4U	;	1.64	;	Structure of a monoclonal antibody complexed with its MHC-I antigen
3V52	;	1.697	;	Structure of a monoclonal antibody complexed with its MHC-I antigen
4MLT	;	2.0	;	Structure of a monodentate 3-hydroxy-4H-pyran-4-thione ligand bound to hCAII
2LF4	;		;	Structure of a monomeric mutant of the HIV-1 capsid protein
7SA3	;	2.25	;	Structure of a monomeric photosystem II core complex from a cyanobacterium acclimated to far-red light
7O3K	;	2.75	;	Structure of a monomeric variant (L135E) of Sandercyanin fluorescent protein bound to biliverdin IX-alpha
6XKE	;	1.55	;	Structure of a mosquito complement inhibitor from Anopheles albimanus
6XL7	;	1.42	;	Structure of a mosquito complement inhibitor from Anopheles freeborni
8VEV	;	3.06	;	Structure of a mouse IgG antibody antigen-binding fragment (Fab) targeting N6-methyladenosine (m6A), an RNA modification, m6A nucleoside ligand
8TCA	;	2.02	;	Structure of a mouse IgG antibody antigen-binding fragment (Fab) targeting N6-methyladenosine (m6A), an RNA modification, no ligand
8SIP	;	1.94	;	Structure of a mouse IgG antibody fragment that binds Inosine, an RNA modification
5AMO	;	2.4	;	Structure of a mouse Olfactomedin-1 disulfide-linked dimer of the Olfactomedin domain and part of the coiled coil
1AQ4	;	3.0	;	STRUCTURE OF A MS2 COAT PROTEIN MUTANT IN COMPLEX WITH AN RNA OPERATOR
3AW5	;	2.0	;	Structure of a multicopper oxidase from the hyperthermophilic archaeon Pyrobaculum aerophilum
1DVR	;	2.36	;	STRUCTURE OF A MUTANT ADENYLATE KINASE LIGATED WITH AN ATP-ANALOGUE SHOWING DOMAIN CLOSURE OVER ATP
3C9M	;	3.4	;	Structure of a mutant bovine rhodopsin in hexagonal crystal form
6ARP	;	1.7	;	Structure of a mutant Cetuximab Fab fragment
2ATK	;	2.5	;	Structure of a mutant KcsA K+ channel
3H97	;	1.7	;	Structure of a mutant methionyl-tRNA synthetase with modified specificity
3H9B	;	1.5	;	Structure of a mutant methionyl-tRNA synthetase with modified specificity complexed with azidonorleucine
3H99	;	1.4	;	Structure of a mutant methionyl-tRNA synthetase with modified specificity complexed with methionine
7FJR	;	2.6	;	Structure of a mutant of OspA
3ZKP	;	2.0	;	Structure of a mutant of P450 EryK in complex with erythromycin B.
2H0M	;	2.26	;	Structure of a Mutant of Rat Annexin A5
3PO4	;	1.8	;	Structure of a mutant of the large fragment of DNA polymerase I from Thermus aquaticus in complex with a blunt-ended DNA and ddATP
3PO5	;	2.39	;	Structure of a mutant of the large fragment of DNA polymerase I from Thermus Auqaticus in complex with an abasic site and ddATP
3NKY	;	2.28	;	Structure of a mutant P44S of Foot-and-mouth disease Virus RNA-dependent RNA polymerase
1FN0	;	2.0	;	STRUCTURE OF A MUTANT WINGED BEAN CHYMOTRYPSIN INHIBITOR PROTEIN, N14D.
7YUY	;	3.5	;	Structure of a mutated membrane-bound glycosyltransferase
2WMZ	;	2.9	;	Structure of a mutated TolC
5VI8	;	2.76	;	Structure of a mycobacterium smegmatis transcription initiation complex with an upstream-fork promoter fragment
2ASB	;	1.5	;	Structure of a Mycobacterium tuberculosis NusA-RNA complex
2ATW	;	2.25	;	Structure of a Mycobacterium tuberculosis NusA-RNA complex
7C72	;	3.00004	;	Structure of a mycobacterium tuberculosis puromycin-hydrolyzing peptidase
1THT	;	2.1	;	STRUCTURE OF A MYRISTOYL-ACP-SPECIFIC THIOESTERASE FROM VIBRIO HARVEYI
6PSL	;	2.1	;	Structure of a N-Me-D-Gln4,D-aza-Thr8,Arg10-teixobactin analogue
8U78	;	1.5	;	Structure of a N-Me-D-Gln4,Lys10-teixobactin analogue
6E00	;	2.2	;	Structure of a N-Me-p-iodo-D-Phe1,N-Me-D-Gln4,Lys10-teixobactin analogue
5TUA	;	3.3	;	structure of a Na+-selective mutant of two-pore channel from Arabidopsis thaliana AtTPC1
6PFZ	;	3.10004	;	Structure of a NAD-Dependent Persulfide Reductase from A. fulgidus
4ZJU	;	1.2	;	Structure of a NADH-dependent enoyl-ACP reductase from Acinetobacter baumannii in complex with NAD
4LT5	;	2.893	;	Structure of a Naegleria Tet-like dioxygenase in complex with 5-methylcytosine DNA
5E7B	;	1.1	;	Structure of a nanobody (vHH) from camel against phage Tuc2009 RBP (BppL, ORF53)
5DA4	;	2.4	;	Structure of a nanobody recognizing the fumarate transporter SLC26Dg
4XT1	;	2.886	;	Structure of a nanobody-bound viral GPCR bound to human chemokine CX3CL1
3P0G	;	3.5	;	Structure of a nanobody-stabilized active state of the beta2 adrenoceptor
7B3Y	;	3.7	;	Structure of a nanoparticle for a COVID-19 vaccine candidate
8ED3	;	3.5	;	Structure of a nanoparticle with icosahedral symmetry
7TAK	;	2.79828	;	Structure of a NAT transporter
5OOL	;	3.06	;	Structure of a native assembly intermediate of the human mitochondrial ribosome with unfolded interfacial rRNA
5OOM	;	3.03	;	Structure of a native assembly intermediate of the human mitochondrial ribosome with unfolded interfacial rRNA
7NRU	;	1.21998	;	Structure of a natural chimera of meningococcal factor H binding protein belonging to NL096 strain
6ABH	;	3.05	;	Structure of a natural red emitting luciferase from Phrixothrix hirtus (P1 crystal form)
6AC3	;	3.6	;	Structure of a natural red emitting luciferase from Phrixothrix hirtus (P3121 crystal form)
2EUW	;	1.68	;	Structure of a Ndt80-DNA complex (MSE mutant mA4T)
2EVF	;	1.56	;	Structure of a Ndt80-DNA complex (MSE mutant mA6T)
2EVH	;	1.989	;	Structure of a Ndt80-DNA complex (MSE mutant mA7G)
2EVG	;	1.55	;	Structure of a Ndt80-DNA complex (MSE mutant mA7T)
2EVI	;	1.8	;	Structure of a Ndt80-DNA complex (MSE mutant mA8T)
2EUZ	;	1.56	;	Structure of a Ndt80-DNA complex (MSE mutant mC5T)
2EUX	;	1.57	;	Structure of a Ndt80-DNA complex (MSE VARIANT vA4G)
7O6Z	;	2.3	;	Structure of a neodymium-containing, XoxF1-type methanol dehydrogenase
6P2S	;	1.65	;	Structure of a nested set of N-terminally extended MHC I-peptides provide novel insights into antigen processing and presentation
6P23	;	1.595	;	Structure of a nested set of N-terminally extended MHC I-peptides provide novel insights into antigen processing presentation
6P27	;	1.593	;	Structure of a nested set of N-terminally extended MHC I-peptides provides novel insights into antigen processing and presentation
6P2C	;	1.396	;	Structure of a nested set of N-terminally extended MHC I-peptides provides novel insights into antigen processing and presentation
6P2F	;	1.482	;	Structure of a nested set of N-terminally extended MHC I-peptides provides novel insights into antigen processing and presentation
4GEZ	;	2.5	;	Structure of a neuraminidase-like protein from A/bat/Guatemala/164/2009
1QFA	;		;	STRUCTURE OF A NEUROPEPTIDE Y Y2 AGONIST
6JEP	;	2.316	;	Structure of a neutralizing antibody bound to the Zika envelope protein domain III
1F9J	;	2.7	;	STRUCTURE OF A NEW CRYSTAL FORM OF TETRAUBIQUITIN
3LTJ	;	1.8	;	Structure of a new family of artificial alpha helicoidal repeat proteins (alpha-Rep) based on thermostable HEAT-like repeats
3LTM	;	2.15	;	Structure of a new family of artificial alpha helicoidal repeat proteins (alpha-Rep) based on thermostable HEAT-like repeats
5UAS	;	1.6	;	Structure of a new family of Polysaccharide lyase PL25-Ulvanlyase bound to -[GlcA(1-4)Rha3S]-
5UAM	;	1.45	;	Structure of a new family of Polysaccharide lyase PL25-Ulvanlyase.
6BUC	;		;	Structure of a new ShKT peptide from the sea anemone Oulactis sp.
6CKD	;		;	Structure of a new ShKT peptide from the sea anemone Oulactis sp: OspTx2a-p1
6CKF	;		;	Structure of a new ShKT peptide from the sea anemone Oulactis sp: OspTx2a-p2
8SED	;		;	Structure of a new ShKT peptide from the sea anemone Telmatactis stephensoni: ShKT-Ts1
6YRS	;	1.7	;	Structure of a new variant of GNCA ancestral beta-lactamase
4U4V	;	2.35	;	Structure of a nitrate/nitrite antiporter NarK in apo inward-open state
4U4T	;	2.4	;	Structure of a nitrate/nitrite antiporter NarK in nitrate-bound inward-open state
4U4W	;	2.4	;	Structure of a nitrate/nitrite antiporter NarK in nitrate-bound occluded state
1M7V	;	1.95	;	STRUCTURE OF A NITRIC OXIDE SYNTHASE HEME PROTEIN FROM BACILLUS SUBTILIS WITH TETRAHYDROFOLATE AND ARGININE BOUND
3SDO	;	2.0	;	Structure of a Nitrilotriacetate monooxygenase from Burkholderia pseudomallei
5XU1	;	3.3	;	Structure of a non-canonical ABC transporter from Streptococcus pneumoniae R6
5CE7	;	2.0	;	Structure of a non-canonical CID of Ctk3
8BDK	;	1.88	;	Structure of a non-canonical histone from archaea
1P59	;	2.5	;	Structure of a non-covalent Endonuclease III-DNA Complex
1AID	;	2.2	;	STRUCTURE OF A NON-PEPTIDE INHIBITOR COMPLEXED WITH HIV-1 PROTEASE: DEVELOPING A CYCLE OF STRUCTURE-BASED DRUG DESIGN
2AID	;	1.9	;	STRUCTURE OF A NON-PEPTIDE INHIBITOR COMPLEXED WITH HIV-1 PROTEASE: DEVELOPING A CYCLE OF STRUCTURE-BASED DRUG DESIGN
3J45	;	9.5	;	Structure of a non-translocating SecY protein channel with the 70S ribosome
6IBQ	;	1.55	;	Structure of a nonameric RNA duplex at room temperature in ChipX microfluidic device
5H2B	;	2.001	;	Structure of a novel antibody G196
6XFQ	;	3.3	;	Structure of a novel antithrombotic agent Agkisacucetin in complex with the platelet glycoprotein Ib receptor
4N2O	;	2.442	;	Structure of a novel autonomous cohesin protein from Ruminococcus flavefaciens
2RHE	;	1.6	;	STRUCTURE OF A NOVEL BENCE-JONES PROTEIN (RHE) FRAGMENT AT 1.6 ANGSTROMS RESOLUTION
7DVZ	;	2.0	;	Structure of a novel beta-mannanase BaMan113A from Bacillus sp. N16-5, N236Y mutation.
7DV7	;	1.44	;	Structure of a novel beta-mannanase BaMan113A from Bacillus sp. N16-5.
7DW8	;	1.9	;	Structure of a novel beta-mannanase BaMan113A with mannobiose, N236Y mutation.
7DWA	;	1.62	;	Structure of a novel beta-mannanase BaMan113A with mannotriose, N236Y mutation
4V17	;	2.0	;	Structure of a novel carbohydrate binding module from glycoside hydrolase family 5 glucanase from Ruminococcus flavefaciens FD-1
4V1I	;	2.59	;	Structure of a novel carbohydrate binding module from glycoside hydrolase family 5 glucanase from Ruminococcus flavefaciens FD-1 at medium resolution
4V1B	;	2.69	;	Structure of a novel carbohydrate binding module from glycoside hydrolase family 5 glucanase from Ruminococcus flavefaciens FD-1 collected at the Zn edge
5AOS	;	1.29	;	Structure of a novel carbohydrate binding module from Ruminococcus flavefaciens FD-1 endoglucanase Cel5A solved at the As edge
7Y3Z	;	2.3	;	Structure of a novel carboxylesterase FEH from Acinetobacter sp. DL-2
2L8A	;		;	Structure of a novel CBM3 lacking the calcium-binding site
4M1R	;	1.8	;	Structure of a novel cellulase 5 from a sugarcane soil metagenomic library
1SRA	;	2.0	;	STRUCTURE OF A NOVEL EXTRACELLULAR CA2+-BINDING MODULE IN BM-40(SLASH)SPARC(SLASH)OSTEONECTIN
4K68	;	2.74	;	Structure of a novel GH10 endoxylanase retrieved from sugarcane soil metagenome
2YCD	;	1.4	;	Structure of a novel Glutathione Transferase from Agrobacterium tumefaciens.
4UFQ	;	1.45	;	Structure of a novel Hyaluronidase (Hyal_Sk) from Streptomyces koganeiensis.
6Z5Y	;	1.01	;	Structure of a novel LPMO from Phytophthora infestans
2V4I	;	2.2	;	Structure of a novel N-acyl-enzyme intermediate of an N-terminal nucleophile (Ntn) hydrolase, OAT2
3VPS	;	1.9	;	Structure of a novel NAD dependent-NDP-hexosamine 5,6-dehydratase, TunA, involved in tunicamycin biosynthesis
5N0J	;	1.949	;	Structure of a novel oxidoreductase from Gloeobacter violaceus
5ODE	;	2.196	;	Structure of a novel oxidoreductase from Gloeobacter violaceus
1IXT	;		;	Structure of a Novel P-Superfamily Spasmodic Conotoxin Reveals an Inhibitory Cystine Knot Motif
1YRX	;	2.3	;	Structure of a novel photoreceptor: the BLUF domain of AppA from Rhodobacter sphaeroides
5C74	;	1.9	;	Structure of a novel protein arginine methyltransferase
2F40	;		;	Structure of a Novel Protein from Backbone-Centered NMR Data and NMR-Assisted Structure Prediction
3TJ2	;	2.1	;	Structure of a novel submicromolar MDM2 inhibitor
4MDN	;	1.905	;	Structure of a novel submicromolar MDM2 inhibitor
4MDQ	;	2.119	;	Structure of a novel submicromolar MDM2 inhibitor
4J19	;	2.9	;	Structure of a novel telomere repeat binding protein bound to DNA
7DBE	;	1.9	;	Structure of a novel transaminase
2MIX	;		;	Structure of a novel venom peptide toxin from sample limited terebrid marine snail
7CDV	;	2.1	;	STRUCTURE OF A NOVEL VIRULENCE REGULATION FACTOR SghR
5FFJ	;	2.84	;	Structure of a nuclease-deletion mutant of the Type ISP restriction-modification enzyme LlaGI in complex with a DNA substrate mimic
8QKT	;	3.261	;	Structure of a nucleosome composed of a palindromic 167-base pair blunt-ended DNA fragment
5LI9	;	1.79	;	Structure of a nucleotide-bound form of PKCiota core kinase domain
1K26	;	1.85	;	Structure of a Nudix Protein from Pyrobaculum aerophilum Solved by the Single Wavelength Anomolous Scattering Method
3TR6	;	2.7	;	Structure of a O-methyltransferase from Coxiella burnetii
5X7F	;	1.997	;	Structure of a O-methyltransferase from Mycobacterium tuberculosis at 2.0 resolution
6EYG	;	1.42	;	Structure of a OpuBC mutant with bound Glycine betaine
6EYH	;	1.6	;	Structure of a OpuBC mutant with bound Glycine betaine
3TR2	;	2.001	;	Structure of a orotidine 5'-phosphate decarboxylase (pyrF) from Coxiella burnetii
7XPI	;	2.0	;	Structure of a oxidoreductase
7YTL	;	2.62	;	Structure of a oxidoreductase in complex with quinone
1G3N	;	2.9	;	STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
2YIH	;	1.7	;	Structure of a Paenibacillus polymyxa Xyloglucanase from GH family 44 with Xyloglucan
2YJQ	;	2.25	;	Structure of a Paenibacillus Polymyxa Xyloglucanase from Glycoside Hydrolase Family 44
2YKK	;	1.79	;	Structure of a Paenibacillus Polymyxa Xyloglucanase from Glycoside Hydrolase Family 44
3ZQ9	;	1.86	;	Structure of a Paenibacillus Polymyxa Xyloglucanase from Glycoside Hydrolase Family 44
1JFH	;	2.03	;	STRUCTURE OF A PANCREATIC ALPHA-AMYLASE BOUND TO A SUBSTRATE ANALOGUE AT 2.03 ANGSTROM RESOLUTION
5WUA	;	5.6	;	Structure of a Pancreatic ATP-sensitive Potassium Channel
4RFS	;	3.232	;	Structure of a pantothenate energy coupling factor transporter
5LI1	;	2.0	;	Structure of a Par3-inhibitory peptide bound to PKCiota core kinase domain
6ZL2	;		;	Structure of a parallel c-Myc modified with 3' duplex stem-loop overhang
6ZTE	;		;	Structure of a parallel c-myc modified with 5' duplex stem-loop and 3' diagonal snap-back loop
6ZL9	;		;	Structure of a parallel c-Myc modified with 5' duplex stem-loop overhang
5A8B	;	2.791	;	Structure of a parallel dimer of the aureochrome 1a LOV domain from Phaeodactylum tricornutum
7ZEM	;		;	Structure of a parallel G-quadruplex with a snapback loop
2O4F	;	1.5	;	Structure of a parallel-stranded guanine tetraplex crystallised with monovalent ions
1HRL	;		;	STRUCTURE OF A PARALYTIC PEPTIDE FROM AN INSECT, MANDUCA SEXTA
2NTZ	;	3.35	;	Structure of a ParB-DNA complex reveals a double B-box interaction
3JAP	;	4.9	;	Structure of a partial yeast 48S preinitiation complex in closed conformation
6GSN	;	5.75	;	Structure of a partial yeast 48S preinitiation complex in closed conformation
6GSM	;	5.15	;	Structure of a partial yeast 48S preinitiation complex in open conformation.
6FYX	;	3.5	;	Structure of a partial yeast 48S preinitiation complex with eIF5 N-terminal domain (model C1)
6FYY	;	3.02	;	Structure of a partial yeast 48S preinitiation complex with eIF5 N-terminal domain (model C2)
7SHT	;	7.29	;	Structure of a partially disrupted IgE high affinity receptor complex bound to an omalizumab variant
3QHR	;	2.17	;	Structure of a pCDK2/CyclinA transition-state mimic
3QHW	;	1.91	;	Structure of a pCDK2/CyclinA transition-state mimic
5WQL	;	2.3	;	Structure of a PDZ-protease bound to a substrate-binding adaptor
1R76	;	2.65	;	Structure of a pectate lyase from Azospirillum irakense
2JDA	;	1.35	;	Structure of a pectin binding carbohydrate binding module determined in an monoclinic crystal form.
2JD9	;	1.8	;	Structure of a pectin binding carbohydrate binding module determined in an orthorhombic crystal form.
1PSA	;	2.9	;	STRUCTURE OF A PEPSIN(SLASH)RENIN INHIBITOR COMPLEX REVEALS A NOVEL CRYSTAL PACKING INDUCED BY MINOR CHEMICAL ALTERATIONS IN THE INHIBITOR
3TR5	;	2.11	;	Structure of a peptide chain release factor 3 (prfC) from Coxiella burnetii
2OD8	;	2.8	;	Structure of a peptide derived from Cdc9 bound to PCNA
2RPW	;		;	Structure of a peptide derived from H+-V-ATPase subunit a
6N9T	;	2.576	;	Structure of a peptide-based photo-affinity cross-linker with Herceptin Fc
5LIH	;	3.25	;	Structure of a peptide-substrate bound to PKCiota core kinase domain
1X3W	;	3.0	;	Structure of a peptide:N-glycanase-Rad23 complex
1X3Z	;	2.8	;	Structure of a peptide:N-glycanase-Rad23 complex
3V2I	;	1.65	;	Structure of a Peptidyl-tRNA hydrolase (PTH) from Burkholderia thailandensis
2MMJ	;		;	Structure of a peptoid analogue of maculatin G15 in DPC micelles
3WZ3	;	1.5	;	Structure of a periplasmic fragment of TraM
2UVG	;	2.2	;	Structure of a periplasmic oligogalacturonide binding protein from Yersinia enterocolitica
2UVI	;	2.3	;	Structure of a periplasmic oligogalacturonide binding protein from Yersinia enterocolitica in complex with 4,5-unsaturated digalacturonic acid
2UVH	;	2.2	;	Structure of a periplasmic oligogalacturonide binding protein from Yersinia enterocolitica in complex with saturated digalacturonic acid
2UVJ	;	1.8	;	Structure of a periplasmic oligogalacturonide binding protein from Yersinia enterocolitica in complex with trigalacturonic acid
8UPI	;	1.55	;	Structure of a periplasmic peptide binding protein from Mesorhizobium sp. AP09 bound to aminoserine
2DVZ	;	2.3	;	Structure of a periplasmic transporter
6ARZ	;	2.5	;	Structure of a phage anti-CRISPR protein
6AS3	;	2.0	;	Structure of a phage anti-CRISPR protein
6AS4	;	2.0	;	Structure of a phage anti-CRISPR protein
6V7U	;	2.08	;	Structure of a phage-encoded quorum sensing anti-activator, Aqs1
6V7V	;	2.3	;	Structure of a phage-encoded quorum sensing anti-activator, Aqs1
6V7X	;	2.9	;	Structure of a phage-encoded quorum sensing anti-activator, Aqs1 bound to LasR
5ED4	;	2.4	;	Structure of a PhoP-DNA complex
6WM5	;	1.961	;	Structure of a phosphatidylinositol-phosphate synthase (PIPS) from Mycobacterium kansasii
6WMV	;	2.142	;	Structure of a phosphatidylinositol-phosphate synthase (PIPS) from Mycobacterium kansasii with evidence of substrate binding
5D91	;	2.501	;	Structure of a phosphatidylinositolphosphate (PIP) synthase from Renibacterium Salmoninarum
5D92	;	3.62	;	Structure of a phosphatidylinositolphosphate (PIP) synthase from Renibacterium Salmoninarum
3I3W	;	2.3	;	Structure of a phosphoglucosamine mutase from Francisella tularensis
3TRJ	;	2.8	;	Structure of a phosphoheptose isomerase from Francisella tularensis
2V1Y	;	2.4	;	Structure of a phosphoinositide 3-kinase alpha adaptor-binding domain (ABD) in a complex with the iSH2 domain from p85 alpha
4XIZ	;	2.0	;	Structure of a phospholipid trafficking complex with substrate
4XHR	;	2.55	;	Structure of a phospholipid trafficking complex, native
6SQ2	;	1.684	;	Structure of a phosphomimetic switch 2 variant of Rab8a in complex with the phospho-Rab binding domain of RILPL2
1BLH	;	2.3	;	STRUCTURE OF A PHOSPHONATE-INHIBITED BETA-LACTAMASE. AN ANALOG OF THE TETRAHEDRAL TRANSITION STATE(SLASH)INTERMEDIATE OF BETA-LACTAM HYDROLYSIS
5ODS	;	3.09	;	Structure of a phosphoprotein-protein complex
3TRH	;	2.203	;	Structure of a phosphoribosylaminoimidazole carboxylase catalytic subunit (purE) from Coxiella burnetii
3R9R	;	1.849	;	Structure of a Phosphoribosylaminoimidazole-succinocarboxamide synthase from Mycobacterium abscessus ATCC 19977 / DSM 44196
2WKP	;	1.9	;	Structure of a photoactivatable Rac1 containing Lov2 Wildtype
2WKQ	;	1.6	;	Structure of a photoactivatable Rac1 containing the Lov2 C450A Mutant
2WKR	;	2.2	;	Structure of a photoactivatable Rac1 containing the Lov2 C450M Mutant
4LJB	;	1.9019	;	Structure of a photobleached state of IrisFP under high intensity laser-light
4LJD	;	2.5	;	Structure of a photobleached state of IrisFP under low intensity laser-light
1HPW	;		;	STRUCTURE OF A PILIN MONOMER FROM PSEUDOMONAS AERUGINOSA: IMPLICATIONS FOR THE ASSEMBLY OF PILI.
6IJZ	;	3.68	;	Structure of a plant cation channel
3NME	;	2.4	;	Structure of a plant phosphatase
4RJ9	;	1.63	;	Structure of a plant specific C2 domain protein, OsGAP1 from rice
2J5L	;	2.9	;	Structure of a Plasmodium falciparum apical membrane antigen 1-Fab F8. 12.19 complex
6ZYV	;	2.15	;	Structure of a Plasmodium PIR protein ectodomain
2J4W	;	2.5	;	Structure of a Plasmodium vivax apical membrane antigen 1-Fab F8.12.19 complex
2X32	;	1.55	;	Structure of a polyisoprenoid binding domain from Saccharophagus degradans implicated in plant cell wall breakdown
2X34	;	1.9	;	Structure of a polyisoprenoid binding domain from Saccharophagus degradans implicated in plant cell wall breakdown
7UBX	;	1.81	;	Structure of a pore forming fragment of Clostridium difficile toxin A in complex with VHH AA6
1XQA	;	1.8	;	Structure of a possible Glyoxalase from Bacillus cereus
1RZ3	;	1.9	;	Structure of a Possible Uridine Kinase from Bacillus stearothermophilus
4HVT	;	1.7	;	Structure of a Post-proline cleaving enzyme from Rickettsia typhi
3BES	;	2.2	;	Structure of a Poxvirus ifngbp/ifng Complex
5NRL	;	7.2	;	Structure of a pre-catalytic spliceosome.
5FPP	;	2.4	;	Structure of a pre-reaction ternary complex between sarin- acetylcholinesterase and HI-6
4V4V	;	15.0	;	Structure of a pre-translocational E. coli ribosome obtained by fitting atomic models for RNA and protein components into cryo-EM map EMD-1056
6FRK	;	3.7	;	Structure of a prehandover mammalian ribosomal SRP and SRP receptor targeting complex
5B01	;	3.45	;	Structure of a prenyltransferase in its unbound form
5XK6	;	1.58	;	Structure of a prenyltransferase soaked with IPP
4HYG	;	3.32	;	Structure of a presenilin family intramembrane aspartate protease in C222 space group
4HYD	;	3.8	;	Structure of a presenilin family intramembrane aspartate protease in C2221 space group
4HYC	;	3.95	;	Structure of a presenilin family intramembrane aspartate protease in P2 space group
3W1C	;	1.3	;	Structure of a pressure sensitive YFP variant YFP-G1
3W1D	;	1.5	;	Structure of a pressure sensitive YFP variant YFP-G3
4TUT	;	0.9	;	Structure of a Prion peptide
3TX2	;	1.5	;	Structure of a Probable 6-phosphogluconolactonase from Mycobacterium abscessus
3ZQU	;	1.5	;	STRUCTURE OF A PROBABLE AROMATIC ACID DECARBOXYLASE
3R9Q	;	2.1	;	Structure of a probable enoyl-coa hydratase/isomerase from Mycobacterium abscessus ATCC 19977 / DSM 44196
1PSQ	;	2.3	;	Structure of a probable thiol peroxidase from Streptococcus pneumoniae
4RKK	;	2.4	;	Structure of a product bound phosphatase
4KYQ	;	1.64	;	Structure of a product bound plant phosphatase
4KYR	;	2.3	;	Structure of a product bound plant phosphatase
6JD8	;	1.457	;	Structure of a proline specific mutant of human cathepsin L
2GC8	;	2.2	;	Structure of a Proline Sulfonamide Inhibitor Bound to HCV NS5b Polymerase
4C3S	;	1.64	;	Structure of a propionaldehyde dehydrogenase from the Clostridium phytofermentans fucose utilisation bacterial microcompartment
3KQX	;	2.01	;	Structure of a protease 1
3KQZ	;	2.39	;	Structure of a protease 2
3KR4	;	2.0	;	Structure of a protease 3
3KR5	;	2.56	;	Structure of a protease 4
1MVA	;	3.0	;	STRUCTURE OF A PROTEIN CAPSID OF THE T45A MUTANT OF PHAGE MS2
1MVB	;	3.0	;	STRUCTURE OF A PROTEIN CAPSID OF THE T59S MUTANT OF PHAGE MS2
7EL1	;	2.22	;	Structure of a protein from bacteria
2LJI	;		;	Structure of a protein from Haloferax volcanii
5WQT	;	2.64	;	Structure of a protein involved in pyroptosis
2FG1	;	1.25	;	Structure of a Protein of Unknown Function from Bacteroides thetaiotaomicron.
3DW8	;	2.85	;	Structure of a Protein Phosphatase 2A Holoenzyme with B55 subunit
2FEK	;		;	Structure of a protein tyrosine phosphatase
3ON2	;	1.96	;	Structure of a protein with unknown function from Rhodococcus sp. RHA1
2Z3X	;	2.1	;	Structure of a Protein-DNA Complex Essential for DNA Protection in Spore of Bacillus Species
7MK1	;	1.9	;	Structure of a protein-modified aptamer complex
6TPH	;		;	Structure of a protein-RNA complex by ssNMR
2BEZ	;	1.6	;	Structure of a proteolitically resistant core from the severe acute respiratory syndrome coronavirus S2 fusion protein
2BEQ	;	1.6	;	Structure of a Proteolytically Resistant Core from the Severe Acute Respiratory Syndrome Coronavirus S2 Fusion Protein
6YKR	;	3.0	;	Structure of a protonation mimic of unplugged C. jejuni MotAB
6VR7	;	2.5	;	Structure of a pseudomurein peptide ligase type C from Methanothermus fervidus
7TZI	;	2.911	;	Structure of a pseudomurein peptide ligase type E from Methanothermobacter thermautotrophicus
6VR8	;	1.9	;	Structure of a pseudomurein peptide ligase type E from Methanothermus fervidus
7UFP	;	2.0	;	Structure of a pseudomurein peptide ligase type E from Methanothermus fervidus
6IBP	;	2.536	;	Structure of a psychrophilic CCA-adding enzyme at room temperature in ChipX microfluidic device
7OTL	;	2.8	;	Structure of a psychrophilic CCA-adding enzyme crystallized by counter-diffusion
6TVZ	;	2.28	;	Structure of a psychrophilic CCA-adding enzyme crystallized in the XtalController device
6Q52	;	2.3	;	Structure of a psychrophilic CCA-adding enzyme in complex with CMPcPP at room temperature in ChipX microfluidic device
4NX8	;	1.698	;	Structure of a PTP-like phytase from Bdellovibrio bacteriovorus
8D38	;	1.72	;	Structure of a purine nucleoside phosphorylase from Geobacillus stearothermophilus
2JLM	;	2.35	;	Structure of a Putative Acetyltransferase (ACIAD1637) from Acinetobacter baylyi ADP1
2VI7	;	2.25	;	Structure of a Putative Acetyltransferase (PA1377)from Pseudomonas aeruginosa
4HR3	;	1.8	;	Structure of a putative acyl-CoA dehydrogenase from Mycobacterium abscessus
3IG4	;	2.89	;	Structure of a putative aminopeptidase P from Bacillus anthracis
3G27	;	2.1	;	Structure of a putative bacteriophage protein from Escherichia coli str. K-12 substr. MG1655
4PYR	;	1.45	;	Structure of a putative branched-chain amino acid ABC transporter from Chromobacterium violaceum ATCC 12472
3FX3	;	2.2	;	Structure of a putative cAMP-binding regulatory protein from Silicibacter pomeroyi DSS-3
2G03	;	2.2	;	Structure of a putative cell filamentation protein from Neisseria meningitidis.
3LZ8	;	2.9	;	Structure of a putative chaperone dnaj from klebsiella pneumoniae subsp. pneumoniae mgh 78578 at 2.9 a resolution.
3I38	;	2.3	;	Structure of a putative chaperone protein dnaj from klebsiella pneumoniae subsp. pneumoniae mgh 78578
4B9E	;	1.4	;	Structure of a putative epoxide hydrolase from Pseudomonas aeruginosa, with bound MFA.
4B9A	;	1.45	;	Structure of a putative epoxide hydrolase from Pseudomonas aeruginosa.
4BB0	;	1.77	;	Structure of a putative epoxide hydrolase Q244E mutant from Pseudomonas aeruginosa, with bound MFA.
4BAZ	;	1.35	;	Structure of a putative epoxide hydrolase Q244E mutant from Pseudomonas aeruginosa.
4BAU	;	1.55	;	Structure of a putative epoxide hydrolase t131d mutant from Pseudomonas aeruginosa, with bound MFA
4BAT	;	1.3	;	Structure of a putative epoxide hydrolase t131d mutant from Pseudomonas aeruginosa.
3S4K	;	1.7	;	Structure of a putative esterase Rv1847/MT1895 from Mycobacterium tuberculosis
1XC3	;	2.1	;	Structure of a Putative Fructokinase from Bacillus subtilis
4S1W	;	1.65	;	Structure of a putative Glutamine--Fructose-6-Phosphate Aminotransferase from Staphylococcus aureus subsp. aureus Mu50
3I4Q	;	1.63	;	Structure of a putative inorganic pyrophosphatase from the oil-degrading bacterium Oleispira antarctica
1RI6	;	2.0	;	Structure of a putative isomerase from E. coli
4RSH	;	2.19	;	Structure of a putative lipolytic protein of G-D-S-L family from Desulfitobacterium hafniense DCB-2
3QFG	;	3.08	;	Structure of a putative lipoprotein from Staphylococcus aureus subsp. aureus NCTC 8325
1YB2	;	2.01	;	Structure of a putative methyltransferase from Thermoplasma acidophilum.
3F0A	;	2.5	;	Structure of a putative n-acetyltransferase (ta0374) in complex with acetyl-coa from thermoplasma acidophilum
3NUQ	;	1.7	;	Structure of a putative nucleotide phosphatase from Saccharomyces cerevisiae
4L82	;	2.0	;	Structure of a putative oxidoreductase from Rickettsia felis
4R3J	;	2.44	;	Structure of a putative peptidoglycan glycosyltransferase from Atopobium parvulum in complex with cefapirin
4R0Q	;	2.0	;	Structure of a putative peptidoglycan glycosyltransferase from Atopobium parvulum in complex with cephalothin
4R1G	;	1.92	;	Structure of a putative peptidoglycan glycosyltransferase from Atopobium parvulum in complex with cloxacillin
4R23	;	1.84	;	Structure of a putative peptidoglycan glycosyltransferase from Atopobium parvulum in complex with dicloxacillin
4RA7	;	1.94	;	Structure of a putative peptidoglycan glycosyltransferase from Atopobium parvulum in complex with nafcillin
4N1X	;	2.0	;	Structure of a putative peptidoglycan glycosyltransferase from Atopobium parvulum in complex with penicillin G
4QJG	;	1.85	;	Structure of a putative peptidoglycan glycosyltransferase from Atopobium parvulum in complex with penicillin V
4PM4	;	2.2	;	Structure of a putative periplasmic iron siderophore binding protein (Rv0265c) from Mycobacterium tuberculosis H37Rv
4YL5	;	1.7	;	Structure of a putative phosphomethylpyrimidine kinase from Acinetobacter baumannii
4YWR	;	1.65	;	Structure of a putative phosphomethylpyrimidine kinase from Acinetobacter baumannii in non-covalent complex with pyridoxal phosphate
2FYF	;	1.5	;	Structure of a putative phosphoserine aminotransferase from Mycobacterium Tuberculosis
3VOM	;	2.1	;	Structure of a putative phosphoserine aminotransferase from mycobacterium tuberculosis
3IC3	;	1.8	;	Structure of a putative pyruvate dehydrogenase from the photosynthetic bacterium Rhodopseudomonas palustrus CGA009
4MHB	;	1.75	;	Structure of a putative reductase from Yersinia pestis
2FCK	;	1.7	;	Structure of a putative ribosomal-protein-serine acetyltransferase from Vibrio cholerae.
3I1J	;	1.9	;	Structure of a putative short chain dehydrogenase from Pseudomonas syringae
3KKD	;	2.1	;	Structure of a putative tetr transcriptional regulator (pa3699) from pseudomonas aeruginosa pa01
4GCV	;	2.3	;	Structure of a Putative transcription factor (PA1374)from Pseudomonas aeruginosa
1Z72	;	1.45	;	Structure of a putative transcriptional regulator from Streptococcus pneumoniae
4KMR	;	1.45	;	Structure of a putative transcriptional regulator of LacI family from Sanguibacter keddieii DSM 10542.
4L83	;	1.7	;	Structure of a putative Ubiquitin-conjugating enzyme E2 from Brugia malayi
3RR6	;	1.58	;	Structure of a putative uncharacterized protein from Mycobacterium abscessus ATCC 19977 / DSM 44196
5JWZ	;	1.695	;	Structure of a Putative Xyloglucanase from the Cellulolytic Bacteria Streptomyces sp. SirexAA-E
3K29	;	2.0	;	Structure of a putative YscO homolog CT670 from Chlamydia trachomatis
1KZH	;	2.55	;	Structure of a pyrophosphate-dependent phosphofructokinase from the Lyme disease spirochete Borrelia burgdorferi
3TRI	;	2.5	;	Structure of a pyrroline-5-carboxylate reductase (proC) from Coxiella burnetii
6FTU	;	2.95	;	Structure of a Quadruplex forming sequence from D. discoideum
8S1W	;		;	Structure of a quadruplex-duplex hybrid with a (-pd+l) loop progression
1JJU	;	2.05	;	Structure of a Quinohemoprotein Amine Dehydrogenase with a Unique Redox Cofactor and Highly Unusual Crosslinking
1YF6	;	2.25	;	Structure of a quintuple mutant of photosynthetic reaction center from rhodobacter sphaeroides
2R2D	;	1.75	;	Structure of a quorum-quenching lactonase (AiiB) from Agrobacterium tumefaciens
2R6T	;	2.61	;	Structure of a R132K variant PduO-type ATP:co(I)rrinoid adenosyltransferase from Lactobacillus reuteri complexed with ATP
6M4Y	;	2.1	;	Structure of a R371A mutant of a Group II PLP dependent decarboxylase from Methanocaldococcus jannaschii
4C4W	;	2.95	;	Structure of a rare, non-standard sequence k-turn bound by L7Ae protein
1S4R	;	1.9	;	Structure of a reaction intermediate in the photocycle of PYP extracted by a SVD-driven analysis
4CLN	;	2.2	;	STRUCTURE OF A RECOMBINANT CALMODULIN FROM DROSOPHILA MELANOGASTER REFINED AT 2.2-ANGSTROMS RESOLUTION
8UYO	;	3.3	;	Structure of a recombinant human PNMA2 capsid
1EYL	;	1.9	;	STRUCTURE OF A RECOMBINANT WINGED BEAN CHYMOTRYPSIN INHIBITOR
6CZJ	;	2.1	;	Structure of a redesigned beta barrel, b10
6CZG	;	2.2	;	Structure of a redesigned beta barrel, b11L5F_LGL
6CZH	;	1.8	;	Structure of a redesigned beta barrel, mFAP0, bound to DFHBI
6CZI	;	2.3	;	Structure of a redesigned beta barrel, mFAP1, bound to DFHBI
5AAM	;	2.49	;	Structure of a redesigned cross-reactive antibody to dengue virus with increased in vivo potency
5AAW	;	3.27	;	Structure of a redesigned cross-reactive antibody to dengue virus with increased in vivo potency
1DW3	;	2.1	;	STRUCTURE OF A REDUCED OXYGEN BINDING CYTOCHROME C
4F2L	;	1.5	;	Structure of a regulatory domain of AMPK
2QG9	;	2.7	;	Structure of a regulatory subunit mutant D19A of ATCase from E. coli
3C71	;	1.9	;	Structure of a ResA variant with a DsbA-like active site motif (CPHC)
1HDT	;	2.6	;	STRUCTURE OF A RETRO-BINDING PEPTIDE INHIBITOR COMPLEXED WITH HUMAN ALPHA-THROMBIN
6DUQ	;	3.7	;	Structure of a Rho-NusG KOW domain complex
1NPQ	;		;	structure of a rhodamine-labeled N-domain Troponin C mutant (Ca2+ saturated) in complex with skeletal Troponin I 115-131
3M4X	;	2.28	;	Structure of a ribosomal methyltransferase
7UPH	;	4.18	;	Structure of a ribosome with tethered subunits
3TZR	;	2.212	;	Structure of a Riboswitch-like RNA-ligand complex from the Hepatitis C Virus Internal Ribosome Entry Site
6EFN	;	1.291	;	Structure of a RiPP maturase, SkfB
2IJK	;	1.55	;	Structure of a Rom protein dimer at 1.55 angstrom resolution
3QVO	;	2.3	;	Structure of a Rossmann-fold NAD(P)-binding family protein from Shigella flexneri.
3S82	;	1.73	;	Structure of a S-adenosylmethionine synthetase from Mycobacterium avium
8SLV	;	2.32	;	Structure of a salivary alpha-glucosidase from the mosquito vector Aedes aegypti.
3ZEU	;	1.653	;	Structure of a Salmonella typhimurium YgjD-YeaZ heterodimer bound to ATPgammaS
3ZET	;	2.31	;	Structure of a Salmonella typhimurium YgjD-YeaZ heterodimer.
3LCC	;	1.8	;	Structure of a SAM-dependent halide methyltransferase from Arabidopsis thaliana
2SAS	;	2.4	;	STRUCTURE OF A SARCOPLASMIC CALCIUM-BINDING PROTEIN FROM AMPHIOXUS REFINED AT 2.4 ANGSTROMS RESOLUTION
2SCP	;	2.0	;	STRUCTURE OF A SARCOPLASMIC CALCIUM-BINDING PROTEIN FROM NEREIS DIVERSICOLOR REFINED AT 2.0 ANGSTROMS RESOLUTION
2XBT	;	1.832	;	Structure of a scaffoldin carbohydrate-binding module family 3b from the cellulosome of Bacteroides cellulosolvens: Structural diversity and implications for carbohydrate binding
4V4W	;	15.0	;	Structure of a SecM-stalled E. coli ribosome complex obtained by fitting atomic models for RNA and protein components into cryo-EM map EMD-1143
4MOY	;	2.1953	;	Structure of a second nuclear PP1 Holoenzyme, crystal form 1
4MP0	;	2.1003	;	Structure of a second nuclear PP1 Holoenzyme, crystal form 2
2VRK	;	2.2	;	Structure of a seleno-methionyl derivative of wild type arabinofuranosidase from Thermobacillus xylanilyticus
4V1R	;	1.8	;	Structure of a selenomethionine derivative of the GH76 alpha- mannanase BT2949 Bacteroides thetaiotaomicron
6BCM	;	2.1	;	Structure of a Self-inhibited N475A variant of the Venezuelan Equine Encephalitis Virus (VEEV) nsP2 cysteine protease
4L9F	;	2.5	;	Structure of a SeMet derivative of PpsR Q-PAS1 from Rb. sphaeroides
5UHS	;	2.8	;	Structure of a SemiSWEET D57A mutant
5UHQ	;	2.78	;	Structure of a SemiSWEET Q20A mutant
4UV0	;	2.49	;	Structure of a semisynthetic phosphorylated DAPK
5FC2	;	1.84	;	Structure of a separase in complex with a pAMK peptide containing a phospho-serine
4HVL	;	2.0	;	Structure of a serine protease MycP1, an essential component of the type VII (ESX-1) secretion system
1IC6	;	0.98	;	STRUCTURE OF A SERINE PROTEASE PROTEINASE K FROM TRITIRACHIUM ALBUM LIMBER AT 0.98 A RESOLUTION
3TRF	;	2.6	;	Structure of a shikimate kinase (aroK) from Coxiella burnetii
5VEG	;	1.99	;	Structure of a Short-Chain Flavodoxin Associated with a Non-Canonical PDU Bacterial Microcompartment
3SVT	;	2.0	;	Structure of a short-chain type dehydrogenase/reductase from Mycobacterium ulcerans
3TL3	;	1.85	;	Structure of a short-chain type dehydrogenase/reductase from Mycobacterium ulcerans
1EYR	;	2.2	;	Structure of a sialic acid activating synthetase, CMP acylneuraminate synthetase in the presence and absence of CDP
1EZI	;	2.0	;	Structure of a sialic acid activating synthetase, CMP acylneuraminate synthetase in the presence and absence of CDP
2CEX	;	2.2	;	Structure of a sialic acid binding protein (SiaP) in the presence of the sialic acid acid analogue Neu5Ac2en
5LWF	;	2.56	;	Structure of a single domain camelid antibody fragment cAb-G10S in complex with the BlaP beta-lactamase from Bacillus licheniformis
4M3K	;	1.48	;	Structure of a single domain camelid antibody fragment cAb-H7S in complex with the BlaP beta-lactamase from Bacillus licheniformis
2X6M	;	1.62	;	Structure of a single domain camelid antibody fragment in complex with a C-terminal peptide of alpha-synuclein
4YCB	;	1.35	;	Structure of a single tryptophan mutant of Acetobacter aceti PurE
5CTJ	;	1.928	;	Structure of a single tryptophan mutant of Acetobacter aceti PurE containing 5-fluorotryptophan
5CVT	;	1.78	;	Structure of a single tryptophan mutant of Acetobacter aceti PurE containing 5-fluorotryptophan, pH 5.4
4YCD	;	1.643	;	Structure of a single tryptophan mutant of Acetobacter aceti PurE with Y154F
4YCC	;	2.257	;	Structure of a single tryptophan mutant of Acetobacter aceti PurE with Y154L mutation
6BXJ	;	2.092	;	Structure of a single-chain beta3 integrin
1MFA	;	1.7	;	STRUCTURE OF A SINGLE-CHAIN FV FRAGMENT COMPLEXED WITH A CARBOHYDRATE ANTIGEN AT 1.7 ANGSTROMS RESOLUTION
4N1H	;	3.0	;	Structure of a single-domain camelid antibody fragment cAb-F11N in complex with the BlaP beta-lactamase from Bacillus licheniformis
4M3J	;	1.95	;	Structure of a single-domain camelid antibody fragment cAb-H7S specific of the BlaP beta-lactamase from Bacillus licheniformis
3TQY	;	2.6001	;	Structure of a single-stranded DNA-binding protein (ssb), from Coxiella burnetii
1MA3	;	2.0	;	Structure of a Sir2 enzyme bound to an acetylated p53 peptide
1NFH	;	2.65	;	Structure of a Sir2 substrate, alba, reveals a mechanism for deactylation-induced enhancement of DNA-binding
1NFJ	;	2.0	;	Structure of a Sir2 substrate, alba, reveals a mechanism for deactylation-induced enhancement of DNA-binding
3BEP	;	1.92	;	Structure of a sliding clamp on DNA
3Q17	;	3.6	;	Structure of a slow CLC Cl-/H+ antiporter from a cyanobacterium in Bromide
7QOE	;	1.2	;	Structure of a small alarmone hydrolase from Leptospira levettii
3D1G	;	1.64	;	Structure of a small molecule inhibitor bound to a DNA sliding clamp
2XM9	;	2.5	;	Structure of a small molecule inhibitor with the kinase domain of Chk2
3Q4J	;	2.3	;	Structure of a small peptide ligand bound to E.coli DNA sliding clamp
3Q4K	;	2.6	;	Structure of a small peptide ligand bound to E.coli DNA sliding clamp
3Q4L	;	1.95	;	Structure of a small peptide ligand bound to E.coli DNA sliding clamp
6V8Y	;	1.53	;	Structure of a Sodium Potassium ion Channel
6R4P	;	3.1	;	Structure of a soluble domain of adenylyl cyclase bound to an activated stimulatory G protein
5URO	;	1.701	;	Structure of a soluble epoxide hydrolase identified in Trichoderma reesei
1CQ3	;	1.85	;	STRUCTURE OF A SOLUBLE SECRETED CHEMOKINE INHIBITOR, VCCI, FROM COWPOX VIRUS
1CDQ	;		;	STRUCTURE OF A SOLUBLE, GLYCOSYLATED FORM OF THE HUMAN COMPLEMENT REGULATORY PROTEIN CD59
1CDR	;		;	STRUCTURE OF A SOLUBLE, GLYCOSYLATED FORM OF THE HUMAN COMPLEMENT REGULATORY PROTEIN CD59
1CDS	;		;	STRUCTURE OF A SOLUBLE, GLYCOSYLATED FORM OF THE HUMAN COMPLEMENT REGULATORY PROTEIN CD59
7VQ6	;	1.39	;	Structure of a specialized glyoxalase from Gossypium hirsutum
5MPS	;	3.85	;	Structure of a spliceosome remodeled for exon ligation
5MQ0	;	4.17	;	Structure of a spliceosome remodeled for exon ligation
5M1G	;		;	Structure of a Spumaretrovirus Gag central domain reveals an ancient retroviral capsid
5M1H	;		;	Structure of a Spumaretrovirus Gag central domain reveals an ancient retroviral capsid
5XRZ	;	3.6	;	Structure of a ssDNA bound to the inner DNA binding site of RAD52
5XS0	;	3.0	;	Structure of a ssDNA bound to the outer DNA binding site of RAD52
4GEU	;	2.65	;	Structure of a stabilised ceSAS-6 dimer
4GEX	;	2.8	;	Structure of a stabilised ceSAS-6 dimer, second crystal form
5M1W	;		;	Structure of a stable G-hairpin
6XAH	;		;	Structure of a Stable Interstrand DNA Crosslink Involving an dA Amino Group and an Abasic Site
4UMN	;	1.99	;	Structure of a stapled peptide antagonist bound to Nutlin-resistant Mdm2.
6Y4Q	;	1.63	;	Structure of a stapled peptide bound to MDM2
1I6X	;	2.2	;	STRUCTURE OF A STAR MUTANT CRP-CAMP AT 2.2 A
8GJZ	;	2.92	;	Structure of a STING receptor from S. pistillata Sp-STING1 bound to 2'3'-cUA
6WT8	;	1.52	;	Structure of a STING-associated CdnE c-di-GMP synthase from Flavobacteriaceae sp.
2X44	;	2.6	;	Structure of a strand-swapped dimeric form of CTLA-4
2W3Z	;	1.45	;	Structure of a Streptococcus mutans CE4 esterase
2W92	;	1.65	;	Structure of a Streptococcus pneumoniae family 85 glycoside hydrolase, Endo-D, in complex with NAG-thiazoline.
2W91	;	1.4	;	Structure of a Streptococcus pneumoniae family 85 glycoside hydrolase, Endo-D.
2J1R	;	1.54	;	Structure of a Streptococcus pneumoniae fucose binding module
2J1S	;	1.5	;	Structure of a Streptococcus pneumoniae fucose binding module in complex with fucose
2J1U	;	1.8	;	Structure of a Streptococcus pneumoniae fucose binding module in complex with the blood group A-tetrasaccharide
2J1V	;	1.45	;	Structure of a Streptococcus pneumoniae fucose binding module in complex with the blood group H-trisaccharide
2J1T	;	1.6	;	Structure of a Streptococcus pneumoniae fucose binding module in complex with the Lewis Y antigen
2J22	;	1.8	;	Structure of a Streptococcus pneumoniae fucose binding module, SpX-3
2W7Y	;	2.35	;	Structure of a Streptococcus pneumoniae solute-binding protein in complex with the blood group A-trisaccharide.
6ITC	;	3.45	;	Structure of a substrate engaged SecA-SecY protein translocation machine
6WCQ	;	8.5	;	Structure of a substrate-bound DQC ubiquitin ligase
3WIC	;	2.6	;	Structure of a substrate/cofactor-unbound glucose dehydrogenase
2EKE	;	1.9	;	Structure of a SUMO-binding-motif mimic bound to Smt3p-Ubc9p: conservation of a noncovalent Ubiquitin-like protein-E2 complex as a platform for selective interactions within a SUMO pathway
1ZYF	;		;	Structure of a Supercoiling Responsive DNA Site
1ZYG	;		;	Structure of a Supercoiling Responsive DNA Site
1ZYH	;		;	Structure of a Supercoiling Responsive DNA site
4GF3	;	1.9	;	Structure of a SycH-YopH Chaperone-Effector Complex
8BWT	;		;	Structure of a symmetrical internal loop motif with three consecutive U:U mismatches from stem-loop 1 in the 3'-UTR of the SARS-CoV2 genomic RNA
1ZR2	;	3.9	;	Structure of a Synaptic gamma-delta Resolvase Tetramer Covalently Linked to two Cleaved DNAs
1ZR4	;	3.4	;	Structure of a Synaptic gamma-delta Resolvase Tetramer Covalently linked to two Cleaved DNAs
6OWF	;	3.0	;	Structure of a synthetic beta-carboxysome shell, T=3
6OWG	;	2.6	;	Structure of a synthetic beta-carboxysome shell, T=4
2OQF	;	2.3	;	Structure of a synthetic, non-natural analogue of RNase A: [N71K(Ade), D83A]RNase A
1D16	;	2.1	;	STRUCTURE OF A T4 HAIRPIN LOOP ON A Z-DNA STEM AND COMPARISON WITH A-RNA AND B-DNA LOOPS
8AF9	;	2.5	;	Structure of a T4SS effector from Brucella sp.
1H38	;	2.9	;	Structure of a T7 RNA polymerase elongation complex at 2.9A resolution
6F1J	;	1.25	;	Structure of a Talaromyces pinophilus GH62 Arabinofuranosidase in complex with AraDNJ at 1.25A resolution
2V1Z	;	1.6	;	Structure of a TEM-1 beta-lactamase insertant allosterically regulated by kanamycin and anions.
2V20	;	1.67	;	Structure of a TEM-1 beta-lactamase insertant allosterically regulated by kanamycin and anions. Complex with sulfate.
1LDN	;	2.5	;	STRUCTURE OF A TERNARY COMPLEX OF AN ALLOSTERIC LACTATE DEHYDROGENASE FROM BACILLUS STEAROTHERMOPHILUS AT 2.5 ANGSTROMS RESOLUTION
1PJ8	;	2.2	;	Structure of a ternary complex of proteinase K, mercury and a substrate-analogue hexapeptide at 2.2 A resolution
3C5G	;	2.2	;	Structure of a ternary complex of the R517K Pol lambda mutant
4LG0	;	2.19	;	Structure of a ternary FOXO1-ETS1 DNA complex
7KFZ	;	3.47	;	Structure of a ternary KRas(G13D)-SOS complex
6CHA	;	1.8	;	STRUCTURE OF A TETRAHEDRAL TRANSITION STATE COMPLEX OF ALPHA-*CHYMOTRYPSIN AT 1.8-*ANGSTROMS RESOLUTION
4AGG	;	2.98	;	Structure of a tetrameric galectin from Cinachyrella sp. (Ball sponge)
4AGR	;	2.1	;	Structure of a tetrameric galectin from Cinachyrella sp. (Ball sponge)
4AGV	;	2.65	;	Structure of a tetrameric galectin from Cinachyrella sp. (Ball sponge)
3HZQ	;	3.82	;	Structure of a tetrameric MscL in an expanded intermediate state
2RFM	;	1.65	;	Structure of a Thermophilic Ankyrin Repeat Protein
4IPA	;	2.3	;	Structure of a thermophilic Arx1
5FRD	;	1.4	;	Structure of a thermophilic esterase
1SNG	;	1.76	;	Structure of a Thermophilic Serpin in the Native State
7C3V	;	2.20043	;	Structure of a thermostable Alcohol dehydrogenase from Kluyveromyces polyspora(KpADH)
1L35	;	1.8	;	STRUCTURE OF A THERMOSTABLE DISULFIDE-BRIDGE MUTANT OF PHAGE T4 LYSOZYME SHOWS THAT AN ENGINEERED CROSSLINK IN A FLEXIBLE REGION DOES NOT INCREASE THE RIGIDITY OF THE FOLDED PROTEIN
1T4M	;	2.0	;	STRUCTURE OF A THERMOSTABLE DOUBLE MUTANT OF BACILLUS SUBTILIS LIPASE OBTAINED THROUGH DIRECTED EVOLUTION
4R9L	;	1.8	;	Structure of a thermostable elevenfold mutant of limonene epoxide hydrolase from Rhodococcus erythropolis, containing two stabilizing disulfide bonds
6AR5	;	2.413	;	Structure of a Thermostable Group II Intron Reverse Transcriptase with Template-Primer and Its Functional and Evolutionary Implications (Duplex Only)
6AR1	;	3.01	;	Structure of a Thermostable Group II Intron Reverse Transcriptase with Template-Primer and Its Functional and Evolutionary Implications (RT/Duplex (Nat))
6AR3	;	3.41	;	Structure of a Thermostable Group II Intron Reverse Transcriptase with Template-Primer and Its Functional and Evolutionary Implications (RT/Duplex (Se-Met))
1KEA	;	2.0	;	STRUCTURE OF A THERMOSTABLE THYMINE-DNA GLYCOSYLASE
1T2N	;	1.8	;	Structure of a thermostable triple mutant of Bacillus subtilis lipase obtained through directed evolution
1Q98	;	1.9	;	Structure of a Thiol Peroxidase from Haemophilus influenzae Rd
6VTJ	;	1.95	;	Structure of a thiolation-reductase di-domain from an archaeal non-ribosomal peptide synthetase
6VTZ	;	2.65	;	Structure of a thiolation-reductase di-domain from an archaeal non-ribosomal peptide synthetase
5J60	;	1.9	;	Structure of a thioredoxin reductase from Gloeobacter violaceus
1F37	;	2.3	;	STRUCTURE OF A THIOREDOXIN-LIKE [2FE-2S] FERREDOXIN FROM AQUIFEX AEOLICUS
6CIU	;	1.7	;	Structure of a Thr-rich interface in an Azami Green tetramer
5XWE	;	1.8	;	Structure of a three finger toxin from Ophiophagus hannah venom
3SAE	;	1.96	;	Structure of a three-domain sesquiterpene synthase: a prospective target for advanced biofuels production
3SDQ	;	2.14	;	Structure of a three-domain sesquiterpene synthase: a prospective target for advanced biofuels production
3SDR	;	1.86	;	Structure of a three-domain sesquiterpene synthase: a prospective target for advanced biofuels production
3SDT	;	1.89	;	Structure of a three-domain sesquiterpene synthase: a prospective target for advanced biofuels production
3SDU	;	1.89	;	Structure of a three-domain sesquiterpene synthase: a prospective target for advanced biofuels production
3SDV	;	2.2	;	Structure of a three-domain sesquiterpene synthase: a prospective target for advanced biofuels production
2HMF	;	2.7	;	Structure of a Threonine Sensitive Aspartokinase from Methanococcus jannaschii Complexed with Mg-ADP and Aspartate
1UX6	;	1.9	;	Structure of a thrombospondin C-terminal fragment reveals a novel calcium core in the type 3 repeats
2UUY	;	1.15	;	Structure of a tick tryptase inhibitor in complex with bovine trypsin
3Q8X	;	2.7	;	Structure of a toxin-antitoxin system bound to its substrate
5VNZ	;	3.41	;	Structure of a TRAF6-Ubc13~Ub complex
5VO0	;	3.9	;	Structure of a TRAF6-Ubc13~Ub complex
7LY6	;	2.73	;	Structure of a trans-acting NRPS oxidase, BmdC, involved in bacillamide biosynthesis
6W8N	;	3.2	;	Structure of a trans-membrane protein
3M16	;	2.79	;	Structure of a Transaldolase from Oleispira antarctica
3J17	;	4.1	;	Structure of a transcribing cypovirus by cryo-electron microscopy
7B0Y	;	3.6	;	Structure of a transcribing RNA polymerase II-U1 snRNP complex
1QLN	;	2.4	;	STRUCTURE OF A TRANSCRIBING T7 RNA POLYMERASE INITIATION COMPLEX
5GNJ	;	2.7	;	Structure of a transcription factor and DNA complex
7VP1	;	2.902	;	Structure of a transcription factor and DNA complex
7VP2	;	1.92	;	Structure of a transcription factor and DNA complex
7VP3	;	3.003	;	Structure of a transcription factor and DNA complex
7VP4	;	3.04	;	Structure of a transcription factor and DNA complex
7VP5	;	2.992	;	Structure of a transcription factor and DNA complex
7VP6	;	2.57	;	Structure of a transcription factor and DNA complex
7VP7	;	2.653	;	Structure of a transcription factor and DNA complex
1XMA	;	2.301	;	Structure of a transcriptional regulator from Clostridium thermocellum Cth-833
5IT2	;	1.7	;	Structure of a transglutaminase 2-specific autoantibody 693-10-B06 Fab fragment
4ZD3	;	2.4	;	Structure of a transglutaminase 2-specific autoantibody Fab fragment
3CR3	;	2.1	;	Structure of a transient complex between Dha-kinase subunits DhaM and DhaL from Lactococcus lactis
1DC7	;		;	STRUCTURE OF A TRANSIENTLY PHOSPHORYLATED ""SWITCH"" IN BACTERIAL SIGNAL TRANSDUCTION
1DC8	;		;	STRUCTURE OF A TRANSIENTLY PHOSPHORYLATED ""SWITCH"" IN BACTERIAL SIGNAL TRANSDUCTION
3TRE	;	2.899	;	Structure of a translation elongation factor P (efp) from Coxiella burnetii
4L0J	;	1.85	;	Structure of a translocation signal domain mediating conjugative transfer by type IV secretion systems
1ORP	;	2.2	;	Structure of a Trapped Endonuclease III-DNA Covalent Intermediate: Estranged-Adenine Complex
1ORN	;	1.7	;	Structure of a Trapped Endonuclease III-DNA Covalent Intermediate: Estranged-Guanine Complex
4D2D	;	2.522	;	Structure of a tri peptide bound POT family peptide transporter
4AV5	;	1.4	;	Structure of a triclinic crystal of the FimH lectin domain in complex with a propynyl biphenyl alpha-D-mannoside, at 1.4 A resolution
5EIK	;	2.3	;	Structure of a Trimeric Intracellular Cation channel from C. elegans in the absence of Ca2+
5EGI	;	3.3	;	Structure of a Trimeric Intracellular Cation channel from C. elegans with bound Ca2+
4UZV	;	3.4	;	Structure of a triple mutant of ASV-TfTrHb
4ATV	;	3.5	;	STRUCTURE OF A TRIPLE MUTANT OF THE NHAA DIMER, CRYSTALLISED AT LOW PH
5LUL	;	1.9	;	Structure of a triple variant of cutinase 2 from Thermobifida cellulosilytica
7CWK	;	1.539	;	Structure of a triple-helix region of human collagen type I
8K4W	;	1.5	;	Structure of a triple-helix region of human collagen type I from Trautec
6JEC	;	2.049	;	Structure of a triple-helix region of human collagen type II
6JKL	;	2.148	;	Structure of a triple-helix region of human collagen type II
6A0A	;	1.502	;	Structure of a triple-helix region of human collagen type III
6A0C	;	1.501	;	Structure of a triple-helix region of human collagen type III
7WWR	;	1.3	;	Structure of a triple-helix region of human collagen type III from Trautec
7WWS	;	1.3	;	Structure of a triple-helix region of human collagen type III from Trautec
7XAN	;	1.5	;	Structure of a triple-helix region of human collagen type III from Trautec
7Y37	;	1.45	;	Structure of a triple-helix region of human collagen type V
7F01	;	1.63	;	Structure of a triple-helix region of human collagen type XVII
8K4X	;	1.45	;	Structure of a triple-helix region of human Collagen type XVII from Trautec
8K4Y	;	1.5	;	Structure of a triple-helix region of human ReCol 3 from Trautec
6R4O	;	4.2	;	Structure of a truncated adenylyl cyclase bound to MANT-GTP, forskolin and an activated stimulatory Galphas protein
3ZYL	;	1.7	;	Structure of a truncated CALM (PICALM) ANTH domain
3T4A	;	3.4	;	Structure of a truncated form of Staphylococcal Complement Inhibitor B bound to human C3c at 3.4 Angstrom resolution
3E9C	;	2.0	;	Structure of a tryptic core fragment of TIGAR from Danio rerio
3CEP	;	2.1	;	Structure of a tryptophan synthase quinonoid intermediate
1TLG	;	2.2	;	STRUCTURE OF A TUNICATE C-TYPE LECTIN COMPLEXED WITH D-GALACTOSE
5VR1	;		;	Structure of a Turripeptide from Unedogemmula bisaya venom
5VZJ	;	3.3	;	STRUCTURE OF A TWELVE COMPONENT MPP6-NUCLEAR RNA EXOSOME COMPLEX BOUND TO RNA
2Z43	;	1.93	;	Structure of a twinned crystal of RadA
3RG2	;	3.1	;	Structure of a two-domain NRPS fusion protein containing the EntE adenylation domain and EntB aryl-carrier protein from enterobactin biosynthesis
2KOW	;		;	Structure of a two-G-tetrad basket-type intramolecular G-quadruplex formed by Giardia telomeric repeat d(TAGGG)4 in K+ solution (with G18-to-INO substitution)
2KF8	;		;	Structure of a two-G-tetrad basket-type intramolecular G-quadruplex formed by human telomeric repeats in K+ solution
2KF7	;		;	Structure of a two-G-tetrad basket-type intramolecular G-quadruplex formed by human telomeric repeats in K+ solution (with G7-to-BRG substitution)
1W4R	;	1.83	;	Structure of a type II thymidine kinase with bound dTTP
6SCE	;	1.83	;	Structure of a Type III CRISPR defence DNA nuclease activated by cyclic oligoadenylate
3EAA	;	2.794	;	Structure of a type six secretion system protein
4KT3	;	1.4362	;	Structure of a type VI secretion system effector-immunity complex from Pseudomonas protegens
4TQ5	;	3.2023	;	Structure of a UbiA homolog from Archaeoglobus fulgidus
4TQ6	;	3.0678	;	Structure of a UbiA homolog from Archaeoglobus fulgidus bound to Cd2+
4TQ4	;	2.5025	;	Structure of a UbiA homolog from Archaeoglobus fulgidus bound to DMAPP and Mg2+
4TQ3	;	2.4076	;	Structure of a UbiA homolog from Archaeoglobus fulgidus bound to GPP and Mg2+
5IA8	;	2.0	;	Structure of a Ubiquitin like protein with an E1 fragment
3VTF	;	2.0	;	Structure of a UDP-glucose dehydrogenase from the hyperthermophilic archaeon Pyrobaculum islandicum
6OE6	;	1.7	;	Structure of a Uncharacterized protein from Leptospira interrogans serogroup Icterohaemorrhagiae serovar Copenhageni (strain Fiocruz L1-130)
5BN3	;	2.0	;	Structure of a unique ATP synthase NeqA-NeqB in complex with ADP from Nanoarcheaum equitans
5BN4	;	2.699	;	Structure of a unique ATP synthase NeqA-NeqB in complex with ANP from Nanoarcheaum equitans
5BO5	;	2.808	;	Structure of a unique ATP synthase subunit NeqB from Nanoarcheaum equitans
3TR7	;	2.1958	;	Structure of a uracil-DNA glycosylase (ung) from Coxiella burnetii
2GWF	;	2.3	;	Structure of a USP8-NRDP1 complex
4XSQ	;	1.79	;	Structure of a variable lymphocyte receptor-like protein Bf66946 from Branchiostoma floridae
4LMO	;	2.37	;	Structure of a vertebrate RNA binding domain of telomerase (TRBD)
2M6J	;		;	Structure of a vertebrate toxin from the badge huntsman spider
4E1F	;	2.1	;	Structure of a VgrG Vibrio cholerae toxin ACD domain Glu16Gln mutant in complex with ADP and Mn++
4E1C	;	2.25	;	Structure of a VgrG Vibrio cholerae toxin ACD domain in complex with ADP and Mg++
4E1D	;	2.49	;	Structure of a VgrG Vibrio cholerae toxin ACD domain in complex with ADP and Mn++
4DTF	;	2.12	;	Structure of a VgrG Vibrio cholerae toxin ACD domain in complex with AMP-PNP and Mg++
4DTH	;	1.78	;	Structure of a VgrG Vibrio cholerae toxin ACD domain in complex with ATP and Mg++
4DTL	;	2.39	;	Structure of a VgrG Vibrio cholerae toxin ACD domain in complex with ATP and Mn++
8GBE	;	1.46	;	Structure of a viral gasdermin protein A47 from Eptesipox virus
4XT3	;	3.801	;	Structure of a viral GPCR bound to human chemokine CX3CL1
3PSE	;	2.3	;	Structure of a viral OTU domain protease bound to interferon-stimulated gene 15 (ISG15)
3PT2	;	2.5	;	Structure of a viral OTU domain protease bound to Ubiquitin
1QRQ	;	2.8	;	STRUCTURE OF A VOLTAGE-DEPENDENT K+ CHANNEL BETA SUBUNIT
6FNW	;	1.8	;	Structure of a volume-regulated anion channel of the LRRC8 family
2F6M	;	2.1	;	Structure of a Vps23-C:Vps28-N subcomplex
1RIE	;	1.5	;	STRUCTURE OF A WATER SOLUBLE FRAGMENT OF THE RIESKE IRON-SULFUR PROTEIN OF THE BOVINE HEART MITOCHONDRIAL CYTOCHROME BC1-COMPLEX
4QTQ	;	2.0	;	Structure of a Xanthomonas Type IV Secretion System related protein
8CZE	;	2.58	;	Structure of a Xenopus Nucleosome with Widom 601 DNA
3S4Z	;	7.8	;	Structure of a Y DNA-FANCI complex
3CXU	;	2.0	;	Structure of a Y149F mutant of epoxide hydrolase from Solanum tuberosum
8BIP	;	3.1	;	Structure of a yeast 80S ribosome-bound N-Acetyltransferase B complex
8BJQ	;	3.8	;	Structure of a yeast 80S ribosome-bound N-Acetyltransferase B complex
6ZCE	;	5.3	;	Structure of a yeast ABCE1-bound 43S pre-initiation complex
6ZU9	;	6.2	;	Structure of a yeast ABCE1-bound 48S initiation complex
6UPH	;	2.7	;	Structure of a Yeast Centromeric Nucleosome at 2.7 Angstrom resolution
6GYK	;	5.1	;	Structure of a yeast closed complex (core CC1)
6GYM	;	6.7	;	Structure of a yeast closed complex with distorted DNA (CCdist)
6GYL	;	4.8	;	Structure of a yeast closed complex with distorted DNA (core CCdist)
1RM1	;	2.5	;	Structure of a Yeast TFIIA/TBP/TATA-box DNA Complex
4F3Q	;	2.15	;	Structure of a YebC family protein (CBU_1566) from Coxiella burnetii
1DN8	;	1.5	;	STRUCTURE OF A Z-DNA WITH TWO DIFFERENT BACKBONE CHAIN CONFORMATIONS. STABILIZATION OF THE DECADEOXYOLIGONUCLEOTIDE D(CGTACGTACG) BY (CO(NH3)6)3+ BINDING TO THE GUANINE
1BMC	;	2.5	;	STRUCTURE OF A ZINC METALLO-BETA-LACTAMASE FROM BACILLUS CEREUS
6KSN	;	2.15	;	Structure of a Zn-bound camelid single domain antibody
6ZQ0	;	1.54	;	Structure of a-l-AraAZI-Bound MgGH51 a-L-Arabinofuranosidase Crystal Type 1
6ZPZ	;	1.71	;	Structure of a-l-AraCS-Bound MgGH51 a-L-Arabinofuranosidase Crystal Type 1
3MJC	;	1.48	;	Structure of A-type Ketoreductases from Modular Polyketide Synthase
3MJE	;	1.36	;	Structure of A-type Ketoreductases from Modular Polyketide Synthase
3MJS	;	1.4	;	Structure of A-type Ketoreductases from Modular Polyketide Synthase
3MJT	;	1.6	;	Structure of A-type Ketoreductases from Modular Polyketide Synthase
3MJV	;	1.46	;	Structure of A-type Ketoreductases from Modular Polyketide Synthase
3GZK	;	1.8	;	Structure of A. Acidocaldarius Cellulase CelA
3H2W	;	2.66	;	Structure of A. acidocaldarius cellulase CelA in complex with cellobiose
3H3K	;	2.1	;	Structure of A. acidocaldarius cellulase CelA in complex with cellotetraose
2GSZ	;	4.2	;	Structure of A. aeolicus PilT with 6 monomers per asymmetric unit
5OOK	;	2.1	;	Structure of A. marina Phycocyanin contains overlapping isoforms
6TIB	;	1.07	;	Structure of A. niger Fdc I327S variant in complex with 2 naphthoic acid
6TIC	;	1.281	;	Structure of A. niger Fdc I327S variant in complex with benzothiophene 2 carboxylic acid
6TIE	;	1.06	;	Structure of A. niger Fdc I327S variant in complex with indol-2-carboxylic acid
7NF4	;	1.69	;	Structure of A. niger Fdc T395M R435P P438W variant (AnFdcII) in complex with prFMN
7NF3	;	1.1	;	Structure of A. niger Fdc T395M variant (AnFdcI) in complex with prFMN
6TIH	;	1.021	;	Structure of A. niger Fdc WT in complex with benzothiophene 2 carboxylic acid
6TIL	;	1.42	;	Structure of A. niger Fdc WT in complex with FMN and 2 naphthoic acid
6TIO	;	1.54	;	Structure of A. niger Fdc Wt in complex with FMN and benzothiophene 2 carboxylic acid
6TIN	;	1.28	;	Structure of A. niger Fdc WT in complex with FMN and indole 2 carboxylic acid
6TIJ	;	1.12	;	Structure of A. niger Fdc WT in complex with indol-2-carboxylic acid
4ZAA	;	1.242	;	Structure of A. niger Fdc1 in complex with 4-vinyl guaiacol
4ZA9	;	1.01	;	Structure of A. niger fdc1 in complex with a phenylpyruvate derived adduct to the prenylated flavin cofactor
4ZAB	;	1.16	;	Structure of A. niger Fdc1 in complex with alpha-fluoro cinnamic acid
4ZA7	;	1.1	;	Structure of A. niger Fdc1 in complex with alpha-methyl cinnamic acid
4ZA5	;	1.1	;	Structure of A. niger Fdc1 with the prenylated-flavin cofactor in the iminium and ketimine forms.
4ZA4	;	1.22	;	Structure of A. niger Fdc1 with the prenylated-flavin cofactor in the iminium form.
2PYW	;	1.9	;	Structure of A. thaliana 5-methylthioribose kinase in complex with ADP and MTR
8DQ6	;	1.56	;	Structure of A. thaliana MIF/D-DT-like protein-1 (MDL1)
8AP3	;	1.4	;	Structure of A. thaliana MIF/D-DT-like protein-2 (MDL2)
8DQA	;	2.0	;	Structure of A. thaliana MIF/D-DT-like protein-3 (MDL3)
5N9Q	;		;	Structure of A. thaliana RCD1(468-567)
6UEP	;	2.05	;	Structure of A. thaliana TBP bound to a DNA site with a C-C mismatch
6UEO	;	2.0	;	Structure of A. thaliana TBP-AC mismatch DNA site
4KWM	;	2.7	;	Structure of a/anhui/5/2005 h5 ha
4KW1	;	2.5	;	Structure of a/egypt/n03072/2010 h5 ha
4KTH	;	2.6	;	Structure of A/Hubei/1/2010 H5 HA
4DIF	;	1.521	;	Structure of A1-type ketoreductase
2RK3	;	1.05	;	Structure of A104T DJ-1
3B38	;	1.85	;	Structure of A104V DJ-1
7CMA	;	2.01	;	Structure of A151R from African swine fever virus Georgia
5YOJ	;	1.5	;	Structure of A17 HIV-1 Protease in Complex with Inhibitor KNI-1657
5LRX	;	2.85	;	Structure of A20 OTU domain bound to ubiquitin
8PWN	;	2.4	;	Structure of A2A adenosine receptor A2AR-StaR2-bRIL, solved at wavelength 2.75 A
8HDP	;	3.2	;	Structure of A2BR bound to endogenous agonists adenosine
8HDO	;	2.87	;	Structure of A2BR bound to synthetic agonists BAY 60-6583
6FT5	;	1.94	;	Structure of A3_A3, an artificial bi-domain protein based on two identical alphaRep A3 domains
6FSQ	;	2.79	;	Structure of A3_bGFPD, an artificial bi-domain protein based on two different alphaRep domains : A3 and a GFP binding domain (bGFPD)
6HWP	;	2.547	;	Structure of A3_bGFPD, an artificial bi-domain protein based on two different alphaRep domains : A3 and a GFP binding domain (bGFPD)
4D5S	;	3.0	;	Structure of A49 from Vaccinia Virus Western Reserve
8OH7	;		;	Structure of A4M4C bound to (KR)4 Solution backbone structure refined by PCS
6BR8	;	2.3	;	Structure of A6 reveals a novel lipid transporter
6BR9	;	2.2	;	Structure of A6 reveals a novel lipid transporter
1QSF	;	2.8	;	STRUCTURE OF A6-TCR BOUND TO HLA-A2 COMPLEXED WITH ALTERED HTLV-1 TAX PEPTIDE Y8A
1V0C	;	2.2	;	Structure of AAC(6')-Ib in complex with Kanamycin C and AcetylCoA.
2VQY	;	1.8	;	Structure of AAC(6')-Ib in complex with Parmomycin and AcetylCoA.
2BUE	;	1.7	;	Structure of AAC(6')-Ib in complex with Ribostamycin and Coenzyme A.
2VBQ	;	2.0	;	Structure of AAC(6')-Iy in complex with bisubstrate analog CoA-S- monomethyl-acetylneamine.
3RX8	;	2.56	;	structure of AaCel9A in complex with cellobiose-like isofagomine
3RX7	;	2.02	;	Structure of AaCel9A in complex with cellotetraose-like isofagomine
3RX5	;	1.99	;	structure of AaCel9A in complex with cellotriose-like isofagomine
7TWD	;	2.11	;	Structure of AAGAB C-terminal dimerization domain
5MQ7	;	5.2	;	Structure of AaLS-13
5MQ3	;	5.4	;	Structure of AaLS-neg
5MPP	;	3.9	;	Structure of AaLS-wt
8DEO	;	2.3	;	Structure of AAP A domain and B-repeats (residues 351-813) from Staphylococcus epidermidis
7SIE	;	1.3	;	Structure of AAP A-domain (residues 351-605) from Staphylococcus epidermidis
3J1Q	;	4.5	;	Structure of AAV-DJ, a Retargeted Gene Therapy Vector: Cryo-Electron Microscopy at 4.5A resolution
2OGW	;	1.83	;	Structure of ABC type zinc transporter from E. coli
7OTI	;	4.2	;	Structure of ABCB1/P-glycoprotein in apo state
7OTG	;	5.4	;	Structure of ABCB1/P-glycoprotein in the presence of the CFTR potentiator ivacaftor
6VXH	;	4.0	;	Structure of ABCG2 bound to imatinib
6VXI	;	3.7	;	Structure of ABCG2 bound to mitoxantrone
6VXJ	;	4.1	;	Structure of ABCG2 bound to SN38
5ZJT	;	2.4	;	Structure of AbdB/Exd complex bound to a 'Black14' DNA sequence
5ZJS	;	2.896	;	Structure of AbdB/Exd complex bound to a 'Blue14' DNA sequence
5ZJR	;	3.03	;	Structure of AbdB/Exd complex bound to a 'Magenta14' DNA sequence
5ZJQ	;	2.443	;	Structure of AbdB/Exd complex bound to a 'Red14' DNA sequence
3K5V	;	1.74	;	Structure of Abl kinase in complex with imatinib and GNF-2
5HP6	;	2.093	;	Structure of AbnA, a GH43 extracellular arabinanase from Geobacillus stearothermophilus (a new conformational state)
8H2X	;	2.69	;	Structure of Acb2
8J8O	;	2.24	;	Structure of Acb2 complexed with 2',3'-cGAMP
8IXZ	;	2.33	;	Structure of Acb2 complexed with 3',2'-cGAMP
8H2J	;	2.4	;	Structure of Acb2 complexed with 3',3'-cGAMP
8IY2	;	2.76	;	Structure of Acb2 complexed with 3',3'-cGAMP and cAAA
8H39	;	2.01	;	Structure of Acb2 complexed with c-di-AMP
8IY0	;	2.26	;	Structure of Acb2 complexed with cAAA
8IY1	;	2.1	;	Structure of Acb2 complexed with cAAG
7AC7	;	3.08	;	Structure of accomodated trans-translation complex on E. Coli stalled ribosome.
2N30	;		;	Structure of Ace-pvhct-NH2
2H12	;	1.85	;	Structure of Acetobacter aceti citrate synthase complexed with oxaloacetate and carboxymethyldethia coenzyme A (CMX)
4YCJ	;	1.845	;	Structure of Acetobacter aceti PurE Y154F
4Z7J	;	1.502	;	Structure of Acetobacter aceti PurE-S57A
5BOS	;	1.712	;	Structure of Acetobacter aceti PurE-S57C, partly oxidized form
5BOR	;	2.0	;	Structure of Acetobacter aceti PurE-S57C, sulfonate form
4ZK2	;	2.749	;	Structure of Acetobacter aceti PurE-S57D
4ZJY	;	1.791	;	Structure of Acetobacter aceti PurE-S57N
4ZC8	;	1.754	;	Structure of Acetobacter aceti PurE-S57T
4ZMB	;	1.808	;	Structure of Acetobacter aceti PurE-S57V,Y154F
5M45	;	1.87	;	Structure of Acetone Carboxylase purified from Xanthobacter autotrophicus
6ISV	;	2.5	;	Structure of acetophenone reductase from Geotrichum candidum NBRC 4597 in complex with NAD
7N7Z	;	2.02	;	Structure of Acetyl-CoA acetyltransferase from Syntrophomonas wolfei
3S2X	;	2.35	;	Structure of acetyl-Coenzyme A synthase Alpha subunit C-terminal domain
5GOL	;	2.11	;	Structure of acetyl-Coenzyme A synthase Alpha subunit C-terminal domain F598H mutant
5H6W	;	2.2	;	Structure of acetyl-Coenzyme A synthase Alpha subunit C-terminal domain F598H mutant
8DVX	;	1.5	;	Structure of acetylated Pig somatic Cytochrome c (Aly39) at 1.5A
1OED	;	4.0	;	STRUCTURE OF ACETYLCHOLINE RECEPTOR PORE FROM ELECTRON IMAGES
1H22	;	2.15	;	Structure of acetylcholinesterase (E.C. 3.1.1.7) complexed with (S,S)-(-)-bis(10)-hupyridone at 2.15A resolution
1H23	;	2.15	;	Structure of acetylcholinesterase (E.C. 3.1.1.7) complexed with (S,S)-(-)-bis(12)-hupyridone at 2.15A resolution
1ODC	;	2.2	;	STRUCTURE OF ACETYLCHOLINESTERASE (E.C. 3.1.1.7) COMPLEXED WITH N-4'-QUINOLYL-N'-9""-(1"",2"",3"",4""-TETRAHYDROACRIDINYL)-1,8- DIAMINOOCTANE AT 2.2A RESOLUTION
1UT6	;	2.4	;	Structure of acetylcholinesterase (E.C. 3.1.1.7) complexed with N-9-(1',2',3',4'-Tetrahydroacridinyl)-1,8- diaminooctane at 2.4 angstroms resolution.
1GPK	;	2.1	;	Structure of Acetylcholinesterase Complex with (+)-Huperzine A at 2.1A Resolution
1DX6	;	2.3	;	STRUCTURE OF ACETYLCHOLINESTERASE COMPLEXED WITH (-)-GALANTHAMINE AT 2.3A RESOLUTION
1E66	;	2.1	;	STRUCTURE OF ACETYLCHOLINESTERASE COMPLEXED WITH (-)-HUPRINE X AT 2.1A RESOLUTION
1GPN	;	2.35	;	STRUCTURE OF ACETYLCHOLINESTERASE COMPLEXED WITH HUPERZINE B AT 2.35A RESOLUTION
2F7V	;	1.75	;	Structure of acetylcitrulline deacetylase complexed with one Co
2F8H	;	1.75	;	Structure of acetylcitrulline deacetylase from Xanthomonas campestris in metal-free form
3FFE	;	2.25	;	Structure of Achromobactin Synthetase Protein D, (AcsD)
2NT1	;	2.3	;	Structure of acid-beta-glucosidase at neutral pH
6MOZ	;	2.1	;	Structure of acid-beta-glucosidase in complex with an aromatic pyrrolidine iminosugar inhibitor
2NSX	;	2.11	;	Structure of acid-beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease
4NTW	;	2.07	;	Structure of acid-sensing ion channel in complex with snake toxin
4NTX	;	2.27	;	Structure of acid-sensing ion channel in complex with snake toxin and amiloride
8D2L	;	2.21	;	Structure of Acidothermus cellulolyticus Cas9 ternary complex (Cleavage Intermediate 1)
8D2K	;	2.43	;	Structure of Acidothermus cellulolyticus Cas9 ternary complex (Cleavage Intermediate 2)
8D2Q	;	2.58	;	Structure of Acidothermus cellulolyticus Cas9 ternary complex (Post-cleavage 1)
8D2O	;	2.66	;	Structure of Acidothermus cellulolyticus Cas9 ternary complex (Post-cleavage 2)
8D2N	;	2.88	;	Structure of Acidothermus cellulolyticus Cas9 ternary complex (Pre-cleavage)
8D2P	;	2.78	;	Structure of Acidothermus cellulolyticus Cas9 ternary complex (Target bound)
6WAM	;	2.6	;	Structure of Acinetobacter baumannii Cap4 SAVED/CARF-domain containing receptor
6VM6	;	2.1	;	Structure of Acinetobacter baumannii Cap4 SAVED/CARF-domain containing receptor with the cyclic trinucleotide 2'3'3'-cAAA
6WAN	;	2.4	;	Structure of Acinetobacter baumannii Cap4 SAVED/CARF-domain containing receptor with the cyclic trinucleotide 3'3'3'-cAAA
5WI3	;	1.81	;	Structure of Acinetobacter baumannii carbapenemase OXA-239 K82D bound to cefotaxime
5WI7	;	1.861	;	Structure of Acinetobacter baumannii carbapenemase OXA-239 K82D bound to doripenem
5WIB	;	1.87	;	Structure of Acinetobacter baumannii carbapenemase OXA-239 K82D bound to imipenem
6EU4	;	1.794	;	Structure of Acinetobacter phage vb_AbaP_AS12 gp42 tailspike
8JER	;	3.45	;	Structure of Acipimox-GPR109A-G protein complex
7KP6	;	1.79	;	Structure of Ack1 kinase in complex with a selective inhibitor
7RMP	;	2.7	;	Structure of ACLY D1026A - substrates-asym
7RKZ	;	2.6	;	Structure of ACLY D1026A-substrates-asym-int
6POE	;	3.5	;	Structure of ACLY in complex with CoA
6UUZ	;	3.0	;	Structure of ACLY in the presence of citrate and CoA
8G1F	;	2.4	;	Structure of ACLY-D1026A-products
8G5D	;	2.5	;	Structure of ACLY-D1026A-products, local refinement of ASH domain
8G1E	;	2.8	;	Structure of ACLY-D1026A-products-asym
7RIG	;	2.2	;	Structure of ACLY-D1026A-substrates
8G5C	;	2.2	;	Structure of ACLY-D1026A-substrates, local refinement of ASH domain
6FLY	;	2.749	;	Structure of AcmJRL, a mannose binding jacalin related lectin from Ananas comosus, in complex with mannose.
6FLZ	;	1.895	;	Structure of AcmJRL, a mannose binding jacalin related lectin from Ananas comosus, in complex with methyl-mannose.
6FLW	;	1.8	;	Structure of AcmJRL, a mannose binding jacalin related lectin from Ananas comosus.
6XB3	;	1.9	;	Structure of AcNPV poxin in post-reactive state with Gp[2'-5']Ap[3']
7FI4	;	3.03	;	Structure of AcrIF13
7FIA	;	2.13	;	Structure of AcrIF23
6UX5	;		;	Structure of acrorhagin I from the sea anemone Actinia equina
5XZD	;	1.9	;	Structure of acryloyl-CoA hydratase AcuH from Roseovarius nubinhibens ISM
5GXD	;	2.001	;	Structure of acryloyl-CoA lyase PrpE from Dinoroseobacter shibae DFL 12
4RWT	;	2.98	;	Structure of actin-Lmod complex
4HIV	;	2.6	;	Structure of actinomycin D d(ATGCGGCAT) complex
1W4Z	;	2.5	;	Structure of actinorhodin polyketide (actIII) Reductase
5ACN	;	2.1	;	STRUCTURE OF ACTIVATED ACONITASE. FORMATION OF THE (4FE-4S) CLUSTER IN THE CRYSTAL
6ACN	;	2.5	;	STRUCTURE OF ACTIVATED ACONITASE. FORMATION OF THE (4FE-4S) CLUSTER IN THE CRYSTAL
1O6K	;	1.7	;	Structure of activated form of PKB kinase domain S474D with GSK3 peptide and AMP-PNP
2G83	;	2.8	;	Structure of activated G-alpha-i1 bound to a nucleotide-state-selective peptide: Minimal determinants for recognizing the active form of a G protein alpha subunit
3ZXW	;	2.1	;	STRUCTURE OF ACTIVATED RUBISCO FROM THERMOSYNECHOCOCCUS ELONGATUS COMPLEXED WITH 2-CARBOXYARABINITOL-1,5-DIPHOSPHATE
8TL0	;	3.1	;	Structure of activated SAVED-CHAT filament
6GMH	;	3.1	;	Structure of activated transcription complex Pol II-DSIF-PAF-SPT6
4JQI	;	2.6	;	Structure of active beta-arrestin1 bound to a G protein-coupled receptor phosphopeptide
1GIA	;	2.0	;	STRUCTURE OF ACTIVE CONFORMATIONS OF GIA1 AND THE MECHANISM OF GTP HYDROLYSIS
1GIL	;	2.3	;	STRUCTURE OF ACTIVE CONFORMATIONS OF GIA1 AND THE MECHANISM OF GTP HYDROLYSIS
5OHX	;	3.2	;	Structure of active cystathionine B-synthase from Apis mellifera
6SWY	;	3.2	;	Structure of active GID E3 ubiquitin ligase complex minus Gid2 and delta Gid9 RING domain
4MQS	;	3.5	;	Structure of active human M2 muscarinic acetylcholine receptor bound to the agonist iperoxo
4MQT	;	3.7	;	Structure of active human M2 muscarinic acetylcholine receptor bound to the agonist iperoxo and allosteric modulator LY2119620
3F7T	;	1.8	;	Structure of active IspH shows a novel fold with a [3Fe-4S] cluster in the catalytic centre
7T6F	;	3.6	;	Structure of active Janus Kinase (JAK) dimer complexed with cytokine receptor intracellular domain
7OL0	;	3.0	;	Structure of active transcription elongation complex Pol II-DSIF (SPT5-KOW5)
7OKX	;	3.3	;	Structure of active transcription elongation complex Pol II-DSIF (SPT5-KOW5)-ELL2-EAF1 (composite structure)
7OKY	;	4.14	;	Structure of active transcription elongation complex Pol II-DSIF-ELL2-EAF1(composite structure)
3BBA	;	3.2	;	Structure of active wild-type Prevotella intermedia interpain A cysteine protease
7WQW	;	3.2	;	Structure of Active-EP
4XEE	;	2.9	;	Structure of active-like neurotensin receptor
4XES	;	2.6	;	Structure of active-like neurotensin receptor
7WQZ	;	3.7	;	Structure of Active-mutEP
1DSS	;	1.88	;	STRUCTURE OF ACTIVE-SITE CARBOXYMETHYLATED D-GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE FROM PALINURUS VERSICOLOR
6PYM	;	1.20002	;	Structure of active-site serine mutant of ESP, serine protease from Staphylococcus epidermidis
7OLY	;	3.265	;	Structure of activin A in complex with an ActRIIB-Alk4 fusion reveal insight into activin receptor interactions
2FHS	;	2.7	;	Structure of Acyl Carrier Protein Bound to FabI, the Enoyl Reductase from Escherichia Coli
8H6S	;	3.0	;	Structure of acyltransferase VinK in complex with the loading acyl carrier protein of vicenistatin PKS
2B7T	;		;	Structure of ADAR2 dsRBM1
2B7V	;		;	Structure of ADAR2 dsRBM2
7FH5	;	2.0	;	Structure of AdaV
7V52	;	2.38	;	Structure of AdaV
7V54	;	2.12	;	Structure of AdaV
7V56	;	2.27	;	Structure of AdaV
7V57	;	2.35	;	Structure of AdaV
4QD4	;	1.8	;	Structure of ADC-68, a Novel Carbapenem-Hydrolyzing Class C Extended-Spectrum -Lactamase from Acinetobacter baumannii
4U0X	;	2.03	;	Structure of ADC-7 beta-lactamase in complex with boronic acid inhibitor S02030
3U4Q	;	2.8	;	Structure of AddAB-DNA complex at 2.8 angstroms
1AQI	;	2.6	;	STRUCTURE OF ADENINE-N6-DNA-METHYLTRANSFERASE TAQI
1AQJ	;	2.6	;	STRUCTURE OF ADENINE-N6-DNA-METHYLTRANSFERASE TAQI
2QA0	;	2.6	;	Structure of Adeno-Associated virus serotype 8
7WJW	;	3.87	;	Structure of Adeno-associated virus serotype 9
7WQO	;	2.85	;	Structure of Adeno-associated virus serotype PHP.eB
5IPI	;	3.8	;	Structure of Adeno-associated virus type 2 VLP
3J1S	;	8.5	;	Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20
4BWV	;	1.8	;	Structure of Adenosine 5-prime-phosphosulfate Reductase apr-b from Physcomitrella Patens
5CB6	;	2.79	;	Structure of adenosine-5'-phosphosulfate kinase
6F6O	;	1.49	;	Structure of Adenovirus 3 fiber head V239D mutant
2C95	;	1.71	;	Structure of adenylate kinase 1 in complex with P1,P4-di(adenosine) tetraphosphate
2BWJ	;	2.3	;	Structure of adenylate kinase 5
7APU	;	1.36	;	Structure of Adenylate kinase from Escherichia coli in complex with two ADP molecules refined at 1.36 A resolution.
2HVQ	;	2.4	;	Structure of Adenylated full-length T4 RNA Ligase 2
7WEW	;	2.3	;	Structure of adenylation domain of epsilon-poly-L-lysine synthase
3UQ8	;	1.7	;	Structure of adenylation domain of Haemophilus influenzae DNA ligases bound to NAD+ in adenylated state.
5N9W	;	2.456	;	Structure of adenylation domain THR1 involved in the biosynthesis of 4-chlorothreonine in Streptomyces SP.OH-5093, apo structure
5N9X	;	2.396	;	Structure of adenylation domain THR1 involved in the biosynthesis of 4-chlorothreonine in Streptomyces SP.OH-5093, ligand bound structure
1ADI	;	2.5	;	STRUCTURE OF ADENYLOSUCCINATE SYNTHETASE AT PH 6.5 AND 25 DEGREES CELSIUS
1CH8	;	2.5	;	STRUCTURE OF ADENYLOSUCCINATE SYNTHETASE FROM E. COLI COMPLEXED WITH A STRINGENT EFFECTOR, PPG2':3'P
1CIB	;	2.3	;	STRUCTURE OF ADENYLOSUCCINATE SYNTHETASE FROM E. COLI COMPLEXED WITH GDP, IMP, HADACIDIN, AND NO3
1CG0	;	2.5	;	STRUCTURE OF ADENYLOSUCCINATE SYNTHETASE FROM E. COLI COMPLEXED WITH HADACIDIN, GDP, 6-PHOSPHORYL-IMP, AND MG2+
1ADE	;	2.0	;	STRUCTURE OF ADENYLOSUCCINATE SYNTHETASE PH 7 AT 25 DEGREES CELSIUS
8BUZ	;	3.5	;	Structure of Adenylyl cyclase 8 bound to stimulatory G-protein, Ca2+/Calmodulin, Forskolin and MANT-GTP
7PDG	;	4.3	;	structure of adenylyl cyclase 9 in complex with DARPin C4 and ATP-aS
7PDH	;	4.0	;	structure of adenylyl cyclase 9 in complex with DARPin C4 and ATP-aS
7PD8	;	4.2	;	Structure of Adenylyl cyclase 9 in complex with DARPin C4 and MANT-GTP
7PDE	;	4.5	;	Structure of Adenylyl cyclase 9 in complex with Gs protein alpha subunit and MANT-GTP
7PD4	;	4.9	;	structure of Adenylyl cyclase 9 in complex with MANT-GTP
6YC7	;	1.8	;	Structure of adenylylated C. glutamicum GlnK
1JNR	;	1.6	;	Structure of adenylylsulfate reductase from the hyperthermophilic Archaeoglobus fulgidus at 1.6 resolution
1JNZ	;	2.5	;	Structure of adenylylsulfate reductase from the hyperthermophilic Archaeoglobus fulgidus at 1.6 resolution
3JV7	;	2.0	;	Structure of ADH-A from Rhodococcus ruber
6SCG	;	1.65	;	Structure of AdhE form 1
6SCI	;	1.95	;	Structure of AdhE form 1
3OB6	;	3.0	;	Structure of AdiC(N101A) in the open-to-out Arg+ bound conformation
8UYI	;	3.13	;	Structure of ADP-bound and phosphorylated Pediculus humanus (Ph) PINK1 dimer
2WQN	;	2.3	;	Structure of ADP-bound human Nek7
3J95	;	7.6	;	Structure of ADP-bound N-ethylmaleimide sensitive factor determined by single particle cryoelectron microscopy
1ZM2	;	3.07	;	Structure of ADP-ribosylated eEF2 in complex with catalytic fragment of ETA
7Z7I	;	3.5	;	Structure of ADP-ribosylated F-actin
1E1N	;	2.4	;	Structure of adrenodoxin reductase at 2.4 Angstrom in crystal form A'
1E1L	;	2.3	;	STRUCTURE OF ADRENODOXIN REDUCTASE IN COMPLEX WITH NADP obtained by cocrystallisation
1CJC	;	1.7	;	STRUCTURE OF ADRENODOXIN REDUCTASE OF MITOCHONDRIAL P450 SYSTEMS
8JNI	;	3.2	;	Structure of AE2 in complex with PIP2
6OG0	;	1.85	;	Structure of Aedes aegypti OBP22
6OPB	;	2.0	;	Structure of Aedes aegypti OBP22 in the complex with arachidic acid
6NBN	;		;	Structure of Aedes aegypti OBP22 in the complex with arachidonic acid
6OII	;	1.85	;	Structure of Aedes aegypti OBP22 in the complex with arachidonic acid
6OTL	;	2.59	;	Structure of Aedes aegypti OBP22 in the complex with benzaldehyde
6P2E	;	1.9	;	Structure of Aedes aegypti OBP22 in the complex with benzaldehyde
6OGH	;	1.85	;	Structure of Aedes aegypti OBP22 in the complex with linoleic acid
6OMW	;	2.1	;	Structure of Aedes aegypti OBP22 in the complex with palmitoleic acid
6LH8	;	1.729	;	Structure of aerolysin-like protein (Bombina maxima)
6LHZ	;	2.52	;	Structure of aerolysin-like protein (Bombina maxima)
4KRX	;	1.8	;	Structure of Aes from E. coli
4KRY	;	2.3	;	Structure of Aes from E. coli in covalent complex with PMS
1XZ9	;		;	Structure of AF-6 PDZ domain
4Q7C	;	3.102	;	Structure of AF2299, a CDP-alcohol phosphotransferase
4O6N	;	2.1	;	Structure of AF2299, a CDP-alcohol phosphotransferase (CDP-bound)
4O6M	;	1.901	;	Structure of AF2299, a CDP-alcohol phosphotransferase (CMP-bound)
3ZC0	;	2.982	;	Structure of AfC3PO - duplex RNA complex
6R80	;	2.2	;	Structure of AFF4 C-terminal homology domain
6Z0O	;	2.5974	;	Structure of Affimer-NP bound to Crimean-Congo Haemorrhagic Fever Virus Nucleocapsid Protein
8KGL	;	4.3	;	Structure of African swine fever virus topoisomerase II
8KGM	;	4.8	;	Structure of African swine fever virus topoisomerase II in complex with dsDNA
8KGN	;	5.9	;	Structure of African swine fever virus topoisomerase II in complex with dsDNA
8KGO	;	3.4	;	Structure of African swine fever virus topoisomerase II in complex with dsDNA
8KGP	;	3.3	;	Structure of African swine fever virus topoisomerase II in complex with dsDNA
8KGQ	;	5.6	;	Structure of African swine fever virus topoisomerase II in complex with dsDNA
8KGR	;	3.2	;	Structure of African swine fever virus topoisomerase II in complex with dsDNA
8KGS	;	2.603	;	Structure of African swine fever virus topoisomerase II in complex with dsDNA
8KGT	;	2.3	;	Structure of African swine fever virus topoisomerase II in complex with dsDNA
1K4A	;		;	STRUCTURE OF AGAA RNA TETRALOOP, NMR, 20 STRUCTURES
4FQT	;	2.2	;	Structure of AgamOBP1 Bound to 6-methyl-5-hepten-2-one
2CDO	;	1.64	;	structure of agarase carbohydrate binding module in complex with neoagarohexaose
7MTD	;	3.5	;	Structure of aged SARS-CoV-2 S2P spike at pH 7.4
5LJ7	;	3.25	;	Structure of Aggregatibacter actinomycetemcomitans MacB bound to ATP (P21)
5LIL	;	3.35	;	Structure of Aggregatibacter actinomycetemcomitans MacB bound to ATPyS (P21)
5LJ6	;	3.9	;	Structure of Aggregatibacter actinomycetemcomitans MacB bound to ATPyS (P6522)
4XYO	;	2.0	;	Structure of AgrA LytTR domain
4XXE	;	3.2	;	Structure of AgrA LytTR domain in complex with promoters
4XYQ	;	2.4	;	Structure of AgrA LytTR domain in complex with promoters
6HQH	;	1.8	;	Structure of Agrobacterium tumefaciens B6 strain PBP SocA complexed with Deoxyfructosylglutamine (DFG) at 1.8 A resolution
8FOY	;	2.9	;	Structure of Agrobacterium tumefaciens bacteriophage Milano contracted tail-sheath
8FOU	;	3.3	;	Structure of Agrobacterium tumefaciens bacteriophage Milano contracted tail-tube
8FOP	;	3.2	;	Structure of Agrobacterium tumefaciens bacteriophage Milano curved tail
5L9S	;	2.49	;	Structure of Agrobacterium tumefaciens C58 strain PBP AttC in open unliganded conformation
2CC3	;	2.2	;	Structure of Agrobacterium tumefaciens VirB8 protein
1K4B	;		;	STRUCTURE OF AGUU RNA TETRALOOP, NMR, 20 STRUCTURES
8PVE	;	3.3	;	Structure of AHIR determined by cryoEM at 100 keV
1KNC	;	2.0	;	Structure of AhpD from Mycobacterium tuberculosis, a novel enzyme with thioredoxin-like activity.
6M0U	;	2.29	;	Structure of AhSYMRK kinase domain mutant - K625E
4RD4	;	1.3	;	Structure of aIF2 gamma from sulfolobus solfataricus bound to gdpnp
4RD0	;	1.713	;	Structure of aIF2-gamma D19A variant from Sulfolobus solfataricus bound to GDP
4RCZ	;	1.429	;	Structure of aIF2-gamma D19A variant from Sulfolobus solfataricus bound to GDPNP
4RCY	;	1.65	;	Structure of aIF2-gamma D19A variant from Sulfolobus solfataricus bound to GTP
4RD6	;	1.944	;	Structure of aIF2-gamma from Sulfolobus solfataricus bound to GDP
4RD3	;	1.69	;	Structure of aIF2-gamma H97A variant from Sulfolobus solfataricus bound to GDP and Pi
4RD2	;	1.585	;	Structure of aIF2-gamma H97A variant from Sulfolobus solfataricus bound to GDPNP
4RD1	;	1.5	;	Structure of aIF2-gamma H97A variant from Sulfolobus solfataricus bound to GTP
7YYP	;	2.9	;	Structure of aIF5B from Pyrococcus abyssi complexed with GDP
4UE2	;	2.02	;	Structure of air-treated anaerobically purified D. fructosovorans NiFe-hydrogenase
8BBS	;	1.4	;	Structure of AKR1C3 in complex with a bile acid fused tetrazole inhibitor
2OON	;		;	Structure of Ala14-PYY in aqueous solution
1L6T	;		;	STRUCTURE OF ALA24/ASP61 TO ASP24/ASN61 SUBSTITUTED SUBUNIT C OF ESCHERICHIA COLI ATP SYNTHASE
4BHY	;	3.25	;	Structure of alanine racemase from Aeromonas hydrophila
5TXR	;	1.9	;	Structure of ALAS from S. cerevisiae non-covalently bound to PLP cofactor
8EIM	;	2.1	;	Structure of ALAS with C-terminal truncation from S. cerevisiae
1H0X	;	2.6	;	Structure of Alba: an archaeal chromatin protein modulated by acetylation
1H0Y	;	2.8	;	Structure of Alba: an archaeal chromatin protein modulated by acetylation
2AFN	;	2.0	;	STRUCTURE OF ALCALIGENES FAECALIS NITRITE REDUCTASE AND A COPPER SITE MUTANT, M150E, THAT CONTAINS ZINC
1AS7	;	2.0	;	STRUCTURE OF ALCALIGENES FAECALIS NITRITE REDUCTASE AT CRYO TEMPERATURE
1NTD	;	2.3	;	STRUCTURE OF ALCALIGENES FAECALIS NITRITE REDUCTASE MUTANT M150E THAT CONTAINS ZINC
1AQ8	;	2.0	;	STRUCTURE OF ALCALIGENES FAECALIS NITRITE REDUCTASE REDUCED WITH ASCORBATE
2VM3	;	1.8	;	Structure of Alcaligenes xylosoxidans in space group R3 - 1 of 2
2VM4	;	1.9	;	Structure of Alcaligenes xylosoxidans nitrite reductase in space group R3 - 2 of 2
7YMB	;	1.8	;	Structure of Alcohol dehydrogenase from Candida glabrata(CgADH)complexed with NADPH
3RJ5	;	1.45	;	Structure of alcohol dehydrogenase from Drosophila lebanonesis T114V mutant complexed with NAD+
3RJ9	;	1.98	;	Structure of alcohol dehydrogenase from Drosophila lebanonesis T114V mutant complexed with NAD+
5Z2X	;	1.98	;	Structure of Alcohol dehydrogenase from Kluyveromyces polyspora(KpADH)
7YMU	;	1.9	;	Structure of Alcohol dehydrogenase from [Candida] glabrata
7BU2	;	1.553	;	Structure of alcohol dehydrogenase YjgB from Escherichia coli
7BU3	;	2.0	;	Structure of alcohol dehydrogenase YjgB in complex with NADP from Escherichia coli
6D97	;	2.2	;	Structure of aldehyde dehydrogenase 12 (ALDH12) from Zea mays
4QF6	;	1.9	;	Structure of Aldehyde Dehydrogenase from Bacillus cereus, E194S mutant
4QET	;	2.6	;	Structure of Aldehyde Dehydrogenase from Bacillus cereus, G224D mutant
3H4G	;	1.85	;	Structure of aldehyde reductase holoenzyme in complex with potent aldose reductase inhibitor Fidarestat: Implications for inhibitor binding and selectivity
5L2M	;	1.7	;	Structure of ALDH1A1 in complex with BUC11
5L2N	;	1.7	;	Structure of ALDH1A1 in complex with BUC25
7RLU	;	2.9	;	Structure of ALDH1L1 (10-formyltetrahydrofolate dehydrogenase) in complex with NADP
5L13	;	2.4	;	Structure of ALDH2 in complex with 2P3
7MES	;	1.37	;	Structure of ALDH4A1 complexed with trans-4-Hydroxy-D-proline
7MER	;	1.74	;	Structure of ALDH4A1 complexed with trans-4-Hydroxy-L-proline
8OF1	;	1.81	;	Structure of ALDH5F1 from moss Physcomitrium patens in complex with NAD+ in the contracted conformation
6O4H	;	2.05	;	Structure of ALDH7A1 mutant A171V complexed with NAD
6O4I	;	1.75	;	Structure of ALDH7A1 mutant E399D complexed with alpha-aminoadipate
6O4L	;	1.85	;	Structure of ALDH7A1 mutant E399D complexed with NAD
6U2X	;	2.15	;	Structure of ALDH7A1 mutant E399G complexed with NAD
6O4K	;	2.06	;	Structure of ALDH7A1 mutant E399Q complexed with NAD
6O4F	;	1.9	;	Structure of ALDH7A1 mutant N167S complexed with alpha-aminoadipate
6O4E	;	1.75	;	Structure of ALDH7A1 mutant N167S complexed with NAD
6O4G	;	2.05	;	Structure of ALDH7A1 mutant P169S complexed with alpha-aminoadipate
6V0Z	;	2.02	;	Structure of ALDH7A1 mutant R441C complexed with NAD
6O4D	;	1.88	;	Structure of ALDH7A1 mutant W175A complexed with L-pipecolic acid
6O4C	;	1.7	;	Structure of ALDH7A1 mutant W175A complexed with NAD
6O4B	;	1.85	;	Structure of ALDH7A1 mutant W175G complexed with NAD
6VWF	;	2.64	;	Structure of ALDH9A1 complexed with NAD+ in space group C222
6VR6	;	2.5	;	Structure of ALDH9A1 complexed with NAD+ in space group P1
8RB6	;	2.0	;	Structure of Aldo-Keto Reductase 1C3 (AKR1C3) in complex with an inhibitor M689, with the 3-hydroxy-benzoisoxazole moiety. Resolution 2.0A
3KRB	;	1.75	;	Structure of Aldose Reductase from Giardia Lamblia at 1.75A Resolution
4ZGX	;	3.2	;	Structure of aldosterone synthase (CYP11B2) in complex with (+)-(R)-N-(4-(4-chloro-3-fluorophenyl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide
6XZ9	;	2.77	;	Structure of aldosterone synthase (CYP11B2) in complex with 5-chloro-3,3-dimethyl-2-[5-[1-(1-methylpyrazole-4-carbonyl)azetidin-3-yl]oxy-3-pyridyl]isoindolin-1-one
6XZ8	;	3.0	;	Structure of aldosterone synthase (CYP11B2) in complex with N-[(1R)-1-[5-(6-chloro-1,1-dimethyl-3-oxo-isoindolin-2-yl)-3-pyridyl]ethyl]methanesulfonamide
3LRK	;	1.95	;	Structure of alfa-galactosidase (MEL1) from Saccharomyces cerevisiae
3LRL	;	2.4	;	Structure of alfa-galactosidase (MEL1) from Saccharomyces cerevisiae with melibiose
3LRM	;	2.7	;	Structure of alfa-galactosidase from Saccharomyces cerevisiae with raffinose
5GQQ	;	2.2	;	Structure of ALG-2/HEBP2 Complex
3RBH	;	2.301	;	Structure of alginate export protein AlgE from Pseudomonas aeruginosa
6KCW	;	2.28	;	Structure of alginate lyase Aly36B
6KZK	;	2.789	;	Structure of alginate lyase Aly36B mutant K143A/M171A in complex with alginate trisaccharide
6KCV	;	2.282	;	Structure of alginate lyase Aly36B mutant K143A/Y185A in complex with alginate tetrasaccharide
7C8G	;	2.1	;	Structure of alginate lyase AlyC3
7C8F	;	1.461	;	Structure of alginate lyase AlyC3 in complex with dimannuronate(2M)
8PZ4	;	1.77	;	Structure of alginate transporter, AlgE, solved at wavelength 2.755 A
5H6U	;	2.006	;	Structure of alginate-binding protein AlgQ2 in complex with an alginate pentasaccharide
5H71	;	1.549	;	Structure of alginate-binding protein AlgQ2 in complex with an alginate trisaccharide
1Y3Q	;	1.9	;	Structure of AlgQ1, alginate-binding protein
1Y3N	;	1.6	;	Structure of AlgQ1, alginate-binding protein, complexed with an alginate disaccharide
1Y3P	;	2.0	;	Structure of AlgQ1, alginate-binding protein, complexed with an alginate tetrasaccharide
2OEW	;	2.55	;	Structure of ALIX/AIP1 Bro1 Domain
2OEX	;	2.58	;	Structure of ALIX/AIP1 V Domain
3HMM	;	1.7	;	Structure of Alk5 + GW855857
4Y7P	;	2.1	;	Structure of alkaline D-peptidase from Bacillus cereus
1ZEF	;	1.9	;	structure of alkaline phosphatase from human placenta in complex with its uncompetitive inhibitor L-Phe
2IUC	;	1.95	;	Structure of alkaline phosphatase from the Antarctic bacterium TAB5
1BSL	;	1.95	;	STRUCTURE OF ALKANAL MONOOXYGENASE BETA CHAIN
1SG3	;	2.6	;	Structure of allantoicase
3J7I	;	8.9	;	Structure of alpha- and beta- tubulin in GMPCPP-microtubules
4CHA	;	1.68	;	STRUCTURE OF ALPHA-*CHYMOTRYPSIN REFINED AT 1.68 ANGSTROMS RESOLUTION
3JAE	;	3.9	;	Structure of alpha-1 glycine receptor by single particle electron cryo-microscopy, glycine-bound state
3JAF	;	3.8	;	Structure of alpha-1 glycine receptor by single particle electron cryo-microscopy, glycine/ivermectin-bound state
3JAD	;	3.9	;	Structure of alpha-1 glycine receptor by single particle electron cryo-microscopy, strychnine-bound state
2PLH	;	2.5	;	STRUCTURE OF ALPHA-1-PUROTHIONIN AT ROOM TEMPERATURE AND 2.8 ANGSTROMS RESOLUTION
1VJS	;	1.7	;	STRUCTURE OF ALPHA-AMYLASE PRECURSOR
6ZFM	;	1.9	;	Structure of alpha-Cobratoxin with a peptide inhibitor
4LFT	;	1.7	;	Structure of alpha-elapitoxin-Dpp2d isolated from Black Mamba (Dendroaspis polylepis) venom
2XN2	;	1.58	;	Structure of alpha-galactosidase from Lactobacillus acidophilus NCFM with galactose
2XN1	;	2.3	;	Structure of alpha-galactosidase from Lactobacillus acidophilus NCFM with TRIS
2XN0	;	2.5	;	Structure of alpha-galactosidase from Lactobacillus acidophilus NCFM, PtCl4 derivative
5VCJ	;	3.16	;	Structure of alpha-galactosylphytosphingosine bound by CD1d and in complex with the Va14Vb8.2 TCR
6CW9	;	2.0	;	Structure of alpha-GC[8,16P] bound by CD1d and in complex with the Va14Vb8.2 TCR
6CW6	;	2.85	;	Structure of alpha-GC[8,18] bound by CD1d and in complex with the Va14Vb8.2 TCR
2RGH	;	2.3	;	Structure of Alpha-Glycerophosphate Oxidase from Streptococcus sp.: A Template for the Mitochondrial Alpha-Glycerophosphate Dehydrogenase
2RGO	;	2.4	;	Structure of Alpha-Glycerophosphate Oxidase from Streptococcus sp.: A Template for the Mitochondrial Alpha-Glycerophosphate Dehydrogenase
6CX7	;	2.6	;	Structure of alpha-GSA[12,6P] bound by CD1d and in complex with the Va14Vb8.2 TCR
6CX9	;	2.36	;	Structure of alpha-GSA[16,6P] bound by CD1d and in complex with the Va14Vb8.2 TCR
6CXA	;	2.65	;	Structure of alpha-GSA[20,6P] bound by CD1d and in complex with the Va14Vb8.2 TCR
6CXE	;	2.05	;	Structure of alpha-GSA[26,6P] bound by CD1d and in complex with the Va14Vb8.2 TCR
6CXF	;	2.5	;	Structure of alpha-GSA[26,P5p] bound by CD1d and in complex with the Va14Vb8.2 TCR
6CWB	;	2.85	;	Structure of alpha-GSA[8,4P] bound by CD1d and in complex with the Va14Vb8.2 TCR
6CWE	;	2.2	;	Structure of alpha-GSA[8,6P] bound by CD1d and in complex with the Va14Vb8.2 TCR
6CX5	;	2.4	;	Structure of alpha-GSA[8,8P] bound by CD1d and in complex with the Va14Vb8.2 TCR
8I0A	;	2.01	;	Structure of alpha-L-Arabinofuranosidase from Trametes hirsuta
6I60	;	2.743	;	Structure of alpha-L-rhamnosidase from Dictyoglumus thermophilum
6H6B	;	3.4	;	Structure of alpha-synuclein fibrils
8FPT	;		;	STRUCTURE OF ALPHA-SYNUCLEIN FIBRILS DERIVED FROM HUMAN LEWY BODY DEMENTIA TISSUE
4BXL	;		;	Structure of alpha-synuclein in complex with an engineered binding protein
8V2I	;	2.9	;	Structure of alpha1B and betaI/IVb microtubule bound to GMPCPP
7CEC	;	3.9	;	Structure of alpha6beta1 integrin in complex with laminin-511
7P2D	;	3.2	;	Structure of alphaMbeta2/Cd11bCD18 headpiece in complex with a nanobody
7OG6	;	3.3	;	Structure of Alternanthera Mosaic VLP by cryoEM
6BTM	;	3.4	;	Structure of Alternative Complex III from Flavobacterium johnsoniae (Wild Type)
2OTK	;		;	Structure of Alzheimer Ab peptide in complex with an engineered binding protein
3QAC	;	2.275	;	Structure of amaranth 11S proglobulin seed storage protein from Amaranthus hypochondriacus L.
8U4P	;	3.15	;	Structure of AMD3100-bound CXCR4/Gi complex
7ZNP	;	2.15	;	Structure of AmedSP
7WA3	;	2.28	;	Structure of American mink ACE2
7L0J	;	2.6	;	Structure of AMH bound to AMHR2-ECD
8C0J	;	3.381	;	Structure of AmiB enzymatic domain bound to the EnvC LytM domain
6SQ8	;	2.59	;	Structure of amide bond synthetase McbA from Marinactinospora thermotolerans
6H1B	;	2.8	;	Structure of amide bond synthetase Mcba K483A mutant from Marinactinospora thermotolerans
6IAQ	;	1.91	;	Structure of Amine Dehydrogenase from Mycobacterium smegmatis
6GIO	;	1.87	;	Structure of Amino Acid Amide Racemase from Ochrobactrum anthropi
8J1C	;	2.2	;	Structure of amino acid dehydrogenase in complex with NADP
8J1G	;	2.5	;	Structure of amino acid dehydrogenase in complex with NADPH
8HYE	;	2.2	;	Structure of amino acid dehydrogenase-2752 with ligand
8HYH	;	2.39	;	Structure of amino acid dehydrogenase3448
5WYF	;	2.12	;	Structure of amino acid racemase, 2.12 A
5WYA	;	2.65	;	Structure of amino acid racemase, 2.65 A
4YSV	;	2.77	;	Structure of aminoacid racemase in apo-form
4YSN	;	1.94	;	Structure of aminoacid racemase in complex with PLP
2J6L	;	1.3	;	Structure of aminoadipate-semialdehyde dehydrogenase
2BYD	;	2.0	;	Structure of aminoadipate-semialdehyde dehydrogenase- phosphopantetheinyl transferase
2C43	;	1.93	;	STRUCTURE OF AMINOADIPATE-SEMIALDEHYDE DEHYDROGENASE- PHOSPHOPANTETHEINYL TRANSFERASE IN COMPLEX WITH COENZYME A
2CG5	;	2.7	;	Structure of aminoadipate-semialdehyde dehydrogenase- phosphopantetheinyl transferase in complex with cytosolic acyl carrier protein and coenzyme A
4I9B	;	1.9	;	Structure of aminoaldehyde dehydrogenase 1 from Solanum lycopersium (SlAMADH1) with a thiohemiacetal intermediate
7QU9	;	2.14	;	Structure of aminodeoxychorismate synthase component 1 (PabB) from Bacillus subtilis spizizenii.
1UA1	;	2.0	;	Structure of aminofluorene adduct paired opposite cytosine at the polymerase active site.
6FUC	;	1.17	;	Structure of aminoglycoside phosphotransferase APH(3'')-Id from Streptomyces rimosus ATCC10970
6FUX	;	1.65	;	Structure of aminoglycoside phosphotransferase APH(3'')-Id from Streptomyces rimosus ATCC10970 in complex with ADP and streptomycin
1XJO	;	1.75	;	STRUCTURE OF AMINOPEPTIDASE
2HPO	;	1.65	;	Structure of Aminopeptidase N from E. coli Suggests a Compartmentalized, Gated Active Site
1WL9	;	1.9	;	Structure of aminopeptidase P from E. coli
7VNO	;	1.8	;	Structure of aminotransferase
2O1B	;	1.95	;	Structure of aminotransferase from Staphylococcus aureus
4JXU	;	2.4	;	Structure of aminotransferase ilvE2 from Sinorhizobium meliloti complexed with PLP
7VNT	;	1.92	;	Structure of aminotransferase-substrate complex
7VO1	;	2.99	;	Structure of aminotransferase-substrate complex
6BLA	;	1.55	;	Structure of AMM01 Fab, an anti EBV gH/gL neutralizing antibody
8UYH	;	2.84	;	Structure of AMP-PNP-bound Pediculus humanus (Ph) PINK1 dimer
8SS8	;	2.81	;	Structure of AMPA receptor GluA2 complex with auxiliary subunit TARP gamma-5 bound to competitive antagonist ZK and antiepileptic drug perampanel (closed state)
8SS2	;	3.58	;	Structure of AMPA receptor GluA2 complex with auxiliary subunits TARP gamma-5 and cornichon-2 bound to competitive antagonist ZK and channel blocker spermidine (closed state)
8SS6	;	3.01	;	Structure of AMPA receptor GluA2 complex with auxiliary subunits TARP gamma-5 and cornichon-2 bound to competitive antagonist ZK, channel blocker spermidine and antiepileptic drug perampanel (closed state)
8SS7	;	2.76	;	Structure of AMPA receptor GluA2 complex with auxiliary subunits TARP gamma-5 and cornichon-2 bound to competitive antagonist ZK, channel blocker spermidine and antiepileptic drug perampanel (closed state)
8SSA	;	3.88	;	Structure of AMPA receptor GluA2 complex with auxiliary subunits TARP gamma-5 and cornichon-2 bound to glutamate and channel blocker spermidine (desensitized state)
5VOT	;	4.9	;	Structure of AMPA receptor-TARP complex
5VOU	;	6.4	;	Structure of AMPA receptor-TARP complex
5VOV	;	7.7	;	Structure of AMPA receptor-TARP complex
2P9V	;	1.8	;	Structure of AmpC beta-lactamase with cross-linked active site after exposure to small molecule inhibitor
4XUX	;	1.75	;	Structure of ampC bound to RPX-7009 at 1.75 A
7TI1	;	2.0	;	Structure of AmpC bound to RPX-7063 at 2.0A
5XPW	;	2.003	;	Structure of amphioxus IgVJ-C2 molecule
5UFU	;	3.45	;	Structure of AMPK bound to activator
6E4T	;	3.4	;	Structure of AMPK bound to activator
6E4U	;	3.27	;	Structure of AMPK bound to activator
6E4W	;	3.35	;	Structure of AMPK bound to activator
4QFS	;	3.55	;	Structure of AMPK in complex with Br2-A769662core activator and STAUROSPORINE inhibitor
4QFR	;	3.34	;	Structure of AMPK in complex with Cl-A769662 activator and STAUROSPORINE inhibitor
4QFG	;	3.46	;	Structure of AMPK in complex with STAUROSPORINE inhibitor and in the absence of a synthetic activator
2HCB	;	3.51	;	Structure of AMPPCP-bound DnaA from Aquifex aeolicus
6KNY	;	2.1	;	Structure of Amuc_1100 without transmembrane region from Akkermansia muciniphila
2MXX	;		;	Structure of Amylase binding Protein A of Streptococcous gordonii: a potential receptor for human salivary amylase enzyme
5E5V	;	1.24	;	Structure of amyloid forming peptide NFGAILS (residues 22-28) from Islet Amyloid Polypeptide
2LLM	;		;	Structure of amyloid precursor protein's transmembrane domain
5TXD	;	1.452	;	Structure of amyloid-beta derived peptide - NKGAIF
5E61	;	1.79	;	Structure of amyloid-forming peptide FGAILSS (residues 23-29) from islet amyloid polypeptide
3DVF	;	1.8	;	Structure of amyloidogenic kappa 1 Bence Jones protein
1FP9	;	3.1	;	STRUCTURE OF AMYLOMALTASE FROM THERMUS THERMOPHILUS HB8 IN SPACE GROUP C2
1EXL	;		;	STRUCTURE OF AN 11-MER DNA DUPLEX CONTAINING THE CARBOCYCLIC NUCLEOTIDE ANALOG: 2'-DEOXYARISTEROMYCIN
8F1T	;	12.1	;	Structure of an 18mer DegP cage bound to the client protein hTRF1
8F20	;	2.23	;	Structure of an A-tract B-DNA Dodecamer: 5'-CGCAAAAAAGCG-3
5IJU	;	1.7	;	Structure of an AA10 Lytic Polysaccharide Monooxygenase from Bacillus amyloliquefaciens with Cu(II) bound
7ZE9	;	2.646	;	Structure of an AA16 LPMO-like protein
1OU8	;	1.6	;	structure of an AAA+ protease delivery protein in complex with a peptide degradation tag
5NJ3	;	3.78	;	Structure of an ABC transporter: complete structure
5NJG	;	3.78	;	Structure of an ABC transporter: part of the structure that could be built de novo
4ZJP	;	1.63	;	Structure of an ABC-Transporter Solute Binding Protein (SBP_IPR025997) from Actinobacillus Succinogenes (Asuc_0197, TARGET EFI-511067) with bound beta-D-ribopyranose
5VFY	;	2.49	;	Structure of an accessory protein of the pCW3 relaxosome
5VFX	;	2.81	;	Structure of an accessory protein of the pCW3 relaxosome in complex with the origin of transfer (oriT) DNA
2R10	;	2.2	;	Structure of an acetylated Rsc4 tandem bromodomain Histone Chimera
6AVE	;	3.7	;	Structure of an acid sensing ion channel in a resting state at high pH
5WKU	;	2.95	;	Structure of an acid sensing ion channel in a resting state with barium
5WKV	;	3.2	;	Structure of an acid sensing ion channel in a resting state with calcium
2QTS	;	1.9	;	Structure of an acid-sensing ion channel 1 at 1.9 A resolution and low pH
6VTK	;	2.82	;	Structure of an acid-sensing ion channel solubilized by styrene maleic acid and in a desensitized state at low pH
6VTL	;	3.65	;	Structure of an acid-sensing ion channel solubilized by styrene maleic acid and in a resting state at high pH
1M8T	;	2.1	;	Structure of an acidic Phospholipase A2 from the venom of Ophiophagus hannah at 2.1 resolution from a hemihedrally twinned crystal form
7DTR	;	2.1	;	Structure of an AcrIF protein
1UUR	;	2.7	;	Structure of an activated Dictyostelium STAT in its DNA-unbound form
1UUS	;	2.8	;	Structure of an activated Dictyostelium STAT in its DNA-unbound form
4CFH	;	3.24	;	Structure of an active form of mammalian AMPK
4LJO	;	1.564	;	Structure of an active ligase (HOIP)/ubiquitin transfer complex
4LJP	;	2.15	;	Structure of an active ligase (HOIP-H889A)/ubiquitin transfer complex
2WAB	;	1.9	;	Structure of an active site mutant of a family two carbohydrate esterase from Clostridium thermocellum in complex with celluohexase
2X5K	;	2.37	;	Structure of an active site mutant of the D-Erythrose-4-Phosphate Dehydrogenase from E. coli
32C2	;	3.0	;	STRUCTURE OF AN ACTIVITY SUPPRESSING FAB FRAGMENT TO CYTOCHROME P450 AROMATASE
6OR3	;	1.45	;	Structure of an Acyl Intermediate of Thermomyces Lanuginosa Lipase With Palmitic Acid in an Orthorhombic Crystal
1GBT	;	2.0	;	STRUCTURE OF AN ACYL-ENZYME INTERMEDIATE DURING CATALYSIS: (GUANIDINOBENZOYL) TRYPSIN
3TRG	;	1.601	;	Structure of an acylphosphatase from Coxiella burnetii
3TRB	;	2.001	;	Structure of an addiction module antidote protein of a HigA (higA) family from Coxiella burnetii
4Y0V	;	1.8	;	Structure of an ADP ribosylation factor from Entamoeba histolytica HM-1:IMSS bound to Mg-GDP
4YLG	;	1.8	;	Structure of an ADP ribosylation factor from Entamoeba histolytica HM-1:IMSS bound to Mg-GDP
5T5W	;	2.847	;	Structure of an affinity matured lambda-IFN/IFN-lambdaR1/IL-10Rbeta receptor complex
4K65	;	2.9	;	Structure of an airborne transmissible avian influenza H5 hemagglutinin mutant from the influenza virus A/Indonesia/5/2005
4K66	;	3.005	;	Structure of an airborne transmissible avian influenza H5 hemagglutinin mutant from the influenza virus A/Indonesia/5/2005 complexed with avian receptor analog LSTa
4K67	;	2.7	;	Structure of an airborne transmissible avian influenza H5 hemagglutinin mutant from the influenza virus A/Indonesia/5/2005 complexed with human receptor analog LSTc
1GAB	;		;	STRUCTURE OF AN ALBUMIN-BINDING DOMAIN, NMR, 20 STRUCTURES
1PRB	;		;	STRUCTURE OF AN ALBUMIN-BINDING DOMAIN, NMR, MINIMIZED AVERAGE STRUCTURE
2KZE	;		;	Structure of an all-parallel-stranded G-quadruplex formed by hTERT promoter sequence
7MQQ	;	1.15	;	Structure of an allelic variant of Puccinia graminis f. sp. tritici (Pgt) effector AvrSr50 (QCMJC)
6KQI	;	3.245	;	Structure of an allosteric modulator bound to the CB1 cannabinoid receptor
8P5Q	;	2.14	;	Structure of an ALOG domain from Arabidopsis thaliana in complex with DNA
3VM7	;	2.25	;	Structure of an Alpha-Amylase from Malbranchea cinnamomea
3TRD	;	1.5	;	Structure of an alpha-beta serine hydrolase homologue from Coxiella burnetii
5UBJ	;	1.7	;	Structure of an alpha-L-arabinofuranosidase (GH62) from Aspergillus nidulans
8FB4	;	1.49	;	Structure of an alternating AT 16-mer bound by diamidine DB1476: 5'-GCTGGATATATCCAGC-3
8F94	;	1.08	;	Structure of an alternating AT 16-mer: 5'-GCTGGATATATCCAGC-3
8F2Y	;	1.78	;	Structure of an alternating AT dodecamer: 5'-CGCGATATCGCG-3
1DN9	;	2.2	;	STRUCTURE OF AN ALTERNATING-B DNA HELIX AND ITS RELATIONSHIP TO A-TRACT DNA
5WEC	;	1.563	;	Structure of an alternative pilotin from the type II secretion system of Vibrio cholerae
7ZNJ	;	2.4	;	Structure of an ALYREF-exon junction complex hexamer
2YB1	;	1.898	;	Structure of an amidohydrolase from Chromobacterium violaceum (EFI target EFI-500202) with bound Mn, AMP and phosphate.
2YB4	;	2.2	;	Structure of an amidohydrolase from Chromobacterium violaceum (EFI target EFI-500202) with bound SO4, no metal
3UWC	;	1.8	;	Structure of an aminotransferase (DegT-DnrJ-EryC1-StrS family) from Coxiella burnetii in complex with PMP
4XFN	;	1.85	;	Structure of an Amyloid forming peptide AEVVFT from Human Transthyretin
3PZZ	;	1.29	;	Structure of an amyloid forming peptide GAIIGL (29-34) from amyloid beta
3OVJ	;	1.8	;	Structure of an amyloid forming peptide KLVFFA from amyloid beta in complex with orange G
3OW9	;	1.8	;	Structure of an amyloid forming peptide KLVFFA from amyloid beta, alternate polymorph II
3Q2X	;	1.451	;	Structure of an amyloid forming peptide NKGAII (residues 27-32) from amyloid beta
3FTR	;	1.61	;	Structure of an amyloid forming peptide SSTNVG from IAPP (alternate polymorph)
2ON9	;	1.51	;	Structure of an amyloid forming peptide VQIVYK from the repeat region of Tau
4NP8	;	1.51	;	Structure of an amyloid forming peptide VQIVYK from the second repeat region of tau (alternate polymorph)
3OVL	;	1.81	;	Structure of an amyloid forming peptide VQIVYK from the TAU protein in complex with orange G
4XFO	;	1.35	;	Structure of an amyloid-forming segment TAVVTN from human Transthyretin
6Z1M	;	2.45	;	Structure of an Ancestral glycosidase (family 1) bound to heme
6OYU	;	2.95	;	Structure of an ancestral-reconstructed cytochrome P450 1B1 with alpha-naphthoflavone
6OYV	;	3.101	;	Structure of an ancestral-reconstructed cytochrome P450 1B1 with estradiol
8IDE	;	3.21	;	Structure of an ancient TsaD-TsaC-SUA5-TcdA modular enzyme (TsaN)
6XMB	;	2.31	;	Structure of an anophensin from Anopheles stephensi
7F45	;	3.52	;	Structure of an Anti-CRISPR protein
1BQL	;	2.6	;	STRUCTURE OF AN ANTI-HEL FAB FRAGMENT COMPLEXED WITH BOBWHITE QUAIL LYSOZYME
6QB9	;	1.85	;	Structure of an anti-Mcl1 scFv
6QF9	;	1.43	;	Structure of an anti-Mcl1 scFv
6QFC	;	1.96	;	Structure of an anti-Mcl1 scFv
3QXT	;	1.7	;	Structure of an Anti-Methotrexate CDR1-3 Graft VHH Antibody in Complex with Methotrexate
3QXV	;	2.5	;	Structure of an Anti-Methotrexate CDR1-4 Graft VHH Antibody in Complex with Methotrexate
2HH0	;	2.85	;	Structure of an Anti-PrP Fab, P-Clone, in Complex with its Cognate Bovine Peptide Epitope.
3P2E	;	1.68	;	Structure of an antibiotic related Methyltransferase
3P2I	;	2.4	;	Structure of an antibiotic related Methyltransferase
3P2K	;	2.7	;	Structure of an antibiotic related Methyltransferase
3PB3	;	1.9	;	Structure of an Antibiotic Related Methyltransferase
3HFM	;	3.0	;	STRUCTURE OF AN ANTIBODY-ANTIGEN COMPLEX. CRYSTAL STRUCTURE OF THE HY/HEL-10 FAB-LYSOZYME COMPLEX
2IFF	;	2.65	;	STRUCTURE OF AN ANTIBODY-LYSOZYME COMPLEX: EFFECT OF A CONSERVATIVE MUTATION
2MBJ	;		;	Structure of an antiparallel (2+2) G-quadruplex formed by human telomeric repeats in Na+ solution (with G22-to-BrG substitution)
2VOA	;	1.7	;	Structure of an AP Endonuclease from Archaeoglobus fulgidus
4YII	;	1.804	;	Structure of an APC2-UBCH10 complex reveals distinctive cullin-RING ligase mechanism for Anaphase-promoting complex/Cyclosome
6W8O	;	3.4	;	Structure of an Apo membrane protein
4X57	;	2.8	;	Structure of an Arabidopsis E2 / Membrane-anchored Ubiquitin-fold Protein Complex
6TMF	;	2.8	;	Structure of an archaeal ABCE1-bound ribosomal post-splitting complex
2YCE	;	1.93	;	Structure of an Archaeal fructose-1,6-bisphosphate aldolase with the catalytic Lys covalently bound to the carbinolamine intermediate of the substrate.
2QMU	;	3.2	;	Structure of an archaeal heterotrimeric initiation factor 2 reveals a nucleotide state between the GTP and the GDP states
2QN6	;	2.15	;	Structure of an archaeal heterotrimeric initiation factor 2 reveals a nucleotide state between the GTP and the GDP states
4Y7K	;	3.5	;	Structure of an archaeal mechanosensitive channel in closed state
4Y7J	;	4.1	;	Structure of an archaeal mechanosensitive channel in expanded state
2IZO	;	2.9	;	Structure of an Archaeal PCNA1-PCNA2-FEN1 Complex
1GO3	;	1.75	;	Structure of an archeal homolog of the eukaryotic RNA polymerase II RPB4/RPB7 complex
3HXM	;	3.1	;	Structure of an argonaute complexed with guide DNA and target RNA duplex containing two mismatches.
3GD1	;	3.5	;	Structure of an Arrestin/Clathrin complex reveals a novel clathrin binding domain that modulates receptor trafficking
6LMH	;	2.805	;	Structure of an ASFV-derived histone-like protein pA104R
5CD1	;	3.6	;	Structure of an asymmetric tetramer of human tRNA m1A58 methyltransferase in a complex with SAH and tRNA3Lys
4BND	;	1.5	;	Structure of an atypical alpha-phosphoglucomutase similar to eukaryotic phosphomannomutases
3T7Y	;	2.1	;	Structure of an autocleavage-inactive mutant of the cytoplasmic domain of CT091, the YscU homologue of Chlamydia trachomatis
2W59	;	1.75	;	STRUCTURE OF AN AVIAN IGY-FC 3-4 FRAGMENT
3D6R	;	1.997	;	Structure of an avian influenza A virus NS1 protein effector domain
7DEA	;	2.84	;	Structure of an avian influenza H5 hemagglutinin from the influenza virus A/duck Northern China/22/2017 (H5N6)
7DEB	;	2.6	;	Structure of an avian influenza H5 hemagglutinin from the influenza virus A/duck/Eastern China/L0230/2010 (H5N2)
7WL5	;	2.8	;	Structure of an avian influenza H5 hemagglutinin from the influenza virus A/Equine/Guangxi/25/2010(H5N1) and A/Equine/Guangxi/68/2010(H5N1)
4K62	;	2.502	;	Structure of an avian influenza H5 hemagglutinin from the influenza virus A/Indonesia/5/2005
4K63	;	3.1	;	Structure of an avian influenza H5 hemagglutinin from the influenza virus complexed with avian receptor analog LSTa
4K64	;	2.604	;	Structure of an avian influenza H5 hemagglutinin from the influenza virus complexed with human receptor analog LSTc
1U6Z	;	1.9	;	Structure of an E. coli Exopolyphosphatase: Insight into the processive hydrolysis of polyphosphate and its regulation
6QF6	;	2.59	;	Structure of an E.coli expressed anti-Mcl1 scFv
5L4O	;	2.799	;	Structure of an E.coli initiator tRNAfMet A1-U72 variant
7K5J	;	3.42	;	Structure of an E1-E2-ubiquitin thioester mimetic
4CCG	;	2.4	;	Structure of an E2-E3 complex
6FWL	;	1.12	;	Structure of an E333Q variant of the GH99 endo-alpha-mannanase from Bacteroides xylanisolvens in complex alpha-Glc-1,3-(1,2-anhydro-carba-mannose)
6FWQ	;	1.65	;	Structure of an E333Q variant of the GH99 endo-alpha-mannanase from Bacteroides xylanisolvens in complex with alpha-1,3-mannobiose and alpha-1,2-mannobiose
5MEL	;	1.2	;	Structure of an E333Q variant of the GH99 endo-alpha-mannanase from Bacteroides xylanisolvens in complex with Glc-alpha-1,3-(3R,4R,5R)-5-(hydroxymethyl)cyclohex-1,2-ene-3,4-diol
4V28	;	1.2	;	Structure of an E333Q variant of the GH99 endo-alpha-mannanase from Bacteroides xylanisolvens in complex with Man-Man-Methylumbelliferone
6FWG	;	1.07	;	Structure of an E333Q variant of the GH99 endo-alpha-mannanase from Bacteroides xylanisolvens in complex with tetramannoside yeast mannan fragment
6FWO	;	1.34	;	Structure of an E336Q variant of the GH99 endo-alpha-mannanase from Bacteroides xylanisolvens in complex with alpha-Glc-1,3-1,2-anhydro-mannose hydrolyzed by enzyme
1C4Z	;	2.6	;	STRUCTURE OF AN E6AP-UBCH7 COMPLEX: INSIGHTS INTO THE UBIQUITINATION PATHWAY
4KDT	;	2.6	;	Structure of an early native-like intermediate of beta2-microglobulin amyloidosis
2OWH	;	2.5	;	Structure of an early-microsecond photolyzed state of CO-bjFixLH
2OWJ	;	2.5	;	Structure of an early-microsecond photolyzed state of CO-bjFixLH, dark state
2Y6S	;	2.8	;	Structure of an Ebolavirus-protective antibody in complex with its mucin-domain linear epitope
1RSC	;	2.3	;	STRUCTURE OF AN EFFECTOR INDUCED INACTIVATED STATE OF RIBULOSE BISPHOSPHATE CARBOXYLASE(SLASH)OXYGENASE: THE BINARY COMPLEX BETWEEN ENZYME AND XYLULOSE BISPHOSPHATE
5K36	;	3.1	;	Structure of an eleven component nuclear RNA exosome complex bound to RNA
3RTY	;	2.85	;	Structure of an Enclosed Dimer Formed by The Drosophila Period Protein
6HA9	;	2.0	;	Structure of an endo-Xyloglucanase from Cellvibrio japonicus complexed with XXXG(2F)-beta-DNP
7JPT	;	3.2	;	Structure of an endocytic receptor
7JPU	;	5.0	;	Structure of an endocytic receptor
7ZNK	;	3.9	;	Structure of an endogenous human TREX complex bound to mRNA
3ZZJ	;	2.5	;	Structure of an engineered aspartate aminotransferase
3ZZK	;	1.78	;	Structure of an engineered aspartate aminotransferase
4A00	;	2.34	;	Structure of an engineered aspartate aminotransferase
5DII	;	1.804	;	Structure of an engineered bacterial microcompartment shell protein binding a [4Fe-4S] cluster
7AUD	;	2.96	;	Structure of an engineered helicase domain construct for human Bloom syndrome protein (BLM)
1DCA	;	2.2	;	STRUCTURE OF AN ENGINEERED METAL BINDING SITE IN HUMAN CARBONIC ANHYDRASE II REVEALS THE ARCHITECTURE OF A REGULATORY CYSTEINE SWITCH
1DCB	;	2.1	;	STRUCTURE OF AN ENGINEERED METAL BINDING SITE IN HUMAN CARBONIC ANHYDRASE II REVEALS THE ARCHITECTURE OF A REGULATORY CYSTEINE SWITCH
5A5C	;	2.097	;	Structure of an engineered neuronal LRRTM2 adhesion molecule
1QW7	;	1.9	;	Structure of an Engineered Organophosphorous Hydrolase with Increased Activity Toward Hydrolysis of Phosphothiolate Bonds
6CO2	;	2.49	;	Structure of an engineered protein (NUDT16TI) in complex with 53BP1 Tudor domains
2L8L	;		;	Structure of an engineered splicing intein mutant based on Mycobacterium tuberculosis RecA
3TQP	;	2.2	;	Structure of an enolase (eno) from Coxiella burnetii
6P5U	;	2.1	;	Structure of an enoyl-CoA hydratase/aldolase isolated from a lignin-degrading consortium
2O6I	;	2.55	;	Structure of an Enterococcus Faecalis HD Domain Phosphohydrolase
3IRH	;	2.4	;	Structure of an Enterococcus Faecalis HD-domain protein complexed with dGTP and dATP
4LRL	;	2.35	;	Structure of an Enterococcus Faecalis HD-domain protein complexed with dGTP and dTTP
6IX4	;	1.511	;	Structure of an epoxide hydrolase from Aspergillus usamii E001 (AuEH2) at 1.51 Angstroms resolution
7ZTA	;	2.7	;	Structure of an Escherichia coli 70S ribosome stalled by Tetracenomycin X during translation of an MAAAPQK(C) peptide
2BON	;	1.9	;	Structure of an Escherichia coli lipid kinase (YegS)
3I6Y	;	1.75	;	Structure of an esterase from the oil-degrading bacterium Oleispira antarctica
6H6X	;	2.25	;	Structure of an evolved dimeric form of the UbiD-class enzyme HmfF from Pelotomaculum thermopropionicum in complex with prFMN
1T0Z	;	2.6	;	Structure of an Excitatory Insect-specific Toxin with an Analgesic Effect on Mammalian from Scorpion Buthus martensii Karsch
2OG4	;	2.0	;	Structure of an expanded Jab1-MPN-like domain of splicing factor Prp8p from yeast
3D30	;	1.9	;	Structure of an expansin like protein from Bacillus Subtilis at 1.9A resolution
7JQE	;	2.4	;	Structure of an extracellular fragment of EsaA from Streptococcus gallolyticus
2D2M	;	2.85	;	Structure of an extracellular giant hemoglobin of the gutless beard worm Oligobrachia mashikoi
2D2N	;	3.2	;	Structure of an extracellular giant hemoglobin of the gutless beard worm Oligobrachia mashikoi
2IYL	;	2.1	;	Structure of an FtsY:GDP complex
6HKT	;	9.7	;	Structure of an H1-bound 6-nucleosome array
4Y9S	;	2.0	;	structure of an H300N mutant of potato epoxide hydrolase, StEH1
3RU8	;	2.07	;	Structure of an HIV epitope scaffold in complex with neutralizing antibody b12 Fab
6NDS	;	1.65	;	Structure of an HMG-CoA lyase from Acenitobacter baumannii in complex with coenzyme A and 3-methylmalate
7KD3	;	2.3	;	Structure of an HxlR/DUF24 family transcription regulator, CdTR_3200 from hypervirulent Clostridioides difficile R20291
8OFC	;		;	Structure of an i-motif domain with the cytosine analog 1,3-diaza-2-oxophenoxacione (tC) at neutral pH
2Z8V	;	2.35	;	Structure of an IgNAR-AMA1 complex
2Z8W	;	2.45	;	Structure of an IgNAR-AMA1 complex
5JUG	;	0.96	;	Structure of an inactive (E45Q) variant of a beta-1,4-mannanase, SsGH134, in complex with Man5
6ZFN	;	1.1	;	Structure of an inactive E404Q variant of the catalytic domain of human endo-alpha-mannosidase MANEA in complex with 1-methyl alpha-1,2-mannobiose
6ZJ1	;	1.957	;	Structure of an inactive E404Q variant of the catalytic domain of human endo-alpha-mannosidase MANEA in complex with tetrasaccharide N-glycan fragment and hexatungstotellurate(VI) TEW
3OJG	;	1.6	;	Structure of an inactive lactonase from Geobacillus kaustophilus with bound N-butyryl-DL-homoserine lactone
2VRQ	;	2.0	;	STRUCTURE OF AN INACTIVE MUTANT OF ARABINOFURANOSIDASE FROM THERMOBACILLUS XYLANILYTICUS IN COMPLEX WITH A PENTASACCHARIDE
3BXM	;	1.71	;	Structure of an inactive mutant of human glutamate carboxypeptidase II [GCPII(E424A)] in complex with N-acetyl-Asp-Glu (NAAG)
6Q4Z	;	1.55	;	Structure of an inactive variant (D94N) of MPT-2, a GDP-Man-dependent mannosyltransferase from Leishmania mexicana, in complex with beta-1,2-mannobiose
1QXQ	;		;	STRUCTURE OF AN INDOLICIDIN PEPTIDE DERIVATIVE WITH HIGHER CHARGE
1HR1	;		;	Structure of an indolicidin peptide derivative with P-->A substitution
6WKO	;	2.401	;	Structure of an influenza C virus hemagglutinin-esterase-fusion (HEF2) intermediate
7PWD	;	2.6	;	Structure of an inhibited GRK2-G-beta and G-gamma complex
1FIV	;	2.0	;	STRUCTURE OF AN INHIBITOR COMPLEX OF PROTEINASE FROM FELINE IMMUNODEFICIENCY VIRUS
6FFC	;	3.56	;	Structure of an inhibitor-bound ABC transporter
4BBS	;	3.6	;	Structure of an initially transcribing RNA polymerase II-TFIIB complex
6V8Q	;	2.69958	;	Structure of an inner membrane protein required for PhoPQ regulated increases in outer membrane cardiolipin
3TR4	;	2.0	;	Structure of an inorganic pyrophosphatase (ppa) from Coxiella burnetii
1XNQ	;	3.05	;	Structure of an Inosine-Adenine Wobble Base Pair Complex in the Context of the Decoding Center
7NP7	;	4.03	;	Structure of an intact ESX-5 inner membrane complex, Composite C1 model
7NPR	;	3.82	;	Structure of an intact ESX-5 inner membrane complex, Composite C3 model
4QUV	;	2.743	;	Structure of an integral membrane delta(14)-sterol reductase
7U6P	;	2.35	;	Structure of an intellectual disability-associated ornithine decarboxylase variant G84R
7U6U	;	1.85	;	Structure of an intellectual disability-associated ornithine decarboxylase variant G84R in complex with PLP
6KVB	;		;	Structure of an intra-locked G-quadruplex
2KM3	;		;	Structure of an intramolecular G-quadruplex containing a G.C.G.C tetrad formed by human telomeric variant CTAGGG repeats
8B28	;	1.75	;	Structure of an intron-retention variant of the plant immune signalling protein EDS1 from Vitis vinifera
3TXY	;	1.7	;	Structure of an Isochorismatase family protein (BTH_II2229) from Burkholderia thailandensis
7WW2	;	2.7	;	Structure of an Isocytosine specific deaminase Vcz
8IS4	;	1.9	;	Structure of an Isocytosine specific deaminase Vcz in complexed with 5-FU
8IS5	;	2.1	;	Structure of an Isocytosine specific deaminase Vcz with close state
6JYV	;	1.651	;	Structure of an isopenicillin N synthase from Pseudomonas aeruginosa PAO1
7PYL	;	1.7	;	Structure of an LPMO (expressed in E.coli) at 1.49x10^4 Gy
7PYU	;	1.4	;	Structure of an LPMO (expressed in E.coli) at 1.49x10^4 Gy
7PYP	;	1.6	;	Structure of an LPMO (expressed in E.coli) at 2.13x10^6 Gy
7PYN	;	1.4	;	Structure of an LPMO (expressed in E.coli) at 2.31x10^5 Gy
7PYO	;	1.4	;	Structure of an LPMO (expressed in E.coli) at 2.31x10^5 Gy
7PYM	;	1.75	;	Structure of an LPMO (expressed in E.coli) at 5.61x10^4 Gy
7PYQ	;	1.6	;	Structure of an LPMO (expressed in E.coli) at 6.35x10^6 Gy
7PZ7	;	1.8	;	Structure of an LPMO at 1.13x10^6 Gy
7PZ4	;	1.85	;	Structure of an LPMO at 2.07x10^4 Gy
7PZ6	;	1.45	;	Structure of an LPMO at 2.22x10^5 Gy
7PZ8	;	1.4	;	Structure of an LPMO at 3.12x10^6 Gy
7PZ3	;	1.9	;	Structure of an LPMO at 5.37x10^3 Gy
7PZ5	;	1.45	;	Structure of an LPMO at 9.56x10^4 Gy
7PXT	;	2.4	;	Structure of an LPMO, collected from serial synchrotron crystallography data.
2BNG	;	2.5	;	Structure of an M.tuberculosis LEH-like epoxide hydrolase
2I3H	;	1.62	;	Structure of an ML-IAP/XIAP chimera bound to a 4-mer peptide (AVPW)
1TW6	;	1.713	;	Structure of an ML-IAP/XIAP chimera bound to a 9mer peptide derived from Smac
2I3I	;	2.3	;	Structure of an ML-IAP/XIAP chimera bound to a peptidomimetic
3F7H	;	1.8	;	Structure of an ML-IAP/XIAP chimera bound to a peptidomimetic
3F7I	;	1.9	;	Structure of an ML-IAP/XIAP chimera bound to a peptidomimetic
3GT9	;	1.7	;	Structure of an ML-IAP/XIAP chimera bound to a peptidomimetic
3GTA	;	1.7	;	Structure of an ML-IAP/XIAP chimera bound to a peptidomimetic
1P16	;	2.7	;	Structure of an mRNA capping enzyme bound to the phosphorylated carboxyl-terminal domain of RNA polymerase II
5MV0	;	1.93	;	Structure of an N-terminal domain of a reptarenavirus L protein
2N5N	;		;	Structure of an N-terminal domain of CHD4
4CKN	;	2.9	;	Structure of an N-terminal fragment of Leishmania SAS-6 containing parts of its coiled coil domain, F257E mutant
4CKP	;	3.45	;	Structure of an N-terminal fragment of Leishmania SAS-6 that contains part of its coiled coil domain
2N58	;		;	Structure of an N-terminal membrane-anchoring region of the glycosyltransferase WaaG
2YEP	;	2.7	;	STRUCTURE OF AN N-TERMINAL NUCLEOPHILE (NTN) HYDROLASE, OAT2, IN COMPLEX WITH GLUTAMATE
2OZK	;	2.9	;	Structure of an N-Terminal Truncated Form of Nendou (NSP15) From SARS-CORONAVIRUS
3E1S	;	2.2	;	Structure of an N-terminal truncation of Deinococcus radiodurans RecD2
2W4E	;	2.0	;	Structure of an N-terminally truncated Nudix hydrolase DR2204 from Deinococcus radiodurans
6ULO	;	1.3	;	Structure of an N-terminally truncated uncharacterized protein from Leptospira interrogans serogroup Icterohaemorrhagiae serovar Copenhageni (strain Fiocruz L1-130)
2EVJ	;	1.89	;	Structure of an Ndt80-DNA complex (MSE mutant mA9C)
5HGV	;	2.05	;	Structure of an O-GlcNAc transferase point mutant, D554N in complex with peptide
2G7H	;		;	Structure of an O6-Methylguanine DNA Methyltransferase from Methanococcus jannaschii (MJ1529)
472D	;	1.9	;	STRUCTURE OF AN OCTAMER RNA WITH TANDEM GG/UU MISPAIRS
4J8R	;	2.303	;	Structure of an octapeptide repeat of the prion protein bound to the POM2 Fab antibody fragment
3TR8	;	2.503	;	Structure of an oligoribonuclease (orn) from Coxiella burnetii
4GRX	;	2.6	;	Structure of an omega-aminotransferase from Paracoccus denitrificans
3LWW	;	3.15	;	Structure of an open and closed conformation of Human Importin Beta bound to the Snurportin1 IBB-domain trapped in the same crystallographic asymmetric unit
5CSC	;	2.8	;	STRUCTURE OF AN OPEN FORM OF CHICKEN HEART CITRATE SYNTHASE AT 2.8 ANGSTROMS RESOLUTION
8AXV	;	2.8	;	Structure of an open form of CHIKV nsP1 capping pores
7WZ4	;	3.0	;	Structure of an orphan GPCR-G protein signaling complex
8EY0	;	2.4	;	Structure of an orthogonal PYR1*:HAB1* chemical-induced dimerization module in complex with mandipropamid
2B3X	;	2.54	;	Structure of an orthorhombic crystal form of human cytosolic aconitase (IRP1)
5C4I	;	2.274	;	Structure of an Oxalate Oxidoreductase
5K0A	;	1.706	;	Structure of an oxidoreductase from Synechocystis sp. PCC6803
5JRI	;	1.952	;	Structure of an oxidoreductase SeMet-labelled from Synechocystis sp. PCC6803
3K2O	;	1.75	;	Structure of an oxygenase
4P5O	;	3.1071	;	Structure of an RBX1-UBC12~NEDD8-CUL1-DCN1 complex: a RING-E3-E2~ubiquitin-like protein-substrate intermediate trapped in action
3TQM	;	2.45	;	Structure of an ribosomal subunit interface protein from Coxiella burnetii
205D	;	2.64	;	STRUCTURE OF AN RNA DOUBLE HELIX INCLUDING URACIL-URACIL BASE PAIRS IN AN INTERNAL LOOP
438D	;	2.5	;	STRUCTURE OF AN RNA DUPLEX R(GGGCGCUCC)2 WITH NON-ADJACENT G.U BASE PAIRS
1UUU	;		;	STRUCTURE OF AN RNA HAIRPIN LOOP WITH A 5'-CGUUUCG-3' LOOP MOTIF BY HETERONUCLEAR NMR SPECTROSCOPY AND DISTANCE GEOMETRY, 15 STRUCTURES
5OIK	;	3.7	;	Structure of an RNA polymerase II-DSIF transcription elongation complex
3DS7	;	1.85	;	Structure of an RNA-2'-deoxyguanosine complex
6HMJ	;	2.51	;	Structure of an RNA-binding Light-Oxygen-Voltage Receptor
4OO1	;	3.3	;	Structure of an Rrp6-RNA exosome complex bound to poly(A) RNA
4LCD	;	3.1	;	Structure of an Rsp5xUbxSna3 complex: Mechanism of ubiquitin ligation and lysine prioritization by a HECT E3
3SZQ	;	2.353	;	Structure of an S. pombe APTX/DNA/AMP/Zn complex
2WND	;	1.6	;	Structure of an S100A7 triple mutant
5AN3	;	2.82	;	Structure of an Sgt1-Skp1 Complex
2PNA	;		;	STRUCTURE OF AN SH2 DOMAIN OF THE P85 ALPHA SUBUNIT OF PHOSPHATIDYLINOSITOL-3-OH KINASE
2PNB	;		;	STRUCTURE OF AN SH2 DOMAIN OF THE P85 ALPHA SUBUNIT OF PHOSPHATIDYLINOSITOL-3-OH KINASE
7DU0	;	1.96	;	Structure of an type I-F anti-crispr protein
4NQK	;	3.7	;	Structure of an Ubiquitin complex
3H36	;	1.8	;	Structure of an uncharacterized domain in polyribonucleotide nucleotidyltransferase from Streptococcus mutans UA159
6OHZ	;	2.05	;	Structure of an uncharacterized protein from Leptospira borgpetersenii serovar Hardjo-bovis (strain JB197)
6OKH	;	1.85	;	Structure of an uncharacterized protein from Leptospira borgpetersenii serovar Hardjo-bovis (strain JB197)
2BF1	;	4.0	;	Structure of an unliganded and fully-glycosylated SIV gp120 envelope glycoprotein
2YG8	;	2.0	;	Structure of an unusual 3-Methyladenine DNA Glycosylase II (Alka) from Deinococcus radiodurans
2YG9	;	1.95	;	Structure of an unusual 3-Methyladenine DNA Glycosylase II (Alka) from Deinococcus radiodurans
4LE5	;	1.7	;	Structure of an Unusual S-adenosylmethionine synthetase from Campylobacter jejuni
4LJC	;	1.86	;	Structure of an X-ray-induced photobleached state of IrisFP
2KP3	;		;	Structure of ANA-RNA hybrid duplex
5HGR	;	1.681	;	Structure of Anabaena (Nostoc) sp. PCC 7120 Orange Carotenoid Protein binding canthaxanthin
5FCY	;	2.508	;	Structure of Anabaena (Nostoc) sp. PCC 7120 Red Carotenoid Protein binding a mixture of carotenoids
5FCX	;	3.206	;	Structure of Anabaena (Nostoc) sp. PCC 7120 Red Carotenoid Protein binding canthaxanthin
2M3G	;		;	Structure of Anabaena Sensory Rhodopsin Determined by Solid State NMR Spectroscopy
5UK6	;		;	Structure of Anabaena Sensory Rhodopsin Determined by Solid State NMR Spectroscopy and DEER
4UD2	;	2.3	;	Structure of anaerobically purified D. fructosovorans NiFe- hydrogenase
8OVY	;	1.537	;	Structure of analogue of superfolded GFP
5J6Z	;		;	Structure of anastellin bound to beta-strands A and B from the third type III domain of fibronectin
4P80	;	1.6	;	Structure of ancestral PyrR protein (AncGREENPyrR)
4P81	;	1.8	;	Structure of ancestral PyrR protein (AncORANGEPyrR)
4P3K	;	1.7	;	Structure of ancestral PyrR protein (PLUMPyrR)
6Y6Q	;	2.7	;	Structure of Andes virus envelope glycoprotein Gc in postfusion conformation
7T83	;	2.1	;	Structure of angiotensin II type I receptor (AT1R) nanobody antagonist AT118i4h32
7T84	;	1.6	;	Structure of angiotensin II type I receptor (AT1R) nanobody antagonist AT118i4h32 G26D T57I variant
3CCR	;	3.0	;	Structure of Anisomycin resistant 50S Ribosomal Subunit: 23S rRNA mutation A2488C. Density for anisomycin is visible but not included in the model.
3CCQ	;	2.9	;	Structure of Anisomycin resistant 50S Ribosomal Subunit: 23S rRNA mutation A2488U
3CC7	;	2.7	;	Structure of Anisomycin resistant 50S Ribosomal Subunit: 23S rRNA mutation C2487U
3CCJ	;	3.3	;	Structure of Anisomycin resistant 50S Ribosomal Subunit: 23S rRNA mutation C2534U
3CCS	;	2.95	;	Structure of Anisomycin resistant 50S Ribosomal Subunit: 23S rRNA mutation G2482A
3CCU	;	2.8	;	Structure of Anisomycin resistant 50S Ribosomal Subunit: 23S rRNA mutation G2482C
3CCM	;	2.55	;	Structure of Anisomycin resistant 50S Ribosomal Subunit: 23S rRNA mutation G2611U
3CCV	;	2.9	;	Structure of Anisomycin resistant 50S Ribosomal Subunit: 23S rRNA mutation G2616A
3CCE	;	2.75	;	Structure of Anisomycin resistant 50S Ribosomal Subunit: 23S rRNA mutation U2535A
3CCL	;	2.9	;	Structure of Anisomycin resistant 50S Ribosomal Subunit: 23S rRNA mutation U2535C. Density for Anisomycin is visible but not included in model.
4O60	;	2.52	;	Structure of ankyrin repeat protein
2CH1	;	2.4	;	Structure of Anopheles gambiae 3-hydroxykynurenine transaminase
4F7F	;	1.8	;	Structure of Anopheles gambiae odorant binding protein 20
3V2L	;	1.8	;	Structure of Anopheles gambiae odorant binding protein 20 bound to polyethylene glycol
4GTN	;	2.032	;	Structure of anthranilate phosphoribosyl transferase from acinetobacter baylyi
5CWA	;	2.1	;	Structure of Anthranilate Synthase Component I (TrpE) from Mycobacterium tuberculosis with inhibitor bound
1S26	;	3.0	;	Structure of Anthrax Edema Factor-Calmodulin-alpha,beta-methyleneadenosine 5'-triphosphate Complex Reveals an Alternative Mode of ATP Binding to the Catalytic Site
3BKM	;	1.6	;	Structure of anti-amyloid-beta Fab WO2 (Form A, P212121)
5XLI	;	1.696	;	Structure of anti-Angiotensin II type2 receptor antibody (D5711-4A03)
7UE9	;	1.75	;	Structure of anti-C3d Fab(3d8b) in complex with C3d
2VL5	;	2.1	;	Structure of anti-collagen type II FAb CIIC1
6JHV	;	2.321	;	Structure of anti-CRISPR AcrIIC3
6JHW	;	2.04	;	Structure of anti-CRISPR AcrIIC3 and NmeCas9 HNH
7MSL	;	1.73	;	Structure of anti-CRISPR AcrIIC4 from Haemophilus parainfluenzae
6N05	;	2.5	;	Structure of anti-crispr protein, AcrIIC2
6W4V	;	2.1	;	Structure of anti-ferroportin Fab45D8
2G60	;	1.85	;	Structure of anti-FLAG M2 Fab domain
7BG1	;	1.86	;	Structure of anti-FLAG M2 Fab domain remodeled based on proteomic sequencing
6KS2	;	1.753	;	Structure of anti-Ghrelin receptor antibody
6UUP	;	2.20002	;	Structure of anti-hCD33 conditional scFv
6UY3	;	2.0	;	Structure of anti-hCD33 conditional scFv with methotrexate
6KVF	;	2.79	;	Structure of anti-hCXCR2 abN48 in complex with its CXCR2 epitope
6KVA	;	2.2	;	Structure of anti-hCXCR2 abN48-2 in complex with its CXCR2 epitope
5UXQ	;	2.415	;	Structure of anti-HIV trimer apex antibody PGT143
3LRG	;	2.05	;	Structure of anti-huntingtin VL domain
3LRH	;	2.6	;	Structure of anti-huntingtin VL domain in complex with huntingtin peptide
7S8G	;	2.57	;	Structure of anti-LASV Fab 25.10C with FNQI mutation
6QBC	;	1.56	;	structure of anti-Mcl1 Fab
6K84	;		;	Structure of anti-prion RNA aptamer
7KKJ	;	2.05	;	Structure of anti-SARS-CoV-2 Spike nanobody mNb6
5E2U	;	2.4	;	Structure of anti-TAU AT8 FAB in the presence of phosphopeptide
8TFN	;	2.54	;	Structure of anti-TCRvbeta6-5 antibody in complex with the cognate TCR
4K23	;	1.6	;	Structure of anti-uPAR Fab ATN-658
4K24	;	4.5	;	Structure of anti-uPAR Fab ATN-658 in complex with uPAR
1PP5	;		;	Structure of Antibacterial Peptide Microcin J25: a 21-Residue Lariat Protoknot
7BWL	;	2.25	;	Structure of antibiotic sequester from Pseudomonas aerurinosa
5WN9	;	1.551	;	Structure of antibody 2D10 bound to the central conserved region of RSV G
5WNA	;	2.4	;	Structure of antibody 3D3 bound to the central conserved region of RSV G
5WNB	;	2.4	;	Structure of antibody 3D3 bound to the linear epitope of RSV G
7T8W	;	3.1	;	Structure of antibody 3G12 bound to Respiratory Syncytial Virus G central conserved domain mutant S177Q
6UVO	;	2.9	;	Structure of antibody 3G12 bound to the central conserved domain of RSV G
6LDW	;	1.6	;	Structure of antibody C9 in complex with methylated peptide
5N47	;	3.0	;	Structure of Anticalin N7E in complex with the three-domain fragment Fn7B8 of human oncofetal fibronectin
5N48	;	1.6	;	Structure of Anticalin N9B in complex with extra-domain B of human oncofetal fibronectin
1MSI	;	1.25	;	STRUCTURE OF ANTIFREEZE GLYCOPROTEIN QAE(HPLC 12)
5UEK	;	1.7	;	Structure of antigen-Fab 12E complex with Histone chaperone ASF1
5UCB	;	1.521	;	Structure of antigen-Fab complex with engineered switch residue region.
5UEA	;	1.701	;	Structure of antigen-Fab complex with Histone chaperone ASF1
2MJQ	;		;	Structure of antimicrobial peptide anoplin in DPC micelles
1OT0	;		;	Structure of Antimicrobial Peptide, HP (2-20) and its Analogues Derived from Helicobacter pylori, as Determined by 1H NMR Spectroscopy
1P0G	;		;	Structure of Antimicrobial Peptide, HP (2-20) and its Analogues Derived from Helicobacter pylori, as Determined by 1H NMR Spectroscopy
2R9Y	;	2.65	;	Structure of antiplasmin
5VBL	;	2.6	;	Structure of apelin receptor in complex with agonist peptide
2RH5	;	2.48	;	Structure of Apo Adenylate Kinase from Aquifex Aeolicus
2RH8	;	2.22	;	Structure of apo anthocyanidin reductase from vitis vinifera
3HFS	;	3.17	;	Structure of apo anthocyanidin reductase from vitis vinifera
4PRS	;	1.47	;	Structure of apo ArgBP from T. maritima
5W56	;	2.03	;	Structure of Apo AztC
6N01	;	1.98	;	Structure of apo AztD from Citrobacter koseri
5A9V	;	3.31	;	Structure of apo BipA
3QDS	;	1.15	;	Structure of apo Boletus edulis lectin
4GGT	;	1.693	;	Structure of apo Bradavidin2 (Form B)
5HT1	;	2.651	;	Structure of apo C. glabrata FKBP12
3OO0	;	1.55	;	Structure of apo CheY A113P
6Y9I	;	1.9	;	Structure of apo Chimpanzee Polyomavirus VP1
8U4N	;	2.72	;	Structure of Apo CXCR4/Gi complex
4ELX	;	2.191	;	Structure of apo E.coli. 1,4-dihydroxy-2- naphthoyl CoA synthases with Cl
6Y67	;	2.618	;	Structure of apo Finch Polyomavirus VP1
5I98	;	1.999	;	Structure of apo FKBP12(P104G) from C. albicans
4Z1A	;	2.0	;	Structure of apo form KDO8PS from H.pylori
3MD9	;	1.5	;	Structure of apo form of a periplasmic heme binding protein
2WK7	;	2.5	;	Structure of apo form of Vibrio cholerae CqsA
2Q9A	;	2.24	;	Structure of Apo FTSY
6Y65	;	1.45	;	Structure of apo Goose Hemorrhagic Polyomavirus VP1
6CPY	;	1.7	;	Structure of apo GRMZM2G135359 pseudokinase
3MOK	;	1.55	;	Structure of Apo HasAp from Pseudomonas aeruginosa to 1.55A Resolution
6QYH	;	1.94	;	Structure of Apo HPAB from E.coli
4ZVW	;	2.4	;	Structure of apo human ALDH7A1 in space group C2
4ZVX	;	1.9	;	Structure of apo human ALDH7A1 in space group P4212
6W4S	;	3.2	;	Structure of apo human ferroportin in lipid nanodisc
2WQM	;	2.1	;	Structure of apo human Nek7
6Y5Z	;	1.549	;	Structure of apo Human Polyomavirus 12 VP1
5UAX	;	1.85	;	Structure of apo human PYCR-1 crystallized in space group C2
5UAW	;	1.85	;	Structure of apo human PYCR-1 crystallized in space group P21212
6TEJ	;	2.7	;	Structure of apo IrtAB devoid SID in complex with sybody Syb_NL5
5YBJ	;	2.341	;	Structure of apo KANK1 ankyrin domain
6WU1	;	3.09	;	Structure of apo LaINDY
6KLC	;	3.9	;	Structure of apo Lassa virus polymerase
6KLD	;	3.58	;	Structure of apo Machupo virus polymerase
4WMS	;	1.9	;	STRUCTURE OF APO MBP-MCL1 AT 1.9A
6Y5X	;	2.3	;	Structure of apo New Jersey Polyomavirus VP1
5I4Z	;	1.95	;	Structure of apo OmoMYC
5IY2	;	1.15	;	Structure of apo OXA-143 carbapenemase
5HTG	;	2.4	;	Structure of apo P1 form of Candida albicans FKBP12
4FD8	;	1.52	;	Structure of apo S70C SHV beta-lactamase
7AR6	;	1.4	;	Structure of apo SARS-CoV-2 Main Protease with large beta angle, space group C2.
7AR5	;	1.4	;	Structure of apo SARS-CoV-2 Main Protease with small beta angle, space group C2.
8H3D	;	3.27	;	Structure of apo SARS-CoV-2 spike protein with one RBD up
6Y61	;	2.45	;	Structure of apo Sheep Polyomavirus VP1
3SZI	;	1.4	;	Structure of apo shwanavidin (P21 form)
2Q5R	;	2.3	;	Structure of apo Staphylococcus aureus D-tagatose-6-phosphate kinase
5M0X	;	1.8	;	Structure of apo structure of GH36 alpha-galactosidase from Thermotoga maritima
2R60	;	1.8	;	Structure of apo Sucrose Phosphate Synthase (SPS) of Halothermothrix orenii
6E4O	;	1.8	;	Structure of apo T. brucei RRM: P4(1)2(1)2 form
1LIO	;	2.5	;	STRUCTURE OF APO T. GONDII ADENOSINE KINASE
8R5Q	;	2.62	;	Structure of apo TDO with a bound inhibitor
8R5R	;	3.078	;	Structure of apo TDO with a bound inhibitor
6ZD1	;	2.47	;	Structure of apo telomerase from Candida Tropicalis
6ZD6	;	2.64	;	Structure of apo telomerase from Candida Tropicalis
6ZD2	;	2.84	;	Structure of apo telomerase from Candida Tropicalis truncated from C-terminal domain
8OX0	;	2.52	;	Structure of apo telomeric nucleosome
1SXI	;	3.0	;	Structure of apo transcription regulator B. megaterium
6UPB	;	1.89	;	Structure of apo trehalose-6-phosphate phosphatase from Salmonella typhimurium
1P4O	;	1.5	;	Structure of Apo unactivated IGF-1R KInase domain at 1.5A resolution.
6W3B	;	2.57	;	Structure of apo unphosphorylated IRE1
7K57	;	3.7	;	Structure of apo VCP dodecamer generated from bacterially recombinant VCP/p97
7K59	;	4.2	;	Structure of apo VCP hexamer generated from bacterially recombinant VCP/p97
6K20	;	2.58	;	Structure of Apo YdiU
8EZW	;	2.0	;	Structure of Apo ZrgA deletion 124-184 from Vibrio cholerae
6CPE	;	2.45	;	Structure of apo, dephosphorylated Aurora A (122-403) in an active conformation
5UL2	;	2.552	;	Structure of Apo, SeMet-labeled Cobalamin-dependent S-adenosylmethionine radical enzyme OxsB
1WFC	;	2.3	;	STRUCTURE OF APO, UNPHOSPHORYLATED, P38 MITOGEN ACTIVATED PROTEIN KINASE P38 (P38 MAP KINASE) THE MAMMALIAN HOMOLOGUE OF THE YEAST HOG1 PROTEIN
1BI0	;	2.3	;	STRUCTURE OF APO-AND HOLO-DIPHTHERIA TOXIN REPRESSOR
1BI1	;	2.2	;	STRUCTURE OF APO-AND HOLO-DIPHTHERIA TOXIN REPRESSOR
1BI2	;	2.3	;	STRUCTURE OF APO-AND HOLO-DIPHTHERIA TOXIN REPRESSOR
1BI3	;	2.4	;	STRUCTURE OF APO-AND HOLO-DIPHTHERIA TOXIN REPRESSOR
1AIZ	;	1.8	;	STRUCTURE OF APO-AZURIN FROM ALCALIGENES DENITRIFICANS AT 1.8 ANGSTROMS RESOLUTION
1AZB	;	2.2	;	STRUCTURE OF APO-AZURIN FROM ALCALIGENES DENITRIFICANS AT 1.8 ANGSTROMS RESOLUTION
1AZC	;	1.8	;	STRUCTURE OF APO-AZURIN FROM ALCALIGENES DENITRIFICANS AT 1.8 ANGSTROMS RESOLUTION
8I97	;	3.19	;	Structure of Apo-C3aR-Go complex (Glacios)
8I9S	;	3.26	;	Structure of Apo-C3aR-Go complex (Titan)
2IX7	;	2.5	;	Structure of apo-calmodulin bound to unconventional myosin V
3U9B	;	3.2	;	Structure of apo-CATI
6EDM	;	1.4	;	Structure of apo-CDD-1 beta-lactamase
7LNO	;	1.58	;	Structure of apo-CDD-1 beta-lactamase in imidazole and MPD
6VXF	;	3.5	;	Structure of apo-closed ABCG2
6YWP	;	2.25	;	Structure of apo-CutA
5IQY	;	2.4	;	Structure of apo-Dehydroascorbate Reductase from Pennisetum Glaucum phased by Iodide-SAD method
1BYI	;	0.97	;	STRUCTURE OF APO-DETHIOBIOTIN SYNTHASE AT 0.97 ANGSTROMS RESOLUTION
7QIA	;	3.5	;	Structure of apo-EleNRMT in complex with two nanobodies at 3.5A
3V8Y	;	2.15	;	Structure of apo-glycogenin truncated at residue 270
3V8Z	;	2.2	;	Structure of apo-glycogenin truncated at residue 270 complexed with UDP
7XPZ	;	3.4	;	Structure of Apo-hSLC19A1
7VQ1	;	3.76	;	Structure of Apo-hsTRPM2 channel
7VQ2	;	3.68	;	Structure of Apo-hsTRPM2 channel TM domain
6RWV	;	1.63864	;	Structure of apo-LmCpfC
5MYP	;	1.95	;	Structure of apo-TbALDH3
4CVP	;	2.11	;	Structure of Apobacterioferritin
4CVR	;	1.1	;	Structure of Apobacterioferritin Y25F variant
4CVS	;	1.392	;	Structure of Apobacterioferritin Y45F variant
4CVT	;	1.794	;	Structure of Apobacterioferritin Y58F variant
8FIM	;	2.22	;	Structure of APOBEC3A (E72A inactive mutant) in complex with TTC-hairpin DNA substrate
7V66	;	1.89	;	Structure of Apoferritin
1FTG	;	2.0	;	STRUCTURE OF APOFLAVODOXIN: CLOSURE OF A TYROSINE/TRYPTOPHAN AROMATIC GATE LEADS TO A COMPACT FOLD
2YG2	;	1.7	;	Structure of apolioprotein M in complex with Sphingosine 1-Phosphate
3GAD	;	1.8	;	Structure of apomif
1OWL	;	1.8	;	Structure of apophotolyase from Anacystis nidulans
1HQV	;	2.3	;	STRUCTURE OF APOPTOSIS-LINKED PROTEIN ALG-2
1TT5	;	2.6	;	Structure of APPBP1-UBA3-Ubc12N26: a unique E1-E2 interaction required for optimal conjugation of the ubiquitin-like protein NEDD8
2NVU	;	2.8	;	Structure of APPBP1-UBA3~NEDD8-NEDD8-MgATP-Ubc12(C111A), a trapped ubiquitin-like protein activation complex
5WZK	;	2.8	;	Structure of APUM23-deletion-of-insert-region-GGAAUUGACGG
5WZG	;	2.55	;	Structure of APUM23-GAAUUGACGG
5WZH	;	2.509	;	Structure of APUM23-GGAAUUGACGG
5WZI	;	2.75	;	Structure of APUM23-GGAGUUGACGG
5WZJ	;	2.101	;	Structure of APUM23-GGAUUUGACGG
8SYJ	;	2.2	;	Structure of apurinic/apyrimidinic DNA lyase TK0353 from Thermococcus kodakarensis (Iodide crystal form)
8GM7	;	1.75	;	Structure of apurinic/apyrimidinic DNA Lyase TK0353 from Thermococcus kodakarensis (Native Crystal Form)
8GM6	;	1.98	;	Structure of apurinic/apyrimidinic DNA lyase TK0353 from Thermococcus kodakarensis (Selenomethionine)
2E55	;	2.15	;	Structure of AQ2163 protein from Aquifex aeolicus
7CJS	;	1.8	;	structure of aquaporin
1FQY	;	3.8	;	STRUCTURE OF AQUAPORIN-1 AT 3.8 A RESOLUTION BY ELECTRON CRYSTALLOGRAPHY
3IYZ	;	10.0	;	Structure of Aquaporin-4 S180D mutant at 10.0 A resolution from electron micrograph
2ZZ9	;	2.8	;	Structure of aquaporin-4 S180D mutant at 2.8 A resolution by electron crystallography
2NUB	;	3.2	;	Structure of Aquifex aeolicus Argonuate
2PNF	;	1.8	;	Structure of Aquifex Aeolicus FabG 3-oxoacyl-(acyl-carrier protein) reductase
2ZXH	;	3.2	;	Structure of Aquifex aeolicus GidA in the form I crystal
2ZXI	;	2.3	;	Structure of Aquifex aeolicus GidA in the form II crystal
8YT4	;	1.42	;	Structure of Aquifex aeolicus Lumazine Synthase by Cryo-Electron Microscopy to 1.42 Angstrom Resolution
4TYX	;	1.64	;	Structure of aquoferric sperm whale myoglobin L29H/F33Y/F43H/S92A mutant
4MQI	;	1.92	;	Structure of Aquomet Hemoglobin Bristol-Alesha alphawtbetaV67M
4MQH	;	2.5	;	Structure of Aquomet Hemoglobin Evans alphaV62Mbetawt
3V49	;	1.7	;	Structure of ar lbd with activator peptide and sarm inhibitor 1
3V4A	;	1.95	;	Structure of ar lbd with activator peptide and sarm inhibitor 2
3LE2	;	2.2	;	Structure of Arabidopsis AtSerpin1. Native Stressed Conformation
5LAL	;	1.4	;	Structure of Arabidopsis dirigent protein AtDIR6
6DHV	;	2.099	;	Structure of Arabidopsis Fatty Acid Amide Hydrolase
6DII	;	3.2	;	Structure of Arabidopsis Fatty Acid Amide Hydrolase in Complex with methyl linolenyl fluorophosphonate
3ADG	;	1.7	;	Structure of Arabidopsis HYL1 and its molecular implications for miRNA processing
3ADI	;	3.2	;	Structure of Arabidopsis HYL1 and its molecular implications for miRNA processing
3ADJ	;	3.0	;	Structure of Arabidopsis HYL1 and its molecular implications for miRNA processing
2QSU	;	2.0	;	Structure of Arabidopsis thaliana 5'-Methylthioadenosine nucleosidase in apo form
7XA9	;	2.84	;	Structure of Arabidopsis thaliana CLCa
6R88	;	1.6	;	Structure of Arabidopsis thaliana GLR3.3 ligand-binding domain in complex with glycine
6R89	;	2.5	;	Structure of Arabidopsis thaliana GLR3.3 ligand-binding domain in complex with L-cysteine
6R85	;	2.0	;	Structure of Arabidopsis thaliana GLR3.3 ligand-binding domain in complex with L-glutamate
6R8A	;	3.1	;	Structure of Arabidopsis thaliana GLR3.3 ligand-binding domain in complex with L-methionine
6ILT	;	2.2	;	Structure of Arabidopsis thaliana Ribokinase complexed with ATP and Magnesium ion
6ILS	;	1.8	;	Structure of Arabidopsis thaliana Ribokinase complexed with Ribose and ATP
6ILR	;	1.972	;	Structure of Arabidopsis thaliana Ribokinase in unligand form
7LHV	;	2.75	;	Structure of Arabidopsis thaliana sulfate transporter AtSULTR4;1
6ZPY	;	1.27	;	Structure of Arabinose-Bound MgGH51 a-L-Arabinofuranosidase Crystal Type 1
6ZQ1	;	1.7	;	Structure of AraDNJ-Bound MgGH51 a-L-Arabinofuranosidase Crystal Type 1
2KY6	;		;	Structure of ARC92VBD/MED25ACID
3PEN	;	2.3005	;	Structure of archaeal initiation factor aIF2gamma subunit delta 37-47 from Sulfolobus solfataricus in the GDP-bound form.
1WNU	;	2.8	;	Structure of Archaeal Trans-Editing Protein AlaX in complex with L-serine
1WXO	;	1.88	;	Structure of Archaeal Trans-Editing Protein AlaX in complex with zinc
1NEE	;		;	Structure of archaeal translation factor aIF2beta from Methanobacterium thermoautrophicum
2FWR	;	2.6	;	Structure of Archaeoglobus Fulgidis XPB
6FSW	;	1.9	;	Structure of Archaeoglobus fulgidus SBDS protein at 1.9 Angstrom
6ZXY	;	2.75	;	Structure of Archaeoglobus fulgidus Trm11 m2G10 tRNA methyltransferase enzyme
6ZXV	;	1.88	;	Structure of Archaeoglobus fulgidus Trm11 m2G10 tRNA methyltransferase enzyme bound to sinefungin
6ZXW	;	2.19	;	Structure of Archaeoglobus fulgidus Trm11-Trm112 m2G10 tRNA methyltransferase complex bound to sinefungin
1YAR	;	1.9	;	Structure of Archeabacterial 20S proteasome mutant D9S- PA26 complex
1YAU	;	2.4	;	Structure of Archeabacterial 20S proteasome- PA26 complex
4N2P	;	1.435	;	Structure of Archease from Pyrococcus horikoshii
6HU6	;	1.904	;	Structure of ARF1 RNA
1RE0	;	2.4	;	Structure of ARF1-GDP bound to Sec7 domain complexed with Brefeldin A
5MDV	;	2.97	;	Structure of ArfA and RF2 bound to the 70S ribosome (accommodated state)
5MDY	;	3.35	;	Structure of ArfA and TtRF2 bound to the 70S ribosome (pre-accommodated state)
5MDW	;	3.06	;	Structure of ArfA(A18T) and RF2 bound to the 70S ribosome (pre-accommodated state)
8ACI	;	1.85	;	Structure of ARG-117 Fab in complex with a fragment of complement C2, neutral pH
3L1L	;	3.002	;	Structure of Arg-bound Escherichia coli AdiC
8E5N	;	2.538	;	Structure of ARG1 complex with pyrrolidine-based non-boronic acid inhibitor 10
8E5M	;	1.84	;	Structure of ARG1 complex with pyrrolidine-based non-boronic acid inhibitor 6
6SS6	;	3.25	;	Structure of arginase-2 in complex with the inhibitory human antigen-binding fragment Fab C0020187
6SS2	;	2.4	;	Structure of arginase-2 in complex with the inhibitory human antigen-binding fragment Fab C0021158
6SS4	;	2.9	;	Structure of arginase-2 in complex with the inhibitory human antigen-binding fragment Fab C0021181
1RXX	;	2.45	;	Structure of arginine deiminase
1SD0	;	2.3	;	Structure of arginine kinase C271A mutant
1P52	;	1.9	;	Structure of Arginine kinase E314D mutant
6KY3	;	1.34	;	Structure of arginine kinase H284A mutant
6GVC	;	2.6	;	Structure of ArhGAP12 bound to G-Actin
3LNQ	;	2.25	;	Structure of Aristaless homeodomain in complex with DNA
3UKU	;	2.75	;	Structure of Arp2/3 complex with bound inhibitor CK-869
8A5D	;	2.9	;	Structure of Arp4-Ies4-N-actin-Arp8-Ino80HSA subcomplex (A-module) of Chaetomium thermophilum INO80
8A5P	;	3.4	;	Structure of Arp4-Ies4-N-actin-Arp8-Ino80HSA subcomplex (A-module) of Chaetomium thermophilum INO80 on curved DNA
8A5Q	;	3.3	;	Structure of Arp4-Ies4-N-actin-Arp8-Ino80HSA subcomplex (A-module) of Chaetomium thermophilum INO80 on straight DNA
8A5A	;	3.3	;	Structure of Arp4-Ies4-N-actin-Arp8-Ino80HSA subcomplex (A-module) of INO80
8A5O	;	3.2	;	Structure of Arp4-Ies4-N-actin-Arp8-Ino80HSA subcomplex (A-module) of S. cerevisiae INO80
4I6M	;	2.801	;	Structure of Arp7-Arp9-Snf2(HSA)-RTT102 subcomplex of SWI/SNF chromatin remodeler.
8AS2	;	3.2	;	Structure of arrestin2 in complex with 4P CCR5 phosphopeptide and Fab30
8AS3	;	3.5	;	Structure of arrestin2 in complex with 6P CCR5 phosphopeptide and Fab30
6X8W	;	1.972	;	Structure of ArrX Y138A mutant protein bound to sulfate from Chrysiogenes arsenatis
3GXQ	;	2.35	;	Structure of ArtA and DNA complex
6F5F	;	2.98	;	Structure of ARTD2/PARP2 WGR domain bound to double strand DNA with 5 nucleotide overhang and 5'phosphate
6F1K	;	2.2	;	Structure of ARTD2/PARP2 WGR domain bound to double strand DNA without 5'phosphate
6F5B	;	2.8	;	Structure of ARTD2/PARP2 WGR domain bound to double stranded DNA with 5'phosphate
7APV	;	1.95	;	Structure of Artemis/DCLRE1C/SNM1C in complex with Ceftriaxone
1J4U	;	2.9	;	Structure of Artocarpin Complexed with Me-alpha-Mannose
1J4S	;	2.5	;	Structure of Artocarpin: a Lectin with Mannose Specificity (Form 1)
1J4T	;	2.4	;	Structure of Artocarpin: a Lectin with Mannose Specificity (Form 2)
5L2P	;	2.56	;	Structure of arylesterase
2J6P	;	2.15	;	STRUCTURE OF AS-SB REDUCTASE FROM LEISHMANIA MAJOR
6K99	;	4.1	;	Structure of ASC CARD filament
6O22	;		;	Structure of Asf1-H3:H4-Rtt109-Vps75 histone chaperone-lysine acetyltransferase complex with the histone substrate.
6VRE	;	2.29	;	Structure of ASK1 bound to BIO-1772961
6NDK	;	3.64	;	Structure of ASLSufA6 A37.5 bound to the 70S A site
5K5O	;	3.2	;	Structure of AspA-26mer DNA complex
5K5Q	;	2.649	;	Structure of AspA-DNA complex: novel centromere bindng protein-centromere complex
1IVR	;	2.4	;	STRUCTURE OF ASPARTATE AMINOTRANSFERASE
4F5F	;	2.25	;	Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.
2GYY	;	2.1	;	Structure of aspartate semialdehyde dehydrogenase (ASADH) from Streptococcus pneumoniae
2GZ2	;	2.1	;	Structure of Aspartate Semialdehyde Dehydrogenase (ASADH) from Streptococcus pneumoniae complexed with 2',5'-ADP
2GZ1	;	1.8	;	Structure of Aspartate Semialdehyde Dehydrogenase (ASADH) from Streptococcus pneumoniae complexed with NADP
2GZ3	;	2.1	;	Structure of Aspartate Semialdehyde Dehydrogenase (ASADH) from Streptococcus pneumoniae complexed with NADP and aspartate-semialdehyde
8CP2	;	2.1	;	Structure of Aspartate-N-hydroxylase (FzmM)from Streptomyces sp. V2: complex with NADPH and L-aspartate
8CP5	;	2.54	;	Structure of Aspartate-N-hydroxylase (FzmM)from Streptomyces sp. V2: complex with NADPH and Sulphate
1YS4	;	2.29	;	Structure of Aspartate-Semialdehyde Dehydrogenase from Methanococcus jannaschii
5CKU	;	2.1	;	Structure of Aspergillus fumigatus ornithine hydroxylase (SidA) mutant N323A bound to NADP and ornithine
5DXL	;	1.573	;	Structure of Aspergillus fumigatus trehalose-6-phosphate phosphatase crystal form 1
5DXN	;	1.65	;	Structure of Aspergillus fumigatus trehalose-6-phosphate phosphatase crystal form 2
5DXO	;	1.9	;	Structure of Aspergillus fumigatus trehalose-6-phosphate phosphatase crystal form 3
5HVM	;	2.815	;	Structure of Aspergillus fumigatus trehalose-6-phosphate synthase A in complex with UDP and validoxylamine A
5HVO	;	2.467	;	Structure of Aspergillus fumigatus trehalose-6-phosphate synthase B in complex with UDP and validoxylamine A
4U8I	;	2.05	;	Structure of Aspergillus fumigatus UDP-Galactopyranose mutase mutant F66A
4U8N	;	2.3	;	Structure of Aspergillus fumigatus UDP-Galactopyranose mutase mutant F66A complexed with UDP
4WX1	;	2.2	;	Structure of Aspergillus fumigatus UDP-Galactopyranose mutase mutant F66A determined from a crystal soaked with UDP-Galactopyranose
4U8L	;	2.3	;	Structure of Aspergillus fumigatus UDP-Galactopyranose mutase mutant N207A
4U8O	;	2.3	;	Structure of Aspergillus fumigatus UDP-Galactopyranose mutase mutant N207A complexed with UDP
4U8K	;	2.2	;	Structure of Aspergillus fumigatus UDP-Galactopyranose mutase mutant Q107A
4U8J	;	2.3	;	Structure of Aspergillus fumigatus UDP-Galactopyranose mutase mutant Y104A
4U8M	;	2.3	;	Structure of Aspergillus fumigatus UDP-Galactopyranose mutase mutant Y317A
4U8P	;	2.05	;	Structure of Aspergillus fumigatus UDP-Galactopyranose mutase mutant Y317A complexed with UDP
1KS5	;	2.1	;	Structure of Aspergillus niger endoglucanase
1QO7	;	1.8	;	Structure of Aspergillus niger epoxide hydrolase
4MAI	;	1.4	;	Structure of Aspergillus oryzae AA11 Lytic Polysaccharide Monooxygenase with Cu(I)
4MAH	;	1.55	;	Structure of Aspergillus oryzae AA11 Lytic Polysaccharide Monooxygenase with Zn
3QPD	;	1.571	;	Structure of Aspergillus oryzae cutinase expressed in Pichia pastoris, crystallized in the presence of Paraoxon
3N8Y	;	2.6	;	Structure of Aspirin Acetylated Cyclooxygenase-1 in Complex with Diclofenac
1AST	;	1.8	;	STRUCTURE OF ASTACIN AND IMPLICATIONS FOR ACTIVATION OF ASTACINS AND ZINC-LIGATION OF COLLAGENASES
1QJJ	;	1.86	;	Structure of astacin with a hydroxamic acid inhibitor
1QJI	;	2.14	;	Structure of astacin with a transition-state analogue inhibitor
5J67	;	3.16	;	Structure of Astrotactin-2, a conserved vertebrate-specific and perforin-like membrane protein involved in neuronal development
5J68	;	5.221	;	Structure of Astrotactin-2, a conserved vertebrate-specific and perforin-like membrane protein involved in neuronal development
5J69	;	3.63	;	Structure of Astrotactin-2, a conserved vertebrate-specific and perforin-like membrane protein involved in neuronal development
5TXT	;	2.7	;	Structure of asymmetric apo/holo ALAS dimer from S. cerevisiae
1SE9	;		;	Structure of At3g01050, a ubiquitin-fold protein from Arabidopsis thaliana
7N5A	;	3.95	;	Structure of AtAtm3 in the closed conformation
7N58	;	3.4	;	Structure of AtAtm3 in the inward-facing conformation
7N59	;	3.6	;	Structure of AtAtm3 in the inward-facing conformation with GSSG bound
7N5B	;	3.8	;	Structure of AtAtm3 in the outward-facing conformation
4HWC	;	1.798	;	Structure of ATBAG1
6HYN	;	1.14	;	Structure of ATG13 LIR motif bound to GABARAP
6HOL	;	1.4	;	Structure of ATG14 LIR motif bound to GABARAPL1
8W9O	;	2.8	;	structure of AtHKT1;1 in KCl at 2.8 Angstroms resolution
8W9N	;	2.7	;	Structure of AtHKT1;1 in NaCl at 2.7 Angstroms resolution
7VO8	;	1.75	;	Structure of AtHPPD complexed with LSY-1
6Y8X	;	2.25	;	Structure of Atlantic Herring (Clupea Harengus) Phosphoglucomutase 5 (PGM5)
7TLM	;	1.8	;	Structure of Atopobium parvulum SufS
7TLR	;	2.1	;	Structure of Atopobium parvulum SufS A34Y mutant
7TLQ	;	2.2	;	Structure of Atopobium parvulum SufS C375S
7TLP	;	2.99	;	Structure of Atopobium parvulum SufS K235R
6JPF	;	3.52	;	Structure of atOSCA1.1 channel at 3.52A
5Z1F	;	4.8	;	Structure of atOSCA3.1 channel
7UXW	;	2.57	;	Structure of ATP and GTP bind to Cyclic GMP AMP synthase (cGAS) through Mg coordination
4RVC	;	1.77	;	Structure of ATP binding subunit of ABC transporter
6RMD	;	2.8	;	Structure of ATP bound Plasmodium falciparum IMP-nucleotidase
4GXR	;	2.0	;	Structure of ATP bound RpMatB-BxBclM chimera B3
6HXJ	;	2.58	;	Structure of ATP citrate lyase from Chlorobium limicola in complex with citrate and coenzyme A.
6HXI	;	2.1	;	Structure of ATP citrate lyase from Methanothrix soehngenii in complex with citrate and coenzyme A
6UIA	;	4.3	;	Structure of ATP citrate lyase with CoA in a partially open conformation
3WVQ	;	1.955	;	Structure of ATP grasp protein
3WVR	;	2.175	;	Structure of ATP grasp protein with AMP
7LKZ	;	3.27	;	Structure of ATP-bound human ABCA4
3J94	;	4.2	;	Structure of ATP-bound N-ethylmaleimide sensitive factor determined by single particle cryoelectron microscopy
6QV0	;	3.12	;	Structure of ATP-bound outward-facing TM287/288 in complex with sybody Sb_TM35
7LKP	;	3.27	;	Structure of ATP-free human ABCA4
7DRO	;	3.25	;	Structure of ATP-grasp ligase PsnB complexed with minimal precursor
7DRM	;	3.28	;	Structure of ATP-grasp ligase PsnB complexed with minimal precursor, Mg, and ADP
7DRP	;	2.98	;	Structure of ATP-grasp ligase PsnB complexed with phosphomimetic variant of minimal precursor, Mg, and ADP
7DRN	;	3.56	;	Structure of ATP-grasp ligase PsnB complexed with precursor peptide PsnA2 and AMPPNP
1Q1K	;	2.9	;	Structure of ATP-phosphoribosyltransferase from E. coli complexed with PR-ATP
7XUN	;	3.4	;	Structure of ATP7B C983S/C985S/D1027A mutant
7XUK	;	3.3	;	Structure of ATP7B C983S/C985S/D1027A mutant in presence of ATOX1
8IOY	;	4.0	;	Structure of ATP7B C983S/C985S/D1027A mutant with AMP-PNP
7XUO	;	3.6	;	Structure of ATP7B C983S/C985S/D1027A mutant with cisplatin in presence of ATOX1
7XUM	;	3.8	;	Structure of ATP7B C983S/C985S/D1027A mutant with Cu+ in presence of ATOX1
7SI6	;	3.32	;	Structure of ATP7B in state 1
7SI7	;	3.49	;	Structure of ATP7B in state 2
4HUT	;	1.95	;	Structure of ATP:co(I)rrinoid adenosyltransferase (CobA) from Salmonella enterica in complex with four and five-coordinate cob(II)alamin and ATP
6O09	;	2.06	;	Structure of AtPCNA in complex with the PIP motif of ATXR6
6QV2	;	4.23	;	Structure of ATPgS-bound outward-facing TM287/288 in complex with nanobody Nb_TM#2
6QV1	;	3.48	;	Structure of ATPgS-bound outward-facing TM287/288 in complex with nanobody Nb_TM1
6QUZ	;	3.21	;	Structure of ATPgS-bound outward-facing TM287/288 in complex with sybody Sb_TM35
6QIM	;	3.7	;	Structure of AtPIP2;4
4GR2	;	2.0	;	Structure of AtRbcX1 from Arabidopsis thaliana.
7AL8	;	2.85	;	Structure of ATSI with bovine trypsin
7FHN	;	3.3	;	Structure of AtTPC1 D240A/D454A/E528A mutant with 1 mM Ca2+
7FHO	;	2.8	;	Structure of AtTPC1 D240A/D454A/E528A mutant with 50 mM Ca2+
6CX0	;	3.501	;	Structure of AtTPC1 D376A
7FHK	;	3.3	;	Structure of AtTPC1 with 1 mM Ca2+
7FHL	;	3.1	;	Structure of AtTPC1 with 50 mM Ca2+
6E1N	;	3.7	;	Structure of AtTPC1(DDE) in state 1
6E1P	;	3.7	;	Structure of AtTPC1(DDE) in state 2
6E1M	;	3.3	;	Structure of AtTPC1(DDE) reconstituted in saposin A
6E1K	;	3.3	;	Structure of AtTPC1(DDE) reconstituted in saposin A with cat06 Fab
3IPC	;	1.3	;	Structure of ATU2422-GABA F77A mutant receptor in complex with leucine
3IP5	;	1.35	;	Structure of Atu2422-GABA receptor in complex with alanine
3IPA	;	1.55	;	Structure of ATU2422-GABA receptor in complex with alanine
3IP9	;	1.8	;	Structure of Atu2422-GABA receptor in complex with GABA
3IP6	;	1.4	;	Structure of Atu2422-GABA receptor in complex with proline
3IP7	;	1.7	;	Structure of Atu2422-GABA receptor in complex with valine
4EQ7	;	1.91	;	Structure of Atu4243-GABA receptor
4EUO	;	1.28	;	Structure of Atu4243-GABA sensor
8UOO	;	1.65	;	Structure of atypical asparaginase from Rhodospirillum rubrum
8UPC	;	1.2	;	Structure of atypical asparaginase from Rhodospirillum rubrum (mutant K158M)
8UP7	;	1.7	;	Structure of atypical asparaginase from Rhodospirillum rubrum (mutant K19A)
8UP6	;	1.7	;	Structure of atypical asparaginase from Rhodospirillum rubrum (mutant K19A) in complex with L-Asp
8UOR	;	1.45	;	Structure of atypical asparaginase from Rhodospirillum rubrum (mutant K19E)
8UP9	;	1.47	;	Structure of atypical asparaginase from Rhodospirillum rubrum (mutant K19Q)
8UOW	;	1.6	;	Structure of atypical asparaginase from Rhodospirillum rubrum (mutant Y21A)
8UP3	;	1.76	;	Structure of atypical asparaginase from Rhodospirillum rubrum (mutant Y21F)
8UP8	;	1.9	;	Structure of atypical asparaginase from Rhodospirillum rubrum (mutant Y21F, complex with L-Asp)
8UOU	;	1.35	;	Structure of atypical asparaginase from Rhodospirillum rubrum in complex with L-Asp
6C83	;	2.55	;	Structure of Aurora A (122-403) bound to inhibitory Monobody Mb2 and AMPPCP
2X81	;	2.91	;	STRUCTURE OF AURORA A IN COMPLEX WITH MLN8054
4DHF	;	2.8	;	Structure of Aurora A mutant bound to Biogenidec cpd 15
2VRX	;	1.86	;	Structure of Aurora B kinase in complex with ZM447439
3W18	;	2.5	;	Structure of Aurora kinase A complexed to benzoimidazole-indazole inhibitor XIII
3W2C	;	2.45	;	Structure of Aurora kinase A complexed to benzoimidazole-indazole inhibitor XV
3W16	;	2.8	;	Structure of Aurora kinase A complexed to pyrazole-aminoquinoline inhibitor III
8GUW	;	2.7	;	Structure of Aurora Kinase A in complex with activator peptide
2J4Z	;	2.0	;	Structure of Aurora-2 in complex with PHA-680626
2J50	;	3.0	;	Structure of Aurora-2 in complex with PHA-739358
1OL5	;	2.5	;	Structure of Aurora-A 122-403, phosphorylated on Thr287, Thr288 and bound to TPX2 1-43
2XNG	;	2.605	;	Structure of Aurora-A bound to a selective imidazopyrazine inhibitor
2XNE	;	2.8	;	Structure of Aurora-A bound to an imidazopyrazine inhibitor
3EFW	;	2.29	;	Structure of AuroraA with pyridyl-pyrimidine urea inhibitor
5X9K	;	1.798	;	Structure of AusH from Aspergillus nidulans
3PL6	;	2.55	;	Structure of Autoimmune TCR Hy.1B11 in complex with HLA-DQ1 and MBP 85-99
7APJ	;	2.05	;	Structure of autoinhibited Akt1 reveals mechanism of PIP3-mediated activation
7RX9	;	3.22	;	Structure of autoinhibited P-Rex1
1NG2	;	1.7	;	Structure of autoinhibited p47phox
5LQQ	;	2.4	;	Structure of Autotaxin (ENPP2) with LM350
6WPA	;	3.09	;	Structure of AvaR1 bound to DNA half-site
1JSO	;	2.4	;	STRUCTURE OF AVIAN H5 HAEMAGGLUTININ BOUND TO LSTC RECEPTOR ANALOG
1JSN	;	2.4	;	STRUCTURE OF AVIAN H5 HAEMAGGLUTININ COMPLEXED WITH LSTA RECEPTRO ANALOG
2VRS	;	1.75	;	Structure of avian reovirus sigmaC117-326, C2 crystal form
2JJL	;	2.3	;	Structure of avian reovirus sigmaC117-326, P321 crystal form
4HEF	;	1.86	;	Structure of avibactam bound to Pseudomonas aeruginosa AmpC
2A5C	;	2.5	;	Structure of Avidin in complex with the ligand 8-oxodeoxyadenosine
2A8G	;	1.99	;	Structure of Avidin in complex with the ligand deoxyguanosine
1NQN	;	1.8	;	Structure of Avm-W110K (W110K mutant of avidin)
5BN1	;	1.6	;	Structure of Axe2-W215I, an acetyl xylan esterase from Geobacillus stearothermophilus
8JTK	;	1.57	;	Structure of AYWB phytoplasma SAP05 recognizing AtRpn10
8I4K	;	1.84	;	Structure of Azami Red1.0, a red fluorescent protein engineered from Azami Green
6QU0	;	1.8	;	Structure of azoreductase from Bacillus sp. A01
6S6T	;	4.1	;	Structure of Azospirillum brasilense Glutamate Synthase in a4b3 oligomeric state
6S6S	;	3.9	;	Structure of Azospirillum brasilense Glutamate Synthase in a4b4 oligomeric state.
6S6U	;	3.5	;	Structure of Azospirillum brasilense Glutamate Synthase in a6b4 oligomeric state.
6S6X	;	3.5	;	Structure of Azospirillum brasilense Glutamate Synthase in a6b6 oligomeric state.
5NSF	;	2.426	;	Structure of AzuAla
2AZA	;	1.8	;	STRUCTURE OF AZURIN FROM ALCALIGENES DENITRIFICANS. REFINEMENT AT 1.8 ANGSTROMS RESOLUTION AND COMPARISON OF THE TWO CRYSTALLOGRAPHICALLY INDEPENDENT MOLECULES
7ALO	;	1.8	;	Structure of B*27:09/photoRL9
3EIL	;	2.6	;	Structure of B-DNA d(CGTTAATTAACG)2 in the presence of Manganese
4MBZ	;	1.75	;	Structure of B-Lymphotropic Polyomavirus VP1 in complex with 3'-sialyllactosamine
4MBY	;	1.48	;	Structure of B-Lymphotropic Polyomavirus VP1 in complex with 3'-sialyllactose
3BP9	;	2.6	;	Structure of B-tropic MLV capsid N-terminal domain
5F51	;	2.53	;	Structure of B. abortus WrbA-related protein A (apo)
5F4B	;	2.498	;	Structure of B. abortus WrbA-related protein A (WrpA)
1YQY	;	2.3	;	Structure of B. Anthrax Lethal factor in complex with a hydroxamate inhibitor
5HDJ	;	1.89	;	Structure of B. megaterium NfrA1
5HEI	;	2.84	;	Structure of B. megaterium NfrA2
5VMA	;	1.95	;	Structure of B. pumilus GH48 in complex with a cellobio-derived isofagomine
4APZ	;	2.01	;	Structure of B. subtilis genomic dUTPase YncF in complex with dU, PPi and Mg in P1
4R25	;	2.5193	;	Structure of B. subtilis GlnK
4RX6	;	2.5994	;	Structure of B. subtilis GlnK-ATP complex to 2.6 Angstrom
1T4A	;	2.0	;	Structure of B. Subtilis PurS C2 Crystal Form
2OGG	;	2.5	;	Structure of B. subtilis trehalose repressor (TreR) effector binding domain
1PUJ	;	2.0	;	Structure of B. subtilis YlqF GTPase
2CFX	;	2.4	;	Structure of B.subtilis LrpC
4FQM	;	3.45	;	Structure of B/Brisbane/60/2008 Influenza Hemagglutinin
6FYW	;	2.2	;	Structure of B/Brisbane/60/2008 Influenza Hemagglutinin in complex with SD83
7LSB	;	2.492	;	Structure of B1, a monoclonal VEGFR2 antibody parental of KD035
1ZEG	;	1.6	;	STRUCTURE OF B28 ASP INSULIN IN COMPLEX WITH PHENOL
5NDC	;	2.3	;	Structure of ba3-type cytochrome c oxidase from Thermus thermophilus by serial femtosecond crystallography
3HVG	;	2.26	;	Structure of bace (beta secretase) in Complex with EV0
3MSJ	;	1.8	;	Structure of bace (beta secretase) in complex with inhibitor
3HW1	;	2.48	;	Structure of Bace (beta secretase) in complex with ligand EV2
4DJY	;	1.86	;	Structure of BACE Bound to (R)-5-cyclopropyl-2-imino-3-methyl-5-(3-(5-(prop-1-yn-1-yl)pyridin-3-yl)phenyl)imidazolidin-4-one
4HA5	;	1.83	;	Structure of BACE Bound to (S)-3-(5-(2-imino-1,4-dimethyl-6-oxohexahydropyrimidin-4-yl)thiophen-3-yl)benzonitrile
4FS4	;	1.74	;	Structure of BACE Bound to (S)-4-(3'-methoxy-[1,1'-biphenyl]-3-yl)-1,4-dimethyl-6-oxotetrahydropyrimidin-2(1H)-iminium
4H3G	;	1.85	;	Structure of BACE Bound to 2-((7aR)-7a-(4-(3-cyanophenyl)thiophen-2-yl)-2-imino-3-methyl-4-oxohexahydro-1H-pyrrolo[3,4-d]pyrimidin-6(2H)-yl)nicotinonitrile
4H3J	;	1.6	;	Structure of BACE Bound to 2-fluoro-5-(5-(2-imino-3-methyl-4-oxo-6-phenyloctahydro-1H-pyrrolo[3,4-d]pyrimidin-7a-yl)thiophen-2-yl)benzonitrile
4DJU	;	1.8	;	Structure of BACE Bound to 2-imino-3-methyl-5,5-diphenylimidazolidin-4-one
4DJW	;	1.9	;	Structure of BACE Bound to 2-imino-3-methyl-5-phenyl-5-(3-(pyridin-3-yl)phenyl)imidazolidin-4-one
4DJV	;	1.73	;	Structure of BACE Bound to 2-imino-5-(3'-methoxy-[1,1'-biphenyl]-3-yl)-3-methyl-5-phenylimidazolidin-4-one
4H3I	;	1.96	;	Structure of BACE Bound to 3-(5-((7aR)-2-imino-6-(3-methoxypyridin-2-yl)-3-methyl-4-oxooctahydro-1H-pyrrolo[3,4-d]pyrimidin-7a-yl)thiophen-3-yl)benzonitrile
4H3F	;	1.7	;	Structure of BACE Bound to 3-(5-((7aR)-2-imino-6-(6-methoxypyridin-2-yl)-3-methyl-4-oxooctahydro-1H-pyrrolo[3,4-d]pyrimidin-7a-yl)thiophen-3-yl)benzonitrile
4DJX	;	1.5	;	Structure of BACE Bound to 5-(3-(5-chloropyridin-3-yl)phenyl)-5-cyclopropyl-2-imino-3-methylimidazolidin-4-one
3KMY	;	1.9	;	Structure of BACE bound to SCH12472
3KMX	;	1.7	;	Structure of BACE bound to SCH346572
3L58	;	1.8	;	Structure of BACE Bound to SCH589432
3KN0	;	1.9	;	Structure of BACE bound to SCH708236
3CIC	;	1.75	;	Structure of BACE Bound to SCH709583
3L59	;	2.0	;	Structure of BACE Bound to SCH710413
3L5B	;	1.8	;	Structure of BACE Bound to SCH713601
2QMD	;	1.65	;	Structure of BACE Bound to SCH722924
3L5C	;	1.8	;	Structure of BACE Bound to SCH723871
3L5D	;	1.75	;	Structure of BACE Bound to SCH723873
3CID	;	1.8	;	Structure of BACE Bound to SCH726222
3CIB	;	1.72	;	Structure of BACE Bound to SCH727596
2QP8	;	1.5	;	Structure of BACE Bound to SCH734723
2QMF	;	1.75	;	Structure of BACE Bound to SCH735310
3L5E	;	1.53	;	Structure of BACE Bound to SCH736062
3L5F	;	1.7	;	Structure of BACE Bound to SCH736201
3LPJ	;	1.79	;	Structure of BACE Bound to SCH743641
3LNK	;	1.8	;	Structure of BACE bound to SCH743813
3LPI	;	2.05	;	Structure of BACE Bound to SCH745132
2QMG	;	1.89	;	Structure of BACE Bound to SCH745966
3LPK	;	1.93	;	Structure of BACE Bound to SCH747123
2Q11	;	2.4	;	Structure of BACE complexed to compound 1
2Q15	;	2.4	;	Structure of BACE complexed to compound 3a
4FRS	;	1.7	;	Structure of BACE in complex with (S)-4-(3-chloro-5-(5-(prop-1-yn-1-yl)pyridin-3-yl)thiophen-2-yl)-1,4-dimethyl-6-oxotetrahydropyrimidin-2(1H)-iminium
4DH6	;	2.5	;	Structure of Bace-1 (Beta-Secretase) in Complex with (2R)-N-((2S,3R)-1-(benzo[d][1,3]dioxol-5-yl)-3-hydroxy-4-((S)-6'-neopentyl-3',4'-dihydrospiro[cyclobutane-1,2'-pyrano[2,3-b]pyridine]-4'-ylamino)butan-2-yl)-2-methoxypropanamide
3RSV	;	2.5	;	Structure of Bace-1 (Beta-Secretase) in complex with (R)-3-(2-amino-6-o-tolylquinolin-3-yl)-N-((R)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-methylpropanamide
3RVI	;	2.65	;	Structure of Bace-1 (Beta-Secretase) in Complex with 2-((2-Amino-6-o-tolylquinolin-3-yl)methyl)-N-(cyclohexylmethyl)pentanamide
3RTN	;	2.7	;	Structure of Bace-1 (Beta-Secretase) in Complex with 3-(2-Amino-6-o-tolylquinolin-3-yl)-N-cyclohexylpropanamide
3RU1	;	2.3	;	Structure of Bace-1 (Beta-Secretase) in Complex with 3-(2-Aminoquinolin-3-yl)-N-(cyclohexylmethyl)propanamide
3RTM	;	2.76	;	Structure of Bace-1 (Beta-Secretase) in Complex with 3-(2-Aminoquinolin-3-yl)-N-cyclohexyl-N-methylpropanamide
3RTH	;	2.7	;	Structure of Bace-1 (Beta-Secretase) in Complex with 6-(2-(3,3-Dimethylbut-1-ynyl)phenyl)quinolin-2-amine
3RSX	;	2.48	;	Structure of Bace-1 (Beta-Secretase) in Complex with 6-(Thiophen-3-yl)quinolin-2-amine
6C2I	;	1.95	;	Structure of Bace-1 (Beta-Secretase) in complex with : N-(3-((1R,5S,6R)-3-amino-5-methyl-2-oxa-4-azabicyclo[4.1.0]hept-3-en-5-yl)-4-fluorophenyl)-5-methoxypyrazine-2-carboxamide
4DUS	;	2.5	;	Structure of Bace-1 (Beta-Secretase) in complex with N-((2S,3R)-1-(4-fluorophenyl)-3-hydroxy-4-((6'-neopentyl-3',4'-dihydrospiro[cyclobutane-1,2'-pyrano[2,3-b]pyridin]-4'-yl)amino)butan-2-yl)acetamide
4H1E	;	1.9	;	Structure of BACE-1 Bound to (7aR)-6-benzoyl-7a-(4-(3-cyanophenyl)thiophen-2-yl)-3-methyl-4-oxohexahydro-1H-pyrrolo[3,4-d]pyrimidin-2(3H)-iminium
6OD6	;	2.0	;	Structure of BACE-1 in complex with Ligand 13
6E3Z	;	1.94	;	Structure of Bace-1 in complex with Ligand 8
2QK5	;	2.2	;	Structure of BACE1 bound to SCH626485
4TRZ	;	3.25	;	Structure of BACE1 complex with 2-thiophenyl HEA-type inhibitor
4TRY	;	2.75	;	Structure of BACE1 complex with a HEA-type inhibitor
4TRW	;	2.85	;	Structure of BACE1 complex with a syn-HEA-type inhibitor
5YGX	;	2.2	;	Structure of BACE1 in complex with N-(3-((4R,5R,6S)-2-amino-6-(1,1-difluoroethyl)-5-fluoro-4-methyl-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-5-(fluoromethoxy)pyrazine-2-carboxamide
2IFY	;	2.38	;	Structure of Bacillus anthracis cofactor-independent phosphoglucerate mutase
5V8E	;	2.2	;	Structure of Bacillus cereus PatB1
5V8D	;	2.001	;	Structure of Bacillus cereus PatB1 with sulfonyl adduct
8SM3	;	3.0	;	Structure of Bacillus cereus VD045 Gabija GajA-GajB Complex
2GJR	;	2.1	;	Structure of bacillus halmapalus alpha-amylase without any substrate analogues
2GJP	;	1.9	;	Structure of Bacillus halmapalus alpha-amylase, crystallized with the substrate analogue acarbose and maltose
5J21	;	2.0	;	Structure of Bacillus NanoRNase A (WT)
5IPP	;	1.95	;	Structure of Bacillus NanoRNase A active site mutant bound to a mononucleotide
4UBP	;	1.55	;	STRUCTURE OF BACILLUS PASTEURII UREASE INHIBITED WITH ACETOHYDROXAMIC ACID AT 1.55 A RESOLUTION
7QRU	;	2.24	;	Structure of Bacillus pseudofirmus Mrp antiporter complex, monomer
4QOL	;	1.65	;	Structure of Bacillus pumilus catalase
4QON	;	1.8	;	Structure of Bacillus pumilus catalase with catechol bound.
4QOR	;	1.95	;	Structure of Bacillus pumilus catalase with chlorophenol bound.
4QOQ	;	1.7	;	Structure of Bacillus pumilus catalase with guaiacol bound
4QOP	;	1.9	;	Structure of Bacillus pumilus catalase with hydroquinone bound.
4QOO	;	1.75	;	Structure of Bacillus pumilus catalase with resorcinol bound.
7S3L	;	2.6	;	Structure of Bacillus subtilis CcrZ (previously called YtmP)
2C6X	;	3.4	;	Structure of Bacillus subtilis citrate synthase
3TVZ	;	2.0	;	Structure of Bacillus subtilis HmoB
7BZE	;	1.658	;	Structure of Bacillus subtilis HxlR, K13A mutant
7BZD	;	2.612	;	Structure of Bacillus subtilis HxlR, wild type
7BZG	;	2.9	;	Structure of Bacillus subtilis HxlR, wild type in complex with formaldehyde and DNA
5VX6	;	3.197	;	Structure of Bacillus subtilis Inhibitor of motility (MotI/DgrA)
1WPM	;	2.05	;	Structure of Bacillus subtilis inorganic pyrophosphatase
1X37	;		;	Structure of Bacillus subtilis Lon protease SSD domain
2WHK	;	1.7	;	Structure of Bacillus subtilis mannanase man26
4OYH	;	2.409	;	Structure of Bacillus subtilis MobB
1KAM	;	2.1	;	Structure of Bacillus subtilis Nicotinic Acid Mononucleotide Adenylyl Transferase
1KAQ	;	3.2	;	Structure of Bacillus subtilis Nicotinic Acid Mononucleotide Adenylyl Transferase
4D3U	;	1.981	;	Structure of Bacillus subtilis Nitric Oxide Synthase H128S in complex with N-{3-[(1S)-2-(3-{(Z)-[amino(thiophen-2-yl)methylidene]amino}phenoxy)-1-hydroxyethyl]phenyl}thiophene-2-carboximidamide
4D7I	;	1.96	;	Structure of Bacillus subtilis nitric oxide synthase I218V in complex with 6-(4-(((3-Fluorophenethyl)amino)methyl)phenyl)-4-methylpyridin-2- amine
5G6K	;	1.951	;	Structure of Bacillus subtilis Nitric Oxide Synthase I218V in complex with 7-((3-(2-(Methylamino)ethyl)phenoxy)methyl)quinolin-2- amine
5G6I	;	1.981	;	Structure of Bacillus subtilis Nitric Oxide Synthase I218V in complex with 7-((3-(Methylamino)methyl)phenoxy)methyl)quinolin-2-amine
5G6C	;	2.13	;	Structure of Bacillus subtilis Nitric Oxide Synthase I218V in complex with 7-((3-Fluorophenethylamino)ethyl)quinolin-2-amine
5G6P	;	2.18	;	Structure of Bacillus subtilis Nitric Oxide Synthase I218V in complex with 7-((4-(Dimethylamino)methyl)phenoxy)methyl)quinolin-2- amine
4D3V	;	1.88	;	Structure of Bacillus subtilis Nitric Oxide Synthase I218V in complex with N-{3-[(1S)-2-(3-{(Z)-[amino(thiophen-2-yl)methylidene]amino}phenoxy)-1-hydroxyethyl]phenyl}thiophene-2-carboximidamide
4LWA	;	2.06	;	Structure of Bacillus subtilis nitric oxide synthase in complex with ((2S, 3S)-1,3-bis((6-(2,5-dimethyl-1H-pyrrol-1-yl)-4-methylpyridin-2-yl)methoxy)-2-aminobutane
4UGG	;	2.356	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with (R)-6-(2-Amino-2-(3-(2-(6-amino-4-methylpyridin-2-yl)ethyl)phenyl) ethyl)-4-methylpyridin-2-amine
4UGN	;	2.09	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with (S)-N-(3-(((Pyrrolidin-2-ylmethyl)amino)methyl)phenyl)thiophene-2- carboximidamide
4UG7	;	1.76	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 3,5-bis(2-(6-amino-4-methylpyridin-2-yl)ethyl)benzonitrile
4D3N	;	2.13	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 3-(2-(6-Amino-4-methylpyridin-2-yl)ethyl)-5-((2-(pyridin-2-yl)ethyl)amino)benzonitrile
4D3M	;	1.741	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 3-(2-(6-Amino-4-methylpyridin-2-yl)ethyl)-5-(2-(4-methyl-6-(methylamino)pyridin-2-yl)ethyl)benzonitrile
4UGJ	;	1.78	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 3-(2-(6-Amino-4-methylpyridin-2-yl)ethyl)-5-(methyl(2-(methylamino) ethyl)amino)benzonitrile
4UQS	;	2.15	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 3-Bromo-7-Nitroindazole
4UGE	;	2.14	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 4-methyl-6-((3-(piperidin-4-ylmethoxy)phenoxy)methyl)pyridin-2-amine
5G66	;	1.76	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 4-methylquinolin-2-amine
4UGC	;	1.801	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 6,6'-(((2S)-3-aminopropane-1,2-diyl)bis(oxymethanediyl))bis(4- methylpyridin-2-amine)
4UG9	;	1.841	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 6,6'-((4-(3-aminopropyl)benzene-1,3-diyl)diethane-2,1-diyl)bis(4- methylpyridin-2-amine)
4D3K	;	2.017	;	Structure of Bacillus subtilis nitric oxide synthase in complex with 6,6'-((5-(3-aminopropyl)-1,3-phenylene)bis(ethane-2,1-diyl))bis(4- methylpyridin-2-amine)
4D3I	;	2.09	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 6,6'-((5-(aminomethyl)-1,3-phenylene)bis(ethane-2,1-diyl))bis(4- methylpyridin-2-amine)
4D3J	;	1.67	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 6,6'-(2,2'-(5-amino-1,3-phenylene)bis(ethane-2,1-diyl))bis(4- methylpyridin-2-amine)
4UG6	;	1.81	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 6,6'-(pyridine-3,5-diyldiethane-2,1-diyl)bis(4-methylpyridin-2-amine)
4UGD	;	2.03	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 6-((((2S)-1-amino-4-((6-amino-4-methylpyridin-2-yl)methoxy)butan-2-yl) oxy)methyl)-4-methylpyridin-2-amine
4LWB	;	2.15	;	Structure of Bacillus subtilis nitric oxide synthase in complex with 6-((((3R,5S)-5-(((6-amino-4-methylpyridin-2-yl)methoxy)methyl)pyrrolidin-3-yl)oxy)methyl)-4-methylpyridin-2-amine
4UGF	;	1.81	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 6-((((3S, 5R)-5-(((6-amino-4-methylpyridin-2-yl)methoxy)methyl) pyrrolidin-3-yl)oxy)methyl)-4-methylpyridin-2-amine
4UGB	;	1.912	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 6-(((5-(((2-(3-fluorophenyl)ethyl)amino)methyl)pyridin-3-yl)oxy) methyl)-4-methylpyridin-2-amine
4UGA	;	1.9	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 6-((3-(((2-(3-fluorophenyl)ethyl)amino)methyl)phenoxy)methyl)-4- methylpyridin-2-amine
4UG5	;	2.352	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 6-(2-(5-(2-(2-amino-6-methylpyridin-4-yl)ethyl)pyridin-3-yl)ethyl)-4- methylpyridin-2-amine
4UGK	;	1.62	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 6-(2-(5-(2-(Dimethylamino)ethyl)pyridin-3-yl)ethyl)-4-methylpyridin-2- amine
4D3O	;	1.9	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 6-(3-(2-(1H-Pyrrolo(2,3-b)pyridin-6-yl)ethyl)-5-(aminomethyl) phenethyl)-4-methylpyridin-2-amine
4D7J	;	1.55	;	Structure of Bacillus subtilis nitric oxide synthase in complex with 6-(4-(((3-Fluorophenethyl)amino)methyl)phenyl)-4-methylpyridin-2- amine
4UG8	;	1.888	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 6-(5-((3R,4R)-4-((6-azanyl-4-methyl-pyridin-2-yl)methyl)pyrrolidin-3- yl)oxypentyl)-4-methyl-pyridin-2-amine
5G6F	;	2.26	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 7-(((3-((Dimethylamino)methyl)phenyl)amino)methyl) quinolin-2-amine
5G6D	;	1.821	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 7-(((3-(Dimethylamino)benzyl)amino)methyl)quinolin-2-amine
5G6E	;	2.111	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 7-(((3-(Pyridin-3-yl)propyl)amino)methyl)quinolin-2-amine
5G6Q	;	2.03	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 7-(((5-((Methylamino)methyl)pyridin-3-yl)oxy)methyl) quinolin-2-amine
5G6G	;	1.981	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 7-((2-((Methylamino)methyl)phenoxy)methyl)quinolin-2-amine
6XK8	;	2.25	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 7-((3-((((6-aminopyridin-2-yl)methyl)amino)methyl)phenoxy)methyl)quinolin-2-amine
5G6J	;	1.88	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 7-((3-(2-(Methylamino)ethyl)phenoxy)methyl)quinolin-2- amine
5G6H	;	1.911	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 7-((3-(Methylamino)methyl)phenoxy)methyl)quinolin-2-amine
5G6M	;	1.77	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 7-((3-Aminomethyl)phenoxy)methyl)quinolin-2-amine
5G6A	;	1.92	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 7-((3-Fluorophenethylamino)ethyl)quinolin-2-amine
5G67	;	1.97	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 7-((3-Fluorophenethylamino)methyl)quinolin-2-amine
5G6N	;	1.91	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 7-((4-(Dimethylamino)methyl)phenoxy)methyl)quinolin-2- amine
5G6L	;	2.034	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 7-((4-Chloro-3-((methylamino)methyl)phenoxy)methyl) quinolin-2-amine
4D7H	;	2.02	;	Structure of Bacillus subtilis nitric oxide synthase in complex with 7-(2-(3-(3-Fluorophenyl(propylamino)ethyl))quinolin-2- amine
5G68	;	1.63	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 7-(2-(3-(3-Fluorophenyl(propylamino)methyl))quinolin-2- amine
5G69	;	2.016	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 7-(2-(3-Fluorobenzylamino)ethyl)quinolin-2-amine
4UGP	;	1.8	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with N',N'-(((2R)-3-aminopropane-1,2-diyl)bis(oxymethanediylbenzene-3,1- diyl))dithiophene-2-carboximidamide
4UGU	;	1.801	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with N'-(4-(((2S,4R)-4-(3-((C-thiophen-2-ylcarbonimidoyl)amino)phenoxy) pyrrolidin-2-yl)methoxy)phenyl)thiophene-2-carboximidamide
4UGQ	;	1.85	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with N,N''-(((2S)-3-aminopropane-1,2-diyl)bis(oxymethanediylbenzene-3,1- diyl))dithiophene-2-carboximidamide
4UGS	;	1.99	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with N,N'-(ethane-1,2-diylbis(oxybenzene-3,1-diyl))dithiophene-2- carboximidamide
4UGM	;	2.09	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with N,N'-(ethane-1,2-diyldibenzene-3,1-diyl)dithiophene-2-carboximidamide
4UGR	;	2.09	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with N-(3-(((2S,4S)-4-((3-((C-thiophen-2-ylcarbonimidoyl)amino)phenyl) methoxy)pyrrolidin-2-yl)methoxymethyl)phenyl)thiophene-2- carboximidamide
4UGX	;	1.86	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with N-(3-((ethyl(2-(3-fluorophenyl)ethyl)amino)methyl)phenyl)thiophene-2- carboximidamide
4UGT	;	2.03	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with N-(3-((pyrrolidin-3-yloxy)methyl)phenyl)thiophene-2-carboximidamide
4UGO	;	2.38	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with N-(4-(2-(ethyl(3-(((E)-imino(thiophen-2-yl)methyl)amino)benzyl)amino) ethyl)phenyl)thiophene-2-carboximidamide
4UQR	;	1.72	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with N-omega-Nitro-L-Arginine
4D3T	;	1.55	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with N-{3-[(1S)-2-(3-{(Z)-[amino(thiophen-2-yl)methylidene]amino}phenoxy)-1-hydroxyethyl]phenyl}thiophene-2-carboximidamide
4UGL	;	1.82	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with N1-(3-(2-(6-Amino-4-methylpyridin-2-yl)ethyl)-5-fluorophenyl)-N1- cyclopropyl-N2-methylethane-1,2-diamine
4UGH	;	1.994	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with N1-(3-(2-(6-Amino-4-methylpyridin-2-yl)ethyl)phenyl)-N1,N2- dimethylethane-1,2-diamine
4UGY	;	1.801	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with N1-(5-(2-(6-Amino-4-methylpyridin-2-yl)ethyl)pyridin-3-yl)-N1,N2- dimethylethane-1,2-diamine
4UGI	;	1.801	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with N1-(6-(2-(6-Amino-4-methylpyridin-2-yl)ethyl)pyridin-2-yl)-N1,N2- dimethylethane-1,2-diamine
5G65	;	2.03	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with quinolin-2-amine
5G6B	;	1.801	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with two molecules of 7-((3-Fluorophenethylamino)ethyl)quinolin-2-amine
5G6O	;	1.719	;	Structure of Bacillus subtilis Nitric Oxide Synthase in complex with two molecules of 7-((4-(Dimethylamino)methyl)phenoxy)methyl)quinolin- 2- amine
1W1A	;	2.25	;	Structure of Bacillus subtilis PdaA in complex with NAG, a family 4 Carbohydrate esterase.
1W1B	;	2.1	;	Structure of Bacillus subtilis PdaA with Cadmium, a family 4 Carbohydrate esterase.
1W17	;	1.9	;	Structure of Bacillus subtilis PdaA, a family 4 Carbohydrate esterase.
8ACU	;	2.97	;	Structure of Bacillus subtilis Rel in complex with DarB
1KYH	;	1.6	;	Structure of Bacillus subtilis YxkO, a Member of the UPF0031 Family and a Putative Kinase
7SNO	;	2.1	;	Structure of Bacple_01701(H214N), a 6-O-galactose porphyran sulfatase
7SNJ	;	1.74	;	Structure of Bacple_01701, a 6-O-galactose porphyran sulfatase
7SNK	;	2.0	;	Structure of Bacple_01702, a GH29 family glycoside hydrolase
8EP4	;	1.94	;	Structure of Bacple_01703
8EW1	;	1.8	;	Structure of Bacple_01703-E145L
5LMV	;	4.9	;	Structure of bacterial 30S-IF1-IF2-IF3-mRNA-tRNA translation pre-initiation complex(state-III)
5LMN	;	3.55	;	Structure of bacterial 30S-IF1-IF3-mRNA translation pre-initiation complex (state-1A)
5LMO	;	4.3	;	Structure of bacterial 30S-IF1-IF3-mRNA translation pre-initiation complex (state-1B)
5LMP	;	5.35	;	Structure of bacterial 30S-IF1-IF3-mRNA translation pre-initiation complex (state-1C)
5LMR	;	4.45	;	Structure of bacterial 30S-IF1-IF3-mRNA-tRNA translation pre-initiation complex(state-2B)
5LMS	;	5.1	;	Structure of bacterial 30S-IF1-IF3-mRNA-tRNA translation pre-initiation complex(state-2C)
5LMT	;	4.15	;	Structure of bacterial 30S-IF1-IF3-mRNA-tRNA translation pre-initiation complex(state-3)
5LMQ	;	4.2	;	Structure of bacterial 30S-IF1-IF3-mRNA-tRNA translation pre-initiation complex, open form (state-2A)
5LMU	;	4.0	;	Structure of bacterial 30S-IF3-mRNA-tRNA translation pre-initiation complex, closed form (state-4)
4P02	;	2.65	;	Structure of Bacterial Cellulose Synthase with cyclic-di-GMP bound.
3C1Y	;	2.1	;	Structure of bacterial DNA damage sensor protein with co-purified and co-crystallized ligand
5FPO	;	1.83	;	Structure of Bacterial DNA Ligase with small-molecule ligand 1H- indazol-7-amine (AT4213) in an alternate binding site.
5FPR	;	2.0	;	Structure of Bacterial DNA Ligase with small-molecule ligand pyrimidin-2-amine (AT371) in an alternate binding site.
4IT9	;	1.7	;	Structure of Bacterial Enzyme
4ITA	;	1.4	;	Structure of bacterial enzyme in complex with cofactor
4ITB	;	1.4	;	Structure of bacterial enzyme in complex with cofactor and substrate
6SIH	;	4.7	;	Structure of bacterial flagellar capping protein FliD
2WY4	;	1.35	;	Structure of bacterial globin from Campylobacter jejuni at 1.35 A resolution
8PX7	;	3.4	;	Structure of Bacterial Multidrug Efflux transporter AcrB, solved at wavelength 3.02 A
5OGL	;	2.7	;	Structure of bacterial oligosaccharyltransferase PglB in complex with an acceptor peptide and an lipid-linked oligosaccharide analog
4QM7	;	1.8	;	Structure of bacterial polynucleotide kinase bound to GTP and pDNA
4QM6	;	1.5	;	Structure of bacterial polynucleotide kinase bound to GTP and RNA
4MDF	;	1.727	;	Structure of bacterial polynucleotide kinase Michaelis complex bound to GTP and DNA
4MDE	;	1.8	;	Structure of bacterial polynucleotide kinase product complex bound to GDP and DNA
3AQK	;	3.65	;	Structure of bacterial protein (apo form I)
3AQL	;	3.0	;	Structure of bacterial protein (apo form II)
3AQM	;	3.15	;	Structure of bacterial protein (form II)
8PVA	;	4.5	;	Structure of bacterial ribosome determined by cryoEM at 100 keV
7RFQ	;	1.27	;	STRUCTURE OF BACTERIAL SYLF DOMAIN CONTAINING PROTEIN, BETA CELL EXPANSION FACTOR A (BEFA)
5WED	;	2.15	;	Structure of bacterial type II NADH dehydrogenase from Caldalkalibacillus thermarum at 2.15A resolution
4NWZ	;	2.5	;	Structure of bacterial type II NADH dehydrogenase from Caldalkalibacillus thermarum at 2.5A resolution
6BDO	;	2.8	;	Structure of bacterial type II NADH dehydrogenase from Caldalkalibacillus thermarum complexed with a quinone inhibitor HQNO at 2.8A resolution
7UM1	;	4.2	;	Structure of bacteriophage AR9 non-virion RNAP polymerase holoenzyme determined by cryo-EM
1ZDJ	;	2.9	;	STRUCTURE OF BACTERIOPHAGE COAT PROTEIN-LOOP RNA COMPLEX
1ZDK	;	2.86	;	STRUCTURE OF BACTERIOPHAGE COAT PROTEIN-LOOP RNA COMPLEX
2OB9	;	2.3	;	Structure of bacteriophage HK97 tail assembly chaperone
1RIO	;	2.3	;	Structure of bacteriophage lambda cI-NTD in complex with sigma-region4 of Thermus aquaticus bound to DNA
1ZPQ	;	2.8	;	STRUCTURE OF BACTERIOPHAGE LAMBDA CII protein
1ZS4	;	1.7	;	Structure of bacteriophage lambda cII protein in complex with DNA
7T4F	;	2.7	;	Structure of bacteriophage lambda tube protein V in C3
7T2E	;	2.7	;	Structure of bacteriophage lambda tube protein V in C6
7UYX	;	2.63	;	Structure of bacteriophage PA1c gp2
3A9L	;	1.9	;	Structure of Bacteriophage poly-gamma-glutamate hydrolase
1DWN	;	3.5	;	Structure of bacteriophage PP7 from Pseudomonas aeruginosa at 3.7 A resolution
4OK7	;	1.9	;	Structure of bacteriophage SPN1S endolysin from Salmonella typhimurium
2LFP	;		;	Structure of bacteriophage SPP1 gp17 protein
5A20	;	7.6	;	Structure of bacteriophage SPP1 head-to-tail interface filled with DNA and tape measure protein
5A21	;	7.2	;	Structure of bacteriophage SPP1 head-to-tail interface without DNA and tape measure protein
2WSH	;	1.9	;	Structure of bacteriophage T4 EndoII E118A mutant
1EL6	;	2.0	;	STRUCTURE OF BACTERIOPHAGE T4 GENE PRODUCT 11, THE INTERFACE BETWEEN THE BASEPLATE AND SHORT TAIL FIBERS
5IW9	;	2.47	;	Structure of bacteriophage T4 gp25, sheath polymerization initiator
2LZM	;	1.7	;	STRUCTURE OF BACTERIOPHAGE T4 LYSOZYME REFINED AT 1.7 ANGSTROMS RESOLUTION
6N7N	;	3.5	;	Structure of bacteriophage T7 E343Q mutant gp4 helicase-primase in complex with ssDNA, dTTP, AC dinucleotide and CTP (form I)
6N7S	;	4.6	;	Structure of bacteriophage T7 E343Q mutant gp4 helicase-primase in complex with ssDNA, dTTP, AC dinucleotide and CTP (form II)
6N7T	;	3.9	;	Structure of bacteriophage T7 E343Q mutant gp4 helicase-primase in complex with ssDNA, dTTP, AC dinucleotide and CTP (form III)
6N7I	;	3.2	;	Structure of bacteriophage T7 E343Q mutant gp4 helicase-primase in complex with ssDNA, dTTP, AC dinucleotide and CTP (gp4(5)-DNA)
6N7V	;	3.8	;	Structure of bacteriophage T7 gp4 (helicase-primase, E343Q mutant) in complex with ssDNA, dTTP, AC dinucleotide, and CTP (from multiple lead complexes)
6N9V	;	4.0	;	Structure of bacteriophage T7 lagging-strand DNA polymerase (D5A/E7A) and gp4 (helicase/primase) bound to DNA including RNA/DNA hybrid, and an incoming dTTP (LagS1)
6N9W	;	4.0	;	Structure of bacteriophage T7 lagging-strand DNA polymerase (D5A/E7A) and gp4 (helicase/primase) bound to DNA including RNA/DNA hybrid, and an incoming dTTP (LagS2)
6N9X	;	4.1	;	Structure of bacteriophage T7 lagging-strand DNA polymerase (D5A/E7A) and gp4 (helicase/primase) bound to DNA including RNA/DNA hybrid, and an incoming dTTP (LagS3)
6N9U	;	3.7	;	Structure of bacteriophage T7 lagging-strand DNA polymerase (D5A/E7A) interacting with primase domains of two gp4 subunits bound to an RNA/DNA hybrid and dTTP (from LagS1)
6N7W	;	4.5	;	Structure of bacteriophage T7 leading-strand DNA polymerase (D5A/E7A)/Trx in complex with a DNA fork and incoming dTTP (from multiple lead complexes)
4OV0	;	2.0	;	Structure of Bacteriorhdopsin Transferred from Amphipol A8-35 to a Lipidic Mesophase
1QM8	;	2.5	;	Structure of Bacteriorhodopsin at 100 K
2AT9	;	3.0	;	STRUCTURE OF BACTERIORHODOPSIN AT 3.0 ANGSTROM BY ELECTRON CRYSTALLOGRAPHY
1AT9	;	2.8	;	STRUCTURE OF BACTERIORHODOPSIN AT 3.0 ANGSTROM DETERMINED BY ELECTRON CRYSTALLOGRAPHY
5BR2	;	1.8	;	Structure of bacteriorhodopsin crystallized from ND-MSP1
5BR5	;	2.0	;	Structure of bacteriorhodopsin crystallized from ND-MSP1E3D1
5VN7	;	2.7	;	Structure of bacteriorhodopsin from crystals grown at 20 deg Celcius using GlyNCOC15+4 as an LCP host lipid
5VN9	;	2.594	;	Structure of bacteriorhodopsin from crystals grown at 4 deg C using GlyNCOC15+4 as an LCP host lipid
3NSB	;	1.78	;	Structure of bacteriorhodopsin ground state before and after X-ray modification
5A44	;	2.29	;	Structure of Bacteriorhodopsin obtained from 20um crystals by multi crystal data collection
5A45	;	2.57	;	Structure of Bacteriorhodopsin obtained from 5um crystals by multi crystal data collection
2ZZL	;	2.03	;	Structure of bacteriorhodopsin's M intermediate at pH 7
3MBV	;	2.0	;	Structure of bacterirhodopsin crystallized in betta-XylOC(16+4) meso phase
8SWT	;	1.66	;	Structure of Bacteroides fragilis PNP bound to transition state analog IMMUCILLIN H and sulfate
5FHD	;	2.0	;	Structure of Bacteroides sp Pif1 complexed with tailed dsDNA resulting in ssDNA bound complex
1TN0	;	2.5	;	Structure of bacterorhodopsin mutant A51P
1TN5	;	2.2	;	Structure of bacterorhodopsin mutant K41P
3P0K	;	1.47	;	Structure of Baculovirus Sulfhydryl Oxidase Ac92
3QZY	;	2.14	;	Structure of Baculovirus Sulfhydryl Oxidase Ac92
1TUH	;	1.85	;	Structure of Bal32a from a Soil-Derived Mobile Gene Cassette
6Y8Z	;	2.05	;	Structure of Baltic Herring (Clupea Harengus) Phosphoglucomutase 5 (PGM5)
6Y8Y	;	1.95	;	Structure of Baltic Herring (Clupea Harengus) Phosphoglucomutase 5 (PGM5) with bound Glucose-1-Phosphate
7RI6	;	5.9	;	Structure of BAM in MSP1E3D1 nanodiscs prepared from E. coli outer membranes
4PK1	;	3.1	;	Structure of BamB fused to a BamA POTRA domain fragment
3ZW0	;	1.6	;	Structure of BambL lectin from Burkholderia ambifaria
3ZW1	;	1.6	;	Structure of Bambl lectine in complex with lewix x antigen
3ZWE	;	1.75	;	Structure of BambL, a lectin from Burkholderia ambifaria, complexed with blood group B epitope
2YHC	;	1.8	;	Structure of BamD from E. coli
5WAQ	;	2.501	;	Structure of BamD from Neisseria gonorrhoeae
5WAM	;	2.45	;	Structure of BamE from Neisseria gonorrhoeae
3MIV	;	3.5	;	Structure of Banana lectin - Glc-alpha(1,2)-Glc complex
1X1V	;	2.45	;	Structure Of Banana Lectin- Methyl-Alpha-Mannose Complex
3MIT	;	2.32	;	Structure of Banana lectin-alpha-D-mannose complex
3MIU	;	2.63	;	Structure of Banana Lectin-pentamannose complex
8K4A	;	2.64	;	Structure of Banna virus core
8W9R	;	4.8	;	Structure of Banna virus core
1W9Z	;	2.56	;	Structure of Bannavirus VP9
8OFF	;	3.4	;	Structure of BARD1 ARD-BRCTs in complex with H2AKc15ub nucleosomes (Map1)
6BNO	;	5.5	;	Structure of bare actin filament
6BNU	;	7.5	;	Structure of bare actin filament, backbone-averaged with sidechains truncated to alanine
4A7N	;	8.9	;	Structure of bare F-actin filaments obtained from the same sample as the Actin-Tropomyosin-Myosin Complex
4HLN	;	2.7	;	Structure of barley starch synthase I in complex with maltooligosaccharide
8J9K	;	3.5	;	Structure of basal beta-arrestin2
3O83	;	1.9	;	Structure of BasE N-terminal domain from Acinetobacter baumannii bound to 2-(4-n-dodecyl-1,2,3-triazol-1-yl)-5'-O-[N-(2-hydroxybenzoyl)sulfamoyl]adenosine
3O82	;	2.7	;	Structure of BasE N-terminal domain from Acinetobacter baumannii bound to 5'-O-[N-(2,3-dihydroxybenzoyl)sulfamoyl] adenosine
3U17	;	2.1	;	Structure of BasE N-terminal domain from Acinetobacter baumannii bound to 6-(p-benzoyl)phenyl-1-(pyridin-4-ylmethyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid
3U16	;	2.1	;	Structure of BasE N-terminal domain from Acinetobacter baumannii bound to 6-(p-benzyloxy)phenyl-1-(pyridin-4-ylmethyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid.
3O84	;	2.1	;	Structure of BasE N-terminal domain from Acinetobacter baumannii bound to 6-phenyl-1-(pyridin-4-ylmethyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid.
8FQC	;	3.2	;	Structure of baseplate with receptor binding complex of Agrobacterium phage Milano
7W6R	;	2.6	;	Structure of Bat coronavirus RaTG13 spike receptor-binding domain complexed with its receptor equine ACE2
5D79	;	1.849	;	Structure of BBE-like #28 from Arabidopsis thaliana
2AUA	;	2.35	;	Structure of BC2332: A Protein of Unknown Function from Bacillus cereus
2YQ7	;	1.901	;	Structure of Bcl-xL bound to BimLOCK
2YQ6	;	1.799	;	Structure of Bcl-xL bound to BimSAHB
1BXL	;		;	STRUCTURE OF BCL-XL/BAK PEPTIDE COMPLEX, NMR, MINIMIZED AVERAGE STRUCTURE
1PBW	;	2.0	;	STRUCTURE OF BCR-HOMOLOGY (BH) DOMAIN
6EA5	;	4.75	;	Structure of BDBV GPcl in complex with the pan-ebolavirus mAb ADI-15878
7OC9	;	1.5	;	Structure of Bdellovibrio bacteriovorus Bd0675
7O21	;	1.34	;	Structure of Bdellovibrio bacteriovorus Bd1075
6HOK	;	1.61	;	Structure of Beclin1 LIR (S96E) motif bound to GABARAP
6HOJ	;	1.51	;	Structure of Beclin1 LIR motif bound to GABARAP
6HOI	;	1.14	;	Structure of Beclin1 LIR motif bound to GABARAPL1
5YR0	;	1.9	;	Structure of Beclin1-UVRAG coiled coil domain complex
8EYU	;	1.95	;	Structure of Beetroot dimer bound to DFAME
8EYV	;	2.55	;	Structure of Beetroot dimer bound to DFHO
7Z39	;	1.6	;	Structure of Belumosudil bound to CK2alpha
3IAE	;	2.3	;	Structure of benzaldehyde lyase A28S mutant with benzoylphosphonate
3IAF	;	2.8	;	Structure of benzaldehyde lyase A28S mutant with monomethyl benzoylphosphonate
6A50	;	1.8	;	structure of benzoylformate decarboxylases in complex with cofactor TPP
3D2H	;	1.65	;	Structure of berberine bridge enzyme from Eschscholzia californica, monoclinic crystal form
3D2J	;	2.05	;	Structure of berberine bridge enzyme from Eschscholzia californica, tetragonal crystal form
3D2D	;	2.796	;	Structure of berberine bridge enzyme in complex with (S)-reticuline
3FW9	;	1.489	;	Structure of berberine bridge enzyme in complex with (S)-scoulerine
3GSY	;	1.63	;	Structure of berberine bridge enzyme in complex with dehydroscoulerine
3FW8	;	1.5	;	Structure of berberine bridge enzyme, C166A variant
3FWA	;	1.496	;	Structure of berberine bridge enzyme, C166A variant in complex with (S)-reticuline
3FW7	;	1.825	;	Structure of berberine bridge enzyme, H104A variant
4EC3	;	2.6501	;	Structure of berberine bridge enzyme, H174A variant in complex with (S)-reticuline
4KKU	;	2.35	;	Structure of BesA (Selenomethinone derivative - P212121)
1BTV	;		;	STRUCTURE OF BET V 1, NMR, 20 STRUCTURES
5IDI	;	1.9	;	Structure of beta glucosidase 1A from Thermotoga neapolitana, mutant E349A
3K55	;	3.35	;	Structure of beta hairpin deletion mutant of beta toxin from Staphylococcus aureus
2CCR	;	2.3	;	Structure of Beta-1,4-Galactanase
2J74	;	2.6	;	Structure of Beta-1,4-Galactanase
8GP3	;	4.8	;	Structure of beta-arrestin1 in complex with a phosphopeptide corresponding to the human C-X-C chemokine receptor type 4, CXCR4
8I0Q	;	4.45	;	Structure of beta-arrestin1 in complex with a phosphopeptide corresponding to the human C-X-C chemokine receptor type 4, CXCR4 (Local refine)
8GO8	;	3.41	;	Structure of beta-arrestin1 in complex with a phosphopeptide corresponding to the human C5a anaphylatoxin chemotactic receptor 1, C5aR1
8I0N	;	3.26	;	Structure of beta-arrestin1 in complex with a phosphopeptide corresponding to the human C5a anaphylatoxin chemotactic receptor 1, C5aR1 (Local refine)
8JA3	;	3.94	;	Structure of beta-arrestin1 in complex with C3aRpp
8J8Z	;	3.4	;	Structure of beta-arrestin1 in complex with D6Rpp
8GO9	;	3.35	;	Structure of beta-arrestin2 in complex with a phosphopeptide corresponding to the human Atypical chemokine receptor 2, ACKR2 (D6R)
8GOO	;	4.4	;	Structure of beta-arrestin2 in complex with a phosphopeptide corresponding to the human C5a anaphylatoxin chemotactic receptor 1, C5aR1
8I0Z	;	4.33	;	Structure of beta-arrestin2 in complex with a phosphopeptide corresponding to the human C5a anaphylatoxin chemotactic receptor 1, C5aR1 (Local refine)
8GOC	;	4.18	;	Structure of beta-arrestin2 in complex with a phosphopeptide corresponding to the human Vasopressin V2 receptor, V2R
8I10	;	3.96	;	Structure of beta-arrestin2 in complex with a phosphopeptide corresponding to the human Vasopressin V2 receptor, V2R (Local refine)
8J8V	;	3.22	;	Structure of beta-arrestin2 in complex with D6Rpp (Local Refine)
8J8R	;	2.9	;	Structure of beta-arrestin2 in complex with M2Rpp
4DJS	;	3.029	;	Structure of beta-catenin in complex with a stapled peptide inhibitor
7UWI	;	2.32	;	Structure of beta-catenin in complex with FP01567, a Helicon Polypeptide
7UWO	;	2.75	;	Structure of beta-catenin in complex with FP05874, a Helicon Polypeptide
3OUW	;	2.91	;	Structure of beta-catenin with Lef-1
3OUX	;	2.4	;	Structure of beta-catenin with phosphorylated Lef-1
6XXW	;	1.851	;	Structure of beta-D-Glucuronidase for Dictyoglomus thermophilum.
6S2B	;	1.88	;	Structure of beta-fructofuranosidase from Schwanniomyces occidentalis complexed with fructosyl-erythritol
6S1T	;	2.09	;	Structure of beta-fructofuranosidase from Schwanniomyces occidentalis complexed with sucrose
3J7H	;	3.2	;	Structure of beta-galactosidase at 3.2-A resolution obtained by cryo-electron microscopy
5IFP	;	1.71	;	STRUCTURE OF BETA-GALACTOSIDASE FROM ASPERGILLUS NIGER
6S6Z	;	2.0	;	Structure of beta-Galactosidase from Thermotoga maritima
6SD0	;	3.7	;	Structure of beta-galactosidase from Thermotoga maritima.
2X42	;	2.099	;	Structure of beta-glucosidase 3B from Thermotoga neapolitana in complex with alpha-D-glucose
2X41	;	2.05	;	Structure of beta-glucosidase 3B from Thermotoga neapolitana in complex with glucose
2X40	;	2.313	;	Structure of beta-glucosidase 3B from Thermotoga neapolitana in complex with glycerol
6R4K	;	2.13	;	Structure of beta-glucosidase A from Paenibacillus polymyxa complexed with a monovalent inhibitor
6QWI	;	2.85	;	Structure of beta-glucosidase A from Paenibacillus polymyxa complexed with multivalent inhibitors.
1UG6	;	0.99	;	Structure of beta-glucosidase at atomic resolution from thermus thermophilus HB8
4HA4	;	1.37	;	Structure of beta-glycosidase from Acidilobus saccharovorans in complex with glycerol
4HA3	;	1.46	;	Structure of beta-glycosidase from Acidilobus saccharovorans in complex with Tris
1UWQ	;	2.02	;	Structure of beta-glycosidase from Sulfolobus solfataricus
1UWR	;	2.14	;	Structure of beta-glycosidase from Sulfolobus solfataricus in complex with 2-deoxy-2-fluoro-galactose
1UWS	;	1.95	;	Structure of beta-glycosidase from Sulfolobus solfataricus in complex with 2-deoxy-2-fluoro-glucose
7UZ1	;	1.58	;	Structure of beta-glycosidase from Sulfolobus solfataricus in complex with C5a-bromo-valienide.
7UZ2	;	1.83	;	Structure of beta-glycosidase from Sulfolobus solfataricus in complex with C5a-fluoro-valienide.
1UWT	;	1.95	;	Structure of beta-glycosidase from Sulfolobus solfataricus in complex with D-galactohydroximo-1,5-lactam
1UWU	;	1.95	;	Structure of beta-glycosidase from Sulfolobus solfataricus in complex with D-glucohydroximo-1,5-lactam
1TR9	;	1.8	;	Structure of beta-hexosaminidase from Vibrio cholerae
3SJ7	;	2.5	;	Structure of beta-ketoacetyl-CoA reductase (FabG) from Staphylococcus aureus complex with NADPH
4XOX	;	2.01	;	Structure of beta-ketoacyl-ACP synthase I (FabB) from Vibrio Cholerae
6NFJ	;	3.19	;	Structure of Beta-Klotho in Complex with FGF19 C-terminal peptide
1KGF	;	2.2	;	STRUCTURE OF BETA-LACTAMASE ASN 170 GLN MUTANT
1KGE	;	2.0	;	STRUCTURE OF BETA-LACTAMASE ASN 170 MET MUTANT
1GHI	;	2.3	;	STRUCTURE OF BETA-LACTAMASE GLU166ASP:ASN170GLN MUTANT
1KGG	;	2.3	;	STRUCTURE OF BETA-LACTAMASE GLU166GLN:ASN170ASP MUTANT
2NYP	;	1.84	;	Structure of beta-lactamase II from Bacillus cereus. R121H, C221D doble mutant with two zinc ions.
2NZF	;	2.28	;	Structure of beta-lactamase II from Bacillus cereus. R121H, C221S double mutant. Space group C2.
2NZE	;	1.8	;	Structure of beta-lactamase II from Bacillus cereus. R121H, C221S double mutant. Space group P3121.
1DJA	;	1.9	;	STRUCTURE OF BETA-LACTAMASE PRECURSOR, K73H MUTANT, AT 298K
1DJC	;	2.0	;	STRUCTURE OF BETA-LACTAMASE PRECURSOR, S70A MUTANT, AT 120K
1DJB	;	2.1	;	STRUCTURE OF BETA-LACTAMASE PRECURSOR, S70A MUTANT, AT 298K
7QOR	;	1.999	;	Structure of beta-lactamase TEM-171
7QLP	;	2.3	;	Structure of beta-lactamase TEM-171 complexed with tazobactam intermediate at 2.3 A resolution
7QNK	;	2.5	;	Structure of beta-lactamase TEM-171 complexed with tazobactam intermediate at 2.5 A resolution
1XPB	;	1.9	;	STRUCTURE OF BETA-LACTAMASE TEM1
7DVJ	;	1.65	;	Structure of beta-mannanase BaMan113A with mannobiose
5O6P	;	2.2	;	Structure of beta-phosphoglucomutase D10N mutant in complex with glucose-1,6-bisphosphate
5O6R	;	1.36	;	Structure of beta-phosphoglucomutase D10N mutant in complex with glucose-1-phosphate and aluminium tetrafluoride
4C4T	;	1.5	;	Structure of beta-phosphoglucomutase in complex with a phosphonate analogue of beta-glucose-1-phosphate and aluminium tetrafluoride
4C4R	;	1.1	;	Structure of beta-phosphoglucomutase in complex with a phosphonate analogue of beta-glucose-1-phosphate and magnesium trifluoride
4C4S	;	1.5	;	Structure of beta-phosphoglucomutase in complex with an alpha- fluorophosphonate analogue of beta-glucose-1-phosphate and magnesium trifluoride
2WFA	;	1.65	;	Structure of Beta-Phosphoglucomutase inhibited with Beryllium trifluoride, in an open conformation.
2WF9	;	1.4	;	Structure of Beta-Phosphoglucomutase inhibited with Glucose-6- phosphate, and Beryllium trifluoride, crystal form 2
2WF8	;	1.2	;	Structure of Beta-Phosphoglucomutase inhibited with Glucose-6- phosphate, Glucose-1-phosphate and Beryllium trifluoride
2WF7	;	1.05	;	Structure of Beta-Phosphoglucomutase inhibited with Glucose-6- phosphonate and Aluminium tetrafluoride
2WF6	;	1.4	;	Structure of Beta-Phosphoglucomutase inhibited with Glucose-6-phosphate and Aluminium tetrafluoride
2WF5	;	1.3	;	Structure of Beta-Phosphoglucomutase inhibited with Glucose-6-phosphate and trifluoromagnesate
1Z4O	;	1.9	;	Structure of beta-phosphoglucomutase with inhibitor bound alpha-galactose 1-phosphate
1Z4N	;	1.97	;	Structure of beta-phosphoglucomutase with inhibitor bound alpha-galactose 1-phosphate cocrystallized with Fluoride
6XHE	;	1.88	;	Structure of beta-prolinyl 5'-O-adenosine phosphoramidate
1BHP	;	1.7	;	STRUCTURE OF BETA-PUROTHIONIN AT ROOM TEMPERATURE AND 1.7 ANGSTROMS RESOLUTION
1FKN	;	1.9	;	Structure of Beta-Secretase Complexed with Inhibitor
4GID	;	2.0	;	Structure of beta-secretase complexed with inhibitor
6IFA	;	1.9	;	Structure of beta-trefoil lectin from Entamoeba histolytica
6N48	;	3.2	;	Structure of beta2 adrenergic receptor bound to BI167107, Nanobody 6B9, and a positive allosteric modulator
6E67	;	3.7	;	Structure of beta2 adrenergic receptor fused to a Gs peptide
4QKX	;	3.3	;	Structure of beta2 adrenoceptor bound to a covalent agonist and an engineered nanobody
4LDO	;	3.2	;	Structure of beta2 adrenoceptor bound to adrenaline and an engineered nanobody
4LDE	;	2.79	;	Structure of beta2 adrenoceptor bound to BI167107 and an engineered nanobody
5X7D	;	2.703	;	Structure of beta2 adrenoceptor bound to carazolol and an intracellular allosteric antagonist
5JQH	;	3.2	;	Structure of beta2 adrenoceptor bound to carazolol and inactive-state stabilizing nanobody, Nb60
4LDL	;	3.1	;	Structure of beta2 adrenoceptor bound to hydroxybenzylisoproterenol and an engineered nanobody
1BUN	;	2.45	;	STRUCTURE OF BETA2-BUNGAROTOXIN: POTASSIUM CHANNEL BINDING BY KUNITZ MODULES AND TARGETED PHOSPHOLIPASE ACTION
6BFT	;	2.55	;	Structure of Bevacizumab Fab mutant in complex with VEGF
7SUK	;	3.99	;	Structure of Bfr2-Lcp5 Complex Observed in the Small Subunit Processome Isolated from R2TP-depleted Yeast Cells
7BBS	;	2.3	;	Structure of Bg10: an alcohol-tolerant and glucose-stimulated B-glucosidase
5WH9	;	2.3	;	Structure of BH1999 gentisyl-coenzyme A thioesterase
1MPV	;		;	Structure of bhpBR3, the BAFF-binding loop of BR3 embedded in a beta-hairpin peptide
6Z14	;	1.67	;	Structure of Bifidobacterium bifidum GH20 beta-N-beta-N-acetylhexosaminidase E553Q variant in complex with 4MU-6SGlcNAc-derived oxazoline
6LD6	;	2.204	;	Structure of Bifidobacterium dentium beta-glucuronidase
6LD0	;	1.901	;	Structure of Bifidobacterium dentium beta-glucuronidase complexed with C6-hexyl uronic isofagomine
6LDC	;	2.181	;	Structure of Bifidobacterium dentium beta-glucuronidase complexed with C6-nonyl uronic isofagomine
6LDD	;	2.205	;	Structure of Bifidobacterium dentium beta-glucuronidase complexed with C6-propyl uronic isofagomine
5Z1B	;	1.45	;	Structure of Bifidobacterium dentium beta-glucuronidase complexed with coumarin-3-O-glucuronide
6LDB	;	1.651	;	Structure of Bifidobacterium dentium beta-glucuronidase complexed with uronic isofagomine
4A0H	;	2.808	;	Structure of bifunctional DAPA aminotransferase-DTB synthetase from Arabidopsis thaliana bound to 7-keto 8-amino pelargonic acid (KAPA)
4A0R	;	2.68	;	Structure of bifunctional DAPA aminotransferase-DTB synthetase from Arabidopsis thaliana bound to dethiobiotin (DTB).
4A0G	;	2.502	;	Structure of bifunctional DAPA aminotransferase-DTB synthetase from Arabidopsis thaliana in its apo form.
4CXP	;	1.22	;	Structure of bifunctional endonuclease (AtBFN2) from Arabidopsis thaliana in complex with sulfate
4CXV	;	2.0	;	Structure of bifunctional endonuclease (AtBFN2) in complex with phosphate.
3R1M	;	1.5	;	Structure of bifunctional fructose 1,6-bisphosphate aldolase/phosphatase (aldolase form)
3CL9	;	3.3	;	Structure of bifunctional TcDHFR-TS in complex with MTX
3CLB	;	3.0	;	Structure of bifunctional TcDHFR-TS in complex with TMQ
1AKN	;	2.8	;	STRUCTURE OF BILE-SALT ACTIVATED LIPASE
1LC0	;	1.2	;	Structure of Biliverdin Reductase and the Enzyme-NADH Complex
7RBW	;	2.05	;	Structure of Biliverdin-binding Serpin of Boana punctata (polka-dot tree frog)
4K96	;	2.084	;	Structure of Binary Complex of cGAS with Bound dsDNA
1BUJ	;		;	STRUCTURE OF BINASE IN SOLUTION
2RBI	;	2.2	;	STRUCTURE OF BINASE MUTANT HIS 101 ASN
2PB0	;	1.96	;	Structure of biosynthetic N-acetylornithine aminotransferase from Salmonella typhimurium: studies on substrate specificity and inhibitor binding
2PB2	;	1.91	;	Structure of biosynthetic N-acetylornithine aminotransferase from Salmonella typhimurium: studies on substrate specificity and inhibitor binding
2EVB	;	1.55	;	Structure of Biotin Carboxyl Carrier Protein (74Val start) from Pyrococcus horikoshi OT3 Ligand Free Form I
2D5D	;	1.55	;	Structure of Biotin Carboxyl Carrier Protein (74Val start) from Pyrococcus horikoshi OT3 Ligand Free Form II
5GU9	;	1.9	;	Structure of biotin carboxyl carrier protein from pyrococcus horikoshi OT3 (delta N79) A138I mutant
5GUA	;	1.5	;	Structure of biotin carboxyl carrier protein from pyrococcus horikoshi OT3 (delta N79) A138Y mutant
5GU8	;	1.8	;	Structure of biotin carboxyl carrier protein from pyrococcus horikoshi OT3 (delta N79) wild type
1DV1	;	1.9	;	STRUCTURE OF BIOTIN CARBOXYLASE (APO)
3M1D	;	2.0	;	Structure of BIR1 from cIAP1
4AUQ	;	2.176	;	Structure of BIRC7-UbcH5b-Ub complex.
8FIS	;	3.18	;	Structure of Bispecific CAP256V2LS-J3 Fab in complex with BG505 DS-SOSIP.664
6IFJ	;	2.4	;	Structure of bispecific Fc
2MOP	;		;	Structure of Bitistatin A
2MP5	;		;	Structure of Bitistatin B
1XJ6	;	1.9	;	Structure of bjFixLH in the unliganded ferrous form
6H2G	;	2.8	;	Structure of BlaC from Mycobacterium tuberculosis bound to the propionaldehyde ester adduct of clavulanic acid.
6H2C	;	1.93	;	Structure of BlaC from Mycobacterium tuberculosis bound to the trans-enamine adduct derived from clavulanic acid.
6H2K	;	1.9	;	Structure of BlaC from Mycobacterium tuberculosis bound to the trans-enamine adduct of sulbactam.
6H2I	;	2.72	;	Structure of BlaC from Mycobacterium tuberculosis bound to the trans-enamine adduct of tazobactam.
6H2H	;	1.62	;	Structure of BlaC from Mycobacterium tuberculosis covalently bound to avibactam.
8BV4	;	1.95	;	Structure of BlaC from Mycobacterium tuberculosis in complex with vaborbactam
5MQC	;	3.4	;	Structure of black queen cell virus
3WE2	;	2.7	;	Structure of BLM RQC domain bound to a phosphate ion
3WE3	;	2.9	;	Structure of BLM RQC domain bound to an arsenate ion
4NEO	;	2.1	;	Structure of BlmI, a type-II acyl-carrier-protein from Streptomyces verticillus involved in bleomycin biosynthesis
7K66	;	3.92	;	Structure of Blood Coagulation Factor VIII in Complex with an Anti-C1 Domain Pathogenic Antibody Inhibitor
5OXB	;	1.38	;	Structure of blue-light irradiated Cerulean
6HN8	;	1.997	;	Structure of BM3 heme domain in complex with troglitazone
3UST	;	2.1	;	Structure of BmNPV ORF075 (p33)
2WC5	;	1.9	;	Structure of BMori GOBP2 (General Odorant Binding Protein 2)
2WCM	;	1.5	;	Structure of BMori GOBP2 (General Odorant Binding Protein 2) with (10E)-hexadecen-12-yn-1-ol
2WCJ	;	1.4	;	Structure of BMori GOBP2 (General Odorant Binding Protein 2) with (10E,12Z)-tetradecadien-1-ol
2WCL	;	1.61	;	Structure of BMori GOBP2 (General Odorant Binding Protein 2) with (8E, 10Z)-hexadecadien-1-ol
2WCH	;	1.7	;	Structure of BMori GOBP2 (General Odorant Binding Protein 2) with bombykal
2WC6	;	1.9	;	Structure of BMori GOBP2 (General Odorant Binding Protein 2) with bombykol and water to Arg 110
2WCK	;	1.61	;	Structure of BMori GOBP2 (General Odorant Binding Protein 2) without ligand
6ANY	;	2.25	;	Structure of BmVAL-1
3QDU	;	2.0	;	Structure of Boletus edulis lectin in complex with N,N-diacetyl chitobiose
3QDT	;	1.3	;	Structure of Boletus edulis lectin in complex with T-antigen disaccharide
2JNT	;		;	Structure of Bombyx mori Chemosensory Protein 1 in Solution
6DKK	;	2.7	;	Structure of BoNT
6MHJ	;	3.019	;	Structure of BoNT mutant
2NM1	;	2.15	;	Structure of BoNT/B in complex with its protein receptor
4J38	;	2.83	;	Structure of Borrelia burgdorferi Outer surface protein E in complex with Factor H domains 19-20
3ULE	;	2.5	;	Structure of Bos taurus Arp2/3 complex with bound inhibitor CK-869 and ATP
3DXK	;	2.7	;	Structure of Bos Taurus Arp2/3 Complex with Bound Inhibitor CK0944636
3DXM	;	2.85	;	Structure of Bos taurus Arp2/3 Complex with Bound Inhibitor CK0993548
5KLV	;	2.652	;	Structure of bos taurus cytochrome bc1 with fenamidone inhibited
4KBB	;	2.3	;	Structure of Botulinum neurotoxin B binding domain in complex with both synaptotagmin II and GD1a
2QN0	;	1.75	;	Structure of Botulinum neurotoxin serotype C1 light chain protease
6BVD	;	2.09	;	Structure of Botulinum Neurotoxin Serotype HA Light Chain
1HB6	;	2.0	;	Structure of bovine Acyl-CoA binding protein in orthorhombic crystal form
1HB8	;	2.0	;	Structure of bovine Acyl-CoA binding protein in tetragonal crystal form
6QN8	;	2.12	;	Structure of bovine anti-RSV Fab B13
6QN9	;	1.89	;	Structure of bovine anti-RSV Fab B4
6QNA	;	2.62	;	Structure of bovine anti-RSV hybrid Fab B13HC-B4LC
6QN7	;	2.15	;	Structure of bovine anti-RSV hybrid Fab B4HC-B13LC
2P9S	;	2.68	;	Structure of bovine Arp2/3 complex co-crystallized with ATP/Mg2+
1HLU	;	2.65	;	STRUCTURE OF BOVINE BETA-ACTIN-PROFILIN COMPLEX WITH ACTIN BOUND ATP PHOSPHATES SOLVENT ACCESSIBLE
8CI3	;	2.33	;	Structure of bovine CD46 ectodomain (SCR 1-2)
8CJV	;	2.84	;	Structure of bovine CD46 ectodomain (SCR 1-4)
4KCP	;	2.07	;	Structure of bovine endotheial nitric oxide synthase heme domain in complex with N-(4-(2-((3-(thiophene-2-carboximidamido)benzyl)amino)ethyl)phenyl)thiophene-2-carboximidamide
4CVG	;	2.31	;	Structure of bovine endothelial nitric oxide synthase heme domain (H4B-free) supplemented with 50uM Zn acetate and with poor binding of 6-acetyl-2-amino-7,7-dimethyl-7,8-dihydropteridin-4(3H)-one.
4K5K	;	2.0	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with ((2S, 3S)-1,3-bis((6-(2,5-dimethyl-1H-pyrrol-1-yl)-4-methylpyridin-2-yl)methoxy)-2-aminobutane
4D38	;	2.3	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with (1R,2R)-2-(3-fluorobenzyl)-N-{2-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]ethyl}cyclopropanamine
4CUM	;	2.33	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with (9aS)-2-amino-9a-methyl-6,7,8,9,9a,10-hexahydrobenzo[g]pteridin-4(3H)-one
4CUN	;	2.48	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with (9aS)-2-amino-9a-methyl-8,9,9a,10-tetrahydrobenzo[g]pteridine-4,6(3H,7H)-dione
4D33	;	2.087	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with (N1-(2-(1H-imidazol-1-yl)pyrimidin-4-yl)-N2-(3- fluorophenethyl)ethane-1,2-diamine
4K5I	;	2.08	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with (R)-1,2-bis((2-amino-4-methylpyridin-6-yl)-methoxy)-propan-3-amine
4CTY	;	2.3	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with (R)-6-(2-Amino-2-(3-(2-(6-amino-4-methylpyridin-2-yl) ethyl)phenyl)ethyl)-4-methylpyridin-2-amine
4CU0	;	2.08	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with (R)-6-(3-amino-2-(5-(2-(6-amino-4-methylpyridin-2-yl) ethyl)pyridin-3-yl)propyl)-4-methylpyridin-2-amine
4K5H	;	2.25	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with (S)-1,2-bis((2-amino-4-methylpyridin-6-yl)-methoxy)-propan-3-amine
4K5J	;	2.36	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with (S)-1,3-bis((2-amino-4-methylpyridin-6-yl)-methoxy)-butan-4-amine
4CTZ	;	2.01	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with (S)-6-(2-amino-2-(3-(2-(4-methylpyridin-2-yl)ethyl)phenyl)ethyl)-4-methylpyridin-2-amine
4D34	;	2.25	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 2-(2-(1H-imidazol-1-yl)pyrimidin-4-yl)-N-(3- fluorophenethyl)ethan-1-amine
4IMX	;	2.25	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 3,5-bis(2-(6-amino-4-methylpyridin-2-yl)ethyl)benzonitrile
4UHA	;	2.2	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 3-(2-(6-Amino-4-methylpyridin-2-yl)ethyl)-5-(methyl(2-(methylamino)ethyl)amino)benzonitrile
4D3A	;	2.252	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 3-(3-fluorophenyl)-N-2-(2-(5-methyl-1H-imidazol-1-yl) pyrimidin-4-yl)ethylpropan-1-amine
5UOD	;	2.01	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 3-[(2-Amino-4-methylquinolin-7-yl)methoxy]-5-((methylamino)methyl)benzonitrile
5VVA	;	2.55	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 4-(2-(((2-Amino-4-methylquinolin-7-yl)methyl)amino)ethyl)-2-methylbenzonitrile
5VV9	;	2.5	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 4-(2-(((2-Amino-4-methylquinolin-7-yl)methyl)amino)ethyl)benzonitrile
5VVG	;	2.3	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 4-(2-(((2-Aminoquinolin-7-yl)methyl)amino)ethyl)-2-chlorobenzonitrile
5VV8	;	2.15	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 4-(2-(((2-Aminoquinolin-7-yl)methyl)amino)ethyl)-2-methylbenzonitrile
5VVN	;	2.4	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 4-(2-(((2-Aminoquinolin-7-yl)methyl)amino)ethyl)benzonitrile
4CWW	;	2.16	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 4-METHYL-6-(((3R,4R)-4-((5-(4-METHYLPYRIDIN-2-YL)PENTYL) OXY)PYRROLIDIN-3-YL)METHYL)PYRIDIN-2-AMINE
4CWV	;	2.34	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 4-METHYL-6-(((3R,4R)-4-((5-(PYRIDIN-2-YL)PENTYL)OXY) PYRROLIDIN-3-YL)METHYL)PYRIDIN-2-AMINE
5FVY	;	2.098	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 4-methyl-6-(2-(5-(4-methylpiperazin-1-yl)pyridin-3-yl) ethyl)pyridin-2-amine
4JSL	;	2.04	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 6,6'-(heptane-1,7-diyl)bis(4-methylpyridin-2-amine)
4JSK	;	2.28	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 6,6'-(pentane-1,5-diyl)bis(4-methylpyridin-2-amine)
4LUW	;	2.25	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 6-((((3R,5S)-5-(((6-amino-4-methylpyridin-2-yl)methoxy)methyl)pyrrolidin-3-yl)oxy)methyl)-4-methylpyridin-2-amine
4C3A	;	2.2	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 6-((((3S, 5R)-5-(((6-amino-4-methylpyridin-2-yl)methoxy) methyl)pyrrolidin-3-yl)oxy) methyl)-4-methylpyridin-2-amine
3PNH	;	1.93	;	Structure of Bovine Endothelial Nitric Oxide Synthase Heme Domain in complex with 6-(((3R,4R)-4-(2-((2-FLUORO-2-(3-FLUOROPHENYL) ETHYL)AMINO)ETHOXY)PYRROLIDIN-3-YL)METHYL)-4-METHYLPYRIDIN-2-AMINE
4JSM	;	2.25	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 6-(((5-(((3-fluorophenethyl)amino)methyl)pyridin-3-yl)oxy)methyl)-4-methylpyridin-2-amine
5FVZ	;	2.048	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 6-(2-(5-(3-(dimethylamino)propyl)pyridin-3-yl)ethyl)-4-methylpyridin-2-amine
4CWY	;	2.15	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 6-(5-(((3R,4R)-4-((6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL) PYRROLIDIN-3-YL)OXY)PENTYL)-4-METHYLPYRIDIN-2-AMINE
4CX2	;	2.04	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 6-(5-(((3R,4R)-4-((6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL) PYRROLIDIN-3-YL)OXY)PENTYL)-4-METHYLPYRIDIN-2-AMINE
4CUL	;	2.23	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 6-acetyl-2-amino-7,7-dimethyl-7,8-dihydropteridin-4(3H)-one
4CU1	;	1.89	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 6-[(2S)-3-amino-2-{5-[2-(6-amino-4-methylpyridin-2-yl)ethyl]pyridin-3-yl}propyl]-4-methylpyridin-2-amine
5ADN	;	2.0	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 7-(((3-((Dimethylamino)methyl)phenyl)amino)methyl) quinolin-2-amine
5VV7	;	2.2	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 7-(((3-(Pyridin-3-yl)propyl)amino)methyl)quinolin-2-amine
5VV6	;	2.0	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 7-(((4-(Dimethylamino)phenethyl)amino)methyl)quinolin-2-amine
5ADJ	;	2.217	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 7-((3-(2-(Methylamino)ethyl)phenoxy)methyl)quinolin-2- amine
5ADK	;	1.805	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 7-((3-(Dimethylamino)methyl)phenoxy)methyl)quinolin-2- amine
5ADL	;	2.205	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 7-((3-(Methylamino)methyl)phenoxy)methyl)quinolin-2- amine
5ADM	;	2.196	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 7-((3-Aminomethyl)phenoxy)methyl)quinolin-2-amine
4CFT	;	1.79	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 7-((3-Fluorophenethylamino)ethyl)quinolin-2-amine
4CAR	;	2.05	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 7-((3-Fluorophenethylamino)methyl)quinolin-2-amine
5FJ2	;	2.05	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 7-((4-CHLORO-3-((METHYLAMINO)METHYL) PHENOXY)METHYL)QUINOLIN-2-AMINE
5FJ3	;	2.2	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with 7-((4-CHLORO-3-((METHYLAMINO)METHYL) PHENOXY)METHYL)QUINOLIN-2-AMINE in the absence of acetate
4UPQ	;	2.03	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with N',N'-{[(2R)-3-aminopropane-1,2-diyl]bis(oxymethanediylbenzene-3,1-diyl)}dithiophene-2-carboximidamide
4UPT	;	2.2	;	structure of bovine endothelial nitric oxide synthase heme domain in complex with n'-[4-[[(2s,4r)-4-[3-[(c-thiophen-2-ylcarbonimidoyl)amino]phenoxy]pyrrolidin-2-yl]methoxy]phenyl]thiophene-2-carboximidamide
4UPR	;	1.93	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with N,N''-{[(2S)-3-aminopropane-1,2-diyl]bis(oxymethanediylbenzene-3,1-diyl)}dithiophene-2-carboximidamide
4KCR	;	2.09	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with N-(3-(((3-fluorophenethyl)amino)methyl)phenyl)thiophene-2-carboximidamide
4KCS	;	2.05	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with N-(3-((ethyl(3-fluorophenethyl)amino)methyl)phenyl)thiophene-2-carboximidamide
4KCQ	;	2.03	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with N-(4-(2-(ethyl(3-(thiophene-2-carboximidamido)benzyl)amino)ethyl)phenyl)thiophene-2-carboximidamide
4D36	;	2.052	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with N-2-(2-(1H-imidazol-1-yl)pyrimidin-4-yl)ethyl-3-(3- chlorophenyl)propan-1-amine
4D35	;	2.18	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with N-2-(2-(1H-imidazol-1-yl)pyrimidin-4-yl)ethyl-3-(3- fluorophenyl)propan-1-amine
4UPS	;	1.95	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with N-[3-({[(3S,5S)-5-{[(3-{[(Z)-imino(thiophen-2-yl)methyl]amino}benzyl)oxy]methyl}pyrrolidin-3-yl]oxy}methyl) phenyl]thiophene-2-carboximidamide
4D37	;	2.1	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with N-{[(1R,2R)-2-(3-fluorophenyl)cyclopropyl]methyl}-2-[2-(1H-imidazol-1-yl) pyrimidin-4-yl]ethanamine
4UH9	;	2.14	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with N1-(3-(2-(6-Amino-4-methylpyridin-2-yl)ethyl)-5- fluorophenyl)-N1,N2-dimethylethane-1,2-diamine
4UH7	;	2.235	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with N1-(3-(2-(6-Amino-4-methylpyridin-2-yl)ethyl)phenyl)-N1, N2-dimethylethane-1,2-diamine
4UH8	;	2.3	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with N1-(5-(2-(6-Amino-4-methylpyridin-2-yl)ethyl)pyridin-3- yl)-N1,N2-dimethylethane-1,2-diamine
4D39	;	2.0	;	Structure of bovine endothelial nitric oxide synthase heme domain in complex with2-(2-(1H-imidazol-1-yl)pyrimidin-4-yl)-N-(3-cyanobenzyl) ethan-1-amine
4CX1	;	2.13	;	Structure of bovine endothelial nitric oxide synthase L111A mutant heme domain in complex with 4-METHYL-6-(((3R,4R)-4-((5-(4- METHYLPYRIDIN-2-YL)PENTYL)OXY)PYRROLIDIN-3-YL)METHYL)PYRIDIN-2-AMINE
4CWZ	;	2.08	;	Structure of bovine endothelial nitric oxide synthase Y477A mutant heme domain in complex with 4-METHYL-6-(((3R,4R)-4-((5-(4- METHYLPYRIDIN-2-YL)PENTYL)OXY)PYRROLIDIN-3-YL)METHYL)PYRIDIN-2-AMINE
4CX0	;	2.2	;	Structure of bovine endothelial nitric oxide synthase Y477A mutant heme domain in complex with 6-((((3S, 5R)-5-(((6-AMINO-4- METHYLPYRIDIN-2-YL)METHOXY)METHYL)PYRROLIDIN-3-YL)OXY)METHYL)-4- METHYLPYRIDIN-2-AMINE
2G6O	;	1.9	;	Structure of bovine eNOS heme domain (BH4-free) complexed with CO
3E7S	;	2.5	;	Structure of bovine eNOS oxygenase domain with inhibitor AR-C95791
3JCZ	;	3.26	;	Structure of bovine glutamate dehydrogenase in the unliganded state
1OCC	;	2.8	;	STRUCTURE OF BOVINE HEART CYTOCHROME C OXIDASE AT THE FULLY OXIDIZED STATE
5GLS	;	1.93	;	Structure of bovine Lactoperoxidase with a partially modified covalent bond with heme moiety
6M7E	;	2.42	;	Structure of bovine lactoperoxidase with multiple iodide ions in the distaline heme cavity.
1RHD	;	2.5	;	STRUCTURE OF BOVINE LIVER RHODANESE. I. STRUCTURE DETERMINATION AT 2.5 ANGSTROMS RESOLUTION AND A COMPARISON OF THE CONFORMATION AND SEQUENCE OF ITS TWO DOMAINS
1L0L	;	2.35	;	structure of bovine mitochondrial cytochrome bc1 complex with a bound fungicide famoxadone
8CEM	;	3.0	;	Structure of bovine native C3, re-refinement
1BP2	;	1.7	;	STRUCTURE OF BOVINE PANCREATIC PHOSPHOLIPASE A2 AT 1.7 ANGSTROMS RESOLUTION
1U1B	;	2.0	;	Structure of bovine pancreatic Ribonuclease A in complex with 3'-phosphothymidine (3'-5')-pyrophosphate adenosine 3'-phosphate
5PTI	;	1.0	;	STRUCTURE OF BOVINE PANCREATIC TRYPSIN INHIBITOR. RESULTS OF JOINT NEUTRON AND X-RAY REFINEMENT OF CRYSTAL FORM II
1ZWC	;		;	STRUCTURE OF BOVINE PARATHYROID HORMONE FRAGMENT 1-37, NMR, 10 STRUCTURES
8SF8	;	1.7	;	Structure of bovine PKA bound to (R)-N-(4-(1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl)-2-amino-4-methylpentanamide
2PF1	;	2.8	;	STRUCTURE OF BOVINE PROTHROMBIN FRAGMENT 1 REFINED AT 2.25 ANGSTROMS RESOLUTION
1JFP	;		;	Structure of bovine rhodopsin (dark adapted)
1LN6	;		;	STRUCTURE OF BOVINE RHODOPSIN (Metarhodopsin II)
1GZM	;	2.65	;	Structure of Bovine Rhodopsin in a Trigonal Crystal Form
4PEQ	;	2.211	;	Structure of bovine ribonuclease inhibitor complexed with bovine ribonuclease I
3OSL	;	6.0	;	Structure of bovine thrombin-activatable fibrinolysis inhibitor in complex with tick carboxypeptidase inhibitor
3I26	;	1.8	;	Structure of bovine torovirus Hemagglutinin-Esterase
3I27	;	2.0	;	Structure of bovine torovirus Hemagglutinin-Esterase in complex with receptor
7AYS	;	2.1	;	Structure of bovine trypsin determined from single femtosecond snapshots per orientation at room temperature
4XOJ	;	0.91	;	Structure of bovine trypsin in complex with analogues of sunflower inhibitor 1 (SFTI-1)
3ITI	;	1.55	;	Structure of bovine trypsin with the MAD triangle B3C
1TGN	;	1.65	;	STRUCTURE OF BOVINE TRYPSINOGEN AT 1.9 ANGSTROMS RESOLUTION
7ZAO	;	2.2	;	Structure of BPP43_05035 of Brachyspira pilosicoli
5BU6	;	1.951	;	Structure of BpsB deaceylase domain from Bordetella bronchiseptica
1LD5	;		;	STRUCTURE OF BPTI MUTANT A16V
1LD6	;		;	STRUCTURE OF BPTI_8A MUTANT
5CTM	;	1.0	;	Structure of BPu1 beta-lactamase
5CTN	;	1.35	;	Structure of BPu1 beta-lactamase
4WBR	;	1.4	;	Structure of Bradyrhizobium japonicum ScoI with copper bound
8QQG	;	2.979	;	Structure of BRAF in Complex With Exarafenib (KIN-2787).
4Y18	;	3.5	;	Structure of BRCA1 BRCT domains in complex with Abraxas double phosphorylated peptide
4Y2G	;	2.5	;	Structure of BRCA1 BRCT domains in complex with Abraxas single phosphorylated peptide
4LR6	;	1.29	;	Structure of BRD4 bromodomain 1 with a 3-methyl-4-phenylisoxazol-5-amine fragment
4LRG	;	2.21	;	Structure of BRD4 bromodomain 1 with a dimethyl thiophene isoxazole azepine carboxamide
2WP1	;	2.1	;	Structure of Brdt bromodomain 2 bound to an acetylated histone H3 peptide
2WP2	;	2.37	;	Structure of Brdt bromodomain BD1 bound to a diacetylated histone H4 peptide.
4R7E	;	2.251	;	Structure of Bre1 RING domain
8T3Y	;	3.47	;	Structure of Bre1-nucleosome complex - state1
8T3W	;	3.25	;	Structure of Bre1-nucleosome complex - state2
8T3T	;	3.21	;	Structure of Bre1-nucleosome complex - state3
4BF5	;	1.45	;	Structure of broad spectrum racemase from Aeromonas hydrophila
6WOS	;	1.645	;	Structure of broadly neutralizing antibody AR3B
5UIY	;	1.687	;	Structure of Bromodomain from human BAZ1A
5TB6	;	1.79	;	Structure of bromodomain of CREBBP with a pyrazolo[4,3-c]pyridin fragment
4U83	;	1.8	;	Structure of Brucella Abortus Butyryl-CoA dehydrogenase
7DPY	;	1.8	;	Structure of Brucella abortus PhiA
7DNP	;	2.0	;	Structure of Brucella abortus SagA
4X0G	;	3.2065	;	Structure of Bsg25A binding with DNA
4I94	;	1.8	;	Structure of BSK8 in complex with AMP-PNP
2LK9	;		;	Structure of BST-2/Tetherin Transmembrane Domain
7NZJ	;	1.98	;	Structure of bsTrmB apo
3ZOR	;	2.95	;	Structure of BsUDG
3ZOQ	;	1.45	;	Structure of BsUDG-p56 complex
3EHM	;	2.0	;	Structure of BT1043
7NWR	;	2.0	;	Structure of BT1526, a myo-inositol-1-phosphate synthase
5G2U	;	1.43	;	Structure of BT1596,a 2-O GAG sulfatase
5G2V	;	1.39	;	Structure of BT4656 in complex with its substrate D-Glucosamine-2-N, 6-O-disulfate.
4AK1	;	1.95	;	Structure of BT4661, a SusE-like surface located polysaccharide binding protein from the Bacteroides thetaiotaomicron heparin utilisation locus
4AK2	;	1.35	;	Structure of BT4661, a SusE-like surface located polysaccharide binding protein from the Bacteroides thetaiotaomicron heparin utilisation locus
1CS3	;	2.0	;	STRUCTURE OF BTB/POZ TRANSCRIPTION REPRESSION DOMAIN FROM PROMELOCYTIC LEUKEMIA ZINC FINGER ONCOPROTEIN
7DXF	;	2.9	;	Structure of BTDM-bound human TRPC6 nanodisc at 2.9 angstrom in high calcium state
3CXI	;	1.83	;	Structure of BthTX-I complexed with alpha-tocopherol
8FD9	;	1.7	;	Structure of BTK kinase domain with the second-generation inhibitor acalabrutinib
8FF0	;	2.6	;	Structure of BTK kinase domain with the second-generation inhibitor tirabrutinib
5P9G	;	1.75	;	Structure of BTK with RN486
2BTO	;	2.5	;	Structure of BtubA from Prosthecobacter dejongeii
2BTQ	;	3.2	;	Structure of BtubAB heterodimer from Prosthecobacter dejongeii
4QPM	;	2.202	;	Structure of Bub1 kinase domain
2QPQ	;	1.92	;	Structure of Bug27 from Bordetella pertussis
5K1R	;	2.104	;	Structure of Burkholderia pseudomallei K96243 sphingosine-1-phosphate lyase Bpss2021
3B1P	;	1.7	;	Structure of Burkholderia thailandensis nucleoside kinase (BthNK) in complex with ADP-inosine
3B1N	;	1.55	;	Structure of Burkholderia thailandensis nucleoside kinase (BthNK) in complex with ADP-mizoribine
3B1R	;	2.0	;	Structure of Burkholderia thailandensis nucleoside kinase (BthNK) in complex with AMP-Mg-AMP
3B1Q	;	1.7	;	Structure of Burkholderia thailandensis nucleoside kinase (BthNK) in complex with inosine
3B1O	;	2.1	;	Structure of Burkholderia thailandensis nucleoside kinase (BthNK) in ligand-free form
7VEN	;	1.45	;	Structure of burosumab Fab
1X9J	;	3.0	;	Structure of butyrate kinase 2 reveals both open- and citrate-induced closed conformations: implications for substrate-induced fit conformational changes
2YQ3	;	3.29	;	Structure of BVDV1 envelope glycoprotein E2, pH5
2YQ2	;	2.58	;	Structure of BVDV1 envelope glycoprotein E2, pH8
4EUU	;	1.8	;	Structure of BX-795 Complexed with Human TBK1 Kinase Domain Phosphorylated on Ser172
4EUT	;	2.6	;	Structure of BX-795 Complexed with Unphosphorylated Human TBK1 Kinase-ULD Domain
7WH0	;	1.8	;	structure of C elegans BCMO-1
7WH1	;	1.9	;	structure of C elegans BCMO-2
5J3X	;	2.822	;	Structure of c-CBL Y371F
2Y1N	;	1.999	;	Structure of c-Cbl-ZAP-70 peptide complex
6HH1	;	2.25	;	Structure of c-Kit with allosteric inhibitor 3G8
3EFK	;	2.2	;	Structure of c-Met with pyrimidone inhibitor 50
3EFJ	;	2.6	;	Structure of c-Met with pyrimidone inhibitor 7
5TOU	;	2.04	;	STRUCTURE OF C-PHYCOCYANIN FROM ARCTIC PSEUDANABAENA SP. LW0831
2W0I	;	1.8	;	Structure Of C-Terminal Actin Depolymerizing Factor Homology (Adf-H) Domain Of Human Twinfilin-2
4L9U	;	1.6014	;	Structure of C-terminal coiled coil of RasGRP1
2KTL	;		;	Structure of C-terminal domain from mtTyrRS of A. nidulans
4OGP	;	2.15	;	Structure of C-terminal domain from S. cerevisiae Pat1 decapping activator (Space group : P21)
4OJJ	;	2.32	;	Structure of C-terminal domain from S. cerevisiae Pat1 decapping activator (Space group : P212121)
5LMG	;	1.89	;	Structure of C-terminal domain from S. cerevisiae Pat1 decapping activator bound to Dcp2 HLM10 peptide (region 954-970)
5LM5	;	2.6	;	Structure of C-terminal domain from S. cerevisiae Pat1 decapping activator bound to Dcp2 HLM2 peptide (region 435-451)
5LMF	;	2.15	;	Structure of C-terminal domain from S. cerevisiae Pat1 decapping activator bound to Dcp2 HLM3 peptide (region 484-500)
2FZL	;	2.9	;	Structure of C-terminal domain of Archaeoglobus fulgidus XPB
2N1G	;		;	Structure of C-terminal domain of human polymerase Rev1 in complex with PolD3 RIR-motif
2LYC	;		;	Structure of C-terminal domain of Ska1
4RXI	;	1.9	;	Structure of C-terminal domain of uncharacterized protein from Legionella pneumophila
8S94	;	3.94	;	Structure of C-terminal domains of Walker B mutated MCM8/9 heterohexamer complex with ADP
2L6M	;		;	Structure of C-terminal dsRBD of the Fission Yeast DICER (Dcr1)
6VLS	;	3.2	;	Structure of C-terminal fragment of Vip3A toxin
8TZE	;	2.9	;	Structure of C-terminal half of LRRK2 bound to GZD-824
3OUE	;	2.15	;	Structure of C-terminal hexaheme fragment of GSU1996
8TXZ	;	3.05	;	Structure of C-terminal LRRK2 bound to MLi-2
8TZC	;	2.7	;	Structure of C-terminal LRRK2 bound to MLi-2 (G2019S mutant)
8TZG	;	2.7	;	Structure of C-terminal LRRK2 bound to MLi-2 (I2020T mutant)
2JDL	;	2.2	;	Structure of C-terminal region of acidic P2 ribosomal protein complexed with trichosanthin
2RQQ	;		;	Structure of C-terminal region of Cdt1
7XQF	;	2.3	;	Structure of C-terminal truncated connexin43/Cx43/GJA1 gap junction intercellular channel in POPE/CHS nanodiscs
7XQD	;	2.7	;	Structure of C-terminal truncated connexin43/Cx43/GJA1 gap junction intercellular channel in POPE/CHS nanodiscs (C1 symmetry)
7F94	;	3.6	;	Structure of C-terminal truncated connexin43/Cx43/GJA1 gap junction intercellular channel with two conformationally different hemichannels
6RNH	;	3.7	;	Structure of C-terminal truncated Plasmodium falciparum IMP-nucleotidase
7YZN	;	1.7	;	Structure of C-terminally truncated aIF5B from Pyrococcus abyssi complexed with GTP
4ZGO	;	2.063	;	Structure of C-terminally truncated Cdc123 from Schizosaccharomyces pombe
7TUI	;	2.66	;	Structure of C. albicans FAS in an inhibited state
5DXI	;	2.0	;	Structure of C. albicans Trehalose-6-phosphate phosphatase C-terminal domain
6CG8	;	2.299	;	Structure of C. crescentus GapR-DNA
2QAZ	;	2.7	;	Structure of C. crescentus SspB ortholog
4ZAD	;	2.46	;	Structure of C. dubliensis Fdc1 with the prenylated-flavin cofactor in the iminium form.
4TRK	;	1.751	;	Structure of C. elegans HIM-3
4TZJ	;	2.851	;	Structure of C. elegans HIM-3 bound to HTP-3 closure motif-4
4TZO	;	2.4	;	Structure of C. elegans HTP-1 bound to HIM-3 closure motif
4TZQ	;	2.3	;	Structure of C. elegans HTP-1 bound to HTP-3 motif-1
4TZL	;	2.537	;	Structure of C. elegans HTP-2 bound to HIM-3 closure motif, P21 form
4TZS	;	2.55	;	Structure of C. elegans HTP-2 bound to HIM-3 closure motif, P212121 form
4DHI	;	1.8	;	Structure of C. elegans OTUB1 bound to human UBC13
4XGU	;	2.301	;	Structure of C. elegans PCH-2
7USY	;	3.54	;	Structure of C. elegans TMC-1 complex with ARRD-6
8EDC	;	2.89	;	Structure of C. elegans UNC-5 IG 1+2 Domains
8EDI	;	2.11	;	Structure of C. elegans UNC-5 IG 1+2 Domains bound to Heparin dp4
8EDK	;	2.5	;	Structure of C. elegans UNC-6 LamN and EGF domains
6PWY	;	1.81	;	Structure of C. elegans ZK177.8, SAMHD1 ortholog
5HUA	;	1.3	;	Structure of C. glabrata FKBP12-FK506 complex
4XHG	;	2.15	;	Structure of C. glabrata Hrr25 bound to ADP (formate condition)
4XH0	;	1.99	;	Structure of C. glabrata Hrr25 bound to ADP (SO4 condition)
4XHH	;	2.908	;	Structure of C. glabrata Hrr25, Apo state
6YC6	;	2.2	;	Structure of C. glutamicum GlnK
6SX4	;	2.796	;	Structure of C. glutamicum mycoloyltransferase A
1LL4	;	2.8	;	STRUCTURE OF C. IMMITIS CHITINASE 1 COMPLEXED WITH ALLOSAMIDIN
6YKM	;	3.1	;	Structure of C. jejuni MotAB
4QL6	;	2.97	;	Structure of C. trachomatis CT441
4F9V	;	2.1	;	Structure of C113A/C136A mutant variant of glycosylated glutaminyl cyclase from Drosophila melanogaster
2YJS	;	1.9	;	Structure of C1156Y Mutant Anaplastic Lymphoma Kinase
5AAC	;	1.7	;	Structure of C1156Y Mutant Human Anaplastic Lymphoma Kinase in Complex with Crizotinib
5A9U	;	1.6	;	Structure of C1156Y Mutant Human Anaplastic Lymphoma Kinase in Complex with PF-06463922 ((10R)-7-amino-12-fluoro-2,10,16-trimethyl- 15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11) benzoxadiazacyclotetradecine-3-carbonitrile).
5AAB	;	2.2	;	Structure of C1156Y,L1198F Mutant Human Anaplastic Lymphoma Kinase in Complex with Crizotinib
5AA8	;	1.86	;	Structure of C1156Y,L1198F Mutant Human Anaplastic Lymphoma Kinase in Complex with PF-06463922 ((10R)-7-amino-12-fluoro-2,10,16-trimethyl- 15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11) benzoxadiazacyclotetradecine-3-carbonitrile).
2GMC	;		;	Structure of C12-LF11 bound to the DPC micelles
2GMD	;		;	Structure of C12-LF11 bound to the SDS micelles
3PWA	;	2.04	;	Structure of C126A mutant of Plasmodium falciparum triosephosphate isomerase
3PY2	;	1.93	;	Structure of C126S mutant of Plasmodium falciparum triosephosphate isomerase
3PVF	;	1.73	;	Structure of C126S mutant of Plasmodium falciparum triosephosphate isomerase complexed with PGA
4FF7	;	1.86	;	Structure of C126S mutant of Saccharomyces cerevisiae triosephosphate isomerase
7N61	;	3.5	;	structure of C2 projections and MIPs
7S51	;	1.4	;	Structure of C208A Sortase A from Streptococcus pyogenes bound to LPATA peptide
7S4O	;	1.396	;	Structure of C208A Sortase A from Streptococcus pyogenes bound to LPATS peptide
4L6P	;	2.68	;	Structure of C22Y Mutant PCNA protein defective in DNA mismatch repair
6J3Z	;	3.6	;	Structure of C2S1M1-type PSII-FCPII supercomplex from diatom
6J3Y	;	3.3	;	Structure of C2S2-type PSII-FCPII supercomplex from diatom
7OUI	;	2.79	;	Structure of C2S2M2-type Photosystem supercomplex from Arabidopsis thaliana (digitonin-extracted)
6J40	;	3.8	;	Structure of C2S2M2-type PSII-FCPII supercomplex from diatom
7VD5	;	2.5	;	Structure of C2S2M2-type PSII-FCPII supercomplex from diatom
2JVH	;		;	Structure of C3-binding domain 4 of S. aureus protein Sbi
2JVG	;		;	Structure of C3-binding domain 4 of Staphylococcus aureus protein Sbi
7FF1	;	1.689	;	Structure of C34E136G/N36
6JQK	;	1.498	;	Structure of C34M/N36
6KTS	;	1.65	;	Structure of C34N126K/N36
5AK8	;	1.48	;	Structure of C351A mutant of Porphyromonas gingivalis peptidylarginine deiminase
8I9L	;	3.18	;	Structure of C3a-C3aR-Go complex (Composite map)
2A9G	;	2.3	;	Structure of C406A arginine deiminase in complex with L-arginine
2N63	;		;	Structure of C4VG16KRKP
8IA2	;	3.21	;	Structure of C5a bound human C5aR1 in complex with Go (Composite map)
1XF1	;	1.9	;	Structure of C5a peptidase- a key virulence factor from Streptococcus
8HPT	;	3.39	;	Structure of C5a-pep bound mouse C5aR1 in complex with Go
4L60	;	3.003	;	Structure of C81R Mutant PCNA Protein Defective in Mismatch Repair
2QQH	;	2.5	;	Structure of C8a-MACPF reveals mechanism of membrane attack in complement immune defense
7MGE	;	3.94	;	Structure of C9orf72:SMCR8:WDR41 in complex with ARF1
5ZTF	;	3.45	;	Structure of Ca2+ ATPase
6JJU	;	3.2	;	Structure of Ca2+ ATPase
7DD6	;	3.2	;	Structure of Ca2+/L-Trp-bonnd Calcium-Sensing Receptor in active state
2YEV	;	2.36	;	Structure of caa3-type cytochrome oxidase
3DWT	;	2.9	;	Structure of CabBCII-10 nanobody
4Z1C	;	1.93	;	Structure of Cadmium bound KDO8PS from H.pylori
1C1J	;	2.8	;	STRUCTURE OF CADMIUM-SUBSTITUTED PHOSPHOLIPASE A2 FROM AGKISTRONDON HALYS PALLAS AT 2.8 ANGSTROMS RESOLUTION
3QSL	;	2.0	;	Structure of CAE31940 from Bordetella bronchiseptica RB50
2JS9	;		;	Structure of caenopore-5 (81 Pro cis conformer)
2G64	;	1.8	;	Structure of Caenorhabditis elegans 6-pyruvoyl tetrahydropterin synthase
1OHU	;	2.03	;	Structure of Caenorhabditis elegans CED-9
7YVZ	;	1.7	;	Structure of Caenorhabditis elegans CISD-1/mitoNEET
2HB6	;	2.0	;	Structure of Caenorhabditis elegans leucine aminopeptidase (LAP1)
2HC9	;	1.85	;	Structure of Caenorhabditis elegans leucine aminopeptidase-zinc complex (LAP1)
2O3J	;	1.88	;	Structure of Caenorhabditis Elegans UDP-Glucose Dehydrogenase
3CWY	;	2.75	;	Structure of CagD from H. pylori pathogenicity island crystallized in the presence of Cu(II) ions
6OEE	;	3.8	;	Structure of CagT from a cryo-EM reconstruction of a T4SS
6OEG	;	3.8	;	Structure of CagX from a cryo-EM reconstruction of a T4SS
6ODI	;	3.8	;	Structure of CagY from a cryo-EM reconstruction of a T4SS
6UUQ	;	1.849	;	Structure of Calcineurin bound to RCAN1
5SVE	;	2.596	;	Structure of Calcineurin in complex with NFATc1 LxVP peptide
6NUC	;	1.9	;	Structure of Calcineurin in complex with NHE1 peptide
6NUF	;	1.9	;	Structure of Calcineurin in complex with NHE1 peptide
6NUU	;	2.3	;	Structure of Calcineurin mutant in complex with NHE1 peptide
3QJK	;	3.001	;	Structure of Calcium Binding Protein-1 from Entamoeba histolytica in complex with Lead
3PX1	;	3.0	;	Structure of Calcium Binding Protein-1 from Entamoeba histolytica in complex with Strontium
3WYN	;	1.68	;	Structure of calcium bound cutinase Est119 from Thermobifida alba.
2NBF	;		;	Structure of calcium-bound form of Penicillium antifungal protein (PAF)
5OYB	;	3.75	;	Structure of calcium-bound mTMEM16A chloride channel at 3.75 A resolution
7B5C	;	3.7	;	Structure of calcium-bound mTMEM16A(ac) chloride channel at 3.7 A resolution
7B5E	;	4.1	;	Structure of calcium-bound mTMEM16A(ac)-I551A chloride channel at 4.1 A resolution
8QZC	;	3.29	;	Structure of calcium-bound mTMEM16A(ac)-L647V/I733V chloride channel at 3.29 A resolution
4ZCU	;	2.1	;	Structure of calcium-bound regulatory domain of the human ATP-Mg/Pi carrier in the P2 form
4ZCV	;	2.8	;	Structure of calcium-bound regulatory domain of the human ATP-Mg/Pi carrier in the P212121 form
5OYG	;	4.06	;	Structure of calcium-free mTMEM16A chloride channel at 4.06 A resolution
7B5D	;	3.3	;	Structure of calcium-free mTMEM16A(ac)-I551A chloride channel at 3.3 A resolution
1AJ4	;		;	STRUCTURE OF CALCIUM-SATURATED CARDIAC TROPONIN C, NMR, 1 STRUCTURE
2CTN	;		;	STRUCTURE OF CALCIUM-SATURATED CARDIAC TROPONIN C, NMR, 30 STRUCTURES
3CTN	;		;	STRUCTURE OF CALCIUM-SATURATED CARDIAC TROPONIN C, NMR, 30 STRUCTURES
7DD7	;	3.2	;	Structure of Calcium-Sensing Receptor in complex with Evocalcet
7DD5	;	3.2	;	Structure of Calcium-Sensing Receptor in complex with NPS-2143
6D5B	;	2.0	;	Structure of Caldicellulosiruptor danielii CBM3 module of glycoside hydrolase WP_045175321
6D5C	;	1.9	;	Structure of Caldicellulosiruptor danielii GH10 module of glycoside hydrolase WP_045175321
6D5D	;	1.9	;	Structure of Caldicellulosiruptor danielii GH48 module of glycoside hydrolase WP_045175321
5F6T	;	2.201	;	Structure of calexcitin-Gd3+ complex.
3ZYK	;	1.8	;	Structure of CALM (PICALM) ANTH domain
3ZYM	;	2.03	;	Structure of CALM (PICALM) in complex with VAMP8
2F2O	;	2.17	;	Structure of calmodulin bound to a calcineurin peptide: a new way of making an old binding mode
2F2P	;	2.6	;	Structure of calmodulin bound to a calcineurin peptide: a new way of making an old binding mode
4Q5U	;	1.95	;	Structure of calmodulin bound to its recognition site from calcineurin
7KL5	;	1.65	;	Structure of Calmodulin Bound to the Cardiac Ryanodine Receptor (RyR2) at Residues: Phe4246 to Val4271
1SY9	;		;	Structure of calmodulin complexed with a fragment of the olfactory CNG channel
3IF7	;	1.6	;	Structure of Calmodulin complexed with its first endogenous inhibitor, sphingosylphosphorylcholine
2JZI	;		;	Structure of Calmodulin complexed with the Calmodulin Binding Domain of Calcineurin
5J8H	;		;	Structure of calmodulin in a complex with a peptide derived from a calmodulin-dependent kinase
1XA5	;	2.12	;	Structure of Calmodulin in complex with KAR-2, a bis-indol alkaloid
3CLN	;	2.2	;	STRUCTURE OF CALMODULIN REFINED AT 2.2 ANGSTROMS RESOLUTION
6M7H	;	1.6	;	Structure of calmodulin with KN93
1NX0	;	2.3	;	Structure of Calpain Domain 6 in Complex with Calpastatin DIC
6VQP	;	2.0	;	Structure of CalU17 from the Calicheamicin Biosynthesis Pathway of Micromonospora echinospora
7ML6	;	2.1	;	Structure of CalU17 from the Calicheamicin Biosynthesis Pathway of Micromonospora echinospora
7MSY	;	2.21	;	Structure of CalU17 from the Calicheamicin Biosynthesis Pathway of Micromonospora echinospora
6HGC	;	3.02	;	Structure of Calypso in complex with DEUBAD of ASX
1DTZ	;	2.65	;	STRUCTURE OF CAMEL APO-LACTOFERRIN DEMONSTRATES ITS DUAL ROLE IN SEQUESTERING AND TRANSPORTING FERRIC IONS SIMULTANEOUSLY:CRYSTAL STRUCTURE OF CAMEL APO-LACTOFERRIN AT 2.6A RESOLUTION.
5YV8	;	1.927	;	Structure of CaMKK2 in complex with CKI-002
5YV9	;	2.53	;	Structure of CaMKK2 in complex with CKI-009
5YVA	;	2.574	;	Structure of CaMKK2 in complex with CKI-010
5YVB	;	2.02	;	Structure of CaMKK2 in complex with CKI-011
5YVC	;	2.02	;	Structure of CaMKK2 in complex with CKI-012
4IB3	;	2.2	;	Structure of cAMP dependent protein kinase A in complex with ADP, phosphorylated peptide pSP20, and no metal
4IAZ	;	1.85	;	Structure of cAMP dependent protein kinase A in complex with high Ba2+ concentration, ADP and phosphorylated peptide pSP20
4IB1	;	1.63	;	Structure of cAMP dependent protein kinase A in complex with high K+ concentration, ADP and phosphorylated peptide pSP20
2C1B	;	2.0	;	Structure of cAMP-dependent protein kinase complexed with (4R,2S)-5'-(4-(4-Chlorobenzyloxy)pyrrolidin-2-ylmethanesulfonyl)isoquinoline
2JDS	;	2.0	;	Structure of cAMP-dependent protein kinase complexed with A-443654
2C1A	;	1.95	;	Structure of cAMP-dependent protein kinase complexed with Isoquinoline-5-sulfonic acid (2-(2-(4-chlorobenzyloxy)ethylamino) ethyl)amide
7V0G	;	1.63	;	Structure of cAMP-dependent protein kinase using a MD-MX procedure, produced using 1.63 Angstrom data
7UJX	;	2.4	;	Structure of cAMP-dependent protein kinase using a MD-MX procedure, produced using 2.4 Angstrom data
1YDR	;	2.2	;	STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE, ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H7 PROTEIN KINASE INHIBITOR 1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE
1YDS	;	2.2	;	Structure of CAMP-dependent protein kinase, alpha-catalytic subunit in complex with H8 protein kinase inhibitor [N-(2-methylamino)ethyl]-5-isoquinolinesulfonamide
1YDT	;	2.3	;	STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE, ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H89 PROTEIN KINASE INHIBITOR N-[2-(4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE
4C9N	;	2.2	;	Structure of camphor and hydroxycamphor bound D259N mutant of CYP101D1
4C9K	;	2.18	;	Structure of Camphor and Hydroxycamphor bound wild type CYP101D1
4C9P	;	1.799	;	Structure of camphor bound T260A mutant of CYP101D1
8G1N	;	2.74	;	Structure of Campylobacter concisus PglC I57M/Q175M Variant with modeled C-terminus
8E37	;	3.01	;	Structure of Campylobacter concisus wild-type SeMet PglC
7BDV	;	2.02	;	Structure of Can2 from Sulfobacillus thermosulfidooxidans in complex with cyclic tetra-adenylate (cA4)
8Q5I	;	2.45	;	Structure of Candida albicans 80S ribosome in complex with cephaeline
7Q08	;	2.56	;	Structure of Candida albicans 80S ribosome in complex with cycloheximide
7Q0F	;	2.64	;	Structure of Candida albicans 80S ribosome in complex with phyllanthoside
7V6F	;	2.98	;	Structure of Candida albicans Fructose-1,6-bisphosphate aldolase complexed with G3P
7V6G	;	2.343	;	Structure of Candida albicans Fructose-1,6-bisphosphate aldolase mutation C157S with CN39
4H1G	;	2.15	;	Structure of Candida albicans Kar3 motor domain fused to maltose-binding protein
5HUS	;	1.751	;	Structure of Candida albicans trehalose synthase regulatory protein C-terminal domain
5DXF	;	2.563	;	Structure of Candida albicans trehalose-6-phosphate phosphatase N-terminal domain
5HUV	;	2.002	;	Structure of Candida albicans trehalose-6-phosphate synthase E341R/E346R in complex with UDP-glucose
5HUU	;	2.37	;	Structure of Candida albicans trehalose-6-phosphate synthase in complex with UDP and glucose-6-phosphate
5HVL	;	1.796	;	Structure of Candida albicans trehalose-6-phosphate synthase in complex with UDP and validoxylamine A
5HUT	;	1.9	;	Structure of Candida albicans trehalose-6-phosphate synthase in complex with UDP-glucose
6ISP	;	1.88	;	structure of Candida antarctica Lipase B mutant
6MJE	;	2.5	;	Structure of Candida glabrata Csm1: S. cerevisiae Dsn1 complex
6MJB	;	2.27	;	Structure of Candida glabrata Csm1:Dsn1(14-72) complex
6MJC	;	1.79	;	Structure of Candida glabrata Csm1:Dsn1(43-67DD) complex
6MJ8	;	3.03	;	Structure of Candida glabrata Csm1:Mam1 complex
6OAS	;	3.0	;	Structure of canine parvovirus in complex with transferrin receptor type-1
6Z3T	;	2.69	;	Structure of canine Sec61 inhibited by mycolactone
7V3Z	;	3.29	;	Structure of cannabinoid receptor type 1(CB1)
7RWK	;	2.39	;	Structure of Cap5 from Asticcacaulis sp.
7RWM	;	3.4	;	Structure of Cap5 from Lactococcus lactis
7PDZ	;	3.8	;	Structure of capping protein bound to the barbed end of a cytoplasmic actin filament
5OSW	;	1.78	;	Structure of caprine serum albumin in complex with 3,5-diiodosalicylic acid
5ORI	;	1.94	;	Structure of caprine serum albumin in orthorhombic crystal system
5OTB	;	2.5	;	Structure of caprine serum albumin in P1 space group
8FXP	;	4.04	;	Structure of capsid of Agrobacterium phage Milano
4AXS	;	2.5	;	Structure of Carbamate Kinase from Mycoplasma penetrans
1BXR	;	2.1	;	STRUCTURE OF CARBAMOYL PHOSPHATE SYNTHETASE COMPLEXED WITH THE ATP ANALOG AMPPNP
8AI7	;	2.13	;	Structure of carbamoylated human butyrylcholinesterase upon reaction with 3-(((2-cycloheptylethyl)(methyl)amino)methyl)-1H-indol-7-yl N,N-dimethylcarbamate
6NZ8	;	1.2	;	Structure of carbamylated apo OXA-231 carbapenemase
1NX8	;	2.3	;	Structure of carbapenem synthase (CarC) complexed with N-acetyl proline
6RYM	;	1.46	;	Structure of carbohydrate recognition domain with GlcNAc bound
4MQG	;	1.68	;	Structure of Carbonmonoxy Adult Hemoglobin Bristol-Alesha alphawtbetaV67M
4C4O	;	2.05	;	Structure of carbonyl reductase CPCR2 from Candida parapsilosis in complex with NADH
1YME	;	1.53	;	STRUCTURE OF CARBOXYPEPTIDASE
1CPB	;	2.8	;	STRUCTURE OF CARBOXYPEPTIDASE B AT 2.8 ANGSTROMS RESOLUTION
7KO5	;	7.8	;	Structure of cardiac native thin filament at pCa=5.8 having upper and lower troponins in Ca2+ bound state
7KO4	;	8.0	;	Structure of cardiac native thin filament at pCa=5.8 having upper and lower troponins in Ca2+ free state
7KOR	;	7.8	;	Structure of cardiac native thin filament at pCa=5.8 having upper troponin in Ca2+ bound state and lower troponin in Ca2+ free state
1MXL	;		;	STRUCTURE OF CARDIAC TROPONIN C-TROPONIN I COMPLEX
8D49	;	3.2	;	Structure of Cas12a2 binary complex
8D4B	;	2.92	;	Structure of Cas12a2 ternary complex
7WAH	;	2.45	;	Structure of Cas7-11 in complex with guide RNA and target RNA
7Y8T	;	2.9	;	Structure of Cas7-11-crRNA in complex with TPR-CHAT
7Y8Y	;	3.0	;	Structure of Cas7-11-crRNA-tgRNA in complex with TPR-CHAT
2C47	;	2.4	;	Structure of casein kinase 1 gamma 2
2CHL	;	1.95	;	Structure of casein kinase 1 gamma 3
2IZR	;	1.3	;	Structure of casein kinase gamma 3 in complex with inhibitor
2IZS	;	1.95	;	Structure of casein kinase gamma 3 in complex with inhibitor
2IZT	;	2.0	;	Structure of casein kinase gamma 3 in complex with inhibitor
2IZU	;	1.85	;	Structure of casein kinase gamma 3 in complex with inhibitor
3SEN	;	3.1	;	Structure of Caskin1 Tandem SAMs
1NME	;	1.6	;	Structure of Casp-3 with tethered salicylate
6VIE	;	3.4	;	Structure of caspase-1 in complex with gasdermin D
7P16	;	4.3	;	Structure of caspase-3 cleaved rXKR9 in complex with a sybody at 4.3A
1NW9	;	2.4	;	STRUCTURE OF CASPASE-9 IN AN INHIBITORY COMPLEX WITH XIAP-BIR3
7YOJ	;	3.36	;	Structure of CasPi with guide RNA and target DNA
8PVD	;	3.4	;	Structure of catalase determined by cryoEM at 100 keV
1IPH	;	2.8	;	STRUCTURE OF CATALASE HPII FROM ESCHERICHIA COLI
2IYE	;	2.6	;	Structure of catalytic CPx-ATPase domain CopB-B
2I0E	;	2.6	;	Structure of catalytic domain of human protein kinase C beta II complexed with a bisindolylmaleimide inhibitor
1KFW	;	1.74	;	Structure of catalytic domain of psychrophilic chitinase B from Arthrobacter TAD20
7YZ9	;	1.97	;	Structure of catalytic domain of Rv1625c bound to nanobody NB4
5UBW	;	2.394	;	Structure of catalytic domain of Ssel
2GJZ	;	2.65	;	Structure of Catalytic Elimination Antibody 13G5 from a crystal in space group P2(1)
2GK0	;	2.45	;	Structure of Catalytic Elimination Antibody 13G5 from a twinned crystal in space group C2
5GYJ	;	2.801	;	Structure of catalytically active sortase from Clostridium difficile
2NOE	;	2.2	;	Structure of catalytically inactive G42A human 8-oxoguanine glycosylase complexed to 8-oxoguanine DNA
2NOB	;	2.1	;	Structure of catalytically inactive H270A human 8-oxoguanine glycosylase crosslinked to 8-oxoguanine DNA
2NOL	;	2.57	;	Structure of catalytically inactive human 8-oxoguanine glycosylase distal crosslink to oxoG DNA
2NOH	;	2.01	;	Structure of catalytically inactive Q315A human 8-oxoguanine glycosylase complexed to 8-oxoguanine DNA
1DLM	;	2.0	;	STRUCTURE OF CATECHOL 1,2-DIOXYGENASE FROM ACINETOBACTER CALCOACETICUS NATIVE DATA
1DLQ	;	2.3	;	STRUCTURE OF CATECHOL 1,2-DIOXYGENASE FROM ACINETOBACTER SP. ADP1 INHIBITED BY BOUND MERCURY
1DMH	;	1.7	;	STRUCTURE OF CATECHOL 1,2-DIOXYGENASE FROM ACINETOBACTER SP. ADP1 WITH BOUND 4-METHYLCATECHOL
1DLT	;	1.9	;	STRUCTURE OF CATECHOL 1,2-DIOXYGENASE FROM ACINETOBACTER SP. ADP1 WITH BOUND CATECHOL
1MPY	;	2.8	;	STRUCTURE OF CATECHOL 2,3-DIOXYGENASE (METAPYROCATECHASE) FROM PSEUDOMONAS PUTIDA MT-2
6RT8	;	2.19	;	Structure of catharanthine synthase - an alpha-beta hydrolase from Catharanthus roseus with a cleaviminium intermediate bound
6AY2	;	1.6	;	Structure of CathB with covalently linked Compound 28
6YI7	;	1.29	;	Structure of cathepsin B1 from Schistosoma mansoni (SmCB1) in complex with an azanitrile inhibitor
3QSD	;	1.3	;	Structure of cathepsin B1 from Schistosoma mansoni in complex with CA074 inhibitor
3S3Q	;	1.8	;	Structure of cathepsin B1 from Schistosoma mansoni in complex with K11017 inhibitor
3S3R	;	2.64	;	Structure of cathepsin B1 from Schistosoma mansoni in complex with K11777 inhibitor
5OGR	;	1.55	;	Structure of cathepsin B1 from Schistosoma mansoni in complex with WRR286 inhibitor
5OGQ	;	1.91	;	Structure of cathepsin B1 from Schistosoma mansoni in complex with WRR391 inhibitor
4OBZ	;	2.9	;	Structure of Cathepsin D with inhibitor 2-(3,4-dimethoxyphenyl)-N-[N-(4-methylbenzyl)carbamimidoyl]acetamide
4OC6	;	2.64	;	Structure of Cathepsin D with inhibitor 2-bromo-N-[(2S,3S)-4-{[2-(2,4-dichlorophenyl)ethyl][3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propanoyl]amino}-3-hydroxy-1-(3-phenoxyphenyl)butan-2-yl]-4,5-dimethoxybenzamide
4OD9	;	1.9	;	Structure of Cathepsin D with inhibitor N-(3,4-dimethoxybenzyl)-Nalpha-{N-[(3,4-dimethoxyphenyl)acetyl]carbamimidoyl}-D-phenylalaninamide
7QBL	;	2.0	;	Structure of cathepsin K in complex with the 3-cyano-3-aza-beta-amino acid inhibitor Gu2602
7QBN	;	1.55	;	Structure of cathepsin K in complex with the azadipeptide nitrile inhibitor Gu1303
4N79	;	2.62	;	Structure of Cathepsin K-dermatan sulfate complex
6YYO	;	1.5	;	Structure of Cathepsin S in complex with Compound 1
6YYN	;	2.22	;	Structure of Cathepsin S in complex with Compound 14
6YYP	;	2.05	;	Structure of Cathepsin S in complex with Compound 2
6YYR	;	1.3	;	Structure of Cathepsin S in complex with Compound 20b
6YYQ	;	2.51	;	Structure of Cathepsin S in complex with Compound 3
3U9F	;	2.9	;	Structure of CATI in complex with chloramphenicol
1C39	;	1.85	;	STRUCTURE OF CATION-DEPENDENT MANNOSE 6-PHOSPHATE RECEPTOR BOUND TO PENTAMANNOSYL PHOSPHATE
3KWB	;	2.02	;	Structure of CatK covalently bound to a dioxo-triazine inhibitor
7RGV	;	2.63	;	Structure of Caulobacter crescentus Suppressor of copper sensitivity protein C
5K8J	;	1.6	;	Structure of Caulobacter crescentus VapBC1 (apo form)
5L6M	;	1.9	;	Structure of Caulobacter crescentus VapBC1 (VapB1deltaC:VapC1 form)
5L6L	;	2.7	;	Structure of Caulobacter crescentus VapBC1 bound to operator DNA
5KMD	;	3.2	;	Structure of CavAb in complex with amlodipine
5KLS	;	3.299	;	Structure of CavAb in complex with Br-dihydropyridine derivative UK-59811
5KMH	;	3.2	;	Structure of CavAb in complex with Br-verapamil
6KE5	;	2.803	;	Structure of CavAb in complex with Diltiazem and Amlodipine
6JUH	;	3.0	;	structure of CavAb in complex with efonidipine
5KMF	;	3.2	;	Structure of CavAb in complex with nimodipine
5KLG	;	3.3	;	Structure of CavAb(W195Y) in complex with Br-dihydropyridine derivative UK-59811
8FMH	;	1.87	;	Structure of CBASS Cap5 from Pseudomonas syringae as an activated tetramer with the cyclic dinucleotide 3'2'-c-dGAMP ligand (2 tetramers in the AU)
8FMF	;	2.1	;	Structure of CBASS Cap5 from Pseudomonas syringae as an activated tetramer with the cyclic dinucleotide 3'2'-c-diAMP ligand (1 tetramer in the AU)
8FMG	;	1.79	;	Structure of CBASS Cap5 from Pseudomonas syringae as an activated tetramer with the cyclic dinucleotide 3'2'-c-diAMP ligand (3 tetramers in the AU)
8FM1	;	3.16	;	Structure of CBASS Cap5 from Pseudomonas syringae in the absence of a ligand (apo form dimer)
3GFO	;	2.3	;	Structure of cbiO1 from clostridium perfringens: Part of the ABC transporter complex cbiONQ.
6XAR	;	2.501	;	Structure of CBL tyrosine kinase binding domain (TKBD) with C-terminal tail of Src-like kinase protein 2 (SLAP2)
4GPL	;	3.0	;	Structure of Cbl(TKB) bound to a phosphorylated pentapeptide
7ZVO	;	1.65	;	Structure of CBM BT0996-C from Bacteroides thetaiotaomicron
7BLK	;	1.06	;	Structure of CBM BT3015C from Bacteroides thetaiotaomicron
7BLG	;	1.18	;	Structure of CBM BT3015C from Bacteroides thetaiotaomicron in complex with galactose
7BLH	;	1.79	;	Structure of CBM BT3015C from Bacteroides thetaiotaomicron in complex with O-GalNAc core 1-Thr
7BLJ	;	1.76	;	Structure of CBM BT3015C from Bacteroides thetaiotaomicron in complex with O-GalNAc core 2-Thr
2C3W	;	1.81	;	Structure of CBM25 from Bacillus halodurans amylase in complex with maltotetraose
2C3G	;	2.0	;	Structure of CBM26 from Bacillus halodurans amylase
2C3H	;	2.24	;	Structure of CBM26 from Bacillus halodurans amylase in complex with maltose
2J1A	;	1.49	;	Structure of CBM32 from Clostridium perfringens beta-N- acetylhexosaminidase GH84C in complex with galactose
4LPL	;	1.35	;	Structure of CBM32-1 from a family 31 glycoside hydrolase from Clostridium perfringens
4LQR	;	1.58	;	Structure of CBM32-3 from a family 31 glycoside hydrolase from Clostridium perfringens
4LKS	;	1.5	;	Structure of CBM32-3 from a family 31 glycoside hydrolase from Clostridium perfringens in complex with galactose
4P5Y	;	2.5	;	Structure of CBM32-3 from a family 31 glycoside hydrolase from Clostridium perfringens in complex with N-acetylgalactosamine
4QB1	;	2.19	;	Structure of CBM35 from Paenibacillus barcinonensis
4QB6	;	1.35	;	Structure of CBM35 in complex with aldouronic acid
4QB2	;	1.5	;	Structure of CBM35 in complex with glucuronic acid
3ZQW	;	1.07	;	Structure of CBM3b of major scaffoldin subunit ScaA from Acetivibrio cellulolyticus
3ZUC	;	1.001	;	Structure of CBM3b of major scaffoldin subunit ScaA from Acetivibrio cellulolyticus determined from the crystals grown in the presence of Nickel
3ZU8	;	1.801	;	STRUCTURE OF CBM3B OF MAJOR SCAFFOLDIN SUBUNIT SCAA FROM ACETIVIBRIO CELLULOLYTICUS DETERMINED ON THE NIKEL ABSORPTION EDGE
5KLC	;	1.746	;	Structure of CBM_E1, a novel carbohydrate-binding module found by sugar cane soil metagenome
5KLE	;	1.5	;	Structure of CBM_E1, a novel carbohydrate-binding module found by sugar cane soil metagenome, complexed with cellopentaose
5KLF	;	1.801	;	Structure of CBM_E1, a novel carbohydrate-binding module found by sugar cane soil metagenome, complexed with cellopentaose and gadolinium ion
2L14	;		;	Structure of CBP nuclear coactivator binding domain in complex with p53 TAD
6JYX	;	2.0	;	Structure of CbpJ from Streptococcus Pneumoniae TIGR4
5T1A	;	2.806	;	Structure of CC Chemokine Receptor 2 with Orthosteric and Allosteric Antagonists
8B45	;	1.6	;	Structure of CC-Tri with Aib@b,c: CC-Tri-(UbUc)4
1QVG	;	2.9	;	Structure of CCA oligonucleotide bound to the tRNA binding sites of the large ribosomal subunit of Haloarcula marismortui
7EOF	;	2.733	;	Structure of CCDC25-DNA complex
6LAN	;	1.41	;	Structure of CCDC50 and LC3B complex
2NAX	;		;	Structure of CCHC zinc finger domain of Pcf11
6KFS	;	1.2	;	Structure of CCM related protein
6SCR	;	1.8	;	Structure of CcmK4 from Synechocystis sp. PCC6803
2JGW	;		;	Structure of CCP module 7 of complement factor H - The AMD at risk varient (402H)
2JGX	;		;	Structure of CCP module 7 of complement factor H - The AMD Not at risk varient (402Y)
3OQN	;	3.3	;	Structure of ccpa-hpr-ser46-p-gntr-down cre
3OQM	;	2.96	;	structure of ccpa-hpr-ser46p-ackA2 complex
6IXI	;	2.07	;	structure of Cd-bound periplasmic metal binding protein from candidatus liberibacter asiaticus
7U08	;	3.30692	;	Structure of CD148 fibronectin type III domain 1 and 2
7U01	;	2.29708	;	Structure of CD148 fibronectin type III domain 2
6VJA	;	3.3	;	Structure of CD20 in complex with rituximab Fab
2JXB	;		;	Structure of CD3epsilon-Nck2 first SH3 domain complex
7LO6	;	3.9	;	Structure of CD4 mimetic BNM-III-170 in complex with BG505 SOSIP.664 HIV-1 Env trimer and 17b Fab
7LOK	;	3.9	;	Structure of CD4 mimetic M48U1 in complex with BG505 SOSIP.664 HIV-1 Env trimer and 17b Fab
1I9R	;	3.1	;	STRUCTURE OF CD40L IN COMPLEX WITH THE FAB FRAGMENT OF HUMANIZED 5C8 ANTIBODY
8G94	;	3.15	;	Structure of CD69-bound S1PR1 coupled to heterotrimeric Gi
4ZGQ	;	3.0	;	Structure of Cdc123 bound to eIF2-gammaDIII domain
4ZGP	;	1.85	;	Structure of Cdc123 from Schizosaccharomyces pombe
6G84	;	2.47	;	Structure of Cdc14 bound to CBK1 PxL motif
6G85	;	1.528	;	Structure of Cdc14 bound to CBK1 PxL motif
6G86	;	1.74	;	Structure of Cdc14 bound to SIC1 PxL motif
1OHD	;	2.6	;	structure of cdc14 in complex with tungstate
1OHE	;	2.2	;	Structure of cdc14b phosphatase with a peptide ligand
5UNP	;	2.92	;	Structure of CDC2-Like Kinase 2 (CLK2) in Complex with Compound T-025 [N2-methyl-N4-(pyrimidin-2-ylmethyl)-5-(quinolin-6-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine]
1NF3	;	2.1	;	Structure of Cdc42 in a complex with the GTPase-binding domain of the cell polarity protein, Par6
1BD8	;	1.8	;	STRUCTURE OF CDK INHIBITOR P19INK4D
6CKX	;	2.8	;	Structure of CDK12/CycK in complex with a small molecule inhibitor N-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)-N-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)acetamide
1VYZ	;	2.21	;	Structure of CDK2 complexed with PNU-181227
2BTR	;	1.85	;	STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873
2BTS	;	1.99	;	STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032
4BZD	;	1.83	;	Structure of CDK2 in complex with a benzimidazopyrimidine
3PJ8	;	1.96	;	Structure of CDK2 in complex with a Pyrazolo[4,3-d]pyrimidine Bioisostere of Roscovitine.
2W05	;	1.9	;	Structure of CDK2 in complex with an imidazolyl pyrimidine, compound 5b
2W06	;	2.04	;	Structure of CDK2 in complex with an imidazolyl pyrimidine, compound 5c
4BCK	;	2.052	;	Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor
4BCM	;	2.45	;	Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor
4BCN	;	2.1	;	Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor
4BCO	;	2.05	;	Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor
4BCP	;	2.26	;	Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor
4BCQ	;	2.4	;	Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor
7UXI	;	2.07	;	Structure of CDK2 in complex with FP19711, a Helicon Polypeptide
7UXK	;	2.63	;	Structure of CDK2 in complex with FP24322, a Helicon Polypeptide
2DUV	;	2.2	;	Structure of CDK2 with a 3-hydroxychromones
2WIP	;	2.8	;	STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1-METHYL-4,5-DIHYDRO- 1H-PYRAZOLO[4,3-H] QUINAZOLINE-3-CARBOXYLIC ACID
2WXV	;	2.6	;	Structure of CDK2-CYCLIN A with a Pyrazolo(4,3-h) quinazoline-3- carboxamide inhibitor
2BKZ	;	2.6	;	STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
2C4G	;	2.7	;	STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
2BPM	;	2.4	;	STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
2WIH	;	2.5	;	STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
3TNW	;	2.0	;	Structure of CDK2/cyclin A in complex with CAN508
6SG4	;	2.43	;	Structure of CDK2/cyclin A M246Q, S247EN
1VYW	;	2.3	;	Structure of CDK2/Cyclin A with PNU-292137
7SJ3	;	2.51	;	Structure of CDK4-Cyclin D3 bound to abemaciclib
7CNG	;	3.49	;	Structure of CDK5R1 bound FEM1B
6LDP	;	2.35	;	Structure of CDK5R1-bound FEM1C
8I0M	;	2.7772	;	Structure of CDK6 in complex with inhibitor
4BCF	;	3.011	;	Structure of CDK9 in complex with cyclin T and a 2-amino-4-heteroaryl- pyrimidine inhibitor
4BCG	;	3.085	;	Structure of CDK9 in complex with cyclin T and a 2-amino-4-heteroaryl- pyrimidine inhibitor
4BCH	;	2.958	;	Structure of CDK9 in complex with cyclin T and a 2-amino-4-heteroaryl- pyrimidine inhibitor
4BCI	;	3.1	;	Structure of CDK9 in complex with cyclin T and a 2-amino-4-heteroaryl- pyrimidine inhibitor
4BCJ	;	3.162	;	Structure of CDK9 in complex with cyclin T and a 2-amino-4-heteroaryl- pyrimidine inhibitor
3TNI	;	3.234	;	structure of CDK9/cyclin T F241L
8I0L	;	3.6	;	Structure of CDK9/cyclin T1 in complex with inhibitor
3LQ5	;	3.0	;	Structure of CDK9/CyclinT in complex with S-CR8
3MY1	;	2.8	;	Structure of CDK9/cyclinT1 in complex with DRB
5IEN	;	2.089	;	Structure of CDL2.2, a computationally designed Vitamin-D3 binder
5IEO	;	1.851	;	Structure of CDL2.3a, a computationally designed Vitamin-D3 binder
5IEP	;	1.893	;	Structure of CDL2.3b, a computationally designed Vitamin-D3 binder
3KZ5	;	1.58	;	Structure of cdomain
1WVG	;	1.8	;	Structure of CDP-D-glucose 4,6-dehydratase from Salmonella typhi
5MLQ	;	3.18	;	Structure of CDPS from Nocardia brasiliensis
5MLP	;	1.99	;	Structure of CDPS from Rickettsiella grylli
6EZ3	;	3.0	;	Structure of CDPS from Staphylococcus haemolyticus
2F1N	;	1.73	;	Structure of CdtB, the biologically active subunit of Cytolethal Distending Toxin
7Q3O	;	2.78	;	Structure of CDX1 bound to hydroxymethylated DNA
6ES2	;	2.95	;	Structure of CDX2-DNA(CAA)
6ES3	;	2.57	;	Structure of CDX2-DNA(TCG)
5A3M	;	1.75	;	Structure of Cea1A in complex with Chitobiose
5A3L	;	1.66	;	Structure of Cea1A in complex with N-Acetylglucosamine
8BW0	;	3.11	;	Structure of CEACAM5 A3-B3 domain in Complex with Tusamitamab Fab
3LQR	;	3.896	;	Structure of CED-4:CED-3 complex
6PQC	;	2.1	;	Structure of cefotaxime-CDD-1 beta-lactamase complex
2MGQ	;		;	Structure of CEH37 Homeodomain
3C73	;	2.5	;	Structure of CEHC variant ResA
2L7U	;		;	Structure of CEL-PEP-RAGE V domain complex
3LN1	;	2.4	;	Structure of celecoxib bound at the COX-2 active site
2F6S	;	2.5	;	Structure of cell filamentation protein (fic) from Helicobacter pylori
2XSP	;	1.7	;	Structure of Cellobiohydrolase 1 (Cel7A) from Heterobasidion annosum
5ZHB	;	1.85	;	Structure of Cellobiose 2-Epimerase from Bacillus thermoamylovorans B4167
4OY7	;	1.5	;	Structure of cellulose active LPMO CelS2 (ScLPMO10C) in complex with Copper.
1GYD	;	2.05	;	Structure of Cellvibrio cellulosa alpha-L-arabinanase
1GYE	;	2.5	;	Structure of Cellvibrio cellulosa alpha-L-arabinanase complexed with Arabinohexaose
6M4I	;	1.9	;	Structure of CENP-E motor domain at 1.9 angstrom resolution
1WRU	;	2.1	;	Structure of central hub elucidated by X-ray analysis of gene product 44; baseplate component of bacteriophage Mu
7JLH	;	1.57	;	Structure of Centromeric Satellite III Non-canonical Duplex
1JW0	;	2.5	;	Structure of cephalosporin acylase in complex with glutarate
1JVZ	;	2.6	;	Structure of cephalosporin acylase in complex with glutaryl-7-aminocephalosporanic acid
6TJJ	;	1.59	;	Structure of Cerezyme at pH 4.6
5OXC	;	1.02	;	Structure of Cerulean Fluorescent Protein at 1.02 Angstrom resolution
2WSO	;	1.15	;	Structure of Cerulean Fluorescent Protein at physiological pH
4EJX	;	4.69	;	Structure of ceruloplasmin-myeloperoxidase complex
6ARU	;	3.2	;	Structure of Cetuximab Fab mutant in complex with EGFR extracellular domain
5I2I	;	2.551	;	Structure of cetuximab Fab with cyclic F3Q variant of the meditope
6AYN	;	2.48	;	Structure of cetuximab with aminoheptanoic acid-linked N-(3-aminopropyl)-L-arginine meditope variant
6AZK	;	2.477	;	Structure of cetuximab with aminoheptanoic acid-linked N-(3-hydroxypropyl)-L-arginine meditope variant
6AU5	;	2.484	;	Structure of cetuximab with aminoheptanoic acid-linked n-butylarginine meditope variant
6AZL	;	2.482	;	Structure of cetuximab with aminoheptanoic acid-linked N-carboxyethylarginine meditope variant
6AXP	;	2.484	;	Structure of cetuximab with aminoheptanoic acid-linked n-octylarginine meditope variant
5LRU	;	2.2	;	Structure of Cezanne/OTUD7B OTU domain
5LRV	;	2.8	;	Structure of Cezanne/OTUD7B OTU domain bound to Lys11-linked diubiquitin
5LRW	;	2.0	;	Structure of Cezanne/OTUD7B OTU domain bound to ubiquitin
4Y2O	;	2.419	;	Structure of CFA/I pili chaperone-major subunit complex (CfaA-CfaB)
4Y2L	;	1.746	;	Structure of CFA/I pili major subunit CfaB trimer
4Y2N	;	2.4	;	Structure of CFA/I pili major subunit CfaB trimer
5CW5	;	2.736	;	Structure of CfBRCC36-CfKIAA0157 complex (QSQ mutant)
5CW4	;	2.543	;	Structure of CfBRCC36-CfKIAA0157 complex (Selenium Edge)
5CW3	;	2.55	;	Structure of CfBRCC36-CfKIAA0157 complex (Zn Edge)
8OKX	;	3.51	;	Structure of cGAS in complex with SPSB3-ELOBC
7P43	;	1.93	;	Structure of CgGBE in complex with maltotriose
7P44	;	2.4	;	Structure of CgGBE in P21212 space group
7P45	;	2.09	;	Structure of CgGBE in P212121 space group
6WEK	;	2.7	;	Structure of cGMP-bound WT TAX-4 reconstituted in lipid nanodiscs
6WEL	;	2.5	;	Structure of cGMP-unbound F403V/V407A mutant TAX-4 reconstituted in lipid nanodiscs
6WEJ	;	2.6	;	Structure of cGMP-unbound WT TAX-4 reconstituted in lipid nanodiscs
4XM4	;	2.95	;	Structure of Chaetomium Mex67:Mtr2 subunits
5JM6	;	2.758	;	Structure of Chaetomium thermophilum mApe1
5HAZ	;	2.1	;	Structure of Chaetomium thermophilum Nup170 CTD
5D5Y	;	1.03	;	Structure of Chaetomium thermophilum Skn7 coiled-coil domain, crystal form I
5D5Z	;	1.7	;	Structure of Chaetomium thermophilum Skn7 coiled-coil domain, crystal form II
5D60	;	1.9	;	Structure of Chaetomium thermophilum Skn7 coiled-coil domain, crystal form III
4O9I	;	2.6	;	Structure of CHD4 double chromodomains depicts cooperative folding for DNA binding
6Q3M	;	2.52	;	Structure of CHD4 PHD2 - tandem chromodomains
6GUU	;	2.95	;	Structure of CHD5 PHD2 - tandem chromodomains
1I5C	;	1.9	;	STRUCTURE OF CHEA DOMAIN P4 IN COMPLEX WITH ADP
1I5A	;	1.9	;	STRUCTURE OF CHEA DOMAIN P4 IN COMPLEX WITH ADPCP AND MANGANESE
1I5B	;	1.94	;	STRUCTURE OF CHEA DOMAIN P4 IN COMPLEX WITH ADPNP AND MANGANESE
6MI6	;	2.95	;	STRUCTURE OF CHEA DOMAIN P4 IN COMPLEX WITH AN ADP ANALOG
1I5D	;	2.9	;	STRUCTURE OF CHEA DOMAIN P4 IN COMPLEX WITH TNP-ATP
1WVP	;	1.53	;	Structure of chemically modified myoglobin with distal N-tetrazolyl-histidine E7(64)
2NWD	;	1.04	;	Structure of chemically synthesized human lysozyme at 1 Angstrom resolution
5CHY	;	2.0	;	STRUCTURE OF CHEMOTAXIS PROTEIN CHEY
6CHY	;	2.33	;	STRUCTURE OF CHEMOTAXIS PROTEIN CHEY
1AB5	;	2.4	;	STRUCTURE OF CHEY MUTANT F14N, V21T
1AB6	;	2.2	;	STRUCTURE OF CHEY MUTANT F14N, V86T
3RVO	;	1.55	;	Structure of CheY-Mn2+ Complex with substitutions at 59 and 89: N59D E89Y
8R42	;	2.32	;	Structure of CHI3L1 in complex with inhibititor 2
8R41	;	2.25	;	Structure of CHI3L1 in complex with inhibitor 1
3S3W	;	2.6	;	Structure of chicken acid-sensing ion channel 1 at 2.6 a resolution and ph 7.5
3S3X	;	2.99	;	Structure of chicken acid-sensing ion channel 1 AT 3.0 A resolution in complex with psalmotoxin
1ALA	;	2.25	;	STRUCTURE OF CHICKEN ANNEXIN V AT 2.25-ANGSTROMS RESOLUTION
3DBX	;	2.0	;	Structure of chicken CD1-2 with bound fatty acid
7JM6	;	2.92	;	Structure of chicken CLC-7
5JAJ	;	1.5	;	Structure of chicken LGP2 witha 5'p 10-mer dsRNA and ADP-AlF4-Mg.
6NF6	;	3.32	;	Structure of chicken Otop3 in nanodiscs
1TOP	;	1.78	;	STRUCTURE OF CHICKEN SKELETAL MUSCLE TROPONIN-C AT 1.78 ANGSTROMS RESOLUTION
5TGB	;	2.741	;	Structure of chimeric 02-CB Fab, a VRC01-like germline antibody
5TF1	;	1.858	;	Structure of chimeric 02-CC Fab, a VRC01-like germline antibody
5TFS	;	2.319	;	Structure of chimeric 02-K Fab, a VRC01-like germline antibody
7RQQ	;	1.89	;	Structure of chimeric antibody F10heavy_L9light with PfCSP peptide NANPNVDP
7RQR	;	2.23	;	Structure of chimeric antibody L9heavy_F10light with PfCSP peptide NANPNVDP
8ESH	;	2.72	;	Structure of chimeric HLA-A*02:01 bound to CMV peptide
8ERX	;	2.07	;	Structure of chimeric HLA-A*11:01-A*02:01 bound to HIV-1 RT peptide
2ROT	;		;	Structure of chimeric variant of SH3 domain- SHH
3FJO	;	2.5	;	Structure of chimeric YH CPR
7ZYA	;	1.12	;	Structure of Chit33 from Trichoderma harzianum.
6EPB	;	1.75	;	Structure of Chitinase 42 from Trichoderma harzianum
4LGX	;	1.49	;	Structure of Chitinase D from Serratia proteamaculans revealed an unusually constrained substrate binding site
2Y8V	;	1.99	;	Structure of chitinase, ChiC, from Aspergillus fumigatus.
8R4X	;	1.54	;	Structure of Chitinase-3-like protein 1 in complex with inhibitor 30
5OPR	;	1.95	;	Structure of CHK1 10-pt. mutant complex with aminopyridine LRRK2 inhibitor
5OP4	;	2.0	;	Structure of CHK1 10-pt. mutant complex with aminopyrimidine LRRK2 inhibitor
5OOT	;	2.1	;	Structure of CHK1 10-pt. mutant complex with aminopyrimido-benzodiazepinone LRRK2 inhibitor
5OOP	;	1.7	;	Structure of CHK1 10-pt. mutant complex with AMP-PNP
5OP2	;	1.9	;	Structure of CHK1 10-pt. mutant complex with arylbenzamide LRRK2 inhibitor
5OPB	;	1.55	;	Structure of CHK1 10-pt. mutant complex with indazole LRRK2 inhibitor
7SUF	;	1.48	;	Structure of CHK1 10-pt. mutant complex with LRRK2 inhibitor 06
7SUG	;	1.48	;	Structure of CHK1 10-pt. mutant complex with LRRK2 inhibitor 09
7SUH	;	2.46	;	Structure of CHK1 10-pt. mutant complex with LRRK2 inhibitor 15
7MCK	;	1.65	;	Structure of CHK1 10-pt. mutant complex with LRRK2 inhibitor 18
7SUI	;	2.119	;	Structure of CHK1 10-pt. mutant complex with LRRK2 inhibitor 22
7SUJ	;	2.299	;	Structure of CHK1 10-pt. mutant complex with LRRK2 inhibitor 24
5OPS	;	2.0	;	Structure of CHK1 10-pt. mutant complex with pyrrolopyridine LRRK2 inhibitor
5OPU	;	1.55	;	Structure of CHK1 10-pt. mutant complex with pyrrolopyridine LRRK2 inhibitor
5OPV	;	1.9	;	Structure of CHK1 10-pt. mutant complex with pyrrolopyridine LRRK2 inhibitor
5OP5	;	1.9	;	Structure of CHK1 10-pt. mutant complex with pyrrolopyrimidine LRRK2 inhibitor
5OP7	;	1.8	;	Structure of CHK1 10-pt. mutant complex with pyrrolopyrimidine LRRK2 inhibitor
5OOR	;	1.9	;	Structure of CHK1 10-pt. mutant complex with staurosporine
5OQ6	;	1.95	;	Structure of CHK1 12-pt. mutant complex with aminopyrimido-benzodiazepinone LRRK2 inhibitor
5OQ8	;	2.0	;	Structure of CHK1 12-pt. mutant complex with arylbenzamide LRRK2 inhibitor
5OQ5	;	1.4	;	Structure of CHK1 8-pt. mutant complex with aminopyrimido-benzodiazepinone LRRK2 inhibitor
5OQ7	;	2.1	;	Structure of CHK1 8-pt. mutant complex with arylbenzamide LRRK2 inhibitor
6GZU	;	1.47	;	Structure of Chlamydia abortus effector protein ChlaDUB
6FDU	;	2.3	;	Structure of Chlamydia trachomatis effector protein Cdu1 bound to Compound 3
6FDQ	;	2.3	;	Structure of Chlamydia trachomatis effector protein Cdu1 bound to Compound 5
6FDK	;	1.6	;	Structure of Chlamydia trachomatis effector protein Cdu1 bound to ubiquitin
5HAG	;	2.1	;	Structure of Chlamydia trachomatis effector protein ChlaDUB1
6GZT	;	2.1	;	Structure of Chlamydia trachomatis effector protein ChlaDUB1 bound to Coenzyme A
6GZS	;	1.9	;	Structure of Chlamydia trachomatis effector protein ChlaDUB1 bound to ubiquitin
6FQ4	;	2.89	;	Structure of Chlamydial virulence factor TarP and vinculin head domain
4XDI	;	1.893	;	Structure of Chlamydomonas reinhardtii THB1
1NJI	;	3.0	;	Structure of chloramphenicol bound to the 50S ribosomal subunit
2Q2T	;	2.3	;	Structure of Chlorella virus DNA ligase-adenylate bound to a 5' phosphorylated nick
2Q2U	;	3.0	;	Structure of Chlorella virus DNA ligase-product DNA complex
7CRT	;	1.85	;	Structure of Chloride ion pumping rhodopsin (ClR) with NTQ motif 100 ps after light activation (0.17mJ/mm2)
7CRS	;	1.85	;	Structure of Chloride ion pumping rhodopsin (ClR) with NTQ motif 100 ps after light activation (0.90mJ/mm2)
7CRX	;	1.85	;	Structure of Chloride ion pumping rhodopsin (ClR) with NTQ motif 100 ps after light activation (2.63mJ/mm2)
7CRY	;	1.85	;	Structure of Chloride ion pumping rhodopsin (ClR) with NTQ motif 100 ps after light activation (6.49 mJ/mm2)
7CRL	;	1.85	;	Structure of Chloride ion pumping rhodopsin (ClR) with NTQ motif 50 ps after light activation
7L22	;	1.925	;	Structure of chloride soak form of ArrX from Chrysiogenes arsenatis
3NN2	;	1.94	;	Structure of chlorite dismutase from Candidatus Nitrospira defluvii in complex with cyanide
3NN1	;	1.85	;	Structure of chlorite dismutase from Candidatus Nitrospira defluvii in complex with imidazole
3NN3	;	2.6	;	Structure of chlorite dismutase from Candidatus Nitrospira defluvii R173A mutant
3NN4	;	2.7	;	Structure of chlorite dismutase from Candidatus Nitrospira defluvii R173K mutant
4WWS	;	2.0	;	Structure of Chlorite dismutase-like Protein from Listeria monocytogenes
6RHG	;	1.22	;	Structure of Chloroflexus aggregans Cagg_3753 LOV domain
6Y7R	;	1.6	;	Structure of Chloroflexus aggregans Cagg_3753 LOV domain C85A A56P variant (CagFbFP)
6Y7U	;	1.6	;	Structure of Chloroflexus aggregans Cagg_3753 LOV domain C85A A95P variant (CagFbFP)
6RHF	;	1.07	;	Structure of Chloroflexus aggregans Cagg_3753 LOV domain C85A variant (CagFbFP)
7AB7	;	1.8	;	Structure of Chloroflexus aggregans flavin based fluorescent protein (CagFbFP) I52T Q148K variant
7AB6	;	1.9	;	Structure of Chloroflexus aggregans flavin based fluorescent protein (CagFbFP) I52T variant
6YWH	;	1.07	;	Structure of Chloroflexus aggregans flavin based fluorescent protein (CagFbFP) Q148D variant
6YWI	;	1.13	;	Structure of Chloroflexus aggregans flavin based fluorescent protein (CagFbFP) Q148E variant
6YWQ	;	1.27	;	Structure of Chloroflexus aggregans flavin based fluorescent protein (CagFbFP) Q148H variant
6YWR	;	1.5	;	Structure of Chloroflexus aggregans flavin based fluorescent protein (CagFbFP) Q148H variant (space group C2)
6YX6	;	1.5	;	Structure of Chloroflexus aggregans flavin based fluorescent protein (CagFbFP) Q148K variant (no morpholine)
6YXB	;	1.5	;	Structure of Chloroflexus aggregans flavin based fluorescent protein (CagFbFP) Q148K variant (space group P21)
6YX4	;	1.36	;	Structure of Chloroflexus aggregans flavin based fluorescent protein (CagFbFP) Q148K variant with morpholine
6YWG	;	1.45	;	Structure of Chloroflexus aggregans flavin based fluorescent protein (CagFbFP) Q148N variant
6YXC	;	1.65	;	Structure of Chloroflexus aggregans flavin based fluorescent protein (CagFbFP) Q148R variant
8PKY	;	1.4	;	Structure of Chloroflexus aggregans flavin based fluorescent protein (CagFbFP) Q148V variant
8PM1	;	1.5	;	Structure of Chloroflexus aggregans flavin based fluorescent protein (CagFbFP) variant I52V A85Q
7OO9	;	1.2	;	Structure of Chloroflexus islandicus LOV domain C85A variant (CisFbFP)
2J5M	;	1.75	;	Structure of Chloroperoxidase Compound 0
8FJD	;	4.46	;	Structure of chlorophyllase from Triticum aestivum
4AK9	;	1.8	;	Structure of chloroplast FtsY from Physcomitrella patens
4N16	;	1.54	;	Structure of cholate bound to human carbonic anhydrase II
7N4V	;	3.58	;	Structure of cholesterol-bound human NPC1L1
6WHP	;	2.25	;	Structure of Choline kinase from Cryptococcus neoformans var. grubii serotype A
2D8D	;	1.15	;	Structure of Chorismate Mutase (Form I) from Thermus Thermophilus HB8
2D8E	;	1.75	;	Structure of Chorismate Mutase (Form II) from Thermus Thermophilus HB8
6YIF	;	1.81	;	Structure of Chromosomal Passenger Complex (CPC) bound to phosphorylated Histone 3 peptide at 1.8 A.
6YIH	;	2.55	;	Structure of Chromosomal Passenger Complex (CPC) bound to phosphorylated Histone 3 peptide at 2.6 A.
5IHS	;	1.1	;	Structure of CHU_2103 from Cytophaga hutchinsonii
6GCH	;	2.1	;	STRUCTURE OF CHYMOTRYPSIN-*TRIFLUOROMETHYL KETONE INHIBITOR COMPLEXES. COMPARISON OF SLOWLY AND RAPIDLY EQUILIBRATING INHIBITORS
7GCH	;	1.8	;	STRUCTURE OF CHYMOTRYPSIN-*TRIFLUOROMETHYL KETONE INHIBITOR COMPLEXES. COMPARISON OF SLOWLY AND RAPIDLY EQUILIBRATING INHIBITORS
6W74	;	2.11	;	Structure of cIAP with compound 15
2L9M	;		;	Structure of cIAP1 CARD
8DSF	;	1.5	;	Structure of cIAP1 with BCCov
8DSO	;	2.334	;	Structure of cIAP1, BTK and BCCov
4KMN	;	1.523	;	Structure of cIAP1-BIR3 and inhibitor
5GYL	;	2.2	;	Structure of Cicer arietinum 11S gloubulin
4NKU	;	1.94	;	Structure of Cid1 in complex with its short product ApU
4NKT	;	1.9	;	Structure of Cid1 in complex with the UTP analog UMPNPP
3L6J	;	2.3	;	Structure of cinaciguat (bay 58-2667) bound to nostoc H-NOX domain
4GM7	;	2.6	;	Structure of cinnamic acid bound bovine lactoperoxidase at 2.6A resolution.
2DDE	;		;	Structure of cinnamycin complexed with lysophosphatidylethanolamine
8T05	;	3.22	;	Structure of Ciona Myomaker bound to Fab1A1
4WU9	;	2.6	;	Structure of cisPtNAP-NCP145
1U5V	;	1.85	;	Structure of CitE complexed with triphosphate group of ATP form Mycobacterium tuberculosis
1U5H	;	1.65	;	Structure of Citrate Lyase beta subunit from Mycobacterium tuberculosis
4TVM	;	2.6	;	Structure of Citrate Synthase from Mycobacterium tuberculosis
4YBO	;	2.179	;	Structure of Citrate Synthase from the Thermoacidophilic Euryarchaeon Thermolasma acidophilum
8GM9	;	2.4	;	Structure of Citrate Synthase(CitA) in Mycobacterium Tuberculosis
2J80	;	1.6	;	Structure of Citrate-bound Periplasmic Domain of Sensor Histidine Kinase CitA
2V9A	;	2.0	;	Structure of Citrate-free Periplasmic Domain of Sensor Histidine Kinase CitA
6HXP	;	1.45	;	Structure of citryl-CoA lyase from Hydrogenobacter thermophilus
6HXQ	;	2.91	;	Structure of citryl-CoA synthetase from Hydrogenobacter thermophilus
7X39	;	2.85	;	Structure of CIZ1 bound ERH
5FV8	;	1.99	;	Structure of cJun-FosW coiled coil complex.
1RQF	;	2.89	;	Structure of CK2 beta subunit crystallized in the presence of a p21WAF1 peptide
7XTO	;	2.48	;	Structure of ClA2 reveal the Mechanism of soil bacterial derived chlorinase
1HZO	;	1.75	;	STRUCTURE OF CLASS A CEPHALOSPORINASE FROM PROTEUS VULGARIS K1
7T8Y	;	1.8	;	Structure of Class A sortase from Streptococcus pyogenes bound to lipid II mimetic, LPATA: Thr-in conformation
7T8Z	;	1.9	;	Structure of Class A sortase from Streptococcus pyogenes bound to lipid II mimetic, LPATA: Thr-out conformation
3C4U	;	1.83	;	Structure of class II fructose-biphosphate aldolase from helicobacter pylori
6EEU	;	1.93	;	Structure of class II HMG-CoA reductase from Delftia acidovorans
6EEV	;	1.49	;	Structure of class II HMG-CoA reductase from Delftia acidovorans with mevalonate bound
6DIO	;	2.14	;	Structure of class II HMG-CoA reductase from Delftia acidovorans with NAD bound
4KK6	;	3.183	;	Structure of CLC-ec1 deltaNC construct in 20mM Bromide
8H4X	;	1.93	;	Structure of cleaved Serpin B9
1JXQ	;	2.8	;	Structure of cleaved, CARD domain deleted Caspase-9
6LOM	;	3.73	;	Structure of CLHM1 from Caenorhabditis Elegans
3H6S	;	2.22	;	Structure of clitocypin - cathepsin V complex
6Q8P	;	3.0	;	Structure of CLK1 with bound N-methyl-10-nitropyrido[3,4-g]quinazolin-2-amine
2JJN	;	1.59	;	Structure of closed cytochrome P450 EryK
6NNH	;	1.523	;	Structure of Closed state of Dihydrofolate reductase from Mycobacterium tuberculosis in complex with NADPH and cycloguanil
6NNI	;	1.561	;	Structure of closed state of Dihydrofolate reductase from Mycobacterium tuberculosis in complex with NADPH and pyrimethamine
4JEN	;	3.0	;	Structure of Clostridium botulinum CMP N-glycosidase, BcmB
7UAV	;	2.2	;	Structure of Clostridium botulinum prophage Tad1 in apo state
7UAW	;	1.72	;	Structure of Clostridium botulinum prophage Tad1 in complex with 1''-2' gcADPR
8SMD	;	2.1	;	Structure of Clostridium botulinum prophage Tad1 in complex with 1''-3' gcADPR
6QZK	;	3.548	;	Structure of Clostridium butyricum Argonaute bound to a guide DNA (5' deoxycytidine) and a 19-mer target DNA
4P5H	;	3.38	;	Structure of Clostridium perfringens Enterotoxin with a peptide derived from a modified version of ECL-2 of Claudin 2
8SWU	;	2.34	;	Structure of Clostridium perfringens PNP bound to transition state analog IMMUCILLIN H and sulfate
4JT2	;	2.49	;	Structure of Clostridium thermocellum polynucleotide kinase bound to CTP
4JT4	;	2.01	;	Structure of Clostridium thermocellum polynucleotide kinase bound to dATP
4JSY	;	2.14	;	Structure of Clostridium thermocellum polynucleotide kinase bound to GTP
4JST	;	2.03	;	Structure of Clostridium thermocellum polynucleotide kinase bound to UTP
8B9U	;	2.25	;	Structure of ClpC1 NTD from Mycobacterium tuberculosis
6PBA	;	1.77	;	Structure of ClpC1-NTD
6PBQ	;	1.6	;	Structure of ClpC1-NTD
7AA4	;	1.68	;	Structure of ClpC1-NTD bound to a CymA analogue
6PBS	;	2.5	;	Structure of ClpC1-NTD in complex with Ecumicin
6UCR	;	2.3	;	Structure of ClpC1-NTD L92S L96P
3TT7	;	2.558	;	Structure of ClpP from Bacillus subtilis in complex with DFP
3TT6	;	2.592	;	Structure of ClpP from Bacillus subtilis in compressed state
3KTG	;	2.4	;	Structure of ClpP from Bacillus subtilis in monoclinic crystal form
3KTH	;	3.0	;	Structure of ClpP from Bacillus subtilis in orthorombic crystal form
3MT6	;	1.901	;	Structure of ClpP from Escherichia coli in complex with ADEP1
6TTY	;	1.9	;	Structure of ClpP from Staphylococcus aureus (apo, closed state)
7WGS	;	2.11	;	Structure of ClpP from Staphylococcus aureus in complex with (S)-ZG197
5VZ2	;	2.26	;	Structure of ClpP from Staphylococcus aureus in complex with Acyldepsipeptide
6PMD	;	2.21	;	Structure of ClpP from Staphylococcus aureus in complex with Acyldepsipeptide
6PKA	;	2.25	;	Structure of ClpP from Staphylococcus aureus in complex with ureadepsipeptide
3KTI	;	2.0	;	Structure of ClpP in complex with ADEP1
3KTJ	;	2.6	;	Structure of ClpP in complex with ADEP2 in monoclinic crystal form
3KTK	;	2.6	;	Structure of ClpP in complex with ADEP2 in triclinic crystal form
5IKJ	;	2.3	;	Structure of Clr2 bound to the Clr1 C-terminus
6Z2A	;	2.456	;	Structure of Clr4 mutant - F256A/F310A/F427A bound to SAH
8JQE	;	2.31	;	Structure of CmCBDA in complex with Mn2+ and glycerol
8JQF	;	1.85	;	Structure of CmCBDA in complex with Ni2+ and Glycerol
4P5N	;	1.49	;	Structure of CNAG_02591 from Cryptococcus neoformans
4CXF	;	1.75	;	Structure of CnrH in complex with the cytosolic domain of CnrY
5L26	;	3.4	;	Structure of CNTnw in an inward-facing substrate-bound state
5L27	;	4.1	;	Structure of CNTnw N149L in the intermediate 1 state
5L24	;	4.1	;	Structure of CNTnw N149L in the intermediate 2 state
5U9W	;	3.555	;	Structure of CNTnw N149L in the intermediate 3 state
5L2B	;	3.8	;	Structure of CNTnw N149S, E332A in an outward-facing state
5L2A	;	3.45	;	Structure of CNTnw N149S,F366A in an outward-facing state
1XMH	;	2.32	;	Structure of Co(II) reconstituted methane monooxygenase hydroxylase from M. capsulatus (Bath)
3OJJ	;	1.72	;	Structure of Co-substituted Homoprotocatechuate 2,3-Dioxygenase from B.fuscum at 1.72 Ang resolution
3OJK	;	1.68	;	Structure of Co-substituted Homoprotocatechuate 2,3-Dioxygenase in complex with 4-nitrocatechol at 1.68 Ang resolution
5DSO	;	1.4	;	Structure of CO2 bound apo-form of human carbonic anhydrase II with 0 sec (no) warming
5DSR	;	1.3	;	Structure of CO2 released apo-form of human carbonic anhydrase II with 10 min warming
5DSQ	;	1.5	;	Structure of CO2 released apo-form of human carbonic anhydrase II with 3 min warming
5DSP	;	1.4	;	Structure of CO2 released apo-form of human carbonic anhydrase II with 40 sec warming
5DSL	;	1.45	;	Structure of CO2 released holo-form of human carbonic anhydrase II with 10 min warming
5DSM	;	1.3	;	Structure of CO2 released holo-form of human carbonic anhydrase II with 25 min warming
5DSK	;	1.3	;	Structure of CO2 released holo-form of human carbonic anhydrase II with 3 min warming
2BB6	;	2.0	;	Structure of Cobalamin-complexed Bovine Transcobalamin in Monoclinic Crystal Form
2BBC	;	2.4	;	Structure of Cobalamin-complexed Bovine Transcobalamin in trigonal crystal form
8G3H	;	3.6	;	Structure of cobalamin-dependent methionine synthase (MetH) in a resting state
5UL4	;	1.85	;	Structure of Cobalamin-dependent S-adenosylmethionine radical enzyme OxsB with aqua-cobalamin and S-adenosylmethionine bound
5UL3	;	1.8	;	Structure of Cobalamin-dependent S-adenosylmethionine radical enzyme OxsB with aqua-cobalamin bound
1CAH	;	1.88	;	STRUCTURE OF COBALT CARBONIC ANHYDRASE COMPLEXED WITH BICARBONATE
8OGE	;	1.46	;	Structure of cobalt(II) substituted double mutant human carbonic anhydrase II bound to thiocyanate
5M2Q	;	1.7	;	Structure of cobinamide-bound BtuF mutant W66F, the periplasmic vitamin B12 binding protein in E.coli
5M3B	;	1.5	;	Structure of cobinamide-bound BtuF mutant W66L, the periplasmic vitamin B12 binding protein in E.coli
5M34	;	1.6	;	Structure of cobinamide-bound BtuF mutant W66Y, the periplasmic vitamin B12 binding protein in E.coli
5M29	;	1.5	;	Structure of cobinamide-bound BtuF, the periplasmic vitamin B12 binding protein in E.coli
2CDX	;		;	STRUCTURE OF COBRA CARDIOTOXIN CTXI AS DERIVED FROM NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY AND DISTANCE GEOMETRY CALCULATIONS
4JRB	;	2.414	;	Structure of Cockroach Allergen Bla g 1 Tandem Repeat as a EGFP fusion
7QOA	;	2.4	;	Structure of CodB, a cytosine transporter in an outward-facing conformation
1YQZ	;	1.54	;	Structure of Coenzyme A-Disulfide Reductase from Staphylococcus aureus refined at 1.54 Angstrom resolution
1F07	;	2.0	;	STRUCTURE OF COENZYME F420 DEPENDENT TETRAHYDROMETHANOPTERIN REDUCTASE FROM METHANOBACTERIUM THERMOAUTOTROPHICUM
1EZW	;	1.65	;	STRUCTURE OF COENZYME F420 DEPENDENT TETRAHYDROMETHANOPTERIN REDUCTASE FROM METHANOPYRUS KANDLERI
1JAX	;	1.8	;	Structure of Coenzyme F420H2:NADP+ Oxidoreductase (FNO)
1JAY	;	1.65	;	Structure of Coenzyme F420H2:NADP+ Oxidoreductase (FNO) with its substrates bound
7S3G	;	1.66	;	Structure of cofactor pyridoxal 5-phosphate bound human ornithine decarboxylase in complex with citrate at the catalytic center
7S3F	;	2.49	;	Structure of cofactor pyridoxal 5-phosphate bound human ornithine decarboxylase in complex with its inhibitor 1-amino-oxy-3-aminopropane
4KEF	;	1.098	;	Structure of Cofilin Mutant (cof1-159p)
5TDY	;	2.105	;	Structure of cofolded FliFc:FliGn complex from Thermotoga maritima
3OGK	;	2.8	;	Structure of COI1-ASK1 in complex with coronatine and an incomplete JAZ1 degron
3OGM	;	3.34	;	Structure of COI1-ASK1 in complex with coronatine and the JAZ1 degron
3OGL	;	3.18	;	Structure of COI1-ASK1 in complex with JA-isoleucine and the JAZ1 degron
3V5B	;	3.0	;	Structure of Coil 2b of human lamin
5CX2	;	2.21	;	Structure of coiled coil domain of Leishmania donovani coronin
7DGX	;	2.06	;	Structure of coiled coil domain of Trypanosoma brucei coronin
4NQJ	;	2.152	;	Structure of coiled-coil domain
4YTO	;	2.0	;	Structure of coiled-coil domain of SYCP1
7OWX	;	1.929	;	Structure of coiled-coil tetramer from SARS-CoV-2 spike stalk region
3I2Z	;	1.1	;	Structure of cold shock protein E from Salmonella typhimurium
1UNK	;	1.8	;	STRUCTURE OF COLICIN E7 IMMUNITY PROTEIN
5D5G	;	1.74	;	Structure of colocasia esculenta agglutinin
5D9Z	;	1.85	;	Structure of Colocasia Esculenta Agglutinin with mannose bound
2BHV	;	3.0	;	Structure of ComB10 of the Com Type IV secretion system of Helicobacter pylori
3PVM	;	4.3	;	Structure of Complement C5 in Complex with CVF
3PRX	;	4.3	;	Structure of Complement C5 in Complex with CVF and SSL7
5I5K	;	4.2	;	Structure of complement C5 in complex with eculizumab
8AYH	;	3.35	;	Structure of Complement C5 in Complex with small molecule inhibitor and CVF
3KLS	;	3.6	;	Structure of complement C5 in complex with SSL7
3KM9	;	4.2	;	Structure of complement C5 in complex with the C-terminal beta-grasp domain of SSL7
3KXV	;	2.004	;	Structure of complement Factor H variant Q1139A
3KZJ	;	1.65	;	Structure of complement Factor H variant R1203A
5O35	;	4.2	;	Structure of complement proteins complex
3R62	;	1.52	;	Structure of complement regulator Factor H mutant, T1184R.
4BOB	;	2.53	;	Structure of Complement regulator-acquiring surface protein 3 (CRASP- 3, ErpP or BBN38) from Borrelia burgdorferi
3FCS	;	2.55	;	Structure of complete ectodomain of integrin aIIBb3
6TED	;	3.1	;	Structure of complete, activated transcription complex Pol II-DSIF-PAF-SPT6 uncovers allosteric elongation activation by RTF1
1FMS	;	1.9	;	Structure of complex between cyclohexyl-bis-furamidine and d(CGCGAATTCGCG)
2B3T	;	3.1	;	Structure of complex between E. coli translation termination factor RF1 and the PrmC methyltransferase
2IYB	;	2.35	;	Structure of complex between the 3rd LIM domain of TES and the EVH1 domain of Mena
8G0M	;	2.25	;	Structure of complex between TV6.6 and CD98hc ECD
3CX5	;	1.9	;	Structure of complex III with bound cytochrome c in reduced state and definition of a minimal core interface for electron transfer.
2MPS	;		;	Structure of complex of MDM2(3-109) and P73 TAD(10-25)
4HVP	;	2.3	;	Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 Angstroms resolution
6OHP	;	2.6	;	Structure of compound 1 (halopemide) bound human Phospholipase D2 catalytic domain
8CNC	;	1.46	;	Structure of compound 1 bound KMT9
8R14	;	1.336	;	Structure of compound 11 bound to SARS-CoV-2 main protease
8R16	;	1.3	;	Structure of compound 12 bound to SARS-CoV-2 main protease
8AEM	;	1.6	;	Structure of Compound 13 bound to CK2alpha
8SIX	;	1.55	;	Structure of Compound 13 bound to the CHK1 10-point mutant
8AEK	;	1.65	;	Structure of Compound 14 bound to CK2alpha
8AEC	;	1.09	;	Structure of Compound 17 bound to CK2alpha
8SIV	;	1.759	;	Structure of Compound 2 bound to the CHK1 10-point mutant
6OHS	;	3.2	;	Structure of compound 3 (ML299) bound human Phospholipase D2 catalytic domain
7SVP	;	2.9	;	Structure of compound 34 bound to human Phospholipase D2 catalytic domain
6OHQ	;	2.694	;	Structure of compound 4 bound human Phospholipase D2 catalytic domain
6OHR	;	3.2	;	Structure of compound 5 bound human Phospholipase D1 catalytic domain
8SIW	;	1.877	;	Structure of Compound 5 bound to the CHK1 10-point mutant
3LN0	;	2.2	;	Structure of compound 5c-S bound at the active site of COX-2
7ZYD	;	1.404	;	Structure of Compound 6 Bound to CK2alpha
8R11	;	1.31	;	Structure of compound 7 bound to SARS-CoV-2 main protease
8R12	;	1.587	;	Structure of compound 8 bound to SARS-CoV-2 main protease
8WMK	;	2.17	;	Structure of ConA/Man2
8WMG	;	1.97	;	Structure of ConA/Man3
4P9X	;	2.06	;	Structure of ConA/Rh3Glu complex
4P9W	;	2.11	;	Structure of ConA/Rh3Man
4P9Y	;	1.89	;	Structure of ConA/Rh4man
3CNA	;	2.4	;	STRUCTURE OF CONCANAVALIN A AT 2.4 ANGSTROMS RESOLUTION
1TEI	;	2.7	;	STRUCTURE OF CONCANAVALIN A COMPLEXED TO BETA-D-GLCNAC (1,2)ALPHA-D-MAN-(1,6)[BETA-D-GLCNAC(1,2)ALPHA-D-MAN (1,6)]ALPHA-D-MAN
6RYJ	;	1.25	;	structure of conglutinin carbohydrate recognition domain with ethylene glycol bound
6RYN	;	1.0	;	Structure of conglutinin carbohydrate recognition domain with GlcNAc-alpha-1-phosphate bound
6MHQ	;	3.4	;	Structure of connexin-46 intercellular gap junction channel at 3.4 angstrom resolution by cryoEM
6MHY	;	3.4	;	Structure of connexin-50 intercellular gap junction channel at 3.4 angstrom resolution by cryoEM
7XQ9	;	3.3	;	Structure of connexin43/Cx43/GJA1 gap junction intercellular channel in GDN detergents at pH ~8.0
7F92	;	3.1	;	Structure of connexin43/Cx43/GJA1 gap junction intercellular channel in LMNG/CHS detergents at pH ~8.0
7F93	;	3.6	;	Structure of connexin43/Cx43/GJA1 gap junction intercellular channel in nanodiscs with soybean lipids at pH ~8.0
7XQB	;	3.0	;	Structure of connexin43/Cx43/GJA1 gap junction intercellular channel in POPE/CHS nanodiscs at pH ~8.0
7LQR	;		;	Structure of conotoxin CIC
1WVQ	;	1.45	;	Structure of conserved hypothetical protein PAE2307 from Pyrobaculum aerophilum
1I36	;	2.0	;	Structure of Conserved Protein MTH1747 of Unknown Function Reveals Structural Similarity with 3-Hydroxyacid Dehydrogenases
2FB6	;	1.46	;	Structure of Conserved Protein of Unknown Function BT1422 from Bacteroides thetaiotaomicron
2NN5	;	1.45	;	Structure of Conserved Protein of Unknown Function EF2215 from Enterococcus faecalis
1Z6M	;	1.3	;	Structure of Conserved Protein of Unknown Function from Enterococcus faecalis V583
2D9R	;	2.01	;	Structure of Conserved Protein of Unknown Function PG0164 from Porphyromonas gingivalis [W83]
1RLK	;	1.95	;	Structure of Conserved Protein of Unknown Function TA0108 from Thermoplasma acidophilum
1ZKI	;	1.7	;	Structure of conserved protein PA5202 from Pseudomonas aeruginosa
1Y9B	;	2.2	;	Structure of Conserved Putative Transcriptional Factor from Vibrio cholerae O1 biovar eltor str. N16961
5T04	;	3.3	;	STRUCTURE OF CONSTITUTIVELY ACTIVE NEUROTENSIN RECEPTOR
2N55	;		;	Structure of constitutively monomeric CXCL12 in complex with the CXCR4 N-terminus
7USX	;	3.09	;	Structure of Contracted C. elegans TMC-1 complex
5JYQ	;	1.95	;	Structure of Conus Geographus insulin G1
2HKX	;	2.3	;	Structure of CooA mutant (N127L/S128L) from Carboxydothermus hydrogenoformans
4QFT	;	1.76	;	Structure of COP9 signalosome complex subunit 6
7L5C	;	2.55	;	Structure of copper bound MEMO1
8UM6	;	1.95	;	Structure of copper bound to YcnI W137F
7MEK	;	2.11	;	Structure of copper bound to Ycnl
4YSR	;	1.34	;	Structure of copper nitrite reductase from Geobacillus thermodenitrificans - 16.6 MGy
4YSS	;	1.5	;	Structure of copper nitrite reductase from Geobacillus thermodenitrificans - 16.7 MGy
4YST	;	1.34	;	Structure of copper nitrite reductase from Geobacillus thermodenitrificans - 24.9 MGy
4YSU	;	1.5	;	Structure of copper nitrite reductase from Geobacillus thermodenitrificans - 25.0 MGy
4YSP	;	1.34	;	Structure of copper nitrite reductase from Geobacillus thermodenitrificans - 8.32 MGy
4YSQ	;	1.5	;	Structure of copper nitrite reductase from Geobacillus thermodenitrificans - 8.38 MGy
3X1E	;	1.25	;	Structure of copper-containing nitrite reductase from Geobacillus thermodenitrificans without chloride
4B3E	;	2.15	;	Structure of copper-zinc superoxide dismutase complexed with bicarbonate.
5LOQ	;	1.69	;	Structure of coproheme bound HemQ from Listeria monocytogenes
6XUC	;	1.8702	;	Structure of coproheme decarboxylase from Corynebacterium diphteriae in complex with coproheme
6XUB	;	1.78	;	Structure of coproheme decarboxylase from Corynebacterium diphteriae in complex with monovinyl monopropionyl deuteroheme
7Q4F	;	2.15	;	Structure of coproheme decarboxylase from Corynebacterium dipththeriae W183Y mutant in complex with coproheme
7Q4G	;	1.82	;	Structure of coproheme decarboxylase from Corynebacterium dipththeriae Y135A mutant in complex with coproheme
6FXQ	;	1.69	;	Structure of coproheme decarboxylase from Listeria monocytogenes during turnover
6FXJ	;	1.79	;	Structure of coproheme decarboxylase from Listeria monocytogenes in complex with iron coproporphyrin III
6SV3	;	1.64001	;	Structure of coproheme-LmCpfC
8AT8	;	1.51	;	Structure of coproporphyrin III-LmCpfC
8AW7	;	2.64	;	Structure of coproporphyrin III-LmCpfC R45L
8EFM	;	2.13	;	Structure of coral STING receptor from Stylophora pistillata in complex with 2',3'-cGAMP
2CK2	;	2.0	;	Structure of core-swapped mutant of fibronectin
3CL5	;	1.8	;	Structure of coronavirus hemagglutinin-esterase in complex with 4,9-O-diacetyl sialic acid
1LVO	;	1.96	;	Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain
7BBH	;	2.9	;	Structure of Coronavirus Spike from Smuggled Guangdong Pangolin
2V95	;	1.93	;	Structure of Corticosteroid-Binding Globulin in complex with Cortisol
8AU6	;	2.0	;	Structure of Corynebacterium glutamicum Cg1604, a cell division regulator
8FU7	;	3.21	;	Structure of Covid Spike variant deltaN135 in fully closed form
8FU8	;	3.08	;	Structure of Covid Spike variant deltaN135 with one erect RBD
8FU9	;	3.52	;	Structure of Covid Spike variant deltaN25 with one erect RBD
6W63	;	2.1	;	Structure of COVID-19 main protease bound to potent broad-spectrum non-covalent inhibitor X77
7DOK	;	2.73	;	Structure of COVID-19 RNA-dependent RNA polymerase (extended conformation) bound to penciclovir
7DFG	;	2.7	;	Structure of COVID-19 RNA-dependent RNA polymerase bound to favipiravir
7DOI	;	2.6	;	Structure of COVID-19 RNA-dependent RNA polymerase bound to penciclovir.
7DFH	;	2.97	;	Structure of COVID-19 RNA-dependent RNA polymerase bound to ribavirin
7D4F	;	2.57	;	Structure of COVID-19 RNA-dependent RNA polymerase bound to suramin
7BZ5	;	1.84	;	Structure of COVID-19 virus spike receptor-binding domain complexed with a neutralizing antibody
5KTH	;	2.21	;	Structure of cow mincle complexed with brartemicin
5KTI	;	1.8	;	Structure of cow mincle complexed with KMJ1
4ZRW	;	2.6	;	Structure of cow mincle complexed with trehalose
4ZRV	;	2.095	;	Structure of cow mincle CRD complexed with trehalose mono butyrate
4HKJ	;	3.0	;	Structure of Cowpox CPXV203 in complex with MHCI (H-2Kb)
6SMG	;	3.5	;	Structure of Coxsackievirus A10
6SNB	;	4.4	;	Structure of Coxsackievirus A10 A-particle
6SNW	;	3.9	;	Structure of Coxsackievirus A10 complexed with its receptor KREMEN1
8F7Y	;	2.8	;	Structure of Coxsackievirus A10 frozen at -183 degree embedded in crystalline ice
8POA	;	1.6	;	Structure of Coxsackievirus A16 (G-10) 2A protease
5ABJ	;	2.75	;	Structure of Coxsackievirus A16 in complex with GPP3
5XS4	;	3.1	;	Structure of Coxsackievirus A6 (CVA6) virus A-particle
5XS7	;	3.8	;	Structure of Coxsackievirus A6 (CVA6) virus A-particle in complex with the neutralizing antibody fragment 1D5
5XS5	;	3.3	;	Structure of Coxsackievirus A6 (CVA6) virus procapsid particle
5NFS	;	1.8	;	Structure of coxsackievirus B3 3C protease in complex with the alpha-ketoamide (S)-N-benzyl-3-((S)-2-cinnamamido-3-phenylpropanamido)-2-oxo-4-((S)-2-oxopyrrolidin-3-yl)butanamide (cinnamoyl-phenylalanine-GlnLactam-CO-CO-NH-benzyl)
8R5Y	;	2.7	;	Structure of coxsackievirus B5 capsid (mutant CVB5F.cas.genogroupB) - A particle
8R5Z	;	2.6	;	Structure of coxsackievirus B5 capsid (mutant CVB5F.cas.genogroupB) - E particle
8R5X	;	3.6	;	Structure of coxsackievirus B5 capsid (mutant CVB5F.cas.genogroupB) - F particle
5ID6	;	2.382	;	Structure of Cpf1/RNA Complex
5YR2	;	1.799	;	Structure of cpGFP66BPA
6PV4	;	2.2	;	Structure of CpGH84A
6PV5	;	2.18	;	Structure of CpGH84B
6PWI	;	2.65	;	Structure of CpGH84D
4AVT	;	3.2	;	Structure of CPHPC bound to Serum Amyloid P Component
4AVV	;	1.6	;	Structure of CPHPC bound to Serum Amyloid P Component
5D4P	;	2.2	;	Structure of CPII bound to ADP and bicarbonate, from Thiomonas intermedia K12
5D4N	;	1.6	;	Structure of CPII bound to ADP, AMP and acetate, from Thiomonas intermedia K12
5D4O	;	1.8	;	Structure of CPII, a nitrogen regulatory PII-like protein from Thiomonas intermedia K12, bound to ADP, AMP and bicarbonate.
7XSS	;	3.2	;	Structure of Craspase-CTR
7XT4	;	3.08	;	Structure of Craspase-NTR
7XSR	;	2.97	;	Structure of Craspase-target RNA
2JZJ	;		;	Structure of CrCVNH (C. richardii CVNH)
6QST	;	2.1	;	Structure of CREBBP bromodomain with compound 2 bound
4CJ7	;	3.2	;	Structure of Crenactin, an archeal actin-like protein
3HHF	;	2.3	;	Structure of CrgA regulatory domain, a LysR-type transcriptional regulator from Neisseria meningitidis.
2MMU	;		;	Structure of CrgA, a Cell Division Structural and Regulatory Protein from Mycobacterium tuberculosis, in Lipid Bilayers
3HHG	;	3.2	;	Structure of CrgA, a LysR-type transcriptional regulator from Neisseria meningitidis.
3NKD	;	1.95	;	Structure of CRISP-associated protein Cas1 from Escherichia coli str. K-12
2Y8W	;	1.8	;	Structure of CRISPR endoribonuclease Cse3 bound to 20 nt RNA
8E2W	;	2.95	;	Structure of CRISPR-Associated DinG
3QHQ	;	2.0	;	Structure of CRISPR-associated protein Csn2
8JAL	;	3.3	;	Structure of CRL2APPBP2 bound with RxxGP degron (dimer)
8JAQ	;	3.26	;	Structure of CRL2APPBP2 bound with RxxGP degron (tetramer)
8JAR	;	3.3	;	Structure of CRL2APPBP2 bound with RxxGPAA degron (dimer)
8JAS	;	3.54	;	Structure of CRL2APPBP2 bound with RxxGPAA degron (tetramer)
8JAU	;	3.22	;	Structure of CRL2APPBP2 bound with the C-degron of MRPL28 (dimer)
8JAV	;	3.44	;	Structure of CRL2APPBP2 bound with the C-degron of MRPL28 (tetramer)
7Z8B	;	2.8	;	Structure of CRL7FBXW8 reveals coupling with CUL1-RBX1/ROC1 for multi-cullin-RING E3-catalyzed ubiquitin ligation
2UWI	;	2.0	;	Structure of CrmE, a poxvirus TNF receptor
6ZSV	;	2.3	;	Structure of crocagin biosynthetic protein CgnB
8A2N	;	2.35	;	Structure of crocagin biosynthetic protein CgnD
6ZSU	;	2.0	;	Structure of crocagin biosynthetic protein CgnE
6JCJ	;	2.5	;	Structure of crolibulin in complex with tubulin
4G37	;	2.396	;	Structure of cross-linked firefly luciferase in second catalytic conformation
4Q4J	;	3.2	;	Structure of crosslinked TM287/288_S498C_S520C mutant
4Y0K	;	2.203	;	Structure of crotonyl-CoA carboxylase/reductase AntE in complex with NADP
4Y1B	;	1.5	;	Structure of crotonyl-CoA carboxylase/reductase AntE V350A in complex with NADP
1I5Z	;	1.9	;	STRUCTURE OF CRP-CAMP AT 1.9 A
6O2X	;	1.193	;	Structure of cruzain bound to MMTS inhibitor
2VTB	;	2.01	;	Structure of cryptochrome 3 - DNA complex
6LZ3	;	3.2	;	Structure of cryptochrome in active conformation
3K8G	;	1.95	;	Structure of crystal form I of TP0453
3K8H	;	2.39	;	Structure of crystal form I of TP0453
3K8J	;	2.2	;	Structure of crystal form III of TP0453
3K8I	;	2.2	;	Structure of crystal form IV of TP0453
7Z3J	;	2.0	;	Structure of crystallisable rat Phospholipase C gamma 1 in complex with inositol 1,4,5-trisphosphate
1O8S	;	1.15	;	Structure of CsCBM6-3 from Clostridium stercorarium in complex with cellobiose
1OD3	;	1.0	;	Structure of CSCBM6-3 From Clostridium stercorarium in complex with laminaribiose
1NAE	;	2.05	;	Structure of CsCBM6-3 from Clostridium stercorarium in complex with xylotriose
8T0P	;	1.73	;	Structure of Cse4 bound to Ame1 and Okp1
8CGC	;	1.925	;	Structure of CSF1R in complex with a pyrollopyrimidine (compound 23)
3N4S	;	2.35	;	Structure of Csm1 C-terminal domain, P21212 form
3N4R	;	2.602	;	Structure of Csm1 C-terminal domain, R3 form
3N4X	;	3.408	;	Structure of Csm1 full-length
3N7N	;	3.9	;	Structure of Csm1/Lrs4 complex
8PCW	;	3.54	;	Structure of Csm6' from Streptococcus thermophilus
8PE3	;	1.96	;	Structure of Csm6' from Streptococcus thermophilus in complex with cyclic hexa-adenylate (cA6)
6JY5	;	2.15	;	Structure of CsoS4B from Halothiobacillus neapolitanus
4B9I	;	1.5	;	Structure of CssA subunit complemented with donor strand from CssB subunit of enterotoxigenic Escherichia coli colonization factor CS6
2N6S	;		;	Structure of CssA4 (bottom stem) of CssA thermometer
4B9G	;	1.04	;	Structure of CssB subunit complemented with donor strand from CssA subunit of enterotoxigenic Escherichia coli colonization factor CS6
6YUD	;	1.84	;	Structure of Csx3/Crn3 from Archaeoglobus fulgidus in complex with cyclic tetra-adenylate (cA4)
7ELM	;	2.88	;	Structure of Csy-AcrIF24
7ELN	;	3.0	;	Structure of Csy-AcrIF24-dsDNA
7WE6	;	3.2	;	Structure of Csy-AcrIF24-dsDNA
7YHS	;	3.37	;	Structure of Csy-AcrIF4-dsDNA
7EQG	;	3.2	;	Structure of Csy-AcrIF5
6K5V	;	2.69	;	Structure of CSY4 Apo-form
7PQX	;	3.08	;	Structure of CtAtm1 in the inward-facing open conformation
7PRU	;	3.2	;	Structure of CtAtm1 in the inward-facing partially occluded with cargo bound
7PRO	;	3.0	;	Structure of CtAtm1 in the inward-open with Glutathione-complexed [2Fe-2S] cluster bound
7PR1	;	2.81	;	Structure of CtAtm1 in the occluded conformation with ATP bound
7PSD	;	3.0	;	Structure of CtAtm1(E603Q) in the inward-facing open conformation
7UF8	;	2.5	;	Structure of CtdP in complex with penicimutamide E and NADP+
6PTJ	;	3.8	;	Structure of Ctf4 trimer in complex with one CMG helicase
6PTO	;	7.0	;	Structure of Ctf4 trimer in complex with three CMG helicases
6PTN	;	5.8	;	Structure of Ctf4 trimer in complex with two CMG helicases
2Y8K	;	1.47	;	Structure of CtGH5-CBM6, an arabinoxylan-specific xylanase.
5KKL	;	2.94	;	Structure of ctPRC2 in complex with H3K27me3 and H3K27M
6AF0	;	2.88	;	Structure of Ctr9, Paf1 and Cdc73 ternary complex from Myceliophthora thermophila
6V7H	;	1.0	;	Structure of CTX-M-14 bound to Vaborbactam at 1.0 A
4XUZ	;	1.5	;	Structure of CTX-M-15 bound to RPX-7009 at 1.5 A
7TI0	;	1.5	;	Structure of CTX-M-15 bound to RPX-7063 at 1.5A
6Z7J	;	1.14	;	Structure of CTX-M-15 crystallised in the presence of enmetazobactam (AAI101)
7BDS	;	0.91	;	Structure of CTX-M-15 crystallised in the presence of tazobactam
6Z7H	;	1.42	;	Structure of CTX-M-15 E166Q mutant crystallised in the presence of enmetazobactam (AAI101)
7BDR	;	0.91	;	Structure of CTX-M-15 E166Q mutant crystallised in the presence of tazobactam (AAI101)
7QQC	;	0.95	;	Structure of CTX-M-15 K73A mutant
7QQ5	;	0.95	;	Structure of CTX-M-15 K73A mutant crystallised in the presence of enmetazobactam (AAI101)
2QDW	;	0.92	;	Structure of Cu(I) form of the M51A mutant of amicyanin
2FT7	;	1.4	;	Structure of Cu(I)azurin at pH 6, with the metal-binding loop sequence ""CTFPGHSALM"" replaced with ""CTPHPM""
2FT8	;	1.55	;	Structure of Cu(I)azurin, pH8, with the metal-binding loop sequence ""CTFPGHSALM"" replaced with ""CTPHPM""
2LEL	;		;	Structure of Cu(I)Cu(II)-CopK from Cupriavidus metallidurans CH34
2FTA	;	1.61	;	Structure of Cu(II)azurin with the metal-binding loop sequence ""CTFPGHSALM"" replaced with ""CTPHPFM""
2FT6	;	1.25	;	Structure of Cu(II)azurin with the metal-binding loop sequence ""CTFPGHSALM"" replaced with ""CTPHPM""
5B7F	;	1.45	;	Structure of CueO - the signal peptide was truncated by HRV3C protease
6GDU	;	1.75	;	Structure of CutA from Synechococcus elongatus PCC7942
6GDW	;	1.8	;	Structure of CutA from Synechococcus elongatus PCC7942 complexed with 2 molecules of Bis-Tris
6GDX	;	1.17	;	Structure of CutA from Synechococcus elongatus PCC7942 complexed with 3 molecules of Bis-Tris
6GDV	;	2.0	;	Structure of CutA from Synechococcus elongatus PCC7942 complexed with Bis-Tris molecule
5A0U	;	2.4	;	Structure of CutC choline lyase choline bound form from Klebsiella pneumoniae.
5A0Z	;	3.0	;	STRUCTURE OF CUTC CHOLINE LYASE CHOLINE FREE FORM FROM KLEBSIELLA PNEUMONIAE
1CEX	;	1.0	;	STRUCTURE OF CUTINASE
1OXM	;	2.3	;	STRUCTURE OF CUTINASE
5LUI	;	1.5	;	Structure of cutinase 1 from Thermobifida cellulosilytica
5LUJ	;	2.2	;	Structure of cutinase 2 from Thermobifida cellulosilytica
4PSC	;	1.15	;	Structure of cutinase from Trichoderma reesei in its native form.
7RKF	;	4.0	;	Structure of CX3CL1-US28-G11iN18-scFv16 in TL-state
7RKM	;	3.5	;	Structure of CX3CL1-US28-Gi-scFv16 in C-state
7RKN	;	3.6	;	Structure of CX3CL1-US28-Gi-scFv16 in OC-state
8U4O	;	3.29	;	Structure of CXCL12-bound CXCR4/Gi complex
2NWG	;	2.07	;	Structure of CXCL12:heparin disaccharide complex
8K2W	;	3.0	;	Structure of CXCR3 complexed with antagonist AMG487
8HNN	;	3.6	;	Structure of CXCR3 complexed with antagonist SCH546738
7O74	;	1.61	;	Structure of cyanase from Pseudomonas lactis
1DW9	;	1.65	;	Structure of cyanase reveals that a novel dimeric and decameric arrangement of subunits is required for formation of the enzyme active site
1DWK	;	1.65	;	STRUCTURE OF CYANASE WITH THE DI-ANION OXALATE BOUND AT THE ENZYME ACTIVE SITE
4C9O	;	1.977	;	Structure of Cyanide and Camphor bound D259N mutant of CYP101D1
4L4D	;	2.104	;	Structure of cyanide and camphor bound P450cam mutant L358A
4L4E	;	1.261	;	Structure of cyanide and camphor bound P450cam mutant L358A/K178G
4L4F	;	1.294	;	Structure of cyanide and camphor bound P450cam mutant L358A/K178G/D182N
4L4G	;	1.55	;	Structure of cyanide and camphor bound P450cam mutant L358P/K178G
4C9L	;	1.801	;	Structure of Cyanide and Camphor bound wild type CYP101D1
6KIG	;	2.9	;	Structure of cyanobacterial photosystem I-IsiA supercomplex
6KIF	;	3.3	;	Structure of cyanobacterial photosystem I-IsiA-flavodoxin supercomplex
7COU	;	2.25	;	Structure of cyanobacterial photosystem II in the dark S1 state
6NOP	;	1.7	;	Structure of Cyanothece McdA(D38A)-ATP complex
6NOO	;	2.5	;	Structure of Cyanothece McdA-AMPPNP complex
6NOY	;	3.46	;	Structure of Cyanothece McdB
6NON	;	2.68	;	Structure of Cyanthece apo McdA
2AK0	;		;	Structure of cyclic conotoxin MII-7
6ANN	;	0.76	;	Structure of cyclic D-Leu-N-methyl-D-Phe-2-Abz-D-Ala at 0.76 Angstrom
4K8V	;	2.0	;	Structure of cyclic GMP-AMP Synthase (cGAS)
5D1I	;	2.0	;	Structure of Cyclic nucleotide-binding-like protein from Brucella abortus bv. 1 str. 9-941
1FOZ	;		;	STRUCTURE OF CYCLIC PEPTIDE INHIBITORS OF MAMMALIAN RIBONUCLEOTIDE REDUCTASE
1JKW	;	2.6	;	STRUCTURE OF CYCLIN MCS2
5FP6	;	1.85	;	Structure of cyclin-dependent kinase 2 with small-molecule ligand 3-(4,7-dichloro-1H-indol-3-yl)prop-2-yn-1-ol (AT17833) in an alternate binding site.
5FP5	;	2.16	;	Structure of cyclin-dependent kinase 2 with small-molecule ligand 4- fluorobenzoic acid (AT222) in an alternate binding site.
2G6E	;	1.3	;	Structure of cyclized F64L S65A Y66S GFP variant
8CGT	;	2.4	;	STRUCTURE OF CYCLODEXTRIN GLYCOSYLTRANSFERASE COMPLEXED WITH A THIO-MALTOHEXAOSE
9CGT	;	2.5	;	STRUCTURE OF CYCLODEXTRIN GLYCOSYLTRANSFERASE COMPLEXED WITH A THIO-MALTOPENTAOSE
3CGT	;	2.4	;	STRUCTURE OF CYCLODEXTRIN GLYCOSYLTRANSFERASE COMPLEXED WITH ITS MAIN PRODUCT BETA-CYCLODEXTRIN
1CGT	;	2.0	;	STRUCTURE OF CYCLODEXTRIN GLYCOSYLTRANSFERASE REFINED AT 2.0 ANGSTROMS RESOLUTION
6Y4B	;	5.0	;	Structure of cyclodipeptide synthase from Candidatus Glomeribacter gigasporarum bound to Phe-tRNAPhe
7P9A	;	1.5	;	Structure of cyclohex-1-ene-1-carboxyl-CoA dehydrogenase complexed with cyclohex-1,5-diene-1-carboxyl-CoA
7P9X	;	1.65	;	Structure of cyclohex-1-ene-1-carboxyl-CoA dehydrogenase complexed with cyclohex-1-ene-1-carboxyl-CoA
7V4X	;	2.33	;	Structure of cyclohexanone monooxygenase mutant from Acinetobacter calcoaceticus
7V50	;	2.3	;	Structure of cyclohexanone monooxygenase mutant from Acinetobacter calcoaceticus
5LUD	;	1.25	;	Structure of Cyclophilin A in complex with 2,3-Diaminopyridine
5NOX	;	1.49	;	Structure of cyclophilin A in complex with 2-chloropyridin-3-amine
5NOY	;	1.43	;	Structure of cyclophilin A in complex with 3,4-diaminobenzamide
5NOZ	;	1.61	;	Structure of cyclophilin A in complex with 3,4-diaminobenzohydrazide
5NOS	;	1.35	;	Structure of cyclophilin A in complex with 3-amino-1H-pyridin-2-one
5NOQ	;	1.6	;	Structure of cyclophilin A in complex with 3-chloropyridin-2-amine
5NOR	;	1.8	;	Structure of cyclophilin A in complex with 3-methylpyridin-2-amine
5NOT	;	1.45	;	Structure of cyclophilin A in complex with 4-chloropyrimidin-5-amine
4N1N	;	1.5	;	Structure of Cyclophilin A in complex with Benzamide.
4N1R	;	1.8	;	Structure of Cyclophilin A in complex with benzenesulfonohydrazide.
4N1S	;	1.47	;	Structure of Cyclophilin A in complex with benzohydrazide.
4N1Q	;	1.65	;	Structure of Cyclophilin A in complex with cyclohexanecarboxamide.
4N1M	;	1.15	;	Structure of Cyclophilin A in complex with GlyPro.
5NOU	;	1.3	;	Structure of cyclophilin A in complex with hexahydropyrimidin-2-one
5NOV	;	2.0	;	Structure of cyclophilin A in complex with hexahydropyrimidine-2-thione
4N1P	;	1.9	;	Structure of Cyclophilin A in complex with Picolinamide.
5NOW	;	1.48	;	Structure of cyclophilin A in complex with pyridine-3,4-diamine
4N1O	;	1.75	;	Structure of Cyclophilin A in complex with Saccharin.
4JCP	;	1.65	;	Structure of Cyclophilin B from Brugia malayi
1VBS	;	2.0	;	STRUCTURE OF CYCLOPHILIN COMPLEXED WITH (D)ALA CONTAINING TETRAPEPTIDE
1VBT	;	2.3	;	Structure of cyclophilin complexed with sulfur-substituted tetrapeptide AAPF
7TGT	;	1.06	;	Structure of Cyclophilin D Peptidyl-Prolyl Isomerase Domain bound to Macrocyclic Inhibitor A26
7TGU	;	1.21	;	Structure of Cyclophilin D Peptidyl-Prolyl Isomerase Domain bound to Macrocyclic Inhibitor B1
7TGV	;	1.46	;	Structure of Cyclophilin D Peptidyl-Prolyl Isomerase Domain bound to Macrocyclic Inhibitor B2
7TH6	;	0.97	;	Structure of Cyclophilin D Peptidyl-Prolyl Isomerase Domain bound to Macrocyclic Inhibitor B21
7TH7	;	1.3	;	Structure of Cyclophilin D Peptidyl-Prolyl Isomerase Domain bound to Macrocyclic Inhibitor B23
7THC	;	1.57	;	Structure of Cyclophilin D Peptidyl-Prolyl Isomerase Domain bound to Macrocyclic Inhibitor B25
7TH1	;	1.52	;	Structure of Cyclophilin D Peptidyl-Prolyl Isomerase Domain bound to Macrocyclic Inhibitor B3
7THD	;	1.16	;	Structure of Cyclophilin D Peptidyl-Prolyl Isomerase Domain bound to Macrocyclic Inhibitor B52
7THF	;	1.1	;	Structure of Cyclophilin D Peptidyl-Prolyl Isomerase Domain bound to Macrocyclic Inhibitor B53
7TGS	;	1.75	;	Structure of Cyclophilin D Peptidyl-Prolyl Isomerase Domain bound to Macrocyclic Inhibitor JOMBt
1ZNU	;		;	Structure of cyclotide Kalata B1 in DPC micelles solution
7OWD	;	1.71	;	Structure of CYLD CAP-Gly3 (467-552) bound to Ub; tetragonal space group
7OWC	;	1.85	;	Structure of CYLD CAP-Gly3 (467-565) bound to Ub; orthorhobic space group
5XNT	;	2.7	;	Structure of CYP106A2 from Bacillus sp. PAMC 23377
5CJE	;	2.5	;	Structure of CYP107L2
5CWE	;	2.39	;	Structure of CYP107L2 from Streptomyces avermitilis with lauric acid
5BV5	;	2.7	;	Structure of CYP119 with T213A and C317H mutations
4G48	;	1.5	;	Structure of CYP121 in complex with 4-(4-phenoxy-1H-pyrazol-3-yl)benzene-1,3-diol
1N4G	;	1.8	;	Structure of CYP121, a Mycobacterial P450, in Complex with Iodopyrazole
6G71	;	1.7	;	Structure of CYP1232A24 from Arthrobacter sp.
7P5T	;	1.3	;	Structure of CYP142 from Mycobacterium tuberculosis in complex with inhibitor MEK216
5FYF	;	2.04	;	Structure of CYP153A from Marinobacter aquaeolei
5FYG	;	2.22	;	Structure of CYP153A from Marinobacter aquaeolei in complex with hydroxydodecanoic acid
7ANT	;	1.52	;	Structure of CYP153A from Polaromonas sp.
7AO7	;	2.55	;	Structure of CYP153A from Polaromonas sp. in complex with octan-1-ol
5EM4	;	3.02	;	Structure of CYP2B4 F244W in a ligand free conformation
4ZV8	;	2.24	;	Structure of CYP2B6 (Y226H/K262R) with additional mutation Y244W in complex with alpha-Pinene
5V5Z	;	2.9	;	Structure of CYP51 from the pathogen Candida albicans
5JLC	;	2.4	;	Structure of CYP51 from the pathogen Candida glabrata
6A15	;	1.79	;	Structure of CYP90B1 in complex with cholesterol
6YJK	;	2.37	;	Structure of CYRI-B (FAM49B) from Rhincodon typus
6YJJ	;	2.4	;	Structure of CYRI-B (FAM49B) from Rhincodon typus (selenomethionine derivative)
1AG0	;	2.4	;	STRUCTURE OF CYS 112 ASP AZURIN FROM PSEUDOMONAS AERUGINOSA
5NA6	;	1.9	;	Structure of Cys-null Se-Met DPP III from Bacteroides thetaiotaomicron
7BA4	;	2.0	;	Structure of Cystathionine gamma-lyase from Pseudomonas aeruginosa
3ELP	;	2.4	;	Structure of cystationine gamma lyase
4DWK	;	3.0	;	Structure of cystein free insulin degrading enzyme with compound bdm41671 ((s)-2-{2-[carboxymethyl-(3-phenyl-propyl)-amino]-acetylamino}-3-(1h-imidazol-4-yl)-propionic acid methyl ester)
4LTE	;	2.705	;	Structure of Cysteine-free Human Insulin Degrading Enzyme in Complex with Macrocyclic Inhibitor
6EDS	;	3.18072	;	Structure of Cysteine-free Human Insulin-Degrading Enzyme in complex with Glucagon and Substrate-selective Macrocyclic Inhibitor 63
6MQ3	;	3.56915	;	Structure of Cysteine-free Human Insulin-Degrading Enzyme in complex with Substrate-selective Macrocycle Inhibitor 63
6BYZ	;	2.95625	;	Structure of Cysteine-free Human Insulin-Degrading Enzyme in complex with Substrate-selective Macrocyclic Inhibitor 37
6D9Z	;	3.40213	;	Structure of CysZ, a sulfate permease from Pseudomonas Denitrificans
6D79	;	3.501	;	Structure of CysZ, a sulfate permease from Pseudomonas Fragi
4E22	;	2.323	;	Structure of cytidine monophosphate kinase from Yersinia pseudotuberculosis
7BBT	;	3.023	;	Structure of cytochrome c in complex with a p-benzyl-sulfonato-calix[8]arene-PEG pseudorotaxane
1M57	;	3.0	;	Structure of cytochrome c oxidase from Rhodobacter sphaeroides (EQ(I-286) mutant))
1M56	;	2.3	;	Structure of cytochrome c oxidase from Rhodobactor sphaeroides (Wild Type)
2V23	;	1.8	;	Structure of cytochrome c peroxidase mutant N184R Y36A
1JDL	;	1.7	;	Structure of cytochrome c2 from Rhodospirillum Centenum
6Q2U	;	1.85	;	Structure of Cytochrome C4 from Pseudomonas aeruginosa
351C	;	1.6	;	STRUCTURE OF CYTOCHROME C551 FROM P. AERUGINOSA REFINED AT 1.6 ANGSTROMS RESOLUTION AND COMPARISON OF THE TWO REDOX FORMS
451C	;	1.6	;	STRUCTURE OF CYTOCHROME C551 FROM P. AERUGINOSA REFINED AT 1.6 ANGSTROMS RESOLUTION AND COMPARISON OF THE TWO REDOX FORMS
4G45	;	1.53	;	Structure of cytochrome CYP121 in complex with 2-methylquinolin-6-amine
1EWH	;	2.35	;	STRUCTURE OF CYTOCHROME F FROM CHLAMYDOMONAS REINHARDTII
1FAG	;	2.7	;	STRUCTURE OF CYTOCHROME P450
1FAH	;	2.3	;	STRUCTURE OF CYTOCHROME P450
2Q6N	;	3.2	;	Structure of Cytochrome P450 2B4 with Bound 1-(4-cholorophenyl)imidazole
2BDM	;	2.3	;	Structure of Cytochrome P450 2B4 with Bound Bifonazole
5TFT	;	2.71	;	Structure of cytochrome P450 2D6 (CYP2D6) BACE1 inhibitor complex
5TFU	;	2.75	;	Structure of cytochrome P450 2D6 (CYP2D6) BACE1 inhibitor complex
5T6Q	;	2.701	;	Structure of cytochrome P450 4B1 (CYP4B1) complexed with octane: An n-Alkane and fatty acid omega-hydroxylase with a covalently bound heme
6C94	;	2.72	;	Structure Of Cytochrome P450 4B1 (CYP4B1) Complexed with the Inhibitor HET0016
6IAO	;	2.16	;	Structure of Cytochrome P450 BM3 M11 mutant in complex with DTT at resolution 2.16A
6GMF	;	1.55	;	Structure of Cytochrome P450 CYP109Q5 from Chondromyces apiculatus
4G47	;	1.34	;	Structure of cytochrome P450 CYP121 in complex with 4-(1H-1,2,4-triazol-1-yl)phenol
4G46	;	1.52	;	Structure of cytochrome P450 CYP121 in complex with 4-oxo-4,5,6,7-tetrahydrobenzofuran-3-carboxylate
2XFH	;	1.9	;	Structure of cytochrome P450 EryK cocrystallized with inhibitor clotrimazole.
2JJP	;	2.1	;	Structure of cytochrome P450 EryK in complex with inhibitor ketoconazole (KC)
2JJO	;	1.99	;	Structure of cytochrome P450 EryK in complex with its natural substrate erD
4L54	;	2.3	;	Structure of cytochrome P450 OleT, ligand-free
3A4H	;	3.06	;	Structure of cytochrome P450 vdh from Pseudonocardia autotrophica (orthorhombic crystal form)
3A4G	;	1.75	;	Structure of cytochrome P450 vdh from Pseudonocardia autotrophica (trigonal crystal form)
3A4Z	;	2.2	;	Structure of cytochrome P450 Vdh mutant (Vdh-K1) obtained by directed evolution
3A51	;	2.0	;	Structure of cytochrome P450 Vdh mutant (Vdh-K1) obtained by directed evolution with bound 25-hydroxyvitamin D3
3A50	;	2.05	;	Structure of cytochrome P450 Vdh mutant (Vdh-K1) obtained by directed evolution with bound vitamin D3
3VRM	;	2.57	;	Structure of cytochrome P450 Vdh mutant T107A with bound vitamin D3
5Y5G	;	1.36	;	Structure of cytochrome P450nor in NO-bound state: damaged by high-dose (5.7 MGy) X-ray
5Y5F	;	1.5	;	Structure of cytochrome P450nor in NO-bound state: damaged by low-dose (0.72 MGy) X-ray
8FZ8	;	1.43	;	Structure of cytochrome P450sky2
6WPL	;	2.097	;	Structure of Cytochrome P450tcu
3MEB	;	1.9	;	Structure of cytoplasmic aspartate aminotransferase from giardia lamblia
4HHX	;	1.88	;	Structure of cytoplasmic domain of TCPE from Vibrio cholerae
3IBY	;	2.5	;	Structure of cytosolic domain of L. pneumophila FeoB
1G2R	;	1.35	;	Structure of Cytosolic Protein of Unknown Function Coded by Gene from NUSA/INFB Region, a YlxR Homologue
1NG6	;	1.4	;	Structure of Cytosolic Protein of Unknown Function YqeY from Bacillus subtilis
1YLM	;	1.83	;	Structure of Cytosolic Protein of Unknown Function YutE from Bacillus subtilis
4V5K	;	3.2	;	Structure of cytotoxic domain of colicin E3 bound to the 70S ribosome
1KXI	;	2.19	;	STRUCTURE OF CYTOTOXIN HOMOLOG PRECURSOR
1ZAD	;		;	Structure of cytotoxin I (CTI) from Naja Oxiana in complex with DPC micelle
3F8O	;	1.72	;	Structure of d(CACGCG).d(CGCGTG) with low concentration of PdCl2
317D	;	1.9	;	STRUCTURE OF D(CCTAGGG): COMPARISON WITH NINE ISOMORPHOUS OCTAMER SEQUENCES REVEALS FOUR DISTINCT PATTERNS OF SEQUENCE-DEPENDENT INTERMOLECULAR INTERACTIONS
399D	;	1.9	;	STRUCTURE OF D(CGCCCGCGGGCG)
1DXY	;	1.86	;	STRUCTURE OF D-2-HYDROXYISOCAPROATE DEHYDROGENASE
2Q2Q	;	2.02	;	Structure of D-3-Hydroxybutyrate Dehydrogenase from Pseudomonas putida
2Q2V	;	1.9	;	Structure of D-3-Hydroxybutyrate Dehydrogenase from Pseudomonas putida
2Q2W	;	2.12	;	Structure of D-3-Hydroxybutyrate Dehydrogenase from Pseudomonas putida
2YZM	;	2.21	;	Structure of D-Alanine:D-Alanine Ligase with substrate from Thermus thermophilus HB8
5GZ3	;	1.59	;	Structure of D-amino acid dehydrogenase in complex with NADP
5GZ6	;	1.74	;	Structure of D-amino acid dehydrogenase in complex with NADPH and 2-keto-6-aminocapronic acid
8HY5	;	2.1	;	Structure of D-amino acid oxidase mutant R38H
6LEI	;	2.8	;	Structure of D-carbamoylase from Nitratireductor indicus
6LCG	;	2.7	;	Structure of D-carbamoylase mutant from Nitratireductor indicus
6LE2	;	2.14	;	Structure of D-carbamoylase mutant from Nitratireductor indicus
6LED	;	2.37	;	Structure of D-carbamoylase mutant from Nitratireductor indicus
7LC0	;	2.6	;	Structure of D-Glucosaminate-6-phosphate Ammonia-lyase
7LCE	;	2.58	;	Structure of D-Glucosaminate-6-phosphate Ammonia-lyase
1NFG	;	2.7	;	Structure of D-hydantoinase
6ANM	;	0.64	;	Structure of D-Leu-D-Phe-2-Abz-D-Ala at 0.64 Angstrom
6N2H	;	1.72	;	Structure of D-ornithine/D-lysine decarboxylase from Salmonella typhimurium
1LK7	;	2.0	;	Structure of D-Ribose-5-Phosphate Isomerase from in complex with phospho-erythronic acid
7OOJ	;	2.6	;	Structure of D-Thr53 Ubiquitin
2F7N	;	2.0	;	Structure of D. radiodurans Dps-1
4YVB	;	1.351	;	Structure of D128N streptavidin
3SAQ	;	3.51	;	Structure of D13, the scaffolding protein of vaccinia virus
3SAM	;	2.55	;	Structure of D13, the scaffolding protein of vaccinia virus (mutant D513G)
3H8W	;	2.8	;	Structure of D132N T4 RNase H in the presence of divalent magnesium
5SYH	;	1.65	;	Structure of D141A variant of B. pseudomallei KatG
5SYI	;	1.7	;	Structure of D141A variant of B. pseudomallei KatG complexed with INH
1Y7A	;	1.77	;	Structure of D153H/K328W E. coli alkaline phosphatase in presence of cobalt at 1.77 A resolution
1GYH	;	1.89	;	Structure of D158A Cellvibrio cellulosa alpha-L-arabinanase mutant
3USQ	;	2.4	;	Structure of D159S/Y194F glycogenin mutant truncated at residue 270
7ZY9	;	1.6	;	Structure of D165A/D167A double mutant of Chit33 from Trichoderma harzianum complexed with chitintetraose.
2ACI	;	2.5	;	Structure of D166A arginine deiminase
6YLJ	;	1.75	;	Structure of D169A/E171A double mutant of chitinase Chit42 from Trichoderma harzianum complexed with chitinhexaose.
7AKQ	;	2.32	;	Structure of D169A/E171A double mutant of chitinase Chit42 from Trichoderma harzianum complexed with chitintetraose obtained by soaking.
6YN4	;	1.82	;	Structure of D169A/E171A double mutant of chitinase Chit42 from Trichoderma harzianum complexed with chitintetraose.
7A5W	;	1.4	;	Structure of D172N BlaC from Mycobacterium tuberculosis
8BTU	;	1.8	;	Structure of D179N BlaC from Mycobacterium tuberculosis
8BTV	;	1.95	;	Structure of D179N BlaC from Mycobacterium tuberculosis bound to the trans-enamine adduct of sulbactam
8BTW	;	1.9	;	Structure of D179N BlaC from Mycobacterium tuberculosis in complex with vaborbactam
8BES	;	1.86	;	Structure of D188A-fructofuranosidase from Rhodotorula dairenensis in complex with fructose
8BEU	;	2.27	;	Structure of D188A-fructofuranosidase from Rhodotorula dairenensis in complex with raffinose
8BET	;	2.38	;	Structure of D188A-fructofuranosidase from Rhodotorula dairenesis in complex with sucrose
6WAS	;	1.904	;	Structure of D19.PA8 Fab in complex with 1FD6 16055 V1V2 scaffold
3H8S	;	2.51	;	Structure of D19N T4 RNase H in the presence of divalent magnesium
2NB0	;		;	Structure of D19S variant of the Penicillium Antifungal Protein (PAF)
3CF0	;	3.0	;	Structure of D2 subdomain of P97/VCP in complex with ADP
2W8M	;	2.4	;	Structure of D212, a nuclease from a fusselovirus.
2HSE	;	2.6	;	Structure of D236A E. coli Aspartate Transcarbamoylase in the presence of phosphonoacetamide and l-Aspartate at 2.60 A resolution
2A0F	;	2.9	;	Structure of D236A mutant E. coli Aspartate Transcarbamoylase in presence of Phosphonoacetamide at 2.90 A resolution
6S3D	;	3.0	;	Structure of D25 Fab in complex with scaffold S0_2.126
2ABR	;	2.9	;	Structure of D280A arginine deiminase with L-arginine forming a S-alkylthiouronium reaction intermediate
3WVX	;	1.58	;	Structure of D48A hen egg white lysozyme
3WVY	;	1.56	;	Structure of D48A hen egg white lysozyme in complex with (GlcNAc)4
3U14	;	2.24	;	Structure of D50A-fructofuranosidase from Schwanniomyces occidentalis complexed with inulin
5FKB	;	1.78	;	Structure of D80A-fructofuranosidase from Xanthophyllomyces dendrorhous complexed with 1-Kestose
6FJG	;	1.73	;	Structure of D80A-fructofuranosidase from Xanthophyllomyces dendrorhous complexed with fructose and 4-nitrophenol
5FMC	;	1.84	;	Structure of D80A-fructofuranosidase from Xanthophyllomyces dendrorhous complexed with fructose and BIS-TRIS propane buffer
6S2H	;	1.8	;	Structure Of D80A-Fructofuranosidase From Xanthophyllomyces Dendrorhous Complexed With Fructose And Catechol
6S2G	;	2.03	;	Structure Of D80A-Fructofuranosidase From Xanthophyllomyces Dendrorhous Complexed With Fructose And Epigallocatechin Gallate (Egcg)
6FJE	;	1.85	;	Structure of D80A-fructofuranosidase from Xanthophyllomyces dendrorhous complexed with fructose and glucose
5FMB	;	1.91	;	Structure of D80A-fructofuranosidase from Xanthophyllomyces dendrorhous complexed with fructose and HEPES buffer
6S3Z	;	1.85	;	Structure Of D80A-Fructofuranosidase From Xanthophyllomyces Dendrorhous Complexed With Fructose And hydroquinone
5NSL	;	1.7	;	Structure of D80A-fructofuranosidase from Xanthophyllomyces dendrorhous complexed with fructose and hydroxytyrosol
5O47	;	1.91	;	Structure of D80A-fructofuranosidase from Xanthophyllomyces dendrorhous complexed with fructosyl-hydroxytyrosol
5FK8	;	1.88	;	Structure of D80A-fructofuranosidase from Xanthophyllomyces dendrorhous complexed with Neo-erlose
5FK7	;	2.05	;	Structure of D80A-fructofuranosidase from Xanthophyllomyces dendrorhous complexed with neokestose
5FMD	;	1.78	;	Structure of D80A-fructofuranosidase from Xanthophyllomyces dendrorhous complexed with nystose
5FKC	;	1.82	;	Structure of D80A-fructofuranosidase from Xanthophyllomyces dendrorhous complexed with Raffinose
5FIX	;	2.01	;	Structure of D80A-fructofuranosidase from Xanthophyllomyces dendrorhous complexed with sucrose
6S82	;	1.85	;	Structure Of D80A-Fructofuranosidase From Xanthophyllomyces Dendrorhous Complexed With Tris-buffer molecule And hydroquinone
2H4C	;	2.6	;	Structure of Daboiatoxin (heterodimeric PLA2 venom)
6XTZ	;	2.21	;	Structure of Dally-like protein in complex with O-palmitoleoyl serine
6XB6	;	1.45	;	Structure of Danaus plexippus poxin cGAMP nuclease
2Y0A	;	2.6	;	Structure of DAPK1 construct residues 1-304
8AD6	;	1.52	;	Structure of DarB bound to c-di-AMP
3J9L	;	4.0	;	Structure of Dark apoptosome from Drosophila melanogaster
3J9K	;	4.1	;	Structure of Dark apoptosome in complex with Dronc CARD domain
7PGZ	;	0.9	;	Structure of dark-adapted AsLOV2 Q513L
7PGX	;	1.001	;	Structure of dark-adapted AsLOV2 wild type
6JYA	;	1.803	;	Structure of dark-state marine bacterial chloride importer, NM-R3, with CW laser (ND-10%) at 95K.
6JY8	;	1.9	;	Structure of dark-state marine bacterial chloride importer, NM-R3, with CW laser (ND-3%) at 95K.
6JYC	;	1.892	;	Structure of dark-state marine bacterial chloride importer, NM-R3, with CW laser (ND-30%) at 95K.
6JYE	;	1.9	;	Structure of dark-state marine bacterial chloride importer, NM-R3, with Pulse laser (ND-1%) at 140K.
6JY6	;	1.8	;	Structure of dark-state marine bacterial chloride importer, NM-R3, with Pulse laser (ND-1%) at 95K.
3F5C	;	3.0	;	Structure of Dax-1:LRH-1 complex
2WAU	;	3.0	;	Structure of DBL6 epsilon domain from VAR2CSA
2Y8D	;	1.84	;	STRUCTURE OF DBL6 EPSILON DOMAIN FROM VAR2CSA STRAIN FCR3
6WZY	;	1.5	;	Structure of DbNA(10) peptides bound to H-2Db MHC-I
6X00	;	1.55	;	Structure of DbNA(11) peptides bound to H-2Db MHC-I
6MJG	;	2.123	;	Structure of dbOphMA in Complex with SAH and Methylated Peptide
6OAN	;	2.9	;	Structure of DBP in complex with human neutralizing antibody 053054
6OAO	;	3.497	;	Structure of DBP in complex with human neutralizing antibody 092096
1XPH	;	1.41	;	Structure of DC-SIGNR and a portion of repeat domain 8
5MVJ	;	2.5	;	Structure of DC8E8 Fab at pH 6.5 crystallized in space-group P1
5MTH	;	1.73	;	Structure of DC8E8 Fab at pH 6.5 crystallized in spacegroup P21
5MX3	;	2.98	;	Structure of DC8E8 Fab crystallized at pH 8.5
5X83	;	2.997	;	Structure of DCC FN456 domains
3LAF	;	2.4	;	Structure of DCC, a netrin-1 receptor
7YKM	;	1.5	;	Structure of DciA DUF721 domain from Deinococcus radiodurans
6P5W	;	1.69	;	Structure of DCN1 bound to 3-methyl-N-((4S,5S)-3-methyl-6-oxo-1-phenyl-4-(p-tolyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-b]pyridin-5-yl)benzamide
7KWA	;	1.572	;	Structure of DCN1 bound to N-((4S,5S)-3-(aminomethyl)-7-ethyl-4-(4-fluorophenyl)-6-oxo-1-phenyl-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-b]pyridin-5-yl)-3-(trifluoromethyl)benzamide
6P5V	;	1.398	;	Structure of DCN1 bound to N-((4S,5S)-7-ethyl-4-(4-fluorophenyl)-3-methyl-6-oxo-1-phenyl-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-b]pyridin-5-yl)-3-methylbenzamide
5V88	;	1.601	;	Structure of DCN1 bound to NAcM-COV
5V83	;	2.002	;	Structure of DCN1 bound to NAcM-HIT
5V86	;	1.374	;	Structure of DCN1 bound to NAcM-OPT
5V89	;	1.55	;	Structure of DCN4 PONY domain bound to CUL1 WHB
1ST4	;	2.02	;	Structure of DcpS bound to m7GpppA
1ST0	;	1.9	;	Structure of DcpS bound to m7GpppG
8B8H	;	1.78	;	Structure of DCS-resistant variant D322N of alanine racemase from M. tuberculosis in complex with DCS
8AHW	;	1.58	;	Structure of DCS-resistant variant D322N of alanine racemase from Mycobacterium tuberculosis
8BU7	;	3.245	;	Structure of DDB1 bound to 21195-engaged CDK12-cyclin K
8BUA	;	3.193	;	Structure of DDB1 bound to 919278-engaged CDK12-cyclin K
6TD3	;	3.46	;	Structure of DDB1 bound to CR8-engaged CDK12-cyclinK
8BUC	;	3.85	;	Structure of DDB1 bound to dCeMM3-engaged CDK12-cyclin K
8BUB	;	3.42	;	Structure of DDB1 bound to dCeMM4-engaged CDK12-cyclin K
8BUI	;	3.5	;	Structure of DDB1 bound to DRF-053-engaged CDK12-cyclin K
8BUJ	;	3.62	;	Structure of DDB1 bound to DS06-engaged CDK12-cyclin K
8BUK	;	3.41	;	Structure of DDB1 bound to DS08-engaged CDK12-cyclin K
8BUL	;	3.4	;	Structure of DDB1 bound to DS11-engaged CDK12-cyclin K
8BUM	;	3.36	;	Structure of DDB1 bound to DS15-engaged CDK12-cyclin K
8BUN	;	3.08	;	Structure of DDB1 bound to DS16-engaged CDK12-cyclin K
8BU1	;	2.98	;	Structure of DDB1 bound to DS17-engaged CDK12-cyclin K
8BU2	;	3.13	;	Structure of DDB1 bound to DS18-engaged CDK12-cyclin K
8BU3	;	3.42	;	Structure of DDB1 bound to DS19-engaged CDK12-cyclin K
8BU4	;	3.09	;	Structure of DDB1 bound to DS22-engaged CDK12-cyclin K
8BUO	;	3.58	;	Structure of DDB1 bound to DS24-engaged CDK12-cyclin K
8BUP	;	3.41	;	Structure of DDB1 bound to DS30-engaged CDK12-cyclin K
8BUQ	;	3.2	;	Structure of DDB1 bound to DS43-engaged CDK12-cyclin K
8BUR	;	3.64	;	Structure of DDB1 bound to DS50-engaged CDK12-cyclin K
8BU6	;	3.45	;	Structure of DDB1 bound to DS55-engaged CDK12-cyclin K
8BUS	;	3.26	;	Structure of DDB1 bound to DS59-engaged CDK12-cyclin K
8BUT	;	3.25	;	Structure of DDB1 bound to DS61-engaged CDK12-cyclin K
8BUG	;	3.53	;	Structure of DDB1 bound to HQ461-engaged CDK12-cyclin K
8BU9	;	3.51	;	Structure of DDB1 bound to roscovitine-engaged CDK12-cyclin K
8BU5	;	3.134	;	Structure of DDB1 bound to SR-4835-engaged CDK12-cyclin K
8BUH	;	3.79	;	Structure of DDB1 bound to WX3-engaged CDK12-cyclin K
8BUE	;	3.25	;	Structure of DDB1 bound to Z11-engaged CDK12-cyclin K
8BUF	;	3.3	;	Structure of DDB1 bound to Z12-engaged CDK12-cyclin K
8BUD	;	3.2	;	Structure of DDB1 bound to Z7-engaged CDK12-cyclin K
6H0F	;	3.25	;	Structure of DDB1-CRBN-pomalidomide complex bound to IKZF1(ZF2)
6Q0R	;	2.9	;	Structure of DDB1-DDA1-DCAF15 complex bound to E7820 and RBM39
6Q0W	;	2.9	;	Structure of DDB1-DDA1-DCAF15 complex bound to Indisulam and RBM39
6Q0V	;	2.9	;	Structure of DDB1-DDA1-DCAF15 complex bound to tasisulam and RBM39
4A0K	;	5.93	;	STRUCTURE OF DDB1-DDB2-CUL4A-RBX1 BOUND TO A 12 BP ABASIC SITE CONTAINING DNA-DUPLEX
4A0L	;	7.4	;	Structure of DDB1-DDB2-CUL4B-RBX1 bound to a 12 bp abasic site containing DNA-duplex
8HLE	;	1.91	;	Structure of DddY-DMSOP complex
3R5L	;	1.55	;	Structure of Ddn, the Deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis involved in bioreductive activation of PA-824
3R5P	;	1.85	;	Structure of Ddn, the Deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis involved in bioreductive activation of PA-824
3R5R	;	2.101	;	Structure of Ddn, the Deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis involved in bioreductive activation of PA-824, with co-factor F420
3R5W	;	1.786	;	Structure of Ddn, the Deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis involved in bioreductive activation of PA-824, with co-factor F420
5FDP	;	2.25	;	Structure of DDR1 receptor tyrosine kinase in complex with D2099 inhibitor at 2.25 Angstroms resolution.
5FDX	;	2.65	;	Structure of DDR1 receptor tyrosine kinase in complex with D2164 inhibitor at 2.65 Angstroms resolution.
7BE6	;	1.87082	;	Structure of DDR1 receptor tyrosine kinase in complex with inhibitor SR159
7AZB	;	2.62	;	Structure of DDR2 DS domain in complex with VHH
7AYM	;	2.12	;	Structure of DDR2 Kinase domain in complex with IBZ3
3LJM	;	1.36	;	Structure of de novo designed apo peptide coil SER L9C
7MWR	;	2.2	;	Structure of De Novo designed beta sheet heterodimer LHD101A53/B4
7MWQ	;	2.56	;	Structure of De Novo designed beta sheet heterodimer LHD29A53/B53
7RMX	;	1.65	;	Structure of De Novo designed tunable symmetric protein pockets
5ETI	;	2.8	;	Structure of dead kinase MAPK14
5ETF	;	2.4	;	Structure of dead kinase MAPK14 with bound the KIM domain of MKK6
7F0N	;	1.6	;	Structure of deamidated Ubiquitin
2YAK	;	2.2	;	Structure of death-associated protein Kinase 1 (dapk1) in complex with a ruthenium octasporine ligand (OSV)
1XTK	;	2.4	;	structure of DECD to DEAD mutation of human UAP56
2LQU	;		;	Structure of decorbin-binding protein A from Borrelia burgdorferi
2MTC	;		;	Structure of decorin binding protein A from strain N40 of Borrelia burgdorferi
7RR3	;	2.24	;	Structure of Deep-Sea Phage NrS-1 Primase-Polymerase N300 in complex with calcium and ddCTP
7RR4	;	1.86	;	Structure of Deep-Sea Phage NrS-1 Primase-Polymerase N300 in complex with magnesium and pyrophosphate
6F5J	;	3.1	;	Structure of deformed wing virus carrying the GFP gene
5L7Q	;	3.5	;	Structure of deformed wing virus, a honeybee pathogen
5L8Q	;	3.5	;	Structure of deformed wing virus, a honeybee pathogen
5MUP	;	3.8	;	Structure of deformed wing virus, a honeybee pathogen
5MV5	;	3.1	;	Structure of deformed wing virus, a honeybee pathogen
5MV6	;	3.5	;	Structure of deformed wing virus, a honeybee pathogen
5B6L	;	2.801	;	Structure of Deg protease HhoA from Synechocystis sp. PCC 6803
5GND	;	2.5	;	Structure of Deg protease HhoA from Synechocystis sp. PCC 6803
8EJN	;	1.481	;	Structure of dehaloperoxidase A in complex with 2,4-dichlorophenol
7SJF	;	1.96	;	Structure of Dehaloperoxidase B in Complex with Thymol
7SJG	;	1.4	;	Structure of Dehaloperoxidase B in Complex with Thymoquinone
3GNX	;	2.0	;	Structure of dehydrated D-xylose isomerase from streptomyces rubiginosus
5EVO	;	2.51	;	Structure of Dehydroascrobate Reductase from Pennisetum Americanum in complex with two non-native ligands, Acetate in the G-site and Glycerol in the H-site
7WRW	;	3.00008	;	Structure of Deinococcus radiodurans HerA
7WRX	;	3.40004	;	Structure of Deinococcus radiodurans HerA-ADP complex
1R0M	;	1.3	;	Structure of Deinococcus radiodurans N-acylamino acid racemase at 1.3 : insights into a flexible binding pocket and evolution of enzymatic activity
3UDG	;	2.4	;	Structure of Deinococcus radiodurans SSB bound to ssDNA
2VLI	;	1.95	;	Structure of Deinococcus radiodurans tunicamycin resistance protein
7BR4	;	1.95	;	Structure of deletion mutant of alpha-glucuronidase (TM0752) from Thermotoga maritima
8AR6	;	2.2	;	Structure of Delta 57-NCOA7 in space group P41212
4UXX	;	2.701	;	Structure of delta4-DgkA with AMPPCP in 9.9 MAG
4UXW	;	3.15	;	Structure of delta4-DgkA-apo in 9.9 MAG
4UYO	;	2.18	;	Structure of delta7-DgkA in 7.9 MAG by serial femtosecond crystatallography to 2.18 angstrom resolution
4UXZ	;	2.18	;	Structure of delta7-DgkA-syn in 7.9 MAG to 2.18 angstrom resolution
1K4R	;	24.0	;	Structure of Dengue Virus
8FE3	;	10.2	;	Structure of dengue virus (DENV2) in complex with prM12, an anti-PrM monoclonal antibody
8FE4	;	9.8	;	Structure of dengue virus (DENV2) in complex with prM13, an anti-PrM monoclonal antibody
4AL8	;	1.66	;	Structure of Dengue virus DIII in complex with Fab 2H12
4ALA	;	1.84	;	Structure of Dengue virus DIII in complex with Fab 2H12
4BZ2	;	2.03	;	Structure of dengue virus EDIII in complex with Fab 2D73
4BZ1	;	2.15	;	Structure of dengue virus EDIII in complex with Fab 3e31
6MO0	;	2.7	;	Structure of dengue virus protease with an allosteric Inhibitor that blocks replication
6MO1	;	3.0	;	Structure of dengue virus protease with an allosteric Inhibitor that blocks replication
6MO2	;	2.8	;	Structure of dengue virus protease with an allosteric Inhibitor that blocks replication
4GT0	;	2.57	;	Structure of dengue virus serotype 1 sE containing stem to residue 421
4AM0	;	3.02	;	Structure of Dengue virus strain 4 DIII in complex with Fab 2H12
1NIH	;	2.6	;	Structure of deoxy-quaternary haemoglobin with liganded beta subunits
2JAQ	;	2.3	;	Structure of deoxyadenosine kinase from M. mycoides with bound dCTP
2JAS	;	2.7	;	Structure of deoxyadenosine kinase from M.mycoides with bound dATP
2JAT	;	2.6	;	Structure of deoxyadenosine kinase from M.mycoides with products dcmp and a flexible dcdp bound
1LNL	;	3.3	;	Structure of deoxygenated hemocyanin from Rapana thomasiana
1HBH	;	2.2	;	STRUCTURE OF DEOXYHAEMOGLOBIN OF THE ANTARCTIC FISH PAGOTHENIA BERNACCHII AND STRUCTURAL BASIS OF THE ROOT EFFECT
1DNP	;	2.3	;	STRUCTURE OF DEOXYRIBODIPYRIMIDINE PHOTOLYASE
4C3R	;	2.79	;	Structure of dephosphorylated Aurora A (122-403) bound to AMPPCP
6CPF	;	2.3	;	Structure of dephosphorylated Aurora A (122-403) bound to AMPPCP in an active conformation
4C3P	;	2.69	;	Structure of dephosphorylated Aurora A (122-403) bound to TPX2 and AMPPCP
6CPG	;	2.8	;	Structure of dephosphorylated Aurora A (122-403) in complex with inhibiting monobody and AT9283 in an inactive conformation
7UA5	;	2.83	;	Structure of dephosphorylated human RyR2 in the closed state
7UA9	;	3.59	;	Structure of dephosphorylated human RyR2 in the open state
3P4W	;	3.2	;	Structure of desflurane bound to a pentameric ligand-gated ion channel, GLIC
4J9J	;	2.3	;	Structure of designed HisF
3QBV	;	2.65	;	Structure of designed orthogonal interaction between CDC42 and nucleotide exchange domains of intersectin
5K7J	;	1.39	;	Structure of designed zinc binding protein ZE2 bound to Zn2+
3DSQ	;	2.1	;	Structure of Desulfitobacterium hafniense PylSc, a pyrrolysyl tRNA synthetase
2XSJ	;	2.5	;	Structure of desulforubidin from Desulfomicrobium norvegicum
2A3M	;	1.5	;	Structure of Desulfovibrio desulfuricans G20 tetraheme cytochrome (oxidized form)
2A3P	;	2.3	;	Structure of Desulfovibrio desulfuricans G20 tetraheme cytochrome with bound molybdate
8DMB	;	3.1	;	Structure of Desulfovirgula thermocuniculi IsrB (DtIsrB) in complex with omega RNA and target DNA
6K9P	;	2.047	;	Structure of Deubiquitinase
6KBE	;	2.339	;	Structure of Deubiquitinase
6RYB	;	2.315	;	Structure of deubiquitinase for PR-ubiquitination 1 -Dup1
5LDA	;	1.9	;	Structure of deubiquitinating enzyme homolog (Pyrococcus furiosus JAMM1) in complex with ubiquitin-like SAMP2.
5LD9	;	1.733	;	Structure of deubiquitinating enzyme homolog, Pyrococcus furiosus JAMM1.
4XB3	;	2.093	;	Structure of dextran glucosidase
4WLC	;	2.402	;	Structure of dextran glucosidase with glucose
3CT4	;	2.498	;	Structure of Dha-kinase subunit DhaK from L. Lactis
5UII	;	1.351	;	structure of DHFR with bound buformin and NADP
5UIO	;	1.929	;	structure of DHFR with bound DAP, p-ABG and NADP
5UIP	;	1.9	;	structure of DHFR with bound DAP, p-ABG and NADP
5UIH	;	1.647	;	structure of DHFR with bound phenformin and NADP
8VHM	;	2.26	;	Structure of DHODH in Complex with Fragment 2
8VHL	;	1.93	;	Structure of DHODH in Complex with Ligand 17
4FH6	;	1.44	;	Structure of DHP A in complex with 2,4,6-tribromophenol in 10% DMSO
4FH7	;	1.74	;	Structure of DHP A in complex with 2,4,6-tribromophenol in 20% methanol
7U5T	;	3.43	;	Structure of DHQS/EPSPS dimer from Candida albicans Aro1
5LRM	;	1.75	;	Structure of di-zinc MCR-1 in P41212 space group
1M0O	;	2.4	;	Structure of Dialkylglycine Decarboxylase Complexed with 1-Amino-1-methylpropanephosphonate
1M0P	;	2.6	;	Structure of Dialkylglycine Decarboxylase Complexed with 1-Amino-1-phenylethanephosphonate
1M0N	;	2.2	;	Structure of Dialkylglycine Decarboxylase Complexed with 1-Aminocyclopentanephosphonate
1M0Q	;	2.0	;	Structure of Dialkylglycine Decarboxylase Complexed with S-1-aminoethanephosphonate
4JEK	;	2.4	;	Structure of dibenzothiophene monooxygenase (DszC) from Rhodococcus erythropolis
7DEY	;	2.897	;	Structure of Dicer from Pichia stipitis
1FCK	;	2.2	;	STRUCTURE OF DICERIC HUMAN LACTOFERRIN
4KW0	;	1.49	;	Structure of Dickerson-Drew Dodecamer with 2'-MeSe-ara-G modification
6X5D	;	1.15	;	Structure of Dickerson-Drew Dodecamer with 2'-MeSe-ara-T modification
5Z2H	;	1.674	;	Structure of Dictyostelium discoideum mitochondrial calcium uniporter N-terminal domain(DdMCU-NTD)
5Z2I	;	2.141	;	Structure of Dictyostelium discoideum mitochondrial calcium uniporter N-ternimal domain (Se-DdMCU-NTD)
5EJY	;	1.9	;	Structure of Dictyostelium Discoideum Myosin VII MyTH4-FERM MF1 domain
5EJQ	;	2.19	;	Structure of Dictyostelium Discoideum Myosin VII MyTH4-FERM MF1 domain, mutant 2
5EJR	;	2.0	;	Structure of Dictyostelium Discoideum Myosin VII MyTH4-FERM MF2 domain
5EJS	;	2.7	;	Structure of Dictyostelium Discoideum Myosin VII MyTH4-FERM MF2 domain, mutant 1
2I0N	;		;	Structure of Dictyostelium discoideum Myosin VII SH3 domain with adjacent proline rich region
2M3H	;		;	Structure of Dido PHD domain
4P93	;	1.85	;	Structure of Dienelactone Hydrolase at 1.85 A resolution crystallised in the C2 space group
7PPT	;	1.42	;	Structure of diFe-Sulerythrin at 0.26 MGy total absorbed dose
7PPU	;	1.34	;	Structure of diFe-Sulerythrin at 0.57 MGy total absorbed dose
7PPV	;	1.36	;	Structure of diFe-Sulerythrin at 2.70 MGy total absorbed dose
1BLF	;	2.8	;	STRUCTURE OF DIFERRIC BOVINE LACTOFERRIN AT 2.8 ANGSTROMS RESOLUTION
1BIY	;	3.37	;	STRUCTURE OF DIFERRIC BUFFALO LACTOFERRIN
1CE2	;	2.5	;	STRUCTURE OF DIFERRIC BUFFALO LACTOFERRIN AT 2.5A RESOLUTION
1LFG	;	2.2	;	Structure of diferric human lactoferrin
1B1X	;	2.62	;	STRUCTURE OF DIFERRIC MARE LACTOFERRIN AT 2.62A RESOLUTION
3QT4	;	2.11	;	Structure of digestive procathepsin L 3 of Tenebrio molitor larval midgut
3QJ3	;	1.85	;	Structure of digestive procathepsin L2 proteinase from Tenebrio molitor larval midgut
5US6	;	2.61	;	Structure of Dihydrodipicolinate Reductase from Vibrio vulnificus Bound to NADH and 2,6 Pyridine Dicarboxylic Acid with Intact Polyhistidine Tag
3S8H	;	2.7	;	Structure of dihydrodipicolinate synthase complexed with 3-Hydroxypropanoic acid(HPA)at 2.70 A resolution
3IRD	;	2.23	;	Structure of dihydrodipicolinate synthase from Clostridium botulinum
4FHA	;	1.88	;	Structure of Dihydrodipicolinate Synthase from Streptococcus pneumoniae,bound to pyruvate and lysine
4XKY	;	2.1	;	Structure of dihydrodipicolinate synthase from the commensal bacterium Bacteroides thetaiotaomicron at 2.1 A resolution
3TUU	;	2.2	;	Structure of dihydrodipicolinate synthase from the common grapevine
2PUR	;	1.7	;	Structure of dihydrodipicolinate synthase mutant Thr44Ser at 1.7 A.
2C29	;	1.81	;	Structure of dihydroflavonol reductase from Vitis vinifera at 1.8 A.
1VIE	;	1.7	;	STRUCTURE OF DIHYDROFOLATE REDUCTASE
1VIF	;	1.8	;	STRUCTURE OF DIHYDROFOLATE REDUCTASE
1RF7	;	1.8	;	STRUCTURE OF DIHYDROFOLATE REDUCTASE COMPLEXED WITH DIHYDROFOLATE
1RX7	;	2.3	;	STRUCTURE OF DIHYDROFOLATE REDUCTASE COMPLEXED WITH FOLATE
6NND	;	1.7	;	Structure of Dihydrofolate reductase from Mycobacterium tuberculosis in complex with NADPH and dihydrofolate
6NNC	;	1.8	;	Structure of Dihydrofolate reductase from Mycobacterium tuberculosis in complex with NADPH and pemetrexed
1OJT	;	2.75	;	STRUCTURE OF DIHYDROLIPOAMIDE DEHYDROGENASE
1AJZ	;	2.0	;	STRUCTURE OF DIHYDROPTEROATE PYROPHOSPHORYLASE
2GVW	;	1.86	;	Structure of diisopropyl fluorophosphatase (DFPase) holoenzyme (RT)
2GVV	;	1.73	;	Structure of diisopropyl fluorophosphatase (DFPase) in complex with dicyclopentylphosphoroamidate (DcPPA)
2GVX	;	2.0	;	Structure of diisopropyl fluorophosphatase (DFPase), mutant D229N / N175D
1LK6	;	2.8	;	Structure of dimeric antithrombin complexed with a P14-P9 reactive loop peptide and an exogenous tripeptide
1R1L	;	2.7	;	Structure of dimeric antithrombin complexed with a P14-P9 reactive loop peptide and an exogenous tripeptide (formyl-norleucine-LF)
6NY6	;	3.74	;	Structure of dimeric Escherichia coli toxin YoeB bound to the Thermus thermophilus 30S ribosome
8S9K	;	2.72	;	Structure of dimeric FAM111A SPD S541A Mutant
8C06	;	2.7	;	Structure of Dimeric HECT E3 Ubiquitin Ligase UBR5
3MOL	;	1.2	;	Structure of dimeric holo HasAp H32A Mutant from Pseudomonas aeruginosa to 1.20A Resolution
4R0B	;	2.45	;	Structure of dimeric human glycodelin
8E05	;	4.6	;	Structure of dimeric LRRK1
8H93	;	3.01	;	Structure of dimeric mouse SCMC core complex
7T4L	;	3.28	;	Structure of dimeric phosphorylated Pediculus humanus (Ph) PINK1 with extended alpha-C helix in chain B
7T4K	;	3.25	;	Structure of dimeric phosphorylated Pediculus humanus (Ph) PINK1 with kinked alpha-C helix in chain B
6UE7	;	2.9	;	Structure of dimeric sIgA complex
7A0Y	;	2.45	;	Structure of dimeric sodium proton antiporter NhaA K300R variant, at pH 8.2, crystallized with chimeric Fab antibodies
7A0X	;	2.37	;	Structure of dimeric sodium proton antiporter NhaA, at pH 6.0, crystallized with chimeric Fab antibodies
7A0W	;	2.04	;	Structure of dimeric sodium proton antiporter NhaA, at pH 8.5, crystallized with chimeric Fab antibodies
7T4N	;	2.35	;	Structure of dimeric unphosphorylated Pediculus humanus (Ph) PINK1 D357A mutant
7E17	;	2.96	;	Structure of dimeric uPAR
7V63	;	2.906	;	Structure of dimeric uPAR at low pH
6LVC	;	3.0	;	Structure of Dimethylformamidase, dimer
6LVB	;	2.8	;	Structure of Dimethylformamidase, tetramer
6LVE	;	3.1	;	Structure of Dimethylformamidase, tetramer, E521A mutant
6LVD	;	3.2	;	Structure of Dimethylformamidase, tetramer, Y440A mutant
1PJ7	;	2.1	;	Structure of dimethylglycine oxidase of Arthrobacter globiformis in complex with folinic acid
6FWR	;	2.5	;	Structure of DinG in complex with ssDNA
6FWS	;	2.5	;	Structure of DinG in complex with ssDNA and ADPBeF
7YWA	;	3.26	;	Structure of DinI in complex with RecA filament
1UC5	;	2.3	;	Structure of diol dehydratase complexed with (R)-1,2-propanediol
1UC4	;	1.8	;	Structure of diol dehydratase complexed with (S)-1,2-propanediol
3AUJ	;	2.1	;	Structure of diol dehydratase complexed with glycerol
2D0O	;	2.0	;	Structure of diol dehydratase-reactivating factor complexed with ADP and Mg2+
2D0P	;	3.0	;	Structure of diol dehydratase-reactivating factor in nucleotide free form
6W17	;	3.9	;	Structure of Dip1-activated Arp2/3 complex with nucleated actin filament
3IJI	;	1.6	;	Structure of dipeptide epimerase from Bacteroides thetaiotaomicron complexed with L-Ala-D-Glu; nonproductive substrate binding.
3IJQ	;	2.0	;	Structure of dipeptide epimerase from Bacteroides thetaiotaomicron complexed with L-Ala-D-Glu; productive substrate binding.
3IJL	;	1.5	;	Structure of dipeptide epimerase from Bacteroides thetaiotaomicron complexed with L-Pro-D-Glu; nonproductive substrate binding.
5ZUM	;	1.9	;	Structure of dipeptidyl-peptidase III from Corallococcus sp. strain EGB
2DTR	;	1.9	;	STRUCTURE OF DIPHTHERIA TOXIN REPRESSOR
3WYH	;	1.77	;	Structure of disulfide bond deletion mutant of ostrich egg white lysozyme
5J6E	;	3.2	;	Structure of disulfide crosslinked A. fumigatus FKBP12(V91C)
5HLI	;	2.05	;	Structure of Disulfide formed AbfR
1BED	;	2.0	;	STRUCTURE OF DISULFIDE OXIDOREDUCTASE
6ZOY	;	3.1	;	Structure of Disulphide-stabilized SARS-CoV-2 Spike Protein Trimer (x1 disulphide-bond mutant, S383C, D985C, K986P, V987P, single Arg S1/S2 cleavage site) in Closed State
6ZOZ	;	3.5	;	Structure of Disulphide-stabilized SARS-CoV-2 Spike Protein Trimer (x1 disulphide-bond mutant, S383C, D985C, K986P, V987P, single Arg S1/S2 cleavage site) in Locked State
6ZOX	;	3.0	;	Structure of Disulphide-stabilized SARS-CoV-2 Spike Protein Trimer (x2 disulphide-bond mutant, G413C, V987C, single Arg S1/S2 cleavage site)
6HSE	;	2.3	;	Structure of dithionite-reduced RsrR in spacegroup P2(1)
6X0K	;	2.231	;	Structure of dithionite-reduced SidA ornithine hydroxylase with the FAD ""in"" and complexed with L-ornithine
2ND6	;		;	Structure of DK17 in GM1 LUVS
2ND7	;		;	Structure of DK17 in POPC:POPG:Cholesterol:GM1 LUVS
1MZR	;	2.13	;	Structure of dkga from E.coli at 2.13 A resolution solved by molecular replacement
7CJQ	;	2.7	;	Structure of DLA-88*001:04
3WUR	;	1.45	;	Structure of DMP19 Complex with 18-crown-6
1DMS	;	1.88	;	STRUCTURE OF DMSO REDUCTASE
3DMR	;	2.5	;	STRUCTURE OF DMSO REDUCTASE FROM RHODOBACTER CAPSULATUS AT PH 7.0
1BAE	;		;	STRUCTURE OF DNA (5'-D 5MCCTTTACC-3')2, NMR, 1 STRUCTURE
5M1L	;		;	Structure of DNA AGCGA-quadruplex adopted by 15-mer d(GCGAGGGAGCGAGGG), VK34, oligonucleotide found in regulatory region of the PLEKHG3 human gene
5M4W	;		;	Structure of DNA AGCGA-quadruplex adopted by 15-mer oligonucleotide found in regulatory region of the PLEKHG3 human gene with G11 to I11 mutation, d(GCGAGGGAGCIAGGG),VK34_I11
8J0L	;	1.98	;	Structure of DNA binding Domain of Human TFAP2A
8J0Q	;	2.4	;	Structure of DNA binding domain of human TFAP2B
8IK8	;	1.8	;	Structure of DNA binding domain of McrBC endonuclease bound to DNA: L68F mutant
8IJP	;	1.55	;	Structure of DNA binding domain of McrBC endonuclease bound to DNA: L68Y mutant
8IJO	;	1.65	;	Structure of DNA binding domain of McrBC endonuclease bound to DNA: Y41F-L68F double mutant
8IKD	;	2.1	;	Structure of DNA binding domain of McrBC endonuclease bound to DNA: Y41F-L68Y double mutant
8IK4	;	2.1	;	Structure of DNA binding domain of McrBC endonuclease bound to hemimethylated DNA: L68F mutant
7Y3I	;	2.45	;	Structure of DNA bound SALL4
4UX5	;	2.4	;	Structure of DNA complex of PCG2
2LGM	;		;	Structure of DNA Containing an Aristolactam II-dA Lesion
1XCY	;		;	Structure of DNA containing the alpha-anomer of a carbocyclic abasic site
1XCZ	;		;	Structure of DNA containing the beta-anomer of a carbocyclic abasic site
2N2D	;		;	Structure of DNA G-quadruplex adopted by ALS and FTD related GGGGCC repeat with G21 to Br-G21 substitution
1SUU	;	1.75	;	Structure of DNA gyrase A C-terminal domain
3ILW	;	1.603	;	Structure of DNA gyrase subunit A N-terminal domain
1PJR	;	2.5	;	STRUCTURE OF DNA HELICASE
1QHG	;	2.5	;	STRUCTURE OF DNA HELICASE MUTANT WITH ADPNP
1QHH	;	2.5	;	STRUCTURE OF DNA HELICASE WITH ADPNP
7K72	;	2.05	;	Structure of DNA ligase A from Mycobacterium tuberculosis bound to NAD
3BM0	;	1.8	;	Structure of DNA Octamer G(dUSe)G(5-SedU)ACAC
6DJ8	;	2.05	;	Structure of DNA polymerase III subunit beta from Borrelia burgdorferi in complex with a natural product
6DM6	;	2.25	;	Structure of DNA polymerase III subunit beta from Rickettsia conorii in complex with a natural product
6DJK	;	1.85	;	Structure of DNA polymerase III subunit beta from Rickettsia typhi in complex with a natural product
6P81	;	1.75	;	Structure of DNA polymerase III, beta subunit/ beta sliding clamp from Klebsiella pneumoniae, expressed with an N-terminal His-Smt3 fusion tag, in complex with Griselimycin
4U7C	;	2.8	;	Structure of DNA polymerase kappa in complex with benzopyrene adducted DNA
6V8P	;	4.1	;	Structure of DNA Polymerase Zeta (Apo)
7S0T	;	3.05	;	Structure of DNA polymerase zeta with mismatched DNA
6V93	;	3.1	;	Structure of DNA Polymerase Zeta/DNA/dNTP Ternary Complex
1SY8	;		;	Structure of DNA sequence d-TGATCA by two-dimensional nuclear magnetic resonance spec and restrained molecular dynamics
5M2L	;		;	Structure of DNA tetrameric AGCGA-quadruplex adopted by 15-mer d(GCGAGGGAGCGAGGG), VK34, oligonucleotide found in regulatory region of the PLEKHG3 human gene
2JMW	;		;	Structure of DNA-Binding Domain of Arabidopsis GT-1
4IXA	;	2.15	;	Structure of DNA-binding domain of the response regulator SaeR from Staphylococcus epidermidis
2NDP	;		;	Structure of DNA-binding HU protein from micoplasma Mycoplasma gallisepticum
5OGU	;		;	Structure of DNA-binding HU protein from micoplasma Spiroplasma melliferum
7Z6H	;	3.59	;	Structure of DNA-bound human RAD17-RFC clamp loader and 9-1-1 checkpoint clamp
7S8D	;	2.02	;	Structure of DNA-free SgrAI
5XJZ	;	0.98	;	Structure of DNA1-Ag complex
6EPA	;	1.82	;	Structure of dNCS-1 bound to the NCS-1/Ric8a protein/protein interaction regulator IGS-1.76
5YDR	;	2.003	;	Structure of DNMT1 RFTS domain in complex with ubiquitin
6W8J	;	2.445	;	Structure of DNMT3A (R882H) in complex with CAG DNA
6W89	;	2.499	;	Structure of DNMT3A (R882H) in complex with CGA DNA
6W8D	;	2.598	;	Structure of DNMT3A (R882H) in complex with CGT DNA
6W8B	;	2.4	;	Structure of DNMT3A in complex with CGA DNA
2QRV	;	2.89	;	Structure of Dnmt3a-Dnmt3L C-terminal domain complex
4D6K	;	2.1	;	Structure of DNTTIP1 dimerisation domain.
3DD9	;	2.45	;	Structure of DocH66Y dimer
3DD7	;	1.7	;	Structure of DocH66Y in complex with the C-terminal domain of Phd
3OV0	;	3.2	;	Structure of dodecaheme cytochrome c GSU1996
8FWJ	;	2.7	;	Structure of dodecameric KaiC-RS-S413E/S414E complexed with KaiB-RS solved by cryo-EM
8FWI	;	2.9	;	Structure of dodecameric KaiC-RS-S413E/S414E solved by cryo-EM
8HRC	;	2.58	;	Structure of dodecameric RdrB cage
7T4M	;	2.48	;	Structure of dodecameric unphosphorylated Pediculus humanus (Ph) PINK1 D357A mutant
6R1E	;	2.6	;	Structure of dodecin from Streptomyces coelicolor
5HON	;	2.001	;	Structure of Domain 4 of AbnA, a GH43 extracellular arabinanase from Geobacillus stearothermophilus, in complex with arabinotriose
8T8K	;	1.88	;	Structure of Domain of Unknown Function 507 (DUF507) in Space Group C222(1)
8T8L	;	1.9	;	Structure of Domain of Unknown Function 507 (DUF507) in Space Group P3(2)21
1YQH	;	1.7	;	Structure of domain of unknown function DUF77 from Bacillus cereus
2YBY	;	1.58	;	Structure of domains 6 and 7 of the mouse complement regulator Factor H
4O9D	;	2.0	;	Structure of Dos1 propeller
6NN6	;	3.9	;	Structure of Dot1L-H2BK120ub nucleosome complex
7BWD	;	4.32	;	Structure of Dot1L-H2BK34ub Nucleosome Complex
5X42	;	1.8	;	Structure of DotL(590-659)-DotN derived from Legionella pneumophila
5X1E	;	1.999	;	Structure of DotL(656-783)-IcmS-IcmW derived from Legionella pneumophila
5X90	;	2.8	;	Structure of DotL(656-783)-IcmS-IcmW-LvgA derived from Legionella pneumophila
7BWK	;	2.801	;	Structure of DotL(656-783)-IcmS-IcmW-LvgA-VpdB(461-590) derived from Legionella pneumophila
8EFY	;	3.16	;	Structure of double homo-hexameric AAA+ ATPase RuvB motors
3EJ8	;	2.55	;	Structure of double mutant of human iNOS oxygenase domain with bound immidazole
1ZVK	;	2.04	;	Structure of Double mutant, D164N, E78H of Kumamolisin-As
6NE0	;	3.4	;	Structure of double-stranded target DNA engaged Csy complex from Pseudomonas aeruginosa (PA-14)
2BCG	;	1.48	;	Structure of doubly prenylated Ypt1:GDI complex
8A9N	;	1.854	;	Structure of DpA polyamine acetyltransferase in complex with 1,3-DAP
5NA7	;	2.401	;	Structure of DPP III from Bacteroides thetaiotaomicron
5NA8	;	3.29	;	Structure of DPP III from Bacteroides thetaiotaomicron in closed form
6EOM	;	2.103	;	Structure of DPP III from Caldithrix abyssi
3CSK	;	1.95	;	Structure of DPP III from Saccharomyces cerevisiae
4EBB	;	2.0	;	Structure of DPP2
2RIP	;	2.9	;	Structure of DPPIV in complex with an inhibitor
8PV9	;	2.7	;	Structure of DPS determined by cryoEM at 100 keV
6ZGL	;	1.9	;	Structure of DPS determined by movement-free cryoEM with zero dose extrapolation
6SEV	;	2.0	;	Structure of Dps from Listeria innocua soaked with 10 mM zinc for 120 minutes
2YJK	;	2.0	;	Structure of Dps from MICROBACTERIUM ARBORESCENS in the high iron form
2YJJ	;	2.05	;	Structure of Dps from MICROBACTERIUM ARBORESCENS in the low iron form
7STW	;	2.37	;	Structure of DPSL (DNA Protection in Starved Cells - Like) from Pyrococcus furiosus
2AXW	;	1.05	;	Structure of DraD invasin from uropathogenic Escherichia coli
3O5T	;	2.09	;	Structure of DraG-GlnZ complex with ADP
5OVO	;	1.55	;	Structure of DraG-GlnZ-delta42-54 complex from Azospirillum brasilense
7TZV	;	1.65	;	Structure of DriD C-domain bound to 9mer ssDNA
7S9W	;	3.4	;	Structure of DrmAB:ADP:DNA complex
7ALK	;	3.0	;	Structure of Drosophila C2-DSL-EGF1
3MN8	;	2.7	;	Structure of Drosophila melanogaster carboxypeptidase D isoform 1B short
6TBU	;	3.16	;	Structure of Drosophila melanogaster Dispatched
6TD6	;	4.76	;	Structure of Drosophila melanogaster Dispatched bound to a modified Hedgehog ligand, HhN-C85II
7DXI	;	3.53	;	Structure of Drosophila melanogaster GlcNAc-1-phosphotransferase
8W75	;	2.85	;	Structure of Drosophila melanogaster L-2-hydroxyglutarate dehydrogenase
8W7F	;	2.299	;	Structure of Drosophila melanogaster L-2-hydroxyglutarate dehydrogenase bound with FAD and a sulfate ion
8W78	;	2.81	;	Structure of Drosophila melanogaster L-2-hydroxyglutarate dehydrogenase in complex with FAD and 2-oxoglutarate
4BWP	;	3.6	;	Structure of Drosophila Melanogaster PAN3 pseudokinase
7RL3	;	1.75	;	Structure of Drosophila melanogaster Plk4 PB3
3FYQ	;	1.95	;	Structure of Drosophila melanogaster talin IBS2 domain (residues 1981-2168)
7ALJ	;	1.52	;	Structure of Drosophila Notch EGF domains 11-13
7JK4	;	3.4	;	Structure of Drosophila ORC bound to AT-rich DNA and Cdc6
7JK5	;	3.9	;	Structure of Drosophila ORC bound to DNA
7JGR	;	3.9	;	Structure of Drosophila ORC bound to DNA (84 bp) and Cdc6
7JK3	;	3.4	;	Structure of Drosophila ORC bound to GC-rich DNA and Cdc6
7JK2	;	3.2	;	Structure of Drosophila ORC bound to poly(dA/dT) DNA and Cdc6 (conformation 1)
7JGS	;	3.2	;	Structure of Drosophila ORC bound to poly(dA/dT) DNA and Cdc6 (conformation 2)
7JK6	;	4.0	;	Structure of Drosophila ORC in the active conformation
7ALT	;	2.03	;	Structure of Drosophila Serrate C2-DSL-EGF1-EGF2
7MWZ	;	2.0	;	Structure of drosophila STING in complex with 3'2'-cGAMP
6YX5	;	2.14	;	Structure of DrrA from Legionella pneumophilia in complex with human Rab8a
6NV1	;	2.5	;	Structure of drug-resistant V27A mutant of the influenza M2 proton channel bound to spiroadamantyl amine inhibitor
6OUG	;	3.01	;	Structure of drug-resistant V27A mutant of the influenza M2 proton channel bound to spiroadamantyl amine inhibitor, TM + cytosolic helix construct
6DEI	;	1.699	;	Structure of Dse3-Csm1 complex
6IUY	;	2.2	;	Structure of DsGPDH of Dunaliella salina
6L0Y	;	3.0	;	Structure of dsRNA with G-U wobble base pairs
5A5L	;	2.34	;	Structure of dual function FBPase SBPase from Thermosynechococcus elongatus
3R7O	;	2.3	;	Structure of dually phosphorylated c-MET receptor kinase in complex with an MK-2461 analog
4IWD	;	1.99	;	Structure of dually phosphorylated c-MET receptor kinase in complex with an MK-8033 analog
4IZA	;	1.93	;	Structure of Dually Phosphorylated ERK2 bound to the PEA-15 Death Effector Domain
3Q6W	;	1.75	;	Structure of dually-phosphorylated MET receptor kinase in complex with an MK-2461 analog with specificity for the activated receptor
5VS6	;	2.27	;	Structure of DUB complex
5VSB	;	1.85	;	Structure of DUB complex
5VSK	;	3.33	;	Structure of DUB complex
4A2V	;	1.44	;	Structure of duck RIG-I C-terminal domain (CTD)
4A2X	;	4.0	;	Structure of duck RIG-I C-terminal domain (CTD) with 14-mer dSRNA
4A2P	;	3.0	;	Structure of duck RIG-I helicase domain
4A36	;	3.7	;	Structure of duck RIG-I helicase domain bound to 19-mer dsRNA and ATP transition state analogue
4A2Q	;	3.4	;	Structure of duck RIG-I tandem CARDs and helicase domain
6UMQ	;	1.85	;	Structure of DUF89
6UMR	;	2.21	;	Structure of DUF89 - D291A mutant
3PT1	;	1.773	;	Structure of DUF89 from Saccharomyces cerevisiae co-crystallized with F6P.
6RYA	;	2.21	;	Structure of Dup1 mutant H67A:Ubiquitin complex
4JMJ	;	2.382	;	Structure of dusp11
4JMK	;	1.9	;	Structure of dusp8
3TV0	;	2.1492	;	Structure of dynactin p27 subunit
8RGH	;	3.9	;	Structure of dynein-2 intermediate chain DYNC2I1 (WDR60) in complex with the dynein-2 heavy chain DYNC2H1.
8RGG	;	4.0	;	Structure of dynein-2 intermediate chain DYNC2I2 (WDR34) in complex with dynein-2 heavy chain DYNC2H1.
6UBL	;	1.499	;	Structure of DynF from the Dynemicin Biosynthesis Pathway of Micromonospora chersina
8RGI	;	2.02	;	Structure of DYNLT1:DYNLT2B (TCTEX1:TCTEX1D2) heterodimer.
7A4O	;	1.9	;	Structure of DYRK1A in complex with AMPNP
7A5B	;	2.6	;	Structure of DYRK1A in complex with complex 10
7A4R	;	1.8	;	Structure of DYRK1A in complex with compound 1
7AJ5	;	2.0	;	Structure of DYRK1A in complex with compound 10
7A5D	;	1.8	;	Structure of DYRK1A in complex with compound 16
7AJ7	;	2.9	;	Structure of DYRK1A in complex with compound 16
7A4S	;	3.1	;	Structure of DYRK1A in complex with compound 2
7AJ8	;	2.0	;	Structure of DYRK1A in complex with compound 25
7AJA	;	2.2	;	Structure of DYRK1A in complex with compound 28
7A4W	;	2.7	;	Structure of DYRK1A in complex with compound 3
7AJ2	;	2.1	;	Structure of DYRK1A in complex with compound 3
7AJM	;	2.4	;	Structure of DYRK1A in complex with compound 32
7AJS	;	2.15	;	Structure of DYRK1A in complex with compound 33
7A5N	;	2.3	;	Structure of DYRK1A in complex with compound 34
7AJV	;	2.1	;	Structure of DYRK1A in complex with compound 38
7A4Z	;	1.9	;	Structure of DYRK1A in complex with compound 4
7AJW	;	2.8	;	Structure of DYRK1A in complex with compound 46
7A51	;	1.9	;	Structure of DYRK1A in complex with compound 5
7AJ4	;	2.0	;	Structure of DYRK1A in complex with compound 5
7AKL	;	2.0	;	Structure of DYRK1A in complex with compound 50
7AJY	;	2.2	;	Structure of DYRK1A in complex with compound 51
7AK2	;	2.1	;	Structure of DYRK1A in complex with compound 53
7AKA	;	1.9	;	Structure of DYRK1A in complex with compound 54
7AKB	;	2.8	;	Structure of DYRK1A in complex with compound 56
7AKE	;	2.3	;	Structure of DYRK1A in complex with compound 58
7A52	;	2.1	;	Structure of DYRK1A in complex with compound 6
7A53	;	2.2	;	Structure of DYRK1A in complex with compound 7
7A55	;	2.2	;	Structure of DYRK1A in complex with compound 8
7AKF	;	2.6	;	Structure of DYRK2 in complex with compound 50
7AKH	;	2.85	;	Structure of DYRK2 in complex with compound 58
2M92	;		;	Structure of d[AGGGTGGGTGCTGGGGCGCGAAGCATTCGCGAGG] quadruplex-duplex hybrid
2M8Y	;		;	Structure of d[CGCGAAGCATTCGCG] hairpin
2M90	;		;	Structure of d[GCGCGAAGCATTCGCGGGGAGGTGGGGAAGGG] quadruplex-duplex hybrid
2M91	;		;	Structure of d[GGGAAGGGCGCGAAGCATTCGCGAGGTAGG] quadruplex-duplex hybrid
2M8Z	;		;	Structure of d[GGTTGGCGCGAAGCATTCGCGGGTTGG] quadruplex-duplex hybrid
2M93	;		;	Structure of d[TTGGGTGGGCGCGAAGCATTCGCGGGGTGGGT] quadruplex-duplex hybrid
5LMM	;	1.2	;	Structure of E coli Hydrogenase Hyd-1 mutant E28Q
6GKI	;	2.23	;	Structure of E coli MlaC in Variously Loaded States
1FF5	;	2.93	;	STRUCTURE OF E-CADHERIN DOUBLE DOMAIN
3BT7	;	2.43	;	Structure of E. coli 5-Methyluridine Methyltransferase TrmA in complex with 19 nucleotide T-arm analogue
3LRB	;	3.61	;	Structure of E. coli AdiC
3LRC	;	4.004	;	Structure of E. coli AdiC (P1)
1PSW	;	2.0	;	Structure of E. coli ADP-heptose lps heptosyltransferase II
1Y6V	;	1.6	;	Structure of E. coli Alkaline Phosphatase in presence of cobalt at 1.60 A resolution
1ED8	;	1.75	;	STRUCTURE OF E. COLI ALKALINE PHOSPHATASE INHIBITED BY THE INORGANIC PHOSPHATE AT 1.75A RESOLUTION
1ED9	;	1.75	;	STRUCTURE OF E. COLI ALKALINE PHOSPHATASE WITHOUT THE INORGANIC PHOSPHATE AT 1.75A RESOLUTION
8C2O	;	2.35	;	Structure of E. coli AmiA
6T1W	;	3.79	;	Structure of E. coli BamA in complex with lipoprotein RcsF
3LPF	;	2.26	;	Structure of E. coli beta-Glucuronidase bound with a novel, potent inhibitor 1-((6,7-dimethyl-2-oxo-1,2-dihydroquinolin-3-yl)methyl)-1-(2-hydroxyethyl)-3-(3-methoxyphenyl)thiourea
5CZK	;	2.39	;	Structure of E. coli beta-glucuronidase bound with a novel, potent inhibitor 1-((6,8-dimethyl-2-oxo-1,2-dihydroquinolin-3-yl)methyl)-1-(2-hydroxyethyl)-3-(4-hydroxyphenyl)thiourea
4JHZ	;	2.831	;	Structure of E. coli beta-Glucuronidase bound with a novel, potent inhibitor 2-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-N-[(1S,2S,5S)-2,5-dimethoxycyclohexyl]acetamide
3LPG	;	2.425	;	Structure of E. coli beta-Glucuronidase bound with a novel, potent inhibitor 3-(2-fluorophenyl)-1-(2-hydroxyethyl)-1-((6-methyl-2-oxo-1,2-dihydroquinolin-3-yl)methyl)urea
6LEL	;	2.498	;	Structure of E. coli beta-glucuronidase complex with C6-hexyl uronic isofagomine
6LEM	;	3.188	;	Structure of E. coli beta-glucuronidase complex with C6-nonyl uronic isofagomine
6LEJ	;	2.617	;	Structure of E. coli beta-glucuronidase complex with C6-propyl uronic isofagomine
6LEG	;	2.603	;	Structure of E. coli beta-glucuronidase complex with uronic isofagomine
4WF2	;	2.31	;	Structure of E. coli BirA G142A bound to biotinol-5'-AMP
7T5W	;	1.75	;	Structure of E. coli CapH C-terminal domain
7T5V	;	1.26	;	Structure of E. coli CapH C-terminal domain I99M mutant
3MYY	;	2.1	;	Structure of E. Coli CheY mutant A113P bound to Beryllium fluoride
3OO1	;	1.7	;	Structure of E. Coli CheY mutant A113P in the absence of Sulfate
8C0I	;	1.9	;	Structure of E. coli Class 2 L-asparaginase EcAIII, mutant M200L (acyl-enzyme intermediate)
8BKF	;	1.221	;	Structure of E. coli Class 2 L-asparaginase EcAIII, mutant M200T (crystal M200T#o)
8C23	;	1.842	;	Structure of E. coli Class 2 L-asparaginase EcAIII, mutant M200T (monoclinic form M200T#m)
8BI3	;	1.452	;	Structure of E. coli Class 2 L-asparaginase EcAIII, mutant M200W (crystal M200W#1)
8BP9	;	1.7	;	Structure of E. coli Class 2 L-asparaginase EcAIII, mutant M200W (crystal M200W#2)
3O2O	;	2.9	;	Structure of E. coli ClpS ring complex
1J2A	;	1.8	;	Structure of E. coli cyclophilin B K163T mutant
1VAI	;	1.8	;	Structure of e. coli cyclophilin B K163T mutant bound to n-acetyl-ala-ala-pro-ala-7-amino-4-methylcoumarin
1V9T	;	1.7	;	Structure of E. coli cyclophilin B K163T mutant bound to succinyl-ALA-PRO-ALA-P-nitroanilide
7U65	;	2.8	;	Structure of E. coli dGTPase bound to T7 bacteriophage protein Gp1.2
7U66	;	3.1	;	Structure of E. coli dGTPase bound to T7 bacteriophage protein Gp1.2 and dGTP
7U67	;	2.5	;	Structure of E. coli dGTPase bound to T7 bacteriophage protein Gp1.2 and GTP
3DEN	;	2.2	;	Structure of E. coli DHDPS mutant Y107W
1YXD	;	2.0	;	Structure of E. coli dihydrodipicolinate synthase bound with allosteric inhibitor (S)-lysine to 2.0 A
3C0J	;	2.4	;	Structure of E. coli dihydrodipicolinate synthase complexed with hydroxypyruvate
1YXC	;	1.9	;	Structure of E. coli dihydrodipicolinate synthase to 1.9 A
2G1P	;	1.89	;	Structure of E. coli DNA adenine methyltransferase (DAM)
1EU5	;	1.45	;	STRUCTURE OF E. COLI DUTPASE AT 1.45 A
3ZDA	;	1.5	;	Structure of E. coli ExoIX in complex with a fragment of the Flap1 DNA oligonucleotide, potassium and magnesium
3ZDB	;	1.47	;	Structure of E. coli ExoIX in complex with the palindromic 5ov4 DNA oligonucleotide, di-magnesium and potassium
3ZDC	;	1.53	;	Structure of E. coli ExoIX in complex with the palindromic 5ov4 DNA oligonucleotide, potassium and calcium
3ZDD	;	1.5	;	Structure of E. coli ExoIX in complex with the palindromic 5ov6 oligonucleotide and potassium
4JRP	;	1.95	;	Structure of E. coli Exonuclease I in complex with a 5cy-dT13 oligonucleotide
2GFV	;	2.29	;	Structure of E. coli FabF (KASII) C163Q mutant
3HNZ	;	2.75	;	Structure of E. coli FabF(C163A) in Complex with Platensimycin
3G11	;	2.0	;	Structure of E. coli FabF(C163Q) in complex with dihydrophenyl platensimycin
3G0Y	;	2.6	;	Structure of E. coli FabF(C163Q) in complex with dihydroplatensimycin
2GFX	;	2.59	;	Structure of E. coli FabF(C163Q) in complex with Platensimycin
2GFY	;	2.85	;	Structure of E. coli FabF(K335A) mutant with covalently linked dodecanoic acid
3IL9	;	1.85	;	Structure of E. coli FabH
6UMK	;	1.35	;	Structure of E. coli FtsZ(L178E)-GDP complex
6UNX	;	1.4	;	Structure of E. coli FtsZ(L178E)-GTP complex
1SF2	;	2.4	;	Structure of E. coli gamma-aminobutyrate aminotransferase
1HV9	;	2.1	;	STRUCTURE OF E. COLI GLMU: ANALYSIS OF PYROPHOSPHORYLASE AND ACETYLTRANSFERASE ACTIVE SITES
8AB5	;	2.4	;	Structure of E. coli GlpG in complex with peptide derived inhibitor Ac-VRHA-conh-[4-(4-butyl)-phenoxy-1-phenyl-2-butyl]
3D1R	;	1.85	;	Structure of E. coli GlpX with its substrate fructose 1,6-bisphosphate
8PVG	;	3.4	;	Structure of E. coli glutamine synthetase determined by cryoEM at 100 keV
4JXZ	;	2.4	;	Structure of E. coli glutaminyl-tRNA synthetase bound to ATP and a tRNA(Gln) acceptor containing a UUG anticodon
1GRX	;		;	STRUCTURE OF E. COLI GLUTAREDOXIN
6G94	;	2.5	;	Structure of E. coli hydrogenase-1 C19G variant in complex with cytochrome b
4GD3	;	3.3	;	Structure of E. coli hydrogenase-1 in complex with cytochrome b
3FOZ	;	2.5	;	Structure of E. coli Isopentenyl-tRNA transferase in complex with E. coli tRNA(Phe)
1D9E	;	2.4	;	STRUCTURE OF E. COLI KDO8P SYNTHASE
7SEF	;	3.55	;	Structure of E. coli LetB delta (Ring6) mutant, Ring 1 in the open state (Model 2, Rings 1-3 only)
7SEE	;	3.2	;	Structure of E. coli LetB delta (Ring6) mutant, Ring1 in the closed state (Model 1)
2AQ9	;	1.8	;	Structure of E. coli LpxA with a bound peptide that is competitive with acyl-ACP
4D8J	;	3.55	;	Structure of E. coli MatP-mats complex
5UW8	;	2.15	;	Structure of E. coli MCE protein MlaD, core MCE domain
5UW2	;	2.85	;	Structure of E. coli MCE protein MlaD, periplasmic domain
5UVN	;	3.96	;	Structure of E. coli MCE protein PqiB, periplasmic domain
1FR9	;	1.65	;	STRUCTURE OF E. COLI MOBA
1FRW	;	1.75	;	STRUCTURE OF E. COLI MOBA WITH BOUND GTP AND MANGANESE
2WCI	;	1.9	;	Structure of E. coli monothiol glutaredoxin GRX4 homodimer
7T5U	;	1.02	;	Structure of E. coli MS115-1 CapH N-terminal domain
6P80	;	1.5	;	Structure of E. coli MS115-1 CdnC + ATP
6U7B	;	2.09	;	Structure of E. coli MS115-1 CdnC:HORMA-deltaN complex
6P8V	;	2.64	;	Structure of E. coli MS115-1 HORMA:CdnC:Trip13 complex
6P7Q	;	1.66	;	Structure of E. coli MS115-1 NucC, 5'-pApA bound form
6P7O	;	1.752	;	Structure of E. coli MS115-1 NucC, Apo form
6P7P	;	1.665	;	Structure of E. coli MS115-1 NucC, cAAA-bound form
4K1G	;	1.9	;	Structure of E. coli Nfo(Endo IV)-H69A mutant bound to a cleaved DNA duplex containing a alphadA:T basepair
5LM9	;	2.143	;	Structure of E. coli NusA
6YN0	;	2.4	;	Structure of E. coli PBP1b with a FtsN peptide activating transglycosylase activity
5UWA	;	1.501	;	Structure of E. coli phospholipid binding protein MlaC
4JOM	;	2.9	;	Structure of E. coli Pol III 3mPHP mutant
3QSB	;	1.9	;	Structure of E. coli polIIIbeta with (Z)-5-(1-((4'-Fluorobiphenyl-4-yl)methoxyimino)butyl)-2,2-dimethyl-4,6-dioxocyclohexanecarbonitrile
8SUX	;	2.93	;	Structure of E. coli PtuA hexamer
2AUK	;	2.3	;	Structure of E. coli RNA polymerase beta' G/G' insert
4S2Y	;	1.6	;	Structure of E. coli RppH bound to RNA and three magnesium ions
4S2X	;	1.5	;	Structure of E. coli RppH bound to RNA and two magnesium ions
4S2W	;	1.992	;	Structure of E. coli RppH bound to sulfate ions
5OC0	;	1.97	;	Structure of E. coli superoxide oxidase
1QF6	;	2.9	;	STRUCTURE OF E. COLI THREONYL-TRNA SYNTHETASE COMPLEXED WITH ITS COGNATE TRNA
2O5C	;	2.35	;	Structure of E. coli topoisomerase III in complex with an 8-base single stranded oligonucleotide. Frozen in glucose pH 5.5
2O5E	;	2.5	;	Structure of E. coli topoisomerase III in complex with an 8-base single stranded oligonucleotide. Frozen in glucose pH 7.0
2O54	;	2.5	;	Structure of E. coli topoisomerase III in complex with an 8-base single stranded oligonucleotide. Frozen in glycerol at pH 7.0
2O59	;	2.5	;	Structure of E. coli topoisomerase III in complex with an 8-base single stranded oligonucleotide. Frozen in glycerol pH 8.0
2O19	;	2.45	;	Structure of E. coli topoisomersae III in complex with an 8-base single stranded oligonucleotide. Frozen in glycerol at pH 5.5
2KC8	;		;	Structure of E. coli toxin RelE (R81A/R83A) mutant in complex with antitoxin RelBc (K47-L79) peptide
2KC9	;		;	Structure of E. coli toxin RelE (R81A/R83A) mutant in the free state
4JYK	;	1.7	;	Structure of E. coli Transcriptional Regulator RutR with bound uracil
1SI7	;	2.2	;	Structure of E. coli tRNA psi 13 pseudouridine synthase TruD
3TH8	;	2.114	;	Structure of E. coli undecaprenyl diphosphate synthase complexed with BPH-1063
4H2O	;	2.14	;	Structure of E. coli undecaprenyl diphosphate synthase in complex with BPH-1248
4H38	;	1.95	;	Structure of E. coli undecaprenyl diphosphate synthase in complex with BPH-1297
4H3A	;	1.98	;	Structure of E. coli undecaprenyl diphosphate synthase in complex with BPH-1330
4H2J	;	1.81	;	Structure of E. coli undecaprenyl diphosphate synthase in complex with BPH-1354
4H2M	;	1.78	;	Structure of E. coli undecaprenyl diphosphate synthase in complex with BPH-1408
3WYJ	;	2.1	;	Structure of E. coli undecaprenyl diphosphate synthase in complex with BPH-789
5ZHE	;	2.18	;	STRUCTURE OF E. COLI UNDECAPRENYL DIPHOSPHATE SYNTHASE IN COMPLEX WITH BPH-981
4H3C	;	1.93	;	Structure of E. coli undecaprenyl diphosphate synthase in complex with BPH-987
7T2S	;	1.82	;	Structure of E. coli upec-117 Cap18 3'-5' exonuclease
1LX7	;	2.0	;	Structure of E. coli uridine phosphorylase at 2.0A
1U1E	;	2.001	;	Structure of e. coli uridine phosphorylase complexed to 5(phenylseleno)acyclouridine (PSAU)
1U1F	;	2.3	;	Structure of e. coli uridine phosphorylase complexed to 5-(m-(benzyloxy)benzyl)acyclouridine (BBAU)
1U1G	;	1.95	;	Structure of E. coli uridine phosphorylase complexed to 5-(m-(benzyloxy)benzyl)barbituric acid (BBBA)
1U1D	;	2.001	;	Structure of e. coli uridine phosphorylase complexed to 5-(phenylthio)acyclouridine (ptau)
1U1C	;	2.2	;	Structure of E. coli uridine phosphorylase complexed to 5-benzylacyclouridine (BAU)
1TGV	;	2.2	;	Structure of E. coli Uridine Phosphorylase complexed with 5-Fluorouridine and sulfate
1TGY	;	2.2	;	Structure of E. coli Uridine Phosphorylase complexed with uracil and ribose 1-phosphate
3WDO	;	3.15	;	Structure of E. coli YajR transporter
1PUG	;	2.2	;	Structure of E. coli Ybab
5AQ6	;	1.79	;	Structure of E. coli ZinT at 1.79 Angstrom
4ELS	;	2.303	;	Structure of E. Coli. 1,4-dihydroxy-2- naphthoyl coenzyme A synthases (MENB) in complex with bicarbonate
4ELW	;	2.551	;	Structure of E. coli. 1,4-dihydroxy-2- naphthoyl coenzyme A synthases (MENB) in complex with nitrate
3Q87	;	1.997	;	Structure of E. cuniculi Mtq2-Trm112 complex responible for the methylation of eRF1 translation termination factor
3IL5	;	2.6	;	Structure of E. faecalis FabH in complex with 2-({4-bromo-3-[(diethylamino)sulfonyl]benzoyl}amino)benzoic acid
3IL6	;	2.5	;	Structure of E. faecalis FabH in complex with 2-({4-[(3R,5S)-3,5-dimethylpiperidin-1-yl]-3-phenoxybenzoyl}amino)benzoic acid
3IL4	;	3.0	;	Structure of E. faecalis FabH in complex with acetyl CoA
3DPC	;	2.3	;	Structure of E.coli Alkaline Phosphatase Mutant in Complex with a Phosphorylated Peptide
2CG4	;	2.4	;	Structure of E.coli AsnC
8BQO	;	2.1	;	Structure of E.coli Class 2 L-asparaginase EcAIII, mutant M200I
7QSF	;	1.6	;	Structure of E.coli Class 2 L-asparaginase EcAIII, mutant RDM1-12 (G206C, R207T, D210A, S211A)
7QYM	;	1.2	;	Structure of E.coli Class 2 L-asparaginase EcAIII, mutant RDM1-18 (R207V, D210P, S211W)
7QYX	;	1.85	;	Structure of E.coli Class 2 L-asparaginase EcAIII, mutant RDM1-24 (R207A, D210S, S211T)
7R5C	;	2.2	;	Structure of E.coli Class 2 L-asparaginase EcAIII, mutant RDM1-29 (G206C, R207S, D210L, S211V)
7QTC	;	2.55	;	Structure of E.coli Class 2 L-asparaginase EcAIII, mutant RDM1-3 (G206H, R207T, D210P, S211Q)
7QVR	;	1.9	;	Structure of E.coli Class 2 L-asparaginase EcAIII, mutant RDM1-37 (G206S, R207T, D210S)
7R1G	;	1.95	;	Structure of E.coli Class 2 L-asparaginase EcAIII, mutant RDM1-38 (R207C, D210S, S211V)
7QQ8	;	1.8	;	Structure of E.coli Class 2 L-asparaginase EcAIII, mutant RDM1-8 (G206Y, R207Q, D210P, S211T)
7QY6	;	1.65	;	Structure of E.coli Class 2 L-asparaginase EcAIII, wild type (WT EcAIII)
5FKZ	;	5.5	;	Structure of E.coli Constitutive lysine decarboxylase
6NPF	;	2.57	;	Structure of E.coli enolase in complex with an analog of the natural product SF-2312 metabolite.
2G1H	;	1.86	;	Structure of E.coli FabD complexed with glycerol
2G2Y	;	2.26	;	Structure of E.coli FabD complexed with malonate
2G2Z	;	2.8	;	Structure of E.coli FabD complexed with malonyl-CoA
2G2O	;	1.76	;	Structure of E.coli FabD complexed with sulfate
3HO2	;	2.0	;	Structure of E.coli FabF(C163A) in complex with Platencin
3HO9	;	1.9	;	Structure of E.coli FabF(C163A) in complex with Platencin A1
5GK7	;	1.8	;	Structure of E.Coli fructose 1,6-bisphosphate aldolase bound to Tris
5GK8	;	2.002	;	Structure of E.Coli fructose 1,6-bisphosphate aldolase, Acetate bound form
5GK6	;	1.8	;	Structure of E.Coli fructose 1,6-bisphosphate aldolase, Citrate bound form
2VYN	;	2.2	;	Structure of E.Coli GAPDH Rat Sperm GAPDH heterotetramer
2VYV	;	2.38	;	Structure of E.Coli GAPDH Rat Sperm GAPDH heterotetramer
3SBO	;	3.204	;	Structure of E.coli GDH from native source
5F5B	;	2.3	;	Structure of E.Coli GlpG complexed with peptidic inhibitor Ac-VRMA-CHO
5MT8	;	1.95	;	Structure of E.coli GlpG in complex with peptide derived inhibitor Ac-RVRHA-cmk
5MT6	;	2.16	;	Structure of E.coli GlpG in complex with peptide derived inhibitor Ac-RVRHA-phenylethyl-ketoamide
5MT7	;	2.05	;	Structure of E.coli GlpG in complex with peptide derived inhibitor Ac-VRHA-cmk
5F5G	;	2.3	;	Structure of E.Coli GlpG Y205F mutant complexed with peptidic inhibitor Ac-RMA-CHO in the DMPC/CHAPSO bicelle
1GSG	;	2.8	;	Structure of E.coli glutaminyl-tRNA synthetase complexed with trnagln and ATP at 2.8 Angstroms resolution
5FKX	;	6.1	;	Structure of E.coli inducible lysine decarboxylase at active pH
2BZ3	;	2.0	;	Structure of E.coli KAS I H298E mutant in complex with C12 fatty acid
2BZ4	;	1.86	;	structure of E.coli KAS I H298Q mutant
2BYZ	;	1.95	;	Structure of E.coli KAS I H298Q mutant in complex with C12 fatty acid
2XTU	;	1.85	;	Structure of E.coli rhomboid protease GlpG active site mutant, S201T in trigonal crystal form
3ZMI	;	2.2	;	Structure of E.coli rhomboid protease GlpG in complex with monobactam L29
3ZOT	;	2.399	;	Structure of E.coli rhomboid protease GlpG in complex with monobactam L29 (data set 2)
3ZMJ	;	2.3	;	Structure of E.coli rhomboid protease GlpG in complex with monobactam L61
3ZMH	;	2.3	;	Structure of E.coli rhomboid protease GlpG in complex with monobactam L62
2XTV	;	1.7	;	Structure of E.coli rhomboid protease GlpG, active site mutant, S201T, orthorhombic crystal form
6QE0	;	1.394	;	Structure of E.coli RlmJ in complex with a bisubstrate analogue (BA2)
6QDX	;	2.1	;	Structure of E.coli RlmJ in complex with a bisubstrate analogue (BA4)
7P9O	;	2.095	;	Structure of E.coli RlmJ in complex with a SAM analogue (CA)
7P8Q	;	2.289	;	Structure of E.coli RlmJ in complex with an RNA conjugate (GA-SAM)
7P9I	;	1.594	;	Structure of E.coli RlmJ in complex with an RNA conjugate (GAA-SAM)
6QE5	;	1.61	;	Structure of E.coli RlmJ in complex with the natural cofactor product S-adenosyl-homocysteine (SAH)
1Q8R	;	1.899	;	Structure of E.coli RusA Holliday junction resolvase
8EEA	;	2.6	;	Structure of E.coli Septu (PtuAB) complex
1JP3	;	1.8	;	Structure of E.coli undecaprenyl pyrophosphate synthase
2KZ9	;		;	Structure of E1-69 of Yeast V-ATPase
1KCN	;		;	Structure of e109 Zeta Peptide, an Antagonist of the High-Affinity IgE Receptor
1KCO	;		;	Structure of e131 Zeta Peptide, a Potent Antagonist of the High-Affinity IgE Receptor
8FND	;	3.0	;	Structure of E138K HIV-1 intasome with Dolutegravir bound
8FNG	;	2.2	;	Structure of E138K HIV-1 intasome with Dolutegravir bound
8FNJ	;	2.4	;	Structure of E138K/G140A HIV-1 intasome with Dolutegravir bound
8FNQ	;	2.8	;	Structure of E138K/G140A/Q148K HIV-1 intasome with 4d bound
8FNN	;	2.7	;	Structure of E138K/G140A/Q148K HIV-1 intasome with Dolutegravir bound
8FNO	;	2.5	;	Structure of E138K/G140A/Q148R HIV-1 intasome with Dolutegravir bound
8FNP	;	2.2	;	Structure of E138K/G140S/Q148H HIV-1 intasome with Dolutegravir bound
8FNL	;	2.8	;	Structure of E138K/Q148K HIV-1 intasome with Dolutegravir bound
6GAM	;	1.4	;	Structure of E14Q variant of E. coli hydrogenase-2 (as-isolated enzyme)
2RK6	;	1.15	;	Structure of E163K DJ-1
3B3A	;	1.5	;	Structure of E163K/R145E DJ-1
3EJY	;	3.2	;	Structure of E203H mutant of E.coli Cl-/H+ antiporter, CLC-ec1
3EJZ	;	2.9	;	Structure of E203V mutant E.coli Cl-/H+ exchanger, CLC-ec1
3U75	;	2.68	;	Structure of E230A-fructofuranosidase from Schwanniomyces occidentalis complexed with fructosylnystose
6EV9	;	1.64	;	Structure of E277D A. niger Fdc1 with prFMN in the hydroxylated form
6EVA	;	1.64	;	Structure of E277Q A. niger fdc1 in complex with a phenylpyruvate derived adduct to the prenylated flavin cofactor
6EV8	;	1.03	;	Structure of E277Q A. niger Fdc1 with prFMN in the hydroxylated form
6EV7	;	1.06	;	Structure of E282D A. niger Fdc1 with prFMN in the iminium form
6EVC	;	1.18	;	Structure of E282Q A. niger Fdc1 in complex with pentafluoro-cinnamic acid
6EV6	;	1.1	;	Structure of E282Q A. niger Fdc1 with prFMN in the hydroxylated and ketimine forms
6EVB	;	1.13	;	Structure of E282Q A. niger Fdc1 with prFMN in the iminium form
6EVF	;	2.06	;	Structure of E285D S. cerevisiae Fdc1 with prFMN in the hydroxylated form
5IFT	;	2.45	;	STRUCTURE OF E298Q-BETA-GALACTOSIDASE FROM ASPERGILLUS NIGER IN COMPLEX WITH 3-b-Galactopyranosyl glucose
5MGC	;	2.3	;	STRUCTURE OF E298Q-BETA-GALACTOSIDASE FROM ASPERGILLUS NIGER IN COMPLEX WITH 4-Galactosyl-lactose
5JUV	;	2.27	;	STRUCTURE OF E298Q-BETA-GALACTOSIDASE FROM ASPERGILLUS NIGER IN COMPLEX WITH 6-b-Galactopyranosyl galactose
5MGD	;	2.15	;	STRUCTURE OF E298Q-BETA-GALACTOSIDASE FROM ASPERGILLUS NIGER IN COMPLEX WITH 6-Galactosyl-lactose
5IHR	;	2.4	;	STRUCTURE OF E298Q-BETA-GALACTOSIDASE FROM ASPERGILLUS NIGER IN COMPLEX WITH ALLOLACTOSE
4YO2	;	3.073	;	Structure of E2F8, an atypical member of E2F family of transcription factors
8ST9	;	2.5	;	Structure of E3 ligase NleL bound to ubiquitin
8ST8	;	1.75	;	Structure of E3 ligase SopA bound to ubiquitin
8ST7	;	1.44	;	Structure of E3 ligase VsHECT bound to ubiquitin
3DYC	;	2.303	;	Structure of E322Y Alkaline Phosphatase in Complex with Inorganic Phosphate
3ECK	;	1.6	;	Structure of E323L Homoprotocatechuate 2,3-dioxygenase from Brevibacterium fuscum in complex with putative O-O bond cleavage intermediate formed via in crystallo reaction with 4-sulfonyl catechol at low oxygen concentrations
3ECJ	;	1.65	;	Structure of E323L mutant of Homoprotocatechuate 2,3-Dioxygenase from Brevibacterium fuscum at 1.65A resolution
3V4W	;	3.7	;	Structure of E347K mutant of Lamin
2B7R	;	1.7	;	Structure of E378D mutant flavocytochrome c3
7A5U	;	1.5	;	Structure of E37A BlaC from Mycobacterium tuberculosis
4ENP	;	1.5	;	Structure of E530A variant E. coli KatE
4ENQ	;	1.9	;	Structure of E530D variant E. coli KatE
4ENR	;	1.6	;	Structure of E530I variant E. coli KatE
4ENS	;	1.6	;	Structure of E530Q variant of E. coli KatE
1D5F	;	2.8	;	STRUCTURE OF E6AP: INSIGHTS INTO UBIQUITINATION PATHWAY
6TO0	;	1.88	;	Structure of E70A mutant of Rex8A from Paenibacillus barcinonensis complexed with 2(3)-alpha-L-arabinofuranosyl-xylotriose.
6TRH	;	1.86	;	Structure of E70A mutant of Rex8A from Paenibacillus barcinonensis complexed with 3(3)-alpha-L-arabinofuranosyl-xylotetraose.
6TOW	;	2.05	;	Structure of E70A mutant of Rex8A from Paenibacillus barcinonensis complexed with xylotetraose.
6TPP	;	2.64	;	Structure of E70A mutant of Rex8A from Paenibacillus barcinonensis.
5IBS	;	2.32	;	Structure of E76Q, a Cancer-Associated Mutation of the Oncogenic Phosphatase SHP2
7ZT8	;	2.29	;	Structure of E8 TCR in complex in human MR1 bound to 3FBA
7ZT5	;	2.09	;	Structure of E8 TCR in complex in human MR1 bound to 3FSA
7ZT9	;	2.13	;	Structure of E8 TCR in complex in human MR1 bound to 4FBA
7ZT7	;	1.84	;	Structure of E8 TCR in complex in human MR1 bound to 5FSA
7ZT3	;	2.4	;	Structure of E8 TCR in complex in human MR1 K43A
7ZT2	;	2.4	;	Structure of E8 TCR in complex with human MR1 bound to 5-OP-RU
7ZT4	;	2.02	;	Structure of E8 TCR in complex with human MR1 bound to 6FP
3PSV	;	2.0	;	Structure of E97D mutant of TIM from Plasmodium falciparum
3PSW	;	1.99	;	Structure of E97Q mutant of TIM from Plasmodium falciparum
6HQ2	;	2.45	;	Structure of EAL Enzyme Bd1971 - apo form
6HQ5	;	2.83	;	Structure of EAL Enzyme Bd1971 - cAMP and cyclic-di-GMP bound form
6HQ4	;	2.63	;	Structure of EAL enzyme Bd1971 - cAMP bound form
6HQ7	;	2.46	;	Structure of EAL Enzyme Bd1971 - cGMP bound form
6HQ3	;	2.79	;	Structure of EAL Enzyme Bd1971 - halfsite-occupied form
6KTW	;	1.931	;	structure of EanB with hercynine
1N9F	;	1.8	;	Structure of earth-grown oxidized Myoglobin mutant YQR (ISS6A)
1N9I	;	1.6	;	structure of earth-grown oxidized myoglobin mutant YQR (ISS8A)
5HC1	;	3.1	;	Structure of EAV NSP11 H141A mutant at 3.10A
5HBZ	;	3.1	;	Structure of EAV NSP11 K170A mutant at 3.10A
5F17	;	3.2	;	Structure of EAV NSP11 K170A mutant at 3.19A
4YPI	;	3.71	;	Structure of Ebola virus nucleoprotein N-terminal fragment bound to a peptide derived from Ebola VP35
4D9O	;	2.0	;	Structure of ebolavirus protein VP24 from Reston
7SWD	;	3.59	;	Structure of EBOV GP lacking the mucin-like domain with 1C11 scFv and 1C3 Fab bound
8DPL	;	2.53	;	Structure of EBOV GP lacking the mucin-like domain with 2.1.1D5 scFv and 6D6 scFv bound
8DPM	;	3.0	;	Structure of EBOV GP lacking the mucin-like domain with 9.20.1A2 Fab and 6D6 scFv bound
6EA7	;	4.25	;	Structure of EBOV GPcl in complex with the pan-ebolavirus mAb ADI-15878
6OHU	;	3.526	;	Structure of EBP and tamoxifen
6OHT	;	3.2	;	Structure of EBP and U18666A
7MKA	;	3.54	;	Structure of EC+EC (leading EC-focused)
1WUZ	;		;	Structure of EC1 domain of CNR
7TNI	;	1.9	;	Structure of EC12 Y1392W variant of BT-R1 from Manduca sexta, a Cry1A toxin binding domain
4KK7	;	1.68	;	Structure of EccB1 from the type VII (ESX-1) secretion system of Mycobacterium tuberculosis.
6SGY	;	4.6	;	Structure of EccB3 dimer from the ESX-3 core complex
4FG6	;	3.019	;	Structure of EcCLC E148A mutant in Glutamate
2NDO	;		;	Structure of EcDsbA-sulfonamide1 complex
3R9T	;	1.75	;	Structure of EchA1_1 from Mycobacterium paratuberculosis ATCC BAA-968 / K-10
8B9F	;	3.93	;	Structure of Echovirus 11 complexed with DAF (CD55) calculated from symmetry expansion
7B5F	;	2.9	;	Structure of echovirus 18 in complex with neonatal Fc receptor
4OXF	;	1.5	;	Structure of ECP in complex with citrate ions at 1.50 Angstroms
4OXB	;	1.5	;	Structure of ECP with sulphate anions at 1.50 Angstroms
4OWZ	;	1.47	;	Structure of ECP/H15A mutant.
4B56	;	3.0	;	Structure of ectonucleotide pyrophosphatase-phosphodiesterase-1 (NPP1)
3HB0	;	2.5	;	Structure of edeya2 complexed with bef3
4DK3	;	2.76	;	Structure of Editosome protein
4DK6	;	2.65	;	Structure of Editosome protein
4DKA	;	1.97	;	Structure of Editosome protein
4DNI	;	2.55	;	Structure of Editosome protein
7MSB	;	1.9	;	Structure of EED bound to EEDi-4259
7MSD	;	2.2	;	Structure of EED bound to EEDi-6068
6W7G	;	1.85	;	Structure of EED bound to inhibitor 1056
6W7F	;	2.2	;	Structure of EED bound to inhibitor 5285
3JZN	;	2.6	;	Structure of EED in apo form
3JZG	;	2.1	;	Structure of EED in complex with H3K27me3
2E1R	;	3.15	;	Structure of eEF2 in complex with a sordarin derivative
2NPF	;	2.9	;	Structure of eEF2 in complex with moriniafungin
1ZM9	;	2.8	;	Structure of eEF2-ETA in complex with PJ34
5I2L	;	1.85	;	Structure of EF-hand containing protein
5I2O	;	1.952	;	Structure of EF-hand containing protein
5I2Q	;	1.935	;	Structure of EF-hand containing protein
4V6A	;	3.1	;	Structure of EF-P bound to the 70S ribosome.
6OHH	;	2.1	;	Structure of EF1p2_mFAP2b bound to DFHBI
2OKG	;	1.65	;	Structure of effector binding domain of central glycolytic gene regulator (CggR) from B. subtilis
2RGP	;	2.0	;	Structure of EGFR in complex with hydrazone, a potent dual inhibitor
7LGS	;	3.1	;	Structure of EGFR_D770_N771insNPG/V948R in complex with covalent inhibitor Osimertinib.
7C2P	;	2.1	;	Structure of Egk Peptide
6K2F	;	1.55	;	Structure of Eh TWINFILIN
2JQ6	;		;	Structure of EH-domain of EHD1
6QG0	;	4.15	;	Structure of eIF2B-eIF2 (phosphorylated at Ser51) complex (model 1)
6QG1	;	4.25	;	Structure of eIF2B-eIF2 (phosphorylated at Ser51) complex (model 2)
6QG2	;	4.55	;	Structure of eIF2B-eIF2 (phosphorylated at Ser51) complex (model A)
6QG3	;	9.4	;	Structure of eIF2B-eIF2 (phosphorylated at Ser51) complex (model B)
6QG5	;	10.1	;	Structure of eIF2B-eIF2 (phosphorylated at Ser51) complex (model C)
6QG6	;	10.4	;	Structure of eIF2B-eIF2 (phosphorylated at Ser51) complex (model D)
4AXG	;	2.8	;	Structure of eIF4E-Cup complex
6Z29	;		;	Structure of eIF4G1 (37-49) - PUB1 RRM3 chimera in solution
6I50	;	1.69	;	Structure of Eiger TNF from S. frugiperda
3W0E	;	1.8	;	Structure of elastase inhibitor AFUEI (crystal form II)
3W0D	;	2.3	;	Structure of elastase inhibitor AFUEI (cyrstal form I)
7T2R	;	3.2	;	Structure of electron bifurcating Ni-Fe hydrogenase complex HydABCSL in FMN-free apo state
7T30	;	3.0	;	Structure of electron bifurcating Ni-Fe hydrogenase complex HydABCSL in FMN/NAD(H) bound state
1VLX	;	1.9	;	STRUCTURE OF ELECTRON TRANSFER (COBALT-PROTEIN)
1O96	;	3.1	;	Structure of electron transferring flavoprotein for Methylophilus methylotrophus.
1O97	;	1.6	;	Structure of electron transferring flavoprotein from Methylophilus methylotrophus, recognition loop removed by limited proteolysis
8F04	;		;	Structure of elevenin-Vc1 from venom of the Australian cone snail Conus victoriae
6E0M	;	1.52	;	Structure of Elizabethkingia meningoseptica CdnE cyclic dinucleotide synthase
6E0N	;	1.5	;	Structure of Elizabethkingia meningoseptica CdnE cyclic dinucleotide synthase with GTP and Apcpp
6E0O	;	1.25	;	Structure of Elizabethkingia meningoseptica CdnE cyclic dinucleotide synthase with pppA[3'-5']pA
1Z3F	;	1.5	;	Structure of ellipticine in complex with a 6-bp DNA
7B3D	;	2.8	;	Structure of elongating SARS-CoV-2 RNA-dependent RNA polymerase with AMP at position -4 (structure 3)
7B3B	;	3.1	;	Structure of elongating SARS-CoV-2 RNA-dependent RNA polymerase with Remdesivir at position -3 (structure 1)
7B3C	;	3.4	;	Structure of elongating SARS-CoV-2 RNA-dependent RNA polymerase with Remdesivir at position -4 (structure 2)
2KA3	;		;	Structure of EMILIN-1 C1Q-like domain
2OII	;		;	Structure of EMILIN-1 C1q-like domain
8BQN	;	3.1	;	Structure of empty Coxsackievirus A10 embedded in crystalline ice frozen at -140 degree
2FZ1	;	2.9	;	Structure of Empty Head Turnip Yellow Mosaic Virus (ATC) at 100 K
2H8V	;	2.6	;	Structure of empty Pheromone Binding Protein ASP1 from the Honeybee Apis mellifera L
7T00	;	3.91	;	Structure of EmrE-D3 mutant in complex with monobody L10 and benzyltrimethylammonium
7SVX	;	3.9	;	Structure of EmrE-D3 mutant in complex with monobody L10 and harmane
7MGX	;	3.13	;	Structure of EmrE-D3 mutant in complex with monobody L10 and methyl viologen
7SSU	;	3.22	;	Structure of EmrE-D3 mutant in complex with monobody L10 and methyltriphenylphosphonium
7SV9	;	3.36	;	Structure of EmrE-D3 mutant in complex with monobody L10 and TPP
7MH6	;	2.85	;	Structure of EmrE-D3 mutant in complex with monobody L10 in low pH (protonated state)
1V7P	;	1.9	;	Structure of EMS16-alpha2-I domain complex
3G02	;	1.5	;	Structure of enantioselective mutant of epoxide hydrolase from Aspergillus niger generated by directed evolution
1UKR	;	2.4	;	STRUCTURE OF ENDO-1,4-BETA-XYLANASE C
1WZZ	;	1.65	;	Structure of endo-beta-1,4-glucanase CMCax from Acetobacter xylinum
3FHA	;	2.0	;	Structure of endo-beta-N-acetylglucosaminidase A
3FHQ	;	2.452	;	Structure of endo-beta-N-acetylglucosaminidase A
5YDZ	;	5.8	;	structure of endo-lysosomal TRPML1 channel inserting into amphipol: state 1
5YE1	;	5.8	;	structure of endo-lysosomal TRPML1 channel inserting into amphipol: state 2
5YE5	;	5.8	;	structure of endo-lysosomal TRPML1 channel inserting into nanodisc
2BWC	;	2.15	;	Structure of Endoglucanase 12A (Cel12A) from Rhodothermus marinus in complex with cellopentaose (5 minute soak)
2BWA	;	1.68	;	Structure of Endoglucanase 12A (Cel12A) from Rhodothermus marinus in complex with cellopentaose, 20 minute soak.
3ENG	;	1.9	;	STRUCTURE OF ENDOGLUCANASE V CELLOBIOSE COMPLEX
4ENG	;	1.9	;	STRUCTURE OF ENDOGLUCANASE V CELLOHEXAOSE COMPLEX
5GKJ	;	3.2	;	Structure of EndoMS in apo form
5GKE	;	2.4	;	Structure of EndoMS-dsDNA1 complex
5GKF	;	2.8	;	Structure of EndoMS-dsDNA1' complex
5GKG	;	2.6	;	Structure of EndoMS-dsDNA1'' complex
5GKH	;	2.9	;	Structure of EndoMS-dsDNA2 complex
5GKI	;	2.9	;	Structure of EndoMS-dsDNA3 complex
3N6C	;	3.06	;	Structure of endothelial nitric oxide synthase H373S single mutant heme domain complexed with 4-(2-(6-(2-(6-amino-4-methylpyridin-2-yl)ethyl)pyridin-2-yl)ethyl)-6-methylpyridin-2-amine
3N6D	;	3.05	;	Structure of endothelial nitric oxide synthase H373S single mutant heme domain complexed with 6,6'-(2,2'-(5-amino-1,3-phenylene)bis(ethane-2,1-diyl))bis(4-methylpyridin-2-amine)
3N6B	;	3.1	;	Structure of endothelial nitric oxide synthase H373S single mutant heme domain complexed with 6,6'-(2,2'-(pyridine-3,5-diyl)bis(ethane-2,1-diyl))bis(4-methylpyridin-2-amine)
3N5S	;	2.18	;	Structure of endothelial nitric oxide synthase heme domain complexed with 4-(2-(5-(2-(6-amino-4-methylpyridin-2-yl)ethyl)pyridin-3-yl)ethyl)-6-methylpyridin-2-amine
3N5P	;	2.39	;	Structure of endothelial nitric oxide synthase heme domain complexed with 4-(2-(6-(2-(6-amino-4-methylpyridin-2-yl)ethyl)pyridin-2-yl)ethyl)-6-methylpyridin-2-amine
3N5R	;	2.57	;	Structure of endothelial nitric oxide synthase heme domain complexed with 4-(3-(2-(6-amino-4-methylpyridin-2-yl)ethyl)phenethyl)-6-methylpyridin-2-amine
3N5Q	;	2.9	;	Structure of endothelial nitric oxide synthase heme domain complexed with 6,6'-(2,2'-(5-amino-1,3-phenylene)bis(ethane-2,1-diyl))bis(4-methylpyridin-2-amine)
3N5T	;	2.52	;	Structure of endothelial nitric oxide synthase heme domain complexed with 6,6'-(2,2'-(pyridine-3,5-diyl)bis(ethane-2,1-diyl))bis(4-methylpyridin-2-amine)
3NLE	;	1.95	;	Structure of endothelial nitric oxide synthase heme domain complexed with 6-{{(3'R,4'R)-3'-[2""-(3'''-fluorophenethylamino)ethoxy]pyrrolidin-4'-yl}methyl}-4-methylpyridin-2-amine
3NLF	;	2.32	;	Structure of endothelial nitric oxide synthase heme domain complexed with 6-{{(3'R,4'S)-3'-[2""-(3'''-fluorophenethylamino)ethoxy]pyrrolidin-4'-yl}methyl}-4-methylpyridin-2-amine
3NLG	;	2.38	;	Structure of endothelial nitric oxide synthase heme domain complexed with 6-{{(3'S,4'R)-3'-[2""-(3'''-fluorophenethylamino)ethoxy]pyrrolidin-4'-yl}methyl}-4-methylpyridin-2-amine
3NLD	;	2.285	;	Structure of endothelial nitric oxide synthase heme domain complexed with 6-{{(3'S,4'S)-3'-[2""-(3'''-fluorophenethylamino)ethoxy]pyrrolidin-4'-yl}methyl}-4-methylpyridin-2-amine
3JWZ	;	2.4	;	Structure of endothelial nitric oxide synthase heme domain complexed with N1-[(3' S,4' R)-4'-((6""-amino-4""-methylpyridin-2""-yl)methyl)pyrrolidin-3'-yl]-N2-(3'-fluorophenethyl)ethane-1,2-diamine tetrahydrochloride
3JWX	;	2.0	;	Structure of endothelial nitric oxide synthase heme domain complexed with N1-[(3'R,4'R)-4'-((6""-amino-4""-methylpyridin-2""-yl)methyl)pyrrolidin-3'-yl]-N2-(3'-fluorophenethyl)ethane-1,2-diamine tetrahydrochloride
3JWW	;	2.2	;	Structure of endothelial nitric oxide synthase heme domain complexed with N1-[(3'S,4'S)-4'-((6""-amino-4""-methylpyridin-2""-yl)methyl)pyrrolidin-3'-yl]-N2- (3'-fluorophenethyl)ethane-1,2-diamine tetrahydrochloride
3NLU	;	2.65	;	Structure of endothelial nitric oxide synthase heme domain complexed with N1-{(3'R,4'R)-4'-[(6""-amino-4""-methylpyridin-2""-yl)methyl]pyrrolidin-3'-yl}-N2-(3'-fluorophenethyl)ethane-1,2-diamine tetrahydrochloride
3JWY	;	2.24	;	Structure of endothelial nitric oxide synthase heme domain complexed with N1-{(3'R,4'S)-4'-[(6""-amino-4""-methylpyridin-2""-yl)methyl]pyrrolidin-3'-yl}-N2-(3'-fluorophenethyl)ethane-1,2-diamine tetrahydrochloride
3NLT	;	2.74	;	Structure of endothelial nitric oxide synthase heme domain complexed with N1-{(3'S,4'S)-4'-[(6""-amino-4""-methylpyridin-2""-yl)methyl]pyrrolidin-3'-yl}- N2-(3'-fluorophenethyl)ethane-1,2-diamine tetrahydrochloride
3NLH	;	2.1	;	Structure of endothelial nitric oxide synthase heme domain N368D mutant complexed with 6-{{(3'S,4'S)-3'-[2""-(3'''-fluorophenethylamino)ethoxy]pyrrolidin-4'-yl}methyl}-4-methylpyridin-2-amine
3N68	;	2.53	;	Structure of endothelial nitric oxide synthase heme domain N368D/V106M double mutant complexed with 4-(3-(2-(6-amino-4-methylpyridin-2-yl)ethyl)phenethyl)-6-methylpyridin-2-amine
3N6E	;	2.2	;	Structure of endothelial nitric oxide synthase N368D mutant heme domain complexed with 6,6'-(2,2'-(5-amino-1,3-phenylene)bis(ethane-2,1-diyl))bis(4-methylpyridin-2-amine)
3NLI	;	1.98	;	Structure of endothelial nitric oxide synthase N368D mutant heme domain complexed with 6-{{(3'R,4'R)-3'-[2""-(3'''-fluorophenethylamino)ethoxy]pyrrolidin-4'-yl}methyl}-4-methylpyridin-2-amine
3N6G	;	2.21	;	Structure of endothelial nitric oxide synthase N368D single mutant heme domain complexed with 4-(2-(5-(2-(6-amino-4-methylpyridin-2-yl)ethyl)pyridin-3-yl)ethyl)-6-methylpyridin-2-amine
3N6F	;	2.18	;	Structure of endothelial nitric oxide synthase N368D single mutant heme domain complexed with 6,6'-(2,2'-(pyridine-3,5-diyl)bis(ethane-2,1-diyl))bis(4-methylpyridin-2-amine)
3N6A	;	2.49	;	Structure of endothelial nitric oxide synthase N368D/V106M double mutant heme domain complexed with 4-(2-(5-(2-(6-amino-4-methylpyridin-2-yl)ethyl)pyridin-3-yl)ethyl)-6-methylpyridin-2-amine
3N67	;	2.09	;	Structure of endothelial nitric oxide synthase N368D/V106M double mutant heme domain complexed with 6,6'-(2,2'-(5-amino-1,3-phenylene)bis(ethane-2,1-diyl))bis(4-methylpyridin-2-amine)
3N69	;	2.65	;	Structure of endothelial nitric oxide synthase N368D/V106M double mutant heme domain complexed with 6,6'-(2,2'-(pyridine-3,5-diyl)bis(ethane-2,1-diyl))bis(4-methylpyridin-2-amine)
3DQS	;	2.03	;	Structure of endothelial NOS heme domain in complex with a inhibitor (+-)-N1-{cis-4'-[(6""-amino-4""-methylpyridin-2""-yl)methyl]pyrrolidin-3'-yl}-N2-(4'-chlorobenzyl)ethane-1,2-diamine
3DQT	;	2.54	;	Structure of endothelial NOS heme domain in complex with a inhibitor (+-)-N1-{trans-4'-[(6""-amino-4""-methylpyridin-2""-yl)methyl]pyrrolidin-3'-yl}-N2-(3'-chlorobenzyl)ethane-1,2-diamine
6UFF	;	2.007	;	Structure of Ene-reductase 1 NostocER1 from cyanobacteria
1PUI	;	2.0	;	Structure of EngB GTPase
8E01	;	3.4	;	Structure of engineered nano-cage fusion protein
4P83	;	2.5	;	Structure of engineered PyrR protein (PURPLE PyrR)
4P84	;	2.2	;	Structure of engineered PyrR protein (VIOLET PyrR)
3TCX	;	3.6	;	Structure of Engineered Single Domain ICAM-1 D1 with High-Affinity aL Integrin I Domain of Native C-Terminal Helix Conformation
5OX8	;	1.29	;	Structure of Enhanced Cyan Fluorescent Protein at pH 5.0
2WSN	;	1.37	;	Structure of Enhanced Cyan Fluorescent Protein at physiological pH
7E4X	;	3.08	;	Structure of Enolase from Mycobacterium tuberculosis
7UGU	;	2.6	;	Structure of enolase from streptococcus pyogenes
1EY3	;	2.3	;	STRUCTURE OF ENOYL-COA HYDRATASE COMPLEXED WITH THE SUBSTRATE DAC-COA
7K73	;	1.8	;	Structure of Enoyl-[acyl-carrier-protein] reductase [NADH] from Mycobacterium fortuitum bound to NAD
5EGE	;	2.0	;	Structure of ENPP6, a choline-specific glycerophosphodiester-phosphodiesterase
5EGH	;	1.803	;	Structure of ENPP6, a choline-specific glycerophosphodiester-phosphodiesterase in complex with phosphocholine
3PJD	;	2.5	;	Structure of ENR G93A mutant-NAD+-Triclosan complex
3PJE	;	2.5	;	Structure of ENR G93S mutant-NAD+-triclosan complex
3PJF	;	1.9	;	Structure of ENR G93V mutant-NAD+-triclosan complex
4IZ6	;	2.4	;	Structure of EntE and EntB, an NRPS adenylation-PCP fusion protein with pseudo translational symmetry
7TSQ	;	2.11	;	Structure of Enterobacter cloacae Cap2 bound to CdnD02 C-terminus, AMP state
7TSX	;	1.77	;	Structure of Enterobacter cloacae Cap2 bound to CdnD02 C-terminus, Apo state
7TQD	;	2.9	;	Structure of Enterobacter cloacae Cap2-CdnD02 2:1 complex
7TO3	;	2.74	;	Structure of Enterobacter cloacae Cap2-CdnD02 2:2 complex
6IL7	;	2.5	;	Structure of Enterococcus faecalis (V583) alkylhydroperoxide reductase subunit F (AhpF) C503A mutant
8OFO	;	2.45	;	Structure of Enterococcus faecium CdaA
6LQD	;	3.264	;	Structure of Enterovirus 71 in complex with NLD-22
8CNY	;	1.51	;	Structure of Enterovirus A71 3C protease
8CNX	;	1.49	;	Structure of Enterovirus D68 3C protease
8J6D	;	3.1	;	Structure of EP141-C3aR-Go complex
8I95	;	2.88	;	Structure of EP54-C3aR-Go complex
8I9A	;	3.57	;	Structure of EP54-C3aR-Gq complex
4ASL	;	1.24	;	Structure of Epa1A in complex with the T-antigen (Gal-b1-3- GalNAc)
3CF6	;	2.2	;	Structure of Epac2 in complex with cyclic-AMP and Rap
7Q5D	;	1.8	;	Structure of EPCR in a non-canonical conformation
5YO1	;	2.5	;	Structure of ePepN E298A mutant in complex with Puromycin
7CSO	;	2.39	;	Structure of Ephexin4 DH-PH-SH3
7CSP	;	3.0	;	Structure of Ephexin4 IDPSH
7CSR	;	3.0	;	Structure of Ephexin4 R676L
4P2K	;	1.499	;	Structure of Ephrin type-A receptor 2
4PDO	;	2.104	;	Structure of Ephrin type-A receptor 2
4TRL	;	2.452	;	Structure of Ephrin type-A receptor 2
2RR0	;		;	Structure of epidermal growth factor-like repeat 12 of mouse Notch-1 receptor
6PMH	;	2.3	;	Structure of Epimerase Mth375 from the thermophilic pseudomurein-containing methanogen Methanothermobacter thermautotrophicus
6PNL	;	2.01	;	Structure of Epimerase Mth375 from the thermophilic pseudomurein-containing methanogen Methanothermobacter thermautotrophicus
4WQQ	;	1.7	;	Structure of EPNH mutant of CEL-I
5T8Y	;	2.653	;	Structure of epoxyqueuosine reductase from Bacillus subtilis with the Asp134 catalytic loop swung out of the active site.
5D6S	;	2.65	;	Structure of epoxyqueuosine reductase from Streptococcus thermophilus.
1G6T	;	1.6	;	STRUCTURE OF EPSP SYNTHASE LIGANDED WITH SHIKIMATE-3-PHOSPHATE
1G6S	;	1.5	;	STRUCTURE OF EPSP SYNTHASE LIGANDED WITH SHIKIMATE-3-PHOSPHATE AND GLYPHOSATE
1I6B	;	3.2	;	STRUCTURE OF EQUINE APOLACTOFERRIN AT 3.2 A RESOLUTION USING CRYSTALS GROWN AT 303K
6Q0M	;	1.2	;	Structure of Erbin PDZ derivative E-14 with a high-affinity peptide
6DEX	;	2.1	;	Structure of Eremothecium gossypii Shu1:Shu2 complex
1W9G	;	2.0	;	Structure of ERH (Enhencer of Rudimentary Gene)
7EJS	;	2.387	;	Structure of ERH-2 bound to PICS-1
7EJO	;	2.191	;	Structure of ERH-2 bound to TOST-1
3R63	;	1.7	;	Structure of ERK2 (SPE) mutant (S246E)
1HZM	;		;	STRUCTURE OF ERK2 BINDING DOMAIN OF MAPK PHOSPHATASE MKP-3: STRUCTURAL INSIGHTS INTO MKP-3 ACTIVATION BY ERK2
4QTE	;	1.5	;	Structure of ERK2 in complex with VTX-11e, 4-{2-[(2-CHLORO-4-FLUOROPHENYL)AMINO]-5-METHYLPYRIMIDIN-4-YL}-N-[(1S)-1-(3-CHLOROPHENYL)-2-HYDROXYETHYL]-1H-PYRROLE-2-CARBOXAMIDE
7NSP	;	3.5	;	Structure of ErmDL-Erythromycin-stalled 70S E. coli ribosomal complex with A and P-tRNA
7NSO	;	2.9	;	Structure of ErmDL-Erythromycin-stalled 70S E. coli ribosomal complex with P-tRNA
7NSQ	;	3.1	;	Structure of ErmDL-Telithromycin-stalled 70S E. coli ribosomal complex with A and P-tRNA
1RP4	;	2.2	;	Structure of Ero1p, Source of Disulfide Bonds for Oxidative Protein Folding in the Cell
1RQ1	;	2.8	;	Structure of Ero1p, Source of Disulfide Bonds for Oxidative Protein Folding in the Cell
1ECA	;	1.4	;	STRUCTURE OF ERYTHROCRUORIN IN DIFFERENT LIGAND STATES REFINED AT 1.4 ANGSTROMS RESOLUTION
1ECD	;	1.4	;	STRUCTURE OF ERYTHROCRUORIN IN DIFFERENT LIGAND STATES REFINED AT 1.4 ANGSTROMS RESOLUTION
1ECN	;	1.4	;	STRUCTURE OF ERYTHROCRUORIN IN DIFFERENT LIGAND STATES REFINED AT 1.4 ANGSTROMS RESOLUTION
1ECO	;	1.4	;	STRUCTURE OF ERYTHROCRUORIN IN DIFFERENT LIGAND STATES REFINED AT 1.4 ANGSTROMS RESOLUTION
4GKV	;	2.008	;	Structure of Escherichia coli AdhP (ethanol-inducible dehydrogenase) with bound NAD
6V2M	;	1.66	;	Structure of Escherichia coli Asp269Asn mutant phosphoenolpyruvate carboxykinase
2BYW	;	1.7	;	Structure of Escherichia coli beta-ketoacyl (acyl carrier protein) synthase I LYS328ALA mutant
6OIY	;	3.29	;	Structure of Escherichia coli bound to dGTP
8FTD	;	2.76	;	Structure of Escherichia coli CedA in complex with transcription initiation complex
6OIW	;	3.35	;	Structure of Escherichia coli dGTPase bound to dGTP-1-thiol
6OIX	;	3.15	;	Structure of Escherichia coli dGTPase bound to GTP
6HDE	;	1.82	;	Structure of Escherichia coli dUTPase Q93H mutant
3JCD	;	3.7	;	Structure of Escherichia coli EF4 in posttranslocational ribosomes (Post EF4)
3JCE	;	3.2	;	Structure of Escherichia coli EF4 in pretranslocational ribosomes (Pre EF4)
2GLT	;	2.2	;	STRUCTURE OF ESCHERICHIA COLI GLUTATHIONE SYNTHETASE AT PH 6.0.
1GSH	;	2.0	;	STRUCTURE OF ESCHERICHIA COLI GLUTATHIONE SYNTHETASE AT PH 7.5
1P7T	;	1.95	;	Structure of Escherichia coli malate synthase G:pyruvate:acetyl-Coenzyme A abortive ternary complex at 1.95 angstrom resolution
4F9J	;	2.103	;	Structure of Escherichia coli PgaB 42-655 in complex with iron
4F9D	;	1.9	;	Structure of Escherichia coli PgaB 42-655 in complex with nickel
4P7R	;	1.8	;	Structure of Escherichia coli PgaB C-terminal domain in complex with a poly-beta-1,6-N-acetyl-D-glucosamine (PNAG) hexamer
4P7N	;	1.89	;	Structure of Escherichia coli PgaB C-terminal domain in complex with glucosamine
4P7Q	;	1.651	;	Structure of Escherichia coli PgaB C-terminal domain in complex with N-acetylglucosamine
4P7O	;	1.48	;	Structure of Escherichia coli PgaB C-terminal domain, P1 crystal form
4P7L	;	1.802	;	Structure of Escherichia coli PgaB C-terminal domain, P212121 crystal form
1EYZ	;	1.75	;	STRUCTURE OF ESCHERICHIA COLI PURT-ENCODED GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE COMPLEXED WITH MG AND AMPPNP
1EZ1	;	1.75	;	STRUCTURE OF ESCHERICHIA COLI PURT-ENCODED GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE COMPLEXED WITH MG, AMPPNP, AND GAR
1O8B	;	1.25	;	Structure of Escherichia coli ribose-5-phosphate isomerase, RpiA, complexed with arabinose-5-phosphate.
1BDF	;	2.5	;	STRUCTURE OF ESCHERICHIA COLI RNA POLYMERASE ALPHA SUBUNIT N-TERMINAL DOMAIN
4LNL	;	2.1	;	Structure of Escherichia coli Threonine Aldolase in Complex with Allo-Thr
4LNM	;	2.1	;	Structure of Escherichia coli Threonine Aldolase in Complex with Serine
4LNJ	;	2.1	;	Structure of Escherichia coli Threonine Aldolase in Unliganded Form
1WPB	;	2.0	;	Structure of Escherichia coli yfbU gene product
5KOA	;	2.67	;	Structure of Escherichia coli ZapD bound to the C-terminal tail of FtsZ
8AP4	;	3.0	;	Structure of Escherischia coli heat shock protein Hsp15 in complex with ribosomal 50S subunits bearing peptidyl-tRNA
6SP0	;	1.77	;	Structure of Esco2 acetyltransferase in complex with CoA
4WUU	;	3.047	;	Structure of ESK1 in complex with HLA-A*0201/WT1
4JCN	;	1.8	;	Structure of ESP, serine protease from Staphylococcus epidermidis
8AKO	;	2.293	;	Structure of EspB-EspK complex: the non-identical twin of the PE-PPE-EspG secretion mechanism.
3Q1C	;	1.596	;	Structure of EspG Protein
3PCR	;	2.5	;	Structure of EspG-Arf6 complex
3PCS	;	2.86	;	Structure of EspG-PAK2 autoinhibitory Ialpha3 helix complex
5VBA	;	2.27	;	Structure of EspG1 chaperone from the type VII (ESX-1) secretion system determined with the assistance of N-terminal T4 lysozyme fusion
4L4W	;	2.036	;	Structure of EspG3 chaperone from the type VII (ESX-3) secretion system
5SXL	;	2.46	;	Structure of EspG3 chaperone from the type VII (ESX-3) secretion system, space group P3221
4RCL	;	2.7	;	Structure of EspG3 chaperone from the type VII (ESX-3) secretion system, space group P43212
7VKJ	;	1.45	;	Structure of ESRP1 qRRM3 domain
8SPU	;	2.8	;	Structure of ESRRB nucleosome bound OCT4 at site c
3K7U	;	2.1	;	Structure of essential protein from Trypanosoma brucei
3K80	;	2.4	;	Structure of essential protein from Trypanosoma brucei
8BH9	;	2.09	;	Structure of Est1 from Candida Tropicalis in complex with TLC1 telomerase RNA fragment 427-435 / 496-504
8BH8	;	2.88	;	Structure of Est1 from Candida Tropicalis in complex with TLC1 telomerase RNA fragment 444-456
5AH1	;	1.2	;	Structure of EstA from Clostridium botulinum
7ATQ	;	1.59	;	Structure of EstD11 in complex with cyclohexane carboxylic acid
7AUY	;	2.28	;	Structure of EstD11 in complex with Fluorescein
7AV5	;	1.97	;	Structure of EstD11 in complex with Fluorescein
7AT4	;	1.7	;	Structure of EstD11 in complex with Naproxen
7AT3	;	1.4	;	Structure of EstD11 in complex with Naproxen and methanol
7ATF	;	1.2	;	Structure of EstD11 in complex with p-Nitrophenol
7NB5	;	2.13	;	Structure of EstD11 S144A in complex with naproxen p-nitrophenol ester
7ZR3	;	2.01	;	STRUCTURE OF ESTER-HYDROLASE EH0 FROM THE METAGENOME OF SORGHUM BICOLOR RHIZOSPHERE FROM THE HENFAES RESEARCH CENTRE (GWYNEDD, WALES)
6I8F	;	2.11	;	STRUCTURE OF ESTER-HYDROLASE EH1AB1 FROM THE METAGENOME OF LAKE ARREO
6RKY	;	2.79	;	STRUCTURE OF ESTER-HYDROLASE EH1AB1 FROM THE METAGENOME OF LAKE ARREO COMPLEXED WITH A DERIVATIVE OF BIPYRIDINE PHOSPHONATE
6I8D	;	3.2	;	STRUCTURE OF ESTER-HYDROLASE EH1AB1 FROM THE METAGENOME OF LAKE ARREO COMPLEXED WITH A DERIVATIVE OF BUTYL 4-NITROPHENYL HEXYLPHOSPHONATE
6RB0	;	2.35	;	STRUCTURE OF ESTER-HYDROLASE EH1AB1 FROM THE METAGENOME OF LAKE ARREO COMPLEXED WITH A DERIVATIVE OF METHYL 4-NITROPHENYL HEXYLPHOSPHONATE
6SXP	;	2.15	;	STRUCTURE OF ESTER-HYDROLASE EH3 FROM THE METAGENOME OF MARINE SEDIMENTS AT MILAZZO HARBOR (SICILY, ITALY)
8PC7	;	2.4	;	STRUCTURE OF ESTER-HYDROLASE EH3 FROM THE METAGENOME OF MARINE SEDIMENTS AT MILAZZO HARBOR (SICILY, ITALY) COMPLEXED WITH A DERIVATIVE OF BIPYRIDINE PHOSPHONATE
6SYL	;	2.95	;	STRUCTURE OF ESTER-HYDROLASE EH3 FROM THE METAGENOME OF MARINE SEDIMENTS AT MILAZZO HARBOR (SICILY, ITALY) COMPLEXED WITH A DERIVATIVE OF BUTYL 4-NITROPHENYL HEXYLPHOSPHONATE
7PP8	;	2.65	;	STRUCTURE OF ESTER-HYDROLASE EH7 FROM METAGENOME OF MARINE SEDIMENTS AT MILAZZO HARBOR (SICILY, ITALY) COMPLEXED WITH A DERIVATIVE OF METHYL 4-NITROPHENYL HEXYLPHOSPHONATE
7PP3	;	2.25	;	STRUCTURE OF ESTER-HYDROLASE EH7 FROM THE METAGENOME OF MARINE SEDIMENTS AT MILAZZO HARBOR (SICILY, ITALY)
7PU6	;	2.92	;	STRUCTURE OF ESTER-HYDROLASE EH7 FROM THE METAGENOME OF MARINE SEDIMENTS AT MILAZZO HARBOR (SICILY, ITALY) COMPLEXED WITH A DERIVATIVE OF OCTYL 4-NITROPHENYL HEXYLPHOSPHONATE
5HC4	;	2.0	;	Structure of esterase Est22
5HC2	;	1.986	;	Structure of esterase Est22 mutant-S188A with p-nitrophenol
5HC0	;	1.4	;	Structure of esterase Est22 with p-nitrophenol
7U1C	;	2.09	;	Structure of EstG crystalized with SO4 and Tris
2J7X	;	2.1	;	STRUCTURE OF ESTRADIOL-BOUND ESTROGEN RECEPTOR BETA LBD IN COMPLEX WITH LXXLL MOTIF FROM NCOA5
4XY3	;	3.04	;	Structure of ESX-1 secreted protein EspB
6LAR	;	3.7	;	Structure of ESX-3 complex
4XP8	;	2.03	;	Structure of EtgA D60N mutant
2QW8	;	1.6	;	Structure of Eugenol Synthase from Ocimum basilicum
2QX7	;	1.75	;	Structure of Eugenol Synthase from Ocimum basilicum
2QYS	;	1.8	;	Structure of Eugenol Synthase from Ocimum basilicum
2QZZ	;	1.6	;	Structure of Eugenol Synthase from Ocimum basilicum
2R6J	;	1.5	;	Structure of Eugenol Synthase from Ocimum basilicum
2R2G	;	1.8	;	Structure of Eugenol Synthase from Ocimum basilicum complexed with EMDF
5U8S	;	6.1	;	Structure of eukaryotic CMG helicase at a replication fork
5U8T	;	4.9	;	Structure of Eukaryotic CMG Helicase at a Replication Fork and Implications
4U0S	;	2.49	;	Structure of Eukaryotic fic domain containing protein with ADP
3K8T	;	2.1	;	Structure of eukaryotic rnr large subunit R1 complexed with designed adp analog compound
5K4B	;	1.399	;	Structure of eukaryotic translation initiation factor 3 subunit D (eIF3d) cap binding domain from Nasonia vitripennis, Crystal form 1
5K4C	;	1.698	;	Structure of eukaryotic translation initiation factor 3 subunit D (eIF3d) cap binding domain from Nasonia vitripennis, Crystal form 2
5K4D	;	2.0	;	Structure of eukaryotic translation initiation factor 3 subunit D (eIF3d) cap binding domain from Nasonia vitripennis, Crystal form 3
3ZWL	;	2.2	;	Structure of eukaryotic translation initiation factor eIF3i complex with eIF3b C-terminus (655-700)
3MPV	;	2.6	;	Structure of EUTL in the zinc-induced open form
3MPW	;	2.7	;	Structure of EUTM in 2-D protein membrane
3MPY	;	2.0	;	Structure of EUTM in 2-D protein membrane
3SJO	;	1.702	;	structure of EV71 3C in complex with Rupintrivir (AG7088)
6I2K	;	3.4	;	Structure of EV71 complexed with its receptor SCARB2
6Z3Q	;	2.7	;	Structure of EV71 in complex with a protective antibody 38-1-10A Fab
6Z3P	;	2.8	;	Structure of EV71 in complex with a protective antibody 38-3-11A Fab
8HI2	;	3.2	;	Structure of EV71 VLP frozen at -183 degree embedded in crystalline ice
4BWB	;	3.57	;	Structure of Evolved Agonist-bound Neurotensin Receptor 1 Mutant without Lysozyme Fusion
6YE4	;	3.2	;	Structure of ExbB pentamer from Serratia marcescens by single particle cryo electron microscopy
7LJ2	;	2.4	;	Structure of Exo-L-galactose-6-sulfatase BuS1_11 from Bacteroides uniformis in complex with neoporphyrabiose
2MHX	;		;	Structure of Exocyclic R,R N6,N6-(2,3-Dihydroxy-1,4-butadiyl)-2'-Deoxyadenosine Adduct Induced by 1,2,3,4-Diepoxybutane in DNA
2MHZ	;		;	Structure of Exocyclic S,S N6,N6-(2,3-Dihydroxy-1,4-butadiyl)-2'-Deoxyadenosine Adduct Induced by 1,2,3,4-Diepoxybutane in DNA
4Q66	;	3.354	;	Structure of Exomer bound to Arf1.
6JNP	;	2.261	;	Structure of ExoT-SpcS Complex from Pseudomonas aeruginosa in 2.2 Angstrom
7USW	;	3.1	;	Structure of Expanded C. elegans TMC-1 complex
6EYO	;	3.7	;	Structure of extended IgE-Fc in complex with two anti-IgE Fabs
4B9X	;	2.8	;	Structure of extended Tudor domain TD3 from mouse TDRD1
4B9W	;	2.1	;	Structure of extended Tudor domain TD3 from mouse TDRD1 in complex with MILI peptide containing dimethylarginine 45.
3O8E	;	2.84	;	Structure of extracelllar portion of CD46 in complex with Adenovirus type 11 knob
5UMO	;	2.26	;	STRUCTURE OF EXTRACELLULAR SIGNAL-REGULATED KINASE
5L80	;	2.8	;	Structure of Exuperantia EXO-like and SAM-like domains
5L7Z	;	2.37	;	Structure of Exuperantia EXO-like domain
2D1L	;	1.85	;	Structure of F-actin binding domain IMD of MIM (Missing In Metastasis)
5LQY	;	7.8	;	Structure of F-ATPase from Pichia angusta, in state2
5LQZ	;	7.0	;	Structure of F-ATPase from Pichia angusta, state1
5LQX	;	7.9	;	Structure of F-ATPase from Pichia angusta, state3
6ALX	;	3.3	;	Structure of F. tularensis MglA-SspA solved in the presence of polyP
2MU4	;		;	Structure of F. tularensis Virulence Determinant
2YJR	;	1.9	;	Structure of F1174L Mutant Anaplastic Lymphoma Kinase
6R0E	;	1.91	;	Structure of F11TCR in complex with DR1 MHC Class II presenting PKYVKQNTLKLAT
2IJI	;	2.3	;	Structure of F14H mutant of ColE1 Rom protein
4AK8	;	1.4	;	Structure of F241L mutant of langerin carbohydrate recognition domain.
5I6V	;	1.87	;	Structure of F285S, a Cancer-Associated Mutation of the Oncogenic Phosphatase SHP2
4CSZ	;	1.75	;	STRUCTURE OF F306C MUTANT OF NITRITE REDUCTASE FROM Achromobacter XYLOSOXIDANS WITH NITRITE BOUND
3TTT	;	1.58	;	Structure of F413Y variant of E. coli KatE
3TTU	;	1.89	;	Structure of F413Y/H128N double variant of E. coli KatE
7KL8	;	2.469	;	Structure of F420 binding protein Rv1558 from Mycobacterium tuberculosis with F420 bound
4ZKY	;	1.65	;	Structure of F420 binding protein, MSMEG_6526, from Mycobacterium smegmatis
5JV4	;	1.7	;	Structure of F420 binding protein, MSMEG_6526, from Mycobacterium smegmatis with F420 bound
3IQF	;	2.1	;	Structure of F420 dependent methylene-tetrahydromethanopterin dehydrogenase in complex with methenyl-tetrahydromethanopterin
3IQZ	;	2.1	;	Structure of F420 dependent methylene-tetrahydromethanopterin dehydrogenase in complex with methylene-tetrahydromethanopterin
3IQE	;	1.8	;	Structure of F420 dependent methylene-tetrahydromethanopterin dehydrogenase in complex with methylene-tetrahydromethanopterin and coenzyme F420
6WTA	;	1.67	;	Structure of F420-H2 Dependent Oxidoreductase (FDOR-A) MSMEG_2027 in complex with F420
4Y9I	;	1.498	;	Structure of F420-H2 Dependent Reductase (FDR-A) msmeg_2027
6FRN	;	1.74	;	Structure of F420H2 oxidase (FprA) co-crystallized with 10mM Tb-Xo4 and calcium chloride
1MX2	;	2.25	;	Structure of F71N mutant of p18INK4c
4DO3	;	2.25	;	Structure of FAAH with a non-steroidal anti-inflammatory drug
2LYH	;		;	Structure of Faap24 residues 141-215
2I9L	;	3.1	;	Structure of Fab 7D11 from a neutralizing antibody against the poxvirus L1 protein
7ST5	;	2.2	;	Structure of Fab CC-95251 in complex with SIRP-alpha
2FR4	;	1.95	;	Structure of Fab DNA-1 complexed with a stem-loop DNA ligand
1XF2	;	2.3	;	Structure of Fab DNA-1 complexed with dT3
3S62	;	4.01	;	Structure of Fab fragment of malaria transmission blocking antibody 2A8 against P. vivax P25 protein
2W9D	;	1.57	;	Structure of Fab fragment of the ICSM 18 - anti-Prp therapeutic antibody at 1.57 A resolution.
6VI1	;	2.4	;	Structure of Fab4 bound to P22 TerL(1-33)
6XMI	;	1.51	;	Structure of Fab4 bound to P22 TerL(1-33)
5GVJ	;	1.9	;	Structure of FabK (M276A) mutant from Thermotoga maritima
5GVH	;	2.294	;	Structure of FabK from Thermotoga maritima
7YF1	;	1.7	;	Structure of FABP at 1.7 Angstroms resolution.
2XQW	;	2.306	;	Structure of Factor H domains 19-20 in complex with complement C3d
4Z1V	;	2.1	;	Structure of Factor Inhibiting HIF (FIH) in complex with Fe, NO, and NOG
4JYU	;	1.8	;	Structure of factor VIIA in complex with the inhibitor (2R)-2-[(1-AMINOISOQUINOLIN-6-YL)AMINO]-2-[3-ETHOXY-4-(PROPAN-2-YLOXY)PHENYL]-N-(PHENYLSULFONYL)ETHANAMIDE
4JYV	;	2.19	;	Structure of factor VIIA in complex with the inhibitor (2R)-2-[3-ETHOXY-4-(PROPAN-2-YLOXY)PHENYL]-2-(ISOQUINOLIN-6-YLAMINO)-N-[(3-SULFAMOYLPHENYL)SULFONYL]ETHANAMIDE
4ISI	;	1.94	;	Structure of FACTOR VIIA in complex with the inhibitor (6S)-N-(4-CARBAMIMIDOYLBENZYL)-1-CHLORO-3-(CYCLOBUTYLAMINO)-8,8-DIETHYL-4-OXO-4,6,7,8-TETRAHYDROPYRROLO[1,2-A]PYRAZINE-6-CARBOXAMIDE
4JZE	;	1.52	;	Structure of factor VIIA in complex with the inhibitor 2-{2-[(1-aminoisoquinolin-6-yl)carbamoyl]-6-methoxypyridin-3-yl}-5-{[(2S)-1-hydroxy-3,3-dimethylbutan-2-yl]carbamoyl}benzoic acid
4JZF	;	1.84	;	Structure of factor VIIA in complex with the inhibitor 2-{2-[(3-carbamoylphenyl)carbamoyl]-6-methoxypyridin-3-yl}-5-{[(2S)-1-hydroxy-3,3-dimethylbutan-2-yl]carbamoyl}benzoic acid
4JZD	;	2.2	;	Structure of factor VIIA in complex with the inhibitor 2-{2-[(4-carbamimidoylphenyl)carbamoyl]-6-methoxypyridin-3-yl}-5-{[(2S)-1-hydroxy-3,3-dimethylbutan-2-yl]carbamoyl}benzoic acid
4ISH	;	1.82	;	Structure of FACTOR VIIA in complex with the inhibitor BMS-593214 also known as 2'-[(6R,6AR,11BR)-2-CARBAMIMIDOYL-6,6A,7,11B-TETRAHYDRO-5H-INDENO[2,1-C]QUINOLIN-6-YL]-5'-HYDROXY-4'-METHOXYBIPHENYL-4-CARBOXYLIC ACID
6UPK	;	4.9	;	Structure of FACT_subnucleosome complex 1
6UPL	;	7.4	;	Structure of FACT_subnucleosome complex 2
5EY9	;	2.5	;	Structure of FadD32 from Mycobacterium marinum complexed to AMPC12
5EY8	;	3.5	;	Structure of FadD32 from Mycobacterium smegmatis complexed to AMPC20
6FJ4	;	1.7	;	Structure of FAE solved by SAD from data collected at the peak of the Selenium absorption edge on ID30B
5FXM	;	1.99	;	Structure of FAE solved by SAD from data collected by Direct Data Collection (DDC) using the ESRF RoboDiff goniometer
3ZI7	;	2.3	;	STRUCTURE OF FAE SOLVED BY SAD FROM DATA COLLECTED BY DIRECT DATA COLLECTION (DDC) USING THE GROB ROBOT GONIOMETER
8GT0	;	3.28	;	Structure of falcipain and human Stefin A complex
8GT7	;	3.28	;	Structure of falcipain and human Stefin A mutant complex
1J83	;	1.7	;	STRUCTURE OF FAM17 CARBOHYDRATE BINDING MODULE FROM CLOSTRIDIUM CELLULOVORANS
1J84	;	2.02	;	STRUCTURE OF FAM17 CARBOHYDRATE BINDING MODULE FROM CLOSTRIDIUM CELLULOVORANS WITH BOUND CELLOTETRAOSE
2YOQ	;	2.35	;	Structure of FAM3B PANDER E30 construct
2WC3	;	2.0	;	Structure of family 1 beta-glucosidase from Thermotoga maritima in complex with 3-imino-2-oxa-(+)-8-epi-castanospermine
2WBG	;	1.85	;	Structure of family 1 beta-glucosidase from Thermotoga maritima in complex with 3-imino-2-oxa-(+)-castanospermine
2WC4	;	1.7	;	Structure of family 1 beta-glucosidase from Thermotoga maritima in complex with 3-imino-2-thia-(+)-castanospermine
2WYN	;	2.1	;	Structure of family 37 trehalase from Escherichia coli in complex with a casuarine-6-O-a-D-glucoside analogue
2W9M	;	2.46	;	Structure of family X DNA polymerase from Deinococcus radiodurans
6LHV	;	4.59	;	Structure of FANCA and FANCG Complex
6TNI	;	3.4	;	Structure of FANCD2 homodimer
6TNG	;	4.1	;	Structure of FANCD2 in complex with FANCI
3S51	;	3.3	;	Structure of FANCI
3RGU	;	3.0	;	Structure of Fap-NRa at pH 5.0
8PXC	;	1.973	;	Structure of Fap1, a domain of the accessory Sec-dependent serine-rich glycoprotein adhesin from Streptococcus oralis, solved at wavelength 3.06 A
2R2L	;	2.23	;	Structure of Farnesyl Protein Transferase bound to PB-93
1UBV	;	2.5	;	STRUCTURE OF FARNESYL PYROPHOSPHATE SYNTHETASE
1UBW	;	2.5	;	STRUCTURE OF FARNESYL PYROPHOSPHATE SYNTHETASE
1UBX	;	2.5	;	STRUCTURE OF FARNESYL PYROPHOSPHATE SYNTHETASE
1UBY	;	2.4	;	STRUCTURE OF FARNESYL PYROPHOSPHATE SYNTHETASE
3P53	;	2.0	;	Structure of fascin
5NCC	;	3.12	;	Structure of Fatty acid Photodecarboxylase in complex with FAD and palmitic acid
6QL6	;	2.9	;	Structure of Fatty acid synthase complex from Saccharomyces cerevisiae at 2.9 Angstrom
6QL9	;	2.82	;	Structure of Fatty acid synthase complex from Saccharomyces cerevisiae at 2.9 Angstrom
6QL5	;	2.8	;	Structure of fatty acid synthase complex with bound gamma subunit from Saccharomyces cerevisiae at 2.8 angstrom
6QL7	;	4.6	;	Structure of fatty acid synthase complex with bound gamma subunit from Saccharomyces cerevisiae at 4.6 angstrom
3V5X	;	1.85	;	Structure of FBXL5 hemerythrin domain, C2 cell
3V5Z	;	2.1847	;	Structure of FBXL5 hemerythrin domain, C2 cell, grown anaerobically
3V5Y	;	2.1	;	Structure of FBXL5 hemerythrin domain, P2(1) cell
4X4M	;	3.485	;	Structure of FcgammaRI in complex with Fc reveals the importance of glycan recognition for high affinity IgG binding
8J7Z	;	2.72	;	Structure of FCP trimer in Cyclotella meneghiniana
5U8Z	;	1.9	;	Structure of Fe-CAO1 in complex with beta-fluororesveratrol
1T47	;	2.5	;	Structure of fe2-HPPD bound to NTBC
1B11	;	1.9	;	STRUCTURE OF FELINE IMMUNODEFICIENCY VIRUS PROTEASE COMPLEXED WITH TL-3-093
6LF0	;	2.11	;	Structure of FEM1C
3B8M	;	2.7	;	Structure of FepE- Bacterial Polysaccharide Co-polymerase
3B8N	;	3.1	;	Structure of FepE- Bacterial Polysaccharide Co-polymerase
7C3M	;	3.6	;	Structure of FERM protein
1XER	;	2.0	;	STRUCTURE OF FERREDOXIN
2CJO	;		;	STRUCTURE OF FERREDOXIN, NMR, 10 STRUCTURES
2CJN	;		;	STRUCTURE OF FERREDOXIN, NMR, MINIMIZED AVERAGE STRUCTURE
1GR1	;	2.5	;	Structure of Ferredoxin-NADP+ Reductase with Glu 139 replaced by Lys (E139K)
1GO2	;	1.7	;	Structure of Ferredoxin-NADP+ Reductase with Lys 72 replaced by Glu (K72E)
1H5A	;	1.6	;	STRUCTURE OF FERRIC HORSERADISH PEROXIDASE C1A IN COMPLEX WITH ACETATE
5NHK	;	1.8	;	Structure of Ferric uptake regulator from francisella tularensis with Iron
6H1C	;	2.34	;	Structure of Ferric uptake regulator from Pseudomonas aeruginosa with manganese.
2CCY	;	1.67	;	STRUCTURE OF FERRICYTOCHROME C(PRIME) FROM RHODOSPIRILLUM MOLISCHIANUM AT 1.67 ANGSTROMS RESOLUTION
1V3W	;	1.5	;	Structure of Ferripyochelin binding protein from Pyrococcus horikoshii OT3
1V67	;	2.3	;	Structure of ferripyochelin binding protein from pyrococcus horikoshii OT3
1C9E	;	2.3	;	STRUCTURE OF FERROCHELATASE WITH COPPER(II) N-METHYLMESOPORPHYRIN COMPLEX BOUND AT THE ACTIVE SITE
1H58	;	1.7	;	STRUCTURE OF FERROUS HORSERADISH PEROXIDASE C1A
6RPD	;	1.52	;	Structure of ferrous KpDyP in complex with cyanide
4XAE	;	2.769	;	Structure of Feruloyl-CoA 6-hydroxylase (F6H) from Arabidopsis thaliana
5ABR	;	2.11	;	Structure of FeSI protein from Azotobacter vinelandii
6YAV	;	1.65	;	Structure of FeSII (Shethna) protein from Azotobacter vinelandii
8EIT	;	2.8	;	Structure of FFAR1-Gq complex bound to DHA
8EJC	;	3.0	;	Structure of FFAR1-Gq complex bound to TAK-875
8EJK	;	3.4	;	Structure of FFAR1-Gq complex bound to TAK-875 in a lipid nanodisc
6YJI	;	1.64	;	Structure of FgCelDH7C
6YJO	;	2.38	;	Structure of FgChi7B
4WUN	;	1.65	;	Structure of FGFR1 in complex with AZD4547 (N-{3-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R,5S)-3,5-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) at 1.65 angstrom
2MIU	;		;	Structure of FHL2 LIM adaptor and its Interaction with Ski
4FIL	;	2.4	;	Structure of FhuD2 from Staphylococcus Aureus with Bound Ferrioxamine B
1G82	;	2.6	;	STRUCTURE OF FIBROBLAST GROWTH FACTOR 9
8AFO	;	1.99	;	Structure of fibronectin 2 and 3 of L1CAM at 2.0 Angstrom
8AFP	;	3.0	;	Structure of fibronectin 2 and 3 of L1CAM at 3.0 Angstrom
3R8Q	;	2.4	;	Structure of Fibronectin domain 12-14
3RGH	;	2.44	;	Structure of filamin A immunoglobulin-like repeat 10 from Homo sapiens
6JZK	;	2.1	;	Structure of FimA type-1 (FimA1) prepilin of the type V major fimbrium
6JZJ	;	1.6	;	Structure of FimA type-2 (FimA2) prepilin of the type V major fimbrium
6Y6A	;	2.65	;	Structure of Finch Polyomavirus VP1 in complex with 2-O-Methyl-5-N-acetyl-alpha-D-neuraminic acid
5EU8	;	2.447	;	Structure of FIPV main protease in complex with dual inhibitors
2V31	;		;	Structure of First Catalytic Cysteine Half-domain of mouse ubiquitin- activating enzyme
2LAX	;		;	Structure of first WW domain of human YAP in complex with a human Smad1 doubly-phosphorilated derived peptide.
6S1L	;	1.94	;	Structure of fission yeast Mis16
6S1R	;	1.8	;	Structure of fission yeast Mis16 bound to histone H4
6S29	;	1.988	;	Structure of fission yeast Mis16-Mis19 complex
4XPZ	;	1.45	;	Structure of fission yeast RNA polymerase II CTD phosphatase Fcp1-R271A bound to aluminum fluoride
4XQ0	;	1.85	;	Structure of fission yeast RNA polymerase II CTD phosphatase Fcp1-R271A bound to beryllium fluoride
6HKG	;	1.87	;	Structure of FISW84 Fab Fragment
2H1O	;	3.0	;	Structure of FitAB bound to IR36 DNA fragment
5J90	;	1.3932	;	Structure of Fjoh_4558, a chitin-binding SusD homolog from Flavobacterium johnsoniae
1ROU	;		;	STRUCTURE OF FKBP59-I, THE N-TERMINAL DOMAIN OF A 59 KDA FK506-BINDING PROTEIN, NMR, 22 STRUCTURES
1ROT	;		;	STRUCTURE OF FKBP59-I, THE N-TERMINAL DOMAIN OF A 59 KDA FK506-BINDING PROTEIN, NMR, MINIMIZED AVERAGE STRUCTURE
4YG7	;	3.77	;	Structure of FL autorepression promoter complex
8CIH	;	2.0	;	Structure of FL CINP
4USQ	;	2.39	;	Structure of flavin-containing monooxygenase from Cellvibrio sp. BR
4USR	;	1.83	;	Structure of flavin-containing monooxygenase from Pseudomonas stutzeri NF13
5BVA	;	1.873	;	Structure of flavin-dependent brominase Bmp2
5BUL	;	1.9784	;	Structure of flavin-dependent brominase Bmp2 triple mutant Y302S F306V A345W
5BUK	;	1.95	;	Structure of flavin-dependent chlorinase Mpy16
8I8Z	;	2.4	;	Structure of flavone 4'-O-glucoside 7-O-glucosyltransferase from Nemophila menziesii, apo form
8I94	;	2.43	;	Structure of flavone 4'-O-glucoside 7-O-glucosyltransferase from Nemophila menziesii, complex with luteolin
8I90	;	2.1	;	Structure of flavone 4'-O-glucoside 7-O-glucosyltransferase from Nemophila menziesii, complex with UDP-glucose
5J1J	;	1.55	;	Structure of FleN-AMPPNP complex
3W1E	;	2.0	;	Structure of FlgT, a flagellar basal body component protein
3AJW	;	2.1	;	Structure of FliJ, a soluble component of flagellar type III export apparatus
2HP7	;	2.0	;	Structure of FliM provides insight into assembly of the switch complex in the bacterial flagella motor
1J2O	;		;	Structure of FLIN2, a complex containing the N-terminal LIM domain of LMO2 and ldb1-LID
6LEA	;	2.95	;	Structure of FliS chaperone in complex with flagellin and HP1076
3A7M	;	3.2	;	Structure of FliT, the flagellar type III chaperone for FliD
5XR1	;		;	Structure of FLN IG21 domain in complex with C-terminal peptide of beta-2
3AXY	;	2.4	;	Structure of Florigen Activation Complex Consisting of Rice Florigen Hd3a, 14-3-3 Protein GF14 and Rice FD Homolog OsFD1
5B6I	;	1.95	;	Structure of fluorinase from Streptomyces sp. MA37
1Y37	;	1.5	;	Structure of Fluoroacetate Dehalogenase from Burkholderia sp. FA1
4GDN	;	3.2	;	Structure of FmtA-like protein
7JGU	;	1.2	;	Structure of FN3tt mut
4I4F	;	1.75	;	Structure of Focal Adhesion Kinase catalytic domain in complex with an allosteric binding pyrazolobenzothiazine compound.
4I4E	;	1.55	;	Structure of Focal Adhesion Kinase catalytic domain in complex with hinge binding pyrazolobenzothiazine compound.
4EBV	;	1.67	;	Structure of Focal Adhesion Kinase catalytic domain in complex with novel allosteric inhibitor
4EBW	;	2.65	;	Structure of Focal Adhesion Kinase catalytic domain in complex with novel allosteric inhibitor
8EE7	;	2.72	;	Structure of focused PtuA(dimer) and PtuB(monomer) complex
4AY9	;	2.5	;	Structure of follicle-stimulating hormone in complex with the entire ectodomain of its receptor
4MQW	;	2.9	;	Structure of follicle-stimulating hormone in complex with the entire ectodomain of its receptor (P31)
6PTI	;	1.7	;	STRUCTURE OF FORM III CRYSTALS OF BOVINE PANCREATIC TRYPSIN INHIBITOR
7Q1Z	;	3.4	;	Structure of formaldehyde cross-linked SARS-CoV-2 S glycoprotein
3KCU	;	2.243	;	Structure of formate channel
3KCV	;	3.198	;	Structure of formate channel
1T3T	;	1.9	;	Structure of Formylglycinamide synthetase
6S07	;	1.04	;	Structure of formylglycine-generating enzyme at 1.04 A in complex with copper and substrate reveals an acidic pocket for binding and acti-vation of molecular oxygen.
3OEE	;	2.74	;	Structure of four mutant forms of yeast F1 ATPase: alpha-F405S
3OFN	;	3.2	;	Structure of four mutant forms of yeast F1 ATPase: alpha-N67I
3OEH	;	3.0	;	Structure of four mutant forms of yeast F1 ATPase: beta-V279F
3OE7	;	3.19	;	Structure of four mutant forms of yeast f1 ATPase: gamma-I270T
7DJK	;	2.80145	;	Structure of four truncated and mutated forms of quenching protein
7DJL	;	2.96078	;	Structure of four truncated and mutated forms of quenching protein
7DJM	;	1.7	;	Structure of four truncated and mutated forms of quenching protein
7DJJ	;	2.69806	;	Structure of four truncated and mutated forms of quenching protein lumenal domains
7CBY	;	1.646	;	Structure of FOXG1 DNA binding domain bound to DBE2 DNA site
7FJ2	;	3.098	;	Structure of FOXM1 homodimer bound to a palindromic DNA site
7TDW	;	4.0	;	Structure of FOXP3-DNA complex
7TDX	;	3.1	;	Structure of FOXP3-DNA complex
3KSL	;	2.05	;	Structure of FPT bound to DATFP-DH-GPP
1O1R	;	2.3	;	Structure of FPT bound to GGPP
2BED	;	2.7	;	Structure of FPT bound to inhibitor SCH207736
1O1S	;	2.3	;	Structure of FPT bound to isoprenoid analog 3b
1O1T	;	2.1	;	Structure of FPT bound to the CVIM-FPP product
1O5M	;	2.3	;	Structure of FPT bound to the inhibitor SCH66336
6K2G	;	2.22	;	Structure of FraE in the monomer state
6I70	;	2.1	;	Structure of Fragaria ananassa O-methyltransferase - apo form
6YJW	;	2.1	;	Structure of Fragaria ananassa O-methyltransferase crystallized with PAS polypeptide
6I71	;	1.4	;	Structure of Fragaria ananassa O-methyltransferase in complex with S-adenosylhomocysteine
6I72	;	1.5	;	Structure of Fragaria ananassa O-methyltransferase in complex with S-adenosylhomocysteine and caffeic acid
6I73	;	1.35	;	Structure of Fragaria ananassa O-methyltransferase in complex with S-adenosylhomocysteine and protocatechuic aldehyde
2R8U	;	1.35	;	Structure of fragment of human end-binding protein 1 (EB1) containing the N-terminal domain at 1.35 A resolution
6U9G	;	3.98	;	Structure of Francisella PdpA-VgrG Complex, half-lidded
6U9F	;	4.35	;	Structure of Francisella PdpA-VgrG Complex, Lidded
2D1G	;	1.75	;	Structure of Francisella tularensis Acid Phosphatase A (AcpA) bound to orthovanadate
5U56	;	2.65	;	Structure of Francisella tularensis heterodimeric SspA (MglA-SspA)
5U51	;	2.8	;	Structure of Francisella tularensis heterodimeric SspA (MglA-SspA) in complex with ppGpp
4DOV	;	1.696	;	Structure of free mouse ORC1 BAH domain
3BWQ	;	2.3	;	Structure of free SV40 VP1 pentamer
7MTC	;	2.6	;	Structure of freshly purified SARS-CoV-2 S2P spike at pH 7.4
1QMO	;	3.5	;	Structure of FRIL, a legume lectin that delays hematopoietic progenitor maturation
3RFB	;	2.3	;	Structure of fRMsr
3KSI	;	1.7	;	structure of fRMsr of Staphylococcus aureus (complex with 2-propanol)
3KSG	;	2.3	;	structure of fRMsr of Staphylococcus aureus (complex with substrate)
3KSH	;	1.5	;	Structure of fRMsr of Staphylococcus aureus (oxidized form)
3KSF	;	1.9	;	structure of fRMsr of Staphylococcus aureus (reduced form)
5XWH	;	2.0	;	Structure of FrnE, a novel disulfide oxidoreductase from Deinococcus radiodurans crystallized in the presence of GSH
8BEQ	;	2.07	;	Structure of fructofuranosidase from Rhodotorula dairenensis
3KF3	;	1.9	;	Structure of fructofuranosidase from Schwanniomyces occidentalis complexed with fructose
5ANN	;	2.14	;	Structure of fructofuranosidase from Xanthophyllomyces dendrorhous
1DOS	;	1.67	;	STRUCTURE OF FRUCTOSE-BISPHOSPHATE ALDOLASE
4RSL	;	1.9	;	Structure of fructosyl peptide oxidase from E. terrenum
1LR9	;	2.5	;	STRUCTURE OF Fs1, THE HEPARIN-BINDING DOMAIN OF FOLLISTATIN
5K6D	;	1.139	;	Structure of FS50 an antagonist of NaV1.5
6JZA	;	2.3	;	Structure of Fstl1
6WEG	;	2.95	;	Structure of Ft (MglA-SspA)-ppGpp-PigR peptide complex
4Y5T	;	1.949	;	Structure of FtmOx1 apo with metal Iron
4Y5S	;	2.543	;	Structure of FtmOx1 with a-Ketoglutarate as co-substrate
2Q9B	;	2.3	;	Structure of FTSY:GMPPNP Complex
2Q9C	;	2.2	;	Structure of FTSY:GMPPNP with MGCL Complex
6Q8H	;	1.707	;	Structure of Fucosylated D-antimicrobial peptide SB10 in complex with the Fucose-binding lectin PA-IIL at 1.707 Angstrom resolution
6Q87	;	2.541	;	Structure of Fucosylated D-antimicrobial peptide SB10 in complex with the Fucose-binding lectin PA-IIL at 2.541 Angstrom resolution
6Q85	;	1.99	;	Structure of Fucosylated D-antimicrobial peptide SB11 in complex with the Fucose-binding lectin PA-IIL at 1.990 Angstrom resolution
6Q77	;	2.002	;	Structure of Fucosylated D-antimicrobial peptide SB12 in complex with the Fucose-binding lectin PA-IIL at 2.002 Angstrom resolution
6Q8D	;	1.63	;	Structure of Fucosylated D-antimicrobial peptide SB15 in complex with the Fucose-binding lectin PA-IIL at 1.630 Angstrom resolution
6Q86	;	2.008	;	Structure of Fucosylated D-antimicrobial peptide SB4 in complex with the Fucose-binding lectin PA-IIL at 2.008 Angstrom resolution
6Q79	;	2.009	;	Structure of Fucosylated D-antimicrobial peptide SB4 in complex with the Fucose-binding lectin PA-IIL at 2.009 Angstrom resolution
6Q6W	;	1.438	;	Structure of Fucosylated D-antimicrobial peptide SB5 in complex with the Fucose-binding lectin PA-IIL at 1.438 Angstrom resolution
6Q6X	;	1.525	;	Structure of Fucosylated D-antimicrobial peptide SB6 in complex with the Fucose-binding lectin PA-IIL at 1.525 Angstrom resolution
6Q8G	;	1.19	;	Structure of Fucosylated D-antimicrobial peptide SB8 in complex with the Fucose-binding lectin PA-IIL at 1.190 Angstrom resolution
8K42	;	2.64	;	Structure of full Banna virus
8W9P	;	2.7	;	Structure of full Banna virus
7LSW	;	3.05	;	Structure of Full Beta-Hairpin LIR from FNIP2 Bound to GABARAP
4EC8	;	3.6	;	Structure of full length CDK9 in complex with cyclinT and DRB
4W8Y	;	3.0	;	Structure of full length Cmr2 from Pyrococcus furiosus (Manganese bound form)
5LOE	;	3.0	;	Structure of full length Cody from Bacillus subtilis in complex with Ile
2O1V	;	2.45	;	Structure of full length GRP94 with ADP bound
2O1U	;	2.4	;	Structure of full length GRP94 with AMP-PNP bound
7MYJ	;	2.95	;	Structure of full length human AMPK (a2b1g1) in complex with a small molecule activator MSG011
6B2E	;	3.8	;	Structure of full length human AMPK (a2b2g1) in complex with a small molecule activator SC4.
5ISO	;	2.63	;	STRUCTURE OF FULL LENGTH HUMAN AMPK (NON-PHOSPHORYLATED AT T-LOOP) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR, A BENZIMIDAZOLE DERIVATIVE (991)
4CFE	;	3.023	;	Structure of full length human AMPK in complex with a small molecule activator, a benzimidazole derivative (991)
4CFF	;	3.924	;	Structure of full length human AMPK in complex with a small molecule activator, a thienopyridone derivative (A-769662)
8TZF	;	3.4	;	Structure of full length LRRK2 bound to GZD-824 (I2020T mutant)
7QPR	;	2.513	;	Structure of full length SpoT
2F8V	;	2.75	;	Structure of full length telethonin in complex with the N-terminus of titin
2GAJ	;	1.95	;	Structure of Full Length Topoisomerase I from Thermotoga maritima in monoclinic crystal form
2GAI	;	1.7	;	Structure of Full Length Topoisomerase I from Thermotoga maritima in triclinic crystal form
5LNH	;	3.0	;	Structure of full length Unliganded CodY from Bacillus subtilis
5LOJ	;	3.71	;	Structure of full length unliganded CodY from Bacillus subtilis
5LOO	;	4.5	;	Structure of full length unliganded CodY from Bacillus subtilis
8FO3	;	2.0	;	Structure of full-length amyloidogenic immunoglobulin light chain H9 in complex with (E)-3-nitro-4-(2-(2-phenylpropylidene)hydrazineyl)benzenesulfonamide
8FO5	;	1.89	;	Structure of full-length amyloidogenic immunoglobulin light chain H9 in complex with 1-(1-(phenylsulfonyl)-1H-pyrrol-3-yl)ethan-1-one
8FO4	;	2.0	;	Structure of full-length amyloidogenic immunoglobulin light chain H9 in complex with 6-methyl-2-(2-((1E,2E)-3-(2-nitrophenyl)allylidene)hydrazineyl)pyrimidin-4-ol
1MCX	;	2.03	;	STRUCTURE OF FULL-LENGTH ANNEXIN A1 IN THE PRESENCE OF CALCIUM
8IQH	;	3.67	;	Structure of Full-Length AsfvPrimPol in Apo-Form
8IQI	;	3.32	;	Structure of Full-Length AsfvPrimPol in Complex-Form
6Y97	;	4.33	;	Structure of full-length CD20 in complex with Obinutuzumab Fab
6Y9A	;	4.2	;	Structure of full-length CD20 in complex with Obinutuzumab Fab
6Y92	;	4.73	;	Structure of full-length CD20 in complex with Ofatumumab Fab
6Y90	;	3.69	;	Structure of full-length CD20 in complex with Rituximab Fab
4CB9	;	3.0	;	Structure of full-length CTNNBL1 in P43212 space group
5NRO	;	3.25	;	Structure of full-length DnaK with bound J-domain
4GU5	;	2.3	;	Structure of Full-length Drosophila Cryptochrome
4A2W	;	3.7	;	Structure of full-length duck RIG-I
5H7V	;	3.82	;	Structure of full-length extracellular domain of HAI-1 at pH 4.6
7LVT	;	4.6	;	Structure of full-length GluK1 with L-Glu
3E9E	;	2.1	;	Structure of full-length H11A mutant form of TIGAR from Danio rerio
6G9O	;	4.25	;	Structure of full-length homomeric mLRRC8A volume-regulated anion channel at 4.25 A resolution
6B1U	;	2.77	;	Structure of full-length human AMPK (a2b1g1) in complex with a small molecule activator SC4
2KN6	;		;	Structure of full-length human ASC (Apoptosis-associated speck-like protein containing a CARD)
6MG4	;	1.75	;	Structure of full-length human lambda-6A light chain JTO
6MG5	;	1.8	;	Structure of full-length human lambda-6A light chain JTO in complex with coumarin 1
6W4Y	;	1.91	;	Structure of full-length human lambda-6A light chain JTO in complex with hydantoin stabilizer
7LMN	;	2.01	;	Structure of full-length human lambda-6A light chain JTO in complex with stabilizer 26 [2-(7-(diethylamino)-4-methyl-2-oxo-2H-chromen-3-yl)ethyl (3-(1H-imidazol-4-yl)benzyl)carbamate]
7LMO	;	1.99	;	Structure of full-length human lambda-6A light chain JTO in complex with stabilizer 34 [3-(2-(7-(diethylamino)-4-methyl-2-oxo-2H-chromen-3-yl)ethyl)-7-(1H-imidazole-5-carbonyl)-1,3,7-triazaspiro[4.4]nonane-2,4-dione]
7LMP	;	2.29	;	Structure of full-length human lambda-6A light chain JTO in complex with stabilizer 36 [3-(2-(7-(diethylamino)-4-methyl-2-oxo-2H-chromen-3-yl)ethyl)-8-(1H-imidazole-4-carbonyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione]
7LMQ	;	1.91	;	Structure of full-length human lambda-6A light chain JTO in complex with stabilizer 62 [4-methyl-3-(morpholinomethyl)-7-(1-phenylethoxy)-2H-chromen-2-one]
7LMR	;	2.09	;	Structure of full-length human lambda-6A light chain JTO in complex with stabilizer 63 [4-methyl-3-(morpholinomethyl)-7-(2-phenylpropoxy)-2H-chromen-2-one]
7RTP	;	2.09	;	Structure of full-length human lambda-6A light chain JTO in complex with urea stabilizer 20 [1-(2-(7-(diethylamino)-4-methyl-2-oxo-2H-chromen-3-yl)ethyl)-3-(pyridin-3-ylmethyl)urea]
5EOG	;	3.05	;	Structure of full-length human MAB21L1
5EOM	;	2.55	;	Structure of full-length human MAB21L1 with bound CTP
7K39	;	3.0	;	Structure of full-length influenza HA with a head-binding antibody at pH 5.2, conformation A, neutral pH-like
7K3A	;	4.2	;	Structure of full-length influenza HA with a head-binding antibody at pH 5.2, conformation B, fusion peptide release
7K3B	;	3.4	;	Structure of full-length influenza HA with a head-binding antibody at pH 5.2, conformation C, central helices splay
7K37	;	2.8	;	Structure of full-length influenza HA with a head-binding antibody at pH 7.8
6HJQ	;	4.1	;	Structure of Full-length Influenza Hemagglutinin (A/duck/Alberta/35/76) in complex with FISW84 Fab Fragment
6HJR	;	4.2	;	Structure of full-length Influenza Hemagglutinin with tilted transmembrane (A/duck/Alberta/35/76[H1N1])
6MU1	;	4.1	;	Structure of full-length IP3R1 channel bound with Adenophostin A
6MU2	;	3.9	;	Structure of full-length IP3R1 channel in the Apo-state
3JAV	;	4.7	;	Structure of full-length IP3R1 channel in the apo-state determined by single particle cryo-EM
7LHE	;	3.3	;	Structure of full-length IP3R1 channel reconstituted into lipid nanodisc in the apo-state
7LHF	;	2.96	;	Structure of full-length IP3R1 channel solubilized in LNMG & lipid in the apo-state
6Z6B	;	3.961	;	Structure of full-length La Crosse virus L protein (polymerase)
8TRG	;	2.93	;	Structure of full-length LexA bound to a RecA filament
8TZH	;	3.9	;	Structure of full-length LRRK2 bound to MLi-2 (I2020T mutant)
5B5V	;	2.193	;	Structure of full-length MOB1b
3OML	;	2.15	;	Structure of full-length peroxisomal multifunctional enzyme type 2 from Drosophila melanogaster
1FBL	;	2.5	;	STRUCTURE OF FULL-LENGTH PORCINE SYNOVIAL COLLAGENASE (MMP1) REVEALS A C-TERMINAL DOMAIN CONTAINING A CALCIUM-LINKED, FOUR-BLADED BETA-PROPELLER
7P14	;	3.66	;	Structure of full-length rXKR9 in complex with a sybody at 3.66A
3E9D	;	2.0	;	Structure of full-length TIGAR from Danio rerio
2M6B	;		;	Structure of full-length transmembrane domains of human glycine receptor alpha1 monomer subunit
5U0B	;	3.0	;	Structure of full-length Zika virus NS5
6PWU	;	6.2	;	Structure of full-length, fully glycosylated, non-modified HIV-1 gp160 bound to PG16 Fab
6ULC	;	4.6	;	Structure of full-length, fully glycosylated, non-modified HIV-1 gp160 bound to PG16 Fab at a nominal resolution of 4.6 Angstrom
7Q3Y	;	4.34	;	Structure of full-length, monomeric, soluble somatic angiotensin I-converting enzyme showing the N- and C-terminal ellipsoid domains
1P9B	;	2.0	;	Structure of fully ligated Adenylosuccinate synthetase from Plasmodium falciparum
5F2U	;	1.85	;	Structure of Fully modified farnesylated INPP5E Peptide in complex with PDE6D
3T5G	;	1.7	;	Structure of fully modified farnesylated Rheb in complex with PDE6D
3T5I	;	2.1	;	Structure of Fully modified farnesylated Rheb Peptide in complex with PDE6D
5E8F	;	2.1	;	Structure of Fully modified geranylgeranylated PDE6C Peptide in complex with PDE6D
6FPW	;	1.35	;	Structure of fully reduced Hydrogenase (Hyd-1)
6FPI	;	1.5	;	Structure of fully reduced Hydrogenase (Hyd-1) variant E28Q
6GAL	;	1.25	;	Structure of fully reduced Hydrogenase (Hyd-1) variant E28Q collected at pH 10
6GAN	;	1.6	;	Structure of fully reduced Hydrogenase (Hyd-2) variant E14Q
6G7R	;	1.2	;	Structure of fully reduced variant E28Q of E. coli hydrogenase-1 at pH 8
4OSY	;	1.91	;	STRUCTURE of FULLY-CLEAVED GLYCINE-BOUND HUMAN L-ASPARAGINASE PROTEIN
1FKA	;	3.3	;	STRUCTURE OF FUNCTIONALLY ACTIVATED SMALL RIBOSOMAL SUBUNIT AT 3.3 A RESOLUTION
3Q31	;	2.703	;	Structure of fungal alpha Carbonic Anhydrase from Aspergillus oryzae
4UOJ	;	2.5	;	Structure of Fungal beta-mannosidase (GH2) from Trichoderma harzianum
4CVU	;	1.9	;	Structure of Fungal beta-mannosidase from Glycoside Hydrolase Family 2 of Trichoderma harzianum
1BEG	;		;	STRUCTURE OF FUNGAL ELICITOR, NMR, 18 STRUCTURES
6CC7	;	1.87	;	Structure of Fungal GH62 from Thielavia terretris
7UBA	;	1.599	;	Structure of fungal Hop1 CBR domain
5WQF	;	2.001	;	Structure of fungal meroterpenoid isomerase Trt14
5WQI	;	1.899	;	Structure of fungal meroterpenoid isomerase Trt14 complexed with hydrolyzed product
5WQH	;	2.102	;	Structure of fungal meroterpenoid isomerase Trt14 complexed with substrate analog and endo-terretonin D
5WQG	;	2.3	;	Structure of fungal meroterpenoid isomerase Trt14 complexed with terretonin D
3QPA	;	0.85	;	Structure of Fusarium Solani Cutinase expressed in Pichia pastoris
3QPC	;	0.978	;	Structure of Fusarium Solani Cutinase expressed in Pichia pastoris, crystallized in the presence of Paraoxon
7QI3	;	1.8	;	Structure of Fusarium verticillioides NAT1 (FDB2) N-malonyltransferase
1PZQ	;		;	Structure of fused docking domains from the erythromycin polyketide synthase (DEBS), a model for the interaction between DEBS 2 and DEBS 3: The A domain
1PZR	;		;	Structure of fused docking domains from the erythromycin polyketide synthase (DEBS), a model for the interaction between DEBS2 and DEBS3: the B domain
3F85	;	2.1	;	Structure of fusion complex of homo trimeric major pilin subunits CfaB of CFA/I fimbirae from ETEC E. coli
3F84	;	2.35	;	Structure of fusion complex of major pilin CfaB and major pilin CfaB of CFA/I pilus from ETEC E. coli
3F83	;	2.3	;	Structure of fusion complex of the minor pilin CfaE and major pilin CfaB of CFA/I pili from ETEC E. coli
6OUS	;	3.4	;	Structure of fusion glycoprotein from human respiratory syncytial virus
2PT2	;	2.0	;	Structure of FutA1 with Iron(II)
3F11	;	2.0	;	Structure of futa1 with iron(III)
4BMY	;	1.65	;	Structure of futalosine hydrolase mutant of Helicobacter pylori strain 26695
4BMZ	;	1.79	;	Structure of futalosine hydrolase mutant of Helicobacter pylori strain 26695
4BN0	;	2.11	;	Structure of futalosine hydrolase mutant of Helicobacter pylori strain 26695
2MRJ	;		;	Structure of Fyn protein SH2 bound
6VU8	;	4.14	;	Structure of G-alpha-i bound to its chaperone Ric-8A
1Y3A	;	2.5	;	Structure of G-Alpha-I1 bound to a GDP-selective peptide provides insight into guanine nucleotide exchange
6VU5	;	3.5	;	Structure of G-alpha-q bound to its chaperone Ric-8A
4ANL	;	1.7	;	Structure of G1269A Mutant Anaplastic Lymphoma Kinase
4ANQ	;	1.76	;	Structure of G1269A Mutant Anaplastic Lymphoma Kinase in Complex with Crizotinib
7A74	;	1.6	;	Structure of G132N BlaC from Mycobacterium tuberculosis
7A71	;	1.4	;	Structure of G132S BlaC from Mycobacterium tuberculosis
7A72	;	1.3	;	Structure of G132S BlaC from Mycobacterium tuberculosis bound to the trans-enamine adduct of sulbactam
8FNM	;	2.8	;	Structure of G140A/Q148K HIV-1 intasome with Dolutegravir bound
2NOI	;	2.35	;	Structure of G42A human 8-oxoguanine glycosylase crosslinked to undamaged G-containing DNA
2KWY	;		;	Structure of G61-101
3SDN	;	1.5	;	Structure of G65I sperm whale myoglobin mutant
7SNH	;	2.2	;	Structure of G6PD-D200N tetramer bound to NADP+
7SNI	;	2.5	;	Structure of G6PD-D200N tetramer bound to NADP+ and G6P
7UAL	;	2.9	;	Structure of G6PD-D200N tetramer bound to NADP+ and G6P with no symmetry applied
7UC2	;	2.5	;	Structure of G6PD-D200N tetramer bound to NADP+ with no symmetry applied
7SNF	;	3.5	;	Structure of G6PD-WT dimer
7UAG	;	3.5	;	Structure of G6PD-WT dimer
7TOF	;	3.7	;	Structure of G6PD-WT dimer with no symmetry applied
7SNG	;	2.8	;	structure of G6PD-WT tetramer
7TOE	;	3.0	;	Structure of G6PD-WT tetramer with no symmetry imposed
6NE7	;	1.99	;	Structure of G810A mutant of RET protein tyrosine kinase domain.
7XUA	;	1.87	;	Structure of G9a in complex with compound 10a
7XUB	;	2.0	;	Structure of G9a in complex with compound 10d
7XUC	;	1.67	;	Structure of G9a in complex with compound 11a
7XUD	;	1.45	;	Structure of G9a in complex with compound 26a
7X73	;	1.49	;	Structure of G9a in complex with RK-701
5T0K	;	1.7	;	Structure of G9a SET-domain with H3K9M mutant peptide and SAM
5JHN	;	1.67	;	Structure of G9a SET-domain with Histone H3K9Ala mutant peptide and bound S-adenosylmethionine
5JIN	;	1.85	;	Structure of G9a SET-domain with Histone H3K9M mutant peptide and bound S-adenosylmethionine
5JJ0	;	1.72	;	Structure of G9a SET-domain with Histone H3K9M peptide and excess SAH
5JIY	;	1.48	;	Structure of G9a SET-domain with Histone H3K9norLeucine mutant peptide and bound S-adenosylmethionine
4ATP	;	2.8	;	Structure of GABA-transaminase A1R958 from Arthrobacter aurescens in complex with PLP
8PVB	;	3.6	;	Structure of GABAAR determined by cryoEM at 100 keV
7CDB	;	1.949	;	Structure of GABARAPL1 in complex with GABA(A) receptor gamma 2
8WY5	;	3.12	;	Structure of Gabija GajA in complex with DNA
8JQB	;	3.2	;	Structure of Gabija GajA-GajB 4:4 Complex
6P4Z	;	1.8	;	Structure of gadolinium-caged cobalt (III) insulin hexamer
4C57	;	2.55	;	Structure of GAK kinase in complex with a nanobody
4C58	;	2.16	;	Structure of GAK kinase in complex with nanobody (NbGAK_4)
4C59	;	2.8	;	Structure of GAK kinase in complex with nanobody (NbGAK_4)
3ZR5	;	2.1	;	STRUCTURE OF GALACTOCEREBROSIDASE FROM MOUSE
3ZR6	;	2.44	;	STRUCTURE OF GALACTOCEREBROSIDASE FROM MOUSE IN COMPLEX WITH GALACTOSE
4AKC	;	2.3	;	Structure of Galactose Binding lectin from Champedak (CGB) with Gal(beta)1,3-GalNac
4AKB	;	1.95	;	Structure of Galactose Binding lectin from Champedak (CGB) with Galactose
4UNM	;	1.77	;	Structure of Galactose Oxidase homologue from Streptomyces lividans
6GLW	;	1.9	;	Structure of galectin-10 in complex with the Fab fragment of a Charcot-Leyden crystal solubilizing antibody, 1D11
6GLX	;	3.396	;	Structure of galectin-10 in complex with the Fab fragment of a Charcot-Leyden crystal solubilizing antibody, 4E8
6GKU	;	1.91	;	Structure of galectin-10 in complex with the Fab fragment of a Charcot-Leyden crystal solubilizing antibody, 6F5
5NF7	;	1.59	;	Structure of Galectin-3 CRD in complex with compound 1
5NF9	;	1.87	;	Structure of Galectin-3 CRD in complex with compound 2
5NFA	;	1.59	;	Structure of Galectin-3 CRD in complex with compound 3
5NFB	;	1.59	;	Structure of Galectin-3 CRD in complex with compound 4
5NFC	;	1.59	;	Structure of Galectin-3 CRD in complex with glycerol
6Y78	;	1.7	;	Structure of galectin-3C in complex with lactose determined by serial crystallography using a silicon nitride membrane support
6Y4C	;	1.7	;	Structure of galectin-3C in complex with lactose determined by serial crystallography using an XtalTool support
4PER	;	1.92	;	Structure of Gallus gallus ribonuclease inhibitor complexed with Gallus gallus ribonuclease I
3GCT	;	1.6	;	STRUCTURE OF GAMMA-*CHYMOTRYPSIN IN THE RANGE $P*H 2.0 TO $P*H 10.5 SUGGESTS THAT GAMMA-CHYMOTRYPSIN IS A COVALENT ACYL-ENZYME ADDUCT AT LOW $P*H
1SFF	;	1.9	;	Structure of gamma-aminobutyrate aminotransferase complex with aminooxyacetate
2GCT	;	1.8	;	STRUCTURE OF GAMMA-CHYMOTRYPSIN IN THE RANGE PH 2.0 TO PH 10.5 SUGGESTS THAT GAMMA-CHYMOTRYPSIN IS A COVALENT ACYL-ENZYME ADDUCT AT LOW PH
1L9X	;	1.6	;	Structure of gamma-Glutamyl Hydrolase
6V5V	;	3.8	;	Structure of gamma-tubulin in the native human gamma-tubulin ring complex
5FM1	;	8.0	;	Structure of gamma-tubulin small complex based on a cryo-EM map, chemical cross-links, and a remotely related structure
4ZEP	;	2.21	;	Structure of Gan1D, a 6-phospho-beta-galactosidase from Geobacillus stearothermophilus, in complex with 6-phospho-glucose
4ZE4	;	1.92	;	Structure of Gan1D, a putative 6-phospho-beta-galactosidase from Geobacillus stearothermophilus
4ZEN	;	1.93	;	Structure of Gan1D, a putative 6-phospho-beta-galactosidase from Geobacillus stearothermophilus, in complex with 6-phospho-beta-galactose
4ZFM	;	1.4	;	Structure of Gan1D-E170Q in complex with cellobiose-6-phosphate
4ZE5	;	1.48	;	Structure of Gan1D-E170Q, a catalytic mutant of a putative 6-phospho-beta-galactosidase from Geobacillus stearothermophilus
3AJI	;	2.05	;	Structure of Gankyrin-S6ATPase photo-cross-linked site-specifically, and incoporated by genetic code expansion
3KTZ	;	1.6	;	Structure of GAP31
3KU0	;	1.9	;	Structure of GAP31 with adenine at its binding pocket
3PYM	;	2.0	;	Structure of GAPDH 3 from S.cerevisiae at 2.0 A resolution
8PVF	;	2.9	;	Structure of GAPDH determined by cryoEM at 100 keV
8BR4	;	3.29	;	Structure of GAPDH from Mycobacterium tuberculosis
3ZCX	;	2.19	;	Structure of GAPDH from Thermosynechococcus elongatus
4BOY	;	2.15	;	Structure of GAPDH from Thermosynechococcus elongatus
3ZDF	;	2.34	;	Structure of GAPDH with CP12 peptide from Thermosynechococcus elongatus
5X57	;	1.45	;	Structure of GAR domain of ACF7
6GFF	;	3.1	;	Structure of GARP (LRRC32) in complex with latent TGF-beta1 and MHG-8 Fab
4LMY	;	1.6	;	Structure of GAS PerR-Zn-Zn
1ZQ1	;	3.0	;	Structure of GatDE tRNA-Dependent Amidotransferase from Pyrococcus abyssi
5G47	;	2.45	;	Structure of Gc glycoprotein from severe fever with thrombocytopenia syndrome virus in the trimeric postfusion conformation
6V6C	;	4.5	;	Structure of GCP6 in the native human gamma-tubulin ring complex
2Y0F	;	2.5	;	STRUCTURE OF GCPE (IspG) FROM THERMUS THERMOPHILUS HB27
8EXZ	;	2.82	;	Structure of GDAP1 containing CMT mutant T157P
7MRZ	;	3.0	;	Structure of GDF11 bound to fused ActRIIB-ECD and Alk4-ECD with Anti-ActRIIB Fab fragment
5A9X	;	3.8	;	Structure of GDP bound BipA
5A9W	;	3.7	;	Structure of GDPCP BipA
7XGR	;	2.6	;	Structure of Gemin5 C-terminal region (protomer)
1Y8A	;	1.4	;	Structure of gene product AF1437 from Archaeoglobus fulgidus
4H9V	;	1.971	;	Structure of Geobacillus kaustophilus lactonase, mutant E101G/R230C with Zn2+
4H9X	;	2.201	;	Structure of Geobacillus kaustophilus lactonase, mutant E101G/R230C/D266N with Zn2+ and bound N-butyryl-DL-homoserine lactone
4H9T	;	2.097	;	Structure of Geobacillus kaustophilus lactonase, mutant E101N with bound N-butyryl-DL-homoserine lactone
4H9Z	;	2.6	;	Structure of Geobacillus kaustophilus lactonase, mutant E101N with Mn2+
4H9Y	;	2.085	;	Structure of Geobacillus kaustophilus lactonase, mutant E101N with Zn2+
4HA0	;	1.902	;	Structure of Geobacillus kaustophilus lactonase, mutant R230D with Zn2+
4H9U	;	2.099	;	Structure of Geobacillus kaustophilus lactonase, wild-type with Zn2+
6JSU	;	1.8	;	Structure of Geobacillus kaustophilus lactonase, Y99C/D266N double mutant
6JSS	;	2.16	;	Structure of Geobacillus kaustophilus lactonase, Y99P mutant
6JST	;	1.726	;	Structure of Geobacillus kaustophilus lactonase, Y99P/D266N double mutant with bound 3-oxo-C8-HSL
7NA0	;	1.9	;	Structure of Geobacter sulfurreducens proline utilization A (PutA) variant A206W
4PD1	;	1.975	;	Structure of gephyrin E domain with Glycine-beta receptor peptide
4XVU	;	2.35	;	Structure of Get3 bound to the transmembrane domain of Nyv1
4XTR	;	2.05	;	Structure of Get3 bound to the transmembrane domain of Pep12
4XWO	;	2.75	;	Structure of Get3 bound to the transmembrane domain of Sec22
8ELF	;	2.0	;	Structure of Get3d, a homolog of Get3, from Arabidopsis thaliana
3P42	;	1.91	;	Structure of GfcC (YmcB), protein encoded by the E. coli group 4 capsule operon
6GO8	;	1.648	;	Structure of GFPmut2 crystallized at pH 6
6GO9	;	1.672	;	Structure of GFPmut2 crystallized at pH 6 and transferred to pH 7
6GRM	;	2.3	;	Structure of GFPmut2 crystallized at pH 6 and transferred to pH 9
6GQG	;	1.792	;	Structure of GFPmut2 crystallized at pH 8.5
6GQH	;	2.4	;	Structure of GFPmut2 crystallized at pH 8.5 and transferred to pH 6
6B9O	;	1.841	;	Structure of GH 38 Jack Bean alpha-mannosidase
6B9P	;	1.996	;	Structure of GH 38 Jack Bean alpha-mannosidase in complex with a 36-valent iminosugar cluster inhibitor
8J5L	;	2.095	;	Structure of GH1 Br2 beta-glucosidase E163Q mutant from bovine rumen metagenome
8J5M	;	1.621	;	Structure of GH1 Br2 beta-glucosidase E350G mutant from bovine rumen metagenome
8J3M	;	1.999	;	Structure of GH1 Br2 beta-glucosidase from bovine rumen metagenome
4W8L	;	1.76	;	Structure of GH10 from Paenibacillus barcinonensis
5YLH	;	2.29	;	Structure of GH113 beta-1,4-mannanase
5YLL	;	1.81	;	Structure of GH113 beta-1,4-mannanase complex with M6.
6NUN	;	1.87	;	Structure of GH32 hydrolase from Bifidobacterium adolescentis in complex with frutose
5M1I	;	1.55	;	Structure of GH36 alpha-galactosidase from Thermotoga maritima in a covalent complex with a cyclopropyl carbasugar.
5M16	;	1.62	;	Structure of GH36 alpha-galactosidase from Thermotoga maritima in complex with a hydrolysed cyclopropyl carbasugar.
5M12	;	1.53	;	Structure of GH36 alpha-galactosidase from Thermotoga maritima in complex with intact cyclopropyl-carbasugar.
8HCJ	;	2.566	;	Structure of GH43 family enzyme, Xylan 1, 4 Beta- xylosidase from pseudopedobacter saltans
5ABE	;	2.0	;	Structure of GH84 with ligand
5ABF	;	2.1	;	Structure of GH84 with ligand
5ABG	;	2.0	;	Structure of GH84 with ligand
5ABH	;	1.95	;	Structure of GH84 with ligand
3KZF	;	3.0	;	Structure of Giardia Carbamate Kinase
2QVW	;	3.0	;	Structure of Giardia Dicer refined against twinned data
3GAK	;	2.9	;	Structure of Giardia fructose-1,6-biphosphate aldolase
3GB6	;	2.0	;	Structure of Giardia fructose-1,6-biphosphate aldolase D83A mutant in complex with fructose-1,6-bisphosphate
3OHI	;	2.3	;	Structure of Giardia fructose-1,6-biphosphate aldolase in complex with 3-hydroxy-2-pyridone
2ISV	;	2.3	;	Structure of Giardia fructose-1,6-biphosphate aldolase in complex with phosphoglycolohydroxamate
2ISW	;	1.75	;	Structure of Giardia fructose-1,6-biphosphate aldolase in complex with phosphoglycolohydroxamate
3GAY	;	1.8	;	Structure of Giardia fructose-1,6-biphosphate aldolase in complex with tagatose-1,6-biphosphate
8EN2	;	1.85	;	Structure of GII.10 norovirus in complex with Nanobody 34
8EMZ	;	1.4	;	Structure of GII.17 norovirus in complex with Nanobody 2
8EN3	;	2.1	;	Structure of GII.17 norovirus in complex with Nanobody 45
8EN0	;	2.99	;	Structure of GII.17 norovirus in complex with Nanobody 7
8EN1	;	2.4	;	Structure of GII.4 norovirus in complex with Nanobody 30
8EN4	;	2.3	;	Structure of GII.4 norovirus in complex with Nanobody 53
8EN5	;	1.6	;	Structure of GII.4 norovirus in complex with Nanobody 56
8EN6	;	1.6	;	Structure of GII.4 norovirus in complex with Nanobody 76
8EMY	;	1.7	;	Structure of GII.4 norovirus in complex with Nanobody 82
7JIE	;	2.254	;	Structure of GII.4 P-domain in Complex with NORO-320 FAB
2EEY	;	1.94	;	Structure of GK0241 protein from Geobacillus kaustophilus
6K59	;		;	Structure of Glargine insulin in 20% acetic acid-d4 (pH 1.9)
5JNB	;	2.486	;	structure of GLD-2/RNP-8 complex
5ZXL	;	2.794	;	Structure of GldA from E.coli
6YS8	;	3.9	;	Structure of GldLM, the proton-powered motor that drives protein transport and gliding motility
7SAZ	;	3.0	;	Structure of GldLM, the proton-powered motor that drives Type IX protein secretion and gliding motility in Capnocytophaga canimorsus
7SAU	;	3.0	;	Structure of GldLM, the proton-powered motor that drives Type IX protein secretion and gliding motility in Schleiferia thermophila
7SAX	;	3.0	;	Structure of GldLM, the proton-powered motor that drives Type IX protein secretion and gliding motility in Sphingobacterium wenxiniae
1J3W	;	1.5	;	Structure of Gliding protein-mglB from Thermus Thermophilus HB8
2J9C	;	1.3	;	Structure of GlnK1 with bound effectors indicates regulatory mechanism for ammonia uptake
2J9D	;	2.1	;	Structure of GlnK1 with bound effectors indicates regulatory mechanism for ammonia uptake
2J9E	;	1.62	;	Structure of GlnK1 with bound effectors indicates regulatory mechanism for ammonia uptake
4R4E	;	2.57	;	Structure of GlnR-DNA complex
2JHH	;	1.7	;	Structure of globular heads of M-ficolin at acidic pH
2JHM	;	1.52	;	Structure of globular heads of M-ficolin at neutral pH
2JHI	;	1.8	;	Structure of globular heads of M-ficolin complexed with N-acetyl-D- galactosamine
2JHK	;	1.75	;	Structure of globular heads of M-ficolin complexed with N-acetyl-D- glucosamine
2JHL	;	1.75	;	Structure of globular heads of M-ficolin complexed with sialic acid
4JW0	;	1.7	;	Structure of Gloeobacter violaceus CcmL
2XOW	;	2.09	;	Structure of GlpG in complex with a mechanism-based isocoumarin inhibitor
1P3E	;	1.72	;	Structure of Glu endopeptidase in complex with MPD
6HCA	;	1.882	;	STRUCTURE OF GLUA2 LIGAND-BINDING DOMAIN (S1S1J) IN COMPLEX WITH POSITIVE ALLOSTERIC MODULATOR TDPAM02 AT 1.8 A RESOLUTION
6Q54	;	1.4	;	Structure of GluA2 ligand-binding domain (S1S2J) in complex with the agonist (S)-2-Amino-3-(1-ethyl-4-hydroxy-1H-1,2,3-triazol-5-yl)propanoic acid at 1.4 A resolution
6Q60	;	1.55	;	Structure of GluA2 ligand-binding domain (S1S2J) in complex with the agonist (S)-2-Amino-3-(2-methyl-5-hydroxy-2H-1,2,3-triazol-4-yl)propanoic acid at 1.55 A resolution
6HCH	;	1.6	;	STRUCTURE OF GLUA2 LIGAND-BINDING DOMAIN (S1S2J-L504Y-N775S) IN COMPLEX WITH GLUTAMATE AND TDPAM01 AT 1.6 A RESOLUTION.
6HC9	;	2.4	;	STRUCTURE OF GLUA2 LIGAND-BINDING DOMAIN (S1S2J-L504Y-N775S) IN COMPLEX WITH GLUTAMATE AND TDPAM02 AT 2.4 A RESOLUTION.
6HCB	;	1.9	;	STRUCTURE OF GLUA2 LIGAND-BINDING DOMAIN (S1S2J-N775S) IN COMPLEX WITH GLUTAMATE AND TDPAM01 AT 1.9 A RESOLUTION.
6HCC	;	1.617	;	STRUCTURE OF GLUA2 LIGAND-BINDING DOMAIN (S1S2J-N775S) IN COMPLEX WITH GLUTAMATE AND TDPAM02 AT 1.6 A RESOLUTION.
4U4G	;	4.49	;	Structure of GluA2* in complex with competitive antagonist ZK 200775
4U4F	;	4.79	;	Structure of GluA2* in complex with partial agonist (S)-5-Nitrowillardiine
4H8J	;	1.8	;	Structure of GluA2-LBD in complex with MES
6GIV	;	1.75	;	Structure of GluA2-N775S ligand-binding domain (S1S2J) in complex with glutamate and Rubidium Bromide at 1.75 A resolution
6RUQ	;	4.65	;	Structure of GluA2cryst in complex the antagonist ZK200775 and the negative allosteric modulator GYKI53655 at 4.65 A resolution
6GL4	;	1.948	;	Structure of GluA2o ligand-binding domain (S1S2J) in complex with glutamate and sodium bromide at 1.95 A resolution
4AIE	;	2.05	;	Structure of glucan-1,6-alpha-glucosidase from Lactobacillus acidophilus NCFM
3FF1	;	1.65	;	Structure of Glucose 6-phosphate Isomerase from Staphylococcus aureus
1O1H	;	1.4	;	STRUCTURE OF GLUCOSE ISOMERASE DERIVATIZED WITH KR.
5M2V	;	3.18	;	Structure of GluK1 ligand-binding domain (S1S2) in complex with (2S,4R)-4-(2-carboxyphenoxy)pyrrolidine-2-carboxylic acid at 3.18 A resolution
4QF9	;	2.28	;	Structure of GluK1 ligand-binding domain (S1S2) in complex with (S)-2-amino-4-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-6-yl)butanoic acid at 2.28 A resolution
5NF5	;	2.85	;	Structure of GluK1 ligand-binding domain (S1S2) in complex with CIP-AS at 2.85 A resolution
5NEB	;	2.05	;	Structure of GluK1 ligand-binding domain (S1S2) in complex with LM-12b at 2.05 A resolution
6SBT	;	2.3	;	Structure of GluK1 ligand-binding domain (S1S2) in complex with N-(7-(1H-imidazol-1-yl)-2,3-dioxo-6-(trifluoromethyl)-3,4-dihydroquinoxalin-1(2H)-yl benzamide at 2.3 A resolution
6FZ4	;	1.85	;	Structure of GluK1 ligand-binding domain in complex with N-(7-fluoro-2,3-dioxo-6-(trifluoromethyl)-3,4-dihydroquinoxalin-1(2H)-yl)-2-hydroxybenzamide at 1.85 A resolution
4H8I	;	2.0	;	Structure of GluK2-LBD in complex with GluAzo
5NF6	;	2.55	;	Structure of GluK3 ligand-binding domain (S1S2) in complex with CIP-AS at 2.55 A resolution
5O4F	;	2.1	;	Structure of GluK3 ligand-binding domain (S1S2) in complex with the agonist LM-12b at 2.10 A resolution
7YFO	;	6.4	;	Structure of GluN1a E698C-GluN2D NMDA receptor in cystines crosslinked state.
7YFR	;	5.1	;	Structure of GluN1a E698C-GluN2D NMDA receptor in cystines non-crosslinked state.
7YFF	;	3.6	;	Structure of GluN1a-GluN2D NMDA receptor in complex with agonist glycine and competitive antagonist CPP.
7YFL	;	3.9	;	Structure of GluN1a-GluN2D NMDA receptor in complex with agonists glycine and glutamate.
7YFM	;	5.1	;	Structure of GluN1b-GluN2D NMDA receptor in complex with agonists glycine and glutamate.
1GTM	;	2.2	;	STRUCTURE OF GLUTAMATE DEHYDROGENASE
3ETD	;	2.5	;	Structure of glutamate dehydrogenase complexed with bithionol
6H9F	;	2.1	;	Structure of glutamate mutase reconstituted with bishomo-coenzyme B12
6H9E	;	1.82	;	Structure of glutamate mutase reconstituted with homo-coenzyme B12
7LZ0	;	2.29	;	Structure of glutamate receptor-like channel GLR3.4 ligand-binding domain in complex with glutamate
7LZ2	;	1.5	;	Structure of glutamate receptor-like channel GLR3.4 ligand-binding domain in complex with methionine
7LZ1	;	1.51	;	Structure of glutamate receptor-like channel GLR3.4 ligand-binding domain in complex with serine
1XFH	;	3.5	;	Structure of glutamate transporter homolog from Pyrococcus horikoshii
6XWR	;	3.22	;	Structure of glutamate transporter homologue GltTk in sodium only condition
6XWN	;	3.47	;	Structure of glutamate transporter homologue GltTk in the presence of TBOA inhibitor
6XWQ	;	3.41	;	Structure of glutamate transporter homologue GltTk in the saturated conditions
6XWO	;	3.39	;	Structure of glutamate transporter homologue GltTk in the unsaturated conditions - inward-inward-outward configuration
6XWP	;	3.38	;	Structure of glutamate transporter homologue GltTk in unsaturated conditions - outward-outward-inward configuration
7NGH	;	3.5	;	Structure of glutamate transporter homologue in complex with Sybody
4DJI	;	3.187	;	Structure of glutamate-GABA antiporter GadC
4DJK	;	3.097	;	Structure of glutamate-GABA antiporter GadC
3MDN	;	2.09	;	Structure of glutamine aminotransferase class-II domain protein (SPO2029) from silicibacter pomeroyi
5KHA	;	2.1	;	Structure of glutamine-dependent NAD+ synthetase from Acinetobacter baumannii in complex with adenosine diphosphate (ADP)
5H4V	;	3.0	;	Structure of glutamyl-tRNA synthetase (Xoo1504) from Xanthomonas oryzae pv. oryzae
3PNY	;	1.7	;	Structure of Glutamyl-tRNA synthetase from Mycobacterium tuberculosis in space group P21
8CDF	;	1.77	;	Structure of glutarate hydroxylase (GlaH) from Escherichia coli at a resolution of 1.8 angstrom obtained as a contaminant during routine use of E. coli as an expression host
2RAB	;	2.5	;	Structure of glutathione amide reductase from Chromatium gracile in complex with NAD
1GNW	;	2.2	;	STRUCTURE OF GLUTATHIONE S-TRANSFERASE
1AW9	;	2.2	;	STRUCTURE OF GLUTATHIONE S-TRANSFERASE III IN APO FORM
3PR8	;	1.8	;	Structure of Glutathione S-transferase(PP0183) from Pseudomonas putida in complex with GSH
1AXD	;	2.5	;	STRUCTURE OF GLUTATHIONE S-TRANSFERASE-I BOUND WITH THE LIGAND LACTOYLGLUTATHIONE
1GSA	;	2.0	;	STRUCTURE OF GLUTATHIONE SYNTHETASE COMPLEXED WITH ADP AND GLUTATHIONE
2OAD	;	2.5	;	Structure of Glutathione-S-Transferase C169A Mutant
2CAI	;	2.26	;	Structure of Glutathione-S-Transferase mutant, R21L, from Schistosoma Haematobium
7U4S	;	2.68	;	Structure of Glyceraldehyde-3-Phosphate Dehydrogenase from Candida albicans
8DE5	;	2.02	;	Structure of glyceraldehyde-3-phosphate dehydrogenase from Paracoccidioides lutzii
5XN8	;	2.33	;	Structure of glycerol dehydrogenase crystallised as a contaminant
1TXG	;	1.7	;	Structure of glycerol-3-phosphate dehydrogenase from Archaeoglobus fulgidus
4FGW	;	2.45	;	Structure of Glycerol-3-Phosphate Dehydrogenase, GPD1, from Sacharomyces Cerevisiae
5FB3	;	2.45	;	Structure of glycerophosphate dehydrogenase in complex with NADPH
8YK5	;	2.1	;	Structure of glycerophosphoethanolamine ethanolaminephosphodiesterase from Streptomyces sanglieri
6KHR	;	2.786	;	Structure of glycinamide-RNase-transformylase T from Mycobacterium tuberculosis
1NBH	;	2.8	;	Structure of glycine N-methyltransferase complexed with S-adenosylmethionine and acetate, GNMT:SAM:Ace
1RYI	;	1.8	;	STRUCTURE OF GLYCINE OXIDASE WITH BOUND INHIBITOR GLYCOLATE
6EER	;	1.82	;	Structure of glycine-bound GoxA from Pseudoalteromonas luteoviolacea
6XHC	;	1.6	;	Structure of glycinyl 5'-O-adenosine phosphoramidate
2KUY	;		;	Structure of Glycocin F
2BIS	;	2.8	;	Structure of glycogen synthase from Pyrococcus abyssi
3PUP	;	2.99	;	Structure of Glycogen Synthase Kinase 3 beta (GSK3B) in complex with a ruthenium octasporine ligand (OS1)
1I09	;	2.7	;	STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
1ZCT	;	2.6	;	structure of glycogenin truncated at residue 270 in a complex with UDP
5ZBM	;	2.8	;	Structure of glycolate oxidase containing FMN from Nicotiana benthamiana
5ZBN	;	2.32	;	Structure of glycolate oxidase without FMN from Nicotiana benthamiana
6C69	;	1.937	;	Structure of glycolipid aGSA[12,6P] in complex with mouse CD1d
6C6A	;	2.45	;	Structure of glycolipid aGSA[16,6P] in complex with mouse CD1d
6C6C	;	2.08	;	Structure of glycolipid aGSA[20,6P] in complex with mouse CD1d
6C6E	;	2.18	;	Structure of glycolipid aGSA[26,6P] in complex with mouse CD1d
6C6F	;	1.67	;	Structure of glycolipid aGSA[26,P5p] in complex with mouse CD1d
6C5M	;	2.45	;	Structure of glycolipid aGSA[8,9] in complex with mouse CD1d
6C6H	;	2.0	;	Structure of glycolipid aGSA[8,P5m] in complex with mouse CD1d
6C6J	;	1.79	;	Structure of glycolipid aGSA[8,P5p] in complex with mouse CD1d
6OJP	;	2.17	;	Structure of glycolipid alpha-GSA[8,6P] in complex with mouse CD1d
1GWB	;	2.8	;	STRUCTURE OF GLYCOPROTEIN 1B
5ZS0	;	3.29	;	Structure of glycoprotein B Domain IV of pseudorabies virus with 7B11 antibody
6NOB	;	2.44	;	Structure of Glycoside Hydrolase family 32 from Bifidobacterium adolescentis
2X0N	;	3.2	;	Structure of glycosomal glyceraldehyde-3-phosphate dehydrogenase from Trypanosoma brucei determined from Laue data
1K3T	;	1.95	;	Structure of Glycosomal Glyceraldehyde-3-Phosphate Dehydrogenase from Trypanosoma cruzi Complexed with Chalepin, a Coumarin Derivative Inhibitor
3IDS	;	1.8	;	Structure of Glycosomal Glyceraldehyde-3-Phosphate Dehydrogenase from Trypanosoma cruzi in complex with the irreversible iodoacetamide inhibitor
3DMT	;	2.3	;	Structure of Glycosomal Glyceraldehyde-3-Phosphate Dehydrogenase from Trypanosoma cruzi in complex with the irreversible iodoacetate inhibitor
4E9H	;	3.0	;	structure of glycosylase domain of MBD4 bound to 5hmU containing DNA
4F9U	;	1.8	;	Structure of glycosylated glutaminyl cyclase from Drosophila melanogaster
5LHD	;	2.6	;	Structure of glycosylated human aminopeptidase N
3SI0	;	2.1	;	Structure of glycosylated human glutaminyl cyclase
8DGG	;	3.78	;	Structure of glycosylated LAG-3 homodimer
3SI1	;	2.9	;	Structure of glycosylated murine glutaminyl cyclase
3SI2	;	1.8	;	Structure of glycosylated murine glutaminyl cyclase in presence of the inhibitor PQ50 (PDBD150)
5HNS	;	2.45	;	Structure of glycosylated NPC1 luminal domain C
8IXQ	;	2.1	;	Structure of glycosyltransferase LmbT in complex with GDP and ergothioneine
3DOJ	;	2.101	;	Structure of Glyoxylate reductase 1 from Arabidopsis (AtGLYR1)
6U9U	;	2.26	;	Structure of GM9_TH8seq732127 FAB
1YJP	;	1.8	;	Structure of GNNQQNY from yeast prion Sup35
5K2G	;	1.1	;	Structure of GNNQQNY from yeast prion Sup35 in space group P21 determined by MicroED
5K2H	;	1.05	;	Structure of GNNQQNY from yeast prion Sup35 in space group P212121 determined by MicroED
8FFT	;	2.1	;	Structure of GntC, a PLP-dependent enzyme catalyzing L-enduracididine biosynthesis from (S)-4-hydroxy-L-arginine
8FFU	;	2.04	;	Structure of GntC, a PLP-dependent enzyme catalyzing L-enduracididine biosynthesis from (S)-4-hydroxy-L-arginine, with the substrate bound
5WYE	;		;	Structure of gold nano particle-tagged VG16KRKP in Salmonella typhi LPS
6Y66	;	1.95	;	Structure of Goose Hemorrhagic Polyomavirus VP1 in complex with 2-O-Methyl-5-N-acetyl-alpha-D-neuraminic acid
6BYW	;	2.05	;	Structure of GoxA from Pseudoalteromonas luteoviolacea
6HHK	;	2.38	;	Structure of gp105 of Listeria bacteriophage A511
6L1Y	;	2.469	;	structure of gp120/CD4 with a non-canonical surface
3VGX	;	1.74	;	Structure of gp41 T21/Cp621-652
2LP7	;		;	Structure of gp41-M-MAT, a membrane associated MPER trimer from HIV-1 gp41.
3J4A	;	12.0	;	Structure of gp8 connector protein
8HMV	;	2.91	;	Structure of GPR21-Gs complex
8K4N	;	2.83	;	Structure of GPR34-Gi complex
7DR2	;	3.8	;	Structure of GraFix PSI tetramer from Cyanophora paradoxa
7XSP	;	2.89	;	Structure of gRAMP-target RNA
3FZZ	;	2.5	;	Structure of GrC
3G01	;	2.5	;	Structure of GrC mutant E192R/E193G
3LYN	;	1.7	;	STRUCTURE OF GREEN ABALONE LYSIN DIMER
1GFL	;	1.9	;	STRUCTURE OF GREEN FLUORESCENT PROTEIN
3T15	;	2.95	;	Structure of green-type Rubisco activase from tobacco
3PEL	;	1.9	;	Structure of Greyhound Hemoglobin: Origin of High Oxygen Affinity
4KT5	;	2.7	;	Structure of GrlR-GrlA complex
3E3C	;	2.5	;	Structure of GrlR-lipid complex
8BL2	;	2.3	;	Structure of GroEL-ATP complex plunge frozen 200 ms after reaction initiation
8BMD	;	2.8	;	Structure of GroEL-ATP complex under continuous turnover conditions
8BL7	;	4.4	;	Structure of GroEL-nucleotide complex in ADP-like conformation plunged 13 ms after mixing with ATP
8BLE	;	4.0	;	Structure of GroEL-nucleotide complex in ADP-like conformation plunged 50 ms after mixing with ATP
8BMO	;	3.4	;	Structure of GroEL:GroES complex exhibiting ADP-conformation in trans ring obtained under the continuous turnover conditions
8BM0	;	3.4	;	Structure of GroEL:GroES-ATP complex plunge frozen 200 ms after reaction initiation
8BMT	;	2.5	;	Structure of GroEL:GroES-ATP complex plunge frozen 200 ms after reaction initiation
8BM1	;	2.7	;	Structure of GroEL:GroES-ATP complex under continuous turnover conditions
1KGB	;	1.65	;	structure of ground-state bacteriorhodopsin
3C9L	;	2.646	;	Structure of ground-state bovine rhodospin in a hexagonal crystal form
3ZLH	;	2.9	;	Structure of group A Streptococcal enolase
3ZLF	;	2.15	;	Structure of group A Streptococcal enolase K312A mutant
3ZLG	;	2.1	;	Structure of group A Streptococcal enolase K362A mutant
6ASQ	;	2.35	;	Structure of Grp94 bound to methyl 2-[2-(2-benzylpyridin-3-yl)ethyl]-3-chloro-4,6-dihydroxybenzoate, a pan-Hsp90 inhibitor
5ULS	;	2.622	;	Structure of GRP94 in the active conformation
5WMT	;	2.748	;	Structure of GRP94 N-terminal Domain bound to resorcinylic inhibitor BnIm.
6C91	;	2.895	;	Structure of GRP94 with a resorcinylic inhibitor.
6BAW	;	2.703	;	Structure of GRP94 with a selective resorcinylic inhibitor.
6ASP	;	2.696	;	Structure of Grp94 with methyl 3-chloro-2-(2-(1-(2-ethoxybenzyl)-1 H-imidazol-2-yl)ethyl)-4,6-dihydroxybenzoate, a Grp94-selective inhibitor and promising therapeutic lead for treating myocilin-associated glaucoma
4S0R	;	3.5	;	Structure of GS-TnrA complex
3LGO	;	2.85	;	Structure of Gse1p, member of the GSE/EGO complex
8IYW	;	3.45	;	Structure of GSK256073-GPR109A-G-protein complex
4E7W	;	3.3	;	Structure of GSK3 from Ustilago maydis
2RQG	;		;	Structure of GSPT1/ERF3A-PABC
2RQH	;		;	Structure of GSPT1/ERF3A-PABC
5UEH	;	2.0	;	Structure of GSTO1 covalently conjugated to quinolinic acid fluorosulfate
1XUE	;		;	STRUCTURE OF GTGGAATGCAATGGAAC HAIRPIN, NMR, 10 STRUCTURES
7UYQ	;	2.57	;	Structure of GTP binds to Cyclic GMP AMP synthase (cGAS) through Mg coordination
1WUR	;	1.82	;	Structure of GTP cyclohydrolase I Complexed with 8-oxo-dGTP
1WUQ	;	2.0	;	Structure of GTP cyclohydrolase I Complexed with 8-oxo-GTP
1WM9	;	2.2	;	Structure of GTP cyclohydrolase I from Thermus thermophilus HB8
1GIT	;	2.6	;	STRUCTURE OF GTP-BINDING PROTEIN
3LAW	;	2.8	;	Structure of GTP-bound L129F mutant Rab7
1Z0J	;	1.32	;	Structure of GTP-Bound Rab22Q64L GTPase in complex with the minimal Rab binding domain of Rabenosyn-5
1Z0K	;	1.92	;	Structure of GTP-Bound Rab4Q67L GTPase in complex with the central Rab binding domain of Rabenosyn-5
6N0B	;	1.739	;	Structure of GTPase Domain of Human Septin 7 at High Resolution
6N12	;	2.23	;	Structure of GTPase Domain of Human Septin 7 at High Resolution
6QWQ	;	1.9	;	Structure of gtPebB
6QX6	;	1.65	;	Structure of gtPebB-dihydrobiliverdin complex
1HOO	;	2.3	;	STRUCTURE OF GUANINE NUCLEOTIDE (GPPCP) COMPLEX OF ADENYLOSUCCINATE SYNTHETASE FROM E. COLI AT PH 6.5 AND 25 DEGREES CELSIUS
1HON	;	2.3	;	STRUCTURE OF GUANINE NUCLEOTIDE (GPPCP) COMPLEX OF ADENYLOSUCCINATE SYNTHETASE FROM ESCHERICHIA COLI AT PH 6.5 AND 25 DEGREE CELSIUS
1HOP	;	2.3	;	STRUCTURE OF GUANINE NUCLEOTIDE (GPPCP) COMPLEX OF ADENYLOSUCCINATE SYNTHETASE FROM ESCHERICHIA COLI AT PH 6.5 AND 25 DEGREES CELSIUS
6UC7	;	1.798	;	Structure of guanine riboswitch bound to N2-acetyl guanine
3TR0	;	1.851	;	Structure of guanylate kinase (gmk) from Coxiella burnetii
1CKN	;	2.5	;	STRUCTURE OF GUANYLYLATED MRNA CAPPING ENZYME COMPLEXED WITH GTP
8DCG	;	2.35	;	Structure of guanylylated RNA ligase RtcB from Pyrococcus horikoshii
4YKB	;	3.5	;	Structure of GUN4 from Chlamydomonas reinhardtii
1Z3X	;	1.5	;	Structure of Gun4 from Thermosynechococcus elongatus
1Z3Y	;	1.7	;	Structure of Gun4-1 from Thermosynechococcus elongatus
5MZM	;	2.4	;	Structure of H-2Db in complex with TEIPP APL Trh4 p3P
6GB7	;	2.15	;	Structure of H-2Db with scoop loop from tapasin
6GB5	;	2.3	;	Structure of H-2Db with truncated SEV peptide and GL
6GB6	;	1.78	;	Structure of H-2Kb with dipeptide GL
2E9N	;	2.5	;	Structure of h-CHK1 complexed with A767085
2E9P	;	2.6	;	Structure of h-CHK1 complexed with A771129
2E9U	;	2.0	;	Structure of h-CHK1 complexed with A780125
2E9V	;	2.0	;	Structure of h-CHK1 complexed with A859017
2E9O	;	2.1	;	Structure of h-CHK1 complexed with AA582939
3B50	;	1.4	;	Structure of H. influenzae sialic acid binding protein bound to Neu5Ac.
6FAQ	;	1.95	;	Structure of H. salinarum RosR (vng0258) grown from KBr
6FDH	;	1.85	;	Structure of H. salinarum RosR (vng0258) grown from KCl
6EZ1	;	1.75004	;	Structure of h. salinarum RosR (vng0258) grown from NaBr
6F5C	;	1.55	;	Structure of h. salinarum RosR (vng0258) grown from NaCl
6GME	;	1.802	;	Structure of H. sapiens SPT6 tandem SH2 domain
3LWV	;	2.499	;	Structure of H/ACA RNP bound to a substrate RNA containing 2'-deoxyuridine
3LWQ	;	2.678	;	Structure of H/ACA RNP bound to a substrate RNA containing 3MU
3LWR	;	2.203	;	Structure of H/ACA RNP bound to a substrate RNA containing 4SU
3LWP	;	2.5	;	Structure of H/ACA RNP bound to a substrate RNA containing 5BrdU
3LWO	;	2.855	;	Structure of H/ACA RNP bound to a substrate RNA containing 5BrU
6FYT	;	2.8	;	Structure of H1 (A/solomon Islands/3/06) Influenza Hemagglutinin in complex with SD38
2WRG	;	3.0	;	structure of H1 1918 hemagglutinin with human receptor
2WRH	;	3.0	;	structure of H1 duck albert hemagglutinin with human receptor
7SCO	;	3.37	;	Structure of H1 influenza hemagglutinin bound to Fab 310-39G10
7SCN	;	3.02	;	Structure of H1 NC99 influenza hemagglutinin bound to Fab 310-63E6
4QY0	;	2.47	;	Structure of H10 from human-infecting H10N8
4QY1	;	2.594	;	Structure of H10 from human-infecting H10N8 in complex with avian receptor
4QY2	;	2.399	;	Structure of H10 from human-infecting H10N8 virus in complex with human receptor analog
4X08	;	1.34	;	Structure of H128N/ECP mutant in complex with sulphate anions at 1.34 Angstroms.
7V7X	;	2.7	;	Structure of H194A AdaV
2WRF	;	3.1	;	structure of H2 avian jena hemagglutinin with human receptor
2WRD	;	3.0	;	structure of H2 japan hemagglutinin
2WRE	;	3.001	;	structure of H2 japan hemagglutinin with human receptor
4UEW	;	2.08	;	Structure of H2-treated anaerobically purified D. fructosovorans NiFe- hydrogenase
5BWG	;	1.75	;	Structure of H200C variant of Homoprotocatechuate 2,3-Dioxygenase from B.fuscum at 1.75 Ang resolution
5BWH	;	1.46	;	Structure of H200C variant of Homoprotocatechuate 2,3-Dioxygenase from B.fuscum in complex with HPCA at 1.46 Ang resolution
4Z6L	;	1.65	;	Structure of H200E variant of Homoprotocatechuate 2,3-Dioxygenase from B.fuscum at 1.65 Ang resolution
4Z6U	;	1.48	;	Structure of H200E variant of Homoprotocatechuate 2,3-Dioxygenase from B.fuscum in complex with 4-nitrocatechol at 1.48 Ang resolution
4Z6R	;	1.7	;	Structure of H200E variant of Homoprotocatechuate 2,3-Dioxygenase from B.fuscum in complex with 4-sulfonyl catechol at 1.70 Ang resolution
4Z6O	;	1.63	;	Structure of H200E variant of Homoprotocatechuate 2,3-Dioxygenase from B.fuscum in complex with HPCA at 1.63 Ang resolution
4Z6N	;	1.52	;	Structure of H200N variant of Homoprotocatechuate 2,3-Dioxygenase from B.fuscum at 1.52 Ang resolution
4Z6W	;	1.57	;	Structure of H200N variant of Homoprotocatechuate 2,3-Dioxygenase from B.fuscum in complex with 4-nitrocatechol at 1.57 Ang resolution
4Z6T	;	1.5	;	Structure of H200N variant of Homoprotocatechuate 2,3-Dioxygenase from B.fuscum in complex with 4-sulfonyl catechol at 1.50 Ang resolution
4Z6Q	;	1.57	;	Structure of H200N variant of Homoprotocatechuate 2,3-Dioxygenase from B.fuscum in complex with HPCA at 1.57 Ang resolution
4Z6M	;	1.35	;	Structure of H200Q variant of Homoprotocatechuate 2,3-Dioxygenase from B.fuscum at 1.35 Ang resolution
4Z6V	;	1.37	;	Structure of H200Q variant of Homoprotocatechuate 2,3-Dioxygenase from B.fuscum in complex with 4-nitrocatechol at 1.37 Ang resolution
4Z6S	;	1.42	;	Structure of H200Q variant of Homoprotocatechuate 2,3-Dioxygenase from B.fuscum in complex with 4-sulfonyl catechol at 1.42 Ang resolution
4Z6P	;	1.75	;	Structure of H200Q variant of Homoprotocatechuate 2,3-Dioxygenase from B.fuscum in complex with HPCA at 1.75 Ang resolution
4Z1B	;	2.4	;	Structure of H204A mutant KDO8PS from H.pylori
6JN7	;	2.04	;	Structure of H216A mutant closed form peptidoglycan peptidase
6JN8	;	2.106	;	Structure of H216A mutant open form peptidoglycan peptidase
6F89	;	2.81	;	Structure of H234A/Y235A P.abyssi Sua5
6JMZ	;	1.92	;	Structure of H247A mutant open form peptidoglycan peptidase
6JN1	;	2.382	;	Structure of H247A mutant peptidoglycan peptidase complex with penta peptide
6JN0	;	2.164	;	Structure of H247A mutant peptidoglycan peptidase complex with tetra-tri peptide
2AAF	;	2.3	;	Structure of H278A arginine deiminase with L-arginine forming a S-alkylthiouronium reaction intermediate
1JSM	;	1.9	;	STRUCTURE OF H5 AVIAN HAEMAGGLUTININ
4GL1	;	1.5	;	Structure of H64A/N62L/N67L Human Carbonic Anhydrase II triple mutant
6FYU	;	2.643	;	Structure of H7(A/Shanghai/2/2013) Influenza Hemagglutinin in complex SD36
5VE9	;	2.795	;	Structure of hACF7 EF1-EF2-GAR domains
8TTO	;	2.0	;	Structure of Hachiman anti-defense 1 (Had1)
7LRW	;		;	Structure of Hact-2
7LT7	;		;	Structure of Hact-3
7MJ3	;		;	Structure of Hact-4
7LX4	;		;	Structure of Hact-SCRiP1
1COH	;	2.9	;	STRUCTURE OF HAEMOGLOBIN IN THE DEOXY QUATERNARY STATE WITH LIGAND BOUND AT THE ALPHA HAEMS
3IL3	;	2.7	;	Structure of Haemophilus influenzae FabH
1JJW	;	1.9	;	Structure of Haemophilus influenzae HslV Protein at 1.9 A Resolution
3ZTV	;	1.3	;	Structure of Haemophilus influenzae NAD nucleotidase (NadN)
3ZU0	;	2.001	;	Structure of Haemophilus influenzae NAD nucleotidase (NadN)
1JMV	;	1.85	;	Structure of Haemophylus influenzae Universal Stress Protein At 1.85A Resolution
5V76	;	1.55	;	Structure of Haliangium ochraceum BMC-T HO-3341
5DIH	;	2.444	;	Structure of Haliangium ochraceum BMC-T HO-5812
5V75	;	1.7	;	Structure of Haliangium ochraceum BMC-T HO-5816
1ZMT	;	1.7	;	Structure of haloalcohol dehalogenase HheC of Agrobacterium radiobacter AD1 in complex with (R)-para-nitro styrene oxide, with a water molecule in the halide-binding site
4HZG	;	1.95	;	Structure of haloalkane dehalogenase DhaA from Rhodococcus rhodochrous
3G9X	;	0.95	;	Structure of haloalkane dehalogenase DhaA14 mutant I135F from Rhodococcus rhodochrous
8B5O	;	1.597	;	Structure of haloalkane dehalogenase DmmarA from Mycobacterium marinum at pH 5.5
8B5K	;	1.849	;	Structure of haloalkane dehalogenase DmmarA from Mycobacterium marinum at pH 6.5
3FWH	;	1.22	;	Structure of haloalkane dehalogenase mutant Dha15 (I135F/C176Y) from Rhodococcus rhodochrous
7O3O	;	1.25	;	Structure of haloalkane dehalogenase mutant DhaA80(T148L, G171Q, A172V, C176F) from Rhodococcus rhodochrous with ionic liquid
5FLK	;	0.99	;	Structure of haloalkane dehalogenase variant DhaA101
7O8B	;	1.75	;	Structure of haloalkane dehalogenase variant DhaA80 from Rhodococcus rhodochrous
5VGU	;	1.80719	;	Structure of Halothece sp. PCC 7418 CcmK4
3HJ6	;	2.8	;	Structure of Halothermothrix orenii fructokinase (FRK)
7DHQ	;	2.7	;	Structure of Halothiobacillus neapolitanus Microcompartments Protein CsoS1D
8VXY	;	3.19	;	Structure of HamA(E138A,K140A)B-plasmid DNA complex from the Escherichia coli Hachiman defense system
8VX9	;	2.65	;	Structure of HamAB apo complex from the Escherichia coli Hachiman defense system
8VXA	;	2.79	;	Structure of HamB-DNA complex, conformation 1, from the Escherichia coli Hachiman defense system
8VXC	;	2.93	;	Structure of HamB-DNA complex, conformation 2, from the Escherichia coli Hachiman defense system
3ZX6	;	2.65	;	Structure of Hamp(AF1503)-Tsr fusion - Hamp (A291V) mutant
6Y6P	;	1.938	;	Structure of Hantaan virus envelope glycoprotein Gn
5LJY	;	3.0	;	Structure of hantavirus envelope glycoprotein Gc in complex with scFv A5
5LJZ	;	1.6	;	Structure of hantavirus envelope glycoprotein Gc in postfusion conformation
5LK0	;	1.8	;	Structure of hantavirus envelope glycoprotein Gc in postfusion conformation in presence of 100 mM KCL
5LK1	;	1.7	;	Structure of hantavirus envelope glycoprotein Gc in postfusion conformation in presence of 200 mM KCL
5LK2	;	1.6	;	Structure of hantavirus envelope glycoprotein Gc in postfusion conformation in presence of 300 mM KCL
5LK3	;	1.5	;	Structure of hantavirus envelope glycoprotein Gc in postfusion conformation in presence of 500 mM KCL
5LJX	;	1.4	;	Structure of hantavirus envelope glycoprotein Gc in postfusion conformation in presence of 600 mM KCL
1QP9	;	2.8	;	STRUCTURE OF HAP1-PC7 COMPLEXED TO THE UAS OF CYC7
8AUP	;	2.17	;	Structure of hARG1 with a novel inhibitor.
3K1R	;	2.3	;	Structure of harmonin NPDZ1 in complex with the SAM-PBM of Sans
4JRU	;	1.2	;	Structure of haze forming proteins in white wines: Vitis vinifera thaumatin-like proteins
4L5H	;	1.8	;	Structure of haze forming proteins in white wines: Vitis vinifera thaumatin-like proteins
4MBT	;	1.65	;	Structure of haze forming proteins in white wines: Vitis vinifera thaumatin-like proteins
7JXZ	;	2.23	;	Structure of HbA with compound (S)-4
7JY1	;	1.59	;	Structure of HbA with compound 19
7JY3	;	1.48	;	Structure of HbA with compound 23 (PF-07059013)
7JY0	;	1.63	;	Structure of HbA with compound 9
3PT8	;	1.762	;	Structure of HbII-III-CN from Lucina pectinata at pH 5.0
3PT7	;	2.15	;	Structure of HbII-III-Oxy from Lucina pectinata at pH 5.0
3TPA	;	2.0001	;	Structure of HbpA2 from Haemophilus parasuis
4IWZ	;	1.598	;	structure of hCAII in complex with an acetazolamide derivative
4K1Q	;	1.699	;	Structure of hCAIX mimic (hCAII with 5 mutations in active site)
4K0S	;	1.802	;	Structure of HCAIX mimic (HCAII with 5 mutations in active site) in complex with acetazolamide
4K0T	;	1.78	;	Structure of HCAIX mimic (HCAII with 5 mutations in active site) in complex with chlorzolamide
4K13	;	1.6	;	Structure of HCAIX mimic (HCAII with 5 mutations in active site) in complex with dorzolamide
4K0Z	;	1.799	;	Structure of HCAIX mimic (HCAII with 5 mutations in active site) in complex with methazolamide
5HUY	;	1.979	;	Structure of HCMV Small Terminase NLS bound to importin alpha
6BDC	;	2.496	;	Structure of Hcp1 from Flavobacterium johnsoniae
3RSJ	;	2.0	;	Structure of HCRF in complex with Ganglioside GD1a
5ERW	;	2.9	;	Structure of HCV E2 glycoprotein antigenic Epitope II bound to the broadly neutralizing antibody HC84-26
3EYD	;	2.3	;	Structure of HCV NS3-4A Protease with an Inhibitor Derived from a Boronic Acid
2QE2	;	2.9	;	Structure of HCV NS5B Bound to an Anthranilic Acid Inhibitor
2QE5	;	2.6	;	Structure of HCV NS5B Bound to an Anthranilic Acid Inhibitor
1NS3	;	2.8	;	STRUCTURE OF HCV PROTEASE (BK STRAIN)
6VMX	;	3.1	;	Structure of HD14 TCR in complex with HLA-B7 presenting an EBV epitope
5G1C	;	1.81	;	Structure of HDAC like protein from Bordetella Alcaligenes bound the photoswitchable pyrazole Inhibitor CEW395
5G3W	;	1.6	;	Structure of HDAC like protein from Bordetella Alcaligenes in complex with the photoswitchable inhibitor CEW65
7ZZP	;	1.52	;	Structure of HDAC2 complexed with an inhibitory ligand
7MOZ	;	1.543	;	Structure of HDAC2 in complex with a macrocyclic inhibitor (compound 25)
7MOS	;	1.704	;	Structure of HDAC2 in complex with a macrocyclic inhibitor (compound 4)
7MOX	;	1.69	;	Structure of HDAC2 in complex with an inhibitor (compound 14)
7MOY	;	1.78	;	Structure of HDAC2 in complex with an inhibitor (compound 19)
7MOT	;	1.54	;	Structure of HDAC2 in complex with an inhibitor (compound 9)
4A69	;	2.06	;	Structure of HDAC3 bound to corepressor and inositol tetraphosphate
2VQQ	;	1.9	;	Structure of HDAC4 catalytic domain (a double cysteine-to-alanine mutant) bound to a trifluoromethylketone inhbitor
2VQM	;	1.8	;	Structure of HDAC4 catalytic domain bound to a hydroxamic acid inhbitor
2VQJ	;	2.1	;	Structure of HDAC4 catalytic domain bound to a trifluoromethylketone inhbitor
2VQO	;	2.15	;	Structure of HDAC4 catalytic domain with a gain-of-function muation bound to a trifluoromethylketone inhbitor
2VQV	;	3.3	;	Structure of HDAC4 catalytic domain with a gain-of-function mutation bound to a hydroxamic acid inhibitor
8G44	;	1.55	;	Structure of HDAC6 zinc-finger ubiquitin binding domain in complex with 3-(3-(2-(benzylamino)-2-oxoethyl)-4-oxo-3,4-dihydroquinazolin-2-yl)propanoic acid
8G43	;	1.55	;	Structure of HDAC6 zinc-finger ubiquitin binding domain in complex with 3-(3-(2-(methylamino)-2-oxoethyl)-4-oxo-3,4-dihydroquinazolin-2-yl)propanoic acid
8G45	;	1.62	;	Structure of HDAC6 zinc-finger ubiquitin binding domain in complex with SGC-UBD253 chemical probe
6CE6	;	1.6	;	Structure of HDAC6 zinc-finger ubiquitin binding domain soaked with 3,3'-(benzo[1,2-d:5,4-d']bis(thiazole)-2,6-diyl)dipropionic acid
4B6H	;	2.6	;	Structure of hDcp1a in complex with proline rich sequence of PNRC2
3VBG	;	2.8	;	Structure of hDM2 with Dimer Inducing Indolyl Hydantoin RO-2443
3U15	;	1.8	;	Structure of hDMX with Dimer Inducing Indolyl Hydantoin RO-2443
6TJR	;	1.43	;	Structure of HdrA-like subunit from Hyphomicrobium denitrificans
6IAW	;	3.8	;	Structure of head fiber and inner core protein gp22 of native bacteriophage P68
3FCU	;	2.9	;	Structure of headpiece of integrin aIIBb3 in open conformation
5FPE	;	1.96	;	Structure of heat shock-related 70kDA protein 2 with small-molecule ligand 1H-1,2,4-triazol-3-amine (AT485) in an alternate binding site.
5FPN	;	1.96	;	Structure of heat shock-related 70kDA protein 2 with small-molecule ligand 3,5-dimethyl-1H-pyrazole-4-carboxylic acid (AT9084) in an alternate binding site.
5FPM	;	1.96	;	Structure of heat shock-related 70kDA protein 2 with small-molecule ligand 5-phenyl-1,3,4-oxadiazole-2-thiol (AT809) in an alternate binding site.
5FPD	;	1.97	;	Structure of heat shock-related 70kDA protein 2 with small-molecule ligand pyrazine-2-carboxamide (AT513) in an alternate binding site.
8C07	;	3.3	;	Structure of HECT E3 UBR5 forming K48 linked Ubiquitin chains
7Q6Z	;	3.59	;	Structure of Hedgehog acyltransferase (HHAT) in complex with megabody 177 bound to IMP-1575
7Q1U	;	2.7	;	Structure of Hedgehog acyltransferase (HHAT) in complex with megabody 177 bound to non-hydrolysable palmitoyl-CoA (Composite Map)
6MCJ	;	1.712	;	Structure of Helical Carotenoid Protein 2 from Fremyella diplosiphon
8T8D	;	2.9	;	Structure of Helicobacter pylori adhesin A, HpaA
4ZH0	;	1.91	;	Structure of Helicobacter pylori adhesin BabA determined by SeMet SAD
1QWL	;	1.6	;	Structure of Helicobacter pylori catalase
1QWM	;	1.6	;	Structure of Helicobacter pylori catalase with formic acid bound
4RNZ	;	1.98	;	Structure of Helicobacter pylori Csd3 from the hexagonal crystal
4RNY	;	2.0	;	Structure of Helicobacter pylori Csd3 from the orthorhombic crystal
4Y4V	;	2.04	;	Structure of Helicobacter pylori Csd6 in the D-Ala-bound state
4XZZ	;	2.03	;	Structure of Helicobacter pylori Csd6 in the ligand-free state
8DP7	;	3.35	;	Structure of Helicobacter pylori EgtU bound to EGT
2EW5	;	2.2	;	Structure of Helicobacter Pylori peptide deformylase in complex with inhibitor
2EW6	;	2.2	;	Structure of Helicobacter Pylori peptide deformylase in complex with inhibitor
6IUB	;	1.902	;	Structure of Helicobacter pylori Soj protein
6IUD	;	2.506	;	Structure of Helicobacter pylori Soj-ADP complex bound to DNA
6IUC	;	3.4	;	Structure of Helicobacter pylori Soj-ATP complex bound to DNA
2XB9	;	2.75	;	Structure of Helicobacter pylori type II dehydroquinase in complex with inhibitor compound (2R)-2-(4-methoxybenzyl)-3-dehydroquinic acid
2XDA	;	1.85	;	STRUCTURE OF HELICOBACTER PYLORI TYPE II DEHYDROQUINASE IN COMPLEX WITH INHIBITOR COMPOUND (4R,6R,7S)-2-(2-Cyclopropyl)ethyl-4,6,7- trihydroxy-4,5,6,7-tetrahydrobenzo(b)thiophene-4-carboxylic acid
2XD9	;	1.95	;	STRUCTURE OF HELICOBACTER PYLORI TYPE II DEHYDROQUINASE IN COMPLEX WITH INHIBITOR COMPOUND (4R,6R,7S)-4,6,7-Trihydroxy-2-((E)-prop-1- enyl)-4,5,6,7-tetrahydrobenzo(b)thiophene-4-carboxylic acid
4B6R	;	2.0	;	Structure of Helicobacter pylori Type II Dehydroquinase inhibited by (2S)-2-(4-methoxy)benzyl-3-dehydroquinic acid
4B6S	;	1.9	;	Structure of Helicobacter pylori Type II Dehydroquinase inhibited by (2S)-2-Perfluorobenzyl-3-dehydroquinic acid
2WKS	;	2.95	;	Structure of Helicobacter pylori Type II Dehydroquinase with a new carbasugar-thiophene inhibitor.
2MEQ	;		;	Structure of Helix 69 from Escherichia coli 23S Ribosomal RNA
2MER	;		;	Structure of helix 69 from escherichia coli 23s ribosomal rna
4Q56	;	1.38	;	Structure of Helix aspersa agglutinin with natural glycosylation and N-acetyl-alpha-D-galactosamine (GalNAc)
2CGY	;	2.8	;	STRUCTURE OF HELIX POMATIA AGGLUTININ WITH FORSMANN ANTIGEN
2CE6	;	2.4	;	Structure of Helix Pomatia agglutinin with no ligands
2CGZ	;	2.8	;	Structure of Helix Pomatia agglutinin with Tn antigen
2CCV	;	1.3	;	Structure of Helix Pomatia agglutinin with zinc and N-acetyl-alpha-D- galactoseamine (GalNAc)
4NRJ	;	2.53	;	Structure of hemagglutinin with F95Y mutation of influenza virus B/Lee/40
4NRL	;	2.72	;	Structure of hemagglutinin with F95Y mutation of influenza virus B/Lee/40
4NRK	;	2.63	;	Structure of hemagglutinin with F95Y mutation of influenza virus B/Lee/40 complex with LSTc
5BNC	;	2.25	;	Structure of heme binding protein MSMEG_6519 from Mycobacterium smegmatis
5KZL	;	1.73	;	Structure of Heme Oxygenase from Leptospira interrogans
4WMH	;	2.5	;	Structure of heme oxygenase-2 containing residues 1-288 lacking the membrane spanning region
3QUG	;	1.7	;	Structure of heme transport protein IsdH-NEAT3 from S. aureus in complex with Gallium-porphyrin
3VTM	;	2.8	;	Structure of heme transport protein IsdH-NEAT3 from S. aureus in complex with Indium-porphyrin
3QUH	;	2.7	;	Structure of heme transport protein IsdH-NEAT3 from S. aureus in complex with Manganese(III)-porphyrin
3HX9	;	1.75	;	Structure of heme-degrader, MhuD (Rv3592), from Mycobacterium tuberculosis with two hemes bound in its active site
7ZPB	;	2.31	;	Structure of hemiacetylated human butyrylcholinesterase upon reaction with 8-(3-(4-(prop-2-yn-1-yl)piperazin-1-yl)propoxy)quinoline-2-carbaldehyde
3WHM	;	1.85	;	Structure of Hemoglobin Complex with 18-crown-6
3A59	;	3.41	;	Structure of Hemoglobin from flightless bird (Struthio camelus)
7SGR	;	2.9	;	Structure of hemolysin A secretion system HlyB/D complex
8DCK	;	3.4	;	Structure of hemolysin A secretion system HlyB/D complex, ATP-bound
7AC2	;	1.507	;	Structure of Hen Egg White Lysozyme collected by rotation serial crystallography on a COC membrane at a synchrotron source
6TVY	;	1.51	;	Structure of hen egg white lysozyme crystallized in the presence of Tb-Xo4 crystallophore in the XtalController device
1YIK	;	1.75	;	Structure of Hen egg white lysozyme soaked with Cu-cyclam
1YIL	;	1.6	;	Structure of Hen egg white lysozyme soaked with Cu2-Xylylbicyclam
2H9K	;	1.75	;	Structure of Hen egg white lysozyme soaked with Ni-cyclam
2H9J	;	1.75	;	Structure of Hen egg white lysozyme soaked with Ni2-Xylylbicyclam
3E3D	;	1.55	;	Structure of hen egg white lysozyme with the magic triangle I3C
1DPX	;	1.65	;	STRUCTURE OF HEN EGG-WHITE LYSOZYME
6YJX	;	1.2	;	Structure of Hen egg-white lysozyme crystallized with PAS polypeptide
2HUB	;	1.201	;	Structure of Hen Egg-White Lysozyme Determined from crystals grown in pH 7.5
4WMG	;	2.5	;	Structure of hen egg-white lysozyme from a microfludic harvesting device using synchrotron radiation (2.5A)
7KNK	;	1.45	;	STRUCTURE OF HEN EGG-WHITE LYSOZYME grown with Kitchen recipe
1DPW	;	1.64	;	STRUCTURE OF HEN EGG-WHITE LYSOZYME IN COMPLEX WITH MPD
6JZI	;	2.0	;	Structure of hen egg-white lysozyme obtained from SFX experiments under atmospheric pressure
6B7W	;	1.482	;	Structure of hen egg-white lysozyme pre-treated with high pressure (600 MPa) under isobaric condition
6B7V	;	1.482	;	Structure of hen egg-white lysozyme pre-treated with high-pressure homogenization at 120 MPa
6B7U	;	1.581	;	Structure of hen egg-white lysozyme without high-pressure pre-treatment
3IKW	;	1.3	;	Structure of Heparinase I from Bacteroides thetaiotaomicron
3ILR	;	1.5	;	Structure of Heparinase I from Bacteroides thetaiotaomicron in complex with tetrasaccharide product
3E80	;	2.35	;	Structure of Heparinase II complexed with heparan sulfate degradation disaccharide product
8GIH	;	2.65	;	Structure of Hepatitis B Virus Capsid Y132A mutant in complex with Compound 24
2OBO	;	2.6	;	Structure of HEPATITIS C VIRAL NS3 protease domain complexed with NS4A peptide and ketoamide SCH476776
2OC8	;	2.66	;	Structure of Hepatitis C Viral NS3 protease domain complexed with NS4A peptide and ketoamide SCH503034
2OC7	;	2.7	;	Structure of Hepatitis C Viral NS3 protease domain complexed with NS4A peptide and ketoamide SCH571696
5FPT	;	2.72	;	Structure of hepatitis C virus (HCV) full-length NS3 complex with small-molecule ligand 2-(1-methyl-1H-indol-3-yl)acetic acid (AT3437) in an alternate binding site.
5FPS	;	2.68	;	Structure of hepatitis C virus (HCV) full-length NS3 complex with small-molecule ligand 3-aminobenzene-1,2-dicarboxylic acid (AT1246) in an alternate binding site.
5FPY	;	2.52	;	Structure of hepatitis C virus (HCV) full-length NS3 complex with small-molecule ligand 5-bromo-1-methyl-1H-indole-2-carboxylic acid (AT21457) in an alternate binding site.
7MWW	;	2.71	;	Structure of hepatitis C virus envelope full-length glycoprotein 2 (eE2) from J6 genotype
4Z0X	;	2.0	;	Structure of Hepatitis C Virus Envelope glycoprotein E2 antigenic region 434-446 bound to the broadly neutralizing antibody HC26AM
4MWF	;	2.645	;	Structure of Hepatitis C Virus Envelope Glycoprotein E2 core bound to broadly neutralizing antibody AR3C
6WO5	;	2.619	;	Structure of Hepatitis C Virus Envelope Glycoprotein E2 core from genotype 1a bound to neutralizing antibody 212.1.1 and non neutralizing antibody E1
6WOQ	;	3.667	;	Structure of Hepatitis C Virus Envelope Glycoprotein E2 core from genotype 1a bound to neutralizing antibody HC1AM and non neutralizing antibody E1
6BKB	;	2.799	;	Structure of Hepatitis C Virus Envelope Glycoprotein E2 core from genotype 6a bound to broadly neutralizing antibody AR3A
6BKC	;	2.6	;	Structure of Hepatitis C Virus Envelope Glycoprotein E2 core from genotype 6a bound to broadly neutralizing antibody AR3B
6BKD	;	3.25	;	Structure of Hepatitis C Virus Envelope Glycoprotein E2 core from genotype 6a bound to broadly neutralizing antibody AR3D
6WO4	;	2.349	;	Structure of Hepatitis C Virus Envelope Glycoprotein E2 core from genotype 6a bound to broadly neutralizing antibody HC11
7JTG	;	2.6	;	Structure of Hepatitis C Virus Envelope Glycoprotein E2 core from genotype 6a bound to broadly neutralizing antibody RM11-43
7JTF	;	3.35	;	Structure of Hepatitis C Virus Envelope Glycoprotein E2 core from genotype 6a bound to broadly neutralizing antibody RM2-01
6WO3	;	2.382	;	Structure of Hepatitis C Virus Envelope Glycoprotein E2 core from genotype 6a bound to broadly neutralizing antibody U1
6UYG	;	3.375	;	Structure of Hepatitis C Virus Envelope Glycoprotein E2c3 core from genotype 6a bound to broadly neutralizing antibody AR3A and non neutralizing antibody E1
6UYD	;	1.897	;	Structure of Hepatitis C Virus Envelope Glycoprotein E2mc3-v1 redesigned core from genotype 1a bound to broadly neutralizing antibody AR3C
6UYF	;	2.06	;	Structure of Hepatitis C Virus Envelope Glycoprotein E2mc3-v1 redesigned core from genotype 6a bound to broadly neutralizing antibody AR3B
6UYM	;	2.848	;	Structure of Hepatitis C Virus Envelope Glycoprotein E2mc3-v6 redesigned core from genotype 1a bound to broadly neutralizing antibody AR3C
8DK6	;	2.45	;	Structure of hepatitis C virus envelope N-terminal truncated glycoprotein 2 (E2) (residues 456-713) from J6 genotype
2ZKU	;	1.95	;	Structure of hepatitis C virus NS5B polymerase in a new crystal form
8HR8	;	3.3	;	Structure of heptameric RdrA ring
8HRA	;	3.76	;	Structure of heptameric RdrA ring in RNA-loading state
3WSQ	;	3.5	;	Structure of HER2 with an Fab
8J4U	;	2.97	;	Structure of HerA-Sir2 complex from Escherichia coli Nezha system
6MH2	;	2.8	;	Structure of Herceptin Fab without antigen
4BOM	;	27.0	;	Structure of herpesvirus fusion glycoprotein B-bilayer complex revealing the protein-membrane and lateral protein-protein interaction
5A3G	;		;	Structure of herpesvirus nuclear egress complex subunit M50
2PY2	;	1.7	;	Structure of Herring Type II Antifreeze Protein
1DXW	;		;	structure of hetero complex of non structural protein (NS) of hepatitis C virus (HCV) and synthetic peptidic compound
8B41	;	3.8	;	Structure of heteromeric LRRC8A/C (1:1 co-transfected) Volume-Regulated Anion Channel in complex with synthetic nanobody Sb1
8B42	;	6.6	;	Structure of heteromeric LRRC8A/C Volume-Regulated Anion Channel.
3AH8	;	2.9	;	Structure of heterotrimeric G protein Galpha-q beta gamma in complex with an inhibitor YM-254890
4MXW	;	3.6	;	Structure of heterotrimeric lymphotoxin LTa1b2 bound to lymphotoxin beta receptor LTbR and anti-LTa Fab
7KBU	;	2.27	;	Structure of Hevin FS-EC
6HT2	;	2.6	;	STRUCTURE OF HEWL BY ELECTRON DIFFRACTION AND MICROFOCUS DIFFRACTION
6HU5	;	2.8	;	STRUCTURE OF HEWL BY ELECTRON DIFFRACTION AND MICROFOCUS DIFFRACTION
6AGN	;	1.08	;	Structure of HEWL co-crystallised with Cinnamaldehyde
6AGR	;	1.22	;	Structure of HEWL co-crystallised with phenylethyl alcohol
6ADF	;	1.08	;	Structure of HEWL co-crystallised with TEMED
6MQV	;	2.0	;	Structure of HEWL from LCP injector using synchrotron radiation
4ZIX	;	1.89	;	Structure of HEWL using Serial Femtosecond Crystallography of Soluble Proteins in Lipidic Cubic Phase
8CD6	;	1.85	;	structure of HEX-1 (cyto V2) from N. crassa grown in living insect cells, diffracted at 100K and resolved using CrystFEL
8CD4	;	1.83	;	structure of HEX-1 from N. crassa crystallized in cellulo (cytosol), diffracted at 100K and resolved using CrystFEL
8CD5	;	1.56	;	structure of HEX-1 from N. crassa crystallized in cellulo, diffracted at 100K and resolved using CrystFEL
8CGX	;	1.85	;	structure of HEX-1 from N. crassa crystallized in cellulo, diffracted at 100K and resolved using XDS
3EQ2	;	3.401	;	Structure of Hexagonal Crystal form of Pseudomonas aeruginosa RssB
1TEW	;	1.65	;	STRUCTURE OF HEXAGONAL TURKEY EGG WHITE LYSOZYME AT 1.65 ANGSTROMS RESOLUTION
5NMU	;	2.15	;	Structure of hexameric CBS-CP12 protein from bloom-forming cyanobacteria
7PTR	;	3.46	;	Structure of hexameric S-layer protein from Haloferax volcanii archaea
8BEI	;	3.06	;	Structure of hexameric subcomplexes (Truncation Delta2-6) of the fractal citrate synthase from Synechococcus elongatus PCC7942
2KT3	;		;	Structure of Hg-NmerA, Hg(II) complex of the N-terminal domain of Tn501 Mercuric Reductase
6HB1	;	2.33	;	Structure of Hgh1, crystal form I
6HB2	;	2.7	;	Structure of Hgh1, crystal form I, Selenomethionine derivative
6HB3	;	3.0	;	Structure of Hgh1, crystal form II
4KBL	;	3.3	;	Structure of HHARI, a RING-IBR-RING ubiquitin ligase: autoinhibition of an Ariadne-family E3 and insights into ligation mechanism
4KC9	;	3.603	;	Structure of HHARI, a RING-IBR-RING ubiquitin ligase: autoinhibition of an Ariadne-family E3 and insights into ligation mechanism
1NO5	;	1.8	;	Structure of HI0073 from Haemophilus influenzae, the nucleotide binding domain of the HI0073/HI0074 two protein nucleotidyl transferase.
1JOG	;	2.4	;	Structure of HI0074 from Heamophilus Influenzae reveals the fold of a substrate binding domain of a nucleotidyltransferase
1MWQ	;	0.99	;	Structure of HI0828, a Hypothetical Protein from Haemophilus influenzae with a Putative Active-Site Phosphohistidine
1JO0	;	1.37	;	Structure of HI1333, a Hypothetical Protein from Haemophilus influenzae with Structural Similarity to RNA-binding Proteins
1MW5	;	2.1	;	Structure of HI1480 from Haemophilus influenzae
7YKW	;	3.6	;	Structure of hIAPP fibril at 3.6 Angstroms resolution
7YL3	;	3.2	;	Structure of hIAPP-TF-type1
7YL0	;	3.2	;	Structure of hIAPP-TF-type2
7YL7	;	3.3	;	Structure of hIAPP-TF-type3
8CK4	;	2.29	;	STRUCTURE OF HIF2A-ARNT HETERODIMER IN COMPLEX WITH (4S)-1-(3,5-difluorophenyl)-5,5-difluoro-3-methanesulfonyl-4,5,6,7-tetrahydro-2-benzothiophen-4-ol
8CK3	;	1.707	;	STRUCTURE OF HIF2A-ARNT HETERODIMER IN COMPLEX WITH (S)-1-(3,5-Difluoro-phenyl)-5,5-difluoro-3-methanesulfonyl-5,6-dihydro-4H-cyclopenta[c]thiophen-4-ol
8CK8	;	2.302	;	STRUCTURE OF HIF2A-ARNT HETERODIMER IN COMPLEX WITH (S)-1-Cyclohexyloxy-5,5-difluoro-3-methanesulfonyl-5,6-dihydro-4H-cyclopenta[c]thiophen-4-ol
6ZZY	;	3.16	;	Structure of high-light grown Chlorella ohadii photosystem I
3TPT	;	2.25	;	Structure of HipA(D309Q) bound to ADP
3TPB	;	1.88	;	Structure of HipA(S150A)
3FBR	;	3.5	;	structure of HipA-amppnp-peptide
5K98	;	3.99	;	Structure of HipA-HipB-O2-O3 complex
1CM2	;	1.8	;	STRUCTURE OF HIS15ASP HPR AFTER HYDROLYSIS OF RINGED SPECIES.
5DRU	;	2.083	;	Structure of His387Ala mutant of the propionaldehyde dehydrogenase from the Clostridium phytofermentans fucose utilisation bacterial microcompartment
1HCD	;		;	STRUCTURE OF HISACTOPHILIN IS SIMILAR TO INTERLEUKIN-1 BETA AND FIBROBLAST GROWTH FACTOR
1HCE	;		;	STRUCTURE OF HISACTOPHILIN IS SIMILAR TO INTERLEUKIN-1 BETA AND FIBROBLAST GROWTH FACTOR
4EWN	;	1.903	;	Structure of HisF-D130V+D176V with bound rCdRP
4EVZ	;	1.462	;	Structure of HisF-LUCA
4RDX	;	2.55	;	Structure of histidinyl-tRNA synthetase in complex with tRNA(His)
6A58	;	1.57	;	Structure of histone demethylase REF6
6A59	;	1.82	;	Structure of histone demethylase REF6 at 1.8A
6A57	;	2.7	;	Structure of histone demethylase REF6 complexed with DNA
1MUF	;	2.26	;	Structure of histone H3 K4-specific methyltransferase SET7/9
1MT6	;	2.2	;	Structure of histone H3 K4-specific methyltransferase SET7/9 with AdoHcy
5BS7	;	3.3	;	Structure of histone H3/H4 in complex with Spt2
5BSA	;	4.611	;	Structure of histone H3/H4 in complex with Spt2
6BX3	;	4.3	;	Structure of histone H3k4 methyltransferase
5CEH	;	3.14	;	Structure of histone lysine demethylase KDM5A in complex with selective inhibitor
5T5K	;	4.0	;	Structure of histone-based chromatin in Archaea
6J2S	;	1.73005	;	Structure of HitA bound to gallium from Pseudomonas aeruginosa
6PUT	;	2.9	;	Structure of HIV cleaved synaptic complex (CSC) intasome bound with calcium
6PUW	;	2.9	;	Structure of HIV cleaved synaptic complex (CSC) intasome bound with magnesium and Bictegravir (BIC)
6V3K	;	3.4	;	Structure of HIV cleaved synaptic complex (CSC) intasome bound with magnesium and INSTI XZ419 (compound 4c)
6PUY	;	2.8	;	Structure of HIV cleaved synaptic complex (CSC) intasome bound with magnesium and INSTI XZ426 (compound 4d)
6PUZ	;	2.8	;	Structure of HIV cleaved synaptic complex (CSC) intasome bound with magnesium and INSTI XZ446 (compound 4f)
3T3C	;	2.1	;	Structure of HIV PR resistant patient derived mutant (comprising 22 mutations) in complex with DRV
1MRX	;	2.0	;	Structure of HIV protease (Mutant Q7K L33I L63I V82F I84V ) complexed with KNI-577
1MRW	;	2.0	;	Structure of HIV protease (Mutant Q7K L33I L63I) complexed with KNI-577
2HB2	;	2.3	;	Structure of HIV protease 6X mutant in apo form
2HC0	;	1.3	;	Structure of HIV protease 6X mutant in complex with AB-2.
2HB4	;	2.15	;	Structure of HIV Protease NL4-3 in an Unliganded State
6N3D	;	1.13	;	Structure of HIV Tat-specific factor 1 U2AF Homology Motif (APO-State)
6N3F	;	2.099	;	Structure of HIV Tat-specific factor 1 U2AF Homology Motif bound to SF3b1 ULM5
6N3E	;	1.893	;	Structure of HIV Tat-specific factor 1 U2AF Homology Motif bound to U2AF ligand motif 4
8FYI	;	3.4	;	Structure of HIV-1 BG505 SOSIP-HT1 in complex with one CD4 molecule
8FYJ	;	4.0	;	Structure of HIV-1 BG505 SOSIP-HT2 in complex with two CD4 molecules (class I)
6OBH	;	2.96	;	Structure of HIV-1 CA 1/2-hexamer
6EC2	;	3.4	;	Structure of HIV-1 CA 1/3-hexamer
6MQO	;	3.2	;	Structure of HIV-1 CA G208R
6MQA	;	3.199	;	Structure of HIV-1 CA P207S
6MQP	;	3.296	;	Structure of HIV-1 CA T210K
6RWG	;		;	Structure of HIV-1 CAcSP1NC mutant(W41A,M42A) interacting with maturation inhibitor EP39
7URN	;	3.43	;	Structure of HIV-1 capsid declination
8EJL	;	3.9	;	Structure of HIV-1 capsid declination in complex with CPSF6-FG peptide
3J34	;	8.6	;	Structure of HIV-1 Capsid Protein by Cryo-EM
3J4F	;	8.6	;	Structure of HIV-1 capsid protein by cryo-EM
3HI1	;	2.9	;	Structure of HIV-1 gp120 (core with V3) in Complex with CD4-Binding-Site Antibody F105
3JWD	;	2.61	;	Structure of HIV-1 gp120 with gp41-Interactive Region: Layered Architecture and Basis of Conformational Mobility
3JWO	;	3.51	;	Structure of HIV-1 gp120 with gp41-Interactive Region: Layered Architecture and Basis of Conformational Mobility
3VH7	;	2.019	;	Structure of HIV-1 gp41 NHR/fusion inhibitor complex P21
3VGY	;	2.034	;	Structure of HIV-1 gp41 NHR/fusion inhibitor complex P321
3L3V	;	2.0	;	Structure of HIV-1 integrase core domain in complex with sucrose
6VRG	;	2.4	;	Structure of HIV-1 integrase with native amino-terminal sequence
6NCJ	;	2.0	;	Structure of HIV-1 Integrase with potent 5,6,7,8-Tetrahydro-1,6-naphthyridine Derivatives Allosteric Site Inhibitors
7MRL	;	3.15	;	Structure of HIV-1 matrix domain bound to human tRNALys3
2LYB	;		;	Structure of HIV-1 myr(-) matrix protein in complex with 1,2-dioctanoyl-sn-phosphatidyl-L-serine
2LYA	;		;	Structure of HIV-1 myr(-) matrix protein in complex with 1,2-dioctanoyl-sn-phosphatidylcholine
2AQU	;	2.0	;	Structure of HIV-1 protease bound to atazanavir
1DMP	;	2.0	;	STRUCTURE OF HIV-1 PROTEASE COMPLEX
2NXD	;	2.0	;	Structure of HIV-1 protease D25N complexed with rt-rh analogue peptide GLY-ALA-ASP-ILE-PHE*TYR-LEU-ASP-GLY-ALA
2NXM	;	2.25	;	Structure of HIV-1 protease D25N complexed with the rt-rh analogue peptide GLY-ALA-GLN-THR-PHE*TYR-VAL-ASP-GLY-ALA
2NXL	;	2.0	;	Structure of HIV-1 protease D25N complexed with the rt-rh analogue peptide GLY-ALA-GLU-VAL-PHE*TYR-VAL-ASP-GLY-ALA
5YOK	;	0.85	;	Structure of HIV-1 Protease in Complex with Inhibitor KNI-1657
3FX5	;	0.93	;	Structure of HIV-1 Protease in Complex with Potent Inhibitor KNI-272 Determined by High Resolution X-ray Crystallography
2ZYE	;	1.9	;	Structure of HIV-1 Protease in Complex with Potent Inhibitor KNI-272 Determined by Neutron Crystallography
2B7Z	;	2.2	;	Structure of HIV-1 protease mutant bound to indinavir
2B60	;	2.2	;	Structure of HIV-1 protease mutant bound to Ritonavir
6OR7	;	2.53	;	Structure of HIV-1 Reverse Transcriptase (RT) in complex with DNA AND (-)FTC-TP
6OTZ	;	2.857	;	Structure of HIV-1 Reverse Transcriptase (RT) in complex with dsDNA and (+)FTC-TP
6WPH	;	2.72	;	Structure of HIV-1 Reverse Transcriptase (RT) in complex with dsDNA and (-)-FTC
6OUN	;	2.656	;	Structure of HIV-1 Reverse Transcriptase (RT) in complex with dsDNA and (-)3TC-TP
6P2G	;	2.99	;	Structure of HIV-1 Reverse Transcriptase (RT) in complex with dsDNA and D-ddCTP
6WPF	;	2.53	;	Structure of HIV-1 Reverse Transcriptase (RT) in complex with dsDNA and d4T
6WPJ	;	2.73	;	Structure of HIV-1 Reverse Transcriptase (RT) in complex with dsDNA and d4T
6P1I	;	2.74	;	Structure of HIV-1 Reverse Transcriptase (RT) in complex with dsDNA and dCTP
6P1X	;	2.553	;	Structure of HIV-1 Reverse Transcriptase (RT) in complex with dsDNA and L-ddCTP
6ELI	;	2.2	;	Structure of HIV-1 reverse transcriptase (RT) in complex with rilpivirine and an RNase H inhibitor XZ462
6AMO	;	2.497	;	STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) TERNARY COMPLEX WITH A DOUBLE STRANDED DNA AND AN INCOMING D4TTP AT PH 7.0
6AN2	;	2.7	;	STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) TERNARY COMPLEX WITH A DOUBLE STRANDED DNA AND AN INCOMING D4TTP AT PH 7.5
6AN8	;	2.596	;	STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) TERNARY COMPLEX WITH A DOUBLE STRANDED DNA AND AN INCOMING D4TTP AT PH 8.0
6ANQ	;	2.586	;	STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) TERNARY COMPLEX WITH A DOUBLE STRANDED DNA AND AN INCOMING D4TTP AT PH 8.5
6ASW	;	2.605	;	STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) TERNARY COMPLEX WITH A DOUBLE STRANDED DNA AND AN INCOMING D4TTP AT PH 9.0
6AVT	;	2.603	;	STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) TERNARY COMPLEX WITH A DOUBLE STRANDED DNA AND AN INCOMING D4TTP AT PH 9.5 WITH CROSS-LINKING TO FIRST BASE TEMPLATE OVERHANG
6AVM	;	2.502	;	STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) TERNARY COMPLEX WITH A DOUBLE STRANDED DNA AND AN INCOMING D4TTP AT PH 9.5 WITH CROSS-LINKING TO SECOND BASE TEMPLATE OVERHANG
5TXL	;	2.501	;	STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) TERNARY COMPLEX WITH A DOUBLE STRANDED DNA AND AN INCOMING DATP
5TXM	;	2.7	;	STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) TERNARY COMPLEX WITH A DOUBLE STRANDED DNA AND AN INCOMING DDATP
6BHJ	;	2.81	;	Structure of HIV-1 Reverse Transcriptase Bound to a 38-mer Hairpin Template-Primer RNA-DNA Aptamer
5D3G	;	2.3	;	Structure of HIV-1 Reverse Transcriptase Bound to a Novel 38-mer Hairpin Template-Primer DNA Aptamer
1HNI	;	2.8	;	STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN A COMPLEX WITH THE NONNUCLEOSIDE INHIBITOR ALPHA-APA R 95845 AT 2.8 ANGSTROMS RESOLUTION
5HLF	;	2.95	;	STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE In COMPLEX WITH A 38-MER HAIRPIN TEMPLATE-PRIMER DNA APTAMER AND AN ALPHA-CARBOXYPHOSPHONATE INHIBITOR
5HRO	;	2.75	;	STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE In COMPLEX WITH A DNA aptamer and an Alpha-carboxy nucleoside phosphonate inhibitor (alpha-CNP)
5HP1	;	2.9	;	STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE In COMPLEX WITH A DNA aptamer and FOSCARNET, a Pyrophosphate analog
5I42	;	3.3	;	Structure of HIV-1 Reverse Transcriptase in complex with a DNA aptamer, AZTTP, and CA(2+) ion
3QIP	;	2.0926	;	Structure of HIV-1 reverse transcriptase in complex with an RNase H inhibitor and nevirapine
6O9E	;	2.4	;	Structure of HIV-1 Reverse Transcriptase in complex with DNA and INDOPY-1
7LRY	;	2.45	;	Structure of HIV-1 Reverse Transcriptase in complex with DNA, (-)FTC-TP, and CA(2+) ion
7LRM	;	3.14	;	Structure of HIV-1 Reverse Transcriptase in complex with DNA, dCTP, and CA(2+) ion
7LRI	;	3.05	;	Structure of HIV-1 Reverse Transcriptase in complex with DNA, dTTP, and CA(2+) ion
7LRX	;	2.9	;	Structure of HIV-1 Reverse Transcriptase in complex with DNA, L-dCTP, and CA(2+) ion
7LSK	;	2.7	;	Structure of HIV-1 Reverse Transcriptase in complex with DNA, L-dTTP, and CA(2+) ion
7KJV	;	2.8	;	Structure of HIV-1 reverse transcriptase initiation complex core
7KJW	;	2.9	;	Structure of HIV-1 reverse transcriptase initiation complex core with efavirenz
7KJX	;	3.1	;	Structure of HIV-1 reverse transcriptase initiation complex core with nevirapine
5I3U	;	3.0	;	STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE N-SITE COMPLEX; CATALYTIC INCORPORATION OF AZTMP to A DNA aptamer in CRYSTAL
6BSI	;	3.25	;	Structure of HIV-1 RT complexed with an RNA/DNA hybrid containing the polypurine-tract sequence
6BSJ	;	2.89	;	Structure of HIV-1 RT complexed with an RNA/DNA hybrid sequence non-preferred for RNA hydrolysis
6BSG	;	2.44	;	Structure of HIV-1 RT complexed with RNA/DNA hybrid in an RNA hydrolysis-off mode
6BSH	;	2.649	;	Structure of HIV-1 RT complexed with RNA/DNA hybrid in the RNA hydrolysis mode
4ZHR	;	2.601	;	Structure of HIV-1 RT Q151M mutant
1HNV	;	3.0	;	STRUCTURE OF HIV-1 RT(SLASH)TIBO R 86183 COMPLEX REVEALS SIMILARITY IN THE BINDING OF DIVERSE NONNUCLEOSIDE INHIBITORS
6XQI	;	2.34	;	Structure of HIV-1 Vpr in complex with the human nucleotide excision repair protein hHR23A
6XQJ	;		;	Structure of HIV-1 Vpr in complex with the human nucleotide excision repair protein hHR23A
2B8R	;	2.6	;	Structure oF HIV-1(LAI) genomic RNA DIS
2B8S	;	2.76	;	Structure of HIV-1(MAL) genomic RNA DIS
2BB9	;	1.35	;	Structure of HIV1 protease and AKC4p_133a complex.
2BBB	;	1.7	;	Structure of HIV1 protease and hh1_173_3a complex.
4YOI	;	1.82	;	Structure of HKU4 3CLpro bound to non-covalent inhibitor 1A
3TO2	;	2.6	;	Structure of HLA-A*0201 complexed with peptide Md3-C9 derived from a clustering region of restricted cytotoxic T lymphocyte epitope from SARS-CoV M protein
8EB2	;	2.9	;	Structure of HLA-A*02:01 in complex with NY-ESO-1 peptide and PA2.1 Fab
7T5M	;	1.67	;	Structure of HLA-A*02:01-FLPTPEELGLLGPPRPQVLA complex
8SBL	;	3.0	;	Structure of HLA-A*24:02 in complex with peptide, LYLPVRVLI
8SBK	;	1.8	;	Structure of HLA-A*24:02 in complex with peptide, LYLPVRVLI (ATG2A).
4WJ5	;	1.65	;	Structure of HLA-A2 in complex with an altered peptide ligands based on Mart-1 variant epitope
4L3C	;	2.64	;	Structure of HLA-A2 in complex with D76N b2m mutant and NY-ESO1 double mutant
5E00	;	1.7	;	Structure of HLA-A2 P130
5WSH	;	2.0	;	Structure of HLA-A2 P130
5F7D	;	2.3	;	Structure of HLA-A2:01 with peptide G11N
5EOT	;	2.1	;	Structure of HLA-A2:01 with peptide G13E
5ENW	;	1.85	;	Structure of HLA-A2:01 with peptide G9L
5FA3	;	1.86	;	Structure of HLA-A2:01 with peptide G9V
6O51	;	1.55	;	Structure of HLA-A2:01 with peptide MM90
6O4Y	;	1.58	;	Structure of HLA-A2:01 with peptide MM91
6O4Z	;	1.5	;	Structure of HLA-A2:01 with peptide MM92
6O53	;	1.4	;	Structure of HLA-A2:01 with peptide MM96
5FDW	;	2.7	;	Structure of HLA-A2:01 with peptide Y10L
5FA4	;	2.4	;	Structure of HLA-A2:01 with peptide Y16R
5F9J	;	2.51	;	Structure of HLA-A2:01 with peptide Y9L
5D9S	;	1.87	;	Structure of HLA-A2:01 with the 11-mer peptide F11V
5DDH	;	1.5	;	Structure of HLA-A2:01 with the 12-mer peptide F12K
4HX1	;	1.802	;	Structure of HLA-A68 complexed with a tumor antigen derived peptide
4HWZ	;	2.397	;	Structure of HLA-A68 complexed with an HIV derived peptide
4I48	;	2.799	;	Structure of HLA-A68 complexed with an HIV Env derived peptide
7S7E	;	2.04	;	STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH DOT1L(998-1006) PEPTIDE
7S7F	;	1.88	;	STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH DOT1L(998-1006) PHOSPHOPEPTIDE
7S8F	;	1.8	;	STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH MLL(747-755) PEPTIDE AND BOUND GLYCEROL
7S8E	;	1.6	;	STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH MLL(747-755) PHOSPHOPEPTIDE AND BOUND GLYCEROL
7S8A	;	2.1	;	STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH MLL(747-755) PHOSPHOPEPTIDE, CUBIC CRYSTAL FORM
7S79	;	1.53	;	STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH SYNTHETIC PHOSPHONO-MLL PEPTIDE ANALOG
7S7D	;	1.56	;	STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH SYNTHETIC SULFO-MLL PEPTIDE ANALOG
5IEK	;	1.8	;	Structure of HLA-B*40:02 in complex with the endogenous peptide REFSKEPEL
5IEH	;	1.5	;	Structure of HLA-B*40:02 in complex with the phosphorylated endogenous peptide REF(p)SKEPEL
4OV5	;	2.199	;	Structure of HLA-DR1 with a bound peptide with non-optimal alanine in the P1 pocket
5V4N	;	3.405	;	Structure of HLA-DR1 with bound alpha3(135-145) peptide
5V4M	;	2.1	;	Structure of HLA-DR15 with bound alpha3(135-145) peptide
8AEU	;	2.0	;	Structure of hMDM2 in complex with Nutlin-3a-aa
6P7K	;	1.722	;	Structure of HMG-CoA reductase from Burkholderia cenocepacia
8I6K	;	2.4	;	Structure of hMNDA HIN with dsDNA
4GPH	;	1.7	;	Structure of HmuO, heme oxygenase from Corynebacterium diphtheriae, in complex with the putative reaction intermediates between Fe3+-biliverdin and biliverdin (data set IV)
6DHS	;	3.5	;	Structure of hnRNP H qRRM1,2
2I5W	;	2.6	;	Structure of hOGG1 crosslinked to DNA sampling a normal G adjacent to an oxoG
4OYK	;	2.0001	;	Structure of HOIP PUB domain bound to OTULIN PIM
3HS1	;	2.51	;	Structure of Holliday junction formed by d(CCGGTACCGG); Crystal grown with CoCl2
4PSH	;	2.6	;	Structure of holo ArgBP from T. maritima
5W57	;	2.3	;	Structure of Holo AztC
3NU1	;	2.5	;	Structure of holo form of a periplasmic heme binding protein
2WK8	;	2.1	;	Structure of holo form of Vibrio cholerae CqsA
3MOM	;	2.25	;	Structure of holo HasAp H32A mutant complexed with imidazole from Pseudomonas aeruginosa to 2.25A Resolution
1GD1	;	1.8	;	STRUCTURE OF HOLO-GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE FROM BACILLUS STEAROTHERMOPHILUS AT 1.8 ANGSTROMS RESOLUTION
1SZJ	;	2.0	;	STRUCTURE OF HOLO-GLYCERALDEHYDE-3-PHOSPHATE-DEHYDROGENASE FROM PALINURUS VERSICOLOR REFINED 2.0 ANGSTROM RESOLUTION
4DG9	;	2.55	;	Structure of holo-PA1221, an NRPS protein containing adenylation and PCP domains bound to vinylsulfonamide inhibitor
1Z67	;	1.45	;	Structure of Homeodomain-like Protein of Unknown Function S4005 from Shigella flexneri
8OS9	;	1.7	;	Structure of Homo sapiens 2'-deoxynucleoside 5'-phosphate N-hydrolase 1 (DNPH1)
8OSC	;	1.42	;	Structure of Homo sapiens 2'-deoxynucleoside 5'-phosphate N-hydrolase 1 (DNPH1) bound to deoxyuridine 5'- monophosphate
5FPQ	;	2.4	;	Structure of Homo sapiens acetylcholinesterase phosphonylated by sarin.
7PHQ	;	8.45	;	Structure of homo-dimeric Staphylococcus capitis divalent metal ion transporter (DMT) by NabFab-fiducial assisted cryo-EM
7A0H	;	2.22	;	Structure of homodimeric actin capping protein alpha subunit from Plasmodium berghei
8CBB	;	2.71	;	Structure of homodimeric luciferase from Enhygromyxa salina
3ZDS	;	1.7	;	Structure of homogentisate 1,2-dioxygenase in complex with reaction intermediates of homogentisate with oxygen.
3KAL	;	1.9	;	Structure of homoglutathione synthetase from Glycine max in closed conformation with homoglutathione, ADP, a sulfate ion, and three magnesium ions bound
3KAK	;	2.11	;	Structure of homoglutathione synthetase from Glycine max in open conformation with gamma-glutamyl-cysteine bound.
2HL6	;	1.55	;	Structure of homologously expressed Ferrulate esterase of Aspergillus niger in complex with CAPS
7P5V	;	3.06	;	Structure of homomeric LRRC8A Volume-Regulated Anion Channel in complex with synthetic nanobody Sb1
7P5W	;	3.5	;	Structure of homomeric LRRC8A Volume-Regulated Anion Channel in complex with synthetic nanobody Sb2
7P5Y	;	3.29	;	Structure of homomeric LRRC8A Volume-Regulated Anion Channel in complex with synthetic nanobody Sb3
7P60	;	3.8	;	Structure of homomeric LRRC8A Volume-Regulated Anion Channel in complex with synthetic nanobody Sb4 at 1:0.5 ratio
7P6K	;	3.8	;	Structure of homomeric LRRC8A Volume-Regulated Anion Channel in complex with synthetic nanobody Sb5
8B40	;	4.6	;	Structure of homomeric LRRC8C Volume-Regulated Anion Channel
6G9L	;	5.01	;	Structure of homomeric mLRRC8A volume-regulated anion channel at 5.01 A resolution
2IGA	;	1.95	;	Structure of Homoprotocatechuate 2,3-Dioxygenase from B. fuscum in complex with reactive intermediates formed via in crystallo reaction with 4-nitrocatechol at low oxygen concentrations.
4GHH	;	1.55	;	Structure of Homoprotocatechuate 2,3-Dioxygenase from B.fuscum in complex with 4-Nitrocatechol at 1.55 Ang resolution
4Z6Z	;	1.52	;	Structure of Homoprotocatechuate 2,3-Dioxygenase from B.fuscum in complex with 4-sulfonyl catechol at 1.52 Ang resolution
4GHG	;	1.5	;	Structure of Homoprotocatechuate 2,3-Dioxygenase from B.fuscum in complex with HPCA at 1.50 Ang resolution
6WLB	;	3.5	;	Structure of homotrimeric poplar cellulose synthase isoform 8
3ESK	;	2.05	;	Structure of HOP TPR2A domain in complex with the non-cognate Hsc70 peptide ligand
7V4Z	;	1.16	;	Structure of Horcolin native form
6FHW	;	3.6	;	Structure of Hormoconis resinae Glucoamylase
1HCH	;	1.57	;	Structure of horseradish peroxidase C1A compound I
1H55	;	1.61	;	STRUCTURE OF HORSERADISH PEROXIDASE C1A COMPOUND II
1H57	;	1.6	;	Structure of horseradish peroxidase C1A compound III
8PQ4	;	2.25	;	Structure of HosA transcriptional regulator from enteropathogenic Escherichia coli O127:H6 (strain E2348/69)
5YNY	;	2.3	;	Structure of house dust mite allergen Der F 21 in PEG2KMME
5YNX	;	1.49	;	Structure of house dust mite allergen Der f 21 in PEG400
2IBJ	;	1.55	;	Structure of House Fly Cytochrome B5
7PSX	;	2.0	;	Structure of HOXB13 bound to hydroxymethylated DNA
5EF6	;	3.0	;	Structure of HOXB13 complex with methylated DNA
5EEA	;	2.195	;	Structure of HOXB13-DNA(CAA) complex
5EDN	;	3.2	;	Structure of HOXB13-DNA(TCG) complex
8IPG	;	1.64	;	Structure of HP101/N44
6QYI	;	1.8	;	Structure of HPAB from E.coli in complex with FAD
5MLL	;	1.9	;	Structure of HpDprA at 1.9 Angstroms resolution
2G72	;	2.0	;	Structure of hPNMT with inhibitor 3-fluoromethyl-7-thiomorpholinosulfonamide-THIQ and AdoMet
2G71	;	2.2	;	Structure of hPNMT with inhibitor 3-fluoromethyl-7-trifluoropropyl-THIQ and AdoHcy
2G8N	;	2.15	;	Structure of hPNMT with inhibitor 3-Hydroxymethyl-7-(N-4-chlorophenylaminosulfonyl)-THIQ and AdoHcy
2ONY	;	2.6	;	Structure of hPNMT with inhibitor 7-(N-4-chlorophenylaminosulfonyl)-THIQ and AdoHcy
6MXO	;	2.04	;	Structure of HPoleta incorporating dCTP opposite the 3-prime Pt(DACH)-GG
2DPJ	;	2.3	;	structure of hPoli with DNA and dTTP
6M6D	;	1.842	;	Structure of HPPD complexed with a synthesized inhibitor
6SJA	;	1.5	;	Structure of HPV16 E6 oncoprotein in complex with IRF3 LxxLL motif
6SIV	;	1.752	;	Structure of HPV16 E6 oncoprotein in complex with mutant IRF3 LxxLL motif
6SJV	;	2.029	;	Structure of HPV18 E6 oncoprotein in complex with mutant E6AP LxxLL motif
6SMV	;	2.14	;	Structure of HPV49 E6 protein in complex with MAML1 LxxLL motif
2RRD	;		;	Structure of HRDC domain from human Bloom syndrome protein, BLM
6MUN	;		;	Structure of hRpn10 bound to UBQLN2 UBL
6J7V	;	16.0	;	Structure of HRPV6 VP5 fitted in the cryoEM density of the spike
6KU7	;	2.15	;	structure of HRV-C 3C protein
6KU8	;	2.05	;	structure of HRV-C 3C protein with rupintrivir
3VDD	;	3.2	;	Structure of HRV2 capsid complexed with antiviral compound BTA798
4W2R	;	2.81	;	Structure of Hs/AcPRC2 in complex with 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one
6B3W	;	3.05	;	Structure of Hs/AcPRC2 in complex with 5,8-dichloro-7-(3,5-dimethyl-1,2-oxazol-4-yl)-2-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one
5IJ7	;	2.62	;	Structure of Hs/AcPRC2 in complex with a pyridone inhibitor
4XOI	;	2.092	;	Structure of hsAnillin bound with RhoA(Q63L) at 2.1 Angstroms resolution
4A08	;	3.0	;	Structure of hsDDB1-drDDB2 bound to a 13 bp CPD-duplex (purine at D-1 position) at 3.0 A resolution (CPD 1)
3EI1	;	2.8	;	Structure of hsDDB1-drDDB2 bound to a 14 bp 6-4 photoproduct containing DNA-duplex
4A09	;	3.1	;	Structure of hsDDB1-drDDB2 bound to a 15 bp CPD-duplex (purine at D-1 position) at 3.1 A resolution (CPD 2)
3EI2	;	2.6	;	Structure of hsDDB1-drDDB2 bound to a 16 bp abasic site containing DNA-duplex
4A0A	;	3.6	;	Structure of hsDDB1-drDDB2 bound to a 16 bp CPD-duplex (pyrimidine at D-1 position) at 3.6 A resolution (CPD 3)
4A0B	;	3.8	;	Structure of hsDDB1-drDDB2 bound to a 16 bp CPD-duplex (pyrimidine at D-1 position) at 3.8 A resolution (CPD 4)
6PAY	;	2.199	;	Structure of HsICDH1:Mg(II):ICT:NADPH(50%) complex reveals structural basis for observation of half-sites reactivity
7S3V	;	3.249	;	Structure of HsKYNase_66, an evolved variant of human kynureninase with greatly increased activity towards kynurenine
7XQ1	;	3.4	;	Structure of hSLC19A1+2'3'-CDAS
7XQ2	;	3.3	;	Structure of hSLC19A1+2'3'-cGAMP
7XQ0	;	3.0	;	Structure of hSLC19A1+3'3'-CDA
8GOE	;	3.0	;	Structure of hSLC19A1+5-MTHF
8GOF	;	3.0	;	Structure of hSLC19A1+PMX
7BZW	;	4.6	;	Structure of Hsp21
3FT8	;	2.0	;	Structure of HSP90 bound with a noval fragment.
3FT5	;	1.9	;	Structure of HSP90 bound with a novel fragment
6CEO	;	1.896	;	Structure of Hsp90 NTD with a GRP94-selective resorcinylic inhibitor.
2XAB	;	1.9	;	Structure of HSP90 with an inhibitor bound
4BQG	;	1.9	;	structure of HSP90 with an inhibitor bound
4BQJ	;	2.0	;	structure of HSP90 with an inhibitor bound
4B7P	;	1.7	;	Structure of HSP90 with NMS-E973 inhibitor bound
2XDK	;	1.97	;	Structure of HSP90 with small molecule inhibitor bound
2XDL	;	1.98	;	Structure of HSP90 with small molecule inhibitor bound
2XDS	;	1.97	;	Structure of HSP90 with small molecule inhibitor bound
2XDU	;	1.74	;	Structure of HSP90 with small molecule inhibitor bound
2XDX	;	2.42	;	Structure of HSP90 with small molecule inhibitor bound
2XHR	;	2.2	;	Structure of HSP90 with small molecule inhibitor bound
2XHT	;	2.27	;	Structure of HSP90 with small molecule inhibitor bound
2XHX	;	2.801	;	Structure of HSP90 with small molecule inhibitor bound
2XJG	;	2.25	;	Structure of HSP90 with small molecule inhibitor bound
2XJJ	;	1.9	;	Structure of HSP90 with small molecule inhibitor bound
2XJX	;	1.66	;	Structure of HSP90 with small molecule inhibitor bound
2XK2	;	1.95	;	Structure of HSP90 with small molecule inhibitor bound
6HTU	;	2.888	;	Structure of hStau1 dsRBD3-4 in complex with ARF1 RNA
7KVX	;	2.48	;	Structure of hSTING in complex with novel carbocyclic pyrimidine CDN 1
7KVZ	;	2.35	;	Structure of hSTING in complex with novel carbocyclic pyrimidine CDN-2
7KW1	;	1.8	;	Structure of hSTING in complex with novel carbocyclic pyrimidine CDN-3
5HUW	;	1.95	;	Structure of HSV-1 Large Terminase NLS bound to importin alpha
4MYW	;	3.189	;	Structure of HSV-2 gD bound to nectin-1
6M6I	;	4.05	;	Structure of HSV2 B-capsid portal vertex
6M6H	;	4.5	;	Structure of HSV2 C-capsid portal vertex
6M6G	;	5.39	;	Structure of HSV2 viron capsid portal vertex
3TP3	;	1.86	;	Structure of HTH-type transcriptional regulator EthR, G106W mutant
4TZN	;	3.115	;	Structure of HTP-2 bound to HTP-3 motif-6
5LVT	;	2.1	;	Structure of HU protein from Lactococcus lactis
7D9R	;	3.7	;	Structure of huamn soluble guanylate cyclase in the riociguat and NO-bound state
7D9S	;	3.9	;	Structure of huamn soluble guanylate cyclase in the YC1 and NO-bound state
3PLU	;	1.4	;	Structure of Hub-1 protein in complex with Snu66 peptide (HINDI)
3PLV	;	1.9	;	Structure of Hub-1 protein in complex with Snu66 peptide (HINDII)
2BEL	;	2.11	;	Structure of human 11-beta-hydroxysteroid dehydrogenase in complex with NADP and carbenoxolone
6BYJ	;	2.9	;	Structure of human 14-3-3 gamma bound to O-GlcNAc peptide
6V4N	;	2.5	;	Structure of human 1G05 Fab in complex with influenza virus neuraminidase from B/Phuket/3073/2013
7LXV	;	3.4	;	Structure of human 20S proteasome with bound MPI-5
6V4O	;	2.8	;	Structure of human 2E01 Fab in complex with influenza virus neuraminidase from B/Phuket/3073/2013
6MGP	;	2.13	;	Structure of human 4-1BB / 4-1BBL complex
6FIB	;	2.7	;	Structure of human 4-1BB ligand
6MGE	;	2.95	;	Structure of human 4-1BBL
1CB0	;	1.7	;	STRUCTURE OF HUMAN 5'-DEOXY-5'-METHYLTHIOADENOSINE PHOSPHORYLASE AT 1.7 A RESOLUTION
1CG6	;	1.7	;	STRUCTURE OF HUMAN 5'-DEOXY-5'-METHYLTHIOADENOSINE PHOSPHORYLASE COMPLEXED WITH 5'-DEOXY-5'-METHYLTHIOADENOSINE AND SULFATE AT 1.7 A RESOLUTION
1SD2	;	2.1	;	STRUCTURE OF HUMAN 5'-DEOXY-5'-METHYLTHIOADENOSINE PHOSPHORYLASE COMPLEXED WITH 5'-METHYLTHIOTUBERCIDIN
1SD1	;	2.03	;	STRUCTURE OF HUMAN 5'-DEOXY-5'-METHYLTHIOADENOSINE PHOSPHORYLASE COMPLEXED WITH FORMYCIN A
6FCX	;	2.5	;	Structure of human 5,10-methylenetetrahydrofolate reductase (MTHFR)
3KTU	;	2.3	;	Structure of human 8-oxoGuanine Glycosylase 1 bound to fluorninated oxoG-containing DNA
7ZFW	;	3.8	;	Structure of human 80S ribosome obtained from ssDNA coated grid
6JZH	;	2.25	;	Structure of human A2A adenosine receptor in complex with ZM241385 obtained from SFX experiments under atmospheric pressure
1QSE	;	2.8	;	STRUCTURE OF HUMAN A6-TCR BOUND TO HLA-A2 COMPLEXED WITH ALTERED HTLV-1 TAX PEPTIDE V7R
4M0E	;	2.0	;	Structure of human acetylcholinesterase in complex with dihydrotanshinone I
4M0F	;	2.304	;	Structure of human acetylcholinesterase in complex with territrem B
3LMS	;	2.5	;	Structure of human activated thrombin-activatable fibrinolysis inhibitor, TAFIa, in complex with tick-derived funnelin inhibitor, TCI.
2ARV	;	2.0	;	Structure of human Activin A
8ESV	;	3.3	;	Structure of human ADAM10-Tspan15 complex bound to 11G2 vFab
7KFN	;	2.5	;	Structure of Human Adenosine Deaminase Acting on dsRNA (ADAR2) bound to dsRNA containing a 2'-deoxy Benner's Base Z opposite the edited base
1BX4	;	1.5	;	STRUCTURE OF HUMAN ADENOSINE KINASE AT 1.50 ANGSTROMS
5FGY	;	2.1	;	Structure of human adenovirus 2 protease with cofactor pVIC
1AVP	;	2.6	;	STRUCTURE OF HUMAN ADENOVIRUS 2 PROTEINASE WITH ITS 11 AMINO ACID COFACTOR
2WGU	;	1.8	;	Structure of human adenovirus serotype 37 fibre head in complex with a sialic acid derivative, O-Methyl 5-N- methoxycarbonyl -3,5-dideoxy- D-glycero-a-D-galacto-2-nonulopyranosylonic acid
2WGT	;	1.8	;	Structure of human adenovirus serotype 37 fibre head in complex with a sialic acid derivative, O-Methyl 5-N-propaonyl-3,5-dideoxy-D- glycero-a-D-galacto-2-nonulopyranosylonic acid
2C9Y	;	2.1	;	Structure of human adenylate kinase 2
1ZD8	;	1.48	;	Structure of human adenylate kinase 3 like 1
6G4Q	;	2.59	;	Structure of human ADP-forming succinyl-CoA ligase complex SUCLG1-SUCLA2
1Z6X	;	2.7	;	Structure Of Human ADP-Ribosylation Factor 4
2B6H	;	1.764	;	Structure of human ADP-ribosylation factor 5
1ZD9	;	1.7	;	Structure of human ADP-ribosylation factor-like 10B
2H18	;	1.902	;	Structure of human ADP-ribosylation factor-like 10B (ARL10B)
2AL7	;	1.85	;	Structure Of Human ADP-Ribosylation Factor-Like 10C
1Z6Y	;	2.4	;	Structure Of Human ADP-Ribosylation Factor-Like 5
2H16	;	2.0	;	Structure of human ADP-ribosylation factor-like 5 (ARL5)
2H17	;	1.7	;	Structure of human ADP-ribosylation factor-like 5 (ARL5)
1YZG	;	2.0	;	Structure of Human ADP-ribosylation factor-like 8
4ILE	;	2.676	;	Structure of human ADP-ribosylation factor-like 8A binding to GDP
5HHY	;	1.7	;	Structure of human Alanine:Glyoxylate Aminotransferase major allele (AGT-Ma) showing X-Ray induced reduction of PLP internal aldimine to 4'-deoxy-piridoxine-phosphate (PLR)
6QAO	;	2.89	;	Structure of human aldehyde dehydrogenase 9A1 in P21 space group
4WP7	;	1.8	;	Structure of human ALDH1A1 with inhibitor CM026
4X4L	;	1.85	;	Structure of human ALDH1A1 with inhibitor CM037
5TEI	;	2.1	;	Structure of human ALDH1A1 with inhibitor CM039
4WPN	;	1.95	;	Structure of human ALDH1A1 with inhibitor CM053
4OE5	;	1.95	;	Structure of Human ALDH4A1 Crystallized in Space Group P21
4ZVY	;	1.9	;	Structure of human ALDH7A1 complexed with NAD+ in space group P4212
6QAK	;	2.5	;	Structure of human ALDH9 in P21212 space group
1XDL	;	3.0	;	Structure of human aldolase B associated with hereditary fructose intolerance (A149P), at 277K
1XDM	;	3.0	;	Structure of human aldolase B associated with hereditary fructose intolerance (A149P), at 291K
8B34	;	0.97	;	Structure of Human Aldose Reductase Mutant A299G with a Citrate Molecule Bound in the Anion Binding Pocket
8AQP	;	0.96	;	Structure of Human Aldose Reductase Mutant A299G/L300A with a Citrate Molecule Bound in the Anion Binding Pocket
8AQG	;	0.95	;	Structure of Human Aldose Reductase Mutant A299G/L300G with a Citrate Molecule Bound in the Anion Binding Pocket
6Y03	;	1.69	;	Structure of Human Aldose Reductase Mutant L300/301A with a Citrate Molecule Bound in the Anion Binding Pocket
6T5G	;	1.28	;	Structure of Human Aldose Reductase Mutant L300A with a Citrate Molecule Bound in the Anion Binding Pocket
8A4N	;	0.93	;	Structure of Human Aldose Reductase Mutant L300G with a Citrate Molecule Bound in the Anion Binding Pocket
6T27	;	1.11	;	Structure of Human Aldose Reductase Mutant L301A with a Citrate Molecule Bound in the Anion Binding Pocket
4DVQ	;	2.49	;	Structure of human aldosterone synthase, CYP11B2, in complex with deoxycorticosterone
4FDH	;	2.71	;	Structure of human aldosterone synthase, CYP11B2, in complex with fadrozole
4O61	;	1.9	;	Structure of human ALKBH5 crystallized in the presence of citrate
8IF3	;	3.23	;	Structure of human alpha-2/delta-1 with mirogabalin
8IF4	;	3.23	;	Structure of human alpha-2/delta-1 without mirogabalin
1R46	;	3.25	;	Structure of human alpha-galactosidase
1R47	;	3.45	;	Structure of human alpha-galactosidase
6CFS	;	2.07	;	Structure of Human alpha-Phosphomannomutase 1 containing mutation M186Q
6CFR	;	2.07	;	Structure of Human alpha-Phosphomannomutase 1 containing mutation R183I
6CFU	;	2.244	;	Structure of Human alpha-Phosphomannomutase 1 containing mutations R180K and R183K
6CFT	;	2.43	;	Structure of Human alpha-Phosphomannomutase 1 containing mutations R180T and R183I
6CFV	;	1.918	;	Structure of Human alpha-Phosphomannomutase 1 in complex with Inosine Monophosphate
2THF	;	2.1	;	STRUCTURE OF HUMAN ALPHA-THROMBIN Y225F MUTANT BOUND TO D-PHE-PRO-ARG-CHLOROMETHYLKETONE
1B7X	;	2.1	;	STRUCTURE OF HUMAN ALPHA-THROMBIN Y225I MUTANT BOUND TO D-PHE-PRO-ARG-CHLOROMETHYLKETONE
1THP	;	2.1	;	STRUCTURE OF HUMAN ALPHA-THROMBIN Y225P MUTANT BOUND TO D-PHE-PRO-ARG-CHLOROMETHYLKETONE
5NUB	;	1.6	;	Structure of human amniotic fluid RBP4 saturated with laurate
5NU9	;	1.5	;	Structure of human amniotic fluid RBP4 saturated with palmitate
6CDT	;	1.8	;	Structure of Human Anaplastic Lymphoma Kinase Domain
7R7R	;	1.935	;	Structure of Human Anaplastic Lymphoma Kinase Domain in complex with ((2~{R})-2-[5-[6-amino-5-[(1~{R})-1-[5-fluoro-2-(triazol-2-yl)phenyl]ethoxy]-3-pyridyl]-4-methyl-thiazol-2-yl]propane-1,2-diol)
7R7K	;	1.831	;	Structure of Human Anaplastic Lymphoma Kinase Domain in complex with (4-[6-amino-5-[(1~{R})-1-[5-fluoro-2-(triazol-2-yl)phenyl]ethoxy]-3-pyridyl]isoindolin-1-one)
5KZ0	;	2.3	;	Structure of Human Anaplastic Lymphoma Kinase in Complex With 2-[(1R)-1-{[2-amino-5-(1,3-dimethyl-1H-pyrazol-4-yl)pyridin-3-yl]oxy}ethyl]-4-fluoro-N,N-dimethylbenzamide
2XB7	;	2.5	;	Structure of Human Anaplastic Lymphoma Kinase in complex with NVP- TAE684
2XBA	;	1.95	;	Structure of Human Anaplastic Lymphoma Kinase in complex with PHA- E429
1XJL	;	2.59	;	Structure of human annexin A2 in the presence of calcium ions
3LMJ	;	2.2	;	Structure of human anti HIV 21c Fab
2YK1	;	1.85	;	Structure of human anti-nicotine Fab fragment in complex with nicotine
2YKL	;	2.1	;	Structure of human anti-nicotine Fab fragment in complex with nicotine-11-yl-methyl-(4-ethylamino-4-oxo)-butanoate
4ZGZ	;	5.81	;	STRUCTURE OF HUMAN ANTIZYME INHIBITOR IN COMPLEX WITH A C-TERMINAL FRAGMENT OF ANTIZYME
4WJ9	;	1.74	;	Structure of Human apo ALDH1A1
8PVH	;	2.9	;	Structure of human apo ALDH1A1 determined by cryoEM at 100 keV
5WRW	;	2.91	;	Structure of human apo-SRP72
8HHS	;	2.4	;	Structure of human apoferritin embedded in crystalline ice
7ZG7	;	1.77	;	Structure of human Apoferritin obtained from ssDNA coated grid
1CB6	;	2.0	;	STRUCTURE OF HUMAN APOLACTOFERRIN AT 2.0 A RESOLUTION.
8BTX	;	1.84	;	Structure of human Archease
2QIU	;	2.0	;	Structure of Human Arg-Insulin
4KRE	;	1.754	;	Structure of Human Argonaute-1 bound to endogenous Sf9 RNA
4KRF	;	2.101	;	Structure of Human Argonaute-1 let-7 complex
4KXT	;	2.294	;	Structure of human ARGONAUTE1 in complex with guide RNA
6D36	;	1.7	;	Structure of human ARH3 bound to ADP-ribose and magnesium
6D3A	;	1.60001	;	Structure of human ARH3 D314E bound to ADP-ribose and magnesium
7ARW	;	1.31	;	Structure of human ARH3 E41A bound to alpha-NAD+ and magnesium
5EE5	;	2.279	;	Structure of human ARL1 in complex with the DCB domain of BIG1
2ASK	;	1.55	;	Structure of human Artemin
8QEY	;	4.0	;	Structure of human Asc1/CD98hc heteromeric amino acid transporter
7P4I	;	4.2	;	Structure of human ASCT1 transporter
7LO0	;	2.71	;	Structure of human ASF1a in complex with a TLK2 peptide
2IIJ	;		;	Structure of human Asf1a in complex with histone H3
4TZ8	;	2.15	;	Structure of human ATAD2 bromodomain bound to fragment inhibitor
4WZG	;	1.9	;	Structure of human ATG101
2D1I	;	2.0	;	Structure of human Atg4b
5D7G	;	3.0	;	Structure of human ATG5 E122D-ATG16L1 complex at 3.0 Angstroms
5NPW	;	3.1	;	Structure of human ATG5-ATG16L1(ATG5BD) complex (C2)
5NPV	;	3.1	;	Structure of human ATG5-ATG16L1(ATG5BD) complex (I4)
6WQZ	;	2.8	;	Structure of human ATG9A, the only transmembrane protein of the core autophagy machinery
6WR4	;	2.9	;	Structure of human ATG9A, the only transmembrane protein of the core autophagy machinery
6POF	;	4.3	;	Structure of human ATP citrate lyase
6UUW	;	2.85	;	Structure of human ATP citrate lyase E599Q mutant in complex with Mg2+, citrate, ATP and CoA
6UI9	;	3.1	;	Structure of human ATP citrate lyase in complex with acetyl-CoA and oxaloacetate
6UV5	;	3.4	;	Structure of human ATP citrate lyase in complex with acetyl-CoA and oxaloacetate
7LJ9	;	3.0	;	Structure of human ATP citrate lyase in complex with acetyl-CoA and oxaloacetate
7LLA	;	2.97	;	Structure of human ATP citrate lyase in complex with acetyl-CoA and oxaloacetate (EM map was generated in Cryosparc with non-uniform refinement)
6D5X	;	2.4	;	Structure of Human ATP:Cobalamin Adenosyltransferase bound to ATP, Adenosylcobalamin, and Triphosphate
6D5K	;	2.85	;	Structure of Human ATP:Cobalamin Adenosyltransferase bound to ATP, and Adenosylcobalamin
2IDX	;	2.5	;	Structure of Human ATP:Cobalamin adenosyltransferase bound to ATP.
7RUV	;	2.1	;	Structure of Human ATP:Cobalamin Adenosyltransferase E193K bound to adenosylcobalamin
7RUU	;	1.85	;	Structure of Human ATP:Cobalamin Adenosyltransferase R190C bound to adenosylcobalamin
7RUT	;	1.5	;	Structure of Human ATP:Cobalamin Adenosyltransferase R190C bound to ATP
3QBN	;	3.5	;	Structure of Human Aurora A in Complex with a diaminopyrimidine
1OL7	;	2.75	;	Structure of Human Aurora-A 122-403 phosphorylated on Thr287, Thr288
6YV1	;	3.4	;	Structure of human b(0,+)AT1
7XQ8	;	3.3	;	Structure of human B-cell antigen receptor of the IgM isotype
6LTH	;	3.0	;	Structure of human BAF Base module
7YUG	;	1.1	;	Structure of human BANP BEN domain
6QGH	;	2.0	;	Structure of human Bcl-2 in complex with ABT-263
6QGG	;	1.5	;	Structure of human Bcl-2 in complex with analogue of ABT-737
6QGJ	;	1.9	;	Structure of human Bcl-2 in complex with fragment/ABT-263 hybrid
6QG8	;	1.9	;	Structure of human Bcl-2 in complex with PUMA BH3 peptide
6QGK	;	1.8	;	Structure of human Bcl-2 in complex with THIQ-phenyl pyrazole compound
1R2D	;	1.95	;	Structure of Human Bcl-XL at 1.95 Angstroms
7JHK	;	2.3436	;	Structure of human beta 1,3-N-acetylglucosaminyltransferase 2 in unliganded form
7JHI	;	2.5	;	Structure of human beta 1,3-N-acetylglucosaminyltransferase 2 iodide-derivative
8TIC	;	2.7	;	Structure of human beta 1,3-N-acetylglucosaminyltransferase 2 with compound 1
8SZ3	;	2.32	;	Structure of human beta 1,3-N-acetylglucosaminyltransferase 2 with compound 7j
8TJC	;	2.2	;	Structure of human beta 1,3-N-acetylglucosaminyltransferase 2 with compound 8a
7JHM	;	2.19	;	Structure of human beta 1,3-N-acetylglucosaminyltransferase 2 with N-acetyl-lactosamine
7JHO	;	1.85	;	Structure of human beta 1,3-N-acetylglucosaminyltransferase 2 with UDP
7JHN	;	2.2	;	Structure of human beta 1,3-N-acetylglucosaminyltransferase 2 with UDP and trisaccharide GlcNAc-beta1-3Gal-beta1-4GlcNAc
7JHL	;	2.26	;	Structure of human beta 1,3-N-acetylglucosaminyltransferase 2 with UDP-N-acetylglucosamine
4P7H	;	3.2	;	Structure of Human beta-Cardiac Myosin Motor Domain::GFP chimera
7BU7	;	2.6	;	Structure of human beta1 adrenergic receptor bound to BI-167107 and nanobody 6B9
7BVQ	;	2.5	;	Structure of human beta1 adrenergic receptor bound to carazolol
7BTS	;	3.13	;	Structure of human beta1 adrenergic receptor bound to epinephrine and nanobody 6B9
7BU6	;	2.7	;	Structure of human beta1 adrenergic receptor bound to norepinephrine and nanobody 6B9
7XKA	;	3.1	;	Structure of human beta2 adrenergic receptor bound to constrained epinephrine
7XK9	;	3.4	;	Structure of human beta2 adrenergic receptor bound to constrained isoproterenol
6LR0	;	3.5	;	structure of human bile salt exporter ABCB11
6FNE	;	2.501	;	Structure of human Brag2 (Sec7-PH domains) with the inhibitor Bragsin bound to the PH domain
4IGK	;	1.75	;	Structure of human BRCA1 BRCT in complex with ATRIP peptide
4IFI	;	2.2	;	Structure of human BRCA1 BRCT in complex with BAAT peptide
8SB6	;	1.8	;	Structure of human BRD2-BD1 bound to a histone H4 acetyl-methyllysine peptide
3D1N	;	2.51	;	Structure of human Brn-5 transcription factor in complex with corticotrophin-releasing hormone gene promoter
6OMU	;	1.41	;	Structure of human Bruton's Tyrosine Kinase in complex with Evobrutinib
5DMZ	;	2.4	;	Structure of human Bub1 kinase domain phosphorylated at Ser969
6SAM	;	2.5	;	Structure of human butyrylcholinesterase in complex with 1-(2,3-dihydro-1H-inden2-yl)piperidin-3-yl N-phenyl carbamate
2J4C	;	2.75	;	Structure of human Butyrylcholinesterase in complex with 10mM HgCl2
8CGO	;	2.65	;	Structure of human butyrylcholinesterase in complex with N-{[2-(benzyloxy)-3-methoxyphenyl]methyl}-N-[3-(2-fluorophenyl)propyl]cyclobutanamine
2Y1K	;	2.5	;	STRUCTURE OF HUMAN BUTYRYLCHOLINESTERASE INHIBITED BY CBDP (12H SOAK): PHOSPHOSERINE ADDUCT
4BBZ	;	2.7	;	Structure of human butyrylcholinesterase inhibited by CBDP (2-min soak): Cresyl-phosphoserine adduct
1KSW	;	2.8	;	Structure of Human c-Src Tyrosine Kinase (Thr338Gly Mutant) in Complex with N6-benzyl ADP
7QIV	;	2.8	;	Structure of human C3b in complex with the EWE nanobody
5HYP	;	3.024	;	Structure of human C4b-binding protein alpha cain CCP domains 1 and 2 in complex with the hypervariable region of group A Streptococcus M28 protein
5HYU	;	2.561	;	Structure of human C4b-binding protein alpha chain CCP domains 1 and 2 in complex with the hypervariable region of group A Streptococcus M2 protein
5HZP	;	2.74	;	Structure of human C4b-binding protein alpha chain CCP domains 1 and 2 in complex with the hypervariable region of group A Streptococcus M49 protein.
5I0Q	;	2.293	;	Structure of human C4b-binding protein alpha chain CCP domains 1 and 2 in complex with the hypervariable region of mutant group A Streptococcus M2 (K65A, N66A) protein
5HYT	;	2.54	;	Structure of human C4b-binidng protein alpha chain CCP domains 1 and 2 in complex with the hypervariable region of group A Streptococcus M22 protein
8JZZ	;	3.31	;	Structure of human C5a-desArg bound human C5aR1 in complex with Go
2VZ6	;	2.3	;	Structure of human calcium calmodulin dependent protein kinase type II alpha (CAMK2A) in complex with Indirubin E804
2P0R	;	2.5	;	Structure of Human Calpain 9 in complex with Leupeptin
4ITP	;	1.697	;	Structure of human carbonic anhydrase II bound to a benzene sulfonamide
3OYQ	;	1.47	;	Structure of Human Carbonic Anhydrase II complexed with 5,6-DIHYDRO-BENZO[H]CINNOLIN-3-YLAMINE
4ILX	;	1.6	;	Structure of human carbonic anhydrase II in complex with an adamantyl sulfonamide inhibitor
3U3A	;	1.549	;	structure of Human Carbonic Anhydrase II V143I
1XQ0	;	1.76	;	Structure of human carbonic anhydrase II with 4-[(3-bromo-4-O-sulfamoylbenzyl)(4-cyanophenyl)amino]-4H-[1,2,4]-triazole
1XPZ	;	2.02	;	Structure of human carbonic anhydrase II with 4-[4-O-sulfamoylbenzyl)(4-cyanophenyl)amino]-4H-[1,2,4]-triazole
1YFF	;	2.4	;	STRUCTURE OF HUMAN CARBONMONOXYHEMOGLOBIN C (BETA E6K): TWO QUATERNARY STATES (R2 and R3) IN ONE CRYSTAL
6KN8	;	4.8	;	Structure of human cardiac thin filament in the calcium bound state
6KN7	;	6.6	;	Structure of human cardiac thin filament in the calcium free state
1NM8	;	1.6	;	Structure of Human Carnitine Acetyltransferase: Molecular Basis for Fatty Acyl Transfer
2CMW	;	1.75	;	Structure of Human Casein kinase 1 gamma-1 in complex with 2-(2- Hydroxyethylamino)-6-(3-chloroanilino)-9-isopropylpurine
7NXL	;	1.8	;	Structure of human cathepsin K in complex with the acrylamide inhibitor Gu3110
7NXM	;	1.72	;	Structure of human cathepsin K in complex with the selective activity-based probe Gu3416
6PXF	;	1.85	;	Structure of human Cathepsin K with an ectosteric inhibitor at 1.85 Angstrom resolution
7JIC	;	3.8	;	Structure of human CD19-CD81 co-receptor complex bound to coltuximab Fab fragment
4MQ7	;	2.6032	;	Structure of human CD1d-sulfatide
3S6C	;	2.9	;	Structure of human CD1e
2JJS	;	1.85	;	Structure of human CD47 in complex with human signal regulatory protein (SIRP) alpha
2JJT	;	2.3	;	Structure of human CD47 in complex with human signal regulatory protein (SIRP) alpha
4CMM	;	1.92	;	Structure of human CD47 in complex with human Signal Regulatory Protein (SIRP) alpha v1
6HXW	;	2.78	;	structure of human CD73 in complex with antibody IPH53
8PHD	;	2.08	;	Structure of Human Cdc123 bound to domain 3 of eIF2 gamma and ATP
3NR9	;	2.89	;	Structure of human CDC2-like kinase 2 (CLK2)
4ENZ	;	2.6	;	Structure of human ceruloplasmin at 2.6 A resolution
4LEV	;	1.952	;	Structure of human cGAS
4LEW	;	2.04	;	Structure of human cGAS
6Y5D	;	4.1	;	Structure of human cGAS (K394E) bound to the nucleosome
6Y5E	;	3.15	;	Structure of human cGAS (K394E) bound to the nucleosome (focused refinement of cGAS-NCP subcomplex)
5LTL	;	1.45	;	Structure of human chemokine CCL16
1GUV	;	2.35	;	Structure of human chitotriosidase
3FRV	;	3.7	;	Structure of Human CHMP3 (residues 1-150)
1HCN	;	2.6	;	STRUCTURE OF HUMAN CHORIONIC GONADOTROPIN AT 2.6 ANGSTROMS RESOLUTION FROM MAD ANALYSIS OF THE SELENOMETHIONYL PROTEIN
6OD0	;	2.15	;	Structure of human CIB1 in complex with peptide inhibitor UNC10245092
6OCX	;	1.9	;	Structure of human CIB1 in complex with peptide inhibitor UNC10245109
2KDK	;		;	Structure of human circadian clock protein BMAL2 C-terminal PAS domain
7L1X	;	1.8	;	Structure of human CK2 alpha kinase (catalytic subunit) with the inhibitor 108600.
3RPS	;	2.3	;	Structure of human CK2alpha in complex with the ATP-competitive inhibitor 3-(4,5,6,7-tetrabromo-1H-benzotriazol-1-yl)propan-1-ol
7A04	;	2.15	;	Structure of human CKa1 in complex with compound b
7A06	;	1.8	;	Structure of human CKa1 in complex with compound o
6MQ5	;	2.146	;	Structure of human CLASP1 TOG1
7JM7	;	2.82	;	Structure of human CLC-7/OSTM1 complex
2R4V	;	1.85	;	Structure of human CLIC2, crystal form A
2R5G	;	1.86	;	Structure of human CLIC2, crystal form B
5K8R	;	2.5	;	Structure of human clustered protocadherin gamma B3 EC1-4
4BEX	;	2.8	;	Structure of human Cofilin1
5JPN	;	3.6	;	Structure of human complement C4 rebuilt using iMDFF
6RQJ	;	3.5	;	Structure of human complement C5 complexed with tick inhibitors OmCI, RaCI1 and CirpT1
2G7I	;	1.75	;	Structure of Human Complement Factor H Carboxyl Terminal Domains 19-20: a Basis for Atypical Hemolytic Uremic Syndrome
8GN7	;	3.0	;	structure of human connexin 40.1 intercellular gap junction channel by cryoEM
8GN8	;	3.5	;	structure of human connexin 40.1 pentameric hemichannel by cryoEM
8GNB	;	3.9	;	structure of human connexin 40.1 side-by-side decamer channel by cryoEM
8UD9	;	2.04	;	Structure of human constitutive 20S proteasome complexed with the inhibitor TDI-8304
6DEW	;	2.0	;	Structure of human COQ9 protein with bound isoprene.
6FV1	;	2.3	;	Structure of human coronavirus NL63 main protease in complex with the alpha-ketoamide (S)-N-((S)-4-(benzylamino)-3,4-dioxo-1-((S)-2-oxopyrrolidin-3-yl)butan-2-yl)-2-cinnamamido-4-methylpentanamide (cinnamoyl-leucine-GlnLactam-CO-CO-NH-benzyl)
6FV2	;	2.95	;	Structure of human coronavirus NL63 main protease in complex with the alpha-ketoamide (S)-N-benzyl-3-((S)-2-cinnamamido-3-phenylpropanamido)-2-oxo-4-((S)-2-oxopyrrolidin-3-yl)butanamide (cinnamoyl-phenylalanine-GlnLactam-CO-CO-NH-benzyl)
5NH0	;	2.35	;	Structure of human coronavirus NL63 main protease in complex with the alpha-ketoamide tert-Butyl ((S)-4-(benzylamino)-3,4-dioxo-1-((S)-2-oxopyrrolidin-3-yl)b- utan-2-yl)carbamate (tert-butyl -GlnLactam-CO-CO-NH-benzyl)
2I7T	;	2.1	;	Structure of human CPSF-73
2I7V	;	2.1	;	Structure of Human CPSF-73
1PU0	;	1.7	;	Structure of Human Cu,Zn Superoxide Dismutase
2LNL	;		;	Structure of human CXCR1 in phospholipid bilayers
4O68	;	2.436	;	Structure of human cyclic GMP-AMP synthase (cGAS)
1YND	;	1.6	;	Structure of human cyclophilin A in complex with the novel immunosuppressant sanglifehrin A at 1.6A resolution
6M7X	;	2.095	;	Structure of human CYP11B1 in complex with fadrozole
1JBQ	;	2.6	;	STRUCTURE OF HUMAN CYSTATHIONINE BETA-SYNTHASE: A UNIQUE PYRIDOXAL 5'-PHOSPHATE DEPENDENT HEMEPROTEIN
1RN7	;	2.5	;	Structure of human cystatin D
1ROA	;	1.8	;	Structure of human cystatin D
5Z62	;	3.6	;	Structure of human cytochrome c oxidase
6O5Y	;	3.17	;	Structure of Human Cytochrome P450 1A1 with 5-amino-N-(5-((4R,5R)-4-amino-5-fluoroazepan-1-yl)-1-methyl-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)thiazole-4-carboxamide)
6DWM	;	2.85	;	Structure of Human Cytochrome P450 1A1 with Bergamottin
6UDL	;	2.85	;	Structure of Human Cytochrome P450 1A1 with Duocarmycin Prodrug (S) ICT-2700
6UDM	;	3.075	;	Structure of Human Cytochrome P450 1A1 with Duocarmycin Prodrug (S) ICT-2726
6DWN	;	3.0	;	Structure of Human Cytochrome P450 1A1 with Erlotinib
1OG2	;	2.6	;	Structure of human cytochrome P450 CYP2C9
1OG5	;	2.55	;	Structure of human cytochrome P450 CYP2C9
4JM0	;	3.25	;	Structure of Human Cytomegalovirus Immune Modulator UL141
8DYV	;	3.97	;	Structure of human cytoplasmic dynein-1 bound to one Lis1
8DYU	;	4.0	;	Structure of human cytoplasmic dynein-1 bound to two Lis1 proteins
2I7D	;	1.2	;	Structure of Human cytosolic deoxyribonucleotidase in complex with deoxyuridine, AlF4 and Mg2+
3CTZ	;	1.6	;	Structure of human cytosolic X-prolyl aminopeptidase
6HZZ	;	2.52	;	Structure of human D-glucuronyl C5 epimerase
6I02	;	2.45	;	Structure of human D-glucuronyl C5 epimerase in complex with product
6I01	;	2.1	;	Structure of human D-glucuronyl C5 epimerase in complex with substrate
6XQQ	;	2.68	;	Structure of human D462-E4 TCR
6XQP	;	2.9	;	Structure of human D462-E4 TCR in complex with human MR1-5-OP-RU
6RKF	;	3.219	;	Structure of human DASPO
1P61	;	2.21	;	Structure of human dCK complexed with 2'-Deoxycytidine and ADP, P 43 21 2 space group
1P60	;	1.96	;	Structure of human dCK complexed with 2'-Deoxycytidine and ADP, Space group C 2 2 21
1P5Z	;	1.6	;	Structure of human dCK complexed with cytarabine and ADP-MG
1P62	;	1.9	;	Structure of human dCK complexed with gemcitabine and ADP-MG
7ABS	;	1.97	;	Structure of human DCLRE1C/Artemis in complex with DNA - re-evaluation of 6WO0
1XML	;	2.0	;	Structure of human Dcps
1XMM	;	2.5	;	Structure of human Dcps bound to m7GDP
8AJM	;	2.83	;	Structure of human DDB1-DCAF12 in complex with the C-terminus of CCT5
1W6U	;	1.75	;	Structure of human DECR ternary complex
2W6V	;	1.8	;	Structure of Human deoxy Hemoglobin A in complex with Xenon
4D50	;	1.7	;	Structure of human deoxyhypusine hydroxylase
4D4Z	;	1.7	;	STRUCTURE OF HUMAN DEOXYHYPUSINE HYDROXYLASE in complex with glycerol
1HCG	;	2.2	;	STRUCTURE OF HUMAN DES(1-45) FACTOR XA AT 2.2 ANGSTROMS RESOLUTION
6BML	;	2.95	;	Structure of human DHHC20 palmitoyltransferase, irreversibly inhibited by 2-bromopalmitate
6BMM	;	2.35	;	Structure of human DHHC20 palmitoyltransferase, space group P21
6BMN	;	2.25	;	Structure of human DHHC20 palmitoyltransferase, space group P63
4NGD	;	1.958	;	Structure of human Dicer Platform-PAZ-Connector Helix cassette in complex with 12-mer siRNA having 5'-p and UU-3' ends (1.95 Angstrom resolution)
4NGC	;	2.104	;	Structure of human Dicer Platform-PAZ-Connector Helix cassette in complex with 12-mer siRNA having UA-3' ends (2.1 Angstrom resolution)
4NGB	;	2.25	;	Structure of human Dicer Platform-PAZ-Connector Helix cassette in complex with 12-mer siRNA having UU-3' ends (2.25 Angstrom resolution)
4NGG	;	2.6	;	Structure of human Dicer Platform-PAZ-Connector Helix cassette in complex with 13-mer siRNA having 5'-A and UU-3' ends (2.6 Angstrom resolution)
4NH3	;	2.616	;	Structure of human Dicer Platform-PAZ-Connector Helix cassette in complex with 13-mer siRNA having 5'-pU and UU-3' ends (2.6 Angstrom resolution)
4NH5	;	2.55	;	Structure of human Dicer Platform-PAZ-Connector Helix cassette in complex with 14-mer siRNA having 5'-pUU and UU-3' ends (2.55 Angstrom resolution)
4NH6	;	2.551	;	Structure of human Dicer Platform-PAZ-Connector Helix cassette in complex with 15-mer siRNA having 5'-pUUU and UU-3' ends (2.55 Angstrom resolution)
4NHA	;	3.401	;	Structure of human Dicer Platform-PAZ-Connector Helix cassette in complex with 16-mer siRNA having 5'-p and UU-3' ends (3.4 Angstrom resolution)
4NGF	;	3.101	;	Structure of human Dicer Platform-PAZ-Connector Helix cassette in complex with 17-mer siRNA having 5'-p and UU-3' ends (3.1 Angstrom resolution)
1SQY	;	2.5	;	Structure of human diferric lactoferrin at 2.5A resolution using crystals grown at pH 6.5
5ZF4	;	1.66	;	Structure of human dihydroorotate dehydrogenase in complex with 275-10-COOMe
5ZF8	;	1.7	;	Structure of human dihydroorotate dehydrogenase in complex with 277-11-OAc
5ZF7	;	1.79	;	Structure of human dihydroorotate dehydrogenase in complex with 277-9-OH
5ZF9	;	1.77	;	Structure of human dihydroorotate dehydrogenase in complex with 280-12
5ZFA	;	1.75	;	Structure of human dihydroorotate dehydrogenase in complex with 287-12-OCOiPr
5ZFB	;	2.0	;	Structure of human dihydroorotate dehydrogenase in complex with ascofuranone (open-form)
3W7R	;	1.68	;	Structure of Human dihydroorotate dehydrogenase in complex with mii-4-097
3ZWS	;	1.6	;	Structure of Human Dihydroorotate Dehydrogenase with a Bound Inhibitor
3ZWT	;	1.55	;	Structure of Human Dihydroorotate Dehydrogenase with a Bound Inhibitor
7PWY	;	2.5	;	Structure of human dimeric ACMSD in complex with the inhibitor TES-1025
4WJL	;	3.4	;	Structure of human dipeptidyl peptidase 10 (DPPY): a modulator of neuronal Kv4 channels
6XE6	;	4.53	;	Structure of Human Dispatched-1 (DISP1)
4Z6C	;	2.677	;	Structure of human DNA polymerase beta 279NA mutant complexed with G in the template base paired with incoming non-hydrolyzable CTP
4Z6D	;	2.51	;	Structure of human DNA polymerase beta 279NA mutant complexed with G in the template base paired with incoming non-hydrolyzable TTP
4Z6E	;	2.752	;	Structure of human DNA polymerase beta 279NA mutant complexed with G in the template base paired with incoming non-hydrolyzable TTP and MANGANESE
4Z6F	;	2.444	;	Structure of human DNA polymerase beta 279NA mutant complexed with G in the template base paired with incoming non-hydrolyzable TTP and MANGANESE
7MZ3	;	2.418	;	Structure of human DNA polymerase beta complexed with 3-deaza-3-methyladenine (3dMeA) as the template base in a 1-nucleotide gapped DNA
7MZ8	;	2.6	;	Structure of human DNA polymerase beta complexed with 3-deaza-3-methyladenine (3dMeA) at N-1 of the template base paired with incoming dTTP
7MZ4	;	2.076	;	Structure of human DNA polymerase beta complexed with 3-deaza-3-methyladenine (3dMeA) in the template base paired with incoming dTTP
4YMM	;	2.199	;	Structure of human DNA polymerase beta complexed with 7BG as the template base in a 1-nucleotide gapped DNA
4M2Y	;	2.27	;	Structure of human DNA polymerase beta complexed with 8-BrG as the template base in a 1-nucleotide gapped DNA
6CLY	;	2.186	;	Structure of human DNA polymerase beta complexed with 8-ClG as the template base in a 1-nucleotide gapped DNA
6CUB	;	2.05	;	Structure of human DNA polymerase beta complexed with 8-ClG in the template base paired with incoming non-hydrolyzable ATP and MANGANESE
6CPQ	;	1.93	;	Structure of human DNA polymerase beta complexed with 8-ClG in the template base paired with incoming non-hydrolyzable CTP
6CU9	;	2.04	;	Structure of human DNA polymerase beta complexed with 8-ClG in the template base paired with incoming non-hydrolyzable CTP and MANGANESE
6CRH	;	2.327	;	Structure of human DNA polymerase beta complexed with 8-ClG in the template base paired with incoming non-hydrolyzable GTP
6CUA	;	2.17	;	Structure of human DNA polymerase beta complexed with 8-ClG in the template base paired with incoming non-hydrolyzable GTP and MANGANESE
4NLK	;	2.494	;	Structure of human DNA polymerase beta complexed with 8BrG in the template base-paired with incoming non-hydrolyzable CTP
6E3R	;	2.26	;	Structure of human DNA polymerase beta complexed with 8OA as the template base in a 1-nucleotide gapped DNA
6E3X	;	2.65	;	Structure of human DNA polymerase beta complexed with 8OA in the template base paired with incoming non-hydrolyzable ATP
6E3W	;	2.02	;	Structure of human DNA polymerase beta complexed with 8OA in the template base paired with incoming non-hydrolyzable GTP
6E3V	;	1.96	;	Structure of human DNA polymerase beta complexed with 8OA in the template base paired with incoming non-hydrolyzable TTP
4PHA	;	2.52	;	Structure of human DNA polymerase beta complexed with A in the template base paired with incoming non-hydrolyzable CTP
4PHD	;	2.21	;	Structure of human DNA polymerase beta complexed with A in the template base paired with incoming non-hydrolyzable CTP and MANGANESE
4NM1	;	2.415	;	Structure of human DNA polymerase beta complexed with a nicked DNA containing a 8BrG-C at N-1 position and G-C at N position
4NM2	;	2.524	;	Structure of human DNA polymerase beta complexed with a nicked DNA containing a 8BrG-G at N-1 position and G-C at N position
4PH5	;	2.55	;	Structure of human DNA polymerase beta complexed with a nicked DNA containing a AC at N-1 position and GC at N position
4PGY	;	2.26	;	Structure of human DNA polymerase beta complexed with a nicked DNA containing a GT at N-1 position and GC at N position
7MZ0	;	2.021	;	Structure of human DNA polymerase beta complexed with dzA as the template base in a 1-nucleotide gapped DNA
7MZ2	;	2.088	;	Structure of human DNA polymerase beta complexed with dzA at N-1 of the template base paired with incoming dTTP
7MZ1	;	2.175	;	Structure of human DNA polymerase beta complexed with dzA in the template base paired with incoming non-hydrolyzable TTP
4PGQ	;	2.3	;	Structure of human DNA polymerase beta complexed with G in the template base paired with incoming non-hydrolyzable TTP
4PGX	;	2.077	;	Structure of human DNA polymerase beta complexed with G in the template base paired with incoming non-hydrolyzable TTP and MANGANESE
4TUP	;	1.8	;	Structure of human DNA polymerase beta complexed with GG as the template (GG0b) in a 1-nucleotide gapped DNA
4YMN	;	2.591	;	Structure of human DNA polymerase beta complexed with N7BG in the template base paired with incoming non-hydrolyzable CTP
4YMO	;	2.148	;	Structure of human DNA polymerase beta complexed with N7BG in the template opposite to incoming non-hydrolyzable CTP WITH MANGANESE IN THE ACTIVE SITE
4YN4	;	2.243	;	Structure of human DNA polymerase beta complexed with N7BG in the template opposite to incoming non-hydrolyzable dTTP WITH MANGANESE IN THE ACTIVE SITE
4NLZ	;	2.683	;	Structure of human DNA polymerase beta complexed with nicked DNA containing a mismatched template 8BrG and incoming GTP
4MF8	;	2.32	;	Structure of human DNA polymerase beta complexed with nicked DNA containing a mismatched template O6MG and incoming CTP
4MFA	;	2.27	;	Structure of human DNA polymerase beta complexed with nicked DNA containing a mismatched template O6MG and incoming TTP
4NLN	;	2.261	;	Structure of human DNA polymerase beta complexed with nicked DNA containing a template 8BrG and incoming CTP
4MF2	;	2.4	;	Structure of human DNA polymerase beta complexed with O6MG as the template base in a 1-nucleotide gapped DNA
4MFC	;	2.13	;	Structure of human DNA polymerase beta complexed with O6MG in the template base paired with incoming non-hydrolyzable CTP
4MFF	;	2.55	;	Structure of human DNA polymerase beta complexed with O6MG in the template base paired with incoming non-hydrolyzable TTP
4PHE	;	2.15	;	Structure of human DNA polymerase beta complexed with T in the template base paired with incoming non-hydrolyzable GTP
4PHP	;	2.6	;	Structure of human DNA polymerase beta complexed with T in the template base paired with incoming non-hydrolyzable GTP and MANGANESE
5DBB	;	2.25	;	Structure of human DNA polymerase beta Host-Guest complex with the dG base paired with a dA
5DBC	;	2.402	;	Structure of human DNA polymerase beta Host-Guest complex with the dG base paired with a dG
5DBA	;	1.965	;	Structure of human DNA polymerase beta Host-Guest complex with the dG base paired with a dT
5DB8	;	2.547	;	Structure of human DNA polymerase beta Host-Guest complex with the N7MG base paired with a dA
5DB6	;	2.83	;	Structure of human DNA polymerase beta Host-Guest complex with the N7MG base paired with a dC
5DB9	;	2.45	;	Structure of human DNA polymerase beta Host-Guest complex with the N7MG base paired with a dG
5DB7	;	2.209	;	Structure of human DNA polymerase beta Host-Guest complex with the N7MG base paired with a dT
5HHI	;	2.517	;	Structure of human DNA polymerase beta Host-Guest complexed with CBZ-platinated N7-G
5HHH	;	2.363	;	Structure of human DNA polymerase beta Host-Guest complexed with the control G for N7-CBZ-platination
6U2O	;	2.3	;	Structure of human DNA polymerase beta misinserting dAMPNPP opposite the 5'G of the cisplatin Pt-GG intrastrand crosslink
6U6B	;	3.108	;	Structure of human DNA polymerase beta misinserting dAMPNPP opposite the 5'G of the cisplatin Pt-GG intrastrand crosslink with Manganese in the active site
6PKZ	;	2.74	;	Structure of human DNA polymerase beta N279A complexed with 8OA in the template base paired with incoming non-hydrolyzable GTP
4M47	;	2.37	;	structure of human DNA polymerase complexed with 8-BrG in the template base paired with incoming non-hydrolyzable GTP
4O5C	;	2.363	;	Structure of human DNA polymerase complexed with N7-MG as the template base in a 1-nucleotide gapped DNA
4O5K	;	2.058	;	Structure of human DNA polymerase complexed with N7MG in the template base paired with incoming non-hydrolyzable CTP
4O5E	;	2.532	;	Structure of human DNA polymerase complexed with N7MG in the template base paired with incoming non-hydrolyzable TTP
4P2H	;	1.987	;	Structure of human DNA polymerase complexed with N7MG in the template opposite to incoming non-hydrolyzable TTP with manganese in the active site
6PLC	;	2.5	;	Structure of human DNA polymerase eta complexed with 8OA in the template base paired with incoming non-hydrolyzable GTP
6PL8	;	2.17	;	Structure of human DNA polymerase eta complexed with 8OA in the template base paired with incoming non-hydrolyzable TTP
6PL7	;	2.5	;	Structure of human DNA polymerase eta complexed with A in the template base paired with incoming non-hydrolyzable TTP
6UI2	;	2.35	;	Structure of human DNA polymerase eta complexed with N7MG in the template base paired with incoming non-hydrolyzable CTP
5ULW	;	2.617	;	Structure of human DNA polymerase iota bound to template 1-methyl-deoxyadenosine
5ULX	;	1.96	;	Structure of human DNA polymerase iota bound to template 1-methyl-deoxyadenosine crystallized in the presence of dCTP
3EPG	;	2.5	;	Structure of Human DNA Polymerase Iota complexed with N2-ethylguanine
3EPI	;	2.9	;	Structure of Human DNA Polymerase Iota complexed with N2-ethylguanine and incoming TTP
5W2C	;	2.5	;	Structure of human DNA polymerase kappa in complex with Lucidin-derived DNA adduct and incoming dAMPNPP
5W2A	;	2.9	;	Structure of human DNA polymerase kappa in complex with Lucidin-derived DNA adduct and incoming dCMPNPP
3IN5	;	3.2	;	Structure of human DNA polymerase kappa inserting dATP opposite an 8-oxoG DNA lesion
6CST	;	2.0	;	Structure of human DNA polymerase kappa with DNA
6O3O	;	2.8	;	Structure of human DNAM-1 (CD226) bound to nectin-like protein-5 (necl-5)
3SWR	;	2.49	;	Structure of human DNMT1 (601-1600) in complex with Sinefungin
1G55	;	1.8	;	Structure of human DNMT2, an enigmatic DNA methyltransferase homologue
5SZB	;	1.2	;	Structure of human Dpf3 double-PHD domain bound to histone H3 tail peptide with acetylated K14
5SZC	;	1.193	;	Structure of human Dpf3 double-PHD domain bound to histone H3 tail peptide with monomethylated K4 and acetylated K14
3KWJ	;	2.8	;	Structure of human DPP-IV with (2S,3S,11bS)-3-(3-Fluoromethyl-phenyl)-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ylamine
3OC0	;	2.7	;	Structure of human DPP-IV with HTS hit (2S,3S,11bS)-3-butyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ylamine
7OUP	;	2.65	;	Structure of human DPP3 in complex with a hydroxyethylene transition state peptidomimetic
5E2Q	;	2.404	;	Structure of human DPP3 in complex with angiotensin-II
5EHH	;	2.38	;	Structure of human DPP3 in complex with endomorphin-2.
5E3C	;	2.765	;	Structure of human DPP3 in complex with hemorphin like opioid peptide IVYPW
5E33	;	1.837	;	Structure of human DPP3 in complex with met-enkephalin
5E3A	;	2.05	;	Structure of human DPP3 in complex with opioid peptide leu-enkephalin
3T6B	;	2.4	;	Structure of human DPPIII in complex with the opioid peptide Tynorphin, at 2.4 Angstroms
3T6J	;	2.976	;	Structure of human DPPIII in complex with the opioid peptide Tynorphin, at 3.0 Angstroms
2Y96	;	2.38	;	Structure of human dual-specificity phosphatase 27
3DWB	;	2.38	;	structure of human ECE-1 complexed with phosphoramidon
2JGB	;	1.7	;	Structure of human eIF4E homologous protein 4EHP with m7GTP
6POW	;	2.15	;	Structure of human endotheial nitric oxide synthase heme domain in complex with 7-(5-(Aminomethyl)pyridin-3-yl)-4-methylquinolin-2-amine
8UFS	;	2.05	;	Structure of human endothelial nitric oxide synthase E361Q mutant heme domain obtain after soaking crystal with 4-methyl-7-(4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepin-7-yl)quinolin-2-amine dihydrochloride
7UAO	;	1.9	;	Structure of human endothelial nitric oxide synthase heme domain in complex with (6-(3-(4,4-difluoropiperidin-1-yl)propyl)-4-methylpyridin-2-amine)
5UOB	;	2.292	;	Structure of human endothelial nitric oxide synthase heme domain in complex with (R)-3-[(2-amino-4-methylquinolin-7-yl)methoxy]-5-(2-(methylamino)propyl)benzonitrile
6NH2	;	2.29	;	Structure of human endothelial nitric oxide synthase heme domain in complex with (R)-6-(3-fluoro-5-(2-(pyrrolidin-2-yl)ethyl)phenethyl)-4-methylpyridin-2-amine
5UOC	;	2.2	;	Structure of human endothelial nitric oxide synthase heme domain in complex with (S)-3-[(2-amino-4-methylquinolin-7-yl)methoxy]-5-(2-(methylamino)propyl)benzonitrile
6NHF	;	1.83	;	Structure of human endothelial nitric oxide synthase heme domain in complex with (S)-6-(2,3-difluoro-5-(2-(1-methylazetidin-2-yl)ethyl)phenethyl)-4-methylpyridin-2-amine
6NH3	;	2.01	;	Structure of human endothelial nitric oxide synthase heme domain in complex with (S)-6-(3-fluoro-5-(2-(pyrrolidin-2-yl)ethyl)phenethyl)-4-methylpyridin-2-amine
5UOA	;	2.2	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 3-[(2-Amino-4-methylquinolin-7-yl)methoxy]-5-((methylamino)methyl)benzonitrile
5UO8	;	2.18	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 3-[(2-aminoquinolin-7-yl)methoxy]-5-((methylamino)methyl)benzonitrile
6PP2	;	2.02	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 4-((4-(2-Amino-4-methylquinolin-7-yl)-2-(aminomethyl)phenoxy)methyl)benzonitrile
5VVC	;	2.4	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 4-(2-(((2-Amino-4-methylquinolin-7-yl)methyl)amino)ethyl)-2-methylbenzonitrile
5VVD	;	2.25	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 4-(2-(((2-Amino-4-methylquinolin-7-yl)methyl)amino)ethyl)benzonitrile
5VVB	;	2.15	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 4-(2-(((2-Aminoquinolin-7-yl)methyl)amino)ethyl)-2-methylbenzonitrile
8FGQ	;	2.2	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 4-(5-(2-(dimethylamino)ethyl)-2,3-difluorophenethyl)-6-methylpyrimidin-2-amine
8FGU	;	2.0	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 4-(difluoromethyl)-6-(5-(2-(dimethylamino)ethyl)-2,3-difluorophenethyl)pyridin-2-amine
7TSI	;	2.1	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 4-methyl-6-(3-((methylamino)methyl)phenyl)pyridin-2-amine
7TSM	;	1.85	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 4-methyl-6-(3-(4-methylpiperazin-1-yl)prop-1-yn-1-yl)pyridin-2-amine bishydrochloride
7TSL	;	1.9	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 4-methyl-6-(3-(4-methylpiperazin-1-yl)propyl)pyridin-2-amine
7TSK	;	2.049	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 4-methyl-6-(3-(methylamino)prop-1-yn-1-yl)pyridin-2-amine
7TSH	;	2.145	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 4-methyl-6-(3-(methylamino)propyl)pyridin-2-amine
8UFR	;	1.871	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 4-methyl-7-(4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepin-7-yl)quinolin-2-amine dihydrochloride
4D1P	;	1.731	;	Structure of human endothelial nitric oxide synthase heme domain IN COMPLEX WITH 6-((((3S, 5R)-5-(((6-AMINO-4-METHYLPYRIDIN-2-YL)METHOXY) METHYL)PYRROLIDIN-3-YL)OXY) METHYL)-4-METHYLPYRIDIN-2-AMINE
8FGT	;	1.9	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 6-(2,3-difluoro-5-(2-(4-methylpiperazin-1-yl)ethyl)phenethyl)-4-methylpyridin-2-amine
7TSN	;	2.08	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 6-(3-(3,3-difluoroazetidin-1-yl)prop-1-yn-1-yl)-4-methylpyridin-2-amine
7TSO	;	2.0	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 6-(3-(3,3-difluoroazetidin-1-yl)propyl)-4-methylpyridin-2-amine
6NH7	;	1.9	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 6-(3-(3-(dimethylamino)propyl)-2,5,6-trifluorophenethyl)-4-methylpyridin-2-amine
7TSP	;	2.0	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 6-(3-(4,4-difluoropiperidin-1-yl)prop-1-yn-1-yl)-4-methylpyridin-2-amine
7TSG	;	1.85	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 6-(3-(dimethylamino)propyl)-4-methylpyridin-2-amine
6NH5	;	1.959	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 6-(3-fluoro-5-(2-((2R,4S)-4-fluoro-1-methylpyrrolidin-2-yl)ethyl)phenethyl)-4-methylpyridin-2-amine
6NH4	;	2.27	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 6-(3-fluoro-5-(2-((2R,4S)-4-fluoropyrrolidin-2-yl)ethyl)phenethyl)-4-methylpyridin-2-amine
6NH1	;	2.216	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 6-(3-fluoro-5-(3-(methylamino)prop-1-yn-1-yl)phenethyl)-4-methylpyridin-2-amine
6AV6	;	2.08	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 6-(3-Fluoro-5-(3-(methylamino)propyl)phenethyl)-4-methylpyridin-2-amine
8FGS	;	1.8449	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 6-(5-(2-(diethylamino)ethyl)-2,3-difluorophenethyl)-4-methylpyridin-2-amine
8FGP	;	1.88	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 6-(5-(2-(dimethylamino)ethyl)-2,3-difluorophenethyl)-4-methoxypyridin-2-amine
8FGO	;	1.799	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 6-(5-(2-(dimethylamino)ethyl)-2,3-difluorophenethyl)-4-methylpyridin-2-amine
8FGN	;	2.2	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 6-(5-(2-(dimethylamino)ethyl)-2,3-difluorophenethyl)pyridin-2-amine
8FGR	;	1.98	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 6-(5-(2-aminoethyl)-2,3-difluorophenethyl)-4-methylpyridin-2-amine
6NH8	;	1.8	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 6-(5-(3-(dimethylamino)propyl)-2,3,4-trifluorophenethyl)-4-methylpyridin-2-amine
7M56	;	1.957	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 7-((3-(3-aminophenethyl)phenoxy)methyl)quinolin-2-amine
6POV	;	2.047	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 7-(3-(2-Aminoethyl)phenyl)-4-methylquinolin-2-amine
6PP0	;	1.97	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 7-(3-(Aminomethyl)-4-(cyclobutylmethoxy)phenyl)-4-methylquinolin-2-amine
6PP1	;	1.76	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 7-(3-(Aminomethyl)-4-(cyclopropylmethoxy)phenyl)-4-methylquinolin-2-amine
6PP3	;	1.95	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 7-(3-(Aminomethyl)-4-(pyridin-2-ylmethoxy)phenyl)-4-methylquinolin-2-amine
6PP4	;	2.2	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 7-(3-(Aminomethyl)-4-(pyridin-3-ylmethoxy)phenyl)-4-methylquinolin-2-amine
6POZ	;	2.2	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 7-(3-(Aminomethyl)-4-isopropoxyphenyl)-4-methylquinolin-2-amine
6POY	;	2.3	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 7-(3-(Aminomethyl)-4-propoxyphenyl)-4-methylquinolin-2-amine
6POU	;	2.194	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 7-(4-(2-Aminoethyl)phenyl)-4-methylquinolin-2-amine
8UFU	;	2.05	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 7-(9-amino-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-4-methylquinolin-2-amine
5UO9	;	2.19	;	Structure of human endothelial nitric oxide synthase heme domain in complex with 7-[(3-Ethyl-5-((methylamino)methyl)phenoxy)methyl]quinolin-2-amine
6AV7	;	1.916	;	Structure of human endothelial nitric oxide synthase heme domain in complex with HW69
6CIE	;	1.95	;	Structure of human endothelial nitric oxide synthase heme domain in complex with N-(1-(2-(Ethyl(methyl)amino)ethyl)-1,2,3,4-tetrahydroquino-lin-6-yl)thiophene-2-carboximidamide
4D1O	;	1.819	;	Structure of human endothelial nitric oxide synthase heme domain with L-Arg bound
8UFT	;	1.78	;	Structure of human endothelial nitric oxide synthase P370N mutant heme domain in complex with 4-methyl-7-(4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepin-7-yl)quinolin-2-amine
6POX	;	2.197	;	Structure of human endothelialnitric oxide synthase heme domain in complex with 7-(3-(Aminomethyl)-4-ethoxyphenyl)-4-methylquinolin-2-amine
5TD9	;	2.318	;	Structure of Human Enolase 2
5EU9	;	2.047	;	Structure of Human Enolase 2 in complex with ((3S,5S)-1,5-dihydroxy-3-methyl-2-oxopyrrolidin-3-yl)phosphonic acid
5IDZ	;	2.63	;	Structure of Human Enolase 2 in complex with (S)-(1-hydroxy-2-oxopiperidin-3-yl)phosphonate
4ZA0	;	2.31	;	Structure of Human Enolase 2 in complex with Phosphonoacetohydroxamate
7MBH	;	2.1	;	Structure of Human Enolase 2 in complex with phosphoserine
4ZCW	;	1.992	;	Structure of Human Enolase 2 in complex with SF2312
5TIJ	;	2.634	;	Structure of Human Enolase 2 with ((3S,5S)-1,5-dihydroxy-3-methyl-2-oxopyrrolidin-3-yl)phosphonate (purified enantiomer)
8GHR	;	3.2	;	Structure of human ENPP1 in complex with variable heavy domain VH27.2
4QTB	;	1.4	;	Structure of human ERK1 in complex with SCH772984 revealing a novel inhibitor-induced binding pocket
4QTA	;	1.45	;	Structure of human ERK2 in complex with SCH772984 revealing a novel inhibitor-induced binding pocket
8TBS	;	2.35	;	Structure of human erythrocyte pyruvate kinase in complex with an allosteric activator AG-946
8TBU	;	2.35	;	Structure of human erythrocyte pyruvate kinase in complex with an allosteric activator Compound 12
8TBT	;	2.34	;	Structure of human erythrocyte pyruvate kinase in complex with an allosteric activator Compound 2
5J4O	;	1.54	;	Structure of human erythrocytic Spectrin alpha chain repeats 16-17
6HRH	;	2.3	;	Structure of human erythroid-specific 5'-aminolevulinate synthase, ALAS2
7XR4	;	3.4	;	Structure of human excitatory amino acid transporter 2 (EAAT2) in complex with glutamate
7XR6	;	3.4	;	Structure of human excitatory amino acid transporter 2 (EAAT2) in complex with WAY-213613
7NSG	;	3.34	;	Structure of human excitatory amino acid transporter 3 (EAAT3) in complex with HIP-B
6S3Q	;	3.34	;	Structure of human excitatory amino acid transporter 3 (EAAT3) in complex with TFB-TBOA
1QFK	;	2.8	;	STRUCTURE OF HUMAN FACTOR VIIA AND ITS IMPLICATIONS FOR THE TRIGGERING OF BLOOD COAGULATION
6Y0F	;	2.924	;	Structure of human FAPalpha in complex with linagliptin
2HO2	;	1.33	;	Structure of human FE65-WW domain in complex with hMena peptide.
2Y5C	;	1.7	;	Structure of human ferredoxin 2 (Fdx2)in complex with 2Fe2S cluster
2FG4	;	2.1	;	Structure of Human Ferritin L Chain
2FG8	;	2.5	;	Structure of Human Ferritin L Chain
2FFX	;	1.9	;	Structure of Human Ferritin L. Chain
2HRE	;	2.5	;	Structure of human ferrochelatase variant E343K with protoporphyrin IX bound
6WBV	;	2.5	;	Structure of human ferroportin bound to hepcidin and cobalt in lipid nanodisc
7TZ2	;	2.55	;	Structure of human Fibrinogen-like protein 1
1FDH	;	2.5	;	STRUCTURE OF HUMAN FOETAL DEOXYHAEMOGLOBIN
6WW2	;	3.7	;	Structure of human Frizzled5 by fiducial-assisted cryo-EM
4E5Y	;	2.37	;	Structure of human FX protein, the key enzyme in the biosynthesis of GDP-L-fucose
3BEJ	;	1.9	;	Structure of human FXR in complex with MFA-1 and co-activator peptide
8A3O	;	2.9	;	Structure of human Fy-4
8A3P	;	2.7	;	Structure of human Fy-5.
7T7L	;	2.2	;	Structure of human G9a SET-domain (EHMT2) in complex with covalent inhibitor (Compound 1)
5VSC	;	1.4	;	Structure of human G9a SET-domain (EHMT2) in complex with inhibitor 13
5VSE	;	1.6	;	Structure of human G9a SET-domain (EHMT2) in complex with inhibitor 17: N~2~-cyclopentyl-6,7-dimethoxy-N~2~-methyl-N~4~-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine
5TUY	;	2.6	;	Structure of human G9a SET-domain (EHMT2) in complex with inhibitor MS0124
6WIV	;	3.3	;	Structure of human GABA(B) receptor in an inactive state
6ZGW	;	2.3	;	Structure of human galactokinase 1 bound with (4-chlorophenyl)methyl pyridine-3-carboxylate
6Q90	;	2.4	;	Structure of human galactokinase 1 bound with 1-(4-Methoxyphenyl)-3-(4-pyridinyl)urea
6ZGV	;	2.3	;	Structure of human galactokinase 1 bound with 2-(4-chlorophenyl)-N-(pyrimidin-2-yl)acetamide
6ZGX	;	1.86	;	Structure of human galactokinase 1 bound with 2-(4-chlorophenyl)-N-(pyrimidin-2-yl)acetamide
6ZGY	;	2.3	;	Structure of human galactokinase 1 bound with 2-(4-chlorophenyl)-N-(pyrimidin-2-yl)acetamide
6ZGZ	;	2.3	;	Structure of human galactokinase 1 bound with 2-(4-chlorophenyl)-N-(pyrimidin-2-yl)acetamide
6ZH0	;	2.5	;	Structure of human galactokinase 1 bound with 2-(4-chlorophenyl)-N-(pyrimidin-2-yl)acetamide
6QJE	;	2.4	;	Structure of human galactokinase 1 bound with 4-{[2-(Methylsulfonyl)-1H-imidazol-1-yl]methyl}-1,3-thiazole
6Q91	;	2.4	;	Structure of human galactokinase 1 bound with 5-Chloro-N-isobutyl-2-methoxybenzamide
7OZX	;	2.3	;	Structure of human galactokinase 1 bound with azepan-1-yl(2,6-difluorophenyl)methanone
6Q3W	;	1.962	;	Structure of human galactokinase 1 bound with Ethyl 1-(2-pyrazinyl)-4-piperidinecarboxylate
6Q8Z	;	2.4	;	Structure of human galactokinase 1 bound with N-(Cyclobutylmethyl)-1,5-dimethyl-1H-pyrazole-4-carboxamide
6Q3X	;	2.1	;	Structure of human galactokinase in complex with galactose and 2'-(benzo[d]oxazol-2-ylamino)-7',8'-dihydro-1'H-spiro[cyclohexane-1,4'-quinazolin]-5'(6'H)-one
6ZFH	;	2.439	;	Structure of human galactokinase in complex with galactose and 2'-(benzo[d]oxazol-2-ylamino)-7',8'-dihydro-1'H-spiro[cyclopentane-1,4'-quinazolin]-5'(6'H)-one
6GR2	;	2.49	;	Structure of human galactokinase in complex with galactose and ADP
6GQD	;	1.523	;	Structure of human galactose-1-phosphate uridylyltransferase (GALT), with crystallization epitope mutations A21Y:A22T:T23P:R25L
6M5Y	;	1.38	;	Structure of human galectin-1 tandem-repeat mutant with lactose
7XFA	;	0.98	;	Structure of human Galectin-3 CRD in complex with monosaccharide inhibitor
7CXA	;	1.97	;	Structure of human Galectin-3 CRD in complex with TD-139 belonging to P31 space group.
1FIC	;	2.5	;	STRUCTURE OF HUMAN GAMMA FIBRINOGEN 30 KD CARBOXYL TERMINAL FRAGMENT
1FID	;	2.1	;	STRUCTURE OF HUMAN GAMMA FIBRINOGEN 30 KD CARBOXYL TERMINAL FRAGMENT
4NIK	;	2.5	;	Structure of human Gankyrin in complex to the single chain antibody F5
7BBL	;	1.521	;	Structure of human Gemin6/Gemin7/Gemin8 trimeric complex
6XPB	;	1.74	;	Structure of human GGT1 in complex with 2-amino-4-(((1-((carboxymethyl)amino)-1-oxobutan-2-yl)oxy)(phenoxy)phosphoryl)butanoic acid (ACPB) molecule
7LD9	;	1.42	;	Structure of human GGT1 in complex with ABBA
6XPC	;	2.26	;	Structure of human GGT1 in complex with full GSH molecule
7LA5	;	2.07	;	Structure of human GGT1 in complex with Lnt1-172 compound.
7LBC	;	2.28	;	Structure of human GGT1 in complex with Lnt2-65 compound
3Q2U	;	1.85	;	Structure of Human Glioma Pathogenesis-related Protein 1 Reveals Unique loops and surface motifs.
5YBY	;	1.429	;	Structure of human Gliomedin
7T7M	;	2.85	;	Structure of human GLP SET-domain (EHMT1) in complex with covalent inhibitor (Compound 1)
5VSD	;	1.85	;	Structure of human GLP SET-domain (EHMT1) in complex with inhibitor 13
5VSF	;	1.7	;	Structure of human GLP SET-domain (EHMT1) in complex with inhibitor 17
5TUZ	;	1.95	;	Structure of human GLP SET-domain (EHMT1) in complex with inhibitor MS0124
2PVV	;	2.11	;	Structure of human glutamate carboxypeptidase II (GCPII) in complex with L-serine-O-sulfate
1L1F	;	2.7	;	Structure of human glutamate dehydrogenase-apo form
1BWC	;	2.1	;	STRUCTURE OF HUMAN GLUTATHIONE REDUCTASE COMPLEXED with AJOENE INHIBITOR AND SUBVERSIVE SUBSTRATE
3SQP	;	2.21	;	Structure of human glutathione reductase complexed with pyocyanin, an agent with antimalarial activity
2F3M	;	2.7	;	Structure of human GLUTATHIONE S-TRANSFERASE M1A-1A complexed with 1-(S-(GLUTATHIONYL)-2,4,6-TRINITROCYCLOHEXADIENATE ANION
3N9J	;	1.85	;	Structure of human Glutathione Transferase Pi class in complex with Ethacraplatin
2BLE	;	1.9	;	Structure of human guanosine monophosphate reductase GMPR1 in complex with GMP
2BWG	;	2.4	;	Structure of human guanosine monophosphate reductase GMPR1 in complex with GMP
1DG3	;	1.8	;	STRUCTURE OF HUMAN GUANYLATE BINDING PROTEIN-1 IN NUCLEOTIDE FREE FORM
8ODO	;	2.2	;	Structure of human guanylylated RTCB in complex with Archease
6TB2	;	2.9	;	Structure of human haptoglobin-hemoglobin bound to S. aureus IsdH
4QTC	;	1.4	;	Structure of human haspin (GSG2) in complex with SCH772984 revealing the first type-I binding mode
4OUC	;	1.9	;	Structure of human haspin in complex with histone H3 substrate
2VUW	;	1.8	;	Structure of human haspin kinase domain
6GYN	;	3.4	;	Structure of human HCN4 hyperpolarization-activated cyclic nucleotide-gated ion channel
6GYO	;	3.4	;	Structure of human HCN4 hyperpolarization-activated cyclic nucleotide-gated ion channel in complex with cAMP
7KBH	;	2.68	;	Structure of Human HDAC2 in complex with a 2-substituted benzamide inhibitor (compound 16)
7KBG	;	1.26	;	Structure of Human HDAC2 in complex with a 2-substituted benzamide inhibitor (compound 20)
6XDM	;	1.56	;	STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH AN ARYL KETONE INHIBITOR
6WBW	;	1.46	;	Structure of Human HDAC2 in complex with an ethyl ketone inhibitor
6WBZ	;	1.32	;	Structure of Human HDAC2 in complex with an ethyl ketone inhibitor containing a spiro-bicyclic group
7JS8	;	1.634	;	STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH AN ETHYL KETONE INHIBITOR CONTAINING A SPIRO-BICYCLIC GROUP (COMPOUND 22)
7LTL	;	1.49	;	STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH AN INHIBITOR LACKING A ZINC BINDING GROUP (COMPOUND 19)
7LTK	;	1.59	;	STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH AN INHIBITOR THAT LACKS A ZINC BINDING GROUP (COMPOUND 12)
7LTG	;	1.8	;	STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH APICIDIN
4LY1	;	1.57	;	Structure of Human HDAC2 in complex with inhibitor 4-(acetylamino)-N-[2-amino-5-(thiophen-2-yl)phenyl]benzamide
6XEB	;	1.5	;	STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH KETONE INHIBITOR (COMPOUND E)
6XEC	;	1.701	;	STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH KETONE INHIBITOR (COMPOUND O)
4LXZ	;	1.85	;	Structure of Human HDAC2 in complex with SAHA (vorinostat)
6GPW	;	1.6	;	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD)
6GQ6	;	2.25	;	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) in complex with ADP
6GPT	;	2.0	;	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) in complex with AMPCP
6GQR	;	2.05	;	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) in complex with AMPCPP
6GPY	;	2.25	;	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) in complex with AMPPNP
6GPR	;	2.35	;	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) in complex with cAMP
8AGI	;	2.1	;	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) in complex with JMC31
6GP4	;	1.7	;	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A
6GP8	;	1.75	;	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A in complex AMPCPP
6GPP	;	1.51	;	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A in complex with ADP
6GPH	;	1.56	;	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A in complex with AMPCP
6GPF	;	1.55	;	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A in complex with AMPPNP
6GPO	;	1.48	;	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A in complex with cAMP
8AGJ	;	2.32	;	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A in complex with JMC31
6GR4	;	1.5	;	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R
6GR5	;	1.34	;	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R in complex with ADP
6GQS	;	1.43	;	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R in complex with AMPCP
6GR1	;	2.05	;	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R in complex with AMPCPP
6GR3	;	1.88	;	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R in complex with AMPPNP
6GQU	;	1.72	;	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R in complex with cAMP
8AGL	;	2.2	;	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R in complex with JMC31
3S9G	;	2.1	;	Structure of human Hexim1 (delta stammer) coiled coil domain
5NU7	;	1.5	;	Structure of human holo plasma RBP4
5VYY	;	1.792	;	Structure of human Hsp90-alpha bound to resorcinylic inhibitor BnIm
2H55	;	2.0	;	Structure of human Hsp90-alpha bound to the potent water soluble inhibitor PU-DZ8
2FWY	;	2.1	;	Structure of human Hsp90-alpha bound to the potent water soluble inhibitor PU-H64
2FWZ	;	2.1	;	Structure of human Hsp90-alpha bound to the potent water soluble inhibitor PU-H71
2PE4	;	2.0	;	Structure of Human Hyaluronidase 1, a Hyaluronan Hydrolyzing Enzyme Involved in Tumor Growth and Angiogenesis
7R4O	;	1.5	;	Structure of human hydroxyacid oxidase 1 bound with 2-((4H-1,2,4-triazol-3-yl)thio)-1-(4-(3-chlorophenyl)piperazin-1-yl)ethan-1-one
7R4N	;	1.7	;	Structure of human hydroxyacid oxidase 1 bound with 5-bromo-N-methyl-1H-indazole-3-carboxamide
7R4P	;	1.37	;	Structure of human hydroxyacid oxidase 1 bound with 6-amino-1-benzyl-5-(methylamino)pyrimidine-2,4(1H,3H)-dione
6GMB	;	1.35	;	Structure of human hydroxyacid oxidase 1 bound with FMN and glycolate
2PD6	;	2.0	;	Structure of human hydroxysteroid dehydrogenase type 8, HSD17B8
4A7U	;	0.98	;	Structure of human I113T SOD1 complexed with adrenaline in the p21 space group.
4A7Q	;	1.22	;	Structure of human I113T SOD1 mutant complexed with 4-(4-methyl-1,4- diazepan-1-yl)quinazoline in the p21 space group.
4A7G	;	1.24	;	Structure of human I113T SOD1 mutant complexed with 4-methylpiperazin- 1-yl)quinazoline in the p21 space group.
4A7S	;	1.06	;	Structure of human I113T SOD1 mutant complexed with 5-Fluorouridine in the p21 space group
4A7V	;	1.0	;	Structure of human I113T SOD1 mutant complexed with dopamine in the p21 space group
4A7T	;	1.45	;	Structure of human I113T SOD1 mutant complexed with isoproteranol in the p21 space group
7WRQ	;	3.6	;	Structure of Human IGF1/IGFBP3/ALS Ternary Complex
2V5N	;	3.2	;	STRUCTURE OF HUMAN IGF2R DOMAINS 11-12
2V5O	;	2.91	;	STRUCTURE OF HUMAN IGF2R DOMAINS 11-14
7LBL	;	2.13	;	Structure of Human IgG1 Fc
1KZS	;		;	Structure of Human Immunodeficiency Virus Type 1 Vpr(34-51) Peptide in Aqueous TFE Solution
1KZV	;		;	Structure of Human Immunodeficiency Virus Type 1 Vpr(34-51) Peptide in Chloroform Methanol
1KZT	;		;	Structure of Human Immunodeficiency Virus Type 1 Vpr(34-51) Peptide in DPC Micelle Containing Aqueous Solution
6I0M	;	2.567	;	Structure of human IMP dehydrogenase, isoform 2, bound to GDP
6I0O	;	2.623	;	Structure of human IMP dehydrogenase, isoform 2, bound to GTP
7A62	;	2.43796	;	Structure of human indoleamine-2,3-dioxygenase 1 (hIDO1) with a complete JK loop
7XHO	;	3.29	;	Structure of human inner kinetochore CCAN complex
7XHN	;	3.71	;	Structure of human inner kinetochore CCAN-DNA complex
4CX7	;	3.16	;	Structure of human iNOS heme domain in complex with (R)-6-(3-AMINO-2-(5-(2-(6-AMINO-4- METHYLPYRIDIN-2-YL)ETHYL)PYRIDIN-3-YL)PROPYL)-4- METHYLPYRIDIN-2-AMINE
2ODT	;	2.01	;	Structure of human Inositol 1,3,4-trisphosphate 5/6-kinase
4AS4	;	1.7	;	Structure of human inositol monophosphatase 1
3E7G	;	2.2	;	Structure of human INOSOX with inhibitor AR-C95791
3E7Y	;	1.6	;	Structure of human insulin
3E7Z	;	1.7	;	Structure of human insulin
2OMH	;	1.36	;	Structure of human insulin cocrystallized with ARG-12 peptide in presence of urea
2OMI	;	2.24	;	Structure of human insulin cocrystallized with protamine
2OMG	;	1.52	;	Structure of human insulin cocrystallized with protamine and urea
2OM1	;	1.97	;	Structure of human insulin in presence of thiocyanate at pH 6.5
2OLZ	;	1.7	;	Structure of human insulin in presence of thiocyanate at pH 7.0
2OM0	;	2.05	;	Structure of human insulin in presence of urea at pH 6.5
2OLY	;	1.7	;	Structure of human insulin in presence of urea at pH 7.0
4WMQ	;	1.8	;	Structure of Human Intelectin-1
4WMY	;	1.601	;	Structure of Human intelectin-1 in complex with allyl-beta-galactofuranose
6USC	;	1.59	;	Structure of Human Intelectin-1 in complex with KO
5K5G	;		;	Structure of human islet amyloid polypeptide in complex with an engineered binding protein
2PNY	;	1.81	;	Structure of Human Isopentenyl-diphosphate Delta-isomerase 2
1IVH	;	2.6	;	STRUCTURE OF HUMAN ISOVALERYL-COA DEHYDROGENASE AT 2.6 ANGSTROMS RESOLUTION: STRUCTURAL BASIS FOR SUBSTRATE SPECIFICITY
3FRS	;	2.61	;	Structure of human IST1(NTD) (residues 1-189)(p43212)
3FRR	;	1.8	;	Structure of human IST1(NTD) - (residues 1-189)(P21)
5IXD	;	2.85	;	Structure of human JAK1 FERM/SH2 in complex with IFN lambda receptor
5IXI	;	2.57	;	Structure of human JAK1 FERM/SH2 in complex with IFNLR1/IL10RA chimera
6E2Q	;	2.65	;	Structure of human JAK2 FERM/SH2 in complex with Erythropoietin Receptor
6E2P	;	2.83	;	Structure of human JAK2 FERM/SH2 in complex with Leptin Receptor
4QTD	;	1.5	;	Structure of human JNK1 in complex with SCH772984 and the AMPPNP-hydrolysed triphosphate revealing the second type-I binding mode
6UZZ	;	3.1	;	structure of human KCNQ1-CaM complex
6V00	;	3.1	;	structure of human KCNQ1-KCNE3-CaM complex
6V01	;	3.9	;	structure of human KCNQ1-KCNE3-CaM complex with PIP2
7VNR	;	2.8	;	Structure of human KCNQ4-ML213 complex in digitonin
7VNQ	;	2.96	;	Structure of human KCNQ4-ML213 complex in nanodisc
7VNP	;	2.79	;	Structure of human KCNQ4-ML213 complex with PIP2
6S4L	;	2.42	;	Structure of human KCTD1
8PNR	;	2.25	;	Structure of human KCTD15 BTB domain mutant G88D crystal form 1
8PNM	;	1.94	;	Structure of human KCTD15 BTB domain mutant G88D crystal form 2
5WBM	;	2.16	;	Structure of human Ketohexokinase complexed with hits from fragment screening
5WBO	;	2.25	;	Structure of human Ketohexokinase complexed with hits from fragment screening
5WBP	;	2.74	;	Structure of human Ketohexokinase complexed with hits from fragment screening
5WBQ	;	2.4	;	Structure of human Ketohexokinase complexed with hits from fragment screening
5WBR	;	2.58	;	Structure of human Ketohexokinase complexed with hits from fragment screening
5WBZ	;	2.4	;	Structure of human Ketohexokinase complexed with hits from fragment screening
6UL7	;	2.3	;	Structure of human ketohexokinase-C in complex with fructose, NO3, and osthole
7U5B	;	2.371	;	Structure of Human KLK5 bound to anti-KLK5 Fab
7SSX	;	2.89	;	Structure of human Kv1.3
7SSY	;	2.89	;	Structure of human Kv1.3 (alternate conformation)
7SSZ	;	3.25	;	Structure of human Kv1.3 with A0194009G09 nanobodies
8DFL	;	3.25	;	Structure of human Kv1.3 with A0194009G09 nanobodies (alternate conformation)
7SSV	;	3.39	;	Structure of human Kv1.3 with Fab-ShK fusion
4R30	;	2.3	;	Structure of human laforin dual specificity phosphatase domain
7TZH	;	2.43	;	Structure of human LAG3 domains 3-4 in complex with antibody single chain-variable fragment
7TZG	;	3.71	;	Structure of human LAG3 in complex with antibody single-chain variable fragment
2CD0	;	1.8	;	STRUCTURE OF HUMAN LAMBDA-6 LIGHT CHAIN DIMER WIL
1CD0	;	1.9	;	STRUCTURE OF HUMAN LAMDA-6 LIGHT CHAIN DIMER JTO
7WZ8	;	6.4	;	Structure of human langerin complex in Birbeck granules
3KMM	;	2.8	;	Structure of human LCK kinase with a small molecule inhibitor
6TYD	;	2.803	;	Structure of human LDB1 in complex with SSBP2
7N0A	;	3.1	;	Structure of Human Leukaemia Inhibitory Factor with Fab MSC1
5BPP	;	2.03	;	Structure of human Leukotriene A4 hydrolase in complex with inhibitor 4AZ
4DPR	;	2.02	;	Structure of human Leukotriene A4 hydrolase in complex with inhibitor captopril
5AEN	;	1.864	;	Structure of human Leukotriene A4 hydrolase in complex with inhibitor dimethyl(2- (4-phenoxyphenoxy)ethyl)amine
4R7L	;	1.66	;	Structure of Human Leukotriene A4 Hydrolase in complex with inhibitor H1
3U9W	;	1.25	;	Structure of human Leukotriene A4 hydrolase in complex with inhibitor sc57461A
3HKK	;	2.9	;	Structure of human Leukotriene C4 synthase in complex with glutathione sulfonate
3LEO	;	2.1	;	Structure of human Leukotriene C4 synthase mutant R31Q in complex with glutathione
3STN	;	2.595	;	Structure of human LFABP (apo-LFABP)
3VG7	;	1.44	;	Structure of human LFABP at high resolution from S-SAD
3STM	;	2.216	;	Structure of human LFABP in complex with one molecule of palmitic acid
8Y6B	;	3.49	;	Structure of human LGI1-ADAM22 complex in space group P212121
1TEH	;	2.7	;	STRUCTURE OF HUMAN LIVER CHICHI ALCOHOL DEHYDROGENASE (A GLUTATHIONE-DEPENDENT FORMALDEHYDE DEHYDROGENASE)
6LS5	;	2.031	;	Structure of human liver FBPase complexed with covalent allosteric inhibitor
2FIX	;	3.5	;	Structure of human liver FBPase complexed with potent benzoxazole allosteric inhibitiors
2FIE	;	2.81	;	Structure of human liver FBPase complexed with potent benzoxazole allosteric inhibitors
2FHY	;	2.95	;	Structure of human liver FPBase complexed with a novel benzoxazole as allosteric inhibitor
7QDN	;	1.695	;	Structure of human liver pyruvate kinase from which the B domain has been deleted
5UNJ	;	1.959	;	Structure of Human Liver Receptor Homolog 1 in complex with PGC1a and RJW100
2P85	;	2.35	;	Structure of Human Lung Cytochrome P450 2A13 with indole bound in two alternate conformations
4DZO	;	1.76	;	Structure of Human Mad1 C-terminal Domain Reveals Its Involvement in Kinetochore Targeting
6PUL	;	1.84	;	Structure of human MAIT A-F7 TCR in complex with human MR1 3'D-5-OP-RU
6PUM	;	1.96	;	Structure of human MAIT A-F7 TCR in complex with human MR1-2'D-5-OP-RU
6PUG	;	1.8	;	Structure of human MAIT A-F7 TCR in complex with human MR1-2`OH-Ethyl-5-OP-U
6PUJ	;	1.92	;	Structure of human MAIT A-F7 TCR in complex with human MR1-3`OH-Propyl-5-OP-U
6PUE	;	1.9	;	Structure of human MAIT A-F7 TCR in complex with human MR1-4'D-5-OP-RU
6PUI	;	1.96	;	Structure of human MAIT A-F7 TCR in complex with human MR1-4'OH-Butyl-5-OP-U
6PUF	;	1.92	;	Structure of human MAIT A-F7 TCR in complex with human MR1-5'D-5-OP-RU
6PUD	;	1.8	;	Structure of human MAIT A-F7 TCR in complex with human MR1-5'OH-Pentyl-5-OP-U
6PUC	;	1.85	;	Structure of human MAIT A-F7 TCR in complex with human MR1-5-OP-RU
6PVC	;	1.96	;	Structure of human MAIT A-F7 TCR in complex with human MR1-DB28
6PUK	;	2.08	;	Structure of human MAIT A-F7 TCR in complex with human MR1-JYM72
6PVD	;	2.14	;	Structure of human MAIT A-F7 TCR in complex with human MR1-NV18.1
6PUH	;	1.88	;	Structure of human MAIT A-F7 TCR in complex with human MR1-Ribityl-less
6W9V	;	1.95	;	Structure of human MAIT A-F7 TCR in complex with patient MR1-R9H without ligand
6W9U	;	1.89	;	Structure of human MAIT A-F7 TCR in complex with patient MR1-R9H-Ac-6-FP
4L4T	;	2.0	;	Structure of human MAIT TCR in complex with human MR1-6-FP
4L4V	;	1.9	;	Structure of human MAIT TCR in complex with human MR1-RL-6-Me-7-OH
1EFK	;	2.6	;	STRUCTURE OF HUMAN MALIC ENZYME IN COMPLEX WITH KETOMALONATE
2VRL	;	2.4	;	Structure of human MAO B in complex with benzylhydrazine
2VRM	;	2.3	;	Structure of human MAO B in complex with phenyethylhydrazine
2V61	;	1.7	;	Structure of human MAO B in complex with the selective inhibitor 7-(3- chlorobenzyloxy)-4-(methylamino)methyl-coumarin
2V60	;	2.0	;	Structure of human MAO B in complex with the selective inhibitor 7-(3- chlorobenzyloxy)-4-carboxaldehyde-coumarin
2V5Z	;	1.6	;	Structure of human MAO B in complex with the selective inhibitor safinamide
2VRG	;		;	Structure of human MCFD2
6QFI	;	2.4	;	Structure of human Mcl-1 in complex with BIM BH3 peptide
6QFQ	;	1.6	;	Structure of human Mcl-1 in complex with indole acid inhibitor
6QFM	;	2.0	;	Structure of human Mcl-1 in complex with PUMA BH3 peptide
6QGD	;	1.8	;	Structure of human Mcl-1 in complex with thienopyrimidine inhibitor
1T4E	;	2.6	;	Structure of Human MDM2 in complex with a Benzodiazepine Inhibitor
1T4F	;	1.9	;	Structure of human MDM2 in complex with an optimized p53 peptide
3G03	;	1.8	;	Structure of human MDM2 in complex with high affinity peptide
3LBK	;	2.3	;	Structure of human MDM2 protein in complex with a small molecule inhibitor
3LBL	;	1.6	;	Structure of human MDM2 protein in complex with Mi-63-analog
2VYR	;	2.0	;	Structure of human MDM4 N-terminal domain bound to a single domain antibody
3FDO	;	1.4	;	Structure of human MDMX in complex with high affinity peptide
3LBJ	;	1.5	;	Structure of human MDMX protein in complex with a small molecule inhibitor
4IF5	;	1.7	;	Structure of human Mec17
5IXB	;	1.39	;	Structure of human Melanoma Inhibitory Activity (MIA) Protein in complex with Pyrimidin-2-amine
3P1A	;	1.7	;	Structure of human Membrane-associated Tyrosine- and Threonine-specific cdc2-inhibitory kinase MYT1 (PKMYT1)
6GFI	;	2.3	;	Structure of Human Mesotrypsin in complex with APPI variant T11V/M17R/I18F/F34V
5D6E	;	1.49	;	Structure of human methionine aminopeptidase 2 with covalent spiroepoxytriazole inhibitor (-)-31b
5CLS	;	1.75	;	Structure of human methionine aminopeptidase-2 complexed with spiroepoxytriazole inhibitor (+)-31a
5D6F	;	1.55	;	Structure of human methionine aminopeptidase-2 complexed with spiroepoxytriazole inhibitor (+)-31b
7ZMK	;	3.4	;	Structure of human MFAP4 in complex with the Fab fragment of the AS0326 monoclonal antibody
7Y4S	;	3.5	;	Structure of human MG53 homo-dimer
4I5B	;	2.12	;	Structure of human MHC class II protein HLA-DR1 carrying an influenza hemagglutinin peptide partially filling the binding groove
3T1N	;	2.6	;	Structure of human MICROCEPHALIN (MCPH1) TANDEM BRCT domains in complex with a CDC27 phosphopeptide
3SZM	;	2.63	;	STRUCTURE OF HUMAN MICROCEPHALIN (MCPH1) TANDEM BRCT DOMAINS IN COMPLEX WITH A GAMMA-H2AX PHOSPHOPEPTIDE
3U3Z	;	1.5	;	Structure of human microcephalin (MCPH1) tandem BRCT domains in complex with an H2A.X peptide phosphorylated at Ser139 and Tyr142
4GQS	;	2.87	;	Structure of Human Microsomal Cytochrome P450 (CYP) 2C19
2HCI	;	1.81	;	Structure of Human Mip-3a Chemokine
6RW5	;	3.14	;	Structure of human mitochondrial 28S ribosome in complex with mitochondrial IF2 and IF3
6RW4	;	2.97	;	Structure of human mitochondrial 28S ribosome in complex with mitochondrial IF3
4L6A	;	1.4	;	Structure of human mitochondrial 5'(3')-deoxyribonucleotidase
6W1D	;	1.795	;	Structure of human mitochondrial complex Nfs1-ISCU2 (WT)-ISD11 with E.coli ACP1 at 1.8 A resolution (NIAU)2
6WI2	;	1.95	;	Structure of human mitochondrial complex Nfs1-ISCU2-ISD11 with E.coli ACP1 at 1.95 A resolution (NIAU)2. N-terminal mutation of ISCU2 (L35) traps Nfs1 Cys loop in the active site of ISCU2 without metal present.
2C2N	;	1.55	;	Structure of human mitochondrial malonyltransferase
7A8P	;	3.5	;	Structure of human mitochondrial RNA polymerase in complex with IMT inhibitor.
7ONU	;	3.0	;	Structure of human mitochondrial RNase P in complex with mitochondrial pre-tRNA-Tyr
5OL8	;	1.9	;	Structure of human mitochondrial transcription elongation factor (TEFM) C-terminal domain
5OL9	;	1.302	;	Structure of human mitochondrial transcription elongation factor (TEFM) N-terminal domain
6NF8	;	3.48	;	Structure of human mitochondrial translation initiation factor 3 bound to the small ribosomal subunit -Class I
6NEQ	;	3.32	;	Structure of human mitochondrial translation initiation factor 3 bound to the small ribosomal subunit-Class-II
5ZRV	;	7.7	;	Structure of human mitochondrial trifunctional protein, octamer
5ZQZ	;	4.2	;	Structure of human mitochondrial trifunctional protein, tetramer
2AC3	;	2.1	;	Structure of human Mnk2 Kinase Domain
2AC5	;	3.2	;	Structure of human Mnk2 Kinase Domain mutant D228G
6AX1	;	2.26	;	Structure of human monoacylglycerol lipase bound to a covalent inhibitor
6BQ0	;	2.0	;	Structure of human monoacylglycerol lipase bound to a covalent inhibitor
3W9D	;	2.32	;	Structure of Human Monoclonal Antibody E317 Fab
3W9E	;	2.3	;	Structure of Human Monoclonal Antibody E317 Fab Complex with HSV-2 gD
7LQD	;	1.95	;	Structure of Human MPS1 (TTK) covalently bound to RMS-07 inhibitor
5U16	;	2.0	;	Structure of human MR1-2-OH-1-NA in complex with human MAIT A-F7 TCR
5U6Q	;	1.9	;	Structure of human MR1-3-F-SA in complex with human MAIT A-F7 TCR
4PJA	;	2.68	;	Structure of human MR1-5-OP-RU in complex with human MAIT B-B10 TCR
4PJB	;	2.85	;	Structure of human MR1-5-OP-RU in complex with human MAIT B-F3-C1 TCR
4PJC	;	2.5	;	Structure of human MR1-5-OP-RU in complex with human MAIT C-A11 TCR
4PJD	;	2.78	;	Structure of human MR1-5-OP-RU in complex with human MAIT C-C10 TCR
5D5M	;	2.2	;	Structure of human MR1-5-OP-RU in complex with human MAIT M33.64 TCR
5D7J	;	1.97	;	Structure of human MR1-5-OP-RU in complex with human MAIT M33.64(Y95alphaF) TCR
4PJ9	;	2.0	;	Structure of human MR1-5-OP-RU in complex with human MAIT TRAJ20 TCR
4PJ8	;	3.3	;	Structure of human MR1-5-OP-RU in complex with human MAIT TRBV20 TCR
4PJ7	;	2.5	;	Structure of human MR1-5-OP-RU in complex with human MAIT TRBV6-4 TCR
5D7L	;	3.4	;	Structure of human MR1-5-OP-RU in complex with human MAV36 TCR
5U72	;	2.5	;	Structure of human MR1-5OH-DCF in complex with human MAIT A-F7 TCR
4PJE	;	1.95	;	Structure of human MR1-Ac-6-FP in complex with human MAIT B-B10 TCR
4PJF	;	2.45	;	Structure of human MR1-Ac-6-FP in complex with human MAIT B-C10 TCR
4PJG	;	2.4	;	Structure of human MR1-Ac-6-FP in complex with human MAIT B-F3-C1 TCR
4PJH	;	2.0	;	Structure of human MR1-Ac-6-FP in complex with human MAIT B-G8 TCR
4PJX	;	2.25	;	Structure of human MR1-Ac-6-FP in complex with human MAIT C-A11 TCR
4PJI	;	2.5	;	Structure of human MR1-Ac-6-FP in complex with human MAIT C-C10 TCR
5D7I	;	2.0	;	Structure of human MR1-Ac-6-FP in complex with human MAIT M33.64 TCR
4PJ5	;	2.0	;	Structure of human MR1-Ac-6-FP in complex with human MAIT TRBV6-1 TCR
5U17	;	2.15	;	Structure of human MR1-DA-6-FP in complex with human MAIT A-F7 TCR
5U1R	;	2.7	;	Structure of human MR1-diclofenac in complex with human MAIT A-F7 TCR
7UFJ	;	2.5	;	Structure of human MR1-ethylvanillin in complex with human MAIT A-F7 TCR
5U2V	;	2.2	;	Structure of human MR1-HMB in complex with human MAIT A-F7 TCR
4N1T	;	1.6	;	Structure of human MTH1 in complex with TH287
4N1U	;	1.6	;	Structure of human MTH1 in complex with TH588
6S4E	;	1.9	;	Structure of human MTHFD2 in complex with TH7299
6S4A	;	1.95	;	Structure of human MTHFD2 in complex with TH9028
6S4F	;	2.2	;	Structure of human MTHFD2 in complex with TH9619
7QEI	;	2.1	;	Structure of human MTHFD2L in complex with TH7299
3HXT	;	1.9	;	Structure of human MTHFS
3HY3	;	1.8	;	Structure of human MTHFS with 10-formyltetrahydrofolate
3HY6	;	2.1	;	Structure of human MTHFS with ADP
3HY4	;	2.795	;	Structure of human MTHFS with N5-iminium phosphate
4CCA	;	2.6	;	Structure of human Munc18-2
1ZJH	;	2.2	;	Structure of human muscle pyruvate kinase (PKM2)
5MV9	;	2.6	;	Structure of human Myosin 7a C-terminal MyTH4-FERM domain in complex with harmonin-a PDZ3 domain
5MV8	;	1.88	;	Structure of human Myosin 7b C-terminal MyTH4-FERM domain in complex with harmonin-a PDZ3 domain
5MV7	;	2.44	;	Structure of human Myosin 7b C-terminal MyTH4-FERM MF2 domain
2VD5	;	2.8	;	Structure of Human Myotonic Dystrophy Protein Kinase in Complex with the Bisindoylmaleide inhibitor BIM VIII
5SZK	;	2.8	;	Structure of human N-terminally engineered Rab1b in complex with the bMERB domain of Mical-cL
6FY4	;	2.76	;	Structure of human NAD(P) H:quinone oxidoreductase in complex with N-(2-bromophenyl)pyrrolidine-1-sulfonamide
3LF5	;	1.25	;	Structure of Human NADH cytochrome b5 oxidoreductase (Ncb5or) b5 Domain to 1.25A Resolution
4QN9	;	2.652	;	Structure of human NAPE-PLD
8I5B	;	2.7	;	Structure of human Nav1.7 in complex with bupivacaine
8J4F	;	3.0	;	Structure of human Nav1.7 in complex with Hardwickii acid
8I5G	;	2.7	;	Structure of human Nav1.7 in complex with PF-05089771
8I5X	;	2.9	;	Structure of human Nav1.7 in complex with Vinpocetine
8I5Y	;	2.6	;	Structure of human Nav1.7 in complex with vixotrigine
8GAU	;	3.6	;	Structure of human NDS.1 Fab and 1G01 Fab in complex with influenza virus neuraminidase from A/Indiana/10/2011 (H3N2v)
8GAT	;	3.0	;	Structure of human NDS.1 Fab and 1G01 Fab in complex with influenza virus neuraminidase from A/Indiana/10/2011 (H3N2v), based on consensus cryo-EM map with only Fab 1G01 resolved
8GAV	;	2.7	;	Structure of human NDS.3 Fab in complex with influenza virus neuraminidase from A/Darwin/09/2021 (H3N2)
5LV0	;	2.7	;	Structure of Human Neurolysin (E475Q) in complex with amyloid-beta 35-40 peptide product
5LUZ	;	2.7	;	Structure of Human Neurolysin (E475Q) in complex with neurotensin peptide products
5UO6	;	1.96	;	Structure of human neuronal nitric oxide synthase heme domain in complex with (R)-3-[(2-amino-4-methylquinolin-7-yl)methoxy]-5-(2-(methylamino)propyl)benzonitrile
5UO5	;	2.0	;	Structure of human neuronal nitric oxide synthase heme domain in complex with (RS)-3-[(2-amino-4-methylquinolin-7-yl)methoxy]-5-(2-(methylamino)propyl)benzonitrile
5UO7	;	2.06	;	Structure of human neuronal nitric oxide synthase heme domain in complex with (S)-3-[(2-amino-4-methylquinolin-7-yl)methoxy]-5-(2-(methylamino)propyl)benzonitrile
5UO3	;	2.2	;	Structure of human neuronal nitric oxide synthase heme domain in complex with 3-[(2-amino-4-methylquinolin-7-yl)methoxy]-5-((methylamino)methyl)benzonitrile
5UO4	;	2.0	;	Structure of human neuronal nitric oxide synthase heme domain in complex with 3-[(2-amino-4-methylquinolin-7-yl)methoxy]-5-(2-(methylamino)ethyl)benzonitrile
5UO1	;	1.9	;	Structure of human neuronal nitric oxide synthase heme domain in complex with 3-[(2-aminoquinolin-7-yl)methoxy]-5-((methylamino)methyl)benzonitrile
5VV5	;	2.15	;	Structure of human neuronal nitric oxide synthase heme domain in complex with 4-(2-(((2-Amino-4-methylquinolin-7-yl)methyl)amino)ethyl)-2-methylbenzonitrile
5VV4	;	2.1	;	Structure of human neuronal nitric oxide synthase heme domain in complex with 4-(2-(((2-Aminoquinolin-7-yl)methyl)amino)ethyl)-2-methylbenzonitrile
5VV3	;	2.18	;	Structure of human neuronal nitric oxide synthase heme domain in complex with 4-(2-(((2-Aminoquinolin-7-yl)methyl)amino)ethyl)benzonitrile
5VV1	;	1.95	;	Structure of human neuronal nitric oxide synthase heme domain in complex with 7-(((3-(4-Methoxypyridin-3-yl)propyl)amino)methyl)quinolin-2-amine
5VV0	;	1.8	;	Structure of human neuronal nitric oxide synthase heme domain in complex with 7-(((3-(4-Methylpyridin-3-yl)propyl)amino)methyl)quinolin-2-amine
5VV2	;	2.0	;	Structure of human neuronal nitric oxide synthase heme domain in complex with 7-(((3-(5-Fluoropyridin-3-yl)propyl)amino)methyl)quinolin-2-amine
5VUW	;	2.03	;	Structure of human neuronal nitric oxide synthase heme domain in complex with 7-(((3-(Dimethylamino)benzyl)amino)methyl)quinolin-2-amine
5VUZ	;	1.97	;	Structure of human neuronal nitric oxide synthase heme domain in complex with 7-(((3-(Pyridin-3-yl)propyl)amino)methyl)quinolin-2-amine
5VUV	;	1.983	;	Structure of human neuronal nitric oxide synthase heme domain in complex with 7-(((3-Fluorophenyl)amino)methyl)quinolin-2-amine Dihydrochloride
5VUX	;	2.3	;	Structure of human neuronal nitric oxide synthase heme domain in complex with 7-(((4-(Dimethylamino)benzyl)amino)methyl)quinolin-2-amine
5VUY	;	2.154	;	Structure of human neuronal nitric oxide synthase heme domain in complex with 7-(((4-(Dimethylamino)phenethyl)amino)methyl)quinolin-2-amine
5UO2	;	1.947	;	Structure of human neuronal nitric oxide synthase heme domain in complex with 7-[(3-Ethyl-5-((methylamino)methyl)phenoxy)methyl]quinolin-2-amine
6AV5	;	1.9	;	Structure of human neuronal nitric oxide synthase R354A/G356D mutant heme domain in complex with 6-(2-(5-Fluoro-3'-((methylamino)methyl)-[1,1'-biphenyl]-3-yl)ethyl)-4-methylpyridin-2-amine
7UAM	;	1.837	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with (6-(3-(4,4-difluoropiperidin-1-yl)propyl)-4-methylpyridin-2-amine)
6NGF	;	1.993	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with (R)-6-(2,3-difluoro-5-(2-(1-methylpyrrolidin-2-yl)ethyl)phenethyl)-4-methylpyridin-2-amine
6NG5	;	1.96	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with (R)-6-(3-fluoro-5-(2-(1-methylpyrrolidin-2-yl)ethyl)phenethyl)-4-methylpyridin-2-amine
6NG4	;	1.776	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with (R)-6-(3-fluoro-5-(2-(pyrrolidin-2-yl)ethyl)phenethyl)-4-methylpyridin-2-amine
6NHC	;	2.16	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with (S)-6-(2,3-difluoro-5-(2-(1-methylazetidin-2-yl)ethyl)phenethyl)-4-methylpyridin-2-amine
6NGH	;	2.0	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with (S)-6-(2,3-difluoro-5-(2-(1-methylpyrrolidin-2-yl)ethyl)phenethyl)-4-methylpyridin-2-amine
6NGI	;	1.8	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with (S)-6-(2,3-difluoro-5-(2-(4-methylmorpholin-3-yl)ethyl)phenethyl)-4-methylpyridin-2-amine
6NG6	;	2.044	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with (S)-6-(3-fluoro-5-(2-(pyrrolidin-2-yl)ethyl)phenethyl)-4-methylpyridin-2-amine
6AV0	;	1.996	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 3-(2-(6-Amino-4-methylpyridin-2-yl)ethyl)-5-(3-(methylamino)propyl)benzonitrile
6PO8	;	1.898	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 4-((4-(2-Amino-4-methylquinolin-7-yl)-2-(aminomethyl)phenoxy)methyl)benzonitrile
8FGI	;	2.15	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 4-(5-(2-(dimethylamino)ethyl)-2,3-difluorophenethyl)-6-methylpyrimidin-2-amine
8FGM	;	2.1	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 4-(difluoromethyl)-6-(5-(2-(dimethylamino)ethyl)-2,3-difluorophenethyl)pyridin-2-amine
7TS8	;	2.3	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 4-chloro-6-((5-(2-(dimethylamino)ethyl)-2,3-difluorophenyl)ethynyl)pyridin-2-amine
6AV3	;	1.95	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 4-Methyl-6-(2-(5-(3-((methylamino)methyl)phenyl)pyridin-3-yl)ethyl)pyridin-2-amine
6AV4	;	1.867	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 4-Methyl-6-(2-(5-(4-((methylamino)methyl)phenyl)pyridin-3-yl)ethyl)pyridin-2-amine
7TS6	;	1.8	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 4-methyl-6-(3-((methylamino)methyl)phenyl)pyridin-2-amine
6AUY	;	1.92	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 4-Methyl-6-(3-(3-(methylamino)propyl)phenethyl)pyridin-2-amine
7TS4	;	1.85	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 4-methyl-6-(3-(4-methylpiperazin-1-yl)prop-1-yn-1-yl)pyridin-2-amine
7TS5	;	1.84	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 4-methyl-6-(3-(methylamino)prop-1-yn-1-yl)pyridin-2-amine
7TS7	;	1.9	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 4-methyl-6-(3-(methylamino)propyl)pyridin-2-amine
8UFP	;	1.9	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 4-methyl-7-(4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepin-7-yl)quinolin-2-amine dihydrochloride
8FGL	;	2.1	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 6-(2,3-difluoro-5-(2-(4-methylpiperazin-1-yl)ethyl)phenethyl)-4-methylpyridin-2-amine
6NGE	;	2.102	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 6-(2,3-difluoro-5-(3-(methylamino)prop-1-yn-1-yl)phenethyl)-4-methylpyridin-2-amine
7TS3	;	2.099	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 6-(3-(3,3-difluoroazetidin-1-yl)prop-1-yn-1-yl)-4-methylpyridin-2-amine
7TS2	;	1.9758	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 6-(3-(3,3-difluoroazetidin-1-yl)propyl)-4-methylpyridin-2-amine
6NG2	;	1.93	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 6-(3-(3-(dimethylamino)prop-1-yn-1-yl)-5-fluorophenethyl)-4-methylpyridin-2-amine
6NGC	;	1.998	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 6-(3-(3-(dimethylamino)propyl)-2,5,6-trifluorophenethyl)-4-methylpyridin-2-amine
6NGB	;	1.9	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 6-(3-(3-(dimethylamino)propyl)-2,5-difluorophenethyl)-4-methylpyridin-2-amine
6NGA	;	1.98	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 6-(3-(3-(dimethylamino)propyl)-2,6-difluorophenethyl)-4-methylpyridin-2-amine
6AV2	;	2.1	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 6-(3-(3-(dimethylamino)propyl)-5-(trifluoromethyl)phenethyl)-4-methylpyridin-2-amine
6AV1	;	2.45	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 6-(3-(3-(Dimethylamino)propyl)-5-fluorophenethyl)-4-methylpyridin-2-amine
7TS1	;	2.06	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 6-(3-(4,4-difluoropiperidin-1-yl)prop-1-yn-1-yl)-4-methylpyridin-2-amine
6NG7	;	2.0	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 6-(3-fluoro-5-(2-((2R,4S)-4-fluoro-1-methylpyrrolidin-2-yl)ethyl)phenethyl)-4-methylpyridin-2-amine
6NG1	;	2.15	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 6-(3-fluoro-5-(3-(methylamino)prop-1-yn-1-yl)phenethyl)-4-methylpyridin-2-amine
6AUZ	;	2.0	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 6-(3-Fluoro-5-(3-(methylamino)propyl)phenethyl)-4-methylpyridin-2-amine
7US7	;	1.93	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 6-(4-(dimethylamino)but-1-yn-1-yl)-4-methylpyridin-2-amine
7US8	;	1.82	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 6-(4-(dimethylamino)butyl)-4-methylpyridin-2-amine
6NHB	;	2.03	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 6-(5-(2-((2S,4R)-4-ethoxy-1-methylpyrrolidin-2-yl)ethyl)-2,3-difluorophenethyl)-4-methylpyridin-2-amine
8FGK	;	2.25	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 6-(5-(2-(diethylamino)ethyl)-2,3-difluorophenethyl)-4-methylpyridin-2-amine
8FGH	;	2.17	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 6-(5-(2-(dimethylamino)ethyl)-2,3-difluorophenethyl)-4-methoxypyridin-2-amine
8FGJ	;	2.15	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 6-(5-(2-(dimethylamino)ethyl)-2,3-difluorophenethyl)-4-methoxypyridin-2-amine
8FGG	;	1.859	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 6-(5-(2-(dimethylamino)ethyl)-2,3-difluorophenethyl)-4-methylpyridin-2-amine
8FGF	;	1.83	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 6-(5-(2-(dimethylamino)ethyl)-2,3-difluorophenethyl)pyridin-2-amine
6NGD	;	1.8	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 6-(5-(3-(dimethylamino)propyl)-2,3,4-trifluorophenethyl)-4-methylpyridin-2-amine
6NG8	;	1.9	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 6-(5-(3-(dimethylamino)propyl)-2,3-difluorophenethyl)-4-methylpyridin-2-amine
6PNC	;	2.15	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 7-(3-(2-Aminoethyl)phenyl)-4-methylquinolin-2-amine
6PND	;	2.4	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 7-(3-(2-Aminoethyl)phenyl)-4-methylquinolin-2-amine
6PO5	;	1.82	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 7-(3-(Aminomethyl)-4-(cyclobutylmethoxy)phenyl)-4-methylquinolin-2-amine
6PO7	;	1.95	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 7-(3-(Aminomethyl)-4-(cyclopropylmethoxy)phenyl)-4-methylquinolin-2-amine
6POC	;	1.998	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 7-(3-(Aminomethyl)-4-(oxazol-4-ylmethoxy)phenyl)-4-methylquinolin-2-amine
6PO9	;	1.808	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 7-(3-(Aminomethyl)-4-(pyridin-2-ylmethoxy)phenyl)-4-methylquinolin-2-amine
6POA	;	1.809	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 7-(3-(Aminomethyl)-4-(pyridin-3-ylmethoxy)phenyl)-4-methylquinolin-2-amine
6POB	;	1.95	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 7-(3-(Aminomethyl)-4-(thiazol-4-ylmethoxy)phenyl)-4-methylquinolin-2-amine
6POT	;	2.3	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 7-(3-(Aminomethyl)-4-(thiazol-5-ylmethoxy)phenyl)-4-methylquinolin-2-amine
6PNF	;	2.1	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 7-(3-(Aminomethyl)-4-ethoxyphenyl)-4-methylquinolin-2-amine
6PNH	;	1.85	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 7-(3-(Aminomethyl)-4-isopropoxyphenyl)-4-methylquinolin-2-amine
6PNG	;	1.775	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 7-(3-(Aminomethyl)-4-propoxyphenyl)-4-methylquinolin-2-amine
6PNA	;	1.95	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 7-(4-(2-Aminoethyl)phenyl)-4-methylquinolin-2-amine
6PNB	;	2.05	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 7-(4-(Aminomethyl)phenyl)-4-methylquinolin-2-amine
6PNE	;	2.1	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with 7-(5-(Aminomethyl)pyridin-3-yl)-4-methylquinolin-2-amine
6CID	;	1.75	;	Structure of human neuronal nitric oxide synthase R354A/G357D mutant heme domain in complex with N-(1-(Piperidin-4-yl)indolin-5-yl)thiophene-2-carboximidamide
8UFQ	;	1.98	;	Structure of human neuronal nitric oxide synthase R354A/G357D/E597Q mutant heme domain obtained after soaking crystal with 4-methyl-7-(4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepin-7-yl)quinolin-2-amine dihydrochloride
8C5G	;	2.7	;	Structure of human Neuropilin-1 b1b2 domains in complex with Chlorotoxin (Leiurus quinquestriatus)
5DQ0	;	1.8	;	Structure of human neuropilin-2 b1 domain with novel and unique zinc binding site
1DMT	;	2.1	;	STRUCTURE OF HUMAN NEUTRAL ENDOPEPTIDASE COMPLEXED WITH PHOSPHORAMIDON
1MNC	;	2.1	;	STRUCTURE OF HUMAN NEUTROPHIL COLLAGENASE REVEALS LARGE S1' SPECIFICITY POCKET
3Q76	;	1.861	;	Structure of human neutrophil elastase (uncomplexed)
7CBK	;	2.7	;	Structure of Human Neutrophil Elastase Ecotin complex
3Q77	;	1.998	;	Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor
1HNE	;	1.84	;	Structure of human neutrophil elastase in complex with a peptide chloromethyl ketone inhibitor at 1.84-angstroms resolution
5U74	;	3.335	;	Structure of human Niemann-Pick C1 protein
6IAP	;	2.9	;	structure of human NKp46 in complex with antibody NKp46-1 and NKp46-4
6IAS	;	1.75	;	structure of human NKp46 in complex with antibody NKp46-1 and NKp46-4
6PAV	;	2.52	;	Structure of Human NMT1 with products CoA and myristoyl-lysine peptide with acetylated N-terminus
6PAU	;	1.93	;	Structure of Human NMT2 with myristoyl-lysine peptide and CoA products
6CHH	;	2.3	;	Structure of human NNMT in complex with bisubstrate inhibitor MS2756
7EHZ	;	2.5	;	Structure of human NNMT in complex with macrocyclic peptide 2
7EI2	;	2.08	;	Structure of human NNMT in complex with macrocyclic peptide 8
7EGU	;	1.9	;	Structure of human NNMT in complex with macrocyclic peptide X
4D1N	;	2.03	;	Structure of human nNOS heme domain with L-Arg bound
4UCH	;	2.2	;	Structure of human nNOS R354A G357D mutant heme domain in complex with 3-(((2-((2-(1H-IMIDAZOL-1-YL)PYRIMIDIN-4-YL)ETHYL)AMINO)METHYL) BENZONITRILE
4UH6	;	1.98	;	Structure of human nNOS R354A G357D mutant heme domain in complex with 3-(2-(6-Amino-4-methylpyridin-2-yl)ethyl)-5-(methyl(2-(methylamino)ethyl)amino)benzonitrile
5FVV	;	2.05	;	Structure of human nNOS R354A G357D mutant heme domain in complex with 4-methyl-6-(2-(5-(1-methylpiperidin-4-yl)pyridin-3-yl)ethyl) pyridin-2-amine
5FVW	;	2.2	;	Structure of human nNOS R354A G357D mutant heme domain in complex with 4-methyl-6-(2-(5-(3-(methylamino)propyl)pyridin-3-yl)ethyl) pyridin-2-amine
5FVU	;	2.224	;	Structure of human nNOS R354A G357D mutant heme domain in complex with 4-methyl-6-(2-(5-(4-methylpiperazin-1-yl)pyridin-3-yl)ethyl) pyridin-2-amine
5ADF	;	1.966	;	Structure of human nNOS R354A G357D mutant heme domain in complex with 7-(((3-((Dimethylamino)methyl)phenyl)amino)methyl)quinolin-2- amine
5ADI	;	2.2	;	Structure of human nNOS R354A G357D mutant heme domain in complex with 7-(((5-((Methylamino)methyl)pyridin-3-yl)oxy)methyl)quinolin-2- amine
5ADG	;	1.982	;	Structure of human nNOS R354A G357D mutant heme domain in complex with 7-((4-Chloro-3-((methylamino)methyl)phenoxy)methyl)quinolin-2- amine
4V3U	;	2.3	;	Structure of human nNOS R354A G357D mutant heme domain in complex with N-2-(2-(1H-imidazol-1-yl)pyrimidin-4-yl)ethyl-3-(pyridin-3-yl) propan-1-amine
4UH5	;	1.983	;	Structure of human nNOS R354A G357D mutant heme domain in complex with N1-(5-(2-(6-Amino-4-methylpyridin-2-yl)ethyl)pyridin-3-yl)-N1,N2- dimethylethane-1,2-diamine
5FVX	;	2.3	;	Structure of human nNOS R354A G357D mutant heme domain in complex with with 6-(2-(5-(3-(DIMETHYLAMINO)PROPYL) PYRIDIN-3-YL)ETHYL)-4-METHYLPYRIDIN-2-AMINE
6MAL	;	2.6	;	Structure of human Nocturnin C-terminal domain
4GMJ	;	2.7	;	Structure of human NOT1 MIF4G domain co-crystallized with CAF1
3V79	;	3.85	;	Structure of human Notch1 transcription complex including CSL, RAM, ANK, and MAML-1 on HES-1 promoter DNA sequence
5KWY	;	2.405	;	Structure of human NPC1 middle lumenal domain bound to NPC2
7N4U	;	3.34	;	Structure of human NPC1L1
7N4X	;	3.33	;	Structure of human NPC1L1 mutant-W347R
7RDS	;	2.5	;	Structure of human NTHL1
7RDT	;	2.1	;	Structure of human NTHL1 - linker 1 chimera
1ZS6	;	2.3	;	structure of human nucleoside-diphosphate kinase 3
5M7R	;	2.35	;	Structure of human O-GlcNAc hydrolase
5M7S	;	2.4	;	Structure of human O-GlcNAc hydrolase with bound transition state analog ThiametG
5M7U	;	2.3	;	Structure of human O-GlcNAc hydrolase with new iminocyclitol type inhibitor
5M7T	;	2.6	;	Structure of human O-GlcNAc hydrolase with PugNAc type inhibitor
3PE3	;	2.78	;	Structure of human O-GlcNAc transferase and its complex with a peptide substrate
3PE4	;	1.95	;	Structure of human O-GlcNAc transferase and its complex with a peptide substrate
8CM9	;	2.8	;	Structure of human O-GlcNAc transferase in complex with UDP and tP11
7ZH6	;	3.67	;	Structure of human OCT3 in complex with inhibitor Corticosterone
7ZHA	;	3.55	;	Structure of human OCT3 in complex with inhibitor decynium-22
7ZH0	;	3.2	;	Structure of human OCT3 in lipid nanodisc
4ZGY	;	2.63	;	STRUCTURE of HUMAN ORNITHINE DECARBOXYLASE IN COMPLEX WITH A C-TERMINAL FRAGMENT OF ANTIZYME
6IYB	;	2.091	;	Structure of human ORP1 ANK - Rab7 complex
7DEI	;	2.6	;	Structure of human ORP3 ORD domain in complex with PI(4)P
7DEJ	;	2.7	;	Structure of human ORP3 ORD in apo-form
4ONI	;	1.8	;	Structure of Human Orphan Receptor LRH1 bound to two bacterial phospholipids
1W6K	;	2.1	;	Structure of human OSC in complex with Lanosterol
1W6J	;	2.2	;	Structure of human OSC in complex with Ro 48-8071
1HHO	;	2.1	;	STRUCTURE OF HUMAN OXYHAEMOGLOBIN AT 2.1 ANGSTROMS RESOLUTION
2Q0N	;	1.75	;	Structure of human p21 activating kinase 4 (PAK4) in complex with a consensus peptide
6AH4	;	3.296	;	Structure of human P2X3 receptor in complex with ATP and Ca2+ ion
6AH5	;	3.819	;	Structure of human P2X3 receptor in complex with ATP and Mg2+ ion
3KQ7	;	1.8	;	Structure of human p38alpha with N-[4-methyl-3-(6-{[2-(1-methylpyrrolidin-2-yl)ethyl]amino}pyridine-3-amido)phenyl]-2-(morpholin-4-yl)pyridine-4-carboxamide
4ZTH	;	2.15	;	Structure of human p38aMAPK-arylpyridazinylpyridine fragment complex used in inhibitor discovery
7MDM	;	4.86	;	Structure of human p97 ATPase L464P mutant
7MDO	;	4.12	;	Structure of human p97 ATPase L464P mutant
7JY5	;	2.89	;	Structure of human p97 in complex with ATPgammaS and Npl4/Ufd1 (masked around p97)
6NDU	;	2.1	;	Structure of human PACRG-MEIG1 complex
6NEP	;	2.09763	;	Structure of human PACRG-MEIG1 complex
6UCC	;	2.6	;	Structure of human PACRG-MEIG1 complex (limited proteolysis)
4M6T	;	2.498	;	Structure of human Paf1 and Leo1 complex
1B2Y	;	3.2	;	STRUCTURE OF HUMAN PANCREATIC ALPHA-AMYLASE IN COMPLEX WITH THE CARBOHYDRATE INHIBITOR ACARBOSE
2PVS	;	3.0	;	Structure of human pancreatic lipase related protein 2 mutant N336Q
7EV8	;	3.234	;	Structure of Human Parainfluenza Virus 3 Unassembled Nucleoprotein in Complex with its viral chaperone
1HPH	;		;	STRUCTURE OF HUMAN PARATHYROID HORMONE 1-37 IN SOLUTION
1ZWA	;		;	STRUCTURE OF HUMAN PARATHYROID HORMONE FRAGMENT 1-34, NMR, 10 STRUCTURES
1ZWB	;		;	STRUCTURE OF HUMAN PARATHYROID HORMONE FRAGMENT 2-37, NMR, 10 STRUCTURES
1ZWD	;		;	STRUCTURE OF HUMAN PARATHYROID HORMONE FRAGMENT 3-37, NMR, 10 STRUCTURES
1ZWE	;		;	STRUCTURE OF HUMAN PARATHYROID HORMONE FRAGMENT 4-37, NMR, 10 STRUCTURES
3C4M	;	1.95	;	Structure of human parathyroid hormone in complex with the extracellular domain of its G-protein-coupled receptor (PTH1R)
4B1J	;	2.08	;	Structure of human PARG catalytic domain in complex with ADP-HPD
4B1H	;	2.0	;	Structure of human PARG catalytic domain in complex with ADP-ribose
4B1I	;	2.14	;	Structure of human PARG catalytic domain in complex with OA-ADP-HPD
6O9X	;	1.7	;	Structure of human PARG complexed with JA2-4
6O9Y	;	2.0	;	Structure of human PARG complexed with JA2-8
6OA0	;	2.0	;	Structure of human PARG complexed with JA2-9
6OA1	;	1.8	;	Structure of human PARG complexed with JA2120
6OAL	;	1.6	;	Structure of human PARG complexed with JA2120
6OA3	;	1.9	;	Structure of human PARG complexed with JA2131
6OAK	;	1.7	;	Structure of human PARG complexed with JA2131
7KG1	;	1.65	;	Structure of human PARG complexed with PARG-002
7KG8	;	1.43	;	Structure of human PARG complexed with PARG-061
7KFP	;	1.9	;	Structure of human PARG complexed with PARG-119
7KG0	;	1.66	;	Structure of human PARG complexed with PARG-131
7KG7	;	1.85	;	Structure of human PARG complexed with PARG-292
7KG6	;	1.96	;	Structure of human PARG complexed with PARG-322
8PQ0	;	1.48	;	Structure of human PARK7 in complex with GK16R
8PPW	;	1.53	;	Structure of human PARK7 in complex with GK16S
5C9V	;	2.35	;	Structure of human Parkin G319A
4DQY	;	3.25	;	Structure of Human PARP-1 bound to a DNA double strand break
4OPX	;	3.314	;	Structure of Human PARP-1 bound to a DNA double strand break in complex with (2R)-5-fluoro-2-methyl-2,3-dihydro-1-benzofuran-7-carboxamide
4OQA	;	3.65	;	Structure of Human PARP-1 bound to a DNA double strand break in complex with (2Z)-2-(2,4-dihydroxybenzylidene)-3-oxo-2,3-dihydro-1-benzofuran-7-carboxamide
4OQB	;	3.362	;	Structure of Human PARP-1 bound to a DNA double strand break in complex with (2Z)-2-{4-[2-(morpholin-4-yl)ethoxy]benzylidene}-3-oxo-2,3-dihydro-1-benzofuran-7-carboxamide
5WS0	;	2.6	;	Structure of human PARP1 catalytic domain bound to a benzoimidazole inhibitor
5WS1	;	1.9	;	Structure of human PARP1 catalytic domain bound to a benzoimidazole inhibitor
5WRZ	;	2.2	;	Structure of human PARP1 catalytic domain bound to a phthalazinone inhibitor
5KPN	;	2.3	;	Structure of human PARP1 catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitor
5KPO	;	2.65	;	Structure of human PARP1 catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitor
5KPP	;	2.33	;	Structure of human PARP1 catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitor
5KPQ	;	2.55	;	Structure of human PARP1 catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitor
5WRQ	;	2.65	;	Structure of human PARP1 catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitor
5WRY	;	2.3	;	Structure of human PARP1 catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitor
5WTC	;	2.2	;	Structure of human PARP1 catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitor
4ZZZ	;	1.9	;	Structure of human PARP1 catalytic domain bound to an isoindolinone inhibitor
5A00	;	2.75	;	Structure of human PARP1 catalytic domain bound to an isoindolinone inhibitor
7S68	;	3.3	;	Structure of human PARP1 domains (Zn1, Zn3, WGR and HD) bound to a DNA double strand break.
7S81	;	3.6	;	Structure of human PARP1 domains (Zn1, Zn3, WGR, HD) bound to a DNA double strand break.
4ZZY	;	2.2	;	Structure of human PARP2 catalytic domain bound to an isoindolinone inhibitor
6OEU	;	3.5	;	Structure of human Patched1
6OEV	;	3.8	;	Structure of human Patched1 in complex with native Sonic Hedgehog
3P87	;	2.99	;	Structure of human PCNA bound to RNASEH2B PIP box peptide
5O45	;	0.99	;	Structure of human PD-L1 in complex with inhibitor
5O4Y	;	2.3	;	Structure of human PD-L1 in complex with inhibitor
6YCR	;	1.54	;	Structure of human PD-L1 in complex with inhibitor
8ALX	;	1.1	;	Structure of human PD-L1 in complex with inhibitor
7OUN	;	1.9	;	Structure of human PD-L1 in complex with macrocyclic inhibitor
1UU8	;	2.5	;	Structure of human PDK1 kinase domain in complex with BIM-1
1UU7	;	1.9	;	Structure of human PDK1 kinase domain in complex with BIM-2
1UU9	;	1.95	;	Structure of human PDK1 kinase domain in complex with BIM-3
1UVR	;	2.81	;	Structure of human PDK1 kinase domain in complex with BIM-8
1UU3	;	1.7	;	Structure of human PDK1 kinase domain in complex with LY333531
1OKY	;	2.3	;	Structure of human PDK1 kinase domain in complex with staurosporine
1OKZ	;	2.51	;	Structure of human PDK1 kinase domain in complex with UCN-01
2UZC	;	1.5	;	Structure of human PDLIM5 in complex with the C-terminal peptide of human alpha-actinin-1
5JCG	;	2.8	;	Structure of Human Peroxiredoxin 3 as three stacked rings
7AAH	;	1.4	;	Structure of human pERp1
8WEJ	;	2.79	;	Structure of human phagocyte NADPH oxidase in the activated state
8GZ3	;	3.3	;	Structure of human phagocyte NADPH oxidase in the resting state
8X2L	;	2.99	;	Structure of human phagocyte NADPH oxidase in the resting state in the presence of 2 mM NADPH
1LN3	;	2.9	;	Structure of Human Phosphatidylcholine Transfer Protein in Complex with Palmitoyl-Linoleoyl Phosphatidylcholine (Seleno-Met Protein)
2JKV	;	2.532	;	Structure of human Phosphogluconate Dehydrogenase in complex with NADPH at 2.53A
6OHO	;	2.0	;	Structure of human Phospholipase D2 catalytic domain
2Y7J	;	2.5	;	Structure of human phosphorylase kinase, gamma 2
8SOR	;	3.96	;	Structure of human PI3KC3-C1 complex
5FHH	;	3.6	;	Structure of human Pif1 helicase domain residues 200-641
6WTL	;	2.85	;	Structure of Human pir-miRNA-19b-2 Apical Loop and One-base-pair Fused to the YdaO Riboswitch Scaffold
6N5O	;	2.708	;	Structure of Human pir-miRNA-202 Apical Loop and One-base-pair Fused to the YdaO Riboswitch Scaffold
6N5N	;	2.951	;	Structure of Human pir-miRNA-208a Apical Loop and One-base-pair Fused to the YdaO Riboswitch Scaffold
6WTR	;	3.082	;	Structure of Human pir-miRNA-300 Apical Loop Fused to the YdaO Riboswitch Scaffold
6N5S	;	2.802	;	Structure of Human pir-miRNA-320b-2 Apical Loop and One-base-pair Stem Fused to the YdaO Riboswitch Scaffold
6N5P	;	2.991	;	Structure of Human pir-miRNA-340 Apical Loop and One-base-pair Fused to the YdaO Riboswitch Scaffold
6N5Q	;	2.946	;	Structure of Human pir-miRNA-378a Apical Loop and One-base-pair Fused to the YdaO Riboswitch Scaffold
6N5T	;	2.787	;	Structure of Human pir-miRNA-378a Apical Loop Fused to the YdaO Riboswitch Scaffold
6N5K	;	3.098	;	Structure of Human pir-miRNA-449c Apical Loop and One-base-pair Fused to the YdaO Riboswitch Scaffold
4GL5	;	3.48	;	Structure of human placental aromatase complexed with designed inhibitor HDDG029 (compound 4)
4GL7	;	3.9	;	Structure of human placental aromatase complexed with designed inhibitor HDDG046 (compound 5)
1P49	;	2.6	;	Structure of Human Placental Estrone/DHEA Sulfatase
1A7A	;	2.8	;	STRUCTURE OF HUMAN PLACENTAL S-ADENOSYLHOMOCYSTEINE HYDROLASE: DETERMINATION OF A 30 SELENIUM ATOM SUBSTRUCTURE FROM DATA AT A SINGLE WAVELENGTH
8EG3	;	2.04	;	Structure of human placental steroid (estrone/DHEA) sulfatase at 2.0 angstrom resolution
6X0T	;	1.388	;	Structure of human plasma factor XIIa in complex with (2S)-1-(N,3-dicyclohexyl-D-alanyl)-4-[(4R,5S)-4-methyl-5-phenyl-4,5-dihydro-1,3-oxazol-2-yl]-N-[(thiophen-2-yl)methyl]piperazine-2-carboxamide (compound 8h)
6X0S	;	1.898	;	Structure of human plasma factor XIIa in complex with (2S)-4-(5-chloro-1,3-benzoxazol-2-yl)-1-(N,3-dicyclohexyl-D-alanyl)-N-[(thiophen-2-yl)methyl]piperazine-2-carboxamide (compound 7)
5TJX	;	1.408	;	Structure of human plasma kallikrein
6O1S	;	1.7	;	Structure of human plasma kallikrein protease domain with inhibitor
8BJT	;	2.188	;	Structure of human PLK1 in complex with 2-Allyl-1-[6-(1-hydroxy-1-methyl-ethyl)-pyridin-2-yl]-6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-1,2-dihydro-pyrazolo[3,4-d]pyrimidin-3-one
8CRC	;	1.65	;	Structure of human Plk1 PBD in complex with Allopole-A
3HIK	;	1.77	;	Structure of human Plk1-PBD in complex with PLHSpT
3HIH	;	1.7	;	Structure of human Plk1-PBD with glycerol and sulfate in the phophopeptide binding site
1YZ3	;	2.4	;	Structure of human pnmt complexed with cofactor product adohcy and inhibitor SK&F 64139
2AN5	;	2.5	;	Structure of human PNMT complexed with S-adenosyl-homocysteine and an inhibitor, trans-(1S,2S)-2-amino-1-tetralol
2G70	;	2.4	;	Structure of human PNMT in complex with inhibitor 3-hydroxymethyl-7-nitro-THIQ and AdoMet (SAM)
1V3Q	;	2.8	;	Structure of human PNP complexed with DDI
5UXH	;	2.41	;	Structure of Human POFUT1 in complex with GDP-fucose
5UX6	;	2.09	;	Structure of Human POFUT1 in its apo form
6Z9C	;	2.8	;	Structure of human POLDIP2, a multifaceted adaptor protein in metabolism and genome stability
5LS6	;	3.47	;	Structure of Human Polycomb Repressive Complex 2 (PRC2) with inhibitor
5HYN	;	2.95	;	Structure of Human Polycomb Repressive Complex 2 (PRC2) with oncogenic histone H3K27M peptide
6Y60	;	1.798	;	Structure of Human Polyomavirus 12 VP1 in complex with 3'-Sialyllactosamine
4PCG	;	1.8	;	Structure of Human Polyomavirus 6 (HPyV6) VP1 pentamer
4PCH	;	1.7	;	Structure of Human Polyomavirus 7 (HPyV7) VP1 pentamer
4POS	;	2.0	;	Structure of Human Polyomavirus 9 VP1 pentamer in complex with 3'-sialyllactosamine
4POR	;	2.09	;	Structure of Human Polyomavirus 9 VP1 pentamer in complex with 3'-sialyllactose
4POT	;	2.1	;	Structure of Human Polyomavirus 9 VP1 pentamer in complex with N-glycolylneuraminic acid containing 3'-sialyllactosamine
3ECR	;	2.182	;	Structure of human porphobilinogen deaminase
8SH0	;	2.16	;	Structure of human POT1 DNA binding domain bound to a 5'-phosphorylated junction of a telomeric DNA hairpin with a 3'-overhang
8SH1	;	2.6	;	Structure of human POT1 DNA binding domain bound to a 5'-phosphorylated junction of a telomeric double-stranded DNA duplex with a 3'-overhang
7S1O	;	2.55	;	Structure of human POT1C
7S1U	;	2.55	;	Structure of human POT1C
7AIP	;	3.12	;	Structure of Human Potassium Chloride Transporter KCC1 in NaCl (Reference Map)
7AIQ	;	3.72	;	Structure of Human Potassium Chloride Transporter KCC1 in NaCl (Subclass 1)
7AIR	;	3.66	;	Structure of Human Potassium Chloride Transporter KCC1 in NaCl (Subclass 2)
6Y5R	;	3.76	;	Structure of Human Potassium Chloride Transporter KCC3 S45D/T940D/T997D in NaCl
7AIN	;	3.2	;	Structure of Human Potassium Chloride Transporter KCC3 S45D/T940D/T997D in NaCl (Reference Map)
7AIO	;	3.31	;	Structure of Human Potassium Chloride Transporter KCC3 S45D/T940D/T997D in NaCl (Subclass)
6Y5V	;	4.08	;	Structure of Human Potassium Chloride Transporter KCC3b (S45D/T940D/T997D) in KCl
6ENQ	;	2.2	;	Structure of human PPAR gamma LBD in complex with Lanifibranor (IVA337)
7TD5	;	2.994	;	Structure of human PRC2-EZH1 containing phosphorylated SUZ12
6BNS	;	2.56	;	STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND TETHERED WITH SRC co-activator peptide and Compound 25a AKA BICYCLIC HEXAFLUOROISOPROPYL 2 ALCOHOL SULFONAMIDES
6NX1	;	2.27	;	STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND TETHERED WITH SRC CO-ACTIVATOR PEPTIDE AND COMPOUND-3 AKA 1,1,1,3,3,3-HEXAFLUORO-2-{4-[1-(4- LUOROBENZENESULFONYL)CYCLOPENTYL]PHENYL}PROPAN-2-OL
6XP9	;	2.27	;	STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND TETHERED WITH SRC co-activator peptide IN COMPLEX WITH (S,S)-1
4S0T	;	3.14	;	STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND WITH ADNECTIN-1 AND COMPOUND-1
4S0S	;	2.8	;	STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN with ADNECTIN-1
4XHD	;	2.4	;	STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN WITH COMPOUND-1
7LGW	;	2.7	;	Structure of human Prestin in nanodisc in the presence of NaCl
7LGU	;	2.3	;	Structure of human prestin in the presence of NaCl
7LH2	;	3.43	;	Structure of human prestin in the presence of sodium salicylate and sodium sulfate
7LH3	;	4.3	;	Structure of human prestin in the presence of sodium sulfate
1V3A	;		;	Structure of human PRL-3, the phosphatase associated with cancer metastasis
6RPG	;	2.7	;	Structure of human Programmed cell death 1 ligand 1 (PD-L1) with inhibitor
7BEA	;	2.45	;	Structure of human Programmed cell death 1 ligand 1 (PD-L1) with inhibitor
5J89	;	2.2	;	Structure of human Programmed cell death 1 ligand 1 (PD-L1) with low molecular mass inhibitor
5J8O	;	2.3	;	Structure of human Programmed cell death 1 ligand 1 (PD-L1) with low molecular mass inhibitor
5NIU	;	2.01	;	Structure of human Programmed cell death 1 ligand 1 (PD-L1) with low molecular mass inhibitor
6R3K	;	2.2	;	Structure of human Programmed cell death 1 ligand 1 (PD-L1) with low molecular mass inhibitor
7NLD	;	2.3	;	Structure of human Programmed cell death 1 ligand 1 (PD-L1) with low molecular mass inhibitor
3EE2	;	1.91	;	Structure of human prostaglandin D-synthase (hGSTS1-1) in complex with nocodazole
4IB5	;	2.2	;	Structure of human protein kinase CK2 catalytic subunit in complex with a CK2beta-competitive cyclic peptide
3NKS	;	1.9	;	Structure of human protoporphyrinogen IX oxidase
4IVM	;	2.769	;	Structure of human protoporphyrinogen IX oxidase(R59G)
4IVO	;	2.597	;	Structure of human protoporphyrinogen IX oxidase(R59Q)
8PYV	;	1.77	;	Structure of Human PS-1 GSH-analog complex, solved at wavelength 2.755 A
2IXM	;	1.5	;	Structure of human PTPA
2A0Y	;	2.28	;	Structure of human purine nucleoside phosphorylase H257D mutant
2A0X	;	2.28	;	Structure of human purine nucleoside phosphorylase H257F mutant
2A0W	;	2.28	;	Structure of human purine nucleoside phosphorylase H257G mutant
1RSZ	;	2.2	;	Structure of human purine nucleoside phosphorylase in complex with DADMe-Immucillin-H and sulfate
1RR6	;	2.5	;	Structure of human purine nucleoside phosphorylase in complex with Immucillin-H and phosphate
1RT9	;	2.3	;	Structure of human purine nucleoside phosphorylase in complex with Immucillin-H and sulfate
2Q7O	;	2.9	;	Structure of human purine nucleoside phosphorylase in complex with L-Immucillin-H
3BGS	;	2.099	;	Structure of human purine nucleoside phosphorylase with L-DADMe-ImmH and phosphate
1XG5	;	1.53	;	Structure of human putative dehydrogenase MGC4172 in complex with NADP
5UAT	;	1.92	;	Structure of human PYCR-1 complexed with NADPH
5UAV	;	1.85	;	Structure of human PYCR-1 complexed with NADPH and L-tetrahydrofuroic acid
5UAU	;	1.9	;	Structure of human PYCR-1 complexed with proline
6XP3	;	1.93	;	Structure of human PYCR1 complexed with cyclopentanecarboxylic acid
6XOZ	;	2.35	;	Structure of human PYCR1 complexed with L-tetrahydro-2-furoic acid
6XP1	;	1.75	;	Structure of human PYCR1 complexed with L-thiazolidine-2-carboxylate
6XP2	;	2.3	;	Structure of human PYCR1 complexed with L-thiazolidine-4-carboxylate
6XP0	;	1.95	;	Structure of human PYCR1 complexed with N-formyl L-proline
6LHM	;	3.4	;	Structure of human PYCR2
2DEZ	;		;	Structure of human PYY
7XLQ	;	3.1	;	Structure of human R-type voltage-gated CaV2.3-alpha2/delta1-beta1 channel complex in the ligand-free (apo) state
7YG5	;	3.0	;	Structure of human R-type voltage-gated CaV2.3-alpha2/delta1-beta1 channel complex in the topiramate-bound state
5LPN	;	2.8	;	Structure of human Rab10 in complex with the bMERB domain of Mical-1
5SZJ	;	2.66	;	Structure of human Rab10 in complex with the bMERB domain of Mical-cL
5SZH	;	2.3	;	Structure of human Rab1b in complex with the bMERB domain of Mical-cL
5SZI	;	2.85	;	Structure of human Rab8a in complex with the bMERB domain of Mical-cL
6IY1	;	2.11	;	Structure of human Ras-related protein Rab11
2WWY	;	2.9	;	Structure of human RECQ-like helicase in complex with a DNA substrate
4U7D	;	3.4	;	Structure of human RECQ-like helicase in complex with an oligonucleotide
4EKC	;	7.4	;	Structure of human regulator of G protein signaling 2 (RGS2) in complex with murine Galpha-q(R183C)
4EKD	;	2.71	;	Structure of human regulator of G protein signaling 2 (RGS2) in complex with murine Galpha-q(R183C)
8A4A	;	2.52	;	Structure of human Rep15 in complex with bovine Rab3C.
8A4C	;	2.75	;	Structure of human Rep15:Rab3B complex.
8A4B	;	2.8	;	Structure of human Rep15:Rab3B_Q81L complex.
5VJ2	;	2.22	;	Structure of human respiratory syncytial virus non-structural protein 1 (NS1)
7LDK	;	2.82	;	Structure of human respiratory syncytial virus nonstructural protein 2 (NS2)
6DRF	;		;	Structure of human Retinal Degeneration 3(RD3) Protein
3GQC	;	2.5	;	Structure of human Rev1-DNA-dNTP ternary complex
3ABD	;	1.9	;	Structure of human REV7 in complex with a human REV3 fragment in a monoclinic crystal
3ABE	;	2.6	;	Structure of human REV7 in complex with a human REV3 fragment in a tetragonal crystal
5C3Y	;	2.6	;	Structure of human ribokinase crystallized with AMPPNP
6Y0G	;	3.2	;	Structure of human ribosome in classical-PRE state
6Y57	;	3.5	;	Structure of human ribosome in hybrid-PRE state
6Y2L	;	3.0	;	Structure of human ribosome in POST state
6OLI	;	3.5	;	Structure of human ribosome nascent chain complex selectively stalled by a drug-like small molecule (USO1-RNC)
6NW2	;	2.0	;	Structure of human RIPK1 kinase domain in complex with compound 11
6NYH	;	2.1	;	Structure of human RIPK1 kinase domain in complex with GNE684
7MON	;	2.23	;	Structure of human RIPK3-MLKL complex
7DN3	;	3.5	;	Structure of Human RNA Polymerase III elongation complex
4X09	;	1.722	;	Structure of human RNase 6 in complex with sulphate anions
3ZBF	;	2.2	;	Structure of Human ROS1 Kinase Domain in Complex with Crizotinib
4UXL	;	2.4	;	Structure of Human ROS1 Kinase Domain in Complex with PF-06463922
2XV4	;	2.95	;	Structure of Human RPC62 (partial)
8BTT	;	2.6	;	Structure of human RTCB
8ODP	;	2.3	;	Structure of human RTCB with GMPCPP in complex with Archease
6WCW	;	2.8	;	Structure of human Rubicon RH domain in complex with GTP-bound Rab7
8UQ3	;	3.18	;	Structure of human RyR2-S2808D in the closed state in the presence of ARM210
8UQ5	;	3.96	;	Structure of human RyR2-S2808D in the primed state in the presence of Rapamycin
8UQ2	;	2.98	;	Structure of human RyR2-S2808D in the subprimed state
8UQ4	;	3.64	;	Structure of human RyR2-S2808D in the subprimed state in the presence of H2O2/NOC-12/GSH
4AQI	;	1.7	;	Structure of human S100A15 bound to zinc and calcium
4AQJ	;	1.6	;	Structure of human S100A7 D24G bound to zinc and calcium
2WOS	;	1.7	;	Structure of human S100A7 in complex with 2,6 ANS
7UJN	;	2.89	;	Structure of Human SAMHD1 with Non-Hydrolysable dGTP Analog
4UEX	;	1.8	;	Structure of human Saposin A at lysosomal pH
7SN1	;	1.467	;	Structure of human SARS-CoV-2 neutralizing antibody C1C-A3 Fab
7SN2	;	4.3	;	Structure of human SARS-CoV-2 neutralizing antibody C1C-A3 Fab
7SN3	;	3.1	;	Structure of human SARS-CoV-2 spike glycoprotein trimer bound by neutralizing antibody C1C-A3 Fab (variable region)
4YH1	;	2.2	;	Structure of Human Scp1 bound to cis-proline peptidomimetic CTD phospho-Ser5 peptide
3GZC	;	2.1	;	Structure of human selenocysteine lyase
8PHV	;	1.97	;	Structure of Human selenomethionylated Cdc123 bound to domain 3 of eIF2 gamma
1TH0	;	2.2	;	Structure of human Senp2
1TGZ	;	2.8	;	Structure of human Senp2 in complex with SUMO-1
7R2E	;	1.74	;	Structure of human Senp7 with SUMO2
2X7G	;	2.5	;	Structure of human serine-arginine-rich protein-specific kinase 2 (SRPK2) bound to purvalanol B
7TXT	;	3.0	;	Structure of human serotonin transporter bound to small molecule '8090 in lipid nanodisc and NaCl
6M4R	;	2.49	;	Structure of Human Serum Albumin
6HSC	;	1.9	;	Structure of Human Serum Albumin in complex with Aristolochic Acid at 1.9 A resolution
7OV6	;	1.9	;	Structure of Human Serum Albumin in complex with Aristolochic Acid I at 1.9 A resolution - Optimized
7OV5	;	1.9	;	Structure of Human Serum Albumin in complex with Aristolochic Acid II at 1.9 A resolution
3TDL	;	2.6	;	Structure of human serum albumin in complex with DAUDA
7OV1	;	1.9	;	Structure of Human Serum Albumin in complex with Myristic Acid
2VDB	;	2.52	;	Structure of human serum albumin with S-naproxen and the GA module
7EEK	;	2.5	;	Structure of Human serum albumin-Au compound complex
4IP8	;	2.193	;	Structure of human serum amyloid A1
5WTD	;	2.501	;	Structure of human serum transferrin bound ruthenium at N-lobe
7LMS	;	3.5	;	Structure of human SetD3 methyl-transferase in complex with 2A protease from Coxsackievirus B3
6BOZ	;	2.4	;	Structure of human SETD8 in complex with covalent inhibitor MS4138
2O3D	;		;	Structure of human SF2/ASF RNA recognition motif 2 (RRM2)
5WPA	;	2.29	;	Structure of human SFPQ/PSPC1 heterodimer
7WMV	;	3.2	;	Structure of human SGLT1-MAP17 complex bound with LX2761
7YNI	;	3.26	;	Structure of human SGLT1-MAP17 complex bound with substrate 4D4FDG in the occluded conformation
7VSI	;	2.95	;	Structure of human SGLT2-MAP17 complex bound with empagliflozin
7YNJ	;	3.33	;	Structure of human SGLT2-MAP17 complex bound with substrate AMG in the occluded conformation
7YNK	;	3.48	;	Structure of human SGLT2-MAP17 complex in the apo state in the inward-facing conformation
8HDH	;	3.1	;	Structure of human SGLT2-MAP17 complex with Canagliflozin
8HEZ	;	2.8	;	Structure of human SGLT2-MAP17 complex with Dapagliflozin
8HIN	;	3.3	;	Structure of human SGLT2-MAP17 complex with Phlorizin
8HG7	;	3.1	;	Structure of human SGLT2-MAP17 complex with Sotagliflozin
8HB0	;	2.9	;	Structure of human SGLT2-MAP17 complex with TA1887
7L9P	;	3.6	;	Structure of human SHLD2-SHLD3-REV7-TRIP13(E253Q) complex
6FL5	;	3.6	;	Structure of human SHMT1-H135N-R137A-E168N mutant at 3.6 Ang. resolution
5X3V	;	2.85	;	Structure of human SHMT2 protein mutant
2JIF	;	2.0	;	Structure of human short-branched chain acyl-CoA dehydrogenase (ACADSB)
7R75	;	2.83	;	Structure of human SHP2 in complex with compound 16
7R7D	;	2.6	;	Structure of human SHP2 in complex with compound 22
7R7I	;	2.85	;	Structure of human SHP2 in complex with compound 27
7R7L	;	3.0	;	Structure of human SHP2 in complex with compound 30
6WU8	;	2.4	;	Structure of human SHP2 in complex with inhibitor IACS-13909
6CMQ	;	2.9	;	Structure of human SHP2 without N-SH2 domain
5BO8	;	2.7	;	Structure of human sialyltransferase ST8SiaIII
5BO6	;	2.07	;	Structure of human sialyltransferase ST8SiaIII in complex with CDP
5BO9	;	2.3	;	Structure of human sialyltransferase ST8SiaIII in complex with CMP-3FNeu5Ac and Sia-6S-LacNAc
5BO7	;	1.85	;	Structure of human sialyltransferase ST8SiaIII in complex with CTP
8SKU	;	3.2	;	Structure of human SIgA1 in complex with human CD89 (FcaR1)
8SKV	;	3.1	;	Structure of human SIgA1 in complex with Streptococcus pyogenes protein M4 (Arp4)
2JJU	;	1.19	;	Structure of human signal regulatory protein (sirp) beta
2JJV	;	1.8	;	Structure of human signal regulatory protein (sirp) beta(2)
2JJW	;	1.7	;	Structure of human signal regulatory protein (sirp) gamma
5MAR	;	1.89	;	Structure of human SIRT2 in complex with 1,2,4-Oxadiazole inhibitor and ADP ribose.
3ZGV	;	2.27	;	Structure of human SIRT2 in complex with ADP-ribose
4BN4	;	1.3	;	Structure of human SIRT3 in complex with ADP-ribose
4BN5	;	3.25	;	Structure of human SIRT3 in complex with SRT1720 inhibitor
5MAT	;	2.069	;	Structure of human Sirtuin 2 in complex with a selective thienopyrimidinone based inhibitor
6AR0	;	1.08	;	Structure of human SLMAP FHA domain
6AR2	;	1.55	;	Structure of human SLMAP FHA domain in complex with pMST2
2HWX	;	1.9	;	Structure of human SMG6 E1282C PIN domain mutant.
6XBJ	;	3.88	;	Structure of human SMO-D384R complex with Gi
6XBK	;	3.24	;	Structure of human SMO-G111C/I496C complex with Gi
6XBM	;	3.14	;	Structure of human SMO-Gi complex with 24(S),25-EC
6XBL	;	3.96	;	Structure of human SMO-Gi complex with SAG
5L7D	;	3.2	;	Structure of human Smoothened in complex with cholesterol
7ZI0	;	3.0	;	Structure of human Smoothened in complex with cholesterol and SAG
5L7I	;	3.3	;	Structure of human Smoothened in complex with Vismodegib
6OT0	;	3.84	;	Structure of human Smoothened-Gi complex
3OMG	;	1.85	;	Structure of human SND1 extended tudor domain in complex with the symmetrically dimethylated arginine PIWIL1 peptide R14me2s
3OMC	;	1.77	;	Structure of human SND1 extended tudor domain in complex with the symmetrically dimethylated arginine PIWIL1 peptide R4me2s
4FZS	;	2.8	;	Structure of human SNX1 BAR domain
5YTU	;	1.9	;	Structure of human SOD1 complexed with isoproteranol in C2221 space group
5K02	;	1.99	;	Structure of human SOD1 with T2D mutation
8JP0	;	3.5	;	structure of human sodium-calciumexchanger NCX1
8IL7	;	1.95	;	Structure of human soluble Adenylyl Cyclase in complex with lactate
7D9U	;	3.8	;	Structure of human soluble guanylate cyclase in the cinciguat-bound activated state
7D9T	;	4.1	;	Structure of human soluble guanylate cyclase in the cinciguat-bound inactive state
6JT1	;	3.9	;	Structure of human soluble guanylate cyclase in the heme oxidised state
8HBE	;	3.2	;	Structure of human soluble guanylate cyclase in the inactive state at 3.1 angstrom
6JT2	;	3.8	;	Structure of human soluble guanylate cyclase in the NO activated state
8HBF	;	3.1	;	Structure of human soluble guanylate cyclase in the NO+Rio state at 3.1 angstrom
8HBH	;	3.1	;	Structure of human soluble guanylate cyclase in the NO-activated state at 3.1 angstrom
6JT0	;	4.0	;	Structure of human soluble guanylate cyclase in the unliganded state
8OPQ	;	3.28	;	Structure of Human Solute Carrier 26 family member A6 (SLC26A6) anion transporter in an inward-facing state
2C6F	;	3.01	;	Structure of human somatic angiontensin-I converting enzyme N domain
2C6N	;	3.0	;	Structure of human somatic angiontensin-I converting enzyme N domain with lisinopril
6PJV	;	1.43	;	Structure of Human Sonic Hedgehog in complex with Zinc and Magnesium
6T7A	;	3.7	;	Structure of human Sox11 transcription factor in complex with a nucleosome
6T7D	;	4.4	;	Structure of human Sox11 transcription factor in complex with a nucleosome
6T78	;	2.504	;	Structure of human Sox11 transcription factor in complex with a short DNA fragment
6T7B	;	5.1	;	Structure of human Sox2 transcription factor in complex with a nucleosome
7S7J	;	1.15	;	Structure of Human SPASTIN-IST1 complex.
7OY0	;	2.09	;	Structure of human Spermine Oxidase in complex with a highly selective allosteric inhibitor
5EBE	;	3.0	;	Structure of human sphingomyelinase phosphodiesterase like 3A (SMPDL3A) with 5' CMP
5EBB	;	2.6	;	Structure of human sphingomyelinase phosphodiesterase like 3A (SMPDL3A) with Zn2+
8YJM	;	4.15	;	Structure of human SPT16 MD-CTD and MCM2 HBD chaperoning a histone H3-H4 tetramer and a single chain H2B-H2A chimera
8YJF	;	4.4	;	Structure of human SPT16 MD-CTD and MCM2 HBD chaperoning a histone H3-H4 tetramer and an H2A-H2B dimer
7YQE	;	3.5	;	Structure of human SRC regulatory domains in complex with the C-terminal PRRP motifs of GPR54.
6HPJ	;		;	Structure of human SRSF1 RRM1 bound to AACAAA RNA
6L1D	;	1.95	;	Structure of human StAR-related lipid transfer protein 4
6L1M	;	1.7	;	Structure of human StAR-related lipid transfer protein 4 mutant - LWNI107-110GG
7MHC	;	2.32	;	Structure of human STING in complex with MK-1454
5W5G	;	2.48	;	Structure of Human Sts-1 histidine phosphatase domain
5VR6	;	1.87	;	Structure of Human Sts-1 histidine phosphatase domain with sulfate bound
5WDI	;	2.43	;	Structure of Human Sts-2 histidine phosphatase domain
4FI9	;	3.05	;	Structure of human SUN-KASH complex
3UNP	;	2.39	;	Structure of human SUN2 SUN domain
6JXR	;	3.7	;	Structure of human T cell receptor-CD3 complex
5UYX	;	3.5	;	Structure of Human T-complex protein 1 subunit epsilon (CCT5)
5UYZ	;	3.6	;	Structure of Human T-complex protein 1 subunit epsilon (CCT5) mutant His147Arg
6IP3	;	1.4	;	Structure of human telomeric DNA at 1.4 Angstroms resolution
2LD8	;		;	Structure of Human Telomeric DNA in Crowded Solution
6IP7	;	1.55	;	Structure of human telomeric DNA with 5-Selenophene-modified deoxyuridine at residue 11
6ISW	;	2.3	;	Structure of human telomeric DNA with 5-selenophene-modified deoxyuridine at residue 12
5C7L	;	1.862	;	Structure of human testis-specific glyceraldehyde-3-phosphate dehydrogenase apo form
5C7O	;	1.729	;	Structure of human testis-specific glyceraldehyde-3-phosphate dehydrogenase holo form with NAD+
8J0R	;	2.1	;	Structure of human TFAP2A in complex with DNA
6ERO	;	1.75	;	Structure of human TFB2M
5FUR	;	8.5	;	Structure of human TFIID-IIA bound to core promoter DNA
3NDQ	;	1.933	;	Structure of Human TFIIS Domain II
1UVZ	;	2.01	;	structure of human thioredoxin 2
2IW6	;	2.3	;	STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2IW9	;	2.0	;	STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2IW8	;	2.3	;	STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V-H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
1OGU	;	2.6	;	STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
1OI9	;	2.1	;	Structure of human Thr160-phospho CDK2/cyclin A complexed with a 6-cyclohexylmethyloxy-2-anilino-purine inhibitor
1OIU	;	2.0	;	Structure of human Thr160-phospho CDK2/cyclin A complexed with a 6-cyclohexylmethyloxy-2-anilino-purine inhibitor
1OIY	;	2.4	;	Structure of human Thr160-phospho CDK2/cyclin A complexed with a 6-cyclohexylmethyloxy-2-anilino-purine inhibitor
1H1P	;	2.1	;	Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU2058
1H1R	;	2.0	;	Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU6086
1H1Q	;	2.5	;	Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU6094
1H1S	;	2.0	;	Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU6102
3R3G	;	1.75	;	Structure of human thrombin with residues 145-150 of murine thrombin.
4GYH	;	3.005	;	Structure of human thymidylate synthase at high salt conditions
1YPV	;	1.8	;	Structure of human thymidylate synthase at low salt conditions
4H1I	;	3.095	;	Structure of human thymidylate synthase at low salt conditions
4E28	;	2.302	;	Structure of human thymidylate synthase in inactive conformation with a novel non-peptidic inhibitor
1HW3	;	2.0	;	STRUCTURE OF HUMAN THYMIDYLATE SYNTHASE SUGGESTS ADVANTAGES OF CHEMOTHERAPY WITH NONCOMPETITIVE INHIBITORS
2RBA	;	2.79	;	Structure of Human Thymine DNA Glycosylase Bound to Abasic and Undamaged DNA
6D0L	;	1.97	;	Structure of human TIRR
6CO1	;	2.179	;	Structure of human TIRR in complex with 53BP1 Tudor domains
2BB5	;	3.2	;	Structure of Human Transcobalamin in complex with Cobalamin
7LIV	;	3.6	;	Structure of human transfer RNA visualized in the cytomegalovirus, a DNA virus
7LJ3	;	2.9	;	Structure of human transfer RNA visualized in the cytomegalovirus, a DNA virus
1SUV	;	7.5	;	Structure of Human Transferrin Receptor-Transferrin Complex
5NV6	;	2.93	;	Structure of human transforming growth factor beta-induced protein (TGFBIp).
6E75	;	1.5	;	Structure of Human Transthyretin Asp38Ala Mutant
6E78	;	1.499	;	Structure of Human Transthyretin Asp38Ala Mutant in Complex with Diflunisal
6E77	;	1.6	;	Structure of Human Transthyretin Asp38Ala Mutant in Complex with Tafamidis
6E76	;	1.6	;	Structure of Human Transthyretin Asp38Ala/Thr119Met Mutant
6D0W	;	1.7	;	Structure of human transthyretin complex with analgesic inhibitor
1E3F	;	1.9	;	Structure of human transthyretin complexed with bromophenols: a new mode of binding
1E4H	;	1.8	;	Structure of human transthyretin complexed with bromophenols: a new mode of binding
1E5A	;	1.8	;	Structure of human transthyretin complexed with bromophenols: a new mode of binding
4D7B	;	1.15	;	Structure of human transthyretin in complex with Tolcapone
6E74	;	1.6	;	Structure of Human Transthyretin Leu55Pro Mutant in Complex with Tafamidis
5FO2	;	1.449	;	Structure of human transthyretin mutant A108I
5FW6	;	1.3	;	Structure of human transthyretin mutant A108V
5FW7	;	1.2	;	Structure of human transthyretin mutant A109V
5FW8	;	1.6	;	Structure of human transthyretin mutant E89K
6E73	;	1.797	;	Structure of Human Transthyretin Val30Met Mutant in Complex with Diflunisal
6E72	;	1.45	;	Structure of Human Transthyretin Val30Met Mutant in Complex with Tafamidis
6E71	;	1.5	;	Structure of Human Transthyretin Val30Met/Thr119Met Mutant
7TQN	;	1.8	;	Structure of human TREX1
7TQO	;	1.25	;	Structure of human TREX1
7TQP	;	1.95	;	Structure of human TREX1
7TQQ	;	2.2	;	Structure of human TREX1-DNA complex
4ZVJ	;	1.6996	;	Structure of human triose phosphate isomerase K13M
6NLH	;	2.199	;	Structure of human triose phosphate isomerase R189A
5VQ9	;	3.02	;	Structure of human TRIP13, Apo form
5VQA	;	2.54	;	Structure of human TRIP13, ATP-bound form
5MO9	;	2.594	;	Structure of human TrkB receptor ligand binding domain in complex with the Fab frgment of antibody AB20
7CV1	;	4.0	;	Structure of human tRNAHis guanylyltransferase (Thg1) in the presence of human mitochondrial tRNAHis
6X2J	;	3.0	;	Structure of human TRPA1 in complex with agonist GNE551
7JUP	;	3.05	;	Structure of human TRPA1 in complex with antagonist compound 21
6WJ5	;	3.6	;	Structure of human TRPA1 in complex with inhibitor GDC-0334
7D4P	;	2.7	;	Structure of human TRPC5 in complex with clemizole
7D4Q	;	2.74	;	Structure of human TRPC5 in complex with HC-070
7MGL	;	2.9	;	Structure of human TRPML1 with ML-SI3
7XJ3	;	3.54	;	Structure of human TRPV3
7XJ0	;	2.53	;	Structure of human TRPV3 in complex with Trpvicin
6MHW	;	4.0	;	Structure of human TRPV3 in the presence of 2-APB in C2 symmetry (1)
6MHX	;	4.0	;	Structure of human TRPV3 in the presence of 2-APB in C2 symmetry (2)
6MHV	;	3.5	;	Structure of human TRPV3 in the presence of 2-APB in C4 symmetry
7XJ1	;	2.93	;	Structure of human TRPV3_G573S in complex with Trpvicin in C2 symmetry
7XJ2	;	3.64	;	Structure of human TRPV3_G573S in complex with Trpvicin in C4 symmetry
1H4W	;	1.7	;	Structure of human trypsin IV (brain trypsin)
2AKE	;	3.1	;	Structure of human tryptophanyl-tRNA synthetase in complex with tRNA(Trp)
2DR2	;	3.0	;	Structure of human tryptophanyl-tRNA synthetase in complex with tRNA(Trp)
5J11	;	2.56	;	Structure of human TSLP in complex with TSLPR and IL-7Ralpha
5J12	;	3.55	;	Structure of human TSLP:TSLPR in complex with mouse IL-7Ralpha
3C5N	;	1.8	;	Structure of human TULP1 in complex with IP3
5M2I	;	2.15	;	Structure of human Tumor Necrosis Factor (TNF) in complex with the Llama VHH1
5W0B	;	2.614	;	Structure of human TUT7 catalytic module (CM)
5W0O	;	2.488	;	Structure of human TUT7 catalytic module (CM) in complex with dsRNA
5W0M	;	2.298	;	Structure of human TUT7 catalytic module (CM) in complex with U5 RNA
5W0N	;	2.497	;	Structure of human TUT7 catalytic module (CM) in complex with UMPNPP and U2 RNA
3NER	;	1.45	;	Structure of Human Type B Cytochrome b5
7ROU	;	1.7	;	Structure of human tyrosyl tRNA synthetase in complex with ML901-Tyr
1XTJ	;	2.7	;	structure of human UAP56 in complex with ADP
1ZUO	;	1.8	;	Structure of Human Ubiquitin-Conjugating Enzyme (UBCi) Involved in Embryo Attachment and Implantation
2AWF	;	2.1	;	Structure of human Ubiquitin-conjugating enzyme E2 G1
2CYX	;	2.56	;	Structure of human ubiquitin-conjugating enzyme E2 G2 (UBE2G2/UBC7)
8PW1	;	2.2	;	Structure of human UCHL1 in complex with CG341 inhibitor
8HBW	;	2.57	;	Structure of human UCP1 in the ATP-bound state
8J1N	;	2.51	;	Structure of human UCP1 in the DNP-bound state
8HBV	;	2.51	;	Structure of human UCP1 in the nucleotide-free state
1EK6	;	1.5	;	STRUCTURE OF HUMAN UDP-GALACTOSE 4-EPIMERASE COMPLEXED WITH NADH AND UDP-GLUCOSE
1EK5	;	1.8	;	STRUCTURE OF HUMAN UDP-GALACTOSE 4-EPIMERASE IN COMPLEX WITH NAD+
2Q3E	;	2.0	;	Structure of human UDP-glucose dehydrogenase complexed with NADH and UDP-glucose
8SOI	;	4.2	;	Structure of human ULK1 complex core (2:1:1 stoichiometry)
8SQZ	;	5.85	;	Structure of human ULK1 complex core (2:2:2 stoichiometry) in the PI3KC3-C1 mixture
8SRM	;	4.46	;	Structure of human ULK1 complex core (2:2:2 stoichiometry) of the ATG13(450-517) mutant
8SRQ	;	6.2	;	Structure of human ULK1C:PI3KC3-C1 supercomplex
6U5L	;	1.75	;	Structure of human ULK4 in complex with an inhibitor
6VBA	;	1.8	;	Structure of human Uracil DNA Glycosylase (UDG) bound to Aurintricarboxylic acid (ATA)
5NUA	;	1.6	;	Structure of human urine RBP4 saturated with laurate
5NU8	;	1.59	;	Structure of human urine RBP4 saturated with palmitate
2FD6	;	1.9	;	Structure of Human Urokinase Plasminogen Activator in Complex with Urokinase Receptor and an anti-upar antibody at 1.9 A
6D31	;	1.2	;	Structure of human Usb1 with adenosine 5'-monophosphate
5V1M	;	1.47	;	Structure of human Usb1 with uridine 5'-monophosphate
6D2Z	;	1.18	;	Structure of human Usb1 with uridine-adenosine, inactive H208Q mutant
6D30	;	1.17	;	Structure of human Usb1 with uridine-uridine, inactive H208Q mutant
6HEL	;	2.941	;	Structure of human USP25
6HEJ	;	2.79	;	Structure of human USP28
6HEK	;	3.03	;	Structure of human USP28 bound to Ubiquitin-PA
7P99	;	1.8	;	Structure of human USPL1 in complex with SUMO2
7ZJV	;	2.4	;	Structure of human USPL1 in covalent complex with DeltaN-SUMO2/3-PA probe
7ZJU	;	2.17	;	Structure of human USPL1 in covalent complex with SUMO3-2Br probe
6VXU	;	2.0	;	Structure of Human Vaccinia-related Kinase 1 (VRK1) bound to ACH471
6VZH	;	2.55	;	Structure of Human Vaccinia-related Kinase 1 (VRK1) Bound to LDSM311
1VPF	;	2.5	;	STRUCTURE OF HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR
6J8H	;	3.2	;	Structure of human voltage-gated sodium channel Nav1.7 in complex with auxiliary beta subunits, huwentoxin-IV and saxitoxin (Y1755 down)
6J8G	;	3.2	;	Structure of human voltage-gated sodium channel Nav1.7 in complex with auxiliary beta subunits, huwentoxin-IV and saxitoxin (Y1755 up)
6J8J	;	3.2	;	Structure of human voltage-gated sodium channel Nav1.7 in complex with auxiliary beta subunits, ProTx-II and tetrodotoxin (Y1755 down)
6J8I	;	3.2	;	Structure of human voltage-gated sodium channel Nav1.7 in complex with auxiliary beta subunits, ProTx-II and tetrodotoxin (Y1755 up)
6DJB	;	4.4	;	Structure of human Volume Regulated Anion Channel composed of SWELL1 (LRRC8A)
8BB5	;	2.2	;	Structure of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC with Aryl linker
8BB4	;	2.8	;	Structure of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC with C3 linker
8BB3	;	1.8	;	Structure of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC with PEG linker (conformation #1)
8BB2	;	2.05	;	Structure of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC with PEG linker (conformation #2)
1X8B	;	1.81	;	Structure of human Wee1A kinase: kinase domain complexed with inhibitor PD0407824
7D4Y	;	2.962	;	Structure of human wild-type peptidylarginine deiminase type III (PAD3)
8TZS	;	3.84	;	Structure of human WLS
8TZR	;	3.5	;	Structure of human Wnt3a bound to WLS and CALR
8TZO	;	3.1	;	Structure of human Wnt7a bound to WLS and CALR
8TZP	;	3.23	;	Structure of human Wnt7a bound to WLS and RECK
3II6	;	2.4	;	Structure of human Xrcc4 in complex with the tandem BRCT domains of DNA LigaseIV.
2XIK	;	1.97	;	Structure of Human YSK1 (Yeast Sps1-Ste20-related Kinase 1)
2VNA	;	2.17	;	Structure of Human Zinc-binding Alcohol Dehydrogenase 1 (ZADH1)
5J4K	;	1.346	;	Structure of humanised RadA-mutant humRadA22F in complex with 1-Indane-6-carboxylic acid
5J4H	;	1.374	;	Structure of humanised RadA-mutant humRadA22F in complex with indole-6-carboxylic acid
5JFG	;	1.77	;	Structure of humanised RadA-mutant humRadA22F in complex with peptide FHTA
6CNW	;	0.92	;	STRUCTURE OF HUMANIZED SINGLE DOMAIN ANTIBODY SD84
3P0E	;	2.0	;	Structure of hUPP2 in an active conformation with bound 5-benzylacyclouridine
3P0F	;	1.54	;	Structure of hUPP2 in an inactive conformation with bound 5-benzylacyclouridine
6GD1	;	2.01	;	Structure of HuR RRM3
6GD2	;	1.9	;	Structure of HuR RRM3 in complex with RNA
6GD3	;	1.35	;	Structure of HuR RRM3 in complex with RNA (UAUUUA)
6G2K	;	2.01	;	Structure of HuR RRM3 in complex with RNA (UUUUUU)
5V00	;	1.8	;	Structure of HutD from Pseudomonas fluorescens SBW25 (Formate condition)
5FCC	;	1.94	;	Structure of HutD from Pseudomonas fluorescens SBW25 (NaCl condition)
4OJA	;	2.277	;	Structure of Hydra Cu-Zn superoxide dismutase
1ZGT	;	1.45	;	Structure of hydrogenated rat gamma E crystallin in H2O
2AMG	;	2.0	;	STRUCTURE OF HYDROLASE (GLYCOSIDASE)
5PTP	;	1.34	;	STRUCTURE OF HYDROLASE (SERINE PROTEINASE)
3RZZ	;	2.2	;	Structure of Hydroxyethylphoshphonate Dioxygenase Y98F Mutant
3HPD	;	1.85	;	Structure of hydroxyethylthiazole kinase protein from pyrococcus horikoshii OT3
5CM5	;	2.09	;	Structure of Hydroxyethylthiazole Kinase ThiM from Staphylococcus aureus
5COJ	;	1.9	;	Structure of Hydroxyethylthiazole kinase ThiM from Staphylococcus aureus in complex with native substrate 2-(4-methyl-1,3-thiazol-5-yl)ethanol.
5CGA	;	1.87	;	Structure of Hydroxyethylthiazole kinase ThiM from Staphylococcus aureus in complex with substrate analog 2-(1,3,5-trimethyl-1H-pyrazole-4-yl)ethanol
5CGE	;	1.62	;	Structure of Hydroxyethylthiazole Kinase ThiM from Staphylococcus aureus in complex with substrate analog 2-(2-methyl-1H-imidazole-1-yl)ethanol
2CVZ	;	1.8	;	Structure of hydroxyisobutyrate dehydrogenase from thermus thermophilus HB8
3BA1	;	1.47	;	Structure of hydroxyphenylpyruvate reductase from coleus blumei
3BAZ	;	2.2	;	Structure of hydroxyphenylpyruvate reductase from coleus blumei in complex with NADP+
8CVB	;	1.532	;	Structure of Hyoscyamine 6-beta Hydroxylase in complex with iron, 2-oxoglutarate, and 6-OH-hyoscyamine
8CV8	;	1.532	;	Structure of Hyoscyamine 6-beta Hydroxylase in complex with iron, 2-oxoglutarate, and hyoscyamine
8CVA	;	1.581	;	Structure of Hyoscyamine 6-beta Hydroxylase in complex with iron, succinate, and 6-OH-hyoscyamine
8CVD	;	1.717	;	Structure of Hyoscyamine 6-beta Hydroxylase in complex with iron, succinate, and scopolamine
8CVC	;	1.791	;	Structure of Hyoscyamine 6-beta Hydroxylase in complex with vanadyl, succinate, and 6-OH-hyoscyamine
8CV9	;	1.79	;	Structure of Hyoscyamine 6-beta Hydroxylase in complex with vanadyl, succinate, and hyoscyamine
5X9M	;	0.93	;	Structure of hyper-sweet thaumatin (D21N)
2D91	;	2.1	;	Structure of HYPER-VIL-lysozyme
2D8P	;	2.3	;	Structure of HYPER-VIL-thaumatin
2D8W	;	2.0	;	Structure of HYPER-VIL-trypsin
7LF5	;	2.6	;	Structure of Hyperglycosylated Human IgG1 Fc (Fc267)
7LFN	;	2.6	;	Structure of Hyperglycosylated Human IgG1 Fc (Fc267_329)
7LF9	;	2.2	;	Structure of Hyperglycosylated Human IgG1 Fc (Fc329)
6SP5	;	1.6	;	Structure of hyperstable haloalkane dehalogenase variant DhaA115
6SP8	;	1.55	;	Structure of hyperstable haloalkane dehalogenase variant DhaA115 prepared by the 'soak-and-freeze' method under 150 bar of krypton pressure
8OE2	;	1.51	;	Structure of hyperstable haloalkane dehalogenase variant DhaA223
8OE6	;	1.31	;	Structure of hyperstable haloalkane dehalogenase variant DhaA231
3WXP	;	1.42	;	Structure of hyperthermophilic family 12 endocellulase (E197A) from Pyrococcus furiosus in complex with cellobiose
3WY6	;	1.45	;	Structure of hyperthermophilic family 12 endocellulase (E197A) from Pyrococcus furiosus in complex with laminaribiose
3WQ1	;	1.3	;	Structure of hyperthermophilic family 12 endocellulase from Pyrococcus furiosus in complex with cello-oligosaccharide
3WQ0	;	1.22	;	Structure of hyperthermophilic family 12 endocellulase from Pyrococcus furiosus in complex with gluco-oligosaccharide
3WR0	;	1.16	;	Structure of hyperthermophilic family 12 endocellulase mutant from Pyrococcus furiosus
3IWT	;	1.9	;	Structure of hypothetical molybdenum cofactor biosynthesis protein B from Sulfolobus tokodaii
4NPX	;	1.93	;	Structure of hypothetical protein Cj0539 from Campylobacter jejuni
2AR1	;	1.602	;	Structure of Hypothetical protein from Leishmania major
2EWC	;	2.15	;	Structure of hypothetical protein from Streptococcus pyogenes M1 GAS, member of highly conserved yjgF family of proteins
4PAW	;	2.23	;	Structure of hypothetical protein HP1257.
4PAV	;	2.3	;	Structure of hypothetical protein SA1046 from S. aureus.
7WRK	;	1.78	;	Structure of hypothetical protein TTHA1873 from Thermus thermophilus
7WWN	;	2.05	;	Structure of hypothetical protein TTHA1873 from Thermus thermophilus with Potassium mercuric iodide
8GZ0	;	2.22	;	Structure of hypothetical protein TTHA1873 with phosphate from Thermus thermophilus
5KEF	;	2.23	;	Structure of hypothetical Staphylococcus protein SA0856 with zinc
7QHP	;	1.82	;	Structure of I-Ag7 with a bound hybrid insulin peptide
3P9S	;	1.9	;	Structure of I274A variant of E. coli KatE
3P9Q	;	1.48	;	Structure of I274C variant of E. coli KatE
3PQ2	;	1.79	;	Structure of I274C variant of E. coli KatE[] - Images 1-6
3PQ4	;	1.79	;	Structure of I274C variant of E. coli KatE[] - Images 13-18
3PQ5	;	1.8	;	Structure of I274C variant of E. coli KatE[] - Images 19-24
3PQ6	;	1.8	;	Structure of I274C variant of E. coli KatE[] - Images 25-30
3PQ7	;	1.8	;	Structure of I274C variant of E. coli KatE[] - Images 31-36
3PQ8	;	1.8	;	Structure of I274C variant of E. coli KatE[] - Images 37-42
3PQ3	;	1.79	;	Structure of I274C variant of E. coli KatE[] - Images 7-12
3P9R	;	1.9	;	Structure of I274G variant of E. coli KatE
3P9P	;	1.5	;	Structure of I274V variant of E. coli KatE
7SOI	;	2.0	;	Structure of I552A Soybean Lipoxygenase at 277K
6FJL	;	1.7	;	Structure of IbpS from Dickeya dadantii
6YO6	;	6.0	;	Structure of iC3b1
4WCJ	;	1.7	;	Structure of IcaB from Ammonifex degensii
4HCX	;	2.18	;	Structure of ICDH-1 from M.tuberculosis complexed with NADPH & Mn2+
2W9E	;	2.9	;	Structure of ICSM 18 (anti-Prp therapeutic antibody) Fab fragment complexed with human Prp fragment 119-231
5SVO	;	1.87	;	Structure of IDH2 mutant R140Q
5SVN	;	2.1	;	Structure of IDH2 mutant R172K
3DR3	;	2.0	;	Structure of IDP00107, a potential N-acetyl-gamma-glutamylphosphate reductase from Shigella flexneri
3ERP	;	1.55	;	Structure of IDP01002, a putative oxidoreductase from and essential gene of Salmonella typhimurium
3G1Z	;	1.95	;	Structure of IDP01693/yjeA, a potential t-RNA synthetase from Salmonella typhimurium
8BEG	;	1.84	;	Structure of Ig-like domains from PrgB
6SRU	;	2.532	;	Structure of Ig-like V-type domian of mouse Programmed cell death 1 ligand 1 (PD-L1)
8C1C	;	4.1	;	Structure of IgE bound to the ectodomain of FceRIa
5HYS	;	2.5	;	Structure of IgE complexed with omalizumab
8R61	;	3.1	;	Structure of IgE delta epsilon 3-4 in complex with a kappa binding nanobody
9EQ4	;	8.4	;	Structure of IgE HMM5 bound to FceRIa cryo-EM class 5
9EQ3	;	6.9	;	Structure of IgE HMM5 bound to FceRIa cryo-EM class 8
2OJ9	;	2.0	;	Structure of IGF-1R kinase domain complexed with a benzimidazole inhibitor
7X13	;	3.7	;	Structure of IgG-Fc hexamer
4S1D	;	2.5	;	Structure of IgG1 Fab fragment in complex with Biotincytidinamide
1YEH	;	2.55	;	STRUCTURE OF IGG2A FAB FRAGMENT
1YEG	;	2.0	;	STRUCTURE OF IGG2A FAB FRAGMENT (D2.3) COMPLEXED WITH REACTION PRODUCT
1YEF	;	2.0	;	STRUCTURE OF IGG2A FAB FRAGMENT (D2.3) COMPLEXED WITH SUBSTRATE ANALOGUE
6OL5	;	2.9	;	Structure of iglb12 Fab in complex with anti-idiotype ib3 Fab
6OL6	;	2.6	;	Structure of iglb12 scFv in complex with anti-idiotype ib2 Fab
6HRG	;	2.12	;	Structure of Igni18, a novel metallo hydrolase from the hyperthermophilic archaeon Ignicoccus hospitalis KIN4/I
5KYH	;	4.0	;	Structure of Iho670 Flagellar-like Filament
1VKR	;		;	STRUCTURE OF IIB DOMAIN OF THE MANNITOL-SPECIFIC PERMEASE ENZYME II
2JZH	;		;	structure of IIB domain of the mannose transporter of E. coli
3L7F	;	2.6	;	Structure of IL-13 antibody H2L6, A humanized variant OF C836
2VXS	;	2.63	;	Structure of IL-17A in complex with a potent, fully human neutralising antibody
4XFS	;	1.91	;	Structure of IL-18 SER Mutant I
4XFT	;	2.0	;	Structure of IL-18 SER Mutant III
4XFU	;	2.85	;	Structure of IL-18 SER Mutant V
3DGC	;	2.5	;	Structure of IL-22/IL-22R1
2BB0	;	2.0	;	Structure of Imidazolonepropionase from Bacillus subtilis
6GRL	;	1.6	;	Structure of imine reductase (apo form) at 1.6 A resolution from Saccharomonospora xinjiangensis
4D3D	;	1.71	;	Structure of Imine Reductase BcSIRED from Bacillus cereus BAG3X2
7A3W	;	1.59	;	Structure of Imine Reductase from Pseudomonas sp.
8PUA	;	3.7	;	Structure of immature HTLV-1 CA-NTD from in vitro assembled MA126-CANC tubes: axis angle -05 degrees
8PU9	;	3.7	;	Structure of immature HTLV-1 CA-NTD from in vitro assembled MA126-CANC tubes: axis angle -10 degrees
8PU8	;	4.0	;	Structure of immature HTLV-1 CA-NTD from in vitro assembled MA126-CANC tubes: axis angle -15 degrees
8PU7	;	4.8	;	Structure of immature HTLV-1 CA-NTD from in vitro assembled MA126-CANC tubes: axis angle -20 degrees
8PUB	;	4.0	;	Structure of immature HTLV-1 CA-NTD from in vitro assembled MA126-CANC tubes: axis angle 0 degrees
8PUC	;	4.3	;	Structure of immature HTLV-1 CA-NTD from in vitro assembled MA126-CANC tubes: axis angle 05 degrees
8PUD	;	4.5	;	Structure of immature HTLV-1 CA-NTD from in vitro assembled MA126-CANC tubes: axis angle 10 degrees
8PUE	;	6.9	;	Structure of immature HTLV-1 CA-NTD from in vitro assembled MA126-CANC tubes: axis angle 15 degrees
8PUF	;	6.1	;	Structure of immature HTLV-1 CA-NTD from in vitro assembled MA126-CANC tubes: axis angle 20 degrees
8PU6	;	3.4	;	Structure of immature HTLV-1 CA-NTD from in vitro assembled MA126-CANC tubes: pooled class
5CD3	;	2.9	;	Structure of immature VRC01-class antibody DRVIA7
2OF6	;	24.0	;	Structure of immature West Nile virus
5H7Y	;	2.195	;	Structure of immunity protein TplEi of T6SS from Pseudomonas aeruginosa complexed with ""L"" peptide
1IGT	;	2.8	;	STRUCTURE OF IMMUNOGLOBULIN
1IGY	;	3.2	;	STRUCTURE OF IMMUNOGLOBULIN
6RME	;	3.4	;	Structure of IMP bound Plasmodium falciparum IMP-nucleotidase mutant D172N
5MCP	;	2.4	;	Structure of IMP dehydrogenase from Ashbya gossypii bound to ATP
5TC3	;	2.462	;	Structure of IMP dehydrogenase from Ashbya gossypii bound to ATP and GDP
4XTI	;	1.5	;	Structure of IMP dehydrogenase of Ashbya gossypii with IMP bound to the active site
6ZYS	;	1.87001	;	Structure of IMP-1 with 2-Mercaptomethyl-thiazolidine D-syn-1b
6ZYR	;	1.87	;	Structure of IMP-1 with 2-Mercaptomethyl-thiazolidine L-anti-1b
6YI4	;	1.7	;	Structure of IMP-13 metallo-beta-lactamase complexed with citrate anion
6S0H	;	2.85	;	Structure of IMP-13 metallo-beta-lactamase complexed with hydrolysed doripenem
6RZS	;	2.2	;	Structure of IMP-13 metallo-beta-lactamase complexed with hydrolysed ertapenem
6RZR	;	1.9	;	Structure of IMP-13 metallo-beta-lactamase complexed with hydrolysed imipenem
6R73	;	2.3	;	Structure of IMP-13 metallo-beta-lactamase complexed with hydrolysed meropenem
6R78	;	2.21	;	Structure of IMP-13 metallo-beta-lactamase in apo form (loop closed)
6R79	;	1.9	;	Structure of IMP-13 metallo-beta-lactamase in apo form (loop open)
6ROL	;	2.1	;	Structure of IMP2 KH34 domains
7JTV	;	2.45	;	Structure of IMPa from Pseudomonas aeruginosa in complex with an O-glycopeptide
7LEQ	;	2.24	;	Structure of importin a2 bound to p50 NLS
7LEU	;	2.82	;	Structure of importin a2 bound to p65-NLS
7LET	;	2.4	;	Structure of importin a2 bound to the p50- and p65-NLSs
7LFC	;	2.1	;	Structure of importin a3 bound to p50 NLS
7LF4	;	2.85	;	Structure of importin a3 bound to the p50- and p65-NLSs
3TJ3	;	2.702	;	Structure of importin a5 bound to the N-terminus of Nup50
1QGK	;	2.5	;	STRUCTURE OF IMPORTIN BETA BOUND TO THE IBB DOMAIN OF IMPORTIN ALPHA
1QGR	;	2.3	;	STRUCTURE OF IMPORTIN BETA BOUND TO THE IBB DOMAIN OF IMPORTIN ALPHA (II CRYSTAL FORM, GROWN AT LOW PH)
7UNK	;	3.45	;	Structure of Importin-4 bound to the H3-H4-ASF1 histone-histone chaperone complex
4MZ5	;	2.1	;	Structure of importin-alpha: dUTPase NLS complex
4MZ6	;	1.88	;	Structure of importin-alpha: dUTPase S11E NLS mutant complex
6Z0C	;	1.85	;	Structure of in silico modelled artificial Maquette-3 protein
6HPF	;	1.36	;	Structure of Inactive E165Q mutant of fungal non-CBM carrying GH26 endo-b-mannanase from Yunnania penicillata in complex with alpha-62-61-di-galactosyl-mannotriose
7ATD	;	1.45	;	Structure of inactive EstD11 S144A in complex with methyl-naproxen
5F09	;	1.85	;	Structure of inactive GCPII mutant in complex with beta-citryl glutamate
3IW8	;	2.0	;	Structure of Inactive Human p38 MAP Kinase in Complex with a Thiazole-Urea
5NG3	;	2.6	;	Structure of inactive kinase RIP2K(K47R)
5ETC	;	2.422	;	Structure of inactive MAPK14 with ordered Activation Loop
2JF6	;	2.82	;	Structure of inactive mutant of Strictosidine Glucosidase in complex with strictosidine
7WQX	;	2.7	;	Structure of Inactive-EP
3R0H	;	2.6	;	Structure of INAD PDZ45 in complex with NG2 peptide
7VRN	;	3.4	;	Structure of infectious bursal disease virus Gt strain
7VRP	;	3.8	;	Structure of infectious bursal disease virus Gx strain
4CB6	;	1.9	;	Structure of Influenza A H5N1 PB2 cap-binding domain with bound cap analogue (compound 11)
4CB7	;	1.85	;	Structure of Influenza A H5N1 PB2 cap-binding domain with bound cap analogue (compound 8e)
4CB5	;	1.5	;	Structure of Influenza A H5N1 PB2 cap-binding domain with bound cap analogue (compound 8f)
4CB4	;	1.6	;	Structure of Influenza A H5N1 PB2 cap-binding domain with bound m7GTP
3ZTN	;	3.001	;	STRUCTURE OF INFLUENZA A NEUTRALIZING ANTIBODY SELECTED FROM CULTURES OF SINGLE HUMAN PLASMA CELLS IN COMPLEX WITH HUMAN H1 INFLUENZA HAEMAGGLUTININ.
3ZTJ	;	3.41	;	Structure of influenza A neutralizing antibody selected from cultures of single human plasma cells in complex with human H3 Influenza haemagglutinin.
7XME	;	2.521	;	Structure of Influenza A virus polymerase basic protein 2 (PB2) with an azazindole derivative
5EF9	;	1.7	;	Structure of Influenza B Lee PB2 cap-binding domain
5EFC	;	1.9	;	Structure of Influenza B Lee PB2 cap-binding domain bound to GTP
5EFA	;	1.9	;	Structure of Influenza B Lee PB2 cap-binding domain bound to m7GTP
4ORO	;	2.4	;	Structure of Influenza B PB2 cap-binding domain complex with GDP
4OR6	;	2.293	;	Structure of Influenza B PB2 cap-binding domain with Q325F mutation complex with GDP
4OR4	;	2.21	;	Structure of Influenza B PB2 cap-binding domain with Q325F mutation complex with m7GDP
4NKJ	;	2.4535	;	Structure of influenza B virus hemagglutinin at membrane fusion pH
6KV5	;	4.6	;	Structure of influenza D virus apo polymerase
6KUJ	;	3.4	;	Structure of influenza D virus polymerase bound to cRNA promoter in class 1
6KUV	;	4.1	;	Structure of influenza D virus polymerase bound to cRNA promoter in class 2
6KUK	;	3.9	;	Structure of influenza D virus polymerase bound to vRNA promoter in mode A conformation (class A1)
6KUP	;	4.3	;	Structure of influenza D virus polymerase bound to vRNA promoter in Mode A conformation(Class A2)
6KUR	;	3.7	;	Structure of influenza D virus polymerase bound to vRNA promoter in Mode B conformation (Class B1)
6KUT	;	4.1	;	Structure of influenza D virus polymerase bound to vRNA promoter in Mode B conformation (Class B2)
6KUU	;	4.0	;	Structure of influenza D virus polymerase bound to vRNA promoter in Mode B conformation (Class B3)
2WR2	;	2.4	;	structure of influenza H2 avian hemagglutinin with avian receptor
2WR5	;	2.65	;	structure of influenza H2 duck Ontario hemagglutinin
2WR3	;	2.5	;	structure of influenza H2 duck Ontario hemagglutinin with avian receptor
2WR4	;	2.5	;	structure of influenza H2 duck Ontario hemagglutinin with human receptor
2WR1	;	2.1	;	structure of influenza H2 hemagglutinin with human receptor
1HTM	;	2.5	;	STRUCTURE OF INFLUENZA HAEMAGGLUTININ AT THE PH OF MEMBRANE FUSION
3EYJ	;	2.6	;	Structure of Influenza Haemagglutinin in complex with an inhibitor of membrane fusion
3EYK	;	2.5	;	Structure of Influenza Haemagglutinin in complex with an inhibitor of membrane fusion
3EYM	;	2.8	;	Structure of Influenza Haemagglutinin in complex with an inhibitor of membrane fusion
6HJN	;	3.3	;	Structure of Influenza Hemagglutinin ectodomain (A/duck/Alberta/35/76)
6HJP	;	3.3	;	Structure of Influenza Hemagglutinin ectodomain (A/duck/Alberta/35/76) in complex with FISW84 Fab Fragment
6D96	;	2.15	;	Structure of influenza neuraminidase from strain A/BrevigMission/1/1918(H1N1) expressed in HEK-293E cells
4O8G	;	1.652	;	Structure of Infrared Fluorescent Protein 1.4
5AJG	;	1.11	;	Structure of Infrared Fluorescent Protein IFP1.4 AT 1.11 Angstrom resolution
4CQH	;	1.14	;	Structure of Infrared Fluorescent Protein IFP2.0
4TRN	;	1.95	;	STRUCTURE OF INHA FROM MYCOBACTERIUM TUBERCULOSIS COMPLEXED TO NADH
8OTL	;	2.108	;	structure of InhA from Mycobacterium tuberculosis in complex with 5-(((4-(2-hydroxyphenoxy)benzyl)(octyl)amino)methyl)-2-phenoxyphenol
8OTN	;	1.962	;	structure of InhA from mycobacterium tuberculosis in complex with inhibitor 7-((1-(3-Hydroxy-4-phenoxybenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methyl-2H-chromen-2-one
8OTM	;	1.6	;	structure of InhA from mycobacterium tuberculosis in complex with N-((1-(3-hydroxy-4-phenoxybenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2-oxo-2H-chromene-3-carboxamide
3EAH	;	2.44	;	Structure of inhibited human eNOS oxygenase domain
3EAI	;	2.2	;	Structure of inhibited murine iNOS oxygenase domain
3EBD	;	2.4	;	Structure of inhibited murine iNOS oxygenase domain
3EBF	;	2.29	;	Structure of inhibited murine iNOS oxygenase domain
1TRY	;	1.55	;	STRUCTURE OF INHIBITED TRYPSIN FROM FUSARIUM OXYSPORUM AT 1.55 ANGSTROMS
7WR7	;	3.1	;	Structure of Inhibited-EP
8G92	;	3.6	;	Structure of inhibitor 16d-bound SPNS2
2NMX	;	1.55	;	Structure of inhibitor binding to Carbonic Anhydrase I
2NN1	;	1.65	;	Structure of inhibitor binding to Carbonic Anhydrase I
2NN7	;	1.85	;	Structure of inhibitor binding to Carbonic Anhydrase I
2NNG	;	1.2	;	Structure of inhibitor binding to Carbonic Anhydrase II
2NNO	;	1.01	;	Structure of inhibitor binding to Carbonic Anhydrase II
2NNS	;	1.03	;	Structure of inhibitor binding to Carbonic Anhydrase II
2NNV	;	1.1	;	Structure of inhibitor binding to Carbonic Anhydrase II
3IGP	;	1.65	;	Structure of inhibitor binding to Carbonic Anhydrase II
6ETI	;	3.1	;	Structure of inhibitor-bound ABCG2
6FEQ	;	3.6	;	Structure of inhibitor-bound ABCG2
2VQW	;	3.0	;	Structure of inhibitor-free HDAC4 catalytic domain (with gain-of- function mutation His332Tyr)
4PT7	;	2.35	;	Structure of initiator
4CAH	;	1.901	;	Structure of inner DysF domain of human dysferlin
4CAI	;	2.2	;	Structure of inner DysF domain of human dysferlin
6QLE	;	3.55	;	Structure of inner kinetochore CCAN complex
6QLF	;	3.45	;	Structure of inner kinetochore CCAN complex with mask1
6QLD	;	4.15	;	Structure of inner kinetochore CCAN-Cenp-A complex
4CHM	;	2.1	;	Structure of Inner Membrane Complex (IMC) Sub-compartment Protein 1 (ISP1) from Toxoplasma gondii
4CHJ	;	2.32	;	Structure of Inner Membrane Complex (IMC) Sub-compartment Protein 3 (ISP3) from Toxoplasma gondii
1E9G	;	1.15	;	STRUCTURE OF INORGANIC PYROPHOSPHATASE
1I40	;	1.1	;	STRUCTURE OF INORGANIC PYROPHOSPHATASE
1I6T	;	1.2	;	STRUCTURE OF INORGANIC PYROPHOSPHATASE
1JFD	;	2.2	;	STRUCTURE OF INORGANIC PYROPHOSPHATASE
1M38	;	1.8	;	Structure of Inorganic Pyrophosphatase
1OBW	;	1.9	;	STRUCTURE OF INORGANIC PYROPHOSPHATASE
1WGI	;	2.2	;	STRUCTURE OF INORGANIC PYROPHOSPHATASE
1WGJ	;	2.0	;	STRUCTURE OF INORGANIC PYROPHOSPHATASE
5H4F	;	2.05	;	Structure of inorganic pyrophosphatase crystallised as a contaminant
4UM4	;	2.65	;	STRUCTURE OF INORGANIC PYROPHOSPHATASE FROM ESCHERICHIA COLI IN COMPLEX WITH SULFATE
1MJW	;	1.95	;	STRUCTURE OF INORGANIC PYROPHOSPHATASE MUTANT D42N
1MJX	;	2.15	;	STRUCTURE OF INORGANIC PYROPHOSPHATASE MUTANT D65N
1MJY	;	2.1	;	STRUCTURE OF INORGANIC PYROPHOSPHATASE MUTANT D70N
1MJZ	;	2.2	;	STRUCTURE OF INORGANIC PYROPHOSPHATASE MUTANT D97N
6KCF	;	2.55	;	Structure of Inosine 5'-monophosphate Dehydrogenase from Candidatus Liberibacter asiaticus str. psy62
5ZHH	;	1.89	;	Structure of Inositol monophosphatase from Anabaena (Nostoc) sp. PCC 7120
2HHM	;	2.1	;	STRUCTURE OF INOSITOL MONOPHOSPHATASE, THE PUTATIVE TARGET OF LITHIUM THERAPY
1Y52	;	1.7	;	structure of insect cell (Baculovirus) expressed AVR4 (C122S)-biotin complex
3SSB	;	1.8	;	Structure of Insect Metalloproteinase Inhibitor in Complex with Thermolysin
2MI5	;		;	Structure of insect-specific sodium channel toxin mu-Dc1a
1XDA	;	1.8	;	STRUCTURE OF INSULIN
1ZEH	;	1.5	;	STRUCTURE OF INSULIN
7AC4	;	1.46	;	Structure of insulin collected by rotation serial crystallography on a COC membrane at a synchrotron source
7PHT	;		;	Structure of Insulin receptor's transmembrane domain
7PL4	;		;	Structure of Insulin receptor-related receptor's transmembrane domain
7PH8	;		;	Structure of Insulin-like growth factor 1 receptor's transmembrane domain
3INS	;	2.2	;	STRUCTURE OF INSULIN. RESULTS OF JOINT NEUTRON AND X-RAY REFINEMENT
3INS	;	1.5	;	STRUCTURE OF INSULIN. RESULTS OF JOINT NEUTRON AND X-RAY REFINEMENT
6LNR	;	1.66	;	Structure of intact chitinase with hevein domain from the plant Simarouba glauca, known for its traditional anti-inflammatory efficacy
2GF5	;		;	Structure of intact FADD (MORT1)
8RBX	;	4.1	;	Structure of Integrator-PP2A bound to a paused RNA polymerase II-DSIF-NELF-nucleosome complex
8RC4	;	3.1	;	Structure of Integrator-PP2A complex
8RBZ	;	3.7	;	Structure of Integrator-PP2A-SOSS-CTD post-termination complex
5HGJ	;	1.399	;	Structure of integrin alpha1beta1 and alpha2beta1 I-domains explain differential calcium-mediated ligand recognition
3K72	;	3.7	;	Structure of integrin alphaX beta2
3K71	;	3.95	;	Structure of integrin alphaX beta2 ectodomain
3K6S	;	3.5	;	Structure of integrin alphaXbeta2 ectodomain
4HI8	;	1.203	;	Structure of integrin-linked kinase ankyrin repeat domain in complex with PINCH1 LIM1 domain collected at high energy, wavelength 0.32800
5L04	;	2.1	;	STRUCTURE OF INTERFERON LAMBDA 1 RECEPTOR WITH HUMAN KINASE JAK1
8QY4	;	3.06	;	Structure of interleukin 11 (gp130 P496L mutant).
1I16	;		;	STRUCTURE OF INTERLEUKIN 16: IMPLICATIONS FOR FUNCTION, NMR, 20 STRUCTURES
4HSA	;	3.15	;	Structure of interleukin 17a in complex with il17ra receptor
2ILA	;	2.3	;	STRUCTURE OF INTERLEUKIN 1ALPHA AT 2.7-ANGSTROMS RESOLUTION
3LTQ	;	2.1	;	Structure of Interleukin 1B solved by SAD using an inserted Lanthanide Binding Tag
5NJD	;	3.9	;	Structure of Interleukin 23 in complex with Briakinumab FAb
8QY6	;	3.16	;	Structure of interleukin 6 (gp130 P496L mutant).
8QY5	;	3.1	;	Structure of interleukin 6.
8EPA	;	3.4	;	Structure of interleukin receptor common gamma chain (IL2Rgamma) in complex with two antibodies
5FB8	;	2.07	;	Structure of Interleukin-16 bound to the 14.1 antibody
1Z92	;	2.8	;	structure of interleukin-2 with its alpha receptor
3DUH	;	2.3	;	Structure of Interleukin-23
4O9H	;	2.42	;	Structure of Interleukin-6 in complex with a Camelid Fab fragment
4I05	;	1.9	;	Structure of intermediate processing form of cathepsin B1 from Schistosoma mansoni
3KQ4	;	3.3	;	Structure of Intrinsic Factor-Cobalamin bound to its receptor Cubilin
3KF5	;	2.9	;	Structure of invertase from Schwanniomyces occidentalis
2C3V	;	1.39	;	Structure of iodinated CBM25 from Bacillus halodurans amylase
2C3X	;	2.7	;	Structure of iodinated CBM25 from Bacillus halodurans amylase in complex with maltotetraose
3IDE	;	3.35	;	Structure of IPNV subviral particle
8TWD	;	3.3	;	Structure of IraM-bound RssB
7EML	;	1.25	;	Structure of IrCp* immobilized apo-D38H-rHLFr
8AFK	;	2.015	;	Structure of iRFP variant C15S/N136R/V256C in complex with phycocyanobilin
5FVG	;	1.9	;	Structure of IrisFP at 100 K.
5FVI	;	2.397	;	Structure of IrisFP in mineral grease at 100 K.
6HHB	;	1.8	;	Structure of iron bound IbpS from Dickeya dadantii
7KQ8	;	2.15	;	Structure of iron bound MEMO1
6C75	;	2.4	;	Structure of Iron containing alcohol dehydrogenase from Thermococcus thioreducens in a monoclinic crystal form
6C7L	;	1.91	;	Structure of Iron containing alcohol dehydrogenase from Thermococcus thioreducens in a tetragonal crystal form
6C76	;	2.1	;	Structure of Iron containing alcohol dehydrogenase from Thermococcus thioreducens in an orthorhombic crystal form
2BPI	;	2.52	;	Structure of Iron dependent superoxide dismutase from P. falciparum.
5CRY	;	2.79	;	Structure of iron-saturated C-lobe of bovine lactoferrin at pH 6.8 indicates the softening of iron coordination
7KQ4	;	2.261	;	Structure of isethionate sulfite-lyase from Bilophila wadsworthia with glycerol bound
7KQ3	;	2.688	;	Structure of isethionate sulfite-lyase from Bilophila wadsworthia with substrate isethionate bound
5CHW	;	2.1	;	Structure of ISG15 in space group P212121
1IKA	;	2.7	;	STRUCTURE OF ISOCITRATE DEHYDROGENASE WITH ALPHA-KETOGLUTARATE AT 2.7 ANGSTROMS RESOLUTION: CONFORMATIONAL CHANGES INDUCED BY DECARBOXYLATION OF ISOCITRATE
4WCH	;	2.05	;	Structure of Isolated D Chain of Gigant Hemoglobin from Glossoscolex paulistus
1E5W	;	2.7	;	Structure of isolated FERM domain and first long helix of moesin
5LL2	;	2.6	;	Structure of Isoleucine 2-epimerase from Lactobacillus buchneri (apo form)
2V2E	;	1.68	;	Structure of isoniazid (INH) bound to cytochrome c peroxidase mutant N184R Y36A
2VCF	;	1.8	;	Structure of isoniazid (INH) bound to cytosolic soybean ascorbate peroxidase
2VCS	;	1.68	;	Structure of isoniazid (INH) bound to cytosolic soybean ascorbate peroxidase mutant H42A
2VCN	;	1.2	;	Structure of isoniazid (INH) bound to cytosolic soybean ascorbate peroxidase mutant W41A
6DCH	;	1.8	;	Structure of isonitrile biosynthesis enzyme ScoE
2Y3Z	;	1.83	;	Structure of Isopropylmalate dehydrogenase from Thermus thermophilus - apo enzyme
2Y41	;	2.2	;	Structure of Isopropylmalate dehydrogenase from Thermus thermophilus - complex with IPM and MN
2Y40	;	2.5	;	Structure of Isopropylmalate dehydrogenase from Thermus thermophilus - complex with Mn
2Y42	;	2.5	;	Structure of Isopropylmalate dehydrogenase from Thermus thermophilus - complex with NADH and Mn
4F7I	;	2.0	;	Structure of Isopropylmalate dehydrogenase from Thermus thermophilus in complex with IPM, Mn and NADH
4OV9	;	2.2	;	Structure of isopropylmalate synthase binding with alpha-isopropylmalate
3VE3	;	1.6	;	Structure of IT Intermediate from time-resolved laue crystallography
6UOX	;	4.02	;	Structure of itraconazole-bound NPC1
1GPQ	;	1.6	;	Structure of ivy complexed with its target, HEWL
8FE2	;	2.34	;	Structure of J-PKAc chimera complexed with Aplithianine A
8FE5	;	2.51	;	Structure of J-PKAc chimera complexed with Aplithianine B
8FEC	;	2.7	;	Structure of J-PKAc chimera complexed with Aplithianine derivative
8EWY	;	5.5	;	Structure of Janus Kinase (JAK) dimer complexed with cytokine receptor intracellular domain
3Q32	;	2.5	;	Structure of Janus kinase 2 with a pyrrolotriazine inhibitor
5WSN	;	4.3	;	Structure of Japanese encephalitis virus
4GSO	;	2.6	;	structure of Jararacussin-I
4R8T	;	2.133	;	Structure of JEV protease
5YWO	;	4.7	;	Structure of JEV-2F2 Fab complex
2WWJ	;	2.6	;	STRUCTURE OF JMJD2A COMPLEXED WITH INHIBITOR 10A
3LD8	;	2.7	;	Structure of JMJD6 and Fab Fragments
6MEV	;	2.6	;	Structure of JMJD6 bound to Mono-Methyl Arginine.
3LDB	;	2.7	;	Structure of JMJD6 complexd with ALPHA-KETOGLUTARATE and Fab Fragment.
4PDV	;	1.821	;	Structure of K+ selective NaK mutant in barium and potassium
4PDL	;	1.7	;	Structure of K+ selective NaK mutant in caesium
5L44	;	1.75	;	Structure of K-26-DCP in complex with the K-26 tripeptide
8SWP	;	2.1	;	Structure of K. lactis PNP bound to hypoxanthine
8SWQ	;	1.979	;	Structure of K. lactis PNP bound to transition state analog DADMe-IMMUCILLIN H and sulfate
8SWR	;	2.3	;	Structure of K. lactis PNP S42E variant bound to transition state analog DADMe-IMMUCILLIN G and sulfate
8SWS	;	1.99	;	Structure of K. lactis PNP S42E-H98R variant bound to transition state analog DADMe-IMMUCILLIN G and sulfate
5KEC	;	1.949	;	Structure of K. pneumonia MrkH in its apo state.
5KGO	;	2.9	;	Structure of K. pneumonia MrkH-c-di-GMP complex
3NOB	;	2.19	;	Structure of K11-linked di-ubiquitin
5L43	;	1.8	;	Structure of K26-DCP
4OF9	;	1.241	;	Structure of K42N variant of sperm whale myoglobin
4OOD	;	1.24	;	Structure of K42Y mutant of sperm whale myoglobin
8F1F	;	1.85	;	Structure of K48-linked tri-ubiquitin in complex with cyclic peptide
6Z1B	;	2.25	;	Structure of K52-acetylated RutR in complex with uracil.
2OPB	;	2.8	;	Structure of K57A hPNMT with inhibitor 3-fluoromethyl-7-thiomorpholinosulfonamide-THIQ and AdoHcy
2OBF	;	2.3	;	Structure of K57A hPNMT with inhibitor 3-Hydroxymethyl-7-(N-4-chlorophenylaminosulfonyl)-THIQ and AdoHcy (SAH)
2ONZ	;	2.8	;	Structure of K57A hPNMT with inhibitor 7-(N-4-chlorophenylaminosulfonyl)-THIQ and AdoHcy
5C5E	;	2.82	;	Structure of KaiA dimer in complex with C-terminal KaiC peptide at 2.8 A resolution
8FWQ	;	3.96	;	Structure of kainate receptor GluK2 in complex with the positive allosteric modulator BPAM344
5YBE	;	2.111	;	Structure of KANK1/KIF21A complex
6PYC	;	3.6	;	Structure of kappa-on-heavy (KoH) antibody Fab bound to the cardiac hormone marinobufagenin
2XS3	;	2.4	;	Structure of karilysin catalytic MMP domain
2XS4	;	1.7	;	Structure of karilysin catalytic MMP domain in complex with magnesium
4IN9	;	1.55	;	Structure of karilysin MMP-like catalytic domain in complex with inhibitory tetrapeptide SWFP
4R3V	;	2.01	;	Structure of karilysin propeptide and catalytic MMP domain
6PT7	;	2.15	;	Structure of KatE1 catalase from Acinetobacter sp. Ver3
4LCU	;	2.752	;	Structure of KcsA with E118A mutation
5E1A	;	3.4	;	Structure of KcsA with L24C/R117C mutations
4LBE	;	2.751	;	Structure of KcsA with R122A mutation
7LSI	;	2.4	;	Structure of KD035, a VEGFR2 monoclonal antibody
8SZT	;	2.5	;	Structure of Kdac1 from Acinetobacter baumannii
8SZU	;	1.75	;	Structure of Kdac1-Citarinostat complex from Acinetobacter baumannii
7P1F	;	1.45	;	Structure of KDNase from Aspergillus terrerus in complex with 2,3-didehydro-2,3-dideoxy-D-glycero-D-galacto-nonulosonic acid.
7P1E	;	1.53	;	Structure of KDNase from Aspergillus Terrerus in complex with 2,3-difluoro-2-keto-3-deoxynononic acid
7P1D	;	1.69	;	Structure of KDNase from Aspergillus Terrerus in complex with 2-keto-3-deoxynononic acid
7P1O	;	1.6	;	Structure of KDNase from Aspergillus Terrerus in complex with 2-keto-3-deoxynononic acid
7P1S	;	1.92	;	Structure of KDNase from Trichophyton Rubrum in complex with 2,3-didehydro-2,3-dideoxy-D-glycero-D-galacto-nonulosonic acid.
7P1Q	;	0.91	;	Structure of KDNase from Trichophyton Rubrum in complex with 2-keto-3-deoxynononic acid
7P1U	;	0.99	;	Structure of KDNase from Trichophyton Rubrum in complex with 2-keto-3-deoxynononic acid
1WAU	;	2.8	;	Structure of KDPG Aldolase E45N mutant
4L7B	;	2.41	;	Structure of keap1 kelch domain with (1S,2R)-2-{[(1S)-1-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}cyclohexanecarboxylic acid
4L7D	;	2.25	;	Structure of keap1 kelch domain with (1S,2R)-2-{[(1S)-5-methyl-1-[(1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}cyclohexanecarboxylic acid
4L7C	;	2.4	;	Structure of keap1 kelch domain with 2-{[(1S)-2-{[(1R,2S)-2-(1H-tetrazol-5-yl)cyclohexyl]carbonyl}-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl}-1H-isoindole-1,3(2H)-dione
4N1B	;	2.55	;	STRUCTURE OF KEAP1 KELCH DOMAIN WITH(1S,2R)-2-[(1S)-1-[(1-oxo-2,3-dihydro-1H-isoindol-2-Yl)methyl]-1,2,3,4-tetrahydroisoquinoline-2-Carbonyl]cyclohexane-1-carboxylic acid
3SLK	;	3.0	;	Structure of ketoreductase and enoylreductase didomain from modular polyketide synthase
3WOH	;	2.5	;	Structure of Ketoreductase SiaM from Streptomyces sp. A7248
4W97	;	1.6	;	Structure of ketosteroid transcriptional regulator KstR2 of Mycobacterium tuberculosis
6W0N	;	2.41	;	Structure of KHK in complex with compound 2
6W0W	;	2.8	;	Structure of KHK in complex with compound 3
6W0X	;	2.38	;	Structure of KHK in complex with compound 4 (6-[(1~{S},5~{R})-6-(hydroxymethyl)-3-azabicyclo[3.1.0]hexan-3-yl]-2-[(2~{S},3~{R})-2-methyl-3-oxidanyl-azetidin-1-yl]-4-(trifluoromethyl)pyridine-3-carbonitrile)
6W0Y	;	2.54	;	Structure of KHK in complex with compound 6 (2-[(1~{R},5~{S})-3-[5-cyano-6-[(2~{S},3~{R})-2-methyl-3-oxidanyl-azetidin-1-yl]-4-(trifluoromethyl)pyridin-2-yl]-3-azabicyclo[3.1.0]hexan-6-yl]ethanoic acid)
6W0Z	;	2.3	;	Structure of KHK in complex with compound 8 (2-[(1~{S},5~{R})-3-[2-[(2~{S})-2-methylazetidin-1-yl]-6-(trifluoromethyl)pyrimidin-4-yl]-3-azabicyclo[3.1.0]hexan-6-yl]ethanoic acid)
3KV9	;	2.29	;	Structure of KIAA1718 Jumonji domain
3KVA	;	2.79	;	Structure of KIAA1718 Jumonji domain in complex with alpha-ketoglutarate
3KVB	;	2.69	;	Structure of KIAA1718 Jumonji domain in complex with N-oxalylglycine
3KV6	;	2.89	;	Structure of KIAA1718, human Jumonji demethylase, in complex with alpha-ketoglutarate
3KV5	;	2.39	;	Structure of KIAA1718, human Jumonji demethylase, in complex with N-oxalylglycine
6J69	;	2.753	;	Structure of KIBRA and Dendrin Complex
6J68	;	2.495	;	Structure of KIBRA and LATS1 Complex
7KPV	;	3.8	;	Structure of kinase and Central lobes of yeast CKM
6R14	;		;	Structure of kiteplatinated dsDNA
7SS6	;	1.74	;	Structure of Klebsiella LpxH in complex with JH-LPH-45
7VUL	;	1.59	;	Structure of Klebsiella Phage P560 depolymerase
8K8K	;	1.99	;	Structure of Klebsiella pneumonia ModA
8K8L	;	1.77	;	Structure of Klebsiella pneumonia ModA with molybdate
3QVA	;	1.755	;	Structure of Klebsiella pneumoniae 5-hydroxyisourate hydrolase
3LWL	;	2.25	;	Structure of Klenow fragment of Taq polymerase in complex with an abasic site
4M9E	;	1.851	;	Structure of Klf4 zinc finger DNA binding domain in complex with methylated DNA
8EBL	;	1.37	;	Structure of KLHDC2 substrate binding domain bound to C-degron from EPHB2
8EBM	;	1.58	;	Structure of KLHDC2 substrate binding domain bound to KLHDC2's C-degron mimic
8EBN	;	2.6	;	Structure of KLHDC2-EloB/C tetrameric assembly
4EXV	;	3.0	;	Structure of Kluyveromyces lactis Hsv2p
6PFQ	;	1.8	;	Structure of Kluyveromyces marxianus Usb1
6PGL	;	1.845	;	Structure of Kluyveromyces marxianus Usb1 with uridine monophosphate
6QH8	;	2.2	;	Structure of knotted YibK from P. aeruginosa
4PL7	;	2.3	;	Structure of Komagataella pastoris actin-thymosin beta4 hybrid
6V1J	;	1.3	;	Structure of KPC-2 bound to QPX7728 at 1.30 A
7TI2	;	1.75	;	Structure of KPC-2 bound to RPX-7063 at 1.75A
6V7I	;	1.25	;	Structure of KPC-2 bound to Vaborbactam at 1.25 A
7STF	;	3.14	;	Structure of KRAS G12V/HLA-A*03:01 in complex with antibody fragment V2
8DVG	;	2.594	;	Structure of KRAS WT(7-16)-HLA-A*03:01
1KRN	;	1.67	;	STRUCTURE OF KRINGLE 4 AT 4C TEMPERATURE AND 1.67 ANGSTROMS RESOLUTION
5OSG	;	2.9	;	Structure of KSRP in context of Leishmania donovani 80S
5OPT	;	4.0	;	Structure of KSRP in context of Trypanosoma cruzi 40S
2MY6	;		;	Structure of KstB-PCP(apo)
6TYZ	;	1.51077	;	Structure of Ku80 von Willebrand domain complexed with APLF Ku Binding Motif
6TYU	;	1.46863	;	Structure of Ku80 von Willebrand domain complexed with MRI Ku Binding Motif
6TYV	;	1.92611	;	Structure of Ku80 von Willebrand domain complexed with WRN Ku Binding Motif
6TYT	;	2.40349	;	Structure of Ku80 von Willebrand domain S229A mutant complexed with APLF and XLF Ku Binding Motif
6TYW	;	1.69966	;	Structure of Ku80 von Willebrand domain S229A mutant complexed with APLF Ku Binding Motif
6TYX	;	1.89944	;	Structure of Ku80 von Willebrand domain S229A mutant complexed with XLF Ku Binding Motif
8EA1	;	2.29	;	Structure of kudzu 2-hydroxyisoflavanone dehydratase in complex with P-NITROPHENOL
1SIO	;	1.8	;	Structure of Kumamolisin-As complexed with a covalently-bound inhibitor, AcIPF
1ZVJ	;	2.03	;	Structure of Kumamolisin-AS mutant, D164N
1AQ6	;	1.95	;	STRUCTURE OF L-2-HALOACID DEHALOGENASE FROM XANTHOBACTER AUTOTROPHICUS
1QQ5	;	1.52	;	STRUCTURE OF L-2-HALOACID DEHALOGENASE FROM XANTHOBACTER AUTOTROPHICUS
1QQ6	;	2.1	;	STRUCTURE OF L-2-HALOACID DEHALOGENASE FROM XANTHOBACTER AUTOTROPHICUS WITH CHLOROACETIC ACID COVALENTLY BOUND
1QQ7	;	1.7	;	STRUCTURE OF L-2-HALOACID DEHALOGENASE FROM XANTHOBACTER AUTOTROPHICUS WITH CHLOROPROPIONIC ACID COVALENTLY BOUND
3FKK	;	2.1	;	Structure of L-2-keto-3-deoxyarabonate dehydratase
3FKR	;	1.801	;	Structure of L-2-keto-3-deoxyarabonate dehydratase complex with pyruvate
5FJM	;	2.0	;	Structure of L-Amino acid deaminase from Proteus myxofaciens
5FJN	;	1.75	;	Structure of L-Amino acid deaminase from Proteus myxofaciens in complex with anthranilate
2IID	;	1.8	;	Structure of L-amino acid oxidase from Calloselasma rhodostoma in complex with L-phenylalanine
4E0V	;	3.1	;	Structure of L-amino acid oxidase from the B. jararacussu venom
1B65	;	1.82	;	Structure of l-aminopeptidase d-ala-esterase/amidase from ochrobactrum anthropi, a prototype for the serine aminopeptidases, reveals a new variant among the ntn hydrolase fold
1WSA	;	2.2	;	STRUCTURE OF L-ASPARAGINASE II PRECURSOR
1CHU	;	2.2	;	STRUCTURE OF L-ASPARTATE OXIDASE: IMPLICATIONS FOR THE SUCCINATE DEHYDROGENASE/ FUMARATE REDUCATSE FAMILY
7E0C	;	2.65	;	Structure of L-glutamate oxidase R305E mutant
7E0D	;	2.7	;	Structure of L-glutamate oxidase R305E mutant in complex with L-arginine
2W43	;	1.66	;	Structure of L-haloacid dehalogenase from S. tokodaii
6OR9	;	1.8	;	Structure of L-lactate dehydrogenase from Trichoplusia ni
3X0V	;	1.9	;	Structure of L-lysine oxidase
7C3I	;	2.3	;	Structure of L-lysine oxidase D212A/D315A
7C3J	;	2.2	;	Structure of L-lysine oxidase D212A/D315A in complex with L-phenylalanine
7C3L	;	1.8	;	Structure of L-lysine oxidase D212A/D315A in complex with L-tyrosine
7C3H	;	1.7	;	Structure of L-lysine oxidase in complex with L-lysine
7D4C	;	1.97	;	Structure of L-lysine oxidase precursor
7D4E	;	1.85	;	Structure of L-lysine oxidase precursor in complex with L-lysine (1.0 M)
7D4D	;	2.29	;	Structure of L-lysine oxidase precursor in complex with L-lysine (1.24M)
2UYT	;	1.55	;	Structure of L-rhamnulose kinase in complex with ADP and beta-L- rhamnulose.
3VYL	;	2.7	;	Structure of L-ribulose 3-epimerase
7BPF	;	1.75	;	Structure of L-threoninol nucleic acid - RNA complex
3D3W	;	1.87	;	Structure of L-Xylulose Reductase with bound coenzyme, phosphate and hydroxide.
7BJ8	;	1.69	;	Structure of L1 with 2-Mercaptomethyl-thiazolidine D-syn-1b
2YHV	;	1.9	;	Structure of L1196M Mutant Anaplastic Lymphoma Kinase
2YFX	;	1.7	;	Structure of L1196M Mutant Anaplastic Lymphoma Kinase in Complex with Crizotinib
4CD0	;	2.23	;	Structure of L1196M Mutant Human Anaplastic Lymphoma Kinase in Complex with 2-(5-(6-amino-5-((R)-1-(5-fluoro-2-(2H-1,2,3-triazol-2- yl)phenyl)ethoxy)pyridin-3-yl)-4-methylthiazol-2-yl)propane-1,2-diol
4CLJ	;	1.66	;	Structure of L1196M Mutant Human Anaplastic Lymphoma Kinase in Complex with PF-06463922 ((10R)-7-amino-12-fluoro-2,10,16-trimethyl- 15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11) benzoxadiazacyclotetradecine-3-carbonitrile).
4ANS	;	1.85	;	Structure of L1196M,G1269A Double Mutant Anaplastic Lymphoma Kinase in Complex with Crizotinib
5AAA	;	1.73	;	Structure of L1198F Mutant Human Anaplastic Lymphoma Kinase in Complex with Crizotinib
5AA9	;	1.93	;	Structure of L1198F Mutant Human Anaplastic Lymphoma Kinase in Complex with PF-06463922 ((10R)-7-amino-12-fluoro-2,10,16-trimethyl- 15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11) benzoxadiazacyclotetradecine-3-carbonitrile).
8CVG	;	1.56	;	Structure of L289F Hyoscyamine 6-beta Hydroxylase in complex with iron, 2-oxoglutarate, and 6-OH-hyoscyamine
8CVE	;	1.53	;	Structure of L289F Hyoscyamine 6-beta Hydroxylase in complex with iron, 2-oxoglutarate, and hyoscyamine
8CVH	;	2.03	;	Structure of L289F Hyoscyamine 6-beta Hydroxylase in complex with vanadyl, succinate, and 6-OH-hyoscyamine
8CVF	;	1.532	;	Structure of L289F Hyoscyamine 6-beta Hydroxylase in complex with vanadyl, succinate, and hyoscyamine
2BLJ	;	1.8	;	Structure of L29W MbCO
6SUD	;	1.74	;	Structure of L320A mutant of Rex8A from Paenibacillus barcinonensis complexed with xylose.
6SHY	;	1.81	;	Structure of L320A/H321S double mutant of Rex8A from Paenibacillus barcinonensis
4L49	;	2.128	;	Structure of L358A mutant of P450cam bound to camphor
4L4A	;	2.103	;	Structure of L358A/K178G mutant of P450cam bound to camphor
4L4B	;	2.099	;	Structure of L358A/K178G/D182N mutant of P450cam bound to camphor
4L4C	;	2.2	;	Structure of L358P/K178G mutant of P450cam bound to camphor
6N1Y	;	2.15	;	Structure of L509V CAO1 - growth condition 1
6N20	;	1.95	;	Structure of L509V CAO1 - growth condition 2
1NW8	;	2.25	;	Structure of L72P mutant beta class N6-adenine DNA methyltransferase RsrI
4X4K	;	2.3	;	Structure of laccase from Botrytis aclada with full copper content
2HG2	;	2.2	;	Structure of Lactaldehyde Dehydrogenase
2ZFA	;	1.81	;	Structure of Lactate Oxidase at pH4.5 from AEROCOCCUS VIRIDANS
5J9G	;	2.21	;	Structure of Lactobacillus acidophilus glyceraldehyde-3-phosphate dehydrogenase at 2.21 angstrom resolution
8BLS	;	2.1	;	Structure of Lactobacillus salivarius (Ls) bile salt hydrolase(BSH) in complex with Glycocholate (GCA)
8BLT	;	2.1	;	Structure of Lactobacillus salivarius (Ls) bile salt hydrolase(BSH) in complex with taurocholate (TCA)
2BSD	;	2.3	;	Structure of Lactococcal Bacteriophage p2 Receptor Binding Protein
2BSE	;	2.7	;	Structure of Lactococcal Bacteriophage p2 Receptor Binding Protein in complex with a llama VHH domain
5YI0	;	2.3	;	Structure of Lactococcus lactis ZitR, C30AH42A mutant
5YI1	;	2.2	;	Structure of Lactococcus lactis ZitR, C30AH42A mutant in apo form
5YHY	;	1.65	;	Structure of Lactococcus lactis ZitR, C30S mutant
5YI3	;	2.9	;	Structure of Lactococcus lactis ZitR, C30S mutant in complex with DNA
5YHZ	;	1.9	;	Structure of Lactococcus lactis ZitR, E41A mutant
5YHX	;	2.4	;	Structure of Lactococcus lactis ZitR, wild type
5YI2	;	2.6	;	Structure of Lactococcus lactis ZitR, wild type in complex with DNA
6WTW	;	2.86	;	Structure of LaINDY crystallized in the presence of alpha-ketoglutarate and malate
8GMU	;	2.78	;	Structure of lambda repressor in complex with RecA filament
1IFR	;	1.4	;	Structure of Lamin A/C Globular Domain
3HJT	;	2.5	;	Structure of laminin binding protein (Lmb) of Streptococcus agalactiae A bifunctional protein with adhesin and metal transporting activity
7QPI	;	2.5	;	Structure of lamprey VDR in complex with 1,25D3
4N33	;	1.85	;	Structure of langerin CRD complexed with GlcNAc-beta1-3Gal-beta1-4Glc-beta-CH2CH2N3
4N35	;	1.85	;	Structure of langerin CRD I313 complexed with GlcNAc-beta1-3Gal-beta1-4Glc-beta-CH2CH2N3
4N38	;	2.0	;	Structure of langerin CRD I313 D288 complexed with GlcNAc-beta1-3Gal-beta1-4GlcNAc-beta-CH2CH2N3
4N36	;	1.85	;	Structure of langerin CRD I313 D288 complexed with Me-GlcNAc
4N37	;	2.0	;	Structure of langerin CRD I313 D288 complexed with Me-Man
4N34	;	1.75	;	Structure of langerin CRD I313 with alpha-MeGlcNAc
4N32	;	1.75	;	Structure of langerin CRD with alpha-Me-GlcNAc.
5Z3N	;	1.91	;	Structure of large fragment of DNA Polymerase I from Thermus aquaticus Host-Guest complex with the unnatural base 5fC pair with dA
5YTG	;	2.07	;	Structure of large fragment of DNA Polymerase I from Thermus aquaticus Host-Guest complex with the unnatural base I-fC pair with dA
5YTF	;	1.98	;	Structure of large fragment of DNA Polymerase I from Thermus aquaticus Host-Guest complex with the unnatural base M-fC pair with dA
5YTH	;	2.53	;	Structure of large fragment of DNA Polymerase I from Thermus aquaticus Host-Guest complex with the unnatural base M-fC pair with dG
1DPI	;	2.8	;	STRUCTURE OF LARGE FRAGMENT OF ESCHERICHIA COLI DNA POLYMERASE I COMPLEXED WITH D/TMP
1N8R	;	3.0	;	Structure of large ribosomal subunit in complex with virginiamycin M
5OE8	;	2.2	;	Structure of large terminase from the thermophilic bacteriophage D6E (Crystal form 2)
5OEE	;	2.6	;	Structure of large terminase from the thermophilic bacteriophage D6E (Crystal form 3)
5OEB	;	3.1	;	Structure of large terminase from the thermophilic bacteriophage D6E in complex with ADP (Crystal form 3)
5OEA	;	3.0	;	Structure of large terminase from the thermophilic bacteriophage D6E in complex with ATP-gamma-S (Crystal form 3)
5OE9	;	2.4	;	Structure of large terminase from the thermophilic bacteriophage D6E in complex with sulfate (Crystal form 2)
8GAP	;	3.8	;	Structure of LARP7 protein p65-telomerase RNA complex in telomerase
5O0Z	;	1.28	;	Structure of laspartomycin C in complex with geranyl-phosphate
7TYV	;	2.8	;	Structure of Lassa Virus glycoprotein (Josiah) bound to Fab 25.10C
6P91	;	4.0	;	Structure of Lassa virus glycoprotein bound to Fab 18.5C
7S8H	;	2.7	;	Structure of Lassa virus glycoprotein bound to Fab 18.5C and Fab 36.1F
6P95	;	3.5	;	Structure of Lassa virus glycoprotein in complex with Fab 25.6A
7CKL	;	3.88	;	Structure of Lassa virus polymerase bound to Z matrix protein
7ELA	;	3.4	;	Structure of Lassa virus polymerase in complex with 3'-vRNA and Z mutant (F36A)
2M37	;		;	Structure of lasso peptide astexin-1
2LTI	;		;	Structure of lasso peptide Astexin1
2M8F	;		;	Structure of lasso peptide astexin3
2MLJ	;		;	Structure of Lasso Peptide Caulonodin V
2LX6	;		;	Structure of Lasso Peptide Caulosegnin I
2MFV	;		;	Structure of lasso peptide xanthomonin ii
3J2I	;	11.9	;	Structure of late pre-60S ribosomal subunits with nuclear export factor Arx1 bound at the peptide exit tunnel
6ELS	;	1.346	;	Structure of latent apple tyrosinase (MdPPO1)
8EFK	;	3.0	;	Structure of Lates calcarifer DNA polymerase theta polymerase domain with hairpin DNA
8EF9	;	2.4	;	Structure of Lates calcarifer DNA polymerase theta polymerase domain with long duplex DNA, complex Ia
8EFC	;	2.8	;	Structure of Lates calcarifer DNA polymerase theta polymerase domain with long duplex DNA, complex Ia
8E2L	;	3.51	;	Structure of Lates calcarifer Twinkle helicase with ATP and DNA
5O1M	;	2.2	;	Structure of Latex Clearing Protein LCP in the closed state
5O1L	;	1.48	;	Structure of Latex Clearing Protein LCP in the open state with bound imidazole
6NME	;	5.67	;	Structure of LbCas12a-crRNA
6KL9	;	3.25	;	Structure of LbCas12a-crRNA complex bound to AcrVA4 (form A complex)
6KLB	;	4.1	;	Structure of LbCas12a-crRNA complex bound to AcrVA4 (form B complex)
8SS5	;	3.56	;	Structure of LBD-TMD of AMPA receptor GluA2 in complex with auxiliary subunit TARP gamma-5 (apo state)
8SS9	;	2.72	;	Structure of LBD-TMD of AMPA receptor GluA2 in complex with auxiliary subunit TARP gamma-5 bound to competitive antagonist ZK and antiepileptic drug perampanel (closed state)
8SS4	;	3.3	;	Structure of LBD-TMD of AMPA receptor GluA2 in complex with auxiliary subunits TARP gamma-5 and cornichon-2 (apo state)
8SS3	;	3.21	;	Structure of LBD-TMD of AMPA receptor GluA2 in complex with auxiliary subunits TARP gamma-5 and cornichon-2 bound to competitive antagonist ZK and channel blocker spermidine (closed state)
8SSB	;	3.66	;	Structure of LBD-TMD of AMPA receptor GluA2 in complex with auxiliary subunits TARP gamma-5 and cornichon-2 bound to glutamate and channel blocker spermidine (desensitized state)
3U3G	;	1.4	;	Structure of LC11-RNase H1 Isolated from Compost by Metagenomic Approach: Insight into the Structural Bases for Unusual Enzymatic Properties of Sto-RNase H1
3ZKE	;	2.2	;	Structure of LC8 in complex with Nek9 peptide
3ZKF	;	2.6	;	Structure of LC8 in complex with Nek9 phosphopeptide
4C3F	;	1.72	;	Structure of Lck in complex with a compound discovered by Virtual Fragment Linking
4JMX	;	2.55	;	Structure of LD transpeptidase LdtMt1 in complex with imipenem
2VY2	;	2.3	;	Structure of LEAFY transcription factor from Arabidopsis thaliana in complex with DNA from AG-I promoter
2VY1	;	2.104	;	Structure of LEAFY transcription factor from Arabidopsis thaliana in complex with DNA from AP1 promoter
5J76	;	2.1	;	Structure of Lectin from Colocasia esculenta(L.) Schott
6KBJ	;	2.2	;	Structure of Lectin from Pleurotus ostreatus in complex with malonate
5DUY	;	2.12	;	Structure of lectin from the sea mussel Crenomytilus grayanus
6S01	;	3.2	;	Structure of LEDGF PWWP domain bound H3K36 methylated nucleosome
8CBN	;	3.34	;	structure of LEDGF/p75 PWWP domain bound to the H3K36 trimethylated dinucleosome
8CBQ	;	4.0	;	structure of LEDGF/p75 PWWP domain bound to the H3K36 trimethylated dinucleosome
6RVV	;	3.7	;	Structure of left-handed protein cage consisting of 24 eleven-membered ring proteins held together by gold (I) bridges.
6MCA	;	2.455	;	Structure of Legionella Effector AnkH
7KJ6	;	2.5	;	Structure of Legionella Effector LegA15
3PV4	;	3.1	;	Structure of Legionella fallonii DegQ (Delta-PDZ2 variant)
3PV5	;	2.4	;	Structure of Legionella fallonii DegQ (N189G/P190G variant)
3PV3	;	3.1	;	Structure of Legionella fallonii DegQ (S193A variant)
3PV2	;	2.15	;	Structure of Legionella fallonii DegQ (wt)
9B8D	;	1.72	;	Structure of Legionella pneumophila Ceg10
4YO1	;	2.8	;	Structure of Legionella pneumophila DegQ (delta PDZ2 variant)
4YNN	;	3.2	;	Structure of Legionella pneumophila DegQ (S190A variant)
5X1H	;	3.005	;	Structure of Legionella pneumophila DotN
5CDH	;	2.001	;	Structure of Legionella pneumophila Histidine Acid Phosphatase complexed with L(+)-tartrate
8Q4E	;	1.9	;	Structure of Legionella pneumophila Lcl C-terminal domain
8QK8	;	1.9	;	Structure of Legionella pneumophila Lcl C-terminal domain bound to sulphate
7ELV	;	1.5	;	Structure of legume lectin domain from Methanocaldococcus jannaschii in apo form
7EXO	;	1.75	;	Structure of legume lectin domain from Methanocaldococcus jannaschii in mannose bound form
5ZBT	;	2.4	;	Structure of legume lectin-like domain from Entamoeba histolytica
3QW3	;	1.7	;	Structure of Leishmania donovani OMP decarboxylase
3QW4	;	3.0	;	Structure of Leishmania donovani UMP synthase
5OL0	;	1.99	;	Structure of Leishmania infantum Silent Information Regulator 2 related protein 1 (LiSIR2rp1) in complex with acetylated p53 peptide
6FXW	;	1.57	;	Structure of Leishmania infantum type B ribose 5-phosphate isomerase
5AMM	;	2.09	;	Structure of Leishmania major peroxidase D211N mutant
5AL9	;	1.37	;	Structure of Leishmania major peroxidase D211R mutant (high res)
5ALA	;	2.73	;	Structure of Leishmania major peroxidase D211R mutant (low res)
3NGU	;	2.29	;	Structure of Leishmania NDKb complexed with ADP.
3NGT	;	2.57	;	Structure of Leishmania NDKb complexed with AMP.
3NGS	;	1.8	;	Structure of Leishmania nucleoside diphosphate kinase b with ordered nucleotide-binding loop
5CAA	;	2.3	;	Structure of Leishmania nucleoside diphosphate kinase mutant P100S/del5-Cterm
5CAB	;	2.953	;	Structure of Leishmania nucleoside diphostate kinase mutant Del5-Cterm
5C7P	;	3.144	;	Structure of Leishmania nucleoside diphostate kinase mutant P95S
6H7B	;	1.89	;	Structure of Leishmania PABP1 (domain J) complexed with a peptide containing the PAM2 motif of eIF4E4.
6H7A	;	2.03	;	Structure of Leishmania PABP1 (domain J).
8F5O	;	3.5	;	Structure of Leishmania tarentolae IFT-A (state 1)
8F5P	;	3.4	;	Structure of Leishmania tarentolae IFT-A (state 2)
8B48	;	2.65	;	Structure of Lentithecium fluviatile carbohydrate esterase from the CE15 family (LfCE15C)
4U06	;	1.9	;	Structure of Leptospira interrogans LRR protein LIC10831
4U08	;	1.95	;	Structure of Leptospira interrogans LRR protein LIC11098
4TZH	;	1.39	;	Structure of Leptospira interrogans LRR protein LIC12234
4U09	;	1.95	;	Structure of Leptospira interrogans LRR protein LIC12759
7YJW	;	3.2	;	Structure of Leptospira santarosai serovar shermani LRR protein LSS01692
6LX0	;	1.99	;	Structure of Leptospira santarosai serovar shermani LRR protein LSS11580
8FI0	;	3.0	;	Structure of Lettuce aptamer bound to DFAME
8FHX	;	2.5	;	Structure of Lettuce aptamer bound to DFHBI-1T
8FHV	;	2.5	;	Structure of Lettuce aptamer bound to DFHBI-1T with thallium I ions
8FHZ	;	2.6	;	Structure of Lettuce aptamer bound to DFHO
8FI1	;	2.6	;	Structure of Lettuce C20G bound to DFHO
8FI8	;	2.8	;	Structure of Lettuce C20T bound to DFAME
8FI2	;	3.0	;	Structure of Lettuce C20T bound to DFHBI-1T
8FI7	;	2.9	;	Structure of Lettuce C20T bound to DFHO
6ACF	;	3.0	;	structure of leucine dehydrogenase from Geobacillus stearothermophilus by cryo-EM
7THY	;	5.2	;	Structure of Leucine Rich Repeat Kinase 2's ROC domain interacting with the microtubule facing the minus end
7THZ	;	5.0	;	Structure of Leucine Rich Repeat Kinase 2's ROC domain interacting with the microtubule facing the plus end
5NTH	;	2.5	;	Structure of Leucyl aminopeptidase from Leishmania major in complex with actinonin
5NSQ	;	3.0	;	Structure of Leucyl aminopeptidase from Trypanosoma brucei in complex with Actinonin
5NTD	;	2.3	;	Structure of Leucyl aminopeptidase from Trypanosoma brucei in complex with Bestatin
5NTG	;	2.32	;	Structure of Leucyl aminopeptidase from Trypanosoma cruzi in complex with citrate
2DPS	;	2.4	;	Structure of Leucyl/phenylalanyl-tRNA-protein transferase
1HS6	;	1.95	;	STRUCTURE OF LEUKOTRIENE A4 HYDROLASE COMPLEXED WITH BESTATIN.
1GW6	;	2.2	;	STRUCTURE OF LEUKOTRIENE A4 HYDROLASE D375N MUTANT
4GAA	;	2.26	;	Structure of Leukotriene A4 hydrolase from Xenopus laevis complexed with inhibitor bestatin
8GMS	;	3.31	;	Structure of LexA in complex with RecA filament
4G5S	;	3.62	;	Structure of LGN GL3/Galphai3 complex
4G5Q	;	2.9	;	Structure of LGN GL4/Galphai1 complex
4G5R	;	3.481	;	Structure of LGN GL4/Galphai3 complex
4G5O	;	2.9	;	Structure of LGN GL4/Galphai3(Q147L) complex
2FKW	;	2.45	;	Structure of LH2 from Rps. acidophila crystallized in lipidic mesophases
5HOD	;	2.682	;	Structure of LHX4 transcription factor complexed with DNA
5E4L	;	2.44	;	Structure of ligand binding region of uPARAP at pH 5.3
5E4K	;	2.58	;	Structure of ligand binding region of uPARAP at pH 7.4
5EW6	;	2.29	;	Structure of ligand binding region of uPARAP at pH 7.4 without calcium
4UR9	;	2.2	;	Structure of ligand bound glycosylhydrolase
5EGY	;	2.741	;	Structure of ligand free human DPP3 in closed form.
6XKD	;	3.2	;	Structure of ligand-bound mouse cGAMP hydrolase ENPP1
7RLT	;	3.7	;	Structure of ligand-free ALDH1L1 (10-formyltetrahydrofolate dehydrogenase)
1XF4	;	2.5	;	Structure of ligand-free Fab DNA-1 in space group P321 solved from crystals with perfect hemihedral twinning
1XF3	;	2.3	;	Structure of ligand-free Fab DNA-1 in space group P65
8IMR	;	1.3	;	Structure of ligand-free human macrophage migration inhibitory factor
1JW4	;	2.0	;	Structure of ligand-free maltodextrin-binding protein
4TWE	;	1.75	;	Structure of ligand-free N-acetylated-alpha-linked-acidic-dipeptidase like protein (NAALADaseL)
3KDH	;	1.653	;	Structure of ligand-free PYL2
1B33	;	2.3	;	STRUCTURE OF LIGHT HARVESTING COMPLEX OF ALLOPHYCOCYANIN ALPHA AND BETA CHAINS/CORE-LINKER COMPLEX AP*LC7.8
7PH0	;	0.979	;	Structure of light-adapted AsLOV2 Q513L
7PGY	;	1.09	;	Structure of light-adapted AsLOV2 wild type
6JYB	;	1.802	;	Structure of light-state marine bacterial chloride importer, NM-R3, with CW laser (ND-10%) at 95K.
6JY9	;	1.9	;	Structure of light-state marine bacterial chloride importer, NM-R3, with CW laser (ND-3%) at 95K.
6JYD	;	2.007	;	Structure of light-state marine bacterial chloride importer, NM-R3, with CW laser (ND-30%) at 95K.
6JYF	;	2.004	;	Structure of light-state marine bacterial chloride importer, NM-R3, with Pulse laser (ND-1%) at 140K.
6JY7	;	1.8	;	Structure of light-state marine bacterial chloride importer, NM-R3, with Pulse laser (ND-1%) at 95K.
7B8W	;	2.8	;	Structure of LIMK1 Kinase domain with allosteric inhibitor TH-470
5JPP	;	2.5	;	Structure of limonene epoxide hydrolase mutant - H-2-H5
5JPU	;	1.5	;	Structure of limonene epoxide hydrolase mutant - H-2-H5 complex with (S,S)-cyclohexane-1,2-diol
7U0I	;	2.6	;	Structure of LIN28b nucleosome bound 2 OCT4
7U0G	;	2.6	;	structure of LIN28b nucleosome bound 3 OCT4
5FD3	;	2.42	;	Structure of Lin54 tesmin domain bound to DNA
1G5F	;	1.8	;	STRUCTURE OF LINB COMPLEXED WITH 1,2-DICHLOROETHANE
8SXU	;	3.66	;	Structure of LINE-1 ORF2p with an oligo(A) template
8SXT	;	3.3	;	Structure of LINE-1 ORF2p with template:primer hybrid
7UDS	;	3.1	;	Structure of lineage I (Pinneo) Lassa virus glycoprotein bound to Fab 25.10C
8EJE	;	3.69	;	Structure of lineage II Lassa virus glycoprotein complex (strain NIG08-A41)
8EJD	;	3.8	;	Structure of lineage IV Lassa virus glycoprotein complex (strain Josiah)
8EJF	;	3.72	;	Structure of lineage V Lassa virus glycoprotein complex (strain Soromba-R)
8EJG	;	3.13	;	Structure of lineage VII Lassa virus glycoprotein complex (strain Togo/2016/7082)
2Y5M	;	1.08	;	STRUCTURE OF LINEAR GRAMICIDIN D OBTAINED USING TYPE I CRYSTALS GROWN IN A 7.7 MONOACYLGLYCEROL LIPID CUBIC PHASE.
2Y6N	;	1.26	;	STRUCTURE OF LINEAR GRAMICIDIN D OBTAINED USING TYPE I CRYSTALS GROWN IN A 8.8 MONOACYLGLYCEROL LIPID CUBIC PHASE.
2XDC	;	1.7	;	Structure of linear gramicidin D obtained using Type I crystals grown in a lipid cubic phase.
3ZQ8	;	1.7	;	STRUCTURE OF LINEAR GRAMICIDIN D OBTAINED USING TYPE I CRYSTALS GROWN IN A monovaccenin LIPID CUBIC PHASE
1OIL	;	2.1	;	STRUCTURE OF LIPASE
5AH0	;	2.5	;	STRUCTURE OF LIPASE 1 FROM PELOSINUS FERMENTANS
7V6D	;	2.5	;	Structure of lipase B from Lasiodiplodia theobromae
6ISR	;	2.6	;	structure of lipase mutant with Cys-His-Asp catalytic triad
6ISQ	;	1.86	;	structure of Lipase mutant with oxided Cys-His-Asp catalytic triad
7APN	;	2.0	;	Structure of Lipase TL from bulk agarose grown crystal
7APP	;	1.7	;	Structure of Lipase TL from capillary grown crystal in the presence of agarose
5JWY	;	3.2	;	Structure of lipid phosphate phosphatase PgpB complex with PE
4UOO	;	3.0	;	Structure of lipoteichoic acid synthase LtaS from Listeria monocytogenes
4UOR	;	2.194	;	Structure of lipoteichoic acid synthase LtaS from Listeria monocytogenes in complex with glycerol phosphate
4UWX	;	1.65	;	Structure of liprin-alpha3 in complex with mDia1 Diaphanous- inhibitory domain
7FS1	;	1.863	;	Structure of liver pyruvate kinase in complex with allosteric modulator 11
7FS2	;	2.374	;	Structure of liver pyruvate kinase in complex with allosteric modulator 13
7FS3	;	1.655	;	Structure of liver pyruvate kinase in complex with allosteric modulator 15
7FS4	;	2.19	;	Structure of liver pyruvate kinase in complex with allosteric modulator 16
7FS5	;	2.182	;	Structure of liver pyruvate kinase in complex with allosteric modulator 17
7FS6	;	2.241	;	Structure of liver pyruvate kinase in complex with allosteric modulator 18
7FS7	;	2.774	;	Structure of liver pyruvate kinase in complex with allosteric modulator 20
7FS8	;	2.098	;	Structure of liver pyruvate kinase in complex with allosteric modulator 21
7FS9	;	1.721	;	Structure of liver pyruvate kinase in complex with allosteric modulator 22
7FSA	;	1.909	;	Structure of liver pyruvate kinase in complex with allosteric modulator 24
7FRV	;	2.004	;	Structure of liver pyruvate kinase in complex with allosteric modulator 3
7FRW	;	1.737	;	Structure of liver pyruvate kinase in complex with allosteric modulator 4
7FSB	;	2.495	;	Structure of liver pyruvate kinase in complex with allosteric modulator 41
7FSC	;	1.855	;	Structure of liver pyruvate kinase in complex with allosteric modulator 42
7FSD	;	1.769	;	Structure of liver pyruvate kinase in complex with allosteric modulator 44
7FRX	;	1.847	;	Structure of liver pyruvate kinase in complex with allosteric modulator 5
7FRY	;	1.958	;	Structure of liver pyruvate kinase in complex with allosteric modulator 6
7FRZ	;	2.085	;	Structure of liver pyruvate kinase in complex with allosteric modulator 7
7FS0	;	2.412	;	Structure of liver pyruvate kinase in complex with allosteric modulator 8
5SCL	;	2.134	;	Structure of liver pyruvate kinase in complex with anthraquinone derivative 1
5SCH	;	2.089	;	Structure of liver pyruvate kinase in complex with anthraquinone derivative 100
5SCG	;	1.937	;	Structure of liver pyruvate kinase in complex with anthraquinone derivative 101
5SCI	;	2.155	;	Structure of liver pyruvate kinase in complex with anthraquinone derivative 105
5SCJ	;	2.354	;	Structure of liver pyruvate kinase in complex with anthraquinone derivative 106
5SDT	;	1.944	;	Structure of liver pyruvate kinase in complex with anthraquinone derivative 15
5SC8	;	1.77	;	Structure of liver pyruvate kinase in complex with anthraquinone derivative 17
5SCB	;	1.8	;	Structure of liver pyruvate kinase in complex with anthraquinone derivative 28
5SC9	;	1.685	;	Structure of liver pyruvate kinase in complex with anthraquinone derivative 29
5SCA	;	1.918	;	Structure of liver pyruvate kinase in complex with anthraquinone derivative 36
5SCK	;	1.717	;	Structure of liver pyruvate kinase in complex with anthraquinone derivative 42
7QZU	;	1.964	;	Structure of liver pyruvate kinase in complex with anthraquinone derivative 47
5SCE	;	2.147	;	Structure of liver pyruvate kinase in complex with anthraquinone derivative 55
5SCC	;	1.885	;	Structure of liver pyruvate kinase in complex with anthraquinone derivative 57
5SCD	;	2.041	;	Structure of liver pyruvate kinase in complex with anthraquinone derivative 58
5SCF	;	2.185	;	Structure of liver pyruvate kinase in complex with anthraquinone derivative 99
3JB4	;	3.8	;	Structure of Ljungan virus: insight into picornavirus packaging
6J3A	;	2.38	;	Structure of LmbA2991HD
6J3I	;	2.5	;	Structure of LmbA2991T421A
2R8Q	;	1.5	;	Structure of LmjPDEB1 in complex with IBMX
3LU2	;	2.2	;	Structure of lmo2462, a Listeria monocytogenes amidohydrolase family putative dipeptidase
6LE6	;	2.33	;	Structure of LNLPTQGRAR bound FEM1C
2OO4	;	2.003	;	Structure of LNR-HD (Negative Regulatory Region) from human Notch 2
4CIH	;	2.22	;	Structure of LntA-K180D-K181D from Listeria monocytogenes
354D	;	1.5	;	Structure of loop E FROM E. coli 5S RRNA
6ZZX	;	2.7	;	Structure of low-light grown Chlorella ohadii Photosystem I
6LW4	;	2.7	;	Structure of Lpg2148/Lpg2149 complex
6LP2	;	2.479	;	Structure of Lpg2148/UBE2N-Ub complex
6FVB	;	3.297	;	Structure of Lph2 , a novel bidirectional nuclear transport receptor in S. cerevisiae
7PYX	;	1.6	;	Structure of LPMO (expressed in E.coli) with cellotriose at 2.74x10^5 Gy
7PYZ	;	1.6	;	Structure of LPMO (expressed in E.coli) with cellotriose at 2.97x10^6 Gy
7PYY	;	1.2	;	Structure of LPMO (expressed in E.coli) with cellotriose at 5.05x10^5 Gy
7PYW	;	1.4	;	Structure of LPMO (expressed in E.coli) with cellotriose at 5.62x10^4 Gy
7PZ0	;	1.2	;	Structure of LPMO (expressed in E.coli) with cellotriose at 9.81x10^6 Gy
7PB7	;	1.8	;	Structure of LPMO domain of colonization factor GbpA from Vibrio cholerae in the presence of calcium
7PB6	;	1.5	;	Structure of LPMO domain of colonization factor GbpA from Vibrio cholerae in the presence of potassium
7PYF	;	1.9	;	Structure of LPMO in complex with cellotetraose at 1.39x10^5 Gy
7PYH	;	1.9	;	Structure of LPMO in complex with cellotetraose at 1.45x10^6 Gy
7PYG	;	1.9	;	Structure of LPMO in complex with cellotetraose at 3.6x10^5 Gy
7PYE	;	2.1	;	Structure of LPMO in complex with cellotetraose at 5.99x10^4 Gy
7PYI	;	2.05	;	Structure of LPMO in complex with cellotetraose at 6.65x10^6 Gy
7PYD	;	2.21	;	Structure of LPMO in complex with cellotetraose at 7.88x10^3 Gy
5OPF	;	1.081	;	Structure of LPMO10B from from Micromonospora aurantiaca
6DEH	;	1.8	;	Structure of LpnE Effector Protein from Legionella pneumophila (sp. Philadelphia)
4E6U	;	1.41	;	Structure of LpxA from Acinetobacter baumannii at 1.4A resolution (P63 form)
4E6T	;	1.8	;	Structure of LpxA from Acinetobacter baumannii at 1.8A resolution (P212121 form)
4MDT	;	2.59	;	Structure of LpxC bound to the reaction product UDP-(3-O-(R-3-hydroxymyristoyl))-glucosamine
2J65	;	2.2	;	Structure of LpxC from Aquifex aeolicus in complex with UDP
3NZK	;	1.8	;	Structure of LpxC from Yersinia enterocolitica Complexed with CHIR090 Inhibitor
4E79	;	2.66	;	Structure of LpxD from Acinetobacter baumannii at 2.66A resolution (P4322 form)
4E75	;	2.85	;	Structure of LpxD from Acinetobacter baumannii at 2.85A resolution (P21 form)
4GGM	;	2.897	;	Structure of LpxI
4J6E	;	2.52	;	Structure of LPXI D225A Mutant
6H15	;	2.6	;	Structure of LRP6 P3E3P4E4 in complex with VHH L-P2-B10
6H16	;	2.9	;	Structure of LRP6 P3E3P4E4 in complex with VHH L-P2-D07
8DXN	;	3.4	;	Structure of LRRC8C-LRRC8A(IL125) Chimera, Class 1
8DXO	;	3.6	;	Structure of LRRC8C-LRRC8A(IL125) Chimera, Class 2
8DXP	;	3.7	;	Structure of LRRC8C-LRRC8A(IL125) Chimera, Class 3
8DXQ	;	3.8	;	Structure of LRRC8C-LRRC8A(IL125) Chimera, Class 4
8DXR	;	4.0	;	Structure of LRRC8C-LRRC8A(IL125) Chimera, Class 5
7LI4	;	3.1	;	Structure of LRRK2 after symmetry expansion
8E80	;	1.49	;	Structure of LRRK2-CHK1 10-pt. mutant complex with heteroaryl-1H-indazole LRRK2 inhibitor 14
8E81	;	1.62	;	Structure of LRRK2-CHK1 10-pt. mutant complex with heteroaryl-1H-indazole LRRK2 inhibitor 25
4KUM	;	3.05	;	Structure of LSD1-CoREST-Tetrahydrofolate complex
4XBF	;	2.803	;	Structure of LSD1:CoREST in complex with ssRNA
6R1T	;	4.02	;	Structure of LSD2/NPAC-linker/nucleosome core particle complex: Class 1, free nuclesome
6R1U	;	4.36	;	Structure of LSD2/NPAC-linker/nucleosome core particle complex: Class 2
6R25	;	4.61	;	Structure of LSD2/NPAC-linker/nucleosome core particle complex: Class 3
4EQQ	;	2.05	;	Structure of Ltp, a superinfection exclusion protein from the Streptococcus thermophilus temperate phage TP-J34
3DDY	;	2.5	;	Structure of lumazine protein, an optical transponder of luminescent bacteria
8PVJ	;	3.0	;	Structure of lumazine synthase determined by cryoEM at 100 keV
6FRI	;	2.297	;	Structure of LuxB from Photobacterium leiognathi
4YR7	;	2.533	;	Structure of LuxP In Complex With 1-deoxy-alpha-L-xylulofuranose-1,2-borate
7AMT	;	2.6	;	Structure of LuxR with DNA (activation)
7AMN	;	2.3	;	Structure of LuxR with DNA (repression)
7FAW	;	2.438	;	Structure of LW domain from Yeast
4MXV	;	3.2	;	Structure of Lymphotoxin alpha bound to anti-LTa Fab
2QCT	;	2.8	;	Structure of Lyp with inhibitor I-C11
2YBG	;	1.9	;	Structure of Lys120-acetylated p53 core domain
5AF4	;	1.85	;	Structure of Lys33-linked diUb
5AF6	;	3.4	;	Structure of Lys33-linked diUb bound to Trabid NZF1
5AF5	;	1.68	;	Structure of Lys33-linked triUb S.G. P 212121
3ZU1	;	1.6	;	Structure of LysB29(Nepsilon omega-carboxyheptadecanoyl) des(B30) Human Insulin
7LF6	;	3.5	;	Structure of lysosomal membrane protein
4R0F	;	1.941	;	Structure of Lysozyme Dimer at 318K
6YOB	;	1.85	;	Structure of Lysozyme from COC IMISX setup collected by rotation serial crystallography on crystals prelocated by 2D X-ray phase-contrast imaging
6YOC	;	1.86	;	Structure of Lysozyme from COC IMISX setup collected by still serial crystallography on crystals prelocated by 2D X-ray phase-contrast imaging
6YOD	;	1.601	;	Structure of Lysozyme from SiN IMISX setup collected by rotation serial crystallography on crystals prelocated by 2D X-ray phase-contrast imaging
6YOE	;	1.85	;	Structure of Lysozyme from SiN IMISX setup collected by still serial crystallography on crystals prelocated by 2D X-ray phase-contrast imaging
5IEL	;	1.15	;	Structure of Lysozyme labeled with fluorescein isothiocyanate (FITC) at 1.15 Angstroms resolution
7C09	;	2.2	;	Structure of lysozyme obtained in SSRF using serial crystallography
7DLN	;	2.15	;	Structure of lysozyme obtained on SSRF using serial synchrotron crystallography
5FST	;	1.2	;	Structure of lysozyme prepared by the 'soak-and-freeze' method under 100 bar of krypton pressure
3J4G	;	2.9	;	Structure of lysozyme solved by MicroED to 2.9 A
1HC0	;	1.82	;	structure of lysozyme with periodate
4C5F	;	2.34	;	Structure of Lytic Transglycosylase MltC from Escherichia coli at 2.3 A resolution.
4CFO	;	2.9	;	Structure of Lytic Transglycosylase MltC from Escherichia coli in complex with tetrasaccharide at 2.9 A resolution.
6GHY	;	2.12	;	Structure of Lytic Transglycosylase MltE inactive mutant E64Q from E.coli
6GI3	;	1.38	;	Structure of Lytic Transglycosylase MltE mutant S73A from E.coli
6GI4	;	1.35	;	Structure of Lytic Transglycosylase MltE mutant S75A from E.coli
6GHZ	;	2.33	;	Structure of Lytic Transglycosylase MltE mutant Y192F from E.coli
6UM2	;	4.32	;	Structure of M-6-P/IGFII Receptor and IGFII complex
6UM1	;	3.46	;	Structure of M-6-P/IGFII Receptor at pH 4.5
3BOW	;	2.4	;	Structure of M-calpain in complex with Calpastatin
3EJJ	;	2.4	;	Structure of M-CSF bound to the first three domains of FMS
5XNN	;	3.6	;	Structure of M-LHCII and CP24 complexes in the stacked C2S2M2-type PSII-LHCII supercomplex from Pisum sativum
5XNO	;	3.5	;	Structure of M-LHCII and CP24 complexes in the unstacked C2S2M2-type PSII-LHCII supercomplex from Pisum sativum
8SVD	;	3.49	;	Structure of M. baixiangningiae DarR-DNA complex reveals novel dimer-of-dimers DNA binding
8SUA	;	1.6	;	Structure of M. baixiangningiae DarR-ligand complex
6QE6	;	2.36	;	Structure of M. capricolum TrmK in complex with the natural cofactor product S-adenosyl-homocysteine (SAH)
8DF9	;	3.24	;	Structure of M. kandleri topoisomerase V in complex with DNA. 38 base pair asymmetric DNA complex
8DF7	;	3.52	;	Structure of M. kandleri topoisomerase V in complex with DNA. 38 base pair symmetric DNA complex
8DFB	;	3.17	;	Structure of M. kandleri topoisomerase V in complex with DNA. 39 base pair symmetric DNA complex
8DF8	;	2.92	;	Structure of M. kandleri topoisomerase V in complex with DNA. 40 base pair symmetric DNA complex
3P63	;	2.3	;	Structure of M. laminosus Ferredoxin with a shorter L1,2 loop
8UFJ	;	2.45	;	Structure of M. mazei GS(R167L-A168G) apo form
6NF9	;	3.89	;	Structure of M. spretus Endogenous Virus Element (EVE) Virus-like particle (VLP)
4ZFQ	;	2.799	;	Structure of M. tuberculosis (3,3) L,D-Transpeptidase, LdtMt5. (Meropenen-adduct form)
5DJF	;	1.7	;	Structure of M. tuberculosis CysQ, a PAP phosphatase - ligand-free structure
5DJI	;	1.659	;	Structure of M. tuberculosis CysQ, a PAP phosphatase with AMP, PO4, and 2Mg bound
5DJH	;	1.451	;	Structure of M. tuberculosis CysQ, a PAP phosphatase with AMP, PO4, and 3Mg bound
5DJG	;	1.951	;	Structure of M. tuberculosis CysQ, a PAP phosphatase with PAP, Mg, and Li bound
5DJK	;	1.799	;	Structure of M. tuberculosis CysQ, a PAP phosphatase with PO4 and 2Ca bound
5DJJ	;	1.501	;	Structure of M. tuberculosis CysQ, a PAP phosphatase with PO4 and 2Mg bound
1P9L	;	2.3	;	Structure of M. tuberculosis dihydrodipicolinate reductase in complex with NADH and 2,6 PDC
5HJZ	;	1.976	;	Structure of M. tuberculosis MazF-mt1 (Rv2801c) in complex with RNA
4X0E	;	2.41	;	Structure of M. tuberculosis nicotinate mono nucleotide adenylyltransferase
4QHC	;	1.899	;	Structure of M.Tuberculosis Betalactamase (Blac) with inhibitor having novel mechanism
6ZFZ	;	2.17	;	Structure of M1-StaR-T4L in complex with 77-LH-28-1 at 2.17A
6ZG9	;	2.5	;	Structure of M1-StaR-T4L in complex with GSK1034702 at 2.5A
6ZG4	;	2.33	;	Structure of M1-StaR-T4L in complex with HTL0009936 at 2.35A
1JWP	;	1.75	;	Structure of M182T mutant of TEM-1 beta-lactamase
4FXF	;	2.55	;	Structure of M2 pyruvate kinase in complex with phenylalanine
4FXJ	;	2.9	;	Structure of M2 pyruvate kinase in complex with phenylalanine
2RK4	;	1.15	;	Structure of M26I DJ-1
3B36	;	1.5	;	Structure of M26L DJ-1
1BY2	;	2.0	;	STRUCTURE OF M2BP SCAVENGER RECEPTOR CYSTEINE-RICH DOMAIN
7RAO	;	2.29	;	Structure of M66I mutant of disulfide stabilized HIV-1 CA hexamer
8GDV	;	3.3	;	Structure of M66I mutant of disulfide stabilized HIV-1 CA hexamer in complex with CPSF6 peptide and IP6
3ZBM	;	1.87	;	Structure of M92A variant of three-domain heme-Cu nitrite reductase from Ralstonia pickettii
2IDS	;	1.0	;	Structure of M98A mutant of amicyanin, Cu(I)
2IDQ	;	0.9	;	Structure of M98A mutant of amicyanin, Cu(II)
2IDU	;	0.95	;	Structure of M98Q mutant of amicyanin, Cu(I)
2IDT	;	1.0	;	Structure of M98Q mutant of amicyanin, Cu(II)
7VQA	;	1.79	;	Structure of MA1831 from Methanosarcina acetivorans in complex with dimethylallyl diphosphate.
7VQB	;	2.11	;	Structure of MA1831 from Methanosarcina acetivorans in complex with farnesyl pyrophosphate and dimethylallyl diphosphate
7VQD	;	2.39	;	Structure of MA1831 from Methanosarcina acetivorans in complex with farnesyl pyrophosphate and geranylgeranyl pyrophosphate.
7VQ9	;	1.89	;	Structure of MA1831 from Methanosarcina acetivorans in complex with farnesyl thiopyrophosphate and isopentyl S-thiolodiphosphate
7VQC	;	2.45	;	Structure of MA1831 from Methanosarcina acetivorans in complex with pyrophosphate
3J3Z	;	23.4	;	Structure of MA28-7 neutralizing antibody Fab fragment from electron cryo-microscopy of enterovirus 71 complexed with a Fab fragment
7ELB	;	4.1	;	Structure of Machupo virus L polymerase in complex with Z protein (dimeric form)
7EL9	;	3.2	;	Structure of Machupo virus L polymerase in complex with Z protein and 3'-vRNA (dimeric complex)
7CKM	;	3.37	;	Structure of Machupo virus polymerase bound to Z matrix protein (monomeric complex)
5E3B	;	1.6	;	Structure of macrodomain protein from Streptomyces coelicolor
3HOF	;	1.9	;	Structure of macrophage migration inhibitory factor (MIF) with caffeic acid at 1.9A resolution
3CE4	;	1.55	;	Structure of Macrophage Migration Inhibitory Factor Covalently Inhibited by PMSF Treatment
3T5S	;	2.3	;	Structure of macrophage migration inhibitory factor from Giardia lamblia
5MU5	;	2.3	;	Structure of MAf glycosyltransferase from Magnetospirillum magneticum AMB-1
7QIC	;	4.1	;	Structure of magnesium-bound EleNRMT in complex with two nanobodies at 4.1A
5JJG	;	1.72	;	Structure of magnesium-loaded ALG-2
5GWY	;	2.852	;	Structure of Main Protease from Human Coronavirus NL63: Insights for Wide Spectrum Anti-Coronavirus Drug Design
7UPV	;	1.84	;	Structure of maize BZR1-type beta-amylase provides new insights into its noncatalytic adaptation
4ML8	;	2.7	;	Structure of maize cytokinin oxidase/dehydrogenase 2 (ZmCKO2)
4MLA	;	2.04	;	Structure of maize cytokinin oxidase/dehydrogenase 2 (ZmCKO2)
5CVC	;	2.09	;	Structure of maize serine racemase
5OXE	;	3.7	;	Structure of major capsid protein VP1 of Aeropyrum pernix bacilliform virus 1 APBV1
5YYL	;	2.65	;	Structure of Major Royal Jelly Protein 1 Oligomer
2V51	;	2.35	;	Structure of MAL-RPEL1 complexed to actin
2V52	;	1.45	;	Structure of MAL-RPEL2 complexed to G-actin
4TVO	;	1.5	;	Structure of Malate Dehydrogenase from Mycobacterium tuberculosis
1V9N	;	2.1	;	Structure of Malate Dehydrogenase from Pyrococcus horikoshii OT3
5KVV	;	2.01	;	Structure of Malate Dehydrogenase in complex with NADH from Mycobacterium tuberculosis
7KMV	;	1.8	;	Structure of Malaysian Banana Lectin F84T
6NKH	;	1.6	;	Structure of MalC Reductase/Diels-Alderase from Malbranchea aurantiaca
2V6K	;	1.3	;	Structure of Maleyl Pyruvate Isomerase, a bacterial glutathione-s- transferase in Zeta class, in complex with substrate analogue dicarboxyethyl glutathione
4DPK	;	2.05	;	Structure of malonyl-coenzyme A reductase from crenarchaeota
4DPM	;	2.3	;	Structure of malonyl-coenzyme A reductase from crenarchaeota in complex with CoA
4DPL	;	1.9	;	Structure of malonyl-coenzyme A reductase from crenarchaeota in complex with NadP
6LCU	;	2.45	;	structure of maltooligosyltrehalose synthase from Arthrobacter ramosus
4NDZ	;	3.45	;	Structure of Maltose Binding Protein fusion to 2-O-Sulfotransferase with bound heptasaccharide and PAP
1JW5	;	2.0	;	Structure of Maltose Bound to Open-form Maltodextrin-binding Protein in P1 Crystal
4R0Y	;	2.0	;	Structure of Maltose-binding Protein Fusion with the C-terminal GH1 domain of Guanylate Kinase-associated Protein from Rattus norvegicus
1EZ9	;	1.9	;	STRUCTURE OF MALTOTETRAITOL BOUND TO OPEN-FORM MALTODEXTRIN BINDING PROTEIN IN P1 CRYSTAL FORM
1FQA	;	1.9	;	STRUCTURE OF MALTOTETRAITOL BOUND TO OPEN-FORM MALTODEXTRIN BINDING PROTEIN IN P2(1)CRYSTAL FORM
1FQB	;	1.9	;	STRUCTURE OF MALTOTRIOTOL BOUND TO OPEN-FORM MALTODEXTRIN BINDING PROTEIN IN P2(1)CRYSTAL FORM
1PO5	;	1.6	;	Structure of mammalian cytochrome P450 2B4
1SUO	;	1.9	;	Structure of mammalian cytochrome P450 2B4 with bound 4-(4-chlorophenyl)imidazole
1DT6	;	3.0	;	STRUCTURE OF MAMMALIAN CYTOCHROME P450 2C5
5A5T	;	6.0	;	Structure of mammalian eIF3 in the context of the 43S preinitiation complex
5A5U	;	9.0	;	Structure of mammalian eIF3 in the context of the 43S preinitiation complex
1Y2A	;	2.2	;	Structure of mammalian importin bound to the non-classical PLSCR1-NLS
7CU3	;	2.65	;	Structure of mammalian NALCN-FAM155A complex at 2.65 angstrom
7W7G	;	3.2	;	Structure of Mammalian NALCN-FAM155A-UNC79-UNC80 quanternary complex
6VJI	;	2.54	;	Structure of mammalian NEIL2 from Monodelphis domestica
8TH9	;	2.08	;	Structure of mammalian NEIL2 from Monodelphis domestica in complex with THF-containing DNA
8A40	;	3.0	;	Structure of mammalian Pol II-TFIIS elongation complex
5LDW	;	4.27	;	Structure of mammalian respiratory Complex I, class1
5LC5	;	4.35	;	Structure of mammalian respiratory Complex I, class2
5LDX	;	5.6	;	Structure of mammalian respiratory Complex I, class3.
6EXV	;	3.6	;	Structure of mammalian RNA polymerase II elongation complex inhibited by Alpha-amanitin
8IB2	;	3.8	;	Structure of mammalian spectrin-actin junctional complex of membrane skeleton, Pointed-end segment, headpiece domain of dematin optimized
8IAH	;	3.6	;	Structure of mammalian spectrin-actin junctional complex of membrane skeleton, State I, Global map
8IAI	;	3.5	;	Structure of mammalian spectrin-actin junctional complex of membrane skeleton, State II, Global map
3KKY	;	1.8	;	Structure of Manganese Superoxide Dismutase from Deinococcus Radiodurans in the orthorhombic space group P212121: A case study of mistaken identity
8U5K	;	2.8	;	Structure of Mango II aptamer bound to T01-6A
8U5P	;	2.9	;	Structure of Mango II aptamer bound to T01-6A-B
8U5R	;	2.6	;	Structure of Mango II variant aptamer bound to T01-6A
8U5T	;	2.2	;	Structure of Mango II variant aptamer bound to T01-6A-B
8U5Z	;	2.5	;	Structure of Mango II variant aptamer bound to T01-7M-B
8U60	;	3.3	;	Structure of Mango II variant2 aptamer bound to T01-6A
8U5J	;	1.7	;	Structure of Mango III variant aptamer bound to T01-07M-B
4KA3	;	2.707	;	Structure of MAP kinase in complex with a docking peptide
3CTQ	;	1.95	;	Structure of MAP kinase p38 in complex with a 1-o-tolyl-1,2,3-triazole-4-carboxamide
7UMU	;	2.51	;	Structure of MAP kinase phosphatase 5 in complex with 3,3-dimethyl-1-((5,6-dihydrobenzo[h]quinazolin-2-yl)thio)butan-2-one, an allosteric inhibitor
7UMV	;	1.8	;	Structure of MAP kinase phosphatase 5 in complex with 3,3-dimethyl-1-((5,6-dihydropyrido[2,3-h]quinazolin-2-yl)thio)butan-2-one, an allosteric inhibitor
6MC1	;	2.7	;	Structure of MAP kinase phosphatase 5 in complex with 3,3-dimethyl-1-((9-(methylthio)-5,6-dihydrothieno[3,4-h]quinazolin-2-yl)thio)butan-2-one, an allosteric inhibitor
7UN0	;	3.0	;	Structure of MAP kinase phosphatase 5 in complex with 3,3-dimethyl-1-((9-chloro-5,6-dihydrobenzo[h]quinazolin-2-yl)thio)butan-2-one, an allosteric inhibitor
7U4R	;	3.14	;	Structure of MAP kinase phosphatase 5 in complex with 3,3-dimethyl-1-((9-propyl-5,6-dihydrothieno[2,3-h]quinazolin-2-yl)thio)butan-2-one, an allosteric inhibitor
7U4O	;	2.3	;	Structure of MAP kinase phosphatase 5 in complex with 3,3-dimethyl-1-((9-propyl-5,6-dihydrothieno[3,4-h]quinazolin-2-yl)thio)butan-2-one, an allosteric inhibitor
7UN4	;	2.7	;	Structure of MAP kinase phosphatase 5 in complex with 3,3-dimethyl-1-((9-propyl-5,6-dihydrothieno[3,4-h]quinazolin-2-yl)thio)butan-2-one, an allosteric inhibitor
5ETA	;	2.8	;	Structure of MAPK14 with bound the KIM domain of the Toxoplasma protein GRA24
6Y68	;	2.4	;	Structure of Maporal virus envelope glycoprotein Gc in postfusion conformation
2B34	;	2.141	;	Structure of MAR1 Ribonuclease from Caenorhabditis elegans
1B7U	;	3.8	;	Structure of Mare Apolactoferrin: the N and C Lobes are in the Closed Form
7AVN	;	1.6	;	Structure of marine actinobacteria clade rhodopsin (MacR) in orange form in P1 space group
7AVO	;	1.7	;	Structure of marine actinobacteria clade rhodopsin (MacR) in orange form in P1211 space group
7AVP	;	1.09	;	Structure of marine actinobacteria clade rhodopsin (MacR) in violet form
6JH5	;	1.54	;	Structure of Marine bacterial laminarinase
6M6P	;	2.27	;	Structure of Marine bacterial laminarinase mutant E135A in complex with 1,3-beta-cellotriosyl-glucose
6JHJ	;	1.69	;	Structure of Marine bacterial laminarinase mutant-E135A
4LZ6	;	3.2	;	Structure of MATE multidrug transporter DinF-BH
4LZ9	;	3.7	;	Structure of MATE multidrug transporter DinF-BH in complex with R6G
5TVT	;	2.28	;	Structure of Maternal Embryonic Leucine Zipper Kinase
5TWL	;	2.42	;	Structure of Maternal Embryonic Leucine Zipper Kinase
5TWU	;	2.603	;	Structure of Maternal Embryonic Leucine Zipper Kinase
5TWY	;	2.91	;	Structure of Maternal Embryonic Leucine Zipper Kinase
5TWZ	;	2.631	;	Structure of Maternal Embryonic Leucine Zipper Kinase
5TX3	;	2.9	;	Structure of Maternal Embryonic Leucine Zipper Kinase
6VXR	;	2.1	;	Structure of Maternal embryonic leucine zipper kinase bound to LDSM276
2GV7	;	2.2	;	Structure of Matriptase in Complex with Inhibitor CJ-672
6Y6N	;	2.03	;	Structure of mature activin A with small molecule 2
6Y6O	;	2.04	;	Structure of mature activin A with small molecule 42
3DPM	;	2.35	;	Structure of mature CPAF complexed with lactacystin
4I07	;	1.3	;	Structure of mature form of cathepsin B1 from Schistosoma mansoni
7OF4	;	2.7	;	Structure of mature human mitochondrial ribosome large subunit in complex with GTPBP6 (PTC conformation 1).
7OF6	;	2.6	;	Structure of mature human mitochondrial ribosome large subunit in complex with GTPBP6 (PTC conformation 2).
1SPJ	;	1.7	;	STRUCTURE OF MATURE HUMAN TISSUE KALLIKREIN (HUMAN KALLIKREIN 1 OR KLK1) AT 1.70 ANGSTROM RESOLUTION WITH VACANT ACTIVE SITE
6ULH	;	1.968	;	Structure of MavC in complex with its substrate in R3 spacegroup
6P5H	;	1.53	;	Structure of MavC middle insertion domain
5OJ9	;	1.483	;	Structure of Mb NMH
6F18	;	1.8	;	Structure of Mb NMH H64V, V68A mutant complex with EDA
6F1A	;	2.399	;	Structure of Mb NMH H64V, V68A mutant complex with EDA incubated at room temperature for 20 min
6F19	;	1.895	;	Structure of Mb NMH H64V, V68A mutant complex with EDA incubated at room temperature for 5 min
6F17	;	1.45	;	Structure of Mb NMH H64V, V68A mutant resting state
8QBJ	;	1.8	;	Structure of mBaoJin at pH 4.6
8Q79	;	1.45	;	Structure of mBaoJin at pH 6.5
8QDD	;	1.6	;	Structure of mBaoJin at pH 8.5
8YQ4	;	1.9	;	Structure of mBaoJin2
4EJY	;	2.0	;	Structure of MBOgg1 in complex with high affinity DNA ligand
4EJZ	;	3.05	;	Structure of MBOgg1 in complex with low affinity DNA ligand
5Y2G	;	3.0	;	Structure of MBP tagged GBS CAMP
8EL0	;	1.917	;	Structure of MBP-Mcl-1 in complex with a macrocyclic compound
8EL1	;	2.406	;	Structure of MBP-Mcl-1 in complex with ABBV-467
6QYN	;	2.5	;	Structure of MBP-Mcl-1 in complex with compound 10d
6QYO	;	2.1	;	Structure of MBP-Mcl-1 in complex with compound 18a
6YBJ	;	2.5	;	Structure of MBP-Mcl-1 in complex with compound 3e
6YBK	;	2.0	;	Structure of MBP-Mcl-1 in complex with compound 4d
6QXJ	;	1.7	;	Structure of MBP-Mcl-1 in complex with compound 6a
6QYK	;	2.3	;	Structure of MBP-Mcl-1 in complex with compound 7a
6QYL	;	2.2	;	Structure of MBP-Mcl-1 in complex with compound 8a
6QZ7	;	2.2	;	Structure of MBP-Mcl-1 in complex with compound 8b
6YBL	;	2.1	;	Structure of MBP-Mcl-1 in complex with compound 9m
8EKX	;	1.55	;	Structure of MBP-Mcl-1 in complex with MIK665
4WMT	;	2.35	;	STRUCTURE OF MBP-MCL1 BOUND TO ligand 1 AT 2.35A
4WMU	;	1.55	;	STRUCTURE OF MBP-MCL1 BOUND TO ligand 2 AT 1.55A
4WMV	;	2.4	;	STRUCTURE OF MBP-MCL1 BOUND TO ligand 4 AT 2.4A
5OJA	;	1.347	;	Structure of MbQ
5OJB	;	1.543	;	Structure of MbQ NMH
5OJC	;	1.25	;	Structure of MbQ2.1 NMH
3X27	;	2.481	;	Structure of McbB in complex with tryptophan
4IIX	;	1.229	;	Structure of MccF in complex with glutamyl sulfamoyl guanosine
4IIY	;	1.2	;	Structure of MccF in complex with glutamyl sulfamoyl inosine
3ILQ	;	2.05	;	Structure of mCD1d with bound glycolipid BbGL-2c from Borrelia burgdorferi
3ILP	;	1.85	;	Structure of mCD1d with bound glycolipid BbGL-2f from Borrelia burgdorferi
8FEF	;	2.71	;	Structure of Mce1 transporter from Mycobacterium smegmatis (Map0)
8FEE	;	2.9	;	Structure of Mce1 transporter from Mycobacterium smegmatis in the absence of LucB (Map2)
8FED	;	2.76	;	Structure of Mce1-LucB complex from Mycobacterium smegmatis (Map1)
7NB4	;	1.9	;	Structure of Mcl-1 complex with compound 1
7NB7	;	2.82	;	Structure of Mcl-1 complex with compound 6b
6QZ8	;	2.15	;	Structure of Mcl-1 in complex with compound 10d
6QYP	;	2.2	;	Structure of Mcl-1 in complex with compound 13
6YBG	;	2.1	;	Structure of Mcl-1 in complex with compound 2g
6QZ5	;	2.0	;	Structure of Mcl-1 in complex with compound 8a
6QZ6	;	1.9	;	Structure of Mcl-1 in complex with compound 8b
6QZB	;	2.0	;	Structure of Mcl-1 in complex with compound 8d
4WMR	;	1.7	;	STRUCTURE OF MCL1 BOUND TO BRD inhibitor ligand 1 AT 1.7A
4JBZ	;	2.4	;	Structure of Mcm10 coiled-coil region
7PT7	;	3.8	;	Structure of MCM2-7 DH complexed with Cdc7-Dbf4 in the presence of ADP:BeF3, state I
7PT6	;	3.2	;	Structure of MCM2-7 DH complexed with Cdc7-Dbf4 in the presence of ATPgS, state III
7VSR	;	4.5	;	Structure of McrBC (stalkless mutant)
6HZ5	;	4.2	;	Structure of McrBC without DNA binding domains (Class 1)
6HZ6	;	4.3	;	Structure of McrBC without DNA binding domains (Class 2)
6HZ7	;	4.3	;	Structure of McrBC without DNA binding domains (Class 3)
6HZ8	;	4.3	;	Structure of McrBC without DNA binding domains (Class 4)
6HZ9	;	4.8	;	Structure of McrBC without DNA binding domains (Class 5)
6HZ4	;	3.6	;	Structure of McrBC without DNA binding domains (one half of the full complex)
8JBR	;	2.5	;	Structure of McyA2-CAPCP
8HLK	;	2.7	;	Structure of McyB-C1A1 complexed with L-Leu and AMP
4R0M	;	2.45	;	Structure of McyG A-PCP complexed with phenylalanyl-adenylate
4ZFI	;	2.0	;	Structure of Mdm2 with low molecular weight inhibitor
5OAI	;	2.0	;	Structure of MDM2 with low molecular weight inhibitor
5J7F	;	2.0	;	Structure of MDM2 with low molecular weight inhibitor with aliphatic linker.
5J7G	;	1.85	;	Structure of MDM2 with low molecular weight inhibitor with aliphatic linker.
4ZGK	;	2.0	;	Structure of Mdm2 with low molecular weight inhibitor.
5MNJ	;	2.16	;	Structure of MDM2-MDMX-UbcH5B-ubiquitin complex
4PTA	;	2.6003	;	Structure of MDR initiator
5ZNZ	;	2.55	;	Structure of mDR3 DD with MBP tag mutant-I387V
5ZNY	;	2.74	;	Structure of mDR3_DD-C363G with MBP tag
3DNU	;	1.54	;	structure of MDT protein
3HZI	;	2.98	;	Structure of mdt protein
3PXI	;	6.926	;	Structure of MecA108:ClpC
2Y1R	;	2.595	;	Structure of MecA121 & ClpC N-domain complex
3PXG	;	3.654	;	Structure of MecA121 and ClpC1-485 complex
6MGW	;	3.5	;	Structure of mechanically activated ion channel OSCA1.2 in LMNG
6MGV	;	3.1	;	Structure of mechanically activated ion channel OSCA1.2 in nanodisc
8T56	;	2.8	;	Structure of mechanically activated ion channel OSCA1.2 in peptidiscs
8T57	;	2.7	;	Structure of mechanically activated ion channel OSCA2.3 in peptidiscs
7N5E	;	2.8	;	Structure of Mechanosensitive Ion Channel Flycatcher1 in GDN
7N5F	;	2.7	;	Structure of Mechanosensitive Ion Channel Flycatcher1 Protomer in 'Down' conformation in GDN
7N5G	;	2.4	;	Structure of Mechanosensitive Ion Channel Flycatcher1 Protomer in 'Up' conformation in GDN
5JW5	;	1.9	;	Structure of MEDI8852 Fab Fragment
5JW4	;	3.7	;	Structure of MEDI8852 Fab Fragment in Complex with H5 HA
5JW3	;	3.75	;	Structure of MEDI8852 Fab Fragment in Complex with H7 HA
5U3D	;	1.77	;	STRUCTURE OF MEDITOPE ENABLED TRASTUZUMAB I83E VARIANT
3KOV	;	2.9	;	Structure of MEF2A bound to DNA reveals a completely folded MADS-box/MEF2 domain that recognizes DNA and recruits transcription co-factors
2OPC	;	1.43	;	Structure of Melampsora lini avirulence protein, AvrL567-A
2QVT	;	2.26	;	Structure of Melampsora lini avirulence protein, AvrL567-D
1OA9	;	2.0	;	Structure of Melanocarpus albomyces endoglucanase
1OA7	;	2.0	;	Structure of Melanocarpus albomyces endoglucanase in complex with cellobiose
1I1J	;	1.39	;	STRUCTURE OF MELANOMA INHIBITORY ACTIVITY PROTEIN: A MEMBER OF A NEW FAMILY OF SECRETED PROTEINS
4D2P	;	2.55	;	Structure of MELK in complex with inhibitors
4D2T	;	2.7	;	Structure of MELK in complex with inhibitors
4D2V	;	2.45	;	Structure of MELK in complex with inhibitors
4D2W	;	1.92	;	Structure of MELK in complex with inhibitors
4UMP	;	2.3	;	Structure of MELK in complex with inhibitors
4UMQ	;	2.6	;	Structure of MELK in complex with inhibitors
4UMR	;	3.0	;	Structure of MELK in complex with inhibitors
4UMT	;	1.98	;	Structure of MELK in complex with inhibitors
4UMU	;	2.02	;	Structure of MELK in complex with inhibitors
4OEB	;	1.85	;	Structure of membrane binding protein pleurotolysin A from Pleurotus ostreatus
4OEJ	;	2.2	;	Structure of membrane binding protein pleurotolysin B from Pleurotus ostreatus
6QXA	;	3.41	;	Structure of membrane bound pyrophosphatase from Thermotoga maritima in complex with imidodiphosphate and N-[(2-amino-6-benzothiazolyl)methyl]-1H-indole-2-carboxamide (ATC)
5JSI	;	2.0	;	Structure of membrane protein
6K1H	;	3.52	;	Structure of membrane protein
6W8P	;	3.6	;	Structure of membrane protein with ions
7M8H	;	1.75	;	Structure of Memo1 C244S metal binding site mutant at 1.75A
2XMZ	;	1.94	;	Structure of MenH from S. aureus
6GOY	;	1.65	;	Structure of mEos4b in the green fluorescent state
6GOZ	;	2.406	;	Structure of mEos4b in the green long-lived dark state
6GP0	;	1.5	;	Structure of mEos4b in the red fluorescent state
6GP1	;	1.504	;	Structure of mEos4b in the red long-lived dark state
5X1Y	;	3.48	;	Structure of mercuric reductase from Lysinibacillus sphaericus
2H3O	;		;	Structure of MERFT, a membrane protein with two trans-membrane helices
4ZRJ	;	2.3	;	Structure of Merlin-FERM and CTD
7T40	;	1.7	;	Structure of MERS 3CL protease in complex with inhibitor 10c
7T41	;	2.1	;	Structure of MERS 3CL protease in complex with inhibitor 14c
7T3Y	;	1.9	;	Structure of MERS 3CL protease in complex with inhibitor 8c
7T3Z	;	1.95	;	Structure of MERS 3CL protease in complex with inhibitor 9c
7TQ7	;	1.7	;	Structure of MERS 3CL protease in complex with the cyclopropane based inhibitor 13c
7TQ8	;	1.65	;	Structure of MERS 3CL protease in complex with the cyclopropane based inhibitor 14d
8CZT	;	2.1	;	Structure of MERS 3CL protease in complex with the cyclopropane based inhibitor 15d
8CZU	;	2.7	;	Structure of MERS 3CL protease in complex with the cyclopropane based inhibitor 16d
8DGY	;	1.65	;	Structure of MERS 3CL protease in complex with the cyclopropane based inhibitor 16d (high resolution)
8CZV	;	1.95	;	Structure of MERS 3CL protease in complex with the cyclopropane based inhibitor 17d
4ZPT	;	2.591	;	Structure of MERS-Coronavirus Spike Receptor-binding Domain (England1 Strain) in Complex with Vaccine-Elicited Murine Neutralizing Antibody D12 (Crystal Form 1)
4ZPV	;	3.2	;	Structure of MERS-Coronavirus Spike Receptor-binding Domain (England1 Strain) in Complex with Vaccine-Elicited Murine Neutralizing Antibody D12 (Crystal Form 2)
5GMQ	;	2.703	;	Structure of MERS-CoV RBD in complex with a fully human antibody MCA1
2BSZ	;	2.0	;	Structure of Mesorhizobium loti arylamine N-acetyltransferase 1
3DKC	;	1.52	;	Structure of MET receptor tyrosine kinase in complex with ATP
3DKF	;	1.8	;	Structure of MET receptor tyrosine kinase in complex with inhibitor SGX-523
6G7D	;	1.35	;	Structure of MeT1 from Mycobacterium hassiacum in complex with SAM and glycerol.
1PXS	;	2.2	;	Structure of Met56Ala mutant of Bacteriorhodopsin
5VTL	;	1.8231	;	Structure of metacyclic invariant surface protein , Tb427.07.360, from Trypanosoma brucei.
8B3W	;	1.681	;	Structure of metacyclic VSG (mVSG) 1954 from Trypanosoma brucei
8B3B	;	1.949	;	Structure of metacyclic VSG (mVSG) 531 from Trypanosoma brucei
5CW6	;	3.193	;	Structure of metal dependent enzyme DrBRCC36
2WKO	;	1.97	;	Structure of metal loaded Pathogenic SOD1 Mutant G93A.
2O6F	;	1.63	;	Structure of metal- free rTp34 from Treponema pallidum
4HX8	;	2.001	;	Structure of metal-free MNTR mutant E11K
4UDN	;	2.21	;	structure of metal-free periplasmic metal binding protein from candidatus liberibacter asiaticus
6RPN	;	1.409	;	Structure of metallo beta lactamase VIM-2 with cyclic boronate APC308.
7L91	;	2.2	;	Structure of Metallo Beta-Lactamase L1 in a Complex with Hydrolyzed Moxalactam Determined by Pink-Beam Serial Crystallography
4TZF	;	1.22	;	Structure of metallo-beta lactamase
4TZ9	;	2.1269	;	Structure of Metallo-beta-lactamase
4TZE	;	1.574	;	Structure of metallo-beta-lactamase
2RT8	;		;	Structure of metallo-dna in solution
6UUG	;	1.685	;	Structure of methanesulfinate monooxygenase MsuC from Pseudomonas fluorescens at 1.69 angstrom resolution
6U76	;	2.1	;	Structure of methanesulfinate monooxygenase MsuC from Pseudomonas fluorescens.
3T7Z	;	1.7	;	Structure of Methanocaldococcus jannaschii Nop N-terminal domain
3EZX	;	2.56	;	Structure of Methanosarcina barkeri monomethylamine corrinoid protein
4WNR	;	2.9	;	Structure of methanosarcina barkeri Roco2 RocCORdC bound to GDP
1MWU	;	2.6	;	Structure of methicillin acyl-Penicillin binding protein 2a from methicillin resistant Staphylococcus aureus strain 27r at 2.60 A resolution.
4QRE	;	1.7	;	Structure of Methionyl-tRNA Synthetase in complex with 1-(4-{4-[(1H-benzimidazol-2-ylmethyl)amino]-6-(4,5-dimethoxy-2-methylphenoxy)pyrimidin-2-yl}piperazin-1-yl)ethanone
4QRD	;	1.97	;	Structure of Methionyl-tRNA Synthetase in complex with N-(1H-benzimidazol-2-ylmethyl)-N'-(2,4-dichlorophenyl)-6-(morpholin-4-yl)-1,3,5-triazine-2,4-diamine
3H9C	;	1.4	;	Structure of methionyl-tRNA synthetase: crystal form 2
8OQ3	;	2.9	;	Structure of methylamine treated human complement C3
4UE6	;	2.3	;	Structure of methylene blue-treated anaerobically purified D. fructosovorans NiFe-hydrogenase
1LU9	;	1.9	;	Structure of methylene-tetrahydromethanopterin dehydrogenase from Methylobacterium extorquens AM1
1LUA	;	1.9	;	Structure of methylene-tetrahydromethanopterin dehydrogenase from Methylobacterium extorquens AM1 complexed with NADP
6TM3	;	1.08	;	Structure of methylene-tetrahydromethanopterin dehydrogenase from Methylorubrum extorquens AM1 in a close conformation containing NADP+ and methylene-H4MPT
6TLK	;	1.8	;	Structure of methylene-tetrahydromethanopterin dehydrogenase from Methylorubrum extorquens AM1 in an open conformation containing NADP+ and methylene-H4MPT
1EGH	;	2.0	;	STRUCTURE OF METHYLGLYOXAL SYNTHASE COMPLEXED WITH THE COMPETITIVE INHIBITOR 2-PHOSPHOGLYCOLATE
5H3L	;	2.1	;	Structure of methylglyoxal synthase crystallised as a contaminant
6DCB	;	1.998	;	Structure of methylphosphate capping enzyme methyltransferase domain in complex with 5' end of 7SK RNA
6DCC	;	2.1	;	Structure of methylphosphate capping enzyme methyltransferase domain in complex with 5' end of 7SK RNA
8GMY	;	1.7	;	Structure of methyltransferase
8GMZ	;	1.88	;	Structure of methyltransferase
7R7O	;	1.58	;	Structure of methyltransferase domain of Spb1 boudn to SAM
4UD6	;	2.12	;	Structure of methylviologen-treated anaerobically purified D. fructosovorans NiFe-hydrogenase
7RX6	;	1.8	;	Structure of METTL3-METTL14(R298C) mutant methyltransferase complex
7RX8	;	1.85	;	Structure of METTL3-METTL14(R298H) mutant methyltransferase complex
7RX7	;	1.645	;	Structure of METTL3-METTL14(R298P) mutant methyltransferase complex
7F1E	;	2.589	;	Structure of METTL6 bound with SAM
2GS8	;	1.5	;	Structure of mevalonate pyrophosphate decarboxylase from Streptococcus pyogenes
4WWU	;	3.301	;	Structure of Mex67:Mtr2
6XEO	;	5.5	;	Structure of Mfd bound to dsDNA
6M9W	;	1.5	;	Structure of Mg-free KRAS4b (2-169) bound to GDP with the switch-I in fully open conformation
3UCW	;	1.76	;	Structure of MG2+ bound N-Terminal domain of Calmodulin
3UCY	;	1.8	;	Structure of Mg2+ bound N-terminal domain of calmodulin in the presence of Zn2+
6B7H	;	2.82	;	Structure of mGluR3 with an agonist
3L6F	;	2.1	;	Structure of MHC class II molecule HLA-DR1 complexed with phosphopeptide MART-1
4GUP	;	3.2	;	Structure of MHC-class I related molecule MR1
8BP6	;	2.8	;	Structure of MHC-class I related molecule MR1 with bound M3Ade
6QZ1	;	1.7	;	Structure of MHETase from Ideonella sakaiensis
6QZ2	;	1.9	;	Structure of MHETase from Ideonella sakaiensis
6QZ3	;	1.6	;	Structure of MHETase from Ideonella sakaiensis
6QZ4	;	1.8	;	Structure of MHETase from Ideonella sakaiensis
2JLN	;	2.85	;	Structure of Mhp1, a nucleobase-cation-symport-1 family transporter
4D1D	;	3.7	;	STRUCTURE OF MHP1, A NUCLEOBASE-CATION-SYMPORT-1 FAMILY TRANSPORTER with the inhibitor 5-(2-naphthylmethyl)-L-hydantoin.
4D1B	;	3.8	;	STRUCTURE OF MHP1, A NUCLEOBASE-CATION-SYMPORT-1 FAMILY TRANSPORTER, IN A CLOSED CONFORMATION WITH BENZYL-HYDANTOIN
4D1C	;	3.7	;	STRUCTURE OF MHP1, A NUCLEOBASE-CATION-SYMPORT-1 FAMILY TRANSPORTER, IN A CLOSED CONFORMATION WITH bromovinylhydantoin bound.
4D1A	;	3.4	;	STRUCTURE OF MHP1, A NUCLEOBASE-CATION-SYMPORT-1 FAMILY TRANSPORTER, IN A CLOSED CONFORMATION WITH INDOLYLMETHYL-HYDANTOIN
4H2R	;	2.473	;	Structure of MHPCO Y270F mutant, 5-hydroxynicotinic acid complex
4H2Q	;	1.502	;	structure of MHPCO-5HN complex
1N9H	;	1.8	;	structure of microgravity-grown oxidized myoglobin mutant YQR (ISS6A)
1N9X	;	1.6	;	structure of microgravity-grown oxidized myoglobin mutant YQR (ISS8A)
1NAZ	;	1.04	;	structure of microgravity-grown oxidized myoglobin mutant YQR (ISS8A)
2H8A	;	3.2	;	Structure of Microsomal Glutathione Transferase 1 in Complex with Glutathione
2O1T	;	3.2	;	Structure of Middle plus C-terminal domains (M+C) of GRP94
3GAC	;	2.1	;	Structure of mif with HPP
4JEL	;	1.952	;	Structure of MilB Streptomyces rimofaciens CMP N-glycosidase
3G2X	;	2.7	;	Structure of mimivirus NDK +Kpn - N62L double mutant complexed with dTDP
3ISE	;	2.8	;	Structure of mineralized Bfrb (double soak) from Pseudomonas aeruginosa to 2.8A Resolution
3IS7	;	2.1	;	Structure of mineralized Bfrb from Pseudomonas aeruginosa to 2.1A Resolution
3IS8	;	2.25	;	Structure of mineralized Bfrb soaked with FeSO4 from Pseudomonas aeruginosa to 2.25A Resolution
5OGA	;		;	Structure of minimal i-motif domain
6FQ2	;	2.31	;	Structure of minimal sequence for left -handed G-quadruplex formation
7QF2	;	1.07	;	Structure of miniSOG reconstituted with riboflavin as a cofactor
1INQ	;	2.2	;	Structure of Minor Histocompatibility Antigen peptide, H13a, complexed to H2-Db
1JUF	;	2.0	;	Structure of Minor Histocompatibility Antigen peptide, H13b, complexed to H2-Db
5DVW	;	1.75	;	Structure of minor nucleoprotein V30 from Zaire ebolavirus
5D77	;	1.3	;	Structure of Mip6 RRM3 Domain
1N1N	;		;	Structure of Mispairing of the Deoxycytosine with Deoxyadenosine 5' to the 8,9-Dihydro-8-(N7-guanyl)-9-Hydroxy-Aflatoxin B1 Adduct
5LY9	;	1.65	;	Structure of MITat 1.1
1OKC	;	2.2	;	structure of mitochondrial ADP/ATP carrier in complex with carboxyatractyloside
7TZ6	;	2.88	;	Structure of mitochondrial bc1 in complex with ck-2-68
2C9H	;	1.8	;	Structure of mitochondrial beta-ketoacyl synthase
6IG2	;	2.882	;	Structure of mitochondrial CDP-DAG synthase Tam41 complexed with CTP, delta 74, F240A
6IG4	;	2.261	;	Structure of mitochondrial CDP-DAG synthase Tam41, delta 74
8ESW	;	3.3	;	Structure of mitochondrial complex I from Drosophila melanogaster, Flexible-class 1
8ESZ	;	3.4	;	Structure of mitochondrial complex I from Drosophila melanogaster, Helix-locked state
4IYN	;	2.312	;	Structure of mitochondrial Hsp90 (TRAP1) with ADP-ALF4-
4J0B	;	2.352	;	Structure of mitochondrial Hsp90 (TRAP1) with ADP-BeF3
4BOC	;	2.65	;	Structure of mitochondrial RNA polymerase elongation complex
5OLA	;	3.904	;	Structure of mitochondrial transcription elongation complex in complex with elongation factor TEFM
2CLQ	;	2.3	;	Structure of mitogen-activated protein kinase kinase kinase 5
7NFD	;	3.51	;	Structure of mitoxantrone-bound ABCG2
4C3K	;	3.099	;	Structure of mixed PII-ADP complexes from S. elongatus
2XWY	;	2.53	;	Structure of MK-3281, a Potent Non-Nucleoside Finger-Loop Inhibitor, in complex with the Hepatitis C Virus NS5B Polymerase
2PZY	;	2.9	;	Structure of MK2 Complexed with Compound 76
8IYH	;	3.3	;	Structure of MK6892-GPR109A-G-protein complex
8TEB	;	2.2	;	Structure of MKbur
6YIP	;	1.43	;	Structure of MKLP2 coiled coil
8TFO	;	2.0	;	Structure of MKvar
5AOR	;	2.08	;	Structure of MLE RNA ADP AlF4 complex
4UY9	;	2.81	;	Structure of MLK1 kinase domain with leucine zipper 1
4UYA	;	2.8	;	Structure of MLK4 kinase domain with ATPgammaS
4BTF	;	2.604	;	Structure of MLKL
8JHN	;	3.75	;	Structure of MMF-GPR109A-G protein complex
7YEW	;	2.5	;	Structure of MmIGF2BP3 in complex with 7-mer RNA
7YEX	;	2.0	;	Structure of MmIGF2BP3 in complex with 8-mer RNA
7YEY	;	1.85	;	Structure of MmIGF2BP3-KH12 in complex with 8-mer RNA
4JA1	;	1.96	;	Structure of MMP3 complexed with a platinum-based inhibitor
4DPE	;	1.96	;	Structure of MMP3 complexed with a platinum-based inhibitor.
4G9L	;	1.88	;	Structure of MMP3 complexed with NNGH inhibitor.
6IHK	;	2.23	;	Structure of MMPA CoA ligase in complex with ADP
6IJC	;	2.3	;	Structure of MMPA-CoA dehydrogenase from Roseovarius nubinhibens ISM
7N6B	;	2.66	;	Structure of MmpL3 reconstituted into lipid nanodisc in the TMM bound state
5F13	;	2.393	;	Structure of Mn bound DUF89 from Saccharomyces cerevisiae
1XMF	;	2.32	;	Structure of Mn(II)-Soaked Apo Methane Monooxygenase Hydroxylase Crystals from M. capsulatus (Bath)
4UDO	;	2.22	;	structure of Mn-bound periplasmic metal binding protein from candidatus liberibacter asiaticus
7QPS	;	2.79	;	Structure of Mn-free SpoT
3OJN	;	1.65	;	Structure of Mn-substituted Homoprotocatechuate 2,3-Dioxygenase at 1.65 Ang resolution
3BZA	;	1.7	;	Structure of Mn-substituted Homoprotocatechuate 2,3-Dioxygenase from B.fuscum at 1.7 Ang resolution
3UCT	;	1.9	;	Structure of Mn2+-bound N-terminal domain of calmodulin in the presence of Zn2+
5WVD	;	3.0	;	Structure of Mnk1 in complex with DS12881479
3UJP	;	2.7	;	Structure of MntC protein at 2.7A
4HX7	;	1.9	;	Structure of MNTR E11K mutant complexed with Cd2+
4HV6	;	2.3	;	Structure of MNTR H77A mutant in apo- and mn-bound forms
4HX4	;	1.65	;	Structure of MNTR mutant E11K complexed with Mn2+
2FB3	;	2.349	;	Structure of MoaA in complex with 5'-GTP
1TV8	;	2.2	;	Structure of MoaA in complex with S-adenosylmethionine
2IZ7	;	2.32	;	structure of Moco Carrier Protein from Chlamydomonas reinhardtii
7DSU	;	3.2	;	Structure of Mod subunit of the Type III restriction-modification enzyme Mbo45V
1DR8	;	2.7	;	STRUCTURE OF MODIFIED 3-ISOPROPYLMALATE DEHYDROGENASE AT THE C-TERMINUS, HD177
1DR0	;	2.2	;	STRUCTURE OF MODIFIED 3-ISOPROPYLMALATE DEHYDROGENASE AT THE C-TERMINUS, HD708
1DPZ	;	2.8	;	STRUCTURE OF MODIFIED 3-ISOPROPYLMALATE DEHYDROGENASE AT THE C-TERMINUS, HD711
4A4B	;	2.789	;	Structure of modified phosphoTyr371-c-Cbl-UbcH5B-ZAP-70 complex
4QAW	;	2.4	;	Structure of modular Xyn30D from Paenibacillus barcinonensis
2M05	;		;	Structure of module 2 from the E1 domain of C. elegans APL-1
5GWW	;	2.3	;	Structure of MoeN5-Sso7d fusion protein in complex with a permethylated substrate analogue
5GWV	;	2.4	;	Structure of MoeN5-Sso7d fusion protein in complex with a substrate analogue
5B0K	;	2.75	;	Structure of MoeN5-Sso7d fusion protein in complex with beta-decyl maltoside
5B0M	;	3.05	;	Structure of MoeN5-Sso7d fusion protein in complex with beta-dodecyl maltoside
5B0L	;	2.8	;	Structure of MoeN5-Sso7d fusion protein in complex with beta-nonyl glucoside
5B0I	;	2.26	;	Structure of MoeN5-Sso7d fusion protein in complex with beta-octyl glucoside
5B0J	;	2.5	;	Structure of MoeN5-Sso7d fusion protein in complex with beta-undecyl maltoside
5B03	;	2.6	;	Structure of MoeN5-Sso7d fusion protein in complex with geranyl pyrophosphate
6J8W	;	2.35	;	Structure of MOEN5-SSO7D fusion protein in complex with lig 1
6J8V	;	2.23	;	Structure of MOEN5-SSO7D fusion protein in complex with ligand 2
5NOP	;	1.94	;	Structure of Mojiang virus attachment glycoprotein
6AOM	;	2.87	;	Structure of molecular chaperone Grp94 bound to selective inhibitor methyl 2-[2-(2-benzylphenyl)ethyl]-3-chloro-4,6-dihydroxybenzoate
6AOL	;	2.764	;	Structure of molecular chaperone Grp94 bound to selective inhibitor methyl 3-chloro-2-(2-{2-[(4-fluorophenyl)methyl]phenyl}ethyl)-4,6-dihydroxybenzoate
7EVA	;	2.083	;	Structure of molecular chaperone SycE of Yersinia enterocolitica
1MN8	;	1.0	;	Structure of Moloney Murine Leukaemia Virus Matrix Protein
8WPE	;	2.7	;	Structure of monkeypox virus polymerase complex F8-A22-E4-H5 (tag-free A22) with exogenous DNA
8WPP	;	3.1	;	Structure of monkeypox virus polymerase complex F8-A22-E4-H5 with endogenous DNA
8WPK	;	2.7	;	Structure of monkeypox virus polymerase complex F8-A22-E4-H5 with exgenous DNA
8WPF	;	3.0	;	Structure of monkeypox virus polymerase complex F8-A22-E4-H5 with exogenous DNA bearing one abasic site
5GRU	;	1.955	;	Structure of mono-specific diabody
6VAF	;	3.9	;	Structure of mono-ubiquitinated FANCD2 bound to non-ubiquitinated FANCI and to DNA
3TBL	;	2.903	;	Structure of Mono-ubiquitinated PCNA: Implications for DNA Polymerase Switching and Okazaki Fragment Maturation
5LRN	;	1.55	;	Structure of mono-zinc MCR-1 in P21 space group
7JW7	;	2.63	;	Structure of monobody 27 human MLKL pseudokinase domain complex
7JXU	;	2.44	;	Structure of monobody 32 human MLKL pseudokinase domain complex
6UX8	;	2.5	;	Structure of monobody 33 MLKL N-terminal domain complex
5A3Z	;	1.59	;	Structure of monoclinic Lysozyme obtained by multi crystal data collection
1PPN	;	1.6	;	STRUCTURE OF MONOCLINIC PAPAIN AT 1.60 ANGSTROMS RESOLUTION
4RLR	;	2.002	;	Structure of monoheme cytochrome PccH from Geobacter sulfurreducens
7T1E	;	1.459	;	Structure of monomeric and dimeric human CCL20
3MBT	;	2.6	;	Structure of monomeric Blc from E. coli
7ELC	;	3.1	;	Structure of monomeric complex of MACV L bound to Z and 3'-vRNA
8S9L	;	1.85	;	Structure of monomeric FAM111A SPD V347D Mutant
5WDZ	;		;	Structure of monomeric Interleukin-8 (1-66)
8E04	;	3.8	;	Structure of monomeric LRRK1
5XP1	;	2.88	;	Structure of monomeric mutant of REI immunoglobulin light chain variable domain crystallized at pH 6
5XQY	;	2.9	;	Structure of monomeric mutant of REI immunoglobulin light chain variable domain crystallized at pH 8
2B0T	;	1.75	;	Structure of Monomeric NADP Isocitrate dehydrogenase
4FBS	;	1.7	;	Structure of monomeric NT from Euprosthenops australis Major Ampullate Spidroin 1 (MaSp1)
7EDA	;	2.78	;	Structure of monomeric photosystem II
4CSD	;	1.35	;	Structure of Monomeric Ralstonia solanacearum lectin
6TNF	;	3.8	;	Structure of monoubiquitinated FANCD2 in complex with FANCI and DNA
6VM5	;	2.35	;	Structure of Moraxella osloensis Cap4 SAVED/CARF-domain containing receptor
2R14	;	1.4	;	Structure of morphinone reductase in complex with tetrahydroNAD
3GX9	;	2.28	;	Structure of morphinone reductase N189A mutant in complex with tetrahydroNAD
6PMT	;	2.3	;	Structure of Mortalin-NBD with adenosine-5'-monophosphate and thiodiphosphate
6P2U	;	2.0	;	Structure of Mortalin-NBD with N6-propargyladenosine-5'-diphosphate
4MDB	;	1.7	;	Structure of Mos1 transposase catalytic domain and Raltegravir with Mg
4MDA	;	1.7	;	Structure of Mos1 transposase catalytic domain and Raltegravir with Mn
2VC6	;	1.95	;	Structure of MosA from S. meliloti with pyruvate bound
6K5P	;	1.805	;	Structure of mosquito-larvicidal Binary toxin receptor, Cqm1
6T19	;	1.85	;	Structure of mosquitocidal Cyt1A protoxin obtained by Serial Femtosecond Crystallography on in vivo grown crystals soaked with DTT at pH 7
6T1A	;	1.85	;	Structure of mosquitocidal Cyt1Aa protoxin obtained by Serial Femtosecond Crystallography on in vivo grown crystals at pH 10
7ZM5	;	1.62	;	Structure of Mossman virus receptor binding protein
4LGZ	;	1.675	;	Structure of mouse 1-Pyrroline-5-Carboxylate Dehydrogenase (ALDH4A1) complexed with acetate
4LH3	;	1.813	;	Structure of mouse 1-Pyrroline-5-Carboxylate Dehydrogenase (ALDH4A1) complexed with glutarate
4LH0	;	1.674	;	Structure of mouse 1-Pyrroline-5-Carboxylate Dehydrogenase (ALDH4A1) complexed with glyoxylate
4LH1	;	1.673	;	Structure of mouse 1-Pyrroline-5-Carboxylate Dehydrogenase (ALDH4A1) complexed with malonate
4LH2	;	1.673	;	Structure of mouse 1-Pyrroline-5-Carboxylate Dehydrogenase (ALDH4A1) complexed with succinate
2VOH	;	1.9	;	Structure of mouse A1 bound to the Bak BH3-domain
2VOI	;	2.1	;	Structure of mouse A1 bound to the Bid BH3-domain
2VOG	;	1.9	;	Structure of mouse A1 bound to the Bmf BH3-domain
2VOF	;	1.8	;	Structure of mouse A1 bound to the Puma BH3-domain
4A16	;	2.65	;	Structure of mouse Acetylcholinesterase complex with Huprine derivative
4BC0	;	3.35	;	Structure of mouse acetylcholinesterase inhibited by CBDP (12-h soak) : Cresyl-phosphoserine adduct
4BC1	;	2.95	;	Structure of mouse acetylcholinesterase inhibited by CBDP (30-min soak): cresyl-saligenin-phosphoserine adduct
5I91	;	1.76	;	Structure of Mouse Acirecutone dioxygenase with to Ni2+ and 2-keto-4-(methylthio)-butyric acid in the active site
5I8Y	;	1.942	;	Structure of Mouse Acireductone Dioxygenase bound to Co2+ and 2-keto-4-(methylthio)-butyric acid
5I93	;	2.236	;	Structure of Mouse Acireductone dioxygenase with Ni2+ and 2-ketopentanoic acid in the active site
5I8T	;	1.751	;	Structure of Mouse Acireductone dioxygenase with Ni2+ ion and D-lactic acid in the active site
5I8S	;	1.89	;	Structure of Mouse Acireductone dioxygenase with Ni2+ ion and pentanoic acid in the active site
5CCF	;	2.1	;	Structure of Mouse ADP-Dependent Glucokinase
7AZN	;	2.09	;	Structure of mouse AsterC (GramD1c) with a new cholesterol-derived compound
2Z8H	;	2.5	;	Structure of mouse Bach1 BTB domain
7R86	;	1.65	;	Structure of mouse BAI1 (ADGRB1) in complex with mouse Nogo receptor (RTN4R)
7R85	;	1.45	;	Structure of mouse Bai1 (ADGRB1) TSR3 domain
7R84	;	1.336	;	Structure of mouse BAI1 (ADGRB1) TSR3 domain in P21 space group
3BOD	;	1.7	;	Structure of mouse beta-neurexin 1
3BOP	;	3.0	;	Structure of mouse beta-neurexin 2D4
1DDB	;		;	STRUCTURE OF MOUSE BID, NMR, 20 STRUCTURES
3GMQ	;	1.8	;	Structure of mouse CD1d expressed in SF9 cells, no ligand added
3GMN	;	1.7	;	Structure of mouse CD1d in complex with C10Ph
3GML	;	1.7	;	Structure of mouse CD1d in complex with C6Ph
3GMM	;	1.8	;	Structure of mouse CD1d in complex with C8Ph
3GMR	;	1.9	;	Structure of mouse CD1d in complex with C8Ph, different space group
3GMO	;	1.6	;	Structure of mouse CD1d in complex with C8PhF
4MX7	;	2.24	;	Structure of mouse CD1d in complex with dioleoyl-phosphatidic acid
3GMP	;	1.7	;	Structure of mouse CD1d in complex with PBS-25
5TW2	;	1.75	;	Structure of mouse CD1d with bound alpha-galactosylsphingamide JG168
5TW5	;	1.85	;	Structure of mouse CD1d with bound glycosphingolipid JJ112
6OMG	;	2.1	;	Structure of mouse CD1D- Glc-DAG (sn-1 C18:0, sn-2 C18:1c9)-iNKT TCR Ternary complex
4LEY	;	2.5	;	Structure of mouse cGAS bound to 18 bp DNA
4LEZ	;	2.36	;	Structure of mouse cGAS bound to an 18bp DNA and cGAS product
4ZI9	;	1.7	;	Structure of mouse clustered PcdhgA1 EC1-3
4ZI8	;	1.698	;	Structure of mouse clustered PcdhgC3 EC1-3
6KIT	;	1.57	;	Structure of mouse CXorf40A, Selenomethionine derivative
7UCW	;	1.35	;	Structure of mouse Decr1 in complex with 2'-5' oligoadenylate
4PMW	;	2.95	;	Structure of mouse Dis3L2 in complex with oligoU RNA substrate
8E11	;	1.8	;	Structure of mouse DNA polymerase Beta (PolB) mutant
4DA4	;	2.6	;	Structure of mouse DNMT1 (731-1602) bound to hemimethylated CpG DNA
5AOY	;	1.75	;	Structure of mouse Endonuclease V
4CCC	;	2.09	;	STRUCTURE OF MOUSE GALACTOCEREBROSIDASE WITH 4NBDG: ENZYME-SUBSTRATE COMPLEX
4CCD	;	1.97	;	STRUCTURE OF MOUSE GALACTOCEREBROSIDASE WITH D-GALACTAL: ENZYME- INTERMEDIATE COMPLEX
4CCE	;	2.06	;	STRUCTURE OF MOUSE GALACTOCEREBROSIDASE WITH GALACTOSE: ENZYME- PRODUCT COMPLEX
7CXB	;	1.46	;	Structure of mouse Galectin-3 CRD in complex with TD-139 belonging to P6522 space group.
7CXC	;	1.4	;	Structure of mouse Galectin-3 CRD point mutant (V160A) in complex with TD-139 belonging to P121 space group.
2V2U	;	1.9	;	Structure of Mouse gammaC-crystallin
6NWX	;	2.0	;	Structure of mouse GILT, an enzyme involved in antigen processing
6LBJ	;	2.70444	;	Structure of mouse GLD-2 (Terminal nucleotidyltransferase 2, TENT2)
5KKB	;	1.774	;	Structure of mouse Golgi alpha-1,2-mannosidase IA and Man9GlcNAc2-PA complex
1NXC	;	1.51	;	Structure of mouse Golgi alpha-1,2-mannosidase IA reveals the molecular basis for substrate specificity among Class I enzymes (family 47 glycosidases)
3WNW	;	2.24	;	Structure of Mouse H-chain modified ferritin
8PVC	;	2.6	;	Structure of mouse heavy-chain apoferritin determined by cryoEM at 100 keV
4YI0	;	1.806	;	Structure of mouse importin a1 bound to Pom121NLS
6WBB	;	2.663	;	Structure of Mouse Importin alpha - MLH1-E475A NLS peptide complex
6P6A	;	2.151	;	Structure of Mouse Importin alpha - NIT2 NLS peptide complex
6P6E	;	1.99	;	Structure of Mouse Importin alpha - PAC3 NLS peptide complex
6WBA	;	2.151	;	Structure of Mouse Importin alpha MLH1- R470A NLS Peptide Complex
7M60	;	2.3	;	Structure of Mouse Importin alpha MLH1-S467A NLS Peptide Complex
7TMX	;	2.3	;	Structure of Mouse Importin alpha NEIL1 NLS Peptide Complex
7TMY	;	2.21	;	Structure of Mouse Importin alpha NEIL3 NLS Peptide Complex
6WBC	;	2.15	;	Structure of Mouse Importin alpha- MLH1-R472K NLS Peptide Complex
4AS5	;	2.43	;	Structure of mouse inositol monophosphatase 1
4EXP	;	2.8	;	Structure of mouse Interleukin-34 in complex with mouse FMS
6P2D	;	1.794	;	Structure of mouse ketohexokinase-C in complex with fructose and ADP
8HPX	;	3.68	;	Structure of mouse LGI1 LRR domain in space group P65
8T03	;	2.72	;	Structure of mouse Myomaker bound to Fab18G7 in detergent
8T04	;	2.98	;	Structure of mouse Myomaker bound to Fab18G7 in nanodiscs
8T06	;	3.32	;	Structure of mouse Myomaker mutant-R107A bound to Fab18G7
8T07	;	3.38	;	Structure of mouse Myomaker mutant-Y118A bound to Fab18G7
4DOW	;	1.95	;	Structure of mouse ORC1 BAH domain bound to H4K20me2
4LSG	;	3.8	;	Structure of Mouse P-Glycoprotein
8E10	;	1.65	;	Structure of mouse polymerase beta
6M7K	;	1.1	;	Structure of mouse RECON (AKR1C13) in complex with cyclic AMP-AMP-GMP (cAAG)
6BZH	;	2.5	;	Structure of mouse RIG-I tandem CARDs
8VJJ	;	2.53	;	Structure of mouse RyR1 (EGTA-only dataset)
8VJK	;	2.92	;	Structure of mouse RyR1 (high-Ca2+/CFF/ATP dataset)
8VK3	;	3.21	;	Structure of mouse RyR1 in complex with S100A1 (EGTA-only dataset)
8VK4	;	3.56	;	Structure of mouse RyR1 in complex with S100A1 (high-Ca2+/CFF/ATP dataset)
8H95	;	3.38	;	Structure of mouse SCMC bound with full-length FILIA
8H94	;	2.9	;	Structure of mouse SCMC bound with KH domain of FILIA
8H96	;	2.78	;	Structure of mouse SCMC core complex
6DD9	;	2.3	;	Structure of mouse SYCP3, P1 form
6DD8	;	2.6	;	Structure of mouse SYCP3, P21 form
2X3X	;	3.35	;	structure of mouse syndapin I (crystal form 1)
2X3W	;	2.64	;	structure of mouse syndapin I (crystal form 2)
6W10	;	1.80003	;	Structure of mouse TREX1 with E198K disease-associated mutation
6A45	;	1.904	;	Structure of mouse TREX2
4E1Z	;	2.5	;	Structure of mouse Tyk-2 complexed to a 3-aminoindazole inhibitor
4E20	;	2.6	;	Structure of mouse Tyk-2 complexed to a 3-aminoindazole inhibitor
3TN0	;	3.2	;	Structure of mouse Va14Vb8.2NKT TCR-mouse CD1d-a-C-Galactosylceramide complex
5TKK	;	1.55	;	Structure of mouse vaccination-elicited HIV neutralizing antibody vFP5.01 in complex with HIV-1 fusion peptide residue 512-519
3TO4	;	3.1	;	Structure of mouse Valpha14Vbeta2-mouseCD1d-alpha-Galactosylceramide
4P2A	;	2.7	;	Structure of mouse VPS26A bound to rat SNX27 PDZ domain
2E6M	;	2.0	;	structure of mouse werner exonuclease domain
6ENS	;	1.3	;	Structure of mouse wild-type RKIP
2E6L	;	2.2	;	structure of mouse WRN exonuclease domain
4AJV	;	2.7	;	Structure of mouse ZP-C domain of TGF-Beta-Receptor-3
2LN0	;		;	Structure of MOZ
6JBP	;	2.217	;	Structure of MP-4 from Mucuna pruriens at 2.22 Angstroms
8C9K	;	1.72	;	Structure of Mpox virus poxin
8GQT	;	2.09	;	Structure of Mpro complexed with Quercetin
8BGD	;	1.621	;	Structure of Mpro from SARS-CoV-2 in complex with FGA147
8BGA	;	1.982	;	Structure of Mpro in complex with FGA146
6Q4W	;	1.55	;	Structure of MPT-1, a GDP-Man-dependent mannosyltransferase from Leishmania mexicana
6Q4X	;	1.55	;	Structure of MPT-2, a GDP-Man-dependent mannosyltransferase from Leishmania mexicana
6Q4Y	;	1.7	;	Structure of MPT-2, a GDP-Man-dependent mannosyltransferase from Leishmania mexicana, in complex with mannose
6Q50	;	1.6	;	Structure of MPT-4, a mannose phosphorylase from Leishmania mexicana, in complex with phosphate ion
5D7K	;	1.9	;	Structure of MR1-reactive MAV36 TCR
4YIX	;	2.6	;	Structure of MRB1590 bound to ADP
4YIY	;	3.016	;	Structure of MRB1590 bound to AMP-PNP
7E1C	;	1.9	;	Structure of MreB3 from Spiroplasma eriocheiris
7E1G	;	1.75	;	Structure of MreB3 from Spiroplasma eriocheiris
1CKO	;	3.1	;	STRUCTURE OF MRNA CAPPING ENZYME IN COMPLEX WITH THE CAP ANALOG GPPPG
4L8R	;	2.6	;	Structure of mrna stem-loop, human stem-loop binding protein and 3'hexo ternary complex
7D3U	;	3.0	;	Structure of Mrp complex from Dietzia sp. DQ12-45-1b
7REF	;	2.1	;	Structure of MS3494 from Mycobacterium smegmatis
8DZD	;	1.901	;	Structure of MS3494 from Mycobacterium smegmatis bound to sucrose
7S0N	;		;	Structure of MS3494 from Mycobacterium Smegmatis determined by Solution NMR
7BCW	;	3.5	;	Structure of MsbA in Salipro with ADP vanadate
4DEZ	;	2.6	;	Structure of MsDpo4
5HTL	;	1.371	;	Structure of MshE with cdg
3HCI	;	2.59	;	Structure of MsrB from Xanthomonas campestris (complex-like form)
3HCJ	;	1.66	;	Structure of MsrB from Xanthomonas campestris (oxidized form)
3SQX	;	2.112	;	Structure of Mss116p (NTE and C-tail double deletion) bound to ssRNA and AMP-PNP
3SQW	;	1.909	;	Structure of Mss116p (NTE deletion) bound to ssRNA and AMP-PNP
3I62	;	1.95	;	Structure of Mss116p bound to ssRNA and ADP-Aluminum Fluoride
3I61	;	2.1	;	Structure of Mss116p bound to ssRNA and ADP-Beryllium Fluoride
3I5X	;	1.9	;	Structure of Mss116p bound to ssRNA and AMP-PNP
3I5Y	;	2.49	;	Structure of Mss116p bound to ssRNA containing a single 5-BrU and AMP-PNP
4W8E	;	1.79	;	Structure of MST3 with a pyrrolopyrimidine inhibitor (PF-06645342)
1MP2	;	2.3	;	Structure of MT-ADPRase (Apoenzyme), a Nudix hydrolase from Mycobacterium tuberculosis
1KJN	;	2.2	;	Structure of MT0777
3Q80	;	2.0	;	Structure of Mtb 2-C-methyl-D-erythritol 4-phosphate cytidyltransferase (IspD) Complexed with CDP-ME
3Q7U	;	2.1	;	Structure of Mtb 2-C-methyl-D-erythritol 4-phosphate cytidyltransferase (IspD) complexed with CTP
3OKR	;	2.4	;	Structure of Mtb apo 2-C-methyl-D-erythritol 4-phosphate cytidyltransferase (IspD)
3IOS	;	1.6	;	Structure of MTB dsbF in its mixed oxidized and reduced forms
4U33	;	3.293	;	Structure of Mtb GlgE bound to maltose
7KMY	;	2.21	;	Structure of Mtb Lpd bound to 010705
4M52	;	2.4	;	Structure of Mtb Lpd bound to SL827
4KBJ	;	2.4532	;	Structure of Mtb RNAP Beta subunit B1 and B2 domains
8IQU	;	2.64	;	Structure of MtbFadD23 with PhU-AMS
3TOE	;	2.197	;	Structure of Mth10b
1OQK	;		;	Structure of Mth11: A homologue of human RNase P protein Rpp29
2WNY	;	1.95	;	Structure of Mth689, a DUF54 protein from Methanothermobacter thermautotrophicus
8B8Q	;	2.94	;	Structure of mTMEM16F in lipid Nanodiscs in the presence of Ca2+
4JSN	;	3.2	;	structure of mTORdeltaN-mLST8 complex
4JSP	;	3.3	;	structure of mTORDeltaN-mLST8-ATPgammaS-Mg complex
4JT6	;	3.6	;	structure of mTORDeltaN-mLST8-PI-103 complex
4JSX	;	3.5	;	structure of mTORDeltaN-mLST8-Torin2 complex
4X2M	;	2.0	;	Structure of Mtr2
2XGJ	;	2.9	;	Structure of Mtr4, a DExH helicase involved in nuclear RNA processing and surveillance
7XEV	;	3.27	;	Structure of mTRPV2_2-APB
7XEU	;	2.77	;	Structure of mTRPV2_E2
7XEW	;	2.59	;	Structure of mTRPV2_Q525F
7XER	;	2.47	;	Structure of mTRPV2_Q525T
4DCF	;	2.7	;	Structure of MTX-II from Bothrops brazili
1MUC	;	1.85	;	STRUCTURE OF MUCONATE LACTONIZING ENZYME AT 1.85 ANGSTROMS RESOLUTION
6K3D	;	1.919	;	Structure of multicopper oxidase mutant
7PHP	;	3.47	;	Structure of Multidrug and Toxin Compound Extrusion (MATE) transporter NorM by NabFab-fiducial assisted cryo-EM
3TTP	;	2.23	;	Structure of multiresistant HIV-1 protease in complex with darunavir
7EWQ	;	3.5	;	Structure of Mumps virus nucleocapsid ring
7T7R	;	10.0	;	Structure of Munc13-1 C1-C2B-MUN-C2C trimer between lipid bilayers
3VCY	;	1.925	;	Structure of MurA (UDP-N-acetylglucosamine enolpyruvyl transferase), from Vibrio fischeri in complex with substrate UDP-N-acetylglucosamine and the drug fosfomycin.
1EYN	;	1.7	;	Structure of mura liganded with the extrinsic fluorescence probe ANS
6ZM8	;	0.78	;	Structure of muramidase from Acremonium alcalophilum
6ZMV	;	1.4	;	Structure of muramidase from Trichobolus zukalii
5VVW	;	2.3	;	Structure of MurC from Pseudomonas aeruginosa
2XJA	;	3.0	;	Structure of MurE from M.tuberculosis with dipeptide and ADP
1E8C	;	2.0	;	Structure of MurE the UDP-N-acetylmuramyl tripeptide synthetase from E. coli
4KX3	;	2.1	;	Structure of murine cytosolic 5'-nucleotidase III complexed with thymidine monophosphate
4FE3	;	1.74	;	Structure of murine cytosolic 5'-nucleotidase III complexed with uridinine monophosphate
2BPD	;	1.5	;	STRUCTURE OF MURINE DECTIN-1
2BPE	;	2.25	;	STRUCTURE OF MURINE DECTIN-1
2BPH	;	2.2	;	STRUCTURE OF MURINE DECTIN-1
4JBM	;	2.218	;	Structure of murine DNA binding protein bound with ds DNA
4LU5	;	2.9	;	Structure of murine IgG2a A20G2-Fab in complex with vaccinia antigen A33R at the resolution of 2.9 Angstroms
4M1G	;	1.6	;	Structure of murine IgG2a A27D7-Fab in complex with vaccinia antigen A33R at the resolution of 1.6 Angstroms
4LQF	;	2.3	;	Structure of murine IgG2b A2C7-Fab in complex with vaccinia antigen A33R at the resolution of 2.3 Angstroms
3E7T	;	2.6	;	Structure of murine iNOS oxygenase domain with inhibitor AR-C102222
3E6T	;	2.5	;	Structure of murine INOS oxygenase domain with inhibitor AR-C118901
3E6O	;	2.6	;	Structure of murine INOS oxygenase domain with inhibitor AR-C124355
3E6N	;	2.4	;	Structure of murine INOS oxygenase domain with inhibitor AR-C125813
3E68	;	2.2	;	Structure of murine INOS oxygenase domain with inhibitor AR-C130232
3E6L	;	2.3	;	Structure of murine INOS oxygenase domain with inhibitor AR-C132283
3E7I	;	2.9	;	Structure of murine inos oxygenase domain with inhibitor AR-C94864
3E7M	;	2.0	;	Structure of murine iNOS oxygenase domain with inhibitor AR-C95791
7TZE	;	2.12	;	Structure of murine LAG3 domains 1-2
6GZA	;	1.89	;	Structure of murine leukemia virus capsid C-terminal domain
8A1D	;	3.0	;	Structure of murine perforin-2 (Mpeg1) pore in ring form
8A1S	;	4.0	;	Structure of murine perforin-2 (Mpeg1) pore in twisted form
6G70	;	3.3	;	Structure of murine Prpf39
6RTF	;	7.77	;	Structure of murine Solute Carrier 26 family member A9 (Slc26a9) anion transporter in an intermediate state
6RTC	;	3.96	;	Structure of murine Solute Carrier 26 family member A9 (Slc26a9) anion transporter in the inward-facing state
2N2O	;		;	Structure of murine tumour necrosis factor alpha CDE RNA
6CC4	;	3.5	;	Structure of MurJ from Escherichia coli
4O2L	;	2.4	;	Structure of Mus musculus Rheb G63A mutant bound to GTP
4O2R	;	2.25	;	Structure of Mus musculus Rheb G63V mutant bound to GDP
8J97	;	3.2	;	Structure of Muscarinic receptor (M2R) in complex with beta-arrestin1 (Local refine, cross-linked)
8JAF	;	3.1	;	Structure of Muscarinic receptor (M2R) in complex with beta-arrestin1 (Local Refine, non-cross linked)
4XJX	;	2.4	;	STRUCTURE OF MUTANT (E165H) OF THE HSDR SUBUNIT OF THE ECOR124I RESTRICTION ENZYME IN COMPLEX WITH ATP
1K1K	;	2.0	;	Structure of Mutant Human Carbonmonoxyhemoglobin C (beta E6K) at 2.0 Angstrom Resolution in Phosphate Buffer.
6JD0	;	1.805	;	Structure of mutant human cathepsin L, engineered for GAG binding
1ZWI	;	2.5	;	Structure of mutant KcsA potassium channel
3K7P	;	1.4	;	Structure of mutant of ribose 5-phosphate isomerase type B from Trypanosoma cruzi.
1X10	;	2.0	;	Structure of Mutant Pyrrolidone Carboxyl Peptidase (E192A) from a Hyperthermophile, Pyrococcus furiosus
1X12	;	2.0	;	Structure of Mutant Pyrrolidone Carboxyl Peptidase (E192D) from a Hyperthermophile, Pyrococcus furiosus
1Z8W	;	2.0	;	Structure of Mutant Pyrrolidone Carboxyl Peptidase (E192I) from a Hyperthermophile, Pyrococcus furiosus
1Z8T	;	2.5	;	Structure of Mutant Pyrrolidone Carboxyl Peptidase (E192Q) from a Hyperthermophile, Pyrococcus furiosus
1Z8X	;	2.0	;	Structure of Mutant Pyrrolidone Carboxyl Peptidase (E192V) from a Hyperthermophile, Pyrococcus furiosus
4FB9	;	1.75	;	Structure of mutant RIP from barley seeds
4FBA	;	1.85	;	Structure of mutant RIP from barley seeds in complex with adenine
4FBB	;	1.8	;	Structure of mutant RIP from barley seeds in complex with adenine (AMP-incubated)
4FBC	;	1.7	;	Structure of mutant RIP from barley seeds in complex with AMP
6LCV	;	2.84	;	structure of Mutant S44P of maltooligosyltrehalose synthase from Arthrobacter ramosus
5W6K	;	2.339	;	Structure of mutant Taq Polymerase incorporating unnatural base pairs Z:P
2DZT	;	2.4	;	Structure of mutant tryptophan synthase alpha-subunit (D110A) from a hyperthermophile, Pyrococcus furiosus
2DZU	;	2.46	;	Structure of mutant tryptophan synthase alpha-subunit (D110N) from a hyperthermophile, Pyrococcus furiosus
2DZV	;	2.4	;	Structure of mutant tryptophan synthase alpha-subunit (D146A) from a hyperthermophile, Pyrococcus furiosus
2DZP	;	2.4	;	Structure of mutant tryptophan synthase alpha-subunit (D17N) from a hyperthermophile, Pyrococcus furiosus
2DZS	;	2.4	;	Structure of mutant tryptophan synthase alpha-subunit (E103A) from a hyperthermophile, Pyrococcus furiosus
2DZX	;	2.4	;	Structure of mutant tryptophan synthase alpha-subunit (E131-132A) from a hyperthermophile, Pyrococcus furiosus
2DZW	;	2.4	;	Structure of mutant tryptophan synthase alpha-subunit (E244A) from a hyperthermophile, Pyrococcus furiosus
2E09	;	2.4	;	Structure of mutant tryptophan synthase alpha-subunit (E74A) from a hyperthermophile, Pyrococcus furiosus
2W23	;	1.94	;	Structure of mutant W169Y of Pleurotus eryngii versatile peroxidase (VP)
3DKG	;	1.91	;	Structure of Mutant(Y1248L) MET receptor tyrosine kinase in complex with inhibitor SGX-523
4CIS	;	2.05	;	Structure of MutM in complex with carbocyclic 8-oxo-G containing DNA
4GUQ	;	3.7	;	Structure of mutS139F p73 DNA binding domain complexed with 20BP DNA response element
7R1D	;	3.5	;	Structure of MuvB complex
1IDZ	;		;	STRUCTURE OF MYB TRANSFORMING PROTEIN, NMR, 20 STRUCTURES
1IDY	;		;	STRUCTURE OF MYB TRANSFORMING PROTEIN, NMR, MINIMIZED AVERAGE STRUCTURE
4RS9	;	1.95	;	Structure of Myc3 N-terminal JAZ-binding domain [44-238] in complex with Jas motif of JAZ9
3II4	;	2.42	;	Structure of mycobacterial lipoamide dehydrogenase bound to a triazaspirodimethoxybenzoyl inhibitor
4U94	;	1.473	;	Structure of mycobacterial maltokinase, the missing link in the essential GlgE-pathway
4U98	;	1.15	;	Structure of mycobacterial maltokinase, the missing link in the essential GlgE-pathway (AppCp complex)
4WZY	;	1.71	;	Structure of mycobacterial maltokinase, the missing link in the essential GlgE-pathway (ATP complex)
4LS9	;	2.2	;	Structure of mycobacterial nrnA homolog reveals multifunctional nuclease activities
1Y25	;	2.1	;	structure of mycobacterial thiol peroxidase Tpx
6G80	;	2.05	;	Structure of Mycobacterium hassiacum MeT1 from orthorhombic crystals.
6TVP	;	1.9	;	Structure of Mycobacterium smegmatis alpha-maltose-1-phosphate synthase GlgM
7D5I	;	2.79	;	Structure of Mycobacterium smegmatis bd complex in the apo-form.
6YXU	;	3.08	;	Structure of Mycobacterium smegmatis HelD protein in complex with RNA polymerase core - State I, primary channel engaged
6YYS	;	3.08	;	Structure of Mycobacterium smegmatis HelD protein in complex with RNA polymerase core - State II, primary channel engaged and active site interfering
6Z11	;	3.36	;	Structure of Mycobacterium smegmatis HelD protein in complex with RNA polymerase core - State III, primary channel dis-engaged and active site interfering
5V9X	;	2.797	;	Structure of Mycobacterium smegmatis helicase Lhr bound to ssDNA and AMP-PNP
2XW7	;	2.0	;	Structure of Mycobacterium smegmatis putative reductase MS0308
6F6W	;	3.81	;	Structure of Mycobacterium smegmatis RNA polymerase core
6EYD	;	4.22	;	Structure of Mycobacterium smegmatis RNA polymerase Sigma-A holoenzyme
8FR8	;	2.76	;	Structure of Mycobacterium smegmatis Rsh bound to a 70S translation initiation complex
6LUM	;	2.84	;	Structure of Mycobacterium smegmatis succinate dehydrogenase 2
5VI5	;	3.196	;	Structure of Mycobacterium smegmatis transcription initiation complex with a full transcription bubble
5CJ5	;	3.13	;	Structure of Mycobacterium thermoresistibile GlgE APO form at 3.13A resolution
5CIM	;	3.32	;	Structure of Mycobacterium thermoresistibile GlgE in complex with maltose (cocrystallisation with maltose-1-phosphate) at 3.32A resolution
5CGM	;	1.95	;	Structure of Mycobacterium thermoresistibile GlgE in complex with maltose at 1.95A resolution
5JIJ	;	1.82	;	Structure of Mycobacterium thermoresistibile trehalose-6-phosphate synthase (APO form).
5K41	;	1.971	;	Structure of Mycobacterium thermoresistibile trehalose-6-phosphate synthase in a complex with ADP-glucose.
5K42	;	1.921	;	Structure of Mycobacterium thermoresistibile trehalose-6-phosphate synthase in a complex with GDP-glucose.
5K44	;	1.925	;	Structure of Mycobacterium thermoresistibile trehalose-6-phosphate synthase in a complex with Trehalose-6-phosphate.
5K5C	;	1.848	;	Structure of Mycobacterium thermoresistibile trehalose-6-phosphate synthase in a complex with Trehalose.
5L3K	;	2.305	;	Structure of Mycobacterium thermoresistibile trehalose-6-phosphate synthase in a ternary complex with ADP and fructose-6-phosphate
5JIO	;	1.711	;	Structure of Mycobacterium thermoresistibile trehalose-6-phosphate synthase ternary complex with ADP and Glucose-6-phosphate.
7YZI	;	3.83	;	Structure of Mycobacterium tuberculosis adenylyl cyclase Rv1625c / Cya
7YZK	;	3.57	;	Structure of Mycobacterium tuberculosis adenylyl cyclase Rv1625c / Cya
7O1I	;	2.3	;	Structure of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme alpha-E141A mutant
7O1K	;	2.86	;	Structure of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme alpha-E141A, beta-C92A mutant
7O1G	;	3.03	;	Structure of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme alpha-E141A-H462A, beta-C92A mutant
7O1L	;	2.38	;	Structure of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme alpha-H462A mutant
7O1M	;	2.89	;	Structure of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme alpha-H462A, beta-C92A mutant
7O1J	;	2.36	;	Structure of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme beta-C92A mutant
8OPW	;	2.52	;	Structure of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme in complex with Caffeine (Fragment-B-51)
8OPY	;	2.45	;	Structure of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme in complex with Fragment-B-DNQ
8OQL	;	2.7	;	Structure of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme in complex with Fragment-M-1
8OQM	;	3.2	;	Structure of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme in complex with Fragment-M-10
8OQV	;	2.78	;	Structure of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme in complex with Fragment-M-109
8OQO	;	2.6	;	Structure of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme in complex with Fragment-M-49
8OQN	;	2.2	;	Structure of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme in complex with Fragment-M-53
8PF8	;	2.23	;	Structure of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme in complex with Fragment-M-72
8OQP	;	2.18	;	Structure of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme in complex with Fragment-M-76
8OQQ	;	2.59	;	Structure of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme in complex with Fragment-M-79
8OQR	;	2.4	;	Structure of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme in complex with Fragment-M-80
8OQS	;	2.33	;	Structure of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme in complex with Fragment-M-83
8OQT	;	2.62	;	Structure of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme in complex with Fragment-M-91
8OQU	;	2.89	;	Structure of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme in complex with Fragment-M-92
7O4V	;	2.42	;	Structure of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme in complex with oxidized nicotinamide adenine dinucleotide
8OPV	;	2.8	;	Structure of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme in complex with Resveratrol (Fragment-B-H11)
8OPU	;	3.04	;	Structure of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme in complex with Sulfamethoxazole (Fragment-B-E1)
8OPX	;	2.9	;	Structure of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme in complex with Trehalose (Fragment-B-TRE)
7O4Q	;	2.1	;	Structure of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme in space group C2221 (unliganded)
7O4S	;	2.79	;	Structure of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme with Coenzyme A bound at the hydratase, thiolase active sites and additional binding site (CoA(ECH2))
7O4T	;	2.1	;	Structure of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme with Coenzyme A bound at the hydratase, thiolase active sites and possible additional binding site (CoA(ECH/HAD))
7O4R	;	2.79	;	Structure of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme with Coenzyme A bound at the thiolase active sites and additional binding site (CoA(HAD/KAT))
2IJ7	;	1.9	;	Structure of Mycobacterium tuberculosis CYP121 in complex with the antifungal drug fluconazole
3PVV	;	2.0	;	Structure of Mycobacterium tuberculosis DnaA-DBD in complex with box1 DNA
3PVP	;	2.3	;	Structure of Mycobacterium tuberculosis DnaA-DBD in complex with box2 DNA
3LOJ	;	1.25	;	Structure of Mycobacterium tuberculosis dUTPase H145A mutant
4GCY	;	1.5	;	Structure of Mycobacterium tuberculosis dUTPase H21W mutant
3ZHY	;	2.3	;	Structure of Mycobacterium tuberculosis DXR in complex with a di- substituted fosmidomycin analogue
3ZHX	;	2.0	;	Structure of Mycobacterium tuberculosis DXR in complex with a fosmidomycin analogue
3ZHZ	;	2.25	;	Structure of Mycobacterium tuberculosis DXR in complex with a fosmidomycin analogue
3ZI0	;	1.9	;	Structure of Mycobacterium tuberculosis DXR in complex with a fosmidomycin analogue
2PR2	;	2.5	;	Structure of Mycobacterium tuberculosis enoyl-ACP reductase with bound INH-NADP.
4NQW	;	2.4	;	Structure of Mycobacterium tuberculosis extracytoplasmic function sigma factor SigK in complex with the cytosolic domain of its cognate anti-sigma factor RskA
6GJC	;	3.3	;	Structure of Mycobacterium tuberculosis Fatty Acid Synthase - I
4A22	;	1.9	;	Structure of Mycobacterium tuberculosis fructose 1,6-bisphosphate aldolase bound to N-(4-hydroxybutyl)- glycolohydroxamic acid bis- phosphate
4A21	;	2.35	;	Structure of Mycobacterium tuberculosis fructose 1,6-bisphosphate aldolase bound to sulfate
6GE9	;	2.26	;	Structure of Mycobacterium tuberculosis GlmU bound to Glc-1P and Ac-CoA
5U3F	;	1.695	;	Structure of Mycobacterium tuberculosis IlvE, a branched-chain amino acid transaminase, in complex with D-cycloserine derivative
1NWA	;	1.5	;	Structure of Mycobacterium tuberculosis Methionine Sulfoxide Reductase A in Complex with Protein-bound Methionine
6OXC	;	1.9	;	Structure of Mycobacterium tuberculosis methylmalonyl-CoA mutase with adenosyl cobalamin
6OXD	;	2.0	;	Structure of Mycobacterium tuberculosis methylmalonyl-CoA mutase with adenosyl cobalamin
3HEM	;	2.39	;	Structure of Mycobacterium tuberculosis Mycolic Acid Cyclopropane Synthase CmaA2 in Complex with Dioctylamine
6BUV	;	1.86	;	Structure of Mycobacterium tuberculosis NadD in complex with inhibitor [(1~{R},2~{R},5~{S})-5-methyl-2-propan-2-yl-cyclohexyl] 2-[3-methyl-2-(phenoxymethyl)benzimidazol-1-yl]ethanoate
4S1O	;	1.84	;	Structure of Mycobacterium tuberculosis NadD in complex with NADP
4YBR	;	1.65	;	Structure of Mycobacterium tuberculosis NadD in complex with NADP, P21212
5DAS	;	2.2	;	Structure of Mycobacterium tuberculosis NadD in complex with NADP, P21212, form 2
1ZJ8	;	2.8	;	Structure of Mycobacterium tuberculosis NirA protein
1ZJ9	;	2.9	;	Structure of Mycobacterium tuberculosis NirA protein
5TRG	;	2.804	;	Structure of Mycobacterium tuberculosis proteasome in complex with N,C-capped dipeptide DPLG-2
5TRS	;	3.08357	;	Structure of Mycobacterium tuberculosis proteasome in complex with N,C-capped dipeptide PKS2144
5TRR	;	3.103	;	Structure of Mycobacterium tuberculosis proteasome in complex with N,C-capped dipeptide PKS2169
5TRY	;	3.00001	;	Structure of Mycobacterium tuberculosis proteasome in complex with N,C-capped dipeptide PKS2206
5TS0	;	2.8468	;	Structure of Mycobacterium tuberculosis proteasome in complex with N,C-capped dipeptide PKS2208
1USL	;	1.88	;	Structure Of Mycobacterium tuberculosis Ribose-5-Phosphate Isomerase, RpiB, Rv2465c, Complexed With Phosphate.
2BET	;	2.2	;	Structure of Mycobacterium tuberculosis Ribose-5-Phosphate Isomerase, RpiB, Rv2465c, in complex with 4-phospho-D-erythronate.
2BES	;	2.1	;	Structure of Mycobacterium tuberculosis Ribose-5-Phosphate Isomerase, RpiB, Rv2465c, in complex with 4-phospho-D-erythronohydroxamic acid.
4KDD	;	1.9	;	Structure of Mycobacterium tuberculosis ribosome recycling factor in presence of detergent
2PFC	;	2.3	;	Structure of Mycobacterium tuberculosis Rv0098
2VP8	;	2.64	;	Structure of Mycobacterium tuberculosis Rv1207
2D1F	;	2.5	;	Structure of Mycobacterium tuberculosis threonine synthase
5MWO	;	1.962	;	Structure of Mycobacterium Tuberculosis Transcriptional Regulatory Repressor Protein (EthR) in complex with fragment 7E8.
5MXK	;	1.932	;	Structure of Mycobacterium Tuberculosis Transcriptional Regulatory Repressor Protein (EthR) in complex with fragment 7G9.
3TA6	;	1.41	;	Structure of Mycobacterium tuberculosis triosephosphate isomerase
3TAO	;	1.45	;	Structure of Mycobacterium tuberculosis triosephosphate isomerase bound to phosphoglycolohydroxamate
5OCW	;	4.0	;	Structure of Mycobacterium tuberculosis tryptophan synthase in space group F222
2Y71	;	1.5	;	Structure of Mycobacterium tuberculosis type II dehydroquinase complexed with (1R,4S,5R)-1,4,5-trihydroxy-3-((5-methylbenzo(b) thiophen-2-yl)methoxy)cyclohex-2-enecarboxylate
2Y77	;	1.5	;	Structure of Mycobacterium tuberculosis type II dehydroquinase complexed with (1R,4S,5R)-3-(benzo(b)thiophen-2-ylmethoxy)-1,4,5- trihydroxy-2-(thiophen-2-ylmethyl)cyclohex-2-enecarboxylate
2Y76	;	2.5	;	Structure of Mycobacterium tuberculosis type II dehydroquinase complexed with (1R,4S,5R)-3-(benzo(b)thiophen-5-ylmethoxy)-2-(benzo(b) thiophen-5-ylmethyl)-1,4,5-trihydroxycyclohex-2-enecarboxylate
2XB8	;	2.4	;	Structure of Mycobacterium tuberculosis type II dehydroquinase in complex with inhibitor compound (2R)-2-(4-methoxybenzyl)-3- dehydroquinic acid
4B6Q	;	1.54	;	Structure of Mycobacterium tuberculosis Type II Dehydroquinase inhibited by (2R)-2-(benzothiophen-5-yl)methyl-3-dehydroquinic acid
4B6O	;	2.0	;	Structure of Mycobacterium tuberculosis Type II Dehydroquinase inhibited by (2S)-2-(4-methoxy)benzyl-3-dehydroquinic acid
4B6P	;	2.3	;	Structure of Mycobacterium tuberculosis Type II Dehydroquinase inhibited by (2S)-2-Perfluorobenzyl-3-dehydroquinic acid
4KG7	;	1.5	;	Structure of MycP3 protease from the type VII (ESX-3) secretion system.
1NEU	;	1.9	;	STRUCTURE OF MYELIN MEMBRANE ADHESION MOLECULE P0
1YIV	;	2.1	;	Structure of myelin P2 protein from Equine spinal cord
6IXR	;	2.854	;	Structure of Myo2-GTD in complex with Inp2
6IXP	;	2.733	;	Structure of Myo2-GTD in complex with Mmr1
6IXQ	;	3.06	;	Structure of Myo2-GTD in complex with Smy1
4LL6	;	2.3	;	Structure of Myo4p globular tail domain.
1MZ0	;	1.6	;	STRUCTURE OF MYOGLOBIN MB-YQR 316 ns AFTER PHOTOLYSIS OF CARBON MONOXIDE SOLVED FROM LAUE DATA AT RT.
2MHR	;	1.3	;	STRUCTURE OF MYOHEMERYTHRIN IN THE AZIDOMET STATE AT 1.7(SLASH)1.3 ANGSTROMS RESOLUTION
3PVL	;	2.8	;	Structure of myosin VIIa MyTH4-FERM-SH3 in complex with the CEN1 of Sans
5F3B	;	1.76	;	Structure of myostatin in complex with chimeric RK35 antibody
5F3H	;	2.7	;	Structure of myostatin in complex with humanized RK35 antibody
5GWD	;	1.89	;	Structure of Myroilysin
5ZJK	;	2.6	;	Structure of myroilysin
7U0V	;	2.45	;	Structure of myxoma virus M062 protein variant Lau
7U0W	;	3.205	;	Structure of myxoma virus M062 protein variant MAV
6X0U	;	3.6	;	Structure of MZT1/GCP3-NHD and MZT1/GCP6-NHD in the gamma-TuRC lumenal bridge
6X0V	;	4.5	;	Structure of MZT2/GCP-NHD and CDK5Rap2 at position 13 of the gamma-TuRC
3BEN	;	1.65	;	Structure of N-(12-imidazolyl-dodecanoyl)-L-leucine inhibitor bound to the heme domain of Cytochrome P450-BM3
4AAJ	;	1.75	;	Structure of N-(5'-phosphoribosyl)anthranilate isomerase from Pyrococcus furiosus
4AYU	;	1.5	;	Structure of N-Acetyl-D-Proline bound to serum amyloid P component
4AVS	;	1.399	;	Structure of N-Acetyl-L-Proline bound to Serum Amyloid P Component
7PA1	;	2.2	;	Structure of N-acetylglucosamine kinase from Plesiomonas shigelloides in complex with AMP-PNP in the absence of N-acetylglucoseamine substrate
2YHY	;	1.82	;	Structure of N-Acetylmannosamine kinase in complex with N- acetylmannosamine and ADP
5ZKN	;	2.205	;	Structure of N-acetylmannosamine-6-phosphate 2-epimerase from Fusobacterium nucleatum
3Q58	;	1.8	;	Structure of N-acetylmannosamine-6-Phosphate Epimerase from Salmonella enterica
5ZJB	;	1.699	;	Structure of N-acetylmannosamine-6-phosphate-2-epimerase from Vibrio cholerae
5ZJP	;	2.66	;	Structure of N-acetylmannosamine-6-phosphate-2-epimerase from Vibrio cholerae with N-acetylglucosamine-6-phosphate
5ZJN	;	2.66	;	Structure of N-acetylmannosamine-6-phosphate-2-epimerase from Vibrio cholerae with N-acetylmannosamine-6-phosphate
4NF1	;	1.3986	;	Structure of N-acetyltransferase domain of X. fastidiosa NAGS/K without his-tag
4YF9	;	2.6	;	Structure of N-acylhomoserine lactone acylase MacQ
4YFA	;	2.2	;	Structure of N-acylhomoserine lactone acylase MacQ in complex with decanoic acid
4YFB	;	1.75	;	Structure of N-acylhomoserine lactone acylase MacQ in complex with phenylacetic acid
5C9I	;	1.8	;	Structure of N-acylhomoserine lactone acylase MacQ shortened spacer mutant (delta202-208) in uncleaved form
7KH2	;	2.05	;	Structure of N-citrylornithine decarboxylase bound with PLP
6BBE	;	1.898	;	Structure of N-glycosylated porcine surfactant protein-D
6BBD	;	1.898	;	Structure of N-glycosylated porcine surfactant protein-D complexed with glycerol
2WUU	;	1.42	;	Structure of N-myristoyltransferase from L. donovani
1ZWF	;		;	STRUCTURE OF N-TERMINAL ACETYLATED HUMAN PARATHYROID HORMONE, NMR, 10 STRUCTURES
2VAC	;	1.7	;	Structure of N-terminal Actin Depolymerizing Factor homology (ADF-H) domain of human twinfilin-2
6LHW	;	4.84	;	Structure of N-terminal and C-terminal domains of FANCA
1Y2O	;	2.2	;	Structure of N-terminal domain IRSp53/BAIAP2
2LWF	;		;	Structure of N-terminal domain of a plant Grx
2Y7M	;	1.98	;	Structure of N-terminal domain of Candida albicans als9-2 (Pt derivative)
2Y7N	;	2.0	;	Structure of N-terminal domain of Candida albicans als9-2 - Apo Form
2Y7O	;	1.75	;	Structure of N-terminal domain of Candida albicans als9-2 - G299W mutant
2YLH	;	1.7	;	Structure of N-terminal domain of Candida albicans Als9-2 G299W mutant
2Y7L	;	1.49	;	Structure of N-terminal domain of Candida albicans Als9-2 in complex with human fibrinogen gamma peptide
2QCZ	;	2.7	;	Structure of N-terminal domain of E. Coli YaeT
2QDF	;	2.2	;	Structure of N-terminal domain of E. Coli YaeT
1MJD	;		;	Structure of N-terminal domain of human doublecortin
3NHZ	;	2.5	;	Structure of N-terminal Domain of MtrA
3RW7	;	3.0	;	Structure of N-terminal domain of nuclear RNA export factor TAP
6JRE	;	2.59	;	Structure of N-terminal domain of Plasmodium vivax p43 (PfNTD) solved by Co-SAD phasing
4IPH	;	1.94	;	Structure of N-terminal domain of RPA70 in complex with VU079104 inhibitor
3UBD	;	1.53	;	Structure of N-terminal domain of RSK2 kinase in complex with flavonoid glycoside SL0101
8S92	;	4.06	;	Structure of N-terminal domains of Walker B mutated MCM8/9 heterohexamer complex with ADP
1MFW	;	1.6	;	STRUCTURE OF N-TERMINAL DOUBLECORTIN DOMAIN FROM DCLK: SELENOMETHIONINE LABELED PROTEIN
1MG4	;	1.504	;	STRUCTURE OF N-TERMINAL DOUBLECORTIN DOMAIN FROM DCLK: WILD TYPE PROTEIN
3T9L	;	1.5	;	Structure of N-terminal DUSP-UBL domains of human USP15
2BRA	;	2.0	;	Structure of N-Terminal FAD Binding motif of mouse MICAL
3OUQ	;	2.6	;	Structure of N-terminal hexaheme fragment of GSU1996
4EL9	;	1.55	;	Structure of N-terminal kinase domain of RSK2 with afzelin
4GUE	;	1.8	;	Structure of N-terminal kinase domain of RSK2 with flavonoid glycoside quercitrin
8FA3	;		;	Structure of N-terminal of Schistosoma japonicum asparaginyl-tRNA synthetase
2O1W	;	3.4	;	Structure of N-terminal plus middle domains (N+M) of GRP94
8A55	;	0.99	;	Structure of N-terminal SARS-CoV-2 nonstructural protein 1 (nsp1) at atomic resolution
6RMW	;	3.5	;	Structure of N-terminal truncated IMP bound Plasmodium falciparum IMP-nucleotidase
3NVI	;	2.709	;	Structure of N-terminal truncated Nop56/58 bound with L7Ae and box C/D RNA
6RN1	;	3.0	;	Structure of N-terminal truncated Plasmodium falciparum IMP-nucleotidase
4D5R	;	1.9	;	Structure of N-terminally truncated A49 from Vaccinia Virus Western Reserve
4D5T	;	1.84	;	Structure of N-terminally truncated A49 from Vaccinia Virus Western Reserve
6U1B	;	2.08009	;	Structure of N-terminus locked Esp with eight pro-peptide residues - V67C, D255C
6TYA	;	2.06594	;	Structure of N-terminus locked Esp with one pro-peptide residue - V67C, D255C
6CXB	;	1.701	;	Structure of N-truncated R1-type pyocin tail fiber at 1.7 angstrom resolution
6CU2	;	2.58	;	Structure of N-truncated R2-type pyocin tail fiber at 2.6 angstrom resolution
3EBC	;	2.55	;	Structure of N141A HincII with Cognate DNA
2HIN	;	1.05	;	Structure of N15 Cro at 1.05 A: an ortholog of lambda Cro with a completely different but equally effective dimerization mechanism
6ON0	;	1.6	;	STRUCTURE OF N15 CRO COMPLEXED WITH CONSENSUS OPERATOR DNA
4ZPY	;	3.8	;	Structure of N170A MVM mutant empty capsid
5U22	;	1.748	;	Structure of N2152 from Neocallimastix frontalis
1PI5	;	1.49	;	Structure of N289A mutant of AmpC in complex with SM2, carboxyphenylglycylboronic acid bearing the cephalothin R1 side chain
1PI4	;	1.39	;	Structure of N289A mutant of AmpC in complex with SM3, a phenylglyclboronic acid bearing the cephalothin R1 side chain
2VMQ	;	1.67	;	Structure of N341AbsSHMT crystallized in the presence of L-allo-Thr
1B6S	;	2.5	;	STRUCTURE OF N5-CARBOXYAMINOIMIDAZOLE RIBONUCLEOTIDE SYNTHETASE
3A3R	;	1.9	;	Structure of N59D HEN EGG-WHITE LYSOZYME
3A3Q	;	2.0	;	Structure of N59D HEN EGG-WHITE LYSOZYME in complex with (GlcNAc)3
6K0X	;	2.2	;	Structure of N6AMT1-TRMT112 Complex with SAM
7RMM	;	1.97	;	Structure of N74D mutant of disulfide stabilized HIV-1 CA hexamer
5NNP	;	2.602	;	Structure of Naa15/Naa10 bound to HypK-THB
5NNR	;	3.1	;	Structure of Naa15/Naa10 bound to HypK-THB
3ZJ1	;		;	Structure of Nab2p tandem zinc finger 12
3ZJ2	;		;	Structure of Nab2p tandem zinc finger 34
2KVI	;		;	Structure of Nab3 RRM
7N29	;	2.8	;	Structure of NAD kinase
3Q4G	;	2.4	;	Structure of NAD synthetase from Vibrio cholerae
8G83	;	3.03	;	Structure of NAD+ consuming protein Acinetobacter baumannii TIR domain
7WVH	;	2.45	;	Structure of NAD+ glycohydrolase/Streptolysin O complex from Group A streptococcus
4Q16	;	2.6	;	Structure of NAD+ Synthetase from Deinococcus radiodurans
6ACH	;	3.2	;	Structure of NAD+-bound leucine dehydrogenase from Geobacillus stearothermophilus by cryo-EM
4KXQ	;	1.849	;	Structure of NAD-dependent protein deacetylase sirtuin-1 (closed state, 1.85 A)
4IF6	;	2.25	;	Structure of NAD-dependent protein deacetylase sirtuin-1 (closed state, 2.25 A)
4IG9	;	2.64	;	Structure of NAD-dependent protein deacetylase sirtuin-1 (open state, 2.64 A)
7BRF	;	2.15	;	Structure of NADH complex of Thermotoga maritima alpha-glucuronidase at 2.15 Angstrom resolution
1NPX	;	2.16	;	STRUCTURE OF NADH PEROXIDASE FROM STREPTOCOCCUS FAECALIS 10C1 REFINED AT 2.16 ANGSTROMS RESOLUTION
5GV8	;	0.78	;	Structure of NADH-cytochrome b5 reductase refined with the multipolar atomic model at 0.78A
5GV7	;	0.8	;	Structure of NADH-cytochrome b5 reductase refined with the multipolar atomic model at 0.80 A
8PXL	;	1.6	;	Structure of NADH-DEPENDENT FERREDOXIN REDUCTASE, BPHA4, solved at wavelength 1.37 A
8PXK	;	3.77	;	Structure of NADH-DEPENDENT FERREDOXIN REDUCTASE, BPHA4, solved at wavelength 5.76 A
4XDY	;	1.535	;	Structure of NADH-preferring ketol-acid reductoisomerase from an uncultured archean
2GQA	;	1.7	;	Structure of NADH-reduced SYE1, an OYE homologue from S. oneidensis
7Q5Y	;	2.7	;	Structure of NADH:ubichinon oxidoreductase (complex I) of the hyperthermophilic eubacterium Aquifex aeolicus
1KEV	;	2.05	;	STRUCTURE OF NADP-DEPENDENT ALCOHOL DEHYDROGENASE
1VDC	;	2.5	;	STRUCTURE OF NADPH DEPENDENT THIOREDOXIN REDUCTASE
1PYF	;	1.8	;	Structure of NADPH-dependent family 11 aldo-keto reductase AKR11A(apo)
1PZ0	;	2.35	;	Structure of NADPH-dependent family 11 aldo-keto reductase AKR11A(holo)
1PZ1	;	2.2	;	Structure of NADPH-dependent family 11 aldo-keto reductase AKR11B(holo)
2ON7	;	2.4	;	Structure of NaGST-1
2ON5	;	1.9	;	Structure of NaGST-2
8H7R	;	2.0	;	Structure of nanobody 11A in complex with coumaphos
8H7M	;	1.87	;	Structure of nanobody 11A in complex with parathion
8H7I	;	2.4	;	Structure of nanobody 11A in complex with quinalphos
8H7N	;	1.99	;	Structure of nanobody 11A in complex with triazophos
8JLY	;	1.29	;	Structure of nanobody in complex with alpha-synuclein peptide
5M2W	;	1.5	;	Structure of nanobody nb18 raised against TssK from E. coli T6SS
7EH3	;		;	Structure of Nanobody Nb23 in solution using NMR spectroscopy
8IRW	;	1.55	;	Structure of nanobody Nb9 against parathion
6DO1	;	2.901	;	Structure of nanobody-stabilized angiotensin II type 1 receptor bound to S1I8
5KP9	;	5.7	;	Structure of Nanoparticle Released from Enveloped Protein Nanoparticle
8CXL	;	1.98	;	Structure of NapH3, a vanadium-dependent haloperoxidase homolog catalyzing the stereospecific alpha-hydroxyketone rearrangement reaction in napyradiomycin biosynthesis
1PNB	;		;	STRUCTURE OF NAPIN BNIB, NMR, 10 STRUCTURES
3DZW	;	1.7	;	Structure of Narcissus pseudonarcissus lectin complex with Mannobiose at 1.7 A resolution, form II
2CBA	;	1.54	;	STRUCTURE OF NATIVE AND APO CARBONIC ANHYDRASE II AND SOME OF ITS ANION-LIGAND COMPLEXES
2CBB	;	1.67	;	STRUCTURE OF NATIVE AND APO CARBONIC ANHYDRASE II AND SOME OF ITS ANION-LIGAND COMPLEXES
2CBC	;	1.88	;	STRUCTURE OF NATIVE AND APO CARBONIC ANHYDRASE II AND SOME OF ITS ANION-LIGAND COMPLEXES
2CBD	;	1.67	;	STRUCTURE OF NATIVE AND APO CARBONIC ANHYDRASE II AND SOME OF ITS ANION-LIGAND COMPLEXES
2CBE	;	1.82	;	STRUCTURE OF NATIVE AND APO CARBONIC ANHYDRASE II AND SOME OF ITS ANION-LIGAND COMPLEXES
6Q3G	;	3.8	;	Structure of native bacteriophage P68
2WHE	;	1.55	;	Structure of native Beta-Phosphoglucomutase in an open conformation without bound ligands.
2Y1M	;	2.67	;	Structure of native c-Cbl
1M4L	;	1.25	;	STRUCTURE OF NATIVE CARBOXYPEPTIDASE A AT 1.25 RESOLUTION
1HQ4	;	2.7	;	STRUCTURE OF NATIVE CATALYTIC ANTIBODY HA5-19A4
3OJT	;	1.7	;	Structure of native Fe-containing Homoprotocatechuate 2,3-Dioxygenase at 1.70 Ang resolution
6TVQ	;	1.45	;	Structure of native gp41 derived peptide fusion inhibitor
6TVU	;	1.25	;	Structure of native gp41 derived peptide fusion inhibitor
6TVW	;	1.45	;	Structure of native gp41 derived peptide fusion inhibitor
5G0Z	;	2.001	;	Structure of native granulovirus polyhedrin determined using an X-ray free-electron laser
4G0B	;	3.0	;	Structure of native HCT from Coffea canephora
5F14	;	1.148	;	Structure of native hen egg-white lysozyme
1YTQ	;	1.7	;	Structure of Native Human Beta B2 Crystallin
8OGI	;	1.547	;	Structure of native human eosinophil peroxidase
3F5N	;	3.15	;	Structure of native human neuroserpin
3JA9	;	22.0	;	Structure of native human PCNA
4IP9	;	2.5	;	Structure of native human serum amyloid A1
3KVE	;	2.57	;	Structure of native L-amino acid oxidase from Vipera ammodytes ammodytes: stabilization of the quaternary structure by divalent ions and structural changes in the dynamic active site
7Z53	;	2.28	;	Structure of native leukocyte myeloperoxidase in complex with a truncated version (SPIN truncated) of the Staphyloccal Peroxidase Inhibitor SPIN from Staphylococcus aureus
7QZR	;	2.18	;	Structure of native leukocyte myeloperoxidase in complex with the Staphyloccal Peroxidase Inhibitor SPIN from Staphylococcus aureus
2XPY	;	2.73	;	Structure of Native Leukotriene A4 Hydrolase from Saccharomyces cerevisiae
1ELT	;	1.61	;	STRUCTURE OF NATIVE PANCREATIC ELASTASE FROM NORTH ATLANTIC SALMON AT 1.61 ANGSTROMS RESOLUTION
3EST	;	1.65	;	STRUCTURE OF NATIVE PORCINE PANCREATIC ELASTASE AT 1.65 ANGSTROMS RESOLUTION
1FMU	;	2.7	;	STRUCTURE OF NATIVE PROTEINASE A IN P3221 SPACE GROUP.
1FMX	;	2.61	;	STRUCTURE OF NATIVE PROTEINASE A IN THE SPACE GROUP P21
4L9B	;	1.75	;	Structure of native RBP from lactococcal phage 1358 (CsI derivative)
7ASD	;	3.5	;	Structure of native royal jelly filaments
2O6D	;	1.86	;	Structure of native rTp34 from Treponema pallidum
2O6E	;	1.9	;	Structure of native rTp34 from Treponema pallidum from zinc-soaked crystals
2VA9	;	2.4	;	Structure of native TcAChE after a 9 seconds annealing to room temperature during the first 5 seconds of which laser irradiation at 266nm took place
2UBP	;	2.0	;	STRUCTURE OF NATIVE UREASE FROM BACILLUS PASTEURII
4GQK	;	2.36	;	Structure of Native VgrG1-ACD with ADP (no cations)
2XPZ	;	2.3	;	Structure of native yeast LTA4 hydrolase
4KJS	;	3.05	;	Structure of native YfkE
7QTQ	;	3.3	;	Structure of Native, iodinated bovine thyroglobulin solved on strepavidin affinity grids.
4BFL	;	1.64	;	Structure of natively expressed catalase HPII
1YK0	;	2.4	;	structure of natriuretic peptide receptor-C complexed with atrial natriuretic peptide
1YK1	;	2.9	;	structure of natriuretic peptide receptor-C complexed with brain natriuretic peptide
8DIX	;	3.3	;	Structure of NavAb L98R as a basis for the human Nav1.7 Inherited Erythromelalgia L823R mutation
7K48	;	3.6	;	Structure of NavAb/Nav1.7-VS2A chimera trapped in the resting state by tarantula toxin m3-Huwentoxin-IV
4OXS	;	2.8	;	Structure of NavMS in complex with channel blocking compound
4P9P	;	2.91	;	Structure of NavMS in complex with channel blocking compound
4PA3	;	3.25	;	Structure of NavMS in complex with channel blocking compound
4PA4	;	3.02	;	Structure of NavMS in complex with channel blocking compound
4PA9	;	3.43	;	Structure of NavMS in complex with channel blocking compound
4P30	;	3.31	;	Structure of NavMS mutant in presence of PI1 compound
4PA7	;	3.02	;	Structure of NavMS pore and C-terminal domain crystallised in presence of channel blocking compound
4PA6	;	3.36	;	Structure of NavMS pore and C-terminal domain crystallised in the presence of channel blocking compound
4P2Z	;	3.08	;	Structure of NavMS T207A/F214A
4EIZ	;	2.2	;	Structure of Nb113 bound to apoDHFR
5NLU	;	1.193	;	Structure of Nb36 crystal form 1
5NLW	;	1.5	;	Structure of Nb36 crystal form 2
1XFA	;	3.1	;	Structure of NBD1 from murine CFTR- F508R mutant
1XF9	;	2.7	;	Structure of NBD1 from murine CFTR- F508S mutant
4Q7K	;	1.8	;	Structure of NBD287 of TM287/288
4Q7L	;	2.35	;	Structure of NBD288 of TM287/288
4Q7M	;	2.3	;	Structure of NBD288-Avi of TM287/288
2JZL	;		;	Structure of NcCVNH (N. CRASSA CVNH)
6VRY	;	1.4	;	Structure of NCI09 fab in complex with SIV V2 peptide
6M7D	;	2.9	;	Structure of ncleoprotein of sendai virus
5JWB	;	2.7	;	Structure of NDH2 from plasmodium falciparum in complex with NADH
5JWC	;	2.051	;	Structure of NDH2 from plasmodium falciparum in complex with RYL-552
6V1M	;	1.05	;	Structure of NDM-1 bound to QPX7728 at 1.05 A
6XBE	;	1.8	;	Structure of NDM-1 in complex with macrocycle inhibitor NDM1i-1F
6XBF	;	2.2	;	Structure of NDM-1 in complex with macrocycle inhibitor NDM1i-1G
6XCI	;	1.6	;	Structure of NDM-1 in complex with macrocycle inhibitor NDM1i-3D
6ZYQ	;	1.7	;	Structure of NDM-1 with 2-Mercaptomethyl-thiazolidine D-syn-1b
6ZYP	;	1.4	;	Structure of NDM-1 with 2-Mercaptomethyl-thiazolidine L-anti-1b
4TZB	;	2.029	;	Structure of NDM-Metallo-beta-lactamase
3FKB	;	1.65	;	Structure of NDPK H122G and tenofovir-diphosphate
1MN4	;	2.2	;	Structure of Ndt80 (Residues 59-340) DNA-binding domain core
1ZX3	;	2.5	;	Structure of NE0241 Protein of Unknown Function from Nitrosomonas europaea
8FWG	;	3.45	;	Structure of neck and portal vertex of Agrobacterium phage Milano, C5 symmetry
8FXR	;	4.5	;	Structure of neck with portal vertex of capsid of Agrobacterium phage Milano
7LP1	;	1.35	;	Structure of Nedd4L WW3 domain
7LP2	;	1.88	;	Structure of Nedd4L WW3 domain
7LP3	;	1.61	;	Structure of Nedd4L WW3 domain
7LP4	;		;	Structure of Nedd4L WW3 domain
7LP5	;		;	Structure of Nedd4L WW3 domain
1NDD	;	1.6	;	STRUCTURE OF NEDD8
3GZN	;	3.0	;	Structure of NEDD8-activating enzyme in complex with NEDD8 and MLN4924
7ONI	;	3.4	;	Structure of Neddylated CUL5 C-terminal region-RBX2-ARIH2*
7SIN	;	5.9	;	Structure of negative allosteric modulator-bound inactive human calcium-sensing receptor
8TJG	;	1.45	;	Structure of Nei2 from Mycobacterium smegmatis in complex with Zn2+
7TJB	;	1.30003	;	Structure of Neisseria gonorrhoeae peptidoglycan O-acetyltransferase B (PatB)
7TLV	;	1.50001	;	Structure of Neisseria gonorrhoeae peptidoglycan O-acetyltransferase B (PatB) substituted with selenomethionine
7TRR	;	1.80002	;	Structure of Neisseria gonorrhoeae peptidoglycan O-acetyltransferase B (PatB) with methylsulfonyl adduct
2YK6	;	2.83	;	Structure of Neisseria LOS-specific sialyltransferase (NST), in complex with CDP.
2YK7	;	2.18	;	Structure of Neisseria LOS-specific sialyltransferase (NST), in complex with CMP-3F-Neu5Ac.
2YK5	;	2.32	;	Structure of Neisseria LOS-specific sialyltransferase (NST), in complex with CMP.
2YK4	;	1.94	;	Structure of Neisseria LOS-specific sialyltransferase (NST).
4V1J	;	1.43	;	Structure of Neisseria meningitidis Major Pillin
2XKE	;	2.203	;	Structure of Nek2 bound to Aminipyrazine Compound 5
2XKD	;	1.96	;	Structure of Nek2 bound to aminopyrazine compound 12
2XKC	;	2.5	;	Structure of Nek2 bound to aminopyrazine compound 14
2XK8	;	2.001	;	Structure of Nek2 bound to aminopyrazine compound 15
2XK4	;	2.1	;	Structure of Nek2 bound to aminopyrazine compound 17
2XKF	;	2.35	;	Structure of Nek2 bound to aminopyrazine compound 2
2XK7	;	1.992	;	Structure of Nek2 bound to aminopyrazine compound 23
2XK3	;	2.2	;	Structure of Nek2 bound to Aminopyrazine compound 35
2XK6	;	2.2	;	Structure of Nek2 bound to aminopyrazine compound 36
2XNM	;	1.85	;	Structure of NEK2 bound to CCT
2XNN	;	2.5	;	Structure of Nek2 bound to CCT242430
2XNO	;	1.98	;	Structure of Nek2 bound to CCT243779
2XNP	;	1.98	;	Structure of Nek2 bound to CCT244858
2WQO	;	2.167	;	STRUCTURE OF NEK2 BOUND TO THE AMINOPYRIDINE CCT241950
3LZV	;	2.15	;	Structure of Nelfinavir-resistant HIV-1 protease (D30N/N88D) in complex with Darunavir.
6MI3	;	1.783	;	Structure of NEMO(51-112) with N- and C-terminal coiled-coil adaptors.
7WPO	;	3.5	;	Structure of NeoCOV RBD binding to Bat37 ACE2
5ZYS	;	1.78	;	Structure of Nephrin/MAGI1 complex
5OXW	;	2.61	;	Structure of NeqN from Nanoarchaeum equitans
5ZLR	;	2.001	;	Structure of NeuC
1V0Z	;	1.84	;	Structure of Neuraminidase from English duck subtype N6
1W1X	;	2.0	;	Structure of Neuraminidase from English duck subtype N6 complexed with 30 mM sialic acid (NANA, Neu5Ac), crystal soaked for 3 hours at 277 K.
1W20	;	2.08	;	Structure of Neuraminidase from English duck subtype N6 complexed with 30 mM sialic acid (NANA, Neu5Ac), crystal soaked for 3 hours at 291 K
1W21	;	2.08	;	Structure of Neuraminidase from English duck subtype N6 complexed with 30 mM sialic acid (NANA, Neu5Ac), crystal soaked for 43 hours at 291 K.
2CML	;	2.15	;	Structure of Neuraminidase from English Duck Subtype N6 Complexed with 30 MM ZANAMIVIR, Crystal Soaked for 3 Hours at 291 K.
7XVR	;	2.4	;	Structure of neuraminidase from influenza B-like viruses derived from spiny eel
7XVU	;	1.6	;	Structure of neuraminidase from influenza B-like viruses derived from spiny eel
7XVV	;	1.85	;	Structure of neuraminidase from influenza B-like viruses derived from spiny eel
7XVW	;	1.94	;	Structure of neuraminidase from influenza B-like viruses derived from spiny eel
2C4L	;	2.15	;	Structure of Neuraminidase Subtype N9 Complexed with 30 MM Sialic Acid (NANA, NEU5AC), Crystal Soaked for 24 Hours at 291 K and Finally Backsoaked for 30 Min in a Cryoprotectant Solution which did not contain NEU5AC
2C4A	;	2.15	;	Structure of Neuraminidase Subtype N9 Complexed with 30 MM Sialic Acid (NANA, NEU5AC), Crystal Soaked for 3 Hours at 291 K.
3QCW	;	2.65	;	Structure of neurexin 1 alpha (domains LNS1-LNS6), no splice inserts
3R05	;	2.95	;	Structure of neurexin 1 alpha (domains LNS1-LNS6), with splice insert SS3
3N64	;	1.95	;	Structure of neuronal nitric oxide synthase D597N mutant heme domain in complex with 6,6'-(2,2'-(5-amino-1,3-phenylene)bis(ethane-2,1-diyl))bis(4-methylpyridin-2-amine)
3N62	;	1.95	;	Structure of neuronal nitric oxide synthase D597N mutant heme domain in complex with 6,6'-(2,2'-(pyridine-3,5-diyl)bis(ethane-2,1-diyl))bis(4-methylpyridin-2-amine)
3N63	;	2.0	;	Structure of neuronal nitric oxide synthase D597N/M336V mutant heme domain in complex with 6,6'-(2,2'-(5-amino-1,3-phenylene)bis(ethane-2,1-diyl))bis(4-methylpyridin-2-amine)
3N61	;	1.95	;	Structure of neuronal nitric oxide synthase D597N/M336V mutant heme domain in complex with 6,6'-(2,2'-(pyridine-3,5-diyl)bis(ethane-2,1-diyl))bis(4-methylpyridin-2-amine)
3NLQ	;	2.15	;	Structure of neuronal nitric oxide synthase D597N/M336V mutant heme domain in complex with 6-{{(3'R,4'R)-3'-[2""-(3'''-fluorophenethylamino)ethoxy]pyrrolidin-4'-yl}methyl}-4-methylpyridin-2-amine
3NLR	;	2.1	;	Structure of neuronal nitric oxide synthase D597N/M336V mutant heme domain in complex with 6-{{(3'R,4'S)-3'-[2""-(3'''-fluorophenethylamino)ethoxy]pyrrolidin-4'-yl}methyl}-4-methylpyridin-2-amine
3NLP	;	2.02	;	Structure of neuronal nitric oxide synthase D597N/M336V mutant heme domain in complex with 6-{{(3'S,4'S)-3'-[2""-(3'''-fluorophenethylamino)ethoxy]pyrrolidin-4'-yl}methyl}-4-methylpyridin-2-amine
3JX6	;	2.35	;	Structure of neuronal nitric oxide synthase D597N/M336V/Y706A mutant heme domain complexed with N1-[(3' R,4' R)-4'-((6""-amino-4""-methylpyridin-2""-yl)methyl)pyrrolidin-3'-yl]-N2-(3'-fluorophenethyl)ethane-1,2-diamine tetrahydrochloride
3NLJ	;	2.2	;	Structure of neuronal nitric oxide synthase D597N/M336V/Y706A triple mutant heme domain complexed with 6-{{(3'R,4'R)-3'-[2""-(3'''-fluorophenethylamino)ethoxy] pyrrolidin-4'-yl}methyl}-4-methylpyridin-2-amine
3JT4	;	1.8	;	Structure of neuronal nitric oxide synthase heme domain complexed with N~5~-[(3-(ethylsulfanyl)propanimidoyl]-L-ornithine
3JT5	;	2.1	;	Structure of neuronal nitric oxide synthase heme domain complexed with N~5~-[2-(ethylsulfanyl)ethanimidoyl]-L-ornithine
3JT3	;	2.15	;	Structure of neuronal nitric oxide synthase heme domain complexed with N~5~-[2-(methylsulfanyl)ethanimidoyl]-L-ornithine
3JT7	;	2.1	;	Structure of neuronal nitric oxide synthase heme domain complexed with N~5~-[2-(propylsulfanyl)ethanimidoyl]-L-ornithine
3JT6	;	2.2	;	Structure of neuronal nitric oxide synthase heme domain complexed with N~5~-[4-(methylsulfanyl)butanimidoyl]-L-ornithine
3JT8	;	1.95	;	Structure of neuronal nitric oxide synthase heme domain complexed with N~5~-{3-[(1-methylethyl)sulfanyl]propanimidoyl}-L-ornithine
4K5G	;	1.85	;	Structure of neuronal nitric oxide synthase heme domain in complex with ((2S, 3S)-1,3-bis((6-(2,5-dimethyl-1H-pyrrol-1-yl)-4-methylpyridin-2-yl)methoxy)-2-aminobutane
4K5E	;	1.892	;	Structure of neuronal nitric oxide synthase heme domain in complex with (R)-1,2-bis((2-amino-4-methylpyridin-6-yl)-methoxy)-propan-3-amine
4K5D	;	2.096	;	Structure of neuronal nitric oxide synthase heme domain in complex with (S)-1,2-bis((2-amino-4-methylpyridin-6-yl)-methoxy)-propan-3-amine
4K5F	;	2.2	;	Structure of neuronal nitric oxide synthase heme domain in complex with (S)-1,3-bis((2-amino-4-methylpyridin-6-yl)-methoxy)-butan-4-amine
3TYN	;	1.968	;	Structure of neuronal nitric oxide synthase heme domain in complex with 2-(((2-(((3S,4S)-4-((6-amino-4-methylpyridin-2-yl)methyl)pyrrolidin-3-yl)oxy)ethyl)amino)methyl)phenol
3N5X	;	1.8	;	Structure of neuronal nitric oxide synthase heme domain in complex with 4-(2-(5-(2-(6-amino-4-methylpyridin-2-yl)ethyl)pyridin-3-yl)ethyl)-6-methylpyridin-2-amine
3N5Z	;	2.18	;	Structure of neuronal nitric oxide synthase heme domain in complex with 4-(2-(6-(2-(6-amino-4-methylpyridin-2-yl)ethyl)pyridin-2-yl)ethyl)-6-methylpyridin-2-amine
3N5V	;	2.3	;	Structure of neuronal nitric oxide synthase heme domain in complex with 4-(3-(2-(6-amino-4-methylpyridin-2-yl)ethyl)phenethyl)-6-methylpyridin-2-amine
3N60	;	1.98	;	Structure of neuronal nitric oxide synthase heme domain in complex with 6,6'-(2,2'-(5-amino-1,3-phenylene)bis(ethane-2,1-diyl))bis(4-methylpyridin-2-amine)
3N5Y	;	2.05	;	Structure of neuronal nitric oxide synthase heme domain in complex with 6,6'-(2,2'-(pyridine-2,6-diyl)bis(ethane-2,1-diyl))bis(4-methylpyridin-2-amine)
3N5W	;	1.73	;	Structure of neuronal nitric oxide synthase heme domain in complex with 6,6'-(2,2'-(pyridine-3,5-diyl)bis(ethane-2,1-diyl))bis(4-methylpyridin-2-amine)
3N2R	;	1.9	;	Structure of neuronal nitric oxide synthase heme domain in complex with 6-(((3R,4R/3S,4S)-4-(3-Phenoxyphenoxy)pyrrolidin-3-yl)methyl)pyridin-2-amine
3TYL	;	1.9	;	Structure of neuronal nitric oxide synthase heme domain in complex with 6-(((3S,4S)-4-(2-((2-fluorobenzyl)amino)ethoxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine
3TYM	;	2.0	;	Structure of neuronal nitric oxide synthase heme domain in complex with 6-(((3S,4S)-4-(2-((2-methoxybenzyl)amino)ethoxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine
3TYO	;	1.927	;	Structure of neuronal nitric oxide synthase heme domain in complex with 6-(((3S,4S)-4-(2-((furan-2-ylmethyl)amino)ethoxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine
4EUX	;	2.14	;	Structure of neuronal nitric oxide synthase heme domain in complex with 6-(5-(((3R,4R)-4-((6-amino-4-methylpyridin-2-yl)methyl)pyrrolidin-3-yl)oxy)pentyl)-4-methylpyridin-2-amine
3NLM	;	1.85	;	Structure of neuronal nitric oxide synthase heme domain in complex with 6-{{(3'R,4'R)-3'-[2""-(3'''-fluorophenethylamino)ethoxy]pyrrolidin-4'-yl}methyl}-4-methylpyridin-2-amine
4KCJ	;	2.05	;	Structure of neuronal nitric oxide synthase heme domain in complex with N,N'-((ethane-1,2-diylbis(oxy))bis(3,1-phenylene))bis(thiophene-2-carboximidamide)
4KCI	;	2.27	;	Structure of neuronal nitric oxide synthase heme domain in complex with N,N'-(ethane-1,2-diylbis(3,1-phenylene))bis(thiophene-2-carboximidamide)
4KCH	;	2.15	;	Structure of neuronal nitric oxide synthase heme domain in complex with N,N'-([1,1'-biphenyl]-3,3'-diyl)bis(thiophene-2-carboximidamide)
4KCN	;	1.85	;	Structure of neuronal nitric oxide synthase heme domain in complex with N-(3-(((3-fluorophenethyl)amino)methyl)phenyl)thiophene-2-carboximidamide
4KCO	;	1.86	;	Structure of neuronal nitric oxide synthase heme domain in complex with N-(3-((ethyl(3-fluorophenethyl)amino)methyl)phenyl)thiophene-2-carboximidamide
4KCK	;	2.1	;	Structure of neuronal nitric oxide synthase heme domain in complex with N-(3-(2-((3-(thiophene-2-carboximidamido)benzyl)amino)ethyl)phenyl)thiophene-2-carboximidamide
4KCL	;	1.93	;	Structure of neuronal nitric oxide synthase heme domain in complex with N-(4-(2-((3-(thiophene-2-carboximidamido)benzyl)amino)ethyl)phenyl)thiophene-2-carboximidamide
4KCM	;	2.074	;	Structure of neuronal nitric oxide synthase heme domain in complex with N-(4-(2-(ethyl(3-(thiophene-2-carboximidamido)benzyl)amino)ethyl)phenyl)thiophene-2-carboximidamide
3JT9	;	2.1	;	Structure of neuronal nitric oxide synthase heme domain in the ferrous state complexed with N~5~-[2-(ethylsulfanyl)ethanimidoyl]-L-ornithine
3JTA	;	2.18	;	Structure of neuronal nitric oxide synthase heme domain in the ferrous state complexed with N~5~-[4-(methylsulfanyl)butanimidoyl]-L-ornithine
3Q9A	;	2.24	;	Structure of neuronal nitric oxide synthase in the ferric state in complex with N-5-[2-(ethylsulfanyl)ethanimidoyl]-L-ornithine
3Q99	;	2.15	;	Structure of neuronal nitric oxide synthase in the ferric state in complex with N~5~-[(3-(ethylsulfanyl)propanimidoyl]-L-ornithine
3JWS	;	1.95	;	Structure of neuronal nitric oxide synthase R349A mutant heme domain complexed with N1-[(3' S,4'S)-4'-((6""-amino-4""-methylpyridin-2""-yl)methyl)pyrrolidin-3'-yl]-N2-(3'-fluorophenethyl)ethane-1,2-diamine tetrahydrochloride
3NLN	;	2.0	;	Structure of neuronal nitric oxide synthase R349A mutant heme domain in complex with 6-{{(3'R,4'S)-3'-[2""-(3'''-fluorophenethylamino)ethoxy]pyrrolidin-4'-yl}methyl}-4-methylpyridin-2-amine
3NLO	;	2.3	;	Structure of neuronal nitric oxide synthase R349A mutant heme domain in complex with 6-{{(3'S,4'R)-3'-[2""-(3'''-fluorophenethylamino)ethoxy]pyrrolidin-4'-yl}methyl}-4-methylpyridin-2-amine
3NLK	;	2.02	;	Structure of neuronal nitric oxide synthase R349A mutant heme domain in complex with 6-{{(3'S,4'S)-3'-[2""-(3'''-fluorophenethylamino)ethoxy]pyrrolidin-4'-yl}methyl}-4-methylpyridin-2-amine
3N66	;	1.78	;	Structure of neuronal nitric oxide synthase S602H mutant heme domain in complex with 6,6'-(2,2'-(5-amino-1,3-phenylene)bis(ethane-2,1-diyl))bis(4-methylpyridin-2-amine)
3N65	;	1.8	;	Structure of neuronal nitric oxide synthase S602H mutant heme domain in complex with 6,6'-(2,2'-(pyridine-3,5-diyl)bis(ethane-2,1-diyl))bis(4-methylpyridin-2-amine)
3DQR	;	2.4	;	Structure of neuronal NOS D597N/M336V mutant heme domain in complex with a inhibitor (+-)-N1-{cis-4'-[(6""-aminopyridin-2""-yl)methyl]pyrrolidin-3'-yl}ethane-1,2-diamine
3B3M	;	1.95	;	Structure of neuronal NOS heme domain in complex with a inhibitor (+-)-3-{cis-4'-[(6""-aminopyridin-2""-yl)methyl]pyrrolidin-3'-ylamino}propan-1-ol
3B3O	;	2.05	;	Structure of neuronal nos heme domain in complex with a inhibitor (+-)-n1-{cis-4'-[(6""-amino-4""-methylpyridin-2""-yl)methyl]pyrrolidin-3'-yl}-n2-(4'-chlorobenzyl)ethane-1,2-diamine
3B3P	;	2.45	;	Structure of neuronal nos heme domain in complex with a inhibitor (+-)-n1-{cis-4'-[(6""-amino-4""-methylpyridin-2""-yl)methyl]pyrrolidin-3'-yl}-n2-(4'-chlorobenzyl)ethane-1,2-diamine
3B3N	;	1.98	;	Structure of neuronal NOS heme domain in complex with a inhibitor (+-)-N1-{cis-4'-[(6""-aminopyridin-2""-yl)methyl]pyrrolidin-3'-yl}ethane-1,2-diamine
4BWK	;	3.3	;	Structure of Neurospora crassa PAN3 pseudokinase
4BWX	;	2.85	;	Structure of Neurospora crassa PAN3 pseudokinase mutant
5GZN	;	3.0	;	Structure of neutralizing antibody bound to Zika envelope protein
5GZO	;	2.755	;	Structure of neutralizing antibody bound to Zika envelope protein
7N6R	;	3.93	;	Structure of nevanimibe bound human ACAT2
6VUM	;	3.67	;	Structure of nevanimibe-bound human tetrameric ACAT1
1VER	;	2.82	;	Structure of New Antigen Receptor variable domain from sharks
1VES	;	2.18	;	Structure of New Antigen Receptor variable domain from sharks
2COQ	;	2.1	;	Structure of new antigen receptor variable domain from sharks
2YWY	;	2.71	;	Structure of new antigen receptor variable domain from sharks
2YWZ	;	2.21	;	Structure of new antigen receptor variable domain from sharks
3ZR9	;	1.91	;	Structure of New Delhi Metallo-Beta-lactamase 1 (NDM-1)
5WIH	;	1.35	;	Structure of New Delhi Metallo-Beta-lactamase 12 (NDM-12)
5WIG	;	1.4	;	Structure of New Delhi Metallo-Beta-lactamase 4 (NDM-4)
6Y5Y	;	1.8	;	Structure of New Jersey Polyomavirus VP1 in complex with 3'-Sialyllactose
1BFS	;	2.2	;	STRUCTURE OF NF-KB P50 HOMODIMER BOUND TO A KB SITE
1BFT	;	2.0	;	STRUCTURE OF NF-KB P50 HOMODIMER BOUND TO A KB SITE
7VUP	;	3.4	;	Structure of NF-kB p52 homodimer bound to +1/-1 swap P-Selectin kB DNA fragment
7W7L	;	3.0	;	Structure of NF-kB p52 homodimer bound to 13-mer A/T-centric P-Selectin kB DNA fragment
7VUQ	;	3.1	;	Structure of NF-kB p52 homodimer bound to A/T-centric P-Selectin kB DNA fragment
7CLI	;	3.0	;	Structure of NF-kB p52 homodimer bound to P-Selectin kB DNA fragment
2I9T	;	2.8	;	Structure of NF-kB p65-p50 heterodimer bound to PRDII element of B-interferon promoter
1P7H	;	2.6	;	Structure of NFAT1 bound as a dimer to the HIV-1 LTR kB element
3N2S	;	1.95	;	Structure of NfrA1 nitroreductase from B. subtilis
4I49	;	2.75	;	Structure of ngNAGS bound with bisubstrate analog CoA-NAG
6VJN	;	2.0	;	Structure of NHP D11A.B5Fab in complex with 16055 V2b peptide
6XLZ	;	2.8	;	Structure of NHP D11A.F2 Fab in complex with 16055 V2b peptide
8IY9	;	3.37	;	Structure of Niacin-GPR109A-G protein complex
7RKK	;	2.76	;	Structure of Nicotinamide N-Methyltransferase (NNMT) in complex with II399 (C2 space group)
7RKL	;	2.08	;	Structure of Nicotinamide N-Methyltransferase (NNMT) in complex with II399 (P1 space group)
7SOK	;	2.08	;	Structure of Nicotinamide N-Methyltransferase (NNMT) in complex with inhibitor II329
6PVE	;	2.3	;	Structure of Nicotinamide N-Methyltransferase (NNMT) in complex with inhibitor LL319
6PVS	;	2.575	;	Structure of Nicotinamide N-Methyltransferase (NNMT) in complex with inhibitor LL320
3U7Y	;	2.4478	;	Structure of NIH45-46 Fab in complex with gp120 of 93TH057 HIV
1M7Z	;	2.14	;	Structure of Nitric Oxide Synthase Heme Protein from Bacillus Subtilis with N-Hydroxy-Arginine and Tetrahydrofolate Bound
6HNS	;	1.84	;	Structure of Nitrincola lacisaponensis flavin-containing monooxygenase (FMO) in complex with FAD and NADP+
1AS6	;	1.8	;	STRUCTURE OF NITRITE BOUND TO OXIDIZED ALCALIGENES FAECALIS NITRITE REDUCTASE AT CRYO TEMPERATURE
1AS8	;	1.85	;	STRUCTURE OF NITRITE BOUND TO REDUCED ALCALIGENES FAECALIS NITRITE REDUCTASE AT CRYO TEMPERATURE
7B04	;	2.97	;	Structure of Nitrite oxidoreductase (Nxr) from the anammox bacterium Kuenenia stuttgartiensis.
5UE6	;	2.35	;	Structure of nitrite reductase AniA from Neisseria gonorrhoeae, space group I4122
5TB7	;	1.9	;	Structure of nitrite reductase AniA from Neisseria gonorrhoeae, space group P212121
1MWS	;	2.0	;	Structure of nitrocefin acyl-Penicillin binding protein 2a from methicillin resistant Staphylococcus aureus strain 27r at 2.00 A resolution.
1KQD	;	1.9	;	Structure of Nitroreductase from E. cloacae Bound with 2e-Reduced Flavin Mononucleotide (FMN)
1KQC	;	1.8	;	Structure of Nitroreductase from E. cloacae Complex with Inhibitor Acetate
1KQB	;	1.8	;	Structure of Nitroreductase from E. cloacae complex with inhibitor benzoate
5J8D	;	1.85	;	Structure of nitroreductase from E. cloacae complexed with nicotinic acid adenine dinucleotide
5J8G	;	1.9	;	Structure of nitroreductase from E. cloacae complexed with para-nitrobenzoic acid
2PTU	;	2.38	;	Structure of NK cell receptor 2B4 (CD244)
2PTT	;	1.63	;	Structure of NK cell receptor 2B4 (CD244) bound to its ligand CD48
3FF9	;	1.8	;	Structure of NK cell receptor KLRG1
3FF7	;	1.8	;	Structure of NK cell receptor KLRG1 bound to E-cadherin
3FF8	;	2.0	;	Structure of NK cell receptor KLRG1 bound to E-cadherin
2PTV	;	1.66	;	Structure of NK cell receptor ligand CD48
6NPH	;	2.9	;	Structure of NKCC1 TM domain
3CII	;	4.41	;	Structure of NKG2A/CD94 bound to HLA-E
7FC3	;	3.19	;	structure of NL63 receptor-binding domain complexed with horse ACE2
6BIM	;	1.547	;	Structure of NlpC1 from Trichomonas vaginalis
6BIO	;	1.2	;	Structure of NlpC1 from Trichomonas vaginalis
6BIQ	;	2.3	;	Structure of NlpC2 from Trichomonas vaginalis
6K8J	;	3.3	;	Structure of NLRC4 CARD filament
6K7V	;	3.7	;	Structure of NLRP1 CARD filament
8SXN	;	4.04	;	Structure of NLRP3 and NEK7 complex
5V5O	;	2.243	;	Structure of NLS2K of influenza A virus nucleoprotein bound to importin alpha
5V5P	;	2.15	;	Structure of NLS2R of influenza A virus nucleoprotein bound to importin alpha
5UI4	;	2.75	;	Structure of NME1 covalently conjugated to imidazole fluorosulfate
2KT2	;		;	Structure of NmerA, the N-terminal HMA domain of Tn501 Mercuric Reductase
3FIU	;	1.85	;	Structure of NMN synthetase from Francisella tularensis
2OLX	;	1.42	;	Structure of NNQQ Peptide from Yeast Prion SUP35
3CAE	;	3.0	;	Structure of NNQQNY as an insert in T7 endonuclease I
5K2F	;	1.0	;	Structure of NNQQNY from yeast prion Sup35 with cadmium acetate determined by MicroED
1YJO	;	1.3	;	Structure of NNQQNY from yeast prion Sup35 with zinc acetate
5K2E	;	1.0	;	Structure of NNQQNY from yeast prion Sup35 with zinc acetate determined by MicroED
4GCT	;	2.45	;	structure of No factor protein-DNA complex
4GCK	;	2.05	;	structure of no-dna complex
4GCL	;	2.65	;	structure of no-dna factor
5NU6	;	1.68	;	Structure of non-fluorescent human amniotic fluid RBP4
5NTY	;	2.0	;	Structure of non-fluorescent human plasma RBP4
5NU2	;	1.5	;	Structure of non-fluorescent human urine RBP4
6XJJ	;	2.7	;	Structure of non-heme iron enzyme TropC: Radical tropolone biosynthesis
7UTT	;	2.04	;	Structure of Non-hydrolyzable ATP (ApCpp) binds to Cyclic GMP AMP synthase (cGAS) through Mn coordination
3ISF	;	2.07	;	Structure of non-mineralized Bfrb (as-isolated) from Pseudomonas aeruginosa to 2.07A Resolution
4IZ7	;	1.8	;	Structure of Non-Phosphorylated ERK2 bound to the PEA-15 Death Effector Domain
1DUW	;	1.89	;	STRUCTURE OF NONAHEME CYTOCHROME C
7BWQ	;	2.954	;	Structure of nonstructural protein Nsp9 from SARS-CoV-2
5WTX	;	3.074	;	Structure of Nop9
5WTY	;	2.785	;	Structure of Nop9 RNA complex
8OI3	;	1.5	;	Structure of NopD with AtSUMO2
7D5Q	;	3.6	;	Structure of NorC transporter (K398A mutant) in an outward-open conformation in complex with a single-chain Indian camelid antibody
7D5P	;	3.65	;	Structure of NorC transporter in an outward-open conformation in complex with a single-chain Indian camelid antibody
8U1W	;	1.84	;	Structure of Norovirus (Hu/GII.4/Sydney/NSW0514/2012/AU) protease bound to inhibitor NV-004
8U1V	;	2.79	;	Structure of Norovirus (Hu/GII.4/Sydney/NSW0514/2012/AU) protease in the ligand-free state
8FY4	;	2.57	;	Structure of NOT1:NOT10:NOT11 module of the chicken CCR4-NOT complex
8FY3	;	2.88	;	Structure of NOT1:NOT10:NOT11 module of the human CCR4-NOT complex
6YXI	;	1.34	;	Structure of Notum in complex with a 1-(3-Chlorophenyl)-2,5-dimethyl-1H-pyrrole-3-carboxylic acid inhibitor
6LZG	;	2.5	;	Structure of novel coronavirus spike receptor-binding domain complexed with its receptor ACE2
4HCS	;	1.28	;	Structure of Novel subfamily CX chemokine solved by sulfur SAD
2NX6	;		;	Structure of NOWA cysteine rich domain 6
2NX7	;		;	Structure of NOWA cysteine rich domain 8
3R3L	;	2.449	;	Structure of NP protein from Lassa AV strain
2J8I	;	2.1	;	Structure of NP275, a pentapeptide repeat protein from Nostoc punctiforme
1TT4	;	2.801	;	Structure of NP459575, a predicted glutathione synthase from Salmonella typhimurium
6V3F	;	3.7	;	Structure of NPC1-like intracellular cholesterol transporter 1 (NPC1L1)
6V3H	;	3.5	;	Structure of NPC1-like intracellular cholesterol transporter 1 (NPC1L1) in complex with an ezetimibe analog
8V14	;	1.9	;	Structure of NRAP-1 and its role in NMDAR signaling
6GC3	;		;	Structure of Nrd1 CID - Sen1 NIM complex
2LO6	;		;	Structure of Nrd1 CID bound to phosphorylated RNAP II CTD
5O1W	;	2.3	;	Structure of Nrd1 RNA binding domain
5O1X	;	1.6	;	Structure of Nrd1 RNA binding domain
5O1Z	;	3.4	;	Structure of Nrd1 RNA binding domain in complex with RNA (CGUAAA)
5O1Y	;	2.45	;	Structure of Nrd1 RNA binding domain in complex with RNA (GUAA)
5O20	;	3.53	;	Structure of Nrd1 RNA binding domain in complex with RNA (UUAGUAAUCC)
2MOW	;		;	Structure of Nrd1p CID - Trf4p NIM complex
3EE8	;	2.6	;	Structure of NS1 effector domain
3EE9	;	2.14	;	Structure of NS1 effector domain
6LEN	;	2.383	;	Structure of NS11 bound FEM1C
2MKB	;		;	Structure of NS2(113-137) GBVB protein
2LZP	;		;	Structure of NS2(2-32) GBVB protein
2LZQ	;		;	Structure of NS2(32-57) GBVB protein
5GJ4	;	1.839	;	Structure of NS2B-NS3 Protease from Zika Virus caught after self-cleavage
2OC0	;	2.3	;	Structure of NS3 complexed with a ketoamide inhibitor SCh491762
5WDX	;	2.23	;	Structure of NS3 from HCV strain JFH-1 that is an unusually robust helicase that is primed to bind and unwind viral RNA
5KQR	;	1.331	;	Structure of NS5 methyltransferase from Zika virus bound to S-adenosylmethionine
5KQS	;	1.5	;	Structure of NS5 methyltransferase from Zika virus bound to S-adenosylmethionine and 7-methyl-guanosine-5'-diphosphate
7QUJ	;	1.85	;	Structure of NsNEPS2, a 7S-cis-trans nepetalactone synthase
7R2V	;	2.53	;	Structure of nsp14 from SARS-CoV-2 in complex with SAH
7TW8	;	1.55	;	Structure of nsp14 N7-MethylTransferase domain fused with TELSAM bound to SAH
7TW7	;	1.62	;	Structure of nsp14 N7-MethylTransferase domain fused with TELSAM bound to SAM
8FRJ	;	1.57	;	Structure of nsp14 N7-MethylTransferase domain fused with TELSAM bound to SGC0946
8FRK	;	1.61	;	Structure of nsp14 N7-MethylTransferase domain fused with TELSAM bound to SGC8158
7TW9	;	1.41	;	Structure of nsp14 N7-MethylTransferase domain fused with TELSAM bound to Sinefungin
4Z6G	;	2.654	;	Structure of NT domain
2NXP	;	2.17	;	Structure of NTD2 domain of the human TAF5 subunit of TFIID
2DVP	;	1.9	;	Structure of NTPase from Pyroccous horikoshii
7L0Q	;	4.3	;	Structure of NTS-NTSR1-Gi complex in lipid nanodisc, canonical state, with AHD
7L0P	;	4.1	;	Structure of NTS-NTSR1-Gi complex in lipid nanodisc, canonical state, without AHD
7L0S	;	4.5	;	Structure of NTS-NTSR1-Gi complex in lipid nanodisc, noncanonical state, with AHD
7L0R	;	4.2	;	Structure of NTS-NTSR1-Gi complex in lipid nanodisc, noncanonical state, without AHD
3RW6	;	2.3	;	Structure of nuclear RNA export factor TAP bound to CTE RNA
1ZO2	;	1.6	;	Structure of nuclear transport factor 2 (Ntf2) from Cryptosporidium parvum
6USM	;	3.37	;	Structure of nuclease domain of human parvovirus B19 non-structural protein 1 in complex with zinc
5XBL	;	3.052	;	Structure of nuclease in complex with associated protein
2Q2K	;	3.0	;	Structure of nucleic-acid binding protein
2QX5	;	2.5	;	Structure of nucleoporin Nic96
1KDN	;	2.0	;	STRUCTURE OF NUCLEOSIDE DIPHOSPHATE KINASE
4HR2	;	1.95	;	Structure of nucleoside diphosphate kinase (NDK) from Burkholderia thailandensis bound to ADP
1S59	;	2.6	;	Structure of nucleoside diphosphate kinase 2 with bound dGTP from Arabidopsis
1B4S	;	2.5	;	STRUCTURE OF NUCLEOSIDE DIPHOSPHATE KINASE H122G MUTANT
8Q3M	;	2.503	;	Structure of Nucleosome Core with a Bound Kaposi Sarcoma Associated Herpesvirus LANA Peptide Having a Methionine to Ornithine Substitution
8Q36	;	2.604	;	Structure of Nucleosome Core with a Bound Metallopeptide Conjugate (Foamy Virus GAG Peptide-Au[I] Compound)
8Q3X	;	2.301	;	Structure of Nucleosome Core with a Bound Metallopeptide Conjugate (Kaposi Sarcoma Associated Herpesvirus LANA Peptide-Au[I] Compound)
7XFH	;	2.9	;	Structure of nucleosome-AAG complex (A-30I, post-catalytic state)
7XFL	;	2.8	;	Structure of nucleosome-AAG complex (A-53I, free state)
7XFM	;	3.1	;	Structure of nucleosome-AAG complex (A-53I, post-catalytic state)
7XNP	;	2.9	;	Structure of nucleosome-AAG complex (A-55I, post-catalytic state)
7XFJ	;	3.0	;	Structure of nucleosome-AAG complex (T-50I, post-catalytic state)
6LTJ	;	3.7	;	Structure of nucleosome-bound human BAF complex
8G57	;	3.07	;	Structure of nucleosome-bound Sirtuin 6 deacetylase
8X19	;	3.2	;	Structure of nucleosome-bound SRCAP-C in the ADP-BeFx-bound state
8X1C	;	3.2	;	Structure of nucleosome-bound SRCAP-C in the ADP-bound state
8X15	;	3.2	;	Structure of nucleosome-bound SRCAP-C in the apo state
5O9G	;	4.8	;	Structure of nucleosome-Chd1 complex
7XFC	;	2.9	;	Structure of nucleosome-DI complex (-30I, Apo state)
7XFI	;	2.9	;	Structure of nucleosome-DI complex (-50I, Apo state)
7XFN	;	2.8	;	Structure of nucleosome-DI complex (-55I, Apo state)
6GFA	;	2.0	;	Structure of Nucleotide binding domain of HSP110, ATP and Mg2+ complexed
1V7R	;	1.4	;	Structure of nucleotide triphosphate pyrophosphatase from pyrococcus horikoshii OT3
2E5X	;	2.0	;	Structure of nucleotide triphosphate pyrophosphatase from pyrococcus horikoshii OT3
6S8F	;	4.0	;	Structure of nucleotide-bound Tel1/ATM
8UYF	;	2.75	;	Structure of nucleotide-free Pediculus humanus (Ph) PINK1 dimer
1SR6	;	2.75	;	Structure of nucleotide-free scallop myosin S1
1GUP	;	1.8	;	STRUCTURE OF NUCLEOTIDYLTRANSFERASE COMPLEXED WITH UDP-GALACTOSE
1GUQ	;	1.8	;	STRUCTURE OF NUCLEOTIDYLTRANSFERASE COMPLEXED WITH UDP-GLUCOSE
5LPG	;	1.7	;	Structure of NUDT15 in complex with 6-thio-GMP
7B7V	;	1.6	;	Structure of NUDT15 in complex with Acyclovir monophosphate
7AOM	;	1.95	;	Structure of NUDT15 in complex with Ganciclovir triphosphate
7R0D	;	1.7	;	Structure of NUDT15 in complex with Geranyl monophosphate
6T5J	;	1.6	;	Structure of NUDT15 in complex with inhibitor TH1760
7AOP	;	2.35	;	Structure of NUDT15 in complex with inhibitor TH8321
7NR6	;	1.8	;	Structure of NUDT15 in complex with NSC56456
7B63	;	1.6	;	Structure of NUDT15 in complex with TH7755
7B65	;	1.6	;	Structure of NUDT15 R139C Mutant in complex with TH7755
7B66	;	1.6	;	Structure of NUDT15 R139H Mutant in complex with TH7755
7B64	;	1.5	;	Structure of NUDT15 V18I Mutant in complex with TH7755
7B67	;	1.45	;	Structure of NUDT15 V18_V19insGV Mutant in complex with TH7755
1QVJ	;	1.91	;	structure of NUDT9 complexed with ribose-5-phosphate
3F7F	;	2.6	;	Structure of Nup120
3H7N	;	3.0	;	Structure of Nup120
2OSZ	;	2.85	;	Structure of Nup58/45 suggests flexible nuclear pore diameter by intermolecular sliding
6LUO	;	2.302	;	Structure of nurse shark beta-2-microglobulin
7JOQ	;	3.95	;	Structure of NV1 small terminase
5HZN	;	2.2	;	Structure of NVP-AEW541 in complex with IGF-1R kinase
5I1Z	;	1.6	;	Structure of nvPizza2-H16S58
2JC3	;	2.3	;	Structure of O-Acetylserine Sulfhydrylase B from Salmonella Typhimurium
3IQI	;	1.7	;	Structure of O-Acetylserine Sulfhydrylase in Complex with Peptide MNENI
3IQG	;	1.9	;	Structure of O-Acetylserine Sulfhydrylase in Complex with Peptide MNWNI
3IQH	;	1.9	;	Structure of O-Acetylserine Sulfhydrylase in Complex with Peptide MNYDI
2RR2	;		;	Structure of O-fucosylated epidermal growth factor-like repeat 12 of mouse Notch-1 receptor
4HQI	;	1.7	;	Structure of O6-Benzyl-2'-deoxyguanosine opposite perimidinone-derived synthetic nucleoside in DNA duplex
5H0I	;	2.56	;	Structure of OaAEP1 asparaginyl peptide ligase in its proenzyme form
5M04	;	1.85	;	Structure of ObgE from Escherichia coli
7NZA	;	1.199	;	Structure of OBP1 from Varroa destructor, form P2<1>
7NYJ	;	1.81	;	Structure of OBP1 from Varroa destructor, form P3<2>21
4Z45	;	2.02	;	Structure of OBP3 from the currant-lettuce aphid Nasonovia ribisnigri
4Z39	;	1.3	;	Structure of OBP3 from the vetch aphid Megoura viciae
7SB3	;	3.3	;	Structure of OC43 spike in complex with polyclonal Fab1 (Donor 269)
7SB4	;	4.7	;	Structure of OC43 spike in complex with polyclonal Fab2 (Donor 1412)
7SB5	;	4.2	;	Structure of OC43 spike in complex with polyclonal Fab3 (Donor 1412)
7SBV	;	3.1	;	Structure of OC43 spike in complex with polyclonal Fab4 (Donor 269)
7SBW	;	3.2	;	Structure of OC43 spike in complex with polyclonal Fab5 (Donor 1051)
7SBX	;	3.0	;	Structure of OC43 spike in complex with polyclonal Fab6 (Donor 1051)
7SBY	;	3.0	;	Structure of OC43 spike in complex with polyclonal Fab7 (Donor 269)
4FB0	;	3.22	;	Structure of Oceanobacillus iheyensis group II intron C377G mutant in a ligand-free state in the presence of K+ and Mg2+
6T3K	;	3.44	;	Structure of Oceanobacillus iheyensis group II intron G-mutant (C289G/C358G/G385C) in the presence of K+, Mg2+ and 5'-exon
6T3N	;	3.22	;	Structure of Oceanobacillus iheyensis group II intron G-mutant (C289G/C358G/G385C) in the presence of Na+, Mg2+ and 5'-exon
4E8R	;	3.36	;	Structure of Oceanobacillus iheyensis group II intron in a ligand-free state in the presence of Cs+ and Mg2+
4E8V	;	3.995	;	Structure of Oceanobacillus iheyensis group II intron in a ligand-free state in the presence of K+ and Ba2+
4E8M	;	3.5	;	Structure of Oceanobacillus iheyensis group II intron in a ligand-free state in the presence of K+ and Mg2+
4FAX	;	3.1	;	Structure of Oceanobacillus iheyensis group II intron in a ligand-free state in the presence of Na+ and Mg2+
4E8N	;	2.96	;	Structure of Oceanobacillus iheyensis group II intron in a ligand-free state in the presence of NH4+ and Mg2+
4E8P	;	3.28	;	Structure of Oceanobacillus iheyensis group II intron in a ligand-free state in the presence of Rb+ and Mg2+
4E8Q	;	2.84	;	Structure of Oceanobacillus iheyensis group II intron in a ligand-free state in the presence of Tl+ and Mg2+
4FAQ	;	3.11	;	Structure of Oceanobacillus iheyensis group II intron in the presence of K+, Ca2+ and 5'-exon
4E8K	;	3.03	;	Structure of Oceanobacillus iheyensis group II intron in the presence of K+, Ca2+ and a non-hydrolyzed oligonucleotide substrate
4E8T	;	3.34	;	Structure of Oceanobacillus iheyensis group II intron in the presence of K+, Ca2+ and an oligonucleotide fragment substrate (low energy dataset)
4FAR	;	2.86	;	Structure of Oceanobacillus iheyensis group II intron in the presence of K+, Mg2+ and 5'-exon
4FAW	;	2.7	;	Structure of Oceanobacillus iheyensis group II intron in the presence of K+, Mg2+ and a hydrolyzed oligonucleotide fragment
4FAU	;	2.87	;	Structure of Oceanobacillus iheyensis group II intron in the presence of Li+, Mg2+ and 5'-exon
6T3R	;	3.57	;	Structure of Oceanobacillus iheyensis group II intron U-mutant (C289U/C358U/G385A) in the presence of K+, Mg2+ and 5'-exon
6T3S	;	3.28	;	Structure of Oceanobacillus iheyensis group II intron U-mutant (C289U/C358U/G385A) in the presence of Na+, Mg2+ and 5'-exon
7YTH	;	1.93	;	Structure of OCPx1 from Nostoc flagelliforme CCNUN1
7YTF	;	2.65	;	Structure of OCPx2 from Nostoc flagelliforme CCNUN1
1S7Z	;	1.83	;	Structure of Ocr from Bacteriophage T7
7QDI	;	2.34	;	Structure of octameric left-handed 310-helix bundle: D-310HD
3IQD	;	2.8	;	Structure of Octopine-dehydrogenase in complex with NADH and Agmatine
5NGH	;	2.8	;	Structure of Odorant Binding Protein 3 from Giant Panda (Ailuropoda melanoleuca)
4WOH	;	1.34	;	Structure of of human dual-specificity phosphatase 22 (E24A/K28A/K30A/C88S) complexed with 4-nitrophenolphosphate
1Q5X	;	2.0	;	Structure of OF RRAA (MENG), a protein inhibitor of RNA processing
2O70	;	1.8	;	Structure of OHCU decarboxylase from zebrafish
2O73	;	1.8	;	Structure of OHCU decarboxylase in complex with allantoin
2O74	;	1.8	;	Structure of OHCU decarboxylase in complex with guanine
7XPW	;	1.77	;	Structure of OhTRP14
3ODH	;	2.3	;	Structure of OkrAI/DNA complex
4UIR	;	2.75	;	Structure of oleate hydratase from Elizabethkingia meningoseptica
1B05	;	2.0	;	Structure of oligo-peptide binding protein complexed with LYS-CYS-LYS
3SDM	;	6.6	;	Structure of oligomeric kinase/RNase Ire1 in complex with an oligonucleotide
1XCS	;	1.4	;	structure of oligonucleotide/drug complex
2XE4	;	1.65	;	Structure of Oligopeptidase B from Leishmania major
4X7S	;	1.9	;	Structure of omalizumab Fab fragment crystal form 1
4X7T	;	3.0	;	Structure of Omalizumab Fab fragment, crystal form 2
6U97	;	1.13	;	Structure of OmcF_H47I mutant
5ZNU	;		;	Structure of omega conotoxin Bu8
5I50	;	2.701	;	Structure of OmoMYC bound to double-stranded DNA
2ZLD	;	3.0	;	Structure of OmpF co-crystallized with T83
4D5U	;	3.5	;	Structure of OmpF in I2
2ZFG	;	1.59	;	Structure of OMPF PORIN
3K1B	;	4.39	;	Structure of OmpF porin
7FDY	;	3.1	;	Structure of OmpF1
7FF7	;	3.38	;	Structure of OmpF2
8PYZ	;	2.7	;	Structure of Ompk36GD from Klebsiella pneumonia, solved at wavelength 4.13 A
1TU7	;	1.5	;	Structure of Onchocerca Volvulus Pi-class Glutathione S-transferase
1TU8	;	1.8	;	STructure of Onchoverca volvulus Pi-class Glutathione S-transferase with its kompetitive inhibitor s-hexyl-GSH
1OMD	;	1.85	;	STRUCTURE OF ONCOMODULIN REFINED AT 1.85 ANGSTROMS RESOLUTION. AN EXAMPLE OF EXTENSIVE MOLECULAR AGGREGATION VIA CA2+
3A3X	;	1.7	;	Structure of OpdA mutant (G60A/A80V/R118Q/K185R/Q206P/D208G/I260T/G273S)
3A3W	;	1.85	;	Structure of OpdA mutant (G60A/A80V/S92A/R118Q/K185R/Q206P/D208G/I260T/G273S) with diethyl 4-methoxyphenyl phosphate bound in the active site
3OQE	;	1.9	;	Structure of OpdA mutant Y257F
3OOD	;	1.89	;	Structure of OpdA Y257F mutant soaked with diethyl 4-methoxyphenyl phosphate for 20 hours.
6JMX	;	1.859	;	Structure of open form of peptidoglycan peptidase
8DMO	;	3.9	;	Structure of open, inward-facing MsbA from E. coli
1RKM	;	2.4	;	STRUCTURE OF OPPA
2RKM	;	1.8	;	STRUCTURE OF OPPA COMPLEXED WITH LYS-LYS
6LBG	;	2.51	;	Structure of OR51B2 bound FEM1C
4XB5	;	1.9	;	Structure of orange carotenoid protein binding canthaxanthin
7ZSF	;	1.36	;	Structure of Orange Carotenoid Protein with canthaxanthin bound
7ZSG	;	1.39	;	Structure of Orange Carotenoid Protein with canthaxanthin bound after 1 minute of illumination
7ZSJ	;	1.41	;	Structure of Orange Carotenoid Protein with canthaxanthin bound after 10 minutes of illumination
7ZSH	;	1.42	;	Structure of Orange Carotenoid Protein with canthaxanthin bound after 2 minutes of illumination
7ZSI	;	1.399	;	Structure of Orange Carotenoid Protein with canthaxanthin bound after 5 minutes of illumination
2H36	;	2.95	;	Structure of ORF14 from Sulfolobus Islandicus Filamentous Virus (SIFV)
3II2	;	2.0	;	Structure of ORF157 from Acidianus Filamentous Virus 1
3II3	;	2.7	;	Structure of ORF157 from Acidianus filamentous Virus 1
3ILD	;	3.1	;	Structure of ORF157-K57A from Acidianus filamentous virus 1
5IPX	;	2.4	;	Structure of ORF49 from KSHV
6EKV	;	2.1	;	Structure of OrfX2 from Clostridium botulinum A2
4KA8	;	1.9	;	Structure of Organellar OligoPeptidase
4KA7	;	1.8	;	Structure of Organellar OligoPeptidase (E572Q) in complex with an endogenous substrate
2BYL	;	2.15	;	Structure of ornithine aminotransferase triple mutant Y85I Y55A G320F
4AMU	;	2.5	;	Structure of ornithine carbamoyltransferase from Mycoplasma penetrans with a P321 space group
1EIX	;	2.5	;	STRUCTURE OF OROTIDINE 5'-MONOPHOSPHATE DECARBOXYLASE FROM E. COLI, CO-CRYSTALLISED WITH THE INHIBITOR BMP
5Z2N	;	2.14	;	Structure of Orp1L N-terminal Domain
5Z2M	;	2.142	;	Structure of Orp1L/Rab7 complex
8TL1	;	3.16	;	Structure of Orthoreovirus RNA Chaperone SigmaNS N17
8TKA	;	3.0	;	Structure of Orthoreovirus RNA Chaperone SigmaNS R6A mutant
8TL8	;	3.2	;	Structure of Orthoreovirus RNA Chaperone SigmaNS R6A mutant in complex with bile acid
3F7A	;	4.308	;	Structure of Orthorhombic crystal form of Pseudomonas aeruginosa RssB
2WG7	;	2.0	;	Structure of Oryza Sativa (Rice) PLA2
2WG9	;	2.0	;	Structure of Oryza Sativa (Rice) PLA2, complex with octanoic acid
2WG8	;	2.3	;	Structure of Oryza Sativa (Rice) PLA2, orthorhombic crystal form
3W94	;	2.002	;	Structure of Oryzias latipes enteropeptidase light chain
4FES	;	2.0	;	Structure of OSH4 in complex with cholesterol analogs
4F4B	;	1.87	;	Structure of OSH4 with a cholesterol analog
3SPW	;	2.6	;	Structure of Osh4p/Kes1p in complex with phosphatidylinositol 4-phosphate
4B2Z	;	1.95	;	Structure of Osh6 in complex with phosphatidylserine
4PH7	;	2.55	;	Structure of Osh6p in complex with phosphatidylinositol 4-phosphate
2D7V	;	1.97	;	Structure of OsmC-like Protein of Unknown Function VCA0330 from Vibrio cholerae O1 biovar eltor str. N16961
1UKK	;	1.6	;	Structure of Osmotically Inducible Protein C from Thermus thermophilus
8EFX	;	1.85	;	Structure of OtDUB DUB Domain disulfide crosslinked with Ubiquitin
1TFF	;	2.1	;	Structure of Otubain-2
4BOP	;	2.1	;	Structure of OTUD1 OTU domain
4BOQ	;	1.47	;	Structure of OTUD2 OTU domain
4BOZ	;	3.03	;	Structure of OTUD2 OTU domain in complex with K11-linked di ubiquitin
4BOS	;	2.35	;	Structure of OTUD2 OTU domain in complex with Ubiquitin K11-linked peptide
4BOU	;	1.55	;	Structure of OTUD3 OTU domain
5OE7	;	2.95	;	Structure of OTULIN bound to the Met1-linked diubiquitin activity probe
7K5B	;	4.5	;	Structure of outer-arm dynein bound to microtubule doublet in microtubule binding state 2 (MTBS-2)
7K58	;	4.0	;	Structure of outer-arm dyneins bound to microtubule with microtubule binding state 1(MTBS-1)
6KGA	;	3.3	;	Structure of Ovalbumin from Emu (Dromaius novaehollandiae)
3BY4	;	1.55	;	Structure of Ovarian Tumor (OTU) domain in complex with Ubiquitin
3C0R	;	2.315	;	Structure of Ovarian Tumor (OTU) domain in complex with Ubiquitin
5D22	;	1.994	;	Structure of ovine granulocyte-macrophage colony-stimulating factor
5ORF	;	2.54	;	Structure of ovine serum albumin in P1 space group
6S59	;	3.7	;	Structure of ovine transhydrogenase in the apo state
6QTI	;	2.9	;	Structure of ovine transhydrogenase in the presence of NADP+ in a ""double face-down"" conformation
6QUE	;	3.7	;	Structure of ovine transhydrogenase in the presence of NADP+ in a ""single face-down"" conformation
4JF5	;	1.15	;	Structure of OXA-23 at pH 4.1
4JF6	;	2.5	;	Structure of OXA-23 at pH 7.0
6V1O	;	1.8	;	Structure of OXA-48 bound to QPX7728 at 1.80 A
4ZDX	;	2.001	;	Structure of OXA-51 beta-lactamase
1E4D	;	1.8	;	Structure of OXA10 beta-lactamase at pH 8.3
5VG3	;	1.451	;	Structure of Oxalate Decarboxylase from Bacillus subtilis at pH 4.6
1B7Z	;	2.7	;	STRUCTURE OF OXALATE SUBSTITUTED DIFERRIC MARE LACTOFERRIN FROM COLOSTRUM
3M0J	;	1.55	;	Structure of oxaloacetate acetylhydrolase in complex with the inhibitor 3,3-difluorooxalacetate
3M0K	;	1.65	;	Structure of oxaloacetate acetylhydrolase in complex with the product oxalate
5LGX	;	1.5	;	Structure of Oxidised Pentaerythritol Tetranitrate Reductase
2CE0	;	1.24	;	Structure of oxidized Arabidopsis thaliana cytochrome 6A
2OAN	;	2.606	;	Structure of oxidized beta-actin
7TIE	;	1.9	;	Structure of oxidized bovine cytochrome c oxidase at 1.90 Angstrom resolution obtained by synchrotron X-rays
7TIH	;	2.35	;	Structure of oxidized bovine cytochrome c oxidase with reduced metal centers induced by synchrotron X-ray exposure
1XLP	;	2.0	;	Structure of oxidized C73S putidaredoxin from Pseudomonas putida
4H6Q	;	1.359	;	Structure of oxidized Deinococcus radiodurans proline dehydrogenase complexed with L-tetrahydrofuroic acid
2N3B	;		;	Structure of oxidized horse heart cytochrome c encapsulated in reverse micelles
3RYM	;	1.7039	;	Structure of Oxidized M98K mutant of Amicyanin
3IE9	;	2.1	;	Structure of oxidized M98L mutant of amicyanin
2PFB	;	1.93	;	Structure of oxidized OhrR from Xanthamonas campestris
3PLY	;	2.2	;	Structure of Oxidized P96G Mutant of Amicyanin
1DW0	;	1.82	;	STRUCTURE OF OXIDIZED SHP, AN OXYGEN BINDING CYTOCHROME C
6X0I	;	1.95	;	Structure of oxidized SidA ornithine hydroxylase with the FAD ""in"" and complexed with NADP
6X0H	;	2.087	;	Structure of oxidized SidA ornithine hydroxylase with the FAD in the ""out"" conformation
1SF5	;	1.1	;	Structure of oxidized state of the P94A mutant of amicyanin
5F3R	;	2.04	;	Structure of oxidized UDP-galactopyranose mutase from Mycobacterium smegmatis in complex with magnesium ion
5ER9	;	1.689	;	Structure of oxidized UDP-galactopyranose mutase from Mycobacterium smegmatis in complex with UDP in mixed conformation and closed form
5EQD	;	1.83	;	Structure of oxidized UDP-galactopyranose mutase from Mycobacterium smegmatis in complex with UDP in opened and closed form
6OP7	;	1.37	;	Structure of oxidized VIM-20
4P5R	;	1.09	;	Structure of oxidized W45Y mutant of amicyanin
1SPU	;	2.0	;	STRUCTURE OF OXIDOREDUCTASE
1VJW	;	1.75	;	STRUCTURE OF OXIDOREDUCTASE (NADP+(A),FERREDOXIN(A))
3O1A	;	2.5	;	Structure of OxyE (CYP165D3), a Cytochrome P450 Involved in Teicoplanin Biosynthesis
8B7G	;	1.3	;	Structure of oxygen-degraded rsCherry
7UWT	;	1.85	;	Structure of Oxygen-Insensitive NAD(P)H-dependent Nitroreductase NfsB_Vv F70A/F108Y (NTR 2.0) in complex with FMN at 1.85 Angstroms resolution
8JTL	;	1.78	;	Structure of OY phytoplasma SAP05 binding with AtRpn10
3GR7	;	2.3	;	Structure of OYE from Geobacillus kaustophilus, hexagonal crystal form
3GR8	;	2.5	;	Structure of OYE from Geobacillus kaustophilus, orthorhombic crystal form
5YSX	;	1.202	;	Structure of P domain of GII.2 Noroviruses
5N5V	;	2.3	;	Structure of p-boronophenylalanyl tRNA synthetase - apo form
5N5U	;	1.6	;	Structure of p-boronophenylalanyl tRNA synthetase in complex with p-boronophenylalanine and adenosine monophosphate
3G5U	;	3.8	;	Structure of P-glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
3G60	;	4.4	;	Structure of P-glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
3G61	;	4.35	;	Structure of P-glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
6GDI	;	7.9	;	Structure of P-glycoprotein(ABCB1) in the post-hydrolytic state
6Q81	;	7.9	;	Structure of P-glycoprotein(ABCB1) in the post-hydrolytic state
8AGA	;	2.21	;	Structure of p-hydroxy benzoic acid ligand bound HosA transcriptional regulator from enteropathogenic Escherichia coli O127:H6 (strain E2348/69)
4GLB	;	2.69	;	Structure of p-nitrobenzaldehyde inhibited lipase from Thermomyces lanuginosa at 2.69 A resolution
2V7F	;	1.15	;	Structure of P. abyssi RPS19 protein
2J8M	;	1.44	;	Structure of P. aeruginosa acetyltransferase PA4866
2J8N	;	2.35	;	Structure of P. aeruginosa acetyltransferase PA4866 solved at room temperature
2J8R	;	1.55	;	Structure of P. aeruginosa acetyltransferase PA4866 solved in complex with L-Methionine sulfoximine
6P8J	;	1.47	;	Structure of P. aeruginosa ATCC27853 CdnD D62N/D64N mutant bound to ATP
6P82	;	2.05	;	Structure of P. aeruginosa ATCC27853 CdnD, Apo form 1
6P8U	;	1.893	;	Structure of P. aeruginosa ATCC27853 CdnD:HORMA2:Peptide 1 complex
6P8P	;	1.635	;	Structure of P. aeruginosa ATCC27853 HORMA1
6P8S	;	2.0	;	Structure of P. aeruginosa ATCC27853 HORMA1:HORMA2:Peptide 1 complex
6P8R	;	2.141	;	Structure of P. aeruginosa ATCC27853 HORMA2
6P8O	;	1.604	;	Structure of P. aeruginosa ATCC27853 HORMA2-deltaC
6Q1H	;	1.45	;	Structure of P. aeruginosa ATCC27853 NucC, cAAA-bound form
6I47	;	1.9	;	Structure of P. aeruginosa LpxC with compound 10: (2RS)-4-(5-(2-Fluoro-4-methoxyphenyl)-1-oxoisoindolin-2-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide
6I48	;	2.196	;	Structure of P. aeruginosa LpxC with compound 12: (2R)-4-(6-(2-Fluoro-4-methoxyphenyl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide
6I49	;	1.94	;	Structure of P. aeruginosa LpxC with compound 17a: (2R)-N-Hydroxy-2-methyl-2-(methylsulfonyl)-4(6((4(morpholinomethyl)phenyl)ethynyl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)yl)butanamide
6I4A	;	2.251	;	Structure of P. aeruginosa LpxC with compound 18d: (2R)-N-Hydroxy-4-(6-((1-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamide
6I46	;	1.75	;	Structure of P. aeruginosa LpxC with compound 8: (2RS)-4-(5-(2-Fluoro-4-methoxyphenyl)-2-oxooxazol-3(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide
7TB5	;	2.3	;	Structure of P. aeruginosa PA17 CapW
7AU1	;	1.36	;	Structure of P. aeruginosa PBP3 in complex with a benzoxaborole (Compound 12)
7AU8	;	1.79	;	Structure of P. aeruginosa PBP3 in complex with a benzoxaborole (Compound 13)
7AU9	;	2.137	;	Structure of P. aeruginosa PBP3 in complex with a benzoxaborole (Compound 14)
7AUB	;	1.907	;	Structure of P. aeruginosa PBP3 in complex with a benzoxaborole (Compound 15)
7ATW	;	1.44	;	Structure of P. aeruginosa PBP3 in complex with a benzoxaborole (Compound 3)
7ATX	;	1.795	;	Structure of P. aeruginosa PBP3 in complex with a benzoxaborole (Compound 4)
7AU0	;	2.17	;	Structure of P. aeruginosa PBP3 in complex with a benzoxaborole (Compound 7)
7ATM	;	1.582	;	Structure of P. aeruginosa PBP3 in complex with a phenyl boronic acid (Compound 1)
7ATO	;	1.587	;	Structure of P. aeruginosa PBP3 in complex with an aryl boronic acid (Compound 2)
7AUH	;	2.012	;	Structure of P. aeruginosa PBP3 in complex with vaborbactam
6CL5	;	2.324	;	Structure of P. aeruginosa R1 pyocin fiber PALES_06171 comprising C-terminal residues 323-701
6CL6	;	1.898	;	Structure of P. aeruginosa R2 pyocin fiber PA0620 comprising C-terminal residues 323-691
1KKT	;	2.2	;	Structure of P. citrinum alpha 1,2-mannosidase reveals the basis for differences in specificity of the ER and Golgi Class I enzymes
1KRE	;	2.2	;	STRUCTURE OF P. CITRINUM ALPHA 1,2-MANNOSIDASE REVEALS THE BASIS FOR DIFFERENCES IN SPECIFICITY OF THE ER AND GOLGI CLASS I ENZYMES
1KRF	;	2.2	;	STRUCTURE OF P. CITRINUM ALPHA 1,2-MANNOSIDASE REVEALS THE BASIS FOR DIFFERENCES IN SPECIFICITY OF THE ER AND GOLGI CLASS I ENZYMES
1OB3	;	1.9	;	Structure of P. falciparum PfPK5
1V0O	;	1.9	;	Structure of P. falciparum PfPK5-Indirubin-5-sulphonate ligand complex
1V0P	;	2.0	;	Structure of P. falciparum PfPK5-Purvalanol B ligand complex
7R51	;	1.808	;	Structure of P. gingivalis DPP11 in complex with the dipeptide Arg-Asp
5X6N	;	3.0	;	Structure of P. Knowlesi DBL Domain Capable of binding Human Duffy Antigen
7Z7H	;	3.8	;	Structure of P. luminescens TccC3-F-actin complex
1HEZ	;	2.7	;	Structure of P. magnus protein L bound to a human IgM Fab.
1MHH	;	2.1	;	Structure of P. magnus protein L mutant bound to a mouse Fab
4PX8	;	1.25	;	Structure of P. vulgaris HigB toxin
5IWH	;	1.101	;	Structure of P. vulgaris HigB toxin delta H92
5IXL	;	1.55	;	Structure of P. vulgaris HigB toxin Y91A variant
1Z25	;	2.7	;	Structure of P.furiosus Argonaute with bound Mn2+
8R88	;	1.95	;	Structure of P107T BlaC from Mycobacterium tuberculosis
5OX7	;	2.4	;	Structure of P110 from Mycoplasma genitalium at 2.4A with potassium ion
6R3T	;	2.73	;	Structure of P110 from Mycoplasma Genitalium at 2.7A
6R41	;	2.21	;	Structure of P110 from Mycoplasma genitalium complexed with 3'SL
6R43	;	2.52	;	Structure of P110 from Mycoplasma Genitalium complexed with 6'-SL
8AJ8	;	8.5	;	Structure of p110 gamma bound to the p84 regulatory subunit
8DP0	;	2.96	;	Structure of p110 gamma bound to the Ras inhibitory nanobody NB7
6NCT	;	3.35	;	Structure of p110alpha/niSH2 - vector data collection
8OE1	;	1.9	;	Structure of P167S BlaC from Mycobacterium tuberculosis at pH 5
8OE5	;	1.8	;	Structure of P167S BlaC from Mycobacterium tuberculosis at pH 6.3
1MX4	;	2.0	;	Structure of p18INK4c (F82Q)
1MX6	;	2.0	;	Structure of p18INK4c (F92N)
8IDX	;	1.75	;	Structure of p205 HIN
4NJD	;	2.5	;	Structure of p21-activated kinase 4 with a novel inhibitor KY-04031
1CTQ	;	1.26	;	STRUCTURE OF P21RAS IN COMPLEX WITH GPPNHP AT 100 K
1QRA	;	1.6	;	STRUCTURE OF P21RAS IN COMPLEX WITH GTP AT 100 K
4DKW	;	2.02	;	Structure of P22 Large terminase nuclease domain
3C9I	;	1.95	;	Structure of P22 Tail-Needle GP26 Bound to Xenon Gas
7A6Z	;	1.3	;	Structure of P226G BlaC from Mycobacterium tuberculosis
4E5B	;	2.0	;	Structure of p38a MAP kinase without BOG
2OZA	;	2.7	;	Structure of p38alpha complex
5IUT	;	2.34	;	STRUCTURE OF P450 2B4 F202W MUTANT
5IUZ	;	2.73	;	STRUCTURE OF P450 2B4 F202W MUTANT (CYMAL-5)
4KEY	;	2.05	;	Structure of P450 BM3 A82F F87V in complex with omeprazole
4O4P	;	1.83	;	Structure of P450 BM3 A82F F87V in complex with S-omeprazol
4G44	;	1.24	;	Structure of P450 CYP121 in complex with lead compound MB286, 3-((1H-1,2,4-triazol-1-yl)methyl)aniline
3WEC	;	2.19	;	Structure of P450 RauA (CYP1050A1) complexed with a biosynthetic intermediate of aurachin RE
5EX8	;	2.1	;	Structure of P450 StaF from glycopeptide antibiotic A47934 biosynthesis; ethylene glycol cryo
5EX9	;	2.2	;	Structure of P450 StaF from glycopeptide antibiotic A47934 biosynthesis; glycerol cryo
5EX6	;	2.4	;	Structure of P450 StaH from glycopeptide antibiotic A47934 biosynthesis
8U3N	;	2.15	;	Structure of P450Blt from Micromonospora sp. MW-13
8U2M	;	1.79	;	Structure of P450Blt from Micromonospora sp. MW-13 in Complex with Biarylitide
8UKZ	;	1.95	;	Structure of P450Blt from Micromonospora sp. MW-13 with E238A Mutation
3RWL	;	2.0	;	Structure of P450pyr hydroxylase
4L0E	;	2.7	;	Structure of P450sky (CYP163B3), a cytochrome P450 from skyllamycin biosynthesis (heme-coordinated expression tag)
4L0F	;	1.9	;	Structure of P450sky (CYP163B3), a cytochrome P450 from skyllamycin biosynthesis (open active site)
4PWV	;	3.0	;	Structure of P450sky (CYP163B3), a cytochrome P450 from skyllamycin biosynthesis in complex with a peptidyl carrier protein domain
4PXH	;	2.7	;	Structure of P450sky (CYP163B3), a cytochrome P450 from skyllamycin biosynthesis in complex with a peptidyl carrier protein domain
6EKT	;	1.75	;	Structure of P47 from Clostridium botulinum A2
7WVL	;	3.0	;	Structure of P4A2 Fab in complex with Spike-RBD from SARS-CoV-2
4J4D	;	2.0	;	Structure of P51G Cyanovirin-N swapped dimer in the P21212 space group
4J4C	;	1.9	;	Structure of P51G Cyanovirin-N swapped dimer in the P3221 space group
4J4G	;	1.92	;	Structure of P51G Cyanovirin-N swapped tetramer in the C2 space group
4J4F	;	1.9	;	Structure of P51G Cyanovirin-N swapped tetramer in the P212121 space group
4J4E	;	2.4	;	Structure of P51G Cyanovirin-N swapped trimer in the P212121 space group
8CG7	;	1.53	;	Structure of p53 cancer mutant Y220C with arylation at Cys182 and Cys277
6XMS	;	3.4	;	Structure of P5A-ATPase Spf1, AlF4-bound form
6XMQ	;	3.7	;	Structure of P5A-ATPase Spf1, AMP-PCP-bound form
6XMP	;	3.5	;	Structure of P5A-ATPase Spf1, Apo form
6XMT	;	3.3	;	Structure of P5A-ATPase Spf1, BeF3-bound form
6XMU	;	3.3	;	Structure of P5A-ATPase Spf1, endogenous substrate-bound
3QYM	;	3.2	;	Structure of p63 DNA Binding Domain in Complex with a 10 Base Pair A/T Rich Response Element Half Site
3US2	;	4.2	;	Structure of p63 DNA Binding Domain in Complex with a 19 Base Pair A/T Rich Response Element Containing Two Half Sites with a Single Base Pair Overlap
3QYN	;	2.5	;	Structure of p63 DNA Binding Domain in Complex with a 22 Base Pair A/T Rich Response Element Containing 2 Base Pair Spacer Between Half Sites
3US0	;	2.5	;	Structure of p63 DNA Binding Domain in Complex with a 22 Base Pair A/T Rich Response Element Containing a Two Base Pair ""AT"" Spacer Between Half Sites
3US1	;	2.8	;	Structure of p63 DNA Binding Domain in Complex with a 22 Base Pair Response Element Containing a Two Base Pair ""GC"" Spacer Between Half Sites
5N2O	;		;	Structure Of P63 SAM Domain L514F Mutant Causative Of AEC Syndrome
4GUO	;	3.19	;	structure of p73 DNA binding domain complex with 12 bp DNA
3VD0	;	2.95	;	structure of p73 DNA binding domain tetramer modulates p73 transactivation
3VD1	;	2.95	;	structure of p73 DNA binding domain tetramer modulates p73 transactivation
3VD2	;	4.0	;	structure of p73 DNA binding domain tetramer modulates p73 transactivation
2YQB	;	1.41	;	Structure of P93A variant of three-domain heme-Cu nitrite reductase from Ralstonia pickettii at 1.4 A resolution
7MHS	;	3.6	;	Structure of p97 (subunits A to E) with substrate engaged
4KLN	;	2.62	;	Structure of p97 N-D1 A232E mutant in complex with ATPgS
5DYG	;	2.2	;	Structure of p97 N-D1 L198W mutant in complex with ADP
4KOD	;	2.96	;	Structure of p97 N-D1 R155H mutant in complex with ADP
3HU3	;	2.2	;	Structure of p97 N-D1 R155H mutant in complex with ATPgS
4KO8	;	1.98	;	Structure of p97 N-D1 R155H mutant in complex with ATPgS
3HU2	;	2.85	;	Structure of p97 N-D1 R86A mutant in complex with ATPgS
3HU1	;	2.81	;	Structure of p97 N-D1 R95G mutant in complex with ATPgS
5DYI	;	3.71	;	Structure of p97 N-D1 wild-type in complex with ADP
7PUX	;	1.73	;	Structure of p97 N-D1(L198W) in complex with Fragment TROLL2
3CF3	;	4.25	;	Structure of P97/vcp in complex with ADP
3CF1	;	4.4	;	Structure of P97/vcp in complex with ADP/ADP.alfx
3CF2	;	3.5	;	Structure of P97/vcp in complex with ADP/AMP-PNP
4DG8	;	2.15	;	Structure of PA1221, an NRPS protein containing adenylation and PCP domains
2XU8	;	1.98	;	Structure of Pa1645
8PVI	;	3.7	;	Structure of PaaZ determined by cryoEM at 100 keV
6JQM	;	3.3	;	Structure of PaaZ with NADPH
6JQL	;	2.9	;	Structure of PaaZ, a bifunctional enzyme
6JQO	;	3.1	;	Structure of PaaZ, a bifunctional enzyme in complex with NADP+ and CCoA
6JQN	;	3.1	;	Structure of PaaZ, a bifunctional enzyme in complex with NADP+ and OCoA
7WJP	;	2.25	;	Structure of PadR-like protein from Listeria monocytogenes
2GL0	;	2.25	;	Structure of PAE2307 in complex with adenosine
4G75	;	1.7	;	Structure of PaeM, a colicin M-like bacteriocin produced by Pseudomonas aeruginosa
4G76	;	2.385	;	Structure of PaeM, a colicin M-like bacteriocin produced by Pseudomonas aeruginosa
7TDP	;	1.98	;	Structure of Paenibacillus polymyxa GS bound to Met-Sox-P-ADP (Transition state complex) to 1.98 Angstom
7U2R	;	1.85	;	Structure of Paenibacillus sp. J14 Apyc1
6F2P	;	2.6	;	Structure of Paenibacillus xanthan lyase to 2.6 A resolution
7U2S	;	1.55	;	Structure of Paenibacillus xerothermodurans Apyc1 in the apo state
1RKI	;	1.6	;	Structure of pag5_736 from P. aerophilum with three disulphide bonds
4NFB	;	1.6	;	Structure of paired immunoglobulin-like type 2 receptor (PILR )
4NFC	;	2.2	;	Structure of paired immunoglobulin-like type 2 receptor (PILR )
4XSK	;	1.5	;	Structure of PAItrap, an uPA mutant
5I0B	;	3.09	;	Structure of PAK4
5YW8	;	4.4	;	Structure of pancreatic ATP-sensitive potassium channel bound with ATPgammaS (all particles at 4.4A)
5YW9	;	5.0	;	Structure of pancreatic ATP-sensitive potassium channel bound with ATPgammaS (class1 5.0A)
5YWA	;	6.1	;	Structure of pancreatic ATP-sensitive potassium channel bound with ATPgammaS (CTD class 2 at 6.1A)
5YKF	;	4.33	;	Structure of pancreatic ATP-sensitive potassium channel bound with glibenclamide and ATPgammaS (3D class1 at 4.33A)
5YKG	;	4.57	;	Structure of pancreatic ATP-sensitive potassium channel bound with glibenclamide and ATPgammaS (Class2 at 4.57A)
5YW7	;	4.4	;	Structure of pancreatic ATP-sensitive potassium channel bound with glibenclamide and ATPgammaS (focused refinement on SUR1 ABC transporter module at 4.4A)
5YKE	;	4.11	;	Structure of pancreatic ATP-sensitive potassium channel bound with glibenclamide and ATPgammaS (focused refinement on TM at 4.11A)
5YWC	;	4.3	;	Structure of pancreatic ATP-sensitive potassium channel bound with Mg-ADP (CTD class1 at 4.3A)
5YWB	;	5.2	;	Structure of pancreatic ATP-sensitive potassium channel bound with Mg-ADP (CTD class2 at 5.2A)
5YWD	;	4.2	;	Structure of pancreatic ATP-sensitive potassium channel bound with Mg-ADP (focused refinement of SUR1 ABC transporter module at 4.22A)
6JB1	;	3.3	;	Structure of pancreatic ATP-sensitive potassium channel bound with repaglinide and ATPgammaS at 3.3A resolution
6W7T	;	3.01	;	Structure of PaP3 small terminase
9PAP	;	1.65	;	STRUCTURE OF PAPAIN REFINED AT 1.65 ANGSTROMS RESOLUTION
6J4N	;	2.1	;	Structure of papua new guinea MBL-1(PNGM-1) native
3EZ6	;	2.58	;	Structure of parA-ADP complex:tetragonal form
1CLM	;	1.8	;	STRUCTURE OF PARAMECIUM TETRAURELIA CALMODULIN AT 1.8 ANGSTROMS RESOLUTION
6S7M	;	1.75846	;	Structure of parasitic PEX14 in complex with a benzo[b]thiophene-7-carboxylic acid.
3FFD	;	2.0	;	Structure of parathyroid hormone-related protein complexed to a neutralizing monoclonal antibody
1ZX4	;	2.98	;	Structure of ParB bound to DNA
4E03	;	2.45	;	Structure of ParF-ADP form 2
4DZZ	;	1.8	;	Structure of ParF-ADP, crystal form 1
4E09	;	2.99	;	Structure of ParF-AMPPCP, I422 form
7US1	;	2.484	;	Structure of parkin (R0RB) bound to two phospho-ubiquitin molecules
4I1H	;	2.0	;	Structure of Parkin E3 ligase
4I1F	;	1.58	;	Structure of Parkin-S223P E3 ligase
4PJT	;	2.35	;	Structure of PARP1 catalytic domain bound to inhibitor BMN 673
4ZZX	;	1.65	;	Structure of PARP2 catalytic domain bound to an isoindolinone inhibitor
4PJV	;	2.5	;	Structure of PARP2 catalytic domain bound to inhibitor BMN 673
8K49	;	2.9	;	Structure of partial Banna virus
8W9Q	;	5.7	;	Structure of partial Banna virus
7LT6	;	1.8	;	Structure of Partial Beta-Hairpin LIR from FNIP2 Bound to GABARAP
6HSM	;	2.0	;	Structure of partially reduced RsrR in space group P2(1)2(1)2(1)
6NN3	;	3.22	;	Structure of parvovirus B19 decorated with Fab molecules from a human antibody
5MG0	;	1.65	;	Structure of PAS-GAF fragment of Deinococcus phytochrome by serial femtosecond crystallography
4H6V	;	1.7	;	Structure of Patellamide maturation protease PatA
4H6X	;	2.0	;	Structure of Patellamide maturation protease PatG
5ETE	;	2.1	;	Structure of pathogen-related yeast protein, Pry1 in complex with a competitive inhibitor of cholesterol binding
7PY2	;	2.59	;	Structure of pathological TDP-43 filaments from ALS with FTLD
7XWH	;	2.31	;	structure of patulin-detoxifying enzyme with NADP+
7XWI	;	2.22	;	structure of patulin-detoxifying enzyme with NADPH
7XWJ	;	2.12	;	structure of patulin-detoxifying enzyme Y155F with NADPH
7XWK	;	2.12	;	structure of patulin-detoxifying enzyme Y155F with NADPH and substrate
7XWL	;	2.02	;	structure of patulin-detoxifying enzyme Y155F/V187F with NADPH
7XWM	;	1.98	;	structure of patulin-detoxifying enzyme Y155F/V187K with NADPH
7XWN	;	2.1	;	structure of patulin-detoxifying enzyme Y155F/V187K with NADPH and substrate
6GML	;	3.2	;	Structure of paused transcription complex Pol II-DSIF-NELF
8UHG	;	2.7	;	Structure of paused transcription complex Pol II-DSIF-NELF - poised post-translocated
8UHD	;	2.8	;	Structure of paused transcription complex Pol II-DSIF-NELF - post-translocated
8UHA	;	3.5	;	Structure of paused transcription complex Pol II-DSIF-NELF - tilted
4HR1	;	2.5	;	Structure of PAV1-137, a protein from the virus PAV1 that infects Pyrococcus abyssi.
3WTD	;	2.35	;	Structure of PAXX
3WTF	;	3.451	;	Structure of PAXX
3UMD	;	1.8	;	Structure of pB intermediate of Photoactive yellow protein (PYP) at pH 4.
3UME	;	1.8	;	Structure of pB intermediate of Photoactive yellow protein (PYP) at pH 7
3PNR	;	2.6	;	Structure of PbICP-C in complex with falcipain-2
2J7V	;	1.9	;	Structure of PBP-A
2J8Y	;	1.9	;	Structure of PBP-A acyl-enzyme complex with penicillin-G
2J9O	;	1.5	;	Structure of PBP-A, L158E mutant
2JBF	;	1.7	;	Structure of PBP-A, L158E mutant. Acyl-enzyme complex with penicillin- G.
7A66	;	1.85	;	structure of Pcc2 from Pyrococcus abyssi
4II5	;	2.15	;	Structure of PCDK2/CYCLINA bound to ADP and 1 MAGNESIUM ION
4I3Z	;	2.05	;	Structure of pCDK2/CyclinA bound to ADP and 2 Magnesium ions
4IZN	;	2.15	;	Structure of pcDronpa-A69T mutant
6HYL	;	1.559	;	Structure of PCM1 LIR motif bound to GABARAP
6HYM	;	1.86	;	Structure of PCM1 LIR motif bound to GABARAP
3VKX	;	2.1	;	Structure of PCNA
5T9D	;	3.27	;	Structure of PCNA acetylated on K20
3WGW	;	2.8	;	Structure of PCNA bound to a small molecule inhibitor
6T7Y	;	2.7	;	Structure of PCNA bound to cPIP motif of DP2 from P. abyssi
8E62	;	1.8	;	STRUCTURE OF Pcryo_0615 from Psychrobacter cryohalolentis, an N-acetyltransferase required to produce Diacetamido-2,3-dideoxy-D-glucuronic acid
6O1Z	;	3.1	;	Structure of pCW3 conjugation coupling protein TcpA hexagonal crystal form
6O1X	;	2.46	;	Structure of pCW3 conjugation coupling protein TcpA monomer form with ATPgS
6O1W	;	2.2	;	Structure of pCW3 conjugation coupling protein TcpA monomer orthorhombic crystal form
6O1Y	;	2.7	;	Structure of pCW3 conjugation coupling protein TcpA monomeric form with ATP
5OWG	;	2.2	;	Structure of PcyX_EBK42635
5JDR	;	2.7	;	Structure of PD-L1
5N2D	;	2.35	;	Structure of PD-L1/small-molecule inhibitor complex
5N2F	;	1.7	;	Structure of PD-L1/small-molecule inhibitor complex
7WKU	;	2.6	;	Structure of PDCoV Mpro in complex with an inhibitor
3QPN	;	2.0	;	Structure of PDE10-inhibitor complex
3QPO	;	1.8	;	Structure of PDE10-inhibitor complex
3QPP	;	1.8	;	Structure of PDE10-inhibitor complex
1ZKN	;	2.1	;	Structure of PDE4D2-IBMX
4V5B	;	3.74	;	Structure of PDF binding helix in complex with the ribosome.
7WPZ	;	3.8	;	Structure of PDF-2180-COV RBD binding to Bat37 ACE2
2C0G	;	1.75	;	Structure of PDI-related Chaperone, Wind mutant-Y53S
2C1Y	;	2.25	;	Structure of PDI-related Chaperone, Wind mutant-Y55K
2C0E	;	2.35	;	Structure of PDI-related Chaperone, Wind with his-tag on C-terminus.
2BIY	;	1.95	;	Structure of PDK1-S241A mutant kinase domain
7UXP	;	2.62	;	Structure of PDL1 in complex with FP28132, a Helicon Polypeptide
7UXQ	;	2.89	;	Structure of PDL1 in complex with FP28135, a Helicon Polypeptide
7UX5	;	3.35	;	Structure of PDL1 in complex with FP28136, a Helicon Polypeptide
7UXO	;	2.25	;	Structure of PDL1 in complex with FP30790, a Helicon Polypeptide
6U9E	;	4.21	;	Structure of PdpA-VgrG Complex, Lidless
6RG0	;	3.074	;	Structure of pdxj
4XXX	;	1.5	;	Structure of PE-PPE domains of ESX-1 secreted protein EspB, C2221
4XWP	;	1.82	;	Structure of PE-PPE domains of ESX-1 secreted protein EspB, C2221 in presence of Ca
4XXN	;	2.14	;	Structure of PE-PPE domains of ESX-1 secreted protein EspB, I222
6VJ5	;	2.4	;	Structure of PE25-PPE41(A124L) in complex with EspG5 chaperone from the type VII (ESX-5) secretion system
6VHR	;	3.3	;	Structure of PE5-PPE4-EspG3 complex from the type VII (ESX-3) secretion system, space group I422
6UUJ	;	3.0	;	Structure of PE5-PPE4-EspG3 complex from the type VII (ESX-3) secretion system, space group P212121
1HKD	;	2.09	;	Structure of pea lectin in complex with alpha-methyl-D-glucopyranoside
6AWY	;	2.1	;	Structure of peanut allergen Ara h 8.01.
4HWV	;	1.37	;	Structure of Pectate Lyase from Acidovorax avenae subsp citrulli
2QX3	;	2.0	;	Structure of pectate lyase II from Xanthomonas campestris pv. campestris str. ATCC 33913
2Q0U	;	1.45	;	Structure of Pectenotoxin-2 and Latrunculin B Bound to Actin
2Q0R	;	1.7	;	Structure of Pectenotoxin-2 Bound to Actin
5CAW	;	2.62	;	Structure of Pediculus humanus Parkin bound to phospho-ubiquitin
6RHT	;	1.9	;	Structure of Pediococcus acidilactici putative lactate oxidase WT protein
6W81	;	1.55	;	Structure of PEDV main protease bound to potent broad-spectrum non-covalent inhibitor X77
3EGB	;	3.25	;	Structure of Pellino2 FHA domain at 3.3 Angstroms resolution.
1OMQ	;		;	Structure of penetratin in bicellar solution
1VQQ	;	1.8	;	Structure of Penicillin binding protein 2a from methicillin resistant Staphylococcus aureus strain 27r at 1.80 A resolution.
1MWT	;	2.45	;	Structure of penicillin G acyl-Penicillin binding protein 2a from methicillin resistant Staphylococcus aureus strain 27r at 2.45 A resolution.
5J9R	;	2.8	;	Structure of Penicillin V acylase from Agrobacterium tumefaciens
4WL2	;	2.5	;	Structure of penicillin V acylase from Pectobacterium atrosepticum
8GPW	;	2.06	;	Structure of Penicillin-binding protein 3 (PBP3) from Klebsiella pneumoniae with ligand 18G
3MZD	;	1.9	;	Structure of penicillin-binding protein 5 from E. coli: cloxacillin acyl-enzyme complex
3MZF	;	1.5	;	Structure of penicillin-binding protein 5 from E. coli: imipenem acyl-enzyme complex
3MZE	;	2.1	;	Structure of penicillin-binding protein 5 from E.coli: cefoxitin acyl-enzyme complex
3UPP	;	2.4	;	Structure of penicillin-binding protein A from M. tuberculosis: ceftrixaone acyl-enzyme complex
3UPN	;	2.2	;	Structure of penicillin-binding protein A from M. tuberculosis: imipenem acyl-enzyme complex
3UPO	;	2.3	;	Structure of penicillin-binding protein A from M. tuberculosis: penicillin G acyl-enzyme complex
1PME	;	2.0	;	STRUCTURE OF PENTA MUTANT HUMAN ERK2 MAP KINASE COMPLEXED WITH A SPECIFIC INHIBITOR OF HUMAN P38 MAP KINASE
1GVO	;	1.38	;	STRUCTURE OF PENTAERYTHRITOL TETRANITRATE REDUCTASE AND COMPLEXED WITH 2,4 DINITROPHENOL
1GVR	;	1.38	;	STRUCTURE OF PENTAERYTHRITOL TETRANITRATE REDUCTASE AND COMPLEXED WITH 2,4,6 TRINITROTOLUENE
1GVQ	;	2.0	;	STRUCTURE OF PENTAERYTHRITOL TETRANITRATE REDUCTASE AND COMPLEXED WITH 2-CYCLOHEXENONE
1GVS	;	1.38	;	Structure of pentaerythritol tetranitrate reductase and complexed with picric acid
1H50	;	1.5	;	Structure of Pentaerythritol Tetranitrate Reductase and complexes
1VYR	;	0.9	;	Structure of pentaerythritol tetranitrate reductase complexed with picric acid
1H62	;	1.9	;	Structure of Pentaerythritol tetranitrate reductase in complex with 1,4-androstadien-3,17-dione
1H61	;	1.4	;	Structure of Pentaerythritol Tetranitrate Reductase in complex with prednisone
1H60	;	1.6	;	Structure of Pentaerythritol Tetranitrate Reductase in complex with progesterone
1VYP	;	1.27	;	Structure of pentaerythritol tetranitrate reductase W102F mutant and complexed with picric acid
1VYS	;	1.8	;	STRUCTURE OF PENTAERYTHRITOL TETRANITRATE REDUCTASE W102Y MUTANT AND COMPLEXED WITH PICRIC ACID
7PTU	;	3.87	;	Structure of pentameric S-layer protein from Halofaerax volcanii
6UEA	;	3.0	;	Structure of pentameric sIgA complex
1O08	;	1.2	;	Structure of Pentavalent Phosphorous Intermediate of an Enzyme Catalyzed Phosphoryl transfer Reaction observed on cocrystallization with Glucose 1-phosphate
1O03	;	1.4	;	Structure of Pentavalent Phosphorous Intermediate of an Enzyme Catalyzed Phosphoryl transfer Reaction observed on cocrystallization with Glucose 6-phosphate
4Z1D	;	1.65	;	Structure of PEP and zinc bound KDO8PS from H.pylori
7E51	;	3.23	;	Structure of PEP bound Enolase from Mycobacterium tuberculosis
4E9B	;	1.7	;	Structure of Peptide Deformylase form Helicobacter Pylori in complex with actinonin
4E9A	;	1.662	;	Structure of Peptide Deformylase form Helicobacter Pylori in complex with inhibitor
1LM4	;	1.45	;	Structure of Peptide Deformylase from Staphylococcus aureus at 1.45 A
6R28	;		;	Structure of peptide P7, which binds Cdc42 and inhibits effector interactions.
6H8L	;	1.54	;	Structure of peptidoglycan deacetylase PdaC from Bacillus subtilis
6H8N	;	1.26	;	Structure of peptidoglycan deacetylase PdaC from Bacillus subtilis - mutant D285S
8AUD	;	4.5	;	Structure of peptidoglycan hydrolase Cg1735 from Corynebacterium glutamicum, orthorhombic crystal form
8AUC	;	3.5	;	Structure of peptidoglycan hydrolase Cg1735 from Corynebacterium glutamicum, trigonal crystal form
4IKO	;	1.9	;	Structure of Peptidyl- tRNA Hydrolase from Acinetobacter baumannii at 1.90 A resolution
3FVZ	;	2.35	;	Structure of Peptidyl-alpha-hydroxyglycine alpha-Amidating Lyase (PAL)
3FW0	;	2.52	;	Structure of Peptidyl-alpha-hydroxyglycine alpha-Amidating Lyase (PAL) bound to alpha-hydroxyhippuric acid (non-peptidic substrate)
1G6D	;	2.9	;	STRUCTURE OF PEPTIDYL-D(CGCAATTGCG) IN THE PRESENCE OF ZINC IONS
6IVV	;	1.26	;	Structure of peptidyl-tRNA hydrolase from Acinetobacter baumannii with multiple surface binding regions at 1.26A resolution
6YOF	;	2.45	;	Structure of PepTSt from COC IMISX setup collected by rotation serial crystallography on crystals prelocated by 2D X-ray phase-contrast imaging
6YOG	;	2.3	;	Structure of PepTSt from COC IMISX setup collected by still serial crystallography on crystals prelocated by 2D X-ray phase-contrast imaging
5B7E	;	1.42	;	Structure of perdeuterated CueO
5B7M	;	1.8	;	Structure of perdeuterated CueO - the signal peptide was truncated by HRV3C protease
2X21	;	1.75	;	Structure of Peridinin-Chlorophyll-Protein reconstituted with BChl-a
2X20	;	1.95	;	Structure of Peridinin-Chlorophyll-Protein reconstituted with Chl-b
2X1Z	;	1.8	;	Structure of Peridinin-Chlorophyll-Protein reconstituted with Chl-d
2M11	;		;	Structure of perimidinone-derived synthetic nucleoside paired with guanine in DNA duplex
2F5X	;	1.72	;	Structure of periplasmic binding protein BugD
4CL2	;	1.63	;	structure of periplasmic metal binding protein from candidatus liberibacter asiaticus
5Z66	;	1.8	;	Structure of periplasmic trehalase from Diamondback moth gut bacteria complexed with validoxylamine
5Z6H	;	2.3	;	Structure of periplasmic trehalase from Diamondback moth gut bacteria in the apo form
3W6G	;	2.25	;	Structure of peroxiredoxin from anaerobic hyperthermophilic archaeon Pyrococcus horikoshii
5JLY	;	3.051	;	Structure of Peroxiredoxin-1 from Schistosoma japonicum
3CVP	;	2.0	;	Structure of Peroxisomal Targeting Signal 1 (PTS1) binding domain of Trypanosoma brucei Peroxin 5 (TbPEX5)complexed to PTS1 peptide (10-SKL)
3CVQ	;	3.01	;	Structure of Peroxisomal Targeting Signal 1 (PTS1) binding domain of Trypanosoma brucei Peroxin 5 (TbPEX5)complexed to PTS1 peptide (7-SKL)
3CVN	;	2.0	;	Structure of Peroxisomal Targeting Signal 1 (PTS1) binding domain of Trypanosoma brucei Peroxin 5 (TbPEX5)complexed to T. brucei Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) PTS1 peptide
3CVL	;	2.15	;	Structure of Peroxisomal Targeting Signal 1 (PTS1) binding domain of Trypanosoma brucei Peroxin 5 (TbPEX5)complexed to T. brucei Phosphofructokinase (PFK) PTS1 peptide
3CV0	;	2.0	;	Structure of Peroxisomal Targeting Signal 1 (PTS1) binding domain of Trypanosoma brucei Peroxin 5 (TbPEX5)complexed to T. brucei Phosphoglucoisomerase (PGI) PTS1 peptide
3W15	;	1.8	;	Structure of peroxisomal targeting signal 2 (PTS2) of Saccharomyces cerevisiae 3-ketoacyl-CoA thiolase in complex with Pex7p and Pex21p
4LLU	;	2.16	;	Structure of Pertuzumab Fab with light chain Clambda at 2.16A
2ABB	;	1.0	;	Structure of PETN reductase Y186F in complex with cyanide
2W85	;		;	Structure of Pex14 in complex with Pex19
2W84	;		;	Structure of Pex14 in complex with Pex5
4BXU	;		;	Structure of Pex14 in complex with Pex5 LVxEF motif
4O8U	;	2.345	;	Structure of PF2046
7RQP	;	2.98	;	Structure of PfCSP NPNV binding antibody L9
6B5P	;	2.297	;	Structure of PfCSP peptide 20 with human antibody CIS42
6B5L	;	2.4	;	Structure of PfCSP peptide 20 with human protective antibody CIS43
7SG6	;	1.55	;	Structure of PfCSP peptide 21 with antibody CIS43_Var10
7SG5	;	1.4	;	Structure of PfCSP peptide 21 with antibody CIS43_Var2
7RAJ	;	3.0	;	Structure of PfCSP peptide 21 with antibody iGL-CIS43.D3
7UFN	;	2.2	;	Structure of PfCSP peptide 21 with antibody P3-21
7UFO	;	1.8	;	Structure of PfCSP peptide 21 with antibody P3-42
7UFQ	;	2.3	;	Structure of PfCSP peptide 21 with antibody P3-43
6B5R	;	1.775	;	Structure of PfCSP peptide 21 with human antibody CIS42
6B5M	;	1.79	;	Structure of PfCSP peptide 21 with human protective antibody CIS43
6B5S	;	1.983	;	Structure of PfCSP peptide 25 with human antibody CIS42
6B5N	;	1.98	;	Structure of PfCSP peptide 25 with human protective antibody CIS43
6B5T	;	2.222	;	Structure of PfCSP peptide 29 with human antibody CIS42
6B5O	;	2.194	;	Structure of PfCSP peptide 29 with human protective antibody CIS43
7WN0	;	3.64	;	Structure of PfENT1(Y190A) in complex with nanobody 19
7E26	;	2.29	;	Structure of PfFNT in apo state
7E27	;	2.29	;	Structure of PfFNT in complex with MMV007839
6XJ9	;	2.0	;	Structure of PfGH50B
7DIV	;	1.64	;	Structure of PfGrx1 in the intermediate state with cadmium
7DIT	;	1.8	;	Structure of PfGrx1 in the intermediate state with cadmium and cesium
7DIW	;	1.671	;	Structure of PfGrx1 in the intermediate state with mercury
7DIU	;	1.879	;	Structure of PfGrx1 in the intermediate state with platinum and cesium
7DJ0	;	1.67	;	Structure of PfGrx1 in the reduced state using BME
7DIZ	;	1.8	;	Structure of PfGrx1 in the reduced state using DTT
7DIK	;	1.55	;	Structure of PfGrx1 with barium
7DIM	;	1.68	;	Structure of PfGrx1 with cadmium
7DIL	;	1.71	;	Structure of PfGrx1 with cesium
7DIN	;	1.799	;	Structure of PfGrx1 with cobalt
7DIO	;	1.899	;	Structure of PfGrx1 with iron
7DIP	;	1.731	;	Structure of PfGrx1 with manganese
7DIR	;	1.65	;	Structure of PfGrx1 with mercury
7DIQ	;	1.87	;	Structure of PfGrx1 with zinc
5LG9	;		;	Structure of PfIMP2 (Immune Mapped Protein 2 from Plasmodium falciparum) - an antigenic protein
6TU7	;	3.1	;	Structure of PfMyoA decorated Plasmodium Act1 filament
7WN1	;	3.11	;	Structure of PfNT1(Y190A) in complex with nanobody 48 and inosine
7YDQ	;	4.04	;	Structure of PfNT1(Y190A)-GFP in complex with GSK4
5TXW	;	1.86	;	Structure of Pfp1 protease from Thermococcus thioreducens: large cell H3 crystal form
7R66	;	1.44	;	Structure of Pfp1 protease from Thermococcus thioreducens: large unit cell at 1.44 A resolution
5TW0	;	1.96	;	Structure of Pfp1 protease from Thermococcus thioreducens: small cell H3 crystal form
3LRS	;	2.37	;	Structure of PG16, an antibody with broad and potent neutralization of HIV-1
2ZKT	;	2.4	;	Structure of PH0037 protein from Pyrococcus horikoshii
2IT1	;	1.94	;	Structure of PH0203 protein from Pyrococcus horikoshii
2DC4	;	1.65	;	Structure of PH1012 protein from Pyrococcus Horikoshii OT3
2IT2	;	1.5	;	Structure of PH1069 protein from Pyrococcus horikoshii
2IT3	;	2.1	;	Structure of PH1069 protein from Pyrococcus horikoshii
2DRV	;	1.6	;	Structure of PH1069 protein from Pyrococcus horikoshii OT3
4WJ0	;	2.85	;	Structure of PH1245, a cas1 from Pyrococcus horikoshii
2DCL	;	2.28	;	Structure of PH1503 protein from Pyrococcus Horikoshii OT3
2FKO	;	1.85	;	Structure of PH1591 from Pyrococcus horikoshii OT3
2EKN	;	2.05	;	Structure of PH1811 protein from Pyrococcus horikoshii
2EEN	;	1.65	;	Structure of PH1819 protein from Pyrococcus Horikoshii OT3
2DVN	;	1.6	;	Structure of PH1917 protein with the complex of IMP from Pyrococcus horikoshii
2DVO	;	2.21	;	Structure of PH1917 protein with the complex of ITP from Pyrococcus horikoshii
5XAV	;	1.479	;	Structure of PhaC from Chromobacterium sp. USM2
2CRO	;	2.35	;	STRUCTURE OF PHAGE 434 CRO PROTEIN AT 2.35 ANGSTROMS RESOLUTION
1ZUG	;		;	STRUCTURE OF PHAGE 434 CRO PROTEIN, NMR, 20 STRUCTURES
7T28	;	2.68	;	Structure of phage Bsp38 anti-Pycsar nuclease Apyc1 in apo state
7T26	;	1.14	;	Structure of phage FBB1 anti-CBASS nuclease Acb1 in apo state
7T27	;	1.2	;	Structure of phage FBB1 anti-CBASS nuclease Acb1-3'3'-cGAMP complex in post reaction state
2POH	;	2.1	;	Structure of Phage P22 Tail Needle gp26
4IOS	;	2.4	;	Structure of phage TP901-1 RBP (ORF49) in complex with nanobody 11.
4JG2	;	1.3	;	Structure of phage-related protein from Bacillus cereus ATCC 10987
5ZVW	;	2.292	;	Structure of phAimR-Ligand
1Z3W	;	1.7	;	Structure of Phanerochaete chrysosporium cellobiohydrolase Cel7D (CBH58) in complex with cellobioimidazole
1Z3T	;	1.7	;	Structure of Phanerochaete chrysosporium cellobiohydrolase Cel7D (CBH58) in complex with cellobiose
1Z3V	;	1.61	;	Structure of Phanerochaete chrysosporium cellobiohydrolase Cel7D (CBH58) in complex with lactose
4BTV	;	1.594	;	Structure of PhaZ7 PHB depolymerase in complex with 3HB trimer
4BYM	;	1.598	;	Structure of PhaZ7 PHB depolymerase Y105E mutant
2LGG	;		;	Structure of PHD domain of UHRF1 in complex with H3 peptide
5V1B	;	2.49	;	Structure of PHD1 in complex with 1,2,4-Triazolo-[1,5-a]pyridine
5V18	;	2.15	;	Structure of PHD2 in complex with 1,2,4-Triazolo-[1,5-a]pyridine
7UJV	;	1.8	;	Structure of PHD2 in complex with HIF2a-CODD
3HGU	;	1.95	;	Structure of Phenazine Antibiotic Biosynthesis Protein
3HGV	;	2.3	;	Structure of Phenazine Antibiotic Biosynthesis Protein
3L2K	;	2.8	;	Structure of phenazine antibiotic biosynthesis protein with substrate
5KHB	;		;	Structure of Phenol-soluble modulin Alpha1
4ALB	;	3.03	;	Structure of Phenolic Acid Decarboxylase from Bacillus subtilis: Tyr19Ala mutant in complex with coumaric acid
3GYR	;	2.3	;	Structure of Phenoxazinone synthase from Streptomyces antibioticus reveals a new type 2 copper center.
4QYJ	;	2.83	;	Structure of Phenylacetaldehyde Dehydrogenase from Pseudomonas putida S12
6HQF	;	1.76	;	Structure of Phenylalanine ammonia-lyase from Petroselinum crispum in complex with (R)-APEP
2PHM	;	2.6	;	STRUCTURE OF PHENYLALANINE HYDROXYLASE DEPHOSPHORYLATED
6XHF	;	1.45	;	Structure of Phenylalanyl-5'-O-adenosine phosphoramidate
4INW	;	1.14	;	Structure of Pheromone-binding protein 1 in complex with (11Z,13Z)-hexadecadienal
4INX	;	1.853	;	Structure of Pheromone-binding protein 1 in complex with (Z,Z)-11,13- hexadecadienol
3KV4	;	2.19	;	Structure of PHF8 in complex with histone H3
3TPV	;	2.3	;	Structure of pHipA bound to ADP
3TPD	;	1.5	;	Structure of pHipA, monoclinic form
6X1S	;	1.65	;	Structure of pHis Fab (SC1-1) in complex with pHis mimetic peptide
6X1U	;	1.641	;	Structure of pHis Fab (SC39-4) in complex with pHis mimetic peptide
6X1V	;	2.11	;	Structure of pHis Fab (SC44-8) in complex with pHis mimetic peptide
6X1T	;	2.34	;	Structure of pHis Fab (SC50-3) in complex with pHis mimetic peptide
6X1W	;	1.95	;	Structure of pHis Fab (SC56-2) in complex with pHis mimetic peptide
2YEQ	;	1.93	;	Structure of PhoD
3R0J	;	2.5	;	Structure of PhoP from Mycobacterium tuberculosis
5LMK	;	2.4	;	Structure of phopsho-CDK2-cyclin A in complex with an ATP-competitive inhibitor
1RKV	;	1.9	;	Structure of Phosphate complex of ThrH from Pseudomonas aeruginosa
7RSA	;	1.26	;	STRUCTURE OF PHOSPHATE-FREE RIBONUCLEASE A REFINED AT 1.26 ANGSTROMS
3TQK	;	2.3	;	Structure of Phospho-2-dehydro-3-deoxyheptonate aldolase from Francisella tularensis SCHU S4
6GLC	;	1.8	;	Structure of phospho-Parkin bound to phospho-ubiquitin
1OS1	;	1.8	;	Structure of Phosphoenolpyruvate Carboxykinase complexed with ATP,Mg, Ca and pyruvate.
3O8L	;	3.2	;	Structure of phosphofructokinase from rabbit skeletal muscle
3O8N	;	3.2	;	Structure of phosphofructokinase from rabbit skeletal muscle
3O8O	;	2.9	;	Structure of phosphofructokinase from Saccharomyces cerevisiae
4NG4	;	2.78	;	Structure of phosphoglycerate kinase (CBU_1782) from Coxiella burnetii
1XQ9	;	2.58	;	Structure of Phosphoglycerate Mutase from Plasmodium falciparum at 2.6 Resolution
5I01	;	2.37	;	Structure of phosphoheptose isomerase GmhA from Neisseria gonorrhoeae
5JHA	;	2.51	;	Structure of Phosphoinositide 3-kinase gamma (PI3K) bound to the potent inhibitor PIKin2
5JHB	;	2.48	;	Structure of Phosphoinositide 3-kinase gamma (PI3K) bound to the potent inhibitor PIKin3
1FB2	;	1.95	;	STRUCTURE OF PHOSPHOLIPASE A2 FROM DABOIA RUSSELLI PULCHELLA AT 1.95
4Q6X	;	2.14	;	Structure of phospholipase D Beta1B1i from Sicarius terrosus venom at 2.14 A resolution
6WHE	;	1.73	;	Structure of phosphomimetic Rab8a GTPase (T72E) in the GTP-bound state
1IHP	;	2.5	;	STRUCTURE OF PHOSPHOMONOESTERASE
5EQN	;	2.3	;	Structure of phosphonate hydroxylase
4QYW	;	1.597	;	Structure of phosphono-CheY from T.maritima
4I3W	;	2.24	;	Structure of phosphonoacetaldehyde dehydrogenase in complex with gylceraldehyde-3-phosphate and cofactor NAD+
4I3U	;	2.1	;	Structure of phosphonoacetaldehyde dehydrogenase in complex with phosphonoacetaldehyde
4I3V	;	2.0	;	Structure of phosphonoacetaldehyde dehydrogenase in complex with phosphonoacetaldehyde and cofactor NAD+
4I3X	;	2.07	;	Structure of phosphonoacetaldehyde dehydrogenase in complex with phosphonoacetate and cofactor NAD+
4I3T	;	2.1	;	Structure of phosphonoacetaldehyde dehydrogenase in the apo state
4F3R	;	2.25	;	Structure of phosphopantetheine adenylyltransferase (CBU_0288) from Coxiella burnetii
6W3C	;	2.3	;	Structure of phosphorylated apo IRE1
5OPD	;	2.75	;	Structure of phosphorylated EF-Tu in complex with GTP
2HWG	;	2.7	;	Structure of phosphorylated Enzyme I of the phosphoenolpyruvate:sugar phosphotransferase system
1VRV	;		;	Structure of phosphorylated IIB (C384(SEP)) domain of the mannitol-specific permease enzyme II
6W3E	;	2.737	;	Structure of phosphorylated IRE1 in complex with G-0701
3Q52	;	1.801	;	Structure of phosphorylated PAK1 kinase domain
3Q53	;	2.09	;	Structure of phosphorylated PAK1 kinase domain in complex with ATP
1PHZ	;	2.2	;	STRUCTURE OF PHOSPHORYLATED PHENYLALANINE HYDROXYLASE
4FXW	;	2.29	;	Structure of phosphorylated SF1 complex with U2AF65-UHM domain
3DDP	;	2.7	;	Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor CR8
3BHT	;	2.0	;	Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor meriolin 3
3BHU	;	2.3	;	Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor meriolin 5
3DDQ	;	1.8	;	Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor roscovitine
3BHV	;	2.1	;	Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor variolin B
5MI3	;	2.8	;	Structure of phosphorylated translation elongation factor EF-Tu from E. coli
5W7T	;	2.01	;	STRUCTURE OF PHOSPHORYLATED WNK1
4JFZ	;	1.75	;	Structure of phosphoserine (pSAb) scaffold bound to pSer peptide
1BJN	;	2.3	;	STRUCTURE OF PHOSPHOSERINE AMINOTRANSFERASE FROM ESCHERICHIA COLI
8I28	;	2.8	;	Structure of Phosphoserine Aminotransferase from Saccharomyces cerevisiae
4JG0	;	1.81	;	Structure of phosphoserine/threonine (pSTAb) scaffold bound to pSer peptide
4JG1	;	1.55	;	Structure of phosphoserine/threonine (pSTAb) scaffold bound to pThr peptide
2ECK	;	2.8	;	STRUCTURE OF PHOSPHOTRANSFERASE
3B2T	;	1.8	;	Structure of phosphotransferase
3OXP	;	1.2	;	Structure of phosphotransferase enzyme II, A component from Yersinia pestis CO92 at 1.2 A resolution
1LXT	;	2.7	;	STRUCTURE OF PHOSPHOTRANSFERASE PHOSPHOGLUCOMUTASE FROM RABBIT
3WML	;	1.99	;	Structure of phosphotriesterase mutant (S308L/Y309A) from Agrobacterium radiobacter
4NP7	;	1.99	;	Structure of phosphotriesterase mutant (S308L/Y309A) from Agrobacterium radiobacter with diethyl thiophosphate bound in the active site
2O4Q	;	1.95	;	Structure of Phosphotriesterase mutant G60A
2OQL	;	1.8	;	Structure of Phosphotriesterase mutant H254Q/H257F
2OB3	;	1.04	;	Structure of Phosphotriesterase mutant H257Y/L303T
2O4M	;	1.64	;	Structure of Phosphotriesterase mutant I106G/F132G/H257Y
3ZNI	;	2.21	;	Structure of phosphoTyr363-Cbl-b - UbcH5B-Ub - ZAP-70 peptide complex
4A49	;	2.214	;	Structure of phosphoTyr371-c-Cbl-UbcH5B complex
4A4C	;	2.704	;	Structure of phosphoTyr371-c-Cbl-UbcH5B-ZAP-70 complex
4JFX	;	1.95	;	Structure of phosphotyrosine (pTyr) scaffold bound to pTyr peptide
5O76	;	2.473	;	Structure of phosphoY371 c-CBL in complex with ZAP70-peptide and UbV.pCBL ubiquitin variant
5KYV	;	2.5	;	Structure of Photinus pyralis Luciferase green shifted light emitting variant
5KYT	;	2.001	;	Structure of Photinus pyralis Luciferase red light emitting variant
1QNF	;	1.8	;	STRUCTURE OF PHOTOLYASE
5LGZ	;	1.5	;	Structure of Photoreduced Pentaerythritol Tetranitrate Reductase
6SUF	;	3.4	;	Structure of Photorhabdus luminescens Tc holotoxin pore
6SUE	;	3.4	;	Structure of Photorhabdus luminescens Tc holotoxin pore, Mutation TccC3-D651A
5Y5S	;	1.9	;	Structure of photosynthetic LH1-RC super-complex at 1.9 angstrom resolution
7VRJ	;	2.81	;	STRUCTURE OF PHOTOSYNTHETIC LH1-RC SUPER-COMPLEX OF Allochromatium tepidum
7YML	;	2.6	;	Structure of photosynthetic LH1-RC super-complex of Rhodobacter capsulatus
7VY2	;	2.75	;	STRUCTURE OF PHOTOSYNTHETIC LH1-RC SUPER-COMPLEX OF RHODOBACTER SPHAEROIDES DIMER
7VY3	;	2.63	;	STRUCTURE OF PHOTOSYNTHETIC LH1-RC SUPER-COMPLEX OF RHODOBACTER SPHAEROIDES LACKING PROTEIN-U
7F0L	;	2.94	;	STRUCTURE OF PHOTOSYNTHETIC LH1-RC SUPER-COMPLEX OF RHODOBACTER SPHAEROIDES MONOMER
7XXF	;	2.24	;	Structure of photosynthetic LH1-RC super-complex of Rhodopila globiformis
7EQD	;	2.76	;	STRUCTURE OF PHOTOSYNTHETIC LH1-RC SUPER-COMPLEX OF RHODOSPIRILLUM RUBRUM
7C9R	;	2.82	;	STRUCTURE OF PHOTOSYNTHETIC LH1-RC SUPER-COMPLEX OF THIORHODOVIBRIO STRAIN 970
7Z8D	;	2.14	;	Structure of Photosynthetic Reaction Center From Rhodobacter Sphaeroides strain RV by fixed-target serial synchrotron crystallography (room temperature, 26keV)
1KBY	;	2.5	;	Structure of Photosynthetic Reaction Center with bacteriochlorophyll-bacteriopheophytin heterodimer
6PNJ	;	3.19	;	Structure of Photosystem I Acclimated to Far-red Light
5ZJI	;	3.3	;	Structure of photosystem I supercomplex with light-harvesting complexes I and II
7S3D	;	2.91	;	Structure of photosystem I with bound ferredoxin from Synechococcus sp. PCC 7335 acclimated to far-red light
6NKI	;	2.6	;	Structure of PhqB Reductase Domain from Penicillium fellutanum
6NKM	;	1.896	;	Structure of PhqE D166N Reductase/Diels-Alderase from Penicillium fellutanum in complex with NADP+ and substrate
6NKK	;	2.299	;	Structure of PhqE Reductase/Diels-Alderase from Penicillium fellutanum in complex with NADP+ and premalbrancheamide
1PHN	;	1.65	;	STRUCTURE OF PHYCOCYANIN FROM CYANIDIUM CALDARIUM AT 1.65A RESOLUTION
2VCK	;	1.8	;	Structure of Phycoerythrobilin Synthase PebS from the Cyanophage P-SSM2 in Complex with the bound Substrate Biliverdin IXa
2VCL	;	1.55	;	Structure of Phycoerythrobilin Synthase PebS from the Cyanophage P-SSM2 in the substrate free form
6JEL	;	2.3	;	Structure of Phytolacca americana apo UGT2
6JEN	;	2.65	;	Structure of Phytolacca americana UGT2 complexed with UDP-2fluoro-glucose and pterostilbene
6JEM	;	2.6	;	Structure of Phytolacca americana UGT2 complexed with UDP-2fluoro-glucose and resveratrol
6LZX	;	3.101	;	Structure of Phytolacca americana UGT3 with 15-crown-5
6LZY	;	2.4	;	Structure of Phytolacca americana UGT3 with 18-crown-6
4PS3	;	2.9	;	Structure of PI3K gamma in complex with 1-[6-(5-methoxypyridin-3-yl)-1,3-benzothiazol-2-yl]-3-[2-(1-propyl-1H-imidazol-4-yl)ethyl]urea
4XX5	;	2.76	;	Structure of PI3K gamma in complex with an inhibitor
4XZ4	;	2.6	;	Structure of PI3K gamma in complex with an inhibitor
3DBS	;	2.8	;	Structure of PI3K gamma in complex with GDC0941
4PS8	;	2.99	;	Structure of PI3K gamma in complex with N-[6-(5,6-dimethoxypyridin-3-yl)-1,3-benzothiazol-2-yl]acetamide
4PS7	;	2.69	;	Structure of PI3K gamma in complex with N-[6-(pyridin-3-yl)-1,3-benzothiazol-2-yl]acetamide
3L08	;	2.7	;	Structure of Pi3K gamma with a potent inhibitor: GSK2126458
4KZ0	;	2.87	;	Structure of PI3K gamma with Imidazopyridine inhibitors
4KZC	;	3.25	;	Structure of PI3K gamma with Imidazopyridine inhibitors
3L54	;	2.3	;	Structure of Pi3K gamma with inhibitor
3ENJ	;	1.78	;	Structure of Pig Heart Citrate Synthase at 1.78 A resolution
1VJD	;	1.9	;	Structure of pig muscle PGK complexed with ATP
1VJC	;	2.1	;	Structure of pig muscle PGK complexed with MgATP
1HX0	;	1.38	;	Structure of pig pancreatic alpha-amylase complexed with the ""truncate"" acarbose molecule (pseudotrisaccharide)
2XUL	;	2.2	;	Structure of PII from Synechococcus elongatus in complex with 2- oxoglutarate at high 2-OG concentrations
2XZW	;	1.95	;	STRUCTURE OF PII FROM SYNECHOCOCCUS ELONGATUS IN COMPLEX WITH 2- OXOGLUTARATE AT LOW 2-OG CONCENTRATIONS
1HWU	;	2.1	;	STRUCTURE OF PII PROTEIN FROM HERBASPIRILLUM SEROPEDICAE
4CNY	;	1.2	;	Structure of PII signaling protein GlnZ from Azospirillum brasilense
4CNZ	;	1.7	;	Structure of PII signaling protein GlnZ from Azospirillum brasilense in complex with adenosine diphosphate
4CO0	;	1.4	;	Structure of PII signaling protein GlnZ from Azospirillum brasilense in complex with adenosine diphosphate
4CO1	;	1.5	;	Structure of PII signaling protein GlnZ from Azospirillum brasilense in complex with adenosine diphosphate
4CO2	;	1.8	;	Structure of PII signaling protein GlnZ from Azospirillum brasilense in complex with adenosine diphosphate
4CO3	;	1.05	;	Structure of PII signaling protein GlnZ from Azospirillum brasilense in complex with adenosine triphosphate
4CO4	;	1.5	;	Structure of PII signaling protein GlnZ from Azospirillum brasilense in complex with adenosine triphosphate
4CO5	;	1.8	;	Structure of PII signaling protein GlnZ from Azospirillum brasilense in complex with tartrate
7R9V	;	2.69	;	Structure of PIK3CA with covalent inhibitor 19
7R9Y	;	2.85	;	Structure of PIK3CA with covalent inhibitor 22
4NFD	;	1.708	;	Structure of PILR L108W mutant in complex with sialic acid
1YI4	;	2.4	;	Structure of Pim-1 bound to adenosine
4K18	;	2.051	;	Structure of PIM-1 kinase bound to 5-(4-cyanobenzyl)-N-(4-fluorophenyl)-7-hydroxypyrazolo[1,5-a]pyrimidine-3-carboxamide
4K0Y	;	1.954	;	Structure of PIM-1 kinase bound to N-(4-fluorophenyl)-7-hydroxy-5-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
4K1B	;	2.082	;	Structure of PIM-1 kinase bound to N-(5-(2-fluorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-((((3R,4R)-3-fluoropiperidin-4-yl)methyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxamide
3A99	;	1.6	;	Structure of PIM-1 kinase crystallized in the presence of P27KIP1 Carboxy-terminal peptide
2HWY	;	2.75	;	Structure of PIN domain of human SMG5.
2HWW	;	1.8	;	Structure of PIN domain of human SMG6
5H4G	;	1.77	;	Structure of PIN-domain protein (VapC4 toxin) from Pyrococcus horikoshii determined at 1.77 A resolution
5H4H	;	2.23	;	Structure of PIN-domain protein (VapC4 toxin) from Pyrococcus horikoshii determined at 2.2 A resolution
3WH0	;	1.6	;	Structure of Pin1 Complex with 18-crown-6
4TNS	;	1.33	;	Structure of Pin1 PPIase domain bound with all-trans retinoic acid
2M8I	;		;	Structure of Pin1 WW domain
2M8J	;		;	Structure of Pin1 WW domain phospho-mimic S16E
5VTJ	;	1.5	;	Structure of Pin1 WW Domain Sequence 1 Substituted with [S,S]ACPC
5VTI	;	1.8	;	Structure of Pin1 WW Domain Sequence 3 with [R,R]-ACPC Loop Substitution
5VTK	;	1.99	;	Structure of Pin1 WW Domain Variant 1 with beta3-Ser Loop Substitution
6EQI	;	3.1	;	Structure of PINK1 bound to ubiquitin
5NM8	;	1.93	;	Structure of PipY, the COG0325 family member of Synechococcus elongatus PCC7942, with PLP bound
5NLC	;	1.9	;	Structure of PipY, the COG0325 family member of Synechococcus elongatus PCC7942,without PLP
4HHH	;	2.2	;	Structure of Pisum sativum Rubisco
4MKV	;	2.15	;	Structure of Pisum sativum Rubisco with ABA
1UW5	;	2.9	;	Structure of PITP-alpha complexed to phosphatidylinositol
2VO7	;	1.98	;	Structure of PKA complexed with 4-(4-Chlorobenzyl)-1-(7H-pyrrolo(2,3- d)pyrimidin-4-yl)piperidin-4-ylamine
7U9Q	;	3.11	;	Structure of PKA phosphorylated human RyR2 in the closed state
7U9T	;	2.68	;	Structure of PKA phosphorylated human RyR2 in the closed state in the presence of Calmodulin
7U9R	;	3.69	;	Structure of PKA phosphorylated human RyR2 in the open state
7U9X	;	2.58	;	Structure of PKA phosphorylated human RyR2-R2474S in the closed state
7UA1	;	2.99	;	Structure of PKA phosphorylated human RyR2-R2474S in the closed state in the presence of ARM210
7UA3	;	2.97	;	Structure of PKA phosphorylated human RyR2-R2474S in the closed state in the presence of Calmodulin
7U9Z	;	3.29	;	Structure of PKA phosphorylated human RyR2-R2474S in the open state
7UA4	;	2.93	;	Structure of PKA phosphorylated human RyR2-R2474S in the open state in the presence of Calmodulin
8UXE	;	3.53	;	Structure of PKA phosphorylated human RyR2-R420Q in the closed state in the presence of ARM210
8UXC	;	2.86	;	Structure of PKA phosphorylated human RyR2-R420Q in the primed state
8UXG	;	3.08	;	Structure of PKA phosphorylated human RyR2-R420W in the closed state in the presence of ARM210
8UXI	;	3.29	;	Structure of PKA phosphorylated human RyR2-R420W in the open state in the presence of calcium
8UXM	;	3.56	;	Structure of PKA phosphorylated human RyR2-R420W in the open state in the presence of calcium and calmodulin
8UXF	;	3.13	;	Structure of PKA phosphorylated human RyR2-R420W in the primed state
8UXH	;	3.52	;	Structure of PKA phosphorylated human RyR2-R420W in the primed state in the presence of calcium
8UXL	;	3.12	;	Structure of PKA phosphorylated human RyR2-R420W in the primed state in the presence of calcium and calmodulin
3KKV	;	1.8	;	Structure of PKA with a protein Kinase B-selective inhibitor.
2VNY	;	1.96	;	Structure of PKA-PKB chimera complexed with (1-(9H-Purin-6-yl) piperidin-4-yl)amine
2VNW	;	2.09	;	Structure of PKA-PKB chimera complexed with (1-(9H-Purin-6-yl) piperidin-4-yl)methanamine
4AXA	;	1.9	;	Structure of PKA-PKB chimera complexed with (1S)-2-amino-1-(4- chlorophenyl)-1-(4-(1H-pyrazol-4-yl)phenyl)ethan-1-ol
2UW5	;	2.14	;	Structure of PKA-PKB chimera complexed with (R)-2-(4-chloro-phenyl)- 2-(4-1H-pyrazol-4-yl)-phenyl)-ethylamine
2UW6	;	2.23	;	Structure of PKA-PKB chimera complexed with (S)-2-(4-chloro-phenyl)- 2-(4-1H-pyrazol-4-yl)-phenyl)-ethylamine
2UW4	;	2.0	;	Structure of PKA-PKB chimera complexed with 2-(4-(5-methyl-1H-pyrazol- 4-yl)-phenyl)-ethylamine
2UW8	;	2.0	;	Structure of PKA-PKB chimera complexed with 2-(4-chloro-phenyl)-2- phenyl-ethylamine
2UW7	;	2.1	;	Structure of PKA-PKB chimera complexed with 4-(4-chloro-phenyl)-4-(4- (1H-pyrazol-4-yl)-phenyl)-piperidine
2VO6	;	1.97	;	Structure of PKA-PKB chimera complexed with 4-(4-Chlorobenzyl)-1-(7H- pyrrolo(2,3-d)pyrimidin-4-yl)piperidin-4-ylamine
2UW3	;	2.19	;	Structure of PKA-PKB chimera complexed with 5-methyl-4-phenyl-1H- pyrazole
2UW0	;	2.0	;	Structure of PKA-PKB chimera complexed with 6-(4-(4-(4-Chloro-phenyl) -piperidin-4-yl)-phenyl)-9H-purine
2UVX	;	2.0	;	Structure of PKA-PKB chimera complexed with 7-azaindole
2JDV	;	2.08	;	Structure of PKA-PKB chimera complexed with A-443654
2VO0	;	1.94	;	Structure of PKA-PKB chimera complexed with C-(4-(4-Chlorophenyl)-1-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)piperidin-4-yl)methylamine
2VO3	;	1.98	;	Structure of PKA-PKB chimera complexed with C-(4-(4-Chlorophenyl)-1-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)piperidin-4-yl)methylamine
2UVZ	;	1.94	;	Structure of PKA-PKB chimera complexed with C-Phenyl-C-(4-(9H-purin-6- yl)-phenyl)-methylamine
2JDT	;	2.15	;	Structure of PKA-PKB chimera complexed with ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL)AMIDE
2UVY	;	1.95	;	Structure of PKA-PKB chimera complexed with methyl-(4-(9H-purin-6-yl)- benzyl)-amine
1GZN	;	2.5	;	Structure of PKB kinase domain
2UW9	;	2.1	;	STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH 4-(4-chloro-phenyl)-4-(4-(1H-pyrazol-4-yl)-phenyl)-piperidine
2JDO	;	1.8	;	STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL)AMIDE
2JDR	;	2.3	;	STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH THE INHIBITOR A-443654
2UVM	;	1.94	;	Structure of PKBalpha PH domain in complex with a novel inositol headgroup surrogate, benzene 1,2,3,4-tetrakisphosphate
4DC2	;	2.4	;	Structure of PKC in Complex with a Substrate Peptide from Par-3
7D7E	;	3.4	;	Structure of PKD1L3-CTD/PKD2L1 in apo state
7D7F	;	3.1	;	Structure of PKD1L3-CTD/PKD2L1 in calcium-bound state
8HK7	;	3.0	;	Structure of PKD2-F604P (Polycystin-2, TRPP2) with ML-SA1
8K3S	;	3.0	;	Structure of PKD2-F604P complex
6BYP	;	1.9	;	Structure of PL24 family Polysaccharide lyase-LOR107
5GKD	;	2.194	;	Structure of PL6 family alginate lyase AlyGC
5GKQ	;	2.565	;	Structure of PL6 family alginate lyase AlyGC mutant-R241A
7Q73	;	1.9	;	Structure of Pla1 apo
7Q74	;	2.599	;	Structure of Pla1 apo, with a C-terminal deletion
7Q72	;	2.8	;	Structure of Pla1 in complex with Red1
7DKZ	;	2.393	;	Structure of plant photosystem I-light harvesting complex I supercomplex
4U5X	;	1.9	;	Structure of plant small GTPase OsRac1 complexed with the non-hydrolyzable GTP analog GMPPNP
1LF4	;	1.9	;	STRUCTURE OF PLASMEPSIN II
4Z22	;	2.62	;	structure of plasmepsin II from Plasmodium Falciparum complexed with inhibitor DR718A
4YA8	;	3.301	;	structure of plasmepsin II from Plasmodium Falciparum complexed with inhibitor PG394
4Y6M	;	2.27	;	Structure of plasmepsin II from Plasmodium falciparum complexed with inhibitor PG418
1XE5	;	2.4	;	Structure of plasmepsin II in complex of an pepstatin analogue
1XE6	;	2.8	;	Structure of plasmepsin II in complex of an pepstatin analogue
7QYH	;	3.33	;	Structure of plasmepsin II in complex with 2-aminoquinazolin-4(3H)-one based open-flap inhibitor
1XDH	;	1.7	;	Structure of plasmepsin II in complex with pepstatin A
7RY7	;	2.1	;	Structure of Plasmepsin X (PM10, PMX) from Plasmodium falciparum 3D7
8DSR	;	2.85	;	Structure of Plasmepsin X (PM10, PMX) from Plasmodium falciparum 3D7 in complex with UCB7362
6Q1U	;	2.3467	;	Structure of plasmin and peptide complex
6TU4	;	2.6	;	Structure of Plasmodium Actin1 filament
7LXT	;	3.4	;	Structure of Plasmodium falciparum 20S proteasome with bound bortezomib
7LXU	;	3.1	;	Structure of Plasmodium falciparum 20S proteasome with bound MPI-5
3MMR	;	2.14	;	Structure of Plasmodium falciparum Arginase in complex with ABH
5JMW	;	1.55	;	Structure of Plasmodium falciparum DXR in complex with a beta-substituted fosmidomycin analogue, LC50 and manganese
5JAZ	;	1.4	;	Structure of Plasmodium falciparum DXR in complex with a beta-substituted fosmidomycin analogue, LC51 and manganese
5JBI	;	1.7	;	Structure of Plasmodium falciparum DXR in complex with a beta-substituted fosmidomycin analogue, LC52 and manganese
5JNL	;	1.6	;	Structure of Plasmodium falciparum DXR in complex with a beta-substituted fosmidomycin analogue, LC54 and manganese
5JC1	;	1.65	;	Structure of Plasmodium falciparum DXR in complex with a beta-substituted fosmidomycin analogue, LC55 and manganese
5JO0	;	1.8	;	Structure of Plasmodium falciparum DXR in complex with a beta-substituted fosmidomycin analogue, LC56 and manganese
5JMP	;	1.7	;	Structure of Plasmodium falciparum DXR in complex with a beta-substituted fosmidomycin analogue, LC57 and manganese
4Y6S	;	2.1	;	Structure of Plasmodium falciparum DXR in complex with a beta-substituted fosmidomycin analogue, RC134, and manganese
4Y6R	;	1.9	;	Structure of Plasmodium falciparum DXR in complex with a beta-substituted fosmidomycin analogue, RC137, and manganese
4Y67	;	1.6	;	Structure of Plasmodium falciparum DXR in complex with a beta-substituted fosmidomycin analogue, RC176, and manganese
4Y6P	;	1.9	;	Structure of Plasmodium falciparum DXR in complex with a beta-substituted fosmidomycin analogue, RC177, and manganese
6RMO	;	2.6	;	Structure of Plasmodium falciparum IMP-nucleotidase
2A94	;	1.5	;	Structure of Plasmodium falciparum lactate dehydrogenase complexed to APADH.
3ZH2	;	2.1	;	Structure of Plasmodium falciparum lactate dehydrogenase in complex with a DNA aptamer
3LG0	;	2.3	;	Structure of Plasmodium falciparum ornithine delta-aminotransferase
6Z2L	;	1.95	;	Structure of Plasmodium falciparum P113 bound to antibody P3.2
4CWA	;	2.02	;	Structure of Plasmodium Falciparum Spermidine Synthase in Complex with 1H-Benzimidazole-2-pentanamine
4J56	;	2.371	;	Structure of Plasmodium falciparum thioredoxin reductase-thioredoxin complex
4J57	;	2.5	;	Structure of Plasmodium falciparum thioredoxin reductase-thioredoxin complex
6OHG	;	2.385	;	Structure of Plasmodium falciparum vaccine candidate Pfs230D1M in complex with the Fab of a transmission blocking antibody
4KP7	;	2.0	;	Structure of Plasmodium IspC in complex with a beta-thia-isostere derivative of Fosmidomycin
6Y3A	;	1.49	;	Structure of Plasmodium vivax phosphoglycerate kinase
2MGP	;		;	Structure of Plasmodium Yoelii Merozoite Surface Protein 1 - C-terminal Domain
2MGR	;		;	Structure of Plasmodium Yoelii Merozoite Surface Protein 1 - C-terminal Domain, E28K mutant
5LR8	;	2.7	;	Structure of plastidial phosphorylase Pho1 from Barley
3P72	;	1.9	;	structure of platelet Glycoprotein 1b alpha with a bound peptide inhibitor
2MN3	;		;	Structure of Platypus 'Intermediate' Defensin-like Peptide (Int-DLP)
2C5L	;	1.9	;	Structure of PLC epsilon Ras association domain with hRas
2N6F	;		;	Structure of Pleiotrophin
5V6R	;	2.7	;	Structure of Plexin D1 intracellular domain
2RKU	;	1.95	;	Structure of PLK1 in complex with BI2536
4O56	;	1.8	;	Structure of PLK1 in complex with peptide
3THB	;	2.5	;	Structure of PLK1 kinase domain in complex with a benzolactam-derived inhibitor
6HBS	;	1.65	;	Structure of PLP internal aldimine form of Sphingopyxis sp. MTA144 FumI protein
6HBV	;	1.65	;	Structure of PLP internal aldimine form of Sphingopyxis sp. MTA144 FumI protein
2WK9	;	1.9	;	Structure of Plp_Thr aldimine form of Vibrio cholerae CqsA
2WKA	;	1.91	;	Structure of Plp_Thr_decanoyl-CoA aldimine form of Vibrio cholerae CqsA
7SJK	;	1.208	;	Structure of PLS A-domain (residues 391-656) from Staphylococcus aureus
7SP2	;	2.75	;	Structure of PLS A-domain (residues 391-656; 513-518 deletion mutant) from Staphylococcus aureus
1YB0	;	1.86	;	Structure of PlyL
8VLQ	;	2.07	;	Structure of PmHMGR bound to mevalonate, CoA and NAD 5 minutes after reaction initiation at pH 9
8GDN	;	1.99	;	Structure of PmHMGR bound to mevalonate, CoA and NAD.
5CR6	;	1.98	;	Structure of pneumolysin at 1.98 A resolution
4R4X	;	1.9	;	Structure of PNGF-II in C2 space group
4R4Z	;	2.81	;	Structure of PNGF-II in P21 space group
4XRU	;	3.41	;	Structure of Pnkp1/Rnl/Hen1 complex
2AN4	;	2.2	;	Structure of PNMT complexed with S-adenosyl-L-homocysteine and the acceptor substrate octopamine
2AN3	;	2.2	;	Structure of PNMT with S-adenosyl-L-homocysteine and the semi-rigid analogue acceptor substrate cis-(1R,2S)-2-amino-1-tetralol.
5KK1	;	3.38	;	Structure of pNOB8 AspA-DNA complex.
5K5Z	;	2.369	;	Structure of pnob8 ParA
5U1J	;	2.95	;	Structure of pNOB8 ParA bound to nonspecific DNA
4RS7	;	1.9	;	Structure of pNOB8 ParB-C
8UI0	;	2.7	;	Structure of poised transcription complex Pol II-DSIF-NELF - pre-translocated
1D6A	;	2.1	;	STRUCTURE OF POKEWEED ANTIVIRAL PROTEIN COMPLEXED WITH GUANINE
1J1Q	;	1.8	;	Structure of Pokeweed Antiviral Protein from Seeds (PAP-S1)
1J1R	;	1.9	;	Structure of Pokeweed Antiviral Protein from Seeds (PAP-S1) Complexed with Adenine
4IQJ	;	3.2	;	Structure of PolIIIalpha-Tauc-DNA complex suggests an atomic model of the replisome
7LJI	;	1.85	;	Structure of poly(aspartic acid) hydrolase PahZ2 with Gd+3 bound
7LJH	;	2.5	;	Structure of poly(aspartic acid) hydrolase PahZ2 with Zn+2 bound
1H83	;	1.9	;	STRUCTURE OF POLYAMINE OXIDASE IN COMPLEX WITH 1,8-DIAMINOOCTANE
1H82	;	1.9	;	STRUCTURE OF POLYAMINE OXIDASE IN COMPLEX WITH GUAZATINE
1H81	;	2.1	;	STRUCTURE OF POLYAMINE OXIDASE IN THE REDUCED STATE
1SJW	;	1.35	;	Structure of polyketide cyclase SnoaL
1Q9J	;	2.75	;	Structure of polyketide synthase associated protein 5 from Mycobacterium tuberculosis
4IUJ	;	1.9	;	Structure of Polymerase acid protein (PA) from Influenzavirus A Influenza A virus A, WILSON-SMITH/1933 (H1N1)
4IRD	;	2.48	;	Structure of Polymerase-DNA complex
4IRK	;	2.32	;	structure of Polymerase-DNA complex, dna
4EXT	;	1.9	;	Structure of polymerase-interacting domain of human Rev1 in complex with translesional synthesis polymerase zeta
6Z1S	;	1.53	;	Structure of Polyphenol Oxidase (mutant G292N) from Thermothelomyces thermophila
7PLJ	;	1.64	;	Structure of Polyphosphate kinase 2 from Deinococcus radiodurans, in complex with ATP and polyphosphates.
5LL0	;	1.96	;	Structure of Polyphosphate Kinase 2 from Francisella tularensis SCHU S4 with polyphosphate
5LLB	;	1.92	;	Structure of Polyphosphate Kinase 2 from Francisella tularensis with AMPPCH2PPP and polyphosphate
5LLF	;	2.31	;	Structure of Polyphosphate Kinase 2 mutant D117N from Francisella tularensis with polyphosphate
5LC9	;	1.903	;	Structure of Polyphosphate Kinase from Meiothermus ruber Apo-form
5LCD	;	2.66	;	Structure of Polyphosphate Kinase from Meiothermus ruber bound to AMP
5O6K	;	2.903	;	Structure of Polyphosphate Kinase from Meiothermus ruber N121D
5O6M	;	2.3	;	Structure of Polyphosphate Kinase from Meiothermus ruber N121D bound to ATP
6D6K	;	2.5	;	Structure of polyribonucleotide nucleotidyltransferase from Acinetobacter baumannii
4DGI	;	2.4	;	Structure of POM1 FAB fragment complexed with human PrPc Fragment 120-230
4H88	;	1.9	;	Structure of POM1 FAB fragment complexed with mouse PrPc Fragment 120-230
6AQ7	;	1.83	;	Structure of POM6 FAB fragment complexed with mouse PrPc
3WPX	;	2.3	;	Structure of PomBc4, a periplasmic fragment of PomB from Vibrio alginolyticus
3WPW	;	2.0	;	Structure of PomBc5, a periplasmic fragment of PomB from Vibrio
7F3N	;	2.35186	;	Structure of PopP2 in apo form
6R1I	;	2.634	;	Structure of porcine Aichi virus polymerase
1EXS	;	2.39	;	STRUCTURE OF PORCINE BETA-LACTOGLOBULIN
4JLZ	;	2.27	;	Structure of porcine cGAS in complex with bound UTP
2GSR	;	2.11	;	Structure of porcine class pi glutathione s-transferase
4KB6	;	3.0754	;	Structure of porcine cyclic GMP AMP synthase (CGAS) in complex with DNA, ATP and GTP
4JLX	;	2.004	;	Structure of porcine cyclic GMP-AMP synthase (cGAS)
7XNM	;	3.58	;	Structure of porcine dipeptidyl peptidase 4 inhibitory peptide complex
2GMJ	;	2.6	;	Structure of Porcine Electron Transfer Flavoprotein-Ubiquinone Oxidoreductase
2GMH	;	2.5	;	Structure of Porcine Electron Transfer Flavoprotein-Ubiquinone Oxidoreductase in Complexed with Ubiquinone
7INS	;	2.0	;	STRUCTURE OF PORCINE INSULIN COCRYSTALLIZED WITH CLUPEINE Z
7U8P	;	3.7	;	Structure of porcine kidney V-ATPase with SidK, Rotary State 1
7U8Q	;	4.1	;	Structure of porcine kidney V-ATPase with SidK, Rotary State 2
7U8R	;	3.8	;	Structure of porcine kidney V-ATPase with SidK, Rotary State 3
1DHK	;	1.85	;	STRUCTURE OF PORCINE PANCREATIC ALPHA-AMYLASE
8B49	;	1.19	;	STRUCTURE OF PORCINE PANCREATIC ELASTASE BOUND TO A FRAGMENT (m-toluoylcarbonyl group) OF A 5-AZAINDOLE INHIBITOR
8B53	;	1.25	;	Structure of porcine pancreatic elastase bound to a fragment of a 4-azaindole inhibitor
8B1Y	;	1.12	;	STRUCTURE OF PORCINE PANCREATIC ELASTASE BOUND TO A FRAGMENT OF A 5-AZAINDAZOLE INHIBITOR
8B04	;	1.6	;	STRUCTURE OF PORCINE PANCREATIC ELASTASE BOUND TO A FRAGMENT OF AN ISOXAZOLONE INHIBITOR
3HGP	;	0.94	;	Structure of porcine pancreatic elastase complexed with a potent peptidyl inhibitor FR130180 determined by high resolution crystallography
3HGN	;	1.65	;	Structure of porcine pancreatic elastase complexed with a potent peptidyl inhibitor FR130180 determined by neutron crystallography
3HGN	;	1.201	;	Structure of porcine pancreatic elastase complexed with a potent peptidyl inhibitor FR130180 determined by neutron crystallography
1BRU	;	2.3	;	STRUCTURE OF PORCINE PANCREATIC ELASTASE COMPLEXED WITH THE ELASTASE INHIBITOR GR143783
2FOG	;	1.9	;	Structure of porcine pancreatic elastase in 40% trifluoroethanol
2FOH	;	1.8	;	Structure of porcine pancreatic elastase in 40% trifluoroethanol
2FOA	;	1.9	;	Structure of porcine pancreatic elastase in 40/50/10 % benzene
2FOB	;	1.9	;	Structure of porcine pancreatic elastase in 40/50/10 cyclohexane
2FOC	;	2.0	;	Structure of porcine pancreatic elastase in 55% dimethylformamide
2FOD	;	2.0	;	Structure of porcine pancreatic elastase in 80% ethanol
2FOE	;	2.2	;	Structure of porcine pancreatic elastase in 80% hexane
2FOF	;	2.2	;	Structure of porcine pancreatic elastase in 80% isopropanol
2FO9	;	2.0	;	Structure of porcine pancreatic elastase in 95% acetone
1QR3	;	1.6	;	Structure of porcine pancreatic elastase in complex with FR901277, a novel macrocyclic inhibitor of elastases at 1.6 angstrom resolution
6TH7	;	2.2	;	Structure of porcine pancreatic elastase in complex with tutuilamide
3E3T	;	1.6	;	Structure of porcine pancreatic elastase with the magic triangle I3C
1P2P	;	2.6	;	STRUCTURE OF PORCINE PANCREATIC PHOSPHOLIPASE A2 AT 2.6 ANGSTROMS RESOLUTION AND COMPARISON WITH BOVINE PHOSPHOLIPASE A2
4DN8	;	2.2	;	Structure of porcine surfactant protein D neck and carbohydrate recognition domain complexed with mannose
3I1K	;	2.1	;	Structure of porcine torovirus Hemagglutinin-Esterase
3I1L	;	2.79	;	Structure of porcine torovirus Hemagglutinin-Esterase in complex with its receptor
1EJA	;	2.7	;	STRUCTURE OF PORCINE TRYPSIN COMPLEXED WITH BDELLASTASIN, AN ANTISTASIN-TYPE INHIBITOR
7U8O	;	3.5	;	Structure of porcine V-ATPase with mEAK7 and SidK, Rotary state 2
6RHY	;		;	Structure of pore-forming amyloid-beta tetramers
4D64	;	3.2	;	Structure of porin Omp-Pst1 from P. stuartii; the crystallographic symmetry generates a dimer of trimers.
4D65	;	2.2	;	Structure of porin Omp-Pst2 from P. stuartii; the asymmetric unit contains a dimer of trimers.
2POR	;	1.8	;	STRUCTURE OF PORIN REFINED AT 1.8 ANGSTROMS RESOLUTION
7SAT	;	3.9	;	Structure of PorLM, the proton-powered motor that drives Type IX protein secretion
1PDA	;	1.76	;	STRUCTURE OF PORPHOBILINOGEN DEAMINASE REVEALS A FLEXIBLE MULTIDOMAIN POLYMERASE WITH A SINGLE CATALYTIC SITE
3H8T	;	1.8	;	Structure of Porphyromonas gingivalis heme-binding protein HmuY in complex with Heme
7SIL	;	2.7	;	Structure of positive allosteric modulator-bound active human calcium-sensing receptor
7SIM	;	2.7	;	Structure of positive allosteric modulator-free active human calcium-sensing receptor
6LXT	;	2.9	;	Structure of post fusion core of 2019-nCoV S2 subunit
7COT	;	2.16	;	Structure of post fusion core of SARS-CoV-2 S2 subunit
5L0W	;	3.035	;	Structure of post-translational translocation Sec71/Sec72 complex
7ACR	;	3.44	;	Structure of post-translocated trans-translation complex on E. coli stalled ribosome.
2CJP	;	1.95	;	Structure of potato (Solanum tuberosum) epoxide hydrolase I (StEH1)
5DZU	;	2.12	;	Structure of potato cathepsin D inhibitor
3JRV	;	1.6	;	Structure of poxvirus K7 protein in complex with RNA helicase DDX3
6GHM	;	2.15	;	Structure of PP1 alpha phosphatase bound to ASPP2
6ZEE	;	1.9	;	Structure of PP1(7-300) bound to Phactr1 (507-580) at pH8.4
6ZEF	;	1.94	;	Structure of PP1(7-300) bound to Phactr1 (516-580) at pH 5.25
6ZEG	;	1.09	;	Structure of PP1-IRSp53 chimera [PP1(7-304) + linker (G/S)x9 + IRSp53(449-465)] bound to Phactr1 (516-580)
6ZEI	;	1.39	;	Structure of PP1-IRSp53 S455E chimera [PP1(7-304) + linker (G/S)x9 + IRSp53(449-465)] bound to Phactr1 (516-580)
6ZEJ	;	1.78	;	Structure of PP1-Phactr1 chimera [PP1(7-304) + linker (SGSGS) + Phactr1(526-580)]
6ZEH	;	1.3	;	Structure of PP1-spectrin alpha II chimera [PP1(7-304) + linker (G/S)x9 + spectrin alpha II (1025-1039)] bound to Phactr1 (516-580)
5WG8	;	1.65	;	Structure of PP5C with LB-100; 7-oxabicyclo[2.2.1]heptane-2,3-dicarbonyl moiety modeled in the density
4BCR	;	2.497	;	Structure of PPARalpha in complex with WY14643
3ET1	;	2.5	;	Structure of PPARalpha with 3-[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid
6L96	;	3.2	;	Structure of PPARalpha-LBD/pemafibrate/SRC1 peptide
3ET2	;	2.24	;	Structure of PPARdelta with 3-[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid
6T1V	;	2.21	;	Structure of PPARg H494Y mutant in complex with GW1929
5Y2T	;	1.7	;	Structure of PPARgamma ligand binding domain - lobeglitazone complex
3TY0	;	2.0	;	Structure of PPARgamma ligand binding domain in complex with (R)-5-(3-((3-(6-methoxybenzo[d]isoxazol-3-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)phenyl)-5-methyloxazolidine-2,4-dione
5Y2O	;	1.801	;	Structure of PPARgamma ligand binding domain-pioglitazone complex
3ET0	;	2.4	;	Structure of PPARgamma with 3-(5-Methoxy-1H-indol-3-yl)-propionic acid
3ET3	;	1.95	;	Structure of PPARgamma with 3-[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid
5A9Y	;	4.0	;	Structure of ppGpp BipA
7UXM	;	1.2	;	Structure of PPIA in complex with FP29092, a Helicon Polypeptide
7UXJ	;	2.07	;	Structure of PPIA in complex with FP29102, a Helicon Polypeptide
7UXN	;	1.36	;	Structure of PPIA in complex with FP29103, a Helicon Polypeptide
7ABT	;	1.31	;	Structure of PPIA in complex with PR dipeptide repeat
8HZ8	;	1.81	;	Structure of PPIA in complex with the peptide of NRF2
1RJD	;	1.8	;	Structure of PPM1, a leucine carboxy methyltransferase involved in the regulation of protein phosphatase 2A activity
1RJE	;	2.0	;	Structure of PPM1, a leucine carboxy methyltransferase involved in the regulation of protein phosphatase 2A activity
1RJF	;	2.25	;	Structure of PPM1, a leucine carboxy methyltransferase involved in the regulation of protein phosphatase 2A activity
1RJG	;	2.61	;	Structure of PPM1, a leucine carboxy methyltransferase involved in the regulation of protein phosphatase 2A activity
7N0Z	;	2.19	;	Structure of PPM1H phosphatase with manganese ions at the active site
7N6Q	;	3.87	;	Structure of PPPA bound human ACAT2
4L9G	;	2.2	;	Structure of PpsR N-Q-PAS1 from Rb. sphaeroides
4L9E	;	1.65	;	Structure of PpsR Q-PAS1 from Rb. sphaeroides
4HH2	;	2.8	;	Structure of PpsR without the HTH motif from Rb. sphaeroides
7KGW	;	1.99	;	Structure of PQS Response Protein PqsE in Complex N-(3-(1H-pyrazol-5-yl)phenyl)-1H-indazole-7-carboxamide
7KGX	;	2.0	;	Structure of PQS Response Protein PqsE in Complex with 4-(3-(2-methyl-2-morpholinobutyl)ureido)-N-(thiazol-2-yl)benzamide
7TZA	;	2.1	;	Structure of PQS Response Protein PqsE in complex with N-(4-(3-neopentylureido)phenyl)-1H-indazole-7-carboxamide
7TZ9	;	2.01	;	Structure of PQS Response Protein PqsE(E182W) Variant
7U6G	;	2.45	;	Structure of PQS Response Protein PqsE(E182W,E280A) Variant
6AWW	;	2.3	;	Structure of PR 10 Allergen Ara h 8.01 in complex with 3-Hydroxy-2-naphthoic acid
6AWR	;	1.6	;	Structure of PR 10 Allergen Ara h 8.01 in complex with ANS
6AWU	;	3.05	;	Structure of PR 10 Allergen Ara h 8.01 in complex with caffeic acid
6AWS	;	2.35	;	Structure of PR 10 Allergen Ara h 8.01 in complex with quercetin
6B1D	;	2.51	;	Structure of PR 10 Allergen Ara h 8.01 with Quercetin
6AWT	;	2.3	;	Structure of PR 10 Allergen in complex with epicatechin
6AX0	;	2.5	;	Structure of PR-10 Allergen Ara h 8.01 in complex with epicatechin
6AWX	;	2.7	;	Structure of PR-10 Allergen Ara h 8.01.
6AWZ	;	1.9	;	Structure of PR-10 allergen from peanut (Ara h 8.01).
2FFS	;	2.5	;	Structure of PR10-allergen-like protein PA1206 from Pseudomonas aeruginosa PAO1
6EWX	;	2.771	;	Structure of Pragmin pseudo-kinase reveals a dimerization mechanism to regulate protein tyrosine phosphorylation and nuclear transcription
7Z34	;	3.8	;	Structure of pre-60S particle bound to DRG1(AFG2).
7ABZ	;	3.21	;	Structure of pre-accomodated trans-translation complex on E. coli stalled ribosome.
8FCS	;		;	Structure of pre-miR-31 reveals an active role in Dicer processing
2PAB	;	1.8	;	STRUCTURE OF PREALBUMIN, SECONDARY, TERTIARY AND QUATERNARY INTERACTIONS DETERMINED BY FOURIER REFINEMENT AT 1.8 ANGSTROMS
5EUI	;	1.45	;	Structure of predicted ancestral pika hemoglobin
5A86	;	2.25	;	Structure of pregnane X receptor in complex with a Sphingosine 1- Phosphate Receptor 1 Antagonist
4H6W	;	2.45	;	Structure of Prenylagaramide maturation protease PagA
7FHB	;	1.9	;	Structure of prenyltransferase from Streptomyces sp. (strain CL190) with bound GPP
7FHE	;	2.5	;	Structure of prenyltransferase mutant Q295F from Streptomyces sp. (strain CL190)
7FHC	;	2.06	;	Structure of prenyltransferase mutant V49W from Streptomyces sp. (strain CL190)
7FHF	;	2.5	;	Structure of prenyltransferase mutant V49W/Y288F/Q295F from Streptomyces sp. (strain CL190)
7FHD	;	3.5	;	Structure of prenyltransferase mutant Y288P from Streptomyces sp. (strain CL190)
4RN6	;	3.0	;	Structure of prethrombin-2 mutant s195a bound to the active site inhibitor argatroban
3BB7	;	1.5	;	Structure of Prevotella intermedia prointerpain A fragment 39-359 (mutant C154A)
6XB4	;	1.9	;	Structure of PrGV poxin in post-reactive state with Gp[2'-5']Ap[3']
2AXU	;	2.9	;	Structure of PrgX
2AWI	;	2.25	;	Structure of PrgX Y153C mutant
2AXV	;	3.0	;	Structure of PrgX Y153C mutant
5X9J	;	2.1	;	Structure of PrhC from Penicillium brasilianum NBRC 6234
5OP0	;	1.84	;	Structure of Prim-PolC from Mycobacterium smegmatis
7OLA	;	3.3	;	Structure of Primase-Helicase in SaPI5
7OM0	;	3.1	;	Structure of Primase-Helicase in SaPI5
5LXQ	;	3.335	;	Structure of PRL-1 in complex with the Bateman domain of CNNM2
5MMZ	;	2.4	;	Structure of PRL-1 in complex with the Bateman domain of CNNM2
6CKC	;	2.8	;	Structure of PRMT5:MEP50 in complex with LLY-283, a potent and selective inhibitor of PRMT5, with antitumor activity
5HLZ	;	2.851	;	Structure of Pro-Activin A Complex at 2.85 A resolution
5HLY	;	2.302	;	Structure of Pro-Activin A Precursor at 2.3 A Resolution
6Q24	;	1.85	;	Structure of pro-Esp mutant- S235A
6Q12	;	2.2	;	Structure of pro-Esp mutant- S66V
2NN3	;	3.0	;	structure of pro-sf-caspase-1
1PXR	;	1.7	;	Structure of Pro50Ala mutant of Bacteriorhodopsin
3L8C	;	2.41	;	Structure of probable D-alanine--poly(phosphoribitol) ligase subunit-1 from Streptococcus pyogenes
3LGX	;	2.6	;	Structure of probable D-alanine-poly(phosphoribitol) ligase subunit-1 from Streptococcus pyogenes with ATP
3LXZ	;	1.76	;	Structure of probable Glutathione S-transferase(PP0183) from Pseudomonas putida
3QLD	;	1.85	;	Structure of Probable Mandelate Racemase (AaLAA1DRAFT_2112) from Alicyclobacillus Acidocaldarius
3LME	;	2.74	;	Structure of probable translation initiation inhibitor from (RPA2473) from Rhodopseudomonas palustris
3LUF	;	1.76	;	Structure of probable two-component system response regulator/GGDEF domain protein
4OX8	;	1.9031	;	Structure of Prochlorococcus marinus str. MIT 9313 CsoS1
6B6J	;	1.9	;	Structure of profilin Art v4
3P24	;	1.8	;	Structure of profragilysin-3 from Bacteroides fragilis
6EL3	;	1.899	;	Structure of Progesterone 5beta-Reductase from Arabidopsis thaliana in complex with NADP
2V6F	;	2.4	;	Structure of Progesterone 5beta-Reductase from Digitalis Lanata
2V6G	;	2.3	;	Structure of Progesterone 5beta-Reductase from Digitalis Lanata in complex with NADP
1MFK	;		;	Structure of Prokaryotic SECIS mRNA Hairpin
5NBC	;	1.699	;	Structure of Prokaryotic Transcription Factors
5UX5	;	2.7	;	Structure of Proline Utilization A (PutA) from Corynebacterium freiburgense
6BSN	;	2.15	;	Structure of proline utilization A (PutA) with proline bound in remote sites
5KF6	;	1.7	;	Structure of proline utilization A from Sinorhizobium meliloti complexed with L-tetrahydrofuroic acid and NAD+ in space group P21
5KF7	;	1.9	;	Structure of proline utilization A from Sinorhizobium meliloti complexed with L-tetrahydrofuroic acid and NAD+ in space group P3121
7MY9	;	1.628	;	Structure of proline utilization A with 1,3-dithiolane-2-carboxylate bound in the proline dehydrogenase active site
6X9B	;	1.46	;	Structure of proline utilization A with cis-4-hydroxy-D-proline bound in the L-glutamate-gamma-semialdehyde dehydrogenase active site
6X99	;	1.56	;	Structure of proline utilization A with D-proline bound in the L-glutamate-gamma-semialdehyde dehydrogenase active site
6X9C	;	1.44	;	Structure of proline utilization A with L-proline bound in the L-glutamate-gamma-semialdehyde dehydrogenase active site
7MYB	;	1.52	;	Structure of proline utilization A with tetrahydrothiophene-2-carboxylate bound in the proline dehydrogenase active site
6VZ9	;	1.52	;	Structure of proline utilization A with the FAD covalently modified by L-thiazolidine-2-carboxylate
6UFP	;	1.737	;	Structure of proline utilization A with the FAD covalently modified by L-thiazolidine-2-carboxylate and three cysteines (Cys46, Cys470, Cys638) modified to S,S-(2-HYDROXYETHYL)THIOCYSTEINE
7MYC	;	1.9	;	Structure of proline utilization A with the FAD covalently modified by tetrahydrothiophene
7MYA	;	1.56	;	Structure of proline utilization A with the FAD covalently-modified by 1,3-dithiolane
6X9A	;	1.41	;	Structure of proline utilization A with trans-4-hydroxy-D-proline bound in the L-glutamate-gamma-semialdehyde dehydrogenase active site
6X9D	;	1.54	;	Structure of proline utilization A with trans-4-hydroxy-L-proline bound in the L-glutamate-gamma-semialdehyde dehydrogenase active site
4X43	;	1.65	;	Structure of proline-free E. coli Thioredoxin
6XHD	;	1.51	;	Structure of Prolinyl-5'-O-adenosine phosphoramidate
8B57	;	2.42	;	Structure of prolyl endoprotease from Aspergillus niger CBS 109712
8BBX	;	2.7	;	Structure of prolyl endoprotease from Aspergillus niger CBS 109712 in space group C222(1)
4JZR	;	2.1	;	Structure of Prolyl Hydroxylase Domain-containing Protein (PHD) with Inhibitors
6RV6	;	3.507	;	Structure of properdin lacking TSR3 based on anomalous data
5BWY	;	2.644	;	Structure of proplasmepsin II from Plasmodium falciparum, Space Group P43212
5JOD	;	1.528	;	Structure of proplasmepsin IV from Plasmodium falciparum
3P50	;	3.3	;	Structure of propofol bound to a pentameric ligand-gated ion channel, GLIC
6GG1	;	1.3	;	Structure of PROSS-edited human interleukin 24
1RY0	;	1.69	;	Structure of prostaglandin F synthase with prostaglandin D2
5H5L	;	1.999	;	Structure of prostaglandin synthase D of Nilaparvata lugens
3GYL	;	1.3	;	Structure of Prostasin at 1.3 Angstroms resolution in complex with a Calcium Ion.
3GYM	;	2.8	;	Structure of Prostasin in Complex with Aprotinin
8XJ4	;	3.19	;	Structure of prostatic acid phosphatase in human semen
4TKX	;	1.6	;	Structure of Protease
6F2H	;	2.19	;	Structure of Protease 1 from Pyrococcus horikoshii co-crystallized in presence of 10 mM Tb-Xo4 and potassium iodide.
6Q3T	;	2.15	;	Structure of Protease1 from Pyrococcus horikoshii at room temperature in ChipX microfluidic device
7QO8	;	1.95	;	Structure of Protease1 from Pyrococcus horikoshii in space group 19 with a hexamer in the asymmetric unit
3Q5W	;	2.75	;	Structure of proteasome tether
3Q5X	;	2.98	;	Structure of proteasome tether
4G4S	;	2.49	;	Structure of Proteasome-Pba1-Pba2 Complex
6Z3K	;	2.7	;	Structure of protective antibody 38-1-10A Fab
1GZO	;	2.75	;	Structure of protein kinase B unphosphorylated
5F9E	;	2.0	;	Structure of Protein Kinase C theta with compound 10: 2,2-dimethyl-7-(2-oxidanylidene-3~{H}-imidazo[4,5-b]pyridin-1-yl)-1-(phenylmethyl)-3~{H}-quinazolin-4-one
7AT5	;	1.77	;	Structure of protein kinase ck2 catalytic subunit (csnk2a1 gene product) in complex with the bivalent inhibitor KN2
7AT9	;	1.05	;	Structure of protein kinase ck2 catalytic subunit (csnk2a2 gene product) in complex with the ATP-competitive inhibitor MB002 and the alphaD-pocket ligand 3,4-dichlorophenethylamine
7ATV	;	0.98	;	Structure of protein kinase ck2 catalytic subunit (csnk2a2 gene product) in complex with the bivalent inhibitor KN2
5OOI	;	1.998	;	STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA') IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
6HMQ	;	0.97	;	STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA'; CSNK2A2 GENE PRODUCT) IN COMPLEX WITH THE BENZOTRIAZOLE-TYPE INHIBITOR MB002
8Q77	;	1.255	;	STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA'; CSNK2A2 GENE PRODUCT) IN COMPLEX WITH THE BISUBSTRATE INHIBITOR ARC-780
6HMD	;	1.0	;	STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA'; CSNK2A2 gene product) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR AR18
6HMC	;	1.03	;	STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA'; CSNK2A2 gene product) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR THN27
8QCD	;	1.03	;	STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA'; CSNK2A2 GENE PRODUCT) IN COMPLEX WITH THE INHIBITOR 4,5,6,7-TETRABROMOBENZOTRIAZOLE
6HMB	;	1.04	;	STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA'; CSNK2A2 Gene product) IN COMPLEX WITH the inhibitor CX-4945 (Silmitasertib)
8QBU	;	1.09	;	STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA'; CSNK2A2 GENE PRODUCT) IN COMPLEX WITH THE INHIBITOR CX-4945 AND THE ALPHA-D-POCKET LIGAND 3,4-DICHLORO PHENETHYLAMINE (DPA)
8Q9S	;	1.352	;	STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA'; CSNK2A2 GENE PRODUCT) IN COMPLEX WITH THE INHIBITOR SGC-CK2-1
6SPX	;	1.994	;	Structure of protein kinase CK2 catalytic subunit in complex with the CK2beta-competitive bisubstrate inhibitor ARC1502
6SPW	;	1.599	;	Structure of protein kinase CK2 catalytic subunit with the CK2beta-competitive bisubstrate inhibitor ARC3140
7PSU	;	1.77	;	Structure of protein kinase CK2alpha mutant K198R associated with the Okur-Chung Neurodevelopmental Syndrome
1SDS	;	1.8	;	Structure of protein L7Ae bound to a K-turn derived from an archaeal box H/ACA sRNA
2I6H	;	1.75	;	Structure of Protein of Unknown Function ATU0120 from Agrobacterium tumefaciens
2GAX	;	1.801	;	Structure of Protein of Unknown Function Atu0240 from Agrobacteriium tumerfaciencs str. C58
1RFZ	;	2.8	;	Structure of Protein of Unknown Function from Bacillus stearothermophilus
1U9D	;	1.7	;	Structure of Protein of Unknown Function from Vibrio cholerae O1 biovar eltor str. N16961
2GTS	;	2.1	;	Structure of Protein of Unknown Function HP0062 from Helicobacter pylori
1L1S	;	2.3	;	Structure of Protein of Unknown Function MTH1491 from Methanobacterium thermoautotrophicum
1NC5	;	1.6	;	Structure of Protein of Unknown Function of YteR from Bacillus Subtilis
1Y0N	;	2.0	;	Structure of Protein of Unknown Function PA3463 from Pseudomonas aeruginosa PAO1
1Y0K	;	1.75	;	Structure of Protein of Unknown Function PA4535 from Pseudomonas aeruginosa strain PAO1, Monooxygenase Superfamily
1ZL0	;	1.1	;	Structure of Protein of Unknown Function PA5198 from Pseudomonas aeruginosa
2GFQ	;	1.75	;	Structure of Protein of Unknown Function PH0006 from Pyrococcus horikoshii
2HHG	;	1.2	;	Structure of Protein of Unknown Function RPA3614, Possible Tyrosine Phosphatase, from Rhodopseudomonas palustris CGA009
2IL5	;	2.3	;	Structure of Protein of Unknown Function SA2116 from Staphylococcus aureus
1MK4	;	1.7	;	Structure of Protein of Unknown Function YqjY from Bacillus subtilis, Probable Acetyltransferase
1PV5	;	1.75	;	Structure of Protein of Unknown Function YwqG from Bacillus subtilis
3ICF	;	2.3	;	Structure of Protein serine/threonine phosphatase from Saccharomyces cerevisiae with similarity to human phosphatase PP5
2C8M	;	1.89	;	Structure of protein Ta0514, putative lipoate protein ligase from T. acidophilum with bound lipoic acid
2C7I	;	2.1	;	Structure of protein Ta0514, putative lipoate protein ligase from T. acidophilum.
2CM3	;	2.1	;	Structure of Protein Tyrosine Phosphatase 1B (C2)
2CM2	;	1.5	;	Structure of Protein Tyrosine Phosphatase 1B (P212121)
4Y14	;	1.898	;	Structure of protein tyrosine phosphatase 1B complexed with inhibitor (PTP1B:CPT157633)
6BV6	;	2.2	;	Structure of proteinaceous RNase P 1 (PRORP1) from A. thaliana after 3-hour soak with juglone
6BV5	;	1.79	;	Structure of proteinaceous RNase P 1 (PRORP1) from A. thaliana after 45-minute soak with juglone
6BV9	;	2.1	;	Structure of proteinaceous RNase P 1 (PRORP1) from A. thaliana after overnight soak with juglone
6BV8	;	2.1	;	Structure of proteinaceous RNase P 1 (PRORP1) from A. thaliana complexed with Mn after 3-hour soak with juglone
7C0P	;	2.15	;	Structure of proteinase K obtained in SSRF using serial crystallography
3GT3	;	1.5	;	Structure of proteinase K with the mad triangle B3C
3GT4	;	1.76	;	Structure of proteinase K with the magic triangle I3C
1M85	;	2.0	;	Structure of Proteus mirabilis catalase for the native form
2CAH	;	2.7	;	STRUCTURE OF PROTEUS MIRABILIS PR CATALASE FOR THE NATIVE FORM (E-FE(III)) COMPLEXED WITH NADPH
3PCJ	;	2.13	;	STRUCTURE OF PROTOCATECHUATE 3,4-DIOXYGENASE COMPLEXED WITH 2-HYDROXYISONICOTINIC ACID N-OXIDE
3PCL	;	2.15	;	STRUCTURE OF PROTOCATECHUATE 3,4-DIOXYGENASE COMPLEXED WITH 2-HYDROXYISONICOTINIC ACID N-OXIDE AND CYANIDE
3PCA	;	2.2	;	STRUCTURE OF PROTOCATECHUATE 3,4-DIOXYGENASE COMPLEXED WITH 3,4-DIHYDROXYBENZOATE
3PCN	;	2.4	;	STRUCTURE OF PROTOCATECHUATE 3,4-DIOXYGENASE COMPLEXED WITH 3,4-DIHYDROXYPHENYLACETATE
3PCH	;	2.05	;	STRUCTURE OF PROTOCATECHUATE 3,4-DIOXYGENASE COMPLEXED WITH 3-CHLORO-4-HYDROXYBENZOATE
3PCF	;	2.15	;	STRUCTURE OF PROTOCATECHUATE 3,4-DIOXYGENASE COMPLEXED WITH 3-FLURO-4-HYDROXYBENZOATE
3PCB	;	2.19	;	STRUCTURE OF PROTOCATECHUATE 3,4-DIOXYGENASE COMPLEXED WITH 3-HYDROXYBENZOATE
3PCE	;	2.06	;	STRUCTURE OF PROTOCATECHUATE 3,4-DIOXYGENASE COMPLEXED WITH 3-HYDROXYPHENYLACETATE
3PCI	;	2.21	;	STRUCTURE OF PROTOCATECHUATE 3,4-DIOXYGENASE COMPLEXED WITH 3-IODO-4-HYDROXYBENZOATE
3PCC	;	1.98	;	STRUCTURE OF PROTOCATECHUATE 3,4-DIOXYGENASE COMPLEXED WITH 4-HYDROXYBENZOATE
3PCK	;	2.13	;	STRUCTURE OF PROTOCATECHUATE 3,4-DIOXYGENASE COMPLEXED WITH 6-HYDROXYNICOTINIC ACID N-OXIDE
3PCM	;	2.25	;	STRUCTURE OF PROTOCATECHUATE 3,4-DIOXYGENASE COMPLEXED WITH 6-HYDROXYNICOTINIC ACID N-OXIDE AND CYANIDE
3PCG	;	1.96	;	STRUCTURE OF PROTOCATECHUATE 3,4-DIOXYGENASE COMPLEXED WITH THE INHIBITOR 4-HYDROXYPHENYLACETATE
2PCD	;	2.15	;	STRUCTURE OF PROTOCATECHUATE 3,4-DIOXYGENASE FROM PSEUDOMONAS AERUGINOSA AT 2.15 ANGSTROMS RESOLUTION
2VEE	;	2.6	;	Structure of protoglobin from Methanosarcina acetivorans C2A
6SGX	;	3.7	;	Structure of protomer 1 of the ESX-3 core complex
6SGZ	;	3.9	;	Structure of protomer 2 of the ESX-3 core complex
4XXG	;	0.85	;	Structure of protonated Cholesterol Oxidase from Streptomyces SA-COO
2IVE	;	2.7	;	Structure of protoporphyrinogen oxidase from Myxococcus xanthus
2IVD	;	2.3	;	Structure of protoporphyrinogen oxidase from Myxococcus xanthus with acifluorfen
4CN8	;	2.45	;	Structure of proximal thread matrix protein 1 (PTMP1) from the mussel byssus
4CNB	;	1.95	;	Structure of proximal thread matrix protein 1 (PTMP1) from the mussel byssus - Crystal form 2
4CN9	;	1.9	;	structure of proximal thread matrix protein 1 (PTMP1) from the mussel byssus with zinc occupied MIDAS motif
5EYI	;	2.16	;	Structure of PRRSV apo-NSP11 at 2.16A
2Y6X	;	1.6	;	Structure of Psb27 from Thermosynechococcus elongatus
3ZPN	;	2.361	;	Structure of Psb28
5MJO	;	1.55	;	Structure of Psb29 at 1.55A
5MJR	;	1.38	;	Structure of Psb29 at 1.55A
5MJW	;	2.47	;	Structure of Psb29 at 1.55A
5MLF	;	3.637	;	Structure of Psb29 at 1.55A
2VU4	;	1.98	;	Structure of PsbP protein from Spinacia oleracea at 1.98 A resolution
5GNV	;	2.596	;	Structure of PSD-95/MAP1A complex reveals unique target recognition mode of MAGUK GK domain
5NCE	;		;	Structure of PsDef1 defensin from Pinus sylvestris
3F79	;	2.8	;	Structure of pseudo-centered cell crystal form of the C-terminal phosphatase domain of P. aeruginosa RssB
4BJ4	;	1.722	;	Structure of Pseudomonas aeruginosa amidase Ampdh2
8AC7	;	1.4	;	Structure of Pseudomonas aeruginosa aminopeptidase, PaAP
8ACK	;	1.784	;	Structure of Pseudomonas aeruginosa aminopeptidase, PaAP
8ACR	;	2.1	;	Structure of Pseudomonas aeruginosa aminopeptidase, PaAP
8AC9	;	2.351	;	Structure of Pseudomonas aeruginosa aminopeptidase, PaAP_T
8ACG	;	2.84	;	Structure of Pseudomonas aeruginosa aminopeptidase, PaAP_T E340A mutant
7BOR	;	1.901	;	Structure of Pseudomonas aeruginosa CoA-bound OdaA
5WYB	;	2.25	;	Structure of Pseudomonas aeruginosa DspI
3OYY	;	1.75	;	Structure of Pseudomonas aeruginosa elongation factor P
4JB6	;	2.4	;	Structure of Pseudomonas aeruginosa FabF mutant C164Q
7OC0	;	1.78	;	Structure of Pseudomonas aeruginosa FabF mutant C164Q in complex with a ligand (2S,4R)-2-(thiophen-2-yl)thiazolidine-4-carboxylic acid
7OC1	;	1.8	;	Structure of Pseudomonas aeruginosa FabF mutant C164Q in complex with Platensimycin
6G3U	;	2.707	;	Structure of Pseudomonas aeruginosa Isocitrate Dehydrogenase, IDH
6G1O	;	1.882	;	Structure of Pseudomonas aeruginosa Isocitrate Lyase, ICL
1W8H	;	1.75	;	structure of pseudomonas aeruginosa lectin II (PA-IIL)complexed with lewisA trisaccharide
2W7Q	;	1.88	;	Structure of Pseudomonas aeruginosa LolA
5DEM	;	1.81	;	Structure of Pseudomonas aeruginosa LpxA
5DG3	;	2.3	;	Structure of Pseudomonas aeruginosa LpxA in complex with UDP-3-O-(R-3-hydroxydecanoyl)-GlcNAc
5DEP	;	2.16	;	Structure of Pseudomonas aeruginosa LpxA in complex with UDP-GlcNAc
7CRD	;	1.901	;	Structure of Pseudomonas aeruginosa OdaA
8JU7	;	1.8	;	Structure of Pseudomonas aeruginosa ParS sensor domain
6Y6Z	;	1.7	;	Structure of Pseudomonas aeruginosa Penicillin-Binding Protein 3 (PBP3) in complex with Compound 1
6Y6U	;	1.55	;	Structure of Pseudomonas aeruginosa Penicillin-Binding Protein 3 (PBP3) in complex with Compound 6
6R3X	;	1.59	;	Structure of Pseudomonas aeruginosa Penicillin-Binding Protein 3 (PBP3) in complex with piperacillin
4K2F	;	1.99	;	Structure of Pseudomonas aeruginosa PvdQ bound to BRD-A08522488
4K2G	;	2.3	;	Structure of Pseudomonas aeruginosa PvdQ bound to BRD-A33442372
3SRC	;	2.0	;	Structure of Pseudomonas aeruginosa PvdQ bound to NS2028
3SRB	;	1.8	;	Structure of Pseudomonas aeruginosa PvdQ bound to SMER28
3RD3	;	2.4	;	Structure of Pseudomonas aeruginosa transcriptional regulator PA2196
3L91	;	1.66	;	Structure of Pseudomonas aerugionsa PvdQ bound to octanoate
3SRA	;	2.3	;	Structure of Pseudomonas aerugionsa PvdQ covalently acylated with myristic acid from PVDIq
1GQI	;	1.48	;	Structure of Pseudomonas cellulosa alpha-D-glucuronidase
1GQK	;	1.9	;	Structure of Pseudomonas cellulosa alpha-D-glucuronidase complexed with glucuronic acid
1GQL	;	1.67	;	Structure of Pseudomonas cellulosa alpha-D-glucuronidase complexed with glucuronic acid and xylotriose
1GQJ	;	1.9	;	Structure of Pseudomonas cellulosa alpha-D-glucuronidase complexed with xylobiose
3PJT	;	2.5154	;	Structure of Pseudomonas fluorescence LapD EAL domain complexed with c-di-GMP, C2221
3PJU	;	2.4991	;	Structure of Pseudomonas fluorescence LapD EAL domain complexed with c-di-GMP, P6522
3PJW	;	3.1006	;	Structure of Pseudomonas fluorescence LapD GGDEF-EAL dual domain, I23
3PJX	;	2.0002	;	Structure of Pseudomonas fluorescence LapD GGDEF-EAL dual domain, P32
3PJV	;	1.7727	;	Structure of Pseudomonas fluorescence LapD periplasmic domain
1JOI	;	2.05	;	STRUCTURE OF PSEUDOMONAS FLUORESCENS HOLO AZURIN
1BF2	;	2.0	;	STRUCTURE OF PSEUDOMONAS ISOAMYLASE
1CNO	;	2.2	;	STRUCTURE OF PSEUDOMONAS NAUTICA CYTOCHROME C552, BY MAD METHOD
7X0F	;	2.2	;	Structure of Pseudomonas NRPS protein, AmbB-TC bound to Ppant
7X17	;	2.5	;	Structure of Pseudomonas NRPS protein, AmbB-TC bound to Ppant-L-Ala
7X0E	;	2.1	;	Structure of Pseudomonas NRPS protein, AmbB-TC in apo form
2Q0I	;	1.57	;	Structure of Pseudomonas Quinolone Signal Response Protein PqsE
2Q0J	;	2.1	;	Structure of Pseudomonas Quinolone Signal Response Protein PqsE
3DH8	;	1.8	;	Structure of Pseudomonas Quinolone Signal Response Protein PqsE
6MW4	;	1.55	;	Structure of pseudoprotease CspC from Clostridioides difficile
6KMX	;	2.41	;	Structure of PSI from H. hongdechloris grown under far-red light condition
6KMW	;	2.35	;	Structure of PSI from H. hongdechloris grown under white light condition
6JEO	;	3.3	;	Structure of PSI tetramer from Anabaena
6K33	;	2.74	;	Structure of PSI-isiA supercomplex from Thermosynechococcus vulcanus
6IGZ	;	3.49	;	Structure of PSI-LHCI
6JLU	;	3.02	;	Structure of PSII-FCP supercomplex from a centric diatom Chaetoceros gracilis at 3.02 angstrom resolution
8W4O	;	3.23	;	Structure of PSII-FCPII-G/H complex in the PSII-FCPII supercomplex from Cyclotella meneghiniana
8W4P	;	3.48	;	Structure of PSII-FCPII-I/J/K complex in the PSII-FCPII supercomplex from Cyclotella meneghiniana
7NHP	;	2.72	;	Structure of PSII-I (PSII with Psb27, Psb28, and Psb34)
7NHQ	;	2.68	;	Structure of PSII-I prime (PSII with Psb28, and Psb34)
7NHO	;	2.66	;	Structure of PSII-M
5BX9	;	2.001	;	Structure of PslG from Pseudomonas aeruginosa
5BXA	;	1.9	;	Structure of PslG from Pseudomonas aeruginosa in complex with mannose
7T8U	;	4.3	;	Structure of PSMbeta2 nanotubes
4D3G	;	3.0	;	Structure of PstA
4D3H	;	2.0	;	Structure of PstA
6A03	;	2.597	;	Structure of pSTING complex
6A04	;	1.9	;	Structure of pSTING complex
6A05	;	2.2	;	Structure of pSTING complex
6A06	;	1.792	;	Structure of pSTING complex
6IYF	;	1.764	;	Structure of pSTING complex
2N3O	;		;	Structure of PTB RRM1(41-163) bound to an RNA stemloop containing a structured loop derived from viral internal ribosomal entry site RNA
6RMG	;	3.4	;	Structure of PTCH1 bound to a modified Hedgehog ligand ShhN-C24II
3BMN	;	1.98	;	Structure of Pteridine Reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor (NADP+) and inhibitor (Compound AX3)
3BMO	;	1.6	;	Structure of Pteridine Reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor (NADP+) and inhibitor (Compound AX4)
3BMQ	;	1.7	;	Structure of Pteridine Reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor (NADP+) and inhibitor (Compound AX5)
3GN2	;	1.6	;	Structure of Pteridine Reductase 1 (PTR1) from TRYPANOSOMA BRUCEI in ternary complex with cofactor (NADP+) and inhibitor (DDD00066730)
3GN1	;	2.0	;	Structure of Pteridine Reductase 1 (PTR1) from TRYPANOSOMA BRUCEI in ternary complex with cofactor (NADP+) and inhibitor (DDD00067116)
3BMC	;	2.6	;	Structure of Pteridine Reductase 1 (PTR1) from Trypanosoma brucei in ternary complex with cofactor (NADP+) and substrate (folate)
2QHX	;	2.61	;	Structure of Pteridine Reductase from Leishmania major complexed with a ligand
6L03	;	2.084	;	structure of PTP-MEG2 and MUNC18-1-pY145 peptide complex
6KZQ	;	1.7	;	structure of PTP-MEG2 and NSF-pY83 peptide complex
5T19	;	2.1001	;	Structure of PTP1B complexed with N-(3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methyl-[1,1'-biphenyl]-4-yl)acetamide
1LQF	;	2.5	;	Structure of PTP1b in Complex with a Peptidic Bisphosphonate Inhibitor
3SME	;	1.7	;	Structure of PTP1B inactivated by H2O2/bicarbonate
3MCV	;	1.7	;	Structure of PTR1 from Trypanosoma brucei in ternary complex with 2,4-diamino-5-[2-(2,5-dimethoxyphenyl)ethyl]thieno[2,3-d]-pyrimidine and NADP+
3URR	;	1.397	;	Structure of PTS IIA-like nitrogen-regulatory protein PtsN (BTH_I0484) (ptsN)
8EE4	;	2.6	;	Structure of PtuA
2FW1	;	2.0	;	Structure of PurE (N5-carboxyaminoimidazole ribonucleotide mutase) from the acidophilic bacterium Acetobacter aceti, at pH 8.5
5CLF	;	2.0	;	Structure of PurE (N5-carboxyaminoimidazole ribonucleotide mutase) from the acidophilic bacterium Acetobacter aceti, at pH 8.5
2FWJ	;	1.95	;	Structure of PurE (N5-carboxyaminoimidazole ribonucleotide mutase) from the acidophilic bacterium Acetobacter aceti, complexed with AIR (5-aminoimidazole ribonucleotide)
5CLI	;	1.948	;	Structure of PurE (N5-carboxyaminoimidazole ribonucleotide mutase) from the acidophilic bacterium Acetobacter aceti, complexed with AIR (5-aminoimidazole ribonucleotide)
2FWI	;	1.94	;	Structure of PurE (N5-carboxyaminoimidazole ribonucleotide mutase) H59D, from the acidophilic bacterium Acetobacter aceti, complexed with 5-aminoimidazole ribonucleotide (AIR)
2FW9	;	1.75	;	Structure of PurE (N5-carboxyaminoimidazole ribonucleotide mutase) H59F from the acidophilic bacterium Acetobacter aceti, at pH 8
2FW7	;	1.75	;	Structure of PurE (N5-carboxyaminoimidazole ribonucleotide mutase) H59N from the acidophilic bacterium Acetobacter aceti, at pH 8
5CLH	;	1.75	;	Structure of PurE (N5-carboxyaminoimidazole ribonucleotide mutase) H59N from the acidophilic bacterium Acetobacter aceti, at pH 8
2FWP	;	1.85	;	Structure of PurE (N5-carboxyaminoimidazole ribonucleotide mutase) H59N from the acidophilic bacterium Acetobacter aceti, bound to isocair
5CLJ	;	1.85	;	Structure of PurE (N5-carboxyaminoimidazole ribonucleotide mutase) H59N from the acidophilic bacterium Acetobacter aceti, complexed with AIR (5-aminoimidazole ribonucleotide) and CO2
2FWB	;	2.0	;	Structure of PurE (N5-carboxyaminoimidazole ribonucleotide mutase) H89F from the acidophilic bacterium Acetobacter aceti, at pH 8
2FW8	;	1.75	;	Structure of PurE (N5-carboxyaminoimidazole ribonucleotide mutase) H89G from the acidophilic bacterium Acetobacter aceti, at pH 8
2FWA	;	1.9	;	Structure of PurE (N5-carboxyaminoimidazole ribonucleotide mutase) H89N from the acidophilic bacterium Acetobacter aceti, at pH 7
2FW6	;	1.85	;	Structure of PurE (N5-carboxyaminoimidazole ribonucleotide mutase) mutant H59N from the acidophilic bacterium Acetobacter aceti, at pH 5.4
5CLG	;	1.85	;	Structure of PurE (N5-carboxyaminoimidazole ribonucleotide mutase) mutant H59N from the acidophilic bacterium Acetobacter aceti, at pH 5.4
6OTT	;	2.55	;	Structure of PurF in complex with ppApp
2P4S	;	2.2	;	Structure of Purine Nucleoside Phosphorylase from Anopheles gambiae in complex with DADMe-ImmH
3D54	;	3.5	;	Structure of PurLQS from Thermotoga maritima
3ZK4	;	1.65	;	Structure of purple acid phosphatase PPD1 isolated from yellow lupin (Lupinus luteus) seeds
3G17	;	2.3	;	Structure of putative 2-dehydropantoate 2-reductase from staphylococcus aureus
3N07	;	1.76	;	Structure of putative 3-deoxy-D-manno-octulosonate 8-phosphate phosphatase from Vibrio cholerae
3I4F	;	2.39	;	Structure of putative 3-oxoacyl-reductase from bacillus thuringiensis
1UFH	;	2.2	;	Structure of putative acetyltransferase, YYCN protein of Bacillus subtilis
3IP1	;	2.09	;	Structure of putative alcohol dehydrogenase (TM_042) from Thermotoga maritima
1JN9	;	2.3	;	Structure of Putative Asparaginase Encoded by Escherichia coli ybiK Gene
2XIO	;	1.19	;	Structure of putative deoxyribonuclease TATDN1 isoform a
3LYB	;	2.66	;	Structure of putative endoribonuclease(KP1_3112) from Klebsiella pneumoniae
3PWX	;	2.5	;	Structure of putative flagellar hook-associated protein from Vibrio parahaemolyticus
4HYR	;	1.84	;	Structure of putative Glucarate dehydratase from Acidaminococcus sp. D21 with unusual static disorder
3N1U	;	1.8	;	Structure of putative HAD superfamily (subfamily III A) hydrolase from Legionella pneumophila
3HUL	;	2.19	;	Structure of putative homoserine kinase thrB from Listeria monocytogenes
2E1C	;	2.1	;	Structure of Putative HTH-type transcriptional regulator PH1519/DNA Complex
3P7M	;	2.2	;	Structure of putative lactate dehydrogenase from Francisella tularensis subsp. tularensis SCHU S4
1WOT	;		;	Structure of putative minimal nucleotidyltransferase
3GPI	;	1.44	;	Structure of putative NAD-dependent epimerase/dehydratase from methylobacillus flagellatus
3G2E	;	2.0	;	Structure of putative OORC subunit of 2-oxoglutarate:acceptor oxidoreductase from Campylobacter jejuni
2AQW	;	2.0	;	Structure of putative orotidine-monophosphate-decarboxylase from Plasmodium yoelii (PY01515)
3IP3	;	2.14	;	Structure of putative oxidoreductase (TM_0425) from Thermotoga maritima
3GFG	;	2.59	;	Structure of putative oxidoreductase yvaA from Bacillus subtilis in triclinic form
3IOY	;	1.9	;	Structure of putative short-chain dehydrogenase (Saro_0793) from Novosphingobium aromaticivorans
7US3	;	2.2	;	Structure of Putrescine N-hydroxylase Involved Complexed with NADP+
4YLM	;	2.05	;	Structure of PvcB, an Fe, alpha-ketoglutarate dependent oxygenase from an isonitrile synthetic pathway
5HH9	;	1.47	;	Structure of PvdN from Pseudomonas aeruginosa
5HHA	;	1.24	;	Structure of PvdO from Pseudomonas aeruginosa
3L94	;	1.95	;	Structure of PvdQ covalently acylated with myristate
2N1C	;		;	Structure of PvHCt, an antimicrobial peptide from shrimp litopenaeus vannamei
6I7Q	;	1.798	;	Structure of pVHL-elongin B-elongin C (VCB) in complex with hydroxylated-HIF-2alpha (523-542) in the C2221 form
6I7R	;	1.949	;	Structure of pVHL-elongin B-elongin C (VCB) in complex with hydroxylated-HIF-2alpha (523-542) in the P43212 form
1PVI	;	2.6	;	STRUCTURE OF PVUII ENDONUCLEASE WITH COGNATE DNA
5Z5O	;	1.92	;	Structure of Pycnonodysostosis disease related I249T mutant of human cathepsin K
8TCX	;	1.72	;	Structure of PYCR1 complexed with 2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid
8TCZ	;	2.1	;	Structure of PYCR1 complexed with 2-(pyridin-2-yl)cyclopropane-1-carboxylic acid
8TCU	;	2.0	;	Structure of PYCR1 complexed with 2-chloro-5-(2-oxoimidazolidin-1-yl)benzoic acid
8TCW	;	1.94	;	Structure of PYCR1 complexed with 2-methyl-3-(2-oxoimidazolidin-1-yl)benzoic acid
8TD1	;	1.88	;	Structure of PYCR1 complexed with 3-(6-Oxa-9-azaspiro(4.5)decane-9-carbonyl)benzoic acid
8TCV	;	1.74	;	Structure of PYCR1 complexed with 4-bromobenzene-1,3-dicarboxylic acid
8TD0	;	2.2	;	Structure of PYCR1 complexed with 5-oxo-7a-phenyl-hexahydropyrrolo[2,1-b][1,3]thiazole-3-carboxylic acid
8TCY	;	1.95	;	Structure of PYCR1 complexed with 7-fluoro-2-oxo-1,2,3,4-tetrahydroquinoline-6-carboxylic acid
8DKG	;	1.85	;	Structure of PYCR1 Thr171Met variant complexed with NADH
5B6A	;	2.0	;	Structure of Pyridoxal Kinasefrom Pseudomonas Aeruginosa
1M8V	;	2.6	;	Structure of Pyrococcus abyssii Sm Protein in Complex with a Uridine Heptamer
1Z26	;	2.5	;	Structure of Pyrococcus furiosus Argonaute with bound tungstate
1KA2	;	2.2	;	Structure of Pyrococcus furiosus Carboxypeptidase Apo-Mg
1K9X	;	2.3	;	Structure of Pyrococcus furiosus carboxypeptidase Apo-Yb
1KA4	;	3.0	;	Structure of Pyrococcus furiosus carboxypeptidase Nat-Pb
7EI1	;	3.9	;	Structure of Pyrococcus furiosus Cas1Cas2 complex
2WR8	;	1.77	;	Structure of Pyrococcus horikoshii SAM hydroxide adenosyltransferase in complex with SAH
5MY4	;	2.211	;	Structure of Pyroglutamate-Abeta-specific Fab c#17 in complex with human Abeta-pE3-12PEGb
5MYK	;	1.6	;	Structure of Pyroglutamate-Abeta-specific Fab c#17 in complex with murine Abeta-pE3-18PEGb
5MYX	;	1.492	;	Structure of Pyroglutamate-Abeta-specific Fab c#24 in complex with human Abeta-pE3-18
5MYO	;	1.59	;	Structure of Pyroglutamate-Abeta-specific Fab c#6 in complex with human Abeta-pE3-12-PEGb
4P82	;	1.3	;	Structure of PyrR protein from Bacillus subtilis
4P86	;	1.93	;	Structure of PyrR protein from Bacillus subtilis with GMP
4CH3	;	2.28	;	Structure of pyrrolysyl-tRNA synthetase in complex with adenylated butyryl lysine
4CH4	;	2.16	;	Structure of pyrrolysyl-tRNA synthetase in complex with adenylated crotonyl lysine
4CH6	;	2.05	;	Structure of pyrrolysyl-tRNA synthetase in complex with adenylated propargyloxycarbonyl lysine
4CH5	;	2.2	;	Structure of pyrrolysyl-tRNA synthetase in complex with adenylated propionyl lysine
2Q8F	;	2.03	;	Structure of pyruvate dehydrogenase kinase isoform 1
2Q8H	;	2.0	;	Structure of pyruvate dehydrogenase kinase isoform 1 in complex with dichloroacetate (DCA)
2Q8G	;	1.9	;	Structure of pyruvate dehydrogenase kinase isoform 1 in complex with glucose-lowering drug AZD7545
8FHU	;	1.801	;	Structure of Pyruvate dehydrogenase phosphatase regulatory subunit epitope presented by H2-Dd
8FHL	;	2.194	;	Structure of pyruvate dehydrogenase phosphatase regulatory subunit neoepitope presented by H2-Dd
1HQ6	;	2.7	;	STRUCTURE OF PYRUVOYL-DEPENDENT HISTIDINE DECARBOXYLASE AT PH 8
8FNH	;	2.5	;	Structure of Q148K HIV-1 intasome with Dolutegravir bound
5TXO	;	2.546	;	STRUCTURE OF Q151M complex (A62V, V75I, F77L, F116Y, Q151M) mutant HIV-1 REVERSE TRANSCRIPTASE (RT) TERNARY COMPLEX WITH A DOUBLE STRANDED DNA AND AN INCOMING DATP
5TXP	;	2.7	;	STRUCTURE OF Q151M complex (A62V, V75I, F77L, F116Y, Q151M) mutant HIV-1 REVERSE TRANSCRIPTASE (RT) TERNARY COMPLEX WITH A DOUBLE STRANDED DNA AND AN INCOMING DDATP
5TXN	;	2.55	;	STRUCTURE OF Q151M MUTANT HIV-1 REVERSE TRANSCRIPTASE (RT) TERNARY COMPLEX WITH A DOUBLE STRANDED DNA AND AN INCOMING DATP
2NOZ	;	2.43	;	Structure of Q315F human 8-oxoguanine glycosylase distal crosslink to 8-oxoguanine DNA
2NOF	;	2.35	;	Structure of Q315F human 8-oxoguanine glycosylase proximal crosslink to 8-oxoguanine DNA
7RAR	;	2.15	;	Structure of Q67H mutant of disulfide stabilized HIV-1 CA hexamer
7RHM	;	2.16	;	Structure of Q67H/N74D mutant of disulfide stabilized HIV-1 CA hexamer
3PM1	;	2.8	;	Structure of QacR E90Q bound to Ethidium
2GBY	;	2.9	;	Structure of QacR Multidrug Transcriptional Regulator Bound to Bivalent Diamidine Berenil
2G0E	;	2.88	;	Structure of QacR Multidrug Transcriptional Regulator Bound to Trivalent and Bivalent Diamidine Drugs
2XTW	;	2.803	;	Structure of QnrB1 (Full length), a plasmid-mediated fluoroquinolone resistance protein
2XTX	;	2.2	;	Structure of QnrB1 (M102R-Trypsin Treated), a plasmid-mediated fluoroquinolone resistance protein
2XTY	;	1.8	;	Structure of QnrB1 (R167E-Trypsin Treated), a plasmid-mediated fluoroquinolone resistance protein
5CGO	;	1.5	;	Structure of quasiracemic Ala-Magainin 2 with a beta amino acid substitution at position 13
5CGN	;	2.2	;	Structure of quasiracemic Ala-Magainin 2 with a beta amino acid substitution at position 8
3ULU	;	3.52	;	Structure of quaternary complex of human TLR3ecd with three Fabs (Form1)
3ULV	;	3.522	;	Structure of quaternary complex of human TLR3ecd with three Fabs (Form2)
6I0K	;	1.64	;	Structure of quinolinate synthase in complex with 4-mercaptophthalic acid
6I0R	;	2.1	;	Structure of quinolinate synthase in complex with 5-mercaptopyridine-2,3-dicarboxylic acid
6I0P	;	1.9	;	Structure of quinolinate synthase in complex with 6-mercaptopyridine-2,3-dicarboxylic acid
5F35	;	1.6	;	Structure of quinolinate synthase in complex with citrate
5F33	;	1.45	;	Structure of quinolinate synthase in complex with phosphoglycolohydroxamate
5F3D	;	1.9	;	Structure of quinolinate synthase in complex with reaction intermediate W
6F4L	;	2.3	;	Structure of quinolinate synthase with inhibitor-derived quinolinate
6F48	;	1.5	;	Structure of quinolinate synthase with reaction intermediates X and Y
5LQM	;	1.62	;	Structure of quinolinate synthase Y21F mutant in complex with citrate
5LQS	;	1.9	;	Structure of quinolinate synthase Y21F mutant in complex with substrate-derived quinolinate
1QPQ	;	2.45	;	Structure of Quinolinic Acid Phosphoribosyltransferase from Mycobacterium Tuberculosis: A Potential TB Drug Target
1LJ0	;	2.0	;	Structure of quintuple mutant of the rat outer mitocondrial cytochrome b5.
5V1K	;	1.18	;	Structure of R-GNA dodecamer
1ZJZ	;	1.1	;	Structure of R-specific alcohol dehydrogenase (mutant G37D) from Lactobacillus brevis in complex with phenylethanol and NAD
1ZK1	;	1.78	;	Structure of R-specific alcohol dehydrogenase (mutant G37D) from Lactobacillus brevis in complex with phenylethanol and NAD
1ZJY	;	1.05	;	Structure of R-specific alcohol dehydrogenase (mutant G37D) from Lactobacillus brevis in complex with phenylethanol and NADH
1ZK0	;	1.55	;	Structure of R-specific alcohol dehydrogenase (mutant G37D) from Lactobacillus brevis in complex with phenylethanol and NADH
1ZK4	;	1.0	;	Structure of R-specific alcohol dehydrogenase (wildtype) from Lactobacillus brevis in complex with acetophenone and NADP
6EVD	;	1.19	;	Structure of R173A A. niger Fdc1 with prFMN in the hydroxylated form
6EVE	;	2.05	;	Structure of R175A S. cerevisiae Fdc1 with prFMN in the iminium form
1NBI	;	3.0	;	Structure of R175K mutated glycine N-methyltransferase complexed with S-adenosylmethionine, R175K:SAM.
8IBW	;	3.6	;	Structure of R2 with 3'UTR and DNA in binding state
8IBX	;	3.74	;	Structure of R2 with 3'UTR and DNA in unwinding state
8IBY	;	3.47	;	Structure of R2 with 5'ORF
8IBZ	;	3.04	;	Structure of R2 with 5'ORF and 3'UTR
2CAQ	;	2.0	;	Structure of R21L mutant of Sh28GST in complex with GSH
2C8U	;	2.0	;	Structure of R21Q mutant of Sh28GST
3V4Q	;	3.06	;	Structure of R335W mutant of human Lamin
5YET	;	2.806	;	Structure of R354_WT
6R42	;	1.72	;	Structure of R504C mutant of Pseudomonas aeruginosa Penicillin-Binding Protein 3 (PBP3) in complex with piperacillin
8JNJ	;	3.3	;	Structure of R932A/K1147A/H1148A mutant AE2
1LTX	;	2.7	;	Structure of Rab Escort Protein-1 in complex with Rab geranylgeranyl transferase and isoprenoid
2K6S	;		;	Structure of Rab11-FIP2 C-terminal Coiled-coil Domain
4D0G	;	2.5	;	Structure of Rab14 in complex with Rab-Coupling Protein (RCP)
3CWZ	;	3.2	;	Structure of RAB6(GTP)-R6IP1 complex
2FU5	;	2.0	;	structure of Rab8 in complex with MSS4
8BPO	;	2.8	;	Structure of rabbit 80S ribosome translating beta-tubulin in complex with tetratricopeptide protein 5 (TTC5) and S-phase Cyclin A Associated Protein residing in the ER (SCAPER)
6T59	;	3.11	;	Structure of rabbit 80S ribosome translating beta-tubulin in complex with tetratricopeptide protein 5 and nascent chain-associated complex
1QZ6	;	1.6	;	Structure of rabbit actin in complex with jaspisamide A
1QZ5	;	1.45	;	Structure of rabbit actin in complex with kabiramide C
6MGO	;	2.2	;	Structure of rabbit actin in complex with Mycalolide B
2ASM	;	1.6	;	Structure of Rabbit Actin In Complex With Reidispongiolide A
2ASP	;	1.64	;	Structure of Rabbit Actin In Complex With Reidispongiolide C
2ASO	;	1.7	;	Structure of Rabbit Actin In Complex With Sphinxolide B
6W7V	;	1.7	;	Structure of rabbit actin in complex with truncated analog of Mycalolide B
6QRI	;	2.4	;	Structure of rabbit G-actin in complex with chivosazole A
2GJ4	;	1.6	;	Structure of rabbit muscle glycogen phosphorylase in complex with ligand
2GM9	;	2.3	;	Structure of rabbit muscle glycogen phosphorylase in complex with thienopyrrole
3PMG	;	2.4	;	STRUCTURE OF RABBIT MUSCLE PHOSPHOGLUCOMUTASE AT 2.4 ANGSTROMS RESOLUTION. USE OF FREEZING POINT DEPRESSANT AND REDUCED TEMPERATURE TO ENHANCE DIFFRACTIVITY
1PKN	;	2.9	;	STRUCTURE OF RABBIT MUSCLE PYRUVATE KINASE COMPLEXED WITH MN2+, K+, AND PYRUVATE
5J8V	;	4.9	;	Structure of rabbit ryanodine receptor RyR1 open state activated by calcium ion
5T9M	;	4.0	;	Structure of rabbit RyR1 (Ca2+-only dataset, class 1)
5T9N	;	3.8	;	Structure of rabbit RyR1 (Ca2+-only dataset, class 2)
5T9R	;	5.8	;	Structure of rabbit RyR1 (Ca2+-only dataset, class 3)
5T9S	;	4.2	;	Structure of rabbit RyR1 (Ca2+-only dataset, class 4)
5TAL	;	4.3	;	Structure of rabbit RyR1 (Caffeine/ATP/Ca2+ dataset, class 1&2)
5T9V	;	4.4	;	Structure of rabbit RyR1 (Caffeine/ATP/Ca2+ dataset, class 1)
5TA3	;	4.4	;	Structure of rabbit RyR1 (Caffeine/ATP/Ca2+ dataset, class 2)
5TAQ	;	4.1	;	Structure of rabbit RyR1 (Caffeine/ATP/Ca2+ dataset, class 3&4)
5TAN	;	4.3	;	Structure of rabbit RyR1 (Caffeine/ATP/Ca2+ dataset, class 3)
5TAM	;	4.3	;	Structure of rabbit RyR1 (Caffeine/ATP/Ca2+ dataset, class 4)
5TAP	;	4.4	;	Structure of rabbit RyR1 (Caffeine/ATP/EGTA dataset, all particles)
5TAS	;	6.2	;	Structure of rabbit RyR1 (Caffeine/ATP/EGTA dataset, class 1)
5TAT	;	4.8	;	Structure of rabbit RyR1 (Caffeine/ATP/EGTA dataset, class 2)
5TAU	;	6.2	;	Structure of rabbit RyR1 (Caffeine/ATP/EGTA dataset, class 3)
5TAV	;	4.8	;	Structure of rabbit RyR1 (Caffeine/ATP/EGTA dataset, class 4)
5TB0	;	4.4	;	Structure of rabbit RyR1 (EGTA-only dataset, all particles)
5TB1	;	4.6	;	Structure of rabbit RyR1 (EGTA-only dataset, class 1)
5TB2	;	4.6	;	Structure of rabbit RyR1 (EGTA-only dataset, class 2)
5TB3	;	4.7	;	Structure of rabbit RyR1 (EGTA-only dataset, class 3)
5TB4	;	4.5	;	Structure of rabbit RyR1 (EGTA-only dataset, class 4)
5TAW	;	4.4	;	Structure of rabbit RyR1 (ryanodine dataset, all particles)
5TAX	;	6.6	;	Structure of rabbit RyR1 (ryanodine dataset, class 1)
5TAY	;	4.6	;	Structure of rabbit RyR1 (ryanodine dataset, class 2)
5TAZ	;	4.3	;	Structure of rabbit RyR1 (ryanodine dataset, class 3)
5L1D	;	11.0	;	Structure of rabbit RyR2 in complex with FKBP12.6 in a closed state (conformation C1)
4PL8	;	2.0	;	Structure of rabbit skeletal muscle actin in complex with a hybrid peptide comprising thymosin beta4 and the lysine-rich region of Cordon-Bleu
8S3E	;	2.39	;	Structure of rabbit Slo1 in complex with gamma1/LRRC26
1YZM	;	1.5	;	Structure of Rabenosyn (458-503), Rab4 binding domain
1UKV	;	1.5	;	Structure of RabGDP-dissociation inhibitor in complex with prenylated YPT1 GTPase
6UEB	;	3.3	;	Structure of Rabies SAD-B19 L-P complex from cryo-EM
6LGX	;	3.097	;	Structure of Rabies virus glycoprotein at basic pH
6LGW	;	2.9037	;	Structure of Rabies virus glycoprotein in complex with neutralizing antibody 523-11 at acidic pH
7T5G	;	1.7	;	Structure of rabies virus phosphoprotein C-terminal domain, S210E mutant
7T5H	;	1.5	;	Structure of rabies virus phosphoprotein C-terminal domain, wild type
4NP9	;	1.92	;	Structure of Rabphilin C2A domain bound to IP3
6AGP	;		;	Structure of Rac1 in the low-affinity state for Mg2+
5I44	;	2.621	;	Structure of RacA-DNA complex; P21 form
4MGP	;	1.75	;	Structure of racemic Ala-(8,13,18) Magainin 2
4GWT	;	2.25	;	Structure of racemic Pin1 WW domain cocrystallized with DL-malic acid
4GWV	;	3.05	;	Structure of racemic Pin1 WW domain cocrystallized with tri-ammonium citrate
5G34	;	1.9	;	Structure of Rad14 in complex with acetylaminoanthracene-C8-guanine containing DNA
5G32	;	2.2	;	Structure of Rad14 in complex with acetylaminophenyl-guanine containing DNA
5G35	;	2.0	;	Structure of Rad14 in complex with acetylaminopyren-C8-guanine containing DNA
5G33	;	2.4	;	Structure of Rad14 in complex with acetylnaphtyl-guanine containing DNA
5A39	;	2.8	;	Structure of Rad14 in complex with cisplatin containing DNA
4R62	;	2.28	;	Structure of Rad6~Ub
6WTE	;	1.67	;	Structure of radical S-adenosylmethionine methyltransferase, TsrM, from Kitasatospora setae with cobalamin and [4Fe-4S] cluster bound
6WTF	;	2.19	;	Structure of radical S-adenosylmethionine methyltransferase, TsrM, from Kitasatospora setae with tryptophan substrate and SAM analog (aza-SAM) bound
2HQ0	;	1.4	;	Structure of RafE from Streptococcus pneumoniae
6XNX	;	2.7	;	Structure of RAG1 (R848M/E649V)-RAG2-DNA Strand Transfer Complex (Dynamic-Form)
6XNY	;	2.9	;	Structure of RAG1 (R848M/E649V)-RAG2-DNA Strand Transfer Complex (Paired-Form)
6XNZ	;	3.8	;	Structure of RAG1 (R848M/E649V)-RAG2-DNA Target Capture Complex
5CX8	;	2.4	;	Structure of RagB, a major immunodominant virulence factor of Porphyromonas gingivalis.
2WGO	;		;	Structure of ranaspumin-2, a surfactant protein from the foam nests of a tropical frog
6AXF	;	3.1	;	Structure of RasGRP2 in complex with Rap1B
6AXG	;	3.302	;	Structure of RasGRP4 in complex with HRas
6EOW	;	1.8	;	Structure of Raspberry Ketone Synthase with Hydroxybenzalacetone
1K2S	;	2.55	;	Structure of rat brain nNOS heme domain complexed with NG-allyl-L-arginine
1K2R	;	2.15	;	Structure of rat brain nNOS heme domain complexed with NG-nitro-L-arginine
1K2T	;	2.2	;	Structure of rat brain nNOS heme domain complexed with S-ethyl-N-phenyl-isothiourea
1K2U	;	2.2	;	Structure of rat brain nNOS heme domain complexed with S-ethyl-N-[4-(trifluoromethyl)phenyl] isothiourea
4YWD	;	2.1	;	Structure of rat cytosolic pepck in complex with 2,3-Pyridine dicarboxylic acid
4YW8	;	1.55	;	Structure of rat cytosolic pepck in complex with 3-mercaptopicolinic acid
4YW9	;	1.4	;	Structure of rat cytosolic pepck in complex with 3-mercaptopicolinic acid and GTP
4YWB	;	1.5	;	Structure of rat cytosolic pepck in complex with 3-mercaptopicolinic acid and oxalic acid
4GMM	;	1.736	;	Structure of rat cytosolic PEPCK Ld_1g in complex with Beta-Sulfopyruvate and GTP
4GMU	;	1.2	;	Structure of rat cytosolic PEPCK Ld_1g in complex with oxalate and GTP
4GMW	;	1.75	;	Structure of rat cytosolic PEPCK Ld_1g in complex with PEP and GDP
4GMZ	;	2.05	;	Structure of rat cytosolic PEPCK Ld_2g in complex with Beta-Sulfopyruvate and GTP
4GNM	;	1.5	;	Structure of rat cytosolic PEPCK Ld_2g in complex with oxalate and GTP
4GNL	;	1.7	;	Structure of rat cytosolic PEPCK Ld_2g in complex with PEP and GDP
4GNO	;	1.5	;	Structure of rat cytosolic PEPCK Ld_3g in complex with Beta-Sulfopyruvate and GTP
4GNQ	;	1.4	;	Structure of rat cytosolic PEPCK Ld_3g in complex with oxalate and GTP
4GNP	;	1.744	;	Structure of rat cytosolic PEPCK Ld_3g in complex with PEP and GDP
1QBQ	;	2.4	;	STRUCTURE OF RAT FARNESYL PROTEIN TRANSFERASE COMPLEXED WITH A CVIM PEPTIDE AND ALPHA-HYDROXYFARNESYLPHOSPHONIC ACID.
6LBK	;	2.49569	;	Structure of rat GLD-2 (Terminal nucleotidyltransferase 2, TENT2)
4KJG	;	2.38	;	Structure of Rat Intestinal Alkaline Phosphatase expressed in insect cell
5ADD	;	2.1	;	Structure of rat neuronal nitric oxide synthase d597n m336v mutant heme domain in complex with 7-((3-(methylamino)methyl) phenoxy)methyl)quinolin-2-amine
5G0O	;	1.85	;	Structure of rat neuronal nitric oxide synthase D597N mutant heme domain in complex with 4-METHYL-6-(2-(5-(4-METHYLPIPERAZIN-1-YL) PYRIDIN-3-YL)ETHYL)PYRIDIN-2-AMINE
5G0N	;	1.936	;	Structure of rat neuronal nitric oxide synthase D597N mutant heme domain in complex with N1-(5-(2-(6-AMINO-4-METHYLPYRIDIN-2-YL)ETHYL) PYRIDIN-3-YL)-N1,N2-DIMETHYLETHANE-1,2-DIAMINE
3JX1	;	2.0	;	Structure of rat neuronal nitric oxide synthase D597N mutant heme domain in complex with N1-{(3'R,4'R)-4'-[(6""-amino-4""-methylpyridin-2""-yl)methyl]pyrrolidin-3'-yl}-N2-(3'-fluorophenethyl)ethane-1,2-diamine
3JX0	;	2.2	;	Structure of rat neuronal nitric oxide synthase D597N mutant heme domain in complex with N1-{(3'S,4'S)-4'-[(6""-amino-4""-methylpyridin-2""-yl)methyl]pyrrolidin-3'-yl}-N2-(3'-fluorophenethyl)ethane-1,2-diamine
3JX3	;	1.95	;	Structure of rat neuronal nitric oxide synthase D597N/M336V mutant heme domain in complex with N1-{(3'R,4'R)-4'-[(6""-amino-4""-methylpyridin-2""-yl)methyl]pyrrolidin-3'-yl}-N2-(3'-fluorophenethyl)ethane-1,2-diamine
3JX4	;	2.26	;	Structure of rat neuronal nitric oxide synthase D597N/M336V mutant heme domain in complex with N1-{(3'R,4'S)-4'-[(6""-amino-4""-methylpyridin-2""-yl)methyl]pyrrolidin-3'-yl}-N2-(3'-fluorophenethyl)ethane-1,2-diamine
3JX5	;	2.15	;	Structure of rat neuronal nitric oxide synthase D597N/M336V mutant heme domain in complex with N1-{(3'S,4'R)-4'-[(6""-amino-4""-methylpyridin-2""-yl)methyl]pyrrolidin-3'-yl}-N2-(3'-fluorophenethyl)ethane-1,2-diamine
3JX2	;	2.1	;	Structure of rat neuronal nitric oxide synthase D597N/M336V mutant heme domain in complex with N1-{(3'S,4'S)-4'-[(6""-amino-4""-methylpyridin-2""-yl)methyl]pyrrolidin-3'-yl}-N2-(3'-fluorophenethyl)ethane-1,2-diamine
4CX5	;	1.8	;	Structure of rat neuronal nitric oxide synthase H341L mutant heme domain in complex with 4-METHYL-6-(((3R,4R)-4-((5-(PYRIDIN-2-YL) PENTYL)OXY)PYRROLIDIN-3-YL)METHYL)PYRIDIN-2-AMINE
4CX6	;	1.9	;	Structure of rat neuronal nitric oxide synthase H341L mutant heme domain in complex with 6-((((3S, 5R)-5-(((6-AMINO-4-METHYLPYRIDIN-2- YL)METHOXY)METHYL)PYRROLIDIN-3-YL)OXY)METHYL)-4-METHYLPYRIDIN-2-AMINE
8FGV	;	1.848	;	Structure of rat neuronal nitric oxide synthase H692F mutant heme domain in complex with 6-(5-(2-(dimethylamino)ethyl)-2,3-difluorophenethyl)-4-methoxypyridin-2-amine
3NNY	;	2.1	;	Structure of rat neuronal nitric oxide synthase heme domain complexed with 6-(((3R,4R)-4-(2-(3-Fluorophenethylamino)ethoxy)pyrrolidin-3-yl)methyl)pyridin-2-amine
3NNZ	;	1.97	;	Structure of rat neuronal nitric oxide synthase heme domain complexed with 6-(((3S,4S)-4-(2-(3-Fluorophenethylamino)ethoxy)pyrrolidin-3-yl)methyl)pyridin-2-amine
4D2Y	;	1.981	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with (1R,2R)-2-(3-fluorobenzyl)-N-{2-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]ethyl}cyclopropanamine
4D2Z	;	1.886	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with (1S,2S)-2-(3-fluorobenzyl)-N-{2-[2-(1H-imidazol-1-YL)pyrimidin-4-YL]ethyl}cyclopropanamine
5AGK	;	2.0	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with (2S)-2-Amino-5-(2-(methylsulfinyl)acetimidamido) pentanoic acid
4GQE	;	1.8	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with (5E)-5-[(N-tert-butoxycarbamimidoyl)imino]-L-norvaline
5UNZ	;	1.95	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with (R)-3-[(2-amino-4-methylquinolin-7-yl)methoxy]-5-(2-(methylamino)propyl)benzonitrile
6NGY	;	1.928	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with (R)-6-(2,3-difluoro-5-(2-(1-methylpyrrolidin-2-yl)ethyl)phenethyl)-4-methylpyridin-2-amine
4CTQ	;	2.0	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with (R)-6-(2-Amino-2-(3-(2-(6-amino-4-methylpyridin-2-yl) ethyl)phenyl)ethyl)-4-methylpyridin-2-amine
4CTW	;	1.9	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with (R)-6-(3-amino-2-(5-(2-(6-amino-4-methylpyridin-2-yl) ethyl)pyridin-3-yl)propyl)-4-methylpyridin-2-amine
6NGM	;	1.693	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with (R)-6-(3-fluoro-5-(2-(1-methylpyrrolidin-2-yl)ethyl)phenethyl)-4-methylpyridin-2-amine
6NGL	;	1.83	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with (R)-6-(3-fluoro-5-(2-(pyrrolidin-2-yl)ethyl)phenethyl)-4-methylpyridin-2-amine
5UNY	;	1.82	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with (RS)-3-[(2-amino-4-methylquinolin-7-yl)methoxy]-5-(2-(methylamino)propyl)benzonitrile
5AGL	;	1.94	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with (S)-2-Amino-5-(2-(methylsulfonyl)acetimidamido)pentanoic acid
5AGN	;	1.95	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with (S)-2-Amino-5-(2-hydroxyacetimidamido)pentanoic acid
5AGO	;	1.902	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with (S)-2-Amino-5-(2-mercaptoacetimidamido)pentanoic acid
5AGP	;	2.1	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with (S)-2-Amino-5-(2-mercaptoacetimidamido)pentanoic acid
5AGM	;	1.84	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with (S)-2-Amino-5-(2-oxoacetimidamido)pentanoic acid
5UO0	;	1.97	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with (S)-3-[(2-amino-4-methylquinolin-7-yl)methoxy]-5-(2-(methylamino)propyl)benzonitrile
6NHD	;	2.1	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with (S)-6-(2,3-difluoro-5-(2-(1-methylazetidin-2-yl)ethyl)phenethyl)-4-methylpyridin-2-amine
6NGZ	;	2.0	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with (S)-6-(2,3-difluoro-5-(2-(1-methylpyrrolidin-2-yl)ethyl)phenethyl)-4-methylpyridin-2-amine
6NH0	;	1.898	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with (S)-6-(2,3-difluoro-5-(2-(4-methylmorpholin-3-yl)ethyl)phenethyl)-4-methylpyridin-2-amine
4CTT	;	2.3	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with (S)-6-(2-amino-2-(3-(2-(4-methylpyridin-2-yl)ethyl)phenyl)ethyl)-4-methylpyridin-2-amine
4CTP	;	2.05	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with (S)-6-(2-Amino-2-(3-(2-(6-amino-4-methylpyridin-2-yl) ethyl)phenyl)ethyl)-4-methylpyridin-2-amine
4CTX	;	1.82	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with (S)-6-(3-amino-2-(5-(2-(6-amino-4-methylpyridin-2-yl) ethyl)pyridin-3-yl)propyl)-4-methylpyridin-2-amine
6NGP	;	1.976	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with (S)-6-(3-fluoro-5-(2-(1-methylpyrrolidin-2-yl)ethyl)phenethyl)-4-methylpyridin-2-amine
6NGN	;	1.9	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with (S)-6-(3-fluoro-5-(2-(pyrrolidin-2-yl)ethyl)phenethyl)-4-methylpyridin-2-amine
4V3Z	;	2.052	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 2-(2-(1H-imidazol-1-yl)pyrimidin-4-yl)-N-(2-(3- fluorophenyl)cyclopropylmethyl)ethan-1-amine
4V3W	;	2.13	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 2-(2-(1H-imidazol-1-yl)pyrimidin-4-yl)-N-(3- fluorophenethyl)ethan-1-amine
4D31	;	1.951	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 2-(2-(1H-imidazol-1-yl)pyrimidin-4-yl)-N-(3-cyanobenzyl) ethan-1-amine
4CTR	;	2.2	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 2-(6-Amino-4-methylpyridin-2-yl)-1-(3-(2-(6-amino-4- methylpyridin-2-yl)ethyl )phenyl)ethan-1-ol
6AUS	;	1.7	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 3-(2-(6-Amino-4-methylpyridin-2-yl)ethyl)-5-(3-(methylamino)propyl)benzonitrile
4UH4	;	1.95	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 3-(2-(6-Amino-4-methylpyridin-2-yl)ethyl)-5-(methyl(2-(methylamino)ethyl)amino)benzonitrile
4D32	;	2.103	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 3-(3-fluorophenyl)-N-2-(2-(5-methyl-1H-imidazol-1-yl) pyrimidin-4-yl)ethylpropan-1-amine
5UNU	;	2.05	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 3-[(2-amino-4-methylquinolin-7-yl)methoxy]-5-((methylamino)methyl)benzonitrile
5UNX	;	2.03	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 3-[(2-amino-4-methylquinolin-7-yl)methoxy]-5-(2-(methylamino)ethyl)benzonitrile
5UNR	;	1.95	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 3-[(2-aminoquinolin-7-yl)methoxy]-5-((methylamino)methyl)benzonitrile
5UNW	;	2.044	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 3-[2-(2-amino-4-methylquinolin-7-yl)ethyl]-5-((methylamino)methyl)benzonitrile
5VUU	;	1.96	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 4-(2-(((2-Amino-4-methylquinolin-7-yl)methyl)amino)ethyl)-2-methylbenzonitrile
5VUT	;	2.0	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 4-(2-(((2-Amino-4-methylquinolin-7-yl)methyl)amino)ethyl)benzonitrile
5VUS	;	1.95	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 4-(2-(((2-Aminoquinolin-7-yl)methyl)amino)ethyl)-2-chlorobenzonitrile
5VUR	;	1.97	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 4-(2-(((2-Aminoquinolin-7-yl)methyl)amino)ethyl)-2-methylbenzonitrile
5VUQ	;	2.002	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 4-(2-(((2-Aminoquinolin-7-yl)methyl)amino)ethyl)benzonitrile
8FGB	;	1.91	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 4-(5-(2-(dimethylamino)ethyl)-2,3-difluorophenethyl)-6-methylpyrimidin-2-amine
4JSH	;	2.35	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 4-methyl-6-((3-(piperidin-4-ylmethoxy)phenoxy)methyl)pyridin-2-amine
5FVR	;	1.842	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 4-METHYL-6-(2-(5-(1-METHYLPIPERIDIN-4-YL)PYRIDIN-3-YL) ETHYL)PYRIDIN-2-AMINE
6AUV	;	1.76	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 4-Methyl-6-(2-(5-(3-((methylamino)methyl)phenyl)pyridin-3-yl)ethyl)pyridin-2-amine
5FVS	;	1.948	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 4-methyl-6-(2-(5-(3-(methylamino)propyl)pyridin-3-yl) ethyl)pyridin-2-amine
6AUW	;	1.7	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 4-Methyl-6-(2-(5-(4-((methylamino)methyl)phenyl)pyridin-3-yl)ethyl)pyridin-2-amine
5FVQ	;	1.95	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 4-methyl-6-(2-(5-(4-methylpiperazin-1-yl)pyridin-3-yl) ethyl)pyridin-2-amine
6AUQ	;	1.95	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 4-Methyl-6-(3-(3-(methylamino)propyl)phenethyl)pyridin-2-amine
5FVP	;	2.099	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 4-methyl-6-[2-(5-morpholin-4-ylpyridin-3-yl)ethyl]pyridin-2-amine
5UNT	;	2.05	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 4-Methyl-7-[(3-((methylamino)methyl)phenoxy)methyl]quinolin-2-amine
5UNV	;	2.0	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 4-Methyl-7-[3-((methylamino)methyl)phenethyl]quinolin-2-amine
4IMS	;	2.15	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6,6'-((5-(3-aminopropyl)-1,3-phenylene)bis(ethane-2,1-diyl))bis(4-methylpyridin-2-amine)
4JSF	;	2.05	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6,6'-(heptane-1,7-diyl)bis(4-methylpyridin-2-amine)
4JSE	;	1.97	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6,6'-(pentane-1,5-diyl)bis(4-methylpyridin-2-amine)
4LUX	;	1.86	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-((((3R,5S)-5-(((6-amino-4-methylpyridin-2-yl)methoxy)methyl)pyrrolidin-3-yl)oxy)methyl)-4-methylpyridin-2-amine
4C39	;	1.98	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-((((3S, 5R)-5-(((6-amino-4-methylpyridin-2-yl)methoxy) methyl)pyrrolidin-3-yl)oxy)methyl)-4-methylpyridin-2-amine
3NLX	;	1.87	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(((3R,4R)-4-(2- (2,2-Difluoro-2-(3-fluorophenyl)ethylamino)ethoxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine
3NLY	;	1.99	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(((3R,4R)-4-(2- (2,2-Difluoro-2-(4-fluorophenyl)ethylamino)ethoxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine
3SVQ	;	2.18	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(((3R,4R)-4-(2-((2,2-Difluoro-2-(2,3-difluorophenyl)ethyl)amino)ethoxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine
3PNF	;	1.94	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(((3R,4R)-4-(2-((2,2-Difluoro-2-(2-chlorophenyl)ethyl)amino)ethoxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine
3SVP	;	2.05	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(((3R,4R)-4-(2-((2,2-Difluoro-2-(3-chloro-5-fluorophenyl)ethyl)amino)ethoxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine
3PNE	;	1.97	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(((3R,4R)-4-(2-((2,2-Difluoro-2-(3-chlorophenyl)ethyl)amino)ethoxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine
3PNG	;	1.88	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(((3R,4R)-4-(2-((2-fluoro-2-(3-fluorophenyl)ethyl)amino)ethoxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine
3NM0	;	1.81	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(((3R,4R)-4-(2-(2,2-Difluoro-2-phenylethylamino)ethoxy) pyrrolidin-3-yl)methyl)-4-methyl-3,4,5,6-tetrahydropyridin-2-amine
3NLZ	;	1.92	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(((3R,4R)-4-(2-(2,2-Difluoro-2-phenylethylamino)ethoxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine
3NLV	;	2.1	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(((3S,4S)-4-(2-(2,2-Difluoro-2-(3-fluorophenyl)ethylamino)ethoxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine
3NLW	;	2.1	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(((3S,4S)-4-(2-(2,2-Difluoro-2-(piperidin-2-yl)ethylamino)ethoxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine
4JSJ	;	1.92	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(((5-(((3-fluorophenethyl)amino)methyl)pyridin-3-yl)oxy)methyl)-4-methylpyridin-2-amine
4JSI	;	2.09	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-((3-(((3-fluorophenethyl)amino)methyl)phenoxy)methyl)-4-methylpyridin-2-amine
4JSG	;	1.94	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-((3-(3-aminopropoxy)phenoxy)methyl)-4-methylpyridin-2-amine
6NGX	;	1.773	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(2,3-difluoro-5-(3-(methylamino)prop-1-yn-1-yl)phenethyl)-4-methylpyridin-2-amine
5FW0	;	1.8	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(2-(5-((2-methoxyethyl)(methyl)amino)pyridin-3-yl) ethyl)-4-methylpyridin-2-amine
5FVT	;	1.828	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(2-(5-(3-(dimethylamino)propyl)pyridin-3-yl)ethyl)-4- methylpyridin-2-amine
5FVO	;	2.12	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(2-(5-(3-methoxypropylamino)pyridin-3-yl)ethyl)-4- methylpyridin-2-amine
6AUX	;	1.9	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(2-(5-Fluoro-3'-((methylamino)methyl)-[1,1'-biphenyl]-3-yl)ethyl)-4-methylpyridin-2-amine
6NGK	;	1.83	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(3-(3-(dimethylamino)prop-1-yn-1-yl)-5-fluorophenethyl)-4-methylpyridin-2-amine
6NGV	;	1.829	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(3-(3-(dimethylamino)propyl)-2,5,6-trifluorophenethyl)-4-methylpyridin-2-amine
6NGU	;	2.0	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(3-(3-(dimethylamino)propyl)-2,5-difluorophenethyl)-4-methylpyridin-2-amine
6NGT	;	1.942	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(3-(3-(dimethylamino)propyl)-2,6-difluorophenethyl)-4-methylpyridin-2-amine
6AUU	;	1.85	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(3-(3-(dimethylamino)propyl)-5-(trifluoromethyl)phenethyl)-4-methylpyridin-2-amine
6AUT	;	1.9	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(3-(3-(Dimethylamino)propyl)-5-fluorophenethyl)-4-methylpyridin-2-amine
7TSF	;	1.776	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(3-(4,4-difluoropiperidin-1-yl)prop-1-yn-1-yl)-4-methylpyridin-2-amine
4CTU	;	2.16	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(3-Amino-2-(3-(2-(6-amino-4-methylpyridin-2-yl)ethyl) phenyl)propyl)-4-methylpyridin-2-amine
4CTV	;	1.78	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(3-amino-2-(6-(2-(6-amino-4-methylpyridin-2-yl)ethyl) pyridin-2-yl)propyl)-4-methylpyridin-2-amine
6NGR	;	1.819	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(3-fluoro-5-(2-((2R,4S)-4-fluoro-1-methylpyrrolidin-2-yl)ethyl)phenethyl)-4-methylpyridin-2-amine
6NGQ	;	1.95	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(3-fluoro-5-(2-((2R,4S)-4-fluoropyrrolidin-2-yl)ethyl)phenethyl)-4-methylpyridin-2-amine
6NGJ	;	1.756	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(3-fluoro-5-(3-(methylamino)prop-1-yn-1-yl)phenethyl)-4-methylpyridin-2-amine
6AUR	;	1.75	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(3-Fluoro-5-(3-(methylamino)propyl)phenethyl)-4-methylpyridin-2-amine
4D7O	;	1.78	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(4-(((3-Fluorophenethyl)amino)methyl)phenyl)-4- methylpyridin-2-amine
6NHE	;	1.999	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(5-(2-((2S,4R)-4-ethoxy-1-methylpyrrolidin-2-yl)ethyl)-2,3-difluorophenethyl)-4-methylpyridin-2-amine
8FGA	;	1.8947	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(5-(2-(dimethylamino)ethyl)-2,3-difluorophenethyl)-4-methylpyridin-2-amine
8FG9	;	1.95	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(5-(2-(dimethylamino)ethyl)-2,3-difluorophenethyl)pyridin-2-amine
8FGC	;	1.779	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(5-(2-aminoethyl)-2,3-difluorophenethyl)-4-methylpyridin-2-amine
6NGW	;	1.858	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(5-(3-(dimethylamino)propyl)-2,3,4-trifluorophenethyl)-4-methylpyridin-2-amine
6NGS	;	1.9	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(5-(3-(dimethylamino)propyl)-2,3-difluorophenethyl)-4-methylpyridin-2-amine
5ADA	;	1.98	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(((3-((Dimethylamino)methyl)phenyl)amino)methyl) quinolin-2-amine
5VUO	;	1.8	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(((3-(4-Methoxypyridin-3-yl)propyl)amino)methyl)quinolin-2-amine
5VUN	;	1.745	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(((3-(4-Methylpyridin-3-yl)propyl)amino)methyl)quinolin-2-amine
5VUP	;	1.94	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(((3-(5-Fluoropyridin-3-yl)propyl)amino)methyl)quinolin-2-amine
5VUJ	;	1.952	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(((3-(Dimethylamino)benzyl)amino)methyl)quinolin-2-amine
5VUM	;	2.1	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(((3-(Pyridin-3-yl)propyl)amino)methyl)quinolin-2-amine
5VUI	;	2.06	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(((3-Fluorophenyl)amino)methyl)quinolin-2-amine Dihydrochloride
5VUK	;	1.95	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(((4-(Dimethylamino)benzyl)amino)methyl)quinolin-2-amine
5VUL	;	2.0	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(((4-(Dimethylamino)phenethyl)amino)methyl)quinolin-2-amine
5ADC	;	2.1	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(((5-((Methylamino)methyl)pyridin-3-yl)oxy)methyl) quinolin-2-amine
7S40	;	1.7969	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-((3-((((6-aminopyridin-2-yl)methyl)amino)methyl)phenoxy)methyl)quinolin-2-amine
7S3X	;	1.95	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-((3-(((pyridin-2-ylmethyl)amino)methyl)phenoxy)methyl)quinolin-2-amine
5AD4	;	1.981	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-((3-(2-(Dimethylamino)ethyl)phenoxy)methyl)quinolin-2- amine
5AD5	;	1.9	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-((3-(2-(Methylamino)ethyl)phenoxy)methyl)quinolin-2- amine
5AD6	;	2.005	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-((3-(Dimethylamino)methyl)phenoxy)methyl)quinolin-2- amine
5AD7	;	1.95	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-((3-(Methylamino)methyl)phenoxy)methyl)quinolin-2- amine
5AD8	;	1.905	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-((3-Aminomethyl)phenoxy)methyl)quinolin-2-amine
4CAQ	;	1.95	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-((3-Chlorophenethylamino)ethyl)quinolin-2-amine
4CDT	;	2.0	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-((3-Fluorophenethylamino)ethyl)quinolin-2-amine
4CAM	;	1.83	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-((3-Fluorophenethylamino)methyl)quinolin-2-amine
5AD9	;	2.3	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-((4-(Dimethylamino)methyl)phenoxy)methyl)quinolin-2- amine
5ADB	;	2.05	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-((4-Chloro-3-((methylamino)methyl)phenoxy)methyl) quinolin-2-amine
4CAO	;	1.98	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(2-(3-(3-Fluorophenyl(propylamino)ethyl))quinolin-2- amine
4CAP	;	2.06	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(2-(3-(3-Fluorophenyl(propylamino)methyl))quinolin-2- amine
4CAN	;	1.91	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(2-(3-Fluorobenzylamino)ethyl)quinolin-2-amine
6PMX	;	2.05	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(3-(2-Aminoethyl)phenyl)-4-methylquinolin-2-amine
6PMY	;	1.95	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(3-(2-Aminoethyl)phenyl)-4-methylquinolin-2-amine
6PN3	;	1.8	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(3-(Aminomethyl)-4-(cyclobutylmethoxy)phenyl)-4-methylquinolin-2-amine
6PN4	;	1.898	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(3-(Aminomethyl)-4-(cyclopropylmethoxy)phenyl)-4-methylquinolin-2-amine
6PN8	;	1.838	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(3-(Aminomethyl)-4-(oxazol-4-ylmethoxy)phenyl)-4-methylquinolin-2-amine
6PN5	;	1.699	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(3-(Aminomethyl)-4-(pyridin-2-ylmethoxy)phenyl)-4-methylquinolin-2-amine
6PN6	;	1.843	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(3-(Aminomethyl)-4-(pyridin-3-ylmethoxy)phenyl)-4-methylquinolin-2-amine
6PN7	;	1.878	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(3-(Aminomethyl)-4-(thiazol-4-ylmethoxy)phenyl)-4-methylquinolin-2-amine
6PN9	;	1.84	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(3-(Aminomethyl)-4-(thiazol-5-ylmethoxy)phenyl)-4-methylquinolin-2-amine
6PN0	;	2.229	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(3-(Aminomethyl)-4-ethoxyphenyl)-4-methylquinolin-2-amine
6PN2	;	1.877	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(3-(Aminomethyl)-4-isopropoxyphenyl)-4-methylquinolin-2-amine
6PN1	;	2.196	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(3-(Aminomethyl)-4-propoxyphenyl)-4-methylquinolin-2-amine
6PMV	;	1.8	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(4-(2-Aminoethyl)phenyl)-4-methylquinolin-2-amine
6PMW	;	1.748	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(4-(Aminomethyl)phenyl)-4-methylquinolin-2-amine
6PMZ	;	2.1	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(5-(Aminomethyl)pyridin-3-yl)-4-methylquinolin-2-amine
5UNS	;	1.9	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-[(3-Ethyl-5-((methylamino)methyl)phenoxy)methyl]quinolin-2-amine
4UPM	;	1.9	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with N',N'-{[(2R)-3-aminopropane-1,2-diyl]bis(oxymethanediylbenzene-3,1-diyl)}dithiophene-2-carboximidamide
4UPP	;	1.91	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with N'-[4-[[(2S,4R)-4-[3-[(C-thiophen-2-ylcarbonimidoyl)amino]phenoxy]pyrrolidin-2-yl]methoxy]phenyl]thiophene-2-carboximidamide
4UPN	;	2.09	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with N,N''-{[(2S)-3-aminopropane-1,2-diyl]bis(oxymethanediylbenzene-3,1-diyl)}dithiophene-2-carboximidamide
4V3V	;	2.06	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with N-(2-(1H-imidazol-1-yl)-4-pyrimidylmethyl)-3-(3- fluorophenyl)propan-1-amine
4V3Y	;	1.962	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with N-2-(2-(1H-imidazol-1-yl)pyrimidin-4-yl)ethyl-3-(3- chlorophenyl)propan-1-amine
4V3X	;	1.99	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with N-2-(2-(1H-imidazol-1-yl)pyrimidin-4-yl)ethyl-3-(3- fluorophenyl)propan-1-amine
4D30	;	1.962	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with N-2-(2-(1H-imidazol-1-yl)pyrimidin-4-yl)ethyl-3-(pyridin- 3-yl)propan-1-amine
4UPO	;	1.95	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with N-[3-({[(3S,5S)-5-{[(3-{[(Z)-imino(thiophen-2-yl)methyl]amino}benzyl)oxy]methyl}pyrrolidin-3-yl]oxy}methyl)phenyl]thiophene-2-carboximidamide
4D3B	;	1.798	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with N1-(2-(1H-imidazol-1-yl)pyrimidin-4-yl)-N2-(3- fluorophenethyl)ethane-1,2-diamine
4UH3	;	2.03	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with N1-(3-(2-(6-Amino-4-methylpyridin-2-yl)ethyl)-5- fluorophenyl)-N1,N2-dimethylethane-1,2-diamine
4UH2	;	1.991	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with N1-(3-(2-(6-Amino-4-methylpyridin-2-yl)ethyl)-5-(trifluoromethyl)phenyl)-N1,N2-dimethylethane-1,2-diamine
4UGZ	;	2.076	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with N1-(3-(2-(6-Amino-4-methylpyridin-2-yl)ethyl)phenyl)-N1, N2-dimethylethane-1,2-diamine
4UH1	;	1.8	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with N1-(5-(2-(6-Amino-4-methylpyridin-2-yl)ethyl)pyridin-3- yl)-N1,N2-dimethylethane-1,2-diamine
4UH0	;	2.039	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with N1-(6-(2-(6-Amino-4-methylpyridin-2-yl)ethyl)pyridin-2- yl)-N1,N2-dimethylethane-1,2-diamine
7S3Z	;	1.7297	;	Structure of rat neuronal nitric oxide synthase heme domain in complex with N2-((3-((2-aminoquinolin-7-yl)methoxy)phenoxy)methyl)pyridine-2,6-diamine
4IMW	;	2.2	;	Structure of rat neuronal nitric oxide synthase in complex with 3,5-bis(2-(6-amino-4-methylpyridin-2-yl)ethyl)benzonitrile
4IMT	;	2.2	;	Structure of rat neuronal nitric oxide synthase in complex with 6,6'-((4-(3-aminopropyl)-1,3-phenylene)bis(ethane-2,1-diyl))bis(4-methylpyridin-2-amine)
4IMU	;	2.03	;	Structure of rat neuronal nitric oxide synthase in complex with 6,6'-((5-(aminomethyl)-1,3-phenylene)bis(ethane-2,1-diyl))bis(4-methylpyridin-2-amine)
4CX4	;	1.98	;	Structure of rat neuronal nitric oxide synthase M336V D597N mutant heme domain in complex with 4-METHYL-6-(((3R,4R)-4-((5-(4- METHYLPYRIDIN-2-YL)PENTYL)OXY)PYRROLIDIN-3-YL)METHYL)PYRIDIN-2-AMINE
4CX3	;	1.97	;	Structure of rat neuronal nitric oxide synthase M336V D597N mutant heme domain in complex with 4-METHYL-6-(((3R,4R)-4-((5-(PYRIDIN-2-YL) PENTYL)OXY)PYRROLIDIN-3-YL)METHYL)PYRIDIN-2-AMINE
5G0P	;	2.1	;	Structure of rat neuronal nitric oxide synthase M336V D597N mutant heme domain in complex with 6-(2-(5-(3-(DIMETHYLAMINO)PROPYL)PYRIDIN- 3-YL)ETHYL)-4-METHYLPYRIDIN-2-AMINE
5ADE	;	2.1	;	Structure of rat neuronal nitric oxide synthase M336V D597N mutant heme domain in complex with 7-((4-Chloro-3-((methylamino)methyl) phenoxy)methyl)quinolin-2-amine
7UAN	;	1.6969	;	Structure of rat neuronal nitric oxide synthase R349A heme domain in complex with (6-(3-(4,4-difluoropiperidin-1-yl)propyl)-4-methylpyridin-2-amine)
7TSB	;	1.8177	;	Structure of rat neuronal nitric oxide synthase R349A heme domain in complex with 4-methyl-6-(3-(methylamino)prop-1-yn-1-yl)pyridin-2-amine
7TS9	;	1.8526	;	Structure of rat neuronal nitric oxide synthase R349A heme domain in complex with 6-(3-(dimethylamino)propyl)-4-methylpyridin-2-amine
8FGE	;	1.89	;	Structure of rat neuronal nitric oxide synthase R349A mutant heme domain in complex with 4-(difluoromethyl)-6-(5-(2-(dimethylamino)ethyl)-2,3-difluorophenethyl)pyridin-2-amine dihydrochloride
7TSC	;	1.7959	;	Structure of rat neuronal nitric oxide synthase R349A mutant heme domain in complex with 4-methyl-6-(3-(4-methylpiperazin-1-yl)propyl)pyridin-2-amine
7TSD	;	1.769	;	Structure of rat neuronal nitric oxide synthase R349A mutant heme domain in complex with 6-(3-(3,3-difluoroazetidin-1-yl)prop-1-yn-1-yl)-4-methylpyridin-2-amine
7TSE	;	1.85	;	Structure of rat neuronal nitric oxide synthase R349A mutant heme domain in complex with 6-(3-(3,3-difluoroazetidin-1-yl)propyl)-4-methylpyridin-2-amine
8FGD	;	1.776	;	Structure of rat neuronal nitric oxide synthase R349A mutant heme domain in complex with 6-(5-(2-(diethylamino)ethyl)-2,3-difluorophenethyl)-4-methylpyridin-2-amine
3JWT	;	2.01	;	Structure of rat neuronal nitric oxide synthase R349A mutant heme domain in complex with N1-{(3'R,4'R)-4'-[(6""-amino-4""-methylpyridin-2""-yl)methyl]pyrrolidin-3'-yl}-N2-(3'-fluorophenethyl)ethane-1,2-diamine
3JWU	;	1.93	;	Structure of rat neuronal nitric oxide synthase R349A mutant heme domain in complex with N1-{(3'R,4'S)-4'-[(6""-amino-4""-methylpyridin-2""-yl)methyl]pyrrolidin-3'-yl}-N2-(3'-fluorophenethyl)ethane-1,2-diamine tetrahydrochloride
3JWV	;	1.98	;	Structure of rat neuronal nitric oxide synthase R349A mutant heme domain in complex with N1-{(3'S,4'R)-4'-[(6""-amino-4""-methylpyridin-2""-yl)methyl]pyrrolidin-3'-yl}-N2-(3'-fluorophenethyl)ethane-1,2-diamine
7TSA	;	2.03	;	Structure of rat neuronal nitric oxide synthase R349A/H692F mutant heme domain in complex with 4-methyl-6-(3-((methylamino)methyl)phenyl)pyridin-2-amine
1OM5	;	2.3	;	STRUCTURE OF RAT NEURONAL NOS HEME DOMAIN WITH 3-BROMO-7-NITROINDAZOLE BOUND
1OM4	;	1.75	;	STRUCTURE OF RAT NEURONAL NOS HEME DOMAIN WITH L-ARGININE BOUND
3UFV	;	2.078	;	Structure of rat nitric oxide synthase heme domain in complex with 4-methyl-6-(((3R,4R)-4-((5-(4-methylpyridin-2-yl)pentyl)oxy)pyrrolidin-3-yl)methyl)pyridin-2-amine
3UFU	;	1.886	;	Structure of rat nitric oxide synthase heme domain in complex with 4-methyl-6-(((3R,4R)-4-((5-(pyridin-2-yl)pentyl)oxy)pyrrolidin-3-yl)methyl)pyridin-2-amine
3UFR	;	2.097	;	Structure of rat nitric oxide synthase heme domain in complex with 6-(((3R,4R)-4-(((E)-5-(3-fluorophenyl)pent-4-en-1-yl)oxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine
3UFS	;	1.971	;	Structure of rat nitric oxide synthase heme domain in complex with 6-(((3R,4R)-4-((5-(3-chloro-5-fluorophenyl)pentyl)oxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine
3UFP	;	2.1	;	Structure of rat nitric oxide synthase heme domain in complex with 6-(((3R,4R)-4-((5-(3-fluorophenyl)pentyl)oxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine
3UFW	;	2.0	;	Structure of rat nitric oxide synthase heme domain in complex with 6-(((3R,4R)-4-((5-(6-aminopyridin-2-yl)pentyl)oxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine
3UFT	;	2.078	;	Structure of rat nitric oxide synthase heme domain in complex with 6-(((3R,4R)-4-(4-(3-chloro-5-fluorophenoxy)butoxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine
3UFQ	;	2.058	;	Structure of rat nitric oxide synthase heme domain in complex with 6-(((3S,4S)-4-(((E)-5-(3-fluorophenyl)pent-4-en-1-yl)oxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine
3UFO	;	2.169	;	Structure of rat nitric oxide synthase heme domain in complex with 6-(((3S,4S)-4-((5-(3-fluorophenyl)pentyl)oxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine
2G6J	;	2.3	;	Structure of rat nNOS (L337N) heme domain (4-aminobiopterin bound) complexed with NO
2G6L	;	2.05	;	Structure of rat nNOS heme domain (BH2 bound) complexed with NO
2G6I	;	1.9	;	Structure of rat nNOS heme domain (BH2-bound) in the reduced form
2G6M	;	1.85	;	Structure of rat nNOS heme domain (BH4 bound) complexed with CO
2G6K	;	2.0	;	Structure of rat nNOS heme domain (BH4 bound) complexed with NO
2G6H	;	2.0	;	Structure of rat nNOS heme domain (BH4 bound) in the reduced form
4FW0	;	1.95	;	Structure of rat nNOS heme domain in complex with N(delta)-methyl- N(omega)-hydroxy-L-arginine
4FVX	;	2.0	;	Structure of rat nNOS heme domain in complex with N(omega)-ethoxy-L-arginine
4FVY	;	1.7	;	Structure of rat nNOS heme domain in complex with N(omega)-hydroxy- N(omega)-methyl-L-arginine
4FVW	;	1.81	;	Structure of rat nNOS heme domain in complex with N(omega)-methoxy-L-arginine
4FVZ	;	1.99	;	Structure of rat nNOS heme domain in complex with N(omega)-methyl- N(omega)-methoxy-L-arginine
3KJ4	;	3.1	;	Structure of rat Nogo receptor bound to 1D9 antagonist antibody
8SDU	;	2.05	;	Structure of rat organic anion transporter 1 (OAT1)
8SDY	;	2.79	;	Structure of rat organic anion transporter 1 (OAT1) in complex with para-aminohippuric acid (PAH)
8SDZ	;	2.86	;	Structure of rat organic anion transporter 1 (OAT1) in complex with probenecid
1QFC	;	2.7	;	STRUCTURE OF RAT PURPLE ACID PHOSPHATASE
1DPO	;	1.59	;	STRUCTURE OF RAT TRYPSIN
4YSW	;	1.99	;	Structure of rat xanthine oxidoreductase, C-terminal deletion protein variant, NADH bound form
4YTY	;	2.2	;	Structure of rat xanthine oxidoreductase, C535A/C992R/C1324S, NADH bound form
3CJ1	;	1.7	;	Structure of Rattus norvegicus NTPDase2
3CJ7	;	1.8	;	Structure of Rattus norvegicus NTPDase2 in complex with AMP
3CJA	;	2.1	;	Structure of Rattus norvegicus NTPDase2 in complex with calcium and AMPPNP
3CJ9	;	1.8	;	Structure of Rattus norvegicus NTPDase2 in complex with calcium, AMP and phosphate
6WO6	;	2.8	;	Structure of RavA (lpp0008) E38A/K39A surface entropy reduction mutant
1N4M	;	2.2	;	Structure of Rb tumor suppressor bound to the transactivation domain of E2F-2
7THE	;	3.87	;	Structure of RBD directed antibody DH1042 in complex with SARS-CoV-2 spike: Local refinement of RBD-Fab interface
8DTK	;	3.77	;	Structure of RBD directed antibody DH1047 in complex with SARS-CoV-2 spike: Local refinement of RBD-Fab interace
4A9A	;	2.67	;	Structure of Rbg1 in complex with Tma46 dfrp domain
5TRD	;	1.85	;	Structure of RbkR (Riboflavin Kinase) from Thermoplasma acidophilum determined in complex with CTP and its cognate DNA operator
7DDQ	;	2.84	;	Structure of RC-LH1-PufX from Rhodobacter veldkampii
5F29	;	1.821	;	Structure of RCK domain with cda
5EI0	;	2.5	;	Structure of RCL-cleaved vaspin (serpinA12)
4CLQ	;	2.02	;	Structure of Rcl1p - Bms1p complex
7Y4R	;	2.51	;	Structure of RclX
6ZIX	;	3.4	;	Structure of RcsB from Salmonella enterica serovar Typhimurium bound to promoter P1flhDC in the presence of phosphomimetic BeF3-
6ZJ2	;	3.38	;	Structure of RcsB from Salmonella enterica serovar Typhimurium bound to promoter rprA in the presence of phosphomimetic BeF3-
8FNT	;	2.52	;	Structure of RdrA from Escherichia coli RADAR defense system
8FNU	;	2.5	;	Structure of RdrA from Streptococcus suis RADAR defense system
8HR7	;	3.96	;	Structure of RdrA-RdrB complex
8FNW	;	6.73	;	Structure of RdrA-RdrB complex from Escherichia coli RADAR defense system
8FNV	;	2.11	;	Structure of RdrB from Escherichia coli RADAR defense system
2I7O	;	1.5	;	Structure of Re(4,7-dimethyl-phen)(Thr124His)(Lys122Trp)(His83Gln)AzCu(II), a Rhenium modified Azurin mutant
4K9J	;	1.7	;	Structure of Re(CO)3(4,7-dimethyl-phen)(Thr126His)(Lys122Trp)(His83Glu)(Trp48Phe)(Tyr72Phe)(Tyr108Phe)AzCu(II), a Rhenium modified Azurin mutant
7DVO	;	1.8	;	Structure of Reaction Intermediate of Cytochrome P450 NO Reductase (P450nor) Determined by XFEL
5INW	;	2.7	;	Structure of reaction loop cleaved lamprey angiotensinogen
1G19	;	3.0	;	STRUCTURE OF RECA PROTEIN
1UBC	;	3.8	;	Structure of Reca Protein
4NUX	;	2.295	;	Structure of receptor A
1GM5	;	3.24	;	Structure of RecG bound to three-way DNA junction
6LRD	;	1.90134	;	Structure of RecJ complexed with a 5'-P-dSpacer-modified ssDNA
5F55	;	2.6	;	Structure of RecJ complexed with DNA
5F56	;	2.3	;	Structure of RecJ complexed with DNA and SSB-ct
5F54	;	2.7	;	Structure of RecJ complexed with dTMP
1FZD	;	2.1	;	STRUCTURE OF RECOMBINANT ALPHAEC DOMAIN FROM HUMAN FIBRINOGEN-420
6Z3I	;	1.8	;	Structure of recombinant beta-glucocerebrosidase in complex with bifunctional cyclophellitol aziridine activity based probe
5NFG	;	2.375	;	Structure of recombinant cardosin B from Cynara cardunculus
4D5G	;	2.0	;	Structure of recombinant CDH-H28AN484A
3HBG	;	1.9	;	Structure of recombinant Chicken Liver Sulfite Oxidase mutant C185S
3HBQ	;	2.8	;	Structure of recombinant Chicken Liver Sulfite Oxidase mutant Cys 185 Ala
1H3J	;	2.0	;	STRUCTURE OF RECOMBINANT COPRINUS CINEREUS PEROXIDASE DETERMINED TO 2.0 A
1XME	;	2.3	;	Structure of Recombinant Cytochrome ba3 Oxidase from Thermus thermophilus
4FAA	;	2.8	;	Structure of Recombinant Cytochrome ba3 Oxidase mutant A120F+A204F from Thermus thermophilus
4FA7	;	2.5	;	Structure of Recombinant Cytochrome ba3 Oxidase mutant A204F from Thermus thermophilus
4N4Y	;	2.9	;	Structure of Recombinant Cytochrome ba3 Oxidase mutant G232V from Thermus thermophilus
4G7R	;	3.05	;	Structure of Recombinant Cytochrome ba3 Oxidase mutant V236A from Thermus thermophilus
4G7S	;	2.0	;	Structure of Recombinant Cytochrome ba3 Oxidase mutant V236I from Thermus thermophilus
4G7Q	;	2.6	;	Structure of Recombinant Cytochrome ba3 Oxidase mutant V236L from Thermus thermophilus
4G72	;	3.19	;	Structure of Recombinant Cytochrome ba3 Oxidase mutant V236M from Thermus thermophilus
4G71	;	2.9	;	Structure of Recombinant Cytochrome ba3 Oxidase mutant V236N from Thermus thermophilus
4G70	;	2.6	;	Structure of Recombinant Cytochrome ba3 Oxidase mutant V236T from Thermus thermophilus
4GP4	;	2.8	;	Structure of Recombinant Cytochrome ba3 Oxidase mutant Y133F from Thermus thermophilus
4GP5	;	2.7	;	Structure of Recombinant Cytochrome ba3 Oxidase mutant Y133W from Thermus thermophilus
4GP8	;	2.8	;	Structure of Recombinant Cytochrome ba3 Oxidase mutant Y133W+T231F from Thermus thermophilus
6BMG	;	1.88	;	Structure of Recombinant Dwarf Sperm Whale Myoglobin (Oxy)
3JTM	;	1.3	;	Structure of recombinant formate dehydrogenase from Arabidopsis thaliana
4HZH	;	3.3	;	Structure of recombinant Gla-domainless prothrombin mutant S525A
5G3X	;	1.66	;	Structure of recombinant granulovirus polyhedrin
3ET4	;	1.7	;	Structure of Recombinant Haemophilus Influenzae E(P4) Acid Phosphatase
3OCY	;	1.4	;	Structure of Recombinant Haemophilus Influenzae e(P4) Acid Phosphatase Complexed with inorganic phosphate
3OCZ	;	1.35	;	Structure of Recombinant Haemophilus influenzae e(P4) Acid Phosphatase Complexed with the inhibitor adenosine 5-O-thiomonophosphate
3ET5	;	2.0	;	Structure of Recombinant Haemophilus Influenzae E(P4) Acid Phosphatase Complexed with tungstate
3SF0	;	1.35	;	Structure of Recombinant Haemophilus Influenzae e(P4) Acid Phosphatase mutant D64N complexed with 5'AMP
3OCX	;	1.901	;	Structure of Recombinant Haemophilus influenzae e(P4) Acid Phosphatase mutant D66N complexed with 2'-AMP
3OCW	;	1.85	;	Structure of Recombinant Haemophilus influenzae e(P4) Acid Phosphatase mutant D66N complexed with 3'-AMP
3OCV	;	1.551	;	Structure of Recombinant Haemophilus Influenzae e(P4) Acid Phosphatase mutant D66N complexed with 5'-AMP
3OCU	;	1.35	;	Structure of Recombinant Haemophilus Influenzae e(P4) Acid Phosphatase mutant D66N complexed with NMN
6YTP	;	1.7	;	Structure of recombinant human beta-glucocerebrosidase in complex with azide tagged cyclophellitol epoxide inhibitor
6Z39	;	1.7	;	Structure of recombinant human beta-glucocerebrosidase in complex with BODIPY functionalised epoxide activity based probe
7NWV	;	1.86	;	Structure of recombinant human beta-glucocerebrosidase in complex with BODIPY Tagged Cyclophellitol activity based probe
6YTR	;	1.7	;	Structure of recombinant human beta-glucocerebrosidase in complex with cyclophellitol aziridine inhibitor
8AWK	;	1.58	;	Structure of recombinant human beta-glucocerebrosidase in complex with D-carbaxylosyl chloride
6YV3	;	1.8	;	Structure of recombinant human beta-glucocerebrosidase in complex with galacto-configured cyclophellitol aziridine inhibitor
8AWR	;	1.49	;	Structure of recombinant human beta-glucocerebrosidase in complex with L-carbaxylosyl chloride
8AX3	;	1.59	;	Structure of recombinant human beta-glucocerebrosidase in complex with L-carbaxylosyl fluoride
6YUT	;	1.76	;	Structure of recombinant human beta-glucocerebrosidase in complex with N-acyl functionalised cyclophellitol aziridine
6RUA	;	2.75	;	Structure of recombinant human butyrylcholinesterase in complex with a coumarin-based fluorescent probe linked to sulfonamide type inhibitor.
6R6V	;	2.5	;	Structure of recombinant human butyrylcholinesterase in complex with a fluorescent coumarin-based probe
6R6W	;	2.474	;	Structure of recombinant human butyrylcholinesterase in complex with a fluorescent NBD-based probe
3ZCF	;	1.65	;	Structure of recombinant human cytochrome c
4KQ8	;	3.29	;	Structure of Recombinant Human Cytochrome P450 Aromatase
4AWN	;	1.95	;	Structure of recombinant human DNase I (rhDNaseI) in complex with Magnesium and Phosphate.
7KIU	;	2.22	;	Structure of recombinant human DNase1L3 in complex with Mg2+
7QJ5	;	8.7	;	Structure of recombinant human gamma-Tubulin Ring Complex (spokes 1-14)
7QJC	;	16.1	;	Structure of recombinant human gamma-Tubulin Ring Complex (spokes 1-14, homogeneous dataset)
7QJ9	;	8.1	;	Structure of recombinant human gamma-Tubulin Ring Complex 10-spoked assembly intermediate (spokes 3-12, homogeneous dataset)
7QJ6	;	7.8	;	Structure of recombinant human gamma-Tubulin Ring Complex 10-spoked assembly intermediate (spokes 3-12, substoichiometric spokes 13-14)
7QJ4	;	9.0	;	Structure of recombinant human gamma-Tubulin Ring Complex 10-spoked assembly intermediate (spokes 5-14)
7QJ7	;	8.7	;	Structure of recombinant human gamma-Tubulin Ring Complex 12-spoked assembly intermediate (spokes 1-12 substoichiometric spokes 13-14)
7QJA	;	9.2	;	Structure of recombinant human gamma-Tubulin Ring Complex 12-spoked assembly intermediate (spokes 1-12, homogeneous dataset)
7QJB	;	9.2	;	Structure of recombinant human gamma-Tubulin Ring Complex 12-spoked assembly intermediate (spokes 3-14, homogeneous dataset)
7QJ8	;	8.7	;	Structure of recombinant human gamma-Tubulin Ring Complex 12-spoked assembly intermediate (spokes 3-14, substoichiometric spokes 1-2)
7QJE	;	7.8	;	Structure of recombinant human gamma-Tubulin Ring Complex 4-spoked assembly intermediate (spokes 9-12)
7QJ0	;	5.32	;	Structure of recombinant human gamma-Tubulin Ring Complex 6-spoked assembly intermediate (spokes 7-12)
7QJ2	;	8.6	;	Structure of recombinant human gamma-Tubulin Ring Complex 8-spoked assembly intermediate (spokes 5-12)
7QJ3	;	7.6	;	Structure of recombinant human gamma-Tubulin Ring Complex 8-spoked assembly intermediate (spokes 7-14)
7QJD	;	7.1	;	Structure of recombinant human gamma-Tubulin Ring Complex without actin
2BJJ	;	2.4	;	Structure of recombinant human lactoferrin produced in the milk of transgenic cows
2REN	;	2.5	;	STRUCTURE OF RECOMBINANT HUMAN RENIN, A TARGET FOR CARDIOVASCULAR-ACTIVE DRUGS, AT 2.5 ANGSTROMS RESOLUTION
1BBC	;	2.2	;	STRUCTURE OF RECOMBINANT HUMAN RHEUMATOID ARTHRITIC SYNOVIAL FLUID PHOSPHOLIPASE A2 AT 2.2 ANGSTROMS RESOLUTION
1G6J	;		;	STRUCTURE OF RECOMBINANT HUMAN UBIQUITIN IN AOT REVERSE MICELLES
1CXV	;	2.0	;	STRUCTURE OF RECOMBINANT MOUSE COLLAGENASE-3 (MMP-13)
1LB3	;	1.21	;	Structure of recombinant mouse L chain ferritin at 1.2 A resolution
5M6B	;	3.25	;	structure of recombinant mushroom tyrosinase (abPPO4)
7VMO	;	3.5	;	Structure of recombinant RyR2 (Ca2+ dataset, class 1, open state)
7VMP	;	3.5	;	Structure of recombinant RyR2 (Ca2+ dataset, class 2, open state)
7VMQ	;	3.7	;	Structure of recombinant RyR2 (Ca2+ dataset, class 3, open state)
7VML	;	3.3	;	Structure of recombinant RyR2 (EGTA dataset, class 1&2, closed state)
7VMM	;	3.5	;	Structure of recombinant RyR2 (EGTA dataset, class 1, closed state)
7VMN	;	3.5	;	Structure of recombinant RyR2 (EGTA dataset, class 2, closed state)
7VMS	;	3.8	;	Structure of recombinant RyR2 mutant K4593A (Ca2+ dataset)
7VMR	;	3.3	;	Structure of recombinant RyR2 mutant K4593A (EGTA dataset)
3X3Q	;	1.5	;	Structure of recombinant thaumatin in the presence of 1.0M PST, pH7 at 293K
7UAK	;	3.38	;	Structure of recombinantly assembled A53E alpha-synuclein fibrils
6UFR	;	2.5	;	Structure of recombinantly assembled E46K alpha-synuclein fibrils
3VE5	;	2.8	;	Structure of recombination mediator protein RecR16-196 deletion mutant
3VDU	;	2.8	;	Structure of recombination mediator protein RecRK21G mutant
7A8R	;	2.31	;	Structure of RecQL from Bos taurus
7UB2	;	3.4	;	Structure of RecT protein from Listeria innoccua phage A118 in complex with 83-mer annealed duplex
7UBB	;	4.5	;	Structure of RecT protein from Listeria innoccua phage A118 in complex with 83-mer ssDNA
8TFU	;	1.482	;	Structure of Red beta C-terminal domain in complex with SSB C-terminal peptide, Form 1
8TG7	;	1.775	;	Structure of Red beta C-terminal domain in complex with SSB C-terminal peptide, Form 2
8TG8	;	1.576	;	Structure of Red beta C-terminal domain in complex with SSB C-terminal peptide, Form 3
8TGC	;	1.484	;	Structure of Red beta C-terminal domain in complex with SSB C-terminal peptide, Form 4
4LLM	;	1.75	;	Structure of redesigned IgG1 first constant and lambda domains (CH1:Clambda constant redesign 1, CRD1) at 1.75A
4LLQ	;	1.42	;	Structure of redesigned IgG1 first constant and lambda domains (CH1:Clambda constant redesign 2 beta, CRD2b) at 1.42A
5HLG	;	3.0	;	Structure of reduced AbfR bound to DNA
2CE1	;	1.4	;	Structure of reduced Arabidopsis thaliana cytochrome 6A
1L6V	;		;	STRUCTURE OF REDUCED BOVINE ADRENODOXIN
7THU	;	1.93	;	Structure of reduced bovine cytochrome c oxidase at 1.93 Angstrom resolution obtained by synchrotron X-rays
2PEX	;	1.9	;	Structure of reduced C22S OhrR from Xanthamonas Campestris
1XLO	;	1.84	;	Structure of reduced C73S/C85S putidaredoxin, a [2Fe-2S] ferredoxin from Pseudomonas putida
3DR0	;	1.23	;	Structure of reduced cytochrome c6 from Synechococcus sp. PCC 7002
4H6R	;	1.75	;	Structure of reduced Deinococcus radiodurans proline dehydrogenase
3U9M	;	1.95	;	Structure of reduced human FBXL5 hemerythrin like domain
2YMV	;	1.6	;	Structure of Reduced M Smegmatis 5246, a homologue of M.Tuberculosis Acg
3IEA	;	2.2	;	Structure of reduced M98L mutant of amicyanin
2ABA	;	1.05	;	Structure of reduced PETN reductase in complex with progesterone
6X0J	;	2.335	;	Structure of reduced SidA ornithine hydroxylase with the FAD ""in"" and complexed with NADP and L-ornithine
4P5S	;	1.02	;	Structure of reduced W45Y mutant of amicyanin
1SDQ	;	1.69	;	Structure of reduced-NO adduct of mesopone cytochrome c peroxidase
6EOD	;	2.2	;	Structure of Reductive Aminase from Aspergillus terreus in complex with NADPH
6SKX	;	2.25	;	Structure of Reductive Aminase from Neosartorya fumigata
6SLE	;	2.77	;	Structure of Reductive Aminase from Neosartorya fumigata in complex with NADP+
8U4Q	;	3.36	;	Structure of REGN7663 Fab-bound CXCR4/Gi complex
8U4R	;	3.1	;	Structure of REGN7663-Fab bound CXCR4
5DO9	;	2.6	;	Structure of regulator of G protein signaling 8 (RGS8) in complex with AlF4-activated Galpha-q
4CGR	;	2.1	;	Structure of Regulator Protein SCO3201 from Streptomyces coelicolor
2QGF	;	2.2	;	Structure of regulatory chain mutant H20A of asparate transcarbamoylase from E. coli
5KPS	;	3.9	;	Structure of RelA bound to ribosome in absence of A/R tRNA (Structure I)
5KPV	;	4.1	;	Structure of RelA bound to ribosome in presence of A/R tRNA (Structure II)
5KPW	;	3.9	;	Structure of RelA bound to ribosome in presence of A/R tRNA (Structure III)
5KPX	;	3.9	;	Structure of RelA bound to ribosome in presence of A/R tRNA (Structure IV)
5IQR	;	3.0	;	Structure of RelA bound to the 70S ribosome
4V7K	;	3.6	;	Structure of RelE nuclease bound to the 70S ribosome (postcleavage state)
4V7J	;	3.3	;	Structure of RelE nuclease bound to the 70S ribosome (precleavage state)
3R0E	;	2.4	;	Structure of Remusatia vivipara lectin
3S6X	;	2.25	;	Structure of reovirus attachment protein sigma1 in complex with alpha-2,3-sialyllactose
3S6Y	;	2.79	;	Structure of reovirus attachment protein sigma1 in complex with alpha-2,6-sialyllactose
3S6Z	;	2.28	;	Structure of reovirus attachment protein sigma1 in complex with alpha-2,8-disialyllactose
3EOY	;	3.4	;	Structure of Reovirus sigma1 in Complex with Its Receptor Junctional Adhesion Molecule-A
5KBJ	;	3.09	;	Structure of Rep-DNA complex
6YYT	;	2.9	;	Structure of replicating SARS-CoV-2 polymerase
2AJQ	;	2.6	;	Structure of replicative DNA polymerase provides insigts into the mechanisms for processivity, frameshifting and editing
2KVZ	;		;	Structure of residues 161-235 of putative peptidoglycan binding protein lmo0835 from Listeria monocytogenes: target LmR64B of the Northeast Structural Genomics Consortium
4CCF	;	2.65	;	Structure of Respiratory Syncytial Virus F protein head domain
4V5V	;	3.6	;	Structure of respiratory syncytial virus nucleocapsid protein, P1 crystal form
2YHM	;	3.6	;	Structure of respiratory syncytial virus nucleocapsid protein, P212121 crystal form
8FU3	;	2.88	;	Structure Of Respiratory Syncytial Virus Polymerase with Novel Non-Nucleoside Inhibitor
3I42	;	2.15	;	Structure of response regulator receiver domain (CheY-like) from Methylobacillus flagellatus
1BAM	;	1.95	;	STRUCTURE OF RESTRICTION ENDONUCLEASE BAMHI PHASED AT 1.95 ANGSTROMS RESOLUTION BY MAD ANALYSIS
2P0J	;	2.1	;	Structure of restriction endonuclease BstYI bound to non-cognate DNA
2FOK	;	2.3	;	STRUCTURE OF RESTRICTION ENDONUCLEASE FOKI
1FOK	;	2.8	;	STRUCTURE OF RESTRICTION ENDONUCLEASE FOKI BOUND TO DNA
6JWD	;		;	structure of RET G-quadruplex in complex with berberine
6JWE	;		;	structure of RET G-quadruplex in complex with colchicine
7NZN	;	2.39	;	Structure of RET kinase domain bound to inhibitor JB-48
6NEC	;	1.87	;	STRUCTURE OF RET PROTEIN TYROSINE KINASE DOMAIN IN COMPLEX WITH NINTEDANIB
7JU5	;	1.9	;	Structure of RET protein tyrosine kinase in complex with pralsetinib
7JU6	;	2.06	;	Structure of RET protein tyrosine kinase in complex with selpercatinib
5F0J	;	2.7	;	Structure of retromer VPS26-VPS35 subunits bound to SNX3
5F0L	;	3.2	;	Structure of retromer VPS26-VPS35 subunits bound to SNX3 and DMT1
5F0M	;	3.1	;	Structure of retromer VPS26-VPS35 subunits bound to SNX3 and DMT1 (SeMet labeled)
5F0P	;	2.78	;	Structure of retromer VPS26-VPS35 subunits bound to SNX3 and DMT1(L557M) (SeMet labeled)
5OSI	;	2.52	;	Structure of retromer VPS29-VPS35C subunits complexed with RidL harpin loop (163-176)
5OSH	;	4.3	;	Structure of retromer VPS29-VPS35C subunits complexed with RidL N-terminal domain (1-236)
3OSP	;	2.5	;	Structure of rev1
6M7A	;	1.9	;	Structure of REV7-R124A complexed with SHLD3(28-73)
6M7B	;	1.77	;	Structure of REV7-R124A complexed with SHLD3(37-73)
6SRD	;	1.93	;	Structure of Rex8A from Paenibacillus barcinonensis complexed with xylose.
4B60	;	1.83	;	Structure of rFnBPA(189-505) in complex with fibrinogen gamma chain C- terminal peptide
6K83	;	2.39	;	Structure of RGLG1 mutant-D207G
6IFB	;	1.37	;	Structure of rhamnose bound beta-trefoil lectin from Entamoeba histolytica
6Q2F	;	2.2	;	Structure of Rhamnosidase from Novosphingobium sp. PP1Y
5YXH	;	2.04	;	Structure of Rheb-GDP
3SEA	;	2.0	;	Structure of Rheb-Y35A mutant in GDP- and GMPPNP-bound forms
6PB3	;	2.048	;	Structure of Rhizobiales Trip13
3TW7	;	3.1	;	Structure of Rhizobium etli pyruvate carboxylase T882A crystallized without acetyl coenzyme-A
3TW6	;	2.4	;	Structure of Rhizobium etli pyruvate carboxylase T882A with the allosteric activator, acetyl coenzyme-A
1RHO	;	2.5	;	STRUCTURE OF RHO GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR
4E46	;	1.26	;	Structure of Rhodococcus rhodochrous haloalkane dehalogenase DhaA in complex with 2-propanol
3FBW	;	1.23	;	Structure of Rhodococcus rhodochrous haloalkane dehalogenase DhaA mutant C176Y
3SK0	;	1.78	;	structure of Rhodococcus rhodochrous haloalkane dehalogenase DhaA mutant DhaA12
3RK4	;	1.31	;	Structure of Rhodococcus rhodochrous haloalkane dehalogenase mutant DhaA31
4FWB	;	1.26	;	Structure of Rhodococcus rhodochrous haloalkane dehalogenase mutant DhaA31 in complex with 1, 2, 3 - trichloropropane
8T5Y	;	1.44	;	Structure of Rhodococcus sp. USK13 DarR(K44A)-cAMP complex
8SUK	;	2.45	;	Structure of Rhodococcus sp. USK13 DarR-c-di-AMP complex
2VRP	;	2.41	;	Structure of rhodocytin
5CUO	;	1.544	;	Structure of Rhodopseudomonas palustris PduL - CoA bound form
5CUP	;	2.1	;	Structure of Rhodopseudomonas palustris PduL - phosphate bound form
6E0K	;	1.6	;	Structure of Rhodothermus marinus CdnE c-UMP-AMP synthase
6E0L	;	2.25	;	Structure of Rhodothermus marinus CdnE c-UMP-AMP synthase with Apcpp and Upnpp
3H31	;	1.0	;	Structure of Rhodothermus marinus HiPIP at 1.0 A resolution
1AJW	;		;	STRUCTURE OF RHOGDI: A C-TERMINAL BINDING DOMAIN TARGETS AN N-TERMINAL INHIBITORY PEPTIDE TO GTPASES, NMR, 20 STRUCTURES
1GDF	;		;	STRUCTURE OF RHOGDI: A C-TERMINAL BINDING DOMAIN TARGETS AN N-TERMINAL INHIBITORY PEPTIDE TO GTPASES, NMR, MINIMIZED AVERAGE STRUCTURE
6S5W	;	1.07	;	Structure of Rib domain 'Rib Long' from Lactobacillus acidophilus
6S5Z	;	1.8	;	Structure of Rib R28N from Streptococcus pyogenes
6SX1	;	1.25	;	Structure of Rib Standard, a Rib domain from Lactobacillus acidophilus
4P8J	;	1.96	;	Structure of ribB
4P6P	;	1.862	;	Structure of ribB complexed with inhibitor (4PEH) and metal ions
4P6C	;	1.86	;	Structure of ribB complexed with inhibitor 4PEH
4P6D	;	1.59	;	Structure of ribB complexed with PO4 ion
4P8E	;	2.04	;	Structure of ribB complexed with substrate (Ru5P) and metal ions
4P77	;	2.04	;	Structure of ribB complexed with substrate Ru5P
6WHJ	;	2.65	;	Structure of Ribokinase from Giardia lamblia
1AFU	;	2.0	;	STRUCTURE OF RIBONUCLEASE A AT 2.0 ANGSTROMS FROM MONOCLINIC CRYSTALS
4OOH	;	1.89	;	Structure of RIBONUCLEASE A at 40C
8PX0	;	1.8	;	Structure of ribonuclease A, solved at wavelength 2.75 A
4HAA	;	1.9	;	Structure of Ribonuclease Binase Glu43Ala/Phe81Ala Mutant
1RNH	;	2.0	;	STRUCTURE OF RIBONUCLEASE H PHASED AT 2 ANGSTROMS RESOLUTION BY MAD ANALYSIS OF THE SELENOMETHIONYL PROTEIN
3D5G	;	1.8	;	Structure of ribonuclease Sa2 complexes with mononucleotides: new aspects of catalytic reaction and substrate recognition
8RNT	;	1.8	;	STRUCTURE OF RIBONUCLEASE T1 COMPLEXED WITH ZINC(II) AT 1.8 ANGSTROMS RESOLUTION: A ZN2+.6H2O.CARBOXYLATE CLATHRATE
5YU2	;	1.75	;	Structure of Ribonuclease YabJ
1PBL	;		;	STRUCTURE OF RIBONUCLEIC ACID, NMR, 1 STRUCTURE
1PBM	;		;	STRUCTURE OF RIBONUCLEIC ACID, NMR, 1 STRUCTURE
1MWG	;		;	STRUCTURE OF RIBONUCLEIC ACID, NMR, MINIMIZED AVERAGE STRUCTURE
7B9P	;	2.646	;	Structure of Ribonucleotide reductase from Rhodobacter sphaeroides
1RLR	;	2.5	;	STRUCTURE OF RIBONUCLEOTIDE REDUCTASE PROTEIN R1
7BET	;	2.3	;	Structure of Ribonucleotide reductase R2 from Escherichia coli collected by femtosecond serial crystallography on a COC membrane
7AI9	;	2.0	;	Structure of Ribonucleotide reductase R2 from Escherichia coli collected by rotation serial crystallography on a COC membrane at a synchrotron source
7AI8	;	2.1	;	Structure of Ribonucleotide reductase R2 from Escherichia coli collected by still serial crystallography on a COC membrane at a synchrotron source
3IXQ	;	1.78	;	Structure of ribose 5-phosphate isomerase a from methanocaldococcus jannaschii
3M1P	;	2.2	;	Structure of ribose 5-phosphate isomerase type B from Trypanosoma cruzi, soaked with allose-6-phosphate
6YE5	;		;	Structure of ribosomal binding factor A RbfA of Staphylococcus aureus bacterium by NMR
7RR5	;	3.23	;	Structure of ribosomal complex bound with Rbg1/Tma46
2HW8	;	2.1	;	Structure of ribosomal protein L1-mRNA complex at 2.1 resolution.
2KDS	;		;	Structure of Ribosomal Protein L14e from Sulfolobus solfataricus
1G1X	;	2.6	;	STRUCTURE OF RIBOSOMAL PROTEINS S15, S6, S18, AND 16S RIBOSOMAL RNA
2D3O	;	3.35	;	Structure of Ribosome Binding Domain of the Trigger Factor on the 50S ribosomal subunit from D. radiodurans
5IMQ	;	3.8	;	Structure of ribosome bound to cofactor at 3.8 angstrom resolution
5IMR	;	5.7	;	Structure of ribosome bound to cofactor at 5.7 angstrom resolution
3A1P	;	2.3	;	Structure of Ribosome maturation protein RimM and Ribosomal protein S19
7QWS	;	3.4	;	Structure of ribosome translating beta-tubulin in complex with TTC5 and NAC
4AQY	;	3.5	;	Structure of ribosome-apramycin complexes
2NOQ	;	7.3	;	Structure of ribosome-bound cricket paralysis virus IRES RNA
6S5X	;	1.7	;	Structure of RibR, the most N-terminal Rib domain from Group B Streptococcus species Streptococcus agalactiae
5WSK	;	1.781	;	Structure of Ribulose-1,5-bisphosphate carboxylase/oxygenase from wheat
1PSY	;		;	STRUCTURE OF RicC3, NMR, 20 STRUCTURES
1CCR	;	1.5	;	STRUCTURE OF RICE FERRICYTOCHROME C AT 2.0 ANGSTROMS RESOLUTION
3AXM	;	1.65	;	Structure of rice Rubisco in complex with 6PG
3AXK	;	1.9	;	Structure of rice Rubisco in complex with NADP(H)
4MX1	;	1.59	;	Structure of ricin A chain bound with 2-amino-4-oxo-N-(2-(3-phenylureido)ethyl)-3,4-dihydropteridine-7-carboxamide
4MX5	;	1.52	;	Structure of ricin A chain bound with benzyl-(2-(2-amino-4-oxo-3,4-dihydropteridine-7-carboxamido)ethyl)carbamate
1IL5	;	2.8	;	STRUCTURE OF RICIN A CHAIN BOUND WITH INHIBITOR 2,5-DIAMINO-4,6-DIHYDROXYPYRIMIDINE (DDP)
1IL3	;	2.8	;	STRUCTURE OF RICIN A CHAIN BOUND WITH INHIBITOR 7-DEAZAGUANINE
1IL9	;	3.1	;	STRUCTURE OF RICIN A CHAIN BOUND WITH INHIBITOR 8-METHYL-9-OXOGUANINE
1IL4	;	2.6	;	STRUCTURE OF RICIN A CHAIN BOUND WITH INHIBITOR 9-DEAZAGUANINE
4ESI	;	1.87	;	Structure of ricin A chain bound with N-((1H-1,2,3-triazol-4-yl)methyl-2-amino-4-oxo-3,4-dihydropteridine-7-carboxamide
4HV3	;	1.54	;	Structure of Ricin A chain bound with N-(N-(pterin-7-yl)carbonyl-L-serinyl)-L-tryptophan
4HUO	;	1.52	;	Structure of Ricin A chain bound with N-(N-(pterin-7-yl)carbonylglycyl)-L-phenylalanine
4HUP	;	1.699	;	Structure of ricin A chain bound with N-(N-(pterin-7-yl)carbonylglycyl)-L-phenylalanyl)-L-phenylalanine
4HV7	;	1.869	;	Structure of ricin A chain bound with N-(N-(pterin-7-yl)carbonylglycyl)glycine
1OBS	;	2.2	;	STRUCTURE OF RICIN A CHAIN MUTANT
1OBT	;	2.8	;	STRUCTURE OF RICIN A CHAIN MUTANT, COMPLEX WITH AMP
5HAM	;	2.4	;	Structure of Rickettsia bellii effector protein RickCE
5KOW	;	2.1	;	Structure of rifampicin monooxygenase
5KOX	;	1.8	;	Structure of rifampicin monooxygenase complexed with rifampicin
6C7S	;	2.1	;	Structure of Rifampicin Monooxygenase with Product Bound
7EEI	;	3.6	;	Structure of Rift Valley fever virus RNA-dependent RNA polymerase
7BAI	;	3.4	;	Structure of RIG-I CTD (I875A) bound to p-RNA
7BAH	;	1.89	;	Structure of RIG-I CTD bound to OH-RNA
6RVW	;	3.7	;	Structure of right-handed protein cage consisting of 24 eleven-membered ring proteins held together by gold (I) bridges.
1V10	;	1.7	;	Structure of Rigidoporus lignosus laccase from hemihedrally twinned crystals
5D0I	;	1.9	;	Structure of RING finger protein 165
4FBH	;	2.3	;	Structure of RIP from barley seeds
5YRN	;	4.1	;	Structure of RIP2 CARD domain
6GFJ	;	3.3	;	Structure of RIP2 CARD domain fused to crystallisable MBP tag
6GGS	;	3.94	;	Structure of RIP2 CARD filament
8AZA	;	3.15	;	Structure of RIP2K dimer bound to the XIAP BIR2 domain
5NG2	;	2.8	;	Structure of RIP2K(D146N) with bound Staurosporine
5NG0	;	2.0	;	Structure of RIP2K(L294F) with bound AMPPCP
4KAQ	;	2.48	;	Structure of rituximab Fab
3SRP	;	2.14	;	Structure of Rivax: A Human Ricin Vaccine
6L0V	;	1.347	;	Structure of RLD2 BRX domain bound to LZY3 CCL motif
6L0W	;	1.591	;	Structure of RLD2 BRX domain bound to LZY3 CCL motif
6X3B	;	1.91	;	Structure of RMD from Pseudomonas aeruginosa complexed with NADPH
1EBQ	;		;	STRUCTURE OF RNA (5'-GGUGGGCGCAGCUUCGGCUGCGGUACCAC-3'), NMR, 5 STRUCTURES
1EBR	;		;	STRUCTURE OF RNA (5'-GGUGGGCGCAGCUUCGGCUGCGGUACCAC-3'), NMR, 5 STRUCTURES
1EBS	;		;	STRUCTURE OF RNA (5'-GGUGGGCGCAGCUUCGGCUGCGGUACCAC-3'), NMR, 5 STRUCTURES
1MIS	;		;	STRUCTURE OF RNA (5'-R(GP*CP*GP*GP*AP*CP*GP*C)-3') ANTI-PARALLEL RNA DUPLEX WITH TANDEM G:A MISMATCHES, NMR, MINIMIZED AVERAGE STRUCTURE
2EVZ	;		;	Structure of RNA Binding Domains 3 and 4 of Polypyrimidine Tract Binding Protein
1G3A	;		;	STRUCTURE OF RNA DUPLEXES (CIGCGICG)2
4XGT	;	3.09	;	Structure of RNA Helicase FRH a Critical Component of the Neurospora Crassa Circadian Clock
5DZR	;	3.161	;	Structure of RNA Helicase FRH a Critical Component of the Neurospora Crassa Circadian Clock
5E02	;	3.8	;	Structure of RNA Helicase FRH a Critical Component of the Neurospora Crassa Circadian Clock
6VEM	;	1.56	;	Structure of RNA octamer
6PTG	;	2.95	;	Structure of RNA polymerase binding protein and transcriptional regulator Dks from Chlamydia trachomatis L2 (LGV434)
5ZVS	;	3.8	;	Structure of RNA polymerase complex and genome within a dsRNA virus provides insights into the mechanisms of transcription and assembly
5ZVT	;	3.3	;	Structure of RNA polymerase complex and genome within a dsRNA virus provides insights into the mechanisms of transcription and assembly
4C2M	;	2.8	;	Structure of RNA polymerase I at 2.8 A resolution
5IP7	;	3.52	;	Structure of RNA Polymerase II-Tfg1 peptide complex
4BBR	;	3.4	;	Structure of RNA polymerase II-TFIIB complex
5IP9	;	3.9	;	Structure of RNA Polymerase II-TFIIF complex
5FVC	;	4.17	;	Structure of RNA-bound decameric HMPV nucleoprotein
7ROZ	;	3.1	;	Structure of RNA-dependent RNA polymerase 2 (RDR2) from Arabidopsis thaliana
3L0O	;	2.35	;	Structure of RNA-free Rho transcription termination factor from Thermotoga maritima
2X1B	;	1.8	;	Structure of RNA15 RRM
2X1F	;	1.6	;	Structure of Rna15 RRM with bound RNA (GU)
2X1A	;	2.05	;	Structure of Rna15 RRM with RNA bound (G)
5OGH	;	1.16	;	Structure of RNase A at high resolution (1.16 A) in complex with 3'-CMP and sulphate ions
5ET4	;	2.1	;	Structure of RNase A-K7H/R10H in complex with 3'-CMP
4OKE	;	1.7	;	Structure of RNase AS, a polyadenylate-specific exoribonuclease affecting mycobacterial virulence in vivo
6K6S	;	2.993	;	Structure of RNase J1 from Staphylococcus epidermidis
6K6W	;	2.7	;	Structure of RNase J2 from Staphylococcus epidermidis
3SDJ	;	3.65	;	Structure of RNase-inactive point mutant of oligomeric kinase/RNase Ire1
3C4B	;	1.68	;	Structure of RNaseIIIb and dsRNA binding domains of mouse Dicer
3C4T	;	2.8	;	Structure of RNaseIIIb and dsRNA binding domains of mouse Dicer
6U94	;	2.35	;	Structure of RND efflux system, outer membrane lipoprotein, NodT family from Burkholderia mallei ATCC 23344
8GCB	;	2.39	;	Structure of RNF125 in complex with a UbcH5b~Ub conjugate
8GBQ	;	1.74	;	Structure of RNF125 in complex with UbcH5b
5ULH	;	1.95	;	Structure of RNF165 in complex with a UbcH5b~Ub conjugate
7UY2	;	2.51	;	Structure of RNF31 in complex with FP06649, a Helicon Polypeptide
7UYJ	;	2.32	;	Structure of RNF31 in complex with FP06652, a Helicon Polypeptide
7UYK	;	2.7	;	Structure of RNF31 in complex with FP06655, a Helicon Polypeptide
4CWC	;	2.9	;	Structure of Rolling Circle Replication Initiator Protein (RepDE) from Staphylococcus aureus
4CIJ	;	2.3	;	Structure of Rolling Circle Replication Initiator Protein from Geobacillus stearothermophilus.
5UFO	;	2.802	;	Structure of RORgt bound to
5UFR	;	2.068	;	Structure of RORgt bound to
5UHI	;	3.198	;	Structure of RORgt bound to
5W4R	;	3.002	;	Structure of RORgt bound to a tertiary alcohol
5W4V	;	2.65	;	Structure of RORgt bound to a tertiary alcohol
6E3G	;	2.1	;	Structure of RORgt in complex with a novel agonist.
6B30	;	2.69	;	Structure of RORgt in complex with a novel inverse agonist 1
6B31	;	3.18	;	Structure of RORgt in complex with a novel inverse agonist 2
6B33	;	2.48	;	Structure of RORgt in complex with a novel inverse agonist 3
6BR3	;	3.0	;	Structure of RORgt in complex with a novel inverse agonist TAK-828.
6E3E	;	2.47	;	Structure of RORgt in complex with a novel inverse agonist.
6BR2	;	3.18	;	Structure of RORgt in complex with a novel isoquinoline inverse agonist.
5GSF	;		;	Structure of roseltide rT1
5JER	;	2.913	;	Structure of Rotavirus NSP1 bound to IRF-3
3FMG	;	3.4	;	Structure of rotavirus outer capsid protein VP7 trimer in complex with a neutralizing Fab
4R4C	;	1.4	;	Structure of RPA70N in complex with 5-(4-((4-(5-carboxyfuran-2-yl)-2-chlorobenzamido)methyl)phenyl)-1-(3,4-dichlorophenyl)-1H-pyrazole-3-carboxylic acid
4R4I	;	1.4	;	Structure of RPA70N in complex with 5-(4-((6-(5-carboxyfuran-2-yl)-1-thioxo-3,4-dihydroisoquinolin-2(1H)-yl)methyl)phenyl)-1-(3,4-dichlorophenyl)-1H-pyrazole-3-carboxylic acid
5N8A	;	1.28	;	Structure of RPA70N in complex with PrimPol (fragment 480-560)
5N85	;	2.0	;	Structure of RPA70N in complex with PrimPol (fragment 514-525)
7F4G	;	2.78	;	Structure of RPAP2-bound RNA polymerase II
4F3D	;	2.5	;	Structure of RPE65: P65 crystal form grown in Fos-Choline-10
4F30	;	3.15	;	Structure of RPE65: P6522 crystal form grown in ammonium phosphate solution
4F3A	;	2.6	;	Structure of RPE65: P6522 crystal form, iridium derivative
7ZQ7	;	3.0	;	Structure of RpF-1
4XD9	;	2.35	;	Structure of Rpf2-Rrs1 complex involved in ribosome biogenesis
7YFV	;	2.2	;	Structure of Rpgrip1l CC1
7YFU	;	1.5	;	Structure of Rpgrip1l CC2
7ZUW	;	4.3	;	Structure of RQT (C1) bound to the stalled ribosome in a disome unit from S. cerevisiae
6LE1	;	2.3	;	Structure of RRM2 domain of DND1 protein
5D78	;	1.251	;	Structure of RRM3 Domain of Mip6 at 1.25 A Resolution
4J0X	;	2.502	;	Structure of Rrp9
4MLG	;	2.7	;	Structure of RS223-Beta-xylosidase
8B65	;	1.55	;	Structure of rsCherry crystallized in anaerobic conditions
4XOV	;	1.2	;	Structure of rsGreen0.7 in the green-off-state
4XOW	;	1.25	;	Structure of rsGreen0.7 in the green-on-state
4JG7	;	3.0002	;	Structure of RSK2 CTD bound to 3-(3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)phenyl)-2-cyanoacrylamide
4JG8	;	3.1002	;	Structure of RSK2 T493M CTD mutant bound to 2-cyano-N-(1-hydroxy-2-methylpropan-2-yl)-3-(3-(3,4,5-trimethoxyphenyl)-1H-indazol-5-yl)acrylamide
4I6S	;	1.54	;	Structure of RSL mutant W76A in complex with L-fucose
7OBZ	;	2.0	;	Structure of RsLOV D109G
7OB0	;	1.9	;	Structure of RsLOV d2 variant
8T85	;	2.38	;	Structure of RssB bound to beryllofluoride
1KSK	;	2.0	;	STRUCTURE OF RSUA
1KSL	;	2.1	;	STRUCTURE OF RSUA
1KSV	;	2.65	;	STRUCTURE OF RSUA
7LVW	;	2.1	;	Structure of RSV F in Complex with VHH Cl184
7LVU	;	1.94	;	Structure of RSV F-directed VHH Cl184
3TW1	;	1.772	;	Structure of Rtt106-AHN
3NPL	;	2.4	;	Structure of Ru(bpy)2(A-Phen)(K97C) P450 BM3 heme domain, a ruthenium modified P450 BM3 mutant
5KHC	;	11.1	;	Structure of rubella virus E1 glycoprotein ectodomain fitted into sub-tomogram averaged surface spike density of rubella virus
5NV3	;	3.39	;	Structure of Rubisco from Rhodobacter sphaeroides in complex with CABP
2YBV	;	2.3	;	STRUCTURE OF RUBISCO FROM THERMOSYNECHOCOCCUS ELONGATUS
2H21	;	2.45	;	Structure of Rubisco LSMT bound to AdoMet
2H2E	;	2.6	;	Structure of Rubisco LSMT bound to AzaAdoMet and Lysine
2H2J	;	2.45	;	Structure of Rubisco LSMT bound to Sinefungin and Monomethyllysine
2H23	;	2.45	;	Structure of Rubisco LSMT bound to Trimethyllysine and AdoHcy
7RXN	;	1.5	;	STRUCTURE OF RUBREDOXIN FROM DESULFOVIBRIO VULGARIS AT 1.5 A RESOLUTION
2H8C	;	3.1	;	Structure of RusA D70N in complex with DNA
8BKD	;	1.4	;	structure of RutB
8BLL	;	1.54	;	Structure of RutB
8BLM	;	1.9	;	Structure of RutB
8BLN	;	1.88	;	Structure of RutB
3M1S	;	3.134	;	Structure of Ruthenium Half-Sandwich Complex Bound to Glycogen Synthase Kinase 3
1BEX	;	2.3	;	STRUCTURE OF RUTHENIUM-MODIFIED PSEUDOMONAS AERUGINOSA AZURIN
1IXS	;	3.2	;	Structure of RuvB complexed with RuvA domain III
1HQC	;	3.2	;	STRUCTURE OF RUVB FROM THERMUS THERMOPHILUS HB8
8DQY	;	2.1	;	Structure of Rv0455c from Mycobacterium tuberculosis
8DRG	;	1.8	;	Structure of Rv0455c from Mycobacterium tuberculosis
8DRI	;	2.0	;	Structure of Rv0455c from Mycobacterium tuberculosis
3HYS	;	2.3	;	Structure of Rv0554 from Mycobacterium tuberculosis complexed with Malonic Acid
1Y0H	;	1.6	;	Structure of Rv0793 from Mycobacterium tuberculosis
2EV3	;	2.68	;	Structure of Rv1264N, the regulatory domain of the mycobacterial adenylyl cylcase Rv1264, at pH 5.3
2EV1	;	1.6	;	Structure of Rv1264N, the regulatory domain of the mycobacterial adenylyl cylcase Rv1264, at pH 6.0
2EV2	;	2.35	;	Structure of Rv1264N, the regulatory domain of the mycobacterial adenylyl cylcase Rv1264, at pH 8.5
2EV4	;	2.28	;	Structure of Rv1264N, the regulatory domain of the mycobacterial adenylyl cylcase Rv1264, with a salt precipitant
2XIV	;	1.4	;	Structure of Rv1477, hypothetical invasion protein of Mycobacterium tuberculosis
4BEG	;	1.42	;	Structure of Rv2140c, a phosphatidyl-ethanolamine binding protein from Mycobacterium tuberculosis in complex with sulphate
2CHC	;	1.69	;	Structure of Rv3472(D26N), a function unknown protein from Mycobacterium tuberculosis
1NXJ	;	1.9	;	Structure of Rv3853 from Mycobacterium tuberculosis
6EGU	;	2.3	;	Structure of RVFV envelope protein Gc in postfusion conformation in complex with 1,2-dipropionyl-sn-glycero-3-phosphocholine
6EGT	;	2.5	;	Structure of RVFV envelope protein Gc in postfusion conformation in complex with MES
6IEK	;	2.7	;	Structure of RVFV Gn and human monoclonal antibody R12
6IEA	;	2.0	;	Structure of RVFV Gn and human monoclonal antibody R13
6IEB	;	2.409	;	Structure of RVFV Gn and human monoclonal antibody R15
6IEC	;	3.2	;	Structure of RVFV Gn and human monoclonal antibody R17
8WOJ	;	1.768	;	Structure of RxLR121 effector from phytophthora capsici
6FOO	;	8.2	;	Structure of Ryanodine Receptor 1 in nanodiscs in the presence of calcium and ATP
6FG3	;	7.3	;	Structure of Ryanodine receptor 1 in nanodiscs in the presence of calcium, ATP and ryanodine
6M2W	;	3.8	;	Structure of RyR1 (Ca2+/Caffeine/ATP/CaM1234/CHL)
7CF9	;	4.7	;	Structure of RyR1 (Ca2+/CHL)
5GKY	;	3.8	;	Structure of RyR1 in a closed state (C1 conformer)
5GKZ	;	4.0	;	Structure of RyR1 in a closed state (C3 conformer)
5GL0	;	4.2	;	Structure of RyR1 in a closed state (C4 conformer)
5GL1	;	5.7	;	Structure of RyR1 in an open state
6JRR	;	3.9	;	Structure of RyR2 (*F/A/C/L-Ca2+ dataset)
6JRS	;	3.7	;	Structure of RyR2 (*F/A/C/L-Ca2+/Ca2+-CaM dataset)
6JI0	;	4.2	;	Structure of RyR2 (F/A/C/Ca2+ dataset)
6JIY	;	3.9	;	Structure of RyR2 (F/A/C/H-Ca2+/Ca2+CaM dataset)
6JII	;	4.2	;	Structure of RyR2 (F/A/C/L-Ca2+/apo-CaM-M dataset)
6JIU	;	4.2	;	Structure of RyR2 (F/A/C/L-Ca2+/Ca2+CaM dataset)
6JH6	;	4.8	;	Structure of RyR2 (F/A/Ca2+ dataset)
6JI8	;	3.6	;	Structure of RyR2 (F/apoCaM dataset)
6JHN	;	4.5	;	Structure of RyR2 (F/C/Ca2+ dataset)
6JGZ	;	4.6	;	Structure of RyR2 (F/P/Ca2+ dataset)
6JV2	;	4.4	;	Structure of RyR2 (P/L-Ca2+/Ca2+-CaM dataset)
4YVF	;	2.7	;	Structure of S-adenosyl-L-homocysteine hydrolase
1YY3	;	2.88	;	Structure of S-Adenosylmethionine:tRNA Ribosyltransferase-Isomerase (QueA)
6WPU	;	2.084	;	Structure of S-allyl-L-cysteine S-oxygenase from Allium sativum
5V1L	;	1.2	;	Structure of S-GNA dodecamer
1SLT	;	1.9	;	STRUCTURE OF S-LECTIN, A DEVELOPMENTALLY REGULATED VERTEBRATE BETA-GALACTOSIDE BINDING PROTEIN
6RZV	;	20.6	;	Structure of s-Mgm1 decorating the inner surface of tubulated lipid membranes
6RZW	;	18.8	;	Structure of s-Mgm1 decorating the inner surface of tubulated lipid membranes in the GTPgammaS bound state
6RZT	;	14.7	;	Structure of s-Mgm1 decorating the outer surface of tubulated lipid membranes
6RZU	;	14.7	;	Structure of s-Mgm1 decorating the outer surface of tubulated lipid membranes in the GTPgammaS bound state
4DLB	;	2.1	;	Structure of S-nitrosoglutathione reductase from tomato (Solanum lycopersicum) crystallized in presence of NADH and glutathione
9B8E	;	1.4	;	Structure of S-nitrosylated Legionella pneumophila Ceg10.
4TQ2	;	1.95	;	Structure of S-type Phycobiliprotein Lyase CPES from Guillardia theta
4IJA	;	2.1	;	Structure of S. aureus methicillin resistance factor MecR2
1DEE	;	2.7	;	Structure of S. aureus protein A bound to a human IgM Fab
7OIW	;	2.63	;	Structure of S. aureus Rel catalytic domains in complex with pppGpp
3WYI	;	2.0	;	Structure of S. aureus undecaprenyl diphosphate synthase
4H8E	;	1.3	;	Structure of S. aureus undecaprenyl diphosphate synthase in complex with FPP and sulfate
4U82	;	1.66	;	Structure of S. aureus undecaprenyl diphosphate synthase in complex with FSPP and sulfate
5JM9	;	24.0	;	Structure of S. cerevesiae mApe1 dodecamer
4QTT	;	2.0	;	Structure of S. cerevisiae Bud23-Trm112 complex involved in formation of m7G1575 on 18S rRNA (apo-form)
4QTU	;	2.124	;	Structure of S. cerevisiae Bud23-Trm112 complex involved in formation of m7G1575 on 18S rRNA (SAM bound form)
2VGN	;	2.505	;	Structure of S. cerevisiae Dom34, a translation termination-like factor involved in RNA quality control pathways and interacting with Hbs1 (SelenoMet-labeled protein)
2VGM	;	2.6	;	Structure of S. cerevisiae Dom34, a translation termination-like factor involved in RNA quality control pathways and interacting with Hbs1 (Unlabeled protein)
4ZAC	;	1.65	;	Structure of S. cerevisiae Fdc1 with the prenylated-flavin cofactor in the iminium form.
2AGK	;	1.3	;	Structure of S. cerevisiae His6 protein
8CWW	;	2.74	;	Structure of S. cerevisiae Hop1 CBR bound to a nucleosome
4XHL	;	3.01	;	Structure of S. cerevisiae Hrr25 1-394 (K38R mutant)
5CYZ	;	1.841	;	Structure of S. cerevisiae Hrr25:Mam1 complex, form 1
5CZO	;	2.894	;	Structure of S. cerevisiae Hrr25:Mam1 complex, form 2
6FNU	;	1.56	;	Structure of S. cerevisiae Methylenetetrahydrofolate reductase 1, catalytic domain
3V60	;	2.6	;	Structure of S. cerevisiae PCNA conjugated to SUMO on lysine 164
3V61	;	2.8	;	Structure of S. cerevisiae PCNA conjugated to SUMO on lysine 164
6P2R	;	3.2	;	Structure of S. cerevisiae protein O-mannosyltransferase Pmt1-Pmt2 complex bound to the sugar donor
6P25	;	3.2	;	Structure of S. cerevisiae protein O-mannosyltransferase Pmt1-Pmt2 complex bound to the sugar donor and a peptide acceptor
8FS3	;	2.93	;	Structure of S. cerevisiae Rad24-RFC loading the 9-1-1 clamp onto a 10-nt gapped DNA in step 1 (open 9-1-1 and shoulder bound DNA only)
8FS4	;	2.94	;	Structure of S. cerevisiae Rad24-RFC loading the 9-1-1 clamp onto a 10-nt gapped DNA in step 2 (open 9-1-1 ring and flexibly bound chamber DNA)
8FS5	;	2.76	;	Structure of S. cerevisiae Rad24-RFC loading the 9-1-1 clamp onto a 10-nt gapped DNA in step 3 (open 9-1-1 and stably bound chamber DNA)
8FS6	;	2.9	;	Structure of S. cerevisiae Rad24-RFC loading the 9-1-1 clamp onto a 10-nt gapped DNA in step 4 (partially closed 9-1-1 and stably bound chamber DNA)
8FS7	;	2.85	;	Structure of S. cerevisiae Rad24-RFC loading the 9-1-1 clamp onto a 10-nt gapped DNA in step 5 (closed 9-1-1 and stably bound chamber DNA)
8FS8	;	3.04	;	Structure of S. cerevisiae Rad24-RFC loading the 9-1-1 clamp onto a 5-nt gapped DNA (9-1-1 encircling fully bound DNA)
3MGU	;	2.8	;	Structure of S. cerevisiae Tpa1 protein, a proline hydroxylase modifying ribosomal protein Rps23
2J6A	;	1.7	;	Structure of S. cerevisiae Trm112 protein, a methyltransferase activator
5V3N	;	1.3	;	Structure of S. cerevisiae Ulp2-Tof2-Csm1 complex
5V1A	;	2.14	;	Structure of S. cerevisiae Ulp2:Csm1 complex
6BZF	;	2.286	;	Structure of S. cerevisiae Zip2:Spo16 complex, C2 form
6BZG	;	2.13	;	Structure of S. cerevisiae Zip2:Spo16 complex, P212121 form
6AMA	;	3.09	;	Structure of S. coelicolor/S. venezuelae BldC-smeA-ssfA complex to 3.09 Angstrom
8TN2	;	1.75	;	Structure of S. hygroscopicus aminotransferase MppQ complexed with pyridoxal-5'-phosphate (PLP)
8TN3	;	1.63	;	Structure of S. hygroscopicus aminotransferase MppQ complexed with pyridoxamine 5'-phosphate (PMP)
7TB6	;	1.89	;	Structure of S. maltophilia CapW
1NH6	;	2.05	;	Structure of S. marcescens chitinase A, E315L, complex with hexasaccharide
1IHZ	;	1.65	;	Structure of S. nuclease mutant quintuple mutant V23L/V66L/I72L/I92L/V99L
1II3	;	1.72	;	Structure of S. nuclease quintuple mutant V23I/V66L/I72L/I92L/V99L
1EY7	;	1.88	;	STRUCTURE OF S. NUCLEASE STABILIZING MUTANT S128A
1EY4	;	1.6	;	STRUCTURE OF S. NUCLEASE STABILIZING MUTANT S59A
1EY5	;	1.7	;	STRUCTURE OF S. NUCLEASE STABILIZING MUTANT T33V
1EZ8	;	1.85	;	STRUCTURE OF S. NUCLEASE STABILIZING MUTANT T33V
1EY6	;	1.75	;	STRUCTURE OF S. NUCLEASE STABILIZING MUTANT T41I
1EY9	;	1.72	;	STRUCTURE OF S. NUCLEASE STABILIZING QUADRUPLE MUTANT T41I/P117G/H124L/S128A
1EYA	;	2.0	;	STRUCTURE OF S. NUCLEASE STABILIZING QUINTUPLE MUTANT T33V/T41I/P117G/H124L/S128A
1EYC	;	1.85	;	STRUCTURE OF S. NUCLEASE STABILIZING QUINTUPLE MUTANT T41I/S59A/P117G/H124L/S128A
1EZ6	;	1.9	;	STRUCTURE OF S. NUCLEASE STABILIZING SEXTUPLE MUTANT T33V/T41I/S59A/P117G/H124L/S128A
1EY8	;	1.75	;	STRUCTURE OF S. NUCLEASE STABILIZING TRIPLE MUTANT P117G/H124L/S128A
5DV0	;	3.299	;	Structure of S. pneumoniae D39 sortase A
6W18	;	4.2	;	Structure of S. pombe Arp2/3 complex in inactive state
3FHO	;	2.8	;	Structure of S. pombe Dbp5
6S2W	;	1.95	;	Structure of S. pombe Erh1, a protein important for meiotic mRNA decay in mitosis and meiosis progression.
6PPQ	;	1.81	;	Structure of S. pombe Lsm1-7 with RNA, polyuridine with 3' adenosine
6PPV	;	2.05	;	Structure of S. pombe Lsm1-7 with RNA, polyuridine with 3' guanosine
6PPP	;	2.33	;	Structure of S. pombe Lsm2-8 with processed U6 snRNA
6PPN	;	1.91	;	Structure of S. pombe Lsm2-8 with unprocessed U6 snRNA
6YYM	;	2.63	;	Structure of S. pombe Mei2 RRM3 domain bound to RNA
6FPP	;	1.93	;	Structure of S. pombe Mmi1
6FPX	;	1.97	;	Structure of S. pombe Mmi1 in complex with 11-mer RNA
6FPQ	;	1.42	;	Structure of S. pombe Mmi1 in complex with 7-mer RNA
3QTM	;	2.15	;	Structure of S. pombe nuclear import adaptor Nro1 (Space group P21)
3QTN	;	3.499	;	Structure of S. pombe nuclear import adaptor Nro1 (Space group P6522)
4PN0	;	2.6	;	Structure of S. pombe Pct1 RNA triphosphatase
4PN1	;	2.803	;	Structure of S. pombe Pct1 RNA triphosphatase in complex with the Spt5 CTD
3G10	;	2.597	;	Structure of S. pombe Pop2p - Mg2+ and Mn2+ bound form
3G0Z	;	2.004	;	Structure of S. pombe Pop2p - Zn2+ and Mn2+ bound form
6TZN	;	1.35	;	Structure of S. pombe telomerase accessory protein Pof8 C-terminal domain
7BB3	;	2.158	;	Structure of S. pombe YG-box oligomer
2VL7	;	2.25	;	Structure of S. tokodaii Xpd4
7U3B	;	3.6	;	Structure of S. venezuelae GlgX bound to c-di-GMP and acarbose (pH 8.5)
7U3D	;	2.4	;	Structure of S. venezuelae GlgX-c-di-GMP-acarbose complex (4.6)
6PFV	;	3.0	;	Structure of S. venezuelae RisG-WhiG-c-di-GMP complex: orthorhombic crystal form
6PFJ	;	2.08	;	Structure of S. venezuelae RsiG-WhiG-(ci-di-GMP) complex, P64 crystal form
6EMW	;	11.0	;	Structure of S.aureus ClpC in complex with MecA
2G3I	;	2.1	;	Structure of S.olivaceoviridis xylanase Q88A/R275A mutant
2G3J	;	2.7	;	Structure of S.olivaceoviridis xylanase Q88A/R275A mutant
2G4F	;	2.65	;	Structure of S.olivaceoviridis xylanase Q88A/R275A mutant
6LZ1	;	3.2	;	Structure of S.pombe alpha-mannosidase Ams1
4ETO	;	1.54	;	Structure of S100A4 in complex with non-muscle myosin-IIA peptide
3M0W	;	2.8	;	Structure of S100A4 with PCP
2G9Y	;	2.0	;	Structure of S102T E. coli alkaline phosphatase in presence of phosphate at 2.00 A resolution
2GA3	;	2.2	;	Structure of S102T E. coli Alkaline Phosphatase-phosphate intermediate at 2.20A resolution
2WQE	;	2.5	;	Structure of S155R Aurora-A somatic mutant
6SYA	;	2.27	;	STRUCTURE OF S192A-ESTER-HYDROLASE EH3 FROM THE METAGENOME OF MARINE SEDIMENTS AT MILAZZO HARBOR (SICILY, ITALY) COMPLEXED WITH METHYL (2R)-2-PHENYLPROPANOATE
6SXY	;	2.06	;	STRUCTURE OF S192A-ESTER-HYDROLASE EH3 FROM THE METAGENOME OF MARINE SEDIMENTS AT MILAZZO HARBOR (SICILY, ITALY) COMPLEXED WITH METHYL (2S)-2-PHENYLPROPANOATE
7VD6	;	2.8	;	Structure of S1M1-type FCPII complex from diatom
7T6B	;	3.19	;	Structure of S1PR2-heterotrimeric G13 signaling complex
3ZXY	;	1.58	;	Structure of S218A mutant of the protease domain of PatA
2R2H	;	2.0	;	Structure of S25-2 in Complex with Ko
5Z2J	;	1.87	;	structure of S38A mutant metal-free periplasmic metal binding protein from candidatus liberibacter asiaticus
5Z2K	;	1.8	;	Structure of S38A mutant Mn-bound periplasmic metal binding protein from candidatus liberibacter asiaticus
5IBM	;	2.18	;	Structure of S502P, a Cancer-Associated Mutation of the Oncogenic Phosphatase SHP2
5DQ9	;	1.95	;	Structure of S55-3 Fab in complex with Lipid A
5DQD	;	1.94	;	Structure of S55-5 Fab in complex with lipid A carbohydrate backbone
1YX4	;		;	Structure of S5a bound to monoubiquitin provides a model for polyubiquitin recognition
2HGY	;	2.05	;	Structure of S65A Y66F E222A GFP variant after cyclization and carbon-carbon bond cleavage
2HGD	;	1.6	;	Structure of S65A Y66F GFP variant with an oxidized chromophore
2G16	;	2.0	;	Structure of S65A Y66S GFP variant after backbone fragmentation
5W46	;	1.18	;	Structure of S65D Phosphomimetic Ubiquitin Refined at 1.2 Angstroms Resolution
2G3D	;	1.35	;	Structure of S65G Y66A GFP variant after spontaneous peptide hydrolysis
2G2S	;	1.2	;	Structure of S65G Y66S GFP variant after spontaneous peptide hydrolysis
2G5Z	;	1.8	;	Structure of S65G Y66S GFP variant after spontaneous peptide hydrolysis and decarboxylation
2HCG	;	1.35	;	Structure of S65T Y66F GFP variant after cyclization, carbon-carbon bond cleavage, and oxygen incorporation reactions
2HFC	;	1.2	;	Structure of S65T Y66F R96A GFP variant in precursor state
3IKC	;	2.6	;	Structure of S67-27 in Complex with Kdo(2.8)-7-O-methyl-Kdo
3IJY	;	2.85	;	Structure of S67-27 in Complex with Kdo(2.8)Kdo
3IJH	;	2.1	;	Structure of S67-27 in Complex with Ko
3IJS	;	2.55	;	Structure of S67-27 in Complex with TSBP
6H28	;	1.19	;	Structure of S70A BlaC from Mycobacterium tuberculosis obtained from crystals produced in the absence of DTT
6H2A	;	2.54	;	Structure of S70A BlaC from Mycobacterium tuberculosis obtained from crystals produced in the presence of DTT
4FH2	;	1.44	;	Structure of s70c beta-lactamase bound to sulbactam
6H27	;	1.63	;	Structure of S70C BlaC from Mycobacterium tuberculosis
5UCX	;	2.4	;	Structure of S78C Human Peroxiredoxin 3 as three stacked rings
6R9I	;	3.0	;	Structure of Saccharomyces cerevisiae apo Pan2 pseudoubiquitin hydrolase-RNA exonuclease (UCH-Exo) module
6R9J	;	3.326	;	Structure of Saccharomyces cerevisiae apo Pan2 pseudoubiquitin hydrolase-RNA exonuclease (UCH-Exo) module in complex with A7 RNA
6R9Q	;	3.079	;	Structure of Saccharomyces cerevisiae apo Pan2 pseudoubiquitin hydrolase-RNA exonuclease (UCH-Exo) module in complex with AACCAA RNA
6R9O	;	3.319	;	Structure of Saccharomyces cerevisiae apo Pan2 pseudoubiquitin hydrolase-RNA exonuclease (UCH-Exo) module in complex with AAGGA RNA
6R9M	;	3.329	;	Structure of Saccharomyces cerevisiae apo Pan2 pseudoubiquitin hydrolase-RNA exonuclease (UCH-Exo) module in complex with AAGGAA RNA
6R9P	;	2.98	;	Structure of Saccharomyces cerevisiae apo Pan2 pseudoubiquitin hydrolase-RNA exonuclease (UCH-Exo) module in complex with AAUUAA RNA
2M9V	;		;	Structure of Saccharomyces cerevisiae Est3 protein
4EQV	;	3.4	;	Structure of Saccharomyces cerevisiae invertase
4PEW	;	1.51	;	Structure of sacteLam55A from Streptomyces sp. SirexAA-E
4YOM	;	2.49	;	Structure of SAD kinase
6TB4	;	3.8	;	Structure of SAGA bound to TBP
6TBM	;	20.0	;	Structure of SAGA bound to TBP, including Spt8 and DUB
7S2X	;	2.85	;	Structure of SalC, a gamma-lactam-beta-lactone bicyclase for salinosporamide biosynthesis
7Y3L	;	2.5	;	Structure of SALL3 ZFC4 bound with 12 bp AT-rich dsDNA
7Y3M	;	2.723	;	Structure of SALL4 ZFC1 bound with 16 bp AT-rich dsDNA
7Y3K	;	2.501	;	Structure of SALL4 ZFC4 bound with 16 bp AT-rich dsDNA
4CUJ	;	1.88	;	Structure of Salmonella D-Lactate Dehydrogenase
4CUK	;	2.18	;	Structure of Salmonella D-Lactate Dehydrogenase in complex with NADH
6CGI	;	2.3	;	Structure of Salmonella Effector SseK3
6DUS	;	2.6	;	Structure of Salmonella Effector SseK3 E258Q mutant
8PX1	;	2.1	;	Structure of salmonella effector SseK3, solved at wavelength 2.75 A
5HAF	;	2.7	;	Structure of Salmonella enterica effector protein SseL
6V3Z	;	1.9	;	Structure of Salmonella enteritidis Sen1395
6KFK	;	4.1	;	Structure of Salmonella flagellar hook reveals intermolecular domain interactions for the universal joint function
2MC7	;		;	Structure of Salmonella MgtR
6SE1	;	1.08	;	Structure of Salmonella ser. Paratyphi A lipopolysaccharide acetyltransferase periplasmic domain
2FM9	;	2.0	;	Structure of Salmonella SipA residues 48-264
7AK8	;	2.5	;	Structure of Salmonella TacT1 toxin bound to TacA1 antitoxin C-terminal peptide
7AK7	;	2.14	;	Structure of Salmonella TacT2 toxin bound to TacA2 antitoxin
7AK9	;	2.55	;	Structure of Salmonella TacT3 toxin bound to TacA3 antitoxin C-terminal peptide
6OFH	;	3.7	;	Structure of Salmonella type III secretion system needle filament
6V40	;	2.104	;	Structure of Salmonella Typhi TtsA
4CLM	;	1.4	;	Structure of Salmonella typhi type I dehydroquinase irreversibly inhibited with a 1,3,4-trihydroxyciclohexane-1-carboxylic acid derivative
2YLB	;	1.15	;	Structure of Salmonella typhimurium Hfq at 1.15 A
2YLC	;	1.3	;	Structure of Salmonella typhimurium Hfq in complex with U6 RNA
5KX4	;	1.94	;	Structure of SALO
8R4V	;	1.9	;	Structure of Salt-inducible kinase 3 in complex with inhibitor
8R4U	;	2.416	;	Structure of salt-inducible kinase 3 with inhibitors
6UK5	;	2.6	;	Structure of SAM bound CalS10, an amino pentose methyltransferase from Micromonospora echinaspora involved in calicheamicin biosynthesis
6YOP	;	1.1	;	Structure of SAMM50 LIR bound to GABARAP
6YOO	;	1.06	;	Structure of SAMM50 LIR bound to GABARAPL1
2N1U	;		;	Structure of SAP30L corepressor protein
6TRV	;	2.4	;	Structure of SapL1 lectin in complex with alpha methyl fucoside
6SLR	;	2.38	;	Structure of saposin B in complex with atovaquone
4V2O	;	2.13	;	Structure of saposin B in complex with chloroquine
7DXG	;	2.9	;	Structure of SAR7334-bound TRPC6 at 2.9 angstrom
430D	;	2.1	;	STRUCTURE OF SARCIN/RICIN LOOP FROM RAT 28S RRNA
7R0A	;	2.8	;	Structure of sarin phosphonylated acetylcholinesterase in complex with 2-((hydroxyimino)methyl)-1-(5-(4-methyl-3-nitrobenzamido)pentyl)pyridinium
3AW1	;	2.0	;	Structure of SARS 3CL protease auto-proteolysis resistant mutant in the absent of inhibitor
3AW0	;	2.3	;	Structure of SARS 3CL protease with peptidic aldehyde inhibitor
3AVZ	;	2.46	;	Structure of SARS 3CL protease with peptidic aldehyde inhibitor containing cyclohexyl side chain
5N5O	;	2.0	;	Structure of SARS coronavirus main protease in complex with the alpha-ketoamide (S)-N-benzyl-3-((S)-2-cinnamamido-3-cyclopropylpropanamido)-2-oxo-4-((S)-2-oxopyrrolidin-3-yl)butanamide (Cinnamoyl-cyclopropylalanine-GlnLactam-CO-CO-NH-benzyl)
5N19	;	1.62	;	Structure of SARS coronavirus main protease in complex with the alpha-ketoamide (S)-N-benzyl-3-((S)-2-cinnamamido-3-phenylpropanamido)-2-oxo-4-((S)-2-oxopyrrolidin-3-yl)butanamide
2AJF	;	2.9	;	Structure of SARS coronavirus spike receptor-binding domain complexed with its receptor
2C3S	;	1.9	;	Structure Of Sars Cov Main Proteinase At 1.9 A (Ph6.5)
7LMC	;	2.977	;	Structure of SARS CoV-2 main protease shows simultaneous processing of its N- and C-terminii
6WCO	;	1.48	;	Structure of SARS main protease bound to inhibitor X47
5E6J	;	2.85	;	Structure of SARS PLpro bound to a Lys48-linked di-ubiquitin activity based probe
4TWW	;	2.42	;	Structure of SARS-3CL protease complex with a Bromobenzoyl (S,R)-N-decalin type inhibitor
5C5N	;	1.69	;	Structure of SARS-3CL protease complex with a phenyl-beta-alanyl (R,S)-N-decalin type inhibitor
5C5O	;	1.5	;	Structure of SARS-3CL protease complex with a phenyl-beta-alanyl (S,R)-N-decalin type inhibitor
4WY3	;	1.89	;	Structure of SARS-3CL protease complex with a phenylbenzoyl (R,S)-N-decalin type inhibitor
4TWY	;	1.6	;	Structure of SARS-3CL protease complex with a phenylbenzoyl (S,R)-N-decalin type inhibitor
6W79	;	1.46	;	Structure of SARS-CoV main protease bound to potent broad-spectrum non-covalent inhibitor X77
7SG4	;	3.43	;	Structure of SARS-CoV S protein in complex with Receptor Binding Domain antibody DH1047
5XLR	;	3.8	;	Structure of SARS-CoV spike glycoprotein
8EQS	;	3.1	;	Structure of SARS-CoV-1 Orf3a in late endosome/lysosome-like environment, MSP1D1 nanodisc
8H15	;	3.14182	;	Structure of SARS-CoV-1 Spike Protein (S/native) at pH 5.5, Closed Conformation
8H16	;	3.35534	;	Structure of SARS-CoV-1 Spike Protein (S/native) at pH 5.5, Open Conformation
8H11	;	2.72	;	Structure of SARS-CoV-1 Spike Protein with Engineered x1 Disulfide (S370C and D967C), Closed Conformation
8H0X	;	2.57	;	Structure of SARS-CoV-1 Spike Protein with Engineered x1 Disulfide (S370C and D967C), Locked-1 Conformation
8H0Y	;	2.85	;	Structure of SARS-CoV-1 Spike Protein with Engineered x1 Disulfide (S370C and D967C), Locked-112 Conformation
8H0Z	;	2.99	;	Structure of SARS-CoV-1 Spike Protein with Engineered x1 Disulfide (S370C and D967C), Locked-122 Conformation
8H10	;	2.99	;	Structure of SARS-CoV-1 Spike Protein with Engineered x1 Disulfide (S370C and D967C), Locked-2 Conformation
8H13	;	4.05	;	Structure of SARS-CoV-1 Spike Protein with Engineered x2 Disulfide (G400C and V969C), Closed Conformation
8H12	;	3.44681	;	Structure of SARS-CoV-1 Spike Protein with Engineered x2 Disulfide (G400C and V969C), Locked-2 Conformation
8H14	;	3.39	;	Structure of SARS-CoV-1 Spike Protein with Engineered x3 Disulfide (D414C and V969C), Locked-1 Conformation
7T49	;	1.75	;	Structure of SARS-CoV-2 3CL protease in complex with inhibitor 10c
7T4A	;	1.8	;	Structure of SARS-CoV-2 3CL protease in complex with inhibitor 11c
7LZU	;	1.6	;	Structure of SARS-CoV-2 3CL protease in complex with inhibitor 12b
7M00	;	2.0	;	Structure of SARS-CoV-2 3CL protease in complex with inhibitor 13c
7M01	;	1.65	;	Structure of SARS-CoV-2 3CL protease in complex with inhibitor 14c
7T4B	;	1.6	;	Structure of SARS-CoV-2 3CL protease in complex with inhibitor 14c
7M02	;	1.8	;	Structure of SARS-CoV-2 3CL protease in complex with inhibitor 17c
7M03	;	2.0	;	Structure of SARS-CoV-2 3CL protease in complex with inhibitor 18c
7LZV	;	1.6	;	Structure of SARS-CoV-2 3CL protease in complex with inhibitor 19b
7LZX	;	1.65	;	Structure of SARS-CoV-2 3CL protease in complex with inhibitor 1c
7LZW	;	2.2	;	Structure of SARS-CoV-2 3CL protease in complex with inhibitor 20b (deuterated analog of 19b)
7M04	;	1.75	;	Structure of SARS-CoV-2 3CL protease in complex with inhibitor 21c
7T42	;	1.6	;	Structure of SARS-CoV-2 3CL protease in complex with inhibitor 2c
7LZY	;	1.85	;	Structure of SARS-CoV-2 3CL protease in complex with inhibitor 3c
7T43	;	1.7	;	Structure of SARS-CoV-2 3CL protease in complex with inhibitor 3c
7T44	;	1.45	;	Structure of SARS-CoV-2 3CL protease in complex with inhibitor 4c
7LZZ	;	2.0	;	Structure of SARS-CoV-2 3CL protease in complex with inhibitor 5c
7T45	;	1.65	;	Structure of SARS-CoV-2 3CL protease in complex with inhibitor 7c
7LZT	;	1.55	;	Structure of SARS-CoV-2 3CL protease in complex with inhibitor 8b
7T46	;	1.45	;	Structure of SARS-CoV-2 3CL protease in complex with inhibitor 8c
7T48	;	1.9	;	Structure of SARS-CoV-2 3CL protease in complex with inhibitor 9c
7TQ5	;	1.65	;	Structure of SARS-CoV-2 3CL protease in complex with the cyclopropane based inhibitor 10d
7TQ6	;	1.55	;	Structure of SARS-CoV-2 3CL protease in complex with the cyclopropane based inhibitor 13d
8CZW	;	1.7	;	Structure of SARS-CoV-2 3CL protease in complex with the cyclopropane based inhibitor 15d
8CZX	;	1.65	;	Structure of SARS-CoV-2 3CL protease in complex with the cyclopropane based inhibitor 17d
7TQ2	;	2.3	;	Structure of SARS-CoV-2 3CL protease in complex with the cyclopropane based inhibitor 1c
7TQ3	;	2.0	;	Structure of SARS-CoV-2 3CL protease in complex with the cyclopropane based inhibitor 5c
7TQ4	;	2.45	;	Structure of SARS-CoV-2 3CL protease in complex with the cyclopropane based inhibitor 6c
7JJJ	;	4.5	;	Structure of SARS-CoV-2 3Q-2P full-length dimers of spike trimers
7JJI	;	3.6	;	Structure of SARS-CoV-2 3Q-2P full-length prefusion spike trimer (C3 symmetry)
7EKF	;	2.85	;	Structure of SARS-CoV-2 Alpha variant spike receptor-binding domain complexed with human ACE2
7XNF	;	2.79	;	Structure of SARS-CoV-2 antibody P2C-1F11 with GX/P2V/2017 RBD
7XSW	;	3.3	;	Structure of SARS-CoV-2 antibody S309 with GX/P2V/2017 RBD
7KRN	;	3.4	;	Structure of SARS-CoV-2 backtracked complex bound to nsp13 helicase - nsp13(1)-BTC
7KRP	;	3.2	;	Structure of SARS-CoV-2 backtracked complex complex bound to nsp13 helicase - BTC (local refinement)
7KRO	;	3.6	;	Structure of SARS-CoV-2 backtracked complex complex bound to nsp13 helicase - nsp13(2)-BTC
7EKG	;	2.63	;	Structure of SARS-CoV-2 Beta variant spike receptor-binding domain complexed with human ACE2
6VW1	;	2.68	;	Structure of SARS-CoV-2 chimeric receptor-binding domain complexed with its receptor human ACE2
7XU5	;	3.1	;	Structure of SARS-CoV-2 D614G Spike Protein with Engineered x3 Disulfide (x3(D427C, V987C) and single Arg S1/S2 cleavage site), Closed Conformation
7XU4	;	3.2	;	Structure of SARS-CoV-2 D614G Spike Protein with Engineered x3 Disulfide (x3(D427C, V987C) and single Arg S1/S2 cleavage site), Locked-2 Conformation
7WNM	;	2.7	;	Structure of SARS-CoV-2 Gamma variant receptor-binding domain complexed with high affinity human ACE2 mutant (T27F,R273Q)
7EKC	;	2.8	;	Structure of SARS-CoV-2 Gamma variant spike receptor-binding domain complexed with human ACE2
7CZ4	;	2.64	;	Structure of SARS-CoV-2 macro domain in complex with ADP-ribose
7ADW	;	1.63	;	Structure of SARS-CoV-2 Main Protease bound to 2,4'-Dimethylpropiophenone.
6YNQ	;	1.8	;	Structure of SARS-CoV-2 Main Protease bound to 2-Methyl-1-tetralone.
7ANS	;	1.7	;	Structure of SARS-CoV-2 Main Protease bound to Adrafinil.
7AXO	;	1.65	;	Structure of SARS-CoV-2 Main Protease bound to AR-42.
7AGA	;	1.68	;	Structure of SARS-CoV-2 Main Protease bound to AT7519
6YVF	;	1.6	;	Structure of SARS-CoV-2 Main Protease bound to AZD6482.
7AKU	;	2.5	;	Structure of SARS-CoV-2 Main Protease bound to Calpeptin.
7AOL	;	1.47	;	Structure of SARS-CoV-2 Main Protease bound to Climbazole
7AWW	;	1.65	;	Structure of SARS-CoV-2 Main Protease bound to Clonidine
7A1U	;	1.67	;	Structure of SARS-CoV-2 Main Protease bound to Fusidic Acid.
7AX6	;	1.95	;	Structure of SARS-CoV-2 Main Protease bound to Glutathione isopropyl ester
7AQI	;	1.7	;	Structure of SARS-CoV-2 Main Protease bound to Ifenprodil
7AF0	;	1.7	;	Structure of SARS-CoV-2 Main Protease bound to Ipidacrine.
7AY7	;	1.55	;	Structure of SARS-CoV-2 Main Protease bound to Isofloxythepin
7AWU	;	2.07	;	Structure of SARS-CoV-2 Main Protease bound to LSN2463359.
7AHA	;	1.68	;	Structure of SARS-CoV-2 Main Protease bound to Maleate.
7AP6	;	1.78	;	Structure of SARS-CoV-2 Main Protease bound to MUT056399.
7AMJ	;	1.59	;	Structure of SARS-CoV-2 Main Protease bound to PD 168568.
7AXM	;	1.4	;	Structure of SARS-CoV-2 Main Protease bound to Pelitinib
7B83	;	1.8	;	Structure of SARS-CoV-2 Main Protease bound to pyrithione zinc
7ABU	;	1.6	;	Structure of SARS-CoV-2 Main Protease bound to RS102895
7AVD	;	1.8	;	Structure of SARS-CoV-2 Main Protease bound to SEN1269 ligand
7AWR	;	1.34	;	Structure of SARS-CoV-2 Main Protease bound to Tegafur
7AWS	;	1.81	;	Structure of SARS-CoV-2 Main Protease bound to TH-302.
7ARF	;	2.0	;	Structure of SARS-CoV-2 Main Protease bound to thioglucose.
7APH	;	1.65	;	Structure of SARS-CoV-2 Main Protease bound to Tofogliflozin.
7AK4	;	1.63	;	Structure of SARS-CoV-2 Main Protease bound to Tretazicar.
7AQJ	;	2.59	;	Structure of SARS-CoV-2 Main Protease bound to Triglycidyl isocyanurate.
7AQE	;	1.39	;	Structure of SARS-CoV-2 Main Protease bound to UNC-2327
7RFR	;	1.626	;	Structure of SARS-CoV-2 main protease in complex with a covalent inhibitor
7RFS	;	1.91	;	Structure of SARS-CoV-2 main protease in complex with a covalent inhibitor
7RFU	;	2.498	;	Structure of SARS-CoV-2 main protease in complex with a covalent inhibitor
7RFW	;	1.729	;	Structure of SARS-CoV-2 main protease in complex with a covalent inhibitor
7TGR	;	1.68	;	Structure of SARS-CoV-2 main protease in complex with GC376
8DS1	;	2.19	;	Structure of SARS-CoV-2 Mpro in complex with nsp12-nsp13 (C12) cut site sequence
8DS2	;	1.6	;	Structure of SARS-CoV-2 Mpro in complex with the nsp13-nsp14 (C13) cut site sequence (form 2)
7U28	;	1.679	;	Structure of SARS-CoV-2 Mpro Lambda (G15S) in complex with Nirmatrelvir (PF-07321332)
7U29	;	2.088	;	Structure of SARS-CoV-2 Mpro mutant (K90R) in complex with Nirmatrelvir (PF-07321332)
7TLL	;	1.63	;	Structure of SARS-CoV-2 Mpro Omicron P132H in complex with Nirmatrelvir (PF-07321332)
7K7P	;	1.77	;	Structure of SARS-CoV-2 nonstuctural protein 1
7LW3	;	2.3	;	Structure of SARS-CoV-2 nsp16/nsp10 complex in presence of Cap-1 analog (m7GpppAmU) and SAH
7LW4	;	2.5	;	Structure of SARS-CoV-2 nsp16/nsp10 complex in presence of S-adenosyl-L-homocysteine (SAH)
6WKS	;	1.8	;	Structure of SARS-CoV-2 nsp16/nsp10 in complex with RNA cap analogue (m7GpppA) and S-adenosylmethionine
8AZL	;	2.2	;	Structure of SARS-CoV-2 NSP3 macrodomain in complex with 2'-deoxy-2'-fluoro-ADPR
8AZI	;	1.9	;	Structure of SARS-CoV-2 NSP3 macrodomain in complex with 2'-deoxy-ADPR
8AZM	;	2.1	;	Structure of SARS-CoV-2 NSP3 macrodomain in complex with 8Br-ADPR
8AZD	;	2.0	;	Structure of SARS-CoV-2 NSP3 macrodomain in complex with ADPR
8AZN	;	1.6	;	Structure of SARS-CoV-2 NSP3 macrodomain in complex with alpha-1-O-Me-ADPR
8AZO	;	1.9	;	Structure of SARS-CoV-2 NSP3 macrodomain in complex with beta-ethyl-ADP
8AZP	;	1.6	;	Structure of SARS-CoV-2 NSP3 macrodomain in complex with beta-methyl-ADP
8AZC	;	0.93	;	Structure of SARS-CoV-2 NSP3 macrodomain in the apo form
6WZO	;	1.42	;	Structure of SARS-CoV-2 Nucleocapsid dimerization domain, P1 form
6WZQ	;	1.45	;	Structure of SARS-CoV-2 Nucleocapsid dimerization domain, P21 form
7UW3	;	1.7	;	Structure of SARS-CoV-2 Nucleocapsid Protein N-Terminal Domain
7PKU	;		;	Structure of SARS-CoV-2 nucleoprotein in dynamic complex with its viral partner nsp3a
8F0G	;	3.35	;	Structure of SARS-CoV-2 Omicron BA.1 spike in complex with antibody Fab 1C3
8DZI	;	3.5	;	Structure of SARS-CoV-2 Omicron BA.1.1.529 Spike trimer with one RBD down in complex with the Fab fragment of human neutralizing antibody MB.02
8DZH	;	3.2	;	Structure of SARS-CoV-2 Omicron BA.1.1.529 Spike trimer with two RBDs down in complex with the Fab fragment of human neutralizing antibody MB.02
8H5C	;	2.9	;	Structure of SARS-CoV-2 Omicron BA.2.75 RBD in complex with human ACE2
8EQU	;	2.8	;	Structure of SARS-CoV-2 Orf3a in late endosome/lysosome-like environment, Saposin A nanodisc
8EQJ	;	3.0	;	Structure of SARS-CoV-2 Orf3a in late endosome/lysosome-like membrane environment, MSP1D1 nanodisc
8EQT	;	3.4	;	Structure of SARS-CoV-2 Orf3a in plasma membrane-like environment, MSP1D1 nanodisc
7XMN	;	2.3	;	Structure of SARS-CoV-2 ORF8
7JTL	;	2.04	;	Structure of SARS-CoV-2 ORF8 accessory protein
7QCJ	;	1.84	;	Structure of SARS-CoV-2 Papain-like Protease bound to N-(2,4-dihydroxybenzylidene)-thiosemicarbazone
7QCK	;	1.92	;	Structure of SARS-CoV-2 Papain-like Protease bound to N-(2,5-dihydroxybenzylidene)-thiosemicarbazone
7QCG	;	1.75	;	Structure of SARS-CoV-2 Papain-like Protease bound to N-(2-pyrrolidyl)-3,4,5-trihydroxybenzoylhydrazone
7QCI	;	1.76	;	Structure of SARS-CoV-2 Papain-like Protease bound to N-(3,4-dihydroxybenzylidene)-thiosemicarbazone
7QCH	;	1.88	;	Structure of SARS-CoV-2 Papain-like Protease bound to N-(3,5-dimethoxy-4-hydroxybenzyliden)thiosemicarbazone
7QCM	;	1.77	;	Structure of SARS-CoV-2 Papain-like Protease bound to N-(3-methoxy-4-hydroxy-acetophenone)thiosemicarbazone
7NFV	;	1.42	;	Structure of SARS-CoV-2 Papain-like protease PLpro
7OFU	;	1.72	;	Structure of SARS-CoV-2 Papain-like protease PLpro in complex with 3, 4-Dihydroxybenzoic acid, methyl ester
7OFS	;	1.9	;	Structure of SARS-CoV-2 Papain-like protease PLpro in complex with 4-(2-hydroxyethyl)phenol
7OFT	;	1.95	;	Structure of SARS-CoV-2 Papain-like protease PLpro in complex with p-hydroxybenzaldehyde
6XEZ	;	3.5	;	Structure of SARS-CoV-2 replication-transcription complex bound to nsp13 helicase - nsp13(2)-RTC
8GY6	;		;	Structure of SARS-CoV-2 RNA-dependent RNA polymerase with gossypol binding
7LCN	;	3.35	;	Structure of SARS-CoV-2 S protein in complex with N-terminal domain antibody DH1050.1
7LAB	;	2.97	;	Structure of SARS-CoV-2 S protein in complex with N-terminal domain antibody DH1052
7LAA	;	3.42	;	Structure of SARS-CoV-2 S protein in complex with Receptor Binding Domain antibody DH1041
7LD1	;	3.4	;	Structure of SARS-CoV-2 S protein in complex with Receptor Binding Domain antibody DH1047
7MTE	;	3.2	;	Structure of SARS-CoV-2 S2P spike at pH 7.4 refolded by low-pH treatment
6XLU	;	2.4	;	Structure of SARS-CoV-2 spike at pH 4.0
7JWY	;	2.5	;	Structure of SARS-CoV-2 spike at pH 4.5
6XM5	;	3.1	;	Structure of SARS-CoV-2 spike at pH 5.5, all RBDs down
6XM3	;	2.9	;	Structure of SARS-CoV-2 spike at pH 5.5, single RBD up, conformation 1
6XM4	;	2.9	;	Structure of SARS-CoV-2 spike at pH 5.5, single RBD up, conformation 2
7M3I	;	2.8	;	Structure of SARS-CoV-2 spike protein receptor binding domain in complex with a neutralizing antibody, CV2-75 Fab
6XE1	;	2.75	;	Structure of SARS-CoV-2 spike protein receptor binding domain in complex with a potent neutralizing antibody, CV30 Fab
6ZP1	;	3.3	;	Structure of SARS-CoV-2 Spike Protein Trimer (K986P, V987P, single Arg S1/S2 cleavage site) in Closed State
6ZP2	;	3.1	;	Structure of SARS-CoV-2 Spike Protein Trimer (K986P, V987P, single Arg S1/S2 cleavage site) in Locked State
6ZP0	;	3.0	;	Structure of SARS-CoV-2 Spike Protein Trimer (single Arg S1/S2 cleavage site) in Closed State
7XU3	;	3.0	;	Structure of SARS-CoV-2 Spike Protein with Engineered x3 Disulfide (x3(D427C, V987C) and single Arg S1/S2 cleavage site), Closed Conformation
7XU6	;	2.9	;	Structure of SARS-CoV-2 Spike Protein with Engineered x3 Disulfide (x3(D427C, V987C) and single Arg S1/S2 cleavage site), incubated in Low pH after 40-Day Storage in PBS, Locked-2 Conformation
7XTZ	;	2.8	;	Structure of SARS-CoV-2 Spike Protein with Engineered x3 Disulfide (x3(D427C, V987C) and single Arg S1/S2 cleavage site), Locked-1 Conformation
7XU1	;	3.0	;	Structure of SARS-CoV-2 Spike Protein with Engineered x3 Disulfide (x3(D427C, V987C) and single Arg S1/S2 cleavage site), Locked-122 Conformation
7XU2	;	3.2	;	Structure of SARS-CoV-2 Spike Protein with Engineered x3 Disulfide (x3(D427C, V987C) and single Arg S1/S2 cleavage site), Locked-2 Conformation
7XU0	;	2.9	;	Structure of SARS-CoV-2 Spike Protein with Engineered x3 Disulfide (x3(D427C, V987C) and single Arg S1/S2 cleavage site), Locked-211 Conformation
7L4Z	;	3.96	;	Structure of SARS-CoV-2 spike RBD in complex with cyclic peptide
8HGM	;	3.4	;	Structure of SARS-CoV-2 spike RBD in complex with neutralizing antibody NIV-11
7YH6	;	3.4	;	Structure of SARS-CoV-2 spike RBD in complex with neutralizing antibody NIV-8
7DMU	;	3.2	;	Structure of SARS-CoV-2 spike receptor-binding domain complexed with high affinity ACE2 mutant 3N39
7W6U	;	2.56	;	Structure of SARS-CoV-2 spike receptor-binding domain complexed with its receptor equine ACE2
7WA1	;	2.9	;	Structure of SARS-CoV-2 spike receptor-binding domain F486L mutation complexed with American mink ACE2
7EKE	;	2.7	;	Structure of SARS-CoV-2 spike receptor-binding domain F486L mutation complexed with human ACE2
7EFP	;	2.698	;	Structure of SARS-CoV-2 spike receptor-binding domain in complex with high affinity ACE2 mutant (S19W,N330Y)
7EFR	;	2.494	;	Structure of SARS-CoV-2 spike receptor-binding domain in complex with high affinity ACE2 mutant (T27W,N330Y)
7W8S	;	2.85	;	Structure of SARS-CoV-2 spike receptor-binding domain Y453F mutation complexed with American mink ACE2
7EKH	;	2.4	;	Structure of SARS-CoV-2 spike receptor-binding domain Y453F mutation complexed with human ACE2
8F0H	;	3.18	;	Structure of SARS-CoV-2 spike with antibody Fabs 2A10 and 1H2 (Local refinement of the RBD and Fabs 1H2 and 2A10)
8IOU	;	3.18	;	Structure of SARS-CoV-2 XBB.1 spike glycoprotein in complex with ACE2 (1-up state)
8IOV	;	3.29	;	Structure of SARS-CoV-2 XBB.1 spike RBD in complex with ACE2
8JYN	;	3.04	;	Structure of SARS-CoV-2 XBB.1.5 spike glycoprotein in complex with ACE2 (1-up state)
8JYO	;	3.2	;	Structure of SARS-CoV-2 XBB.1.5 spike glycoprotein in complex with ACE2 (2-up state)
8JYP	;	3.38	;	Structure of SARS-CoV-2 XBB.1.5 spike RBD in complex with ACE2
7MBI	;	2.15	;	Structure of SARS-CoV2 3CL protease covalently bound to peptidomimetic inhibitor
8UTE	;	1.45	;	Structure of SARS-Cov2 3CLPro in complex with Compound 27
8UPV	;	1.57	;	Structure of SARS-Cov2 3CLPro in complex with Compound 33
8UPW	;	1.44	;	Structure of SARS-Cov2 3CLPro in complex with Compound 34
8UPS	;	2.44	;	Structure of SARS-Cov2 3CLPro in complex with Compound 5
7NXH	;	2.1	;	Structure of SARS-CoV2 NSP5 (3C-like proteinase) determined in-house
8EUA	;	3.1	;	Structure of SARS-CoV2 PLpro bound to a covalent inhibitor
7DG6	;	2.4	;	Structure of SARS-Cov2-Mpro-1-302
6XKR	;	2.59	;	Structure of Sasanlimab Fab in complex with PD-1
7SMH	;	1.65	;	Structure of SASG A-domain (residues 163-419) from Staphylococcus aureus
7RWS	;	1.8	;	Structure of SAVED domain of Cap5 from Lactococcus lactis in complex with cGAMP
1NQM	;	1.7	;	Structure of Savm-W120K, streptavidin mutant
3MQE	;	2.8	;	Structure of SC-75416 bound at the COX-2 active site
1S5G	;	3.1	;	Structure of Scallop myosin S1 reveals a novel nucleotide conformation
5XBM	;	3.501	;	Structure of SCARB2-JL2 complex
6OJJ	;	2.406	;	Structure of ScAtg3 with truncations in N-terminal and flexible region (FR)
1N4X	;	1.7	;	Structure of scFv 1696 at acidic pH
6JLH	;	2.37	;	Structure of SCGN in complex with a Snap25 peptide
8GYD	;	1.7	;	Structure of Schistosoma japonicum Glutathione S-transferase bound with the ligand complex of 16
2V6O	;	2.2	;	Structure of Schistosoma mansoni Thioredoxin-Glutathione Reductase (SmTGR)
4P27	;	2.16	;	Structure of Schistosoma mansoni venom allergen-like protein 4 (SmVAL4)
7Y8K	;	2.08	;	Structure of ScIRED wild-type from Streptomyces clavuligerus
7Y8L	;	2.41	;	Structure of ScIRED-R2-V3 from Streptomyces clavuligerus in complex with 5-(2,5-difluorophenyl)-3,4-dihydro-2H-pyrrole
7Y8M	;	2.28	;	Structure of ScIRED-R2-V3 from Streptomyces clavuligerus in complex with 5-(3-fluorophenyl)-3,4-dihydro-2H-pyrrole
7Y8N	;	2.2	;	Structure of ScIRED-R3-V4 from Streptomyces clavuligerus in complex with 5-(2,5-difluorophenyl)-3,4-dihydro-2H-pyrrole
7Y8O	;	2.3	;	Structure of ScIRED-R3-V4 from Streptomyces clavuligerus in complex with 5-(3-fluorophenyl)-3,4-dihydro-2H-pyrrole
6XRR	;	1.9	;	Structure of SciW bound to the Rhs1 Transmembrane Domain from Salmonella typhimurium
4OY6	;	1.29	;	Structure of ScLPMO10B in complex with copper.
4OY8	;	1.4	;	Structure of ScLPMO10B in complex with zinc.
3FIW	;	2.2	;	Structure of SCO0253, a Tetr-family transcriptional regulator from Streptomyces coelicolor
7AA8	;	1.25	;	Structure of SCOC LIR bound to GABARAP
7AA7	;	1.45	;	Structure of SCOC pS12/pS18 LIR motif bound to GABARAPL1
7AA9	;	1.72	;	Structure of SCOC pT13/pT15 LIR motif bound to GABARAPL1
1SN1	;	1.7	;	STRUCTURE OF SCORPION NEUROTOXIN BMK M1
1SN4	;	1.3	;	STRUCTURE OF SCORPION NEUROTOXIN BMK M4
1SNB	;	1.9	;	STRUCTURE OF SCORPION NEUROTOXIN BMK M8
2SN3	;	1.2	;	STRUCTURE OF SCORPION TOXIN VARIANT-3 AT 1.2 ANGSTROMS RESOLUTION
1S2K	;	2.0	;	Structure of SCP-B a member of the Eqolisin family of Peptidases in a complex with a Tripeptide Ala-Ile-His
1S2B	;	2.1	;	Structure of SCP-B the first member of the Eqolisin family of Peptidases to have its structure determined
6DU2	;	2.5	;	Structure of Scp1 D96N bound to REST-pS861/4 peptide
6DU3	;	2.58	;	Structure of Scp1 D96N bound to REST-pS861/4 peptide
5O6B	;	2.029	;	Structure of ScPif1 in complex with GGGTTTT and ADP-AlF4
5O6D	;	3.283	;	Structure of ScPif1 in complex with polydT and ATPgS
5O6E	;	3.345	;	Structure of ScPif1 in complex with TTTGGGTT and ADP-AlF4
2R5Y	;	2.6	;	Structure of Scr/Exd complex bound to a consensus Hox-Exd site
2R5Z	;	2.6	;	Structure of Scr/Exd complex bound to a DNA sequence derived from the fkh gene
5FGU	;	1.896	;	Structure of Sda1 nuclease apoprotein as an EGFP fixed-arm fusion
5FGW	;	1.95	;	Structure of Sda1 nuclease with bound zinc ion
2IXS	;	2.0	;	Structure of SdaI restriction endonuclease
8EFW	;	2.81	;	Structure of SdeA DUB Domain disulfide crosslinked with Ubiquitin
2KEC	;		;	Structure of SDF-1/CXCL12
2KED	;		;	Structure of SDF-1/CXCL12
2KEE	;		;	Structure of SDF-1/CXCL12
2K03	;		;	Structure of SDF1 in complex with the CXCR4 N-terminus containing a sulfotyrosine at postition 21
2K04	;		;	Structure of SDF1 in complex with the CXCR4 N-terminus containing no sulfotyrosines
2K05	;		;	Structure of SDF1 in complex with the CXCR4 N-terminus containing sulfotyrosines at postitions 7, 12 and 21
5KYN	;	2.552	;	Structure of Sec23 and TANGO1 complex
2QTV	;	2.5	;	Structure of Sec23-Sar1 complexed with the active fragment of Sec31
8QOA	;	2.0	;	Structure of SecM-stalled Escherichia coli 70S ribosome
7K0C	;	3.3	;	Structure of Secretory IgM Core
7AE4	;	3.31	;	Structure of Sedimentibacter hydroxybenzoicus vanillic acid decarboxylase (ShVdcCD) in closed form
7AE5	;	2.19	;	Structure of Sedimentibacter hydroxybenzoicus vanillic acid decarboxylase (ShVdcCD) in open form
7AE7	;	2.66	;	Structure of Sedimentibacter hydroxybenzoicus vanillic acid decarboxylase (ShVdcCD) in open form, with truncated ShVdcD (V59X)
2Y3J	;	1.99	;	Structure of segment AIIGLM from the amyloid-beta peptide (Ab, residues 30-35)
2Y2A	;	1.91	;	Structure of segment KLVFFA from the amyloid-beta peptide (Ab, residues 16-21), alternate polymorph I
2Y29	;	2.3	;	Structure of segment KLVFFA from the amyloid-beta peptide (Ab, residues 16-21), alternate polymorph III
2Y3K	;	1.9	;	Structure of segment MVGGVVIA from the amyloid-beta peptide (Ab, residues 35-42), alternate polymorph 1
2Y3L	;	2.1	;	Structure of segment MVGGVVIA from the amyloid-beta peptide (Ab, residues 35-42), alternate polymorph 2
5LZC	;	4.8	;	Structure of SelB-Sec-tRNASec bound to the 70S ribosome in the codon reading state (CR)
5LZD	;	3.4	;	Structure of SelB-Sec-tRNASec bound to the 70S ribosome in the GTPase activated state (GA)
5LZB	;	5.3	;	Structure of SelB-Sec-tRNASec bound to the 70S ribosome in the initial binding state (IB)
4A0F	;	2.714	;	Structure of selenomethionine substituted bifunctional DAPA aminotransferase-dethiobiotin synthetase from Arabidopsis thaliana in its apo form.
5GN3	;	2.281	;	Structure of selenomethionine-labelled Uracil DNA glycosylase (BdiUNG) from Bradyrhizobium diazoefficiens
2O6C	;	1.7	;	Structure of selenomethionyl rTp34 from Treponema pallidum
8Q3C	;	3.1	;	Structure of Selenomonas ruminantium lactate dehydrogenase I85R mutant
2PT0	;	1.7	;	Structure of Selenomonas ruminantium PTP-like phytase with the active site cysteine oxidized to cysteine-sulfonic acid
8A8N	;	6.7	;	Structure of self-assembling engineered protein nanocage (EPN) fused with hepatitis A pX protein
3ZXX	;	1.95	;	Structure of self-cleaved protease domain of PatA
4B9J	;	2.542	;	Structure of self-complemented CssA subunit of enterotoxigenic Escherichia coli colonization factor CS6
2IMD	;	1.6	;	Structure of SeMet 2-hydroxychromene-2-carboxylate isomerase (HCCA isomerase)
1MWR	;	2.45	;	Structure of SeMet Penicillin binding protein 2a from methicillin resistant Staphylococcus aureus strain 27r (trigonal form) at 2.45 A resolution.
5ZVV	;	2.2	;	Structure of SeMet-phAimR
5ZW5	;	2.4	;	Structure of SeMet-spAimR
8IHP	;	3.0	;	Structure of Semliki Forest virus VLP in complex with the receptor VLDLR-LA3
8JJQ	;	1.64	;	Structure of SenB in complex with UDP-GalNAc at 1.64 Angstroms resolution
8JJN	;	1.98	;	Structure of SenB in complex with UDP-Glc and PO4- at 1.98 Angstroms resolution
8JJT	;	1.88	;	Structure of SenB in complex with UDP-GlcNAc at 1.88 Angstroms resolution
6KP3	;	2.2	;	STRUCTURE OF SENDAI VIRUS Y3/ALIX-BRO1 DOMAIN COMPLEX
6ADS	;	2.84	;	Structure of Seneca Valley Virus in acidic conditions
6ADT	;	3.22	;	Structure of Seneca Valley Virus in neutral condition
3CJI	;	2.3	;	Structure of Seneca Valley Virus-001
3ZO5	;	2.15	;	Structure of SENP2-Loop1 in complex with preSUMO-2
2I89	;	2.1	;	Structure of septuple mutant of Rat Outer Mitochondrial Membrane Cytochrome B5
1TDL	;	1.8	;	Structure of Ser130Gly SHV-1 beta-lactamase
1S80	;	2.7	;	Structure of Serine Acetyltransferase from Haemophilis influenzae Rd
6UXH	;	1.858	;	Structure of serine hydroxymethyltransferase 8 from Glycine max cultivar Essex complexed with PLP
6UXI	;	2.1	;	Structure of serine hydroxymethyltransferase 8 from Glycine max cultivar Essex complexed with PLP-Glycine
6UXJ	;	1.4	;	Structure of serine hydroxymethyltransferase 8 from Glycine max cultivar Essex complexed with PLP-glycine and 5-formyltetrahydrofolate
6UXK	;	2.1	;	Structure of serine hydroxymethyltransferase 8 from Glycine max cultivar Forrest complexed with PLP
6UXL	;	2.35	;	Structure of serine hydroxymethyltransferase 8 from Glycine max cultivar Forrest complexed with PLP-Glycine
1TOC	;	3.1	;	STRUCTURE OF SERINE PROTEINASE
2PQ2	;	1.82	;	Structure of serine proteinase K complex with a highly flexible hydrophobic peptide at 1.8A resolution
7Z4V	;	1.644	;	Structure of Serine-Threonine kinase STK25 in complex with compound
1S95	;	1.6	;	Structure of serine/threonine protein phosphatase 5
7BPG	;	1.7	;	Structure of serinol nucleic acid - RNA complex
6XEW	;	2.0	;	Structure of Serratia marcescens 2,3-butanediol dehydrogenase
6VSP	;	1.9	;	Structure of Serratia marcescens 2,3-butanediol dehydrogenase mutant Q247A
6XEX	;	1.8	;	Structure of Serratia marcescens 2,3-butanediol dehydrogenase mutant Q247A/V139Q
7C92	;	2.32	;	Structure of Serratia marcescens chitinase B complexed with compound 6k
7CB1	;	1.98	;	Structure of Serratia marcescens chitinase B complexed with compound 6q
6ELU	;	2.3	;	Structure of Serum Resistance Associated protein from T. b. rhodesiense
1N6A	;	1.7	;	Structure of SET7/9
1N6C	;	2.3	;	Structure of SET7/9
8ONT	;	3.66	;	Structure of Setaria italica NRAT in complex with a nanobody
6ICT	;	1.952	;	Structure of SETD3 bound to SAH and methylated actin
6ICV	;	2.15	;	Structure of SETD3 bound to SAH and unmodified actin
6L42	;	3.4	;	Structure of severe fever with thrombocytopenia syndrome virus L protein
1SVQ	;		;	STRUCTURE OF SEVERIN DOMAIN 2 IN SOLUTION
1SVR	;		;	STRUCTURE OF SEVERIN DOMAIN 2 IN SOLUTION
4FXX	;	2.4801	;	Structure of SF1 coiled-coil domain
7BJ9	;	1.21001	;	Structure of Sfh-I with 2-Mercaptomethyl-thiazolidine L-anti-1a
7PU5	;	2.999	;	Structure of SFPQ-NONO complex
8ILQ	;	4.3	;	Structure of SFTSV Gn-Gc heterodimer
5Z6Y	;	1.87	;	Structure of sfYFP48S95C66BPA
5YR3	;	1.901	;	Structure of sfYFP66BPA
7O8C	;	2.0	;	Structure of SGBP BO2743 from Bacteroides ovatus
7NOX	;	1.43	;	Structure of SGBP BO2743 from Bacteroides ovatus in complex with mixed-linked gluco-nonasaccharide
2CA8	;	2.49	;	Structure of Sh28GST in complex with GSH at pH 6.0
2C80	;	2.3	;	Structure of Sh28GST in complex with S-hexyl Glutathione
3THK	;	1.7	;	Structure of SH3 chimera with a type II ligand linked to the chain C-terminal
3JV3	;	2.4	;	Structure of SH3E-DH unit of murine intersectin-1L
7SIP	;	3.0	;	Structure of shaker-IR
7SJ1	;	2.9	;	Structure of shaker-W434F
4LL7	;	2.31	;	Structure of She3p amino terminus.
6Y63	;	1.651	;	Structure of Sheep Polyomavirus VP1 in complex with 3'-Sialyllactosamine
6Y64	;	1.6	;	Structure of Sheep Polyomavirus VP1 in complex with 6'-Sialyllactosamine
2OAW	;	1.9	;	Structure of SHH variant of ""Bergerac"" chimera of spectrin SH3
6X6H	;	1.88	;	Structure of Shiga toxin 2 with a C-terminal peptide of ribosomal P stalk proteins
3MXG	;	2.49	;	Structure of Shiga Toxin type 2 (Stx2) B Pentamer Mutant Q40L
5B0N	;	1.8	;	Structure of Shigella effector LRR domain
5B0T	;	2.0	;	Structure of Shigella effector LRR domain
4BVU	;	2.7	;	Structure of Shigella effector OspG in complex with host UbcH5c- Ubiquitin conjugate
1NPY	;	1.75	;	Structure of shikimate 5-dehydrogenase-like protein HI0607
2DFT	;	2.8	;	Structure of shikimate kinase from Mycobacterium tuberculosis complexed with ADP and Mg at 2.8 angstrons of resolution
2DFN	;	1.93	;	Structure of shikimate kinase from Mycobacterium tuberculosis complexed with ADP and shikimate at 1.9 angstrons of resolution
7BYI	;	2.76	;	Structure of SHMT2 in complex with CBX
8AVJ	;	2.1	;	Structure of short apo agroavidin with the Hoef tail.
8AVP	;	2.87	;	Structure of short biotin complexed agroavidin with the Hoef tail.
3TL0	;	2.05	;	Structure of SHP2 N-SH2 domain in complex with RLNpYAQLWHR peptide
3ZUZ	;	1.5	;	Structure of Shq1p C-terminal domain
1SHV	;	1.98	;	STRUCTURE OF SHV-1 BETA-LACTAMASE
4JPM	;	1.14	;	Structure of SHV-1 beta-lactamase in complex with the 7-alkylidenecephalosporin DCM-1-10 at 1.14 Ang resolution
1VM1	;	2.02	;	STRUCTURE OF SHV-1 BETA-LACTAMASE INHIBITED BY TAZOBACTAM
3T2X	;	1.15	;	Structure of shwanavidin low affinity mutant (F43A)
2V4C	;	1.7	;	Structure of sialic acid binding protein (SiaP) in the presence of KDN
4MMP	;	1.57	;	Structure of Sialic Acid Binding Protein from Pasturella Multocida
6MFL	;	1.9	;	Structure of siderophore binding protein BauB bound to a complex between two molecules of acinetobactin and ferric iron.
6TEK	;	1.8	;	Structure of siderophore interaction domain of IrtAB
7XLZ	;	1.19	;	Structure of siderophore-interacting protein from Vibrio anguillarum
7PQE	;	3.7	;	Structure of SidJ/CaM bound to SdeA in post-catalysis state
7PPO	;	2.91	;	Structure of SidJ/CaM bound to SdeA in pre-glutamylation state
5UI8	;	3.76	;	structure of sigmaN-holoenzyme
4C9F	;	2.6	;	Structure of SIGN-R1 in complex with Sulfodextran
4KWB	;	2.39	;	Structure of signal peptide peptidase A with C-termini bound in the active sites: insights into specificity, self-processing and regulation
2GO5	;	7.4	;	Structure of signal recognition particle receptor (SR) in complex with signal recognition particle (SRP) and ribosome nascent chain complex
1EHC	;	2.26	;	STRUCTURE OF SIGNAL TRANSDUCTION PROTEIN CHEY
1NLO	;		;	STRUCTURE OF SIGNAL TRANSDUCTION PROTEIN, NMR, MINIMIZED AVERAGE STRUCTURE
1NLP	;		;	STRUCTURE OF SIGNAL TRANSDUCTION PROTEIN, NMR, MINIMIZED AVERAGE STRUCTURE
8G04	;	3.4	;	Structure of signaling thrombopoietin-MPL receptor complex
6BEK	;	1.7	;	Structure of sIHF bound to an 8bp palindromic DNA
6LBN	;	2.899	;	Structure of SIL1-bound FEM1C
6LEY	;	2.39	;	Structure of Sil1G bound FEM1C
3JCB	;		;	Structure of Simian Immunodeficiency Virus Envelope Spikes bound with CD4 and Monoclonal Antibody 36D5
3JCC	;		;	Structure of Simian Immunodeficiency Virus Envelope Spikes bound with CD4 and Monoclonal Antibody 36D5
5E06	;	3.001	;	Structure of Sin Nombre virus nucleoprotein in long-axis crystal form
5E05	;	2.3	;	Structure of Sin Nombre virus nucleoprotein in shot-axis crystal form
5VYF	;	2.9	;	Structure of single chain Fel d 1 bound to a neutralizing antibody
6KMY	;		;	Structure of single disulfide peptide Czon1107-P5A
6KNO	;		;	Structure of single disulfide peptide Czon1107-P7A (minor conformer)
6KNP	;		;	Structure of single disulfide peptide Czon1107-P7A(major conformer)
6KN2	;		;	Structure of single disulfide peptide Czon1107-WT (major conformer)
6KN3	;		;	Structure of single disulfide peptide Czon1107-WT (minor conformer)
6FYS	;	2.0	;	Structure of single domain antibody SD83
8EFV	;	2.97	;	Structure of single homo-hexameric Holliday junction ATP-dependent DNA helicase RuvB motor
1KAW	;	2.9	;	STRUCTURE OF SINGLE STRANDED DNA BINDING PROTEIN (SSB)
1SE8	;	1.8	;	Structure of single-stranded DNA-binding protein (SSB) from D. radiodurans
6LP5	;	1.98	;	Structure of Sinonovacula constricta ferritin
3PDH	;	1.8	;	Structure of Sir2Tm bound to a propionylated peptide
6OWT	;	3.8	;	Structure of SIVsmm Nef and SMM tetherin bound to the clathrin adaptor AP-2 complex
6E3B	;	2.5	;	STRUCTURE OF Siw14 CATALYTIC CORE
5XGP	;	2.077	;	structure of Sizzled from Xenopus laevis at 2.08 angstroms resolution
1SQ9	;	1.9	;	Structure of Ski8p, a WD repeat protein involved in mRNA degradation and meiotic recombination
1JTW	;		;	Structure of SL4 RNA from the HIV-1 Packaging Signal
8C02	;	4.09	;	Structure of SLC40/ferroportin in complex with synthetic nanobody Sy3 in occluded conformation
8C03	;	3.89	;	Structure of SLC40/ferroportin in complex with vamifeport and synthetic nanobody Sy12 in outward-facing conformation
8BZY	;	3.24	;	Structure of SLC40/ferroportin in complex with vamifeport and synthetic nanobody Sy3 in occluded conformation
1T3I	;	1.8	;	Structure of slr0077/SufS, the Essential Cysteine Desulfurase from Synechocystis PCC 6803
4ODR	;	1.929	;	Structure of SlyD delta-IF from Thermus thermophilus in complex with FK506
4ODP	;	1.747	;	Structure of SlyD delta-IF from Thermus thermophilus in complex with S2-W23A peptide
4ODQ	;	2.0	;	Structure of SlyD delta-IF from Thermus thermophilus in complex with S3 peptide
4ODO	;	1.599	;	Structure of SlyD from Thermus thermophilus in complex with FK506
4ODL	;	2.916	;	Structure of SlyD from Thermus thermophilus in complex with S2 peptide
4ODN	;	1.598	;	Structure of SlyD from Thermus thermophilus in complex with S2-plus peptide
4ODM	;	1.75	;	Structure of SlyD from Thermus thermophilus in complex with S2-W23A peptide
4ODK	;	1.401	;	Structure of SlyD from Thermus thermophilus in complex with T1 peptide
3EFG	;	2.0	;	Structure of SlyX protein from Xanthomonas campestris pv. campestris str. ATCC 33913
1XTQ	;	2.0	;	Structure of small GTPase human Rheb in complex with GDP
1XTR	;	2.65	;	Structure of small GTPase human Rheb in complex with GppNHp
1XTS	;	2.8	;	Structure of small GTPase human Rheb in complex with GTP
7A4P	;	4.2	;	Structure of small high-light grown Chlorella ohadii photosystem I
2FCJ	;	1.3	;	Structure of small TOPRIM domain protein from Bacillus stearothermophilus.
2I5R	;	1.65	;	Structure of small Toprim domain-containing protein from B. stearothermophilus in complex with Mg2+
2VD4	;	1.9	;	Structure of small-molecule inhibitor of Glmu from Haemophilus influenzae reveals an allosteric binding site
7EL6	;	2.802	;	Structure of SMCR8 bound FEM1B
2W53	;	2.0	;	Structure of SmeT, the repressor of the Stenotrophomonas maltophilia multidrug efflux pump SmeDEF.
6L53	;	3.63	;	Structure of SMG1
6Z3R	;	2.97	;	Structure of SMG1-8-9 kinase complex bound to UPF1-LSQ
6L54	;	3.43	;	Structure of SMG189
4OD6	;	1.199	;	Structure of Smr domain of MutS2 from Deinococcus radiodurans, Mn2+ soaked
2M7Z	;		;	Structure of SmTSP2EC2
6OUX	;	1.94	;	Structure of SMUL_1544, a decarboxylase from Sulfurospirillum multivorans
3TG5	;	2.3	;	Structure of SMYD2 in complex with p53 and SAH
3TG4	;	2.0	;	Structure of SMYD2 in complex with SAM
7ZX7	;	3.4	;	Structure of SNAPc containing Pol II pre-initiation complex bound to U1 snRNA promoter (CC)
7ZX8	;	3.0	;	Structure of SNAPc containing Pol II pre-initiation complex bound to U1 snRNA promoter (OC)
7ZXE	;	3.5	;	Structure of SNAPc containing Pol II pre-initiation complex bound to U1 snRNA promoter (OC)
7ZWD	;	3.0	;	Structure of SNAPc containing Pol II pre-initiation complex bound to U5 snRNA promoter (CC)
7ZWC	;	3.2	;	Structure of SNAPc:TBP-TFIIA-TFIIB sub-complex bound to U5 snRNA promoter
7V1L	;	2.849	;	Structure of sNASP core in complex with H3 alpha3 helix peptide
6IY3	;	3.67	;	Structure of Snf2-MMTV-A nucleosome complex at shl-2 in ADP state
6IY2	;	3.47	;	Structure of Snf2-MMTV-A nucleosome complex at shl2 in ADP state
5Z3V	;	4.22	;	Structure of Snf2-nucleosome complex at shl-2 in ADP BeFx state
5Z3U	;	4.31	;	Structure of Snf2-nucleosome complex at shl2 in ADP BeFx state
5Z3O	;	3.62	;	Structure of Snf2-nucleosome complex in ADP state
5Z3L	;	4.31	;	Structure of Snf2-nucleosome complex in apo state
5BO4	;	2.9	;	Structure of SOCS2:Elongin C:Elongin B from DMSO-treated crystals
3V5U	;	1.9	;	Structure of Sodium/Calcium Exchanger from Methanocaldococcus jannaschii DSM 2661
3V5S	;	3.5	;	Structure of Sodium/Calcium Exchanger from Methanococcus jannaschii
4Y2V	;	2.4	;	Structure of soluble epoxide hydrolase in complex with (4-bromo-3-cyclopropyl-1H-pyrazol-1-yl)acetic acid
4Y2S	;	2.3	;	Structure of soluble epoxide hydrolase in complex with 1-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-ol
4Y2Q	;	2.4	;	Structure of soluble epoxide hydrolase in complex with 1-[3-(trifluoromethyl)pyridin-2-yl]piperazine
4Y2Y	;	2.3	;	Structure of soluble epoxide hydrolase in complex with 2-(2-fluorophenyl)-N-[(5-methyl-2-thienyl)methyl]ethanamine
4Y2R	;	2.45	;	Structure of soluble epoxide hydrolase in complex with 2-(piperazin-1-yl)nicotinonitrile
4Y2X	;	2.5	;	Structure of soluble epoxide hydrolase in complex with 2-({[2-(adamantan-1-yl)ethyl]amino}methyl)phenol
4Y2T	;	2.4	;	Structure of soluble epoxide hydrolase in complex with 3-[4-(benzyloxy)phenyl]propan-1-ol
4Y2P	;	2.05	;	Structure of soluble epoxide hydrolase in complex with N-methyl-1-[3-(pyridin-3-yl)phenyl]methanamine
4Y2J	;	2.15	;	Structure of soluble epoxide hydrolase in complex with N-[(1-methyl-1H-pyrazol-3-yl)methyl]-2-phenylethanamine
4Y2U	;	2.75	;	Structure of soluble epoxide hydrolase in complex with tert-butyl 1,2,3,4-tetrahydroquinolin-3-ylcarbamate
7A26	;	2.98	;	Structure of soluble SmhA crystal form 1 of the tripartite alpha-pore forming toxin, Smh, from Serratia marcescens.
7A27	;	2.57	;	Structure of soluble SmhA crystal form 2 of the tripartite alpha-pore forming toxin, Smh, from Serratia marcescens.
6ZZH	;	1.86	;	Structure of soluble SmhB crystal form 2 of the tripartite alpha-pore forming toxin, Smh, from Serratia marcescens.
6ZZ5	;	1.84	;	Structure of soluble SmhB of the tripartite alpha-pore forming toxin, Smh, from Serratia marcescens.
7XAV	;	2.87	;	Structure of somatostatin receptor 2 bound with lanreotide.
7XAU	;	2.97	;	Structure of somatostatin receptor 2 bound with octreotide.
7XAT	;	2.85	;	Structure of somatostatin receptor 2 bound with SST14.
3MKW	;	2.99	;	Structure of sopB(155-272)-18mer complex, I23 form
3MKZ	;	2.98	;	Structure of SopB(155-272)-18mer complex, P21 form
3MKY	;	2.86	;	Structure of SopB(155-323)-18mer DNA complex, I23 form
6PEI	;	2.1	;	Structure of sorbitol dehydrogenase from Sinorhizobium meliloti 1021
6PEJ	;	2.0	;	Structure of sorbitol dehydrogenase from Sinorhizobium meliloti 1021 bound to sorbitol
5AOG	;	1.27	;	Structure of Sorghum peroxidase
1IJA	;		;	Structure of Sortase
4O8T	;	2.48	;	Structure of sortase A C207A mutant from Streptococcus pneumoniae
4O8L	;	2.7	;	Structure of sortase A from Streptococcus pneumoniae
7S53	;	1.6	;	Structure of Sortase A from Streptococcus pyogenes with the b7-b8 loop sequence from Listeria monocytogenes Sortase A
7S57	;	1.7	;	Structure of Sortase A from Streptococcus pyogenes with the b7-b8 loop sequence of Enterococcus faecalis Sortase A
5GO5	;	1.65	;	Structure of sortase E from Streptomyces avermitilis
5GO6	;	1.7	;	Structure of sortase E T196V mutant from Streptomyces avermitilis
6SG8	;	2.5	;	Structure of Sosuga virus receptor binding protein
3F27	;	2.75	;	Structure of Sox17 Bound to DNA
4Y60	;	1.75	;	Structure of SOX18-HMG/PROX1-DNA
8EFN	;	1.73	;	Structure of Sp-STING3 from Stylophora pistillata coral in complex with 3',3'-cGAMP
1QVN	;	2.7	;	Structure of SP4160 Bound to IL-2 V69A
7U1Y	;	1.81	;	Structure of SPAC806.04c protein from fission yeast bound to AlF4 and Co2+
7T7K	;	1.9	;	Structure of SPAC806.04c protein from fission yeast bound to Co2+
7T7O	;	2.16	;	Structure of SPAC806.04c protein from fission yeast covalently bound to BeF3
7U1V	;	2.1	;	Structure of SPAC806.04c protein from fission yeast covalently bound to BeF3
7U1X	;	2.12	;	Structure of SPAC806.04c protein from fission yeast covalently bound to BeF3
5ZW6	;	2.05	;	Structure of spAimR
6P10	;	2.301	;	Structure of spastin AAA domain (N527C mutant) in complex with JNJ-7706621 inhibitor
6P13	;	2.1	;	Structure of spastin AAA domain (T692A mutant) in complex with a diaminotriazole-based inhibitor (crystal form A)
6P14	;	1.93001	;	Structure of spastin AAA domain (T692A mutant) in complex with a diaminotriazole-based inhibitor (crystal form B)
6P11	;	2.15	;	Structure of spastin AAA domain (T692A mutant) in complex with JNJ-7706621 inhibitor
6P12	;	1.94132	;	Structure of spastin AAA domain (wild-type) in complex with diaminotriazole-based inhibitor
6NYV	;	2.425	;	Structure of spastin AAA domain in complex with a quinazoline-based inhibitor
6NYW	;	2.189	;	Structure of spastin AAA domain N527C mutant in complex with 8-fluoroquinazoline-based inhibitor
6PEK	;	4.2	;	Structure of Spastin Hexamer (Subunit A-E) in complex with substrate peptide
6PEN	;	4.2	;	Structure of Spastin Hexamer (whole model) in complex with substrate peptide
5LJM	;	1.454	;	Structure of SPATA2 PUB domain
7T7N	;	2.0	;	Structure of SPCC1393.13 protein from fission yeast
5KAY	;	1.8	;	Structure of Spelter bound to Zn2+
5XKV	;	1.4	;	structure of sperm whale myoglobin F138W
6LPW	;	2.401	;	Structure of Spermidine disinapoyl transferases(SDT) from Arabidopsis thaliana
6LPV	;	2.297	;	structure of Spermidine hydroxycinnamoyl transferases from Arabidopsis thaliana
5UG4	;	2.15	;	Structure of spermidine N-acetyltransferase SpeG from Vibrio cholerae
6HIP	;	1.2	;	Structure of SPF45 UHM bound to HIV-1 Rev ULM
6G7G	;		;	Structure of SPH (Self-Incompatibility Protein Homologue) proteins, a widespread family of small, highly stable, secreted proteins from plants
1F2E	;	2.3	;	STRUCTURE OF SPHINGOMONAD, GLUTATHIONE S-TRANSFERASE COMPLEXED WITH GLUTATHIONE
6CYW	;	1.95	;	Structure of sphingomyelin in complex with mouse CD1d
8CMX	;	3.46	;	Structure of sphingosine-1-phosphate lyase (SPL) from Aspergillus fumigatus
2N6O	;		;	Structure of spider-venom peptide Hm1a
2IGC	;	1.4	;	Structure of Spin labeled T4 Lysozyme Mutant T115R1A
2Q9D	;	1.4	;	Structure of spin-labeled T4 lysozyme mutant A41R1
2NTH	;	1.8	;	Structure of Spin-labeled T4 Lysozyme Mutant L118R1
2Q9E	;	2.1	;	Structure of spin-labeled T4 lysozyme mutant S44R1
2OU8	;	1.8	;	Structure of Spin-labeled T4 Lysozyme Mutant T115R1 at Room Temperature
2OU9	;	1.55	;	Structure of Spin-labeled T4 Lysozyme Mutant T115R1/R119A
2NTG	;	1.4	;	Structure of Spin-labeled T4 Lysozyme Mutant T115R7
5LWO	;	1.183	;	Structure of Spin-labelled T4 lysozyme mutant L115C-R119C-R1 at 100K
5NX0	;	1.803	;	Structure of Spin-labelled T4 lysozyme mutant L115C-R119C-R1 at room temperature
5JDT	;	1.0	;	Structure of Spin-labelled T4 lysozyme mutant L118C-R1 at 100K
5G27	;	1.61	;	Structure of Spin-labelled T4 lysozyme mutant L118C-R1 at Room Temperature
2AKJ	;	2.8	;	Structure of spinach nitrite reductase
1U4C	;	2.35	;	Structure of spindle checkpoint protein Bub3
3L10	;	2.8	;	Structure of split monoubiquitinated PCNA with ubiquitin in position one
3L0W	;	2.8	;	Structure of split monoubiquitinated PCNA with ubiquitin in position two
3L0X	;	3.0	;	Structure of split yeast PCNA
8SME	;	2.36	;	Structure of SPO1 phage Tad2 in apo state
8SMG	;	2.1	;	Structure of SPO1 phage Tad2 in complex with 1''-2' gcADPR
8SMF	;	1.75	;	Structure of SPO1 phage Tad2 in complex with 1''-3' gcADPR
7AC6	;	3.0	;	Structure of sponge-phase grown PepTst2 collected by rotation serial crystallography on a COC membrane at a synchrotron source
7KLZ	;	3.4	;	Structure of SPOP MATH domain in complex with a Geminin peptide
2WNK	;	1.55	;	Structure of SporoSAG from Toxoplasma gondii
5XJ2	;	2.84	;	Structure of spRlmCD with U747 RNA
5IIT	;	2.134	;	Structure of SPX domain of the yeast inorganic polyphophate polymerase Vtc4 crystallized by carrier-driven crystallization in fusion with the macro domain of human histone macroH2A1.1
5LNC	;	3.29	;	Structure of SPX domain of the yeast inorganic polyphophate polymerase Vtc4 crystallized by carrier-driven crystallization in fusion with the macro domain of human histone macroH2A1.1
7LQY	;	3.19	;	Structure of squirrel TRPV1 in apo state
7LR0	;	3.81	;	Structure of squirrel TRPV1 in complex with capsaicin
7LQZ	;	3.41	;	Structure of squirrel TRPV1 in complex with RTX
4IL6	;	2.1	;	Structure of Sr-substituted photosystem II
2M8D	;		;	Structure of SRSF1 RRM2 in complex with the RNA 5'-UGAAGGAC-3'
7YM1	;	2.36	;	Structure of SsbA protein in complex with the anticancer drug 5-fluorouracil
2I8E	;	1.59	;	Structure of SSO1404, a predicted DNA repair-associated protein from Sulfolobus solfataricus P2
7MPD	;	1.05	;	Structure of SsoPTP bound to 2-chloroethylsulfonate
7MPC	;	1.75	;	Structure of SsoPTP bound to vanadate
1ROW	;	2.0	;	Structure of SSP-19, an MSP-domain protein like family member in Caenorhabditis elegans
1OU9	;	1.8	;	Structure of SspB, a AAA+ protease delivery protein
7DRR	;	3.48	;	Structure of SspE-R100A protein
7DRS	;	3.42	;	Structure of SspE_40224
7DRI	;	2.72	;	Structure of SspE_CTD_41658
2ONW	;	1.51	;	Structure of SSTSSA, a fibril forming peptide from Bovine Pancreatic Ribonuclease (RNase A, residues 15-20)
2EKL	;	1.77	;	Structure of ST1218 protein from Sulfolobus tokodaii
2EKM	;	2.06	;	Structure of ST1219 protein from Sulfolobus tokodaii
5XNL	;	2.7	;	Structure of stacked C2S2M2-type PSII-LHCII supercomplex from Pisum sativum
2M18	;		;	Structure of stacked G-quadruplex formed by human TERRA sequence in potassium solution
2MVJ	;		;	Structure of Stage V sporulation protein M (SpoVM) P9A mutant
4WK3	;	2.6	;	Structure of Staphyloccus aureus PstA
4RGO	;	1.8	;	Structure of Staphylococcal Enterotoxin B bound to the neutralizing antibody 14G8
4RGM	;	2.689	;	Structure of Staphylococcal Enterotoxin B bound to the neutralizing antibody 20B1
4RGN	;	2.698	;	Structure of Staphylococcal Enterotoxin B bound to two neutralizing antibodies, 14G8 and 6D3
1CK1	;	2.6	;	STRUCTURE OF STAPHYLOCOCCAL ENTEROTOXIN C3
6KRY	;	1.8	;	Structure of staphylococcal enterotoxin SEN
4HA8	;	2.65	;	Structure of Staphylococcus aureus biotin protein ligase in complex with biotin acetylene
4DQ2	;	2.5	;	Structure of staphylococcus aureus biotin protein ligase in complex with biotinol-5'-amp
8R04	;	2.1	;	Structure of Staphylococcus aureus ClpP Bound to the Covalent Active Site Inhibitor Cystargolide A
2JGV	;	2.0	;	STRUCTURE OF Staphylococcus aureus D-TAGATOSE-6-PHOSPHATE KINASE in complex with ADP
2JG1	;	2.0	;	STRUCTURE OF Staphylococcus aureus D-TAGATOSE-6-PHOSPHATE KINASE with cofactor and substrate
3QSU	;	2.2	;	Structure of Staphylococcus aureus Hfq in complex with A7 RNA
7O4M	;	1.3	;	Structure of Staphylococcus aureus m1A22-tRNA methyltransferase
7O4O	;	1.52	;	Structure of Staphylococcus aureus m1A22-tRNA methyltransferase in complex with S-adenosylhomocysteine
7O4N	;	1.4	;	Structure of Staphylococcus aureus m1A22-tRNA methyltransferase in complex with S-adenosylmethionine
4K3V	;	2.2	;	Structure of Staphylococcus aureus MntC
6VJP	;	1.711	;	Structure of Staphylococcus aureus peptidoglycan O-acetyltransferase A (OatA) C-terminal catalytic domain
6WN9	;	1.55	;	Structure of Staphylococcus aureus peptidoglycan O-acetyltransferase A (OatA) C-terminal catalytic domain, Zn-bound
6D1R	;	1.995	;	Structure of Staphylococcus aureus RNase P protein at 2.0 angstrom
6OV1	;	1.66	;	Structure of Staphylococcus aureus RNase P protein mutant with defective mRNA degradation activity
1NYQ	;	3.2	;	Structure of Staphylococcus aureus threonyl-tRNA synthetase complexed with an analogue of threonyl adenylate
1NYR	;	2.8	;	Structure of Staphylococcus aureus threonyl-tRNA synthetase complexed with ATP
7PIJ	;	3.78	;	Structure of Staphylococcus capitis divalent metal ion transporter (DMT) by NabFab-fiducial assisted cryo-EM
4OXR	;	2.0	;	Structure of Staphylococcus pseudintermedius metal-binding protein SitA in complex with Manganese
4OXQ	;	2.62	;	Structure of Staphylococcus pseudintermedius metal-binding protein SitA in complex with Zinc
8BXT	;	1.6	;	Structure of StayGold
7TAI	;	3.2	;	Structure of STEAP2 in complex with ligands
1EXZ	;	2.3	;	STRUCTURE OF STEM CELL FACTOR
6WIG	;	2.1	;	Structure of STENOFOLIA Protein HD domain bound with DNA
8J9F	;	2.85	;	Structure of STG-hydrolyzing beta-glucosidase 1 (PSTG1)
8IK3	;	3.3	;	Structure of Stimulator of interferon genes/ligand complex
8GSZ	;	3.65	;	Structure of STING SAVI-related mutant V147L
6WT9	;	2.3	;	Structure of STING-associated CdnE c-di-GMP synthase from Capnocytophaga granulosa
2L2B	;		;	Structure of StnII-Y111N, a mutant of the sea anemone actinoporin Sticholysin II
3GNI	;	2.35	;	Structure of STRAD and MO25
8PXG	;	1.8	;	Structure of Streptactin, solved at wavelength 2.75 A
8GOG	;	2.0	;	Structure of streptavidin mutant (S112Y-K121E) complexed with biotin-cyclopentadienyl-rhodium (III)(Cp*-Rh(III))
3MP9	;	1.2	;	Structure of Streptococcal protein G B1 domain at pH 3.0
1FNU	;	1.94	;	STRUCTURE OF STREPTOCOCCAL PYROGENIC EXOTOXIN A
1FNV	;	3.6	;	STRUCTURE OF STREPTOCOCCAL PYROGENIC EXOTOXIN A
1WPP	;	2.05	;	Structure of Streptococcus gordonii inorganic pyrophosphatase
3QKW	;	2.287	;	Structure of Streptococcus parasangunini Gtf3 glycosyltransferase
5KKY	;	2.393	;	Structure of Streptococcus pneumonia NanA bound with inhibitor 9N3Neu5Ac2en
4MBC	;	1.75	;	Structure of Streptococcus pneumonia ParE in complex with AZ13053807
4MOT	;	1.75	;	Structure of Streptococcus pneumonia pare in complex with AZ13072886
4MB9	;	1.85	;	Structure of Streptococcus pneumonia ParE in complex with AZ13102335
2C1G	;	1.75	;	Structure of Streptococcus pneumoniae peptidoglycan deacetylase (SpPgdA)
2C1I	;	1.35	;	Structure of Streptococcus pneumoniae peptidoglycan deacetylase (SpPgdA) D 275 N Mutant.
5UFY	;	1.12	;	Structure of Streptococcus pneumoniae peptidoglycan O-acetyltransferase A (OatA) C-terminal catalytic domain
5UG1	;	2.1	;	Structure of Streptococcus pneumoniae peptidoglycan O-acetyltransferase A (OatA) C-terminal catalytic domain with methylsulfonyl adduct
2DP5	;	3.55	;	Structure of streptococcus pyogenes bacteriophage-associated hyaluronate lyase Hylp2
3DHO	;	1.8	;	Structure of Streptogramin Acetyltransferase in Complex with an Inhibitor
1GTZ	;	1.6	;	Structure of STREPTOMYCES COELICOLOR TYPE II DEHYDROQUINASE R23A MUTANT IN COMPLEX WITH DEHYDROSHIKIMATE
6AMK	;	3.288	;	Structure of Streptomyces venezuelae BldC-whiI opt complex
2JF7	;	2.48	;	Structure of Strictosidine Glucosidase
4IMB	;	2.703	;	Structure of strictosidine synthase in complex with 2-(1-methyl-1H-indol-3-yl)ethanamine
4IYG	;	2.702	;	Structure of strictosidine synthase in complex with 2-(1H-INDOL-3-YL)-N-METHYLETHANAMINE
2VAQ	;	3.01	;	STRUCTURE OF STRICTOSIDINE SYNTHASE IN COMPLEX WITH INHIBITOR
2V91	;	3.01	;	STRUCTURE OF STRICTOSIDINE SYNTHASE IN COMPLEX WITH STRICTOSIDINE
2FP8	;	2.3	;	Structure of Strictosidine Synthase, the Biosynthetic Entry to the Monoterpenoid Indole Alkaloid Family
2FPB	;	2.8	;	Structure of Strictosidine Synthase, the Biosynthetic Entry to the Monoterpenoid Indole Alkaloid Family
2FPC	;	3.0	;	Structure of Strictosidine Synthase, the Biosynthetic Entry to the Monoterpenoid Indole Alkaloid Family
3MDK	;	1.85	;	Structure of stringent starvation protein A (sspA) from Pseudomonas putida
3LYK	;	2.1	;	Structure of stringent starvation protein A homolog from Haemophilus influenzae
3LYP	;	1.6	;	Structure of stringent starvation protein A homolog from Pseudomonas fluorescens
8U5M	;	2.46	;	Structure of Sts-1 HP domain with rebamipide
8U7E	;	2.63	;	Structure of Sts-1 HP domain with rebamipide derivative
7KDF	;	2.72	;	Structure of Stu2 Bound to dwarf Ndc80c
2XA5	;	1.09	;	Structure of substrate binding protein SiaP (A11N) in complex with Neu5Ac
7Z11	;	3.2	;	Structure of substrate bound DRG1 (AFG2)
4C9M	;	1.801	;	Structure of substrate free, glycerol bound wild type CYP101D1
5GZ1	;	1.78	;	Structure of substrate/cofactor-free D-amino acid dehydrogenase
5FAX	;	2.0	;	Structure of subtilase SubHal from Bacillus halmapalus
5FBZ	;	1.9	;	Structure of subtilase SubHal from Bacillus halmapalus - complex with chymotrypsin inhibitor CI2A
1PXQ	;		;	Structure of Subtilisin A
4KGB	;	2.64	;	Structure of succinyl-CoA: 3-ketoacid CoA transferase from Drosophila melanogaster
5M9X	;	2.349	;	Structure of sucrose phosphorylase from Bifidobacterium adolescentis bound to glycosylated resveratrol
6FME	;	1.51	;	Structure of sucrose phosphorylase from Bifidobacterium adolescentis bound to glycosylated resveratrol
5MAN	;	2.04	;	Structure of sucrose phosphorylase from Bifidobacterium adolescentis bound to nigerose
5MB2	;	1.752	;	Structure of sucrose phosphorylase from Bifidobacterium adolescentis bound to nigerose
6NU7	;	1.9	;	Structure of sucrose-6-phosphate hydrolase from Lactobacillus gasseri
6NU8	;	1.8	;	Structure of sucrose-6-phosphate hydrolase from Lactobacillus gasseri in complex with fructose
4ZGH	;	2.9	;	Structure of Sugar Binding Protein Pneumolysin
2RQZ	;		;	Structure of sugar modified epidermal growth factor-like repeat 12 of mouse Notch-1 receptor
2QFL	;	1.9	;	Structure of SuhB: Inositol monophosphatase and extragenic suppressor from E. coli
7DUT	;	2.1	;	Structure of Sulfolobus solfataricus SegA protein
7DWR	;	2.8	;	Structure of Sulfolobus solfataricus SegA-ADP complex bound to DNA
7DV3	;	2.6	;	Structure of Sulfolobus solfataricus SegA-AMPPNP protein
7DUV	;	3.2	;	Structure of Sulfolobus solfataricus SegB protein
7DV2	;	3.1	;	Structure of Sulfolobus solfataricus SegB-DNA complex
3F8D	;	1.4	;	Structure of Sulfolobus solfataricus Thioredoxin reductase Mutant C147A
3F8P	;	1.8	;	Structure of Sulfolobus solfataricus TrxR-B3
5ZTB	;	2.2	;	Structure of Sulfurtransferase
4DGH	;	1.9	;	Structure of SulP Transporter STAS Domain from Vibrio Cholerae Refined to 1.9 Angstrom Resolution
4DGF	;	1.6	;	Structure of SulP Transporter STAS Domain from Wolinella Succinogenes Refined to 1.6 Angstrom Resolution
2VRR	;	2.22	;	Structure of SUMO modified Ubc9
2N9E	;		;	Structure of SUMO-2 bound to phosphorylated RAP80 SIM
6XOI	;	2.0	;	Structure of SUMO1-ML00752641 adduct bound to SAE
6XOH	;	2.226	;	Structure of SUMO1-ML00789344 adduct bound to SAE
6XOG	;	1.98	;	Structure of SUMO1-ML786519 adduct bound to SAE
3PGE	;	2.8	;	Structure of sumoylated PCNA
7NXX	;	2.189	;	Structure of Superoxide Dismutase 1 (SOD1) in complex with nanobody 2 (Nb2).
1VZG	;	1.69	;	Structure of superoxide reductase bound to ferrocyanide and active site expansion upon X-ray induced photoreduction
1VZH	;	1.69	;	Structure of superoxide reductase bound to ferrocyanide and active site expansion upon X-ray induced photoreduction
1VZI	;	1.15	;	Structure of superoxide reductase bound to ferrocyanide and active site expansion upon X-ray induced photoreduction
7WIT	;	3.21	;	Structure of SUR1 in complex with mitiglinide
6JB3	;	3.53	;	Structure of SUR1 subunit bound with repaglinide
7Y1J	;	3.0	;	Structure of SUR2A in complex with Mg-ATP and repaglinide in the inward-facing conformation.
7Y1K	;	3.8	;	Structure of SUR2A in complex with Mg-ATP, Mg-ADP and repaglinide in the inward-facing conformation
7VLU	;	3.3	;	Structure of SUR2A in complex with Mg-ATP/ADP and P1075
7Y1L	;	3.73	;	Structure of SUR2B in complex with Mg-ATP and repaglinide in the inward-facing conformation
7Y1M	;	3.57	;	Structure of SUR2B in complex with Mg-ATP, Mg-ADP, and repaglinide in the inward-facing conformation
7Y1N	;	3.61	;	Structure of SUR2B in complex with Mg-ATP, Mg-ADP, and repaglinide in the partially occluded state
7VLR	;	3.4	;	Structure of SUR2B in complex with Mg-ATP/ADP
7VLT	;	3.1	;	Structure of SUR2B in complex with Mg-ATP/ADP and levcromakalim
7VLS	;	3.3	;	Structure of SUR2B in complex with MgATP/ADP and P1075
4UJ6	;	3.4	;	Structure of surface layer protein SbsC, domains 1-6
5FTX	;	4.1	;	Structure of surface layer protein SbsC, domains 4-9
4UJ8	;	1.7	;	Structure of surface layer protein SbsC, domains 6-7
5FTY	;	2.6	;	Structure of surface layer protein SbsC, domains 6-7 (monoclinic form)
3BVD	;	3.37	;	Structure of Surface-engineered Cytochrome ba3 Oxidase from Thermus thermophilus under Xenon Pressure, 100psi 5min
2VSQ	;	2.6	;	Structure of surfactin A synthetase C (SrfA-C), a nonribosomal peptide synthetase termination module
7BLL	;	1.76	;	Structure of SusD homologue BT3013 from Bacteroides thetaiotaomicron
4FEM	;	2.5	;	Structure of SusE with alpha-cyclodextrin
1SVO	;	2.6	;	Structure of SV40 large T antigen helicase domain
2LS1	;		;	Structure of Sviceucin, an antibacterial type I lasso peptide from Streptomyces sviceus
6TDA	;	15.0	;	Structure of SWI/SNF chromatin remodeler RSC bound to a nucleosome
7C8W	;	2.77	;	Structure of sybody MR17 in complex with the SARS-CoV-2 S receptor-binding domain (RBD)
7CAN	;	2.94	;	Structure of sybody MR17-K99Y in complex with the SARS-CoV-2 S Receptor-binding domain (RBD)
7D30	;	2.1	;	Structure of sybody MR17-SR31 fusion in complex with the SARS-CoV-2 S Receptor Binding domain (RBD)
7D2Z	;	1.97	;	Structure of sybody SR31 in complex with the SARS-CoV-2 S Receptor Binding domain (RBD)
7C8V	;	2.15	;	Structure of sybody SR4 in complex with the SARS-CoV-2 S Receptor Binding domain (RBD)
2GQ8	;	1.7	;	Structure of SYE1, an OYE homologue from S. ondeidensis, in complex with p-hydroxyacetophenone
2GQ9	;	1.7	;	Structure of SYE1, an OYE homologue from S. oneidensis, in complex with p-hydroxybenzaldehyde
4FX7	;	2.076	;	Structure of Sym2 D9V+D55V+D130V+D176V
4V11	;	1.95	;	Structure of Synaptotagmin-1 with SV2A peptide phosphorylated at Thr84
4OX7	;	2.1001	;	Structure of Synechococcus elongatus PCC 7942 CcmK2
4OX6	;	1.3367	;	Structure of Synechococcus elongatus PCC 7942 CcmK4
8BCM	;	2.15	;	Structure of Synechococcus elongatus PCC 7942 Rubisco recombinantly expressed from E.coli
5Y2W	;	2.2	;	Structure of Synechocystis PCC6803 CcmR regulatory domain in complex with 2-PG
5OY0	;	2.501	;	Structure of synechocystis photosystem I trimer at 2.5A resolution
1M25	;		;	STRUCTURE OF SYNTHETIC 26-MER PEPTIDE CONTAINING 145-169 SHEEP PRION PROTEIN SEGMENT AND C-TERMINAL CYSTEINE IN TFE SOLUTION
6OS0	;	2.9	;	Structure of synthetic nanobody-stabilized angiotensin II type 1 receptor bound to angiotensin II
6OS1	;	2.794	;	Structure of synthetic nanobody-stabilized angiotensin II type 1 receptor bound to TRV023
6OS2	;	2.7	;	Structure of synthetic nanobody-stabilized angiotensin II type 1 receptor bound to TRV026
3Q0H	;	1.7	;	Structure of T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT)
3RQ3	;	2.7	;	Structure of T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) in hexagonal crystal form
1CDJ	;	2.5	;	STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4
1CDY	;	2.0	;	STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4 MUTANT WITH GLY 47 REPLACED BY SER
1CDU	;	2.7	;	STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4 MUTANT WITH PHE 43 REPLACED BY VAL
1WIP	;	4.0	;	STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4, MONOCLINIC CRYSTAL FORM
1WIO	;	3.9	;	STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4, TETRAGONAL CRYSTAL FORM
1WIQ	;	5.0	;	STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4, TRIGONAL CRYSTAL FORM
5HI8	;	1.8	;	Structure of T-type Phycobiliprotein Lyase CpeT from Prochlorococcus phage P-HM1
7NF2	;	1.33	;	Structure of T. atroviride Fdc variant TaFdcV in complex with prFMN crotonic acid adduct
7NEY	;	1.74	;	Structure of T. atroviride Fdc wild-type (TaFdc) in complex with prFMN
7NF1	;	1.77	;	Structure of T. atroviride variant TaFdcV in complex with prFMN-butynoic acid adduct
4WJG	;	3.1	;	Structure of T. brucei haptoglobin-hemoglobin receptor binding to human haptoglobin-hemoglobin
6NL1	;	2.297	;	Structure of T. brucei MERS1 protein in its apo form
6P5R	;	2.45	;	Structure of T. brucei MERS1-GDP complex
6U9X	;	2.6	;	Structure of T. brucei MERS1-RNA complex
8DPK	;	1.94	;	structure of T. brucei RESC5
6MD3	;	2.29	;	Structure of T. brucei RRP44 PIN domain
1LIK	;	2.55	;	STRUCTURE OF T. GONDII ADENOSINE KINASE BOUND TO ADENOSINE
1LII	;	1.73	;	STRUCTURE OF T. GONDII ADENOSINE KINASE BOUND TO ADENOSINE 2 AND AMP-PCP
1LIJ	;	1.86	;	STRUCTURE OF T. GONDII ADENOSINE KINASE BOUND TO PRODRUG 2 7-IODOTUBERCIDIN AND AMP-PCP
6D7A	;	1.13	;	Structure of T. gondii PLP1 beta-rich domain
1YAB	;	3.4	;	Structure of T. maritima FliN flagellar rotor protein
5E7K	;	3.2	;	Structure of T. thermophilus 70S ribosome complex with mRNA and cognate tRNALys in the A-site
5EL4	;	3.15	;	Structure of T. thermophilus 70S ribosome complex with mRNA and tRNALys in the A-site with a U-U mismatch in the first position
5EL6	;	3.1	;	Structure of T. thermophilus 70S ribosome complex with mRNA and tRNALys in the A-site with a U-U mismatch in the first position and antibiotic paromomycin
5EL5	;	3.15	;	Structure of T. thermophilus 70S ribosome complex with mRNA and tRNALys in the A-site with a U-U mismatch in the second position
5EL7	;	3.15	;	Structure of T. thermophilus 70S ribosome complex with mRNA and tRNALys in the A-site with a U-U mismatch in the second position and antibiotic paromomycin
5E81	;	2.95	;	Structure of T. thermophilus 70S ribosome complex with mRNA and tRNALys in the A-site with wobble pair
6GSL	;	3.16	;	Structure of T. thermophilus 70S ribosome complex with mRNA, tRNAfMet and cognate tRNAArg in the A-site
6GSJ	;	2.96	;	Structure of T. thermophilus 70S ribosome complex with mRNA, tRNAfMet and cognate tRNAThr in the A-site
5IBB	;	2.96	;	Structure of T. thermophilus 70S ribosome complex with mRNA, tRNAfMet and cognate tRNAVal in the A-site
5IB8	;	3.13	;	Structure of T. thermophilus 70S ribosome complex with mRNA, tRNAfMet and near-cognate tRNALys with U-G mismatch in the A-site
6GSK	;	3.36	;	Structure of T. thermophilus 70S ribosome complex with mRNA, tRNAfMet and near-cognate tRNAThr in the A-site
5IB7	;	2.99	;	Structure of T. thermophilus 70S ribosome complex with mRNA, tRNAfMet, near-cognate tRNALys with U-G mismatch in the A-site and antibiotic paromomycin
6SJC	;	2.23	;	Structure of T. thermophilus AspRS in Complex with 5'-O-(N-(L-aspartyl)-sulfamoyl)adenosine
6HHX	;	2.1	;	Structure of T. thermophilus AspRS in Complex with 5'-O-(N-(L-aspartyl)-sulfamoyl)cytidine
6HHV	;	2.18	;	Structure of T. thermophilus AspRS in Complex with 5'-O-(N-(L-aspartyl)-sulfamoyl)N3-methyluridine
6HHW	;	2.2	;	Structure of T. thermophilus AspRS in Complex with 5'-O-(N-(L-aspartyl)-sulfamoyl)uridine
3DH7	;	2.97	;	Structure of T. thermophilus IDI-2 in complex with PPi
4PJ0	;	2.437	;	Structure of T.elongatus Photosystem II, rows of dimers crystal packing
5UIZ	;	2.0	;	Structure of T.fusca AA10A
5AEM	;	3.4	;	Structure of t131 N-terminal TPR array
5ZCX	;	2.299	;	Structure of T20/N39
1EGD	;	2.4	;	STRUCTURE OF T255E, E376G MUTANT OF HUMAN MEDIUM CHAIN ACYL-COA DEHYDROGENASE
1EGE	;	2.75	;	STRUCTURE OF T255E, E376G MUTANT OF HUMAN MEDIUM CHAIN ACYL-COA DEHYDROGENASE
1EGC	;	2.6	;	STRUCTURE OF T255E, E376G MUTANT OF HUMAN MEDIUM CHAIN ACYL-COA DEHYDROGENASE COMPLEXED WITH OCTANOYL-COA
3U61	;	3.2	;	Structure of T4 Bacteriophage Clamp Loader Bound To Closed Clamp, DNA and ATP Analog and ADP
3U60	;	3.34	;	Structure of T4 Bacteriophage Clamp Loader Bound To Open Clamp, DNA and ATP Analog
3U5Z	;	3.5	;	Structure of T4 Bacteriophage clamp loader bound to the T4 clamp, primer-template DNA, and ATP analog
8UH7	;	2.628	;	Structure of T4 Bacteriophage clamp loader bound to the T4 clamp, primer-template DNA, and ATP analog
8UK9	;	3.1	;	Structure of T4 Bacteriophage clamp loader mutant D110C bound to the T4 clamp, primer-template DNA, and ATP analog
2HVS	;	2.5	;	Structure of T4 RNA Ligase 2 with Nicked 5'-Adenylated nucleic acid duplex containing a 2'-deoxyribonucleotide at the nick
2HVR	;	2.45	;	Structure of T4 RNA Ligase 2 with Nicked 5'-Adenylated nucleic acid duplex containing a 3'-deoxyribonucleotide at the nick
5UJ0	;	2.3	;	Structure of T4Pnkp 3' phosphatase covalently bound to BeF3
7K5C	;	2.7	;	Structure of T7 DNA ejectosome periplasmic tunnel
6P7E	;	3.001	;	Structure of T7 DNA Polymerase Bound to a Primer/Template DNA and a Peptide that Mimics the C-terminal Tail of the Primase-Helicase
3J4B	;	12.0	;	Structure of T7 gatekeeper protein (gp11)
2LMC	;		;	Structure of T7 transcription factor Gp2-E. coli RNAp jaw domain complex
1W08	;	2.5	;	STRUCTURE OF T70N HUMAN LYSOZYME
4I24	;	1.8	;	Structure of T790M EGFR kinase domain co-crystallized with dacomitinib
3V90	;	2.0	;	Structure of T82M glycogenin mutant truncated at residue 270
3V91	;	2.0	;	Structure of T82M glycogenin mutant truncated at residue 270 complexed with UDP-glucose
2QH1	;	2.0	;	Structure of TA289, a CBS-rubredoxin-like protein, in its Fe+2-bound state
2J4O	;	2.25	;	Structure of TAB1
2W5V	;	1.78	;	Structure of TAB5 alkaline phosphatase mutant His 135 Asp with Mg bound in the M3 site.
2W5W	;	1.79	;	Structure of TAB5 alkaline phosphatase mutant His 135 Asp with Zn bound in the M3 site.
2W5X	;	1.99	;	Structure of TAB5 alkaline phosphatase mutant His 135 Glu with Mg bound in the M3 site.
6RS4	;	1.3	;	Structure of tabersonine synthase - an alpha-beta hydrolase from Catharanthus roseus
7R2F	;	2.3	;	Structure of tabun inhibited acetylcholinesterase in complex with 2-((hydroxyimino)methyl)-1-(5-(4-methyl-3-nitrobenzamido)pentyl)pyridinium
5WXG	;	1.703	;	Structure of TAF PHD finger domain binds to H3(1-15)K4ac
2P6V	;	2.0	;	Structure of TAFH domain of the human TAF4 subunit of TFIID
1GVF	;	1.45	;	Structure of tagatose-1,6-bisphosphate aldolase
8W9V	;	2.9	;	structure of TaHKT2;1 in KCl at 2.9 Angstroms resolution
8W9T	;	2.6	;	Structure of TaHKT2;1 in NaCl at 2.6 Angstroms resolution
8FWM	;	3.49	;	Structure of tail-neck junction of Agrobacterium phage Milano
5Z4A	;	1.637	;	Structure of Tailor in complex with AGU RNA
5Z4D	;	1.803	;	Structure of Tailor in complex with AGUU RNA
5Z4J	;	1.82	;	Structure of Tailor in complex with U4 RNA
5Z4M	;	1.74	;	Structure of TailorD343A with bound UTP and Mg
1TYU	;	1.8	;	STRUCTURE OF TAILSPIKE-PROTEIN
1TYV	;	1.8	;	STRUCTURE OF TAILSPIKE-PROTEIN
1TYW	;	1.8	;	STRUCTURE OF TAILSPIKE-PROTEIN
7NTI	;	1.98	;	Structure of TAK1 in complex with compound 22
7NTH	;	1.97	;	Structure of TAK1 in complex with compound 54
3UGM	;	3.0	;	Structure of TAL effector PthXo1 bound to its DNA target
4EY0	;	2.8	;	Structure of tandem SH2 domains from PLCgamma1
6S5Y	;	2.3	;	Structure of tandemly arrayed consecutive Rib domains (Rib2R) from Group B Streptococcal species Streptococcus agalactiae
4IM0	;	2.4001	;	Structure of Tank-Binding Kinase 1
4IM2	;	2.5001	;	Structure of Tank-Binding Kinase 1
4IM3	;	3.342	;	Structure of Tank-Binding Kinase 1
8EHE	;	1.1	;	Structure of Tannerella forsythia potempin C in complex with mirolase
8EHD	;	1.8	;	Structure of Tannerella forsythia potempin E
8EHB	;	2.4	;	Structure of Tannerella forsythia selenomethionine-derivatized potempin D mutant I53M
8EHC	;	2.0	;	Structure of Tannerella forsythia selenomethionine-derivatized potempin E
1TAQ	;	2.4	;	STRUCTURE OF TAQ DNA POLYMERASE
1LVJ	;		;	STRUCTURE OF TAR RNA COMPLEXED WITH A TAT-TAR INTERACTION NANOMOLAR INHIBITOR THAT WAS IDENTIFIED BY COMPUTATIONAL SCREENING
7NEQ	;	3.12	;	Structure of tariquidar-bound ABCG2
1PCZ	;	2.2	;	STRUCTURE OF TATA-BINDING PROTEIN
8CAQ	;	2.3	;	Structure of Tau filaments Type I from Subacute Sclerosing Panencephalitis
8CAX	;	3.7	;	Structure of Tau filaments Type II from Subacute Sclerosing Panencephalitis
4TQE	;	1.6	;	Structure of tau peptide in complex with Tau5 antibody Fab fragment
5NVB	;		;	Structure of Tau(254-268) bound to F-actin
5N5A	;		;	Structure of Tau(254-290) bound to F-actin
2MZ7	;		;	Structure of Tau(267-312) bound to Microtubules
5N5B	;		;	Structure of Tau(292-319) bound to F-actin
4TPR	;	1.6	;	Structure of Tau5 antibody Fab fragment
8PXH	;	1.77	;	Structure of TauA from E. coli, solved at wavelength 2.375 A
7N16	;	3.2	;	Structure of TAX-4_R421W apo closed state
7N17	;	3.1	;	Structure of TAX-4_R421W apo open state
7N15	;	2.9	;	Structure of TAX-4_R421W w/cGMP open state
5GN0	;	2.9	;	Structure of TAZ-TEAD complex
5NNO	;	2.5	;	Structure of TbALDH3 complexed with NAD and AN3057 aldehyde
2JZK	;		;	Structure of TbCVNH (T. BORCHII CVNH)
6UEQ	;	2.4	;	Structure of TBP bound to C-C mismatch containing TATA site
6NJQ	;	2.75	;	Structure of TBP-Hoogsteen containing DNA complex
1BYF	;	2.0	;	STRUCTURE OF TC14; A C-TYPE LECTIN FROM THE TUNICATE POLYANDROCARPA MISAKIENSIS
7U2P	;	2.596	;	Structure of TcdA GTD in complex with RhoA
1OQV	;	1.3	;	Structure of TcpA, the Type IV pilin subunit from the toxin co-regulated pilus of Vibrio cholerae classical biotype
8CG3	;	2.39	;	Structure of TDP-43 amyloid filament from type A FTLD-TDP (variant 1)
8CGG	;	2.5	;	Structure of TDP-43 amyloid filament from type A FTLD-TDP (variant 2)
8CGH	;	2.68	;	Structure of TDP-43 amyloid filament from type A FTLD-TDP (variant 3)
6W7L	;	1.856	;	Structure of Tdp1 catalytic domain in complex with inhibitor XZ632p
6W4R	;	1.819	;	Structure of Tdp1 catalytic domain in complex with inhibitor XZ633p
6W7K	;	1.7	;	Structure of Tdp1 catalytic domain in complex with inhibitor XZ634p
6W7J	;	1.489	;	Structure of Tdp1 catalytic domain in complex with inhibitor XZ635p
8P5P	;	1.9	;	Structure of TECPR1 N-terminal DysF domain
5FSB	;	1.65	;	Structure of tectonin 2 from laccaria bicolor in complex with 2-o-methyl-methyl-seleno-beta-l-fucopyranoside
5FSC	;	1.95	;	Structure of tectonin 2 from Laccaria bicolor in complex with allyl- alpha_4-methyl-mannoside
5UKH	;	1.98	;	Structure of TelC from Streptococcus intermedius B196
6G3S	;	2.3	;	Structure of tellurium-centred Anderson-Evans polyoxotungstate (TEW) bound to the nucleotide binding domain of HSP70. Second structure of two TEW-HSP70 structures deposited.
6G3R	;	1.4	;	Structure of tellurium-centred Anderson-Evans polyoxotungstate (TEW) bound to the nucleotide binding domain of HSP70. Structure one of two TEW-HSP70 structures deposited.
6ZDQ	;	2.98	;	Structure of telomerase from Candida albicans in complexe with TWJ fragment of telomeric RNA
6ZDU	;	3.45	;	Structure of telomerase from Candida albicans in complexe with TWJ fragment of telomeric RNA
6ZDP	;	2.85	;	Structure of telomerase from Candida Tropicalis in complexe with TWJ fragment of telomeric RNA
8RQU	;	2.9	;	Structure of TEM1 beta-lactamase variant 70.a
1YAF	;	2.6	;	Structure of TenA from Bacillus subtilis
1JAE	;	1.65	;	STRUCTURE OF TENEBRIO MOLITOR LARVAL ALPHA-AMYLASE
1TMQ	;	2.5	;	STRUCTURE OF TENEBRIO MOLITOR LARVAL ALPHA-AMYLASE IN COMPLEX WITH RAGI BIFUNCTIONAL INHIBITOR
1YAD	;	2.1	;	Structure of TenI from Bacillus subtilis
4K9A	;	2.264	;	Structure of Ternary Complex of cGAS with dsDNA and Bound 5 -pG(2 ,5 )pA
7V0R	;	2.51	;	Structure of Ternary Complex of cGAS with dsDNA and Bound 5 -ppcpG(2 ,5 )pA
4K99	;	1.95	;	Structure of Ternary Complex of cGAS with dsDNA and Bound 5 -pppdG(2 ,5 )pdG
4K98	;	1.94	;	Structure of Ternary Complex of cGAS with dsDNA and Bound 5 -pppG(2 ,5 )pG
7UYZ	;	2.49	;	Structure of Ternary Complex of cGAS with dsDNA and Bound 5 -pppG(2 ,5 )pG
7UZR	;	2.7	;	Structure of Ternary Complex of cGAS with dsDNA and Bound 5 -pppG(2 ,5 )pG
7V0C	;	2.57	;	Structure of Ternary Complex of cGAS with dsDNA and Bound 5 -pppG(2 ,5 )pG
7V0W	;	2.66	;	Structure of Ternary Complex of cGAS with dsDNA and Bound 5 -pppG(2,5 )pA
8EAE	;	2.56	;	Structure of Ternary Complex of cGAS with dsDNA and Bound 5-pppG(2,5)pI
8ECC	;	2.44	;	Structure of Ternary Complex of cGAS with dsDNA and Bound 5-pppI(2,5)pA
4K97	;	2.41	;	Structure of Ternary Complex of cGAS with dsDNA and Bound ATP
4K9B	;	2.26	;	Structure of Ternary Complex of cGAS with dsDNA and Bound c[G(2 ,5 )pA(3 ,5 )p]
1FJX	;	2.26	;	STRUCTURE OF TERNARY COMPLEX OF HHAI METHYLTRANSFERASE MUTANT (T250G) IN COMPLEX WITH DNA AND ADOHCY
1CSC	;	1.7	;	Structure of ternary complexes of citrate synthase with D-and L-malate: Mechanistic implications
2CSC	;	1.7	;	Structure of ternary complexes of CITRATE SYNTHASE WITH D-AND L-MALATE: mechanistic implications
3CSC	;	1.9	;	STRUCTURE OF TERNARY COMPLEXES OF CITRATE SYNTHASE WITH D-AND L-MALATE: MECHANISTIC IMPLICATIONS
4CSC	;	1.9	;	STRUCTURE OF TERNARY COMPLEXES OF CITRATE SYNTHASE WITH D-AND L-MALATE: MECHANISTIC IMPLICATIONS
6E53	;	2.8	;	Structure of TERT in complex with a novel telomerase inhibitor
2OC2	;	2.25	;	Structure of testis ACE with RXPA380
3ZQF	;	2.56	;	Structure of Tetracycline repressor in complex with antiinducer peptide-TAP1
3ZQG	;	2.45	;	Structure of Tetracycline repressor in complex with antiinducer peptide-TAP2
3ZQI	;	1.5	;	Structure of Tetracycline repressor in complex with inducer peptide- TIP2
3ZQH	;	1.6	;	Structure of Tetracycline repressor in complex with inducer peptide- TIP3
8HR9	;	3.03	;	Structure of tetradecameric RdrA ring
8HRB	;	3.78	;	Structure of tetradecameric RdrA ring in RNA-loading state
1F4J	;	2.4	;	STRUCTURE OF TETRAGONAL CRYSTALS OF HUMAN ERYTHROCYTE CATALASE
1IEE	;	0.94	;	STRUCTURE OF TETRAGONAL HEN EGG WHITE LYSOZYME AT 0.94 A FROM CRYSTALS GROWN BY THE COUNTER-DIFFUSION METHOD
6FRQ	;	1.69	;	Structure of tetragonal Hen Egg-White Lysozyme co-crystallized in presence of 100 mM Tb-Xo4 and 100 mM Potassium sodium tartrate tetrahydrate.
5DL9	;	1.38	;	Structure of Tetragonal Lysozyme in complex with Iodine solved by UWO Students
5DLA	;	1.22	;	Structure of Tetragonal Lysozyme solved by UWO Students
3FSX	;	2.15	;	Structure of tetrahydrodipicolinate N-succinyltransferase (Rv1201c; DapD) from Mycobacterium tuberculosis
3FSY	;	1.97	;	Structure of tetrahydrodipicolinate N-succinyltransferase (Rv1201c;DapD) in complex with succinyl-CoA from Mycobacterium tuberculosis
5DFM	;	2.301	;	Structure of Tetrahymena telomerase p19 fused to MBP
5DFN	;	2.382	;	Structure of Tetrahymena Telomerase P45 C-terminal domain
8U4T	;	3.38	;	Structure of tetrameric CXCR4 in complex with REGN7663 Fab
5U1C	;	3.9	;	Structure of tetrameric HIV-1 Strand Transfer Complex Intasome
5JM1	;	1.95	;	Structure of tetrameric jacalin complexed with a trisaccharide, Gal alpha-(1,3) Gal beta-(1,4) Gal
5J51	;	1.67	;	Structure of tetrameric jacalin complexed with Gal alpha-(1,4) Gal
5J4X	;	1.65	;	Structure of tetrameric jacalin complexed with Gal beta-(1,3) Gal-beta-OMe
5J50	;	2.05	;	Structure of tetrameric jacalin complexed with Gal beta-(1,3) GalNAc-alpha-OPNP
5J4T	;	1.94	;	Structure of tetrameric jacalin complexed with GlcNAc beta-(1,3) Gal-beta-OMe
5EGQ	;	2.5	;	Structure of tetrameric rat phenylalanine hydroxylase mutant R270K, residues 25-453
5FGJ	;	3.6	;	Structure of tetrameric rat phenylalanine hydroxylase, residues 1-453
6UE8	;	3.0	;	Structure of tetrameric sIgA complex (Class 1)
6UE9	;	2.9	;	Structure of tetrameric sIgA complex (Class 2)
8FFI	;	2.7	;	Structure of tetramerized MapSPARTA upon guide RNA-mediated target DNA binding
7KS6	;		;	STRUCTURE OF TETRASACCHARIDE BUILDING BLOCK OF A SULFATED FUCAN FROM LYTECHINUS VARIEGATUS
1TBE	;	2.4	;	STRUCTURE OF TETRAUBIQUITIN SHOWS HOW MULTIUBIQUITIN CHAINS CAN BE FORMED
7Q60	;	3.13	;	Structure of TEV cleaved A2ML1 (A2ML1-TE)
7Q62	;	3.18	;	Structure of TEV cleaved A2ML1 dimer (A2ML1-TT dimer)
7Q61	;	2.88	;	Structure of TEV conjugated A2ML1 (A2ML1-TC)
7K01	;	3.9	;	Structure of TFIIH in TFIIH/Rad4-Rad23-Rad33 DNA opening complex
7K04	;	9.25	;	Structure of TFIIH/Rad4-Rad23-Rad33/DNA in DNA opening
3ZBD	;	1.49	;	Structure of TGEV nsp1
5TX6	;	2.746	;	Structure of TGF-beta2 derivative with deletion of residues 52-71 and 10 single amino acid mutations (mmTGF-beta2-7M)
5OUO	;	1.11	;	Structure of TgPLP1 APCbeta domain
5OUP	;	2.03	;	Structure of TgPLP1 MACPF domain
5OUQ	;	5.11	;	Structure of TgPLP1 MACPF domain
5OWN	;	3.11	;	Structure of TgPLP1 MACPF domain
7T5T	;	1.35	;	Structure of Thauera sp. K11 CapP
2G4Y	;	1.98	;	structure of thaumatin at 2.0 A wavelength
6FJ6	;	1.08	;	Structure of Thaumatin collected at 100K on ID30B
7AT6	;	1.46	;	Structure of thaumatin collected by femtosecond serial crystallography on a COC membrane
7AC3	;	1.65	;	Structure of thaumatin collected by rotation serial crystallography on a COC membrane at a synchrotron source
6FJ8	;	1.5	;	Structure of Thaumatin collected from an in situ crystal collected on ID30B at 12.7 keV.
6FJ9	;	1.5	;	Structure of Thaumatin collected from an in situ crystal on ID30B at 17.5 keV.
1LXZ	;	1.25	;	Structure of thaumatin crystallized in the presence of glycerol
1LY0	;	1.36	;	Structure of thaumatin crystallized in the presence of glycerol
6S1D	;	2.65	;	Structure of thaumatin determined at SwissFEL using native-SAD at 4.57 keV from 20,000 diffraction patterns
6S19	;	2.65	;	Structure of thaumatin determined at SwissFEL using native-SAD at 4.57 keV from all available diffraction patterns
7O44	;	2.0	;	Structure of thaumatin determined at SwissFEL using native-SAD at 5.99 keV with photon energy bandwidth of 0.26%
7O5J	;	2.05	;	Structure of thaumatin determined at SwissFEL using native-SAD at 6.02 keV with photon energy bandwidth of 2.15% and pinkIndexer
7O5K	;	2.05	;	Structure of thaumatin determined at SwissFEL using native-SAD at 6.02 keV with photon energy bandwidth of 2.15% and pinkIndexer with 30000 indexed images
7O51	;	2.2	;	Structure of thaumatin determined at SwissFEL using native-SAD at 6.02 keV with photon energy bandwidth of 2.15% and XGANDALF
7O53	;	2.2	;	Structure of thaumatin determined at SwissFEL using native-SAD at 6.02 keV with photon energy bandwidth of 2.15% and XGANDALF with 50000 indexed images
6S1G	;	2.0	;	Structure of thaumatin determined at SwissFEL using native-SAD at 6.06 keV from 50,000 diffraction patterns.
6S1E	;	1.95	;	Structure of thaumatin determined at SwissFEL using native-SAD at 6.06 keV from all available diffraction patterns
1PP3	;	1.6	;	Structure of thaumatin in a hexagonal space group
5A47	;	1.2	;	Structure of Thaumatin obtained by multi crystal data collection
3E3S	;	1.73	;	Structure of thaumatin with the magic triangle I3C
4ZXR	;	1.92	;	Structure of Thaumatin wrapped in graphene within vacuum
8PZ5	;	3.2	;	Structure of ThcOx, solved at wavelength 3.099 A
3FZE	;	1.601	;	Structure of the 'minimal scaffold' (ms) domain of Ste5 that cocatalyzes Fus3 phosphorylation by Ste7
2A51	;		;	Structure of the (13-51) domain of the nucleocapsid protein NCp8 from SIVlhoest
7RTK	;	2.5	;	Structure of the (NIAU)2 complex with N-terminal mutation of ISCU2 Y35D at 2.5 A resolution
5NCQ	;	3.0	;	Structure of the (SR) Ca2+-ATPase bound to a Tetrahydrocarbazole and TNP-ATP
6YAA	;	3.4	;	Structure of the (SR) Ca2+-ATPase bound to the inhibitor compound CAD204520 and TNP-ATP
1T5T	;	2.9	;	Structure of the (SR)Ca2+-ATPase Ca2-E1-ADP:AlF4- form
1T5S	;	2.6	;	Structure of the (SR)Ca2+-ATPase Ca2-E1-AMPPCP form
3N8G	;	2.585	;	Structure of the (SR)Ca2+-ATPase Ca2-E1-CaAMPPCP form
1XP5	;	3.0	;	Structure Of The (Sr)Ca2+-ATPase E2-AlF4- Form
3N5K	;	2.2	;	Structure Of The (Sr)Ca2+-ATPase E2-AlF4- Form
4NAB	;	3.5	;	Structure of the (SR)Ca2+-ATPase mutant E309Q in the Ca2-E1-MgAMPPCP form
6RB2	;	3.20001	;	Structure of the (SR)Ca2+-ATPase mutant E340A in the Ca2-E1-CaAMPPCP form
5WTT	;	2.7	;	Structure of the 093G9 Fab in complex with the epitope peptide
2KTP	;		;	Structure of the 1,N2-ethenodeoxyguanosine lesion opposite a one-base deletion in duplex DNA
5WM8	;	1.92	;	Structure of the 10R (+)-cis-BP-dG modified Rev1 ternary complex
5WM1	;	1.85	;	Structure of the 10S (+)-trans-BP-dG modified Rev1 ternary complex
5WMB	;	2.25	;	Structure of the 10S (-)-cis-BP-dG modified Rev1 ternary complex (the BP residue is disordered)
3S34	;	2.2	;	Structure of the 1121B Fab fragment
2O98	;	2.7	;	Structure of the 14-3-3 / H+-ATPase plant complex
4DX0	;	3.4	;	Structure of the 14-3-3/PMA2 complex stabilized by a pyrazole derivative
3M50	;	2.6	;	Structure of the 14-3-3/PMA2 complex stabilized by Epibestatin
3M51	;	3.25	;	Structure of the 14-3-3/PMA2 complex stabilized by Pyrrolidone1
3FZG	;	2.0	;	Structure of the 16S rRNA methylase ArmA
3FRI	;	1.8	;	Structure of the 16S rRNA methylase RmtB, I222
3FRH	;	1.2	;	Structure of the 16S rRNA methylase RmtB, P21
7CCQ	;	3.8	;	Structure of the 1:1 cGAS-nucleosome complex
4P9G	;	2.2	;	Structure of the 2,4'-dihydroxyacetophenone dioxygenase from Alcaligenes sp.
5BPX	;	1.88	;	Structure of the 2,4'-dihydroxyacetophenone dioxygenase from Alcaligenes sp. 4HAP.
3TQX	;	2.304	;	Structure of the 2-amino-3-ketobutyrate coenzyme A ligase (kbl) from Coxiella burnetii
6M1W	;	2.75	;	Structure of the 2-Aminoisobutyric acid Monooxygenase Hydroxylase
6M2I	;	2.45	;	Structure of the 2-Aminoisobutyric acid Monooxygenase Hydroxylase
3TQG	;	2.3	;	Structure of the 2-methylcitrate synthase (prpC) from Coxiella burnetii
1MUM	;	1.9	;	Structure of the 2-Methylisocitrate Lyase (PrpB) from Escherichia coli
4A0S	;	1.9	;	STRUCTURE OF THE 2-OCTENOYL-COA CARBOXYLASE REDUCTASE CINF IN COMPLEX WITH NADP AND 2-OCTENOYL-COA
6U3J	;	2.25	;	Structure of the 2-oxoadipate dehydrogenase DHTKD1
5KED	;	2.65	;	Structure of the 2.65 Angstrom P2(1) crystal of K. pneumonia MrkH
6LVN	;	2.47	;	Structure of the 2019-nCoV HR2 Domain
2O45	;	3.6	;	Structure of the 23S rRNA of the large ribosomal subunit from Deinococcus Radiodurans in complex with the macrolide RU-69874
5A5B	;	9.5	;	Structure of the 26S proteasome-Ubp6 complex
7QO3	;	6.1	;	Structure of the 26S proteasome-Ubp6 complex in the si state (Core Particle and Lid)
7CCR	;	4.9	;	Structure of the 2:2 cGAS-nucleosome complex
7ZRY	;	2.7	;	Structure of the 2a splicing variant of the full-length human LSD1 bound to CoREST (delta305)
6CNJ	;	3.7	;	Structure of the 2alpha3beta stiochiometry of the human Alpha4Beta2 nicotinic receptor
2CKB	;	3.0	;	STRUCTURE OF THE 2C/KB/DEV8 COMPLEX
2OI9	;	2.35	;	Structure of the 2C/Ld/QL9 allogeneic complex
6COK	;	1.89	;	Structure of the 2nd TOG domain from yeast CLASP protein STU1
2QAR	;	2.4	;	Structure of the 2TEL crystallization module fused to T4 lysozyme with a helical linker.
2QB0	;	2.56	;	Structure of the 2TEL crystallization module fused to T4 lysozyme with an Ala-Gly-Pro linker.
1BLU	;	2.1	;	STRUCTURE OF THE 2[4FE-4S] FERREDOXIN FROM CHROMATIUM VINOSUM
2FGO	;	1.32	;	Structure of the 2[4FE-4S] ferredoxin from Pseudomonas aeruginosa
3PHP	;		;	STRUCTURE OF THE 3' HAIRPIN OF THE TYMV PSEUDOKNOT: PREFORMATION IN RNA FOLDING
3TQD	;	1.8	;	Structure of the 3-deoxy-D-manno-octulosonate cytidylyltransferase (kdsB) from Coxiella burnetii
4UBV	;	1.95	;	Structure of the 3-ketoacyl-CoA thiolase FadA5 from M. tuberculosis with an partially acetylated cysteine in complex with acetyl-CoA and CoA
5ME0	;	13.5	;	Structure of the 30S Pre-Initiation Complex 1 (30S IC-1) Stalled by GE81112
5ME1	;	13.5	;	Structure of the 30S Pre-Initiation Complex 2 (30S IC-2) Stalled by GE81112
5O5J	;	3.45	;	Structure of the 30S small ribosomal subunit from Mycobacterium smegmatis
5X8R	;	3.7	;	Structure of the 30S small subunit of chloroplast ribosome from spinach
8JSH	;	4.4	;	Structure of the 30S-body-IF3 complex from Escherichia coli
8JSG	;	4.6	;	Structure of the 30S-IF3 complex from Escherichia coli
6AI1	;	3.5	;	Structure of the 328-692 fragment of FlhA (D456V)
7CTN	;	2.8	;	Structure of the 328-692 fragment of FlhA (E351A/D356A)
6AI2	;	3.3	;	Structure of the 328-692 fragment of FlhA (F459A)
6AI0	;	2.4	;	Structure of the 328-692 fragment of FlhA (orthorhombic form)
6AI3	;	3.3	;	Structure of the 328-692 fragment of FlhA (T490M)
6CNK	;	3.9	;	Structure of the 3alpha2beta stiochiometry of the human Alpha4Beta2 nicotinic receptor
3E3Q	;	2.95	;	Structure of the 3alpham13 high-affinity mutant of the 2C TCR in complex with Ld/QL9
7BCZ	;	2.4	;	Structure of the 4'-phosphopantetheinyl transferase PcpS from Pseudomonas aeruginosa
7B4S	;	1.38	;	Structure of the 4'-phosphopantetheinyl transferase PptAb from Mycobacterium abscessus in complex with Coenzyme A and compound 153786 from the NCI Open Database
7B4R	;	1.4	;	Structure of the 4'-phosphopantetheinyl transferase PptAb from Mycobacterium abscessus in complex with Coenzyme A and N-(2,6-diethylphenyl)-N'-(N-ethylcarbamimidoyl)urea
6T3T	;	2.1	;	Structure of the 4-hydroxy-tetrahydrodipicolinate synthase from the thermoacidophilic methanotroph Methylacidiphilum fumariolicum SolV
6AHQ	;	3.398	;	Structure of the 40-167 fragment of FliL
5LL6	;	3.9	;	Structure of the 40S ABCE1 post-splitting complex in ribosome recycling and translation initiation
2LAG	;		;	Structure of the 44 kDa complex of interferon-alpha2 with the extracellular part of IFNAR2 obtained by 2D-double difference NOESY
6DWI	;	2.39	;	Structure of the 4462 Antibody Fab fragment bound to a Staphylococcus aureus wall techoic acid analog
6DWA	;	1.922	;	Structure of the 4497 Antibody Fab fragment bound to a Staphylococcus aureus wall techoic acid analog
7RRO	;	3.4	;	Structure of the 48-nm repeat doublet microtubule from bovine tracheal cilia
5OXV	;	6.721	;	Structure of the 4_601_157 tetranucleosome (C2 form)
5OY7	;	5.774	;	Structure of the 4_601_157 tetranucleosome (P1 form)
1ZBB	;	9.0	;	Structure of the 4_601_167 Tetranucleosome
5O60	;	3.18	;	Structure of the 50S large ribosomal subunit from Mycobacterium smegmatis
5X8T	;	3.3	;	Structure of the 50S large subunit of chloroplast ribosome from spinach
6DDD	;	3.1	;	Structure of the 50S ribosomal subunit from Methicillin Resistant Staphylococcus aureus in complex with the oxazolidinone antibiotic LZD-5
6DDG	;	3.1	;	Structure of the 50S ribosomal subunit from Methicillin Resistant Staphylococcus aureus in complex with the oxazolidinone antibiotic LZD-6
6WRU	;	3.1	;	Structure of the 50S subunit of the ribosome from Methicillin Resistant Staphylococcus aureus in complex with an isomer of the tedizolid
6WQN	;	2.9	;	Structure of the 50S subunit of the ribosome from Methicillin Resistant Staphylococcus aureus in complex with the antibiotic, contezolid
6WQQ	;	3.1	;	Structure of the 50S subunit of the ribosome from Methicillin Resistant Staphylococcus aureus in complex with the antibiotic, radezolid
6WRS	;	3.2	;	Structure of the 50S subunit of the ribosome from Methicillin Resistant Staphylococcus aureus in complex with the antibiotic, tedizolid
8RHN	;	4.5	;	Structure of the 55LCC ATPase complex
5AJ4	;	3.8	;	Structure of the 55S mammalian mitoribosome.
6AHP	;	2.1	;	Structure of the 58-167 fragment of FliL
7CIK	;	2.29	;	Structure of the 58-213 fragment of FliF
2WQ7	;	2.0	;	Structure of the 6-4 photolyase of D. melanogaster in complex with the non-natural N4-methyl T(6-4)C lesion
2WQ6	;	2.3	;	Structure of the 6-4 photolyase of D. melanogaster in complex with the non-natural N4-methyl T(Dewar)C lesion
1UP7	;	2.4	;	Structure of the 6-phospho-beta glucosidase from Thermotoga maritima at 2.4 Angstrom resolution in the tetragonal form with NAD and glucose-6-phosphate
1UP6	;	2.55	;	Structure of the 6-phospho-beta glucosidase from Thermotoga maritima at 2.55 Angstrom resolution in the tetragonal form with manganese, NAD+ and glucose-6-phosphate
1UP4	;	2.85	;	Structure of the 6-phospho-beta glucosidase from Thermotoga maritima at 2.85 Angstrom resolution in the monoclinic form
6DW2	;	1.7	;	Structure of the 6078 Antibody Fab fragment bound to a Staphylococcus aureus wall techoic acid analog
2NXV	;	1.1	;	Structure of the 6th ORF of the Rhodobacter blastica ATPase operon; Majastridin
6MSV	;	2.4	;	Structure of the 6th type III domain from human fibronectin
5MMM	;	3.4	;	Structure of the 70S chloroplast ribosome
5X8P	;	3.4	;	Structure of the 70S chloroplast ribosome from spinach
5J7L	;	3.0	;	Structure of the 70S E coli ribosome with the U1052G mutation in the 16S rRNA bound to tetracycline
5MDZ	;	3.1	;	Structure of the 70S ribosome (empty A site)
4V5J	;	3.1	;	Structure of the 70S ribosome bound to Release factor 2 and a substrate analog provides insights into catalysis of peptide release
5LZF	;	4.6	;	Structure of the 70S ribosome with fMetSec-tRNASec in the hybrid pre-translocation state (H)
5LZE	;	3.5	;	Structure of the 70S ribosome with Sec-tRNASec in the classical pre-translocation state (C)
5LZA	;	3.6	;	Structure of the 70S ribosome with SECIS-mRNA and P-site tRNA (Initial complex, IC)
7PJT	;	6.0	;	Structure of the 70S ribosome with tRNAs in hybrid state 1 (H1)
7PJU	;	9.5	;	Structure of the 70S ribosome with tRNAs in hybrid state 2 (H2)
7PJS	;	2.35	;	Structure of the 70S ribosome with tRNAs in the classical pre-translocation state and apramycin (C)
7PJY	;	3.1	;	Structure of the 70S-EF-G-GDP ribosome complex with tRNAs in chimeric state 1 (CHI1-EF-G-GDP)
7PJZ	;	6.0	;	Structure of the 70S-EF-G-GDP ribosome complex with tRNAs in chimeric state 2 (CHI2-EF-G-GDP)
7PJX	;	6.5	;	Structure of the 70S-EF-G-GDP ribosome complex with tRNAs in hybrid state 1 (H1-EF-G-GDP)
7PJV	;	3.1	;	Structure of the 70S-EF-G-GDP-Pi ribosome complex with tRNAs in hybrid state 1 (H1-EF-G-GDP-Pi)
7PJW	;	4.0	;	Structure of the 70S-EF-G-GDP-Pi ribosome complex with tRNAs in hybrid state 2 (H2-EF-G-GDP-Pi)
3J7P	;	3.5	;	Structure of the 80S mammalian ribosome bound to eEF2
4V7H	;	8.9	;	Structure of the 80S rRNA and proteins and P/E tRNA for eukaryotic ribosome based on cryo-EM map of Thermomyces lanuginosus ribosome at 8.9A resolution
6EYN	;	2.4	;	Structure of the 8D6 (anti-IgE) Fab
5MSC	;	1.85	;	Structure of the A domain of carboxylic acid reductase (CAR) from Nocardia iowensis in complex with AMP
5MSD	;	1.71	;	Structure of the A domain of carboxylic acid reductase (CAR) from Nocardia iowensis in complex with AMP and benzoic acid
5MSQ	;	1.74	;	Structure of the A domain of carboxylic acid reductase (CAR) from Nocardia iowensis in complex with AMP and iodide
5MST	;	1.72	;	Structure of the A domain of carboxylic acid reductase (CAR) from Segniliparus rugosus in complex with AMP and a co-purified carboxylic acid
5MSS	;	1.96	;	Structure of the A-PCP didomain of carboxylic acid reductase (CAR) from Segniliparus rugosus in complex with AMP
5MSW	;	2.33	;	Structure of the A-PCP didomain of carboxylic acid reductase (CAR) from Segniliparus rugosus in complex with AMP
7QPK	;	2.75	;	Structure of the A-region of Awp14 from Candida glabrata
2HC8	;	1.65	;	Structure of the A. fulgidus CopA A-domain
6GUM	;	1.792	;	Structure of the A.thaliana E1 UFD domain in complex with E2
2OXV	;	1.95	;	Structure of the A138T promiscuous mutant of the EcoRI restriction endonuclease bound to its cognate recognition site.
2VFJ	;	3.2	;	Structure of the A20 Ovarian Tumour (OTU) domain
6IX2	;	1.478	;	Structure of the A214C/A250I mutant of an epoxide hydrolase from Aspergillus usamii E001 (AuEH2) at 1.48 Angstroms resolution
3LSV	;	3.15	;	Structure of the A237F mutant of the pentameric ligand gated ion channel from Gloeobacter Violaceus
1SMJ	;	2.75	;	Structure of the A264E mutant of cytochrome P450 BM3 complexed with palmitoleate
2IJ3	;	1.9	;	Structure of the A264H mutant of cytochrome P450 BM3
2IJ4	;	2.4	;	Structure of the A264K mutant of cytochrome P450 BM3
6S0Q	;	2.65	;	Structure of the A2A adenosine receptor determined at SwissFEL using native-SAD at 4.57 keV from 50,000 diffraction patterns
6S0L	;	2.65	;	Structure of the A2A adenosine receptor determined at SwissFEL using native-SAD at 4.57 keV from all available diffraction patterns
5OM4	;	2.0	;	Structure of the A2A-StaR2-bRIL562-Compound 4e complex at 1.86A obtained from in meso soaking experiments (24 hour soak).
5OLZ	;	1.9	;	Structure of the A2A-StaR2-bRIL562-Compound 4e complex at 1.9A obtained from bespoke co-crystallisation experiments.
5OM1	;	2.1	;	Structure of the A2A-StaR2-bRIL562-Compound 4e complex at 2.1A obtained from in meso soaking experiments (1 hour soak).
5OLV	;	1.998	;	Structure of the A2A-StaR2-bRIL562-LUAA47070 complex at 2.0A obtained from in meso soaking experiments.
5OLO	;	3.1	;	Structure of the A2A-StaR2-bRIL562-Tozadenant complex at 3.1A obtained from in meso soaking experiments.
5OLH	;	2.6	;	Structure of the A2A-StaR2-bRIL562-Vipadenant complex at 2.6A obtained from in meso soaking experiments.
5OLG	;	1.87	;	Structure of the A2A-StaR2-bRIL562-ZM241385 complex at 1.86A obtained from in meso soaking experiments.
4KEW	;	1.89	;	structure of the A82F BM3 heme domain in complex with omeprazole
4KF0	;	1.45	;	Structure of the A82F P450 BM3 heme domain
7VBS	;	1.998	;	Structure of the AAA+ ATPase domain of the transcriptional regulator GtrR in Burkholderia cenocepacia
1OUL	;	2.2	;	Structure of the AAA+ protease delivery protein SspB
2HNS	;		;	Structure of the AAGU tetraloop
5DRP	;	1.889	;	Structure of the AaLpxC/LPC-023 Complex
4NDM	;	3.0065	;	Structure of the AB18.1 TCR
6XAB	;	1.781	;	Structure of the acetate-bound form of ArrX from Chrysiogenes arsenatis
6ESQ	;	2.95	;	Structure of the acetoacetyl-CoA thiolase/HMG-CoA synthase complex from Methanothermococcus thermolithotrophicus soaked with acetyl-CoA
6ET9	;	2.75	;	Structure of the acetoacetyl-CoA-thiolase/HMG-CoA-synthase complex from Methanothermococcus thermolithotrophicus at 2.75 A
7VZG	;	2.61	;	Structure of the Acidobacteria homodimeric reaction center bound with cytochrome c (the larger form)
7VZR	;	2.22	;	Structure of the Acidobacteria homodimeric reaction center bound with cytochrome c (the smaller form)
1U4D	;	2.1	;	Structure of the ACK1 Kinase Domain bound to Debromohymenialdisine
3HOP	;	2.3	;	Structure of the actin-binding domain of human filamin A
3HOR	;	2.7	;	Structure of the actin-binding domain of human filamin A (reduced)
3HOC	;	2.3	;	Structure of the actin-binding domain of human filamin A mutant E254K
3DAW	;	2.55	;	Structure of the actin-depolymerizing factor homology domain in complex with actin
4A7L	;	8.1	;	Structure of the Actin-Tropomyosin-Myosin Complex (rigor ATM 1)
4A7H	;	7.8	;	Structure of the Actin-Tropomyosin-Myosin Complex (rigor ATM 2)
4A7F	;	7.7	;	Structure of the Actin-Tropomyosin-Myosin Complex (rigor ATM 3)
7JLU	;	3.8	;	Structure of the activated Roq1 resistosome directly recognizing the pathogen effector XopQ
7JLV	;	3.8	;	Structure of the activated Roq1 resistosome directly recognizing the pathogen effector XopQ
7JLX	;	4.6	;	Structure of the activated Roq1 resistosome directly recognizing the pathogen effector XopQ (TIR domains)
7QBM	;	1.88	;	Structure of the activation intermediate of cathepsin K in complex with the 3-cyano-3-aza-beta-amino acid inhibitor Gu2602
7QBO	;	1.9	;	Structure of the activation intermediate of cathepsin K in complex with the azadipeptide nitrile inhibitor Gu1303
1QLO	;		;	Structure of the active domain of the herpes simplex virus protein ICP47 in water/sodium dodecyl sulfate solution determined by nuclear magnetic resonance spectroscopy
1NI2	;	2.3	;	Structure of the active FERM domain of Ezrin
5LOP	;	3.5	;	Structure of the active form of /K. lactis/ Dcp1-Dcp2-Edc3 decapping complex bound to m7GDP
5UJM	;	18.0	;	Structure of the active form of human Origin Recognition Complex and its ATPase motor module
5UJ7	;	3.394	;	Structure of the active form of human Origin Recognition Complex ATPase motor module, complex subunitS 1, 4, 5
8BTY	;	1.7	;	Structure of the active form of ScpB, the C5a-peptidase from Streptococcus agalactiae.
6EIB	;	1.941	;	Structure of the active GGEEF domain of a diguanylate cyclase from Vibrio cholerae.
5LDH	;	2.7	;	STRUCTURE OF THE ACTIVE TERNARY COMPLEX OF PIG HEART LACTATE DEHYDROGENASE WITH S-LAC-NAD AT 2.7 ANGSTROMS RESOLUTION
4QBU	;	1.7	;	Structure of the Acyl Transferase domain of ZmaA
2VZK	;	2.33	;	Structure of the acyl-enzyme complex of an N-terminal nucleophile (Ntn) hydrolase, OAT2
7AGP	;	2.4	;	Structure of the AcylTransferase domain of Mycocerosic Acid Synthase from Mycobacterium tuberculosis
7AGS	;	3.1	;	Structure of the AcylTransferase domain of Mycocerosic Acid Synthase from Mycobacterium tuberculosis acylated MethylMalonyl-CoenzymeA
1SZV	;		;	Structure of the Adaptor Protein p14 reveals a Profilin-like Fold with Novel Function
5SWD	;	2.5	;	Structure of the adenine riboswitch aptamer domain in an intermediate-bound state
7MTW	;	2.99	;	Structure of the adeno-associated virus 9 capsid at pH 4.0
7MTP	;	2.79	;	Structure of the adeno-associated virus 9 capsid at pH 5.5
7MTG	;	2.67	;	Structure of the adeno-associated virus 9 capsid at pH 6.0
7MT0	;	2.82	;	Structure of the adeno-associated virus 9 capsid at pH 7.4
7MUA	;	2.68	;	Structure of the adeno-associated virus 9 capsid at pH pH 5.5 in complex with terminal galactose
7MTZ	;	2.43	;	Structure of the adeno-associated virus 9 capsid at pH pH 7.4 in complex with terminal galactose
5EGC	;	3.011	;	Structure of the Adeno-Associated Virus Serotype 1 sialic acid complex
5G53	;	3.4	;	Structure of the adenosine A2A receptor bound to an engineered G protein
4ZDG	;	3.2	;	Structure of the Adenovirus 14p1 knob domain
4LIY	;	2.1	;	Structure of the adenovirus 3 knob domain K217E and F224S mutant
1B04	;	2.8	;	STRUCTURE OF THE ADENYLATION DOMAIN OF AN NAD+ DEPENDENT LIGASE
8BOZ	;	3.6	;	structure of the Adherent-Invasive Escherichia coli Tle3/Tli3 T6SS effector/immunity complex
8JMT	;	3.3	;	Structure of the adhesion GPCR ADGRL3 in the apo state
1PHP	;	1.65	;	STRUCTURE OF THE ADP COMPLEX OF THE 3-PHOSPHOGLYCERATE KINASE FROM BACILLUS STEAROTHERMOPHILUS AT 1.65 ANGSTROMS
6SH3	;	3.4	;	Structure of the ADP state of the heptameric Bcs1 AAA-ATPase
5G4F	;	7.0	;	Structure of the ADP-bound VAT complex
7ZBQ	;		;	Structure of the ADP-ribosyltransferase TccC3HVR from Photorhabdus Luminescens
1KHZ	;	2.04	;	Structure of the ADPR-ase in complex with AMPCPR and Mg
2YNM	;	2.1	;	Structure of the ADPxAlF3-Stabilized Transition State of the Nitrogenase-like Dark-Operative Protochlorophyllide Oxidoreductase Complex from Prochlorococcus marinus with Its Substrate Protochlorophyllide a
2V1U	;	3.1	;	STRUCTURE OF THE AEROPYRUM PERNIX ORC1 PROTEIN IN COMPLEX WITH DNA
1W5S	;	2.4	;	Structure of the Aeropyrum Pernix ORC2 protein (ADP form)
1W5T	;	2.4	;	Structure of the Aeropyrum Pernix ORC2 protein (ADPNP-ADP complexes)
2BP1	;	2.4	;	Structure of the aflatoxin aldehyde reductase in complex with NADPH
6KU9	;	2.67	;	Structure of the African swine fever virus major capsid protein p72
6GRJ	;	2.94	;	Structure of the AhlB pore of the tripartite alpha-pore forming toxin, AHL, from Aeromonas hydrophila.
7OT9	;	2.8	;	Structure of the AI-2 exporter family protein YdiK from E. coli
4P2V	;	2.51	;	Structure of the AI-2 processing enzyme LsrF in complex with the product of the LsrG reaction P-HPD
6G58	;	1.9	;	Structure of the alanine racemase from Staphylococcus aureus in complex with a pyridoxal 5' phosphate-derivative
6G59	;	2.45	;	Structure of the alanine racemase from Staphylococcus aureus in complex with an pyridoxal-6- phosphate derivative
3EFM	;	2.33	;	Structure of the alcaligin outer membrane recepteur FauA from Bordetella pertussis
3ZDR	;	2.504	;	Structure of the Alcohol dehydrogenase (ADH) domain of a bifunctional ADHE dehydrogenase from Geobacillus thermoglucosidasius NCIMB 11955
8OFM	;	1.831	;	Structure of the ALDEHYDE DEHYDROGENASE 5F1 (ALDH5F1) from the moss Physcomitrium patens in complex with NAD in an extended conformation
5KET	;	2.85	;	Structure of the aldo-keto reductase from Coptotermes gestroi
4HBK	;	2.2	;	Structure of the Aldose Reductase from Schistosoma japonicum
4RT1	;	1.7	;	Structure of the Alg44 PilZ domain (R95A mutant) from Pseudomonas aeruginosa PAO1 in complex with c-di-GMP
4RT0	;	1.8	;	Structure of the Alg44 PilZ domain from Pseudomonas aeruginosa PAO1 in complex with c-di-GMP
5ETZ	;	1.8	;	Structure of the all-trans isomer of pharaonis halorhodopsin in the absence of halide ions
1GPH	;	3.0	;	STRUCTURE OF THE ALLOSTERIC REGULATORY ENZYME OF PURINE BIOSYNTHESIS
7O4U	;	2.7	;	Structure of the alpha subunit of Mycobacterium tuberculosis beta-oxidation trifunctional enzyme in complex with oxidized nicotinamide adenine dinucleotide
6RJ8	;	1.42	;	Structure of the alpha-beta hydrolase CorS from Tabernathe iboga
5M1Z	;	2.0	;	STRUCTURE OF THE ALPHA-L-ARABINOFURANOSIDASE ARB93A FROM FUSARIUM GRAMINEARUM IN COMPLEX WITH AN hydroximolactone INHIBITOR
2YDT	;	1.6	;	STRUCTURE OF THE ALPHA-L-ARABINOFURANOSIDASE ARB93A from FUSARIUM Graminearum in complexe with an iminosugar inhibitor
7LTS	;	2.32	;	Structure of the alpha-N-methyltransferase (SonM mutant R67A) and RiPP precursor (SonA) heteromeric complex (with SAH)
7LTF	;	2.2	;	Structure of the alpha-N-methyltransferase (SonM mutant Y58F) and RiPP precursor (SonA) heteromeric complex (no cofactor)
7LTH	;	2.1	;	Structure of the alpha-N-methyltransferase (SonM mutant Y93F) and RiPP precursor (SonA) heteromeric complex (no cofactor)
8T1S	;	2.0	;	Structure of the alpha-N-methyltransferase (SonM) and RiPP precursor (SonA with QSY deletion) heteromeric complex (bound to SAH)
8T1T	;	1.55	;	Structure of the alpha-N-methyltransferase (SonM) and RiPP precursor (SonA with QSY deletion) heteromeric complex (bound to SAM)
7LTC	;	2.0	;	Structure of the alpha-N-methyltransferase (SonM) and RiPP precursor (SonA) heteromeric complex (no cofactor)
7LTE	;	2.0	;	Structure of the alpha-N-methyltransferase (SonM) and RiPP precursor (SonA) heteromeric complex (with SAH)
6I42	;	1.38	;	Structure of the alpha-Synuclein PreNAC/Cyclophilin A-complex
4U9Y	;	2.201	;	Structure of the alpha-tubulin acetyltransferase alpha-TAT1/Mec-17 in complex with CoA
4U9Z	;	1.802	;	Structure of the alpha-tubulin acetyltransferase alpha-TAT1/Mec-17 in complex with CoA
4GS4	;	2.112	;	Structure of the alpha-tubulin acetyltransferase, alpha-TAT1
7EJ0	;	3.2	;	Structure of the alpha2A-adrenergic receptor GoA signaling complex
7EJ8	;	3.0	;	Structure of the alpha2A-adrenergic receptor GoA signaling complex bound to brimonidine
7EJA	;	3.6	;	Structure of the alpha2A-adrenergic receptor GoA signaling complex bound to dexmedetomidine
7EJK	;	3.4	;	Structure of the alpha2A-adrenergic receptor GoA signaling complex bound to oxymetazoline
4LE8	;	1.75	;	Structure of the Als3 adhesin from Candida albicans, residues 1-299 (mature sequence)
4LEB	;	1.4	;	Structure of the Als3 adhesin from Candida albicans, residues 1-299 (mature sequence) in complex with hepta-threonine
4LEE	;	3.0	;	Structure of the Als3 adhesin from Candida albicans, residues 1-313 (mature sequence), triple mutant in the binding cavity: K59M, A116V, Y301F
2FKL	;	2.5	;	Structure of the Alzheimer's Amyloid Precursor Protein (APP) Copper Binding Domain (Residues 126- 189 of APP)
2FJZ	;	1.61	;	Structure of the Alzheimer's Amyloid Precursor Protein (APP) copper binding domain (residues 133 to 189) in 'small unit cell' form, metal-free
2FK3	;	2.4	;	Structure of the Alzheimer's Amyloid Precursor Protein (APP) Copper Binding Domain in 'large unit cell' form
2FMA	;	0.85	;	Structure of the Alzheimer's Amyloid Precursor Protein (APP) Copper Binding Domain in 'small unit cell' form, atomic resolution
2FK2	;	1.65	;	Structure of the Alzheimer's Amyloid Precursor Protein (APP) Copper Binding Domain in 'small unit cell' form, Cu(I)-bound
2FK1	;	1.6	;	Structure of the Alzheimer's Amyloid Precursor Protein (APP) Copper Binding Domain in 'small unit cell' form, Cu(II)-bound
1OWT	;		;	Structure of the Alzheimer's disease amyloid precursor protein copper binding domain
2H95	;		;	Structure of the Amantadine-Blocked Influenza A M2 Proton Channel Trans-membrane Domain by Solid-state NMR spectroscopy
4CP8	;	2.5	;	Structure of the amidase domain of allophanate hydrolase from Pseudomonas sp strain ADP
5K4A	;	2.3	;	Structure of the amidase mutant E79A at 2.3 Angstrom resolution
3TQL	;	1.594	;	Structure of the amino acid ABC transporter, periplasmic amino acid-binding protein from Coxiella burnetii.
8FWT	;	3.09	;	Structure of the amino terminal domain of kainate receptor GluK2 in complex with the positive allosteric modulator BPAM344 and competitive antagonist DNQX
2Y4Z	;	2.001	;	Structure of the amino-terminal capsid restriction escape mutation N- MLV L10W
2XFV	;	1.9	;	Structure of the amino-terminal domain from the cell-cycle regulator Swi6
2KFV	;		;	Structure of the amino-terminal domain of human FK506-binding protein 3 / Northeast Structural Genomics Consortium Target HT99A
8FWR	;	3.1	;	Structure of the amino-terminal domain of kainate receptor GluK2 in complex with the positive allosteric modulator BPAM344
8FWV	;	3.03	;	Structure of the amino-terminal domain of kainate receptor GluK2 in complex with the positive allosteric modulator BPAM344 and noncompetitive inhibitor perampanel
1R69	;	2.0	;	STRUCTURE OF THE AMINO-TERMINAL DOMAIN OF PHAGE 434 REPRESSOR AT 2.0 ANGSTROMS RESOLUTION
4I8Q	;	2.65	;	Structure of the aminoaldehyde dehydrogenase 1 E260A mutant from Solanum lycopersicum (SlAMADH1-E260A)
6BFF	;	1.7	;	Structure of the aminoglycoside acetyltransferase AAC(6')-Im
2KYG	;		;	Structure of the AML1-ETO Nervy Domain - PKA(RIIa) complex and its contribution to AML1-ETO activity
6GJE	;	2.3	;	Structure of the Amnionless(20-357)-Cubilin(36-135) complex
6YK3	;	1.2	;	Structure of the AMPA receptor GluA2o ligand-binding domain (S1S2J) in complex with the compound ( S) - 1- [2'-Amino-2'-carboxyethyl]-5 ,7- dihydropyrrolo[3,4-d]pyrimidin-2,4(1H,3H)-dione at resolution 1.20A
6YK4	;	0.999	;	Structure of the AMPA receptor GluA2o ligand-binding domain (S1S2J) in complex with the compound ( S) - 1- [2'-Amino-2'-carboxyethyl]-6-methyl-5 ,7- dihydropyrrolo[3,4-d]pyrimidin-2,4(1H,3H)-dione at resolution 1.00A
6YK5	;	1.15	;	Structure of the AMPA receptor GluA2o ligand-binding domain (S1S2J) in complex with the compound (S)-1-(2'-Amino-2'-carboxyethyl)-5,7-dihydrofuro[3,4-d]- pyrimidine-2,4(1H,3H)-dione at resolution 1.15A
6YK6	;	1.469	;	Structure of the AMPA receptor GluA2o ligand-binding domain (S1S2J) in complex with the compound (S)-1-(2'-Amino-2'-carboxyethyl)furo[3,4-d]pyrimidin-2,4-dione at resolution 1.47A
6YK2	;	1.612	;	Structure of the AMPA receptor GluA2o ligand-binding domain (S1S2J) in complex with the compound (S)-1-[2'-Amino-2'-carboxyethyl]-5,7-dihydrothieno[3,4-d]pyrimidin- 2,4(1H,3H)-dione at resolution 1.60A
6FPJ	;	1.96	;	Structure of the AMPAR GluA3 N-terminal domain bound to phosphate
3KOS	;	1.83	;	Structure of the AmpR effector binding domain from Citrobacter freundii
5E5X	;	1.61	;	Structure of the amyloid forming peptide ANFLVH (residues 13-18) from islet amyloid polypeptide
4QXX	;	1.445	;	Structure of the amyloid forming peptide GNLVS (residues 26-30) from the eosinophil major basic protein (EMBP)
5E5Z	;	1.664	;	Structure of the amyloid forming peptide LVHSSN (residues
6C88	;	1.851	;	STRUCTURE OF THE AMYLOID FORMING PEPTIDE VAVHVF FROM TRANSTHYRETIN
4RIL	;	1.43	;	Structure of the amyloid forming segment, GAVVTGVTAVA, from the NAC domain of Parkinson's disease protein alpha-synuclein, residues 68-78, determined by electron diffraction
8ONQ	;	1.5	;	Structure of the amyloid-forming peptide Ac-EFIAWL from human GLP-1
8ANJ	;	1.55	;	Structure of the amyloid-forming peptide DFINWL from human GLP-2
8ANN	;	1.24	;	Structure of the amyloid-forming peptide LFIEWL from exendin-4, grown from acetonitrile / water
8ANL	;	1.75	;	Structure of the amyloid-forming peptide LFIEWL from exendin-4, grown from water
8ANI	;	1.35	;	Structure of the amyloid-forming peptide LYIQWL from Tc5b, grown from 10% ethanol
8ANH	;	1.25	;	Structure of the amyloid-forming peptide LYIQWL from Tc5b, grown from 30% acetonitrile
8ANG	;	1.5	;	Structure of the amyloid-forming peptide LYIQWL from Tc5b, grown from 30% ethanol
8ANM	;	0.9	;	Structure of the amyloid-forming peptide LYIQWL from Tc5b, grown from water
8ANK	;	1.3	;	Structure of the amyloid-forming peptide pEFIAWL from human GLP-1
4RP6	;	1.703	;	Structure of the amyloid-forming segment LTIITLE from p53 (residues 252-258)
4RP7	;	1.576	;	Structure of the amyloid-forming segment TIITLE from p53 (residues 253-258)
1FP8	;	2.3	;	STRUCTURE OF THE AMYLOMALTASE FROM THERMUS THERMOPHILUS HB8 IN SPACE GROUP P21212
1J7A	;	1.8	;	STRUCTURE OF THE ANABAENA FERREDOXIN D68K MUTANT
1J7B	;	1.8	;	STRUCTURE OF THE ANABAENA FERREDOXIN MUTANT E94K
1J7C	;	1.8	;	STRUCTURE OF THE ANABAENA FERREDOXIN MUTANT E95K
7Y3F	;	2.62	;	Structure of the Anabaena PSI-monomer-IsiA supercomplex
6W9L	;	1.45	;	Structure of the Ancestral Glucocorticoid Receptor 2 ligand binding domain in complex with deacetylated deflazacort and PGC1a coregulator fragment
6NWK	;	1.65	;	Structure of the Ancestral Glucocorticoid Receptor 2 ligand binding domain in complex with dexamethasone and PGC1a coregulator fragment
6NWL	;	1.595	;	Structure of the Ancestral Glucocorticoid Receptor 2 ligand binding domain in complex with hydrocortisone and PGC1a coregulator fragment
6W9K	;	1.6	;	Structure of the Ancestral Glucocorticoid Receptor 2 ligand binding domain in complex with Prednisolone and PGC1a coregulator fragment
6W9M	;	1.59	;	Structure of the Ancestral Glucocorticoid Receptor 2 ligand binding domain in complex with vamorolone and SHP coregulator fragment
8AJA	;	2.59	;	Structure of the Ancestral Scaffold Antigen-5 of Coronavirus Spike protein
8AJL	;	2.77	;	Structure of the Ancestral Scaffold Antigen-6 of Coronavirus Spike protein
1Z3U	;	2.25	;	Structure of the Angiopoietin-2 Recptor Binding Domain and Identification of Surfaces Involved in Tie2 Recognition
5FCJ	;	3.1	;	Structure of the anisomycin-containing uL3 W255C mutant 80S yeast ribosome
5AAR	;	1.87	;	Structure of the ankyrin domain of an Arabidopsis Thaliana potassium channel
5K34	;	1.15	;	Structure of the ankyrin domain of AnkB from Legionella Pneumophila
1OT8	;	2.0	;	Structure of the Ankyrin Domain of the Drosophila Notch Receptor
2CH2	;	2.7	;	Structure of the Anopheles gambiae 3-hydroxykynurenine transaminase in complex with inhibitor
6Z1Z	;	1.7	;	Structure of the anti-CD9 nanobody 4C8
1ZEA	;	1.78	;	Structure of the anti-cholera toxin antibody Fab fragment TE33 in complex with a D-peptide
4OTX	;	2.1	;	Structure of the anti-Francisella tularensis O-antigen antibody N203 Fab fragment
5T4Z	;	1.991	;	STRUCTURE OF THE ANTI-HIV ANTIBODY DH501 THAT BINDS GP120 V3 GLYCAN AND THE BASE OF V3 WITH FREE MAN9 GLYCAN
1VMP	;		;	STRUCTURE OF THE ANTI-HIV CHEMOKINE VMIP-II
7UCE	;	2.25	;	Structure of the anti-HIV-1 neutralizing antibody BG24 Fab fragment
4GLR	;	1.9	;	Structure of the anti-ptau Fab (pT231/pS235_1) in complex with phosphoepitope pT231/pS235
1H4Y	;	1.61	;	Structure of the Anti-Sigma Factor Antagonist SpoIIAA in its Unphosphorylated Form
1H4Z	;	2.74	;	Structure of the Anti-Sigma Factor Antagonist SpoIIAA in its Unphosphorylated Form
5OFR	;	3.4	;	Structure of the antibacterial peptide ABC transporter McjD in a high energy outward occluded intermediate state
5OFP	;	4.71	;	Structure of the antibacterial peptide ABC transporter McjD in an apo inward occluded conformation
8PX9	;	2.8	;	Structure of the antibacterial peptide ABC transporter McjD, solved at wavelength 2.75 A
5EA0	;	2.0	;	Structure of the antibody 7968 with human complement factor H-derived peptide
4YDV	;	2.7	;	STRUCTURE OF THE ANTIBODY 7B2 THAT CAPTURES HIV-1 VIRIONS
6W51	;	3.53	;	Structure of the antibody fragment H2 in complex with HLA-A*02:01/p53R175H
1SKK	;		;	Structure of the antimicrobial hexapeptide cyc-(KKWWKF) bound to DPC micelles
1SKL	;		;	Structure of the antimicrobial hexapeptide cyc-(RRNalNalRF) bound to DPC micelles
1QVK	;		;	Structure of the antimicrobial hexapeptide cyc-(RRWWRF) bound to DPC micelles
1QVL	;		;	Structure of the antimicrobial hexapeptide cyc-(RRWWRF) bound to SDS micelles
1SKI	;		;	Structure of the antimicrobial hexapeptide cyc-(RRYYRF) bound to DPC micelles
2OTQ	;		;	Structure of the antimicrobial peptide cyclo(RRWFWR) bound to DPC micelles
2MLU	;		;	Structure of the antimicrobial peptide LsbB in DPC micelles
2MLV	;		;	Structure of the antimicrobial peptide LsbB in TFE/water
1NCO	;	1.8	;	STRUCTURE OF THE ANTITUMOR PROTEIN-CHROMOPHORE COMPLEX NEOCARZINOSTATIN
7PLN	;	3.15	;	Structure of the APCbeta domain of Plasmodium vivax perforin-like protein 1
6DWC	;	2.27	;	Structure of the apo 4497 antibody Fab fragment
1ZM3	;	3.07	;	Structure of the apo eEF2-ETA complex
8TS5	;	2.1	;	Structure of the apo FabS1C_C1
4MKR	;	2.58	;	Structure of the apo form of a Zingiber officinale double bond reductase
6ESK	;	1.75	;	Structure of the apo form of AioX from Rhizobium sp. str. NT-26
5D4L	;	2.3	;	Structure of the apo form of CPII from Thiomonas intermedia K12, a nitrogen regulatory PII-like protein
4TRM	;	1.8	;	Structure of the apo form of InhA from Mycobacterium tuberculosis
3I5M	;	2.72	;	Structure of the apo form of leucoanthocyanidin reductase from vitis vinifera
8BFO	;	1.99	;	Structure of the apo form of Mpro from SARS-CoV-2
8BFQ	;	1.863	;	Structure of the apo form of Mpro from SARS-CoV-2
5OVJ	;	1.7	;	Structure of the apo form of Mycobacterium smegmatis MabA
7U39	;	3.51	;	Structure of the apo form of Streptomyces venezuelae GlgX, the glycogen debranching enzyme
7BFY	;	1.5	;	Structure of the apo form of the N terminal domain of Bc2L-C lectin (1-131)
5N08	;	3.90095	;	Structure of the apo form of the NO response regulator NsrR
7ME6	;	2.053	;	Structure of the apo form of YcnI
4OYJ	;	3.0	;	Structure of the apo HOIP PUB domain
5H8F	;	1.81	;	Structure of the apo human GluN1/GluN2A LBD
3Q6U	;	1.6	;	Structure of the apo MET receptor kinase in the dually-phosphorylated, activated state
5ISW	;	1.75	;	Structure of the apo PCP-E didomain of the gramicidin S synthetase A
5I41	;	1.8	;	Structure of the apo RacA DNA binding domain
6ZA7	;	2.34	;	Structure of the apo transcriptional repressor Atu1419 (VanR) from agrobacterium fabrum
1BD3	;	1.93	;	STRUCTURE OF THE APO URACIL PHOSPHORIBOSYLTRANSFERASE, 2 MUTANT C128V
1A6X	;		;	STRUCTURE OF THE APO-BIOTIN CARBOXYL CARRIER PROTEIN (APO-BCCP87) OF ESCHERICHIA COLI ACETYL-COA CARBOXYLASE, NMR, 49 STRUCTURES
6M9U	;	2.2	;	Structure of the apo-form of 20beta-Hydroxysteroid Dehydrogenase from Bifidobacterium adolescentis strain L2-32
4B5Z	;	2.2	;	Structure of the apo-rFnBPA(189-505) from Staphylococcus aureus
7OGR	;	3.0	;	Structure of the apo-state of the bacteriophage PhiKZ non-virion RNA polymerase
7OGP	;	3.3	;	Structure of the apo-state of the bacteriophage PhiKZ non-virion RNA polymerase - class including clamp
6SH4	;	4.4	;	Structure of the Apo1 state of the heptameric Bcs1 AAA-ATPase.
6SH5	;	4.6	;	Structure of the Apo2 state of the heptameric Bcs1 AAA-ATPase
8OF3	;	1.348	;	Structure of the apoform of ALDEHYDE DEHYDROGENASE 5F1 (ALDH5F1) from the moss Physcomitrium patens
1Z6T	;	2.21	;	Structure of the apoptotic protease-activating factor 1 bound to ADP
4HH3	;	1.75	;	Structure of the AppA-PpsR2 core complex from Rb. sphaeroides
5DRO	;	2.01	;	Structure of the Aquifex aeolicus LpxC/LPC-011 Complex
5U86	;	1.62	;	Structure of the Aquifex aeolicus LpxC/LPC-069 complex
8WP0	;	3.4	;	Structure of the Arabidopsis E529Q/E1174Q ABCB19 in the ATP bound state
4YZH	;	2.0	;	Structure of the Arabidopsis TAP38/PPH1 in complex with pLhcb1 phosphopeptide substrate
4YZG	;	1.6	;	Structure of the Arabidopsis TAP38/PPH1, a state-transition phosphatase responsible for dephosphorylation of LHCII
2V07	;	1.6	;	Structure of the Arabidopsis thaliana cytochrome c6A V52Q variant
2HJ3	;	2.5	;	Structure of the Arabidopsis Thaliana Erv1 Thiol Oxidase
1V1F	;	3.0	;	Structure of the Arabidopsis thaliana SOS3 complexed with Calcium(II) and Manganese(II) ions
1V1G	;	2.7	;	Structure of the Arabidopsis thaliana SOS3 complexed with Calcium(II) ion
8D00	;	2.8	;	Structure of the Arabidopsis thaliana SPIRAL2 TOG domain
2CKY	;	2.9	;	Structure of the Arabidopsis thaliana thiamine pyrophosphate riboswitch with its regulatory ligand
5NQS	;	2.61	;	Structure of the Arabidopsis Thaliana TOPLESS N-terminal domain
5NQV	;	1.95	;	Structure of the Arabidopsis Thaliana TOPLESS N-terminal domain
2YCB	;	3.1	;	Structure of the archaeal beta-CASP protein with N-terminal KH domains from Methanothermobacter thermautotrophicus
3RSB	;	2.8	;	Structure of the Archaeal GTP:AdoCbi-P Guanylyltransferase (CobY) from Methanocaldococcus jannaschii
2AHO	;	3.0	;	Structure of the archaeal initiation factor eIF2 alpha-gamma heterodimer from Sulfolobus solfataricus complexed with GDPNP
2VWB	;	3.05	;	Structure of the archaeal Kae1-Bud32 fusion protein MJ1130: a model for the eukaryotic EKC-KEOPS subcomplex involved in transcription and telomere homeostasis.
5DMP	;	1.793	;	Structure of the Archaeal NHEJ Phosphoesterase from Methanocella paludicola.
6SS5	;	1.78	;	Structure of the arginase-2-inhibitory human antigen-binding fragment Fab C0020187
6SRV	;	2.4	;	Structure of the arginase-2-inhibitory human antigen-binding fragment Fab C0021144
6SRX	;	1.9	;	Structure of the arginase-2-inhibitory human antigen-binding fragment Fab C0021158
6TUL	;	2.25	;	Structure of the arginase-2-inhibitory human antigen-binding fragment Fab C0021177
6SS0	;	1.7	;	Structure of the arginase-2-inhibitory human antigen-binding fragment Fab C0021181
1B4A	;	2.5	;	STRUCTURE OF THE ARGININE REPRESSOR FROM BACILLUS STEAROTHERMOPHILUS
6GGV	;	2.69	;	Structure of the arginine-bound form of truncated (residues 20-233) ArgBP from T. maritima
5G5S	;	2.29	;	Structure of the Argonaute protein from Methanocaldcoccus janaschii
5G5T	;	2.85	;	Structure of the Argonaute protein from Methanocaldcoccus janaschii in complex with guide DNA
8ACF	;	1.8	;	Structure of the argX-117 in complex with a complement C2 fragment at low pH
4BAS	;	2.0	;	Structure of the Arl6 BBS3 Small GTPase from Trypanosoma brucei with bound nucleotide analogue GppNp
3JU0	;	1.6	;	Structure of the arm-type binding domain of HAI7 integrase
3JTZ	;	1.3	;	Structure of the arm-type binding domain of HPI integrase
1XM9	;	2.8	;	Structure of the armadillo repeat domain of plakophilin 1
6XL2	;	1.74	;	Structure of the arsenate-bound form of ArrX from Chrysiogenes arsenatis
2JGO	;	1.81	;	Structure of the arsenated de novo designed peptide Coil Ser L9C
6EU7	;	3.0	;	Structure of the arsenite-bound form of AioX from Rhizobium sp. str. NT-26
6BZX	;	3.107	;	Structure of the artificial complex alpha-Rep/Octarellin V.1 crystallized by counter diffusion in a capillary
2C8E	;	1.6	;	Structure of the ARTT motif E214N mutant C3bot1 Exoenzyme (Free state, crystal form III)
2C8F	;	2.5	;	Structure of the ARTT motif E214N mutant C3bot1 Exoenzyme (NAD-bound state, crystal form III)
2C8D	;	2.2	;	Structure of the ARTT motif Q212A mutant C3bot1 Exoenzyme (Free state, crystal form I)
2C8B	;	1.7	;	Structure of the ARTT motif Q212A mutant C3bot1 Exoenzyme (Free state, crystal form II)
2C8C	;	2.7	;	Structure of the ARTT motif Q212A mutant C3bot1 Exoenzyme (NAD-bound state, crystal form I)
4GUZ	;	1.8	;	Structure of the arylamine N-acetyltransferase from Mycobacterium abscessus
5ULM	;	2.1	;	Structure of the ASK1 central regulatory region
4JPR	;	2.001	;	Structure of the ASLV fusion subunit core
2RSP	;	2.0	;	STRUCTURE OF THE ASPARTIC PROTEASE FROM ROUS SARCOMA RETROVIRUS REFINED AT 2 ANGSTROMS RESOLUTION
6NJO	;	3.34	;	Structure of the assembled ATPase EscN from the enteropathogenic E. coli (EPEC) type III secretion system
6NJP	;	3.29	;	Structure of the assembled ATPase EscN in complex with its central stalk EscO from the enteropathogenic E. coli (EPEC) type III secretion system
8A28	;	2.4	;	Structure of the astacin zymogen of LAST-MAM from Limulus polyphemus
8I4T	;	5.2	;	Structure of the asymmetric unit of SFTSV virion
6GTO	;	2.97	;	Structure of the AtaR antitoxin
6GTP	;	2.5	;	Structure of the AtaT Y144F mutant toxin
6GTQ	;	2.49	;	Structure of the AtaT Y144F mutant toxin bound to the C-terminus of the antitoxin AtaR
6GTR	;	2.99	;	Structure of the AtaT Y144F mutant toxin bound to the C-terminus of the antitoxin AtaR and Acetyl-CoA
6GTS	;	3.357	;	Structure of the AtaT-AtaR complex bound DNA
1JWA	;	2.9	;	Structure of the ATP-bound MoeB-MoaD Protein Complex
2WLK	;	2.8	;	STRUCTURE OF THE ATP-SENSITIVE INWARD RECTIFIER POTASSIUM CHANNEL FROM MAGNETOSPIRILLUM MAGNETOTACTICUM
1Z47	;	1.9	;	Structure of the ATPase subunit CysA of the putative sulfate ATP-binding cassette (ABC) transporter from Alicyclobacillus acidocaldarius
5G4G	;	7.8	;	Structure of the ATPgS-bound VAT complex
5DNY	;	3.11	;	Structure of the ATPrS-Mre11/Rad50-DNA complex
5F3W	;	3.11	;	Structure of the ATPrS-Mre11/Rad50-DNA complex
4B6D	;	2.2	;	Structure of the atypical C1 domain of MgcRacGAP
8AT4	;	33.0	;	Structure of the augmin holocomplex in closed conformation
8AT3	;	33.0	;	Structure of the augmin holocomplex in open conformation
8AT2	;	7.7	;	Structure of the augmin TIII subcomplex
8Y6P	;	3.9	;	Structure of the auto-inhibited Dark monomer
3RNV	;	2.0	;	Structure of the autocatalytic cysteine protease domain of potyvirus helper-component proteinase
7NB6	;	3.3	;	Structure of the autoinducer-2 exporter TqsA from E. coli
2L3S	;		;	Structure of the autoinhibited Crk
8PR5	;	8.6	;	Structure of the autoinhibited dynactin p150glued projection
5EK7	;	1.901	;	Structure of the autoinhibited Epha2 JMS-KD
4BM9	;	2.25	;	Structure of the autoinhibited Parkin catalytic domain
7MF3	;	3.4	;	Structure of the autoinhibited state of smooth muscle myosin-2
7QNQ	;	1.89	;	Structure of the Aux2 relaxosome protein of plasmid pLS20
7Y9T	;	3.1	;	Structure of the auxin exporter PIN1 in Arabidopsis thaliana in the apo state
7Y9V	;	3.2	;	Structure of the auxin exporter PIN1 in Arabidopsis thaliana in the IAA-bound state
7Y9U	;	3.3	;	Structure of the auxin exporter PIN1 in Arabidopsis thaliana in the NPA-bound state
7LNR	;	1.83	;	Structure of the avibactam-CDD-1 120 minute complex in imidazole and MPD
7LNQ	;	1.73	;	Structure of the avibactam-CDD-1 3 minute complex in imidazole and MPD
7R0C	;	4.73	;	Structure of the AVP-V2R-arrestin2-ScFv30 complex
2YPF	;	2.55	;	Structure of the AvrBs3-DNA complex provides new insights into the initial thymine-recognition mechanism
1EMU	;	1.9	;	STRUCTURE OF THE AXIN RGS-HOMOLOGOUS DOMAIN IN COMPLEX WITH A SAMP REPEAT FROM APC
5U6B	;	2.84	;	Structure of the Axl kinase domain in complex with a macrocyclic inhibitor
6QKN	;	2.3	;	Structure of the azide-inhibited form of cytochrome c peroxidase from obligate human pathogenic bacterium Neisseria gonorrhoeae
4UO4	;	2.6	;	Structure of the A_Canine_Colorado_17864_06 H3 haemagglutinin
4UO5	;	2.7	;	Structure of the A_Canine_Colorado_17864_06 H3 haemagglutinin in complex with 3SLN
4UO7	;	3.0	;	Structure of the A_Canine_Colorado_17864_06 H3 haemagglutinin in complex with 6SO4 Sialyl Lewis X
4UO8	;	3.0	;	Structure of the A_Canine_Colorado_17864_06 H3 haemagglutinin in complex with 6SO4-3SLN
4UO6	;	2.9	;	Structure of the A_Canine_Colorado_17864_06 H3 haemagglutinin in complex with Sialyl Lewis X
4UOA	;	2.5	;	Structure of the A_Canine_Colorado_17864_06 H3 haemagglutinin Met29Ile mutant
4UO9	;	3.2	;	Structure of the A_Canine_Colorado_17864_06 H3 haemagglutinin Ser30Thr mutant
4UNW	;	2.6	;	Structure of the A_Equine_Newmarket_2_93 H3 haemagglutinin
4UNX	;	3.2	;	Structure of the A_Equine_Newmarket_2_93 H3 haemagglutinin in complex with 3SLN
4UNY	;	2.9	;	Structure of the A_Equine_Newmarket_2_93 H3 haemagglutinin in complex with 6SO4-3SLN
4UNZ	;	2.9	;	Structure of the A_Equine_Newmarket_2_93 H3 haemagglutinin in complex with 6SO4-Sialyl Lewis X
4UO0	;	1.9	;	Structure of the A_Equine_Richmond_07 H3 haemagglutinin
4UO1	;	3.0	;	Structure of the A_Equine_Richmond_07 H3 haemagglutinin in complex with 3SLN
4UO2	;	2.7	;	Structure of the A_Equine_Richmond_07 H3 haemagglutinin in complex with Sialyl Lewis X
4UO3	;	2.87	;	Structure of the A_Equine_Richmond_07 H3 haemagglutinin mutant Ser30Thr
4CYV	;	2.3	;	Structure of the A_mallard_Sweden_51_2002 H10 Avian Haemmaglutinin
4CYZ	;	2.4	;	Structure of the A_mallard_Sweden_51_2002 H10 Avian Haemmaglutinin in complex with avian receptor analog LSTA
4CZ0	;	3.2	;	Structure of the A_mallard_Sweden_51_2002 H10 Avian Haemmaglutinin in complex with avian receptor analog Su-3SLN
4CYW	;	2.6	;	Structure of the A_mallard_Sweden_51_2002 H10 Avian Haemmaglutinin in complex with human receptor analog 6-SLN
5DNB	;	1.4	;	STRUCTURE OF THE B-DNA DECAMER C-C-A-A-C-G-T-T-G-G AND COMPARISON WITH ISOMORPHOUS DECAMERS C-C-A-A-G-A-T-T-G-G AND C-C-A-G-G-C-C-T-G-G
2FB8	;	2.9	;	Structure of the B-Raf kinase domain bound to SB-590885
6VMY	;	3.25	;	Structure of the B. subtilis cobalamin riboswitch
7QH4	;	5.45	;	Structure of the B. subtilis disome - collided 70S ribosome
7QGU	;	4.75	;	Structure of the B. subtilis disome - stalled 70S ribosome
6ZFB	;	3.9	;	Structure of the B. subtilis RNA POLYMERASE in complex with HelD (dimer)
6ZCA	;	4.2	;	Structure of the B. subtilis RNA POLYMERASE in complex with HelD (monomer)
3IV9	;	3.25	;	Structure of the B12-dependent Methionine Synthase (MetH) C-teminal half in a ""His-On"" conformation
3IVA	;	2.7	;	Structure of the B12-dependent Methionine Synthase (MetH) C-teminal half with AdoHcy bound
4MTJ	;	2.4	;	Structure of the b12-independent glycerol dehydratase with 1,2-propanediol bound
2FJH	;	3.1	;	Structure of the B20-4 Fab, a phage derived Fab fragment, in complex with VEGF
5OS9	;	1.8	;	Structure of the B3 DNA-Binding Domain of NGA1
6HHU	;	2.7	;	Structure of the Bacillus anthracis Sap S-layer assembly domain
6QX4	;	3.27	;	Structure of the Bacillus anthracis Sap S-layer assembly domain
3R8Y	;	1.7	;	Structure of the Bacillus anthracis tetrahydropicolinate succinyltransferase
1H4X	;	1.16	;	Structure of the Bacillus Cell Fate Determinant SpoIIAA in the Phosphorylated Form
1KU0	;	2.0	;	Structure of the Bacillus stearothermophilus L1 lipase
5NJT	;	3.8	;	Structure of the Bacillus subtilis hibernating 100S ribosome reveals the basis for 70S dimerization.
2XY3	;	2.55	;	Structure of the Bacillus subtilis prophage dUTPase with dUpNHpp
2XX6	;	1.74	;	Structure of the Bacillus subtilis prophage dUTPase, YosS
5NMO	;	1.899	;	Structure of the Bacillus subtilis Smc Joint domain
5ZUG	;	2.802	;	Structure of the bacterial acetate channel SatP
2XJ4	;	1.6	;	Structure of the bacterial cell division regulator protein MipZ
3QXF	;	1.85	;	Structure of the bacterial cellulose synthase subunit Z
7F81	;	1.93	;	Structure of the bacterial cellulose synthase subunit Z from Enterobacter sp. CJF-002
7F82	;	1.3	;	Structure of the bacterial cellulose synthase subunit Z in complex with cellooligosaccharides from Enterobacter sp. CJF-002
3QXQ	;	2.2	;	Structure of the bacterial cellulose synthase subunit Z in complex with cellopentaose
1WCV	;	1.6	;	Structure of the bacterial chromosome segregation protein Soj
2BEJ	;	2.1	;	Structure of the bacterial chromosome segregation protein Soj
2BEK	;	1.8	;	Structure of the bacterial chromosome segregation protein Soj
6JZT	;	7.1	;	Structure of the bacterial flagellar hook from Salmonella typhimurium
6JZR	;	7.4	;	Structure of the bacterial flagellar polyrod
5YBI	;	2.268	;	Structure of the bacterial pathogens ATPase with substrate AMPPNP
5ZT1	;	3.114	;	Structure of the bacterial pathogens ATPase with substrate ATP gamma S
2JQT	;		;	Structure of the bacterial replication origin-associated protein Cnu
7K00	;	1.98	;	Structure of the Bacterial Ribosome at 2 Angstrom Resolution
4V6T	;	8.3	;	Structure of the bacterial ribosome complexed by tmRNA-SmpB and EF-G during translocation and MLD-loading
7Y7C	;	2.51	;	Structure of the Bacterial Ribosome with human tRNA Asp(G34) and mRNA(GAU)
7Y7F	;	2.43	;	Structure of the Bacterial Ribosome with human tRNA Asp(ManQ34) and mRNA(GAC)
7Y7E	;	2.41	;	Structure of the Bacterial Ribosome with human tRNA Asp(ManQ34) and mRNA(GAU)
7Y7D	;	2.58	;	Structure of the Bacterial Ribosome with human tRNA Asp(Q34) and mRNA(GAU)
7Y7H	;	2.51	;	Structure of the Bacterial Ribosome with human tRNA Tyr(GalQ34) and mRNA(UAC)
7Y7G	;	2.34	;	Structure of the Bacterial Ribosome with human tRNA Tyr(GalQ34) and mRNA(UAU)
7AQC	;	2.99	;	Structure of the bacterial RQC complex (Decoding State)
7AQD	;	3.1	;	Structure of the bacterial RQC complex (Translocating State)
5LFB	;	5.0	;	Structure of the bacterial sex F pilus (12.5 Angstrom rise)
5LER	;	5.0	;	Structure of the bacterial sex F pilus (13.2 Angstrom rise)
5LEG	;	3.6	;	Structure of the bacterial sex F pilus (pED208)
6TKT	;		;	Structure of the bacterial toxin phenomycin
7PZT	;	1.84	;	Structure of the bacterial toxin, TecA, an asparagine deamidase from Alcaligenes faecalis.
7Q97	;	3.3	;	Structure of the bacterial type VI secretion system effector RhsA.
4RDT	;	3.2	;	Structure of the bacterial Zn-transporter ZnuD from Neisseria meningitidis (flexible conformation bound to a zinc ion)
4RDR	;	2.472	;	Structure of the bacterial Zn-transporter ZnuD from Neisseria meningitidis (locked conformation bound to zinc and cadmium ions)
4RVW	;	4.477	;	Structure of the bacterial Zn-transporter ZnuD from Neisseria meningitidis (soaked with 20 micromolar Zinc)
4EO2	;	3.007	;	Structure of the bacteriophage C1 tail knob protein, gp12
4EP0	;	4.0	;	Structure of the bacteriophage C1 tail knob protein, gp12
8K37	;	3.5	;	Structure of the bacteriophage lambda neck
8K39	;	4.0	;	Structure of the bacteriophage lambda portal vertex
8K35	;	3.44	;	Structure of the bacteriophage lambda tail tip complex
8K36	;	3.48	;	Structure of the bacteriophage lambda tail tube
1IJG	;	2.9	;	Structure of the Bacteriophage phi29 Head-Tail Connector Protein
5JBL	;	1.943	;	Structure of the bacteriophage T4 capsid assembly protease, gp21.
2XGF	;	2.2	;	Structure of the bacteriophage T4 long tail fibre needle-shaped receptor-binding tip
4HUH	;	3.2	;	Structure of the bacteriophage T4 tail terminator protein, gp15 (C-terminal truncation mutant 1-261).
4HUD	;	2.7001	;	Structure of the bacteriophage T4 tail terminator protein, gp15.
6F2M	;	1.8	;	Structure of the bacteriophage T5 distal tail protein pb9 co-crystallized with 10mM Tb-Xo4
5BRJ	;	1.922	;	Structure of the bacteriophytochrome response regulator AtBRR
7LJO	;	1.76	;	Structure of the Bacteroides fragilis CD-NTase CdnB in complex with ADP
2OMK	;	1.8	;	Structure of the Bacteroides Thetaiotaomicron Thiamin Pyrophosphokinase
6LYQ	;	3.19	;	Structure of the BAM complex
6LYR	;	3.28	;	Structure of the BAM complex
6LYS	;	3.05	;	Structure of the BAM complex
6LYU	;	4.2	;	Structure of the BAM complex
4CVW	;	2.67	;	Structure of the barley limit dextrinase-limit dextrinase inhibitor complex
6RS2	;	3.694	;	Structure of the Bateman module of human CNNM4.
4TN3	;	3.1989	;	Structure of the BBox-Coiled-coil region of Rhesus Trim5alpha
2P1L	;	2.5	;	Structure of the Bcl-XL:Beclin 1 complex
1K1F	;	2.2	;	Structure of the Bcr-Abl Oncoprotein Oligomerization domain
2MW6	;		;	Structure of the bee venom toxin melittin with [(C5H5)Ru]+ fragment attached to the tryptophan residue
5Y9K	;	1.9	;	Structure of the belimumab Fab fragment
2CFH	;	2.3	;	Structure of the Bet3-TPC6B core of TRAPP
1NW7	;	2.1	;	Structure of the beta class N6-adenine DNA methyltransferase RsrI bound to S-ADENOSYL-L-HOMOCYSTEINE
1NW5	;	2.05	;	Structure of the beta class N6-adenine DNA methyltransferase RsrI bound to S-ADENOSYLMETHIONINE
1NW6	;	1.94	;	Structure of the beta class N6-adenine DNA methyltransferase RsrI bound to sinefungin
3OBA	;	2.75	;	Structure of the beta-galactosidase from Kluyveromyces lactis
3OB8	;	2.8	;	Structure of the beta-galactosidase from Kluyveromyces lactis in complex with galactose
5C37	;	2.3	;	Structure of the beta-ketoacyl reductase domain of human fatty acid synthase bound to a spiro-imidazolone inhibitor
1GCE	;	1.8	;	STRUCTURE OF THE BETA-LACTAMASE OF ENTEROBACTER CLOACAE GC1
6KR8	;		;	Structure of the beta2 adrenergic receptor in the full agonist bound state
2X89	;	2.16	;	Structure of the Beta2_microglobulin involved in amyloidogenesis
2C1L	;	1.9	;	Structure of the BfiI restriction endonuclease
7UCF	;	4.0	;	Structure of the BG505 SOSIP.664 trimer in complex with neutralizing antibody Fab fragments 10-1074 and BG24
1TT9	;	3.42	;	Structure of the bifunctional and Golgi associated formiminotransferase cyclodeaminase octamer
1OGH	;	1.88	;	Structure of the bifunctional dCTP deaminase-dUTPase from Methanocaldococcus jannaschii
6A9W	;	1.8	;	Structure of the bifunctional DNA primase-polymerase from phage NrS-1
1W55	;	2.3	;	Structure of the Bifunctional IspDF from Campylobacter jejuni
1W57	;	3.09	;	Structure of the Bifunctional IspDF from Campylobacter jejuni containing Zn
2VPS	;	2.75	;	Structure Of The Bifunctional Leishmania Major Trypanothione Synthetase-Amidase
6YXA	;	3.95	;	Structure of the bifunctional Rel enzyme from B. subtilis
3D0F	;	1.64	;	Structure of the BIG_1156.2 domain of putative penicillin-binding protein MrcA from Nitrosomonas europaea ATCC 19718
5JAB	;	1.65	;	Structure of the biliverdin reductase Rv2074 from Mycobacterium tuberculosis in complex with F420
4GPC	;	1.85	;	Structure of the biliverdin-HmuO, heme oxygenase from Corynebacterium diphtheriae
3I6I	;	1.75	;	Structure of the binary complex leucoanthocyanidin reductase - NADPH from vitis vinifera
3I6Q	;	1.87	;	Structure of the binary complex leucoanthocyanidin reductase-NADPH from vitis vinifera
4NH4	;	2.1	;	Structure of the binary complex of a zingiber officinale double bond reductase in complex with NADP
4WE3	;	2.6	;	STRUCTURE OF THE BINARY COMPLEX OF A ZINGIBER OFFICINALE DOUBLE BOND REDUCTASE IN COMPLEX WITH NADP MONOCLINIC CRYSTAL FORM
2FZW	;	1.84	;	Structure of the binary complex of the E67L mutant of human glutathione-dependent formaldehyde dehydrogenase with NAD(H)
1BTN	;	2.0	;	STRUCTURE OF THE BINDING SITE FOR INOSITOL PHOSPHATES IN A PH DOMAIN
2LZF	;		;	Structure of the biofilm matrix promoter AbbA from B. subtilis
1BDO	;	1.8	;	STRUCTURE OF THE BIOTINYL DOMAIN OF ACETYL-COENZYME A CARBOXYLASE DETERMINED BY MAD PHASING
1U78	;	2.69	;	Structure of the bipartite DNA-binding domain of Tc3 transposase bound to transposon DNA
3F7G	;	2.3	;	Structure of the BIR domain from ML-IAP bound to a peptidomimetic
1XB0	;	2.2	;	Structure of the BIR domain of IAP-like protein 2
7NK0	;	3.3	;	Structure of the BIR1 domain of cIAP2
5TZF	;	2.4	;	Structure of the BldD CTD(D116A)-(c-di-GMP)2 intermediate, form 1
5TZG	;	2.5	;	Structure of the BldD CTD(D116A)-(c-di-GMP)2, form 2
4KC1	;	1.5	;	Structure of the blood group glycosyltransferase AAglyB in complex with a pyridine inhibitor as a neutral pyrophosphate surrogate
4KC2	;	1.7	;	Structure of the blood group glycosyltransferase AAglyB in complex with a pyridine inhibitor as a neutral pyrophosphate surrogate
4KC4	;	1.6	;	Structure of the blood group glycosyltransferase AAglyB in complex with a pyridine inhibitor as a neutral pyrophosphate surrogate
2OV0	;	0.75	;	Structure of the blue copper protein Amicyanin to 0.75 A resolution
1XFQ	;		;	structure of the blue shifted intermediate state of the photoactive yellow protein lacking the N-terminal part
6H1T	;	2.08	;	Structure of the BM3 heme domain in complex with clotrimazole
6H1S	;	1.95	;	Structure of the BM3 heme domain in complex with fluconazole
6H1L	;	1.968	;	Structure of the BM3 heme domain in complex with tioconazole
6H1O	;	1.734	;	Structure of the BM3 heme domain in complex with voriconazole
5SZG	;	2.7	;	Structure of the bMERB domain of Mical-3
3D0T	;	2.55	;	Structure of the BNB domain of the Hsp70 cochaperone Bag2
1GD6	;	2.5	;	STRUCTURE OF THE BOMBYX MORI LYSOZYME
1REU	;	2.65	;	Structure of the bone morphogenetic protein 2 mutant L51P
6GCI	;	3.3	;	Structure of the bongkrekic acid-inhibited mitochondrial ADP/ATP carrier
7O6Q	;	1.88	;	Structure of the borneol dehydrogenase 1 of salvia rosmarinus
7O6P	;	2.04	;	Structure of the borneol dehydrogenase 2 of Salvia officinalis
6ZZ0	;	3.1	;	Structure of the borneol dehydrogenase of Salvia rosmarinus (apo)
6ZZT	;	2.6	;	Structure of the borneol dehydrogenases of Salvia rosmarinus (high salt condition)
6ZYZ	;	2.27	;	Structure of the borneol dehydrogenases of Salvia rosmarinus with NAD+
6T6Z	;	1.7	;	Structure of the Bottromycin epimerase BotH in complex with a bottromycin A2 derivative
6T6Y	;	1.4	;	Structure of the Bottromycin epimerase BotH in complex with Bottromycin A2
6T70	;	1.58	;	Structure of the Bottromycin epimerase BotH in complex with Bottromycin A2 derivative
6T6X	;	1.25	;	Structure of the Bottromycin epimerase BotH in complex with substrate
1G89	;		;	STRUCTURE OF THE BOVINE ANTIMICROBIAL PEPTIDE INDOLICIDIN BOUND TO DODECYLPHOSPHOCHOLINE MICELLES
1G8C	;		;	STRUCTURE OF THE BOVINE ANTIMICROBIAL PEPTIDE INDOLICIDIN BOUND TO SODIUM DODECYL SULFATE MICELLES
4UE0	;	1.17	;	Structure of the bovine atadenovirus type 4 fibre head protein
6VBU	;	3.1	;	Structure of the bovine BBSome complex
6VBV	;	3.5	;	Structure of the bovine BBSome:ARL6:GTP complex
4GCR	;	1.47	;	STRUCTURE OF THE BOVINE EYE LENS PROTEIN GAMMA-B (GAMMA-II)-CRYSTALLIN AT 1.47 ANGSTROMS
1GCS	;	2.0	;	STRUCTURE OF THE BOVINE GAMMA-B CRYSTALLIN AT 150K
2DVC	;	3.0	;	Structure of the bovine lactoferrin C-lobe complex with sucrose at 3.0 A resolution
6D81	;	2.248	;	Structure of the Bovine p85a BH domain
6D82	;	2.407	;	Structure of the Bovine p85a BH domain
6D86	;	2.301	;	Structure of the Bovine p85a BH domain
6D85	;	2.203	;	Structure of the Bovine p85a BH domain E217K mutant
6MRP	;	2.403	;	Structure of the Bovine p85a BH domain R228E mutant
6D87	;	2.7	;	Structure of the Bovine p85alpha BH domain, R262T mutant
7LJN	;	1.6	;	Structure of the Bradyrhizobium diazoefficiens CD-NTase CdnG in complex with GTP
1BND	;	2.3	;	STRUCTURE OF THE BRAIN-DERIVED NEUROTROPHIC FACTOR(SLASH)NEUROTROPHIN 3 HETERODIMER
4OZ6	;	2.786	;	Structure of the Branched Intermediate in Protein Splicing
7R0X	;	2.83	;	Structure of the branching thioesterase from oocydin biosynthesis
4ZLR	;	2.3	;	Structure of the Brat-NHL domain bound to consensus RNA motif
1Y98	;	2.5	;	Structure of the BRCT repeats of BRCA1 bound to a CtIP phosphopeptide.
6Y7H	;	1.8	;	Structure of the BRD9 bromodomain and compound 11
6Y7J	;	1.6	;	Structure of the BRD9 bromodomain and compound 15
6Y7I	;	1.6	;	Structure of the BRD9 bromodomain and compound 2
6Y7K	;	1.2	;	Structure of the BRD9 bromodomain and compound 27
6Y7L	;	1.8	;	Structure of the BRD9 bromodomain and TP-472
6SY2	;		;	Structure of the BRK domain of the SWI/SNF chromatin remodelling complex subunit BRG1 reveals a potential role in protein-protein interactions
4GAY	;	2.65	;	Structure of the broadly neutralizing antibody AP33
4GAJ	;	2.51	;	Structure of the broadly neutralizing antibody AP33 in complex with its HCV epitope (E2 residues 411-424)
4GAG	;	1.8	;	Structure of the broadly neutralizing antibody AP33 in complex with its HCV epitope (E2 residues 412-423)
6WOR	;	2.601	;	Structure of the broadly neutralizing antibody HC1AM
4QUT	;	1.7	;	Structure of the bromodomain of human ATPase family AAA domain-containing protein 2 (ATAD2) complexed with Histone H4-K(ac)12
4QUU	;	1.8	;	Structure of the bromodomain of human ATPase family AAA domain-containing protein 2 (ATAD2) complexed with Histone H4-K(ac)5
4QST	;	2.05	;	Structure of the bromodomain of human ATPase family AAA domain-containing protein 2 (ATAD2) in complex with 1-methylquinolin 2-one
4QSX	;	1.93	;	Structure of the bromodomain of human ATPase family AAA domain-containing protein 2 (ATAD2) in complex with 3'-deoxy thymidine
4QSW	;	1.8	;	Structure of the bromodomain of human ATPase family AAA domain-containing protein 2 (ATAD2) in complex with 5-methyl uridine
4QSP	;	1.6	;	Structure of the bromodomain of human ATPase family AAA domain-containing protein 2 (ATAD2) in complex with acetyl-lysine
4QSS	;	2.0	;	Structure of the bromodomain of human ATPase family AAA domain-containing protein 2 (ATAD2) in complex with N-Methyl-2-pyrrolidone (NMP)
4QSV	;	1.9	;	Structure of the bromodomain of human ATPase family AAA domain-containing protein 2 (ATAD2) in complex with thymidine
4QSU	;	1.9	;	Structure of the bromodomain of human ATPase family AAA domain-containing protein 2 (ATAD2) in complex with thymine
4QSQ	;	1.8	;	Structure of the bromodomain of human ATPase family AAA domain-containing protein 2 (ATAD2) with bound DMSO
4QSR	;	2.0	;	Structure of the bromodomain of human ATPase family AAA domain-containing protein 2 (ATAD2) with bound MPD
5Z1G	;	2.294	;	Structure of the Brx1 and Ebp2 complex
4I92	;	1.6	;	Structure of the BSK8 kinase domain
4I93	;	1.5	;	Structure of the BSK8 kinase domain (SeMet labeled)
2PPI	;	2.4	;	Structure of the BTB (Tramtrack and Bric a brac) domain of human Gigaxonin
6GFB	;	2.08	;	Structure of the BTB/POZ domain of human 90K
6GFC	;	3.3	;	Structure of the BTB/POZ domain of human 90K
1XAU	;	1.8	;	STRUCTURE OF THE BTLA ECTODOMAIN
2GSK	;	2.1	;	Structure of the BtuB:TonB Complex
4WYB	;	3.493	;	Structure of the Bud6 flank domain in complex with actin
4ACO	;	1.89	;	Structure of the budding yeast Ndc10 N-terminal domain
2BFW	;	1.8	;	Structure of the C domain of glycogen synthase from Pyrococcus abyssi
1AUV	;	2.15	;	STRUCTURE OF THE C DOMAIN OF SYNAPSIN IA FROM BOVINE BRAIN
1AUX	;	2.3	;	STRUCTURE OF THE C DOMAIN OF SYNAPSIN IA FROM BOVINE BRAIN WITH CALCIUM ATP-GAMMA-S BOUND
4MJN	;	6.0	;	Structure of the c ring of the CF1FO ATP synthases.
1B7V	;	1.7	;	Structure of the C-553 cytochrome from Bacillus pasteruii to 1.7 A resolution
2KXW	;		;	Structure of the C-domain Fragment of apo Calmodulin Bound to the IQ motif of Nav1.2
2M5E	;		;	Structure of the C-domain of Calcium-saturated Calmodulin bound to the IQ motif of NaV1.2
1IH0	;		;	Structure of the C-domain of Human Cardiac Troponin C in Complex with Ca2+ Sensitizer EMD 57033
4L11	;	2.55	;	Structure of the C-linker/CNBHD of agERG channels
3UKN	;	2.2	;	Structure of the C-linker/CNBHD of zELK channels in C 2 2 21 space group
3UKV	;	2.7	;	Structure of the C-linker/CNBHD of zELK channels in P 1 21 1 space group, crystallized in the presence of cAMP
3UKT	;	2.3	;	Structure of the C-linker/CNBHD of zELK channels in P1 21 1 space group
2KRH	;		;	Structure of the C-terminal actin binding domain of ABRA
4AYN	;	2.06	;	Structure of the C-terminal barrel of Neisseria meningitidis FHbp Variant 2
8OJN	;	2.51	;	Structure of the C-terminal beta helix domain of the Bdellovibrio bacteriovorus Bd3182 fibre
8ONB	;	1.12	;	Structure of the C-terminal beta helix domain of the Bdellovibrio bacteriovorus Bd3182 fibre
8ONC	;	2.0	;	Structure of the C-terminal beta helix domain of the Bdellovibrio bacteriovorus Bd3182 fibre
6WH2	;	2.414	;	Structure of the C-terminal BRCT domain of human XRCC1
6OFP	;	2.006	;	Structure of the C-terminal cargo binding domain of human Bicaudal D2
5KC1	;	2.2	;	Structure of the C-terminal dimerization domain of Atg38
2GE7	;	2.0	;	Structure of the C-terminal dimerization domain of infectious bronchitis virus nucleocapsid protein
2GE8	;	2.2	;	Structure of the C-terminal dimerization domain of infectious bronchitis virus nucleocapsid protein
4NFA	;	2.497	;	Structure of the C-terminal doamin of Knl1
3HCH	;	2.1	;	Structure of the C-terminal domain (MsrB) of Neisseria meningitidis PilB (complex with substrate)
3HCG	;	1.82	;	Structure of the C-terminal domain (MsrB) of Neisseria meningitidis PilB (reduced form)
3L9A	;	1.3	;	Structure of the C-terminal domain from a Streptococcus mutans hypothetical
2LSY	;		;	Structure of the C-terminal domain from human REV1
1XU6	;		;	Structure of the C-terminal domain from Trypanosoma brucei Variant Surface Glycoprotein MITat1.2
3GWO	;	1.65	;	Structure of the C-terminal Domain of a Putative HIV-1 gp41 Fusion Intermediate
3H00	;	2.2	;	Structure of the C-terminal Domain of a Putative HIV-1 gp41 Fusion Intermediate
3H01	;	1.7	;	Structure of the C-terminal Domain of a Putative HIV-1 gp41 Fusion Intermediate
5MUS	;	2.009	;	Structure of the C-terminal domain of a reptarenavirus L protein
3KDK	;	2.26	;	Structure of the C-terminal domain of Bacillus subtilis MutL bound to Zn2+
2YH5	;	1.25	;	Structure of the C-terminal domain of BamC
3T6A	;	2.4	;	Structure of the C-terminal domain of BCAR3
6X7I	;		;	Structure of the C-terminal domain of BCL-XL in membrane
6SWZ	;	1.995	;	Structure of the C-terminal domain of C. glutamicum mycoloyltransferase A
8B9O	;	2.0	;	Structure of the C-terminal domain of ClpC2 from Mycobacterium smegmatis
3OA7	;	2.3	;	Structure of the C-terminal domain of Cnm67, a core component of the spindle pole body of Saccharomyces cerevisiae
2HYX	;	1.9	;	Structure of the C-terminal domain of DipZ from Mycobacterium tuberculosis
5XDM	;	3.004	;	Structure of the C-terminal domain of E. coli MinC at 3.0 angstrom resolution
2KFG	;		;	Structure of the C-terminal domain of EHD1 in complex with FNYESTDPFTAK
2KFH	;		;	Structure of the C-terminal domain of EHD1 with FNYESTGPFTAK
2KFF	;		;	Structure of the C-terminal domain of EHD1 with FNYESTNPFTAK
2LJZ	;		;	Structure of the C-terminal domain of HPV16 E6 oncoprotein
5NH1	;	2.04	;	Structure of the C-terminal domain of human Gasdermin D
3H8H	;	2.0	;	Structure of the C-terminal domain of human RNF2/RING1B;
4JQF	;	1.6	;	Structure of the C-terminal domain of human telomeric Stn1
1YO8	;	2.6	;	Structure of the C-terminal domain of human thrombospondin-2
2FIM	;	1.9	;	Structure of the C-terminal domain of Human Tubby-like protein 1
5BU0	;	2.35	;	Structure of the C-terminal domain of lpg1496 from Legionella pneumophila
5BU2	;	2.11	;	Structure of the C-terminal domain of lpg1496 from Legionella pneumophila in complex with nucleotide
3GZF	;	2.756	;	Structure of the C-terminal domain of nsp4 from Feline Coronavirus
4I9Y	;	1.75	;	Structure of the C-terminal domain of Nup358
4RHA	;	1.75	;	Structure of the C-terminal domain of outer-membrane protein OmpA from Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S
1COK	;		;	STRUCTURE OF THE C-TERMINAL DOMAIN OF P73
6VXG	;		;	Structure of the C-terminal Domain of RAGE and Its Inhibitor
2QX2	;	1.9	;	Structure of the C-terminal domain of sex pheromone staph-cAM373 precursor from Staphylococcus aureus
8OK3	;	1.5	;	Structure of the C-terminal domain of the Bdellovibrio bacteriovorus Bd2133 fibre
3GFP	;	1.8	;	Structure of the C-terminal domain of the DEAD-box protein Dbp5
4LKU	;	1.45	;	Structure of the C-terminal domain of the E. coli mechanosensitive channel of large conductance
3FMY	;	1.4	;	Structure of the C-terminal domain of the E. coli protein MQSA (YgiT/b3021)
5NBB	;		;	Structure of the C-terminal domain of the Escherichia Coli ProQ RNA binding protein
7KD4	;	1.312	;	Structure of the C-terminal domain of the Menangle virus phosphoprotein (residues 329 -388), fused to MBP. Space group P21.
7KD5	;	1.551	;	Structure of the C-terminal domain of the Menangle virus phosphoprotein (residues 329 -388), fused to MBP. Space group P212121
4KYC	;	1.95	;	Structure of the C-terminal domain of the Menangle virus phosphoprotein, fused to MBP.
1VYI	;	1.5	;	Structure of the c-terminal domain of the polymerase cofactor of rabies virus: insights in function and evolution.
7NXR	;	1.9	;	Structure of the C-terminal domain of the pORF19 capsid protein from murid gammaherpesvirus 68 (MuHV-68)
7NXP	;	1.896	;	Structure of the C-terminal domain of the pUL77 capsid protein from human cytomegalovirus (HCMV)
1CTF	;	1.7	;	STRUCTURE OF THE C-TERMINAL DOMAIN OF THE RIBOSOMAL PROTEIN L7/L12 FROM ESCHERICHIA COLI AT 1.7 ANGSTROMS
4E4W	;	2.5	;	Structure of the C-terminal domain of the Saccharomyces cerevisiae MUTL alpha (MLH1/PMS1) heterodimer
4FMO	;	3.04	;	Structure of the C-terminal domain of the Saccharomyces cerevisiae MUTL alpha (MLH1/PMS1) heterodimer bound to a fragment of exo1
4FMN	;	2.69	;	Structure of the C-terminal domain of the Saccharomyces cerevisiae MUTL alpha (MLH1/PMS1) heterodimer bound to a fragment of NTG2
4OFQ	;	1.8	;	Structure of the C-terminal domain of the Streptococcus pyogenes antigen I/II-family protein AspA
4FC9	;	1.8	;	Structure of the C-terminal domain of the type III effector Xcv3220 (XopL)
5D17	;	2.85	;	Structure of the C-terminal domain of TnsE at 2.85 resolution
5D16	;	1.76	;	Structure of the C-terminal domain of TnsE double mutant - A453V/D523N
3H4C	;	2.3	;	Structure of the C-terminal Domain of Transcription Factor IIB from Trypanosoma brucei
6HEM	;	1.72	;	Structure of the C-terminal domain of USP25 (748-1048)
3FD3	;	1.7	;	Structure of the C-terminal domains of a LysR family protein from Agrobacterium tumefaciens str. C58.
5CYY	;	2.2	;	Structure of the C-terminal domains of DipZ from Mycobacterium tuberculosis
8ON4	;	1.41	;	Structure of the C-terminal domains of the Bdellovibrio bacteriovorus Bd1334 fibre
8OND	;	2.5	;	Structure of the C-terminal domains of the Bdellovibrio bacteriovorus Bd2133 fibre
8OL4	;	1.84	;	Structure of the C-terminal domains of the Bdellovibrio bacteriovorus Bd2439 fibre in complex with GlcNAc
1GO5	;		;	Structure of the C-terminal FG-binding domain of human Tap
4PS2	;	2.0	;	Structure of the C-terminal fragment (87-165) of E.coli EAEC TssB molecule
8TYQ	;	2.99	;	Structure of the C-terminal half of LRRK2 bound to GZD-824 (G2019S mutant)
8TZB	;	3.1	;	Structure of the C-terminal half of LRRK2 bound to GZD-824 (I2020T mutant)
2IUM	;	1.6	;	Structure of the C-terminal head domain of the avian adenovirus CELO long fibre (C2 crystal form)
2IUN	;	2.8	;	Structure of the C-terminal head domain of the avian adenovirus CELO long fibre (P21 crystal form)
6ITX	;	2.75	;	Structure of the C-terminal head domain of the avian adenovirus EDSV fiber
7VXO	;	1.6	;	Structure of the C-terminal head domain of the Fowl Adenovirus serotype 4 (FAdV-4) fibre-2 protein
2VTW	;	2.0	;	Structure of the C-terminal head domain of the fowl adenovirus type 1 short fibre
7X5T	;	1.65	;	Structure of the C-terminal head domain of the fowl adenovirus type 4 fiber 1
7W83	;	1.29	;	Structure of the C-terminal head domain of the fowl adenovirus type 4 fiber 2
5KS5	;		;	Structure of the C-terminal Helical Repeat Domain of Elongation Factor 2 Kinase
6NX4	;		;	Structure of the C-terminal Helical Repeat Domain of Eukaryotic Elongation Factor 2 Kinase (eEF-2K)
2DQV	;	2.7	;	Structure of the C-terminal lobe of bovine lactoferrin in complex with galactose at 2.7 A resolution
2N1P	;		;	Structure of the C-terminal membrane domain of HCV NS5B protein
4GKR	;	2.69	;	Structure of the C-terminal motor domain of Kar3 from Candida glabrata
2KHM	;		;	Structure of the C-terminal non-repetitive domain of the spider dragline silk protein ADF-3
1XX0	;		;	Structure of the C-terminal PH domain of human pleckstrin
3ES2	;	2.95	;	Structure of the C-terminal phosphatase domain of P. aeruginonsa RssB
2ROZ	;		;	Structure of the C-terminal PID Domain of Fe65L1 Complexed with the Cytoplasmic Tail of APP Reveals a Novel Peptide Binding Mode
8SXE	;	3.55	;	Structure of the C-terminal protease CtpA-LbcA complex of Pseudomonas aeruginosa
8SXH	;	3.94	;	Structure of the C-terminal protease CtpA-LbcA complex of Pseudomonas aeruginosa
2BT7	;	2.35	;	Structure of the C-terminal receptor-binding domain of avian reovirus fibre sigmaC, Cd crystal form
2BT8	;	3.0	;	Structure of the C-terminal receptor-binding domain of avian reovirus fibre sigmaC, space group P6322.
2BSF	;	2.1	;	Structure of the C-terminal receptor-binding domain of avian reovirus fibre sigmaC, Zn crystal form.
3SW0	;	1.8	;	Structure of the C-terminal region (modules 18-20) of complement regulator Factor H
3IM1	;	1.65	;	Structure of the C-terminal Sec63 unit of yeast Brr2, P212121 Form
3IM2	;	1.99	;	Structure of the C-terminal Sec63 unit of yeast Brr2, P41212 Form
4TT9	;	2.3	;	Structure of the C-terminal SpoA domain of Shigella flexneri Spa33
5KTF	;		;	Structure of the C-terminal transmembrane domain of scavenger receptor BI (SR-BI)
4K22	;	2.0	;	Structure of the C-terminal truncated form of E.Coli C5-hydroxylase UBII involved in ubiquinone (Q8) biosynthesis
5FM4	;	2.8	;	Structure of the C-terminally extended domain My4 of human myomesin (space group P21)
5FM8	;	2.05	;	Structure of the C-terminally extended domain My4 of human myomesin (space group P65)
8AK4	;	3.36	;	Structure of the C-terminally truncated NAD+-dependent DNA ligase from the poly-extremophile Deinococcus radiodurans
3FG6	;	3.0	;	Structure of the C-terminus of Adseverin
1T8C	;		;	Structure of the C-type lectin domain of CD23
1T8D	;		;	Structure of the C-type lectin domain of CD23
3BOK	;	1.25	;	Structure of the C. botulinum neurotoxin serotype A apo-enzyme
6XCB	;	1.74	;	Structure of the C. botulinum neurotoxin serotype A light chain protease in complex with covalent inhibitor 20
6XCC	;	1.9	;	Structure of the C. botulinum neurotoxin serotype A light chain protease in complex with covalent inhibitor 21
6XCD	;	1.92	;	Structure of the C. botulinum neurotoxin serotype A light chain protease in complex with covalent inhibitor 22
6XCE	;	2.5	;	Structure of the C. botulinum neurotoxin serotype A light chain protease in complex with covalent inhibitor 53
6XCF	;	1.68	;	Structure of the C. botulinum neurotoxin serotype A light chain protease in complex with noncovalent inhibitor 59
3BOO	;	1.4	;	Structure of the C. botulinum neurotoxin serotype A with an inhibitory peptide bound
5VGV	;	2.6	;	Structure of the C. botulinum neurotoxin serotype A with Cu bound
5VGX	;	2.15	;	Structure of the C. botulinum neurotoxin serotype A with Hg bound
3BON	;	1.2	;	Structure of the C. botulinum neurotoxin serotype A with Zn2+ cofactor bound
7U02	;	2.48	;	Structure of the C. crescentus DriD C-domain bound to ssDNA
5N97	;	7.4	;	Structure of the C. crescentus S-layer
8TP8	;	2.74	;	Structure of the C. crescentus WYL-activator, DriD, bound to ssDNA and cognate DNA
3PEE	;	2.1	;	Structure of the C. difficile TcdB cysteine protease domain
3PA8	;	2.0	;	Structure of the C. difficile TcdB cysteine protease domain in complex with a peptide inhibitor
8CXK	;	1.3	;	Structure of the C. elegans HIM-3 R93Y mutant
5CA5	;	2.4	;	Structure of the C. elegans NONO-1 homodimer
5MJ7	;	1.65	;	Structure of the C. elegans nucleoside hydrolase
4YV4	;	1.8	;	Structure of the C. elegans SAS-5 coiled coil domain
4YNH	;	1.0	;	Structure of the C. elegans SAS-5 Implico dimerization domain
3ZHE	;	3.0	;	Structure of the C. elegans SMG5-SMG7 complex
8TKP	;	2.9	;	Structure of the C. elegans TMC-2 complex
7VPT	;	2.5	;	Structure of the C. glabrata importin alpha ARM domain - Upc2 NLS fusion
4AF5	;	1.9	;	Structure of the C. glutamicum AcnR Crystal Form I
4ACI	;	1.65	;	Structure of the C. glutamicum AcnR Crystal Form II
7Z6E	;	2.14	;	Structure of the C1-PH-CNH regulatory module of MRCK1
1A2N	;	2.8	;	STRUCTURE OF THE C115A MUTANT OF MURA COMPLEXED WITH THE FLUORINATED ANALOG OF THE REACTION TETRAHEDRAL INTERMEDIATE
3UZT	;	3.51	;	Structure of the C13.18 RNA Aptamer in Complex with G Protein-Coupled Receptor Kinase 2
3UZS	;	4.52	;	Structure of the C13.28 RNA Aptamer Bound to the G Protein-Coupled Receptor Kinase 2-Heterotrimeric G Protein Beta 1 and Gamma 2 Subunit Complex
2W5J	;	3.8	;	Structure of the c14-rotor ring of the proton translocating chloroplast ATP synthase
3M31	;	1.85	;	Structure of the C150A/C295A mutant of S. cerevisiae Ero1p
1GMI	;	1.7	;	Structure of the c2 domain from novel protein kinase C epsilon
5K5D	;	2.45	;	Structure of the C2221 form of Pnob8-like ParB-N domain
2B4U	;	2.0	;	Structure of the C252S mutant of Selenomonas ruminantium PTP-like phytase
8ENU	;	3.22	;	Structure of the C3bB proconvertase in complex with lufaxin
8EOK	;	3.53	;	Structure of the C3bB proconvertase in complex with lufaxin and factor Xa
1CHC	;		;	STRUCTURE OF THE C3HC4 DOMAIN BY 1H-NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; A NEW STRUCTURAL CLASS OF ZINC-FINGER
7D5V	;	2.102	;	Structure of the C646A mutant of peptidylarginine deiminase type III (PAD3)
6T1C	;	2.0	;	Structure of the C7S mutant of mosquitocidal Cyt1A protoxin obtained by Serial Femtosecond Crystallography on in vivo grown crystals at pH 7
4UBT	;	1.7	;	Structure of the C93S variant of the 3-ketoacyl-CoA thiolase FadA5 from M. tuberculosis in complex with a steroid and CoA.
7O2W	;		;	Structure of the C9orf72-SMCR8 complex
2Q91	;	1.63	;	Structure of the Ca2+-Bound Activated Form of the S100A4 Metastasis Factor
7D5R	;	3.148	;	Structure of the Ca2+-bound C646A mutant of peptidylarginine deiminase type III (PAD3)
5LOW	;	2.8	;	Structure of the Ca2+-bound Rabphilin 3A C2B domain SNAP25 complex (P21 space group)
5LOB	;	3.3	;	Structure of the Ca2+-bound Rabphilin3A C2B- SNAP25 complex (C2 space group)
5CCG	;	3.5	;	Structure of the Ca2+-bound synaptotagmin-1 SNARE complex (long unit cell form)
5KJ8	;	4.1	;	Structure of the Ca2+-bound synaptotagmin-1 SNARE complex (long unit cell form) - from synchrotron diffraction
5KJ7	;	3.5	;	Structure of the Ca2+-bound synaptotagmin-1 SNARE complex (long unit cell form) - from XFEL diffraction
5CCH	;	3.6	;	Structure of the Ca2+-bound synaptotagmin-1 SNARE complex (short unit cell form)
7DAN	;	3.1	;	Structure of the Ca2+-bound wild-type peptidylarginine deiminase type III (PAD3)
1OQP	;		;	STRUCTURE OF THE CA2+/C-TERMINAL DOMAIN OF CALTRACTIN IN COMPLEX WITH THE CDC31P-BINDING DOMAIN FROM KAR1P
3BA6	;	2.8	;	Structure of the Ca2E1P phosphoenzyme intermediate of the SERCA Ca2+-ATPase
8DEI	;	2.81	;	Structure of the Cac1 KER domain
6Z3U	;	2.6	;	Structure of the CAK complex form Chaetomium thermophilum
6Z4X	;	2.98	;	Structure of the CAK complex form Chaetomium thermophilum bound to ATP-gamma-S
2JOG	;		;	Structure of the calcineurin-NFAT complex
2CCO	;		;	STRUCTURE OF THE CALCIUM CHANNEL BLOCKER OMEGA CONOTOXIN GVIA, NMR, 20 STRUCTURES
1RJH	;		;	Structure of the Calcium Free Form of the C-type Lectin-like Domain of Tetranectin
1MSB	;	2.3	;	STRUCTURE OF THE CALCIUM-DEPENDENT LECTIN DOMAIN FROM A RAT MANNOSE-BINDING PROTEIN DETERMINED BY MAD PHASING
1EL4	;	1.73	;	STRUCTURE OF THE CALCIUM-REGULATED PHOTOPROTEIN OBELIN DETERMINED BY SULFUR SAS
8B0R	;	2.2	;	Structure of the CalpL/cA4 complex
8B0U	;	3.29	;	Structure of the CalpL/T10 complex
3H6A	;	1.608	;	Structure of the Calx-beta domain of integrin beta4 crystallized in the presence of calcium
2BYV	;	2.7	;	Structure of the cAMP responsive exchange factor Epac2 in its auto- inhibited state
8DQD	;	1.78	;	Structure of the Campylobacter concisus glycosyltransferase PglA
8DVW	;	2.29	;	Structure of the Campylobacter concisus glycosyltransferase PglA R203Q
8DVZ	;	2.27	;	Structure of the Campylobacter concisus glycosyltransferase PglA R282V variant
2V25	;	1.49	;	Structure of the Campylobacter jejuni antigen Peb1A, an aspartate and glutamate receptor with bound aspartate
6X80	;	3.5	;	Structure of the Campylobacter jejuni G508A Flagellar Filament
3TSO	;	1.8	;	Structure of the cancer associated Rab25 protein in complex with FIP2
4A0C	;	3.8	;	Structure of the CAND1-CUL4B-RBX1 complex
7Q0P	;	2.77	;	Structure of the Candida albicans 80S ribosome in complex with anisomycin
7Q0R	;	2.67	;	Structure of the Candida albicans 80S ribosome in complex with blasticidin s
2WFE	;	2.9	;	Structure of the Candida albicans cytosolic leucyl-tRNA synthetase editing domain
2WFG	;	2.2	;	Structure of the Candida albicans cytosolic leucyl-tRNA synthetase editing domain bound to a benzoxaborole-AMP adduct
7ANZ	;	3.6	;	Structure of the Candida albicans gamma-Tubulin Small Complex
2OX2	;		;	Structure of the cantionic, antimicrobial hexapeptide cyclo(RRWWFR) bound to DPC-micelles
4U6O	;	1.3	;	STRUCTURE OF THE CAP-BINDING DOMAIN OF INFLUENZA VIRUS POLYMERASE SUBUNIT PB2
2VQZ	;	2.3	;	Structure of the cap-binding domain of influenza virus polymerase subunit PB2 with bound m7GTP
6QHG	;	1.483	;	Structure of the cap-binding domain of Rift Valley Fever virus L protein
3J9J	;	3.275	;	Structure of the capsaicin receptor, TRPV1, determined by single particle electron cryo-microscopy
4BTP	;	3.7	;	Structure of the capsid protein P1 of the bacteriophage phi8
1E19	;	1.5	;	Structure of the carbamate kinase-like carbamoyl phosphate synthetase from the hyperthermophilic archaeon Pyrococcus furiosus bound to ADP
5VYB	;	2.4	;	Structure of the carbohydrate recognition domain of Dectin-2 complexed with a mammalian-type high mannose Man9GlcNAc2 oligosaccharide
3P5I	;	1.8	;	Structure of the carbohydrate-recognition domain of human Langerin with 6-SO4-Gal-GlcNAc
3P5G	;	1.6027	;	Structure of the carbohydrate-recognition domain of human Langerin with Blood group B trisaccharide (Gal alpha1-3(Fuc alpha1-2)Gal)
3P5H	;	1.6051	;	Structure of the carbohydrate-recognition domain of human Langerin with Laminaritriose
3P5F	;	1.7501	;	Structure of the carbohydrate-recognition domain of human Langerin with man2 (Man alpha1-2 Man)
3P5E	;	1.7012	;	Structure of the carbohydrate-recognition domain of human Langerin with man4 (Man alpha1-3(Man alpha1-6)Man alpha1-6Man)
3P5D	;	1.8013	;	Structure of the carbohydrate-recognition domain of human Langerin with man5 (Man alpha1-3(Man alpha1-6)Man alpha1-6)(Man- alpha1-3)Man
4KZW	;	1.85	;	Structure of the carbohydrate-recognition domain of the C-type lectin mincle
4KZV	;	1.4	;	Structure of the carbohydrate-recognition domain of the C-type lectin mincle bound to trehalose
6K9S	;	1.55	;	Structure of the Carbonylruthenium Mesoporphyrin IX-Reconstituted CYP102A1 Haem Domain with N-Abietoyl-L-Tryptophan
8UM1	;		;	Structure of the Carboxy terminus of Oleate Hydratase
4A0U	;	2.0	;	Structure of the carboxy-terminal domain of bacteriophage T7 fibre gp17 containing residues 371-553, C2221 crystal form.
4A0T	;	1.9	;	Structure of the carboxy-terminal domain of bacteriophage T7 fibre gp17 containing residues 371-553.
4UW8	;	2.52	;	Structure of the carboxy-terminal domain of the bacteriophage T5 L- shaped tail fiber with its intra-molecular chaperone domain
4UW7	;	2.52	;	Structure of the carboxy-terminal domain of the bacteriophage T5 L- shaped tail fiber without its intra-molecular chaperone domain
5AQ5	;	2.3	;	Structure of the Carboxy-Terminal Domain of the Bacteriophage T5 L- Shaped Tail Fibre
3ZPE	;	2.2	;	Structure of the carboxy-terminal domain of the turkey type 3 siadenovirus fibre
3ZPF	;	2.2	;	Structure of the carboxy-terminal domain of the turkey type 3 siadenovirus fibre
4D62	;	2.5	;	Structure of the carboxy-terminal domain of the turkey type 3 siadenovirus fibre, avirulent form complexed with 3-sialyllactose.
4D63	;	2.2	;	Structure of the carboxy-terminal domain of the turkey type 3 siadenovirus fibre, avirulent form complexed with 6-sialyllactose.
4CW8	;	2.3	;	Structure of the carboxy-terminal domain of the turkey type 3 siadenovirus fibre, virulent form
1CTL	;		;	STRUCTURE OF THE CARBOXY-TERMINAL LIM DOMAIN FROM THE CYSTEINE RICH PROTEIN CRP
4JX4	;	2.98	;	Structure of the carboxyl transferase domain from Rhizobium etli pyruvate carboxylase
4MIM	;	2.65	;	Structure of the carboxyl transferase domain from Rhizobium etli pyruvate carboxylase with 3-bromopyruvate
4MFE	;	2.61	;	Structure of the carboxyl transferase domain from Rhizobium etli pyruvate carboxylase with 3-hydroxypyruvate
4MFD	;	2.55	;	Structure of the carboxyl transferase domain from Rhizobium etli pyruvate carboxylase with oxalate
4LOC	;	2.26	;	Structure of the carboxyl transferase domain from Rhizobium etli pyruvate carboxylase with oxamate and biotin
4JX5	;	2.55	;	Structure of the carboxyl transferase domain from Rhizobium etli pyruvate carboxylase with pyruvate
4M6V	;	2.4	;	Structure of the carboxyl transferase domain from Rhizobium etli pyruvate carboxylase with pyruvate and biocytin
4JX6	;	2.78	;	Structure of the carboxyl transferase domain Y628A from Rhizobium etli pyruvate carboxylase with pyruvate
4A94	;	1.7	;	Structure of the carboxypeptidase inhibitor from Nerita versicolor in complex with human CPA4
5WVC	;	2.993	;	Structure of the CARD-CARD disk
4J5L	;	2.2	;	Structure of the Cargo Binding Domain from Human Myosin Va
4J5M	;	2.07	;	Structure of the Cargo Binding Domain from Human Myosin Vb
4L8T	;	2.95	;	Structure of the Cargo Binding Domain from Human Myosin Vc
6D84	;	6.72	;	Structure of the cargo bound AP-1:Arf1:tetherin-Nef (L164A, L165A) dileucine mutant dimer
6D83	;	4.27	;	Structure of the cargo bound AP-1:Arf1:tetherin-Nef (L164A, L165A) dileucine mutant dimer monomeric subunit
6CM9	;	3.73	;	Structure of the cargo bound AP-1:Arf1:tetherin-Nef closed trimer monomeric subunit
6DFF	;	3.9	;	Structure of the cargo bound AP-1:Arf1:tetherin-Nef monomer
6CRI	;	6.8	;	Structure of the cargo bound AP-1:Arf1:tetherin-Nef stable closed trimer
7Y9X	;	2.49	;	Structure of the Cas7-11-Csx29-guide RNA complex
7Y9Y	;	2.77	;	Structure of the Cas7-11-Csx29-guide RNA-target RNA (no PFS) complex
8GS2	;	2.84	;	Structure of the Cas7-11-Csx29-guide RNA-target RNA (non-matching PFS) complex
5O7H	;	3.0	;	Structure of the Cascade-I-Fv complex from Shewanella putrefaciens
5O6U	;	3.25	;	Structure of the Cascade-I-Fv R-loop complex from Shewanella putrefaciens
4EKN	;	2.4996	;	Structure of the catalytic chain of Methanococcus jannaschii Aspartate Transcarbamoylase in a hexagonal crystal form
4A05	;	1.9	;	Structure of the catalytic core domain of the cellobiohydrolase, Cel6A, from Chaetomium thermophilum
1T3N	;	2.3	;	Structure of the catalytic core of DNA polymerase Iota in complex with DNA and dTTP
3U1N	;	3.1	;	Structure of the catalytic core of human SAMHD1
4D4A	;	1.4	;	Structure of the catalytic domain (BcGH76) of the Bacillus circulans GH76 alpha mannanase, Aman6.
1QYU	;	2.0	;	Structure of the catalytic domain of 23S rRNA pseudouridine synthase RluD
4DFS	;	3.754	;	Structure of the catalytic domain of an endo-1,3-beta-glucanase (laminarinase) from Thermotoga petrophila RKU-1
6FRV	;	2.3	;	Structure of the catalytic domain of Aspergillus niger Glucoamylase
1JWQ	;	1.8	;	Structure of the catalytic domain of CwlV, N-acetylmuramoyl-L-alanine amidase from Bacillus(Paenibacillus) polymyxa var.colistinus
4PL9	;	1.9	;	Structure of the catalytic domain of ETR1 from Arabidopsis thaliana
1CGL	;	2.4	;	Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor
2HD0	;	2.28	;	Structure of the catalytic domain of hepatitis C virus NS2
1LN0	;	2.0	;	Structure of the Catalytic Domain of Homing Endonuclease I-TevI
1F6W	;	2.3	;	STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN BILE SALT ACTIVATED LIPASE
1NW3	;	2.5	;	Structure of the Catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase
6ZFQ	;	1.2	;	Structure of the catalytic domain of human endo-alpha-mannosidase MANEA in complex with bis-tris
6ZJ5	;	2.269	;	Structure of the catalytic domain of human endo-alpha-mannosidase MANEA in complex with GlcDMJ and hexatungstotellurate(VI) TEW
6ZDL	;	1.9	;	Structure of the catalytic domain of human endo-alpha-mannosidase MANEA in complex with GlcIFG and hexatungstotellurate(VI) TEW
6ZFA	;	1.8	;	Structure of the catalytic domain of human endo-alpha-mannosidase MANEA in complex with GlcIFG, alpha-1,2-mannobiose and hexatungstotellurate(VI) TEW
6ZDF	;	3.0	;	Structure of the catalytic domain of human endo-alpha-mannosidase MANEA in complex with HEPES
6ZDK	;	2.0	;	Structure of the catalytic domain of human endo-alpha-mannosidase MANEA in complex with HEPES and hexatungstotellurate(VI) TEW
6ZDC	;	2.251	;	Structure of the catalytic domain of human endo-alpha-mannosidase MANEA in complex with nickel
2TCL	;	2.2	;	STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN FIBROBLAST COLLAGENASE COMPLEXED WITH AN INHIBITOR
3USN	;		;	STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN FIBROBLAST STROMELYSIN-1 INHIBITED WITH THE THIADIAZOLE INHIBITOR IPNU-107859, NMR, 1 STRUCTURE
2OU7	;	2.4	;	Structure of the Catalytic Domain of Human Polo-like Kinase 1
2OWB	;	2.1	;	Structure of the Catalytic Domain of Human Polo-like Kinase 1
2WZ1	;	1.63	;	STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN SOLUBLE GUANYLATE CYCLASE 1 BETA 3.
2GFO	;	2.0	;	Structure of the Catalytic Domain of Human Ubiquitin Carboxyl-terminal Hydrolase 8
2J0A	;	1.8	;	Structure of the catalytic domain of mouse Manic Fringe
2J0B	;	2.1	;	Structure of the catalytic domain of mouse Manic Fringe in complex with UDP and manganese
8COZ	;	1.438	;	Structure of the catalytic domain of P. vivax Sub1 (triclinic crystal form)
8COY	;	1.507	;	Structure of the catalytic domain of P. vivax Sub1 (triclinic crystal form) in complex with inhibitor
8CP0	;	3.251	;	Structure of the catalytic domain of P. vivax Sub1 (trigonal crystal form)
7KK2	;	1.695	;	Structure of the catalytic domain of PARP1
7KK5	;	1.7	;	Structure of the catalytic domain of PARP1 in complex with niraparib
7KK4	;	1.96	;	Structure of the catalytic domain of PARP1 in complex with olaparib
7KK3	;	2.06	;	Structure of the catalytic domain of PARP1 in complex with talazoparib
7KK6	;	2.06	;	Structure of the catalytic domain of PARP1 in complex with veliparib
4BPC	;	2.1	;	Structure of the Catalytic Domain of Protein Tyrosine Phosphatase Sigma in the Sulfenic Acid Form
8FK4	;	3.25	;	Structure of the catalytic domain of Streptococcus mutans GtfB complexed to acarbose in orthorhombic space group P21212
8FJC	;	2.5	;	Structure of the catalytic domain of Streptococcus mutans GtfB complexed to acarbose in tetragonal space group P4322
8FJ9	;	2.5	;	Structure of the catalytic domain of Streptococcus mutans GtfB in tetragonal space group P4322
2VVZ	;	2.5	;	Structure of the catalytic domain of Streptococcus pneumoniae sialidase NanA
6S2U	;	2.95	;	Structure of the catalytic domain of T. thermophilus Rel in complex with AMP and ppGpp
7KKM	;	1.58	;	Structure of the catalytic domain of tankyrase 1
7KKP	;	1.4	;	Structure of the catalytic domain of tankyrase 1 in complex with niraparib
7KKO	;	1.56	;	Structure of the catalytic domain of tankyrase 1 in complex with olaparib
7KKN	;	1.48	;	Structure of the catalytic domain of tankyrase 1 in complex with talazoparib
7KKQ	;	1.59	;	Structure of the catalytic domain of tankyrase 1 in complex with veliparib
6ZBX	;	1.35	;	Structure of the catalytic domain of the Bacillus circulans alpha-1,6 Mannanase in complex with an alpha-1,6- alpha-manno-cyclophellitol carbasugar-stabilised trisaccharide inhibitor
7NL5	;	1.4	;	Structure of the catalytic domain of the Bacillus circulans alpha-1,6 Mannanase in complex with an alpha-1,6-alpha-manno-cyclophellitol trisaccharide inhibitor
2PI7	;	2.59	;	Structure of the catalytic domain of the chick retinal neurite inhibitor-Receptor Protein Tyrosine Phosphatase CRYP-2/cPTPRO
5T6O	;	1.8	;	Structure of the catalytic domain of the class I polyhydroxybutyrate synthase from Cupriavidus necator
2W20	;	1.49	;	Structure of the catalytic domain of the native NanA sialidase from Streptococcus pneumoniae
4G29	;	1.7	;	Structure of the Catalytic Domain of the Salmonella Virulence Factor SseI
4G2B	;	2.05	;	Structure of the Catalytic Domain of the Salmonella Virulence Factor SseI
6HEH	;	2.26	;	Structure of the catalytic domain of USP28 (insertion deleted)
6HEI	;	1.64	;	Structure of the catalytic domain of USP28 (insertion deleted) bound to Ubiquitin-PA
1NB8	;	2.3	;	Structure of the catalytic domain of USP7 (HAUSP)
3RDR	;	2.2	;	Structure of the catalytic domain of XlyA
4NTT	;	3.5	;	Structure of the catalytic subunit of cAMP-dependent protein kinase bound to ADP and one magnesium ion
8QCG	;	1.04	;	STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 (CK2ALPHA') IN COMPLEX WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMPPNP
8QF1	;	1.32	;	STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 (CK2ALPHA') IN COMPLEX WITH THE NON-HYDROLYZABLE GTP ANALOGUE GMPPNP
3KYL	;	2.7	;	Structure of the catalytic subunit of telomerase bound to its RNA template and telomeric DNA
3DU5	;	3.25	;	Structure of the catalytic subunit of telomerase, TERT
3DU6	;	2.71	;	Structure of the catalytic subunit of telomerase, TERT
7EEB	;	2.9	;	Structure of the CatSpermasome
7PEO	;	4.37	;	Structure of the Caulobacter crescentus S-layer protein RsaA N-terminal domain bound to LPS and soaked with Holmium
5LY8	;	1.28	;	Structure of the CBM2 module of Lactobacillus casei BL23 phage J-1 evolved Dit.
4XUO	;	1.7	;	Structure of the CBM22-1 xylan-binding domain from Paenibacillus barcinonensis Xyn10C
4XUN	;	1.75	;	Structure of the CBM22-2 xylan-binding domain from Paenibacillus barcinonensis Xyn10C
4XUR	;	1.67	;	Structure of the CBM22-2 xylan-binding domain from Paenibacillus barcinonensis Xyn10C in complex with xylotetraose
4XUQ	;	1.95	;	Structure of the CBM22-2 xylan-binding domain from Paenibacillus barcinonensis Xyn10C in complex with xylotriose
4XUT	;	1.8	;	Structure of the CBM22-2 xylan-binding domain in complex with 1,3:1,4 Beta-glucotetraose B from Paenibacillus barcinonensis Xyn10C
7CFH	;	2.0	;	Structure of the CBS domain of the bacterial CNNM/CorC family Mg2+ transporter
7CFI	;	2.45	;	Structure of the CBS domain of the bacterial CNNM/CorC family Mg2+ transporter in complex with ATP
7CFK	;	2.9	;	Structure of the CBS domain of the bacterial CNNM/CorC family Mg2+ transporter in complex with the novel inhibitor IGN95a
3K2V	;	1.95	;	Structure of the CBS pair of a putative D-arabinose 5-phosphate isomerase from Klebsiella pneumoniae subsp. pneumoniae.
2RPT	;		;	Structure of the CC mismatch from the thymidylate synthase binding site 1 hairpin and analysis of its interaction with paromomycin
4HGY	;	3.0	;	Structure of the CcbJ Methyltransferase from Streptomyces caelestis
4HGZ	;	2.7	;	Structure of the CcbJ Methyltransferase from Streptomyces caelestis
4HH4	;	2.9	;	Structure of the CcbJ Methyltransferase from Streptomyces caelestis
4WH9	;	1.5	;	Structure of the CDC25B Phosphatase Catalytic Domain with Bound Inhibitor
4WH7	;	1.62	;	Structure of the CDC25B Phosphatase Catalytic Domain with Bound Ligand
2KLO	;		;	Structure of the Cdt1 C-terminal domain
5CXU	;	1.6	;	Structure of the CE1 ferulic acid esterase AmCE1/Fae1A, from the anaerobic fungi Anaeromyces mucronatus in the absence of substrate
4YIQ	;	1.85	;	Structure of the CEACAM6-CEACAM8 heterodimer
3LQQ	;	3.534	;	Structure of the CED-4 Apoptosome
5XCY	;	1.199	;	Structure of the cellobiohydrolase Cel6A from Phanerochaete chrysosporium at 1.2 angstrom
5XCZ	;	2.1	;	Structure of the cellobiohydrolase Cel6A from Phanerochaete chrysosporium in complex with cellobiose at 2.1 angstrom
3BQF	;	2.24	;	Structure of the central domain (MsrA) of Neisseria meningitidis PilB (complex with a substrate)
3BQH	;	1.95	;	Structure of the central domain (MsrA) of Neisseria meningitidis PilB (oxidized form)
3BQE	;	2.0	;	Structure of the central domain (MsrA) of Neisseria meningitidis PilB (reduced form)
3BQG	;	2.0	;	Structure of the central domain (MsrA) of Neisseria meningitidis PilB (sulfenic acid form)
3K81	;	3.4	;	Structure of the central interaction protein from the Trypanosoma brucei editosome in complex with single domain antibodies
4MYP	;	1.8	;	Structure of the central NEAT domain, N2, of the listerial Hbp2 protein complexed with heme
4NLA	;	2.7	;	Structure of the central NEAT domain, N2, of the listerial Hbp2 protein, apo form
4NFU	;	2.21	;	Structure of the central plant immunity signaling node EDS1 in complex with its interaction partner SAG101
3PE0	;	2.95	;	Structure of the central region of the plakin domain of plectin
2VKZ	;	4.0	;	Structure of the cerulenin-inhibited fungal fatty acid synthase type I multienzyme complex
3FAV	;	2.15	;	Structure of the CFP10-ESAT6 complex from Mycobacterium tuberculosis
7LT1	;	2.4	;	Structure of the cGAS-like receptor human MB21D2
4OJK	;	2.657	;	Structure of the cGMP Dependent Protein Kinase II and Rab11b Complex
4KNH	;	2.702	;	Structure of the Chaetomium thermophilum adaptor nucleoporin Nup192 N-terminal domain
4WPM	;	2.4	;	Structure of the Chaetomium thermophilum Mex67:Mtr2 Complex
6DG4	;	1.442	;	Structure of the Chaetomium thermophilum Ulp1-like SUMO protease catalytic domain
1PI7	;		;	Structure of the channel-forming trans-membrane domain of Virus protein ""u"" (Vpu) from HIV-1
1PI8	;		;	Structure of the channel-forming trans-membrane domain of Virus protein ""u"" (Vpu) from HIV-1
1PJE	;		;	Structure of the channel-forming trans-membrane domain of Virus protein ""u""(Vpu) from HIV-1
6TMW	;	5.91	;	Structure of the chaperonin gp146 from the bacteriophage EL (Pseudomonas aeruginosa) in complex with ADP
6TMX	;	5.8	;	Structure of the chaperonin gp146 from the bacteriophage EL (Pseudomonas aeruginosa) in complex with ATPgammaS
6TMV	;	3.45	;	Structure of the chaperonin gp146 from the bacteriophage EL (Pseudomonas aeruginosa) in the apo state
3E9J	;	3.7	;	Structure of the charge-transfer intermediate of the transmembrane redox catalyst DsbB
6YMZ	;	2.3	;	Structure of the CheB methylsterase from P. atrosepticum SCRI1043
3RVP	;	2.404	;	Structure of the CheY-BeF3 Complex with substitutions at 59 and 89: N59D and E89K
3RVJ	;	2.1	;	Structure of the CheY-BeF3 Complex with substitutions at 59 and 89: N59D and E89Q
3RVL	;	1.55	;	Structure of the CheY-BeF3 Complex with substitutions at 59 and 89: N59D and E89R
3RVN	;	2.25	;	Structure of the CheY-BeF3 Complex with substitutions at 59 and 89: N59D and E89Y
3RVM	;	1.45	;	Structure of the CheY-Mn2+ Complex with substitutions at 59 and 89: N59D and E89R
3RVQ	;	1.15	;	Structure of the CheY-Mn2+ Complex with substitutions at 59 and 89: N59D E89K
3RVK	;	1.16	;	Structure of the CheY-Mn2+ Complex with substitutions at 59 and 89: N59D E89Q
3RVR	;	2.1	;	Structure of the CheYN59D/E89R Molybdate complex
3RVS	;	2.1	;	Structure of the CheYN59D/E89R Tungstate complex
4E0R	;	2.26	;	Structure of the chicken MHC class I molecule BF2*0401
4G43	;	1.803	;	Structure of the chicken MHC class I molecule BF2*0401 complexed to P5E
4G42	;	2.294	;	Structure of the Chicken MHC Class I Molecule BF2*0401 complexed to pepitde P8D
3TRK	;	2.397	;	Structure of the Chikungunya virus nsP2 protease
4KBQ	;	2.91	;	Structure of the CHIP-TPR domain in complex with the Hsc70 Lid-Tail domains
2LHS	;		;	Structure of the chitin binding protein 21 (CBP21)
7BLY	;	1.81	;	Structure of the chitin deacetylase AngCDA from Aspergillus niger
2IW0	;	1.81	;	Structure of the chitin deacetylase from the fungal pathogen Colletotrichum lindemuthianum
1DXJ	;	1.8	;	Structure of the chitinase from jack bean
6OF9	;	3.0	;	Structure of the Chlamydamonas reinhardtii CamKII hub homology domain
6WA9	;	4.62	;	Structure of the Chlamydia pneumoniae CdsV and CdsO protein complex
6WA6	;	2.8	;	Structure of the Chlamydia pneumoniae CdsV protein
6YRL	;	2.343	;	Structure of the Chlamydomonas reinhardtii SAS-6 coiled-coil domain, C2 crystal form
6YRN	;	2.43	;	Structure of the Chlamydomonas reinhardtii SAS-6 coiled-coil domain, P2 crystal form
2IZ6	;	1.6	;	Structure of the Chlamydomonas rheinhardtii Moco Carrier Protein
1RYN	;	1.75	;	Structure of the Chloroplast Group II Intron Splicing Factor CRS2
6ERI	;	3.0	;	Structure of the chloroplast ribosome with chl-RRF and hibernation-promoting factor
5I9J	;	1.74	;	Structure of the cholesterol and lutein-binding domain of human STARD3 at 1.74A
2LBG	;		;	Structure of the CHR of the Prion protein in DPC Micelles
1AP0	;		;	STRUCTURE OF THE CHROMATIN BINDING (CHROMO) DOMAIN FROM MOUSE MODIFIER PROTEIN 1, NMR, 26 STRUCTURES
6FTX	;	4.5	;	Structure of the chromatin remodelling enzyme Chd1 bound to a ubiquitinylated nucleosome
6JMW	;	1.85	;	Structure of the Chromium Protoporphyrin IX-Reconstituted CYP102A1 Haem Domain with N-Abietoyl-L-Tryptophan
3BO6	;	1.4	;	Structure of the Chromobacterium violaceum VirA (SpvC) Phosphothreonine Lyase effector protein
4PLL	;	2.6	;	Structure of the chromodaomain of MRG2 in complex with H3K36me3
1GUW	;		;	STRUCTURE OF THE CHROMODOMAIN FROM MOUSE HP1beta IN COMPLEX WITH THE LYSINE 9-METHYL HISTONE H3 N-TERMINAL PEPTIDE, NMR, 25 STRUCTURES
4PLI	;	1.651	;	Structure of the chromodomain of MRG2 in complex with H3K36me3
4PL6	;	1.681	;	Structure of the chromodomain of MRG2 in complex with H3K4me3
1ZTU	;	2.5	;	Structure of the chromophore binding domain of bacterial phytochrome
6BAF	;	1.85	;	Structure of the chromophore binding domain of Stigmatella aurantiaca phytochrome P1, wild-type
3EB5	;	2.0	;	Structure of the cIAP2 RING domain
3EB6	;	3.4	;	Structure of the cIAP2 RING domain bound to UbcH5b
4FBJ	;	1.6	;	Structure of the Cif:Nedd8 complex - Photorhabdus luminescens Cycle Inhibiting Factor in complex with human Nedd8
4F8C	;	1.95	;	Structure of the Cif:Nedd8 complex - Yersinia pseudotuberculosis Cycle Inhibiting Factor in complex with human Nedd8
2ALJ	;		;	Structure of the cis confomer of the major extracytoplasmic domain of the bacterial cell division protein divib from geobacillus stearothermophilus
6ZZF	;		;	Structure of the cis-(Tyr39-Pro40) form of the Human Secreted Ly-6/uPAR Related Protein-1 (SLURP-1)
8BGB	;	1.7	;	Structure of the citrate-bound extracytoplasmic PAS domain of histidine kinase CitA from Geobacillus thermodenitrificans
5MPT	;	1.648	;	Structure of the citrinin polyketide synthase CMeT domain
3KOT	;	1.9	;	Structure of the Citrobacter freundii effector binding domain containing three amino acid substitutions: T103V, S221A and Y264F
6HXO	;	1.5	;	Structure of the citryl-CoA lyase core module of Chlorobium limicola ATP citrate lyase (space group P21)
6HXN	;	1.7	;	Structure of the citryl-CoA lyase core module of Chlorobium limicola ATP citrate lyase (space group P3121)
6HXK	;	1.85	;	Structure of the citryl-CoA lyase core module of human ATP citrate lyase in complex with citrate
6HXL	;	1.35	;	Structure of the citryl-CoA lyase core module of human ATP citrate lyase in complex with citrate and CoASH (space group P21)
6HXM	;	1.3	;	Structure of the citryl-CoA lyase core module of human ATP citrate lyase in complex with citrate and CoASH in space group C2221
8T7G	;	2.0	;	Structure of the CK variant of Fab F1 (FabC-F1)
2FEE	;	3.2	;	Structure of the Cl-/H+ exchanger CLC-ec1 from E.Coli in NaBr
7V1N	;	3.2	;	Structure of the Clade 2 C. difficile TcdB in complex with its receptor TFPI
4L6R	;	3.3	;	Structure of the class B human glucagon G protein coupled receptor
3PCT	;	1.85	;	Structure of the class C acid phosphatase from Pasteurella multocida
3ISG	;	1.4	;	Structure of the class D beta-lactamase OXA-1 in complex with doripenem
1K6S	;	2.03	;	STRUCTURE OF THE CLASS D BETA-LACTAMASE OXA-10 IN COMPLEX WITH A PHENYLBORONIC ACID
1K6R	;	2.3	;	STRUCTURE OF THE CLASS D BETA-LACTAMASE OXA-10 IN COMPLEX WITH MOXALACTAM
4X53	;	2.3	;	Structure of the class D Beta-Lactamase OXA-160 V130D in Acyl-Enzyme Complex with Aztreonam
4X56	;	2.28	;	Structure of the class D Beta-Lactamase OXA-160 V130D in Acyl-Enzyme Complex with Ceftazidime
4X55	;	1.941	;	Structure of the class D Beta-Lactamase OXA-225 K82D in Acyl-Enzyme Complex with Ceftazidime
4F94	;	2.4	;	Structure of the Class D Beta-Lactamase OXA-24 K84D in Acyl-Enzyme Complex with Oxacillin
5WPK	;	2.3	;	Structure of the class II 3-hydroxy-3-methylglutaryl-CoA reductase from Streptococcus pneumoniae bound to HMG-CoA and in a partially closed conformation
5WPJ	;	2.0	;	Structure of the class II 3-hydroxy-3-methylglutaryl-CoA reductase from Streptococcus pneumoniae bound to NADPH in open conformations
7JS3	;	2.4	;	Structure of the Class II Fructose-1,6-Bisphophatase from Francisella tularensis
8G5W	;	2.0	;	Structure of the Class II Fructose-1,6-Bisphophatase from Francisella tularensis complexed with native metal cofactor Mn++
7TXA	;	2.4	;	Structure of the Class II Fructose-1,6-Bisphophatase from Francisella tularensis complexed with native metal cofactor Mn++ and product F6P
8G5X	;	2.2	;	Structure of the Class II Fructose-1,6-Bisphophatase from Francisella tularensis complexed with native metal cofactor Mn++ and substrate Fructose-1,6-Bisphosphate
7TXB	;	3.71	;	Structure of the Class II Fructose-1,6-Bisphophatase from Mycobacterium tuberculosis complexed with substrate F1,6BP
7TXG	;	1.9	;	Structure of the Class II Fructose-1,6-Bisphosphatase from Francisella tularensis with native Mn++ divalent cation and partially occupied product F6P
4KJQ	;	2.875	;	Structure of the CLC-ec1 deltaNC construct in 100mM fluoride
4KJW	;	3.03	;	Structure of the CLC-ec1 deltaNC construct in 100mM fluoride and 20mM bromide
4KK5	;	3.171	;	Structure of the CLC-ec1 deltaNC construct in 20mM fluoride and 20mM bromide
4KJP	;	3.2	;	Structure of the CLC-ec1 deltaNC construct in the absence of halide
4GIP	;	2.0	;	Structure of the cleavage-activated prefusion form of the parainfluenza virus 5 (PIV5) fusion protein
6BJ5	;	2.5	;	Structure of the Clinically used Myxomaviral Serine Protease Inhibitor 1 (SERP-1)
6SKZ	;	3.4	;	Structure of the closed conformation of CtTel1
6V1S	;	3.8	;	Structure of the Clostridioides difficile transferase toxin
1GZE	;	2.7	;	Structure of the Clostridium botulinum C3 exoenzyme (L177C mutant)
1GZF	;	1.95	;	Structure of the Clostridium botulinum C3 exoenzyme (wild-type) in complex with NAD
4AXJ	;	1.62	;	Structure of the Clostridium difficile EutM protein
4AXO	;	1.0	;	Structure of the Clostridium difficile EutQ protein
4AXI	;	1.51	;	Structure of the Clostridium difficile EutS protein
4I0W	;	1.6	;	Structure of the Clostridium Perfringens CspB protease
7MFK	;	2.13	;	Structure of the Clostridium perfringens GH89 in complex with alpha-HNJNAc
7MFL	;	2.0	;	Structure of the Clostridium perfringens GH89 in complex with beta-HNJNAc
2CBI	;	2.25	;	Structure of the Clostridium perfringens NagJ family 84 glycoside hydrolase, a homologue of human O-GlcNAcase
2CBJ	;	2.35	;	Structure of the Clostridium perfringens NagJ family 84 glycoside hydrolase, a homologue of human O-GlcNAcase in complex with PUGNAc
4P15	;	1.85	;	Structure of the ClpC N-terminal domain from an alkaliphilic Bacillus lehensis G1 species
3Q7H	;	2.5	;	Structure of the ClpP subunit of the ATP-dependent Clp Protease from Coxiella burnetii
6TTZ	;	2.2	;	Structure of the ClpP:ADEP4-complex from Staphylococcus aureus (open state)
7PZA	;	2.72	;	Structure of the Clr-cAMP-DNA complex
7PZB	;	3.12	;	Structure of the Clr-cAMP-DNA complex
3GBZ	;	1.85	;	Structure of the CMGC CDK Kinase from Giardia lamblia
3GC0	;	2.0	;	Structure of the CMGC CDK Kinase from Giardia lamblia in complex with AMP
3UNG	;	2.31	;	Structure of the Cmr2 subunit of the CRISPR RNA silencing complex
3UR3	;	2.405	;	Structure of the Cmr2 subunit of the CRISPR RNA silencing complex
4H4K	;	2.804	;	Structure of the Cmr2-Cmr3 subcomplex of the Cmr RNA-silencing complex
1NH4	;		;	Structure of the coat protein in fd filamentous bacteriophage particles
6JVC	;	1.75	;	Structure of the Cobalt Protoporphyrin IX-Reconstituted CYP102A1 Haem Domain with N-Abietoyl-L-Tryptophan
1K1E	;	1.67	;	Structure Of the cobalt-bound form of the deoxy-D-mannose-octulosonate 8-phosphate phosphatase (YrbI) From Haemophilus Influenzae (HI1679)
1MAT	;	2.4	;	STRUCTURE OF THE COBALT-DEPENDENT METHIONINE AMINOPEPTIDASE FROM ESCHERICHIA COLI: A NEW TYPE OF PROTEOLYTIC ENZYME
8GSI	;	2.02	;	Structure of the cobolimab Fab
3CF4	;	2.0	;	Structure of the CODH component of the M. barkeri ACDS complex
1CCW	;	1.6	;	STRUCTURE OF THE COENZYME B12 DEPENDENT ENZYME GLUTAMATE MUTASE FROM CLOSTRIDIUM COCHLEARIUM
1ROP	;	1.7	;	STRUCTURE OF THE COL*E1 ROP PROTEIN AT 1.7 ANGSTROMS RESOLUTION
2V27	;	1.5	;	Structure of the cold active phenylalanine hydroxylase from Colwellia psychrerythraea 34H
6BPQ	;	4.1	;	Structure of the cold- and menthol-sensing ion channel TRPM8
3L6W	;	4.0	;	Structure of the collar functional unit (KLH1-H) of keyhole limpet hemocyanin
7QG8	;	3.97	;	Structure of the collided E. coli disome - VemP-stalled 70S ribosome
2BE1	;	2.983	;	Structure of the compact lumenal domain of yeast Ire1
8COH	;	1.3	;	Structure of the complement C5 specific nanobody TPP-3444
3BK7	;	2.8	;	Structure of the complete ABCE1/RNAase-L Inhibitor protein from Pyrococcus abysii
4WFL	;	2.49	;	Structure of the complete bacterial SRP Alu domain
4WFM	;	3.1	;	Structure of the complete bacterial SRP Alu domain
6RFL	;	2.76	;	Structure of the complete Vaccinia DNA-dependent RNA polymerase complex
1AKE	;	2.0	;	STRUCTURE OF THE COMPLEX BETWEEN ADENYLATE KINASE FROM ESCHERICHIA COLI AND THE INHIBITOR AP5A REFINED AT 1.9 ANGSTROMS RESOLUTION: A MODEL FOR A CATALYTIC TRANSITION STATE
1GL1	;	2.1	;	structure of the complex between bovine alpha-chymotrypsin and PMP-C, an inhibitor from the insect Locusta migratoria
1GL0	;	3.0	;	structure of the complex between bovine alpha-chymotrypsin and PMP-D2v, an inhibitor from the insect Locusta migratoria
2YSU	;	3.5	;	Structure of the complex between BtuB and Colicin E2 receptor binding domain
1UJW	;	2.75	;	Structure of the complex between BtuB and Colicin E3 Receptor binding domain
2MGU	;		;	Structure of the complex between calmodulin and the binding domain of HIV-1 matrix protein
2YIN	;	2.7	;	STRUCTURE OF THE COMPLEX BETWEEN Dock2 AND Rac1.
2WMN	;	2.391	;	Structure of the complex between DOCK9 and Cdc42-GDP.
2WM9	;	2.2	;	Structure of the complex between DOCK9 and Cdc42.
2WMO	;	2.2	;	Structure of the complex between DOCK9 and Cdc42.
4IZ5	;	3.19	;	Structure of the complex between ERK2 phosphomimetic mutant and PEA-15
7NE1	;	3.15	;	Structure of the complex between Netrin-1 and its receptor Neogenin
3T6G	;	2.5	;	Structure of the complex between NSP3 (SHEP1) and p130Cas
1RJL	;	2.6	;	Structure of the complex between OspB-CT and bactericidal Fab-H6831
4BD9	;	2.2	;	Structure of the complex between SmCI and human carboxypeptidase A4
8ED4	;	2.25	;	Structure of the complex between the arsenite oxidase and its native electron acceptor cytochrome c552 from Pseudorhizobium sp. str. NT-26
4L96	;	2.38	;	Structure of the complex between the F360L PPARgamma mutant and the ligand LT175 (space group I222)
4ASW	;		;	Structure of the complex between the N-terminal dimerisation domain of Sgt2 and the UBL domain of Get5
1TSI	;	2.84	;	STRUCTURE OF THE COMPLEX BETWEEN TRYPANOSOMAL TRIOSEPHOSPHATE ISOMERASE AND N-HYDROXY-4-PHOSPHONO-BUTANAMIDE: BINDING AT THE ACTIVE SITE DESPITE AN ""OPEN"" FLEXIBLE LOOP
1SV3	;	1.35	;	Structure of the complex formed between Phospholipase A2 and 4-methoxybenzoic acid at 1.3A resolution.
5CDB	;	1.7	;	Structure of the complex of a bimolecular human telomeric DNA with a 13-diphenylalkyl Berberine derivative
4P1D	;	1.55	;	Structure of the complex of a bimolecular human telomeric DNA with Coptisine
1QGC	;	30.0	;	STRUCTURE OF THE COMPLEX OF A FAB FRAGMENT OF A NEUTRALIZING ANTIBODY WITH FOOT AND MOUTH DISEASE VIRUS
2F6D	;	1.6	;	Structure of the complex of a glucoamylase from Saccharomycopsis fibuligera with acarbose
5CCW	;	1.89	;	Structure of the complex of a human telomeric DNA with Au(caffein-2-ylidene)2
6H5R	;	2.0	;	Structure of the complex of a human telomeric DNA with bis(1-butyl-3-methyl-imidazole-2-ylidene) gold(I)
3H4S	;	2.4	;	Structure of the complex of a mitotic kinesin with its calcium binding regulator
7RZA	;	4.26	;	Structure of the complex of AMPA receptor GluA2 with auxiliary subunit GSG1L bound to agonist quisqualate
7RZ9	;	4.15	;	Structure of the complex of AMPA receptor GluA2 with auxiliary subunit GSG1L in the apo state
7RZ6	;	4.4	;	Structure of the complex of AMPA receptor GluA2 with auxiliary subunit TARP gamma-5 bound to agonist glutamate
7RZ7	;	4.2	;	Structure of the complex of AMPA receptor GluA2 with auxiliary subunit TARP gamma-5 bound to agonist Quisqualate
7RZ4	;	3.6	;	Structure of the complex of AMPA receptor GluA2 with auxiliary subunit TARP gamma-5 bound to competitive antagonist ZK 200775
3R6R	;	2.4	;	Structure of the complex of an intramolecular human telomeric DNA with Berberine formed in K+ solution
2V17	;	1.65	;	Structure of the complex of antibody MN423 with a fragment of tau protein
3DL8	;	7.5	;	Structure of the complex of aquifex aeolicus SecYEG and bacillus subtilis SecA
3BXI	;	2.3	;	Structure of the complex of bovine lactoperoxidase with its catalyzed product hypothiocyanate ion at 2.3A resolution
3IB2	;	2.29	;	structure of the complex of C-terminal half (C-lobe) of bovine lactoferrin with alpha-methyl-4-(2-methylpropyl) benzene acetic acid
2NWJ	;	2.25	;	Structure of the complex of C-terminal lobe of bovine lactoferrin with disaccharide at 1.75 A resolution
2DS9	;	2.8	;	Structure of the complex of C-terminal lobe of bovine lactoferrin with mannose at 2.8 A resolution
2OCU	;	2.38	;	Structure of the complex of C-terminal lobe of bovine lactoferrin with N-(4-hydroxyphenyl) acetamide at 2.38 A resolution
2DWJ	;	2.3	;	Structure of the complex of C-terminal lobe of bovine lactoferrin with raffinose at 2.3 A resolution
2DXY	;	2.03	;	Structure of the complex of C-terminal lobe of bovine lactoferrin with trehalose at 2.0 A resolution
2DSF	;	2.8	;	Structure of the complex of C-terminal lobe of bovine lactoferrin with xylose at 2.8A resolution
1MXE	;	1.7	;	Structure of the Complex of Calmodulin with the Target Sequence of CaMKI
7XU8	;	2.15	;	Structure of the complex of camel peptidoglycan recognition protein-short (PGRP-S) with heptanoic acid at 2.15 A resolution.
2VMD	;	1.9	;	Structure of the complex of discoidin II from Dictyostelium discoideum with beta-methyl-galactose
2VMC	;	1.9	;	Structure of the complex of discoidin II from Dictyostelium discoideum with N-acetyl-galactosamine
5JPM	;	3.75	;	Structure of the complex of human complement C4 with MASP-2 rebuilt using iMDFF
6WH1	;	2.4	;	Structure of the complex of human DNA ligase III-alpha and XRCC1 BRCT domains
4ZQK	;	2.45	;	Structure of the complex of human programmed death-1 (PD-1) and its ligand PD-L1.
1WHS	;	2.0	;	STRUCTURE OF THE COMPLEX OF L-BENZYLSUCCINATE WITH WHEAT SERINE CARBOXYPEPTIDASE II AT 2.0 ANGSTROMS RESOLUTION
1WHT	;	2.0	;	STRUCTURE OF THE COMPLEX OF L-BENZYLSUCCINATE WITH WHEAT SERINE CARBOXYPEPTIDASE II AT 2.0 ANGSTROMS RESOLUTION
1LCC	;		;	STRUCTURE OF THE COMPLEX OF LAC REPRESSOR HEADPIECE AND AN 11 BASE-PAIR HALF-OPERATOR DETERMINED BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY AND RESTRAINED MOLECULAR DYNAMICS
1LCD	;		;	STRUCTURE OF THE COMPLEX OF LAC REPRESSOR HEADPIECE AND AN 11 BASE-PAIR HALF-OPERATOR DETERMINED BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY AND RESTRAINED MOLECULAR DYNAMICS
2DYX	;	2.0	;	Structure of the complex of lactoferrin C-lobe with melibiose at 2.0 A resolution
2DWA	;	2.07	;	Structure of the complex of lactoferrin C-terminal half with fucose at 2.07 A resolution
7WYJ	;	1.89	;	Structure of the complex of lactoperoxidase with nitric oxide catalytic product nitrite at 1.89 A resolution
7RYZ	;	4.15	;	Structure of the complex of LBD-TMD part of AMPA receptor GluA2 with auxiliary subunit GSG1L bound to agonist quisqualate
7RYY	;	4.4	;	Structure of the complex of LBD-TMD part of AMPA receptor GluA2 with auxiliary subunit TARP gamma-5 bound to agonist glutamate
7RZ8	;	4.1	;	Structure of the complex of LBD-TMD part of AMPA receptor GluA2 with auxiliary subunit TARP gamma-5 bound to agonist quisqualate
7RZ5	;	3.3	;	Structure of the complex of LBD-TMD part of AMPA receptor GluA2 with auxiliary subunit TARP gamma-5 bound to competitive antagonist ZK 200775
2GF3	;	1.3	;	Structure of the complex of monomeric sarcosine with its substrate analogue inhibitor 2-furoic acid at 1.3 A resolution.
2DPZ	;	2.1	;	Structure of the complex of phospholipase A2 with N-(4-hydroxyphenyl)- acetamide at 2.1 A resolution
1UVO	;	1.85	;	Structure Of The Complex Of Porcine Pancreatic Elastase In Complex With Cadmium Refined At 1.85 A Resolution (Crystal A)
1UVP	;	1.85	;	Structure Of The Complex Of Porcine Pancreatic Elastase In Complex With Cadmium Refined At 1.85 A Resolution (Crystal B)
1PEK	;	2.2	;	STRUCTURE OF THE COMPLEX OF PROTEINASE K WITH A SUBSTRATE-ANALOGUE HEXA-PEPTIDE INHIBITOR AT 2.2 ANGSTROMS RESOLUTION
2ATE	;	1.8	;	Structure of the complex of PurE with NitroAIR
2WR6	;	1.8	;	Structure of the complex of RBP4 with linoleic acid
7VE3	;	2.7	;	Structure of the complex of sheep lactoperoxidase with hypoiodite at 2.70 A resolution
4U7I	;	1.794	;	Structure of the complex of Spartin MIT and IST1 MIM
3SGB	;	1.8	;	STRUCTURE OF THE COMPLEX OF STREPTOMYCES GRISEUS PROTEASE B AND THE THIRD DOMAIN OF THE TURKEY OVOMUCOID INHIBITOR AT 1.8 ANGSTROMS RESOLUTION
4SGB	;	2.1	;	STRUCTURE OF THE COMPLEX OF STREPTOMYCES GRISEUS PROTEINASE B AND POLYPEPTIDE CHYMOTRYPSIN INHIBITOR-1 FROM RUSSET BURBANK POTATO TUBERS AT 2.1 ANGSTROMS RESOLUTION
2V98	;	3.0	;	Structure of the complex of TcAChE with 1-(2-nitrophenyl)-2,2,2- trifluoroethyl-arsenocholine after a 9 seconds annealing to room temperature, during the first 5 seconds of which laser irradiation at 266nm took place
2LPB	;		;	Structure of the complex of the central activation domain of Gcn4 bound to the mediator co-activator domain 1 of Gal11/med15
4BFI	;	3.22	;	Structure of the complex of the extracellular portions of mouse CD200R and mouse CD200
6H41	;	2.75	;	Structure of the complex of the IL-5 inhibitory peptide AF17121 bound to the IL-5 receptor IL-5Ralpha
1E91	;		;	Structure of the complex of the Mad1-Sin3B interaction domains
4GI1	;	2.43	;	Structure of the complex of three phase partition treated lipase from Thermomyces lanuginosa with 16-hydroxypalmitic acid at 2.4 A resolution
1YHL	;	1.95	;	Structure of the complex of Trypanosoma cruzi farnesyl diphosphate synthase with risedronate, dmapp and mg+2
1YHM	;	2.5	;	Structure of the complex of Trypanosoma cruzi farnesyl disphosphate synthase with alendronate, Isopentenyl diphosphate and mg+2
5CSO	;	1.78	;	Structure of the complex of type 1 ribosome inactivating protein from Momordica balsamina with a nucleoside, cytidine at 1.78 A resolution
5CST	;	1.78	;	Structure of the complex of type 1 ribosome inactivating protein from Momordica balsamina with a nucleotide, cytidine diphosphate at 1.78 A resolution
4ZU0	;	1.8	;	Structure of the complex of type 1 ribosome inactivating protein from Momordica balsamina with a nucleotide, cytidine monophosphate at 1.80 A resolution
4ZZ6	;	2.0	;	Structure of the complex of type 1 ribosome inactivating protein from Momordica balsamina with a nucleotide, cytidine triphosphate at 2.0A resolution
4ZT8	;	1.98	;	Structure of the complex of type 1 ribosome inactivating protein from Momordica balsamina with a pyrimidine base, cytosine at 1.98 A resolution
4RZJ	;	1.98	;	Structure of the complex of type 1 ribosome inactivating protein from Momordica balsamina with N-acetylglucosamine at 1.98 Angstrom resolution using crystals grown in different conditions
5CIX	;	1.88	;	Structure of the complex of type 1 Ribosome inactivating protein with triethanolamine at 1.88 Angstrom resolution
2MRO	;		;	Structure of the complex of ubiquitin and the UBA domain from DNA-damage-inducible 1 protein (Ddi1)
2MWS	;		;	Structure of the complex of ubiquitin and the ubiquitin-like (UBL) domain of Ddi1
4U7Y	;	2.502	;	Structure of the complex of VPS4B MIT and IST1 MIM
1TJ9	;	1.1	;	Structure of the complexed formed between group II phospholipase A2 and a rationally designed tetra peptide,Val-Ala-Arg-Ser at 1.1A resolution
2ZW3	;	3.5	;	Structure of the connexin-26 gap junction channel at 3.5 angstrom resolution
2K7M	;		;	Structure of the Connexin40 Carboxyl terminal Domain
1UT4	;	2.5	;	Structure of the conserved domain of ANAC, a member of the NAC family of transcription factors
1UT7	;	1.9	;	Structure of the conserved domain of ANAC, a member of the NAC family of transcription factors
2V1L	;	2.13	;	Structure of the conserved hypothetical protein VC1805 from pathogenicity island VPI-2 of Vibrio cholerae O1 biovar eltor str. N16961 shares structural homology with the human P32 protein
2OBB	;	2.2	;	Structure of the conserved protein coded by locus BT_0820 from Bacteroides thetaiotaomicron
1YOX	;	2.3	;	Structure of the conserved Protein of Unknown Function PA3696 from Pseudomonas aeruginosa
5FG0	;	2.41	;	Structure of the conserved yeast listerin (Ltn1) N-terminal domain, MONOCLINIC FORM
5FG1	;	2.55	;	Structure of the conserved yeast listerin (Ltn1) selenomethionine-substituted N-terminal domain, TRIGONAL FORM
5URX	;	28.0	;	Structure of the contracted type VI secretion system sheath in Myxococcus xanthus
4HJI	;	1.6	;	Structure of the CooA pilin subunit from enterotoxigenic Escherichia coli
1I1Q	;	1.9	;	STRUCTURE OF THE COOPERATIVE ALLOSTERIC ANTHRANILATE SYNTHASE FROM SALMONELLA TYPHIMURIUM
2IEF	;	2.601	;	Structure of the cooperative Excisionase (Xis)-DNA complex reveals a micronucleoprotein filament
4UIG	;	2.0	;	Structure of the copper sensitive operon repressor from Streptomyces lividans at pH6
6Q6B	;	1.9	;	Structure of the copper storage protein, Ccsp, from Streptomyces lividans loaded with 10 copper equivalents
4A8X	;	1.9	;	Structure of the core ASAP complex
2K9L	;		;	Structure of the Core Binding Domain of sigma54
2K9M	;		;	Structure of the Core Binding Domain of sigma54
6QBM	;	2.5	;	structure of the core domaine of Knr4, an intrinsically disordered protein from Saccharomyces cerevisiae - mutant S200A
6QBQ	;	2.35	;	structure of the core domaine of Knr4, an intrinsically disordered protein from Saccharomyces cerevisiae - mutant S200A S203A
6QBN	;	2.4	;	structure of the core domaine of Knr4, an intrinsically disordered protein from Saccharomyces cerevisiae - mutant S200D
6QBR	;	2.15	;	structure of the core domaine of Knr4, an intrinsically disordered protein from Saccharomyces cerevisiae - mutant S200D, S203D
6QBO	;	2.75	;	structure of the core domaine of Knr4, an intrinsically disordered protein from Saccharomyces cerevisiae - mutant S203A
6QBP	;	2.4	;	structure of the core domaine of Knr4, an intrinsically disordered protein from Saccharomyces cerevisiae - mutant S203D
5J1B	;	2.5	;	structure of the core domaine of Knr4, an intrinsically disordered protein from Saccharomyces cerevisiae - WT.
4WEB	;	2.4	;	Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2
7MWX	;	3.32	;	Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2 with tamarin CD81
4MEW	;	1.993	;	Structure of the core fragment of human PR70
2LKL	;		;	Structure of the core intracellular domain of PfEMP1
7AO9	;	6.1	;	Structure of the core MTA1/HDAC1/MBD2 NURD deacetylase complex
6S3L	;	3.2	;	Structure of the core of the flagellar export apparatus from Vibrio mimicus, the FliPQR-FlhB complex.
5LJ3	;	3.8	;	Structure of the core of the yeast spliceosome immediately after branching
7S94	;	2.0	;	Structure of the core postfusion porcine endogenous retrovirus fusion protein
6R6B	;	3.5	;	Structure of the core Shigella flexneri type III secretion system export gate complex SctRST (Spa24/Spa9/Spa29).
6RO4	;	3.5	;	Structure of the core TFIIH-XPA-DNA complex
6RIC	;	2.8	;	Structure of the core Vaccinia Virus DNA-dependent RNA polymerase complex
3HR6	;	1.6	;	Structure of the Corynebacterium diphtheriae major pilin SpaA points to a modular pilus assembly stabilizing isopeptide bonds
3HTL	;	1.8	;	Structure of the Corynebacterium diphtheriae major pilin SpaA points to a modular pilus assembly with stabilizing isopeptide bonds
1JWB	;	2.1	;	Structure of the Covalent Acyl-Adenylate Form of the MoeB-MoaD Protein Complex
4XTD	;	2.05	;	Structure of the covalent intermediate E-XMP* of the IMP dehydrogenase of Ashbya gossypii
2CIT	;	1.4	;	Structure of the covalent intermediate of a family 26 lichenase
5MGA	;	3.0	;	Structure of the Cpf1 endonuclease R-loop complex after DNA cleavage
7XSQ	;	2.88	;	Structure of the Craspase
2VXB	;	2.3	;	Structure of the Crb2-BRCT2 domain
2VXC	;	3.1	;	Structure of the Crb2-BRCT2 domain complex with phosphopeptide.
5L3W	;	2.4	;	Structure of the crenarchaeal FtsY GTPase bound to GDP
5L3V	;	2.3	;	Structure of the crenarchaeal SRP54 GTPase bound to GDP
6W2T	;	3.36	;	Structure of the Cricket Paralysis Virus 5-UTR IRES (CrPV 5-UTR-IRES) bound to the small ribosomal subunit in the closed state (Class 2)
6W2S	;	3.47	;	Structure of the Cricket Paralysis Virus 5-UTR IRES (CrPV 5-UTR-IRES) bound to the small ribosomal subunit in the open state (Class 1)
4AKL	;	2.1	;	Structure of the Crimean-Congo Haemorrhagic Fever Virus Nucleocapsid Protein
2PIJ	;	1.7	;	Structure of the Cro protein from prophage Pfl 6 in Pseudomonas fluorescens Pf-5
3BD1	;	1.4	;	Structure of the Cro protein from putative prophage element Xfaso 1 in Xylella fastidiosa strain Ann-1
7AXQ	;	1.562	;	Structure of the cryo-trapped WDR5:CS-VIP8 cocrystal after illumination at 405 nm and 180 K
7LU8	;		;	Structure of the cryptic HMA domain of the human copper transporter ATP7A
1ROB	;	1.6	;	STRUCTURE OF THE CRYSTALLINE COMPLEX OF CYTIDYLIC ACID (2'-CMP) WITH RIBONUCLEASE AT 1.6 ANGSTROMS RESOLUTION
1RCA	;	1.9	;	STRUCTURE OF THE CRYSTALLINE COMPLEX OF DEOXYCYTIDYLYL-3',5'-GUANOSINE (3',5'-DCPDG) CO-CRYSTALISED WITH RIBONUCLEASE AT 1.9 ANGSTROMS RESOLUTION. RETROBINDING IN PANCREATIC RNASEA IS INDEPENDENT OF MODE OF INHIBITOR INTROMISSION
3EUD	;	2.4	;	Structure of the CS domain of the essential H/ACA RNP assembly protein Shq1p
1WA5	;	2.0	;	Structure of the Cse1:Imp-alpha:RanGTP complex
5IC9	;	3.7	;	Structure of the CTD complex of Utp12 and Utp13
5ICA	;	3.507	;	Structure of the CTD complex of UTP12, Utp13, Utp1 and Utp21
5MDT	;	1.62	;	Structure of the CTD-interacting domain (CID) of Seb1 from S. pombe.
2QDV	;	0.89	;	Structure of the Cu(II) form of the M51A mutant of amicyanin
2MYX	;		;	Structure of the CUE domain of yeast Cue1
1LDD	;	2.0	;	Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF Ubiquitin Ligase Complex
1LDJ	;	3.0	;	Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF Ubiquitin Ligase Complex
1LDK	;	3.1	;	Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF Ubiquitin Ligase Complex
2WZK	;	2.05	;	Structure of the Cul5 N-terminal domain at 2.05A resolution.
6SI7	;	3.4	;	Structure of the curli secretion-assembly complex CsgG:CsgF
4UV2	;	2.8	;	Structure of the curli transport lipoprotein CsgG in a non-lipidated, pre-pore conformation
4UV3	;	3.59	;	Structure of the curli transport lipoprotein CsgG in its membrane- bound conformation
7RAG	;	2.4	;	Structure of the CwlD amidase from Clostridioides difficile in complex with the GerS lipoprotein
2LL2	;		;	Structure of the Cx43 C-terminal domain bound to tubulin
5OX9	;	1.56	;	Structure of the Cyan Fluorescent Protein SCFP3A at pH 4.5
1DW1	;	1.9	;	STRUCTURE OF THE CYANIDE COMPLEX OF SHP, AN OXYGEN BINDING CYTOCHROME C
3S5X	;	1.65	;	Structure of the cyanobacterial Oscillatoria Agardhii Agglutinin (OAA) in complex with a3,a6 mannopentaose
3S5V	;	1.55	;	Structure of the cyanobacterial Oscillatoria Agardhii Agglutinin (OAA) in free state obtained at -180 degrees Celsius
3S60	;	1.6	;	Structure of the cyanobacterial Oscillatoria Agardhii Agglutinin (OAA) in free state obtained at 25 degree Celsius
8CMY	;	3.79	;	Structure of the Cyanobium sp. PCC 7001 determined with C1 symmetry
3ZSU	;	1.6	;	Structure of the CyanoQ protein from Thermosynechococcus elongatus
5T13	;	2.19	;	Structure of the Cyanuric Acid Hydrolase TrzD Reveals Product Exit Channel
2AJW	;		;	Structure of the cyclic conotoxin MII-6
4NVP	;	2.5	;	Structure of the cyclic nucleotide-binding domain of HCN4 channel complexed with 7-CH-cAMP
2N7G	;		;	Structure of the cyclic nucleotide-binding homology domain of the hERG channel
3EFY	;	1.7	;	Structure of the Cyclomodulin Cif from Pathogenic Escherichia coli
2HQ6	;	1.75	;	Structure of the Cyclophilin_CeCYP16-Like Domain of the Serologically Defined Colon Cancer Antigen 10 from Homo Sapiens
1TPY	;	2.2	;	Structure of the cyclopropane synthase MmaA2 from Mycobacterium tuberculosis
6VVG	;	2.01	;	Structure of the Cydia pomonella Granulovirus kinase, PK-1
2VHF	;	2.8	;	Structure of the CYLD USP domain
7WY4	;	1.45	;	Structure of the CYP102A1 F87A Haem Domain with N-Enanthyl-L-Prolyl-L-Phenylalanine in complex with Styrene
7CX6	;	1.69	;	Structure of the CYP102A1 Haem Domain with N-(5-Cyclohexyl)valeroyl-L-Phenylalanine in complex with (R)-(+)-1-Phenylethylamine
7CP8	;	1.68	;	Structure of the CYP102A1 Haem Domain with N-(5-Cyclohexyl)valeroyl-L-Phenylalanine in complex with (R)-1-Indanylamine
7CX8	;	1.7	;	Structure of the CYP102A1 Haem Domain with N-(5-Cyclohexyl)valeroyl-L-Phenylalanine in complex with (R)-1-Tetralylamine
6JO1	;	2.1	;	Structure of the CYP102A1 Haem Domain with N-(S)-Ibuprofenoyl-L-Phenylalanine
7E46	;	1.91	;	Structure of the CYP102A1 Haem Domain with N-Carboxybenzyl-L-Prolyl-L-Phenylalanine in complex with (S)-(-)-1-Phenylethylamine
7D0T	;	1.74	;	Structure of the CYP102A1 Haem Domain with N-Carboxybenzyl-L-Prolyl-L-Phenylalanine in complex with (S)-1-Indanylamine
7CVR	;	1.6	;	Structure of the CYP102A1 Haem Domain with N-Carboxybenzyl-L-Prolyl-L-Phenylalanine in complex with (S)-1-Tetralylamine
7COO	;	1.49	;	Structure of the CYP102A1 Haem Domain with N-Carboxybenzyl-L-Prolyl-L-Phenylalanine in complex with Cyclohexylamine
6JS8	;	1.36	;	Structure of the CYP102A1 Haem Domain with N-Dehydroabietoyl-L-Tryptophan
6K58	;	1.41	;	Structure of the CYP102A1 Haem Domain with N-Enanthyl-L-Prolyl-L-Phenylalanine
7D0U	;	1.68	;	Structure of the CYP102A1 Haem Domain with N-enanthyl-L-prolyl-L-phenylalanine in complex with Ethylamine
7D1F	;	1.45	;	Structure of the CYP102A1 Haem Domain with N-enanthyl-L-prolyl-L-phenylalanine in complex with Methylamine
7CZI	;	1.64	;	Structure of the CYP102A1 Haem Domain with N-{2-[4-(Trifluoromethoxy)phenoxy]}acetoyl-L-Phenylalanine
7CKN	;	1.55	;	Structure of the CYP102A1 Haem Domain with N-{2-[4-(Trifluoromethoxy)phenoxy]}acetoyl-L-Phenylalanine in complex with Isopropylamine
7CON	;	1.46	;	Structure of the CYP102A1 Haem Domain with N-{2-[4-(Trifluoromethoxy)phenoxy]}acetoyl-L-Phenylalanine in complex with n-Propylamine
1SP7	;		;	Structure of the Cys-rich C-terminal domain of Hydra minicollagen
4D03	;	1.81	;	Structure of the Cys65Asp mutant of phenylacetone monooxygenase: oxidised state
4D04	;	1.75	;	Structure of the Cys65Asp mutant of phenylacetone monooxygenase: reduced state
3KXR	;	2.41	;	Structure of the cystathionine beta-synthase pair domain of the putative Mg2+ transporter SO5017 from Shewanella oneidensis MR-1.
6ZOP	;		;	Structure of the cysteine-rich domain of PiggyMac, a domesticated PiggyBac transposase involved in programmed genome rearrangements
6MM1	;	1.9	;	Structure of the cysteine-rich region from human EHMT2
3TQO	;	2.3	;	Structure of the cysteinyl-tRNA synthetase (cysS) from Coxiella burnetii.
2LCV	;		;	Structure of the Cytidine Repressor DNA-Binding Domain; an alternate calculation
1Q90	;	3.1	;	Structure of the cytochrome b6f (plastohydroquinone : plastocyanin oxidoreductase) from Chlamydomonas reinhardtii
1LS9	;	1.3	;	Structure of the Cytochrome c6 from the Green Alga Cladophora glomerata
7AYX	;	2.53	;	Structure of the cytochrome P450 AryC from Streptomyces roseosporus NRRL 15998
2UYY	;	2.5	;	Structure of the cytokine-like nuclear factor n-pac
4PN6	;	3.0	;	Structure of the Cytomegalovirus-Encoded m04 Glycoprotein
1EXB	;	2.1	;	STRUCTURE OF THE CYTOPLASMIC BETA SUBUNIT-T1 ASSEMBLY OF VOLTAGE-DEPENDENT K CHANNELS
5NBG	;	2.15	;	Structure of the cytoplasmic domain I of OutF in the D. dadantii type II secretion system
3A5I	;	2.8	;	Structure of the cytoplasmic domain of FlhA
3MYD	;	2.4	;	Structure of the Cytoplasmic domain of FlhA from Helicobacter pylori
6UID	;	1.45	;	Structure of the cytoplasmic domain of the T3SS sorting platform protein PscD from P. aeruginosa
6UIE	;	2.55	;	Structure of the cytoplasmic domain of the T3SS sorting platform protein PscK from P. aeruginosa
5FQ1	;	1.76	;	Structure of the cytoplasmic PAS domain of the Geobacillus thermodenitrificans histidine kinase CitA
3JZ3	;	2.5	;	Structure of the cytoplasmic segment of histidine kinase QseC
1TO4	;	1.55	;	Structure of the cytosolic Cu,Zn SOD from S. mansoni
1TO5	;	2.2	;	Structure of the cytosolic Cu,Zn SOD from S. mansoni
5X1U	;	1.8	;	Structure of the cytosolic domain of DotM derived from Legionella pneumophila
3I8X	;	2.25	;	Structure of the cytosolic domain of E. coli FeoB, GDP-bound form
3I92	;	3.0	;	Structure of the cytosolic domain of E. coli FeoB, GppCH2p-bound form
3I8S	;	1.8	;	Structure of the cytosolic domain of E. coli FeoB, nucleotide-free form
8OQH	;	1.76	;	Structure of the cytosolic domain of lysosome-associated TMEM55B
4A4Y	;	1.57	;	Structure of the Cytosolic Domain of the Shigella T3SS component MxiG
1RK8	;	1.9	;	Structure of the cytosolic protein PYM bound to the Mago-Y14 core of the exon junction complex
3TQT	;	1.88	;	Structure of the D-alanine-D-alanine ligase from Coxiella burnetii
2XF8	;	2.95	;	Structure of the D-Erythrose-4-Phosphate Dehydrogenase from E. coli in complex with a NAD cofactor analog (3-Chloroacetyl adenine pyridine dinucleotide) and sulfate anion
1LK5	;	1.75	;	Structure of the D-Ribose-5-Phosphate Isomerase from Pyrococcus horikoshii
4V6W	;	6.0	;	Structure of the D. melanogaster 80S ribosome
5OK2	;	1.1	;	Structure of the D10N mutant of beta-phosphoglucomutase from Lactococcus lactis inhibited with glucose 6-phosphate and tetrafluoroaluminate to 1.1A resolution.
5OK0	;	2.15	;	Structure of the D10N mutant of beta-phosphoglucomutase from Lactococcus lactis trapped with native reaction intermediate beta-glucose 1,6-bisphosphate to 2.2A resolution.
4RSD	;	1.6	;	STRUCTURE OF THE D121A VARIANT OF RIBONUCLEASE A
3RSD	;	1.6	;	STRUCTURE OF THE D121N VARIANT OF RIBONUCLEASE A
6ZBM	;	1.47	;	Structure of the D125N mutant of the catalytic domain of the Bacillus circulans alpha-1,6 Mannanase in complex with an alpha-1,6-alpha-manno-cyclophellitol carbasugar-stabilised trisaccharide inhibitor
6ZBW	;	1.4	;	Structure of the D125N mutant of the catalytic domain of the Bacillus circulans alpha-1,6 Mannanase in complex with an alpha-1,6-alpha-manno-cyclophellitol trisaccharide inhibitor
3O6Z	;	2.05	;	Structure of the D152A E.coli GDP-mannose hydrolase (yffh) in complex with Mg++
1LL6	;	2.8	;	STRUCTURE OF THE D169N MUTANT OF C. IMMITIS CHITINASE 1
1E0Y	;	2.75	;	Structure of the D170S/T457E double mutant of vanillyl-alcohol oxidase
1QWS	;	1.9	;	Structure of the D181N variant of catalase HPII from E. coli
2Y6E	;	2.4	;	Structure of the D1D2 domain of USP4, the conserved catalytic domain
6CM4	;	2.867	;	Structure of the D2 Dopamine Receptor Bound to the Atypical Antipsychotic Drug Risperidone
2B4P	;	1.81	;	Structure of the D223N mutant of Selenomonas ruminantium PTP-like phytase
1U5O	;	2.5	;	Structure of the D23A mutant of the nuclear transport carrier NTF2
1Z4Q	;	2.05	;	Structure of the D41N variant of the human mitochondrial deoxyribonucleotidase in complex with 2',3'-dideoxy-2',3-didehydrothymidine 5'-monophosphate (d4T-MP)
1Z4P	;	2.0	;	Structure of the D41N variant of the human mitochondrial deoxyribonucleotidase in complex with deoxyriboguanosine 5'-monophosphate
1Z4I	;	1.98	;	Structure of the D41N variant of the human mitochondrial deoxyribonucleotidase in complex with deoxyribouridine 5'-monophosphate
1Z4K	;	1.75	;	Structure of the D41N variant of the human mitochondrial deoxyribonucleotidase in complex with thymidine 3'-monophosphate
1Z4L	;	1.8	;	Structure of the D41N variant of the human mitochondrial deoxyribonucleotidase in complex with thymidine 5'-monophosphate
1Z4J	;	1.8	;	Structure of the D41N variant of the human mitochondrial deoxyribonucleotidase in complex with uridine 2'-monophosphate
1Z4M	;	1.7	;	Structure of the D41N variant of the human mitochondrial deoxyribonucleotidase in complex with uridine 5'-monophosphate
1IBU	;	3.1	;	STRUCTURE OF THE D53,54N MUTANT OF HISTIDINE DECARBOXYLASE AT 25 C
1IBT	;	2.6	;	STRUCTURE OF THE D53,54N MUTANT OF HISTIDINE DECARBOXYLASE AT-170 C
1IBW	;	3.2	;	STRUCTURE OF THE D53,54N MUTANT OF HISTIDINE DECARBOXYLASE BOUND WITH HISTIDINE METHYL ESTER AT 25 C
1IBV	;	2.5	;	STRUCTURE OF THE D53,54N MUTANT OF HISTIDINE DECARBOXYLASE BOUND WITH HISTIDINE METHYL ESTER AT-170 C
1P5X	;	2.0	;	STRUCTURE OF THE D55N MUTANT OF PHOSPHOLIPASE C FROM BACILLUS CEREUS
1P6D	;	2.0	;	STRUCTURE OF THE D55N MUTANT OF PHOSPHOLIPASE C FROM BACILLUS CEREUS IN COMPLEX WITH (3S)-3,4,DI-N-HEXANOYLOXYBUTYL-1-PHOSPHOCHOLINE
1P6E	;	2.3	;	STRUCTURE OF THE D55N MUTANT OF PHOSPHOLIPASE C FROM BACILLUS CEREUS IN COMPLEX WITH 1,2-DI-N-PENTANOYL-SN-GLYCERO-3-DITHIOPHOSPHOCHOLINE
1MGY	;	2.0	;	Structure of the D85S mutant of bacteriorhodopsin with bromide bound
3BIN	;	2.3	;	Structure of the DAL-1 and TSLC1 (372-383) complex
6Z26	;	2.32	;	Structure of the Danio rerio SAS-6 coiled-coil domain
2L34	;		;	Structure of the DAP12 transmembrane homodimer
2L35	;		;	Structure of the DAP12-NKG2C transmembrane heterotrimer
6TAP	;	3.5	;	Structure of the dArc1 capsid
6TAQ	;	3.9	;	Structure of the dArc2 capsid
5DKK	;	2.5	;	Structure of the dark-state monomer of the blue light photoreceptor Aureochrome 1a LOV from P. tricornutum
7NRI	;	3.03	;	Structure of the darobactin-bound E. coli BAM complex (BamABCDE)
6CFZ	;	4.5	;	Structure of the DASH/Dam1 complex shows its role at the yeast kinetochore-microtubule interface
2K29	;		;	Structure of the DBD domain of E. coli antitoxin RelB
5Z5K	;	2.493	;	Structure of the DCC-Draxin complex
5MSN	;	2.002	;	Structure of the Dcc1 Protein
5MSM	;	2.29	;	Structure of the Dcc1-Ctf8-Ctf18C Trimer
8WQR	;	3.08	;	Structure of the DDB1-AMBRA1 E3 ligase receptor complex linked to cell cycle regulation
4CI2	;	2.95	;	Structure of the DDB1-CRBN E3 ubiquitin ligase bound to lenalidomide
4CI3	;	3.5	;	Structure of the DDB1-CRBN E3 ubiquitin ligase bound to Pomalidomide
4CI1	;	2.98	;	Structure of the DDB1-CRBN E3 ubiquitin ligase bound to thalidomide
6H0G	;	4.25	;	Structure of the DDB1-CRBN-pomalidomide complex bound to ZNF692(ZF4)
3ZOS	;	1.92	;	Structure of the DDR1 kinase domain in complex with ponatinib
2G9N	;	2.25	;	Structure of the DEAD domain of Human eukaryotic initiation factor 4A, eIF4A
8CNT	;	1.9	;	Structure of the DEAH-box helicase Prp16 in complex with ADP
4B0R	;	2.6	;	Structure of the Deamidase-Depupylase Dop of the Prokaryotic Ubiquitin-like Modification Pathway
5LRT	;	1.85	;	Structure of the Deamidase-Depupylase Dop of the Prokaryotic Ubiquitin-like Modification Pathway in Complex with ADP and Phosphate
4B0S	;	2.85	;	Structure of the Deamidase-Depupylase Dop of the Prokaryotic Ubiquitin-like Modification Pathway in Complex with ATP
5LG6	;	2.5	;	Structure of the deglycosylated porcine aminopeptidase N ectodomain
5NJI	;	1.6	;	Structure of the dehydratase domain of PpsC from Mycobacterium tuberculosis in complex with C12:1-CoA
7SYS	;	3.5	;	Structure of the delta dII IRES eIF2-containing 48S initiation complex, closed conformation. Structure 12(delta dII).
7SYX	;	3.7	;	Structure of the delta dII IRES eIF5B-containing 48S initiation complex, closed conformation. Structure 15(delta dII)
7SYU	;	4.6	;	Structure of the delta dII IRES w/o eIF2 48S initiation complex, closed conformation. Structure 13(delta dII)
4EJ4	;	3.4	;	Structure of the delta opioid receptor bound to naltrindole
2QF0	;	2.5	;	Structure of the delta PDZ truncation of the DegS protease
2QF3	;	2.04	;	Structure of the delta PDZ truncation of the DegS protease
1R6A	;	2.6	;	Structure of the dengue virus 2'O methyltransferase in complex with s-adenosyl homocysteine and ribavirin 5' triphosphate
1VTR	;	1.04	;	STRUCTURE OF THE DEOXYTETRANUCLEOTIDE D-PAPTPAPT AND A SEQUENCE-DEPENDENT MODEL FOR POLY(DA-DT)
7V6B	;	3.3	;	Structure of the Dicer-2-R2D2 heterodimer
7V6C	;	3.3	;	Structure of the Dicer-2-R2D2 heterodimer bound to small RNA duplex
5U3G	;	2.3	;	Structure of the Dickeya dadantii ykkC riboswitch bound to guanidinium
7PXO	;	1.95	;	Structure of the Diels Alderase enzyme AbyU, from Micromonospora maris, co-crystallised with a non transformable substrate analogue
3TQB	;	2.4	;	Structure of the dihydrofolate reductase (folA) from Coxiella burnetii in complex with folate
3TQ9	;	2.3	;	Structure of the dihydrofolate reductase (folA) from Coxiella burnetii in complex with methotrexate
3TQA	;	2.3	;	Structure of the dihydrofolate reductase (folA) from Coxiella burnetii in complex with NADPH
3TQ8	;	1.9	;	Structure of the dihydrofolate reductase (folA) from Coxiella burnetii in complex with trimethoprim
7QRF	;	2.28	;	Structure of the dimeric complex between precursor membrane ectodomain (prM) and envelope protein ectodomain (E) from tick-borne encephalitis virus
8K53	;	3.8	;	Structure of the Dimeric Human CNTN2 Ig 1-6-FNIII 1-2 Domain in an Asymmetric State
1JYF	;	3.0	;	Structure of the Dimeric Lac Repressor with an 11-residue C-terminal Deletion.
1JWL	;	4.0	;	Structure of the Dimeric lac Repressor/Operator O1/ONPF Complex
8BGL	;	2.0	;	Structure of the dimeric rsCherryRev1.4
8PEK	;		;	Structure of the dimeric, periplasmic domain of ExbD
3L32	;	1.5	;	Structure of the dimerisation domain of the rabies virus phosphoprotein
2MJ2	;		;	Structure of the dimerization domain of the human polyoma, JC virus agnoprotein is an amphipathic alpha-helix.
1M23	;		;	STRUCTURE OF THE DIMERIZED CYTOPLASMIC DOMAIN OF P23 IN SOLUTION
1P23	;		;	STRUCTURE OF THE DIMERIZED CYTOPLASMIC DOMAIN OF P23 IN SOLUTION, NMR, 10 STRUCTURES
3TQS	;	1.98	;	Structure of the dimethyladenosine transferase (ksgA) from Coxiella burnetii
4ILT	;	2.55	;	Structure of the dioxygenase domain of SACTE_2871, a novel dioxygenase carbohydrate-binding protein fusion from the cellulolytic bacterium Streptomyces sp. SirexAA-E
4ILV	;	2.06	;	Structure of the dioxygenase domain of SACTE_2871, a novel dioxygenase carbohydrate-binding protein fusion from the cellulolytic bacterium Streptomyces sp. SirexAA-E
4REV	;	1.95	;	Structure of the dirigent protein DRR206
2WN2	;	1.82	;	Structure of the discoidin I from Dictyostelium discoideum in complex with galactose beta 1-3 galNAc at 1.8 A resolution.
2W95	;	1.75	;	STructure of the Discoidin I from Dictyostelium discoideum in complex with GalNAc at 1.75 angstrom resolution
5FZP	;	1.7	;	Structure of the dispase autolysis inducing protein from Streptomyces mobaraensis
3MMC	;	2.04	;	Structure of the dissimilatory sulfite reductase from Archaeoglobus fulgidus
5NC1	;	2.0	;	Structure of the distal domain of mouse adenovirus 2 fibre bound to N-acetyl-glucosamine
5N83	;	2.76	;	Structure of the distal domain of mouse adenovirus 2 fibre, methylmercury chloride derivative
5N8D	;	1.8	;	Structure of the distal domain of mouse adenovirus 2 fibre, P21 native
5NBH	;	1.7	;	Structure of the distal domain of mouse adenovirus 2 fibre, P212121 native
8CP7	;	1.9	;	Structure of the disulfide-locked substrate binding protein HiSiaP.
5OAK	;	1.5	;	Structure of the dmPar3 PDZ1 domain in complex with the dmPar6 PBM
6IYA	;	3.0	;	Structure of the DNA binding domain of antitoxin CopASO
8CSH	;	2.25	;	Structure of the DNA binding domain of pSK1 Par partition protein bound to centromere DNA
1J9I	;		;	STRUCTURE OF THE DNA BINDING DOMAIN OF THE GPNU1 SUBUNIT OF LAMBDA TERMINASE
1T2K	;	3.0	;	Structure Of The DNA Binding Domains Of IRF3, ATF-2 and Jun Bound To DNA
2AS5	;	2.7	;	Structure of the DNA binding domains of NFAT and FOXP2 bound specifically to DNA.
1A02	;	2.7	;	STRUCTURE OF THE DNA BINDING DOMAINS OF NFAT, FOS AND JUN BOUND TO DNA
4CO8	;	1.05	;	Structure of the DNA binding ETS domain of human ETV4
4UUV	;	2.8	;	Structure of the DNA binding ETS domain of human ETV4 in complex with DNA
2AF1	;	3.1	;	Structure of the DNA coiled-coil formed by d(CGATATATATAT)
2LEV	;		;	Structure of the DNA complex of the C-Terminal domain of Ler
2MXF	;		;	Structure of the DNA complex of the C-Terminal domain of MvaT
5LIT	;	1.25	;	Structure of the DNA duplex d(AAATTT)2 with the potential antiparasitic drug 6XV at 1.25 A resolution
6GIM	;	1.43	;	Structure of the DNA duplex d(AAATTT)2 with [N-(3-chloro-4-((4,5-dihydro-1H-imidazol-2-yl)amino)phenyl)-4-((4,5-dihydro-1H-imidazol-2- yl)amino)benzamide] - (drug JNI18)
4U9M	;	3.13	;	Structure of the DNA duplex d(ATTAAT)2 with Hoogsteen hydrogen bonds
243D	;	1.9	;	STRUCTURE OF THE DNA OCTANUCLEOTIDE D(ACGTACGT)2
1OQY	;		;	Structure of the DNA repair protein hHR23a
1D3Y	;	2.0	;	STRUCTURE OF THE DNA TOPOISOMERASE VI A SUBUNIT
2GPE	;	1.9	;	Structure of the DNA-binding domain of E. Coli Proline Utilization A (PUTA)
5FO5	;	2.16	;	Structure of the DNA-binding domain of Escherichia coli methionine biosynthesis regulator MetR
5LXU	;	2.14	;	Structure of the DNA-binding domain of LUX ARRHYTHMO
7NB0	;	2.1	;	Structure of the DNA-binding domain of SEPALLATA 3
4U88	;	2.355	;	Structure of the DNA-Binding Domain of the Response Regulator SaeR from Staphylococcus aureus
8A2Q	;	3.53	;	Structure of the DNA-bound FANCD2-FANCI complex containing phosphomimetic FANCI
4A04	;	2.58	;	Structure of the DNA-bound T-box domain of human TBX1, a transcription factor associated with the DiGeorge syndrome
1DD9	;	1.6	;	STRUCTURE OF THE DNAG CATALYTIC CORE
1DDE	;	1.7	;	STRUCTURE OF THE DNAG CATALYTIC CORE
3B39	;	2.35	;	Structure of the DnaG primase catalytic domain bound to ssDNA
7CLY	;	1.432	;	Structure of the DOCK8 DHR-1 domain crystallized with di-C8-phosphatidylinositol-(4,5)-bisphosphate
5B6P	;	2.0	;	Structure of the dodecameric type-II dehydrogenate dehydratase from Acinetobacter baumannii at 2.00 A resolution
3MCA	;	2.74	;	Structure of the Dom34-Hbs1 Complex and implications for its role in No-Go decay
3IZQ	;	9.5	;	Structure of the Dom34-Hbs1-GDPNP complex bound to a translating ribosome
5YS2	;	2.698	;	Structure of the domain IV(D_IV) of Pseudorabies virus glycoprotein B( PRV gB)
5LZK	;	1.575	;	Structure of the domain of unknown function DUF1669 from human FAM83B
5UC3	;	2.009	;	Structure of the dominant negative mutant Glucocorticoid Receptor alpha (L733K/N734P) complexed with RU-486
1C74	;	1.9	;	Structure of the double mutant (K53,56M) of phospholipase A2
1NU0	;	1.6	;	Structure of the double mutant (L6M; F134M, SeMet form) of yqgF from Escherichia coli, a hypothetical protein
4P0Y	;	1.4	;	Structure of the double stranded DNA binding type IV secretion protein TraN from Enterococcus
4P0Z	;	1.35	;	Structure of the double stranded DNA binding type IV secretion protein TraN from Enterococcus
4PM3	;	1.8	;	Structure of the double-stranded DNA binding type IV secretion protein TraN from Enterococcus
1QU6	;		;	STRUCTURE OF THE DOUBLE-STRANDED RNA-BINDING DOMAIN OF THE PROTEIN KINASE PKR REVEALS THE MOLECULAR BASIS OF ITS DSRNA-MEDIATED ACTIVATION
4MNH	;	3.3	;	Structure of the DP10.7 TCR
4MNG	;	3.0058	;	Structure of the DP10.7 TCR with CD1d-sulfatide
4V4L	;	6.9	;	Structure of the Drosophila apoptosome
5EUP	;	2.5	;	Structure of the Drosophila melanogaster CP190 BTB domain
7MWY	;	1.84	;	Structure of the drosophila STING cyclic dinucleotide binding domain
4Q47	;	2.899	;	Structure of the DrRecQ Catalytic Core in complex with ADP
2B6M	;	2.65	;	Structure of the DsbA mutant (P31A-C33A)
2B3S	;	1.96	;	structure of the DSBA mutant (P31G-C33A)
1OHG	;	3.45	;	STRUCTURE OF THE DSDNA BACTERIOPHAGE HK97 MATURE EMPTY CAPSID
3CQ2	;	1.9	;	Structure of the DTDP-4-Keto-L-Rhamnose Reductase related protein (other form) from Thermus Thermophilus HB8
3CQ3	;	2.1	;	Structure of the DTDP-4-Keto-L-Rhamnose Reductase related protein (other form) from Thermus Thermophilus HB8
3CQ1	;	1.9	;	Structure of the DTDP-4-Keto-L-Rhamnose Reductase related protein (TT1362) from Thermus Thermophilus HB8
7PWH	;	1.9	;	Structure of the dTDP-sugar epimerase StrM
7PWI	;	1.326	;	Structure of the dTDP-sugar epimerase StrM
7UCG	;	3.5	;	Structure of the DU422 SOSIP.664 trimer in complex with neutralizing antibody Fab fragments 10-1074 and BG24
2RIO	;	2.4	;	Structure of the dual enzyme Ire1 reveals the basis for catalysis and regulation of non-conventional splicing
2LG0	;		;	structure of the duplex containing (5'S)-8,5'-cyclo-2'-deoxyadenosine
2LG3	;		;	Structure of the duplex containing HNE derived (6S,8R,11S) gamma-HO-PdG when placed opposite dT
2LG2	;		;	Structure of the duplex containing HNE derived (6S,8R,11S) N2-dG cyclic hemiacetal when placed opposite dT
2LFY	;		;	Structure of the duplex when (5'S)-8,5'-cyclo-2'-deoxyguanosine is placed opposite dA
2LFX	;		;	Structure of the duplex when (5'S)-8,5'-cyclo-2'-deoxyguanosine is placed opposite dT
3PPA	;	2.35	;	Structure of the Dusp-Ubl domains of Usp15
6SC2	;	3.9	;	Structure of the dynein-2 complex; IFT-train bound model
6RLA	;	3.9	;	Structure of the dynein-2 complex; motor domains
6RLB	;	4.5	;	Structure of the dynein-2 complex; tail domain
5J8A	;	3.1	;	Structure of the E coli 70S ribosome with the U1052G mutation in 16S rRNA bound to tigecycline
5J88	;	3.32	;	Structure of the E coli 70S ribosome with the U1060A mutation in 16S rRNA
4N7B	;	2.198	;	Structure of the E-1-hydroxy-2-methyl-but-2-enyl-4-diphosphate reductase from Plasmodium falciparum
1GA0	;	1.6	;	STRUCTURE OF THE E. CLOACAE GC1 BETA-LACTAMASE WITH A CEPHALOSPORIN SULFONE INHIBITOR
3J5L	;	6.6	;	Structure of the E. coli 50S subunit with ErmBL nascent chain
3J7Z	;	3.9	;	Structure of the E. coli 50S subunit with ErmCL nascent chain
1LB2	;	3.1	;	Structure of the E. coli alpha C-terminal domain of RNA polymerase in complex with CAP and DNA
3O9X	;	2.0999	;	Structure of the E. coli antitoxin MqsA (YgiT/b3021) in complex with its gene promoter
4XB6	;	1.7	;	Structure of the E. coli C-P lyase core complex
2WMP	;	2.3	;	Structure of the E. coli chaperone PapD in complex with the pilin domain of the PapGII adhesin
3ME0	;	2.03	;	Structure of the E. coli chaperone PAPD in complex with the pilin domain of the PapGII adhesin
8VAQ	;	3.8	;	Structure of the E. coli clamp loader bound to the beta clamp in a Closed-DNA1 conformation
8VAR	;	3.9	;	Structure of the E. coli clamp loader bound to the beta clamp in a Closed-DNA2 conformation
8VAP	;	3.0	;	Structure of the E. coli clamp loader bound to the beta clamp in a Fully-Open conformation
8VAL	;	3.7	;	Structure of the E. coli clamp loader bound to the beta clamp in a Open-DNAp/t conformation
8VAT	;	3.2	;	Structure of the E. coli clamp loader bound to the beta clamp in a Open-RNAp/t conformation
8VAM	;	3.9	;	Structure of the E. coli clamp loader bound to the beta clamp in a Semi-Open conformation
8VAS	;	3.8	;	Structure of the E. coli clamp loader bound to the beta clamp in an Altered-Collar conformation
8VAN	;	7.7	;	Structure of the E. coli clamp loader bound to the beta clamp in an Initial-Binding conformation
1V74	;	2.0	;	Structure of the E. coli colicin D bound to its immunity protein ImmD
2O1C	;	1.8	;	Structure of the E. coli dihydroneopterin triphosphate pyrophosphohydrolase
2O5W	;	2.6	;	Structure of the E. coli dihydroneopterin triphosphate pyrophosphohydrolase in complex with Sm+3 and pyrophosphate
7QGH	;	4.48	;	Structure of the E. coli disome - collided 70S ribosome
2GT2	;	2.0	;	Structure of the E. coli GDP-mannose mannosyl hydrolase
2PYU	;	2.02	;	Structure of the E. coli inosine triphosphate pyrophosphatase RgdB in complex with IMP
2Q16	;	1.95	;	Structure of the E. coli inosine triphosphate pyrophosphatase RgdB in complex with ITP
1XS0	;	1.58	;	Structure of the E. coli Ivy protein
5LJ9	;	2.3	;	Structure of the E. coli MacB ABC domain (C2221)
5LJA	;	2.4	;	Structure of the E. coli MacB ABC domain (P6122)
5LJ8	;	1.95	;	Structure of the E. coli MacB periplasmic domain (P21)
4ADV	;	13.5	;	Structure of the E. coli methyltransferase KsgA bound to the E. coli 30S ribosomal subunit
5HBU	;	2.6	;	Structure of the E. coli nucleoid occlusion protein SlmA bound to DNA and the C-terminal tail of the cytoskeletal cell division protein FtsZ
1PSU	;	2.2	;	Structure of the E. coli PaaI protein from the phyenylacetic acid degradation operon
2FS2	;	2.0	;	Structure of the E. coli PaaI protein from the phyenylacetic acid degradation operon
1ZVT	;	1.7	;	Structure of the E. coli ParC C-terminal domain
4Q65	;	3.4	;	Structure of the E. coli Peptide Transporter YbgH
2IDO	;	2.1	;	Structure of the E. coli Pol III epsilon-Hot proofreading complex
3GN5	;	2.15	;	Structure of the E. coli protein MqsA (YgiT/b3021)
7SQN	;	2.25	;	Structure of the E. coli PutA proline dehydrogenase domain (residues 86-630) complexed with (2S)-oxetane-2-carboxylic acid
7MWT	;	2.19	;	Structure of the E. coli PutA proline dehydrogenase domain (residues 86-630) complexed with 1,1-Cyclobutanedicarboxylate
7MWU	;	1.69	;	Structure of the E. coli PutA proline dehydrogenase domain (residues 86-630) complexed with cyclobutanecarboxylic acid
7MWV	;	1.69	;	Structure of the E. coli PutA proline dehydrogenase domain (residues 86-630) complexed with cyclopropanecarboxylic acid
2FZN	;	2.0	;	Structure of the E. coli PutA proline dehydrogenase domain reduced by dithionite and complexed with proline
2FZM	;	2.3	;	Structure of the E. coli PutA proline dehydrogenase domain reduced by dithionite and complexed with SO2
1ML5	;	14.0	;	Structure of the E. coli ribosomal termination complex with release factor 2
4V66	;	9.0	;	Structure of the E. coli ribosome and the tRNAs in Post-accommodation state
4V65	;	9.0	;	Structure of the E. coli ribosome in the Pre-accommodation state
2IY3	;	16.0	;	Structure of the E. Coli Signal Regognition Particle
2YHS	;	1.6	;	Structure of the E. coli SRP receptor FtsY
3SXU	;	1.85	;	Structure of the E. coli SSB-DNA polymerase III interface
2MX1	;		;	Structure of the E. coli Threonylcarbamoyl-AMP Synthase TSAC
2VRH	;	19.0	;	Structure of the E. coli trigger factor bound to a translating ribosome
4Q2M	;	1.489	;	Structure of the E. coli YajR Transporter YAM Domain Combined Iodine
1H3D	;	2.7	;	STRUCTURE OF THE E.COLI ATP-PHOSPHORIBOSYLTRANSFERASE
8PAY	;	1.21	;	Structure of the E.coli DNA polymerase sliding clamp with a covalently bound peptide 2.
8PAT	;	1.45	;	Structure of the E.coli DNA polymerase sliding clamp with a covalently bound peptide 3.
3OAA	;	3.26	;	Structure of the E.coli F1-ATP synthase inhibited by subunit Epsilon
3O52	;	2.5	;	Structure of the E.coli GDP-mannose hydrolase (yffh) in complex with tartrate
3O61	;	2.45	;	Structure of the E100A E.coli GDP-mannose hydrolase (yffh) in complex with GDP-mannose and Mg++
3O69	;	2.1	;	Structure of the E100A E.coli GDP-mannose hydrolase (yffh) in complex with Mg++
4BXQ	;	1.9	;	Structure of the E1021V mutant of the TCP10 domain of Danio rerio CPAP
7KPP	;	1.45	;	Structure of the E102A mutant of a GNAT superfamily PA3944 acetyltransferase
2KOY	;		;	Structure of the E1064A mutant of the N-domain of Wilson Disease Associated Protein
4KKL	;	2.85	;	Structure of the E148A mutant of CLC-ec1 delta NC construct in 100mM fluoride
4KKA	;	3.0	;	Structure of the E148A mutant of CLC-ec1 deltaNC construct in 100mM fluoride and 20mM Bromide
4KK9	;	2.997	;	Structure of the E148A mutant of CLC-ec1 deltaNC construct in 100mM fluoride and 2mM Bromide
4KKC	;	3.18	;	Structure of the E148A mutant of CLC-ec1 deltaNC construct in 20mM Bromide
4KKB	;	3.021	;	Structure of the E148A mutant of CLC-ec1 deltaNC construct in 20mM fluoride and 20mM Bromide
3DET	;	2.8	;	Structure of the E148A, Y445A doubly ungated mutant of E.coli CLC_Ec1, Cl-/H+ antiporter
4KK8	;	2.86	;	Structure of the E148Q mutant of CLC-ec1 deltaNC construct in 100mM fluoride
4LOU	;	2.981	;	Structure of the E148Q mutant of CLC-ec1 deltaNC construct in the absence of halide
1LL7	;	2.0	;	STRUCTURE OF THE E171Q MUTANT OF C. IMMITIS CHITINASE 1
2XFW	;	1.65	;	Structure of the E192N mutant of E. coli N-acetylneuraminic acid lyase in complex with pyruvate in crystal form III
2WNZ	;	1.85	;	Structure of the E192N mutant of E. coli N-acetylneuraminic acid lyase in complex with pyruvate in space group P21 crystal form I
2WNQ	;	1.8	;	Structure of the E192N mutant of E. coli N-acetylneuraminic acid lyase in space group P21
3B9B	;	2.65	;	Structure of the E2 beryllium fluoride complex of the SERCA Ca2+-ATPase
6GV3	;	1.201	;	Structure of the E2 conjugating enzyme, SCE1, from Arabidopsis thaliana.
6LSC	;	3.21	;	Structure of the E202Y mutant of the Cl-/H+ antiporter CLC-ec1 from E.coli: a re-refined model of the 4FTP model
2FEC	;	3.967	;	Structure of the E203Q mutant of the Cl-/H+ exchanger CLC-ec1 from E.Coli
2FED	;	3.317	;	Structure of the E203Q mutant of the Cl-/H+ exchanger CLC-ec1 from E.Coli
3EI0	;	3.5	;	Structure of the E221A mutant of the Gloebacter violaceus pentameric ligand gated ion channnel (GLIC)
2YDP	;	1.85	;	Structure of the E242A mutant of the alpha-l-arabinofuranosidase arb93a from fusarium graminearum in complex with an iminosugar inhibitor
4WUO	;	2.05	;	Structure of the E270A Mutant Isopropylmalate dehydrogenase from Thermus thermophilus in complex with IPM, Mn and NADH
5W4P	;	2.19	;	Structure of the E28A mutant of the HIV-1 capsid protein
7P47	;	3.314	;	Structure of the E3 ligase Smc5/Nse2 in complex with Ubc9-SUMO thioester mimetic
4PEX	;	1.75	;	Structure of the E502A variant of sacteLam55A from Streptomyces sp. SirexAA-E in complex with glucose
4PF0	;	1.75	;	Structure of the E502A variant of sacteLam55A from Streptomyces sp. SirexAA-E in complex with laminarihexaose
4PEZ	;	1.9	;	Structure of the E502A variant of sacteLam55A from Streptomyces sp. SirexAA-E in complex with laminaritetraose
4PEY	;	1.5	;	Structure of the E502A variant of sacteLam55A from Streptomyces sp. SirexAA-E in complex with laminaritriose
5N2H	;	2.81	;	Structure of the E9 DNA polymerase exonuclease deficient mutant (D166A+E168A) from vaccinia virus
5N2E	;	2.74	;	Structure of the E9 DNA polymerase from vaccinia virus
5N2G	;	2.78	;	Structure of the E9 DNA polymerase from vaccinia virus in complex with manganese
8OPR	;	1.811	;	Structure of the EA1 surface layer of Bacillus anthracis
5MWN	;	2.2	;	Structure of the EAEC T6SS component TssK N-terminal domain in complex with llama nanobodies nbK18 and nbK27
4LLO	;	1.995	;	Structure of the eag domain-CNBHD complex of the mouse EAG1 channel
8ARV	;	1.9	;	Structure of the EAL domain of BifA from Pseudomonas aeruginosa
5T42	;		;	Structure of the Ebola virus envelope protein MPER/TM domain and its interaction with the fusion loop explains their fusion activity
3FKE	;	1.4	;	Structure of the Ebola VP35 Interferon Inhibitory Domain
3VNE	;	2.0	;	Structure of the ebolavirus protein VP24 from Sudan
3VNF	;	2.1	;	Structure of the ebolavirus protein VP24 from Sudan
6Z20	;	2.68	;	Structure of the EC2 domain of CD9 in complex with nanobody 4C8
6Z1V	;	1.33	;	Structure of the EC2 domain of CD9 in complex with nanobody 4E8
4HLU	;	2.7003	;	Structure of the EcfA-A' heterodimer bound to ADP
8PAE	;	1.2	;	Structure of the ectodomain of Atypical Porcine Pestivirus E2 at 1.2A resolution
4BSU	;	3.2	;	Structure of the ectodomain of LGR5 in complex with R-spondin-1 (Fu1Fu2) in C2 crystal form
4BSS	;	3.2	;	Structure of the ectodomain of LGR5 in complex with R-spondin-1 (Fu1Fu2) in P21 crystal form
4BSR	;	3.2	;	Structure of the ectodomain of LGR5 in complex with R-spondin-1 (Fu1Fu2) in P22121 crystal form
4BST	;	4.3	;	Structure of the ectodomain of LGR5 in complex with R-spondin-1 (Fu1Fu2) in P6122 crystal form
4UFR	;	2.2	;	Structure of the ectodomain of LGR5 in complex with R-spondin-2 (Fu1Fu2)
5YS6	;	3.1	;	Structure of the ectodomain of pseudorabies virus glycoproten B
5U8R	;	3.00002	;	Structure of the ectodomain of the human Type 1 insulin-like growth factor receptor
5U8Q	;	3.27104	;	Structure of the ectodomain of the human Type 1 insulin-like growth factor receptor in complex with IGF-I
1ZM4	;	2.9	;	Structure of the eEF2-ETA-bTAD complex
3B8H	;	2.5	;	Structure of the eEF2-ExoA(E546A)-NAD+ complex
3B82	;	2.35	;	Structure of the eEF2-ExoA(E546H)-NAD+ complex
3B78	;	2.5	;	Structure of the eEF2-ExoA(R551H)-NAD+ complex
2ZIT	;	3.0	;	Structure of the eEF2-ExoA-NAD+ complex
4J32	;	1.8	;	Structure of the effector - immunity system Tae4 / Tai4 from Salmonella typhimurium
4J30	;	2.3	;	Structure of the effector - immunity system Tae4 / Tai4 from Salmonella typhimurium, selenomethionine variant
4FGI	;	3.2	;	Structure of the effector - immunity system Tse1 / Tsi1 from Pseudomonas aeruginosa
5FIA	;	1.75	;	Structure of the effector protein LpiR1 (Lpg0634) from Legionella pneumophila
5JG4	;	2.4	;	Structure of the effector protein LpiR1 (Lpg0634) from Legionella pneumophila
5UFK	;	2.3	;	Structure of the effector protein SidK (lpg0968) from Legionella pneumophila
5UF5	;	2.4	;	Structure of the effector protein SidK (lpg0968) from Legionella pneumophila (domain-swapped dimer)
4FGE	;	1.7	;	Structure of the effector protein Tse1 from Pseudomonas aeruginosa
4FGD	;	2.6	;	Structure of the effector protein Tse1 from Pseudomonas aeruginosa, selenomethionine variant
3TB6	;	2.21	;	Structure of the effector-binding domain of arabinose repressor AraR from Bacillus subtilis
4OQQ	;	1.8	;	Structure of the effector-binding domain of deoxyribonucleoside regulator DeoR from Bacillus subtilis
4OQP	;	1.6	;	Structure of the effector-binding domain of deoxyribonucleoside regulator DeoR from Bacillus subtilis in complex with deoxyribose-5-phosphate
1FSB	;		;	STRUCTURE OF THE EGF DOMAIN OF P-SELECTIN, NMR, 19 STRUCTURES
1APQ	;		;	STRUCTURE OF THE EGF-LIKE MODULE OF HUMAN C1R, NMR, 19 STRUCTURES
5DFT	;	2.5	;	Structure of the Eleventh Type III Domain from Human Fibronectin
7A5G	;	4.33	;	Structure of the elongating human mitoribosome bound to mtEF-Tu.GMPPCP and A/T mt-tRNA
4X33	;	1.45	;	Structure of the Elongator cofactor complex Kti11/Kti13 at 1.45A
3PZT	;	1.97	;	Structure of the endo-1,4-beta-glucanase from Bacillus subtilis 168 with manganese(II) ion
7B2L	;	3.9	;	Structure of the endocytic adaptor complex AENTH
2Q7Y	;	1.95	;	Structure of the endogenous iNKT cell ligand iGb3 bound to mCD1d
1UP0	;	1.75	;	Structure of the endoglucanase Cel6 from Mycobacterium tuberculosis in complex with cellobiose at 1.75 angstrom
1UP2	;	1.9	;	Structure of the endoglucanase Cel6 from Mycobacterium tuberculosis in complex with glucose-isofagomine at 1.9 angstrom
1UP3	;	1.6	;	Structure of the endoglucanase Cel6 from Mycobacterium tuberculosis in complex with METHYL-CELLOBIOSYL-4-DEOXY-4-THIO-BETA-D-CELLOBIOSIDE at 1.6 angstrom
1UOZ	;	1.1	;	Structure of the endoglucanase Cel6 from Mycobacterium tuberculosis in complex with thiocellopentaose at 1.1 angstrom
4XST	;	3.0	;	Structure of the endoglycosidase-H treated L1-CR domains of the human insulin receptor in complex with residues 697-719 of the human insulin receptor (A-isoform)
8ONG	;		;	Structure of the endothelial monocyte activating polypeptide II (EMAP II) in solution
3RQO	;	2.08	;	Structure of the endothelial nitric oxide synthase heme domain in complex with 6-(((3R,4R)-4-(2-((1S,2R/1R,2S)-2-(3-Clorophenyl)cyclopropylamino)ethoxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine
3RQP	;	2.35	;	Structure of the endothelial nitric oxide synthase heme domain in complex with 6-{[(3R,4R)-4-(2-{[(2R/2S)-1-(3-fluorophenyl)propan-2-yl]amino}ethoxy)pyrrolidin-3-yl]methyl}-4-methylpyridin-2-amine
3JAJ	;	3.75	;	Structure of the engaged state of the mammalian SRP-ribosome complex
6TF8	;	1.903	;	Structure of the engineered artificial aldolase I133F RA95.5-8F with a bound substrate, pentan-2-one
6YPI	;	1.479	;	Structure of the engineered metallo-Diels-Alderase DA7 W16G,K58Q,L77R,T78R
7BWW	;	1.5	;	Structure of the engineered metallo-Diels-Alderase DA7 W16S
5OD1	;	1.34	;	Structure of the engineered metalloesterase MID1sc10 complexed with a phosphonate transition state analogue
5OD9	;	1.13	;	Structure of the engineered metalloesterase MID1sc9
4A29	;	1.1	;	Structure of the engineered retro-aldolase RA95.0
4A2S	;	1.4	;	Structure of the engineered retro-aldolase RA95.5
4A2R	;	1.302	;	Structure of the engineered retro-aldolase RA95.5-5
5AOU	;	1.1	;	Structure of the engineered retro-aldolase RA95.5-8F apo
6TFA	;	2.163	;	Structure of the engineered retro-aldolase RA95.5-8F F112L
5AN7	;	1.1	;	Structure of the engineered retro-aldolase RA95.5-8F with a bound 1,3-diketone inhibitor
4EWJ	;	2.403	;	structure of the enloase from Streptococcus suis serotype 2
3ZU3	;	1.802	;	Structure of the enoyl-ACP reductase FabV from Yersinia pestis with the cofactor NADH (MR, cleaved Histag)
3ZU2	;	2.1	;	Structure of the enoyl-ACP reductase FabV from Yersinia pestis with the cofactor NADH (SIRAS)
3ZU4	;	2.01	;	Structure of the enoyl-ACP reductase FabV from Yersinia pestis with the cofactor NADH and the 2-pyridone inhibitor PT172
3ZU5	;	2.0	;	Structure of the enoyl-ACP reductase FabV from Yersinia pestis with the cofactor NADH and the 2-pyridone inhibitor PT173
4TRO	;	1.4	;	Structure of the enoyl-ACP reductase of Mycobacterium tuberculosis InhA, inhibited with the active metabolite of isoniazid
7LJL	;	1.45	;	Structure of the Enterobacter cloacae CD-NTase CdnD in complex with ATP
2C2A	;	1.9	;	Structure of the entire cytoplasmic portion of a sensor histidine kinase protein
5AYH	;	3.011	;	Structure of the entire dynein stalk region
3WUQ	;	3.5	;	Structure of the entire stalk region of the dynein motor domain
5XEB	;	2.497	;	Structure of the envelope glycoprotein of Dhori virus
4ETW	;	2.05	;	Structure of the Enzyme-ACP Substrate Gatekeeper Complex Required for Biotin Synthesis
4XEG	;	1.72	;	Structure of the enzyme-product complex resulting from TDG action on a G/hmU mismatch
5CYS	;	2.45	;	Structure of the enzyme-product complex resulting from TDG action on a GcaC mismatch
4Z7B	;	2.02	;	Structure of the enzyme-product complex resulting from TDG action on a GfC mismatch
4Z7Z	;	1.83	;	Structure of the enzyme-product complex resulting from TDG action on a GT mismatch in the presence of excess base
4Z47	;	1.45	;	Structure of the enzyme-product complex resulting from TDG action on a GU mismatch in the presence of excess base
7K7K	;	3.56	;	Structure of the EPEC type III secretion injectisome EspA filament
8TRT	;	3.0	;	Structure of the EphA2 CRD bound to FabS1CE_C1, monoclinic form
8TRS	;	1.9	;	Structure of the EphA2 CRD bound to FabS1CE_C1, trigonal form
4W4Z	;	2.41	;	Structure of the EphA4 LBD in complex with peptide
4W50	;	2.42	;	Structure of the EphA4 LBD in complex with peptide
1EPA	;	2.1	;	STRUCTURE OF THE EPIDIDYMAL RETINOIC ACID-BINDING PROTEIN AT 2.1 ANGSTROMS RESOLUTION
1EPB	;	2.2	;	STRUCTURE OF THE EPIDIDYMAL RETINOIC ACID-BINDING PROTEIN AT 2.1 ANGSTROMS RESOLUTION
5LSS	;	1.79	;	Structure of the Epigenetic Oncogene MMSET and inhibition by N-Alkyl Sinefungin Derivatives
5LSU	;	2.14	;	Structure of the Epigenetic Oncogene MMSET and inhibition by N-Alkyl Sinefungin Derivatives
5LSX	;	2.9	;	Structure of the Epigenetic Oncogene MMSET and inhibition by N-Alkyl Sinefungin Derivatives
5LSY	;	1.62	;	Structure of the Epigenetic Oncogene MMSET and inhibition by N-Alkyl Sinefungin Derivatives
5LSZ	;	1.62	;	Structure of the Epigenetic Oncogene MMSET and inhibition by N-Alkyl Sinefungin Derivatives
5LT6	;	2.05	;	Structure of the Epigenetic Oncogene MMSET and inhibition by N-Alkyl Sinefungin Derivatives
5LT7	;	1.51	;	Structure of the Epigenetic Oncogene MMSET and inhibition by N-Alkyl Sinefungin Derivatives
5LT8	;	1.57	;	Structure of the Epigenetic Oncogene MMSET and inhibition by N-Alkyl Sinefungin Derivatives
2JXC	;		;	Structure of the EPS15-EH2 Stonin2 Complex
2YMW	;	2.41	;	Structure of the epsilon-lysine oxidase from Marinomonas mediterranea
6EPI	;	2.8	;	Structure of the epsilon_1 / zeta_1 antitoxin / toxin system from Neisseria gonorrhoeae in complex with UNAM-4P.
6EPG	;	2.4	;	Structure of the epsilon_1 / zeta_1 antitoxin / toxin system from Neisseria gonorrhoeae.
6EPH	;	2.7	;	Structure of the epsilon_1 / zeta_1 antitoxin toxin system from Neisseria gonorrhoeae in complex with UNAM.
1KG0	;	2.65	;	Structure of the Epstein-Barr Virus gp42 Protein Bound to the MHC class II Receptor HLA-DR1
7JHJ	;	3.2	;	Structure of the Epstein-Barr virus GPCR BILF1 in complex with human Gi
2CH8	;	2.3	;	Structure of the Epstein-Barr Virus Oncogene BARF1
2C9L	;	2.25	;	Structure of the Epstein-Barr virus ZEBRA protein
2C9N	;	3.3	;	Structure of the Epstein-Barr virus ZEBRA protein at approximately 3. 5 Angstrom resolution
2I9F	;	2.0	;	Structure of the equine arterivirus nucleocapsid protein
1TVT	;		;	STRUCTURE OF THE EQUINE INFECTIOUS ANEMIA VIRUS TAT PROTEIN
6Q0N	;	1.18	;	Structure of the Erbin PDB domain in complex with a high-affinity peptide
6Q0U	;	1.89	;	Structure of the Erbin PDZ variant E-6a with a high-affinity C-terminal peptide
4MT8	;	1.9	;	Structure of the ERS1 dimerization and histidine phosphotransfer domain from Arabidopsis thaliana
4MTX	;	2.15	;	Structure of the ERS1 dimerization and histidine phosphotransfer domain from Arabidopsis thaliana
8G7R	;	2.8	;	Structure of the Escherichia coli 70S ribosome in complex with A-site tRNAIle(LAU) bound to the cognate AUA codon (Structure III)
8G7P	;	2.9	;	Structure of the Escherichia coli 70S ribosome in complex with EF-Tu and Ile-tRNAIle(LAU) bound to the cognate AUA codon (Structure I)
8G7Q	;	3.1	;	Structure of the Escherichia coli 70S ribosome in complex with EF-Tu and Ile-tRNAIle(LAU) bound to the near-cognate AUG codon (Structure II)
8G7S	;	3.1	;	Structure of the Escherichia coli 70S ribosome in complex with P-site tRNAIle(LAU) bound to the cognate AUA codon (Structure IV)
1OTS	;	2.51	;	Structure of the Escherichia coli ClC Chloride channel and Fab Complex
1OTT	;	3.0	;	Structure of the Escherichia coli ClC Chloride channel E148A mutant and Fab Complex
1OTU	;	3.3	;	Structure of the Escherichia coli ClC Chloride channel E148Q mutant and Fab Complex
2HTK	;	3.41	;	Structure of the Escherichia coli ClC chloride channel Y445A mutant and Fab complex
2HTL	;	3.4	;	Structure of the Escherichia coli ClC chloride channel Y445F mutant and Fab complex
2HT2	;	3.32	;	Structure of the Escherichia coli ClC chloride channel Y445H mutant and Fab complex
2HT3	;	3.3	;	Structure of the Escherichia coli ClC chloride channel Y445L mutant and Fab complex
2HT4	;	3.2	;	Structure of the Escherichia coli ClC chloride channel Y445W mutant and Fab complex
2AVU	;	3.0	;	Structure of the Escherichia coli FlhDC complex, a prokaryotic heteromeric regulator of transcription
7Z0T	;	3.4	;	Structure of the Escherichia coli formate hydrogenlyase complex (aerobic preparation, composite structure)
7Z0S	;	2.6	;	Structure of the Escherichia coli formate hydrogenlyase complex (anaerobic preparation, without formate dehydrogenase H)
6SPN	;	1.45	;	Structure of the Escherichia coli methionyl-tRNA synthetase complexed with beta-methionine
6SPO	;	1.2	;	Structure of the Escherichia coli methionyl-tRNA synthetase complexed with methionine
6SPP	;	1.49	;	Structure of the Escherichia coli methionyl-tRNA synthetase variant VI298
6SPR	;	1.48	;	Structure of the Escherichia coli methionyl-tRNA synthetase variant VI298 complexed with beta-methionine
6SPQ	;	1.38	;	Structure of the Escherichia coli methionyl-tRNA synthetase variant VI298 complexed with methionine
5JC9	;	3.03	;	Structure of the Escherichia coli ribosome with the U1052G mutation in the 16S rRNA
1PIL	;	2.7	;	STRUCTURE OF THE ESCHERICHIA COLI SIGNAL TRANSDUCING PROTEIN PII
2HLF	;	3.3	;	Structure of the Escherichis coli ClC chloride channel Y445E mutant and Fab complex
2F66	;	2.8	;	Structure of the ESCRT-I endosomal trafficking complex
1U5T	;	3.6	;	Structure of the ESCRT-II endosomal trafficking complex
6XLP	;	2.0	;	Structure of the essential inner membrane lipopolysaccharide-PbgA complex
7UDA	;	2.47	;	Structure of the EstG
6SGW	;	3.8	;	Structure of the ESX-3 core complex
4WAS	;	1.7	;	STRUCTURE OF THE ETR1P/NADP/CROTONYL-COA COMPLEX
2R8J	;	3.1	;	Structure of the Eukaryotic DNA Polymerase eta in complex with 1,2-d(GpG)-cisplatin containing DNA
2R8K	;	3.3	;	Structure of the Eukaryotic DNA Polymerase eta in complex with 1,2-d(GpG)-cisplatin containing DNA
5VG9	;	4.0	;	Structure of the eukaryotic intramembrane Ras methyltransferase ICMT (isoprenylcysteine carboxyl methyltransferase) without a monobody
3JC5	;	4.7	;	Structure of the eukaryotic replicative CMG helicase and pumpjack motion
3JC6	;	3.7	;	Structure of the eukaryotic replicative CMG helicase and pumpjack motion
3JC7	;	4.8	;	Structure of the eukaryotic replicative CMG helicase and pumpjack motion
3D2V	;	2.0	;	Structure of the eukaryotic TPP-specific riboswitch bound to the antibacterial compound pyrithiamine pyrophosphate
7WYL	;	1.31	;	Structure of the EV71 3Cpro with 337 inhibitor
7WYO	;	1.402	;	Structure of the EV71 3Cpro with 338 inhibitor
6UH1	;	3.04	;	Structure of the EVA71 strain 11316 capsid
2W3Y	;	2.0	;	Structure of the Evf virulence factor
5SV1	;	3.5	;	Structure of the ExbB/ExbD complex from E. coli at pH 4.5
5SV0	;	2.6	;	Structure of the ExbB/ExbD complex from E. coli at pH 7.0
5ZFP	;	2.84	;	Structure of the ExbB/ExbD hexameric complex
5ZFU	;	6.7	;	Structure of the ExbB/ExbD hexameric complex (ExbB6ExbD3TM)
5ZFV	;	7.1	;	Structure of the ExbB/ExbD pentameric complex (ExbB5ExbD1TM)
7LNP	;	2.7	;	Structure of the exo-alpha-L-galactosidase BpGH29 (D264N mutant) from Bacteroides plebeius in complex with paranitrophenyl-alpha-L-galactopyranoside
7LJJ	;	1.9	;	Structure of the Exo-alpha-L-galactosidase BpGH29 from Bacteroides plebeius
7LK7	;	2.19	;	Structure of the Exo-alpha-L-galactosidase BpGH29 from Bacteroides plebeius in complex with L-galactose
7LHA	;	1.95	;	Structure of the Exo-L-galactose-6-sulfatase BuS1_11 from Bacteroides uniformis
2O1J	;	2.7	;	Structure of the extended diarrhea-inducing domain of rotavirus enterotoxigenic protein NSP4
2O1K	;	1.67	;	Structure of the extended diarrhea-inducing domain of rotavirus enterotoxigenic protein NSP4
7AOA	;	19.4	;	Structure of the extended MTA1/HDAC1/MBD2/RBBP4 NURD deacetylase complex
5URW	;	24.0	;	Structure of the extended type VI secretion system sheath in Myxococcus xanthus
2Y3M	;	2.3	;	Structure of the extra-membranous domain of the secretin HofQ from Actinobacillus actinomycetemcomitans
1J71	;	1.8	;	Structure of the extracellular aspartic proteinase from Candida tropicalis yeast.
4K55	;	1.91	;	Structure of the extracellular domain of butyrophilin BTN3A1 in complex with (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP)
4JKW	;	2.01	;	Structure of the extracellular domain of butyrophilin BTN3A1 in complex with Isopentenyl pyrophosphate (IPP)
4LIQ	;	2.6	;	Structure of the extracellular domain of human CSF-1 receptor in complex with the Fab fragment of RG7155
1NQL	;	2.8	;	Structure of the extracellular domain of human epidermal growth factor (EGF) receptor in an inactive (low pH) complex with EGF.
2XVT	;	2.05	;	Structure of the extracellular domain of human RAMP2
5DMJ	;	2.79	;	Structure of the extracellular domain of the CD40 in complex with 3H56-5 DAB
5IHL	;	3.3	;	STRUCTURE OF THE EXTRACELLULAR DOMAIN OF THE CD40 IN COMPLEX WITH 3H56-5 DAB
5DMI	;	3.69	;	Structure of the extracellular domain of the CD40 in complex with CHI220 FAB
1YY9	;	2.605	;	Structure of the extracellular domain of the epidermal growth factor receptor in complex with the Fab fragment of cetuximab/Erbitux/IMC-C225
4BFG	;	2.08	;	Structure of the extracellular portion of mouse CD200R
4BFE	;	2.5	;	Structure of the extracellular portion of mouse CD200RLa
2IFG	;	3.4	;	Structure of the extracellular segment of human TRKA in complex with nerve growth factor
7ME5	;	2.0	;	Structure of the extracellular WNT-binding module in Drl-2
7ME4	;	1.75	;	Structure of the extracellular WNT-binding module in Drosophila Ror2/Nrk
2GIL	;	1.82	;	Structure of the extremely slow GTPase Rab6A in the GTP bound form at 1.8 resolution
8RTY	;	6.25	;	Structure of the F-actin barbed end bound by Cdc12 and profilin (ring complex) at a resolution of 6.3 Angstrom
8RU2	;	3.49	;	Structure of the F-actin barbed end bound by formin mDia1
3J8A	;	3.7	;	Structure of the F-actin-tropomyosin complex
5JLF	;	3.6	;	Structure of the F-actin-tropomyosin complex (Reprocessed)
2X3V	;	2.45	;	Structure of The F-BAR Domain of Mouse Syndapin I
3D34	;	1.8	;	Structure of the F-spondin domain of mindin
5FL7	;	3.5	;	Structure of the F1c10 complex from Yarrowia lipolytica ATP synthase
4S3G	;	2.5	;	Structure of the F249X mutant of Phosphatidylinositol-specific phospholipase C from Staphylococcus aureus
4CSP	;	1.7	;	Structure of the F306C mutant of nitrite reductase from Achromobacter xylosoxidans
6VC7	;	2.05	;	Structure of the F349A mutant of the periplasmic domain of YejM from Salmonella typhimurium
3F6L	;	2.801	;	Structure of the F4 fimbrial chaperone FaeE
3TTV	;	1.45	;	Structure of the F413E variant of E. coli KatE
3TTW	;	1.62	;	Structure of the F413E variant of E. coli KatE
3TTX	;	1.74	;	Structure of the F413K variant of E. coli KatE
1DN0	;	2.28	;	STRUCTURE OF THE FAB FRAGMENT FROM A HUMAN IGM COLD AGGLUTININ
3UJT	;	2.1	;	Structure of the Fab fragment of Ab-52, an antibody that binds the O-antigen of Francisella tularensis
3EO1	;	3.1	;	Structure of the Fab Fragment of GC-1008 in Complex with Transforming Growth Factor-Beta 3
4KPH	;	2.59	;	Structure of the Fab fragment of N62, a protective monoclonal antibody to the nonreducing end of Francisella tularensis O-antigen
4PB0	;	2.5	;	Structure of the Fab fragment of the anti-Francisella tularensis GroEL antibody Ab53
4PB9	;	2.6	;	Structure of the Fab fragment of the anti-Francisella tularensis GroEL antibody Ab64
4KHO	;	2.0	;	Structure of the FACT complex Subunit Spt16M
4B1T	;	1.78	;	Structure of the factor Xa-like trypsin variant triple-Ala (TA) in complex with eglin C
4B2A	;	1.89	;	Structure of the factor Xa-like trypsin variant triple-Ala (TGA) in complex with eglin C
4B2B	;	1.36	;	Structure of the factor Xa-like trypsin variant triple-Ala (TGPA) in complex with eglin C
4B2C	;	1.43	;	Structure of the factor Xa-like trypsin variant triple-Ala (TPA) in complex with eglin C
4YBN	;	1.9	;	Structure of the FAD and Heme binding protein msmeg_4975 from Mycobacterium smegmatis
6ECI	;	2.69	;	Structure of the FAD binding protein MSMEG_5243 from Mycobacterium smegmatis
2XQX	;	2.01	;	Structure of the family 32 carbohydrate-binding module from Streptococcus pneumoniae EndoD
5MDN	;	2.8	;	Structure of the family B DNA polymerase from the hyperthermophilic archaeon Pyrobaculum calidifontis
6F8Z	;	2.5	;	Structure of the family GH92 alpha-mannosidase BT3130 from Bacteroides thetaiotaomicron
6F90	;	2.4	;	Structure of the family GH92 alpha-mannosidase BT3130 from Bacteroides thetaiotaomicron in complex with Mannoimidazole (ManI)
6F91	;	1.8	;	Structure of the family GH92 alpha-mannosidase BT3965 from Bacteroides thetaiotaomicron
6F92	;	1.9	;	Structure of the family GH92 alpha-mannosidase BT3965 from Bacteroides thetaiotaomicron in complex with Mannoimidazole (ManI)
2WVY	;	2.26	;	STRUCTURE OF THE FAMILY GH92 INVERTING MANNOSIDASE BT2199 FROM BACTEROIDES THETAIOTAOMICRON VPI-5482
2WW2	;	1.9	;	Structure of the Family GH92 Inverting Mannosidase BT2199 from Bacteroides thetaiotaomicron VPI-5482
2WVX	;	1.9	;	Structure of the Family GH92 Inverting Mannosidase BT3990 from Bacteroides thetaiotaomicron VPI-5482
2WVZ	;	2.4	;	Structure of the Family GH92 Inverting Mannosidase BT3990 from Bacteroides thetaiotaomicron VPI-5482
2WW0	;	2.8	;	Structure of the Family GH92 Inverting Mannosidase BT3990 from Bacteroides thetaiotaomicron VPI-5482
2WZS	;	2.25	;	Structure of the Family GH92 Inverting Mannosidase BT3990 from Bacteroides thetaiotaomicron VPI-5482 in complex with Mannoimidazole
2WW1	;	2.25	;	Structure of the Family GH92 Inverting Mannosidase BT3990 from Bacteroides thetaiotaomicron VPI-5482 in complex with Thiomannobioside
2WW3	;	2.1	;	Structure of the Family GH92 Inverting Mannosidase BT3990 from Bacteroides thetaiotaomicron VPI-5482 in complex with thiomannobioside
2ENX	;	2.8	;	Structure of the family II inorganic pyrophosphatase from Streptococcus agalactiae at 2.8 resolution
7PJJ	;	3.086	;	Structure of the Family-3 Glycosyl Hydrolase BcpE2 from Streptomyces scabies
2EXJ	;	2.2	;	Structure of the family43 beta-Xylosidase D128G mutant from geobacillus stearothermophilus in complex with xylobiose
2EXI	;	2.15	;	Structure of the family43 beta-Xylosidase D15G mutant from geobacillus stearothermophilus
2EXK	;	2.2	;	Structure of the family43 beta-Xylosidase E187G from geobacillus stearothermophilus in complex with xylobiose
2EXH	;	1.88	;	Structure of the family43 beta-Xylosidase from geobacillus stearothermophilus
3S4W	;	3.408	;	Structure of the FANCI-FANCD2 complex
6SRI	;	4.2	;	Structure of the Fanconi anaemia core complex
6SRS	;	4.6	;	Structure of the Fanconi anaemia core subcomplex
6VAA	;	3.4	;	Structure of the Fanconi Anemia ID complex bound to ICL DNA
4CVN	;	2.121	;	Structure of the Fap7-Rps14 complex
4CW7	;	2.46	;	Structure of the Fap7-Rps14 complex in complex with ATP
7COY	;	2.5	;	Structure of the far-red light utilizing photosystem I of Acaryochloris marina
8UHE	;	2.78	;	Structure of the far-red light-absorbing allophycocyanin core expressed during FaRLiP
8UHI	;	2.35	;	Structure of the far-red light-absorbing allophycocyanin core expressed during FaRLiP
3OQ9	;	6.8	;	Structure of the FAS/FADD death domain assembly
1YWJ	;		;	Structure of the FBP11WW1 domain
1YWI	;		;	Structure of the FBP11WW1 domain complexed to the peptide APPTPPPLPP
7T1Y	;	2.55	;	Structure of the Fbw7-Skp1-MycCdegron complex
7T1Z	;	2.77	;	Structure of the Fbw7-Skp1-MycNdegron complex
4GPF	;	1.9	;	Structure of the Fe3+-biliverdin-HmuO, heme oxygenase from Corynebacterium diphtheriae (data set III)
4P3X	;	1.65	;	Structure of the Fe4S4 quinolinate synthase NadA from Thermotoga maritima
1FCA	;	1.8	;	STRUCTURE OF THE FERREDOXIN FROM CLOSTRIDIUM ACIDURICI: MODEL AT 1.8 ANGSTROMS RESOLUTION
6I96	;	1.85	;	Structure of the ferrioxamine B transporter FoxA from Pseudomonas aeruginosa in complex with ferrioxamine B
6I97	;	3.35	;	Structure of the ferrioxamine B transporter FoxA from Pseudomonas aeruginosa in complex with ferrioxamine B and a C-terminal TonB fragment
6I98	;	2.8	;	Structure of the ferrioxamine B transporter FoxA from Pseudomonas aeruginosa, apo state
1YWC	;	1.0	;	Structure of the ferrous CO complex of NP4 from Rhodnius Prolixus at pH 7.0
5FRT	;	2.34	;	Structure of the FeSII (shethna) protein of Azotobacter vinelandii
5T2S	;	2.4	;	Structure of the FHA1 domain of Rad53 bound simultaneously to the BRCT domain of Dbf4 and a phosphopeptide.
5T2F	;	2.66	;	Structure of the FHA1 domain of Rad53 bound to the BRCT domain of Dbf4
1AY2	;	2.6	;	STRUCTURE OF THE FIBER-FORMING PROTEIN PILIN AT 2.6 ANGSTROMS RESOLUTION
1DUG	;	1.8	;	STRUCTURE OF THE FIBRINOGEN G CHAIN INTEGRIN BINDING AND FACTOR XIIIA CROSSLINKING SITES OBTAINED THROUGH CARRIER PROTEIN DRIVEN CRYSTALLIZATION
2JYD	;		;	Structure of the fifth zinc finger of Myelin Transcription Factor 1
2JX1	;		;	Structure of the fifth zinc finger of Myelin Transcription Factor 1 in complex with RARE DNA
3UXF	;	1.603	;	Structure of the fimbrial protein FimP from Actonomyces oris
4AVJ	;	2.105	;	Structure of the FimH lectin domain in the trigonal space group, in complex with a methanol triazol ethyl phenyl alpha-D-mannoside at 2.1 A resolution
4AV0	;	2.099	;	Structure of the FimH lectin domain in the trigonal space group, in complex with a methoxy phenyl propynyl alpha-D-mannoside at 2.1 A resolution
4AVI	;	2.4	;	Structure of the FimH lectin domain in the trigonal space group, in complex with a methyl ester octyl alpha-D-mannoside at 2.4 A resolution
4AVH	;	2.105	;	Structure of the FimH lectin domain in the trigonal space group, in complex with a thioalkyl alpha-D-mannoside at 2.1 A resolution
4AUY	;	2.102	;	Structure of the FimH lectin domain in the trigonal space group, in complex with an hydroxyl propynyl phenyl alpha-D-mannoside at 2.1 A resolution
5LUU	;	1.61	;	Structure of the first bromodomain of BRD4 with a pyrazolo[4,3-c]pyridin fragment
1RSY	;	1.9	;	STRUCTURE OF THE FIRST C2-DOMAIN OF SYNAPTOTAGMIN I: A NOVEL CA2+(SLASH)PHOSPHOLIPID BINDING FOLD
3QR5	;	2.3	;	Structure of the first domain of a cardiac Ryanodine Receptor mutant with exon 3 deleted
2Y79	;	1.8	;	STRUCTURE OF THE FIRST GAF DOMAIN E87A MUTANT OF MYCOBACTERIUM TUBERCULOSIS DOSS
2Y8H	;	1.9	;	STRUCTURE OF THE FIRST GAF DOMAIN E87G MUTANT OF MYCOBACTERIUM TUBERCULOSIS DOSS
2W3D	;	2.0	;	Structure of the first GAF domain of Mycobacterium tuberculosis DosS
7UYG	;	1.5	;	Structure of the first OTU domain from Legionella pneumophila effector protein LotA
7UYH	;	2.8	;	Structure of the first OTU domain from Legionella pneumophila effector protein LotA bound to K6-linked diUb
1O0K	;	1.17	;	Structure of the First Parallel DNA Quadruplex-drug Complex
2L5U	;		;	Structure of the first PHD finger (PHD1) from CHD4 (Mi2b)
4L1M	;	2.6	;	Structure of the first RCC1-like domain of HERC2
4TVE	;	1.8	;	Structure Of the First Two Thioredoxin Domains of Naumovozyma dairenensis Eps1p
4TW5	;	2.37	;	Structure Of the First Two Thioredoxin Domains of Saccharomyces cerevisiae Eps1p
2LB0	;		;	Structure of the first WW domain of human Smurf1 in complex with a di-phosphorylated human Smad1 derived peptide
2LAZ	;		;	Structure of the first WW domain of human Smurf1 in complex with a mono-phosphorylated human Smad1 derived peptide
2LAY	;		;	Structure of the first WW domain of human YAP in complex with a phosphorylated human Smad1 derived peptide
5TRU	;	3.0	;	Structure of the first-in-class checkpoint inhibitor Ipilimumab bound to human CTLA-4
6TAR	;	2.8	;	Structure of the five-fold capsomer of the dArc1 capsid
6TAT	;	3.7	;	Structure of the five-fold capsomer of the dArc2 capsid
8RB4	;	3.2	;	Structure of the five-fold capsomer of the PNMA2 capsid
8BAJ	;	1.2	;	Structure of the FK1 domain of the FKBP51 G64S variant in complex with (1S,5S,6R)-10-((3,5-dichlorophenyl)sulfonyl)-5-(hydroxymethyl)-3-(pyridin-2-ylmethyl)-3,10-diazabicyclo[4.3.1]decan-2-one
8BA6	;	1.1	;	Structure of the FK1 domain of the FKBP51 G64S variant in complex with (2R,5S,12R)-12-cyclohexyl-2-[2-(3,4-dimethoxyphenyl)ethyl]-15,15,16-trimethyl-3,19-dioxa-10,13,16-triazatricyclo[18.3.1.0^5,^10]tetracosa-1(24),20,22-triene-4,11,14,17-tetrone
7R0L	;	1.1	;	Structure of the FK1 domain of the FKBP51 G64S variant in complex with SAFit1
7A6W	;	1.85	;	Structure of the FKBP51FK1 domain in complex with the macrocyclic SAFit analogue 33-(Z)
7B9Z	;	1.44	;	Structure of the FKBP51FK1 domain in complex with the macrocyclic SAFit analogue 35-(E)
7AWX	;	2.2	;	Structure of the FKBP51FK1 domain in complex with the macrocyclic SAFit analogue 55
7A6X	;	1.67	;	Structure of the FKBP51FK1 domain in complex with the macrocyclic SAFit analogue 56
7BA0	;	1.14	;	Structure of the FKBP51FK1 domain in complex with the macrocyclic SAFit analogue 63
7B9Y	;	1.35	;	Structure of the FKBP51FK1 domain in complex with the macrocyclic SAFit analogue 64a
6YSL	;	3.5	;	Structure of the flagellar MotAB stator complex from Bacillus subtilis
6YSF	;	3.4	;	Structure of the flagellar MotAB stator complex from Clostridium sporogenes
7VWP	;	2.3	;	Structure of the flavin-dependent monooxygenase FlsO1 from the biosynthesis of fluostatinsin
6RK0	;	0.99	;	Structure of the Flavocytochrome Anf3 from Azotobacter vinelandii
4IV9	;	1.951	;	Structure of the Flavoprotein Tryptophan-2-Monooxygenase
5B0O	;	3.0	;	Structure of the FliH-FliI complex
6S3R	;	3.5	;	Structure of the FliPQR complex from the flagellar type 3 secretion system of Pseudomonas savastanoi.
6S3S	;	4.1	;	Structure of the FliPQR complex from the flagellar type 3 secretion system of Vibrio mimicus.
4JDX	;	2.5	;	Structure of the Fluorescence Recovery Protein from Synechocystis sp PCC 6803
4JDQ	;	3.52	;	Structure of the Fluorescence Recovery Protein from Synechocystis sp PCC 6803, R60K mutant
8AG8	;	1.8	;	Structure of the Fluorescence Recovery-like protein FRPL from Pseudomonas borbori
6S67	;	2.47	;	Structure of the Fluorescent Protein AausFP1 from Aequorea cf. australis at pH 7.0
6S68	;	2.06	;	Structure of the Fluorescent Protein AausFP2 from Aequorea cf. australis at pH 7.6
2C9I	;	1.82	;	Structure of the fluorescent protein asFP499 from Anemonia sulcata
2C9J	;	1.35	;	Structure of the fluorescent protein cmFP512 at 1.35A from Cerianthus membranaceus
7Z7P	;	1.95	;	Structure of the fluorescent protein NeonCyan0.95 at pH 5.6
7Z7O	;	1.51	;	Structure of the fluorescent protein NeonCyan0.95 at pH 7.5
1QOL	;	3.0	;	STRUCTURE OF THE FMDV LEADER PROTEASE
3VDI	;	1.99	;	Structure of the FMO protein from Pelodictyon phaeum
8OHI	;	2.8	;	Structure of the Fmoc-Tau-PAM4 Type 2 amyloid fibril
8OHP	;	2.7	;	Structure of the Fmoc-Tau-PAM4 Type 3 amyloid fibril
8OI0	;	2.9	;	Structure of the Fmoc-Tau-PAM4 Type 4 amyloid fibril
7O0H	;	3.09	;	Structure of the foamy viral protease-reverse transcriptase dRH in complex with ds DNA.
7O24	;	4.8	;	Structure of the foamy viral protease-reverse transcriptase in complex with dsDNA.
7O0G	;	3.1	;	Structure of the foamy viral protease-reverse transcriptase in complex with RNA/DNA hybrid.
4QBB	;	1.6	;	Structure of the foot-and-mouth disease virus leader proteinase in complex with inhibitor (N~2~-[(3S)-4-({(2R)-1-[(4-CARBAMIMIDAMIDOBUTYL)AMINO]-4-METHYL-1-OXOPENTAN-2-YL}AMINO)-3-HYDROXY-4-OXOBUTANOYL]-L-ARGINYL-L-PROLINAMIDE)
6XAD	;	1.893	;	Structure of the formate-bound form of ArrX from Chrysiogenes arsenatis
8RTT	;	3.56	;	Structure of the formin Cdc12 bound to the barbed end of phalloidin-stabilized F-actin.
8RV2	;	3.41	;	Structure of the formin INF2 bound to the barbed end of F-actin.
8J8P	;	2.7	;	Structure of the four-component Paf1 complex from Saccharomyces eubayanus
8J8Q	;	3.11	;	Structure of the four-component Paf1 complex from Saccharomyces eubayanus
3T1W	;	2.4	;	Structure of the four-domain fragment Fn7B89 of oncofetal fibronectin
7RMA	;	2.0	;	Structure of the fourth UIM (Ubiquitin Interacting Motif) of ANKRD13D in complex with a high affinity UbV (Ubiquitin Variant)
3G73	;	2.21	;	Structure of the FOXM1 DNA binding
5ODW	;	2.8	;	Structure of the FpvAI-pyocin S2 complex
4IDB	;	1.55	;	Structure of the Fragaria x ananassa enone oxidoreductase in complex with NADP+
4IDE	;	1.6	;	Structure of the Fragaria x ananassa enone oxidoreductase in complex with NADP+ and EDHMF
4IDD	;	1.5	;	Structure of the Fragaria x ananassa enone oxidoreductase in complex with NADPH and EHMF
4IDC	;	1.4	;	Structure of the Fragaria x ananassa enone oxidoreductase in complex with NADPH and HDMF
4IDF	;	1.55	;	Structure of the Fragaria x ananassa enone oxidoreductase in complex with NADPH and HMF
4IDA	;	1.6	;	Structure of the Fragaria x ananassa enone oxidoreductase in its apo form
6ONT	;	1.803	;	Structure of the Francisella response regulator 1452 receiver domain
5UIC	;	2.487	;	Structure of the Francisella response regulator receiver domain, QseB
5WBH	;	1.75	;	Structure of the FRB domain of mTOR bound to a substrate recruitment peptide of S6K1
4P9T	;	2.5	;	Structure of the free form of the N-terminal VH1 domain of monomeric alpha-catenin
7KEK	;	8.0	;	Structure of the free outer-arm dynein in pre-parallel state
3UU9	;	2.2	;	Structure of the free TvNiRb form of Thioalkalivibrio nitratireducens cytochrome c nitrite reductase
5TZ0	;	3.025	;	Structure of the Fremyella diplosiphon Fluorescence Recovery Protein
6PQ1	;	1.61	;	Structure of the Fremyella diplosiphon OCP1
8JSC	;	2.16	;	Structure of the FSP1 protein from Human
7MYZ	;	3.4	;	Structure of the full length 5-TM receptor CD47 bound to Fab B6H12
2HRO	;	2.5	;	Structure of the full-lenght Enzyme I of the PTS system from Staphylococcus carnosus
6OQ5	;	3.87	;	Structure of the full-length Clostridium difficile toxin B in complex with 3 VHHs
7NH9	;	3.03	;	structure of the full-length CmaX protein
1ZVU	;	3.0	;	Structure of the full-length E. coli ParC subunit
5XEZ	;	3.0	;	Structure of the Full-length glucagon class B G protein-coupled receptor
5XF1	;	3.19	;	Structure of the Full-length glucagon class B G protein-coupled receptor
4W8J	;	2.78	;	Structure of the full-length insecticidal protein Cry1Ac reveals intriguing details of toxin packaging into in vivo formed crystals
8EAQ	;	3.26	;	Structure of the full-length IP3R1 channel determined at high Ca2+
8EAR	;	3.5	;	Structure of the full-length IP3R1 channel determined in the presence of Calcium/IP3/ATP
3RPK	;	2.8	;	Structure of the Full-Length Major Pilin RrgB from Streptococcus pneumoniae
4HSS	;	2.5	;	Structure of the Full-Length Major Pilin SpaD from Corynebacterium diphtheriae
4ZMS	;	1.9	;	Structure of the full-length response regulator spr1814 in complex with a phosphate analogue and B3C
5HI9	;	4.4	;	Structure of the full-length TRPV2 channel by cryo-electron microscopy
3WEE	;	3.1	;	Structure of the full-length yeast Arp7-Arp9 Heterodimer
2H0N	;	1.53	;	Structure of the fully modified left-handed cyclohexene nucleic acid sequence GTGTACAC
1ZZH	;	2.7	;	Structure of the fully oxidized di-heme cytochrome c peroxidase from R. capsulatus
2C9K	;	2.8	;	Structure of the functional form of the mosquito-larvicidal Cry4Aa toxin from Bacillus thuringiensis at 2.8 A resolution
7NY1	;	3.26	;	Structure of the fungal plasma membrane proton pump Pma1 in its auto-inhibited state - hexameric assembly
7NXF	;	3.1	;	Structure of the fungal plasma membrane proton pump Pma1 in its auto-inhibited state - monomer unit
2WAS	;	1.9	;	Structure of the fungal type I FAS PPT domain
2WAT	;	2.2	;	Structure of the fungal type I FAS PPT domain in complex with CoA
4E4B	;	2.8	;	Structure of the fusidic acid resistance protein FusB
2YB5	;	2.1	;	Structure of the fusidic acid resistance protein FusC
2J8K	;	1.5	;	Structure of the fusion of NP275 and NP276, pentapeptide repeat proteins from Nostoc punctiforme
7F19	;	1.773	;	Structure of the G304E mutant of CueO
2FJG	;	2.8	;	Structure of the G6 Fab, a phage derived Fab fragment, in complex with VEGF
2FJF	;	2.65	;	Structure of the G6 Fab, a phage derived VEGF binding Fab
1CZG	;	2.5	;	STRUCTURE OF THE G62T MUTANT OF SHIGA-LIKE TOXIN I B SUBUNIT
6PA0	;	2.05	;	Structure of the G77A mutant in Sodium Chloride
1F5M	;	1.9	;	STRUCTURE OF THE GAF DOMAIN
3TRC	;	1.65	;	Structure of the GAF domain from a phosphoenolpyruvate-protein phosphotransferase (ptsP) from Coxiella burnetii
8VT7	;	2.66	;	Structure of the gamma tubulin ring complex nucleated microtubule protofilament.
6OAT	;	3.17	;	Structure of the Ganjam virus OTU bound to sheep ISG15
2V3M	;	2.74	;	Structure of the Gar1 domain of NAf1
1ODH	;	2.85	;	Structure of the GCM domain bound to DNA
4S23	;	1.65	;	Structure of the GcpE-HMBPP complex from Thermus thermophilius
4G9P	;	1.55	;	Structure of the GcpE-MEcPP (IspG) complex from Thermus thermophilus
6CTZ	;	1.34	;	Structure of the GDP and kanamycin complex of APH(2"")-IIia
3TDV	;	2.2	;	Structure of the GDP complex of wild-type aminoglycoside 2'-phosphotransferase-IIIa
1EFM	;	2.7	;	STRUCTURE OF THE GDP DOMAIN OF EF-TU AND LOCATION OF THE AMINO ACIDS HOMOLOGOUS TO RAS ONCOGENE PROTEINS
6EG8	;	2.8	;	Structure of the GDP-bound Gs heterotrimer
8C7D	;	1.86	;	Structure of the GEF Kalirin DH2 Domain
5GXI	;	1.85	;	Structure of the Gemin5 WD40 domain in complex with AAUUUUUGAG
4KFS	;	1.946	;	Structure of the genome packaging NTPase B204 from Sulfolobus turreted icosahedral virus 2 in complex with AMP
4KFU	;	1.892	;	Structure of the genome packaging NTPase B204 from Sulfolobus turreted icosahedral virus 2 in complex with AMPPCP
4KFT	;	2.241	;	Structure of the genome packaging NTPase B204 from Sulfolobus turreted icosahedral virus 2 in complex with ATP-gammaS
4KFR	;	1.956	;	Structure of the genome packaging NTPase B204 from Sulfolobus turreted icosahedral virus 2 in complex with sulfate
3GSZ	;	1.9	;	Structure of the genotype 2B HCV polymerase
3HVO	;	2.0	;	Structure of the genotype 2B HCV polymerase bound to a NNI
3HAM	;	2.5	;	Structure of the gentamicin-APH(2"")-IIa complex
2NBG	;		;	Structure of the Geobacillus stearothermophilus IF2 G3-subdomain
2Q20	;	1.3	;	Structure of the germline Vk1 O18/O8 light chain variable domain homodimer
3OGO	;	2.8	;	Structure of the GFP:GFP-nanobody complex at 2.8 A resolution in spacegroup P21212
8XLD	;	2.1	;	Structure of the GFP:GFP-nanobody complex from Biortus.
1OM9	;	2.5	;	Structure of the GGA1-appendage in complex with the p56 binding peptide
4AYO	;	0.85	;	Structure of The GH47 processing alpha-1,2-mannosidase from Caulobacter strain K31
4AYQ	;	1.1	;	Structure of The GH47 processing alpha-1,2-mannosidase from Caulobacter strain K31 in complex with mannoimidazole
4AYR	;	1.1	;	Structure of The GH47 processing alpha-1,2-mannosidase from Caulobacter strain K31 in complex with noeuromycin
4AYP	;	0.85	;	Structure of The GH47 processing alpha-1,2-mannosidase from Caulobacter strain K31 in complex with thiomannobioside
4V1S	;	1.5	;	Structure of the GH76 alpha-mannanase BT2949 from Bacteroides thetaiotaomicron
6SHD	;	2.0	;	Structure of the GH76A alpha-1,6-mannanase from Salegentibacter sp. HEL1_6
2XSG	;	2.0	;	Structure of the gh92 family glycosyl hydrolase ccman5
4AQ0	;	2.09	;	Structure of the Gh92 Family Glycosyl Hydrolase Ccman5 in complex with deoxymannojirimycin
6FWP	;	1.08	;	Structure of the GH99 endo-alpha-mannanase from Bacteroides xylanisolvens in complex with alpha-1,3-mannobiose and alpha-1,2-mannobiose
6HMG	;	1.27	;	Structure of the GH99 endo-alpha-mannanase from Bacteroides xylanisolvens in complex with alpha-Glc-1,3-(1,2-anhydro-carba-glucosamine)
6HMH	;	1.03	;	Structure of the GH99 endo-alpha-mannanase from Bacteroides xylanisolvens in complex with alpha-Glc-1,3-(1,2-anhydro-carba-glucosamine) and alpha-1,2-mannobiose
6FWI	;	1.25	;	Structure of the GH99 endo-alpha-mannanase from Bacteroides xylanisolvens in complex with alpha-Glc-1,3-(1,2-anhydro-carba-mannosamine)
6FWJ	;	1.04	;	Structure of the GH99 endo-alpha-mannanase from Bacteroides xylanisolvens in complex with alpha-Glc-1,3-(1,2-anhydro-carba-mannosamine) and alpha-1,2-mannobiose
6FWM	;	1.28	;	Structure of the GH99 endo-alpha-mannanase from Bacteroides xylanisolvens in complex with alpha-Glc-1,3-1,2-anhydro-mannose hydrolyzed by enzyme
6ZJ6	;	1.09	;	Structure of the GH99 endo-alpha-mannanase from Bacteroides xylanisolvens in complex with cyclohexylmethyl-Glc-1,3-isofagomine
5M17	;	1.03	;	Structure of the GH99 endo-alpha-mannanase from Bacteroides xylanisolvens in complex with mannose-alpha-1,3-1,2-dideoxymannose
5M3W	;	1.04	;	Structure of the GH99 endo-alpha-mannanase from Bacteroides xylanisolvens in complex with mannose-alpha-1,3-1,2-dideoxymannose and alpha-1,2-mannobiose
6FAM	;	1.13	;	Structure of the GH99 endo-alpha-mannanase from Bacteroides xylanisolvens in complex with mannose-alpha-1,3-2-aminodeoxymannojirimycin
5M5D	;	1.07	;	Structure of the GH99 endo-alpha-mannanase from Bacteroides xylanisolvens in complex with mannose-alpha-1,3-D-glucal
5MC8	;	1.18	;	Structure of the GH99 endo-alpha-mannanase from Bacteroides xylanisolvens in complex with mannose-alpha-1,3-D-glucal and alpha-1,2-mannobiose
4V27	;	1.9	;	Structure of the GH99 endo-alpha-mannanase from Bacteroides xylanisolvens in complex with mannose-alpha-1,3-isofagomine
6FAR	;	1.3	;	Structure of the GH99 endo-alpha-mannanase from Bacteroides xylanisolvens in complex with mannose-alpha-1,3-mannoimidazole
5LYR	;	1.14	;	Structure of the GH99 endo-alpha-mannanase from Bacteroides xylanisolvens in complex with mannose-alpha-1,3-noeuromycin
5M03	;	1.05	;	Structure of the GH99 endo-alpha-mannanase from Bacteroides xylanisolvens in complex with mannose-alpha-1,3-noeuromycin and 1,2-alpha-mannobiose
4AD0	;	2.09	;	Structure of the GH99 endo-alpha-mannosidase from Bacteriodes thetaiotaomicron in complex with BIS-TRIS-Propane
4ACZ	;	1.99	;	Structure of the GH99 endo-alpha-mannosidase from Bacteroides thetaiotaomicron
4AD1	;	1.9	;	Structure of the GH99 endo-alpha-mannosidase from Bacteroides xylanisolvens
4AD3	;	2.0	;	Structure of the GH99 endo-alpha-mannosidase from Bacteroides xylanisolvens in complex with Glucose-1,3-deoxymannojirimycin
4AD5	;	1.9	;	Structure of the GH99 endo-alpha-mannosidase from Bacteroides xylanisolvens in complex with glucose-1,3-deoxymannojirimycin and alpha-1,2-mannobiose
4AD2	;	2.1	;	Structure of the GH99 endo-alpha-mannosidase from Bacteroides xylanisolvens in complex with glucose-1,3-isofagomine
4AD4	;	1.9	;	Structure of the GH99 endo-alpha-mannosidase from Bacteroides xylanisolvens in complex with glucose-1,3-isofagomine and alpha-1,2- mannobiose
4UTF	;	1.3	;	Structure of the GH99 endo-alpha-mannosidase from Bacteroides xylanisolvens in complex with mannose-alpha-1,3-isofagomine and alpha- 1,2-mannobiose
8ATM	;	3.3	;	Structure of the giant inhibitor of apoptosis, BIRC6 (composite map)
8ATO	;	3.0	;	Structure of the giant inhibitor of apoptosis, BIRC6 bound to the regulator SMAC
8C3T	;	2.11	;	Structure of the GIsul2 transposon excisionase
4A0X	;	2.4	;	Structure of the global transcription regulator FapR from Staphylococcus aureus
4A0Y	;	2.6	;	Structure of the global transcription regulator FapR from Staphylococcus aureus
4A12	;	3.15	;	Structure of the global transcription regulator FapR from Staphylococcus aureus in complex with DNA operator
4A0Z	;	1.9	;	Structure of the global transcription regulator FapR from Staphylococcus aureus in complex with malonyl-CoA
6W5Q	;	2.2	;	Structure of the globular C-terminal domain of P. aeruginosa LpoP
1ZWT	;		;	Structure of the globular head domain of the bundlin, BfpA, of the bundle-forming pilus of Enteropathogenic E.coli
7TVQ	;		;	Structure of the globular isoform of the novel conotoxin PnID derived from Conus pennaceus
6ZYU	;	1.9	;	Structure of the GluA2 ligand-binding domain (L483Y-N754S) in complex with glutamate and BPAM549
3O2J	;	1.95	;	Structure of the GluA2 NTD-dimer interface mutant, N54A
3N6V	;	3.2	;	Structure of the GluA2 NTD-dimer interface mutant, T78A
5YQZ	;	3.0	;	Structure of the glucagon receptor in complex with a glucagon analogue
7LZH	;	3.57	;	Structure of the glutamate receptor-like channel AtGLR3.4
7LZI	;	4.39	;	Structure of the glutamate receptor-like channel AtGLR3.4
6VEA	;	1.58	;	Structure of the Glutamate-Like Receptor GLR3.2 ligand-binding domain in complex with Glycine
6VE8	;	1.75	;	Structure of the Glutamate-Like Receptor GLR3.2 ligand-binding domain in complex with Methionine
2NV0	;	1.73	;	Structure of the glutaminase subunit Pdx2 (YaaE) of PLP synthase from Bacillus subtilis
6QN3	;	2.3	;	Structure of the Glutamine II Riboswitch
6LBP	;	3.065	;	Structure of the Glutamine Phosphoribosylpyrophosphate Amidotransferase from Arabidopsis thaliana
3MPJ	;	2.1	;	Structure of the glutaryl-coenzyme A dehydrogenase
3MPI	;	2.05	;	Structure of the glutaryl-coenzyme A dehydrogenase glutaryl-CoA complex
4MYH	;	3.38	;	Structure of the Glutathione bound mitochondrial ABC transporter, Atm1
5F0G	;	1.6	;	Structure of the glutathione transferase delta 2 from Drosophila melanogaster
2NTO	;	2.095	;	Structure of the Glutathione Transferase from Ochrobactrum anthropi in complex with glutathione
3IXM	;	1.9	;	Structure of the Gly74Cys mutant of arylmalonate decarboxylase in the sulfate ion associated form
3N2T	;	2.0	;	Structure of the glycerol dehydrogenase AKR11B4 from Gluconobacter oxydans
5DN4	;	1.8	;	Structure of the glycoside hydrolase domain from Salmonella typhimurium FlgJ
5TCB	;	1.535	;	Structure of the glycoside hydrolase domain of PelA from Pseudomonas aeruginosa
5TSY	;	1.9	;	Structure of the glycoside hydrolase domain of PelA variant E218A from Pseudomonas aeruginosa
4EA5	;	2.14	;	Structure of the glycoslyase domain of MBD4 bound to a 5hmU containing DNA
4E9E	;	1.9	;	Structure of the glycosylase domain of MBD4
4EA4	;	2.0	;	Structure of the glycosylase domain of MBD4 bound to 5hmU-containing DNA
4E9F	;	1.79	;	Structure of the glycosylase domain of MBD4 bound to AP site containing DNA
4E9G	;	2.35	;	structure of the glycosylase domain of MBD4 bound to thymine containing DNA
1CDB	;		;	STRUCTURE OF THE GLYCOSYLATED ADHESION DOMAIN OF HUMAN T LYMPHOCYTE GLYCOPROTEIN CD2
2YJN	;	3.091	;	Structure of the glycosyltransferase EryCIII from the erythromycin biosynthetic pathway, in complex with its activating partner, EryCII
3TQI	;	2.84	;	Structure of the GMP synthase (guaA) from Coxiella burnetii
2R3C	;	1.73	;	Structure of the gp41 N-peptide in complex with the HIV entry inhibitor PIE1
2R5B	;	2.0	;	Structure of the gp41 N-trimer in complex with the HIV entry inhibitor PIE7
2R5D	;	1.66	;	Structure of the gp41 N-trimer in complex with the HIV entry inhibitor PIE7
2LVN	;		;	Structure of the gp78 CUE domain
2LVO	;		;	Structure of the gp78CUE domain bound to monubiquitin
7QA8	;	2.7	;	Structure of the GPCR dimer Ste2 bound to an antagonist
7QBI	;	3.46	;	Structure of the GPCR dimer Ste2 in the active-like state bound to agonist
7QBC	;	3.53	;	Structure of the GPCR dimer Ste2 in the inactive-like state bound to agonist
7Y89	;	3.02	;	Structure of the GPR17-Gi complex
7EJX	;	2.4	;	Structure of the GPR88-Gi1 signaling complex bound to a synthetic ligand
6JO5	;	2.9	;	Structure of the green algal photosystem I supercomplex with light-harvesting complex I
6JO6	;	2.9	;	Structure of the green algal photosystem I supercomplex with light-harvesting complex I
5HK5	;	2.9	;	Structure of the Grem2-GDF5 Inhibitory Complex
7YWY	;	3.4	;	Structure of the GroEL chaperonin in complex with the CnoX chaperedoxin
8BLD	;	4.4	;	Structure of the GroEL(ATP7/ADP7) complex plunged 13 ms after mixing with ATP
8BLF	;	3.9	;	Structure of the GroEL(ATP7/ADP7) complex plunged 50 ms after mixing with ATP
8BLY	;	3.2	;	Structure of the GroEL-ATP complex plunge-frozen 13 ms after mixing with ATP
8BLC	;	2.7	;	Structure of the GroEL-ATP complex plunge-frozen 50 ms after mixing with ATP
1RYM	;	1.8	;	Structure of the Group II Intron Splicing Factor CRS2
8H0Q	;	3.3	;	Structure of the GRP14-27-GRPR-Gq complex
7UBY	;	2.1	;	Structure of the GTD domain of Clostridium difficile toxin A in complex with VHH AH3
6OQ8	;	2.2	;	Structure of the GTD domain of Clostridium difficile toxin B in complex with VHH 7F
6OQ7	;	2.39	;	Structure of the GTD domain of Clostridium difficile toxin B in complex with VHH E3
1XZP	;	2.3	;	Structure of the GTP-binding protein TrmE from Thermotoga maritima
1XZQ	;	2.9	;	Structure of the GTP-binding protein TrmE from Thermotoga maritima complexed with 5-formyl-THF
7VBW	;	2.5	;	Structure of the GTP-bound AAA+ ATPase domain of the transcriptional regulator GtrR in Burkholderia cenocepacia
5L3R	;	2.5	;	Structure of the GTPase heterodimer of chloroplast SRP54 and FtsY from Arabidopsis thaliana
5L3S	;	1.9	;	Structure of the GTPase heterodimer of crenarchaeal SRP54 and FtsY
5L3Q	;	3.2	;	Structure of the GTPase heterodimer of human SRP54 and SRalpha
6Y32	;	2.6	;	Structure of the GTPase heterodimer of human SRP54 and SRalpha
6X90	;	2.26	;	Structure of the guanine nucleotide exchange factor Sec12 bound to the small GTPase Sar1
7KPW	;	4.9	;	Structure of the H-lobe of yeast CKM
6QZL	;	1.98	;	Structure of the H1 domain of human KCTD12
6QB7	;	2.23	;	Structure of the H1 domain of human KCTD16
6G57	;	2.8	;	Structure of the H1 domain of human KCTD8
1HLW	;	1.9	;	STRUCTURE OF THE H122A MUTANT OF THE NUCLEOSIDE DIPHOSPHATE KINASE
1F3F	;	1.85	;	STRUCTURE OF THE H122G NUCLEOSIDE DIPHOSPHATE KINASE / D4T-TRIPHOSPHATE.MG COMPLEX
3LL4	;	2.49	;	Structure of the H13A mutant of Ykr043C in complex with fructose-1,6-bisphosphate
4O8C	;	2.0	;	Structure of the H170Y mutant of thermostable p-nitrophenylphosphatase from Bacillus Stearothermophilus
3V1H	;	1.9	;	Structure of the H258Y mutant of Phosphatidylinositol-specific phospholipase C from Staphylococcus aureus
4I9T	;	2.0	;	Structure of the H258Y mutant of the phosphatidylinositol-specific phospholipase C from Staphylococcus aureus
7NA5	;	2.5	;	Structure of the H2DB-TCR ternary complex with HSF2 melanoma neoantigen
2HUE	;	1.7	;	Structure of the H3-H4 chaperone Asf1 bound to histones H3 and H4
1QLT	;	2.2	;	STRUCTURE OF THE H422A MUTANT OF THE FLAVOENZYME VANILLYL-ALCOHOL OXIDASE
1QLU	;	2.4	;	STRUCTURE OF THE H422A MUTANT VANILLYL-ALCOHOL OXIDASE IN COMPLEX WITH ISOEUGENOL
5V9F	;	2.05	;	Structure of the H477R variant of rat cytosolic PEPCK in complex with beta sulfopyruvate and GTP.
5V97	;	1.8	;	Structure of the H477R variant of rat cytosolic PEPCK in complex with GTP.
5V95	;	2.3	;	Structure of the H477R variant of rat cytosolic PEPCK in complex with manganese.
5V9G	;	1.95	;	Structure of the H477R variant of rat cytosolic PEPCK in complex with oxalate and GTP.
5V9H	;	2.15	;	Structure of the H477R variant of rat cytosolic PEPCK in complex with phosphoglycolate and GDP.
3OJ1	;	1.52	;	Structure of the H55D mutant of dehaloperoxidase-hemoglobin A from Amphitrite ornata
3OK5	;	1.72	;	Structure of the H55D mutant of dehaloperoxidase-hemoglobin A from Amphitriti ornata with 4-Bromophenol inhibitor
1E8G	;	2.1	;	STRUCTURE OF THE H61T DOUBLE MUTANT OF VANILLYL-ALCOHOL OXIDASE IN COMPLEX WITH FLUORO-CRESOL
1E8F	;	2.9	;	STRUCTURE OF THE H61T MUTANT OF THE FLAVOENZYME VANILLYL-ALCOHOL OXIDASE IN THE APO FORM
1E8H	;	2.6	;	STRUCTURE OF THE H61T MUTANT OF THE FLAVOENZYME VANILLYL-ALCOHOL OXIDASE IN THE APO FORM COMPLEXED BY ADP
1JXZ	;	1.9	;	Structure of the H90Q mutant of 4-Chlorobenzoyl-Coenzyme A Dehalogenase complexed with 4-hydroxybenzoyl-Coenzyme A (product)
5L84	;	2.9	;	Structure of the H959F variant of the PpsC dehydratase domain from Mycobacterium tuberculosis
6CGJ	;	1.75	;	Structure of the HAD domain of effector protein Lem4 (lpg1101) from Legionella pneumophila
6CDW	;	1.84	;	Structure of the HAD domain of effector protein Lem4 (lpg1101) from Legionella pneumophila (inactive mutant)
6CGK	;	1.668	;	Structure of the HAD domain of effector protein Lem4 (lpg1101) from Legionella pneumophila (inactive mutant)with phosphate bound in the active site
2J0P	;	1.7	;	Structure of the haem-chaperone Proteobacteria-protein HemS
2J0R	;	1.9	;	Structure of the haem-chaperone Proteobacteria-protein HemS
5K8K	;	2.55	;	Structure of the Haemophilus influenzae LpxH-lipid X complex
5DJB	;	1.798	;	Structure of the Haliangium ochraceum BMC-H shell protein
8FJ5	;	2.9	;	Structure of the Haloferax volcanii archaeal type IV pilus
5OPG	;	2.15	;	Structure of the Hantaan virus Gn glycoprotein ectodomain
7NKS	;	3.5	;	Structure of the Hantaan virus Gn glycoprotein ectodomain in complex with Fab HTN-Gn1
5FSG	;	3.209	;	Structure of the hantavirus nucleoprotein provides insights into the mechanism of RNA encapsidation and a template for drug design
4F4O	;	2.9	;	Structure of the Haptoglobin-Haemoglobin Complex
7JMS	;	2.78	;	Structure of the Hazara virus OTU bound to ubiquitin
4XUW	;	1.1	;	Structure of the hazelnut allergen, Cor a 8
2WY3	;	1.8	;	Structure of the HCMV UL16-MICB complex elucidates select binding of a viral immunoevasin to diverse NKG2D ligands
4HKH	;	1.69	;	Structure of the Hcp1 protein from E. coli EAEC 042 pathovar, mutants N93W-S158W
7SYG	;	4.3	;	Structure of the HCV IRES binding to the 40S ribosomal subunit, closed conformation. Structure 1(delta dII)
7SYH	;	4.6	;	Structure of the HCV IRES binding to the 40S ribosomal subunit, closed conformation. Structure 2(delta dII)
7SYI	;	4.5	;	Structure of the HCV IRES binding to the 40S ribosomal subunit, closed conformation. Structure 3(delta dII)
7SYJ	;	4.8	;	Structure of the HCV IRES binding to the 40S ribosomal subunit, closed conformation. Structure 4(delta dII)
7SYK	;	4.2	;	Structure of the HCV IRES binding to the 40S ribosomal subunit, closed conformation. Structure 5(delta dII)
7SYL	;	4.5	;	Structure of the HCV IRES bound to the 40S ribosomal subunit, closed conformation. Structure 6(delta dII)
7SYO	;	4.6	;	Structure of the HCV IRES bound to the 40S ribosomal subunit, head open. Structure 9(delta dII)
7SYM	;	4.8	;	Structure of the HCV IRES bound to the 40S ribosomal subunit, head opening. Structure 7(delta dII)
7SYN	;	4.0	;	Structure of the HCV IRES bound to the 40S ribosomal subunit, head opening. Structure 8(delta dII)
5A2Q	;	3.9	;	Structure of the HCV IRES bound to the human ribosome
2OC1	;	2.7	;	Structure of the HCV NS3/4A Protease Inhibitor CVS4819
5KZP	;	2.262	;	Structure of the HCV1-C1 Antibody-Antigen Complex
5TKA	;	2.048	;	Structure of the HD-domain phosphohydrolase OxsA
5TK9	;	1.843	;	Structure of the HD-domain phosphohydrolase OxsA with Oxetanocin-A bound
5TK6	;	1.924	;	Structure of the HD-domain phosphohydrolase OxsA with Oxetanocin-A diphosphate bound
5TK8	;	1.64	;	Structure of the HD-domain phosphohydrolase OxsA with Oxetanocin-A monophosphate bound
5TK7	;	1.904	;	Structure of the HD-domain phosphohydrolase OxsA with Oxetanocin-A triphosphate bound
2OQS	;		;	Structure of the hDLG/SAP97 PDZ2 in complex with HPV-18 papillomavirus E6 peptide
3D9X	;	1.13	;	Structure of the head of the Bartonella adhesin BadA
4UFT	;	4.3	;	Structure of the helical Measles virus nucleocapsid
4IRV	;	2.04	;	Structure of the Helicobacter pylori CagA Oncogene Bound to the Human Tumor Suppressor Apoptosis-stimulating Protein of p53-2
4DJ7	;	2.81	;	Structure of the hemagglutinin complexed with 3SLN from a highly pathogenic H7N7 influenza virus
4DJ8	;	2.8	;	Structure of the hemagglutinin complexed with 6SLN from a highly pathogenic H7N7 influenza virus
4DJ6	;	2.61	;	Structure of the hemagglutinin from a highly pathogenic H7N7 influenza virus
1V2I	;	2.2	;	Structure of the hemagglutinin-neuraminidase from human parainfluenza virus type III
1V3B	;	2.0	;	Structure of the hemagglutinin-neuraminidase from human parainfluenza virus type III
4WEF	;	2.5	;	Structure of the Hemagglutinin-neuraminidase from Human parainfluenza virus type III: complex with difluorosialic acid
1V3C	;	2.3	;	Structure of the hemagglutinin-neuraminidase from human parainfluenza virus type III: complex with NEU5AC
1V3D	;	2.28	;	Structure of the hemagglutinin-neuraminidase from human parainfluenza virus type III: complex with NEU5AC2EN
1V3E	;	1.89	;	Structure of the hemagglutinin-neuraminidase from human parainfluenza virus type III: complex with ZANAMAVIR
2OVI	;	2.05	;	Structure of the Heme Binding Protein ChuX
4K8F	;	2.7	;	Structure of the heme domain of CooA from Rhodospirillum rubrum
7NEV	;	1.7	;	Structure of the hemiacetal complex between the SARS-CoV-2 Main Protease and Leupeptin
3ELL	;	1.7	;	Structure of the hemophore from Pseudomonas aeruginosa (HasAp)
3KTM	;	2.7	;	Structure of the Heparin-induced E1-Dimer of the Amyloid Precursor Protein (APP)
4N0Y	;	1.749	;	Structure of the Hepatitis C Envelope Glycoprotein E1 antigenic region 314-324 bound to the cross-neutralizing antibody IGH526
4XVJ	;	2.0	;	STRUCTURE OF THE HEPATITIS C VIRUS ENVELOPE GLYCOPROTEIN E2 ANTIGENIC 2 REGION 412-423 BOUND TO THE BROADLY NEUTRALIZING ANTIBODY HC33.1
6BZY	;	1.6	;	Structure of the Hepatitis C virus envelope glycoprotein E2 antigenic region 412-423 bound to the 22D11 broadly neutralizing antibody
6BZU	;	2.7	;	Structure of the Hepatitis C virus envelope glycoprotein E2 antigenic region 412-423 bound to the broadly neutralizing antibody 19B3
4WHT	;	2.22	;	Structure of the Hepatitis C virus envelope glycoprotein E2 antigenic region 412-423 bound to the broadly neutralizing antibody 3/11, P1 crystal form
4WHY	;	2.62	;	Structure of the Hepatitis C virus envelope glycoprotein E2 antigenic region 412-423 bound to the broadly neutralizing antibody 3/11, P21 crystal form
4G6A	;	2.501	;	Structure of the Hepatitis C virus envelope glycoprotein E2 antigenic region 412-423 bound to the broadly neutralizing antibody AP33
4DGY	;	1.798	;	Structure of the Hepatitis C virus envelope glycoprotein E2 antigenic region 412-423 bound to the broadly neutralizing antibody HCV1, C2 form
4DGV	;	1.805	;	Structure of the Hepatitis C virus envelope glycoprotein E2 antigenic region 412-423 bound to the broadly neutralizing antibody HCV1, P2(1) form
6BZV	;	2.654	;	Structure of the Hepatitis C virus envelope glycoprotein E2 antigenic region 412-423 bound to the GL precursor of the broadly neutralizing antibody 19B3
6BZW	;	2.2	;	Structure of the Hepatitis C virus envelope glycoprotein E2 antigenic region 412-423 bound to the GL precursor of the broadly neutralizing antibody AP33
1HEI	;	2.1	;	STRUCTURE OF THE HEPATITIS C VIRUS RNA HELICASE DOMAIN
5NPH	;	1.7	;	Structure of the Hepatitis C virus strain J4 glycoprotein E2 antigenic region 532-540 bound to the Fab fragment of the non-neutralizing antibody DAO5
5NPI	;	2.0	;	Structure of the Hepatitis C virus strain J4 glycoprotein E2 antigenic region 532-540 bound to the single chain variable fragment of the non-neutralizing antibody DAO5
5NPJ	;	1.9	;	Structure of the Hepatitis C virus strain JFH1 glycoprotein E2 antigenic region 532-540 bound to the single chain variable fragment of the non-neutralizing antibody DAO5
7MN6	;	3.09	;	Structure of the HER2 S310F/HER3/NRG1b Heterodimer Extracellular Domain
7MN5	;	2.93	;	Structure of the HER2/HER3/NRG1b Heterodimer Extracellular Domain
7MN8	;	3.45	;	Structure of the HER2/HER3/NRG1b Heterodimer Extracellular Domain bound to Trastuzumab Fab
8U4K	;	4.27	;	Structure of the HER2/HER4/BTC Heterodimer Extracellular Domain
8U4L	;	3.31	;	Structure of the HER2/HER4/NRG1b Heterodimer Extracellular Domain
1M6B	;	2.6	;	Structure of the HER3 (ERBB3) Extracellular Domain
8U4J	;	3.7	;	Structure of the HER4/BTC Homodimer Extracellular Domain
8U4I	;	3.38	;	Structure of the HER4/NRG1b Homodimer Extracellular Domain
5ZZ8	;	3.75	;	Structure of the Herpes simplex virus type 2 C-capsid with capsid-vertex-specific component
2WVN	;	2.62	;	Structure of the HET-s N-terminal domain
2WVO	;	2.3	;	Structure of the HET-S N-terminal domain
2WVQ	;	2.0	;	Structure of the HET-s N-terminal domain. Mutant D23A, P33H
2RNM	;		;	Structure of The HET-s(218-289) prion in its amyloid form obtained by solid-state NMR
7QRE	;	2.7	;	Structure of the hetero-tetramer complex between precursor membrane protein fragment (pr) and envelope protein (E) from tick-borne encephalitis virus
5TGC	;	3.245	;	Structure of the hetero-trimer of Rtt102-Arp7/9 bound to ATP
4BS9	;	2.9	;	Structure of the heterocyclase TruD
1RJ9	;	1.9	;	Structure of the heterodimer of the conserved GTPase domains of the Signal Recognition Particle (Ffh) and Its Receptor (FtsY)
4AKX	;	2.94	;	Structure of the heterodimeric complex ExoU-SpcU from the type III secretion system (T3SS) of Pseudomonas aeruginosa
7LTR	;	1.75	;	Structure of the heteromeric complex between the alpha-N-methyltransferase (SonM) and a truncated construct of the RiPP precursor (SonA) (with SAM)
7PCS	;	2.25	;	Structure of the heterotetrameric SDR family member BbsCD
2UWJ	;	2.0	;	Structure of the heterotrimeric complex which regulates type III secretion needle formation
2WTK	;	2.65	;	Structure of the heterotrimeric LKB1-STRADalpha-MO25alpha complex
7KI6	;	2.8	;	Structure of the HeV F glycoprotein in complex with the 1F5 neutralizing antibody
3QDW	;	1.9	;	Structure of the hexagonal form of the Boletus edulis lectin in complex with N-acetyl glucosamine and N-acetyl galactosamine
3QDY	;	2.0	;	Structure of the hexagonal form of the Boletus edulis lectin in complex with T-antigen disaccharide and N,N-diacetyl chitobiose
7OZS	;	3.5	;	Structure of the hexameric 5S RNP from C. thermophilum
1XAT	;	3.2	;	STRUCTURE OF THE HEXAPEPTIDE XENOBIOTIC ACETYLTRANSFERASE FROM PSEUDOMONAS AERUGINOSA
7NBU	;	3.11	;	Structure of the HigB1 toxin mutant K95A from Mycobacterium tuberculosis (Rv1955) and its target, the cspA mRNA, on the E. coli Ribosome.
6S8V	;	1.8	;	Structure of the high affinity Anticalin P3D11 in complex with the human CD98 heavy chain ectodomain
6SUA	;	2.75	;	Structure of the high affinity engineered lipocalin C1B12 in complex with the mouse CD98 heavy chain ectodomain
4B9N	;	2.2	;	Structure of the high fidelity DNA polymerase I correctly bypassing the oxidative formamidopyrimidine-dA DNA lesion.
4B9M	;	2.05	;	Structure of the high fidelity DNA polymerase I with an oxidative formamidopyrimidine-dA DNA lesion -thymine basepair in the post- insertion site.
4B9U	;	2.1	;	Structure of the high fidelity DNA polymerase I with an oxidative formamidopyrimidine-dG DNA lesion -dA basepair in the post-insertion site.
4B9T	;	2.65	;	Structure of the high fidelity DNA polymerase I with an oxidative formamidopyrimidine-dG DNA lesion -dC basepair in the post-insertion site.
4B9S	;	1.73	;	Structure of the high fidelity DNA polymerase I with an oxidative formamidopyrimidine-dG DNA lesion outside of the pre-insertion site.
4B9V	;	2.0	;	Structure of the high fidelity DNA polymerase I with extending from an oxidative formamidopyrimidine-dG DNA lesion -dA basepair.
4B9L	;	2.05	;	Structure of the high fidelity DNA polymerase I with the oxidative formamidopyrimidine-dA DNA lesion in the pre-insertion site.
7UWK	;	4.4	;	Structure of the higher-order IL-25-IL-17RB complex
7Z50	;	2.65	;	Structure of the highly diabetogenic 4.1-T cell receptor targeting a hybrid insulin peptide bound to I-Ag7.
1HGT	;	2.2	;	STRUCTURE OF THE HIRUGEN AND HIRULOG 1 COMPLEXES OF ALPHA-THROMBIN
2HGT	;	2.2	;	STRUCTURE OF THE HIRUGEN AND HIRULOG 1 COMPLEXES OF ALPHA-THROMBIN
1ABI	;	2.3	;	STRUCTURE OF THE HIRULOG 3-THROMBIN COMPLEX AND NATURE OF THE S' SUBSITES OF SUBSTRATES AND INHIBITORS
1ABJ	;	2.4	;	STRUCTURE OF THE HIRULOG 3-THROMBIN COMPLEX AND NATURE OF THE S' SUBSITES OF SUBSTRATES AND INHIBITORS
1I59	;	1.8	;	STRUCTURE OF THE HISTIDINE KINASE CHEA ATP-BINDING DOMAIN IN COMPLEX WITH ADPNP AND MAGENSIUM
1I58	;	1.6	;	STRUCTURE OF THE HISTIDINE KINASE CHEA ATP-BINDING DOMAIN IN COMPLEX WITH ATP ANALOG ADPCP AND MAGNESIUM
2WIO	;	2.0	;	Structure of the histidine tagged, open cytochrome P450 Eryk from S. erythraea
3AAD	;	3.3	;	Structure of the histone chaperone CIA/ASF1-double bromodomain complex linking histone modifications and site-specific histone eviction
5IKK	;	2.4	;	Structure of the histone deacetylase Clr3
2IDC	;	2.2	;	Structure of the Histone H3-Asf1 Chaperone Interaction
1KKS	;		;	Structure of the histone mRNA hairpin required for cell cycle regulation of histone gene expression
5UP4	;	9.0	;	Structure of the HIV-1 Capsid Protein and spacer peptide 1 by Cryo-EM
1A43	;	2.6	;	STRUCTURE OF THE HIV-1 CAPSID PROTEIN DIMERIZATION DOMAIN AT 2.6A RESOLUTION
2L94	;		;	Structure of the HIV-1 frameshift site RNA bound to a small molecule inhibitor of viral replication
3G9R	;	2.0	;	Structure of the HIV-1 gp41 Membrane-Proximal Ectodomain Region in a Putative Prefusion Conformation
7LOH	;		;	Structure of the HIV-1 gp41 transmembrane domain and cytoplasmic tail
6UJU	;		;	Structure of the HIV-1 gp41 transmembrane domain and cytoplasmic tail (LLP2)
2H3Z	;		;	Structure of the HIV-1 matrix protein bound to di-C4-phosphatidylinositol-(4,5)-bisphosphate
2H3V	;		;	Structure of the HIV-1 Matrix protein bound to di-C8-phosphatidylinositol-(4,5)-bisphosphate
1EN1	;		;	STRUCTURE OF THE HIV-1 MINUS STRAND PRIMER BINDING SITE
1A1T	;		;	STRUCTURE OF THE HIV-1 NUCLEOCAPSID PROTEIN BOUND TO THE SL3 PSI-RNA RECOGNITION ELEMENT, NMR, 25 STRUCTURES
8VGT	;	2.9	;	Structure of the HKU1 RBD bound to the human TMPRSS2 receptor
5W1V	;	3.31	;	Structure of the HLA-E-VMAPRTLIL/GF4 TCR complex
2ESV	;	2.6	;	Structure of the HLA-E-VMAPRTLIL/KK50.4 TCR complex
5W1W	;	3.1	;	Structure of the HLA-E-VMAPRTLVL/GF4 TCR complex
1HME	;		;	STRUCTURE OF THE HMG BOX MOTIF IN THE B-DOMAIN OF HMG1
1HMF	;		;	STRUCTURE OF THE HMG BOX MOTIF IN THE B-DOMAIN OF HMG1
5OIX	;	1.61	;	Structure of the HMPV P oligomerization domain at 1.6 A
5OIY	;	2.2	;	Structure of the HMPV P oligomerization domain at 2.2 A
6N07	;	3.6	;	Structure of the HO BMC shell: BMC-TD focused map, open inner pore, compacted shell
5LJN	;	2.701	;	Structure of the HOIP PUB domain bound to SPATA2 PIM peptide
5EDV	;	3.48	;	Structure of the HOIP-RBR/UbcH5B~ubiquitin transfer complex
2CRX	;	2.5	;	STRUCTURE OF THE HOLLIDAY JUNCTION INTERMEDIATE IN CRE-LOXP SITE-SPECIFIC RECOMBINATION
5ISX	;	2.335	;	Structure of the holo PCP-E didomain of the gramicidin S synthetase A
1B8I	;	2.4	;	STRUCTURE OF THE HOMEOTIC UBX/EXD/DNA TERNARY COMPLEX
6YS4	;	2.11	;	Structure of the Homo sapiens SAS-6 coiled-coil domain
7UWJ	;	3.2	;	Structure of the homodimeric IL-25-IL-17RB binary complex
3GVM	;	2.15	;	Structure of the homodimeric WXG-100 family protein from Streptococcus agalactiae
3GWK	;	1.3	;	Structure of the homodimeric WXG-100 family protein from Streptococcus agalactiae
4G6T	;	1.56	;	Structure of the HopA1-SchA Chaperone-Effector Complex
7AT0	;	1.2	;	Structure of the Hormone-Sensitive Lipase like EstD11
1XWV	;	1.83	;	Structure of the house dust mite allergen Der f 2: Implications for function and molecular basis of IgE cross-reactivity
3TQF	;	2.8	;	Structure of the Hpr(Ser) kinase/phosphatase from Coxiella burnetii
3IQT	;	1.4	;	Structure of the HPT domain of Sensor protein barA from Escherichia coli CFT073.
3EI3	;	2.3	;	Structure of the hsDDB1-drDDB2 complex
4A11	;	3.31	;	Structure of the hsDDB1-hsCSA complex
3EI4	;	3.3	;	Structure of the hsDDB1-hsDDB2 complex
1N19	;	1.86	;	Structure of the HSOD A4V mutant
3C7N	;	3.115	;	Structure of the Hsp110:Hsc70 Nucleotide Exchange Complex
2VW5	;	1.9	;	Structure Of The Hsp90 Inhibitor 7-O-carbamoylpremacbecin Bound To The N- Terminus Of Yeast Hsp90
2VWC	;	2.4	;	STRUCTURE OF THE HSP90 INHIBITOR MACBECIN BOUND TO THE N-TERMINUS OF YEAST HSP90.
6QBW	;	2.4	;	Structure of the HTLV-2 integrase catalytic core domain in complex with calcium
6QBV	;	2.45	;	Structure of the HTLV-2 integrase catalytic core domain in complex with magnesium (dimeric form)
6QBT	;	2.29	;	Structure of the HTLV-2 integrase catalytic core domain in complex with magnesium (trimeric form)
1JVR	;		;	STRUCTURE OF THE HTLV-II MATRIX PROTEIN, NMR, 20 STRUCTURES
8RC0	;	3.2	;	Structure of the human 20S U5 snRNP
8Q91	;	3.1	;	Structure of the human 20S U5 snRNP core
5GJQ	;	4.35	;	Structure of the human 26S proteasome bound to USP14-UbAl
6MHR	;	2.8	;	Structure of the human 4-1BB / Urelumab Fab complex
6MI2	;	2.72	;	Structure of the human 4-1BB / Utomilumab Fab complex
7QP7	;	3.7	;	Structure of the human 48S initiation complex in closed state (h48S AUG closed)
7QP6	;	4.7	;	Structure of the human 48S initiation complex in open state (h48S AUG open)
7AYY	;	2.0	;	Structure of the human 8-oxoguanine DNA Glycosylase hOGG1 in complex with activator TH10785
6RLW	;	2.0	;	Structure of the human 8-oxoguanine DNA Glycosylase hOGG1 in complex with inhibitor TH5487
4UG0	;	3.6	;	STRUCTURE OF THE HUMAN 80S RIBOSOME
4V6X	;	5.0	;	Structure of the human 80S ribosome
8E7M	;	3.3	;	Structure of the human ACE2 receptor in complex with antibody Fab fragment, 05B04
6QAP	;	2.3	;	Structure of the human aldehyde dehydrogenase 9A1 in C2 space group
7LRZ	;	1.91	;	Structure of the Human ALK GRD
7LS0	;	3.05	;	Structure of the Human ALK GRD bound to AUG
4CCU	;	2.0	;	Structure of the Human Anaplastic Lymphoma Kinase in Complex with 2-(5-(6-amino-5-((R)-1-(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)ethoxy) pyridin-3-yl)-4-methylthiazol-2-yl)propan-2-ol
4CCB	;	2.03	;	Structure of the Human Anaplastic Lymphoma Kinase in Complex with 3-((R)-1-(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)ethoxy)-5-(5-methyl-1H- pyrazol-4-yl)pyridin-2-amine
2XP2	;	1.9	;	Structure of the Human Anaplastic Lymphoma Kinase in Complex with Crizotinib (PF-02341066)
4CLI	;	2.05	;	Structure of the Human Anaplastic Lymphoma Kinase in Complex with PF- 06463922 ((10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16, 17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11) benzoxadiazacyclotetradecine-3-carbonitrile).
4CMU	;	1.8	;	Structure of the Human Anaplastic Lymphoma Kinase in Complex with the inhibitor (10R)-7-amino-12-fluoro-1,3,10,16-tetramethyl-16,17-dihydro- 1H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecin-15(10H)-one
4CTB	;	1.79	;	Structure of the Human Anaplastic Lymphoma Kinase in Complex with the inhibitor (5R)-8-amino-3-fluoro-5,19-dimethyl-20-oxo-5,18,19,20- tetrahydro-7,11-(azeno)pyrido(2',1':2,3)imidazo(4,5-h)(2,5,11) benzoxadiazacyclotetradecine-14-carbonitrile
4CMO	;	2.05	;	Structure of the Human Anaplastic Lymphoma Kinase in Complex with the inhibitor 2-((1R)-1-((3-amino-6-(2-methoxypyridin-3-yl)pyrazin-2-yl) oxy)ethyl)-4-fluoro-N-methylbenzamide
4CMT	;	1.73	;	Structure of the Human Anaplastic Lymphoma Kinase in Complex with the inhibitor 3-((1R)-1-(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)ethoxy)- 5-(3-(methylsulfonyl)phenyl)pyridin-2-amine
4CNH	;	1.9	;	Structure of the Human Anaplastic Lymphoma Kinase in Complex with the inhibitor 3-((1R)-1-(5-fluoro-2-methoxyphenyl)ethoxy)-5-(1-methyl-1H- 1,2,3-triazol-5-yl)pyridin-2-amine
4CTC	;	2.03	;	Structure of the Human Anaplastic Lymphoma Kinase in Complex with the inhibitor 7-amino-3-cyclopropyl-12-fluoro-1,10,16-trimethyl-16,17- dihydro-1H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11) benzoxadiazacyclotetradecin-15(10H)-one
5G04	;	3.9	;	Structure of the human APC-Cdc20-Hsl1 complex
5A31	;	4.3	;	Structure of the human APC-Cdh1-Hsl1-UbcH10 complex.
6O9M	;	4.4	;	Structure of the human apo TFIIH
6HXH	;	3.3	;	Structure of the human ATP citrate lyase holoenzyme in complex with citrate, coenzyme A and Mg.ADP
6QFB	;	3.25	;	Structure of the human ATP citrate lyase holoenzyme in complex with citrate, coenzyme A and Mg.ADP
8ACT	;	3.6	;	structure of the human beta-cardiac myosin folded-back off state
2FXM	;	2.7	;	Structure of the human beta-myosin S2 fragment
2FXO	;	2.5	;	Structure of the human beta-myosin S2 fragment
7VRB	;	2.389	;	Structure of the Human BRG1/SS18 complex
6XD3	;	3.3	;	Structure of the human CAK in complex with THZ1
6QZH	;	2.1	;	Structure of the human CC Chemokine Receptor 7 in complex with the intracellular allosteric antagonist Cmp2105 and the insertion protein Sialidase NanA
7R5S	;	2.83	;	Structure of the human CCAN bound to alpha satellite DNA
7PII	;	2.68	;	Structure of the human CCAN CENP-A alpha-satellite complex
7R5R	;	2.44	;	Structure of the human CCAN CENP-A alpha-satellite complex
7R5V	;	4.55	;	Structure of the human CCAN CENP-A alpha-satellite complex
7YWX	;	12.0	;	Structure of the human CCAN CENP-A alpha-satellite complex
7PKN	;	3.2	;	Structure of the human CCAN deltaCT complex
7YYH	;	8.9	;	Structure of the human CCANdeltaT CENP-A alpha-satellite complex
6XBZ	;	2.8	;	Structure of the human CDK-activating kinase
6CT9	;	2.26	;	Structure of the human cGAS-DNA complex
6CTA	;	2.779	;	Structure of the human cGAS-DNA complex with ATP
6VVO	;	3.4	;	Structure of the human clamp loader (Replication Factor C, RFC) bound to the sliding clamp (Proliferating Cell Nuclear Antigen, PCNA)
5CGC	;	3.101	;	Structure of the human class C GPCR metabotropic glutamate receptor 5 transmembrane domain in complex with the negative allosteric modulator 3-chloro-4-fluoro-5-[6-(1H-pyrazol-1-yl)pyrimidin-4-yl]benzonitrile
5CGD	;	2.603	;	Structure of the human class C GPCR metabotropic glutamate receptor 5 transmembrane domain in complex with the negative allosteric modulator 3-chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile - (HTL14242)
4OO9	;	2.6	;	Structure of the human class C GPCR metabotropic glutamate receptor 5 transmembrane domain in complex with the negative allosteric modulator mavoglurant
1HLA	;	3.5	;	STRUCTURE OF THE HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN, HLA-A2
8HVT	;	3.6	;	Structure of the human CLC-7/Ostm1 complex reveals a novel state
7CQ6	;	3.0	;	Structure of the human CLCN7-OSTM1 complex
7CQ7	;	3.55	;	Structure of the human CLCN7-OSTM1 complex with ADP
7CQ5	;	2.6	;	Structure of the human CLCN7-OSTM1 complex with ATP
4CQO	;	2.8	;	Structure of the human CNOT1 superfamily homology domain in complex with a Nanos1 peptide
7VOI	;	4.38	;	Structure of the human CNOT1(MIF4G)-CNOT6L-CNOT7 complex
1GR3	;	2.0	;	Structure of the human collagen X NC1 trimer
4B3Z	;	3.05	;	Structure of the human collapsin response mediator protein-1, a lung cancer suppressor
8P0V	;	6.5	;	Structure of the human Commander complex coiled coils, DENND10 and partial Retriever subcomplex
8P0W	;	2.9	;	Structure of the human Commander complex COMMD ring
8P0X	;	7.5	;	Structure of the human Commander complex Retriever Subcomplex
7SSP	;	3.5	;	Structure of the human COQ7:COQ9 complex by single-particle electron cryo-microscopy, unliganded state
7US6	;	3.8	;	Structure of the human coronavirus CCoV-HuPn-2018 spike glycoprotein with domain 0 in the proximal conformation
7USA	;	2.8	;	Structure of the human coronavirus CCoV-HuPn-2018 spike glycoprotein with domain 0 in the swung out conformation
7Q3D	;	3.35	;	Structure of the human CPLANE complex
7NP9	;	1.14	;	Structure of the human CR3 - CD11bCD18 specific nanobody hCR3Nb1
4WRL	;	2.802	;	Structure of the human CSF-1:CSF-1R complex
4WRM	;	6.853	;	Structure of the human CSF-1:CSF-1R complex
8JDK	;	2.26	;	Structure of the Human cytoplasmic Ribosome with human tRNA Asp(ManQ34) and mRNA(GAU)
8JDJ	;	2.5	;	Structure of the Human cytoplasmic Ribosome with human tRNA Asp(Q34) and mRNA(GAU)
8JDL	;	2.42	;	Structure of the Human cytoplasmic Ribosome with human tRNA Tyr(GalQ34) and mRNA(UAU) (non-rotated state)
8JDM	;	2.67	;	Structure of the Human cytoplasmic Ribosome with human tRNA Tyr(GalQ34) and mRNA(UAU) (rotated state)
2WFD	;	3.25	;	Structure of the human cytosolic leucyl-tRNA synthetase editing domain
1SNT	;	1.75	;	Structure of the human cytosolic sialidase Neu2
1VCU	;	2.85	;	Structure of the human cytosolic sialidase Neu2 in complex with the inhibitor DANA
5WIU	;	1.962	;	Structure of the human D4 Dopamine receptor in complex with Nemonapride
6FCV	;	2.92	;	Structure of the human DDB1-CSA complex
8AJN	;	3.0	;	Structure of the human DDB1-DCAF12 complex
8ROX	;	3.3	;	Structure of the human DDB1-DDA1-DCAF15 E3 ubiquitin ligase bound to compound furan 12
8ROY	;	3.1	;	Structure of the human DDB1-DDA1-DCAF15 E3 ubiquitin ligase bound to compound furan 24
6SJ7	;	3.54	;	Structure of the human DDB1-DDA1-DCAF15 E3 ubiquitin ligase bound to RBM39 and Indisulam
6PAI	;	2.9	;	Structure of the human DDB1-DDA1-DCAF15 E3 ubiquitin ligase bound to RBM39 and sulfonamide E7820
2WAX	;	2.3	;	Structure of the human DDX6 C-terminal domain in complex with an EDC3- FDF peptide
2WAY	;	2.3	;	Structure of the human DDX6 C-terminal domain in complex with an EDC3- FDF peptide
4G69	;	2.0	;	Structure of the Human Discs Large 1 PDZ2 - Adenomatous Polyposis Coli Cytoskeletal Polarity Complex
3PBL	;	2.89	;	Structure of the human dopamine D3 receptor in complex with eticlopride
2JGC	;	2.4	;	Structure of the human eIF4E homologous protein, 4EHP without ligand bound
6NH6	;	2.189	;	Structure of the human endothelial nitric oxide synthase heme domain in complex with 6-(3-(3-(dimethylamino)propyl)-2,6-difluorophenethyl)-4-methylpyridin-2-amine
6CIF	;	2.2	;	Structure of the human endothelial nitric oxide synthase heme domain in complex with N-(1-(Piperidin-4-yl)indolin-5-yl)thiophene-2-carboximidamide
4A2Y	;	1.7	;	STRUCTURE OF THE HUMAN EOSINOPHIL CATIONIC PROTEIN IN COMPLEX WITH CITRATE ANIONS
4A2O	;	1.69	;	STRUCTURE OF THE HUMAN EOSINOPHIL CATIONIC PROTEIN IN COMPLEX WITH SULFATE ANIONS
4L0P	;	2.26	;	Structure of the human EphA3 receptor ligand binding domain complexed with ephrin-A5
8S9S	;	3.6	;	Structure of the human ER membrane protein complex (EMC) in GDN
6WW7	;	3.4	;	Structure of the human ER membrane protein complex in a lipid nanodisc
7RLO	;	2.6	;	Structure of the human eukaryotic translation initiation factor 2B (eIF2B) in complex with a viral protein NSs
2HYI	;	2.3	;	Structure of the human exon junction complex with a trapped DEAD-box helicase bound to RNA
7KZP	;	3.1	;	Structure of the human Fanconi anaemia Core complex
7KZQ	;	4.3	;	Structure of the human Fanconi anaemia Core-ID complex
7KZR	;	4.4	;	Structure of the human Fanconi Anaemia Core-UBE2T-ID complex
7KZV	;	4.2	;	Structure of the human fanconi anaemia Core-UBE2T-ID-DNA complex in closed state
7KZT	;	4.2	;	Structure of the human fanconi anaemia Core-UBE2T-ID-DNA complex in intermediate state
7KZS	;	4.2	;	Structure of the human fanconi anaemia Core-UBE2T-ID-DNA complex in open state
3HHD	;	2.15	;	Structure of the Human Fatty Acid Synthase KS-MAT Didomain as a Framework for Inhibitor Design.
5NQH	;	2.6	;	Structure of the human Fe65-PTB2 homodimer
7T6T	;	3.2	;	Structure of the human FPR1-Gi complex with fMLFII
7T6U	;	2.9	;	Structure of the human FPR2-Gi complex with CGEN-855A
7T6S	;	3.0	;	Structure of the human FPR2-Gi complex with compound C43
7T6V	;	3.1	;	Structure of the human FPR2-Gi complex with fMLFII
6NZU	;	3.2	;	Structure of the human frataxin-bound iron-sulfur cluster assembly complex
1K8P	;	2.4	;	Structure of the Human G-quadruplex reveals a novel topology
6H8C	;		;	Structure of the human GABARAPL2 protein in complex with the UBA5 LIR motif
7RUQ	;	1.79	;	Structure of the human GIGYF1-TNRC6C complex
7RUP	;	1.23	;	Structure of the human GIGYF2-TNRC6A complex
5VEX	;	3.0	;	Structure of the human GLP-1 receptor complex with NNC0640
5VEW	;	2.7	;	Structure of the human GLP-1 receptor complex with PF-06372222
5H8S	;	1.703	;	Structure of the human GluA2 LBD in complex with GNE3419
5C65	;	2.65	;	Structure of the human glucose transporter GLUT3 / SLC2A3
7EU7	;	3.5	;	Structure of the human GluN1-GluN2A NMDA receptor in complex with S-ketamine, glycine and glutamate
7EU8	;	4.07	;	Structure of the human GluN1-GluN2B NMDA receptor in complex with S-ketamine,glycine and glutamate
5I2K	;	2.86	;	Structure of the human GluN1/GluN2A LBD in complex with 7-{[ethyl(4-fluorophenyl)amino]methyl}-N,2-dimethyl-5-oxo-5H-[1,3]thiazolo[3,2-a]pyrimidine-3-carboxamide (compound 19)
5TP9	;	2.4	;	Structure of the human GluN1/GluN2A LBD in complex with compound 2 (GNE9178)
5TPA	;	2.48	;	Structure of the human GluN1/GluN2A LBD in complex with compound 9 (GNE3500)
5KDT	;	2.44	;	Structure of the human GluN1/GluN2A LBD in complex with GNE0723
5H8H	;	2.23	;	Structure of the human GluN1/GluN2A LBD in complex with GNE3419
5KCJ	;	2.09	;	Structure of the human GluN1/GluN2A LBD in complex with GNE6901
5H8Q	;	1.9	;	Structure of the human GluN1/GluN2A LBD in complex with GNE8324
5I2N	;	2.12	;	Structure of the human GluN1/GluN2A LBD in complex with N-ethyl-7-{[2-fluoro-3-(trifluoromethyl)phenyl]methyl}-2-methyl-5-oxo-5H-[1,3]thiazolo[3,2-a]pyrimidine-3-carboxamide (compound 29)
5H8N	;	2.5	;	Structure of the human GluN1/GluN2A LBD in complex with NAM
7EOT	;	3.8	;	Structure of the human GluN1/GluN2A NMDA receptor in the CGP-78608/glutamate bound state
6IRF	;	5.1	;	Structure of the human GluN1/GluN2A NMDA receptor in the glutamate/glycine-bound state at pH 6.3, Class I
6IRG	;	5.5	;	Structure of the human GluN1/GluN2A NMDA receptor in the glutamate/glycine-bound state at pH 6.3, Class II
6IRH	;	7.8	;	Structure of the human GluN1/GluN2A NMDA receptor in the glutamate/glycine-bound state at pH 6.3, Class III
6IRA	;	4.5	;	Structure of the human GluN1/GluN2A NMDA receptor in the glutamate/glycine-bound state at pH 7.8
7EOQ	;	4.1	;	Structure of the human GluN1/GluN2A NMDA receptor in the glycine/CPP bound state
7EOS	;	3.9	;	Structure of the human GluN1/GluN2A NMDA receptor in the glycine/glutamate bound state
7EOR	;	4.0	;	Structure of the human GluN1/GluN2A NMDA receptor in the glycine/glutamate/GNE-6901 bound state
7EOU	;	4.3	;	Structure of the human GluN1/GluN2A NMDA receptor in the glycine/glutamate/GNE-6901/9-AA bound state
5U6O	;	3.5	;	Structure of the human HCN1 hyperpolarization-activated cyclic nucleotide-gated ion channel
5U6P	;	3.51	;	Structure of the human HCN1 hyperpolarization-activated cyclic nucleotide-gated ion channel in complex with cAMP
3WBG	;	2.15	;	Structure of the human heart fatty acid-binding protein in complex with 1-anilinonaphtalene-8-sulphonic acid
5SW7	;	1.851	;	Structure of the Human Hemoglobin Mutant Hb Providence (A-Gly-C:V1M; B,D:V1M,K82D; Ferrous, carbonmonoxy bound)
6Z1N	;	2.3	;	Structure of the human heterotetrameric cis-prenyltransferase complex
7PAY	;	2.4	;	Structure of the human heterotetrameric cis-prenyltransferase complex in complex with magnesium and GGsPP
7PAX	;	2.0	;	Structure of the human heterotetrameric cis-prenyltransferase complex in complex with magnesium, FsPP and IPP
7PB1	;	2.59	;	Structure of the human heterotetrameric cis-prenyltransferase complex in complex with magnesium, GGPP and IsPP
7PB0	;	2.301	;	Structure of the human heterotetrameric cis-prenyltransferase complex in complex with magnesium, GGsPP and IsPP
3RZE	;	3.1	;	Structure of the human histamine H1 receptor in complex with doxepin
5ZSU	;	4.25	;	Structure of the human homo-hexameric LRRC8A channel at 4.25 Angstroms
6M04	;	4.36	;	Structure of the human homo-hexameric LRRC8D channel at 4.36 Angstroms
3O0I	;	1.47	;	Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor PU-H54
2A7L	;	1.82	;	Structure of the human hypothetical ubiquitin-conjugating enzyme, LOC55284
1F6A	;	3.5	;	Structure of the human ige-fc bound to its high affinity receptor fc(epsilon)ri(alpha)
7QOO	;	4.6	;	Structure of the human inner kinetochore CCAN complex
4ZXB	;	3.3	;	Structure of the human insulin receptor ectodomain, IRDeltabeta construct, in complex with four Fab molecules
6N77	;	1.64	;	Structure of the human JAK1 kinase domain with compound 15
6N79	;	2.27	;	Structure of the human JAK1 kinase domain with compound 20
6N78	;	1.83	;	Structure of the human JAK1 kinase domain with compound 21
6N7B	;	1.81	;	Structure of the human JAK1 kinase domain with compound 38
6N7A	;	1.33	;	Structure of the human JAK1 kinase domain with compound 39
6N7D	;	1.78	;	Structure of the human JAK1 kinase domain with compound 54
6N7C	;	1.69	;	Structure of the human JAK1 kinase domain with compound 56
4DJH	;	2.9	;	Structure of the human kappa opioid receptor in complex with JDTic
8FD7	;	3.1	;	Structure of the human L-type voltage-gated calcium channel Cav1.2 complexed with gabapentin
8EOG	;	3.3	;	Structure of the human L-type voltage-gated calcium channel Cav1.2 complexed with L-leucine
5YK5	;	2.03	;	structure of the human Lamtor4-Lamtor5 complex
3P7F	;	2.5	;	Structure of the human Langerin carbohydrate recognition domain
3P7H	;	2.3	;	Structure of the human Langerin carbohydrate recognition domain in complex with maltose
3P7G	;	1.5	;	Structure of the human Langerin carbohydrate recognition domain in complex with mannose
7TYG	;	1.9	;	Structure of the human leucine rich repeat protein SHOC2, residues 80-582
2W7A	;	1.4	;	Structure of the human LINE-1 ORF1p central domain
6FIA	;	2.65	;	Structure of the human LINE-1 ORF1p coiled coil domain
2YKO	;	2.1	;	Structure of the human LINE-1 ORF1p trimer
2YKP	;	3.1	;	Structure of the human LINE-1 ORF1p trimer
2YKQ	;	3.1	;	Structure of the human LINE-1 ORF1p trimer
5CXV	;	2.7	;	Structure of the human M1 muscarinic acetylcholine receptor bound to antagonist Tiotropium
3UON	;	3.0	;	Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist
1T9G	;	2.9	;	Structure of the human MCAD:ETF complex
2A1T	;	2.8	;	Structure of the human MCAD:ETF E165betaA complex
3DAB	;	1.9	;	Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain
3DAC	;	1.8	;	Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain
7FH1	;	3.34	;	Structure of the human Meckelin
7LBM	;	4.8	;	Structure of the human Mediator-bound transcription pre-initiation complex
5VXA	;	2.1	;	Structure of the human Mesh1-NADPH complex
5L1X	;	3.3	;	Structure of the Human Metapneumovirus Fusion Protein in the Postfusion Conformation
4DAG	;	3.3904	;	Structure of the Human Metapneumovirus Fusion Protein with Neutralizing Antibody Identifies a Pneumovirus Antigenic Site
6U5O	;	3.7	;	Structure of the Human Metapneumovirus Polymerase bound to the phosphoprotein tetramer
7QPD	;	3.73	;	Structure of the human MHC I peptide-loading complex editing module
6XQO	;	3.1	;	Structure of the human MICU1-MICU2 heterodimer, calcium bound, in association with a lipid nanodisc
4TNT	;	2.3938	;	Structure of the human mineralocorticoid receptor in complex with DNA
4AYT	;	2.85	;	STRUCTURE OF THE HUMAN MITOCHONDRIAL ABC TRANSPORTER, ABCB10
3ZDQ	;	2.85	;	STRUCTURE OF THE HUMAN MITOCHONDRIAL ABC TRANSPORTER, ABCB10 (NUCLEOTIDE-FREE FORM)
4AYW	;	3.3	;	STRUCTURE OF THE HUMAN MITOCHONDRIAL ABC TRANSPORTER, ABCB10 (PLATE FORM)
4AYX	;	2.9	;	STRUCTURE OF THE HUMAN MITOCHONDRIAL ABC TRANSPORTER, ABCB10 (ROD FORM B)
6UXE	;	1.57	;	Structure of the human mitochondrial desulfurase complex Nfs1-ISCU2(M140I)-ISD11 with E.coli ACP1 at 1.57 A resolution showing flexibility of N terminal end of ISCU2
7AZP	;	3.5	;	Structure of the human mitochondrial HSPD1 single ring
5I35	;	2.3	;	Structure of the Human mitochondrial kinase COQ8A R611K with AMPPNP (Cerebellar Ataxia and Ubiquinone Deficiency Through Loss of Unorthodox Kinase Activity)
3J9M	;	3.5	;	Structure of the human mitochondrial ribosome (class 1)
6VLZ	;	2.97	;	Structure of the human mitochondrial ribosome-EF-G1 complex (ClassI)
6VMI	;	2.96	;	Structure of the human mitochondrial ribosome-EF-G1 complex (ClassIII)
6ERQ	;	4.5	;	Structure of the human mitochondrial transcription initiation complex at the HSP promoter
6ERP	;	4.502	;	Structure of the human mitochondrial transcription initiation complex at the LSP promoter
3W8Q	;	2.2	;	Structure of the Human Mitogen-Activated Protein Kinase Kinase 1 (MEK1)
5YT3	;	2.9	;	Structure of the Human Mitogen-Activated Protein Kinase Kinase 1 S218D and S222D mutant
7PD3	;	3.4	;	Structure of the human mitoribosomal large subunit in complex with NSUN4.MTERF4.GTPBP7 and MALSU1.L0R8F8.mt-ACP
7A5K	;	3.7	;	Structure of the human mitoribosome in the post translocation state bound to mtEF-G1
7A5I	;	3.7	;	Structure of the human mitoribosome with A- P-and E-site mt-tRNAs
3OB9	;	2.5	;	Structure of the human MSL3 chromo-barrel domain at 2.5 Angstrom resolution
2CBZ	;	1.5	;	Structure of the human Multidrug Resistance Protein 1 Nucleotide Binding Domain 1
3AU5	;	2.55	;	Structure of the human myosin-X MyTH4-FERM cassette
3AU4	;	1.9	;	Structure of the human myosin-X MyTH4-FERM cassette bound to its specific cargo, DCC
1P6F	;	2.2	;	Structure of the human natural cytotoxicity receptor NKp46
6CIC	;	1.752	;	Structure of the human nitric oxide synthase R354A/G357D mutant heme domain in complex with N-(1-(2-(Ethyl(methyl)amino)ethyl)-1,2,3,4-tetrahydroquino-lin-6-yl)thiophene-2-carboximidamide
6BT1	;	1.48	;	Structure of the human Nocturnin catalytic domain
6BT2	;	2.411	;	Structure of the human Nocturnin catalytic domain with bound sulfate anion
8PMP	;	3.43	;	Structure of the human nuclear cap-binding complex bound to ARS2[147-871] and m7GTP
8BY6	;	3.19	;	Structure of the human nuclear cap-binding complex bound to NCBP3(560-620) and cap-analogue m7GpppG
8PNT	;	3.46	;	Structure of the human nuclear cap-binding complex bound to PHAX and m7G-capped RNA
1H2V	;	2.0	;	Structure of the human nuclear cap-binding-complex (CBC)
1H2T	;	2.1	;	Structure of the human nuclear cap-binding-complex (CBC) in complex with a cap analogue m7GpppG
1H2U	;	2.4	;	Structure of the human nuclear cap-binding-complex (CBC) in complex with a cap analogue m7GpppG
8PPR	;	3.0	;	Structure of the human outer kinetochore KMN network complex
4NTJ	;	2.62	;	Structure of the human P2Y12 receptor in complex with an antithrombotic drug
2WTT	;	2.3	;	Structure of the human p73 tetramerization domain (crystal form II)
2OXE	;	2.8	;	Structure of the Human Pancreatic Lipase-related Protein 2
1CMI	;	2.5	;	STRUCTURE OF THE HUMAN PIN/LC8 DIMER WITH A BOUND PEPTIDE
6A70	;	3.6	;	Structure of the human PKD1/PKD2 complex
6ENY	;	5.8	;	Structure of the human PLC editing module
1W4M	;		;	Structure of the human pleckstrin DEP domain by multidimensional NMR
7S1T	;	2.9	;	Structure of the human POT1-TPP1 complex
5UN7	;	2.1	;	Structure of the human POT1-TPP1 telomeric complex
7SQF	;	3.1	;	Structure of the human proton-activated chloride channel ASOR in activated conformation
7SQH	;	2.5	;	Structure of the human proton-activated chloride channel ASOR in desensitized conformation
7SQG	;	2.6	;	Structure of the human proton-activated chloride channel ASOR in resting conformation
5LBY	;	1.4	;	Structure of the human quinone reductase 2 (NQO2) in complex with crenolanib
5LBT	;	1.75	;	Structure of the human quinone reductase 2 (NQO2) in complex with imiquimod
5LBZ	;	1.4	;	Structure of the human quinone reductase 2 (NQO2) in complex with pacritinib
5LBU	;	1.65	;	Structure of the human quinone reductase 2 (NQO2) in complex with to CL097
5LBW	;	1.9	;	Structure of the human quinone reductase 2 (NQO2) in complex with volitinib
6S5H	;	2.0	;	Structure of the human RAB38 in complex with GTP
6S5F	;	1.7	;	Structure of the human RAB39B in complex with GMPPNP
6Y7G	;	2.3	;	Structure of the human RAB3C in complex with GDP
6ZRC	;	2.6	;	Structure of the human RBAP48 in complex with a macrocyclic peptide cyclized via a xylene linker attached to two cysteines
6ZRD	;	2.5	;	STRUCTURE OF THE HUMAN RBAP48 in complex with a macrocyclic peptide cyclized via a xylene linker attached to two cysteines
4PBY	;	2.5	;	Structure of the human RbAp48-MTA1(656-686) complex
4PBZ	;	2.15	;	Structure of the human RbAp48-MTA1(670-695) complex
4PC0	;	2.5	;	Structure of the human RbAp48-MTA1(670-711) complex
5FXY	;	3.2	;	Structure of the human RBBP4:MTA1(464-546) complex
6G16	;	2.8	;	Structure of the human RBBP4:MTA1(464-546) complex showing loop exchange
2UZX	;	2.8	;	Structure of the human receptor tyrosine kinase Met in complex with the Listeria monocytogenes invasion protein InlB: Crystal form I
2UZY	;	4.0	;	Structure of the human receptor tyrosine kinase Met in complex with the Listeria monocytogenes invasion protein inlb: low resolution, Crystal form II
1L1O	;	2.8	;	Structure of the human Replication Protein A (RPA) trimerization core
6PZQ	;	2.703	;	Structure of the human respiratory syncytial virus M2-1 protein in complex with a short positive-sense gene-end RNA
2NN6	;	3.35	;	Structure of the human RNA exosome composed of Rrp41, Rrp45, Rrp46, Rrp43, Mtr3, Rrp42, Csl4, Rrp4, and Rrp40
6Z4A	;	1.46	;	Structure of the human SAS-6 N-terminal domain, F131E mutant
2Q2F	;	1.5	;	Structure of the human Selenoprotein S (VCP-interacting membrane protein)
2L9N	;		;	Structure of the human Shwachman-Bodian-Diamond syndrome (SBDS) protein
2KDO	;		;	Structure of the human Shwachman-Bodian-Diamond syndrome protein, SBDS
4QGK	;	2.1	;	Structure of the Human Sjogren Larsson Syndrome enzyme fatty aldehyde dehydrogenase (FALDH)
4HPF	;	3.4	;	Structure of the human SLO3 gating ring
4JKV	;	2.45	;	Structure of the human smoothened 7TM receptor in complex with an antitumor agent
4QIM	;	2.61	;	Structure of the human smoothened receptor in complex with ANTA XV
4QIN	;	2.6	;	Structure of the human smoothened receptor in complex with SAG1.5
4N4W	;	2.8	;	Structure of the human smoothened receptor in complex with SANT-1.
4PQO	;	2.55	;	Structure of the human SNX14 PX domain in space group I41
7ZYI	;	2.88	;	Structure of the human sodium/bile acid cotransporter (NTCP) in complex with Fab and nanobody
2V24	;	2.2	;	Structure of the human SPRY domain-containing SOCS box protein SSB-4
4P3E	;	3.5	;	Structure of the human SRP S domain
5M73	;	3.4	;	Structure of the human SRP S domain with SRP72 RNA-binding domain
5M72	;	1.6	;	Structure of the human SRP68-72 protein-binding domain complex
4P3F	;	1.699	;	Structure of the human SRP68-RBD
6L47	;	3.5	;	Structure of the human sterol O-acyltransferase 1 in complex with CI-976
6L48	;	3.5	;	Structure of the human sterol O-acyltransferase 1 in resting state
8GJX	;	2.6	;	Structure of the human STING receptor bound to 2'3'-cUA
5UGW	;	2.31	;	STRUCTURE OF THE HUMAN TELOMERASE THUMB DOMAIN
7APK	;	3.3	;	Structure of the human THO - UAP56 complex
7RRM	;	1.72	;	Structure of the human TMED1 (p24gamma1) Golgi dynamics Domain
7ZNL	;	3.45	;	Structure of the human TREX core THO-UAP56 complex
7ZRZ	;	3.09	;	Structure of the human tRNA splicing endonuclease defines substrate recognition
6CUD	;	3.3	;	Structure of the human TRPC3 in a lipid-occupied, closed state
6MHS	;	3.2	;	Structure of the human TRPV3 channel in a putative sensitized conformation
6MHO	;	3.4	;	Structure of the human TRPV3 channel in the apo conformation
4ZNY	;	2.4	;	Structure of the human TSG101-UEV Domain in complex with the PTAP motif of the p19 gag protein of the Human T-cell Leukemia type I virus
4YC1	;	2.0	;	Structure of the human TSG101-UEV domain in the P321 space group
6QW6	;	2.92	;	Structure of the human U5.U4/U6 tri-snRNP at 2.9A resolution.
2A4D	;	1.69	;	Structure of the human ubiquitin-conjugating enzyme E2 variant 1 (UEV-1)
8BJA	;	3.0	;	Structure of the human UBR5 Dimer.
8E0Q	;	2.66	;	Structure of the human UBR5 HECT-type E3 ubiquitin ligase in a C2 symmetric dimeric form
8D4X	;	2.8	;	Structure of the human UBR5 HECT-type E3 ubiquitin ligase in a dimeric form
8EWI	;	3.5	;	Structure of the human UBR5 HECT-type E3 ubiquitin ligase in a tetrameric form
7OVC	;		;	Structure of the human UFC1 protein in complex with the UBA5 C-terminal UFC1-binding motif.
8THR	;	3.12	;	Structure of the human vesicular monoamine transporter 2 (VMAT2) bound to tetrabenazine in an occluded conformation
2JK4	;	4.1	;	Structure of the human voltage-dependent anion channel
6AGF	;	3.2	;	Structure of the human voltage-gated sodium channel Nav1.4 in complex with beta1
6N8C	;		;	Structure of the Huntingtin tetramer/dimer mixture determined by paramagnetic NMR
1WMQ	;	1.6	;	Structure of the HutP antitermination complex bound to a single stranded region of hut mRNA
3H1D	;	1.892	;	Structure of the HUWE1 HECT Domain
5M3C	;	2.8	;	Structure of the hybrid domain (GGDEF-EAL) of PA0575 from Pseudomonas aeruginosa PAO1 at 2.8 Ang. with GTP and Ca2+ bound to the active site of the GGDEF domain
1IHA	;	1.6	;	Structure of the Hybrid RNA/DNA R-GCUUCGGC-D[BR]U in Presence of RH(NH3)6+++
1IDW	;	1.8	;	STRUCTURE OF THE HYBRID RNA/DNA R-GCUUCGGC-D[CL]U IN PRESENCE OF RH(NH3)6+++
1ICG	;	1.53	;	STRUCTURE OF THE HYBRID RNA/DNA R-GCUUCGGC-D[F]U IN PRESENCE OF IR(NH3)6+++
1ID9	;	1.6	;	STRUCTURE OF THE HYBRID RNA/DNA R-GCUUCGGC-D[F]U IN PRESENCE OF RH(NH3)6+++
3DQZ	;	2.504	;	Structure of the hydroxynitrile lyase from Arabidopsis thaliana
6OAY	;	3.3	;	Structure of the hyperactive ClpB mutant K476C, bound to casein, post-state
6OAX	;	2.9	;	Structure of the hyperactive ClpB mutant K476C, bound to casein, pre-state
3PZI	;	1.55	;	Structure of the hyperthermostable endo-1,4-beta-D-mannanase from Thermotoga petrophila RKU-1 in complex with beta-D-glucose
3PZO	;	1.55	;	Structure of the hyperthermostable endo-1,4-beta-D-mannanase from Thermotoga petrophila RKU-1 in complex with three maltose molecules
3PZN	;	1.5	;	Structure of the hyperthermostable endo-1,4-beta-D-mannanase from Thermotoga petrophila RKU-1 with citrate and glycerol
3PZQ	;	1.92	;	Structure of the hyperthermostable endo-1,4-beta-D-mannanase from Thermotoga petrophila RKU-1 with maltose and glycerol
3PZM	;	1.5	;	Structure of the hyperthermostable endo-1,4-beta-D-mannanase from Thermotoga petrophila RKU-1 with three glycerol molecules
8P6K	;	1.918	;	Structure of the hypervariable region of Streptococcus pyogenes M3 protein
8P6J	;	2.324	;	Structure of the hypervariable region of Streptococcus pyogenes M3 protein in complex with a collagen peptide
1YEL	;		;	Structure of the hypothetical Arabidopsis thaliana protein At1g16640.1
1ZCH	;	1.85	;	Structure of the hypothetical oxidoreductase YcnD from Bacillus subtilis
2W56	;	1.9	;	Structure of the hypothetical protein VC0508 from Vibrio cholerae VSP- II pathogenicity island
1NNX	;	1.45	;	Structure of the hypothetical protein ygiW from E. coli.
6AXW	;	2.4	;	Structure of the I124A mutant of the HIV-1 capsid protein
6MI4	;	2.50009	;	Structure of the I65M mutant of NEMO(51-112) with N- and C-terminal coiled-coil adaptors.
6S8T	;	2.17	;	Structure of the ICAM-1-binding PfEMP1 IT4var13 DBLbeta domain
3J7Q	;	3.4	;	Structure of the idle mammalian ribosome-Sec61 complex
8BBG	;	3.5	;	Structure of the IFT-A complex; anterograde IFT-A train model
8BBF	;	8.0	;	Structure of the IFT-A complex; IFT-A1 module
8BBE	;	3.5	;	Structure of the IFT-A complex; IFT-A2 module
1BOE	;		;	STRUCTURE OF THE IGF BINDING DOMAIN OF THE INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN-5 (IGFBP-5): IMPLICATIONS FOR IGF AND IGF-I RECEPTOR INTERACTIONS
3LQM	;	2.14	;	Structure of the IL-10R2 Common Chain
7UWM	;	2.5	;	Structure of the IL-17A-IL-17RA binary complex
7UWN	;	3.01	;	Structure of the IL-17A-IL-17RA-IL-17RC ternary complex
4DEP	;	3.1	;	Structure of the IL-1b signaling complex
7UWL	;	3.7	;	Structure of the IL-25-IL-17RB-IL-17RA ternary complex
8TLD	;	3.6	;	Structure of the IL-5 Signaling Complex
6E8S	;	2.35	;	Structure of the iMango-III aptamer bound to TO1-Biotin
6PQ7	;	3.0	;	Structure of the iMango-III fluorescent aptamer at room temperature.
3PH2	;	1.4	;	Structure of the imidazole-adduct of the Phormidium laminosum cytochrome c6 Q51V variant
1DY6	;	2.13	;	Structure of the imipenem-hydrolyzing beta-lactamase SME-1
8PUH	;	6.2	;	Structure of the immature HTLV-1 CA lattice from full-length Gag VLPs: CA-CTD refinement
8PUG	;	5.9	;	Structure of the immature HTLV-1 CA lattice from full-length Gag VLPs: CA-NTD refinement
5JJ1	;	3.3	;	Structure of the Immature Procapsid Conformation of P22 Portal Protein
4ARD	;	7.0	;	Structure of the immature retroviral capsid at 8A resolution by cryo- electron microscopy
4ARG	;	7.0	;	Structure of the immature retroviral capsid at 8A resolution by cryo- electron microscopy
5IHB	;	2.24	;	Structure of the immune receptor CD33
5J06	;	2.66	;	Structure of the immune receptor CD33 in complex with 3'-sialyllactose
5J0B	;	2.48	;	Structure of the immune receptor CD33 in complex with 6'-sialyllactose
2J8H	;	1.99	;	Structure of the immunoglobulin tandem repeat A168-A169 of titin
2J8O	;	2.49	;	Structure of the immunoglobulin tandem repeat of titin A168-A169
2FRG	;	1.19	;	Structure of the immunoglobulin-like domain of human TLT-1
2VSC	;	1.9	;	Structure of the immunoglobulin-superfamily ectodomain of human CD47
4XWU	;	1.75	;	Structure of the IMP dehydrogenase from Ashbya gossypii
4Z87	;	2.25	;	Structure of the IMP dehydrogenase from Ashbya gossypii bound to GDP
8P4Q	;	1.88	;	Structure of the IMP dehydrogenase related protein GUAB3 from Synechocystis PCC 6803
5C1F	;	2.3551	;	Structure of the Imp2 F-BAR domain
4Z0G	;	1.25	;	Structure of the IMPDH from Ashbya gossypii bound to GMP
2CIU	;	1.6	;	Structure of the IMS domain of the mitochondrial import protein Tim21 from S. cerevisiae
7N9F	;	37.0	;	Structure of the in situ yeast NPC
5FJ5	;	4.8	;	Structure of the in vitro assembled bacteriophage phi6 polymerase complex
4EKF	;	0.98	;	Structure of the Inactive Adenovirus Proteinase at 0.98 Angstrom Resolution
4LZL	;	1.55	;	Structure of the inactive form of the regulatory domain from the repressor of iron transport regulator (RitR)
7D8N	;	2.753	;	Structure of the inactive form of wild-type peptidylarginine deiminase type III (PAD3) crystallized under the condition with high concentrations of Ca2+
4ARL	;	1.999	;	Structure of the inactive pesticin D207A mutant
4ARP	;	2.296	;	Structure of the inactive pesticin E178A mutant
4ARM	;	2.002	;	Structure of the inactive pesticin T201A mutant
4ELL	;	1.98	;	Structure of the inactive retinoblastoma protein pocket domain
5O7F	;	1.9	;	Structure of the inactive T.maritima PDE (TM1595) D80N D154N mutant with GMP and Mn2+
5O70	;	1.55	;	Structure of the inactive T.maritima PDE (TM1595) D80N D154N mutant with reaction products 2 AMP
5O4Z	;	1.7	;	Structure of the inactive T.maritima PDE (TM1595) D80N D154N mutant with substrate 5'-pApA
5O58	;	1.55	;	Structure of the inactive T.maritima PDE (TM1595) D80N D154N mutant with substrate 5'-pApG
2LJB	;		;	Structure of the influenza AM2-BM2 chimeric channel
2LJC	;		;	Structure of the influenza AM2-BM2 chimeric channel bound to rimantadine
2Q0S	;	1.5	;	Structure of the Inhibitor bound form of M. Smegmatis Aryl Esterase
1O3W	;	1.85	;	Structure of the inhibitor free triple mutant (K53,56,120M) of phospholipase A2
6E7D	;	2.9	;	Structure of the inhibitory NKR-P1B receptor bound to the host-encoded ligand, Clr-b
7TN9	;	3.1	;	Structure of the Inmazeb cocktail and resistance to escape against Ebola virus
4JD0	;	1.8	;	Structure of the inositol-1-phosphate CTP transferase from T. maritima.
8UVT	;	2.9	;	Structure of the insect gustatory receptor Gr9 from Bombyx mori
8UVU	;	3.0	;	Structure of the insect gustatory receptor Gr9 from Bombyx mori in complex with D-fructose
8VV3	;	2.61	;	Structure of the insect gustatory receptor Gr9 from Bombyx mori in complex with L-sorbose
2KSL	;		;	Structure of the insecticidal toxin TaITX-1
1K3A	;	2.1	;	Structure of the Insulin-like Growth Factor 1 Receptor Kinase
5V74	;	3.51015	;	Structure of the intact Haliangium ochraceum microcompartment shell
8GWA	;	2.9	;	Structure of the intact photosynthetic light-harvesting antenna-reaction center complex from a green sulfur bacterium
7BFQ	;	4.15	;	Structure of the Integrator cleavage module with extended INTS4 and rigid body docked INTS9/11 CTD
7BFP	;	3.56	;	Structure of the Integrator cleavage module with INTS4/9/11
7KN0	;		;	Structure of the integrin aIIb(W968V)b3 transmembrane complex
1Q7D	;	1.8	;	Structure of the integrin alpha2beta1 binding collagen peptide
2N9Y	;		;	Structure of the Integrin alphaIIb-beta3(A711P) Transmembrane Complex
6V4P	;	2.8	;	Structure of the integrin AlphaIIbBeta3-Abciximab complex
2L91	;		;	Structure of the Integrin beta3 (A711P,K716A) Transmembrane Segment
4GS7	;	2.35	;	Structure of the Interleukin-15 quaternary complex
6JZF	;	2.534	;	Structure of the intermembrane space region of PARC6
6JZN	;	2.894	;	Structure of the intermembrane space region of PARC6-PDV1
3NAF	;	3.1	;	Structure of the Intracellular Gating Ring from the Human High-conductance Ca2+ gated K+ Channel (BK Channel)
3UQC	;	2.256	;	Structure of the Intracellular Kinase Homology Domain of Rv3910 at 2.2 A resolution
7LIR	;	2.6	;	Structure of the invertebrate ALK GRD
6O94	;	1.98	;	Structure of the IRAK4 kinase domain with compound 17
6O95	;	1.77	;	Structure of the IRAK4 kinase domain with compound 41
6O9D	;	2.51	;	Structure of the IRAK4 kinase domain with compound 5
5U1M	;	1.8	;	Structure of the IRS-1 PTB Domain Bound to the Juxtamembrane Region of the Insulin Receptor
1T3M	;	1.65	;	Structure of the isoaspartyl peptidase with L-asparaginase activity from E. coli
3REM	;	1.95	;	Structure of the Isochorismate-Pyruvate Lyase from Pseudomonas aerugionsa with Bound Salicylate and Pyruvate
8TH2	;	2.6	;	Structure of the isoflavene-forming dirigent protein PsPTS2
6ZIL	;	3.12	;	Structure of the isolated REC domain of RcsB from Salmonella enterica serovar Typhimurium in the apo form
6ZII	;	2.5	;	Structure of the isolated REC domain of RcsB from Salmonella enterica serovar Typhimurium in the presence of phosphomimetic BeF3-
5LL3	;	2.15	;	Structure of the Isoleucine 2-epimerase from Lactobacillus buchneri (PLP complex form)
8BY2	;	3.18	;	Structure of the K+/H+ exchanger KefC with GSH.
6P7V	;	4.0	;	Structure of the K. lactis CBF3 core
6P7W	;	4.1	;	Structure of the K. lactis CBF3 core - Ndc10 D1 complex
6P7X	;	4.3	;	Structure of the K. lactis CBF3 core - Ndc10 D1D2 complex
7SBE	;	2.65	;	Structure of the K. lactis telomerase RNA binding domain
5HSZ	;	2.3	;	Structure of the K. pneumonia SlmA protein bound to the C-terminal tail of the cytoskeletal cell division protein FtsZ
5K58	;	2.772	;	Structure of the K. pneumonia SlmA-DNA complex bound to the C-terminal of the cell division protein FtsZ
8BXG	;	3.16	;	Structure of the K/H exchanger KefC.
1SVK	;	2.0	;	Structure of the K180P mutant of Gi alpha subunit bound to AlF4 and GDP
1SVS	;	1.5	;	Structure of the K180P mutant of Gi alpha subunit bound to GppNHp.
2XQ2	;	2.73	;	Structure of the K294A mutant of vSGLT
2ZJY	;	2.8	;	Structure of the K349P mutant of Gi alpha 1 subunit bound to ALF4 and GDP
2ZJZ	;	2.6	;	Structure of the K349P mutant of Gi alpha 1 subunit bound to GDP
1STX	;	2.1	;	Structure of the K38A mutant of EcoRV bound to cognate DNA and Mn2+
8DZL	;	1.36	;	Structure of the K39Q mutant of rat somatic Cytochrome c at 1.36A
8AIW	;	2.0	;	Structure of the K5/CagI complex
3RSK	;	2.0	;	STRUCTURE OF THE K7A/R10A/K66A VARIANT OF RIBONUCLEASE A
4RSK	;	2.1	;	STRUCTURE OF THE K7A/R10A/K66A VARIANT OF RIBONUCLEASE A COMPLEXED WITH 3'-UMP
1YAE	;	3.11	;	Structure of the Kainate Receptor Subunit GluR6 Agonist Binding Domain Complexed with Domoic Acid
6BFH	;	1.95	;	Structure of the kanamycin complex of aminoglycoside acetyltransferase AAC(6')-Im
5YBU	;	1.89	;	Structure of the KANK1 ankyrin domain in complex with KIF21A peptide
2C1T	;	2.6	;	Structure of the Kap60p:Nup2 complex
7AG9	;	3.3	;	Structure of the Kar9 protein
1QBK	;	3.0	;	STRUCTURE OF THE KARYOPHERIN BETA2-RAN GPPNHP NUCLEAR TRANSPORT COMPLEX
6NFU	;	2.09	;	Structure of the KcsA-G77A mutant or the 2,4-ion bound configuration of a K+ channel selectivity filter.
6NFV	;	2.13	;	Structure of the KcsA-G77C mutant or the 2,4-ion bound configuration of a K+ channel selectivity filter.
7SQW	;	3.21	;	Structure of the KcsA-W67F mutant with the activation gate in the closed conformation
6TE1	;	3.11	;	Structure of the KDM1A/CoREST complex with the inhibitor 2-[3-{4-chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethanol
5LHH	;	3.05	;	Structure of the KDM1A/CoREST complex with the inhibitor 4-ethyl-N-[3-(methoxymethyl)-2-[[4-[[(3R)-pyrrolidin-3-yl]methoxy]phenoxy]methyl]phenyl]thieno[3,2-b]pyrrole-5-carboxamide
5LHG	;	3.34	;	Structure of the KDM1A/CoREST complex with the inhibitor 4-methyl-N-[4-[[4-(1-methylpiperidin-4-yl)oxyphenoxy]methyl]phenyl]thieno[3,2-b]pyrrole-5-carboxamide
5LHI	;	3.4	;	Structure of the KDM1A/CoREST complex with the inhibitor N-[3-(ethoxymethyl)-2-[[4-[[(3R)-pyrrolidin-3-yl]methoxy]phenoxy]methyl]phenyl]-4-methylthieno[3,2-b]pyrrole-5-carboxamide
5MRW	;	2.9	;	Structure of the KdpFABC complex
5FNQ	;	1.91	;	Structure of the Keap1 Kelch domain in complex with a small molecule inhibitor.
5FNR	;	1.89	;	Structure of the Keap1 Kelch domain in complex with a small molecule inhibitor.
5FNS	;	1.79	;	Structure of the Keap1 Kelch domain in complex with a small molecule inhibitor.
5FNT	;	1.79	;	Structure of the Keap1 Kelch domain in complex with a small molecule inhibitor.
5FNU	;	1.78	;	Structure of the Keap1 Kelch domain in complex with a small molecule inhibitor.
5FZJ	;	2.01	;	Structure of the Keap1 Kelch domain in complex with a small molecule inhibitor.
5FZN	;	1.97	;	Structure of the Keap1 Kelch domain in complex with a small molecule inhibitor.
8IN0	;	1.8	;	Structure of the Keap1 Kelch domain in complex with PGAM5-derived peptide
8CRA	;	2.4	;	Structure of the keratin-like domain of SEPALLATA3 and AGAMOUS from Arabidopsis thaliana
4Z37	;	1.998	;	Structure of the ketosynthase of module 2 of C0ZGQ5 (trans-AT PKS) from Brevibacillus brevis
2HG4	;	2.73	;	Structure of the ketosynthase-acyltransferase didomain of module 5 from DEBS.
5EL3	;	1.59	;	Structure of the KH domain of T-STAR
5ELS	;	2.873	;	Structure of the KH domain of T-STAR in complex with AAAUAA RNA
5ELR	;	2.3	;	Structure of the KH-QUA2 domain of T-STAR in complex with AAUAAU RNA
3OSE	;	1.7	;	Structure of the Kinase Associated Domain 1 (KA1) from MARK1 kinase
3OSM	;	1.7	;	Structure of the Kinase Associated Domain-1 (KA1) from Kcc4p
3OST	;	1.694	;	Structure of the Kinase Associated-1 (KA1) from Kcc4p
2F4J	;	1.91	;	Structure of the Kinase Domain of an Imatinib-Resistant Abl Mutant in Complex with the Aurora Kinase Inhibitor VX-680
3LQ8	;	2.02	;	Structure of the kinase domain of c-Met bound to XL880 (GSK1363089)
6HP9	;	1.96	;	Structure of the kinase domain of human DDR1 in complex with a 2-Amino-2,3-Dihydro-1H-Indene-5-Carboxamide-based inhibitor
6GWR	;	2.07	;	Structure of the kinase domain of human DDR1 in complex with a potent and selective inhibitor of DDR1 and DDR2
4C8B	;	2.75	;	Structure of the kinase domain of human RIPK2 in complex with ponatinib
6FU5	;	3.26	;	Structure of the kinase domain of human RIPK2 in complex with the inhibitor CSLP18
6S1F	;	3.11	;	Structure of the kinase domain of human RIPK2 in complex with the inhibitor CSLP3
6RX7	;	1.63	;	Structure of the KIV type 2 (KIV-2) domain of lipoprotein (a)
6PIB	;	2.26	;	Structure of the Klebsiella pneumoniae LpxH-AZ1 complex
8YGY	;	2.401	;	Structure of the KLK1 from Biortus.
5IT7	;	3.6	;	Structure of the Kluyveromyces lactis 80S ribosome in complex with the cricket paralysis virus IRES and eEF2
4NF9	;	2.8	;	Structure of the Knl1/Nsl1 complex
4YTK	;	1.0904	;	Structure of the KOW1-Linker1 domain of Transcription Elongation Factor Spt5
4YTL	;	1.601	;	Structure of the KOW2-KOW3 Domain of Transcription Elongation Factor Spt5.
6HOS	;	2.15	;	Structure of the KpFlo2 adhesin domain in complex with glycerol
4QMF	;	2.804	;	Structure of the Krr1 and Faf1 complex from Saccharomyces cerevisiae
5DVH	;	1.8	;	Structure of the Kunitz-type cysteine protease inhibitor PCPI-3 from potato
6OAR	;	2.063	;	Structure of the Kupe virus OTU bound to the C-terminal domain of sheep ISG15
5A22	;	3.8	;	Structure of the L protein of vesicular stomatitis virus from electron cryomicroscopy
2W11	;	1.9	;	Structure of the L-2-haloacid dehalogenase from Sulfolobus tokodaii
1M1C	;	3.5	;	Structure of the L-A virus
2LBP	;	2.4	;	STRUCTURE OF THE L-LEUCINE-BINDING PROTEIN REFINED AT 2.4 ANGSTROMS RESOLUTION AND COMPARISON WITH THE LEU(SLASH)ILE(SLASH)VAL-BINDING PROTEIN STRUCTURE
7TU6	;	2.7	;	Structure of the L. blandensis dGTPase bound to dATP
7TU0	;	2.04	;	Structure of the L. blandensis dGTPase bound to Mn
7TU3	;	2.17	;	Structure of the L. blandensis dGTPase del55-58 mutant
7TU4	;	2.26	;	Structure of the L. blandensis dGTPase del55-58 mutant bound to Mn
7TU7	;	2.5	;	Structure of the L. blandensis dGTPase H125A mutant bound to dGTP
7TU8	;	2.6	;	Structure of the L. blandensis dGTPase H125A mutant bound to dGTP and dATP
7TU5	;	2.1	;	Structure of the L. blandensis dGTPase in the apo form
7TU1	;	1.8	;	Structure of the L. blandensis dGTPase R37A mutant
7TU2	;	2.13	;	Structure of the L. blandensis dGTPase R37A mutant bound to Mn
1MZP	;	2.65	;	Structure of the L1 protuberance in the ribosome
4HSW	;	1.22	;	Structure of the L100F mutant of dehaloperoxidase-hemoglobin A from Amphitrite ornata
4KMV	;	1.44	;	Structure of the L100F MUTANT OF DEHALOPEROXIDASE-HEMOGLOBIN A FROM AMPHITRITE ORNATA WITH 2,4,6-TRICHLOROPHENOL
4HSX	;	1.12	;	Structure of the L100F mutant of dehaloperoxidase-hemoglobin A from Amphitrite ornata with 4-bromophenol
4KJT	;	1.44	;	Structure of the L100F MUTANT OF DEHALOPEROXIDASE-HEMOGLOBIN A FROM AMPHITRITE ORNATA WITH OXYGEN
3V9E	;	1.7	;	Structure of the L499M mutant of the laccase from B.aclada
5AMQ	;	3.0	;	Structure of the La Crosse Bunyavirus polymerase in complex with the 3' and 5' viral RNA
5AMR	;	2.57	;	Structure of the La Crosse Bunyavirus polymerase in complex with the 3' viral RNA
2YJG	;	1.8	;	Structure of the lactate racemase apoprotein from Thermoanaerobacterium thermosaccharolyticum
4RGG	;	2.15	;	Structure of the lactococcal phage 1358 receptor binding protein in complex with GlcNAc-1P
6XN5	;	2.97	;	Structure of the Lactococcus lactis Csm Apo- CRISPR-Cas Complex
6XN4	;	3.35	;	Structure of the Lactococcus lactis Csm CTR_3:2 CRISPR-Cas Complex
6XN3	;	3.0	;	Structure of the Lactococcus lactis Csm CTR_4:3 CRISPR-Cas Complex
6XN7	;	3.47	;	Structure of the Lactococcus lactis Csm NTR CRISPR-Cas Complex
1ZRU	;	1.73	;	structure of the lactophage p2 receptor binding protein in complex with glycerol
2W2S	;	2.75	;	Structure of the Lagos bat virus matrix protein
8IB1	;	1.95	;	Structure of the LAH31 Fab bound to an influenza virus HA epitope peptide
6WU4	;	3.71	;	Structure of the LaINDY-alpha-ketoglutarate complex
6WU2	;	3.36	;	Structure of the LaINDY-malate complex
1AE9	;	1.9	;	STRUCTURE OF THE LAMBDA INTEGRASE CATALYTIC CORE
4ZLH	;	2.0	;	Structure of the LapB cytoplasmic domain at 2 angstroms
1KT0	;	2.7	;	Structure of the Large FKBP-like Protein, FKBP51, Involved in Steroid Receptor Complexes
1KT1	;	2.8	;	Structure of the Large FKBP-like Protein, FKBP51, Involved in Steroid Receptor Complexes
3LWM	;	2.186	;	Structure of the large fragment of thermus aquaticus DNA polymerase I in complex with a blunt-ended DNA and ddATP
1KK0	;	1.95	;	Structure of the large gamma subunit of initiation factor eIF2 from Pyrococcus abyssi
1KJZ	;	1.85	;	Structure of the large gamma subunit of initiation factor eIF2 from Pyrococcus abyssi-G235D mutant
1KK2	;	2.1	;	Structure of the large gamma subunit of initiation factor eIF2 from Pyrococcus abyssi-G235D mutant complexed with GDP-Mg2+
1KK1	;	1.8	;	Structure of the large gamma subunit of initiation factor eIF2 from Pyrococcus abyssi-G235D mutant complexed with GDPNP-Mg2+
1NO7	;	2.9	;	Structure of the Large Protease Resistant Upper Domain of VP5, the Major Capsid Protein of Herpes Simplex Virus-1
3J7Y	;	3.4	;	Structure of the large ribosomal subunit from human mitochondria
5H1S	;	3.5	;	Structure of the large subunit of the chloro-ribosome
5MMI	;	3.2	;	Structure of the large subunit of the chloroplast ribosome
4V19	;	3.4	;	Structure of the large subunit of the mammalian mitoribosome, part 1 of 2
4V1A	;	3.4	;	Structure of the large subunit of the mammalian mitoribosome, part 2 of 2
7T0X	;	4.4	;	Structure of the larger diameter PSMalpha3 nanotube
5J01	;	3.39	;	Structure of the lariat form of a chimeric derivative of the Oceanobacillus iheyensis group II intron in the presence of NH4+ and MG2+.
5J02	;	3.493	;	Structure of the lariat form of a chimeric derivative of the Oceanobacillus iheyensis group II intron in the presence of NH4+, MG2+ and an inactive 5' exon.
5C0V	;	2.2	;	Structure of the LARP1-unique domain DM15
7AG5	;	1.04	;	Structure of the Laspartomycin C double mutant G4D D-allo-Thr9D-Dap in complex with Geranyl phosphate
7ANY	;	1.135	;	Structure of the Laspartomycin C Friulimicin-like mutant in complex with Geranyl phosphate
6S5I	;	2.45	;	Structure of the Lausanne variant of myxoma virus M062 protein
4U9C	;	1.995	;	STRUCTURE OF THE LBPB N-LOBE FROM NEISSERIA MENINGITIDIS
4OX3	;	2.0	;	Structure of the LdcB LD-carboxypeptidase reveals the molecular basis of peptidoglycan recognition
4OX5	;	1.8	;	Structure of the LdcB LD-carboxypeptidase reveals the molecular basis of peptidoglycan recognition
4OXD	;	2.8	;	Structure of the LdcB LD-carboxypeptidase reveals the molecular basis of peptidoglycan recognition
6FJ1	;	2.69	;	Structure of the Ldtfm-avibactam carbamoyl enzyme
7Z62	;	1.53	;	Structure of the LecA lectin from Pseudomonas aeruginosa in complex with a biaryl-thiogalactoside
7Z63	;	1.75	;	Structure of the LecA lectin from Pseudomonas aeruginosa in complex with a biaryl-thiogalactoside
5MB1	;	1.65	;	STRUCTURE OF THE LECB LECTIN FROM PSEUDOMONAS AERUGINOSA STRAIN PA14 IN COMPLEX WITH 2,4,6-Trimethylphenylsulfonamide-N-methyl-L-fucopyranoside
5MAY	;	1.65	;	STRUCTURE OF THE LECB LECTIN FROM PSEUDOMONAS AERUGINOSA STRAIN PA14 IN COMPLEX WITH 2-Thiophenesulfonamide-N-(beta-L-fucopyranosyl methyl)
5MAZ	;	1.45	;	STRUCTURE OF THE LECB LECTIN FROM PSEUDOMONAS AERUGINOSA STRAIN PA14 IN COMPLEX WITH 3-Thiophenesulfonamide-2,5-dimethyl-N-methyl-beta-L-fucopyranoside
5A6X	;	1.55	;	Structure of the LecB lectin from Pseudomonas aeruginosa strain PA14 in complex with alpha-methyl-fucoside
5A6Z	;	1.5	;	Structure of the LecB lectin from Pseudomonas aeruginosa strain PA14 in complex with lewis a
5A70	;	1.6	;	Structure of the LecB lectin from Pseudomonas aeruginosa strain PA14 in complex with lewis x tetrasaccharide
5A6Y	;	1.4	;	Structure of the LecB lectin from Pseudomonas aeruginosa strain PA14 in complex with mannose-alpha1,3mannoside
6R35	;	1.8	;	Structure of the LecB lectin from Pseudomonas aeruginosa strain PAO1 in complex with lewis x tetrasaccharide
8AIJ	;	1.5	;	STRUCTURE OF THE LECB LECTIN FROM PSEUDOMONAS AERUGINOSA STRAIN PAO1 IN COMPLEX WITH N-(alpha-L-Fucopyranosyl)benzamide (6)
8AIY	;	1.55	;	STRUCTURE OF THE LECB LECTIN FROM PSEUDOMONAS AERUGINOSA STRAIN PAO1 IN COMPLEX WITH N-(beta-L-Fucopyranosyl)-biphenyl-3-carboxamide (4i)
3ZW2	;	1.6	;	Structure of the lectin Bambl from Burkholderia ambifaria in complex with blood group H type 1 tetrasaccharide
3ZVX	;	2.1	;	STRUCTURE OF THE LECTIN FROM PLATYPODIUM ELEGANS IN COMPLEX WITH A TRIMANNOSIDE
3ZYR	;	1.65	;	Structure of the lectin from Platypodium elegans in complex with heptasaccharide
1JOT	;	2.2	;	STRUCTURE OF THE LECTIN MPA COMPLEXED WITH T-ANTIGEN DISACCHARIDE
5K35	;	2.85	;	Structure of the Legionella effector, AnkB, in complex with human Skp1
8AGG	;	3.6	;	Structure of the Legionella phosphocholine hydrolase Lem3
8ALK	;	2.15	;	Structure of the Legionella phosphocholine hydrolase Lem3 in complex with its substrate Rab1
5OT4	;	3.0	;	Structure of the Legionella pneumophila effector RidL (1-866)
6SY9	;	2.1	;	Structure of the Legionella pneumophila response regulator LqsR
2JQD	;		;	Structure of the Leucine-Rich Repeat domain of LANP
4FCG	;	2.0	;	Structure of the leucine-rich repeat domain of the type III effector XCV3220 (XopL)
8FAC	;	3.92	;	Structure of the leucine-rich repeat kinase 1 monomer
3E0G	;	3.1	;	Structure of the Leukemia Inhibitory Factor Receptor (LIF-R) domains D1-D5
1L1C	;		;	Structure of the LicT Bacterial Antiterminator Protein in Complex with its RNA Target
7AD9	;	3.5	;	Structure of the Lifeact-F-actin complex
2HXR	;	2.05	;	Structure of the ligand binding domain of E. coli CynR, a transcriptional regulator controlling cyanate metabolism
7QEJ	;	1.81	;	Structure of the ligand binding domain of the antibiotic biosynthesis regulator AdmX from the rhizobacterium Serratia plymuthica A153 bound to the auxin indole-3-acetic acid (IAA).
7QEK	;	2.25	;	Structure of the ligand binding domain of the antibiotic biosynthesis regulator AdmX from the rhizobacterium Serratia plymuthica A153 bound to the auxin indole-3-piruvic acid (IPA).
3ATP	;	2.5	;	Structure of the ligand binding domain of the bacterial serine chemoreceptor Tsr with ligand
7PSG	;	1.91	;	Structure of the ligand binding domain of the PacA (ECA2226) chemoreceptor of Pectobacterium atrosepticum SCRI1043 in complex with betaine.
7PRR	;	1.8	;	Structure of the ligand binding domain of the PctD (PA4633) chemoreceptor of Pseudomonas aeruginosa PAO1 in complex with acetylcholine
7PRQ	;	2.0	;	Structure of the ligand binding domain of the PctD (PA4633) chemoreceptor of Pseudomonas aeruginosa PAO1 in complex with choline.
1XAP	;	2.1	;	Structure of the ligand binding domain of the Retinoic Acid Receptor beta
6XA3	;	2.96	;	Structure of the ligand free P450 monooxygenase TamI
8FWS	;	3.23	;	Structure of the ligand-binding and transmembrane domains of kainate receptor GluK2 in complex with the positive allosteric modulator BPAM344
8FWU	;	3.18	;	Structure of the ligand-binding and transmembrane domains of kainate receptor GluK2 in complex with the positive allosteric modulator BPAM344 and competitive antagonist DNQX
8FWW	;	3.1	;	Structure of the ligand-binding and transmembrane domains of kainate receptor GluK2 in complex with the positive allosteric modulator BPAM344 and noncompetitive inhibitor perampanel
3BFU	;	1.95	;	Structure of the ligand-binding core of GluR2 in complex with the agonist (R)-TDPA at 1.95 A resolution
3BFT	;	2.27	;	Structure of the ligand-binding core of GluR2 in complex with the agonist (S)-TDPA at 2.25 A resolution
2V3U	;	1.74	;	Structure of the ligand-binding core of the ionotropic glutamate receptor-like GluRdelta2 in complex with D-serine
2V3T	;	2.75	;	Structure of the ligand-binding core of the ionotropic glutamate receptor-like GluRdelta2 in the apo form
4YMA	;	1.895	;	Structure of the ligand-binding domain of GluA2 in complex with the antagonist CNG10109
4YMB	;	1.93	;	Structure of the ligand-binding domain of GluK1 in complex with the antagonist CNG10111
7XB5	;	3.44	;	Structure of the ligand-binding domain of S. cerevisiae Upc2 in fusion with T4 lysozyme
5CC2	;	2.501	;	STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE IONOTROPIC GLUTAMATE RECEPTOR-LIKE GLUD2 IN COMPLEX WITH 7-CKA
3C1Z	;	2.3	;	Structure of the ligand-free form of a bacterial DNA damage sensor protein
6GGP	;	1.03	;	Structure of the ligand-free form of truncated ArgBP (residues 20-233) from T. maritima
7QB9	;	3.1	;	Structure of the ligand-free GPCR dimer Ste2
2G7N	;	1.9	;	Structure of the Light Chain of Botulinum Neurotoxin Serotype A Bound to small Molecule Inhibitors
2G7P	;	2.3	;	Structure of the Light Chain of Botulinum Neurotoxin Serotype A Bound to Small Molecule Inhibitors
2G7Q	;	2.41	;	Structure of the Light Chain of Botulinum Neurotoxin Serotype A Bound to Small Molecule Inhibitors
2G7K	;	2.8	;	Structure of the Light Chain of Botulinum Neurotoxin, Serotype A Bound to small Molecule Inhibitors
7S96	;	1.8	;	Structure of the Light Harvesting Complex PC577 from Hemiselmis pacifica
7TJA	;	1.96	;	Structure of the Light Harvesting Complex PE545 from Proteomonas sulcata
3AEK	;	2.3	;	Structure of the light-independent protochlorophyllide reductase catalyzing a key reduction for greening in the dark
3AEQ	;	2.9	;	Structure of the light-independent protochlorophyllide reductase catalyzing a key reduction for greening in the dark
3AER	;	2.8	;	Structure of the light-independent protochlorophyllide reductase catalyzing a key reduction for greening in the dark
3AES	;	2.5	;	Structure of the light-independent protochlorophyllide reductase catalyzing a key reduction for greening in the dark
3AET	;	2.91	;	Structure of the light-independent protochlorophyllide reductase catalyzing a key reduction for greening in the dark
3AEU	;	2.9	;	Structure of the light-independent protochlorophyllide reductase catalyzing a key reduction for greening in the dark
5DKL	;	2.7	;	Structure of the light-state dimer of the blue light photoreceptor Aureochrome 1a LOV from P. tricornutum
5L6W	;	2.53	;	Structure Of the LIMK1-ATPgammaS-CFL1 Complex
6E7K	;	2.8	;	Structure of the lipoprotein lipase GPIHBP1 complex that mediates plasma triglyceride hydrolysis
8CGM	;	1.7	;	Structure of the lipoprotein transporter LolA from Porphyromonas gingivalis
7TEC	;	3.45	;	Structure of the Listeria monocytogenes GlnR-DNA complex to 3.45 Angstrom
5WXN	;	2.93	;	Structure of the LKB1 and 14-3-3 complex
6FIJ	;	2.77	;	Structure of the loading/condensing region (SAT-KS-MAT) of the cercosporin fungal non-reducing polyketide synthase (NR-PKS) CTB1
1WOA	;	2.8	;	Structure of the loop6 hinge mutant of Plasmodium falciparum Triosephosphate Isomerase, W168F, complexed with Glycerol-2-phosphate
8E8U	;	2.65	;	Structure of the LOR domain of human AASS
5NT7	;	1.4	;	Structure of the LOTUS domain of Oskar in complex with the C-terminal RecA-like domain of Vasa
8A6I	;		;	Structure of the low complexity domain of TDP-43 (fragment 309-350) with methionine sulfoxide modifications
2E7X	;	1.8	;	Structure of the Lrp/AsnC like transcriptional regulator from Sulfolobus tokodaii 7 complexed with its cognate ligand
4WYK	;	3.4	;	Structure of the LRR and NTF2-like domains of NXF1 complexed with NXT1
7LHT	;	3.5	;	Structure of the LRRK2 dimer
7LI3	;	3.8	;	Structure of the LRRK2 G2019S mutant
7LHW	;	3.7	;	Structure of the LRRK2 monomer
3SWN	;	2.5	;	Structure of the LSm657 Complex: An Assembly Intermediate of the LSm1 7 and LSm2 8 Rings
4W8O	;	2.05	;	Structure of the luciferase-like enzyme from the nonluminescent Zophobas morio mealworm
2AY0	;	2.1	;	Structure of the Lys9Met mutant of the E. coli Proline Utilization A (PutA) DNA-binding domain.
8BEZ	;	1.75	;	Structure of the Lysinibacillus sphaericus Tpp49Aa1 pesticidal protein at pH 11
8BEX	;	1.78	;	Structure of the Lysinibacillus sphaericus Tpp49Aa1 pesticidal protein at pH 3
8BEY	;	1.62	;	Structure of the Lysinibacillus sphaericus Tpp49Aa1 pesticidal protein at pH 7
4F7B	;	3.0	;	Structure of the lysosomal domain of limp-2
8S0U	;	1.5	;	Structure of the LytM domain of PrgK from E. faecalis
1DZE	;	2.5	;	Structure of the M Intermediate of Bacteriorhodopsin trapped at 100K
2QBZ	;	2.6	;	Structure of the M-Box Riboswitch Aptamer Domain
8SV6	;	3.56	;	Structure of the M. smegmatis DarR protein
4B6C	;	2.2	;	Structure of the M. smegmatis GyrB ATPase domain in complex with an aminopyrazinamide
7W22	;	2.01	;	Structure of the M. tuberculosis HtrA K436A mutant
7W4W	;	2.0	;	Structure of the M. tuberculosis HtrA K436A mutant at room-temperature
7W21	;	2.0	;	Structure of the M. tuberculosis HtrA N269A mutant
7W4R	;	2.701	;	Structure of the M. tuberculosis HtrA N269A mutant at room-temperature
7W24	;	2.9	;	Structure of the M. tuberculosis HtrA N383A mutant
7W23	;	1.9	;	Structure of the M. tuberculosis HtrA S363A mutant
7W4S	;	2.6	;	Structure of the M. tuberculosis HtrA S363A mutant at room-temperature
7VYZ	;	2.401	;	Structure of the M. tuberculosis HtrA S367A mutant
7W4T	;	2.2	;	Structure of the M. tuberculosis HtrA S367A mutant at room-temperature
7VZ0	;	1.95	;	Structure of the M. tuberculosis HtrA S407A mutant
7W4U	;	2.3	;	Structure of the M. tuberculosis HtrA S407A mutant at room-temperature
7W25	;	2.65	;	Structure of the M. tuberculosis HtrA S413A mutant
7W4V	;	2.7	;	Structure of the M. tuberculosis HtrA S413A mutant at room temperature
5JFO	;	2.907	;	Structure of the M.tuberculosis enoyl-reductase InhA in complex with GSK625
2MIZ	;		;	Structure of the m04/gp34 mouse Cytomegalovirus Immunoevasin core domain
3EBG	;	2.1	;	Structure of the M1 Alanylaminopeptidase from malaria
4R5T	;	1.98	;	Structure of the m1 alanylaminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor
4R5V	;	2.1	;	Structure of the m1 alanylaminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor
4R5X	;	1.85	;	Structure of the m1 alanylaminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor
3EBH	;	1.65	;	Structure of the M1 Alanylaminopeptidase from malaria complexed with bestatin
3EBI	;	2.0	;	Structure of the M1 Alanylaminopeptidase from malaria complexed with the phosphinate dipeptide analog
7JVL	;	2.1	;	Structure of the M101A variant of the SidA ornithine hydroxylase complexed with NADP and the FAD in the ""out"" conformation
7JVK	;	2.2	;	Structure of the M101A variant of the SidA ornithine hydroxylase with the FAD in the ""out"" conformation
4R6T	;	2.6	;	Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor
4R76	;	2.5	;	Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor
4R7M	;	2.85	;	Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor
7BFM	;	2.0	;	Structure of the M198F M298F double mutant of the Streptomyces coelicolor small laccase T1 copper site
2WA7	;	1.85	;	Structure of the M202V mutant of human filamin b actin binding domain at 1.85 Angstrom resolution
7B2K	;	2.2	;	Structure of the M298F mutant of the Streptomyces coelicolor small laccase T1 copper axial ligand.
7B4Y	;	2.19	;	Structure of the M298L mutant of the Streptomyces coelicolor small laccase T1 copper axial ligand
4DAJ	;	3.4	;	Structure of the M3 Muscarinic Acetylcholine Receptor
2CSA	;		;	Structure of the M3 Muscarinic Acetylcholine Receptor Basolateral Sorting Signal
4U14	;	3.57	;	Structure of the M3 muscarinic acetylcholine receptor bound to the antagonist tiotropium crystallized with disulfide-stabilized T4 lysozyme (dsT4L)
7F0V	;	1.494	;	Structure of the M305I mutant of CueO
5DSG	;	2.6	;	Structure of the M4 muscarinic acetylcholine receptor (M4-mT4L) bound to tiotropium
6OL9	;	2.541	;	Structure of the M5 muscarinic acetylcholine receptor (M5-T4L) bound to tiotropium
7AGR	;	2.8	;	Structure of the M624V-S726F mutant of AcylTransferase domain of Mycocerosic Acid Synthase from Mycobacterium tuberculosis soaked with MethylMalonyl Coenzyme A
3E2H	;	3.8	;	Structure of the m67 high-affinity mutant of the 2C TCR in complex with Ld/QL9
5NIK	;	3.3	;	Structure of the MacAB-TolC ABC-type tripartite multidrug efflux pump
5NIL	;	5.3	;	Structure of the MacAB-TolC ABC-type tripartite multidrug efflux pump-MacB section
6H2B	;	3.28	;	Structure of the Macrobrachium rosenbergii Nodavirus
1E9W	;	1.02	;	Structure of the macrocycle thiostrepton solved using the anomalous dispersive contribution from sulfur
3G56	;	2.1	;	Structure of the macrolide biosensor protein, MphR(A)
3FRQ	;	1.76	;	Structure of the macrolide biosensor protein, MphR(A), with erythromcyin
5WK1	;	3.6	;	Structure of the major capsid protein and the capsid stabilizing protein of the marine siphovirus TW1
1YR1	;		;	Structure of the major extracytoplasmic domain of the trans isomer of the bacterial cell division protein divib from geobacillus stearothermophilus
8JFQ	;		;	Structure of the Major G-Quadruplex in the Human EGFR Oncogene Promoter Adopts a Unique Folding Topology with a Distinctive Snap-back Loop
6BBT	;	1.9	;	Structure of the major pilin protein (T-13) from Streptococcus pyogenes serotype GAS131465
6N0A	;	1.75	;	Structure of the major pilin protein (T-18.1) from Streptococcus pyogenes serotype MGAS8232
6BBW	;	1.8	;	Structure of the major pilin protein (T3.2) from Streptococcus pyogenes serotype GAS13637
2XTL	;	1.75	;	Structure of the major pilus backbone protein from Streptococcus Agalactiae
5EQW	;	1.679	;	Structure of the major structural protein D135 of Acidianus tailed spindle virus (ATSV)
4DWH	;	2.5	;	Structure of the major type 1 pilus subunit FIMA bound to the FIMC (2.5 A resolution)
3SQB	;	3.2	;	Structure of the major type 1 pilus subunit FimA bound to the FimC chaperone
4XA2	;	1.98	;	Structure of the Major Type IV pilin of Acinetobacter baumannii
6T8S	;	1.65	;	Structure of the major Type IV pilin PilA1 from Clostridium difficile
5M97	;	1.33	;	Structure of the Mal3 EB1-like domain
2Q8A	;	2.4	;	Structure of the malaria antigen AMA1 in complex with a growth-inhibitory antibody
2Q8B	;	2.3	;	Structure of the malaria antigen AMA1 in complex with a growth-inhibitory antibody
2D4A	;	2.87	;	Structure of the malate dehydrogenase from Aeropyrum pernix
6D6Z	;	2.38	;	Structure of the malate racemase apoprotein from Thermoanaerobacterium thermosaccharolyticum
7S91	;	2.25	;	Structure of the malate racemase mar2 apoprotein from Thermoanaerobacterium thermosaccharolyticum at 2.25 angstroms resolution
6X9G	;	1.68	;	Structure of the malonate-bound form of ArrX from Chrysiogenes arsenatis
3TQE	;	1.5	;	Structure of the malonyl CoA-acyl carrier protein transacylase (fabD) from Coxiella burnetii
7P01	;	2.12	;	Structure of the maltase BaAG2 from Blastobotrys adeninivorans in complex with acarbose
7P07	;	2.13	;	Structure of the maltase BaAG2 from Blastobotrys adeninivorans in complex with glucose
3J7O	;	3.4	;	Structure of the mammalian 60S ribosomal subunit
1CTP	;	2.9	;	STRUCTURE OF THE MAMMALIAN CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND AN INHIBITOR PEPTIDE DISPLAYS AN OPEN CONFORMATION
7N9H	;	2.2	;	Structure of the mammalian importin a1 bound to the TDP-43 NLS
8OEW	;	2.8	;	Structure of the mammalian Pol II-Elongin complex, lacking the ELOA latch (composite structure, structure 2)
8OEU	;	3.04	;	Structure of the mammalian Pol II-SPT6 complex (composite structure, Structure 4)
8OEV	;	2.86	;	Structure of the mammalian Pol II-SPT6-Elongin complex, lacking ELOA latch (composite structure, structure 3)
8OF0	;	3.05	;	Structure of the mammalian Pol II-SPT6-Elongin complex, Structure 1
5LZZ	;	3.47	;	Structure of the mammalian rescue complex with Pelota and Hbs1l (combined)
5LZY	;	3.99	;	Structure of the mammalian rescue complex with Pelota and Hbs1l assembled on a polyadenylated mRNA.
5LZW	;	3.53	;	Structure of the mammalian rescue complex with Pelota and Hbs1l assembled on a truncated mRNA.
5LZX	;	3.67	;	Structure of the mammalian rescue complex with Pelota and Hbs1l assembled on a UGA stop codon.
5LZS	;	3.31	;	Structure of the mammalian ribosomal elongation complex with aminoacyl-tRNA, eEF1A, and didemnin B
3J5Y	;	9.7	;	Structure of the mammalian ribosomal pre-termination complex associated with eRF1-eRF3-GDPNP
5LZU	;	3.75	;	Structure of the mammalian ribosomal termination complex with accommodated eRF1
5LZV	;	3.35	;	Structure of the mammalian ribosomal termination complex with accommodated eRF1(AAQ) and ABCE1.
5LZT	;	3.65	;	Structure of the mammalian ribosomal termination complex with eRF1 and eRF3.
5GJV	;	3.6	;	Structure of the mammalian voltage-gated calcium channel Cav1.1 complex at near atomic resolution
5GJW	;	3.9	;	Structure of the mammalian voltage-gated calcium channel Cav1.1 complex for ClassII map
6JZS	;	1.68	;	Structure of the Manganese Protoporphyrin IX-Reconstituted CYP102A1 Haem Domain with N-Abietoyl-L-Tryptophan in complex with Pyridine
7WG0	;	2.2	;	Structure of the Manganese Protoporphyrin IX-Reconstituted CYP102A1 Heme Domain with N-palmitoyl-L-phenylalanine
5CVI	;	2.804	;	Structure of the manganese regulator SloR
6E8T	;	2.9	;	Structure of the Mango-III (A10U) aptamer bound to TO1-Biotin
6E8U	;	1.55	;	Structure of the Mango-III (A10U) aptamer bound to TO1-Biotin
6UP0	;	2.8	;	Structure of the Mango-III fluorescent aptamer bound to YO3-Biotin
6FMG	;	1.8	;	Structure of the Mannose Transporter IIA Domain from Streptococcus pneumoniae
8A8M	;	4.0	;	Structure of the MAPK p38alpha in complex with its activating MAP2K MKK6
3EF2	;	1.8	;	Structure of the Marasmius oreades mushroom lectin (MOA) in complex with Galalpha(1,3)[Fucalpha(1,2)]Gal and Calcium.
7LV8	;	3.4	;	Structure of the Marseillevirus nucleosome
2JFD	;	2.81	;	Structure of the MAT domain of human FAS
2JFK	;	2.4	;	Structure of the MAT domain of human FAS with malonyl-CoA
6Z70	;	2.0	;	Structure of the MATE family multidrug resistance transporter Aq_128 from Aquifex aeolicus in the outward-facing state
6Z71	;	3.5	;	Structure of the MATE family multidrug resistance transporter Aq_128 from Aquifex aeolicus in the outward-facing state
2VQP	;	1.6	;	Structure of the matrix protein from human Respiratory Syncytial Virus
2YKD	;	1.86	;	Structure of the matrix protein from human respiratory syncytial virus
7NO6	;	6.0	;	Structure of the mature RSV CA lattice: Group I, pentamer-hexamer interface, class 1
7NO7	;	7.5	;	Structure of the mature RSV CA lattice: Group I, pentamer-hexamer interface, class 1""2
7NO8	;	7.9	;	Structure of the mature RSV CA lattice: Group I, pentamer-hexamer interface, class 1""6
7NO9	;	7.6	;	Structure of the mature RSV CA lattice: Group I, pentamer-pentamer interface, class 1'1
7NOB	;	6.7	;	Structure of the mature RSV CA lattice: Group II, hexamer-hexamer interface, class 2'6
7NOA	;	6.4	;	Structure of the mature RSV CA lattice: Group II, hexamer-hexamer interface, class 6
7NOC	;	7.8	;	Structure of the mature RSV CA lattice: Group III, hexamer-hexamer interface, class 3'3
7NOD	;	7.8	;	Structure of the mature RSV CA lattice: Group III, hexamer-hexamer interface, class 3'4
7NOE	;	7.5	;	Structure of the mature RSV CA lattice: Group III, hexamer-hexamer interface, class 3'5
7NOF	;	7.6	;	Structure of the mature RSV CA lattice: Group III, hexamer-hexamer interface, class 4'4
7NOG	;	7.8	;	Structure of the mature RSV CA lattice: Group III, hexamer-hexamer interface, class 4'5
7NOH	;	7.1	;	Structure of the mature RSV CA lattice: Group III, hexamer-hexamer interface, class 5'5
7NOI	;	7.2	;	Structure of the mature RSV CA lattice: Group IV, hexamer-hexamer interface, class 3'Alpha
7NOJ	;	6.7	;	Structure of the mature RSV CA lattice: Group IV, hexamer-hexamer interface, class 3'Beta
7NOK	;	9.1	;	Structure of the mature RSV CA lattice: Group IV, hexamer-hexamer interface, class 3'Gamma
7NOL	;	8.2	;	Structure of the mature RSV CA lattice: Group IV, hexamer-hexamer interface, class 4'Alpha
7NOM	;	6.7	;	Structure of the mature RSV CA lattice: Group IV, hexamer-hexamer interface, class 4'Beta
7NON	;	6.8	;	Structure of the mature RSV CA lattice: Group IV, hexamer-hexamer interface, class 4'Gamma
7NOO	;	7.9	;	Structure of the mature RSV CA lattice: Group IV, hexamer-hexamer interface, class 5'Alpha
7NOP	;	7.8	;	Structure of the mature RSV CA lattice: Group IV, hexamer-hexamer interface, class 5'Beta
7NOQ	;	6.5	;	Structure of the mature RSV CA lattice: Group IV, hexamer-hexamer interface, class 5'Gamma
7NO2	;	4.3	;	Structure of the mature RSV CA lattice: hexamer derived from tubes (C2-symmetric)
7NO5	;	7.4	;	Structure of the mature RSV CA lattice: hexamer with 2 adjacent pentamers (C2 symmetric)
7NO4	;	7.5	;	Structure of the mature RSV CA lattice: hexamer with 3 adjacent pentamers (C3 symmetric)
7NO3	;	5.8	;	Structure of the mature RSV CA lattice: pentamer derived from polyhedral VLPs
7NO0	;	3.1	;	Structure of the mature RSV CA lattice: T=1 CA icosahedron
7NO1	;	7.6	;	Structure of the mature RSV CA lattice: T=3 CA icosahedron
3AJC	;	2.3	;	Structure of the MC domain of FliG (PEV), a CW-biased mutant
8F0Z	;	1.61	;	Structure of the MDM2 P53 binding domain in complex with H101, an all-D Helicon Polypeptide
8F10	;	1.28	;	Structure of the MDM2 P53 binding domain in complex with H102, an all-D Helicon Polypeptide
8F12	;	1.86	;	Structure of the MDM2 P53 binding domain in complex with H103, an all-D Helicon Polypeptide
8F13	;	1.4	;	Structure of the MDM2 P53 binding domain in complex with H103, an all-D Helicon Polypeptide, alternative C-terminus
3INB	;	3.1	;	Structure of the measles virus hemagglutinin bound to the CD46 receptor
6BPZ	;	3.8	;	Structure of the mechanically activated ion channel Piezo1
6RLD	;	2.9	;	STRUCTURE OF THE MECHANOSENSITIVE CHANNEL MSCS EMBEDDED IN THE MEMBRANE BILAYER
6B3R	;	3.8	;	Structure of the mechanosensitive channel Piezo1
5Z10	;	3.97	;	Structure of the mechanosensitive Piezo1 channel
7PZ2	;	1.58	;	Structure of the mechanosensor domain of Wsc1 from Saccharomyces cerevisiae
4GWP	;	4.2	;	Structure of the Mediator Head Module from S. cerevisiae
4GWQ	;	4.5	;	Structure of the Mediator Head Module from S. cerevisiae in complex with the carboxy-terminal domain (CTD) of RNA Polymerase II Rpb1 subunit
3R84	;	2.05	;	Structure of the Mediator head subcomplex Med11/22
2HZM	;	2.4	;	Structure of the Mediator head subcomplex Med18/20
2HZS	;	2.7	;	Structure of the Mediator head submodule Med8C/18/20
1YKH	;	3.0	;	Structure of the mediator MED7/MED21 (Med7/Srb7) subcomplex
1YKE	;	3.3	;	Structure of the mediator MED7/MED21 subcomplex
3FBI	;	2.8	;	Structure of the Mediator submodule Med7N/31
3FBN	;	3.007	;	Structure of the Mediator submodule Med7N/31
1ZP2	;	3.0	;	Structure of the Mediator subunit cyclin C
7QE5	;	4.7	;	Structure of the membrane domains of the sialic acid TRAP transporter HiSiaQM from Haemophilus influenzae
5XU0	;	2.95	;	Structure of the membrane fusion protein Spr0693 from Streptococcus pneumoniae R6
5N6L	;	2.9	;	Structure of the membrane integral lipoprotein N-acyltransferase Lnt C387A mutant from E. coli
5N6H	;	2.9	;	Structure of the membrane integral lipoprotein N-acyltransferase Lnt from E. coli
5N6M	;	3.1	;	Structure of the membrane integral lipoprotein N-acyltransferase Lnt from P. aeruginosa
2MOZ	;		;	Structure of the Membrane Protein MerF, a Bacterial Mercury Transporter, Improved by the Inclusion of Chemical Shift Anisotropy Constraints
7PVD	;	3.7	;	Structure of the membrane soluble spike complex from the Lassa virus in a C1-symmetric map focused on the ectodomain
7PUY	;	3.3	;	Structure of the membrane soluble spike complex from the Lassa virus in a C3-symmetric map
5CR8	;	2.05	;	Structure of the membrane-binding domain of pneumolysin
3HIE	;	2.0	;	Structure of the membrane-binding domain of the Sec3 subunit of the Exocyst complex
2RCR	;	3.1	;	STRUCTURE OF THE MEMBRANE-BOUND PROTEIN PHOTOSYNTHETIC REACTION CENTER FROM RHODOBACTER SPHAEROIDES
6U8Y	;	4.0	;	Structure of the membrane-bound sulfane sulfur reductase (MBS), an archaeal respiratory membrane complex
2X7J	;	2.35	;	Structure of the menaquinone biosynthesis protein MenD from Bacillus subtilis
1AFJ	;		;	STRUCTURE OF THE MERCURY-BOUND FORM OF MERP, THE PERIPLASMIC PROTEIN FROM THE BACTERIAL MERCURY DETOXIFICATION SYSTEM, NMR, 20 STRUCTURES
4MOD	;	1.901	;	Structure of the MERS-CoV fusion core
1NI5	;	2.65	;	Structure of the MesJ PP-ATPase from Escherichia Coli
3H7I	;	1.502	;	Structure of the metal-free D132N T4 RNase H
1J8D	;	2.3	;	Structure Of the metal-free form of the deoxy-D-mannose-octulosonate 8-phosphate phosphatase (YrbI) From Haemophilus Influenzae (HI1679)
1CFH	;		;	STRUCTURE OF THE METAL-FREE GAMMA-CARBOXYGLUTAMIC ACID-RICH MEMBRANE BINDING REGION OF FACTOR IX BY TWO-DIMENSIONAL NMR SPECTROSCOPY
5C3L	;	2.9	;	Structure of the metazoan Nup62.Nup58.Nup54 nucleoporin complex.
3EN9	;	2.67	;	Structure of the Methanococcus jannaschii KAE1-BUD32 fusion protein
4V4N	;	9.0	;	Structure of the Methanococcus jannaschii ribosome-SecYEBeta channel complex
4U9P	;	1.7	;	Structure of the methanofuran/methanopterin biosynthetic enzyme MJ1099 from Methanocaldococcus jannaschii
4RC1	;	2.4	;	Structure of the methanofuran/methanopterin biosynthetic enzyme MJ1099 from Methanocaldococcus jannaschii with PRPP
5ZCW	;	2.7	;	Structure of the Methanosarcina mazei class II CPD-photolyase in complex with intact, phosphodiester linked, CPD-lesion
3TQQ	;	2.0	;	Structure of the methionyl-tRNA formyltransferase (fmt) from Coxiella burnetii
2PZX	;	3.5	;	Structure of the methuselah ectodomain with peptide inhibitor
8G1U	;	2.83	;	Structure of the methylosome-Lsm10/11 complex
2WA1	;	2.0	;	Structure of the methyltransferase domain from Modoc Virus, a Flavivirus with No Known Vector (NKV)
2WA2	;	1.8	;	Structure of the methyltransferase domain from Modoc Virus, a Flavivirus with No Known Vector (NKV)
2ZFU	;	2.0	;	Structure of the methyltransferase-like domain of nucleomethylin
4WP6	;	1.7	;	Structure of the Mex67 LRR domain from Chaetomium thermophilum
8HBN	;	3.81	;	Structure of the Mex67-Mtr2-1 heterodimer
2CHE	;	1.8	;	STRUCTURE OF THE MG2+-BOUND FORM OF CHEY AND MECHANISM OF PHOSPHORYL TRANSFER IN BACTERIAL CHEMOTAXIS
2CHF	;	1.8	;	STRUCTURE OF THE MG2+-BOUND FORM OF CHEY AND THE MECHANISM OF PHOSPHORYL TRANSFER IN BACTERIAL CHEMOTAXIS
5CCI	;	4.1	;	Structure of the Mg2+-bound synaptotagmin-1 SNARE complex (short unit cell form)
2C0C	;	1.45	;	Structure of the MGC45594 gene product
1B3J	;	3.0	;	STRUCTURE OF THE MHC CLASS I HOMOLOG MIC-A, A GAMMADELTA T CELL LIGAND
1JE6	;	2.5	;	Structure of the MHC Class I Homolog MICB
3VJ6	;	1.9	;	Structure of the MHC class Ib molecule Qa-1b
2NNA	;	2.1	;	Structure of the MHC class II molecule HLA-DQ8 bound with a deamidated gluten peptide
2K2S	;		;	structure of the MIC1-GLD/MIC6-EGF complex from Toxoplasma gondii
2CIP	;	1.4	;	Structure of the Michaelis complex of a family 26 lichenase
2WBK	;	2.1	;	Structure of the Michaelis complex of beta-mannosidase, Man2A, provides insight into the conformational itinerary of mannoside hydrolysis
6CI8	;	1.7	;	Structure of the microcompartment-associated aminoacetone dehydrogenase
6EF6	;	1.35	;	Structure of the microcompartment-associated aminopropanol kinase
4L3I	;	3.6005	;	Structure of the microtubule associated protein PRC1 (Protein Regulator of Cytokinesis 1)
4L6Y	;	3.3015	;	Structure of the microtubule associated protein PRC1 (Protein Regulator of Cytokinesis 1)
4P1Z	;	2.3	;	Structure of the MID domain from MIWI
2JUN	;		;	Structure of the MID1 tandem B-boxes reveals an interaction reminiscent of intermolecular RING heterodimers
5BTY	;	1.15	;	Structure of the middle domain of lpg1496 from Legionella pneumophila in P21 space group
5BTZ	;	1.6	;	Structure of the middle domain of lpg1496 from Legionella pneumophila in P212121 space group
6EUY	;	3.0	;	Structure of the midlink and cap-binding domains of influenza A polymerase PB2 subunit with a bound azaindazole cap-binding inhibitor
6EUV	;	2.7	;	Structure of the midlink and cap-binding domains of influenza A polymerase PB2 subunit with a bound azaindole cap-binding inhibitor (VX-787)
6EUX	;	2.05	;	Structure of the midlink and cap-binding domains of influenza B polymerase PB2 subunit with a bound azaindazole cap-binding inhibitor
7PTV	;	3.3	;	Structure of the Mimivirus genomic fibre asymmetric unit
7YX4	;	3.7	;	Structure of the Mimivirus genomic fibre in its compact 5-start helix form
7YX3	;	4.0	;	Structure of the Mimivirus genomic fibre in its compact 6-start helix form
7YX5	;	3.7	;	Structure of the Mimivirus genomic fibre in its relaxed 5-start helix form
5T51	;	2.2007	;	Structure of the MIND Complex Shows a Regulatory Focus of Yeast Kinetochore Assembly
5T58	;	3.2131	;	Structure of the MIND Complex Shows a Regulatory Focus of Yeast Kinetochore Assembly
5T59	;	2.405	;	Structure of the MIND Complex Shows a Regulatory Focus of Yeast Kinetochore Assembly
5T6J	;	1.752	;	Structure of the MIND Complex Shows a Regulatory Focus of Yeast Kinetochore Assembly
7ODF	;	2.66	;	Structure of the mini-RNA-guided endonuclease CRISPR-Cas_phi3
5LXR	;	2.0	;	Structure of the minimal RBM7 - ZCCHC8 Complex
5LXY	;	2.85	;	Structure of the minimal RBM7 - ZCCHC8 Complex
4F2H	;	3.192	;	Structure of the minimal Ste5 VWA domain subject to autoinhibition by the Ste5 PH domain
7MU8	;	1.7	;	Structure of the minimally glycosylated human CEACAM1 N-terminal domain
2QV8	;	2.0	;	Structure of the minor pseudopilin EpsH from the Type 2 Secretion System of Vibrio cholerae
3NJE	;	1.85	;	Structure of the Minor Pseudopilin XcpW from the Pseudomonas aeruginosa Type II Secretion System
2V6Y	;	2.4	;	Structure of the MIT domain from a S. solfataricus Vps4-like ATPase
2C0D	;	1.78	;	Structure of the mitochondrial 2-cys peroxiredoxin from Plasmodium falciparum
4MYC	;	3.06	;	Structure of the mitochondrial ABC transporter, Atm1
8A22	;	2.91	;	Structure of the mitochondrial ribosome from Polytomella magna
8APN	;	3.1	;	Structure of the mitochondrial ribosome from Polytomella magna with tRNA bound to the P site
8APO	;	3.2	;	Structure of the mitochondrial ribosome from Polytomella magna with tRNAs bound to the A and P sites
6Z1P	;	3.7	;	Structure of the mitochondrial ribosome from Tetrahymena thermophila
2LCK	;		;	Structure of the mitochondrial uncoupling protein 2 determined by NMR molecular fragment replacement
6QFL	;	2.2	;	Structure of the mitogen activated kinase kinase 7 active conformation
6QFR	;	2.3	;	Structure of the mitogen activated kinase kinase 7 dfg-out conformation
6QFT	;	2.7	;	Structure of the mitogen activated kinase kinase 7 in complex with pyrazolopyrimidin 1b
6QG7	;	2.1	;	Structure of the mitogen activated kinase kinase 7 in complex with pyrazolopyrimidine 1k
6QHR	;	2.52	;	Structure of the mitogen activated kinase kinase 7 in complex with pyrazolopyrimidine 1m
6QG4	;	2.3	;	Structure of the mitogen activated kinase kinase 7 in complex with pyrazolopyrimidine inhibitor 1h
3GWZ	;	1.91	;	Structure of the Mitomycin 7-O-methyltransferase MmcR
3GXO	;	2.3	;	Structure of the Mitomycin 7-O-methyltransferase MmcR with bound Mitomycin A
3ZSN	;	1.9	;	Structure of the mixed-function P450 MycG F286A mutant in complex with mycinamicin IV
4AW3	;	2.05	;	Structure of the mixed-function P450 MycG F286V mutant in complex with mycinamicin V in P1 space group
2Y46	;	1.83	;	Structure of the mixed-function P450 MycG in complex with mycinamicin IV in C 2 2 21 space group
2Y98	;	1.65	;	Structure of the mixed-function P450 MycG in complex with mycinamicin IV in P21212 space group
2Y5N	;	1.62	;	Structure of the mixed-function P450 MycG in complex with mycinamicin V in P21 space group
2YGX	;	2.39	;	Structure of the mixed-function P450 MycG in P21 space group
6FU3	;	1.8	;	Structure of the mixed-valence, active form, of cytochrome c peroxidase from obligate human pathogenic bacterium Neisseria gonorrhoeae
4Z4P	;	2.2	;	Structure of the MLL4 SET Domain
3NTW	;	2.6	;	Structure of the MLLE domain of EDD in complex with a PAM2 peptide from Paip1
7LUL	;	1.65	;	Structure of the MM2 Erbin PDZ variant in complex with a high-affinity peptide
6UBH	;	1.8	;	Structure of the MM7 Erbin PDZ variant in complex with a high-affinity peptide
1DSV	;		;	STRUCTURE OF THE MMTV NUCLEOCAPSID PROTEIN (C-TERMINAL ZINC FINGER)
1DSQ	;		;	STRUCTURE OF THE MMTV NUCLEOCAPSID PROTEIN (ZINC FINGER 1)
2GJ8	;	1.7	;	Structure of the MnmE G-domain in complex with GDP*AlF4-, Mg2+ and K+
2GJA	;	1.85	;	Structure of the MnmE G-domain in complex with GDP*AlF4-, Mg2+ and NH4+
2GJ9	;	2.0	;	Structure of the MnmE G-domain in complex with GDP*AlF4-, Mg2+ and Rb+
3R61	;	1.9002	;	Structure of the MntR Co2+ Complex
3R60	;	1.8	;	Structure of the MntR Fe2+ Complex
4HV5	;	1.9	;	Structure of the MNTR FE2+ complex with E site metal binding
2FB2	;	2.25	;	Structure of the MoaA Arg17/266/268/Ala triple mutant
5XQZ	;	2.1	;	Structure of the MOB1-NDR2 complex
1PS5	;	2.0	;	STRUCTURE OF THE MONOCLINIC C2 FORM OF HEN EGG-WHITE LYSOZYME AT 2.0 ANGSTROMS RESOLUTION
1EV6	;	1.9	;	Structure of the monoclinic form of the M-cresol/insulin R6 hexamer
6DVU	;	1.8	;	Structure of the Monoclinic-1 (Monocl-1) Crystal Form of Human Apolipoprotein C1
6DXR	;	2.0	;	Structure of the Monoclinic-2 (Monocl-2) Crystal Form of Human Apolipoprotein C1
6NF3	;	2.33	;	Structure of the Monoclinic-3 (Monocln-3) Crystal Form of Human Apolipoprotein C1
4I22	;	1.71	;	Structure of the monomeric (V948R)gefitinib/erlotinib resistant double mutant (L858R+T790M) EGFR kinase domain co-crystallized with gefitinib
1PWJ	;		;	Structure of the Monomeric 8-kDa Dynein Light Chain and Mechanism of Domain Swapped Dimer Assembly
1PWK	;		;	Structure of the Monomeric 8-kDa Dynein Light Chain and Mechanism of Domain Swapped Dimer Assembly
1YNT	;	3.1	;	Structure of the monomeric form of T. gondii SAG1 surface antigen bound to a human Fab
2LJX	;		;	Structure of the monomeric N-terminal domain of HPV16 E6 oncoprotein
2IWV	;	2.3	;	Structure of the monomeric outer membrane porin OmpG in the open and closed conformation
2IWW	;	2.7	;	Structure of the monomeric outer membrane porin OmpG in the open and closed conformation
2JBR	;	2.3	;	Structure of the monooxygenase component of p-hydroxyphenylacetate hydroxylase from Acinetobacter baumanni
2JBS	;	2.8	;	Structure of the monooxygenase component of p-hydroxyphenylacetate hydroxylase from Acinetobacter baumannii
2JBT	;	2.8	;	Structure of the monooxygenase component of p-hydroxyphenylacetate hydroxylase from Acinetobacter baumannii
6YT3	;	2.85	;	Structure of the MoStoNano fusion protein
7AYZ	;	2.6	;	Structure of the mouse 8-oxoguanine DNA Glycosylase mOGG1 in complex with activator TH10785
7ZG3	;	2.3	;	Structure of the mouse 8-oxoguanine DNA Glycosylase mOGG1 in complex with ligand TH011228
7QEL	;	2.5	;	Structure of the mouse 8-oxoguanine DNA Glycosylase mOGG1 in complex with ligand TH011247
7Z5R	;	2.5	;	Structure of the mouse 8-oxoguanine DNA Glycosylase mOGG1 in complex with ligand TH012035
7ZC7	;	2.3	;	Structure of the mouse 8-oxoguanine DNA Glycosylase mOGG1 in complex with ligand TH012941
7Z3Y	;	2.35	;	Structure of the mouse 8-oxoguanine DNA Glycosylase mOGG1 in complex with ligand TH013545
7Z5B	;	2.6	;	Structure of the mouse 8-oxoguanine DNA Glycosylase mOGG1 in complex with ligand TH013546
8CEX	;	2.3	;	Structure of the mouse 8-oxoguanine DNA Glycosylase mOGG1 in complex with ligand TH11227
8CEY	;	1.95	;	Structure of the mouse 8-oxoguanine DNA Glycosylase mOGG1 in complex with ligand TH11233
8BQ7	;	2.6	;	Structure of the mouse 8-oxoguanine DNA Glycosylase mOGG1 in complex with ligand TH2829
6G3Y	;	2.51	;	Structure of the mouse 8-oxoguanine DNA Glycosylase mOGG1 in complex with ligand TH5675
7PZ1	;	2.45	;	Structure of the mouse 8-oxoguanine DNA Glycosylase mOGG1 in complex with ligand TH8535
6G40	;	2.49	;	Structure of the mouse 8-oxoguanine DNA Glycosylase mOGG1 in complex with ligand TH9525
7AZ0	;	2.4	;	Structure of the mouse 8-oxoguanine DNA Glycosylase mOGG1 in complex with TH12161
4IRJ	;	3.0	;	Structure of the mouse CD1d-4ClPhC-alpha-GalCer-iNKT TCR complex
3QUX	;	2.91	;	Structure of the mouse CD1d-alpha-C-GalCer-iNKT TCR complex
3QUY	;	2.25	;	Structure of the mouse CD1d-BnNH-GSL-1'-iNKT TCR complex
3TA3	;	2.7	;	Structure of the mouse CD1d-Glc-DAG-s2-iNKT TCR complex
3RTQ	;	2.8	;	Structure of the mouse CD1d-HS44-iNKT TCR complex
3QUZ	;	2.3	;	Structure of the mouse CD1d-NU-alpha-GalCer-iNKT TCR complex
4IRS	;	2.8	;	Structure of the mouse CD1d-PyrC-alpha-GalCer-iNKT TCR complex
3TVM	;	2.8	;	Structure of the mouse CD1d-SMC124-iNKT TCR complex
6I9Q	;	2.1	;	Structure of the mouse CD98 heavy chain ectodomain
7Q3E	;	3.35	;	Structure of the mouse CPLANE-RSG1 complex
2Q86	;	1.85	;	Structure of the mouse invariant NKT cell receptor Valpha14
5IRI	;	2.8	;	Structure of the mouse SAD-B AIS-KA1 fragment
6FFY	;	3.9	;	Structure of the mouse SorCS2-NGF complex
5Z96	;	3.28	;	Structure of the mouse TRPC4 ion channel
6JZO	;	3.28	;	Structure of the mouse TRPC4 ion channel
2PLY	;	2.6	;	Structure of the mRNA binding fragment of elongation factor SelB in complex with SECIS RNA.
3U1L	;	1.64	;	Structure of the mRNA splicing complex component Cwc2
3U1M	;	1.95	;	Structure of the mRNA splicing complex component Cwc2
2PJP	;	2.3	;	Structure of the mRNA-binding domain of elongation factor SelB from E.coli in complex with SECIS RNA
6Z16	;	2.98	;	Structure of the Mrp antiporter complex
4RKG	;	2.5	;	Structure of the MSL2 CXC domain bound with a non-specific (GC)6 DNA
4RKH	;	2.0	;	Structure of the MSL2 CXC domain bound with a specific MRE sequence
5XY9	;	2.303	;	Structure of the MST4 and 14-3-3 complex
1MR2	;	2.3	;	Structure of the MT-ADPRase in complex with 1 Mn2+ ion and AMP-CP (a inhibitor), a nudix enzyme
1MK1	;	2.0	;	Structure of the MT-ADPRase in complex with ADPR, a Nudix enzyme
1MQE	;	2.0	;	Structure of the MT-ADPRase in complex with gadolidium and ADP-ribose, a Nudix enzyme
1MQW	;	2.3	;	Structure of the MT-ADPRase in complex with three Mn2+ ions and AMPCPR, a Nudix enzyme
7AO8	;	4.5	;	Structure of the MTA1/HDAC1/MBD2 NURD deacetylase complex
4KBM	;	2.1146	;	Structure of the Mtb CarD/RNAP Beta subunit B1-B2 domains complex
6R2Q	;	2.697	;	Structure of the Mtr complex
5OOQ	;	3.2	;	Structure of the Mtr4 Nop53 Complex
8QOT	;	3.2	;	Structure of the mu opioid receptor bound to the antagonist nanobody NbE
7QCL	;	3.36	;	Structure of the MUCIN-2 Cterminal domains
7QCU	;	3.25	;	Structure of the MUCIN-2 Cterminal domains partially deglycosylated.
7QCN	;	3.4	;	Structure of the MUCIN-2 Cterminal domains: vWCN to TIL domains with a C2 symmetry
2ONJ	;	3.4	;	Structure of the multidrug ABC transporter Sav1866 from S. aureus in complex with AMP-PNP
2GFP	;	3.5	;	Structure of the Multidrug Transporter EmrD from Escherichia coli
1E8T	;	2.5	;	Structure of the multifunctional paramyxovirus hemagglutinin-neuraminidase
1E8U	;	2.0	;	Structure of the multifunctional paramyxovirus hemagglutinin-neuraminidase
1E8V	;	2.0	;	Structure of the multifunctional paramyxovirus hemagglutinin-neuraminidase
4EIJ	;	2.2001	;	Structure of the Mumps virus phosphoprotein oligomerization domain
5EOR	;	2.27	;	Structure of the murine antibody Fab 8E3 bound to the vaccinia virus A27 peptide 101-110
7PLL	;		;	Structure of the murine cortactin C-SH3 domain in complex with a Pyk2 proline-rich ligand
5EOQ	;	1.95	;	Structure of the murine Fab 1G6 bound to the vaccinia virus A27 peptide 31-40
2YMY	;	1.69	;	Structure of the murine Nore1-Sarah domain
8PM2	;	2.92	;	Structure of the murine trace amine-associated receptor TAAR7f bound to N,N-dimethylcyclohexylamine (DMCH) in complex with mini-Gs trimeric G protein
2V8O	;	1.9	;	Structure of the Murray Valley encephalitis virus RNA helicase to 1. 9A resolution
5K8Y	;	2.4	;	Structure of the Mus musclus Langerin carbohydrate recognition domain
5M62	;	1.7	;	Structure of the Mus musclus Langerin carbohydrate recognition domain in complex with glucose
1CG1	;	2.5	;	STRUCTURE OF THE MUTANT (K16Q) OF ADENYLOSUCCINATE SYNTHETASE FROM E. COLI COMPLEXED WITH HADACIDIN, GDP, 6-PHOSPHORYL-IMP, AND MG2+
1CG3	;	2.5	;	STRUCTURE OF THE MUTANT (R143L) OF ADENYLOSUCCINATE SYNTHETASE FROM E. COLI COMPLEXED WITH HADACIDIN, GDP, 6-PHOSPHORYL-IMP, AND MG2+
1CG4	;	2.5	;	STRUCTURE OF THE MUTANT (R303L) OF ADENYLOSUCCINATE SYNTHETASE FROM E. COLI COMPLEXED WITH, GDP, 6-PHOSPHORYL-IMP, AND MG2+
4I01	;	2.3	;	Structure of the mutant Catabolite gen activator protein V140L
4I0B	;	1.5	;	structure of the mutant Catabolite gene activator protein H160L
4I0A	;	2.2	;	structure of the mutant Catabolite gene activator protein V132A
4I09	;	2.05	;	structure of the mutant Catabolite gene activator protein V132L
4I02	;	1.75	;	structure of the mutant Catabolite gene activator protein V140A
2X9I	;	2.2	;	Structure of the Mutant D105N of Phycoerythrobilin Synthase PebS from the Cyanophage P-SSM2 in complex with bound substrate Biliverdin IXA
2X9J	;	1.85	;	Structure of the Mutant D206N of Phycoerythrobilin Synthase PebS from the Cyanophage P-SSM2 in complex with bound substrate Biliverdin IXA
1JT9	;	2.06	;	Structure of the mutant F174A T form of the Glucosamine-6-Phosphate deaminase from E.coli
3KXX	;	3.2	;	Structure of the mutant Fibroblast Growth Factor receptor 1
1QF7	;	2.2	;	STRUCTURE OF THE MUTANT HIS392GLN OF CATALASE HPII FROM E. COLI
2QET	;	1.24	;	Structure of the mutant S211A of the ribosome inactivating protein PDL4 from P. dioica in complex with adenine
4B30	;	2.1	;	Structure of the mutant V44A of the fluorescent protein KillerRed
1CF9	;	1.8	;	Structure of the mutant VAL169CYS of catalase HPII from Escherichia coli
7B9F	;	3.0	;	Structure of the mycobacterial ESX-5 Type VII Secretion System hexameric pore complex
7B9S	;	3.4	;	Structure of the mycobacterial ESX-5 Type VII Secretion System hexameric pore complex
8D6Y	;	10.0	;	Structure of the Mycobacterium tuberculosis 20S proteasome bound to the ADP-bound Mpa ATPase
8D6X	;	3.2	;	Structure of the Mycobacterium tuberculosis 20S proteasome bound to the ATP-bound Mpa ATPase
8D6W	;	3.0	;	Structure of the Mycobacterium tuberculosis 20S proteasome bound to the C-terminal GQYL motif of the ADP-bound Mpa ATPase
8D6V	;	3.2	;	Structure of the Mycobacterium tuberculosis 20S proteasome bound to the C-terminal GQYL motif of the ATP-bound Mpa ATPase
4RFV	;	1.69	;	Structure of the Mycobacterium tuberculosis APS kinase CysC Cys556Ala mutant
4BZP	;	1.47	;	Structure of the Mycobacterium tuberculosis APS kinase CysC in complex with ADP
4BZQ	;	2.1	;	Structure of the Mycobacterium tuberculosis APS kinase CysC in complex with ADP and APS
4BZX	;	1.7	;	Structure of the Mycobacterium tuberculosis APS kinase CysC in complex with AMPPNP and APS
3H6D	;	1.8	;	Structure of the mycobacterium tuberculosis DUTPase D28N mutant
8GB3	;	3.7	;	Structure of the Mycobacterium tuberculosis Hsp70 protein DnaK bound to the nucleotide exchange factor GrpE
3ZEI	;	2.0	;	Structure of the Mycobacterium tuberculosis O-Acetylserine Sulfhydrylase (OASS) CysK1 in complex with a small molecule inhibitor
4M6G	;	2.104	;	Structure of the Mycobacterium tuberculosis peptidoglycan amidase Rv3717 in complex with L-Alanine-iso-D-Glutamine reaction product
2X9Q	;	2.02	;	Structure of the Mycobacterium tuberculosis protein, Rv2275, demonstrates that cyclodipeptide synthetases are related to type I tRNA-Synthetases.
4CKZ	;	2.52	;	Structure of the Mycobacterium tuberculosis Type II Dehydroquinase D88N mutant
4CKY	;	1.65	;	Structure of the Mycobacterium tuberculosis Type II Dehydroquinase inhibited by a 3-dehydroquinic acid derivative
4CL0	;	3.1	;	Structure of the Mycobacterium tuberculosis Type II Dehydroquinase inhibited by a 3-dehydroquinic acid derivative
4CKW	;	2.7	;	Structure of the Mycobacterium tuberculosis Type II Dehydroquinase N12S mutant (Crystal Form 1)
4CKX	;	2.6	;	Structure of the Mycobacterium tuberculosis Type II Dehydroquinase N12S mutant (Crystal Form 2)
4KXR	;	2.6	;	Structure of the Mycobacterium tuberculosis type VII secretion system chaperone EspG5 in complex with PE25-PPE41 dimer
7ADK	;	2.8	;	Structure of the mycoplasma MIB and MIP proteins
7ADJ	;	2.8	;	Structure of the mycoplasma MIB protein
7ADM	;	3.5	;	Structure of the mycoplasma MIB protein
3PZD	;	2.5	;	Structure of the myosin X MyTH4-FERM/DCC complex
6ZZW	;	1.9	;	Structure of the N terminal domain of Bc2L-C lectin (1-131) in complex with Globo H (H-type 3) and CAS No 912569-62-1
6TIG	;	1.9	;	Structure of the N terminal domain of Bc2L-C lectin (1-131) in complex with Globo H (H-type 3) antigen
6TID	;	1.614	;	Structure of the N terminal domain of Bc2L-C lectin (1-131) in complex with H-type 1 antigen
4UD1	;	2.48	;	Structure of the N Terminal domain of the MERS CoV nucleocapsid
4P5W	;	2.4	;	Structure of the N- and C-terminal domain fusion of the human mitochondrial aspartate/glutamate carrier Citrin in the calcium-bound state
4ENE	;	2.4	;	Structure of the N- and C-terminal trimmed ClC-ec1 Cl-/H+ antiporter and Fab Complex
7ZZK	;	1.5	;	Structure of the N-acetyl-D-glucosamine oxidase from Ralstonia Solanacearum
4K30	;	2.103	;	Structure of the N-acetyltransferase domain of human N-acetylglutamate synthase
4NEX	;	1.6955	;	Structure of the N-acetyltransferase domain of X. fastidiosa NAGS/K
3O2F	;	2.0	;	Structure of the N-domain of GRP94 bound to the HSP90 inhibitor PU-H54
7AGW	;	1.511	;	Structure of the N-domain of the K+/H+ antiporter subunit KhtT at pH 6.5
7AHT	;	2.16	;	Structure of the N-domain of the K+/H+ antiporter subunit KhtT at pH 7.5
7AGY	;	1.54	;	Structure of the N-domain of the K+/H+ antiporter subunit KhtT at pH 8.5
2JCD	;	2.11	;	Structure of the N-oxygenase AurF from Streptomyces thioluteus
6ROY	;	2.1	;	Structure of the N-SH2 domain of the human tyrosine-protein phosphatase non-receptor type 11 in complex with the phosphorylated immune receptor tyrosine-based inhibitory motif
6ROZ	;	2.89	;	Structure of the N-SH2 domain of the human tyrosine-protein phosphatase non-receptor type 11 in complex with the phosphorylated immune receptor tyrosine-based switch motif
1L6N	;		;	STRUCTURE OF THE N-TERMINAL 283-RESIDUE FRAGMENT OF THE HIV-1 GAG POLYPROTEIN
2RND	;		;	Structure of the N-terminal BARpeptide in DPC micelles
2RMY	;		;	Structure of the N-terminal BARpeptide in SDS micelles
2WT8	;	1.6	;	Structure of the N-terminal BRCT domain of human microcephalin (Mcph1)
3PA6	;	1.5	;	Structure of the N-terminal BRCT domain of human microcephalin (MCPH1)
3KTF	;	1.6	;	Structure of the N-terminal BRCT domain of human microcephalin (MCPH1).
2WLV	;	1.25	;	Structure of the N-terminal capsid domain of HIV-2
2WLW	;	1.5	;	Structure of the N-terminal capsid domain of HIV-2
6S2V	;	2.96	;	Structure of the N-terminal catalytic region of T. thermophilus Rel
6S2T	;	2.75	;	Structure of the N-terminal catalytic region of T. thermophilus Rel bound to ppGpp
4XUP	;	2.43	;	Structure of the N-terminal CBM22-1-CBM22-2 tandem domain from Paenibacillus barcinonensis Xyn10C
3M4R	;	2.0	;	Structure of the N-terminal Class II Aldolase domain of a conserved protein from Thermoplasma acidophilum
2JA9	;	2.2	;	Structure of the N-terminal deletion of yeast exosome component Rrp40
5X4R	;	1.5	;	Structure of the N-terminal domain (NTD) of MERS-CoV spike protein
5X4S	;	2.2	;	Structure of the N-terminal domain (NTD)of SARS-CoV spike protein
6PZJ	;	1.75	;	Structure of the N-terminal domain (residues 43-304) of Methyl-accepting chemotaxis protein from Leptospira interrogans serogroup Icterohaemorrhagiae serovar Copenhageni (strain Fiocruz L1-130)
1E32	;	2.9	;	Structure of the N-Terminal domain and the D1 AAA domain of membrane fusion ATPase p97
2GEC	;	1.3	;	Structure of the N-terminal domain of avian infectious bronchitis virus nucleocapsid protein (strain Gray) in a novel dimeric arrangement
2YH6	;	1.55	;	Structure of the N-terminal domain of BamC from E. coli
7OLU	;	1.793	;	Structure of the N-terminal domain of BC2L-C lectin (1-131) in complex with a synthetic beta-C-fucoside ligand
8BRO	;	1.55	;	Structure of the N-terminal domain of BC2L-C lectin (1-131) in complex with a synthetic beta-fucosylamide
7OLW	;	1.32	;	Structure of the N-terminal domain of BC2L-C lectin (1-131) in complex with a synthetic beta-N-fucoside ligand
7OLN	;	1.92	;	Structure of the N-terminal domain of BC2L-C lectin (1-131) in complex with Lewis y antigen
3PYI	;	2.104	;	Structure of the N-terminal domain of C. elegans SAS-6
2XGU	;	1.502	;	Structure of the N-terminal domain of capsid protein from Rabbit Endogenous Lentivirus (RELIK)
2XGV	;	2.0	;	Structure of the N-terminal domain of capsid protein from Rabbit Endogenous Lentivirus (RELIK)
1B47	;	2.2	;	STRUCTURE OF THE N-TERMINAL DOMAIN OF CBL IN COMPLEX WITH ITS BINDING SITE IN ZAP-70
8R8C	;	1.55	;	Structure of the N-terminal domain of CMA from Cucumis melo in complex with N-acetylgalactosamine
8R8A	;	1.317	;	Structure of the N-terminal domain of CMA in complex with N-acetyllactosamine
4LMT	;	1.71	;	Structure of The N-terminal domain of Coronavirus Nucleocapsid Protein complexed with NSC663284
6P0X	;	2.4	;	Structure of the N-terminal domain of effector protein SpvB from Salmonella typhimurium strain LT2
1V4A	;	2.0	;	Structure of the N-terminal Domain of Escherichia coli Glutamine Synthetase adenylyltransferase
2D68	;	1.6	;	Structure of the N-terminal domain of FOP (FGFR1OP) protein
2BKD	;		;	Structure of the N-terminal domain of Fragile X Mental Retardation Protein
2KFX	;		;	Structure of the N-terminal domain of human cardiac troponin C bound to calcium ion and to the inhibitor W7
2A9U	;	2.1	;	Structure of the N-terminal domain of Human Ubiquitin carboxyl-terminal hydrolase 8 (USP8)
4CKM	;	2.15	;	Structure of the N-terminal domain of Leishmania SAS-6
5UDF	;	2.35	;	Structure of the N-terminal domain of lipoprotein-releasing system transmembrane protein LolE from Acinetobacter baumannii
5BTW	;	1.2	;	Structure of the N-terminal domain of lpg1496 from Legionella pneumophila
5BTX	;	2.1	;	Structure of the N-terminal domain of lpg1496 from Legionella pneumophila in complex with nucleotide
6KL2	;	2.63	;	Structure of the N-terminal domain of Middle East respiratory syndrome coronavirus nucleocapsid protein
6KL5	;	3.09	;	Structure of The N-terminal domain of Middle East respiratory syndrome coronavirus Nucleocapsid Protein complexed with Benzyl 2-(Hydroxymethyl)-1-Indolinecarboxylate
2FY6	;	1.9	;	Structure of the N-terminal domain of Neisseria meningitidis PilB
4GA0	;	1.15	;	Structure of the N-terminal domain of Nup358
4GA1	;	1.15	;	Structure of the N-terminal domain of Nup358
4GA2	;	0.95	;	Structure of the N-terminal domain of Nup358
4XB4	;	1.544	;	Structure of the N-terminal domain of OCP binding canthaxanthin
2X8X	;	1.97	;	Structure of the N-terminal domain of Omp85 from the Thermophilic Cyanobacterium Thermosynechococcus elongatus
1WLF	;	2.05	;	Structure of the N-terminal domain of PEX1 AAA-ATPase: Characterization of a putative adaptor-binding domain
6KJK	;	1.3	;	Structure of the N-terminal domain of PorA
4IPD	;	1.51	;	Structure of the N-terminal domain of RPA70, E100R mutant
4IPC	;	1.22	;	Structure of the N-terminal domain of RPA70, E7R mutant
4IPG	;	1.58	;	Structure of the N-terminal domain of RPA70, E7R, E100R mutant
4YNZ	;	2.0	;	Structure of the N-terminal domain of SAD
1S0P	;	1.4	;	Structure of the N-Terminal Domain of the Adenylyl Cyclase-Associated Protein (CAP) from Dictyostelium discoideum.
3HI2	;	2.0	;	Structure of the N-terminal domain of the E. coli antitoxin MqsA (YgiT/b3021) in complex with the E. coli toxin MqsR (YgiU/b3022)
3GA8	;	1.7	;	Structure of the N-terminal domain of the E. coli protein MqsA (YgiT/b3021)
4A3X	;	1.65	;	Structure of the N-terminal domain of the Epa1 adhesin (Epa1-Np) from the pathogenic yeast Candida glabrata, in complex with calcium and lactose
5NB9	;		;	Structure of the N-terminal domain of the Escherichia Coli ProQ RNA binding protein
4LHL	;	1.43	;	Structure of the N-terminal domain of the Flo1 adhesin (N-Flo1p) from the yeast Saccharomyces cerevisiae
4LHN	;	2.12	;	Structure of the N-terminal domain of the Flo1 adhesin (N-Flo1p) from the yeast Saccharomyces cerevisiae, in complex with calcium and mannose
4P60	;	2.4	;	Structure of the N-terminal domain of the human mitochondrial aspartate/glutamate carrier Aralar in the apo state
4P5X	;	2.261	;	Structure of the N-terminal domain of the human mitochondrial aspartate/glutamate carrier Aralar in the calcium-bound state
1BYW	;	2.6	;	STRUCTURE OF THE N-TERMINAL DOMAIN OF THE HUMAN-ERG POTASSIUM CHANNEL
4LHK	;	1.73	;	Structure of the N-terminal domain of the Lg-Flo1 adhesin (N-Lg-Flo1p) from the yeast Saccharomyces pastorianus, in complex with calcium and alpha-1,2-mannobiose
1GWP	;		;	STRUCTURE OF THE N-TERMINAL DOMAIN OF THE MATURE HIV-1 CAPSID PROTEIN
5ABK	;		;	Structure of the N-terminal domain of the metalloprotease PrtV from Vibrio cholerae
1A4H	;	2.5	;	STRUCTURE OF THE N-TERMINAL DOMAIN OF THE YEAST HSP90 CHAPERONE IN COMPLEX WITH GELDANAMYCIN
5NPT	;	2.4	;	Structure of the N-terminal domain of the yeast telomerase reverse transcriptase
7UGC	;		;	Structure of the N-terminal domain of ViaA
6LFA	;	2.3	;	Structure of the N-terminal domain of Wag31
2D27	;	2.21	;	Structure of the N-terminal domain of XpsE (crystal form I4122)
2D28	;	2.0	;	Structure of the N-terminal domain of XpsE (crystal form P43212)
5XFN	;	1.9	;	Structure of the N-terminal domains of PHF1
5XFO	;	1.9	;	Structure of the N-terminal domains of PHF1
4J3K	;	2.0	;	Structure of the N-terminal domian of human coronavirus OC43 nucleocapsid protein
1J54	;	1.7	;	Structure of the N-terminal exonuclease domain of the epsilon subunit of E.coli DNA polymerase III at pH 5.8
1J53	;	1.8	;	Structure of the N-terminal Exonuclease Domain of the Epsilon Subunit of E.coli DNA Polymerase III at pH 8.5
4U9R	;	2.17	;	Structure of the N-terminal Extension from Cupriavidus metallidurans CzcP
2XRB	;	2.5	;	Structure of the N-terminal four domains of the complement regulator Rat Crry
2XRD	;	3.5	;	Structure of the N-terminal four domains of the complement regulator Rat Crry
3GS3	;	2.4	;	Structure of the N-terminal HEAT Domain of Symplekin from D. melanogaster
4NQI	;	2.21	;	Structure of the N-terminal I-BAR domain (1-259) of D.Discoideum IBARa
4LUN	;	1.641	;	Structure of the N-terminal mIF4G domain from S. cerevisiae Upf2, a protein involved in the degradation of mRNAs containing premature stop codons
6YXO	;	2.0	;	Structure of the N-terminal module of the human SWI/SNF-subunit BAF155/SMARCC1
2YK0	;	2.8	;	Structure of the N-terminal NTS-DBL1-alpha and CIDR-gamma double domain of the PfEMP1 protein from Plasmodium falciparum varO strain.
7SZX	;	3.5	;	Structure of the N-terminal nuclease and origin binding domain of Human Parvovirus B19
2BVE	;	2.2	;	Structure of the N-terminal of Sialoadhesin in complex with 2-Phenyl- Prop5Ac
4J7O	;	2.175	;	Structure of the N-terminal Repeat Domain of Rickettsia Sca2
1SSK	;		;	Structure of the N-terminal RNA-binding Domain of the SARS CoV Nucleocapsid Protein
2JM2	;		;	Structure of the N-terminal subdomain of insulin-like growth factor (IGF) binding protein-6 and its interactions with IGFs
2G3P	;	1.9	;	STRUCTURE OF THE N-TERMINAL TWO DOMAINS OF THE INFECTIVITY PROTEIN G3P OF FILAMENTOUS PHAGE FD
2P08	;	2.0	;	Structure of the N-terminally truncated PAS domain of signal transduction histidine kinase from Nostoc punctiforme PCC 73102 with homology to the H-NOXA/H-NOBA domain of the soluble guanylyl cyclase
3MVS	;	1.1	;	Structure of the N-terminus of Cadherin 23
2IFS	;		;	Structure of the N-WASP EVH1 domain in complex with an extended WIP peptide
1MKE	;		;	Structure of the N-WASP EVH1 Domain-WIP complex
4EA3	;	3.013	;	Structure of the N/OFQ Opioid Receptor in Complex with a Peptide Mimetic
4JTM	;	1.43	;	Structure of the N0 domain of the type II secretin from enterotoxigenic Escherichia coli
4IZL	;	2.8	;	Structure Of The N248A Mutant of the PANTON-VALENTINE LEUCOCIDIN S Component from STAPHYLOCOCCUS AUREUS
4F2U	;	2.19	;	Structure of the N254Y/H258Y double mutant of the Phosphatidylinositol-Specific Phospholipase C from S.aureus
4I90	;	1.65	;	Structure of the N254Y/H258Y mutant of the phosphatidylinositol-specific phospholipase C from S. aureus bound to choline
4I9J	;	1.85	;	Structure of the N254Y/H258Y mutant of the phosphatidylinositol-specific phospholipase C from S. aureus bound to diC4PC
4I9M	;	2.2	;	Structure of the N254Y/H258Y mutant of the phosphatidylinositol-specific phospholipase C from Staphylococcus aureus bound to HEPES
1XGZ	;	2.0	;	Structure of the N298S variant of human pancreatic alpha-amylase
1XH0	;	2.0	;	Structure of the N298S variant of human pancreatic alpha-amylase complexed with acarbose
1XH1	;	2.03	;	Structure of the N298S variant of human pancreatic alpha-amylase complexed with chloride
1XH2	;	2.2	;	Structure of the N298S variant of human pancreatic alpha-amylase complexed with chloride and acarbose
7ABO	;	1.95	;	Structure of the N318H variant of the reversible pyrrole-2-carboxylic acid decarboxylase PA0254/HudA in complex with FMN
8DOM	;	1.89	;	Structure of the N358Y single variant ofserine hydroxymethyltransferase 8 from Glycine max cultivar Essex complexed with PLP
8DSK	;	1.63	;	Structure of the N358Y variant of serine hydroxymethyltransferase 8 in complex with PLP, glycine, and formyl tetrahydrofolate
2XXG	;	1.6	;	STRUCTURE OF THE N90S MUTANT OF NITRITE REDUCTASE FROM ALCALIGENES XYLOSOXIDANS
2XX1	;	3.0	;	STRUCTURE OF THE N90S MUTANT OF NITRITE REDUCTASE FROM ALCALIGENES XYLOSOXIDANS complexed with nitrite
2XX0	;	1.46	;	STRUCTURE OF THE N90S-H254F MUTANT OF NITRITE REDUCTASE FROM ALCALIGENES XYLOSOXIDANS
3AOU	;	3.14	;	Structure of the Na+ unbound rotor ring modified with N,N f-Dicyclohexylcarbodiimide of the Na+-transporting V-ATPase
2JO1	;		;	Structure of the Na,K-ATPase regulatory protein FXYD1 in micelles
2MKV	;		;	Structure of the NA,K-ATPASE regulatory protein FXYD2b in micelles
7JSK	;	3.04	;	Structure of the NaCT-Citrate complex
7JSJ	;	3.12	;	Structure of the NaCT-PF2 complex
1EDZ	;	2.8	;	STRUCTURE OF THE NAD-DEPENDENT 5,10-METHYLENETETRAHYDROFOLATE DEHYDROGENASE FROM SACCHAROMYCES CEREVISIAE
6OW4	;	1.99	;	Structure of the NADH-bound form of 20beta-Hydroxysteroid Dehydrogenase from Bifidobacterium adolescentis strain L2-32
7SSS	;	2.4	;	Structure of the NADH-bound human COQ7:COQ9 complex by single-particle electron cryo-microscopy
4ZN0	;	2.6	;	Structure of the NADPH-dependent thioredoxin reductase from Methanosarcina mazei
7NOZ	;	3.9	;	Structure of the nanobody stablized properdin bound alternative pathway proconvertase C3b:FB:FP
6H1F	;	1.9	;	Structure of the nanobody-stabilized gelsolin D187N variant (second domain)
5G2E	;	6.7	;	Structure of the Nap1 H2A H2B complex
1JNI	;	1.25	;	Structure of the NapB subunit of the periplasmic nitrate reductase from Haemophilus influenzae.
4AKK	;	2.145	;	Structure of the NasR transcription antiterminator
1TLV	;	1.95	;	Structure of the native and inactive LicT PRD from B. subtilis
7KO7	;	8.3	;	Structure of the native cardiac thin filament at pCa=5.8 having upper Tn in Ca2+ free state and lower Tn in Ca2+ bound state
4XFY	;	2.8	;	Structure of the native full-length dehydrated HIV-1 capsid protein
4XFX	;	2.43	;	Structure of the native full-length HIV-1 capsid protein
6SLQ	;	4.4	;	Structure of the native full-length HIV-1 capsid protein A92E in helical assembly (-12,11)
6SLU	;	4.7	;	Structure of the native full-length HIV-1 capsid protein A92E in helical assembly (-13,11)
6SKM	;	4.9	;	Structure of the native full-length HIV-1 capsid protein A92E in helical assembly (-13,12)
6AY9	;	2.5	;	Structure of the native full-length HIV-1 capsid protein in complex with CPSF6 peptide
6ZDJ	;	5.8	;	Structure of the native full-length HIV-1 capsid protein in complex with Cyclophilin A from helical assembly (-13,10)
6Y9X	;	4.4	;	Structure of the native full-length HIV-1 capsid protein in complex with Cyclophilin A from helical assembly (-13,7)
6Y9W	;	4.1	;	Structure of the native full-length HIV-1 capsid protein in complex with Cyclophilin A from helical assembly (-13,8)
6Y9Z	;	4.8	;	Structure of the native full-length HIV-1 capsid protein in complex with Cyclophilin A from helical assembly (-13,9)
6Y9Y	;	6.1	;	Structure of the native full-length HIV-1 capsid protein in complex with Cyclophilin A from helical assembly (-7,13)
6Y9V	;	6.9	;	Structure of the native full-length HIV-1 capsid protein in complex with Cyclophilin A from helical assembly (-8,13)
6AYA	;	2.4	;	Structure of the native full-length HIV-1 capsid protein in complex with Nup153 peptide
4XFZ	;	2.7	;	Structure of the native full-length HIV-1 capsid protein in complex with PF-3450074 (PF74)
6SMU	;	5.0	;	Structure of the native full-length HIV-1 capsid protein in helical assembly (-13,12)
6SKK	;	3.6	;	Structure of the native full-length HIV-1 capsid protein in helical assembly (-13,8)
6SKN	;	4.5	;	Structure of the native full-length HIV-1 capsid protein in helical assembly (-13,8)
6V6S	;	4.3	;	Structure of the native human gamma-tubulin ring complex
2Q0Q	;	1.5	;	Structure of the Native M. Smegmatis Aryl Esterase
1JW9	;	1.7	;	Structure of the Native MoeB-MoaD Protein Complex
2R22	;	1.4	;	Structure of the native RNA tridecamer r(GCGUUUGAAACGC) at 1.5 A (NatMn)
5NCS	;	3.0	;	Structure of the native serpin-type proteinase inhibitor, miropin.
6K9Q	;	3.1	;	Structure of the native supercoiled hook as a universal joint
6ZMB	;	1.7	;	Structure of the native tRNA-Monooxygenase enzyme MiaE
2I7B	;	1.99	;	Structure of the naturally occuring mutant of human ABO(H) Blood group B glycosyltransferase: GTB/A268T
5XSY	;	4.0	;	Structure of the Nav1.4-beta1 complex from electric eel
6S2P	;	2.5	;	Structure of the NB-ARC domain from the Tomato immune receptor NRC1
6TJV	;	3.2	;	Structure of the NDH-1MS complex from Thermosynechococcus elongatus
4G9K	;	2.7	;	Structure of the Ndi1 protein from Saccharomyces cerevisiae
5YJY	;	3.4	;	Structure of the Ndi1 protein from Saccharomyces cerevisiae in complex with AC0-12.
5YJX	;	3.21	;	Structure of the Ndi1 protein from Saccharomyces cerevisiae in complex with myxothiazol.
4GAP	;	2.9	;	Structure of the Ndi1 protein from Saccharomyces cerevisiae in complex with NAD+
4GAV	;	3.0	;	Structure of the Ndi1 protein from Saccharomyces cerevisiae in complex with quinone
5YJW	;	1.85	;	Structure of the Ndi1 protein from Saccharomyces cerevisiae in complex with the competitive inhibitor, stigmatellin.
4GKQ	;	2.99	;	Structure of the neck and C-terminal motor homology domain of ViK1 from Candida glabrata
3JQH	;	2.201	;	Structure of the neck region of the glycan-binding receptor DC-SIGNR
7MDI	;	4.3	;	Structure of the Neisseria gonorrhoeae ribonucleotide reductase in the inactive state
2HIL	;	12.5	;	Structure of the Neisseria gonorrhoeae Type IV pilus filament from x-ray crystallography and electron cryomicroscopy
2OPD	;	2.5	;	Structure of the Neisseria meningitidis minor Type IV pilin, PilX
8JJ6	;	2.72	;	Structure of the NELF-BCE complex
4CPM	;	2.75	;	Structure of the Neuraminidase from the B/Brisbane/60/2008 virus in complex with Oseltamivir
4CPN	;	2.4	;	Structure of the Neuraminidase from the B/Brisbane/60/2008 virus in complex with Zanamivir
4CPL	;	2.0	;	Structure of the Neuraminidase from the B/Brisbane/60/2008 virus.
4CPO	;	2.2	;	Structure of the Neuraminidase from the B/Lyon/CHU/15.216/2011 virus
4CPY	;	1.8	;	Structure of the Neuraminidase from the B/Lyon/CHU/15.216/2011 virus in complex with Oseltamivir
4CPZ	;	2.2	;	Structure of the Neuraminidase from the B/Lyon/CHU/15.216/2011 virus in complex with Zanamivir
3RQK	;	2.21	;	Structure of the neuronal nitric oxide synthase heme domain in complex with 4-methyl-6-{[(3R,4R)-4-(2-{[(1R,2S)-2-(3-methylphenyl)cyclopropyl]amino}ethoxy)pyrrolidin-3-yl]methyl}pyridin-2-amine and its isomer
3RQN	;	1.95	;	Structure of the neuronal nitric oxide synthase heme domain in complex with 6-(((3*R*,4*R*)-4-(2-(((*S* )-1-(3-fluorophenyl)propan-2-yl)amino)ethoxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine
3RQJ	;	1.84	;	Structure of the neuronal nitric oxide synthase heme domain in complex with 6-(((3R,4R)-4-(2-((1S,2R)-2-(3-Fluorophenyl)cyclopropylamino)ethoxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine
3RQL	;	1.93	;	Structure of the neuronal nitric oxide synthase heme domain in complex with 6-(((3R,4R)-4-(2-((1S,2R/1R,2S)-2-(3-Clorophenyl)cyclopropylamino)ethoxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine
3RQM	;	1.95	;	Structure of the neuronal nitric oxide synthase heme domain in complex with 6-{[(3R,4R)-4-(2-{[(2R/2S)-1-(3-fluorophenyl)propan-2-yl]amino}ethoxy)pyrrolidin-3-yl]methyl}-4-methylpyridin-2-amine
4DEQ	;	2.649	;	Structure of the Neuropilin-1/VEGF-A complex
4CZW	;	2.6	;	Structure of the Neurospora crassa Pan2 catalytic unit (protease and nuclease domain)
4CZV	;	2.1	;	Structure of the Neurospora crassa Pan2 WD40 domain
1ML9	;	1.98	;	Structure of the Neurospora SET domain protein DIM-5, a histone lysine methyltransferase
3MAW	;	3.5	;	Structure of the Newcastle disease virus F protein in the post-fusion conformation
2QY9	;	1.9	;	Structure of the NG+1 construct of the E. coli SRP receptor FtsY
4AU5	;	3.696	;	Structure of the NhaA dimer, crystallised at low pH
4K1P	;	2.05	;	Structure of the NheA component of the Nhe toxin from Bacillus cereus
5DMU	;	1.949	;	Structure of the NHEJ polymerase from Methanocella paludicola
4R94	;	1.668	;	Structure of the nickase domain of NS1 from MVM complexed with magnesium
3TQV	;	2.62	;	Structure of the nicotinate-nucleotide pyrophosphorylase from Francisella tularensis.
4NOX	;	2.722	;	Structure of the nine-bladed beta-propeller of eIF3b
1DW2	;	2.2	;	STRUCTURE OF THE NITRIC OXIDE COMPLEX OF REDUCED SHP, AN OXYGEN BINDING CYTOCHROME C
4WNA	;	2.0	;	Structure of the Nitrogenase MoFe Protein from Azotobacter vinelandii Pressurized with Xenon
4WN9	;	1.9	;	Structure of the Nitrogenase MoFe Protein from Clostridium pasteurianum Pressurized with Xenon
7KI4	;	2.9	;	Structure of the NiV F glycoprotein in complex with the 12B2 neutralizing antibody
6NPJ	;	3.8	;	Structure of the NKCC1 CTD
8H0P	;	3.15	;	Structure of the NMB30-NMBR and Gq complex
4ZRL	;	2.28	;	Structure of the non canonical Poly(A) polymerase complex GLD-2 - GLD-3
2OQ9	;		;	Structure of the non-canonical Mcol5 of Hydra nematocysts
3GPN	;	2.5	;	Structure of the non-trimeric form of the E113G PCNA mutant protein
3X2R	;	2.9	;	Structure of the nonameric bacterial amyloid secretion channel CsgG
6FT6	;	3.9	;	Structure of the Nop53 pre-60S particle bound to the exosome nuclear cofactors
3NK6	;	2.0	;	Structure of the Nosiheptide-resistance methyltransferase
3NK7	;	2.1	;	Structure of the Nosiheptide-resistance methyltransferase S-adenosyl-L-methionine Complex
4C0D	;	3.2	;	Structure of the NOT module of the human CCR4-NOT complex (CNOT1-CNOT2-CNOT3)
4C0F	;	2.4	;	Structure of the NOT-box domain of human CNOT2
4C0G	;	2.4	;	Structure of the NOT-box domain of human CNOT3
4C0E	;	3.2	;	Structure of the NOT1 superfamily homology domain from Chaetomium thermophilum
6XSW	;	2.98	;	Structure of the Notch3 NRR in complex with an antibody Fab Fragment
3MWN	;	2.6	;	Structure of the Novel 14 kDa Fragment of alpha-Subunit of Phycoerythrin from the Starving Cyanobacterium Phormidium Tenue
2L73	;		;	Structure of the NOXO1b PX domain
4IYP	;	2.797	;	structure of the nPP2Ac-alpha4 complex
5JRZ	;	1.62	;	Structure of the NS3 helicase from the French Polynesia strain of the Zika virus
5ULP	;	1.55	;	Structure of the NS5 methyltransferase from Zika bound to MS2042
2VRI	;	1.9	;	Structure of the NSP3 X-domain of human coronavirus NL63
5BXQ	;	2.5	;	Structure of the NTF2:RanGDP complex
1NFK	;	2.3	;	STRUCTURE OF THE NUCLEAR FACTOR KAPPA-B (NF-KB) P50 HOMODIMER
6FSZ	;	4.6	;	Structure of the nuclear RNA exosome
4XGL	;	1.8	;	Structure of the nuclease subunit of human mitochondrial RNase P (MRPP3) at 1.8A
4XGM	;	1.98	;	Structure of the nuclease subunit of human mitochondrial RNase P (MRPP3) at 1.98A
3BBZ	;	2.1	;	Structure of the nucleocapsid-binding domain from the mumps virus phosphoprotein
4CA9	;		;	Structure of the Nucleoplasmin-like N-terminal domain of Drosophila FKBP39
3OUO	;	2.3	;	Structure of the Nucleoprotein from Rift Valley Fever Virus
3OV9	;	1.6	;	Structure of the Nucleoprotein from Rift Valley Fever Virus
1F6T	;	1.92	;	STRUCTURE OF THE NUCLEOSIDE DIPHOSPHATE KINASE/ALPHA-BORANO(RP)-TDP.MG COMPLEX
8COM	;	3.3	;	Structure of the Nucleosome Core Particle from Trypanosoma brucei
5IDV	;	1.45	;	Structure of the nucleotide binding domain of an ABC transporter MsbA from Acinetobacter baumannii
2AKA	;	1.9	;	Structure of the nucleotide-free myosin II motor domain from Dictyostelium discoideum fused to the GTPase domain of dynamin 1 from Rattus norvegicus
1XSA	;		;	Structure of the nudix enzyme AP4A hydrolase from homo sapiens (E63A mutant)
1XSC	;		;	Structure of the nudix enzyme AP4A hydrolase from homo sapiens (E63A mutant) in complex with ATP
1XSB	;		;	Structure of the nudix enzyme AP4A hydrolase from homo sapiens (E63A mutant) in complex with ATP. No ATP restraints included
3TKN	;	3.4	;	Structure of the Nup82-Nup159-Nup98 heterotrimer
6CO7	;	3.07	;	Structure of the nvTRPM2 channel in complex with Ca2+
2WK1	;	1.4	;	Structure of the O-methyltransferase NovP
1LNZ	;	2.6	;	Structure of the Obg GTP-binding protein
1VAO	;	2.5	;	STRUCTURE OF THE OCTAMERIC FLAVOENZYME VANILLYL-ALCOHOL OXIDASE
1AHV	;	3.1	;	STRUCTURE OF THE OCTAMERIC FLAVOENZYME VANILLYL-ALCOHOL OXIDASE IN COMPLEX WITH 2-NITRO-P-CRESOL
1AHZ	;	3.3	;	STRUCTURE OF THE OCTAMERIC FLAVOENZYME VANILLYL-ALCOHOL OXIDASE IN COMPLEX WITH 4-(1-HEPTENYL)PHENOL
2VAO	;	2.8	;	STRUCTURE OF THE OCTAMERIC FLAVOENZYME VANILLYL-ALCOHOL OXIDASE IN COMPLEX WITH ISOEUGENOL
1AHU	;	2.7	;	STRUCTURE OF THE OCTAMERIC FLAVOENZYME VANILLYL-ALCOHOL OXIDASE IN COMPLEX WITH P-CRESOL
1W1M	;	3.0	;	STRUCTURE OF THE OCTAMERIC FLAVOENZYME VANILLYL-ALCOHOL OXIDASE: Glu502Gly Mutant
1W1K	;	2.55	;	STRUCTURE OF THE OCTAMERIC FLAVOENZYME VANILLYL-ALCOHOL OXIDASE: Ile238Thr Mutant
1W1L	;	2.7	;	STRUCTURE OF THE OCTAMERIC FLAVOENZYME VANILLYL-ALCOHOL OXIDASE: Phe454Tyr Mutant
1W1J	;	2.7	;	STRUCTURE OF THE OCTAMERIC FLAVOENZYME VANILLYL-ALCOHOL OXIDASE: The505Ser Mutant
2QMI	;	2.2	;	Structure of the octameric penicillin-binding protein homologue from Pyrococcus abyssi
7AKC	;	1.6	;	Structure of the of AcylTransferase domain of phenolphthiocerol/phtiocerol synthase A from Mycobacterium bovis (BCG)
7XHT	;	2.55	;	Structure of the OgeuIscB-omega RNA-target DNA complex
4E2D	;	1.997	;	Structure of the old yellow enzyme from Trypanosoma cruzi
2UX0	;	2.46	;	Structure of the oligomerisation domain of calcium-calmodulin dependent protein kinase II gamma
1B4B	;	2.2	;	STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF THE ARGININE REPRESSOR FROM BACILLUS STEAROTHERMOPHILUS
446D	;	3.0	;	STRUCTURE OF THE OLIGONUCLEOTIDE D(CGTATATACG) AS A SITE SPECIFIC COMPLEX WITH NICKEL IONS
1R1M	;	1.9	;	Structure of the OmpA-like domain of RmpM from Neisseria meningitidis
1Q1V	;		;	Structure of the Oncoprotein DEK: a putative DNA-binding Domain Related to the Winged Helix Motif
2DVW	;	2.3	;	Structure of the Oncoprotein Gankyrin in Complex with S6 ATPase of the 26S Proteasome
2DWZ	;	2.4	;	Structure of the Oncoprotein Gankyrin in Complex with S6 ATPase of the 26S Proteasome
2VDF	;	1.95	;	Structure of the OpcA adhesion from Neisseria meningitidis determined by crystallization from the cubic mesophase
5U95	;	2.25	;	Structure of the open conformation of 4-coumarate-CoA ligase from Nicotiana tabacum
6SL1	;	3.6	;	Structure of the open conformation of CtTel1
7QCZ	;	1.85	;	Structure of the orange carotenoid protein from Planktothrix agardhii binding canthaxanthin in the C2 space group
7QD2	;	1.4	;	Structure of the orange carotenoid protein from Planktothrix agardhii binding canthaxanthin in the P21 space group
7QD0	;	1.7	;	Structure of the orange carotenoid protein from Planktothrix agardhii binding echinenone in the C2 space group
7QD1	;	1.71	;	Structure of the orange carotenoid protein from Planktothrix agardhii binding echinenone in the P21 space group
8AJ2	;	2.2	;	structure of the ordered core of Knr4 (loop 189-217 deleted)
7SQO	;	3.17	;	Structure of the orexin-2 receptor(OX2R) bound to TAK-925, Gi and scFv16
4ART	;	2.15	;	STRUCTURE OF THE ORF273 PROTEIN FROM THE ACIDIANUS TWO-TAILED VIRUS
4ATS	;	3.85	;	Structure of the ORF273 protein from the Acidianus two-tailed virus
5EQC	;	2.2	;	Structure of the ornithine aminotransferase from Toxoplasma gondii crystallized in presence of oxidized glutathione reveals partial occupancy of PLP at the protein active site
5E5I	;	1.7	;	Structure of the ornithine aminotransferase from Toxoplasma gondii in complex with inactivator
4ANF	;	2.6	;	Structure of the ornithine carbamoyltransferase from Mycoplasma penetrans with a P23 Space group
6DZ6	;	3.0	;	Structure of the Orthorhombic (Orthrhmb) Crystal Form of Human Apolipoprotein C1
3QDV	;	1.3	;	Structure of the orthorhombic form of the Boletus edulis lectin in complex with N-acetyl glucosamine and N-acetyl galactosamine
3QDX	;	1.7	;	Structure of the orthorhombic form of the Boletus edulis lectin in complex with T-antigen disaccharide and N,N-diacetyl chitobiose
1AH8	;	2.1	;	STRUCTURE OF THE ORTHORHOMBIC FORM OF THE N-TERMINAL DOMAIN OF THE YEAST HSP90 CHAPERONE
2VWI	;	2.15	;	Structure of the OSR1 kinase, a hypertension drug target
4Q3G	;	2.787	;	Structure of the OsSERK2 leucine rich repeat extracellular domain
4Q3I	;	2.35	;	Structure of the OsSERK2 leucine rich repeat extracellular domain
6I9C	;	1.77	;	Structure of the OTU domain of OTULIN G281R mutant
6SAK	;	2.0	;	Structure of the OTULINcat C129A - SNX27 PDZ domain complex.
4C4V	;	3.0	;	Structure of the outer membrane protein insertase BamA with one POTRA domain.
7OKN	;	3.34	;	Structure of the outer-membrane core complex (inner ring) from a conjugative type IV secretion system
7OKO	;	3.4	;	Structure of the outer-membrane core complex (outer ring) from a conjugative type IV secretion system
7TPM	;	1.9	;	Structure of the outer-membrane lipoprotein carrier protein (LolA) from Borrelia burgdorferi
1M6K	;	1.5	;	Structure of the OXA-1 class D beta-lactamase
1W4V	;	1.8	;	structure of the oxidised form of human thioredoxin 2
2WPN	;	2.04	;	Structure of the oxidised, as-isolated NiFeSe hydrogenase from D. vulgaris Hildenborough
2AMS	;	1.4	;	Structure of the oxidized Hipip from thermochromatium tepidum at 1.4 angstrom resolution
1FLV	;	2.0	;	STRUCTURE OF THE OXIDIZED LONG CHAIN FLAVODOXIN FROM ANABAENA 7120 AT 2 ANGSTROMS RESOLUTION
1YQW	;	1.83	;	Structure of the Oxidized Unready Form of Ni-Fe Hydrogenase
7WY2	;	1.45	;	Structure of the Oxomolybdenum Mesoporphyrin IX-Reconstituted CYP102A1 F87A Mutant Haem Domain with N-Enanthyl-L-Prolyl-L-Phenylalanine in complex with Styrene
7WY3	;	1.6	;	Structure of the Oxomolybdenum Mesoporphyrin IX-Reconstituted CYP102A1 F87V Mutant Haem Domain with N-(5-Cyclohexyl)valeroyl-L-Phenylalanine in complex with Styrene
6JMH	;	1.46	;	Structure of the Oxomolybdenum Mesoporphyrin IX-Reconstituted CYP102A1 Haem Domain with N-Abietoyl-L-Tryptophan
7WY1	;	1.6	;	Structure of the Oxomolybdenum Mesoporphyrin IX-Reconstituted CYP102A1 Haem Domain with N-Enanthyl-L-Prolyl-L-Phenylalanine in complex with Styerene
3IHM	;	2.3	;	Structure of the oxygenase component of a Pseudomonas styrene monooxygenase
4P26	;	1.9	;	Structure of the P domain from a GI.7 Norovirus variant in complex with A-type 2 HBGA
4P1V	;	1.5497	;	Structure of the P domain from a GI.7 Norovirus variant in complex with H-type 2 HBGA
4P3I	;	1.6941	;	Structure of the P domain from a GI.7 Norovirus variant in complex with LeA HBGA.
4P2N	;	1.7	;	Structure of the P domain from a GI.7 Norovirus variant in complex with LeX HBGA
4P25	;	1.4991	;	Structure of the P domain from a GI.7 Norovirus variant in complex with LeY HBGA.
2VQI	;	3.2	;	Structure of the P pilus usher (PapC) translocation pore
6YSU	;	3.7	;	Structure of the P+0 ArfB-ribosome complex in the post-hydrolysis state
6YSS	;	2.6	;	Structure of the P+9 ArfB-ribosome complex in the post-hydrolysis state
6YST	;	3.2	;	Structure of the P+9 ArfB-ribosome complex with P/E hybrid tRNA in the post-hydrolysis state
6YSR	;	3.1	;	Structure of the P+9 stalled ribosome complex
7P1G	;	3.2	;	Structure of the P. aeruginosa ExoY-F-actin complex
2UV0	;	1.8	;	Structure of the P. aeruginosa LasR ligand-binding domain bound to its autoinducer
4JLE	;	2.35	;	Structure of the P. falciparum PFI1780w PHIST domain
2XTQ	;	2.31	;	Structure of the P107A Colicin M mutant from E. coli
6AXR	;	2.3	;	Structure of the P122A mutant of the HIV-1 capsid protein
7UJI	;	2.3	;	Structure of the P130R single variant of serine hydroxymethyltransferase 8 from Glycine max cultivar Essex complexed with PLP
7UJH	;	2.24	;	Structure of the P130R single variant of serine hydroxymethyltransferase 8 from Glycine max cultivar Essex complexed with PLP and glycine
2XTR	;	2.14	;	Structure of the P176A Colicin M mutant from E. coli
5FJ6	;	7.9	;	Structure of the P2 polymerase inside in vitro assembled bacteriophage phi6 polymerase complex
5FJ7	;	7.9	;	Structure of the P2 polymerase inside in vitro assembled bacteriophage phi6 polymerase complex, with P1 included
7YXW	;	2.5	;	Structure of the p22phox A200G mutant in complex with p47phox peptide
1OV3	;	1.8	;	Structure of the p22phox-p47phox complex
3C04	;	2.2	;	Structure of the P368G mutant of PMM/PGM from P. aeruginosa
3BKQ	;	2.05	;	Structure of the P368G mutant of PMM/PGM in complex with its substrate
4L40	;	2.5	;	Structure of the P450 OleT with a C20 fatty acid substrate bound
4KF2	;	1.82	;	Structure of the P4509 BM3 A82F F87V heme domain
5AOJ	;	1.47	;	Structure of the p53 cancer mutant Y220C in complex with 2-hydroxy-3, 5-diiodo-4-(1H-pyrrol-1-yl)benzoic acid
5AOI	;	1.78	;	Structure of the p53 cancer mutant Y220C in complex with an indole- based small molecule
6GGF	;	1.32	;	Structure of the p53 cancer mutant Y220C in complex with small-molecule stabilizer PK9328
5AOL	;	1.5	;	Structure of the p53 cancer mutant Y220C with bound 3-bromo-5-(trifluoromethyl)benzene-1,2-diamine
5AB9	;	1.36	;	Structure of the p53 cancer mutant Y220C with bound small molecule 7- ethyl-3-(piperidin-4-yl)-1H-indole
5AOK	;	1.35	;	Structure of the p53 cancer mutant Y220C with bound small molecule PhiKan7099
5AOM	;	1.74	;	Structure of the p53 cancer mutant Y220C with bound small molecule PhiKan883
5ABA	;	1.62	;	Structure of the p53 cancer mutant Y220C with bound small-molecule stabilizer PhiKan5149
5A7B	;	1.4	;	Structure of the p53 cancer Y220C bound to the stabilizing small molecule PhiKan5211
2X0V	;	1.8	;	STRUCTURE OF THE P53 CORE DOMAIN MUTANT Y220C BOUND TO 4-(trifluoromethyl)benzene-1,2-diamine
2X0W	;	2.1	;	STRUCTURE OF THE P53 CORE DOMAIN MUTANT Y220C BOUND TO 5,6-dimethoxy- 2-methylbenzothiazole
2X0U	;	1.6	;	STRUCTURE OF THE P53 CORE DOMAIN MUTANT Y220C BOUND TO A 2-amino substituted benzothiazole scaffold
3ZME	;	1.35	;	Structure of the p53 core domain mutant Y220C bound to the small molecule PhiKan7242
4AGM	;	1.52	;	Structure of the p53 core domain mutant Y220C bound to the stabilizing small molecule PhiKan5086
4AGN	;	1.6	;	Structure of the p53 core domain mutant Y220C bound to the stabilizing small molecule PhiKan5116
4AGO	;	1.45	;	Structure of the p53 core domain mutant Y220C bound to the stabilizing small molecule PhiKan5174
4AGP	;	1.5	;	Structure of the p53 core domain mutant Y220C bound to the stabilizing small molecule PhiKan5176
4AGQ	;	1.42	;	Structure of the p53 core domain mutant Y220C bound to the stabilizing small molecule PhiKan5196
4AGL	;	1.7	;	Structure of the p53 core domain mutant Y220C bound to the stabilizing small molecule PhiKan784
2VUK	;	1.5	;	Structure of the p53 core domain mutant Y220C bound to the stabilizing small-molecule drug PhiKan083
6XRE	;	4.6	;	Structure of the p53/RNA polymerase II assembly
2M6X	;		;	Structure of the p7 channel of Hepatitis C virus, genotype 5a
3RSP	;	1.7	;	STRUCTURE OF THE P93G VARIANT OF RIBONUCLEASE A
4A6S	;	2.15	;	Structure of the PAIL lectin from Pseudomonas aeruginosa in complex with 2-Naphtyl-1-thio-beta-D-galactopyranoside
1N8S	;	3.04	;	Structure of the pancreatic lipase-colipase complex
1PVL	;	2.0	;	STRUCTURE OF THE PANTON-VALENTINE LEUCOCIDIN F COMPONENT FROM STAPHYLOCOCCUS AUREUS
1T5R	;	2.0	;	STRUCTURE OF THE PANTON-VALENTINE LEUCOCIDIN S COMPONENT FROM STAPHYLOCOCCUS AUREUS
3TQC	;	2.3	;	Structure of the pantothenate kinase (coaA) from Coxiella burnetii
1X8S	;	2.503	;	Structure of the Par-6 PDZ domain with a Pals1 internal ligand
4JF7	;	2.5018	;	Structure of the parainfluenza virus 5 (PIV5) hemagglutinin-neuraminidase (HN) ectodomain
3TSI	;	2.651	;	Structure of the parainfluenza virus 5 (PIV5) hemagglutinin-neuraminidase (HN) stalk domain
2B9B	;	2.85	;	Structure of the Parainfluenza Virus 5 F Protein in its Metastable, Pre-fusion Conformation
4XJN	;	3.11	;	Structure of the parainfluenza virus 5 nucleocapsid-RNA complex: an insight into paramyxovirus polymerase activity
1NP9	;		;	Structure of the parallel-stranded DNA quadruplex d(TTAGGGA)4 containing the human telomeric repeat
6ZU5	;	2.9	;	Structure of the Paranosema locustae ribosome in complex with Lso2
5DFY	;	1.6	;	Structure of the parental state of GAF3 from Slr1393 of Synechocystis sp. PCC6803 (in vitro assembled protein/chromophore)
5DFX	;	1.8	;	Structure of the parental state of GAF3 from Slr1393 of Synechocystis sp. PCC6803 (in vivo assembled protein/chromophore)
2ZFO	;	1.95	;	Structure of the partially unliganded met state of 400 kDa hemoglobin: Insights into ligand-induced structural changes of giant hemoglobins
8PX4	;	2.5	;	Structure of the PAS domain code by the LIC_11128 gene from Leptospira interrogans serovar Copenhageni Fiocruz, solved at wavelength 3.09 A
6ZJ8	;	2.4	;	Structure of the PAS domain from Bordetella pertussis BvgS
2BKF	;	1.56	;	Structure of the PB1 domain of NBR1
1TS0	;	1.6	;	Structure of the pB1 intermediate from time-resolved Laue crystallography
1TS6	;	1.6	;	Structure of the pB2 intermediate from time-resolved Laue crystallography
6HLX	;	1.65	;	Structure of the PBP AgaA in complex with agropinic acid from A.tumefacien R10
6EPY	;	2.04	;	Structure of the PBP MelB (Atu4661) in complex with raffinose from A.fabrum C58
4P0I	;	1.89	;	Structure of the PBP NocT
4POW	;	1.55	;	Structure of the PBP NocT in complex with pyronopaline
4PP0	;	1.57	;	Structure of the PBP NocT-M117N in complex with pyronopaline
6TG2	;	2.21	;	Structure of the PBP/SBP MotA in complex with mannopinic acid from A.tumefacien R10
4U1D	;	3.3	;	Structure of the PCI domain of translation initiation factor eIF3a
3P83	;	3.05	;	Structure of the PCNA:RNase HII complex from Archaeoglobus fulgidus.
6OLA	;	3.3	;	Structure of the PCV2d virus-like particle
2PW3	;	1.56	;	Structure of the PDE4D-cAMP complex
2VKI	;	1.8	;	Structure of the PDK1 PH domain K465E mutant
3PDV	;	2.2	;	Structure of the PDlim2 PDZ domain in complex with the C-terminal 6-peptide extension of NS1
5FRP	;	2.895	;	Structure of the Pds5-Scc1 complex and implications for cohesin function
5FRR	;	5.8	;	Structure of the Pds5-Scc1 complex and implications for cohesin function
5FRS	;	4.073	;	Structure of the Pds5-Scc1 complex and implications for cohesin function
3CI1	;	1.9	;	Structure of the PduO-type ATP:co(I)rrinoid adenosyltransferase from Lactobacillus reuteri complexed with four-coordinate cob(II)alamin and ATP
3CI4	;	2.0	;	Structure of the PduO-type ATP:co(I)rrinoid adenosyltransferase from Lactobacillus reuteri complexed with four-coordinate cob(II)inamide and ATP
3CI3	;	1.11	;	Structure of the PduO-type ATP:co(I)rrinoid adenosyltransferase from Lactobacillus reuteri complexed with partial adenosylcobalamin and PPPi
7VGE	;	4.0	;	Structure of the PDZ deleted variant of HtrA2 protease (S306A)
2W7R	;	1.6	;	Structure of the PDZ domain of Human Microtubule associated serine- threonine kinase 4
2PA1	;	1.7	;	Structure of the PDZ domain of human PDLIM2 bound to a C-terminal extension from human beta-tropomyosin
2Q3G	;	1.11	;	Structure of the PDZ domain of human PDLIM7 bound to a C-terminal extension from human beta-tropomyosin
2VZ5	;	1.738	;	Structure of the PDZ domain of Tax1 (human T-cell leukemia virus type I) binding protein 3
8DS6	;	4.9	;	Structure of the PEAK3 pseudokinase homodimer
8DP5	;	3.1	;	Structure of the PEAK3/14-3-3 complex
5CRF	;	1.8	;	Structure of the penicillin-binding protein PonA1 from Mycobacterium Tuberculosis
7NXQ	;	2.422	;	Structure of the pentameric C-terminal domain of the capsid protein from Kaposi's sarcoma-associated herpesvirus (KSHV)
6SSP	;	3.25	;	Structure of the pentameric ligand-gated ion channel ELIC in complex with a NAM nanobody
6SSI	;	2.59	;	Structure of the pentameric ligand-gated ion channel ELIC in complex with a PAM nanobody
2XT2	;	1.999	;	Structure of the pentapeptide repeat protein AlbG, a resistance factor for the topoisomerase poison albicidin.
2XT4	;	2.394	;	Structure of the pentapeptide repeat protein AlbG, a resistance factor for the topoisomerase poison albicidin.
2W7Z	;	1.6	;	Structure of the pentapeptide repeat protein EfsQnr, a DNA gyrase inhibitor. Free amines modified by cyclic pentylation with glutaraldehyde.
1FF3	;	1.9	;	STRUCTURE OF THE PEPTIDE METHIONINE SULFOXIDE REDUCTASE FROM ESCHERICHIA COLI
3PBI	;	1.6	;	Structure of the peptidoglycan hydrolase RipB (Rv1478) from Mycobacterium tuberculosis at 1.6 resolution
7D56	;	3.175	;	Structure of the peptidylarginine deiminase type III (PAD3) in complex with Cl-amidine
2HE9	;	2.0	;	Structure of the peptidylprolyl isomerase domain of the human NK-tumour recognition protein
6L4T	;	2.6	;	Structure of the peripheral FCPI from diatom
4TKO	;	2.85	;	Structure of the periplasmic adaptor protein EmrA
7NPS	;	3.81	;	Structure of the periplasmic assembly from the ESX-5 inner membrane complex, C1 model
6I7W	;	1.8	;	Structure of the periplasmic binding protein (PBP) AccA in complex with 2-glucose-2-O-lactic acid phosphate (G2LP) from Agrobacterium fabrum C58
6EQ8	;	2.19	;	Structure of the periplasmic binding protein (PBP) MelB (Atu4661) in complex with galactinol from agrobacterium fabrum C58
6EQ0	;	2.45	;	Structure of the periplasmic binding protein (PBP) MelB (atu4661) in complex with galactose from agrobacterium tumefacien C58
6EQ1	;	2.1	;	Structure of the periplasmic binding protein (PBP) MelB (Atu4661) in complex with stachyose from agrobacterium fabrum C58
5OT9	;	2.45	;	Structure of the periplasmic binding protein (PBP) NocT from A.tumefaciens C58 in complex with histopine.
5OTC	;	2.2	;	Structure of the periplasmic binding protein (PBP) NocT from Agrobacterium tumefaciens C58 in complex with noroctopinic acid.
5OTA	;	2.1	;	Structure of the periplasmic binding protein (PBP) NocT from Agrobacterium tumefaciens C58 in complex with octopinic acid
5OT8	;	2.35	;	Structure of the periplasmic binding protein (PBP) NocT-G97S mutant from A. tumefaciens C58 in complex with octopine.
5ORG	;	1.99	;	Structure of the periplasmic binding protein (PBP) OccJ from A. tumefaciens B6 in complex with octopine.
5ORE	;	2.35	;	Structure of the periplasmic binding protein (PBP) OccJ from agrobacterium tumefaciens B6
4R72	;	1.6	;	Structure of the periplasmic binding protein AfuA from Actinobacillus pleuropneumoniae (apo form)
4R73	;	1.6	;	Structure of the periplasmic binding protein AfuA from Actinobacillus pleuropneumoniae (endogenous glucose-6-phosphate and mannose-6-phosphate bound)
4R74	;	1.93	;	Structure of the periplasmic binding protein AfuA from Actinobacillus pleuropneumoniae (exogenous fructose-6-phosphate bound)
4R75	;	1.278	;	Structure of the periplasmic binding protein AfuA from Actinobacillus pleuropneumoniae (exogenous sedoheptulose-7-phosphate bound)
6FT2	;	1.25	;	Structure of the periplasmic binding protein LAO-Q122A in complex with arginine.
5ITO	;	2.35	;	Structure of the periplasmic binding protein M117N-NocT from A. tumefaciens in complex with octopine
6EPZ	;	1.8	;	Structure of the periplasmic binding protein MelB (Atu4661) in complex with melibiose from Agrobacterium fabrum C58
5ITP	;	1.85	;	Structure of the periplasmic binding protein NocT from A.tumefaciens in complex with octopine
6WCE	;	1.754	;	Structure of the periplasmic binding protein P5PA
1GU6	;	2.5	;	Structure of the Periplasmic Cytochrome c Nitrite Reductase from Escherichia coli
1P1L	;	2.0	;	Structure of the Periplasmic divalent cation tolerance protein CutA from Archaeoglobus fulgidus
3WZ4	;	2.2	;	Structure of the periplasmic domain of DotI (crystal form I)
3WZ5	;	3.5	;	Structure of the periplasmic domain of DotI (crystal form II)
8P9R	;	1.52	;	Structure of the periplasmic domain of ExbD from E. coli in complex with TonB
5H72	;	2.4	;	Structure of the periplasmic domain of FliP
7SB2	;	3.4	;	Structure of the periplasmic domain of GldM from Capnocytophaga canimorsus
2ZOV	;	2.0	;	Structure of the periplasmic domain of MotB from Salmonella (crystal form I)
2ZVY	;	1.75	;	Structure of the periplasmic domain of MotB from Salmonella (crystal form II)
2ZVZ	;	2.4	;	Structure of the periplasmic domain of MotB from Salmonella (crystal form III)
6IF6	;	1.9	;	Structure of the periplasmic domain of SflA
4A2L	;	2.6	;	Structure of the periplasmic domain of the heparin and heparan sulphate sensing hybrid two component system BT4663 in apo and ligand bound forms
4A2M	;	3.4	;	Structure of the periplasmic domain of the heparin and heparan sulphate sensing hybrid two component system BT4663 in apo and ligand bound forms
5Y3Z	;	2.0	;	Structure of the periplasmic domain of the MotB L119P mutant from Salmonella (crystal form 1)
5Y40	;	2.8	;	Structure of the periplasmic domain of the MotB L119P mutant from Salmonella (crystal form 2)
4BHQ	;	2.05	;	Structure of the periplasmic domain of the PilN type IV pilus biogenesis protein from Thermus thermophilus
6VAT	;	2.35	;	Structure of the periplasmic domain of YejM from Salmonella typhimurium
6VDF	;	1.92	;	Structure of the periplasmic domain of YejM from Salmonella typhimurium (twinned)
4UEY	;	1.9	;	Structure of the periplasmic domain PhoQ double mutant (W104C-A128C)
6DUZ	;	3.6	;	Structure of the periplasmic domains of PrgH and PrgK from the assembled Salmonella type III secretion injectisome needle complex
1ESZ	;	2.0	;	STRUCTURE OF THE PERIPLASMIC FERRIC SIDEROPHORE BINDING PROTEIN FHUD COMPLEXED WITH COPROGEN
3GBP	;	2.4	;	STRUCTURE OF THE PERIPLASMIC GLUCOSE/GALACTOSE RECEPTOR OF SALMONELLA TYPHIMURIUM
4U65	;	2.1	;	Structure of the periplasmic output domain of the Legionella pneumophila LapD ortholog CdgS9 in complex with Pseudomonas fluorescens LapG
4U64	;	2.141	;	Structure of the periplasmic output domain of the Legionella pneumophila LapD ortholog CdgS9 in the apo state
3QZC	;	2.85	;	Structure of the periplasmic stress response protein CpxP
2WUA	;	1.8	;	Structure of the peroxisomal 3-ketoacyl-CoA thiolase from Sunflower
8C0V	;	4.1	;	Structure of the peroxisomal Pex1/Pex6 ATPase complex bound to a substrate in single seam state
8C0W	;	4.7	;	Structure of the peroxisomal Pex1/Pex6 ATPase complex bound to a substrate in twin seam state
7T92	;	3.1	;	Structure of the peroxisomal retro-translocon formed by a heterotrimeric ubiquitin ligase complex
4ARQ	;	2.6	;	Structure of the pesticin S89C, S285C double mutant
6S8U	;	3.67	;	Structure of the PfEMP1 IT4var13 DBLbeta domain bound to ICAM-1
7DIS	;	1.901	;	Structure of the PfGrx1 with platinum
5C5K	;	3.31	;	Structure of the Pfr form of a canonical phytochrome
6AU1	;	1.76	;	Structure of the PgaB (BpsB) glycoside hydrolase domain from Bordetella bronchiseptica
8YHP	;	1.95	;	Structure of the PGK1 from Biortus.
3EP1	;	2.1	;	Structure of the PGRP-Hd from Alvinella pompejana
4B1U	;	2.0	;	Structure of the Phactr1 RPEL domain and RPEL motif directed assemblies with G-actin reveal the molecular basis for actin binding cooperativity.
4B1Z	;	3.3	;	Structure of the Phactr1 RPEL domain bound to G-actin
4B1X	;	1.8	;	Structure of the Phactr1 RPEL-2 bound to G-actin
4B1W	;	1.95	;	Structure of the Phactr1 RPEL-2 domain bound to actin
4B1Y	;	1.29	;	Structure of the Phactr1 RPEL-3 bound to G-actin
4B1V	;	1.75	;	Structure of the Phactr1 RPEL-N domain bound to G-actin
7UM0	;	3.8	;	Structure of the phage AR9 non-virion RNA polymerase holoenzyme in complex with two DNA oligonucleotides containing the AR9 P077 promoter as determined by cryo-EM
8U7I	;	2.57	;	Structure of the phage immune evasion protein Gad1 bound to the Gabija GajAB complex
4V5I	;	5.464	;	Structure of the Phage P2 Baseplate in its Activated Conformation with Ca
2X53	;	3.9	;	Structure of the phage p2 baseplate in its activated conformation with Sr
3RB8	;	2.6	;	Structure of the phage tubulin PhuZ(SeMet)-GDP
3R4V	;	1.67	;	Structure of the phage tubulin PhuZ-GDP
3F3B	;	2.5	;	Structure of the phage-like element PBSX protein xkdH from Bacillus Subtilus. Northeast Structural Genomics Consortium target SR352.
2P26	;	1.75	;	Structure of the PHE2 and PHE3 fragments of the integrin beta2 subunit
2P28	;	2.2	;	Structure of the PHE2 and PHE3 fragments of the integrin beta2 subunit
2INN	;	2.7	;	Structure of the Phenol Hydroxyalse-Regulatory Protein Complex
2INP	;	2.3	;	Structure of the Phenol Hydroxylase-Regulatory Protein Complex
1PBY	;	1.7	;	Structure of the Phenylhydrazine Adduct of the Quinohemoprotein Amine Dehydrogenase from Paracoccus denitrificans at 1.7 A Resolution
2PK9	;	2.906	;	Structure of the Pho85-Pho80 CDK-cyclin Complex of the Phosphate-responsive Signal Transduction Pathway
2PMI	;	2.9	;	Structure of the Pho85-Pho80 CDK-cyclin Complex of the Phosphate-responsive Signal Transduction Pathway with Bound ATP-gamma-S
3T91	;	2.64	;	Structure of the Phosphatase Domain of the Cell Fate Determinant SpoIIE from Bacillus subtilis
3T9Q	;	2.76	;	Structure of the Phosphatase Domain of the Cell Fate Determinant SpoIIE from Bacillus subtilis (Mn presoaked)
5MQH	;	2.45	;	Structure of the Phosphatase Domain of the Cell Fate Determinant SpoIIE from Bacillus subtilis in a crystal form without domain swapping
6ESV	;	1.78	;	Structure of the phosphate-bound form of AioX from Rhizobium sp. str. NT-26
6SLD	;	1.4	;	Structure of the Phosphatidylcholine Binding Mutant of Yeast Sec14 Homolog Sfh1 (S175I,T177I) in Complex with Phosphatidylinositol
1B7A	;	2.25	;	STRUCTURE OF THE PHOSPHATIDYLETHANOLAMINE-BINDING PROTEIN FROM BOVINE BRAIN
3V18	;	2.34	;	Structure of the Phosphatidylinositol-specific phospholipase C from Staphylococcus aureus
7MEZ	;	2.89	;	Structure of the phosphoinositide 3-kinase p110 gamma (PIK3CG) p101 (PIK3R5) complex
7NXE	;	2.1	;	Structure of the Phospholipase C gamma 1 tSH2 domain in complex with a phosphorylated KSHV pK15 peptide
5MI8	;	2.18	;	Structure of the phosphomimetic mutant of EF-Tu T383E
5MI9	;	3.3	;	Structure of the phosphomimetic mutant of the elongation factor EF-Tu T62E
5MSV	;	2.34	;	Structure of the phosphopantetheine modified PCP-R didomain of carboxylic acid reductase (CAR) in complex with NADP
4MRT	;	2.0	;	Structure of the Phosphopantetheine Transferase Sfp in Complex with Coenzyme A and a Peptidyl Carrier Protein
3TQR	;	1.97	;	Structure of the phosphoribosylglycinamide formyltransferase (purN) in complex with CHES from Coxiella burnetii
3G7C	;	2.0	;	Structure of the Phosphorylation Mimetic of Occludin C-term Tail
2G57	;		;	Structure of the Phosphorylation Motif of the oncogenic Protein beta-Catenin Recognized By a Selective Monoclonal Antibody
7X1Y	;	3.3	;	Structure of the phosphorylation-site double mutant S431A/T432A of the KaiC circadian clock protein
7X1Z	;	3.3	;	Structure of the phosphorylation-site double mutant S431E/T432E of the KaiC circadian clock protein
2P1W	;	2.3	;	structure of the phosphothreonine lyase SpvC, the effector protein from Salmonella
4IF2	;	2.27	;	Structure of the phosphotriesterase from Mycobacterium tuberculosis
7S97	;	2.35	;	Structure of the Photoacclimated Light Harvesting Complex PC577 from Hemiselmis pacifica
7TLF	;	2.8	;	Structure of the photoacclimated Light Harvesting Complex PE545 from Proteomonas sulcata
1YST	;	3.0	;	STRUCTURE OF THE PHOTOCHEMICAL REACTION CENTER OF A SPHEROIDENE CONTAINING PURPLE BACTERIUM, RHODOBACTER SPHAEROIDES Y, AT 3 ANGSTROMS RESOLUTION
5MG1	;	3.3	;	Structure of the photosensory module of Deinococcus phytochrome by serial femtosecond X-ray crystallography
6HUM	;	3.34	;	Structure of the photosynthetic complex I from Thermosynechococcus elongatus
1PCR	;	2.65	;	STRUCTURE OF THE PHOTOSYNTHETIC REACTION CENTRE FROM RHODOBACTER SPHAEROIDES AT 2.65 ANGSTROMS RESOLUTION: COFACTORS AND PROTEIN-COFACTOR INTERACTIONS
1RG5	;	2.5	;	Structure of the photosynthetic reaction centre from Rhodobacter sphaeroides carotenoidless strain R-26.1
5Y6P	;	3.5	;	Structure of the phycobilisome from the red alga Griffithsia pacifica
6KGX	;	2.8	;	Structure of the phycobilisome from the red alga Porphyridium purpureum
7EZX	;	3.0	;	Structure of the phycobilisome from the red alga Porphyridium purpureum in Middle Light
3T0Y	;	2.102	;	Structure of the PhyR anti-anti-sigma domain bound to the anti-sigma factor, NepR
3N0R	;	1.251	;	Structure of the PhyR stress response regulator at 1.25 Angstrom resolution
3ZHC	;	2.3	;	Structure of the phytase from Citrobacter braakii at 2.3 angstrom resolution.
4BWI	;	2.6	;	Structure of the phytochrome Cph2 from Synechocystis sp. PCC6803
1PKS	;		;	STRUCTURE OF THE PI3K SH3 DOMAIN AND ANALYSIS OF THE SH3 FAMILY
1PKT	;		;	STRUCTURE OF THE PI3K SH3 DOMAIN AND ANALYSIS OF THE SH3 FAMILY
2LUI	;		;	Structure of the PICK PDZ domain in complex with the DAT C-terminal
2GW8	;	1.85	;	Structure of the PII signal transduction protein of Neisseria meningitidis at 1.85 resolution
3UTK	;	1.65	;	Structure of the pilotin of the type II secretion system
2WW8	;	1.9	;	Structure of the pilus adhesin (RrgA) from Streptococcus pneumoniae
2X9W	;	1.92	;	STRUCTURE OF THE PILUS BACKBONE (RRGB) FROM STREPTOCOCCUS PNEUMONIAE
2X9X	;	1.5	;	STRUCTURE OF THE PILUS BACKBONE (RRGB) FROM STREPTOCOCCUS PNEUMONIAE
2X9Y	;	2.33	;	STRUCTURE OF THE PILUS BACKBONE (RRGB) FROM STREPTOCOCCUS PNEUMONIAE
2X9Z	;	1.3	;	STRUCTURE OF THE PILUS BACKBONE (RRGB) FROM STREPTOCOCCUS PNEUMONIAE
4FOU	;	2.1	;	Structure of the PilZ-FimX(EAL domain)-c-di-GMP complex responsible for the regulation of bacterial Type IV pilus biogenesis
5YZ4	;	2.135	;	Structure of the PIN domain endonuclease Utp24
5KBZ	;	1.803	;	Structure of the PksA Product Template domain in complex with a phosphopantetheine mimetic
7O77	;	2.321	;	Structure of the PL6 family alginate lyase Patl3640 from Pseudoalteromonas atlantica T6c
7O7T	;	2.05	;	Structure of the PL6 family alginate lyase Patl3640 from Pseudoalteromonas atlantica T6c in complex with 4-deoxy-L-erythro-5-hexoseulose uronic acid
7O7A	;	1.99	;	Structure of the PL6 family alginate lyase Pedsa0632 from Pseudopedobacter saltans
7O84	;	2.177	;	Structure of the PL6 family alginate lyase Pedsa0632 from Pseudopedobacter saltans in complex with substrate
7O78	;	1.58	;	Structure of the PL6 family chondroitinase B from Pseudopedobacter saltans, Pedsa3807
7O79	;	1.93	;	Structure of the PL6 family polysaccharide lyase Pedsa3628 from Pseudopedobacter saltans
1N4N	;		;	Structure of the Plant Defensin PhD1 from Petunia Hybrida
6I8H	;	3.682	;	Structure of the plant immune signaling node EDS1 (enhanced disease susceptibility 1) in complex with nanobody ENB15
6Q6Z	;	3.476	;	Structure of the plant immune signaling node EDS1 (enhanced disease susceptibility 1) in complex with nanobody ENB21
6I8G	;	2.344	;	Structure of the plant immune signaling node EDS1 (enhanced disease susceptibility 1) in complex with nanobody ENB73
1W1Z	;	2.6	;	Structure of the plant like 5-Aminolaevulinic Acid Dehydratase from Chlorobium vibrioforme
6XYW	;	3.86	;	Structure of the plant mitochondrial ribosome
1L3A	;	2.3	;	Structure of the plant transcriptional regulator PBF-2
4KWC	;	1.994	;	Structure of the plantazolicin methyltransferase BpumL in complex with SAH
2LOE	;		;	Structure of the Plasmodium 6-cysteine s48/45 Domain
8G6F	;	2.58	;	Structure of the Plasmodium falciparum 20S proteasome beta-6 A117D mutant complexed with inhibitor WLW-vs
8G6E	;	2.18	;	Structure of the Plasmodium falciparum 20S proteasome complexed with inhibitor TDI-8304
5UMD	;	3.2	;	Structure of the Plasmodium falciparum 80S ribosome bound to the antimalarial drug mefloquine
6SSZ	;	3.45	;	Structure of the Plasmodium falciparum falcipain 2 protease in complex with an (E)-chalcone inhibitor.
6ZHI	;	3.25	;	Structure of the Plasmodium falciparum Hsp70-x substrate binding domain in complex with hydrophobic peptide
6SY0	;	3.102	;	Structure of the Plasmodium falciparum SIP2 DNA-binding AP2 tandem repeat in complex with two SPE2 half-sites
2AUC	;	2.6	;	Structure of the Plasmodium MTIP-MyoA complex, a key component of the parasite invasion motor
8QMA	;	3.5	;	Structure of the plastid-encoded RNA polymerase complex (PEP) from Sinapis alba
1FB8	;	2.4	;	STRUCTURE OF THE PLECKSTRIN HOMOLOGY DOMAIN FROM DAPP1/PHISH
1FAO	;	1.8	;	STRUCTURE OF THE PLECKSTRIN HOMOLOGY DOMAIN FROM DAPP1/PHISH IN COMPLEX WITH INOSITOL 1,3,4,5-TETRAKISPHOSPHATE
1FHX	;	2.5	;	Structure of the pleckstrin homology domain from GRP1 in complex with inositol 1,3,4,5-tetrakisphosphate
1FHW	;	1.9	;	Structure of the pleckstrin homology domain from GRP1 in complex with inositol(1,3,4,5,6)pentakisphosphate
1MAI	;	1.9	;	STRUCTURE OF THE PLECKSTRIN HOMOLOGY DOMAIN FROM PHOSPHOLIPASE C DELTA IN COMPLEX WITH INOSITOL TRISPHOSPHATE
4XB0	;	2.701	;	Structure of the Plk2 polo-box domain
2NV2	;	2.12	;	Structure of the PLP synthase complex Pdx1/2 (YaaD/E) from Bacillus subtilis
2ISS	;	2.9	;	Structure of the PLP synthase Holoenzyme from Thermotoga maritima
5DJ1	;	2.102	;	Structure of the PLP-Dependent L-Arginine Hydroxylase MppP Holoenzyme
5DJ3	;	2.227	;	Structure of the PLP-Dependent L-Arginine Hydroxylase MppP with D-Arginine Bound
6ZQP	;	1.6	;	Structure of the Pmt2-MIR domain with bound ligands
6ZQQ	;	1.9	;	Structure of the Pmt3-MIR domain with bound ligands
2C8G	;	2.0	;	Structure of the PN loop Q182A mutant C3bot1 Exoenzyme (Free state, crystal form I)
2C8H	;	1.65	;	Structure of the PN loop Q182A mutant C3bot1 Exoenzyme (NAD-bound state, crystal form I)
4XRP	;	3.3	;	Structure of the Pnkp1/Rnl/Hen1 RNA repair complex
8RB3	;	3.2	;	Structure of the PNMA2 capsid
5K5A	;	2.825	;	Structure of the pNOB8-like ParB N-domain
2GCL	;	2.21	;	Structure of the Pob3 Middle domain
8B3D	;	2.6	;	Structure of the Pol II-TCR-ELOF1 complex.
8A9O	;	1.587	;	Structure of the polyamine acetyltransferase DpA
5EKE	;	3.001	;	Structure of the polyisoprenyl-phosphate glycosyltransferase GtrB (F215A mutant)
5EKP	;	3.194	;	Structure of the polyisoprenyl-phosphate glycosyltransferase GtrB (WT)
4NBQ	;	2.9138	;	Structure of the polynucleotide phosphorylase (CBU_0852) from Coxiella burnetii
4PHB	;	2.1781	;	Structure of the polysaccharide lyase-like protein Cthe_2159 from C. thermocellum, Gadolinium derivative
4PEU	;	1.8001	;	Structure of the polysaccharide lyase-like protein Cthe_2159 from C. thermocellum, native form with Calcium bound
5CXW	;	1.75	;	Structure of the PonA1 protein from Mycobacterium Tuberculosis in complex with penicillin V
5LDS	;	2.0	;	Structure of the porcine aminopeptidase N ectodomain
6TOP	;	1.55	;	Structure of the PorE C-terminal domain, a protein of T9SS from Porphyromonas gingivalis
6G8Z	;	3.66	;	Structure of the pore domain of homomeric mLRRC8A volume-regulated anion channel at 3.66 A resolution
6OQ6	;	2.97	;	Structure of the pore forming fragment of Clostridium difficile toxin B in complex with VHH 5D
7VBB	;	2.81	;	Structure of the post state human RNA Polymerase I Elongation Complex
7QRG	;	2.8	;	Structure of the post-fusion complex between precursor membrane ectodomain (prM) and envelope ectodomain protein (E) from tick-borne encephalitis virus
428D	;	1.75	;	STRUCTURE OF THE POTASSIUM FORM OF CGCGAATTCGCG: DNA DEFORMATION BY ELECTROSTATIC COLLAPSE AROUND SMALL CATIONS
6CJ6	;	2.1	;	Structure of the poxvirus protein F9
2IF5	;	2.0	;	Structure of the POZ domain of human LRF, a master regulator of oncogenesis
5UCG	;	3.906	;	Structure of the PP2C Phosphatase Domain and a Fragment of the Regulatory Domain of the Cell Fate Determinant SpoIIE from Bacillus Subtilis
8SOT	;	1.99	;	Structure of the PPIase domain of borrelial BB0108
2AWG	;	1.6	;	Structure of the PPIase domain of the Human FK506-binding protein 8
3DAS	;	1.6	;	Structure of the PQQ-bound form of Aldose Sugar Dehydrogenase (Adh) from Streptomyces coelicolor
1TS8	;	1.6	;	Structure of the pR cis planar intermediate from time-resolved Laue crystallography
1TS7	;	1.6	;	Structure of the pR cis wobble and pR E46Q intermediates from time-resolved Laue crystallography
6XAZ	;	1.7	;	Structure of the PR domain from human PRDM5
2N1I	;		;	Structure of the PR domain from PRDM16
6XAU	;	1.89	;	Structure of the PR domain from PRDM3
6CGA	;	3.5	;	Structure of the PR-DUB complex
7VBA	;	2.89	;	Structure of the pre state human RNA Polymerase I Elongation Complex
6H2F	;	2.55	;	Structure of the pre-pore AhlB of the tripartite alpha-pore forming toxin, AHL, from Aeromonas hydrophila.
3TNX	;	2.62	;	Structure of the precursor of a thermostable variant of papain at 2.6 Angstroem resolution
3USV	;	3.8	;	Structure of the precursor of a thermostable variant of papain at 3.8 A resolution from a crystal soaked at pH 4
1OR8	;	2.35	;	Structure of the Predominant protein arginine methyltransferase PRMT1
1ORH	;	2.64	;	Structure of the Predominant Protein Arginine Methyltransferase PRMT1
1ORI	;	2.5	;	Structure of the predominant protein arginine methyltransferase PRMT1
6Z97	;	3.4	;	Structure of the prefusion SARS-CoV-2 spike glycoprotein
5B00	;	2.95	;	Structure of the prenyltransferase MoeN5 in complex with geranyl pyrophosphate
5B02	;	2.21	;	Structure of the prenyltransferase MoeN5 with a fusion protein tag of Sso7d
4G1I	;	1.85	;	Structure of the PrgH periplasmic domain
2MKY	;		;	Structure of the PrgK first periplasmic domain
5IJ8	;	2.99	;	Structure of the primary oncogenic mutant Y641N Hs/AcPRC2 in complex with a pyridone inhibitor
6FPC	;	1.75	;	Structure of the PRO-PRO endopeptidase (PPEP-2) from Paenibacillus alvei
1NES	;	1.65	;	STRUCTURE OF THE PRODUCT COMPLEX OF ACETYL-ALA-PRO-ALA WITH PORCINE PANCREATIC ELASTASE AT 1.65 ANGSTROMS RESOLUTION
5CCX	;	2.1	;	Structure of the product complex of tRNA m1A58 methyltransferase with tRNA3Lys as substrate
2C7A	;	2.5	;	STRUCTURE OF THE PROGESTERONE RECEPTOR-DNA COMPLEX
1OHC	;	2.5	;	Structure of the proline directed phosphatase cdc14
2L3P	;		;	Structure of the prolyl cis isomer of the Crk Protein
2L3Q	;		;	Structure of the prolyl trans isomer of the Crk Protein
5JXJ	;	2.0	;	Structure of the proprotein convertase furin complexed to meta-guanidinomethyl-Phac-RVR-Amba in presence of EDTA
2HNL	;	2.0	;	Structure of the prostaglandin D synthase from the parasitic nematode Onchocerca volvulus
3LGI	;	1.652	;	Structure of the protease domain of DegS (DegS-deltaPDZ) at 1.65 A
2SAM	;	2.4	;	STRUCTURE OF THE PROTEASE FROM SIMIAN IMMUNODEFICIENCY VIRUS: COMPLEX WITH AN IRREVERSIBLE NON-PEPTIDE INHIBITOR
2FXA	;	2.4	;	Structure of the Protease Production Regulatory Protein hpr from Bacillus subtilis.
1UJB	;	2.06	;	Structure of the protein histidine phosphatase SixA
1UJC	;	1.9	;	Structure of the protein histidine phosphatase SixA complexed with tungstate
6G4J	;	1.599	;	Structure of the protein kinase YabT from Bacillus subtilis in complex with an alphaREP crystallization helper
2IE4	;	2.6	;	Structure of the Protein Phosphatase 2A Core Enzyme Bound to okadaic acid
2IE3	;	2.8	;	Structure of the Protein Phosphatase 2A Core Enzyme Bound to Tumor-inducing Toxins
2NPP	;	3.3	;	Structure of the Protein Phosphatase 2A Holoenzyme
2X36	;	2.0	;	Structure of the proteolytic domain of the Human Mitochondrial Lon protease
6SJH	;	1.5	;	Structure of the PRY-SPRY domain of human Trim16L/Trim70
2NBI	;		;	Structure of the PSCD-region of the cell wall protein pleuralin-1
2MK0	;		;	Structure of the PSCD4-domain of the cell wall protein pleuralin-1 from the diatom Cylindrotheca fusiformis
4L68	;	2.0	;	Structure of the psedudokinase domain of BIR2, an immune regulator of the RLK/Pelle family
7Q4T	;	1.27	;	Structure of the Pseudomonas aeruginosa bacteriophage JG004 endolysin Pae87 bound to a peptidoglycan fragment.
7Q4S	;	2.5	;	Structure of the Pseudomonas aeruginosa bacteriophage JG004 endolysin Pae87, apo form.
7ULA	;	2.46	;	Structure of the Pseudomonas putida AlgKX modification and secretion complex
6GW6	;	2.205	;	Structure of the Pseudomonas putida RES-Xre toxin-antitoxin complex
6L4U	;	2.4	;	Structure of the PSI-FCPI supercomplex from diatom
3K13	;	2.0	;	Structure of the pterin-binding domain MeTr of 5-methyltetrahydrofolate-homocysteine methyltransferase from Bacteroides thetaiotaomicron
6OOC	;	2.6	;	Structure of the pterocarpan synthase dirigent protein GePTS1
6OOD	;	1.5	;	Structure of the pterocarpan synthase dirigent protein PsPTS1
6CZ2	;	2.5	;	Structure of the PTK6 kinase domain
6CZ3	;	1.8	;	Structure of the PTK6 kinase domain bound to a type I inhibitor (3-fluoro-4-{[6-methyl-3-(1H-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)(morpholin-4-yl)methanone
6CZ4	;	1.5	;	Structure of the PTK6 kinase domain bound to a type II inhibitor 2-{[(3R,4S)-3-fluoro-1-{[4-(trifluoromethoxy)phenyl]acetyl}piperidin-4-yl]oxy}-5-(1-methyl-1H-imidazol-4-yl)pyridine-3-carboxamide
3TJY	;	1.7	;	Structure of the Pto-binding domain of HopPmaL generated by limited chymotrypsin digestion
3SVI	;	1.8	;	Structure of the Pto-binding domain of HopPmaL generated by limited thermolysin digestion
7K67	;	1.6	;	Structure of the PTP-like myo-inositol phosphatase from Desulfovibrio magneticus
7K6Y	;	1.75	;	Structure of the PTP-like myo-inositol phosphatase from Desulfovibrio magneticus (high salt)
7K6W	;	2.3	;	Structure of the PTP-like myo-inositol phosphatase from Desulfovibrio magneticus in complex with myo-inositol hexakisphosphate
7SDB	;	2.0	;	Structure of the PTP-like myo-inositol phosphatase from Legionella pneumophila str. Paris in complex with myo-inositol hexakisphosphate
7SDD	;	1.85	;	Structure of the PTP-like myo-inositol phosphatase from Legionella pneumophila str. Paris in complex with myo-inositol-(1,3,4,5)-tetrakisphosphate
4WU3	;	2.2	;	Structure of the PTP-like myo-inositol phosphatase from Mitsuokella multacida in complex with myo-inositol-(1,3,4,5)-tetrakisphosphate
4WTY	;	2.1	;	Structure of the PTP-like myo-inositol phosphatase from Selenomonas ruminantium in complex with myo-inositol-(1,3,4,5)-tetrakisphosphate
4WU2	;	2.15	;	Structure of the PTP-like myo-inositol phosphatase from Selenomonas ruminantium in complex with myo-inositol-(1,4,5)-trikisphosphate
3D1O	;	2.1	;	Structure of the PTP-Like Phytase Expressed by Selenomonas Ruminantium at an Ionic Strength of 300 mM
3D1Q	;	2.1	;	Structure of the PTP-Like Phytase Expressed by Selenomonas Ruminantium at an Ionic Strength of 400 mM
3D1H	;	2.1	;	Structure of the PTP-Like Phytase Expressed by Selenomonas Ruminantium at an Ionic Strength of 500 mM
2PSZ	;	2.0	;	Structure of the PTP-like Phytase expressed by Selenomonas ruminantium at low ionic strength
3MOZ	;	1.6	;	Structure of the PTP-like phytase from Selenomonas ruminantium in complex with myo-inositol (1,2,3,5,6)pentakisphosphate
3O3L	;	1.85	;	Structure of the PTP-like phytase from Selenomonas ruminantium in complex with myo-inositol (1,3,4,5)tetrakisphosphate
3MMJ	;	1.6	;	Structure of the PTP-like phytase from Selenomonas ruminantium in complex with myo-inositol hexakisphosphate
6SAP	;		;	Structure of the PUB domain from Ubiquitin Regulatory X domain protein 1 (UBXD1)
5WDA	;	5.0	;	Structure of the PulG pseudopilus
4B0T	;	2.159	;	Structure of the Pup Ligase PafA of the Prokaryotic Ubiquitin-like Modification Pathway in Complex with ADP
3KUU	;	1.41	;	Structure of the PurE Phosphoribosylaminoimidazole Carboxylase Catalytic Subunit from Yersinia pestis
1D48	;	1.0	;	STRUCTURE OF THE PURE-SPERMINE FORM OF Z-DNA (MAGNESIUM FREE) AT 1 ANGSTROM RESOLUTION
246D	;	2.2	;	STRUCTURE OF THE PURINE-PYRIMIDINE ALTERNATING RNA DOUBLE HELIX, R(GUAUAUA)D(C) , WITH A 3'-TERMINAL DEOXY RESIDUE
1VPW	;	2.7	;	STRUCTURE OF THE PURR MUTANT, L54M, BOUND TO HYPOXANTHINE AND PURF OPERATOR DNA
1WET	;	2.6	;	STRUCTURE OF THE PURR-GUANINE-PURF OPERATOR COMPLEX
5O95	;	1.491	;	Structure of the putative methyltransferase Lpg2936 from Legionella pneumophila
5O96	;	2.3	;	Structure of the putative methyltransferase Lpg2936 from Legionella pneumophila in complex with the bound cofactor SAM
1H6H	;	1.7	;	Structure of the PX domain from p40phox bound to phosphatidylinositol 3-phosphate
2IWL	;	2.6	;	Structure of the PX Domain of Phosphoinositide 3-Kinase-C2alpha
8YGX	;	2.0	;	Structure of the PYK2 from Biortus.
2IP2	;	1.8	;	Structure of the Pyocyanin Biosynthetic Protein PhzM
3ZVU	;	2.1	;	Structure of the PYR1 His60Pro mutant in complex with the HAB1 phosphatase and Abscisic acid
4C5J	;	1.45	;	Structure of the pyridoxal kinase from Staphylococcus aureus
4C5K	;	1.4	;	Structure of the pyridoxal kinase from Staphylococcus aureus in complex with ADP
4C5M	;	1.45	;	Structure of the pyridoxal kinase from Staphylococcus aureus in complex with AMP-PCP
4C5N	;	1.75	;	Structure of the pyridoxal kinase from Staphylococcus aureus in complex with AMP-PCP and pyridoxal
4C5L	;	1.85	;	Structure of the pyridoxal kinase from Staphylococcus aureus in complex with pyridoxal
1N66	;		;	Structure of the pyrimidine-rich internal loop in the Y-domain of poliovirus 3'UTR
8FK7	;	4.3	;	Structure of the Pyrobaculum calidifontis flagellar-like archaeal type IV pilus
5G5C	;	1.18	;	Structure of the Pyrococcus furiosus Esterase Pf2001 with space group C2221
5G5M	;	2.07	;	Structure of the Pyrococcus Furiosus Esterase Pf2001 with space group P21
5LCN	;	2.6	;	STRUCTURE OF THE PYROCOCCUS FURIOSUS ESTERASE PF2001 WITH SPACE GROUP P212121
5G59	;	1.613	;	Structure of the Pyrococcus Furiosus Esterase Pf2001 with space group P3121
4FX9	;	2.7	;	Structure of the Pyrococcus horikoshii CoA persulfide/polysulfide reductase
7QF5	;	1.37	;	Structure of the Q103L mutant of miniSOG
1SVU	;	2.66	;	Structure of the Q237W mutant of HhaI DNA methyltransferase: an insight into protein-protein interactions
4H8Q	;	1.7	;	Structure of the Q29T IsdX2-NEAT5 mutant in complex with heme
1ZVQ	;	2.0	;	Structure of the Q61G mutant of Ras in the GDP-bound form
2P4T	;	1.15	;	Structure of the Q67H mutant of R67 dihydrofolate reductase-NADP+ complex reveals a novel cofactor binding mode
3MMP	;	2.5	;	Structure of the Qb replicase, an RNA-dependent RNA polymerase consisting of viral and host proteins
4R71	;	3.21	;	Structure of the Qbeta holoenzyme complex in the P1211 crystal form
5VCL	;	2.05	;	Structure of the Qdm peptide bound to Qa-1a
5ELT	;	2.13	;	Structure of the QUA1-KH domain of T-STAR in complex with UAAU RNA
7P4P	;	1.75	;	Structure of the quinolinate synthase A84L variant complexed with citrate
7P4Q	;	2.2	;	Structure of the quinolinate synthase S124A variant complexed with citrate
7P4M	;	1.55	;	Structure of the quinolinate synthase Y107F variant in an empty open form
3TQH	;	2.44	;	Structure of the quinone oxidoreductase from Coxiella burnetii
6CH0	;	2.15	;	Structure of the Quorum Quenching lactonase from Alicyclobacillus acidoterrestris bound to a glycerol molecule
6CGY	;	1.65	;	Structure of the Quorum Quenching lactonase from Alicyclobacillus acidoterrestris bound to a phosphate anion
6CGZ	;	1.8	;	Structure of the Quorum Quenching lactonase from Alicyclobacillus acidoterrestris bound to C6-AHL
6N9I	;	1.6	;	Structure of the Quorum Quenching lactonase from Parageobacillus caldoxylosilyticus - free
6N9Q	;	2.35	;	Structure of the Quorum Quenching lactonase from Parageobacillus caldoxylosilyticus bind to substrate C4-AHL
6N9R	;	1.75	;	Structure of the Quorum Quenching lactonase from Parageobacillus caldoxylosilyticus bound to substrate 3-oxo-C12-AHL
5MSO	;	1.2	;	Structure of the R domain of carboxylic acid reductase (CAR) from Mycobacterium marinum in complex with NADP
5MSU	;	1.74	;	Structure of the R domain of carboxylic acid reductase (CAR) from Mycobacterium marinum in complex with NADP, P21 form
4ZA6	;	1.97	;	Structure of the R. erythropolis transcriptional repressor QsdR from TetR family
5VMQ	;	2.012	;	STRUCTURE OF THE R105A MUTANT CATALYTIC TRIMER OF ESCHERICHIA COLI ASPARTATE TRANSCARBAMOYLASE AT 2.0-A RESOLUTION
2QGR	;	2.7	;	Structure of the R178A mutant of delta PDZ DegS protease
3ZI8	;	1.5	;	Structure of the R17A mutant of the Ralstonia soleanacerum lectin at 1.5 Angstrom in complex with L-fucose
5W4O	;	2.093	;	Structure of the R18A mutant of the HIV-1 capsid protein
5W4Q	;	2.285	;	Structure of the R18A/E28A mutant of the HIV-1 capsid protein
6KYD	;	3.1	;	Structure of the R217A mutant of Clostridium difficile sortase B
2B4O	;	2.3	;	Structure of the R258K mutant of Selenomonas ruminantium PTP-like phytase
2KDZ	;		;	Structure of the R2R3 DNA binding domain of MYB1 protein from protozoan parasite trichomonas vaginalis in complex with MRE-1/MRE-2R DNA
5IPK	;	3.7	;	Structure of the R432A variant of Adeno-associated virus type 2 VLP
7QF4	;	1.17	;	Structure of the R57Q mutant of miniSOG expressed in E. coli in LB medium enriched with riboflavin
7QF3	;	1.1	;	Structure of the R57Q mutant of miniSOG expressed in E. coli in regular LB medium
3F45	;	2.0	;	Structure of the R75A mutant of rat alpha-Parvalbumin
7QLA	;	3.85	;	Structure of the Rab GEF complex Mon1-Ccz1
6HCJ	;	3.8	;	Structure of the rabbit 80S ribosome on globin mRNA in the rotated state with A/P and P/E tRNAs
8RJB	;	2.69243	;	Structure of the rabbit 80S ribosome stalled on a 2-TMD rhodopsin intermediate in complex with Sec61-RAMP4
8RJC	;	2.90061	;	Structure of the rabbit 80S ribosome stalled on a 2-TMD rhodopsin intermediate in complex with Sec61-TRAP, open conformation 1
8RJD	;	2.78574	;	Structure of the rabbit 80S ribosome stalled on a 2-TMD rhodopsin intermediate in complex with Sec61-TRAP, open conformation 2
7TM3	;	3.25	;	Structure of the rabbit 80S ribosome stalled on a 2-TMD Rhodopsin intermediate in complex with the multipass translocon
7TUT	;	3.88	;	Structure of the rabbit 80S ribosome stalled on a 4-TMD Rhodopsin intermediate in complex with the multipass translocon
6HCF	;	3.9	;	Structure of the rabbit 80S ribosome stalled on globin mRNA at the stop codon
6HCQ	;	6.5	;	Structure of the rabbit collided di-ribosome (collided monosome)
6HCM	;	6.8	;	Structure of the rabbit collided di-ribosome (stalled monosome)
3J8H	;	3.8	;	Structure of the rabbit ryanodine receptor RyR1 in complex with FKBP12 at 3.8 Angstrom resolution
1E96	;	2.4	;	Structure of the Rac/p67phox complex
5LCL	;	2.2	;	STRUCTURE OF the RAD14 DNA-binding domain IN COMPLEX WITH C8-aminofluorene- GUANINE CONTAINING DNA
5LCM	;	1.9	;	STRUCTURE OF the RAD14 DNA-binding domain IN COMPLEX WITH N2-acetylaminonaphtyl- GUANINE CONTAINING DNA
7Z38	;	3.16	;	Structure of the RAF1-HSP90-CDC37 complex (RHC-I)
7Z37	;	3.67	;	Structure of the RAF1-HSP90-CDC37 complex (RHC-II)
6SM3	;	3.3	;	Structure of the RagAB peptide importer in the 'closed-closed' state
6SMQ	;	3.3	;	Structure of the RagAB peptide importer in the 'open-closed' state
6SML	;	3.4	;	Structure of the RagAB peptide importer in the 'open-open' state
6SLI	;	3.38	;	Structure of the RagAB peptide transporter
6SLJ	;	3.04	;	Structure of the RagAB peptide transporter
6SLN	;	2.61	;	Structure of the RagAB peptide transporter
2Y8G	;	1.61	;	Structure of the Ran-binding domain from human RanBP3 (E352A-R353V double mutant)
2Y8F	;	2.1	;	Structure of the Ran-binding domain from human RanBP3 (wild type)
1RRP	;	2.96	;	STRUCTURE OF THE RAN-GPPNHP-RANBD1 COMPLEX
6T3H	;	3.039	;	Structure of the Rap conjugation gene regulator of the plasmid pLS20 in apo form
6T46	;	2.45	;	Structure of the Rap conjugation gene regulator of the plasmid pLS20 in complex with the Phr* peptide
3BRW	;	3.4	;	Structure of the Rap-RapGAP complex
7YFG	;	3.6	;	Structure of the Rat GluN1-GluN2C NMDA receptor in complex with glycine and glutamate (major class in asymmetry)
8HDK	;	4.3	;	Structure of the Rat GluN1-GluN2C NMDA receptor in complex with glycine and glutamate (minor class in symmetry)
7YFH	;	3.0	;	Structure of the Rat GluN1-GluN2C NMDA receptor in complex with glycine, glutamate and (R)-PYD-106
6ENT	;	2.66	;	Structure of the rat RKIP variant delta143-146
7YFI	;	3.3	;	Structure of the Rat tri-heteromeric GluN1-GluN2A-GluN2C NMDA receptor in complex with glycine and glutamate
8SBE	;	3.8	;	Structure of the rat vesicular glutamate transporter 2 determined by single-particle Cryo-EM
2AZE	;	2.55	;	Structure of the Rb C-terminal domain bound to an E2F1-DP1 heterodimer
5OV3	;	2.45	;	Structure of the RbBP5 beta-propeller domain
6SD5	;	3.1	;	Structure of the RBM2 inner ring of Salmonella flagella MS-ring protein FliF with 22-fold symmetry applied
6SD2	;	3.1	;	Structure of the RBM2inner region of the Salmonella flagella MS-ring protein FliF with 21-fold symmetry applied.
6TRE	;	3.3	;	Structure of the RBM3/collar region of the Salmonella flagella MS-ring protein FliF with 32-fold symmetry applied
6SD1	;	2.6	;	Structure of the RBM3/collar region of the Salmonella flagella MS-ring protein FliF with 33-fold symmetry applied
6SD4	;	2.8	;	Structure of the RBM3/collar region of the Salmonella flagella MS-ring protein FliF with 34-fold symmetry applied
4L92	;	2.1	;	Structure of the RBP from lactococcal phage 1358 in complex with 2 GlcNAc molecules
4L99	;	2.2	;	Structure of the RBP from lactococcal phage 1358 in complex with glycerol
4L97	;	2.61	;	Structure of the RBP of lactococcal phage 1358 in complex with glucose-1-phosphate
6DKS	;	2.78	;	Structure of the Rbpj-SHARP-DNA Repressor Complex
4RCR	;	2.8	;	STRUCTURE OF THE REACTION CENTER FROM RHODOBACTER SPHAEROIDES R-26 AND 2.4.1: PROTEIN-COFACTOR (BACTERIOCHLOROPHYLL, BACTERIOPHEOPHYTIN, AND CAROTENOID) INTERACTIONS
1RQK	;	2.7	;	Structure of the reaction centre from Rhodobacter sphaeroides carotenoidless strain R-26.1 reconstituted with 3,4-dihydrospheroidene
1RGN	;	2.8	;	Structure of the reaction centre from Rhodobacter sphaeroides carotenoidless strain R-26.1 reconstituted with spheroidene
1YRQ	;	2.1	;	Structure of the ready oxidized form of [NiFe]-hydrogenase
3EPT	;	2.97	;	Structure of the rebeccamycin biosynthetic enzyme RebC with reduced flavin
6HFG	;	2.5	;	Structure of the REC114 PH domain
1REA	;	2.7	;	STRUCTURE OF THE RECA PROTEIN-ADP COMPLEX
1ZIT	;		;	Structure of the receiver domain of NtrC4 from Aquifex aeolicus
4KQZ	;	2.514	;	structure of the receptor binding domain (RBD) of MERS-CoV spike
2F0C	;	1.65	;	Structure of the Receptor Binding Protein (ORF49, bbp) from lactophage tp901-1
1OCY	;	1.5	;	Structure of the receptor-binding domain of the bacteriophage T4 short tail fibre
2V5I	;	1.6	;	Structure of the receptor-binding protein of bacteriophage Det7: a podoviral tailspike in a myovirus
7QJ1	;	7.0	;	Structure of the recombinant human gamma-Tubulin Ring Complex 6-spoked assembly intermediate (spokes 7-12, homogeneous dataset)
4UP4	;	1.95	;	Structure of the recombinant lectin PVL from Psathyrella velutina in complex with GlcNAcb-D-1,3Galactoside
1MF1	;	2.7	;	Structure of the Recombinant Mouse-Muscle Adenylosuccinate Synthetase Complexed with AMP
1MF0	;	2.5	;	Structure of the Recombinant Mouse-Muscle Adenylosuccinate Synthetase Complexed with AMP, GDP, HPO4(2-), and Mg(2+)
1MEZ	;	2.4	;	Structure of the Recombinant Mouse-Muscle Adenylosuccinate Synthetase Complexed with SAMP, GDP, SO4(2-), and Mg(2+)
1LCT	;	2.0	;	STRUCTURE OF THE RECOMBINANT N-TERMINAL LOBE OF HUMAN LACTOFERRIN AT 2.0 ANGSTROMS RESOLUTION
2XWZ	;	2.34	;	STRUCTURE OF THE RECOMBINANT NATIVE NITRITE REDUCTASE FROM ALCALIGENES XYLOSOXIDANS complexed with nitrite
5Z67	;	2.2	;	Structure of the recombination mediator protein RecF in RecFOR pathway
5Z68	;	3.0	;	Structure of the recombination mediator protein RecF-ATP in RecFOR pathway
5Z69	;	2.102	;	Structure of the recombination mediator protein RecF-ATPrS in RecFOR pathway
3IIS	;	1.4	;	Structure of the reconstituted Peridinin-Chlorophyll a-Protein (RFPCP)
3IIU	;	1.45	;	Structure of the reconstituted Peridinin-Chlorophyll a-Protein (RFPCP) mutant N89L
8A85	;	2.67	;	Structure of the Reconstructed Ancestor of Phenolic Acid Decarboxylase AncPAD134
8B30	;	2.7	;	Structure of the Reconstructed Ancestor of Phenolic Acid Decarboxylase AncPAD31
8ADX	;	1.6	;	Structure of the Reconstructed Ancestor of Phenolic Acid Decarboxylase AncPAD55
8C66	;	1.6	;	Structure of the Reconstructed Ancestor of Phenolic Acid Decarboxylase AncPAD55
1OYW	;	1.8	;	Structure of the RecQ Catalytic Core
1OYY	;	2.5	;	Structure of the RecQ Catalytic Core bound to ATP-gamma-S
4Q48	;	2.797	;	Structure of the RecQ Catalytic Core from Deinococcus radiodurans
5LK4	;	1.47	;	Structure of the Red Fluorescent Protein mScarlet at pH 7.8
7ZCT	;	1.33	;	Structure of the red fluorescent protein mScarlet3 at pH 7.5
3EWK	;	2.34	;	Structure of the redox sensor domain of Methylococcus capsulatus (Bath) MmoS
1FT9	;	2.6	;	STRUCTURE OF THE REDUCED (FEII) CO-SENSING PROTEIN FROM R. RUBRUM
3EH3	;	3.1	;	Structure of the reduced form of cytochrome ba3 oxidase from Thermus thermophilus
3EH4	;	2.9	;	Structure of the reduced form of cytochrome ba3 oxidase from Thermus thermophilus
3EH5	;	2.8	;	Structure of the reduced form of cytochrome ba3 oxidase from Thermus thermophilus
1W89	;	2.0	;	Structure of the reduced form of human thioredoxin 2
1AFI	;		;	STRUCTURE OF THE REDUCED FORM OF MERP, THE PERIPLASMIC PROTEIN FROM THE BACTERIAL MERCURY DETOXIFICATION SYSTEM, NMR, 20 STRUCTURES
1SF3	;	1.05	;	Structure of the reduced form of the P94A mutant of amicyanin
1H63	;	1.62	;	Structure of the reduced Pentaerythritol Tetranitrate Reductase
4M6H	;	2.194	;	Structure of the reduced, metal-free form of Mycobacterium tuberculosis peptidoglycan amidase Rv3717
4M6I	;	2.666	;	Structure of the reduced, Zn-bound form of Mycobacterium tuberculosis peptidoglycan amidase Rv3717
6O6O	;	1.63	;	Structure of the regulator FasR from Mycobacterium tuberculosis
6O6N	;	1.7	;	Structure of the regulator FasR from Mycobacterium tuberculosis in complex with C20-CoA
6O6P	;	3.851	;	Structure of the regulator FasR from Mycobacterium tuberculosis in complex with DNA
2BT2	;	1.9	;	Structure of the regulator of G-protein signaling 16
1ZV4	;	2.4	;	Structure of the Regulator of G-Protein Signaling 17 (RGSZ2)
2AF0	;	2.3	;	Structure of the Regulator of G-Protein Signaling Domain of RGS2
2ES0	;	2.1	;	Structure of the regulator of G-protein signaling domain of RGS6
2A72	;	2.0	;	Structure of the regulator of G-protein signaling domain of RGS7
1GLA	;	2.6	;	STRUCTURE OF THE REGULATORY COMPLEX OF ESCHERICHIA COLI IIIGLC WITH GLYCEROL KINASE
1GLB	;	2.6	;	STRUCTURE OF THE REGULATORY COMPLEX OF ESCHERICHIA COLI IIIGLC WITH GLYCEROL KINASE
3S1T	;	1.63	;	Structure of the regulatory domain of aspartokinase (Rv3709c; AK-beta) in complex with threonine from Mycobacterium tuberculosis
2M76	;		;	Structure of the Regulatory Domain of Human Brain Carnitine Palmitoyltransferase 1
1SCM	;	2.8	;	STRUCTURE OF THE REGULATORY DOMAIN OF SCALLOP MYOSIN AT 2.8 ANGSTROMS RESOLUTION
5U93	;	1.999	;	Structure of the Regulatory Domain of the AraC Family Transcriptional Activator RhaR
5U9E	;	2.02	;	Structure of the Regulatory Domain of the AraC Family Transcriptional Activator RhaR
2YA3	;	2.51	;	STRUCTURE OF THE REGULATORY FRAGMENT OF MAMMALIAN AMPK IN COMPLEX WITH COUMARIN ADP
2Y8Q	;	2.8	;	Structure of the regulatory fragment of mammalian AMPK in complex with one ADP
2Y8L	;	2.5	;	Structure of the regulatory fragment of mammalian aMPK in complex with two ADP
3T4N	;	2.3	;	Structure of the regulatory fragment of Saccharomyces cerevisiae AMPK in complex with ADP
3TE5	;	2.5	;	structure of the regulatory fragment of sacchromyces cerevisiae ampk in complex with NADH
3TDH	;	2.3	;	Structure of the regulatory fragment of sccharomyces cerevisiae AMPK in complex with AMP
1LXF	;		;	Structure of the Regulatory N-domain of Human Cardiac Troponin C in Complex with Human Cardiac Troponin-I(147-163) and Bepridil
4ER8	;	2.6	;	Structure of the REP associates tyrosine transposase bound to a REP hairpin
6HBC	;	2.78	;	Structure of the repeat unit in the network formed by CcmM and Rubisco from Synechococcus elongatus
1IG9	;	2.6	;	Structure of the Replicating Complex of a Pol Alpha Family DNA Polymerase
3CFP	;	2.5	;	Structure of the replicating complex of a POL Alpha family DNA Polymerase, ternary complex 1
3CFR	;	2.4	;	Structure of the replicating complex of a POL Alpha family DNA Polymerase, ternary complex 2
3EPZ	;	2.31	;	Structure of the replication foci-targeting sequence of human DNA cytosine methyltransferase DNMT1
4Q4G	;	0.97	;	Structure of the Resuscitation Promoting Factor Interacting protein RipA mutated at C383
4Q4T	;	1.63	;	Structure of the Resuscitation Promoting Factor Interacting protein RipA mutated at E444
4Q4N	;	1.38	;	Structure of the Resuscitation Promoting Factor Interacting protein RipA mutated at H432
3C4Q	;	2.8	;	Structure of the retaining glycosyltransferase MshA : The first step in mycothiol biosynthesis. Organism : Corynebacterium glutamicum- Complex with UDP
3C48	;	2.1	;	Structure of the retaining glycosyltransferase MshA: The first step in mycothiol biosynthesis. Organism: Corynebacterium glutamicum- APO (OPEN) structure.
3C4V	;	2.6	;	Structure of the retaining glycosyltransferase MshA:The first step in mycothiol biosynthesis. Organism: Corynebacterium glutamicum : Complex with UDP and 1L-INS-1-P.
1L8R	;	1.65	;	Structure of the Retinal Determination Protein Dachshund Reveals a DNA-Binding Motif
2R7G	;	1.671	;	Structure of the retinoblastoma protein pocket domain in complex with adenovirus E1A CR1 domain
4FJO	;	2.718	;	Structure of the Rev1 CTD-Rev3/7-Pol kappa RIR complex
7ABN	;	1.65	;	Structure of the reversible pyrrole-2-carboxylic acid decarboxylase PA0254/HudA
1DEC	;		;	STRUCTURE OF THE RGD PROTEIN DECORSIN: CONSERVED MOTIF AND DISTINCT FUNCTION IN LEECH PROTEINS THAT AFFECT BLOOD CLOTTING
1HTJ	;	2.2	;	STRUCTURE OF THE RGS-LIKE DOMAIN FROM PDZ-RHOGEF
3UV9	;	1.549	;	Structure of the rhesus monkey TRIM5alpha deltav1 PRYSPRY domain
2LM3	;		;	Structure of the rhesus monkey TRIM5alpha PRYSPRY domain
1DOA	;	2.6	;	Structure of the rho family gtp-binding protein cdc42 in complex with the multifunctional regulator rhogdi
6K24	;	2.1	;	Structure of the Rhodium Mesoporphyrin IX-Reconstituted CYP102A1 Haem Domain with N-Abietoyl-L-Tryptophan
7OS0	;	2.2	;	Structure of the Rhodobacter capsulatus Cas13a-crRNA binary complex
2V9Z	;	3.0	;	Structure of the Rhodococcus haloalkane dehalogenase mutant with enhanced enantioselectivity
8SVA	;	2.96	;	Structure of the Rhodococcus sp. USK13 DarR-20 bp DNA complex
6OY9	;	3.9	;	Structure of the Rhodopsin-Transducin Complex
6OYA	;	3.3	;	Structure of the Rhodopsin-Transducin-Nanobody Complex
1DGW	;	1.7	;	Structure of the rhombohedral crystal of canavalin from jack bean
1EV3	;	1.78	;	Structure of the rhombohedral form of the M-cresol/insulin R6 hexamer
4IGL	;	2.49	;	Structure of the RHS-repeat containing BC component of the secreted ABC toxin complex from Yersinia entomophaga
7TVR	;		;	Structure of the ribbon isoform of the novel conotoxin PnID derived from Conus pennaceus
2RBF	;	2.25	;	Structure of the ribbon-helix-helix domain of Escherichia coli PutA (PutA52) complexed with operator DNA (O2)
1DUL	;	1.8	;	STRUCTURE OF THE RIBONUCLEOPROTEIN CORE OF THE E. COLI SIGNAL RECOGNITION PARTICLE
1SMQ	;	3.1	;	Structure of the Ribonucleotide Reductase Rnr2 Homodimer from Saccharomyces cerevisiae
1SMS	;	3.1	;	Structure of the Ribonucleotide Reductase Rnr4 Homodimer from Saccharomyces cerevisiae
4V4B	;	11.7	;	Structure of the ribosomal 80S-eEF2-sordarin complex from yeast obtained by docking atomic models for RNA and protein components into a 11.7 A cryo-EM map.
6CAO	;	3.45	;	Structure of the ribosomal decoding complex at ambient temperature
4V5A	;	3.5	;	Structure of the Ribosome Recycling Factor bound to the Thermus thermophilus 70S ribosome with mRNA, ASL-Phe and tRNA-fMet
4V7C	;	7.6	;	Structure of the Ribosome with Elongation Factor G Trapped in the Pre-Translocation State (pre-translocation 70S*tRNA structure)
4V7D	;	7.6	;	Structure of the Ribosome with Elongation Factor G Trapped in the Pre-Translocation State (pre-translocation 70S*tRNA*EF-G structure)
7QWR	;	2.9	;	Structure of the ribosome-nascent chain containing an ER signal sequence in complex with NAC
4V6M	;	7.1	;	Structure of the ribosome-SecYE complex in the membrane environment
1E4P	;		;	Structure of the ribozyme substrate hairpin of Neurospora VS RNA. A close look at the cleavage site
6OCE	;	4.9	;	Structure of the rice hyperosmolality-gated ion channel OSCA1.2
6WNC	;	2.2	;	Structure of the Rieske non-heme iron oxygenase GxtA
7SZG	;	2.69	;	Structure of the Rieske Non-heme Iron Oxygenase GxtA Pressurized with Xenon
7SZF	;	1.79	;	Structure of the Rieske Non-heme Iron Oxygenase GxtA with beta-Saxitoxinol Bound
6WND	;	2.18	;	Structure of the Rieske non-heme iron oxygenase GxtA with dideoxysaxitoxin bound
7SZE	;	1.74	;	Structure of the Rieske Non-heme Iron Oxygenase GxtA with Saxitoxin Bound
6WN3	;	1.86	;	Structure of the Rieske non-heme iron oxygenase SxtT
7SZH	;	1.79	;	Structure of the Rieske Non-heme Iron Oxygenase SxtT with beta-saxitoxinol Bound
6WNB	;	2.1	;	Structure of the Rieske non-heme iron oxygenase SxtT with dideoxysaxitoxin bound
5OOO	;	2.2	;	Structure of the Rift Valley fever virus NSs protein core domain
6GPG	;	2.894	;	Structure of the RIG-I Singleton-Merten syndrome variant C268F
5ZCK	;	1.271	;	Structure of the RIP3 core region
2G0C	;	1.7	;	Structure of the RNA binding domain (residues 404-479) of the Bacillus subtilis YxiN protein
2CJK	;		;	Structure of the RNA binding domain of Hrp1 in complex with RNA
2OG3	;	1.85	;	structure of the rna binding domain of n protein from SARS coronavirus in cubic crystal form
3MOJ	;	2.902	;	Structure of the RNA binding domain of the Bacillus subtilis YxiN protein complexed with a fragment of 23S ribosomal RNA
2R20	;	1.3	;	Structure of the RNA brominated tridecamer r(GCGUU-5BUGAAACGC) at 1.3 A (Br2)
2R1S	;	1.4	;	Structure of the RNA brominated tridecamer r(GCGUU-5BUGAAACGC) at 1.4 A (Br1)
2R21	;	1.59	;	Structure of the RNA brominated tridecamer r(GCGUU-5BUGAAACGC) at 1.6 A (BrMn)
2LQZ	;		;	Structure of the RNA claw of the DNA packaging motor of bacteriophage 29
6I1V	;		;	Structure of the RNA duplex containing pseudouridine residue (5'-Cp(PSU)pG-3' sequence context)
6I1W	;		;	Structure of the RNA duplex containing pseudouridine residue (5'-Gp(PSU)pC-3' sequence context)
1OSU	;	1.4	;	STRUCTURE OF THE RNA HEXAMER, R(UUCGCG), WITH A 5'-UU-OVERHANG EXHIBITING HOOGSTEEN-LIKE TRANS U-U BASE PAIRS
4IT0	;	2.4	;	Structure of the RNA ligase RtcB-GMP/Mn(II) complex
3CLJ	;	2.1	;	Structure of the RNA polymerase II CTD-interacting domain of Nrd1
6GOV	;	3.7	;	Structure of THE RNA POLYMERASE LAMBDA-BASED ANTITERMINATION COMPLEX
2YI8	;	2.3	;	Structure of the RNA polymerase VP1 from Infectious Pancreatic Necrosis Virus
2YIA	;	3.02	;	Structure of the RNA polymerase VP1 from Infectious Pancreatic Necrosis Virus
2YIB	;	3.8	;	Structure of the RNA polymerase VP1 from Infectious Pancreatic Necrosis Virus
2YI9	;	2.2	;	Structure of the RNA polymerase VP1 from Infectious Pancreatic Necrosis Virus in complex with magnesium
3EES	;	1.9	;	Structure of the RNA pyrophosphohydrolase BdRppH
3EF5	;	2.6	;	Structure of the RNA pyrophosphohydrolase BdRppH in complex with dGTP
3FFU	;	2.8	;	Structure of the RNA pyrophosphohydrolase BdRppH in complex with GTP and magnesium
3EEU	;	2.0	;	Structure of the RNA pyrophosphohydrolase BdRppH in complex with Holmium
5MDU	;	1.02	;	Structure of the RNA recognition motif (RRM) of Seb1 from S. pombe.
8PX5	;	1.77	;	Structure of the RNA recognition motif (RRM) of Seb1 from S. pombe., solved at wavelength 2.75 A
1ZC5	;		;	Structure of the RNA signal essential for translational frameshifting in HIV-1
3EXC	;	2.25	;	Structure of the RNA'se SSO8090 from Sulfolobus solfataricus
1A8V	;	2.0	;	STRUCTURE OF THE RNA-BINDING DOMAIN OF THE RHO TRANSCRIPTION TERMINATOR
7BW4	;	3.7	;	Structure of the RNA-dependent RNA polymerase from SARS-CoV-2
1J3L	;	2.3	;	Structure of the RNA-processing inhibitor RraA from Thermus thermophilis
2J7N	;	2.3	;	Structure of the RNAi polymerase from Neurospora crassa
2J7O	;	3.5	;	STRUCTURE OF THE RNAI POLYMERASE FROM NEUROSPORA CRASSA
2ZEJ	;	2.0	;	Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase
3D6T	;	2.43	;	Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase
8BX7	;	2.76	;	Structure of the rod CNG channel bound to calmodulin
1YCE	;	2.4	;	Structure of the rotor ring of F-type Na+-ATPase from Ilyobacter tartaricus
6CO4	;		;	Structure of the Rpn13-Rpn2 complex provides insights for Rpn13 and Uch37 as anticancer targets
7ZPQ	;	3.47	;	Structure of the RQT-bound 80S ribosome from S. cerevisiae (C1)
7ZRS	;	4.8	;	Structure of the RQT-bound 80S ribosome from S. cerevisiae (C2) - composite map
4WFC	;	2.35	;	Structure of the Rrp6-Rrp47 interaction
4WFD	;	2.4	;	Structure of the Rrp6-Rrp47-Mtr4 interaction
6T72	;	3.7	;	Structure of the RsaA N-terminal domain bound to LPS
2R0V	;	2.35	;	Structure of the Rsc4 tandem bromodomain acetylated at K25
2R0Y	;	1.75	;	Structure of the Rsc4 tandem bromodomain in complex with an acetylated H3 peptide
3RRR	;	2.821	;	Structure of the RSV F protein in the post-fusion conformation
3RRT	;	3.2	;	Structure of the RSV F protein in the post-fusion conformation
3Q33	;	2.8	;	Structure of the Rtt109-AcCoA/Vps75 Complex and Implications for Chaperone-Mediated Histone Acetylation
3Q35	;	3.3	;	Structure of the Rtt109-AcCoA/Vps75 complex and implications for chaperone-mediated histone acetylation
1DSZ	;	1.7	;	STRUCTURE OF THE RXR/RAR DNA-BINDING DOMAIN HETERODIMER IN COMPLEX WITH THE RETINOIC ACID RESPONSE ELEMENT DR1
4UWA	;	6.1	;	Structure of the ryanodine receptor at resolution of 6.1 A in closed state
4UWE	;	8.5	;	Structure of the ryanodine receptor at resolution of 8.5 A in partially open state
3NPQ	;	2.1814	;	Structure of the S-adenosylhomocysteine riboswitch at 2.18 A
3NPN	;	2.792	;	Structure of the s-adenosylhomocysteine riboswitch at 3.0A
1TV7	;	2.8	;	Structure of the S-adenosylmethionine dependent Enzyme MoaA
2GIS	;	2.9	;	Structure of the S-adenosylmethionine riboswitch mRNA regulatory element
2MVI	;		;	Structure of the S-glycosylated bacteriocin ASM1
4UJ7	;	1.54	;	Structure of the S-layer protein SbsC, domains 5-6
6Z46	;	3.698	;	Structure of the S. acidocaldarius 20S proteasome (Saci0613/Saci0662)
2PK0	;	2.65	;	Structure of the S. agalactiae serine/threonine phosphatase at 2.65 resolution
7TJ4	;	1.8	;	Structure of the S. aureus amidase LytH and activator ActH extracellular domains
5JM0	;	6.3	;	Structure of the S. cerevisiae alpha-mannosidase 1
6WB9	;	3.0	;	Structure of the S. cerevisiae ER membrane complex
7MCA	;	3.6	;	Structure of the S. cerevisiae origin recognition complex bound to the replication initiator Cdc6 and the ARS1 origin DNA.
7RD8	;	5.64	;	Structure of the S. cerevisiae P4B ATPase lipid flippase in the E1-ATP state
7RD6	;	3.25	;	Structure of the S. cerevisiae P4B ATPase lipid flippase in the E2P state
7RD7	;	3.08	;	Structure of the S. cerevisiae P4B ATPase lipid flippase in the E2P-transition state
7KY6	;	3.1	;	Structure of the S. cerevisiae phosphatidylcholine flippase Dnf1-Lem3 complex in the apo E1 state
7KYB	;	3.2	;	Structure of the S. cerevisiae phosphatidylcholine flippase Dnf1-Lem3 complex in the E1-ADP state
7KYC	;	2.8	;	Structure of the S. cerevisiae phosphatidylcholine flippase Dnf1-Lem3 complex in the E2P state
7KY7	;	3.08	;	Structure of the S. cerevisiae phosphatidylcholine flippase Dnf2-Lem3 complex in the apo E1 state
7KY9	;	4.05	;	Structure of the S. cerevisiae phosphatidylcholine flippase Dnf2-Lem3 complex in the E1-ADP state
7KY8	;	3.85	;	Structure of the S. cerevisiae phosphatidylcholine flippase Dnf2-Lem3 complex in the E1-ATP state
7KYA	;	3.5	;	Structure of the S. cerevisiae phosphatidylcholine flippase Dnf2-Lem3 complex in the E2P state
7KY5	;	3.98	;	Structure of the S. cerevisiae phosphatidylcholine flippase Dnf2-Lem3 complex in the E2P transition state
6U0M	;	3.9	;	Structure of the S. cerevisiae replicative helicase CMG in complex with a forked DNA
3V62	;	2.9	;	Structure of the S. cerevisiae Srs2 C-terminal domain in complex with PCNA conjugated to SUMO on lysine 164
6BOX	;	2.412	;	Structure of the S. pombe Clr4 catalytic domain bound to SAH
6BP4	;	2.7701	;	Structure of the S. pombe Clr4 catalytic domain bound to SAM
3HUE	;	2.8	;	Structure of the S. pombe Nbs1 FHA-BRCT1-BRCT2 domains
3I0M	;	2.6	;	Structure of the S. pombe Nbs1 FHA/BRCT-repeat domain
3I0N	;	2.3	;	Structure of the S. pombe Nbs1 FHA/BRCT-repeat domain
3HUF	;	2.15	;	Structure of the S. pombe Nbs1-Ctp1 complex
4OB4	;	2.8	;	Structure of the S. venezulae BldD DNA-binding domain
5XGR	;	2.1	;	Structure of the S1 subunit C-terminal domain from bat-derived coronavirus HKU5 spike protein
8T7F	;	3.5	;	Structure of the S1 variant of Fab F1
7ABV	;	2.065	;	Structure of the S1-cleaved mouse Notch1 Negative Regulatory Region (NRR)
4IP7	;	1.8	;	Structure of the S12D variant of human liver pyruvate kinase in complex with citrate and FBP.
6CXU	;	2.49	;	Structure of the S167H mutant of human indoleamine 2,3 dioxygenase in complex with tryptophan and cyanide
6CXV	;	2.6	;	Structure of the S167H mutant of human indoleamine 2,3 dioxygenase in complex with tryptophan and cyanide
8T7I	;	2.6	;	Structure of the S1CE variant of Fab F1 (FabS1CE-F1)
6HR5	;	2.912	;	Structure of the S1_25 family sulfatase module of the rhamnosidase FA22250 from Formosa agariphila
5OXA	;	1.16	;	Structure of the S205A mutant of the Cyan Fluorescent Protein Cerulean at pH 7.0
6KYC	;	2.604	;	Structure of the S207A mutant of Clostridium difficile sortase B
4ENT	;	1.7	;	Structure of the S234A variant of E. coli KatE
4ENU	;	1.7	;	Structure of the S234D variant of E. coli KatE
4ENV	;	1.7	;	Structure of the S234I variant of E. coli KatE
4ENW	;	1.9	;	Structure of the S234N variant of E. coli KatE
4LDR	;	2.292	;	Structure of the S283Y mutant of MRDI
7AGQ	;	2.8	;	Structure of the S726F mutant of AcylTransferase domain of Mycocerosic Acid Synthase from Mycobacterium tuberculosis
7AGT	;	2.901	;	Structure of the S726F mutant of AcylTransferase domain of Mycocerosic Acid Synthase from Mycobacterium tuberculosis acylated with Malonyl-coenzyme A
7AGU	;	3.1	;	Structure of the S726F mutant of AcylTransferase domain of Mycocerosic Acid Synthase from Mycobacterium tuberculosis acylated with MethylMalonyl-coenzyme A
7XR8	;	1.94	;	Structure of the S8 family protease A4095
6QNX	;	2.7	;	Structure of the SA2/SCC1/CTCF complex
8FJS	;	3.0	;	Structure of the Saccharolobus solfataricus archaeal type IV pilus at 3 Angstrom resolution
4H62	;	3.0	;	Structure of the Saccharomyces cerevisiae Mediator subcomplex Med17C/Med11C/Med22C
4Q8G	;	2.1	;	Structure of the Saccharomyces cerevisiae PAN2 pseudoubiquitin-hydrolase
4Q8H	;	3.1	;	Structure of the Saccharomyces cerevisiae PAN2 pseudoubiquitin-hydrolase-RNase module
4XR7	;	3.796	;	Structure of the Saccharomyces cerevisiae PAN2-PAN3 core complex
6WJV	;	3.5	;	Structure of the Saccharomyces cerevisiae polymerase epsilon holoenzyme
7KC0	;	3.2	;	Structure of the Saccharomyces cerevisiae replicative polymerase delta in complex with a primer/template and the PCNA clamp
5G5P	;	5.3	;	Structure of the Saccharomyces cerevisiae TREX-2 complex
5L3T	;	4.927	;	Structure of the Saccharomyces cerevisiae TREX-2 complex
4FIP	;	2.686	;	Structure of the SAGA Ubp8(S144N)/Sgf11(1-72, Delta-ZnF)/Sus1/Sgf73 DUB module
4FK5	;	2.032	;	Structure of the SAGA Ubp8(S144N)/Sgf11/Sus1/Sgf73 DUB module
4FJC	;	2.826	;	Structure of the SAGA Ubp8/Sgf11(1-72, Delta-ZnF)/Sus1/Sgf73 DUB module
3MHH	;	2.45	;	Structure of the SAGA Ubp8/Sgf11/Sus1/Sgf73 DUB module
3MHS	;	1.89	;	Structure of the SAGA Ubp8/Sgf11/Sus1/Sgf73 DUB module bound to ubiquitin aldehyde
7LJM	;	2.6	;	Structure of the Salmonella enterica CD-NTase CdnD in complex with GTP
3IGS	;	1.5	;	Structure of the Salmonella enterica N-acetylmannosamine-6-phosphate 2-epimerase
4HAH	;	1.8	;	Structure of the Salmonella plasmid virulence C protein (SpvC)
4H43	;	2.304	;	Structure of the Salmonella plasmid virulence C protein (SpvC) H106N mutant.
6ZNH	;	3.6	;	Structure of the Salmonella PrgI needle filament attached to the basal body
6Q14	;	3.8	;	Structure of the Salmonella SPI-1 injectisome NC-base
6Q15	;	5.15	;	Structure of the Salmonella SPI-1 injectisome needle complex
6DWB	;	3.3	;	Structure of the Salmonella SPI-1 type III secretion injectisome needle filament
6DV6	;	3.9	;	Structure of the Salmonella SPI-1 type III secretion injectisome secretin InvG (residues 176-end) in the open gate state
6DV3	;	4.1	;	Structure of the Salmonella SPI-1 type III secretion injectisome secretin InvG in the open gate state
7ZTB	;	2.312	;	Structure of the Salmonella tRNA pyrophosphokinase CapRel
4UIO	;	1.35	;	Structure of the Salmonella typhi Type I Dehydroquinase covalently inhibited by a 3-dehydroquinic acid derivative
4CNO	;	1.5	;	Structure of the Salmonella typhi Type I dehydroquinase inhibited by a 3-dehydroquinic acid derivative
4CNP	;	1.15	;	Structure of the Salmonella typhi type I dehydroquinase inhibited by a 3-epiquinic acid derivative
3HZN	;	2.4	;	Structure of the Salmonella typhimurium nfnB dihydropteridine reductase
1JYO	;	1.9	;	Structure of the Salmonella Virulence Effector SptP in Complex with its Secretion Chaperone SicP
5LIR	;	1.75	;	Structure of the SALTY Sigma cross-reacting protein 27A (SCRP-27A) from Salmonella typhimurium
2QKQ	;	2.1	;	Structure of the SAM Domain of Human Ephrin Type-B Receptor 4
2ES6	;		;	Structure of the SAM domain of Vts1p
2ESE	;		;	Structure of the SAM domain of Vts1p in complex with RNA
5AP8	;	2.246	;	Structure of the SAM-dependent rRNA:acp-transferase Tsr3 from S. solfataricus
5APG	;	1.6	;	Structure of the SAM-dependent rRNA:acp-transferase Tsr3 from Vulcanisaeta distributa
4OQU	;	3.2	;	Structure of the SAM-I/IV riboswitch (env87(deltaU92))
4L81	;	2.95	;	Structure of the SAM-I/IV riboswitch (env87(deltaU92, deltaG93))
1XAK	;	1.8	;	STRUCTURE OF THE SARS-CORONAVIRUS ORF7A ACCESSORY PROTEIN
7RKS	;	2.7	;	Structure of the SARS-CoV receptor binding domain in complex with the human neutralizing antibody Fab fragment, C118
7AKJ	;	3.8	;	Structure of the SARS-CoV spike glycoprotein in complex with the 47D11 neutralizing antibody Fab fragment
7ZQW	;	2.53	;	Structure of the SARS-CoV-1 main protease in complex with AG7404
7M2P	;	1.7	;	Structure of the SARS-CoV-2 3CL protease in complex with inhibitor 18
7P35	;	2.256	;	Structure of the SARS-CoV-2 3CL protease in complex with rupintrivir
7FCE	;	3.1	;	Structure of the SARS-CoV-2 A372T spike glycoprotein (closed)
7FCD	;	3.9	;	Structure of the SARS-CoV-2 A372T spike glycoprotein (open)
8K5G	;	3.41	;	Structure of the SARS-CoV-2 BA.1 RBD with UT28-RD
8K5H	;	3.22	;	Structure of the SARS-CoV-2 BA.1 spike with UT28-RD
8GS6	;	2.86	;	Structure of the SARS-CoV-2 BA.2.75 spike glycoprotein (closed state 1)
6WOJ	;	2.2	;	Structure of the SARS-CoV-2 macrodomain (NSP3) in complex with ADP-ribose
7ZQV	;	2.26	;	Structure of the SARS-CoV-2 main protease in complex with AG7404
7TUU	;	1.85	;	Structure of the SARS-CoV-2 main protease in complex with halicin
7SDC	;	1.85	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MI-09
7JPZ	;	1.6	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI1
7RVM	;	1.95	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI11
7RVN	;	1.63	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI12
7UUB	;	1.63	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI12
7RVO	;	1.8	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI13
7RVP	;	1.9	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI14
7RVQ	;	2.48	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI16
7RVR	;	2.46	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI18
7RVS	;	1.85	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI19
7UUC	;	1.6	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI19
7RVT	;	2.1	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI20
7RVU	;	2.5	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI21
7RVV	;	3.0	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI22
7RVW	;	1.85	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI23
7RVX	;	1.85	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI24
7RVY	;	1.85	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI25
7RVZ	;	1.9	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI26
7RW0	;	1.85	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI27
7RW1	;	2.5	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI28
7S6W	;	2.29	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI29
7JQ0	;	1.65	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI3
7S6X	;	1.8	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI30
7S6Y	;	1.85	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI32
7S6Z	;	1.85	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI33
7UUD	;	1.85	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI33
7S70	;	2.6	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI34
7S71	;	1.85	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI35
7S72	;	2.5	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI36
7S73	;	1.85	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI37
8EOY	;	2.28	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI37
8STZ	;	1.85	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI37
7S74	;	1.7	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI38
7JQ1	;	1.65	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI4
7S75	;	1.8	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI42
7SD9	;	1.85	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI48
7SDA	;	1.85	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI49
7JQ2	;	1.4	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI5
7JQ3	;	2.1	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI6
8STY	;	1.9	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI60
7JQ4	;	1.65	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI7
7JQ5	;	1.9	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI8
7UUA	;	1.85	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI8
7UUE	;	1.85	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI85
7SH9	;	1.85	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI86
7SH7	;	1.85	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI87
7SH8	;	1.8	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI88
7TE0	;	2.0	;	Structure of the SARS-CoV-2 main protease in complex with inhibitor PF-07321332
7WYM	;	2.05	;	Structure of the SARS-COV-2 main protease with 337 inhibitor
7WYP	;	2.3	;	Structure of the SARS-COV-2 main protease with EN102 inhibitor
7N0I	;	2.2	;	Structure of the SARS-CoV-2 N protein C-terminal domain bound to single-domain antibody E2
7R98	;	2.51	;	Structure of the SARS-CoV-2 N protein RNA-binding domain bound to single-domain antibody B6
7N0R	;	1.42	;	Structure of the SARS-CoV-2 N protein RNA-binding domain bound to single-domain antibody C2
7JME	;	1.55	;	Structure of the SARS-CoV-2 NSP3 Macro X domain in complex with cyclic AMP
7UAQ	;	3.1	;	Structure of the SARS-CoV-2 NTD in complex with C1520, local refinement
7UZ8	;	3.1	;	Structure of the SARS-CoV-2 Omicron BA.1 S 6P trimer in complex with the mouse antibody Fab fragment, M8a-31
7TIK	;	2.4	;	Structure of the SARS-CoV-2 Omicron spike post-fusion bundle
6W37	;	2.9	;	STRUCTURE OF THE SARS-CoV-2 ORF7A ENCODED ACCESSORY PROTEIN
7JX6	;	1.61	;	STRUCTURE OF THE SARS-CoV-2 ORF8 ENCODED ACCESSORY PROTEIN
7M6D	;	3.1	;	Structure of the SARS-CoV-2 RBD in complex with neutralizing antibodies BG4-25 and CR3022
7R8L	;	2.6	;	Structure of the SARS-CoV-2 RBD in complex with neutralizing antibody C099 and CR3022
7S0B	;	2.9	;	Structure of the SARS-CoV-2 RBD in complex with neutralizing antibody N-612-056
7UZD	;	3.0	;	Structure of the SARS-CoV-2 RBD in complex with the mouse antibody Fab fragment, HSW-2
7UZC	;	2.2	;	Structure of the SARS-CoV-2 RBD in complex with the mouse antibody Fab fragment, M8a-34
7RKU	;	3.2	;	Structure of the SARS-CoV-2 receptor binding domain in complex with the human neutralizing antibody Fab fragment, C022
7K8M	;	3.2	;	Structure of the SARS-CoV-2 receptor binding domain in complex with the human neutralizing antibody Fab fragment, C102
7M6I	;	4.0	;	Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, BG1-24
7M6H	;	4.0	;	Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, BG7-20
7K8S	;	3.4	;	Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C002 (state 1)
7K8V	;	3.8	;	Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C110
7K8W	;	3.6	;	Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C119
7K8X	;	3.9	;	Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C121 (State 1)
7K8Y	;	4.4	;	Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C121 (State 2)
7K8Z	;	3.5	;	Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C135
7R8M	;	3.4	;	Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C032
7R8N	;	3.55	;	Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C051
7RKV	;	3.45	;	Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C118 (State 1)
7R8O	;	3.5	;	Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C548
7S0D	;	3.5	;	Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody N-612-014
7S0C	;	3.25	;	Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody N-612-017
7KL9	;	4.1	;	Structure of the SARS-CoV-2 S 6P trimer in complex with the ACE2 protein decoy, CTC-445.2 (State 4)
7M6F	;	3.9	;	Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, BG1-22
7M6E	;	3.3	;	Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, BG10-19
7M6G	;	3.7	;	Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, BG7-15
7K8T	;	3.4	;	Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, C002 (State 2)
7K8U	;	3.8	;	Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, C104
7K90	;	3.24	;	Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, C144
7SC1	;	3.2	;	Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, R40-1G8
7UZA	;	3.1	;	Structure of the SARS-CoV-2 S 6P trimer in complex with the mouse antibody Fab fragment, HSW-1
7UZ6	;	2.8	;	Structure of the SARS-CoV-2 S 6P trimer in complex with the mouse antibody Fab fragment, M8a-28
7UZ4	;	3.1	;	Structure of the SARS-CoV-2 S 6P trimer in complex with the mouse antibody Fab fragment, M8a-3
7UZ7	;	2.9	;	Structure of the SARS-CoV-2 S 6P trimer in complex with the mouse antibody Fab fragment, M8a-31
7UZ9	;	3.5	;	Structure of the SARS-CoV-2 S 6P trimer in complex with the mouse antibody Fab fragment, M8a-34
7UZ5	;	3.2	;	Structure of the SARS-CoV-2 S 6P trimer in complex with the mouse antibody Fab fragment, M8a-6
7UAP	;	2.8	;	Structure of the SARS-CoV-2 S 6P trimer in complex with the neutralizing antibody Fab fragment, C1520
7UAR	;	3.5	;	Structure of the SARS-CoV-2 S 6P trimer in complex with the neutralizing antibody Fab fragment, C1717
7UZB	;	4.1	;	Structure of the SARS-CoV-2 S S1 doamin in complex with the mouse antibody Fab fragment, HSW-2
7S0E	;	4.9	;	Structure of the SARS-CoV-2 S1 subunit in complex with antibody N-612-004
6VXX	;	2.8	;	Structure of the SARS-CoV-2 spike glycoprotein (closed state)
7VNC	;	3.7	;	Structure of the SARS-CoV-2 spike glycoprotein in complex with a human single domain antibody n3113 (UDD-state, state 1)
7VND	;	3.6	;	Structure of the SARS-CoV-2 spike glycoprotein in complex with a human single domain antibody n3113 (UUD-state, state 2)
7VNE	;	3.5	;	Structure of the SARS-CoV-2 spike glycoprotein in complex with a human single domain antibody n3113.1 (UUU-state)
8C8P	;	4.1	;	Structure of the SARS-CoV-2 spike glycoprotein in complex with the 10D12 heavy-chain-only antibody (local refinement)
7AKD	;	4.0	;	Structure of the SARS-CoV-2 spike glycoprotein in complex with the 47D11 neutralizing antibody Fab fragment
7R40	;	2.9	;	Structure of the SARS-CoV-2 spike glycoprotein in complex with the 87G7 antibody Fab fragment
6XCM	;	3.42	;	Structure of the SARS-CoV-2 spike glycoprotein in complex with the C105 neutralizing antibody Fab fragment (state 1)
6XCN	;	3.66	;	Structure of the SARS-CoV-2 spike glycoprotein in complex with the C105 neutralizing antibody Fab fragment (state 2)
8BON	;	3.2	;	Structure of the SARS-CoV-2 spike glycoprotein in complex with the macrocyclic peptide S1B3inL1
6WPS	;	3.1	;	Structure of the SARS-CoV-2 spike glycoprotein in complex with the S309 neutralizing antibody Fab fragment
6WPT	;	3.7	;	Structure of the SARS-CoV-2 spike glycoprotein in complex with the S309 neutralizing antibody Fab fragment (open state)
8DYA	;	3.67	;	Structure of the SARS-CoV-2 spike glycoprotein S2 subunit
6YOR	;	3.9	;	Structure of the SARS-CoV-2 spike S1 protein in complex with CR3022 Fab
7MW2	;	2.97	;	Structure of the SARS-CoV-2 Spike trimer with all RBDs down in complex with the Fab fragment of human neutralizing antibody clone 6
7MW5	;	3.42	;	Structure of the SARS-CoV-2 Spike trimer with one RBD down in complex with the Fab fragment of human neutralizing antibody clone 2
7MW4	;	3.42	;	Structure of the SARS-CoV-2 Spike trimer with one RBD down in complex with the Fab fragment of human neutralizing antibody clone 6
7MW6	;	3.22	;	Structure of the SARS-CoV-2 Spike trimer with three RBDs up in complex with the Fab fragment of human neutralizing antibody clone 2
7MW3	;	3.15	;	Structure of the SARS-CoV-2 Spike trimer with two RBDs down in complex with the Fab fragment of human neutralizing antibody clone 6
8IOS	;	2.5	;	Structure of the SARS-CoV-2 XBB.1 spike glycoprotein (closed-1 state)
8IOT	;	2.51	;	Structure of the SARS-CoV-2 XBB.1 spike glycoprotein (closed-2 state)
8JYK	;	2.59	;	Structure of the SARS-CoV-2 XBB.1.5 spike glycoprotein (closed state 1)
8JYM	;	2.79	;	Structure of the SARS-CoV-2 XBB.1.5 spike glycoprotein (closed state 2)
8CX9	;	3.5	;	Structure of the SARS-COV2 PLpro (C111S) in complex with a dimeric Ubv that inhibits activity by an unusual allosteric mechanism
8GNA	;	2.8	;	Structure of the SbCas7-11-crRNA-NTR complex
8GU6	;	3.1	;	Structure of the SbCas7-11-crRNA-NTR-Csx29 complex
6R5S	;	2.75	;	Structure of the SBP FpvC from pseudomonas aeruginosa in complex with Fe(II)
6RU4	;	2.49	;	Structure of the SBP FpvC from pseudomonas aeruginosa in complex with Mn2+
6R3Z	;	1.65	;	Structure of the SBP FpvC in complex with Ni2+ ion from P. aeruginosa in P212121 space group
6R44	;	1.99	;	Structure of the SBP FpvC in complex with Ni2+ ion from P.aeruginosa from P21 space group
4AQ1	;	2.42	;	Structure of the SbsB S-layer protein of Geobacillus stearothermophilus PV72p2 in complex with nanobody KB6
3JAN	;	3.75	;	Structure of the scanning state of the mammalian SRP-ribosome complex
5ME3	;	2.85	;	Structure of the Scc2 C-terminus
4H63	;	3.4	;	Structure of the Schizosaccharomyces pombe Mediator head module
3C0T	;	2.4	;	Structure of the Schizosaccharomyces pombe Mediator subcomplex Med8C/18
4H61	;	2.7	;	Structure of the Schizosaccharomyces pombe Mediator subunit Med6
1NI3	;	2.8	;	Structure of the Schizosaccharomyces pombe YchF GTPase
6RUR	;	6.0	;	Structure of the SCIN stabilized C3bBb convertase bound to properdin
6RUV	;	6.15	;	Structure of the SCIN stabilized C3bBb convertase bound to Properdin and a the non-inhibitory nanobody hFPNb1
2YPB	;	2.87	;	Structure of the SCL:E47 complex bound to DNA
2YPA	;	2.8	;	Structure of the SCL:E47:LMO2:LDB1 complex bound to DNA
2KYJ	;		;	Structure of the scorpion toxin U1-Liotoxin-Lw1a
5F4Y	;	3.293	;	Structure of the SD2 domain of Human Shroom2
1PV0	;		;	Structure of the Sda antikinase
5CRA	;	2.64	;	Structure of the SdeA DUB Domain
5CRC	;	2.853	;	Structure of the SdeA DUB Domain
5EUL	;	3.7	;	Structure of the SecA-SecY complex with a translocating polypeptide substrate
7XHB	;	3.33	;	Structure of the SecA/SecYE/proOmpA(4Y)-sfGFP complex with ADP
7XHA	;	3.35	;	Structure of the SecA/SecYE/proOmpA(4Y)-sfGFP complex with ADP.BeF3-.
2HJV	;	1.95	;	Structure of the second domain (residues 207-368) of the Bacillus subtilis YxiN protein
2LB2	;		;	Structure of the second domain of human Nedd4L in complex with a phosphorylated pTPY motif derived from human Smad3
2LB1	;		;	Structure of the second domain of human Smurf1 in complex with a human Smad1 derived peptide
1FF1	;		;	STRUCTURE OF THE SECOND EPS15 HOMOLOGY DOMAIN OF HUMAN EPS15 IN COMPLEX WITH PTGSSSTNPFL
1F8H	;		;	STRUCTURE OF THE SECOND EPS15 HOMOLOGY DOMAIN OF HUMAN EPS15 IN COMPLEX WITH PTGSSSTNPFR
1EH2	;		;	STRUCTURE OF THE SECOND EPS15 HOMOLOGY DOMAIN OF HUMAN EPS15, NMR, 20 STRUCTURES
7F9X	;	1.97	;	Structure of the second OTU domain of LotA
2JXO	;		;	Structure of the second PDZ domain of NHERF-1
2RCZ	;	1.7	;	Structure of the second PDZ domain of ZO-1
2KG0	;		;	Structure of the second qRRM domain of hnRNP F in complex with a AGGGAU G-tract RNA
5GQO	;	2.5	;	Structure of the second Single Stranded DNA Binding protein (SSBb) from Mycobacterium smegmatis
3GHP	;	2.487	;	Structure of the second type II cohesin module from the adaptor ScaA scaffoldin of Acetivibrio cellulolyticus (including long C-terminal linker)
2LAW	;		;	Structure of the second WW domain from human YAP in complex with a human Smad1 derived peptide
3J46	;	10.1	;	Structure of the SecY protein translocation channel in action
3RZC	;	2.8	;	Structure of the self-antigen iGb3 bound to mouse CD1d and in complex with the iNKT TCR
6XOR	;		;	Structure of the Self-Association Domain of Swallow
6PTL	;	2.5	;	Structure of the self-association domain of the chromatin looping factor LDB1
6SJW	;		;	Structure of the self-processing module of iron-regulated FrpC of N. Meningitidis with calcium ions
1Q47	;	2.8	;	Structure of the Semaphorin 3A Receptor-Binding Module
3F6I	;	2.788	;	Structure of the SeMet labeled F4 fibrial chaperone FaeE
7CG5	;	2.85	;	Structure of the sensor domain (long construct) of the anti-sigma factor RsgI4 in Pseudobacteroides cellulosolvens
7CG8	;	1.5	;	Structure of the sensor domain (short construct) of the anti-sigma factor RsgI4 in Pseudobacteroides cellulosolvens
3CSN	;	3.0	;	Structure of the Serratia marcescens hemophore receptor HasR in complex with its hemophore HasA
3CSL	;	2.7	;	Structure of the Serratia marcescens hemophore receptor HasR in complex with its hemophore HasA and heme
3DDR	;	2.8	;	Structure of the Serratia marcescens hemophore receptor HasR-Ile671Gly mutant in complex with its hemophore HasA and heme
1MVH	;	2.3	;	structure of the SET domain histone lysine methyltransferase Clr4
1MVX	;	3.0	;	structure of the SET domain histone lysine methyltransferase Clr4
8ASG	;	3.2	;	Structure of the SFTSV L protein bound in a resting state [RESTING]
8AS6	;	3.4	;	Structure of the SFTSV L protein bound to 5' cRNA hook [5' HOOK]
8ASB	;	3.6	;	Structure of the SFTSV L protein stalled at early elongation with the endonuclease domain in a raised conformation [EARLY-ELONGATION-ENDO]
8AS7	;	2.6	;	Structure of the SFTSV L protein stalled at early elongation [EARLY-ELONGATION]
8ASD	;	2.6	;	Structure of the SFTSV L protein stalled at late elongation [LATE-ELONGATION]
3GXW	;	1.9	;	Structure of the SH2 domain of the Candida glabrata transcription elongation factor Spt6, crystal form A
3GXX	;	2.4	;	Structure of the SH2 domain of the Candida glabrata transcription elongation factor Spt6, crystal form B
4F14	;	1.2	;	Structure of the SH3 domain of human nebulette in complex with a peptide of XIRP2
5K26	;	1.2	;	Structure of the SH3 domain of MLK3 bound to peptide generated from phage display
6AQB	;	1.5	;	Structure of the SH3 domain of MLK3 bound to peptide generated from phage display
7WOI	;	2.73	;	Structure of the shaft pilin Spa2 from Corynebacterium glutamicum
3NTA	;	2.01	;	Structure of the Shewanella loihica PV-4 NADH-dependent persulfide reductase
3NT6	;	2.0	;	Structure of the Shewanella loihica PV-4 NADH-dependent persulfide reductase C43S/C531S Double Mutant
3NTD	;	1.99	;	Structure of the Shewanella loihica PV-4 NADH-dependent persulfide reductase C531S Mutant
4OCG	;	2.75	;	Structure of the Shewanella loihica PV-4 NADH-dependent persulfide reductase F161A Mutant
4A5P	;	3.15	;	Structure of the Shigella flexneri MxiA protein
5ECW	;	1.94	;	Structure of the Shigella flexneri VapC mutant D7A
5ED0	;	2.1	;	Structure of the Shigella flexneri VapC mutant D7N
5ECD	;	1.75	;	Structure of the Shigella flexneri VapC mutant D98N crystal form 1
5ECY	;	2.0	;	Structure of the Shigella flexneri VapC mutant D98N crystal form 2
6ZNI	;	3.6	;	Structure of the Shigella MxiH needle filament attached to the basal body
8E8T	;	2.18	;	Structure of the short LOR domain of human AASS
8E8V	;	2.45	;	Structure of the short LOR domain of human AASS bound to N-ethylsuccinimide
3TKZ	;	1.8	;	Structure of the SHP-2 N-SH2 domain in a 1:2 complex with RVIpYFVPLNR peptide
3UAH	;	1.6	;	Structure of the Shq1 specific domain from Saccharomyces cerevisiae
3UAI	;	3.06	;	Structure of the Shq1-Cbf5-Nop10-Gar1 complex from Saccharomyces cerevisiae
3ZV0	;	2.8	;	Structure of the SHQ1P-CBF5P complex
3SZJ	;	1.45	;	Structure of the shwanavidin-biotin complex
4MNP	;	2.5	;	Structure of the Sialic Acid Binding Protein from Fusobacterium Nucleatum subsp. nucleatum ATCC 25586
7T3E	;	1.04	;	Structure of the sialic acid bound Tripartite ATP-independent Periplasmic (TRAP) periplasmic component SiaP from Photobacterium profundum
378D	;	2.4	;	STRUCTURE OF THE SIDE-BY-SIDE BINDING OF DISTAMYCIN TO DNA
7LRN	;	2.85	;	Structure of the Siderophore Interacting Protein from Acinetbacter baumannii
5DH2	;	2.59	;	Structure of the siderophore periplasmic binding protein from the fuscachelin gene cluster of Thermobifida fusca in I222
5DH1	;	2.842	;	Structure of the siderophore periplasmic binding protein from the fuscachelin gene cluster of Thermobifida fusca in P21
5DH0	;	2.444	;	Structure of the siderophore periplasmic binding protein from the fuscachelin gene cluster of Thermobifida fusca in P41
3EUL	;	1.9	;	Structure of the signal receiver domain of the putative response regulator NarL from Mycobacterium tuberculosis
1RY1	;	12.0	;	Structure of the signal recognition particle interacting with the elongation-arrested ribosome
2UV3	;	1.8	;	Structure of the signal-regulatory protein (SIRP) alpha domain that binds CD47.
1F2X	;	2.1	;	STRUCTURE OF THE SINGLE-DOMAIN CAMELID ANTIBODY CAB-CA05
7U5U	;	3.16	;	Structure of the SK/DHQase/DHSD dimer from Candida albicans Aro1
2OVP	;	2.9	;	Structure of the Skp1-Fbw7 complex
2OVQ	;	2.6	;	Structure of the Skp1-Fbw7-CyclinEdegC complex
2OVR	;	2.5	;	Structure of the Skp1-Fbw7-CyclinEdegN complex
3RDV	;	1.75	;	Structure of the SLAIN2c-CLIPCG1 complex
5SV9	;	5.9	;	Structure of the SLC4 transporter Bor1p in an inward-facing conformation
6XJL	;	2.0	;	Structure of the SM protein Vps45
2J5X	;	2.8	;	STRUCTURE OF THE SMALL G PROTEIN ARF6 IN COMPLEX WITH GTPGAMMAS
5MMJ	;	3.6	;	Structure of the small subunit of the chloroplast ribosome
8PAQ	;	1.6	;	Structure of the small subunit of the laccase-like Nlac protein from Pleurotus eryngii
5AJ3	;	3.6	;	Structure of the small subunit of the mammalian mitoribosome
7SZZ	;	3.9	;	Structure of the smaller diameter PSMalpha3 nanotubes
2B7G	;		;	Structure of the Smaug Recognition RNA Element
6SYT	;	3.45	;	Structure of the SMG1-SMG8-SMG9 complex
7A0G	;	6.979	;	Structure of the SmhB pore of the tripartite alpha-pore forming toxin, Smh, from Serratia marcescens.
7QGR	;	5.7	;	Structure of the SmrB-bound E. coli disome - collided 70S ribosome
7QGN	;	3.37	;	Structure of the SmrB-bound E. coli disome - stalled 70S ribosome
7M3Q	;	2.5	;	Structure of the Smurf2 HECT Domain with a High Affinity Ubiquitin Variant (UbV)
5G5N	;	2.3	;	Structure of the snake adenovirus 1 hexon-interlacing LH3 protein, methylmercury chloride derivative
5G5O	;	2.0	;	Structure of the snake adenovirus 1 hexon-interlacing LH3 protein, native
8CI5	;	3.2	;	Structure of the SNV L protein bound to 5' RNA
8A1G	;	2.5	;	Structure of the SNX1-SNX5 complex
8ABQ	;	2.81	;	Structure of the SNX1-SNX5 complex, Pt derivative
4GXB	;	1.8	;	Structure of the SNX17 atypical FERM domain bound to the NPxY motif of P-selectin
4TKN	;	3.0	;	Structure of the SNX17 FERM domain bound to the second NPxF motif of KRIT1
6E8R	;	2.268	;	Structure of the SNX32 PX domain in complex with Chlamydial protein IncE in space group I121
5TGJ	;	2.6	;	Structure of the SNX5 PX domain in complex with chlamydial protein IncE in space group I2
5TGI	;	1.98	;	Structure of the SNX5 PX domain in complex with chlamydial protein IncE in space group P212121
5TGH	;	2.8	;	Structure of the SNX5 PX domain in complex with chlamydial protein IncE in space group P32
4JGH	;	3.0	;	Structure of the SOCS2-Elongin BC complex bound to an N-terminal fragment of Cullin5
4CZB	;	3.5	;	Structure of the sodium proton antiporter MjNhaP1 from Methanocaldococcus jannaschii at pH 8.
4CZ9	;	3.5	;	Structure of the sodium proton antiporter PaNhaP from Pyrococcus abyssii at pH 4.
4CZ8	;	3.15	;	Structure of the sodium proton antiporter PaNhaP from Pyrococcus abyssii at pH 8.
4CZA	;	3.2	;	Structure of the sodium proton antiporter PaNhaP from Pyrococcus abyssii with bound thallium ion.
5WIV	;	2.143	;	Structure of the sodium-bound human D4 Dopamine receptor in complex with Nemonapride
7UUY	;	3.3	;	Structure of the sodium/iodide symporter (NIS)
7UV0	;	3.1	;	Structure of the sodium/iodide symporter (NIS) in complex with iodide and sodium
7UUZ	;	3.2	;	Structure of the sodium/iodide symporter (NIS) in complex with perrhenate and sodium
6GRK	;	2.33	;	Structure of the soluble AhlB of the tripartite alpha-pore forming toxin, AHL, from Aeromonas hydrophila.
6H2D	;	2.62	;	Structure of the soluble AhlC of the tripartite alpha-pore forming toxin, AHL, from Aeromonas hydrophila.
6H2E	;	2.35	;	Structure of the soluble AhlC of the tripartite alpha-pore forming toxin, AHL, from Aeromonas hydrophila.
6R1J	;	1.92	;	Structure of the soluble AhlC triple head mutant of the tripartite alpha-pore forming toxin, AHL, from Aeromonas hydrophila.
1QL4	;	1.5	;	Structure of the soluble domain of cytochrome c552 from Paracoccus denitrificans in the oxidised state
1QL3	;	1.4	;	Structure of the soluble domain of cytochrome c552 from Paracoccus denitrificans in the reduced state
3M97	;	1.332	;	Structure of the soluble domain of cytochrome c552 with its flexible linker segment from Paracoccus denitrificans
5CYU	;	3.07	;	Structure of the soluble domain of EccB1 from the Mycobacterium smegmatis ESX-1 secretion system.
4KAY	;	1.781	;	Structure of the soluble domain of Lipooligosaccharide phosphoethanolamine transferase A from Neisseria meningitidis - complex with Zn
2VKJ	;	1.65	;	Structure of the soluble domain of the membrane protein TM1634 from Thermotoga maritima
2VKO	;	1.79	;	Structure of the soluble domain of the membrane protein TM1634 from Thermotoga maritima
1CKV	;		;	STRUCTURE OF THE SOLUBLE METHANE MONOOXYGENASE REGULATORY PROTEIN B
4PO7	;	2.66	;	Structure of the Sortilin:neurotensin complex at excess neurotensin concentration
3U2B	;	2.402	;	Structure of the Sox4 HMG domain bound to DNA
8J7S	;	2.84	;	Structure of the SPARTA complex
6VPC	;	3.2	;	Structure of the SpCas9 DNA adenine base editor - ABE8e
5J1F	;	3.0	;	Structure of the spectrin repeats 5 and 6 of the plakin domain of plectin
5J1H	;	2.8	;	Structure of the spectrin repeats 5 and 6 of the plakin domain of plectin
5J1G	;	1.8	;	Structure of the spectrin repeats 7 and 8 of the plakin domain of plectin
5J1I	;	2.801	;	Structure of the spectrin repeats 7, 8, and 9 of the plakin domain of plectin
3TTH	;	3.298	;	Structure of the spermidine N1-acetyltransferase (speG) from Coxiella burnetii
4IA4	;	3.1	;	Structure of the spinach aquaporin SoPIP2;1 at pH 6
8GKH	;	2.7	;	Structure of the Spizellomyces punctatus Fanzor (SpuFz) in complex with omega RNA and target DNA
4NHO	;	2.0	;	Structure of the spliceosomal DEAD-box protein Prp28
4R3F	;	1.3	;	Structure of the spliceosomal peptidyl-prolyl cis-trans isomerase Cwc27 from Chaetomium thermophilum
4R3E	;	2.0	;	Structure of the spliceosomal peptidyl-prolyl cis-trans isomerase Cwc27 from Homo sapiens
2L5I	;		;	structure of the spliceosomal phosphopeptide P140 (non-phosphorylated form)
2L5J	;		;	structure of the spliceosomal phosphopeptide P140 (phosphorylated form)
7A5J	;	3.1	;	Structure of the split human mitoribosomal large subunit with P-and E-site mt-tRNAs
7A5H	;	3.3	;	Structure of the split human mitoribosomal large subunit with rescue factors mtRF-R and MTRES1
3TUF	;	2.26	;	Structure of the SpoIIQ-SpoIIIAH pore forming complex.
1MNN	;	1.4	;	Structure of the sporulation specific transcription factor Ndt80 bound to DNA
7PEG	;	1.77	;	Structure of the sporulation/germination protein YhcN from Bacillus subtilis
7XPN	;	3.98	;	Structure of the Spring Viraemia of Carp Virus Nucleoprotein
7YG7	;	3.7	;	Structure of the Spring Viraemia of Carp Virus ribonucleoprotein Complex
3TOJ	;	2.07	;	Structure of the SPRY domain of human Ash2L
4IOY	;	1.945	;	Structure of the Spt16 Middle Domain Reveals Functional Features of the Histone Chaperone FACT
4KHB	;	2.4	;	Structure of the Spt16D Pob3N heterodimer
5IJJ	;	1.95	;	Structure of the SPX domain of Chaetomium thermophilum Glycerophosphodiester Phosphodiesterase 1 in complex with inositol hexakisphosphate (InsP6)
5IJH	;	2.43	;	Structure of the SPX domain of the human phosphate transporter XPR1 in complex with a sulfate ion
5IIG	;	2.99	;	Structure of the SPX-TTM domain fragment of the yeast inorganic polyphophate polymerase Vtc4 (form A).
5IIQ	;	3.03	;	Structure of the SPX-TTM domain fragment of the yeast inorganic polyphophate polymerase Vtc4 (form B).
2ES5	;		;	Structure of the SRE RNA
4GYC	;	2.0501	;	Structure of the SRII(D75N mutant)/HtrII Complex in I212121 space group (""U"" shape)
5JJE	;	1.9	;	Structure of the SRII/HtrII Complex in I212121 space group (""U"" shape)
5JJF	;	1.9	;	Structure of the SRII/HtrII Complex in I212121 space group (""U"" shape) - M state
5JJJ	;	2.5	;	Structure of the SRII/HtrII Complex in P64 space group (""U"" shape)
5JJN	;	2.25	;	Structure of the SRII/HtrII(G83F) Complex in P212121 space group (""V"" shape)
4P3G	;	2.7	;	Structure of the SRP68-RBD from Chaetomium thermophilum
6PAJ	;	2.0	;	Structure of the SrrAB Histidine Kinase DHp-CA domain
4UAH	;	1.73	;	Structure of the Ssl1 laccase mutant H99N with depleted type-2 copper ion
4UAN	;	1.8	;	Structure of the Ssl1 laccase mutant H99Q with depleted type-2 copper ion
4W1T	;	1.55	;	Structure of the Ssl1 laccase mutant H99Y with depleted type-2 copper ion
4WTQ	;	1.8	;	Structure of the Ssl1 laccase mutant M295L
4GNI	;	1.796	;	Structure of the Ssz1 ATPase bound to ATP and Magnesium
4FG0	;	3.899	;	Structure of the St. Louis Encephalitis Virus envelope protein in the fusogenic trimer conformation.
5IFR	;	2.2	;	Structure of the stable UBE2D3-UbDha conjugate
7A5F	;	4.4	;	Structure of the stalled human mitoribosome with P- and E-site mt-tRNAs
5FJ0	;	2.2	;	Structure of the standard kink turn HmKt-7 as simple duplex in P4222 space group
5FJ4	;	2.95	;	Structure of the standard kink turn HmKt-7 as stem loop bound with U1A and L7Ae proteins
5FJ1	;	2.75	;	Structure of the standard kink turn HmKt-7 as stem loop in P212121 space group
6Q8U	;	1.99	;	Structure of the standard kink turn HmKt-7 variant A2bm6A bound with AfL7Ae protein
6Q8V	;	2.09	;	Structure of the standard kink turn HmKt-7 variant A2bm6A.
4G4K	;	1.52	;	Structure of the Staphylococcus aureus AgrA LytTR Domain
3BS1	;	1.6	;	Structure of the Staphylococcus aureus AgrA LytTR Domain Bound to DNA Reveals a Beta Fold with a Novel Mode of Binding
2IHY	;	1.9	;	Structure of the Staphylococcus aureus putative ATPase subunit of an ATP-binding cassette (ABC) transporter
3V3B	;	2.0	;	Structure of the Stapled p53 Peptide Bound to Mdm2
5AFG	;	1.9	;	Structure of the Stapled Peptide Bound to Mdm2
4UE1	;	1.45	;	Structure of the stapled peptide YS-01 bound to MDM2
4UD7	;	1.6	;	Structure of the stapled peptide YS-02 bound to MDM2
4JVY	;	2.853	;	Structure of the STAR (signal transduction and activation of RNA) domain of GLD-1 bound to RNA
4JVH	;	3.501	;	Structure of the star domain of quaking protein in complex with RNA
5EMO	;	3.03	;	Structure of the star domain of T-STAR in complex with AUUAAA RNA
7ML5	;	2.35	;	Structure of the Starch Branching Enzyme I (BEI) complexed with maltododecaose from Oryza sativa L
3VU2	;	2.23	;	Structure of the Starch Branching Enzyme I (BEI) complexed with maltopentaose from Oryza sativa L
3AMK	;	1.9	;	Structure of the Starch Branching Enzyme I (BEI) from Oryza sativa L
3AML	;	1.7	;	Structure of the Starch Branching Enzyme I (BEI) from Oryza sativa L
1YP0	;	1.5	;	Structure of the steroidogenic factor-1 ligand binding domain bound to phospholipid and a SHP peptide motif
4D7T	;	2.582	;	Structure of the SthK Carboxy-Terminal Region in complex with cAMP
4D7S	;	2.55	;	Structure of the SthK Carboxy-Terminal Region in complex with cGMP
6CJQ	;	3.42	;	Structure of the SthK cyclic nucleotide-gated potassium channel
6CJU	;	3.35	;	Structure of the SthK cyclic nucleotide-gated potassium channel in complex with cAMP
6CJT	;	3.46	;	Structure of the SthK cyclic nucleotide-gated potassium channel in complex with cGMP
7OUH	;	3.5	;	Structure of the STLV intasome:B56 complex bound to the strand-transfer inhibitor bictegravir
7OUF	;	3.0	;	Structure of the STLV intasome:B56 complex bound to the strand-transfer inhibitor XZ450
5SY1	;	3.9	;	Structure of the STRA6 receptor for retinol uptake in complex with calmodulin
4OQ1	;	1.85	;	Structure of the Streptococcal ancillary pilin
1Y08	;	1.93	;	Structure of the Streptococcal Endopeptidase IdeS, a Novel Cysteine Proteinase with Strict Specificity for IgG
4K48	;	2.49	;	Structure of the Streptococcus pneumoniae leucyl-tRNA synthetase editing domain
4K47	;	2.02	;	Structure of the Streptococcus pneumoniae leucyl-tRNA synthetase editing domain bound to a benzoxaborole-AMP adduct
3ZPP	;	2.28	;	Structure of the Streptococcus pneumoniae surface protein and adhesin PfbA
2WYH	;	1.9	;	Structure of the Streptococcus pyogenes family GH38 alpha-mannosidase
2WYI	;	2.6	;	Structure of the Streptococcus pyogenes family GH38 alpha-mannosidase complexed with swainsonine
7BDN	;	2.7	;	Structure of the Streptomyces coelicolor small laccase - cubic crystal form
6I0I	;	1.448	;	Structure of the streptomyces subtilisin and TAMP inhibitor (SSTI)
7U3A	;	3.34	;	Structure of the Streptomyces venezuelae GlgX-c-di-GMP complex
3HAV	;	2.45	;	Structure of the streptomycin-ATP-APH(2"")-IIa ternary complex
3FAJ	;	1.7	;	Structure of the structural protein P131 of the archaeal virus Acidianus Two-tailed virus (ATV)
3OI7	;	2.4	;	Structure of the structure of the H13A mutant of Ykr043C in complex with sedoheptulose-1,7-bisphosphate
8F14	;	1.69	;	Structure of the STUB1 TPR domain in complex with H201, an all-D Helicon Polypeptide
8F15	;	1.73	;	Structure of the STUB1 TPR domain in complex with H202, an all-D Helicon Polypeptide
8F16	;	1.56	;	Structure of the STUB1 TPR domain in complex with H203, an all-D Helicon Polypeptide
8F17	;	2.21	;	Structure of the STUB1 TPR domain in complex with H204, an all-D Helicon Polypeptide
4F07	;	2.3	;	Structure of the Styrene Monooxygenase Flavin Reductase (SMOB) from Pseudomonas putida S12
5E24	;	2.14	;	Structure of the Su(H)-Hairless-DNA Repressor Complex
2Y08	;	1.7	;	Structure of the substrate-free FAD-dependent tirandamycin oxidase TamL
2R0C	;	1.8	;	Structure of the substrate-free form of the rebeccamycin biosynthetic enzyme REBC
4GOH	;	1.8	;	Structure of the substrate-free HmuO, HO from Corynebacterium diphtheriae
5NCU	;	1.7	;	Structure of the subtilisin induced serpin-type proteinase inhibitor, miropin.
6X6B	;	1.67	;	Structure of the sulfate-bound form of ArrX from Chrysiogenes arsenatis
1FLP	;	1.5	;	STRUCTURE OF THE SULFIDE-REACTIVE HEMOGLOBIN FROM THE CLAM LUCINA PECTINATA: CRYSTALLOGRAPHIC ANALYSIS AT 1.5 ANGSTROMS RESOLUTION
2NNC	;	2.14	;	Structure of the sulfur carrier protein SoxY from Chlorobium limicola f thiosulfatophilum
2NNF	;	2.39	;	Structure of the sulfur carrier protein SoxY from Chlorobium limicola f thiosulfatophilum
3TQJ	;	2.004	;	Structure of the superoxide dismutase (Fe) (sodB) from Coxiella burnetii
1Z3I	;	3.0	;	Structure of the SWI2/SNF2 chromatin remodeling domain of eukaryotic Rad54
2VFX	;	1.95	;	Structure of the Symmetric Mad2 Dimer
1ZNN	;	2.2	;	Structure of the synthase subunit of PLP synthase
2NV1	;	2.08	;	Structure of the synthase subunit Pdx1 (YaaD) of PLP synthase from Bacillus subtilis
3FEM	;	3.02	;	Structure of the synthase subunit Pdx1.1 (Snz1) of PLP synthase from Saccharomyces cerevisiae
4YFS	;	2.1	;	Structure of the synthetic Duffy Binding Protein (DBP) antigen DEKnull relevant for malaria vaccine design
5HU6	;	2.9	;	Structure of the T. brucei haptoglobin-haemoglobin receptor bound to human haptolgobin-haemoglobin
6E4P	;	1.949	;	Structure of the T. brucei RRM domain in complex with RNA
6E4N	;	1.801	;	Structure of the T. brucei TbRGG2 RRM domain: apo R3 crystal form
5LB9	;	2.1	;	Structure of the T175V Etr1p mutant in the monoclinic form P21
5LBX	;	2.5	;	Structure of the T175V Etr1p mutant in the trigonal form P312 in complex with NADP and crotonyl-CoA
4UCQ	;	2.6	;	Structure of the T18D small subunit mutant of D. fructosovorans NiFe- hydrogenase
4UCX	;	1.95	;	Structure of the T18G small subunit mutant of D. fructosovorans NiFe- hydrogenase
4UCW	;	2.3	;	Structure of the T18V small subunit mutant of D. fructosovorans NiFe- hydrogenase
7Z7Q	;	1.6	;	Structure of the T207D single-point mutant of the fluorescent protein NeonCyan1 at pH 6.5
4IYC	;	2.75	;	Structure of the T244A mutant of the PANTON-VALENTINE LEUCOCIDIN component from STAPHYLOCOCCUS AUREUS
6XYR	;	2.079	;	Structure of the T4Lnano fusion protein
6AXX	;	2.6	;	Structure of the T58A/I124A mutant of the HIV-1 capsid protein
6AXT	;	2.4	;	Structure of the T58S/T107I/P122A mutant of the HIV-1 capsid protein
6AXV	;	2.77	;	Structure of the T58S/T107I/P122A mutant of the HIV-1 capsid protein in complex with PF-3450074 (PF74)
3EXX	;	1.35	;	Structure of the T6 human insulin derivative with nickel at 1.35 A resolution
5M38	;	2.6	;	Structure of the TagL peptidoglycan binding domain from EAEC T6SS
7BBA	;	2.43	;	Structure of the TagL peptidoglycan binding domain from EAEC T6SS
8ON5	;	2.3	;	Structure of the tail fibre from an extracellular contractile injection system from Photorhabdus bacteria
6MNI	;	1.696	;	Structure of the tandem CACHE domain of PscC
2KZT	;		;	Structure of the Tandem MA-3 Region of Pdcd4
3FSS	;	1.432	;	Structure of the tandem PH domains of Rtt106
3TVV	;	2.589	;	Structure of the tandem PH domains of Rtt106 (residues 68-315)
2XP1	;	2.2	;	Structure of the tandem SH2 domains from Antonospora locustae transcription elongation factor Spt6
3F41	;	2.3	;	Structure of the tandemly repeated protein tyrosine phosphatase like phytase from Mitsuokella multacida
4B4A	;	3.5	;	Structure of the TatC core of the twin arginine protein translocation system
8OH2	;	2.6	;	Structure of the Tau-PAM4 Type 1 amyloid fibril
4Z6Y	;	2.81	;	Structure of the TBC1D7-TSC1 complex
2XTC	;	2.22	;	Structure of the TBL1 tetramerisation domain
2XTD	;	3.2	;	Structure of the TBL1 tetramerisation domain
2XTE	;	3.9	;	Structure of the TBL1 tetramerisation domain
7NE0	;	3.25	;	Structure of the ternary complex between Netrin-1, Repulsive-Guidance Molecule-B (RGMB) and Neogenin
4WGG	;	2.4	;	STRUCTURE OF THE TERNARY COMPLEX OF A ZINGIBER OFFICINALE DOUBLE BOND REDUCTASE IN COMPLEX WITH NADP AND CONIFERYL ALDEHYDE
4K7T	;	1.1	;	Structure of the ternary complex of bacitracin, zinc, and geranyl-pyrophosphate
8ING	;	1.98	;	Structure of the ternary complex of lactoperoxidase with substrate nitric oxide (NO) and product nitrite ion (NO2) at 1.98 A resolution
4Q9E	;	2.31	;	Structure of the ternary complex of peptidoglycan recognition protein, PGRP-S with N-acetyl glucosamine and paranitro benzaldehyde at 2.3 A resolution
7DY5	;	2.3	;	Structure of the ternary complex of peptidoglycan recognition protein-short (PGRP-S) with hexanoic acid and tartaric acid at 2.30A resolution
6RPU	;	2.11	;	Structure of the ternary complex of the IMPDH enzyme from Ashbya gossypii bound to the dinucleoside polyphosphate Ap5G and GDP
3V11	;	5.0	;	Structure of the ternary initiation complex AIF2:GDPNP:methionylated initiator TRNA
1BUI	;	2.65	;	Structure of the ternary microplasmin-staphylokinase-microplasmin complex: a proteinase-cofactor-substrate complex in action
4F37	;	2.57	;	Structure of the tethered N-terminus of Alzheimer's disease A peptide
4A99	;	2.18	;	STRUCTURE OF THE TETRACYCLINE DEGRADING MONOOXYGENASE TETX IN COMPLEX WITH MINOCYCLINE
4A6N	;	2.3	;	STRUCTURE OF THE TETRACYCLINE DEGRADING MONOOXYGENASE TETX IN COMPLEX WITH TIGECYCLINE
2XDO	;	2.09	;	Structure of the Tetracycline degrading Monooxygenase TetX2 from Bacteroides thetaiotaomicron
2W2C	;	2.7	;	STRUCTURE OF THE TETRADECAMERIC OLIGOMERISATION DOMAIN OF CALCIUM- CALMODULIN DEPENDENT PROTEIN KINASE II DELTA
3EW5	;	3.1	;	Structure of the tetragonal crystal form of X (ADRP) domain from FCoV
1AH6	;	1.8	;	STRUCTURE OF THE TETRAGONAL FORM OF THE N-TERMINAL DOMAIN OF THE YEAST HSP90 CHAPERONE
1Y5Y	;	2.0	;	Structure of the tetrahydromethanopterin dependent formaldehyde-activating enzyme (Fae) from Methylobacterium extorquens AM1
1Y60	;	1.9	;	Structure of the tetrahydromethanopterin dependent formaldehyde-activating enzyme (Fae) from Methylobacterium extorquens AM1 with bound 5,10-methylene tetrahydromethanopterin
1X8W	;	3.8	;	Structure of the Tetrahymena Ribozyme: Base Triple Sandwich and Metal Ion at the Active Site
2MEX	;		;	Structure of the tetrameric building block of the Salmonella Typhimurium PrgI Type three secretion system needle
1WNT	;	2.3	;	Structure of the tetrameric form of Human L-Xylulose Reductase
3CQD	;	1.98	;	Structure of the tetrameric inhibited form of phosphofructokinase-2 from Escherichia coli
1VZJ	;	2.35	;	Structure of the tetramerization domain of acetylcholinesterase: four-fold interaction of a WWW motif with a left-handed polyproline helix
4GJW	;	3.0	;	Structure of the tetramerization domain of Nipah virus phosphoprotein
8BNY	;	1.429	;	Structure of the tetramerization domain of pLS20 conjugation repressor Rco
2Y6R	;	3.1	;	Structure of the TetX monooxygenase in complex with the substrate 7- chlortetracycline
2Y6Q	;	2.37	;	Structure of the TetX monooxygenase in complex with the substrate 7- Iodtetracycline
6YJ6	;	3.1	;	Structure of the TFIIIC subcomplex tauA
3KO0	;	2.3	;	Structure of the tfp-ca2+-bound activated form of the s100a4 Metastasis factor
3G7M	;	2.91	;	Structure of the thaumatin-like xylanase inhibitor TLXI
5DA0	;	3.2	;	Structure of the the SLC26 transporter SLC26Dg in complex with a nanobody
8H09	;	1.81	;	Structure of the thermolabile hemolysin from Vibrio alginolyticus (apo form)
8H0C	;	1.98	;	Structure of the thermolabile hemolysin from Vibrio alginolyticus (in complex with arachidonic acid)
8H0D	;	2.01	;	Structure of the thermolabile hemolysin from Vibrio alginolyticus (in complex with docosahexaenoic acid)
8H0A	;	1.94	;	Structure of the thermolabile hemolysin from Vibrio alginolyticus (in complex with lauric acid)
8H0B	;	1.931	;	Structure of the thermolabile hemolysin from Vibrio alginolyticus (in complex with oleic acid)
5LLM	;	3.25	;	Structure of the thermostabilized EAAT1 cryst mutant in complex with L-ASP and the allosteric inhibitor UCPH101
7AWM	;	3.25	;	Structure of the thermostabilized EAAT1 cryst mutant in complex with L-ASP, three sodium ions and the allosteric inhibitor UCPH101
7AWN	;	3.92	;	Structure of the thermostabilized EAAT1 cryst mutant in complex with rubidium and barium and the allosteric inhibitor UCPH101
5MJU	;	3.71	;	Structure of the thermostabilized EAAT1 cryst mutant in complex with the competititve inhibitor TFB-TBOA and the allosteric inhibitor UCPH101
7AWQ	;	3.65	;	Structure of the thermostabilized EAAT1 cryst-E386Q mutant in complex with L-ASP, sodium ions and the allosteric inhibitor UCPH101
7AWL	;	3.7	;	Structure of the thermostabilized EAAT1 cryst-II mutant in complex with barium and the allosteric inhibitor UCPH101
5LLU	;	3.32	;	Structure of the thermostabilized EAAT1 cryst-II mutant in complex with L-ASP
7AWP	;	3.91	;	Structure of the thermostabilized EAAT1 cryst-II mutant in complex with rubidium and barium ions and the allosteric inhibitor UCPH101
7CFF	;	2.0	;	Structure of the thermostabilized transmembrane domain of the bacterial CNNM/CorC family Mg2+ transporter in complex with Mg2+
4XZ5	;	2.596	;	Structure of the thermostable alpha-Carbonic Anydrase from Thiomicrospira crunogena XCL-2 gammaproteobacterium
1WL7	;	1.9	;	Structure of the thermostable arabinanase
3S2C	;	3.0	;	Structure of the thermostable GH51 alpha-L-arabinofuranosidase from Thermotoga petrophila RKU-1
1VBL	;	1.91	;	Structure of the thermostable pectate lyase PL 47
5LM4	;	3.1	;	Structure of the thermostalilized EAAT1 cryst-II mutant in complex with L-ASP and the allosteric inhibitor UCPH101
7EC9	;	1.8	;	Structure of the Thermotoga maritima Family 5 endo-glucanase in complex with 1-deoxynojiromycin
5UHT	;	2.68	;	Structure of the Thermotoga maritima HK853-BeF3-RR468 complex at pH 5.0
1J5E	;	3.05	;	Structure of the Thermus thermophilus 30S Ribosomal Subunit
1N32	;	3.0	;	Structure of the Thermus thermophilus 30S ribosomal subunit bound to codon and near-cognate transfer RNA anticodon stem-loop mismatched at the first codon position at the a site with paromomycin
1N33	;	3.35	;	Structure of the Thermus thermophilus 30S ribosomal subunit bound to codon and near-cognate transfer rna anticodon stem-loop mismatched at the second codon position at the a site with paromomycin
6MPF	;	3.33	;	Structure of the Thermus thermophilus 30S ribosomal subunit complexed with a 2-thiocytidine (s2C32) and inosine (I34) modified anticodon stem loop (ASL) of Escherichia coli transfer RNA Arginine 1 (TRNAARG1) bound to an mRNA with an CGC-codon in the A-site and paromomycin
6MPI	;	3.33	;	Structure of the Thermus thermophilus 30S ribosomal subunit complexed with a 2-thiocytidine (s2C32) and inosine (I34) modified anticodon stem loop (ASL) of Escherichia coli transfer RNA Arginine 1 (TRNAARG1) bound to an mRNA with an CGU-codon in the A-site and paromomycin
3T1H	;	3.11	;	Structure of the Thermus thermophilus 30S ribosomal subunit complexed with a human anti-codon stem loop (HASL) of transfer RNA lysine 3 (tRNALys3) bound to an mRNA with an AAA-codon in the A-site and Paromomycin
3T1Y	;	2.8	;	Structure of the Thermus thermophilus 30S ribosomal subunit complexed with a human anti-codon stem loop (HASL) of transfer RNA Lysine 3 (TRNALYS3) bound to an mRNA with an AAG-codon in the A-site and paromomycin
4GKK	;	3.2	;	Structure of the Thermus thermophilus 30S ribosomal subunit complexed with a human mitochondrial anticodon stem loop (ASL) of transfer RNA Methionine (TRNAMET) bound to an mRNA with an AUA-codon in the A-site and paromomycin
4GKJ	;	3.298	;	Structure of the Thermus thermophilus 30S ribosomal subunit complexed with a human mitochondrial anticodon stem loop (ASL) of transfer RNA Methionine (TRNAMET) bound to an mRNA with an AUG-codon in the A-site and paromomycin.
2UUC	;	3.1	;	Structure of the Thermus thermophilus 30S ribosomal subunit complexed with a Valine-ASL with cmo5U in position 34 bound to an mRNA with a GUA-codon in the A-site and paromomycin.
2UUA	;	2.9	;	Structure of the Thermus thermophilus 30S ribosomal subunit complexed with a Valine-ASL with cmo5U in position 34 bound to an mRNA with a GUC-codon in the A-site and paromomycin.
2UU9	;	3.1	;	Structure of the Thermus thermophilus 30S ribosomal subunit complexed with a Valine-ASL with cmo5U in position 34 bound to an mRNA with a GUG-codon in the A-site and paromomycin.
2UUB	;	2.8	;	Structure of the Thermus thermophilus 30S ribosomal subunit complexed with a Valine-ASL with cmo5U in position 34 bound to an mRNA with a GUU-codon in the A-site and paromomycin.
6MKN	;	3.46	;	Structure of the Thermus thermophilus 30S ribosomal subunit complexed with an inosine (I34) modified anticodon stem loop (ASL) of Escherichia coli transfer RNA Arginine 2 (TRNAARG2) bound to an mRNA with an CGU-codon in the A-site and paromomycin
6DTI	;	3.54	;	Structure of the Thermus thermophilus 30S ribosomal subunit complexed with an unmodifed anticodon stem loop (ASL) of Escherichia coli transfer RNA Arginine 2 (TRNAARG2) bound to an mRNA with an CGU-codon in the A-site and paromomycin
1IBM	;	3.31	;	STRUCTURE OF THE THERMUS THERMOPHILUS 30S RIBOSOMAL SUBUNIT IN COMPLEX WITH A MESSENGER RNA FRAGMENT AND COGNATE TRANSFER RNA ANTICODON STEM-LOOP BOUND AT THE A SITE
1IBL	;	3.11	;	STRUCTURE OF THE THERMUS THERMOPHILUS 30S RIBOSOMAL SUBUNIT IN COMPLEX WITH A MESSENGER RNA FRAGMENT AND COGNATE TRANSFER RNA ANTICODON STEM-LOOP BOUND AT THE A SITE AND WITH THE ANTIBIOTIC PAROMOMYCIN
4KHP	;	3.1	;	Structure of the Thermus thermophilus 30S ribosomal subunit in complex with de-6-MSA-pactamycin
1HNZ	;	3.3	;	STRUCTURE OF THE THERMUS THERMOPHILUS 30S RIBOSOMAL SUBUNIT IN COMPLEX WITH HYGROMYCIN B
1HNX	;	3.4	;	STRUCTURE OF THE THERMUS THERMOPHILUS 30S RIBOSOMAL SUBUNIT IN COMPLEX WITH PACTAMYCIN
1HNW	;	3.4	;	STRUCTURE OF THE THERMUS THERMOPHILUS 30S RIBOSOMAL SUBUNIT IN COMPLEX WITH TETRACYCLINE
1IBK	;	3.31	;	STRUCTURE OF THE THERMUS THERMOPHILUS 30S RIBOSOMAL SUBUNIT IN COMPLEX WITH THE ANTIBIOTIC PAROMOMYCIN
1FJG	;	3.0	;	STRUCTURE OF THE THERMUS THERMOPHILUS 30S RIBOSOMAL SUBUNIT IN COMPLEX WITH THE ANTIBIOTICS STREPTOMYCIN, SPECTINOMYCIN, AND PAROMOMYCIN
1N34	;	3.8	;	Structure of the Thermus thermophilus 30S ribosomal subunit in the presence of codon and crystallographically disordered near-cognate transfer rna anticodon stem-loop mismatched at the first codon position
1N36	;	3.65	;	Structure of the Thermus thermophilus 30S ribosomal subunit in the presence of crystallographically disordered codon and near-cognate transfer RNA anticodon stem-loop mismatched at the second codon position
4V7Y	;	3.0	;	Structure of the Thermus thermophilus 70S ribosome complexed with azithromycin.
4V51	;	2.8	;	Structure of the Thermus thermophilus 70S ribosome complexed with mRNA, tRNA and paromomycin
4V7Z	;	3.1	;	Structure of the Thermus thermophilus 70S ribosome complexed with telithromycin.
4V5D	;	3.5	;	Structure of the Thermus thermophilus 70S ribosome in complex with mRNA, paromomycin, acylated A- and P-site tRNAs, and E-site tRNA.
4V5C	;	3.3	;	Structure of the Thermus thermophilus 70S ribosome in complex with mRNA, paromomycin, acylated A-site tRNA, deacylated P-site tRNA, and E-site tRNA.
4V7W	;	3.0	;	Structure of the Thermus thermophilus ribosome complexed with chloramphenicol.
4V7X	;	3.0	;	Structure of the Thermus thermophilus ribosome complexed with erythromycin.
4LVV	;	2.1	;	Structure of the THF riboswitch
4LVZ	;	1.77	;	Structure of the THF riboswitch bound to 2,6-diaminopurine
4LVW	;	1.768	;	Structure of the THF riboswitch bound to 7-deazaguanine
4LW0	;	1.889	;	Structure of the THF riboswitch bound to adenine
4LVY	;	2.0	;	Structure of the THF riboswitch bound to pemetrexed
4LVX	;	1.9	;	Structure of the THF riboswitch bound to tetrahydrobiopterin
3D2X	;	2.5	;	Structure of the thiamine pyrophosphate-specific riboswitch bound to oxythiamine pyrophosphate
1TYG	;	3.15	;	Structure of the thiazole synthase/ThiS complex
5MVA	;	27.7	;	Structure of the thin filament at high calcium concentration
2ZO5	;	1.7	;	Structure of the Thioalkalivibrio nitratireducens cytochrome c nitrite reductase in a complex with azide
3OWM	;	1.65	;	Structure of the Thioalkalivibrio nitratireducens cytochrome c nitrite reductase in a complex with hydroxylamine
3D1I	;	1.8	;	Structure of the Thioalkalivibrio nitratireducens cytochrome c nitrite reductase in a complex with nitrite
3RKH	;	1.83	;	Structure of the Thioalkalivibrio nitratireducens cytochrome c nitrite reductase in a complex with nitrite (full occupancy)
3MMO	;	1.55	;	Structure of the Thioalkalivibrio nitratireducens cytochrome c nitrite reductase in complex with cyanide
3GM6	;	1.8	;	Structure of the Thioalkalivibrio nitratireducens cytochrome c nitrite reductase in complex with phosphate
3F29	;	2.0	;	Structure of the Thioalkalivibrio nitratireducens cytochrome c nitrite reductase in complex with sulfite
3LGQ	;	1.8	;	Structure of the Thioalkalivibrio nitratireducens cytochrome c nitrite reductase in complex with sulfite (modified Tyr-303)
3LG1	;	1.95	;	Structure of the Thioalkalivibrio nitratireducens cytochrome c nitrite reductase reduced by sodium borohydride (in complex with sulfite)
3FO3	;	1.4	;	Structure of the Thioalkalivibrio nitratireducens cytochrome c nitrite reductase reduced by sodium dithionite (sulfite complex)
3SCE	;	1.45	;	Structure of the Thioalkalivibrio nitratireducens cytochrome c nitrite reductase with a covalent bond between the CE1 atom of Tyr303 and the CG atom of Gln360 (TvNiRb)
3TTB	;	2.0	;	Structure of the Thioalkalivibrio paradoxus cytochrome c nitrite reductase in complex with sulfite
3D6I	;	1.5	;	Structure of the Thioredoxin-like Domain of Yeast Glutaredoxin 3
3GYQ	;	2.45	;	Structure of the Thiostrepton-Resistance Methyltransferase S-adenosyl-L-methionine Complex
3PDY	;	2.2182	;	Structure of the third and fourth spectrin repeats of the plakin domain of plectin
1C07	;		;	STRUCTURE OF THE THIRD EPS15 HOMOLOGY DOMAIN OF HUMAN EPS15
2YS9	;		;	structure of the third Homeodomain from the human homeobox and leucine zipper protein, Homez
1ZZJ	;	2.3	;	Structure of the third KH domain of hnRNP K in complex with 15-mer ssDNA
2KG1	;		;	Structure of the third qRRM domain of hnRNP F in complex with a AGGGAU G-tract RNA
2N1K	;		;	Structure of the Third Type III Domain from Human Fibronectin
2KVF	;		;	Structure of the three-Cys2His2 domain of mouse testis zinc finger protein
2KVG	;		;	Structure of the three-Cys2His2 domain of mouse testis zinc finger protein
2KVH	;		;	Structure of the three-Cys2His2 domain of mouse testis zinc finger protein
8RB5	;	3.3	;	Structure of the three-fold capsomer of the PNMA2 capsid
2W8X	;	1.6	;	Structure of the tick ion-channel modulator Ra-KLP
2WQB	;	2.95	;	Structure of the Tie2 kinase domain in complex with a thiazolopyrimidine inhibitor
2GUZ	;	2.0	;	Structure of the Tim14-Tim16 complex of the mitochondrial protein import motor
4LZP	;	3.15	;	Structure of the TIR domain of the immunosuppressor BtpA from Brucella
5WEZ	;	2.74	;	Structure of the Tir-CesT effector-chaperone complex
6XA2	;	2.64	;	Structure of the tirandamycin C-bound P450 monooxygenase TamI
2Y3R	;	1.79	;	Structure of the tirandamycin-bound FAD-dependent tirandamycin oxidase TamL in P21 space group
2Y4G	;	2.03	;	Structure of the Tirandamycin-bound FAD-dependent tirandamycin oxidase TamL in P212121 space group
2Y3S	;	1.67	;	Structure of the tirandamycine-bound FAD-dependent tirandamycin oxidase TamL in C2 space group
6SJL	;	2.6	;	Structure of the Tle1 effector bound to the VgrG spike from the Type 6 secretion system
6NPK	;	3.6	;	Structure of the TM domain
6EN0	;	2.8	;	Structure of the Tn1549 transposon Integrase (aa 82-397) in complex with circular intermediate DNA (CI5-DNA)
6EN1	;	2.67	;	Structure of the Tn1549 transposon Integrase (aa 82-397, R225K) in complex with a circular intermediate DNA (CI6a-DNA)
6EN2	;	2.67	;	Structure of the Tn1549 transposon Integrase (aa 82-397, R225K) in complex with a circular intermediate DNA (CI6b-DNA)
6EMZ	;	2.79	;	Structure of the Tn1549 transposon Integrase (aa 82-397, R225K) in complex with circular intermediate DNA (CI5-DNA)
6EMY	;	2.5	;	Structure of the Tn1549 transposon Integrase (aa 82-397, Y379F) in complex with transposon right end DNA
5LPH	;	2.25	;	Structure of the TOG domain of human Cep104
4LXR	;	2.2	;	Structure of the Toll - Spatzle complex, a molecular hub in Drosophila development and innate immunity
4LXS	;	3.3	;	Structure of the Toll - Spatzle complex, a molecular hub in Drosophila development and innate immunity (glycosylated form)
4WQM	;	1.62	;	Structure of the toluene 4-monooxygenase NADH oxidoreductase T4moF, K270S K271S variant
1T0Q	;	2.15	;	Structure of the Toluene/o-Xylene Monooxygenase Hydroxylase
3RNB	;	2.64	;	Structure of the Toluene/o-Xylene Monooxygenase Hydroxylase T201S/F176W Double Mutant
3RNC	;	2.74	;	Structure of the Toluene/o-Xylene Monooxygenase Hydroxylase T201S/I100A Double Mutant
3RNA	;	3.0	;	Structure of the Toluene/o-Xylene Monooxygenase Hydroxylase T201S/I100W Double Mutant
3RNE	;	2.5	;	Structure of the Toluene/o-Xylene Monooxygenase Hydroxylase T201S/I276E Double Mutant
3RN9	;	2.8	;	Structure of the Toluene/o-Xylene Monooxygenase Hydroxylase T201S/L272E Double Mutant
3RNF	;	2.2	;	Structure of the Toluene/o-Xylene Monooxygenase Hydroxylase T201S/V271A Double Mutant
3RNG	;	2.81	;	Structure of the Toluene/o-Xylene Monooxygenase Hydroxylase T201S/W167E Double Mutant
1T0S	;	2.2	;	Structure of the Toluene/o-Xylene Monooxygenase Hydroxylase with 4-bromophenol bound
465D	;	1.6	;	STRUCTURE OF THE TOPOISOMERASE II POISON BOUND TO DNA
7NUR	;	3.125	;	Structure of the Toxoplasma gondii kinase Ron13, kinase-dead mutant
5LYN	;	2.0	;	Structure of the Tpr Domain of Sgt2 in complex with yeast Ssa1 peptide fragment
5TO5	;	2.5	;	Structure of the TPR oligomerization domain
5TO6	;	2.7	;	Structure of the TPR oligomerization domain
5TO7	;	2.6	;	Structure of the TPR oligomerization domain
5TVB	;	2.75	;	Structure of the TPR oligomerization domain
6ZZE	;		;	Structure of the trans-(Tyr39-Pro40) form of the Human Secreted Ly-6/uPAR Related Protein-1 (SLURP-1)
7QYF	;	3.3	;	Structure of the transaminase PluriZyme variant (TR2E2)
7QYG	;	3.6	;	Structure of the transaminase TR2
7QX3	;	3.6	;	Structure of the transaminase TR2E2 with EOS
2EUL	;	2.4	;	Structure of the transcription factor Gfh1.
2KEL	;		;	Structure of the transcription regulator SvtR from the hyperthermophilic archaeal virus SIRV1
1UB9	;	2.05	;	Structure of the transcriptional regulator homologue protein from Pyrococcus horikoshii OT3
3TQN	;	2.8	;	Structure of the transcriptional regulator of the GntR family, from Coxiella burnetii.
2HXO	;	2.4	;	Structure of the transcriptional regulator SCO7222, a TetR from Streptomyces coelicolor
6ZA3	;	2.05	;	Structure of the transcriptional repressor Atu1419 (VanR) from agrobacterium fabrum in complex a palindromic DNA (C2221 space group)
6ZAB	;	2.8	;	Structure of the transcriptional repressor Atu1419 (VanR) from agrobacterium fabrum in complex a palindromic DNA (P6422 space group)
6Z74	;	2.0	;	Structure of the transcriptional repressor Atu1419 (VanR) in complex with a fortuitous citrate from agrobacterium fabrum
6ZA0	;	1.65	;	Structure of the transcriptional repressor Atu1419 (VanR) in complex with a fortuitous citrate from agrobacterium fabrum (P21212 space group)
2Z12	;	1.15	;	Structure of the transformed monoclinic lysozyme by controlled dehydration
3EO0	;	1.75	;	Structure of the Transforming Growth Factor-Beta Neutralizing Antibody GC-1008
3J7R	;	3.9	;	Structure of the translating mammalian ribosome-Sec61 complex
7R81	;	2.7	;	Structure of the translating Neurospora crassa ribosome arrested by cycloheximide
3JUX	;	3.1	;	Structure of the translocation ATPase SecA from Thermotoga maritima
5JYN	;		;	Structure of the transmembrane domain of HIV-1 gp41 in bicelle
2N7R	;		;	Structure of the transmembrane domain of human nicastrin in DPC micelles
2N7Q	;		;	Structure of the transmembrane domain of human nicastrin in SDS micelles
7DCV	;		;	Structure of the transmembrane domain of human PD-L1
8J3V	;		;	Structure of the transmembrane domain of human PD-L2
6ITH	;		;	Structure of the transmembrane domain of syndecan 2 in micelles
7CFG	;	3.2	;	Structure of the transmembrane domain of the bacterial CNNM/CorC family Mg2+ transporter in complex with Mg2+
7VU5	;		;	Structure of the transmembrane domain of the CD28 dimer
6NHW	;		;	Structure of the transmembrane domain of the Death Receptor 5 - Dimer of Trimer
6NHY	;		;	Structure of the transmembrane domain of the Death Receptor 5 mutant (G217Y) - Trimer Only
2MXB	;		;	Structure of the transmembrane domain of the mouse erythropoietin receptor
5IOF	;	4.2	;	Structure of the transmembrane domain of the transporter SLC26Dg
2N4X	;		;	Structure of the Transmembrane Electron Transporter CcdA
6F46	;		;	Structure of the transmembrane helix of BclxL in phospholipid nanodiscs
1MP6	;		;	Structure of the transmembrane region of the M2 protein H+ channel by solid state NMR spectroscopy
2NQW	;	1.3	;	Structure of the transporter associated domain from PG_0272, a CBS domain protein from Porphyromonas gingivalis
3F2K	;	1.85	;	Structure of the transposase domain of human Histone-lysine N-methyltransferase SETMAR
8BTK	;	3.5	;	Structure of the TRAP complex with the Sec translocon and a translating ribosome
6Z0I	;		;	Structure of the TREM2 transmembrane helix in complex with DAP12 in DPC micelles
5WIR	;	2.1	;	Structure of the TRF1-TERB1 interface
3ZQC	;	2.9	;	Structure of the Trichomonas vaginalis Myb3 DNA-binding domain bound to a promoter sequence reveals a unique C-terminal beta-hairpin conformation
1RCF	;	1.4	;	STRUCTURE OF THE TRIGONAL FORM OF RECOMBINANT OXIDIZED FLAVODOXIN FROM ANABAENA 7120 AT 1.40 ANGSTROMS RESOLUTION
4CFG	;	2.8	;	Structure of the TRIM25 coiled-coil
6YXE	;	2.1	;	Structure of the Trim69 RING domain
3GPM	;	3.8	;	Structure of the trimeric form of the E113G PCNA mutant protein
6U66	;	0.99	;	Structure of the trimeric globular domain of Adiponectin
6U6N	;	2.15	;	Structure of the trimeric globular domain of Adiponectin mutant - D187A Q188A
2KNK	;		;	Structure of the trimethylene N2-dG:N2-dG interstrand cross-link in 5'-CpG-3' sequence context
2KNL	;		;	Structure of the trimethylene N2-dG:N2-dG interstrand cross-link in the 5'-GpC-3' sequence context
7TIM	;	1.9	;	STRUCTURE OF THE TRIOSEPHOSPHATE ISOMERASE-PHOSPHOGLYCOLOHYDROXAMATE COMPLEX: AN ANALOGUE OF THE INTERMEDIATE ON THE REACTION PATHWAY
6QAJ	;	2.901	;	Structure of the tripartite motif of KAP1/TRIM28
1KC2	;	2.1	;	structure of the triple (Lys(beta)D3Ala, Asp(beta)C8Ala, AspCD2Ala) mutant of the Src SH2 domain bound to the PQpYEEIPI peptide
1O2E	;	2.6	;	Structure of the triple mutant (K53,56,120M) + Anisic acid complex of phospholipase A2
1GH4	;	1.9	;	Structure of the triple mutant (K56M, K120M, K121M) of phospholipase A2
5E7T	;	2.9	;	Structure of the tripod (BppUct-A-L) from the baseplate of bacteriophage Tuc2009
6ZMA	;	2.15	;	Structure of the tRNA-Monooxygenase enzyme MiaE frozen under 140 bar of krypton using the soak and freeze methodology
6ZMC	;	2.5	;	Structure of the tRNA-Monooxygenase enzyme MiaE frozen under 2000 bar using the high pressure freezing method
3MTU	;	2.1	;	Structure of the Tropomyosin Overlap Complex from Chicken Smooth Muscle
3MUD	;	2.2	;	Structure of the Tropomyosin Overlap Complex from Chicken Smooth Muscle
1GTN	;	2.5	;	Structure of the trp RNA-binding attenuation protein (TRAP) bound to an RNA molecule containing 11 GAGCC repeats
3J9P	;	4.24	;	Structure of the TRPA1 ion channel determined by electron cryo-microscopy
6O6R	;	3.2	;	Structure of the TRPM8 cold receptor by single particle electron cryo-microscopy, AMTB-bound state
6O77	;	3.2	;	Structure of the TRPM8 cold receptor by single particle electron cryo-microscopy, calcium-bound state
6O6A	;	3.6	;	Structure of the TRPM8 cold receptor by single particle electron cryo-microscopy, ligand-free state
6O72	;	3.0	;	Structure of the TRPM8 cold receptor by single particle electron cryo-microscopy, TC-I 2014-bound state
6HRS	;	2.95	;	Structure of the TRPML2 ELD at pH 4.5
6HRR	;	2.0	;	Structure of the TRPML2 ELD at pH 6.5
6OT2	;	4.1	;	Structure of the TRPV3 K169A sensitized mutant in apo form at 4.1 A resolution
6OT5	;	3.6	;	Structure of the TRPV3 K169A sensitized mutant in the presence of 2-APB at 3.6 A resolution
5BU1	;	1.6	;	Structure of the truncated C-terminal domain of lpg1496 from Legionella pneumophila
8FN5	;	1.92	;	Structure of the truncated catalytic domain of Streptococcus mutans GtfD
3B8K	;	8.8	;	Structure of the Truncated Human Dihydrolipoyl Acetyltransferase (E2)
4GKP	;	2.42	;	Structure of the truncated neck and C-terminal motor homology domain of ViK1 from Candida glabrata
6XZ6	;	2.7	;	Structure of the trypanosome brucei factor H receptor bound to domain D5 of bovine factor H
5NCW	;	1.5	;	Structure of the trypsin induced serpin-type proteinase inhibitor, miropin (V367K/K368A mutant).
5NCT	;	1.6	;	Structure of the trypsin induced serpin-type proteinase inhibitor, miropin.
1TAB	;	2.3	;	STRUCTURE OF THE TRYPSIN-BINDING DOMAIN OF BOWMAN-BIRK TYPE PROTEASE INHIBITOR AND ITS INTERACTION WITH TRYPSIN
4GE1	;	2.15	;	Structure of the tryptamine complex of the amine binding protein of Rhodnius prolixus
2UUX	;	1.4	;	Structure of the tryptase inhibitor TdPI from a tick
5T6M	;	1.8	;	Structure of the tryptophan synthase b-subunit from Pyroccus furiosus with b-methyltryptophan non-covalently bound
6SSH	;	1.4	;	Structure of the TSC2 GAP domain
5HIU	;	2.5	;	Structure of the TSC2 N-terminus
1KPP	;		;	Structure of the Tsg101 UEV domain
1KPQ	;		;	Structure of the Tsg101 UEV domain
1M4Q	;		;	STRUCTURE OF THE TSG101 UEV DOMAIN IN COMPLEX WITH A HIV-1 PTAP ""LATE DOMAIN"" PEPTIDE, CNS ENSEMBLE
1M4P	;		;	Structure of the Tsg101 UEV domain in complex with a HIV-1 PTAP ""late domain"" peptide, DYANA Ensemble
4EJE	;	2.2	;	Structure Of The Tsg101 UEV Domain In Complex With an Ebola PTAP late Domain Peptide
4BHR	;	1.7	;	Structure of the TTHA1221 type IV pilin protein from Thermus thermophilus
5VLQ	;	2.285	;	Structure of the TTLL3 Glycylase
3UL9	;	2.45	;	structure of the TV3 mutant M41E
3S7W	;	1.79	;	Structure of the TvNiRb form of Thioalkalivibrio nitratireducens cytochrome c nitrite reductase with an oxidized Gln360 in a complex with hydroxylamine
1IAM	;	2.1	;	STRUCTURE OF THE TWO AMINO-TERMINAL DOMAINS OF HUMAN INTERCELLULAR ADHESION MOLECULE-1, ICAM-1
5M9F	;	1.8	;	Structure of the two C-terminal domains of bacteriophage K gp144
3ZD1	;	2.0	;	STRUCTURE OF THE TWO C-TERMINAL DOMAINS OF COMPLEMENT FACTOR H RELATED PROTEIN 2
3C2U	;	1.3	;	Structure of the two subsite D-xylosidase from Selenomonas ruminantium in complex with 1,3-bis[tris(hydroxymethyl)methylamino]propane
4OVA	;	3.0	;	Structure of the two tandem Tudor domains and a new identified KH0 domain from human Fragile X Mental Retardation Protein
5W43	;	3.15	;	Structure of the two-component response regulator RcsB-DNA complex
6TAS	;	2.75	;	Structure of the two-fold capsomer of the dArc1 capsid
6TAU	;	3.7	;	Structure of the two-fold capsomer of the dArc2 capsid
8RB7	;	3.2	;	Structure of the two-fold capsomer of the PNMA2 capsid
2JGP	;	1.85	;	Structure of the TycC5-6 PCP-C bidomain of the tyrocidine synthetase TycC
8ANE	;	3.2	;	Structure of the type I-G CRISPR effector
8B2X	;	8.0	;	Structure of the type I-G CRISPR effector
2BM3	;	1.8	;	Structure of the Type II cohesin from Clostridium thermocellum SdbA
4FTF	;	1.48	;	Structure of the Type II secretion system pilotin AspS from Vibrio cholerae
6VAP	;	1.93	;	Structure of the type II thioesterase BorB from the borrelidin biosynthetic cluster
2F9T	;	2.2	;	Structure of the type III CoaA from Pseudomonas aeruginosa
2F9W	;	1.9	;	Structure of the type III CoaA from Pseudomonas aeruginosa
3I0U	;	2.7	;	Structure of the type III effector/phosphothreonine lyase OspF from Shigella flexneri
4UR4	;	1.45	;	Structure of the type III fish antifreeze protein from Zoarces viviparus ZvAFP13
4UR6	;	1.2	;	Structure of the type III fish antifreeze protein from Zoarces viviparus ZvAFP6
2H3G	;	2.0	;	Structure of the Type III Pantothenate Kinase (CoaX) from Bacillus Anthracis
4D9V	;	2.519	;	Structure of the Type III Secretion System Protein
7XSO	;	3.01	;	Structure of the type III-E CRISPR-Cas effector gRAMP
5ZMM	;	3.15	;	Structure of the Type IV phosphorothioation-dependent restriction endonuclease ScoMcrA
6GV9	;	8.0	;	Structure of the type IV pilus from enterohemorrhagic Escherichia coli (EHEC)
2M7G	;		;	Structure of the Type IVa Major Pilin from the Electrically Conductive Bacterial Nanowires of Geobacter sulfurreducens
4F4M	;	2.677	;	Structure of the type VI peptidoglycan amidase effector Tse1 (C30A) from Pseudomonas aeruginosa
4EOB	;	2.611	;	Structure of the type VI peptidoglycan amidase effector Tse1 from Pseudomonas aeruginosa
6N38	;	3.7	;	Structure of the type VI secretion system TssK-TssF-TssG baseplate subcomplex revealed by cryo-electron microscopy - full map sharpened
2K3U	;		;	Structure of the tyrosine-sulfated C5a receptor N-terminus in complex with the immune evasion protein CHIPS.
2J5B	;	2.2	;	Structure of the Tyrosyl tRNA synthetase from Acanthamoeba polyphaga Mimivirus complexed with tyrosynol
6SQT	;	1.84	;	Structure of the U1A variant A1-98 Y31H/Q36R/F56W triple mutant
6SQN	;	2.05	;	Structure of the U1A variant A1-98 Y31H/Q36R/F56W triple mutant co-crystallized with RNA
6SQQ	;	2.37	;	Structure of the U1A variant A1-98 Y31H/Q36R/F56W triple mutant in complex with RNA obtained by soaking
6SR7	;	1.86	;	Structure of the U1A variant A1-98 Y31H/Q36R/K98W
6SQV	;	2.45	;	Structure of the U1A variant A1-98 Y31H/Q36R/R70W
7ONB	;	3.1	;	Structure of the U2 5' module of the A3'-SSA complex
1VTM	;	3.5	;	STRUCTURE OF THE U2 STRAIN OF TOBACCO MOSAIC VIRUS REFINED AT 3.5 ANGSTROMS RESOLUTION USING X-RAY FIBER DIFFRACTION
3IVN	;	2.8	;	Structure of the U65C mutant A-riboswitch aptamer from the Bacillus subtilis pbuE operon
6G5R	;		;	Structure of the UB2H domain of E.coli PBP1B in complex with LpoB
2MJ5	;		;	Structure of the UBA Domain of Human NBR1 in Complex with Ubiquitin
2OXQ	;	2.9	;	Structure of the UbcH5 :CHIP U-box complex
8OIF	;	3.5	;	Structure of the UBE1L activating enzyme bound to ISG15 and UBE2L6
6H6V	;	2.66	;	Structure of the UbiD-class enzyme HmfF from Pelotomaculum thermopropionicum in complex with FMN
5VSX	;	2.1	;	Structure of the Ubl domain of Sacsin
5VSZ	;	2.4	;	Structure of the Ubl domain of Sacsin mutant L78M
3M99	;	2.7	;	Structure of the Ubp8-Sgf11-Sgf73-Sus1 SAGA DUB module
3NY1	;	2.085	;	Structure of the ubr-box of the UBR1 ubiquitin ligase
3NY3	;	1.6	;	Structure of the ubr-box of UBR2 in complex with N-degron
3NY2	;	2.61	;	Structure of the ubr-box of UBR2 ubiquitin ligase
2DZK	;		;	Structure of the UBX domain in Mouse UBX Domain-Containing Protein 2
4BMJ	;	2.75	;	Structure of the UBZ1and2 tandem of the ubiquitin-binding adaptor protein TAX1BP1
3DXB	;	2.2	;	Structure of the UHM domain of Puf60 fused to thioredoxin
4FZH	;	3.5008	;	Structure of the Ulster Strain Newcastle Disease Virus Hemagglutinin-Neuraminidase Reveals Auto-Inhibitory Interactions Associated with Low Virulence
7WKI	;	2.6	;	Structure of the ultra-affinity complex between CFH and a nanobody
6VI2	;	1.15	;	Structure of the unaligned Fab4
5K28	;	1.5	;	Structure of the unbound SH3 domain of MLK3
3H35	;	2.15	;	Structure of the uncharacterized protein ABO_0056 from the hydrocarbon-degrading marine bacterium Alcanivorax borkumensis SK2.
1ZTM	;	3.05	;	Structure of the Uncleaved Paramyxovirus (hPIV3) Fusion Protein
8RU0	;	3.08	;	Structure of the undecorated barbed end of F-actin.
3QTB	;	2.1	;	Structure of the universal stress protein from Archaeoglobus fulgidus in complex with dAMP
5IIE	;	2.8	;	STRUCTURE OF THE UNLIGANDED ANTI-HIV ANTIBODY DH501 THAT BINDS GP120 V3 GLYCAN AND THE BASE OF V3
1FOT	;	2.8	;	STRUCTURE OF THE UNLIGANDED CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT FROM SACCHAROMYCES CEREVISIAE
5F89	;	2.7842	;	Structure of the Unliganded Fab from HIV-1 Neutralising Antibody CAP248-2B that Binds to the gp120 C-terminus - gp41 Interface
5MP6	;	1.959	;	Structure of the Unliganded Fab from HIV-1 Neutralizing Antibody CAP248-2B that Binds to the gp120 C-terminus - gp41 Interface, at two Angstrom resolution.
5JXI	;	2.0	;	Structure of the unliganded form of the proprotein convertase furin in presence of EDTA.
5JXG	;	1.8	;	Structure of the unliganded form of the proprotein convertase furin.
4I8Y	;	2.1	;	Structure of the unliganded N254Y/H258Y mutant of the phosphatidylinositol-specific phospholipase C from S. aureus
5MSP	;	2.41	;	Structure of the unmodified PCP-R didomain of carboxylic acid reductase (CAR) from Segniliparus rugosus in complex with NADP, F2221 form
5MSR	;	2.37	;	Structure of the unmodified PCP-R domain of carboxylic acid reductase (CAR) from Segniliparus rugosus in complex with NADPH, P43 form
2V97	;	2.4	;	Structure of the unphotolysed complex of TcAChE with 1-(2- nitrophenyl)-2,2,2-trifluoroethyl-arsenocholine after a 9 seconds annealing to room temperature
2V96	;	2.4	;	Structure of the unphotolysed complex of TcAChE with 1-(2- nitrophenyl)-2,2,2-trifluoroethyl-arsenocholine at 100K
4UPE	;	1.8	;	Structure of the unready Ni-A state of the S499C mutant of D. fructosovorans NiFe-hydrogenase
1YQ9	;	2.35	;	Structure of the unready oxidized form of [NiFe] hydrogenase
1JLR	;	2.45	;	STRUCTURE OF THE URACIL PHOSPHORIBOSYLTRANSFERASE GTP COMPLEX 2 MUTANT C128V
1JLS	;	2.5	;	STRUCTURE OF THE URACIL PHOSPHORIBOSYLTRANSFERASE URACIL/CPR 2 MUTANT C128V
1UPF	;	2.3	;	STRUCTURE OF THE URACIL PHOSPHORIBOSYLTRANSFERASE, MUTANT C128V BOUND TO THE DRUG 5-FLUOROURACIL
1UPU	;	2.5	;	STRUCTURE OF THE URACIL PHOSPHORIBOSYLTRANSFERASE, MUTANT C128V, BOUND TO PRODUCT URIDINE-1-MONOPHOSPHATE (UMP)
3CXN	;	1.55	;	Structure of the Urease Accessory Protein UreF from Helicobacter pylori
6CRN	;	2.5	;	Structure of the USP15 deubiquitinase domain in complex with a high-affinity first-generation Ubv
6CPM	;	2.011	;	Structure of the USP15 deubiquitinase domain in complex with a third-generation inhibitory Ubv
6ML1	;	1.9	;	Structure of the USP15 deubiquitinase domain in complex with an affinity-matured inhibitory Ubv
6DJ9	;	3.1	;	Structure of the USP15 DUSP domain in complex with a high-affinity Ubiquitin Variant (UbV)
6H4K	;	2.05	;	Structure of the Usp25 C-terminal domain
6FPF	;	2.2	;	Structure of the Ustilago maydis chorismate mutase 1
6FPG	;	1.8	;	Structure of the Ustilago maydis chorismate mutase 1 in complex with a Zea mays kiwellin
6TI2	;	2.75	;	Structure of the Ustilago maydis chorismate mutase 1 in complex with KWL1-b from Zea mays
5XPV	;	1.9	;	Structure of the V domain of amphioxus IgVJ-C2
3EEB	;	2.1	;	Structure of the V. cholerae RTX cysteine protease domain
3GCD	;	2.35	;	Structure of the V. cholerae RTX cysteine protease domain in complex with an aza-Leucine peptide inhibitor
7P1H	;	3.9	;	Structure of the V. vulnificus ExoY-G-actin-profilin complex
6AXY	;	2.78	;	Structure of the V11I/T58A/I124A mutant of the HIV-1 capsid protein
6AXS	;	2.402	;	Structure of the V11I/T58A/P122A mutant of the HIV-1 capsid protein
7R0J	;	4.23	;	Structure of the V2 receptor Cter-arrestin2-ScFv30 complex
4UEQ	;	1.7	;	Structure of the V74C large subunit mutant of D. fructosovorans NiFe- hydrogenase
3H3X	;	2.7	;	Structure of the V74M large subunit mutant of NI-FE hydrogenase in an oxidized state
7PZY	;	2.32	;	Structure of the vacant Candida albicans 80S ribosome
5FCI	;	3.4	;	Structure of the vacant uL3 W255C mutant 80S yeast ribosome
6RFG	;	1.897	;	Structure of the Vaccinia core protein E11
8GP6	;	2.7	;	Structure of the vaccinia virus A16/G9 sub-complex from the orthopoxvirus entry-fusion complex
4LQK	;	1.99	;	Structure of the vaccinia virus NF- B antagonist A46
8DMM	;	3.47	;	Structure of the vanadate-trapped MsbA bound to KDL
1LVE	;	1.95	;	STRUCTURE OF THE VARIABLE DOMAIN OF HUMAN IMMUNOGLOBULIN K-4 LIGHT CHAIN LEN
5LVE	;	2.0	;	STRUCTURE OF THE VARIABLE DOMAIN OF HUMAN IMMUNOGLOBULIN K-4 LIGHT CHAIN LEN
4HGA	;	2.799	;	Structure of the variant histone H3.3-H4 heterodimer in complex with its chaperone DAXX
8FCK	;	6.88	;	Structure of the vertebrate augmin complex
6TF9	;	4.8	;	Structure of the vertebrate gamma-Tubulin Ring Complex
6U1X	;	3.0	;	Structure of the Vesicular Stomatitis Virus L Protein in Complex with Its Phosphoprotein Cofactor (3.0 A resolution)
2W2R	;	1.83	;	Structure of the vesicular stomatitis virus matrix protein
4U0N	;	2.102	;	Structure of the Vibrio cholerae di-nucleotide cyclase (DncV) deletion mutant D-loop
4U03	;	2.041	;	Structure of the vibrio cholerae di-nucleotide cyclase (DncV) in complex with GTP and 5MTHFGLU2
4U0L	;	2.1	;	Structure of the Vibrio cholerae di-nucleotide cyclase (DncV) mutant D131A-D133A
4U0M	;	2.3	;	Structure of the Vibrio cholerae di-nucleotide cyclase (DncV) mutant D193N in complex with ATP, GTP and 5MTHFGLU2
1YG2	;	2.2	;	Structure of the Vibrio cholerae virulence activator AphA
4UA4	;	1.25	;	Structure of the VIM-2 Metallo-beta-Lactamase in Complex with a Bisthiazolidine Inhibitor
5TZN	;	2.6	;	Structure of the viral immunoevasin m12 (Smith) bound to the natural killer cell receptor NKR-P1B (B6)
1F0C	;	2.26	;	STRUCTURE OF THE VIRAL SERPIN CRMA
2XXN	;	1.6	;	Structure of the vIRF4-HAUSP TRAF domain complex
4CSB	;	1.9	;	Structure of the Virulence-Associated Protein VapD from the intracellular pathogen Rhodococcus equi.
7JSN	;	3.2	;	Structure of the Visual Signaling Complex between Transducin and Phosphodiesterase 6
8YHV	;	2.35	;	Structure of the VP40 from Biortus.
7UMT	;	3.4	;	Structure of the VP5*/VP8* assembly from the human rotavirus strain CDC-9 - Reversed conformation
7UMS	;	3.5	;	Structure of the VP5*/VP8* assembly from the human rotavirus strain CDC-9 in complex with antibody 41 - Upright conformation
7RSJ	;	1.881	;	Structure of the VPS34 kinase domain with compound 14
7RSP	;	1.67	;	Structure of the VPS34 kinase domain with compound 14
7RSV	;	1.78	;	Structure of the VPS34 kinase domain with compound 5
3Q68	;	2.705	;	Structure of the Vps75-Rtt109 histone chaperone-lysine acetyltransferase complex (Full-length proteins in space group P212121)
3Q66	;	2.705	;	Structure of the Vps75-Rtt109 histone chaperone-lysine acetyltransferase complex (Full-length proteins in space group P6122)
2WA6	;	1.95	;	Structure of the W148R mutant of human filamin b actin binding domain at 1.95 Angstrom resolution
3RLM	;	2.13	;	Structure of the W199F MauG/pre-Methylamine Dehydrogenase complex after treatment with hydrogen peroxide
1CZW	;	2.5	;	STRUCTURE OF THE W34A MUTANT OF SHIGA-LIKE TOXIN I B SUBUNIT
2OR2	;	1.84	;	Structure of the W47A/W242A Mutant of Bacterial Phosphatidylinositol-Specific Phospholipase C
7AP7	;	1.15	;	Structure of the W64R amyloidogenic variant of human lysozyme
3L7I	;	2.7	;	Structure of the Wall Teichoic Acid Polymerase TagF
3L7K	;	3.1	;	Structure of the Wall Teichoic Acid Polymerase TagF, H444N + CDPG (15 minute soak)
3L7L	;	2.95	;	Structure of the Wall Teichoic Acid Polymerase TagF, H444N + CDPG (30 minute soak)
3L7J	;	2.81	;	Structure of the Wall Teichoic Acid Polymerase TagF, H444N variant
3L7M	;	2.85	;	Structure of the Wall Teichoic Acid Polymerase TagF, H548A
5IC7	;	2.331	;	Structure of the WD domain of UTP18
5NUV	;	1.55	;	Structure of the WD40-domain of human ATG16L1
8B2Y	;	2.83	;	Structure of the weakly red fluorescent protein csiFP4 from Clytia simplex
2HG0	;	3.0	;	Structure of the West Nile Virus envelope glycoprotein
4HZF	;	1.48	;	structure of the wild type Catabolite gene Activator Protein
5J91	;	2.96	;	Structure of the Wild-type 70S E coli ribosome bound to Tigecycline
8WOI	;	3.4	;	Structure of the wild-type Arabidopsis ABCB19 in the apo state
8WOO	;	3.9	;	Structure of the wild-type Arabidopsis ABCB19 in the brassinolide and AMP-PNP bound state
8WOM	;	3.5	;	Structure of the wild-type Arabidopsis ABCB19 in the brassinolide-bound state
2C89	;	1.85	;	Structure of the wild-type C3bot1 Exoenzyme (Free state, crystal form I)
2C8A	;	1.7	;	Structure of the wild-type C3bot1 Exoenzyme (Nicotinamide-bound state, crystal form I)
1OCB	;	1.75	;	Structure of the wild-type cellobiohydrolase Cel6A from Humicolas insolens in complex with a fluorescent substrate
2VME	;	2.45	;	Structure of the wild-type discoidin II from Dictyostelium discoideum
1KK3	;	1.9	;	Structure of the wild-type large gamma subunit of initiation factor eIF2 from Pyrococcus abyssi complexed with GDP-Mg2+
7M9F	;	2.7	;	Structure of the wild-type native full-length HIV-1 capsid protein in complex with ZW-1261
4BXP	;	1.7	;	Structure of the wild-type TCP10 domain of Danio rerio CPAP
4BXR	;	2.2	;	Structure of the wild-type TCP10 domain of Danio rerio CPAP in complex with a peptide of Danio rerio STIL
1LKY	;	2.3	;	Structure of the wild-type TEL-SAM polymer
2JP9	;		;	Structure of the Wilms Tumor Suppressor Protein Zinc Finger Domain Bound to DNA
2JPA	;		;	Structure of the Wilms Tumor Suppressor Protein Zinc Finger Domain Bound to DNA
2PRT	;	3.15	;	Structure of the Wilms Tumor Suppressor Protein Zinc Finger Domain Bound to DNA
4WBH	;	2.2	;	STRUCTURE OF THE WNT DEACYLASE NOTUM - CRYSTAL FORM I APO - 2.2A
4UYW	;	1.7	;	STRUCTURE OF THE WNT DEACYLASE NOTUM - CRYSTAL FORM I HEPARIN FRAGMENT COMPLEX - 1.7A
4UYU	;	2.3	;	STRUCTURE OF THE WNT DEACYLASE NOTUM - CRYSTAL FORM I IODIDE COMPLEX - 2.3A
4UZL	;	2.1	;	STRUCTURE OF THE WNT DEACYLASE NOTUM - CRYSTAL FORM I MYRISTOLEATE COMPLEX - 2.1A
4UYZ	;	2.8	;	STRUCTURE OF THE WNT DEACYLASE NOTUM - CRYSTAL FORM II - 2.8A
4UZ1	;	1.4	;	STRUCTURE OF THE WNT DEACYLASE NOTUM - CRYSTAL FORM III - 1.4A
4UZ5	;	2.1	;	STRUCTURE OF THE WNT DEACYLASE NOTUM - CRYSTAL FORM IV - 2.1A
4UZ6	;	1.9	;	STRUCTURE OF THE WNT DEACYLASE NOTUM - CRYSTAL FORM V - SOS COMPLEX - 1.9A
4UZ7	;	2.2	;	STRUCTURE OF THE WNT DEACYLASE NOTUM - CRYSTAL FORM VI - 2.2A
4UZ9	;	2.2	;	STRUCTURE OF THE WNT DEACYLASE NOTUM - CRYSTAL FORM VII - SOS COMPLEX - 2.2A
4UZA	;	2.4	;	STRUCTURE OF THE WNT DEACYLASE NOTUM - CRYSTAL FORM VIII - PHOSPHATE COMPLEX - 2.4A
4UZJ	;	2.4	;	STRUCTURE OF THE WNT DEACYLASE NOTUM FROM DROSOPHILA - CRYSTAL FORM I - 2.4A
4UZK	;	1.9	;	STRUCTURE OF THE WNT DEACYLASE NOTUM FROM DROSOPHILA - CRYSTAL FORM II - 1.9A
6R8Q	;	1.5	;	STRUCTURE OF THE WNT DEACYLASE NOTUM IN COMPLEX WITH A BENZOTRIAZOLE FRAGMENT
6YUW	;	1.94	;	STRUCTURE OF THE WNT DEACYLASE NOTUM IN COMPLEX WITH A PYRROLE-3-CARBOXYLIC ACID FRAGMENT 454
6YUY	;	2.0	;	STRUCTURE OF THE WNT DEACYLASE NOTUM IN COMPLEX WITH A PYRROLE-3-CARBOXYLIC ACID FRAGMENT 471
6YV4	;	2.0	;	STRUCTURE OF THE WNT DEACYLASE NOTUM IN COMPLEX WITH A PYRROLE-3-CARBOXYLIC ACID FRAGMENT 686
6YV0	;	2.0	;	STRUCTURE OF THE WNT DEACYLASE NOTUM IN COMPLEX WITH A PYRROLIDINE-3-CARBOXYLIC ACID FRAGMENT 587
6YV2	;	2.1	;	STRUCTURE OF THE WNT DEACYLASE NOTUM IN COMPLEX WITH A PYRROLIDINE-3-CARBOXYLIC ACID FRAGMENT 598
6R8R	;	1.27	;	Structure of the Wnt deacylase Notum in complex with isoquinoline 45
4UZQ	;	1.5	;	STRUCTURE OF THE WNT DEACYLASE NOTUM IN COMPLEX WITH O-PALMITOLEOYL SERINE - CRYSTAL FORM IX - 1.5A
3ZIK	;	2.14	;	Structure of the Wpl1 protein
3ZIL	;	2.012	;	Structure of the Wpl1 protein
5J5B	;	2.8	;	Structure of the WT E coli ribosome bound to tetracycline
7SYP	;	4.0	;	Structure of the wt IRES and 40S ribosome binary complex, open conformation. Structure 10(wt)
7SYQ	;	3.8	;	Structure of the wt IRES and 40S ribosome ternary complex, open conformation. Structure 11(wt)
7SYR	;	3.6	;	Structure of the wt IRES eIF2-containing 48S initiation complex, closed conformation. Structure 12(wt).
7SYW	;	3.7	;	Structure of the wt IRES eIF5B-containing 48S initiation complex, closed conformation. Structure 15(wt)
7SYV	;	3.9	;	Structure of the wt IRES eIF5B-containing pre-48S initiation complex, open conformation. Structure 14(wt)
7SYT	;	4.4	;	Structure of the wt IRES w/o eIF2 48S initiation complex, closed conformation. Structure 13(wt)
5TZD	;	1.749	;	Structure of the WT S. venezulae BldD-(CTD-c-di-GMP)2 assembly intermediate
2VGR	;	2.1	;	Structure of the WT-Phycoerythrobilin Synthase PebS from the Cyanophage P-SSM2 in Complex with the bound Substrate Biliverdin IXa
6RY3	;	1.374	;	Structure of the WUS homeodomain
2LB3	;		;	Structure of the WW domain of PIN1 in complex with a human phosphorylated Smad3 derived peptide
8PXW	;		;	Structure of the WW domain tandem of PRPF40A
8PXX	;		;	Structure of the WW domain tandem of PRPF40A in complex with SF1
5I84	;	2.98	;	Structure of the Xanthomonas citri phosphate-binding protein PhoX
2GST	;	1.8	;	STRUCTURE OF THE XENOBIOTIC SUBSTRATE BINDING SITE OF A GLUTATHIONE S-TRANSFERASE AS REVEALED BY X-RAY CRYSTALLOGRAPHIC ANALYSIS OF PRODUCT COMPLEXES WITH THE DIASTEREOMERS OF 9-(S-GLUTATHIONYL)-10-HYDROXY-9, 10-DIHYDROPHENANTHRENE
3GST	;	1.9	;	STRUCTURE OF THE XENOBIOTIC SUBSTRATE BINDING SITE OF A GLUTATHIONE S-TRANSFERASE AS REVEALED BY X-RAY CRYSTALLOGRAPHIC ANALYSIS OF PRODUCT COMPLEXES WITH THE DIASTEREOMERS OF 9-(S-GLUTATHIONYL)-10-HYDROXY-9, 10-DIHYDROPHENANTHRENE
2KN7	;		;	Structure of the XPF-single strand DNA complex
4C1U	;	2.0	;	Structure of the xylo-oligosaccharide specific solute binding protein from Bifidobacterium animalis subsp. lactis Bl-04 in complex with arabinoxylobiose
4C1T	;	2.39	;	Structure of the xylo-oligosaccharide specific solute binding protein from Bifidobacterium animalis subsp. lactis Bl-04 in complex with arabinoxylotriose
3ZKK	;	2.198	;	Structure of the xylo-oligosaccharide specific solute binding protein from Bifidobacterium animalis subsp. lactis Bl-04 in complex with xylotetraose
3ZKL	;	2.397	;	Structure of the xylo-oligosaccharide specific solute binding protein from Bifidobacterium animalis subsp. lactis Bl-04 in complex with xylotriose
5MXJ	;	2.8	;	Structure of the Y108F mutant of vanillyl alcohol oxidase
4BWL	;	2.0	;	Structure of the Y137A mutant of E. coli N-acetylneuraminic acid lyase in complex with pyruvate, N-acetyl-D-mannosamine and N- acetylneuraminic acid
4IYT	;	2.2	;	Structure Of The Y184A Mutant Of The PANTON-VALENTINE LEUCOCIDIN S Component From STAPHYLOCOCCUS AUREUS
6F4D	;	2.0	;	Structure of the Y21F variant of quinolinate synthase in complex with PGH
6G74	;	2.0	;	Structure of the Y21F variant of quinolinate synthase in complex with phthalate
4J0O	;	2.5	;	Structure of the Y246A Mutant of the PANTON-VALENTINE LEUCOCIDIN S Component from STAPHYLOCOCCUS AUREUS
4IYA	;	1.55	;	Structure of the Y250A mutant of the PANTON-VALENTINE LEUCOCIDIN S component from STAPHYLOCOCCUS AUREUS
3ZQ5	;	1.95	;	Structure of the Y263F mutant of the cyanobacterial phytochrome Cph1
4KMW	;	1.79	;	Structure of the Y34N MUTANT OF DEHALOPEROXIDASE-HEMOGLOBIN A FROM AMPHITRITE ORNATA WITH 2,4,6-TRICHLOROPHENOL
4KN3	;	1.78	;	Structure of the Y34NS91G double mutant of Dehaloperoxidase from Amphitrite ornata with 2,4,6-trichlorophenol
3ZOO	;	1.35	;	Structure of the Y46F mutant of human cytochrome c
5MXU	;	2.8	;	Structure of the Y503F mutant of vanillyl alcohol oxidase
1NI0	;	2.5	;	Structure of the Y94F mutant of the restriction endonuclease PvuII
2RU9	;		;	Structure of the YAM domain of E. coli Transporter YajR
8GA8	;	3.5	;	Structure of the yeast (HDAC) Rpd3L complex
3JCK	;	3.5	;	Structure of the yeast 26S proteasome lid sub-complex
5APO	;	3.41	;	Structure of the yeast 60S ribosomal subunit in complex with Arx1, Alb1 and C-terminally tagged Rei1
5APN	;	3.91	;	Structure of the yeast 60S ribosomal subunit in complex with Arx1, Alb1 and N-terminally tagged Rei1
1YAG	;	1.9	;	STRUCTURE OF THE YEAST ACTIN-HUMAN GELSOLIN SEGMENT 1 COMPLEX
7KPX	;	4.4	;	Structure of the yeast CKM
7TI8	;	3.5	;	Structure of the yeast clamp loader (Replication Factor C RFC) bound to the open sliding clamp (Proliferating Cell Nuclear Antigen PCNA)
7TKU	;	4.0	;	Structure of the yeast clamp loader (Replication Factor C RFC) bound to the open sliding clamp (Proliferating Cell Nuclear Antigen PCNA)
7TIB	;	3.4	;	Structure of the yeast clamp loader (Replication Factor C RFC) bound to the open sliding clamp (Proliferating Cell Nuclear Antigen PCNA) and primer-template DNA
7TID	;	3.3	;	Structure of the yeast clamp loader (Replication Factor C RFC) bound to the sliding clamp (Proliferating Cell Nuclear Antigen PCNA) and primer-template DNA
7THJ	;	3.8	;	Structure of the yeast clamp loader (Replication Factor C RFC) bound to the sliding clamp (Proliferating Cell Nuclear Antigen PCNA) in an autoinhibited conformation
7THV	;	4.0	;	Structure of the yeast clamp loader (Replication Factor C RFC) bound to the sliding clamp (Proliferating Cell Nuclear Antigen PCNA) in an autoinhibited conformation
7TIC	;	3.9	;	Structure of the yeast clamp loader (Replication Factor C RFC) bound to the sliding clamp (Proliferating Cell Nuclear Antigen PCNA) in an autoinhibited conformation
4XMM	;	7.384	;	Structure of the yeast coat nucleoporin complex, space group C2
4XMN	;	7.6	;	Structure of the yeast coat nucleoporin complex, space group P212121
5ZYP	;	2.532	;	Structure of the Yeast Ctr9/Paf1 complex
1EZV	;	2.3	;	STRUCTURE OF THE YEAST CYTOCHROME BC1 COMPLEX CO-CRYSTALLIZED WITH AN ANTIBODY FV-FRAGMENT
3P48	;	1.67	;	Structure of the yeast dUTPase DUT1 in complex with dUMPNPP
2P22	;	2.7	;	Structure of the Yeast ESCRT-I Heterotetramer Core
5BQJ	;	2.1	;	Structure of the yeast F1FO ATPase C10 ring with 21-hydroxy-oligomycin
4F4S	;	1.9	;	Structure of the yeast F1Fo ATPase c10 ring with bound oligomycin
5BPS	;	2.1	;	Structure of the yeast F1FO ATPase C10 ring with oligomycin A
5BQ6	;	2.3	;	Structure of the yeast F1FO ATPase C10 ring with oligomycin B
5BQA	;	2.1	;	Structure of the yeast F1FO ATPase C10 ring with oligomycin C
7NRD	;	4.36	;	Structure of the yeast Gcn1 bound to a colliding stalled 80S ribosome with MBF1, A/P-tRNA and P/E-tRNA
7NRC	;	3.9	;	Structure of the yeast Gcn1 bound to a leading stalled 80S ribosome with Rbg2, Gir2, A- and P-tRNA and eIF5A
3PBP	;	2.6	;	Structure of the yeast heterotrimeric Nup82-Nup159-Nup116 nucleoporin complex
1Q17	;	2.7	;	Structure of the yeast Hst2 protein deacetylase in ternary complex with 2'-O-acetyl ADP ribose and histone peptide
1Q1A	;	1.5	;	Structure of the yeast Hst2 protein deacetylase in ternary complex with 2'-O-acetyl ADP ribose and histone peptide
5IT9	;	3.8	;	Structure of the yeast Kluyveromyces lactis small ribosomal subunit in complex with the cricket paralysis virus IRES.
3J6B	;	3.2	;	Structure of the yeast mitochondrial large ribosomal subunit
5MRC	;	3.25	;	Structure of the yeast mitochondrial ribosome - Class A
5MRE	;	3.75	;	Structure of the yeast mitochondrial ribosome - Class B
5MRF	;	4.97	;	Structure of the yeast mitochondrial ribosome - Class C
2H0R	;	2.9	;	Structure of the Yeast Nicotinamidase Pnc1p
8ESC	;	3.1	;	Structure of the Yeast NuA4 Histone Acetyltransferase Complex
2HBJ	;	2.1	;	Structure of the yeast nuclear exosome component, Rrp6p, reveals an interplay between the active site and the HRDC domain
2HBK	;	2.25	;	Structure of the yeast nuclear exosome component, Rrp6p, reveals an interplay between the active site and the HRDC domain; Protein in complex with Mn
2HBL	;	2.3	;	Structure of the yeast nuclear exosome component, Rrp6p, reveals an interplay between the active site and the HRDC domain; Protein in complex with Mn, Zn, and AMP
2HBM	;	2.7	;	Structure of the yeast nuclear exosome component, Rrp6p, reveals an interplay between the active site and the HRDC domain; Protein in complex with Mn, Zn, and UMP
6C4W	;	2.4	;	Structure of the yeast Pichia membranifaciens cytochrome c
3B5N	;	1.6	;	Structure of the yeast plasma membrane SNARE complex
2JKD	;	2.5	;	Structure of the yeast Pml1 splicing factor and its integration into the RES complex
7SGZ	;	3.17	;	Structure of the yeast Rad24-RFC loader bound to DNA and the closed 9-1-1 clamp
7SH2	;	3.23	;	Structure of the yeast Rad24-RFC loader bound to DNA and the open 9-1-1 clamp
2FVU	;	2.0	;	Structure of the yeast Sir3 BAH domain
7VRC	;	2.147	;	Structure of the Yeast SNF11/SNF2 complex
7U05	;	3.7	;	Structure of the yeast TRAPPII-Rab11/Ypt32 complex in the closed/closed state (composite structure)
7U06	;	4.2	;	Structure of the yeast TRAPPII-Rab11/Ypt32 complex in the closed/open state (composite structure)
7KMT	;	3.7	;	Structure of the yeast TRAPPIII-Ypt1(Rab1) complex
2QIZ	;	2.56	;	Structure of the yeast U-box-containing ubiquitin ligase Ufd2p
2QJ0	;	2.65	;	Structure of the yeast U-box-containing ubiquitin ligase Ufd2p
2A08	;	1.54	;	Structure of the yeast YHH6 SH3 domain
3FK3	;	2.3	;	Structure of the Yeats Domain, Yaf9
8OFN	;	3.48	;	Structure of the yellow fever virus (Asibi strain) dimeric envelope protein
3DPW	;	1.59	;	Structure of the Yellow Fluorescent Protein Citrine Frozen at 1 Atmosphere Number 1: Structure 1 in a Series of 26 High Pressure Structures
3DQO	;	1.5	;	Structure of the Yellow Fluorescent Protein Citrine Frozen at 1 Atmosphere Number 2: Structure 2 in a Series of 26 High Pressure Structures
3DQL	;	1.47	;	Structure of the Yellow Fluorescent Protein Citrine Frozen at 1000 Atmospheres Number 1: Structure 5 in a Series of 26 High Pressure Structures
3DQK	;	1.4	;	Structure of the Yellow Fluorescent Protein Citrine Frozen at 1000 Atmospheres Number 2: Structure 6 in a Series of 26 High Pressure Structures
3DQJ	;	1.51	;	Structure of the Yellow Fluorescent Protein Citrine Frozen at 1000 Atmospheres Number 3: Structure 7 in a Series of 26 High Pressure Structures
3DQI	;	1.42	;	Structure of the Yellow Fluorescent Protein Citrine Frozen at 1000 Atmospheres Number 4: Structure 8 in a Series of 26 High Pressure Structures
3DQH	;	1.45	;	Structure of the Yellow Fluorescent Protein Citrine Frozen at 1000 Atmospheres Number 5: Structure 9 in a Series of 26 High Pressure Structures
3DQF	;	1.46	;	Structure of the Yellow Fluorescent Protein Citrine Frozen at 1000 Atmospheres Number 6: Structure 10 in a Series of 26 High Pressure Structures
3DQE	;	1.43	;	Structure of the Yellow Fluorescent Protein Citrine Frozen at 1250 Atmospheres Number 1: Structure 11 in a Series of 26 High Pressure Structures
3DQD	;	1.4	;	Structure of the Yellow Fluorescent Protein Citrine Frozen at 1250 Atmospheres Number 2: Structure 12 in a Series of 26 High Pressure Structures
3DQC	;	1.49	;	Structure of the Yellow Fluorescent Protein Citrine Frozen at 1250 Atmospheres Number 3: Structure 13 in a Series of 26 High Pressure Structures
3DQA	;	1.44	;	Structure of the Yellow Fluorescent Protein Citrine Frozen at 1250 Atmospheres Number 4: Structure 14 in a Series of 26 High Pressure Structures
3DQ9	;	1.4	;	Structure of the Yellow Fluorescent Protein Citrine Frozen at 1500 Atmospheres Number 1: Structure 15 in a Series of 26 High Pressure Structures
3DQ8	;	1.51	;	Structure of the Yellow Fluorescent Protein Citrine Frozen at 1500 Atmospheres Number 2: Structure 16 in a Series of 26 High Pressure Structures
3DQ7	;	1.23	;	Structure of the Yellow Fluorescent Protein Citrine Frozen at 1920 Atmospheres Number 1: Structure 17 in a Series of 26 High Pressure Structures
3DQ6	;	1.6	;	Structure of the Yellow Fluorescent Protein Citrine Frozen at 1920 Atmospheres Number 2: Structure 18 in a Series of 26 High Pressure Structures
3DQ5	;	1.5	;	Structure of the Yellow Fluorescent Protein Citrine Frozen at 1960 Atmospheres: Structure 19 in a Series of 26 High Pressure Structures
3DQU	;	1.42	;	Structure of the Yellow Fluorescent Protein Citrine Frozen at 2000 Atmospheres Number 1: Structure 20 in a Series of 26 High Pressure Structures
3DQ4	;	1.47	;	Structure of the Yellow Fluorescent Protein Citrine Frozen at 2000 Atmospheres Number 2: Structure 20 in a Series of 26 High Pressure Structures
3DQ3	;	1.7	;	Structure of the Yellow Fluorescent Protein Citrine Frozen at 2500 Atmospheres: Structure 22 in a Series of 26 High Pressure Structures
3DQ2	;	1.6	;	Structure of the Yellow Fluorescent Protein Citrine Frozen at 4000 Atmospheres Number 1: Structure 23 in a Series of 26 High Pressure Structures
3DQ1	;	1.7	;	Structure of the Yellow Fluorescent Protein Citrine Frozen at 4000 Atmospheres Number 2: Structure 24 in a Series of 26 High Pressure Structures
3DPZ	;	1.7	;	Structure of the Yellow Fluorescent Protein Citrine Frozen at 4000 Atmospheres Number 3: Structure 25 in a Series of 26 High Pressure Structures
3DQN	;	1.44	;	Structure of the Yellow Fluorescent Protein Citrine Frozen at 500 Atmospheres: Structure 3 in a Series of 26 High Pressure Structures
3DPX	;	1.5	;	Structure of the Yellow Fluorescent Protein Citrine Frozen at 5000 Atmospheres: Structure 26 in a Series of 26 High Pressure Structures
3DQM	;	1.44	;	Structure of the Yellow Fluorescent Protein Citrine Frozen at 750 Atmospheres: Structure 4 in a Series of 26 High Pressure Structures
5LTQ	;	2.05	;	Structure of the Yellow Fluorescent Protein lanYFP from Branchiostoma lanceolatum at pH 7.5
5LTP	;	1.7	;	Structure of the Yellow-Green Fluorescent Protein mNeonGreen from Branchiostoma lanceolatum at the acidic pH 4.5
5LTR	;	1.21	;	Structure of the Yellow-Green Fluorescent Protein mNeonGreen from Branchiostoma lanceolatum at the near physiological pH 8.0
2VGX	;	1.95	;	Structure of the Yersinia enterocolitica Type III Secretion Translocator Chaperone SycD
2P58	;	1.8	;	Structure of the Yersinia pestis Type III secretion system needle protein YscF in complex with its chaperones YscE/YscG
3R3S	;	1.25	;	Structure of the YghA Oxidoreductase from Salmonella enterica
2F2H	;	1.95	;	Structure of the YicI thiosugar Michaelis complex
3KUX	;	2.75	;	Structure of the YPO2259 putative oxidoreductase from Yersinia pestis
3R3R	;	1.2	;	Structure of the YrdA ferripyochelin binding protein from Salmonella enterica
6I1D	;	2.28	;	Structure of the Ysh1-Mpe1 nuclease complex from S.cerevisiae
2DS7	;	2.5	;	Structure of the ZBD in the hexagonal crystal form
2DS5	;	1.5	;	Structure of the ZBD in the orthorhomibic crystal from
2DS6	;	2.0	;	Structure of the ZBD in the tetragonal crystal form
2DS8	;	1.6	;	Structure of the ZBD-XB complex
5JPS	;	1.78	;	Structure of the Zika Virus NS3 Helicase Domain
2KKH	;		;	Structure of the zinc binding domain of the ATPase HMA4
5LPI	;	1.8	;	Structure of the zinc finger array of Cep104
2QFI	;	3.8	;	Structure of the zinc transporter YiiP
1D0Q	;	1.71	;	STRUCTURE OF THE ZINC-BINDING DOMAIN OF BACILLUS STEAROTHERMOPHILUS DNA PRIMASE
1ZH1	;	2.5	;	Structure of the zinc-binding domain of HCV NS5A
2G43	;	2.09	;	Structure of the ZNF UBP domain from deubiquitinating enzyme isopeptidase T (IsoT)
1FXI	;	2.2	;	STRUCTURE OF THE [2FE-2S] FERREDOXIN I FROM THE BLUE-GREEN ALGA APHANOTHECE SACRUM AT 2.2 ANGSTROMS RESOLUTION
5N07	;	1.95	;	Structure of the [4Fe-4S] form of the NO response regulator NsrR
2FLA	;	0.95	;	Structure of thereduced HiPIP from thermochromatium tepidum at 0.95 angstrom resolution
6KK7	;	3.1	;	Structure of thermal-stabilised(M6) human GLP-1 receptor transmembrane domain
6KK1	;	2.8	;	Structure of thermal-stabilised(M8) human GLP-1 receptor transmembrane domain
6KJV	;	2.8	;	Structure of thermal-stabilised(M9) human GLP-1 receptor transmembrane domain
1GZJ	;	1.62	;	Structure of Thermoascus aurantiacus family 5 endoglucanase
5FW4	;	1.8	;	Structure of Thermobifida fusca DyP-type Peroxidase and Activity towards Kraft Lignin and Lignin Model Compounds
6T3E	;	2.6	;	Structure of Thermococcus litoralis Delta(1)-pyrroline-2-carboxylate reductase in complex with NADH and L-proline
5O8N	;	1.9	;	Structure of thermolysin at room temperature via a method of acoustically induced rotation.
5MA7	;	1.3	;	Structure of thermolysin in complex with inhibitor (JC306).
3QGO	;	1.45	;	Structure of Thermolysin in complex with L-Phenylalanine methylester
3QH1	;	1.55	;	Structure of Thermolysin in complex with N-benzyloxycarbonyl-L-aspartic acid
3QH5	;	1.5	;	Structure of Thermolysin in complex with N-Carbobenzyloxy-L-aspartic acid and L-Phenylalanine Methyl Ester
5FSP	;	1.7	;	Structure of thermolysin prepared by the 'soak-and-freeze' method under 100 bar of krypton pressure
5FSS	;	1.5	;	Structure of thermolysin prepared by the 'soak-and-freeze' method under 40 bar of krypton pressure
5FSJ	;	1.201	;	Structure of thermolysin prepared by the 'soak-and-freeze' method under 45 bar of oxygen pressure
5FXN	;	1.45	;	Structure of thermolysin solved by SAD from data collected by Direct Data Collection (DDC) using the ESRF RoboDiff goniometer
3ZI6	;	2.0	;	Structure of thermolysin solved by SAD from data collected by Direct Data Collection (DDC) using the GRob robot goniometer
6FJ2	;	1.43	;	Structure of Thermolysin solved from SAD data collected at the peak of the Zn absorption edge on ID30B
8FJQ	;	1.62	;	Structure of Thermomonospora curvata heme-containing DyP-type peroxidase E293G mutant
8FJR	;	1.49	;	Structure of Thermomonospora curvata heme-containing DyP-type peroxidase E293H mutant
7RMU	;	2.1	;	Structure of Thermomonospora curvata heme-containing DyP-type peroxidase with a modified axial ligand
4XD7	;	3.9	;	Structure of thermophilic F1-ATPase inhibited by epsilon subunit
2DTX	;	1.6	;	Structure of Thermoplasma acidophilum aldohexose dehydrogenase (AldT) in complex with D-mannose
2DTE	;	1.65	;	Structure of Thermoplasma acidophilum aldohexose dehydrogenase (AldT) in complex with NADH
2DTD	;	2.1	;	Structure of Thermoplasma acidophilum aldohexose dehydrogenase (AldT) in ligand-free form
3VTZ	;	2.3	;	Structure of Thermoplasma volcanium aldohexose dehydrogenase
7PQQ	;	3.3	;	Structure of thermostabilised human NTCP in complex with Megabody 91
7PQG	;	3.7	;	Structure of thermostabilised human NTCP in complex with nanobody 87
3ZEV	;	3.0	;	Structure of Thermostable Agonist-bound Neurotensin Receptor 1 Mutant without Lysozyme Fusion
5L8Z	;	1.4	;	Structure of thermostable DNA-binding HU protein from micoplasma Spiroplasma melliferum
4R9K	;	1.5	;	Structure of thermostable eightfold mutant of limonene epoxide hydrolase from Rhodococcus erythropolis
7OIX	;	3.6	;	Structure of thermostable human MFSD2A in complex with thermostable human Sync2
4JVZ	;	2.01	;	Structure of Thermosynechococcus elongatus CcmL
1P1M	;	1.5	;	Structure of Thermotoga maritima amidohydrolase TM0936 bound to Ni and methionine
1XKO	;	2.48	;	Structure of Thermotoga maritima CheX
4YXM	;	2.25	;	Structure of Thermotoga maritima DisA D75N mutant with reaction product c-di-AMP
4YVZ	;	2.495	;	Structure of Thermotoga maritima DisA in complex with 3'-dATP/Mn2+
4YXJ	;	2.55	;	Structure of Thermotoga maritima DisA in complex with ApCpp
7EFZ	;	1.69	;	Structure of Thermotoga maritima GH5 endoglucanase TM1752 in complex with TRIS
1TMI	;	1.7	;	Structure of Thermotoga maritima S63A non-processing mutant S-adenosylmethionine decarboxylase
7LJP	;	2.1	;	Structure of Thermotoga maritima SmpB
2AUJ	;	2.7	;	Structure of Thermus aquaticus RNA polymerase beta'-subunit insert
4K57	;	1.537	;	Structure of Thermus thermophilus 1-pyrroline-5-carboxylate dehydrogenase R100A mutant
4NCA	;	2.489	;	Structure of Thermus thermophilus Argonaute bound to guide DNA 19-mer and target DNA in the presence of Mg2+
4N47	;	2.823	;	Structure of Thermus thermophilus Argonaute bound to guide DNA and 12-mer target DNA
4N41	;	2.248	;	Structure of Thermus thermophilus Argonaute bound to guide DNA and 15-mer target DNA
4NCB	;	2.189	;	Structure of Thermus thermophilus Argonaute bound to guide DNA and 19-mer target DNA with Mg2+
4N76	;	2.89	;	Structure of Thermus thermophilus Argonaute bound to guide DNA and cleaved target DNA with Mn2+
4AN8	;	2.3	;	Structure of Thermus thermophilus CasA (Cse1)
6HWN	;	1.95	;	Structure of Thermus thermophilus ClpP in complex with a tripeptide.
6HWM	;	2.7	;	Structure of Thermus thermophilus ClpP in complex with bortezomib
3QRQ	;	3.194	;	Structure of Thermus Thermophilus Cse3 bound to an RNA representing a pre-cleavage complex
3QRR	;	3.099	;	Structure of Thermus Thermophilus Cse3 bound to an RNA representing a product complex
3QRP	;	2.352	;	Structure of Thermus Thermophilus Cse3 bound to an RNA representing a product mimic complex
3S33	;	4.45	;	Structure of Thermus thermophilus cytochrome ba3 oxidase 10s after Xe depressurization
3S3A	;	4.25	;	Structure of Thermus thermophilus cytochrome ba3 oxidase 120s after Xe depressurization
3S3B	;	3.3	;	Structure of Thermus thermophilus cytochrome ba3 oxidase 240s after Xe depressurization
3S38	;	4.2	;	Structure of Thermus thermophilus cytochrome ba3 oxidase 30s after Xe depressurization
3S3C	;	4.0	;	Structure of Thermus thermophilus cytochrome ba3 oxidase 360s after Xe depressurization
3S3D	;	3.75	;	Structure of Thermus thermophilus cytochrome ba3 oxidase 480s after Xe depressurization
3S39	;	4.8	;	Structure of Thermus thermophilus cytochrome ba3 oxidase 60s after Xe depressurization
1FNM	;	2.8	;	STRUCTURE OF THERMUS THERMOPHILUS EF-G H573A
2G37	;	2.0	;	Structure of Thermus thermophilus L-proline dehydrogenase
5M42	;	2.2	;	Structure of Thermus thermophilus L-proline dehydrogenase lacking alpha helices A, B and C
2EKG	;	1.9	;	Structure of Thermus thermophilus Proline Dehydrogenase inactivated by N-propargylglycine
2DGB	;	2.1	;	Structure of Thermus thermophilus PurS in the P21 Form
7OHG	;	2.507	;	Structure of Thermus thermophilus Rel bound to the non-hydrolasable alarmone analogue
4V8X	;	3.35	;	Structure of Thermus thermophilus ribosome
1ZYR	;	3.0	;	Structure of Thermus thermophilus RNA polymerase holoenzyme in complex with the antibiotic streptolydigin
5CM7	;	1.55	;	Structure of thiamine-monophosphate kinase from Acinetobacter baumannii in complex with adenosine diphosphate (ADP) and thiamine diphosphate (TPP)
6MFM	;	1.9	;	Structure of thiamine-monophosphate kinase from Acinetobacter baumannii in complex with adenosine diphosphate (ADP) and thiamine diphosphate (TPP), orthorhombic crystal form
5CC8	;	1.75	;	Structure of thiamine-monophosphate kinase from Acinetobacter baumannii in complex with AMPPNP
5DD7	;	1.7	;	Structure of thiamine-monophosphate kinase from Acinetobacter baumannii in complex with AMPPNP and thiamine-monophosphate
1NG4	;	2.3	;	Structure of ThiO (glycine oxidase) from Bacillus subtilis
6MLK	;	2.45	;	Structure of Thioesterase from DEBS with a thioesterase-specific antibody
8GQH	;	2.2	;	Structure of Thiolase from Pseudomonas aeruginosa PAO1
8GQI	;	2.21	;	Structure of Thiolase from Pseudomonas aeruginosa PAO1
8GQJ	;	1.78	;	Structure of Thiolase from Pseudomonas aeruginosa PAO1
6NUP	;	1.6	;	Structure of thioredoxin (trxA) from Rickettsia prowazekii str. Madrid E.
6MOS	;	1.80014	;	Structure of thioredoxin 1 from the thermophilic eubacterium Thermosipho africanus TCF52B
2LRC	;		;	Structure of thioredoxin 2 from Pseudomonas aeruginosa PAO1 in its reduced form
8QPD	;		;	Structure of thioredoxin m from pea
7JYP	;	1.6	;	Structure of thioredoxin reductase from the thermophilic eubacterium Thermosipho africanus TCF52B
1ZUD	;	1.98	;	Structure of ThiS-ThiF protein complex
4N4D	;	2.4	;	Structure of ThiT with AV-38 bound
4MUU	;	2.1	;	Structure of ThiT with pyrithiamine bound
5XEA	;	2.093	;	Structure of Thogoto virus envelope glycoprotein
8KG3	;	2.6	;	Structure of THOUSAND-GRAIN WEIGHT 6 (TGW6)
3DOG	;	2.7	;	Structure of Thr 160 phosphorylated CDK2/cyclin A in complex with the inhibitor N-&-N1
2G9X	;	2.5	;	Structure of Thr 160 phosphorylated CDK2/cyclin A in complex with the inhibitor NU6271
7REC	;	2.2	;	Structure of Thr354Asn, Glu355Gln, Thr412Asn, Ile414Met, Ile464His, and Phe467Met mutant human CaMKII alpha hub bound to 5-HDC
6OF8	;	2.1	;	Structure of Thr354Asn, Glu355Gln, Thr412Asn, Ile414Met, Ile464His, and Phe467Met mutant human CamKII-alpha hub domain
4S0X	;	2.1	;	Structure of three phase partition - treated lipase from Thermomyces lanuginosa in complex with lauric acid at 2.1 A resolution
4FLF	;	2.15	;	Structure of three phase partition treated lipase from Thermomyces lanuginosa at 2.15A resolution.
4GWL	;	2.55	;	Structure of three phase partition treated lipase from Thermomyces lanuginosa at 2.55A resolution
3ZIY	;	1.01	;	Structure of three-domain heme-Cu nitrite reductase from Ralstonia pickettii at 1.01 A resolution
4AX3	;	1.6	;	Structure of three-domain heme-Cu nitrite reductase from Ralstonia pickettii at 1.6 A resolution
1E5X	;	2.25	;	Structure of threonine synthase from Arabidopsis thaliana
3BV9	;	1.8	;	Structure of Thrombin Bound to the Inhibitor FM19
1BTH	;	2.3	;	STRUCTURE OF THROMBIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR
1D9I	;	2.3	;	STRUCTURE OF THROMBIN COMPLEXED WITH SELECTIVE NON-ELECTOPHILIC INHIBITORS HAVING CYCLOHEXYL MOIETIES AT P1
1D6W	;	2.0	;	STRUCTURE OF THROMBIN COMPLEXED WITH SELECTIVE NON-ELECTROPHILIC INHIBITORS HAVING CYCLOHEXYL MOIETIES AT P1
2A0Q	;	1.9	;	Structure of thrombin in 400 mM potassium chloride
1A2C	;	2.1	;	Structure of thrombin inhibited by AERUGINOSIN298-A from a BLUE-GREEN ALGA
3GIC	;	1.55	;	Structure of thrombin mutant delta(146-149e) in the free form
4HFP	;	2.4	;	Structure of thrombin mutant S195a bound to the active site inhibitor argatroban
3S7K	;	1.9	;	Structure of thrombin mutant Y225P in the E form
3S7H	;	1.9	;	Structure of thrombin mutant Y225P in the E* form
1T0B	;	1.7	;	Structure of ThuA-like protein from Bacillus stearothermophilus
5UIV	;	2.45	;	Structure of Thymidylate Kinase from Candida albicans Reveals Origin of Broad Substrate Specificity and a Novel Structural Element.
2TDM	;	2.55	;	STRUCTURE OF THYMIDYLATE SYNTHASE
1HW4	;	2.06	;	STRUCTURE OF THYMIDYLATE SYNTHASE SUGGESTS ADVANTAGES OF CHEMOTHERAPY WITH NONCOMPETITIVE INHIBITORS
4FZB	;	2.59	;	Structure of thymidylate synthase ThyX complexed to a new inhibitor
5T2W	;	2.2	;	Structure of thymine DNA glycosylase bound to substrate analog 2'-F-5-formyl-dC
7X1U	;	3.19	;	Structure of Thyrotropin-Releasing Hormone Receptor bound with an Endogenous Peptide Agonist TRH.
7X1T	;	3.26	;	Structure of Thyrotropin-Releasing Hormone Receptor bound with Taltirelin.
6RPT	;	2.7	;	Structure of tick complement inhibitor CirpT1 complexed with macroglobubulin domain 4 of human complement C5
5V52	;	3.1	;	Structure of TIGIT bound to nectin-2 (CD112)
5Y7I	;	3.0	;	Structure of tilapia fish CLIC2
7M3Y	;	1.69	;	Structure of TIM-3 in complex with 8-chloro-2-methyl-9-(3-mehtylpyridin-4-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5(6H)-one (compound 22)
7M3Z	;	1.4	;	Structure of TIM-3 in complex with N-(4-(8-chloro-2-mehtyl-5-oxo-5,6-dihydro-[1,2,4]triazolo[1,5-c]quinazolin-9-yl)-3-methylphenyl)methanesulfonamdide (compound 35)
7M41	;	1.79	;	Structure of TIM-3 in complex with N-(4-(8-chloro-2-methyl-5-oxo-5,6-dihydro-[1,2,4]traizolo[1,5-c]quinazolin-9-yl)-3-methylphenyl)-1H-imidazole-2-sulfonamide (compound 38)
3KAA	;	3.002	;	Structure of Tim-3 in complex with phosphatidylserine
3FHN	;	3.0	;	Structure of Tip20p
6DHX	;	1.75	;	Structure of TipC2 from Streptococcus intermedius B196
5Z78	;	1.762	;	Structure of TIRR/53BP1 complex
8POE	;	4.2	;	Structure of tissue-specific lipid scramblase ATG9B homotrimer, refined with C3 symmetry applied
5H52	;	3.0	;	Structure of Titanium-bound human serum transferrin
6H4L	;	1.6	;	Structure of Titin M4 trigonal form
6GW3	;	1.39	;	Structure of TKS from Cannabis sativa in complex with CoA
1TUL	;	2.2	;	STRUCTURE OF TLP20
4XTK	;	2.7	;	Structure of TM1797, a CAS1 protein from Thermotoga maritima
2K9P	;		;	Structure of TM1_TM2 in LPPG micelles
2XON	;	1.4	;	Structure of TmCBM61 in complex with beta-1,4-galactotriose at 1.4 A resolution
5KC4	;	3.4	;	Structure of TmRibU, orthorhombic crystal form
6Q97	;	3.9	;	Structure of tmRNA SmpB bound in A site of E. coli 70S ribosome
6Q95	;	3.7	;	Structure of tmRNA SmpB bound in A site of T. thermophilus 70S ribosome
6Q98	;	4.3	;	Structure of tmRNA SmpB bound in P site of E. coli 70S ribosome
6Q9A	;	3.7	;	Structure of tmRNA SmpB bound past E site of E. coli 70S ribosome
2OB7	;	13.6	;	Structure of tmRNA-(SmpB)2 complex as inferred from cryo-EM
6B12	;	1.71	;	Structure of Tne2 in complex with Tni2
1CA4	;	2.2	;	STRUCTURE OF TNF RECEPTOR ASSOCIATED FACTOR 2 (TRAF2)
1D0A	;	2.0	;	STRUCTURE OF TNF RECEPTOR ASSOCIATED FACTOR 2 (TRAF2) IN COMPLEX WITH A HUMAN OX40 PEPTIDE
1CZZ	;	2.7	;	STRUCTURE OF TNF RECEPTOR ASSOCIATED FACTOR 2 IN COMPLEX WITH A 17-RESIDUE CD40 PEPTIDE
1D00	;	2.0	;	STRUCTURE OF TNF RECEPTOR ASSOCIATED FACTOR 2 IN COMPLEX WITH A 5-RESIDUE CD40 PEPTIDE
1D01	;	2.0	;	STRUCTURE OF TNF RECEPTOR ASSOCIATED FACTOR 2 IN COMPLEX WITH A HUMAN CD30 PEPTIDE
1D0J	;	2.5	;	STRUCTURE OF TNF RECEPTOR ASSOCIATED FACTOR 2 IN COMPLEX WITH A M4-1BB PEPTIDE
1CA9	;	2.3	;	STRUCTURE OF TNF RECEPTOR ASSOCIATED FACTOR 2 IN COMPLEX WITH A PEPTIDE FROM TNF-R2
5UMZ	;	1.9	;	Structure of TNRC6A NLS in complex with importin-alpha
1A6C	;	3.5	;	STRUCTURE OF TOBACCO RINGSPOT VIRUS
4Y6X	;	2.1	;	Structure of Tobacco streak virus coat protein at 2.1 Angstroms resolution (C2 crystal form)
4Y6T	;	2.4	;	Structure of Tobacco streak virus coat protein dimer at 2.4 Angstroms resolution
2IVZ	;	2.0	;	Structure of TolB in complex with a peptide of the colicin E9 T- domain
1TQQ	;	2.75	;	Structure of TolC in complex with hexamminecobalt
8ODT	;	4.2	;	Structure of TolQR complex from E.coli
3LCA	;	2.19	;	Structure of Tom71 complexed with Hsp70 Ssa1 C terminal tail indicating conformational plasticity
4JDG	;	2.74	;	Structure of Tomato Bifunctional Nuclease TBN1, variant N211D
2TBV	;	2.9	;	STRUCTURE OF TOMATO BUSHY STUNT VIRUS. V. COAT PROTEIN SEQUENCE DETERMINATION AND ITS STRUCTURAL IMPLICATIONS
5Y6J	;	2.811	;	Structure of Tomato spotted wilt virus nucleocapsid protein with alternative oligomerization state
6MRQ	;	1.288	;	Structure of ToPI1 inhibitor from Tityus obscurus scorpion venom in complex with trypsin
3M7G	;	2.4	;	Structure of topoisomerase domain of topoisomerase V protein
1MU5	;	2.0	;	Structure of topoisomerase subunit
1MX0	;	2.3	;	Structure of topoisomerase subunit
7NEZ	;	3.39	;	Structure of topotecan-bound ABCG2
4WHN	;	2.15	;	Structure of toxin-activating acyltransferase (TAAT)
4TU1	;	2.0	;	Structure of Toxoplasma gondii fructose 1,6 bisphosphate aldolase
2XGG	;	2.05	;	Structure of Toxoplasma gondii Micronemal Protein 2 A_I Domain
4OKU	;	3.2	;	Structure of Toxoplasma gondii proMIC2
5U1G	;	3.64	;	Structure of TP228 ParA-AMPPNP-ParB complex
5ZLZ	;	3.581	;	Structure of tPA and PAI-1
6JBI	;	2.5	;	Structure of Tps1 apo structure
6JBW	;	2.65	;	Structure of Tps1/UDP complex
4APN	;	3.2	;	Structure of TR from Leishmania infantum in complex with a diarylpirrole-based inhibitor
3HZF	;	2.5	;	Structure of TR-alfa bound to selective thyromimetic GC-1 in C2 space group
3ILZ	;	1.85	;	Structure of TR-alfa bound to selective thyromimetic GC-1 in P212121 space group
3IMY	;	2.55	;	Structure of TR-beta bound to selective thyromimetic GC-1
5OEJ	;	5.7	;	Structure of Tra1 subunit within the chromatin modifying complex SAGA
7L3L	;	2.8	;	Structure of TRAF5 and TRAF6 RING Hetero dimer
2L98	;		;	Structure of trans-Resveratrol in complex with the cardiac regulatory protein Troponin C
6OM6	;	3.1	;	Structure of trans-translation inhibitor bound to E. coli 70S ribosome with P site tRNA
1BHI	;		;	STRUCTURE OF TRANSACTIVATION DOMAIN OF CRE-BP1/ATF-2, NMR, 20 STRUCTURES
1ONR	;	1.87	;	STRUCTURE OF TRANSALDOLASE B
5FR9	;	2.81	;	Structure of transaminase ATA-117 arRmut11 from Arthrobacter sp. KNK168 inhibited with 1-(4-Bromophenyl)-2-fluoroethylamine
8WAK	;	5.47	;	Structure of transcribing complex 2 (TC2), the initially transcribing complex with Pol II positioned 2nt downstream of TSS.
8WAL	;	8.52	;	Structure of transcribing complex 3 (TC3), the initially transcribing complex with Pol II positioned 3nt downstream of TSS.
8WAN	;	6.07	;	Structure of transcribing complex 4 (TC4), the initially transcribing complex with Pol II positioned 4nt downstream of TSS.
8WAO	;	6.4	;	Structure of transcribing complex 5 (TC5), the initially transcribing complex with Pol II positioned 5nt downstream of TSS.
8WAP	;	5.85	;	Structure of transcribing complex 6 (TC6), the initially transcribing complex with Pol II positioned 6nt downstream of TSS.
8WAQ	;	6.29	;	Structure of transcribing complex 7 (TC7), the initially transcribing complex with Pol II positioned 7nt downstream of TSS.
8WAR	;	7.2	;	Structure of transcribing complex 8 (TC8), the initially transcribing complex with Pol II positioned 8nt downstream of TSS.
8WAS	;	6.13	;	Structure of transcribing complex 9 (TC9), the initially transcribing complex with Pol II positioned 9nt downstream of TSS.
5FLM	;	3.4	;	Structure of transcribing mammalian RNA polymerase II
6I84	;	4.4	;	Structure of transcribing RNA polymerase II-nucleosome complex
8UIS	;	3.23	;	Structure of transcription complex Pol II-DSIF-NELF-TFIIS
6MBW	;	3.29	;	Structure of Transcription Factor
6MBZ	;	3.21	;	Structure of Transcription Factor
4IJJ	;	3.25	;	Structure of transcription factor DksA2 from Pseudomonas aeruginosa
2HDC	;		;	STRUCTURE OF TRANSCRIPTION FACTOR GENESIS/DNA COMPLEX
7Z0O	;	2.8	;	Structure of transcription factor UAF in complex with TBP and 35S rRNA promoter DNA
6JQS	;	2.09	;	Structure of Transcription factor, GerE
2HSG	;	2.5	;	Structure of transcription regulator CcpA in its DNA-free state
2B2N	;	2.1	;	Structure of transcription-repair coupling factor
3UFE	;	1.5	;	Structure of transcriptional antiterminator (BGLG-family) at 1.5 A resolution
1F4S	;		;	STRUCTURE OF TRANSCRIPTIONAL FACTOR ALCR IN COMPLEX WITH A TARGET DNA
1F5E	;		;	STRUCTURE OF TRANSCRIPTIONAL FACTOR ALCR IN COMPLEX WITH A TARGET DNA
7WZE	;	2.65	;	Structure of Transcriptional regulator from Bacillus subtilis (strain 168)
5IPA	;	1.78	;	Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium Tuberculosis in complex with (E)-3-(furan-3-yl)-1-(pyrrolidin-1-yl)prop-2-en-1-one at 1.78A resolution
5J3L	;	1.66	;	Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium Tuberculosis in complex with 1-((2-cyclopentylethyl)sulfonyl)pyrrolidine at 1.66A resolution
5J1Y	;	1.81	;	Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium Tuberculosis in complex with 1-(pyrrolidin-1-yl)-3-(tetrahydrofuran-3-yl)propan-1-one at 1.81A resolution
5J1R	;	1.92	;	Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium Tuberculosis in complex with 3-(furan-3-yl)-1-(pyrrolidin-1-yl)propan-1-one at 1.92A resolution
5F1J	;	1.631	;	Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium Tuberculosis in complex with compound 1 at 1.63A resolution
5F08	;	1.92	;	Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium tuberculosis in complex with compound 14 at 1.92A resolution
5F0F	;	1.76	;	Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium Tuberculosis in complex with compound 15 at 1.76A resolution
5F27	;	1.684	;	Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium Tuberculosis in complex with compound 2 at 1.68A resolution
5EZH	;	1.7	;	Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium Tuberculosis in complex with compound 21 at 1.7A resolution
5EZG	;	1.84	;	Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium Tuberculosis in complex with compound 22 at 1.84A resolution
5F0H	;	1.99	;	Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium Tuberculosis in complex with compound 28 at 1.99A resolution
5F04	;	1.84	;	Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium Tuberculosis in complex with compound 3 at 1.84A resolution
5F0C	;	1.87	;	Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium tuberculosis in complex with compound 4 at 1.87A resolution
5EYR	;	1.57	;	Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium Tuberculosis in complex with compound 5 at 1.57A resolution
5MXV	;	1.626	;	Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium Tuberculosis in complex with compound GSK1107112A at 1.63A resolution
5MYL	;	1.724	;	Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium Tuberculosis in complex with compound GSK1570606A at 1.72A resolution
5MYM	;	2.28	;	Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium Tuberculosis in complex with compound GSK2032710A at 2.28A resolution
5MYN	;	1.564	;	Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium Tuberculosis in complex with compound GSK445886A at 1.56A resolution
5MYR	;	1.828	;	Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium Tuberculosis in complex with compound GSK735816A at 1.83A resolution
5MYS	;	1.587	;	Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium Tuberculosis in complex with compound GSK920684A at 1.59A resolution
5MYT	;	1.61	;	Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium Tuberculosis in complex with compound GSK921295A at 1.61A resolution
5MYW	;	1.77	;	Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium Tuberculosis in complex with compound SB-435634 at 1.77A resolution
5NZ0	;	1.825	;	Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium Tuberculosis in complex with linezolid
5IP6	;	1.93	;	Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium Tuberculosis in complex with N-((tetrahydrofuran-3-yl)methyl)pyrrolidine-1-carboxamide at 1.93A resolution
5IOZ	;	2.02	;	Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium Tuberculosis in complex with N-(cyclopentylmethyl)cyclopentanecarboxamide at 2.02A resolution
5IOY	;	1.77	;	Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium Tuberculosis in complex with N-(cyclopentylmethyl)pyrrolidine-1-carboxamide at 1.77A resolution
5J1U	;	1.8	;	Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium Tuberculosis in complex with N-(furan-3-ylmethyl)pyrrolidine-1-carboxamide at 1.80A resolution
5NZ1	;	2.33	;	Structure of Transcriptional Regulatory Repressor Protein - EthR from Mycobacterium Tuberculosis in complex with sutezolid
5XYK	;	2.57	;	Structure of Transferase
6AI4	;	2.1	;	Structure of Transferase mutant-C21S,C199S
5H5Y	;	2.3	;	Structure of Transferase mutant-C23S,C199S
5H60	;	3.64	;	Structure of Transferase mutant-C23S,C199S
5H61	;	1.86	;	Structure of Transferase mutant-C23S,C199S
5H62	;	1.66	;	Structure of Transferase mutant-C23S,C199S
5H63	;	1.92	;	Structure of Transferase mutant-C23S,C199S
8HIA	;	4.9	;	Structure of transforming growth factor beta induced protein (TGFBIp) G623R fibril
2FSV	;	2.3	;	Structure of transhydrogenase (dI.D135N.NAD+)2(dIII.E155W.NADP+)1 asymmetric complex
2OO5	;	2.6	;	Structure of transhydrogenase (dI.H2NADH)2(dIII.NADP+)1 asymmetric complex
2OOR	;	2.32	;	Structure of transhydrogenase (dI.NAD+)2(dIII.H2NADPH)1 asymmetric complex
2FR8	;	2.6	;	Structure of transhydrogenase (dI.R127A.NAD+)2(dIII.NADP+)1 asymmetric complex
2FRD	;	3.2	;	Structure of Transhydrogenase (dI.S138A.NADH)2(dIII.NADPH)1 asymmetric complex
5IWK	;	3.247	;	Structure of Transient Receptor Potential (TRP) channel TRPV6
5IWR	;	3.85	;	Structure of Transient Receptor Potential (TRP) channel TRPV6 in the presence of barium
5IWP	;	3.65	;	Structure of Transient Receptor Potential (TRP) channel TRPV6 in the presence of calcium
5IWT	;	3.8	;	Structure of Transient Receptor Potential (TRP) channel TRPV6 in the presence of gadolinium
5J3B	;	2.3	;	Structure of translation elongation factor P from Acinetobacter baumannii
7ACJ	;	3.2	;	Structure of translocated trans-translation complex on E. coli stalled ribosome.
1SMZ	;		;	Structure of Transportan in phospholipid bicellar solution
1RVS	;		;	STRUCTURE OF TRANSTHYRETIN IN AMYLOID FIBRILS DETERMINED BY SOLID-STATE MAGIC ANGLE SPINNING NMR
5TZL	;	1.4	;	Structure of transthyretin in complex with the kinetic stabilizer 201
3SSG	;	2.0	;	Structure of transthyretin L55P in complex with Zn
8W1N	;	1.6	;	Structure of transthyretin pathogenic mutation A120S
8W2W	;	2.07	;	Structure of transthyretin synthetic mutation A120L
5Y3O	;	2.7	;	Structure of TRAP1 complexed with DN320
5Y3N	;	2.4	;	Structure of TRAP1 complexed with DN401
5HPH	;	2.429	;	Structure of TRAP1 fragment
6BGT	;	2.7	;	Structure of Trastuzumab Fab mutant in complex with Her2 extracellular domain
5N8M	;		;	Structure of TRBP dsRBD 1 and 2 in complex with a 19 bp siRNA (Complex A)
5N8L	;		;	Structure of TRBP dsRBD 1 and 2 in complex with a 19 bp siRNA (Complex B)
3ADL	;	2.2	;	Structure of TRBP2 and its molecule implications for miRNA processing
1EU8	;	1.9	;	STRUCTURE OF TREHALOSE MALTOSE BINDING PROTEIN FROM THERMOCOCCUS LITORALIS
5H2T	;	2.796	;	Structure of trehalose synthase
5DX9	;	2.15	;	Structure of trehalose-6-phosphate phosphatase from Cryptococcus neoformans
6UPD	;	2.052	;	Structure of trehalose-6-phosphate phosphatase from Salmonella typhimurium in complex with trehalose
6UPC	;	2.505	;	Structure of trehalose-6-phosphate phosphatase from Salmonella typhimurium in complex with trehalose 6-sulfate
6UPE	;	2.244	;	Structure of trehalose-6-phosphate phosphatase from Salmonella typhimurium inhibited by 4-n-octylphenyl alpha-D-glucopyranoside-6-sulfate
6Z0G	;		;	Structure of TREM2 transmembrane helix in DPC micelles
6Z0H	;		;	Structure of TREM2 transmembrane helix K186A variant in DPC micelles
3QZ0	;	1.77	;	Structure of Treponema denticola Factor H Binding protein (FhbB), selenomethionine derivative
2O4G	;	2.35	;	Structure of TREX1 in complex with a nucleotide
3B6O	;	2.1	;	Structure of TREX1 in complex with a nucleotide and an inhibitor ion (lithium)
3B6P	;	2.3	;	Structure of TREX1 in complex with a nucleotide and inhibitor ions (sodium and zinc)
2O4I	;	3.5	;	Structure of TREX1 in complex with DNA
6A4B	;	2.7	;	Structure of TREX2 in complex with a duplex DNA with 2 nucleotide 3'-overhang
6A46	;	2.0	;	Structure of TREX2 in complex with a nucleotide (dCMP)
6A47	;	1.9	;	Structure of TREX2 in complex with a Y structured dsDNA
8OX1	;	2.7	;	Structure of TRF1core in complex with telomeric nucleosome
4RQI	;	2.4405	;	Structure of TRF2/RAP1 secondary interaction binding site
3NAP	;	2.5	;	Structure of Triatoma Virus (TrV)
5CQG	;	2.3	;	Structure of Tribolium telomerase in complex with the highly specific inhibitor BIBR1532
5GW5	;	4.6	;	Structure of TRiC-AMP-PNP
4PSD	;	1.52	;	Structure of Trichoderma reesei cutinase native form.
2F51	;	1.9	;	Structure of Trichomonas vaginalis thioredoxin
7P1R	;	1.75	;	Structure of Trichophyton Rubrum KDNase in complex with 2,3-difluoro-KDN
6XB5	;	2.9	;	Structure of Trichoplusia ni poxin in post-reactive state with Gp[2'-5']Ap[3']
6ADH	;	2.9	;	STRUCTURE OF TRICLINIC TERNARY COMPLEX OF HORSE LIVER ALCOHOL DEHYDROGENASE AT 2.9 ANGSTROMS RESOLUTION
3RM5	;	2.68	;	Structure of Trifunctional THI20 from Yeast
2AAR	;	3.5	;	Structure of trigger factor binding domain in biologically homologous complex with eubacterial ribosome.
4AVK	;	2.4	;	Structure of trigonal FimH lectin domain crystal soaked with an alpha- D-mannoside O-linked to propynyl pyridine at 2.4A resolution
1G0N	;	2.0	;	STRUCTURE OF TRIHYDROXYNAPHTHALENE REDUCTASE IN COMPLEX WITH NADPH AND 4,5,6,7-TETRACHLORO-PHTHALIDE
1DOH	;	2.1	;	STRUCTURE OF TRIHYDROXYNAPHTHALENE REDUCTASE IN COMPLEX WITH NADPH AND 4-NITRO-INDEN-1-ONE
1YBV	;	2.8	;	STRUCTURE OF TRIHYDROXYNAPHTHALENE REDUCTASE IN COMPLEX WITH NADPH AND AN ACTIVE SITE INHIBITOR
1G0O	;	1.7	;	STRUCTURE OF TRIHYDROXYNAPHTHALENE REDUCTASE IN COMPLEX WITH NADPH AND PYROQUILON
7ZJ3	;	2.53	;	Structure of TRIM2 RING domain in complex with UBE2D1~Ub conjugate
8U4S	;	3.35	;	Structure of trimeric CXCR4 in complex with REGN7663 Fab
1HR3	;	5.5	;	STRUCTURE OF TRIMERIC HAEMERYTHRIN
8AE1	;	3.25	;	Structure of trimeric SlpA outer membrane protein
1TIM	;	2.5	;	STRUCTURE OF TRIOSE PHOSPHATE ISOMERASE FROM CHICKEN MUSCLE
3KRS	;	1.55	;	Structure of Triosephosphate Isomerase from Cryptosporidium Parvum at 1.55A Resolution
4POD	;	1.99	;	Structure of Triosephosphate Isomerase I170V mutant human enzyme.
2I9E	;	2.0	;	Structure of Triosephosphate Isomerase of Tenebrio molitor
4POC	;	1.601	;	Structure of Triosephosphate Isomerase Wild Type human enzyme.
8GP7	;		;	Structure of Trioxacarcin A covalently bound to RET G4-DNA
6V4K	;	3.53004	;	Structure of TrkH-TrkA in complex with ADP
6V4J	;	2.97	;	Structure of TrkH-TrkA in complex with ATP
6V4L	;	3.8	;	Structure of TrkH-TrkA in complex with ATPgammaS
2VDV	;	2.3	;	Structure of trm8, m7G methylation enzyme
2VDU	;	2.4	;	Structure of trm8-trm82, THE YEAST TRNA m7G methylation complex
5BOX	;	2.5	;	Structure of TrmBL2, an archaeal chromatin protein, shows a novel mode of DNA binding.
5BPD	;	2.4	;	Structure of TrmBL2, an archaeal chromatin protein, shows a novel mode of DNA binding.
5BPI	;	3.198	;	Structure of TrmBL2, an archaeal chromatin protein, shows a novel mode of DNA binding.
5BQT	;	3.0	;	Structure of TrmBL2, an archaeal chromatin protein, shows a novel mode of DNA binding.
8K5L	;	1.67	;	Structure of tRNA (cmo5U34)-methyltransferase from Fusobacterium nucleatum
3CRM	;	1.9	;	Structure of tRNA Dimethylallyltransferase: RNA Modification through a Channel
3CRQ	;	2.2	;	Structure of tRNA Dimethylallyltransferase: RNA Modification through a Channel
3CRR	;	1.9	;	Structure of tRNA Dimethylallyltransferase: RNA Modification through a Channel
1SGV	;	1.9	;	STRUCTURE OF TRNA PSI55 PSEUDOURIDINE SYNTHASE (TRUB)
2G5H	;	2.5	;	Structure of tRNA-Dependent Amidotransferase GatCAB
2G5I	;	3.35	;	Structure of tRNA-Dependent Amidotransferase GatCAB complexed with ADP-AlF4
2DQN	;	2.55	;	Structure of tRNA-Dependent Amidotransferase GatCAB complexed with Asn
2F2A	;	2.3	;	Structure of tRNA-Dependent Amidotransferase GatCAB complexed with Gln
2DF4	;	3.2	;	Structure of tRNA-Dependent Amidotransferase GatCAB complexed with Mn2+
3H0L	;	2.3	;	Structure of trna-dependent amidotransferase gatcab from aquifex aeolicus
3H0M	;	2.8	;	Structure of trna-dependent amidotransferase gatcab from aquifex aeolicus
3H0R	;	3.0	;	Structure of trna-dependent amidotransferase gatcab from aquifex aeolicus
4WC3	;	3.1	;	Structure of tRNA-processing enzyme complex 1
4WC5	;	3.41	;	Structure of tRNA-processing enzyme complex 3
4WC6	;	3.41	;	Structure of tRNA-processing enzyme complex 4
4WC7	;	3.102	;	Structure of tRNA-processing enzyme complex 5
4X0A	;	3.505	;	Structure of tRNA-processing enzyme complex 6
4X0B	;	3.2	;	Structure of tRNA-processing enzyme complex 7
4WC1	;	3.1	;	Structure of tRNA-processing enzyme with CTP
2B9C	;	2.3	;	Structure of tropomyosin's mid-region: bending and binding sites for actin
6V9W	;	3.1	;	Structure of TRPA1 (ligand-free) with bound calcium, LMNG
6V9Y	;	3.6	;	Structure of TRPA1 bound with A-967079, PMAL-C8
7YKR	;	3.2	;	Structure of TRPA1 in Drosophila melanogaster in a state with 17 ankyrin repeats determined
7YKS	;	3.0	;	Structure of TRPA1 in Drosophila melanogaster in a state with 5 ankyrin repeats determined
6V9V	;	2.6	;	Structure of TRPA1 modified by Bodipy-iodoacetamide with bound calcium, LMNG
6V9X	;	3.3	;	Structure of TRPA1 modified by iodoacetamide, PMAL-C8
7DXB	;	2.7	;	Structure of TRPC3 at 2.7 angstrom in high calcium state
7DXC	;	3.06	;	Structure of TRPC3 at 3.06 angstrom in low calcium state
7DXD	;	3.9	;	Structure of TRPC3 at 3.9 angstrom in 1340 nM free calcium state
7DXE	;	3.2	;	Structure of TRPC3 gain of function mutation R803C at 3.2 angstrom in 1340nM free calcium state
6DRJ	;	3.3	;	Structure of TRPM2 ion channel receptor by single particle electron cryo-microscopy, ADPR/Ca2+ bound state
6DRK	;	3.8	;	Structure of TRPM2 ion channel receptor by single particle electron cryo-microscopy, Apo state
2A4M	;	2.3	;	Structure of Trprs II bound to ATP
4WU8	;	2.45	;	Structure of trPtNAP-NCP145
5IRZ	;	3.28	;	Structure of TRPV1 determined in lipid nanodisc
5IS0	;	3.43	;	Structure of TRPV1 in complex with capsazepine, determined in lipid nanodisc
5IRX	;	2.95	;	Structure of TRPV1 in complex with DkTx and RTX, determined in lipid nanodisc
3J5P	;	3.275	;	Structure of TRPV1 ion channel determined by single particle electron cryo-microscopy
3J5Q	;	3.8	;	Structure of TRPV1 ion channel in complex with DkTx and RTX determined by single particle electron cryo-microscopy
7RAS	;	3.64	;	Structure of TRPV3 in complex with osthole
7RAU	;	3.99	;	Structure of TRPV3 in complex with osthole
6B5V	;	4.8	;	Structure of TRPV5 in complex with econazole
4HSZ	;	2.25	;	Structure of truncated (delta8C) S100A4
6XXG	;	2.099	;	Structure of truncated 1-deoxy-D-xylulose 5-phosphate synthase (DXS) from Deinococcus radiodurans
8A8Y	;	2.1	;	Structure of truncated 1-deoxy-D-xylulose 5-phosphate synthase (DXS) from Klebsiella pneumoniae
8A9C	;	1.8	;	Structure of truncated 1-deoxy-D-xylulose 5-phosphate synthase (DXS) from Klebsiella pneumoniae in complex with cofactor TPP
5HO9	;	2.845	;	Structure of truncated AbnA (domains 1-3), a GH43 arabinanase from Geobacilllus stearothermophilus, in complex with arabinooctaose
2FEP	;	2.45	;	Structure of truncated CcpA in complex with P-Ser-HPr and Sulfate ions
7LQS	;		;	Structure of truncated conotoxin CIC
2MRN	;		;	Structure of truncated EcMazE
2MRU	;		;	Structure of truncated EcMazE-DNA complex
8JJV	;	1.23	;	Structure of truncated form of nanobody in complex with alpha-synuclein peptide
6TD7	;	1.75	;	Structure of truncated hemoglobin THB11 from Chlamydomonas reinhardtii
4ZGI	;	2.701	;	Structure of Truncated Human TIFA
2Z71	;	2.6	;	Structure of truncated mutant CYS1GLY of penicillin V acylase from bacillus sphaericus co-crystallized with penicillin V
5N8Q	;	2.0	;	Structure of truncated Norcoclaurine Synthase from Thalictrum flavum
5NON	;	1.85	;	Structure of truncated Norcoclaurine Synthase from Thalictrum flavum with product mimic
1NO1	;	2.4	;	Structure of truncated variant of B.subtilis SPP1 phage G39P helicase loader/inhibitor protein
1ZI7	;	2.5	;	Structure of truncated yeast oxysterol binding protein Osh4
7JIA	;		;	Structure of truncated zebrafish granulin AaE
7JIY	;		;	Structure of truncated zebrafish paragranulin
8GH2	;	3.66	;	Structure of Trypanosoma (MDH)4-(Pex5)2, close conformation
8GH3	;	3.53	;	Structure of Trypanosoma (MDH)4-(Pex5)2, distal conformation
8GGD	;	3.33	;	Structure of Trypanosoma (MDH)4-Pex5, close conformation
8GGH	;	3.29	;	Structure of Trypanosoma (MDH)4-PEX5, distal conformation
4N08	;	2.6	;	Structure of Trypanosoma brucei brucei adenosine kinase (apo)
4N09	;	2.6	;	Structure of Trypanosoma brucei brucei adenosine kinase in complex with adenosine and AMPPNP
1KV5	;	1.65	;	Structure of Trypanosoma brucei brucei TIM with the salt-bridge-forming residue Arg191 mutated to Ser
1IIH	;	2.2	;	STRUCTURE OF TRYPANOSOMA BRUCEI BRUCEI TRIOSEPHOSPHATE ISOMERASE COMPLEXED WITH 3-PHOSPHOGLYCERATE
1IIG	;	2.6	;	STRUCTURE OF TRYPANOSOMA BRUCEI BRUCEI TRIOSEPHOSPHATE ISOMERASE COMPLEXED WITH 3-PHOSPHONOPROPIONATE
1OEP	;	2.3	;	Structure of Trypanosoma brucei enolase reveals the inhibitory divalent metal site
2C7V	;	2.2	;	Structure of Trypanosoma brucei pteridine reductase (PTR1) in ternary complex with cofactor and the antifolate methotrexate
6FXS	;	2.01	;	Structure of Trypanosoma brucei type B ribose 5-phosphate isomerase
5KMX	;	2.452	;	Structure of Trypanosoma congolense Insect Stage Antigen
3W1A	;	1.42	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with 5-halogenated orotate derivatives
3W1R	;	1.58	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-3-045a
3W1T	;	1.68	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-3-095
3W1U	;	1.85	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-3-111
3W1X	;	1.45	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-3-121
3W22	;	1.98	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-3-125
3W23	;	1.48	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-3-131
3W2J	;	1.42	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-3-135
3W2K	;	1.54	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-3-165
3W2L	;	1.64	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-3-169
3W2M	;	1.58	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-3-183
3W2N	;	1.96	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-3-185
3W2U	;	2.25	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-3-193
3W3O	;	1.96	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-4-053
4JD4	;	1.51	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-4-065
3W70	;	2.6	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-4-095
3W71	;	1.68	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-4-097
3W72	;	1.55	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-4-107
3W73	;	1.78	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-4-129
3W74	;	1.9	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-4-139
3W75	;	1.47	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-4-149
3W76	;	1.58	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-4-189
4JDB	;	1.82	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-5-005
3W7G	;	1.55	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-5-013
3W7H	;	1.67	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-5-015
3W7I	;	1.69	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-5-055
3W7L	;	1.88	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-5-075
3W7C	;	1.75	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-5-077
3W7D	;	1.52	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-5-170
3W7E	;	1.56	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-5-179
3W7J	;	1.58	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-6-040
3W7K	;	1.61	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-6-066
3W83	;	2.8	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-6-097
3W84	;	1.93	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with MII-6-101
3W1Q	;	1.85	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with NL-2
3W87	;	1.43	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with SH-1-103
3W88	;	1.4	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with SH-1-200
3W86	;	1.5	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with SH-1-96
3W6Y	;	2.68	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with TT2-2-199
3W7M	;	2.4	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with TT2-3-063
3W85	;	2.0	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with TT2-3-139
3W7N	;	2.39	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with TT2-3-149
3W7O	;	1.68	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with TT2-3-165
3W7P	;	1.7	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with TT2-4-031
3W7Q	;	1.83	;	Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with TT2-5-127
6FXL	;	1.96	;	Structure of Trypanosoma cruzi type B ribose 5-phosphate isomerase (TcRpiB)
8GI0	;	3.5	;	Structure of Trypanosoma docking complex
6SY7	;	2.75	;	Structure of Trypanosome Brucei Phosphofructokinase in complex with AMP.
2JK6	;	2.95	;	Structure of Trypanothione Reductase from Leishmania infantum
1FG4	;	1.9	;	STRUCTURE OF TRYPAREDOXIN II
1RXP	;	1.7	;	STRUCTURE OF TRYPSIN (ORTHORHOMBIC) WITH 1-(4-TERT-BUTYLCARBAMOYL- PIPERAZINE-1-CARBONYL)-3-(3-GUANIDINO-PROPYL)-4-OXO-AZETIDINE-2-CARBOXYLIC ACID
5FXL	;	1.78	;	Structure of trypsin solved by MR from data collected by Direct Data Collection (DDC) using the ESRF RoboDiff goniometer
7A0N	;	4.3	;	Structure of TSC1 NTD and linker domain
4ZV4	;	3.504	;	Structure of Tse6 in complex with EF-Tu
4ZV0	;	1.401	;	Structure of Tse6 in complex with Tsi6
3RQ9	;	1.0	;	Structure of Tsi2, a Tse2-immunity protein from Pseudomonas aeruginosa
4ZUY	;	1.952	;	Structure of Tsi6 from Pseudomonas aeruginosa
7T7T	;	3.17	;	Structure of TSK/BRU1 bound to histone H3.1
5X7L	;	1.22	;	Structure of TsrD from Streptomyces laurentii
5M2Y	;	1.61	;	Structure of TssK C-terminal domain from E. coli T6SS
5M30	;	2.6	;	Structure of TssK from T6SS EAEC in complex with nanobody nb18
2E37	;	2.3	;	Structure of TT0471 protein from Thermus thermophilus
2EKP	;	1.15	;	Structure of TT0495 protein from Thermus thermophilus
2EKQ	;	1.8	;	Structure of TT0495 protein from Thermus thermophilus
1WP4	;	2.0	;	Structure of TT368 protein from Thermus Thermophilus HB8
7JXY	;	2.15	;	Structure of TTBK1 kinase domain in complex with Compound 18
7JXX	;	1.56	;	Structure of TTBK1 kinase domain in complex with Compound 3
5HXK	;	2.0	;	Structure of TTHA1265
1X7T	;	1.6	;	Structure of TTR R104H: a non-amyloidogenic variant with protective clinical effects
2YJM	;	1.84	;	Structure of TtrD from Archaeoglobus fulgidus
7AC5	;	2.26	;	Structure of Tubulin Darpin complex 1 collected by rotation serial crystallography on a COC membrane at a synchrotron source
7DON	;	1.8	;	Structure of tubulin H392D mutant from Odinarchaeota
6Y4M	;	3.34	;	Structure of Tubulin Tyrosine Ligase in Complex with Tb111
6Y4N	;	2.852	;	Structure of Tubulin Tyrosine Ligase in Complex with Tb116
3M89	;	2.0	;	Structure of TubZ-GTP-g-S
6OHM	;	1.895	;	Structure of tungstate bound human Phospholipase D2 catalytic domain
8BJW	;	2.39	;	Structure of Tupaia Paramyxovirus C protein
2FZ2	;	2.9	;	Structure of Turnip Yellow Mosaic Virus at 100 K
5GWL	;		;	Structure of two CCTG repeats
6T7C	;	4.0	;	Structure of two copies of human Sox11 transcription factor in complex with a nucleosome
1CKM	;	2.5	;	STRUCTURE OF TWO DIFFERENT CONFORMATIONS OF MRNA CAPPING ENZYME IN COMPLEX WITH GTP
1HJQ	;	2.55	;	Structure of two fungal beta-1,4-galactanases: searching for the basis for temperature and pH optimum.
1HJS	;	1.87	;	Structure of two fungal beta-1,4-galactanases: searching for the basis for temperature and pH optimum.
1HJU	;	2.15	;	Structure of two fungal beta-1,4-galactanases: searching for the basis for temperature and pH optimum.
6G0L	;	10.0	;	Structure of two molecules of the chromatin remodelling enzyme Chd1 bound to a nucleosome
6USJ	;	10.5	;	Structure of two nucleosomes bridged by human PARP2
5VXN	;	3.375	;	Structure of two RcsB dimers bound to two parallel DNAs.
5GWQ	;		;	Structure of two TTTA repeats
6BQI	;		;	Structure of two-domain translational regulator Yih1 reveals a possible mechanism of action
6U1L	;		;	Structure of two-domain translational regulator Yih1 reveals a possible mechanism of action
6U1O	;		;	Structure of two-domain translational regulator Yih1 reveals a possible mechanism of action
5F1Z	;	2.65	;	Structure of TYK2 with inhibitor 16: 3-azanyl-5-[(2~{S})-3-methylbutan-2-yl]-7-[1-methyl-5-(2-oxidanylpropan-2-yl)pyrazol-3-yl]-1~{H}-pyrazolo[4,3-c]pyridin-4-one
5F20	;	2.91	;	Structure of TYK2 with inhibitor 4: 3-azanyl-5-(2-methylphenyl)-7-(1-methylpyrazol-3-yl)-1~{H}-pyrazolo[4,3-c]pyridin-4-one
3PX3	;	1.8	;	Structure of TylM1 from Streptomyces fradiae H123A mutant in complex with SAH and dTDP-Quip3N
3PX2	;	1.65	;	Structure of TylM1 from Streptomyces fradiae H123N mutant in complex with SAH and dTDP-Quip3N
3K7O	;	2.0	;	Structure of type B ribose 5-phosphate isomerase from Trypanosoma cruzi
7UMQ	;	3.29	;	Structure of Type I Prion filaments from Gerstmann-Straussler-Scheinker disease
7SBA	;	2.9	;	Structure of type I-D Cascade bound to a dsDNA target
7SBB	;	3.1	;	Structure of type I-D Cascade bound to a ssRNA target
7UN5	;	3.13	;	Structure of Type II Prion filaments from Gerstmann-Straussler-Scheinker disease
6SBB	;	1.95	;	Structure of type II terpene cyclase MstE from Scytonema (apo)
6SBC	;	1.35	;	Structure of type II terpene cyclase MstE from Scytonema in complex with farnesyl dihydroxybenzoate
6SBD	;	1.4	;	Structure of type II terpene cyclase MstE_D109A from Scytonema in complex with merosterolic acid A (product)
6SBE	;	1.4	;	Structure of type II terpene cyclase MstE_D109N from Scytonema in complex with geranylgeranyl dihydroxybenzoate (substrate)
6SBG	;	2.3	;	Structure of type II terpene cyclase MstE_R337A from Scytonema in complex with geranylgeranyl dihydroxybenzoate (substrate)
6SBF	;	1.3	;	Structure of type II terpene cyclase MstE_Y157F from Scytonema (apo)
5HR4	;	2.5964	;	Structure of Type IIL restriction-modification enzyme MmeI in complex with DNA has implications for engineering of new specificities
1M3D	;	2.0	;	Structure of Type IV Collagen NC1 Domains
8GRA	;	2.8	;	Structure of Type VI secretion system cargo delivery vehicle Hcp-VgrG-PAAR
4K6L	;	2.393	;	Structure of Typhoid Toxin
2OOP	;		;	Structure of Tyr7-PYY in solution
5CE9	;	1.8	;	structure of tyrosinase from walnut (Juglans regia)
5HSJ	;	1.9	;	Structure of tyrosine decarboxylase complex with PLP at 1.9 Angstroms resolution
2QAD	;	3.3	;	Structure of tyrosine-sulfated 412d antibody complexed with HIV-1 YU2 gp120 and CD4
2TS1	;	2.3	;	STRUCTURE OF TYROSYL-T/RNA SYNTHETASE REFINED AT 2.3 ANGSTROMS RESOLUTION. INTERACTION OF THE ENZYME WITH THE TYROSYL ADENYLATE INTERMEDIATE
3TS1	;	2.7	;	STRUCTURE OF TYROSYL-T/RNA SYNTHETASE REFINED AT 2.3 ANGSTROMS RESOLUTION. INTERACTION OF THE ENZYME WITH THE TYROSYL ADENYLATE INTERMEDIATE
1TYD	;	2.5	;	STRUCTURE OF TYROSYL-TRNA SYNTHETASE REFINED AT 2.3 ANGSTROMS RESOLUTION. INTERACTION OF THE ENZYME WITH THE TYROSYL ADENYLATE INTERMEDIATE
6DJT	;	1.64	;	Structure of TYW1 with a lysine-pyruvate adduct bound
4GNX	;	2.8	;	Structure of U. maydis Replication protein A bound to ssDNA
5W0G	;	1.07	;	Structure of U2AF65 (U2AF2) RRM1 at 1.07 resolution
5W0H	;	1.11	;	Structure of U2AF65 (U2AF2) RRM2 at 1.11 Angstrom Resolution
4TU7	;	2.087	;	Structure of U2AF65 D231V variant with BrU5 DNA
3VAF	;	2.49	;	Structure of U2AF65 variant with BrU3 DNA
3VAG	;	2.19	;	Structure of U2AF65 variant with BrU3C2 DNA
3VAH	;	2.5	;	Structure of U2AF65 variant with BrU3C4 DNA
3VAI	;	2.2	;	Structure of U2AF65 variant with BrU3C5 DNA
3VAK	;	2.17	;	Structure of U2AF65 variant with BrU5 DNA
4TU8	;	1.918	;	STRUCTURE OF U2AF65 VARIANT WITH BRU5A6 DNA
3VAL	;	2.5	;	Structure of U2AF65 variant with BrU5C1 DNA
3VAM	;	2.4	;	Structure of U2AF65 variant with BrU5C2 DNA
3VAJ	;	1.9	;	Structure of U2AF65 variant with BrU5C6 DNA
4TU9	;	1.992	;	STRUCTURE OF U2AF65 VARIANT WITH BRU5G6 DNA
2G4B	;	2.5	;	Structure of U2AF65 variant with polyuridine tract
4J0W	;	1.7	;	Structure of U3-55K
7PX3	;	3.05	;	Structure of U5 snRNP assembly and recycling factor TSSC4 in complex with BRR2 and Jab1 domain of PRPF8
5L8E	;	2.3	;	Structure of UAF1
5D0K	;	2.65	;	Structure of UbE2D2:RNF165:Ub complex
5D0M	;	1.913	;	Structure of UbE2D2:RNF165:Ub complex
5A4P	;	2.1	;	Structure of UBE2Z provides functional insight into specificity in the FAT10 conjugation machinery
5TR4	;	2.2	;	Structure of Ubiquitin activating enzyme (Uba1) in complex with ubiquitin and TAK-243
2D5G	;	3.2	;	Structure of ubiquitin fold protein R767E mutant
3H1U	;	3.0	;	Structure of ubiquitin in complex with Cd ions
1UBQ	;	1.8	;	STRUCTURE OF UBIQUITIN REFINED AT 1.8 ANGSTROMS RESOLUTION
2OJR	;	2.6	;	Structure of ubiquitin solved by SAD using the Lanthanide-Binding Tag
1BT0	;	1.7	;	STRUCTURE OF UBIQUITIN-LIKE PROTEIN, RUB1
7ZF1	;	4.14	;	Structure of ubiquitinated FANCI in complex with FANCD2 and double-stranded DNA
5LN1	;	3.14	;	STRUCTURE OF UBIQUITYLATED-RPN10 FROM YEAST;
4ZAY	;	1.54	;	Structure of UbiX E49Q in complex with a covalent adduct between dimethylallyl monophosphate and reduced FMN
4ZAG	;	1.68	;	Structure of UbiX E49Q mutant in complex with oxidised FMN and dimethylallyl monophosphate
4ZAL	;	1.62	;	Structure of UbiX E49Q mutant in complex with reduced FMN and dimethylallyl monophosphate
4ZAF	;	1.71	;	Structure of UbiX in complex with oxidised FMN and dimethylallyl monophosphate
4ZAX	;	1.61	;	Structure of UbiX in complex with oxidised prenylated FMN (radical)
4ZAW	;	1.89	;	Structure of UbiX in complex with reduced prenylated FMN
4ZAZ	;	1.45	;	Structure of UbiX Y169F in complex with a covalent adduct formed between reduced FMN and dimethylallyl monophosphate
4ZAN	;	1.76	;	Structure of UbiX Y169F in complex with oxidised FMN and dimethylallyl monophosphate
7ZM0	;	2.24	;	Structure of UCHL1 in complex with GK13S inhibitor
4R16	;	1.55	;	Structure of UDP-D-MAnNAc dehdrogeanse from Pyrococcus horikoshii
3KYB	;	2.3	;	Structure of UDP-galactopyranose mutase bound to flavin mononucleotide
3INR	;	2.3	;	Structure of UDP-galactopyranose mutase bound to UDP-galactose (oxidized)
3INT	;	2.51	;	Structure of UDP-galactopyranose mutase bound to UDP-galactose (reduced)
3GF4	;	2.45	;	Structure of UDP-galactopyranose mutase bound to UDP-glucose
5BR7	;	1.95	;	Structure of UDP-galactopyranose mutase from Corynebacterium diphtheriae in complex with citrate ion
1I8T	;	2.4	;	STRUCTURE OF UDP-GALACTOPYRANOSE MUTASE FROM E.COLI
1WAM	;	2.35	;	Structure of UDP-galactopyranose mutase from Klebsiella Pneumoniae with FADH-
3AW9	;	2.3	;	Structure of UDP-galactose 4-epimerase mutant
1UDA	;	1.8	;	STRUCTURE OF UDP-GALACTOSE-4-EPIMERASE COMPLEXED WITH UDP-4-DEOXY-4-FLUORO-ALPHA-D-GALACTOSE
1UDB	;	1.65	;	STRUCTURE OF UDP-GALACTOSE-4-EPIMERASE COMPLEXED WITH UDP-4-DEOXY-4-FLUORO-ALPHA-D-GLUCOSE
1UDC	;	1.65	;	STRUCTURE OF UDP-GALACTOSE-4-EPIMERASE COMPLEXED WITH UDP-MANNOSE
4TWR	;	1.9	;	Structure of UDP-glucose 4-epimerase from Brucella abortus
3TF5	;	2.3	;	Structure of UDP-glucose dehydrogenase V132 deletion
4R7U	;	2.45	;	Structure of UDP-N-acetylglucosamine 1-carboxyvinyltransferase from Vibrio cholerae in complex with substrate UDP-N-acetylglucosamine and the drug fosfomycin
4HWG	;	2.0	;	Structure of UDP-N-acetylglucosamine 2-epimerase from Rickettsia bellii
1UAE	;	1.8	;	STRUCTURE OF UDP-N-ACETYLGLUCOSAMINE ENOLPYRUVYL TRANSFERASE
7D27	;	2.48	;	Structure of UDP-N-acetylmuramoyl-L-alanyl-D-glutamate--2, 6-diaminopimelate ligase
4ZIY	;	1.85	;	Structure of UDP-N-acetylmuramoylalanyl-D-glutamyl-2,6-diaminopimelate--D-alanyl-D-alanyl ligase from Acinetobacter baumannii
3HBF	;	2.1	;	Structure of UGT78G1 complexed with myricetin and UDP
3HBJ	;	2.1	;	Structure of UGT78G1 complexed with UDP
3ASK	;	2.904	;	Structure of UHRF1 in complex with histone tail
3ASL	;	1.41	;	Structure of UHRF1 in complex with histone tail
3T6R	;	1.95	;	Structure of UHRF1 in complex with unmodified H3 N-terminal tail
3SOU	;	1.8001	;	Structure of UHRF1 PHD finger in complex with histone H3 1-9 peptide
3SOW	;	1.9501	;	Structure of UHRF1 PHD finger in complex with histone H3K4me3 1-9 peptide
3SOX	;	2.6501	;	Structure of UHRF1 PHD finger in the free form
5XPI	;	2.2	;	Structure of UHRF1 TTD in complex with NV01
4PW5	;	2.204	;	structure of UHRF2-SRA in complex with a 5hmC-containing DNA, complex I
4PW6	;	3.789	;	structure of UHRF2-SRA in complex with a 5hmC-containing DNA, complex II
4PW7	;	2.001	;	structure of UHRF2-SRA in complex with a 5mC-containing DNA
3D2U	;	2.21	;	Structure of UL18, a Peptide-Binding Viral MHC Mimic, Bound to a Host Inhibitory Receptor
3LUN	;	1.8	;	Structure of ulilysin mutant M290C
3LUM	;	1.7	;	Structure of ulilysin mutant M290L
2CKI	;	1.7	;	Structure of Ulilysin, a member of the pappalysin family of metzincin metalloendopeptidases.
4WNP	;	1.88	;	Structure of ULK1 bound to a potent inhibitor
5CI7	;	1.74	;	Structure of ULK1 bound to a selective inhibitor
4WNO	;	1.56	;	Structure of ULK1 bound to an inhibitor
6HYO	;	1.07	;	Structure of ULK1 LIR motif bound to GABARAP
6D2C	;	1.906	;	Structure of Ulvan lyase from Nonlaben Ulvanivorans- NLR48
2JI5	;	2.45	;	Structure of UMP kinase from Pyrococcus furiosus complexed with UTP
8GMT	;	3.31	;	Structure of UmuD in complex with RecA filament
5N2K	;	2.219	;	Structure of unbound Briakinumab FAb
5MXA	;	2.501	;	Structure of unbound Interleukin-23
4ZPW	;	3.023	;	Structure of unbound MERS-CoV spike receptor-binding domain (England1 strain).
7UMO	;	2.3	;	Structure of Unc119-inhibitor complex.
3FGX	;	2.9	;	Structure of uncharacterised protein rbstp2171 from bacillus stearothermophilus
3GNL	;	1.5	;	Structure of uncharacterized protein (LMOf2365_1472) from Listeria monocytogenes serotype 4b
2K52	;		;	Structure of uncharacterized protein MJ1198 from Methanocaldococcus jannaschii. Northeast Structural Genomics Target MjR117B
4OSX	;	1.95	;	STRUCTURE of UNCLEAVED GLYCINE-BOUND HUMAN L-ASPARAGINASE PROTEIN
7N6U	;	4.1	;	Structure of uncleaved HIV-1 JR-FL Env glycoprotein trimer in state U1 bound to small Molecule HIV-1 Entry Inhibitor BMS-378806
7N6W	;	4.7	;	Structure of uncleaved HIV-1 JR-FL Env glycoprotein trimer in state U2 bound to small Molecule HIV-1 Entry Inhibitor BMS-378806
1CLE	;	2.0	;	STRUCTURE OF UNCOMPLEXED AND LINOLEATE-BOUND CANDIDA CYLINDRACEA CHOLESTEROL ESTERASE
1W0N	;	0.8	;	Structure of uncomplexed Carbohydrate Binding Domain CBM36
1UCB	;	2.5	;	STRUCTURE OF UNCOMPLEXED FAB COMPARED TO COMPLEX (1CLY, 1CLZ)
3QAS	;	1.7	;	Structure of Undecaprenyl Diphosphate synthase
5OON	;	2.6	;	Structure of Undecaprenyl-Pyrophosphate Phosphatase, BacA
2MD5	;		;	Structure of uninhibited ETV6 ETS domain
6HCD	;	1.9	;	Structure of universal stress protein from Archaeoglobus fulgidus
6K9F	;	3.7	;	Structure of unknow protein 4
4FKM	;	2.2	;	Structure of unliganded and reductively methylated FhuD2 from staphylococcus aureus
5UKP	;	2.0	;	Structure of unliganded anti-gp120 CD4bs antibody DH522.1 Fab
5UKQ	;	2.1	;	Structure of unliganded anti-gp120 CD4bs antibody DH522.2 Fab
5UKR	;	2.712	;	Structure of unliganded anti-gp120 CD4bs antibody DH522.2 Fab in complex with a gp120 core
5UKO	;	2.3	;	Structure of unliganded anti-gp120 CD4bs antibody DH522IA Fab
5UKN	;	1.75	;	Structure of unliganded anti-gp120 CD4bs antibody DH522UCA Fab
2VLB	;	1.92	;	Structure of unliganded arylmalonate decarboxylase
4MBX	;	1.92	;	Structure of unliganded B-Lymphotropic Polyomavirus VP1
4FNA	;	3.5	;	Structure of unliganded FhuD2 from Staphylococcus Aureus
2G69	;	1.35	;	Structure of Unliganded HIV-1 Protease F53L Mutant
6N8W	;	3.09228	;	Structure of Unliganded Hsp90-Beta N-Terminal Domain
2C36	;	2.11	;	Structure of unliganded HSV gD reveals a mechanism for receptor- mediated activation of virus entry
2C3A	;	2.5	;	Structure of unliganded HSV gD reveals a mechanism for receptor- mediated activation of virus entry
4A0D	;	1.75	;	Structure of unliganded human PARG catalytic domain
4B1G	;	1.83	;	Structure of unliganded human PARG catalytic domain
5QUK	;	1.16	;	Structure of unliganded HumRadA1.2
5QUL	;	1.278	;	Structure of unliganded HumRadA1.3
5QUM	;	1.93	;	Structure of unliganded HumRadA1.4
5QUN	;	1.24	;	Structure of unliganded HumRadA1.6
4TZI	;	2.1	;	Structure of unliganded Lyn SH2 domain
6ZPX	;	1.3	;	Structure of Unliganded MgGH51 a-L-Arabinofuranosidase Crystal Type 1
6ZPW	;	1.329	;	Structure of Unliganded MgGH51 a-L-Arabinofuranosidase Crystal Type 2
6ZPV	;	1.2	;	Structure of Unliganded MgGH51 a-L-Arabinofuranosidase Crystal Type 3
6ZPS	;	1.795	;	Structure of Unliganded MgGH51 a-L-Arabinofuranosidase Crystal Type 3 Collected at 2.75 A
5FHG	;	2.0	;	Structure of unliganded Pif1 from Bacteroides sp
5DQJ	;	2.61	;	Structure of unliganded S55-5 Fab
4OFZ	;	3.0	;	Structure of unliganded trehalose-6-phosphate phosphatase from Brugia malayi
6UEV	;	2.7	;	Structure of unliganded tRNA (guanine-N1)-methyltransferase found in Anaplasma phagocytophilum
4POQ	;	2.0	;	Structure of unliganded VP1 pentamer of Human Polyomavirus 9
6VG3	;	1.95	;	Structure of unliganded, inactive PTK7 kinase domain
4GT4	;	2.406	;	Structure of unliganded, inactive Ror2 kinase domain
6UGG	;	1.95	;	Structure of unmodified E. coli tRNA(Asp)
4B09	;	3.3	;	Structure of unphosphorylated BaeR dimer
1Y57	;	1.91	;	Structure of unphosphorylated c-Src in complex with an inhibitor
1OL6	;	3.0	;	Structure of unphosphorylated D274N mutant of Aurora-A
1DCK	;	2.0	;	STRUCTURE OF UNPHOSPHORYLATED FIXJ-N COMPLEXED WITH MN2+
1DCM	;	3.0	;	STRUCTURE OF UNPHOSPHORYLATED FIXJ-N WITH AN ATYPICAL CONFORMER (MONOMER A)
6W3K	;	2.08	;	Structure of unphosphorylated human IRE1 bound to G-9807
6W39	;	1.736	;	Structure of unphosphorylated IRE1 in complex with G-1749
6W3A	;	2.606	;	Structure of unphosphorylated IRE1 in complex with G-7658
3Q4Z	;	1.887	;	Structure of unphosphorylated PAK1 kinase domain
7T3X	;	3.53	;	Structure of unphosphorylated Pediculus humanus (Ph) PINK1 D334A mutant
1YVL	;	3.0	;	Structure of Unphosphorylated STAT1
1Y1U	;	3.21	;	Structure of unphosphorylated STAT5a
6YKP	;	2.98	;	Structure of unplugged C. jejuni MotAB
2YCG	;	1.81	;	Structure of unreduced ferric cytochrome c peroxidase obtained by multicrystal method
5XNM	;	3.2	;	Structure of unstacked C2S2M2-type PSII-LHCII supercomplex from Pisum sativum
4ZGB	;	2.3	;	Structure of untreated lipase from Thermomyces lanuginosa at 2.3 A resolution
4YOE	;	1.92	;	Structure of UP1 bound to RNA 5'-AGU-3'
2IVN	;	1.65	;	Structure of UP1 protein
2IVO	;	2.9	;	Structure of UP1 protein
2IVP	;	2.5	;	Structure of UP1 protein
8RZV	;	1.51	;	Structure of UP1 S4ES6E phosphomimetic mutant in complex with human telomeric repeat DNA
2UP1	;	2.1	;	STRUCTURE OF UP1-TELOMERIC DNA COMPLEX
7KON	;	8.1	;	Structure of upper Tn Ca2+ free (rotated) and lower Tn Ca2+ bound cardiac native thin filament at pCa=5.8
2EHJ	;	2.8	;	Structure of Uracil phosphoribosyl transferase
4S1K	;	2.2	;	Structure of Uranotaenia sapphirina cypovirus (CPV17) polyhedrin at 100 K
4S1L	;	1.752	;	Structure of Uranotaenia sapphirina cypovirus (CPV17) polyhedrin at 298 K
6A4M	;	2.6	;	Structure of urate oxidase from Bacillus subtilis 168
5FRC	;	1.443	;	Structure of urate oxidase prepared by the 'soak-and-freeze' method under 42 bar of oxygen pressure
1GMU	;	1.5	;	Structure of UreE
1GMV	;	2.8	;	Structure of UreE
1GMW	;	1.5	;	Structure of UreE
5L9N	;	1.901	;	Structure of uridylylated GlnB from Escherichia coli bound to ATP
6K5Z	;	2.33	;	Structure of uridylyltransferase
6K9Z	;	1.78	;	STRUCTURE OF URIDYLYLTRANSFERASE MUTANT
2A3J	;		;	Structure of URNdesign, a complete computational redesign of human U1A protein
7JFZ	;	1.7	;	Structure of Urocanate hydratase from Legionella pneumophila bound to NAD
6UEK	;	2.16	;	Structure of Urocanate Hydratase from Trypanosoma cruzi in complex with NAD+
3BT1	;	2.8	;	Structure of urokinase receptor, urokinase and vitronectin complex
3BT2	;	2.5	;	Structure of urokinase receptor, urokinase and vitronectin complex
4ZR8	;	1.5	;	Structure of uroporphyrinogen decarboxylase from Acinetobacter baumannii
1JR2	;	1.84	;	Structure of Uroporphyrinogen III Synthase
6L8K	;	2.999	;	Structure of URT1 in complex with UTP
7RKX	;	3.1	;	Structure of US27-Gi-scFv16 in CL-state
7X2E	;	1.85	;	Structure of USH1C PDZ2 and coiled-coil in complex with CDHR2 C-terminal tail
5L8W	;	2.79	;	Structure of USP12-UB-PRG/UAF1
2AYO	;	3.5	;	Structure of USP14 bound to ubquitin aldehyde
2AYN	;	3.2	;	Structure of USP14, a proteasome-associated deubiquitinating enzyme
7W37	;	3.0	;	Structure of USP14-bound human 26S proteasome in state EA1_UBL
7W38	;	3.1	;	Structure of USP14-bound human 26S proteasome in state EA2.0_UBL
7W39	;	3.2	;	Structure of USP14-bound human 26S proteasome in state EA2.1_UBL
7W3C	;	3.4	;	Structure of USP14-bound human 26S proteasome in substrate-engaged state ED0_USP14
7W3F	;	3.3	;	Structure of USP14-bound human 26S proteasome in substrate-engaged state ED1_USP14
7W3G	;	3.2	;	Structure of USP14-bound human 26S proteasome in substrate-engaged state ED2.0_USP14
7W3H	;	3.2	;	Structure of USP14-bound human 26S proteasome in substrate-engaged state ED2.1_USP14
7W3A	;	3.5	;	Structure of USP14-bound human 26S proteasome in substrate-engaged state ED4_USP14
7W3B	;	3.6	;	Structure of USP14-bound human 26S proteasome in substrate-engaged state ED5_USP14
7W3I	;	3.5	;	Structure of USP14-bound human 26S proteasome in substrate-inhibited state SB_USP14
7W3J	;	3.5	;	Structure of USP14-bound human 26S proteasome in substrate-inhibited state SC_USP14
7W3K	;	3.6	;	Structure of USP14-bound human 26S proteasome in substrate-inhibited state SD4_USP14
7W3M	;	3.5	;	Structure of USP14-bound human 26S proteasome in substrate-inhibited state SD5_USP14
4A3P	;	1.4	;	Structure of USP15 DUSP-UBL deletion mutant
2Y5B	;	2.7	;	Structure of USP21 in complex with linear diubiquitin-aldehyde
8BS3	;	2.2	;	Structure of USP36 in complex with Fubi-PA
8BS9	;	1.9	;	Structure of USP36 in complex with Ubiquitin-PA
5L8H	;	1.85	;	Structure of USP46-UbVME
7MS6	;	1.55	;	Structure of USP5 zinc-finger ubiquitin binding domain co-crystallized with (2-fluoro-4-((4-phenylpiperidin-1-yl)sulfonyl)benzoyl)glycine
6NFT	;	1.65	;	Structure of USP5 zinc-finger ubiquitin binding domain co-crystallized with (4-oxoquinazolin-3(4H)-yl)acetic acid
7MS7	;	1.45	;	Structure of USP5 zinc-finger ubiquitin binding domain co-crystallized with (5-((4-(4-chlorophenyl)piperidin-1-yl)sulfonyl)picolinoyl)glycine
6P9G	;	2.1	;	Structure of USP5 zinc-finger ubiquitin binding domain co-crystallized with 2-(4-oxoquinazolin-3(4H)-yl)propanoic acid
6DXT	;	1.95	;	Structure of USP5 zinc-finger ubiquitin binding domain co-crystallized with 3-(5-phenyl-1,3,4-oxadiazol-2-yl)propanoate
7MS5	;	1.98	;	Structure of USP5 zinc-finger ubiquitin binding domain co-crystallized with 4-(4-(4-(3,4-difluoro-phenyl)-piperidin-1-ylsulfonyl)-phenyl)-4-oxo-butanoic acid
6DXH	;	2.0	;	Structure of USP5 zinc-finger ubiquitin binding domain co-crystallized with 4-(4-tert-butylphenyl)-4-oxobutanoate
5FWI	;	3.4	;	structure of usp7 catalytic domain and three ubl-domains
4YSI	;	1.02	;	Structure of USP7 with a novel viral protein
7EEV	;	2.15	;	Structure of UTP cyclohydrolase
5IC8	;	3.3	;	Structure of UTP6
6UXF	;	1.65	;	Structure of V. metoecus NucC, hexamer form
6UXG	;	2.15	;	Structure of V. metoecus NucC, trimer form
2QMH	;	2.6	;	structure of V267F mutant HprK/P
7SOJ	;	1.85	;	Structure of V750A Soybean Lipoxygenase at 277K
2O8L	;	1.5	;	Structure of V8 protease from staphylococcus aureus
5TKJ	;	2.118	;	Structure of vaccine-elicited diverse HIV-1 neutralizing antibody vFP1.01 in complex with HIV-1 fusion peptide residue 512-519
6CDO	;	2.099	;	Structure of vaccine-elicited HIV-1 neutralizing antibody vFP16.02 in complex with HIV-1 fusion peptide residue 512-519
6CDM	;	2.408	;	Structure of vaccine-elicited HIV-1 neutralizing antibody vFP7.04 in complex with HIV-1 fusion peptide residue 512-519
2JII	;	2.0	;	Structure of vaccinia related kinase 3
3VOP	;	2.2	;	Structure of Vaccinia virus A27
2YGB	;	2.81	;	Structure of vaccinia virus D13 scaffolding protein
2YGC	;	3.02	;	Structure of vaccinia virus D13 scaffolding protein
6B9J	;	2.9	;	Structure of vaccinia virus D8 protein bound to human Fab vv138
5USL	;	2.9	;	Structure of vaccinia virus D8 protein bound to human Fab vv304
5USH	;	2.3	;	Structure of vaccinia virus D8 protein bound to human Fab vv66
6RIE	;	3.1	;	Structure of Vaccinia Virus DNA-dependent RNA polymerase co-transcriptional capping complex
6RID	;	2.9	;	Structure of Vaccinia Virus DNA-dependent RNA polymerase elongation complex
2VVW	;	1.9	;	Structure of Vaccinia virus protein A52
2VVX	;	2.746	;	Structure of Vaccinia virus protein A52
2VVY	;	2.693	;	Structure of Vaccinia virus protein B14
2J87	;	3.1	;	Structure of vaccinia virus thymidine kinase in complex with dTTP: insights for drug design
2V62	;	1.7	;	Structure of vaccinia-related kinase 2
2A22	;	2.198	;	Structure of Vacuolar Protein Sorting 29 from Cryptosporidium Parvum
6EA6	;	1.703	;	Structure of VACV poxin 2'3' cGAMP-specific nuclease
6EA9	;	2.1	;	Structure of VACV Poxin in post-reactive state with Gp[2'-5']Ap[3']
6EA8	;	2.6	;	Structure of VACV poxin in pre-reactive state with nonhydrolyzable 2'3' cGAMP
5ZHF	;	1.65	;	Structure of VanYB unbound
6SD6	;	2.61	;	Structure of VapBC from Shigella sonnei
7FAP	;	3.4	;	Structure of VAR2CSA-CSA 3D7
1VZV	;	3.0	;	STRUCTURE OF VARICELLA-ZOSTER VIRUS PROTEASE
2H7F	;	2.7	;	Structure of variola topoisomerase covalently bound to DNA
2H7G	;	1.9	;	Structure of variola topoisomerase non-covalently bound to DNA
4IF8	;	2.08	;	Structure Of Vaspin
4Y40	;	2.2	;	Structure of Vaspin mutant D305C V383C
4Y3K	;	2.2	;	Structure of Vaspin mutant E379S
5GZS	;	2.601	;	Structure of VC protein
4PD7	;	2.909	;	Structure of vcCNT bound to zebularine
4PB2	;	2.302	;	Structure of vcCNT-7C8C bound to 5-fluorouridine
4PD9	;	3.096	;	Structure of vcCNT-7C8C bound to adenosine
4PDA	;	2.608	;	Structure of vcCNT-7C8C bound to cytidine
4PD8	;	2.75	;	Structure of vcCNT-7C8C bound to pyrrolo-cytidine
4PB1	;	2.803	;	Structure of vcCNT-7C8C bound to ribavirin
6OKZ	;	3.292	;	Structure of VcINDY bound to Fumarate
6OL0	;	3.502	;	Structure of VcINDY bound to Malate
6OL1	;	3.088	;	Structure of VcINDY in complex with Succinate
6WTX	;	3.92	;	Structure of VcINDY in complex with terephthalate
7T9F	;	3.23	;	Structure of VcINDY-apo
7T9G	;	2.83	;	Structure of VcINDY-Na+
6WU3	;	3.16	;	Structure of VcINDY-Na+ in amphipol
6WW5	;	3.15	;	Structure of VcINDY-Na-Fab84 in nanodisc
7K56	;	3.9	;	Structure of VCP dodecamer purified from H1299 cells
7XJN	;	1.79	;	Structure of VcPotD1 in complex with norspermidine
7XJM	;	1.755	;	Structure of VcPotD1 in complex with spermidine
6U3Z	;	1.99002	;	Structure of VD20_5A4 Fab
2QR0	;	3.5	;	Structure of VEGF complexed to a Fab containing TYR and SER in the CDRs
3C7Q	;	2.1	;	Structure of VEGFR2 kinase domain in complex with BIBF1120
7FFF	;	3.0	;	Structure of Venezuelan equine encephalitis virus with the receptor LDLRAD3
7UMK	;	4.1	;	Structure of vesicular stomatitis virus (helical reconstruction, 4.1 A resolution)
7UML	;	3.5	;	Structure of vesicular stomatitis virus (local reconstruction, 3.5 A resolution)
7Q5P	;	3.3	;	Structure of VgrG1 from Pseudomonas protegens.
6H3L	;	4.2	;	Structure of VgrG1 in the Type VI secretion ""pre-firing"" VgrG1-Tse6-EagT6-EF-Tu-Tsi6 complex
6H3N	;	3.25	;	Structure of VgrG1 in the Type VI secretion VgrG1-Tse6-EF-Tu complex embedded in lipid nanodiscs
6DYX	;	1.5	;	Structure of VHH R419 isolated from a pre-immune phage display library
8T6I	;	2.55	;	Structure of VHH-Fab complex with engineered Crystal Kappa region
8T9Y	;	2.52	;	Structure of VHH-Fab complex with engineered Elbow FNQIKG and Crystal Kappa regions
8T8I	;	2.52	;	Structure of VHH-Fab complex with engineered Elbow FNQIKG, Crystal Kappa and SER substitutions
8T58	;	2.23	;	Structure of VHH-Fab complex with engineered FNQIKG elbow region
4WQO	;	3.2	;	Structure of VHL-EloB-EloC-Cul2
4ERC	;	1.15	;	Structure of VHZ bound to metavanadate
4BEU	;	1.15	;	Structure of Vibrio cholerae broad spectrum racemase
4BEQ	;	1.5	;	Structure of Vibrio cholerae broad spectrum racemase double mutant R173A, N174A
4NZ5	;	1.874	;	Structure of Vibrio cholerae chitin de-N-acetylase in complex with 2-(ACETYLAMINO)-2-DEOXY-A-D-GLUCOPYRANOSE (NDG) and cadmium ion
4NZ4	;	1.944	;	Structure of Vibrio cholerae chitin de-N-acetylase in complex with 2-(ACETYLAMINO)-2-DEOXY-A-D-GLUCOPYRANOSE (NDG) and zinc ion
4NYU	;	2.03	;	Structure of Vibrio cholerae chitin de-N-acetylase in complex with acetate ion (ACT) in C 2 2 21
4NYY	;	2.65	;	Structure of Vibrio cholerae chitin de-N-acetylase in complex with acetate ion (ACT) in P 2 21 21
4NY2	;	1.879	;	Structure of Vibrio cholerae chitin de-N-acetylase in complex with acetate ion (ACT) in P 21
4NZ1	;	2.051	;	Structure of Vibrio cholerae chitin de-N-acetylase in complex with DI(N-ACETYL-D-GLUCOSAMINE) (CBS) in P 21
4NZ3	;	2.114	;	Structure of Vibrio cholerae chitin de-N-acetylase in complex with DI(N-ACETYL-D-GLUCOSAMINE) (CBS) in P 21 21 21
4OUI	;	2.17	;	Structure of Vibrio cholerae chitin de-N-acetylase in complex with TRIACETYLCHITOTRIOSE (CTO)
4LK4	;	2.4	;	Structure of Vibrio cholerae VesB protease
2NYQ	;	2.5	;	Structure of Vibrio proteolyticus aminopeptidase with a bound Trp fragment of dLWCF
5YJS	;	2.16	;	Structure of vicilin from Capsicum annuum
3W3E	;	1.5	;	Structure of Vigna unguiculata chitinase with regulation activity of the plant cell wall
2D98	;	2.0	;	Structure of VIL (extra KI/I2 added)-xylanase
2D8O	;	2.38	;	Structure of VIL-thaumatin
2D97	;	2.01	;	Structure of VIL-xylanase
6V1P	;	1.2	;	Structure of VIM-2 bound to QPX7728 at 1.20 A
7A5Z	;	1.29	;	Structure of VIM-2 metallo-beta-lactamase with hydrolysed Faropenem imine product
6ZYO	;	1.45	;	Structure of VIM-2 with 2-Mercaptomethyl-thiazolidine D-syn-1b
6ZYN	;	1.40001	;	Structure of VIM-2 with 2-Mercaptomethyl-thiazolidine L-anti-1b
6OP6	;	1.25	;	Structure of VIM-20 in the reduced state
2GDC	;	2.74	;	Structure of Vinculin VD1 / IpaA560-633 complex
8K4R	;	2.3	;	Structure of VinM-VinL complex
6B4C	;	2.795	;	Structure of Viperin from Trichoderma virens
2CFA	;	2.3	;	Structure of viral flavin-dependant thymidylate synthase ThyX
1VLK	;	1.9	;	STRUCTURE OF VIRAL INTERLEUKIN-10
7EK6	;	1.243	;	Structure of viral peptides IPB19/N52
3AGP	;	2.8	;	Structure of viral polymerase form I
3AGQ	;	3.22	;	Structure of viral polymerase form II
7VCL	;	3.2	;	structure of viral protein BKRF4 in complex with H2A-H2B
7VCQ	;	3.0	;	structure of viral protein BKRF4 in complex with H3.3-H4-ASF1
3AVT	;	2.607	;	Structure of viral RNA polymerase complex 1
3AVU	;	2.907	;	Structure of viral RNA polymerase complex 2
3AVV	;	3.119	;	Structure of viral RNA polymerase complex 3
3AVW	;	2.602	;	Structure of viral RNA polymerase complex 4
3AVX	;	2.406	;	Structure of viral RNA polymerase complex 5
3AVY	;	2.616	;	Structure of viral RNA polymerase complex 6
4AG5	;	2.45	;	Structure of VirB4 of Thermoanaerobacter pseudethanolicus
4AG6	;	2.35	;	Structure of VirB4 of Thermoanaerobacter pseudethanolicus
6RJK	;	1.922	;	Structure of virulence factor SghA from Agrobacterium tumefaciens
5DYR	;	3.0	;	Structure of virulence-associated protein D (VapD) from Xylella fastidiosa
7PVB	;		;	Structure of Viscotoxin A3 from Viscum Album in the complex with DPC micelles
4R9U	;	2.785	;	Structure of vitamin B12 transporter BtuCD in a nucleotide-bound outward facing state
4FI3	;	3.466	;	Structure of vitamin B12 transporter BtuCD-F in a nucleotide-bound state
8IYE	;	1.9	;	Structure of VldE-D158N in complex with GDP
8IYF	;	1.9	;	Structure of VldE-H182A in complex with GDP
5E1J	;	3.308	;	Structure of voltage-gated two-pore channel TPC1 from Arabidopsis thaliana
3NPE	;	3.2	;	Structure of VP14 in complex with oxygen
8K44	;	3.8	;	Structure of VP9 in Banna virus
8GUG	;	2.85	;	Structure of VPA0770 toxin bound to VPA0769 antitoxin in Vibrio parahaemolyticus
5DFZ	;	4.4	;	Structure of Vps34 complex II from S. cerevisiae.
6HOH	;	2.25	;	Structure of VPS34 LIR motif (S249E) bound to GABARAP
6HOG	;	1.26	;	Structure of VPS34 LIR motif bound to GABARAP
5F0K	;	3.074	;	Structure of VPS35 N terminal region
7ZTY	;	2.89	;	Structure of Vps39 N-terminal domain from Chaetomium thermophilum
4LCB	;	2.08	;	Structure of Vps4 homolog from Acidianus hospitalis
7L9X	;	2.81	;	Structure of VPS4B in complex with an allele-specific covalent inhibitor
7TAN	;	3.0	;	Structure of VRK1 C-terminal tail bound to nucleosome core particle
8F0Q	;	2.5	;	Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the acylsulfonamide inhibitor GDC-0310
8F0R	;	2.9	;	Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the arylsulfonamide inhibitor GNE-3565
8F0P	;	2.2	;	Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the hybrid inhibitor GNE-1305
8F0S	;	3.1	;	Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the hybrid inhibitor GNE-9296
2G46	;		;	structure of vSET in complex with meK27 H3 Pept. and cofactor product SAH
5NB8	;	2.1	;	Structure of vWC domain from CCN3
6O66	;	2.452	;	Structure of VX-phosphonylated hAChE in complex with oxime reactivator RS-170B
6U37	;	2.25	;	Structure of VX-phosphonylated hAChE in complex with oxime reactivator RS194B
7JQJ	;	2.2	;	Structure of W45F Glyoxylate/Hydroxypyruvate reductase A from Escherichia Coli in complex with NADP+
3EKC	;	1.8	;	structure of W60V beta-2 microglobulin mutant
8S91	;	4.3	;	Structure of Walker B mutated MCM8/9 heterohexamer complex with ADP
5ODV	;	4.0	;	Structure of Watermelon mosaic virus potyvirus.
2GNQ	;	1.8	;	Structure of wdr5
3EG6	;	1.72	;	Structure of WDR5 bound to MLL1 peptide
7AXU	;	1.68	;	Structure of WDR5:CS-VIP8 cocrystal after illumination in situ
7AXX	;	1.79	;	Structure of WDR5:CS-VIP8 crystal after illumination at 405 nm and room temperature
7KVA	;	3.1	;	Structure of West Nile virus (Kunjin)
8CO8	;	1.91	;	Structure of West Nile Virus NS2B-NS3 protease
6OB1	;		;	Structure of WHB in complex with Ubiquitin Variant
8PXJ	;	2.75	;	Structure of Whitewater Arroyo virus GP1 glycoprotein, solved at wavelength 2.75 A
6EV4	;	1.14	;	Structure of wild type A. niger Fdc1 purified in the dark with prFMN in the iminium form
6EV3	;	1.3	;	Structure of wild type A. niger Fdc1 that has been illuminated with UV light, with prFMN in the iminium and ketimine form
5JZO	;	2.5	;	Structure of wild type amidase at high temperature at 2.5 Angstrom resolution
5JZM	;	1.87	;	Structure of wild type Amidase from Vibrio cholerae 0395 at low temparature at 1.8 Angstroms resolution.
7DVA	;	1.55	;	Structure of wild type Bt4394, a GH20 family sulfoglycosidase, in complex with 6S-GlcNAc
6JMY	;	1.661	;	Structure of wild type closed form of peptidoglycan peptidase
6KV1	;	1.722	;	Structure of wild type closed form of peptidoglycan peptidase ZN SAD
2GFW	;	2.4	;	Structure of wild type E. coli FabF (KASII)
2WNN	;	1.65	;	Structure of wild type E. coli N-acetylneuraminic acid lyase in complex with pyruvate in space group P21
2WO5	;	2.2	;	Structure of wild type E. coli N-acetylneuraminic acid lyase in space group P21 crystal form I
2YGY	;	1.9	;	Structure of wild type E. coli N-acetylneuraminic acid lyase in space group P21 crystal form II
7JQI	;	2.4	;	Structure of wild type Glyoxylate/Hydroxypyruvate reductase A from Escherichia Coli in complex with alpha-ketoglutarate and NADP+
7JQH	;	2.0	;	Structure of wild type Glyoxylate/Hydroxypyruvate reductase A from Escherichia Coli in complex with phosphate and NADP+
2QD5	;	2.3	;	Structure of wild type human ferrochelatase in complex with a lead-porphyrin compound
6E70	;	1.992	;	Structure of Wild Type Human Transthyretin in Complex with Diflunisal
6E6Z	;	1.75	;	Structure of Wild Type Human Transthyretin in Complex with Tafamidis
4O25	;	2.2	;	Structure of Wild Type Mus musculus Rheb bound to GTP
4BRS	;	1.6	;	Structure of wild type PhaZ7 PHB depolymerase
5UZT	;		;	Structure of wild type pre-miR21 apical loop
5UZZ	;		;	Structure of wild type pre-miR21 apical loop
4B7V	;	1.73	;	Structure of wild type Pseudomonas aeruginosa FabF (KASII)
4JPF	;	1.67	;	Structure of wild type Pseudomonas aeruginosa FabF (KASII) in Complex with ligand
4AH7	;	2.3	;	Structure of Wild Type Stapylococcus aureus N-acetylneuraminic acid lyase in complex with pyruvate
6IB7	;	2.245	;	Structure of wild type SuhB
2GOU	;	1.4	;	Structure of wild type, oxidized SYE1, an OYE homologue from S. oneidensis
1M5L	;		;	Structure of wild-type and mutant internal loops from the SL-1 domain of the HIV-1 packaging signal
8I4J	;	1.62	;	Structure of wild-type Azami Green from Galaxea fascicularis
6N21	;	2.04	;	Structure of wild-type CAO1
4C0B	;	2.77	;	Structure of wild-type Clp1p-Pcf11p (454 -563) complex
2PA7	;	1.5	;	Structure of Wild-Type dTDP-4-keto-6-deoxy-D-glucose-3,4-ketoisomerase from Aneurinibacillus thermoaerophilus in complex with TDP
1ZA1	;	2.2	;	Structure of wild-type E. coli Aspartate Transcarbamoylase in the presence of CTP at 2.20 A resolution
1ZA2	;	2.5	;	Structure of wild-type E. coli Aspartate Transcarbamoylase in the presence of CTP, carbamoyl phosphate at 2.50 A resolution
2H3E	;	2.3	;	Structure of wild-type E. coli Aspartate Transcarbamoylase in the presence of N-phosphonacetyl-L-isoasparagine at 2.3A resolution
4MQJ	;	1.8	;	Structure of Wild-type Fetal Human Hemoglobin HbF
4LL3	;	1.95	;	Structure of wild-type HIV protease in complex with darunavir
4U7V	;	1.38	;	Structure of wild-type HIV protease in complex with degraded photosensitive inhibitor
4U7Q	;	1.7	;	Structure of wild-type HIV protease in complex with photosensitive inhibitor PDI-6
5CHZ	;	1.83	;	Structure of wild-type human MBD4 bound to a G:T mismatch
7NGB	;	3.64	;	Structure of Wild-Type Human Potassium Chloride Transporter KCC3 in NaCl (LMNG/CHS)
4LLD	;	1.19	;	Structure of wild-type IgG1 antibody heavy chain constant domain 1 and light chain lambda constant domain (IgG1 CH1:Clambda) at 1.19A
6CME	;	1.92	;	Structure of wild-type ISL2-LID in complex with LHX4-LIM1+2
2V08	;	2.0	;	Structure of wild-type Phormidium laminosum cytochrome c6
7KPR	;	3.09	;	Structure of wild-type PPM1H phosphatase at 3.1 Angstrom resolution
7DR0	;	3.3	;	Structure of Wild-type PSI monomer1 from Cyanophora paradoxa
7DR1	;	3.2	;	Structure of Wild-type PSI monomer2 from Cyanophora paradoxa
1EY0	;	1.6	;	STRUCTURE OF WILD-TYPE S. NUCLEASE AT 1.6 A RESOLUTION
1EYD	;	1.7	;	STRUCTURE OF WILD-TYPE S. NUCLEASE AT 1.7 A RESOLUTION
7JP1	;	1.8	;	Structure of wild-type substrate free SARS-CoV-2 Mpro.
3TCT	;	1.3	;	Structure of wild-type TTR in complex with tafamidis
1XTI	;	1.95	;	Structure of Wildtype human UAP56
4C3L	;	1.6	;	Structure of wildtype PII from S. elongatus at high resolution
4C3M	;	2.149	;	Structure of wildtype PII from S. elongatus at medium resolution
5O25	;	1.75	;	Structure of wildtype T.maritima PDE (TM1595) in ligand-free state
5O1U	;	1.9	;	Structure of wildtype T.maritima PDE (TM1595) with AMP and Mn2+
2C0F	;	2.28	;	Structure of Wind Y53F mutant
7UOS	;	2.9	;	Structure of WNK1 inhibitor complex
1M1S	;	1.8	;	Structure of WR4, a C.elegans MSP family member
1ZWK	;	2.6	;	Structure of WrbA from Pseudomonas aeruginosa
1ZWL	;	2.8	;	Structure of WrbA from Pseudomonas aeruginosa in complex with FMN
7Q6N	;	2.33	;	Structure of WrbA from Salmonella Typhimurium bound to ME0052
7Q6O	;	1.99	;	Structure of WrbA from Yersinia pseudotuberculosis in C2221
7Q6M	;	2.04	;	Structure of WrbA from Yersinia pseudotuberculosis in P1
3AAF	;	1.9	;	Structure of WRN RQC domain bound to double-stranded DNA
2X0F	;	2.55	;	Structure of WsaF in complex with dTDP-beta-L-Rha
7XYJ	;	2.275	;	Structure of WSSV thymidylate synthase in complex with dUMP
7XYK	;	1.433	;	Structure of WSSV thymidylate synthase in complex with dUMP and raltitrexed
8G6W	;	2.02	;	Structure of WT E.coli 70S ribosome complexed with mRNA, P-site fMet-NH-tRNAfMet and A-site ortho-aminobenzoic acid charged NH-tRNAPhe
8G6Y	;	2.09	;	Structure of WT E.coli ribosome 50S subunit with complexed with mRNA, P-site fMet-NH-tRNAfMet and A-site 3-aminopyridine-4-carboxylic acid charged NH-tRNAPhe
8G6X	;	2.31	;	Structure of WT E.coli ribosome 50S subunit with complexed with mRNA, P-site fMet-NH-tRNAfMet and A-site meta-aminobenzoic acid charged NH-tRNAPhe
8FN7	;	2.8	;	Structure of WT HIV-1 intasome bound to Dolutegravir
5DJM	;	1.9	;	Structure of WT Human Glutathione Transferase in complex with cisplatin in the absence of glutathione.
5DJL	;	1.8	;	Structure of WT Human Glutathione Transferase in complex with cisplatin in the presence of glutathione.
7KMU	;	1.51	;	Structure of WT Malaysian Banana Lectin
5AK7	;	1.46	;	Structure of wt Porphyromonas gingivalis peptidylarginine deiminase
6NJA	;	1.92	;	Structure of WT RET protein tyrosine kinase domain at 1.92A resolution.
7YG4	;	3.1	;	Structure of WTAP-VIRMA in the m6A writer complex
4L29	;	3.09	;	Structure of wtMHC class I with NY-ESO1 double mutant
5D73	;	2.33	;	Structure of Wuchereria bancrofti pi-class glutathione S-transferase
5TJQ	;	2.75	;	Structure of WWP2 2,3-linker-HECT
5TJ8	;	2.3	;	Structure of WWP2 WW2-2,3-linker-HECT (no WW2 observed)
5TJ7	;	2.6	;	Structure of WWP2 WW2-2,3-linker-HECT aa 334-398 linked to 485-865
4WL1	;	5.989	;	Structure of WzzE Polysaccharide Co-polymerase
3B8O	;	2.4	;	Structure of WzzE- Bacterial Polysaccharide Co-polymerase
6NFF	;	2.0	;	Structure of X-prolyl dipeptidyl aminopeptidase from Lactobacillus helveticus
3K89	;	1.6	;	Structure of X. oryzae pv. oryzae KACC10331, Xoo0880(fabD) complexed with glycerol
8GP5	;	4.05	;	Structure of X18 UFO protomer in complex with F6 Fab VHVL domain
2RH6	;	1.45	;	Structure of Xac NPP for evaluation of refinement methodology
2GSN	;	1.75	;	Structure of Xac Nucleotide Pyrophosphatase/Phosphodiesterase
2GSU	;	2.0	;	Structure of Xac Nucleotide Pyrophosphatase/Phosphodiesterase in Complex with AMP
2GSO	;	1.3	;	Structure of Xac Nucleotide Pyrophosphatase/Phosphodiesterase in Complex with Vanadate
5HPC	;	2.6	;	Structure of XacCel5A crystallized in the space group P41212
3B9J	;	2.3	;	Structure of Xanthine Oxidase with 2-hydroxy-6-methylpurine
5JP1	;	2.1	;	Structure of Xanthomonas campestris effector protein XopD bound to tomato SUMO
5JP3	;	2.9	;	Structure of Xanthomonas campestris effector protein XopD bound to ubiquitin
6R5Q	;	3.0	;	Structure of XBP1u-paused ribosome nascent chain complex (post-state)
6R6P	;	3.1	;	Structure of XBP1u-paused ribosome nascent chain complex (rotated state)
6R7Q	;	3.9	;	Structure of XBP1u-paused ribosome nascent chain complex with Sec61.
6R6G	;	3.7	;	Structure of XBP1u-paused ribosome nascent chain complex with SRP.
5NGI	;	2.98	;	Structure of XcpQN012
5N1U	;	2.976	;	Structure of xEco2 acetyltransferase domain
5N1W	;	2.3	;	Structure of xEco2 acetyltransferase domain bound to K105-CoA conjugate
5N22	;	1.99	;	Structure of xEco2 acetyltransferase domain bound to K106-CoA conjugate
4AB4	;	1.5	;	Structure of Xenobiotic Reductase B from Pseudomonas putida in complex with TNT
4AEO	;	1.7	;	Structure of Xenobiotic Reductase B from Pseudomonas putida in complex with TNT
7SXM	;	2.503	;	Structure of Xenon-derivatized Methyl-Coenzyme M Reductase from Methanothermobacter marburgensis
8ERO	;	3.2	;	Structure of Xenopus cholinephosphotransferase1 in complex with CDP
8ERP	;	3.7	;	Structure of Xenopus cholinephosphotransferase1 in complex with CDP-choline
7TCP	;	3.84	;	Structure of Xenopus KCNQ1-CaM
7TCI	;	3.9	;	Structure of Xenopus KCNQ1-CaM in complex with ML277
7SHK	;	3.1	;	Structure of Xenopus laevis CRL2Lrr1 (State 1)
7SHL	;	3.5	;	Structure of Xenopus laevis CRL2Lrr1 (State 2)
6LK8	;	5.5	;	Structure of Xenopus laevis Cytoplasmic Ring subunit.
7VCI	;	8.1	;	Structure of Xenopus laevis NPC nuclear ring asymmetric unit
6GJW	;	1.9	;	Structure of XIAP-BIR1 domain in complex with an NF023 analog
4MTZ	;	2.1	;	Structure of XIAP-BIR1 in complex with NF023
6QCI	;	2.3	;	Structure of XIAP-BIR1 V86E mutant
4KMP	;	1.95	;	Structure of XIAP-BIR3 and inhibitor
7KXI	;		;	Structure of XL5-ligated hRpn13 Pru domain
5CVK	;	2.1	;	Structure of Xoo1075, a peptide deformyase from Xanthomonas oryzae pv. oryze, in complex with fragment 493
5CVQ	;	2.5	;	Structure of Xoo1075, a peptide deformylase from Xanthomonas oryzae pv oryzae, in complex with actinonin
5CXJ	;	2.38	;	Structure of Xoo1075, a peptide deformylase from Xanthomonas oryzae pv oryzae, in complex with fragment 124
5CWX	;	2.2	;	Structure of Xoo1075, a peptide deformylase from Xanthomonas oryzae pv oryzae, in complex with fragment 134
5CY8	;	2.38	;	Structure of Xoo1075, a peptide deformylase from Xanthomonas oryzae pv oryze, in complex with fragment 244
5CVP	;	2.0	;	Structure of Xoo1075, a peptide deformylase from Xanthomonas oryzae pv oryze, in complex with fragment 571
5CX0	;	2.5	;	Structure of Xoo1075, a peptide deformylase from Xanthomonas oryzae pv. oryzae, in complex with fragment 322
5CWY	;	2.4	;	Structure of Xoo1075, a peptide deformylase from Xanthomonas oryze pv oryzae, in complex with fragment 83
5CY7	;	2.4	;	Structure of Xoo1075, a peptide deformylase from Xanthomonas oryze pv oryze, in complex with fragment 275
2VSF	;	2.9	;	Structure of XPD from Thermoplasma acidophilum
4EI6	;	1.6	;	Structure of XV19 Valpha1-Vbeta16 Type-II Natural Killer T cell receptor
4FE7	;	2.9	;	structure of xylose-binding transcription activator xylR
7NL2	;	1.8	;	Structure of Xyn11 from Pseudothermotoga thermarum
5CM2	;	2.5	;	Structure of Y. lipolytica Trm9-Trm112 complex, a methyltransferase modifying U34 in the anticodon loop of some tRNAs
2B2K	;	1.97	;	structure of Y104F IDI-1 mutant in complex with EIPP
4BVJ	;	1.599	;	Structure of Y105A mutant of PhaZ7 PHB depolymerase
6JX9	;	1.8	;	Structure of Y17107 complexed HPPD
4BVK	;	1.606	;	Structure of Y190E mutant of PhaZ7 PHB depolymerase
3USR	;	2.1	;	Structure of Y194F glycogenin mutant truncated at residue 270
4GHC	;	1.55	;	Structure of Y257F variant of Homoprotocatechuate 2,3-Dioxygenase from B.fuscum at 1.55 Ang resolution
4GHF	;	1.67	;	Structure of Y257F variant of Homoprotocatechuate 2,3-Dioxygenase from B.fuscum in complex with 4-Nitrocatechol and dioxygen at 1.67 Ang resolution
4GHE	;	1.6	;	Structure of Y257F variant of Homoprotocatechuate 2,3-Dioxygenase from B.fuscum in complex with 4-nitrocatechol at 1.60 Ang resolution
4GHD	;	1.85	;	Structure of Y257F variant of Homoprotocatechuate 2,3-Dioxygenase from B.fuscum in complex with HPCA at 1.85 Ang resolution
4UGW	;	1.901	;	Structure of Y357F Bacillus subtilis Nitric Oxide Synthase in complex with 6-(5-((3R,4R)-4-((6-azanyl-4-methyl-pyridin-2-yl)methyl) pyrrolidin-3-yl)oxypentyl)-4-methyl-pyridin-2-amine
4UGV	;	1.985	;	Structure of Y357F Bacillus subtilis Nitric Oxide Synthase in complex with Arginine and 5,6,7,8-TETRAHYDROBIOPTERIN
8D5D	;	1.54	;	Structure of Y430F D-ornithine/D-lysine decarboxylase complex with D-arginine
8D88	;	1.41	;	Structure of Y430F D-ornithine/D-lysine decarboxylase complex with D-lysine
8D5R	;	1.44	;	Structure of Y430F D-ornithine/D-lysine decarboxylase complex with D-ornithine
8D4I	;	1.32	;	Structure of Y430F D-ornithine/D-lysine decarboxylase complex with putrescine
5Z35	;	1.8	;	Structure of Y68F mutant metal free periplasmic metal binding protein from candidatus liberibacter asiaticus
5ZHA	;	1.84	;	Structure of Y68F mutant Mn-Bound periplasmic metal binding protein from candidatus liberibacter asiaticus
3OG9	;	1.88	;	Structure of YahD with Malic acid
6YJ4	;	2.7	;	Structure of Yarrowia lipolytica complex I at 2.7 A
1J8B	;	1.75	;	Structure of YbaB from Haemophilus influenzae (HI0442), a protein of unknown function
3NVD	;	1.836	;	Structure of YBBD in complex with pugnac
6P6I	;	3.67	;	Structure of YbtPQ importer
6P6J	;	3.4	;	Structure of YbtPQ importer with substrate Ybt-Fe bound
6PE3	;	2.3	;	Structure of YcaO enzyme from Methanocaldococcus jannaschii in complex with ATP
6PEU	;	1.95	;	Structure of YcaO enzyme from Methanocaldococcus jannaschii in complex with peptide
1QZ4	;	2.0	;	Structure of YcfC Protein of Unknown Function Escherichia coli
4LIT	;	2.4	;	Structure of YcfD a Ribosomal oxygenase from Escherichia coli in complex with Cobalt and 2-oxoglutarate.
4LIV	;	2.7	;	Structure of YcfD, a Ribosomal oxygenase from Escherichia coli in complex with Cobalt and succinic acid.
4LIU	;	2.7	;	Structure of YcfD, a Ribosomal oxygenase from Escherichia coli.
4QLN	;	2.65	;	structure of ydao riboswitch binding with c-di-dAMP
4YNX	;	1.5	;	Structure of YdiE from E. coli
3MG8	;	2.59	;	Structure of yeast 20S open-gate proteasome with Compound 16
3SDI	;	2.65	;	Structure of yeast 20S open-gate proteasome with Compound 20
3OEU	;	2.6	;	Structure of yeast 20S open-gate proteasome with Compound 24
3OEV	;	2.85	;	Structure of yeast 20S open-gate proteasome with Compound 25
3SDK	;	2.7	;	Structure of yeast 20S open-gate proteasome with Compound 34
3MG6	;	2.6	;	Structure of yeast 20S open-gate proteasome with Compound 6
3MG7	;	2.78	;	Structure of yeast 20S open-gate proteasome with Compound 8
8OLR	;	2.8	;	Structure of yeast 20S proteasome in complex with the natural product beta-lactone inhibitor Cystargolide A
3MG0	;	2.68	;	Structure of yeast 20S proteasome with bortezomib
3MG4	;	3.11	;	Structure of yeast 20S proteasome with Compound 1
3JCO	;	4.8	;	Structure of yeast 26S proteasome in M1 state derived from Titan dataset
3JCP	;	4.6	;	Structure of yeast 26S proteasome in M2 state derived from Titan dataset
6T7T	;	3.1	;	Structure of yeast 80S ribosome stalled on poly(A) tract.
6T4Q	;	2.6	;	Structure of yeast 80S ribosome stalled on the CGA-CCG inhibitory codon combination.
6T7I	;	3.2	;	Structure of yeast 80S ribosome stalled on the CGA-CGA inhibitory codon combination.
8J6V	;	3.4	;	Structure of yeast Arginyl-tRNA-protein transferase 1
3CSM	;	3.0	;	STRUCTURE OF YEAST CHORISMATE MUTASE WITH BOUND TRP AND AN ENDOOXABICYCLIC INHIBITOR
3CXH	;	2.5	;	Structure of yeast complex III with isoform-2 cytochrome c bound and definition of a minimal core interface for electron transfer.
2I7X	;	2.5	;	Structure of Yeast CPSF-100 (Ydh1p)
7MGM	;	3.1	;	Structure of yeast cytoplasmic dynein with AAA3 Walker B mutation bound to Lis1
4ZDD	;	3.0	;	Structure of yeast D3,D2-enoyl-CoA isomerase bound to sulphate ion
2IS9	;	1.92	;	Structure of yeast DCN-1
6T83	;	4.0	;	Structure of yeast disome (di-ribosome) stalled on poly(A) tract.
2XGQ	;	2.7	;	Structure of yeast DNA polymerase eta in complex with C8-N-acetyl-2- aminoanthracene containing DNA
7LXD	;	4.11	;	Structure of yeast DNA Polymerase Zeta (apo)
2IX3	;	2.7	;	Structure of yeast Elongation Factor 3
2IWH	;	3.0	;	Structure of yeast Elongation Factor 3 in complex with ADPNP
4EJS	;	2.606	;	Structure of yeast elongator subcomplex Elp456
5LOZ	;	1.95	;	STRUCTURE OF YEAST ENT1 ENTH DOMAIN
8F2K	;	2.9	;	Structure of yeast F1-ATPase determined with 100 micromolar cruentaren A
7NS5	;	1.95	;	Structure of yeast Fbp1 (Fructose-1,6-bisphosphatase 1)
1FPW	;		;	STRUCTURE OF YEAST FREQUENIN
2JU0	;		;	Structure of Yeast Frequenin bound to PdtIns 4-kinase
3D5J	;	1.91	;	Structure of yeast Grx2-C30S mutant with glutathionyl mixed disulfide
4XZR	;	2.25	;	Structure of yeast importin a bound to the membrane protein Nuclear Localization Signal sequence of INM protein Heh1
4PVZ	;	2.5	;	Structure of yeast importin a bound to the membrane protein Nuclear Localization Signal sequence of INM protein Heh2
3ND2	;	2.4	;	Structure of Yeast Importin-beta (Kap95p)
2XQ0	;	1.955	;	Structure of yeast LTA4 hydrolase in complex with Bestatin
4C9G	;	2.49	;	Structure of yeast mitochondrial ADP/ATP carrier isoform 2 inhibited by carboxyatractyloside (C2221 crystal form)
4C9H	;	3.2	;	Structure of yeast mitochondrial ADP/ATP carrier isoform 2 inhibited by carboxyatractyloside (P212121 crystal form)
4C9Q	;	3.2	;	Structure of yeast mitochondrial ADP/ATP carrier isoform 3 inhibited by carboxyatractyloside (P21 crystal form)
4C9J	;	3.397	;	Structure of yeast mitochondrial ADP/ATP carrier isoform 3 inhibited by carboxyatractyloside (P212121 crystal form)
6EYW	;	2.88	;	Structure of Yeast Myosin 5 Cargo Binding Domain in Trigonal Space Group
4B8A	;	2.4	;	Structure of yeast NOT1 MIF4G domain co-crystallized with CAF1
5GW4	;	4.7	;	Structure of Yeast NPP-TRiC
8AGE	;	2.8	;	Structure of yeast oligosaccharylransferase complex with acceptor peptide bound
8AGC	;	3.1	;	Structure of yeast oligosaccharylransferase complex with lipid-linked oligosaccharide and non-acceptor peptide bound
8AGB	;	3.0	;	Structure of yeast oligosaccharylransferase complex with lipid-linked oligosaccharide bound
1ZHW	;	1.7	;	Structure of yeast oxysterol binding protein Osh4 in complex with 20-hydroxycholesterol
1ZHX	;	1.5	;	Structure of yeast oxysterol binding protein Osh4 in complex with 25-hydroxycholesterol
1ZHT	;	1.9	;	Structure of yeast oxysterol binding protein Osh4 in complex with 7-hydroxycholesterol
1ZHY	;	1.6	;	Structure of yeast oxysterol binding protein Osh4 in complex with cholesterol
1ZHZ	;	1.9	;	Structure of yeast oxysterol binding protein Osh4 in complex with ergosterol
1FA0	;	2.6	;	STRUCTURE OF YEAST POLY(A) POLYMERASE BOUND TO MANGANATE AND 3'-DATP
2HHP	;	1.8	;	Structure of yeast poly(A) polymerase in a closed conformation.
2O1P	;	2.7	;	Structure of yeast Poly(A) Polymerase in a somewhat closed state
2Q66	;	1.8	;	Structure of Yeast Poly(A) Polymerase with ATP and oligo(A)
2JXR	;	2.4	;	STRUCTURE OF YEAST PROTEINASE A
7MZV	;	3.2	;	Structure of yeast pseudouridine synthase 7 (PUS7)
8XGC	;	3.7	;	Structure of yeast replisome associated with FACT and histone hexamer, Composite map
3TB9	;	2.53	;	Structure of Yeast Ribonucleotide Reductase 1 Q288A with AMPPNP and CDP
3TBA	;	2.8	;	Structure of Yeast Ribonucleotide Reductase 1 Q288A with dGTP and ADP
3S8C	;	2.77	;	Structure of Yeast Ribonucleotide Reductase 1 R293A with AMPPNP and CDP
3S8B	;	2.8	;	Structure of Yeast Ribonucleotide Reductase 1 with AMPPNP and CDP
3S87	;	2.25	;	Structure of Yeast Ribonucleotide Reductase 1 with dGTP and ADP
3S8A	;	2.9	;	Structure of Yeast Ribonucleotide Reductase R293A with dGTP
7A9X	;	2.45	;	Structure of yeast Rmd9p in complex with 16nt target RNA
7A9W	;	2.55	;	Structure of yeast Rmd9p in complex with 20nt target RNA
7Z1N	;	3.9	;	Structure of yeast RNA Polymerase III Delta C53-C37-C11
7Z1M	;	3.4	;	Structure of yeast RNA Polymerase III Elongation Complex (EC)
8BWS	;	3.2	;	Structure of yeast RNA Polymerase III elongation complex at 3.3 A
7Z1L	;	2.8	;	Structure of yeast RNA Polymerase III Pre-Termination Complex (PTC)
7Z1O	;	2.7	;	Structure of yeast RNA Polymerase III PTC + NTPs
7Z2Z	;	3.07	;	Structure of yeast RNA Polymerase III-DNA-Ty1 integrase complex (Pol III-DNA-IN1) at 3.1 A
7Z0H	;	2.6	;	Structure of yeast RNA Polymerase III-Ty1 integrase complex at 2.6 A (focus subunit AC40).
7Z31	;	2.76	;	Structure of yeast RNA Polymerase III-Ty1 integrase complex at 2.7 A (focus subunit C11, no C11 C-terminal Zn-ribbon in the funnel pore).
7Z30	;	2.9	;	Structure of yeast RNA Polymerase III-Ty1 integrase complex at 2.9 A (focus subunit C11 terminal Zn-ribbon in the funnel pore).
6W6V	;	3.0	;	Structure of yeast RNase MRP holoenzyme
4WA6	;	2.36	;	Structure of yeast SAGA DUBm with Sgf73 N59D mutant at 2.36 angstroms resolution
4W4U	;	2.8	;	Structure of yeast SAGA DUBm with Sgf73 Y57A mutant at 2.8 angstroms resolution
6F0E	;	2.6	;	Structure of yeast Sec14p with a picolinamide compound
7ZGA	;	2.302	;	Structure of yeast Sec14p with ergoline
7ZG9	;	1.764	;	Structure of yeast Sec14p with himbacine
7ZGB	;	2.7	;	Structure of yeast Sec14p with NPPM112
7ZGD	;	2.08	;	Structure of yeast Sec14p with NPPM244
7ZGC	;	2.236	;	Structure of yeast Sec14p with NPPM481
6L9J	;	2.642	;	Structure of yeast Snf5 and Swi3 subcomplex
7AM1	;	1.9	;	Structure of yeast Ssd1, a pseudonuclease
5OQJ	;	4.7	;	STRUCTURE OF YEAST TRANSCRIPTION PRE-INITIATION COMPLEX WITH TFIIH
5OQM	;	5.8	;	STRUCTURE OF YEAST TRANSCRIPTION PRE-INITIATION COMPLEX WITH TFIIH AND CORE MEDIATOR
1YPI	;	1.9	;	STRUCTURE OF YEAST TRIOSEPHOSPHATE ISOMERASE AT 1.9-ANGSTROMS RESOLUTION
4YH8	;	1.7	;	Structure of yeast U2AF complex
5VSU	;	3.1	;	Structure of yeast U6 snRNP with 2'-phosphate terminated U6 RNA
6ASO	;	2.71	;	Structure of yeast U6 snRNP with 3'-phosphate terminated U6 RNA
7MEY	;	3.67	;	Structure of yeast Ubr1 in complex with Ubc2 and monoubiquitinated N-degron
7MEX	;	3.35	;	Structure of yeast Ubr1 in complex with Ubc2 and N-degron
5UQJ	;	1.8	;	Structure of yeast Usb1
7N0J	;	1.88	;	Structure of YebY from E. coli K12
1YFP	;	2.5	;	STRUCTURE OF YELLOW-EMISSION VARIANT OF GFP
2YFP	;	2.6	;	STRUCTURE OF YELLOW-EMISSION VARIANT OF GFP
6OJK	;	1.5	;	Structure of YePL2A K291W in Complex with Tetragalacturonic Acid
6OJL	;	1.5	;	Structure of YePL2A R194K in Complex with Pentagalacturonic Acid
7N34	;	1.9	;	Structure of Yersinia aleksiciae Cap15 cyclic dinucleotide receptor, crystal form 1
7N35	;	2.6	;	Structure of Yersinia aleksiciae Cap15 cyclic dinucleotide receptor, crystal form 2
2UVE	;	2.19	;	Structure of Yersinia enterocolitica Family 28 Exopolygalacturonase
2UVF	;	2.1	;	Structure of Yersinia enterocolitica Family 28 Exopolygalacturonase in Complex with Digalaturonic Acid
5N40	;	1.7	;	Structure of Yersinia pseudotuberculosis adhesin InvE
5LDY	;	2.6	;	Structure of Yersinia pseudotuberculosis InvD
3TNY	;	1.55	;	Structure of YfiY from Bacillus cereus bound to the siderophore iron (III) schizokinen
3Q98	;	2.001	;	Structure of ygeW encoded protein from E. coli
1IZM	;	1.95	;	Structure of ygfB from Haemophilus influenzae (HI0817), a Conserved Hypothetical Protein
3F4A	;	1.8	;	Structure of Ygr203w, a yeast protein tyrosine phosphatase of the Rhodanese family
1ODF	;	2.25	;	Structure of YGR205w protein.
3GFR	;	2.403	;	Structure of YhdA, D137L variant
3GFS	;	2.105	;	Structure of YhdA, K109D/D137K variant
3GFQ	;	2.996	;	Structure of YhdA, K109L variant
1J85	;	2.0	;	Structure of YibK from Haemophilus influenzae (HI0766), a truncated sequence homolog of tRNA (guanosine-2'-O-) methyltransferase (SpoU)
1MXI	;	1.7	;	Structure of YibK from Haemophilus influenzae (HI0766): a Methyltransferase with a Cofactor Bound at a Site Formed by a Knot
6QKV	;	2.01	;	Structure of YibK from P. aeruginosa
1TO3	;	2.7	;	Structure of yiht from Salmonella typhimurium
1J7G	;	1.64	;	Structure of YihZ from Haemophilus influenzae (HI0670), a D-Tyr-tRNA(Tyr) deacylase
8B3S	;	2.09	;	Structure of YjbA in complex with ClpC N-terminal Domain
2D4G	;	2.3	;	Structure of YjcG protein, a putative 2'-5' RNA ligase from Bacillus subtilis
2UVK	;	1.5	;	Structure of YjhT
3DR6	;	1.75	;	Structure of yncA, a putative ACETYLTRANSFERASE from Salmonella typhimurium
3DR8	;	1.95	;	Structure of yncA, a putative ACETYLTRANSFERASE from Salmonella typhimurium with its cofactor Acetyl-CoA
2XCE	;	1.85	;	Structure of YncF in complex with dUpNHpp
2XCD	;	1.84	;	Structure of YncF,the genomic dUTPase from Bacillus subtilis
2BAZ	;	2.3	;	Structure of YosS, a putative dUTPase from Bacillus subtilis
3EC1	;	2.36	;	Structure of YqeH GTPase from Geobacillus stearothermophilus (an AtNOS1 / AtNOA1 ortholog)
1NMN	;	2.3	;	Structure of yqgF from Escherichia coli, a hypothetical protein
4RDN	;	2.1	;	Structure of YTH-YTHDF2 in complex with m6A
4RDO	;	2.15	;	Structure of YTH-YTHDF2 in the free state
5CXC	;	3.1	;	Structure of Ytm1 bound to the C-terminal domain of Erb1 in P 65 2 2 space group
5CXB	;	2.1	;	Structure of Ytm1 bound to the C-terminal domain of Erb1 in P21 21 2 space group
5CYK	;	3.0	;	Structure of Ytm1 bound to the C-terminal domain of Erb1-R486E
1TVL	;	2.104	;	Structure of YTNJ from Bacillus subtilis
1YW1	;	2.81	;	Structure Of Ytnj From Bacillus Subtilis in complex with FMN
8OF6	;	2.1	;	Structure of YtoQ
7Z06	;	1.74	;	Structure of YwlG (Q2FF14) from Staphylococcus aureus
8FFJ	;	7.5	;	Structure of Zanidatamab bound to HER2
6S8D	;	3.49	;	Structure of ZEBOV GP in complex with 1T0227 antibody
6S8I	;	2.99	;	Structure of ZEBOV GP in complex with 3T0265 antibody
6S8J	;	2.91	;	Structure of ZEBOV GP in complex with 5T0180 antibody
6NF4	;	2.98	;	Structure of zebrafish Otop1 in nanodiscs
6MYD	;	1.399	;	Structure of zebrafish TRAF6 in complex with STING CTT
2HAC	;		;	Structure of Zeta-Zeta Transmembrane Dimer
6GL0	;	2.2	;	Structure of ZgEngAGH5_4 in complex with a cellotriose
6GL2	;	1.96	;	Structure of ZgEngAGH5_4 wild type at 1.2 Angstrom resolution
6CO8	;	3.1	;	Structure of Zika virus at a resolution of 3.1 Angstrom
7M1V	;	1.6	;	Structure of Zika virus NS2b-NS3 protease mutant binding the compound NSC86314 in the super-open conformation
6UM3	;	2.5	;	Structure of Zika virus NS2b-NS3 protease mutant stabilizing the super-open conformation
6RWZ	;	1.7	;	Structure of Zika virus NS3 helicase in complex with ADP-BeF3
6S0J	;	1.5	;	Structure of Zika virus NS3 helicase in complex with ADP-MgF3(H2O)-
5TMH	;	3.278	;	Structure of Zika virus NS5
5U0C	;	3.0	;	Structure of Zika virus NS5 RNA polymerase domain
5H6V	;	2.422	;	Structure of Zika virus protease in complex with a dipeptide inhibitor
1XXW	;	2.7	;	Structure of zinc induced heterodimer of two calcium free isoforms of phospholipase A2 from Naja naja sagittifera at 2.7A resolution
8OGD	;	1.75	;	Structure of zinc(II) double mutant human carbonic anhydrase II bound to thiocyanate
8F1B	;	2.41	;	Structure of zinc-bound ZrgA deletion 124-184 from Vibrio cholerae
4PXL	;	2.25	;	Structure of Zm ALDH2-3 (RF2C) in complex with NAD
4PZ2	;	2.4	;	Structure of Zm ALDH2-6 (RF2F) in complex with NAD
4PXN	;	2.94	;	Structure of Zm ALDH7 in complex with NAD
4NQ2	;	1.55	;	Structure of Zn(II)-bound metallo-beta-lactamse VIM-2 from Pseudomonas aeruginosa
5AFS	;	2.22	;	structure of Zn-bound periplasmic metal binding protein from candidatus liberibacter asiaticus
2NXA	;	2.29	;	Structure of Zn-dependent Metallo-Beta-Lactamase from Bacillus Cereus R121H, C221D Double Mutant
8G4Y	;	1.41	;	Structure of ZNRF3 ECD bound to peptide MK1-3.6.10
4CDJ	;	1.5	;	Structure of ZNRF3 ectodomain
4CDK	;	2.8	;	Structure of ZNRF3-RSPO1
6XZH	;	2.372	;	Structure of zVDR LBD-Calcitriol in complex with chimera 10
6XZI	;	2.1	;	Structure of zVDR LBD-calcitriol in complex with chimera 11
6XZJ	;	2.1	;	Structure of zVDR LBD-Calcitriol in complex with chimera 12
6XZK	;	2.0	;	Structure of zVDR LBD-Calcitriol in complex with chimera 13
6XZV	;	2.3	;	Structure of zVDR LBD-Calcitriol in complex with chimera 18
4I04	;	1.95	;	Structure of zymogen of cathepsin B1 from Schistosoma mansoni
6RVA	;		;	STRUCTURE OF [ASP58]-IGF-I ANALOGUE
5ZVN	;		;	Structure of [beta Glc-T9,K7]indolicidin, a glycosylated analogue of indolicidin
6J0I	;	2.5	;	Structure of [Co2+-(Chromomycin A3)2]-d(TTGGCGAA)2 complex
2M2O	;		;	Structure of [D-HisB24] insulin analogue at pH 1.9
2M2P	;		;	Structure of [D-HisB24] insulin analogue at pH 8.0
1H19	;	2.1	;	STRUCTURE OF [E271Q]LEUKOTRIENE A4 HYDROLASE
2GP4	;	2.49	;	Structure of [FeS]cluster-free Apo Form of 6-Phosphogluconate Dehydratase from Shewanella oneidensis
2M2M	;		;	Structure of [L-HisB24] insulin analogue at pH 1.9
2M2N	;		;	Structure of [L-HisB24] insulin analogue at pH 8.0
6Z7R	;	1.77	;	Structure of [NiFeSe] hydrogenase from Desulfovibrio vulgaris hildenborough pressurized with Krypton gas - structure wtKr1
6Z8J	;	1.09	;	Structure of [NiFeSe] hydrogenase from Desulfovibrio vulgaris hildenborough pressurized with Oxygen gas - structure wtO2
6Z8O	;	2.2	;	Structure of [NiFeSe] hydrogenase G491A variant from Desulfovibrio vulgaris Hildenborough pressurized with Krypton gas - structure G491A-Kr
6Z9G	;	1.76	;	Structure of [NiFeSe] hydrogenase G491A variant from Desulfovibrio vulgaris Hildenborough pressurized with Oxygen gas - structure G491A-O2
6ZA1	;	1.37	;	Structure of [NiFeSe] hydrogenase G491A variant from Desulfovibrio vulgaris Hildenborough pressurized with Oxygen gas - structure G491A-O2-hd
6Z9O	;	1.53	;	Structure of [NiFeSe] hydrogenase G491S variant from Desulfovibrio vulgaris Hildenborough pressurized with Oxygen gas - structure G491A-O2-ld
6Z8M	;	1.02	;	Structure of [NiFeSe] hydrogenase G491S variant from Desulfovibrio vulgaris Hildenborough pressurized with Oxygen gas - structure G491S-O2
1SQM	;	2.3	;	STRUCTURE OF [R563A] LEUKOTRIENE A4 HYDROLASE
6RSO	;	1.97	;	Structure of [Ru(phen)2(10-NO2-dppz)]2+ bound to the DNA sequence d(TCGGCGCCGA)
5ZVF	;		;	Structure of [T9,K7]indolicidin, a non glycosylated analogue of indolicidin
7S3Y	;	2.08	;	Structure ofrat neuronal nitric oxide synthase heme domain in complex with 7-((3-(2-(6-aminopyridin-2-yl)ethyl)phenoxy)methyl)quinolin-2-amine
1IAV	;	1.8	;	STRUCTURE ON NATIVE (ASN 87) SUBTILISIN FROM BACILLUS LENTUS
2PND	;	1.0	;	Structure or murine CRIg
5KXV	;	0.98	;	Structure Proteinase K at 0.98 Angstroms
5KXU	;	1.2	;	Structure Proteinase K determined by SACLA
1E0U	;	2.8	;	Structure R271L mutant of E. coli pyruvate kinase
1TFN	;		;	STRUCTURE REFINEMENT FOR A 24-NUCLEOTIDE RNA HAIRPIN, NMR, MINIMIZED AVERAGE STRUCTURE
2FBP	;	2.8	;	STRUCTURE REFINEMENT OF FRUCTOSE-1,6-BISPHOSPHATASE AND ITS FRUCTOSE 2,6-BISPHOSPHATE COMPLEX AT 2.8 ANGSTROMS RESOLUTION
3FBP	;	2.8	;	STRUCTURE REFINEMENT OF FRUCTOSE-1,6-BISPHOSPHATASE AND ITS FRUCTOSE 2,6-BISPHOSPHATE COMPLEX AT 2.8 ANGSTROMS RESOLUTION
1VLB	;	1.28	;	STRUCTURE REFINEMENT OF THE ALDEHYDE OXIDOREDUCTASE FROM DESULFOVIBRIO GIGAS AT 1.28 A
1D83	;		;	STRUCTURE REFINEMENT OF THE CHROMOMYCIN DIMER/DNA OLIGOMER COMPLEX IN SOLUTION
1RGD	;		;	STRUCTURE REFINEMENT OF THE GLUCOCORTICOID RECEPTOR-DNA BINDING DOMAIN FROM NMR DATA BY RELAXATION MATRIX CALCULATIONS
5LWU	;	1.109	;	Structure resulting from an endothiapepsin crystal soaked with a dimeric derivative of fragment 177
4HJJ	;	2.1	;	Structure Reveals Function of the Dual Variable Domain Immunoglobulin (DVD-Ig) Molecule
2H8E	;	1.2	;	Structure RusA D70N
1SDY	;	2.5	;	STRUCTURE SOLUTION AND MOLECULAR DYNAMICS REFINEMENT OF THE YEAST CU,ZN ENZYME SUPEROXIDE DISMUTASE
1C8Q	;	2.3	;	STRUCTURE SOLUTION AND REFINEMENT OF THE RECOMBINANT HUMAN SALIVARY AMYLASE
2A6P	;	2.2	;	Structure Solution to 2.2 Angstrom and Functional Characterisation of the Open Reading Frame Rv3214 from Mycobacterium tuberculosis
6YCC	;	1.3	;	Structure the ananain protease from Ananas comosus covalently bound to the E64 inhibitor
6YCD	;	1.35	;	Structure the ananain protease from Ananas comosus covalently bound to the TLCK inhibitor
6YCB	;	1.257	;	Structure the ananain protease from Ananas comosus covalently bound to with the E64 inhibitor
6Y6L	;	1.3	;	Structure the ananain protease from Ananas comosus with a thiomethylated catalytic cysteine
6YCF	;	1.85	;	Structure the bromelain protease from Ananas comosus in complex with the E64 inhibitor
6YCG	;	1.45	;	Structure the bromelain protease from Ananas comosus in complex with the TLCK inhibitor
6YCE	;	1.8	;	Structure the bromelain protease from Ananas comosus with a thiomethylated active cysteine
3ITG	;	2.15	;	Structure the proline utilization A proline dehydrogenase domain (PutA86-630) inactivated with N-propargylglycine
5JXH	;	2.0	;	Structure the proprotein convertase furin in complex with meta-guanidinomethyl-Phac-RVR-Amba at 2.0 Angstrom resolution.
3NG9	;	2.5	;	Structure to Function Correlations for Adeno-associated Virus Serotype 1
3R15	;	1.701	;	Structure Treponema Denticola Factor H Binding Protein
8G66	;	3.45	;	Structure with SJ3149
2LM8	;		;	Structure, Activity and Interactions of the Cysteine Deleted Analog of Tachyplesin-1 with Lipopolysaccharide Micelles
2NC2	;		;	Structure, Dynamics and functional Aspects of the antifungal protein sfPAFB
1QCH	;		;	STRUCTURE, DYNAMICS AND HYDRATION OF THE NOGALAMYCIN-D(ATGCAT)2 COMPLEX DETERMINED BY NMR AND MOLECULAR DYNAMICS SIMULATIONS IN SOLUTION
2MJN	;		;	Structure, dynamics and RNA binding of the multi-domain splicing factor TIA-1
6I3R	;		;	Structure, dynamics and roX2-lncRNA binding of tandem double-stranded RNA binding domains dsRBD1/2 of Drosophila helicase MLE
2MBX	;		;	Structure, dynamics and stability of allergen cod parvalbumin Gad m 1 by solution and high-pressure NMR.
7OO1	;	3.01	;	Structure, function and characterization of a second pyruvate kinase isozyme in Pseudomonas aeruginosa.
2M8G	;		;	Structure, function, and tethering of DNA-binding domains in 54 transcriptional activators
3VFL	;	1.91	;	Structure, Function, Stability and Knockout Phenotype of Dihydrodipicolinate Synthase from Streptococcus pneumoniae
5DQQ	;	2.872	;	Structure, inhibition and regulation of two-pore channel TPC1 from Arabidopsis thaliana
2KBO	;		;	Structure, interaction, and real-time monitoring of the enzymatic reaction of wild type APOBEC3G
4OIT	;	2.24	;	Structure, interactions and evolutionary implications of a domain-swapped lectin dimer from Mycobacterium smegmatis
4OIZ	;	3.4	;	Structure, interactions and evolutionary implications of a domain-swapped lectin dimer from Mycobacterium smegmatis
4OKC	;	2.25	;	Structure, interactions and evolutionary implications of a domain-swapped lectin dimer from Mycobacterium smegmatis
2TSC	;	1.97	;	STRUCTURE, MULTIPLE SITE BINDING, AND SEGMENTAL ACCOMODATION IN THYMIDYLATE SYNTHASE ON BINDING D/UMP AND AN ANTI-FOLATE
2M09	;		;	Structure, phosphorylation and U2AF65 binding of the Nterminal Domain of splicing factor 1 during 3 splice site Recognition
2M0G	;		;	Structure, phosphorylation and U2AF65 binding of the Nterminal Domain of splicing factor 1 during 3 splice site Recognition
2CAB	;	2.0	;	STRUCTURE, REFINEMENT AND FUNCTION OF CARBONIC ANHYDRASE ISOZYMES. REFINEMENT OF HUMAN CARBONIC ANHYDRASE I
5EP4	;	1.5	;	Structure, Regulation, and Inhibition of the Quorum-Sensing Signal Integrator LuxO
2LSW	;		;	Structure, sulfatide-binding properties, and inhibition of platelet aggregation by a Disabled-2-derived peptide
6S8K	;	1.52	;	Structure, Thermodynamics, and Kinetics of Plinabulin Binding to two Tubulin Isotypes
6S8L	;	1.801	;	Structure, Thermodynamics, and Kinetics of Plinabulin Binding to two Tubulin Isotypes
5IH2	;	1.8	;	Structure, thermodynamics, and the role of conformational dynamics in the interactions between the N-terminal SH3 domain of CrkII and proline-rich motifs in cAbl
4ELB	;	2.6	;	Structure-activity relationship guides enantiomeric preference among potent inhibitors of B. anthracis dihydrofolate reductase
4ELE	;	2.35	;	Structure-activity relationship guides enantiomeric preference among potent inhibitors of B. anthracis dihydrofolate reductase
4ELF	;	2.3	;	Structure-activity relationship guides enantiomeric preference among potent inhibitors of B. anthracis dihydrofolate reductase
4ELG	;	2.101	;	Structure-activity relationship guides enantiomeric preference among potent inhibitors of B. anthracis dihydrofolate reductase
4ELH	;	2.103	;	Structure-activity relationship guides enantiomeric preference among potent inhibitors of B. anthracis dihydrofolate reductase
2NDD	;		;	Structure-activity relationship of peptide toxin HelaTx1: a new kappa-KTx subfamily affecting K+ channel
7F8G	;	3.491	;	Structure-activity relationship studies of allosteric inhibitors of EYA2 tyrosine phosphatase
7F8H	;	3.3	;	Structure-activity relationship studies of allosteric inhibitors of EYA2 tyrosine phosphatase
5NKY	;	2.096	;	Structure-activity relationship study of vitamin D analogs with oxolane group in their side chain
5NMA	;	2.8	;	Structure-activity relationship study of vitamin D analogs with oxolane group in their side chain
5NMB	;	2.5	;	Structure-activity relationship study of vitamin D analogs with oxolane group in their side chain
5OJT	;		;	Structure-Activity Relationships and Biological Characterization of a Novel, Potent and Serum Stable C-X-C chemokine receptor type 4 (CXCR4) Antagonist
2AQ7	;	2.3	;	Structure-activity relationships at the 5-posiiton of thiolactomycin: an intact 5(R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coli
2AQB	;	2.19	;	Structure-activity relationships at the 5-position of thiolactomycin: an intact 5(R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherchia coli
1IVA	;		;	STRUCTURE-ACTIVITY RELATIONSHIPS FOR P-TYPE CALCIUM CHANNEL SELECTIVE OMEGA-AGATOXINS
1UYL	;	1.4	;	Structure-Activity Relationships in purine-based inhibitor binding to HSP90 isoforms
1TCG	;		;	STRUCTURE-ACTIVITY RELATIONSHIPS OF MU-CONOTOXIN GIIIA: STRUCTURE DETERMINATION OF ACTIVE AND INACTIVE SODIUM CHANNEL BLOCKER PEPTIDES BY NMR AND SIMULATED ANNEALING CALCULATIONS
1TCH	;		;	STRUCTURE-ACTIVITY RELATIONSHIPS OF MU-CONOTOXIN GIIIA: STRUCTURE DETERMINATION OF ACTIVE AND INACTIVE SODIUM CHANNEL BLOCKER PEPTIDES BY NMR AND SIMULATED ANNEALING CALCULATIONS
1TCJ	;		;	STRUCTURE-ACTIVITY RELATIONSHIPS OF MU-CONOTOXIN GIIIA: STRUCTURE DETERMINATION OF ACTIVE AND INACTIVE SODIUM CHANNEL BLOCKER PEPTIDES BY NMR AND SIMULATED ANNEALING CALCULATIONS
1TCK	;		;	STRUCTURE-ACTIVITY RELATIONSHIPS OF MU-CONOTOXIN GIIIA: STRUCTURE DETERMINATION OF ACTIVE AND INACTIVE SODIUM CHANNEL BLOCKER PEPTIDES BY NMR AND SIMULATED ANNEALING CALCULATIONS
5XXK	;	1.66	;	Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino acids
4Q78	;	1.0	;	Structure-assisted design of carborane-based inhibitors of carbonic anhydrase
2P4D	;	1.8	;	Structure-assisted discovery of Variola major H1 phosphatase inhibitors
1CCS	;	2.35	;	STRUCTURE-ASSISTED REDESIGN OF A PROTEIN-ZINC BINDING SITE WITH FEMTOMOLAR AFFINITY
1CCT	;	2.2	;	STRUCTURE-ASSISTED REDESIGN OF A PROTEIN-ZINC BINDING SITE WITH FEMTOMOLAR AFFINITY
1CCU	;	2.25	;	STRUCTURE-ASSISTED REDESIGN OF A PROTEIN-ZINC BINDING SITE WITH FEMTOMOLAR AFFINITY
3QK2	;	1.643	;	Structure-Based Analysis of the Interaction between the Simian Virus 40 T-Antigen Origin Binding Domain and Single-Stranded DNA
1MJH	;	1.7	;	Structure-based assignment of the biochemical function of hypothetical protein MJ0577: A test case of structural genomics
2QIQ	;	1.9	;	Structure-based Design and Synthesis and Biological Evaluation of Peptidomimetic SARS-3CLpro Inhibitors
1BOZ	;	2.1	;	STRUCTURE-BASED DESIGN AND SYNTHESIS OF LIPOPHILIC 2,4-DIAMINO-6-SUBSTITUTED QUINAZOLINES AND THEIR EVALUATION AS INHIBITORS OF DIHYDROFOLATE REDUCTASE AND POTENTIAL ANTITUMOR AGENTS
6FFN	;	1.75	;	Structure-based design and synthesis of macrocyclic human rhinovirus 3C protease inhibitors
6FFS	;	1.86	;	Structure-based design and synthesis of macrocyclic human rhinovirus 3C protease inhibitors
3BE9	;	2.0	;	Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities
4Q1N	;	2.09	;	Structure-based design of 4-hydroxy-3,5-substituted piperidines as direct renin inhibitors
3GMD	;	2.28	;	Structure-based design of 7-Azaindole-pyrrolidines as inhibitors of 11beta-Hydroxysteroid-Dehydrogenase type I
3QN2	;	1.661	;	Structure-based design of a disulfide-linked oligomeric form of the Simian Virus 40 (SV40) large T antigen DNA binding domain
2Y68	;	1.49	;	Structure-based design of a new series of D-glutamic acid-based inhibitors of bacterial MurD ligase
5SXN	;	2.1	;	Structure-based design of a new series of N-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibitors
5SY2	;	2.25	;	Structure-based design of a new series of N-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibitors
5SY3	;	2.3	;	Structure-based design of a new series of N-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibitors
5SZ9	;	2.85	;	Structure-based design of a new series of N-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibitors
7Z0N	;	2.4	;	Structure-Based Design of a Novel Class of Autotaxin Inhibitors Based on Endogenous Allosteric Modulators
4TYD	;	2.84	;	Structure-based design of a novel series of azetidine inhibitors of the hepatitis C virus NS3/4A serine protease
1FBZ	;	2.4	;	Structure-based design of a novel, osteoclast-selective, nonpeptide Src SH2 inhibitor with in vivo anti-resorptive activity
3CS4	;	2.0	;	Structure-based design of a superagonist ligand for the vitamin D nuclear receptor
3CS6	;	1.8	;	Structure-based design of a superagonist ligand for the vitamin D nuclear receptor
5UOR	;	2.75	;	Structure-Based Design of ASK1 Inhibitors as Potential First-in-Class Agents for Heart Failure
5UOX	;	2.5	;	Structure-Based Design of ASK1 Inhibitors as Potential First-in-Class Agents for Heart Failure
5UP3	;	2.95	;	Structure-Based Design of ASK1 Inhibitors as Potential First-in-Class Agents for Heart Failure
4CFM	;	2.85	;	Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors.
4CFN	;	2.2	;	Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors.
4CFU	;	2.2	;	Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors.
4CFV	;	2.0	;	Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors.
4CFW	;	2.45	;	Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors.
4CFX	;	3.5	;	Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors.
2GTK	;	2.1	;	Structure-based Design of Indole Propionic Acids as Novel PPARag CO-Agonists
4LAE	;	1.69	;	Structure-Based Design of New Dihydrofolate Reductase Antibacterial Agents: 7-(Benzimidazol-1-yl)-2,4-diaminoquinazolines
4LAG	;	1.7	;	Structure-Based Design of New Dihydrofolate Reductase Antibacterial Agents: 7-(Benzimidazol-1-yl)-2,4-diaminoquinazolines
4LAH	;	1.88	;	Structure-Based Design of New Dihydrofolate Reductase Antibacterial Agents: 7-(Benzimidazol-1-yl)-2,4-diaminoquinazolines
4LEK	;	1.7	;	Structure-Based Design of New Dihydrofolate Reductase Antibacterial Agents: 7-(Benzimidazol-1-yl)-2,4-diaminoquinazolines
2BR1	;	2.0	;	Structure-based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand Affinity
2BRB	;	2.1	;	Structure-based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand Affinity
2BRG	;	2.1	;	Structure-based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand Affinity
2BRH	;	2.1	;	Structure-based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand Affinity
2BRM	;	2.2	;	Structure-based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand Affinity
2BRN	;	2.8	;	Structure-based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand Affinity
2BRO	;	2.2	;	Structure-based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand Affinity
4HZT	;	1.8	;	Structure-based design of novel dihydroisoquinoline BACE-1 inhibitors that do not engage the catalytic aspartates
4I0Z	;	1.8	;	Structure-based design of novel dihydroisoquinoline BACE-1 inhibitors that do not engage the catalytic aspartates
4I10	;	2.07	;	Structure-based design of novel dihydroisoquinoline BACE-1 inhibitors that do not engage the catalytic aspartates
4I11	;	1.89	;	Structure-based design of novel dihydroisoquinoline BACE-1 inhibitors that do not engage the catalytic aspartates.
3IK8	;	1.85	;	Structure-Based Design of Novel PIN1 Inhibitors (I)
3IKD	;	2.0	;	Structure-Based Design of Novel PIN1 Inhibitors (I)
3IKG	;	1.86	;	Structure-Based Design of Novel PIN1 Inhibitors (I)
3I6C	;	1.3	;	Structure-Based Design of Novel PIN1 Inhibitors (II)
3JYJ	;	1.87	;	Structure-Based Design of Novel PIN1 Inhibitors (II)
4C4E	;	2.6	;	Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1
4C4F	;	2.36	;	Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1
4C4G	;	2.65	;	Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1
4C4H	;	2.8	;	Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1
4C4I	;	2.65	;	Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1
4C4J	;	2.5	;	Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1
1MF4	;	1.9	;	Structure-based design of potent and selective inhibitors of phospholipase A2: Crystal structure of the complex formed between phosholipase A2 from Naja Naja sagittifera and a designed peptide inhibitor at 1.9 A resolution
7SEJ	;	2.51	;	Structure-based design of prefusion-stabilized human metapneumovirus fusion proteins
7SEM	;	2.2	;	Structure-based design of prefusion-stabilized human metapneumovirus fusion proteins
2BGD	;	2.4	;	Structure-based design of Protein Tyrosine Phosphatase-1B Inhibitors
2BGE	;	1.8	;	Structure-based design of Protein Tyrosine Phosphatase-1B Inhibitors
2PVH	;	2.2	;	Structure-Based Design of Pyrazolo[1,5-a][1,3,5]triazine Derivatives as Potent Inhibitors of Protein Kinase CK2
2PVJ	;	1.7	;	Structure-Based Design of Pyrazolo[1,5-a][1,3,5]triazine Derivatives as Potent Inhibitors of Protein Kinase CK2
2PVK	;	1.9	;	Structure-Based Design of Pyrazolo[1,5-a][1,3,5]triazine Derivatives as Potent Inhibitors of Protein Kinase CK2
2PVL	;	1.9	;	Structure-Based Design of Pyrazolo[1,5-a][1,3,5]triazine Derivatives as Potent Inhibitors of Protein Kinase CK2
2PVM	;	2.0	;	Structure-Based Design of Pyrazolo[1,5-a][1,3,5]triazine Derivatives as Potent Inhibitors of Protein Kinase CK2
2PVN	;	2.0	;	Structure-Based Design of Pyrazolo[1,5-a][1,3,5]triazine Derivatives as Potent Inhibitors of Protein Kinase CK2
1SRF	;	2.0	;	STRUCTURE-BASED DESIGN OF SYNTHETIC AZOBENZENE LIGANDS FOR STREPTAVIDIN
1SRG	;	1.8	;	STRUCTURE-BASED DESIGN OF SYNTHETIC AZOBENZENE LIGANDS FOR STREPTAVIDIN
1SRH	;	2.2	;	STRUCTURE-BASED DESIGN OF SYNTHETIC AZOBENZENE LIGANDS FOR STREPTAVIDIN
1SRI	;	1.65	;	STRUCTURE-BASED DESIGN OF SYNTHETIC AZOBENZENE LIGANDS FOR STREPTAVIDIN
1SRJ	;	1.8	;	STRUCTURE-BASED DESIGN OF SYNTHETIC AZOBENZENE LIGANDS FOR STREPTAVIDIN
1VGN	;	2.63	;	Structure-based design of the irreversible inhibitors to metallo--lactamase (IMP-1)
3R7Q	;	2.5	;	Structure-based design of thienobenzoxepin inhibitors of PI3- kinase
3R7R	;	2.9	;	Structure-based design of thienobenzoxepin inhibitors of PI3-Kinase
6FX0	;	1.9	;	Structure-based design of Trifarotene (CD5789), a potent and selective RAR gamma agonist for the treatment of acne
5WJJ	;	1.6	;	Structure-based Design, Synthesis, and Biological Evaluation of Imidazo[1,2-b]pyridazine-based p38 MAP Kinase Inhibitors
6ANL	;	2.0	;	Structure-based Design, Synthesis, and Biological Evaluation of Imidazo[1,2-b]pyridazine-based p38 MAP Kinase Inhibitors
6M9L	;	2.45	;	Structure-based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]pyridine-2-one based p38 MAP Kinase Inhibitors by scaffold hopping - compound 10
6M95	;	1.8	;	Structure-based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]pyridine-2-one based p38 MAP Kinase Inhibitors by scaffold hopping: compound 1
3ATW	;	2.36	;	Structure-Based Design, Synthesis, Evaluation of Peptide-mimetic SARS 3CL Protease Inhibitors
6V9S	;	3.5	;	Structure-based development of subtype-selective orexin 1 receptor antagonists
2BZ5	;	1.9	;	Structure-based Discovery of a New Class of Hsp90 Inhibitors
6U2S	;	1.5	;	Structure-based discovery of a novel small-molecule inhibitor of methicillin-resistant S. aureus
6U33	;	1.75	;	Structure-based discovery of a novel small-molecule inhibitor of methicillin-resistant S. aureus
6U3F	;	1.78	;	Structure-based discovery of a novel small-molecule inhibitor of methicillin-resistant S. aureus
6U3T	;	2.79	;	Structure-based discovery of a novel small-molecule inhibitor of methicillin-resistant S. aureus
6U3Y	;	2.04	;	Structure-based discovery of a novel small-molecule inhibitor of methicillin-resistant S. aureus
6U49	;	2.35	;	Structure-based discovery of a novel small-molecule inhibitor of methicillin-resistant S. aureus
6U4P	;	2.49	;	Structure-based discovery of a novel small-molecule inhibitor of methicillin-resistant S. aureus
4KFN	;	1.6	;	Structure-Based Discovery of Novel Amide-Containing Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors
4KFO	;	1.6	;	Structure-Based Discovery of Novel Amide-Containing Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors
2GZ7	;	1.856	;	Structure-Based Drug Design and Structural Biology Study of Novel Nonpeptide Inhibitors of SARS-CoV Main Protease
2GZ8	;	1.97	;	Structure-Based Drug Design and Structural Biology Study of Novel Nonpeptide Inhibitors of SARS-CoV Main Protease
2GZ9	;	2.17	;	Structure-Based Drug Design and Structural Biology Study of Novel Nonpeptide Inhibitors of SARS-CoV Main Protease
2G0G	;	2.54	;	Structure-based drug design of a novel family of PPAR partial agonists: virtual screening, x-ray crystallography and in vitro/in vivo biological activities
2G0H	;	2.3	;	Structure-based drug design of a novel family of PPAR partial agonists: virtual screening, x-ray crystallography and in vitro/in vivo biological activities
5V19	;	3.1	;	Structure-based drug design of novel ASK1 inhibitors using a fully integrated lead optimization strategy
5V24	;	2.5	;	Structure-based drug design of novel ASK1 inhibitors using a fully integrated lead optimization strategy
3FDN	;	1.9	;	Structure-based drug design of novel Aurora kinase A inhibitors: Structure basis for potency and specificity
5AC9	;	3.2	;	Structure-based energetics of protein interfaces guide Foot-and-Mouth disease virus vaccine design
5ACA	;	3.5	;	Structure-based energetics of protein interfaces guide Foot-and-Mouth disease virus vaccine design
3LAQ	;	3.2	;	Structure-based engineering of species selectivity in the uPA-uPAR interaction
2VEI	;	1.89	;	Structure-based enzyme engineering efforts with an inactive monomeric TIM variant: the importance of a single point mutation for generating an active site with suitable binding properties
2VEK	;	1.6	;	Structure-based enzyme engineering efforts with an inactive monomeric TIM variant: the importance of a single point mutation for generating an active site with suitable binding properties
2VEL	;	2.3	;	Structure-based enzyme engineering efforts with an inactive monomeric TIM variant: the importance of a single point mutation for generating an active site with suitable binding properties
2VEM	;	2.2	;	Structure-based enzyme engineering efforts with an inactive monomeric TIM variant: the importance of a single point mutation for generating an active site with suitable binding properties
2VEN	;	2.0	;	Structure-based enzyme engineering efforts with an inactive monomeric TIM variant: the importance of a single point mutation for generating an active site with suitable binding properties
1ZS5	;		;	Structure-based evaluation of selective and non-selective small molecules that block HIV-1 TAT and PCAF association
5M0D	;	2.4	;	Structure-based evolution of a hybrid steroid series of Autotaxin inhibitors
5M0E	;	1.95	;	Structure-based evolution of a hybrid steroid series of Autotaxin inhibitors
5M0M	;	2.1	;	Structure-based evolution of a hybrid steroid series of Autotaxin inhibitors
5M0S	;	2.1	;	Structure-based evolution of a hybrid steroid series of Autotaxin inhibitors
6YKG	;	3.12	;	Structure-based exploration of selectivity for ATM inhibitors in Huntingtons disease
2CIQ	;	1.7	;	Structure-based functional annotation: Yeast ymr099c codes for a D- hexose-6-phosphate mutarotase.
2CIR	;	1.6	;	Structure-based functional annotation: Yeast ymr099c codes for a D- hexose-6-phosphate mutarotase. Complex with glucose-6-phosphate
2CIS	;	1.62	;	Structure-based functional annotation: Yeast ymr099c codes for a D- hexose-6-phosphate mutarotase. Complex with tagatose-6-phosphate
1VDH	;	2.0	;	Structure-based functional identification of a novel heme-binding protein from thermus thermophilus HB8
8QIC	;	2.5	;	Structure-based identification of salicylic acid derivatives as malarial threonyl tRNA-synthetase inhibitors
1B78	;	2.2	;	STRUCTURE-BASED IDENTIFICATION OF THE BIOCHEMICAL FUNCTION OF A HYPOTHETICAL PROTEIN FROM METHANOCOCCUS JANNASCHII:MJ0226
2MJP	;	2.2	;	STRUCTURE-BASED IDENTIFICATION OF THE BIOCHEMICAL FUNCTION OF A HYPOTHETICAL PROTEIN FROM METHANOCOCCUS JANNASCHII:MJ0226
4JR5	;	1.906	;	Structure-based Identification of Ureas as Novel Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors
5Y85	;	2.001	;	Structure-based Insights into Self-Cleavage by a Four-way Junctional Twister-Sister Ribozyme
5Y87	;	2.132	;	Structure-based Insights into Self-Cleavage by a Four-way Junctional Twister-Sister Ribozyme
3L2O	;	2.8	;	Structure-Based Mechanism of Dimerization-Dependent Ubiquitination by the SCFFbx4 Ubiquitin Ligase
2W5Q	;	1.2	;	Structure-based mechanism of lipoteichoic acid synthesis by Staphylococcus aureus LtaS.
2W5R	;	1.7	;	Structure-based mechanism of lipoteichoic acid synthesis by Staphylococcus aureus LtaS.
2W5S	;	2.1	;	Structure-based mechanism of lipoteichoic acid synthesis by Staphylococcus aureus LtaS.
2W5T	;	1.6	;	Structure-based mechanism of lipoteichoic acid synthesis by Staphylococcus aureus LtaS.
5TC0	;	2.24	;	Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate
5TD2	;	2.68	;	Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate
3SFC	;	2.1	;	Structure-Based Optimization of Potent 4- and 6-Azaindole-3-Carboxamides as Renin Inhibitors
3NZS	;	2.75	;	Structure-based Optimization of Pyrazolo -Pyrimidine and -Pyridine Inhibitors of PI3-Kinase
3NZU	;	2.6	;	Structure-based Optimization of Pyrazolo -Pyrimidine and -Pyridine Inhibitors of PI3-Kinase
1GK0	;	2.5	;	Structure-based prediction of modifications in glutarylamidase to allow single-step enzymatic production of 7-aminocephalosporanic acid from cephalosporin C
1GK1	;	2.4	;	Structure-based prediction of modifications in glutarylamidase to allow single-step enzymatic production of 7-aminocephalosporanic acid from cephalosporin C
4PC8	;	1.55	;	Structure-based protein engineering efforts on the scaffold of a monomeric triosephosphate isomerase yielding a sugar isomerase
4PCF	;	2.71	;	Structure-based protein engineering of a monomeric triosephosphate isomerase towards changing substrate specificity
1SKG	;	1.21	;	Structure-based rational drug design: Crystal structure of the complex formed between Phospholipase A2 and a pentapeptide Val-Ala-Phe-Arg-Ser
2YG5	;	1.9	;	Structure-based redesign of cofactor binding in Putrescine Oxidase: A394C mutant
2YG7	;	2.75	;	Structure-based redesign of cofactor binding in Putrescine Oxidase: A394C-A396T-Q431G Triple mutant
2YG6	;	2.5	;	Structure-based redesign of cofactor binding in Putrescine Oxidase: P15I-A394C double mutant
2YG4	;	2.3	;	Structure-based redesign of cofactor binding in Putrescine Oxidase: wild type bound to Putrescine
2YG3	;	2.0	;	Structure-based redesign of cofactor binding in Putrescine Oxidase: wild type enzyme
5AYQ	;	1.7	;	Structure-based site-directed photo-crosslinking analyses of multimeric cell-adhesive interactions of VGSC beta subunits
8E1A	;	1.2	;	Structure-based study to overcome cross-reactivity of novel androgen receptor inhibitors
5JYY	;	2.1	;	Structure-based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-resistant Influenza Viruses
7A2D	;		;	Structure-function analyses of dual-BON domain protein DolP identifies phospholipid binding as a new mechanism for protein localisation to the cell division site
3E81	;	1.629	;	Structure-function Analysis of 2-Keto-3-deoxy-D-glycero-D-galacto-nononate-9-phosphate (KDN) Phosphatase Defines a New Clad Within the Type C0 HAD Subfamily
3E84	;	1.85	;	Structure-function Analysis of 2-Keto-3-deoxy-D-glycero-D-galacto-nononate-9-phosphate (KDN) Phosphatase Defines a New Clad Within the Type C0 HAD Subfamily
3E8M	;	1.1	;	Structure-function Analysis of 2-Keto-3-deoxy-D-glycero-D-galacto-nononate-9-phosphate (KDN) Phosphatase Defines a New Clad Within the Type C0 HAD Subfamily
7BJT	;	1.42	;	Structure-function analysis of a new PL17 oligoalginate lyase from the marine bacterium Zobellia galactanivorans DsijT
7BM6	;	2.16	;	Structure-function analysis of a new PL17 oligoalginate lyase from the marine bacterium Zobellia galactanivorans DsijT
5HXU	;	1.83	;	Structure-function analysis of functionally diverse members of the cyclic amide hydrolase family of Toblerone fold enzymes
5HXZ	;	2.36	;	Structure-function analysis of functionally diverse members of the cyclic amide hydrolase family of Toblerone fold enzymes
5HY2	;	2.6	;	Structure-function analysis of functionally diverse members of the cyclic amide hydrolase family of Toblerone fold enzymes
5HY4	;	2.56	;	Structure-function analysis of functionally diverse members of the cyclic amide hydrolase family of Toblerone fold enzymes
3O19	;	1.66	;	Structure-function analysis of human L-Prostaglandin D Synthase bound with fatty acid
3O22	;	1.4	;	Structure-function analysis of human L-Prostaglandin D Synthase bound with fatty acid
3O2Y	;	1.7	;	Structure-function analysis of human L-Prostaglandin D Synthase bound with fatty acid
3HO6	;	1.6	;	Structure-function analysis of inositol hexakisphosphate-induced autoprocessing in clostridium difficile toxin A
3HQJ	;	1.95	;	Structure-function analysis of Mycobacterium tuberculosis acyl carrier protein synthase (AcpS).
3SHM	;	3.019	;	Structure-function Analysis of Receptor Binding in Adeno-Associated Virus Serotype 6 (AAV-6)
4V86	;	3.003	;	Structure-function Analysis of Receptor-binding in Adeno-Associated Virus Serotype 6 (AAV-6)
7UTF	;	2.5	;	Structure-Function characterization of an aldo-keto reductase involved in detoxification of the mycotoxin, deoxynivalenol
1D7L	;	2.2	;	STRUCTURE-FUNCTION CORRELATIONS OF THE REACTION OF REDUCED NICOTINAMIDE ANALOGS WITH P-HYDROXYBENZOATE HYDROXYLASE SUBSTITUTED WITH A SERIES OF 8-SUBSTITUTED FLAVINS
1ISA	;	1.8	;	STRUCTURE-FUNCTION IN E. COLI IRON SUPEROXIDE DISMUTASE: COMPARISONS WITH THE MANGANESE ENZYME FROM T. THERMOPHILUS
1ISB	;	1.85	;	STRUCTURE-FUNCTION IN E. COLI IRON SUPEROXIDE DISMUTASE: COMPARISONS WITH THE MANGANESE ENZYME FROM T. THERMOPHILUS
1ISC	;	1.8	;	STRUCTURE-FUNCTION IN E. COLI IRON SUPEROXIDE DISMUTASE: COMPARISONS WITH THE MANGANESE ENZYME FROM T. THERMOPHILUS
1MNG	;	1.8	;	STRUCTURE-FUNCTION IN E. COLI IRON SUPEROXIDE DISMUTASE: COMPARISONS WITH THE MANGANESE ENZYME FROM T. THERMOPHILUS
5LKS	;	3.6	;	Structure-function insights reveal the human ribosome as a cancer target for antibiotics
3O1E	;	2.5001	;	Structure-function of Gemini derivatives with two different side chains at C-20, Gemini-0072 and Gemini-0097.
1Z32	;	1.6	;	Structure-function relationships in human salivary alpha-amylase: Role of aromatic residues
2BTI	;	2.0	;	Structure-function studies of the RmsA CsrA post-transcriptional global regulator protein family reveals a class of RNA-binding structure
5I3F	;	1.72	;	Structure-Function Studies on Role of Hydrophobic Clamping of a Basic Glutamate in Catalysis by Triosephosphate Isomerase
5I3G	;	1.96	;	Structure-Function Studies on Role of Hydrophobic Clamping of a Basic Glutamate in Catalysis by Triosephosphate Isomerase
5I3H	;	2.25	;	Structure-Function Studies on Role of Hydrophobic Clamping of a Basic Glutamate in Catalysis by Triosephosphate Isomerase
5I3I	;	2.2	;	Structure-Function Studies on Role of Hydrophobic Clamping of a Basic Glutamate in Catalysis by Triosephosphate Isomerase
5I3J	;	1.8	;	Structure-Function Studies on Role of Hydrophobic Clamping of a Basic Glutamate in Catalysis by Triosephosphate Isomerase
5I3K	;	2.209	;	Structure-Function Studies on Role of Hydrophobic Clamping of a Basic Glutamate in Catalysis by Triosephosphate Isomerase
6KBL	;	1.7	;	Structure-function study of AKR4C14, an aldo-keto reductase from Thai Jasmine rice (Oryza sativa L. ssp. Indica cv. KDML105)
3O1D	;	2.4007	;	Structure-function study of Gemini derivatives with two different side chains at C-20, Gemini-0072 and Gemini-0097.
2L1U	;		;	Structure-Functional Analysis of Mammalian MsrB2 protein
2LV3	;		;	Structure-functional characterization of Grx domain of Mus musculus TGR
3KAB	;	2.19	;	Structure-guided design of alpha-amino acid-derived Pin1 inhibitors
3KAC	;	2.0	;	Structure-guided design of alpha-amino acid-derived Pin1 inhibitors
3KAD	;	1.95	;	Structure-guided design of alpha-amino acid-derived Pin1 inhibitors
3KAF	;	2.3	;	Structure-guided design of alpha-amino acid-derived Pin1 inhibitors
3KAG	;	1.9	;	Structure-guided design of alpha-amino acid-derived Pin1 inhibitors
3KAH	;	2.3	;	Structure-guided design of alpha-amino acid-derived Pin1 inhibitors
3KAI	;	1.9	;	Structure-guided design of alpha-amino acid-derived Pin1 inhibitors
3KCE	;	1.9	;	Structure-guided design of alpha-amino acid-derived Pin1 inhibitors
4WVL	;	2.41	;	Structure-Guided DOT1L Probe Optimization by Label-Free Ligand Displacement
5YW4	;	2.047	;	Structure-Guided Engineering of Reductase: Efficient Attenuating Substrate Inhibition in Asymmetric Catalysis
6XIH	;	2.65	;	Structure-guided optimization of a novel class of ASK1 inhibitors with increased sp3 character and an exquisite selectivity profile
7ESS	;	1.93	;	Structure-guided studies of the Holliday junction resolvase RuvX provide novel insights into ATP-stimulated cleavage of branched DNA and RNA substrates
2L8D	;		;	Structure/function of the LBR Tudor domain
2DKK	;	1.97	;	Structure/Function studies of Cytochrome P450 158A1 from Streptomyces Coelicolor A3(2)
3OFG	;	1.367	;	Structured Domain of Caenorhabditis elegans BMY-1
3OFE	;	2.288	;	Structured Domain of Drosophila melanogaster Boca p41 2 2 Crystal form
3OFF	;	2.002	;	Structured Domain of Drosophila melanogaster Boca p65 2 2 Crystal form
3OFH	;	2.013	;	Structured Domain of Mus musculus Mesd
2JM1	;		;	Structures and chemical shift assignments for the ADD domain of the ATRX protein
2LD1	;		;	Structures and chemical shift assignments for the ADD domain of the ATRX protein
3DM9	;	2.2	;	Structures and Conformations in Solution of the Signal Recognition Particle Receptor from the archaeon Pyrococcus furiosus
3DMD	;	2.21	;	Structures and Conformations in Solution of the Signal Recognition Particle Receptor from the archaeon Pyrococcus furiosus
3E70	;	1.97	;	Structures and conformations in solution of the Signal Recognition Particle Receptor from the Archaeon Pyrococcus Furiosus
5O6G	;	2.75	;	Structures and dynamics of mesophilic variants from the homing endonuclease I-DmoI
5O6I	;	2.25	;	Structures and dynamics of mesophilic variants from the homing endonuclease I-DmoI
5B7G	;	1.399	;	Structures and functional analysis of periplasmic 5-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Aeromonas hydrophila
5B7P	;	1.49	;	Structures and functional analysis of periplasmic 5-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Aeromonas hydrophila
5B7Q	;	1.493	;	Structures and functional analysis of periplasmic 5-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Aeromonas hydrophila
2LKE	;		;	Structures and Interaction Analyses of the Integrin Alpha-M Beta-2 Cytoplasmic Tails
2LKJ	;		;	Structures and Interaction Analyses of the Integrin Alpha-M Beta-2 Cytoplasmic Tails
3S66	;	1.401	;	Structures and oxygen affinities of crystalline human hemoglobin C (beta6 Lys) in the R quaternary structures
3S65	;	1.8	;	Structures and oxygen affinities of crystalline human hemoglobin C (beta6 Lys) in the R2 quaternary structures
5LQ3	;	3.55	;	Structures and transport dynamics of the Campylobacter jejuni multidrug efflux pump CmeB
2PU8	;	2.1	;	Structures of 5-methylthioribose kinase reveal substrate specificity and unusual mode of nucleotide binding
2PUI	;	2.2	;	Structures of 5-methylthioribose kinase reveal substrate specificity and unusual mode of nucleotide binding
2PUL	;	2.0	;	Structures of 5-methylthioribose kinase reveal substrate specificity and unusual mode of nucleotide binding
2PUN	;	2.3	;	Structures of 5-methylthioribose kinase reveal substrate specificity and unusual mode of nucleotide binding
2PUP	;	2.6	;	Structures of 5-methylthioribose kinase reveal substrate specificity and unusual mode of nucleotide binding
5GON	;	2.48	;	Structures of a beta-lactam bridged analogue in complex with tubulin
7VPP	;	2.69	;	Structures of a deltacoronavirus spike protein bound to porcine and human receptors indicate the risk of virus adaptation to humans
7VPQ	;	3.1	;	Structures of a deltacoronavirus spike protein bound to porcine and human receptors indicate the risk of virus adaptation to humans
1RMF	;	2.8	;	STRUCTURES OF A MONOCLONAL ANTI-ICAM-1 ANTIBODY R6.5 FRAGMENT AT 2.8 ANGSTROMS RESOLUTION
3MMV	;	2.8	;	Structures of actin-bound WH2 domains of Spire and the implication for filament nucleation
3MN5	;	1.5	;	Structures of actin-bound WH2 domains of Spire and the implication for filament nucleation
3MN6	;	2.0	;	Structures of actin-bound WH2 domains of Spire and the implication for filament nucleation
3MN7	;	2.0	;	Structures of actin-bound WH2 domains of Spire and the implication for filament nucleation
3MN9	;	2.0	;	Structures of actin-bound WH2 domains of Spire and the implication for filament nucleation
2OS0	;	1.3	;	Structures of actinonin bound peptide deformylases from E. faecalis and S. pyogenes
2OS1	;	1.5	;	Structures of actinonin bound peptide deformylases from E. faecalis and S. pyogenes
2OS3	;	2.26	;	Structures of actinonin bound peptide deformylases from E. faecalis and S. pyogenes
1GFI	;	2.2	;	STRUCTURES OF ACTIVE CONFORMATIONS OF GI ALPHA 1 AND THE MECHANISM OF GTP HYDROLYSIS
1DJ2	;	2.9	;	STRUCTURES OF ADENYLOSUCCINATE SYNTHETASE FROM TRITICUM AESTIVUM AND ARABIDOPSIS THALIANA
1DJ3	;	3.0	;	STRUCTURES OF ADENYLOSUCCINATE SYNTHETASE FROM TRITICUM AESTIVUM AND ARABIDOPSIS THALIANA
3U57	;	2.43	;	Structures of Alkaloid Biosynthetic Glucosidases Decode Substrate Specificity
3U5U	;	2.2	;	Structures of Alkaloid Biosynthetic Glucosidases Decode Substrate Specificity
3U5Y	;	2.3	;	Structures of Alkaloid Biosynthetic Glucosidases Decode Substrate Specificity
1CDH	;	2.3	;	STRUCTURES OF AN HIV AND MHC BINDING FRAGMENT FROM HUMAN CD4 AS REFINED IN TWO CRYSTAL LATTICES
1CDI	;	2.9	;	STRUCTURES OF AN HIV AND MHC BINDING FRAGMENT FROM HUMAN CD4 AS REFINED IN TWO CRYSTAL LATTICES
2IL3	;	2.2	;	Structures of an Insect Epsilon-class Glutathione S-transferase from the Malaria Vector Anopheles Gambiae: Evidence for High DDT-detoxifying Activity
2IMI	;	1.4	;	Structures of an Insect Epsilon-class Glutathione S-transferase from the Malaria Vector Anopheles Gambiae: Evidence for High DDT-detoxifying Activity
2IMK	;	1.9	;	Structures of an Insect Epsilon-class Glutathione S-transferase from the Malaria Vector Anopheles Gambiae: Evidence for High DDT-detoxifying Activity
2NSA	;	1.7	;	Structures of and interactions between domains of trigger factor from Themotoga maritim
2NSB	;	3.2	;	Structures of and interactions between domains of trigger factor from Themotoga maritima
2NSC	;	2.2	;	Structures of and interactions between domains of trigger factor from Themotoga maritima
1CDD	;	2.8	;	STRUCTURES OF APO AND COMPLEXED ESCHERICHIA COLI GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE
1CDE	;	2.5	;	STRUCTURES OF APO AND COMPLEXED ESCHERICHIA COLI GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE
3P4H	;	1.1	;	Structures of archaeal members of the LigD 3'-phosphoesterase DNA repair enzyme superfamily
1IVB	;	2.4	;	STRUCTURES OF AROMATIC INHIBITORS OF INFLUENZA VIRUS NEURAMINIDASE
1IVC	;	2.4	;	STRUCTURES OF AROMATIC INHIBITORS OF INFLUENZA VIRUS NEURAMINIDASE
1IVD	;	1.9	;	STRUCTURES OF AROMATIC INHIBITORS OF INFLUENZA VIRUS NEURAMINIDASE
1IVE	;	2.4	;	STRUCTURES OF AROMATIC INHIBITORS OF INFLUENZA VIRUS NEURAMINIDASE
1IVF	;	2.4	;	STRUCTURES OF AROMATIC INHIBITORS OF INFLUENZA VIRUS NEURAMINIDASE
1IVG	;	1.9	;	STRUCTURES OF AROMATIC INHIBITORS OF INFLUENZA VIRUS NEURAMINIDASE
3GB1	;		;	STRUCTURES OF B1 DOMAIN OF STREPTOCOCCAL PROTEIN G
6W19	;	5.5	;	Structures of Capsid and Capsid-Associated Tegument Complex inside the Epstein-Barr Virus
6W2D	;	4.0	;	Structures of Capsid and Capsid-Associated Tegument Complex inside the Epstein-Barr Virus
6W2E	;	4.4	;	Structures of Capsid and Capsid-Associated Tegument Complex inside the Epstein-Barr Virus
7BEG	;	4.2	;	Structures of class I bacterial transcription complexes
7BEF	;	4.5	;	Structures of class II bacterial transcription complexes
3PDD	;	1.72	;	Structures of Clostridium thermocellum CbhA fibronectin(III)-like modules
3PDG	;	1.78	;	Structures of Clostridium thermocellum CbhA fibronectin(III)-like modules
3PE9	;	1.69	;	Structures of Clostridium thermocellum CbhA fibronectin(III)-like modules
4APR	;	2.5	;	STRUCTURES OF COMPLEXES OF RHIZOPUSPEPSIN WITH PEPSTATIN AND OTHER STATINE-CONTAINING INHIBITORS
5APR	;	2.1	;	STRUCTURES OF COMPLEXES OF RHIZOPUSPEPSIN WITH PEPSTATIN AND OTHER STATINE-CONTAINING INHIBITORS
6APR	;	2.5	;	STRUCTURES OF COMPLEXES OF RHIZOPUSPEPSIN WITH PEPSTATIN AND OTHER STATINE-CONTAINING INHIBITORS
4XIA	;	2.3	;	STRUCTURES OF D-XYLOSE ISOMERASE FROM ARTHROBACTER STRAIN B3728 CONTAINING THE INHIBITORS XYLITOL AND D-SORBITOL AT 2.5 ANGSTROMS AND 2.3 ANGSTROMS RESOLUTION, RESPECTIVELY
5XIA	;	2.5	;	STRUCTURES OF D-XYLOSE ISOMERASE FROM ARTHROBACTER STRAIN B3728 CONTAINING THE INHIBITORS XYLITOL AND D-SORBITOL AT 2.5 ANGSTROMS AND 2.3 ANGSTROMS RESOLUTION, RESPECTIVELY
5JSO	;	2.0	;	Structures of DddQ from Ruegeria lac. Reveal Key Residues for Metal Binding and Catalysis - TRIS bound
5LUT	;	2.72	;	Structures of DHBN domain of Gallus gallus BLM helicase
5LUP	;	2.032	;	Structures of DHBN domain of human BLM helicase
5MK5	;	2.16	;	Structures of DHBN domain of human BLM helicase
5LUS	;	1.433	;	Structures of DHBN domain of Pelecanus crispus BLM helicase
3HBB	;	3.0	;	Structures of dihydrofolate reductase-thymidylate synthase of Trypanosoma cruzi in the folate-free state and in complex with two antifolate drugs, trimetrexate and methotrexate
2ZTI	;	2.6	;	Structures of dimeric nonstandard nucleotide triphosphate pyrophosphatase from Pyrococcus horikoshii OT3: functional significance of interprotomer conformational changes
2ND8	;		;	Structures of DK17 in TBLE LUVS
4IJ0	;	1.54	;	Structures of DNA duplexes containing O6-carboxymethylguanine, a lesion associated with gastrointestinal cancer, reveal a mechanism for inducing transition mutation
4ITD	;	1.94	;	Structures of DNA duplexes containing O6-carboxymethylguanine, a lesion associated with gastrointestinal cancer, reveal a mechanism for inducing transition mutation
1ARD	;		;	STRUCTURES OF DNA-BINDING MUTANT ZINC FINGER DOMAINS: IMPLICATIONS FOR DNA BINDING
1ARE	;		;	STRUCTURES OF DNA-BINDING MUTANT ZINC FINGER DOMAINS: IMPLICATIONS FOR DNA BINDING
1ARF	;		;	STRUCTURES OF DNA-BINDING MUTANT ZINC FINGER DOMAINS: IMPLICATIONS FOR DNA BINDING
2W35	;	2.15	;	Structures of endonuclease V with DNA reveal initiation of deaminated adenine repair
2W36	;	2.1	;	Structures of endonuclease V with DNA reveal initiation of deaminated adenine repair
3SO3	;	2.1	;	Structures of Fab-Protease Complexes Reveal a Highly Specific Non-Canonical Mechanism of Inhibition.
2W16	;	2.71	;	Structures of FpvA bound to heterologous pyoverdines
1POD	;	2.1	;	STRUCTURES OF FREE AND INHIBITED HUMAN SECRETORY PHOSPHOLIPASE A2 FROM INFLAMMATORY EXUDATE
1POE	;	2.1	;	STRUCTURES OF FREE AND INHIBITED HUMAN SECRETORY PHOSPHOLIPASE A2 FROM INFLAMMATORY EXUDATE
6V6B	;	3.8	;	Structures of GCP2 and GCP3 in the native human gamma-tubulin ring complex
6V69	;	4.2	;	Structures of GCP4 and GCP5 in the native human gamma-tubulin ring complex
1FS4	;	2.38	;	Structures of glycogen phosphorylase-inhibitor complexes and the implications for structure-based drug design
1FTQ	;	2.35	;	STRUCTURES OF GLYCOGEN PHOSPHORYLASE-INHIBITOR COMPLEXES AND THE IMPLICATIONS FOR STRUCTURE-BASED DRUG DESIGN
1FTW	;	2.36	;	STRUCTURES OF GLYCOGEN PHOSPHORYLASE-INHIBITOR COMPLEXES AND THE IMPLICATIONS FOR STRUCTURE-BASED DRUG DESIGN
1FTY	;	2.38	;	STRUCTURES OF GLYCOGEN PHOSPHORYLASE-INHIBITOR COMPLEXES AND THE IMPLICATIONS FOR STRUCTURE-BASED DRUG DESIGN
1FU4	;	2.36	;	STRUCTURES OF GLYCOGEN PHOSPHORYLASE-INHIBITOR COMPLEXES AND THE IMPLICATIONS FOR STRUCTURE-BASED DRUG DESIGN
1FU7	;	2.36	;	STRUCTURES OF GLYCOGEN PHOSPHORYLASE-INHIBITOR COMPLEXES AND THE IMPLICATIONS FOR STRUCTURE-BASED DRUG DESIGN
1FU8	;	2.35	;	STRUCTURES OF GLYCOGEN PHOSPHORYLASE-INHIBITOR COMPLEXES AND THE IMPLICATIONS FOR STRUCTURE-BASED DRUG DESIGN
1GGN	;	2.36	;	Structures of glycogen phosphorylase-inhibitor complexes and the implications for structure-based drug design
3MXC	;	2.0	;	Structures of Grb2-SH2 Domain and AICD peptide Complexes Reveal a Conformational Switch and Their Functional Implications.
3MXY	;	2.3	;	Structures of Grb2-SH2 Domain and AICD peptide Complexes Reveal a Conformational Switch and Their Functional Implications.
4B3O	;	3.3	;	Structures of HIV-1 RT and RNA-DNA Complex Reveal a Unique RT Conformation and Substrate Interface
4B3P	;	4.839	;	Structures of HIV-1 RT and RNA-DNA Complex Reveal a Unique RT Conformation and Substrate Interface
4B3Q	;	5.0	;	Structures of HIV-1 RT and RNA-DNA Complex Reveal a Unique RT Conformation and Substrate Interface
1Q94	;	2.4	;	Structures of HLA-A*1101 in complex with immunodominant nonamer and decamer HIV-1 epitopes clearly reveal the presence of a middle anchor residue
1QVO	;	2.22	;	STRUCTURES OF HLA-A*1101 IN COMPLEX WITH IMMUNODOMINANT NONAMER AND DECAMER HIV-1 EPITOPES CLEARLY REVEAL THE PRESENCE OF A MIDDLE ANCHOR RESIDUE
8E13	;	1.37	;	Structures of HLA-B8E76C loaded with long peptides reveal novel features at the N-terminus of the groove
8E2Z	;	1.13	;	Structures of HLA-B8E76C loaded with long peptides reveal novel features at the N-terminus of the groove
8E8I	;	1.49	;	Structures of HLA-B8E76C loaded with long peptides reveal novel features at the N-terminus of the groove
8EC5	;	1.22	;	Structures of HLA-B8E76C loaded with long peptides reveal novel features at the N-terminus of the groove
1HLD	;	2.1	;	STRUCTURES OF HORSE LIVER ALCOHOL DEHYDROGENASE COMPLEXED WITH NAD+ AND SUBSTITUTED BENZYL ALCOHOLS
3K54	;	1.94	;	Structures of human Bruton's tyrosine kinase in active and inactive conformations suggests a mechanism of activation for TEC family kinases.
2X7S	;	1.64	;	Structures of human carbonic anhydrase II inhibitor complexes reveal a second binding site for steroidal and non-steroidal inhibitors.
2X7T	;	1.89	;	Structures of human carbonic anhydrase II inhibitor complexes reveal a second binding site for steroidal and non-steroidal inhibitors.
2X7U	;	2.12	;	Structures of human carbonic anhydrase II inhibitor complexes reveal a second binding site for steroidal and non-steroidal inhibitors.
7NA7	;	2.7	;	Structures of human ghrelin receptor-Gi complexes with ghrelin and a synthetic agonist
7NA8	;	2.7	;	Structures of human ghrelin receptor-Gi complexes with ghrelin and a synthetic agonist
5GNS	;	2.702	;	Structures of human Mitofusin 1 provide insight into mitochondrial tethering
1H35	;	2.8	;	Structures of Human Oxidosqualene Cyclase Inhibitors Bound to an Homologous Enzyme
1H36	;	2.8	;	Structures of Human Oxidosqualene Cyclase Inhibitors Bound to an Homologous Enzyme
1H37	;	2.8	;	Structures of Human Oxidosqualene Cyclase Inhibitors Bound to an Homologous Enzyme
1H39	;	2.8	;	Structures of Human Oxidosqualene Cyclase Inhibitors Bound to an Homologous Enzyme
1H3A	;	2.85	;	Structures of Human Oxidosqualene Cyclase Inhibitors Bound to an Homologous Enzyme
1H3C	;	2.9	;	Structures of Human Oxidosqualene Cyclase Inhibitors Bound to an Homologous Enzyme
1O6Q	;	2.8	;	Structures of human oxidosqualene cyclase inhibitors bound to an homologous enzyme
1O6R	;	2.7	;	Structures of human oxidosqualene cyclase inhibitors bound to an homologous enzyme
1O79	;	2.8	;	Structures of human oxidosqualene cyclase inhibitors bound to an homologous enzyme
3OLE	;	1.55	;	Structures of human pancreatic alpha-amylase in complex with acarviostatin II03
3OLG	;	2.3	;	Structures of human pancreatic alpha-amylase in complex with acarviostatin III03
3OLI	;	1.5	;	Structures of human pancreatic alpha-amylase in complex with acarviostatin IV03
3VE4	;	1.6	;	Structures of ICT and PR1 intermediates from time-resolved laue crystallography
4I39	;	1.6	;	Structures of ICT and PR1 intermediates from time-resolved laue crystallography collected at 14ID-B, APS
5AE4	;	3.3	;	Structures of inactive and activated DntR provide conclusive evidence for the mechanism of action of LysR transcription factors
5AE5	;	2.645	;	Structures of inactive and activated DntR provide conclusive evidence for the mechanism of action of LysR transcription factors
2WR0	;	2.45	;	Structures of influenza H2 Hemagglutinins
3OX4	;	2.0	;	Structures of iron-dependent alcohol dehydrogenase 2 from Zymomonas mobilis ZM4 complexed with NAD cofactor
3OWO	;	2.07	;	Structures of iron-dependent alcohol dehydrogenase 2 from Zymomonas mobilis ZM4 with and without NAD cofactor
4I3I	;	1.6	;	Structures of IT intermediate of photoactive yellow protein E46Q mutant from time-resolved laue crystallography collected at 14ID APS
4I38	;	1.6	;	Structures of IT intermediates from time-resolved laue crystallography collected at 14ID-B, APS
2WZP	;	2.6	;	Structures of Lactococcal Phage p2 Baseplate Shed Light on a Novel Mechanism of Host Attachment and Activation in Siphoviridae
4GV3	;	1.68	;	Structures of Lassa and Tacaribe viral nucleoproteins with or without 5 triphosphate dsRNA substrate reveal a unique 3 -5 exoribonuclease mechanism to suppress type I interferon production
4GV6	;	1.98	;	Structures of Lassa and Tacaribe viral nucleoproteins with or without 5 triphosphate dsRNA substrate reveal a unique 3 -5 exoribonuclease mechanism to suppress type I interferon production
5E6R	;	2.901	;	Structures of leukocyte integrin aLb2: The aI domain, the headpiece, and the pocket for the internal ligand
5E6S	;	2.15	;	Structures of leukocyte integrin aLB2: The aI domain, the headpiece, and the pocket for the internal ligand
5E6U	;	2.5	;	Structures of leukocyte integrin aLb2: The aI domain, the headpiece, and the pocket for the internal ligand
2FY2	;	2.25	;	Structures of ligand bound human choline acetyltransferase provide insight into regulation of acetylcholine synthesis
2FY4	;	2.3	;	Structures of ligand bound human choline acetyltransferase provide insight into regulation of acetylcholine synthesis
2FY5	;	2.6	;	Structures of ligand bound human choline acetyltransferase provide insight into regulation of acetylcholine synthesis
2FY3	;	2.27	;	Structures of ligand bound human choline acetyltransferase provides insight into regulation of acetylcholine synthesis
3DNT	;	1.66	;	structures of MDT proteins
1H47	;	1.99	;	Structures of MECP synthase in complex with (i) CMP and (ii) CMP and product
2YMB	;	3.404	;	Structures of MITD1
4A5X	;	1.91	;	Structures of MITD1
4A5Z	;	2.3	;	Structures of MITD1
4EDA	;	2.701	;	Structures of monomeric hemagglutinin and its complex with an Fab fragment of a neutralizing antibody that binds to H1 subtype influenza viruses: molecular basis of infectivity of 2009 pandemic H1N1 influenza A viruses
4EDB	;	2.5	;	Structures of monomeric hemagglutinin and its complex with an Fab fragment of a neutralizing antibody that binds to H1 subtype influenza viruses: molecular basis of infectivity of 2009 pandemic H1N1 influenza A viruses
4RHX	;	2.0322	;	Structures of Mycobacterium tuberculosis 6-oxopurine phosphoribosyltransferase which is a potential target for drug development against this disease
4GFK	;	1.95	;	structures of NO factors
7WS0	;	3.2	;	Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development
7WS1	;	3.4	;	Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development
7WS2	;	3.3	;	Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development
7WS3	;	3.6	;	Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development
7WS5	;	3.7	;	Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development
7WS6	;	3.8	;	Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development
7WS7	;	3.4	;	Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development
7WS8	;	3.0	;	Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development
7WS9	;	2.9	;	Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development
7WSA	;	3.0	;	Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development
1UJ8	;	1.75	;	Structures of ORF3 in Two Crystal Forms, a Member of Isc Machinery of E. coli Involved in the Assembly of Iron-Sulfur Clusters
4KSB	;	3.8001	;	Structures of P-glycoprotein reveal its conformational flexibility and an epitope on the nucleotide-binding domain
4KSC	;	4.0	;	Structures of P-glycoprotein reveal its conformational flexibility and an epitope on the nucleotide-binding domain
4KSD	;	4.1001	;	Structures of P-glycoprotein reveal its conformational flexibility and an epitope on the nucleotide-binding domain
2W75	;	2.9	;	Structures of P. aeruginosa FpvA bound to heterologous pyoverdines: Apo-FpvA
2W78	;	3.0	;	Structures of P. aeruginosa FpvA bound to heterologous pyoverdines: FpvA-Pvd(ATCC13535)-Fe complex
2W6T	;	2.9	;	Structures of P. aeruginosa FpvA bound to heterologous pyoverdines: FpvA-Pvd(DSM50106)-Fe complex
2W6U	;	3.0	;	Structures of P. aeruginosa FpvA bound to heterologous pyoverdines: FpvA-Pvd(G173)-Fe complex
2W76	;	2.8	;	Structures of P. aeruginosa FpvA bound to heterologous pyoverdines: FpvA-Pvd(Pa6)-Fe complex
2W77	;	2.9	;	Structures of P. aeruginosa FpvA bound to heterologous pyoverdines: FpvA-Pvd(Pfl18.1)-Fe complex
4KU7	;	1.65	;	Structures of PKGI Reveal a cGMP-Selective Activation Mechanism
4KU8	;	1.994	;	Structures of PKGI Reveal a cGMP-Selective Activation Mechanism
4HY8	;	1.6	;	Structures of PR1 and PR2 intermediates from time-resolved laue crystallography
4I3A	;	1.6	;	Structures of PR1 and PR2 intermediates from time-resolved laue crystallography collected at 14ID-B, APS
4I3J	;	1.6	;	Structures of PR1 intermediate of photoactive yellow protein E46Q mutant from time-resolved laue crystallography collected AT 14ID APS
3SGA	;	1.8	;	STRUCTURES OF PRODUCT AND INHIBITOR COMPLEXES OF STREPTOMYCES GRISEUS PROTEASE A AT 1.8 ANGSTROMS RESOLUTION. A MODEL FOR SERINE PROTEASE CATALYSIS
4SGA	;	1.8	;	STRUCTURES OF PRODUCT AND INHIBITOR COMPLEXES OF STREPTOMYCES GRISEUS PROTEASE A AT 1.8 ANGSTROMS RESOLUTION. A MODEL FOR SERINE PROTEASE CATALYSIS
5SGA	;	1.8	;	Structures of product and inhibitor complexes of Streptomyces griseus protease a at 1.8 Angstroms resolution. a model for serine protease catalysis
129L	;	1.7	;	STRUCTURES OF RANDOMLY GENERATED MUTANTS OF T4 LYSOZYME SHOW THAT PROTEIN STABILITY CAN BE ENHANCED BY RELAXATION OF STRAIN AND BY IMPROVED HYDROGEN BONDING VIA BOUND SOLVENT
130L	;	1.7	;	STRUCTURES OF RANDOMLY GENERATED MUTANTS OF T4 LYSOZYME SHOW THAT PROTEIN STABILITY CAN BE ENHANCED BY RELAXATION OF STRAIN AND BY IMPROVED HYDROGEN BONDING VIA BOUND SOLVENT
131L	;	1.7	;	STRUCTURES OF RANDOMLY GENERATED MUTANTS OF T4 LYSOZYME SHOW THAT PROTEIN STABILITY CAN BE ENHANCED BY RELAXATION OF STRAIN AND BY IMPROVED HYDROGEN BONDING VIA BOUND SOLVENT
6AXD	;		;	Structures of REV1 UBM2 domain complex with ubiquitin and with the first small-molecule that inhibits the REV1 UBM2-ubiquitin interaction
3JCJ	;	3.7	;	Structures of ribosome-bound initiation factor 2 reveal the mechanism of subunit association
3JCN	;	4.6	;	Structures of ribosome-bound initiation factor 2 reveal the mechanism of subunit association: Initiation Complex I
1RPG	;	1.4	;	STRUCTURES OF RNASE A COMPLEXED WITH 3'-CMP AND D(CPA): ACTIVE SITE CONFORMATION AND CONSERVED WATER MOLECULES
1RPH	;	2.2	;	STRUCTURES OF RNASE A COMPLEXED WITH 3'-CMP AND D(CPA): ACTIVE SITE CONFORMATION AND CONSERVED WATER MOLECULES
4NYE	;	2.69	;	Structures of SAICAR Synthetase (PurC) from Streptococcus pneumoniae with ADP, Mg2+, AIR and L-Asp
1BC8	;	1.93	;	STRUCTURES OF SAP-1 BOUND TO DNA SEQUENCES FROM THE E74 AND C-FOS PROMOTERS PROVIDE INSIGHTS INTO HOW ETS PROTEINS DISCRIMINATE BETWEEN RELATED DNA TARGETS
4JDZ	;	2.1	;	Structures of SdrD from Staphylococcus aureus reveal the molecular mechanism of how the cell surface receptors recognize their ligands
4JE0	;	1.7	;	Structures of SdrD from Staphylococcus aureus reveal the molecular mechanism of how the cell surface receptors recognize their ligands
3IVB	;	1.75	;	Structures of SPOP-Substrate Complexes: Insights into Architectures of BTB-Cul3 Ubiquitin Ligases: SPOPMATH-MacroH2ASBCpep1
3HVE	;	2.8	;	Structures of SPOP-Substrate Complexes: Insights into Molecular Architectures of BTB-Cul3 Ubiquitin Ligases: GigaxoninBTB/3-box
3HTM	;	2.5	;	Structures of SPOP-Substrate Complexes: Insights into Molecular Architectures of BTB-Cul3 Ubiquitin Ligases: SPOPBTB/3-box
3IVQ	;	2.1	;	Structures of SPOP-Substrate Complexes: Insights into Molecular Architectures of BTB-Cul3 Ubiquitin Ligases: SPOPMATH-CiSBC2
3IVV	;	1.25	;	Structures of SPOP-Substrate Complexes: Insights into Molecular Architectures of BTB-Cul3 Ubiquitin Ligases: SPOPMATH-PucSBC1_pep1
3HQM	;	1.74	;	Structures of SPOP-Substrate Complexes: Insights into Molecular Architectures of BTB-Cul3 Ubiquitin Ligases: SPOPMATHx-CiSBC2
3HQH	;	2.3	;	Structures of SPOP-Substrate Complexes: Insights into Molecular Architectures of BTB-Cul3 Ubiquitin Ligases: SPOPMATHx-MacroH2ASBCpep1
3HSV	;	1.43	;	Structures of SPOP-Substrate Complexes: Insights into Molecular Architectures of BTB-Cul3 Ubiquitin Ligases: SPOPMATHx-MacroH2ASBCpep2
3HQI	;	2.62	;	Structures of SPOP-Substrate Complexes: Insights into Molecular Architectures of BTB-Cul3 Ubiquitin Ligases: SPOPMATHx/BTB/3-box-PucSBC1
3HU6	;	2.7	;	Structures of SPOP-Substrate Complexes: Insights into Molecular Architectures of BTB-Cul3 Ubiquitin Ligases: SPOPMATHx/BTB/3-box-PucSBC1
3HQL	;	1.66	;	Structures of SPOP-Substrate Complexes: Insights into Molecular Architectures of BTB-Cul3 Ubiquitin Ligases:SPOPMATHx-PucSBC1_pep2
3DLU	;	1.8	;	Structures of SRP54 and SRP19, the two proteins assembling the ribonucleic core of the Signal Recognition Particle from the archaeon Pyrococcus furiosus.
3DLV	;	1.87	;	Structures of SRP54 and SRP19, the two proteins assembling the ribonucleic core of the Signal Recognition Particle from the archaeon Pyrococcus furiosus.
3DM5	;	2.51	;	Structures of SRP54 and SRP19, the two proteins assembling the ribonucleic core of the Signal Recognition Particle from the archaeon Pyrococcus furiosus.
5JY6	;	2.0	;	Structures of Streptococcus agalactiae GBS GAPDH in different enzymatic states
5JYA	;	2.85	;	Structures of Streptococcus agalactiae GBS GAPDH in different enzymatic states
5JYE	;	2.23	;	Structures of Streptococcus agalactiae GBS GAPDH in different enzymatic states
5JYF	;	2.62	;	Structures of Streptococcus agalactiae GBS GAPDH in different enzymatic states
7S0Y	;	2.79	;	Structures of TcdB in complex with Cdc42
7S0Z	;	2.34	;	Structures of TcdB in complex with R-Ras
2BPF	;	2.9	;	STRUCTURES OF TERNARY COMPLEXES OF RAT DNA POLYMERASE BETA, A DNA TEMPLATE-PRIMER, AND DDCTP
2BPG	;	3.6	;	STRUCTURES OF TERNARY COMPLEXES OF RAT DNA POLYMERASE BETA, A DNA TEMPLATE-PRIMER, AND DDCTP
1TPD	;	2.1	;	STRUCTURES OF THE ""OPEN"" AND ""CLOSED"" STATE OF TRYPANOSOMAL TRIOSEPHOSPHATE ISOMERASE, AS OBSERVED IN A NEW CRYSTAL FORM: IMPLICATIONS FOR THE REACTION MECHANISM
1GHP	;	1.76	;	STRUCTURES OF THE ACYL-ENZYME COMPLEX OF THE STAPHYLOCOCCUS AUREUS BETA-LACTAMASE MUTANT GLU166ASP:ASN170GLN WITH DEGRADED BENZYLPENICILLIN
1GHM	;	1.86	;	Structures of the acyl-enzyme complex of the staphylococcus aureus beta-lactamase mutant GLU166ASP:ASN170GLN with degraded cephaloridine
1TNP	;		;	STRUCTURES OF THE APO AND CALCIUM TROPONIN-C REGULATORY DOMAINS: THE MUSCLE CONTRACTION SWITCH
1TNQ	;		;	STRUCTURES OF THE APO AND CALCIUM TROPONIN-C REGULATORY DOMAINS: THE MUSCLE CONTRACTION SWITCH
1DPR	;	3.0	;	STRUCTURES OF THE APO-AND METAL ION ACTIVATED FORMS OF THE DIPHTHERIA TOX REPRESSOR FROM CORYNEBACTERIUM DIPHTHERIAE
4V9D	;	3.0	;	Structures of the bacterial ribosome in classical and hybrid states of tRNA binding
5CA9	;	2.8	;	Structures of the candida albicans sey1p GTPase in complex with GDPAlF4-
2HKR	;	1.4	;	Structures of the carbinolamine and schiff-base intermediates in the reductive half-reaction of aromatic amine dehydrogenase (AADH) with p-methoxyphenylethylamine
8PAB	;	1.8	;	Structures of the ectodomains of Atypical porcine pestivirus solved by long wavelength sulphur SAD
4ZJ8	;	2.751	;	Structures of the human OX1 orexin receptor bound to selective and dual antagonists
4ZJC	;	2.832	;	Structures of the human OX1 orexin receptor bound to selective and dual antagonists
7RPM	;		;	Structures of the Intracellular Domain and Transmembrane Domain of the Human alpha7 Nicotinic Acetylcholine Receptors
1LEC	;	2.0	;	STRUCTURES OF THE LECTIN IV OF GRIFFONIA SIMPLICIFOLIA AND ITS COMPLEX WITH THE LEWIS B HUMAN BLOOD GROUP DETERMINANT AT 2.0 ANGSTROMS RESOLUTION
1LED	;	2.0	;	STRUCTURES OF THE LECTIN IV OF GRIFFONIA SIMPLICIFOLIA AND ITS COMPLEX WITH THE LEWIS B HUMAN BLOOD GROUP DETERMINANT AT 2.0 ANGSTROMS RESOLUTION
3RO2	;	2.3	;	Structures of the LGN/NuMA complex
1VT7	;	2.5	;	Structures of the mismatched duplex D(GGGTGCCC)
3AOA	;	3.35	;	Structures of the multidrug exporter AcrB reveal a proximal multisite drug-binding pocket
3AOB	;	3.35	;	Structures of the multidrug exporter AcrB reveal a proximal multisite drug-binding pocket
3AOC	;	3.34	;	Structures of the multidrug exporter AcrB reveal a proximal multisite drug-binding pocket
3AOD	;	3.3	;	Structures of the multidrug exporter AcrB reveal a proximal multisite drug-binding pocket
1CWP	;	3.2	;	STRUCTURES OF THE NATIVE AND SWOLLEN FORMS OF COWPEA CHLOROTIC MOTTLE VIRUS DETERMINED BY X-RAY CRYSTALLOGRAPHY AND CRYO-ELECTRON MICROSCOPY
5HAW	;	1.89	;	structures of the NO factor SlmA bound to DNA and the cytoskeletal cell division protein FtsZ
2HPP	;	3.3	;	Structures of the noncovalent complexes of human and bovine prothrombin fragment 2 with human ppack-thrombin
2HPQ	;	3.3	;	Structures of the noncovalent complexes of human and bovine prothrombin fragment 2 with human ppack-thrombin
2V5L	;	2.4	;	Structures of the Open and Closed State of Trypanosomal Triosephosphate Isomerase: as Observed in a New Crystal Form: Implications for the Reaction Mechanism
2N5B	;		;	Structures of the OXIDIZED state of the mutant D24A of yeast thioredoxin 1
6BYR	;	3.661	;	Structures of the PKA RI alpha holoenzyme with the FLHCC driver J-PKAc alpha or native PKAc alpha
6BYS	;	4.75	;	Structures of the PKA RI alpha holoenzyme with the FLHCC driver J-PKAc alpha or native PRKAc alpha
2N5A	;		;	Structures of the REDUCED state of the mutant D24A of yeast thioredoxin 1
2WCO	;	1.94	;	Structures of the Streptomyces coelicolor A3(2) Hyaluronan Lyase in Complex with Oligosaccharide Substrates and an Inhibitor
3PPN	;	2.3	;	Structures of the substrate-binding protein provide insights into the multiple compatible solutes binding specificities of Bacillus subtilis ABC transporter OpuC
3PPO	;	2.7	;	Structures of the substrate-binding protein provide insights into the multiple compatible solutes binding specificities of Bacillus subtilis ABC transporter OpuC
3PPP	;	2.4	;	Structures of the substrate-binding protein provide insights into the multiple compatible solutes binding specificities of Bacillus subtilis ABC transporter OpuC
3PPQ	;	1.91	;	Structures of the substrate-binding protein provide insights into the multiple compatible solutes binding specificities of Bacillus subtilis ABC transporter OpuC
3PPR	;	2.1	;	Structures of the substrate-binding protein provide insights into the multiple compatible solutes binding specificities of Bacillus subtilis ABC transporter OpuC
6NWH	;	2.03	;	Structures of the transcriptional regulator BgaR, a lactose sensor.
6NWJ	;	2.16	;	Structures of the transcriptional regulator BgaR, a lactose sensor.
6NWM	;	2.11	;	Structures of the transcriptional regulator BgaR, a lactose sensor.
6NWO	;	2.11	;	Structures of the transcriptional regulator BgaR, a lactose sensor.
6NX3	;	1.87	;	Structures of the transcriptional regulator BgaR, a lactose sensor.
6B74	;	2.323	;	Structures of the two-chain human plasma Factor XIIa co-crystallized with potent inhibitors
6B77	;	2.37	;	Structures of the two-chain human plasma factor XIIa co-crystallized with potent inhibitors
5CA8	;	2.3	;	Structures of the yeast dynamin-like GTPase Sey1p in complex with GDP
2BVO	;	1.65	;	Structures of Three HIV-1 HLA-B5703-Peptide Complexes and Identification of Related HLAs Potentially Associated with Long-Term Non-Progression
2BVP	;	1.35	;	Structures of Three HIV-1 HLA-B5703-Peptide Complexes and Identification of Related HLAs Potentially Associated with Long-Term Non-Progression
2BVQ	;	2.0	;	Structures of Three HIV-1 HLA-B5703-Peptide Complexes and Identification of Related HLAs Potentially Associated with Long-Term Non-Progression
1THR	;	2.3	;	STRUCTURES OF THROMBIN COMPLEXES WITH A DESIGNED AND A NATURAL EXOSITE INHIBITOR
1THS	;	2.2	;	STRUCTURES OF THROMBIN COMPLEXES WITH A DESIGNED AND A NATURAL EXOSITE INHIBITOR
3H9K	;	2.65	;	Structures of Thymidylate Synthase R163K with Substrates and Inhibitors Show Subunit Asymmetry
3HB8	;	2.74	;	Structures of Thymidylate Synthase R163K with Substrates and Inhibitors Show Subunit Asymmetry
1TDA	;	3.09	;	STRUCTURES OF THYMIDYLATE SYNTHASE WITH A C-TERMINAL DELETION: ROLE OF THE C-TERMINUS IN ALIGNMENT OF D/UMP AND CH2H4FOLATE
1TDB	;	2.65	;	STRUCTURES OF THYMIDYLATE SYNTHASE WITH A C-TERMINAL DELETION: ROLE OF THE C-TERMINUS IN ALIGNMENT OF D/UMP AND CH2H4FOLATE
1TDC	;	2.65	;	STRUCTURES OF THYMIDYLATE SYNTHASE WITH A C-TERMINAL DELETION: ROLE OF THE C-TERMINUS IN ALIGNMENT OF D/UMP AND CH2H4FOLATE
2TDD	;	2.7	;	STRUCTURES OF THYMIDYLATE SYNTHASE WITH A C-TERMINAL DELETION: ROLE OF THE C-TERMINUS IN ALIGNMENT OF D/UMP AND CH2H4FOLATE
4OKR	;	2.601	;	Structures of Toxoplasma gondii MIC2
6J05	;	1.86	;	Structures of two ArsR As(III)-responsive repressors: implications for the mechanism of derepression
6J0E	;	1.6	;	Structures of two ArsR As(III)-responsive repressors: implications for the mechanism of derepression
3K7L	;	2.5	;	Structures of two elapid snake venom metalloproteases with distinct activities highlight the disulfide patterns in the D domain of ADAMalysin family proteins
3K7N	;	2.3	;	Structures of two elapid snake venom metalloproteases with distinct activities highlight the disulfide patterns in the D domain of ADAMalysin family proteins
1LM5	;	1.8	;	Structures of two intermediate filament-binding fragments of desmoplakin reveal a unique repeat motif structure
1LM7	;	3.0	;	Structures of two intermediate filament-binding fragments of desmoplakin reveal a unique repeat motif structure
6TMN	;	1.6	;	Structures of two thermolysin-inhibitor complexes that differ by a single hydrogen bond
1VGA	;	1.8	;	Structures of unligated and inhibitor complexes of W168F mutant of Triosephosphate Isomerase from Plasmodium falciparum
4DOF	;	2.8	;	Structures of Vaccinia Virus Uracil-DNA Glycosylase in New Crystal Forms
4DOG	;	2.3	;	Structures of Vaccinia Virus Uracil-DNA Glycosylase in New Crystal Forms
3J78	;	6.3	;	Structures of yeast 80S ribosome-tRNA complexes in the rotated and non-rotated conformations (Class I - non-rotated ribosome with 2 tRNAs)
3J77	;	6.2	;	Structures of yeast 80S ribosome-tRNA complexes in the rotated and non-rotated conformations (Class II - rotated ribosome with 1 tRNA)
1ZZD	;	2.6	;	Structures of Yeast Ribonucleotide Reductase I
2CVS	;	2.6	;	Structures of Yeast Ribonucleotide Reductase I
2CVT	;	3.2	;	Structures of Yeast Ribonucleotide Reductase I
2CVU	;	2.9	;	Structures of Yeast Ribonucleotide Reductase I
2CVV	;	2.9	;	Structures of Yeast Ribonucleotide Reductase I
2CVW	;	2.4	;	Structures of Yeast Ribonucleotide Reductase I
2CVX	;	2.2	;	Structures of Yeast Ribonucleotide Reductase I
2CVY	;	2.4	;	Structures of Yeast Ribonucleotide Reductase I
2EUD	;	2.3	;	Structures of Yeast Ribonucleotide Reductase I complexed with Ligands and Subunit Peptides
1ZYZ	;	2.9	;	Structures of Yeast Ribonucloetide Reductase I
8CXG	;	3.2	;	Structures of Zika Virus in Complex with Antibodies Targeting E Dimer Epitopes and Basis for Neutralization Efficacy
8CXH	;	3.2	;	Structures of Zika Virus in Complex with Antibodies Targeting E Dimer Epitopes and Basis for Neutralization Efficacy
8CXI	;	3.4	;	Structures of Zika Virus in Complex with Antibodies Targeting E Dimer Epitopes and Basis for Neutralization Efficacy
121P	;	1.54	;	STRUKTUR UND GUANOSINTRIPHOSPHAT-HYDROLYSEMECHANISMUS DES C-TERMINAL VERKUERZTEN MENSCHLICHEN KREBSPROTEINS P21-H-RAS
3V00	;	2.9	;	Studies of a constitutively active G-alpha subunit provide insights into the mechanism of G protein activation.
1GPD	;	2.9	;	STUDIES OF ASYMMETRY IN THE THREE-DIMENSIONAL STRUCTURE OF LOBSTER D-GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE
6DZ1	;	2.26	;	Studies of Ion Transport in K+ Channels
5LYM	;	1.8	;	STUDIES OF MONOCLINIC HEN EGG WHITE LYSOZYME. IV. X-RAY REFINEMENT AT 1.8 ANGSTROM RESOLUTION AND A COMPARISON OF THE VARIABLE REGIONS IN THE POLYMORPHIC FORMS
1SMF	;	2.1	;	Studies on an artificial trypsin inhibitor peptide derived from the mung bean inhibitor
1MRG	;	1.8	;	STUDIES ON CRYSTAL STRUCTURES ACTIVE CENTER GEOMETRY AND DEPURINE MECHANISM OF TWO RIBOSOME-INACTIVATING PROTEINS
1MRH	;	2.0	;	STUDIES ON CRYSTAL STRUCTURES ACTIVE CENTER GEOMETRY AND DEPURINE MECHANISM OF TWO RIBOSOME-INACTIVATING PROTEINS
1MRI	;	2.2	;	STUDIES ON CRYSTAL STRUCTURES ACTIVE CENTER GEOMETRY AND DEPURINE MECHANISM OF TWO RIBOSOME-INACTIVATING PROTEINS
1MRJ	;	1.6	;	STUDIES ON CRYSTAL STRUCTURES ACTIVE CENTER GEOMETRY AND DEPURINE MECHANISM OF TWO RIBOSOME-INACTIVATING PROTEINS
1MRK	;	1.6	;	STUDIES ON CRYSTAL STRUCTURES ACTIVE CENTER GEOMETRY AND DEPURINE MECHANISM OF TWO RIBOSOME-INACTIVATING PROTEINS
4FC6	;	2.1	;	Studies on DCR shed new light on peroxisomal beta-oxidation: Crystal structure of the ternary complex of pDCR
4FC7	;	1.84	;	Studies on DCR shed new light on peroxisomal beta-oxidation: Crystal structure of the ternary complex of pDCR
2AAW	;	2.4	;	Studies on ligand binding and enzyme inhibition of Plasmodium falciparum glutathione S-transferase
1PTK	;	2.4	;	STUDIES ON THE INHIBITORY ACTION OF MERCURY UPON PROTEINASE K
1OO5	;	2.5	;	Studies on the Nitroreductase Prodrug-Activating System. Crystal Structures of the Enzyme Active Form and Complexes with the Inhibitor Dicoumarol and Dinitrobenzamide Prodrugs
7AEI	;	2.65	;	Studies Towards a Reversible EGFR C797S Triple Mutant Inhibitor Series
7AEM	;	2.65	;	Studies Towards a Reversible EGFR C797S Triple Mutant Inhibitor Series
1M9W	;		;	Study of electrostatic potential surface distribution using high resolution side-chain conformation determined by NMR
6K0Y	;	1.7	;	Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor
1DWA	;	2.0	;	STUDY ON RADIATION DAMAGE ON A CRYOCOOLED CRYSTAL. PART 1: STRUCTURE PRIOR TO IRRADIATION
1DWF	;	2.0	;	Study on radiation damage on a cryocooled crystal. Part 2: Structure after irradiation with 9.1*10e15 photons/mm2
1DWH	;	2.0	;	Study on radiation damage on a cryocooled crystal. Part 4: Structure after irradiation with 27.2*10e15 photons/mm2
1DWI	;	2.0	;	Study on radiation damage on a cryocooled crystal. Part 5: Structure after irradiation with 54.0*10e15 photons/mm2
1DWJ	;	2.4	;	study on radiation damage on a cryocooled crystal. Refined part 6: structure after a radiation dose of 54*10e15 photons/mm2
1DWG	;	2.0	;	STUDY ON RADIATION DAMAGE ON A CRYOCOOLED CRYSTAL: PART 3 STRUCTURE AFTER IRRADIATION WITH 18.2*10E15 PHOTONS/MM2.
4GUL	;	1.8	;	Study on structure and function relationships in human ferric Pirin
4ERO	;	2.65	;	Study on structure and function relationships in human Pirin with Cobalt ion
4EWA	;	2.47	;	Study on structure and function relationships in human Pirin with Fe ion
4EWE	;	1.56	;	Study on structure and function relationships in human Pirin with Manganese ion
4EWD	;	2.15	;	Study on structure and function relationships in human Pirin with Mn ion
8TGD	;	2.928	;	STX-478, a Mutant-Selective, Allosteric Inhibitor bound to H1047R PI3Kalpha
8TDU	;	3.11	;	STX-478, a Mutant-Selective, Allosteric Inhibitor bound to PI3Kalpha
2GA4	;	1.8	;	Stx2 with adenine
7UJJ	;	6.5	;	Stx2a and DARPin complex
8GCW	;	3.1	;	Stx2A1(Y77A)-P6 peptide
8CX8	;	1.905	;	Stx2A1-BTB13086
6E9D	;	1.86	;	Sub-2 Angstrom Ewald Curvature-Corrected Single-Particle Cryo-EM Reconstruction of AAV-2 L336C
8C5N	;	0.75	;	Sub-atomic resolution structure of the chitin-binding protein D (CbpD) from Pseudomonas aeruginosa
7MID	;	3.56	;	Sub-complex of Cas4-Cas1-Cas2 bound PAM containing DNA
8PC1	;	18.0	;	Sub-tomogram average of the closed conformation of the Nap adhesion complex from the human pathogen Mycoplasma genitalium.
8PBZ	;	11.0	;	Sub-tomogram average of the Nap adhesion complex from the human pathogen Mycoplasma genitalium at 11 Angstrom.
8PC0	;	17.0	;	Sub-tomogram average of the open conformation of the Nap adhesion complex from the human pathogen Mycoplasma genitalium.
7SKA	;	9.1	;	Sub-tomogram averaged structure of HIV-1 Envelope protein in native membrane
8CSL	;	25.0	;	Sub-tomogram averaging of erythrocyte ankyrin-1 complex
5FT2	;	16.4	;	Sub-tomogram averaging of Lassa virus glycoprotein spike from virus- like particles at pH 5
5FYN	;	15.6	;	Sub-tomogram averaging of Tula virus glycoprotein spike
8WDG	;	0.99	;	Subatomic crystal structure of glucose isomerase from Streptomyces rubiginosus
4G78	;	0.92	;	Subatomic Resolution Crystal Structure of Histidine-containing Phosphotransfer Protein MtHPt2 from Medicago truncatula
4F19	;	0.95	;	Subatomic resolution structure of a high affinity periplasmic phosphate-binding protein (PfluDING) bound with arsenate at pH 4.5
4F18	;	0.96	;	Subatomic resolution structure of a high affinity periplasmic phosphate-binding protein (PfluDING) bound with arsenate at pH 8.5
4F1U	;	0.98	;	Subatomic resolution structure of a high affinity periplasmic phosphate-binding protein (PfluDING) bound with phosphate at pH 4.5
4F1V	;	0.88	;	Subatomic resolution structure of a high affinity periplasmic phosphate-binding protein (PfluDING) bound with phosphate at pH 8.5
8K9N	;	0.86	;	Subatomic resolution structure of Pseudoazurin from Alcaligenes faecalis
2CLY	;	2.8	;	Subcomplex of the stator of bovine mitochondrial ATP synthase
7WFG	;	4.33	;	Subcomplexes A and E in NDH complex from Arabidopsis
7WFF	;	3.59	;	Subcomplexes B,M and L in the Cylic electron transfer supercomplex NDH-PSI from Arabidopsis
5V1E	;		;	Suboptimization of a glycine rich peptide allows the combinatorial space exploration for designing novel antimicrobial peptides
7JYI	;	3.4	;	Subparticle Map of ZIKV MR-766
7CN2	;	3.43	;	Subparticle refinement of human papillomavirus type 16 pesudovirus in complex with H16.001 Fab
7TNS	;	6.7	;	Subpellicular microtubule from detergent-extract Toxoplasma gondii cells
8OP1	;	3.5	;	Subsection of a helical nucleocapsid of the Respiratory Syncytial Virus
1BRN	;	1.76	;	SUBSITE BINDING IN AN RNASE: STRUCTURE OF A BARNASE-TETRANUCLEOTIDE COMPLEX AT 1.76 ANGSTROMS RESOLUTION
1CPU	;	2.0	;	SUBSITE MAPPING OF THE ACTIVE SITE OF HUMAN PANCREATIC ALPHA-AMYLASE USING SUBSTRATES, THE PHARMACOLOGICAL INHIBITOR ACARBOSE, AND AN ACTIVE SITE VARIANT
2CPU	;	2.0	;	SUBSITE MAPPING OF THE ACTIVE SITE OF HUMAN PANCREATIC ALPHA-AMYLASE USING SUBSTRATES, THE PHARMACOLOGICAL INHIBITOR ACARBOSE, AND AN ACTIVE SITE VARIANT
3CPU	;	2.0	;	SUBSITE MAPPING OF THE ACTIVE SITE OF HUMAN PANCREATIC ALPHA-AMYLASE USING SUBSTRATES, THE PHARMACOLOGICAL INHIBITOR ACARBOSE, AND AN ACTIVE SITE VARIANT
7RMG	;	3.0	;	Substance P bound to active human neurokinin 1 receptor in complex with miniGs/q70
7RMH	;	3.1	;	Substance P bound to active human neurokinin 1 receptor in complex with miniGs399
8JBH	;	2.9	;	Substance P bound to active human neurokinin 3 receptor in complex with Gq
2KSA	;		;	Substance P in DMPC/CHAPS isotropic q=0.25 bicelles as a ligand for NK1R
2KSB	;		;	Substance P in isotropic q=0.25 DMPC/CHAPS/GM1 bicelles as a ligand for NK1R
4B5H	;	3.05	;	Substate bound inactive mutant of Neisseria AP endonuclease in presence of metal ions
1U6Q	;	2.02	;	Substituted 2-Naphthamadine inhibitors of Urokinase
1OWD	;	2.32	;	Substituted 2-Naphthamidine inhibitors of urokinase
1OWE	;	1.6	;	Substituted 2-Naphthamidine inhibitors of urokinase
1OWH	;	1.61	;	Substituted 2-Naphthamidine Inhibitors of Urokinase
1OWI	;	2.93	;	Substituted 2-Naphthamidine Inhibitors of Urokinase
1OWJ	;	3.1	;	Substituted 2-Naphthamidine Inhibitors of Urokinase
1OWK	;	2.8	;	Substituted 2-Naphthamidine Inhibitors of Urokinase
1SQA	;	2.0	;	Substituted 2-Naphthamidine Inhibitors of Urokinase
1SQO	;	1.84	;	Substituted 2-Naphthamidine Inhibitors of Urokinase
1SQT	;	1.9	;	Substituted 2-Naphthamidine Inhibitors of Urokinase
6W9H	;	1.995	;	SUBSTITUTED BENZYLOXYTRICYCLIC COMPOUNDS AS RETINOIC ACID-RELATED ORPHAN RECEPTOR GAMMA T AGONISTS
6W9I	;	1.608	;	SUBSTITUTED BENZYLOXYTRICYCLIC COMPOUNDS AS RETINOIC ACID-RELATED ORPHAN RECEPTOR GAMMA T AGONISTS
6XAE	;	2.257	;	SUBSTITUTED BENZYLOXYTRICYCLIC COMPOUNDS AS RETINOIC ACID-RELATED ORPHAN RECEPTOR GAMMA T AGONISTS
2R4F	;	1.7	;	Substituted Pyrazoles as Hepatselective HMG-COA reductase inhibitors
1MYL	;	2.4	;	SUBSTITUTING HYDROPHOBIC RESIDUES FOR A BURIED SALT BRIDGE ENHANCES PROTEIN STABILITY BUT DOES NOT REDUCE CONFORMATIONAL SPECIFICITY
6GHW	;	2.3	;	Substituting the prolines of 4-oxalocrotonate tautomerase with non-canonical analogue (2S)-3,4-dehydroproline
1RBA	;	2.6	;	SUBSTITUTION OF ASP193 TO ASN AT THE ACTIVE SITE OF RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE RESULTS IN CONFORMATIONAL CHANGES
1MRR	;	2.5	;	SUBSTITUTION OF MANGANESE FOR IRON IN RIBONUCLEOTIDE REDUCTASE FROM ESCHERICHIA COLI. SPECTROSCOPIC AND CRYSTALLOGRAPHIC CHARACTERIZATION
276D	;	1.8	;	SUBSTITUTIONS AT C2' OF DAUNOSAMINE IN THE ANTICANCER DAUNORUBICIN ALTER ITS DNA-BINDING SEQUENCE SPECIFICITY
277D	;	1.8	;	SUBSTITUTIONS AT C2' OF DAUNOSAMINE IN THE ANTICANCER DAUNORUBICIN ALTER ITS DNA-BINDING SEQUENCE SPECIFICITY
278D	;	1.8	;	SUBSTITUTIONS AT C2' OF DAUNOSAMINE IN THE ANTICANCER DAUNORUBICIN ALTER ITS DNA-BINDING SEQUENCE SPECIFICITY
288D	;	1.8	;	SUBSTITUTIONS AT C2' OF DAUNOSAMINE IN THE ANTICANCER DAUNORUBICIN ALTER ITS DNA-BINDING SEQUENCE SPECIFICITY
4DBC	;	1.5	;	Substrate Activation in Aspartate Aminotransferase
1FHI	;	3.1	;	SUBSTRATE ANALOG (IB2) COMPLEX WITH THE FRAGILE HISTIDINE TRIAD PROTEIN, FHIT
2FHI	;	2.6	;	SUBSTRATE ANALOG (IB2) COMPLEX WITH THE HIS 96 ASN SUBSTITUTION OF THE FRAGILE HISTIDINE TRIAD PROTEIN, FHIT
5KVS	;	1.28	;	Substrate Analog and NADP+ bound structure of Irp3, a Thiazolinyl Imine Reductase from Yersinia enterocolitica
4QGS	;	1.7	;	Substrate and cofactor-free form of the Aldehyde Reductase YqhD from E. coli.
3ZDW	;	2.4	;	Substrate and dioxygen binding to the endospore coat laccase CotA from Bacillus subtilis
3MK6	;	1.98	;	Substrate and Inhibitor Binding to Pank
3ENQ	;	2.0	;	Substrate and inhibitor complexes of ribose 5-phosphate isomerase A from Vibrio vulnificus YJ016
3ENV	;	2.0	;	Substrate and inhibitor complexes of ribose 5-phosphate isomerase from Vibrio vulnificus YJ016
3ENW	;	2.0	;	Substrate and inhibitor complexes of ribose 5-phosphate isomerase from Vibrio vulnificus YJ016
2XGM	;	2.55	;	Substrate and product analogues as human O-GlcNAc transferase inhibitors.
1AOM	;	1.8	;	SUBSTRATE AND PRODUCT BOUND TO CYTOCHROME CD1 NITRITE REDUCTASE
4ICT	;	1.8	;	Substrate and reaction specificity of Mycobacterium tuberculosis cytochrome P450 CYP121
4IPS	;	1.2	;	Substrate and reaction specificity of Mycobacterium tuberculosis cytochrome P450 CYP121
4IPW	;	1.4	;	Substrate and reaction specificity of Mycobacterium tuberculosis cytochrome P450 CYP121
4IQ7	;	1.9	;	Substrate and reaction specificity of Mycobacterium tuberculosis cytochrome P450 CYP121
4IQ9	;	1.4	;	Substrate and reaction specificity of Mycobacterium tuberculosis cytochrome P450 CYP121
2D0E	;	2.15	;	Substrate assited in Oxygen Activation in Cytochrome P450 158A2
1GRA	;	2.0	;	SUBSTRATE BINDING AND CATALYSIS BY GLUTATHIONE REDUCTASE AS DERIVED FROM REFINED ENZYME: SUBSTRATE CRYSTAL STRUCTURES AT 2 ANGSTROMS RESOLUTION
1GRB	;	1.85	;	SUBSTRATE BINDING AND CATALYSIS BY GLUTATHIONE REDUCTASE AS DERIVED FROM REFINED ENZYME: SUBSTRATE CRYSTAL STRUCTURES AT 2 ANGSTROMS RESOLUTION
1GRE	;	2.0	;	SUBSTRATE BINDING AND CATALYSIS BY GLUTATHIONE REDUCTASE AS DERIVED FROM REFINED ENZYME: SUBSTRATE CRYSTAL STRUCTURES AT 2 ANGSTROMS RESOLUTION
1GRF	;	2.0	;	SUBSTRATE BINDING AND CATALYSIS BY GLUTATHIONE REDUCTASE AS DERIVED FROM REFINED ENZYME: SUBSTRATE CRYSTAL STRUCTURES AT 2 ANGSTROMS RESOLUTION
1GRG	;	2.0	;	SUBSTRATE BINDING AND CATALYSIS BY GLUTATHIONE REDUCTASE AS DERIVED FROM REFINED ENZYME: SUBSTRATE CRYSTAL STRUCTURES AT 2 ANGSTROMS RESOLUTION
4KD5	;	2.4999	;	substrate binding domain of putative molybdenum ABC transporter from Clostridium difficile
3N8E	;	2.8	;	Substrate binding domain of the human Heat Shock 70kDa protein 9 (mortalin)
6C78	;	1.75	;	Substrate Binding Induces Conformational Changes In A Class A Beta Lactamase That Primes It For Catalysis
3C1G	;	2.3	;	Substrate binding, deprotonation and selectivity at the periplasmic entrance of the E. coli ammonia channel AmtB
3C1H	;	2.2	;	Substrate binding, deprotonation and selectivity at the periplasmic entrance of the E. coli ammonia channel AmtB
3C1I	;	2.3	;	Substrate binding, deprotonation and selectivity at the periplasmic entrance of the E. coli ammonia channel AmtB
3C1J	;	2.0	;	Substrate binding, deprotonation and selectivity at the periplasmic entrance of the E. coli ammonia channel AmtB
6L1N	;	2.0	;	Substrate bound BacF structure from Bacillus subtillis
4AQ6	;	1.98	;	substrate bound homogentisate 1,2-dioxygenase
4B5F	;	2.005	;	Substrate bound Neisseria AP endonuclease in absence of metal ions (crystal form 1)
4B5G	;	2.75	;	Substrate bound Neisseria AP endonuclease in absence of metal ions (crystal form 2)
4LLH	;	2.8	;	Substrate bound outward-open state of the symporter BetP
1L7P	;	1.9	;	SUBSTRATE BOUND PHOSPHOSERINE PHOSPHATASE COMPLEX STRUCTURE
5D0Y	;	3.014	;	Substrate bound S-component of folate ECF transporter
4AQ4	;	1.8	;	substrate bound sn-glycerol-3-phosphate binding periplasmic protein ugpB from Escherichia coli
6K0Z	;	2.49673	;	Substrate bound state of Staphylococcus Aureus AldH
6TWK	;	2.25	;	Substrate bound structure of the Ectoine utilization protein EutD (DoeA) from Halomonas elongata
4FAF	;	2.1	;	Substrate CA/p2 in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant
2VZV	;	2.7	;	Substrate Complex of Amycolatopsis orientalis exo-chitosanase CsxA E541A with chitosan
3CO0	;	1.93	;	Substrate Complex of Fluoride-sensitive Engineered Subtilisin SUBT_BACAM
1GVY	;	1.7	;	Substrate distorsion by beta-mannanase from Pseudomonas cellulosa
1GW1	;	1.65	;	Substrate distortion by beta-mannanase from Pseudomonas cellulosa
2F3K	;	1.599	;	Substrate envelope and drug resistance: crystal structure of r01 in complex with wild-type hiv-1 protease
3RKU	;	2.6	;	Substrate Fingerprint and the Structure of NADP+ Dependent Serine Dehydrogenase from Saccharomyces cerevisiae complexed with NADP+
2VE4	;	2.4	;	Substrate free cyanobacterial CYP120A1
6MJM	;	2.2	;	Substrate Free Cytochrome P450 3A5 (CYP3A5)
8SWL	;	3.06	;	Substrate free structure of cytochrome P450 CYP105Q4 from mycobacterium marinum
3NUM	;	2.75	;	Substrate induced remodeling of the active site regulates HtrA1 activity
3NWU	;	3.2	;	Substrate induced remodeling of the active site regulates HtrA1 activity
3NZI	;	2.75	;	Substrate induced remodeling of the active site regulates HtrA1 activity
1TYP	;	2.8	;	SUBSTRATE INTERACTIONS BETWEEN TRYPANOTHIONE REDUCTASE AND N1-GLUTATHIONYLSPERMIDINE DISULPHIDE AT 0.28-NM RESOLUTION
2RJR	;	2.1	;	Substrate mimic bound to SgTAM
4FAE	;	2.3	;	Substrate p2/NC in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant
5A0X	;	1.7	;	Substrate peptide-bound structure of metalloprotease Zmp1 variant E143AY178F from Clostridium difficile
6EPD	;	15.4	;	Substrate processing state 26S proteasome (SPS1)
6EPE	;	12.8	;	Substrate processing state 26S proteasome (SPS2)
6TP8	;	1.55	;	Substrate protein interactions in the limbus region of the catalytic site of Candida antarctica Lipase B
7NSC	;	3.3	;	Substrate receptor scaffolding module of human CTLH E3 ubiquitin ligase
7NS3	;	3.5	;	Substrate receptor scaffolding module of yeast Chelator-GID SR4 E3 ubiquitin ligase bound to Fbp1 substrate
2GC7	;	1.9	;	Substrate reduced, copper free complex of methylamine dehydrogenase, amicyanin and cytochrome c551i from Paracoccus denitrificans.
2RFK	;	2.87	;	Substrate RNA Positioning in the Archaeal H/ACA Ribonucleoprotein Complex
2E2U	;	1.68	;	Substrate Schiff-base analogue of copper amine oxidase from Arthrobacter globiformis formed with 4-hydroxybenzylhydrazine
2E2V	;	1.8	;	Substrate Schiff-base analogue of copper amine oxidase from Arthrobacter globiformis formed with benzylhydrazine
2E2T	;	2.05	;	Substrate Schiff-base analogue of copper amine oxidase from Arthrobacter globiformis formed with phenylhydrazine
2CWU	;	1.85	;	Substrate schiff-base intermediate of copper amine oxidase from arthrobacter globiformis
2D1W	;	1.74	;	Substrate Schiff-Base intermediate with tyramine in copper amine oxidase from Arthrobacter globiformis
1KJ4	;	2.9	;	SUBSTRATE SHAPE DETERMINES SPECIFICITY OF RECOGNITION RECOGNITION FOR HIV-1 PROTEASE: ANALYSIS OF CRYSTAL STRUCTURES OF SIX SUBSTRATE COMPLEXES
1KJ7	;	2.0	;	SUBSTRATE SHAPE DETERMINES SPECIFICITY OF RECOGNITION RECOGNITION FOR HIV-1 PROTEASE: ANALYSIS OF CRYSTAL STRUCTURES OF SIX SUBSTRATE COMPLEXES
1KJF	;	2.0	;	SUBSTRATE SHAPE DETERMINES SPECIFICITY OF RECOGNITION RECOGNITION FOR HIV-1 PROTEASE: ANALYSIS OF CRYSTAL STRUCTURES OF SIX SUBSTRATE COMPLEXES
1KJG	;	2.0	;	SUBSTRATE SHAPE DETERMINES SPECIFICITY OF RECOGNITION RECOGNITION FOR HIV-1 PROTEASE: ANALYSIS OF CRYSTAL STRUCTURES OF SIX SUBSTRATE COMPLEXES
1KJH	;	2.0	;	SUBSTRATE SHAPE DETERMINES SPECIFICITY OF RECOGNITION RECOGNITION FOR HIV-1 PROTEASE: ANALYSIS OF CRYSTAL STRUCTURES OF SIX SUBSTRATE COMPLEXES
1ABF	;	1.9	;	SUBSTRATE SPECIFICITY AND AFFINITY OF A PROTEIN MODULATED BY BOUND WATER MOLECULES
5ABP	;	1.8	;	SUBSTRATE SPECIFICITY AND AFFINITY OF A PROTEIN MODULATED BY BOUND WATER MOLECULES
1UKY	;	2.13	;	SUBSTRATE SPECIFICITY AND ASSEMBLY OF CATALYTIC CENTER DERIVED FROM TWO STRUCTURES OF LIGATED URIDYLATE KINASE
1UKZ	;	1.9	;	SUBSTRATE SPECIFICITY AND ASSEMBLY OF CATALYTIC CENTER DERIVED FROM TWO STRUCTURES OF LIGATED URIDYLATE KINASE
4F5K	;	2.2	;	Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.
4F5I	;	2.2	;	Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.
2OP9	;	1.8	;	Substrate Specificity Profiling and Identification of a New Class of Inhibitor for the Major Protease of the SARS Coronavirus
4OXY	;	2.3501	;	Substrate-binding loop movement with inhibitor PT10 in the tetrameric Mycobacterium tuberculosis enoyl-ACP reductase InhA
7Q4O	;	2.1	;	Substrate-bound A-like U2 snRNP
3UND	;	2.1	;	Substrate-bound crystal structure of 2-dehydro-3-deoxyphosphooctonate aldolase from Burkholderia pseudomallei
8H3S	;	4.9	;	Substrate-bound EP, polyA model
5NV9	;	1.95	;	Substrate-bound outward-open state of a Na+-coupled sialic acid symporter reveals a novel Na+-site
5NVA	;	2.26	;	Substrate-bound outward-open state of a Na+-coupled sialic acid symporter reveals a novel Na+-site
5XWV	;	1.8	;	Substrate-bound Structure of a Ketoreductase from the Second Module of the amphotericin Polyketide Synthases
4OD5	;	3.557	;	Substrate-bound structure of a UbiA homolog from Aeropyrum pernix K1
5XWW	;	1.96	;	Substrate-bound Structure of G355T/Q364H mutant of a Ketoreductase from amphotericin Polyketide Synthases
7RMF	;	7.3	;	Substrate-bound Ura7 filament at low pH
7KZE	;	2.9	;	Substrate-dependent divergence of leukotriene A4 hydrolase aminopeptidase activity
7LLQ	;	2.85	;	Substrate-dependent divergence of leukotriene A4 hydrolase aminopeptidase activity
4DYD	;	1.95	;	Substrate-directed dual catalysis of dicarbonyl compounds by diketoreductase
4E12	;	1.93	;	Substrate-directed dual catalysis of dicarbonyl compounds by diketoreductase
4E13	;	2.08	;	Substrate-directed dual catalysis of dicarbonyl compounds by diketoreductase
7PX9	;	3.8	;	Substrate-engaged mycobacterial Proteasome-associated ATPase - focused 3D refinement (state A)
7PXB	;	4.0	;	Substrate-engaged mycobacterial Proteasome-associated ATPase - focused 3D refinement (state B)
7PXC	;	3.84	;	Substrate-engaged mycobacterial Proteasome-associated ATPase in complex with open-gate 20S CP - composite map (state A)
7PXD	;	4.0	;	Substrate-engaged mycobacterial Proteasome-associated ATPase in complex with open-gate 20S CP - composite map (state B)
8HCO	;	4.1	;	Substrate-engaged TOM complex from yeast
7AH9	;	3.3	;	Substrate-engaged type 3 secretion system needle complex from Salmonella enterica typhimurium - SpaR state 1
7AHI	;	3.3	;	Substrate-engaged type 3 secretion system needle complex from Salmonella enterica typhimurium - SpaR state 2
6YDL	;	1.52	;	Substrate-free beta-phosphoglucomutase from Lactococcus lactis
1Q5E	;	2.65	;	Substrate-free Cytochrome P450epoK
3M10	;	1.727	;	Substrate-free form of Arginine Kinase
2ZQJ	;	2.9	;	Substrate-Free Form of Cytochrome P450BSbeta
7KSL	;	3.5	;	Substrate-free human mitochondrial LONP1
2JG4	;	2.8	;	Substrate-free IDE structure in its closed conformation
8A9Y	;	3.5	;	Substrate-free levan utilisation machinery (utilisome)
1YZP	;	1.6	;	Substrate-free manganese peroxidase
6YDK	;	2.02	;	Substrate-free P146A variant of beta-phosphoglucomutase from Lactococcus lactis
7CL7	;	1.95	;	Substrate-free structure of CYP154C2 from Streptomyces avermitilis in an open conformation
4PZP	;	1.9	;	Substrate-free structure of D-alanine carrier protein ligase DltA from Bacillus cereus
1P88	;		;	Substrate-induced structural changes to the isolated N-terminal domain of 5-enolpyruvylshikimate-3-phosphate synthase
1P89	;		;	Substrate-induced Structural Changes to the Isolated N-Terminal Domain of 5-Enolpyruvylshikimate-3-phosphate Synthase
4OXN	;	2.2926	;	Substrate-like binding mode of inhibitor PT155 to the Mycobacterium tuberculosis enoyl-ACP reductase InhA
6IEN	;	2.7	;	Substrate/product bound Argininosuccinate lyase from Mycobacterium tuberculosis
6K98	;	2.032	;	Substrates promiscuity of xyloglucanases and endoglucanases of glycoside hydrolase 12 family
1GNS	;	1.8	;	SUBTILISIN BPN'
1SUA	;	2.1	;	SUBTILISIN BPN'
1SBI	;	2.2	;	SUBTILISIN BPN' 8397 (E.C. 3.4.21.14) MUTANT (M50F, N76D, G169A, Q206C, N218S)
1YJA	;	1.8	;	SUBTILISIN BPN' 8397+1 (E.C. 3.4.21.14) (MUTANT WITH MET 50 REPLACED BY PHE, ASN 76 REPLACED BY ASP, GLY 169 REPLACED BY ALA, GLN 206 REPLACED BY CYS, ASN 218 REPLACED BY SER AND LYS 256 REPLACED BY TYR) (M50F, N76D, G169A, Q206C, N218S, AND K256Y) IN 20% DIMETHYLFORMAMIDE
1YJB	;	1.8	;	SUBTILISIN BPN' 8397+1 (E.C. 3.4.21.14) (MUTANT WITH MET 50 REPLACED BY PHE, ASN 76 REPLACED BY ASP, GLY 169 REPLACED BY ALA, GLN 206 REPLACED BY CYS, ASN 218 REPLACED BY SER AND LYS 256 REPLACED BY TYR) (M50F, N76D, G169A, Q206C, N218S, AND K256Y) IN 35% DIMETHYLFORMAMIDE
1YJC	;	1.8	;	SUBTILISIN BPN' 8397+1 (E.C. 3.4.21.14) (MUTANT WITH MET 50 REPLACED BY PHE, ASN 76 REPLACED BY ASP, GLY 169 REPLACED BY ALA, GLN 206 REPLACED BY CYS, ASN 218 REPLACED BY SER AND LYS 256 REPLACED BY TYR) (M50F, N76D, G169A, Q206C, N218S, AND K256Y) IN 50% DIMETHYLFORMAMIDE
1SBH	;	1.8	;	SUBTILISIN BPN' 8397+1 (E.C. 3.4.21.14) MUTANT (M50F, N76D, G169A, Q206C, N218S, K256Y)
1SUP	;	1.6	;	SUBTILISIN BPN' AT 1.6 ANGSTROMS RESOLUTION: ANALYSIS OF DISCRETE DISORDER AND COMPARISON OF CRYSTAL FORMS
1DUI	;	2.0	;	Subtilisin BPN' from Bacillus amyloliquefaciens, crystal growth mutant
1SUE	;	1.8	;	SUBTILISIN BPN' FROM BACILLUS AMYLOLIQUEFACIENS, MUTANT
1A2Q	;	1.8	;	SUBTILISIN BPN' MUTANT 7186
1AU9	;	1.8	;	SUBTILISIN BPN' MUTANT 8324 IN CITRATE
1SPB	;	2.0	;	SUBTILISIN BPN' PROSEGMENT (77 RESIDUES) COMPLEXED WITH A MUTANT SUBTILISIN BPN' (266 RESIDUES). CRYSTAL PH 4.6. CRYSTALLIZATION TEMPERATURE 20 C DIFFRACTION TEMPERATURE-160 C
3VSB	;	2.6	;	SUBTILISIN CARLSBERG D-NAPHTHYL-1-ACETAMIDO BORONIC ACID INHIBITOR COMPLEX
1AVT	;	2.0	;	SUBTILISIN CARLSBERG D-PARA-CHLOROPHENYL-1-ACETAMIDO BORONIC ACID INHIBITOR COMPLEX
1BFU	;	2.2	;	SUBTILISIN CARLSBERG IN 20% DIOXANE
1AV7	;	2.6	;	SUBTILISIN CARLSBERG L-NAPHTHYL-1-ACETAMIDO BORONIC ACID INHIBITOR COMPLEX
1VSB	;	2.1	;	SUBTILISIN CARLSBERG L-PARA-CHLOROPHENYL-1-ACETAMIDO BORONIC ACID INHIBITOR COMPLEX
1BH6	;	1.75	;	SUBTILISIN DY IN COMPLEX WITH THE SYNTHETIC INHIBITOR N-BENZYLOXYCARBONYL-ALA-PRO-PHE-CHLOROMETHYL KETONE
1AK9	;	1.8	;	SUBTILISIN MUTANT 8321
1AQN	;	1.8	;	SUBTILISIN MUTANT 8324
6DWQ	;	1.27	;	Subtilisin serine protease modified with the protease inhibitor cyanobenzylsulfonylfluoride
1C3L	;	2.16	;	SUBTILISIN-CARLSBERG COMPLEXED WITH XENON (8 BAR)
7OZR	;	4.5	;	Subtomogram average of authentic mumps virus nucleocapsid from HeLa cell lysate of long helical pitch
8CO6	;	4.7	;	Subtomogram average of Immature Rotavirus TLP penton
8AFY	;	26.0	;	Subtomogram average of membrane-bound Atg18 oligomers
6FTG	;	9.1	;	Subtomogram average of OST-containing ribosome-translocon complexes from canine rough microsomal membranes
8B6L	;	7.6	;	Subtomogram average of the human Sec61-TRAP-OSTA-translocon
7ZC1	;	3.8	;	Subtomogram averaging of Rubisco from Cyanobium carboxysome
7ZBT	;	3.3	;	Subtomogram averaging of Rubisco from native Halothiobacillus carboxysomes
8OH4	;	16.5	;	Subtomogram averaging structure of cofilactin filament inside microtubule lumen of Drosophila S2 cell protrusion.
6XTB	;	4.3	;	Subunit BBS 5 of the human core BBSome complex
1A91	;		;	SUBUNIT C OF THE F1FO ATP SYNTHASE OF ESCHERICHIA COLI; NMR, 10 STRUCTURES
1C0V	;		;	SUBUNIT C OF THE F1FO ATP SYNTHASE OF ESCHERICHIA COLI; NMR, 10 STRUCTURES
2D00	;	2.2	;	Subunit F of V-type ATPase/synthase
6OIG	;	3.8	;	Subunit joining exposes nascent pre-40S rRNA for processing and quality control
6WDR	;	3.7	;	Subunit joining exposes nascent pre-40S rRNA for processing and quality control
4NNZ	;	2.478	;	Subunit PA0372 of heterodimeric zinc protease PA0371-PA0372
6XT9	;	3.8	;	Subunits BBS 1,4,8,9,18 of the human BBSome complex
2C35	;	2.7	;	Subunits Rpb4 and Rpb7 of human RNA polymerase II
5CAE	;	2.2	;	Succinate bound to pig GTP-specific succinyl-CoA synthetase
1VZ5	;	2.15	;	Succinate Complex of AtsK
6WU6	;	3.6	;	succinate-coenzyme Q reductase
7JZ2	;	2.5	;	Succinate: quinone oxidoreductase SQR from E.coli K12
1O9L	;	2.4	;	Succinate:Coenzyme-A Transferase (pig heart)
3NS7	;	2.6	;	Succinic Acid Amides as P2-P3 Replacements for Inhibitors of Interleukin-1beta Converting Enzyme (ICE or Caspase 1)
5GIB	;	2.697	;	Succinic acid bound trypsin crystallized as dimer
1ZWG	;		;	SUCCINYL HUMAN PARATHYROID HORMONE 4-37, NMR, 10 STRUCTURES
2AGG	;	1.28	;	succinyl-AAPK-trypsin acyl-enzyme at 1.28 A resolution
2AGE	;	1.15	;	Succinyl-AAPR-trypsin acyl-enzyme at 1.15 A resolution
8CEI	;	2.2	;	Succinyl-CoA Reductase from Clostridium kluyveri (SucD)
8CEJ	;	2.1	;	Succinyl-CoA Reductase from Clostridium kluyveri (SucD) with Mesaconyl-C1-CoA
8CEK	;	2.15	;	Succinyl-CoA Reductase from Clostridium kluyveri (SucD) with NADPH
6MEL	;	2.06	;	Succinyl-CoA synthase from Campylobacter jejuni
6PFN	;	1.76	;	Succinyl-CoA synthase from Francisella tularensis
6MGG	;	1.78	;	Succinyl-CoA synthase from Francisella tularensis, phosphorylated, in complex with CoA
4EU4	;	2.802	;	Succinyl-CoA: acetate CoA-transferase (AarCH6) in complex with CoA (hexagonal lattice)
1OOY	;	1.7	;	SUCCINYL-COA:3-KETOACID COA TRANSFERASE FROM PIG HEART
1M3E	;	2.5	;	Succinyl-COA:3-ketoacid COA transferase from pig heart (selenomethionine)
3OXO	;	2.3	;	Succinyl-CoA:3-ketoacid CoA transferase from pig heart covalently bound to CoA
4EUD	;	1.95	;	Succinyl-CoA:acetate CoA-transferase (AarC) in complex with CoA and citrate
5DW4	;	1.622	;	Succinyl-CoA:acetate CoA-transferase (AarCH6) bound to acetate
5E5H	;	2.052	;	Succinyl-CoA:acetate CoA-transferase (AarCH6) bound to acetate and degradation products from the acetyl-CoA analogue dethiaacetyl-CoA
5DW6	;	1.548	;	Succinyl-CoA:acetate CoA-transferase (AarCH6) bound to acetate and the CoA analogue 3'-phosphoadenosine 5'-(O-(N-propyl-R-pantothenamide))pyrophosphate (MX)
5DW5	;	1.656	;	Succinyl-CoA:acetate CoA-transferase (AarCH6) bound to the CoA analogue 3'-phosphoadenosine 5'-(O-(N-propylpantothenamide))pyrophosphate (MX)
4EU3	;	1.58	;	Succinyl-CoA:acetate CoA-transferase (AarCH6) in complex with citrate (subunit B) or unliganded (subunit A)
4EU5	;	1.743	;	Succinyl-CoA:acetate CoA-transferase (AarCH6) in complex with CoA
4EU7	;	1.7	;	Succinyl-CoA:acetate CoA-transferase (AarCH6) in complex with CoA and citrate
4EU6	;	1.988	;	Succinyl-CoA:acetate CoA-transferase (AarCH6) in complex with CoA, acetate, and covalent acetylglutamyl anhydride and glutamyl-CoA thioester adducts
4EUB	;	1.973	;	Succinyl-CoA:acetate CoA-transferase (AarCH6-E294A) in complex with CoA
4EUC	;	2.644	;	Succinyl-CoA:acetate CoA-transferase (AarCH6-E294A) in complex with dethiaacetyl-CoA
5DDK	;	2.127	;	Succinyl-CoA:acetate CoA-transferase (AarCH6-N347A) in complex with CoA
4EUA	;	2.398	;	Succinyl-CoA:acetate CoA-transferase (AarCH6-R228E) in complex with CoA (anomalous dataset)
4EU9	;	1.479	;	Succinyl-CoA:acetate CoA-transferase (AarCH6-R228E) in complex with CoA and a covalent glutamyl-CoA thioester adduct
4EU8	;	1.809	;	Succinyl-CoA:acetate CoA-transferase (AarCH6-S71A) in complex with CoA
4YWP	;	1.45	;	Sucrose Binding Site in genetically engineered Carbonic anhydrase IX
2WPG	;	1.9	;	Sucrose Hydrolase
1R7A	;	1.77	;	Sucrose Phosphorylase from Bifidobacterium adolescentis
2GDV	;	2.0	;	Sucrose phosphorylase from BIFIDOBACTERIUM ADOLESCENTIS reacted with sucrose
7QQI	;	1.36	;	Sucrose phosphorylase from Faecalibaculum rodentium
7QQJ	;	2.05	;	Sucrose phosphorylase from Jeotgalibaca ciconiae
6X8A	;	1.06	;	Sucrose-bound structure of Marinomonas primoryensis PA14 carbohydrate-binding domain
6KIH	;	3.0	;	Sucrose-phosphate synthase (tll1590) from Thermosynechococcus elongatus
6LDQ	;	1.92	;	Sucrose-phosphate synthase (tll1590)_27_220_406_426_from Thermosynechococcus elongatus (twinned)
1A0S	;	2.4	;	SUCROSE-SPECIFIC PORIN
1A0T	;	2.4	;	SUCROSE-SPECIFIC PORIN, WITH BOUND SUCROSE MOLECULES
1OH2	;	2.4	;	Sucrose-Specific Porin, with Bound Sucrose Molecules
7THH	;	1.32	;	SUD-C and Ubl2 domains of SARS CoV-2 Nsp3 protein
6OAF	;	2.2	;	Sudan virus nucleoprotein core domain in complex with VP35 chaperoning peptide
2UXT	;	1.9	;	SufI Protein from Escherichia Coli
2UXV	;	2.61	;	SufI Protein from Escherichia Coli
6KFY	;	1.97	;	SufS from Bacillus subtilis in a resting state at 1.96 angstrom resolution
5ZS9	;	2.8	;	SufS from Bacillus subtilis in the resting state
5ZSK	;	3.24	;	SufS from Bacillus subtilis soaked with L-cysteine for 63 sec
5ZSO	;	2.7	;	SufS from Bacillus subtilis, soaked with L-cysteine for 90 sec
6KFZ	;	1.96	;	SufS from Bacillus subtilis, soaked with L-cysteine for 90 sec at 1.96 angstrom resolution
8D8S	;	1.388	;	SufS from Staphylococcus aureus
7XEL	;	1.8	;	SufS soaked with D-penicillamine
7XET	;	2.3	;	SufS with beta-cyano-L-alanine
7YB3	;	1.8	;	SufS with D-cysteine for 1 min
7XEJ	;	1.74	;	SufS with D-cysteine for 5 min
7XEK	;	1.88	;	SufS with D-cysteine for 6 h
7XEN	;	2.47	;	SufS with L-penicillamine
7XEP	;	1.78	;	SufS with L-propargylglycine
5XT5	;	2.34	;	SufS-SufU complex from Bacillus subtilis
8ODQ	;	1.65	;	SufS-SufU complex from Mycobacterium tuberculosis
2GBP	;	1.9	;	SUGAR AND SIGNAL-TRANSDUCER BINDING SITES OF THE ESCHERICHIA COLI GALACTOSE CHEMORECEPTOR PROTEIN
3W38	;	2.79	;	Sugar beet alpha-glucosidase
3W37	;	1.7	;	Sugar beet alpha-glucosidase with acarbose
3WEO	;	1.45	;	Sugar beet alpha-glucosidase with acarviosyl-maltohexaose
3WEN	;	2.59	;	Sugar beet alpha-glucosidase with acarviosyl-maltopentaose
3WEM	;	2.591	;	Sugar beet alpha-glucosidase with acarviosyl-maltotetraose
3WEL	;	1.84	;	Sugar beet alpha-glucosidase with acarviosyl-maltotriose
5DG1	;	3.2	;	Sugar binding protein - human galectin-2
5EWS	;	2.0	;	Sugar binding protein - human galectin-2
5DG2	;	1.612	;	Sugar binding protein - human galectin-2 (dimer)
2CFP	;	3.3	;	Sugar Free Lactose Permease at acidic pH
2CFQ	;	2.95	;	Sugar Free Lactose Permease at neutral pH
5HTY	;	2.815	;	Sugar kinases from Synechococcus elongatus PCC7942-D221A
5HU2	;	2.6	;	Sugar kinases from Synechococcus elongatus PCC7942-T11A
7KMF	;	2.91	;	Sugar phosphate activation of the stress sensor eIF2B
1BVV	;	1.8	;	SUGAR RING DISTORTION IN THE GLYCOSYL-ENZYME INTERMEDIATE OF A FAMILY G/11 XYLANASE
2BVV	;	1.5	;	SUGAR RING DISTORTION IN THE GLYCOSYL-ENZYME INTERMEDIATE OF A FAMILY G/11 XYLANASE.
2QPU	;	1.7	;	Sugar tongs mutant S378P in complex with acarbose
7B0M	;	1.43	;	Sugar transaminase from a metagenome collected from troll oil field production water
7B0D	;	1.27	;	Sugar transaminase from Archaeoglobus veneficus
5XPD	;	2.788	;	Sugar transporter of AtSWEET13 in inward-facing state with a substrate analog
6ABP	;	1.67	;	SUGAR-BINDING AND CRYSTALLOGRAPHIC STUDIES OF AN ARABINOSE-BINDING PROTEIN MUTANT (MET108LEU) WHICH EXHIBITS ENHANCED AFFINITY AND ALTERED SPECIFICITY
7ABP	;	1.67	;	SUGAR-BINDING AND CRYSTALLOGRAPHIC STUDIES OF AN ARABINOSE-BINDING PROTEIN MUTANT (MET108LEU) WHICH EXHIBITS ENHANCED AFFINITY AND ALTERED SPECIFICITY
8ABP	;	1.49	;	SUGAR-BINDING AND CRYSTALLOGRAPHIC STUDIES OF AN ARABINOSE-BINDING PROTEIN MUTANT (MET108LEU) WHICH EXHIBITS ENHANCED AFFINITY AND ALTERED SPECIFICITY
7AAR	;	2.64	;	sugar/H+ symporter STP10 in inward open conformation
7AAQ	;	1.81	;	sugar/H+ symporter STP10 in outward occluded conformation
2G6W	;	2.14	;	Suicide inhibition of a-Oxamine Synthase: Structures of the Covalent Adducts of 8-Amino-7-oxonanoate Synthase with trifluoroalanine
8GOY	;	1.784	;	SulE P44R
7Y0L	;	1.29	;	SulE-S209A
7O89	;	1.16	;	sulerythrin without metals (apo-state)
7YD2	;	1.61	;	SulE_P44R_S209A
4FFA	;	2.5	;	Sulfatase from Mycobacterium tuberculosis
8EVO	;	2.4	;	Sulfatase from Mycobacterium tuberculosis (Rv3406) in complex with inhibitor FG2216
8EVN	;	2.644	;	Sulfatase from Mycobacterium tuberculosis (Rv3406) in complex with N-oxalylglycine (NOG)
8IBM	;	2.2	;	Sulfate bound form of PET-degrading cutinase Cut190 with thermostability-improving mutations of S226P/R228S/Q138A/D250C-E296C/Q123H/N202H and S176A inactivation
2YMM	;	1.64	;	Sulfate bound L-haloacid dehalogenase from a Rhodobacteraceae family bacterium
1H29	;	2.51	;	Sulfate respiration in Desulfovibrio vulgaris Hildenborough: Structure of the 16-heme Cytochrome c HmcA at 2.5 A resolution and a view of its role in transmembrane electron transfer
5YSQ	;	1.47	;	Sulfate-complex structure of a pyrophosphate-dependent kinase in the ribokinase family provides insight into the donor-binding mode
7OZE	;	2.7	;	Sulfated host glycan recognition by carbohydrate sulfatases of the human gut microbiota (BT1624-S1_15)
7OZ8	;	1.95	;	Sulfated host glycan recognition by carbohydrate sulfatases of the human gut microbiota (BT1918_S1_46)
7OZ9	;	1.907	;	Sulfated host glycan recognition by carbohydrate sulfatases of the human gut microbiota (BT3057-S1_16)
7OZC	;	1.75	;	Sulfated host glycan recognition by carbohydrate sulfatases of the human gut microbiota (BT3109_S1_15)
7P24	;	0.97	;	Sulfated host glycan recognition by carbohydrate sulfatases of the human gut microbiota (BT3177_S1_11)
7OZA	;	1.5	;	Sulfated host glycan recognition by carbohydrate sulfatases of the human gut microbiota (BT3796_S1_16)
7P26	;	1.35	;	Sulfated host glycan recognition by carbohydrate sulfatases of the human gut microbiota (BT4631_S1_15)
3GUA	;	3.1	;	Sulfates bound in the vestibule of AChBP
3LLI	;	2.05	;	Sulfhydryl Oxidase Fragment of Human QSOX1
3LLK	;	2.0	;	Sulfhydryl Oxidase Fragment of Human QSOX1
2BLF	;	1.8	;	Sulfite dehydrogenase from Starkeya Novella
2BPB	;	1.9	;	Sulfite dehydrogenase from Starkeya Novella
2CA4	;	2.1	;	Sulfite dehydrogenase from Starkeya Novella mutant
2CA3	;	2.0	;	Sulfite dehydrogenase from Starkeya Novella r55m mutant
2C9X	;	1.8	;	Sulfite dehydrogenase from Starkeya Novella Y236F mutant
1SOX	;	1.9	;	SULFITE OXIDASE FROM CHICKEN LIVER
6Y0K	;	1.7	;	Sulfite oxidase from Thermus thermophilus with coordinated phosphate
5GEP	;	2.1	;	SULFITE REDUCTASE HEMOPROTEIN CARBON MONOXIDE COMPLEX REDUCED WITH CRII EDTA
4GEP	;	2.0	;	SULFITE REDUCTASE HEMOPROTEIN CYANIDE COMPLEX REDUCED WITH CRII EDTA
7GEP	;	2.4	;	SULFITE REDUCTASE HEMOPROTEIN IN COMPLEX WITH A PARTIALLY OXIDIZED SULFIDE SPECIES
8GEP	;	2.2	;	SULFITE REDUCTASE HEMOPROTEIN NITRATE COMPLEX
6GEP	;	1.8	;	SULFITE REDUCTASE HEMOPROTEIN NITRIC OXIDE COMPLEX REDUCED WITH PROFLAVINE EDTA
3GEO	;	2.1	;	SULFITE REDUCTASE HEMOPROTEIN NITRITE COMPLEX
4AOP	;	1.8	;	SULFITE REDUCTASE HEMOPROTEIN PARTIALLY PHOTOREDUCED WITH PROFLAVINE EDTA, PHOSPHATE PARTIALLY BOUND
3AOP	;	2.1	;	SULFITE REDUCTASE HEMOPROTEIN PHOTOREDUCED WITH PROFLAVINE EDTA, SIROHEME FEII,[4FE-4S] +1, PHOSPHATE BOUND
2GEP	;	1.9	;	SULFITE REDUCTASE HEMOPROTEIN, OXIDIZED, SIROHEME FEIII [4FE-4S] +2,SULFITE COMPLEX
1AOP	;	1.6	;	SULFITE REDUCTASE STRUCTURE AT 1.6 ANGSTROM RESOLUTION
5AOP	;	2.2	;	SULFITE REDUCTASE STRUCTURE REDUCED WITH CRII EDTA, 5-COORDINATE SIROHEME, SIROHEME FEII, [4FE-4S] +1
2AOP	;	1.75	;	SULFITE REDUCTASE: REDUCED WITH CRII EDTA, SIROHEME FEII, [4FE-4S] +1, PHOSPHATE BOUND
2X06	;	2.5	;	SULFOLACTATE DEHYDROGENASE FROM METHANOCALDOCOCCUS JANNASCHII
7PNB	;	3.46	;	Sulfolobus acidocaldarius 0406 filament.
8Q30	;	3.22	;	Sulfolobus acidocaldarius AAP filament.
1QEZ	;	2.7	;	SULFOLOBUS ACIDOCALDARIUS INORGANIC PYROPHOSPHATASE: AN ARCHAEL PYROPHOSPHATASE.
1W3N	;	2.1	;	Sulfolobus solfataricus 2-keto-3-deoxygluconate (KDG) aldolase complex with D-KDG
1W3T	;	2.1	;	Sulfolobus solfataricus 2-keto-3-deoxygluconate (KDG) aldolase complex with D-KDGal, D-Glyceraldehyde and pyruvate
1W3I	;	1.7	;	Sulfolobus solfataricus 2-keto-3-deoxygluconate (KDG) aldolase complex with pyruvate
6H7R	;	2.8	;	Sulfolobus solfataricus 2-keto-3-deoxygluconate aldolase T157V/A198L variant
6H7S	;	3.202	;	Sulfolobus solfataricus 2-keto-3-deoxygluconate aldolase T157V/A198L variant in complex with L-2-keto-3deoxy-gluconate
6H2R	;	1.574	;	Sulfolobus solfataricus 2-keto-3-deoxygluconate aldolase T157V/D181Q/A198L variant
6H2S	;	2.17	;	Sulfolobus solfataricus 2-keto-3-deoxygluconate aldolase T157V/D181Q/A198L variant, pyruvate complex
6GV2	;	2.101	;	Sulfolobus solfataricus 2-keto-3-deoxygluconate aldolase Y103F,Y130F,A198F variant in complex with L-2-keto, 3-deoxy-galactonate
6GSO	;	2.0	;	Sulfolobus solfataricus 2-keto-3-deoxygluconate aldolase Y132V,T157C variant
6GT8	;	3.15	;	Sulfolobus solfataricus 2-keto-3-deoxygluconate aldolase Y132V,T157C variant
2BJD	;	1.27	;	Sulfolobus Solfataricus Acylphosphatase. Triclinic space group
4TRB	;	2.4	;	Sulfolobus solfataricus adenine phosphoribosyltransferase
4TRC	;	2.4	;	Sulfolobus solfataricus adenine phosphoribosyltransferase with adenine
4TS7	;	2.8	;	Sulfolobus solfataricus adenine phosphoribosyltransferase with ADP
4TS5	;	2.4	;	Sulfolobus solfataricus adenine phosphoribosyltransferase with AMP
5I3D	;	2.16	;	Sulfolobus solfataricus beta-glycosidase - E387Y mutant
2CD9	;	1.8	;	Sulfolobus solfataricus Glucose Dehydrogenase 1 - apo form
2CDA	;	2.28	;	Sulfolobus solfataricus Glucose Dehydrogenase 1 in complex with NADP
2CDB	;	1.6	;	Sulfolobus solfataricus Glucose Dehydrogenase 1 in complex with NADP and glucose
2CDC	;	1.5	;	Sulfolobus solfataricus Glucose Dehydrogenase 1 in complex with NADP and Xylose
4TKD	;	2.01	;	Sulfolobus solfataricus HJC mutants
4TKK	;	2.4	;	Sulfolobus solfataricus HJC mutants
4TWB	;	2.802	;	Sulfolobus solfataricus ribose-phosphate pyrophosphokinase
1Z5Z	;	2.0	;	Sulfolobus solfataricus SWI2/SNF2 ATPase C-terminal domain
1Z6A	;	3.0	;	Sulfolobus solfataricus SWI2/SNF2 ATPase core domain
1Z63	;	3.0	;	Sulfolobus solfataricus SWI2/SNF2 ATPase core in complex with dsDNA
5N2P	;	2.059	;	Sulfolobus solfataricus Tryptophan Synthase A
6HUL	;	2.55	;	Sulfolobus solfataricus Tryptophan Synthase AB Complex
6HTE	;	1.961	;	Sulfolobus solfataricus Tryptophan Synthase B2a
1XTT	;	1.8	;	Sulfolobus solfataricus uracil phosphoribosyltransferase in complex with uridine 5'-monophosphate (UMP)
1XTU	;	2.8	;	Sulfolobus solfataricus uracil phosphoribosyltransferase in complex with uridine 5'-monophosphate (UMP) and cytidine 5'-triphosphate (CTP)
1XTV	;	2.6	;	Sulfolobus solfataricus uracil phosphoribosyltransferase with uridine 5'-monophosphate (UMP) bound to half of the subunits
6G3Z	;	2.35	;	Sulfolobus sulfataricus 2-keto-3-deoxygluconate (KDG) aldolase complex with D-KDPG
2YDA	;	1.91	;	Sulfolobus sulfataricus 2-keto-3-deoxygluconate aldolase Y103F,Y130F, A198F variant
2YLY	;	3.2	;	Sulfonamides as selective Estrogen Receptor beta Agonists.
7QGW	;	1.3	;	Sulfonated Calpeptin is a promising drug candidate against SARS-CoV-2 infections
8C3D	;	2.0	;	Sulfonated Calpeptin is a promising drug candidate against SARS-CoV-2 infections
4HLD	;	2.0	;	Sulfonylpiperidines as Novel, Antibacterial Inhibitors of Gram-Positive Thymidylate Kinase (TMK): Compound 11
4HLC	;	1.55	;	Sulfonylpiperidines as Novel, Antibacterial Inhibitors of Gram-Positive Thymidylate Kinase (TMK): Compound 5
4GBM	;	1.62	;	Sulfotransferase Domain from the Curacin Biosynthetic Pathway
4GOX	;	2.15	;	Sulfotransferase Domain from the Synechococcus PCC 7002 Olefin Synthase
5VBJ	;	1.944	;	Sulfur as a bromine biomolecular halogen-bond acceptor
5ZMN	;	3.29	;	Sulfur binding domain and SRA domain of ScoMcrA complexed with phosphorothioated DNA
8H0L	;	1.8	;	Sulfur binding domain of Hga complexed with phosphorothioated DNA
5ZMO	;	1.69	;	Sulfur binding domain of ScoMcrA complexed with phosphorothioated DNA
7CC9	;	2.063	;	Sulfur binding domain of SprMcrA complexed with phosphorothioated DNA
7CCD	;	2.42	;	Sulfur binding domain of SprMcrA complexed with phosphorothioated DNA
7CCJ	;	3.3	;	Sulfur binding domain of SprMcrA complexed with phosphorothioated DNA
2CB2	;	1.7	;	Sulfur Oxygenase Reductase from Acidianus Ambivalens
7X9W	;	2.78	;	Sulfur Oxygenase Reductase from Acidianus ambivalens
4US7	;	1.96	;	Sulfur SAD Phased Structure of a Type IV Pilus Protein from Shewanella oneidensis
5FTP	;	3.1	;	sulfur SAD phasing of Cdc23Nterm: data collection with a tailored X- ray beam size at 2.69 A wavelength (4.6 keV)
4BRM	;	2.02	;	Sulfur SAD phasing of the Legionella pneumophila NTPDase1 - crystal form III (closed) in complex with sulfate
5B4F	;	2.75	;	Sulfur Transferase TtuA in complex with iron sulfur cluster
5B4E	;	2.698	;	Sulfur Transferase TtuA in complex with iron sulfur cluster and ATP derivative
5GHA	;	2.502	;	Sulfur Transferase TtuA in complex with Sulfur Carrier TtuB
3I0T	;	2.27	;	Sulfur-SAD at long wavelength: Structure of BH3703 from Bacillus halodurans
3EXD	;	1.49	;	Sulfur-SAD phased HEWL Crystal
1RHS	;	1.36	;	SULFUR-SUBSTITUTED RHODANESE
1BOH	;	2.3	;	SULFUR-SUBSTITUTED RHODANESE (ORTHORHOMBIC FORM)
1E0C	;	1.8	;	SULFURTRANSFERASE FROM AZOTOBACTER VINELANDII
1H4K	;	2.05	;	Sulfurtransferase from Azotobacter vinelandii in complex with hypophosphite
1H4M	;	2.1	;	Sulfurtransferase from Azotobacter vinelandii in complex with phosphate
5MEK	;	1.74	;	Sulphotransferase-18 from Arabidopsis thaliana in complex with 3'-phosphoadenosine 5'-phosphate (PAP)
5MEX	;	1.92	;	Sulphotransferase-18 from Arabidopsis thaliana in complex with 3'-phosphoadenosine 5'-phosphate (PAP)and sinigrin
4U9A	;	2.8	;	Sulphur Anomalous Crystal Structure of Asymmetric IRAK4 Dimer
3Q5G	;	1.77	;	Sulphur SAD structure solution of proteinase K grown in SO4 solution
3Q40	;	1.8	;	Sulphur SAD structure solution of proteinase K grown in SO4-less solution.
1Y8Q	;	2.25	;	SUMO E1 ACTIVATING ENZYME SAE1-SAE2-MG-ATP COMPLEX
1Y8R	;	2.75	;	SUMO E1 ACTIVATING ENZYME SAE1-SAE2-SUMO1-MG-ATP COMPLEX
8UZH	;	2.8	;	SUMO fused Trehalose Synthase (TreS) of Mycobacterium tuberculosis
2HKP	;	2.1	;	SUMO protease Ulp1 with the catalytic cysteine oxidized to a sulfenic acid
2HL8	;	2.0	;	SUMO protease Ulp1 with the catalytic cysteine oxidized to a sulfinic acid
2HL9	;	1.9	;	SUMO protease Ulp1 with the catalytic cysteine oxidized to a sulfonic acid
2K1F	;		;	SUMO-3 from Drosophila melanogaster (dsmt3)
6JXV	;		;	SUMO1 bound to phosphorylated SLS4-SIM peptide from ICP0
6JXU	;		;	SUMO1 bound to SLS4-SIM peptide from ICP0
5TVP	;	2.399	;	SUMO2 bound to Mouse Tdp2 catalytic domain with a 5'-phosphorylated DNA ternary complex
6JXX	;		;	SUMO2 bound to phosphorylated SLS4-SIM peptide from ICP0
2MUX	;		;	SUMO2 non-covalently interacts with USP25 and downregulates its activity
6TNT	;	3.78	;	SUMOylated apoAPC/C with repositioned APC2 WHB domain
7MSN	;	3.0	;	SunS glycosin S-glycosyltransferase
7MSP	;	2.1	;	SunS glycosin S-glycosyltransferase
5NHN	;	1.96	;	Super-Folder Green Fluorescent Protein Artificiall dimer linked via 148 position
6FLR	;	2.51	;	Super-open structure of the AMPAR GluA3 N-terminal domain
5W7H	;	2.75	;	Supercharged arPTE variant R5
6KHI	;	3.0	;	Supercomplex for cylic electron transport in cyanobacteria
6KHJ	;	3.0	;	Supercomplex for electron transfer
8DPD	;	1.51	;	superfolder GFP Tyr74pCNPhe mutant
6OA8	;	1.37	;	Superfolder Green Fluorescent Protein with 4-cyano-L-phenylalanine at the chromophore (position 66)
6B9C	;	1.695	;	Superfolder Green Fluorescent Protein with 4-nitro-L-phenylalanine at the chromophore (position 66)
7YEU	;	1.95	;	Superfolder green fluorescent protein with phosphine unnatural amino acid P3BF
1OLM	;	1.95	;	Supernatant Protein Factor in Complex with RRR-alpha-Tocopherylquinone: A Link between Oxidized Vitamin E and Cholesterol Biosynthesis
3AK1	;	1.57	;	Superoxide dismutase from Aeropyrum pernix K1, apo-form
3AK3	;	1.48	;	Superoxide dismutase from Aeropyrum pernix K1, Fe-bound form
3AK2	;	1.35	;	Superoxide dismutase from Aeropyrum pernix K1, Mn-bound form
1B06	;	2.2	;	SUPEROXIDE DISMUTASE FROM SULFOLOBUS ACIDOCALDARIUS
1FUN	;	2.85	;	SUPEROXIDE DISMUTASE MUTANT WITH LYS 136 REPLACED BY GLU, CYS 6 REPLACED BY ALA AND CYS 111 REPLACED BY SER (K136E, C6A, C111S)
2A03	;	2.33	;	Superoxide dismutase protein from plasmodium berghei
6D52	;	1.6	;	Superoxide dismutase SodCI of Salmonella enterica serovar Typhimurium at 1.6 Angstrom resolution
8AVK	;	2.1	;	Superoxide dismutase SodFM1 from CPR Parkubacteria Wolfebacteria
8AVL	;	1.6	;	Superoxide dismutase SodFM2 from Bacteroides fragilis
2AW9	;	2.7	;	Superoxide dismutase with manganese from Deinococcus radiodurans
4D7P	;	2.001	;	Superoxide reductase (1Fe-SOR) from Giardia intestinalis
4BGL	;	1.9	;	Superoxide reductase (Neelaredoxin) from Archaeoglobus fulgidus
4BFK	;	2.103	;	Superoxide reductase (Neelaredoxin) from Archaeoglobus fulgidus E12Q mutant
4C4U	;	2.583	;	Superoxide reductase (Neelaredoxin) from Archaeoglobus fulgidus E12Q mutant in the reduced form
4C4B	;	2.5	;	Superoxide reductase (Neelaredoxin) from Archaeoglobus fulgidus E12V in the reduced form
4BFJ	;	2.8	;	Superoxide reductase (Neelaredoxin) from Archaeoglobus fulgidus E12V mutant
4BFF	;	2.0	;	Superoxide reductase (Neelaredoxin) from Archaeoglobus fulgidus in the reduced form
4BK8	;	1.847	;	Superoxide reductase (Neelaredoxin) from Ignicoccus hospitalis
4BRV	;	2.05	;	Superoxide reductase (Neelaredoxin) from Ignicoccus hospitalis E23A
4BRJ	;	2.5	;	Superoxide reductase (Neelaredoxin) from Ignicoccus hospitalis T24K
6GQ8	;	1.9	;	Superoxide reductase from Nanoarchaeum equitans
1QDS	;	2.0	;	SUPERSTABLE E65Q MUTANT OF LEISHMANIA MEXICANA TRIOSEPHOSPHATE ISOMERASE (TIM)
2P63	;	2.67	;	Suprafacial orientation of the SCFCdc4 dimer accommodates multiple geometries for substrate ubiquitination
7NSB	;	3.7	;	Supramolecular assembly module of yeast Chelator-GID SR4 E3 ubiquitin ligase
2KWD	;		;	Supramolecular Protein Structure Determination by Site-Specific Long-Range Intermolecular Solid State NMR Spectroscopy
7KV4	;	1.84	;	Surface glycan-binding protein A from Bacteroides fluxus
7KV2	;	1.8	;	Surface glycan-binding protein A from Bacteroides thetaiotaomicron
7KV3	;	2.05	;	Surface glycan-binding protein A from Bacteroides thetaiotaomicron in complex with laminarihexaose
7KV1	;	1.86	;	Surface glycan-binding protein A from Bacteroides uniformis
7KWC	;	2.611	;	Surface glycan-binding protein B (truncated) from Bacteroides thetaiotaomicron
7KV5	;	1.82	;	Surface glycan-binding protein B from Bacteroides fluxus
7KV7	;	1.76	;	Surface glycan-binding protein B from Bacteroides fluxus in complex with laminaritriose
7KV6	;	1.6	;	Surface glycan-binding protein B from Bacteroides fluxus in complex with mixed-linkage glucotriose
7KWB	;	2.6	;	Surface glycan-binding protein B from Bacteroides thetaiotaomicron
4ZWI	;	1.6	;	Surface Lysine Acetylated Human Carbonic Anhydrase II in Complex with a Sulfamate-Based Inhibitor
4CNR	;	2.29	;	Surface residue engineering of bovine carbonic anhydrase to an extreme halophilic enzyme for potential application in postcombustion CO2 capture
4CNV	;	1.62	;	Surface residue engineering of bovine carbonic anhydrase to an extreme halophilic enzyme for potential application in postcombustion CO2 capture
4CNW	;	2.03	;	Surface residue engineering of bovine carbonic anhydrase to an extreme halophilic enzyme for potential application in postcombustion CO2 capture
4CNX	;	1.23	;	Surface residue engineering of bovine carbonic anhydrase to an extreme halophilic enzyme for potential application in postcombustion CO2 capture
6P5T	;	2.1	;	Surface-layer (S-layer) RsaA protein from Caulobacter crescentus bound to strontium and iodide
3PAQ	;	2.1	;	Surfactant Protein A neck and carbohydrate recognition domain (NCRD) complexed with alpha-methylmannose
3PBF	;	1.8	;	Surfactant Protein-A neck and carbohydrate recognition domain (NCRD) complexed with glycerol
3PAR	;	2.3	;	Surfactant Protein-A neck and carbohydrate recognition domain (NCRD) in the absence of ligand
1CHP	;	2.0	;	SURPRISING LEADS FOR A CHOLERA TOXIN RECEPTOR BINDING ANTAGONIST; CRYSTALLOGRAPHIC STUDIES OF CTB MUTANTS
1CHQ	;	2.1	;	SURPRISING LEADS FOR A CHOLERA TOXIN RECEPTOR BINDING ANTAGONIST; CRYSTALLOGRAPHIC STUDIES OF CTB MUTANTS
1P20	;	1.34	;	Surprising Roles of Electrostatic Interactions in DNA-Ligand Complexes
1E31	;	2.71	;	SURVIVIN DIMER H. SAPIENS
6CEP	;	2.0	;	Sus scrofa heart L-lactate dehydrogenase ternary complex with NADH and oxamate
8AA4	;	3.1	;	SusC components of the dextran utilisation system (utilisome)
7NEK	;	2.65	;	SusD protein from human gut uncultured Bacteroides
7M1A	;	1.42	;	SusE-like protein BT2857
7M1B	;	1.5	;	SusE-like protein BT2857
6BS6	;	2.17	;	SusG with mixed linkage amylosaccharide
5D9I	;	1.7	;	SV40 Large T antigen origin binding domain bound to artificial DNA fork
2TBD	;		;	SV40 T ANTIGEN DNA-BINDING DOMAIN, NMR, 30 STRUCTURES
3BWR	;	2.25	;	SV40 VP1 pentamer in complex with GM1 oligosaccharide
6ODG	;	1.0	;	SVQIVY, Crystal Structure of a tau protein fragment
4E0M	;	1.75	;	SVQIVYK segment from human Tau (305-311) displayed on 54-membered macrocycle scaffold (form I)
4E0N	;	1.65	;	SVQIVYK segment from human Tau (305-311) displayed on 54-membered macrocycle scaffold (form II)
4E0O	;	1.82	;	SVQIVYK segment from human Tau (305-311) displayed on 54-membered macrocycle scaffold (form III)
4P2M	;	2.7	;	Swapped Dimer of Mycobacterial Adenylyl cyclase Rv1625c: Form 1
4P2X	;	2.4	;	Swapped Dimer of Mycobacterial Adenylyl cyclase Rv1625c: Form 2
4U17	;	1.99	;	Swapped dimer of the human Fyn-SH2 domain
1XZW	;	2.5	;	Sweet potato purple acid phosphatase/phosphate complex
7W8E	;	1.34	;	Sweet taste protein Brazzein - R43A
7W8H	;	1.501	;	Sweet taste protein Brazzein mutant - D29K
6CFH	;	1.5	;	SWGMMGMLASQ segment from the low complexity domain of TDP-43
6UXV	;	4.7	;	SWI/SNF Body Module
6UXW	;	8.96	;	SWI/SNF nucleosome complex with ADP-BeFx
1ZFD	;		;	SWI5 ZINC FINGER DOMAIN 2, NMR, 45 STRUCTURES
6LJJ	;	1.89	;	Swine dUTPase in complex with alpha,beta-iminodUTP and magnesium ion
1MQT	;	3.3	;	Swine Vesicular Disease Virus coat protein
5IT3	;	1.4	;	Swirm domain of human Lsd1
3HI4	;	2.25	;	Switching catalysis from hydrolysis to perhydrolysis in P. fluorescens esterase
5BT0	;	2.03	;	Switching GFP fluorescence using genetically encoded phenyl azide chemistry through two different non-native post-translational modifications routes at the same position.
5BTT	;	2.14	;	Switching GFP fluorescence using genetically encoded phenyl azide chemistry through two different non-native post-translational modifications routes at the same position.
3H5F	;	1.86	;	Switching the Chirality of the Metal Environment Alters the Coordination Mode in Designed Peptides.
3H5G	;	1.71	;	Switching the Chirality of the Metal Environment Alters the Coordination Mode in Designed Peptides.
5UPB	;	1.912	;	Swit_4259, an Acetoacetate Decarboxylase-like Enzyme from Sphingomonas wittichii RW1
1B7F	;	2.6	;	SXL-LETHAL PROTEIN/RNA COMPLEX
7UCI	;	2.6	;	SxtA Methyltransferase and decarboxylase didomain in complex with Mn2+ and SAH
7UCL	;	2.09	;	SxtA Methyltransferase variant F458H in complex with Mn2+ and malonate
6U1R	;	1.792	;	SxtG an amidinotransferase from the Microseira wollei in Saxitoxin biosynthetic pathway
7MXZ	;	1.47	;	Sy-CrtE apo structure
7MY0	;	1.37	;	Sy-CrtE IPP structure
7MY1	;	1.84	;	Sy-CrtE structure with IPP, N-term His-tag
5CY3	;	1.76	;	SYK catalytic domain complexed with a potent and orally bioavailable benzisothiazole inhibitor
5CXH	;	1.9	;	SYK catalytic domain complexed with a potent orally bioavailable thiazole inhibitor
4RX9	;	1.75	;	SYK Catalytic Domain Complexed with a Potent Pyrimidine Inhibitor
4RX7	;	1.8	;	SYK Catalytic Domain Complexed with a Potent Triazine Inhibitor
4RX8	;	1.59	;	SYK Catalytic Domain Complexed with a Potent Triazine Inhibitor2
5CXZ	;	1.7	;	SYK catalytic domain complexed with naphthyridine inhibitor
4PX6	;	1.6	;	SYK catalytic domain in complex with a potent pyridopyrimidinone inhibitor
4WNM	;	2.5	;	SYK catalytic domain in complex with a potent triazolopyridine inhibitor
6ZCU	;	1.73	;	syk in complex with 57262_SYKB-AZ13344324-2
6SSB	;	2.08	;	syk in complex with compound 30
4F4P	;	2.37	;	SYK in COMPLEX WITH LIGAND LASW836
6ZCX	;	1.66	;	SYK Kinase domain in complex with azabenzimidazole inhibitor 18
6ZC0	;	1.97	;	SYK Kinase domain in complex with azabenzimidazole inhibitor 2b
6ZCP	;	2.2	;	SYK Kinase domain in complex with azabenzimidazole inhibitor 2b
6ZCS	;	1.47	;	SYK Kinase domain in complex with azabenzimidazole inhibitor 3
6ZCR	;	1.73	;	SYK Kinase domain in complex with azabenzimidazole inhibitor 7
6ZCY	;	1.81	;	SYK Kinase domain in complex with diamine inhibitor 16
6ZCQ	;	2.32	;	SYK Kinase domain in complex with diamine inhibitor 5
4YJQ	;	1.34	;	SYK kinase domain in complex with inhibitor GTC000224
4YJR	;	1.32	;	SYK kinase domain in complex with inhibitor GTC000225
8BI2	;	1.508	;	Syk kinase domain in complex with macrocyclic inhibitor 20a
1CSY	;		;	SYK TYROSINE KINASE C-TERMINAL SH2 DOMAIN COMPLEXED WITH A PHOSPHOPEPTIDEFROM THE GAMMA CHAIN OF THE HIGH AFFINITY IMMUNOGLOBIN G RECEPTOR, NMR
1CSZ	;		;	SYK TYROSINE KINASE C-TERMINAL SH2 DOMAIN COMPLEXED WITH A PHOSPHOPEPTIDEFROM THE GAMMA CHAIN OF THE HIGH AFFINITY IMMUNOGLOBIN G RECEPTOR, NMR
4F34	;	1.95	;	Symfoil-4V synthetic protein with T30E/T72E/T116E mutations, and delta His tag
7ZPL	;	3.12	;	Symmetric dimer of influenza A/H7N9 polymerase bound to 5' vRNA hook
8SP0	;	3.33	;	Symmetric dimer of MapSPARTA bound with gRNA/tDNA hybrid
4A7J	;	1.9	;	Symmetric Dimethylation of H3 Arginine 2 is a Novel Histone Mark that Supports Euchromatin Maintenance
6OPO	;	3.5	;	Symmetric model of CD4- and 17-bound B41 HIV-1 Env SOSIP in complex with DDM
6X5B	;	3.6	;	Symmetric model of CD4- and 17-bound B41 HIV-1 Env SOSIP in complex with small molecule GO52
6OTF	;	3.1	;	Symmetric reconstruction of human norovirus GII.2 Snow Mountain Virus Strain VLP in T=3 symmetry
6OUU	;	4.1	;	Symmetric reconstruction of human norovirus GII.4 Minerva strain VLP in T=4 symmetry
3D9B	;	3.42	;	Symmetric structure of E. coli AcrB
1VST	;	2.8	;	Symmetric Sulfolobus solfataricus uracil phosphoribosyltransferase with bound PRPP and GTP
7MI4	;	3.2	;	Symmetrical PAM-PAM prespacer bound Cas4/Cas1/Cas2 complex
4A8C	;	7.5	;	Symmetrized cryo-EM reconstruction of E. coli DegQ 12-mer in complex with a binding peptide
4A8B	;	13.0	;	Symmetrized cryo-EM reconstruction of E. coli DegQ 12-mer in complex with lysozymes
4A9G	;	7.5	;	Symmetrized cryo-EM reconstruction of E. coli DegQ 24-mer in complex with beta-casein
8PE8	;	3.46	;	Symmetry expanded D7 local refined map of mitochondrial heat-shock protein 60-like protein from Chaetomium thermophilum
8VA2	;	4.5	;	Symmetry expanded map of 2 gamma-tubulins bound to 2 alpha tubulins in gamma tubulin ring complex capped microtubule end.
8E06	;	4.3	;	Symmetry expansion of dimeric LRRK1
8E00	;	3.6	;	Symmetry expansion of yeast cytoplasmic dynein-1 bound to Lis1 in the chi conformation.
7KJY	;	3.2	;	Symmetry in Yeast Alcohol Dehydrogenase 1 - Open Form with NADH
7KCB	;	2.77	;	Symmetry in Yeast Alcohol Dehydrogenase 1 -Closed Form with NAD+ and Trifluoroethanol
7KC2	;	2.67	;	Symmetry in Yeast Alcohol Dehydrogenase 1 -Closed Form with NADH
7KCQ	;	3.2	;	Symmetry in Yeast Alcohol Dehydrogenase 1 -Open Form of Apoenzyme
5L0P	;	2.3	;	Symmetry-based assembly of a two-dimensional protein lattice
7Y6U	;	3.2	;	Symmetry-expanded and locally refined protomer structure of IPEC-J2 cell-derived PEDV PT52 S with a CTD-close conformation
7Y6V	;	3.3	;	Symmetry-expanded and locally refined protomer structure of IPEC-J2 cell-derived PEDV PT52 S with a CTD-open conformation
4A0O	;	10.5	;	Symmetry-free cryo-EM map of TRiC in the nucleotide-free (apo) state
5AFF	;	3.398	;	Symportin 1 chaperones 5S RNP assembly during ribosome biogenesis by occupying an essential rRNA binding site
6O8J	;		;	Syn-safencin
6O8R	;		;	Syn-safencin 24
6O8S	;		;	Syn-safencin 56
6O8P	;		;	Syn-safencin 8
6O8T	;		;	Syn-safencin 96
2AWU	;	2.44	;	Synapse associated protein 97 PDZ2 domain variant C378G
2AWW	;	2.21	;	Synapse associated protein 97 PDZ2 domain variant C378G with C-terminal GluR-A peptide
2AWX	;	1.8	;	Synapse associated protein 97 PDZ2 domain variant C378S
8U0O	;	2.05	;	Synaptic complex of human DNA polymerase Lambda DL variant engaged on a DNA double-strand break containing an unpaired 3' primer terminus
8U0P	;	1.9	;	Synaptic complex of human DNA polymerase Lambda DL variant engaged on a noncomplementary DNA double-strand break
5IWZ	;	2.098	;	Synaptonemal complex protein
6CXW	;	1.832	;	Synaptotagmin 1 C2A beta4 chimera with enhanced PIP2 binding function
5T0R	;	1.95	;	Synaptotagmin 1 C2A domain, cadmium-bound
5VFE	;	1.38	;	Synaptotagmin 1 C2A domain, lead-bound
5T0S	;	1.42	;	Synaptotagmin 1 C2B domain, cadmium-bound
5VFG	;	1.82	;	Synaptotagmin 1 C2B domain, lead-bound (high occupancy)
5VFF	;	1.413	;	Synaptotagmin 1 C2B domain, lead-bound (low occupancy)
6MTI	;	10.4	;	Synaptotagmin-1 C2A, C2B domains and SNARE-pin proteins (5CCI) individually docked into Cryo-EM map of C2AB-SNARE complexes helically organized on lipid nanotube surface in presence of Mg2+
2YOA	;	1.5	;	Synaptotagmin-1 C2B domain with phosphoserine
6ANJ	;	1.698	;	Synaptotagmin-7, C2A domain
6ANK	;	2.254	;	Synaptotagmin-7, C2A- and C2B-domains
3N5A	;	1.441	;	Synaptotagmin-7, C2B-domain, calcium bound
1ZYP	;	2.4	;	Synchrotron reduced form of the N-terminal domain of Salmonella typhimurium AhpF
5UNH	;	2.9	;	Synchrotron structure of human angiotensin II type 2 receptor in complex with compound 2 (N-[(furan-2-yl)methyl]-N-(4-oxo-2-propyl-3-{[2'-(2H-tetrazol-5-yl)[1,1'- biphenyl]-4-yl]methyl}-3,4-dihydroquinazolin-6-yl)benzamide)
5ZTK	;	1.75	;	Synchrotron structure of light-driven chloride pump having an NTQ motif
4RWA	;	3.28	;	Synchrotron structure of the human delta opioid receptor in complex with a bifunctional peptide (PSI community target)
2PRK	;	1.5	;	SYNCHROTRON X-RAY DATA COLLECTION AND RESTRAINED LEAST-SQUARES REFINEMENT OF THE CRYSTAL STRUCTURE OF PROTEINASE K AT 1.5 ANGSTROMS RESOLUTION
1XFT	;	3.35	;	Synchrotron X-ray Powder Diffraction Study of Hexagonal Turkey Egg-white Lysozyme
5HNC	;	1.76	;	Synchrotron X-ray single crystal diffraction from protein microcrystals via magnetically oriented microcrystal arrays in gels
7R7G	;	2.25	;	Synechococcus Olefin Synthase FAAL domain A229I/R336A in complex with palmitoyl adenylate and pyrophosphate
7R7E	;	1.99	;	Synechococcus Olefin Synthase FAAL domain in complex with AMP and pyrophosphate
7R7F	;	2.13	;	Synechococcus Olefin Synthase FAAL domain R336A in complex with stearoyl adenylate and pyrophosphate
5KK0	;	2.8	;	Synechocystis ACO mutant - T136A
5KJB	;	2.81	;	Synechocystis apocarotenoid oxygenase (ACO) mutant - Glu150Asp
5KJD	;	2.75	;	Synechocystis apocarotenoid oxygenase (ACO) mutant - Glu150Gln
5KJA	;	2.8	;	Synechocystis apocarotenoid oxygenase (ACO) mutant - Trp149Ala
7CR8	;	3.7	;	Synechocystis Cas1-Cas2-prespacerL complex
7CR6	;	3.72	;	Synechocystis Cas1-Cas2/prespacer binary complex
1Y6I	;	1.78	;	Synechocystis GUN4
7E2S	;	1.05	;	Synechocystis GUN4 in complex with biliverdin IXa
7E2T	;	1.1	;	Synechocystis GUN4 in complex with phycocyanobilin
7E2U	;	1.7	;	Synechocystis GUN4 in complex with phytochrome
7SC7	;	2.8	;	Synechocystis PCC 6803 Phycobilisome core from up-down rod conformation
7SC9	;	2.6	;	Synechocystis PCC 6803 Phycobilisome core, complex with OCP
7SCA	;	2.1	;	Synechocystis PCC 6803 Phycobilisome rod from OCP-PBS complex sample
7SC8	;	2.1	;	Synechocystis PCC 6803 Phycobilisome rod from PBS sample
4EML	;	2.043	;	Synechocystis sp. PCC 6803 1,4-dihydroxy-2-naphthoyl-coenzyme A synthase (MenB) in complex with bicarbonate
4I4Z	;	2.0	;	Synechocystis sp. PCC 6803 1,4-dihydroxy-2-naphthoyl-coenzyme A synthase (MenB) in complex with salicylyl-CoA
4MJC	;	1.409	;	Synechocystis sp. PCC 6803 glutaredoxin A - P84R
4MJA	;	2.0	;	Synechocystis sp. PCC 6803 glutaredoxin A-A75I
4MJB	;	2.111	;	Synechocystis sp. PCC 6803 glutaredoxin A-A79S
4MJE	;	1.2	;	Synechocystis sp. PCC 6803 glutaredoxin A-R27L
7PKA	;	2.16	;	Synechocystis sp. PCC6803 glutathione transferase Chi 1, GSOH bound
7LG5	;	2.63	;	Synechocystis sp. UTEX2470 Cyanophycin synthetase 1 with ATP
1C8L	;	2.3	;	SYNERGISTIC INHIBITION OF GLYCOGEN PHOSPHORYLASE A BY A POTENTIAL ANTIDIABETIC DRUG AND CAFFEINE
7A3M	;	1.01	;	Synergistic stabilization of a double mutant in CI2 from an in-cell library screen
7PF8	;	1.85	;	SynFtn Variant E141A
7PF9	;	1.55	;	SynFtn Variant E141D
5JXC	;	2.5	;	SynGAP Coiled-coil trimer
7R2T	;	2.5	;	SYNJ2BP complex with a phosphorylated Vangl2 peptide at the P-1 position.
8AEL	;	2.2	;	SYNJ2BP complex with a synthetic Vangl2 peptide (3mer).
7R2M	;	2.4	;	SYNJ2BP complex with a synthetic Vangl2 peptide (9mer).
6Q08	;		;	Synoeca peptide was isolated from the venom of wasp synoeca surinama.
1LVF	;	2.1	;	syntaxin 6
1RVV	;	2.4	;	SYNTHASE/RIBOFLAVIN SYNTHASE COMPLEX OF BACILLUS SUBTILIS
2A4F	;	1.9	;	Synthesis and Activity of N-Axyl Azacyclic Urea HIV-1 Protease Inhibitors with High Potency Against Multiple Drug Resistant Viral Strains.
5M96	;	1.77	;	Synthesis and biological evaluation of new triazolo and imidazolopyridine RORgt inverse agonists
5T8E	;	2.71	;	Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs). Part II: Optimization of 4-(pyrrolidin-1-yl)benzonitrile derivatives
5T8J	;	2.7	;	Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs). Part II: Optimization of 4-(pyrrolidin-1-yl)benzonitrile derivatives
5V8Q	;	1.44	;	Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs): Part III
4XUC	;	1.8	;	Synthesis and evaluation of heterocyclic catechol mimics as inhibitors of catechol-O-methyltransferase (COMT): Structure with Cmpd18 (1-(biphenyl-3-yl)-3-hydroxypyridin-4(1H)-one)
4XUE	;	2.3	;	Synthesis and evaluation of heterocyclic catechol mimics as inhibitors of catechol-O-methyltransferase (COMT): Structure with Cmpd27b
4XUD	;	2.4	;	Synthesis and evaluation of heterocyclic catechol mimics as inhibitors of catechol-O-methyltransferase (COMT): Structure with Cmpd32 ([1-(biphenyl-3-yl)-5-hydroxy-4-oxo-1,4-dihydropyridin-3-yl]boronic acid)
4GB1	;	2.62	;	Synthesis and Evaluation of Novel 3-C-alkylated-Neu5Ac2en Derivatives as Probes of Influenza Virus Sialidase 150-loop flexibility
2YER	;	1.83	;	Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors
2YEX	;	1.3	;	Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors
2P33	;	2.4	;	Synthesis and SAR of Aminopyrimidines as Novel c-Jun N-Terminal Kinase (JNK) Inhibitors
4AD6	;	1.85	;	Synthesis and SAR of guanine based analogues for HPPK inhibitors
3VAP	;	2.66	;	Synthesis and SAR Studies of imidazo-[1,2-a]-pyrazine Aurora kinase inhibitors with improved off target kinase selectivity
1QFI	;	0.91	;	SYNTHESIS AND STRUCTURE OF PROLINE RING MODIFIED ACTINOMYCINS OF X TYPE
3DJ8	;	1.51	;	Synthesis of (2S)-2-amino-7,8-epoxyoctanoic acid and structure of its metal-bridging complex with human arginase I
4H42	;	2.01	;	Synthesis of a Weak Basic uPA Inhibitor and Crystal Structure of Complex with uPA
4JQL	;	1.72	;	Synthesis of Benzoquinone-Ansamycin-Inspired Macrocyclic Lactams from Shikimic Acid
2FET	;	2.03	;	Synthesis of C-D-Glycopyranosyl-Hydroquinones and-Benzoquinones. Inhibition of PTP1B. Inhibition of and binding to glycogen phosphorylase in the crystal
2FF5	;	2.03	;	Synthesis of C-D-Glycopyranosyl-Hydroquinones and-Benzoquinones. Inhibition of PTP1B. Inhibition of and binding to glycogen phosphorylase in the crystal
3G5M	;	1.84	;	Synthesis of Casimiroin and Optimization of Its Quinone Reductase 2 and Aromatase Inhibitory activity
3GAM	;	1.98	;	Synthesis of Casimiroin and Optimization of Its Quinone Reductase 2 and Aromatase Inhibitory activity
2VSH	;	2.0	;	Synthesis of CDP-activated ribitol for teichoic acid precursors in Streptococcus pneumoniae
2VSI	;	2.75	;	Synthesis of CDP-activated ribitol for teichoic acid precursors in Streptococcus pneumoniae
3UPH	;	2.0	;	Synthesis of novel 4,5-dihydrofurano indoles and their evaluation as HCV NS5B polymerase inhibitors
3UPI	;	2.0	;	Synthesis of novel 4,5-dihydrofurano indoles and their evaluation as HCV NS5B polymerase inhibitors
4GQI	;	1.948	;	Synthesis of novel MT3 receptor ligands via unusual Knoevenagel condensation
4GR9	;	2.291	;	Synthesis of novel MT3 receptor ligands via unusual Knoevenagel condensation
4UFZ	;	2.33	;	Synthesis of Novel NAD Dependant DNA Ligase Inhibitors via Negishi Cross-Coupling: Development of SAR and Resistance Studies
5ULN	;	1.35	;	Synthesis of novel seleno ureido containing compounds as SLC-0111 analogs. Investigations on carbonic anhydrases activity, glutathione peroxidase and X-ray crystallography
5UMC	;	2.15	;	Synthesis of novel seleno ureido containing compounds as SLC-0111 analogs. Investigations on carbonic anhydrases activity, glutathione peroxidase and X-ray crystallography
6PGX	;	1.36	;	Synthesis of novel tellurides bearing benzensulfonamide moiety as carbonic anhydrase inhibitors with antitumor activity
2FOI	;	2.5	;	Synthesis, Biological Activity, and X-Ray Crystal Structural Analysis of Diaryl Ether Inhibitors of Malarial Enoyl ACP Reductase.
1ZSN	;	2.992	;	Synthesis, Biological Activity, and X-Ray Crystal Structural Analysis of Diaryl Ether Inhibitors of Malarial Enoyl ACP Reductase. Part 1:4'-Substituted Triclosan Derivatives
1ZW1	;	2.9	;	Synthesis, Biological Activity, and X-Ray Crystal Structural Analysis of Diaryl Ether Inhibitors of Malarial Enoyl ACP Reductase. Part 1:4'-Substituted Triclosan Derivatives
1ZXB	;	2.68	;	Synthesis, Biological Activity, and X-Ray Crystal Structural Analysis of Diaryl Ether Inhibitors of Malarial Enoyl ACP Reductase. Part 1:4'-Substituted Triclosan Derivatives
1ZXL	;	3.0	;	Synthesis, Biological Activity, and X-Ray Crystal Structural Analysis of Diaryl Ether Inhibitors of Malarial Enoyl ACP Reductase. Part 1:4'-Substituted Triclosan Derivatives
5A6H	;	1.57	;	Synthesis, carbonic anhydrase inhibition and protein X-ray structure of the unusual natural product primary sulfonamide Psammaplin C
4PZW	;	1.8	;	Synthesis, Characterization and PK/PD Studies of a Series of Spirocyclic Pyranochromene BACE1 Inhibitors
4PZX	;	1.8	;	Synthesis, Characterization and PK/PD Studies of a Series of Spirocyclic Pyranochromene BACE1 Inhibitors
2H1M	;	2.9	;	Synthesis, Oxidation Behavior, Crystallization and Structure of 2'-Methylseleno Guanosine Containing RNAs
2OO8	;	2.2	;	Synthesis, Structural Analysis, and SAR Studies of Triazine Derivatives as Potent, Selective Tie-2 Inhibitors
2OSC	;	2.8	;	Synthesis, Structural Analysis, and SAR Studies of Triazine Derivatives as Potent, Selective Tie-2 Inhibitors
2K1I	;		;	Synthesis, Structure and Activities of an Oral Mucosal Alpha-Defensin from Rhesus Macaque
3P8X	;	1.7	;	Synthesis, Structure, and Biological Activity of des-Side Chain Analogues of 1alpha,25-Dihydroxyvitamin D3 with Substituents at C-18
8TPB	;	1.88	;	Synthesis, X-Ray Crystallographic and Biological Activities of Covalent, Non-Peptidic Inhibitors of SARS-CoV-2 Main Protease
8TPC	;	1.73	;	Synthesis, X-Ray Crystallographic and Biological Activities of Covalent, Non-Peptidic Inhibitors of SARS-CoV-2 Main Protease
8TPD	;	1.68	;	Synthesis, X-Ray Crystallographic and Biological Activities of Covalent, Non-Peptidic Inhibitors of SARS-CoV-2 Main Protease
8TPE	;	1.61	;	Synthesis, X-Ray Crystallographic and Biological Activities of Covalent, Non-Peptidic Inhibitors of SARS-CoV-2 Main Protease
8TPF	;	1.95	;	Synthesis, X-Ray Crystallographic and Biological Activities of Covalent, Non-Peptidic Inhibitors of SARS-CoV-2 Main Protease
8TPG	;	1.692	;	Synthesis, X-Ray Crystallographic and Biological Activities of Covalent, Non-Peptidic Inhibitors of SARS-CoV-2 Main Protease
8TPH	;	1.52	;	Synthesis, X-Ray Crystallographic and Biological Activities of Covalent, Non-Peptidic Inhibitors of SARS-CoV-2 Main Protease
8TPI	;	1.98	;	Synthesis, X-Ray Crystallographic and Biological Activities of Covalent, Non-Peptidic Inhibitors of SARS-CoV-2 Main Protease
1S9Z	;	2.01	;	SYNTHETIC 17 AMINO ACID LONG PEPTIDE THAT FORMS A NATIVE-LIKE COILED-COIL AT AMBIENT TEMPERATURE AND AGGREGATES INTO AMYLOID-LIKE FIBRILS AT HIGHER TEMPERATURES.
8DPY	;	1.0	;	Synthetic Beta Sheet Macrocycle Stabilized by Hydrogen Bond Surrogates
3PJJ	;	1.8	;	Synthetic Dimer of Human Carbonic Anhydrase II
7B4Z	;		;	Synthetic DNA duplex dodecamer
1CS7	;	3.2	;	SYNTHETIC DNA HAIRPIN WITH STILBENEDIETHER LINKER
8CUG	;	1.131	;	Synthetic epi-Novo29 (2R,3S), synchrotron structure
8CUF	;	1.68	;	Synthetic epi-Novo29 (2R,3S), X-ray diffractometer structure
6OTC	;	1.7	;	Synthetic Fab bound to Marburg virus VP35 interferon inhibitory domain
2RHL	;	2.45	;	Synthetic Gene Encoded Bacillus Subtilis FtsZ NCS Dimer with Bound GDP
2RHO	;	2.45	;	Synthetic Gene Encoded Bacillus Subtilis FtsZ NCS Dimer with Bound GDP and GTP-gamma-S
2RHH	;	2.001	;	Synthetic Gene Encoded Bacillus Subtilis FtsZ with Bound Sulfate Ion
2RHJ	;	1.761	;	Synthetic Gene Encoded Bacillus Subtilis FtsZ with Two Sulfate Ions and Sodium Ion in the Nucleotide Pocket
3BLA	;	2.6	;	Synthetic Gene Encoded DcpS bound to inhibitor DG153249
3BL7	;	2.31	;	Synthetic Gene Encoded DcpS bound to inhibitor DG156844
3BL9	;	1.8	;	Synthetic Gene Encoded DcpS bound to inhibitor DG157493
7NXZ	;	1.998	;	Synthetic glycoform of Human Interleukin 6
6NER	;	3.59	;	Synthetic Haliangium ochraceum BMC shell
6CMH	;		;	SYNTHETIC LINEAR MODIFIED ENDOTHELIN-1 AGONIST
3CMH	;		;	SYNTHETIC LINEAR TRUNCATED ENDOTHELIN-1 AGONIST
7RCU	;	2.69	;	Synthetic Max homodimer mimic in complex with DNA
6SNY	;	3.11	;	Synthetic mimic of an EPCR-binding PfEMP1 bound to EPCR
5M13	;	1.372	;	Synthetic nanobody in complex with MBP
5M14	;	1.6	;	Synthetic nanobody in complex with MBP
5M15	;	1.9	;	Synthetic nanobody in complex with MBP
1BCV	;		;	SYNTHETIC PEPTIDE CORRESPONDING TO THE MAJOR IMMUNOGEN SITE OF FMD VIRUS, NMR, 10 STRUCTURES
6HCR	;	3.5	;	Synthetic Self-assembling ADDomer Platform for Highly Efficient Vaccination by Genetically-encoded Multi-epitope Display
1UBI	;	1.8	;	SYNTHETIC STRUCTURAL AND BIOLOGICAL STUDIES OF THE UBIQUITIN SYSTEM. PART 1
1OGW	;	1.32	;	Synthetic Ubiquitin with fluoro-Leu at 50 and 67
2WVP	;	2.4	;	Synthetically modified OmpG
2FCU	;	1.6	;	SyrB2 with alpha-ketoglutarate
2FCV	;	1.8	;	SyrB2 with Fe(II), bromide, and alpha-ketoglutarate
2FCT	;	1.6	;	SyrB2 with Fe(II), chloride, and alpha-ketoglutarate
2LH8	;		;	Syrian hamster prion protein with thiamine
6BWZ	;	1.1	;	SYSGYS from low-complexity domain of FUS, residues 37-42
6BXV	;	1.1	;	SYSSYGQS from low-complexity domain of FUS, residues 54-61
5HPK	;	2.431	;	System-wide modulation of HECT E3 ligases with selective ubiquitin variant probes: NEDD4L and UbV NL.1
5HPL	;	2.31	;	System-wide modulation of HECT E3 ligases with selective ubiquitin variant probes: Rsp5 and UbV R5.4
5HPS	;	2.05	;	System-wide modulation of HECT E3 ligases with selective ubiquitin variant probes: WWP1 and UbV P1.1
5HPT	;	2.84	;	System-wide modulation of HECT E3 ligases with selective ubiquitin variant probes: WWP1, Ubv P2.3 and UBCH7
9B7F	;	1.65	;	S_SAD structure of HEWL using lossless default compression
9B7E	;	1.65	;	S_SAD structure of HEWL using lossy compression data with a compression ratio of 422
1LTH	;	2.5	;	T AND R STATES IN THE CRYSTALS OF BACTERIAL L-LACTATE DEHYDROGENASE REVEAL THE MECHANISM FOR ALLOSTERIC CONTROL
2V2W	;	1.6	;	T CELL CROSS-REACTIVITY AND CONFORMATIONAL CHANGES DURING TCR ENGAGEMENT
2V2X	;	1.6	;	T cell cross-reactivity and conformational changes during TCR engagement.
2OYP	;	1.952	;	T Cell Immunoglobulin Mucin-3 Crystal Structure Revealed a Galectin-9-independent Binding Surface
1L8K	;	2.56	;	T Cell Protein-Tyrosine Phosphatase Structure
4UDT	;	1.35	;	T cell receptor (TRAV22,TRBV7-9) structure
1L0Y	;	2.5	;	T cell receptor beta chain complexed with superantigen SpeA soaked with zinc
7RYL	;	2.0	;	T cell receptor CO3
1H5B	;	1.85	;	T cell receptor Valpha11 (AV11S5) domain
6VQO	;	3.0	;	T cell receptor-p53-HLA-A2 complex
6VRM	;	2.61	;	T cell receptor-p53-HLA-A2 complex
6VRN	;	2.46	;	T cell receptor-p53-HLA-A2 complex
4MJI	;	2.99	;	T cell response to a HIV reverse transcriptase epitope presented by the protective allele HLA-B*51:01
3B69	;	1.67	;	T cruzi Trans-sialidase complex with benzoylated NANA derivative
1XBR	;	2.5	;	T DOMAIN FROM XENOPUS LAEVIS BOUND TO DNA
1VWT	;	1.9	;	T STATE HUMAN HEMOGLOBIN [ALPHA V96W], ALPHA AQUOMET, BETA DEOXY
3QZ7	;	1.998	;	T-3 ternary complex of Dpo4
1JCK	;	3.5	;	T-CELL RECEPTOR BETA CHAIN COMPLEXED WITH SEC3 SUPERANTIGEN
1SBB	;	2.4	;	T-CELL RECEPTOR BETA CHAIN COMPLEXED WITH SUPERANTIGEN SEB
7SCC	;	2.6	;	T-cylinder of Synechocystis PCC 6803 Phycobilisome, complex with OCP - local refinement
7EXY	;		;	T-hairpin structure found in the RNA element involved in the piRNA biogenesis
2Q8M	;	2.05	;	T-like Fructose-1,6-bisphosphatase from Escherichia coli with AMP, Glucose 6-phosphate, and Fructose 1,6-bisphosphate bound
7R94	;	2.6	;	T-Plastin-F-actin complex
7SX9	;	10.0	;	T-Plastin-F-actin complex, anti-parallel bundled state
7SX8	;	9.0	;	T-Plastin-F-actin complex, parallel bundled state
7SXA	;	6.87	;	T-Plastin-F-actin complex, pre-bundling intermediate state
2AIR	;	2.0	;	T-state Active Site of Aspartate Transcarbamylase:Crystal Structure of the Carbamyl Phosphate and L-alanosine Ligated Enzyme
5WRP	;	2.85	;	T-state crystal structure of pyruvate kinase from Mycobacterium tuberculosis
2ZQY	;	2.6	;	T-state structure of allosteric L-lactate dehydrogenase from Lactobacillus casei
1RDY	;	2.2	;	T-STATE STRUCTURE OF THE ARG 243 TO ALA MUTANT OF PIG KIDNEY FRUCTOSE 1,6-BISPHOSPHATASE EXPRESSED IN E. COLI
1RDZ	;	2.05	;	T-STATE STRUCTURE OF THE ARG 243 TO ALA MUTANT OF PIG KIDNEY FRUCTOSE 1,6-BISPHOSPHATASE EXPRESSED IN E. COLI
1Y09	;	2.25	;	T-to-T(High) Quaternary Transitions in Human Hemoglobin: alphaN97A deoxy low-salt
1Y8W	;	2.9	;	T-To-T(High) quaternary transitions in human hemoglobin: alphaR92A oxy (2mM IHP, 20% PEG) (10 test sets)
1YDZ	;	3.3	;	T-To-T(High) quaternary transitions in human hemoglobin: alphaY140F oxy (2MM IHP, 20% PEG) (1 test set)
1Y4V	;	1.84	;	T-To-T(High) quaternary transitions in human hemoglobin: betaC93A deoxy low-salt (1 test set)
1Y5K	;	2.2	;	T-To-T(High) quaternary transitions in human hemoglobin: betaD99A deoxy low-salt (10 test sets)
1Y4Q	;	2.11	;	T-To-T(High) quaternary transitions in human hemoglobin: betaF42A deoxy low-salt (1 test set)
1Y4R	;	2.22	;	T-To-T(High) quaternary transitions in human hemoglobin: betaF45A deoxy low-salt (1 test set)
1Y5J	;	2.03	;	T-To-T(High) quaternary transitions in human hemoglobin: betaH97A deoxy low-salt (1 test set)
1YGF	;	2.7	;	T-to-T(high) quaternary transitions in human hemoglobin: betaH97A oxy (2MM IHP, 20% PEG) (1 test set)
1Y5F	;	2.14	;	T-To-T(High) quaternary transitions in human hemoglobin: betaL96A deoxy low-salt (1 test set)
1Y7G	;	2.1	;	T-To-T(high) quaternary transitions in human hemoglobin: betaN102A deoxy low-salt (1 test set)
1Y7Z	;	1.98	;	T-To-T(High) quaternary transitions in human hemoglobin: betaN108A deoxy low-salt (1 test set)
1Y7C	;	2.1	;	T-To-T(High) quaternary transitions in human hemoglobin: betaP100A deoxy low-salt (1 test set)
1YIH	;	2.0	;	T-to-T(High) quaternary transitions in human hemoglobin: betaP100A oxy (2.2MM IHP, 20% PEG) (1 test set)
1Y7D	;	1.9	;	T-To-T(High) quaternary transitions in human hemoglobin: betaP100G deoxy low-salt (1 test set)
1Y45	;	2.0	;	T-To-T(high) quaternary transitions in human hemoglobin: betaP36A deoxy low-salt (10 test sets)
1YEN	;	2.8	;	T-To-T(High) quaternary transitions in human hemoglobin: betaP36A oxy (2MM IHP, 20% PEG) (10 test sets)
1Y0T	;	2.14	;	T-to-T(High) Quaternary Transitions in Human Hemoglobin: betaV1M deoxy low-salt (1 test set)
1Y22	;	2.16	;	T-To-T(High) quaternary transitions in human hemoglobin: betaV33A deoxy low-salt (1 test set)
1YE0	;	2.5	;	T-To-T(High) quaternary transitions in human hemoglobin: betaV33A oxy (2MM IHP, 20% PEG) (1 test set)
1Y2Z	;	2.07	;	T-To-T(High) quaternary transitions in human hemoglobin: betaV34G deoxy low-salt (1 test set)
1Y4F	;	2.0	;	T-To-T(High) quaternary transitions in human hemoglobin: betaW37A deoxy low-salt (10 test sets)
1YEO	;	2.22	;	T-To-T(High) quaternary transitions in human hemoglobin: betaW37A OXY (10 test sets)
1YGD	;	2.73	;	T-To-T(High) quaternary transitions in human hemoglobin: betaW37E alpha zinc beta oxy (10 TEST SETS)
1Y4P	;	1.98	;	T-To-T(high) quaternary transitions in human hemoglobin: betaW37E deoxy low-salt (10 test sets)
1YEV	;	2.11	;	T-To-T(High) quaternary transitions in human hemoglobin: betaW37E OXY (10 test sets)
1Y4G	;	1.91	;	T-To-T(High) quaternary transitions in human hemoglobin: betaW37G deoxy low-salt (10 test sets)
1YEU	;	2.12	;	T-To-T(High) quaternary transitions in human hemoglobin: betaW37G OXY (10 test sets)
1Y4B	;	2.1	;	T-To-T(High) quaternary transitions in human hemoglobin: betaW37H deoxy low-salt (10 test sets)
1YG5	;	2.7	;	T-To-T(High) quaternary transitions in human hemoglobin: betaW37H OXY (2MM IHP, 20% PEG) (10 test sets)
1Y46	;	2.22	;	T-To-T(High) quaternary transitions in human hemoglobin: betaW37Y deoxy low-salt (10 test sets)
1YEQ	;	2.75	;	T-To-T(High) quaternary transitions in human hemoglobin: betaW37Y OXY (10 test sets)
1Y83	;	1.9	;	T-To-T(High) quaternary transitions in human hemoglobin: betaY145G deoxy low-salt (1 test set)
1Y31	;	2.13	;	T-To-T(High) quaternary transitions in human hemoglobin: betaY35A deoxy low-salt (1 test set)
1YE1	;	4.5	;	T-To-T(High) quaternary transitions in human hemoglobin: betaY35A oxy (2MM IHP, 20% PEG) (1 test set)
1Y35	;	2.12	;	T-To-T(High) quaternary transitions in human hemoglobin: betaY35F deoxy low-salt (1 test set)
1YE2	;	1.8	;	T-To-T(High) quaternary transitions in human hemoglobin: betaY35F oxy (2MM IHP, 20% PEG) (1 test set)
1Y85	;	2.13	;	T-To-T(High) quaternary transitions in human hemoglobin: desHIS146beta deoxy low-salt
1YHR	;	2.6	;	T-To-T(High) quaternary transitions in human hemoglobin: HbA OXY (10.0MM IHP, 20% PEG) (10 test sets)
1YH9	;	2.2	;	T-to-T(High) quaternary transitions in human hemoglobin: HbA OXY (2MM IHP, 20% PEG) (10 test sets)
1YHE	;	2.1	;	T-To-T(High) quaternary transitions in human hemoglobin: HbA OXY (5.0MM IHP, 20% PEG) (10 test sets)
1XZU	;	2.16	;	T-to-THigh Quaternary Transitions in Human Hemoglobin: alphaD94G deoxy low-salt
1XZ5	;	2.11	;	T-to-THigh Quaternary Transitions in Human Hemoglobin: alphaL91A deoxy low-salt
1XZV	;	2.11	;	T-to-THigh Quaternary Transitions in Human Hemoglobin: alphaP95A deoxy low-salt
1XZ7	;	1.9	;	T-to-THigh Quaternary Transitions in Human Hemoglobin: alphaR92A deoxy low-salt
1Y0A	;	2.22	;	T-to-THigh Quaternary Transitions in Human Hemoglobin: alphaY140A deoxy low-salt
1Y0C	;	2.3	;	T-to-THigh Quaternary Transitions in Human Hemoglobin: alphaY140F deoxy low-salt
1Y0W	;	2.14	;	T-to-THigh quaternary Transitions in Human Hemoglobin: betaV1M deoxy low-salt (10 test sets)
1YIE	;	2.4	;	T-to-thigh quaternary transitions in human hemoglobin: betaW37A oxy (2.2MM IHP, 13% PEG) (1 test set)
1Y0D	;	2.1	;	T-to-THigh Quaternary Transitions in Human Hemoglobin: desArg141alpha deoxy low-salt
1XYE	;	2.13	;	T-to-THigh Transitions in Human Hemoglobin: alpha Y42A deoxy low salt
1XY0	;	1.99	;	T-to-THigh Transitions in Human Hemoglobin: alphaK40G deoxy low-salt
1OB5	;	3.1	;	T. aquaticus elongation factor EF-Tu complexed with the antibiotic enacyloxin IIa, a GTP analog, and Phe-tRNA
1LS1	;	1.1	;	T. aquaticus Ffh NG Domain at 1.1A Resolution
7NF0	;	1.35	;	T. atroviride Fdc variant TaFdcV in complex with hydroxylated prFMN
2I19	;	2.28	;	T. Brucei farnesyl diphosphate synthase complexed with bisphosphonate
5AFX	;	2.39	;	T. Brucei Farnesyl Diphosphate Synthase Complexed with Bisphosphonate BPH-1238
5AHU	;	2.69	;	T. Brucei Farnesyl Diphosphate Synthase Complexed with Bisphosphonate BPH-1326
4RXE	;	2.5	;	T. Brucei Farnesyl Diphosphate Synthase Complexed with Bisphosphonate BPH-14
2P1C	;	2.45	;	T. Brucei Farnesyl Diphosphate Synthase Complexed with Bisphosphonate BPH-210
3DYG	;	2.1	;	T. Brucei Farnesyl Diphosphate Synthase Complexed with Bisphosphonate BPH-461
3DYF	;	2.65	;	T. Brucei Farnesyl Diphosphate Synthase Complexed with Bisphosphonate BPH-461 and Isopentyl Diphosphate
2OGD	;	2.0	;	T. Brucei Farnesyl Diphosphate Synthase Complexed with Bisphosphonate BPH-527
5AEL	;	2.6	;	T. Brucei Farnesyl Diphosphate Synthase Complexed with Bisphosphonate BPH-597
3EFQ	;	2.0	;	T. Brucei Farnesyl Diphosphate Synthase Complexed with Bisphosphonate BPH-714
3DYH	;	1.94	;	T. Brucei Farnesyl Diphosphate Synthase Complexed with Bisphosphonate BPH-721
3EGT	;	2.0	;	T. Brucei Farnesyl Diphosphate Synthase Complexed with Bisphosphonate BPH-722
4RXC	;	2.31	;	T. Brucei Farnesyl Diphosphate Synthase Complexed with Homorisedronate BPH-6
2EWG	;	2.48	;	T. brucei Farnesyl Diphosphate Synthase Complexed with Minodronate
4RXD	;	2.0	;	T. Brucei Farnesyl Diphosphate Synthase Complexed with Risedronate
6R36	;	1.67	;	T. brucei farnesyl pyrophosphate synthase (FPPS)
6SII	;	2.33	;	T. brucei FPPS in complex with 1-((1H-indol-3-yl)methyl)-N-(3-chlorobenzyl)piperidin-4-amine
6R39	;	2.6	;	T. brucei FPPS in complex with 1-(carboxymethyl)-1H-benzo[g]indole-2-carboxylic acid
6R38	;	2.33	;	T. brucei FPPS in complex with 2-(2,5-dichlorobenzo[b]thiophen-3-yl)acetic acid
6R37	;	2.1	;	T. brucei FPPS in complex with 2-(5-chlorobenzo[b]thiophen-3-yl)acetic acid
5QT8	;	2.35	;	T. brucei FPPS in complex with CAS 34105-16-3
5QT6	;	2.189	;	T. brucei FPPS in complex with CID 112445
5QTG	;	2.093	;	T. brucei FPPS in complex with CID 126782062
5QTF	;	1.783	;	T. brucei FPPS in complex with CID 144539
5QT9	;	2.199	;	T. brucei FPPS in complex with CID 23155989
5QTH	;	1.887	;	T. brucei FPPS in complex with CID 2799882
5QTA	;	2.113	;	T. brucei FPPS in complex with CID 2804072
5QTB	;	1.965	;	T. brucei FPPS in complex with CID 303798
5QT4	;	2.324	;	T. brucei FPPS in complex with CID 3599333
5QTE	;	2.072	;	T. brucei FPPS in complex with CID 4563894
5QTJ	;	2.101	;	T. brucei FPPS in complex with CID 47256035
5QTI	;	2.112	;	T. brucei FPPS in complex with CID 62483448
5QT7	;	2.292	;	T. brucei FPPS in complex with CID 66669982
5QTK	;	1.857	;	T. brucei FPPS in complex with CID 69539
5QT5	;	2.143	;	T. brucei FPPS in complex with CID 89021
6IAE	;	2.49	;	T. brucei IFT22 GDP-bound crystal structure
6IA7	;	2.3	;	T. brucei IFT22 GTP-bound crystal structure
6IAN	;	3.2	;	T. brucei IFT22/74/81 GTP-bound crystal structure
6EWK	;	2.22	;	T. californica AChE in complex with a 3-hydroxy-2-pyridine aldoxime.
1W41	;	1.7	;	T. celer L30e E90A variant
1W40	;	2.03	;	T. celer L30e K9A variant
1W42	;	1.8	;	T. celer L30e R92A variant
5JDO	;	3.2	;	T. congolense haptoglobin-haemoglobin receptor in complex with haemoglobin
5HCF	;	2.451	;	T. cruzi calreticulin globular domain
6R04	;	1.47	;	T. cruzi FPPS
6R06	;	1.559	;	T. CRUZI FPPS IN COMPLEX WITH (3S,4S)-4-(3,4-dimethylphenoxy)-1-(prop-2-yn-1-yl)piperidin-3-ol
6SI5	;	2.097	;	T. cruzi FPPS in complex with 1-methyl-5-(4,5,6,7-tetrahydrothieno[3,2-c]pyridine-5-carbonyl)pyridin-2(1H)-one
6R09	;	1.28	;	T. cruzi FPPS in complex with 2-(4-((1H-indol-3-yl)methyl)piperazin-1-yl)benzo[d]thiazole
6R07	;	1.57	;	T. cruzi FPPS in complex with 2-(5-chlorobenzo[b]thiophen-3-yl)acetic acid
6R0B	;	1.612	;	T. cruzi FPPS in complex with 3-((4-(5-chlorobenzo[d]thiazol-2-yl)piperazin-1-yl)methyl)-1H-indol-5-ol
6R0A	;	1.32	;	T. cruzi FPPS in complex with 3-((4-(benzo[d]thiazol-2-yl)piperazin-1-yl)methyl)-1H-indol-5-ol
6R08	;	1.44	;	T. cruzi FPPS in complex with 3-(carboxymethyl)-5,7-dichloro-1H-indole-2-carboxylic acid
6SHV	;	1.808	;	T. cruzi FPPS in complex with 5-(4-fluorophenoxy)pyridin-2-amine
6R05	;	1.57	;	T. CRUZI FPPS IN COMPLEX WITH N-BENZYL-6-METHYLPYRIDIN-2-AMINE
8GCC	;	2.94	;	T. cruzi topoisomerase II alpha bound to dsDNA and the covalent inhibitor CT1
5KVW	;	1.59	;	T. danielli thaumatin at 100K, Data set 1
5KVX	;	1.59	;	T. danielli thaumatin at 100K, Data set 2
5KVZ	;	1.592	;	T. danielli thaumatin at 100K, Data set 3
5KW0	;	1.594	;	T. danielli thaumatin at 100K, Data set 5
5KW3	;	1.55	;	T. danielli thaumatin at 278K, Data set 1
5KW4	;	1.55	;	T. danielli thaumatin at 278K, Data set 2
5KW5	;	1.55	;	T. danielli thaumatin at 278K, Data set 3
5KW7	;	1.55	;	T. danielli thaumatin at 278K, Data set 4
5KW8	;	1.55	;	T. danielli thaumatin at 278K, Data set 5
3OM9	;	1.98	;	T. Gondii bradyzoite-specific LDH (LDH1) in complex with NAD and OXQ
1SOW	;	1.9	;	T. gondii bradyzoite-specific LDH (LDH2) in complex with NAD and oxalate
3CZM	;	2.3	;	T. Gondii bradyzoite-specific LDH (LDH2) in complex with NAD and OXQ
6TJ7	;	2.3	;	T. gondii myosin A trimeric complex
6TJ5	;	2.394	;	T. gondii myosin A trimeric complex with ELC1
6TJ6	;	2.0	;	T. gondii myosin A trimeric complex with ELC1, calcium-free
1C3C	;	1.8	;	T. MARITIMA ADENYLOSUCCINATE LYASE
1C3U	;	2.3	;	T. MARITIMA ADENYLOSUCCINATE LYASE
3IWD	;	1.9	;	T. maritima AdoMetDC complex with 5'-Deoxy-5'-dimethyl thioadenosine
3IWC	;	1.9	;	T. maritima AdoMetDC complex with S-Adenosylmethionine methyl ester
3IWB	;	2.06	;	T. maritima AdoMetDC in processed form
4GTC	;	1.97	;	T. Maritima FDTS (E144R mutant) plus FAD
4GTD	;	1.76	;	T. Maritima FDTS (E144R mutant) with FAD and dUMP
4GTE	;	1.89	;	T. Maritima FDTS (E144R mutant) with FAD and Folate
4GTF	;	1.77	;	T. Maritima FDTS (H53A mutant) with FAD, dUMP and Folate
4GTL	;	2.17	;	T. Maritima FDTS (R174K mutant) with FAD
4GT9	;	1.39	;	T. Maritima FDTS with FAD, dUMP and Folate.
4GTA	;	1.5	;	T. Maritima FDTS with FAD, dUMP, and Folinic Acid
4GTB	;	1.7	;	T. Maritima FDTS with FAD, dUMP, and Raltitrexed.
1QC7	;	2.2	;	T. MARITIMA FLIG C-TERMINAL DOMAIN
1TZT	;	1.55	;	T. maritima NusB, P21
1TZU	;	1.85	;	T. maritima NusB, P212121
1TZV	;	1.35	;	T. maritima NusB, P3121, Form 1
1TZW	;	1.6	;	T. maritima NusB, P3121, Form 2
1TZX	;	1.72	;	T. maritima NusB, P3221
2HRU	;	2.8	;	T. maritima PurL complexed with ADP
2HRY	;	2.8	;	T. maritima PurL complexed with AMPPCP
2HS0	;	2.52	;	T. maritima PurL complexed with ATP
2HS3	;	2.3	;	T. maritima PurL complexed with FGAR
2HS4	;	2.7	;	T. maritima PurL complexed with FGAR and AMPPCP
3O3F	;	2.0	;	T. maritima RNase H2 D107N in complex with nucleic acid substrate and magnesium ions
3O3H	;	2.8	;	T. maritima RNase H2 D107N in complex with nucleic acid substrate and manganese ions
4HHT	;	3.1	;	T. maritima RNase H2 G21S in complex with nucleic acid substrate and calcium ions
3O3G	;	2.1	;	T. maritima RNase H2 in complex with nucleic acid substrate and calcium ions
5CHP	;	1.7	;	T. maritima ThyX in complex with TyC5-03
3PIH	;	2.9	;	T. maritima UvrA in complex with fluorescein-modified DNA
4CIC	;	1.6	;	T. potens IscR
2Z75	;	1.7	;	T. tengcongensis glmS ribozyme bound to glucosamine-6-phosphate
3B4C	;	3.0	;	T. tengcongensis glmS ribozyme bound to glucosamine-6-phosphate and a substrate RNA with a 2'5'-phosphodiester linkage
2Z74	;	2.2	;	T. tengcongensis glmS ribozyme bound to glucose-6-phosphate
3B4A	;	2.7	;	T. tengcongensis glmS ribozyme with G40A mutation, bound to glucosamine-6-phosphate
3B4B	;	2.7	;	T. tengcongensis glmS ribozyme with G40A mutation, bound to glucosamine-6-phosphate and a substrate RNA with a 2'5'-phosphodiester linkage
3FUW	;	1.56	;	T. thermophilus 16S rRNA A1518 and A1519 methyltransferase (KsgA) in complex with 5'-methylthioadenosine in space group P212121
3FUX	;	1.68	;	T. thermophilus 16S rRNA A1518 and A1519 methyltransferase (KsgA) in complex with 5'-methylthioadenosine in space group P212121
3FUU	;	1.53	;	T. thermophilus 16S rRNA A1518 and A1519 methyltransferase (KsgA) in complex with Adenosine in space group P212121
3G8A	;	2.1	;	T. thermophilus 16S rRNA G527 methyltransferase in complex with AdoHcy in space group P61
3G89	;	1.5	;	T. thermophilus 16S rRNA G527 methyltransferase in complex with AdoMet and AMP in space group P61
3G8B	;	2.1	;	T. thermophilus 16S rRNA G527 methyltransferase in complex with AdoMet in space group I222
3G88	;	1.87	;	T. thermophilus 16S rRNA G527 methyltransferase in complex with AdoMet in space group P61
3DMG	;	1.55	;	T. Thermophilus 16S rRNA N2 G1207 methyltransferase (RsmC) in complex with AdoHcy
3DMF	;	1.58	;	T. Thermophilus 16S rRNA N2 G1207 methyltransferase (RsmC) in complex with AdoMet
3DMH	;	1.55	;	T. Thermophilus 16S rRNA N2 G1207 methyltransferase (RsmC) in complex with AdoMet and Guanosine
4V68	;	6.4	;	T. thermophilus 70S ribosome in complex with mRNA, tRNAs and EF-Tu.GDP.kirromycin ternary complex, fitted to a 6.4 A Cryo-EM map.
6GZZ	;	4.13	;	T. thermophilus hibernating 100S ribosome (amc)
6GZX	;	4.57	;	T. thermophilus hibernating 100S ribosome (ice)
6GZQ	;	3.28	;	T. thermophilus hibernating 70S ribosome
7TH4	;	1.45	;	T. thermophilus methylenetetrahydrofolate reductase complex with 5-formyltetrahydrofolate
2NXN	;	2.4	;	T. thermophilus ribosomal protein L11 methyltransferase (PrmA) in complex with ribosomal protein L11
2NXE	;	1.75	;	T. thermophilus ribosomal protein L11 methyltransferase (PrmA) in complex with S-Adenosyl-L-Methionine
5XJ0	;	4.004	;	T. thermophilus RNA polymerase holoenzyme bound with gp39 and gp76
4LD0	;	3.75	;	T. thermophilus RuvC in complex with Holliday junction substrate
6S16	;	3.409	;	T. thermophilus RuvC in complex with Holliday junction substrate
5E17	;	3.2	;	T. thermophilus transcription initiation complex having a RRR discriminator sequence and a nontemplate-strand length corresponding to TSS selection at position 7 (RPo-GGG-7)
5E18	;	3.3	;	T. thermophilus transcription initiation complex having a YYY discriminator sequence and a nontemplate-strand length corresponding to TSS selection at position 8 (RPo-CCC-8)
4GY3	;	2.5	;	T. vulcanus Phycocyanin crystallized in 2M Urea
4GXE	;	3.0	;	T. vulcanus Phycocyanin crystallized in 4M Urea
6NBY	;	3.1	;	T.elongatus NDH (composite model)
6NBQ	;	3.1	;	T.elongatus NDH (data-set 1)
6NBX	;	3.5	;	T.elongatus NDH (data-set 2)
1PZE	;	1.95	;	T.gondii LDH1 apo form
1PZG	;	1.6	;	T.gondii LDH1 complexed with APAD and sulfate at 1.6 Angstroms
1PZF	;	2.2	;	T.gondii LDH1 ternary complex with APAD+ and oxalate
1PZH	;	1.9	;	T.gondii LDH1 ternary complex with NAD and oxalate
4V8P	;	3.52	;	T.thermophila 60S ribosomal subunit in complex with initiation factor 6.
7V2L	;	3.3	;	T.thermophilus 30S ribosome with KsgA, class K1k2
7V2M	;	3.4	;	T.thermophilus 30S ribosome with KsgA, class K1k4
7V2N	;	3.6	;	T.thermophilus 30S ribosome with KsgA, class K2
7V2O	;	3.5	;	T.thermophilus 30S ribosome with KsgA, class K4
7V2P	;	3.3	;	T.thermophilus 30S ribosome with KsgA, class K5
7V2Q	;	3.24	;	T.thermophilus 30S ribosome with KsgA, class K6
2NXJ	;	2.3	;	T.thermophilus ribosomal protein L11 methyltransferase (PrmA) in space group P 21 21 2
4BGC	;	1.2	;	T1 domain of the renal potassium channel Kv1.3
7BUK	;	2.644	;	T1 lipase mutant - 5M (D43E/T118N/E226D/E250L/N304E)
1CJ6	;	1.8	;	T11A MUTANT HUMAN LYSOZYME
1CJ7	;	1.8	;	T11V MUTANT HUMAN LYSOZYME
1TS2	;	2.3	;	T128A MUTANT OF TOXIC SHOCK SYNDROME TOXIN-1 FROM S. AUREUS
2BUP	;	1.7	;	T13G Mutant of the ATPASE fragment of Bovine HSC70
1BUP	;	1.7	;	T13S MUTANT OF BOVINE 70 KILODALTON HEAT SHOCK PROTEIN
5DNS	;	3.561	;	t1428 loop variant in P3221
1A6L	;	2.1	;	T14C MUTANT OF AZOTOBACTER VINELANDII FDI
5KSB	;	2.9	;	T15-DQ8.5-glia-gamma1 complex
2GAC	;	2.1	;	T152C MUTANT GLYCOSYLASPARAGINASE FROM FLAVOBACTERIUM MENINGOSEPTICUM
5DN0	;	4.4	;	t1555 loop variant
6AA9	;	2.7	;	T166A mutant of D-Serine deaminase from Salmonella typhimurium
6H8Y	;	1.89	;	T16A variant of beta-phosphoglucomutase from Lactococcus lactis in an open conformer complexed with aluminium tetrafluoride to 1.9 A.
6H8Z	;	1.6	;	T16A variant of beta-phosphoglucomutase from Lactococcus lactis in an open conformer complexed with magnesium trifluoride to 1.6 A.
6H94	;	1.49	;	T16A variant of beta-phosphoglucomutase from Lactococcus lactis with phosphate and TRIS bound in an open conformer to 1.5 A.
3URD	;	1.08	;	T181A mutant of alpha-Lytic Protease
3URC	;	1.1	;	T181G mutant of alpha-Lytic Protease
6EGK	;	1.96	;	T181N Cucumene Synthase
5X99	;	1.73	;	T18V mutant of thermus thermophilus HB8 thymidylate kinase
2ZTU	;	2.0	;	T190A mutant of D-3-hydroxybutyrate dehydrogenase complexed with NAD+
1OSS	;	1.93	;	T190P STREPTOMYCES GRISEUS TRYPSIN IN COMPLEX WITH BENZAMIDINE
2ZTM	;	2.3	;	T190S mutant of D-3-hydroxybutyrate dehydrogenase
8JLN	;	3.24	;	T1AM-bound hTAAR1-Gs protein complex
8JLJ	;	3.1	;	T1AM-bound mTAAR1-Gs protein complex
5MHS	;	3.7	;	T1L reovirus sigma1 complexed with 5C6 Fab fragments
4JHV	;	1.6	;	T2-depleted laccase from Coriolopsis caperata
4JHU	;	1.89	;	T2-depleted laccase from Coriolopsis caperata soaked with CuCl
3N81	;	1.7	;	T244A mutant of Human mitochondrial aldehyde dehydrogenase, apo form
3N83	;	1.9	;	T244A mutant of human mitochondrial aldehyde dehydrogenase, NAD complex
3N82	;	2.25	;	T244A mutant of Human mitochondrial aldehyde dehydrogenase, NADH complex
7AQP	;	2.6	;	T262S, A251S, L254S, L211Q mutant of carboxypeptidase T from Thermoactinomyces vulgaris
1YQO	;	1.9	;	T268A mutant heme domain of flavocytochrome P450 BM3
1YQP	;	1.8	;	T268N mutant cytochrome domain of flavocytochrome P450 BM3
1QT3	;	1.85	;	T26D MUTANT OF T4 LYSOZYME
1QTV	;	2.3	;	T26E APO STRUCTURE OF T4 LYSOZYME
1QT8	;	1.9	;	T26H Mutant of T4 Lysozyme
1QT4	;	2.1	;	T26Q MUTANT OF T4 LYSOZYME
3P67	;	1.5	;	T26S mutant of pentaerythritol tetranitrate reductase containing a bound acetate molecule
7AA3	;	3.56	;	T275P after heme uptake from M. tuberculosis
8RIV	;	2.78	;	T2R-TTL-1-K08 complex
8RIW	;	2.57	;	T2R-TTL-1-L01 complex
8BB1	;	2.8	;	T3 SAM lyase in complex with S-adenosylmethionine synthase
4Z7W	;	2.89	;	T316 complex
2E83	;	1.52	;	T31V mutant of FMN-binding protein from Desulfovibrio vulgaris (Miyazaki F)
5DQA	;	3.27	;	t3284 loop variant of beta1
5DRA	;	3.0	;	t3284 loop variant of beta1
8UJA	;	6.0	;	T33-fn10 - Designed Tetrahedral Protein Cage Using Fragment-based Hydrogen Bond Networks
8UF0	;	2.02	;	T33-ml23 - Designed Tetrahedral Protein Cage Using Machine Learning Algorithms
8UN1	;	3.9	;	T33-ml23 Assembly Intermediate - Designed Tetrahedral Protein Cage Using Machine Learning Algorithms
8UI2	;	2.73	;	T33-ml28 - Designed Tetrahedral Protein Cage Using Machine Learning Algorithms
8UKM	;	4.2	;	T33-ml30 - Designed Tetrahedral Protein Cage Using Machine Learning Algorithms
8UMP	;	2.92	;	T33-ml35 - Designed Tetrahedral Protein Cage Using Machine Learning Algorithms
8UMR	;	4.42	;	T33-ml35 Assembly Intermediate - Designed Tetrahedral Protein Cage Using Machine Learning Algorithms
3VXT	;	2.5	;	T36-5 TCR specific for HLA-A24-Nef134-10
2E0W	;	2.55	;	T391A precursor mutant protein of gamma-Glutamyltranspeptidase from Escherichia coli
5MHR	;	3.0	;	T3D reovirus sigma1 complexed with 9BG5 Fab fragments
8GSG	;	2.05	;	T3R3 form of Human insulin with single Zn
1TLH	;		;	T4 AsiA bound to sigma70 region 4
8DVF	;	3.3	;	T4 Bacteriophage primosome with single strand DNA, state 1
8DVI	;	3.2	;	T4 bacteriophage primosome with single strand DNA, State 2
8DW6	;	3.5	;	T4 bacteriophage primosome with single-strand DNA, State 3
6A9B	;	2.01	;	T4 dCMP hydroxymethylase structure solved by I-SAD using a home source
1NOZ	;	2.2	;	T4 DNA POLYMERASE FRAGMENT (RESIDUES 1-388) AT 110K
2O0K	;	2.5	;	T4 gp17 ATPase domain mutant
2O0J	;	1.8	;	T4 gp17 ATPase domain mutant complexed with ADP
2O0H	;	1.88	;	T4 gp17 ATPase domain mutant complexed with ATP
8T9R	;	3.4	;	T4 highly immunogenic outer capsid protein C-terminal domain bound to a vertex-proximal gp23* capsomer of the prolate capsid in two preferred orientations.
8T1X	;	3.3	;	T4 highly immunogenic outer capsid protein C-terminal domain bound to the vertex-proximal gp23* capsomer of the isometric head in two preferred orientations
1P36	;	1.45	;	T4 LYOSZYME CORE REPACKING MUTANT I100V/TA
2O7A	;	0.84	;	T4 lysozyme C-terminal fragment
1OV7	;	2.0	;	T4 Lysozyme Cavity Mutant L99A/M102Q Bound with 2-Allyl-6-Methyl-Phenol
1OV5	;	2.1	;	T4 Lysozyme Cavity Mutant L99a/M102Q Bound With 2-Allylphenol
1OVH	;	1.95	;	T4 Lysozyme Cavity Mutant L99A/M102Q Bound With 2-Chloro-6-Methyl-Aniline
1OWY	;	1.9	;	T4 Lysozyme Cavity Mutant L99A/M102Q Bound With 2-Propyl-Aniline
1OVJ	;	2.0	;	T4 Lysozyme Cavity Mutant L99A/M102Q Bound with 3-Fluoro-2-Methyl_Aniline
1OWZ	;	1.9	;	T4 Lysozyme Cavity Mutant L99A/M102Q Bound With 4-FluoroPhenEthyl Alcohol
1OVK	;	2.1	;	T4 Lysozyme Cavity Mutant L99A/M102Q Bound with N-Allyl-Aniline
2O4W	;	1.9	;	T4 lysozyme circular permutant
1P37	;	1.57	;	T4 LYSOZYME CORE REPACKING BACK-REVERTANT L102M/CORE10
1PQJ	;	1.9	;	T4 LYSOZYME CORE REPACKING MUTANT A111V/CORE10/TA
1PQD	;	1.65	;	T4 LYSOZYME CORE REPACKING MUTANT CORE10/TA
1PQI	;	1.57	;	T4 LYSOZYME CORE REPACKING MUTANT I118L/CORE7/TA
1P2R	;	1.58	;	T4 LYSOZYME CORE REPACKING MUTANT I78V/TA
1PQO	;	1.65	;	T4 Lysozyme Core Repacking Mutant L118I/TA
1P64	;	1.62	;	T4 LYSOZYME CORE REPACKING MUTANT L133F/TA
1P46	;	1.67	;	T4 lysozyme core repacking mutant M106I/TA
1P6Y	;	1.54	;	T4 LYSOZYME CORE REPACKING MUTANT M120Y/TA
1P7S	;	1.5	;	T4 LYSOZYME CORE REPACKING MUTANT V103I/TA
1PQM	;	1.52	;	T4 Lysozyme Core Repacking Mutant V149I/T152V/TA
1P2L	;	1.58	;	T4 Lysozyme Core Repacking Mutant V87I/TA
7L3E	;	1.13	;	T4 Lysozyme L99A - 3-iodotoluene - cryo
7L3D	;	1.35	;	T4 Lysozyme L99A - 3-iodotoluene - RT
7L3G	;	1.27	;	T4 Lysozyme L99A - 4-iodotoluene - cryo
7L3F	;	1.49	;	T4 Lysozyme L99A - 4-iodotoluene - RT
7L38	;	1.33	;	T4 Lysozyme L99A - Apo - cryo
7L37	;	1.439	;	T4 Lysozyme L99A - Apo - RT
7L3K	;	1.11	;	T4 Lysozyme L99A - benzylacetate - cryo
7L3J	;	1.49	;	T4 Lysozyme L99A - benzylacetate - RT
7L3H	;	1.39	;	T4 Lysozyme L99A - ethylbenzene - RT
7L3B	;	1.27	;	T4 Lysozyme L99A - iodobenzene - RT
7L3C	;	1.31	;	T4 Lysozyme L99A - o-xylene - RT
7L3I	;	1.46	;	T4 Lysozyme L99A - propylbenzene - RT
7L3A	;	1.11	;	T4 Lysozyme L99A - toluene - cryo
7L39	;	1.35	;	T4 Lysozyme L99A - toluene - RT
5JWS	;	1.65	;	T4 Lysozyme L99A with 1-Hydro-2-ethyl-1,2-azaborine Bound
4W52	;	1.5001	;	T4 Lysozyme L99A with Benzene Bound
4W54	;	1.7901	;	T4 Lysozyme L99A with Ethylbenzene Bound
4W57	;	1.6801	;	T4 Lysozyme L99A with n-Butylbenzene Bound
4W59	;	1.39	;	T4 Lysozyme L99A with n-Hexylbenzene Bound
4W58	;	1.8	;	T4 Lysozyme L99A with n-Pentylbenzene Bound
4W55	;	1.6401	;	T4 Lysozyme L99A with n-Propylbenzene Bound
4W51	;	1.45	;	T4 Lysozyme L99A with No Ligand Bound
4W56	;	1.63	;	T4 Lysozyme L99A with sec-Butylbenzene Bound
4W53	;	1.56	;	T4 Lysozyme L99A with Toluene Bound
7SJ6	;	1.72	;	T4 Lysozyme L99A/M102H with 1,2-Azaborine bound
4I7N	;	1.58	;	T4 Lysozyme L99A/M102H with 1-phenyl-2-propyn-1-ol bound
4I7R	;	1.52	;	T4 Lysozyme L99A/M102H with 2-(pyrazolo-1-yl) ethanol bound
4I7M	;	1.48	;	T4 Lysozyme L99A/M102H with 2-allylphenol bound
4I7O	;	1.73	;	T4 Lysozyme L99A/M102H with 2-amino-5-chlorothiazole bound
4I7T	;	1.55	;	T4 Lysozyme L99A/M102H with 2-bromo-5-hydroxybenzaldehyde bound
4EKR	;	1.49	;	T4 Lysozyme L99A/M102H with 2-Cyanophenol Bound
4E97	;	1.3	;	T4 Lysozyme L99A/M102H with 2-Mercaptoethanol Bound
4I7S	;	1.69	;	T4 Lysozyme L99A/M102H with 3-trifluoromethyl-5-methyl pyrazole bound
4I7P	;	1.6	;	T4 Lysozyme L99A/M102H with 4-bromoimidazole bound
4EKQ	;	1.54	;	T4 Lysozyme L99A/M102H with 4-Nitrophenol Bound
4I7Q	;	1.58	;	T4 Lysozyme L99A/M102H with 4-trifluoromethylimidazole bound
4I7J	;	1.67	;	T4 Lysozyme L99A/M102H with benzene bound
4EKS	;	1.64	;	T4 Lysozyme L99A/M102H with Isoxazole Bound
4EKP	;	1.64	;	T4 Lysozyme L99A/M102H with Nitrobenzene Bound
4I7L	;	1.52	;	T4 Lysozyme L99A/M102H with phenol bound
4I7K	;	1.72	;	T4 Lysozyme L99A/M102H with toluene bound
5JWU	;	1.7	;	T4 Lysozyme L99A/M102Q with 1,2-Dihydro-1,2-azaborine Bound
5JWW	;	1.47	;	T4 Lysozyme L99A/M102Q with 1-Hydro-2-ethyl-1,2-azaborine Bound
5JWT	;	1.41	;	T4 Lysozyme L99A/M102Q with Benzene Bound
5JWV	;	1.3	;	T4 Lysozyme L99A/M102Q with Ethylbenzene Bound
3GUN	;	1.5	;	T4 lysozyme M102E/L99A mutant with buried charge in apolar cavity--aniline binding
3GUI	;	1.45	;	T4 lysozyme M102E/L99A mutant with buried charge in apolar cavity--Apo structure
3GUJ	;	1.6	;	T4 lysozyme M102E/L99A mutant with buried charge in apolar cavity--Benzene binding
3GUL	;	2.07	;	T4 lysozyme M102E/L99A mutant with buried charge in apolar cavity--ethylbenzene binding
3GUM	;	2.24	;	T4 lysozyme M102E/L99A mutant with buried charge in apolar cavity--p-xylene binding
3GUO	;	2.16	;	T4 lysozyme M102E/L99A mutant with buried charge in apolar cavity--phenol binding
3GUP	;	1.5	;	T4 lysozyme M102E/L99A mutant with buried charge in apolar cavity--pyridine binding
3GUK	;	1.85	;	T4 lysozyme M102E/L99A mutant with buried charge in apolar cavity--Toluene binding
1CX7	;	1.94	;	T4 LYSOZYME METHIONINE CORE MUTANT
1C6P	;	1.9	;	T4 LYSOZYME MUTANT C54T/C97A IN THE PRESENCE OF 8 ATM ARGON
1C6Q	;	1.9	;	T4 LYSOZYME MUTANT C54T/C97A IN THE PRESENCE OF 8 ATM KRYPTON
1C6T	;	2.0	;	T4 LYSOZYME MUTANT C54T/C97A IN THE PRESENCE OF 8 ATM XENON
1C60	;	2.0	;	T4 LYSOZYME MUTANT C54T/C97A/F153A IN THE PRESENCE OF 8 ATM ARGON
1C61	;	2.0	;	T4 LYSOZYME MUTANT C54T/C97A/F153A IN THE PRESENCE OF 8 ATM KRYPTON
1C62	;	2.3	;	T4 LYSOZYME MUTANT C54T/C97A/F153A IN THE PRESENCE OF 8 ATM XENON
1G1V	;	1.9	;	T4 LYSOZYME MUTANT C54T/C97A/I58T
1C63	;	2.0	;	T4 LYSOZYME MUTANT C54T/C97A/L121A IN THE PRESENCE OF 8 ATM ARGON
1C64	;	2.0	;	T4 LYSOZYME MUTANT C54T/C97A/L121A IN THE PRESENCE OF 8 ATM KRYPTON
1C65	;	2.0	;	T4 LYSOZYME MUTANT C54T/C97A/L121A IN THE PRESENCE OF 8 ATM XENON
1C66	;	2.1	;	T4 LYSOZYME MUTANT C54T/C97A/L121A/L133A IN THE PRESENCE OF 8 ATM ARGON
1C67	;	2.2	;	T4 LYSOZYME MUTANT C54T/C97A/L121A/L133A IN THE PRESENCE OF 8 ATM KRYPTON
1C68	;	2.5	;	T4 LYSOZYME MUTANT C54T/C97A/L121A/L133A IN THE PRESENCE OF 8 ATM XENON
1C69	;	1.8	;	T4 LYSOZYME MUTANT C54T/C97A/L133A IN THE PRESENCE OF 8 ATM ARGON
1C6A	;	2.1	;	T4 LYSOZYME MUTANT C54T/C97A/L133A IN THE PRESENCE OF 8 ATM KRYPTON
1C6B	;	2.2	;	T4 LYSOZYME MUTANT C54T/C97A/L133A IN THE PRESENCE OF 8 ATM XENON
1C6C	;	2.0	;	T4 LYSOZYME MUTANT C54T/C97A/L99A IN THE PRESENCE OF 16 ATM ARGON
1C6D	;	2.0	;	T4 LYSOZYME MUTANT C54T/C97A/L99A IN THE PRESENCE OF 16 ATM KRYPTON
1C6E	;	1.9	;	T4 LYSOZYME MUTANT C54T/C97A/L99A IN THE PRESENCE OF 2 ATM XENON
1C6F	;	2.0	;	T4 LYSOZYME MUTANT C54T/C97A/L99A IN THE PRESENCE OF 32 ATM ARGON
1C6G	;	1.9	;	T4 LYSOZYME MUTANT C54T/C97A/L99A IN THE PRESENCE OF 4 ATM KRYPTON
1C6H	;	1.9	;	T4 LYSOZYME MUTANT C54T/C97A/L99A IN THE PRESENCE OF 4 ATM XENON
1C6I	;	1.9	;	T4 LYSOZYME MUTANT C54T/C97A/L99A IN THE PRESENCE OF 8 ATM ARGON
1C6J	;	1.9	;	T4 LYSOZYME MUTANT C54T/C97A/L99A IN THE PRESENCE OF 8 ATM KRYPTON
1C6K	;	1.9	;	T4 LYSOZYME MUTANT C54T/C97A/L99A IN THE PRESENCE OF 8 ATM XENON
1C6L	;	1.9	;	T4 LYSOZYME MUTANT C54T/C97A/L99A/F153A IN THE PRESENCE OF 8 ATM ARGON
1C6M	;	2.1	;	T4 LYSOZYME MUTANT C54T/C97A/L99A/F153A IN THE PRESENCE OF 8 ATM KRYPTON
1C6N	;	2.2	;	T4 LYSOZYME MUTANT C54T/C97A/L99A/F153A IN THE PRESENCE OF 8 ATM XENON
1I6S	;	1.9	;	T4 LYSOZYME MUTANT C54T/C97A/N101A
1G1W	;	1.8	;	T4 LYSOZYME MUTANT C54T/C97A/Q105M
3C7Z	;	1.67	;	T4 lysozyme mutant D89A/R96H at room temperature
1CV0	;	2.12	;	T4 LYSOZYME MUTANT F104M
1CTW	;	2.1	;	T4 LYSOZYME MUTANT I78A
1CU0	;	2.2	;	T4 LYSOZYME MUTANT I78M
1CVK	;	1.8	;	T4 LYSOZYME MUTANT L118A
1CV4	;	1.9	;	T4 LYSOZYME MUTANT L118M
1CV3	;	1.8	;	T4 LYSOZYME MUTANT L121M
1CV5	;	1.87	;	T4 LYSOZYME MUTANT L133M
1CU2	;	1.85	;	T4 LYSOZYME MUTANT L84M
1CU6	;	2.1	;	T4 LYSOZYME MUTANT L91A
1CU5	;	2.05	;	T4 LYSOZYME MUTANT L91M
7LX6	;	1.05	;	T4 lysozyme mutant L99A
7LX7	;	1.05	;	T4 lysozyme mutant L99A
7LX8	;	1.03	;	T4 lysozyme mutant L99A
7LX9	;	1.19	;	T4 lysozyme mutant L99A
7LXA	;	1.07	;	T4 lysozyme mutant L99A
2B72	;	2.1	;	T4 Lysozyme mutant L99A at 100 MPa
2B73	;	2.15	;	T4 Lysozyme mutant L99A at 100 MPa
2B74	;	2.1	;	T4 Lysozyme mutant L99A at 100 MPa
2B75	;	2.1	;	T4 Lysozyme mutant L99A at 150 MPa
2B6T	;	2.1	;	T4 Lysozyme mutant L99A at 200 MPa
2B6W	;	2.2	;	T4 Lysozyme mutant L99A at 200 MPa
2B6X	;	2.107	;	T4 Lysozyme mutant L99A at 200 MPa
2B6Y	;	2.4	;	T4 Lysozyme mutant L99A at ambient pressure
2B6Z	;	2.4	;	T4 Lysozyme mutant L99A at ambient pressure
2B70	;	2.4	;	T4 Lysozyme mutant L99A at ambient pressure
7LOC	;	1.16	;	T4 lysozyme mutant L99A in complex with 1-bromanyl-4-fluoranyl-benzene
7LOD	;	1.02	;	T4 lysozyme mutant L99A in complex with 1-fluoranyl-4-iodanyl-benzene
7LOE	;	1.01	;	T4 lysozyme mutant L99A in complex with 1-fluoranylnaphthalene
7LOB	;	1.1	;	T4 lysozyme mutant L99A in complex with 1-fluoro-2-[(prop-2-en-1-yl)oxy]benzene
7LOF	;	1.05	;	T4 lysozyme mutant L99A in complex with 2-butylthiophene
7LOG	;	0.99	;	T4 lysozyme mutant L99A in complex with 3-butylpyridine
7LOA	;	1.07	;	T4 lysozyme mutant L99A in complex with 3-fluoroiodobenzene
7LOJ	;	1.5	;	T4 lysozyme mutant L99A in complex with 4-(3-phenylpropyl)aniline
1LGU	;	1.9	;	T4 Lysozyme Mutant L99A/M102Q
1LGW	;	1.85	;	T4 Lysozyme Mutant L99A/M102Q Bound by 2-fluoroaniline
1LGX	;	1.9	;	T4 Lysozyme Mutant L99A/M102Q Bound by 3,5-difluoroaniline
1LI3	;	1.85	;	T4 lysozyme mutant L99A/M102Q bound by 3-chlorophenol
1LI6	;	2.0	;	T4 lysozyme mutant L99A/M102Q bound by 5-methylpyrrole
1LI2	;	2.0	;	T4 Lysozyme Mutant L99A/M102Q Bound by Phenol
231L	;	2.5	;	T4 LYSOZYME MUTANT M106K
234L	;	1.9	;	T4 LYSOZYME MUTANT M106L
232L	;	1.73	;	T4 LYSOZYME MUTANT M120K
233L	;	1.9	;	T4 LYSOZYME MUTANT M120L
230L	;	1.9	;	T4 LYSOZYME MUTANT M6L
3C80	;	1.99	;	T4 Lysozyme mutant R96Y at room temperature
1CUQ	;	2.05	;	T4 LYSOZYME MUTANT V103M
1CV1	;	2.1	;	T4 LYSOZYME MUTANT V111M
1CV6	;	1.9	;	T4 LYSOZYME MUTANT V149M
1CU3	;	2.12	;	T4 LYSOZYME MUTANT V87M
1B6I	;	1.9	;	T4 LYSOZYME MUTANT WITH CYS 54 REPLACED BY THR, CYS 97 REPLACED BY ALA, THR 21 REPLACED BY CYS AND LYS 124 REPLACED BY CYS (C54T,C97A,T21C,K124C)
1EPY	;	1.85	;	T4 LYSOZYME MUTANT, T21H/C54T/C97A/Q141H/T142H
7XE9	;	1.5	;	T4 lysozyme mutant-S44C/C54T/N68C/A93C/C97A/T115C, DMSO 20%
7XEA	;	1.1	;	T4 lysozyme mutant-S44C/C54T/N68C/A93C/C97A/T115C, DMSO 40%, and then backsoaking
7XE7	;	1.05	;	T4 lysozyme mutant-S44C/C54T/N68C/A93C/C97A/T115C, pH10
7XE5	;	1.3	;	T4 lysozyme mutant-S44C/C54T/N68C/A93C/C97A/T115C, pH4
7XE6	;	1.1	;	T4 lysozyme mutant-S44C/C54T/N68C/A93C/C97A/T115C, pH7
6PH0	;	1.947	;	T4 lysozyme pseudo-wild type soaked in TEMPO
6PH1	;	1.632	;	T4 lysozyme pseudo-wild type soaked in TEMPOL
3L64	;	1.9	;	T4 Lysozyme S44E/WT*
1CX6	;	2.01	;	T4 LYSOZYME SUBSTITUTED WITH SELENOMETHIONINE
8F11	;	1.12	;	T4 lysozyme with a 2,6-diazaadamantane nitroxide (DZD) spin label
2O79	;	1.8	;	T4 lysozyme with C-terminal extension
5V7D	;	1.35	;	T4 lysozyme Y18Ymbr
5V7E	;	1.36	;	T4 lysozyme Y18Ymcl
5V7F	;	1.65	;	T4 lysozyme Y18Ymi
1JEJ	;	2.5	;	T4 phage apo BGT
1QKJ	;	2.3	;	T4 Phage B-Glucosyltransferase, Substrate Binding and Proposed Catalytic Mechanism
1C3J	;	1.88	;	T4 PHAGE BETA-GLUCOSYLTRANSFERASE: SUBSTRATE BINDING AND PROPOSED CATALYTIC MECHANISM
1JIX	;	1.65	;	T4 Phage BGT in Complex with Ca2+
1JIU	;	2.5	;	T4 Phage BGT in Complex with Mg2+ : Form I
1JIV	;	2.07	;	T4 phage BGT in complex with Mg2+ : Form II
1JG6	;	1.9	;	T4 phage BGT in complex with UDP
1NVK	;	1.8	;	T4 phage BGT in complex with UDP and a Mn2+ ion at 1.8 A resolution
1JG7	;	1.65	;	T4 phage BGT in complex with UDP and Mn2+
1NZD	;	2.0	;	T4 phage BGT-D100A mutant in complex with UDP-glucose: Form I
1NZF	;	2.1	;	T4 phage BGT-D100A mutant in complex with UDP-glucose: Form II
7CN6	;	1.6	;	T4 phage spackle protein gp61.3
7CN7	;	1.15	;	T4 phage spackle protein gp61.3 complex with lysozyme domain of gp5 tail lysozyme
1RRC	;	2.46	;	T4 POLYNUCLEOTIDE KINASE BOUND TO 5'-GTC-3' SSDNA
1RC8	;	2.75	;	T4 Polynucleotide Kinase bound to 5'-GTCAC-3' ssDNA
1RPZ	;	2.9	;	T4 POLYNUCLEOTIDE KINASE BOUND TO 5'-TGCAC-3' SSDNA
2IA5	;	2.9	;	T4 polynucleotide kinase/phosphatase with bound sulfate and magnesium.
2C5U	;	2.21	;	T4 RNA Ligase (Rnl1) Crystal Structure
5TT6	;	2.187	;	T4 RNA Ligase 1 (K99M)
6D9M	;	1.35	;	T4-Lysozyme fusion to Geobacter GGDEF
1CJ8	;	1.8	;	T40A MUTANT HUMAN LYSOZYME
1CJ9	;	1.8	;	T40V MUTANT HUMAN LYSOZYME
1CKC	;	1.8	;	T43A MUTANT HUMAN LYSOZYME
1CKD	;	1.8	;	T43V MUTANT HUMAN LYSOZYME
1GGO	;	2.6	;	T453A MUTANT OF PYRUVATE, PHOSPHATE DIKINASE
2MML	;		;	T47 phosphorylation of the Mengovirus Leader Protein: NMR Studies of the Phosphorylation of the Mengovirus Leader Protein Reveal Stabilization of Intermolecular Domain Interactions
6C3Z	;	1.681	;	T477A SiRHP
5LFZ	;	1.561	;	T48 deacetylase
5LGC	;	2.09	;	T48 deacetylase with substrate
1YF3	;	2.29	;	T4Dam in Complex with AdoHcy and 13-mer Oligonucleotide Making Non- and Semi-specific (~1/4) Contact
1YFJ	;	2.69	;	T4Dam in Complex with AdoHcy and 15-mer Oligonucleotide Showing Semi-specific and Specific Contact
1YFL	;	3.09	;	T4Dam in Complex with Sinefungin and 16-mer Oligonucleotide Showing Semi-specific and Specific Contact and Flipped Base
7MH2	;	3.57	;	T4GALA Engineered Protein Nanocage
6VMA	;	2.75	;	T4H2 T cell receptor bound to HLA-A2 presenting gp100 peptide (ITDQVPFSV)
6VMC	;	2.85	;	T4H2 T cell receptor bound to HLA-A2 presenting gp100T2L peptide (ILDQVPFSV)
6VM9	;	2.9	;	T4H2 T cell receptor bound to HLA-A2 presenting gp100T2M peptide (IMDQVPFSV)
1EXN	;	2.5	;	T5 5'-EXONUCLEASE
1XO1	;	2.5	;	T5 5'-EXONUCLEASE MUTANT K83A
5TJT	;	9.0	;	T5 bacteriophage major capsid protein - one PB8 hexon
8A8C	;	3.1	;	T5 phage receptor-binding protein pb5 bound to ferrichrome transporter FhuA
8B14	;	2.6	;	T5 Receptor Binding Protein pb5 in complex with its E. coli receptor FhuA
5FAW	;	1.852	;	T502A mutant of choline TMA-lyase
1CKF	;	1.8	;	T52A MUTANT HUMAN LYSOZYME
1CKG	;	2.2	;	T52V MUTANT HUMAN LYSOZYME
4AZD	;	1.62	;	T57V mutant of aspartate decarboxylase
1MSO	;	1.0	;	T6 Human Insulin at 1.0 A Resolution
4Y7M	;	1.92	;	T6SS protein TssM C-terminal domain (835-1129) from EAEC
4Y7L	;	1.51	;	T6SS protein TssM C-terminal domain (869-1107) from EAEC
4Y7O	;	2.24	;	T6SS protein TssM C-terminal domain (869-1107) from EAEC
1TK5	;	2.2	;	T7 DNA polymerase binary complex with 8 oxo guanosine in the templating strand
1SKR	;	2.4	;	T7 DNA Polymerase Complexed To DNA Primer/Template and ddATP
1T7P	;	2.2	;	T7 DNA POLYMERASE COMPLEXED TO DNA PRIMER/TEMPLATE,A NUCLEOSIDE TRIPHOSPHATE, AND ITS PROCESSIVITY FACTOR THIOREDOXIN
1ZYQ	;	2.7	;	T7 DNA polymerase in complex with 8oG and incoming ddATP
1X9W	;	2.3	;	T7 DNA polymerase in complex with a primer/template DNA containing a disordered N-2 aminofluorene on the template, crystallized with dideoxy-ATP as the incoming nucleotide.
1X9S	;	2.7	;	T7 DNA polymerase in complex with a primer/template DNA containing a disordered N-2 aminofluorene on the template, crystallized with dideoxy-CTP as the incoming nucleotide.
1X9M	;	2.1	;	T7 DNA polymerase in complex with an N-2-acetylaminofluorene-adducted DNA
1TK8	;	2.5	;	T7 DNA polymerase ternary complex with 8 oxo guanosine and dAMP at the elongation site
1TKD	;	2.49	;	T7 DNA polymerase ternary complex with 8 oxo guanosine and dCMP at the elongation site
1TK0	;	2.3	;	T7 DNA polymerase ternary complex with 8 oxo guanosine and ddCTP at the insertion site
1T8E	;	2.54	;	T7 DNA Polymerase Ternary Complex with dCTP at the Insertion Site.
1S76	;	2.88	;	T7 RNA polymerase alpha beta methylene ATP elongation complex
2PI5	;	2.9	;	T7 RNA polymerase complexed with a phi10 promoter
1ARO	;	2.8	;	T7 RNA POLYMERASE COMPLEXED WITH T7 LYSOZYME
8DH0	;	2.9	;	T7 RNA polymerase elongation complex with unnatural base dDs
8DH2	;	2.9	;	T7 RNA polymerase elongation complex with unnatural base dDs-ATP mismatch
8DH1	;	2.65	;	T7 RNA polymerase elongation complex with unnatural base dDs-PaTP pair
8DH3	;	3.0	;	T7 RNA polymerase elongation complex with unnatural base dPa
8DH5	;	2.85	;	T7 RNA polymerase elongation complex with unnatural base dPa-ATP mismatch
8DH4	;	2.8	;	T7 RNA polymerase elongation complex with unnatural base dPa-DsTP pair
1S77	;	2.69	;	T7 RNAP product pyrophosphate elongation complex
2BC3	;	1.54	;	T7-tagged full-length streptavidin
2QCB	;	1.65	;	T7-tagged full-length streptavidin complexed with ruthenium ligand
1CKH	;	2.0	;	T70V MUTANT HUMAN LYSOZYME
1T2I	;	1.1	;	T76W mutant of RNase Sa from Streptomyces aureofaciens
2PI4	;	2.5	;	T7RNAP complexed with a phi10 protein and initiating GTPs.
6LZ9	;	2.8	;	t8E4 antibody Fab complexed with the active form of HGF
8JKN	;	2.92	;	T95R mutant IRF4 DNA-binding domain bound to an DNA containing GAAA motif
8JKQ	;	3.09	;	T95R mutant IRF4 DNA-binding domain bound to an DNA containing GACA motif
8JKS	;	3.3	;	T95R mutant IRF4 DNA-binding domain bound to an DNA containing GAGA motif
8JKO	;	2.95	;	T95R mutant IRF4 DNA-binding domain bound to an DNA containing GATA motif
2HHV	;	1.55	;	T:O6-methyl-guanine in the polymerase-2 basepair position
2HW3	;	1.98	;	T:O6-methyl-guanine pair in the polymerase postinsertion site (-1 basepair position)
1X36	;	2.7	;	T=1 capsid of an amino-terminal deletion mutant of SeMV CP
4Y4Y	;	3.0	;	T=1 capsid structure of SeMV Ndel65CP fused with B-domain of S. aureus protein SpA at the N-terminus (C2 crystal form)
4Y5Z	;	2.95	;	T=1 capsid structure of SeMV Ndel65CP fused with B-domain of S. aureus protein SpA at the N-terminus (P1 crystal form)
1VB4	;	3.3	;	T=1 capsid structure of Sesbania mosaic virus coat protein deletion mutant CP-N(delta)36
1VAK	;	3.05	;	T=1 capsid structure of Sesbania mosaic virus coat protein deletion mutant CP-N(delta)65
1VB2	;	3.4	;	T=1 capsid structure of Sesbania mosaic virus coat protein deletion mutant CP-N(delta)65-D146N-D149N
8EEP	;	2.2	;	T=1 particle HIV-1 CA G60A/G61P
7URT	;	2.39	;	T=1 particle HIV-1 CA G60A/G61P/M66A
8EET	;	3.1	;	T=1 particle HIV-1 CA M66A
4RFT	;	3.1	;	T=1 subviral particle of Grouper nervous necrosis virus capsid protein deletion mutant (delta 1-34 & 218-338)
5YL1	;	3.12	;	T=1 subviral particle of Penaeus vannamei nodavirus capsid protein deletion mutant (delta 1-37 & 251-368)
6RRS	;	3.9	;	T=3 MS2 Virus-like particle
1X33	;	3.6	;	T=3 recombinant capsid of SeMV CP
6RRT	;	6.0	;	T=4 MS2 Virus-like-particle
6QN1	;	3.28	;	T=4 quasi-symmetric bacterial microcompartment particle
7VWO	;	2.0	;	TA complex from Mycobacterium tuberculosis
2POM	;	2.27	;	TAB1 with manganese ion
2WX0	;	2.4	;	TAB2 NZF DOMAIN IN COMPLEX WITH Lys63-linked di-ubiquitin, P21
2WWZ	;	1.4	;	TAB2 NZF DOMAIN IN COMPLEX WITH Lys63-linked di-ubiquitin, P212121
2WX1	;	3.0	;	TAB2 NZF DOMAIN IN COMPLEX WITH Lys63-linked tri-ubiquitin, P212121
7ZG6	;	1.95	;	TacA1 antitoxin
4GVE	;	1.73	;	Tacaribe nucleoprotein structure
1JC9	;	2.01	;	TACHYLECTIN 5A FROM TACHYPLEUS TRIDENTATUS (JAPANESE HORSESHOE CRAB)
1TL2	;	2.0	;	TACHYLECTIN-2 FROM TACHYPLEUS TRIDENTATUS (JAPANESE HORSESHOE CRAB)
1WO1	;		;	Tachyplesin I in dodecylphosphocholine micelles
2MDB	;		;	Tachyplesin I in the presence of lipopolysaccharide
2RTV	;		;	Tachyplesin I in water
1MA5	;		;	Tachyplesin I solution structure in the presence of 300mM Dodecylphosphocholine micelles
1MA2	;		;	Tachyplesin I Wild type peptide NMR Structure
7F36	;	3.098	;	TacT complexed with acetyl-glycyl-tRNAGly
5I29	;	1.21	;	TAF1(2) bound to a pyrrolopyridone compound
6BQD	;	2.136	;	TAF1-BD2 bromodomain in complex with (E)-3-(6-(but-2-en-1-yl)-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-N,N-dimethylbenzamide
6DF7	;	2.0	;	TAF1-BD2 in complex with Cpd27 (6-(but-3-en-1-yl)-4-(1-methyl-6-(morpholine-4-carbonyl)-1H-benzo[d]imidazol-4-yl)-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one)
6DF4	;	1.3	;	TAF1-BD2 in complex with Cpd8 (6-(but-3-en-1-yl)-4-(3-(morpholine-4-carbonyl)phenyl)-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one)
7UHE	;	1.66	;	Taf14 ET domain in complex with C-terminal tail of Taf2
8ONS	;	1.97	;	TAF15 amyloid fold in atypical FTLD - Individual 1
4ATG	;	1.89	;	TAF6 C-terminal domain from Antonospora locustae
3MHF	;	1.87	;	Tagatose-1,6-bisphosphate aldolase from Streptococcus pyogenes
5F2I	;	1.95	;	Tagatose-1,6-bisphosphate aldolase from Streptococcus pyogenes Glu163Gln mutant
5F2G	;	1.918	;	Tagatose-1,6-bisphosphate aldolase from Streptococcus pyogenes Glu164Gln mutant in complex with FBP
5F2M	;	1.92	;	Tagatose-1,6-bisphosphate aldolase from Streptococcus pyogenes in complex with competitive inhibitor hexitol-1,6-bisphosphate
5F2L	;	1.755	;	Tagatose-1,6-bisphosphate aldolase from Streptococcus pyogenes in complex with competitive inhibitor talitol-1,6-bisphosphate
5FF7	;	2.092	;	Tagatose-1,6-bisphosphate aldolase from Streptococcus pyogenes in complex with DHAP and G3P
5F4S	;	1.724	;	Tagatose-1,6-bisphosphate aldolase from Streptococcus pyogenes in complex with FBP
5F4W	;	1.663	;	Tagatose-1,6-bisphosphate aldolase from Streptococcus pyogenes in complex with TBP
8C7P	;	3.0	;	Tagless BtuM in complex with cyanocobalamin
6MPT	;	1.649	;	TagT bound to LI-WTA
6MPS	;	1.86	;	TagT bound to LIIa-WTA
2L6J	;		;	Tah1 complexed by MEEVD
7QOL	;	3.33	;	Tail assembly of the phicrAss001 virion with C6 symmetry imposed
7QOJ	;	3.21	;	Tail barrel assembly of the phicrAss001 virion with C12 symmetry imposed
8IYD	;	3.1	;	Tail cap of phage lambda tail
6IAB	;	2.0	;	Tail fiber of Staphylococcus aureus phage P68
8EGS	;	3.92	;	Tail knob structure of Staphylococcus phage Andhra
7JMN	;	3.58	;	Tail module of Mediator complex
7QOK	;	3.38	;	Tail muzzle assembly of the phicrAss001 virion with C6 symmetry imposed
7Z47	;	3.8	;	Tail of bacteriophage SU10
6TSV	;	3.78	;	Tail of empty GTA particle computed with helical refinement, C6 symmetry
6TEA	;	3.89	;	Tail of native GTA particle computed with helical refinement, C6 symmetry
7Z4F	;	4.2	;	Tail of phage SU10 genome release intermediate
7EY9	;	3.4	;	tail proteins
7XDI	;	3.8	;	Tail structure of bacteriophage SSV19
7WMP	;	3.6	;	Tail structure of Helicobacter pylori bacteriophage KHP30
8IYK	;	2.95	;	Tail tip conformation 1 of phage lambda tail
8IYL	;	3.0	;	Tail tip conformation 2 of phage lambda tail
7ZN4	;	4.32	;	Tail tip of siphophage T5 : bent fibre after interaction with its bacterial receptor FhuA
7ZLV	;	4.22	;	Tail tip of siphophage T5 : central fibre protein pb4
7QG9	;	3.45	;	Tail tip of siphophage T5 : common core proteins
7ZN2	;	4.29	;	Tail tip of siphophage T5 : full complex after interaction with its bacterial receptor FhuA
7ZQB	;	3.88	;	Tail tip of siphophage T5 : full structure
7ZQP	;	3.6	;	Tail tip of siphophage T5 : open cone after interaction with bacterial receptor FhuA
7ZHJ	;	3.53	;	Tail tip of siphophage T5 : tip proteins
8EJ5	;	4.9	;	Tail tip structure of Staphylococcus phage Andhra
8HRG	;	4.5	;	Tail tube of DT57C bacteriophage in the full state
5MU4	;	1.9	;	Tail Tubular Protein A of Klebsiella pneumoniae bacteriophage KP32
6TEB	;	4.14	;	Tail-baseplate interface of native GTA particle computed with C6 symmetry
3VDZ	;	2.4	;	Tailoring Encodable Lanthanide-Binding Tags as MRI Contrast Agents: xq-dSE3-Ubiquitin at 2.4 Angstroms
3TOI	;	1.9	;	Tailoring Enzyme Stability and Exploiting Stability-Trait Linkage by Iterative Truncation and Optimization
4N6G	;	2.142	;	Tailoring Small Molecules for an Allosteric Site on Procaspase-6
4N7J	;	1.673	;	Tailoring Small Molecules for an Allosteric Site on Procaspase-6
4N7M	;	2.125	;	Tailoring Small Molecules for an Allosteric Site on Procaspase-6
4NBK	;	1.936	;	Tailoring Small Molecules for an Allosteric Site on Procaspase-6
4NBL	;	1.756	;	Tailoring Small Molecules for an Allosteric Site on Procaspase-6
4NBN	;	1.75	;	Tailoring Small Molecules for an Allosteric Site on Procaspase-6
4N5D	;	2.06	;	Tailoring Small Molecules for an Allosteric Site on Procaspase-6: Cpd1
7RFV	;	3.2	;	Tailspike protein 4 (TSP4) from phage CBA120, residues 1-250, obtained in the presence of PEG8000
7REJ	;	2.6	;	Tailspike protein 4 (TSP4) from phage CBA120, residues 1-335, obtained in the presence of NaK-Tartrate
4XLH	;	1.91	;	Tailspike protein double mutant D339A/E372A of E. coli bacteriophage HK620
4YEL	;	1.72	;	Tailspike protein double mutant D339A/E372A of E. coli bacteriophage HK620 in complex with hexasaccharide
4XMY	;	1.45	;	Tailspike protein double mutant D339A/E372A of E. coli bacteriophage HK620 in complex with pentasaccharide
4XNF	;	1.68	;	Tailspike protein double mutant D339A/E372Q of E. coli bacteriophage HK620
4XR6	;	1.78	;	Tailspike protein double mutant D339A/E372Q of E. coli bacteriophage HK620 in complex with hexasaccharide
4YEJ	;	1.4	;	Tailspike protein double mutant D339A/E372Q of E. coli bacteriophage HK620 in complex with pentasaccharide
4XLC	;	1.85	;	Tailspike protein double mutant D339N/E372A of E. coli bacteriophage HK620
4XLE	;	1.45	;	Tailspike protein double mutant D339N/E372A of E. coli bacteriophage HK620 in complex with hexasaccharide
4XLF	;	1.75	;	Tailspike protein double mutant D339N/E372A of E. coli bacteriophage HK620 in complex with pentasaccharide
4XON	;	2.1	;	Tailspike protein double mutant D339N/E372Q of E. coli bacteriophage HK620
4XOP	;	1.59	;	Tailspike protein double mutant D339N/E372Q of E. coli bacteriophage HK620 in complex with hexasaccharide
4XOR	;	1.5	;	Tailspike protein double mutant D339N/E372Q of E. coli bacteriophage HK620 in complex with pentasaccharide
1CLW	;	2.0	;	TAILSPIKE PROTEIN FROM PHAGE P22, V331A MUTANT
4XL9	;	2.02	;	Tailspike protein mutant D339A of E. coli bacteriophage HK620
4XLA	;	1.47	;	Tailspike protein mutant D339A of E. coli bacteriophage HK620 IN COMPLEX WITH PENTASACCHARIDE
2X6Y	;	1.35	;	Tailspike protein mutant D339A of E.coli bacteriophage HK620 in complex with hexasaccharide
4XKV	;	2.1	;	Tailspike protein mutant D339N of E. coli bacteriophage HK620
4XKW	;	1.45	;	Tailspike protein mutant D339N of E. coli bacteriophage HK620 in complex with pentasaccharide
2X6X	;	1.48	;	Tailspike protein mutant D339N of E.coli bacteriophage HK620 in complex with hexasaccharide
4XN0	;	1.75	;	Tailspike protein mutant E372A of E. coli bacteriophage HK620
4XN3	;	1.65	;	Tailspike protein mutant E372A of E. coli bacteriophage HK620 in complex with hexasaccharide
4XM3	;	1.27	;	Tailspike protein mutant E372A of E. coli bacteriophage HK620 in complex with pentasaccharide
4XQF	;	1.55	;	Tailspike protein mutant E372Q (delta D470/N471) of E. coli bacteriophage HK620
6GVP	;	1.71	;	TAILSPIKE PROTEIN MUTANT E372Q (DELTA N471/S472) OF E. COLI BACTERIOPHAGE HK620 IN COMPLEX WITH HEXASACCHARIDE
6GVR	;	1.85	;	TAILSPIKE PROTEIN MUTANT E372Q (DELTA N471/S472) OF E. COLI BACTERIOPHAGE HK620 IN COMPLEX WITH PENTASACCHARIDE
4AVZ	;	1.82	;	Tailspike protein mutant E372Q of E. coli bacteriophage HK620
4XOT	;	1.06	;	Tailspike protein mutant E372Q of E. coli bacteriophage HK620 in complex with pentasaccharide
2X6W	;	1.35	;	Tailspike protein mutant E372Q of E.coli bacteriophage HK620 in complex with hexasaccharide
2VBE	;	1.98	;	Tailspike protein of bacteriophage Sf6
2VBM	;	2.0	;	Tailspike protein of bacteriophage Sf6 complexed with tetrasaccharide
2X85	;	1.5	;	Tailspike protein of E. coli bacteriophage HK620 in complex with hexasaccharide
6G0X	;	1.41	;	TAILSPIKE PROTEIN OF E. COLI BACTERIOPHAGE HK620 IN COMPLEX WITH PENTASACCHARIDE
2VJI	;	1.38	;	Tailspike protein of E.coli bacteriophage HK620
2VJJ	;	1.59	;	TAILSPIKE PROTEIN OF E.COLI BACTERIOPHAGE HK620 IN COMPLEX WITH HEXASACCHARIDE
4URR	;	1.95	;	Tailspike protein of Sf6 bacteriophage bound to Shigella flexneri O- antigen octasaccharide fragment
1QA3	;	2.0	;	TAILSPIKE PROTEIN, MUTANT A334I
1QA2	;	2.0	;	TAILSPIKE PROTEIN, MUTANT A334V
1QQ1	;	1.8	;	TAILSPIKE PROTEIN, MUTANT E359G
1QA1	;	2.0	;	TAILSPIKE PROTEIN, MUTANT V331G
1QRC	;	2.5	;	TAILSPIKE PROTEIN, MUTANT W391A
8S9Y	;		;	Taipan Natriuretic Peptide C -TNPc
6YQ7	;	1.58	;	Taka-amylase
6YQA	;	1.67	;	Taka-amylase in complex with alpha-glucosyl epi-cyclophellitol aziridine inhibitor
6YQB	;	1.5	;	Taka-amylase in complex with alpha-glucosyl epi-cyclophellitol cyclosulfate inhibitor
6YQ9	;	1.55	;	Taka-amylase in complex with alpha-glucosyl epi-cyclophellitol epoxide inhibitor
6YQC	;	1.35	;	Taka-amylase in complex with alpha-glucosyl epi-cyclophellitol epoxide inhibitor
6WV8	;	3.01	;	Takifugu rubripes VKOR-like C138S mutant with vitamin K1
6WVA	;	3.35	;	Takifugu rubripes VKOR-like with vitamin K1 epoxide at non-catalytic state
6WV9	;	3.35	;	Takifugu rubripes VKOR-like with vitamin K1 in noncatalytic state
6WVB	;	2.872	;	Takifugu rubripes VKOR-like with warfarin
7VTA	;	2.4	;	Talaromyces verruculosus talaropentaene synthase apo
2MWN	;		;	Talin-F3 / RIAM N-terminal Peptide complex
7K16	;	2.1	;	Tamana Bat Virus xrRNA1
2ZSC	;	1.3	;	Tamavidin2, Novel Avidin-like Biotin-Binding Proteins from an Edible Mushroom
2KFL	;		;	Tammar Wallaby Prion Protein (121-230)
1FJ5	;		;	TAMOXIFEN-DNA ADDUCT
1TRR	;	2.4	;	TANDEM BINDING IN CRYSTALS OF A TRP REPRESSOR/OPERATOR HALF-SITE COMPLEX
2H1E	;	2.2	;	Tandem chromodomains of budding yeast CHD1
2B2Y	;	2.35	;	Tandem chromodomains of human CHD1
2B2W	;	2.4	;	Tandem chromodomains of human CHD1 complexed with Histone H3 Tail containing trimethyllysine 4
2B2U	;	2.95	;	Tandem chromodomains of human CHD1 complexed with Histone H3 Tail containing trimethyllysine 4 and dimethylarginine 2
2B2T	;	2.45	;	Tandem chromodomains of human CHD1 complexed with Histone H3 Tail containing trimethyllysine 4 and phosphothreonine 3
4O42	;	1.87	;	Tandem chromodomains of human CHD1 in complex with influenza NS1 C-terminal tail dimethylated at K229
4NW2	;	1.9	;	Tandem chromodomains of human CHD1 in complex with Influenza virus NS1 C-terminal tail trimethylated at K229
7SBI	;	2.23	;	Tandem diubiquitin-like domain from chicken 2'-5'-oligoadenylate synthetase-like protein
1TAN	;		;	TANDEM DNA, NMR, MINIMIZED AVERAGE STRUCTURE
6GZB	;	2.1	;	Tandem GerMN domains of the sporulation protein GerM from Bacillus subtilis
2WPX	;	2.31	;	Tandem GNAT protein from the clavulanic acid biosynthesis pathway (with AcCoA)
2WPW	;	2.38	;	Tandem GNAT protein from the clavulanic acid biosynthesis pathway (without AcCoA)
1QES	;		;	TANDEM GU MISMATCHES IN RNA, NMR, 30 STRUCTURES
1QET	;		;	TANDEM GU MISMATCHES IN RNA, NMR, 30 STRUCTURES
3PXH	;	2.0009	;	Tandem Ig domains of tyrosine phosphatase LAR
3PXJ	;	2.3003	;	Tandem Ig repeats of Dlar
8EB5	;	2.5	;	Tandem of Hermes transposase BED domain in complex with the quasi palindrome of its transposon left-end
3SGR	;	2.17	;	Tandem repeat of amyloid-related segment of alphaB-crystallin residues 90-100 mutant V91L
2OQ1	;	1.9	;	Tandem SH2 domains of ZAP-70 with 19-mer zeta1 peptide
4TVR	;	2.29	;	Tandem Tudor and PHD domains of UHRF2
1XNI	;	2.8	;	Tandem Tudor Domain of 53BP1
6VZC	;		;	Tandem UU:GA mismatch within an RNA helix
1L0Q	;	2.4	;	Tandem YVTN beta-propeller and PKD domains from an archaeal surface layer protein
5ECE	;	2.2	;	Tankyrase 1 with Phthalazinone 1
5EBT	;	2.24	;	Tankyrase 1 with Phthalazinone 2
4L0I	;	2.3	;	Tankyrase 2 catalytic domain in complex with ethyl 4-(4-oxo-4H-chromen-2-yl)benzoate
7R3Z	;	2.25	;	Tankyrase 2 catalytic domain in complex with OUL40
5DCZ	;	2.23	;	Tankyrase 2 complexed with a selective inhibitor
4L2K	;	2.1	;	Tankyrase 2 in complex with 2-(1,3-benzodioxol-5-yl)-4H-chromen-4-one
4L32	;	1.85	;	Tankyrase 2 in complex with 2-[4-(4-methylpiperazine-1-carbonyl)phenyl]chromen-4-one
4J22	;	2.12	;	Tankyrase 2 in complex with 3-chloro-4-(4-methyl-2-oxo-1,2-dihydroquinolin-7-yl)-N-[2-(morpholin-4-yl)ethyl]benzamide
4J3M	;	1.9	;	Tankyrase 2 in complex with 3-chloro-4-(4-methyl-2-oxo-1,2-dihydroquinolin-7-yl)benzoic acid
4J3L	;	2.09	;	Tankyrase 2 in complex with 3-chloro-N-(2-methoxyethyl)-4-(4-methyl-2-oxo-1,2-dihydroquinolin-7-yl)benzamide
4L0V	;	1.7	;	Tankyrase 2 in complex with 4'-chloro flavone
4L0S	;	1.9	;	Tankyrase 2 in complex with 4'-cyano flavone
4L0B	;	1.8	;	Tankyrase 2 in complex with 4'-dimethylamino flavone
4L10	;	1.7	;	Tankyrase 2 in complex with 4'-methoxy flavone
4L0T	;	2.1	;	Tankyrase 2 in complex with 4'-nitro flavone
4L34	;	1.8	;	Tankyrase 2 in complex with 4'-tetrazole flavone
4J1Z	;	2.0	;	Tankyrase 2 in complex with 4-chloro-1,2-dihydrophatalzin-one
4L2G	;	2.05	;	Tankyrase 2 in complex with 6- fluoro flavone
4L2F	;	2.05	;	Tankyrase 2 in complex with 6-chloro flavone
4J21	;	1.93	;	Tankyrase 2 in complex with 7-(4-amino-2-chlorophenyl)-4-methylquinolin-2(1H)-one
8B6M	;	1.6	;	Tankyrase 2 in complex with an inhibitor
6TKN	;	2.5	;	Tankyrase 2 in complex with an inhibitor (OM-1000)
7O6X	;	2.2	;	Tankyrase 2 in complex with an inhibitor (OM-153)
6TG4	;	2.76	;	Tankyrase 2 in complex with an inhibitor (OM-1700)
6TKR	;	2.75	;	Tankyrase 2 in complex with an inhibitor (OM-1704)
6TKS	;	2.5	;	Tankyrase 2 in complex with an inhibitor (OM-1720)
6TKM	;	2.7	;	Tankyrase 2 in complex with an inhibitor (OM-1800)
6TKP	;	2.4	;	Tankyrase 2 in complex with an inhibitor (OM-1900)
6TKQ	;	2.5	;	Tankyrase 2 in complex with an inhibitor (OM-2700)
7R5X	;	2.052	;	Tankyrase 2 in complex with an inhibitor (OUL211)
7OLJ	;	1.8	;	Tankyrase 2 in complex with an inhibitor (OUL219)
7OM1	;	1.7	;	Tankyrase 2 in complex with an inhibitor (OUL220)
7OMC	;	2.1	;	Tankyrase 2 in complex with an inhibitor (OUL228)
4L33	;	2.1	;	Tankyrase 2 in complex with cyanomethyl 4-(4-oxo-4H-chromen-2-yl)benzoate
4HKI	;	2.15	;	Tankyrase 2 in complex with flavone
4L31	;	2.0	;	Tankyrase 2 in complex with methyl 4-(4-oxochromen-2-yl)benzoate
7OJO	;	2.3	;	Tankyrase 2 in complex with two small molecule fragments
3W51	;	2.0	;	Tankyrase in complex with 2-hydroxy-4-methylquinoline
4IUE	;	2.38	;	Tankyrase in complex with 7-(2-fluorophenyl)-4-methyl-1,2-dihydroquinolin-2-one
4W5S	;	2.8	;	Tankyrase in complex with compound
3UH4	;	2.0	;	TANKYRASE-1 complexed with NVP-XAV939
4KRS	;	2.29	;	Tankyrase-1 complexed with small molecule inhibitor
4LI8	;	2.521	;	TANKYRASE-1 complexed with small molecule inhibitor 2-[4-(4-fluorobenzoyl)piperidin-1-yl]-N-[(4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrimidin-2-yl)methyl]-N-(thiophen-2-ylmethyl)acetamide
4LI7	;	2.2	;	TANKYRASE-1 complexed with small molecule inhibitor 4-chloro-5-cyano-N-{2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl}-2-methoxybenzamide
4LI6	;	2.05	;	TANKYRASE-1 Complexed with small molecule inhibitor N-[(4-oxo-3,4-dihydroquinazolin-2-yl)methyl]-3-phenyl-N-(thiophen-2-ylmethyl)propanamide
3UDD	;	1.95	;	Tankyrase-1 in complex with small molecule inhibitor
3UH2	;	2.0	;	Tankyrase-1 in complexed with PJ34
5ZQP	;	1.99	;	Tankyrase-2 in complex with compound 12
6A84	;	1.98	;	Tankyrase-2 in complex with compound 15d
5ZQO	;	2.06	;	Tankyrase-2 in complex with compound 1a
5ZQR	;	1.75	;	Tankyrase-2 in complex with compound 40c
5ZQQ	;	2.29	;	Tankyrase-2 in complex with compound 52
6KRO	;	1.9	;	Tankyrase-2 in complex with RK-582
7CE4	;	1.5	;	Tankyrase2 catalytic domain in complex with K-476
8DHL	;	2.3	;	Tannerella forsythia beta-glucuronidase (L2)
8DHE	;	2.2	;	Tannerella forsythia beta-glucuronidase (mL1)
6R7W	;	1.5	;	Tannerella forsythia mature mirolysin in complex with a cleaved peptide.
6R7V	;	1.4	;	Tannerella forsythia promirolysin mutant E225A
4J0G	;	2.5	;	Tannin acyl hydrolase (mercury derivative)
7K4O	;	1.65	;	Tannin acyl hydrolase from Aspergillus niger
4J0D	;	1.6	;	tannin acyl hydrolase from Lactobacillus plantarum (Cadmium)
4J0C	;	1.65	;	tannin acyl hydrolase from Lactobacillus plantarum (native structure)
4J0I	;	1.75	;	Tannin acyl hydrolase in complex with 3,4-dihydroxybenzoate
4J0J	;	2.0	;	Tannin acyl hydrolase in complex with ethyl 3,5-dihydroxybenzoate
4J0K	;	2.05	;	Tannin acyl hydrolase in complex with ethyl gallate
4J0H	;	1.8	;	Tannin acyl hydrolase in complex with gallic acid
2GCD	;	2.55	;	TAO2 kinase domain-staurosporine structure
1KJM	;	2.35	;	TAP-A-associated rat MHC class I molecule
1KJV	;	1.48	;	TAP-B-associated rat MHC class I molecule
8AIF	;	1.07	;	TapA acts as specific chaperone in TasA non-amyloid filament formation
3F8U	;	2.6	;	Tapasin/ERp57 heterodimer
1TAU	;	3.0	;	TAQ POLYMERASE (E.C.2.7.7.7)/DNA/B-OCTYLGLUCOSIDE COMPLEX
1BGX	;	2.3	;	TAQ POLYMERASE IN COMPLEX WITH TP7, AN INHIBITORY FAB
1YNN	;	3.3	;	Taq RNA polymerase-rifampicin complex
1YNJ	;	3.2	;	Taq RNA polymerase-Sorangicin complex
5L1Z	;	5.9	;	TAR complex with HIV-1 Tat-AFF4-P-TEFb
2A9X	;		;	TAR RNA recognition by a cyclic peptidomimetic of Tat protein
1KIS	;		;	TAR-TAR ""KISSING"" HAIRPIN COMPLEX DERIVED FROM THE HIV GENOME, NMR, 1 STRUCTURE
6NSD	;	1.74	;	Tar14, tryptophan C-6 flavin-dependent halogenase (chlorinase) from taromycin biosynthesis
3DTP	;	20.0	;	Tarantula heavy meromyosin obtained by flexible docking to Tarantula muscle thick filament Cryo-EM 3D-MAP
4J5S	;	1.55	;	TARG1 (C6orf130), Terminal ADP-ribose Glycohydrolase 1 ADP-ribose complex
4J5R	;	1.25	;	TARG1 (C6orf130), Terminal ADP-ribose Glycohydrolase 1 bound to ADP-HPD
4J5Q	;	1.35	;	TARG1 (C6orf130), Terminal ADP-ribose Glycohydrolase 1, apo structure
6PIJ	;	2.9	;	Target DNA-bound V. cholerae TniQ-Cascade complex, closed conformation
1CDL	;	2.0	;	TARGET ENZYME RECOGNITION BY CALMODULIN: 2.4 ANGSTROMS STRUCTURE OF A CALMODULIN-PEPTIDE COMPLEX
2D82	;		;	Target Structure-Based Discovery of Small Molecules that Block Human p53 and CREB Binding Protein (CBP) Association
7OX9	;	2.45	;	Target-bound SpCas9 complex with AAVS1 all-RNA guide
7OXA	;	2.15	;	Target-bound SpCas9 complex with AAVS1 chimeric RNA-DNA guide
7OX7	;	2.6	;	Target-bound SpCas9 complex with TRAC chimeric RNA-DNA guide
7OX8	;	2.75	;	Target-bound SpCas9 complex with TRAC full RNA guide
3EN6	;	2.39	;	Targeted polypharmacology: crystal structure of the c-Src kinase domain in complex with PP102, a multitargeted kinase inhibitor
3EN4	;	2.55	;	Targeted polypharmacology: crystal structure of the c-Src kinase domain in complex with PP121, a multitargeted kinase inhibitor
3EN5	;	2.66	;	Targeted polypharmacology: crystal structure of the c-Src kinase domain in complex with PP494, a multitargeted kinase inhibitor
3EN7	;	2.81	;	Targeted polypharmacology: crystal structure of the c-Src kinase domain in complex with S1, a multitargeted kinase inhibitor
4FCQ	;	2.151	;	Targeting conserved water molecules: Design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization
4FCR	;	1.698	;	Targeting conserved water molecules: Design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization
7M1Z	;	2.27	;	Targeting Enterococcus faecalis HMG-CoA reductase with a novel non-statin inhibitor
7M3H	;	1.27	;	Targeting Enterococcus faecalis HMG-CoA reductase with a novel non-statin inhibitor
7M66	;	2.25	;	Targeting Enterococcus faecalis HMG-CoA reductase with a novel non-statin inhibitor
8PVS	;	1.68	;	Targeting extended blood antigens by Akkermansia muciniphila enzymes unveils a missing link for generating universal donor blood
8PXT	;	2.25	;	Targeting extended blood antigens by Akkermansia muciniphila enzymes unveils a missing link for generating universal donor blood
8PXU	;	1.99	;	Targeting extended blood antigens by Akkermansia muciniphila enzymes unveils a missing link for generating universal donor blood
8PXV	;	2.5	;	Targeting extended blood antigens by Akkermansia muciniphila enzymes unveils a missing link for generating universal donor blood
6FMD	;	1.58	;	Targeting myeloid differentiation using potent human dihydroorotate dehydrogenase (hDHODH) inhibitors based on 2-hydroxypyrazolo[1,5-a]pyridine scaffold
4HLW	;	2.5	;	Targeting the Binding Function 3 (BF3) Site of the Human Androgen Receptor Through Virtual Screening. 2. Development of 2-((2-phenoxyethyl) thio)-1H-benzoimidazole derivatives.
2YLO	;	2.5	;	TARGETING THE BINDING FUNCTION 3 SITE OF THE ANDROGEN RECEPTOR THROUGH IN SILICO MOLECULAR MODELING
2YLP	;	2.3	;	TARGETING THE BINDING FUNCTION 3 SITE OF THE ANDROGEN RECEPTOR THROUGH IN SILICO MOLECULAR MODELING
2YLQ	;	2.4	;	TARGETING THE BINDING FUNCTION 3 SITE OF THE ANDROGEN RECEPTOR THROUGH IN SILICO MOLECULAR MODELING
3ZQT	;	2.29	;	TARGETING THE BINDING FUNCTION 3 SITE OF THE ANDROGEN RECEPTOR THROUGH IN SILICO MOLECULAR MODELING
289D	;	2.2	;	TARGETING THE MINOR GROOVE OF DNA: CRYSTAL STRUCTURES OF TWO COMPLEXES BETWEEN FURAN DERIVATIVES OF BERENIL AND THE DNA DODECAMER D(CGCGAATTCGCG)2
298D	;	2.2	;	TARGETING THE MINOR GROOVE OF DNA: CRYSTAL STRUCTURES OF TWO COMPLEXES BETWEEN FURAN DERIVATIVES OF BERENIL AND THE DNA DODECAMER D(CGCGAATTCGCG)2
5L87	;	0.87	;	Targeting the PEX14-PEX5 interaction by small molecules provides novel therapeutic routes to treat trypanosomiases.
5L8A	;	1.57	;	Targeting the PEX14-PEX5 interaction by small molecules provides novel therapeutic routes to treat trypanosomiases.
5N8V	;	1.55	;	Targeting the PEX14-PEX5 interaction by small molecules provides novel therapeutic routes to treat trypanosomiases.
5K0M	;	1.83	;	Targeting the PRC2 complex through a novel protein-protein interaction inhibitor of EED
8BWW	;		;	Targeting Toll-like receptor-driven systemic inflammation by engineering an innate structural fold into drugs
1P44	;	2.7	;	Targeting tuberculosis and malaria through inhibition of enoyl reductase: compound activity and structural data
1P45	;	2.6	;	Targeting tuberculosis and malaria through inhibition of enoyl reductase: compound activity and structural data
4FCP	;	2.0	;	Targetting conserved water molecules: Design of 4-aryl-5-cyanopyrrolo [2,3-d] pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization
7QNT	;	3.21	;	TarM(Se) native
7QD7	;	2.06	;	TarM(Se)_G117R
7QH9	;	2.689	;	TarM(Se)_G117R-4RboP
8P20	;	2.848	;	TarM(Se)_G117R-UDP-4RboP-glucose
8P1X	;	2.03	;	TarM(Se)_G117R-UDP-glucose
6H1J	;	1.86	;	TarP native
6H4F	;	2.18	;	TarP-3RboP
6HNQ	;	2.4	;	TarP-6RboP-(CH2)6NH2
6H4M	;	2.73	;	TarP-UDP-GlcNAc-3RboP
6H2N	;	1.95	;	TarP-UDP-GlcNAc-Mg
6H21	;	1.8	;	TarP-UDP-GlcNAc-Mn
6WCV	;	1.52	;	Tartryl-CoA bound to human GTP-specific succinyl-CoA synthetase
1LQA	;	1.604	;	TAS PROTEIN FROM ESCHERICHIA COLI IN COMPLEX WITH NADPH
6MZW	;	2.2	;	TAS-120 covalent complex with FGFR1
6MZQ	;	2.0	;	TAS-120 in reversible binding mode with FGFR1
6WLV	;	3.45	;	TASK2 in MSP1D1 lipid nanodisc at pH 6.5
6WM0	;	3.52	;	TASK2 in MSP1D1 lipid nanodisc at pH 8.5
7KI1	;	2.5	;	Taspoglutide-bound Glucagon-Like Peptide-1 (GLP-1) Receptor in Complex with Gs Protein
1TGH	;	2.9	;	TATA BINDING PROTEIN (TBP)/DNA COMPLEX
2LZS	;		;	TatA oligomer
2LZR	;		;	TatA T22P
1D3U	;	2.4	;	TATA-BINDING PROTEIN/TRANSCRIPTION FACTOR (II)B/BRE+TATA-BOX COMPLEX FROM PYROCOCCUS WOESEI
1AIS	;	2.1	;	TATA-BINDING PROTEIN/TRANSCRIPTION FACTOR (II)B/TATA-BOX COMPLEX FROM PYROCOCCUS WOESEI
8G58	;		;	Tau (297-391) in vitro untwisted fibril
8Q88	;	2.95	;	Tau - AD-LIA2 (tau intermediate amyloid)
8Q8E	;	3.81	;	Tau - AD-LIA4 (tau intermediate amyloid)
8Q8F	;	2.93	;	Tau - AD-LIA5 (tau intermediate amyloid)
8Q8D	;	3.04	;	Tau - AD-LIA6 (tau intermediate amyloid)
8Q8L	;	3.04	;	Tau - AD-LIA7 (tau intermediate amyloid)
8QCP	;	3.21	;	Tau - AD-LIA8 (tau intermediate amyloid)
8Q8C	;	1.92	;	Tau - AD-MIA10 (intermediate amyloid)
8Q7T	;	3.0	;	Tau - AD-MIA11
8Q2J	;	2.23	;	Tau - AD-MIA2
8Q2K	;	2.88	;	Tau - AD-MIA3
8Q2L	;	2.2	;	Tau - AD-MIA4
8Q7F	;	3.72	;	Tau - AD-MIA5
8Q7L	;	2.82	;	Tau - AD-MIA6 (tau intermediate amyloid)
8Q7M	;	3.26	;	Tau - AD-MIA7 (tau intermediate amyloid)
8Q7P	;	3.28	;	Tau - AD-MIA8 (intermediate amyloid)
8Q8R	;	2.1	;	Tau - AD-PHF
8Q8M	;	2.95	;	Tau - AD-PHF long crossover
8Q8S	;	2.68	;	Tau - AD-THF
8Q9K	;	3.2	;	Tau - CTE-LIA13 (tau intermediate amyloid)
8Q9L	;	2.76	;	Tau - CTE-LIA14 (tau intermediate amyloid)
8Q9F	;	1.91	;	Tau - CTE-LIA3 (tau intermediate amyloid)
8Q9H	;	2.18	;	Tau - CTE-LIA4 (tau intermediate amyloid)
8Q9G	;	2.65	;	Tau - CTE-LIA5 (tau intermediate amyloid)
8Q9I	;	2.56	;	Tau - CTE-LIA6 (tau intermediate amyloid)
8Q9J	;	2.96	;	Tau - CTE-LIA7 (tau intermediate amyloid)
8Q8U	;	3.3	;	Tau - CTE-MIA1 (tau intermediate amyloid)
8Q99	;	2.7	;	Tau - CTE-MIA10 (tau intermediate amyloid)
8Q9A	;	3.04	;	Tau - CTE-MIA11 (tau intermediate amyloid)
8QCR	;	2.75	;	Tau - CTE-MIA12 (tau intermediate amyloid)
8Q9B	;	3.1	;	Tau - CTE-MIA13 (tau intermediate amyloid)
8Q9C	;	3.4	;	Tau - CTE-MIA14 (tau intermediate amyloid)
8Q9D	;	3.16	;	Tau - CTE-MIA15 (tau intermediate amyloid)
8Q9E	;	2.97	;	Tau - CTE-MIA18 (tau intermediate amyloid)
8Q8V	;	3.8	;	Tau - CTE-MIA3
8Q8W	;	2.85	;	Tau - CTE-MIA4 (tau intermediate amyloid)
8Q8X	;	2.54	;	Tau - CTE-MIA5 (tau intermediate amyloid)
8Q8Y	;	2.88	;	Tau - CTE-MIA6 (tau intermediate amyloid)
8Q8Z	;	3.16	;	Tau - CTE-MIA7 (tau intermediate amyloid)
8Q98	;	1.75	;	Tau - CTE-MIA8 (tau intermediate amyloid)
8Q97	;	2.99	;	Tau - CTE-MIA9 (tau intermediate amyloid)
8Q9M	;	2.65	;	Tau - CTE-type I (tau intermediate amyloid)
8P34	;	2.61	;	Tau filaments extracted from human brain with the DeltaK281 mutation in MAPT
7UPF	;	3.3	;	Tau Paired Helical Filament from Alzheimer's Disease incubated 1 hr. with EGCG
7UPG	;	3.8	;	Tau Paired Helical Filament from Alzheimer's Disease incubated with EGCG for 3 hours
7UPE	;	3.4	;	Tau Paired Helical Filament from Alzheimer's Disease not incubated with EGCG
8BGV	;	3.27	;	Tau Paired Helical Filament from Cellular Fraction of Alzheimer's disease brain
8BGS	;	3.16	;	Tau Paired Helical Filament from Extracellular Vesicles from Alzheimer's disease brain
7PQC	;	4.1	;	tau-microtubule structural ensemble based on CryoEM data
7PQP	;	4.1	;	tau-microtubule structural ensemble based on CryoEM data
8KDX	;	1.01	;	Tau-S214 Phosphorylation Inhibits Fyn Kinase Interaction and Increases the Decay Time of NMDAR-mediated Current
2YN0	;	1.5	;	tau55 histidine phosphatase domain
8Q27	;	2.02	;	Tau: AD-MIA1
6ST1	;	1.55	;	Taurine ABC transporter substrate binding protein TauA from E. coli in complex with 2-(N-Morpholino)ethanesulfonic acid (MES)
6SSY	;	1.62	;	Taurine ABC transporter substrate binding protein TauA from E. coli in complex with 2-Aminoethylphosphonic acid
6ST0	;	1.5	;	Taurine ABC transporter substrate binding protein TauA from E. coli in complex with N-(2-Acetamido)-2-aminoethanesulfonic acid
6STL	;	1.3	;	Taurine ABC transporter substrate binding protein TauA from E. coli in complex with taurine
1GQW	;	3.0	;	Taurine/alpha-ketoglutarate Dioxygenase from Escherichia coli
1GY9	;	2.5	;	Taurine/alpha-ketoglutarate Dioxygenase from Escherichia coli
6EDH	;	1.73	;	Taurine:2OG dioxygenase (TauD) bound to the vanadyl ion, taurine, and succinate
4NNL	;	1.5	;	Tax-Interacting Protein-1 (TIP-1) PDZ domain bound to F-iCAL36 (ANSRFPTSII) peptide
4NNM	;	1.6	;	Tax-Interacting Protein-1 (TIP-1) PDZ domain bound to Y-iCAL36 (YPTSII) peptide
6VC9	;	2.25	;	TB19 complex
6VCA	;	3.73	;	TB38 complex
4NC6	;	1.8	;	Tbc domain of human rab gtpase-activating protein 1
8QQF	;	2.19	;	TBC1D23 PH domain complexed with STX16 TLY motif
2Z5W	;	1.35	;	tBclA, a recombinant spore surface protein from Bacillus anthracis
5V1V	;	1.35	;	TbiB1 in Complex with the TbiA(alpha) Leader Peptide
5V1U	;	2.052	;	TbiB1 in Complex with the TbiA(beta) Leader Peptide
5W5V	;	3.645	;	TBK1 co-crystal structure with amlexanox
6BOE	;	3.598	;	TBK1 in complex with amide-coupled tetrazole analog of amlexanox
6RSR	;	3.15	;	TBK1 in complex with compound 2
6CQ4	;	3.2	;	TBK1 in Complex with Cyclohexyl Analog of Amlexanox
6CQ0	;	3.19	;	TBK1 in Complex with Dimethyl Amino Analog of Amlexanox
6BOD	;	3.197	;	TBK1 in complex with ethyl ester analog of amlexanox
6RST	;	3.29	;	TBK1 in complex with inhibitor compound 24
6RSU	;	2.75	;	TBK1 in complex with Inhibitor compound 35
6CQ5	;	3.354	;	TBK1 in Complex with Sulfone Analog of Amlexanox
6BNY	;	3.341	;	TBK1 in complex with tetrazole analog of amlexanox
5AAQ	;		;	TBK1 recruitment to cytosol-invading Salmonella induces anti- bacterial autophagy
5AAY	;		;	TBK1 recruitment to cytosol-invading Salmonella induces anti- bacterial autophagy
5AAZ	;		;	TBK1 recruitment to cytosol-invading Salmonella induces anti- bacterial autophagy
7UG0	;	2.55	;	TBOA-bound GltPh RSMR mutant in IFS state
7UGJ	;	2.81	;	TBOA-bound GltPh RSMR mutant in OFS state
1MP9	;	2.0	;	TBP from a mesothermophilic archaeon, Sulfolobus acidocaldarius
7OHB	;	3.4	;	TBP-nucleosome complex
4PHL	;	1.95	;	TbrPDEB1-inhibitor complex
7F2W	;	2.16	;	TbUox in complex with uric acid
4S0H	;	2.817	;	TBX5 DB, NKX2.5 HD, ANF DNA Complex
6GPI	;		;	Tc-DNA/DNA duplex
6GMY	;		;	Tc-DNA/RNA duplex
6GN4	;		;	tc-DNA/tc-DNA duplex
4ZRP	;	2.1	;	TC:CD320
7QBE	;	3.0	;	TC:CD320 in complex with nanobody TC-Nb11
7QBD	;	4.18	;	TC:CD320 in complex with nanobody TC-Nb26
7QBF	;	1.85	;	TC:CD320 in complex with nanobody TC-Nb34
7QBG	;	2.69	;	TC:CD320 in complex with nanobody TC-Nb4
4KDP	;	3.6	;	TcaR-ssDNA complex crystal structure reveals the novel ssDNA binding mechanism of the MarR family proteins
4YED	;	1.9	;	TcdA (CsdL)
7N9S	;	5.1	;	TcdB and frizzled-2 CRD complex
8SCF	;		;	TCEIII NMR Structure
8SCH	;		;	TCEI_III NMR Structure
3MBE	;	2.886	;	TCR 21.30 in complex with MHC class II I-Ag7HEL(11-27)
6DFW	;	3.2	;	TCR 8F10 in complex with IAg7-p8G9E
6MF8	;		;	TCR alpha transmembrane domain
1L0X	;	2.8	;	TCR beta chain complexed with streptococcal superantigen SpeA
2WBJ	;	3.0	;	TCR complex
1I9E	;	2.5	;	TCR DOMAIN
5TEZ	;	1.7	;	TCR F50 recgonizing M1-HLA-A2
4H1L	;	3.3	;	TCR interaction with peptide mimics of nickel offers structural insights in nickel contact allergy
4H26	;	2.5	;	TCR interaction with peptide mimics of nickel offers structure insight to nickel contact allergy
4H25	;	2.2	;	TCR interaction with peptide mimics of nickel offers structure insights to nickel contact allergy
7RE9	;	2.77	;	TCR mimic antibody (Fab fragment)
7RE7	;	2.547	;	TCR mimic antibody (Fab fragment) in complex with AFP/HLA-A*02
7N6E	;	3.2	;	TCR peptide HLA-A2 complex
8D5Q	;	2.501	;	TCR TG6 in complex with Ld-HF10
7N2N	;	2.6	;	TCR-antigen complex AS4.2-PRPF3-HLA*B27
8CX4	;	2.2	;	TCR-antigen complex AS8.4-YEIH-HLA*B27
4MNQ	;	2.742	;	TCR-peptide specificity overrides affinity enhancing TCR-MHC interactions
1YMM	;	3.5	;	TCR/HLA-DR2b/MBP-peptide complex
6BJ3	;	1.898	;	TCR55 in complex with HIV(Pol448-456)/HLA-B35
6BJ8	;	1.75	;	TCR55 in complex with Pep20/HLA-B35
6BJ2	;	3.35	;	TCR589 in complex with HIV(Pol448-456)/HLA-B35
3V94	;	2.33	;	TcrPDEC1 catalytic domain in complex with inhibitor wyq16
4Z9V	;	2.099	;	TCTP contains a BH3-like domain, which instead of inhibiting, activates Bcl-xL
6WY8	;	2.1	;	Tcur3481-Tcur3483 steroid ACAD
6WY9	;	2.0	;	Tcur3481-Tcur3483 steroid ACAD G363A variant
5FF8	;	1.7	;	TDG enzyme-product complex
5HF7	;	1.54	;	TDG enzyme-substrate complex
8QX9	;	3.76	;	TDP-43 amyloid fibrils: Morphology-1a
8QXA	;	4.05	;	TDP-43 amyloid fibrils: Morphology-1b
8QXB	;	3.86	;	TDP-43 amyloid fibrils: Morphology-2
7KWZ	;	3.2	;	TDP-43 LCD amyloid fibrils
6Q00	;	0.85	;	TDP2 UBA Domain Bound to Ubiquitin at 0.85 Angstroms Resolution, Crystal Form 1
6Q01	;	0.851	;	TDP2 UBA Domain Bound to Ubiquitin at 0.85 Angstroms Resolution, Crystal Form 2
2LTO	;		;	TDRD3 complex
6GO3	;	2.2	;	TdT chimera (Loop1 of pol mu) - apoenzyme
6GO4	;	1.96	;	TdT chimera (Loop1 of pol mu) - binary complex with ddCTP
6GO7	;	2.55	;	TdT chimera (Loop1 of pol mu) - full DNA synapsis complex
6GO5	;	2.35	;	TdT chimera (Loop1 of pol mu) - Ternary complex with 1-nt gapped DNA substrate
6GO6	;	2.09	;	TdT chimera (Loop1 of pol mu) - ternary complex with downstream dsDNA
4IQU	;	2.4	;	Tdt core in complex with inhibitor (2Z,5E)-6-[4-(4-fluorobenzoyl)-1H-pyrrol-2-yl]-2-hydroxy-4-oxohexa-2,5-dienoic acid
4IQW	;	2.6	;	Tdt core in complex with inhibitor (2Z,5E)-6-[4-(4-fluorobenzoyl)-1H-pyrrol-2-yl]-2-hydroxy-4-oxohexa-2,5-dienoic acid and ssDNA
4IQT	;	2.6	;	Tdt core in complex with inhibitor 6-[4-(3-fluorobenzoyl)-1H-pyrrol-2-yl]-2-hydroxy-4-oxohexa-2,5-dienoic acid
4IQV	;	2.9	;	Tdt core in complex with inhibitor 6-[4-(3-fluorobenzoyl)-1H-pyrrol-2-yl]-2-hydroxy-4-oxohexa-2,5-dienoic acid and ssDNA
4Z8E	;	2.092	;	TEAD DBD mutant -deltaL1
5XJD	;	2.22	;	TEAD in complex with fragment
5NNX	;	3.29	;	TEAD1 bound to DNA
7TYQ	;	1.88	;	TEAD2 bound to Compound 1
7TYU	;	1.78	;	TEAD2 bound to Compound 2
7TYP	;	1.6	;	TEAD2 bound to GNE-7883
8P29	;	2.06	;	TEAD2 in complex with an inhibitor
8POJ	;	2.45	;	TEAD2 in complex with an inhibitor
8POM	;	1.95	;	TEAD2 in complex with an inhibitor
8PON	;	2.2	;	TEAD2 in complex with an inhibitor
8PUX	;	2.05	;	TEAD2 with a covalent inhibitor
8PUY	;	2.2	;	TEAD2 with a covalent inhibitor
6Q2X	;	2.1	;	TEAD4 (216-434) COMPLEXED WITH YAP PEPTIDE (60-100) AND MYRISTOATE (COVALENTLY BOUND) AT 2.1A (P41212 CRYSTAL FORM)
6GEC	;	1.7	;	TEAD4 (216-434) COMPLEXED WITH YAP PEPTIDE (60-100);S94A AND MYRISTOATE (COVALENTLY BOUND) AT 1.70A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA
6GE4	;	1.97	;	TEAD4 (216-434);E263A COMPLEXED WITH YAP PEPTIDE (60-100) AND MYRISTOATE (COVALENTLY BOUND) AT 1.97A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA
6GEE	;	1.96	;	TEAD4 (216-434);E263A COMPLEXED WITH YAP PEPTIDE (60-100); S94A AND MYRISTOATE (COVALENTLY BOUND) AT 1.96A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA
6GEI	;	1.65	;	TEAD4 (216-434);E263A+Y429F COMPLEXED WITH YAP PEPTIDE (60- 100);S94A AND MYRISTOATE (COVALENTLY BOUND TO LYS344, NOT CYS367!) AT 1.65A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA
6GE5	;	2.05	;	TEAD4 (216-434);Y429F COMPLEXED WITH YAP PEPTIDE (60-100) AND MYRISTOATE (COVALENTLY BOUND) AT 2.05A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA
6GEK	;	2.28	;	TEAD4 (216-434);Y429F COMPLEXED WITH YAP PEPTIDE (60-100) AND MYRISTOATE (COVALENTLY BOUND) AT 2.28A (P212121 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA
6GEG	;	2.23	;	TEAD4 (216-434);Y429F COMPLEXED WITH YAP PEPTIDE (60-100); S94A AND MYRISTOATE (COVALENTLY BOUND) AT 2.23A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA
6SEN	;	1.65	;	TEAD4 bound to a FAM181A peptide
6SEO	;	2.55	;	TEAD4 bound to a FAM181B peptide
5OAQ	;	1.95	;	TEAD4 COMPLEXED WITH YAP PEPTIDE AND MYRISTATE (COVALENTLY BOUND)
6Q36	;	2.01	;	TEAD4(216-434) complexed with optimized peptide 9 and myristoate (covalently bound) at 2.01A resolution: Structure-based design of potent linear peptide inhibitors of the YAP-TEAD protein-protein interaction derived from the YAP omega-loop sequence
5NO6	;	2.88	;	TEAD4-HOXB13 complex bound to DNA
6B3O	;	4.1	;	Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion
3MG9	;	2.27	;	Teg 12 Binary Structure Complexed with the Teicoplanin Aglycone
3MGB	;	2.04	;	Teg 12 Ternary Structure Complexed with PAP and the Teicoplanin Aglycone
3MGC	;	2.91	;	Teg12 Apo
3NIB	;	2.7	;	Teg14 Apo
8EN9	;	2.6	;	TehA native-SAD structure determined at 5 keV with a helium environment
6JXC	;	4.1	;	Tel1 kinase butterfly symmetric dimer
6JXA	;	4.3	;	Tel1 kinase compact monomer
3O4Z	;	3.1	;	Tel2 structure and function in the Hsp90-dependent maturation of mTOR and ATR complexes
6XT7	;	1.56	;	Tel25 Hybrid Four-quartet G-quadruplex with K+
6W9P	;	1.99	;	Tel26 Parallel Four-quartet G-quadruplex with K+
3K18	;	1.5	;	Tellurium modified DNA-8mer
6USQ	;	3.62	;	Telomerase Reverse Transcriptase binary complex with Y256A mutation, TERT:DNA
6USO	;	2.54	;	Telomerase Reverse Transcriptase prenucleotide binary complex, TERT:DNA
6USP	;	3.56	;	Telomerase Reverse Transcriptase product complex, TERT:DNA
6USR	;	2.93	;	Telomerase Reverse Transcriptase ternary complex, TERT:DNA:dGpCpp
7V96	;	3.92	;	Telomeric Dinucleosome
7V9C	;	4.5	;	Telomeric Dinucleosome in open state
7V90	;	3.5	;	Telomeric mononucleosome
7V9K	;	8.1	;	Telomeric tetranucleosome
7VA4	;	14.0	;	Telomeric tetranucleosome in open state
7V9J	;	8.0	;	Telomeric trinucleosome
7V9S	;	11.0	;	Telomeric trinucleosome in open state
7U6Q	;	1.9	;	TEM-1 beta-lactamase
8DDZ	;	1.45	;	TEM-1 beta-lactamase A237Y
8DE1	;	1.56	;	TEM-1 beta-lactamase A237Y mutant covalently bound to avibactam
8DE2	;	2.45	;	TEM-1 beta-lactamase A237Y mutant covalently bound to avibactam, a room temperature structure
8DE0	;	1.72	;	TEM-1 beta-lactamase covalently bound to avibactam
1AXB	;	2.0	;	TEM-1 BETA-LACTAMASE FROM ESCHERICHIA COLI INHIBITED WITH AN ACYLATION TRANSITION STATE ANALOG
1PZO	;	1.9	;	TEM-1 Beta-Lactamase in Complex with a Novel, Core-Disrupting, Allosteric Inhibitor
1PZP	;	1.45	;	TEM-1 Beta-Lactamase in Complex with a Novel, Core-Disrupting, Allosteric Inhibitor
3CMZ	;	1.92	;	TEM-1 Class-A beta-lactamase L201P mutant apo structure
1ZG4	;	1.55	;	TEM1 beta lactamase
1ZG6	;	2.1	;	TEM1 beta lactamase mutant S70G
5JX0	;	2.4	;	Temperature sensitive D4 mutant L110F
8G54	;		;	Temperature-dependent structures of tau aggregates
8G55	;		;	Temperature-dependent structures of tau aggregates
7BZA	;		;	Template lasso peptide C24
7BZ7	;		;	Template lasso peptide C24 mutant F15Y
7BZ9	;		;	Template lasso peptide C24 mutant I4A
7BZ8	;		;	Template lasso peptide C24 mutant V3A
6M19	;		;	Template lasso peptide C24 mutant W14F
5J9V	;	1.16	;	Ten minutes iron loaded Rana Catesbeiana H' ferritin variant E57A/E136A/D140A
2GM8	;	2.5	;	TenA Homolog/Thi-4 Thiaminase complexed with product 4-amino-5-hydroxymethyl-2-methylpyrimidine
2GM7	;	2.8	;	TenA Homolog/Thi-4 Thiaminase from Pyrobaculum Aerophilum
1UDD	;	2.15	;	TenA homologue protein from P.horikoshii OT3
1VIW	;	3.0	;	TENEBRIO MOLITOR ALPHA-AMYLASE-INHIBITOR COMPLEX
6SKA	;	3.86	;	Teneurin 2 in complex with Latrophilin 1 Lec-Olf domains
6SKE	;	3.62	;	Teneurin 2 in complex with Latrophilin 2 Lec domain
6FB3	;	2.38	;	Teneurin 2 Partial Extracellular Domain
6FAY	;	3.8	;	Teneurin3 monomer
4B8D	;	4.79	;	TENSEGRITY TRIANGLE FROM ENZYMATICALLY MANUFACTURED DNA
7QID	;	5.0	;	tentative model of the human insulin receptor ectodomain bound by three insulin
5WFB	;	1.382	;	Tepsin tENTH domain 1-136.
5WF9	;	1.8	;	Tepsin tENTH domain 1-153
5WF2	;	1.851	;	Tepsin VHS/ENTH-like Native
5WF1	;	1.954	;	Tepsin VHS/ENTHlike domain SeMet
6SUX	;	1.16	;	Terahertz irradiated structure of bovine trypsin (even frames of crystal x37)
6SV8	;	1.15	;	Terahertz irradiated structure of bovine trypsin (odd frames of crystal x38)
6SVB	;	1.15	;	Terahertz irradiated structure of bovine trypsin (odd frames of crystal x40)
6SVG	;	1.16	;	Terahertz irradiated structure of bovine trypsin (odd frames of crystal x41)
6SVJ	;	1.16	;	Terahertz irradiated structure of bovine trypsin (odd frames of crystal x42)
5KT4	;	2.78	;	Teranry complex of human DNA polymerase iota R96G inserting dCMPNPP opposite template G in the presence of Mg2+
5KT5	;	2.798	;	Teranry complex of human DNA polymerase iota R96G inserting dCMPNPP opposite template G in the presence of Mn2+
5KT6	;	3.54	;	Teranry complex of human DNA polymerase iota(1-445) inserting dCMPNPP opposite template G in the presence of Mg2+
5KT7	;	3.151	;	Teranry complex of human DNA polymerase iota(1-445) inserting dCMPNPP opposite template G in the presence of Mn2+
5KT2	;	2.488	;	Teranry complex of human DNA polymerase iota(26-445) inserting dCMPNPP opposite template G in the presence of Mg2+
5KT3	;	2.64	;	Teranry complex of human DNA polymerase iota(26-445) inserting dCMPNPP opposite template G in the presence of Mn2+
2V15	;	2.1	;	Terbium binding in Streptococcus suis Dpr protein
6ZV9	;	1.85	;	Terbium(III)-bound de novo TIM barrel-ferredoxin fold fusion dimer with 4-glutamate binding site and tryptophan antenna (TFD-EE N6W)
1WKO	;	1.8	;	Terminal flower 1 (tfl1) from arabidopsis thaliana
3GCF	;	2.3	;	Terminal oxygenase of carbazole 1,9a-dioxygenase from Nocardioides aromaticivorans IC177
3GKQ	;	2.1	;	Terminal oxygenase of carbazole 1,9a-dioxygenase from Novosphingobium sp. KA1
2Q0D	;	2.0	;	Terminal uridylyl transferase 4 from Trypanosoma brucei with bound ATP
2Q0C	;	2.2	;	Terminal uridylyl transferase 4 from Trypanosoma brucei with bound CTP
2NOM	;	2.4	;	Terminal uridylyl transferase 4 from Trypanosoma brucei with bound dUTP
2Q0E	;	2.1	;	Terminal uridylyl transferase 4 from Trypanosoma brucei with bound GTP
2Q0G	;	2.3	;	Terminal uridylyl transferase 4 from Trypanosoma brucei with bound UPU
2IKF	;	2.0	;	Terminal uridylyl transferase 4 from Trypanosoma brucei with bound UTP
2Q0F	;	2.4	;	Terminal uridylyl transferase 4 from Trypanosoma brucei with bound UTP and UMP
5KAL	;	2.75	;	Terminal uridylyl transferase 4 from Trypanosoma brucei with bound UTP and UpU
8SCB	;	2.5	;	Terminating ribosome with SRI-41315
2WDF	;	2.08	;	Termus thermophilus Sulfate thiohydrolase SoxB
2WDC	;	1.5	;	Termus thermophilus Sulfate thiohydrolase SoxB in complex with glycerol
2WDD	;	1.5	;	Termus thermophilus Sulfate thiohydrolase SoxB in complex with Sulfate
2WDE	;	1.85	;	Termus thermophilus Sulfate thiohydrolase SoxB in complex with thiosulfate
6MB9	;	2.5	;	Ternary (neomycin/CoA) structure of AAC-IIIb
1SL0	;	3.2	;	Ternary 3' complex of T7 DNA polymerase with a DNA primer/template containing a disordered cis-syn thymine dimer on the template and an incoming nucleotide
1SL2	;	2.3	;	Ternary 5' complex of T7 DNA polymerase with a DNA primer/template containing a cis-syn thymine dimer on the template and an incoming nucleotide
3ZKX	;	2.37	;	TERNARY BACE2 XAPERONE COMPLEX
4TR9	;	2.111	;	Ternary co-crystal structure of fructose-bisphosphate aldolase from Plasmodium falciparum in complex with TRAP and a small molecule inhibitor
7JW9	;	2.39	;	Ternary cocrystal structure of alkanesulfonate monooxygenase MsuD from Pseudomonas fluorescens
4V1D	;	3.1	;	Ternary complex among two human derived single chain antibody fragments and Cn2 toxin from scorpion Centruroides noxius.
4LRR	;	2.41	;	Ternary complex between E. coli thymidylate synthase, dUMP, and F9
4N0U	;	3.8	;	Ternary complex between Neonatal Fc receptor, serum albumin and Fc
1G9H	;	1.8	;	TERNARY COMPLEX BETWEEN PSYCHROPHILIC ALPHA-AMYLASE, COMII (PSEUDO TRI-SACCHARIDE FROM BAYER) AND TRIS (2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL)
1O94	;	2.0	;	Ternary complex between trimethylamine dehydrogenase and electron transferring flavoprotein
1O95	;	3.7	;	Ternary complex between trimethylamine dehydrogenase and electron transferring flavoprotein
8BDS	;	1.72	;	Ternary complex between VCB, BRD4-BD1 and PROTAC 48
8BEB	;	3.18	;	Ternary complex between VCB, BRD4-BD1 and PROTAC 49
8BDX	;	2.93	;	Ternary complex between VCB, BRD4-BD2 and PROTAC 48
8BDT	;	2.7	;	Ternary complex between VCB, BRD4-BD2 and PROTAC 51
6ZH9	;	3.31	;	Ternary complex CR3022 H11-H4 and RBD (SARS-CoV-2)
6A9A	;	1.9	;	Ternary complex crystal structure of dCH with dCMP and THF
6NKV	;	1.85	;	Ternary complex crystal structure of DNA polymerase Beta with ""hot-spot sequence"" with beta-gamma CHF analogue of dGTP
6NKW	;	1.98	;	Ternary complex crystal structure of DNA polymerase Beta with ""hot-spot sequence"" with beta-gamma-methylene dGTP
6NKU	;	1.9	;	Ternary complex crystal structure of DNA polymerase Beta with ""hot-spot sequence"" with dGTP
4RT3	;	1.92	;	Ternary complex crystal structure of DNA polymerase Beta with (alpha, beta)-NH-(beta,gamma)-CH2-dTTP
4RT2	;	1.92	;	Ternary complex crystal structure of DNA polymerase Beta with (alpha,beta)-CH2-(beta,gamma)-NH-dTTP
6PH6	;	2.6	;	Ternary complex crystal structure of DNA polymerase Beta with 2nt-gap with dCTP bound downstream
6N2S	;	2.457	;	Ternary complex crystal structure of DNA polymerase Beta with 5-carboxy-dC (5-caC) at the templating position
6N2T	;	2.6	;	Ternary complex crystal structure of DNA polymerase Beta with 5-hydroxymethyl-dC (5-hmC) at the templating position
6CR3	;	1.95	;	Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CBr2, beta, gamma dATP analogue
6CTX	;	2.02	;	Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CBr2, beta, gamma dCTP analogue
6CRC	;	2.3	;	Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CCL2, beta, gamma dATP analogue
6CTW	;	1.981	;	Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CCL2, beta, gamma dCTP analogue
6CTI	;	2.001	;	Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CCL2, beta, gamma dTTP analogue
6CRB	;	2.151	;	Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CF2, beta, gamma dATP analogue
6CTV	;	2.02	;	Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CF2, beta, gamma dCTP analogue
6CTO	;	2.04	;	Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CF2, beta, gamma dTTP analogue
6CR9	;	1.96	;	Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CFCL, beta, gamma dATP analogue
6CTU	;	1.9	;	Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CFCL, beta, gamma dCTP analogue
6CTN	;	1.92	;	Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CFCL,beta-gamma dTTP analogue
6CR6	;	2.097	;	Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CH-CH3, beta, gamma dATP analogue
6CTP	;	2.2	;	Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CH2, beta, gamma dTTP analogue
6CR5	;	1.982	;	Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CH2-beta, gamma dATP analogue
6CTJ	;	2.1	;	Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CHCH3, beta, gamma dTTP analogue
6CR8	;	2.05	;	Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CHCL (R & S isomers), beta, gamma dATP analogue
6CTT	;	2.0	;	Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CHCL (R &amp; S isomers, beta, gamma dCTP analogue
6G2Q	;	2.148	;	Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CHCL (S-isomer), beta, gamma dTTP analogue
6CTM	;	2.101	;	Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CHCL(R-isomer), beta, gamma dTTP analogue
6CTL	;	2.0	;	Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CHCL-R/S isomers, beta, gamma dTTP analogue
6CTR	;	1.85	;	Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CHF (R & S isomers), beta, gamma dCTP analogue
6CR7	;	2.29	;	Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CHF, beta, gamma dATP analogue
6CTK	;	2.153	;	Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CHF-R/S isomers, beta, gamma dTTP analogue
6CR4	;	1.8	;	Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with dATP
6CTQ	;	1.87	;	Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with dCTP
5J29	;	2.2	;	Ternary complex crystal structure of DNA polymerase Beta with A:A mismatch at the primer terminus
5J2A	;	2.5	;	Ternary complex crystal structure of DNA polymerase Beta with A:C mismatch at the primer terminus
5J2B	;	2.5	;	Ternary complex crystal structure of DNA polymerase Beta with A:C mismatch at the primer terminus
5J2C	;	2.1	;	Ternary complex crystal structure of DNA polymerase Beta with C:A mismatch at the primer terminus
5J2D	;	2.1	;	Ternary complex crystal structure of DNA polymerase Beta with C:C mismatch at the primer terminus
5J2E	;	2.1	;	Ternary complex crystal structure of DNA polymerase Beta with C:T mismatch at the primer terminus
5J2F	;	2.1	;	Ternary complex crystal structure of DNA polymerase Beta with G:A mismatch at the primer terminus
5J2G	;	2.1	;	Ternary complex crystal structure of DNA polymerase Beta with G:G mismatch at the primer terminus
5J2H	;	2.3	;	Ternary complex crystal structure of DNA polymerase Beta with G:T mismatch at the primer terminus
6BEL	;	1.898	;	Ternary complex crystal structure of DNA polymerase Beta with R-isomer of beta-gamma-CHF-dCTP
6BEM	;	1.88	;	Ternary complex crystal structure of DNA polymerase Beta with S-isomer of beta-gamma-CHCL-dCTP
5J2I	;	2.4	;	Ternary complex crystal structure of DNA polymerase Beta with T:C mismatch at the primer terminus
5J2J	;	2.2	;	Ternary complex crystal structure of DNA polymerase Beta with T:G mismatch at the primer terminus
5J2K	;	2.1	;	Ternary complex crystal structure of DNA polymerase Beta with T:T mismatch at the primer terminus
3RJJ	;	2.0	;	Ternary complex crystal structure of DNA Polymerase Beta with template 8odG provides insight into mutagenic lesion bypass
4R66	;	2.25	;	Ternary complex crystal structure of E295K mutant of DNA polymerase Beta
6NL0	;	1.97	;	Ternary complex crystal structure of K289M variant of DNA polymerase Beta with ""hot-spot sequence"" with beta-gamma CF2 analogue of dGTP
6NKY	;	2.094	;	Ternary complex crystal structure of K289M variant of DNA polymerase Beta with ""hot-spot sequence"" with beta-gamma CHF analogue of dGTP
6NKZ	;	2.01	;	Ternary complex crystal structure of K289M variant of DNA polymerase Beta with ""hot-spot sequence"" with beta-gamma methylene dGTP
6NKX	;	1.98	;	Ternary complex crystal structure of K289M variant of DNA polymerase Beta with ""hot-spot sequence"" with dGTP
6NKS	;	2.349	;	Ternary complex crystal structure of K289M variant of DNA polymerase Beta with beta-gamma CHF analog of dGTP
6NKT	;	2.6	;	Ternary complex crystal structure of K289M variant of DNA polymerase Beta with beta-gamma difluoro analogue of dGTP
6NKR	;	2.45	;	Ternary complex crystal structure of K289M variant of DNA polymerase Beta with dGTP
4R65	;	1.95	;	Ternary complex crystal structure of R258A mutant of DNA polymerase Beta
7UUT	;	1.89	;	Ternary complex crystal structure of secondary alcohol dehydrogenases from the Thermoanaerobacter ethanolicus mutants C295A and I86A provides better understanding of catalytic mechanism
6Y3W	;	1.34	;	Ternary complex of 14-3-3 sigma (C38N), Estrogen Related Receptor gamma (DBD) phosphopeptide, and disulfide PPI stabilizer 1
6Y18	;	1.3	;	Ternary complex of 14-3-3 sigma (C38N), Estrogen Related Receptor gamma (DBD) phosphopeptide, and disulfide PPI stabilizer 3
6XXC	;	1.3	;	Ternary complex of 14-3-3 sigma (C38N), Estrogen Related Receptor gamma (DBD) phosphopeptide, and disulfide PPI stabilizer 4
6XY5	;	1.3	;	Ternary complex of 14-3-3 sigma (C38N), Estrogen Related Receptor gamma (DBD) phosphopeptide, and disulfide PPI stabilizer 5
7OQG	;	1.5	;	Ternary complex of 14-3-3 sigma, Amot-p130 phosphopeptide, and WQ136
7OQJ	;	1.4	;	Ternary complex of 14-3-3 sigma, Amot-p130 phosphopeptide, and WQ162
7OQS	;	1.34	;	Ternary complex of 14-3-3 sigma, Amot-p130 phosphopeptide, and WQ177
7OQW	;	1.9	;	Ternary complex of 14-3-3 sigma, Amot-p130 phosphopeptide, and WQ178
7OQU	;	1.4	;	Ternary complex of 14-3-3 sigma, Amot-p130 phosphopeptide, and WQ180
7OPW	;	1.81	;	Ternary complex of 14-3-3 sigma, Estrogen Receptor alfa phosphopeptide, and WQ136
7OQ7	;	1.6	;	Ternary complex of 14-3-3 sigma, Estrogen Receptor alfa phosphopeptide, and WQ162
7OQ8	;	1.43	;	Ternary complex of 14-3-3 sigma, Estrogen Receptor alfa phosphopeptide, and WQ178
7OR3	;	1.8	;	Ternary complex of 14-3-3 sigma, NotchpS1917 phosphopeptide, and WQ136
7OR5	;	1.8	;	Ternary complex of 14-3-3 sigma, NotchpS1917 phosphopeptide, and WQ162
7OR7	;	1.8	;	Ternary complex of 14-3-3 sigma, NotchpS1917 phosphopeptide, and WQ178
7OR8	;	1.8	;	Ternary complex of 14-3-3 sigma, p27pT198 phosphopeptide, and WQ136
7ORS	;	1.8	;	Ternary complex of 14-3-3 sigma, p27pT198 phosphopeptide, and WQ147
7ORG	;	1.8	;	Ternary complex of 14-3-3 sigma, p27pT198 phosphopeptide, and WQ162
7ORT	;	2.33	;	Ternary complex of 14-3-3 sigma, p27pT198 phosphopeptide, and WQ176
7ORH	;	1.8	;	Ternary complex of 14-3-3 sigma, p27pT198 phosphopeptide, and WQ178
7OQ9	;	1.8	;	Ternary complex of 14-3-3 sigma, Pin1pS72 phosphopeptide, and WQ136
7OQA	;	1.8	;	Ternary complex of 14-3-3 sigma, Pin1pS72 phosphopeptide, and WQ162
8ADM	;	1.7	;	Ternary complex of 14-3-3 sigma, Usp8pS718 phosphopeptide and small molecule stabilizer
1OJ4	;	2.01	;	Ternary complex of 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase
1DY3	;	2.0	;	Ternary complex of 7,8-dihydro-6-hydroxymethylpterinpyrophosphokinase from Escherichia coli with ATP and a substrate analogue.
5OMQ	;	2.199	;	Ternary complex of 9N DNA polymerase in the replicative state with three metal ions in the active site
5OMV	;	2.003	;	Ternary complex of 9N DNA polymerase in the replicative state with two metal ions in the active site
1TCO	;	2.5	;	TERNARY COMPLEX OF A CALCINEURIN A FRAGMENT, CALCINEURIN B, FKBP12 AND THE IMMUNOSUPPRESSANT DRUG FK506 (TACROLIMUS)
3MGI	;	2.603	;	Ternary complex of a DNA polymerase lambda loop mutant
6NAS	;	2.9	;	Ternary Complex of Ac-Alpha-Actin with Profilin and AcCoA-NAA80
6NBE	;	2.0	;	Ternary Complex of Ac-Alpha-Actin with Profilin and CoA-NAA80
3PW0	;	2.91	;	Ternary complex of Aflatoxin B1 Adduct modified DNA (AFB1-FAPY) with DNA Polymerase IV and incoming dATP
3PW2	;	2.74	;	Ternary complex of Aflatoxin B1 Adduct modified DNA (AFB1-FAPY) with DNA Polymerase IV and incoming dTTP
3PW4	;	2.9	;	Ternary complex of Aflatoxin B1 Adduct modified DNA (AFB1-N7-Gua) with DNA Polymerase IV and incoming dATP
3PW7	;	2.9	;	Ternary complex of Aflatoxin B1 Adduct modified DNA (AFB1-N7-Gua) with DNA Polymerase IV and incoming dCTP
3PW5	;	3.0	;	Ternary complex of Aflatoxin B1 Adduct modified DNA (AFB1-N7-Gua) with DNA Polymerase IV and incoming dTTP
1A71	;	2.0	;	TERNARY COMPLEX OF AN ACTIVE SITE DOUBLE MUTANT OF HORSE LIVER ALCOHOL DEHYDROGENASE, PHE93=>TRP, VAL203=>ALA WITH NAD AND TRIFLUOROETHANOL
1JU5	;		;	Ternary complex of an Crk SH2 domain, Crk-derived phophopeptide, and Abl SH3 domain by NMR spectroscopy
1QI1	;	3.0	;	Ternary Complex of an NADP Dependent Aldehyde Dehydrogenase
2ANM	;	2.4	;	Ternary complex of an orally active thrombin inhibitor with human thrombin and a c-terminal hirudin derived exo-sit inhibitor
2M2W	;		;	Ternary complex of ASFV Pol X with DNA and MgdGTP
4DQQ	;	1.595	;	Ternary complex of Bacillus DNA Polymerase I Large Fragment E658A, DNA duplex, and rCTP (paired with dG of template) in presence of Mg2+
4DQR	;	1.95	;	Ternary complex of Bacillus DNA Polymerase I Large Fragment E658A, DNA duplex, and rCTP (paired with dG of template) in presence of Mn2+
4DSE	;	1.67	;	Ternary complex of Bacillus DNA Polymerase I Large Fragment F710Y, DNA duplex, and rCTP (paired with dG of template) in presence of Mg2+
4DSF	;	1.661	;	Ternary complex of Bacillus DNA Polymerase I Large Fragment F710Y, DNA duplex, and rCTP (paired with dG of template) in presence of Mn2+
4DQI	;	1.69	;	Ternary complex of Bacillus DNA Polymerase I Large Fragment, DNA duplex, and dCTP (paired with dG of template)
4DQP	;	1.74	;	Ternary complex of Bacillus DNA Polymerase I Large Fragment, DNA duplex, and ddCTP (paired with dG of template)
4DS5	;	1.68	;	Ternary complex of Bacillus DNA Polymerase I Large Fragment, DNA duplex, and rCTP in presence of Mg2+
4DS4	;	1.681	;	Ternary complex of Bacillus DNA Polymerase I Large Fragment, DNA duplex, and rCTP in presence of Mn2+
6NBW	;	2.5	;	Ternary Complex of Beta/Gamma-Actin with Profilin and AnCoA-NAA80
4O3M	;	2.3	;	Ternary complex of Bloom's syndrome helicase
2GOO	;	2.2	;	Ternary Complex of BMP-2 bound to BMPR-Ia-ECD and ActRII-ECD
2DSA	;	2.1	;	Ternary complex of BphK, a bacterial GST
6ZBI	;		;	Ternary complex of Calmodulin bound to 2 molecules of NHE1
8FOW	;	1.6	;	Ternary complex of CDK2 with small molecule ligands TW8672 and Dinaciclib
8FP0	;	1.6	;	Ternary complex of CDK2 with small molecule ligands TW8672 and Roscovitine
4JWN	;	2.39	;	Ternary complex of D256A mutant of DNA Polymerase Beta
4JWM	;	2.0	;	Ternary complex of D256E mutant of DNA Polymerase Beta
3C2L	;	2.6	;	Ternary complex of DNA POLYMERASE BETA with a C:DAPCPP mismatch in the active site
3JPN	;	2.15	;	Ternary complex of DNA polymerase beta with a dideoxy terminated primer and 2'-deoxyguanosine 5'-beta, gamma-dichloro methylene triphosphate
2ISO	;	2.1	;	Ternary complex of DNA Polymerase beta with a dideoxy terminated primer and 2'-deoxyguanosine 5'-beta, gamma-difluoromethylene triphosphate
3JPR	;	2.1	;	Ternary complex of DNA polymerase beta with a dideoxy terminated primer and 2'-deoxyguanosine 5'-beta, gamma-dimethyl methylene triphosphate
3JPT	;	2.15	;	Ternary complex of DNA polymerase beta with a dideoxy terminated primer and 2'-deoxyguanosine 5'-beta, gamma-fluoro chloro methylene triphosphate
3JPS	;	2.0	;	Ternary complex of DNA polymerase beta with a dideoxy terminated primer and 2'-deoxyguanosine 5'-beta, gamma-fluoro methyl methylene triphosphate
2ISP	;	2.2	;	Ternary complex of DNA Polymerase beta with a dideoxy terminated primer and 2'-deoxyguanosine 5'-beta, gamma-methylene triphosphate
3JPQ	;	1.9	;	Ternary complex of DNA polymerase beta with a dideoxy terminated primer and 2'-deoxyguanosine 5'-beta, gamma-monoBromo methylene triphosphate
3JPO	;	2.0	;	Ternary complex of DNA polymerase beta with a dideoxy terminated primer and 2'-deoxyguanosine 5'-beta, gamma-monochloromethylene triphosphate
4DOB	;	2.05	;	Ternary complex of DNA polymerase beta with a dideoxy terminated primer and 2'-deoxyguanosine 5'-beta, gamma-monochlororomethylene triphosphate: Stereoselective binding of R-isomer
4DOC	;	1.949	;	Ternary complex of dna polymerase beta with a dideoxy terminated primer and 2'-deoxyguanosine 5'-beta, gamma-monochlororomethylene triphosphate:binding of S-isomer
2PXI	;	2.1	;	Ternary complex of DNA polymerase beta with a dideoxy terminated primer and 2'-deoxyguanosine 5'-beta, gamma-monofluoromethylene triphosphate
4DOA	;	2.051	;	Ternary complex of dna polymerase beta with a dideoxy terminated primer and 2'-deoxyguanosine 5'-beta, gamma-monofluoromethylene triphosphate: non-interactive binding of s-isomer
4DO9	;	2.05	;	Ternary complex of dna polymerase beta with a dideoxy terminated primer and 2'-deoxyguanosine 5'-beta, gamma-monofluoromethylene triphosphate: stereoselective binding of r-isomer
3JPP	;	2.1	;	Ternary complex of DNA polymerase beta with a dideoxy terminated primer and 2'-deoxyguanosine 5'-beta, gamma-MonoMethyl Methylene triphosphate
3C2M	;	2.15	;	Ternary complex of DNA POLYMERASE BETA with a G:dAPCPP mismatch in the active site
3RJF	;	2.3	;	Ternary complex of DNA Polymerase Beta with a gapped DNA containing (syn)8odG at template position paired with non-hydrolyzable dATP analog (dApCPP)
3RJH	;	2.2	;	Ternary complex of DNA Polymerase Beta with a gapped DNA containing (syn)8odG:dA at primer terminus and dG:dCMP(CF2)PPin the active site
3RJE	;	2.1	;	Ternary complex of DNA Polymerase Beta with a gapped DNA containing 8odG at template position
3RJI	;	2.3	;	Ternary complex of DNA Polymerase Beta with a gapped DNA containing 8odG at template position paired with non-hydrolyzable dCTP analog (dCMP(CF2)PP)
3RJK	;	2.1	;	Ternary complex of DNA Polymerase Beta with a gapped DNA containing 8odG:dC base pair at primer terminus and dG:dCMP(CF2)PP in the active site
3MBY	;	2.0	;	Ternary complex of DNA Polymerase BETA with template base A and 8oxodGTP in the active site with a dideoxy terminated primer
7S9Q	;	1.9	;	Ternary complex of DNA Polymerase Beta with Template Fapy-dG and an incoming dATP analog
7S9P	;	1.86	;	Ternary complex of DNA Polymerase Beta with Template Fapy-dG and an incoming dCTP analog
3IAY	;	2.0	;	Ternary complex of DNA polymerase delta
4M8O	;	2.2	;	TERNARY COMPLEX OF DNA POLYMERASE EPSILON WITH AN INCOMING dATP
3G6X	;	2.08	;	Ternary complex of DNA Polymerase iota:DNA:dGTP with an abasic site at the templating position
3G6Y	;	2.1	;	Ternary complex of DNA Polymerase iota:DNA:dTTP with an abasic site at the templating position
3HWT	;	1.95	;	Ternary complex of DNA polymerase lambda bound to a two nucleotide gapped DNA substrate with a scrunched dA
3HW8	;	1.95	;	ternary complex of DNA polymerase lambda of a two nucleotide gapped DNA substrate with a C in the scrunch site
7COC	;	1.9	;	Ternary complex of DNA polymerase Mu (K438A/Q441A) with 1-nt gapped DNA (T:dGMPNPP)
7COB	;	1.797	;	Ternary complex of DNA polymerase Mu (Q441A) with 1-nt gapped DNA (T:dGMPNPP)
7CO9	;	1.599	;	Ternary complex of DNA polymerase Mu with 1-nt gapped DNA (T:dGMPNPP) and Mg
7COA	;	1.698	;	Ternary complex of DNA polymerase Mu with 1-nt gapped DNA (T:dGMPNPP) and Mn
7CO8	;	1.697	;	Ternary complex of DNA polymerase Mu with 2-nt gapped DNA (T:dGMPNPP)
2W9A	;	2.6	;	Ternary complex of Dpo4 bound to N2,N2-dimethyl-deoxyguanosine modified DNA with incoming dGTP
2W9C	;	2.9	;	Ternary complex of Dpo4 bound to N2,N2-dimethyl-deoxyguanosine modified DNA with incoming dTTP
3ZJU	;	2.4	;	Ternary complex of E .coli leucyl-tRNA synthetase, tRNA(Leu) and the benzoxaborole AN3016 in the editing conformation
3ZJV	;	2.31	;	Ternary complex of E .coli leucyl-tRNA synthetase, tRNA(Leu) and the benzoxaborole AN3213 in the editing conformation
4ARC	;	2.0	;	Ternary complex of E. coli leucyl-tRNA synthetase, tRNA(leu) and leucine in the editing conformation
4AQ7	;	2.5	;	Ternary complex of E. coli leucyl-tRNA synthetase, tRNA(leu) and leucyl-adenylate analogue in the aminoacylation conformation
4ARI	;	2.08	;	Ternary complex of E. coli leucyl-tRNA synthetase, tRNA(leu) and the benzoxaborole AN2679 in the editing conformation
4AS1	;	2.02	;	Ternary complex of E. coli leucyl-tRNA synthetase, tRNA(leu) and the benzoxaborole AN2679 in the editing conformation
3ZGZ	;	2.4	;	Ternary complex of E. coli leucyl-tRNA synthetase, tRNA(leu) and toxic moiety from agrocin 84 (TM84) in aminoacylation-like conformation
3ZJT	;	2.2	;	Ternary complex of E.coli leucyl-tRNA synthetase, tRNA(Leu)574 and the benzoxaborole AN3017 in the editing conformation
6HHP	;	1.802	;	Ternary complex of Estrogen Receptor alpha peptide and 14-3-3 sigma C42 mutant bound to disulfide fragment PPI stabilizer 1
6HMT	;	1.1	;	Ternary complex of Estrogen Receptor alpha peptide and 14-3-3 sigma C42 mutant bound to disulfide fragment PPI stabilizer 2
6HKB	;	1.7	;	Ternary complex of Estrogen Receptor alpha peptide and 14-3-3 sigma C42 mutant bound to disulfide fragment PPI stabilizer 3
6HKF	;	1.801	;	Ternary complex of Estrogen Receptor alpha peptide and 14-3-3 sigma C42 mutant bound to disulfide fragment PPI stabilizer 4
6HN2	;	1.7	;	Ternary complex of Estrogen Receptor alpha peptide and 14-3-3 sigma C42 mutant bound to disulfide fragment PPI stabilizer 5
6HMU	;	1.2	;	Ternary complex of Estrogen Receptor alpha peptide and 14-3-3 sigma C45 mutant bound to disulfide fragment PPI stabilizer 6
6QIP	;	2.45	;	Ternary complex of FcRn ectodomain, FcRn binding optimised human serum albumin and the albumin-biniding side chain of the human growth hormone derivative somapacitan
6QIO	;	1.95	;	Ternary complex of FcRn ectodomain, FcRn binding optimised human serum albumin and the human growth hormone derivative somapacitan
7SCD	;	2.9	;	Ternary complex of fixed-arm Trx-3ost5 (I299E) with 8mer-1 octasaccharide substrate and co-factor product PAP
7SCE	;	2.75	;	Ternary complex of fixed-arm Trx-3ost5 (I299E) with 8mer-2 octasaccharide substrate and co-factor product PAP
4JUZ	;	2.65	;	Ternary complex of gamma-OHPDG adduct modified dna (zero primer) with dna polymerase iv and incoming dgtp
4JV2	;	2.74	;	Ternary complex of gamma-OHPDG adduct modified dna with dna (-1 primer) polymerase iv and incoming datp
4JV1	;	2.3	;	Ternary complex of gamma-OHPDG adduct modified dna with dna (-1 primer) polymerase iv and incoming dgtp
5ERU	;	1.6	;	Ternary complex of GephE - ADP - Molybdenum cluster
5ERV	;	1.8	;	Ternary complex of GephE - ADP - Tungsten cluster
1WPQ	;	2.5	;	Ternary Complex Of Glycerol 3-phosphate Dehydrogenase 1 with NAD and dihydroxyactone
3T5H	;	2.35	;	Ternary complex of HNE Adduct modified DNA (5'-CXG-3' vs 13-mer) with Dpo4 and incoming dDGT
3T5L	;	2.9	;	Ternary complex of HNE Adduct modified DNA (5'-CXG-3' vs 14-mer) with Dpo4 and incoming dDGT
3T5J	;	2.4	;	Ternary complex of HNE Adduct modified DNA (5'-TXG-3' vs 13-mer) with Dpo4 and incoming dDTP
3T5K	;	2.9	;	Ternary complex of HNE Adduct modified DNA (5'-TXG-3' vs 14-mer) with Dpo4 and incoming dDTP
2ALZ	;	2.5	;	Ternary Complex of hPoli with DNA and dCTP
2DPI	;	2.3	;	Ternary complex of hPoli with DNA and dCTP
5AZT	;	3.45	;	Ternary complex of hPPARalpha ligand binding domain, 17-oxoDHA and a SRC1 peptide
6SF2	;	3.3	;	Ternary complex of human bone morphogenetic protein 9 (BMP9) growth factor domain, its prodomain and extracellular domain of activin receptor-like kinase 1 (ALK1).
1QFW	;	3.5	;	TERNARY COMPLEX OF HUMAN CHORIONIC GONADOTROPIN WITH FV ANTI ALPHA SUBUNIT AND FV ANTI BETA SUBUNIT
5HCC	;	2.59	;	Ternary complex of human Complement C5 with Ornithodoros moubata OmCI and Dermacentor andersoni RaCI3.
5HCE	;	3.12	;	Ternary complex of human Complement C5 with Ornithodoros moubata OmCI and Rhipicephalus appendiculatus RaCI1
5HCD	;	2.98	;	Ternary complex of human Complement C5 with Ornithodoros moubata OmCI and Rhipicephalus microplus RaCI2
2OH2	;	3.05	;	Ternary Complex of Human DNA Polymerase
3ISD	;	2.6	;	Ternary complex of human DNA polymerase beta with an abasic site (THF): DAPCPP mismatch
5EWG	;	1.75	;	Ternary complex of human DNA polymerase eta inserting rATP opposite an 8-Oxodeoxyguanosine Lesion
5EWF	;	1.782	;	Ternary complex of human DNA polymerase eta inserting rCTP opposite an 8-Oxodeoxyguanosine Lesion
5EWE	;	1.66	;	Ternary complex of human DNA polymerase eta inserting rCTP opposite template G
2FLL	;	2.6	;	Ternary complex of human DNA polymerase iota with DNA and dTTP
3H4B	;	2.85	;	Ternary complex of human DNA polymerase iota with template U/T and incoming dATP
3H4D	;	2.2	;	Ternary complex of human DNA polymerase iota with template U/T and incoming dGTP
4YD1	;	1.75	;	Ternary complex of human DNA Polymerase Mu with 2-nt gapped DNA substrate and an incoming nonhydrolyzable dUMPNPP
4X0P	;	3.911	;	Ternary complex of human DNA polymerase theta C-terminal domain binding ddATP opposite a tetrahydrofuran AP site analog
4X0Q	;	3.9	;	Ternary complex of human DNA polymerase theta C-terminal domain binding ddGTP opposite dCMP
1MA0	;	2.3	;	Ternary complex of Human glutathione-dependent formaldehyde dehydrogenase with NAD+ and dodecanoic acid
1MC5	;	2.6	;	Ternary complex of Human glutathione-dependent formaldehyde dehydrogenase with S-(hydroxymethyl)glutathione and NADH
6E90	;	2.05	;	Ternary complex of human glycerol 3-phosphate dehydrogenase
3ID8	;	2.4	;	Ternary complex of human pancreatic glucokinase crystallized with activator, glucose and AMP-PNP
5HQ0	;	2.3	;	Ternary complex of human proteins CDK1, Cyclin B and CKS2, bound to an inhibitor
6A22	;	2.55	;	Ternary complex of Human ROR gamma Ligand Binding Domain With Compound T.
1B3O	;	2.9	;	TERNARY COMPLEX OF HUMAN TYPE-II INOSINE MONOPHOSPHATE DEHYDROGENASE WITH 6-CL-IMP AND SELENAZOLE ADENINE DINUCLEOTIDE
1XKD	;	2.3	;	Ternary complex of Isocitrate dehydrogenase from the hyperthermophile Aeropyrum pernix
3HX0	;	3.0	;	ternary complex of L277A, H511A, R514 mutant pol lambda bound to a 2 nucleotide gapped DNA substrate with a scrunched dA
2VOJ	;	2.6	;	Ternary complex of M. tuberculosis Rv2780 with NAD and pyruvate
3IJJ	;	1.25	;	Ternary Complex of Macrophage Migration Inhibitory Factor (MIF) Bound Both to 4-hydroxyphenylpyruvate and to the Allosteric Inhibitor AV1013 (R-stereoisomer)
1N2D	;	2.0	;	Ternary complex of MLC1P bound to IQ2 and IQ3 of Myo2p, a class V myosin
6O9I	;	2.6	;	Ternary complex of mouse ECD with Fab1 and Fab2
4I2B	;	2.2	;	Ternary complex of mouse TdT with ssDNA and AMPcPP
4I2C	;	2.1	;	Ternary complex of mouse TdT with ssDNA and AMPcPP
4I2E	;	2.0	;	Ternary complex of mouse TdT with ssDNA and AMPcPP
4I2H	;	2.75	;	Ternary complex of mouse TdT with ssDNA and AMPcPP
4I27	;	2.6	;	Ternary complex of mouse TdT with ssDNA and incoming nucleotide
5XFR	;	2.25	;	Ternary complex of MTF2, DNA and histone
7ARZ	;	2.15	;	Ternary complex of NAD-dependent formate dehydrogenase from Physcomitrium patens
4NNC	;	2.279	;	Ternary complex of ObcA with C4-CoA adduct and oxalate
6OGX	;	2.77	;	Ternary complex of OX40R (TNFRSF4) bound to Fab1 and Fab2
6G9Q	;	1.89	;	Ternary complex of P14 TCR with murine MHC class I H-2 Db in complex with self-antigen derived from dopamine monooxygenase.
4TYH	;	3.0	;	Ternary complex of P38 and MK2 with a P38 inhibitor
3NG4	;	1.73	;	Ternary complex of peptidoglycan recognition protein (PGRP-S) with Maltose and N-Acetylglucosamine at 1.7 A Resolution
5XFQ	;	2.4	;	Ternary complex of PHF1, a DNA duplex and a histone peptide
13PK	;	2.5	;	TERNARY COMPLEX OF PHOSPHOGLYCERATE KINASE FROM TRYPANOSOMA BRUCEI
6SA0	;	2.209	;	Ternary complex of Prim-PolC from Mycobacterium smegmatis with 2nt gapped DNA and UpNHpp
1PYT	;	2.35	;	TERNARY COMPLEX OF PROCARBOXYPEPTIDASE A, PROPROTEINASE E, AND CHYMOTRYPSINOGEN C
2PAV	;	1.8	;	Ternary complex of Profilin-Actin with the Last Poly-Pro of Human VASP
2PBD	;	1.501	;	Ternary complex of profilin-actin with the poly-PRO-GAB domain of VASP*
1QAX	;	2.8	;	TERNARY COMPLEX OF PSEUDOMONAS MEVALONII HMG-COA REDUCTASE WITH HMG-COA AND NAD+
1QAY	;	2.8	;	TERNARY COMPLEX OF PSEUDOMONAS MEVALONII HMG-COA REDUCTASE WITH MEVALONATE AND NAD+
4KHQ	;	2.186	;	Ternary complex of RB69 mutant L415F wit DUMPNPP
4KHU	;	2.05	;	Ternary complex of rb69 mutant L415F with a ribonucleotide at -1 position
4KHS	;	2.12	;	Ternary complex of RB69 mutant L415F with a ribonucleotide at 0 position
4KHW	;	2.371	;	Ternary complex of RB69 mutant L415F with ribonucleotide at -2 position
4KHY	;	2.25	;	Ternary complex of rb69 mutant L415F with ribonucleotide at -3 position
4KI6	;	2.55	;	Ternary complex of rb69 mutant l415f with ribonucleotides at -1 and -2 position
4KI4	;	2.45	;	Ternary complex of rb69 mutant L415F with ribonucleotides at 0 and -1 position
7QWQ	;	2.83	;	Ternary complex of ribosome nascent chain with SRP and NAC
5VVR	;	5.8	;	Ternary complex of RNA Pol II, transcription scaffold and Rad26
1E5Q	;	2.1	;	Ternary complex of saccharopine reductase from Magnaporthe grisea, NADPH and saccharopine
1HBX	;	3.15	;	Ternary Complex of SAP-1 and SRF with specific SRE DNA
2F69	;	1.3	;	Ternary complex of SET7/9 bound to AdoHcy and a TAF10 peptide
6Z1A	;	2.3	;	Ternary complex of Staphylococcus aureus DNA gyrase with AMK12 and DNA
2XCP	;	2.6	;	TERNARY COMPLEX OF SULFOLOBUS SOLFATARICUS DPO4 DNA POLYMERASE, 7,8- DIHYDRO-8-OXODEOXYGUANINE MODIFIED DNA AND dCTP - MAGNESIUM FORM
2XCA	;	2.5	;	TERNARY COMPLEX OF SULFOLOBUS SOLFATARICUS DPO4 DNA POLYMERASE, 7,8- DIHYDRO-8-OXODEOXYGUANINE MODIFIED DNA AND dGTP - MAGNESIUM FORM
2J6S	;	2.5	;	Ternary complex of Sulfolobus solfataricus Dpo4 DNA polymerase, O6- methylguanine modified DNA, and dATP.
2J6T	;	2.6	;	Ternary complex of Sulfolobus solfataricus Dpo4 DNA polymerase, O6- methylguanine modified DNA, and dATP.
2J6U	;	2.5	;	Ternary complex of Sulfolobus solfataricus Dpo4 DNA polymerase, O6- methylguanine modified DNA, and dGTP.
8DJH	;	1.77	;	Ternary complex of SUMO1 with a phosphomimetic SIM of PML and zinc
8DJI	;	1.97	;	Ternary complex of SUMO1 with the SIM of PML and zinc
1IXY	;	2.5	;	Ternary complex of T4 phage BGT with UDP and a 13 mer DNA duplex
1M5R	;	1.8	;	Ternary complex of T4 phage BGT with UDP and a 13 mer DNA duplex
7KQN	;	2.02	;	Ternary complex of TERT (telomerase reverse transcriptase) with RNA template, DNA primer, an incoming dGTP and a downstream hybrid duplex
3KFD	;	2.995	;	Ternary complex of TGF-b1 reveals isoform-specific ligand recognition and receptor recruitment in the superfamily
2WG1	;	2.2	;	TERNARY COMPLEX OF THE AGED CONJUGATE OF TORPEDO CALIFORNICA ACEYLCHOLINESTERASE WITH SOMAN AND 2-PAM
2AQ4	;	2.32	;	Ternary complex of the catalytic core of REV1 with DNA and dCTP.
1O4X	;		;	TERNARY COMPLEX OF THE DNA BINDING DOMAINS OF THE OCT1 AND SOX2 TRANSCRIPTION FACTORS WITH A 19MER OLIGONUCLEOTIDE FROM THE HOXB1 REGULATORY ELEMENT
1NFB	;	2.9	;	Ternary complex of the human type II Inosine Monophosphate Dedhydrogenase with 6Cl-IMP and NAD
1NF7	;	2.65	;	Ternary complex of the human type II Inosine Monophosphate Dedhydrogenase with Ribavirin Monophosphate and C2-Mycophenolic Adenine Dinucleotide
7LNT	;	2.35	;	Ternary complex of the Isopentenyl Phosphate Kinase from Candidatus methanomethylophilus alvus bound to benzyl monophosphate and ATP
7LNU	;	2.5	;	Ternary complex of the Isopentenyl Phosphate Kinase from Candidatus methanomethylophilus alvus bound to isopentenyl monophosphate and ATP
3CQ8	;	2.5	;	Ternary complex of the L415F mutant RB69 exo(-)polymerase
2W5Z	;	2.2	;	Ternary Complex of the Mixed Lineage Leukaemia (MLL1) SET Domain with the cofactor product S-Adenosylhomocysteine and histone peptide.
2D1K	;	2.5	;	Ternary complex of the WH2 domain of mim with actin-dnase I
2A3Z	;	2.078	;	Ternary complex of the WH2 domain of WASP with Actin-DNAse I
2A40	;	1.8	;	Ternary complex of the WH2 domain of WAVE with Actin-DNAse I
2A41	;	2.6	;	Ternary complex of the WH2 Domain of WIP with Actin-DNAse I
3W34	;	1.91	;	Ternary complex of Thermus thermophilus HB8 uridine-cytidine kinase with substrates
1CI7	;	2.6	;	TERNARY COMPLEX OF THYMIDYLATE SYNTHASE FROM PNEUMOCYSTIS CARINII
8P2K	;	2.9	;	Ternary complex of translating ribosome, NAC and METAP1
7KHH	;	2.281	;	Ternary complex of VHL/BRD4-BD1/Compound9 (4-(3,5-difluoropyridin-2-yl)-N-(11-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-11-oxoundecyl)-10-methyl-7-((methylsulfonyl)methyl)-11-oxo-3,4,10,11-tetrahydro-1H-1,4,10-triazadibenzo[cd,f]azulene-6-carboxamide)
4TQS	;	2.06	;	Ternary complex of Y-family DNA polymerase Dpo4 with (5'S)-8,5'-Cyclo-2'-deoxyguanosine and dCTP
4TQR	;	1.58	;	Ternary complex of Y-family DNA polymerase Dpo4 with (5'S)-8,5'-Cyclo-2'-deoxyguanosine and dTTP
6W8I	;	3.8	;	Ternary complex structure - BTK cIAP compound 15
6W7O	;	2.17	;	Ternary complex structure - BTK cIAP compound 17
5X8F	;	1.763	;	Ternary complex structure of a double mutant I454RA456K of o-Succinylbenzoate CoA Synthetase (MenE) from Bacillus Subtilis bound with AMP and its product analogue OSB-NCoA at 1.76 angstrom
7U8F	;	3.15	;	Ternary complex structure of Cereblon-DDB1 bound to IKZF2(ZF2) and the molecular glue DKY709
8DEY	;	3.7	;	Ternary complex structure of Cereblon-DDB1 bound to IKZF2(ZF2,3) and the molecular glue DKY709
3TFR	;	2.0	;	Ternary complex structure of DNA polymerase beta with a gapped DNA substrate and a, b dAMP(CF2)PP in the active site
3TFS	;	2.0	;	Ternary complex structure of DNA polymerase beta with a gapped DNA substrate and a, b dAMP(CFH)PP in the active site: Stereoselective binding of (S) isomer
1D6N	;	2.7	;	TERNARY COMPLEX STRUCTURE OF HUMAN HGPRTASE, PRPP, MG2+, AND THE INHIBITOR HPP REVEALS THE INVOLVEMENT OF THE FLEXIBLE LOOP IN SUBSTRATE BINDING
4N5S	;	1.67	;	Ternary complex structure of Klenow fragment of Taq DNA polymerase I707L mutant (Cs3C KlenTaq) with DNA and ddCTP
3I52	;	2.28	;	Ternary complex structure of leucoanthocyanidin reductase from vitis vinifera
6NMM	;	2.5	;	Ternary complex structure of the T130K mutant of ANT-4 with Neomycin, AMPCPP and Pyrophosphate
6NMN	;	1.8	;	Ternary complex structure of the T130K mutant of ANT-4'' with Neomycin and ATP (No Pyrophosphate)
4V69	;	6.7	;	Ternary complex-bound E.coli 70S ribosome.
8HR2	;	1.94	;	Ternary Crystal Complex Structure of RBD with NB1B5 and NB1C6
3PNC	;	2.0	;	Ternary crystal structure of a polymerase lambda variant with a GT mispair at the primer terminus and sodium at catalytic metal site
2GCG	;	2.2	;	Ternary Crystal Structure of Human Glyoxylate Reductase/Hydroxypyruvate Reductase
3PMN	;	2.2	;	ternary crystal structure of polymerase lambda variant with a GT mispair at the primer terminus with Mn2+ in the active site
5DKW	;	2.689	;	Ternary crystal structure of polymerase lambda with a GA mispair at the primer terminus with Ca2+ in the active
5AOV	;	1.4	;	Ternary Crystal Structure of Pyrococcus furiosus Glyoxylate Hydroxypyruvate Reductase in presence of glyoxylate
6C09	;	2.95	;	Ternary crystal structure of the 3C8 TCR-CD1c-monoacylglycerol complex
3VWK	;	2.935	;	Ternary crystal structure of the human NKT TCR-CD1d-4'deoxy-alpha-galactosylceramide complex
3VWJ	;	3.093	;	Ternary crystal structure of the human NKT TCR-CD1d-C20:2 complex
3ARD	;	3.01	;	Ternary crystal structure of the mouse NKT TCR-CD1d-3'deoxy-alpha-galactosylceramide
3ARE	;	2.8	;	Ternary crystal structure of the mouse NKT TCR-CD1d-4'deoxy-alpha-galactosylceramide
3ARG	;	3.0	;	Ternary crystal structure of the mouse NKT TCR-CD1d-alpha-glucosylceramide(C20:2)
3ARF	;	2.9	;	Ternary crystal structure of the mouse NKT TCR-CD1d-C20:2
3ARB	;	2.7	;	Ternary crystal structure of the NKT TCR-CD1d-alpha-galactosylceramide analogue-OCH
4UP0	;	1.28	;	Ternary crystal structure of the Pygo2 PHD finger in complex with the B9L HD1 domain and a H3K4me2 peptide
4PTF	;	2.809	;	Ternary crystal structure of yeast DNA polymerase epsilon with template G
4K4H	;	2.1	;	Ternary crystal structures of a human DNA POLYMERASE LAMBDA IN COMPLEX WITH DNA AND (-)3TC-TP.
4K4I	;	2.25	;	Ternary crystal structures of a human DNA POLYMERASE LAMBDA IN COMPLEX WITH DNA AND (-)FTC-TP.
4QWC	;	2.4	;	Ternary Crystal Structures of a Y-family DNA polymerase DPO4 from Sulfobus Solfataricus in Comples with DNA and L-DCDP
4QWA	;	2.2	;	TERNARY CRYSTAL STRUCTURES OF A Y-FAMILY DNA POLYMERASE DPO4 FROM SULFOLOBUS SOLFATARICUS in COMPLEX WITH DNA AND (-)3TC-DP
4QWD	;	2.05	;	TERNARY CRYSTAL STRUCTURES of A Y-FAMILY DNA POLYMERASE DPO4 FROM SULFOLOBUS SOLFATARICUS IN COMPLEX WITH DNA AND (-)3TC-PPNP
4QWE	;	2.2	;	TERNARY CRYSTAL STRUCTURES of A Y-FAMILY DNA POLYMERASE DPO4 FROM SULFOLOBUS SOLFATARICUS IN COMPLEX WITH DNA AND (-)FTC-DP
4QW9	;	2.4	;	TERNARY CRYSTAL STRUCTURES of A Y-FAMILY DNA POLYMERASE DPO4 FROM SULFOLOBUS SOLFATARICUS IN COMPLEX WITH DNA AND (-)FTC-PPNP
4QW8	;	2.29	;	TERNARY CRYSTAL STRUCTURES of A Y-FAMILY DNA POLYMERASE DPO4 FROM SULFOLOBUS SOLFATARICUS IN COMPLEX WITH DNA AND D-DCTP
4K4G	;	2.15	;	Ternary crystal structures of human DNA POLYMERASE LAMBDA IN COMPLEX WITH DNA AND L-DCTP.
1OS2	;	2.15	;	Ternary enzyme-product-inhibitor complexes of human MMP12
4ONT	;	2.15	;	Ternary host recognition complex of complement factor H, C3d, and sialic acid
1D15	;	1.5	;	TERNARY INTERACTIONS OF SPERMINE WITH DNA: 4'-EPIADRIAMYCIN AND OTHER DNA: ANTHRACYCLINE COMPLEXES
6D8P	;	2.1	;	Ternary RsAgo Complex Containing Guide RNA Paired with Target DNA
6D92	;	1.81	;	Ternary RsAgo Complex with Guide RNA and Target DNA Containing A-A non-canonical pair at position 3
6D9K	;	2.0	;	Ternary RsAgo Complex with Guide RNA and Target DNA Containing A-G Non-canonical Pair
6D9L	;	2.6	;	Ternary RsAgo Complex with Guide RNA and Target DNA Containing G-A Non-canonical Pair
6D95	;	1.85	;	Ternary RsAgo Complex with Guide RNA Paired and Target DNA containing A8-A8' Non-Canonical Pair
7PPC	;	3.6	;	Ternary signalling complex of BMP10 bound to ALK1 and BMPRII
7K14	;	2.75	;	Ternary soak structure of alkanesulfonate monooxygenase MsuD from Pseudomonas fluorescens with FMN and methanesulfonate
8B5P	;	1.4	;	Ternary structure of 14-3-3s, ERRg phosphopeptide and dual-reactive compound 10
8B2I	;	1.4	;	Ternary structure of 14-3-3s, ERRg phosphopeptide and dual-reactive compound 4
8B4Q	;	1.4	;	Ternary structure of 14-3-3s, ERRg phosphopeptide and dual-reactive compound 5
8BJN	;	1.4	;	Ternary structure of 14-3-3s, ERRg phosphopeptide and dual-reactive compound 6
8BM5	;	1.4	;	Ternary structure of 14-3-3s, ERRg phosphopeptide and dual-reactive compound 7
8BJG	;	1.4	;	Ternary structure of 14-3-3s, ERRg phosphopeptide and dual-reactive compound 8
8B2K	;	1.4	;	Ternary structure of 14-3-3s, RND3 phosphopeptide and dual-reactive compound 10
8C42	;	1.4	;	Ternary structure of 14-3-3sigma, PKA-responsive ERa phosphopeptide and Fusicoccin-A
8C43	;	1.4	;	Ternary structure of 14-3-3sigma, strep-tagged PKA-responsive ERa phosphopeptide, and Fusicoccin-A.
2Z6Q	;	2.79	;	Ternary structure of Arg165Ala M.HhaI C5-Cytosine DNA methyltransferase with unmodified DNA and AdoHcy
6E16	;	2.4	;	Ternary structure of c-Myc-TBP-TAF1
6E24	;	3.001	;	Ternary structure of c-Myc-TBP-TAF1
7KLF	;	2.301	;	Ternary structure of Dpo4 bound to G in the template base paired with incoming dCTP
5EDW	;	2.62	;	Ternary structure of Dpo4 bound to G in the template base paired with incoming dTTP
7KLE	;	3.003	;	Ternary structure of Dpo4 bound to N7mG in the template base paired with incoming dCTP
6MAC	;	2.34	;	Ternary structure of GDF11 bound to ActRIIB-ECD and Alk5-ECD
6MHT	;	2.05	;	TERNARY STRUCTURE OF HHAI METHYLTRANSFERASE WITH ADOHCY AND DNA CONTAINING 4'-THIO-2'DEOXYCYTIDINE AT THE TARGET
10MH	;	2.55	;	TERNARY STRUCTURE OF HHAI METHYLTRANSFERASE WITH ADOHCY AND HEMIMETHYLATED DNA CONTAINING 5,6-DIHYDRO-5-AZACYTOSINE AT THE TARGET
5MHT	;	2.7	;	TERNARY STRUCTURE OF HHAI METHYLTRANSFERASE WITH HEMIMETHYLATED DNA AND ADOHCY
4MHT	;	2.7	;	TERNARY STRUCTURE OF HHAI METHYLTRANSFERASE WITH NATIVE DNA AND ADOHCY
3MHT	;	2.7	;	TERNARY STRUCTURE OF HHAI METHYLTRANSFERASE WITH UNMODIFIED DNA AND ADOHCY
8OV6	;	3.77	;	Ternary structure of intramolecular bivalent glue degrader IBG1 bound to BRD4 and DCAF16:DDB1deltaBPB
3HSN	;	1.91	;	Ternary structure of neuronal nitric oxide synthase with NHA and CO bound
3HSO	;	2.02	;	Ternary structure of neuronal nitric oxide synthase with NHA and NO bound(1)
3HSP	;	2.2	;	Ternary structure of neuronal nitric oxide synthase with NHA and NO bound(2)
1Q0T	;	3.1	;	Ternary Structure of T4DAM with AdoHcy and DNA
6P06	;	2.3	;	Ternary structure of the E52D mutant of ANT-4 with Neomycin and AMPCPP
6P08	;	2.27	;	Ternary structure of the E52D mutant of ANT-4'' with Neomycin, AMP and Pyrophosphate
2Z6U	;	2.72	;	Ternary structure of the Glu119Ala M.HhaI, C5-Cytosine DNA methyltransferase, with unmodified DNA and AdoHcy
2ZCJ	;	2.75	;	Ternary structure of the Glu119Gln M.HhaI, C5-Cytosine DNA methyltransferase, with unmodified DNA and AdoHcy
4DLG	;	1.89	;	Ternary Structure of the large Fragment of Taq DNA polymerase
3RR8	;	2.4	;	Ternary Structure of the large fragment of Taq DNA polymerase bound to an abasic site and a ddGTP
3RRG	;	2.3	;	Ternary Structure of the large fragment of Taq DNA polymerase bound to an abasic site and a ddGTP
3RRH	;	1.8	;	Ternary Structure of the large fragment of Taq DNA polymerase bound to an abasic site and a ddTTP
3T3F	;	1.9	;	Ternary Structure of the large fragment of Taq DNA polymerase bound to an abasic site and dNITP
4DLE	;	2.44	;	Ternary Structure of the large Fragment of Taq DNA Polymerase: 4-Fluoroproline Variant
6NML	;	2.0	;	Ternary structure of the T130K mutant of ANT-4'' with Neomycin and AMPCPP
2HR1	;	1.96	;	Ternary structure of WT M.HhaI C5-Cytosine DNA methyltransferase with unmodified DNA and AdoHcy
1TC2	;	1.81	;	TERNARY SUBSTRATE COMPLEX OF THE HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE FROM TRYPANOSOMA CRUZI
8ITQ	;	2.07	;	Terpene cyclase AriE mutant - D128A
6VYD	;	1.46	;	Terpenoid Cyclase FgGS in Complex with Mg, Inorganic Pyrophosphate, and Benzyltriethylammonium cation
6W26	;	2.15	;	Terpenoid Cyclase FgGS in Complex with Mg, Inorganic Pyrophosphate, and Imidazole
1B9R	;		;	TERPREDOXIN FROM PSEUDOMONAS SP.
1GDD	;	2.2	;	TERTIARY AND QUATERNARY STRUCTURAL CHANGES IN GIA1 INDUCED BY GTP HYDROLYSIS
3IGI	;	3.125	;	Tertiary Architecture of the Oceanobacillus Iheyensis Group II Intron
1TNM	;		;	TERTIARY STRUCTURE OF AN IMMUNOGLOBULIN-LIKE DOMAIN FROM THE GIANT MUSCLE PROTEIN TITIN: A NEW MEMBER OF THE I SET
1TNN	;		;	Tertiary structure of an immunoglobulin-like domain from the giant muscle protein titin: a new member of the I set
1DV5	;		;	TERTIARY STRUCTURE OF APO-D-ALANYL CARRIER PROTEIN
1HQB	;		;	TERTIARY STRUCTURE OF APO-D-ALANYL CARRIER PROTEIN
6LEK	;		;	Tertiary structure of Barnacle cement protein MrCP20
1ERA	;		;	TERTIARY STRUCTURE OF ERABUTOXIN B IN AQUEOUS SOLUTION ELUCIDATED BY TWO-DIMENSIONAL NUCLEAR MAGNETIC RESONANCE
1FRA	;		;	TERTIARY STRUCTURE OF ERABUTOXIN B IN AQUEOUS SOLUTION ELUCIDATED BY TWO-DIMENSIONAL NUCLEAR MAGNETIC RESONANCE
1A9V	;		;	TERTIARY STRUCTURE OF THE MAJOR HOUSE DUST MITE ALLERGEN DER P 2, NMR, 10 STRUCTURES
4FXC	;	2.5	;	TERTIARY STRUCTURE OF [2FE-2S] FERREDOXIN FROM SPIRULINA PLATENSIS REFINED AT 2.5 ANGSTROMS RESOLUTION: STRUCTURAL COMPARISONS OF PLANT-TYPE FERREDOXINS AND AN ELECTROSTATIC POTENTIAL ANALYSIS
1BZD	;	1.9	;	TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBRIL FORMATION
1BZE	;	1.8	;	TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBRIL FORMATION
1TSH	;	1.7	;	TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBRIL FORMATION
2TRH	;	1.9	;	TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBRIL FORMATION
2TRY	;	2.0	;	TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBRIL FORMATION
6FVJ	;	2.6	;	TesA a major thioesterase from Mycobacterium tuberculosis
6FW5	;	2.75	;	TesA a major thioesterase from Mycobacterium tuberculosis
3BKK	;	2.17	;	Tesis ACE co-crystal structure with ketone ACE inhibitor kAF
6A7J	;	2.71	;	Testerone bound CYP154C4 from Streptomyces sp. ATCC 11861
1JJ8	;	2.75	;	Testing the Water-Mediated HIN Recombinase DNA Recognition by Systematic Mutations
1JKO	;	2.24	;	Testing the Water-Mediated HIN Recombinase DNA Recognition by Systematic Mutations
1JKP	;	2.8	;	Testing the Water-Mediated HIN Recombinase DNA Recognition by Systematic Mutations
1JKQ	;	2.86	;	Testing the Water-Mediated HIN Recombinase DNA Recognition by Systematic Mutations
1JKR	;	2.28	;	Testing the Water-Mediated HIN Recombinase DNA Recognition by Systematic Mutations
1IJW	;	2.4	;	Testing the Water-Mediated Hin Recombinase DNA Recognition by Systematic Mutations.
1JJ6	;	2.3	;	Testing the Water-Mediated Hin Recombinase DNA Recognition by Systematic Mutations.
3BKL	;	2.18	;	Testis ACE co-crystal structure with ketone ACE inhibitor kAW
3L3N	;	2.3	;	Testis ACE co-crystal structure with novel inhibitor lisW
1I9J	;	2.6	;	TESTOSTERONE COMPLEX STRUCTURE OF THE RECOMBINANT MONOCLONAL WILD TYPE ANTI-TESTOSTERONE FAB FRAGMENT
7CL8	;	1.42	;	Testosterone-bound structure of CYP154C2 from Streptomyces avermitilis in an closed conformation
2XB5	;	2.5	;	Tet repressor (class D) in complex with 7-Iodotetracycline
2X9D	;	2.34	;	Tet repressor (class D) in complex with iso-7-chlortetracycline
2VKE	;	1.62	;	Tet repressor class D complexed with cobalt and tetracycline
2X6O	;	2.3	;	Tet Repressor class D in complex with 7-chlor-2-cyano-iso- tetracycline
4AUX	;	2.25	;	Tet repressor class D in complex with 9-nitrotetracycline
2VPR	;	2.49	;	Tet repressor class H in complex with 5a,6- anhydrotetracycline-Mg
1ORK	;	2.4	;	TET REPRESSOR, CLASS D IN COMPLEX WITH 9-(N,N-DIMETHYLGLYCYLAMIDO)-6-DEMETHYL-6-DEOXY-TETRACYCLINE
1A6I	;	2.4	;	TET REPRESSOR, CLASS D VARIANT
2XRL	;	1.85	;	Tet-repressor class D T103A with doxycycline
1AF9	;	2.7	;	TETANUS NEUROTOXIN C FRAGMENT
7OH0	;	3.9	;	Tetanus neurotoxin HC domain in complex with TT104-Fab1
7OH1	;	8.0	;	Tetanus neurotoxin LC-HN domain in complex with TT110-Fab1
7BY5	;	2.27	;	Tetanus neurotoxin mutant-(H233A/E234Q/H237A/Y375F)
7BY4	;	1.5	;	Tetanus neurotoxin receptor binding domain
7BXX	;	2.34	;	Tetanus neurotoxin translocation domain -C467S
1A8D	;	1.57	;	TETANUS TOXIN C FRAGMENT
7P2T	;	2.3	;	Tetartohedrally twinned crystal structure of Schistosoma mansoni HDAC8 in complex with a tricyclic thieno[3,2-b]indole capped hydroxamate-based inhibitor, bromine derivative
7WUI	;	3.1	;	Tethered peptide activation mechanism of adhesion GPCRs ADGRG2 and ADGRG4
7WUJ	;	3.3	;	Tethered peptide activation mechanism of adhesion GPCRs ADGRG2 and ADGRG4
7WUQ	;	2.9	;	Tethered peptide activation mechanism of adhesion GPCRs ADGRG2 and ADGRG4
3CTB	;	2.0	;	Tethered PXR-LBD/SRC-1p apoprotein
6P2B	;	2.3	;	Tethered PXR-LBD/SRC-1p bound to Garcinoic Acid
3HVL	;	2.1	;	Tethered PXR-LBD/SRC-1p complexed with SR-12813
2VKV	;	1.74	;	TetR (BD) variant L17G with reverse phenotype
6NSM	;	2.8	;	TetR family transcriptional regulator CifR C99T-C107S-C181R Cysteines mutant complexed with 26bp double-strand operator DNA
6NSR	;	3.0	;	TetR family transcriptional regulator CifR C99T-C181R cysteine mutant complexed with 26bp double-strand operator DNA and apo-CifR C99T-C181R
6NSN	;	2.6	;	TetR family transcriptional regulator CifR C99T-C181R Cysteines mutant complexed with 26bp double-strand operator DNA
6SY4	;	2.695	;	TetR in complex with the TetR-binding RNA-aptamer K1
6SY6	;	2.9	;	TetR in complex with the TetR-binding RNA-aptamer K2
4AC0	;	2.45	;	TETR(B) IN COMPLEX WITH MINOCYCLINE AND MAGNESIUM
5MRU	;	2.55	;	TetR(class A) in complex with 5a,6-anhydrotetracycline and magnesium
5FKO	;	1.85	;	TetR(D) E147A mutant in complex with anhydrotetracycline and magnesium
6RBL	;	1.9	;	TETR(D) E147A MUTANT IN COMPLEX WITH DOXYCYCLINE AND MAGNESIUM
6RBM	;	2.05	;	TETR(D) E147A MUTANT IN COMPLEX WITH MINOCYCLINE AND MAGNESIUM
6FPL	;	1.602	;	TETR(D) E147A MUTANT IN COMPLEX WITH TETRACYCLINE AND MAGNESIUM
5FKL	;	1.9	;	TetR(D) H100A mutant in complex with anhydrotetracycline and magnesium
6RCR	;	2.05	;	TETR(D) H100A MUTANT IN COMPLEX WITH DOXYCYCLINE AND MAGNESIUM
4D7M	;	1.55	;	TetR(D) in complex with anhydrotetracycline and magnesium
4D7N	;	1.76	;	TetR(D) in complex with anhydrotetracycline and potassium
2XPU	;	1.55	;	TetR(D) in complex with anhydrotetracycline.
2XPV	;	1.49	;	TetR(D) in complex with minocycline and magnesium.
2XPW	;	1.44	;	TetR(D) in complex with oxytetracycline and magnesium.
4ABZ	;	1.886	;	TetR(D) in Complex with Tigecycline and Magnesium, co-crystallized
5FKK	;	1.75	;	TetR(D) N82A mutant in complex with anhydrotetracycline and magnesium
6RGX	;	1.8	;	TETR(D) N82A MUTANT IN COMPLEX WITH DOXYCYCLINE AND MAGNESIUM
6FTS	;	2.0	;	TETR(D) N82A MUTANT IN COMPLEX WITH PEG4
6YR1	;	2.3	;	TetR(D) soaked with Tigecycline I4(1)22
6YR2	;	1.95	;	TetR(D) soaked with Tigecycline P4(1)2(1)2
6QJW	;	2.1	;	TetR(D) T103A mutant in complex with 7-chlortetracycline and magnesium
5FKM	;	1.63	;	TetR(D) T103A mutant in complex with anhydrotetracycline and magnesium, I4(1)22
5FKN	;	1.8	;	TetR(D) T103A mutant in complex with anhydrotetracycline and magnesium, P4(3)2(1)2
6QJX	;	2.1	;	TetR(D) T103A mutant in complex with minocycline and magnesium
6FPM	;	1.85	;	TetR(D) T103A mutant in complex with tetracycline and magnesium
5FWG	;	2.0	;	TETRA-(5-FLUOROTRYPTOPHANYL)-GLUTATHIONE TRANSFERASE
2MK7	;		;	Tetra-O-GalNAc glycosylated mucin sequence from alpha dystroglycan mucin domain
4OQ3	;	2.3	;	Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction
2RES	;	2.2	;	Tetracenomycin ARO/CYC mutant R69A
2REZ	;	1.95	;	Tetracenomycin ARO/CYC NaI Structure
6Y6X	;	2.8	;	Tetracenomycin X bound to the human ribosome
8CF1	;	1.82	;	Tetracycline bound to the 30S head
1BJZ	;	2.2	;	TETRACYCLINE CHELATED MG2+-ION INITIATES HELIX UNWINDING FOR TET REPRESSOR INDUCTION
2TRT	;	2.5	;	TETRACYCLINE REPRESSOR CLASS D
4B1R	;	1.95	;	Tetracycline repressor class D mutant H100A in complex with iso-7- Chlortetracycline
4B3A	;	1.7	;	Tetracycline repressor class D mutant H100A in complex with tetracycline
4D5F	;	2.2	;	tetracycline repressor class H, apo form
4D5C	;	1.7	;	tetracycline repressor class J, apo form
4V2G	;	2.71	;	Tetracycline repressor TetR(D) bound to chlortetracycline and iso- chlortetracycline
4V2F	;	2.4	;	Tetracycline repressor TetR(D), unliganded
4V6V	;	9.8	;	Tetracycline resistance protein Tet(O) bound to the ribosome
7URW	;	3.11	;	Tetradecameric hub domain of CaMKII beta
7URY	;	2.64	;	Tetradecameric hub domain of CaMKII beta
6VE2	;	4.3	;	Tetradecameric PilQ bound by TsaP heptamer from Pseudomonas aeruginosa
6VE3	;	4.3	;	Tetradecameric PilQ from Pseudomonas aeruginosa
5CQW	;	2.65	;	Tetragonal Complex Structure of Protein Kinase CK2 Catalytic Subunit with a Benzotriazole-Based Inhibitor Generated by click-chemistry
1JKT	;	3.5	;	TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
6WUE	;	1.8	;	Tetragonal crystal form of SbtB from Synechocystis PCC6803
1IES	;	2.6	;	TETRAGONAL CRYSTAL STRUCTURE OF NATIVE HORSE SPLEEN FERRITIN
3D1B	;	1.7	;	Tetragonal crystal structure of Tas3 C-terminal alpha motif
6ZDZ	;	2.153	;	Tetragonal crystal structure of the bulky-bulky ketone specific alcohol dehydrogenase from Comamonas testosteroni
7YYJ	;	2.1	;	Tetragonal crystal structure of YTHDF1 YTH domain (544AVV546 mutant)
5EYY	;	1.902	;	Tetragonal Form of Centrolobium tomentosum seed lectin (CTL) complexed with Man1-3Man-OMe.
8A9R	;	1.6	;	Tetragonal Hen Egg-White (HEW) Lysozyme soaked in reduced resazurin in a glovebox and flash-cooled using a miniature-airlock
6F1P	;	1.12	;	Tetragonal Lysozyme crystallized at 298 K and pH 4.5 with phosphate bound
6F1R	;	1.1	;	Tetragonal Lysozyme crystallized at 298 K and pH 4.5 with phosphate bound: control experiment
6RTA	;	1.8	;	Tetragonal lysozyme grown with 300g/L Ficoll
7MQ7	;	1.95	;	Tetragonal Maltose Binding Protein
7MQ6	;	2.372	;	Tetragonal Maltose Binding Protein in the presence of gold
4XF2	;	5.0	;	Tetragonal structure of Arp2/3 complex
7B8I	;	2.55	;	Tetragonal structure of human protein kinase CK2 catalytic subunit in complex with a heparin oligo saccharide
5N95	;	2.6	;	Tetragonal structure of mutant V173I of 3D polymerase from Foot-and-Mouth Disease Virus
5UU7	;	1.60001	;	Tetragonal thermolysin (295 K) in the presence of 50% mpd
5UN3	;	1.60004	;	Tetragonal thermolysin (295 K) in the presence of 50% xylose
6N4W	;	1.4	;	Tetragonal thermolysin (with 50% xylose) cryocooled in a nitrogen gas stream to 100 K
6N4Z	;	1.4	;	Tetragonal thermolysin (with 50% xylose) plunge cooled in liquid nitrogen to 77 K
5UUB	;	1.6	;	Tetragonal thermolysin cryocooled to 100 K with 25% xylose/25% mpd as cryoprotectant
5UU8	;	2.5	;	Tetragonal thermolysin cryocooled to 100 K with 30% xylose as cryoprotectant
5UU9	;	1.59969	;	Tetragonal thermolysin cryocooled to 100 K with 40% xylose as cryoprotectant
5UUD	;	1.6	;	Tetragonal thermolysin cryocooled to 100 K with 50% dmf as cryoprotectant
5UUE	;	1.6	;	Tetragonal thermolysin cryocooled to 100 K with 50% methanol as cryoprotectant
5UUC	;	1.60001	;	Tetragonal thermolysin cryocooled to 100 K with 50% mpd as cryoprotectant
5UUA	;	1.6	;	Tetragonal thermolysin cryocooled to 100 K with 50% xylose as cryoprotectant
3T2J	;	2.0	;	Tetragonal thermolysin in the presence of betaine
3T2I	;	2.1	;	Tetragonal thermolysin in the presence of sarcosine
3T2H	;	1.95	;	Tetragonal thermolysin in the presence of TMAO
6N1R	;	4.0	;	Tetrahedral oligomeric complex of GyrA N-terminal fragment, solved by cryoEM in tetrahedral symmetry
6P3O	;	1.8	;	Tetrahydroprotoberberine N-methyltransferase in complex with (S)-cis-N-methylstylopine and S-adenosylhomocysteine
6P3M	;	1.8	;	Tetrahydroprotoberberine N-methyltransferase in complex with S-adenosylhomocysteine
6P3N	;	1.6	;	Tetrahydroprotoberberine N-methyltransferase in complex with S-adenosylmethionine
6N2J	;	1.8	;	Tetrahydropyridopyrimidines as Covalent Inhibitors of KRAS-G12C
6N2K	;	1.72	;	Tetrahydropyridopyrimidines as Covalent Inhibitors of KRAS-G12C
5BVD	;	1.9	;	Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase
5BVE	;	2.0	;	Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase
5BVF	;	1.9	;	Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase
3O5N	;	1.83	;	Tetrahydroquinoline carboxylates are potent inhibitors of the Shank PDZ domain, a putative target in autism disorders
7UY7	;	4.2	;	Tetrahymena CST with Polymerase alpha-Primase
1M1D	;	2.2	;	TETRAHYMENA GCN5 WITH BOUND BISUBSTRATE ANALOG INHIBITOR
7UY8	;	4.5	;	Tetrahymena Polymerase alpha-Primase
8TJX	;	2.44	;	Tetrahymena Ribozyme cryo-EM scaffold
6WLS	;	6.8	;	Tetrahymena ribozyme models, 6.8 Angstrom resolution
8TJV	;	2.99	;	Tetrahymena Ribozyme scaffolded Fluoride riboswitch
8TJU	;	3.46	;	Tetrahymena Ribozyme scaffolded TABV xrRNA
8TJQ	;	3.4	;	Tetrahymena Ribozyme scaffolded Zika Virus xrRNA
7UY6	;	2.9	;	Tetrahymena telomerase at 2.9 Angstrom resolution
7LMA	;	3.3	;	Tetrahymena telomerase T3D2 structure at 3.3 Angstrom
7LMB	;	3.8	;	Tetrahymena telomerase T5D5 structure at 3.8 Angstrom
7UY5	;	3.5	;	Tetrahymena telomerase with CST
2JYF	;		;	Tetraloop-receptor RNA complex
8V5M	;	9.22	;	Tetramer core subcomplex (conformation 1) of Xenopus laevis DNA polymerase alpha-primase
8V5N	;	8.56	;	Tetramer core subcomplex (conformation 2) of Xenopus laevis DNA polymerase alpha-primase
8V5O	;	8.99	;	Tetramer core subcomplex (conformation 3) of Xenopus laevis DNA polymerase alpha-primase
8X5N	;	2.8	;	Tetramer Gabija with ATP
8X5I	;	3.01	;	tetramer Gabija with ATP (local refinement)
4D3E	;	24.0	;	Tetramer of IpaD, modified from 2J0O, fitted into negative stain electron microscopy reconstruction of the wild type tip complex from the type III secretion system of Shigella flexneri
5GYR	;	1.6	;	Tetrameric Allochromatium vinosum cytochrome c'
7W0X	;		;	Tetrameric antiparallel G-quadruplex formed by natural human telomeric sequence
5A7D	;	3.4	;	Tetrameric assembly of LGN with Inscuteable
4W80	;	3.2	;	Tetrameric BAP29 vDED with disulfide bonds in crystal contacts
4W7Z	;	2.2	;	Tetrameric BAP29 vDED without disulfide bonds
7D2H	;	2.2	;	Tetrameric coiled-coil structure of liprin-alpha2_H2
7D2E	;	1.7	;	Tetrameric coiled-coil structure of liprin-alpha2_H3
5FTU	;	6.01	;	Tetrameric complex of Latrophilin 3, Unc5D and FLRT2
6PIK	;	7.8	;	Tetrameric cryo-EM ArnA
3C62	;	1.87	;	Tetrameric Cytochrome cb562 (H59/D62/H63/H73/A74/H77) Assembly Stabilized by Interprotein Zinc Coordination
3C63	;	1.75	;	Tetrameric Cytochrome cb562 (K34/H59/D62/H63/H73/A74/H77) Assembly Stabilized by Interprotein Zinc Coordination
4H2P	;	1.981	;	Tetrameric form of 2-methyl-3-hydroxypyridine-5-carboxylic acid oxygenase (MHPCO)
4KPR	;	2.4	;	Tetrameric form of rat selenoprotein thioredoxin reductase 1
6JX6	;	2.805	;	Tetrameric form of Smac
7KLU	;	3.5	;	Tetrameric human mitochondrial Hsp90 (TRAP1) in the presence of AMP-PNP
2PAH	;	3.1	;	TETRAMERIC HUMAN PHENYLALANINE HYDROXYLASE
2N89	;		;	Tetrameric i-motif structure of dT-dC-dC-CFL-CFL-dC at acidic pH
6JI1	;	4.1	;	Tetrameric PepTSo2 incorporated in salipro nano particle
1FIU	;	1.6	;	TETRAMERIC RESTRICTION ENDONUCLEASE NGOMIV IN COMPLEX WITH CLEAVED DNA
4M1X	;	1.3	;	Tetrameric ring structure of 201phi2-1p060 from Pseudomonas phage 201phi2-1
6P2P	;	3.1	;	Tetrameric structure of ACAT1
1J2W	;	1.5	;	Tetrameric Structure of aldolase from Thermus thermophilus HB8
1Z9W	;	2.5	;	Tetrameric structure of apo-7,8-Dihydroneopterin Aldolase from Mycobacterium tuberculosis
2JO4	;		;	Tetrameric structure of KIA7 peptide
2JO5	;		;	Tetrameric structure of KIA7F peptide
7P4T	;	3.17	;	Tetrameric structure of murine SapA
6LZ7	;	3.59936	;	Tetrameric structure of ZmCRY1a PHR domain
3FR3	;	1.9	;	Tetramerization and Cooperativity in Plasmodium falciparum glutathione transferase are mediated by the atypic loop 113-118
3FR6	;	2.6	;	Tetramerization and Cooperativity in Plasmodium falciparum glutathione transferase are mediated by the atypic loop 113-118
3FR9	;	2.4	;	Tetramerization and Cooperativity in Plasmodium falciparum glutathione transferase are mediated by the atypic loop 113-118
3FRC	;	2.0	;	Tetramerization and Cooperativity in Plasmodium falciparum glutathione transferase are mediated by the atypic loop 113-118
3KVT	;	2.0	;	TETRAMERIZATION DOMAIN FROM AKV3.1 (SHAW-SUBFAMILY) VOLTAGE-GATED POTASSIUM CHANNEL
3ZDO	;	2.07	;	Tetramerization domain of Measles virus phosphoprotein
2MW4	;		;	Tetramerization domain of the Ciona intestinalis p53/p73-b transcription factor protein
4D1L	;	1.97	;	Tetramerization domain of zebrafish p53 (crystal form I)
4D1M	;	2.2	;	Tetramerization domain of zebrafish p53 (crystal form II)
3U0Z	;	2.9	;	Tetramerization dynamics of the C-terminus underlies isoform-specific cAMP-gating in HCN channels
3U10	;	2.3	;	Tetramerization dynamics of the C-terminus underlies isoform-specific cAMP-gating in HCN channels
3U11	;	2.5	;	Tetramerization dynamics of the C-terminus underlies isoform-specific cAMP-gating in HCN channels
8SPO	;	2.98	;	Tetramerized activation of MapSPARTA bound with NAD+
2KV6	;		;	Tetrapeptide KWKK conjugated to oligonucleotide duplex by a trimethylene tether
6L8A	;	1.95005	;	Tetrathionate hydrolase from Acidithiobacillus ferrooxidans
7CQY	;	2.80036	;	Tetrathionate hydrolase from Acidithiobacillus ferrooxidans mutant - D325N
7CC7	;	1.45	;	Tetratricopeptide repeat (TPR) domain of protein tyrosine phosphatase-interacting protein 51 (PTPIP51)
1A17	;	2.45	;	TETRATRICOPEPTIDE REPEATS OF PROTEIN PHOSPHATASE 5
4GUV	;	2.73	;	TetX derivatized with Xenon
5TDM	;	2.1	;	TEV Cleaved Human ATP Citrate Lyase Bound to 4R-Hydroxycitrate and ADP
5TDF	;	1.8	;	TEV Cleaved Human ATP Citrate Lyase Bound to 4S hydroxycitrate
5TET	;	2.2	;	TEV Cleaved Human ATP Citrate Lyase Bound to 4S Hydroxycitrate
5TDE	;	1.7	;	TEV Cleaved Human ATP Citrate Lyase Bound to Citrate
5TES	;	2.4	;	TEV Cleaved Human ATP Citrate Lyase Bound to Citrate and ADP
5TDZ	;	2.0	;	TEV Cleaved Human ATP Citrate Lyase Bound to Tartrate and ADP
5ZJ3	;	1.88	;	Textilinin-1, A Kunitz-Type Serine Protease Inhibitor From pichia expression system
1W0Y	;	2.5	;	tf7a_3771 complex
1W2K	;	3.0	;	tf7a_4380 complex
6HC3	;	3.1	;	TFAM bound to Site-X
3TMM	;	2.5001	;	TFAM imposes a U-turn on mitochondrial DNA
6HB4	;	3.05	;	TFAM in Complex with Site-Y
6CSK	;		;	TFE-induced NMR structure of a novel bioactive peptide (PaDBS1R2) derived from a Pyrobaculum aerophilum ribosomal protein (L39e)
6CSZ	;		;	TFE-induced NMR structure of a novel bioactive peptide (PaDBS1R3) derived from a Pyrobaculum aerophilum ribosomal protein (L39e)
6CT1	;		;	TFE-induced NMR structure of a novel bioactive peptide (PaDBS1R7) derived from a Pyrobaculum aerophilum ribosomal protein (L39e)
6CT4	;		;	TFE-induced NMR structure of an antimicrobial peptide (EcDBS1R5) derived from a mercury transporter protein (MerP - Escherichia coli)
1IWC	;		;	TFE-induded structure of the N-terminal domain of pig gastric H/K-ATPase
7RDV	;	2.90007	;	TFH TCR bound to MHC Class II IAd presenting aggrecan epitope
1VOL	;	2.7	;	TFIIB (HUMAN CORE DOMAIN)/TBP (A.THALIANA)/TATA ELEMENT TERNARY COMPLEX
7EGE	;	9.0	;	TFIID in canonical conformation
7EGI	;	9.82	;	TFIID in rearranged conformation
7EGF	;	3.16	;	TFIID lobe A subcomplex
7EGG	;	2.77	;	TFIID lobe B subcomplex
7EGH	;	3.04	;	TFIID lobe C subcomplex
7EG8	;	7.4	;	TFIID-based core PIC on PUMA promoter
7EG7	;	6.2	;	TFIID-based core PIC on SCP promoter
7EGB	;	3.3	;	TFIID-based holo PIC on SCP promoter
7EGA	;	4.1	;	TFIID-based intermediate PIC on PUMA promoter
7EG9	;	3.7	;	TFIID-based intermediate PIC on SCP promoter
7ENC	;	4.13	;	TFIID-based PIC-Mediator holo-complex in fully-assembled state (hPIC-MED)
7ENA	;	4.07	;	TFIID-based PIC-Mediator holo-complex in pre-assembled state (pre-hPIC-MED)
7NVX	;	3.9	;	TFIIH in a post-translocated state (with ADP-BeF3)
7NVW	;	4.3	;	TFIIH in a pre-translocated state (without ADP-BeF3)
1TF3	;		;	TFIIIA FINGER 1-3 BOUND TO DNA, NMR, 22 STRUCTURES
8FFZ	;	3.8	;	TFIIIA-TFIIIC-Brf1-TBP complex bound to 5S rRNA gene
5N9G	;	2.7	;	TFIIIB -TBP/Brf2/DNA and SANT domain of Bdp1-
8CLK	;	3.5	;	TFIIIC TauA complex
8CLJ	;	3.2	;	TFIIIC TauB-DNA dimer
8CLI	;	3.2	;	TFIIIC TauB-DNA monomer
6ZUZ	;		;	TFIIS N-terminal domain (TND) from human Elongin-A
6ZV1	;		;	TFIIS N-terminal domain (TND) from human IWS1
6ZV0	;		;	TFIIS N-terminal domain (TND) from human LEDGF/p75
6ZV3	;		;	TFIIS N-terminal domain (TND) from human MED26
6ZV2	;		;	TFIIS N-terminal domain (TND) from human PPP1R10
4RJD	;	2.0	;	TFP bound in alternate orientations to calcium-saturated Calmodulin C-Domains
7NX1	;	1.3	;	TG domain of LTK
6IVD	;	1.975	;	TGEV nsp1 mutant - 91-95sg
3TZM	;	1.7	;	TGF-beta Receptor type 1 in complex with SB431542
5E8T	;	1.7	;	TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D)
5E8Z	;	1.51	;	TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 3-AMINO-6-[4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2-CARBOXAMIDE
5QTZ	;	1.83	;	TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 6-[1-(2,2-DIFLUOROETHYL)-4-(6-METHYLPYRIDIN-2-YL)-1H-IMIDAZOL-5-YL]IMIDAZO[1,2-A]PYRIDINE
5QU0	;	1.67	;	TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 6-[4-(3-CHLORO-4-FLUOROPHENYL)-1-(2-HYDROXYETHYL)-1H-IMIDAZOL-5-YL]IMIDAZO[1,2-B]PYRIDAZINE-3-CARBONITRILE
6B8Y	;	1.65	;	TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH N-(3-fluoropyridin-4-yl)-2-[6-(trifluoromethyl)pyridin-2-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
5QIM	;	1.75	;	TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH N-{4-[3-(5-METHOXYPYRIDIN-2-YL)-1H-PYRROLO[3,2-B] PYRIDIN-2-YL]PYRIDIN-2-YL}ACETAMIDE
5QIK	;	1.58	;	TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH N-{4-[3-(6-fluoropyridin-3-yl)-4-oxo-4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridin-2-yl]pyridin-2-yl}acetamide
5QIL	;	1.98	;	TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH N-{4-[3-(6-METHOXYPYRIDIN-3-YL)-1H-PYRROLO[3,2-B]PYRIDIN-2-YL]PYRIDIN-2-YL}ACETAMIDE
5E8W	;	1.86	;	TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH STAUROSPORINE
5E90	;	2.05	;	TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D,I211V,Y249F, S280T,Y282F,S287N,A350C,L352F) IN COMPLEX WITH 3-AMINO-6- [4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2-CARBOXAMIDE
5E8U	;	2.03	;	TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D,I211V,Y249F,S280T, Y282F,S287N,A350C,L352F)
5E8X	;	1.45	;	TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D,I211V,Y249F,S280T, Y282F,S287N,A350C,L352F) IN COMPLEX WITH STAUROSPORINE
5E8S	;	1.45	;	TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (WT)
5E8V	;	1.69	;	TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431A,R433A,E485A,K488A,R493A,R495A)
5E91	;	2.42	;	TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431A,R433A,E485A,K488A,R493A,R495A) IN COMPLEX WITH 3-AMINO-6-[4-(2- HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL] PYRAZINE-2-CARBOXAMIDE
5E92	;	2.08	;	TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431A,R433A,E485A,K488A,R493A,R495A) IN COMPLEX WITH AMPPNP
5E8Y	;	2.05	;	TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431A,R433A,E485A,K488A,R493A,R495A) IN COMPLEX WITH STAUROSPORINE
5QIN	;	1.57	;	TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN IN COMPLEX WITH N- {4-[3-(6-METHOXYPYRIDIN-3-YL)-1H-PYRROLO[3,2-B]PYRIDIN-2- YL]PYRIDIN-2-YL}ACETAMIDE
5KN5	;	2.8	;	TGFalpha/Epiregulin complex with neutralizing antibody LY3016859
7ASC	;	4.8	;	TGFBIp mutant A546T
7ASG	;	2.0	;	TGFBIp mutant R555W
1ZF6	;	1.5	;	TGG DUPLEX A-DNA
4P8I	;	1.85	;	Tgl - a bacterial spore coat transglutaminase
4PA5	;	1.86	;	Tgl - a bacterial spore coat transglutaminase - cystamine complex
7B08	;	2.394	;	TgoT apo
7B07	;	3.099	;	TgoT_6G12 apo
7B0F	;	2.797	;	TgoT_6G12 Binary complex
7B0G	;	3.0	;	TgoT_6G12 binary with 2 hCTPs
7B0H	;	3.15	;	TgoT_6G12 Ternary complex
7B06	;	2.349	;	TgoT_RT521 apo
4TZA	;	1.9	;	TGP, an extremely thermostable green fluorescent protein created by structure-guided surface engineering
4GHR	;	2.0	;	TGT D102N mutant in complex with lin-benzohypoxanthine inhibitor
6YFW	;	1.26	;	TGT H333F mutant crystallised at pH 8.5
4DXX	;	1.66	;	TGT K52M mutant crystallized at pH 8.5
3BLL	;	1.26	;	TGT mutant in complex with Boc-preQ1
3BLO	;	1.6	;	TGT mutant in complex with queuine
6YGW	;	1.16	;	TGT W178F mutant labelled mit 5F-Trp crystallised at pH 5.5
6YGL	;	1.48	;	TGT W326F mutant labelled mit 5F-Trp crystallised at pH 5.5
6YGM	;	1.23	;	TGT W95F mutant labelled mit 5F-Trp crystallised at pH 5.5
6YGO	;	1.26	;	TGT W95F mutant labelled mit 5F-Trp crystallised at pH 8.5
6YGP	;	1.33	;	TGT WT labelled mit 5F-Trp crystallised at pH 5.5
6YFX	;	1.38	;	TGT Y330F mutant crystallised at pH 5.5
6YGK	;	1.4	;	TGT Y330F mutant crystallised at pH 8.5
4R0U	;	1.38	;	Tgvtava, an amyloid forming segment from alpha synuclein, residues 72-78
8PUM	;	2.6	;	Tha1 L-threonine aldolase (mouse), monoclinic form (C2)
8PUS	;	2.26	;	Tha1 L-threonine aldolase (mouse), orthorhombic form (F222)
6Z82	;	2.3	;	Thalictrum flavumn Norcoclaurine synthase point mutant in complex with a transition state analoge
2AKG	;		;	Thallium form of the G-Quadruplex from Oxytricha Nova, d(G4T4G4)2
4P1A	;	3.75	;	Thallium-bound inward-facing state of the glutamate transporter homologue GltPh
6AAB	;		;	Thanatin in presence of DPC
5XO9	;		;	Thanatin in presence of LPS
5XO3	;		;	Thanatin M21F Free
5XOA	;		;	Thanatin M21F in complex with LPS
6AFQ	;		;	Thanatin M21F in presence of DPC
8IL6	;		;	Thanatin PM15 with LPS
8XTH	;		;	Thanatin PM15Y in LPS
5XOL	;		;	Thanatin R13R14AA in complex with LPS
8X3N	;		;	Thanatin VF16 in complex with LPS
5XOK	;		;	Thanatin Y10M21AA in complex with LPS
3N02	;	1.5	;	Thaumatic crystals grown in loops/micromounts
2BLU	;	1.4	;	Thaumatin After A High Dose X-Ray ""Burn""
8F03	;	1.39	;	Thaumatin Anomalous Dataset at 293 K and 12 keV
8F01	;	1.8	;	Thaumatin Anomalous Dataset at 293 K and 7.1 keV
2BLR	;	1.4	;	Thaumatin Before A High Dose X-Ray ""Burn""
3E0A	;	1.51	;	Thaumatin by Classical hanging drop method after high X-Ray dose on ESRF ID29 beamline
3DZR	;	1.51	;	Thaumatin by Classical hanging drop method before high X-Ray dose on ESRF ID29 beamline
3V7V	;	2.3	;	Thaumatin by Classical Hanging Drop Vapour Diffusion after 1.81 MGy X-Ray dose at ESRF ID29 beamline (Best Case)
3V87	;	2.3	;	Thaumatin by Classical Hanging Drop Vapour Diffusion after 1.81 MGy X-Ray dose at ESRF ID29 beamline (Worst Case)
3V88	;	2.3	;	Thaumatin by Classical Hanging Drop Vapour Diffusion after 18.1 MGy X-Ray dose at ESRF ID29 beamline (Best Case)
3V8A	;	2.3	;	Thaumatin by Classical Hanging Drop Vapour Diffusion after 18.1 MGy X-Ray dose at ESRF ID29 beamline (Worst Case)
3VCH	;	2.3	;	Thaumatin by Classical Hanging Drop Vapour Diffusion after 9.05 MGy X-Ray dose at ESRF ID29 beamline (Best Case)
3VCI	;	2.3	;	Thaumatin by Classical Hanging Drop Vapour Diffusion after 9.05 MGy X-Ray dose at ESRF ID29 beamline (Worst Case)
3V82	;	2.3	;	Thaumatin by LB based Hanging Drop Vapour Diffusion after 1.81 MGy X-Ray dose at ESRF ID29 beamline (Best Case)
3V84	;	2.3	;	Thaumatin by LB based Hanging Drop Vapour Diffusion after 1.81 MGy X-Ray dose at ESRF ID29 beamline (Worst Case)
3VCE	;	2.3	;	Thaumatin by LB based Hanging Drop Vapour Diffusion after 18.1 MGy X-Ray dose at ESRF ID29 beamline (Best Case)
3VCG	;	2.3	;	Thaumatin by LB based Hanging Drop Vapour Diffusion after 18.1 MGy X-Ray dose at ESRF ID29 beamline (Worst Case)
3VCJ	;	2.3	;	Thaumatin by LB Hanging Drop Vapour Diffusion after 9.05 MGy X-Ray dose at ESRF ID29 beamline (Best Case)
3VCK	;	2.3	;	Thaumatin by LB Hanging Drop Vapour Diffusion after 9.05 MGy X-Ray dose at ESRF ID29 beamline (Worst Case)
3DZP	;	1.51	;	Thaumatin by LB nanotemplate method after high X-Ray dose on ESRF ID29 beamline
3DZN	;	1.51	;	Thaumatin by LB nanotemplate method before high X-Ray dose on ESRF ID29 beamline
8FZW	;	1.48	;	Thaumatin crystallized in cyclic olefin copolymer-based microfluidic chips
3N03	;	1.5	;	Thaumatin crystals grown from drops
5TCL	;	3.201	;	Thaumatin from 4.96 A wavelength data collection
2PE7	;	1.46	;	Thaumatin from Thaumatococcus Danielli in complex with tris-dipicolinate Europium
4BAR	;	1.2	;	Thaumatin from Thaumatococcus daniellii structure in complex with the europium tris-hydroxyethyltriazoledipicolinate complex at 1.20 A resolution.
4BAL	;	1.298	;	Thaumatin from Thaumatococcus daniellii structure in complex with the europium tris-hydroxymethyltriazoledipicolinate complex at 1.30 A resolution.
4DIY	;	1.98	;	Thaumatin I by Classical Hanging Drop Method at 1.98A resolution for Unique Water Distribution
4DIZ	;	1.98	;	Thaumatin I by Classical Hanging Drop Method at 1.98A resolution for Unique Water Distribution
4DJ0	;	1.98	;	Thaumatin I by Langmuir-Blodgett Hanging Drop Method at 1.98A resolution for Unique Water Distribution
4DJ1	;	1.98	;	Thaumatin I by Langmuir-Blodgett Hanging Drop Method at 1.98A resolution for Unique Water Distribution
6O8A	;	2.6	;	Thaumatin native-SAD structure determined at 5 keV from microcrystals
8ENA	;	2.5	;	Thaumatin native-SAD structure determined at 5 keV with a helium environmet
7VCG	;	1.25	;	Thaumatin protected by alginate gel
7WXT	;	1.7	;	Thaumatin protected by polyacrylamide gel
4C3C	;	1.8	;	Thaumatin refined against hatrx data for time-point 1
5T3G	;	1.55	;	thaumatin soaked with selenourea for 10 min
6G89	;	2.359	;	Thaumatin solved by Native SAD from a dataset collected in 0.6 second with JUNGFRAU detector
5FGX	;	2.134	;	Thaumatin solved by native sulphur SAD using synchrotron radiation
5FGT	;	2.1	;	Thaumatin solved by native sulphur-SAD using free-electron laser radiation
1RQW	;	1.05	;	Thaumatin Structure at 1.05 A Resolution
5SW0	;	1.269	;	Thaumatin Structure at pH 4.0
5SW1	;	1.1	;	Thaumatin Structure at pH 6.0
5SW2	;	1.2	;	Thaumatin Structure at pH 6.0, orthorhombic type1
5GQP	;	1.296	;	Thaumatin Structure at pH 8.0, orthorhombic type1
3ZEJ	;	1.55	;	Thaumatin structure determined at room temperature by in-situ diffraction in ChipX
5WR8	;	1.55	;	Thaumatin structure determined by SACLA at 1.55 Angstrom
3WXS	;	2.0	;	Thaumatin structure determined by SPring-8 Angstrom Compact free electron Laser (SACLA)
8A9F	;	1.88	;	Thaumatin, 9-11 fs FEL pulses as determined by XTCAV
7P22	;	1.87	;	Thaumatin-like protein of Amycolatopsis rifamycinica
7P23	;	1.5	;	Thaumatin-like protein of Puccinia graminis
5Z2U	;	2.35	;	ThDP-Mn2+ complex of R395A variant of EcMenD soaked with 2-ketoglutarate for 5 min
5Z2R	;	2.3	;	ThDP-Mn2+ complex of R395K variant of EcMenD soaked with 2-ketoglutarate for 5 min
5EJM	;	1.72	;	ThDP-Mn2+ complex of R413A variant of EcMenD soaked with 2-ketoglutarate for 35 min
5Z2P	;	2.3	;	ThDP-Mn2+ complex of R413K variant of EcMenD soaked with 2-ketoglutarate for 5 min
8K3Y	;	4.42	;	The ""5+1"" heteromeric structure of Lon protease consisting of a spiral pentamer with Y224S mutation and an N-terminal-truncated monomeric E613K mutant
1URH	;	2.8	;	The ""Rhodanese"" fold and catalytic mechanism of 3-mercaptopyruvate sulfotransferases: Crystal structure of SseA from Escherichia coli
7W7U	;	3.0	;	The 'Ca2+-unbound' BeF3- of SERCA2b
6D9S	;	2.105	;	The (p)ppGpp-bound crystal structure of HPRT (hypoxanthine phosphoribosyltransferase)
4UUG	;	1.6	;	The (R)-selective amine transaminase from Aspergillus fumigatus with inhibitor bound
4CMD	;	1.68	;	The (R)-selective transaminase from Nectria haematococca
4CMF	;	1.5	;	The (R)-selective transaminase from Nectria haematococca with inhibitor bound
7FEZ	;	0.76	;	The 0.76 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with petroselinic acid
1GCI	;	0.78	;	THE 0.78 ANGSTROMS STRUCTURE OF A SERINE PROTEASE-BACILLUS LENTUS SUBTILISIN
7WKB	;	0.81	;	The 0.81 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with docosahexaenoic acid
7FF6	;	0.83	;	The 0.83 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with cis-vaccenic acid
7WF0	;	0.83	;	The 0.83 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with nervonic acid
7WKG	;	0.84	;	The 0.84 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with erucic acid
7FFK	;	0.84	;	The 0.84 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with palmitoleic acid
7WCI	;	0.85	;	The 0.85 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with two molecules of pelargonic acid
5AVD	;	0.86	;	The 0.86 angstrom structure of elastase crystallized in high-strength agarose hydrogel
1MUW	;	0.86	;	The 0.86 Angstrom Structure of Xylose Isomerase
7WJ1	;	0.86	;	The 0.86 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with arachidonic acid
7FDT	;	0.86	;	The 0.86 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with elaidic acid
7FDU	;	0.86	;	The 0.86 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with heptadecanoic acid
4TKB	;	0.86	;	The 0.86 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with lauric acid
7FBF	;	0.86	;	The 0.86 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with octanoic acid
7X48	;	0.86	;	The 0.86 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with pelargonic acid
4TJZ	;	0.87	;	The 0.87 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with capric acid
7WQ7	;	0.87	;	The 0.87 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with nonadecanoic acid
7WE5	;	0.87	;	The 0.87 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with oleic acid
4TKJ	;	0.87	;	The 0.87 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with palmitic acid
7FFX	;	0.88	;	The 0.88 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with alpha-llinolenic acid
7XHM	;	0.88	;	The 0.88 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with behenic acid
3WVM	;	0.88	;	The 0.88 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with stearic acid
7XHU	;	0.88	;	The 0.88 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with tricosanoic acid
5AVH	;	0.9	;	The 0.90 angstrom structure (I222) of glucose isomerase crystallized in high-strength agarose hydrogel
7WOM	;	0.9	;	The 0.90 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with eicosapentaenoic acid
7WPG	;	0.9	;	The 0.90 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with heptanoic acid
7WDJ	;	0.9	;	The 0.90 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with linoleic acid
7VB1	;	0.9	;	The 0.90 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with trans-vaccenic acid
5B28	;	0.9	;	The 0.90A structure of human FABP3 F16V mutant complexed with palmitic acid
5NC0	;	0.91	;	The 0.91 A resolution structure of the L16G mutant of cytochrome c prime from Alcaligenes xylosoxidans, complexed with nitric oxide
7V5U	;	0.92	;	The 0.92 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with 2-cyclohexadecylacetic acid (CYC16AA)
7XBC	;	0.92	;	The 0.92 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with lignoceric acid
7X50	;	0.93	;	The 0.93 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with heneicosanoic acid
4TKH	;	0.93	;	The 0.93 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with myristic acid
7FG1	;	0.93	;	The 0.93 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with tridecanoic acid
3F1L	;	0.95	;	The 0.95 A structure of an oxidoreductase, yciK from E.coli
1RTQ	;	0.95	;	The 0.95 Angstrom Resolution Crystal Structure of the Aminopeptidase from Aeromonas proteolytica
5AVG	;	0.95	;	The 0.95 angstrom structure of thaumatin crystallized in high-strength agarose hydrogel
7WD6	;	0.95	;	The 0.95 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with hexanoic acid
7FEU	;	0.95	;	The 0.95 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with perfluorononanoic acid
7WPU	;	0.95	;	The 0.95 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with undecanoic acid
7X4J	;	0.96	;	The 0.96 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with arachidic acid
7WPW	;	0.97	;	The 0.97 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with pentadecanoic acid
1F94	;	0.97	;	THE 0.97 RESOLUTION STRUCTURE OF BUCANDIN, A NOVEL TOXIN ISOLATED FROM THE MALAYAN KRAIT
7V2G	;	0.98	;	The 0.98 angstrom structure of the human FABP3 Y19F mutant complexed with palmitic acid
2GCE	;	1.85	;	The 1,1-proton transfer reaction mechanism by alpha-methylacyl-CoA racemase is catalyzed by an aspartate/histidine pair and involves a smooth, methionine-rich surface for binding the fatty acyl moiety
2GD0	;	1.7	;	The 1,1-proton transfer reaction mechanism by alpha-methylacyl-CoA racemase is catalyzed by an aspartate/histidine pair and involves a smooth, methionine-rich surface for binding the fatty acyl moiety
2GD2	;	1.7	;	The 1,1-proton transfer reaction mechanism by alpha-methylacyl-CoA racemase is catalyzed by an aspartate/histidine pair and involves a smooth, methionine-rich surface for binding the fatty acyl moiety
2GD6	;	2.3	;	The 1,1-proton transfer reaction mechanism by alpha-methylacyl-CoA racemase is catalyzed by an aspartate/histidine pair and involves a smooth, methionine-rich surface for binding the fatty acyl moiety
2GCI	;	1.6	;	The 1,1-proton transfer reaction mechanism by alpha-methylacyl-CoA racemase is catalyzed by an asparte/histidine pair and involves a smooth, methionine-rich surface for binding the fatty acyl moiety
6FC9	;		;	The 1,8-bis(aminomethyl)anthracene and Quadruplex-duplex junction complex
1EXR	;	1.0	;	THE 1.0 ANGSTROM CRYSTAL STRUCTURE OF CA+2 BOUND CALMODULIN
4DP9	;	1.0	;	The 1.00 Angstrom crystal structure of oxidized (CuII) poplar plastocyanin A at pH 6.0
4DPB	;	1.0	;	The 1.00 Angstrom crystal structure of oxidized (CuII) poplar plastocyanin A at pH 8.0
7FD7	;	1.0	;	The 1.00 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with perfluoroheptanoic acid
5B27	;	1.02	;	The 1.02A structure of human FABP3 M20S mutant complexed with palmitic acid
5AVN	;	1.03	;	The 1.03 angstrom structure (P212121) of glucose isomerase crystallized in high-strength agarose hydrogel
4DPA	;	1.05	;	The 1.05 Angstrom crystal structure of reduced (CuI) poplar plastocyanin A at pH 6.0
7FEK	;	1.05	;	The 1.05 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with perfluorooctanoic acid
5NGX	;	1.06	;	The 1.06 A resolution structure of the L16G mutant of ferric cytochrome c prime from Alcaligenes xylosoxidans, complexed with nitrite
4DPC	;	1.06	;	The 1.06 Angstrom crystal structure of reduced (CuI) poplar plastocyanin A at pH 8.0
4DP8	;	1.07	;	The 1.07 Angstrom crystal structure of reduced (CuI) poplar plastocyanin A at pH 4.0
4DP7	;	1.08	;	The 1.08 Angstrom crystal structure of oxidized (CuII) poplar plastocyanin A at pH 4.0
4MQ3	;	1.08	;	The 1.1 Angstrom Structure of Catalytic Core Domain of FIV Integrase
1Z53	;	1.13	;	The 1.13 Angstrom Structure of Iron-free Cytochrome c Peroxidase
4LWU	;	1.14	;	The 1.14A Crystal Structure of Humanized Xenopus MDM2 with RO5499252
1AGY	;	1.15	;	The 1.15 angstrom refined structure of fusarium solani pisi cutinase
3WS7	;	1.18	;	The 1.18 A resolution structure of L-serine 3-dehydrogenase complexed with NADP+ and sulfate ion from the hyperthermophilic archaeon Pyrobaculum calidifontis
1Z2U	;	1.1	;	The 1.1A crystallographic structure of ubiquitin-conjugating enzyme (ubc-2) from Caenorhabditis elegans: functional and evolutionary significance
3GVN	;	1.2	;	The 1.2 Angstroem crystal structure of an E.coli tRNASer acceptor stem microhelix reveals two magnesium binding sites
1J98	;	1.2	;	The 1.2 Angstrom Structure of Bacillus subtilis LuxS
1NOT	;	1.2	;	THE 1.2 ANGSTROM STRUCTURE OF G1 ALPHA CONOTOXIN
2KNT	;	1.2	;	THE 1.2 ANGSTROM STRUCTURE OF KUNITZ TYPE DOMAIN C5
1LOK	;	1.2	;	The 1.20 Angstrom Resolution Crystal Structure of the Aminopeptidase from Aeromonas proteolytica Complexed with Tris: A Tale of Buffer Inhibition
6XLR	;	1.23	;	The 1.23 Angstrom crystal structure of galactose oxidase variant with genetically incorporated Cl2-Tyr272
1Y6X	;	1.25	;	The 1.25 A resolution structure of phosphoribosyl-ATP pyrophosphohydrolase from Mycobacterium tuberculosis
3C90	;	1.79	;	The 1.25 A Resolution Structure of Phosphoribosyl-ATP Pyrophosphohydrolase from Mycobacterium tuberculosis, crystal form II
5ZXF	;	1.25	;	The 1.25A Crystal structure of His6-tagged Mdm2 in complex with nutlin-3a
4J7D	;	1.25	;	The 1.25A crystal structure of humanized Xenopus MDM2 with a nutlin fragment, RO5045331
6XKH	;	1.28	;	THE 1.28A CRYSTAL STRUCTURE OF 3CL MAINPRO OF SARS-COV-2 WITH OXIDIZED C145 (sulfinic acid cysteine)
5B29	;	1.28	;	The 1.28A structure of human FABP3 F16V mutant complexed with palmitic acid at room temperature
4J74	;	1.2	;	The 1.2A crystal structure of humanized Xenopus MDM2 with RO0503918 - a nutlin fragment
3B9W	;	1.3	;	The 1.3 A resolution structure of Nitrosomonas europaea Rh50 and mechanistic implications for NH3 transport by Rhesus family proteins
193L	;	1.33	;	THE 1.33 A STRUCTURE OF TETRAGONAL HEN EGG WHITE LYSOZYME
3MBK	;	1.35	;	The 1.35 A Structure of the Phosphatase Domain of the Suppressor of T Cell Receptor Signalling Protein in Complex with Sulphate
4DP1	;	1.35	;	The 1.35 Angstrom crystal structure of reduced (CuI) poplar plastocyanin B at pH 4.0
4YE2	;	3.098	;	The 1.35 structure of a viral RNase L antagonist reveals basis for the 2'-5'-oligoadenylate binding and enzyme activity.
4RPT	;	1.35	;	The 1.35A structure of a viral RNase L antagonist reveals basis for the 2'-5'-oligoadenylate binding and enzyme activity.
4WBK	;	1.37	;	The 1.37 angstrom X-ray structure of the human heart fatty acid-binding protein complexed with stearic acid
2ZMZ	;	1.37	;	The 1.37-A crystal structure of the hydroxylamine-induced deoxy-form of the copper-bound tyrosinase in complex with a caddie protein from Streptomyces castaneoglobisporus
3E2D	;	1.4	;	The 1.4 A crystal structure of the large and cold-active Vibrio sp. alkaline phosphatase
4MLL	;	1.37	;	The 1.4 A structure of the class D beta-lactamase OXA-1 K70D complexed with oxacillin
3MWH	;	2.05	;	The 1.4 Ang crystal structure of the ArsD arsenic metallochaperone provides insights into its interactions with the ArsA ATPase
194L	;	1.4	;	THE 1.40 A STRUCTURE OF SPACEHAB-01 HEN EGG WHITE LYSOZYME
4Y9H	;	1.43	;	The 1.43 angstrom crystal structure of bacteriorhodopsin crystallized from bicelles
1RCQ	;	1.45	;	The 1.45 A crystal structure of alanine racemase from a pathogenic bacterium, Pseudomonas aeruginosa, contains both internal and external aldimine forms
1JBO	;	1.45	;	The 1.45A Three-Dimensional Structure of c-Phycocyanin from the Thermophylic Cyanobacterium Synechococcus elongatus
6XLT	;	1.478	;	The 1.48 Angstrom crystal structure of evolved galactose oxidase variant A3.E7
3C1V	;	1.5	;	The 1.5 A Crystal structure of Ca2+-bound S100A4
3DGT	;	1.5	;	The 1.5 A crystal structure of endo-1,3-beta-glucanase from Streptomyces sioyaensis
6XIP	;	1.5	;	The 1.5 A Crystal Structure of the Co-factor Complex of NSP7 and the C-terminal Domain of NSP8 from SARS CoV-2
2CFE	;	1.5	;	The 1.5 A crystal structure of the Malassezia sympodialis Mala s 6 allergen, a member of the cyclophilin pan-allergen family
1SJ1	;	1.5	;	The 1.5 A Resolution Crystal Structure of [Fe3S4]-Ferredoxin from the hyperthermophilic Archaeon Pyrococcus furiosus
4DP0	;	1.5	;	The 1.5 Angstrom crystal structure of oxidized (CuII) poplar plastocyanin B at pH 4.0
4Z67	;	1.5	;	The 1.5-angstrom crystal structure of Mn(2+)-bound PqqB from Pseudomonas Putida
8DQV	;	1.52	;	The 1.52 angstrom CryoEM structure of the [NiFe]-hydrogenase Huc from Mycobacterium smegmatis - catalytic dimer (Huc2S2L)
4DP4	;	1.54	;	The 1.54 Angstrom crystal structure of reduced (CuI) poplar plastocyanin B at pH 6.0
1IUQ	;	1.55	;	The 1.55 A Crystal Structure of Glycerol-3-Phosphate Acyltransferase
4OO7	;	1.65	;	THE 1.55A CRYSTAL STRUCTURE of NAF1 (MINER1): THE REDOX-ACTIVE 2FE-2S PROTEIN
4Z5Y	;	1.561	;	The 1.56-angstrom crystal structure of copper(II)-bound PqqB from Pseudomonas Putida
2AEX	;	1.58	;	The 1.58A Crystal Structure of Human Coproporphyrinogen Oxidase Reveals the Structural Basis of Hereditary Coproporphyria
1L8N	;	1.5	;	The 1.5A crystal structure of alpha-D-glucuronidase from Bacillus stearothermophilus T-1, complexed with 4-O-methyl-glucuronic acid and xylotriose
3GEN	;	1.6	;	The 1.6 A crystal structure of human bruton's tyrosine kinase bound to a pyrrolopyrimidine-containing compound
3C8Z	;	1.6	;	The 1.6 A Crystal Structure of MshC: The Rate Limiting Enzyme in the Mycothiol Biosynthetic Pathway
2G7E	;	1.6	;	The 1.6 A crystal structure of Vibrio cholerae extracellular endonuclease I
4B5L	;	1.6	;	The 1.6 A High Energy Room Temperature Structure of Proteinase K at 38.4 keV and 0.04 MGy
1JXG	;	1.6	;	The 1.6 A Resolution Crystal Structure of a Mutant Poplar Plastocyanin Bearing a 21-25 Engeneered Disulfide Bridge
2C0Z	;	1.6	;	The 1.6 A resolution crystal structure of NovW: a 4-keto-6-deoxy sugar epimerase from the novobiocin biosynthetic gene cluster of Streptomyces spheroides
1MY6	;	1.6	;	The 1.6 A Structure of Fe-Superoxide Dismutase from the thermophilic cyanobacterium Thermosynechococcus elongatus : Correlation of EPR and Structural Characteristics
1SSC	;	2.0	;	THE 1.6 ANGSTROMS STRUCTURE OF A SEMISYNTHETIC RIBONUCLEASE CRYSTALLIZED FROM AQUEOUS ETHANOL. COMPARISON WITH CRYSTALS FROM SALT SOLUTIONS AND WITH RNASE A FROM AQUEOUS ALCOHOL SOLUTIONS
1PTF	;	1.6	;	THE 1.6 ANGSTROMS STRUCTURE OF HISTIDINE-CONTAINING PHOSPHOTRANSFER PROTEIN HPR FROM STREPTOCOCCUS FAECALIS
1KNT	;	1.6	;	THE 1.6 ANGSTROMS STRUCTURE OF THE KUNITZ-TYPE DOMAIN FROM THE ALPHA3 CHAIN OF THE HUMAN TYPE VI COLLAGEN
4EN1	;	1.62	;	The 1.62A structure of a FRET-optimized Cerulean Fluorescent Protein
4J7E	;	1.63	;	The 1.63A crystal structure of humanized Xenopus MDM2 with a nutlin fragment, RO5524529
1QTX	;	1.65	;	THE 1.65 ANGSTROM STRUCTURE OF CALMODULIN RS20 PEPTIDE COMPLEX
3F4W	;	1.65	;	The 1.65A Crystal Structure of 3-hexulose-6-phosphate synthase from Salmonella typhimurium
1PGX	;	1.66	;	THE 1.66 ANGSTROMS X-RAY STRUCTURE OF THE B2 IMMUNOGLOBULIN-BINDING DOMAIN OF STREPTOCOCCAL PROTEIN G AND COMPARISON TO THE NMR STRUCTURE OF THE B1 DOMAIN
7UUR	;	1.67	;	The 1.67 Angstrom CryoEM structure of the [NiFe]-hydrogenase Huc from Mycobacterium smegmatis - catalytic dimer (Huc2S2L)
4DP6	;	1.67	;	The 1.67 Angstrom crystal structure of reduced (CuI) poplar plastocyanin B at pH 8.0
8Q2E	;	1.68	;	The 1.68-A X-ray crystal structure of Sporosarcina pasteurii urease inhibited by thiram and bound to dimethylditiocarbamate
4Z6X	;	1.68	;	The 1.68-angstrom crystal structure of acitive-site metal-free PqqB from Pseudomonas putida
4LWT	;	1.6	;	The 1.6A Crystal Structure of Humanized Xenopus MDM2 with RO5027344
2H8O	;	1.6	;	The 1.6A crystal structure of the geranyltransferase from Agrobacterium tumefaciens
1NS9	;	1.6	;	The 1.6A Structure of Horse Methemoglobin at pH 7.1
1ECS	;	1.7	;	THE 1.7 A CRYSTAL STRUCTURE OF A BLEOMYCIN RESISTANCE DETERMINANT ENCODED ON THE TRANSPOSON TN5
1K9D	;	1.7	;	The 1.7 A crystal structure of alpha-D-glucuronidase, a family-67 glycoside hydrolase from Bacillus stearothermophilus T-1
2IE2	;	1.7	;	The 1.7 A crystal structure of Dronpa: a photoswitchable green fluorescent protein
1IA8	;	1.7	;	THE 1.7 A CRYSTAL STRUCTURE OF HUMAN CELL CYCLE CHECKPOINT KINASE CHK1
1EWF	;	1.7	;	THE 1.7 ANGSTROM CRYSTAL STRUCTURE OF BPI
3N90	;	1.7	;	The 1.7 Angstrom resolution crystal structure of AT2G44920, a pentapeptide repeat protein from Arabidopsis thaliana thylakoid lumen.
1FVK	;	1.7	;	THE 1.7 ANGSTROM STRUCTURE OF WILD TYPE DISULFIDE BOND FORMATION PROTEIN (DSBA)
1GCA	;	1.7	;	THE 1.7 ANGSTROMS REFINED X-RAY STRUCTURE OF THE PERIPLASMIC GLUCOSE(SLASH)GALACTOSE RECEPTOR FROM SALMONELLA TYPHIMURIUM
1H5U	;	1.76	;	THE 1.76 A RESOLUTION CRYSTAL STRUCTURE OF GLYCOGEN PHOSPHORYLASE B COMPLEXED WITH GLUCOSE AND CP320626, A POTENTIAL ANTIDIABETIC DRUG
3HA9	;	1.7	;	The 1.7A Crystal Structure of a Thioredoxin-like Protein from Aeropyrum pernix
3TBJ	;	1.8	;	The 1.7A crystal structure of Actibind a T2 ribonucleases as antitumorigenic agents
4IPF	;	1.7	;	The 1.7A crystal structure of humanized Xenopus MDM2 with RO5045337
4N5T	;	1.7	;	The 1.7A Crystal Structure of MDMX with a Stapled Peptide, ATSP-7041
1EBL	;	1.8	;	THE 1.8 A CRYSTAL STRUCTURE AND ACTIVE SITE ARCHITECTURE OF BETA-KETOACYL-[ACYL CARRIER PROTEIN] SYNTHASE III (FABH) FROM ESCHERICHIA COLI
2B6N	;	1.8	;	The 1.8 A crystal structure of a Proteinase K like enzyme from a psychrotroph Serratia species
1HYL	;	1.8	;	THE 1.8 A STRUCTURE OF COLLAGENASE FROM HYPODERMA LINEATUM
1BVX	;	1.8	;	THE 1.8 A STRUCTURE OF GEL GROWN TETRAGONAL HEN EGG WHITE LYSOZYME
1BWH	;	1.8	;	THE 1.8 A STRUCTURE OF GROUND CONTROL GROWN TETRAGONAL HEN EGG WHITE LYSOZYME
1BWI	;	1.8	;	THE 1.8 A STRUCTURE OF MICROBATCH OIL DROP GROWN TETRAGONAL HEN EGG WHITE LYSOZYME
1BWJ	;	1.8	;	THE 1.8 A STRUCTURE OF MICROGRAVITY GROWN TETRAGONAL HEN EGG WHITE LYSOZYME
4DP2	;	1.8	;	The 1.8 Angstrom crystal structure of oxidized (CuII) poplar plastocyanin B at pH 6.0
1AFW	;	1.8	;	THE 1.8 ANGSTROM CRYSTAL STRUCTURE OF THE DIMERIC PEROXISOMAL THIOLASE OF SACCHAROMYCES CEREVISIAE
4NYO	;	1.8	;	The 1.8 Angstrom Crystal Structure of the Periplasmic Divalent Cation Tolerance Protein Cuta from Pyrococcus Horikoshii OT3
1YAC	;	1.8	;	THE 1.8 ANGSTROM CRYSTAL STRUCTURE OF THE YCAC GENE PRODUCT FROM ESCHERICHIA COLI REVEALS AN OCTAMERIC HYDROLASE OF UNKNOWN SPECIFICITY
1QS7	;	1.8	;	The 1.8 angstrom structure of calmodulin rs20 peptide complex
1CBM	;	1.74	;	THE 1.8 ANGSTROM STRUCTURE OF CARBONMONOXY-BETA4 HEMOGLOBIN: ANALYSIS OF A HOMOTETRAMER WITH THE R QUATERNARY STRUCTURE OF LIGANDED ALPHA2BETA2 HEMOGLOBIN
1SGC	;	1.8	;	THE 1.8 ANGSTROMS STRUCTURE OF THE COMPLEX BETWEEN CHYMOSTATIN AND STREPTOMYCES GRISEUS PROTEASE A. A MODEL FOR SERINE PROTEASE CATALYTIC TETRAHEDRAL INTERMEDIATES
6XLS	;	1.797	;	The 1.80 Angstrom crystal structure of galactose oxidase variant with genetically incorporated F2-Tyr272
4DP5	;	1.88	;	The 1.88 Angstrom crystal structure of oxidized (CuII) poplar plastocyanin B at pH 8.0
1XFC	;	1.9	;	The 1.9 A crystal structure of alanine racemase from Mycobacterium tuberculosis contains a conserved entryway into the active site
4J6C	;	1.9	;	The 1.9 A crystal structure of CYP154C5 from Nocardia farcinica in complex with progesterone
6W01	;	1.9	;	The 1.9 A Crystal Structure of NSP15 Endoribonuclease from SARS CoV-2 in the Complex with a Citrate
2ID4	;	1.9	;	The 1.9 A structure of Kex2 in complex with an Ac-R-E-R-K-chloromethyl ketone inhibitor.
1F0K	;	1.9	;	THE 1.9 ANGSTROM CRYSTAL STRUCTURE OF E. COLI MURG
1CBL	;	1.8	;	THE 1.9 ANGSTROM STRUCTURE OF DEOXY-BETA4 HEMOGLOBIN: ANALYSIS OF THE PARTITIONING OF QUATERNARY-ASSOCIATED AND LIGAND-INDUCED CHANGES IN TERTIARY STRUCTURE
1VRK	;	1.9	;	THE 1.9 ANGSTROM STRUCTURE OF E84K-CALMODULIN RS20 PEPTIDE COMPLEX
1GCG	;	1.9	;	THE 1.9 ANGSTROMS X-RAY STRUCTURE OF A CLOSED UNLIGANDED FORM OF THE PERIPLASMIC GLUCOSE(SLASH)GALACTOSE RECEPTOR FROM SALMONELLA TYPHIMURIUM
1LI1	;	1.9	;	The 1.9-A crystal structure of the noncollagenous (NC1) domain of human placenta collagen IV shows stabilization via a novel type of covalent Met-Lys cross-link
1GWI	;	1.92	;	The 1.92 A structure of Streptomyces coelicolor A3(2) CYP154C1: A new monooxygenase that functionalizes macrolide ring systems
6WQD	;	1.95	;	The 1.95 A Crystal Structure of the Co-factor Complex of NSP7 and the C-terminal Domain of NSP8 from SARS-CoV-2
2G7F	;	1.95	;	The 1.95 A crystal structure of Vibrio cholerae extracellular endonuclease I
4Z7R	;	1.982	;	The 1.98-angstrom crystal structure of Zn(2+)-bound PqqB from Methylobacterium extorquens
4J3E	;	1.91	;	The 1.9A crystal structure of humanized Xenopus Mdm2 with nutlin-3a
4JRG	;	1.9	;	The 1.9A crystal structure of humanized Xenopus MDM2 with RO5313109 - a pyrrolidine MDM2 inhibitor
1BFF	;	2.0	;	THE 154 AMINO ACID FORM OF HUMAN BASIC FIBROBLAST GROWTH FACTOR
1XQN	;	2.5	;	The 15k neutron structure of saccharide-free concanavalin A
3EW3	;	3.8	;	the 1:2 complex between a Nterminal elongated prolactin and the extra cellular domain of the rat prolactin receptor
3FYM	;	1.0	;	The 1A structure of YmfM, a putative DNA-binding membrane protein from Staphylococcus aureus
1FM2	;	2.0	;	THE 2 ANGSTROM CRYSTAL STRUCTURE OF CEPHALOSPORIN ACYLASE
1O8U	;	2.0	;	The 2 Angstrom Structure of 6-Oxo Camphor Hydrolase: New Structural Diversity in the Crotonase Superfamily
2WS2	;	2.01	;	The 2 Angstrom structure of a Nu-class GST from Haemonchus contortus
1RSM	;	2.0	;	THE 2-ANGSTROMS RESOLUTION STRUCTURE OF A THERMOSTABLE RIBONUCLEASE A CHEMICALLY CROSS-LINKED BETWEEN LYSINE RESIDUES 7 AND 41
1S4V	;	2.0	;	The 2.0 A crystal structure of the KDEL-tailed cysteine endopeptidase functioning in programmed cell death of Ricinus communis endosperm
6PUA	;	2.0	;	The 2.0 A Crystal Structure of the Type B Chloramphenicol Acetyltransferase from Vibrio cholerae
1MHO	;	2.0	;	THE 2.0 A STRUCTURE OF HOLO S100B FROM BOVINE BRAIN
1S96	;	2.0	;	The 2.0 A X-ray structure of Guanylate Kinase from E.coli
1KXG	;	2.0	;	The 2.0 Ang Resolution Structure of BLyS, B Lymphocyte Stimulator.
4K5R	;	2.0	;	The 2.0 angstrom crystal structure of MTMOIV, a baeyer-villiger monooxygenase from the mithramycin biosynthetic pathway in streptomyces argillaceus.
1TE5	;	2.0	;	The 2.0 Angstrom crystal structure of predicted glutamine amidotransferase from Pseudomonas aeruginosa PA01
4NYP	;	2.0	;	The 2.0 Angstrom Crystal Structure of Pyrococcus Horikoshii Cuta1 Complexed With NA+
3DU1	;	2.0	;	The 2.0 Angstrom Resolution Crystal Structure of HetL, a Pentapeptide Repeat Protein involved in Heterocyst Differentiation Regulation from the Cyanobacterium Nostoc sp. Strain PCC 7120
3E56	;	2.01	;	The 2.0 Angstrom Resolution Crystal Structure of NpR1517, a Putative Heterocyst Differentiation Inhibitor from Nostoc punctiforme
1G5Y	;	2.0	;	THE 2.0 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN TETRAMER IN THE PRESENCE OF A NON-ACTIVATING RETINOIC ACID ISOMER.
1GV3	;	2.0	;	The 2.0 Angstrom resolution structure of the catalytic portion of a cyanobacterial membrane-bound manganese superoxide dismutase
2ARL	;	2.0	;	The 2.0 angstroms crystal structure of a pocilloporin at pH 3.5: the structural basis for the linkage between color transition and halide binding
1POH	;	2.0	;	THE 2.0 ANGSTROMS RESOLUTION STRUCTURE OF ESCHERICHIA COLI HISTIDINE-CONTAINING PHOSPHOCARRIER PROTEIN HPR: A REDETERMINATION
1CEW	;	2.0	;	THE 2.0 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF CHICKEN EGG WHITE CYSTATIN AND ITS POSSIBLE MODE OF INTERACTION WITH CYSTEINE PROTEINASES
1UIS	;	2.0	;	The 2.0 crystal structure of eqFP611, a far-red fluorescent protein from the sea anemone Entacmaea quadricolor
1L5X	;	2.0	;	The 2.0-Angstrom resolution crystal structure of a survival protein E (SurE) homolog from Pyrobaculum aerophilum
1FVJ	;	2.06	;	THE 2.06 ANGSTROM STRUCTURE OF THE H32Y MUTANT OF THE DISULFIDE BOND FORMATION PROTEIN (DSBA)
2AO2	;	2.07	;	The 2.07 Angstrom crystal structure of Mycobacterium tuberculosis chorismate mutase reveals unexpected gene duplication and suggests a role in host-pathogen interactions
5L92	;	2.1	;	The 2.1 A crystal structure of CYP109E1 from Bacillus megaterium in complex with corticosterone
1WZ9	;	2.1	;	The 2.1 A structure of a tumour suppressing serpin
1W3W	;	1.99	;	The 2.1 Angstroem resolution structure of annexin A8
3V83	;	2.102	;	The 2.1 angstrom crystal structure of diferric human transferrin
3VE2	;	2.14	;	The 2.1 angstrom crystal structure of Transferrin binding protein B (TbpB) from serogroup B M982 Neisseria meningitidis
1FM9	;	2.1	;	THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND GI262570 AND CO-ACTIVATOR PEPTIDES.
1FM6	;	2.1	;	THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND ROSIGLITAZONE AND CO-ACTIVATOR PEPTIDES.
1CQD	;	2.1	;	THE 2.1 ANGSTROM STRUCTURE OF A CYSTEINE PROTEASE WITH PROLINE SPECIFICITY FROM GINGER RHIZOME, ZINGIBER OFFICINALE
3SDP	;	2.1	;	THE 2.1 ANGSTROMS RESOLUTION STRUCTURE OF IRON SUPEROXIDE DISMUTASE FROM PSEUDOMONAS OVALIS
1VRP	;	2.1	;	The 2.1 Structure of T. californica Creatine Kinase Complexed with the Transition-State Analogue Complex, ADP-Mg 2+ /NO3-/Creatine
6I9Y	;	2.14	;	The 2.14 A X-ray crystal structure of Sporosarcina pasteurii urease in complex with Au(I) ions
1PCS	;	2.15	;	THE 2.15 A CRYSTAL STRUCTURE OF A TRIPLE MUTANT PLASTOCYANIN FROM THE CYANOBACTERIUM SYNECHOCYSTIS SP. PCC 6803
4A3Q	;	2.15	;	The 2.15 Angstrom resolution crystal structure of Staphylococcus aureus alanine racemase
7UTD	;	2.19	;	The 2.19-angstrom CryoEM structure of the [NiFe]-hydrogenase Huc from Mycobacterium smegmatis - Complex minus stalk
2G3O	;	2.1	;	The 2.1A crystal structure of copGFP
2XCS	;	2.1	;	The 2.1A crystal structure of S. aureus Gyrase complex with GSK299423 and DNA
1YZW	;	2.1	;	The 2.1A Crystal Structure of the Far-red Fluorescent Protein HcRed: Inherent Conformational Flexibility of the Chromophore
1NS6	;	2.05	;	The 2.1A Structure of Horse (alpha hemichrome/beta met) Hemoglobin at pH 5.4
5L91	;	2.2	;	The 2.2 A crystal structure of CYP109E1 from Bacillus megaterium bound with four corticosterone molecules
4JBT	;	2.2	;	The 2.2 A crystal structure of CYP154C5 from Nocardia farcinica in complex with androstenedione
4J6B	;	2.2	;	The 2.2 A crystal structure of CYP154C5 from Nocardia farcinica in complex with pregnenolone
1PJP	;	2.2	;	THE 2.2 A CRYSTAL STRUCTURE OF HUMAN CHYMASE IN COMPLEX WITH SUCCINYL-ALA-ALA-PRO-PHE-CHLOROMETHYLKETONE
1R64	;	2.2	;	The 2.2 A crystal structure of Kex2 protease in complex with Ac-Arg-Glu-Lys-boroArg peptidyl boronic acid inhibitor
3B3F	;	2.2	;	The 2.2 A crystal structure of the catalytic domain of coactivator-associated arginine methyl transferase I(CARM1,142-478), in complex with S-adenosyl homocysteine
6U9C	;	2.2	;	The 2.2 A Crystal Structure of the Type B Chloramphenicol Acetyltransferase from Vibrio cholerae in the complex with Acetyl CoA
1GXW	;	2.18	;	the 2.2 A resolution structure of thermolysin crystallized in presence of potassium thiocyanate
3ZD5	;	2.2	;	THE 2.2 A STRUCTURE OF A FULL-LENGTH CATALYTICALLY ACTIVE HAMMERHEAD RIBOZYME
1JVI	;	2.2	;	THE 2.2 ANGSTROM RESOLUTION STRUCTURE OF BACILLUS SUBTILIS LUXS/RIBOSILHOMOCYSTEINE COMPLEX
3VCP	;	2.2	;	The 2.2 Angstrom structure of Stc2 with proline bound in the active site
1TND	;	2.2	;	THE 2.2 ANGSTROMS CRYSTAL STRUCTURE OF TRANSDUCIN-ALPHA COMPLEXED WITH GTP GAMMA S
1NSB	;	2.2	;	THE 2.2 ANGSTROMS RESOLUTION CRYSTAL STRUCTURE OF INFLUENZA B NEURAMINIDASE AND ITS COMPLEX WITH SIALIC ACID
5L94	;	2.25	;	The 2.25 A crystal structure of CYP109E1 from Bacillus megaterium in complex with testosterone
3FRL	;	2.25	;	The 2.25 A crystal structure of LipL32, the major surface antigen of Leptospira interrogans serovar Copenhageni
2CKW	;	2.3	;	The 2.3 A resolution structure of the Sapporo virus RNA dependant RNA polymerase.
3R0R	;	2.35	;	The 2.3 A structure of porcine circovirus 2
1K74	;	2.3	;	The 2.3 Angstrom resolution crystal structure of the heterodimer of the human PPARgamma and RXRalpha ligand binding domains respectively bound with GW409544 and 9-cis retinoic acid and co-activator peptides.
1JQW	;	2.3	;	THE 2.3 ANGSTROM RESOLUTION STRUCTURE OF BACILLUS SUBTILIS LUXS/HOMOCYSTEINE COMPLEX
4LWV	;	2.32	;	The 2.3A Crystal Structure of Humanized Xenopus MDM2 with RO5545353
4J6D	;	2.4	;	The 2.4 A crystal structure of CYP154C5 from Nocardia farcinica in complex with testosterone
3B3G	;	2.4	;	The 2.4 A crystal structure of the apo catalytic domain of coactivator-associated arginine methyl transferase I(CARM1,140-480).
1OT5	;	2.4	;	The 2.4 Angstrom Crystal Structure of Kex2 in complex with a peptidyl-boronic acid inhibitor
2UUT	;	2.4	;	The 2.4 angstrom resolution structure of the D346G mutant of the Sapporo Virus RdRp polymerase
2WRT	;	2.4	;	The 2.4 Angstrom structure of the Fasciola hepatica mu class GST, GST26
1LPB	;	2.46	;	THE 2.46 ANGSTROMS RESOLUTION STRUCTURE OF THE PANCREATIC LIPASE COLIPASE COMPLEX INHIBITED BY A C11 ALKYL PHOSPHONATE
5VES	;	2.4	;	The 2.4A crystal structure of OmpA domain of OmpA from Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S
3ODU	;	2.5	;	The 2.5 A structure of the CXCR4 chemokine receptor in complex with small molecule antagonist IT1t
1W45	;	2.51	;	The 2.5 Angstroem structure of the K16A mutant of annexin A8, which has an intact N-terminus.
1K7L	;	2.5	;	The 2.5 Angstrom resolution crystal structure of the human PPARalpha ligand binding domain bound with GW409544 and a co-activator peptide.
1G1U	;	2.5	;	THE 2.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN IN TETRAMER IN THE ABSENCE OF LIGAND
1PAF	;	2.5	;	THE 2.5 ANGSTROMS STRUCTURE OF POKEWEED ANTIVIRAL PROTEIN
1PAG	;	2.8	;	THE 2.5 ANGSTROMS STRUCTURE OF POKEWEED ANTIVIRAL PROTEIN
4Z5Z	;	2.54	;	The 2.5-angstrom crystal structure of Mg(2+)-bound PqqB from Pseudomonas Putida
4Z60	;	2.5	;	The 2.5-angstrom of crystal structure of Zn(2+)-bound PqqB from Pseudomonas Putida
3B3J	;	2.55	;	The 2.55 A crystal structure of the apo catalytic domain of coactivator-associated arginine methyl transferase I(CARM1:28-507, residues 28-146 and 479-507 not ordered)
4JSC	;	2.5	;	The 2.5A crystal structure of humanized Xenopus MDM2 with RO5316533 - a pyrrolidine MDM2 inhibitor
3EML	;	2.6	;	The 2.6 A Crystal Structure of a Human A2A Adenosine Receptor bound to ZM241385.
3D3L	;	2.6	;	The 2.6 A crystal structure of the lipoxygenase domain of human arachidonate 12-lipoxygenase, 12S-type
2ANT	;	2.6	;	THE 2.6 A STRUCTURE OF ANTITHROMBIN INDICATES A CONFORMATIONAL CHANGE AT THE HEPARIN BINDING SITE
1JGC	;	2.6	;	The 2.6 A Structure Resolution of Rhodobacter capsulatus Bacterioferritin with Metal-free Dinuclear Site and Heme Iron in a Crystallographic Special Position
3EIT	;	2.56	;	the 2.6 angstrom crystal structure of CHBP, the Cif Homologue from Burkholderia pseudomallei
1EQG	;	2.61	;	THE 2.6 ANGSTROM MODEL OF OVINE COX-1 COMPLEXED WITH IBUPROFEN
1LTD	;	2.6	;	THE 2.6 ANGSTROMS REFINED STRUCTURE OF THE ESCHERICHIA COLI RECOMBINANT SACCHAROMYCES CEREVISIAE FLAVOCYTOCHROME B2-SULPHITE COMPLEX
2GSY	;	2.6	;	The 2.6A structure of Infectious Bursal Virus Derived T=1 Particles
3LHB	;	2.7	;	THE 2.7 ANGSTROM CRYSTAL STRUCTURE OF DEOXYGENATED HEMOGLOBIN FROM THE SEA LAMPREY (PETROMYZON MARINUS)
1EQH	;	2.7	;	THE 2.7 ANGSTROM MODEL OF OVINE COX-1 COMPLEXED WITH FLURBIPROFEN
1I3S	;	2.7	;	THE 2.7 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF A MUTATED BACULOVIRUS P35 AFTER CASPASE CLEAVAGE
1HT8	;	2.69	;	THE 2.7 ANGSTROM RESOLUTION MODEL OF OVINE COX-1 COMPLEXED WITH ALCLOFENAC
1HT5	;	2.75	;	THE 2.75 ANGSTROM RESOLUTION MODEL OF OVINE COX-1 COMPLEXED WITH METHYL ESTER FLURBIPROFEN
5UF6	;	2.8	;	The 2.8 A Electron Microscopy Structure of Adeno-Associated Virus-DJ Bound by a Heparanoid Pentasaccharide
1XU8	;	2.8	;	The 2.8 A structure of a tumour suppressing serpin
1GFW	;	2.8	;	THE 2.8 ANGSTROM CRYSTAL STRUCTURE OF CASPASE-3 (APOPAIN OR CPP32)IN COMPLEX WITH AN ISATIN SULFONAMIDE INHIBITOR.
1PXT	;	2.8	;	THE 2.8 ANGSTROMS STRUCTURE OF PEROXISOMAL 3-KETOACYL-COA THIOLASE OF SACCHAROMYCES CEREVISIAE: A FIVE LAYERED A-B-A-B-A STRUCTURE, CONSTRUCTED FROM TWO CORE DOMAINS OF IDENTICAL TOPOLOGY
3VE1	;	2.956	;	The 2.9 angstrom crystal structure of Transferrin binding protein B (TbpB) from serogroup B M982 Neisseria meningitidis in complex with human transferrin
1SER	;	2.9	;	THE 2.9 ANGSTROMS CRYSTAL STRUCTURE OF T. THERMOPHILUS SERYL-TRNA SYNTHETASE COMPLEXED WITH TRNA SER
2XCQ	;	2.98	;	The 2.98A crystal structure of the catalytic core (B'A' region) of Staphylococcus aureus DNA Gyrase
3NSS	;	1.902	;	The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active sites
6M17	;	2.9	;	The 2019-nCoV RBD/ACE2-B0AT1 complex
6MDM	;	4.4	;	The 20S supercomplex engaging the SNAP-25 N-terminus (class 1)
6MDN	;	4.4	;	The 20S supercomplex engaging the SNAP-25 N-terminus (class 2)
2L87	;		;	The 27-residue N-terminus CCR5-peptide in a ternary complex with HIV-1 gp120 and a CD4-mimic peptide
6XRZ	;	6.9	;	The 28-kDa Frameshift Stimulation Element from the SARS-CoV-2 RNA Genome
8ST0	;	2.4	;	The 2alpha3beta stoichiometry of full-length human alpha4beta2 nicotinic acetylcholine receptor in complex with acetylcholine
8SSZ	;	2.64	;	The 2alpha3beta stoichiometry of full-length human alpha4beta2 nicotinic acetylcholine receptor in complex with acetylcholine and calcium
8ST4	;	2.35	;	The 2alpha3beta stoichiometry of human alpha4beta2 nicotinic acetylcholine receptor in complex with acetylcholine
8ST3	;	2.93	;	The 2alpha3beta stoichiometry of human alpha4beta2 nicotinic acetylcholine receptor in complex with acetylcholine and calcium
1QNO	;	2.0	;	The 3-D structure of a Trichoderma reesei b-mannanase from glycoside hydrolase family 5
1QNP	;	1.5	;	The 3-D structure of a Trichoderma reesei b-mannanase from glycoside hydrolase family 5
1QNQ	;	1.65	;	The 3-D structure of a Trichoderma reesei b-mannanase from glycoside hydrolase family 5
1QNR	;	1.4	;	The 3-D structure of a Trichoderma reesei b-mannanase from glycoside hydrolase family 5
1QNS	;	1.5	;	The 3-D structure of a Trichoderma reesei b-mannanase from glycoside hydrolase family 5
1SMR	;	2.0	;	The 3-d structure of mouse submaxillary renin complexed with a decapeptide inhibitor ch-66 based on the 4-16 fragment of rat angiotensinogen
4V1Z	;	1.78	;	The 3-D structure of the cellobiohydrolase, Cel7A, from Aspergillus fumigatus
4V20	;	1.5	;	The 3-D structure of the cellobiohydrolase, Cel7A, from Aspergillus fumigatus, disaccharide complex
1W2V	;	1.55	;	The 3-dimensional structure of a thermostable mutant of a xylanase (Xyn10A) from Cellvibrio japonicus
1W32	;	1.2	;	The 3-dimensional structure of a thermostable mutant of a xylanase (Xyn10A) from Cellvibrio japonicus
1W3H	;	1.5	;	The 3-dimensional structure of a thermostable mutant of a xylanase (Xyn10A) from Cellvibrio japonicus
1W2P	;	1.45	;	The 3-dimensional structure of a xylanase (Xyn10A) from Cellvibrio japonicus
3ZTW	;	1.898	;	The 3-dimensional structure of apo-MpgP, the mannosyl-3- phosphoglycerate phosphatase from Thermus thermophilus HB27 in its apo-form
3ZX5	;	1.81	;	The 3-dimensional structure of MpgP from Thermus thermophilus HB27, covalently bound to vanadate and in complex with alpha- mannosylglycerate and magnesium
3ZW7	;	1.898	;	The 3-dimensional structure of MpgP from Thermus thermophilus HB27, in complex with the alpha-mannosylglycerate and metaphosphate.
3ZU6	;	1.9	;	The 3-dimensional structure of MpgP from Thermus thermophilus HB27, in complex with the alpha-mannosylglycerate and orthophosphate reaction products.
3ZUP	;	1.804	;	The 3-dimensional structure of MpgP from Thermus thermophilus HB27, in complex with the alpha-mannosylglycerate and orthophosphate reaction products.
3ZX4	;	1.74	;	The 3-dimensional structure of MpgP from Thermus thermophilus HB27, in complex with the alpha-mannosylglycerate,orthophosphate and magnesium
3ZWD	;	1.917	;	The 3-dimensional structure of MpgP from Thermus thermophilus HB27, in complex with the alpha-mannosylglycerate.
3ZWK	;	2.099	;	The 3-dimensional structure of MpgP from Thermus thermophilus HB27, in complex with the metavanadate
3ZTY	;	2.5	;	The 3-dimensional structure of the gadolinium derivative of MpgP, the mannosyl-3-phosphoglycerate phosphatase from Thermus thermophilus HB27
3UWN	;	2.15	;	The 3-MBT repeat domain of L3MBTL1 in complex with a methyl-lysine mimic
2C8T	;	3.0	;	The 3.0 A Resolution Structure of Caseinolytic Clp Protease 1 from Mycobacterium tuberculosis
5CTG	;	3.103	;	The 3.1 A resolution structure of a eukaryotic SWEET transporter
1I3P	;	3.1	;	THE 3.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF A MUTATED BACULOVIRUS P35 AFTER CASPASE CLEAVAGE
2XCO	;	3.1	;	The 3.1A crystal structure of the catalytic core (B'A' region) of Staphylococcus aureus DNA Gyrase
3J26	;	3.5	;	The 3.5 A resolution structure of the Sputnik virophage by cryo-EM
2XCR	;	3.5	;	The 3.5A crystal structure of the catalytic core (B'A' region) of Staphylococcus aureus DNA Gyrase complexed with GSK299423 and DNA
5CTH	;	3.69	;	The 3.7 A resolution structure of a eukaryotic SWEET transporter
8ST2	;	2.94	;	The 3alpha2beta stoichiometry of human alpha4beta2 nicotinic acetylcholine receptor in complex with acetylcholine
8ST1	;	3.41	;	The 3alpha2beta stoichiometry of human alpha4beta2 nicotinic acetylcholine receptor in complex with acetylcholine and calcium
2N5E	;		;	The 3D solution structure of discoidal high-density lipoprotein particles
1Q2Z	;		;	The 3D solution structure of the C-terminal region of Ku86
7XKW	;	3.1	;	The 3D strcuture of (-)-cyperene synthase with substrate analogue FSPP
2RKX	;	2.25	;	The 3D structure of chain D, cyclase subunit of imidazoleglycerol_evolvedcerolphosphate synthase
4WRK	;	2.9	;	The 3D structure of D95N mutant DUTPase from phage phi11 of S. aureus reveals the molecular details for the coordination of a structural Mg(II) ion
5JT1	;	1.35	;	The 3D structure of Ni-reconstituted U489C variant of [NiFeSe] hydrogenase from Desulfovibrio vulgaris Hildenborough in the oxidized state at 1.35 Angstrom resolution
5JSH	;	1.3	;	The 3D structure of recombinant [NiFeSe] hydrogenase from Desulfovibrio Vulgaris Hildenborough in the oxidized state at 1.30 Angstrom
1HRZ	;		;	THE 3D STRUCTURE OF THE HUMAN SRY-DNA COMPLEX SOLVED BY MULTI-DIMENSIONAL HETERONUCLEAR-EDITED AND-FILTERED NMR
1HRY	;		;	THE 3D STRUCTURE OF THE HUMAN SRY-DNA COMPLEX SOLVED BY MULTID-DIMENSIONAL HETERONUCLEAR-EDITED AND-FILTERED NMR
5JSY	;	1.04	;	The 3D structure of the Ni-reconstituted U489C variant of [NiFeSe] hydrogenase from Desulfovibrio vulgaris Hildenborough at 1.04 Angstrom resolution
1BHU	;		;	THE 3D STRUCTURE OF THE STREPTOMYCES METALLOPROTEINASE INHIBITOR, SMPI, ISOLATED FROM STREPTOMYCES NIGRESCENS TK-23, NMR, MINIMIZED AVERAGE STRUCTURE
5JSU	;	1.4	;	The 3D structure of the U489C variant of [NiFeSe] hydrogenase from Desulfovibrio vulgaris Hildenborough in the oxidized state at 1.40 Angstrom resolution
5JSK	;	0.95	;	The 3D structure of [NiFeSe] hydrogenase from Desulfovibrio vulgaris Hildenborough in the reduced state at 0.95 Angstrom resolution
6RU9	;	1.355	;	THE 3D STRUCTURE OF [NIFESE] HYDROGENASE G491A VARIANT FROM DESULFOVIBRIO VULGARIS HILDENBOROUGH AT 1.36 ANGSTROM RESOLUTION
6RUC	;	1.199	;	THE 3D STRUCTURE OF [NIFESE] HYDROGENASE G491S VARIANT FROM DESULFOVIBRIO VULGARIS HILDENBOROUGH AT 1.20 ANGSTROM RESOLUTION
6RTP	;	1.1	;	THE 3D STRUCTURE OF [NIFESE] HYDROGENASE G50T VaRIANT FROM DESULFOVIBRIO VULGARIS HILDENBOROUGH AT 1.10 ANGSTROM RESOLUTION
4BGF	;	2.097	;	The 3D-structure of arylamine-N-acetyltransferase from M. tuberculosis
4MUC	;	2.897	;	The 4th and 5th C-terminal domains of Factor H related protein 1
7PET	;	9.5	;	The 4x177 nucleosome array containing H1
4CX9	;	1.43	;	The 5-coordinate proximal NO complex of cytochrome c prime from Shewanella frigidimarina
4PBB	;	3.46	;	The 5-Hydroxymethylcytosine-Specific Restriction Enzyme AbaSI
4PAR	;	2.89	;	The 5-Hydroxymethylcytosine-Specific Restriction Enzyme AbaSI in a Complex with Product-like DNA
4PBA	;	3.301	;	The 5-Hydroxymethylcytosine-Specific Restriction Enzyme AbaSI in a Complex with Substrate-like DNA
8HIJ	;	3.54	;	The 5-MTHF-bound BRIL-SLC19A1/Fab/Nb ternary complex
2QKU	;	2.2	;	The 5th PDZ Domain of InaD in 10mM DTT
7CB2	;	2.15	;	The 6-phosphogluconate dehydrogenase (NADP-bound) from Staphylococcus aureus
7CB5	;	2.54	;	The 6-phosphogluconate dehydrogenase from Staphylococcus aureus (6-phosphogluconate bound)
5JNX	;	6.56	;	The 6.6 A cryo-EM structure of the full-length human NPC1 in complex with the cleaved glycoprotein of Ebola virus
2VY7	;	1.53	;	The 627-domain from influenza A virus polymerase PB2 subunit
2VY8	;	1.2	;	The 627-domain from influenza A virus polymerase PB2 subunit with Glu- 627
4F7U	;	1.898	;	The 6S snRNP assembly intermediate
5VPO	;	3.34	;	The 70S P-site ASL SufA6 complex
5VPP	;	3.9	;	The 70S P-site tRNA SufA6 complex
4V98	;	3.1	;	The 8S snRNP Assembly Intermediate
2VDC	;	9.5	;	THE 9.5 A RESOLUTION STRUCTURE OF GLUTAMATE SYNTHASE FROM CRYO-ELECTRON MICROSCOPY AND ITS OLIGOMERIZATION BEHAVIOR IN SOLUTION: FUNCTIONAL IMPLICATIONS.
2LDT	;		;	The 912-888 alternate conformation for helix 27 of E.coli 16S rRNA
2O94	;	3.0	;	The 97H/F mutant Structure of a glutamine-rich domain from histone deacetylase 4
6LRB	;	2.65	;	The A form apo structure of NrS-1 C terminal region-CTR
6K9E	;	2.9	;	The A form apo structure of NrS-1 C terminal region-CTR(305-718)
7VOH	;	2.197	;	The a-glucosidase QsGH13 from Qipengyuania seohaensis
2V0T	;	2.2	;	The A178L mutation in the C-terminal hinge of the flexible loop-6 of triosephosphate isomerase (TIM) induces a more closed conformation of this hinge region in dimeric and monomeric TIM
2V2C	;	1.89	;	The A178L mutation in the C-terminal hinge of the flexible loop-6 of triosephosphate isomerase (TIM) induces a more closed conformation of this hinge region in dimeric and monomeric TIM
2V2D	;	2.3	;	The A178L mutation in the C-terminal hinge of the flexible loop-6 of triosephosphate isomerase (TIM) induces a more closed conformation of this hinge region in dimeric and monomeric TIM
2V2H	;	1.18	;	The A178L mutation in the C-terminal hinge of the flexible loop-6 of triosephosphate isomerase (TIM) induces a more closed conformation of this hinge region in dimeric and monomeric TIM
1Q9I	;	1.6	;	The A251C:S430C double mutant of flavocytochrome c3 from Shewanella frigidimarina
7S1W	;	3.09	;	The AAVrh.10-glycan complex
1AHO	;	0.96	;	THE AB INITIO STRUCTURE DETERMINATION AND REFINEMENT OF A SCORPION PROTEIN TOXIN
6H0H	;	1.39	;	The ABC transporter associated binding protein from B. animalis subsp. lactis Bl-04 in complex with beta-1,6-galactobiose
6Q5G	;	2.0	;	The ABC transporter associated binding protein from B. animalis subsp. lactis Bl-04 without ligand. SeMet variant
2FF7	;	1.6	;	The ABC-ATPase of the ABC-transporter HlyB in the ADP bound state
8AVY	;	2.9	;	The ABCB1 L335C mutant (mABCB1) in the Apo state
7ZK4	;	2.6	;	The ABCB1 L335C mutant (mABCB1) in the outward facing state
3K90	;	2.0	;	The Abscisic acid receptor PYR1 in complex with Abscisic Acid
3UBI	;	6.8046	;	The Absence of Tertiary Interactions in a Self-Assembled DNA Crystal Structure
7PSA	;	3.4	;	The acetogenin-bound complex I of Mus musculus resolved to 3.4 angstroms
3RIK	;	2.48	;	The acid beta-glucosidase active site exhibits plasticity in binding 3,4,5,6-tetrahydroxyazepane-based inhibitors: implications for pharmacological chaperone design for gaucher disease
3RIL	;	2.4	;	The acid beta-glucosidase active site exhibits plasticity in binding 3,4,5,6-tetrahydroxyazepane-based inhibitors: implications for pharmacological chaperone design for gaucher disease
3FY1	;	1.7	;	The Acidic Mammalian Chitinase catalytic domain in complex with methylallosamidin
8CG5	;	2.7	;	The ACP crosslinked to the KS of the cercosporin fungal non-reducing polyketide synthase (NR-PKS) CTB1 (SAT-KS:ACP-MAT)
8CG6	;	3.4	;	The ACP crosslinked to the SAT of the cercosporin fungal non-reducing polyketide synthase (NR-PKS) CTB1 (ACP:SAT-KS-MAT)
2M6O	;		;	The actinobacterial transcription factor RbpA binds to the principal sigma subunit of RNA polymerase
2M6P	;		;	The actinobacterial transcription factor RbpA binds to the principal sigma subunit of RNA polymerase
2K0Y	;		;	The actinorhodin apo acyl carrier protein from S. coelicolor
2K0X	;		;	The actinorhodin holo acyl carrier protein from S. coelicolor
1TQY	;	2.0	;	The Actinorhodin Ketosynthase/Chain Length Factor
1PPI	;	2.2	;	THE ACTIVE CENTER OF A MAMMALIAN ALPHA-AMYLASE. THE STRUCTURE OF THE COMPLEX OF A PANCREATIC ALPHA-AMYLASE WITH A CARBOHYDRATE INHIBITOR REFINED TO 2.2 ANGSTROMS RESOLUTION
6FLI	;	3.0	;	The active form of a pentameric ion channel (sTeLIC) gated by alkaline pH - Co-crystallization with 4-bromo cinnamic acid
6FVQ	;	3.3	;	The active form of a pentameric ion channel (sTeLIC) gated by alkaline pH - R86A
6FVS	;	3.2	;	The active form of a pentameric ion channel (sTeLIC) gated by alkaline pH - sTeLIC in complex with Barium ions (Ba2+)
6FVR	;	4.2	;	The active form of a pentameric ion channel (sTeLIC) gated by alkaline pH - sTeLIC in complex with Cesium ions (Cs+)
6FL9	;	2.3	;	The active form of a pentameric ion channel (sTeLIC) gated by alkaline pH - Wild type 2.3 Angstrom resolution
1YBA	;	2.24	;	The active form of phosphoglycerate dehydrogenase
1HH8	;	1.8	;	The active N-terminal region of p67phox: Structure at 1.8 Angstrom resolution and biochemical characterizations of the A128V mutant implicated in chronic granulomatous disease
1QAF	;	2.2	;	THE ACTIVE SITE BASE CONTROLS COFACTOR REACTIVITY IN ESCHERICHIA COLI AMINE OXIDASE : X-RAY CRYSTALLOGRAPHIC STUDIES WITH MUTATIONAL VARIANTS
1QAK	;	2.0	;	THE ACTIVE SITE BASE CONTROLS COFACTOR REACTIVITY IN ESCHERICHIA COLI AMINE OXIDASE : X-RAY CRYSTALLOGRAPHIC STUDIES WITH MUTATIONAL VARIANTS
1QAL	;	2.2	;	THE ACTIVE SITE BASE CONTROLS COFACTOR REACTIVITY IN ESCHERICHIA COLI AMINE OXIDASE : X-RAY CRYSTALLOGRAPHIC STUDIES WITH MUTATIONAL VARIANTS
1DYU	;	2.04	;	The active site base controls cofactor reactivity in Escherichia coli amine oxidase: X-ray crystallographic studies with mutational variants.
8J7Q	;	1.69	;	The active site mutant of human inorganic pyrophosphatase
2W9X	;	2.0	;	The active site of a carbohydrate esterase displays divergent catalytic and non-catalytic binding functions
1ER8	;	2.0	;	THE ACTIVE SITE OF ASPARTIC PROTEINASES
3ER3	;	2.0	;	The active site of aspartic proteinases
3ER5	;	1.8	;	THE ACTIVE SITE OF ASPARTIC PROTEINASES
4APE	;	2.1	;	THE ACTIVE SITE OF ASPARTIC PROTEINASES
4ER1	;	2.0	;	THE ACTIVE SITE OF ASPARTIC PROTEINASES
4ER2	;	2.0	;	The active site of aspartic proteinases
5BNW	;	2.4	;	The active site of O-GlcNAc transferase imposes constraints on substrate sequence
1QAE	;	2.05	;	THE ACTIVE SITE OF SERRATIA ENDONUCLEASE CONTAINS A CONSERVED MAGNESIUM-WATER CLUSTER
1O8Q	;	2.6	;	The active site of the molybdenum cofactor biosenthetic protein domain Cnx1G
1O8N	;	2.8	;	The active site of the molybdenum cofactor biosynthetic protein domain Cnx1G
1O8O	;	2.7	;	The active site of the molybdenum cofactor biosynthetic protein domain Cnx1G
1ASZ	;	3.0	;	THE ACTIVE SITE OF YEAST ASPARTYL-TRNA SYNTHETASE: STRUCTURAL AND FUNCTIONAL ASPECTS OF THE AMINOACYLATION REACTION
1MAE	;	2.8	;	The Active Site Structure of Methylamine Dehydrogenase: Hydrazines Identify C6 as the Reactive Site of the Tryptophan Derived Quinone Cofactor
1MAF	;	2.6	;	The Active Site Structure of Methylamine Dehydrogenase: Hydrazines Identify C6 as the Reactive Site of the Tryptophan Derived Quinone Cofactor
2MAD	;	2.25	;	THE ACTIVE SITE STRUCTURE OF METHYLAMINE DEHYDROGENASE: HYDRAZINES IDENTIFY C6 AS THE REACTIVE SITE OF THE TRYPTOPHAN DERIVED QUINONE COFACTOR
7KHT	;	2.504	;	The acyl chains of phosphoinositide PIP3 alter the structure and function of nuclear receptor Steroidogenic Factor-1 (SF-1)
6TIM	;	2.2	;	THE ADAPTABILITY OF THE ACTIVE SITE OF TRYPANOSOMAL TRIOSEPHOSPHATE ISOMERASE AS OBSERVED IN THE CRYSTAL STRUCTURES OF THREE DIFFERENT COMPLEXES
7BCU	;	0.98	;	The adduct of NAMI-A with Hen Egg White Lysozyme at 1.5 hours.
7BD0	;	1.06	;	The adduct of NAMI-A with Hen Egg White Lysozyme at 26 hours.
7BCX	;	1.06	;	The adduct of NAMI-A with Hen Egg White Lysozyme at 8 hours.
7BDM	;	1.07	;	The adduct of NAMI-A with Hen Egg White Lysozyme at 98 hours.
1LIB	;	1.7	;	THE ADIPOCYTE LIPID-BINDING PROTEIN AT 1.6 ANGSTROMS RESOLUTION: CRYSTAL STRUCTURES OF THE APOPROTEIN AND WITH BOUND SATURATED AND UNSATURATED FATTY ACIDS
1LID	;	1.6	;	THE ADIPOCYTE LIPID-BINDING PROTEIN AT 1.6 ANGSTROMS RESOLUTION: CRYSTAL STRUCTURES OF THE APOPROTEIN AND WITH BOUND SATURATED AND UNSATURATED FATTY ACIDS
1LIF	;	1.6	;	THE ADIPOCYTE LIPID-BINDING PROTEIN AT 1.6 ANGSTROMS RESOLUTION: CRYSTAL STRUCTURES OF THE APOPROTEIN AND WITH BOUND SATURATED AND UNSATURATED FATTY ACIDS
6CEQ	;	1.67	;	The Aer2 Receptor from Vibrio cholerae is a Dual PAS-Heme Oxygen Sensor
4AVY	;	2.0	;	The AEROPATH project and Pseudomonas aeruginosa high-throughput crystallographic studies for assessment of potential targets in early stage drug discovery.
4B79	;	1.98	;	THE AEROPATH PROJECT AND PSEUDOMONAS AERUGINOSA HIGH-THROUGHPUT CRYSTALLOGRAPHIC STUDIES FOR ASSESSMENT OF POTENTIAL TARGETS IN EARLY STAGE DRUG DISCOVERY.
4IMY	;	2.94	;	The AFF4 scaffold binds human P-TEFb adjacent to HIV Tat
1AGA	;	3.0	;	THE AGAROSE DOUBLE HELIX AND ITS FUNCTION IN AGAROSE GEL STRUCTURE
5GTP	;	2.35	;	The agonist-free structure of human PPARgamma ligand binding domain in the presence of the SRC-1 coactivator peptide
7VQ7	;	3.6	;	The Al-bound AtALMT1 structure at pH 5 (ALMT1Al/pH5)
3KSJ	;	2.0	;	The alkanesulfonate-binding protein SsuA from Xabthomonas axonopodis pv. citri bound to MES
3KSX	;	1.7	;	The alkanesulfonate-binding protein SsuA from Xanthomonas axonopodis pv. citri bound to MOPS
6QBS	;	1.7	;	The Alkyne Moiety as a Latent Electrophile in Irreversible Covalent Small Molecule Inhibitors of Cathepsin K
7TXF	;	2.47	;	The allosteric binding mode of alphaD-conotoxin VxXXB
3QGN	;	2.1	;	The allosteric E*-E equilibrium is a key property of the trypsin fold
1PSD	;	2.75	;	THE ALLOSTERIC LIGAND SITE IN THE VMAX-TYPE COOPERATIVE ENZYME PHOSPHOGLYCERATE DEHYDROGENASE
9GPB	;	2.9	;	THE ALLOSTERIC TRANSITION OF GLYCOGEN PHOSPHORYLASE
1STY	;	1.67	;	THE ALPHA ANEURISM: A STRUCTURAL MOTIF REVEALED IN AN INSERTION MUTANT OF STAPHYLOCOCCAL NUCLEASE
4FNG	;	1.95	;	The alpha-esterase-7 carboxylesterase, E3, from the blowfly Lucilia cuprina
4FNM	;	1.804	;	The alpha-esterase-7 carboxylesterase, E3, from the blowfly Lucilia cuprina
5IVH	;	1.71	;	The alpha-esterase-7 carboxylesterase, E3, from the blowfly Lucilia cuprina: apo-enzyme ensemble refinement
5IVD	;	1.71	;	The alpha-esterase-7 carboxylesterase, E3, from the blowfly Lucilia cuprina: apo-enzyme qFit multi-conformer model
5IVI	;	1.53	;	The alpha-esterase-7 carboxylesterase, E3, from the blowfly Lucilia cuprina: phosphorylated enzyme qFit multi-conformer model
5IVK	;	1.53	;	The alpha-esterase-7 carboxylesterase, E3, from the blowfly Lucilia cuprina: phosphorylated-enzyme ensemble refinement
3LC6	;	3.1	;	The alternative conformation structure of isocitrate dehydrogenase kinase/phosphatase from E. Coli
1OZI	;		;	The alternatively spliced PDZ2 domain of PTP-BL
1AML	;		;	THE ALZHEIMER`S DISEASE AMYLOID A4 PEPTIDE (RESIDUES 1-40)
4OLS	;	2.27	;	The amidase-2 domain of LysGH15
7LGX	;	1.8	;	The aminoacrylate form of mutant beta-K167T Salmonella typhimurium Tryptophan Synthase in complex with with inhibitor N-(4'-trifluoromethoxybenzenesulfonyl)-2-amino-1-ethylphosphate (F9F) at the enzyme alpha-site, benzimidazole (BZI) at the enzyme beta site and cesium ion at the metal coordination site at 1.80 Angstrom resolution
7LT4	;	1.8	;	The aminoacrylate form of the beta-K167T mutant Tryptophan Synthase at 1.80 Angstrom resolution in complex with N-(4'-trifluoromethoxybenzenesulfonyl)-2-amino-1-ethylphosphate (F9F) at the enzyme alpha-site and cesium ion at the metal coordination site
7KQ9	;	1.5	;	The aminoacrylate form of the beta-Q114A mutant Tryptophan Synthase at 1.50 Angstrom resolution with cesium ion at the metal coordination site
7LEV	;	1.7	;	The aminoacrylate form of the wild-type Salmonella typhimurium Tryptophan Synthase in complex with ammonium ion at the metal coordination site at 1.70 Angstrom resolution
7KWV	;	1.3	;	The aminoacrylate form of the wild-type Salmonella typhimurium Tryptophan Synthase in complex with inhibitor N-(4'-trifluoromethoxybenzenesulfonyl)-2-amino-1-ethylphosphate (F9F) at the enzyme alpha-site and cesium ion at the metal coordination site at 1.30 Angstrom resolution
7L1H	;	1.5	;	The aminoacrylate form of the wild-type Salmonella typhimurium Tryptophan Synthase in complex with inhibitor N-(4'-trifluoromethoxybenzenesulfonyl)-2-amino-1-ethylphosphate (F9F) at the enzyme alpha-site and cesium ion at the metal coordination site at 1.50 Angstrom resolution. Three water molecules are close to the amynoacrylate at the enzyme beta-site
7L03	;	1.6	;	The aminoacrylate form of the wild-type Salmonella typhimurium Tryptophan Synthase in complex with inhibitor N-(4'-trifluoromethoxybenzenesulfonyl)-2-amino-1-ethylphosphate (F9F) at the enzyme alpha-site and sodium ion at the metal coordination site at 1.60 Angstrom resolution. Three water molecules are close to the amynoacrylate at the enzyme beta-site
7KYT	;	1.35	;	The aminoacrylate form of the wild-type Salmonella typhimurium Tryptophan Synthase in complex with inhibitor N-(4'-trifluoromethoxybenzenesulfonyl)-2-amino-1-ethylphosphate (F9F) at the enzyme alpha-site, cesium ion at the metal coordination site and benzimidazole (BZI) at the enzyme beta-site at 1.35 Angstrom resolution
7KXC	;	1.51	;	The aminoacrylate form of the wild-type Salmonella typhimurium Tryptophan Synthase in complex with inhibitor N-(4'-trifluoromethoxybenzenesulfonyl)-2-amino-1-ethylphosphate (F9F) at the enzyme alpha-site, sodium ion at the metal coordination site and benzimidazole (BZI) at the enzyme beta-site at 1.30 Angstrom resolution. One of the beta-Q114 rotamer conformations allows a hydrogen bond to form with the PLP oxygen at the position 3 in the ring
8IB0	;		;	The amyloid structure of mouse RIPK1 RHIM-containing domain by solid-state NMR
2Q7L	;	1.92	;	The Androgen Receptor Prostate Cancer Mutant H874Y Ligand Binding Domain Bound with Testosterone and a TIF2 box3 Coactivator Peptide 740-753
2Q7K	;	1.8	;	The Androgen Receptor Prostate Cancer Mutant H874Y Ligand Binding Domain Bound with Testosterone and an AR 20-30 Peptide
6FN0	;	2.9	;	The animal-like Cryptochrome from Chlamydomonas reinhardtii in complex with 6-4 DNA
1KTH	;	0.95	;	The Anisotropic Refinement Of Kunitz Type Domain C5 at 0.95 Angstrom
3EU9	;	1.99	;	The ankyrin repeat domain of Huntingtin interacting protein 14
5VXR	;	1.4	;	The antigen-binding fragment of MAb24 in complex with a peptide from Hepatitis C Virus E2 epitope I (412-423)
1HHG	;	2.6	;	THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
1HHH	;	3.0	;	THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
1HHI	;	2.5	;	THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
1HHJ	;	2.5	;	THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
1HHK	;	2.5	;	THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
4LXC	;	3.5	;	The antimicrobial peptidase lysostaphin from Staphylococcus simulans
1KY7	;	2.15	;	THE AP-2 CLATHRIN ADAPTOR ALPHA-APPENDAGE IN COMPLEX WITH AMPHIPHYSIN FXDXF
7CB0	;	2.52	;	The apo 6-phosphogluconate dehydrogenase from Staphylococcus aureus (strain Newman)
8U49	;	1.8	;	The Apo Crystal Structure of BlCel9A from Glycoside Hydrolase Family 9
5EC6	;	1.6	;	The apo crystal structure of haemoglobin receptor HpuA from Kingella denitrificans
2PME	;	2.9	;	The Apo crystal Structure of the glycyl-tRNA synthetase
5HJF	;	1.59	;	The apo form of Dps4 from Nostoc punctiforme
1RKA	;	2.3	;	THE APO FORM OF E. COLI RIBOKINASE
2CRL	;		;	The apo form of HMA domain of copper chaperone for superoxide dismutase
4FB7	;	1.3	;	The apo form of idole-3-glycerol phosphate synthase (TrpC) form Mycobacterium tuberculosis
5VM4	;	1.9	;	The apo form of the triclocarban-binding single domain camelid nanobody VHH T10
5VLV	;	1.35	;	The apo form of the triclocarban-binding single domain camelid nanobody VHH T9
5NY5	;	2.501	;	The apo structure of 3,4-dihydroxybenzoic acid decarboxylases from Enterobacter cloacae
4AST	;	2.38	;	The apo structure of a bacterial aldo-keto reductase AKR14A1
4YJM	;	1.952	;	The apo structure of Agrobacterium tumefaciens ClpS2
8H4H	;	2.3	;	The apo structure of Aspergillomarasmine A synthetase
7VKW	;	1.75	;	The apo structure of beta-1,2-glucosyltransferase from Ignavibacterium album
6HV1	;	2.547	;	The apo structure of Dps from Listeria innocua before soaking experiments with Zn, Co and La
1ZLX	;	2.2	;	The apo structure of human glycinamide ribonucleotide transformylase
8IPI	;	2.1	;	The apo structure of human mitochondrial methyltransferase METTL15
7TZO	;	3.28	;	The apo structure of human mTORC2 complex
5Y9O	;	2.554	;	The apo structure of Legionella pneumophila WipA
2AHD	;	3.0	;	The Apo structure of Methanococcus jannaschii phosphodiesterase MJ0936
6K9C	;	2.406	;	The apo structure of NrS-1 C terminal region (305-718)
7XYE	;	2.482	;	The apo structure of Orf1
8AHD	;	2.1	;	The apo structure of the Corramycin phosphotransferase
7XTR	;	2.2	;	The apo structure of the engineered TfCut
7XTS	;	2.21	;	The apo structure of the engineered TfCut S130A
7W5F	;	2.53	;	The apo structure of trichobrasilenol synthase TaTC6 with the space group of monoclinic
7W5G	;	1.8	;	The apo structure of trichobrasilenol synthase TaTC6 with the space group of orthorhombic
8ALS	;	2.3	;	The apo-crystal structure of a variant form of the 28-kDa Schistosoma haematobium glutathione transferase
8BHZ	;	2.4	;	The apo-crystal structure of a variant form of the 28-kDa Schistosoma haematobium glutathione transferase in orthorhombic form
8HGQ	;	2.09	;	The apo-flavodoxin dimer from Synechococcus elongatus PCC 7942
8HGR	;	1.84	;	The apo-flavodoxin monomer from Synechococcus elongatus PCC 7942
7WIA	;	3.22	;	The apo-form of THF-II C22G riboswitch
3WDW	;	1.8	;	The apo-form structure of E113A from Paecilomyces thermophila
7F9I	;	2.5	;	The apo-form structure of EnrR
3WDT	;	1.98	;	The apo-form structure of PtLic16A from Paecilomyces thermophila
3PHL	;	1.9	;	The apo-form UDP-glucose 6-dehydrogenase
3PID	;	1.4	;	The apo-form UDP-glucose 6-dehydrogenase with a C-terminal six-histidine tag
7VQ4	;	3.2	;	The apo-state AtALMT1 structure at pH 7.5(ALMT1apo/pH7.5)
7VQ3	;	3.2	;	The apo-state AtALMT1 structures at pH 5 (ALMT1apo/pH5)
5Z1Z	;	1.97	;	The apo-structure of D-lactate dehydrogenase from Escherichia coli
6ABI	;	2.1	;	The apo-structure of D-lactate dehydrogenase from Fusobacterium nucleatum
6ABJ	;	1.86	;	The apo-structure of D-lactate dehydrogenase from Pseudomonas aeruginosa
6IMU	;	2.0	;	The apo-structure of endo-beta-1,2-glucanase from Talaromyces funiculosus
2NYT	;	2.5	;	The APOBEC2 Crystal Structure and Functional Implications for AID
1Q8Z	;	2.35	;	The apoenzyme structure of the yeast SR protein kinase, Sky1p
8IAB	;	2.96	;	The Arabidopsis CLCa transporter bound with chloride, ATP and PIP2
8IAD	;	3.16	;	The Arabidopsis CLCa transporter bound with nitrate, ATP and PIP2
5TFY	;	3.4	;	The archaeal flagellum of Methanospirillum hungatei strain JF1.
6IAZ	;	1.901	;	The archaeal Methanocaldococcus infernus Elp3 with N-terminus deletion (1-46)
7OFQ	;	3.08	;	The archaellum of Methanocaldococcus villosus
1LTG	;	2.4	;	THE ARG7LYS MUTANT OF HEAT-LABILE ENTEROTOXIN EXHIBITS GREAT FLEXIBILITY OF ACTIVE SITE LOOP 47-56 OF THE A SUBUNIT
2BCT	;	2.9	;	THE ARMADILLO REPEAT REGION FROM MURINE BETA-CATENIN
3BCT	;	2.1	;	THE ARMADILLO REPEAT REGION FROM MURINE BETA-CATENIN
6CZ7	;	1.62	;	The arsenate respiratory reductase (Arr) complex from Shewanella sp. ANA-3
6CZ8	;	1.78	;	The arsenate respiratory reductase (Arr) complex from Shewanella sp. ANA-3 bound to arsenate
6CZ9	;	1.8	;	The arsenate respiratory reductase (Arr) complex from Shewanella sp. ANA-3 bound to arsenite
6CZA	;	1.71	;	The arsenate respiratory reductase (Arr) complex from Shewanella sp. ANA-3 bound to phosphate
1CCA	;	1.8	;	THE ASP-HIS-FE TRIAD OF CYTOCHROME C PEROXIDASE CONTROLS THE REDUCTION POTENTIAL, ELECTRONIC STRUCTURE, AND COUPLING OF THE TRYPTOPHAN FREE-RADICAL TO THE HEME
1CCB	;	2.1	;	THE ASP-HIS-FE TRIAD OF CYTOCHROME C PEROXIDASE CONTROLS THE REDUCTION POTENTIAL, ELECTRONIC STRUCTURE, AND COUPLING OF THE TRYPTOPHAN FREE-RADICAL TO THE HEME
1CCC	;	2.0	;	THE ASP-HIS-FE TRIAD OF CYTOCHROME C PEROXIDASE CONTROLS THE REDUCTION POTENTIAL, ELECTRONIC STRUCTURE, AND COUPLING OF THE TRYPTOPHAN FREE-RADICAL TO THE HEME
2XZI	;	1.45	;	THE ASPERGILLUS FUMIGATUS SIALIDASE IS A KDNASE: STRUCTURAL AND MECHANISTIC INSIGHTS
2XZJ	;	1.84	;	THE ASPERGILLUS FUMIGATUS SIALIDASE IS A KDNASE: STRUCTURAL AND MECHANISTIC INSIGHTS
2XZK	;	1.5	;	THE ASPERGILLUS FUMIGATUS SIALIDASE IS A KDNASE: STRUCTURAL AND MECHANISTIC INSIGHTS
2F86	;	2.64	;	The Association Domain of C. elegans CaMKII
1HZZ	;	2.5	;	THE ASYMMETRIC COMPLEX OF THE TWO NUCLEOTIDE-BINDING COMPONENTS (DI, DIII) OF PROTON-TRANSLOCATING TRANSHYDROGENASE
8I4I	;	2.2	;	The asymmetric structure of homodimeric E. coli TrpRS bound with tryptophanyl adenylate and L-tryptophan
8I1W	;	1.8	;	The asymmetric structure of homodimeric E. coli TrpRS bound with tryptophanyl adenylate at one of its two active pockets
5LBM	;	2.7	;	The asymmetric tetrameric structure of the formaldehyde sensing transcriptional repressor FrmR from Escherichia coli
8I1T	;	2.8	;	The asymmetric unit of P22 empty capsid
8I1V	;	2.6	;	The asymmetric unit of P22 procapsid
6JFH	;	20.0	;	The asymmetric-reconstructed cryo-EM structure of Zika virus-FabZK2B10 complex
8GVE	;	3.17	;	The asymmetry structure of hAE2
6HI7	;	1.743	;	The ATAD2 bromodomain in complex with compound 10
6HI8	;	1.9	;	The ATAD2 bromodomain in complex with compound 11
6EPT	;	1.65	;	The ATAD2 bromodomain in complex with compound 12
6HIA	;	1.897	;	The ATAD2 bromodomain in complex with compound 13
6HIB	;	2.029	;	The ATAD2 bromodomain in complex with compound 14
6HIC	;	1.768	;	The ATAD2 bromodomain in complex with compound 15
6HID	;	1.768	;	The ATAD2 bromodomain in complex with compound 16
6HIE	;	2.05	;	The ATAD2 bromodomain in complex with compound 17
6EPU	;	1.8	;	The ATAD2 bromodomain in complex with compound 2
6EPX	;	1.84	;	The ATAD2 bromodomain in complex with compound 3
6HI3	;	2.4	;	The ATAD2 bromodomain in complex with compound 4
6EPV	;	1.793	;	The ATAD2 bromodomain in complex with compound 5
6EPJ	;	1.652	;	The ATAD2 bromodomain in complex with compound 6
6HI4	;	1.69	;	The ATAD2 bromodomain in complex with compound 7
6HI5	;	1.59	;	The ATAD2 bromodomain in complex with compound 8
6HI6	;	1.64	;	The ATAD2 bromodomain in complex with compound 9
6EPS	;	2.081	;	The ATAD2 bromodomain in complex with compound UZH-DQ41
6EPR	;	2.053	;	The ATAD2 bromodomain in complex with compound UZH-DS15
6EPW	;	1.924	;	The ATAD2 bromodomain in complex with compound UZH-DU32
5D14	;	1.0	;	The atomic resolution crystal structure of human IL-8
6DCM	;	1.031	;	The atomic resolution crystal structure of Kringle 2 variant bound with EACA
1ZWP	;	1.1	;	The atomic resolution Crystal structure of the Phospholipase A2 (PLA2) complex with Nimesulide reveals its weaker binding to PLA2
1QLW	;	1.09	;	The Atomic Resolution Structure of a Novel Bacterial Esterase
4I9V	;	1.02	;	The atomic structure of 5-Hydroxymethyl 2'-deoxycitidine base paired with 2'-deoxyguanosine in Dickerson Drew Dodecamer
6U3Q	;	2.46	;	The atomic structure of a human adeno-associated virus capsid isolate (AAVhu69/AAVv66)
1LP3	;	3.0	;	The Atomic Structure of Adeno-Associated Virus (AAV-2), a Vector for Human Gene Therapy
4YN1	;	1.9	;	THE ATOMIC STRUCTURE OF ANOMALA CUPREA ENTOMOPOXVIRUS (ACEPV) FUSOLIN SPINDLES
1EST	;	2.5	;	THE ATOMIC STRUCTURE OF CRYSTALLINE PORCINE PANCREATIC ELASTASE AT 2.5 ANGSTROMS RESOLUTION. COMPARISONS WITH THE STRUCTURE OF ALPHA-CHYMOTRYPSIN
6Z7N	;	3.77	;	The atomic structure of HAdV-F41 at pH 7.4
1UF2	;	3.5	;	The Atomic Structure of Rice dwarf Virus (RDV)
7EMN	;	3.0	;	The atomic structure of SHP2 E76A mutant
5XZR	;	2.8	;	The atomic structure of SHP2 E76A mutant in complex with allosteric inhibitor 9b
1GFF	;	3.0	;	THE ATOMIC STRUCTURE OF THE DEGRADED PROCAPSID PARTICLE OF THE BACTERIOPHAGE G4: INDUCED STRUCTURAL CHANGES IN THE PRESENCE OF CALCIUM IONS AND FUNCTIONAL IMPLICATIONS
6Z7Q	;	3.8	;	The atomic structure of the HAdVF-41 penton base in solution
6LGN	;	5.3	;	The atomic structure of varicella zoster virus C-capsid
6LGL	;	4.4	;	The atomic structure of varicella-zoster virus A-capsid
4YN2	;	2.02	;	THE ATOMIC STRUCTURE OF WISEANA SPP ENTOMOPOXVIRUS (WSEPV) FUSOLIN SPINDLES
5HV6	;	3.005	;	The ATP binding domain of rifampin phosphotransferase from Listeria monocytogenes
1Q1E	;	2.9	;	The ATPase component of E. coli maltose transporter (MalK) in the nucleotide-free form
6JUI	;	2.402	;	The atypical Myb-like protein Cdc5 contains two distinct nucleic acid-binding surfaces
1LEL	;	2.9	;	The avidin BCAP complex
3TL8	;	2.5	;	The AvrPtoB-BAK1 complex reveals two structurally similar kinaseinteracting domains in a single type III effector
1NDL	;	2.4	;	THE AWD NUCLEOTIDE DIPHOSPHATE KINASE FROM DROSOPHILA
3Q1D	;	2.15	;	The B-box domain of Trim54
355D	;	1.4	;	THE B-DNA DODECAMER AT HIGH RESOLUTION
7RQT	;	1.26	;	THE B-DNA DODECAMER With HIGH RESOLUTION
6FWV	;	2.58	;	The Bacillus anthracis TIE protein
7R4B	;	1.1	;	The Bacillus pumilus chorismate mutase
1F46	;	1.5	;	THE BACTERIAL CELL-DIVISION PROTEIN ZIPA AND ITS INTERACTION WITH AN FTSZ FRAGMENT REVEALED BY X-RAY CRYSTALLOGRAPHY
1F47	;	1.95	;	THE BACTERIAL CELL-DIVISION PROTEIN ZIPA AND ITS INTERACTION WITH AN FTSZ FRAGMENT REVEALED BY X-RAY CRYSTALLOGRAPHY
8HHF	;	3.04	;	The bacterial divisome protein complex FtsB-FtsL-FtsQ
8HHG	;	3.1	;	The bacterial divisome protein complex FtsB-FtsL-FtsQ
8HHH	;	3.3	;	The bacterial divisome protein complex FtsB-FtsL-FtsQ
5NDX	;	2.2	;	The bacterial orthologue of Human a-L-iduronidase does not need N-glycan post-translational modifications to be catalytically competent: Crystallography and QM/MM insights into Mucopolysaccharidosis I
1HPB	;	2.5	;	THE BACTERIAL PERIPLASMIC HISTIDINE-BINDING PROTEIN: STRUCTURE(SLASH)FUNCTION ANALYSIS OF THE LIGAND-BINDING SITE AND COMPARISON WITH RELATED PROTEINS
3ZT9	;	1.75	;	The bacterial stressosome: a modular system that has been adapted to control secondary messenger signaling
3ZTA	;	2.7	;	The bacterial stressosome: a modular system that has been adapted to control secondary messenger signaling
3ZTB	;	2.8	;	The bacterial stressosome: a modular system that has been adapted to control secondary messenger signaling
7JQQ	;	4.1	;	The bacteriophage Phi-29 viral genome packaging motor assembly
1CJD	;	1.85	;	THE BACTERIOPHAGE PRD1 COAT PROTEIN, P3, IS STRUCTURALLY SIMILAR TO HUMAN ADENOVIRUS HEXON
2MDP	;		;	The bacteriophage T7 encoded inhibitor (gp1.2) of E. coli dGTP triphosphohydrolase
7Z8I	;	3.3	;	The barbed end complex of dynactin bound to BICDR1 and the cytoplasmic dynein tails (A2, B1, B2)
6GIY	;	4.3	;	The baseplate complex from the type VI secretion system
6GJ1	;	4.7	;	The baseplate complex from the type VI secretion system
6GJ3	;	4.3	;	The baseplate complex from the type VI secretion system
7V9H	;	2.692	;	The BEN3 domain of protein Bend3
2GOP	;	2.0	;	The beta-propeller domain of the Trilobed protease from Pyrococcus furiosus reveals an open velcro topology
7TRG	;	3.0	;	The beta-tubulin folding intermediate I
7TTN	;	3.3	;	The beta-tubulin folding intermediate II
7TTT	;	2.9	;	The beta-tubulin folding intermediate III
7TUB	;	3.6	;	The beta-tubulin folding intermediate IV
6OBA	;	3.1	;	The beta2 adrenergic receptor bound to a negative allosteric modulator
284D	;	1.1	;	THE BI-LOOP, A NEW GENERAL FOUR-STRANDED DNA MOTIF
4F4U	;	2.0	;	The bicyclic intermediate structure provides insights into the desuccinylation mechanism of SIRT5
4F56	;	1.7	;	The bicyclic intermediate structure provides insights into the desuccinylation mechanism of SIRT5
2CG8	;	2.9	;	The bifunctional dihydroneopterin aldolase 6-hydroxymethyl-7,8- dihydropterin synthase from Streptococcus pneumoniae
6V3P	;	3.25	;	The BIgI domain of beta protein from S. agalactiae bound to CEACAM1
2ZTV	;	1.95	;	The binary complex of D-3-hydroxybutyrate dehydrogenase with NAD+
2X66	;	2.09	;	The binary complex of PrnB (the second enzyme in pyrrolnitrin biosynthesis pathway) and cyanide
1SKN	;	2.5	;	THE BINDING DOMAIN OF SKN-1 IN COMPLEX WITH DNA: A NEW DNA-BINDING MOTIF
4WCG	;	1.5	;	The binding mode of Cyprinid Herpesvirus3 ORF112-Zalpha to Z-DNA
1TVK	;	2.89	;	The binding mode of epothilone A on a,b-tubulin by electron crystallography
4KAP	;	1.45	;	The Binding of Benzoarylsulfonamide Ligands to Human Carbonic Anhydrase is Insensitive to Formal Fluorination of the Ligand
3NC4	;	2.07	;	The binding of beta-D-glucopyranosyl-thiosemicarbazone derivatives to glycogen phosphorylase: a new class of inhibitors
2VXI	;	1.91	;	The binding of heme and zinc in Escherichia coli Bacterioferritin
3TMN	;	1.7	;	THE BINDING OF L-VALYL-L-TRYPTOPHAN TO CRYSTALLINE THERMOLYSIN ILLUSTRATES THE MODE OF INTERACTION OF A PRODUCT OF PEPTIDE HYDROLYSIS
7ONF	;	1.6	;	The binding of p-coumaroyl glucose to glycogen phosphorylase reveals the relationship between structural data and effects on cell metabolome
4GR1	;	2.4	;	THE BINDING OF THE RETRO-ANALOGUE OF GLUTATHIONE DISULFIDE TO GLUTATHIONE REDUCTASE
2VS3	;	2.2	;	THE BINDING OF UDP-GALACTOSE BY AN ACTIVE SITE MUTANT OF alpha-1,3 GALACTOSYLTRANSFERASE (alpha3GT)
2VS4	;	1.77	;	THE BINDING OF UDP-GALACTOSE BY AN ACTIVE SITE MUTANT OF alpha-1,3 GALACTOSYLTRANSFERASE (alpha3GT)
2VS5	;	1.82	;	THE BINDING OF UDP-GALACTOSE BY AN ACTIVE SITE MUTANT OF alpha-1,3 GALACTOSYLTRANSFERASE (alpha3GT)
7CCO	;		;	The binding structure of a lanthanide binding tag (LBT3) with lanthanum ion (La3+)
7CCN	;		;	The binding structure of a lanthanide binding tag (LBT3) with lutetium ion (Lu3+)
2R3V	;	2.5	;	The Biochemical and Structural Basis for Feedback Inhibition of Mevalonate Kinase and Isoprenoid Metabolism
2R42	;	2.4	;	The Biochemical and Structural Basis for feedback Inhibition of Mevalonate Kinase and Isoprenoid Metabolism
3V4X	;	1.952	;	The Biochemical and Structural Basis for Inhibition of Enterococcus faecalis HMG-CoA Synthase, mvaS, by Hymeglusin
3V4N	;	1.6	;	The Biochemical and Structural Basis for Inhibition of Enterococcus faecalis HMG-CoA Synthatse, mvaS, by Hymeglusin
3GLK	;	2.1	;	The biotin carboxylase (BC) domain of human Acetyl-CoA Carboxylase 2 (ACC2)
3GID	;	2.3	;	The biotin carboxylase (BC) domain of human Acetyl-CoA Carboxylase 2 (ACC2) in complex with Soraphen A
3D9U	;	2.3	;	The BIR3 domain of cIAP1 in complex with the N terminal peptide from SMAC/DIABLO (AVPIAQ).
1FBT	;	2.0	;	THE BISPHOSPHATASE DOMAIN OF THE BIFUNCTIONAL RAT LIVER 6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE
1TIP	;	2.2	;	THE BISPHOSPHATASE DOMAIN OF THE BIFUNCTIONAL RAT LIVER 6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE
1H1K	;	10.0	;	THE BLUETONGUE VIRUS (BTV) CORE BINDS DSRNA
5OG9	;	2.09	;	The BM3 mutant WIFI-WC heme domain in complex with testosterone
2C3E	;	2.8	;	The bovine mitochondrial ADP-ATP carrier
1HD9	;		;	The Bowman-Birk Inhibitor Reactive Site Loop Sequence Represents an Independent Structural Beta-Hairpin Motif
3MYW	;	2.5	;	The Bowman-Birk type inhibitor from mung bean in ternary complex with porcine trypsin
5H6Y	;	2.0	;	The BPTF Bromodomain Recognising H4K12Cr peptide
8HII	;	3.57	;	The BRIL-SLC19A1/Fab/Nb ternary complex
1UOY	;	1.5	;	The bubble protein from Penicillium brevicompactum Dierckx exudate.
2LY8	;		;	The budding yeast chaperone Scm3 recognizes the partially unfolded dimer of the centromere-specific Cse4/H4 histone variant
3IWZ	;	2.3	;	The c-di-GMP Responsive Global Regulator CLP Links Cell-Cell Signaling to Virulence Gene Expression in Xanthomonas campestris
3UCZ	;	2.8	;	The c-di-GMP-I riboswitch bound to GpG
3UCU	;	2.8	;	The c-di-GMP-I riboswitch bound to pGpG
1JNK	;	2.3	;	THE C-JUN N-TERMINAL KINASE (JNK3S) COMPLEXED WITH MGAMP-PNP
4CBJ	;	2.8	;	The c-ring ion binding site of the ATP synthase from Bacillus pseudofirmus OF4 is adapted to alkaliphilic cell physiology
4CBK	;	2.42	;	The c-ring ion binding site of the ATP synthase from Bacillus pseudofirmus OF4 is adapted to alkaliphilic cell physiology
7VIM	;	2.2	;	The C-terminal DNA binding domain of EsrB from Edwardsiella piscicida
2BVB	;		;	The C-terminal domain from Micronemal Protein 1 (MIC1) from Toxoplasma Gondii
6SWI	;	1.13	;	The C-terminal domain of AraT, a response regulator from Geobacillus stearothermophilus
4WRP	;	1.9	;	The C-terminal domain of gene product lpg0944 from Legionella pneumophila subsp. pneumophila str. Philadelphia 1
5IAZ	;		;	The C-terminal domain of rice beta-galactosidase 1
4WT4	;	2.81	;	The C-terminal domain of Rubisco Accumulation Factor 1 from Arabidopsis thaliana, crystal form I
4WT5	;	2.568	;	The C-terminal domain of Rubisco Accumulation Factor 1 from Arabidopsis thaliana, crystal form II
8HBR	;	2.2	;	The C-terminal domain of Spiral2
1DOQ	;		;	THE C-TERMINAL DOMAIN OF THE RNA POLYMERASE ALPHA SUBUNIT FROM THERMUS THERMOPHILUS
2LW1	;		;	The C-terminal domain of the Uup protein is a DNA-binding coiled coil motif
8RD6	;		;	the C-terminal domain of TonB protein from Salmonella enterica.
6KNE	;	1.701	;	The C-terminal Domain of Translation Initiation Factor 5 at high pH
6KND	;	1.9	;	The C-terminal Domain of Translation Initiation Factor 5 at low pH
3IHO	;	2.7	;	The C-terminal glycosylase domain of human MBD4
2O7M	;	2.0	;	The C-terminal loop of the homing endonuclease I-CreI is essential for DNA binding and cleavage. Identification of a novel site for specificity engineering in the I-CreI scaffold
3E3X	;	1.95	;	The C-terminal part of BipA protein from Vibrio parahaemolyticus RIMD 2210633
4B02	;	3.3	;	The C-terminal Priming Domain is Strongly Associated with the Main Body of Bacteriophage phi6 RNA-Dependent RNA Polymerase
8SXF	;	3.92	;	The C-terminal protease CtpA-LbcA complex of pseudomonas aeruginosa with the TPR at the high position
8SXG	;	4.14	;	The C-terminal protease CtpA-LbcA complex of pseudomonas aeruginosa with the TPR at the low position
2M7H	;		;	The C-terminal Region of Disintegrin Modulate its 3D Conformation and Cooperate with RGD Loop in Regulating Integrin alpha-IIb beta-3 Recognition
2M7F	;		;	The C-terminal Region of Disintegrin Modulate its 3D Conformation and Cooperate with RGD Loop in Regulating Integrins Recognitions
2M75	;		;	The C-terminal Region of Disintegrin Modulate its 3D Conformation and Cooperate with RGD Loop in Regulating Recognitions of Integrins
5Z9Z	;	2.049	;	The C-terminal RRM domain of Arabidopsis SMALL RNA DEGRADING NUCLEASE 1 (E329A/E330A/E332A)
1TN3	;	2.0	;	THE C-TYPE LECTIN CARBOHYDRATE RECOGNITION DOMAIN OF HUMAN TETRANECTIN
2ROW	;		;	The C1 domain of ROCK II
1I4U	;	1.15	;	THE C1 SUBUNIT OF ALPHA-CRUSTACYANIN
4IZS	;	1.44	;	The C145A mutant of the amidase from Nesterenkonia sp. AN1 in complex with butyramide
7OVG	;	1.65	;	The C146A variant of an amidase from Pyrococcus horikoshii with bound acetamide
6YPA	;	1.58	;	The C146A variant of an amidase from Pyrococcus horikoshii with bound glutaramide
1I5I	;	2.4	;	THE C18S MUTANT OF BOVINE (GAMMA-B)-CRYSTALLIN
6VBS	;	1.7	;	The C2 Crystal form of SodCI Superoxide Dismutase at 1.7 A resolution with 6 molecules in the asymmetric unit.
6IEJ	;	2.206	;	The C2 domain of cytosolic phospholipase A2 alpha bound to phosphatidylcholine
1YRK	;	1.7	;	The C2 Domain of PKC<delta> is a new Phospho-Tyrosine Binding Domain
6V7J	;	2.0	;	The C2221 crystal form of canavalin at 173 K
7W5K	;	2.22	;	The C296A mutant of L-sorbosone dehydrogenase (SNDH) from Gluconobacter Oxydans WSH-004
4NS0	;	1.8	;	The C2A domain of Rabphilin 3A in complex with PI(4,5)P2
5LO8	;	2.5	;	The C2B domain of Rabphilin 3A in complex with PI(4,5)P2
3RPB	;		;	THE C2B-DOMAIN OF RABPHILIN: STRUCTURAL VARIATIONS IN A JANUS-FACED DOMAIN
3UD4	;	2.7	;	The C92U mutant c-di-GMP-I riboswitch bound to GpA
3UD3	;	3.1	;	The C92U mutant c-di-GMP-I riboswitch bound to pGpA
2PF2	;	2.2	;	THE CA+2 ION AND MEMBRANE BINDING STRUCTURE OF THE GLA DOMAIN OF CA-PROTHROMBIN FRAGMENT 1
6TGT	;	2.155	;	The Calcium soaked crystal structure of the DPS2 from DEINOCOCCUS RADIODURANS to 2.16A resolution (Soaked in CaCl2 [5mM] for 20 min).
1P8X	;	2.0	;	The Calcium-Activated C-terminal half of gelsolin
1AVM	;	1.55	;	THE CAMBIALISTIC SUPEROXIDE DISMUTASE (FE-SOD) OF P. SHERMANII COORDINATED BY AZIDE
2CAS	;	3.0	;	THE CANINE PARVOVIRUS EMPTY CAPSID STRUCTURE
5XIX	;	2.25	;	The canonical domain of human asparaginyl-tRNA synthetase
5EG7	;	1.4	;	The cap binding site of influenza virus protein PB2 as a drug target
5EG8	;	1.54	;	The cap binding site of influenza virus protein PB2 as a drug target
5EG9	;	2.3	;	The cap binding site of influenza virus protein PB2 as a drug target
1HW5	;	1.82	;	THE CAP/CRP VARIANT T127L/S128A
7Z49	;	4.2	;	The capsid of bacteriophage SU10.
8TU0	;	2.72	;	The Capsid of Canine Minute Virus
7KMX	;	3.2	;	The capsid of Myoviridae Phage XM1
8TU1	;	2.31	;	The Capsid of Porcine Bocavirus 1
8TU2	;	2.52	;	The Capsid of Rat Bocavirus
8EP2	;	2.37	;	The capsid structure of Aleutian Mink Disease Virus
6O9R	;	2.75	;	The capsid structure of empty AAVrh.10 particles
8EP9	;	3.12	;	The capsid structure of Human Parvovirus 4
7RD1	;	3.07	;	The Capsid Structure of the ChAdOx1 viral vector/chimpanzee adenovirus Y25
7B5V	;	1.7	;	The carbohydrate binding module family 48 (CBM48) and carboxy-terminal carbohydrate esterase family 1 (CE1) domains of the multidomain esterase DmCE1B from Dysgonomonas mossii
7B6B	;	1.41	;	The carbohydrate binding module family 48 (CBM48) and carboxy-terminal carbohydrate esterase family 1 (CE1) domains of the multidomain esterase DmCE1B from Dysgonomonas mossii in complex with methyl ferulate
7VXQ	;	1.77	;	The Carbon Monoxide Complex of [NiFe]-hydrogenase (Hyb-type) from Citrobacter sp. S-77
6QGT	;	1.988	;	The carbon monoxide inhibition of F420-reducing [NiFe] hydrogenase complex from Methanosarcina barkeri
4C3T	;	1.69	;	The Carbonic anhydrase from Thermovibrio ammonificans reveals an interesting intermolecular disulfide contributing to increasing thermal stability of this enzyme
4U7A	;	1.6	;	The carboxy-terminal domain of Erb1 is a seven-bladed beta-propeller that binds RNA.
3PG6	;	1.7	;	The carboxyl terminal domain of human deltex 3-like
6E28	;	1.36	;	The CARD9 CARD domain-swapped dimer
6E27	;	1.811	;	The CARD9 CARD domain-swapped dimer with a zinc ion bound to one of the two zinc binding sites
6AAY	;	2.79	;	the Cas13b binary complex
6IV9	;	1.86	;	the Cas13d binary complex
5M1Y	;	1.904	;	The case of 1lkr held at the PDB and its variable amino acid occupancies; re refinement of 4ow9 to correct this
7BG9	;	3.8	;	The catalytic core lobe of human telomerase in complex with a telomeric DNA substrate
4Q0R	;	2.75	;	The catalytic core of Rad2 (complex I)
4Q0Z	;	2.398	;	The catalytic core of Rad2 in complex with DNA substrate (complex III)
4Q10	;	2.7	;	The catalytic core of Rad2 in complex with DNA substrate (complex IV)
7XRQ	;	2.501	;	The Catalytic Core Structure of Cystathionine beta-Synthase from Candida albicans
3E2T	;	1.9	;	The catalytic domain of chicken tryptophan hydroxylase 1 with bound tryptophan
5XSI	;	2.2	;	The catalytic domain of GdpP
5XSP	;	2.146	;	The catalytic domain of GdpP with 5'-pApA
5XSN	;	2.501	;	The catalytic domain of GdpP with c-di-AMP
5XT3	;	2.591	;	The catalytic domain of GdpP with c-di-GMP
3TMO	;	2.2	;	The catalytic domain of human deubiquitinase DUBA
3TMP	;	1.91	;	The catalytic domain of human deubiquitinase DUBA in complex with ubiquitin aldehyde
3PFY	;	1.702	;	The catalytic domain of human OTUD5
6F6D	;	1.81811	;	The catalytic domain of KDM6B in complex with H3(17-33)K18IA21M peptide
5LHR	;	2.3	;	The catalytic domain of murine urokinase-type plasminogen activator in complex with the active site binding inhibitory nanobody Nb22
5LHN	;	2.55	;	The catalytic domain of murine urokinase-type plasminogen activator in complex with the allosteric inhibitory nanobody Nb7
3N3K	;	2.6	;	The catalytic domain of USP8 in complex with a USP8 specific inhibitor
4D4C	;	1.3	;	The catalytic domain, BcGH76, of Bacillus circulans Aman6 in complex with 1,6-ManDMJ
4D4D	;	1.4	;	The catalytic domain, BcGH76, of Bacillus circulans Aman6 in complex with 1,6-ManIFG
5N0F	;	1.69	;	The catalytic domain, BcGH76, of Bacillus circulans Aman6 in complex with 1,6-ManSIFG
4D4B	;	1.3	;	The catalytic domain, BcGH76, of Bacillus circulans Aman6 in complex with MSMSMe
2PAW	;	2.3	;	THE CATALYTIC FRAGMENT OF POLY(ADP-RIBOSE) POLYMERASE
1PAX	;	2.4	;	THE CATALYTIC FRAGMENT OF POLY(ADP-RIBOSE) POLYMERASE COMPLEXED WITH 3,4-DIHYDRO-5-METHYL-ISOQUINOLINONE
3PAX	;	2.4	;	THE CATALYTIC FRAGMENT OF POLY(ADP-RIBOSE) POLYMERASE COMPLEXED WITH 3-METHOXYBENZAMIDE
2PAX	;	2.4	;	THE CATALYTIC FRAGMENT OF POLY(ADP-RIBOSE) POLYMERASE COMPLEXED WITH 4-AMINO-1,8-NAPHTHALIMIDE
4PAX	;	2.8	;	THE CATALYTIC FRAGMENT OF POLY(ADP-RIBOSE) POLYMERASE COMPLEXED WITH 8-HYDROXY-2-METHYL-3-HYDRO-QUINAZOLIN-4-ONE
6I8T	;	2.1	;	THE CATALYTIC FRAGMENT OF POLY(ADP-RIBOSE) POLYMERASE COMPLEXED WITH AN ISOINDOLINONE INHIBITOR
1A26	;	2.25	;	THE CATALYTIC FRAGMENT OF POLY(ADP-RIBOSE) POLYMERASE COMPLEXED WITH CARBA-NAD
6I8M	;	2.1	;	THE CATALYTIC FRAGMENT OF POLY(ADP-RIBOSE) POLYMERASE COMPLEXED WITH ISOINDOLINONE INHIBITOR
4XJQ	;	1.9	;	The catalytic mechanism of human parainfluenza virus type 3 haemagglutinin-neuraminidase revealed
4XJR	;	3.0	;	The catalytic mechanism of human parainfluenza virus type 3 haemagglutinin-neuraminidase revealed
1QL6	;	2.4	;	THE CATALYTIC MECHANISM OF PHOSPHORYLASE KINASE PROBED BY MUTATIONAL STUDIES
1H46	;	1.52	;	The catalytic module of Cel7D from Phanerochaete chrysosporium as a chiral selector: Structural studies of its complex with the b-blocker (R)-propranolol
1Q8T	;	2.0	;	The Catalytic Subunit of cAMP-dependent Protein Kinase (PKA) in Complex with Rho-kinase Inhibitor Y-27632
1Q8W	;	2.2	;	The Catalytic Subunit of cAMP-dependent Protein Kinase in Complex with Rho-kinase Inhibitor Fasudil (HA-1077)
1Q8U	;	1.9	;	The Catalytic Subunit of cAMP-dependent Protein Kinase in Complex with Rho-kinase Inhibitor H-1152P
4AXX	;	1.74	;	The catalytically active fully closed conformation of human phosphoglycerate kinase in complex with ADP 3-phosphoglycerate and beryllium trifluoride
2X15	;	2.1	;	The catalytically active fully closed conformation of human phosphoglycerate kinase in complex with ADP and 1,3- bisphosphoglycerate
2X13	;	1.74	;	The catalytically active fully closed conformation of human phosphoglycerate kinase in complex with ADP and 3phosphoglycerate
2WZC	;	1.5	;	The catalytically active fully closed conformation of human phosphoglycerate kinase in complex with ADP, 3PG and aluminium tetrafluoride
2WZB	;	1.47	;	The catalytically active fully closed conformation of human phosphoglycerate kinase in complex with ADP, 3PG and magnesium trifluoride
2WZD	;	1.56	;	The catalytically active fully closed conformation of human phosphoglycerate kinase K219A mutant in complex with ADP, 3PG and aluminium trifluoride
2X14	;	1.9	;	The catalytically active fully closed conformation of human phosphoglycerate kinase K219A mutant in complex with AMP-PCP and 3PG
3G38	;	3.04	;	The catalytically inactive mutant Mth0212 (D151N) in complex with an 8 bp dsDNA
8KE9	;	3.76	;	The CBD domain of cyanophage A-1(L) short tail fiber
7LVS	;	2.02	;	The CBP TAZ1 Domain in Complex with a CITED2-HIF-1-Alpha Fusion Peptide
3JTF	;	2.0	;	The CBS Domain Pair Structure of a magnesium and cobalt efflux protein from Bordetella parapertussis in complex with AMP
2NCG	;		;	The CC domain structure from the wheat stem rust resistance protein Sr33 challenges paradigms for dimerization in plant NLR proteins
4DIJ	;	1.9	;	The Central Valine Concept Provides an Entry in a New Class of Non Peptide Inhibitors of the P53-MDM2 Interaction
8BY8	;	2.5	;	The cercosporin fungal non-reducing polyketide synthase (NR-PKS) CTB1 (SAT-KS-MAT)
1YMG	;	2.24	;	The Channel Architecture of Aquaporin O at 2.2 Angstrom Resolution
4V0J	;	2.8	;	The channel-block Ser202Glu, Thr104Lys double mutant of Stearoyl-ACP- Desaturase from Castor bean (Ricinus communis)
4OLK	;	2.694	;	The CHAP domain of LysGH15
5J70	;	2.956	;	The Chd1 DNA-binding domain in complex with 17mer DNA duplex
2Q6P	;	2.1	;	The Chemical Control of Protein Folding: Engineering a Superfolder Green Fluorescent Protein
4ZK9	;	2.6	;	The chemokine binding protein of orf virus complexed with CCL2
4ZKB	;	2.9	;	The chemokine binding protein of orf virus complexed with CCL3
4ZKC	;	3.15	;	The chemokine binding protein of orf virus complexed with CCL7
4V3D	;	2.65	;	The CIDRa domain from HB3var03 PfEMP1 bound to endothelial protein C receptor
4V3E	;	2.9	;	The CIDRa domain from IT4var07 PfEMP1 bound to endothelial protein C receptor
5LGD	;	2.07	;	The CIDRa domain from MCvar1 PfEMP1 bound to CD36
5XUB	;	2.5	;	The citrate-bound trimer of chemoreceptor MCP2201 ligand binding domain
6ITS	;	2.501	;	The citrate-bound trimer of chemoreceptor MCP2201 ligand binding domain
6BS8	;	1.95	;	The class 3 DnaB intein from Mycobacterium smegmatis
6KW3	;	7.13	;	The ClassA RSC-Nucleosome Complex
6KW4	;	7.55	;	The ClassB RSC-Nucleosome Complex
6KW5	;	10.13	;	The ClassC RSC-Nucleosome Complex
6C41	;		;	The clavanin peptide in the presence of TFE (2,2,2-trifluoroethanol), presented a amphipathic alpha-helices from Phe-2 to Val-22 residues
4RLG	;	1.901	;	The clear crystal structure of pyridoxal-dependent decarboxylase from sphaerobacter thermophilus dsm 20745
2MBK	;		;	The Clip-segment of the von Willebrand domain 1 of the BMP modulator protein Crossveinless 2 is preformed
8E4Q	;	3.51	;	The closed C0-state flycatcher TRPM8 structure in complex with PI(4,5)P2
8E4N	;	3.07	;	The closed C1-state mouse TRPM8 structure in complex with PI(4,5)P2
8E4O	;	3.43	;	The closed C1-state mouse TRPM8 structure in complex with putative PI(4,5)P2
1ANK	;	2.0	;	THE CLOSED CONFORMATION OF A HIGHLY FLEXIBLE PROTEIN: THE STRUCTURE OF E. COLI ADENYLATE KINASE WITH BOUND AMP AND AMPPNP
3GDE	;	2.3	;	The closed conformation of ATP-dependent DNA ligase from Archaeoglobus fulgidus
7CYR	;	2.05	;	The closed conformation of MSMEG_1954 from Mycobacterium smegmatis
7W2B	;	3.203	;	The closed conformation of the sigma-1 receptor from Xenopus laevis
7W2C	;	3.335	;	The closed conformation of the sigma-1 receptor from Xenopus laevis complexed with PRE084
7W2D	;	3.471	;	The closed conformation of the sigma-1 receptor from Xenopus laevis complexed with S1RA
3ASV	;	2.7	;	The Closed form of serine dehydrogenase complexed with NADP+
3NID	;	2.3	;	The Closed Headpiece of Integrin alphaIIB beta3 and its Complex with an alpahIIB beta3 -Specific Antagonist That Does Not Induce Opening
3NIF	;	2.4	;	The Closed Headpiece of Integrin IIb 3 and its Complex with an IIb 3 -Specific Antagonist That Does Not Induce Opening
3NIG	;	2.25	;	The Closed Headpiece of Integrin IIb 3 and its Complex with an IIb 3 -Specific Antagonist That Does Not Induce Opening
2QAC	;	1.7	;	The closed MTIP-MyosinA-tail complex from the malaria parasite invasion machinery
2HT1	;	3.51	;	The closed ring structure of the Rho transcription termination factor in complex with nucleic acid in the motor domains
6K85	;	1.606	;	The closed state of RGLG1 mutant-D338A
6K86	;	1.593	;	The closed state of RGLG1 mutant-E378A
6K89	;	1.689	;	The closed state of RGLG1 VWA domain
6K87	;	1.502	;	The closed state of RGLG1 VWA domain with MIDAS is occupied by water
8HMH	;	2.56	;	The closed state of RGLG2-VWA
8Q3B	;	2.69	;	The closed state of the ASFV apo-RNA polymerase
1NYJ	;		;	The closed state structure of M2 protein H+ channel by solid state NMR spectroscopy
5WX1	;	2.35	;	The closed-conformation crystal structure of the full-length pestivirus NS3 with its NS4A protease cofactor segment
2VN5	;	1.9	;	The Clostridium cellulolyticum dockerin displays a dual binding mode for its cohesin partner
2VN6	;	1.49	;	The Clostridium cellulolyticum dockerin displays a dual binding mode for its cohesin partner
7DGK	;	1.75	;	The Co-bound dimeric structure of K78H/G80A/H82A myoglobin
7DGN	;	2.35	;	The Co-bound dimeric structure of K79H/G80A/H81A myoglobin
4TPW	;	1.5	;	The co-complex structure of the translation initiation factor eIF4E with the inhibitor 4EGI-1 reveals an allosteric mechanism for dissociating eIF4G
4TQB	;	1.59	;	The co-complex structure of the translation initiation factor eIF4E with the inhibitor 4EGI-1 reveals an allosteric mechanism for dissociating eIF4G
4TQC	;	1.8	;	The co-complex structure of the translation initiation factor eIF4E with the inhibitor 4EGI-1 reveals an allosteric mechanism for dissociating eIF4G
7E7E	;	3.8	;	The co-crystal structure of ACE2 with Fab
7Y0V	;	2.48	;	The co-crystal structure of BA.1-RBD with Fab-5549
6P7G	;	2.65	;	The co-crystal structure of BRAF(V600E) with PHI1
6P3D	;	2.11	;	The co-crystal structure of BRAF(V600E) with ponatinib
1PJS	;	2.4	;	The co-crystal structure of CysG, the multifunctional methyltransferase/dehydrogenase/ferrochelatase for siroheme synthesis, in complex with it NAD cofactor
6K0J	;	2.352	;	The co-crystal structure of DYRK2 with a small molecule inhibitor
7DHC	;	2.592	;	The co-crystal structure of DYRK2 with a small molecule inhibitor 10
7DHK	;	2.341	;	The co-crystal structure of DYRK2 with a small molecule inhibitor 13
7DHO	;	3.29	;	The co-crystal structure of DYRK2 with a small molecule inhibitor 14
7DJO	;	2.499	;	The co-crystal structure of DYRK2 with a small molecule inhibitor 17
7DL6	;	2.648	;	The co-crystal structure of DYRK2 with a small molecule inhibitor 18
7DHH	;	2.486	;	The co-crystal structure of DYRK2 with a small molecule inhibitor 19
7DHN	;	2.38	;	The co-crystal structure of DYRK2 with a small molecule inhibitor 20
7DH3	;	2.33	;	The co-crystal structure of DYRK2 with a small molecule inhibitor 5
7DG4	;	2.58	;	The co-crystal structure of DYRK2 with a small molecule inhibitor 6
7DH9	;	2.194	;	The co-crystal structure of DYRK2 with a small molecule inhibitor 7
7DHV	;	2.679	;	The co-crystal structure of DYRK2 with a small molecule inhibitor 8
7EJV	;	2.5	;	The co-crystal structure of DYRK2 with YK-2-69
8HLT	;	2.8	;	The co-crystal structure of DYRK2 with YK-2-99B
7UW6	;	1.5	;	The co-crystal structure of low molecular weight protein tyrosine phosphatase (LMW-PTP) with a small molecule inhibitor SPAA-2
6LNQ	;	2.244	;	The co-crystal structure of SARS-CoV 3C Like Protease with aldehyde inhibitor M7
7DGB	;	1.678	;	The co-crystal structure of SARS-CoV-2 main protease with (S)-2-cinnamamido-4-methyl-N-((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)pentanamide
7DGG	;	2.004	;	The co-crystal structure of SARS-CoV-2 main protease with (S)-2-cinnamamido-N-((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)hexanamide
7DGF	;	1.639	;	The co-crystal structure of SARS-CoV-2 main protease with peptidomimetic inhibitor (S)-2-cinnamamido-N-((S)-1-oxo-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)hexanamide
7DGH	;	1.968	;	The co-crystal structure of SARS-CoV-2 main protease with peptidomimetic inhibitor N-((S)-3-methyl-1-(((S)-4-methyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-1-oxobutan-2-yl)-2-naphthamide
7DGI	;	1.898	;	The co-crystal structure of SARS-CoV-2 main protease with peptidomimetic inhibitor N-((S)-3-methyl-1-(((S)-4-methyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-1-oxobutan-2-yl)-4-nitrobenzamide
7DHJ	;	1.962	;	The co-crystal structure of SARS-CoV-2 main protease with the peptidomimetic inhibitor (S)-2-cinnamamido-N-((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)pent-4-ynamide
6LO0	;	1.939	;	The co-crystal structure of Severe Acute Respiratory Syndrome Coronavirus 3C Like Protease with aldehyde M14
6LNY	;	2.245	;	The co-crystal structure of Severe Acute Respiratory Syndrome Coronavirus 3C-Like Protease with aldehyde M15
1MKW	;	2.3	;	THE CO-CRYSTAL STRUCTURE OF UNLIGANDED BOVINE ALPHA-THROMBIN AND PRETHROMBIN-2: MOVEMENT OF THE YPPW SEGMENT AND ACTIVE SITE RESIDUES UPON LIGAND BINDING
1MKX	;	2.2	;	THE CO-CRYSTAL STRUCTURE OF UNLIGANDED BOVINE ALPHA-THROMBIN AND PRETHROMBIN-2: MOVEMENT OF THE YPPW SEGMENT AND ACTIVE SITE RESIDUES UPON LIGAND BINDING
2IYN	;	2.08	;	The co-factor-induced pre-active conformation in PhoB
5UK8	;	2.5	;	The co-structure of (R)-4-(6-(1-(cyclopropylsulfonyl)cyclopropyl)-2-(1H-indol-4-yl)pyrimidin-4-yl)-3-methylmorpholine and a rationally designed PI3K-alpha mutant that mimics ATR
5UL1	;	3.0	;	The co-structure of 3-amino-6-(4-((1-(dimethylamino)propan-2-yl)sulfonyl)phenyl)-N-phenylpyrazine-2-carboxamide and a rationally designed PI3K-alpha mutant that mimics ATR
5UKJ	;	2.8	;	The co-structure of N,N-dimethyl-4-[(6R)-6-methyl-5-(1H-pyrrolo[2,3- b]pyridin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5- a]pyrazin-3-yl]benzenesulfonamide and a rationally designed PI3K-alpha mutant that mimics ATR
6AGX	;	2.95	;	The cocrystal structure of FGFR2 bound with compound 14 harboring 5H-pyrrolo[2,3-b]pyrazine scaffold
2PHH	;	2.7	;	THE COENZYME ANALOGUE ADENOSINE 5-DIPHOSPHORIBOSE DISPLACES FAD IN THE ACTIVE SITE OF P-HYDROXYBENZOATE HYDROXYLASE. AN X-RAY CRYSTALLOGRAPHIC INVESTIGATION
2OZN	;	1.6	;	The Cohesin-Dockerin Complex of NagJ and NagH from Clostridium perfringens
2IC6	;	1.15	;	The Coiled-coil Domain (residues 1-75) Structure of the Sin Nombre Virus Nucleocapsid Protein
2IC9	;	2.0	;	The Coiled-coil Domain (residues 1-93) Structure of the Sin Nombre Virus Nucleocapsid Protein
3CHG	;	2.8	;	The compatible solute-binding protein OpuAC from Bacillus subtilis in complex with DMSA
6HUA	;	3.389	;	the competence regulator ComR from Streptococcus vestibularis in complex with its cognate signaling peptide XIP
2CM4	;	1.9	;	The complement inhibitor OmCI in complex with ricinoleic acid
2CM9	;	2.3	;	The complement inhibitor OmCI in complex with ricinoleic acid
6N1L	;	1.722	;	The complement inhibitory domain of B. burgdorferi BBK32.
7LHD	;	4.6	;	The complete model of phage Qbeta virion
2XE6	;	1.74	;	The complete reaction cycle of human phosphoglycerate kinase: The open binary complex with 3PG
2XE7	;	2.2	;	The complete reaction cycle of human phosphoglycerate kinase: The open ternary complex with 3PG and ADP
2XE8	;	1.79	;	The complete reaction cycle of human phosphoglycerate kinase: The open ternary complex with 3PG and AMP-PNP
2VEA	;	2.21	;	The complete sensory module of the cyanobacterial phytochrome Cph1 in the Pr-state.
4EV6	;	3.2	;	The complete structure of CorA magnesium transporter from Methanocaldococcus jannaschii
2WAQ	;	3.35	;	The complete structure of the archaeal 13-subunit DNA-directed RNA Polymerase
2WB1	;	3.52	;	The complete structure of the archaeal 13-subunit DNA-directed RNA Polymerase
5O61	;	3.31	;	The complete structure of the Mycobacterium smegmatis 70S ribosome
5WLC	;	3.8	;	The complete structure of the small subunit processome
6DKP	;	2.966	;	The complex among DMF5(alpha-D26Y, alpha-Y50A,beta-L98W) TCR, human Class I MHC HLA-A2 and MART-1(26-35)(A27L) peptide
3VXM	;	2.5	;	The complex between C1-28 TCR and HLA-A24 bound to HIV-1 Nef134-10(2F) peptide
2LV6	;		;	The complex between Ca-Calmodulin and skeletal muscle myosin light chain kinase from combination of NMR and aqueous and contrast-matched SAXS data
8GVI	;	3.3	;	The complex between H25-11 TCR and HLA-A24 bound to HIV-1 Nef138-8 peptide
3VXS	;	1.8	;	The complex between H27-14 TCR and HLA-A24 bound to HIV-1 Nef134-10(6L) peptide
3VXR	;	2.4	;	The complex between H27-14 TCR and HLA-A24 bound to HIV-1 Nef134-10(wt) peptide
4L3E	;	2.557	;	The complex between high affinity TCR DMF5(alpha-D26Y,beta-L98W) and human Class I MHC HLA-A2 with the bound MART-1(26-35)(A27L) peptide
6D78	;	2.347	;	The complex between high-affinity TCR DMF5(alpha-D26Y,beta-L98W) and human Class I MHC HLA-A2 with the bound MART-1(27-35)peptide
1CRA	;	1.9	;	THE COMPLEX BETWEEN HUMAN CARBONIC ANHYDRASE II AND THE AROMATIC INHIBITOR 1,2,4-TRIAZOLE
5G64	;	3.715	;	The complex between human IgE-Fc and two anti-IgE Fab fragments
1PER	;	2.5	;	THE COMPLEX BETWEEN PHAGE 434 REPRESSION DNA-BINDING DOMAIN AND OPERATOR SITE OR3: STRUCTURAL DIFFERENCES BETWEEN CONSENSUS AND NON-CONSENSUS HALF-SITES
8GVG	;	3.37	;	The complex between public TCR TD08 and HLA-A24 bound to HIV-1 Nef138-8 (2F) peptide
8GVB	;	3.2	;	The complex between public TCR TD08 and HLA-A24 bound to HIV-1 Nef138-8 peptide
7KDC	;	3.1	;	The complex between RhoD and the Plexin B2 RBD
1RGC	;	2.0	;	THE COMPLEX BETWEEN RIBONUCLEASE T1 AND 3'-GUANYLIC ACID SUGGESTS GEOMETRY OF ENZYMATIC REACTION PATH. AN X-RAY STUDY
3VXU	;	2.7	;	The complex between T36-5 TCR and HLA-A24 bound to HIV-1 Nef134-10(2F) peptide
3W0W	;	2.603	;	The complex between T36-5 TCR and HLA-A24 bound to HIV-1 Nef134-10(2F) peptide in space group P212121
3PWP	;	2.69	;	The complex between TCR A6 and human Class I MHC HLA-A2 with the bound HuD peptide
3H9S	;	2.7	;	The complex between TCR A6 and human Class I MHC HLA-A2 with the bound Tel1p peptide
3D3V	;	2.8	;	The complex between TCR A6 and human Class I MHC HLA-A2 with the modified HTLV-1 TAX (Y5(3,4-difluoroPhenylalanine)) peptide
3D39	;	2.81	;	The complex between TCR A6 and human Class I MHC HLA-A2 with the modified HTLV-1 TAX (Y5(4-fluoroPhenylalanine)) peptide
2GJ6	;	2.56	;	The complex between TCR A6 and human Class I MHC HLA-A2 with the modified HTLV-1 TAX (Y5K-4-[3-Indolyl]-butyric acid) peptide
3QFJ	;	2.29	;	The complex between TCR A6 and human Class I MHC HLA-A2 with the modified TAX (Y5F) peptide
6RSY	;	2.95	;	The complex between TCR a7b2 and human Class I MHC HLA-A0201-WT1 with the bound RMFPNAPYL peptide.
3QDM	;	2.8	;	The complex between TCR DMF4 and human Class I MHC HLA-A2 with the bound MART-1(26-35)(A27L) decameric peptide
3QEQ	;	2.59	;	The complex between TCR DMF4 and human Class I MHC HLA-A2 with the bound MART-1(27-35) nonameric peptide
3QDG	;	2.69	;	The complex between TCR DMF5 and human Class I MHC HLA-A2 with the bound MART-1(26-35)(A27L) peptide
3QDJ	;	2.3	;	The complex between TCR DMF5 and human Class I MHC HLA-A2 with the bound MART-1(27-35) nonameric peptide
4EUP	;	2.88	;	The complex between TCR JKF6 and human Class I MHC HLA-A2 presenting the MART-1(27-35)(A27L) peptide
6Y7P	;	1.75	;	The complex between the eight-bladed symmetrical designer protein Tako8 and 1:2 zirconium(IV) Wells-Dawson (ZrWD)
6Y7O	;	2.3	;	The complex between the eight-bladed symmetrical designer protein Tako8 and the silicotungstic acid Keggin (STA)
4FTV	;	2.74	;	The complex between the high affinity version of A6 TCR (A6c134) and human Class I MHC HLA-A2 with the bound TAX nonameric peptide
1MEE	;	2.0	;	THE COMPLEX BETWEEN THE SUBTILISIN FROM A MESOPHILIC BACTERIUM AND THE LEECH INHIBITOR EGLIN-C
7RK7	;	2.54	;	The complex between TIL 1383i TCR and human Class I MHC HLA-A2 with the bound Tyrosinase(369-377)(N371D) nonameric peptide
6JHO	;	2.1	;	The complex crystal structure of Cagbeta with CagZ revealed a novel regulatory mechanism for T4SS coupling ATPase in Helicobacter pylori
3KXZ	;	2.37	;	The complex crystal structure of LCK with a probe molecule w259
6N6B	;	2.3	;	The complex crystal structure of neuraminidase from A/Minnesota/11/2010 with B10 antibody.
5X4K	;	1.749	;	The complex crystal structure of Pyrococcus furiosus RecJ and CMP
4HLY	;	1.48	;	The complex crystal structure of the DNA binding domain of vIRF-1 from the oncogenic KSHV with DNA
3MHW	;	1.45	;	The complex crystal Structure of Urokianse and 2-Aminobenzothiazole
3MWI	;	2.03	;	The complex crystal Structure of Urokianse and 5-nitro-1H-indole-2-amidine
5YB5	;	1.903	;	The complex crystal structure of VrEH2 mutant M263N with SNO
7FGM	;	2.2	;	The complex crystals structure of the FAF1 UBL1_L-Hsp70 NBD with ADP and phosphate
2TCT	;	2.1	;	THE COMPLEX FORMED BETWEEN TET REPRESSOR AND TETRACYCLINE-MG2+ REVEALS MECHANISM OF ANTIBIOTIC RESISTANCE
6OX7	;	2.75	;	The complex of 1918 NS1-ED and the iSH2 domain of the human p85beta subunit of PI3K
1O9M	;	2.4	;	The Complex of a novel antibiotic with the Aminoacyl Site of the Bacterial Ribosome Revealed by X-Ray Crystallography.
8HMT	;	3.17	;	The complex of ACK1 with the inhibitor 2-142
7VRS	;	2.6	;	The complex of Acyltransferase and Acyl Carrier Protein Domains from module 9 of Salinomycin Polyketide Synthase
4COQ	;	1.55	;	The complex of alpha-Carbonic anhydrase from Thermovibrio ammonificans with inhibitor sulfanilamide.
6ION	;	2.75	;	The complex of C4.4A with its antibody 11H10 Fab fragment
6N0J	;	1.79	;	The complex of CCG-222740 bound to pirin
6N0K	;	1.46	;	The complex of CCG-257081 bound to pirin
2PCF	;		;	THE COMPLEX OF CYTOCHROME F AND PLASTOCYANIN DETERMINED WITH PARAMAGNETIC NMR. BASED ON THE STRUCTURES OF CYTOCHROME F AND PLASTOCYANIN, 10 STRUCTURES
7SVR	;	3.9	;	The complex of dephosphorylated human cystic fibrosis transmembrane conductance regulator (CFTR) and Lumacaftor (VX-809)
7F2F	;	2.55	;	The complex of DNA with the C-terminal domain of TYE7 from Saccharomyces cerevisiae.
5H4R	;	1.7031	;	the complex of Glycoside Hydrolase 5 Lichenase from Caldicellulosiruptor sp. F32 E188Q mutant and cellotetraose
8D5F	;	2.31	;	The complex of Gtf2b neoantigen TGAARFDEF Presented by H2-Dd
8D5E	;	2.46	;	The complex of Gtf2b Peptide TGAASFDEF Presented by H2-Dd
4J4P	;	2.91	;	The complex of human IgE-Fc with two bound Fab fragments
8BH7	;	4.23	;	The complex of immature 30S ribosomal subunit with Ribosome maturation factor P (RimP) from Staphylococcus aureus
7E6U	;	6.0	;	the complex of inactive CaSR and NB2D11
6K1P	;	3.87	;	The complex of ISWI-nucleosome in the ADP.BeF-bound state
4OTJ	;	2.11	;	The complex of murine cyclooxygenase-2 with a conjugate of indomefathin and podophyllotoxin, N-{(succinylpodophyllotoxinyl)but-4-yl}-2-{1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl}acetamide
1UWJ	;	3.5	;	The complex of mutant V599E B-RAF and BAY439006.
8DTU	;	2.447	;	The complex of nanobody 5344N74D with BCL11A ZF6.
8DTN	;	2.199	;	The complex of nanobody 6101 with BCL11A ZF6
7XQV	;	2.76	;	The complex of nanobody Rh57 binding to GTP-bound RhoA active form
1TU2	;		;	THE COMPLEX OF NOSTOC CYTOCHROME F AND PLASTOCYANIN DETERMIN WITH PARAMAGNETIC NMR. BASED ON THE STRUCTURES OF CYTOCHROME F AND PLASTOCYANIN, 10 STRUCTURES
6K9A	;	2.3	;	The complex of NrS-1 N terminal domain (1-305) with dGTP
6JUE	;	1.549	;	The complex of PDZ and PBM
7SVD	;	2.7	;	The complex of phosphorylated human cystic fibrosis transmembrane conductance regulator (CFTR) with ATP/Mg and Lumacaftor (VX-809)
7SV7	;	3.8	;	The complex of phosphorylated human cystic fibrosis transmembrane conductance regulator (CFTR) with ATP/Mg and Tezacaftor (VX-661)
8EIG	;	3.6	;	The complex of phosphorylated human delta F508 cystic fibrosis transmembrane conductance regulator (CFTR) with elexacaftor (VX-445) and ATP/Mg
8EIO	;	2.8	;	The complex of phosphorylated human delta F508 cystic fibrosis transmembrane conductance regulator (CFTR) with elexacaftor (VX-445), lumacaftor (VX-809) and ATP/Mg
8EIQ	;	3.0	;	The complex of phosphorylated human delta F508 cystic fibrosis transmembrane conductance regulator (CFTR) with Trikafta [elexacaftor (VX-445), tezacaftor (VX-661), ivacaftor (VX-770)] and ATP/Mg
2JJ4	;	3.46	;	The complex of PII and acetylglutamate kinase from Synechococcus elongatus PCC7942
3N5B	;	1.9	;	The complex of PII and PipX from Anabaena
3WWE	;	2.1	;	The complex of pOPH with PEG
3WWC	;	1.49	;	The complex of pOPH_S172A of pNPB
3WWD	;	1.65	;	The complex of pOPH_S172C with DMSO
8D5J	;	1.95	;	The complex of Pre-mRNA-Processing Factor 19 (Prpf19) neoantigen KYLQVASHV Presented by H2-Kd
8D5K	;	2.066	;	The complex of Pre-mRNA-Processing Factor 19 (Prpf19) peptide KYLQVASHV Presented by H2-Kd
8IOL	;	2.9	;	The complex of Rubisco large subunit (RbcL)
7VFA	;	1.75	;	the complex of SARS-CoV2 3CL and NB1A2
7VFB	;	2.0	;	the complex of SARS-CoV2 3cl and NB2B4
4UMK	;	3.096	;	The complex of Spo0J and parS DNA in chromosomal partition system
8HAQ	;	2.27	;	The complex of Src with GW8510
1CQF	;	2.2	;	THE COMPLEX OF THE MUTATED SHIGA TOXIN B SUBUNIT AND GB3 TRISACCHARIDE
5AKO	;	2.4	;	The complex of Tse2 and Tsi2 from Pseudomonas aeruginosa
1UWH	;	2.95	;	The complex of wild type B-RAF and BAY439006.
3II5	;	2.79	;	The Complex of wild-type B-RAF with Pyrazolo pyrimidine inhibitor
8DIN	;	2.5	;	The complex structure between human IgG1 Fc and its high affinity receptor FcgRI H174R variant
8DIR	;	2.3	;	The complex structure between human IgG1 Fc and its high affinity receptor FcgRI H174R variant
8DJ7	;	2.39	;	The complex structure between human IgG1 Fc and its high affinity receptor FcgRI H174R variant
2DX5	;	3.35	;	The complex structure between the mouse EAP45-GLUE domain and ubiquitin
4IPN	;	2.411	;	The complex structure of 6-phospho-beta-glucosidase BglA-2 with thiocellobiose-6P from Streptococcus pneumoniae
2ZZN	;	2.95	;	The complex structure of aTrm5 and tRNACys
2ZZM	;	2.65	;	The complex structure of aTrm5 and tRNALeu
7VKZ	;	2.0	;	The complex structure of beta-1,2-glucosyltransferase from Ignavibacterium album with 1-Deoxynojirimycin
7VL6	;	1.75	;	The complex structure of beta-1,2-glucosyltransferase from Ignavibacterium album with arbutin
7VL7	;	1.89	;	The complex structure of beta-1,2-glucosyltransferase from Ignavibacterium album with esculin
7VL2	;	1.8	;	The complex structure of beta-1,2-glucosyltransferase from Ignavibacterium album with ethyl alpha-D-Glucoside
7VKX	;	1.56	;	The complex structure of beta-1,2-glucosyltransferase from Ignavibacterium album with glucose
7VL1	;	1.6	;	The complex structure of beta-1,2-glucosyltransferase from Ignavibacterium album with methyl alpha-D-glucoside
7VL4	;	1.83	;	The complex structure of beta-1,2-glucosyltransferase from Ignavibacterium album with methyl beta-D-glucoside
7VL5	;	1.93	;	The complex structure of beta-1,2-glucosyltransferase from Ignavibacterium album with n-octyl-beta-D-glucoside
7VL0	;	1.79	;	The complex structure of beta-1,2-glucosyltransferase from Ignavibacterium album with p-nitrophenyl-alpha-D-glucopyranoside
7VL3	;	1.82	;	The complex structure of beta-1,2-glucosyltransferase from Ignavibacterium album with phenyl alpha-D-glucoside
7VKY	;	2.0	;	The complex structure of beta-1,2-glucosyltransferase from Ignavibacterium album with sophorose
7X87	;	1.79	;	The complex structure of beta-1,2-glucosyltransferase from Ignavibacterium album with sophotetraose observed as sophorose
4R5Y	;	3.5	;	The complex structure of Braf V600E kinase domain with a novel Braf inhibitor
5VYO	;	2.49	;	The complex structure of Burkholderia pseudomallei DsbA bound to a peptide
5BWM	;	2.5	;	The complex structure of C3cer exoenzyme and GDP bound RhoA (NADH-bound state)
4XSH	;	2.5	;	The complex structure of C3cer exoenzyme and GTP bound RhoA (NADH-bound state)
4XSG	;	1.8	;	The complex structure of C3cer exoenzyme and GTP bound RhoA (NADH-free state)
2R28	;	1.86	;	The complex Structure of Calmodulin Bound to a Calcineurin Peptide
3H39	;	2.854	;	The complex structure of CCA-adding enzyme with ATP
3H3A	;	2.801	;	The complex structure of CCA-adding enzyme with CTP
3WP6	;	1.43	;	The complex structure of CDBFV E109A with xylotriose
1NVS	;	1.8	;	The Complex Structure Of Checkpoint Kinase Chk1/SB218078
1NVR	;	1.8	;	The Complex Structure Of Checkpoint Kinase Chk1/Staurosporine
1NVQ	;	2.0	;	The Complex Structure Of Checkpoint Kinase Chk1/UCN-01
6JO8	;	3.495	;	The complex structure of CHIKV envelope glycoprotein bound to human MXRA8
8HQV	;	1.398	;	The complex structure of COPI cargo sorting module with HCoV-OC43 Spike KTSHxx sorting motif
8HQW	;	1.405	;	The complex structure of COPI cargo sorting module with MHV Spike Hxx sorting motif
8HQT	;	1.8	;	The complex structure of COPI cargo sorting module with SARS-CoV-2 Spike KxHxx sorting motif
8HQX	;	1.538	;	The complex structure of COPI cargo sorting module with TAT-WDM peptide
8HR0	;	3.34	;	The complex structure of COPII coat with HCoV-OC43 DD sorting motif
5GZX	;	2.35	;	The complex structure of D-2-haloacid dehalogenase mutant with D-2-CPA
5GZY	;	2.18	;	The complex structure of D-2-haloacid dehalogenase with L-LA
3WFJ	;	2.8	;	The complex structure of D-mandelate dehydrogenase with NADH
1WR1	;		;	The complex structure of Dsk2p UBA with ubiquitin
4TKY	;	2.5	;	The complex structure of E. coli DsbA bound to a peptide at the DsbA/DsbB interface
3WDY	;	1.94	;	The complex structure of E113A with cellotetraose
3WDX	;	1.9	;	The complex structure of E113A with glucotriose
6KVW	;	2.25	;	The complex structure of EanB/C339A/C370A and hercynine
6KTZ	;	2.0	;	The complex structure of EanB/C412S with hercynine
3W8Z	;	1.8	;	The complex structure of EncM with hydroxytetraketide
3W8X	;	1.82	;	The complex structure of EncM with trifluorotriketide
6IMV	;	2.0	;	The complex structure of endo-beta-1,2-glucanase from Talaromyces funiculosus with sophorose
6IMW	;	2.1	;	The complex structure of endo-beta-1,2-glucanase mutant (E262Q) from Talaromyces funiculosus with beta-1,2-glucan
4UV7	;	2.1	;	The complex structure of extracellular domain of EGFR and GC1118A
4UIP	;	2.95	;	The complex structure of extracellular domain of EGFR with Repebody (rAC1).
7ESA	;	1.8	;	the complex structure of flavin transferase FmnB complexed with FAD
5ZDN	;	2.02	;	The complex structure of FomD with CDP
7ETK	;	1.22027	;	The complex structure of FtmOx1 bond with fumitremorgen B at 1.22 angstrom
7EP7	;	2.6	;	The complex structure of Gpsm2 and Whirlin
5E66	;	3.1	;	The complex structure of Hemagglutinin-esterase-fusion mutant protein from the influenza D virus with receptor analog 9-N-Ac-Sia
5E65	;	2.2	;	The complex structure of Hemagglutinin-esterase-fusion mutant protein from the influenza D virus with receptor analog 9-O-Ac-3'SLN (Tr322)
6QIL	;	2.0	;	The complex structure of hsRosR-S1 (VNG0258H/RosR-S1)
6QFD	;	2.133	;	The complex structure of hsRosR-S4 (vng0258/RosR-S4)
6QH0	;	2.436	;	The complex structure of hsRosR-S5 (VNG0258H/RosR-S5)
6QUA	;	2.681	;	The complex structure of hsRosR-SG (vng0258/RosR-SG)
3WCH	;	2.5	;	The complex structure of HsSQS wtih ligand BPH1237
3WCM	;	2.06	;	The complex structure of HsSQS wtih ligand, ER119884
3WC9	;	2.82	;	The complex structure of HsSQS wtih ligand, FSPP
3WCD	;	2.75	;	The complex structure of HsSQS wtih ligand, WC-9
3WCF	;	2.22	;	The complex structure of HsSQS wtih ligand,BPH1218
3WCI	;	2.3	;	The complex structure of HsSQS wtih ligand,BPH1325
3WCL	;	2.24	;	The complex structure of HsSQS wtih ligand,BPH1344
3WCJ	;	2.2	;	The complex structure of HsSQS wtih ligand,E5700
6KA7	;	3.0	;	The complex structure of Human IgG Fc and its binding Repebody
3WRG	;	2.23	;	The complex structure of HypBA1 with L-arabinose
6LOJ	;	3.72	;	The complex structure of IpaH9.8-LRR and hGBP1
2PXJ	;	2.0	;	The complex structure of JMJD2A and monomethylated H3K36 peptide
2P5B	;	1.99	;	The complex structure of JMJD2A and trimethylated H3K36 peptide
4XLY	;	1.82	;	The complex structure of KS-D75C with substrate CPP
7W3S	;	2.324	;	The complex structure of Larg1-ADPr from Legionella pneumophila
7CZ2	;	1.8	;	The complex structure of MSMEG_1954-ADP from Mycobacterium smegmatis
7XQ6	;	2.0	;	The complex structure of mutant Mpro with inhibitor
4TSR	;	2.07	;	The Complex Structure of Mutant Phytase with IHS
4PZA	;	1.776	;	The complex structure of mycobacterial glucosyl-3-phosphoglycerate phosphatase Rv2419c with inorganic phosphate
7X1M	;	2.74	;	The complex structure of Omicron BA.1 RBD with BD604, S309,and S304
8HWS	;	2.36	;	The complex structure of Omicron BA.4 RBD with BD604, S309, and S304
7WVM	;	3.4	;	The complex structure of PD-1 and cemiplimab
5A2P	;	2.496	;	THE COMPLEX STRUCTURE OF PDZ DOMAINS IN SYNTENIN-1 WITH 4L PEPTIDE
6LRA	;	1.9	;	The complex structure of PHF core domain peptide of tau and antibody's Fab domain.
7FGL	;	2.1	;	The complex structure of PHF core domain peptide of tau, VQIVYK, and antibody's Fab domain.
3WL7	;	1.67	;	The complex structure of pOPH S172C with ligand, ACA
6JAU	;	1.905	;	The complex structure of Pseudomonas aeruginosa MucA/MucB.
3WDU	;	2.25	;	The complex structure of PtLic16A with cellobiose
3WDV	;	1.936	;	The complex structure of PtLic16A with cellotetraose
7XBH	;	3.02	;	The complex structure of RshSTT182/200 RBD bound to human ACE2
7XBF	;	3.51	;	The complex structure of RshSTT182/200 RBD-insert2 bound to human ACE2
5YK0	;	2.102	;	The complex structure of Rv3197-ADP from Mycobacterium tuberculosis
5YK1	;	2.103	;	The complex structure of Rv3197-AMPPNP from Mycobacterium tuberculosis
5YK2	;	2.807	;	The complex structure of Rv3197-erythromycin from Mycobacterium tuberculosis
4KT8	;	2.4	;	The complex structure of Rv3378c-Y51FY90F with substrate, TPP
8I4S	;	2.2	;	the complex structure of SARS-CoV-2 Mpro with D8
5WSY	;	2.0	;	The complex structure of SAV606 with N-carboxymethyl-3-aminobutyrate
7V3E	;	2.12	;	The complex structure of soBcmB and its intermediate product 1a
7V36	;	1.96009	;	The complex structure of soBcmB and its intermediate product 2a
7V2T	;	2.20006	;	The complex structure of SoBcmB and its natural precursor 2
7V34	;	2.00017	;	The complex structure of soBcmB and its product 1d
7V2U	;	2.0001	;	The complex structure of SoBcmB and its product 2f
7V2X	;	2.08387	;	The complex structure of soBcmB and its substrate 1
7V3N	;	1.85001	;	The complex structure of soBcmB-D307A and its natural precursor 2
5G1D	;	2.81	;	The complex structure of syntenin-1 PDZ domain with c-terminal extension
5G1E	;	1.92	;	The complex structure of syntenin-1 PDZ domain with c-terminal extension
5YAO	;	2.611	;	The complex structure of SZ529 and expoxid
3WCB	;	3.0	;	The complex structure of TcSQS with ligand, BPH1237
3WCG	;	2.8	;	The complex structure of TcSQS with ligand, BPH1344
3WCC	;	2.32	;	The complex structure of TcSQS with ligand, E5700
3WCE	;	2.75	;	The complex structure of TcSQS with ligand, ER119884
3WCA	;	2.24	;	The complex structure of TcSQS with ligand, FSPP
4AUB	;	2.05	;	the complex Structure of the bacterial aldo-keto reductase AKR14A1 with NADP and citrate
2VBG	;	1.8	;	The complex structure of the branched-chain keto acid decarboxylase (KdcA) from Lactococcus lactis with 2R-1-hydroxyethyl-deazaThDP
4ERK	;	2.2	;	THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/OLOMOUCINE
3ERK	;	2.1	;	THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/SB220025
3HA8	;	2.48	;	THE COMPLEX STRUCTURE OF THE MAP KINASE P38/Compound 14b
1A9U	;	2.5	;	THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB203580
1BL6	;	2.5	;	THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB216995
1BMK	;	2.4	;	THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB218655
1BL7	;	2.5	;	THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB220025
4E2I	;	5.0	;	The Complex Structure of the SV40 Helicase Large T Antigen and p68 Subunit of DNA Polymerase Alpha-Primase
4XHU	;	2.089	;	The complex structure of Timeless_PAB and PARP-1_catalytic domain
5CZD	;	2.34	;	The complex structure of VinK with VinL
7XQ7	;	2.35	;	The complex structure of WT-Mpro
3VST	;	1.75	;	The complex structure of XylC with Tris
3VSU	;	2.05	;	The complex structure of XylC with xylobiose
3VSV	;	1.48	;	The complex structure of XylC with xylose
8ILB	;	3.0	;	The complexes of RbcL, AtRaf1 and AtBSD2 (LFB)
5FU2	;	1.4	;	The complexity of the Ruminococcus flavefaciens cellulosome reflects an expansion in glycan recognition
5FU3	;	1.61	;	The complexity of the Ruminococcus flavefaciens cellulosome reflects an expansion in glycan recognition
5FU4	;	2.0	;	The complexity of the Ruminococcus flavefaciens cellulosome reflects an expansion in glycan recognition
5FU5	;	1.5	;	The complexity of the Ruminococcus flavefaciens cellulosome reflects an expansion in glycan recognition
7LEP	;	3.25	;	The composite LBD-TMD structure combined from all hippocampal AMPAR subtypes at 3.25 Angstrom resolution
8F7G	;	2.4	;	The condensation domain of surfactin A synthetase C in space group P212121
8F7F	;	1.62	;	The condensation domain of surfactin A synthetase C in space group P43212
8F7H	;	1.93	;	The condensation domain of surfactin A synthetase C variant 18b in space group P212121
8F7I	;	1.58	;	The condensation domain of surfactin A synthetase C variant 18b in space group P43212
4JGW	;	2.3	;	The conformation of a docking site for SH3 domains is pre-selected in the Guanine Nucleotide Exchange Factor Rlf
2D94	;	1.7	;	THE CONFORMATION OF THE DNA DOUBLE HELIX IN THE CRYSTAL IS DEPENDENT ON ITS ENVIRONMENT
1JNV	;	4.4	;	The Conformation of the Epsilon and Gamma Subunits within the E. coli F1 ATPase
1D81	;	2.5	;	THE CONFORMATIONAL VARIABILITY OF AN ADENOSINE. INOSINE BASE-PAIR IN A SYNTHETIC DNA DODECAMER
4GQH	;	3.06	;	The Conformations and Interactions of the Four-Layer Aggregate Revealed by X-ray Crystallography Diffraction Implied the Importance of Peptides at Opposite Ends in Their Assemblies
2X7P	;	2.34	;	The Conserved Candida albicans CA3427 Gene Product Defines a New Family of Proteins Exhibiting the Generic Periplasmic Binding Protein Structural Fold
2X7Q	;	2.0	;	The conserved Candida albicans CA3427 gene product defines a new family of proteins exhibiting the generic periplasmic binding protein structural fold
4DM4	;	2.19	;	The conserved domain of yeast Cdc73
2NS5	;		;	The conserved N-terminal domain of Par-3 adopts a novel PB1-like structure required for Par-3 oligomerization and apical membrane localization
4PYU	;	2.0	;	The conserved ubiquitin-like protein hub1 plays a critical role in splicing in human cells
1BAN	;	2.2	;	THE CONTRIBUTION OF BURIED HYDROGEN BONDS TO PROTEIN STABILITY: THE CRYSTAL STRUCTURES OF TWO BARNASE MUTANTS
1BAO	;	2.2	;	THE CONTRIBUTION OF BURIED HYDROGEN BONDS TO PROTEIN STABILITY: THE CRYSTAL STRUCTURES OF TWO BARNASE MUTANTS
1COO	;		;	THE COOH-TERMINAL DOMAIN OF RNA POLYMERASE ALPHA SUBUNIT
6M5V	;	4.5	;	The coordinate of the hexameric terminase complex in the presence of the ADP-BeF3
6M5T	;	3.6	;	The coordinate of the nuclease domain of the apo terminase complex
6M5S	;	3.9	;	The coordinates of the apo hexameric terminase complex
6M5R	;	3.5	;	The coordinates of the apo monomeric terminase complex
6M5U	;	3.8	;	The coordinates of the monomeric terminase complex in the presence of the ADP-BeF3
5UVR	;	1.7	;	The core region of PilO from the type IV pilus system of Pseudomonas aeruginosa
7PGP	;	3.1	;	The core structure of human neurofibromin isoform 2
8AGY	;	1.5	;	The Corramycin phosphotransferase in complex with Corramycin
3IEO	;	2.0	;	The coumarin-binding site in carbonic anhydrase: the antiepileptic lacosamide as an example
2CNA	;	2.0	;	THE COVALENT AND THREE-DIMENSIONAL STRUCTURE OF CONCANAVALIN A, IV.ATOMIC COORDINATES,HYDROGEN BONDING,AND QUATERNARY STRUCTURE
6BBF	;	6.706	;	The CRAC channel Orai in an open conformation; H206A gain-of-function mutation
6BBG	;	6.9	;	The CRAC channel Orai in an unlatched-closed conformation
6BBH	;	6.1	;	The CRAC channel Orai in an unlatched-closed conformation; K163W loss-of-function mutation
6BBI	;	4.35	;	The CRAC channel Orai in an unlatched-closed conformation; K163W loss-of-function mutation; P42212 crystal form
3S4L	;	2.3	;	The CRISPR-associated Cas3 HD domain protein MJ0384 from Methanocaldococcus jannaschii
7FGR	;	2.2	;	The cross-reaction complex structure with VQIFNK peptide and the tau antibody's Fab domain.
7VTJ	;	2.0	;	The cross-reaction complex structure with VQIIYK peptide and tau antibody's Fab domain.
7FGJ	;	1.89	;	The cross-reaction complex structure with VQILNK peptide and the tau antibody's Fab domain.
6IRO	;	3.4	;	the crosslinked complex of ISWI-nucleosome in the ADP-bound state
6JYL	;	3.37	;	The crosslinked complex of ISWI-nucleosome in the ADP.BeF-bound state
4CY4	;	21.6	;	The Cryo-Electron Microscopy Structure of the CorA channel from Methanocaldococcus jannaschii at 21.6 Angstrom in low magnesium.
5OH0	;	4.2	;	The Cryo-Electron Microscopy Structure of the Type 1 Chaperone-Usher Pilus Rod
7RSI	;	4.9	;	The cryo-EM map of KIF18A bound to KIFBP
4V5X	;	11.5	;	The cryo-EM structure of a 3D DNA-origami object
6B6H	;	3.9	;	The cryo-EM structure of a bacterial class I transcription activation complex
6C26	;	3.5	;	The Cryo-EM structure of a eukaryotic oligosaccharyl transferase complex
8JO0	;	3.6	;	The Cryo-EM structure of a heptameric CED-4/CED-3 catalytic complex
7EU0	;	3.16	;	The cryo-EM structure of A. thaliana Pol IV-RDR2 backtracked complex
7EU1	;	3.86	;	The cryo-EM structure of A. thaliana Pol IV-RDR2 holoenzyme
7XYB	;	3.7	;	The cryo-EM structure of an AlpA-loaded complex
7XYA	;	3.3	;	The cryo-EM structure of an AlpA-loading complex
7CKQ	;	4.4	;	The cryo-EM structure of B. subtilis BmrR transcription activation complex
6QVK	;	3.6	;	The cryo-EM structure of bacteriophage phi29 prohead
7YE2	;	3.8	;	The cryo-EM structure of C. crescentus GcrA-TACdown
7YE1	;	3.7	;	The cryo-EM structure of C. crescentus GcrA-TACup
8HO7	;	2.59	;	The cryo-EM structure of cellobiose phosphorylase from Clostridium thermocellum
8HOB	;	2.19	;	The cryo-EM structure of cellobiose phosphorylase from Clostridium thermocellum ( variant)
8HO9	;	2.25	;	The cryo-EM structure of cellobiose phosphorylase from Clostridium thermocellum (cysteine-to-serine varient)
8HO8	;	2.24	;	The cryo-EM structure of cellobiose phosphorylase from Clostridium thermocellum in complex with cellobiose
8IYR	;	2.6	;	The cryo-EM structure of cellobiose phosphorylase from Clostridium thermocellum in complex with phosphate
7BXT	;	4.2	;	The cryo-EM structure of CENP-A nucleosome in complex with CENP-C peptide and CENP-N N-terminal domain
7BY0	;	4.5	;	The cryo-EM structure of CENP-A nucleosome in complex with the phosphorylated CENP-C
6QX7	;	3.8	;	The cryo-EM structure of connector in bacteriophage phi29 prohead
6LHB	;	3.33	;	The cryo-EM structure of coxsackievirus A16 A-particle
6LHL	;	3.07	;	The cryo-EM structure of coxsackievirus A16 A-particle in complex with Fab 18A7
6LHC	;	3.43	;	The cryo-EM structure of coxsackievirus A16 empty particle
6LHO	;	3.13	;	The cryo-EM structure of coxsackievirus A16 empty particle in complex with Fab 18A7
6LHA	;	3.56	;	The cryo-EM structure of coxsackievirus A16 mature virion
6LHP	;	3.3	;	The cryo-EM structure of coxsackievirus A16 mature virion in complex with Fab 14B10
6LHK	;	2.65	;	The cryo-EM structure of coxsackievirus A16 mature virion in complex with Fab 18A7
6LHQ	;	3.06	;	The cryo-EM structure of coxsackievirus A16 mature virion in complex with Fab NA9D7
8DD7	;	3.3	;	The Cryo-EM structure of Drosophila Cryptochrome in complex with Timeless
6LDI	;	3.69	;	The cryo-EM structure of E. coli CueR transcription activation complex
7C17	;	4.22	;	The cryo-EM structure of E. coli CueR transcription activation complex with fully duplex promoter DNA
8ILM	;	3.3	;	The cryo-EM structure of eight Rubisco large subunits (RbcL), two Arabidopsis thaliana Rubisco accumulation factors 1 (AtRaf1), and seven Arabidopsis thaliana Bundle Sheath Defective 2 (AtBSD2)
7XJX	;	2.7	;	The cryo-EM structure of Fe3+ induced alpha-syn fibril.
6A7F	;	3.4	;	The cryo-EM structure of filamentous bacteriophage IKe major coat protein p8 shell assembly.
8GV3	;	3.05	;	The cryo-EM structure of GSNOR with NYY001
8GVC	;	2.89	;	The cryo-EM structure of hAE2 with bicarbonate
8GV9	;	3.06	;	The cryo-EM structure of hAE2 with chloride ion
8GV8	;	3.08	;	The cryo-EM structure of hAE2 with DIDS
6JHQ	;	3.9	;	The cryo-EM structure of HAV bound to a neutralizing antibody-F4
6JHR	;	3.68	;	The cryo-EM structure of HAV bound to a neutralizing antibody-F6
6JHS	;	3.05	;	The cryo-EM structure of HAV bound to a neutralizing antibody-F7
6JHT	;	3.79	;	The cryo-EM structure of HAV bound to a neutralizing antibody-F9
6LAT	;	3.4	;	The cryo-EM structure of HEV VLP
6LB0	;	3.6	;	The cryo-EM structure of HEV VLP in complex with Fab 8C11
6FXC	;	6.76	;	The cryo-EM structure of hibernating 100S ribosome dimer from pathogenic Staphylococcus aureus
7W5B	;	4.3	;	The cryo-EM structure of human C* complex
5YZG	;	4.1	;	The Cryo-EM Structure of Human Catalytic Step I Spliceosome (C complex) at 4.1 angstrom resolution
7Y4W	;	3.67	;	The cryo-EM structure of human ERAD retro-translocation complex
7Y53	;	3.61	;	The cryo-EM structure of human ERAD retro-translocation complex
7Y59	;	4.51	;	The cryo-EM structure of human ERAD retro-translocation complex
7XUR	;	3.49	;	The cryo-EM structure of human mini-SNAPc in complex with hU6-1 PSE
6M66	;	4.1	;	The Cryo-EM Structure of Human Pannexin 1
6M68	;	4.6	;	The Cryo-EM Structure of Human Pannexin 1 in the Presence of CBX
6M67	;	3.6	;	The Cryo-EM Structure of Human Pannexin 1 with D376E/D379E Mutation
7DN5	;	4.11	;	The cryo-EM structure of human papillomavirus type 58 pseudovirus
8HK1	;	2.7	;	The cryo-EM structure of human pre-17S U2 snRNP
7W59	;	3.6	;	The cryo-EM structure of human pre-C*-I complex
7W5A	;	3.6	;	The cryo-EM structure of human pre-C*-II complex
6AHD	;	3.8	;	The Cryo-EM Structure of Human Pre-catalytic Spliceosome (B complex) at 3.8 angstrom resolution
8W9Y	;	3.5	;	The cryo-EM structure of human sphingomyelin synthase-related protein
8IJQ	;	3.45	;	The cryo-EM structure of human sphingomyelin synthase-related protein in complex with ceramide
8W9W	;	3.74	;	The cryo-EM structure of human sphingomyelin synthase-related protein in complex with ceramide/phosphoethanolamine
8IJR	;	3.29	;	The cryo-EM structure of human sphingomyelin synthase-related protein in complex with diacylglycerol/phosphoethanolamine
5OF4	;	4.4	;	The cryo-EM structure of human TFIIH
7YIX	;	2.96	;	The Cryo-EM Structure of Human Tissue Nonspecific Alkaline Phosphatase and Single-Chain Fragment Variable (ScFv) Complex.
8JM9	;	2.6	;	The cryo-EM structure of insect gustatory receptor Gr43a from Drosophila melanogaster
8JMA	;	2.5	;	The cryo-EM structure of insect gustatory receptor Gr43a from Drosophila melanogaster in complex with fructose
8X82	;	2.8	;	The cryo-EM structure of insect gustatory receptor Gr43a I418A from Drosophila melanogaster
8X83	;	2.8	;	The cryo-EM structure of insect gustatory receptor Gr43a I418A from Drosophila melanogaster in complex with fructose
8X84	;	3.1	;	The cryo-EM structure of insect gustatory receptor Gr43a I418A from Drosophila melanogaster in complex with fructose and calcium
8JME	;	2.5	;	The cryo-EM structure of insect gustatory receptor Gr64a from Drosophila melanogaster
8JMI	;	2.6	;	The cryo-EM structure of insect gustatory receptor Gr64a from Drosophila melanogaster in complex with maltose
8JMH	;	2.5	;	The cryo-EM structure of insect gustatory receptor Gr64a from Drosophila melanogaster in complex with sucrose
8H5B	;	4.03	;	The cryo-EM structure of nuclear transport receptor Kap114p complex with yeast TATA-box binding protein
6JC3	;	4.8	;	The Cryo-EM structure of nucleoprotein-RNA complex of Newcastle disease virus
8I6U	;	7.9	;	The cryo-EM structure of OsCyc1 dimer state
8I6T	;	3.7	;	The cryo-EM structure of OsCyc1 hexamer state
8I6P	;	3.5	;	The cryo-EM structure of OsCyc1 tetramer state
8IH5	;	4.0	;	The cryo-EM structure of OsCyc1 that complexed with GGPP
8JB5	;	2.9	;	The cryo-EM structure of Paeniclostridium sordellii lethal toxin (TcsL)
6QYZ	;	4.6	;	The cryo-EM structure of prohead RNA in bacteriophage phi29 prohead
6SV4	;	3.3	;	The cryo-EM structure of SDD1-stalled collided trisome.
7WLM	;	2.8	;	The Cryo-EM structure of siphonaxanthin chlorophyll a/b type light-harvesting complex II
4ADX	;	6.6	;	The Cryo-EM Structure of the Archaeal 50S Ribosomal Subunit in Complex with Initiation Factor 6
7JZ6	;	2.53	;	The Cryo-EM structure of the Catalase-peroxidase from Escherichia coli
6QZ9	;	3.3	;	The cryo-EM structure of the collar complex and tail axis in bacteriophage phi29
6QZF	;	3.8	;	The cryo-EM structure of the collar complex and tail axis in genome emptied bacteriophage phi29
6QYM	;	3.6	;	The cryo-EM structure of the connector of the genome empited bacteriophage phi29
6QYJ	;	3.4	;	The cryo-EM structure of the connector of the mature bacteriophage phi29
7FIK	;	3.7	;	The cryo-EM structure of the CR subunit from X. laevis NPC
7EVN	;	2.6	;	The cryo-EM structure of the DDX42-SF3b complex
8XBU	;	4.24	;	The cryo-EM structure of the decameric RAD51 ring bound to the nucleosome with the linker DNA binding
8JNE	;	4.68	;	The cryo-EM structure of the decameric RAD51 ring bound to the nucleosome without the linker DNA binding
7CZB	;	3.8	;	The cryo-EM structure of the ERAD retrotranslocation channel formed by human Derlin-1
7JZH	;	3.59	;	The Cryo-EM structure of the Glutamate decarboxylase from Escherichia coli
6QZ0	;	3.2	;	The cryo-EM structure of the head of the genome empited bacteriophage phi29
7EVO	;	2.5	;	The cryo-EM structure of the human 17S U2 snRNP
6PA7	;	2.94	;	The cryo-EM structure of the human DNMT3A2-DNMT3B3 complex bound to nucleosome.
7VPX	;	3.0	;	The cryo-EM structure of the human pre-A complex
8X5D	;	3.1	;	The cryo-EM structure of the Mycobacterium tuberculosis CRISPR-Csm complex
8W9Z	;	3.0	;	The cryo-EM structure of the Nicotiana tabacum PEP-PAP
8WA0	;	2.7	;	The cryo-EM structure of the Nicotiana tabacum PEP-PAP-TEC1
8WA1	;	2.8	;	The cryo-EM structure of the Nicotiana tabacum PEP-PAP-TEC2
8JND	;	3.66	;	The cryo-EM structure of the nonameric RAD51 ring bound to the nucleosome with the linker DNA binding
7FIL	;	3.0	;	The cryo-EM structure of the NTD2 from the X. laevis Nup358
8XBT	;	4.12	;	The cryo-EM structure of the octameric RAD51 ring bound to the nucleosome with the linker DNA binding
4UMM	;	11.6	;	The Cryo-EM structure of the palindromic DNA-bound USP-EcR nuclear receptor reveals an asymmetric organization with allosteric domain positioning
6AH0	;	5.7	;	The Cryo-EM Structure of the Precusor of Human Pre-catalytic Spliceosome (pre-B complex)
8JNF	;	6.91	;	The cryo-EM structure of the RAD51 filament bound to the nucleosome
8XBY	;	7.8	;	The cryo-EM structure of the RAD51 L1 and L2 loops bound to the linker DNA with the blunt end of the nucleosome
8XBV	;	7.61	;	The cryo-EM structure of the RAD51 L1 and L2 loops bound to the linker DNA with the sticky end of the nucleosome
8XBX	;	4.36	;	The cryo-EM structure of the RAD51 L2 loop bound to the linker DNA with the blunt end of the nucleosome
8XBW	;	2.89	;	The cryo-EM structure of the RAD51 N-terminal lobe domain bound to the histone H4 tail of the nucleosome
6Q0X	;	4.2	;	The cryo-EM structure of the SNX-BAR Mvp1 tetramer
8J5Z	;	4.75	;	The cryo-EM structure of the TwOSC1 tetramer
6WTI	;	2.38	;	The Cryo-EM structure of the ubiquinol oxidase from Escherichia coli
7AKV	;	3.6	;	The cryo-EM structure of the Vag8-C1 inhibitor complex
5O6V	;	3.9	;	The cryo-EM structure of Tick-borne encephalitis virus complexed with Fab fragment of neutralizing antibody 19/1786
5O6A	;	3.9	;	The cryo-EM structure of Tick-borne encephalitis virus mature particle
7BJP	;	3.65	;	The cryo-EM structure of vesivirus 2117, an adventitious agent and possible cause of haemorrhagic gastroenteritis in dogs.
5UZ4	;	5.8	;	The cryo-EM structure of YjeQ bound to the 30S subunit suggests a fidelity checkpoint function for this protein in ribosome assembly
5IRE	;	3.8	;	The cryo-EM structure of Zika Virus
3JAU	;	4.8	;	The cryoEM map of EV71 mature viron in complex with the Fab fragment of antibody D5
4UIS	;	4.4	;	The cryoEM structure of human gamma-Secretase complex
7N88	;	3.7	;	The cryoEM structure of LbpB from N. gonorrhoeae in complex with lactoferrin
7UOJ	;	4.02	;	The CryoEM structure of N49-P9.6-FR3 and PGT121 Fabs in complex with BG505 SOSIP.664
7UUS	;	8.0	;	The CryoEM structure of the [NiFe]-hydrogenase Huc from Mycobacterium smegmatis - Full complex focused refinement of stalk
5NW3	;	0.59	;	The cryofrozen atomic resolution X-ray crystal structure of perdeuterated Pyrococcus furiosus Rubredoxin (100K, 0.59A resolution)
5OME	;	0.747	;	The cryofrozen atomic resolution X-ray crystal structure of the reduced form (Fe2+) perdeuterated Pyrococcus furiosus Rubredoxin in D2O (100K, 0.75 Angstrom resolution)
1UB7	;	2.3	;	The Crystal Analysis of Beta-Keroacyl-[Acyl Carrier Protein] Synthase III (FABH)From Thermus Thermophilus.
211D	;	1.6	;	THE CRYSTAL AND MOLECULAR STRUCTURE OF A NEW Z-DNA CRYSTAL FORM: D[CGT(2-NH2-A) CG] AND ITS PLATINATED DERIVATIVE
2OVO	;	1.5	;	THE CRYSTAL AND MOLECULAR STRUCTURE OF THE THIRD DOMAIN OF SILVER PHEASANT OVOMUCOID (OMSVP3)
5ZNG	;	2.189	;	The crystal complex of immune receptor RGA5A_S of Pia from rice (Oryzae sativa) with rice blast (Magnaporthe oryzae) effector protein AVR1-CO39
6LGQ	;	3.0	;	The crystal complex structure of histidine kinase and response regulator
2UZ0	;	1.7	;	The Crystal crystal structure of the estA protein, a virulence factor estA protein from Streptococcus pneumonia
6JOH	;	2.4	;	The crystal of nucleoside diphosphate kinase from Aspergillus flavus
5HBP	;	1.5	;	The crystal of rhodanese domain of YgaP treated with SNOC
5HPA	;	1.66	;	The crystal of rhodanese domain of YgaP treated with sodium thiosulfate
7BPI	;	2.40009	;	The crystal structue of PDE10A complexed with 14
6KO0	;	2.60003	;	The crystal structue of PDE10A complexed with 1i
6KO1	;	2.7	;	The crystal structue of PDE10A complexed with 2d
6KZE	;	2.50003	;	The crystal structue of PDE10A complexed with 4d
4UW9	;	2.3	;	The crystal structural of archaeal beta-phosphoglucomutase from hyper-thermophilic Pyrococcus sp. Strain ST 04
1KP0	;	2.7	;	The Crystal Structure Analysis of Creatine Amidinohydrolase from Actinobacillus
7YTO	;	2.31	;	The Crystal Structure Analysis of Creatine Amidinohydrolase from Alcaligenes sp. KS-85
233D	;	2.4	;	THE CRYSTAL STRUCTURE ANALYSIS OF D(CGCGAASSCGCG)2: A SYNTHETIC DNA DODECAMER DUPLEX CONTAINING FOUR 4'-THIO-2'-DEOXYTHYMIDINE NUCLEOTIDES
1EW6	;	1.78	;	THE CRYSTAL STRUCTURE AND AMINO ACID SEQUENCE OF DEHALOPEROXIDASE FROM AMPHITRITE ORNATA INDICATE COMMON ANCESTRY WITH GLOBINS
1LKI	;	2.0	;	THE CRYSTAL STRUCTURE AND BIOLOGICAL FUNCTION OF LEUKEMIA INHIBITORY FACTOR: IMPLICATIONS FOR RECEPTOR BINDING
1L1Y	;	2.4	;	The Crystal Structure and Catalytic Mechanism of Cellobiohydrolase CelS, the Major Enzymatic Component of the Clostridium thermocellum cellulosome
1L2A	;	2.5	;	The Crystal Structure and Catalytic Mechanism of Cellobiohydrolase CelS, the Major Enzymatic Component of the Clostridium thermocellum cellulosome
1SIQ	;	2.1	;	The Crystal Structure and Mechanism of Human Glutaryl-CoA Dehydrogenase
1SIR	;	2.6	;	The Crystal Structure and Mechanism of Human Glutaryl-CoA Dehydrogenase
1KOH	;	3.8	;	THE CRYSTAL STRUCTURE AND MUTATIONAL ANALYSIS OF A NOVEL RNA-BINDING DOMAIN FOUND IN THE HUMAN TAP NUCLEAR MRNA EXPORT FACTOR
1KOO	;	3.8	;	THE CRYSTAL STRUCTURE AND MUTATIONAL ANALYSIS OF A NOVEL RNA-BINDING DOMAIN FOUND IN THE HUMAN TAP NUCLEAR MRNA EXPORT FACTOR
1AM5	;	2.16	;	THE CRYSTAL STRUCTURE AND PROPOSED AMINO ACID SEQUENCE OF A PEPSIN FROM ATLANTIC COD (GADUS MORHUA)
1PS9	;	2.2	;	The Crystal Structure and Reaction Mechanism of E. coli 2,4-Dienoyl CoA Reductase
2W6K	;	1.7	;	The crystal structure at 1.7 A resolution of CobE, a protein from the cobalamin (vitamin B12) biosynthetic pathway
2W6L	;	1.89	;	The crystal structure at 1.7 A resolution of CobE, a protein from the cobalamin (vitamin B12) biosynthetic pathway
1QI7	;	2.0	;	THE CRYSTAL STRUCTURE AT 2.0 A OF SAPORIN SO6, A RIBOSOME INACTIVATING PROTEIN FROM SAPONARIA OFFICINALIS
6WJM	;	1.0	;	The crystal structure beta-lactamase from Desulfarculus baarsii DSM 2075
3DHT	;	2.98	;	The Crystal Structure Determination of Rat (rattus norvegicus) Hemoglobin
3OEO	;	2.7	;	The crystal structure E. coli Spy
1IC1	;	3.0	;	THE CRYSTAL STRUCTURE FOR THE N-TERMINAL TWO DOMAINS OF ICAM-1
7RSK	;	2.4	;	The crystal structure from microfluidic crystals of glycosyl hydrolase family 2 (GH2) member from Bacteroides cellulosilyticus
5JVH	;	3.58	;	The crystal structure large ribosomal subunit (50S) of Deinococcus radiodurans in complex with evernimicin
8EQ8	;	1.5	;	The crystal structure of 14-3-3 Beta containing 3-nitrotyrosine at position Y130
8EQH	;	1.9	;	The crystal structure of 14-3-3 Beta containing 3-nitrotyrosine at position Y213
6EIH	;	2.7	;	The crystal structure of 14-3-3 epsilon in complex with the phosphorylated NELFE peptide
1YZ5	;	2.8	;	The crystal structure of 14-3-3-sigma at 2.8 angstrom resolution
7UI2	;	1.19	;	The crystal structure of 15kDa Phlebotomus papatasi salivary protein Ppsp15.
3FJN	;	2.3	;	The crystal structure of 17-alpha hydroxysteroid dehydrogenase Y224D mutant.
1Q74	;	1.7	;	The Crystal Structure of 1D-myo-inositol 2-acetamido-2-deoxy-alpha-D-glucopyranoside Deacetylase (MshB)
7X7Z	;	2.903	;	The crystal structure of 2+2/4+2 cyclase PloI4
3GOS	;	1.8	;	The crystal structure of 2,3,4,5-tetrahydropyridine-2-carboxylate N-succinyltransferase from Yersinia pestis CO92
2B15	;	1.7	;	The crystal structure of 2,4-dinitrophenol in complex with human transthyretin
2B14	;	2.0	;	The crystal structure of 2,4-dinitrophenol in complex with the amyloidogenic variant Transthyretin Leu 55 Pro
2B16	;	1.75	;	The crystal structure of 2,4-dinitrophenol in complex with the amyloidogenic variant Transthyretin Tyr78Phe
6ZR8	;	1.79	;	The crystal structure of 2-(4-Benzhydrylpiperazin-1-yl)-N-(4-sulfamoylphenyl)acetamide in complex with human carbonic anhydrase II
6JFV	;	2.6	;	The crystal structure of 2B-2B complex from keratins 5 and 14 (C367A mutant of K14)
7TYE	;	1.94	;	The crystal structure of 3,4-dihydroxy-2-butanone 4-phosphate synthase mutant (G108S) from E. Coli
1FJH	;	1.68	;	THE CRYSTAL STRUCTURE OF 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE FROM COMAMONAS TESTOSTERONI, A MEMBER OF THE SHORT CHAIN DEHYDROGENASE/REDUCTASE FAMILY
6PRS	;	2.373	;	The crystal structure of 3-ethoxybenzoate-bound CYP199A4
1ZVF	;	2.41	;	The crystal structure of 3-hydroxyanthranilate 3,4-dioxygenase from Saccharomyces cerevisiae
6B7J	;	1.44	;	The crystal structure of 3-hydroxydecanoyl-(acyl carrier protein) dehydratase from Vibrio cholerae O1 biovar eltor str. N16961
1V53	;	2.85	;	The crystal structure of 3-isopropylmalate dehydrogenase from Bacillus coagulans
5CEJ	;	2.5	;	The crystal structure of 3-ketoacyl-(acyl-carrier-protein) reductase (FabG) from Yersinia pestis at 2.50A resolution
5CDY	;	2.85	;	The crystal structure of 3-ketoacyl-(acyl-carrier-protein) reductase (FabG) from Yersinia pestis at 2.85A resolution
4AT0	;	1.6	;	The crystal structure of 3-ketosteroid-delta4-(5alpha)-dehydrogenase from Rhodococcus jostii RHA1
4AT2	;	1.6	;	The crystal structure of 3-ketosteroid-delta4-(5alpha)-dehydrogenase from Rhodococcus jostii RHA1 in complex with 4-androstene-3,17- dione
6PQ6	;	1.658	;	The crystal structure of 3-methoxybenzoate-bound CYP199A4
6PRR	;	1.67	;	The crystal structure of 3-methylaminobenzoate-bound CYP199A4
6PQW	;	1.679	;	The crystal structure of 3-methylbenzoate-bound CYP199A4
6PQD	;	1.89	;	The crystal structure of 3-methylthiobenzoate-bound CYP199A4
3U9L	;	2.1	;	The crystal structure of 3-oxoacyl-[acyl-carrier-protein] reductase (NADPH) from Sinorhizobium meliloti
4DRY	;	2.5	;	The crystal structure of 3-oxoacyl-[acyl-carrier-protein] reductase from Rhizobium meliloti
3U5T	;	2.4	;	The crystal structure of 3-oxoacyl-[acyl-carrier-protein] reductase from Sinorhizobium meliloti
6XOA	;	2.1	;	The crystal structure of 3CL MainPro of SARS-CoV-2 with C145S mutation
7JFQ	;	1.55	;	The crystal structure of 3CL MainPro of SARS-CoV-2 with de-oxidized C145
6XKF	;	1.8	;	The crystal structure of 3CL MainPro of SARS-CoV-2 with oxidized Cys145 (Sulfenic acid cysteine).
6U31	;	1.578	;	The crystal structure of 4-(1H-imidazol-1-yl)benzoate-bound CYP199A4
7JXB	;	1.655	;	The crystal structure of 4-(3'-methoxyphenyl)benzoic acid-bound CYP199A4
6U3K	;	1.8	;	The crystal structure of 4-(pyridin-2-yl)benzoate-bound CYP199A4
6C3J	;	1.66	;	The crystal structure of 4-(thiophen-3-yl)benzoate-bound CYP199A4
6BB9	;	2.282	;	The crystal structure of 4-amino-4-deoxychorismate lyase from Salmonella typhimurium LT2
6C2D	;	1.79	;	The crystal structure of 4-cyclohexylbenzoate-bound CYP199A4
5UVB	;	1.54	;	The crystal structure of 4-cyclopropylbenzoate-bound CYP199A4
4KT7	;	2.001	;	The crystal structure of 4-diphosphocytidyl-2C-methyl-D-erythritolsynthase from Anaerococcus prevotii DSM 20548
5U6T	;	1.935	;	The crystal structure of 4-ethoxybenzoate-bound CYP199A4
6OOW	;	1.6	;	The crystal structure of 4-ethylbenzoate bound to T252A mutant of CYP199A4
5U6U	;	1.786	;	The crystal structure of 4-ethylthiobenzoate-bound CYP199A4
2OOF	;	2.2	;	The crystal structure of 4-imidazolone-5-propanoate amidohydrolase from environmental sample
6VJX	;	1.788	;	The crystal structure of 4-isobutylbenzoic acid-bound CYP199A4
6OOX	;	1.774	;	The crystal structure of 4-isopropylbenzoate bound to T252A mutant of CYP199A4
5KDB	;	1.644	;	The crystal structure of 4-isopropylbenzoate-bound CYP199A4
7N60	;	1.892	;	The crystal structure of 4-methoxybenzoate-bound CYP199A S244D mutant
6UNN	;	1.655	;	The crystal structure of 4-methoxycinnamic acid-bound CYP199A4
5U6W	;	2.644	;	The crystal structure of 4-methylaminobenzoate-bound CYP199A4
6PQS	;	1.6	;	The crystal structure of 4-methylbenzoate-bound CYP199A4
5KT1	;	2.015	;	The crystal structure of 4-methylthiobenzoate-bound CYP199A4
8E5J	;	2.3	;	The crystal structure of 4-n-butylbenzoic acid bound CYP199A4
6C3H	;	1.705	;	The crystal structure of 4-n-heptylbenzoate-bound CYP199A4
6U30	;	1.655	;	The crystal structure of 4-pyridin-3-ylbenzoate-bound CYP199A4
6WZP	;	1.65	;	The crystal structure of 4-vinylbenzoate-bound T252A mutant CYP199A4
7KCS	;	1.773	;	The crystal structure of 4-vinylbenzoate-bound wild-type CYP199A4
3M02	;	2.5	;	The Crystal Structure of 5-epi-aristolochene synthase complexed with (2-cis,6-trans)-2-fluorofarnesyl diphosphate
3M01	;	2.6	;	The Crystal Structure of 5-epi-aristolochene synthase complexed with (2-trans,6-trans)-2-fluorofarnesyl diphosphate
3LZ9	;	2.28	;	The Crystal Structure of 5-epi-aristolochene synthase M4 mutant complexed with (2-trans,6-trans)-2-fluorofarnesyl diphosphate
2JCB	;	1.6	;	The crystal structure of 5-formyl-tetrahydrofolate cycloligase from Bacillus anthracis (BA4489)
5IZN	;	2.35	;	The crystal structure of 50S ribosomal protein L25 from Vibrio vulnificus CMCP6
4GPN	;	2.291	;	The crystal structure of 6-P-beta-D-Glucosidase (E375Q mutant) from Streptococcus mutans UA150 in complex with Gentiobiose 6-phosphate.
4IPL	;	2.004	;	The crystal structure of 6-phospho-beta-glucosidase BglA-2 from Streptococcus pneumoniae
3PN8	;	1.693	;	The crystal structure of 6-phospho-beta-glucosidase from Streptococcus mutans UA159
4F66	;	1.479	;	The crystal structure of 6-phospho-beta-glucosidase from Streptococcus mutans UA159 in complex with beta-D-glucose-6-phosphate.
4F79	;	2.54	;	The crystal structure of 6-phospho-beta-glucosidase mutant (E375Q) in complex with Salicin 6-phosphate
4E21	;	2.301	;	The crystal structure of 6-phosphogluconate dehydrogenase from Geobacter metallireducens
5USW	;	1.643	;	The crystal structure of 7,8-dihydropteroate synthase from Vibrio fischeri ES114
5LYS	;	2.32	;	The crystal structure of 7SK 5'-hairpin - Gold derivative
5LYV	;	2.35	;	The crystal structure of 7SK 5'-hairpin - Osmium derivative
3JYF	;	2.43	;	The crystal structure of a 2,3-cyclic nucleotide 2-phosphodiesterase/3-nucleotidase bifunctional periplasmic precursor protein from Klebsiella pneumoniae subsp. pneumoniae MGH 78578
2UVD	;	2.4	;	The crystal structure of a 3-oxoacyl-(acyl carrier protein) reductase from Bacillus anthracis (BA3989)
4YJ6	;	1.7	;	The Crystal Structure of a Bacterial Aryl Acylamidase Belonging to the Amidase signature (AS) enzymes family
4YJI	;	1.73	;	The Crystal Structure of a Bacterial Aryl Acylamidase Belonging to the Amidase signature (AS) enzymes family
3HIM	;	2.2	;	The Crystal Structure of a Bacterial Regulatory Protein in the tetR Family from Rhodococcus RHA1 to 2.2A
7K02	;	3.4	;	The crystal structure of a BAK dimer activated by detergent
6WGP	;	1.5	;	The crystal structure of a beta lactamase from Xanthomonas campestris pv. campestris str. ATCC 33913
6V4W	;	1.29	;	The crystal structure of a beta-lactamase from Chitinophaga pinensis DSM 2588
6X9Y	;	1.9	;	The crystal structure of a Beta-lactamase from Escherichia coli CFT073
6WHL	;	2.3	;	The crystal structure of a beta-lactamase from Legionella pneumophila str. Paris
6WGQ	;	1.8	;	The crystal structure of a beta-lactamase from Shigella flexneri 2a str. 2457T
6WGR	;	1.88	;	The crystal structure of a beta-lactamase from Staphylococcus aureus subsp. aureus USA300_TCH1516
2RET	;	2.21	;	The crystal structure of a binary complex of two pseudopilins: EpsI and EpsJ from the Type 2 Secretion System of Vibrio vulnificus
1SYX	;	2.345	;	The crystal structure of a binary U5 snRNP complex
1XHM	;	2.7	;	The Crystal Structure of a Biologically Active Peptide (SIGK) Bound to a G Protein Beta:Gamma Heterodimer
6B3M	;	3.92	;	The crystal structure of a broadly-reactive human anti-hemagglutinin stalk antibody (70-1F02) in complex with H5 hemagglutinin
1LSP	;	2.45	;	THE CRYSTAL STRUCTURE OF A BULGECIN-INHIBITED G-TYPE LYSOZYME FROM THE EGG-WHITE OF THE AUSTRALIAN BLACK SWAN. A COMPARISON OF THE BINDING OF BULGECIN TO THREE MURAMIDASES
3H6E	;	2.5	;	The crystal structure of a carbohydrate kinase from Novosphingobium aromaticivorans
3LFR	;	1.53	;	The Crystal Structure of a CBS Domain from a Putative Metal Ion Transporter Bound to AMP from Pseudomonas syringae to 1.55A
4NOC	;	2.3	;	The crystal structure of a CBS Domain-containing Protein of Unknown Function from Kribbella flavida DSM 17836.
3HF7	;	2.75	;	The Crystal Structure of a CBS-domain Pair with Bound AMP from Klebsiella pneumoniae to 2.75A
5SV7	;	3.209	;	The Crystal structure of a chaperone
3G6L	;	1.8	;	The crystal structure of a chitinase CrChi1 from the nematophagous fungus Clonostachys rosea
6V6N	;	1.85	;	The crystal structure of a class D beta-lactamase from Agrobacterium tumefaciens
4Q6T	;	1.4	;	The crystal structure of a class V chitininase from Pseudomonas fluorescens Pf-5
8CGE	;	2.5	;	The crystal structure of a cobalt-bound scFv reveals a Tetrameric polyHistidine motif (TetrHis)
5L8S	;	2.5	;	The crystal structure of a cold-adapted acylaminoacyl peptidase reveals a novel quaternary architecture based on the arm-exchange mechanism
6WFV	;	1.7	;	The crystal structure of a collagen galactosylhydroxylysyl glucosyltransferase from human
1LMC	;	2.0	;	THE CRYSTAL STRUCTURE OF A COMPLEX BETWEEN BULGECIN, A BACTERIAL METABOLITE, AND LYSOZYME FROM THE RAINBOW TROUT
6RNR	;	2.003	;	The crystal structure of a complex between the LlFpg protein, a THF-DNA and an inhibitor
6RO2	;	1.821	;	The crystal structure of a complex between the LlFpg protein, a THF-DNA and an inhibitor
6ROK	;	1.95	;	The crystal structure of a complex between the LlFpg protein, a THF-DNA and an inhibitor
6RP0	;	2.25	;	The crystal structure of a complex between the LlFpg protein, a THF-DNA and an inhibitor
6RP7	;	2.0	;	The crystal structure of a complex between the LlFpg protein, a THF-DNA and an inhibitor
1W2Y	;	1.65	;	The crystal structure of a complex of Campylobacter jejuni dUTPase with substrate analogue dUpNHp
2CIC	;	1.7	;	THE CRYSTAL STRUCTURE OF A COMPLEX OF CAMPYLOBACTER JEJUNI DUTPASE WITH SUBSTRATE ANALOGUE DUPNHPP
2CJE	;	2.34	;	THE CRYSTAL STRUCTURE OF A COMPLEX OF Leishmania major DUTPASE WITH SUBSTRATE ANALOGUE DUPNHP
1C28	;	2.1	;	THE CRYSTAL STRUCTURE OF A COMPLMENT-1Q FAMILY PROTEIN SUGGESTS AN EVOLUTIONARY LINK TO TUMOR NECROSIS FACTOR
3E0Y	;	3.1	;	The crystal structure of a conserved domain from a protein of Geobacter sulfurreducens PCA
4GXT	;	1.821	;	The crystal structure of a conserved functionally unknown protein from Anaerococcus prevotii DSM 20548
3LO3	;	2.383	;	The crystal structure of a conserved functionally unknown protein from Colwellia psychrerythraea 34H.
3MUQ	;	2.053	;	The crystal structure of a conserved functionally unknown protein from Vibrio parahaemolyticus RIMD 2210633
3ROB	;	1.48	;	The crystal structure of a conserved protein from Planctomyces limnophilus DSM 3776
2QZI	;	2.2	;	The crystal structure of a conserved protein of unknown function from Streptococcus thermophilus LMG 18311.
3ERM	;	2.45	;	The crystal structure of a conserved protein with unknown function from Pseudomonas syringae pv. tomato str. DC3000
4R55	;	1.8	;	The crystal structure of a Cren7 mutant protein GR and dsDNA complex
5B5I	;	1.599	;	The crystal structure of a crustacean hyperglycemic hormone precursor from the kuruma prawn
3ZJA	;	1.48	;	The crystal structure of a Cu(I) metallochaperone from Streptomyces lividans
3ZK0	;	1.7	;	The crystal structure of a Cu(I) metallochaperone from Streptomyces lividans in its apo form
4RD7	;	1.571	;	The crystal structure of a Cupin 2 conserved barrel domain protein from Salinispora arenicola CNS-205
1CBG	;	2.15	;	THE CRYSTAL STRUCTURE OF A CYANOGENIC BETA-GLUCOSIDASE FROM WHITE CLOVER (TRIFOLIUM REPENS L.), A FAMILY 1 GLYCOSYL-HYDROLASE
2C0Y	;	2.1	;	THE CRYSTAL STRUCTURE OF A CYS25ALA MUTANT OF HUMAN PROCATHEPSIN S
3KZV	;	2.0	;	The crystal structure of a cytoplasmic protein with unknown function from Saccharomyces cerevisiae
1NR8	;	1.66	;	The crystal structure of a D-Lysine-based chiral PNA-DNA duplex
5UXY	;	1.8	;	The crystal structure of a DegV family protein from Eubacterium eligens loaded with heptadecanoic acid to 1.80 Angstrom resolution (ALTERNATIVE REFINEMENT OF PDB 3FDJ with HEPTADECANOIC acid)
6KHU	;	2.098	;	The crystal structure of a DGC protein from Thermotoga maritima
1Z3Z	;	2.9	;	The crystal structure of a DGD mutant: Q52A
3S40	;	2.1	;	The crystal structure of a diacylglycerol kinases from Bacillus anthracis str. Sterne
3GRI	;	2.0	;	The Crystal Structure of a Dihydroorotase from Staphylococcus aureus
3L21	;	2.1	;	The crystal structure of a dimeric mutant of dihydrodipicolinate synthase (DAPA, RV2753C) from Mycobacterium Tuberculosis - DHDPS-A204R
2OJP	;	1.7	;	The crystal structure of a dimeric mutant of Dihydrodipicolinate synthase from E.coli- DHDPS-L197Y
7NRP	;	2.67	;	The crystal structure of a DNA:RNA hybrid duplex sequence CTTTTCTTTG
7OOS	;	2.6	;	The crystal structure of a DNA:RNA hybrid duplex sequence CTTTTCTTTG
7OOO	;	2.57	;	The crystal structure of a DNA:RNA hybrid duplex sequence CTTTTCTTTG containing an LNA-Amide-LNA modification
7OZZ	;	2.7	;	The crystal structure of a DNA:RNA hybrid duplex sequence CTTTTCTTTG with LNA-amide modification
3OCM	;	1.801	;	The crystal structure of a domain from a possible membrane protein of Bordetella parapertussis
3EO4	;	2.19	;	The crystal structure of a domain from Methanocaldococcus jannaschii DSM 2661
3NE8	;	1.239	;	The crystal structure of a domain from N-acetylmuramoyl-l-alanine amidase of Bartonella henselae str. Houston-1
3NZE	;	1.697	;	The crystal structure of a domain of a possible sugar-binding transcriptional regulator from Arthrobacter aurescens TC1.
3IS6	;	1.95	;	The Crystal Structure of a domain of a putative Permease protein from Porphyromonas gingivalis to 2A
3FC7	;	2.65	;	The crystal structure of a domain of HTR-like protein from Haloarcula marismortui ATCC 43049
3LAX	;	1.428	;	The crystal structure of a domain of phenylacetate-coenzyme A ligase from Bacteroides vulgatus ATCC 8482
3HCZ	;	1.88	;	The crystal structure of a domain of possible thiol-disulfide isomerase from Cytophaga hutchinsonii ATCC 33406.
2R5S	;	2.14	;	The crystal structure of a domain of protein VP0806 (unknown function) from Vibrio parahaemolyticus RIMD 2210633
7FFT	;	1.6	;	The crystal structure of a domain-swapped dimeric maltodextrin-binding protein MalE from Salmonella enterica
7FFW	;	1.6	;	The crystal structure of a domain-swapped dimeric maltodextrin-binding protein MalE from Salmonella enterica
3RZV	;	1.67	;	The Crystal Structure of a E280A Mutant of the Catalytic Domain of AMSH
3NYI	;	1.9	;	The crystal structure of a fat acid (stearic acid)-binding protein from Eubacterium ventriosum ATCC 27560.
1LIS	;	1.9	;	THE CRYSTAL STRUCTURE OF A FERTILIZATION PROTEIN
8BHH	;	1.69	;	The crystal structure of a feruloyl esterase C from Fusarium oxysporum in complex with p-coumaric acid
6FAT	;	2.3	;	The crystal structure of a feruloyl esterase C from Fusarium oxysporum.
3NKZ	;	2.112	;	The crystal structure of a flagella protein from Yersinia enterocolitica subsp. enterocolitica 8081
3V76	;	2.51	;	The crystal structure of a flavoprotein from Sinorhizobium meliloti
4M0C	;	2.073	;	The crystal structure of a FMN-dependent NADH-azoreductase from Bacillus anthracis str. Ames Ancestor in complex with FMN.
3MPC	;	1.6	;	The crystal structure of a Fn3-like protein from Clostridium thermocellum
6FKQ	;	3.07	;	THE CRYSTAL STRUCTURE OF A FRAGMENT OF NETRIN-1 IN COMPLEX WITH A FRAGMENT OF DRAXIN
4URT	;	3.1	;	The crystal structure of a fragment of netrin-1 in complex with FN5- FN6 of DCC
6X1L	;	2.0	;	The crystal structure of a functional uncharacterized protein KP1_0663 from Klebsiella pneumoniae subsp. pneumoniae NTUH-K2044
5ES2	;	2.6	;	The crystal structure of a functionally uncharacterized protein LPG0634 from Legionella pneumophila subsp. pneumophila str. Philadelphia 1
4R0J	;	1.715	;	The crystal structure of a functionally uncharacterized protein SMU1763c from Streptococcus mutans
4FCA	;	2.055	;	The crystal structure of a functionally unknown conserved protein from Bacillus anthracis str. Ames.
3L1W	;	1.6	;	The crystal structure of a functionally unknown conserved protein from Enterococcus faecalis V583
3LAE	;	1.453	;	The crystal structure of a functionally unknown conserved protein from Haemophilus influenzae Rd KW20
3FRM	;	2.32	;	The crystal structure of a functionally unknown conserved protein from Staphylococcus epidermidis ATCC 12228.
5EV7	;	2.351	;	The crystal structure of a functionally unknown conserved protein mutant from Bacillus anthracis str. Ames
3U4Y	;	2.994	;	The crystal structure of a functionally unknown protein (Dtox_1751) from Desulfotomaculum acetoxidans DSM 771.
3M33	;	2.195	;	The crystal structure of a functionally unknown protein from Deinococcus radiodurans R1
3O2I	;	2.197	;	The crystal structure of a functionally unknown protein from Leptospirillum sp. Group II UBA
4EAE	;	1.32	;	The crystal structure of a functionally unknown protein from Listeria monocytogenes EGD-e
3O12	;	1.5	;	The crystal structure of a functionally unknown protein from Saccharomyces cerevisiae.
4G6Q	;	2.08	;	The crystal structure of a functionally unknown protein Kfla_6221 from Kribbella flavida DSM 17836
3T8K	;	1.769	;	The crystal structure of a functionally unknown protein Lebu_0176 from Leptotrichia buccalis C-1013-b
4M0M	;	2.192	;	The crystal structure of a functionally unknown protein lpg2422 from Legionella pneumophila subsp. pneumophila str. Philadelphia 1
3MT0	;	1.582	;	The crystal structure of a functionally unknown protein PA1789 from Pseudomonas aeruginosa PAO1
3M05	;	3.145	;	The crystal structure of a functionally unknown protein PEPE_1480 from Pediococcus pentosaceus ATCC 25745
3LAG	;	1.15	;	The crystal structure of a functionally unknown protein RPA4178 from Rhodopseudomonas palustris CGA009
4RD8	;	1.72	;	The crystal structure of a functionally-unknown protein from Legionella pneumophila subsp. pneumophila str. Philadelphia 1
3NEU	;	1.58	;	The crystal structure of a functionally-unknown protein lin1836 from Listeria innocua Clip11262
8XRT	;	2.4	;	The crystal structure of a GH3 enzyme CcBgl3B
8XRV	;	2.4	;	The crystal structure of a GH3 enzyme CcBgl3B with glucose
8XRX	;	2.5	;	The crystal structure of a GH3 enzyme CcBgl3B with glucose and gentiobiose
8XRU	;	2.02	;	The crystal structure of a GH3 enzyme CcBgl3B with glycerol
4YYF	;	1.92	;	The crystal structure of a glycosyl hydrolase of GH3 family member from [Mycobacterium smegmatis str. MC2 155
3RQ0	;	2.02	;	The crystal structure of a glycosyl hydrolases (GH) family protein 16 from Mycobacterium smegmatis str. MC2 155
3PNN	;	1.901	;	The crystal structure of a glycosyltransferase from Porphyromonas gingivalis W83
5UJP	;	1.42	;	The crystal structure of a glyoxalase/bleomycin resistance protein from Streptomyces sp. CB03234
4RT5	;	1.5	;	The crystal structure of a glyoxalase/bleomycin resistance protein/dioxygenase protein from planctomyces limnophilus dsm 3776
2RK9	;	1.6	;	The crystal structure of a glyoxalase/bleomycin resistance protein/dioxygenase superfamily member from Vibrio splendidus 12B01
3IC8	;	2.4	;	The Crystal Structure of a GST-like protein from Pseudomonas syringae to 2.4A
8U4W	;	3.02	;	The crystal structure of a helical domain deleted PARP1 in complex with isoindolinone based inhibitor.
2R2Z	;	1.2	;	The crystal structure of a hemolysin domain from Enterococcus faecalis V583
3OCO	;	2.204	;	The crystal structure of a Hemolysin-like protein containing CBS domain of Oenococcus oeni PSU
1I8F	;	1.75	;	THE CRYSTAL STRUCTURE OF A HEPTAMERIC ARCHAEAL SM PROTEIN: IMPLICATIONS FOR THE EUKARYOTIC SNRNP CORE
5O7G	;	1.9	;	The crystal structure of a highly thermostable carboxyl esterase from Bacillus coagulans
5OLU	;	1.8	;	The crystal structure of a highly thermostable carboxyl esterase from Bacillus coagulans in complex with glycerol
3KDR	;	2.9	;	The Crystal Structure of a HK97 Family Phage Portal Protein from Corynebacterium diphtheriae to 2.9A
2QZ7	;	2.1	;	The crystal structure of a homologue of telluride resistance protein (TerD), SCO6318 from Streptomyces coelicolor A3(2)
3MTJ	;	2.15	;	The Crystal Structure of a Homoserine Dehydrogenase from Thiobacillus denitrificans to 2.15A
2PMF	;	2.85	;	The crystal structure of a human glycyl-tRNA synthetase mutant
4F2C	;	1.35	;	The Crystal Structure of a Human MitoNEET double mutant in which Gly 66 are Asp 67 are both Replaced with Ala Residues
4EZF	;	1.19	;	The Crystal Structure of a Human MitoNEET mutant with an Ala inserted between Asp 67 and Lys 68
4F1E	;	2.4	;	The Crystal Structure of a Human MitoNEET mutant with Asp 67 replaced by a Gly
4F28	;	1.55	;	The Crystal Structure of a Human MitoNEET mutant with Met 62 Replaced by a Gly
1NSK	;	2.8	;	THE CRYSTAL STRUCTURE OF A HUMAN NUCLEOSIDE DIPHOSPHATE KINASE, NM23-H2
6H3M	;	1.821	;	The crystal structure of a human seleno-insulin analog
1WT5	;	2.1	;	The Crystal Structure Of A Humanized Antibody Fv 528
3MPO	;	2.9	;	The crystal structure of a hydrolase from Lactobacillus brevis
3OM8	;	2.25	;	The crystal structure of a hydrolase from Pseudomonas aeruginosa PA01
3S6J	;	2.198	;	The crystal structure of a hydrolase from Pseudomonas syringae
2FI1	;	1.4	;	The crystal structure of a hydrolase from Streptococcus pneumoniae TIGR4
1JJI	;	2.2	;	The Crystal Structure of a Hyper-thermophilic Carboxylesterase from the Archaeon Archaeoglobus fulgidus
3JUR	;	2.05	;	The crystal structure of a hyperthermoactive Exopolygalacturonase from Thermotoga maritima
1MG6	;	1.6	;	The Crystal Structure of a K49 PLA2 from the Snake Venom of Agkistrodon acutus
4O5A	;	1.777	;	The crystal structure of a LacI family transcriptional regulator from Bifidobacterium animalis subsp. lactis DSM 10140
5UFH	;	1.45	;	The crystal structure of a LacI-type transcription regulator from Bifidobacterium animalis subsp. lactis DSM 10140
4IQZ	;	2.1	;	The crystal structure of a large insert in RNA polymerase (RpoC) subunit from E. coli
3E0X	;	1.45	;	The crystal structure of a Lipase-esterase related protein from Clostridium acetobutylicum ATCC 824
1PHR	;	2.1	;	THE CRYSTAL STRUCTURE OF A LOW MOLECULAR PHOSPHOTYROSINE PROTEIN PHOSPHATASE
1PPA	;	2.0	;	THE CRYSTAL STRUCTURE OF A LYSINE 49 PHOSPHOLIPASE A2 FROM THE VENOM OF THE COTTONMOUTH SNAKE AT 2.0 ANGSTROMS RESOLUTION
6AX6	;	2.241	;	The crystal structure of a lysyl hydroxylase from Acanthamoeba polyphaga mimivirus
6AX7	;	2.002	;	The crystal structure of a lysyl hydroxylase from Acanthamoeba polyphaga mimivirus
1P9P	;	2.5	;	The Crystal Structure of a M1G37 tRNA Methyltransferase, TrmD
4MMO	;	2.3363	;	The crystal structure of a M20 family metallo-carboxypeptidase Sso-CP2 from Sulfolobus solfataricus
3SRT	;	2.504	;	The crystal structure of a maltose O-acetyltransferase from Clostridium difficile 630
3E6M	;	2.2	;	The crystal structure of a MarR family transcriptional regulator from Silicibacter pomeroyi DSS.
3S2W	;	2.453	;	The crystal structure of a MarR transcriptional regulator from Methanosarcina mazei Go1
3FQ6	;	2.36	;	The crystal structure of a methyltransferase domain from Bacteroides thetaiotaomicron VPI
3NWG	;	2.7	;	The crystal structure of a microcomparments protein from Desulfitobacterium hafniense DCB
1CZ7	;	2.9	;	THE CRYSTAL STRUCTURE OF A MINUS-END DIRECTED MICROTUBULE MOTOR PROTEIN NCD REVEALS VARIABLE DIMER CONFORMATIONS
8BBH	;	1.619	;	The crystal structure of a mouse Fab fragment TL1 in complex with a human Glucose-6-phosphate isomerase peptide 293-307
5WEQ	;	2.0	;	The crystal structure of a MR78 mutant
1LY8	;	2.05	;	The crystal structure of a mutant enzyme of Coprinus cinereus peroxidase provides an understanding of its increased thermostability and insight into modelling of protein structures
1LHM	;	1.8	;	THE CRYSTAL STRUCTURE OF A MUTANT LYSOZYME C77(SLASH)95A WITH INCREASED SECRETION EFFICIENCY IN YEAST
4O1B	;	1.65	;	The crystal structure of a mutant NAMPT (G217R) in complex with an inhibitor APO866
4O19	;	1.75	;	The crystal structure of a mutant NAMPT (G217V)
4O15	;	1.8	;	The crystal structure of a mutant NAMPT (S165F) in complex with GNE-618
1LLI	;	2.1	;	THE CRYSTAL STRUCTURE OF A MUTANT PROTEIN WITH ALTERED BUT IMPROVED HYDROPHOBIC CORE PACKING
3M1J	;	1.8	;	The crystal structure of a NAMI A-Carbonic Anhydrase II adduct discloses the mode of action of this novel anticancer metallodrug
5UHJ	;	1.75	;	The crystal structure of a natural product biosynthetic enzyme from Streptomyces sp. CB03234
1ANX	;	1.9	;	THE CRYSTAL STRUCTURE OF A NEW HIGH-CALCIUM FORM OF ANNEXIN V
6FYQ	;	2.0	;	The crystal structure of a new transaminase from the marine bacterium Virgibacillus
4OV1	;	2.306	;	The crystal structure of a novel electron transfer ferredoxin from R. palustris HaA2
1XRF	;	1.65	;	The Crystal Structure of a Novel, Latent Dihydroorotase from Aquifex aeolicus at 1.7 A resolution
1XRT	;	1.609	;	The Crystal Structure of a Novel, Latent Dihydroorotase from Aquifex Aeolicus at 1.7 A Resolution
352D	;	0.95	;	THE CRYSTAL STRUCTURE OF A PARALLEL-STRANDED PARALLEL-STRANDED GUANINE TETRAPLEX AT 0.95 ANGSTROM RESOLUTION
1YMP	;	2.2	;	The Crystal Structure of a Partial Mouse Notch-1 Ankyrin Domain: Repeats 4 Through 7 Preserve an Ankyrin Fold
3LUQ	;	2.49	;	The Crystal Structure of a PAS Domain from a Sensory Box Histidine Kinase Regulator from Geobacter sulfurreducens to 2.5A
3PH1	;	2.1	;	The Crystal Structure of a Pathogenic Protein from the Xanthomonas campestris Reveals a New Tetrameric PilZ Domain Self-Assembled via a Unusual Helical Bundle
3RQA	;	2.1	;	The Crystal Structure of a Pathogenic Protein from the Xanthomonas campestris Reveals a New Tetrameric PilZ Domain Self-Assembled via a Unusual Helical Bundle
4GM2	;	2.8	;	The crystal structure of a peptidase from plasmodium falciparum
4YE5	;	2.052	;	The crystal structure of a peptidoglycan synthetase from Bifidobacterium adolescentis ATCC 15703
4LJS	;	2.321	;	The crystal structure of a periplasmic binding protein from Veillonella parvula DSM 2008
4N01	;	1.797	;	The crystal structure of a periplasmic binding protein from Veillonella parvula dsm 2008
1P28	;	1.7	;	The crystal structure of a pheromone binding protein from the cockroach Leucophaea maderae in complex with a component of the pheromonal blend: 3-hydroxy-butan-2-one.
1ORG	;	1.7	;	The crystal structure of a pheromone binding protein from the cockroach Leucophaea maderae reveals a new mechanism of pheromone binding
2PHK	;	2.6	;	THE CRYSTAL STRUCTURE OF A PHOSPHORYLASE KINASE PEPTIDE SUBSTRATE COMPLEX: KINASE SUBSTRATE RECOGNITION
3DSB	;	1.48	;	The crystal structure of a possible acetyltransferase from Clostridium difficile 630
4M7O	;	2.02	;	The crystal structure of a possible an iron-binding (periplasmic solute-binding) protein from Staphylococcus epidermidis ATCC 12228.
3FZ4	;	1.38	;	The crystal structure of a possible arsenate reductase from Streptococcus mutans UA159
4RNL	;	1.8	;	The crystal structure of a possible galactose mutarotase from Streptomyces platensis subsp. rosaceus
3DF8	;	1.65	;	The crystal structure of a possible HxlR family transcriptional factor from Thermoplasma volcanium GSS1
4KV7	;	1.2	;	The crystal structure of a possible leucine/isoleucine/valine-binding protein from Rhodopirellula baltica SH 1
4Q7Q	;	1.451	;	The crystal structure of a possible lipase from Chitinophaga pinensis DSM 2588
3PMM	;	1.899	;	The crystal structure of a possible member of GH105 family from Klebsiella pneumoniae subsp. pneumoniae MGH 78578
3QWT	;	2.183	;	The crystal structure of a possible member of GH105 family from Salmonella enterica subsp. enterica serovar Paratyphi A str. ATCC 9150
3RPC	;	1.49	;	The crystal structure of a possible metal-dependent hydrolase from Veillonella parvula DSM 2008
3LDU	;	1.7	;	The crystal structure of a possible methylase from Clostridium difficile 630.
3U9E	;	2.04	;	The crystal structure of a possible phosphate acetyl/butaryl transferase (from Listeria monocytogenes EGD-e) in complex with CoA.
3UF6	;	1.8	;	The crystal structure of a possible phosphate acetyl/butaryl transferase (from Listeria monocytogenes EGD-e) in complex with CoD (3'-dephosphocoenzyme A)
3TNG	;	2.16	;	The crystal structure of a possible phosphate acetyl/butaryl transferase from Listeria monocytogenes EGD-e.
4JWO	;	1.601	;	The crystal structure of a possible phosphate binding protein from Planctomyces limnophilus DSM 3776
3MZ1	;	1.88	;	The crystal structure of a possible TRANSCRIPTION REGULATOR PROTEIN from Sinorhizobium meliloti 1021
3OCJ	;	1.39	;	The crystal structure of a possilbe exported protein from Bordetella parapertussis
1QPS	;	2.5	;	THE CRYSTAL STRUCTURE OF A POST-REACTIVE COGNATE DNA-ECO RI COMPLEX AT 2.50 A IN THE PRESENCE OF MN2+ ION
3MN2	;	1.8	;	The crystal structure of a probable AraC family transcriptional regulator from Rhodopseudomonas palustris CGA009
2FE7	;	2.0	;	The crystal structure of a probable N-acetyltransferase from Pseudomonas aeruginosa
3LZK	;	1.9	;	The crystal structure of a probably aromatic amino acid degradation proteiN from Sinorhizobium meliloti 1021
5EUF	;	2.8	;	The crystal structure of a protease from Helicobacter pylori
2HLS	;	1.93	;	The crystal structure of a protein disulfide oxidoreductase from Aeropyrum pernix k1
2AYT	;	2.4	;	The crystal structure of a protein disulfide oxidoreductase from aquifex aeolicus
3LXQ	;	1.95	;	The Crystal Structure of a Protein in the Alkaline Phosphatase Superfamily from Vibrio parahaemolyticus to 1.95A
3LVT	;	2.55	;	The Crystal Structure of a Protein in the Glycosyl Hydrolase Family 38 from Enterococcus faecalis to 2.55A
3LEC	;	1.8	;	The Crystal Structure of a protein in the NADB-Rossmann Superfamily from Streptococcus agalactiae to 1.8A
2QH9	;	1.8	;	The crystal structure of a protein of unknown function from Archaeoglobus fulgidus DSM 4304
2P90	;	2.35	;	The crystal structure of a protein of unknown function from Corynebacterium glutamicum ATCC 13032
2O2A	;	2.1	;	The crystal structure of a protein of unknown function from Streptococcus agalactiae
1RYL	;	1.6	;	The Crystal Structure of a Protein of Unknown Function YfbM from Escherichia coli
3D8U	;	2.88	;	The crystal structure of a PurR family transcriptional regulator from Vibrio parahaemolyticus RIMD 2210633
3MUX	;	1.45	;	The Crystal Structure of a putative 4-hydroxy-2-oxoglutarate aldolase from Bacillus anthracis to 1.45A
6E4B	;	2.55	;	The crystal structure of a putative alpha-ribazole-5'-P phosphatase from Escherichia coli str. K-12 substr. MG1655
4EWT	;	2.1	;	The crystal structure of a putative aminohydrolase from methicillin resistant Staphylococcus aureus
3D6K	;	2.0	;	The crystal structure of a putative aminotransferase from Corynebacterium diphtheriae
3ISR	;	1.9	;	The Crystal Structure of a Putative Cysteine Protease from Cytophaga hutchinsonii to 1.9A
3PU5	;	2.05	;	The crystal structure of a putative extracellular solute-binding protein from Bordetella parapertussis
3OPN	;	2.05	;	The crystal structure of a putative hemolysin from Lactococcus lactis
3H05	;	1.65	;	The Crystal Structure of a Putative Nicotinate-nucleotide Adenylyltransferase from Vibrio parahaemolyticus
3IG2	;	2.09	;	The Crystal Structure of a Putative Phenylalanyl-tRNA synthetase (PheRS) beta chain domain from Bacteroides fragilis to 2.1A
3BJV	;	2.4	;	The Crystal Structure of a putative PTS IIA(PtxA) from Streptococcus mutans
3CZC	;	2.02	;	The Crystal Structure of a putative PTS IIB(PtxB) from Streptococcus mutans
4PON	;	1.9	;	The crystal structure of a putative SAM-dependent methyltransferase, YtqB, from Bacillus subtilis
3OXN	;	2.7	;	The crystal structure of a putative transcriptional regulator from Vibrio parahaemolyticus
2IA2	;	2.1	;	The crystal structure of a putative transcriptional regulator RHA06195 from Rhodococcus sp. RHA1
7VOB	;	2.09224	;	The crystal structure of a Radical SAM Enzyme BlsE involved in the Biosynthesis of Blasticidin S
7VOC	;	2.62005	;	The crystal structure of a Radical SAM Enzyme BlsE involved in the Biosynthesis of Blasticidin S
8F23	;	1.93	;	The crystal structure of a rationally designed zinc sensor based on maltose binding protein - Apo conformation
8ETB	;	1.63	;	the crystal structure of a rationally designed zinc sensor based on maltose binding protein - Zn binding conformation
4KVF	;	1.722	;	The crystal structure of a rhamnose ABC transporter, periplasmic rhamnose-binding protein from Kribbella flavida DSM 17836
6MXV	;	1.78	;	The crystal structure of a rhodanese-like family protein from Francisella tularensis subsp. tularensis SCHU S4
3MTI	;	1.95	;	The Crystal Structure of a rRNA Methylase from Streptococcus thermophilus to 1.95A
4NAS	;	1.92	;	The crystal structure of a rubisco-like protein (MtnW) from Alicyclobacillus acidocaldarius subsp. acidocaldarius DSM 446
5G2P	;	1.89	;	The crystal structure of a S-selective transaminase from Arthrobacter sp.
5G2Q	;	2.3	;	The crystal structure of a S-selective transaminase from Arthrobacter sp. with alanine bound
5G0A	;	1.7	;	The crystal structure of a S-selective transaminase from Bacillus megaterium
5G09	;	1.9	;	The crystal structure of a S-selective transaminase from Bacillus megaterium bound with R-alpha-methylbenzylamine
6IV7	;	1.937	;	The crystal structure of a SAM-dependent enzyme from aspergillus flavus
4HDE	;	1.317	;	The crystal structure of a SCO1/SenC family lipoprotein from Bacillus anthracis str. Ames
4J7K	;	1.66	;	The crystal structure of a secreted protein EsxB (Mutant E54Q) from Bacillus anthracis str. Sterne
4J7J	;	1.458	;	The crystal structure of a secreted protein EsxB (Mutant G53A) from Bacillus anthracis str. Sterne
4J41	;	1.522	;	The crystal structure of a secreted protein EsxB (Mutant P67A) from Bacillus anthracis str. Sterne
4J42	;	1.28	;	The crystal structure of a secreted protein EsxB (Mutant Y65F) from Bacillus anthracis str. Sterne
4J10	;	1.44	;	The crystal structure of a secreted protein ESXB (SeMet-labeled) from Bacillus anthracis str. Sterne
4IYH	;	1.881	;	The crystal structure of a secreted protein EsxB (SeMet-labeled, C-term. His-Tagged) from Bacillus anthracis str. Sterne
4IYI	;	2.083	;	The crystal structure of a secreted protein EsxB (wild-type, C-term. His-tagged) from Bacillus anthracis str. Sterne
4J11	;	1.44	;	The crystal structure of a secreted protein ESXB (wild-type, in P21 space group) from Bacillus anthracis str. sterne
3LWA	;	1.75	;	The Crystal Structure of a Secreted Thiol-disulfide Isomerase from Corynebacterium glutamicum to 1.75A
5U98	;	2.0	;	The crystal structure of a self-peptide complexed to Abacavir and HLA-B*57:01
3LHF	;	2.3	;	The Crystal Structure of a Serine Recombinase from Sulfolobus solfataricus to 2.3A
7DAI	;	2.3	;	The crystal structure of a serotonin N-acetyltransferase from Oryza Sativa
6K5M	;	1.793	;	The crystal structure of a serotonin N-acetyltransferase from Oryza Sativa (Rice)
7DAK	;	2.8	;	The crystal structure of a serotonin N-acetyltransferase in complex with 5-Methoxytryptamine and acetyl-CoA from Oryza Sativa
7DAL	;	2.5	;	The crystal structure of a serotonin N-acetyltransferase in complex with serotonin and acetyl-CoA from Oryza Sativa
4HN3	;	2.047	;	The crystal structure of a sex pheromone precursor (lmo1757) from Listeria monocytogenes EGD-e
4E4Y	;	1.803	;	The crystal structure of a short chain dehydrogenase family protein from Francisella tularensis subsp. tularensis SCHU S4
3M1A	;	2.0	;	The Crystal Structure of a Short-chain Dehydrogenase from Streptomyces avermitilis to 2A
4IPT	;	1.546	;	The crystal structure of a short-chain dehydrogenases/reductase (ethylated) from Veillonella parvula DSM 2008
4HNG	;	1.5	;	The crystal structure of a short-chain dehydrogenases/reductase (wide type) from Veillonella parvula DSM 2008
4HNH	;	1.576	;	The crystal structure of a short-chain dehydrogenases/reductase (wide type) from Veillonella parvula DSM 2008 in complex with NADP
6W4L	;	1.31	;	The crystal structure of a single chain H2B-H2A histone chimera from Xenopus laevis
6PXI	;	3.447	;	The crystal structure of a singly capped HslUV complex with an axial pore plug and a HslU E257Q mutation
4PZ0	;	1.25	;	The crystal structure of a solute binding protein from Bacillus anthracis str. Ames in complex with quorum-sensing signal autoinducer-2 (AI-2)
4NQR	;	1.09	;	The crystal structure of a solute-binding protein (N280D mutant) from Anabaena variabilis ATCC 29413 in complex with alanine
4OTZ	;	1.36	;	The crystal structure of a solute-binding protein (N280D mutant) from Anabaena variabilis ATCC 29413 in complex with cystein
4OAT	;	1.199	;	The crystal structure of a solute-binding protein (N280D mutant) from Anabaena variabilis ATCC 29413 in complex with isoleucine.
4OG2	;	1.099	;	The crystal structure of a solute-binding protein (N280D mutant) from Anabaena variabilis ATCC 29413 in complex with leucine
4QYM	;	1.581	;	The crystal structure of a solute-binding protein (N280D mutant) from Anabaena variabilis ATCC 29413 in complex with methionine
4RDC	;	1.198	;	The crystal structure of a solute-binding protein (N280D mutant) from Anabaena variabilis ATCC 29413 in complex with proline
4NV3	;	1.09	;	The crystal structure of a solute-binding protein (N280D mutant) from Anabaena variabilis ATCC 29413 in complex with valine.
4OBB	;	1.526	;	The crystal structure of a solute-binding protein from Anabaena variabilis ATCC 29413 in complex with (3S)-3-methyl-2-oxopentanoic acid.
4RV5	;	1.04	;	The crystal structure of a solute-binding protein from Anabaena variabilis ATCC 29413 in complex with pyruvic acid
3F5R	;	1.7	;	The crystal structure of a subunit of the heterodimeric FACT complex (Spt16p-Pob3p).
4RWE	;	1.65	;	The crystal structure of a sugar-binding transport protein from Yersinia pestis CO92
3DPJ	;	1.9	;	The crystal structure of a TetR transcription regulator from Silicibacter pomeroyi DSS
2HYJ	;	2.19	;	The crystal structure of a tetR-family transcriptional regulator from Streptomyces coelicolor
3F1B	;	2.4	;	The crystal structure of a TetR-like transcriptional regulator from Rhodococcus sp. RHA1.
3MVP	;	1.85	;	The Crystal Structure of a TetR/AcrR transcriptional regulator from Streptococcus mutans to 1.85A
5ZOA	;	1.537	;	The crystal structure of a Thermobifida fusca cutinase
2HPG	;	1.9	;	The crystal structure of a thermophilic TRAP periplasmic binding protein
2XSL	;	1.59	;	The crystal structure of a Thermus thermophilus tRNAGly acceptor stem microhelix at 1.6 Angstroem resolution
5VPJ	;	2.35	;	The crystal structure of a thioesteras from Actinomadura verrucosospora.
3LOR	;	2.2	;	The Crystal Structure of a Thiol-disulfide Isomerase from Corynebacterium glutamicum to 2.2A
3GYK	;	1.76	;	The crystal structure of a thioredoxin-like oxidoreductase from Silicibacter pomeroyi DSS-3
3GNJ	;	1.99	;	The crystal structure of a thioredoxin-related protein from Desulfitobacterium hafniense DCB
1NEZ	;	2.1	;	The Crystal Structure of a TL/CD8aa Complex at 2.1A resolution:Implications for Memory T cell Generation, Co-receptor Preference and Affinity
2FD5	;	1.7	;	The crystal structure of a transcriptional regulator from Pseudomonas aeruginosa PAO1
4DQD	;	1.601	;	The crystal structure of a transporter in complex with 3-phenylpyruvic acid
6RMV	;	1.94	;	The crystal structure of a TRP channel peptide bound to a G protein beta gamma heterodimer
3G1C	;	2.2	;	The crystal structure of a TrpR like protein from Eubacterium eligens ATCC 27750
1R6X	;	1.4	;	The Crystal Structure of a Truncated Form of Yeast ATP Sulfurylase, Lacking the C-Terminal APS Kinase-like Domain, in complex with Sulfate
2DRP	;	2.8	;	THE CRYSTAL STRUCTURE OF A TWO ZINC-FINGER PEPTIDE REVEALS AN EXTENSION TO THE RULES FOR ZINC-FINGER/DNA RECOGNITION
2QVG	;	1.5	;	The crystal structure of a two-component response regulator from Legionella pneumophila
3L34	;	1.7	;	The crystal structure of a two-component sensor domain (2nd form) from Pseudomonas aeruginosa PA01
3N24	;	2.056	;	The crystal structure of a two-component sensor domain (3rd form) from Pseudomonas aeruginosa PA01
3KKB	;	1.881	;	The crystal structure of a two-component sensor domain from Pseudomonas aeruginosa PA01
3OLQ	;	1.816	;	The crystal structure of a universal stress protein E from Proteus mirabilis HI4320
3LOQ	;	2.32	;	The crystal structure of a universal stress protein from Archaeoglobus fulgidus DSM 4304
3IDF	;	2.0	;	The Crystal Structure of a USP-like protein from Wolinella succinogenes to 2.0A
1UN6	;	3.1	;	THE CRYSTAL STRUCTURE OF A ZINC FINGER - RNA COMPLEX REVEALS TWO MODES OF MOLECULAR RECOGNITION
4ID8	;	2.15	;	The crystal structure of a [3Fe-4S] ferredoxin associated with CYP194A4 from R. palustris HaA2
3GGG	;	2.21	;	The crystal structure of A. aeolicus prephenate dehydrogenase in complex with tyrosine and NAD+
3RKL	;	1.7	;	The crystal structure of A81 from Sulfolobus Turreted Icosahedral Virus
3PZ0	;	2.4	;	The crystal structure of AaLeuRS-CP1
3PZ5	;	2.5	;	The crystal structure of AaLeuRS-CP1-D20
6JZZ	;	3.011	;	The crystal structure of AAR-C294S in complex with ADO.
3NND	;	2.8	;	The crystal structure of ABC transporter from Rhodopseudomonas palustris
4RU0	;	2.442	;	The crystal structure of abc transporter permease from pseudomonas fluorescens group
6RKH	;	2.471	;	The crystal structure of AbnE (Selenium derivative), an arabino-oligosaccharide binding protein, in complex with arabinohexaose
6RJY	;	1.621	;	The crystal structure of AbnE, an arabino-oligosaccharide binding protein, in complex with arabinobiose
6RKL	;	2.0	;	The crystal structure of AbnE, an arabino-oligosaccharide binding protein, in complex with arabinoheptaose
6RKJ	;	1.601	;	The crystal structure of AbnE, an arabino-oligosaccharide binding protein, in complex with arabinooctaose
6RKX	;	2.094	;	The crystal structure of AbnE, an arabino-oligosaccharide binding protein, in complex with arabinopentaose
6RL2	;	1.94	;	The crystal structure of AbnE, an arabino-oligosaccharide binding protein, in complex with arabinotetraose
6RL1	;	1.7	;	The crystal structure of AbnE, an arabino-oligosaccharide binding protein, in complex with arabinotriose
1U6M	;	2.4	;	The crystal structure of acetyltransferase
6RO8	;	2.6	;	The crystal structure of Acinetobacter radioresistens CYP116B5 heme domain
6JZQ	;	2.798	;	The crystal structure of acyl-acyl carrier protein (acyl-ACP) reductase (AAR)
6JZU	;	2.181	;	The crystal structure of acyl-acyl carrier protein (acyl-ACP) reductase (AAR) in complex with aldehyde deformylating oxygenase (ADO)
4RM7	;	2.529	;	The crystal structure of acyl-COA dehydrogenase from Slackia heliotrinireducens DSM 20476
4GS5	;	2.018	;	The crystal structure of acyl-CoA synthetase (AMP-forming)/AMP-acid ligase II-like protein from Dyadobacter fermentans DSM 18053
4MFJ	;	2.9	;	The crystal structure of acyltransferase
4MFQ	;	2.0	;	The crystal structure of acyltransferase in complex with CoA and 10C-Teicoplanin
4MFK	;	1.9	;	The crystal structure of acyltransferase in complex with decanoyl-CoA
4MFZ	;	2.1	;	The crystal structure of acyltransferase in complex with decanoyl-CoA
4MFL	;	1.9	;	The crystal structure of acyltransferase in complex with decanoyl-CoA and Tei pseudoaglycone
4MFP	;	2.15	;	The crystal structure of acyltransferase in complex with decanoyl-CoA and Tei pseudoaglycone
4Q38	;	1.99	;	The crystal structure of acyltransferase in complex with decanoyl-CoA and teicoplanin
4Q36	;	2.35	;	The crystal structure of acyltransferase in complex with octanoyl-CoA and teicoplanin
6IIX	;	1.73	;	The crystal structure of acyltransferase mutant, orf11*-W163A, in complex with octanoyl-CoA
3RYS	;	2.601	;	The crystal structure of adenine deaminase (AAur1117) from Arthrobacter aurescens
3OU8	;	2.51	;	The crystal structure of adenosine deaminase from Pseudomonas aeruginosa
3PBM	;	2.591	;	The crystal structure of adenosine deaminase in complex with chloropurine from Pseudomonas aeruginosa
3PAO	;	2.493	;	The crystal structure of adenosine deaminase with adenine bound from Pseudomonas aeruginosa
3PAN	;	2.627	;	The crystal structure of adenosine deaminase with hypoxanthine bound from Pseudomonas aeruginosa
3UBO	;	2.601	;	The crystal structure of adenosine kinase from Sinorhizobium meliloti
3KCN	;	2.45	;	The crystal structure of adenylate cyclase from Rhodopirellula baltica
4PZL	;	2.1	;	The crystal structure of adenylate kinase from Francisella tularensis subsp. tularensis SCHU S4
1DOF	;	2.1	;	THE CRYSTAL STRUCTURE OF ADENYLOSUCCINATE LYASE FROM PYROBACULUM AEROPHILUM: INSIGHTS INTO THERMAL STABILITY AND HUMAN PATHOLOGY
1EQ2	;	2.0	;	THE CRYSTAL STRUCTURE OF ADP-L-GLYCERO-D-MANNOHEPTOSE 6-EPIMERASE
1HUW	;	2.0	;	THE CRYSTAL STRUCTURE OF AFFINITY-MATURED HUMAN GROWTH HORMONE AT 2 ANGSTROMS RESOLUTION
7WLH	;	2.65	;	The crystal structure of African swine fever virus I215L
7VWV	;	2.59	;	The crystal structure of African swine fever virus I73R
4V8N	;	3.1	;	The crystal structure of agmatidine tRNA-Ile2 bound to the 70S ribosome in the A and P site.
3PZL	;	2.7	;	The crystal structure of agmatine ureohydrolase of Thermoplasma volcanium
7XW1	;	2.36	;	The crystal structure of AhpD from Pseudomonas aeruginosa
3QRA	;	1.801	;	The crystal structure of Ail, the attachment invasion locus protein of Yersinia pestis
3QRC	;	1.852	;	The crystal structure of Ail, the attachment invasion locus protein of Yersinia pestis, in complex with the heparin analogue sucrose octasulfate
7F7J	;	1.93	;	The crystal structure of AKR4C17
2VD8	;	1.47	;	The crystal structure of alanine racemase from Bacillus anthracis (BA0252)
2VD9	;	2.1	;	The crystal structure of alanine racemase from Bacillus anthracis (BA0252) with bound L-Ala-P
3S46	;	2.0	;	The crystal structure of alanine racemase from streptococcus pneumoniae
1YFS	;	2.08	;	The crystal structure of alanyl-tRNA synthetase in complex with L-alanine
5MLN	;	1.6	;	The crystal structure of alcohol dehydrogenase 10 from Candida magnoliae
5TJF	;	2.3	;	The crystal structure of Allophycocyanin from the red algae Gracilaria chilensis
1CSM	;	2.2	;	THE CRYSTAL STRUCTURE OF ALLOSTERIC CHORISMATE MUTASE AT 2.2 ANGSTROMS RESOLUTION
5EB4	;	2.3	;	The crystal structure of almond HNL, PaHNL5 V317A, expressed in Aspergillus niger
5EB5	;	2.8	;	The crystal structure of almond HNL, PaHNL5 V317A, in complex with benzyl alcohol
8H3T	;	1.866	;	The crystal structure of AlpH
3DXV	;	2.21	;	The crystal structure of alpha-amino-epsilon-caprolactam racemase from Achromobacter obae
3DXW	;	2.41	;	The crystal structure of alpha-amino-epsilon-caprolactam racemase from Achromobacter obae complexed with epsilon caprolactam
2ZUK	;	2.41	;	The crystal structure of alpha-amino-epsilon-caprolactam racemase from Achromobacter obae complexed with epsilon caprolactam (different binding mode)
2ABX	;	2.5	;	THE CRYSTAL STRUCTURE OF ALPHA-BUNGAROTOXIN AT 2.5 ANGSTROMS RESOLUTION. RELATION TO SOLUTION STRUCTURE AND BINDING TO ACETYLCHOLINE RECEPTOR
1MQR	;	2.0	;	THE CRYSTAL STRUCTURE OF ALPHA-D-GLUCURONIDASE (E386Q) FROM BACILLUS STEAROTHERMOPHILUS T-6
1MQQ	;	1.65	;	THE CRYSTAL STRUCTURE OF ALPHA-D-GLUCURONIDASE FROM BACILLUS STEAROTHERMOPHILUS T-1 COMPLEXED WITH GLUCURONIC ACID
1MQP	;	1.9	;	THE CRYSTAL STRUCTURE OF ALPHA-D-GLUCURONIDASE FROM BACILLUS STEAROTHERMOPHILUS T-6
4THN	;	2.5	;	THE CRYSTAL STRUCTURE OF ALPHA-THROMBIN-HIRUNORM IV COMPLEX REVEALS A NOVEL SPECIFICITY SITE RECOGNITION MODE.
8HFW	;	1.66	;	The crystal structure of alpha/beta fold hydrolase
4MAA	;	2.0	;	The Crystal Structure of Amino Acid ABC Transporter Substrate-binding Protein from Pseudomonas fluorescens Pf-5
1K0E	;	2.0	;	THE CRYSTAL STRUCTURE OF AMINODEOXYCHORISMATE SYNTHASE FROM FORMATE GROWN CRYSTALS
1K0G	;	2.05	;	THE CRYSTAL STRUCTURE OF AMINODEOXYCHORISMATE SYNTHASE FROM PHOSPHATE GROWN CRYSTALS
3F5B	;	2.0	;	The crystal structure of aminoglycoside N(6')acetyltransferase from Legionella pneumophila subsp. pneumophila str. Philadelphia 1.
1Y7E	;	3.2	;	The Crystal Structure of Aminopeptidase I from Borrelia burgdorferi B31
5DYF	;	1.854	;	The crystal structure of Aminopeptidase N in complex with N-benzyl-1,2-diaminoethylphosphonic acid
4KKE	;	2.2	;	The crystal structure of AMP-bound JNK3
1PTW	;	2.3	;	The Crystal Structure of AMP-Bound PDE4 Suggests a Mechanism for Phosphodiesterase Catalysis
5TPT	;	2.422	;	The Crystal Structure of Amyloid Precursor-Like Protein 2 (APLP2) E2 Domain
3RPW	;	1.65	;	The crystal structure of an ABC transporter from Rhodopseudomonas palustris CGA009
6NLP	;	1.9	;	The crystal structure of an ABC transporter periplasmic binding protein YdcS from Escherichia coli BW25113
4I1D	;	2.201	;	The crystal structure of an ABC transporter substrate-binding protein from Bradyrhizobium japonicum USDA 110
1ZR6	;	1.55	;	The crystal structure of an Acremonium strictum glucooligosaccharide oxidase reveals a novel flavinylation
4IGA	;	1.73	;	The crystal structure of an activated Thermotoga maritima CheY with N-terminal region of FliM
3LW7	;	2.3	;	The Crystal Structure of an Adenylate kinase-related protein bound to AMP from sulfolobus solfataricus to 2.3A
4M9D	;	1.821	;	The Crystal structure of an adenylosuccinate synthetase from Bacillus anthracis str. Ames Ancestor in complex with AMP.
4M0G	;	2.152	;	The crystal structure of an adenylosuccinate synthetase from Bacillus anthracis str. Ames Ancestor.
2I5B	;	2.8	;	The crystal structure of an ADP complex of Bacillus subtilis pyridoxal kinase provides evidence for the parralel emergence of enzyme activity during evolution
4JDU	;	1.47	;	The crystal structure of an aerotolerance-related membrane protein from Bacteroides fragilis NCTC 9343 with multiple mutations to serines.
5Z6P	;	2.061	;	The crystal structure of an agarase, AgWH50C
4FTG	;	2.5054	;	The crystal structure of an AHNAK peptide in complex with the S100A10/AnxA2 heterotetramer
1HQT	;	2.2	;	THE CRYSTAL STRUCTURE OF AN ALDEHYDE REDUCTASE Y50F MUTANT-NADP COMPLEX AND ITS IMPLICATIONS FOR SUBSTRATE BINDING
1MME	;	3.1	;	THE CRYSTAL STRUCTURE OF AN ALL-RNA HAMMERHEAD RIBOZYME: A PROPOSED MECHANISM FOR RNA CATALYTIC CLEAVAGE
1ZFT	;	2.33	;	The crystal structure of an all-RNA minimal Hairpin Ribozyme with mutant G8I at the cleavage site
4X5S	;	1.95	;	The crystal structure of an alpha carbonic anhydrase from the extremophilic bacterium Sulfurihydrogenibium azorense.
4G7A	;	1.8	;	The crystal structure of an alpha Carbonic Anhydrase from the extremophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1
3MO4	;	1.901	;	The crystal structure of an alpha-(1-3,4)-fucosidase from Bifidobacterium longum subsp. infantis ATCC 15697
5KBP	;	2.4	;	The crystal structure of an alpha-mannosidase from Enterococcus faecalis V583
3R0V	;	1.383	;	The crystal structure of an alpha/beta hydrolase from Sphaerobacter thermophilus DSM 20745.
5EWQ	;	2.57	;	The crystal structure of an amidase family protein from Bacillus anthracis str. Ames
4I6V	;	2.137	;	The crystal structure of an amidohydrolase 2 from Planctomyces limnophilus DSM 3776
3MSR	;	2.162	;	The crystal structure of an amidohydrolase from Mycoplasma synoviae
3OVG	;	2.059	;	The crystal structure of an amidohydrolase from Mycoplasma synoviae with Zn ion bound
5UID	;	2.18	;	The crystal structure of an aminotransferase TlmJ from Streptoalloteichus hindustanus
4HYL	;	1.751	;	The crystal structure of an anti-sigma-factor antagonist from Haliangium ochraceum DSM 14365
4R3H	;	1.9	;	The crystal structure of an apo RNA binding protein
3AF5	;	2.6	;	The crystal structure of an archaeal CPSF subunit, PH1404 from Pyrococcus horikoshii
3AF6	;	2.6	;	The crystal structure of an archaeal CPSF subunit, PH1404 from Pyrococcus horikoshii complexed with RNA-analog
3OD1	;	1.97	;	The crystal structure of an ATP phosphoribosyltransferase regulatory subunit/histidyl-tRNA synthetase from Bacillus halodurans C
1PY9	;	1.8	;	The crystal structure of an autoantigen in multiple sclerosis
4QN8	;	1.751	;	The crystal structure of an effector protein VipE from Legionella pneumophila subsp. pneumophila str. Philadelphia 1
4Q2B	;	2.12	;	The crystal structure of an endo-1,4-D-glucanase from Pseudomonas putida KT2440
2HYK	;	1.3	;	The crystal structure of an endo-beta-1,3-glucanase from alkaliphilic Nocardiopsis sp.strain F96
1TRI	;	2.4	;	THE CRYSTAL STRUCTURE OF AN ENGINEERED MONOMERIC TRIOSEPHOSPHATE ISOMERASE, MONOTIM: THE CORRECT MODELLING OF AN EIGHT-RESIDUE LOOP
4EXM	;	2.6	;	The crystal structure of an engineered phage lysin containing the binding domain of pesticin and the killing domain of T4-lysozyme
1B0X	;	2.0	;	THE CRYSTAL STRUCTURE OF AN EPH RECEPTOR SAM DOMAIN REVEALS A MECHANISM FOR MODULAR DIMERIZATION.
5F4Z	;	1.82	;	The crystal structure of an epoxide hydrolase from Streptomyces carzinostaticus subsp. neocarzinostaticus
4I19	;	2.148	;	The crystal structure of an epoxide hydrolase from Streptomyces carzinostaticus subsp. neocarzinostaticus.
3SG0	;	1.201	;	The crystal structure of an extracellular ligand-binding receptor from Rhodopseudomonas palustris HaA2
1PSK	;	2.8	;	THE CRYSTAL STRUCTURE OF AN FAB FRAGMENT THAT BINDS TO THE MELANOMA-ASSOCIATED GD2 GANGLIOSIDE
6DXP	;	2.478	;	The crystal structure of an FMN-dependent NADH-azoreductase from Klebsiella pneumoniae
7N2W	;	2.65	;	The crystal structure of an FMN-dependent NADH-azoreductase, AzoA in complex with Red 40
7N2X	;	1.7	;	The crystal structure of an FMN-dependent NADH:quinone oxidoreductase, AzoR from Escherichia coli
4Q7O	;	1.45	;	The crystal structure of an immunity protein NMB0503 from Neisseria meningitidis MC58
1HLO	;	2.8	;	THE CRYSTAL STRUCTURE OF AN INTACT HUMAN MAX-DNA COMPLEX: NEW INSIGHTS INTO MECHANISMS OF TRANSCRIPTIONAL CONTROL
3HB7	;	2.3	;	The Crystal Structure of an Isochorismatase-like Hydrolase from Alkaliphilus metalliredigens to 2.3A
1T2Q	;	1.83	;	The Crystal Structure of an NNA7 Fab that recognizes an N-type blood group antigen
2FI9	;	1.8	;	The crystal structure of an outer membrane protein from the Bartonella henselae
4R3I	;	1.8	;	The crystal structure of an RNA complex
333D	;	2.52	;	THE CRYSTAL STRUCTURE OF AN RNA OLIGOMER INCORPORATING TANDEM ADENOSINE-INOSINE MISMATCHES
1JB8	;	2.38	;	The Crystal Structure of an RNA/DNA Hybrid Reveals Novel Intermolecular Intercalation
1JRI	;	2.8	;	The Crystal Structure of an Sm-like Archaeal Protein with Two Heptamers in the Asymmetric Unit.
3PU6	;	2.6	;	The crystal structure of an uncharacterized protein from Wolinella succinogenes
3FG9	;	1.47	;	The crystal structure of an universal stress protein UspA family protein from Lactobacillus plantarum WCFS1
2FA5	;	1.8	;	The crystal structure of an unliganded multiple antibiotic-resistance repressor (MarR) from Xanthomonas campestris
3URG	;	2.003	;	The crystal structure of Anabaena CcbP
4KWH	;	1.7	;	The crystal structure of angucycline C-6 ketoreductase LanV with bound NADP
4KWI	;	2.0	;	The crystal structure of angucycline C-6 ketoreductase LanV with bound NADP and 11-deoxy-6-oxylandomycinone
1BIT	;	1.83	;	THE CRYSTAL STRUCTURE OF ANIONIC SALMON TRYPSIN IN A SECOND CRYSTAL FORM
1BZX	;	2.1	;	THE CRYSTAL STRUCTURE OF ANIONIC SALMON TRYPSIN IN COMPLEX WITH BOVINE PANCREATIC TRYPSIN INHIBITOR
1QDL	;	2.5	;	THE CRYSTAL STRUCTURE OF ANTHRANILATE SYNTHASE FROM SULFOLOBUS SOLFATARICUS
6U6F	;	2.9	;	The crystal structure of anti-apoptotic Mcl-1 protein in complex with 2, 5-substituted benzoic acid inhibitor 21
1J05	;	1.5	;	The crystal structure of anti-carcinoembryonic antigen monoclonal antibody T84.66 Fv fragment
5B3N	;	1.94	;	The crystal structure of anti-H4K20me1_scFv, 15F11
7URL	;	1.49	;	The crystal structure of anti-HIV_scFv
1NSN	;	2.8	;	THE CRYSTAL STRUCTURE OF ANTIBODY N10-STAPHYLOCOCCAL NUCLEASE COMPLEX AT 2.9 ANGSTROMS RESOLUTION
3DFI	;	2.1	;	The crystal structure of antimicrobial reagent A40926 pseudoaglycone deacetylase Dbv21
8XQK	;	2.85	;	The Crystal Structure of Apaf from Biortus.
8X2Q	;	2.0	;	The Crystal Structure of APC from Biortus.
7WUP	;	2.3	;	The crystal structure of ApiI
4WKG	;	2.7	;	The crystal structure of apo ArnA features an unexpected central binding pocket and provides an explanation for enzymatic coop-erativity
4U2H	;	1.85	;	The crystal structure of apo CalE6, a methionine gamma lyase from Micromonospora echinospora
7UCT	;	2.52	;	The Crystal Structure of Apo Domain-Swapped Dimer F57:H:H:H:H:H:H:R58 Mutant of HCRBPII with Histidine Insertion in the Hinge Loop Region at 2.5 Angstrom Resolution
6WNF	;	1.67	;	The Crystal Structure of Apo Domain-Swapped Dimer Q108K:K40D:T53A:R58L:Q38F:Q4F:F57H Variant of HCRBPII
7UCV	;	2.19	;	The Crystal Structure of Apo Domain-Swapped Dimer Q108K:T51D:A28CL36C R58:H:H:H:N59 HCRBPII with Histidine Insertion in the Hinge Loop Region at 2.19 Angstrom Resolution
6VIT	;	3.2	;	The Crystal Structure of Apo Domain-Swapped dimer Q108K:T51D:I32C Variant of HCRBPII with an Engineered Disulfide Bond
6WP1	;	2.99	;	The Crystal Structure of Apo Domain-Swapped Trimer Q108K:K40L:T51K Variant of HCRBPII
6WNJ	;	2.1	;	The Crystal Structure of Apo Domain-Swapped Trimer Q108K:T51D:A28C:I32C of HCRBPII
4KNV	;	1.993	;	The crystal structure of APO HUMAN HDHD4 FROM SE-MAD
7UCZ	;	1.08	;	The Crystal Structure of Apo Monomer F57:H:H:H:H:H:H:R58 Mutant of HCRBPII with Histidine Insertion in the Hinge Loop Region at 1.1 Angstrom Resolution
7UD1	;	1.32	;	The Crystal Structure of Apo Monomer F57:H:H:H:R58 HCRBPII with Histidine Insertion in the Hinge Loop Region at 1.3 Angstrom Resolution
3E1X	;	1.7	;	The Crystal Structure of Apo Prostasin at 1.7 Angstroms Resolution
3HIF	;	3.59	;	The crystal structure of apo wild type CAP at 3.6 A resolution.
6WP2	;	2.48	;	The Crystal Structure of Apo Zinc-Bound Domain Swapped-Trimer Q108K:K40D:T53A:R58L:Q38F:Q4F:F57H Variant of HCRBPII
3JUJ	;	2.9	;	The crystal structure of apo- UDP-glucose pyrophosphorylase
4GZ7	;	2.0	;	The crystal structure of Apo-dihydropyrimidinase from Tetraodon nigroviridis
5ZYW	;	2.2	;	The crystal structure of apo-HsMGME1 with Mn2+
6A0N	;	2.1	;	The crystal structure of apo-Lpg2622
6KKP	;	2.5	;	The crystal structure of apo-SiaC from Pseudomonas aeruginosa
1XU2	;	2.35	;	The crystal structure of APRIL bound to BCMA
1XU1	;	1.9	;	The crystal structure of APRIL bound to TACI
6VID	;	2.89	;	The Crystal Structure of Aps Domain-Swapped Trimer Q108K:K40D:T53A:R58L:Q38F:Q4F Variant of HCRBPII
5DQR	;	2.7	;	The crystal structure of Arabidopsis 7-hydroxymethyl chlorophyll a reductase (HCAR)
4ZHO	;	2.34	;	The crystal structure of Arabidopsis ferredoxin 2 with 2Fe-2S cluster
5A52	;	1.65	;	The crystal structure of Arabidopsis thaliana CAR1 in complex with one calcium ion
4V29	;	1.6	;	The crystal structure of Arabidopsis thaliana CAR4 in complex with two calcium ions
5A51	;	1.602	;	The crystal structure of Arabidopsis thaliana CAR4 in complex with two calcium ions and phophatidyl serine
5A4X	;	2.2	;	The crystal structure of Arabidopsis thaliana CAR4 in complex with two calcium ions and Zn
5A50	;	2.4	;	The crystal structure of Arabidopsis thaliana CAR4 in complex with two calcium ions, Zn and Phopho Choline
4X1T	;	2.25	;	The crystal structure of Arabidopsis thaliana galactolipid synthase MGD1 in complex with UDP
4WYI	;	2.5	;	The crystal structure of Arabidopsis thaliana galactolipid synthase, MGD1 (apo-form)
2J0V	;	1.78	;	The crystal structure of Arabidopsis thaliana RAC7-ROP9: the first RAS superfamily GTPase from the plant kingdom
4ATW	;	3.0	;	The crystal structure of Arabinofuranosidase
4X3X	;	2.0	;	The crystal structure of Arc C-lobe
4X3I	;	1.8	;	The crystal structure of Arc N-lobe complexed with CAMK2A fragment
3VHX	;	2.81	;	The crystal structure of Arf6-MKLP1 (Mitotic kinesin-like protein 1) complex
4NZP	;	2.307	;	The crystal structure of argininosuccinate synthase from Campylobacter jejuni subsp. jejuni NCTC 11168
4GOK	;	2.6	;	The Crystal structure of Arl2GppNHp in complex with UNC119a
7D6F	;	3.001	;	The crystal structure of ARMS-PBM/MAGI2-PDZ4
7E7L	;	3.53	;	The crystal structure of arylacetate decarboxylase from Olsenella scatoligenes.
3LVQ	;	3.38	;	The crystal structure of ASAP3 in complex with Arf6 in transition state
3LVR	;	3.38	;	The crystal structure of ASAP3 in complex with Arf6 in transition state soaked with Calcium
6KHY	;	3.008	;	The crystal structure of AsfvAP:AG
6KI3	;	2.354	;	The crystal structure of AsfvAP:dF commplex
6IMK	;	2.502	;	The crystal structure of AsfvLIG:CG complex
6IML	;	2.35	;	The crystal structure of AsfvLIG:CT1 complex
6IMN	;	2.7	;	The crystal structure of AsfvLIG:CT2 complex
5HRG	;	2.0	;	The crystal structure of AsfvPolX(D51N mutant):DNA4 binary complex
5HRK	;	2.9	;	The crystal structure of AsfvPolX(H115F mutant): 1nt-gap(P) DNA2:dGTP ternary complex
5HRH	;	3.0	;	The crystal structure of AsfvPolX(H115F/R127A mutant): 1nt-gap(P) DNA2:dGTP ternary complex
5HRL	;	2.4	;	The crystal structure of AsfvPolX: 1nt-gap(P) DNA2: dGTP ternary complex.
5HRF	;	2.25	;	The crystal structure of AsfvPolX: DNA5: dGTP ternary complex
5HRB	;	1.7	;	The crystal structure of AsfvPolX:DNA1 binary complex
5HRI	;	2.2	;	The crystal structure of AsfvPolX:DNA1 binary complex
5HRD	;	1.8	;	The crystal structure of AsfvPolX:DNA2 binary complex
5HRE	;	1.75	;	The crystal structure of AsfvPolX:DNA3 binary complex
3PLX	;	1.747	;	The crystal structure of aspartate alpha-decarboxylase from Campylobacter jejuni subsp. jejuni NCTC 11168
1IUG	;	2.2	;	The crystal structure of aspartate aminotransferase which belongs to subgroup IV from Thermus thermophilus
8WKJ	;	1.7	;	The crystal structure of aspartate aminotransferases Lpg0070 from Legionella pneumophila
8WOU	;	2.14	;	The crystal structure of aspartate aminotransferases Lpg0070 from Legionella pneumophila
3TRS	;	1.6	;	The crystal structure of aspergilloglutamic peptidase from Aspergillus niger
2C3B	;	1.85	;	The Crystal Structure of Aspergillus fumigatus Cyclophilin reveals 3D Domain Swapping of a Central Element
5F19	;	2.04	;	The Crystal Structure of Aspirin Acetylated Human Cyclooxygenase-2
3S2Q	;	1.75	;	The crystal structure of AT5g51720 (AT-NEET)
2NX4	;	1.7	;	The Crystal Structure of athe Putative TetR-family transcriptional regulator Rha06780 from Rhodococcus sp. Rha1.
4PXC	;	1.893	;	The crystal structure of AtUAH in complex with (S)-hydroxyglycine
4PXB	;	1.903	;	The crystal structure of AtUAH in complex with (S)-ureidoglycolate
4PXE	;	1.449	;	The crystal structure of AtUAH in complex with glyoxylate
1OQC	;	1.8	;	The crystal structure of augmenter of liver regeneration: a mammalian FAD dependent sulfhydryl oxidase
3HW3	;	1.9	;	The crystal structure of avian influenza virus PA_N in complex with UMP
2D5I	;	2.2	;	The crystal structure of AzoR (Azo Reductase) from Escherichia coli
1V4B	;	1.8	;	The crystal structure of AzoR (Azo Reductase) from Escherichia coli: Oxidized form
2Z9C	;	2.3	;	The crystal structure of AzoR (azoreductase) from Escherichia coli: AzoR in complex with dicoumarol
2Z9D	;	2.1	;	The crystal structure of AzoR (azoreductase) from Escherichia coli: Oxidized AzoR in orthorhombic crystals
2Z98	;	1.4	;	The crystal structure of AzoR (azoreductase) from Escherichia coli: Oxidized AzoR in tetragonal crystals (The resolution has improved from 1.8 (1v4b) to 1.4 angstrom)
2Z9B	;	1.7	;	The crystal structure of AzoR (azoreductase) from Escherichia coli: Reduced AzoR in tetragonal crystals
4ESE	;	1.45	;	The crystal structure of azoreductase from Yersinia pestis CO92 in complex with FMN.
5JRO	;	2.54	;	The crystal structure of azoreductase from Yersinia pestis CO92 in its Apo form
2GQD	;	2.3	;	The crystal structure of B-ketoacyl-ACP synthase II (FabF) from Staphylococcus aureus
6M37	;	3.1	;	The crystal structure of B. subtilis RsbV/RsbW complex in the hexagonal crystal form
6M36	;	3.4	;	The crystal structure of B. subtilis RsbV/RsbW complex in the monoclinic crystal form
4R2H	;	1.96	;	The Crystal Structure of B204, the DNA-packaging ATPase from Sulfolobus Turreted Icosahedral Virus
5JE8	;	2.1	;	The crystal structure of Bacillus cereus 3-hydroxyisobutyrate dehydrogenase in complex with NAD
1FEZ	;	3.0	;	THE CRYSTAL STRUCTURE OF BACILLUS CEREUS PHOSPHONOACETALDEHYDE HYDROLASE COMPLEXED WITH TUNGSTATE, A PRODUCT ANALOG
2GX8	;	2.2	;	The Crystal Structure of Bacillus cereus protein related to NIF3
4MGR	;	2.55	;	The crystal structure of Bacillus subtilis GabR, an autorepressor and PLP- and GABA-dependent transcriptional activator of gabT
1I6W	;	1.5	;	THE CRYSTAL STRUCTURE OF BACILLUS SUBTILIS LIPASE: A MINIMAL ALPHA/BETA HYDROLASE ENZYME
4NKR	;	2.41	;	The Crystal structure of Bacillus subtilis MobB
2FE3	;	1.75	;	The crystal structure of bacillus subtilis PerR-Zn reveals a novel Zn(Cys)4 Structural redox switch
5IHY	;	2.5	;	The crystal structure of Bacillus subtilis SeMet-YpgQ
5DQV	;	2.0	;	The crystal structure of Bacillus subtilis YpgQ
5DQW	;	2.15	;	The crystal structure of Bacillus subtilis YpgQ in complex with ADP
4POO	;	2.2	;	The crystal structure of Bacillus subtilis YtqB in complex with SAM
1GD8	;	2.3	;	THE CRYSTAL STRUCTURE OF BACTERIA-SPECIFIC L17 RIBOSOMAL PROTEIN.
5Z1A	;	1.859	;	The crystal structure of Bacteroides fragilis beta-glucuronidase in complex with uronic isofagomine
6KZ7	;	2.28	;	The crystal structure of BAF155 SWIRM domain and N-terminal elongated hSNF5 RPT1 domain complex: Chromatin remodeling complex
2JCN	;	1.8	;	The crystal structure of BAK1 - a mitochondrial apoptosis regulator
4K3C	;	2.913	;	The crystal structure of BamA from Haemophilus ducreyi lacking POTRA domains 1-3
4K3B	;	3.2	;	The crystal structure of BamA from Neisseria gonorrhoeae
4IMM	;	2.33	;	The crystal structure of BamB from Moraxella catarrhalis
3Q7M	;	1.651	;	The crystal structure of BamB from the BAM complex in spacegroup I222
3Q7N	;	1.772	;	The crystal structure of BamB from the BAM complex in spacegroup P212121
3Q7O	;	2.091	;	The crystal structure of BamB from the BAM complex in spacegroup P213
8J5J	;	3.0	;	The crystal structure of bat coronavirus RsYN04 RBD bound to the antibody S43
2BZW	;	2.3	;	The crystal structure of BCL-XL in complex with full-length BAD
3DRN	;	2.15	;	The crystal structure of Bcp1 from Sulfolobus Sulfataricus
3HJP	;	2.55	;	The crystal structure of Bcp4 from Sulfolobus Solfataricus
6M2U	;	1.709	;	The crystal structure of benzoate coenzyme A ligase double mutant (H333A/I334A) in complex with 2-chloro-1,3-thiazole-5-carboxylate-AMP
6M2T	;	2.14	;	The crystal structure of benzoate coenzyme A ligase double mutant (H333A/I334A) in complex with 2-methyl-thiazole-5 carboxylate-AMP
4K9Q	;	1.598	;	The Crystal Structure of Benzoylformate Decarboxylase from Polynucleobacter necessarius
3NP6	;	2.3	;	The crystal structure of Berberine bound to DNA d(CGTACG)
7FIR	;	2.2	;	The crystal structure of beta-1,2-mannobiose phosphorylase in complex with 1,4-mannobiose
7FIS	;	2.19	;	The crystal structure of beta-1,2-mannobiose phosphorylase in complex with mannose 1-phosphate (M1P)
1V18	;	2.1	;	The crystal structure of beta-catenin armadillo repeat complexed with a phosphorylated APC 20mer repeat.
3LMY	;	2.8	;	The Crystal Structure of beta-hexosaminidase B in complex with Pyrimethamine
1OX0	;	1.3	;	The crystal structure of beta-ketoacyl-[acyl carrier protein] synthase II from Streptococcus pneumoniae
1OXH	;	2.09	;	The crystal structure of beta-ketoacyl-[acyl carrier protein] synthase II from Streptococcus Pneumoniae, Triclinic form
4EWF	;	2.0	;	The crystal structure of beta-lactamase from Sphaerobacter thermophilus DSM 20745
4PYS	;	1.822	;	The crystal structure of beta-N-acetylhexosaminidase from Bacteroides fragilis NCTC 9343
3NAS	;	3.0	;	The crystal structure of beta-phosphoglucomutase from Bacillus subtilis
5CSB	;	1.719	;	The crystal structure of beta2-microglobulin D76N mutant at room temperature
5CSG	;	1.5	;	The crystal structure of beta2-microglobulin R97Q mutant
7WAT	;	2.0	;	The Crystal Structure of Bifunctional Miltiradiene Synthase from Selaginella moellendorffii
2XLL	;	2.305	;	The crystal structure of bilirubin oxidase from Myrothecium verrucaria
1R30	;	3.4	;	The Crystal Structure of Biotin Synthase, an S-Adenosylmethionine-Dependent Radical Enzyme
1BVP	;	2.6	;	THE CRYSTAL STRUCTURE OF BLUETONGUE VIRUS VP7
8X2A	;	1.3	;	The Crystal Structure of BMX from Biortus.
6V4V	;	1.65	;	The crystal structure of BonA from Acinetobacter baumannii
1CYC	;	2.3	;	THE CRYSTAL STRUCTURE OF BONITO (KATSUO) FERROCYTOCHROME C AT 2.3 ANGSTROMS RESOLUTION. II. STRUCTURE AND FUNCTION
2EWB	;	1.85	;	The crystal structure of Bovine Lens Leucine Aminopeptidase in complex with zofenoprilat
1TGU	;	2.8	;	The crystal structure of bovine liver catalase without NADPH
7A0D	;	1.6	;	The Crystal Structure of Bovine Thrombin in complex with Hirudin (C16U/C28U) at 1.6 Angstroms Resolution
7A0F	;	2.7	;	The Crystal Structure of Bovine Thrombin in complex with Hirudin (C22U/C39U) at 2.7 Angstroms Resolution
7A0E	;	1.9	;	The Crystal Structure of Bovine Thrombin in complex with Hirudin (C6U/C14U) at 1.9 Angstroms Resolution
2O9Q	;	1.7	;	The crystal structure of Bovine Trypsin complexed with a small inhibition peptide ORB2K
6E8V	;	3.79	;	The crystal structure of bovine ultralong antibody BOV-1
6E9G	;	2.904	;	The crystal structure of bovine ultralong antibody BOV-2
6E9H	;	2.0	;	The crystal structure of bovine ultralong antibody BOV-3
6E9I	;	2.5	;	The crystal structure of bovine ultralong antibody BOV-4
6E9K	;	2.193	;	The crystal structure of bovine ultralong antibody BOV-5
6E9Q	;	3.4	;	The crystal structure of bovine ultralong antibody BOV-6
6E9U	;	2.295	;	The crystal structure of bovine ultralong antibody BOV-7
8X2S	;	1.9	;	The Crystal Structure of BPGM from Biortus
3K0H	;	2.7	;	The crystal structure of BRCA1 BRCT in complex with a minimal recognition tetrapeptide with an amidated C-terminus
8YHS	;	1.5	;	The Crystal Structure of BRDT from Biortus.
7L1E	;	3.2	;	The Crystal Structure of Bromide-Bound GtACR1
6HC7	;	2.5	;	The crystal structure of BSAP, a zinc aminopeptidase from Bacillus subtilis (medium resolution)
4WBD	;	1.77	;	The crystal structure of BshC from Bacillus subtilis complexed with citrate and ADP
5N2B	;	1.9	;	The crystal structure of Burkholderia pseudomallei antigen and type I fimbria protein BPSL1626.
167D	;	2.3	;	THE CRYSTAL STRUCTURE OF C-C-A-T-T-A-A-T-G-G: IMPLICATIONS FOR BENDING OF B-DNA AT T-A STEPS
8XEY	;	2.65	;	The Crystal Structure of C-terminal kinase domain of RSK2 from Biortus
3F46	;	1.95	;	The Crystal Structure of C176A Mutated [Fe]-Hydrogenase (Hmd) Holoenzyme from Methanocaldococcus jannaschii
3H65	;	2.15	;	The Crystal Structure of C176A Mutated [Fe]-Hydrogenase (Hmd) Holoenzyme in Complex with Methylenetetrahydromethanopterin
3HBP	;	2.4	;	The crystal structure of C185S mutant of recombinant sulfite oxidase with bound substrate, sulfite, at the active site
3ERB	;	1.8	;	The Crystal Structure of C2b, a Fragment of Complement Component C2 produced during C3-convertase Formation
1OJQ	;	1.68	;	The crystal structure of C3stau2 from S. aureus
1OJZ	;	2.02	;	The crystal structure of C3stau2 from S. aureus with NAD
3O27	;	2.8	;	The crystal structure of C68 from the hybrid virus-plasmid pSSVx
1J55	;	2.0	;	The Crystal Structure of Ca+-bound Human S100P Determined at 2.0A Resolution by X-ray
3TWO	;	2.18	;	The crystal structure of CAD from Helicobacter pylori complexed with NADP(H)
2CT9	;	2.2	;	The crystal structure of calcineurin B homologous proein 1 (CHP1)
1D0N	;	2.5	;	THE CRYSTAL STRUCTURE OF CALCIUM-FREE EQUINE PLASMA GELSOLIN.
6N2C	;	1.75	;	The Crystal Structure of Caldicellulosiruptor hydrothermalis Tapirin C-terminal domain
6N2B	;	2.65	;	The Crystal Structure of Caldicellulosiruptor kristjanssonii Tapirin C-terminal domain
4XPK	;	1.95	;	The crystal structure of Campylobacter jejuni N-acetyltransferase PseH
4XPL	;	1.95	;	The crystal structure of Campylobacter jejuni N-acetyltransferase PseH in complex with acetyl coenzyme A
2CYF	;	1.8	;	The Crystal Structure of Canavalia Maritima Lectin (ConM) in Complex with Trehalose and Maltose
3NL2	;	3.08	;	The Crystal Structure of Candida glabrata THI6, a Bifunctional Enzyme involved in Thiamin Biosyhthesis of Eukaryotes
3NL3	;	3.007	;	The Crystal Structure of Candida glabrata THI6, a Bifunctional Enzyme involved in Thiamin Biosyhthesis of Eukaryotes
3NL5	;	3.3	;	The Crystal Structure of Candida glabrata THI6, a Bifunctional Enzyme involved in Thiamin Biosyhthesis of Eukaryotes
3NL6	;	2.612	;	The Crystal Structure of Candida glabrata THI6, a Bifunctional Enzyme involved in Thiamin Biosyhthesis of Eukaryotes
3NM1	;	3.211	;	The Crystal Structure of Candida glabrata THI6, a Bifunctional Enzyme involved in Thiamin Biosyhthesis of Eukaryotes
3NM3	;	3.102	;	The Crystal Structure of Candida glabrata THI6, a Bifunctional Enzyme involved in Thiamin Biosyhthesis of Eukaryotes
1NX4	;	2.4	;	The crystal structure of carbapenem synthase (CarC)
4TX1	;	1.75	;	The crystal structure of carbohydrate acetylesterase family member from Sinorhizobium meliloti
5KDR	;	2.6	;	The crystal structure of carboxyltransferase from Staphylococcus Aureus bound to the antimicrobial agent moiramide B.
6KMH	;	2.4	;	The crystal structure of CASK/Mint1 complex
8WRA	;	1.45	;	The Crystal Structure of CASP1 from Biortus
3EDR	;	2.45	;	The crystal structure of caspase-7 in complex with Acetyl-LDESD-CHO
3WNU	;	2.2	;	The crystal structure of catalase-peroxidase, KatG, from Synechococcus PCC7942
6HW2	;	1.941	;	The Crystal Structure of CaV beta4c in complex with HP1gamma chromo shadow domains
3LHH	;	2.1	;	The crystal structure of CBS domain protein from Shewanella oneidensis MR-1.
4L4O	;	2.05	;	The crystal structure of CbXyn10B in native form
8H7J	;	2.5	;	The crystal structure of CD163 SRCR5-9
2CCH	;	1.7	;	The crystal structure of CDK2 cyclin A in complex with a substrate peptide derived from CDC modified with a gamma-linked ATP analogue
7XQK	;	2.25	;	The Crystal Structure of CDK3 and CyclinE1 Complex from Biortus.
8H4R	;	2.75	;	The Crystal Structure of CDK3 and CyclinE1 Complex with Dinaciclib from Biortus
2E0P	;	1.6	;	The crystal structure of Cel44A
3P6B	;	2.0	;	The crystal structure of CelK CBM4 from Clostridium thermocellum
1XHN	;	1.95	;	The crystal structure of Cellular Repressor of E1A-stimulated Genes (CREG)
3VVG	;	1.9	;	The Crystal Structure of Cellulase-Inhibitor Complex.
8WR8	;	3.1	;	The Crystal Structure of cGAS from Biortus
4D9Y	;	2.1	;	The crystal structure of Chelerythrine bound to DNA d(CGTACG)
3QTK	;	1.849	;	The crystal structure of chemically synthesized VEGF-A
5DE3	;	1.417	;	The Crystal structure of Chlamydomonas reinhardtii Arl3 bound to GppNHp
5UX9	;	2.7	;	The crystal structure of chloramphenicol acetyltransferase from Vibrio fischeri ES114
6PXA	;	1.82	;	The crystal structure of chloramphenicol acetyltransferase-like protein from Vibrio fischeri ES114 in complex with taurocholic acid
2VXH	;	2.1	;	The crystal structure of chlorite dismutase: a detox enzyme producing molecular oxygen
4AWE	;	1.4	;	The Crystal Structure of Chrysonilia sitophila endo-beta-D-1,4- mannanase
8WBU	;	1.7	;	The crystal structure of circular mannose with mutant H247F of the cellobiose 2-epimerase from Caldicellulosiruptor saccharolyticus
6Q38	;	1.74	;	The Crystal structure of CK2a bound to P1-C4
6Q4Q	;	1.45	;	The Crystal structure of CK2a bound to P2-C4
5OSP	;	1.91	;	The crystal structure of CK2alpha in complex with an analogue of compound 1
5OSR	;	1.57	;	The crystal structure of CK2alpha in complex with an analogue of compound 1
5OTP	;	1.57	;	The crystal structure of CK2alpha in complex with an analogue of compound 22
5OTS	;	1.9	;	The crystal structure of CK2alpha in complex with an analogue of compound 22
5OSU	;	1.63	;	The crystal structure of CK2alpha in complex with analogues of compound 1
5OTY	;	1.48	;	The crystal structure of CK2alpha in complex with CAM4712
6EHK	;	1.4	;	The crystal structure of CK2alpha in complex with CAM4712 and compound 37
5OTZ	;	1.46	;	The crystal structure of CK2alpha in complex with compound 1
5OS8	;	1.55	;	The crystal structure of CK2alpha in complex with compound 11
5OTR	;	1.52	;	The crystal structure of CK2alpha in complex with compound 14
6EII	;	1.935	;	The crystal structure of CK2alpha in complex with compound 18
5OT6	;	1.94	;	The crystal structure of CK2alpha in complex with compound 19
5ORH	;	1.75	;	The crystal structure of CK2alpha in complex with compound 2
5OUE	;	2.01	;	The crystal structure of CK2alpha in complex with compound 20
5OUM	;	2.05	;	The crystal structure of CK2alpha in complex with compound 21
5OUU	;	1.81	;	The crystal structure of CK2alpha in complex with compound 22
5OSZ	;	2.0	;	The crystal structure of CK2alpha in complex with compound 23
5OT5	;	1.63	;	The crystal structure of CK2alpha in complex with compound 24
5OTD	;	1.57	;	The crystal structure of CK2alpha in complex with compound 25
5OTH	;	1.69	;	The crystal structure of CK2alpha in complex with compound 26
5OTI	;	1.59	;	The crystal structure of CK2alpha in complex with compound 27
5OTL	;	1.57	;	The crystal structure of CK2alpha in complex with compound 29
5ORJ	;	1.99	;	The crystal structure of CK2alpha in complex with compound 3
6GMD	;	1.66	;	The crystal structure of CK2alpha in complex with compound 3
5OTO	;	1.51	;	The crystal structure of CK2alpha in complex with compound 30
5OYF	;	1.54	;	The crystal structure of CK2alpha in complex with compound 31
6EHU	;	1.95	;	The crystal structure of CK2alpha in complex with compound 32
5OTQ	;	1.38	;	The crystal structure of CK2alpha in complex with compound 33
5OS7	;	1.66	;	The crystal structure of CK2alpha in complex with compound 4
5OQU	;	2.324	;	The crystal structure of CK2alpha in complex with compound 5
5ORK	;	2.143	;	The crystal structure of CK2alpha in complex with compound 6
5OSL	;	1.95	;	The crystal structure of CK2alpha in complex with compound 7
5OUL	;	1.34	;	The crystal structure of CK2alpha in complex with compound 9
2I34	;	2.0	;	The crystal structure of Class C acid phosphatase from Bacillus anthracis with tungstate bound
6NLW	;	1.85	;	The crystal structure of class D carbapenem-hydrolyzing beta-lactamase BlaA from Shewanella oneidensis MR-1
1VGK	;	2.06	;	The crystal structure of class I Major histocompatibility complex, H-2Kd at 2.0 A resolution
7FF4	;	2.19	;	The crystal structure of Clostridium cellulolyticum LacI family transcriptional regulator Ccel_1438
1KHY	;	1.95	;	The Crystal Structure of ClpB N Terminal Domain, Implication to the Peptide Binding Function of ClpB
8XQU	;	1.85	;	The Crystal Structure of ClpC1-NTD from Biortus.
1L4F	;	2.1	;	The crystal structure of CobT complexed with 4,5-dimethyl-1,2-phenylenediamine and nicotinate mononucleotide
1L4E	;	2.0	;	The crystal structure of CobT complexed with alpha-ribazole-5'-phosphate
6OBN	;	2.7	;	The crystal structure of coexpressed SDS22:PP1 complex
5AX6	;	1.88	;	The crystal structure of CofB, the minor pilin subunit of CFA/III from human enterotoxigenic Escherichia coli.
6L19	;	2.13	;	The crystal structure of competence or damage-inducible protein from Enterobacter asburiae
2A9S	;	1.75	;	The crystal structure of competence/damage inducible protein CihA from Agrobacterium tumefaciens
4EW7	;	1.67	;	The crystal structure of conjugative transfer PAS_like domain from Salmonella enterica subsp. enterica serovar Typhimurium
5ICU	;	1.46	;	The crystal structure of CopC from Methylosinus trichosporium OB3b
4D9X	;	2.44	;	The crystal structure of Coptisine bound to DNA d(CGTACG)
3DXU	;	2.2	;	The crystal structure of core JMJD2D complexed with FE and N-oxalylglycine
3CPR	;	2.2	;	The crystal structure of Corynebacterium glutamicum dihydrodipicolinate synthase to 2.2 A resolution
4Q8B	;	1.91	;	The crystal structure of CotA laccase complexed with sinapic acid
7E5X	;	2.19	;	THE CRYSTAL STRUCTURE OF COVID-19 MAIN PROTEASE apo form at 2.2 angstrom
6M03	;	2.0	;	The crystal structure of COVID-19 main protease in apo form
6LZE	;	1.505	;	The crystal structure of COVID-19 main protease in complex with an inhibitor 11a
6M0K	;	1.504	;	The crystal structure of COVID-19 main protease in complex with an inhibitor 11b
6LU7	;	2.16	;	The crystal structure of COVID-19 main protease in complex with an inhibitor N3
7BQY	;	1.7	;	THE CRYSTAL STRUCTURE OF COVID-19 MAIN PROTEASE IN COMPLEX WITH AN INHIBITOR N3 at 1.7 angstrom
7CA8	;	2.45	;	The crystal structure of COVID-19 main protease in complex with an inhibitor Shikonin
7BUY	;	1.6	;	The crystal structure of COVID-19 main protease in complex with carmofur
7C8U	;	2.35	;	The crystal structure of COVID-19 main protease in complex with GC376
7VAH	;	1.491	;	The crystal structure of COVID-19 main protease in H41A mutation
7C2Q	;	1.93	;	The crystal structure of COVID-19 main protease in the apo state
7DAT	;	2.75	;	The crystal structure of COVID-19 main protease treated by AF
7DAU	;	1.72	;	The crystal structure of COVID-19 main protease treated by GA
7C2Y	;	1.91	;	The crystal structure of COVID-2019 main protease in the apo state
1Z7S	;	3.2	;	The crystal structure of coxsackievirus A21
1D4M	;	2.9	;	THE CRYSTAL STRUCTURE OF COXSACKIEVIRUS A9 TO 2.9 A RESOLUTION
7DMY	;	2.0	;	The crystal structure of Cpd7 in complex with BPTF bromodomain
7DN4	;	2.841	;	The crystal structure of Cpd8 in complex with BPTF bromodomain
3B9Q	;	1.75	;	The crystal structure of cpFtsY from Arabidopsis thaliana
5WVW	;	1.8	;	The crystal structure of Cren7 mutant L28A in complex with dsDNA
5WVZ	;	2.3	;	The crystal structure of Cren7 mutant L28F in complex with dsDNA
5WWC	;	1.9	;	The crystal structure of Cren7 mutant L28M in complex with dsDNA
5WVY	;	2.0	;	The crystal structure of Cren7 mutant L28V in complex with dsDNA
6NYR	;	2.431	;	The crystal structure of CroV588 a novel circular LRR protein structure
6NYS	;	3.1	;	The crystal structure of CroV588 a novel circular LRR protein structure
3IUT	;	1.2	;	The Crystal Structure of Cruzain in Complex with a Tetrafluorophenoxymethyl Ketone Inhibitor
3FFS	;	3.19	;	The Crystal Structure of Cryptosporidium parvum Inosine-5'-Monophosphate Dehydrogenase
8GXO	;	1.74	;	The crystal structure of CsFAOMT1 in complex with SAH
8GXN	;	1.34	;	The crystal structure of CsFAOMT2 in complex with SAH
5XYN	;	3.3	;	The crystal structure of Csm2-Psy3-Shu1-Shu2 complex from budding yeast
5DIJ	;	2.7	;	The crystal structure of CT
5DLK	;	1.8	;	The crystal structure of CT mutant
7ELX	;	2.14	;	The crystal structure of CTLA-4 and Fab
5UQP	;	2.4	;	The crystal structure of cupin protein from Rhodococcus jostii RHA1
6LM0	;	2.65	;	The crystal structure of cyanorhodopsin (CyR) N2098R from cyanobacteria Calothrix sp. NIES-2098
6LM1	;	1.9	;	The crystal structure of cyanorhodopsin (CyR) N4075R from cyanobacteria Tolypothrix sp. NIES-4075
8H79	;	2.07	;	The crystal structure of cyanorhodopsin-II (CyR-II) P7104R from Nodosilinea nodulosa PCC 7104
3KBR	;	1.659	;	The crystal structure of cyclohexadienyl dehydratase precursor from Pseudomonas aeruginosa PA01
6K0F	;	1.634	;	The crystal structure of cyclopenin-bound AsqJ quinary complex
5Z9O	;	2.7	;	The crystal structure of Cyclopropane-fatty-acyl-phospholipid synthase from Lactobacillus acidophilus
5YQA	;	1.38	;	The crystal structure of CYP199A4 binding with 4-n-Propyl benzoic acid
5YQH	;	2.3	;	The crystal structure of CYP199A4 binding with 4-n-Propyl benzoic acid
7TRT	;	1.42	;	The crystal structure of CYP199A4 bound to 4-(furan-2-yl)benzoic acid
7R8S	;	1.366	;	The crystal structure of CYP199A4 bound to 4-n-propylbenzoic acid
7TND	;	1.825	;	The crystal structure of CYP199A4 bound to 4-phenoxybenzoic acid
2OH7	;	2.45	;	The Crystal Structure of Cypovirus Polyhedra containing the Human ZIP-kinase
4Q31	;	2.099	;	The crystal structure of cystathione gamma lyase (CalE6) from Micromonospora echinospora
1R5T	;	2.0	;	The Crystal Structure of Cytidine Deaminase CDD1, an Orphan C to U editase from Yeast
6K63	;	2.073	;	The crystal structure of cytidine deaminase from Klebsiella pneumoniae
2J8W	;	1.29	;	The crystal structure of cytochrome c' from Rubrivivax gelatinosus at 1.3 A Resolution and pH 8.0
2J9B	;	1.5	;	THE CRYSTAL STRUCTURE OF CYTOCHROME C' FROM RUBRIVIVAX GELATINOSUS AT 1.5 A RESOLUTION AND PH 6.3
4UBS	;	2.2	;	The crystal structure of cytochrome P450 105D7 from Streptomyces avermitilis in complex with Diclofenac
1UMO	;	2.59	;	The crystal structure of cytoglobin: the fourth globin type discovered in man
1OMK	;	1.3	;	The Crystal Structure of d(CACG(5IU)G)
1VT5	;	2.25	;	THE CRYSTAL STRUCTURE OF D(CCCCGGGG): A NEW A-FORM VARIANT WITH AN EXTENDED BACKBONE CONFORMATION
2ANA	;	2.5	;	THE CRYSTAL STRUCTURE OF D(G-G-G-G-C-C-C-C). A MODEL FOR POLY(DG).POLY(DC)
1DN6	;	3.0	;	THE CRYSTAL STRUCTURE OF D(GGATGGGAG). AN ESSENTIAL PART OF THE BINDING SITE FOR TRANSCRIPTION FACTOR IIIA
1JTL	;	1.85	;	The crystal structure of d(GGCCAATTGG) Complexed with Distamycin
1K2Z	;	2.38	;	The Crystal Structure of d(GGCCAATTGG) Complexed with Distamycin.
5ANA	;	2.25	;	THE CRYSTAL STRUCTURE OF D(GTACGTAC) AT 2.25 ANGSTROMS RESOLUTION. ARE THE A-DNA'S ALWAYS UNWOUND APPROXIMATELY 10 DEGREES AT THE C-G STEPS
5H01	;	2.194	;	The crystal structure of D-2-halacid dehalogenase mutant
5H00	;	2.64	;	The crystal structure of D-2-haloacid dehalogenase
6DGI	;	2.3	;	The crystal structure of D-alanyl-alanine synthetase A from Vibrio cholerae O1 biovar eltor str. N16961
4RYE	;	1.901	;	The crystal structure of D-ALANYL-D-ALANINE CARBOXYPEPTIDASE from Mycobacterium tuberculosis H37Rv
2DNS	;	2.4	;	The crystal structure of D-amino acid amidase from Ochrobactrum anthropi SV3 complexed with D-Phenylalanine
2EFU	;	2.3	;	The crystal structure of D-amino acid amidase from Ochrobactrum anthropi SV3 complexed with L-phenylalanine
2EFX	;	2.2	;	The crystal structure of D-amino acid amidase from Ochrobactrum anthropi SV3 complexed with L-phenylalanine amide
3V2H	;	3.0	;	The crystal structure of D-beta-hydroxybutyrate dehydrogenase from Sinorhizobium meliloti
3WX0	;	3.3	;	The crystal structure of D-lactate dehydrogenase from Escherichia coli
3WFI	;	1.997	;	The crystal structure of D-mandelate dehydrogenase
7E9W	;	2.1	;	The Crystal Structure of D-psicose-3-epimerase from Biortus.
2FLI	;	1.8	;	The crystal structure of D-ribulose 5-phosphate 3-epimerase from Streptococus pyogenes complexed with D-xylitol 5-phosphate
7TQM	;	1.438	;	The crystal structure of D251N CYP199A4 bound to 4-methylthiobenzoic acid
3QO4	;	2.2	;	The Crystal Structure of Death Receptor 6
3M2T	;	2.3	;	The crystal structure of dehydrogenase from Chromobacterium violaceum
3UOE	;	2.311	;	The crystal structure of dehydrogenase from Sinorhizobium meliloti
2OZE	;	1.83	;	The Crystal structure of Delta protein of pSM19035 from Streptoccocus pyogenes
7PAE	;	1.85	;	The crystal structure of Deltarasin in complex with PDE6D
5VCO	;	2.74	;	THE CRYSTAL STRUCTURE OF DER P 1 ALLERGEN COMPLEXED WITH FAB FRAGMENT OF MAB 10B9
5VCN	;	3.0	;	THE CRYSTAL STRUCTURE OF DER P 1 ALLERGEN COMPLEXED WITH FAB FRAGMENT OF MAB 5H8
2V4J	;	2.1	;	THE CRYSTAL STRUCTURE OF Desulfovibrio vulgaris DISSIMILATORY SULFITE REDUCTASE BOUND TO DsrC PROVIDES NOVEL INSIGHTS INTO THE MECHANISM OF SULFATE RESPIRATION
8HEF	;	1.51	;	The Crystal structure of deuterated S-217622 (Ensitrelvir) bound to the main protease (3CLpro/Mpro) of SARS-CoV-2
5O8R	;	2.8	;	The crystal structure of DfoA bound to FAD and NADP; the desferrioxamine biosynthetic pathway cadaverine monooxygenase from the fire blight disease pathogen Erwinia amylovora
5O8P	;	2.75	;	The crystal structure of DfoA bound to FAD, the desferrioxamine biosynthetic pathway cadaverine monooxygenase from the fire blight disease pathogen Erwinia amylovora
5O7O	;	2.11	;	The crystal structure of DfoC, the desferrioxamine biosynthetic pathway acetyltransferase/Non-Ribosomal Peptide Synthetase (NRPS)-Independent Siderophore (NIS) from the fire blight disease pathogen Erwinia amylovora
5O5C	;	2.1	;	The crystal structure of DfoJ, the desferrioxamine biosynthetic pathway lysine decarboxylase from the fire blight disease pathogen Erwinia amylovora
8ILI	;	1.9	;	The crystal structure of dG(Se-Rp)-DNA:Pol X product binary complex
8ILH	;	2.1	;	The crystal structure of dG(Se-Sp)-DNA:Pol X product binary complex
8ILG	;	1.805	;	The crystal structure of dG-DNA:Pol X product binary complex
8ILE	;	3.0	;	The crystal structure of dGTPalphaSe-Rp:DNApre-II:Pol X substrate ternary complex
8ILF	;	2.3	;	The crystal structure of dGTPalphaSe-Sp:DNApre-II:Pol X substrate ternary complex
5YM0	;	1.842	;	The crystal structure of DHAD
4H01	;	2.0	;	The crystal structure of di-Zn dihydropyrimidinase from Tetraodon nigroviridis
4LCS	;	2.2	;	The crystal structure of di-Zn dihydropyrimidinase in complex with hydantoin
4LCR	;	2.0	;	The crystal structure of di-Zn dihydropyrimidinase in complex with NCBA
4LCQ	;	1.81	;	The crystal structure of di-Zn dihydropyrimidinase in complex with NCBI
1ZC9	;	2.0	;	The crystal structure of dialkylglycine decarboxylase complex with pyridoxamine 5-phosphate
6LT9	;	1.801	;	The crystal structure of diamondback moth ryanodine receptor SPRY1 domain
4WFW	;	2.05	;	The crystal structure of Dickeya dadantii GspB from the type 2 secretion system
1H76	;	2.15	;	The crystal structure of diferric porcine serum transferrin
3QY9	;	1.8	;	The Crystal Structure of Dihydrodipicolinate reductase from Staphylococcus aureus
2R8W	;	1.8	;	The crystal structure of dihydrodipicolinate synthase (Atu0899) from Agrobacterium tumefaciens str. C58
2HMC	;	1.9	;	The Crystal Structure of Dihydrodipicolinate Synthase DapA from Agrobacterium tumefaciens
1ZY8	;	2.59	;	The crystal structure of dihydrolipoamide dehydrogenase and dihydrolipoamide dehydrogenase-binding protein (didomain) subcomplex of human pyruvate dehydrogenase complex.
5NNM	;	1.9	;	The crystal structure of dimeric LL-37
4PQQ	;	1.55	;	The crystal structure of discoidin domain from muskelin
3FK8	;	1.3	;	The crystal structure of disulphide isomerase from Xylella fastidiosa Temecula1
2FEX	;	1.7	;	The Crystal Structure of DJ-1 Superfamily Protein Atu0886 from Agrobacterium tumefaciens
1UCF	;	1.95	;	The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease
2QLC	;	2.3	;	The crystal structure of DNA repair protein RadC from Chlorobium tepidum TLS
4DYU	;	2.75	;	The crystal structure of DNA starvation/stationary phase protection protein Dps from Yersinia pestis KIM 10
6OF5	;	2.3	;	The crystal structure of dodecyloxy(naphthalen-1-yl)methylphosphonic acid in complex with red kidney bean purple acid phosphatase
7UCS	;	1.92	;	The Crystal Structure of Domain-Swapped Dimer Q108K:T51D:A28C:L36C:F57:H:H:H:R58 Mutant of hCRBPII with Histidine Insertion in the Hinge Loop Region at 1.92 Angstrom Resolution
7UCN	;	1.96	;	The Crystal Structure of Domain-Swapped Dimer Q108K:T51D:A28C:L36C:F57:H:R58 Mutant of hCRBPII with a Histidine Insertion in the Hinge Loop Region at 1.96 Angstrom Resolution
7UD3	;	2.37	;	The Crystal Structure of Domain-Swapped Dimer Q108K:T51D:A28C:L36C:F57:W:W:W:R58 Mutant of hCRBPII with a Histidine Insertion in the Hinge Loop Region at 2.36 Angstrom Resolution
7MFZ	;	2.49	;	The Crystal Structure of Domain-Swapped Trimer Q108K:K40D:T53A:R58L:Q38F:Q4F Mutant of HCRBPII Bound with LizFluor3 Chromophore Showing Excited State Intermolecular Proton Transfer
6VIS	;	2.79	;	The Crystal Structure of Domain-Swapped Trimer Q108K:K40D:T53A:R58L:Q38F:Q4F:V62E Variant of HCRBPII
6WP0	;	2.78	;	The Crystal Structure of Domain-Swapped Trimer Q108K:T51D variant of HCRBPII
1DPS	;	1.6	;	THE CRYSTAL STRUCTURE OF DPS, A FERRITIN HOMOLOG THAT BINDS AND PROTECTS DNA
2JH3	;	1.9	;	The crystal structure of DR2241 from Deinococcus radiodurans at 1.9 A resolution reveals a multi-domain protein with structural similarity to chelatases but also with two additional novel domains
3ODN	;	2.4	;	The crystal structure of Drosophila Dally-Like Protein core domain
1NLQ	;	1.5	;	The crystal structure of Drosophila NLP-core provides insight into pentamer formation and histone binding
1KEU	;	2.4	;	The crystal structure of dTDP-D-glucose 4,6-dehydratase (RmlB) from Salmonella enterica serovar Typhimurium with dTDP-D-glucose bound
1KEW	;	1.8	;	The crystal structure of dTDP-D-glucose 4,6-dehydratase (RmlB) from Salmonella enterica serovar Typhimurium with thymidine diphosphate bound
1KER	;	2.2	;	The crystal structure of dTDP-D-glucose 4,6-dehydratase (RmlB) from Streptococcus suis with dTDP-D-glucose bound
1KEP	;	1.8	;	The crystal structure of dTDP-D-glucose 4,6-dehydratase (RmlB) from Streptococcus suis with dTDP-xylose bound
1KET	;	1.8	;	The crystal structure of dTDP-D-glucose 4,6-dehydratase (RmlB) from Streptococcus suis with thymidine diphosphate bound
1G1A	;	2.47	;	THE CRYSTAL STRUCTURE OF DTDP-D-GLUCOSE 4,6-DEHYDRATASE (RMLB)FROM SALMONELLA ENTERICA SEROVAR TYPHIMURIUM
2R5R	;	3.05	;	The crystal structure of DUF198 from Nitrosomonas europaea ATCC 19718
7PAD	;	1.49	;	The crystal structure of DW-0254 in complex with PDE6D
4MQ1	;	2.35	;	The crystal structure of DYRK1a with a bound pyrido[2,3-d]pyrimidine inhibitor
4MQ2	;	2.8	;	The crystal structure of DYRK1a with a bound pyrido[2,3-d]pyrimidine inhibitor
5MFT	;	1.59	;	The crystal structure of E. coli Aminopeptidase N in complex with 7-amino-1-bromo-4-phenyl-5,7,8,9-tetrahydrobenzocyclohepten-6-one
5MFS	;	1.57	;	The crystal structure of E. coli Aminopeptidase N in complex with 7-amino-4-phenyl-5,7,8,9-tetrahydrobenzocyclohepten-6-one
5MFR	;	1.4	;	The crystal structure of E. coli Aminopeptidase N in complex with 7-amino-5,7,8,9-tetrahydrobenzocyclohepten-6-one
2EG8	;	2.2	;	The crystal structure of E. coli dihydroorotase complexed with 5-fluoroorotic acid
2EG7	;	2.0	;	The crystal structure of E. coli dihydroorotase complexed with HDDP
1ETV	;	2.0	;	THE CRYSTAL STRUCTURE OF E. COLI FIS MUTANT G72A
1ETW	;	2.0	;	THE CRYSTAL STRUCTURE OF E. COLI FIS MUTANT G72D
1ETK	;	2.1	;	THE CRYSTAL STRUCTURE OF E. COLI FIS MUTANT Q68A
1ETX	;	1.9	;	THE CRYSTAL STRUCTURE OF E. COLI FIS MUTANT Q74A
1ETO	;	1.9	;	THE CRYSTAL STRUCTURE OF E. COLI FIS MUTANT R71L
1ETQ	;	2.8	;	THE CRYSTAL STRUCTURE OF E. COLI FIS MUTANT R71Y
1SQF	;	2.1	;	The crystal structure of E. coli Fmu binary complex with S-Adenosylmethionine at 2.1 A resolution
1OH5	;	2.9	;	THE CRYSTAL STRUCTURE OF E. COLI MUTS BINDING TO DNA WITH A C:A MISMATCH
1OH7	;	2.5	;	THE CRYSTAL STRUCTURE OF E. COLI MUTS BINDING TO DNA WITH A G:G MISMATCH
1E3M	;	2.2	;	The crystal structure of E. coli MutS binding to DNA with a G:T mismatch
1OH6	;	2.4	;	THE CRYSTAL STRUCTURE OF E. COLI MUTS BINDING TO DNA WITH AN A:A MISMATCH
1OH8	;	2.9	;	THE CRYSTAL STRUCTURE OF E. COLI MUTS BINDING TO DNA WITH AN UNPAIRED THYMIDINE
1DJ0	;	1.5	;	THE CRYSTAL STRUCTURE OF E. COLI PSEUDOURIDINE SYNTHASE I AT 1.5 ANGSTROM RESOLUTION
1ETY	;	2.0	;	THE CRYSTAL STRUCTURE OF E. COLI WILD-TYPE FIS
2O99	;	1.7	;	The crystal structure of E.coli IclR C-terminal fragment in complex with glyoxylate
2CMD	;	1.87	;	THE CRYSTAL STRUCTURE OF E.COLI MALATE DEHYDROGENASE: A COMPLEX OF THE APOENZYME AND CITRATE AT 1.87 ANGSTROMS RESOLUTION
1G2A	;	1.75	;	THE CRYSTAL STRUCTURE OF E.COLI PEPTIDE DEFORMYLASE COMPLEXED WITH ACTINONIN
3K9O	;	1.8	;	The crystal structure of E2-25K and UBB+1 complex
3K9P	;	2.8	;	The crystal structure of E2-25K and ubiquitin complex
2Q8K	;	1.6	;	The crystal structure of Ebp1
4PXD	;	2.2	;	The crystal structure of EcAAH in complex with allantoate
1O8V	;	1.6	;	The crystal structure of Echinococcus granulosus fatty-acid-binding protein 1
1RVE	;	2.5	;	THE CRYSTAL STRUCTURE OF ECORV ENDONUCLEASE AND OF ITS COMPLEXES WITH COGNATE AND NON-COGNATE DNA FRAGMENTS
2RVE	;	3.0	;	THE CRYSTAL STRUCTURE OF ECORV ENDONUCLEASE AND OF ITS COMPLEXES WITH COGNATE AND NON-COGNATE DNA SEGMENTS
4RVE	;	3.0	;	THE CRYSTAL STRUCTURE OF ECORV ENDONUCLEASE AND OF ITS COMPLEXES WITH COGNATE AND NON-COGNATE DNA SEGMENTS
4V5P	;	3.1	;	The crystal structure of EF-Tu and A9C-tRNA-Trp bound to a near- cognate codon on the 70S ribosome
7VMX	;	2.8	;	The Crystal Structure of EF-Tu and EF-Ts complex from Mycobacterium tuberculosis
4V5S	;	3.1	;	The crystal structure of EF-Tu and G24A-tRNA-Trp bound to a cognate codon on the 70S ribosome.
4V5Q	;	3.1	;	The crystal structure of EF-Tu and G24A-tRNA-Trp bound to a near- cognate codon on the 70S ribosome
7VOK	;	3.4	;	The Crystal structure of EF-Tu and GDP from Mycobacterium tuberculosis
4V5R	;	3.1	;	The crystal structure of EF-Tu and Trp-tRNA-Trp bound to a cognate codon on the 70S ribosome.
7VRA	;	2.41	;	The crystal structure of EGFR T790M/C797S with the inhibitor HC5476
7VRE	;	2.507	;	The crystal structure of EGFR T790M/C797S with the inhibitor HCD2892
8XPT	;	3.35	;	The Crystal Structure of EHMT1 from Biortus.
2J0U	;	3.0	;	The crystal structure of eIF4AIII-Barentsz complex at 3.0 A resolution
3EX7	;	2.301	;	The crystal structure of EJC in its transition state
5JW9	;	2.003	;	The Crystal Structure of ELL2 Oclludin Domain and AFF4 peptide
1EFT	;	2.5	;	THE CRYSTAL STRUCTURE OF ELONGATION FACTOR EF-TU FROM THERMUS AQUATICUS IN THE GTP CONFORMATION
1EFG	;	2.7	;	THE CRYSTAL STRUCTURE OF ELONGATION FACTOR G COMPLEXED WITH GDP, AT 2.7 ANGSTROMS RESOLUTION
6AKJ	;	2.7	;	The crystal structure of EMC complex
2VUN	;	1.89	;	The Crystal Structure of Enamidase at 1.9 A Resolution - A new Member of the Amidohydrolase Superfamily
3W8W	;	1.95	;	The crystal structure of EncM
6FY8	;	3.0	;	The crystal structure of EncM bromide soak
6FY9	;	3.65	;	The crystal structure of EncM complex with xenon under 15 bars Xe pressure
6FOW	;	2.04	;	The crystal structure of EncM complexed with dioxygen under 10 bar of oxygen pressure.
6FOQ	;	1.386	;	The crystal structure of EncM complexed with dioxygen under 15 bar of oxygen pressure.
6FP3	;	1.976	;	The crystal structure of EncM complexed with dioxygen under 5 bar of oxygen pressure.
6FYE	;	2.3	;	The crystal structure of EncM H138T mutant
6FYB	;	1.882	;	The crystal structure of EncM L144M mutant
6FYC	;	2.0	;	The crystal structure of EncM L144M mutant complex with dioxygen under 15 bars O2 pressure
6FYD	;	1.76	;	The crystal structure of EncM T139V mutant
6FYA	;	2.6	;	The crystal structure of EncM under anaerobic conditions
6FYF	;	2.2	;	The crystal structure of EncM V135M mutant
6FYG	;	2.55	;	The crystal structure of EncM V135T mutant
5CD2	;	1.55	;	The crystal structure of endo-1,4-D-glucanase from Vibrio fischeri ES114
5C0P	;	1.532	;	The crystal structure of endo-arabinase from Bacteroides thetaiotaomicron VPI-5482
1G87	;	1.6	;	THE CRYSTAL STRUCTURE OF ENDOGLUCANASE 9G FROM CLOSTRIDIUM CELLULOLYTICUM
1GA2	;	1.7	;	THE CRYSTAL STRUCTURE OF ENDOGLUCANASE 9G FROM CLOSTRIDIUM CELLULOLYTICUM COMPLEXED WITH CELLOBIOSE
5GY3	;	1.77	;	The crystal structure of endoglucanase Cel10, a family 8 glycosyl hydrolase from Klebsiella pneumoniae
4RUW	;	1.281	;	The crystal structure of endonuclease/exonuclease/phosphatase from Beutenbergia cavernae DSM 12333
1W7P	;	3.6	;	The crystal structure of endosomal complex ESCRT-II (VPS22/VPS25/VPS36)
4XPU	;	2.4	;	The crystal structure of EndoV from E.coli
6H08	;	1.9	;	The crystal structure of engineered cytochrome c peroxidase from Saccharomyces cerevisiae with a His175Me-His proximal ligand substitution
6Y1T	;	1.5	;	The crystal structure of engineered cytochrome c peroxidase from Saccharomyces cerevisiae with a Trp51 to S-Trp51 modification
6Y2Y	;	1.7	;	The crystal structure of engineered cytochrome c peroxidase from Saccharomyces cerevisiae with Trp51 to S-Trp51 and Trp191Phe modifications
2FKG	;	2.4	;	The Crystal Structure of Engineered OspA
2FKJ	;	3.1	;	The crystal structure of engineered OspA
2HKD	;	1.6	;	The crystal structure of engineered OSPA
4JJT	;	2.496	;	The crystal structure of enoyl-CoA hydratase from Mycobacterium tuberculosis H37Rv
3OSS	;	2.63	;	The crystal structure of enterotoxigenic Escherichia coli GspC-GspD complex from the type II secretion system
8I34	;	2.44	;	The crystal structure of EPD-BCP1 from a marine sponge
8XPV	;	1.55	;	The Crystal Structure of EphA2 from Biortus.
7LKI	;	2.0	;	The crystal structure of Epitope III of HCV envelop protein E2 in complex with antibody 1H8
2E3J	;	2.1	;	The crystal structure of epoxide hydrolase B (Rv1938) from mycobacterium tuberculosis at 2.1 angstrom
5EBX	;	2.0	;	THE CRYSTAL STRUCTURE OF ERABUTOXIN A AT 2.0 ANGSTROMS RESOLUTION
4XZ8	;	2.35	;	The crystal structure of Erve virus nucleoprotein
4XZA	;	1.8	;	The crystal structure of Erve virus nucleoprotein
7OSO	;	1.4	;	The crystal structure of Erwinia tasmaniensis levansucrase in complex with (S)-1,2,4-butanentriol
7EN6	;	2.276	;	The crystal structure of Escherichia coli MurR in apo form
7EN5	;	1.25	;	The crystal structure of Escherichia coli MurR in complex with N-acetylglucosamine-6-phosphate
7EN7	;	1.22	;	The crystal structure of Escherichia coli MurR in complex with N-acetylmuramic-acid-6-phosphate
2C7B	;	2.3	;	The Crystal Structure of EstE1, a New Thermophilic and Thermostable Carboxylesterase Cloned from a Metagenomic Library
1G24	;	1.7	;	THE CRYSTAL STRUCTURE OF EXOENZYME C3 FROM CLOSTRIDIUM BOTULINUM
6J0T	;	2.8	;	The crystal structure of exoinulinase INU1
7TNU	;	1.584	;	The crystal structure of F298V CYP199A4 bound to 4-cyclohexylbenzoic acid
7UDF	;	1.54	;	The crystal structure of F298V CYP199A4 bound to 4-n-propylbenzoic acid
7TNF	;	1.539	;	The crystal structure of F298V CYP199A4 bound to 4-phenylbenzoic acid
8ASR	;	1.66	;	The Crystal structure of F46Y mutant of apo agroavidin
8ASS	;	2.12	;	The Crystal structure of F46Y mutant of the agroavidin-biotin complex
3S8M	;	1.6	;	The Crystal Structure of FabV
2PGO	;	1.26	;	The crystal structure of FAD and ThDP dependent Cyclohexane-1,2-dione Hydrolase (Cdh) from Azoarcus sp. strain 22Lin
2PGN	;	1.2	;	The crystal structure of FAD and ThDP-dependent Cyclohexane-1,2-dione Hydrolase in Complex with Cyclohexane-1,2-dione
8XOX	;	1.9	;	The Crystal Structure of FAK2 from Biortus.
7CZJ	;	1.495	;	The Crystal Structure of Family 20 CBM of Maltotetraose-forming Amylase from Pseudomonas Saccharophila STB07
3T9G	;	1.5	;	The crystal structure of family 3 pectate lyase from Caldicellulosiruptor bescii
7T7Z	;	1.46	;	The crystal structure of family 8 carbohydrate-binding module from Dictyostelium discoideum
7T7Y	;	1.81	;	The crystal structure of family 8 carbohydrate-binding module from Dictyostelium discoideum complexed with iodine atoms
4DRB	;	2.634	;	The crystal structure of FANCM bound MHF complex
3KXW	;	1.851	;	The crystal structure of fatty acid AMP ligase from Legionella pneumophila
3LNV	;	2.0	;	The crystal structure of fatty acyl-adenylate ligase from L. pneumophila in complex with acyl adenylate and pyrophosphate
6UVX	;	2.3	;	The crystal structure of FbiA from Mycobacterium Smegmatis, Apo state
6UW7	;	2.342	;	The crystal structure of FbiA from Mycobacterium smegmatis, Dehydro-F420-0 bound form
6UW1	;	2.205	;	The crystal structure of FbiA from Mycobacterium Smegmatis, Fo bound form
6UW5	;	2.2	;	The crystal structure of FbiA from Mycobacterium smegmatis, GDP and Fo bound form
6UW3	;	2.4	;	The crystal structure of FbiA from Mycobacterium Smegmatis, GDP Bound form
2V2K	;	1.6	;	THE CRYSTAL STRUCTURE OF FDXA, A 7FE FERREDOXIN FROM MYCOBACTERIUM SMEGMATIS
2OIF	;	1.8	;	The crystal structure of ferric cyanide bound barley hexacoordinate hemoglobin.
3QZ3	;	2.099	;	The crystal structure of ferritin from Vibrio cholerae O1 biovar El Tor str. N16961
8X2T	;	2.9	;	The Crystal Structure of FES from Biortus.
5JKG	;	2.352	;	The crystal structure of FGFR4 kinase domain in complex with LY2874455
7VJL	;	2.90017	;	The crystal structure of FGFR4 kinase domain in complex with N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-(2,2,2-trifluoroacetyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
6E4V	;	2.0	;	The Crystal Structure of FhuE from E. coli in complex with its substrate Coprogen
1YCP	;	2.5	;	THE CRYSTAL STRUCTURE OF FIBRINOGEN-AA PEPTIDE 1-23 (F8Y) BOUND TO BOVINE THROMBIN EXPLAINS WHY THE MUTATION OF PHE-8 TO TYROSINE STRONGLY INHIBITS NORMAL CLEAVAGE AT ARGININE-16
1QQK	;	3.1	;	THE CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR 7 (KERATINOCYTE GROWTH FACTOR)
1QQL	;	2.3	;	THE CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR 7/1 CHIMERA
7WW0	;	1.85	;	The crystal structure of FinI complex with SAH
7WUY	;	1.84	;	The crystal structure of FinI in complex with SAM and fischerin
1F36	;	2.65	;	THE CRYSTAL STRUCTURE OF FIS MUTANT K36E REVEALS THAT THE TRANSACTIVATION REGION OF THE FIS PROTEIN CONTAINS EXTENDED MOBILE BETA-HAIRPIN ARMS
2QKL	;	2.33	;	The crystal structure of fission yeast mRNA decapping enzyme Dcp1-Dcp2 complex
2QKM	;	2.8	;	The crystal structure of fission yeast mRNA decapping enzyme Dcp1-Dcp2 complex
2D36	;	2.3	;	The Crystal Structure of Flavin Reductase HpaC
2D37	;	1.7	;	The Crystal Structure of Flavin Reductase HpaC complexed with NAD+
2D38	;	2.05	;	The Crystal Structure of Flavin Reductase HpaC complexed with NADP+
4HEQ	;	1.3	;	The crystal structure of flavodoxin from Desulfovibrio gigas
3OZV	;	2.4	;	The Crystal Structure of flavohemoglobin from R. eutrophus in complex with econazole
3OZW	;	2.3	;	The Crystal Structure of flavohemoglobin from R. eutrophus in complex with ketoconazole
3OZU	;	2.0	;	The Crystal Structure of flavohemoglobin from R. eutrophus in complex with miconazole
5KBN	;	2.48	;	The crystal structure of fluoride channel Fluc Ec2 F80I Mutant
5KOM	;	2.69	;	The crystal structure of fluoride channel Fluc Ec2 F83I Mutant
6BX5	;	3.0	;	The crystal structure of fluoride channel Fluc Ec2 with Monobody S12
6BX4	;	2.55	;	The crystal structure of fluoride channel Fluc Ec2 with Monobody S9
3U7I	;	1.75	;	The crystal structure of FMN-dependent NADH-azoreductase 1 (GBAA0966) from Bacillus anthracis str. Ames Ancestor
7E6V	;	1.832	;	The crystal structure of foot-and-mouth disease virus(FMDV) 2C protein 97-318aa
3M1R	;	2.199	;	The crystal structure of formimidoylglutamase from Bacillus subtilis subsp. subtilis str. 168
1EG7	;	2.5	;	THE CRYSTAL STRUCTURE OF FORMYLTETRAHYDROFOLATE SYNTHETASE FROM MOORELLA THERMOACETICA
3Q94	;	2.301	;	The crystal structure of fructose 1,6-bisphosphate aldolase from Bacillus anthracis str. 'Ames Ancestor'
1FBA	;	1.9	;	THE CRYSTAL STRUCTURE OF FRUCTOSE-1,6-BISPHOSPHATE ALDOLASE FROM DROSOPHILA MELANOGASTER AT 2.5 ANGSTROMS RESOLUTION
4WCT	;	1.67	;	The crystal structure of Fructosyl amine: oxygen oxidoreductase (Amadoriase I) from Aspergillus fumigatus
4XWZ	;	1.9	;	The crystal structure of Fructosyl amine: oxygen oxidoreductase (Amadoriase I) from Aspergillus fumigatus in complex with the substrate fructosyl lysine
7ETL	;	1.99213	;	The crystal structure of FtmOx1-Y68F
3MVK	;	1.65	;	The Crystal Structure of FucU from Bifidobacterium longum to 1.65A
4GOJ	;	2.1	;	The Crystal Structure of full length Arl3GppNHp in complex with UNC119a
2Q9Q	;	2.36	;	The crystal structure of full length human GINS complex
6LOL	;	2.75	;	The crystal structure of full length IpaH9.8
3EFF	;	3.8	;	The Crystal Structure of Full-Length KcsA in its Closed Conformation
3OI8	;	1.989	;	The crystal structure of functionally unknown conserved protein domain from Neisseria meningitidis MC58
3NYM	;	1.9	;	The crystal structure of functionally unknown protein from Neisseria meningitidis MC58
7CJ1	;	3.0	;	The crystal structure of FXIa serine protease domain in complex with benzamidine
5UWG	;	2.56	;	The crystal structure of Fz4-CRD in complex with palmitoleic acid
3GXK	;	1.9	;	The crystal structure of g-type lysozyme from Atlantic cod (Gadus morhua L.) in complex with NAG oligomers sheds new light on substrate binding and the catalytic mechanism. Native structure to 1.9
3GXR	;	1.7	;	The crystal structure of g-type lysozyme from Atlantic cod (Gadus morhua L.) in complex with NAG oligomers sheds new light on substrate binding and the catalytic mechanism. Structure with NAG to 1.7
2G2Q	;	2.5	;	The crystal structure of G4, the poxviral disulfide oxidoreductase essential for cytoplasmic disulfide bond formation
4GXL	;	2.023	;	The crystal structure of Galectin-8 C-CRD in complex with NDP52
4LIH	;	1.85	;	The crystal structure of Gamma-glutamyl-gamma-aminobutyraldehyde dehydrogenase from Burkholderia cenocepacia J2315
6K2D	;	3.6	;	The crystal structure of GBP1 with LRR domain of IpaH9.8
3FAX	;	2.4	;	The crystal structure of GBS pullulanase SAP in complex with maltotetraose
1Q8D	;	1.8	;	The crystal structure of GDNF family co-receptor alpha 1 domain 3
2OEB	;	1.66	;	The crystal structure of gene product Af1862 from Archaeoglobus fulgidus
2ODF	;	1.9	;	The crystal structure of gene product Atu2144 from Agrobacterium tumefaciens
7AHW	;	1.952	;	The crystal structure of gene product PA4063 from Pseudomonas aeruginosa
7ALY	;	2.7	;	The crystal structure of gene product PA4063 from Pseudomonas aeruginosa in complex with Au(I) for phasing
7AMX	;	2.85	;	The crystal structure of gene product PA4063 from Pseudomonas aeruginosa in complex with zinc
7BGO	;	3.301	;	The crystal structure of gene product PA4063 from Pseudomonas aeruginosa in complex with Zn (space group P65)
2OOI	;	2.6	;	The crystal structure of gene product SA0254 from Staphylocococcus aureus subsp. aureus N315
2OD0	;	1.95	;	The crystal structure of gene product VP1028 from Vibrio parahaemolyticus
2HLY	;	1.6	;	The crystal structure of genomics APC5867
3A0F	;	2.5	;	The crystal structure of Geotrichum sp. M128 xyloglucanase
3NPK	;	1.5	;	The crystal structure of geranyltranstransferase from Campylobacter jejuni
5Y1I	;	2.0	;	The crystal structure of GfsF
3POP	;	1.651	;	The crystal structure of GilR, an oxidoreductase that catalyzes the terminal step of gilvocarcin biosynthesis
3PZ6	;	2.6	;	The crystal structure of GlLeuRS-CP1
3UBB	;	2.601	;	The crystal structure of GlpG in complex with a phosphonofluoridate inhibitor
4GG2	;	2.21	;	The crystal structure of glutamate-bound human gamma-glutamyltranspeptidase 1
1KXJ	;	2.8	;	The Crystal Structure of Glutamine Amidotransferase from Thermotoga maritima
4S17	;	2.3	;	The crystal structure of glutamine synthetase from Bifidobacterium adolescentis ATCC 15703
3NIV	;	2.3	;	The crystal structure of Glutathione S-transferase from Legionella pneumophila
4I97	;	2.15	;	The crystal structure of glutathione S-transferase SnigGSTD1A from Scaptomyza nigrita in complex with glutathione
1OBF	;	1.7	;	The crystal structure of Glyceraldehyde 3-phosphate Dehydrogenase from Alcaligenes xylosoxidans at 1.7A resolution.
4DIB	;	2.55	;	The crystal structure of glyceraldehyde-3-phosphate dehydrogenase from Bacillus anthracis str. Sterne
3GG4	;	2.0	;	The crystal structure of glycerol kinase from Yersinia pseudotuberculosis
2G9R	;	2.07	;	The crystal structure of glycogen phosphorylase b in complex with (3R,4R,5R)-5-hydroxymethyl-1-(3-phenylpropyl)-piperidine-3,4-diol
3S0J	;	2.0	;	The crystal structure of glycogen phosphorylase b in complex with 2,5-dihydroxy-4-(beta-D-glucopyranosyl)-chlorobenzene
2OFF	;	2.2	;	The crystal structure of Glycogen Phosphorylase b in complex with a potent allosteric inhibitor
2G9U	;	2.15	;	The crystal structure of glycogen phosphorylase in complex with (3R,4R,5R)-5-hydroxymethyl-1-(3-phenylpropyl)-piperidine-3,4-diol and phosphate
2G9V	;	2.15	;	The crystal structure of glycogen phosphorylase in complex with (3R,4R,5R)-5-hydroxymethylpiperidine-3,4-diol and phosphate
6S51	;	2.37	;	The crystal structure of glycogen phosphorylase in complex with 10
6F3J	;	2.2	;	The crystal structure of Glycogen Phosphorylase in complex with 10a
6F3L	;	1.9	;	The crystal structure of Glycogen Phosphorylase in complex with 10b
6F3R	;	1.9	;	The crystal structure of Glycogen Phosphorylase in complex with 10c
6F3S	;	1.9	;	The crystal structure of Glycogen Phosphorylase in complex with 10d
6F3U	;	2.2	;	The crystal structure of Glycogen Phosphorylase in complex with 10h
6S4R	;	2.3	;	The crystal structure of glycogen phosphorylase in complex with 11
6S4K	;	2.43	;	The crystal structure of glycogen phosphorylase in complex with 12
6S4P	;	2.37	;	The crystal structure of glycogen phosphorylase in complex with 13
6S52	;	2.37	;	The crystal structure of glycogen phosphorylase in complex with 14
6Y5O	;	2.33	;	The crystal structure of glycogen phosphorylase in complex with 20
6Y55	;	2.38	;	The crystal structure of glycogen phosphorylase in complex with 43
6Y5C	;	2.4	;	The crystal structure of glycogen phosphorylase in complex with 52
6S4H	;	2.45	;	The crystal structure of glycogen phosphorylase in complex with 8
6S4O	;	2.35	;	The crystal structure of glycogen phosphorylase in complex with 9
8BZS	;	2.25	;	The crystal structure of glycogen phosphorylase in complex with baicalein
2PYD	;	1.93	;	The crystal structure of Glycogen phosphorylase in complex with glucose at 100 K
6M6L	;	1.5	;	The crystal structure of glycosidase hydrolyzing Notoginsenoside
6M6M	;	2.07	;	The crystal structure of glycosidase mutant
6R5N	;	2.0	;	The crystal structure of Glycoside Hydrolase BglX from P. aeruginosa in complex with 1-deoxynojirimycin
6R5R	;	1.65	;	The crystal structure of Glycoside Hydrolase BglX inactive mutant D286N from P. aeruginosa in complex with cellobiose
6R5P	;	2.85	;	The crystal structure of Glycoside Hydrolase BglX inactive mutant D286N from P. aeruginosa in complex with glucose
6R5T	;	1.6	;	The crystal structure of Glycoside Hydrolase BglX inactive mutant D286N from P. aeruginosa in complex with lactose
6R5V	;	1.8	;	The crystal structure of Glycoside Hydrolase BglX inactive mutant D286N from P. aeruginosa in complex with xylotriose
6R5U	;	2.15	;	The crystal structure of Glycoside Hydrolase BglX inactive mutant from P. aeruginosa in complex with laminaritriose
6B6L	;	2.0	;	The crystal structure of glycosyl hydrolase family 2 (GH2) member from Bacteroides cellulosilyticus DSM 14838
3TEV	;	2.3	;	The crystal structure of glycosyl hydrolase from Deinococcus radiodurans R1
3RF1	;	2.2	;	The crystal structure of glycyl-tRNA synthetase subunit alpha from Campylobacter jejuni subsp. jejuni NCTC 11168
3UFG	;	2.552	;	The crystal structure of glycyl-tRNA synthetase subunit alpha from Campylobacter jejuni subsp. jejuni NCTC in complex with ATP
3RGL	;	2.45	;	The crystal structure of glycyl-tRNA synthetase subunit alpha from Campylobacter jejuni subsp. jejuni NCTC in complex with ATP and glycine
4N04	;	2.489	;	The crystal structure of glyoxalase / bleomycin resistance protein from Catenulispora Acidiphila DSM 44928
8XN6	;	2.4	;	The Crystal Structure of GSK3b from Biortus.
4ARZ	;	3.1	;	The crystal structure of Gtr1p-Gtr2p complexed with GTP-GDP
3BG4	;	2.5	;	The crystal structure of guamerin in complex with chymotrypsin and the development of an elastase-specific inhibitor
7ZWE	;	1.47	;	The Crystal structure of GW8695 bound to CK2alpha
3S0X	;	3.6	;	The crystal structure of GxGD membrane protease FlaK
2CII	;	2.55	;	The crystal structure of H-2Db complexed with a partial peptide epitope suggests an MHC Class I assembly-intermediate
4PG2	;	2.8	;	The crystal structure of H-2Db with a S-glutathionylated peptide
1BII	;	2.4	;	THE CRYSTAL STRUCTURE OF H-2DD MHC CLASS I IN COMPLEX WITH THE HIV-1 DERIVED PEPTIDE P18-110
4URU	;	2.83	;	The crystal structure of H-Ras and SOS in complex with ligands
4URV	;	2.58	;	The crystal structure of H-Ras and SOS in complex with ligands
4URW	;	2.76	;	The crystal structure of H-Ras and SOS in complex with ligands
4URX	;	2.49	;	The crystal structure of H-Ras and SOS in complex with ligands
4URY	;	2.47	;	The crystal structure of H-Ras and SOS in complex with ligands
4URZ	;	2.24	;	The crystal structure of H-Ras and SOS in complex with ligands
4US0	;	2.17	;	The crystal structure of H-Ras and SOS in complex with ligands
4US1	;	2.65	;	The crystal structure of H-Ras and SOS in complex with ligands
4US2	;	2.48	;	The crystal structure of H-Ras and SOS in complex with ligands
6HIT	;	2.5	;	The crystal structure of haemoglobin from Atlantic cod
4HO1	;	1.856	;	The Crystal structure of Haemophilus influenzae O-acetylserine sulfhydrylase at 1.85A resolution
6GWI	;	2.0	;	The crystal structure of Halomonas elongata amino-transferase
4XZE	;	2.9	;	The crystal structure of Hazara virus nucleoprotein
6XXT	;	1.05	;	The crystal structure of hCA II in complex with a 4-(4-aroylpiperazine-1-carbonyl)benzenesulfonamide derivative.
5LMD	;	1.7	;	The crystal structure of hCA II in complex with a benzoxaborole inhibitor
6QYY	;	1.8	;	The crystal structure of head fiber gp8.5 N base in bacteriophage phi29
4INO	;	1.65	;	The crystal structure of Helicobacter pylori Ceue (HP1561)
4INP	;	2.3	;	The crystal structure of Helicobacter pylori Ceue (HP1561) with Ni(II) bound
4LS3	;	1.7	;	THE crystal STRUCTURE OF HELICOBACTER PYLORI CEUE(HP1561)/NI-HIS COMPL
2WLT	;	1.4	;	The crystal structure of Helicobacter pylori L-asparaginase at 1.4 A resolution
4LN4	;	3.1	;	The crystal structure of hemagglutinin form a h7n9 influenza virus (a/shanghai/1/2013) in complex with lstb
4WSR	;	2.5	;	The crystal structure of hemagglutinin form A/chicken/New York/14677-13/1998
4WSS	;	2.8	;	The crystal structure of hemagglutinin form A/chicken/New York/14677-13/1998 in complex with LSTa
4WE4	;	2.351	;	The crystal structure of hemagglutinin from 1968 H3N2 influenza virus
4WA1	;	1.898	;	The crystal structure of hemagglutinin from a H3N8 influenza virus isolated from New England harbor seals
4WA2	;	2.5	;	The crystal structure of hemagglutinin from a H3N8 influenza virus isolated from New England harbor seals in complex with 3'SLN
4LN3	;	2.65	;	The crystal structure of hemagglutinin from a H7N9 influenza virus (A/Shanghai/1/2013)
4LN6	;	2.12	;	The crystal structure of hemagglutinin from a h7n9 influenza virus (a/shanghai/2/2013)
4LN8	;	2.5	;	The crystal structure of hemagglutinin from a h7n9 influenza virus (a/shanghai/2/2013) in complex with lstb
4W8N	;	2.9	;	The crystal structure of hemagglutinin from a swine influenza virus (A/swine/Missouri/2124514/2006)
6N4F	;	3.01	;	The crystal structure of hemagglutinin from A/canine/IL/11613/2015 (H3N2) influenza virus.
6V47	;	2.8	;	The crystal structure of hemagglutinin from A/duck/Memphis/546/1974 (H11N9)
4WSW	;	2.8	;	The crystal structure of hemagglutinin from A/green-winged teal/Texas/Y171/2006 influenza virus
6D7U	;	2.7	;	The crystal structure of hemagglutinin from A/Guangdong/17SF003/2016 H7N9 influenza virus
5HUF	;	2.81	;	The crystal structure of hemagglutinin from A/gyrfalcon/Washington/41088-6/2014 influenza virus
6D8B	;	2.95	;	The crystal structure of hemagglutinin from A/Hong Kong/125/2017 H7N9 influenza virus
6D8D	;	3.55	;	The crystal structure of hemagglutinin from A/Hong Kong/125/2017 influenza virus in complex with LSTb
6D7C	;	2.95	;	The crystal structure of hemagglutinin from A/Hong Kong/61/2016 H7N9 influenza virus
4WSX	;	2.7	;	The crystal structure of hemagglutinin from A/Jiangxi-Donghu/346/2013 influenza virus
6V48	;	3.004	;	The crystal structure of hemagglutinin from A/mallard/Gurjev/263/1982 (H14N5)
4WE5	;	2.1	;	The crystal structure of hemagglutinin from A/Port Chalmers/1/1973 influenza virus
5HU8	;	2.45	;	The crystal structure of hemagglutinin from A/Sichuan/26221/2014 (H5N6) influenza virus
4WSU	;	2.7	;	The crystal structure of hemagglutinin from A/Taiwan/1/2013 in complex with 3'SLN
4WSV	;	3.1	;	The crystal structure of hemagglutinin from A/Taiwan/1/2013 in complex with 6'SLN
4WST	;	2.4	;	The crystal structure of hemagglutinin from A/Taiwan/1/2013 influenza virus
6V46	;	2.248	;	The crystal structure of hemagglutinin from A/turkey/Ontario/6118/1968 (H8N4)
6V49	;	2.5	;	The crystal structure of hemagglutinin from A/wedge-tailed shearwater/Western Australia/2576/1979 (H15N9)
4WE9	;	2.2	;	The crystal structure of hemagglutinin from influenza virus A/Victoria/361/2011 in complex with 3'SLN
6V44	;	2.2	;	The crystal structure of hemagglutinin from swine influenza virus A/swine/Missouri/A01727926/2015
4WE6	;	1.904	;	The crystal structure of hemagglutinin HA1 domain from influenza virus A/Perth/142/2007(H3N2)
4WE8	;	2.1	;	The crystal structure of hemagglutinin of influenza virus A/Victoria/361/2011
3VRF	;	1.55	;	The crystal structure of hemoglobin from woolly mammoth in the carbonmonoxy forms
3VRE	;	2.2	;	The crystal structure of hemoglobin from woolly mammoth in the deoxy form
3VRG	;	1.5	;	The crystal structure of hemoglobin from woolly mammoth in the met form
3NFE	;	2.01	;	The crystal structure of hemoglobin I from trematomus newnesi in deoxygenated state
3NG6	;	2.2	;	The crystal structure of hemoglobin I from Trematomus newnesi in deoxygenated state obtained through an oxidation/reduction cycle in which potassium hexacyanoferrate and sodium dithionite were alternatively added
5KVB	;	1.45	;	The crystal structure of hexachlorocyclohexane dehydrochlorinase LinA-type3 from Novosphingobium barchaimii LL02
6GWK	;	2.15	;	The crystal structure of Hfq from Caulobacter crescentus
1SHY	;	3.22	;	The Crystal Structure of HGF beta-chain in Complex with the Sema Domain of the Met Receptor.
2VD2	;	2.85	;	The crystal structure of HisG from B. subtilis
4ZKI	;	3.401	;	The crystal structure of Histidine Kinase YycG with ADP
3FFH	;	2.31	;	The crystal structure of histidinol-phosphate aminotransferase from Listeria innocua Clip11262.
4U1T	;	2.0	;	The crystal structure of holo CalE6, a methionine gamma lyase from Micromonospora echinospora
5EJD	;	2.49	;	The crystal structure of holo T3CT
1HDG	;	2.5	;	THE CRYSTAL STRUCTURE OF HOLO-GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE FROM THE HYPERTHERMOPHILIC BACTERIUM THERMOTOGA MARITIMA AT 2.5 ANGSTROMS RESOLUTION
8I2M	;	2.1	;	The crystal structure of homodimeric E. coli tryptophanyl-tRNA synthetase bound with niraparib at one of its two active sites
7QVH	;	2.24	;	The crystal structure of HotPETase, an evolved thermostable variant of IsPETase
3QZ6	;	1.999	;	The crystal structure of HpcH/HpaI aldolase from Desulfitobacterium hafniense DCB-2
5EE4	;	2.3	;	The crystal structure of HpuA from Kingella denitrificans in complex with human haemoglobin
8X2R	;	1.45	;	The Crystal Structure of HSP 90-alpha from Biortus.
1NLT	;	2.7	;	The crystal structure of Hsp40 Ydj1
8X87	;	2.2	;	The Crystal Structure of HspBP1 from Biortus.
3LIT	;	2.19	;	The crystal structure of htlv protease complexed with the inhibitor KNI-10681
8HD5	;	2.14	;	The crystal structure of Hu protein in Staphylococcus aureus
2FBK	;	2.3	;	The Crystal Structure of HucR from Deinococcus radiodurans
5DD8	;	2.05	;	The Crystal structure of HucR mutant (HucR-E48Q) from Deinococcus radiodurans
1X6V	;	1.75	;	The crystal structure of human 3'-phosphoadenosine-5'-phosphosulfate synthetase 1
3I2B	;	2.3	;	The crystal structure of human 6 Pyruvoyl Tetrahydrobiopterin Synthase
5OCH	;	3.4	;	The crystal structure of human ABCB8 in an outward-facing state
8H7H	;	2.2779	;	The crystal structure of human abl1 kinase domain in complex with abl1-A-EBA
7W7X	;	2.00001	;	The crystal structure of human abl1 kinase domain in complex with ABL1-A11
8H7F	;	2.45013	;	The crystal structure of human abl1 kinase domain in complex with abl1-B-EBA
7W7Y	;	2.20003	;	The crystal structure of human abl1 kinase domain in complex with ABL2-A5
3QRI	;	2.1	;	The crystal structure of human abl1 kinase domain in complex with DCC-2036
3QRK	;	2.3	;	The crystal structure of human abl1 kinase domain in complex with DP-987
3QRJ	;	1.82	;	The crystal structure of human abl1 kinase domain T315I mutant in complex with DCC-2036
4TWP	;	2.4	;	The crystal structure of human abl1 T315I gatekeeper mutant kinase domain in complex with axitinib
4WA9	;	2.2	;	The crystal structure of human abl1 wild type kinase domain in complex with axitinib
3HMI	;	1.65	;	The crystal structure of human ABL2 in complex with 5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE
3GVU	;	2.05	;	The crystal structure of human ABL2 in complex with GLEEVEC
3FLV	;	1.7	;	The crystal structure of human acyl-CoenzymeA binding domain containing 5
3IAR	;	1.52	;	The crystal structure of human adenosine deaminase
1X9P	;	3.3	;	The crystal structure of human adenovirus 2 penton base
1X9T	;	3.5	;	The crystal structure of human adenovirus 2 penton base in complex with an ad2 N-terminal fibre peptide
1H0C	;	2.5	;	The crystal structure of human alanine:glyoxylate aminotransferase
2WM1	;	2.01	;	The crystal structure of human alpha-amino-beta-carboxymuconate- epsilon-semialdehyde decarboxylase in complex with 1,3- dihydroxyacetonephosphate suggests a regulatory link between NAD synthesis and glycolysis
4W5N	;	2.9	;	The Crystal Structure of Human Argonaute2 Bound to a Defined Guide RNA
4W5T	;	2.5	;	The Crystal Structure of Human Argonaute2 Bound to a Guide and Target RNA Containing Seed Pairing from 2-7
4W5Q	;	3.101	;	The Crystal Structure of Human Argonaute2 Bound to a Guide and Target RNA Containing Seed Pairing from 2-8
4W5R	;	2.5	;	The Crystal Structure of Human Argonaute2 Bound to a Guide and Target RNA Containing Seed Pairing from 2-8 (Long Target)
4W5O	;	1.802	;	The Crystal Structure of Human Argonaute2 Bound to a Guide and Target RNA Containing Seed Pairing from 2-9
2CY7	;	1.9	;	The crystal structure of human Atg4B
2ZZP	;	2.05	;	The crystal structure of human Atg4B(C74S)- LC3(1-124) complex
2Z0D	;	1.9	;	The crystal structure of human Atg4B- LC3(1-120) complex
2Z0E	;	1.9	;	The crystal structure of human Atg4B- LC3(1-124) complex
8JMX	;	2.9502	;	The crystal structure of human aurka kinase domain in complex with AURKA-A2
8JF4	;	2.89288	;	The crystal structure of human AURKA kinase domain in complex with AURKA-compound 9
1CI4	;	1.9	;	THE CRYSTAL STRUCTURE OF HUMAN BARRIER-TO-AUTOINTEGRATION FACTOR (BAF)
7CA4	;	2.7	;	The Crystal Structure of human Bcl-2-like protein 1 from Biortus
2D4F	;	1.7	;	The Crystal Structure of human beta2-microglobulin
2D4D	;	2.1	;	The Crystal Structure of human beta2-microglobulin, L39W W60F W95F Mutant
2W8P	;	2.3	;	The crystal structure of human C340A SSADH
7W7O	;	1.59	;	The crystal structure of human Calpain-1 protease core in complex with 14a
7X79	;	1.8	;	The crystal structure of human Calpain-1 protease core in complex with 14b
8GX3	;	1.99	;	The crystal structure of human Calpain-1 protease core in complex with 14c
6RHK	;	1.44	;	The crystal structure of human carbonic anhydrase II in complex with 4-(3-benzylimidazolidine-1-carbonyl)benzenesulfonamide
6H33	;	1.58	;	The crystal structure of human carbonic anhydrase II in complex with 4-(4-phenyl)-4-hydroxy-1-piperidine-1-carbonyl)benzenesulfonamide.
6H2Z	;	1.94	;	The crystal structure of human carbonic anhydrase II in complex with 4-(4-phenylpiperidine-1-carbonyl)benzenesulfonamide.
6H34	;	1.55	;	The crystal structure of human carbonic anhydrase II in complex with 4-[(4-fluorophenyl)methyl]-1-piperazinyl]benzenesulfonamide.
3MNA	;	1.5	;	The crystal structure of human carbonic anhydrase Ii in complex with a 1,3,5-triazine-substituted benzenesulfonamide inhibitor
4FL7	;	1.85	;	The crystal structure of human carbonic anhydrase II in complex with N-(Hydroxy)-benzamide
8Q1A	;	2.35	;	The Crystal Structure of Human Carbonic Anhydrase IX in Complex with inhibitor
8Q18	;	2.13	;	The Crystal Structure of Human Carbonic Anhydrase IX in Complex with Sulfonamide
8Q19	;	2.63	;	The Crystal Structure of Human Carbonic Anhydrase IX in Complex with Sulfonamide
6H37	;	1.9	;	The crystal structure of human carbonic anhydrase VII in complex with 4-(4-phenyl)-4-hydroxy-1-piperidine-1-carbonyl)benzenesulfonamide
6H36	;	1.85	;	The crystal structure of human carbonic anhydrase VII in complex with 4-(4-phenylpiperidine-1-carbonyl)benzenesulfonamide.
6H38	;	1.7	;	The crystal structure of human carbonic anhydrase VII in complex with 4-[(4-fluorophenyl)methyl]-1-piperazinyl]benzenesulfonamide.
6K0O	;	1.99	;	The crystal structure of human CD163-like homolog SRCR8
1UQS	;	3.1	;	The Crystal Structure of Human CD1b with a Bound Bacterial Glycolipid
1ZT4	;	3.0	;	The crystal structure of human CD1d with and without alpha-Galactosylceramide
2ODB	;	2.4	;	The crystal structure of human cdc42 in complex with the CRIB domain of human p21-activated kinase 6 (PAK6)
6AKX	;	2.8	;	The Crystal structure of Human Chemokine Receptor CCR5 in complex with compound 21
6AKY	;	2.8	;	The Crystal structure of Human Chemokine Receptor CCR5 in complex with compound 34
6Y2H	;	2.154	;	The crystal structure of human chloride intracellular channel protein 5
8Q4I	;	2.1	;	The crystal structure of human chloride intracellular channel protein 5 delta 57-68
8Q4J	;	2.51	;	The crystal structure of human chloride intracellular channel protein 5 delta 57-68 F34D mutant
1VFQ	;	1.9	;	The Crystal Structure of Human Coactosin-like Protein at 1.9 A Resolution
1CSK	;	2.5	;	THE CRYSTAL STRUCTURE OF HUMAN CSKSH3: STRUCTURAL DIVERSITY NEAR THE RT-SRC AND N-SRC LOOP
7W33	;	2.39	;	The crystal structure of human CtsL in complex with 14a
7W34	;	2.89	;	The crystal structure of human CtsL in complex with 14b
8GX2	;	2.0	;	The crystal structure of human CtsL in complex with 14c
6LPF	;	2.49	;	The crystal structure of human cytoplasmic LRS
6LR6	;	3.009	;	The crystal structure of human cytoplasmic LRS
2JFE	;	2.7	;	The crystal structure of human cytosolic beta-glucosidase
5GOY	;	2.278	;	The crystal structure of human cytosolic methionyl-tRNA synthetase in complex with methionine
3WJA	;	2.548	;	The crystal structure of human cytosolic NADP(+)-dependent malic enzyme in apo form
2HHB	;	1.74	;	THE CRYSTAL STRUCTURE OF HUMAN DEOXYHAEMOGLOBIN AT 1.74 ANGSTROMS RESOLUTION
3HHB	;	1.74	;	THE CRYSTAL STRUCTURE OF HUMAN DEOXYHAEMOGLOBIN AT 1.74 ANGSTROMS RESOLUTION
4HHB	;	1.74	;	THE CRYSTAL STRUCTURE OF HUMAN DEOXYHAEMOGLOBIN AT 1.74 ANGSTROMS RESOLUTION
7ESE	;	1.85	;	The Crystal Structure of human DHFR from Biortus
4WXX	;	2.622	;	The crystal structure of human DNMT1(351-1600)
5ZTN	;	2.496	;	The crystal structure of human DYRK2 in complex with Curcumin
5IZK	;	3.25	;	The crystal structure of human eEFSec in complex with GDP
5IZL	;	2.72	;	The crystal structure of human eEFSec in complex with GDPCP
5IZM	;	3.4	;	The crystal structure of human eEFSec in complex with GDPNP
3I85	;	2.5	;	The Crystal Structure of Human EMMPRIN N-terminal Domain 1
3I84	;	2.0	;	The Crystal Structure of Human EMMPRIN N-terminal Domain 1 in P6(1)22 space group
2HW5	;	2.55	;	The crystal structure of human enoyl-coenzyme A (CoA) hydratase short chain 1, ECHS1
1XGW	;	1.9	;	The crystal structure of human enthoprotin N-terminal domain
1DT9	;	2.7	;	THE CRYSTAL STRUCTURE OF HUMAN EUKARYOTIC RELEASE FACTOR ERF1-MECHANISM OF STOP CODON RECOGNITION AND PEPTIDYL-TRNA HYDROLYSIS
6AQ1	;	1.4	;	The crystal structure of human FABP3
4GP3	;	2.25	;	The crystal structure of human fascin 1 K358A mutant
4GOY	;	2.3	;	The crystal structure of human fascin 1 K41A mutant
4GP0	;	2.5	;	The crystal structure of human fascin 1 R149A K150A R151A mutant
4GOV	;	2.2	;	The crystal structure of human fascin 1 S39D mutant
7VOX	;	2.1	;	The crystal structure of human forkhead box protein A in complex with DNA 2
7VOU	;	3.1	;	The crystal structure of human forkhead box protein in complex with DNA 1
7VOV	;	3.15	;	The crystal structure of human forkhead box protein in complex with DNA 2
3FFM	;	2.3	;	The crystal structure of human Gadd45g
2E9X	;	2.3	;	The crystal structure of human GINS core complex
3L50	;	1.9	;	The crystal structure of human Glia Maturation Factor, Gamma (GMFG)
8I0B	;	1.73	;	The crystal structure of human glutamate receptor 2 in complex with LT-102
3L5K	;	2.0	;	The crystal structure of human Haloacid Dehalogenase-like Hydrolase Domain containing 1A (HDHD1A)
3HLT	;	2.3	;	The crystal structure of human haloacid dehalogenase-like hydrolase domain containing 2 (HDHD2)
4KNW	;	2.699	;	The crystal structure of human HDHD4 IN COMPLEX WITH MAGNESIUM AND THE PHOSPHATE MIMETIC VANADATE
4QPP	;	2.52	;	The Crystal Structure of Human HMT1 hnRNP methyltransferase-like protein 6 in complex with compound DS-421 (2-{4-[3-CHLORO-2-(2-METHOXYPHENYL)-1H-INDOL-5-YL]PIPERIDIN-1-YL}-N-METHYLETHANAMINE
1HMP	;	2.5	;	THE CRYSTAL STRUCTURE OF HUMAN HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE WITH BOUND GMP
4QGT	;	2.99	;	The Crystal Structure of Human IgG Fc Domain with Enhanced Aromatic Sequon
7AL7	;	1.801	;	The Crystal Structure of Human IL-18 in Complex With Human IL-18 Binding Protein
4B18	;	2.52	;	The crystal structure of human Importin alpha 5 with TERT NLS peptide
3OG4	;	2.16	;	The crystal structure of human interferon lambda 1 complexed with its high affinity receptor in space group P21212
3OG6	;	2.097	;	The crystal structure of human interferon lambda 1 complexed with its high affinity receptor in space group P212121
4MHL	;	2.09	;	The crystal structure of human interleukin-11
2HZ6	;	3.1	;	The crystal structure of human IRE1-alpha luminal domain
7S6P	;	2.15	;	The crystal structure of human ISG15
2ICJ	;	1.7	;	The crystal structure of human isopentenyl diphophate isomerase
5YAK	;	2.3	;	The crystal structure of human IYD Thr239 mutant with ligand 3-Fluorotyrosine (F-Tyr)
7D4A	;	2.201	;	The Crystal Structure of human JMJD2A Tudor domain from Biortus
7CML	;	2.15	;	The Crystal Structure of human JNK2 from Biortus.
5EFS	;	1.82503	;	The crystal structure of human kynurenine aminotransferase II
2R2N	;	1.95	;	The crystal structure of human kynurenine aminotransferase II in complex with kynurenine
5EUN	;	1.825	;	The Crystal Structure of Human Kynurenine Aminotransferase II, PLP-bound form, at 1.83 A
3F3S	;	2.0	;	The Crystal Structure of Human Lambda-Crystallin, CRYL1
6ZZR	;	2.65	;	The Crystal Structure of human LDHA from Biortus
3O7W	;	2.0	;	The Crystal Structure of Human Leucine Carboxyl Methyltransferase 1
1ZDU	;	2.5	;	The Crystal Structure of Human Liver Receptor Homologue-1
6Y4Y	;	1.75	;	The crystal structure of human MACROD2 in space group P41212
6Y73	;	1.7	;	The crystal structure of human MACROD2 in space group P43
6Y4Z	;	1.9	;	The crystal structure of human MACROD2 in space group P43212
8H7B	;	1.46408	;	The crystal structure of human mcl1 kinase domain in complex with MCL1-M-EBA
6O1E	;	2.41	;	The crystal structure of human MORC3 ATPase-CW in complex with AMPPNP
7ESF	;	1.55	;	The Crystal Structure of human MTH1 from Biortus
4D1E	;	3.5	;	THE CRYSTAL STRUCTURE OF HUMAN MUSCLE ALPHA-ACTININ-2
7CMR	;	2.2	;	The Crystal Structure of human MYST1 from Biortus.
2W4M	;	2.6	;	The Crystal Structure of human N-acetylneuraminic acid phosphatase, NANP
2FFQ	;	1.78	;	The crystal structure of human neuronal Rab6B in its active GTPgS-bound form
2FE4	;	2.3	;	The crystal structure of human neuronal Rab6B in its inactive GDP-bound form
5ZBH	;	3.0	;	The Crystal Structure of Human Neuropeptide Y Y1 Receptor with BMS-193885
5ZBQ	;	2.7	;	The Crystal Structure of human neuropeptide Y Y1 receptor with UR-MK299
7DDZ	;	2.8	;	The Crystal Structure of Human Neuropeptide Y Y2 Receptor with JNJ-31020028
4WQ6	;	1.72	;	The crystal structure of human Nicotinamide phosphoribosyltransferase (NAMPT) in complex with N-(4-{(S)-[1-(2-methylpropyl)piperidin-4-yl]sulfinyl}benzyl)furo[2,3-c]pyridine-2-carboxamide inhibitor (compound 21)
5UN9	;	2.5	;	The crystal structure of human O-GlcNAcase in complex with Thiamet-G
7JX9	;	1.96	;	The crystal structure of human ornithine aminotransferase with an intermediate bound during inactivation by (1S,3S)-3-amino-4-(hexafluoropropan-2-ylidenyl)-cyclopentane-1-carboxylic acid.
2JGY	;	1.95	;	The crystal structure of human orotidine-5'-decarboxylase domain of human uridine monophosphate synthetase (UMPS)
2DYB	;	3.15	;	The crystal structure of human p40(phox)
7D2C	;	1.56	;	The Crystal Structure of human PARP14 from Biortus.
1PSN	;	2.2	;	THE CRYSTAL STRUCTURE OF HUMAN PEPSIN AND ITS COMPLEX WITH PEPSTATIN
1PSO	;	2.0	;	The crystal structure of human pepsin and its complex with pepstatin
2F6Q	;	1.95	;	The crystal structure of human peroxisomal delta3, delta2 enoyl CoA isomerase (PECI)
7CVP	;	2.5	;	The Crystal Structure of human PHGDH from Biortus.
1NUH	;	2.51	;	The crystal structure of human phosphoglucose isomerase complexed with 5-phosphoarabinonate
3CH4	;	1.76	;	The Crystal Structure of Human Phosphomavelonate Kinase At 1.8 A Resolution
1FZV	;	2.0	;	THE CRYSTAL STRUCTURE OF HUMAN PLACENTA GROWTH FACTOR-1 (PLGF-1), AN ANGIOGENIC PROTEIN AT 2.0A RESOLUTION
5F8Z	;	1.5	;	The crystal structure of human Plasma Kallikrein in complex with its peptide inhibitor pkalin-1
5F8T	;	1.75	;	The crystal structure of human Plasma Kallikrein in complex with its peptide inhibitor pkalin-2
5F8X	;	1.55	;	The crystal structure of human plasma kallikrein in complex with its peptide inhibitor pkalin-3
3EQ1	;	2.8	;	The Crystal Structure of Human Porphobilinogen Deaminase at 2.8A resolution
1BY8	;	2.6	;	THE CRYSTAL STRUCTURE OF HUMAN PROCATHEPSIN K
4KWW	;	2.55	;	The crystal structure of human quinolinic acid phosphoribosyltransferase in complex with its inhibitor phthalic acid
2F7S	;	2.7	;	The crystal structure of human Rab27b bound to GDP
2FN4	;	1.65	;	The crystal structure of human Ras-related protein, RRAS, in the GDP-bound state
2ATV	;	1.9	;	The crystal structure of human RERG in the GDP bound state
2GJS	;	1.9	;	The crystal structure of human RRAD in complex with GDP
8YA8	;	2.85	;	The crystal structure of human Rtel1 HHD2 domain
5W4B	;	2.65	;	The crystal structure of human S-adenosylhomocysteine hydrolase (AHCY) bound to benzothiazole inhibitor
5W49	;	2.4	;	The crystal structure of human S-adenosylhomocysteine hydrolase (AHCY) bound to oxadiazole inhibitor
1ODB	;	2.19	;	THE CRYSTAL STRUCTURE OF HUMAN S100A12 - COPPER COMPLEX
2Y74	;	2.95	;	THE CRYSTAL STRUCTURE OF HUMAN SOLUBLE PRIMARY AMINE OXIDASE AOC3 IN THE OFF-COPPER CONFORMATION
7DSF	;	1.8	;	The Crystal Structure of human SPR from Biortus.
2W8R	;	2.4	;	The crystal structure of human SSADH in complex with NAD+
2W8Q	;	2.4	;	The crystal structure of human SSADH in complex with SSA.
1ZDT	;	2.1	;	The Crystal Structure of Human Steroidogenic Factor-1
1O6U	;	2.05	;	The Crystal Structure of Human Supernatant Protein Factor
2P0A	;	1.9	;	The crystal structure of human synapsin III (SYN3) in complex with AMPPNP
7YIW	;	2.89	;	The Crystal Structure of Human Tissue Nonspecific Alkaline Phosphatase (ALPL) at Acidic pH
7YIV	;	3.18	;	The Crystal Structure of Human Tissue Nonspecific Alkaline Phosphatase (ALPL) at Basic pH
1DJL	;	2.0	;	THE CRYSTAL STRUCTURE OF HUMAN TRANSHYDROGENASE DOMAIN III WITH BOUND NADP
7XBI	;	2.16	;	The crystal structure of human TrkA kinase bound to the inhibitor
1RGU	;	2.22	;	The crystal structure of human Tyrosyl-DNA Phosphodiesterase complexed with vanadate, octopamine, and tetranucleotide AGTG
3N32	;	1.795	;	The crystal structure of human Ubiquitin adduct with Zeise's salt
7E9V	;	2.1	;	The Crystal Structure of human UMP-CMP kinase from Biortus.
4DVA	;	1.94	;	The crystal structure of human urokinase-type plasminogen activator catalytic domain
7CM2	;	2.25	;	The Crystal Structure of human USP7 USP domain from Biortus
8TBQ	;	2.593	;	The crystal structure of human VISTA extra cellular domain in complex with Fab fragment of pH-selective anti-VISTA antibody
5ENN	;	2.7	;	The crystal structure of Human VPS34 in complex with a selective and potent inhibitor
4PH4	;	2.8	;	The crystal structure of Human VPS34 in complex with PIK-III
5ZYU	;	1.752	;	The crystal structure of humanMGME1 with single strand DNA2
6OE8	;	1.99	;	The crystal structure of hyper-thermostable AgUricase mutant K12C/E286C
3VGI	;	1.07	;	The crystal structure of hyperthermophilic family 12 endocellulase from Pyrococcus furiosus
3BGK	;	2.5	;	The crystal structure of hypothetic protein SMU.573 from Streptococcus mutans
1U14	;	1.68	;	The crystal structure of hypothetical UPF0244 protein yjjX at resolution 1.68 Angstrom
5A0W	;	2.2	;	THE CRYSTAL STRUCTURE OF I-DMOI E117A IN COMPLEX WITH ITS TARGET DNA AND IN THE PRESENCE OF 2MM MN
5AKM	;	2.4	;	THE CRYSTAL STRUCTURE OF I-DMOI G20S IN COMPLEX WITH ITS TARGET DNA IN THE PRESENCE OF 2MM MG
2VS7	;	2.05	;	The crystal structure of I-DmoI in complex with DNA and Ca
2VS8	;	2.1	;	The crystal structure of I-DmoI in complex with DNA and Mn
4D6N	;	2.35	;	THE CRYSTAL STRUCTURE OF I-DMOI IN COMPLEX WITH ITS TARGET DNA AT 10 DAYS INCUBATION IN 5MM MG (STATE 7)
4UT0	;	2.4	;	THE CRYSTAL STRUCTURE OF I-DMOI IN COMPLEX WITH ITS TARGET DNA AT 10 DAYS INCUBATION IN 5MM MN (STATE 7)
4D6O	;	2.2	;	THE CRYSTAL STRUCTURE OF I-DMOI IN COMPLEX WITH ITS TARGET DNA AT 1H INCUBATION IN 5MM MG (STATE 2)
4UN8	;	2.6	;	THE CRYSTAL STRUCTURE OF I-DMOI IN COMPLEX WITH ITS TARGET DNA AT 1H INCUBATION IN 5MM MN (STATE 2)
4UNA	;	2.3	;	THE CRYSTAL STRUCTURE OF I-DMOI IN COMPLEX WITH ITS TARGET DNA AT 2 DAYS INCUBATION IN 5MM MN (STATE 4)
4UNB	;	2.55	;	THE CRYSTAL STRUCTURE OF I-DMOI IN COMPLEX WITH ITS TARGET DNA AT 6 DAYS INCUBATION IN 5MM MN (STATE 5)
4UNC	;	2.3	;	THE CRYSTAL STRUCTURE OF I-DMOI IN COMPLEX WITH ITS TARGET DNA AT 8 DAYS INCUBATION IN 5MM MN (STATE 6)
4UN9	;	2.734	;	THE CRYSTAL STRUCTURE OF I-DMOI IN COMPLEX WITH ITS TARGET DNA AT 8H INCUBATION IN 5MM MN (STATE 3)
4UN7	;	2.7	;	THE CRYSTAL STRUCTURE OF I-DMOI IN COMPLEX WITH ITS TARGET DNA BEFORE INCUBATION IN 5MM MN (STATE 1)
5AK9	;	2.601	;	THE CRYSTAL STRUCTURE OF I-DMOI Q42AK120M IN COMPLEX WITH ITS TARGET DNA IN THE PRESENCE OF 2MM MN
5AKF	;	2.45	;	THE CRYSTAL STRUCTURE OF I-DMOI Q42AK120M IN COMPLEX WITH ITS TARGET DNA NICKED IN THE CODING STRAND A AND IN THE PRESENCE OF 2MM MN
5AKN	;	2.75	;	THE CRYSTAL STRUCTURE OF I-DMOI Q42AK120M IN COMPLEX WITH ITS TARGET DNA NICKED IN THE non-CODING STRAND B AND IN THE PRESENCE OF 2MM MN
3R7P	;	2.704	;	The crystal structure of I-LtrI
5A0M	;	2.9	;	THE CRYSTAL STRUCTURE OF I-SCEI IN COMPLEX WITH ITS TARGET DNA IN THE PRESENCE OF MN
8EDZ	;	2.65	;	The crystal structure of I38T mutant PA endonuclease (2009/H1N1/CALIFORNIA) in complex with compound SJ000986319
8DIP	;	2.5	;	The crystal structure of I38T mutant PA endonuclease (2009/H1N1/CALIFORNIA) in complex with compound SJ001023030
8E4S	;	2.4	;	The crystal structure of I38T mutant PA endonuclease (2009/H1N1/CALIFORNIA) in complex with compound SJ001023034
8DTW	;	2.33	;	The crystal structure of I38T mutant PA endonuclease (2009/H1N1/CALIFORNIA) in complex with compound SJ001023036
7RKP	;	2.36	;	The crystal structure of I38T mutant PA endonuclease (2009/H1N1/CALIFORNIA) in complex with cyclic compound SJ001034733
7LP8	;	2.55	;	The crystal structure of I38T mutant PA endonuclease (2009/H1N1/CALIFORNIA) in complex with SJ000983476
7N8F	;	2.35	;	The crystal structure of I38T mutant PA endonuclease (2009/H1N1/CALIFORNIA) in complex with SJ000988288
7ML8	;	2.7	;	The crystal structure of I38T mutant PA endonuclease (2009/H1N1/CALIFORNIA) in complex with SJ001023038
1P53	;	3.06	;	The Crystal Structure of ICAM-1 D3-D5 fragment
1ZXQ	;	2.2	;	THE CRYSTAL STRUCTURE OF ICAM-2
8X70	;	1.7	;	The Crystal Structure of IFI16 from Biortus.
5LGJ	;	2.6	;	THE CRYSTAL STRUCTURE OF IGE FC MUTANT - P333C
1O0V	;	2.6	;	The crystal structure of IgE Fc reveals an asymmetrically bent conformation
2WPT	;	1.78	;	The crystal structure of Im2 in complex with colicin E9 DNase
5ZNE	;	1.78	;	The crystal structure of immune receptor RGA5A_S of resistance protein Pia from rice (Oryza sativa)
3QB2	;	2.5	;	The Crystal Structure of Immunity Factor for SPN (IFS)
5JJO	;	2.002	;	The crystal structure of immunity protein PA5088 from Pseudomonas aeruginosa
5YL8	;	1.79	;	The crystal structure of inactive dimeric peptidyl-tRNA hydrolase from Acinetobacter baumannii at 1.79 A resolution
6BMA	;	1.98	;	The crystal structure of indole-3-glycerol phosphate synthase from Campylobacter jejuni subsp. jejuni NCTC 11168
2OH5	;	1.98	;	The Crystal Structure of Infectious Cypovirus Polyhedra
4HZV	;	1.8	;	The crystal structure of influenza A neuraminidase N3
5J4V	;	2.94	;	The crystal structure of Inhibitor Bound to JCV Helicase
5NAL	;	2.2	;	The crystal structure of inhibitor-15 covalently bound to PDE6D
4KKH	;	2.0	;	The crystal structure of inhibitor-bound JNK3
5E1S	;	2.264	;	The Crystal structure of INSR Tyrosine Kinase in complex with the Inhibitor BI 885578
6HDV	;	2.16	;	The crystal structure of intact afifavidin apo form
8WF7	;	1.55	;	The Crystal Structure of integrase from Biortus
8DPV	;	1.48	;	The crystal structure of Interleukin-11, W147A mutant
7YA7	;	1.4	;	The crystal structure of IpaH1.4 LRR domain
7YA8	;	3.4	;	The crystal structure of IpaH2.5 LRR domain
8WTF	;	2.0	;	The Crystal Structure of IRAK4 from Biortus
2W7W	;	1.7	;	The crystal structure of iron superoxide dismutase from Aliivibrio salmonicida.
2IQQ	;	2.66	;	The Crystal Structure of Iron, Sulfur-Dependent L-serine dehydratase from Legionella pneumophila subsp. pneumophila
5YMR	;	2.4	;	The Crystal Structure of IseG
3EPS	;	2.8	;	The crystal structure of isocitrate dehydrogenase kinase/phosphatase from E. coli
3LCB	;	2.9	;	The crystal structure of isocitrate dehydrogenase kinase/phosphatase in complex with its substrate, isocitrate dehydrogenase, from Escherichia coli.
6K5L	;	2.55	;	The crystal structure of isocitrate dehydrogenase kinase/phosphatase wtih two Mn2+ from E. coli
4HOW	;	1.7	;	The crystal structure of isomaltulose synthase from Erwinia rhapontici NX5
4HOX	;	2.0	;	The crystal structure of isomaltulose synthase from Erwinia rhapontici NX5 in complex with Tris
4HOZ	;	2.0	;	The crystal structure of isomaltulose synthase mutant D241A from Erwinia rhapontici NX5 in complex with D-glucose
4HP5	;	2.0	;	The crystal structure of isomaltulose synthase mutant E295A from Erwinia rhapontici NX5 in complex with D-glucose
4HPH	;	1.7	;	The crystal structure of isomaltulose synthase mutant E295Q from Erwinia rhapontici NX5 in complex with its natural substrate sucrose
2POC	;	1.8	;	The crystal structure of isomerase domain of glucosamine-6-phosphate synthase from Candida albicans
2PUT	;	1.9	;	The crystal structure of isomerase domain of glucosamine-6-phosphate synthase from Candida albicans
2PUV	;	1.9	;	The crystal structure of isomerase domain of glucosamine-6-phosphate synthase from Candida albicans
2PUW	;	3.151	;	The crystal structure of isomerase domain of glucosamine-6-phosphate synthase from Candida albicans
6BRM	;	2.55	;	The crystal structure of isothiocyanate hydrolase from Delia radicum gut bacteria
5JIA	;	1.8	;	The Crystal Structure Of IUS-SPRY Domain From RanBP10
5JI7	;	1.51	;	The Crystal Structure Of IUS-SPRY Domain From RanBPM/9
5JI9	;	2.5	;	The Crystal Structure Of IUS-SPRY Domain From RanBPM/9
8G8O	;	2.2	;	The crystal structure of JAK2 in complex with Compound 31
2OQ7	;	2.15	;	The crystal structure of JMJD2A complexed with Ni and N-oxalylglycine
8WD3	;	3.3	;	The Crystal Structure of JMJD2A(M1-L359) from Biortus.
8WUG	;	1.7	;	The Crystal Structure of JMJD2D from Biortus.
5AWM	;	1.79	;	The Crystal Structure of JNK from Drosophila melanogaster Reveals an Evolutionarily Conserved Topology with that of Mammalian JNK Proteins.
8X5M	;	2.0	;	The Crystal Structure of JNK1 from Biortus.
8WGF	;	1.85	;	The Crystal Structure of JNK3 from Biortus.
1PMU	;	2.7	;	The crystal structure of JNK3 in complex with a phenantroline inhibitor
5ZGN	;	2.24	;	The crystal structure of KacTA-DNA complex
6S0R	;	2.5	;	The crystal structure of kanamycin B dioxygenase (KanJ) from Streptomyces kanamyceticus complex with nickel, sulfate and chloride
6S0U	;	2.15	;	The crystal structure of kanamycin B dioxygenase (KanJ) from Streptomyces kanamyceticus in complex with nickel and 2-oxoglutarate
6S0W	;	2.36	;	The crystal structure of kanamycin B dioxygenase (KanJ) from Streptomyces kanamyceticus in complex with nickel and kanamycin B sulfate
6S0V	;	3.0	;	The crystal structure of kanamycin B dioxygenase (KanJ) from Streptomyces kanamyceticus in complex with nickel, neamine and sulfate
6S0S	;	2.4	;	The crystal structure of kanamycin B dioxygenase (KanJ) from Streptomyces kanamyceticus in complex with nickel, ribostamycin B and 2-oxoglutarate
6S0T	;	2.1	;	The crystal structure of kanamycin B dioxygenase (KanJ) from Streptomyces kanamyceticus in complex with nickel, sulfate, soaked with iodide
6JW6	;	2.8	;	The crystal structure of KanD2 in complex with NAD
6JW7	;	2.36	;	The crystal structure of KanD2 in complex with NADH and 3""-deamino-3""-hydroxykanamycin A
6JW8	;	2.4	;	The crystal structure of KanD2 in complex with NADH and 3""-deamino-3""-hydroxykanamycin B
7CL2	;	2.0	;	The crystal structure of KanJ
7CL3	;	2.2	;	The crystal structure of KanJ in complex with kanamycin B
7CL5	;	2.5	;	The crystal structure of KanJ in complex with kanamycin B and N-oxalylglycine
7CL4	;	2.25	;	The crystal structure of KanJ in complex with N-oxalylglycine
7CL6	;	2.44	;	The crystal structure of KanJ in complex with neamine and N-oxalylglycine
4EZH	;	2.52	;	the crystal structure of KDM6B bound with H3K27me3 peptide
8WFG	;	2.251	;	The Crystal Structure of KEAP1 from Biortus.
3ON3	;	2.193	;	The crystal structure of keto/oxoacid ferredoxin oxidoreductase, gamma subunit from Geobacter sulfurreducens PCA
7V4R	;	2.1	;	The crystal structure of KFDV NS3H bound with Pi
6IGN	;	3.451	;	The crystal structure of Kif5b stalk 1 coiled-coil region
4F7H	;	1.9	;	The crystal structure of kindlin-2 pleckstrin homology domain in free form
4BN2	;	2.695	;	The crystal structure of kinesin-like protein KIF15
5Z08	;	2.199	;	The crystal structure of kinetochore subunits Cenp-H/I/K triple complex
1OZG	;	2.3	;	The crystal structure of Klebsiella pneumoniae acetolactate synthase with enzyme-bound cofactor and with an unusual intermediate
1OZH	;	2.0	;	The crystal structure of Klebsiella pneumoniae acetolactate synthase with enzyme-bound cofactor and with an unusual intermediate.
1OZF	;	2.3	;	The crystal structure of Klebsiella pneumoniae acetolactate synthase with enzyme-bound cofactors
3MNL	;	1.8	;	The crystal structure of KstR (Rv3574) from Mycobacterium tuberculosis H37Rv
4XZC	;	2.601	;	The crystal structure of Kupe virus nucleoprotein
8WGQ	;	2.75	;	The Crystal Structure of L-asparaginase from Biortus.
6DKH	;	2.608	;	The crystal structure of L-idonate 5-dehydrogenase from Escherichia coli str. K-12 substr. MG1655
7VID	;	2.5	;	The crystal structure of L-leucine dehydrogenase from Pseudomonas aeruginosa
2QMX	;	2.3	;	The crystal structure of L-Phe inhibited prephenate dehydratase from Chlorobium tepidum TLS
3AI2	;	1.9	;	The crystal structure of L-sorbose reductase from Gluconobacter frateurii complexed with NADPH
3AI3	;	1.8	;	The crystal structure of L-Sorbose reductase from Gluconobacter frateurii complexed with NADPH and L-sorbose
3AI1	;	2.38	;	The crystal structure of L-sorbose reductase from Gluconobacter frateurii complexed with NADPH and L-sorbose reveals the structure bases of its catalytic mechanism and high substrate selectivity
3FKD	;	2.5	;	The crystal structure of L-threonine-O-3-phosphate decarboxylase from Porphyromonas gingivalis
2J6X	;	2.1	;	The crystal structure of lactate oxidase
7JRD	;	2.85	;	The crystal structure of lactoferrin binding protein B (LbpB) from Neisseria meningitidis in complex with human lactoferrin
4OSO	;	2.5	;	The crystal structure of landomycin C-6 ketoreductase LanV with bound NADP and rabelomycin
1MI5	;	2.5	;	The crystal structure of LC13 TcR in complex with HLAB8-EBV peptide complex
8X2P	;	1.4	;	The Crystal Structure of LCK from Biortus.
7DS7	;	2.15	;	The Crystal Structure of Leaf-branch compost cutinase from Biortus.
6ICA	;	2.195	;	The crystal structure of Legionella pneumophila LapA aminopeptidase
2YB0	;	2.28	;	The Crystal Structure of Leishmania major dUTPase in complex deoxyuridine
2YAZ	;	2.4	;	The Crystal Structure of Leishmania major dUTPase in complex dUMP
2YAY	;	1.86	;	The Crystal Structure of Leishmania major dUTPase in complex with substrate analogue dUpNpp
4A26	;	2.7	;	The crystal structure of Leishmania major N5,N10- methylenetetrahydrofolate dehydrogenase/cyclohydrolase
3RIV	;	1.76	;	The Crystal Structure of Leishmania major Peroxidase
3RIW	;	2.37	;	The Crystal Structure of Leishmania major Peroxidase mutant C197T
7PXX	;	1.81	;	The crystal structure of Leishmania major Pteridine Reductase 1 in complex with substrate folic acid
3CB4	;	2.8	;	The Crystal Structure of LepA
1WZ2	;	3.21	;	The crystal structure of Leucyl-tRNA synthetase and tRNA(leucine) complex
3LL3	;	2.002	;	The crystal structure of ligand bound xylulose kinase from Lactobacillus acidophilus
2HVC	;	2.1	;	The Crystal Structure of Ligand-binding Domain (LBD) of human Androgen Receptor in Complex with a selective modulator LGD2226
1ELJ	;	1.85	;	THE CRYSTAL STRUCTURE OF LIGANDED MALTODEXTRIN-BINDING PROTEIN FROM PYROCOCCUS FURIOSUS
7MSG	;	3.5	;	The crystal structure of LIGHT in complex with HVEM and CD160
5G2C	;	2.31	;	The crystal structure of light-driven chloride pump ClR (T102D) mutant at pH 4.5.
5G2D	;	1.8	;	The crystal structure of light-driven chloride pump ClR (T102N) mutant at pH 4.5.
5G54	;	2.0	;	The crystal structure of light-driven chloride pump ClR at pH 4.5
5G2A	;	2.17	;	The crystal structure of light-driven chloride pump ClR at pH 6.0 with Bromide ion.
5G28	;	1.57	;	The crystal structure of light-driven chloride pump ClR at pH 6.0.
5FJG	;	2.0	;	The crystal structure of light-driven chloride pump ClR in pH 4.5.
6K6K	;	2.197	;	The crystal structure of light-driven cyanobacterial chloride importer (N63A/P118A) Mastigocladopsis repens
6K6I	;	1.9	;	The crystal structure of light-driven cyanobacterial chloride importer from Mastigocladopsis repens
6K6J	;	2.5	;	The crystal structure of light-driven cyanobacterial chloride importer from Mastigocladopsis repens with Bromide ion
8WSW	;	2.5	;	The Crystal Structure of LIMK2a from Biortus
3O60	;	2.8	;	The Crystal Structure of Lin0861 from Listeria innocua to 2.8A
3A76	;	2.25	;	The crystal structure of LinA
8WBV	;	1.95	;	The crystal structure of linear mannose with mutant H247F of the cellobiose 2-epimerase from Caldicellulosiruptor saccharolyticus
1XS5	;	1.85	;	The Crystal Structure of Lipoprotein Tp32 from Treponema pallidum
4U0P	;	1.623	;	The Crystal Structure of Lipoyl Synthase in Complex with S-Adenosyl Homocysteine
2XMO	;	1.7	;	The crystal structure of Lmo2642
7EGS	;	1.7	;	The crystal structure of lobe domain of E. coli RNA polymerase complexed with the C-terminal domain of UvrD
1H91	;	1.4	;	The crystal structure of lobster apocrustacyanin A1 using softer X-rays.
5YE7	;	2.312	;	The crystal structure of Lp-PLA2 in complex with a novel inhibitor
5YE8	;	1.851	;	The crystal structure of Lp-PLA2 in complex with a novel inhibitor
5YE9	;	1.876	;	The crystal structure of Lp-PLA2 in complex with a novel inhibitor
5YEA	;	1.805	;	The crystal structure of Lp-PLA2 in complex with a novel inhibitor
5TSC	;	2.008	;	The crystal structure of Lpg2147 from Legionella pneumophila
6A0Q	;	2.2	;	The crystal structure of Lpg2622_E64 complex
3C8K	;	2.9	;	The crystal structure of Ly49C bound to H-2Kb
5D74	;	1.9	;	The crystal structure of Ly7917
5D76	;	2.54	;	The crystal structure of Ly7917 with the hydrolyzing product of MDP
8WFF	;	1.3	;	The Crystal Structure of LYN from Biortus.
7S6O	;	1.25	;	The crystal structure of Lys48-linked di-ubiquitin
7EWT	;	3.4	;	The crystal structure of Lysophospholipid acyltransferase LPCAT3 (MOBAT5) in its monomeric and apo form
4INZ	;	1.7	;	The crystal structure of M145A mutant of an epoxide hydrolase from Bacillus megaterium
8B67	;	2.6	;	The crystal structure of M644G variant of DNA Pol Epsilon containing CTP in the polymerase active site
8B6K	;	2.5	;	The crystal structure of M644G variant of DNA Pol Epsilon containing dCTP in the polymerase active site
8B76	;	2.6	;	The crystal structure of M644G variant of DNA Pol Epsilon containing dTTP in the polymerase active site
8B79	;	2.65	;	The crystal structure of M644G variant of DNA Pol Epsilon containing UTP in the polymerase active site
5YKV	;	2.31	;	The crystal structure of Macrobrachium rosenbergii nodavirus P-domain
5YKX	;	2.0	;	The crystal structure of Macrobrachium rosenbergii nodavirus P-domain with Cd ion
5YKU	;	1.39	;	The crystal structure of Macrobrachium rosenbergii nodavirus P-domain with Zn ions
2IYA	;	1.7	;	The crystal structure of macrolide glycosyltransferases: A blueprint for antibiotic engineering
2IYF	;	1.7	;	The crystal structure of macrolide glycosyltransferases: A blueprint for antibiotic engineering
4HEB	;	2.26	;	The Crystal structure of Maf protein of Bacillus subtilis
6JIJ	;	2.65	;	The Crystal Structure of Main Protease from Mouse Hepatitis Virus A59 in Complex with an inhibitor
1OCL	;	2.0	;	THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 COMPLEXED WITH MALONATE FROM BRADYRHIZOBIUM JAPONICUM
1OCM	;	1.9	;	THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 COVALENTLY COMPLEXED WITH PYROPHOSPHATE FROM BRADYRHIZOBIUM JAPONICUM
1OCK	;	1.8	;	THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 FROM BRADYRHIZOBIUM JAPONICUM
4ISX	;	2.702	;	The crystal structure of maltose o-acetyltransferase from clostridium difficile 630 in complex with acetyl-coa
2XD2	;	2.9	;	The crystal structure of MalX from Streptococcus pneumoniae
2XD3	;	2.0	;	The crystal structure of MalX from Streptococcus pneumoniae in complex with maltopentaose.
5ZZP	;	1.39	;	The crystal structure of Mandelate oxidase
6A0B	;	1.65	;	The crystal structure of Mandelate oxidase mutant Y128F with (R)-3,3,3-trifluoro-2-hydroxy-propionic acid
5ZZX	;	1.49	;	The crystal structure of Mandelate oxidase mutant Y128F with (R)-mandelic acid
6A0D	;	1.65	;	The crystal structure of Mandelate oxidase mutant Y128F with (S)-2-phenylpropanoic acid
6A0G	;	1.8	;	The crystal structure of Mandelate oxidase mutant Y128F with b-Phenyllactate
5ZZY	;	1.5	;	The crystal structure of Mandelate oxidase mutant Y128F with L-Lactate
6A3T	;	2.511	;	The crystal structure of Mandelate oxidase R163L with 2-hydroxy-phenylacetamide
6A00	;	1.59	;	The crystal structure of Mandelate oxidase with (S)-2-phenylpropionate
5ZZQ	;	1.32	;	The crystal structure of Mandelate oxidase with (S)-4-Hydroxymandelic acid
5ZZR	;	1.31	;	The crystal structure of Mandelate oxidase with (S)-mandelic acid
5ZZT	;	1.35	;	The crystal structure of Mandelate oxidase with 3,3-difluoro-2-hydroxy-3-phenylpropionic acid
6A24	;	1.39	;	The crystal structure of Mandelate oxidase with 3-fluoropyruvate
5ZZS	;	1.398	;	The crystal structure of Mandelate oxidase with benzoic acid
6A08	;	1.547	;	The crystal structure of Mandelate oxidase with benzoyl-formic acid
5ZZZ	;	1.446	;	The crystal structure of Mandelate oxidase Y128C with benzoyl-formic acid
6A01	;	1.868	;	The crystal structure of Mandelate oxidase Y128F with 3,3-difluoro-2,2-dihydroxy-3-phenylpropionic acid
6A3D	;	1.923	;	The crystal structure of Mandelate oxidase Y128F with 4-Br-2-hydroxy-methylphenylacetate
6A39	;	1.89	;	The crystal structure of Mandelate oxidase Y128F with C4a-Malic acid-monooxide-FMN adduct
3SSZ	;	2.392	;	The crystal structure of Mandelate racemase/muconate lactonizing enzyme from Rhodobacteraceae bacterium
3U9I	;	2.9	;	The crystal structure of Mandelate racemase/muconate lactonizing enzyme from Roseiflexus sp.
3T4W	;	2.522	;	The crystal structure of mandelate racemase/muconate lactonizing enzyme from Sulfitobacter sp
3H2Z	;	1.9	;	The crystal structure of mannitol-1-phosphate dehydrogenase from Shigella flexneri
3BAN	;	2.9	;	The crystal structure of mannonate dehydratase from Streptococcus suis serotype2
7FIQ	;	2.22	;	The crystal structure of mannose-bound beta-1,2-mannobiose phosphorylase from Thermoanaerobacter sp.
8YGW	;	3.301	;	The Crystal Structure of MAPK11 from Biortus
8X23	;	1.5	;	The Crystal Structure of MAPK13 from Biortus.
8XU4	;	3.4	;	The Crystal Structure of MAPK2 from Biortus.
8XX1	;	2.55	;	The Crystal Structure of MAPKAP kinase 2 domain from Biortus
8XFL	;	3.0	;	The Crystal Structure of MARK4 from Biortus.
2X1D	;	1.64	;	The crystal structure of mature acyl coenzyme A:isopenicillin N acyltransferase from Penicillium chrysogenum
2X1E	;	2.0	;	The crystal structure of mature acyl coenzyme A:isopenicillin N acyltransferase from Penicillium chrysogenum in complex 6- aminopenicillanic acid
3FEO	;	2.5	;	The crystal structure of MBTD1
7M6B	;	1.9	;	The Crystal Structure of Mcbe1
3K05	;	1.33	;	The crystal structure of MDC1 BRCT T2067D in complex with a minimal recognition tetrapeptide with an amidated C-terminus
1RJN	;	2.3	;	The Crystal Structure of MenB (Rv0548c) from Mycobacterium tuberculosis in Complex with the CoA Portion of Naphthoyl CoA
3PCY	;	1.9	;	THE CRYSTAL STRUCTURE OF MERCURY-SUBSTITUTED POPLAR PLASTOCYANIN AT 1.9-ANGSTROMS RESOLUTION
4TQO	;	2.57	;	The crystal structure of methanol dehydrogenase from Methylococcus capsulatus (Bath)
1QLM	;	2.0	;	The crystal structure of methenyltetrahydromethanopterin cyclohydrolase from the hyperthermophilic archaeon Methanopyrus kandleri
4OMA	;	1.6	;	The crystal structure of methionine gamma-lyase from Citrobacter freundii in complex with L-cycloserine pyridoxal-5'-phosphate
3C2I	;	2.5	;	The Crystal Structure of Methyl-CpG Binding Domain of Human MeCP2 in Complex with a Methylated DNA Sequence from BDNF
2X8W	;	1.95	;	The Crystal Structure of Methylglyoxal Synthase from Thermus sp. GH5 Bound to Malonate.
2XW6	;	1.08	;	The Crystal Structure of Methylglyoxal Synthase from Thermus sp. GH5 Bound to Phosphate Ion.
1EF9	;	2.7	;	THE CRYSTAL STRUCTURE OF METHYLMALONYL COA DECARBOXYLASE COMPLEXED WITH 2S-CARBOXYPROPYL COA
4H12	;	2.06	;	The crystal structure of methyltransferase domain of human SET domain-containing protein 2 in complex with S-adenosyl-L-homocysteine
5SBJ	;	1.28	;	The crystal structure of METP in complex with Cd at a resolution of 1.29 A.
5SBI	;	1.799	;	The crystal structure of METP in complex with Co at a resolution of 1.80A.
5SBG	;	1.338	;	The crystal structure of METP in complex with Zn at a resolution of 1.34 A.
2X58	;	2.8	;	The crystal structure of MFE1 liganded with CoA
5BW0	;	2.0	;	The crystal structure of minor pseudopilin binary complex of XcpV and XcpW from the Type 2 secretion system of Pseudomonas aeruginosa
5VTM	;	2.041	;	The crystal structure of minor pseudopilin ternary complex of XcpVWX from the Type 2 secretion system of Pseudomonas aeruginosa
2C2P	;	1.75	;	The crystal structure of mismatch specific uracil-DNA glycosylase (MUG) from Deinococcus radiodurans
2C2Q	;	1.7	;	The crystal structure of mismatch specific uracil-DNA glycosylase (MUG) from Deinococcus radiodurans. Inactive mutant Asp93Ala.
8YHH	;	1.95	;	The Crystal Structure of Mitotic Kinesin Eg5 from Biortus
5F6L	;	1.9	;	The crystal structure of MLL1 (N3861I/Q3867L) in complex with RbBP5 and Ash2L
7W67	;	2.194	;	The crystal structure of MLL1 (N3861I/Q3867L/C3882SS)-RBBP5-ASH2L in complex with H3K4me0 peptide
7W6I	;	2.56	;	The crystal structure of MLL1 (N3861I/Q3867L/C3882SS)-RBBP5-ASH2L in complex with H3K4me1 peptide
7W6J	;	2.68	;	The crystal structure of MLL1 (N3861I/Q3867L/C3882SS)-RBBP5-ASH2L in complex with H3K4me2 peptide
5F5E	;	1.802	;	The Crystal Structure of MLL1 SET domain with N3816I/Q3867L mutation
7BRE	;	2.803	;	The crystal structure of MLL2 in complex with ASH2L and RBBP5
5F59	;	2.801	;	The crystal structure of MLL3 SET domain
7W6L	;	2.26	;	The crystal structure of MLL3-RBBP5-ASH2L in complex with H3K4me0 peptide
8WR5	;	1.7	;	The Crystal Structure of Mms2 from Biortus
8XFM	;	2.6	;	The Crystal Structure of MNK2 from Biortus.
3SGL	;	2.7	;	The crystal structure of MnmC from Yersinia pestis bound with FAD and SAM
1DEQ	;	3.5	;	THE CRYSTAL STRUCTURE OF MODIFIED BOVINE FIBRINOGEN (AT ~4 ANGSTROM RESOLUTION)
1UZ5	;	2.05	;	The Crystal Structure of molybdopterin biosynthesis moea protein from Pyrococcus horikosii
4H00	;	2.0	;	The crystal structure of mon-Zn dihydropyrimidinase from Tetraodon nigroviridis
4YU3	;	2.45	;	The crystal structure of mongoose (Helogale parvula) hemoglobin at pH 8.2
4ZJ0	;	1.5	;	The crystal structure of monomer Q108K:K40L:Y60W CRBPII bound to all-trans-retinal
4BHM	;	2.7	;	The crystal structure of MoSub1-DNA complex reveals a novel DNA binding mode
3CV6	;	2.1	;	The crystal structure of mouse 17-alpha hydroxysteroid dehydrogenase GG225.226PP mutant in complex with inhibitor and cofactor NADP+.
1WC8	;	1.9	;	The crystal structure of mouse bet3p
6ERY	;	1.795	;	The crystal structure of mouse chloride intracellular channel protein 6
6ERZ	;	1.923	;	The crystal structure of mouse chloride intracellular channel protein 6
5GUT	;	2.099	;	The crystal structure of mouse DNMT1 (731-1602) mutant - N1248A
5GUV	;	3.078	;	The crystal structure of mouse DNMT1 (731-1602) mutant - R1279D
2PFT	;	2.25	;	The Crystal Structure of Mouse Exo70 Reveals Unique Features of the Mammalian Exocyst
7MSJ	;	2.1	;	The crystal structure of mouse HVEM
7BYF	;	2.5	;	The crystal structure of mouse ORF10-Rae1-Nup98 complex
4BFM	;	2.35	;	The crystal structure of mouse PK38
4V0V	;	1.61	;	The crystal structure of mouse PP1G in complex with truncated human PPP1R15B (631-660)
4V0W	;	1.55	;	The crystal structure of mouse PP1G in complex with truncated human PPP1R15B (631-669)
4V0X	;	1.85	;	The crystal structure of mouse PP1G in complex with truncated human PPP1R15B (631-684)
4AJT	;	2.5	;	The crystal structure of mouse protein-Z dependent protease inhibitor(mZPI)
5IJD	;	2.7	;	The crystal structure of mouse TLR4/MD-2/lipid A complex
5IJC	;	2.57	;	The crystal structure of mouse TLR4/MD-2/neoseptin-3 complex
3EMN	;	2.3	;	The Crystal Structure of Mouse VDAC1 at 2.3 A resolution
4CQG	;	2.57	;	The crystal structure of MPK38 in complex with OTSSP167, an orally- administrative MELK selective inhibitor
3LWE	;	2.05	;	The crystal structure of MPP8
8CZQ	;	2.78	;	The crystal structure of MtbTOP1 in complex with both G- and T-segments
3FMW	;	2.89	;	The crystal structure of MtmOIV, a Baeyer-Villiger monooxygenase from the mithramycin biosynthetic pathway in Streptomyces argillaceus.
6A9Y	;	2.7	;	The crystal structure of Mu homology domain of SGIP1
2OQY	;	2.0	;	The crystal structure of muconate cycloisomerase from Oceanobacillus iheyensis
1BQS	;	2.2	;	THE CRYSTAL STRUCTURE OF MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1)
5UE8	;	3.35	;	The crystal structure of Munc13-1 C1C2BMUN domain
4X1Q	;	2.28	;	The crystal structure of mupain-1 in complex with murinised human uPA at pH7.4
4ZHM	;	1.9	;	The crystal structure of mupain-1--16-IG in complex with murinised human uPA at pH7.4
4X1R	;	2.1	;	The crystal structure of mupain-1-12 in complex with murinised human uPA at pH7.4
4X1N	;	1.8	;	The crystal structure of mupain-1-16 in complex with murinised human uPA at pH7.4
4X1S	;	1.9	;	The crystal structure of mupain-1-16-D9A in complex with murinised human uPA at pH7.4
4X0W	;	2.1	;	The crystal structure of mupain-1-17 in complex with murinised human uPA
4X1P	;	1.6	;	The crystal structure of mupain-1-17 in complex with murinised human uPA at pH4.6
6A8G	;	2.53	;	The crystal structure of muPAin-1-IG in complex with muPA-SPD at pH8.5
4ZHL	;	2.06	;	The crystal structure of mupain-1-IG in complex with murinised human uPA at pH7.4
6A8N	;	2.489	;	The crystal structure of muPAin-1-IG-2 in complex with muPA-SPD at pH8.5
1Y5R	;	3.0	;	The crystal structure of murine 11b-hydroxysteroid dehydrogenase complexed with corticosterone
1Y5M	;	2.3	;	The crystal structure of murine 11b-hydroxysteroid dehydrogenase: an important therapeutic target for diabetes
1U5Z	;	2.4	;	The Crystal structure of murine APRIL, pH 8.5
1QWJ	;	2.8	;	The Crystal Structure of Murine CMP-5-N-Acetylneuraminic Acid Synthetase
1DQT	;	2.0	;	THE CRYSTAL STRUCTURE OF MURINE CTLA4 (CD152)
1R7R	;	3.6	;	The crystal structure of murine p97/VCP at 3.6A
3WP5	;	1.32	;	The crystal structure of mutant CDBFV E109A from Neocallimastix patriciarum
1YL7	;	2.34	;	the crystal structure of Mycobacterium tuberculosis dihydrodipicolinate reductase (Rv2773c) in complex with NADH (crystal form C)
1R88	;	1.71	;	The crystal structure of Mycobacterium tuberculosis MPT51 (FbpC1)
6CCD	;	1.8	;	The crystal structure of Mycobacterium tuberculosis Rv1747 FHA-1
7E2P	;	1.7	;	The Crystal Structure of Mycoplasma bovis enolase
5L7K	;	2.1	;	The crystal structure of myristoylated NPHP3 peptide in complex with UNC119a
5J4Y	;	2.59	;	The crystal structure of N-(4-(2-(thiazolo[5,4-c]pyridin-2-yl)phenoxy)phenyl)acetamide bound to JCV Helicase
5NCK	;	2.23	;	The Crystal Structure of N-acetylmannosamine kinase in Fusobacterium nucleatum
4RN7	;	1.717	;	The crystal structure of N-acetylmuramoyl-L-alanine amidase from Clostridium difficile 630
8XOV	;	2.55	;	The Crystal Structure of N-terminal kinase domain of human RSK-1 from Biortus.
133D	;	1.8	;	THE CRYSTAL STRUCTURE OF N4-METHYLCYTOSINE.GUANOSIN BASE-PAIRS IN THE SYNTHETIC HEXANUCLEOTIDE D(CGCGM(4)CG)
8B77	;	2.7	;	The crystal structure of N828V variant of DNA Pol Epsilon containing dATP in the polymerase active site
8B7E	;	2.6	;	The crystal structure of N828V variant of DNA Pol Epsilon containing UTP in the polymerase active site
3RHE	;	2.053	;	The crystal structure of NAD-dependent benzaldehyde dehydrogenase from Legionella pneumophila
3A1F	;	2.0	;	The crystal structure of NADPH binding domain of gp91(phox)
3VOU	;	3.2	;	The crystal structure of NaK-NavSulP chimera channel
4O13	;	1.75	;	The crystal structure of NAMPT in complex with GNE-618
8K3K	;	2.43	;	The crystal structure of nanobody Nb4 in complex with receptor binding domain (RBD) of BA.1 Spike protein
5EP6	;	1.451	;	The crystal structure of NAP1 in complex with TBK1
3WP4	;	1.27	;	The crystal structure of native CDBFV from Neocallimastix patriciarum
8ILD	;	2.25	;	The crystal structure of native dGTP:DNApre-I:Pol X substrate ternary complex
3MJZ	;	2.4	;	The crystal structure of native FG41 MSAD
3WVJ	;	1.95	;	The crystal structure of native glycosidic hydrolase
3WRE	;	2.78	;	The crystal structure of native HypBA1 from Bifidobacterium longum JCM 1217
3WRF	;	2.25	;	The crystal structure of native HypBA1 from Bifidobacterium longum JCM 1217
4PK9	;	1.96	;	The Crystal Structure of Native Patatin
1OGL	;	2.4	;	The crystal structure of native Trypanosoma cruzi dUTPase
5GL8	;	1.8	;	The crystal structure of Nattokinase fragments
3C8J	;	2.6	;	The crystal structure of natural killer cell receptor Ly49C
6XMV	;	2.75	;	The crystal structure of Neisseria gonorrhoeae DolP (NGO1985)
6N4D	;	1.8	;	The crystal structure of neuramindase from A/canine/IL/11613/2015 (H3N2) influenza virus.
4WA3	;	1.801	;	The crystal structure of neuraminidase from a H3N8 influenza virus isolated from New England harbor seals
4WA4	;	1.95	;	The crystal structure of neuraminidase from a H3N8 influenza virus isolated from New England harbor seals in complex with oseltamivir carboxylate
4WA5	;	1.95	;	The crystal structure of neuraminidase from a H3N8 influenza virus isolated from New England harbor seals in complex with zanamivir
5HUG	;	1.85	;	The crystal structure of neuraminidase from A/American green-winged teal/Washington/195750/2014 influenza virus
5HUN	;	2.3	;	The crystal structure of neuraminidase from A/gyrfalcon/Washington/41088-6/2014 influenza virus
5HUK	;	2.45	;	The crystal structure of neuraminidase from A/Northern pintail/Washington/40964/2014 influenza virus
5L14	;	1.9	;	The crystal structure of neuraminidase from A/Shanghai/2/2013 (H7N9) influenza virus
5HUM	;	1.6	;	The crystal structure of neuraminidase from A/Sichuan/26221/2014 influenza virus
5L15	;	2.4	;	The crystal structure of neuraminidase in complex with oseltamivir from A/Shanghai/2/2013 (H7N9) influenza virus
5L18	;	1.8	;	The crystal structure of neuraminidase in complex with sialic acid from A/Shanghai/2/2013 (H7N9) influenza virus
5L17	;	2.4	;	The crystal structure of neuraminidase in complex with zanamivir from A/Shanghai/2/2013 (H7N9) influenza virus
1NTN	;	1.9	;	THE CRYSTAL STRUCTURE OF NEUROTOXIN-I FROM NAJA NAJA OXIANA AT 1.9 ANGSTROMS RESOLUTION
3PG4	;	2.0	;	The crystal structure of New Delhi Metallo-beta lactamase (NDM-1)
8YHW	;	2.9	;	The Crystal Structure of NF-kB-inducing Kinase (NIK) from Biortus
4Q3H	;	1.443	;	The crystal structure of NHERF1 PDZ2 CXCR2 complex revealed by the NHERF1 CXCR2 chimeric protein
7REI	;	1.78	;	The crystal structure of nickel bound human ADO C18S C239S variant
3OS4	;	1.601	;	The Crystal Structure of Nicotinate Phosphoribosyltransferase from Yersinia pestis
1Y4Z	;	2.0	;	The crystal structure of Nitrate Reductase A, NarGHI, in complex with the Q-site inhibitor pentachlorophenol
1N70	;	1.6	;	The Crystal Structure of Nitrite Reductase Mutant His287Ala from Rhodobacter Sphaeroides
2BMO	;	1.2	;	The Crystal Structure of Nitrobenzene Dioxygenase
2BMR	;	1.5	;	The Crystal Structure of Nitrobenzene Dioxygenase in complex with 3- nitrotoluene
2BMQ	;	1.55	;	The Crystal Structure of Nitrobenzene Dioxygenase in complex with nitrobenzene
5UU6	;	1.95	;	The crystal structure of nitroreductase A from Vibrio parahaemolyticus RIMD 2210633
4URP	;	2.991	;	The Crystal structure of Nitroreductase from Saccharomyces cerevisiae
4RBN	;	3.05	;	The crystal structure of Nitrosomonas europaea sucrose synthase: Insights into the evolutionary origin of sucrose metabolism in prokaryotes
5DHG	;	3.0	;	The crystal structure of nociceptin/orphanin FQ peptide receptor (NOP) in complex with C-35 (PSI Community Target)
5DHH	;	3.004	;	The crystal structure of nociceptin/orphanin FQ peptide receptor (NOP) in complex with SB-612111 (PSI Community Target)
7VYY	;	2.443	;	The crystal structure of Non-hydrolyzing UDPGlcNAc 2-epimerase
7VZA	;	2.58	;	The crystal structure of Non-hydrolyzing UDPGlcNAc 2-epimerase in complex with UDP
7VZ6	;	2.092	;	The crystal structure of Non-hydrolyzing UDPGlcNAc 2-epimerase in complex with UDP-glucose
4O2I	;	2.2	;	The crystal structure of non-LEE encoded type III effector C from Citrobacter rodentium
2R50	;	2.2	;	The crystal structure of nonsymbiotic corn hemoglobin 1
4ROV	;	1.8	;	The crystal structure of novel APOBEC3G CD2 head-to-tail dimer suggests the binding mode of full-length APOBEC3G to HIV-1 ssDNA
4ROW	;	1.7	;	The crystal structure of novel APOBEC3G CD2 head-to-tail dimer suggests the binding mode of full-length APOBEC3G to HIV-1 ssDNA
3VSM	;	2.0	;	The crystal structure of novel chondroition lyase ODV-E66, baculovirus envelope protein
3VSN	;	2.0	;	The crystal structure of novel chondroition lyase ODV-E66, baculovirus envelope protein
4CMR	;	1.8	;	The crystal structure of novel exo-type maltose-forming amylase(Py04_0872) from Pyrococcus sp. ST04
1E9L	;	2.5	;	The crystal structure of novel mammalian lectin Ym1 suggests a saccharide binding site
4CL1	;	3.5	;	The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors
6W4B	;	2.95	;	The crystal structure of Nsp9 RNA binding protein of SARS CoV-2
5ZVD	;	2.594	;	The crystal structure of NSun6 from Pyrococcus horikoshii
5ZVE	;	2.178	;	The crystal structure of NSun6 from Pyrococcus horikoshii with SAH
5ZVG	;	2.5	;	The crystal structure of NSun6 from Pyrococcus horikoshii with SAM
5ZVH	;	2.5	;	The crystal structure of NSun6 from Pyrococcus horikoshii with SFG
1K5J	;	2.3	;	The Crystal Structure of Nucleoplasmin-Core
7D8G	;	1.5	;	The crystal structure of nucleotide phosphatase Sa1684 from Staphylococcus aureus
3R03	;	2.491	;	The crystal structure of NUDIX hydrolase from Rhodospirillum rubrum
1EYV	;	1.6	;	THE CRYSTAL STRUCTURE OF NUSB FROM MYCOBACTERIUM TUBERCULOSIS
5JIS	;	2.2	;	The Crystal Structure of O-acetyl serine sulfhydralase from Brucella abortus
8BVK	;	2.0	;	The crystal structure of O-glycoside cleaving beta-eliminase from A. tumefaciens AtOGE
1JF0	;	1.82	;	The Crystal Structure of Obelin from Obelia geniculata at 1.82 A Resolution
7O3U	;	1.8	;	The crystal structure of obelin from Obelia longissima bound with v-coelenterazine
6OFD	;	2.2	;	The crystal structure of octadecyloxy(naphthalen-1-yl)methylphosphonic acid in complex with red kidney bean purple acid phosphatase
2D5W	;	1.3	;	The crystal structure of oligopeptide binding protein from Thermus thermophilus HB8 complexed with pentapeptide
5DUN	;	2.64	;	The crystal structure of OMe substituted twister ribozyme
4ERH	;	2.52	;	The crystal structure of OmpA domain of OmpA from Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S
3IRA	;	2.1	;	The crystal structure of one domain of the conserved protein from Methanosarcina mazei Go1
3H92	;	2.2	;	The crystal structure of one domain of the protein with unknown function from Methanocaldococcus jannaschii
3IPJ	;	1.2	;	The crystal structure of one domain of the PTS system, IIabc component from Clostridium difficile
7EKR	;	2.17	;	The crystal structure of Orange carotenoid binding protein 1 (OCP1)
7XLJ	;	2.45	;	The crystal structure of ORE1(ANAC092) NAC domain
3IT6	;	2.4	;	The Crystal Structure of Ornithine Acetyltransferase complexed with Ornithine from Mycobacterium tuberculosis (Rv1653) at 2.4 A
3IT4	;	1.7	;	The Crystal Structure of Ornithine Acetyltransferase from Mycobacterium tuberculosis (Rv1653) at 1.7 A
4F2G	;	2.1	;	The Crystal Structure of Ornithine carbamoyltransferase from Burkholderia thailandensis E264
3CKF	;	1.25	;	The crystal structure of OspA deletion mutant
3CKG	;	1.8	;	The crystal structure of OspA deletion mutant
2I5Z	;	1.2	;	The crystal structure of OspA mutant
2OL6	;	1.6	;	The crystal structure of OspA mutant
2OL7	;	1.35	;	The crystal structure of OspA mutant
2OL8	;	1.9	;	The crystal structure of OspA mutant
2OY1	;	1.86	;	The crystal structure of OspA mutant
2OY5	;	1.8	;	The crystal structure of OspA mutant
2OY7	;	1.55	;	The crystal structure of OspA mutant
2OY8	;	2.0	;	The crystal structure of OspA mutant
2OYB	;	1.3	;	The crystal structure of OspA mutant
2PI3	;	1.4	;	The crystal structure of OspA mutant
3CKA	;	1.65	;	The crystal structure of OspA mutant
3EEX	;	2.49	;	The crystal structure of OspA mutant
4NHE	;	1.95	;	The crystal structure of oxidoreductase (Gfo/Idh/MocA family) from Streptococcus pneumoniae TIGR4 in complex with NADP
3RHA	;	2.052	;	The crystal structure of Oxidoreductase from Arthrobacter aurescens
3RH9	;	2.63	;	The crystal structure of oxidoreductase from Marinobacter aquaeolei
3V5N	;	2.802	;	The crystal structure of oxidoreductase from Sinorhizobium meliloti
2O2Y	;	2.2	;	The crystal structure of P. falciparum enoyl acyl carrier protein reductase
6FP1	;	1.97	;	The crystal structure of P.fluorescens Kynurenine 3-monooxygenase (KMO) in complex with competitive inhibitor No. 1
6FOZ	;	2.15	;	The crystal structure of P.fluorescens Kynurenine 3-monooxygenase (KMO) in complex with competitive inhibitor No. 13
6FPH	;	2.0	;	The crystal structure of P.fluorescens Kynurenine 3-monooxygenase (KMO) in complex with competitive inhibitor No. 1h
6FP0	;	2.03	;	The crystal structure of P.fluorescens Kynurenine 3-monooxygenase (KMO) in complex with competitive inhibitor No. 4
6FOY	;	1.65	;	The crystal structure of P.fluorescens Kynurenine 3-monooxygenase (KMO) in complex with competitive inhibitor No. 9
6FOX	;	1.9	;	The crystal structure of P.fluorescens Kynurenine 3-monooxygenase (KMO) in complex with kynurenine
2UZ8	;	2.0	;	The crystal structure of p18, human translation elongation factor 1 epsilon 1
8YHK	;	3.3	;	The Crystal Structure of P21-Activated Kinases Pak4 from Biortus
4E8A	;	2.7	;	The crystal structure of p38a MAP kinase in complex with PIA24
5OPA	;	1.345	;	The crystal structure of P450 CYP121 in complex with lead compound 7b
5OP9	;	1.455	;	The crystal structure of P450 CYP121 in complex with lead compound 7e
7DVD	;	2.59	;	The crystal structure of p53 DNA binding domain and PUMA complex
8WD2	;	1.85	;	The Crystal Structure of p53 from Biortus.
8XP5	;	2.55	;	The Crystal Structure of p53/BCL-xL fusion complex from Biortus.
7EL4	;	2.11	;	The crystal structure of p53p peptide fragment in complex with the N-terminal domain of MdmX
8X5Z	;	1.8	;	The Crystal Structure of PAK1 kinase domain from Biortus.
7VTO	;	2.59	;	The crystal structure of PAK1 with the inhibitor GW8510
1PJA	;	2.7	;	The crystal structure of palmitoyl protein thioesterase-2 reveals the basis for divergent substrate specificities of the two lysosomal thioesterases (PPT1 and PPT2)
6W9C	;	2.7	;	The crystal structure of papain-like protease of SARS CoV-2
6WRH	;	1.6	;	The crystal structure of Papain-Like Protease of SARS CoV-2 , C111S mutant
6XG3	;	2.48	;	The crystal structure of Papain-Like Protease of SARS CoV-2 , C111S mutant, at room temperature
7JIR	;	2.09	;	The crystal structure of Papain-Like Protease of SARS CoV-2 , C111S mutant, in complex with PLP_Snyder457 inhibitor
7JIT	;	1.95	;	The crystal structure of Papain-Like Protease of SARS CoV-2 , C111S mutant, in complex with PLP_Snyder495 inhibitor
7JIV	;	2.05	;	The crystal structure of Papain-Like Protease of SARS CoV-2 , C111S mutant, in complex with PLP_Snyder530 inhibitor
6WZU	;	1.79	;	The crystal structure of Papain-Like Protease of SARS CoV-2 , P3221 space group
7JN2	;	1.93	;	The crystal structure of Papain-Like Protease of SARS CoV-2 in complex with PLP_Snyder441 inhibitor
7KOL	;	2.58	;	The crystal structure of Papain-Like Protease of SARS CoV-2 in complex with PLP_Snyder496 inhibitor
7JIW	;	2.3	;	The crystal structure of Papain-Like Protease of SARS CoV-2 in complex with PLP_Snyder530 inhibitor
7RBR	;	1.88	;	The crystal structure of Papain-Like Protease of SARS CoV-2, C111S mutant, in complex with a Lys48-linked di-ubiquitin
7M1Y	;	2.02	;	The crystal structure of Papain-Like Protease of SARS CoV-2, C111S mutant, in complex with ebselen
7RBS	;	2.98	;	The crystal structure of Papain-Like Protease of SARS CoV-2, C111S mutant, in complex with human ISG15
7KRX	;	2.72	;	The crystal structure of Papain-Like Protease of SARS CoV-2, C111S mutant, in complex with PLP_Snyder441 inhibitor
7KOJ	;	2.02	;	The crystal structure of Papain-Like Protease of SARS CoV-2, C111S mutant, in complex with PLP_Snyder494 inhibitor
7KOK	;	2.0	;	The crystal structure of Papain-Like Protease of SARS CoV-2, C111S mutant, in complex with PLP_Snyder496 inhibitor
7UV5	;	1.45	;	The crystal structure of Papain-Like Protease of SARS CoV-2, C111S/D286N mutant, in complex with a Lys48-linked di-ubiquitin
6D7J	;	2.24	;	The Crystal Structure of Parabacteroides merdae Beta-Glucuronidase (GUS) with Glycerol in Active-Site
7C62	;	2.027	;	The Crystal Structure of Parkinson disease protein 7 (DJ-1) from Biortus
8XPX	;	1.75	;	The Crystal Structure of PARP12 from Biortus.
8X5J	;	1.7	;	The Crystal Structure of PARP5A from Biortus.
6JM4	;	3.20015	;	The crystal structure of PB1 homo-dimer of human P62/SQSTM1
5ZC3	;	3.005	;	The Crystal Structure of PcRxLR12
2QTW	;	1.9	;	The Crystal Structure of PCSK9 at 1.9 Angstroms Resolution Reveals structural homology to Resistin within the C-terminal domain
8WFR	;	1.95	;	The Crystal Structure of PCSK9 from Biortus.
2XTJ	;	2.7	;	The crystal structure of PCSK9 in complex with 1D05 Fab
5ML3	;	1.4	;	The crystal structure of PDE6D in complex to Deltasonamide1
4JV6	;	1.87	;	The crystal structure of PDE6D in complex to inhibitor-1
5ML8	;	2.6	;	The crystal structure of PDE6D in complex to inhibitor-4
5ML4	;	2.4	;	The crystal structure of PDE6D in complex to inhibitor-7
5ML6	;	1.87	;	The crystal structure of PDE6D in complex to inhibitor-8
5ML2	;	1.6	;	The crystal structure of PDE6D in complex with inhibitor-3
4JV8	;	1.45	;	The crystal structure of PDE6D in complex with rac-S1
4JVF	;	2.4	;	The Crystal structure of PDE6D in complex with the inhibitor (s)-5
7PAC	;	2.05	;	The crystal structure of PDE6D in the apo state
5E80	;	2.6	;	The crystal structure of PDEd in complex with inhibitor-2a
7BQL	;	2.396	;	The crystal structure of PdxI complex with the Alder-ene adduct
2QBW	;	1.8	;	The crystal structure of PDZ-Fibronectin fusion protein
3CH8	;	1.9	;	The crystal structure of PDZ-Fibronectin fusion protein
5GNI	;	3.008	;	The crystal structure of PECAM-1 IgL1-2 trans-homophilic dimer
4N59	;	2.3	;	The Crystal Structure of Pectocin M2 at 2.3 Angstroms
5YKZ	;	1.17	;	The crystal structure of Penaeus vannamei nodavirus P-domain (P21)
5YL0	;	1.22	;	The crystal structure of Penaeus vannamei nodavirus P-domain (P212121)
3TG9	;	2.2	;	The crystal structure of penicillin binding protein from Bacillus halodurans
1V3Y	;	1.81	;	The crystal structure of peptide deformylase from Thermus thermophilus HB8
7E60	;	2.24	;	The crystal structure of peptidoglycan peptidase in complex with inhibitor 1
7E61	;	1.8	;	The crystal structure of peptidoglycan peptidase in complex with inhibitor 2
7E63	;	2.4	;	The crystal structure of peptidoglycan peptidase in complex with inhibitor 2-1
7E64	;	2.9	;	The crystal structure of peptidoglycan peptidase in complex with inhibitor 2-2
7E65	;	2.65	;	The crystal structure of peptidoglycan peptidase in complex with inhibitor 3
7E66	;	2.84	;	The crystal structure of peptidoglycan peptidase in complex with inhibitor 3-1
7E67	;	2.85	;	The crystal structure of peptidoglycan peptidase in complex with inhibitor 3-2
7E69	;	2.61	;	The crystal structure of peptidoglycan peptidase in complex with inhibitor 3-3
2RGV	;	2.05	;	The crystal structure of PerR-Ox highlights 2-oxo-Histidine formation
1PRT	;	2.9	;	THE CRYSTAL STRUCTURE OF PERTUSSIS TOXIN
4EPF	;	2.09	;	The crystal structure of pesticin from Yersinia pestis
4EPI	;	1.74	;	The crystal structure of pesticin-T4 lysozyme hybrid stabilized by engineered disulfide bonds
8B4U	;	1.71	;	The crystal structure of PET46, a PETase enzyme from Candidatus bathyarchaeota
3I2M	;	2.81	;	The Crystal Structure of PF-8, the DNA Polymerase Accessory Subunit from Kaposi s Sarcoma-Associated Herpesvirus
3HSL	;	2.8	;	The Crystal Structure of PF-8, the DNA Polymerase Accessory Subunit from Kaposi's Sarcoma-Associated Herpesvirus
6SBR	;	1.54	;	The crystal structure of PfA-M1 in complex with 7-amino-1,4-dibromo-5,7,8,9-tetrahydrobenzocyclohepten-6-one
6SBQ	;	1.33	;	The crystal structure of PfA-M1 in complex with 7-amino-4-phenyl-5,7,8,9-tetrahydrobenzocyclohepten-6-one
1OGQ	;	1.7	;	The crystal structure of PGIP (polygalacturonase inhibiting protein), a leucine rich repeat protein involved in plant defense
1I4Z	;	2.1	;	THE CRYSTAL STRUCTURE OF PHASCOLOPSIS GOULDII L98Y METHEMERYTHRIN
1I4Y	;	1.8	;	THE CRYSTAL STRUCTURE OF PHASCOLOPSIS GOULDII WILD TYPE METHEMERYTHRIN
2X5X	;	1.2	;	The crystal structure of PhaZ7 at atomic (1.2 Angstrom) resolution reveals details of the active site and suggests a substrate binding mode
2X76	;	1.45	;	The crystal structure of PhaZ7 at atomic (1.2 Angstrom) resolution reveals details of the active site and suggests a substrate binding mode
1EIY	;	3.3	;	THE CRYSTAL STRUCTURE OF PHENYLALANYL-TRNA SYNTHETASE FROM THERMUS THERMOPHILUS COMPLEXED WITH COGNATE TRNAPHE
5UNC	;	1.71	;	The crystal structure of PHOSPHOENOLPYRUVATE PHOSPHOMUTASE from Streptomyces platensis subsp. rosaceus
3IE7	;	1.6	;	The crystal structure of phosphofructokinase (lin2199) from Listeria innocua in complex with ATP at 1.6A
1ZXX	;	1.85	;	The crystal structure of phosphofructokinase from Lactobacillus delbrueckii
3HIC	;	2.02	;	THE CRYSTAL STRUCTURE OF PHOSPHOFRUCTOKINASE(Lin2199)FROM Listeria innocua
1GZV	;	3.51	;	The crystal structure of phosphoglucose isomerase from pig muscle complexed with 5-phosphoarabinonate
2GC0	;	2.0	;	The crystal structure of phosphoglucose isomerase from Pyrococcus furiosus in complex with 5-phospho-D-arabinonohydroxamate and zinc
2GC2	;	2.1	;	The crystal structure of phosphoglucose isomerase from Pyrococcus furiosus in complex with Fructose 6-phosphate and zinc
2GC3	;	2.1	;	The crystal structure of phosphoglucose isomerase from Pyrococcus furiosus in complex with mannose 6-phosphate and zinc
2GC1	;	1.95	;	The crystal structure of phosphoglucose isomerase from Pyrococcus furiosus in complex with sorbitol 6-phosphate and zinc
1N8T	;	2.5	;	The crystal structure of phosphoglucose isomerase from rabbit muscle
1B0Z	;	2.3	;	The crystal structure of phosphoglucose isomerase-an enzyme with autocrine motility factor activity in tumor cells
2PGI	;	2.3	;	THE CRYSTAL STRUCTURE OF PHOSPHOGLUCOSE ISOMERASE-AN ENZYME WITH AUTOCRINE MOTILITY FACTOR ACTIVITY IN TUMOR CELLS
1C7Q	;	2.3	;	THE CRYSTAL STRUCTURE OF PHOSPHOGLUCOSE ISOMERASE/AUTOCRINE MOTILITY FACTOR/NEUROLEUKIN COMPLEXED WITH ITS CARBOHYDRATE PHOSPHATE INHIBITORS AND ITS SUBSTRATE RECOGNITION MECHANISM
1C7R	;	2.5	;	THE CRYSTAL STRUCTURE OF PHOSPHOGLUCOSE ISOMERASE/AUTOCRINE MOTILITY FACTOR/NEUROLEUKIN COMPLEXED WITH ITS CARBOHYDRATE PHOSPHATE INHIBITORS AND ITS SUBSTRATE RECOGNITION MECHANISM
5YRR	;	2.88	;	The crystal structure of Phosphopantetheine adenylyltransferase from Acinetobacter baumannii with Coenzyme A at 2.88 A resolution
1OD6	;	1.5	;	The Crystal Structure of Phosphopantetheine adenylyltransferase from Thermus Thermophilus in complex with 4'-phosphopantetheine
6UNC	;	2.5	;	The crystal structure of Phosphopantetheinyl Hydrolase (PptH) from Mycobacterium tuberculosis
4M9U	;	1.599	;	The crystal structure of phosphoribosylaminoimidazole carboxylase ATPase subunit of Francisella tularensis subsp. tularensis SCHU S4
5JQW	;	2.06	;	The crystal structure of phosphoribosylaminoimidazole carboxylase ATPase subunit of Francisella tularensis subsp. tularensis SCHU S4 in complex with ADP
4MAM	;	1.474	;	The crystal structure of phosphoribosylaminoimidazole carboxylase ATPase subunit of Francisella tularensis subsp. tularensis SCHU S4 in complex with an ADP analog, AMP-CP
4MA5	;	1.809	;	The crystal structure of phosphoribosylaminoimidazole carboxylase ATPase subunit of Francisella tularensis subsp. tularensis SCHU S4 in complex with an ATP analog, AMP-PNP.
4MA0	;	1.982	;	The crystal structure of phosphoribosylaminoimidazole carboxylase ATPase subunit of Francisella tularensis subsp. tularensis SCHU S4 in complex with partially hydrolysed ATP
5CJJ	;	2.42	;	The crystal structure of phosphoribosylglycinamide formyltransferase from Campylobacter jejuni subsp. jejuni NCTC 11168
4S1N	;	2.7	;	The crystal structure of phosphoribosylglycinamide formyltransferase from Streptococcus pneumoniae TIGR4
3A77	;	1.8	;	The crystal structure of phosphorylated IRF-3
1XWM	;	2.5	;	The crystal structure of PhoU (phosphate uptake regulator), Structural genomics
2BV8	;	2.01	;	The crystal structure of Phycocyanin from Gracilaria chilensis.
6INR	;	2.34	;	The crystal structure of phytoplasmal effector causing phyllody symptoms 1 (PHYL1)
5I6U	;	2.842	;	The crystal structure of PI3Kdelta with compound 32
5I4U	;	2.372	;	The crystal structure of PI3Kdelta with compound 34
2EG1	;	1.8	;	The crystal structure of PII protein
2EG2	;	1.72	;	The crystal structure of PII protein
2Z0G	;	2.1	;	The crystal structure of PII protein
8WZD	;	2.05	;	The Crystal Structure of PKCi from Biortus
1WZ3	;	1.8	;	The crystal structure of plant ATG12
2ZFD	;	1.2	;	The crystal structure of plant specific calcium binding protein AtCBL2 in complex with the regulatory domain of AtCIPK14
1OGP	;	2.6	;	The crystal structure of plant sulfite oxidase provides insight into sulfite oxidation in plants and animals
2BMA	;	2.7	;	The crystal structure of Plasmodium falciparum glutamate dehydrogenase, a putative target for novel antimalarial drugs
2H66	;	2.5	;	The Crystal Structure of Plasmodium Vivax 2-Cys peroxiredoxin
7PCY	;	1.8	;	THE CRYSTAL STRUCTURE OF PLASTOCYANIN FROM A GREEN ALGA, ENTEROMORPHA PROLIFERA
8X72	;	2.2	;	The Crystal Structure of PLK1 from Biortus.
7X80	;	1.97	;	The crystal structure of PloI4-C16M/D46A/I137V
7X81	;	2.104	;	The crystal structure of PloI4-C16M/D46A/I137V in complex with exo-2+2 adduct
7X86	;	2.303	;	The crystal structure of PloI4-F124L in complex with endo-4+2 adduct
4CP6	;	1.34	;	The Crystal structure of Pneumococcal vaccine antigen PcpA
6H1V	;	2.7	;	The crystal structure of Pol2CORE in complex with DNA and an incoming nucleotide, carrying an Fe-S cluster
6QIB	;	2.8	;	The crystal structure of Pol2CORE in complex with DNA and an incoming nucleotide, carrying an Fe-S cluster
6FWK	;	2.503	;	The crystal structure of Pol2CORE-M644G in complex with DNA and an incoming nucleotide
8XPG	;	2.7	;	The Crystal Structure of polo box domain of Plk4 from Biortus.
8XB9	;	1.95	;	The Crystal Structure of polo-box domain of PLK1 from Biortus.
5BY9	;	4.0	;	The crystal structure of polyglycilated 14-3-3 protein from Giardia intestinalis
2PCY	;	1.8	;	THE CRYSTAL STRUCTURE OF POPLAR APOPLASTOCYANIN AT 1.8-ANGSTROMS RESOLUTION. THE GEOMETRY OF THE COPPER-BINDING SITE IS CREATED BY THE POLYPEPTIDE
3IFU	;	2.42	;	The Crystal Structure of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Leader Protease Nsp1
4KTB	;	1.936	;	The crystal structure of posible asymmetric diadenosine tetraphosphate (Ap(4)A) hydrolases from Jonesia denitrificans DSM 20603
3BWG	;	2.09	;	The crystal structure of possible transcriptional regulator YydK from Bacillus subtilis subsp. subtilis str. 168
4ZHP	;	2.46	;	The crystal structure of Potato ferredoxin I with 2Fe-2S cluster
8WFE	;	2.2	;	The Crystal Structure of PPARg from Biortus.
2X7K	;	1.15	;	The crystal structure of PPIL1 in complex with cyclosporine A suggests a binding mode for SKIP
2X1C	;	1.85	;	The crystal structure of precursor acyl coenzyme A:isopenicillin N acyltransferase from Penicillium chrysogenum
3K32	;	2.5	;	The crystal structure of predicted subunit of tRNA methyltransferase from Methanocaldococcus jannaschii DSM
3PQB	;	2.324	;	The crystal structure of pregilvocarcin in complex with GilR, an oxidoreductase that catalyzes the terminal step of gilvocarcin biosynthesis
4K5S	;	1.9	;	The crystal structure of premithramycin B in complex with MTMOIV, a baeyer-villiger monooxygenase from the mithramycin biosynthetic pathway in streptomyces argillaceus.
3MWB	;	2.0	;	The Crystal Structure of Prephenate dehydratase in complex with L-Phe from Arthrobacter aurescens to 2.0A
8X5L	;	2.75	;	The Crystal Structure of PRKACA from Biortus.
3HDJ	;	1.7	;	The crystal structure of probable ornithine cyclodeaminase from Bordetella pertussis Tohama I
2ESN	;	2.1	;	The crystal structure of probable transcriptional regulator PA0477 from Pseudomonas aeruginosa
1FAZ	;	1.4	;	THE CRYSTAL STRUCTURE OF PROKARYOTIC PHOSPHOLIPASE A2
1X2E	;	2.4	;	The crystal structure of prolyl aminopeptidase complexed with Ala-TBODA
1X2B	;	2.4	;	The crystal structure of prolyl aminopeptidase complexed with Sar-TBODA
2PMW	;	2.3	;	The Crystal Structure of Proprotein convertase subtilisin kexin type 9 (PCSK9)
1VBJ	;	2.1	;	The crystal structure of prostaglandin F synthase from Trypanosoma brucei
3FVF	;	1.6	;	The Crystal Structure of Prostasin Complexed with Camostat at 1.6 Angstroms Resolution
3TNE	;	2.4	;	The crystal structure of protease Sapp1p from Candida parapsilosis in complex with the HIV protease inhibitor ritonavir
3HIU	;	1.85	;	The crystal structure of protein (XCC3681) from Xanthomonas campestris pv. campestris str. ATCC 33913
2HNG	;	1.63	;	The Crystal Structure of Protein of Unknown Function SP1558 from Streptococcus pneumoniae
2FEF	;	1.9	;	The Crystal Structure of Protein PA2201 from Pseudomonas aeruginosa
4DZR	;	2.551	;	The crystal structure of protein-(glutamine-N5) methyltransferase (release factor-specific) from Alicyclobacillus acidocaldarius subsp. acidocaldarius DSM 446
3OF7	;	1.9	;	The Crystal Structure of Prp20p from Saccharomyces cerevisiae and Its Binding Properties to Gsp1p and Histones
4RTI	;	1.8	;	The crystal structure of PsbP from Spinacia oleracea
4RTH	;	1.6	;	The crystal structure of PsbP from Zea mays
8EJU	;	1.74	;	The crystal structure of Pseudomonas putida PcaR
8EJV	;	2.43	;	The crystal structure of Pseudomonas putida PcaR in complex with succinate
4EQ6	;	1.8	;	The crystal structure of Psy3-Csm2 complex from budding yeast
3L8R	;	2.5	;	The crystal structure of PtcA from S. mutans
8XOY	;	1.55	;	The Crystal Structure of PTP1B from Biortus.
8XQD	;	2.55	;	The Crystal Structure of PTPRG from Biortus.
2F9H	;	1.57	;	The Crystal Structure of PTS System IIA Component from Enterococcus faecalis V583
7VF6	;	1.703	;	The crystal structure of PurZ0
2PJZ	;	1.9	;	The crystal structure of putative Cobalt transport ATP-binding protein (cbiO-2), ST1066
2AFR	;	2.3	;	The Crystal Structure of Putative Precorrin Isomerase CbiC in Cobalamin Biosynthesis
2AFV	;	3.0	;	The Crystal Structure of Putative Precorrin Isomerase CbiC in Cobalamin Biosynthesis
3NRT	;	2.54	;	The crystal structure of putative ryanodine receptor from Bacteroides thetaiotaomicron VPI-5482
3EOQ	;	2.29	;	The crystal structure of putative zinc protease beta-subunit from Thermus thermophilus HB8
1PVU	;	2.4	;	THE CRYSTAL STRUCTURE OF PVUII ENDONUCLEASE REVEALS EXTENSIVE STRUCTURAL HOMOLOGIES TO ECORV
3QJ6	;	2.3	;	The crystal structure of PWWP domain of human Hepatoma-derived growth factor 2 in complex with H3K79me3 peptide
8HIB	;	2.45	;	The crystal structure of Pygo2-LDB1-SSBP2 triple complex
4LE7	;	2.09	;	The Crystal Structure of Pyocin L1 at 2.09 Angstroms
4LEA	;	2.55	;	The Crystal Structure of Pyocin L1 bound to D-mannose at 2.55 Angstroms
4LED	;	2.37	;	The Crystal Structure of Pyocin L1 bound to D-rhamnose at 2.37 Angstroms
3S2S	;	1.7	;	The crystal structure of pyrazinamidase/nicotinamidase from streptococcus mutans UA159
1BRW	;	2.1	;	THE CRYSTAL STRUCTURE OF PYRIMIDINE NUCLEOSIDE PHOSPHORYLASE IN A CLOSED CONFORMATION
2JJQ	;	1.8	;	The crystal structure of Pyrococcus abyssi tRNA (uracil-54, C5)- methyltransferase in complex with S-adenosyl-L-homocysteine
2VS1	;	2.1	;	The crystal structure of Pyrococcus abyssi tRNA (uracil-54, C5)- methyltransferase in complex with S-adenosyl-L-homocysteine
1X7N	;	1.89	;	The crystal structure of Pyrococcus furiosus phosphoglucose isomerase with bound 5-phospho-D-arabinonate and Manganese
5X4H	;	2.801	;	The crystal structure of Pyrococcus furiosus RecJ (wild-type)
5X4J	;	2.04	;	The crystal structure of Pyrococcus furiosus RecJ (Zn-soaking)
1W85	;	2.0	;	The crystal structure of pyruvate dehydrogenase E1 bound to the peripheral subunit binding domain of E2
1W88	;	2.3	;	The crystal structure of pyruvate dehydrogenase E1(D180N,E183Q) bound to the peripheral subunit binding domain of E2
1MT1	;	2.2	;	The Crystal Structure of Pyruvoyl-dependent Arginine Decarboxylase from Methanococcus jannaschii
1N13	;	1.4	;	The Crystal Structure of Pyruvoyl-dependent Arginine Decarboxylase from Methanococcus jannashii
7LSQ	;	1.67131	;	The Crystal Structure of Q108K:K40E:T53A:R58W:Q38F:Q4F:Y19W Mutant of HCRBPII Bound with LizFluor Chromophore Showing Excited State Intermolecular Proton Transfer
7MFX	;	1.59	;	The Crystal Structure of Q108K:K40H:T53A:R58L:Q38F:Q4F Mutant of HCRBPII Bound with FR1 Chromophore Showing Excited State Intermolecular Proton Transfer
7MFY	;	1.26	;	The Crystal Structure of Q108K:K40L:T51V:T53S:R58W:Y19W:A33W:L117E Mutant of HCRBPII Bound with LizFluor
4HQE	;	2.299	;	The crystal structure of QsrR-DNA complex
4HQM	;	2.55	;	The crystal structure of QsrR-menadione complex
1KD5	;	1.58	;	The Crystal Structure of r(GGUCACAGCCC)2 metal free form
1KD4	;	1.85	;	The Crystal Structure of r(GGUCACAGCCC)2, Barium form
1KD3	;	1.8	;	The Crystal Structure of r(GGUCACAGCCC)2, Thallium form
4N05	;	2.605	;	The crystal structure of R43A mutant putative ryanodine receptor from Bacteroides Thetaiotaomicron VPI-5482
4LLC	;	2.0	;	The crystal structure of R60E mutant of the histidine kinase (KinB) sensor domain from Pseudomonas aeruginosa PA01
4LLE	;	1.68	;	The crystal structure of R60L mutant of the histidine kinase (KinB) sensor domain from Pseudomonas aeruginosa PA01
5FZT	;	2.1	;	The crystal structure of R7R8 in complex with a DLC1 fragment.
8WFQ	;	3.5	;	The Crystal Structure of RALDH1 from Biortus.
5JIU	;	2.054	;	The crystal structure of RanBPM/9 IUS-SPRY domain in complex with DDX-4 peptide
4QFI	;	1.784	;	The crystal structure of rat angiogenin-heparin complex
4QFJ	;	2.196	;	The crystal structure of rat angiogenin-heparin complex
7VS3	;	2.595	;	The crystal structure of rat calcium-dependent activator protein for secretion (CAPS) C2PH
6A68	;	2.901	;	the crystal structure of rat calcium-dependent activator protein for secretion (CAPS) DAMH domain
7F5H	;	3.0	;	The crystal structure of RBD-Nanobody complex, DL28 (SC4)
7F5G	;	1.75	;	The crystal structure of RBD-Nanobody complex, DL4 (SA4)
3FUO	;	1.8	;	The Crystal structure of receptor binding domain of botulinum neurotoxin serotype A
1W3S	;	2.4	;	The crystal structure of RecO from Deinococcus radiodurans.
2WUX	;	1.838	;	the crystal structure of recombinant baculovirus polyhedra
7RST	;	1.69	;	The Crystal Structure of Recombinant Chloroperoxidase Expressed in Aspergillus niger
2OH6	;	2.1	;	The Crystal Structure of Recombinant Cypovirus Polyhedra
1RNE	;	2.4	;	THE CRYSTAL STRUCTURE OF RECOMBINANT GLYCOSYLATED HUMAN RENIN ALONE AND IN COMPLEX WITH A TRANSITION STATE ANALOG INHIBITOR
6KYE	;	2.28	;	The crystal structure of recombinant human adult hemoglobin
1NAP	;	1.9	;	THE CRYSTAL STRUCTURE OF RECOMBINANT HUMAN NEUTROPHIL-ACTIVATING PEPTIDE-2 (M6L) AT 1.9-ANGSTROMS RESOLUTION
3COO	;	2.0	;	The crystal structure of Reelin-N domain of F-spondin
2NZJ	;	2.5	;	The crystal structure of REM1 in complex with GDP
1PP4	;	2.5	;	The crystal structure of rhamnogalacturonan acetylesterase in space group P3121
2FV8	;	1.9	;	The crystal structure of RhoB in the GDP-bound state
2P7U	;	1.65	;	The crystal structure of rhodesain, the major cysteine protease of T. brucei rhodesiense, bound to inhibitor K777
1EU1	;	1.3	;	THE CRYSTAL STRUCTURE OF RHODOBACTER SPHAEROIDES DIMETHYLSULFOXIDE REDUCTASE REVEALS TWO DISTINCT MOLYBDENUM COORDINATION ENVIRONMENTS.
2Q3H	;	1.73	;	The crystal structure of RhouA in the GDP-bound state.
2G6V	;	2.6	;	The crystal structure of ribD from Escherichia coli
2OBC	;	3.0	;	The crystal structure of RibD from Escherichia coli in complex with a substrate analogue, ribose 5-phosphate (beta form), bound to the active site of the reductase domain
2O7P	;	3.0	;	The crystal structure of RibD from Escherichia coli in complex with the oxidised NADP+ cofactor in the active site of the reductase domain
1JN4	;	1.8	;	The Crystal Structure of Ribonuclease A in complex with 2'-deoxyuridine 3'-pyrophosphate (P'-5') adenosine
3LXO	;	1.549	;	The crystal structure of ribonuclease A in complex with thymidine-3'-monophosphate
1RBB	;	2.5	;	THE CRYSTAL STRUCTURE OF RIBONUCLEASE B AT 2.5-ANGSTROMS RESOLUTION
1BOL	;	2.0	;	THE CRYSTAL STRUCTURE OF RIBONUCLEASE RH FROM RHIZOPUS NIVEUS AT 2.0 A RESOLUTION
3IGR	;	2.0	;	The Crystal Structure of Ribosomal-protein-S5-alanine Acetyltransferase from Vibrio fischeri to 2.0A
3PTK	;	2.49	;	The crystal structure of rice (Oryza sativa L.) Os4BGlu12
3PTM	;	2.4	;	The crystal structure of rice (Oryza sativa L.) Os4BGlu12 with 2-fluoroglucopyranoside
3PTQ	;	2.45	;	The crystal structure of rice (Oryza sativa L.) Os4BGlu12 with dinitrophenyl 2-deoxy-2-fluoro-beta-D-glucopyranoside
7DV8	;	2.447	;	The crystal structure of rice immune receptor RGA5-HMA2.
3I5H	;	3.4	;	The crystal structure of rigor like squid myosin S1 in the absence of nucleotide
3N6L	;	2.6	;	The crystal structure of RNA-dependent RNA polymerase of EV71 virus
1YRG	;	2.66	;	THE CRYSTAL STRUCTURE OF RNA1P: A NEW FOLD FOR A GTPASE-ACTIVATING PROTEIN
2G8Q	;	1.5	;	The crystal structure of RNase A from monoclinic crystals at 100 K
7ZWG	;	1.31	;	The Crystal structure of RO4493940 bound to CK2alpha
7A4Q	;	1.42	;	The Crystal structure of RO4613269 bound to CK2alpha
7RGU	;	3.2	;	The crystal structure of RocC bound to a transcriptional terminator
7RGT	;	2.02	;	The crystal structure of RocC, containing FinO domain, 1-126
7RGS	;	2.1	;	The crystal structure of RocC, containing FinO domain, 24-126
8XU5	;	3.5	;	The Crystal Structure of RORgT from Biortus.
5H6X	;	1.6	;	The crystal structure of RpoS fragment including a partial region 1.2 and region 2 from intracellular pathogen Legionella pneumophila
3C8O	;	1.9	;	The Crystal Structure of RraA from PAO1
7XBG	;	3.37	;	The crystal structure of RshSTT182/200 RBD-insert2-T346R-Y496G mutant in complex with human ACE2
8WF4	;	2.65	;	The Crystal Structure of RSK1 from Biortus.
8XFY	;	3.2	;	The Crystal Structure of RSK2 from Biortus.
8POF	;	1.85	;	The crystal structure of RsSymEG1 reveals a unique form of smaller GH7 endoglucanases alongside GH7 cellobiohydrolases in protist symbionts of termites
1BXN	;	2.7	;	THE CRYSTAL STRUCTURE OF RUBISCO FROM ALCALIGENES EUTROPHUS TO 2.7 ANGSTROMS.
7FF5	;	2.37	;	The crystal structure of Ruminiclostridium cellulolyticum Phosphocarrier
5Z18	;	2.495	;	The crystal structure of Ruminococcus gnavus beta-glucuronidase
5Z19	;	2.503	;	The crystal structure of Ruminococcus gnavus beta-glucuronidase in complex with uronic isofagomine
3CIS	;	2.9	;	The Crystal Structure of Rv2623 from Mycobacterium tuberculosis
5YO2	;	2.997	;	The crystal structure of Rv2747 from Mycobacterium tuberculosis in complex with Acetyl CoA and L-Arginine
6ADD	;	2.301	;	The crystal structure of Rv2747 from Mycobacterium tuberculosis in complex with CoA and NLQ
6FM4	;	2.7	;	The crystal structure of S. aureus Gyrase complex with ID-130 and DNA
2DCM	;	2.9	;	The Crystal Structure of S603A Mutated Prolyl Tripeptidyl Aminopeptidase Complexed with Substrate
3A7P	;	2.8	;	The crystal structure of Saccharomyces cerevisiae Atg16
2DYT	;	2.5	;	The crystal structure of Saccharomyces cerevisiae Atg3
2DYM	;	2.2	;	The crystal structure of Saccharomyces cerevisiae Atg5- Atg16(1-46) complex
2DYO	;	1.97	;	The crystal structure of Saccharomyces cerevisiae Atg5- Atg16(1-57) complex
2ZPN	;	2.7	;	The crystal structure of Saccharomyces cerevisiae Atg8- Atg19(412-415) complex
1LBQ	;	2.4	;	The crystal structure of Saccharomyces cerevisiae ferrochelatase
6L5T	;	1.72	;	The crystal structure of SADS-CoV Papain Like protease
5F1A	;	2.38	;	The Crystal Structure of Salicylate Bound to Human Cyclooxygenase-2
6L0Z	;	1.6	;	The crystal structure of Salmonella enterica sugar-binding protein MalE
7ZG5	;	2.0	;	The crystal structure of Salmonella TacAT3-DNA complex
4HT3	;	1.3	;	The crystal structure of Salmonella typhimurium Tryptophan Synthase at 1.30A complexed with N-(4'-TRIFLUOROMETHOXYBENZENESULFONYL)-2-AMINO-1-ETHYLPHOSPHATE (F9) inhibitor in the alpha site, internal aldimine
1ZA7	;	2.7	;	The crystal structure of salt stable cowpea cholorotic mottle virus at 2.7 angstroms resolution.
3NX5	;	2.31	;	The crystal structure of Sanguinarine bound to DNA d(CGTACG)
2FA9	;	2.5	;	The crystal structure of Sar1[H79G]-GDP provides insight into the coat-controlled GTP hydrolysis in the disassembly of COP II
2CME	;	2.8	;	The crystal structure of SARS coronavirus ORF-9b protein
2GA6	;	2.7	;	The crystal structure of SARS nsp10 without zinc ion as additive
8H6I	;	1.9	;	The crystal structure of SARS-CoV-2 3C-like protease Double Mutant (L50F and E166V) in complex with a traditional Chinese Medicine Inhibitors
7VIC	;	2.1	;	The crystal structure of SARS-CoV-2 3C-like protease in complex with a traditional Chinese Medicine Inhibitors
7VTH	;	2.0	;	The crystal structure of SARS-CoV-2 3CL protease in complex with compound 1
7VU6	;	1.8	;	The crystal structure of SARS-CoV-2 3CL protease in complex with compound 3
8HBK	;	1.8	;	The crystal structure of SARS-CoV-2 3CL protease in complex with Ensitrelvir
7D64	;	2.45012	;	The crystal structure of SARS-CoV-2 3CLpro with Zinc
8GXG	;	1.69	;	The crystal structure of SARS-CoV-2 main protease in complex with 14a
8GXH	;	1.59	;	The crystal structure of SARS-CoV-2 main protease in complex with 14b
8GXI	;	1.69	;	The crystal structure of SARS-CoV-2 main protease in complex with 14c
7L5D	;	1.58	;	The crystal structure of SARS-CoV-2 Main Protease in complex with demethylated analog of masitinib
7CBT	;	2.346	;	The crystal structure of SARS-CoV-2 main protease in complex with GC376
7JU7	;	1.6	;	The crystal structure of SARS-CoV-2 Main Protease in complex with masitinib
7KYU	;	1.48	;	The crystal structure of SARS-CoV-2 Main Protease with the formation of Cys145-1H-indole-5-carboxylate
6YZ1	;	2.4	;	The crystal structure of SARS-CoV-2 nsp10-nsp16 methyltransferase complex with Sinefungin
7XBY	;	2.85	;	The crystal structure of SARS-CoV-2 Omicron BA.1 variant RBD in complex with equine ACE2
7TVS	;	1.88613	;	The Crystal Structure of SARS-CoV-2 Omicron Mpro (P132H) in complex with demethylated analog of masitinib
7TVX	;	2.094	;	The Crystal Structure of SARS-CoV-2 Omicron Mpro (P132H) in complex with masitinib
7D7K	;	1.9	;	The crystal structure of SARS-CoV-2 papain-like protease in apo form
7D7L	;	2.11	;	The crystal structure of SARS-CoV-2 papain-like protease in complex with YM155
6DNM	;	1.397	;	The crystal structure of SatS c-terminal domain
6DRQ	;	2.3	;	The crystal structure of SatS c-terminal domain in complex with bromine
6LYJ	;	2.1	;	The crystal structure of SAUGI/EBVUDG complex
5AYR	;	2.4	;	The crystal structure of SAUGI/human UDG complex
6LYV	;	2.7	;	The crystal structure of SAUGI/KSHVUDG complex
5WSX	;	2.4	;	The crystal structure of SAV606
6H30	;	2.8	;	The crystal structure of SBD1-SBD2 tandem of GlnPQ transporter
2OFC	;	1.11	;	The crystal structure of Sclerotium rolfsii lectin
2OFD	;	1.96	;	The Crystal Structure of Sclerotium rolfsii lectin in complex with N-acetyl-D-galactosamine
2OFE	;	1.7	;	The Crystal structure of Sclerotium rolfsii lectin in complex with N-acetyl-D-glucosamine
4YLD	;	1.7	;	The crystal structure of Sclerotium Rolfsii lectin variant 1 (SSR1)
4Z2Q	;	1.9	;	The crystal structure of Sclerotium Rolfsii lectin variant 1 (SSR1) in complex with N-acetyl-glucosamine
4Z2S	;	1.7	;	The crystal structure of Sclerotium Rolfsii lectin variant 2 (SSR2) in complex with N-acetyl-glucosamine
7D8F	;	1.15	;	The crystal structure of ScNTM1 in complex with SAH
7D8D	;	1.05	;	The crystal structure of ScNTM1 in complex with SAH and Rps25a hexapeptide
7SCP	;	1.99	;	The crystal structure of ScoE in complex with intermediate
5IHW	;	1.25	;	The crystal structure of SdrE from staphylococcus aureus
6IMJ	;	2.554	;	The crystal structure of Se-AsfvLIG:DNA complex
5HR9	;	2.2	;	The crystal structure of Se-AsfvPolX(L52/163M mutant) in complex with 1nt-gap DNA1
6F03	;	2.2	;	The crystal structure of secreted antigen BPSL2520
3U0O	;	2.25	;	The crystal structure of selenophosphate synthetase from E. coli
1OXW	;	2.2	;	The Crystal Structure of SeMet Patatin
5HD2	;	2.276	;	The crystal structure of SeMet-Cry51Aa2-L11M
5EGF	;	2.29	;	The crystal structure of SeMet-CT
3ICY	;	2.684	;	The crystal structure of sensory box histidine kinase/response regulator domain from Chlorobium tepidum TLS
7DAJ	;	2.3	;	The crystal structure of serotonin N-acetyltransferase in complex with acetyl-CoA from Oryza Sativa
4I35	;	1.501	;	The crystal structure of serralysin
3UXY	;	2.097	;	The crystal structure of short chain dehydrogenase from Rhodobacter sphaeroides
8AST	;	1.55	;	The Crystal structure of short F46Y agroavidin - apo
8ASU	;	2.52	;	The Crystal structure of short F46Y agroavidin - biotin complex
8YHI	;	1.75	;	The Crystal Structure of SHP1 from Biortus.
8WFY	;	2.6	;	The Crystal Structure of SHP2 from Biortus.
6KKO	;	2.099	;	The crystal structure of SiaB-SiaC complex from Pseudomonas aeruginosa
4BBW	;	2.3	;	The crystal structure of Sialidase VPI 5482 (BTSA) from Bacteroides thetaiotaomicron
3K2N	;	2.5	;	The crystal structure of sigma-54-dependent transcriptional regulator domain from Chlorobium Tepidum TLS
6K0L	;	1.58	;	The crystal structure of simian CD163 SRCR5
3ZHK	;	1.962	;	The crystal structure of single domain antibody 2x1 scaffold
3ZHL	;	2.47	;	The crystal structure of single domain antibody 8-14 scaffold
3ZHD	;	1.962	;	The crystal structure of single domain antibody 8-4 scaffold.
6TCI	;	1.47	;	The crystal structure of SleB N-terminal domain
3L9D	;	2.484	;	The Crystal Structure of smu.1046c from Streptococcus mutans UA159
3L7Y	;	1.996	;	The Crystal Structure of SMU.1108c from Streptococcus mutans UA159
3L78	;	1.9	;	The crystal structure of SMU.1142C from Streptococcus mutans UA159
3LA8	;	1.8	;	The Crystal Structure of smu.1229 from Streptococcus mutans UA159
3LBA	;	2.24	;	The Crystal Structure of smu.1229 from Streptococcus mutans UA159 bound to hypoxanthine
3L87	;	2.0	;	The Crystal Structure of smu.143c from Streptococcus mutans UA159
3L9F	;	1.8	;	The Crystal Structure of smu.1604c from Streptococcus mutans UA159
3L7W	;	2.2	;	The Crystal Structure of smu.1704 from Streptococcus mutans UA159
3LD2	;	2.5	;	The Crystal Structure of smu.2055 from Streptococcus mutans UA159
3L9T	;	2.206	;	The Crystal Structure of smu.31 from Streptococcus mutans UA159
3L7X	;	1.699	;	The Crystal Structure of SMU.412c from Streptococcus mutans UA159
3L86	;	2.06	;	The Crystal Structure of smu.665 from Streptococcus mutans UA159
3L9C	;	1.6	;	The Crystal Structure of smu.777 from Streptococcus mutans UA159
3LBB	;	2.1	;	The Crystal Structure of smu.793 from Streptococcus mutans UA159
3LBE	;	1.7	;	The Crystal Structure of smu.793 from Streptococcus mutans UA159 bound to acetyl CoA
3LEH	;	1.7	;	The Crystal Structure of smu.943c from Streptococcus mutans UA159
3UC3	;	1.9	;	The crystal structure of Snf1-related kinase 2.3
3UC4	;	2.3	;	The crystal structure of Snf1-related kinase 2.6
3BFR	;	2.05	;	The crystal structure of Sod2 from Saccharomyces cerevisiae
4GLP	;	4.002	;	The crystal structure of soluble human CD14 reveals a bent solenoid with a hydrophobic amino-terminal pocket.
4XDX	;	0.95	;	The crystal structure of soluble human interleukin 8 expressed in Pichia pastoris
2OQW	;	2.1	;	The crystal structure of sortase B from B.anthracis in complex with AAEK1
2OQZ	;	1.6	;	The crystal structure of sortase B from B.anthracis in complex with AAEK2
7E0B	;	1.29	;	The crystal structure of sorting nexin 27 and PBM complex
4FFJ	;	1.95	;	The crystal structure of spDHBPs from S.pneumoniae
2HTE	;	2.0	;	The crystal structure of spermidine synthase from p. falciparum in complex with 5'-methylthioadenosine
2I7C	;	1.71	;	The crystal structure of spermidine synthase from p. falciparum in complex with AdoDATO
3D43	;	0.8	;	The crystal structure of Sph at 0.8A
4AC7	;	1.5	;	The crystal structure of Sporosarcina pasteurii urease in complex with citrate
6QDY	;	1.416	;	The crystal structure of Sporosarcina pasteurii urease in complex with its substrate urea
4JGR	;	2.4	;	The crystal structure of sporulation kinase D mutant sensor domain, R131A, from Bacillus subtilis subsp at 2.4A resolution
4JGQ	;	2.63	;	The crystal structure of sporulation kinase D mutant sensor domain, r131a, from Bacillus subtilis subsp in co-crystallization with pyruvate
4JGP	;	2.03	;	The crystal structure of sporulation kinase D sensor domain from Bacillus subtilis subsp in complex with pyruvate at 2.0A resolution
4JGO	;	2.28	;	The crystal structure of sporulation kinase d sensor domain from Bacillus subtilis subsp.
3ONT	;	2.65	;	The Crystal Structure of Spot14, a modulator of lipogenesis
3I5I	;	3.3	;	The crystal structure of squid myosin S1 in the presence of SO4 2-
8XN8	;	1.95	;	The Crystal Structure of SRC from Biortus.
2WNW	;	2.0	;	The crystal structure of SrfJ from salmonella typhimurium
2W9J	;	2.6	;	The crystal structure of SRP14 from the Schizosaccharomyces pombe signal recognition particle
4MNN	;	1.8	;	The crystal structure of Sso1120 from Sulfolobus solfataricus
1STN	;	1.7	;	THE CRYSTAL STRUCTURE OF STAPHYLOCOCCAL NUCLEASE REFINED AT 1.7 ANGSTROMS RESOLUTION
5YH5	;	2.9	;	The crystal structure of Staphylococcus aureus CntA in apo form
5YHE	;	2.465	;	The crystal structure of Staphylococcus aureus CntA in complex with staphylopine and cobalt
5YH8	;	2.12	;	The crystal structure of Staphylococcus aureus CntA in complex with staphylopine and nickel
5YHG	;	2.03	;	The crystal structure of Staphylococcus aureus CntA in complex with staphylopine and zinc
6UCD	;	2.85	;	The crystal structure of Staphylococcus aureus super antigen-like protein SSL10
4R2I	;	2.05	;	The Crystal Structure of STIV B204 complexed with AMP-PNP
5D23	;	1.95	;	The crystal structure of STPR from Bombyx mori in complex with 13-bp DNA derived from the +290 site of fibroin gene
3G66	;	1.7	;	The crystal structure of Streptococcus pneumoniae Sortase C provides novel insights into catalysis as well as pilin substrate specificity
3G69	;	2.0	;	The crystal structure of Streptococcus pneumoniae Sortase C provides novel insights into catalysis as well as pilin substrate specificity
4M1U	;	1.56	;	The crystal structure of Stx2 and a disaccharide ligand
7WEX	;	1.99	;	The crystal structure of substrate-free CYP107X1 from Streptomyces avermitilis
5L90	;	2.55	;	The crystal structure of substrate-free CYP109E1 from Bacillus megaterium at 2.55 Angstrom resolution
1OI7	;	1.23	;	The Crystal Structure of Succinyl-CoA synthetase alpha subunit from Thermus Thermophilus
1SCU	;	2.5	;	THE CRYSTAL STRUCTURE OF SUCCINYL-COA SYNTHETASE FROM ESCHERICHIA COLI AT 2.5 ANGSTROMS RESOLUTION
3S27	;	2.91	;	The crystal structure of sucrose synthase-1 from Arabidopsis thaliana and its functional implications.
3S29	;	2.85	;	The crystal structure of sucrose synthase-1 from Arabidopsis thaliana and its functional implications.
3S28	;	2.8	;	The crystal structure of sucrose synthase-1 in complex with a breakdown product of the UDP-glucose
1J30	;	1.7	;	The crystal structure of sulerythrin, a rubrerythrin-like protein from a strictly aerobic and thermoacidiphilic archaeon
6IXJ	;	2.8	;	The crystal structure of sulfoacetaldehyde reductase from Klebsiella oxytoca
1SKQ	;	1.8	;	The crystal structure of Sulfolobus solfataricus elongation factor 1-alpha in complex with magnesium and GDP
3A4R	;	1.0	;	The crystal structure of SUMO-like domain 2 in Nip45
1OOP	;	3.0	;	The Crystal Structure of Swine Vesicular Disease Virus
8X5K	;	1.8	;	The Crystal Structure of SYK from Biortus.
8KBW	;	3.49	;	The crystal structure of syn-copalyl diphosphate synthase from Oryza sativa
4RR5	;	2.427	;	The crystal structure of Synechocystis sp. PCC 6803 Malonyl-CoA: ACP Transacylase
8HJA	;	2.38	;	The crystal structure of syn_CdgR-(c-di-GMP) from Synechocystis sp. PCC 6803
8TAW	;	1.73	;	The crystal structure of T252E CYP199A4 bound to 4-(pyridin-2-yl)benzoic acid
8TAY	;	2.021	;	The crystal structure of T252E CYP199A4 bound to 4-(thiophen-3-yl)benzoic acid
7TP5	;	1.655	;	The crystal structure of T252E CYP199A4 bound to 4-ethylthiobenzoic acid
7TP6	;	1.655	;	The crystal structure of T252E CYP199A4 bound to 4-methylthiobenzoic acid
4ZDO	;	2.65	;	The crystal structure of T325S mutant of human SepSecS in complex with selenocysteine tRNA (tRNASec)
2OCA	;	2.7	;	The crystal structure of T4 UvsW
5A10	;	1.423	;	The crystal structure of Ta-TFP, a thiocyanate-forming protein involved in glucosinolate breakdown (space group C2)
5A11	;	2.47	;	The crystal structure of Ta-TFP, a thiocyanate-forming protein involved in glucosinolate breakdown (space group P21)
2POP	;	3.1	;	The Crystal Structure of TAB1 and BIR1 complex
8XI8	;	3.35	;	The Crystal Structure of TAB1 from Biortus.
3U65	;	1.4	;	The Crystal Structure of Tat-P(T) (Tp0957)
3U64	;	2.3	;	The Crystal Structure of Tat-T (Tp0956)
4C7M	;	2.57	;	The crystal structure of TcpB or BtpA TIR domain
3QH3	;	2.19	;	The crystal structure of TCR A6
3QEU	;	2.09	;	The crystal structure of TCR DMF5
3DFF	;	1.6	;	The crystal structure of teicoplanin pseudoaglycone deacetylase Orf2
3DFK	;	1.8	;	The crystal structure of teicoplanin pseudoaglycone deacetylase Orf2* bound to one of its products decanoic acid
4DQ0	;	2.199	;	The crystal structure of tellurite resistance protein from Escherichia coli O157:H7 str. Sakai
7CE2	;	2.01	;	The Crystal structure of TeNT Hc complexed with neutralizing antibody
6GII	;	1.9	;	The crystal structure of Tepidiphilus thermophilus P450 heme domain
6ND7	;	1.36	;	The crystal structure of TerB co-crystallized with polyporic acid
4V0U	;	7.88	;	The crystal structure of ternary PP1G-PPP1R15B and G-actin complex
4HKU	;	2.302	;	The crystal structure of TetR transcriptional regulator (lmo2814) from Listeria monocytogenes EGD-e
3KKC	;	2.5	;	The crystal structure OF TetR transcriptional regulator from Streptococcus agalactiae 2603V
6XP8	;	1.65	;	The crystal structure of TfuA involved in peptide backbone thioamidation from Methanosarcina acetivorans
8YGZ	;	2.1	;	The Crystal Structure of TGF beta R2 kinase domain from Biortus.
8YHL	;	1.47	;	The Crystal Structure of Tgf-Beta Type I Receptor (Alk5) from Biortus
3TIM	;	2.8	;	THE CRYSTAL STRUCTURE OF THE ""OPEN"" AND THE ""CLOSED"" CONFORMATION OF THE FLEXIBLE LOOP OF TRYPANOSOMAL TRIOSEPHOSPHATE ISOMERASE
2OPG	;	1.5	;	The crystal structure of the 10th PDZ domain of MPDZ
2FNE	;	1.83	;	The crystal structure of the 13th PDZ domain of MPDZ
2O2T	;	2.7	;	The crystal structure of the 1st PDZ domain of MPDZ
7K87	;	2.7	;	The crystal structure of the 2009 H1N1 PA endonuclease in complex with SJ000986436
6V53	;	2.2	;	The crystal structure of the 2009 H1N1 PA endonuclease mutant I38T in complex with SJ000985494
6VIV	;	2.23	;	The crystal structure of the 2009 H1N1 PA endonuclease mutant I38T in complex with SJ000986192
6VL3	;	2.68	;	The crystal structure of the 2009 H1N1 PA endonuclease mutant I38T in complex with SJ000986436
6V6X	;	2.5	;	The crystal structure of the 2009 H1N1 PA endonuclease mutant I38T in complex with SJ000988632
7K77	;	2.78	;	The crystal structure of the 2009 H1N1 PA endonuclease mutant I38T in complex with SJ001008025
6V56	;	2.75	;	The crystal structure of the 2009 H1N1 PA endonuclease wild type in complex with SJ000985494
6V9E	;	2.4	;	The crystal structure of the 2009 H1N1 PA endonuclease wild type in complex with SJ000988632
6VG9	;	2.75	;	The crystal structure of the 2009 H1N1/California PA endonuclease I38T mutant in complex with SJ000986248
6VJH	;	2.55	;	The crystal structure of the 2009 H1N1/California PA endonuclease wild type in complex with SJ000986192
6VBR	;	2.75	;	The crystal structure of the 2009 H1N1/California PA endonuclease wild type in complex with SJ000986248
7K0W	;	2.09	;	The crystal structure of the 2009/H1N1/California PA endonuclease (construct with truncated loop 51-72) in complex with Baloxavir acid
7KAF	;	2.25	;	The crystal structure of the 2009/H1N1/California PA endonuclease I38T (construct with truncated loop 51-72) in complex with baloxavir acid
7LW6	;	2.38	;	The crystal structure of the 2009/H1N1/California PA endonuclease I38T mutant in complex with Raltegravir
7KOP	;	2.33	;	The crystal structure of the 2009/H1N1/California PA endonuclease I38T mutant in complex with SJ000988539
7KBC	;	2.25	;	The crystal structure of the 2009/H1N1/California PA endonuclease mutant E119D (construct with truncated loop 51-72) in complex with baloxavir acid
6W7A	;	2.09	;	The crystal structure of the 2009/H1N1/California PA endonuclease mutant E119D bound to DNA oligomer TAGCAT (uncleaved, 5mM overnight DNA soak)
7KL3	;	1.99	;	The crystal structure of the 2009/H1N1/California PA endonuclease mutant E119D bound to RNA oligomer AG*CAUC (*uncleaveable bond, -UC disordered)
6VLL	;	2.87	;	The crystal structure of the 2009/H1N1/California PA endonuclease mutant I38T in complex with SJ000986213
6WIJ	;	2.44	;	The crystal structure of the 2009/H1N1/California PA endonuclease mutant I38T in complex with SJ000986448
6WHM	;	1.92	;	The crystal structure of the 2009/H1N1/California PA endonuclease wild type bound to DNA oligomer TAGC (cleaved TTAGCATT, 5mM overnight DNA soak)
6WS3	;	2.2	;	The crystal structure of the 2009/H1N1/California PA endonuclease wild type bound to DNA oligomers TG and AGCA (from cleaved GTGAGCAGTG)
6WJ4	;	2.55	;	The crystal structure of the 2009/H1N1/California PA endonuclease wild type in complex with SJ000986448
2OZF	;	1.5	;	The crystal structure of the 2nd PDZ domain of the human NHERF-1 (SLC9A3R1)
1NJO	;	3.7	;	The crystal structure of the 50S Large ribosomal subunit from Deinococcus radiodurans complexed with a short substrate analog ACCPuromycin (ACCP)
1NJP	;	3.5	;	The crystal structure of the 50S Large ribosomal subunit from Deinococcus radiodurans complexed with a tRNA acceptor stem mimic (ASM)
1NJM	;	3.6	;	The crystal structure of the 50S Large ribosomal subunit from Deinococcus radiodurans complexed with a tRNA acceptor stem mimic (ASM) and the antibiotic sparsomycin
1P9X	;	3.4	;	THE CRYSTAL STRUCTURE OF THE 50S LARGE RIBOSOMAL SUBUNIT FROM DEINOCOCCUS RADIODURANS COMPLEXED WITH TELITHROMYCIN KETOLIDE ANTIBIOTIC
1NJN	;	3.7	;	The crystal structure of the 50S Large ribosomal subunit from Deinococcus radiodurans complexed with the antibiotic sparsomycin
1OND	;	3.4	;	THE CRYSTAL STRUCTURE OF THE 50S LARGE RIBOSOMAL SUBUNIT FROM DEINOCOCCUS RADIODURANS COMPLEXED WITH TROLEANDOMYCIN MACROLIDE ANTIBIOTIC
1G7Y	;	2.5	;	THE CRYSTAL STRUCTURE OF THE 58KD VEGETATIVE LECTIN FROM THE TROPICAL LEGUME DOLICHOS BIFLORUS
3QJH	;	1.9	;	The crystal structure of the 5c.c7 TCR
4V5G	;	3.6	;	The crystal structure of the 70S ribosome bound to EF-Tu and tRNA
2FCF	;	1.76	;	The crystal structure of the 7th PDZ domain of MPDZ (MUPP-1)
4WYN	;	1.805	;	The crystal structure of the A109G mutant of RNase A
4WYZ	;	1.449	;	The crystal structure of the A109G mutant of RNase A in complex with 3'UMP
4WYP	;	1.502	;	The crystal structure of the A109G mutant of RNase A in complex with 5'AMP
3LFT	;	1.35	;	The Crystal Structure of the ABC domain in complex with L-Trp from Streptococcus pneumonia to 1.35A
3MY7	;	2.3	;	The Crystal Structure of the ACDH domain of an Alcohol Dehydrogenase from Vibrio parahaemolyticus to 2.25A
3FBU	;	1.8	;	The crystal structure of the acetyltransferase (GNAT family) from Bacillus anthracis
2FIA	;	2.6	;	The crystal structure of the acetyltransferase from Enterococcus faecalis
2I79	;	2.1	;	The crystal structure of the acetyltransferase of GNAT family from Streptococcus pneumoniae
5NL7	;	2.48	;	The crystal structure of the Actin Binding Domain (ABD) of alpha actinin from Entamoeba histolytica
1V5D	;	1.5	;	The crystal structure of the active form chitosanase from Bacillus sp. K17 at pH6.4
5YDA	;	2.353	;	The crystal structure of the Acyl Transferase domain of SpnD
5YDL	;	2.402	;	The crystal structure of the Acyl Transferase domain of SpnD complex with 2-(pent-4-yn-1-yl)malonyl
5YDM	;	2.5	;	The crystal structure of the Acyl Transferase domain of SpnD complex with benzylmalonyl
2OKU	;	1.9	;	The crystal structure of the acyl-CoA dehydrogenase family protein from Porphyromonas gingivalis
6B4R	;	2.55	;	The crystal structure of the aldehyde dehydrogenase KauB from Pseudomonas aeruginosa
1ABN	;	2.4	;	THE CRYSTAL STRUCTURE OF THE ALDOSE REDUCTASE NADPH BINARY COMPLEX
4CQ6	;	1.8	;	The crystal structure of the allene oxide cyclase 2 from Arabidopsis thaliana with bound inhibitor - vernolic acid
4CQ7	;	1.7	;	The crystal structure of the allene oxide cyclase 2 from Arabidopsis thaliana with bound product - OPDA
3N04	;	2.02	;	THE CRYSTAL STRUCTURE OF THE alpha-Glucosidase (FAMILY 31) FROM RUMINOCOCCUS OBEUM ATCC 29174
6C9X	;	1.457	;	THE CRYSTAL STRUCTURE OF THE alpha-Glucosidase (GH 31) FROM RUMINOCOCCUS OBEUM ATCC 29174 in complex with voglibose
6C9Z	;	2.101	;	THE CRYSTAL STRUCTURE OF THE alpha-Glucosidase (GH 31) W169Y mutant FROM RUMINOCOCCUS OBEUM ATCC 29174 in complex with voglibose
3IL0	;	2.2	;	The crystal structure of the aminopeptidase P,XAA-pro aminopeptidase from Streptococcus thermophilus
3E1U	;	2.3	;	The Crystal Structure of the Anti-Viral APOBEC3G Catalytic Domain
1YQV	;	1.7	;	The crystal structure of the antibody Fab HyHEL5 complex with lysozyme at 1.7A resolution
7NM7	;	2.1	;	The crystal structure of the antimycin pathway standalone ketoreductase, AntM
7NM8	;	1.7	;	The crystal structure of the antimycin pathway standalone ketoreductase, AntM, in complex with NADPH
7V4Q	;	1.91	;	The crystal structure of the apo form of KFDV NS3H
5WYG	;	2.356	;	The crystal structure of the apo form of Mtb MazF
2B0J	;	1.75	;	The crystal structure of the apoenzyme of the iron-sulfur-cluster-free hydrogenase (Hmd)
5IXT	;	1.94	;	The crystal structure of the Arabidopsis receptor kinase HAESA LRR ectdomain in complex with a N-terminal extended IDA peptide hormone ligand.
8DN6	;	3.0	;	The crystal structure of the Arabidopsis thaliana Toc75 POTRA domains in complex with fab tc2
1R6Z	;	2.8	;	The Crystal Structure of the Argonaute2 PAZ domain (as a MBP fusion)
2HJG	;	2.5	;	The crystal structure of the B. subtilis YphC GTPase in complex with GDP
1ST3	;	1.4	;	THE CRYSTAL STRUCTURE OF THE BACILLUS LENTUS ALKALINE PROTEASE, SUBTILISIN BL, AT 1.4 ANGSTROMS RESOLUTION
1W2E	;	2.8	;	The Crystal Structure of the Bacterial Cell Division Protein ZapA
1GRL	;	2.8	;	THE CRYSTAL STRUCTURE OF THE BACTERIAL CHAPERONIN GROEL AT 2.8 ANGSTROMS
5JLT	;	2.955	;	The crystal structure of the bacteriophage T4 MotA C-terminal domain in complex with dsDNA reveals a novel protein-DNA recognition motif
6KPD	;	3.2	;	The crystal structure of the BALDIBIS/IDD9 bound to the homodimeric SCL3
2FIC	;	1.99	;	The crystal structure of the BAR domain from human Bin1/Amphiphysin II and its implications for molecular recognition
2J3R	;	2.6	;	The crystal structure of the bet3-trs31 heterodimer.
2J3W	;	2.1	;	The crystal structure of the bet3-trs31-sedlin complex.
2J3T	;	2.4	;	The crystal structure of the bet3-trs33-bet5-trs23 complex.
3ICA	;	2.44	;	The crystal structure of the beta subunit of a phenylalanyl-tRNA synthetase from Porphyromonas gingivalis W83
3E7H	;	1.7	;	The crystal structure of the beta subunit of the DNA-directed RNA polymerase from Vibrio cholerae O1 biovar eltor
3FWW	;	2.5	;	The crystal structure of the bifunctional N-acetylglucosamine-1-phosphate uridyltransferase/glucosamine-1-phosphate acetyltransferase from Yersinia pestis CO92
1Q57	;	3.45	;	The Crystal Structure of the Bifunctional Primase-Helicase of Bacteriophage T7
1JOL	;	1.96	;	THE CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN FOLINIC ACID (LEUCOVORIN) AND E. COLI DIHYDROFOLATE REDUCTASE
1JOM	;	1.9	;	THE CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN FOLINIC ACID (LEUCOVORIN) AND E. COLI DIHYDROFOLATE REDUCTASE
1FK8	;	1.95	;	THE CRYSTAL STRUCTURE OF THE BINARY COMPLEX WITH NAD OF 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE FROM COMAMONAS TESTOSTERONI, A MEMBER OF THE SHORT CHAIN DEHYDROGENASE/REDUCTASE FAMILY
6LY4	;	1.68	;	The crystal structure of the BM3 mutant LG-23 in complex with testosterone
6G26	;	2.49	;	The crystal structure of the Burkholderia pseudomallei HicAB complex
5EE2	;	1.95	;	The crystal structure of the C-terminal beta-barrel of HpuA from Neisseria gonorrhoeae
3LHE	;	1.62	;	The crystal structure of the C-terminal domain of a GntR family transcriptional regulator from Bacillus anthracis str. Sterne
3DMN	;	1.66	;	The crystal structure of the C-terminal domain of a possilbe DNA helicase from Lactobacillus plantarun WCFS1
2EYU	;	1.87	;	The Crystal Structure of the C-terminal Domain of Aquifex aeolicus PilT
5DSD	;	2.31	;	The crystal structure of the C-terminal domain of Ebola (Bundibugyo) nucleoprotein
5E2X	;	2.1	;	The crystal structure of the C-terminal domain of Ebola (Tai Forest) nucleoprotein
4QAZ	;	1.98	;	The crystal structure of the C-terminal domain of Ebola (Zaire) nucleoprotein
4QB0	;	1.75	;	The crystal structure of the C-terminal domain of Ebola (Zaire) nucleoprotein
3CYP	;	1.6	;	The crystal structure of the C-terminal domain of Helicobacter pylori MotB (residues 125-256).
8P0Y	;	4.12	;	The crystal structure of the C-terminal domain of Mengla nucleoprotein
8P10	;	3.26	;	The crystal structure of the C-terminal domain of Mengla nucleoprotein
8P24	;	3.73	;	The crystal structure of the C-terminal domain of Mengla nucleoprotein
3VTO	;	1.44	;	The crystal structure of the C-terminal domain of Mu phage central spike
3VTN	;	1.75	;	The crystal structure of the C-terminal domain of Mu phage central spike - Pt derivative for MAD
7EGT	;	2.581	;	The crystal structure of the C-terminal domain of T. thermophilus UvrD complexed with the N-terminal domain of UvrB
3IUO	;	1.6	;	The Crystal Structure of the C-terminal domain of the ATP-dependent DNA helicase RecQ from Porphyromonas gingivalis to 1.6A
3LSG	;	2.049	;	The crystal structure of the C-terminal domain of the two-component response regulator yesN from Fusobacterium nucleatum subsp. nucleatum ATCC 25586
3D3M	;	1.9	;	The Crystal Structure of the C-terminal region of Death Associated Protein 5(DAP5)
4G07	;	1.95	;	The crystal structure of the C366S mutant of HDH from Brucella suis
4G09	;	1.9	;	The crystal structure of the C366S mutant of HDH from Brucella suis in complex with a substituted benzyl ketone
1UHN	;	2.1	;	The crystal structure of the calcium binding protein AtCBL2 from Arabidopsis thaliana
2JC7	;	2.5	;	The crystal structure of the carbapenemase OXA-24 reveals new insights into the mechanism of carbapenem-hydrolysis
1R1Z	;	2.4	;	The Crystal structure of the Carbohydrate recognition domain of the glycoprotein sorting receptor p58/ERGIC-53 reveals a novel metal binding site and conformational changes associated with calcium ion binding
2F9Y	;	3.2	;	The Crystal Structure of The Carboxyltransferase Subunit of ACC from Escherichia coli
3ET6	;	2.55	;	The crystal structure of the catalytic domain of a eukaryotic guanylate cyclase
3RZU	;	2.5	;	The Crystal Structure of the Catalytic Domain of AMSH
5JMU	;	1.54	;	The crystal structure of the catalytic domain of peptidoglycan N-acetylglucosamine deacetylase from Eubacterium rectale ATCC 33656
1V9K	;	2.0	;	The crystal structure of the catalytic domain of pseudouridine synthase RluC from Escherichia coli
1YFT	;	2.23	;	The crystal structure of the catalytic fragment of alanyl-tRNA synthetase in complex wtih glycine
1RIQ	;	2.14	;	The crystal structure of the catalytic fragment of the alanyl-tRNA synthetase
3H7D	;	2.242	;	The crystal structure of the cathepsin K Variant M5 in complex with chondroitin-4-sulfate
3UK8	;	2.3	;	The crystal structure of the cd-bound domain 3 of the cadmium carbonic anhydrase from marine diatom Thalassiosira weissflogii
8WCT	;	1.9	;	The crystal structure of the CHASE4 domain of iron-sensetive membrane protein (IsmP,Uniprot ID:Q9I243)
6IAK	;	3.95	;	The crystal structure of the chicken CREB3 bZIP
7DA2	;	2.79	;	The crystal structure of the chicken FANCM-MHF complex
8U36	;	2.6	;	The crystal structure of the classical binding interface of Importin alpha 2 and a nuclear localisation signal sequence in Frog siadenovirus core protein VII
8SV0	;	2.2	;	The crystal structure of the classical binding interface of Importin alpha 2 and nuclear localisation signal sequence in Psittacine siadenovirus core protein VII
3A7O	;	2.5	;	The crystal structure of the coiled-coil domain of Saccharomyces cerevisiae Atg16
8EC3	;	1.5	;	The crystal structure of the complement inhibitory domain of Borrelia hermsii FbpC.
1NAB	;	2.15	;	The crystal structure of the complex between a disaccharide anthracycline and the DNA hexamer d(CGATCG) reveals two different binding sites involving two DNA duplexes
3FPT	;	2.7	;	The Crystal Structure of the Complex between Evasin-1 and CCL3
1PVN	;	2.0	;	The crystal structure of the complex between IMP dehydrogenase catalytic domain and a transition state analogue MZP
1OQ9	;	2.4	;	The Crystal Structure of the Complex between Stearoyl Acyl Carrier Protein Desaturase from Ricinus Communis (Castor Bean) and Acetate.
1OQ4	;	2.4	;	The Crystal Structure of the Complex between Stearoyl Acyl Carrier Protein Desaturase from Ricinus Communis (Castor Bean) and Azide.
2BWE	;	3.1	;	The crystal structure of the complex between the UBA and UBL domains of Dsk2
2QP6	;	1.45	;	The crystal structure of the complex of hcaII with a bioreductive antitumor derivative
5CLU	;	1.55	;	THE CRYSTAL STRUCTURE OF THE COMPLEX of HCAII WITH A SACCHARINE DERIVATIVE
4QY3	;	1.5	;	THE CRYSTAL STRUCTURE OF THE COMPLEX of HCAII WITH AN ORTHO-SUBSTITUTED BENZOIC ACID
6YRI	;	1.6	;	THE CRYSTAL STRUCTURE OF THE COMPLEX OF HCAII WITH CAFFEIC ACID
6ZR9	;	2.05	;	The crystal structure of the complex of hCAVII with 2-(4-benzhydrylpiperazin-1-yl)-N-(4-sulfamoylphenyl)acetamide
4U7E	;	1.6	;	The crystal structure of the complex of LIP5 NTD and IST1 MIM
1FZZ	;	1.86	;	THE CRYSTAL STRUCTURE OF THE COMPLEX OF NON-PEPTIDIC INHIBITOR ONO-6818 AND PORCINE PANCREATIC ELASTASE.
3TBE	;	2.85	;	The crystal structure of the complex of Streptococcus agalactiae sortase C1 and MTSET
3CYQ	;	2.3	;	The crystal structure of the complex of the C-terminal domain of Helicobacter pylori MotB (residues 125-256) with N-acetylmuramic acid
2BFN	;	1.6	;	The crystal structure of the complex of the haloalkane dehalogenase LinB with the product of dehalogenation reaction 1,2-dichloropropane.
3FBQ	;	2.71	;	The crystal structure of the conserved domain protein from Bacillus anthracis
2FI0	;	2.1	;	The crystal structure of the conserved domain protein from Streptococcus pneumoniae TIGR4
1GWN	;	2.1	;	The crystal structure of the core domain of RhoE/Rnd3 - a constitutively activated small G protein
2D1X	;	1.9	;	The crystal structure of the cortactin-SH3 domain and AMAP1-peptide complex
5GKC	;	1.892	;	The crystal structure of the CPS-6 H148A/F122A
3O5V	;	1.85	;	The Crystal Structure of the Creatinase/Prolidase N-terminal domain of an X-PRO dipeptidase from Streptococcus pyogenes to 1.85A
4CI7	;	1.4	;	The crystal structure of the cysteine protease and lectin-like domains of Cwp84, a surface layer associated protein of Clostridium difficile
3EFD	;	2.6	;	The crystal structure of the cytoplasmic domain of KcsA
3I12	;	2.2	;	The crystal structure of the D-alanyl-alanine synthetase A from Salmonella enterica subsp. enterica serovar Typhimurium str. LT2
3Q1K	;	2.202	;	The Crystal Structure of the D-alanyl-alanine Synthetase A from Salmonella enterica Typhimurium Complexed with ADP
1RJR	;	2.1	;	The crystal structure of the D-aminoacylase D366A mutant in complex with 100mM ZnCl2
1RJQ	;	1.8	;	The crystal structure of the D-aminoacylase mutant D366A
5KDY	;	1.589	;	The crystal structure of the D251N mutant of CYP199A4 in complex with 4-methoxybenzoate
5HYW	;	3.01	;	The crystal structure of the D3-ASK1 complex
3POC	;	1.99	;	The crystal structure of the D307A mutant of alpha-Glucosidase (FAMILY 31) from Ruminococcus obeum ATCC 29174 in complex with acarbose
3M6D	;	2.9	;	The crystal structure of the d307a mutant of glycoside Hydrolase (family 31) from ruminococcus obeum atcc 29174
3MKK	;	1.91	;	The crystal structure of the D307A mutant of glycoside HYDROLASE (FAMILY 31) from Ruminococcus obeum ATCC 29174 in complex with isomaltose
3M46	;	2.66	;	The crystal structure of the D73A mutant of glycoside HYDROLASE (FAMILY 31) from Ruminococcus obeum ATCC 29174
4E4V	;	2.5283	;	The crystal structure of the dimeric human importin alpha 1 at 2.5 angstrom resolution.
3IBP	;	3.099	;	The Crystal Structure of the Dimerization Domain of Escherichia coli Structural Maintenance of Chromosomes Protein MukB
3FDG	;	1.8	;	The crystal structure of the dipeptidase AC, Metallo peptidase. MEROPS family M19
1DSF	;	2.0	;	THE CRYSTAL STRUCTURE OF THE DISULFIDE-STABILIZED FV FRAGMENT OF ANTICANCER ANTIBODY B1: CONFORMATIONAL INFLUENCE OF AN ENGINEERED DISULFIDE BOND
4HLX	;	2.379	;	The crystal structure of the DNA binding domain of vIRF-1 from the oncogenic KSHV
3EUS	;	1.8	;	The crystal structure of the DNA binding protein from Silicibacter pomeroyi
335D	;	2.4	;	THE CRYSTAL STRUCTURE OF THE DNA DECAMER D(GGCAATTGCG) CONTAINS BOTH MAJOR AND MINOR GROOVE BINDING G.(G.C) TRIPLETS
2GK4	;	1.83	;	The Crystal Structure of the DNA/Pantothenate Metabolism Flavoprotein from Streptococcus pneumoniae
6IEW	;	1.5	;	The crystal structure of the dNxf2 UBA domain in complex with Panoramix
3HCY	;	2.8	;	The crystal structure of the domain of putative two-component sensor histidine kinase protein from Sinorhizobium meliloti 1021
3EEH	;	1.95	;	The crystal structure of the domain of the putative light and redox sensing histidine kinase from Haloarcula marismortui
7OR6	;	2.12	;	The crystal structure of the domain-swapped dimer of onconase
7ORD	;	2.14	;	The crystal structure of the domain-swapped dimer of onconase (2)
5TDH	;	3.0	;	The crystal structure of the dominant negative mutant G protein alpha(i)-1-beta-1-gamma-2 G203A/A326S
3E8L	;	2.48	;	The Crystal Structure of the Double-headed Arrowhead Protease Inhibitor A in Complex with Two Trypsins
6TB5	;	1.83	;	The crystal structure of the DPS2 from DEINOCOCCUS RADIODURANS to 1.83A resolution (sequentially soaked in CaCl2 [5mM] for 20 min, then in Ammonium iron(II) sulfate [10mM] for 2h).
2X6H	;	2.9	;	THE CRYSTAL STRUCTURE OF THE DROSOPHILA CLASS III PI3-KINASE VPS34
2X6F	;	3.3	;	THE CRYSTAL STRUCTURE OF THE DROSOPHILA CLASS III PI3-KINASE VPS34 IN COMPLEX WITH 3-METHYLADENINE
2X6K	;	3.5	;	THE CRYSTAL STRUCTURE OF THE DROSOPHILA CLASS III PI3-KINASE VPS34 IN COMPLEX WITH PI-103
2X6I	;	3.4	;	THE CRYSTAL STRUCTURE OF THE DROSOPHILA CLASS III PI3-KINASE VPS34 IN COMPLEX WITH PIK-90
2X6J	;	3.5	;	THE CRYSTAL STRUCTURE OF THE DROSOPHILA CLASS III PI3-KINASE VPS34 IN COMPLEX WITH PIK-93
4NQL	;	2.3	;	The crystal structure of the DUB domain of AMSH orthologue, Sst2 from S. pombe, in complex with lysine 63-linked diubiquitin
1SQG	;	1.65	;	The crystal structure of the E. coli Fmu apoenzyme at 1.65 A resolution
2ECP	;	2.95	;	THE CRYSTAL STRUCTURE OF THE E. COLI MALTODEXTRIN PHOSPHORYLASE COMPLEX
2R6G	;	2.8	;	The Crystal Structure of the E. coli Maltose Transporter
1G0S	;	1.9	;	THE CRYSTAL STRUCTURE OF THE E.COLI ADP-RIBOSE PYROPHOSPHATASE
2QOM	;	2.66	;	The crystal structure of the E.coli EspP autotransporter Beta-domain.
2O9A	;	1.8	;	The crystal structure of the E.coli IclR C-terminal fragment in complex with pyruvate.
2GS4	;	2.0	;	The crystal structure of the E.coli stress protein YciF.
1A7G	;	2.4	;	THE CRYSTAL STRUCTURE OF THE E2 DNA-BINDING DOMAIN FROM HUMAN PAPILLOMAVIRUS AT 2.4 ANGSTROMS
6Y7N	;	1.6	;	The crystal structure of the eight-bladed symmetrical designer protein Tako8 in the presence of tellurotungstic Anderson-Evans (TEW)
2GOJ	;	2.0	;	The crystal structure of the enzyme Fe-superoxide dismutase from Plasmodium falciparum
2GPC	;	1.9	;	The crystal structure of the enzyme Fe-superoxide dismutase from Trypanosoma cruzi
1HCQ	;	2.4	;	THE CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR DNA-BINDING DOMAIN BOUND TO DNA: HOW RECEPTORS DISCRIMINATE BETWEEN THEIR RESPONSE ELEMENTS
4BTS	;	3.703	;	THE CRYSTAL STRUCTURE OF THE EUKARYOTIC 40S RIBOSOMAL SUBUNIT IN COMPLEX WITH EIF1 AND EIF1A
1UNF	;	1.97	;	The crystal structure of the eukaryotic FeSOD from Vigna unguiculata suggests a new enzymatic mechanism
2J0S	;	2.21	;	The crystal structure of the Exon Junction Complex at 2.2 A resolution
2J0Q	;	3.2	;	The crystal structure of the Exon Junction Complex at 3.2 A resolution
3P98	;	2.1	;	The crystal structure of the extended spectrum beta-lactamase TEM-72 reveals inhibition by citrate
2HFT	;	1.69	;	THE CRYSTAL STRUCTURE OF THE EXTRACELLULAR DOMAIN OF HUMAN TISSUE FACTOR AT 1.7 ANGSTROMS RESOLUTION
2NMS	;	2.6	;	The Crystal Structure of the Extracellular Domain of the Inhibitor Receptor Expressed on Myeloid Cells IREM-1
1C5D	;	2.4	;	THE CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF A RAT MONOCLONAL ANTIBODY AGAINST THE MAIN IMMUNOGENIC REGION OF THE HUMAN MUSCLE ACETYLCHOLINE RECEPTOR
4DVB	;	1.93	;	The crystal structure of the Fab fragment of pro-uPA antibody mAb-112
7FGN	;	1.199	;	The crystal structure of the FAF1 UBL1
2FIY	;	2.1	;	The crystal structure of the FdhE protein from Pseudomonas aeruginosa
7EDR	;	2.527	;	The crystal structure of the FERM and C-terminal domain complex of Drosophila Merlin
6B05	;	1.9	;	The Crystal Structure of the Ferredoxin Protease FusC E83A mutant in complex with Arabidopsis Ferredoxin
6BRS	;	2.3	;	The Crystal Structure of the Ferredoxin Protease FusC in complex with Arabidopsis Ferredoxin, Ethylmercury phosphate soaked dataset
6B03	;	2.7	;	The crystal structure of the ferredoxin protease FusC in complex with its substrate plant ferredoxin
4ZGV	;	3.2	;	The Crystal Structure of the Ferredoxin Receptor FusA from Pectobacterium atrosepticum SCRI1043
4EPA	;	3.2	;	The crystal structure of the ferric yersiniabactin uptake receptor FyuA from Yersinia pestis
6BPN	;	2.1	;	The crystal structure of the Ferric-Catecholate import receptor Fiu from E. coli K12: Open form (C2221)
6BPM	;	2.5	;	The crystal structure of the Ferric-Catecholate import receptor Fiu from K12 E. coli: Closed form (C21)
6BPO	;	2.9	;	The crystal structure of the Ferric-Catecholate import receptor Fiu from K12 E. coli: Closed form (P1)
3DOA	;	2.81	;	The crystal structure of the fibrinogen binding protein from Staphylococcus aureus
1OY0	;	2.8	;	The crystal Structure of the First Enzyme of Pantothenate Biosynthetic Pathway, Ketopantoate Hydroxymethyltransferase from Mycobacterium Tuberculosis Shows a Decameric Assembly and Terminal Helix-Swapping
6OFT	;	2.0	;	The crystal structure of the first half of the periplasmic protease PqqL from Escherichia coli
2OCS	;	1.5	;	The crystal structure of the first PDZ domain of human NHERF-2 (SLC9A3R2)
3D7N	;	2.3	;	The crystal structure of the flavodoxin, WrbA-like protein from Agrobacterium tumefaciens
1QD1	;	1.7	;	THE CRYSTAL STRUCTURE OF THE FORMIMINOTRANSFERASE DOMAIN OF FORMIMINOTRANSFERASE-CYCLODEAMINASE.
3LJL	;	3.2	;	The crystal structure of the full-length transcriptional regulator LuxT from Vibrio parahaemolyticus RIMD 2210633.
4YE9	;	2.7	;	The crystal structure of the G45V mutant of human GlnRS
3O5Y	;	2.45	;	The Crystal Structure of the GAF domain of a two-component sensor histidine kinase from Bacillus halodurans to 2.45A
3EEA	;	1.8	;	The crystal structure of the GAF domain/HD domain protein from Geobacter sulfurreducens
3DS8	;	1.8	;	The crystal structure of the gene lin2722 products from Listeria innocua
7N6H	;	1.28	;	The crystal structure of the GH30 subfamily 10 enzyme, AcXbh30A from Acetivibrio clariflavus
7N6O	;	1.5	;	The crystal structure of the GH30 subfamily 10 enzyme, AcXbh30A from Acetivibrio clariflavus in complex with xylobiose
1UW3	;	2.05	;	The crystal structure of the globular domain of sheep prion protein
3NZN	;	1.1	;	The crystal structure of the Glutaredoxin from Methanosarcina mazei Go1
3IC4	;	1.7	;	The crystal structure of the glutaredoxin(grx-1) from Archaeoglobus fulgidus
2OTD	;	2.6	;	The crystal structure of the glycerophosphodiester phosphodiesterase from Shigella flexneri 2a
2G9Q	;	2.5	;	The crystal structure of the glycogen phosphorylase b- 1AB complex
6R5I	;	1.8	;	The crystal structure of the Glycoside Hydrolase BglX from P. aeruginosa
3TOV	;	2.983	;	The crystal structure of the glycosyl transferase family 9 from Veillonella parvula DSM 2008
2P25	;	1.7	;	The crystal structure of the glyoxalase family protein from Enterococcus faecalis
3CI0	;	2.2	;	The Crystal Structure of the GspK-GspI-GspJ complex from enterotoxigenic Escherichia coli Type 2 Secretion System
5BMU	;	2.6	;	The crystal structure of the GST-like domains complex of AIMP3-EPRS mutant C92SC105SC123S
5A5H	;	2.318	;	The crystal structure of the GST-like domains complex of EPRS C92SC105SC123S mutant-AIMP2
5A34	;	2.6	;	The crystal structure of the GST-like domains complex of EPRS-AIMP2
5A1N	;	2.1	;	The crystal structure of the GST-like domains complex of EPRS-AIMP2 mutant S156D
5B33	;	2.925	;	The crystal structure of the H2AZ nucleosome with H3.3.
2RJW	;	1.55	;	The crystal structure of the H41Y mutant of villin headpiece, P61 SPACE GROUP.
4I84	;	1.5	;	The crystal structure of the Haemophilus influenzae HxuA secretion domain involved in the two-partner secretion pathway
4H32	;	2.7	;	The crystal structure of the hemagglutinin H17 derived the bat influenza A virus
3Q6S	;	1.93	;	The crystal structure of the heterochromatin protein 1 beta chromoshadow domain complexed with a peptide from Shugoshin 1
3AMJ	;	3.0	;	The crystal structure of the heterodimer of M16B peptidase from Sphingomonas sp. A1
5B3G	;	2.0	;	The crystal structure of the heterodimer of SHORT-ROOT and SCARECROW GRAS domains
5B31	;	2.2	;	The crystal structure of the heterotypic H2AZ/H2A nucleosome with H3.1.
5B32	;	2.35	;	The crystal structure of the heterotypic H2AZ/H2A nucleosome with H3.3.
4GRM	;	2.0	;	The crystal structure of the high affinity TCR A6
7Q2U	;	2.27	;	The crystal structure of the HINT1 Q62A mutant.
3FTB	;	2.0	;	The crystal structure of the histidinol-phosphate aminotransferase from Clostridium acetobutylicum
2FFB	;	1.9	;	The crystal structure of the HlyB-NBD E631Q mutant in complex with ADP
3MYF	;	1.8	;	The Crystal Structure of the HPT domain from the Hpt Sensor Hybrid Histidine Kinase from Shewanella to 1.80A
4A1G	;	2.6	;	The crystal structure of the human Bub1 TPR domain in complex with the KI motif of Knl1
2POU	;	1.6	;	The crystal structure of the human carbonic anhydrase II in complex with 4,5-dichloro-benzene-1,3-disulfonamide
2POV	;	1.6	;	The crystal structure of the human carbonic anhydrase II in complex with 4-amino-6-chloro-benzene-1,3-disulfonamide
2POW	;	1.75	;	The crystal structure of the human carbonic anhydrase II in complex with 4-amino-6-trifluoromethyl-benzene-1,3-disulfonamide
5E2R	;	1.6	;	The crystal structure of the human carbonic anhydrase II in complex with a 1,1'-biphenyl-4-sulfonamide inhibitor
5O07	;	1.8	;	The crystal structure of the human carbonic anhydrase II in complex with a nitroimidazole sulfamate inhibitor
4PQ7	;	1.85	;	The crystal structure of the human carbonic anhydrase ii in complex with a sulfamide inhibitor
3IBL	;	1.55	;	The crystal structure of the human carbonic anhydrase II in complex with an aliphatic bis-sulfamate inhibitor
3IBN	;	2.2	;	The crystal structure of the human carbonic anhydrase II in complex with an aliphatic bis-sulfamate inhibitor
3IBI	;	1.93	;	The crystal structure of the human carbonic anhydrase II in complex with an aliphatic sulfamate inhibitor
3IBU	;	1.41	;	The crystal structure of the human carbonic anhydrase II in complex with an aliphatic sulfamate inhibitor
4MO8	;	1.85	;	The crystal structure of the human carbonic anhydrase II in complex with N-[2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl]sulfamide
4LU3	;	2.0	;	The crystal structure of the human carbonic anhydrase XIV
5CJF	;	1.83	;	The crystal structure of the human carbonic anhydrase XIV in complex with a 1,1'-biphenyl-4-sulfonamide inhibitor.
2GF0	;	1.9	;	The crystal structure of the human DiRas1 GTPase in the inactive GDP bound state
1BIX	;	2.2	;	THE CRYSTAL STRUCTURE OF THE HUMAN DNA REPAIR ENDONUCLEASE HAP1 SUGGESTS THE RECOGNITION OF EXTRA-HELICAL DEOXYRIBOSE AT DNA ABASIC SITES
2V4Z	;	2.8	;	The crystal structure of the human G-protein subunit alpha (GNAI3) in complex with an engineered regulator of G-protein signaling type 2 domain (RGS2)
1S3X	;	1.84	;	The crystal structure of the human Hsp70 ATPase domain
2Q87	;	1.7	;	The Crystal Structure of the Human IRp60 Ectodomain
6EHP	;	2.3	;	The crystal structure of the human LAMTOR complex
6EHR	;	2.898	;	The crystal structure of the human LAMTOR-RagA CTD-RagC CTD complex
2X4F	;	2.67	;	The Crystal Structure of the human myosin light chain kinase LOC340156.
2NPA	;	2.3	;	the crystal structure of the human PPARaplpha ligand binding domain in complex with a a-hydroxyimino phenylpropanoic acid
2OVJ	;	1.49	;	The crystal structure of the human Rac GTPase activating protein 1 (RACGAP1) MgcRacGAP.
2G0N	;	1.9	;	The Crystal Structure of the Human RAC3 in complex with GDP and Chloride
2OV2	;	2.1	;	The crystal structure of the human RAC3 in complex with the CRIB domain of human p21-activated kinase 4 (PAK4)
2CLS	;	2.31	;	The crystal structure of the human RND1 GTPase in the active GTP bound state
3HL2	;	2.81	;	The crystal structure of the human SepSecS-tRNASec complex
1KDM	;	2.35	;	THE CRYSTAL STRUCTURE OF THE HUMAN SEX HORMONE-BINDING GLOBULIN (TETRAGONAL CRYSTAL FORM)
5L7A	;	2.102	;	The crystal structure of the Human SNF5/INI1 domain
1UPX	;	1.25	;	The crystal structure of the Hybrid Cluster Protein from Desulfovibrio desulfuricans containing molecules in the oxidized and reduced states.
2FBL	;	1.9	;	The crystal structure of the hypothetical protein NE1496
5EP5	;	2.9	;	The crystal structure of the hypothetical protein SAV0944 mutant (Glu47Ala) from Staphylococcus aureus.
1QCY	;	2.3	;	THE CRYSTAL STRUCTURE OF THE I-DOMAIN OF HUMAN INTEGRIN ALPHA1BETA1
8E1Q	;	2.5	;	The crystal structure of the I38T mutant PA endonuclease (2009/H1N1/CALIFORNIA) in complex with compound SJ001023044
7LM4	;	2.35	;	The crystal structure of the I38T mutant PA Endonuclease (2009/H1N1/CALIFORNIA) in complex with SJ000988503
7KNY	;	2.48	;	The crystal structure of the I38T mutant PA endonuclease (2009/H1N1/California) in complex with SJ000988528
7KNR	;	2.48	;	The crystal structure of the I38T mutant PA endonuclease (2009/H1N1/California) in complex with SJ000988558
8DPU	;	3.78	;	The crystal structure of the IL-11 signalling complex
7F4B	;	2.05	;	The crystal structure of the immature apo-enzyme of homoserine dehydrogenase from the hyperthermophilic archaeon Sulfurisphaera tokodaii.
7F4C	;	1.9	;	The crystal structure of the immature holo-enzyme of homoserine dehydrogenase complexed with NADP and 1,4-butandiol from the hyperthermophilic archaeon Sulfurisphaera tokodaii.
1V5C	;	2.0	;	The crystal structure of the inactive form chitosanase from Bacillus sp. K17 at pH3.7
3IVL	;	2.2	;	The Crystal Structure of the Inactive Peptidase Domain of a Putative Zinc Protease from Bordetella parapertussis to 2.2A
4AFL	;	2.275	;	The crystal structure of the ING4 dimerization domain reveals the functional organization of the ING family of chromatin binding proteins.
3TYP	;	1.9	;	The crystal structure of the inorganic triphosphatase NE1496
4YE6	;	2.4	;	The crystal structure of the intact human GlnRS
6O4P	;	3.429	;	The crystal structure of the interleukin 11 alpha receptor
1OQ7	;	3.2	;	The crystal structure of the iron free (Apo-)form of Stearoyl Acyl Carrier Protein Desaturase from Ricinus Communis (Castor Bean).
6OUY	;	1.6	;	The crystal structure of the isolate tryptophan synthase alpha-chain from Salmonella enterica serovar typhimurium at 1.60 Angstrom resolution
6OSO	;	1.75	;	The crystal structure of the isolate tryptophan synthase alpha-chain from Salmonella enterica serovar typhimurium at 1.75 Angstrom resolution
3GNM	;	2.1	;	The crystal structure of the JAA-F11 monoclonal antibody Fab fragment
5B3H	;	2.7	;	The crystal structure of the JACKDAW/IDD10 bound to the heterodimeric SHR-SCR complex
6KPB	;	2.4	;	The crystal structure of the JACKDAW/IDD10 bound to the homodimeric SCL3
7UAU	;	2.1	;	The crystal structure of the K137A mutant of E. coli YGGS in complex with PLP
1NSW	;	1.9	;	The Crystal Structure of the K18G Mutant of the thioredoxin from Alicyclobacillus acidocaldarius
7UAT	;	2.0	;	The crystal structure of the K36A mutant of E. coli YGGS in complex with PLP
7UBP	;	2.3	;	The crystal structure of the K36A/K137A double mutant of E. coli YGGS in complex with PLP
7UAX	;	2.07	;	The crystal structure of the K36A/K38A double mutant of E. coli YGGS in complex with PLP
7UB4	;	2.4	;	The crystal structure of the K36A/K38A/K233A/K234A quadruple mutant of E. coli YGGS in complex with PLP
7UB8	;	2.3	;	The crystal structure of the K38A/K137A/K233A/K234A quadruple mutant of E. coli YGGS in complex with PLP
2JED	;	2.32	;	The crystal structure of the kinase domain of the protein kinase C theta in complex with NVP-XAA228 at 2.32A resolution.
1R8N	;	1.75	;	The Crystal Structure of the Kunitz (STI) Type Inhibitor from Seeds of Delonix regia
7R3X	;	2.46	;	The crystal structure of the L439V variant of Pol2CORE in complex with DNA and an incoming nucleotide
1ZUJ	;	2.9	;	The crystal structure of the Lactococcus lactis MG1363 DpsA protein
1ZS3	;	2.7	;	The crystal structure of the Lactococcus lactis MG1363 DpsB protein
2OGO	;	3.66	;	The crystal structure of the large ribosomal subunit from Deinococcus radiodurans complexed with the pleuromutilin derivative retapamulin (SB-275833)
2OGN	;	3.56	;	The crystal structure of the large ribosomal subunit from Deinococcus radiodurans complexed with the pleuromutilin derivative SB-280080
2OGM	;	3.5	;	The crystal structure of the large ribosomal subunit from Deinococcus radiodurans complexed with the pleuromutilin derivative SB-571519
4WCE	;	3.526	;	The crystal structure of the large ribosomal subunit of Staphylococcus aureus
4WFB	;	3.43	;	The crystal structure of the large ribosomal subunit of Staphylococcus aureus in complex with BC-3205
5HL7	;	3.55	;	The crystal structure of the large ribosomal subunit of Staphylococcus aureus in complex with lefamulin
5HKV	;	3.66	;	The crystal structure of the large ribosomal subunit of Staphylococcus aureus in complex with lincomycin
4WFA	;	3.392	;	The crystal structure of the large ribosomal subunit of Staphylococcus aureus in complex with linezolid
5NRG	;	3.442	;	The crystal structure of the large ribosomal subunit of Staphylococcus aureus in complex with RB02
4WF9	;	3.427	;	The crystal structure of the large ribosomal subunit of Staphylococcus aureus in complex with telithromycin
3NRK	;	3.1	;	The crystal structure of the leptospiral hypothetical protein LIC12922
5FCE	;	1.798	;	The crystal structure of the ligand binding region of Serine-glutamate repeat protein A (SgrA) of Enterococcus faecium
3ETP	;	2.0	;	The crystal structure of the ligand-binding domain of the EphB2 receptor at 2.0 A resolution
2EG6	;	1.7	;	The crystal structure of the ligand-free dihydroorotase from E. coli
1XOV	;	1.8	;	The crystal structure of the listeria monocytogenes bacteriophage PSA endolysin PlyPSA
3AMI	;	2.4	;	The crystal structure of the M16B metallopeptidase subunit from Sphingomonas sp. A1
3PG2	;	1.8	;	The Crystal structure of the major pilin GBS80 of Streptococcus agalactiae 35 kDa C-terminal fragment
3PF2	;	1.7	;	The Crystal Structure of the Major Pilin GBS80 of Streptococcus agalactiae 35kDa C-terminal fragment
5EYO	;	2.39	;	The crystal structure of the Max bHLH domain in complex with 5-carboxyl cytosine DNA
5HOL	;	1.59	;	The crystal structure of the MERS-CoV macro domain with ADP-ribose
4WUR	;	3.16	;	The crystal structure of the MERS-CoV papain-like protease (C111S) with human ubiquitin
5XJA	;	3.43	;	The Crystal Structure of the Minimal Core Domain of the Microtubule Depolymerizer KIF2C Complexed with ADP-Mg-AlFx
5XJB	;	3.1	;	The Crystal Structure of the Minimal Core Domain of the Microtubule Depolymerizer KIF2C Complexed with ADP-Mg-BeFx
1V8J	;	3.24	;	The Crystal Structure of the Minimal Functional Domain of the Microtubule Destabilizer KIF2C Complexed with Mg-ADP
1V8K	;	2.25	;	The Crystal Structure of the Minimal Functional Domain of the Microtubule Destabilizer KIF2C Complexed with Mg-AMPPNP
4F6T	;	1.6	;	The crystal structure of the molybdenum storage protein (MoSto) from Azotobacter vinelandii loaded with various polyoxometalates
2OGX	;	1.6	;	The crystal structure of the molybdenum storage protein from Azotobacter vinelandii loaded with polyoxotungstates (WSto)
1VDP	;	1.7	;	The crystal structure of the monoclinic form of hen egg white lysozyme at 1.7 angstroms resolution in space
4MH8	;	3.0	;	The crystal structure of the monomeric reverse transcriptase from moloney murine leukemia virus
6TQS	;	2.25	;	The crystal structure of the MSP domain of human MOSPD2 in complex with the conventional FFAT motif of ORP1.
6TQU	;	2.4	;	The crystal structure of the MSP domain of human MOSPD2 in complex with the Phospho-FFAT motif of STARD3.
6TQT	;	1.5	;	The crystal structure of the MSP domain of human MOSPD2.
6TQR	;	1.85	;	The crystal structure of the MSP domain of human VAP-A in complex with the Phospho-FFAT motif of STARD3.
6A6X	;	2.7	;	The crystal structure of the Mtb MazE-MazF-mt9 complex
4F4C	;	3.4	;	The Crystal Structure of the Multi-Drug Transporter
2WXQ	;	2.7	;	The crystal structure of the murine class IA PI 3-kinase p110delta in complex with AS15.
2WXO	;	2.49	;	The crystal structure of the murine class IA PI 3-kinase p110delta in complex with AS5.
2WXM	;	2.8	;	The crystal structure of the murine class IA PI 3-kinase p110delta in complex with DL06.
2WXN	;	2.6	;	The crystal structure of the murine class IA PI 3-kinase p110delta in complex with DL07.
2WXP	;	2.3	;	The crystal structure of the murine class IA PI 3-kinase p110delta in complex with GDC-0941.
2X38	;	2.2	;	The crystal structure of the murine class IA PI 3-kinase p110delta in complex with IC87114.
2WXJ	;	2.6	;	The crystal structure of the murine class IA PI 3-kinase p110delta in complex with INK654.
2WXK	;	2.9	;	The crystal structure of the murine class IA PI 3-kinase p110delta in complex with INK666.
2WXF	;	1.9	;	The crystal structure of the murine class IA PI 3-kinase p110delta in complex with PIK-39.
2WXG	;	2.0	;	The crystal structure of the murine class IA PI 3-kinase p110delta in complex with SW13.
2WXH	;	1.9	;	The crystal structure of the murine class IA PI 3-kinase p110delta in complex with SW14.
2WXI	;	2.8	;	The crystal structure of the murine class IA PI 3-kinase p110delta in complex with SW30.
2WXL	;	1.99	;	The crystal structure of the murine class IA PI 3-kinase p110delta in complex with ZSTK474.
2WXR	;	2.5	;	The crystal structure of the murine class IA PI 3-kinase p110delta.
3V5I	;	2.8	;	The crystal structure of the mutant ClpP S98A (Staphylococcus aureus)
7N55	;	2.33	;	The crystal structure of the mutant I38T PA endonuclease (2009/H1N1/CALIFORNIA) in complex with SJ000988514
4O1A	;	1.87	;	The crystal structure of the mutant NAMPT G217R
6W0V	;	1.381	;	The Crystal Structure of the Mutant Nuclease Domain of Pyocin S8 with its Cognate Immunity Protein
1NW2	;	1.9	;	The crystal structure of the mutant R82E of Thioredoxin from Alicyclobacillus acidocaldarius
3QAO	;	1.874	;	The crystal structure of the N-terminal domain of a MerR-like transcriptional regulator from Listeria monocytogenes EGD-e
5JMB	;	2.05	;	The Crystal structure of the N-terminal domain of a novel cellulases from Bacteroides coprocola
3IWF	;	1.4	;	The Crystal Structure of the N-terminal domain of a RpiR Transcriptional Regulator from Staphylococcus epidermidis to 1.4A
1TJF	;	2.21	;	The crystal structure of the N-terminal domain of CAP indicates variable oligomerisation
4NKN	;	2.79	;	The Crystal Structure of the N-terminal domain of COMMD9
4OE9	;	1.55	;	The crystal structure of the n-terminal domain of COMMD9
3LAZ	;	1.921	;	The crystal structure of the N-terminal domain of D-galactarate dehydratase from Escherichia coli CFT073
1YY6	;	1.7	;	The Crystal Structure of the N-terminal domain of HAUSP/USP7 complexed with an EBNA1 peptide
2FOP	;	2.1	;	The Crystal Structure of the N-terminal domain of HAUSP/USP7 complexed with mdm2 peptide 147-150
2FOO	;	2.2	;	The Crystal Structure of the N-terminal domain of HAUSP/USP7 complexed with p53 peptide 359-362
2FOJ	;	1.6	;	The Crystal Structure of the N-terminal domain of HAUSP/USP7 complexed with p53 peptide 364-367
1XKS	;	2.35	;	The crystal structure of the N-terminal domain of Nup133 reveals a beta-propeller fold common to several nucleoporins
4RXV	;	1.099	;	The crystal structure of the N-terminal fragment of uncharacterized protein from Legionella pneumophila
4KQD	;	1.55	;	The crystal Structure of the N-terminal PAS domain of the F plasmid TraJ
3LLV	;	1.7	;	The Crystal Structure of the NAD(P)-binding domain of an Exopolyphosphatase-related protein from Archaeoglobus fulgidus to 1.7A
3EGW	;	1.9	;	The crystal structure of the NarGHI mutant NarH - C16A
1Y5L	;	2.5	;	The crystal structure of the NarGHI mutant NarI-H66Y
1Y5I	;	1.9	;	The crystal structure of the NarGHI mutant NarI-K86A
1Y5N	;	2.5	;	The crystal structure of the NarGHI mutant NarI-K86A in complex with pentachlorophenol
2JC2	;	2.5	;	The crystal structure of the natural F112L human sorcin mutant
3SI7	;	2.25	;	The crystal structure of the NBD1 domain of the mouse CFTR protein, deltaF508 mutant
4B6G	;	1.4	;	The Crystal Structure of the Neisserial Esterase D.
4GRV	;	2.802	;	The crystal structure of the neurotensin receptor NTS1 in complex with neurotensin (8-13)
5H5N	;	2.0	;	The crystal structure of the NS1 (H17N10) RNA-binding domain
2HRZ	;	1.85	;	The crystal structure of the nucleoside-diphosphate-sugar epimerase from Agrobacterium tumefaciens
5Z30	;	2.45	;	The crystal structure of the nucleosome containing a cancer-associated histone H2A.Z R80C mutant
5B24	;	3.6	;	The crystal structure of the nucleosome containing cyclobutane pyrimidine dimer
5B0Z	;	1.987	;	The crystal structure of the nucleosome containing H3.2, at 1.98 A resolution
5X7X	;	2.184	;	The crystal structure of the nucleosome containing H3.3 at 2.18 angstrom resolution
5GXQ	;	2.85	;	The crystal structure of the nucleosome containing H3.6
5ZBX	;	2.58	;	The crystal structure of the nucleosome containing histone H3.1 CATD(V76Q, K77D)
4XQ7	;	1.6	;	The crystal structure of the OAS-like domain (OLD) of human OASL
1OQB	;	2.8	;	The Crystal Structure of the one-iron form of the di-iron center in Stearoyl Acyl Carrier Protein Desaturase from Ricinus Communis (Castor Bean).
1OPR	;	2.3	;	THE CRYSTAL STRUCTURE OF THE OROTATE PHOSPHORIBOSYLTRANSFERASE COMPLEXED WITH OROTATE AND ALPHA-D-5-PHOSPHORIBOSYL-1-PYROPHOSPHATE
4LOG	;	2.7	;	The crystal structure of the orphan nuclear receptor PNR ligand binding domain fused with MBP
2DTH	;	1.95	;	The Crystal Structure of the Orthorhombic Form of Biotin Protein Ligase From Pyrococcus Horikoshii OT3 in Complex with Biotin and ADP
1VDQ	;	1.5	;	The crystal structure of the orthorhombic form of hen egg white lysozyme at 1.5 angstroms resolution
2ZQ3	;	1.6	;	The crystal structure of the orthorhombic form of hen egg white lysozyme at 1.6 angstroms resolution
1VED	;	1.9	;	The crystal structure of the orthorhombic form of hen egg white lysozyme at 1.9 angstroms resolution in space
2ZQ4	;	2.0	;	The crystal structure of the orthorhombic form of hen egg white lysozyme at 2.0 angstroms resolution
3I76	;	2.0	;	The crystal structure of the orthorhombic form of the putative HAD-hydrolase YfnB from Bacillus subtilis bound to magnesium reveals interdomain movement
1YC9	;	1.8	;	The crystal structure of the outer membrane protein VceC from the bacterial pathogen Vibrio cholerae at 1.8 resolution
6OFR	;	2.4	;	The crystal structure of the outer membrane transporter YddB from Escherichia coli
6V81	;	2.957	;	The crystal structure of the outer-membrane transporter YncD
7W5L	;	2.5	;	The crystal structure of the oxidized form of Gluconobacter oxydans WSH-004 SNDH
2W8N	;	2.0	;	The crystal structure of the oxidized form of human SSADH
2FRE	;	1.9	;	The crystal structure of the oxidoreductase containing FMN
3FBS	;	2.15	;	The crystal structure of the oxidoreductase from Agrobacterium tumefaciens
3N70	;	2.8	;	The Crystal Structure of the P-loop NTPase domain of the Sigma-54 transport activator from E. coli to 2.8A
1XG6	;	2.15	;	The crystal structure of the P1 mutant (Leu to Arg)of a Winged bean chymotrypsin inhibitor(Kunitz)solved at 2.15A resolution
1WYX	;	1.14	;	The Crystal Structure of the p130Cas SH3 Domain at 1.1 A Resolution
4LUL	;	1.89	;	The crystal structure of the P132A, Y133D mutant of Pyrococcus furiosus phosphoglucose isomerase in complex with manganese.
4LUK	;	1.41	;	The crystal structure of the P132A, Y133G mutant of Pyrococcus furiosus phosphoglucose isomerase in complex with manganese and 5-phospho-D-arabinonate.
4LTA	;	2.04	;	The crystal structure of the P132R, Y133G mutant of Pyrococcus furiosus phosphoglucose isomerase in complex with manganese and 5-phospho-D-arabinonate.
4LUM	;	1.79	;	The crystal structure of the P132V mutant of Pyrococcus furiosus phosphoglucose isomerase in complex with manganese and fructose-6- phosphate.
3NWL	;	2.69	;	The crystal structure of the P212121 form of bovine liver catalase previously characterized by electron microscopy
3MQQ	;	1.65	;	The Crystal Structure of the PAS domain in complex with Ethanol of a Transcriptional Regulator in the LuxR family from Burkholderia thailandensis to 1.65A
3MQO	;	1.7	;	The Crystal Structure of the PAS domain in complex with isopropanol of a Transcriptional Regulator in the LuxR family from Burkholderia thailandensis to 1.7A
3NJA	;	2.368	;	The crystal structure of the PAS domain of a GGDEF family protein from Chromobacterium violaceum ATCC 12472.
3KHF	;	1.2	;	The crystal structure of the PDZ domain of human Microtubule Associated Serine/Threonine Kinase 3 (MAST3)
3FWX	;	2.0	;	The crystal structure of the peptide deformylase from Vibrio cholerae O1 biovar El Tor str. N16961
3S02	;	2.5	;	The crystal structure of the periplasmic domain of Helicobacter pylori MotB (residues 103-256)
3S0W	;	2.5	;	The crystal structure of the periplasmic domain of Helicobacter pylori MotB (residues 78-256).
3S0H	;	2.1	;	The crystal structure of the periplasmic domain of Helicobacter pylori MotB (residues 90-256).
3S06	;	1.8	;	The crystal structure of the periplasmic domain of Helicobacter pylori MotB (residues 97-256, P3121).
3S03	;	2.5	;	The crystal structure of the periplasmic domain of Helicobacter pylori MotB (residues 97-256, P43).
3S0Y	;	1.8	;	The crystal structure of the periplasmic domain of MotB (residues 64-256).
6OFS	;	2.6	;	The crystal structure of the periplasmic protease PqqL from Escherichia coli
2X18	;	1.46	;	The crystal structure of the PH domain of human AKT3 protein kinase
1Z1L	;	1.7	;	The Crystal Structure of the Phosphodiesterase 2A Catalytic Domain
2OLS	;	2.4	;	The crystal structure of the phosphoenolpyruvate synthase from Neisseria meningitidis
6ABA	;	1.797	;	The crystal structure of the photoactivated state of Nonlabens marinus Rhodopsin 3
8DN7	;	2.0	;	The crystal structure of the Pisum sativum Toc75 POTRA domains in complex with fab ax9
6G0A	;	2.62	;	The crystal structure of the Pol2 catalytic domain of DNA polymerase epsilon carrying a P301R substitution.
6I8A	;	2.652	;	The crystal structure of the Pol2 catalytic domain of DNA polymerase epsilon carrying a P301R substitution.
5ZCT	;	2.05	;	The crystal structure of the poly-alpha-L-glutamate peptides synthetase RimK at 2.05 angstrom resolution.
2QMW	;	2.3	;	The crystal structure of the prephenate dehydratase (PDT) from Staphylococcus aureus subsp. aureus Mu50
2DPK	;	2.5	;	The Crystal Structure of the Primary Ca2+ Sensor of the Na+/Ca2+ Exchanger
3FH2	;	1.6	;	The crystal structure of the PROBABLE ATP-DEPENDENT PROTEASE (HEAT SHOCK PROTEIN) from Corynebacterium glutamicum
7YVD	;	2.1	;	The crystal structure of the progerin C-terminal peptide and the Ig-like domain of lamin A/C
3DNH	;	1.94	;	The crystal structure of the protein Atu2129 (unknown function) from Agrobacterium tumefaciens str. C58
2R8B	;	2.56	;	The crystal structure of the protein Atu2452 of unknown function from Agrobacterium tumefaciens str. C58
3KBQ	;	2.0	;	The crystal structure of the protein CinA with unknown function from Thermoplasma acidophilum
2B26	;	3.2	;	The crystal structure of the protein complex of yeast Hsp40 Sis1 and Hsp70 Ssa1
3D7L	;	2.06	;	The crystal structure of the protein lin1944 from Listeria innocua .
3EDP	;	2.092	;	The crystal structure of the protein lin2111 (functionally unknown) from Listeria innocua Clip11262
5V85	;	2.003	;	The crystal structure of the protein of DegV family COG1307 from Ruminococcus gnavus ATCC 29149 (alternative refinement of PDB 3JR7 with Vaccenic acid)
3JR7	;	2.0	;	The crystal structure of the protein of DegV family COG1307 with unknown function from Ruminococcus gnavus ATCC 29149
1XM7	;	2.4	;	The Crystal Structure of the Protein of Unknown Function AQ665 from Aquifex aeolicus
1YLN	;	2.2	;	The Crystal Structure of the Protein of Unknown Function VCA0042 from Vibrio cholerae O1
3LMB	;	2.1	;	The crystal structure of the protein OLEI01261 with unknown function from Chlorobaculum tepidum TLS
3LLB	;	1.8	;	The crystal structure of the protein PA3983 with unknown function from Pseudomonas aeruginosa PAO1
3DO8	;	1.6	;	The crystal structure of the protein with unknown function from Archaeoglobus fulgidus
3FVV	;	2.1	;	The crystal structure of the protein with unknown function from Bordetella pertussis Tohama I
3H04	;	1.9	;	The crystal structure of the protein with unknown function from Staphylococcus aureus subsp. aureus Mu50
3FB9	;	1.8	;	The crystal structure of the protein with unknown function from Streptococcus pneumoniae TIGR4
3GAA	;	2.7	;	The crystal structure of the protein with unknown function from Thermoplasma acidophilum
3KZQ	;	2.1	;	The crystal structure of the protein with unknown function from Vibrio parahaemolyticus RIMD 2210633
2VEC	;	1.85	;	The crystal structure of the protein YhaK from Escherichia coli
3MTV	;	2.8	;	The Crystal Structure of the PRRSV Nonstructural Protein Nsp1
7UYY	;	2.7	;	The crystal structure of the Pseudomonas aeruginosa aldehyde dehydrogenase encoded by the PA4189 gene in complex with NADH
3FDD	;	2.35	;	The Crystal Structure of the Pseudomonas dacunhae Aspartate-Beta-Decarboxylase Reveals a Novel Oligomeric Assembly for a Pyridoxal-5-Phosphate Dependent Enzyme
1YUK	;	1.8	;	The crystal structure of the PSI/Hybrid domain/ I-EGF1 segment from the human integrin beta2 at 1.8 resolution
3LOD	;	2.5	;	The crystal structure of the putative acyl-CoA N-acyltransferase from Klebsiella pneumoniae subsp.pneumoniae MGH 78578
3LP5	;	2.0	;	The crystal structure of the putative cell surface hydrolase from Lactobacillus plantarum WCFS1
3MOI	;	2.5	;	The crystal structure of the putative dehydrogenase from Bordetella bronchiseptica RB50
3O0Y	;	1.7	;	The crystal structure of the putative lipoprotein from Colwellia psychrerythraea
3CZX	;	1.6	;	The crystal structure of the putative N-acetylmuramoyl-L-alanine amidase from Neisseria meningitidis
2HAY	;	2.11	;	The Crystal Structure of the Putative NAD(P)H-Flavin Oxidoreductase from Streptococcus pyogenes M1 GAS
2B0C	;	2.0	;	The crystal structure of the putative phosphatase from Escherichia coli
3HFI	;	2.2	;	The crystal structure of the putative regulator from Escherichia coli CFT073
2O0M	;	1.6	;	The crystal structure of the putative SorC family transcriptional regulator from Enterococcus faecalis
3E7Q	;	2.2	;	The crystal structure of the putative transcriptional regulator from Pseudomonas aeruginosa PAO1
2G7G	;	2.01	;	The Crystal Structure of the Putative Transcriptional Regulator Rha04620 from Rhodococcus sp. RHA1
3DQQ	;	2.7	;	The crystal structure of the putative tRNA synthase from Salmonella typhimurium LT2
4QKO	;	1.8	;	The Crystal Structure of the Pyocin S2 Nuclease Domain, Immunity Protein Complex at 1.8 Angstroms
3EC8	;	2.6	;	The crystal structure of the RA domain of FLJ10324 (RADIL)
3CH5	;	2.1	;	The crystal structure of the RanGDP-Nup153ZnF2 complex
2ERY	;	1.7	;	The crystal structure of the Ras related protein RRas2 (RRAS2) in the GDP bound state
1TJD	;	2.5	;	The crystal structure of the reduced disulphide bond isomerase, DsbC, from Escherichia coli
7W5N	;	2.988	;	The crystal structure of the reduced form of Gluconobacter oxydans WSH-004 SNDH
2W8O	;	3.4	;	The crystal structure of the reduced form of human SSADH
6MX1	;	1.671	;	The crystal structure of the regulatory domain of aspartokinase in the bifunctional aspartokinase/homoserine dehydrogenase 1 from Escherichia coli str. K-12 substr. MG1655
6AB9	;	1.75	;	The crystal structure of the relaxed state of Nonlabens marinus Rhodopsin 3
3MZY	;	2.5	;	The Crystal Structure of the RNA polymerase sigma-H factor from Fusobacterium nucleatum to 2.5A
2G8R	;	1.7	;	The crystal structure of the RNase A- 3-N-piperidine-4-carboxyl-3-deoxy-ara-uridine complex
3LEQ	;	1.85	;	The Crystal Structure of the Roadblock/LC7 domain from Streptomyces avermitillis to 1.85A
4JHN	;	1.7	;	The crystal structure of the RPGR RCC1-like domain
4JHP	;	1.9	;	The crystal structure of the RPGR RCC1-like domain in complex with PDE6D
3KE6	;	2.6	;	The crystal structure of the RsbU and RsbW domains of Rv1364c from Mycobacterium tuberculosis
6XNB	;	1.16	;	The Crystal Structure of the S154Y Mutant Carbonyl Reductase from Leifsonia xyli Explains Enhanced Activity for 3,5-Bis(trifluoromethyl)acetophenone Reduction
8A2C	;	1.6	;	The crystal structure of the S178A mutant of PET40, a PETase enzyme from an unclassified Amycolatopsis
5JHE	;	1.8	;	The Crystal Structure of the Saccharomyces cerevisiae Co-Chaperone Cpr7
3O02	;	1.9	;	The Crystal Structure of the Salmonella Type III Secretion System Tip Protein SipD in Complex with Chenodeoxycholate
3O01	;	1.9	;	The Crystal Structure of the Salmonella Type III Secretion System Tip Protein SipD in Complex with Deoxycholate
7CI3	;	2.2	;	The crystal structure of the SARS-CoV-2 ORF7a ectodomain
2FE5	;	1.1	;	The Crystal Structure of the Second PDZ Domain of Human DLG3
2HE4	;	1.45	;	The crystal structure of the second PDZ domain of human NHERF-2 (SLC9A3R2) interacting with a mode 1 PDZ binding motif
3EYI	;	1.45	;	The crystal structure of the second Z-DNA binding domain of human DAI (ZBP1) in complex with Z-DNA
2CN4	;	2.3	;	The crystal structure of the secreted dimeric form of the hemophore HasA reveals a domain swapping with an exchanged heme ligand
3KYZ	;	1.497	;	The crystal structure of the sensor domain of two-component sensor PfeS from Pseudomonas aeruginosa PA01
4UMS	;	1.84	;	The crystal structure of the seventh ScaB type I cohesin from Pseudobacteroides cellulosolvens
5G4X	;	2.166	;	The crystal structure of the SHANK3 N-terminus
7QH5	;	2.2	;	The crystal structure of the sigma factor SigG1 from Streptomyces tsukubaensis NRRL18488
2XXA	;	3.94	;	The Crystal Structure of the Signal Recognition Particle (SRP) in Complex with its Receptor(SR)
3FBY	;	3.15	;	The crystal structure of the signature domain of cartilage oligomeric matrix protein.
1QBZ	;	1.47	;	THE CRYSTAL STRUCTURE OF THE SIV GP41 ECTODOMAIN AT 1.47 A
3A4S	;	2.7	;	The crystal structure of the SLD2:Ubc9 complex
1UOS	;	2.7	;	The Crystal Structure of the Snake Venom Toxin Convulxin
4ZBH	;	1.5	;	THE CRYSTAL STRUCTURE OF THE SOLUBLE DOMAIN OF SULFOLOBUS ACIDOCALDARIUS FLAF
4P94	;	1.651	;	The crystal structure of the soluble domain of Sulfolobus acidocaldarius FlaF (residues 35-164)
4GJ4	;	1.8	;	The Crystal Structure of the soluble Guanylate Cyclase PAS alpha domain from Manduca sexta
2FL4	;	1.6	;	The crystal structure of the spermine/spermidine acetyltransferase from Enterococcus faecalis
1OOW	;	2.0	;	The crystal structure of the spinach plastocyanin double mutant G8D/L12E gives insight into its low reactivity towards photosystem 1 and cytochrome f
4P6Q	;	2.0	;	The crystal structure of the Split End protein SHARP adds a new layer of complexity to proteins containing RNA Recognition Motifs
6MH9	;	2.02	;	The crystal structure of the Staphylococcus aureus Fatty acid Kinase (Fak) B1 protein A121I mutant to 2.02 Angstrom resolution
6NM1	;	2.33	;	The crystal structure of the Staphylococcus aureus Fatty acid Kinase (Fak) B1 protein A158L mutant to 2.33 Angstrom resolution exhibits a conformation change compared to the wild type form
6ALW	;	1.63	;	The crystal structure of the Staphylococcus aureus Fatty acid Kinase (Fak) B1 protein loaded with 12-Methyl Myristic Acid (C15:0) to 1.63 Angstrom resolution
6B9I	;	1.93	;	The crystal structure of the Staphylococcus aureus Fatty acid Kinase (Fak) B1 protein loaded with 14-Methylhexadecanoic Acid (Anteiso C17:0) to 1.93 Angstrom resolution
5WOO	;	1.78	;	The crystal structure of the Staphylococcus aureus Fatty acid Kinase (Fak) B1 protein loaded with Myristic acid (C14:0) to 1.78 Angstrom resolution
5UTO	;	1.83	;	The crystal structure of the Staphylococcus aureus Fatty acid Kinase (Fak) B1 protein loaded with palmitic acid to 1.83 Angstrom resolution
5HZG	;	3.3	;	The crystal structure of the strigolactone-induced AtD14-D3-ASK1 complex
3RNM	;	2.4	;	The crystal structure of the subunit binding of human dihydrolipoamide transacylase (E2b) bound to human dihydrolipoamide dehydrogenase (E3)
2E25	;	2.7	;	The Crystal Structure of the T109S mutant of E. coli Dihydroorotase complexed with an inhibitor 5-fluoroorotate
8DYB	;	1.88	;	The crystal structure of the T252A mutant of CYP199A4 bound to 4-methylthiobenzoic acid
5KDZ	;	1.424	;	The crystal structure of the T252A mutant of CYP199A4 in complex with 4-methoxybenzoate
8TNK	;	1.79	;	The crystal structure of the T252E mutant of CYP199A4 bound to 4-benzylbenzoic acid
4ZDL	;	2.26	;	The crystal structure of the T325S mutant of the human holo SepSecS
3D37	;	2.1	;	The crystal structure of the tail protein from Neisseria meningitidis MC58
4U7W	;	1.899	;	The crystal structure of the terminal R domain from the myxalamid PKS-NRPS biosynthetic pathway
4W4T	;	1.845	;	The crystal structure of the terminal R domain from the myxalamid PKS-NRPS biosynthetic pathway
1SNC	;	1.65	;	THE CRYSTAL STRUCTURE OF THE TERNARY COMPLEX OF STAPHYLOCOCCAL NUCLEASE, CA2+, AND THE INHIBITOR PD*TP, REFINED AT 1.65 ANGSTROMS
1VDS	;	1.6	;	The crystal structure of the tetragonal form of hen egg white lysozyme at 1.6 angstroms resolution in space
1VDT	;	1.7	;	The crystal structure of the tetragonal form of hen egg white lysozyme at 1.7 angstroms resolution under basic conditions in space
3NSX	;	1.569	;	The crystal structure of the The crystal structure of the D420A mutant of the alpha-glucosidase (FAMILY 31) from Ruminococcus obeum ATCC 29174
1EVQ	;	2.6	;	THE CRYSTAL STRUCTURE OF THE THERMOPHILIC CARBOXYLESTERASE EST2 FROM ALICYCLOBACILLUS ACIDOCALDARIUS
3EFE	;	2.3	;	The crystal structure of the thiJ/pfpI family protein from Bacillus anthracis
3HHV	;	1.83	;	The crystal structure of the Thioredoxin A2 from Sulfolobus solfataricus
2OUJ	;	1.9	;	The crystal structure of the Thrombospondin-1 N-terminal domain in complex with fractionated Heparin DP8
7UWG	;	2.16	;	The crystal structure of the TIR domain-containing protein from Acinetobacter baumannii (AbTir)
3IAX	;	2.6	;	The crystal structure of the TolB box of Colicin A in complex with TolB reveals important differences in the recruitment of the common TolB translocation portal used by group A colicins
3G5O	;	2.0	;	The crystal structure of the toxin-antitoxin complex RelBE2 (Rv2865-2866) from Mycobacterium tuberculosis
1I4W	;	2.6	;	THE CRYSTAL STRUCTURE OF THE TRANSCRIPTION FACTOR SC-MTTFB OFFERS INTRIGUING INSIGHTS INTO MITOCHONDRIAL TRANSCRIPTION
3DDV	;	2.65	;	The crystal structure of the transcriptional regulator (GntR family) from Enterococcus faecalis V583
2FQ4	;	1.79	;	The crystal structure of the transcriptional regulator (TetR family) from Bacillus cereus
1LJ9	;	1.6	;	The crystal structure of the transcriptional regulator SlyA
3EUP	;	1.99	;	The crystal structure of the transcriptional regulator, TetR family from Cytophaga hutchinsonii
7KCJ	;	1.997	;	The crystal structure of the translation initiation factor EIF4E5 from Leishmania major
1DA3	;	2.0	;	THE CRYSTAL STRUCTURE OF THE TRIGONAL DECAMER C-G-A-T-C-G-6MEA-T-C-G: A B-DNA HELIX WITH 10.6 BASE-PAIRS PER TURN
2NX8	;	2.0	;	The crystal structure of the tRNA-specific adenosine deaminase from Streptococcus pyogenes
2A5L	;	1.7	;	The crystal structure of the Trp repressor binding protein WrbA from Pseudomonas aeruginosa
8QCW	;	2.9	;	The crystal structure of the truncated form of Lotus japonicus kinase 1
1V6D	;	1.9	;	The crystal structure of the trypsin complex with synthetic heterochiral peptide
3KUF	;	2.7	;	The Crystal Structure of the Tudor Domains from FXR1
3H8Z	;	1.92	;	The Crystal Structure of the Tudor Domains from FXR2
2JE1	;	2.69	;	The crystal Structure of the tumor supressor protein pp32 (Anp32a) :structural insights into the Anp32 family of proteins
3LR1	;	1.8	;	The crystal structure of the tungstate ABC transporter from Geobacter sulfurreducens
5NL6	;	2.05	;	The crystal structure of the two spectrin repeat domains from Entamoeba histolytica
8YHF	;	1.4	;	The Crystal Structure of the Type I TGF beta receptor from Biortus.
2WYQ	;	1.651	;	THE CRYSTAL STRUCTURE OF THE UBIQUITIN-LIKE (UBL) DOMAIN OF HHR23A (HUMAN HOMOLOGUE A OF RAD23)
3I99	;	2.2	;	The crystal structure of the UDP-N-acetylenolpyruvoylglucosamine reductase from the Vibrio cholerae O1 biovar Tor
3L1Q	;	2.5	;	The crystal structure of the undecamer d(TGGCCTTAAGG)
7R3Y	;	2.6	;	The crystal structure of the V426L variant of Pol2CORE in complex with DNA and an incoming nucleotide
4RM4	;	1.771	;	The crystal structure of the versatile cytochrome P450 enzyme CYP109B1 from Bacillus subtilis
8JW3	;	1.45	;	The crystal structure of the viral terpene synthase from Orpheovirus IHUMI-LCC2
6BGC	;	2.082	;	The crystal structure of the W145A variant of TpMglB-2 (Tp0684) with bound glucose
6BGD	;	1.47	;	The crystal structure of the W145A variant of TpMglB-2 (Tp0684) with bound ligand
3NUK	;	2.055	;	THE CRYSTAL STRUCTURE OF THE W169Y mutant of ALPHA-GLUCOSIDASE (FAMILY 31) from RUMINOCOCCUS OBEUM ATCC 29174
6CA1	;	1.95	;	THE CRYSTAL STRUCTURE OF THE W169Y MUTANT OF ALPHA-GLUCOSIDASE (GH 31) FROM RUMINOCOCCUS OBEUM ATCC 29174 in complex with miglitol
6CA3	;	1.743	;	THE CRYSTAL STRUCTURE OF THE W169Y MUTANT OF ALPHA-GLUCOSIDASE (GH 31) FROM RUMINOCOCCUS OBEUM ATCC 29174 in complex with miglitol
3PHA	;	2.173	;	The crystal structure of the W169Y mutant of alpha-glucosidase (gh31 family) from Ruminococcus obeum atcc 29174 in complex with acarbose
7LP7	;	2.5	;	The crystal structure of the wild type PA endonuclease (2009/H1N1/CALIFORNIA) in complex with SJ000983476
7UBQ	;	2.6	;	The crystal structure of the wild-type of E. coli YGGS in complex with PNP
6P66	;	3.0	;	The crystal structure of the XPB complex with Bax1 from Archaeoglobus fulgidus at 3.0 Angstrom resolution
4YE8	;	3.3	;	The crystal structure of the Y57H mutant of human GlnRS
1UXO	;	1.8	;	The crystal structure of the ydeN gene product from B. subtilis
5H5D	;	2.7	;	The crystal structure of the yeast arginine methyltransferase SFM1 complexed with MTA
5H5E	;	2.09	;	The crystal structure of the yeast arginine methyltransferase SFM1 complexed with SAH
5H5F	;	1.7	;	The crystal structure of the yeast arginine methyltransferase SFM1 complexed with SAM
1ZA3	;	3.35	;	The crystal structure of the YSd1 Fab bound to DR5
2FPN	;	2.49	;	The crystal structure of the ywmB protein from Bacillus subtilis
4HOB	;	1.76	;	The crystal structure of the Zalpha domain from Cyprinid Herpes virus 3
1XMK	;	0.97	;	The Crystal structure of the Zb domain from the RNA editing enzyme ADAR1
3DFM	;	2.01	;	The crystal structure of the zinc inhibited form of teicoplanin deacetylase Orf2
1JV0	;	2.0	;	THE CRYSTAL STRUCTURE OF THE ZINC(II) ADDUCT OF THE CAI MICHIGAN 1 VARIANT
1GPZ	;	2.9	;	THE CRYSTAL STRUCTURE OF THE ZYMOGEN CATALYTIC DOMAIN OF COMPLEMENT PROTEASE C1R
4AEF	;	2.34	;	THE CRYSTAL STRUCTURE OF THERMOSTABLE AMYLASE FROM THE PYROCOCCUS
5HXV	;	2.0	;	The crystal structure of thermostable xylanase mutant
6RNV	;	1.27	;	The crystal structure of Thermosynechococcus elongatus protochlorophyllide oxidoreductase (POR)
6RNW	;	1.92	;	The crystal structure of Thermosynechococcus elongatus protochlorophyllide oxidoreductase (POR) in complex with NADP.
1GC9	;	2.3	;	THE CRYSTAL STRUCTURE OF THERMUS THERMOPHILUS 3-ISOPROPYLMALATE DEHYDROGENASE MUTATED AT 172TH FROM ALA TO GLY
1GC8	;	2.5	;	THE CRYSTAL STRUCTURE OF THERMUS THERMOPHILUS 3-ISOPROPYLMALATE DEHYDROGENASE MUTATED AT 172TH FROM ALA TO PHE
3EC5	;	1.75	;	The crystal structure of Thioflavin-T (ThT) binding OspA mutant
4NPB	;	2.147	;	The crystal structure of thiol:disulfide interchange protein DsbC from Yersinia pestis CO92
3HDC	;	1.771	;	The crystal structure of thioredoxin protein from Geobacter metallireducens
3KCM	;	2.45	;	The crystal structure of thioredoxin protein from Geobacter metallireducens
5UWY	;	2.72	;	The crystal structure of thioredoxin reductase from Streptococcus pyogenes MGAS5005
3RAZ	;	2.0	;	The crystal structure of thioredoxin-related protein from Neisseria meningitidis serogroup B
4EDH	;	1.32	;	The crystal structure of thymidylate kinase from Pseudomonas aeruginosa PAO1 in complex with ADP,TMP and Mg.
4GMD	;	1.98	;	The crystal structure of thymidylate kinase from Pseudomonas aeruginosa PAO1 in complex with AZT Monophosphate
4ESH	;	1.95	;	The crystal structure of thymidylate kinase from Pseudomonas aeruginosa PAO1 in complex with deoxythymidine.
4E5U	;	1.812	;	The crystal structure of thymidylate kinase from Pseudomonas aeruginosa PAO1 in complex with thymidine monophosphate.
4R1D	;	1.749	;	The crystal structure of Tle4-Tli4 complex
1PBT	;	1.7	;	The crystal structure of TM1154, oxidoreductase, sol/devB family from Thermotoga maritima
1RJ8	;	2.23	;	The crystal structure of TNF family member EDA-A2
8X88	;	2.7	;	The Crystal Structure of TNIK from Biortus.
2O50	;	2.9	;	The crystal structure of Toxoplasma gondii Enoyl acyl carrier protein reductase
5U2P	;	1.76	;	The crystal structure of Tp0737 from Treponema pallidum
3PJL	;	1.7	;	The crystal structure of Tp34 bound to Co (II) ion at pH 7.5
3PJN	;	1.7	;	The crystal structure of Tp34 bound to Zn(II) ion at pH 7.5
1FC3	;	2.0	;	THE CRYSTAL STRUCTURE OF TRANS-ACTIVATION DOMAIN OF THE SPORULATION RESPONSE REGULATOR, SPO0A
3H5O	;	2.3	;	The crystal structure of transcription regulator GntR from Chromobacterium violaceum
2FBQ	;	1.8	;	The crystal structure of transcriptional regulator PA3006
2FBH	;	1.8	;	The crystal structure of transcriptional regulator PA3341
2FBI	;	2.1	;	The crystal structure of transcriptional regulator PA4135
2A61	;	1.8	;	The crystal structure of transcriptional regulator Tm0710 from Thermotoga maritima
1YSQ	;	1.75	;	The crystal structure of transcriptional regulator YaiJ
2G7S	;	1.4	;	The crystal structure of transcriptional regulator, TetR family, from Agrobacterium tumefaciens
3V89	;	3.1	;	The crystal structure of transferrin binding protein A (TbpA) from Neisseria meningitidis serogroup B in complex with the C-lobe of human transferrin
3V8X	;	2.6	;	The crystal structure of transferrin binding protein A (TbpA) from Neisserial meningitidis serogroup B in complex with full length human transferrin
3V8U	;	2.4	;	The crystal structure of transferrin binding protein B (TbpB) from Neisseria meningitidis serogroup B
4DIO	;	2.6	;	The crystal structure of transhydrogenase from Sinorhizobium meliloti
3P3K	;	2.551	;	The crystal structure of translationally controlled tumor protein (TCTP) of Plasmodium falciparum
3C9J	;	3.5	;	The Crystal structure of Transmembrane domain of M2 protein and Amantadine complex
1S5X	;	2.4	;	The crystal structure of Trematomus bernacchii hemoglobin oxidized by air
1S5Y	;	2.5	;	The crystal structure of Trematomus bernacchii hemoglobin oxidized by ferricyanide
1LA6	;	2.0	;	The crystal structure of Trematomus newnesi hemoglobin in a partial hemichrome state
2IOC	;	2.1	;	The crystal structure of TREX1 explains the 3' nucleotide specificity and reveals a polyproline II helix for protein partenring
1TAH	;	3.0	;	THE CRYSTAL STRUCTURE OF TRIACYLGLYCEROL LIPASE FROM PSEUDOMONAS GLUMAE REVEALS A PARTIALLY REDUNDANT CATALYTIC ASPARTATE
6QIX	;	1.65	;	The crystal structure of Trichuris muris p43
6IET	;	2.101	;	The crystal structure of TRIM66 PHD-Bromo domain
7XAF	;	3.00118	;	The crystal structure of TrkA kinase in complex with 4^6,14-dimethyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-10-oxo-5-oxa-11,14-diaza-1(3,6)-imidazo[1,2-b]pyridazina-4(1,3)-benzenacyclo- tetradecaphan-2-yne-45-carboxamide
8J63	;	3.0005	;	The crystal structure of TrkA kinase in complex with 4^6-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-11-oxo-5-oxa-10,14-diaza-1(3,6)-imidazo[1,2-b]pyridazina-4(1,3)-benzenacyclotetradecaphan-2-yne-4^5-carboxamide
8J61	;	3.05065	;	The crystal structure of TrkA kinase in complex with 4^6-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-14-oxo-5-oxa-13-aza-1(3,6)-imidazo[1,2-b]pyridazina-4(1,3)-benzenacyclotetradecaphan-2-yne-4^5-carboxamide
8J5W	;	2.28041	;	The crystal structure of TrkA(F589L) kinase in complex with N-(3-cyclopropyl-5-((4-methylpiperazin-1-yl)methyl)phenyl)-4^6-methyl-14-oxo-5-oxa-13-aza-1(3,6)-imidazo[1,2-b]pyridazina-4(1,3)-benzenacyclotetradecaphan-2-yne-4^5-carboxamide
8J5X	;	2.09192	;	The crystal structure of TrkA(G595R) kinase in complex with N-(3-cyclopropyl-5-((4-methylpiperazin-1-yl)methyl)phenyl)-4^6-methyl-14-oxo-5-oxa-13-aza-1(3,6)-imidazo[1,2-b]pyridazina-4(1,3)-benzenacyclotetradecaphan-2-yne-4^5-carboxamide
2HMA	;	2.41	;	The Crystal Structure of tRNA (5-Methylaminomethyl-2-Thiouridylate)-Methyltransferase TrmU from Streptococcus pneumoniae
1ZVW	;	2.3	;	The Crystal Structure of TrpD (Rv2192c) from Mycobacterium tuberculosis in Complex with PRPP and Magnesium
1WC9	;	1.6	;	The crystal structure of truncated mouse bet3p
4OJH	;	1.6	;	The crystal structure of truncated, Y86E mutant of S. solfataricus acylphosphatase
4CJX	;	2.05	;	The crystal structure of Trypanosoma brucei N5, N10- methylenetetrahydrofolate dehydrogenase-cyclohydrolase (FolD) complexed with NADP cofactor and inhibitor
7C42	;	2.0	;	The crystal structure of Trypanosoma brucei RNase D
7C43	;	2.3	;	The crystal structure of Trypanosoma brucei RNase D : AMP complex
7C47	;	2.2	;	The crystal structure of Trypanosoma brucei RNase D : CMP complex
7C4C	;	2.265	;	The crystal structure of Trypanosoma brucei RNase D : GMP complex
7C4B	;	2.101	;	The crystal structure of Trypanosoma brucei RNase D : UMP complex
7C45	;	1.769	;	The crystal structure of Trypanosoma brucei RNase D complex with RNA U12
1OGK	;	2.85	;	The crystal structure of Trypanosoma cruzi dUTPase in complex with dUDP
6XIN	;	1.75	;	The crystal structure of tryptophan synthase from Salmonella enterica serovar typhimurium in complex with (2S)-3-Amino-3-imino-2-phenyldiazenylpropanamide at the enzyme alpha-site.
4NEG	;	2.201	;	The crystal structure of tryptophan synthase subunit beta from Bacillus anthracis str. 'Ames Ancestor'
8XPZ	;	2.6	;	The Crystal Structure of TTBK1 from Biortus.
5XLZ	;	2.298	;	The crystal structure of tubulin complexed with a benzylidene derivative of 9(10H)-anthracenone
5XLT	;	2.813	;	The crystal structure of tubulin in complex with 4'-demethylepipodophyllotoxin
3N2N	;	1.8	;	The Crystal Structure of Tumor Endothelial Marker 8 (TEM8) extracellular domain
6DET	;	1.75	;	The crystal structure of Tv2483 bound to L-arginine
1F7Y	;	2.8	;	THE CRYSTAL STRUCTURE OF TWO UUCG LOOPS HIGHLIGHTS THE ROLE PLAYED BY 2'-HYDROXYL GROUPS IN ITS UNUSUAL STABILITY
7C78	;	1.98	;	The crystal structure of type I-F anti-crispr protein AcrIF9
6HSB	;	1.95	;	The crystal structure of type II Dehydroquinase from Acidithiobacillus caldus SM-1
6HS8	;	1.7	;	The crystal structure of type II Dehydroquinase from Butyrivibrio crossotus DSM 2876
6HS9	;	1.05	;	The crystal structure of type II Dehydroquinase from Butyrivibrio crossotus DSM 2876
6HSA	;	0.92	;	The crystal structure of type II Dehydroquinase from Butyrivibrio crossotus DSM 2876
6SME	;	1.7	;	THE CRYSTAL STRUCTURE OF TYPE II DEHYDROQUINASE FROM PROPIONIBACTERIUM ACNES
6HSQ	;	1.46	;	The crystal structure of type II Dehydroquinase from Psychromonas ingrahamii 37 crystal form 1
6HSR	;	2.0	;	The crystal structure of type II Dehydroquinase from Psychromonas ingrahamii 37, 40% ethanol as cryoprotectant
6HSU	;	1.6	;	The crystal structure of type II Dehydroquinase from Psychromonas ingrahamii 37, crystal form 2
6SMF	;	2.343	;	THE CRYSTAL STRUCTURE OF TYPE II DEHYDROQUINASE FROM ZYMOMONAS MOBILIS
4P5F	;	2.1	;	The crystal structure of type III effector protein XopQ complexed with adenosine diphosphate ribose
4DM9	;	2.35	;	The Crystal Structure of Ubiquitin Carboxy-terminal hydrolase L1 (UCHL1) bound to a tripeptide fluoromethyl ketone Z-VAE(OMe)-FMK
8XI7	;	1.95	;	The Crystal Structure of UCHL1 from Biortus.
1PKD	;	2.3	;	THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN A
1XHB	;	2.5	;	The Crystal Structure of UDP-GalNAc: polypeptide alpha-N-acetylgalactosaminyltransferase-T1
3JUK	;	2.3	;	The Crystal Structure of UDP-glucose pyrophosphorylase complexed with UDP-glucose
3M2P	;	2.95	;	The crystal structure of UDP-N-acetylglucosamine 4-epimerase from Bacillus cereus
3EAG	;	2.55	;	The crystal structure of UDP-N-acetylmuramate:L-alanyl-gamma-D-glutamyl-meso-diaminopimelate ligase (MPL) from Neisseria meningitides
3LK7	;	1.5	;	The Crystal Structure of UDP-N-acetylmuramoylalanine-D-glutamate (MurD) ligase from Streptococcus agalactiae to 1.5A
2JJX	;	2.82	;	THE CRYSTAL STRUCTURE OF UMP KINASE FROM BACILLUS ANTHRACIS (BA1797)
5DPO	;	1.644	;	The crystal structure of uncharacterized protein (LPG2149) from Legionella pneumophila
2PPW	;	2.01	;	The crystal structure of uncharacterized Ribose 5-phosphate isomerase RpiB from Streptococcus pneumoniae
6G4T	;	1.91	;	The crystal structure of uninhibited C183S/C217S mutant of human CA VII
2PFK	;	2.4	;	THE CRYSTAL STRUCTURE OF UNLIGANDED PHOSPHOFRUCTOKINASE FROM ESCHERICHIA COLI
3L0U	;	3.0	;	The crystal structure of unmodified tRNAPhe from Escherichia coli
3OX7	;	1.58	;	The crystal structure of uPA complex with peptide inhibitor MH027 at pH4.6
3OY5	;	2.31	;	The crystal structure of uPA complex with peptide inhibitor MH027 at pH7.4
3OY6	;	2.31	;	The crystal structure of uPA complex with peptide inhibitor MH036 at pH4.6
5YC6	;	1.18	;	The crystal structure of uPA in complex with 4-Bromobenzylamirne at pH4.6
5YC7	;	2.0	;	The crystal structure of uPA in complex with 4-Bromobenzylamirne at pH7.4
5Z1C	;	1.45	;	The crystal structure of uPA in complex with 4-Iodobenzylamine at pH7.4
6AG7	;	1.9	;	The crystal structure of uPA in complex with HMA-55F
4DW2	;	2.97	;	The crystal structure of uPA in complex with the Fab fragment of mAb-112
4ZKS	;	1.85	;	The crystal structure of upain-1-W3A in complex with inactive uPA (uPA-S195A) at pH7.4
4ZKN	;	1.36	;	The crystal structure of upain-1-W3A in complex with uPA at pH5.5
4ZKO	;	1.29	;	The crystal structure of upain-1-W3A in complex with uPA at pH7.4
4ZKR	;	1.36	;	The crystal structure of upain-1-W3A in complex with uPA at pH9.0
2BOO	;	1.8	;	The crystal structure of Uracil-DNA N-Glycosylase (UNG) from Deinococcus radiodurans.
4OSP	;	2.25	;	The crystal structure of urdamycin C-6 ketoreductase domain UrdMred with bound NADP and rabelomycin
2KAU	;	2.0	;	THE CRYSTAL STRUCTURE OF UREASE FROM KLEBSIELLA AEROGENES AT 2.2 ANGSTROMS RESOLUTION
8XPN	;	2.1	;	The Crystal Structure of USP8 from Biortus.
8Y9A	;	3.1	;	The Crystal Structure of USP8 from Biortus.
4OJG	;	1.377	;	The crystal structure of V84D mutant of S. solfataricus acylphosphatase
4OJ3	;	2.2	;	The crystal structure of V84P mutant of S. solfataricus Acylphosphatase
5WXV	;	2.3	;	The crystal structure of VabB-ICL domain from Vibrio anguillarum 775
6A9S	;	1.18	;	The crystal structure of vaccinia virus A26 (residues 1-397)
6OCF	;	2.102	;	The crystal structure of VASH1-SVBP complex
3FG7	;	2.0	;	The crystal structure of villin domain 6
5C5T	;	1.598	;	The crystal structure of viral collagen prolyl hydroxylase vCPH from Paramecium Bursaria Chlorella virus-1 - 2OG complex
5C5U	;	1.7	;	The crystal structure of viral collagen prolyl hydroxylase vCPH from Paramecium Bursaria Chlorella virus-1 - Truncated Construct
5Y6Y	;	1.5	;	The crystal structure of VrEH2 mutant M263N
5Y5D	;	1.85	;	The crystal structure of VrEH2 mutant M263W
2CDU	;	1.8	;	The Crystal Structure of Water-forming NAD(P)H Oxidase from Lactobacillus sanfranciscensis
1BWO	;	2.1	;	THE CRYSTAL STRUCTURE OF WHEAT NON-SPECIFIC TRANSFER PROTEIN COMPLEXED WITH TWO MOLECULES OF PHOSPHOLIPID AT 2.1 A RESOLUTION
8DPJ	;	2.45	;	The crystal structure of wild type PA endonuclease (2009/H1N1/CALIFORNIA) in complex with compound SJ001023030
8DQS	;	2.45	;	The crystal structure of wild type PA endonuclease (2009/H1N1/CALIFORNIA) in complex with compound SJ001023032
8E21	;	2.61	;	The crystal structure of wild type PA endonuclease (2009/H1N1/CALIFORNIA) in complex with compound SJ001023034
8DVO	;	2.33	;	The crystal structure of wild type PA endonuclease (2009/H1N1/CALIFORNIA) in complex with compound SJ001023044
7UMR	;	2.53	;	The crystal structure of wild type PA endonuclease (2009/H1N1/CALIFORNIA) in complex with compound SJ001034732-1 (trans-form)
7UUH	;	2.89	;	The crystal structure of wild type PA endonuclease (2009/H1N1/CALIFORNIA) in complex with compound SJ001034732-2 (cis-form)
7MPF	;	2.8	;	The crystal structure of wild type PA endonuclease (2009/H1N1/CALIFORNIA) in complex with SJ000986436
7N68	;	2.26	;	The crystal structure of wild type PA endonuclease (2009/H1N1/CALIFORNIA) in complex with SJ000988288
7MY5	;	2.38	;	The crystal structure of wild type PA endonuclease (2009/H1N1/CALIFORNIA) in complex with SJ000988503
7N47	;	2.37	;	The crystal structure of wild type PA endonuclease (2009/H1N1/CALIFORNIA) in complex with SJ000988514
7MX0	;	2.48	;	The crystal structure of wild type PA endonuclease (2009/H1N1/CALIFORNIA) in complex with SJ000988558
7MTY	;	2.38	;	The crystal structure of wild type PA endonuclease (2009/H1N1/CALIFORNIA) in complex with SJ000988569
7M0N	;	2.4	;	The crystal structure of wild type PA endonuclease (A/Vietnam/1203/2004) in complex with Raltegravir
1NZO	;	1.85	;	The crystal structure of wild type penicillin-binding protein 5 from E. coli
2WUY	;	3.09	;	the crystal structure of wild-type baculovirus polyhedra
8AMH	;	1.73	;	The Crystal structure of wt apo agroavidin
8AN6	;	1.9	;	The Crystal structure of wt apo agroavidin - biotin complex
5CS7	;	2.1	;	The crystal structure of wt beta2-microglobulin at room temperature
7TZY	;	1.992	;	The crystal structure of WT CYP199A4 bound to 4-(2-bromoethyl)benzoic acid
7U00	;	1.657	;	The crystal structure of WT CYP199A4 bound to 4-(2-chloroethyl)benzoic acid
7TRU	;	1.454	;	The crystal structure of WT CYP199A4 bound to 4-(thiophen-2-yl)benzoic acid
8D39	;	1.268	;	The crystal structure of WT CYP199A4 bound to 4-benzoylbenzoic acid
7TZW	;	1.462	;	The crystal structure of WT CYP199A4 bound to 4-chlorobenzoic acid
7TZX	;	1.414	;	The crystal structure of WT CYP199A4 bound to 4-chloromethylbenzoic acid
7TZN	;	1.839	;	The crystal structure of WT CYP199A4 bound to 4-fluorobenzoic acid
7TZM	;	1.524	;	The crystal structure of WT CYP199A4 bound to 4-iodobenzoic acid
5H0J	;	1.801	;	The crystal structure of WT Pedobacter heparinus SMUG2
5H0K	;	2.25	;	The crystal structure of WT Pedobacter heparinus SMUG2
5NHS	;	2.11	;	The crystal structure of Xanthomonas albilineans N5, N10-methylenetetrahydrofolate dehydrogenase-cyclohydrolase (FolD)
2E11	;	1.73	;	The Crystal Structure of XC1258 from Xanthomonas campestris: A CN-hydrolase Superfamily Protein with an Arsenic Adduct in the Active Site
2E12	;	1.7	;	The crystal structure of XC5848 from Xanthomonas campestris adopting a novel variant of Sm-like motif
2GBZ	;	2.3	;	The Crystal Structure of XC847 from Xanthomonas campestris: a 3-5 Oligoribonuclease of DnaQ fold family with a Novel Opposingly-Shifted Helix
5CPL	;	1.57	;	The crystal structure of Xenobiotic reductase A (XenA) from Pseudomonas putida in complex with a nicotinamide mimic (mNH2)
3W0L	;	2.92	;	The crystal structure of Xenopus Glucokinase and Glucokinase Regulatory Protein complex
3L0Q	;	1.61	;	The crystal structure of xlylulose kinase from Yersinia pseudotuberculosis
4EXH	;	2.0	;	The crystal structure of xmrv protease complexed with acetyl-pepstatin
3SM2	;	1.75	;	The crystal structure of XMRV protease complexed with Amprenavir
3SM1	;	1.5	;	The crystal structure of XMRV protease complexed with pepstatin A
3SLZ	;	1.4	;	The crystal structure of XMRV protease complexed with TL-3
6CCI	;	1.85	;	The Crystal Structure of XOAT1
3I8B	;	2.0	;	The crystal structure of xylulose kinase from Bifidobacterium adolescentis
3IFR	;	2.3	;	The crystal structure of xylulose kinase from Rhodospirillum rubrum
3WMS	;	2.3	;	The crystal structure of Y195I mutant alpha-cyclodextrin glycosyltransferase from Paenibacillus macerans
4RJ0	;	1.95	;	The crystal structure of Y333N mutant pyridoxal-dependent decarboxylase from Sphaerobacter thermophilus dsm 20745
4RIZ	;	2.2	;	The crystal structure of Y333Q mutant pyridoxal-dependent decarboxylase from Sphaerobacter thermophilus dsm 20745
4RM1	;	1.99	;	The crystal structure of Y333Q mutant pyridoxal-dependent decarboxylase from Sphaerobacter thermophilus DSM 20745
4ZDP	;	2.703	;	The crystal structure of Y334C mutant of human SepSecS in complex with selenocysteine tRNA (tRNASec)
2G3W	;	1.9	;	The Crystal Structure of YaeQ Protein from Xanthomonas axonopodis pv. citri
3Q34	;	1.7	;	The crystal structure of YceI-like family protein from Pseudomonas syringae
2GLU	;	2.91	;	The crystal structure of YcgJ protein from Bacillus subitilis
1XXL	;	2.1	;	The crystal structure of YcgJ protein from Bacillus subitilis at 2.1 A resolution
1GYJ	;	2.1	;	The Crystal Structure of YdcE, a 4-Oxalocrotonate Tautomerase Homologue from Escherichia coli, Confirms the Structural Basis for Oligomer Diversity
1GYX	;	1.35	;	The Crystal Structure of YdcE, a 4-Oxalocrotonate Tautomerase Homologue from Escherichia coli, Confirms the Structural Basis for Oligomer Diversity
1GYY	;	1.35	;	The Crystal Structure of YdcE, a 4-Oxalocrotonate Tautomerase Homologue from Escherichia coli, Confirms the Structural Basis for Oligomer Diversity
4V81	;	3.8	;	The crystal structure of yeast CCT reveals intrinsic asymmetry of eukaryotic cytosolic chaperonins
1UAQ	;	1.6	;	The crystal structure of yeast cytosine deaminase
1P6O	;	1.14	;	The crystal structure of yeast cytosine deaminase bound to 4(R)-hydroxyl-3,4-dihydropyrimidine at 1.14 angstroms.
1EHZ	;	1.93	;	The crystal structure of yeast phenylalanine tRNA at 1.93 A resolution
7ATR	;	1.55	;	The Crystal Structure of YejA - an ABC Peptide Transporter Receptor
3ED5	;	1.72	;	The crystal structure of YfnB from Bacillus subtilis subsp. subtilis str. 168
3WE9	;	1.92	;	The crystal structure of YisP from Bacillus subtilis subsp. subtilis strain 168
1T9H	;	1.6	;	The crystal structure of YloQ, a circularly permuted GTPase.
1VF8	;	1.31	;	The Crystal Structure of Ym1 at 1.31 A Resolution
8GN3	;	1.8	;	The crystal structure of ZBTB10 ZF1-2 in complex with telomeric vairant repeat TTGGGG
8GN4	;	1.9	;	The crystal structure of ZBTB10 ZF1-2 R767Q in complex with telomeric DNA TTAGGG
1DU5	;	2.5	;	THE CRYSTAL STRUCTURE OF ZEAMATIN.
4O6K	;	2.1	;	The crystal structure of zebrafish IL-22
7DOV	;	2.59	;	The crystal structure of zebrafish tumor necrosis factor alpha
6MH3	;	1.92	;	The crystal structure of Zika virus NS3 helicase domain
3CYY	;	2.4	;	The crystal structure of ZO-1 PDZ2 in complex with the Cx43 peptide
3F47	;	1.75	;	The Crystal Structure of [Fe]-Hydrogenase (Hmd) Holoenzyme from Methanocaldococcus jannaschii
3DAG	;	1.75	;	The crystal structure of [Fe]-hydrogenase holoenzyme (HMD) from METHANOCALDOCOCCUS JANNASCHII
3DAF	;	1.75	;	The crystal structure of [Fe]-hydrogenase holoenzyme (HMD) from METHANOCALDOCOCCUS JANNASCHII cocrystallized with cyanide
5X72	;	1.95	;	The crystal Structure PDE delta in complex with (rac)-p9
5X74	;	2.25	;	The crystal Structure PDE delta in complex with compound (R, R)-1g
5X73	;	2.5	;	The crystal Structure PDE delta in complex with R-p9
6R5O	;	2.4	;	The crystal structure the Glycoside Hydrolase BglX inactive mutant D286N from P. aeruginosa in complex with two glucose molecules
1HEF	;	2.2	;	The crystal structures at 2.2 angstroms resolution of hydroxyethylene-based inhibitors bound to human immunodeficiency virus type 1 protease show that the inhibitors are present in two distinct orientations
1HEG	;	2.2	;	The crystal structures at 2.2 angstroms resolution of hydroxyethylene-based inhibitors bound to human immunodeficiency virus type 1 protease show that the inhibitors are present in two distinct orientations
3KID	;	2.71	;	The Crystal Structures of 2-Aminobenzothiazole-based Inhibitors in Complexes with Urokinase-type Plasminogen Activator
4DNJ	;	1.8	;	The crystal structures of 4-methoxybenzoate bound CYP199A2
4DO1	;	2.0	;	The crystal structures of 4-methoxybenzoate bound CYP199A4
4O1C	;	2.092	;	The crystal structures of a mutant NAMPT H191R
8GQV	;	2.4	;	The Crystal Structures of a Swine SLA-2*HB01 Molecules Complexed with a CTL epitope from Asia1 serotype of Foot-and-mouth disease virus
8GQW	;	2.48	;	The Crystal Structures of a Swine SLA-2*HB01 Molecules Complexed with a CTL epitope from Asia1 serotype of Foot-and-mouth disease virus
2A2G	;	2.9	;	THE CRYSTAL STRUCTURES OF A2U-GLOBULIN AND ITS COMPLEX WITH A HYALINE DROPLET INDUCER.
2A2U	;	2.5	;	THE CRYSTAL STRUCTURES OF A2U-GLOBULIN AND ITS COMPLEX WITH A HYALINE DROPLET INDUCER.
4DNZ	;	2.6	;	The crystal structures of CYP199A4
1OPA	;	1.9	;	THE CRYSTAL STRUCTURES OF HOLO-AND APO-CELLULAR RETINOL BINDING PROTEIN II
1OPB	;	1.9	;	THE CRYSTAL STRUCTURES OF HOLO-AND APO-CELLULAR RETINOL BINDING PROTEIN II
4QYP	;	1.62	;	The Crystal Structures of holo-wt human Cellular Retinol Binding protein II (hCRBPII) bound to Retinal
4QYN	;	1.19	;	The Crystal Structures of holo-wt human Cellular Retinol Binding protein II (hCRBPII) bound to Retinol
6G6J	;	2.25	;	The crystal structures of Human MYC:MAX bHLHZip complex
6G6K	;	1.35	;	The crystal structures of Human MYC:MAX bHLHZip complex
6G6L	;	2.2	;	The crystal structures of Human MYC:MAX bHLHZip complex
1XEI	;	2.1	;	THE CRYSTAL STRUCTURES OF LYSOZYME AT VERY LOW LEVELS OF HYDRATION
1XEJ	;	2.1	;	THE CRYSTAL STRUCTURES OF LYSOZYME AT VERY LOW LEVELS OF HYDRATION
1XEK	;	2.3	;	THE CRYSTAL STRUCTURES OF LYSOZYME AT VERY LOW LEVELS OF HYDRATION
3PQS	;	2.1	;	The crystal structures of porcine pathogen ApH87_TbpB
3PQU	;	2.1	;	The crystal structures of porcine pathogen AsH57_TbpB
1PZA	;	1.8	;	THE CRYSTAL STRUCTURES OF REDUCED PSEUDOAZURIN FROM ALCALIGENES FAECALIS S-6 AT TWO PH VALUES
1PZB	;	1.8	;	THE CRYSTAL STRUCTURES OF REDUCED PSEUDOAZURIN FROM ALCALIGENES FAECALIS S-6 AT TWO PH VALUES
4FCN	;	1.7	;	The crystal structures of several mutants of pleurotus eryngii versatile peroxidase
4FCS	;	1.5	;	The crystal structures of several mutants of pleurotus eryngii versatile peroxidase
4FDQ	;	1.6	;	The crystal structures of several mutants of pleurotus eryngii versatile peroxidase
4FEF	;	2.0	;	The crystal structures of several mutants of pleurotus eryngii versatile peroxidase
4G05	;	2.35	;	The crystal structures of several mutants of Pleurotus eryngii versatile peroxidase
4LQD	;	2.451	;	The crystal structures of the Brucella protein TcpB and the TLR adaptor protein TIRAP show structural differences in microbial TIR mimicry
4LQC	;	2.3	;	The crystal structures of the Brucella protein TcpB and the TLR adaptor protein TIRAP show structural differences in microbial TIR mimicry.
2DPQ	;	1.25	;	The crystal structures of the calcium-bound con-G and con-T(K7gamma) dimeric peptides demonstrate a novel metal-dependent helix-forming motif
2DPR	;	1.7	;	The crystal structures of the calcium-bound con-G and con-T(K7Glu) dimeric peptides demonstrate a novel metal-dependent helix-forming motif
3BTG	;	1.9	;	THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI
3BTH	;	1.75	;	THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI
3BTK	;	1.85	;	THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI
3BTM	;	1.8	;	THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI
3BTQ	;	1.9	;	THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI
3BTT	;	1.9	;	THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI
3BTW	;	2.05	;	THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI
3BTE	;	1.85	;	The Crystal Structures of the Complexes Between Bovine Beta-Trypsin and Ten P1 Variants of BPTI.
3BTF	;	1.8	;	THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI.
3BTD	;	1.9	;	The Crystal Structures of the Complexes Between the Bovine Beta-Trypsin and Ten P1 Variants of BPTI.
1XJX	;	1.7	;	The crystal structures of the DNA binding sites of the RUNX1 transcription factor
1XJY	;	2.0	;	The crystal structures of the DNA binding sites of the RUNX1 transcription factor
4B2T	;	5.5	;	The crystal structures of the eukaryotic chaperonin CCT reveal its functional partitioning
4V8R	;	3.8	;	The crystal structures of the eukaryotic chaperonin CCT reveal its functional partitioning
1VG9	;	2.5	;	The crystal structures of the REP-1 protein in complex with C-terminally truncated Rab7 protein
1VG0	;	2.2	;	The crystal structures of the REP-1 protein in complex with monoprenylated Rab7 protein
1LMO	;	1.8	;	THE CRYSTAL STRUCTURES OF THREE COMPLEXES BETWEEN CHITOOLIGOSACCHARIDES AND LYSOZYME FROM THE RAINBOW TROUT
1LMP	;	2.0	;	THE CRYSTAL STRUCTURES OF THREE COMPLEXES BETWEEN CHITOOLIGOSACCHARIDES AND LYSOZYME FROM THE RAINBOW TROUT
1LMQ	;	1.6	;	THE CRYSTAL STRUCTURES OF THREE COMPLEXES BETWEEN CHITOOLIGOSACCHARIDES AND LYSOZYME FROM THE RAINBOW TROUT
3KIF	;	2.5	;	The crystal structures of two fragments truncated from 5-bladed beta-propeller lectin, tachylectin-2 (Lib1-B7-18 and Lib2-D2-15)
3KIH	;	2.49	;	The crystal structures of two fragments truncated from 5-bladed beta-propeller lectin, tachylectin-2 (Lib2-D2-15)
1SPP	;	2.4	;	THE CRYSTAL STRUCTURES OF TWO MEMBERS OF THE SPERMADHESIN FAMILY REVEAL THE FOLDING OF THE CUB DOMAIN
4P8U	;	2.4	;	The crystal structures of YKL-39 in the absence of chitooligosaccharides was solved to resolutions of 2.4 angstrom
4P8V	;	1.64	;	The crystal structures of YKL-39 in the presence of chitooligosaccharides (GlcNAc2) were solved to resolutions of 1.5 angstrom
4P8W	;	1.87	;	The crystal structures of YKL-39 in the presence of chitooligosaccharides (GlcNAc4) were solved to resolutions of 1.9 angstrom
4P8X	;	2.48	;	The crystal structures of YKL-39 in the presence of chitooligosaccharides (GlcNAc6) were solved to resolutions of 2.48 angstrom
2DRW	;	2.1	;	The crystal structutre of D-amino acid amidase from Ochrobactrum anthropi SV3
4C0W	;	1.6	;	The crystal strucuture of native PpAzoR
4C0X	;	1.499	;	The crystal strucuture of PpAzoR in complex with anthraquinone-2- sulfonate
4C14	;	1.9	;	The crystal strucuture of PpAzoR in complex with reactive black 5 (RB5)
8FXQ	;	1.21	;	The Crystal Sturucture of Rhizopuspepsin with a bound modified peptide inhibitor generated by de novo drug design.
2GNU	;	2.2	;	The crystallization of reaction center from Rhodobacter sphaeroides occurs via a new route
1HDR	;	2.5	;	THE CRYSTALLOGRAPHIC STRUCTURE OF A HUMAN DIHYDROPTERIDINE REDUCTASE NADH BINARY COMPLEX EXPRESSED IN ESCHERICHIA COLI BY A CDNA CONSTRUCTED FROM ITS RAT HOMOLOGUE
2PZN	;	1.0	;	The crystallographic structure of Aldose Reductase IDD393 complex confirms Leu300 as a specificity determinant
4D02	;	1.755	;	The crystallographic structure of Flavorubredoxin from Escherichia coli
1APN	;	2.5	;	THE CRYSTALLOGRAPHIC STRUCTURE OF METAL-FREE CONCANAVALIN A AT 2.5 ANGSTROMS RESOLUTION
4V99	;	2.9	;	The Crystallographic Structure of Panicum Mosaic Virus
1QC9	;	3.0	;	THE CRYSTALLOGRAPHIC STRUCTURE OF RESTRICTION ENDONUCLEASE ECO RI AT 3.3 A IN THE ABSENSE OF DNA
3FPU	;	1.76	;	The crystallographic structure of the Complex between Evasin-1 and CCL3
2FBD	;	1.9	;	The crystallographic structure of the digestive lysozyme 1 from Musca domestica at 1.90 Ang.
3CB7	;	1.9	;	The crystallographic structure of the digestive lysozyme 2 from Musca domestica at 1.9 Ang.
4U8U	;	3.2	;	The Crystallographic structure of the giant hemoglobin from Glossoscolex paulistus at 3.2 A resolution.
7Q71	;	2.0	;	The crystallographic structure of the Ligand Binding domain of the NR7 nuclear receptor from the amphioxus Branchiostoma lanceolatum
1IVP	;	2.5	;	THE CRYSTALLOGRAPHIC STRUCTURE OF THE PROTEASE FROM HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 WITH TWO SYNTHETIC PEPTIDIC TRANSITION STATE ANALOG INHIBITORS
1IVQ	;	2.6	;	THE CRYSTALLOGRAPHIC STRUCTURE OF THE PROTEASE FROM HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 WITH TWO SYNTHETIC PEPTIDIC TRANSITION STATE ANALOG INHIBITORS
4DGS	;	2.5	;	The crystals structure of dehydrogenase from Rhizobium meliloti
7ES4	;	2.3	;	the crystral structure of DndH-C-domain
3OSV	;	2.35	;	The crytsal structure of FLGD from P. Aeruginosa
7ECV	;	3.43	;	The Csy-AcrIF14 complex
7ECW	;	3.1	;	The Csy-AcrIF14-dsDNA complex
6GW7	;		;	The CTD of HpDprA, a DNA binding Winged Helix domain which do not bind dsDNA
7SAO	;	1.77	;	The CTI-homolog pacifastin
7SAP	;	1.79	;	The CTI-homolog pacifastin
2CUA	;	1.6	;	THE CUA DOMAIN OF CYTOCHROME BA3 FROM THERMUS THERMOPHILUS
5CIS	;	2.58	;	The CUB1-EGF-CUB2 domains of rat MBL-associated serine protease-2 (MASP-2) bound to Ca2+
5CKM	;	2.73	;	The CUB1-EGF-CUB2 domains of rat MBL-associated serine protease-2 (MASP-2) bound to Ca2+
5CKN	;	2.6	;	The CUB1-EGF-CUB2 domains of rat MBL-associated serine protease-2 (MASP-2) bound to Ca2+
7WLT	;	3.46	;	the Curved Structure of mPIEZO1 in Lipid Bilayer
6X2I	;	2.87	;	The Cutavirus (CuV) capsid structure
2XZV	;	1.6	;	The cyanobacterial PP2C-like phosphatase tPphA requires three metals in the catalytic center for efficient catalysis
2Y09	;	1.7	;	The cyanobacterial PP2C-like phosphatase tPphA requires three metals in the catalytic center for efficient catalysis
1QFB	;		;	THE CYCLIC PEPTIDE CONTRYPHAN-R FROM CONUS RADIATUS
6JIX	;	2.647	;	The cyrstal structure of taurine:2-oxoglutarate aminotransferase from Bifidobacterium kashiwanohense, in complex with PLP and glutamate
1UZ2	;	1.95	;	The Cys121Ser Mutant of Beta-Lactoglobulin
2GZV	;	1.12	;	The cystal structure of the PDZ domain of human PICK1
5YZ2	;	1.75	;	the cystathionine-beta-synthase (CBS) domain of magnesium and cobalt efflux protein CorC in complex with both C2'- and C3'-endo AMP
1EWM	;	2.0	;	THE CYSTEINE PROTEASE CRUZAIN BOUND TO WRR-112
1EWO	;	2.1	;	THE CYSTEINE PROTEASE CRUZAIN BOUND TO WRR-204
2A05	;		;	The cysteine-rich secretory protein domain of Tpx-1 is related to ion channel toxins and regulates Ryanodine receptor Ca2+ signaling
2FWL	;		;	The cytochrome c552/CuA complex from Thermus thermophilus
6KFW	;	2.0	;	The cytochrome P450 enzyme CxnD for C-S bond formation in chuangxinmycin biosynthesis
5FV0	;	2.91	;	The cytoplasmic domain of EssC
6F3C	;	2.3	;	The cytotoxic [Pt(H2bapbpy)] platinum complex interacting with the CGTACG hexamer
6EZV	;	1.9	;	The cytotoxin MakA from Vibrio cholerae
6T8D	;	2.1	;	The cytotoxin MakB from Vibrio cholerae
6TAO	;	1.98	;	The cytotoxin MakE from Vibrio cholerae
1RK5	;	1.8	;	The D-aminoacylase mutant D366A in complex with 100mM CuCl2
3LCF	;	1.86	;	The D-sialic acid aldolase mutant V251I
3LCL	;	1.83	;	The D-sialic acid aldolase mutant V251I/V265I
3LCG	;	1.78	;	The D-sialic acid aldolase mutant V251L
3LCH	;	2.04	;	The D-sialic acid aldolase mutant V251R
3LCI	;	2.12	;	The D-sialic acid aldolase mutant V251W
6MDO	;	3.9	;	The D1 and D2 domain rings of NSF engaging the SNAP-25 N-terminus within the 20S supercomplex (focused refinement on D1/D2 rings, class 1)
6MDP	;	3.8	;	The D1 and D2 domain rings of NSF engaging the SNAP-25 N-terminus within the 20S supercomplex (focused refinement on D1/D2 rings, class 2)
8R79	;	2.18	;	The D2 domain of human DTX3L
6IJN	;	1.66	;	The D295N mutant of the N6-methyl-AMP deaminase from Arabidopsis thaliana complexed with N6m-AMP
1XB3	;	1.501	;	The D62C/K74C double mutant of Pseudomonas Aeruginosa Azurin
3NHQ	;	2.55	;	The dark Pfr structure of the photosensory core module of P. aeruginosa Bacteriophytochrome
3UE6	;	2.75	;	The dark structure of the blue-light photoreceptor Aureochrome1 LOV
6SWS	;	3.0	;	The DBB dimerization domain of B-cell adaptor for PI3K (BCAP) is required for down regulation of inflammatory signalling through the Toll-like receptor pathway
8EZ6	;	2.0	;	The DBC1/SIRT1 Interaction is Choreographed by Post-translational Modification
5MZA	;	2.78	;	The DBLb domain of PF11_0521 PfEMP1 bound to human ICAM-1
7BCM	;	2.3	;	The DDR1 Kinase Domain Bound To SR302
1IVL	;	2.17	;	THE DE NOVO DESIGN OF AN ANTIBODY COMBINING SITE: CRYSTALLOGRAPHIC ANALYSIS OF THE VL DOMAIN CONFIRMS THE STRUCTURAL MODEL
7ARR	;	1.1	;	The de novo designed hybrid alpha/beta-miniprotein
7ARS	;	1.15	;	The de novo designed hybrid alpha/beta-miniprotein (with Se-Methionine)
5C2M	;	1.9	;	The de novo evolutionary emergence of a symmetrical protein is shaped by folding constraints
5C2N	;	1.65	;	The de novo evolutionary emergence of a symmetrical protein is shaped by folding constraints
6QSR	;	1.85	;	The Dehydratase Heterocomplex ApeI:P from Xenorhabdus doucetiae
2YXV	;	1.81	;	The deletion mutant of Multicopper Oxidase CueO
2YXW	;	1.5	;	The deletion mutant of Multicopper Oxidase CueO
6SL7	;	3.3	;	The Delta Calcium mutant of ALPHA-ACTININ FROM ENTAMOEBA HISTOLYTICA
1SAN	;		;	THE DES(1-6)ANTENNAPEDIA HOMEODOMAIN: COMPARISON OF THE NMR SOLUTION STRUCTURE AND THE DNA BINDING AFFINITY WITH THE INTACT ANTENNAPEDIA HOMEODOMAIN
5FQE	;	1.53	;	The details of glycolipid glycan hydrolysis by the structural analysis of a family 123 glycoside hydrolase from Clostridium perfringens
5FQF	;	2.15	;	The details of glycolipid glycan hydrolysis by the structural analysis of a family 123 glycoside hydrolase from Clostridium perfringens
5FQG	;	2.3	;	The details of glycolipid glycan hydrolysis by the structural analysis of a family 123 glycoside hydrolase from Clostridium perfringens
5FQH	;	2.1	;	The details of glycolipid glycan hydrolysis by the structural analysis of a family 123 glycoside hydrolase from Clostridium perfringens
5FR0	;	1.75	;	The details of glycolipid glycan hydrolysis by the structural analysis of a family 123 glycoside hydrolase from Clostridium perfringens
1PMB	;	2.5	;	THE DETERMINATION OF THE CRYSTAL STRUCTURE OF RECOMBINANT PIG MYOGLOBIN BY MOLECULAR REPLACEMENT AND ITS REFINEMENT
3S1B	;	2.9	;	The Development of Peptide-based Tools for the Analysis of Angiogenesis
3S1K	;	2.55	;	The Development of Peptide-based Tools for the Analysis of Angiogenesis
7TZL	;	2.45	;	The DH dehydratase domain of AlnB
8BNT	;	1.4	;	The DH domain of ARHGEF2 bound to RhoA
3FAI	;	1.7	;	The Di Zinc Carbapenemase CphA N220G mutant
436D	;	1.1	;	THE DICKERSON-DREW B-DNA DODECAMER REVISITED-AT ATOMIC RESOLUTION
5U5N	;	2.1	;	The dimeric crystal structure of HTPA Reductase from Sellaginella moellendorffii
5U5I	;	2.2	;	The dimeric crystal structure of the selenomethionine derivative of HTPA Reductase from Sellaginella moellendorffii
7YCV	;	2.61	;	The Dimeric Format of Truncated PrpA (2-54)and RHH Domain of PrpA
6LTL	;	1.25	;	The dimeric structure of G80A myoglobin
7V5P	;	1.16	;	The dimeric structure of G80A/H81A myoglobin
6LTM	;	1.65	;	The dimeric structure of G80A/H81A/H82A myoglobin
7V5R	;	1.39	;	The dimeric structure of G80A/H81A/L137D myoglobin
7V5Q	;	1.38	;	The dimeric structure of G80A/H81A/L137E myoglobin
7DGJ	;	1.6	;	The dimeric structure of K78H/G80A/H82A myoglobin
7DGM	;	1.62	;	The dimeric structure of K79H/G80A/H81A myoglobin
5NNT	;	2.209	;	The dimeric structure of LL-37 crystallized in DPC
6NCQ	;	1.9	;	The dimerization domain of human SFPQ in space group C2221
2V0X	;	2.2	;	The dimerization domain of LAP2alpha
7ALF	;	1.261	;	The dimethylated RSL - sulfonato-calix[8]arene complex, P3 form, acetate pH 4.0
4PT6	;	2.1	;	The discobody: an engineered discoidin domain from factor VIII that binds v 3 integrin with antibody-like affinities
2RBE	;	1.9	;	The discovery of 2-anilinothiazolones as 11beta-HSD1 inhibitors
5AMN	;	2.57	;	The Discovery of 2-Substituted Phenol Quinazolines as Potent and Selective RET Kinase Inhibitors
4YND	;	2.79	;	The Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2
7BZJ	;	2.0	;	The Discovery of Benzhydrol-Oxaborole Hybrid Derivatives as Leucyl-tRNA Synthetase Inhibitors
2Q1J	;	1.9	;	The discovery of glycine and related amino acid-based factor xa inhibitors
2Y6C	;	1.7	;	The Discovery of MMP7 inhibitors Exploiting a Novel Selectivity Trigger
2Y6D	;	1.6	;	The Discovery of MMP7 Inhibitors Exploiting a Novel Selectivity Trigger
3R00	;	2.1	;	The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors
3R01	;	2.6	;	The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors
3R02	;	1.95	;	The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors
3R04	;	1.7	;	The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors
2Y37	;	2.6	;	The discovery of novel, potent and highly selective inhibitors of inducible nitric oxide synthase (iNOS)
4UX6	;	3.0	;	The discovery of novel, potent and highly selective inhibitors of inducible nitric oxide synthase (iNOS)
2Y7X	;	1.9	;	The discovery of potent and long-acting oral factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs
4CSJ	;	2.3	;	The discovery of potent selective glucocorticoid receptor modulators, suitable for inhalation
3UUO	;	2.11	;	The discovery of potent, selectivity, and orally bioavailable pyrozoloquinolines as PDE10 inhibitors for the treatment of Schizophrenia
6RWF	;	1.64	;	The dissociation mechanism of processive cellulases
6IJU	;	2.4	;	The DNA binding domain of a response regulator ArlR from Staphylococcus aureus
2ROH	;		;	The DNA binding domain of RTBP1
4K4O	;	1.3	;	The DNA Gyrase B ATP binding domain of Enterococcus faecalis in complex with a small molecule inhibitor
4KFG	;	1.6	;	The DNA Gyrase B ATP binding domain of Escherichia coli in complex with a small molecule inhibitor.
6M1S	;	2.254	;	The DNA Gyrase B ATP binding domain of PSEUDOMONAS AERUGINOSA in complex with compound 12o
6M1J	;	1.701	;	The DNA Gyrase B ATP binding domain of PSEUDOMONAS AERUGINOSA in complex with compound 12x
175D	;		;	THE DNA SEQUENCE GCGAATGAGC CONTAINING THE HUMAN CENTROMERE CORE SEQUENCE GAAT FORMS A SELF-COMPLEMENTARY DUPLEX WITH SHEARED G:A PAIRS IN SOLUTION
1ZZF	;		;	The DNA-bound solution structure of HPV-16 E2 DNA-binding domain
2L66	;		;	The DNA-recognition fold of Sso7c4 suggests a new member of SpoVT-AbrB superfamily from archaea.
1LTL	;	3.0	;	THE DODECAMER STRUCTURE OF MCM FROM ARCHAEAL M. THERMOAUTOTROPHICUM
2XSZ	;	3.0	;	The dodecameric human RuvBL1:RuvBL2 complex with truncated domains II
1BJQ	;	2.65	;	THE DOLICHOS BIFLORUS SEED LECTIN IN COMPLEX WITH ADENINE
2K6I	;		;	The domain features of the peripheral stalk subunit H of the methanogenic A1AO ATP synthase and the NMR solution structure of H1-47
8D01	;	2.46	;	The domain-swaped dimer of the HIV-1 CD4bs targeting antibody 21N13
1L5E	;		;	The domain-swapped dimer of CV-N in solution
3IB4	;	1.25	;	The double mutant of Beta-2 microglobulin K58P-W60G
6S42	;	1.4	;	The double mutant(Ile44Leu+Gln102His) of haloalkane dehalogenase DbeA from Bradyrhizobium elkanii USDA94 with an eliminated halide-binding site
6OIE	;	2.075	;	The double PHD finger (DPF) of MORF in complex with histone H3K14cr
1NBO	;	2.6	;	The dual coenzyme specificity of photosynthetic glyceraldehyde-3-phosphate dehydrogenase interpreted by the crystal structure of A4 isoform complexed with NAD
4WOD	;	1.9	;	The duplicated taurocyamine kinase from Schistosoma mansoni complexed with arginine
4WOE	;	2.3	;	The duplicated taurocyamine kinase from Schistosoma mansoni with bound transition state analog (TSA) components
3CBX	;	1.7	;	The Dvl2 PDZ Domain in Complex with the C1 Inhibitory Peptide
3CBY	;	1.5	;	The Dvl2 PDZ Domain in Complex with the N1 Inhibitory Peptide
3CBZ	;	1.38	;	The Dvl2 PDZ Domain in Complex with the N2 Inhibitory Peptide
3CC0	;	1.75	;	The Dvl2 PDZ Domain in Complex with the N3 Inhibitory Peptide
2KB8	;		;	The dynamic alpha-helix structure of micelle-bound human amylin.
5OWI	;		;	The dynamic dimer structure of the chaperone Trigger Factor (conformer 1)
5OWJ	;		;	The dynamic dimer structure of the chaperone Trigger Factor (conformer 2)
6G6U	;	2.74	;	The dynamic nature of the VDAC1 channels in bilayers: human VDAC1 at 2.7 Angstrom resolution
6G73	;	3.27	;	The dynamic nature of the VDAC1 channels in bilayers: human VDAC1 at 3.3 Angstrom resolution
7O4F	;	1.65	;	The DYW domain of A. thaliana OTP86 in its active state
7O4E	;	2.5	;	The DYW domain of A. thaliana OTP86 in its inactive state
2J96	;	2.25	;	The E-configuration of alfa-Phycoerythrocyanin
1BIA	;	2.3	;	THE E. COLI BIOTIN HOLOENZYME SYNTHETASE(SLASH)BIO REPRESSOR CRYSTAL STRUCTURE DELINEATES THE BIOTIN AND DNA-BINDING DOMAINS
1BIB	;	2.8	;	THE E. COLI BIOTIN HOLOENZYME SYNTHETASE(SLASH)BIO REPRESSOR CRYSTAL STRUCTURE DELINEATES THE BIOTIN AND DNA-BINDING DOMAINS
2P5Z	;	2.6	;	The E. coli c3393 protein is a component of the type VI secretion system and exhibits structural similarity to T4 bacteriophage tail proteins gp27 and gp5
6PB5	;	4.52	;	The E. coli class-II CAP-dependent transcription activation complex at the state 1 architecture
6PB6	;	4.29	;	The E. coli class-II CAP-dependent transcription activation complex at the state 2
6PB4	;	4.35	;	The E. coli class-II CAP-dependent transcription activation complex with de novo RNA transcript at the state 2
8BFR	;	1.3	;	The E. coli TrpD2 protein YbiB at 1.3 A resolution
8BFT	;	1.19	;	The E. coli TrpD2 protein YbiB in complex with a C-terminal peptide from ObgE
7W7T	;	3.4	;	The E1-BeF3- 2Ca2+ of SERCA2b
3A6K	;	2.2	;	The E122Q mutant creatininase, Mn-Zn type
4LF0	;	1.1	;	The E142D mutant of the amidase from Geobacillus pallidus
4GYN	;	1.9	;	The E142L mutant of the amidase from Geobacillus pallidus
4GYL	;	1.9	;	The E142L mutant of the amidase from Geobacillus pallidus showing the result of Michael addition of acrylamide at the active site cysteine
7FDF	;	2.05	;	The E145S mutant of the regulatory domain of YeiE, a sulfite sensing LysR-type transcriptional regulator from Cronobacter sakazakii (sulfate-bound form)
5GNX	;	1.8	;	The E171Q mutant structure of Bgl6
4N7X	;	2.5	;	The E254A mutant of the sodium bile acid symporter from Yersinia frederiksenii
4IZW	;	1.6	;	The E41L mutant of the amidase from Nesterenkonia sp. AN1 showing covalent addition of the acetamide moiety of fluoroacetamide at the active site cysteine
2FFN	;	1.8	;	The E41Q mutant of tetraheme cytochrome c3 from Desulfovibrio Vulgaris Miyazaki F
4IZT	;	1.92	;	The E41Q mutant of the amidase from Nesterenkonia sp. AN1 showing covalent addition of the acetamide moiety of fluoroacetamide at the active site cysteine
4IZU	;	1.4	;	The E41Q mutant of the amidase from Nesterenkonia sp. AN1 showing the result of Michael addition of acrylamide at the active site cysteine
4IZV	;	1.65	;	The E41Q/C145A double mutant of the amidase from Nesterenkonia sp. AN1 in complex with acrylamide
6Z3O	;	1.74	;	The E74Q mutant of Small Alarmone Hydrolase SAH from Pseudomonas aeruginosa PAO1
3GYY	;	2.2	;	The ectoine binding protein of the TeaABC TRAP transporter TeaA in the Apo-State
2R0M	;	2.7	;	The effect of a Glu370Asp Mutation in Glutaryl-CoA Dehydrogenase on Proton Transfer to the Dienolate Intermediate
2R0N	;	2.3	;	The effect of a Glu370Asp mutation in Glutaryl-CoA Dehydrogenase on Proton Transfer to the Dienolate Intermediate
5NT5	;	2.3	;	The effect of Berenil and Cacodylateon the crystal structure of d(CGTGAATTCACG)
1COA	;	2.2	;	THE EFFECT OF CAVITY CREATING MUTATIONS IN THE HYDROPHOBIC CORE OF CHYMOTRYPSIN INHIBITOR 2
2PKY	;	1.55	;	The Effect of Deuteration on Protein Structure A High Resolution Comparison of Hydrogenous and Perdeuterated Haloalkane Dehalogenase
2YXP	;	1.53	;	The Effect of Deuteration on Protein Structure A High Resolution Comparison of Hydrogenous and Perdeuterated Haloalkane Dehalogenase
3C1B	;	2.2	;	The effect of H3 K79 dimethylation and H4 K20 trimethylation on nucleosome and chromatin structure
3C1C	;	3.15	;	The effect of H3 K79 dimethylation and H4 K20 trimethylation on nucleosome and chromatin structure
5CPB	;	1.997	;	The effect of isoleucine to alanine mutation on InhA enzyme crystallization pattern and inhibition by ligand PT70 (TCU)
5CP8	;	2.4	;	The effect of isoleucine to alanine mutation on InhA enzyme crystallization pattern and substrate binding loop conformation and flexibility
1ANW	;	2.4	;	THE EFFECT OF METAL BINDING ON THE STRUCTURE OF ANNEXIN V AND IMPLICATIONS FOR MEMBRANE BINDING
6O5H	;	2.84	;	The effect of modifier structure on the activation of leukotriene A4 hydrolase aminopeptidase activity.
5COQ	;	2.3	;	The effect of valine to alanine mutation on InhA enzyme crystallization pattern and substrate binding loop conformation and flexibility
4NG6	;	2.35	;	The effects of Lysine 200 and Phenylalanine 239 Farnesyl Pyrophosphate Synthase (FPPS) mutations on the catalytic activity, crystal structure and inhibition by nitrogen containing bisphosphonates
4NKE	;	1.46	;	The effects of Lysine 200 and Phenylalanine 239 Farnesyl Pyrophosphate Synthase (FPPS) mutations on the catalytic activity, crystal structure and inhibition by nitrogen containing bisphosphonates
4NKF	;	2.0	;	The effects of Lysine 200 and Phenylalanine 239 Farnesyl Pyrophosphate Synthase (FPPS) mutations on the catalytic activity, crystal structure and inhibition by nitrogen containing bisphosphonates
4NUA	;	1.43	;	The effects of Lysine 200 and Phenylalanine 239 Farnesyl Pyrophosphate Synthase (FPPS) mutations on the catalytic activity, crystal structure and inhibition by nitrogen containing bisphosphonates
4OGU	;	2.1	;	The effects of Lysine 200 and Phenylalanine 239 Farnesyl Pyrophosphate Synthase (FPPS) mutations on the catalytic activity, crystal structure and inhibition by nitrogen containing bisphosphonates
8HGS	;	3.81	;	The EGF-bound EGFR ectodomain homodimer
8HGO	;	3.31	;	The EGF-bound EGFR/HER2 ectodomain complex
5LHQ	;	2.6	;	The EGR-cmk active site inhibited catalytic domain of murine urokinase-type plasminogen activator in complex with the allosteric inhibitory nanobody Nb7
1WFO	;		;	The eighth FN3 domain of human sidekick-2
4CHV	;	7.0	;	The electron crystallography structure of the cAMP-bound potassium channel MloK1
6EO1	;	4.5	;	The electron crystallography structure of the cAMP-bound potassium channel MloK1 (PCO-refined)
4CHW	;	7.0	;	The electron crystallography structure of the cAMP-free potassium channel MloK1
5OL2	;	3.1	;	The electron transferring flavoprotein/butyryl-CoA dehydrogenase complex from Clostridium difficile
4NZ0	;	2.8	;	The EMCV 3Dpol structure at 2.8A resolution
4NYZ	;	2.15	;	The EMCV 3Dpol structure with altered motif A conformation at 2.15A resolution
7L6F	;	2.86	;	The empty AAV11 capsid
7L6B	;	2.54	;	The empty AAV12 capsid
7L6I	;	2.76	;	The empty AAV13 capsid
7L5Q	;	2.96	;	The empty AAV7 capsid
5NGK	;	1.9	;	The endo-beta1,6-glucanase BT3312
5NGL	;	1.85	;	The endo-beta1,6-glucanase BT3312
7CEI	;	2.3	;	THE ENDONUCLEASE DOMAIN OF COLICIN E7 IN COMPLEX WITH ITS INHIBITOR IM7 PROTEIN
118L	;	1.8	;	THE ENERGETIC COST AND THE STRUCTURAL CONSEQUENCES OF BURYING A HYDROXYL GROUP WITHIN THE CORE OF A PROTEIN DETERMINED FROM ALA TO SER AND VAL TO THR SUBSTITUTIONS IN T4 LYSOZYME
119L	;	1.65	;	THE ENERGETIC COST AND THE STRUCTURAL CONSEQUENCES OF BURYING A HYDROXYL GROUP WITHIN THE CORE OF A PROTEIN DETERMINED FROM ALA TO SER AND VAL TO THR SUBSTITUTIONS IN T4 LYSOZYME
120L	;	1.8	;	THE ENERGETIC COST AND THE STRUCTURAL CONSEQUENCES OF BURYING A HYDROXYL GROUP WITHIN THE CORE OF A PROTEIN DETERMINED FROM ALA TO SER AND VAL TO THR SUBSTITUTIONS IN T4 LYSOZYME
122L	;	1.8	;	THE ENERGETIC COST AND THE STRUCTURAL CONSEQUENCES OF BURYING A HYDROXYL GROUP WITHIN THE CORE OF A PROTEIN DETERMINED FROM ALA TO SER AND VAL TO THR SUBSTITUTIONS IN T4 LYSOZYME
123L	;	1.8	;	THE ENERGETIC COST AND THE STRUCTURAL CONSEQUENCES OF BURYING A HYDROXYL GROUP WITHIN THE CORE OF A PROTEIN DETERMINED FROM ALA TO SER AND VAL TO THR SUBSTITUTIONS IN T4 LYSOZYME
125L	;	1.85	;	THE ENERGETIC COST AND THE STRUCTURAL CONSEQUENCES OF BURYING A HYDROXYL GROUP WITHIN THE CORE OF A PROTEIN DETERMINED FROM ALA TO SER AND VAL TO THR SUBSTITUTIONS IN T4 LYSOZYME
126L	;	1.8	;	THE ENERGETIC COST AND THE STRUCTURAL CONSEQUENCES OF BURYING A HYDROXYL GROUP WITHIN THE CORE OF A PROTEIN DETERMINED FROM ALA TO SER AND VAL TO THR SUBSTITUTIONS IN T4 LYSOZYME
127L	;	1.85	;	THE ENERGETIC COST AND THE STRUCTURAL CONSEQUENCES OF BURYING A HYDROXYL GROUP WITHIN THE CORE OF A PROTEIN DETERMINED FROM ALA TO SER AND VAL TO THR SUBSTITUTIONS IN T4 LYSOZYME
128L	;	1.7	;	THE ENERGETIC COST AND THE STRUCTURAL CONSEQUENCES OF BURYING A HYDROXYL GROUP WITHIN THE CORE OF A PROTEIN DETERMINED FROM ALA TO SER AND VAL TO THR SUBSTITUTIONS IN T4 LYSOZYME
221L	;	1.7	;	THE ENERGETIC COST AND THE STRUCTURAL CONSEQUENCES OF BURYING A HYDROXYL GROUP WITHIN THE CORE OF A PROTEIN DETERMINED FROM ALA TO SER AND VAL TO THR SUBSTITUTIONS IN T4 LYSOZYME
224L	;	1.85	;	THE ENERGETIC COST AND THE STRUCTURAL CONSEQUENCES OF BURYING A HYDROXYL GROUP WITHIN THE CORE OF A PROTEIN DETERMINED FROM ALA TO SER AND VAL TO THR SUBSTITUTIONS IN T4 LYSOZYME
2YIM	;	1.41	;	The enolisation chemistry of a thioester-dependent racemase: the 1.4 A crystal structure of a complex with a planar reaction intermediate analogue
2KRL	;		;	The ensemble of the solution global structures of the 102-nt ribosome binding structure element of the turnip crinkle virus 3' UTR RNA
2Z1P	;	2.5	;	The Enterococcus faecalis MSCRAMM ACE binds its ligands by the collagen Hug Model
3J22	;	6.3	;	The Enterovirus 71 A-particle
3J23	;	9.2	;	The Enterovirus 71 empty capsid
6ENR	;	1.84	;	The ENTH domain from epsin Ent2
5ONF	;	2.8	;	The ENTH domain from epsin-1
5ON7	;	3.35	;	The ENTH domain from epsin-2 in complex with phosphatidylinositol 4,5-bisphosphate (PIP2)
5OO7	;	1.84	;	The ENTH domain from epsin-2 in complex with phosphatidylinositol 4,5-bisphosphate (PIP2)
7T2P	;	3.47	;	The Envelope Glycoprotein SIVmac239.K180S SOSIP trimer in complex with 3 copies of the neutralizing antibody K11
7T4G	;	3.7	;	The Envelope Glycoprotein SIVmac239.K180S SOSIP trimer in complex with 3 copies of the neutralizing antibody K11
1RK6	;	1.43	;	The enzyme in complex with 50mM CdCl2
8HGP	;	4.53	;	The EREG-bound EGFR/HER2 ectodomain complex
8PND	;	1.9	;	The ES3 intermediate of hydroxymethylbilane synthase R167Q variant
1D0L	;	1.97	;	THE ESCHERICHIA COLI LYTIC TRANSGLYCOSYLASE SLT35 IN COMPLEX WITH BULGECIN A
1D0M	;	2.47	;	THE ESCHERICHIA COLI LYTIC TRANSGLYCOSYLASE SLT35 IN COMPLEX WITH BULGECIN A AND (GLCNAC)2
1D0K	;	2.02	;	THE ESCHERICHIA COLI LYTIC TRANSGLYCOSYLASE SLT35 IN COMPLEX WITH TWO MURODIPEPTIDES (GLCNAC-MURNAC-L-ALA-D-GLU)
1MLA	;	1.5	;	THE ESCHERICHIA COLI MALONYL-COA:ACYL CARRIER PROTEIN TRANSACYLASE AT 1.5-ANGSTROMS RESOLUTION. CRYSTAL STRUCTURE OF A FATTY ACID SYNTHASE COMPONENT
4Q50	;	3.07	;	The Estrogen Receptor Alpha Ligand Binding Domain D538G Mutant in Complex with 4-hydroxytamoxifen
4PXM	;	1.9	;	The Estrogen Receptor Alpha Ligand Binding Domain D538G Mutant in Complex with Estradiol and a glucocorticoid receptor-interacting protein 1 NR box II peptide
7L70	;	2.8	;	The eukaryotic translation initiation factor 2B from Homo sapiens in its apo form
7TRJ	;	2.8	;	The eukaryotic translation initiation factor 2B from Homo sapiens with a H160D mutation in the beta subunit
6PI5	;	1.67	;	The evolving story of AtzT, a periplasmic binding protein
6PI6	;	1.65	;	The evolving story of AtzT, a periplasmic binding protein
6PII	;	1.87	;	The evolving story of AtzT, a periplasmic binding protein
5YJ6	;	1.43	;	The exoglucanase CelS from Clostridium thermocellum
7VS5	;	3.4	;	The expanded head structure of phage T4
3U99	;	1.146	;	The experimental X-ray structure of the new diheme cytochrome type c from Shewanella baltica OS155 sb-DHC
1Z3H	;	3.1	;	The exportin Cse1 in its cargo-free, cytoplasmic state
7JTT	;	1.64	;	The external aldimine crystal structure of Salmonella typhimurium Tryptophan Synthase mutant beta-S377A in complex F9 inhibitor at the alpha-site and cesium ion at the metal coordination site. The single beta-Q114 rotamer conformation allows a hydrogen bond to form with the PLP oxygen at the position 3 in the ring
7JQW	;	1.7	;	The external aldimine crystal structure of Salmonella typhimurium Tryptophan Synthase mutant beta-S377A in complex with cesium ion at the metal coordination site. The single beta-Q114 rotamer conformation allows a hydrogen bond to form with the PLP oxygen at the position 3 in the ring
6XSY	;	1.55	;	The external aldimine crystal structure of Salmonella typhimurium Tryptophan Synthase mutant beta-S377A with inhibitor 2-({[4-(trifluoromethoxy)phenyl]sulfonyl}amino)ethyl dihydrogen phosphate (F9F) at the alpha-site, Cesium ion at the metal coordination site, and (E)-N-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methylidene)-L-serine (KOU) at the beta-site
7KI7	;	1.75	;	The external aldimine crystal structure of the beta-K167T mutant Tryptophan Synthase at 1.75 Angstrom resolution in complex with N-(4'-trifluoromethoxybenzenesulfonyl)-2-amino-1-ethylphosphate (F9F) at the enzyme alpha-site and cesium ion at the metal coordination site
7K5A	;	1.5	;	The external aldimine form of Salmonella typhimurium Tryptophan Synthase mutant beta-Q114A in complex with cesium ion at the metal coordination site.
7JMQ	;	1.6	;	The external aldimine form of the mutant beta-S377A Salmonella thypi tryptophan synthase in open conformation showing dual side chain conformations for the residue beta-Q114, sodium ion at the metal coordination site, and F9 inhibitor at the alpha-site. One of the beta-Q114 rotamer conformations allows a hydrogen bond to form with the PLP oxygen at the position 3 in the ring
6WDU	;	1.4	;	The external aldimine form of the Salmonella thypi wild-type tryptophan synthase in open conformation showing multiple side chain conformations for the residue beta Q114 and sodium ion at the metal coordination site. One of the beta-Q114 rotamer conformations allows a hydrogen bond to form with the PLP oxygen at the position 3 in the ring.
7L5H	;	1.8	;	The external aldimine form of the wild-type Salmonella typhimurium Tryptophan Synthase at 1.80 Angstrom resolution with cesium ion at the metal coordination site
2RON	;		;	The external thioesterase of the Surfactin-Synthetase
5KW2	;	2.76	;	The extra-helical binding site of GPR40 and the structural basis for allosteric agonism and incretin stimulation
3NJP	;	3.304	;	The Extracellular and Transmembrane Domain Interfaces in Epidermal Growth Factor Receptor Signaling
6R0X	;	3.13	;	The extracellular domain of G6b-B in complex with Fab fragment and DP12 heparin oligosaccharide.
8GCE	;	3.12	;	The Extracellular Domain of Integrin AlphaIIbBeta3 in Intermediate State
7AW6	;	1.95	;	The extracellular region of CD33 with bound sialoside analogue P22
7MD2	;	3.1	;	The F1 region of ammocidin-bound Saccharomyces cerevisiae ATP synthase
7MD3	;	3.3	;	The F1 region of apoptolidin-bound Saccharomyces cerevisiae ATP synthase
1OCV	;	2.0	;	the F116W mutant structure of ketosteroid isomerase from Comamonas testosteroni
2EWU	;	1.1	;	The F20H mutant of tetraheme cytochrome c3 from Desulfovibrio Vulgaris Miyazaki F
2YYW	;	1.33	;	The F20M mutant of tetraheme cytochrome c3 from Desulfovibrio Vulgaris Miyazaki F
2EWI	;	1.0	;	The F20Y mutant of tetraheme cytochrome c3 from Desulfovibrio Vulgaris Miyazaki F
1NXG	;	2.5	;	The F383A variant of type II Citrate Synthase complexed with NADH
3F65	;	2.29	;	The F4 fimbrial chaperone FaeE does not self-cap its interactive surfaces
6QGR	;	1.839	;	The F420-reducing [NiFe] hydrogenase complex from Methanosarcina barkeri at the Nia-S state
4OMF	;	1.71	;	The F420-reducing [NiFe]-hydrogenase complex from Methanothermobacter marburgensis, the first X-ray structure of a group 3 family member
7FGK	;	2.3	;	The Fab antibody single structure against tau protein.
8VFU	;	2.45	;	The Fab Crystal Structure of the PAN IL-1 Family Inhibitor Antibody 3G5
8TJT	;	2.7	;	The Fab fragment of an anti-glucagon receptor (GCGR) antibody
1HW1	;	1.5	;	THE FADR-DNA COMPLEX: TRANSCRIPTIONAL CONTROL OF FATTY ACID METABOLISM IN ESCHERICHIA COLI
8U3M	;		;	The FARFAR-MD-NMR ensemble of an HIV-1 TAR excited state
7JU1	;		;	The FARFAR-NMR Ensemble of 29-mer HIV-1 Trans-activation Response Element RNA (N=20)
5XGF	;	2.35	;	The fatty acid-responsive FadR repressor of Vibrio alginolyticus
5DV5	;	2.4	;	The fatty acid-responsive FadR repressor of Vibrio alginolyticus complex with Palmitoyl-CoA
4BWO	;	1.8	;	The FedF adhesin from entrrotoxigenic Escherichia coli is a sulfate- binding lectin
6IBE	;	1.45	;	The FERM domain of Human EPB41L3
8CIU	;	2.393	;	The FERM domain of human moesin mutant H288A
8CIT	;	2.536	;	The FERM domain of human moesin mutant L281R
8CIR	;	1.85	;	The FERM domain of human moesin with a bound peptide identified by phage display
8CIS	;	1.52	;	The FERM domain of human moesin with two bound peptides identified by phage display
1DWL	;		;	The Ferredoxin-Cytochrome complex using heteronuclear NMR and docking simulation
5XGO	;	1.99	;	The Ferritin E-Domain: Toward Understanding Its Role in Protein Cage Assembly Through the Crystal Structure of a Maxi-/Mini-Ferritin Chimera
2KI6	;		;	The FGF1-S100A13-C2A hetero-hexameric complex structure: A component in the non-classical pathway for FGF1 secretion
1GJO	;	2.4	;	The FGFr2 tyrosine kinase domain
5FLY	;	1.598	;	The FhuD protein from S.pseudintermedius
2FVN	;		;	The fibrillar tip complex of the Afa/Dr adhesins from pathogen E. coli displays synergistic binding to 5 1 and v 3 integrins
6EUA	;	2.095	;	The fibrinogen-like domain of human Angptl3
6EUB	;	2.3	;	The fibrinogen-like domain of human Angptl4
2X9B	;	2.92	;	The filamentous phages fd and IF1 use different infection mechanisms
5NFI	;	2.508	;	The fimbrial anchor protein Mfa2 from Porphyromonas gingivalis
5NF2	;	1.73	;	The fimbrial shaft protein Mfa1 from Porphyromonas gingivalis
5NF3	;	1.97	;	The fimbrial shaft protein Mfa1 from Porphyromonas gingivalis-C-terminal deletion
5KHM	;	1.48	;	The first BET bromodomain of BRD4 bound to compound 13 in a bivalent manner
5Z5V	;	1.66	;	The first bromodomain of BRD4 with compound BDF-1253
5Z5T	;	1.991	;	The first bromodomain of BRD4 with compound BDF-2141
5Z5U	;	1.631	;	The first bromodomain of BRD4 with compound BDF-2254
4BW1	;	1.4	;	The first bromodomain of human BRD4 in complex with 3,5 dimethylisoxaxole ligand
4BW2	;	1.92	;	The first bromodomain of human BRD4 in complex with 3,5 dimethylisoxaxole ligand
4BW3	;	1.5	;	The first bromodomain of human BRD4 in complex with 3,5 dimethylisoxaxole ligand
4BW4	;	1.67	;	The first bromodomain of human BRD4 in complex with 3,5 dimethylisoxaxole ligand
1WFM	;		;	The first C2 domain of human synaptotagmin XIII
3QSC	;	2.4	;	The first crystal structure of a human telomeric G-quadruplex DNA bound to a metal-containing ligand (a copper complex)
3QSF	;	2.4	;	The first crystal structure of a human telomeric G-quadruplex DNA bound to a metal-containing ligand (a nickel complex)
1F0I	;	1.4	;	THE FIRST CRYSTAL STRUCTURE OF A PHOSPHOLIPASE D
3ADR	;	1.8	;	The first crystal structure of an archaeal metallo-beta-lactamase superfamily protein; ST1585 from Sulfolobus tokodaii
6A4U	;	1.16	;	The first crystal structure of crustacean ferritin that is a hybrid type of H and L ferritin
6RL5	;	2.45	;	The first crystal structure of the DABA aminotransferase EctB in the ectoine biosynthesis pathway of the model organism Chromohalobacter salexigens DSM 3034
1NOF	;	1.42	;	THE FIRST CRYSTALLOGRAPHIC STRUCTURE OF A XYLANASE FROM GLYCOSYL HYDROLASE FAMILY 5: IMPLICATIONS FOR CATALYSIS
2OUM	;	2.55	;	The first domain of L1 from Thermus thermophilus
2OV7	;	2.3	;	The first domain of the ribosomal protein L1 from Thermus thermophilus
1FF7	;		;	THE FIRST EGF-LIKE DOMAIN FROM HUMAN BLOOD COAGULATION FVII (FUCOSYLATED AT SER-60), NMR, 20 STRUCTURES
1FFM	;		;	THE FIRST EGF-LIKE DOMAIN FROM HUMAN BLOOD COAGULATION FVII (FUCOSYLATED AT SER-60), NMR, MINIMIZED AVERAGE STRUCTURE
1F7E	;		;	THE FIRST EGF-LIKE DOMAIN FROM HUMAN BLOOD COAGULATION FVII, NMR, 20 STRUCTURES
1F7M	;		;	THE FIRST EGF-LIKE DOMAIN FROM HUMAN BLOOD COAGULATION FVII, NMR, MINIMIZED AVERAGE STRUCTURE
1KS0	;		;	The First Fibronectin Type II Module from Human Matrix Metalloproteinase 2
4H9M	;	1.52	;	The first Jack bean urease (Canavalia ensiformis) complex obtained at 1.52 resolution
2FR0	;	1.81	;	The first ketoreductase of the erythromycin synthase (crystal form 1)
2FR1	;	1.79	;	The first ketoreductase of the erythromycin synthase (crystal form 2)
2Z5L	;	1.95	;	The first ketoreductase of the tylosin PKS
1T4X	;		;	The first left-handed RNA structure of (CGCGCG)2, Z-RNA, NMR, 12 structures, determined in high salt
1IU0	;		;	The first PDZ domain of PSD-95
1IU2	;		;	The first PDZ domain of PSD-95
8JWL	;	2.3	;	The first purified state crystal structure of AKRtyl
4LNP	;	1.41	;	The first SH3 domain from CAP/Ponsin in complex with proline rich peptide from Vinculin
5DEN	;	2.9	;	The First Structure of a Full-Length Mammalian Phenylalanine Hydroxylase Reveals the Architecture of an Auto-inhibited Tetramer
1DLI	;	2.31	;	THE FIRST STRUCTURE OF UDP-GLUCOSE DEHYDROGENASE (UDPGDH) REVEALS THE CATALYTIC RESIDUES NECESSARY FOR THE TWO-FOLD OXIDATION
1DLJ	;	1.8	;	THE FIRST STRUCTURE OF UDP-GLUCOSE DEHYDROGENASE (UDPGDH) REVEALS THE CATALYTIC RESIDUES NECESSARY FOR THE TWO-FOLD OXIDATION
6L0X	;	1.3	;	The First Tudor Domain of PHF20L1
5W1A	;	2.227	;	The first X-ray crystal structure of an insect muscle myosin. Drosophila melanogaster, skeletal muscle myosin II, an embryonic isoform, subfragment-1
3H8I	;	2.65	;	The first X-ray structure of a sulfide:quinone oxidoreductase: Insights into sulfide oxidation mechanism
3H8L	;	2.57	;	The first X-ray structure of a sulfide:quinone oxidoreductase: insights into sulfide oxidation mechanism
8FJE	;	3.0	;	The five-repeat design E8
7APT	;	1.131	;	The Fk1 domain of FKBP51 in complex with ((1S,5S,6R)-10-((3,5-dichlorophenyl)sulfonyl)-2-oxo-5-vinyl-3,10-diazabicyclo[4.3.1]decan-3-yl)acetic acid
5OBK	;	1.0	;	The Fk1 domain of FKBP51 in complex with (1S,5S,6R)-10-((3,5-dichlorophenyl)sulfonyl)-5-(hydroxymethyl)-3-(pyridin-2-ylmethyl)-3,10-diazabicyclo[4.3.1]decan-2-one
8CHR	;	1.1	;	The FK1 domain of FKBP51 in complex with (1S,5S,6R)-10-((R)-(3,5-dichlorophenyl)sulfonimidoyl)-3-(pyridin-2-ylmethyl)-5-vinyl-3,10-diazabicyclo[4.3.1]decan-2-one
8CHP	;	1.0	;	The FK1 domain of FKBP51 in complex with (1S,5S,6R)-10-((S)-(3,5-dichlorophenyl)sulfinyl)-3-(pyridin-2-ylmethyl)-5-vinyl-3,10-diazabicyclo[4.3.1]decan-2-one
8CHN	;	0.99	;	The FK1 domain of FKBP51 in complex with (1S,5S,6R)-10-((S)-(3,5-dichlorophenyl)sulfonimidoyl)-3-(pyridin-2-ylmethyl)-5-vinyl-3,10-diazabicyclo[4.3.1]decan-2-one
8CHQ	;	1.01	;	The FK1 domain of FKBP51 in complex with (1S,5S,6R)-10-((S)-3,5-dichloro-N-methylphenylsulfonimidoyl)-3-(pyridin-2-ylmethyl)-5-vinyl-3,10-diazabicyclo[4.3.1]decan-2-one
7APW	;	0.89	;	The Fk1 domain of FKBP51 in complex with (1S,5S,6R)-10-(benzo[d]thiazol-6-ylsulfonyl)-5-(methoxymethyl)-3-(pyridin-2-ylethyl)-3,10-diazabicyclo[4.3.1]decan-2-one
7APQ	;	1.09	;	The Fk1 domain of FKBP51 in complex with (1S,5S,6R)-10-(benzo[d]thiazol-6-ylsulfonyl)-5-(methoxymethyl)-3-(pyridin-2-ylmethyl)-3,10-diazabicyclo[4.3.1]decan-2-one
4W9Q	;	1.08	;	The Fk1 domain of FKBP51 in complex with (1S,5S,6R)-10-[(3,5-dichlorophenyl)sulfonyl]-3-[2-(3,4-dimethoxyphenoxy)ethyl]-5-ethyl-3,10-diazabicyclo[4.3.1]decan-2-one
4TX0	;	1.03	;	The Fk1 domain of FKBP51 in complex with (1S,5S,6R)-10-[(3,5-dichlorophenyl)sulfonyl]-5-(2-methoxyethoxy)-3-(2-methoxyethyl)-3,10-diazabicyclo[4.3.1]decan-2-one
4W9O	;	1.27	;	The Fk1 domain of FKBP51 in complex with (1S,5S,6R)-10-[(3,5-dichlorophenyl)sulfonyl]-5-[(1R)-1,2-dihydroxyethyl]-3-[2-(3,4-dimethoxyphenoxy)ethyl]-3,10-diazabicyclo[4.3.1]decan-2-one
4W9P	;	1.5	;	The Fk1 domain of FKBP51 in complex with (1S,5S,6R)-10-[(3,5-dichlorophenyl)sulfonyl]-5-[(1S)-1,2-dihydroxyethyl]-3-[2-(3,4-dimethoxyphenoxy)ethyl]-3,10-diazabicyclo[4.3.1]decan-2-one
7AOU	;	1.16	;	The Fk1 domain of FKBP51 in complex with (2'R,5'S,12'R)-12'-cyclohexyl-2'-[2-(3,4-dimethoxyphenyl)ethyl]-3',19'-dioxa-10',13',16'-triazaspiro[cyclopropane-1,15'- tricyclo[18.3.1.0-5,10]tetracosane]-1'(24'),20',22'-triene-4',11',14',17'-tetrone
7AWF	;	1.4	;	The Fk1 domain of FKBP51 in complex with (2R,5S,12R)-12-cyclohexyl-2-[2-(3,4-dimethoxyphenyl)ethyl]-15,15,16-trimethyl-3,19-dioxa-10,13,16-triazatricyclo[18.3.1.0^5,^10]tetracosa-1(24),20,22-triene-4,11,14,17-tetrone
7AOT	;	0.85	;	The Fk1 domain of FKBP51 in complex with (2R,5S,12R)-12-cyclohexyl-2-[2-(3,4-dimethoxyphenyl)ethyl]-3,19-dioxa-10,13,16-triazatricyclo[18.3.1.0-5,10]tetracosa- 1(24),20,22-triene-4,11,14,17-tetrone
8CCG	;	1.3	;	The Fk1 domain of FKBP51 in complex with (2R,5S,12S)-12-(thiophen-2-yl)-2-[2-(3,4-dimethoxyphenyl)ethyl]-15,15-dimethyl-3,19-dioxa-10,13,16-triazatricyclo[18.3.1.0^5,^10]tetracosa-1(24),20,22-triene-4,11,14,17-tetrone
7APS	;	0.94	;	The Fk1 domain of FKBP51 in complex with (2S)-2-((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-2-oxo-5-vinyl-3,10-diazabicyclo[4.3.1]decan-3-yl)propanoic acid
6SAF	;	2.05	;	The Fk1 domain of FKBP51 in complex with (S)-(R)-3-(3,4-dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propyl 1-((1R,4aR,8aR)-4-oxodecahydronaphthalene-1-carbonyl)piperidine-2-carboxylate
8CCB	;	1.7	;	The Fk1 domain of FKBP51 in complex with 2-(3-((1R)-1-(((2S)-1-(2-(5-chlorothiophen-2-yl)-2-cyclohexylacetyl)piperidine-2-carbonyl)oxy)-3-(3,4-dimethoxyphenyl)propyl)phenoxy)acetic acid
8CCH	;	1.73	;	The Fk1 domain of FKBP51 in complex with 2-(3-((1R)-1-(((2S)-1-(2-cyclohexyl-2-(thiophen-2-yl)acetyl)piperidine-2-carbonyl)oxy)-3-(3,4-dimethoxyphenyl)propyl)phenoxy)acetic acid
8CCD	;	2.1	;	The Fk1 domain of FKBP51 in complex with 2-(3-((R)-1-(((S)-1-((S)-2-(5-chlorothiophen-2-yl)-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-2-carbonyl)oxy)-3-(3,4-dimethoxyphenyl)propyl)phenoxy)acetic acid
8CCE	;	1.4	;	The Fk1 domain of FKBP51 in complex with 2-(3-((R)-1-(((S)-1-((S)-2-(5-chlorothiophen-2-yl)butanoyl)piperidine-2-carbonyl)oxy)-3-(3,4-dimethoxyphenyl)propyl)phenoxy)acetic acid
8CCF	;	2.0	;	The Fk1 domain of FKBP51 in complex with 2-(3-((R)-1-(((S)-1-((S)-2-(5-chlorothiophen-2-yl)pent-4-enoyl)piperidine-2-carbonyl)oxy)-3-(3,4-dimethoxyphenyl)propyl)phenoxy)acetic acid
8CCC	;	1.55	;	The Fk1 domain of FKBP51 in complex with 2-(3-((R)-1-(((S)-1-((S)-2-(5-chlorothiophen-2-yl)propanoyl)piperidine-2-carbonyl)oxy)-3-(3,4-dimethoxyphenyl)propyl)phenoxy)acetic acid
4TW6	;	1.4	;	The Fk1 domain of FKBP51 in complex with iFit1
4TW7	;	1.25	;	The Fk1 domain of FKBP51 in complex with iFit4
7ETV	;	1.31	;	The FK1 domain of FKBP51 in complex with peptide-inhibitor hit DFPFV
7ETT	;	1.5	;	The FK1 domain of FKBP51 in complex with peptide-inhibitor hit QFPFV
7ETU	;	1.39	;	The FK1 domain of FKBP51 in complex with peptide-inhibitor hit SFPFT
8CCA	;	1.33	;	The Fk1 domain of FKBP51 in complex with SAFit1
5DIT	;	2.25	;	The Fk1 domain of FKBP51 in complex with the new synthetic ligand (1R)-3-(3,4-dimethoxyphenyl)-1-f3-[2-(morpholin-4-yl)ethoxy]phenylgpropyl(2S)-1-[(2S,3R)-2-cyclohexyl-3-hydroxybutanoyl]piperidine-2-carboxylate
5DIV	;	1.65	;	The Fk1 domain of FKBP51 in complex with the new synthetic ligand (S)-N-(1-carbamoylcyclopentyl)-1-((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-2-carboxamide
5DIU	;	1.3	;	The Fk1 domain of FKBP51 in complex with the new synthetic ligand 2-(3-((R)-1-((S)-1-((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-2-carboxamido)-3-(3,4-dimethoxyphenyl)propyl)phenoxy)acetic acid
4TW8	;	3.003	;	The Fk1-Fk2 domains of FKBP52 in complex with iFit-FL
5O4U	;	4.2	;	The flagellin of Pyrococcus furiosus
7WLU	;	6.81	;	The Flattened Structure of mPIEZO1 in Lipid Bilayer
2X2O	;	1.13	;	The flavoprotein NrdI from Bacillus cereus with the initially oxidized FMN cofactor in an intermediate radiation reduced state
2X2P	;	1.15	;	The flavoprotein NrdI from Bacillus cereus with the initially semiquinone FMN cofactor in an intermediate radiation reduced state
2C2W	;	2.0	;	The fluorinase from Streptomyces cattleya is also a chlorinase. Structure of 5'-chloro-5'-deoxyadenosine crystallised in the fluorinase.
1E20	;	2.02	;	The FMN binding protein AtHal3
3S9O	;	2.6	;	The Focal Adhesion Targeting (FAT) domain of the Focal Adhesion Kinase showing N-terminal interactions in cis
8I6J	;	3.82	;	The focused refinement of CCT3-PhLP2A from TRiC-PhLP2A complex in the open state
8I9Q	;	4.22	;	The focused refinement of CCT4-PhLP2A from TRiC-PhLP2A complex in the open state
2WXC	;		;	The folding mechanism of BBL: Plasticity of transition-state structure observed within an ultrafast folding protein family.
1UJX	;		;	The forkhead associated (FHA) domain like structure from mouse polynucleotide kinase 3'-phosphatase
4MU3	;	1.12	;	The form A structure of an E21Q catalytic mutant of A. thaliana IGPD2 in complex with Mn2+ and a mixture of its substrate, 2R3S-IGP, and an inhibitor, 2S3S-IGP, to 1.12 A resolution
4MU4	;	1.41	;	The form B structure of an E21Q catalytic mutant of A. thaliana IGPD2 in complex with Mn2+ and its substrate, 2R3S-IGP, to 1.41 A resolution
2VXP	;	2.5	;	The fourth FAS1 domain structure of human Bigh3
1WFN	;		;	The fourth FN3 domain of human sidekick-2
3H1T	;	2.3	;	The fragment structure of a putative HsdR subunit of a type I restriction enzyme from Vibrio vulnificus YJ016
4EYU	;	2.3	;	The free structure of the mouse C-terminal domain of KDM6B
4AIP	;	2.4	;	The FrpB iron transporter from Neisseria meningitidis (F3-3 variant)
4AIQ	;	2.6	;	The FrpB iron transporter from Neisseria meningitidis (F5-1 variant)
4B7O	;	2.32	;	THE FrpB IRON TRANSPORTER FROM NEISSERIA MENINGITIDIS (F5-1 VARIANT) APOPROTEIN FORM
7L5U	;	3.16	;	The full AAV7 capsid
6IVC	;	1.8	;	The full length of TGEV nsp1
5N9Y	;	4.2	;	The full-length structure of ZntB
7CRN	;	2.26	;	The Functional Characterization and Crystal Structure of the Bifunctional Thioesterase Catalyzing Epimerization and Cyclization
6LK3	;	2.1	;	The Functional Characterization and Crystal Structure of Type II Peptidyl Carrier Protein ColA1a in Collismycins Biosynthesis
1V4Y	;	1.65	;	The functional role of the binuclear metal center in D-aminoacylase. One-metal activation and second-metal attenuation
1V51	;	1.6	;	The functional role of the binuclear metal center in D-aminoacylase. One-metal activation and second-metal attenuation
2J24	;	2.1	;	The functional role of the conserved active site proline of triosephosphate isomerase
2J27	;	1.15	;	The functional role of the conserved active site proline of triosephosphate isomerase
2XUR	;	1.9	;	The G157C mutation in the Escherichia coli sliding clamp specifically affects initiation of replication
1F5G	;		;	The G7(syn)-G4(anti) structure of r(GCAGGCGUGC)2
1F5H	;		;	The G7(syn)-G4(anti) structure of r(GCAGGCGUGC)2
2Z8E	;	1.99	;	The galacto-N-biose-/lacto-N-biose I-binding protein (GL-BP) of the ABC transporter from Bifidobacterium longum in complex with galacto-N-biose
2Z8D	;	1.85	;	The galacto-N-biose-/lacto-N-biose I-binding protein (GL-BP) of the ABC transporter from Bifidobacterium longum in complex with lacto-N-biose
2Z8F	;	1.65	;	The galacto-N-biose-/lacto-N-biose I-binding protein (GL-BP) of the ABC transporter from Bifidobacterium longum in complex with lacto-N-tetraose
1SAU	;	1.12	;	The Gamma subunit of the dissimilatory sulfite reductase (DsrC) from Archaeoglobus fulgidus at 1.1 A resolution
1NF1	;	2.5	;	THE GAP RELATED DOMAIN OF NEUROFIBROMIN
1YSA	;	2.9	;	THE GCN4 BASIC REGION LEUCINE ZIPPER BINDS DNA AS A DIMER OF UNINTERRUPTED ALPHA HELICES: CRYSTAL STRUCTURE OF THE PROTEIN-DNA COMPLEX
3TDW	;	1.7	;	The GDP complex of the aminoglycoside 2'-phosphotransfere-IIIa F108L mutant
7L6E	;	3.15	;	The genome-containing AAV11 capsid
7L6A	;	2.67	;	The genome-containing AAV12 capsid
7L6H	;	3.0	;	The genome-containing AAV13 capsid
1TPA	;	1.9	;	THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
1TPO	;	1.7	;	THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
1TPP	;	1.4	;	THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
2PTC	;	1.9	;	THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
2TGP	;	1.9	;	THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
3PTB	;	1.7	;	THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
3TPI	;	1.9	;	THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
4PTI	;	1.5	;	THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
6EX6	;	2.16	;	The GH127, Beta-arabinofuranosidase, BT3674
5A7V	;	1.35	;	The GH130 family of mannoside phosphorylases contains glycoside hydrolases that target beta-1,2 mannosidic linkages in Candida mannan
6EUF	;	2.2	;	The GH43, Beta 1,3 Galactosidase, BT0265
6EUJ	;	2.75	;	The GH43, Beta 1,3 Galactosidase, BT0265
6EUH	;	2.0	;	The GH43, Beta 1,3 Galactosidase, BT3683 with galactodeoxynojirimycin
6EUG	;	1.61	;	The GH43, Beta 1,3 Galactosidase, BT3683 with galactoimidazole
6EUI	;	1.76	;	The GH43, Beta 1,3 Galactosidase, BT3683 with galactose
4HFH	;	2.65	;	The GLIC pentameric Ligand-Gated Ion Channel (wild-type) complexed to bromoform
4QH4	;	3.2	;	The GLIC pentameric Ligand-Gated Ion Channel (wild-type) crystallized in acetate buffer at pH3
4QH5	;	3.0	;	The GLIC pentameric Ligand-Gated Ion Channel (wild-type) crystallized in phosphate buffer
4QH1	;	3.4	;	The GLIC pentameric Ligand-Gated Ion Channel (wild-type) in complex with bromoacetate
5HCM	;	3.15	;	The GLIC pentameric Ligand-Gated Ion Channel 2-21' cross-linked mutant complexed to bromoform
6HZW	;	2.22	;	THE GLIC PENTAMERIC LIGAND-GATED ION CHANNEL 2.22 resolution
4HFI	;	2.4	;	The GLIC pentameric Ligand-Gated Ion Channel at 2.4 A resolution
3TLS	;	3.2	;	The GLIC pentameric Ligand-Gated Ion Channel E19'P mutant in a locally-closed conformation (LC2 subtype)
4HFB	;	2.75	;	The GLIC pentameric Ligand-Gated Ion Channel F14'A ethanol-sensitive mutant (Apo)
4HFC	;	3.05	;	The GLIC pentameric Ligand-Gated Ion Channel F14'A ethanol-sensitive mutant complexed to 2-bromo-ethanol
4HFD	;	3.1	;	The GLIC pentameric Ligand-Gated Ion Channel F14'A ethanol-sensitive mutant complexed to bromoform
4HFE	;	2.8	;	The GLIC pentameric Ligand-Gated Ion Channel F14'A ethanol-sensitive mutant complexed to ethanol
3TLT	;	3.3	;	The GLIC pentameric Ligand-Gated Ion Channel H11'F mutant in a locally-closed conformation (LC1 subtype)
4ILC	;	2.99	;	The GLIC pentameric ligand-gated ion channel in complex with sulfates
4ZZB	;	3.4	;	The GLIC pentameric Ligand-Gated Ion Channel Locally-closed form complexed to xenon
3UU5	;	2.9	;	The GLIC pentameric Ligand-Gated Ion Channel Loop2-20' mutant reduced in solution
3UU3	;	3.15	;	The GLIC pentameric Ligand-Gated Ion Channel Loop2-20' oxidized mutant in a locally-closed conformation (LC1 subtype)
3UUB	;	2.9	;	The GLIC pentameric Ligand-Gated Ion Channel Loop2-21' mutant reduced in solution
3UU4	;	3.05	;	The GLIC pentameric Ligand-Gated Ion Channel Loop2-21' mutant reduced in the crystal in a locally-closed conformation (LC1 subtype)
3TLW	;	2.6	;	The GLIC pentameric Ligand-Gated Ion Channel Loop2-21' oxidized mutant in a locally-closed conformation (LC2 subtype)
3UU6	;	2.98	;	The GLIC pentameric Ligand-Gated Ion Channel Loop2-22' mutant reduced in solution
3TLV	;	2.9	;	The GLIC pentameric Ligand-Gated Ion Channel Loop2-22' oxidized mutant in a locally-closed conformation (LC3 subtype)
3UU8	;	3.25	;	The GLIC pentameric Ligand-Gated Ion Channel Loop2-24' mutant reduced in solution
3TLU	;	2.85	;	The GLIC pentameric Ligand-Gated Ion Channel Loop2-24' oxidized mutant in a locally-closed conformation (LC1 subtype)
6HZ1	;	2.5	;	THE GLIC PENTAMERIC LIGAND-GATED ION CHANNEL MUTANT E243C
6I08	;	3.0	;	THE GLIC PENTAMERIC LIGAND-GATED ION CHANNEL MUTANT E243C-I201W
6HZ3	;	3.15	;	THE GLIC PENTAMERIC LIGAND-GATED ION CHANNEL MUTANT E243G
6HZ0	;	2.75	;	THE GLIC PENTAMERIC LIGAND-GATED ION CHANNEL MUTANT K248A
6HYZ	;	3.05	;	THE GLIC PENTAMERIC LIGAND-GATED ION CHANNEL MUTANT K248C
6HY5	;	2.58	;	THE GLIC PENTAMERIC LIGAND-GATED ION CHANNEL MUTANT Q193C
6HYR	;	3.5	;	THE GLIC PENTAMERIC LIGAND-GATED ION CHANNEL MUTANT Q193C+MMTS
6HYA	;	3.39	;	THE GLIC PENTAMERIC LIGAND-GATED ION CHANNEL MUTANT Q193L
6HY9	;	2.95	;	THE GLIC PENTAMERIC LIGAND-GATED ION CHANNEL MUTANT Q193M
6HYV	;	2.8	;	THE GLIC PENTAMERIC LIGAND-GATED ION CHANNEL MUTANT Y119A
6HYW	;	2.8	;	THE GLIC PENTAMERIC LIGAND-GATED ION CHANNEL MUTANT Y119F
6HYX	;	3.0	;	THE GLIC PENTAMERIC LIGAND-GATED ION CHANNEL MUTANT Y197F-P250C
4ZZC	;	3.1	;	The GLIC pentameric Ligand-Gated Ion Channel open form complexed to xenon
4NPP	;	3.35	;	The GLIC-His10 wild-type structure in equilibrium between the open and locally-closed (LC) forms
7PRV	;	2.7	;	The glucocorticoid receptor in complex with fluticasone furoate, a PGC1a coactivator fragment and sgk 23bp
7PRW	;	2.502	;	The glucocorticoid receptor in complex with velsecorat, a PGC1a coactivator fragment and sgk 23bp
6SZ0	;	1.74	;	The glucuronoyl esterase OtCE15A H408A variant from Opitutus terrae
6SZ4	;	1.75	;	The glucuronoyl esterase OtCE15A H408A variant from Opitutus terrae in complex with, and covalently linked to, D-glucuronate
7B7H	;	1.8	;	The glucuronoyl esterase OtCE15A R268A variant from Opitutus terrae in complex with, and covalently linked to, D-glucuronate
6T0E	;	1.89	;	The glucuronoyl esterase OtCE15A S267A variant from Opitutus terrae in complex with benzyl D-glucuronoate and D-glucuronate
6SZO	;	2.2	;	The glucuronoyl esterase OtCE15A S267A variant from Opitutus terrae in complex with D-galacturonate
6SYV	;	1.12	;	The glucuronoyl esterase OtCE15A S267A variant from Opitutus terrae in complex with D-glucuronate
4IS4	;	2.35	;	The glutamine synthetase from the dicotyledonous plant M. truncatula is a decamer
3R3E	;	2.205	;	The glutathione bound structure of YqjG, a glutathione transferase homolog from Escherichia coli K-12
3E3N	;	2.7	;	The Glycogen phosphorylase b R state- AMP complex
1Z0N	;	1.49	;	the glycogen-binding domain of the AMP-activated protein kinase
1Z0M	;	1.91	;	the glycogen-binding domain of the AMP-activated protein kinase beta1 subunit
7KRJ	;	2.56	;	The GR-Maturation Complex: Glucocorticoid Receptor in complex with Hsp90 and co-chaperone p23
7WKH	;	1.58	;	the grass carp IFNa
4QRY	;	2.2	;	the ground state and the N intermediate of pharaonis halorhodopsin in complex with bromide ion
5FPH	;	3.2	;	The GTPase domains of the immunity-related Irga6 dimerize in a parallel head-to-head fashion
7BGB	;	3.4	;	The H/ACA RNP lobe of human telomerase
8OUE	;	2.7	;	The H/ACA RNP lobe of human telomerase with the dyskerin thumb loop in a semi-closed conformation
8OUF	;	3.1	;	The H/ACA RNP lobe of human telomerase with the dyskerin thumb loop in an open conformation
2YXC	;	1.5	;	The H25M mutant of tetraheme cytochrome c3 from Desulfovibrio Vulgaris Miyazaki F
7LGI	;		;	The haddock model of GDP KRas in complex with promazine using chemical shift perturbations and intermolecular NOEs
7MQU	;		;	The haddock model of GDP KRas in complex with promethazine using NMR chemical shift perturbations
6V5L	;		;	The HADDOCK structure model of GDP KRas in complex with its allosteric inhibitor E22
6ZVK	;	3.49	;	The Halastavi arva virus (HalV) intergenic region IRES promotes translation by the simplest possible initiation mechanism
7A01	;	3.6	;	The Halastavi arva virus intergenic region IRES promotes translation by the simplest possible initiation mechanism
1KQS	;	3.1	;	The Haloarcula marismortui 50S Complexed with a Pretranslocational Intermediate in Protein Synthesis
2K9H	;		;	The hantavirus glycoprotein G1 tail contains a dual CCHC-type classical zinc fingers
1FL6	;	2.8	;	THE HAPTEN COMPLEXED GERMLINE PRECURSOR TO SULFIDE OXIDASE CATALYTIC ANTIBODY 28B4
5VM6	;	1.5	;	The hapten triclocarban bound to the single domain camelid nanobody VHH T10
5VL2	;	1.9	;	The hapten triclocarban bound to the single domain camelid nanobody VHH T4
5VM0	;	1.79	;	The hapten triclocarban bound to the single domain camelid nanobody VHH T9
4E40	;	1.6	;	The haptoglobin-hemoglobin receptor of Trypanosoma congolense
1DLL	;	1.8	;	The HC fragement of tetanus toxin complexed with lactose
1FV2	;	2.5	;	The Hc fragment of tetanus toxin complexed with an analogue of its ganglioside receptor GT1B
1FV3	;	2.3	;	THE HC FRAGMENT OF TETANUS TOXIN COMPLEXED WITH AN ANALOGUE OF ITS GANGLIOSIDE RECEPTOR GT1B
1DIW	;	2.0	;	THE HC FRAGMENT OF TETANUS TOXIN COMPLEXED WITH GALACTOSE
1D0H	;	2.1	;	THE HC FRAGMENT OF TETANUS TOXIN COMPLEXED WITH N-ACETYL-GALACTOSAMINE
1DFQ	;	2.6	;	THE HC FRAGMENT OF TETANUS TOXIN COMPLEXED WITH SIALIC ACID
6YSQ	;	3.3	;	The hC4Nb8 complement inhibitory nanobody in complex with C4b
3KF2	;	2.5	;	The HCV NS3/NS4A protease apo structure
7F2P	;	3.0	;	The head structure of Helicobacter pylori bacteriophage KHP40
1GW3	;		;	THE HELIX-HINGE-HELIX STRUCTURAL MOTIF IN HUMAN APOLIPOPROTEIN A-I DETERMINED BY NMR SPECTROSCOPY, 1 STRUCTURE
1GW4	;		;	THE HELIX-HINGE-HELIX STRUCTURAL MOTIF IN HUMAN APOLIPOPROTEIN A-I DETERMINED BY NMR SPECTROSCOPY, 1 STRUCTURE
2KXA	;		;	The hemagglutinin fusion peptide (H1 subtype) at pH 7.4
3HTO	;	2.95	;	the hemagglutinin structure of an avian H1N1 influenza A virus
3HTT	;	2.95	;	The hemagglutinin structure of an avian H1N1 influenza A virus in complex with 2,3-sialyllactose
3HTP	;	2.96	;	the hemagglutinin structure of an avian H1N1 influenza A virus in complex with LSTa
3HTQ	;	2.955	;	the hemagglutinin structure of an avian H1N1 influenza A virus in complex with LSTc
6M0A	;	2.2	;	The heme-bound structure of the chloroplast protein At3g03890
2YFV	;	2.32	;	The heterotrimeric complex of Kluyveromyces lactis Scm3, Cse4 and H4
1VTB	;	2.0	;	THE HEXAGONAL CRYSTAL STRUCTURE OF THE A-DNA OCTAMER D(GTGTACAC) AND ITS COMPARISON WITH THE TETRAGONAL STRUCTURE CORRELATED VARIATIONS IN HELICAL PARAMETERS
7T7C	;	10.0	;	The hexagonal organization of Munc13-1 C1-C2B-MUN-C2C domains between lipid bilayers
5T63	;	2.5	;	The HhoA protease from Synechocystis sp. PCC 6803
5T69	;	2.1	;	The HhoA protease from Synechocystis sp. PCC 6803, active site mutant
2YXF	;	1.13	;	The high resolution crystal structure of beta2-microglobulin under physiological conditions
3PNP	;	1.6	;	THE HIGH RESOLUTION CRYSTAL STRUCTURE OF BOVINE SPLEEN PURINE NUCLEOSIDE PHOSPHORYLASE IN COMPLEX FORMS WITH PHOSPHATE AND 9-DEAZAINOSINE
4PNP	;	1.8	;	THE HIGH RESOLUTION CRYSTAL STRUCTURE OF BOVINE SPLEEN PURINE NUCLEOSIDE PHOSPHORYLASE IN COMPLEX FORMS WITH PHOSPHATE AND 9-DEAZAINOSINE
2HBS	;	2.05	;	THE HIGH RESOLUTION CRYSTAL STRUCTURE OF DEOXYHEMOGLOBIN S
3BO8	;	1.8	;	The High Resolution Crystal Structure of HLA-A1 Complexed with the MAGE-A1 Peptide
3BXN	;	1.864	;	The high resolution crystal structure of HLA-B*1402 complexed with a Cathepsin A signal sequence peptide, pCatA
3BP4	;	1.85	;	The high resolution crystal structure of HLA-B*2705 in complex with a Cathepsin A signal sequence peptide pCatA
3BP7	;	1.8	;	The high resolution crystal structure of HLA-B*2709 in complex with a Cathepsin A signal sequence peptide, pCatA
2WQR	;	1.9	;	The high resolution crystal structure of IgE Fc
3PSG	;	1.65	;	THE HIGH RESOLUTION CRYSTAL STRUCTURE OF PORCINE PEPSINOGEN
2P86	;	1.16	;	The high resolution crystal structure of rhodesain, the major cathepsin L protease from T. brucei rhodesiense, bound to inhibitor K11002
2CTB	;	1.5	;	THE HIGH RESOLUTION CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN CARBOXYPEPTIDASE A AND L-PHENYL LACTATE
2CTC	;	1.4	;	THE HIGH RESOLUTION CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN CARBOXYPEPTIDASE A AND L-PHENYL LACTATE
232D	;	1.3	;	THE HIGH RESOLUTION CRYSTAL STRUCTURE OF THE DNA DECAMER D(AGGCATGCCT)
3ZRV	;	1.65	;	The high resolution structure of a dimeric Hamp-Dhp fusion displays asymmetry - A291F mutant
3ZRX	;	1.25	;	The high resolution structure of a dimeric Hamp-Dhp fusion displays strong asymmetry
1FR3	;	1.5	;	THE HIGH RESOLUTION STRUCTURE OF A MOLYBDATE BINDING PROTEIN FROM SPOROMUSA OVATA
5A8D	;	1.65	;	The high resolution structure of a novel alpha-L-arabinofuranosidase (CtGH43) from Clostridium thermocellum ATCC 27405
6YX7	;	1.419	;	The high resolution structure of allophycocyanin from cyanobacterium Nostoc sp. WR13, the P21212 crystal form.
1AXN	;	1.78	;	THE HIGH RESOLUTION STRUCTURE OF ANNEXIN III SHOWS DIFFERENCES WITH ANNEXIN V
5FDA	;	1.549	;	The high resolution structure of apo form dihydrofolate reductase from Yersinia pestis at 1.55 A
3KVS	;	1.5	;	The high resolution structure of C-Phycocyanin from Galdieria Sulphuraria
5YUQ	;	1.56	;	The high resolution structure of chitinase (RmChi1) from the thermophilic fungus Rhizomucor miehei (sp P1)
5HI6	;	2.051	;	The high resolution structure of dihydrofolate reductase from Yersinia pestis complex with methotrexate as closed form
3IP4	;	1.9	;	The high resolution structure of GatCAB
3FED	;	1.29	;	The high resolution structure of human glutamate carboxypeptidase III (GCPIII/NAALADase II) in complex with a transition state analog of Glu-Glu
3FF3	;	1.37	;	The high resolution structure of human glutamate carboxypeptidase III (GCPIII/NAALADase II) in complex with L-glutamate
3FEE	;	1.56	;	The high resolution structure of human glutamate carboxypeptidase III (GCPIII/NAALADase II) in complex with quisqualic acid
1W6S	;	1.2	;	The high resolution structure of methanol dehydrogenase from methylobacterium extorquens
1W0D	;	1.65	;	The high resolution structure of Mycobacterium tuberculosis LeuB (Rv2995c)
1E25	;	1.9	;	The high resolution structure of PER-1 class A beta-lactamase
6TXQ	;	1.73	;	The high resolution structure of the FERM domain and helical linker of human moesin
6XTJ	;	1.6	;	The high resolution structure of the FERM domain of human FERMT2
2PDD	;		;	THE HIGH RESOLUTION STRUCTURE OF THE PERIPHERAL SUBUNIT-BINDING DOMAIN OF DIHYDROLIPOAMIDE ACETYLTRANSFERASE FROM THE PYRUVATE DEHYDROGENASE MULTIENZYME COMPLEX OF BACILLUS STEAROTHERMOPHILUS
2PDE	;		;	THE HIGH RESOLUTION STRUCTURE OF THE PERIPHERAL SUBUNIT-BINDING DOMAIN OF DIHYDROLIPOAMIDE ACETYLTRANSFERASE FROM THE PYRUVATE DEHYDROGENASE MULTIENZYME COMPLEX OF BACILLUS STEAROTHERMOPHILUS
2R4G	;	1.71	;	The high resolution structure of the RNA-binding domain of telomerase
4M6E	;	0.95	;	The high resolution structure of tyrocidine A reveals an amphipathic dimer
2LGD	;		;	The high resolution structure of ubiquitin like domain of UBLCP1
1UWK	;	1.19	;	The High Resolution Structure of Urocanate Hydratase from Pseudomonas putida in complex with urocanate
1NYW	;	1.6	;	The high resolution structures of RmlC from Streptoccus suis in complex with dTDP-D-glucose
1NXM	;	1.3	;	The high resolution structures of RmlC from Streptococcus suis
1NZC	;	1.8	;	The high resolution structures of RmlC from Streptococcus suis in complex with dTDP-D-xylose
1ITI	;		;	THE HIGH RESOLUTION THREE-DIMENSIONAL SOLUTION STRUCTURE OF HUMAN INTERLEUKIN-4 DETERMINED BY MULTI-DIMENSIONAL HETERONUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
2CIO	;	1.5	;	The high resolution x-ray structure of papain complexed with fragments of the Trypanosoma brucei cysteine protease inhibitor ICP.
1YVT	;	1.8	;	The high salt (phosphate) crystal structure of CO Hemoglobin E (Glu26Lys) at physiological pH (pH 7.35)
3DUT	;	1.55	;	The high salt (phosphate) crystal structure of deoxy hemoglobin E (GLU26LYS) at physiological pH (pH 7.35)
2Y7Q	;	3.4	;	THE HIGH-AFFINITY COMPLEX BETWEEN IGE AND ITS RECEPTOR FC EPSILON RI
3Q6B	;	1.5	;	The high-resolution and new form crystal structure of BamA POTRA4-5 from E.coli
244D	;	1.2	;	THE HIGH-RESOLUTION CRYSTAL STRUCTURE OF A PARALLEL-STRANDED GUANINE TETRAPLEX
1N82	;	1.45	;	The high-resolution crystal structure of IXT6, a thermophilic, intracellular xylanase from G. stearothermophilus
2Q8X	;	1.45	;	The high-resolution crystal structure of ixt6, a thermophilic, intracellular xylanase from G. stearothermophilus
3W25	;	1.32	;	The high-resolution crystal structure of TsXylA, intracellular xylanase from /Thermoanaerobacterium saccharolyticum JW/SL-YS485/: the complex of the E146A mutant with xylobiose
3W26	;	1.6	;	The high-resolution crystal structure of TsXylA, intracellular xylanase from /Thermoanaerobacterium saccharolyticum JW/SL-YS485/: the complex of the E146A mutant with xylotriose
3W27	;	1.41	;	The high-resolution crystal structure of TsXylA, intracellular xylanase from /Thermoanaerobacterium saccharolyticum JW/SL-YS485/: the complex of the E251A mutant with xylobiose
3W29	;	1.39	;	The high-resolution crystal structure of TsXylA, intracellular xylanase from /Thermoanaerobacterium saccharolyticum JW/SL-YS485/: the complex of the E251A mutant with xylotetraose
3W28	;	1.39	;	The high-resolution crystal structure of TsXylA, intracellular xylanase from /Thermoanaerobacterium saccharolyticum JW/SL-YS485/: the complex of the E251A mutant with xylotriose
3W24	;	1.35	;	The high-resolution crystal structure of TsXylA, intracellular xylanase from Thermoanaerobacterium saccharolyticum JW/SL-YS485
2G9L	;		;	The High-resolution Solution Conformation of an Antimicrobial Peptide Gaegurin 4 and Its Mode of Membrane Interaction
1HDN	;		;	THE HIGH-RESOLUTION STRUCTURE OF THE HISTIDINE-CONTAINING PHOSPHOCARRIER PROTEIN HPR FROM ESCHERICHIA COLI DETERMINED BY RESTRAINED MOLECULAR DYNAMICS FROM NMR NUCLEAR OVERHAUSER EFFECT DATA
4B0A	;	1.97	;	The high-resolution structure of yTBP-yTAF1 identifies conserved and competing interaction surfaces in transcriptional activation
1TRS	;		;	THE HIGH-RESOLUTION THREE-DIMENSIONAL SOLUTION STRUCTURES OF THE OXIDIZED AND REDUCED STATES OF HUMAN THIOREDOXIN
1TRU	;		;	THE HIGH-RESOLUTION THREE-DIMENSIONAL SOLUTION STRUCTURES OF THE OXIDIZED AND REDUCED STATES OF HUMAN THIOREDOXIN
1TRV	;		;	THE HIGH-RESOLUTION THREE-DIMENSIONAL SOLUTION STRUCTURES OF THE OXIDIZED AND REDUCED STATES OF HUMAN THIOREDOXIN
1TRW	;		;	THE HIGH-RESOLUTION THREE-DIMENSIONAL SOLUTION STRUCTURES OF THE OXIDIZED AND REDUCED STATES OF HUMAN THIOREDOXIN
1CSE	;	1.2	;	THE HIGH-RESOLUTION X-RAY CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN SUBTILISIN CARLSBERG AND EGLIN C, AN ELASTASE INHIBITOR FROM THE LEECH HIRUDO MEDICINALIS. STRUCTURAL ANALYSIS, SUBTILISIN STRUCTURE AND INTERFACE GEOMETRY
4PFX	;	1.66	;	The highly conserved domain of unknown function 1792 has a distinct glycosyltransferase fold
1KWC	;	2.1	;	The His145Ala mutant of 2,3-dihydroxybiphenyl dioxygenase in complex with 2,3-dihydroxybiphenyl
6FSX	;	1.8	;	The hit-and-return system enables efficient time-resolved serial synchrotron crystallography
6GXH	;	1.802	;	The hit-and-return system enables efficient time-resolved serial synchrotron crystallography: FAcD 0MS after reaction initiation
6GXT	;	1.95	;	The hit-and-return system enables efficient time-resolved serial synchrotron crystallography: FAcD2052MS after reaction initiation
6GXD	;	1.8	;	The hit-and-return system enables efficient time-resolved serial synchrotron crystallography: FAcD752MS after reaction initiation
6GXF	;	1.8	;	The hit-and-return system enables efficient time-resolved serial synchrotron crystallography: RADDAM1
6GXL	;	1.8	;	The hit-and-return system enables efficient time-resolved serial synchrotron crystallography: RADDAM2
1MSN	;	2.0	;	The HIV protease (mutant Q7K L33I L63I V82F I84V) complexed with KNI-764 (an inhibitor)
1MSM	;	2.0	;	The HIV protease (mutant Q7K L33I L63I) complexed with KNI-764 (an inhibitor)
6PW6	;	4.5	;	The HIV-1 Envelope Glycoprotein Clone BG505 SOSIP.664 in Complex with Three Copies of the Bovine Broadly Neutralizing Antibody, NC-Cow1, Fragment Antigen Binding Domain
2VBF	;	1.6	;	The holostructure of the branched-chain keto acid decarboxylase (KdcA) from Lactococcus lactis
1R7M	;	2.25	;	The homing endonuclease I-SceI bound to its DNA recognition region
6X1J	;	1.945	;	The homing endonuclease I-WcaI bound to its DNA recognition sequence
8HZ5	;	3.0	;	The homodimer of a biotin carboxylase isoform from chloroflexus aurantiacus
1NZ4	;	1.8	;	The horse heart myoglobin variant K45E/K63E complexed with Cadmium
1NZ5	;	1.7	;	The Horse heart myoglobin variant K45E/K63E complexed with Manganese
3NB3	;	19.0	;	The host outer membrane proteins OmpA and OmpC are packed at specific sites in the Shigella phage Sf6 virion as structural components
5EFV	;	2.2	;	The host-recognition device of Staphylococcus aureus phage Phi11
4XUU	;	2.62	;	The hSac2 domain from human phosphoinositide phosphatase Sac2
3BBU	;	10.0	;	The Hsp15 protein fitted into the low resolution Cryo-EM map of the 50S.nc-tRNA.Hsp15 complex
3BBX	;	10.0	;	The Hsp15 protein fitted into the low resolution Cryo-EM map of the 50S.nc-tRNA.Hsp15 complex
5L4G	;	3.9	;	The human 26S proteasome at 3.9 A
5LN3	;	6.8	;	The human 26S Proteasome at 6.8 Ang.
5L4K	;	3.9	;	The human 26S proteasome lid
2GSF	;	1.77	;	The Human Epha3 Receptor Tyrosine Kinase and Juxtamembrane Region
6ECR	;	2.2	;	The human methylenetetrahydrofolate dehydrogenase/cyclohydrolase (FolD) complexed with NADP
6ECP	;	2.2	;	The human methylenetetrahydrofolate dehydrogenase/cyclohydrolase (FolD) complexed with NADP and inhibitor LY249543
6ECQ	;	2.7	;	The human methylenetetrahydrofolate dehydrogenase/cyclohydrolase (FolD) complexed with NADP and inhibitor LY345899
6C9M	;	2.8	;	The Human NatA (Naa10/Naa15) amino-terminal acetyltransferase complex
6C95	;	3.15	;	The Human NatA (Naa10/Naa15) amino-terminal acetyltransferase complex bound to HYPK
1KPR	;	2.8	;	The human non-classical major histocompatibility complex molecule HLA-E
1KTL	;	3.1	;	The human non-classical major histocompatibility complex molecule HLA-E
1MHE	;	2.85	;	THE HUMAN NON-CLASSICAL MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE HLA-E
3BZE	;	2.5	;	The human non-classical major histocompatibility complex molecule HLA-E
3BZF	;	2.5	;	The human non-classical major histocompatibility complex molecule HLA-E
3AFA	;	2.5	;	The human nucleosome structure
3AV1	;	2.5	;	The human nucleosome structure containing the histone variant H3.2
3AV2	;	2.8	;	The human nucleosome structure containing the histone variant H3.3
5NPS	;	1.68	;	The human O-GlcNAc transferase in complex with a bisubstrate inhibitor
5NPR	;	1.85	;	The human O-GlcNAc transferase in complex with a thiol-linked bisubstrate inhibitor
3ZJ0	;	1.8	;	The human O-GlcNAcase C-terminal domain is a pseudo histone acetyltransferase
4XNV	;	2.2	;	The human P2Y1 receptor in complex with BPTU
4XNW	;	2.7	;	The human P2Y1 receptor in complex with MRS2500
8FZ6	;	2.54	;	The human PI31 complexed with bovine 20S proteasome
2BIL	;	2.55	;	The human protein kinase Pim1 in complex with its consensus peptide Pimtide
8GW8	;	2.9	;	the human PTH1 receptor bound to an intracellular biased agonist
2WFH	;	1.8	;	The Human Slit 2 Dimerization Domain D4
6KE9	;	2.22	;	The Human Telomeric Nucleosome Displays Distinct Structural and Dynamic Properties
6L9H	;	2.6	;	The Human Telomeric Nucleosome Displays Distinct Structural and Dynamic Properties
6LE9	;	2.6	;	The Human Telomeric Nucleosome Displays Distinct Structural and Dynamic Properties
1Y97	;	2.5	;	The human TREX2 3' exonuclease structure suggests a mechanism for efficient non-processive DNA catalysis
4GR7	;	1.7	;	The human W42R Gamma D-Crystallin Mutant Structure at 1.7A Resolution
1OLR	;	1.2	;	The Humicola grisea Cel12A Enzyme Structure at 1.2 A Resolution
2JCP	;	1.3	;	The hyaluronan binding domain of murine CD44
2JCQ	;	1.25	;	The hyaluronan binding domain of murine CD44 in a Type A complex with an HA 8-mer
2JCR	;	2.0	;	The hyaluronan binding domain of murine CD44 in a Type B complex with an HA 8-mer
7OV7	;	1.8	;	The hybrid cage formed between Pizza6-S and Cu(II)-substituted trilacunary Keggin
8CNS	;	1.36	;	The Hybrid Cluster Protein from the thermophilic methanogen Methanothermococcus thermolithotrophicus in a mixed redox state after soaking with hydroxylamine, at 1.36-A resolution.
2CFI	;	1.85	;	The hydrolase domain of human 10-FTHFD in complex with 6- formyltetrahydropterin
8H2D	;	2.9	;	The hypothetical protein from Mycobacterium tuberculosis mutant - E47A
3MSV	;	2.18	;	The hypoxic regulator of sterol synthesis Nro1 is a nuclear import adaptor
3WY0	;	2.001	;	The I375W mutant of CsyB complexed with CoA-SH
7D0K	;	2.79	;	The icosahedral capsid of Omono River virus (strain:LZ)
4BRY	;	2.89	;	The Idas:Geminin heterodimeric parallel coiled-coil
5J79	;	2.69	;	The identification and pharmacological characterization of 6-(tert-butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a highly potent and selective inhibitor of RIP2 Kinase, Compound 3 complex
5J7B	;	2.53	;	The identification and pharmacological characterization of 6-(tert-butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a highly potent and selective inhibitor of RIP2 Kinase, GSK583 complex
4M5G	;	1.31	;	The Identification, Analysis and Structure-Based Development of Novel Inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase
4M5H	;	1.11	;	The Identification, Analysis and Structure-Based Development of Novel Inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase
4M5I	;	1.08	;	The Identification, Analysis and Structure-Based Development of Novel Inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase
4M5J	;	1.696	;	The Identification, Analysis and Structure-Based Development of Novel Inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase
4M5K	;	1.296	;	The Identification, Analysis and Structure-Based Development of Novel Inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase
4M5L	;	1.094	;	The Identification, Analysis and Structure-Based Development of Novel Inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase
4M5M	;	1.118	;	The Identification, Analysis and Structure-Based Development of Novel Inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase
4M5N	;	2.0	;	The Identification, Analysis and Structure-Based Development of Novel Inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase
2YHN	;	3.0	;	The IDOL-UBE2D complex mediates sterol-dependent degradation of the LDL receptor
2YHO	;	2.1	;	The IDOL-UBE2D complex mediates sterol-dependent degradation of the LDL receptor
8CXJ	;	3.05	;	The IgI3 domain of R28 protein from S. pyogenes bound to CEACAM1
6T15	;	3.29	;	The III2-IV(5B)1 respiratory supercomplex from S. cerevisiae
6T0B	;	2.8	;	The III2-IV(5B)2 respiratory supercomplex from S. cerevisiae
6JDP	;	1.601	;	the imm52 family protein TsiT (PA3908) from Pseudomonas aeruginosa
2AXF	;	1.8	;	The Immunogenicity of a Viral Cytotoxic T Cell Epitope is controlled by its MHC-bound Conformation
2AXG	;	2.0	;	The Immunogenicity of a Viral Cytotoxic T Cell Epitope is controlled by its MHC-bound Conformation
8P7F	;	2.0	;	The impact of molecular variants, crystallization conditions and space group on structure-ligand complexes: A case study on Bacterial Phosphotriesterase Variants and complexes
8P7H	;	1.774	;	The impact of molecular variants, crystallization conditions and space group on structure-ligand complexes: A case study on Bacterial Phosphotriesterase Variants and complexes
8P7I	;	1.7	;	The impact of molecular variants, crystallization conditions and space group on structure-ligand complexes: A case study on Bacterial Phosphotriesterase Variants and complexes
8P7K	;	1.929	;	The impact of molecular variants, crystallization conditions and space group on structure-ligand complexes: A case study on Bacterial Phosphotriesterase Variants and complexes
8P7M	;	1.85	;	The impact of molecular variants, crystallization conditions and space group on structure-ligand complexes: A case study on Bacterial Phosphotriesterase Variants and complexes
8P7N	;	3.2	;	The impact of molecular variants, crystallization conditions and space group on structure-ligand complexes: A case study on Bacterial Phosphotriesterase Variants and complexes
8P7Q	;	1.77	;	The impact of molecular variants, crystallization conditions and space group on structure-ligand complexes: A case study on Bacterial Phosphotriesterase Variants and complexes
8P7R	;	1.85	;	The impact of molecular variants, crystallization conditions and space group on structure-ligand complexes: A case study on Bacterial Phosphotriesterase Variants and complexes
8P7S	;	1.77	;	The impact of molecular variants, crystallization conditions and space group on structure-ligand complexes: A case study on Bacterial Phosphotriesterase Variants and complexes
8P7T	;	1.8	;	The impact of molecular variants, crystallization conditions and space group on structure-ligand complexes: A case study on Bacterial Phosphotriesterase Variants and complexes
8P7U	;	1.38	;	The impact of molecular variants, crystallization conditions and space group on structure-ligand complexes: A case study on Bacterial Phosphotriesterase Variants and complexes
8P7V	;	1.737	;	The impact of molecular variants, crystallization conditions and space group on structure-ligand complexes: A case study on Bacterial Phosphotriesterase Variants and complexes
1LYC	;	1.57	;	The impact of the physical and chemical enviroment on the molecular structure of Coprinus cinereus peroxidase
1LYK	;	2.0	;	THE IMPACT OF THE PHYSICAL AND CHEMICAL ENVIROMENT ON THE MOLECULAR STRUCTURE OF COPRINUS CINEREUS PEROXIDASE
1LY9	;	2.0	;	The impact of the physical and chemical environment on the molecular structure of Coprinus cinereus peroxidase
3H0O	;	1.4	;	The importance of CH-Pi stacking interactions between carbohydrate and aromatic residues in truncated Fibrobacter succinogenes 1,3-1,4-beta-D-glucanase
4COT	;	1.9	;	The importance of the Abn2 calcium cluster in the endo-1,5- arabinanase activity from Bacillus subtilis
1GM2	;		;	The independent structure of the antitryptic reactive site loop of Bowman-Birk inhibitor and sunflower trypsin inhibitor-1
1RRU	;	2.35	;	The influence of a chiral amino acid on the helical handedness of PNA in solution and in crystals
1TRD	;	2.5	;	THE INFLUENCE OF CRYSTAL PACKING ON CRYSTALLOGRAPHIC BINDING STUDIES: A NEW CRYSTAL FORM OF TRYPANOSOMAL TIM
2QHC	;	2.802	;	The Influence of I47A Mutation on Reduced Susceptibility to the Protease Inhibitor Lopinavir
2Z54	;	2.31	;	The Influence of I47A Mutation on Reduced Susceptibility to the Protease Inhibitor Lopinavir
1LSA	;	1.7	;	THE INFLUENCE OF TEMPERATURE ON LYSOZYME CRYSTALS. STRUCTURE AND DYNAMICS OF PROTEIN AND WATER
1LSB	;	1.7	;	THE INFLUENCE OF TEMPERATURE ON LYSOZYME CRYSTALS. STRUCTURE AND DYNAMICS OF PROTEIN AND WATER
1LSC	;	1.7	;	THE INFLUENCE OF TEMPERATURE ON LYSOZYME CRYSTALS. STRUCTURE AND DYNAMICS OF PROTEIN AND WATER
1LSD	;	1.7	;	THE INFLUENCE OF TEMPERATURE ON LYSOZYME CRYSTALS. STRUCTURE AND DYNAMICS OF PROTEIN AND WATER
1LSE	;	1.7	;	THE INFLUENCE OF TEMPERATURE ON LYSOZYME CRYSTALS. STRUCTURE AND DYNAMICS OF PROTEIN AND WATER
1LSF	;	1.7	;	THE INFLUENCE OF TEMPERATURE ON LYSOZYME CRYSTALS. STRUCTURE AND DYNAMICS OF PROTEIN AND WATER
1UWN	;	1.2	;	The Initial Events in the Photocycle of Photoactive Yellow Protein: A Common Mechanism on Light Activation in Photoreceptor Proteins
6VE7	;	3.6	;	The inner junction complex of Chlamydomonas reinhardtii doublet microtubule
2LLD	;		;	The Insect Defensin Lucifensin from Lucilia sericata
3VHP	;	1.93	;	The insertion mutant Y61GG of Tm Cel12A
7MQO	;	3.4	;	The insulin receptor ectodomain in complex with a venom hybrid insulin analog - ""head"" region
7MQR	;	4.1	;	The insulin receptor ectodomain in complex with four venom hybrid insulins - symmetric conformation
7MQS	;	4.4	;	The insulin receptor ectodomain in complex with three venom hybrid insulin molecules - asymmetric conformation
1ATH	;	3.2	;	THE INTACT AND CLEAVED HUMAN ANTITHROMBIN III COMPLEX AS A MODEL FOR SERPIN-PROTEINASE INTERACTIONS
2M3E	;		;	The Integrin Alpha L Transmembrane Domain in Bicelles: Structure and Interaction with Integrin Beta 2
6SO3	;	6.2	;	The interacting head motif in insect flight muscle myosin thick filaments
6WRM	;	1.55	;	The interaction of chlorido(1,5-cyclooctadiene)([4-(2-((tert-butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)-1,3-dimethyl-1H-imidazol-3-ide])rhodium(I) with HEWL after 1 month
6WRL	;	1.35	;	The interaction of chlorido(1,5-cyclooctadiene)([4-(2-((tert-butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)-1,3-dimethyl-1H-imidazol-3-ide])rhodium(I) with HEWL after 1 week
3IYP	;	7.2	;	The Interaction of Decay-accelerating Factor with Echovirus 7
6WGO	;	1.3	;	The interaction of dichlorido(3-(anthracen-9-ylmethyl)-1-methylimidazol-2-ylidene)(eta6-p-cymene)ruthenium(II) with HEWL after 1 week
1ERB	;	1.9	;	THE INTERACTION OF N-ETHYL RETINAMIDE WITH PLASMA RETINOL-BINDING PROTEIN (RBP) AND THE CRYSTAL STRUCTURE OF THE RETINOID-RBP COMPLEX AT 1.9 ANGSTROMS RESOLUTION
1FPH	;	2.5	;	THE INTERACTION OF THROMBIN WITH FIBRINOGEN: A STRUCTURAL BASIS FOR ITS SPECIFICITY
2W1L	;	1.51	;	THE INTERDEPENDENCE OF WAVELENGTH, REDUNDANCY AND DOSE IN SULFUR SAD EXPERIMENTS: 0.979 a wavelength 991 images data
2W1X	;	1.7	;	The interdependence of wavelength, redundancy and dose in sulfur SAD experiments: 1.284 A wavelength 360 images data
2W1Y	;	1.73	;	THE INTERDEPENDENCE OF WAVELENGTH, REDUNDANCY AND DOSE IN SULFUR SAD EXPERIMENTS: 1.540 A wavelength 180 images data
2W1M	;	1.78	;	THE INTERDEPENDENCE OF WAVELENGTH, REDUNDANCY AND DOSE IN SULFUR SAD EXPERIMENTS: 2.070 A WAVELENGTH with 2theta 30 degrees data
7CAH	;	3.9	;	The interface of H014 Fab binds to SARS-CoV-2 S
7WRV	;	2.47	;	The interface of JMB2002 Fab binds to SARS-CoV-2 Omicron Variant S
8E4M	;	3.44	;	The intermediate C2-state mouse TRPM8 structure in complex with the cooling agonist C3 and PI(4,5)P2
6JZM	;	1.88	;	The intermediate forming O-C10 bond formation in AsqJ-catalyzed epoxidation
8HD7	;	3.52	;	The intermediate pre-Tet-S1 state of G264A mutated Tetrahymena group I intron with 6nt 3'/5'-exon and 2-aminopurine nucleoside
7XD4	;	3.89	;	The intermediate pre-Tet-S1 state of wild-type Tetrahymena group I intron with 6nt 3'/5'-exon
8GVA	;	3.25	;	The intermediate structure of hAE2 in basic pH
7JHW	;	1.65	;	The internal aldimine crystal structure of Salmonella typhimurium Tryptophan Synthase mutant beta-S377A in complex with inhibitor 2-({[4-(trifluoromethoxy)phenyl]sulfonyl}amino)ethyl dihydrogen phosphate (F9F) at the alpha-site and Cesium ion at the metal coordination site
7JLL	;	1.55	;	The internal aldimine crystal structure of Salmonella typhimurium Tryptophan Synthase mutant beta-S377A in complex with inhibitor 2-({[4-(trifluoromethoxy)phenyl]sulfonyl}amino)ethyl dihydrogen phosphate (F9F) at the alpha-site, Cesium ion at the metal coordination site and L-Tryptophan at the enzyme beta-site
7KMC	;	1.5	;	The internal aldimine crystal structure of the beta-K167T mutant Tryptophan Synthase at 1.50 Angstrom resolution with cesium ion at the metal coordination site
7K0B	;	1.57	;	The internal aldimine form of Salmonella typhimurium Tryptophan Synthase mutant beta-Q114A with cesium ion at the metal coordination site. A random beta-P270L mutation was inserted during PCR step
7L47	;	1.55	;	The internal aldimine form of the beta-K167T mutant Tryptophan Synthase from Salmonella at 1.55 Angstrom resolution with cesium ion at the metal coordination site
7LUT	;	1.6	;	The internal aldimine form of the wild-type Salmonella typhimurium Tryptophan Synthase in complex with cesium ion at the metal coordination site and the product L-tryptophan at the enzyme beta-site at 1.60 Angstrom resolution
7LX1	;	1.61	;	The internal aldimine form of the wild-type Salmonella Typhimurium Tryptophan Synthase in complex with cesium ion at the metal coordination site at 1.61 Angstrom resolution
7LPF	;	1.1	;	The internal aldimine form of the wild-type Salmonella typhimurium Tryptophan Synthase in complex with inhibitor N-(4'-trifluoromethoxybenzenesulfonyl)-2-amino-1-ethylphosphate (F9F) at the enzyme alpha-site and sodium ion at the metal coordination site at 1.10 Angstrom resolution
7LV5	;	1.6	;	The internal aldimine form of the wild-type Salmonella typhimurium Tryptophan Synthase in complex with inhibitor N-(4'-trifluoromethoxybenzenesulfonyl)-2-amino-1-ethylphosphate (F9F) at the enzyme alpha-site, cesium ion at the metal coordination site and L-Histidine at the enzyme beta-site at 1.55 Angstrom resolution
7LKL	;	1.05	;	The internal aldimine form of the wild-type Salmonella typhimurium Tryptophan Synthase in complex with inhibitor N-(4'-trifluoromethoxybenzenesulfonyl)-2-amino-1-ethylphosphate (F9F) at the enzyme alpha-site, cesium ion at the metal coordination site and the product L-tryptophan at the enzyme beta-site at 1.05 Angstrom resolution. One of the beta-Q114 rotamer conformations allows a hydrogen bond to form with the PLP oxygen at the position 3 in the ring
7LTP	;	1.47	;	The internal aldimine form of the wild-type Salmonella typhimurium Tryptophan Synthase in complex with inhibitor N-(4'-trifluoromethoxybenzenesulfonyl)-2-amino-1-ethylphosphate (F9F) at the enzyme alpha-site, cesium ion at the metal coordination site and the product L-tryptophan at the enzyme beta-site at 1.47 Angstrom resolution
7LVX	;	1.55	;	The internal aldimine form of the wild-type Salmonella Typhimurium Tryptophan Synthase in complex with N-(4'-trifluoromethoxybenzenesulfonyl)-2-amino-1-ethylphosphate (F9F) at the enzyme alpha-site and cesium ion at the metal coordination site at 1.55 Angstrom resolution
7M3S	;	1.55	;	The internal aldimine form of the wild-type Salmonella Typhimurium Tryptophan Synthase in complex with N-(4'-trifluoromethoxybenzoyl)-2-amino-1-ethylphosphate (F6F) inhibitor at the alpha-and beta-site, sodium ion at the metal coordination site, and another F6F molecule at the enzyme beta-site at 1.55 Angstrom resolution. One of the beta-Q114 rotamer conformations allows a hydrogen bond to form with the PLP oxygen at the position 3 in the ring
7M2L	;	1.6	;	The internal aldimine form of the wild-type Salmonella Typhimurium Tryptophan Synthase in complex with N-(4'-trifluoromethoxybenzoyl)-2-amino-1-ethylphosphate (F6F) inhibitor at the alpha-and beta-site, sodium ion at the metal coordination site, and another F6F molecule at the enzyme beta-site at 1.60 Angstrom resolution. Two of the beta-Q114 rotamer conformations allows a hydrogen bond to form with the PLP oxygen at the position 3 in the ring
7ME8	;	1.6	;	The internal aldimine form of the wild-type Salmonella Typhimurium Tryptophan Synthase in complex with N-(4'-trifluoromethoxybenzoyl)-2-amino-1-ethylphosphate (F6F) inhibitor at the beta-site, sodium ion at the metal coordination site and dual beta-Q114 rotamer conformation at 1.60 Angstrom resolution
7LY8	;	1.55	;	The internal aldimine form of the wild-type Salmonella Typhimurium Tryptophan Synthase in complex with two molecules of N-(4'-trifluoromethoxybenzoyl)-2-amino-1-ethylphosphate (F6F) inhibitor at the enzyme alpha-site, a single F6F molecule at the enzyme beta-site, and sodium ion at the metal coordination site at 1.55 Angstrom resolution. One of the beta-Q114 rotamer conformations allows a hydrogen bond to form with the PLP oxygen at the position 3 in the ring
7L4D	;	1.6	;	The internal aldimine form of the wild-type Salmonella typhimurium Tryptophan Synthase with cesium ion at the metal coordination site at 1.60 Angstrom resolution
7KU9	;	1.4	;	The internal aldimine form of the wild-type Salmonella typhimurium Tryptophan Synthase with sodium ion at the metal coordination site, two molecules of F6F inhibitor at the enzyme alpha-site and another F6F molecule at the enzyme beta-site at 1.40 Angstrom resolution
7KQF	;	1.47	;	The internal aldimine form of the wild-type Tryptophan Synthase from Salmonella in complex with inhibitor N-(4'-trifluoromethoxybenzenesulfonyl)-2-amino-1-ethylphosphate (F9F) at the enzyme alpha-site and cesium ion at the metal coordination site at 1.47 Angstrom resolution
5HM7	;	1.93	;	The Intracellular domain of Butyrophilin 3A1 protein
2PX9	;		;	The intrinsic affinity between E2 and the Cys domain of E1 in Ubiquitin-like modifications
400D	;	1.65	;	THE INTRINSIC STRUCTURE AND STABILITY OF OUT-OF-ALTERNATION BASE PAIRS IN Z-DNA
1QS5	;	2.5	;	THE INTRODUCTION OF STRAIN AND ITS EFFECTS ON THE STRUCTURE AND STABILITY OF T4 LYSOZYME
1QS9	;	1.85	;	THE INTRODUCTION OF STRAIN AND ITS EFFECTS ON THE STRUCTURE AND STABILITY OF T4 LYSOZYME
1QSB	;	1.8	;	THE INTRODUCTION OF STRAIN AND ITS EFFECTS ON THE STRUCTURE AND STABILITY OF T4 LYSOZYME
1QTB	;	1.9	;	THE INTRODUCTION OF STRAIN AND ITS EFFECTS ON THE STRUCTURE AND STABILITY OF T4 LYSOZYME
1QTC	;	2.5	;	THE INTRODUCTION OF STRAIN AND ITS EFFECTS ON THE STRUCTURE AND STABILITY OF T4 LYSOZYME
1QTD	;	2.5	;	THE INTRODUCTION OF STRAIN AND ITS EFFECTS ON THE STRUCTURE AND STABILITY OF T4 LYSOZYME
1QTH	;	1.9	;	THE INTRODUCTION OF STRAIN AND ITS EFFECTS ON THE STRUCTURE AND STABILITY OF T4 LYSOZYME
1FRN	;	2.0	;	THE INVOLVEMENT OF SER96 IN THE CATALYTIC MECHANISM OF FERREDOXIN-NADP+ REDUCTASE: STRUCTURE-FUNCTION RELATIONSHIP AS STUDIED BY SITE-DIRECTED MUTAGENESIS AND X-RAY CRYSTALLOGRAPHY
4LDS	;	3.2	;	The inward-facing structure of the glucose transporter from Staphylococcus epidermidis
6ZIW	;	2.18	;	The IRAK3 Pseudokinase Domain Bound To ATPgammaS
6KXD	;	1.75	;	The ishigamide ketosynthase/chain length factor
6KXE	;	1.81	;	The ishigamide ketosynthase/chain length factor
6KXF	;	1.98	;	The ishigamide ketosynthase/chain length factor
7LIE	;		;	The isolated chicken ASIC1a thumb domain (ATD-c1a) retains the structure and ligand binding properties of the full length chicken ASIC1a
1EKX	;	1.95	;	THE ISOLATED, UNREGULATED CATALYTIC TRIMER OF ASPARTATE TRANSCARBAMOYLASE COMPLEXED WITH BISUBSTRATE ANALOG PALA (N-(PHOSPHONACETYL)-L-ASPARTATE)
2V4M	;	2.29	;	The isomerase domain of human glutamine-fructose-6-phosphate transaminase 1 (GFPT1) in complex with fructose 6-phosphate
1HAG	;	2.0	;	THE ISOMORPHOUS STRUCTURES OF PRETHROMBIN2, HIRUGEN-AND PPACK-THROMBIN: CHANGES ACCOMPANYING ACTIVATION AND EXOSITE BINDING TO THROMBIN
1HAH	;	2.3	;	THE ISOMORPHOUS STRUCTURES OF PRETHROMBIN2, HIRUGEN-AND PPACK-THROMBIN: CHANGES ACCOMPANYING ACTIVATION AND EXOSITE BINDING TO THROMBIN
1HAI	;	2.4	;	THE ISOMORPHOUS STRUCTURES OF PRETHROMBIN2, HIRUGEN-AND PPACK-THROMBIN: CHANGES ACCOMPANYING ACTIVATION AND EXOSITE BINDING TO THROMBIN
2J4E	;	2.8	;	THE ITP COMPLEX OF HUMAN INOSINE TRIPHOSPHATASE
4K6Z	;	2.73	;	The Jak1 kinase domain in complex with compound 37
4EHZ	;	2.174	;	The Jak1 kinase domain in complex with inhibitor
4I5C	;	2.1	;	The Jak1 kinase domain in complex with inhibitor
5WFJ	;	2.48	;	THE JAK3 KINASE DOMAIN IN COMPLEX WITH A COVALENT INHIBITOR
1JUB	;	1.4	;	The K136E mutant of lactococcus lactis dihydroorotate dehydrogenase A
1OVD	;	2.25	;	THE K136E MUTANT OF LACTOCOCCUS LACTIS DIHYDROOROTATE DEHYDROGENASE A IN COMPLEX WITH OROTATE
1JQV	;	2.1	;	The K213E mutant of Lactococcus lactis Dihydroorotate dehydrogenase A
1XB6	;	1.823	;	The K24R mutant of Pseudomonas Aeruginosa Azurin
1LEI	;	2.7	;	The kB DNA sequence from the HLV-LTR functions as an allosteric regulator of HIV transcription
6RIS	;	2.1	;	The Kb42S variant of the molybdenum storage protein
3BJ4	;	2.0	;	The KCNQ1 (Kv7.1) C-terminus, a multi-tiered scaffold for subunit assembly and protein interaction
2BPU	;	1.35	;	The Kedge Holmium Derivative of Hen Egg-White Lysozyme at high resolution from Single Wavelength Anomalous Diffraction
3CIO	;	2.5	;	The kinase domain of Escherichia coli tyrosine kinase ETK
6SWK	;	1.742	;	The kinase domain of GanS, a histidine kinase from Geobacillus stearothermophilus
6SWJ	;	1.762	;	The kinase domain of GanS, a histidine kinase from Geobacillus stearothermophilus (with Pt)
3LCK	;	1.7	;	THE KINASE DOMAIN OF HUMAN LYMPHOCYTE KINASE (LCK), ACTIVATED FORM (AUTO-PHOSPHORYLATED ON TYR394)
4YJO	;	1.6	;	THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000222
4YJP	;	1.83	;	THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000223
4YJS	;	2.22	;	THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000226
4YJT	;	1.52	;	THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000233
4YJU	;	1.67	;	THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000249
4YJV	;	1.652	;	THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000250
6EJN	;	3.2	;	The KLC2 TPR domain bound to the JIP3 leucine zipper domain
4APV	;	2.095	;	The Klebsiella pneumoniae primosomal PriB protein: identification, crystal structure, and ssDNA binding mode
6CZO	;	2.95	;	The KNL1-PP1 Holoenzyme
7W5Q	;	2.73	;	The Kruppel-associated box (KRAB) domain of human zinc finger protein 568
2JB1	;	1.55	;	The L-amino acid oxidase from Rhodococcus opacus in complex with L- alanine
7O82	;	1.69	;	The L-arginine/agmatine antiporter from E. coli at 1.7 A resolution
1K75	;	1.75	;	The L-histidinol dehydrogenase (hisD) structure implicates domain swapping and gene duplication.
1V2G	;	2.0	;	The L109P mutant of E. coli Thioesterase I/Protease I/Lysophospholipase L1 (TAP) in complexed with octanoic acid
5JSL	;	1.25	;	The L16F mutant of cytochrome c prime from Alcaligenes xylosoxidans: Ferrous form
3HEA	;	1.9	;	The L29P/L124I mutation of Pseudomonas fluorescens esterase
3NBM	;	1.3	;	The lactose-specific IIB component domain structure of the phosphoenolpyruvate:carbohydrate phosphotransferase system (PTS) from Streptococcus pneumoniae.
1JB3	;	1.6	;	The Laminin-Binding Domain of Agrin is structurally related to N-TIMP-1
1JC7	;	2.73	;	The Laminin-Binding Domain of Agrin is Structurally Related to N-TIMP-1
3FWO	;	3.71	;	The large ribosomal subunit from Deinococcus radiodurans complexed with Methymycin
5JVG	;	3.428	;	The large ribosomal subunit from Deinococcus radiodurans in complex with avilamycin
7AIH	;	3.6	;	The Large subunit of the Kinetoplastid mitochondrial ribosome
7CMI	;	2.9	;	The LAT2-4F2hc complex in complex with leucine
7CMH	;	3.4	;	The LAT2-4F2hc complex in complex with tryptophan
1NUV	;	1.81	;	The Leadzyme Ribozyme Bound to Mg(H2O)6(II) and Sr(II) at 1.8 A resolution
1NUJ	;	1.8	;	THE LEADZYME STRUCTURE BOUND TO MG(H20)6(II) AT 1.8 A RESOLUTION
4TRH	;	2.03	;	The Legionella effector SidC defines a unique family of ubiquitin ligases important for bacterial phagosomal remodeling
4BTH	;	1.9	;	The LeuA146Trp,PheB24Tyr Double Mutant of the Quorum Quenching N-acyl Homoserine Lactone Acylase PvdQ Has an Altered Substrate Specificity Towards Small Acyl Chains
2AGI	;	1.14	;	The leupeptin-trypsin covalent complex at 1.14 A resolution
6IOP	;	2.3	;	The ligand binding domain of Mlp24
6IOT	;	2.7	;	The ligand binding domain of Mlp24 with arginine
6IOR	;	2.5	;	The ligand binding domain of Mlp24 with asparagine
6IOQ	;	2.143	;	The ligand binding domain of Mlp24 with glycine
6IOS	;	2.35	;	The ligand binding domain of Mlp24 with proline
6IOU	;	2.1	;	The ligand binding domain of Mlp24 with serine
6IOV	;	2.351	;	The ligand binding domain of Mlp37 with arginine
5AVE	;	1.8	;	The ligand binding domain of Mlp37 with serine
5AVF	;	1.95	;	The ligand binding domain of Mlp37 with taurine
1N4A	;	2.0	;	The Ligand Bound Structure of E.coli BtuF, the Periplasmic Binding Protein for Vitamin B12
5LHS	;	3.047	;	The ligand free catalytic domain of murine urokinase-type plasminogen activator
1OLZ	;	2.0	;	The ligand-binding face of the semaphorins revealed by the high resolution crystal structure of SEMA4D
6HNI	;	1.35	;	The ligand-bound, closed structure of CD0873, a substrate binding protein with adhesive properties from Clostridium difficile.
6HNJ	;	1.8	;	The ligand-bound, open structure of CD0873, a substrate binding protein with adhesive properties from Clostridium difficile.
5XUA	;	2.8	;	The ligand-free dimer of chemoreceptor MCP2201 ligand binding domain
7E2R	;	2.3	;	The ligand-free structure of Arabidopsis thaliana GUN4
1N4D	;	3.0	;	The Ligand-Free Structure of E coli BtuF, the Periplasmic Binding Protein for Vitamin B12
5ZDM	;	1.38	;	The ligand-free structure of FomD
7VEE	;	2.55	;	The ligand-free structure of GfsA KSQ-AT didomain
6L8B	;	2.102	;	The ligand-free structure of human PPARgamma LBD
7CXF	;	2.35	;	The ligand-free structure of human PPARgamma LBD C285Y mutant in the presence of the SRC-1 coactivator peptide
7CXI	;	2.3	;	The ligand-free structure of human PPARgamma LBD F287Y mutant in the presence of the SRC-1 coactivator peptide
6JQ7	;	2.55	;	The ligand-free structure of human PPARgamma LBD in the presence of the SRC-1 coactivator peptide
7CXG	;	1.88	;	The ligand-free structure of human PPARgamma LBD Q286E mutant
7CXH	;	2.3	;	The ligand-free structure of human PPARgamma LBD Q286E mutant in the presence of the SRC-1 coactivator peptide
7CXE	;	2.5	;	The ligand-free structure of human PPARgamma LBD R280C mutant
7CXJ	;	2.65	;	The ligand-free structure of human PPARgamma LBD R288C mutant in the presence of the SRC-1 coactivator peptide
7CXK	;	2.2	;	The ligand-free structure of human PPARgamma LBD R288H mutant in the presence of the SRC-1 coactivator peptide
7CXL	;	2.7	;	The ligand-free structure of human PPARgamma LBD S289C mutant in the presence of the SRC-1 coactivator peptide
6KTM	;	2.7	;	The ligand-free structure of human PPARgamma ligand-binding domain R288A mutant in the presence of the SRC-1 coactivator peptide
3WH9	;	1.57	;	The ligand-free structure of ManBK from Aspergillus niger BK01
6VIH	;	2.993	;	The ligand-free structure of mouse RABL3
6M09	;	2.101	;	The ligand-free structure of the chloroplast protein At3g03890
5IJB	;	2.91	;	The ligand-free structure of the mouse TLR4/MD-2 complex
6HNK	;	2.5	;	The ligand-free, open structure of CD0873, a substrate binding protein with adhesive properties from Clostridium difficile.
4EW9	;	1.6	;	The liganded structure of C. bescii family 3 pectate lyase
4DOE	;	1.561	;	The liganded structure of Cbescii CelA GH9 module
3ULF	;	2.9	;	The light state structure of the blue-light photoreceptor Aureochrome1 LOV
4CTF	;	17.0	;	The limits of structural plasticity in a picornavirus capsid revealed by a massively expanded equine rhinitis A virus particle
4CTG	;	17.0	;	The limits of structural plasticity in a picornavirus capsid revealed by a massively expanded equine rhinitis A virus particle
7ATU	;	2.8	;	The LIMK1 Kinase Domain Bound To LIJTF500025
7ATS	;	2.8	;	The LIMK1 Kinase Domain Bound To LIJTF500127
4A76	;	1.92	;	The Lin28b Cold shock domain in complex with heptathymidine
4A75	;	1.75	;	The Lin28b Cold shock domain in complex with hexathymidine.
4ALP	;	1.48	;	The Lin28b Cold shock domain in complex with hexauridine
1DEG	;	2.9	;	THE LINKER OF DES-GLU84 CALMODULIN IS BENT AS SEEN IN THE CRYSTAL STRUCTURE
8C0E	;	3.6	;	The lipid linked oligosaccharide polymerase Wzy and its regulating co-polymerase Wzz form a complex in vivo and in vitro
6F9M	;	1.298	;	The LIPY/F-motif in an intracellular subtilisin protease is involved in inhibition
7WOP	;	3.51	;	The local refined map of Omicron spike with bispecific antibody FD01
2G50	;	1.65	;	The location of the allosteric amino acid binding site of muscle pyruvate kinase.
4PQD	;	1.332	;	The longer crystal structure of the grow factor like domain from Beta amypoid precusor protein (APP22-126)
6Z42	;	4.0	;	The low resolution structure of a zinc-dependent alcohol dehydrogenase from Halomonas elongata.
1YVQ	;	1.8	;	The low salt (PEG) crystal structure of CO Hemoglobin E (betaE26K) approaching physiological pH (pH 7.5)
131D	;	1.0	;	THE LOW-TEMPERATURE CRYSTAL STRUCTURE OF THE PURE-SPERMINE FORM OF Z-DNA REVEALS BINDING OF A SPERMINE MOLECULE IN THE MINOR GROOVE
5IV8	;	2.938	;	The LPS Transporter LptDE from Klebsiella pneumoniae, core complex
5IV9	;	4.369	;	The LPS Transporter LptDE from Klebsiella pneumoniae, full-length
5IVA	;	2.988	;	The LPS Transporter LptDE from Pseudomonas aeruginosa, core complex
5IXM	;	2.746	;	The LPS Transporter LptDE from Yersinia pestis, core complex
4B5Q	;	1.75	;	The lytic polysaccharide monooxygenase GH61D structure from the basidiomycota fungus Phanerochaete chrysosporium
6YJ1	;	2.3	;	The M23 peptidase domain of the Staphylococcal phage 2638A endolysin
5GNZ	;	2.2	;	The M3 mutant structure of Bgl6
4NHU	;	2.9	;	The M33 TCR p3M33l/H-2 Ld Complex
2BFR	;	2.5	;	The Macro domain is an ADP-ribose binding module
1S2H	;		;	The Mad2 spindle checkpoint protein possesses two distinct natively folded states
1KLQ	;		;	The Mad2 Spindle Checkpoint Protein Undergoes Similar Major Conformational Changes upon Binding to Either Mad1 or Cdc20
7D0L	;	2.95	;	The major capsid of Omono River virus (strain:LZ), protrusion-free status.
6H1K	;		;	The major G-quadruplex form of HIV-1 LTR
1VFR	;	1.8	;	THE MAJOR NAD(P)H:FMN OXIDOREDUCTASE FROM VIBRIO FISCHERI
7VQ5	;	3.1	;	The malate-bound AtALMT1 structure at pH 7.5 (ALMT1malate/pH7.5)
7WRM	;	1.8	;	The malate-bound dimer of chemoreceptor MCP2201 ligand binding domain
4X21	;	1.95	;	The MAP kinase JNK3 as target for halogen bonding
7P1L	;	1.95	;	The MARK3 Kinase Domain Bound To AA-CS-1-008
3ECH	;	1.802	;	The MarR-family repressor MexR in complex with its antirepressor ArmR
7LCG	;	2.42	;	The mature Usutu SAAR-1776, Model A
7LCH	;	2.35	;	The mature Usutu SAAR-1776, Model B
2VYT	;	1.9	;	The MBT repeats of human SCML2 bind to peptides containing mono methylated lysine.
4EDU	;	2.58	;	The MBT repeats of human SCML2 in a complex with histone H2A peptide
3C64	;	2.4	;	The MC179 portion of the Cysteine-rich Interdomain Region (CIDR) of a Plasmodium falciparum Erythrocyte Membrane Protein-1 (PfEMP1)
3MK8	;	2.321	;	The MCL-1 BH3 Helix is an Exclusive MCL-1 Inhibitor and Apoptosis Sensitizer
5LA0	;	1.65	;	The mechanism by which arabinoxylanases can recognise highly decorated xylans
5LA1	;	1.9	;	The mechanism by which arabinoxylanases can recognise highly decorated xylans
5LA2	;	1.65	;	The mechanism by which arabinoxylanases can recognise highly decorated xylans
6ZSH	;	2.2	;	The mechanism of activation of the actin binding protein EHBP1 by Rab8 family members
6ZSI	;	1.914	;	The mechanism of activation of the actin binding protein EHBP1 by Rab8 family members.
6ZSJ	;	2.0	;	The mechanism of activation of the actin binding protein EHBP1 by Rab8 family members.
3ZM9	;	1.9	;	The mechanism of allosteric coupling in choline kinase a1 revealed by a rationally designed inhibitor
1XQE	;	2.1	;	The mechanism of ammonia transport based on the crystal structure of AmtB of E. coli.
1XQF	;	1.8	;	The mechanism of ammonia transport based on the crystal structure of AmtB of E. coli.
1F2W	;	1.9	;	THE MECHANISM OF CYANAMIDE HYDRATION CATALYZED BY CARBONIC ANHYDRASE II REVEALED BY CRYOGENIC X-RAY DIFFRACTION
6BFQ	;	2.6	;	The mechanism of GM-CSF inhibition by human GM-CSF auto-antibodies
6BFS	;	2.0	;	The mechanism of GM-CSF inhibition by human GM-CSF auto-antibodies
5A4I	;	1.23	;	The mechanism of Hydrogen activation by NiFE-hydrogenases
5ADU	;	1.1	;	The Mechanism of Hydrogen Activation by NiFe-hydrogenases
4UE3	;	1.4	;	The Mechanism of Hydrogen Activation by NiFe-hydrogenases and the Importance of the active site Arginine
5A4F	;	1.25	;	The mechanism of Hydrogen Activation by NiFe-hydrogenases.
1OVB	;	2.3	;	THE MECHANISM OF IRON UPTAKE BY TRANSFERRINS: THE STRUCTURE OF AN 18KD NII-DOMAIN FRAGMENT AT 2.3 ANGSTROMS RESOLUTION
4KZF	;	1.85	;	The mechanism of the amidases: The effect of the mutation E142L in the amidase from Geobacillus pallidus
1W8S	;	1.85	;	The mechanism of the Schiff Base Forming Fructose-1,6-bisphosphate Aldolase: Structural analysis of reaction intermediates
2Y0Q	;	2.0	;	The mechanisms of HAMP-mediated signaling in transmembrane receptors - the A291C mutant
2Y0T	;	1.3	;	The mechanisms of HAMP-mediated signaling in transmembrane receptors - the A291F mutant
2Y20	;	1.65	;	The mechanisms of HAMP-mediated signaling in transmembrane receptors - the A291I mutant
2Y21	;	2.45	;	The mechanisms of HAMP-mediated signaling in transmembrane receptors - the A291V mutant
2XNF	;		;	The Mediator Med25 activator interaction domain: Structure and cooperative binding of VP16 subdomains
2M2F	;		;	The membran-proximal domain of ADAM17
2BL2	;	2.1	;	The membrane rotor of the V-type ATPase from Enterococcus hirae
6LY9	;	3.93	;	The membrane-embedded Vo domain of V/A-ATPase from Thermus thermophilus
2M7Y	;		;	The Mengovirus Leader protein
6EJX	;	2.0	;	The metal ion-dependent adhesion site (MIDAS) of the alphaMbeta2 integrin Mac-1 I-domain promiscuously and competitively binds multiple ligands in the regulation of Leukocyte function
4HCB	;	2.0	;	The metal-free form of crystal structure of E.coli ExoI-ssDNA complex
6F1F	;	1.716	;	The methylene thioacetal BPTI (Bovine Pancreatic Trypsin Inhibitor) mutant structure
1GO7	;	2.1	;	The metzincin's methionine: PrtC M226C-E189K double mutant
1GO8	;	2.0	;	The metzincin's methionine: PrtC M226L mutant
2WPD	;	3.432	;	The Mg.ADP inhibited state of the yeast F1c10 ATP synthase
8SDK	;	2.1	;	The MicroED structure of proteinase K crystallized by suspended drop crystallization
6KJN	;		;	The microtubule-binding domains of yeast cytoplasmic dynein in the high affinity state
6KJO	;		;	The microtubule-binding domains of yeast cytoplasmic dynein in the low affinity state
2E35	;		;	the minimized average structure of L11 with rg refinement
8K6T	;	2.8	;	The minor pilin structure of FctB3 in Streptococcus
4IMP	;	2.57	;	The missing linker: a dimerization motif located within polyketide synthase modules
2V50	;	3.0	;	The Missing Part of the Bacterial MexAB-OprM System: Structural determination of the Multidrug Exporter MexB
7BTW	;	2.9	;	The mitochondrial SAM complex from S.cere
7BTX	;	2.8	;	The mitochondrial SAM-Mdm10 supercomplex in GDN micelle from S.cere
7BTY	;	3.2	;	The mitochondrial SAM-Mdm10 supercomplex in Nanodisc from S.cere
4AP0	;	2.594	;	The mitotic kinesin Eg5 in complex with Mg-ADP and ispinesib
8C9Y	;	1.18	;	The MK-RSL - sulfonato-calix[8]arene complex, H32 form
1D2B	;		;	THE MMP-INHIBITORY, N-TERMINAL DOMAIN OF HUMAN TISSUE INHIBITOR OF METALLOPROTEINASES-1 (N-TIMP-1), SOLUTION NMR, 29 STRUCTURES
1DOB	;	2.0	;	THE MOBIL FLAVIN OF 4-OH BENZOATE HYDROXYLASE: MOTION OF A PROSTHETIC GROUP REGULATES CATALYSIS
1DOC	;	2.0	;	THE MOBIL FLAVIN OF 4-OH BENZOATE HYDROXYLASE: MOTION OF A PROSTHETIC GROUP REGULATES CATALYSIS
1DOD	;	2.1	;	THE MOBIL FLAVIN OF 4-OH BENZOATE HYDROXYLASE: MOTION OF A PROSTHETIC GROUP REGULATES CATALYSIS
1DOE	;	2.3	;	THE MOBIL FLAVIN OF 4-OH BENZOATE HYDROXYLASE: MOTION OF A PROSTHETIC GROUP REGULATES CATALYSIS
2BSG	;	15.0	;	The modeled structure of fibritin (gpwac) of bacteriophage T4 based on cryo-EM reconstruction of the extended tail of bacteriophage T4
5OJQ	;	3.7	;	The modeled structure of of wild type extended type VI secretion system sheath/tube complex in vibrio cholerae based on cryo-EM reconstruction of the non-contractile sheath/tube complex
1XXM	;	1.9	;	The modular architecture of protein-protein binding site
4PEP	;	1.8	;	THE MOLECULAR AND CRYSTAL STRUCTURES OF MONOCLINIC PORCINE PEPSIN REFINED AT 1.8 ANGSTROMS RESOLUTION
4U4C	;	2.4	;	The molecular architecture of the TRAMP complex reveals the organization and interplay of its two catalytic activities
4WO4	;	2.5	;	The molecular bases of Delta/Alpha beta T cell-mediated antigen recognition.
4WNQ	;	1.8	;	THE MOLECULAR BASES OF DELTA/ALPHA-BETA T-CELL MEDIATED ANTIGEN RECOGNITION
5A2T	;	5.6	;	The Molecular Basis for Flexibility in the Flexible Filamentous Plant Viruses
1R2A	;		;	THE MOLECULAR BASIS FOR PROTEIN KINASE A ANCHORING REVEALED BY SOLUTION NMR
6RW3	;	3.65	;	The molecular basis for sugar import in malaria parasites.
6C2C	;	1.597	;	The molecular basis for the functional evolution of an organophosphate hydrolysing enzyme
4FDI	;	2.2	;	The molecular basis of mucopolysaccharidosis IV A
4FDJ	;	2.81	;	The molecular basis of mucopolysaccharidosis IV A, complex with GalNAc
2JEG	;	2.38	;	The Molecular Basis of Selectivity of Nucleoside Triphosphate Incorporation Opposite O6-Benzylguanine by Sulfolobus solfataricus DNA Polymerase IV: Steady-state and Pre-steady-state Kinetics and X- Ray Crystallography of Correct and Incorrect Pairing
2JEI	;	2.39	;	The Molecular Basis of Selectivity of Nucleoside Triphosphate Incorporation Opposite O6-Benzylguanine by Sulfolobus solfataricus DNA Polymerase IV: Steady-state and Pre-steady-state Kinetics and X- Ray Crystallography of Correct and Incorrect Pairing
2JEJ	;	1.86	;	The Molecular Basis of Selectivity of Nucleoside Triphosphate Incorporation Opposite O6-Benzylguanine by Sulfolobus solfataricus DNA Polymerase IV: Steady-state and Pre-steady-state Kinetics and X- Ray Crystallography of Correct and Incorrect Pairing
2JEF	;	2.17	;	The Molecular Basis of Selectivity of Nucleotide Triphosphate Incorporation Opposite O6-Benzylguanine by Sulfolobus solfataricus DNA Polymerase IV: Steady-state and Pre-steady-state and X-Ray Crystallography of Correct and Incorrect Pairing
1GKA	;	3.23	;	The molecular basis of the coloration mechanism in lobster shell. beta-crustacyanin at 3.2 A resolution
1OIP	;	1.95	;	The Molecular Basis of Vitamin E Retention: Structure of Human Alpha-Tocopherol Transfer Protein
1OIZ	;	1.88	;	The Molecular Basis of Vitamin E Retention: Structure of Human Alpha-Tocopherol Transfer Protein
1ESC	;	2.1	;	THE MOLECULAR MECHANISM OF ENANTIORECOGNITION BY ESTERASES
1ESD	;	2.3	;	THE MOLECULAR MECHANISM OF ENANTIORECOGNITION BY ESTERASES
1ESE	;	2.4	;	THE MOLECULAR MECHANISM OF ENANTIORECOGNITION BY ESTERASES
5OCE	;	2.41	;	THE MOLECULAR MECHANISM OF SUBSTRATE RECOGNITION AND CATALYSIS OF THE MEMBRANE ACYLTRANSFERASE PatA -- Complex of PatA with palmitate, mannose, and palmitoyl-6-mannose
5UL6	;	1.45	;	The molecular mechanisms by which NS1 of the 1918 Spanish influenza A virus hijack host protein-protein interactions
6ATV	;	1.751	;	The molecular mechanisms by which NS1 of the 1918 Spanish influenza A virus hijack host protein-protein interactions
5BVJ	;	2.0	;	The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta
5BVP	;	2.2	;	The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta
4BW0	;	2.33	;	The molecular recognition of kink turn structure by the L7Ae class of proteins
4C40	;	2.2	;	The molecular recognition of kink turn structure by the L7Ae class of proteins
1D58	;	1.7	;	THE MOLECULAR STRUCTURE OF A 4'-EPIADRIAMYCIN COMPLEX WITH D(TGATCA) AT 1.7 ANGSTROM RESOLUTION-COMPARISON WITH THE STRUCTURE OF 4'-EPIADRIAMYCIN D(TGTACA) AND D(CGATCG) COMPLEXES
1REI	;	2.0	;	THE MOLECULAR STRUCTURE OF A DIMER COMPOSED OF THE VARIABLE PORTIONS OF THE BENCE-JONES PROTEIN REI REFINED AT 2.0 ANGSTROMS RESOLUTION
1VTG	;	1.67	;	THE MOLECULAR STRUCTURE OF A DNA-TRIOSTIN A COMPLEX
1D67	;	1.6	;	THE MOLECULAR STRUCTURE OF AN IDARUBICIN-D(TGATCA) COMPLEX AT HIGH RESOLUTION
1Z24	;	2.6	;	The molecular structure of insecticyanin from the tobacco hornworm Manduca sexta L. at 2.6 A resolution.
1DNH	;	2.25	;	THE MOLECULAR STRUCTURE OF THE COMPLEX OF HOECHST 33258 AND THE DNA DODECAMER D(CGCGAATTCGCG)
2HIP	;	2.5	;	THE MOLECULAR STRUCTURE OF THE HIGH POTENTIAL IRON-SULFUR PROTEIN ISOLATED FROM ECTOTHIORHODOSPIRA HALOPHILA DETERMINED AT 2.5-ANGSTROMS RESOLUTION
4V3P	;	34.0	;	The molecular structure of the left-handed supra-molecular helix of eukaryotic polyribosomes
1DCG	;	1.0	;	THE MOLECULAR STRUCTURE OF THE LEFT-HANDED Z-DNA DOUBLE HELIX AT 1.0 ANGSTROM ATOMIC RESOLUTION. GEOMETRY, CONFORMATION, AND IONIC INTERACTIONS OF D(CGCGCG)
2A0Z	;	2.4	;	The molecular structure of toll-like receptor 3 ligand binding domain
3FIS	;	2.3	;	THE MOLECULAR STRUCTURE OF WILD-TYPE AND A MUTANT FIS PROTEIN: RELATIONSHIP BETWEEN MUTATIONAL CHANGES AND RECOMBINATIONAL ENHANCER FUNCTION OR DNA BINDING
4FIS	;	2.3	;	THE MOLECULAR STRUCTURE OF WILD-TYPE AND A MUTANT FIS PROTEIN: RELATIONSHIP BETWEEN MUTATIONAL CHANGES AND RECOMBINATIONAL ENHANCER FUNCTION OR DNA BINDING
5M35	;	2.38	;	The molecular tweezer CLR01 stabilizes a disordered protein-protein interface
5M36	;	2.45	;	The molecular tweezer CLR01 stabilizes a disordered protein-protein interface
5M37	;	2.35	;	The molecular tweezer CLR01 stabilizes a disordered protein-protein interface
6H74	;	1.801	;	The molybdenum storage protein - L131H
7Z5J	;	2.58	;	The molybdenum storage protein loaded with tungstate
6GX4	;	1.9	;	The molybdenum storage protein: with ATP/Mn2+ and with POM clusters formed under in vitro conditions
1X8H	;	1.6	;	The Mono-Zinc Carbapenemase CphA (N220G mutant) Shows a Zn(II)- NH2 ARG Coordination
1TZ8	;	1.85	;	The monoclinic crystal structure of transthyretin in complex with diethylstilbestrol
2VML	;	2.4	;	The monoclinic structure of phycocyanin from Gloeobacter violaceus
1COM	;	2.2	;	THE MONOFUNCTIONAL CHORISMATE MUTASE FROM BACILLUS SUBTILIS: STRUCTURE DETERMINATION OF CHORISMATE MUTASE AND ITS COMPLEXES WITH A TRANSITION STATE ANALOG AND PREPHENATE, AND IMPLICATIONS ON THE MECHANISM OF ENZYMATIC REACTION
7V9I	;	3.5	;	The Monomer mutant of BEN4 domain of protein Bend3 with DNA
1VAP	;	1.6	;	THE MONOMERIC ASP49 SECRETORY PHOSPHOLIPASE A2 FROM THE VENOM OF AGKISTRIDON PISCIVORUS PISCIVORUS
6LS8	;	2.3	;	The monomeric structure of G80A/H81A/H82A myoglobin
2V5B	;	2.0	;	The monomerization of Triosephosphate Isomerase from Trypanosoma cruzi
1LEM	;	3.0	;	THE MONOSACCHARIDE BINDING SITE OF LENTIL LECTIN: AN X-RAY AND MOLECULAR MODELLING STUDY
3KAR	;	2.3	;	THE MOTOR DOMAIN OF KINESIN-LIKE PROTEIN KAR3, A SACCHAROMYCES CEREVISIAE KINESIN-RELATED PROTEIN
7VDT	;	2.8	;	The motor-nucleosome module of human chromatin remodeling PBAF-nucleosome complex
6X59	;	2.98	;	The mouse cGAS catalytic domain binding to human assembled nucleosome
6X5A	;	4.36	;	The mouse cGAS catalytic domain binding to human nucleosome that purified from HEK293T cells
5XM0	;	2.874	;	The mouse nucleosome structure containing H2A, H2B type3-A, H3.3, and H4
5XM1	;	3.45	;	The mouse nucleosome structure containing H2A, H2B type3-A, H3mm7, and H4
5B1M	;	2.34	;	The mouse nucleosome structure containing H3.1
7DBH	;	3.6	;	The mouse nucleosome structure containing H3mm18
7VBM	;	3.4	;	The mouse nucleosome structure containing H3mm18 aided by PL2-6 scFv
5B1L	;	2.35	;	The mouse nucleosome structure containing H3t
2F4M	;	1.85	;	The Mouse PNGase-HR23 Complex Reveals a Complete Remodulation of the Protein-Protein Interface Compared to its Yeast Orthologs
2F4O	;	2.26	;	The Mouse PNGase-HR23 Complex Reveals a Complete Remodulation of the Protein-Protein Interface Compared to its Yeast Orthologs
1U0O	;	2.7	;	The mouse von Willebrand Factor A1-botrocetin complex
7ML9	;	1.94	;	The Mpp75Aa1.1 beta-pore-forming protein from Brevibacillus laterosporus
3QF7	;	1.9	;	The Mre11:Rad50 complex forms an ATP dependent molecular clamp in DNA double-strand break repair
3QG5	;	3.4	;	The Mre11:Rad50 complex forms an ATP dependent molecular clamp in DNA double-strand break repair
7QGK	;	1.5	;	The mRubyFT protein, Genetically Encoded Blue-to-Red Fluorescent Timer in its red state
3NSY	;	2.1	;	The multi-copper oxidase CueO with six Met to Ser mutations (M358S,M361S,M362S,M364S,M366S,M368S)
2ZOY	;	1.9	;	The multi-drug binding transcriptional repressor CgmR (CGL2612 protein) from C.glutamicum
2PBI	;	1.95	;	The multifunctional nature of Gbeta5/RGS9 revealed from its crystal structure
3C1O	;	1.8	;	The multiple phenylpropene synthases in both Clarkia breweri and Petunia hybrida represent two distinct lineages
3C3X	;	2.15	;	The multiple phenylpropene synthases in both Clarkia breweri and Petunia hybrida represent two distinct lineages
2NR2	;		;	The MUMO (minimal under-restraining minimal over-restraining) method for the determination of native states ensembles of proteins
4Z0L	;	2.29	;	The murine cyclooxygenase-2 complexed with a nido-dicarbaborate-containing indomethacin derivative
2GGL	;	2.4	;	The mutant A222C of Agrobacterium radiobacter N-carbamoyl-D-amino acid amidohydrolase
2GGK	;	2.3	;	The mutant A302C of Agrobacterium radiobacter N-carbamoyl-D-amino-acid amidohydrolase
2GGG	;	2.4	;	The mutant A68C-D72C of Deinococcus Radiodurans N-acylamino acid racemase
2GGH	;	2.2	;	The mutant A68C-D72C-NLQ of Deinococcus Radiodurans Nacylamino acid racemase
7WH6	;	1.58	;	The mutant crystal structure of b-1,4-Xylanase (XynAF1_N179S)
7WH7	;	1.44	;	The mutant crystal structure of b-1,4-Xylanase (XynAF1_N179S) with xylotetraose
7WHA	;	1.83	;	The mutant crystal structure of b-1,4-Xylanase (XynAF1_R246K)
7WHE	;	1.75	;	The mutant crystal structure of b-1,4-Xylanase (XynAF1_R246K) with xylobiose
3WUF	;	2.04	;	The mutant crystal structure of b-1,4-Xylanase (XynAS9_V43P/G44E) from Streptomyces sp. 9
3WUG	;	1.88	;	The mutant crystal structure of b-1,4-Xylanase (XynAS9_V43P/G44E) with xylobiose from Streptomyces sp. 9
6KVH	;	1.2	;	The mutant crystal structure of endo-polygalacturonase (T284A) from Talaromyces leycettanus JCM 12802
7E56	;	1.4	;	The mutant crystal structure of endo-polygalacturonase (T316C/G344C) from Talaromyces leycettanus JCM 12802
1CSA	;		;	THE MUTANT E.COLI F112W CYCLOPHILIN BINDS CYCLOSPORIN A IN NEARLY IDENTICAL CONFORMATION AS HUMAN CYCLOPHILIN
2GGI	;	2.2	;	The mutant E149C-A182C of Deinococcus Radiodurans N-acylamino acid racemase
7DL0	;	2.17	;	The mutant E310G/A314Y of 3,5-DAHDHcca complex with NADPH
7DL1	;	2.72	;	The mutant E310G/G323S structure of 3,5-DAHDHcca complex with NADPH
2FKP	;	2.0	;	The mutant G127C-T313C of Deinococcus Radiodurans N-acylamino acid racemase
7DXO	;	2.4	;	The mutant of bifunctional thioesterase catalyzing epimerization and cyclization
6LAX	;	2.7	;	the mutant SAM-VI riboswitch (U6C) bound to SAM
8IKZ	;	1.75	;	The mutant structure of DHAD
8HS0	;	1.42	;	The mutant structure of DHAD V178W
3T1D	;	2.3	;	The mutant structure of human Siderocalin W79A, R81A, Y106F bound to Enterobactin
4KQE	;	2.739	;	The mutant structure of the human glycyl-tRNA synthetase E71G
7WI1	;	1.61	;	The mutant variant of PNGM-1, H93 was substituuted for alanine to study metal coordination
7BZ3	;	2.0	;	The mutant variant of PNGM-1. H257 was substituted for alanine to study substrate binding.
7BZ4	;	2.16	;	The mutant variant of PNGM-1. H279 was substituted for alanine to study metal coordination.
7BYQ	;	1.96	;	The mutant variant of PNGM-1. H279A was substituted for alanine to study metal coordination.
7BZI	;	1.94	;	The mutant variant of PNGM-1. H91 was substituted for alanine to study metal coordination.
7BZ1	;	2.45	;	The mutant variant of PNGM-1. H96 was substituted for alanine to study metal coordination.
2GGJ	;	2.5	;	The mutant Y218C of Deinococcus Radiodurans N-acylamino acid racemase
4L4P	;	1.9	;	the mutant(E139A) structure in complex with xylotriose
1CMY	;	3.0	;	THE MUTATION BETA99 ASP-TYR STABILIZES Y-A NEW, COMPOSITE QUATERNARY STATE OF HUMAN HEMOGLOBIN
6W6G	;	3.1	;	The Mycobacterium tuberculosis ClpB disaggregase hexamer structure in conformation I in the presence of DnaK chaperone and a model substrate
6W6H	;	3.3	;	The Mycobacterium tuberculosis ClpB disaggregase hexamer structure in conformation II in the presence of DnaK chaperone and a model substrate
6W6I	;	3.5	;	The Mycobacterium tuberculosis ClpB disaggregase hexamer structure in conformation T in the presence of DnaK chaperone and a model substrate
6W6E	;	3.7	;	The Mycobacterium tuberculosis ClpB disaggregase hexamer structure with a locally refined ClpB middle domain and a DnaK nucleotide binding domain
6W6J	;	3.2	;	The Mycobacterium tuberculosis ClpB disaggregase hexamer structure with a locally refined N-terminal domain in the presence of DnaK chaperone and a model substrate
7L6N	;	7.0	;	The Mycobacterium tuberculosis ClpB disaggregase hexamer structure with three locally refined ClpB middle domains and three DnaK nucleotide binding domains
2KSQ	;		;	The myristoylated yeast ARF1 in a GTP and bicelle bound conformation
6LW2	;	2.4	;	The N-arylsulfonyl-indole-2-carboxamide-based inhibitors against fructose-1,6-bisphosphatase
7CVN	;	2.75	;	The N-arylsulfonyl-indole-2-carboxamide-based inhibitors against fructose-1,6-bisphosphatase
2MV3	;		;	The N-domain of the AAA metalloproteinase Yme1 from Saccharomyces cerevisiae
1AHA	;	2.2	;	THE N-GLYCOSIDASE MECHANISM OF RIBOSOME-INACTIVATING PROTEINS IMPLIED BY CRYSTAL STRUCTURES OF ALPHA-MOMORCHARIN
1AHB	;	2.2	;	THE N-GLYCOSIDASE MECHANISM OF RIBOSOME-INACTIVATING PROTEINS IMPLIED BY CRYSTAL STRUCTURES OF ALPHA-MOMORCHARIN
1AHC	;	2.0	;	THE N-GLYCOSIDASE MECHANISM OF RIBOSOME-INACTIVATING PROTEINS IMPLIED BY CRYSTAL STRUCTURES OF ALPHA-MOMORCHARIN
7EXM	;	1.96	;	The N-terminal crystal structure of SARS-CoV-2 NSP2
3QQ6	;	1.9	;	The N-terminal DNA binding domain of SinR from Bacillus subtilis
1E7N	;	2.35	;	The N-terminal domain of beta-B2-crystallin resembles the putative ancestral homodimer
2VZ4	;	2.9	;	The N-terminal domain of MerR-like protein TipAL bound to promoter DNA
6O1Q	;		;	The N-terminal domain of NPHP1 folds into an antiparallel three-stranded coiled coil
8CTF	;	2.14	;	The N-terminal domain of PA endonuclease from the influenza H1N1 viral polymerase in complex with 3-hydroxy-4-oxo-1,4-dihydropyridine-2-carboxylic acid
8DDE	;	2.22	;	The N-terminal domain of PA endonuclease from the influenza H1N1 viral polymerase in complex with 4-(benzyloxy)-6-bromo-2-(1H-tetrazol-5-yl) yridine-3-ol
8DDB	;	2.15	;	The N-terminal domain of PA endonuclease from the influenza H1N1 viral polymerase in complex with 4-(benzyloxy)-6-bromo-3-hydroxypicolinic acid
8DAL	;	2.2	;	The N-terminal domain of PA endonuclease from the influenza H1N1 viral polymerase in complex with 4-(benzyloxy)-6-bromo-3-hydroxypicolinonitrile
8DJY	;	2.5	;	The N-terminal domain of PA endonuclease from the influenza H1N1 viral polymerase in complex with 6-Bromo-2-(4,5-dihydro-1H-imidazol-2-yl)-3-hydroxypyridin-4(1H)-one
8DHN	;	2.4	;	The N-terminal domain of PA endonuclease from the influenza H1N1 viral polymerase in complex with 6-Bromo-3-hydroxy-2-(5-methyl-1,2,4-oxadiazol-3-yl)pyridin-4(1H)-one
7V04	;	1.91	;	The N-terminal domain of PA endonuclease from the influenza H1N1 viral polymerase in complex with 6-bromo-3-hydroxy-4-oxo-1,4-dihydropyridine-2-carboxamide
8DJV	;	2.08	;	The N-terminal domain of PA endonuclease from the influenza H1N1 viral polymerase in complex with 6-Bromo-3-hydroxy-N-methoxy-4-oxo-1,4-dihydropyridine-2-carboxamide
6E6X	;	2.5	;	The N-terminal domain of PA endonuclease from the influenza H1N1 virus in complex with 1-(4-(1H-tetrazol-5-yl)phenyl)-5-hydroxy-2-methylpyridin-4(1H)-one
6DCZ	;	2.89	;	The N-terminal domain of PA endonuclease from the influenza H1N1 virus in complex with 3-hydroxy-4-oxo-4H-pyran-2-carboxylic acid
6E3N	;	3.19	;	The N-terminal domain of PA endonuclease from the influenza H1N1 virus in complex with 3-hydroxy-4-oxo-6-(o-tolyl)-1,4-dihydropyridine-2-carboxylic acid
6E6W	;	2.35	;	The N-terminal domain of PA endonuclease from the influenza H1N1 virus in complex with 3-hydroxy-6-(2-methyl-4-(1H-tetrazol-5-yl)phenyl)-4-oxo-1,4-dihydropyridine-2-carboxylic acid
6E4C	;	2.35	;	The N-terminal domain of PA endonuclease from the influenza H1N1 virus in complex with 3-hydroxy-6-(2-methyl-4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl)-4-oxo-1,4-dihydropyridine-2-carboxylic acid
6E6V	;	2.25	;	The N-terminal domain of PA endonuclease from the influenza H1N1 virus in complex with 3-hydroxy-6-methyl-4-oxo-1,4-dihydropyridine-2-carboxylic acid
6DZQ	;	2.25	;	The N-terminal domain of PA endonuclease from the influenza H1N1 virus in complex with 3-hydroxy-6-methyl-4-oxo-4H-pyran-2-carboxylic acid
6E0Q	;	2.35	;	The N-terminal domain of PA endonuclease from the influenza H1N1 virus in complex with 4,6-dihydroxy-2-methyl-5-oxocyclohepta-1,3,6-triene-1-carboxylic acid
6DCY	;	2.08	;	The N-terminal domain of PA endonuclease from the influenza H1N1 virus in complex with 5-hydroxy-2-methyl-4-oxo-4H-pyran-3-carboxylic acid
6E3O	;	3.19	;	The N-terminal domain of PA endonuclease from the influenza H1N1 virus in complex with 6-(2-ethylphenyl)-3-hydroxy-4-oxo-1,4-dihydropyridine-2-carboxylic acid
6E3P	;	2.8	;	The N-terminal domain of PA endonuclease from the influenza H1N1 virus in complex with 6-(3-(1H-tetrazol-5-yl)phenyl)-3-hydroxy-4-oxo-1,4-dihydropyridine-2-carboxylic acid
6E3M	;	2.65	;	The N-terminal domain of PA endonuclease from the influenza H1N1 virus in complex with 6-(3-carboxyphenyl)-3-hydroxy-4-oxo-1,4-dihydropyridine-2-carboxylic acid
6R0J	;		;	The N-terminal domain of rhomboid protease YqgP
1PKV	;	2.6	;	The N-terminal domain of riboflavin synthase in complex with riboflavin
3DNS	;	2.1	;	The N-terminal domain of Ribosomal-protein-alanine acetyltransferase from Clostridium acetobutylicum ATCC 824
4WT3	;	1.954	;	The N-terminal domain of Rubisco Accumulation Factor 1 from Arabidopsis thaliana
4C0Z	;	2.0	;	The N-terminal domain of the Streptococcus pyogenes pilus tip adhesin Cpa
4ZYA	;	1.65	;	The N-terminal extension domain of human asparaginyl-tRNA synthetase
3K3C	;	1.62	;	The N-terminal PAS domain crystal structure of Rv1364c from Mycobacterium tuberculosis at 1.62
3K3D	;	2.3	;	The N-terminal PAS domain crystal structure of RV1364C from Mycobacterium Tuberculosis at 2.3 angstrom
8HT7	;		;	The N-terminal region of Cdc6 specifically recognizes human DNA G-quadruplex
6YI3	;		;	The N-terminal RNA-binding domain of the SARS-CoV-2 nucleocapsid phosphoprotein
8FK2	;	2.29	;	The N-terminal VicR from Streptococcus mutans
5LGG	;	2.15	;	The N-terminal WD40 domain of Apc1 (Anaphase promoting complex subunit 1)
7CKF	;	2.284	;	The N-terminus of interferon-inducible antiviral protein-dimer
7K1S	;	3.9	;	The N-terminus of varicella-zoster virus glycoprotein B has a functional role in fusion.
5YKB	;	2.76	;	The N253F mutant structure of trehalose synthase from Deinococcus radiodurans reveals an open active-site conformation
5GTW	;	2.93	;	The N253R mutant structures of trehalose synthase from Deinococcus radiodurans display two different active-site conformations
8BJP	;	2.1	;	The N288D mutant cytoplasmic PAS domain of Geobacillus thermodenitrificans histidine kinase CitA
8T48	;	2.0	;	The N4BP1 CUE-like domain in complex with linear di-Ubiquitin
1JRC	;	1.8	;	The N67A mutant of Lactococcus lactis dihydroorotate dehydrogenase A
2VND	;	1.7	;	The N69Q mutant of Vibrio cholerae endonuclease I
3SWM	;	4.25	;	The NAC domain of ANAC019 in complex with DNA, gold derivative
6JKH	;	3.0	;	The NAD+-bound form of human NSDHL
6JKG	;	2.9	;	The NAD+-free form of human NSDHL
7CAT	;	2.5	;	The NADPH binding site on beef liver catalase
8CAT	;	2.5	;	The NADPH binding site on beef liver catalase
7VEM	;	2.39	;	the NADPH-assisted quinone oxidoreductase from Phytophthora capsici
6EFV	;	2.341	;	The NADPH-dependent sulfite reductase flavoprotein adopts an extended conformation that is unique to this diflavin reductase
4KVM	;	2.597	;	The NatA (Naa10p/Naa15p) amino-terminal acetyltransferase complex bound to a bisubstrate analog
4KVO	;	3.15	;	The NatA (Naa10p/Naa15p) amino-terminal acetyltrasferase complex bound to AcCoA
4HNW	;	2.801	;	The NatA Acetyltransferase Complex Bound To Inositol Hexakisphosphate
4HNX	;	2.339	;	The NatA Acetyltransferase Complex Bound To ppGpp
5K18	;	2.73	;	The NatB Acetyltransferase Complex Bound To bisubstrate inhibitor
5K04	;	2.4	;	The NatB Acetyltransferase Complex Bound To CoA and MES
5LYU	;	2.2	;	The native crystal structure of 7SK 5'-hairpin
7DAV	;	1.77	;	The native crystal structure of COVID-19 main protease
5YJZ	;	2.16	;	The native crystal structure of Rv3197 from Mycobacterium tuberculosis
2WDW	;	3.21	;	The Native Crystal Structure of the Primary Hexose Oxidase (Dbv29) in Antibiotic A40926 Biosynthesis
2J5G	;	1.46	;	The Native structure of a beta-Diketone Hydrolase from the Cyanobacterium Anabaena sp. PCC 7120
8FDP	;	1.88	;	The native structure of a dodecamer: 5'-CGCAAATTTGCG-3
7FIP	;	2.39	;	The native structure of beta-1,2-mannobiose phosphorylase from Thermoanaerobacter sp.
5A55	;	1.85	;	The native structure of GH101 from Streptococcus pneumoniae TIGR4
4PZ9	;	1.94	;	The native structure of mycobacterial glucosyl-3-phosphoglycerate phosphatase Rv2419c
4RVS	;	1.8464	;	The native structure of mycobacterial quinone oxidoreductase Rv154c.
4RVU	;	1.7988	;	The native structure of mycobacterial Rv1454c complexed with NADPH
5K7C	;	2.73	;	The native structure of native pistol ribozyme
4UZN	;	2.46	;	The native structure of the family 46 carbohydrate-binding module (CBM46) of endo-beta-1,4-glucanase B (Cel5B) from Bacillus halodurans
2Y73	;	2.6	;	THE NATIVE STRUCTURES OF SOLUBLE HUMAN PRIMARY AMINE OXIDASE AOC3
2ZP8	;	3.2	;	The Nature of the TRAP:Anti-TRAP complex
2ZP9	;	3.2	;	The Nature of the TRAP:Anti-TRAP complex
7KJK	;	3.6	;	The Neck region of Phage XM1 (6-fold symmetry)
5JVS	;	2.248	;	The neck-linker + DAL and alpha 7 helix of Drosophila melanogaster Kinesin-1 fused to EB1
5JVU	;	1.948	;	The neck-linker and alpha 7 helix of Drosophila melanogaster kinesin-1 fused to EB1
5JVP	;	2.1	;	The neck-linker and alpha 7 helix of Homo sapiens CENP-E
5JV3	;	2.006	;	The neck-linker and alpha 7 helix of Homo sapiens Eg5 fused to EB1
5JX1	;	1.67	;	The neck-linker and alpha 7 helix of Mus musculus KIF3A fused to EB1
5JVM	;	1.567	;	The neck-linker and alpha 7 helix of Mus musculus KIF3C
5JVR	;	2.1	;	The neck-linker of Mus musculus KIF3A fused to the alpha 7 helix of Drosophila melanogaster Kinesin-1 fused to EB1
3Q3L	;	2.5	;	The neutron crystallographic structure of inorganic pyrophosphatase from Thermococcus thioreducens
2YZ4	;	2.2	;	The neutron structure of concanavalin A at 2.2 Angstroms
7D3C	;	2.2	;	The newly emerged SARS-like coronavirus HCoV-EMC also has an ""Achilles' heel"": current effective inhibitor targeting a 3C-like protease
4AWL	;	3.08	;	The NF-Y transcription factor is structurally and functionally a sequence specific histone
7DGL	;	1.91	;	The Ni-bound dimeric structure of K78H/G80A/H82A myoglobin
5FMN	;	2.4	;	The nickel-responsive transcriptional regulator InrS
1RNL	;	2.4	;	THE NITRATE/NITRITE RESPONSE REGULATOR PROTEIN NARL FROM NARL
1FP6	;	2.15	;	THE NITROGENASE FE PROTEIN FROM AZOTOBACTER VINELANDII COMPLEXED WITH MGADP
2EU0	;		;	The NMR ensemble structure of the Itk SH2 domain bound to a phosphopeptide
2LSU	;		;	The NMR high resolution structure of yeast Tah1 in a free form
2LSV	;		;	The NMR high resolution structure of yeast Tah1 in complex with the Hsp90 C-terminal tail
2ETZ	;		;	The NMR minimized average structure of the Itk SH2 domain bound to a phosphopeptide
1SHP	;		;	THE NMR SOLUTION STRUCTURE OF A KUNITZ-TYPE PROTEINASE INHIBITOR FROM THE SEA ANEMONE STICHODACTYLA HELIANTHUS
1YYJ	;		;	The NMR solution structure of a redesigned apocytochrome b562:Rd-apocyt b562
1IDI	;		;	THE NMR SOLUTION STRUCTURE OF ALPHA-BUNGAROTOXIN
1IDL	;		;	THE NMR SOLUTION STRUCTURE OF ALPHA-BUNGAROTOXIN
6CWS	;		;	The NMR solution structure of CCL28
1DTK	;		;	THE NMR SOLUTION STRUCTURE OF DENDROTOXIN K FROM THE VENOM OF DENDROASPIS POLYLEPIS POLYLEPIS
1HIC	;		;	THE NMR SOLUTION STRUCTURE OF HIRUDIN(1-51) AND COMPARISON WITH CORRESPONDING THREE-DIMENSIONAL STRUCTURES DETERMINED USING THE COMPLETE 65-RESIDUE HIRUDIN POLYPEPTIDE CHAIN
2N5W	;		;	The NMR solution structure of octyl-tridecaptin A1 in DPC micelles
2JOO	;		;	The NMR Solution Structure of Recombinant RGD-hirudin
5JN6	;		;	The NMR Solution Structure of RPA3313
1F2G	;		;	THE NMR SOLUTION STRUCTURE OF THE 3FE FERREDOXIN II FROM DESULFOVIBRIO GIGAS, 15 STRUCTURES
1IDG	;		;	THE NMR SOLUTION STRUCTURE OF THE COMPLEX FORMED BETWEEN ALPHA-BUNGAROTOXIN AND AN 18MER COGNATE PEPTIDE
1IDH	;		;	THE NMR SOLUTION STRUCTURE OF THE COMPLEX FORMED BETWEEN ALPHA-BUNGAROTOXIN AND AN 18MER COGNATE PEPTIDE
1BW5	;		;	THE NMR SOLUTION STRUCTURE OF THE HOMEODOMAIN OF THE RAT INSULIN GENE ENHANCER PROTEIN ISL-1, 50 STRUCTURES
2KCF	;		;	The NMR solution structure of the isolated Apo Pin1 WW domain
6FGM	;		;	The NMR solution structure of the peptide AC12 from Hypsiboas raniceps
1ERC	;		;	THE NMR SOLUTION STRUCTURE OF THE PHEROMONE ER-1 FROM THE CILIATED PROTOZOAN EUPLOTES RAIKOVI
1ERD	;		;	THE NMR SOLUTION STRUCTURE OF THE PHEROMONE ER-2 FROM THE CILIATED PROTOZOAN EUPLOTES RAIKOVI
2LWP	;		;	The NMR solution structure of the the ubiquitin homology domain of mouse BAG-1
1T3V	;		;	The NMR solution structure of TM1816
2LM9	;		;	The NMR structure of a major allergen from dust mite
1SA8	;		;	THE NMR STRUCTURE OF A STABLE AND COMPACT ALL-beta-SHEET VARIANT OF INTESTINAL FATTY ACID-BINDING PROTEIN
2K2R	;		;	The NMR structure of alpha-parvin CH2/paxillin LD1 complex
2H49	;		;	The NMR Structure of an Internal Loop from 23S Ribosomal RNA of Deinococcus radiodurans Differs from the Structure in the Crystal of the Ribosomal Subunit
5GGM	;		;	The NMR structure of calmodulin in CTAB reverse micelles
1T8V	;		;	The NMR structure of d34a i-fabp: implications for the determinants of ligand binding stoichiometry
1DUF	;		;	THE NMR STRUCTURE OF DNA DODECAMER DETERMINED IN AQUEOUS DILUTE LIQUID CRYSTALLINE PHASE
1GIP	;		;	THE NMR STRUCTURE OF DNA DODECAMER DETERMINED IN AQUEOUS DILUTE LIQUID CRYSTALLINE PHASE
1PD6	;		;	The NMR structure of domain C2 of human cardiac Myosin Binding Protein C
7YFS	;		;	The NMR structure of noursin, a tricyclic ribosomal peptide containing a histidine-to-butyrine crosslink
8HZW	;		;	The NMR structure of noursinH11W peptide
6HJ7	;		;	The NMR structure of NRADD death domain
2KSV	;		;	The NMR structure of protein-glutaminase from Chryseobacterium proteolyticum
2OV6	;		;	The NMR structure of subunit F of the Methanogenic A1Ao ATP synthase and its interaction with the nucleotide-binding subunit B
1DZ5	;		;	The NMR structure of the 38KDa U1A protein-PIE RNA complex reveals the basis of cooperativity in regulation of polyadenylation by human U1A protein
1PBA	;		;	THE NMR STRUCTURE OF THE ACTIVATION DOMAIN ISOLATED FROM PORCINE PROCARBOXYPEPTIDASE B
2KWC	;		;	The NMR structure of the autophagy-related protein Atg8
7BV9	;		;	The NMR structure of the BEN domain from human NAC1
2M5B	;		;	The NMR structure of the BID-BAK complex
5FRG	;		;	The NMR Structure of the Cdc42-interacting region of TOCA1
5K6P	;		;	The NMR structure of the m domain tri-helix bundle and C2 of human cardiac Myosin Binding Protein C
8C8A	;		;	The NMR structure of the MAX28 effector from Magnaporthe oryzae
7ZKD	;		;	The NMR structure of the MAX47 effector from Magnaporthe Oryzae
7ZK0	;		;	The NMR structure of the MAX60 effector from Magnaporthe Oryzae
7ZJY	;		;	The NMR structure of the MAX67 effector from Magnaporthe Oryzae
6AHZ	;		;	The NMR Structure of the Polysialyltranseferase Domain (PSTD) in Polysialyltransferase ST8siaIV
2LA3	;		;	The NMR structure of the protein NP_344798.1 reveals a CCA-adding enzyme head domain
1SPF	;		;	THE NMR STRUCTURE OF THE PULMONARY SURFACTANT-ASSOCIATED POLYPEPTIDE SP-C IN AN APOLAR SOLVENT CONTAINS A VALYL-RICH ALPHA-HELIX
1A63	;		;	THE NMR STRUCTURE OF THE RNA BINDING DOMAIN OF E.COLI RHO FACTOR SUGGESTS POSSIBLE RNA-PROTEIN INTERACTIONS, 10 STRUCTURES
2MS3	;		;	The NMR structure of the rubredoxin domain of the NO Reductase Flavorubredoxin from Escherichia coli
2RPI	;		;	The NMR structure of the submillisecond folding intermediate of the Thermus thermophilus ribonuclease H
2KE4	;		;	The NMR structure of the TC10 and Cdc42 interacting domain of CIP4
7OMK	;		;	The NMR structure of the Zf-GRF domains from the mouse Endonuclease VIII-LIKE 3 (mNEIL3)
2IRN	;		;	The NMR Structures of (rGCUGAGGCU)2 and (rGCGGAUGCU)2
2IRO	;		;	The NMR Structures of (rGCUGAGGCU)2 and (rGCGGAUGCU)2
2HFH	;		;	THE NMR STRUCTURES OF A WINGED HELIX PROTEIN: GENESIS, 20 STRUCTURES
1QDI	;		;	THE NMR STUDY OF DNA QUADRUPLEX STRUCTURE, (12MER) DNA
1QDK	;		;	THE NMR STUDY OF DNA QUADRUPLEX STRUCTURE, (12MER) DNA
1QDF	;		;	THE NMR STUDY OF DNA QUADRUPLEX STRUCTURE, APTAMER (15MER) DNA
1QDH	;		;	THE NMR STUDY OF DNA QUADRUPLEX STRUCTURE, APTAMER (15MER) DNA
1K8V	;		;	The NMR-derived Conformation of Neuropeptide F from Moniezia expansa
1U6C	;		;	The NMR-derived solution structure of the (2S,3S)-N6-(2,3,4-trihydroxybutyl)-2'-deoxyadenosyl DNA adduct of butadiene diol epoxide
3EW0	;	1.4	;	The novel 2Fe-2S outer mitochondrial protein mitoNEET displays conformational flexibility in its N-terminal cytoplasmic tethering domain
3JD7	;	3.9	;	The novel asymmetric entry intermediate of a picornavirus captured with nanodiscs
2WOZ	;	2.0	;	The novel beta-propeller of the BTB-Kelch protein Krp1 provides the binding site for Lasp-1 that is necessary for pseudopodia extension
2LOZ	;		;	The novel binding mode of DLC1 and Tensin2 PTB domain
3ZG6	;	2.2	;	The novel de-long chain fatty acid function of human sirt6
7Z9P	;	2.2	;	The novel DNA binding mechanism of ridinilazole, a precision Clostridiodes difficile antibiotic
4ZKK	;	1.801	;	The novel double-fold structure of d(GCATGCATGC)
5GLG	;	1.8	;	The novel function of Osm1 under anaerobic condition in the ER was revealed by crystal structure of Osm1, a soluble fumarate reductase in yeast
7W0W	;	2.247	;	The novel membrane-proximal sensing mechanism in a broad-ligand binding chemoreceptor McpA of Bacillus velezensis
5KJ2	;	1.95	;	The novel p300/CBP inhibitor A-485 uncovers a unique mechanism of action to target AR in castrate resistant prostate cancer
5CPR	;	2.22	;	The novel SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity
2P7F	;	2.35	;	The Novel Use of a 2',5'-Phosphodiester Linkage as a Reaction Intermediate at the Active Site of a Small Ribozyme
6LPA	;	2.105	;	The nsp1 protein of a new porcine coronavirus
7BV2	;	2.5	;	The nsp12-nsp7-nsp8 complex bound to the template-primer RNA and triphosphate form of Remdesivir(RTP)
7YFP	;	4.0	;	The NuA4 histone acetyltransferase complex from S. cerevisiae
1FVL	;		;	THE NUCLEAR MAGNETIC RESONANCE SOLUTION STRUCTURE OF FLAVORIDIN, AN ANTAGONIST OF THE PLATELET GP IIB-IIIA RECEPTOR
1UUT	;	2.0	;	The Nuclease Domain of Adeno-Associated Virus Rep Complexed with the RBE' Stemloop of the Viral Inverted Terminal Repeat
8AC8	;	1.6	;	The nucleoprotein complex of Rep protein with DUE ssDNA
8AAN	;	2.19	;	The nucleoprotein complex of Rep protein with iteron containing dsDNA and DUE ssDNA.
1E2H	;	1.9	;	The nucleoside binding site of Herpes simplex type 1 thymidine kinase analyzed by X-ray crystallography
1E2I	;	1.9	;	The nucleoside binding site of Herpes simplex type 1 thymidine kinase analyzed by X-ray crystallography
1E2J	;	2.5	;	The nucleoside binding site of Herpes simplex type 1 thymidine kinase analyzed by X-ray crystallography
3A6N	;	2.7	;	The nucleosome containing a testis-specific histone variant, human H3T
3WA9	;	3.07	;	The nucleosome containing human H2A.Z.1
3WAA	;	3.2	;	The nucleosome containing human H2A.Z.2
4Z5T	;	2.8	;	The nucleosome containing human H3.5
3WKJ	;	2.8	;	The nucleosome containing human TSH2B
6V2K	;	2.6	;	The nucleosome structure after H2A-H2B exchange
5B40	;	3.33	;	The nucleosome structure containing H2B-K120 and H4-K31 monoubiquitinations
7Y8R	;	4.4	;	The nucleosome-bound human PBAF complex
6OBY	;	2.87	;	The nucleotide-binding protein AF_226 in complex with ADP from Archaeoglobus fulgidus with Co found by PIXE. Based on 3KB1.
6AL1	;	3.2	;	The NZ-1 Fab complexed with the PDZ tandem fragment of A. aeolicus S2P homolog with the PA12 tag inserted between the residues 181 and 184
6ICC	;	2.0	;	The NZ-1 Fab complexed with the PDZ tandem fragment of A. aeolicus S2P homolog with the PA12 tag inserted between the residues 181 and 186
6ICF	;	4.0	;	The NZ-1 Fab complexed with the PDZ tandem fragment of A. aeolicus S2P homolog with the PA12 tag inserted between the residues 263 and 266
6AL0	;	2.6	;	The NZ-1 Fab complexed with the PDZ tandem fragment of A. aeolicus S2P homolog with the PA12 tag inserted between the residues 263 and 267
7CQC	;	2.5	;	The NZ-1 Fab complexed with the PDZ tandem fragment of A. aeolicus S2P homolog with the PA14 tag inserted between the residues 181 and 184
7CQD	;	3.2	;	The NZ-1 Fab complexed with the PDZ tandem fragment of A. aeolicus S2P homolog with the PA14 tag inserted between the residues 235 and 236
1OTC	;	2.8	;	THE O. NOVA TELOMERE END BINDING PROTEIN COMPLEXED WITH SINGLE STRAND DNA
3IWM	;	3.2	;	The octameric SARS-CoV main protease
4AA6	;	2.6	;	The oestrogen receptor recognizes an imperfectly palindromic response element through an alternative side-chain conformation
1ORF	;	2.4	;	The Oligomeric Structure of Human Granzyme A Reveals the Molecular Determinants of Substrate Specificity
6EZE	;	2.47	;	The open conformation of E.coli Elongation Factor Tu in complex with GDPNP.
7CY2	;	2.75	;	The open conformation of MSMEG_1954 from Mycobacterium smegmatis
8E4L	;	3.32	;	The open state mouse TRPM8 structure in complex with the cooling agonist C3, AITC, and PI(4,5)P2
6K8B	;	2.21	;	The open state of RGLG1 VWA domain
8HMG	;	2.81	;	The open state of RGLG2-VWA
8Q3K	;	2.92	;	The open state of the ASFV apo-RNA polymerase
2VV5	;	3.45	;	The open structure of MscS
2O7L	;	2.5	;	The open-cap conformation of GlpG
8CG4	;	2.6	;	The organise full-length structure of the fungal non-reducing polyketide synthase (NR-PKS) PksA
2NL8	;	2.3	;	The origin binding domain of the SV40 large T antigen bound non specifically to a 17 bp palindrome DNA (sites 1 and 3)
2ITL	;	1.65	;	The origin binding domain of the SV40 large T antigen bound to the functional pen palindrome DNA (23 bp)
3S71	;	1.25	;	The origin of the hydrophobic effect in the molecular recognition of arylsulfonamides by carbonic anhydrase
3S72	;	1.6	;	The origin of the hydrophobic effect in the molecular recognition of arylsulfonamides by carbonic anhydrase
3S73	;	1.75	;	The origin of the hydrophobic effect in the molecular recognition of arylsulfonamides by carbonic anhydrase
3S74	;	1.4	;	The origin of the hydrophobic effect in the molecular recognition of arylsulfonamides by carbonic anhydrase
3S75	;	1.5	;	The origin of the hydrophobic effect in the molecular recognition of arylsulfonamides by carbonic anhydrase
3S76	;	1.6	;	The origin of the hydrophobic effect in the molecular recognition of arylsulfonamides by carbonic anhydrase
3S77	;	1.86	;	The origin of the hydrophobic effect in the molecular recognition of arylsulfonamides by carbonic anhydrase
3S78	;	1.98	;	The origin of the hydrophobic effect in the molecular recognition of arylsulfonamides by carbonic anhydrase
1TT6	;	1.8	;	The orthorhombic crystal structure of transthyretin in complex with diethylstilbestrol
7Y5M	;	1.5	;	The OTU domain of Tacheng Tick Virus 1
8GVF	;	3.09	;	The outward-facing structure of hAE2 in basic pH
7VDV	;	3.4	;	The overall structure of human chromatin remodeling PBAF-nucleosome complex
6M1Y	;	3.2	;	The overall structure of KCC3
7CGE	;	2.9	;	The overall structure of nucleotide free MlaFEDB complex
7CH1	;	2.6	;	The overall structure of SLC26A9
7CH0	;	3.7	;	The overall structure of the MlaFEDB complex in ATP-bound EQclose conformation (Mutation of E170Q on MlaF)
7CGN	;	4.3	;	The overall structure of the MlaFEDB complex in ATP-bound EQtall conformation (Mutation of E170Q on MlaF)
5GAN	;	3.7	;	The overall structure of the yeast spliceosomal U4/U6.U5 tri-snRNP at 3.7 Angstrom
5XM6	;	2.501	;	the overall structure of VrEH2
3DLL	;	3.5	;	The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning
1YIC	;		;	THE OXIDIZED SACCHAROMYCES CEREVISIAE ISO-1-CYTOCHROME C, NMR, 20 STRUCTURES
1H6R	;	1.5	;	The oxidized state of a redox sensitive variant of green fluorescent protein
3A3T	;	2.1	;	The oxidoreductase NmDsbA1 from N. meningitidis
5LHP	;	2.63	;	The p-aminobenzamidine active site inhibited catalytic domain of murine urokinase-type plasminogen activator in complex with the allosteric inhibitory nanobody Nb7
5FMF	;	6.0	;	the P-lobe of RNA polymerase II pre-initiation complex
6VJF	;	2.472	;	The P-Loop K to A mutation of C. therm Vps1 GTPase-BSE
1ZO3	;	13.8	;	The P-site and P/E-site tRNA structures fitted to P/I site codon.
6VBT	;	1.7	;	The P212121 Crystal structure of SodCI Superoxide Dismutase with 2 molecules in the asymmetric unit at 1.7 A resolution
1F42	;	2.5	;	THE P40 DOMAIN OF HUMAN INTERLEUKIN-12
2GB2	;	1.25	;	The P52G mutant of amicyanin in the Cu(II) state.
1JRB	;	1.9	;	The P56A mutant of Lactococcus lactis dihydroorotate dehydrogenase A
3PTH	;	1.7	;	The PABC1 MLLE domain bound to the variant PAM2 motif of LARP4B
3I8D	;	1.61	;	The Pairing Geometry of the Hydrophobic Thymine Analog 2,4-Difluorotoluene in Duplex DNA as Analyzed by X-ray Crystallography
1ML4	;	1.8	;	The PALA-liganded Aspartate transcarbamoylase catalytic subunit from Pyrococcus abyssi
1KA0	;	1.8	;	The PAPase Hal2p complexed with a sodium ion and the reaction product AMP
1KA1	;	1.3	;	The PAPase Hal2p complexed with calcium and magnesium ions and reaction substrate: PAP
1K9Y	;	1.9	;	The PAPase Hal2p complexed with magnesium ions and reaction products: AMP and inorganic phosphate
1K9Z	;	1.5	;	The PAPase Hal2p complexed with zinc ions
2WB3	;	1.9	;	The partial structure of a group A streptococcal phage-encoded tail fibre hyaluronate lyase Hylp3
2WH7	;	1.6	;	The partial structure of a group A streptpcoccal phage-encoded tail fibre hyaluronate lyase Hylp2
6K4I	;		;	The partially disordered conformation of ubiquitin (Q41N variant)
1JGO	;	5.6	;	The Path of Messenger RNA Through the Ribosome. THIS FILE, 1JGO, CONTAINS THE 30S RIBOSOME SUBUNIT, THREE TRNA, AND MRNA MOLECULES. 50S RIBOSOME SUBUNIT IS IN THE FILE 1GIY
1JGP	;	7.0	;	The Path of Messenger RNA Through the Ribosome. THIS FILE, 1JGP, CONTAINS THE 30S RIBOSOME SUBUNIT, THREE TRNA, AND MRNA MOLECULES. 50S RIBOSOME SUBUNIT IS IN THE FILE 1GIY
1JGQ	;	5.0	;	The Path of Messenger RNA Through the Ribosome. THIS FILE, 1JGQ, CONTAINS THE 30S RIBOSOME SUBUNIT, THREE TRNA, AND MRNA MOLECULES. 50S RIBOSOME SUBUNIT IS IN THE FILE 1GIY
4TSF	;	3.2	;	The Pathway of Binding of the Intrinsically Disordered Mitochondrial Inhibitor Protein to F1-ATPase
4TT3	;	3.21	;	The Pathway of Binding of the Intrinsically Disordered Mitochondrial Inhibitor Protein to F1-ATPase
2JX0	;		;	The paxillin-binding domain (PBD) of G Protein Coupled Receptor (GPCR)-kinase (GRK) interacting protein 1 (GIT1)
4BBV	;	1.6	;	The PB0 Photocycle Intermediate of Photoactive Yellow Protein
7D33	;	2.117	;	The Pb2+ complexed structure of TBA G8C mutant
7QQM	;	1.6	;	The PDZ domain of LRRC7 fused with ANXA2
7P71	;	2.6	;	The PDZ domain of MAGI1_2 complexed with the PDZ-binding motif of HPV35-E6
7PC4	;	2.3	;	The PDZ domain of SNTB1 complexed with the PDZ-binding motif of HTLV1-TAX1
7PC7	;	2.1	;	The PDZ domain of SNTG1 complexed with the acetylated PDZ-binding motif of PTEN
7QQN	;	2.45	;	The PDZ domain of SNTG1 complexed with the acetylated PDZ-binding motif of TRPV3
7PC8	;	2.5	;	The PDZ domain of SNTG1 complexed with the phosphomimetic mutant PDZ-binding motif of RSK1
7QQL	;	2.44	;	The PDZ domain of SNTG2 complexed with the phosphorylated PDZ-binding motif of RSK1
7P72	;	2.15	;	The PDZ domain of SNX27 complexed with the PDZ-binding motif of MERS-E
7PCB	;	2.0	;	The PDZ domain of SNX27 fused with ANXA2
7P73	;	1.85	;	The PDZ domain of SYNJ2BP complexed with the PDZ-binding motif of HTLV1-TAX1
7PC9	;	2.4	;	The PDZ domain of SYNJ2BP complexed with the PDZ-binding motif of HTLV1-TAX1
7P74	;	1.9	;	The PDZ domain of SYNJ2BP complexed with the phosphorylated PDZ-binding motif of RSK1
8BLU	;	1.5	;	The PDZ domains of human SDCBP
8BLV	;	1.5	;	The PDZ domains of human SDCBP with a bound SDC4 C-terminal peptide
6AKQ	;	1.9	;	The PDZ tandem fragment of A. aeolicus S2P homolog with the PA12 tag inserted between the residues 263 and 267
7P70	;	2.0	;	The PDZ-domain of SNTB1 complexed with the PDZ-binding motif of HPV35-E6
1M5Z	;		;	The PDZ7 of Glutamate Receptor Interacting Protein Binds to its Target via a Novel Hydrophobic Surface Area
4IL9	;	2.83	;	The pentameric ligand-gated ion channel GLIC A237F in complex with bromide
4ILA	;	3.5	;	The pentameric ligand-gated ion channel GLIC A237F in complex with Cesium
4ILB	;	3.15	;	The pentameric ligand-gated ion channel GLIC A237F in complex with Rubidium
4IL4	;	3.3	;	The pentameric ligand-gated ion channel GLIC in complex with Se-DDM
7T7W	;		;	The peptide Lt-MAP4 is an analog derived from the Ltc-3a. The primary sequence of the parental peptide was used as template for rational design, using the amino acid residues for modification of charge and hydrophobicity.
6MI9	;		;	The peptide PaAMP1B3 is an analog derived from the PaAMP1. The sequence of the ribosomal protein of Pyrobaculum aerophylum was used as template for rational design, using the Joker algorithm.
4BVM	;	0.93	;	The peripheral membrane protein P2 from human myelin at atomic resolution
5OAH	;	1.8	;	THE PERIPLASMIC BINDING PROTEIN CEUE OF CAMPYLOBACTER JEJUNI BINDS THE IRON(III) COMPLEX OF Azotochelin
5ADV	;	2.1	;	The Periplasmic Binding Protein CeuE of Campylobacter jejuni preferentially binds the iron(III) complex of the Linear Dimer Component of Enterobactin
5ADW	;	1.9	;	The Periplasmic Binding Protein CeuE of Campylobacter jejuni preferentially binds the iron(III) complex of the Linear Dimer Component of Enterobactin
5OCP	;	1.7	;	The periplasmic binding protein component of the arabinose ABC transporter from Shewanella sp. ANA-3 bound to alpha and beta-L-arabinofuranose
3WKL	;	2.8	;	The periplasmic PDZ tandem fragment of the RseP homologue from Aquifex aeolicus
3WKM	;	2.2	;	The periplasmic PDZ tandem fragment of the RseP homologue from Aquifex aeolicus in complex with the Fab fragment
6TT2	;	1.36	;	The PH domain of Bruton's tyrosine kinase mutant R28C
6TUH	;	2.25	;	The PH domain of Bruton's tyrosine kinase mutant R28C
3CRO	;	2.5	;	THE PHAGE 434 CRO/OR1 COMPLEX AT 2.5 ANGSTROMS RESOLUTION
1RPE	;	2.5	;	THE PHAGE 434 OR2/R1-69 COMPLEX AT 2.5 ANGSTROMS RESOLUTION
5XHT	;		;	The PHD finger of human Kiaa1045 protein
2PNX	;	1.8	;	The PHD finger of ING4 in complex with an H3K4Me3 histone peptide
4II4	;	2.799	;	The Phenylacetyl-CoA monooxygenase - mutant PaaA E49Q K68Q - PaaC wild type subcomplex with benzoyl-CoA
4IIT	;	4.3	;	The Phenylacetyl-CoA monooxygenase PaaABC subcomplex with phenylacetyl-CoA
3PWQ	;	2.65	;	The Phenylacetyl-CoA monooxygenase PaaAC subcomplex
3PVT	;	2.03	;	The Phenylacetyl-CoA monooxygenase PaaAC subcomplex with 3-hydroxybutanoyl-CoA
3PW8	;	2.97	;	The Phenylacetyl-CoA monooxygenase PaaAC subcomplex with acetyl-CoA
3PVR	;	2.1	;	The Phenylacetyl-CoA monooxygenase PaaAC subcomplex with benzoyl-CoA
3PVY	;	2.15	;	The Phenylacetyl-CoA monooxygenase PaaAC subcomplex with coenzyme A
3PW1	;	2.25	;	The Phenylacetyl-CoA monooxygenase PaaAC subcomplex with phenylacetyl-CoA
7JQ6	;	2.9	;	The Phi-28 gp11 DNA packaging Motor
7JQ7	;	2.895	;	The Phi-28 gp11 DNA packaging Motor
7JQP	;	2.89	;	The Phi-28 gp11 DNA packaging Motor
3TPE	;	1.9	;	The phipa p3121 structure
1RB8	;	3.5	;	The phiX174 DNA binding protein J in two different capsid environments.
6IBD	;	1.48	;	The Phosphatase and C2 domains of Human SHIP1
8PDH	;	1.45	;	The phosphatase and C2 domains of SHIP1 with covalent Z1742148362
8PDI	;	1.3	;	The phosphatase and C2 domains of SHIP1 with covalent Z1763271112
8PDG	;	1.4	;	The phosphatase and C2 domains of SHIP1 with covalent Z2738285202
8PDJ	;	1.4	;	The phosphatase and C2 domains of SHIP1 with covalent Z56948267
1PFH	;		;	THE PHOSPHORYLATED FORM OF THE HISTIDINE-CONTAINING PHOSPHOCARRIER PROTEIN HPR
6R26	;	3.11	;	The photosensory core module (PAS-GAF-PHY) of the bacterial phytochrome Agp1 (AtBphP1) locked in a Pr-like state
5I5L	;	2.7	;	The photosensory module (PAS-GAF-PHY) of the bacterial phytochrome Agp1 (AtBphP1) in the Pr form, chromophore modelled with an endocyclic double bond in pyrrole ring A
8FZ5	;	2.23	;	The PI31-free Bovine 20S proteasome
5AIZ	;	1.7	;	The PIAS-like coactivator Zmiz1 is a direct and selective cofactor of Notch1 in T-cell development and leukemia
7LKO	;	2.88	;	The PilB(N-terminal)-PilZ complex of the Type IV pilus from Xanthomonas citri (2.9 A)
7LKN	;	1.71	;	The PilB(N-terminal_P70S mutant)-PilZ complex (SeMet)
7LKM	;	2.0	;	The PilB(N-terminal_P70S mutant)-PilZ complex of the Type IV pilus from Xanthomonas citri
7LKQ	;	3.4	;	The PilZ(delta107-117)-FimX(GGDEF-EAL) complex from Xanthomonas citri
8I9J	;	6.39	;	The PKR and E3L complex
4Z62	;	2.9	;	The plant peptide hormone free receptor
4Z5W	;	2.2	;	The plant peptide hormone receptor
4Z61	;	2.75	;	The plant peptide hormone receptor complex
4Z64	;	2.659	;	the plant peptide hormone receptor complex in arabidopsis
4Z63	;	2.514	;	The plant peptide hormone receptor in arabidopsis
1YVB	;	2.7	;	the Plasmodium falciparum Cysteine Protease Falcipain-2
3U12	;	2.08	;	The pleckstrin homology (PH) domain of USP37
3RYT	;	3.582	;	The Plexin A1 intracellular region in complex with Rac1
5V6T	;	3.189	;	The Plexin D1 intracellular region in complex with GIPC1
2YXQ	;	3.5	;	The plug domain of the SecY protein stablizes the closed state of the translocation channel and maintains a membrane seal
2YXR	;	3.6	;	The plug domain of the SecY protein stablizes the closed state of the translocation channel and maintains a membrane seal
8YOU	;	1.8	;	The pmTcDH complex structure with an inhibitor SeCN
6ZO4	;	8.2	;	The pointed end complex of dynactin bound to BICD2
6ZNM	;	4.1	;	The pointed end complex of dynactin bound to BICDR1
7Z8M	;	3.37	;	The pointed end complex of dynactin bound to BICDR1
6ZNN	;	4.5	;	The pointed end complex of dynactin bound to Hook3
6ZNO	;	6.8	;	The pointed end complex of dynactin with the p150 projection docked
1Q4K	;	2.3	;	The polo-box domain of Plk1 in complex with a phospho-peptide
5FMW	;	6.7	;	The poly-C9 component of the Complement Membrane Attack Complex
2LID	;		;	The polyserine tract of Nasonia vitripennis Vg residues 351-385
7PAG	;	4.0	;	The pore conformation of lymphocyte perforin
6RB9	;	3.2	;	The pore structure of Clostridium perfringens epsilon toxin
2BK1	;	29.0	;	The pore structure of pneumolysin, obtained by fitting the alpha carbon trace of perfringolysin O into a cryo-EM map
7EY6	;	4.3	;	The portal protein (GP8) of bacteriophage T7
1CIL	;	1.6	;	THE POSITIONS OF HIS-64 AND A BOUND WATER IN HUMAN CARBONIC ANHYDRASE II UPON BINDING THREE STRUCTURALLY RELATED INHIBITORS
1CIM	;	2.1	;	THE POSITIONS OF HIS-64 AND A BOUND WATER IN HUMAN CARBONIC ANHYDRASE II UPON BINDING THREE STRUCTURALLY RELATED INHIBITORS
1CIN	;	2.1	;	THE POSITIONS OF HIS-64 AND A BOUND WATER IN HUMAN CARBONIC ANHYDRASE II UPON BINDING THREE STRUCTURALLY RELATED INHIBITORS
5YOW	;	2.1	;	The post-fusion structure of the Heartland virus Gc glycoprotein
5ZKX	;	2.3	;	The postfusion structure of human-infecting Bourbon virus envelope glycoprotein
8PQ7	;	2.1	;	The Potato Late Blight pathogen (Phytophthora infestans) effector protein Pi04134 in complex with potato protein phosphatase type 1c (PP1c).
4B9O	;	1.6	;	The PR0 Photocycle Intermediate of Photoactive Yellow Protein
4BBT	;	1.6	;	The PR1 Photocycle Intermediate of Photoactive Yellow Protein
4BBU	;	1.6	;	The PR2 Photocycle Intermediate of Photoactive Yellow Protein
7XYM	;	3.3	;	The pre-fusion structure of Thogotovirus dhori envelope glycoprotein
7XD7	;	3.02	;	The pre-Tet-C state of wild-type Tetrahymena group I intron with 30nt 3'/5'-exon
2BK2	;	28.0	;	The prepore structure of pneumolysin, obtained by fitting the alpha carbon trace of perfringolysin O into a cryo-EM map
5BNA	;	2.6	;	THE PRIMARY MODE OF BINDING OF CISPLATIN TO A B-DNA DODECAMER: C-G-C-G-A-A-T-T-C-G-C-G
1ARB	;	1.2	;	THE PRIMARY STRUCTURE AND STRUCTURAL CHARACTERISTICS OF ACHROMOBACTER LYTICUS PROTEASE I, A LYSINE-SPECIFIC SERINE PROTEASE
1ARC	;	2.0	;	THE PRIMARY STRUCTURE AND STRUCTURAL CHARACTERISTICS OF ACHROMOBACTER LYTICUS PROTEASE I, A LYSINE-SPECIFIC SERINE PROTEASE
1WKM	;	2.3	;	THE PRODUCT BOUND FORM OF THE MN(II)LOADED METHIONINE AMINOPEPTIDASE FROM HYPERTHERMOPHILE PYROCOCCUS FURIOSUS
3HRR	;	1.9	;	The Product Template Domain from PksA with Harris Compound Bound
3HRQ	;	1.8	;	The Product Template Domain from PksA with palmitate bound
7VWK	;	2.0	;	The product template domain of AviM
2JSP	;		;	The prokaryotic Cys2His2 zinc finger adopts a novel fold as revealed by the NMR structure of A. tumefaciens Ros DNA binding domain
1X9Y	;	2.5	;	The prostaphopain B structure
5T35	;	2.7	;	The PROTAC MZ1 in complex with the second bromodomain of Brd4 and pVHL:ElonginC:ElonginB
2M63	;		;	The protease-resistant N-terminal domain of TIR-domain containing adaptor molecule-1, TICAM-1
3HVD	;	3.209	;	The Protective Antigen Component of Anthrax Toxin Forms Functional Octameric Complexes
2LE8	;		;	The protein complex for DNA replication
6LP9	;	1.803	;	the protein of cat virus
2MUU	;		;	The Proteolytic Activity of Ubiquitin-specific Protease 28 Is Modulated by the N-terminal Domain
1HRM	;	1.7	;	THE PROXIMAL LIGAND VARIANT HIS93TYR OF HORSE HEART MYOGLOBIN
3LRV	;	2.6	;	The Prp19 WD40 Domain Contains a Conserved Protein Interaction Region Essential for its Function.
6MWY	;	2.594	;	The Prp8 intein of Cryptococcus gattii
6MX6	;	1.749	;	The Prp8 intein of Cryptococcus neoformans
6OWU	;	1.84	;	THE PRP8 INTEIN OF CRYPTOCOCCUS NEOFORMANS in complex with Zn2+
6MYL	;	3.06	;	The Prp8 intein-cisplatin complex
3C6D	;	12.5	;	The pseudo-atomic structure of dengue immature virus
3IXY	;	23.0	;	The pseudo-atomic structure of dengue immature virus in complex with Fab fragments of the anti-fusion loop antibody E53
3IXX	;	15.0	;	The pseudo-atomic structure of West Nile immature virus in complex with Fab fragments of the anti-fusion loop antibody E53
4OLI	;	2.8	;	The pseudokinase/kinase protein from JAK-family member TYK2
8K3B	;	1.9	;	The Pseudomonas aeruginosa RccR protein complexed with KDPG
4DBB	;	1.901	;	The PTB domain of Mint1 is autoinhibited by a helix in the C-terminal linker region
6IWD	;	1.8	;	The PTP domain of human PTPN14 in a complex with the CR3 domain of HPV18 E7
2CCQ	;	1.6	;	The PUB domain functions as a p97 binding module in human peptide N-glycanase.
2CM0	;	1.9	;	The PUB domain functions as a p97 binding module in human peptide N-glycanase.
2RU6	;		;	The pure alternative state of ubiquitin
4ND9	;	2.3	;	The putative substrate binding domain of ABC-type transporter from Agrobacterium tumefaciens in open conformation
3FLG	;	1.8	;	The PWWP domain of Human DNA (cytosine-5-)-methyltransferase 3 beta
3QKJ	;	2.04	;	The PWWP domain of human DNA (CYTOSINE-5-)-METHYLTRANSFERASE 3 BETA in complex with a bis-tris molecule
2RAI	;	3.2	;	The PX-BAR membrane remodeling unit of Sorting Nexin 9
5IE8	;		;	The pyrazinoic acid binding domain of Ribosomal Protein S1 from Mycobacterium tuberculosis
2NNB	;	1.9	;	The Q403K mutant heme domain of flavocytochrome P450 BM3
4V4U	;	10.0	;	The quasi-atomic model of Human Adenovirus type 5 capsid
2C9G	;	9.3	;	THE QUASI-ATOMIC MODEL OF THE ADENOVIRUS TYPE 3 PENTON BASE DODECAHEDRON
2C9F	;	16.5	;	THE QUASI-ATOMIC MODEL OF THE ADENOVIRUS TYPE 3 PENTON DODECAHEDRON
6K0E	;	1.707	;	The quinary complex of AsqJ-Fe-2OG-dehydrocyclopeptin-dioxygen
2WYC	;	1.9	;	The quorum quenching N-acyl homoserine lactone acylase PvdQ in complex with 3-oxo-lauric acid
2WYD	;	1.901	;	The quorum quenching N-acyl homoserine lactone acylase PvdQ in complex with dodecanoic acid
2WYE	;	1.8	;	The quorum quenching N-acyl homoserine lactone acylase PvdQ is an Ntn- Hydrolase with an unusual substrate-binding pocket
2WYB	;	2.1	;	The quorum quenching N-acyl homoserine lactone acylase PvdQ with a covalently bound dodecanoic acid
4KH0	;	2.25	;	The R state structure of E. coli ATCase with ATP and Magnesium bound
4KGV	;	2.1	;	The R state structure of E. coli ATCase with ATP bound
4KGX	;	2.202	;	The R state structure of E. coli ATCase with CTP bound
4KH1	;	2.2	;	The R state structure of E. coli ATCase with CTP,UTP, and Magnesium bound
4KGZ	;	2.4	;	The R state structure of E. coli ATCase with UTP and Magnesium bound
3E3L	;	2.59	;	The R-state Glycogen Phosphorylase
6L3V	;	2.63	;	The R15G mutant of human Cx31.3/GJC3 connexin hemichannel
8H1G	;	1.43	;	The R406T mutant form of the Aquifex aeolicus MutL endonuclease domain
2AU7	;	1.05	;	The R43Q active site variant of E.coli inorganic pyrophosphatase
1JQX	;	1.7	;	The R57A mutant of Lactococcus lactis dihydroorotate dehydrogenase A
117E	;	2.15	;	THE R78K AND D117E ACTIVE SITE VARIANTS OF SACCHAROMYCES CEREVISIAE SOLUBLE INORGANIC PYROPHOSPHATASE: STRUCTURAL STUDIES AND MECHANISTIC IMPLICATIONS
8PRK	;	1.85	;	THE R78K AND D117E ACTIVE SITE VARIANTS OF SACCHAROMYCES CEREVISIAE SOLUBLE INORGANIC PYROPHOSPHATASE: STRUCTURAL STUDIES AND MECHANISTIC IMPLICATIONS
6SUR	;	3.467	;	The Rab33B-Atg16L1 crystal structure
1US8	;	2.1	;	The Rad50 signature motif: essential to ATP binding and biological function
8I9M	;	5.19	;	The RAGE and HMGB1 complex
2ELG	;	1.0	;	The rare crystallographic structure of d(CGCGCG)2: The natural spermidine molecule bound to the minor groove of left-handed Z-DNA d(CGCGCG)2 at 10 degree celsius
1RRB	;		;	THE RAS-BINDING DOMAIN OF RAF-1 FROM RAT, NMR, 1 STRUCTURE
3GBI	;	4.018	;	The Rational Design and Structural Analysis of a Self-Assembled Three-Dimensional DNA Crystal
3G8V	;	2.4	;	The rationally designed catalytically inactive mutant Mth0212(D151N)
4V9F	;	2.404	;	The re-refined crystal structure of the Haloarcula marismortui large ribosomal subunit at 2.4 Angstrom resolution: more complete structure of the L7/L12 and L1 stalk, L5 and LX proteins
4CQB	;	1.84	;	The reaction mechanism of the N-isopropylammelide isopropylaminohydrolase AtzC: insights from structural and mutagenesis studies
4CQC	;	2.2	;	The reaction mechanism of the N-isopropylammelide isopropylaminohydrolase AtzC: insights from structural and mutagenesis studies
4CQD	;	2.25	;	The reaction mechanism of the N-isopropylammelide isopropylaminohydrolase AtzC: insights from structural and mutagenesis studies
2RIW	;	2.04	;	The Reactive loop cleaved human Thyroxine Binding Globulin complexed with thyroxine
6SWB	;	2.259	;	The REC domain of AraT, a response regulator from Geobacillus stearothermophilus
6SWL	;	2.17	;	The REC domain of XynC, a response regulator from Geobacillus stearothermophilus
7QNW	;	2.4	;	The receptor binding domain of SARS-CoV-2 Omicron variant spike glycoprotein in complex with Beta-55 and EY6A Fabs
7QNX	;	2.92	;	The receptor binding domain of SARS-CoV-2 spike glycoprotein in complex with Beta-55 and EY6A Fabs
7QNY	;	2.84	;	The receptor binding domain of SARS-CoV-2 spike glycoprotein in complex with COVOX-58 and COVOX-158 Fabs
1NCN	;	2.7	;	the receptor-binding domain of human B7-2
1N7U	;	2.4	;	THE RECEPTOR-BINDING PROTEIN P2 OF BACTERIOPHAGE PRD1: CRYSTAL FORM I
1N7V	;	2.2	;	THE RECEPTOR-BINDING PROTEIN P2 OF BACTERIOPHAGE PRD1: CRYSTAL FORM III
8IPC	;	2.2	;	The recombinant NZ-1 Fab complexed with the PDZ tandem fragment of A. aeolicus S2P homolog with the PA14 tag inserted between the residues 181 and 184
2OWY	;	2.5	;	The recombination-associated protein RdgC adopts a novel toroidal architecture for DNA binding
2DE6	;	1.8	;	The reduced complex between oxygenase and ferredoxin in carbazole 1,9a-dioxygenase
3PAV	;	1.45	;	The reduced form of CueO
4NQY	;	2.6	;	The reduced form of MJ0499
4Y0M	;	2.3	;	The reduced form of OxyR regulatory domain from Psedomonas aeruginosa
1MCT	;	1.6	;	THE REFINED 1.6 ANGSTROMS RESOLUTION CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN PORCINE BETA-TRYPSIN AND MCTI-A, A TRYPSIN INHIBITOR OF SQUASH FAMILY
1ONC	;	1.7	;	THE REFINED 1.7 ANGSTROMS X-RAY CRYSTALLOGRAPHIC STRUCTURE OF P-30, AN AMPHIBIAN RIBONUCLEASE WITH ANTI-TUMOR ACTIVITY
1PPB	;	1.92	;	THE REFINED 1.9 ANGSTROMS CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN: INTERACTION WITH D-PHE-PRO-ARG CHLOROMETHYLKETONE AND SIGNIFICANCE OF THE TYR-PRO-PRO-TRP INSERTION SEGMENT
1PPE	;	2.0	;	THE REFINED 2.0 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN BOVINE BETA-TRYPSIN AND CMTI-I, A TRYPSIN INHIBITOR FROM SQUASH SEEDS (CUCURBITA MAXIMA): TOPOLOGICAL SIMILARITY OF THE SQUASH SEED INHIBITORS WITH THE CARBOXYPEPTIDASE A INHIBITOR FROM POTATOES
1HUC	;	2.1	;	THE REFINED 2.15 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF HUMAN LIVER CATHEPSIN B: THE STRUCTURAL BASIS FOR ITS SPECIFICITY
4TPI	;	2.2	;	THE REFINED 2.2-ANGSTROMS (0.22-NM) X-RAY CRYSTAL STRUCTURE OF THE TERNARY COMPLEX FORMED BY BOVINE TRYPSINOGEN, VALINE-VALINE AND THE ARG15 ANALOGUE OF BOVINE PANCREATIC TRYPSIN INHIBITOR
1PPG	;	2.3	;	The refined 2.3 angstroms crystal structure of human leukocyte elastase in a complex with a valine chloromethyl ketone inhibitor
1STF	;	2.37	;	THE REFINED 2.4 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF RECOMBINANT HUMAN STEFIN B IN COMPLEX WITH THE CYSTEINE PROTEINASE PAPAIN: A NOVEL TYPE OF PROTEINASE INHIBITOR INTERACTION
1SRN	;	1.8	;	THE REFINED CRYSTAL STRUCTURE OF A FULLY ACTIVE SEMISYNTHETIC RIBONUCLEASE AT 1.8 ANGSTROMS RESOLUTION
2CTX	;	2.4	;	THE REFINED CRYSTAL STRUCTURE OF ALPHA-COBRATOXIN FROM NAJA NAJA SIAMENSIS AT 2.4-ANGSTROMS RESOLUTION
2BAA	;	1.8	;	THE REFINED CRYSTAL STRUCTURE OF AN ENDOCHITINASE FROM HORDEUM VULGARE L. SEEDS TO 1.8 ANGSTROMS RESOLUTION
1PP2	;	2.5	;	THE REFINED CRYSTAL STRUCTURE OF DIMERIC PHOSPHOLIPASE A2 AT 2.5 ANGSTROMS. ACCESS TO A SHIELDED CATALYTIC CENTER
1LMN	;	1.8	;	THE REFINED CRYSTAL STRUCTURE OF LYSOZYME FROM THE RAINBOW TROUT (ONCORHYNCHUS MYKISS)
1SBC	;	2.5	;	THE REFINED CRYSTAL STRUCTURE OF SUBTILISIN CARLSBERG AT 2.5 ANGSTROMS RESOLUTION
3CC2	;	2.4	;	The Refined Crystal Structure of the Haloarcula Marismortui Large Ribosomal Subunit at 2.4 Angstrom Resolution with rrnA Sequence for the 23S rRNA and Genome-derived Sequences for r-Proteins
3PTE	;	1.6	;	THE REFINED CRYSTALLOGRAPHIC STRUCTURE OF A DD-PEPTIDASE PENICILLIN-TARGET ENZYME AT 1.6 A RESOLUTION
2MS2	;	2.8	;	THE REFINED STRUCTURE OF BACTERIOPHAGE MS2 AT 2.8 ANGSTROMS RESOLUTION
2I18	;		;	The refined structure of C-terminal domain of an EF-hand Calcium binding Protein from Entamoeba Histolytica
1CON	;	2.0	;	THE REFINED STRUCTURE OF CADMIUM SUBSTITUTED CONCANAVALIN A AT 2.0 ANGSTROMS RESOLUTION
4CAB	;	2.599	;	The refined structure of catalase DR1998 from Deinococcus radiodurans at 2.6 A resolution
1DDT	;	2.0	;	THE REFINED STRUCTURE OF DIMERIC DIPHTHERIA TOXIN AT 2.0 ANGSTROMS RESOLUTION
1MDT	;	2.3	;	THE REFINED STRUCTURE OF MONOMERIC DIPHTHERIA TOXIN AT 2.3 ANGSTROMS RESOLUTION
1OHF	;	2.8	;	The refined structure of Nudaurelia capensis omega virus
1LVL	;	2.45	;	THE REFINED STRUCTURE OF PSEUDOMONAS PUTIDA LIPOAMIDE DEHYDROGENASE COMPLEXED WITH NAD+ AT 2.45 ANGSTROMS RESOLUTION
2SNV	;	2.8	;	THE REFINED STRUCTURE OF SINDBIS VIRUS CORE PROTEIN IN COMPARISON WITH OTHER CHYMOTRYPSIN-LIKE SERINE PROTEINASE STRUCTURES
2PK4	;	2.25	;	THE REFINED STRUCTURE OF THE EPSILON-AMINOCAPROIC ACID COMPLEX OF HUMAN PLASMINOGEN KRINGLE
4HTC	;	2.3	;	THE REFINED STRUCTURE OF THE HIRUDIN-THROMBIN COMPLEX
1GP1	;	2.0	;	THE REFINED STRUCTURE OF THE SELENOENZYME GLUTATHIONE PEROXIDASE AT 0.2-NM RESOLUTION
3ICB	;	2.3	;	THE REFINED STRUCTURE OF VITAMIN D-DEPENDENT CALCIUM-BINDING PROTEIN FROM BOVINE INTESTINE. MOLECULAR DETAILS, ION BINDING, AND IMPLICATIONS FOR THE STRUCTURE OF OTHER CALCIUM-BINDING PROTEINS
1POW	;	2.5	;	THE REFINED STRUCTURES OF A STABILIZED MUTANT AND OF WILD-TYPE PYRUVATE OXIDASE FROM LACTOBACILLUS PLANTARUM
1POX	;	2.1	;	THE REFINED STRUCTURES OF A STABILIZED MUTANT AND OF WILD-TYPE PYRUVATE OXIDASE FROM LACTOBACILLUS PLANTARUM
153L	;	1.6	;	THE REFINED STRUCTURES OF GOOSE LYSOZYME AND ITS COMPLEX WITH A BOUND TRISACCHARIDE SHOW THAT THE ""GOOSE-TYPE LYSOZYMES LACK A CATALYTIC ASPARTATE
154L	;	1.6	;	THE REFINED STRUCTURES OF GOOSE LYSOZYME AND ITS COMPLEX WITH A BOUND TRISACCHARIDE SHOW THAT THE ""GOOSE-TYPE LYSOZYMES LACK A CATALYTIC ASPARTATE
2HSD	;	2.64	;	THE REFINED THREE-DIMENSIONAL STRUCTURE OF 3ALPHA,20BETA-HYDROXYSTEROID DEHYDROGENASE AND POSSIBLE ROLES OF THE RESIDUES CONSERVED IN SHORT-CHAIN DEHYDROGENASES
2BBV	;	2.8	;	THE REFINED THREE-DIMENSIONAL STRUCTURE OF AN INSECT VIRUS AT 2.8 ANGSTROMS RESOLUTION
1PKM	;	2.6	;	THE REFINED THREE-DIMENSIONAL STRUCTURE OF CAT MUSCLE (M1) PYRUVATE KINASE, AT A RESOLUTION OF 2.6 ANGSTROMS
2PEC	;	2.2	;	THE REFINED THREE-DIMENSIONAL STRUCTURE OF PECTATE LYASE C FROM ERWINIA CHRYSANTHEMI AT 2.2 ANGSTROMS RESOLUTION: IMPLICATIONS FOR AN ENZYMATIC MECHANISM
5CHA	;	1.67	;	THE REFINEMENT AND THE STRUCTURE OF THE DIMER OF ALPHA-*CHYMOTRYPSIN AT 1.67-*ANGSTROMS RESOLUTION
4SBV	;	2.8	;	The REFINEMENT OF SOUTHERN BEAN MOSAIC VIRUS IN RECIPROCAL SPACE
7ERQ	;	1.95	;	The regulatory domain of YeiE, a sulfite sensing LysR-type transcriptional regulator from Cronobacter sakazakii (ligand-free form)
7ERP	;	2.03	;	The regulatory domain of YeiE, a sulfite sensing LysR-type transcriptional regulator from Cronobacter sakazakii (sulfite-bound form)
4GO5	;	2.6	;	The regulatory subunit of aspartate kinase from Mycobacterium tuberculosis
4GO7	;	2.0	;	The regulatory subunit of aspartate kinase in complex with threonine from Mycobacterium tuberculosis
8HD6	;	3.73	;	The relaxed pre-Tet-S1 state of G264A mutated Tetrahymena group I intron with 6nt 3'/5'-exon and 2-aminopurine nucleoside
7XD3	;	4.05	;	The relaxed pre-Tet-S1 state of wild-type Tetrahymena group I intron with 6nt 3'/5'-exon
1KSR	;		;	THE REPEATING SEGMENTS OF THE F-ACTIN CROSS-LINKING GELATION FACTOR (ABP-120) HAVE AN IMMUNOGLOBULIN FOLD, NMR, 20 STRUCTURES
4BKK	;		;	The Respiratory Syncytial Virus nucleoprotein-RNA complex forms a left-handed helical nucleocapsid.
235L	;	1.9	;	THE RESPONSE OF T4 LYSOZYME TO LARGE-TO-SMALL SUBSTITUTIONS WITHIN THE CORE AND ITS RELATION TO THE HYDROPHOBIC EFFECT
236L	;	1.9	;	THE RESPONSE OF T4 LYSOZYME TO LARGE-TO-SMALL SUBSTITUTIONS WITHIN THE CORE AND ITS RELATION TO THE HYDROPHOBIC EFFECT
237L	;	1.7	;	THE RESPONSE OF T4 LYSOZYME TO LARGE-TO-SMALL SUBSTITUTIONS WITHIN THE CORE AND ITS RELATION TO THE HYDROPHOBIC EFFECT
238L	;	1.8	;	THE RESPONSE OF T4 LYSOZYME TO LARGE-TO-SMALL SUBSTITUTIONS WITHIN THE CORE AND ITS RELATION TO THE HYDROPHOBIC EFFECT
239L	;	1.8	;	THE RESPONSE OF T4 LYSOZYME TO LARGE-TO-SMALL SUBSTITUTIONS WITHIN THE CORE AND ITS RELATION TO THE HYDROPHOBIC EFFECT
240L	;	1.75	;	THE RESPONSE OF T4 LYSOZYME TO LARGE-TO-SMALL SUBSTITUTIONS WITHIN THE CORE AND ITS RELATION TO THE HYDROPHOBIC EFFECT
241L	;	1.7	;	THE RESPONSE OF T4 LYSOZYME TO LARGE-TO-SMALL SUBSTITUTIONS WITHIN THE CORE AND ITS RELATION TO THE HYDROPHOBIC EFFECT
242L	;	1.8	;	THE RESPONSE OF T4 LYSOZYME TO LARGE-TO-SMALL SUBSTITUTIONS WITHIN THE CORE AND ITS RELATION TO THE HYDROPHOBIC EFFECT
243L	;	1.75	;	THE RESPONSE OF T4 LYSOZYME TO LARGE-TO-SMALL SUBSTITUTIONS WITHIN THE CORE AND ITS RELATION TO THE HYDROPHOBIC EFFECT
244L	;	1.7	;	THE RESPONSE OF T4 LYSOZYME TO LARGE-TO-SMALL SUBSTITUTIONS WITHIN THE CORE AND ITS RELATION TO THE HYDROPHOBIC EFFECT
245L	;	1.8	;	THE RESPONSE OF T4 LYSOZYME TO LARGE-TO-SMALL SUBSTITUTIONS WITHIN THE CORE AND ITS RELATION TO THE HYDROPHOBIC EFFECT
246L	;	1.8	;	THE RESPONSE OF T4 LYSOZYME TO LARGE-TO-SMALL SUBSTITUTIONS WITHIN THE CORE AND ITS RELATION TO THE HYDROPHOBIC EFFECT
247L	;	1.75	;	THE RESPONSE OF T4 LYSOZYME TO LARGE-TO-SMALL SUBSTITUTIONS WITHIN THE CORE AND ITS RELATION TO THE HYDROPHOBIC EFFECT
248L	;	1.9	;	THE RESPONSE OF T4 LYSOZYME TO LARGE-TO-SMALL SUBSTITUTIONS WITHIN THE CORE AND ITS RELATION TO THE HYDROPHOBIC EFFECT
249L	;	1.9	;	THE RESPONSE OF T4 LYSOZYME TO LARGE-TO-SMALL SUBSTITUTIONS WITHIN THE CORE AND ITS RELATION TO THE HYDROPHOBIC EFFECT
250L	;	1.8	;	THE RESPONSE OF T4 LYSOZYME TO LARGE-TO-SMALL SUBSTITUTIONS WITHIN THE CORE AND ITS RELATION TO THE HYDROPHOBIC EFFECT
251L	;	2.6	;	THE RESPONSE OF T4 LYSOZYME TO LARGE-TO-SMALL SUBSTITUTIONS WITHIN THE CORE AND ITS RELATION TO THE HYDROPHOBIC EFFECT
5E3J	;	2.1	;	The response regulator RstA is a potential drug target for Acinetobacter baumannii
1Z4H	;		;	The response regulator TorI belongs to a new family of atypical excisionase
5WVI	;	6.3	;	The resting state of yeast proteasome
4NPQ	;	4.35	;	The resting-state conformation of the GLIC ligand-gated ion channel
1D8V	;		;	THE RESTRAINED AND MINIMIZED AVERAGE NMR STRUCTURE OF MAP30.
3QQN	;	2.309	;	The retinal specific CD147 Ig0 domain: from molecular structure to biological activity
3S8I	;	1.7	;	The retroviral-like protease (RVP) domain of human DDI1
2OSA	;	1.8	;	The Rho-GAP domain of human N-chimaerin
1Q5Q	;	2.6	;	The Rhodococcus 20S proteasome
1Q5R	;	3.1	;	The Rhodococcus 20S proteasome with unprocessed pro-peptides
3D7B	;	1.6	;	The Ribonuclease A- 5'-Deoxy-5'-N-pyrrolidinouridine complex
3BN0	;	2.0	;	The ribosomal protein S16 from Aquifex aeolicus
7T0Y	;	1.8	;	The Ribosomal RNA Processing 1B Protein Phosphatase-1 Holoenzyme
8IWO	;	3.09	;	The rice Na+/H+ antiporter SOS1 in an auto-inhibited state
6RMH	;	9.6	;	The Rigid-body refined model of the normal Huntingtin.
2Q3X	;	1.73	;	The RIM1alpha C2B domain
2MWX	;		;	The RING Domain of human Promyelocytic Leukemia Protein (PML)
5ZI6	;	2.2	;	The RING domain structure of MEX-3C
8I2N	;	2.29	;	The RIPK1 kinase domain in complex with QY7-2B compound
2FOW	;		;	THE RNA BINDING DOMAIN OF RIBOSOMAL PROTEIN L11: THREE-DIMENSIONAL STRUCTURE OF THE RNA-BOUND FORM OF THE PROTEIN, NMR, 26 STRUCTURES
1FOY	;		;	THE RNA BINDING DOMAIN OF RIBOSOMAL PROTEIN L11: THREE-DIMENSIONAL STRUCTURE OF THE RNA-BOUND FORM OF THE PROTEIN, NMR, MINIMIZED AVERAGE STRUCTURE
1I9K	;		;	THE RNA I-MOTIF
1SZ9	;	2.1	;	The RNA polymerase II CTD in mRNA processing: beta-turn recognition and beta-spiral model
1SZA	;	2.2	;	The RNA polymerase II CTD in mRNA processing: beta-turn recognition and beta-spiral model
6IZY	;	2.11	;	The RNA-dependent RNA polymerase domain of dengue 2 NS5
6IZX	;	2.43	;	The RNA-dependent RNA polymerase domain of dengue 2 NS5, bound with RK-0404678
6J00	;	2.14	;	The RNA-dependent RNA polymerase domain of dengue 3 NS5
6IZZ	;	1.97	;	The RNA-dependent RNA polymerase domain of dengue 3 NS5, bound with RK-0404678
3D6O	;	1.58	;	The RNase A- 5'-Deoxy-5'-N-(ethyl isonipecotatyl)uridine complex
3D6Q	;	1.6	;	The RNase A- 5'-Deoxy-5'-N-piperidinouridine complex
1CRG	;	2.0	;	THE ROLE OF A CONSERVED INTERNAL WATER MOLECULE AND ITS ASSOCIATED HYDROGEN BOND NETWORK IN CYTOCHROME C
1CRH	;	1.9	;	THE ROLE OF A CONSERVED INTERNAL WATER MOLECULE AND ITS ASSOCIATED HYDROGEN BOND NETWORK IN CYTOCHROME C
1CRI	;	2.0	;	THE ROLE OF A CONSERVED INTERNAL WATER MOLECULE AND ITS ASSOCIATED HYDROGEN BOND NETWORK IN CYTOCHROME C
1CRJ	;	2.05	;	THE ROLE OF A CONSERVED INTERNAL WATER MOLECULE AND ITS ASSOCIATED HYDROGEN BOND NETWORK IN CYTOCHROME C
7S0V	;	1.95	;	The role of an Asp-Asp pair in the structure, function and inhibition of CTX-M Class A Beta-lactamase
1WDP	;	1.27	;	The role of an inner loop in the catalytic mechanism of soybean beta-amylase
1WDQ	;	1.28	;	The role of an inner loop in the catalytic mechanism of soybean beta-amylase
1WDR	;	1.35	;	The role of an inner loop in the catalytic mechanism of soybean beta-amylase
1WDS	;	1.64	;	The role of an inner loop in the catalytic mechanism of soybean beta-amylase
3BDZ	;	2.0	;	The Role of Asn 242 in P450cin
3BE0	;	3.05	;	The Role of Asn 242 in P450cin
1CMT	;	2.1	;	THE ROLE OF ASPARTATE-235 IN THE BINDING OF CATIONS TO AN ARTIFICIAL CAVITY AT THE RADICAL SITE OF CYTOCHROME C PEROXIDASE
1CMU	;	2.1	;	THE ROLE OF ASPARTATE-235 IN THE BINDING OF CATIONS TO AN ARTIFICIAL CAVITY AT THE RADICAL SITE OF CYTOCHROME C PEROXIDASE
1H6X	;	2.25	;	The role of conserved amino acids in the cleft of the C-terminal family 22 carbohydrate binding module of Clostridium thermocellum Xyn10B in ligand binding
1H6Y	;	2.2	;	The role of conserved amino acids in the cleft of the C-terminal family 22 carbohydrate binding module of Clostridium thermocellum Xyn10B in ligand binding
2AAD	;	2.0	;	THE ROLE OF HISTIDINE-40 IN RIBONUCLEASE T1 CATALYSIS: THREE-DIMENSIONAL STRUCTURES OF THE PARTIALLY ACTIVE HIS40LYS MUTANT
2AAE	;	1.8	;	THE ROLE OF HISTIDINE-40 IN RIBONUCLEASE T1 CATALYSIS: THREE-DIMENSIONAL STRUCTURES OF THE PARTIALLY ACTIVE HIS40LYS MUTANT
311D	;	2.2	;	THE ROLE OF HYDROGEN BONDING IN MINOR-GROOVE DRUG-DNA RECOGNITION. STRUCTURE OF A BIS-AMIDINIUM DERIVATIVE OF HOECHST 33258 COMPLEXED TO THE DODECANUCLEOTIDE D(CGCGAATTCGCG)2
3TZO	;	1.76	;	The role of I87 of CYP158A2 in oxidative coupling reaction
5DE9	;	1.76	;	The role of Ile87 of CYP158A2 in oxidative coupling reaction
2J30	;	1.4	;	The Role of Loop Bundle Hydrogen Bonds in the Maturation and Activity of (Pro)caspase-3
2J33	;	2.0	;	The Role of Loop Bundle Hydrogen Bonds in the Maturation and Activity of (Pro)caspase-3
2J31	;	1.5	;	The Role of Loop Bundle Hydrogen Bonds in the Maturation and Activity of(Pro)caspase-3
2J32	;	1.3	;	The Role of Loop Bundle Hydrogen Bonds in the Maturation and Activity of(Pro)caspase-3
1MDR	;	2.1	;	THE ROLE OF LYSINE 166 IN THE MECHANISM OF MANDELATE RACEMASE FROM PSEUDOMONAS PUTIDA: MECHANISTIC AND CRYSTALLOGRAPHIC EVIDENCE FOR STEREOSPECIFIC ALKYLATION BY (R)-ALPHA-PHENYLGLYCIDATE
4N9U	;	2.11	;	The role of lysine 200 in the human farnesyl pyrophosphate synthase catalytic mechanism and the mode of inhibition by the nitrogen-containing bisphosphonates
1NGT	;	2.04	;	The Role of Minor Groove Functional Groups in DNA Hydration
1D5D	;	2.25	;	The role of phenylalanine 8 in the stabilization of the s protein-s peptide interaction: packing and cavities
1D5E	;	2.25	;	The role of phenylalanine 8 in the stabilization of the S protein-S peptide interaction: Packing and cavities
4R8H	;	1.46	;	The role of protein-ligand contacts in allosteric regulation of the Escherichia coli Catabolite Activator Protein
2FYY	;	1.5	;	The role of T cell receptor alpha genes in directing human MHC restriction
2FZ3	;	1.9	;	The role of T cell receptor alpha genes in directing human MHC restriction
5EUC	;	2.65	;	The role of the C-terminal region on the oligomeric state and enzymatic activity of Trypanosoma cruzi hypoxanthine phosphoribosyl transferase
1XYL	;	1.8	;	THE ROLE OF THE DIVALENT METAL ION IN SUGAR BINDING, RING OPENING, AND ISOMERIZATION BY D-XYLOSE ISOMERASE: REPLACEMENT OF A CATALYTIC METAL BY AN AMINO-ACID
1XYM	;	1.8	;	THE ROLE OF THE DIVALENT METAL ION IN SUGAR BINDING, RING OPENING, AND ISOMERIZATION BY D-XYLOSE ISOMERASE: REPLACEMENT OF A CATALYTIC METAL BY AN AMINO-ACID
4Q23	;	1.98	;	The role of threonine 201 and tyrosine 204 in the human farnesyl pyrophosphate synthase catalytic mechanism and the mode of inhibition by the nitrogen-containing bisphosphonates
1MIK	;	1.76	;	THE ROLE OF WATER MOLECULES IN THE STRUCTURE-BASED DESIGN OF (5-HYDROXYNORVALINE)-2-CYCLOSPORIN: SYNTHESIS, BIOLOGICAL ACTIVITY, AND CRYSTALLOGRAPHIC ANALYSIS WITH CYCLOPHILIN A
1V3H	;	1.6	;	The roles of Glu186 and Glu380 in the catalytic reaction of soybean beta-amylase
1V3I	;	1.9	;	The roles of Glu186 and Glu380 in the catalytic reaction of soybean beta-amylase
3M3A	;	1.37	;	The roles of glutamates and metal ions in a rationally designed nitric oxide reductase based on myoglobin: Cu(II)-I107E FeBMb (Cu(II) binding to FeB site)
3M39	;	1.65	;	The roles of glutamates and metal ions in a rationally designed nitric oxide reductase based on myoglobin: Fe(II)-I107E FeBMb (Fe(II) binding to FeB site)
3M38	;	1.42	;	The roles of Glutamates and Metal ions in a rationally designed nitric oxide reductase based on myoglobin: I107E FeBMb (No metal ion binding to FeB site)
3M3B	;	1.6	;	The roles of glutamates and metal ions in a rationally designed nitric oxide reductase based on myoglobin: Zn(II)-I107E FeBMb (Zn(II) binding to FeB site)
6QQ3	;	1.53	;	The room temperature structure of lysozyme via the acoustic levitation of a droplet
6TU9	;	1.94	;	The ROR1 Pseudokinase Domain Bound To Ponatinib
8UK2	;	8.0	;	The rotavirus VP5*/VP8* conformational transition permeabilizes membranes to Ca2+ (class 5 reconstruction)
8UK3	;	8.0	;	The rotavirus VP5*/VP8* conformational transition permeabilizes membranes to Ca2+ (class 6 reconstruction)
2WBR	;		;	The RRM domain in GW182 proteins contributes to miRNA-mediated gene silencing
8C9Z	;	1.18	;	The RSL - sulfonato-calix[8]arene complex, H32 form, citrate pH 6.0
6Z5G	;	1.278	;	The RSL - sulfonato-calix[8]arene complex, I23 form, citrate pH 4.0, solved by S-SAD
6Z5M	;	1.6	;	The RSL - sulfonato-calix[8]arene complex, I23 form, Gly-HCl pH 2.2
6Z5X	;	1.14	;	The RSL - sulfonato-calix[8]arene complex, P213 form, acetate pH 4.8
6Z60	;	1.166	;	The RSL - sulfonato-calix[8]arene complex, P213 form, CAPS pH 9.5
6Z5W	;	1.187	;	The RSL - sulfonato-calix[8]arene complex, P213 form, MES pH 6.8
6Z62	;	1.156	;	The RSL - sulfonato-calix[8]arene complex, P213 form, TRIS-HCl pH 8.5
6Z5Q	;	1.29	;	The RSL - sulfonato-calix[8]arene complex, P3 form, acetate pH 4.0
8Q6A	;	2.61	;	The RSL-D32N - sulfonato-calix[8]arene complex, I213 form, citrate pH 4.0
8Q6B	;	1.52	;	The RSL-D32N - sulfonato-calix[8]arene complex, I23 form, citrate pH 4.0, obtained by cross-seeding
8Q6C	;	1.38	;	The RSL-D32N - sulfonato-calix[8]arene complex, P63 form, acetate pH 4.0
6Z5Z	;	1.124	;	The RSL-R6 - sulfonato-calix[8]arene complex, P213 form, TRIS-HCl pH 8.5
6Z5P	;	1.42	;	The RSL-R8 - sulfonato-calix[8]arene complex, P3 form, TRIS-HCl pH 8.5
7ALG	;	1.452	;	The RSLex - sulfonato-calix[8]arene complex, P3 form, acetate pH 4.0
8IO2	;	3.1	;	The Rubisco assembly intermidate of Arabidopsis thaliana Rubisco accumulation factor 1 (AtRaf1) and Rubisco large subunit (RbcL)
8IOJ	;	4.1	;	The Rubisco assembly intermidiate of Rubisco large subunit (RbcL) and Arabidopsis thaliana Rubisco accumulation factor 1 (AtRaf1)
1EAQ	;	1.25	;	The RUNX1 Runt domain at 1.25A resolution: A structural switch and specifically bound chloride ions modulate DNA binding
1EAO	;	1.4	;	THE RUNX1 Runt domain at 1.4A resolution: a structural switch and specifically bound chloride ions modulate DNA binding
1EAN	;	1.7	;	THE RUNX1 Runt domain at 1.70A resolution: A structural switch and specifically bound chloride ions modulate DNA binding
6TUA	;	2.38	;	The RYK Pseudokinase Domain
7API	;	3.0	;	THE S VARIANT OF HUMAN ALPHA1-ANTITRYPSIN, STRUCTURE AND IMPLICATIONS FOR FUNCTION AND METABOLISM
8API	;	3.1	;	THE S VARIANT OF HUMAN ALPHA1-ANTITRYPSIN, STRUCTURE AND IMPLICATIONS FOR FUNCTION AND METABOLISM
9API	;	3.0	;	THE S VARIANT OF HUMAN ALPHA1-ANTITRYPSIN, STRUCTURE AND IMPLICATIONS FOR FUNCTION AND METABOLISM
3U3P	;	2.09	;	The S-SAD phased crystal structure of the ecto-domain of Death Receptor 6 (DR6)
3U3Q	;	2.7	;	The S-SAD phased crystal structure of the ecto-domain of Death Receptor 6 (DR6)
3U3S	;	2.7	;	The S-SAD phased crystal structure of the ecto-domain of Death Receptor 6 (DR6)
3U3T	;	3.21	;	The S-SAD phased crystal structure of the ecto-domain of Death Receptor 6 (DR6)
3U3V	;	2.96	;	The S-SAD phased crystal structure of the ecto-domain of Death Receptor 6 (DR6)
6MJH	;	2.06	;	The S31N mutant of the influenza A M2 proton channel in two distinct conformational states
2CCL	;	2.03	;	THE S45A, T46A MUTANT OF THE TYPE I COHESIN-DOCKERIN COMPLEX FROM THE CELLULOSOME OF CLOSTRIDIUM THERMOCELLUM
1N2M	;	1.9	;	The S53A Proenzyme Structure of Methanococcus jannaschii.
1MSV	;	1.75	;	The S68A S-adenosylmethionine decarboxylase proenzyme processing mutant.
3G06	;	1.9	;	The Salmonella Virulence Effector SspH2 Functions As A Novel E3 Ligase
6BRG	;	3.5	;	The SAM domain of mouse SAMHD1 is critical for its activation and regulation
6BRH	;	3.4	;	The SAM domain of mouse SAMHD1 is critical for its activation and regulation
6BRK	;	3.5	;	The SAM domain of mouse SAMHD1 is critical for its activation and regulation
2KYK	;		;	The sandwich region between two LMP2A PY motif regulates the interaction between AIP4WW2domain and PY motif
1NMK	;	2.1	;	The Sanglifehrin-Cyclophilin Interaction: Degradation Work, Synthetic Macrocyclic Analogues, X-ray Crystal Structure and Binding Data
1H1J	;		;	The SAP domain is a DNA-Binding Domain Capable of Binding S/MAR DNA
4DFF	;	2.11	;	The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia
1SCL	;		;	THE SARCIN-RICIN LOOP, A MODULAR RNA
7ACT	;		;	The SARS-CoV-2 nucleocapsid phosphoprotein N-terminal domain in complex with 10mer ssRNA
7ACS	;		;	The SARS-CoV-2 nucleocapsid phosphoprotein N-terminal domain in complex with 7mer dsRNA
7X91	;	4.3	;	The SARS-CoV-2 receptor binding domain bound with an Fv-clasp form of a human neutralizing antibody Ab496
7X8Y	;	4.1	;	The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab159
7X8Z	;	4.1	;	The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab188
7X90	;	4.2	;	The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab326
7X8W	;	3.1	;	The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab354
7X92	;	4.1	;	The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab445
7X95	;	3.9	;	The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab709
7X94	;	4.0	;	The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab712
7X93	;	3.3	;	The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab765
7Y6N	;	4.4	;	The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab803
7Y6L	;	3.5	;	The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab816
7X96	;	3.4	;	The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab847
7R4R	;	3.9	;	The SARS-CoV-2 spike in complex with the 1.10 neutralizing nanobody
7R4Q	;	3.6	;	The SARS-CoV-2 spike in complex with the 1.29 neutralizing nanobody
7R4I	;	3.2	;	The SARS-CoV-2 spike in complex with the 2.15 neutralizing nanobody
7LX5	;	3.44	;	The SARS-CoV-2 spike protein receptor binding domain bound to neutralizing nanobodies WNb 2 and WNb 10
7PFL	;	1.8	;	The SARS-CoV2 major protease (Mpro) apo structure to 1.8 A resolution
6UUE	;	1.389	;	The Se-Met Structure of the Vibrio vulnificus ToxR periplasmic domain
6FAE	;	2.35	;	The Sec7 domain of IQSEC2 (Brag1) in complex with the small GTPase Arf1
4WO3	;	2.73	;	THE SECOND C-KIT DNA QUADRUPLEX CRYSTAL STRUCTURE
2QVK	;	1.451	;	The second Ca2+-binding domain of the Na+-Ca2+ exchanger is essential for regulation: crystal structures and mutational analysis
2QVM	;	1.703	;	The second Ca2+-binding domain of the Na+-Ca2+ exchanger is essential for regulation: crystal structures and mutational analysis
2LRS	;		;	The second dsRBD domain from A. thaliana DICER-LIKE 1
7PC3	;	1.95	;	The second PDZ domain of DLG1 complexed with the PDZ-binding motif of HTLV1-TAX1
5E22	;	1.797	;	The second PDZ domain of Ligand of Numb protein X 2 in the presence of an electric field of ~1 MV/cm along the crystallographic x axis, with eightfold extrapolation of structure factor differences.
8JWK	;	2.32	;	The second purified state crystal structure of AKRtyl
7WPC	;	2.57	;	The second RBD of SARS-CoV-2 Omicron Variant in complexed with RBD-ACE2
4LN2	;	1.0	;	The second SH3 domain from CAP/Ponsin in complex with proline rich peptide from Vinculin
2O9S	;	0.83	;	The second SH3 domain from ponsin
2O9V	;	1.63	;	The second SH3 domain from Ponsin in complex with the paxillin proline rich region
4QAH	;	2.403	;	The second sphere residue T263 is important for function and activity of PTP1B through modulating WPD loop
4QAP	;	1.903	;	The second sphere residue T263 is important for function and activity of PTP1B through modulating WPD loop
4QBE	;	2.292	;	The second sphere residue T263 is important for function and activity of PTP1B through modulating WPD loop
4QBW	;	1.912	;	The second sphere residue T263 is important for function and activity of PTP1B through modulating WPD loop
4Q46	;	1.8	;	The second structure of Influenza B PB2 cap-binding domain complex with GDP
1CXW	;		;	THE SECOND TYPE II MODULE FROM HUMAN MATRIX METALLOPROTEINASE 2
3ON9	;	1.57	;	The SECRET domain from Ectromelia virus
3ONA	;	2.6	;	The SECRET domain in complex with CX3CL1
5AAS	;		;	The selective autophagy receptor TAX1BP1 is required for autophagy- dependent capture of cytosolic Salmonella typhimurium
1HQN	;	2.2	;	THE SELENOMETHIONINE DERIVATIVE OF P3, THE MAJOR COAT PROTEIN OF THE LIPID-CONTAINING BACTERIOPHAGE PRD1.
6IV8	;	2.15	;	the selenomethionine(SeMet)-derived Cas13d binary complex
4UZ8	;	2.3	;	The SeMet structure of the family 46 carbohydrate-binding module (CBM46) of endo-beta-1,4-glucanase B (Cel5B) from Bacillus halodurans
5GPO	;	1.701	;	The sensor domain structure of the zinc-responsive histidine kinase CzcS from Pseudomonas Aeruginosa
1ION	;	2.3	;	THE SEPTUM SITE-DETERMINING PROTEIN MIND COMPLEXED WITH MG-ADP FROM PYROCOCCUS HORIKOSHII OT3
1TCA	;	1.55	;	THE SEQUENCE, CRYSTAL STRUCTURE DETERMINATION AND REFINEMENT OF TWO CRYSTAL FORMS OF LIPASE B FROM CANDIDA ANTARCTICA
1TCB	;	2.1	;	THE SEQUENCE, CRYSTAL STRUCTURE DETERMINATION AND REFINEMENT OF TWO CRYSTAL FORMS OF LIPASE B FROM CANDIDA ANTARCTICA
1TCC	;	2.5	;	THE SEQUENCE, CRYSTAL STRUCTURE DETERMINATION AND REFINEMENT OF TWO CRYSTAL FORMS OF LIPASE B FROM CANDIDA ANTARCTICA
1EKB	;	2.3	;	THE SERINE PROTEASE DOMAIN OF ENTEROPEPTIDASE BOUND TO INHIBITOR VAL-ASP-ASP-ASP-ASP-LYS-CHLOROMETHANE
1Z23	;		;	The serine-rich domain from Crk-associated substrate (p130Cas)
7B9Q	;	2.78	;	The SERp optimized structure of Ribonucleotide reductase from Rhodobacter sphaeroides
3CLZ	;	2.2	;	The set and ring associated (SRA) domain of UHRF1 bound to methylated DNA
8ATK	;		;	The SH2 domain of mouse SH2B1
1AOJ	;	2.5	;	THE SH3 DOMAIN OF EPS8 EXISTS AS A NOVEL INTERTWINED DIMER
6CQ7	;	2.0	;	The SH3 domain of MLK3 in complex with poly-proline peptide derived from Htt
5WZZ	;	2.103	;	The SIAH E3 ubiquitin ligases promote Wnt/ beta-catenin signaling through mediating Wnt-induced Axin degradation
3SAO	;	1.8	;	The Siderocalin Ex-FABP functions through dual ligand specificities
2FFH	;	3.2	;	THE SIGNAL SEQUENCE BINDING PROTEIN FFH FROM THERMUS AQUATICUS
1UAT	;	1.9	;	The significance of the flexible loop in the azurin (Az-iso2) from the obligate methylotroph Methylomonas sp. strain J
7CB6	;	2.64	;	The silver-bound 6-phosphogluconate dehydrogenase from Staphylococcus aureus (strain Newman)
5AH2	;	2.129	;	The sliding clamp of Mycobacterium smegmatis in complex with a natural product.
5AH4	;	2.313	;	The sliding clamp of Mycobacterium smegmatis in complex with a natural product.
5AGU	;	2.173	;	The sliding clamp of Mycobacterium tuberculosis in complex with a natural product.
5AGV	;	1.93	;	The sliding clamp of Mycobacterium tuberculosis in complex with a natural product.
3RAP	;	2.2	;	The small G protein Rap2 in a non catalytic complex with GTP
2RAP	;	2.6	;	THE SMALL G PROTEIN RAP2A IN COMPLEX WITH GTP
4TRG	;	2.59	;	the SNL domain of SidC
6L85	;	2.302	;	The sodium-dependent phosphate transporter
1XSW	;		;	The solid-state NMR structure of Kaliotoxin
3NVO	;	2.3	;	The Soluble Domain Structure of the ZntB Zn2+ Efflux System
3NWI	;	3.13	;	The Soluble Domain Structure of the ZntB Zn2+ Efflux System
1QUT	;	2.44	;	THE SOLUBLE LYTIC TRANSGLYCOSYLASE SLT35 FROM ESCHERICHIA COLI IN COMPLEX WITH N-ACETYLGLUCOSAMINE
1CCH	;		;	THE SOLUTION CONFORMATION OF CYTOCHROME C-551 FROM P.STUTZERI ZOBELL DETERMINED BY NMR+
1HUA	;		;	THE SOLUTION CONFORMATION OF HYALURONAN: A COMBINED NMR AND MOLECULAR DYNAMICS STUDY
1PU3	;		;	The Solution NMR Structure and Dynamics of a Recombinant Onconase with Altered N-terminal and Met23 residues
5SXY	;		;	The solution NMR structure for the PqqD truncation of Methylobacterium extorquens PqqCD representing a functional and stand-alone ribosomally synthesized and post-translational modified (RiPP) recognition element (RRE)
1HM1	;		;	THE SOLUTION NMR STRUCTURE OF A THERMALLY STABLE FAPY ADDUCT OF AFLATOXIN B1 IN AN OLIGODEOXYNUCLEOTIDE DUPLEX REFINED FROM DISTANCE RESTRAINED MOLECULAR DYNAMICS SIMULATED ANNEALING, MINIMIZED AVERAGE STRUCTURE
1AWO	;		;	THE SOLUTION NMR STRUCTURE OF ABL SH3 AND ITS RELATIONSHIP TO SH2 IN THE SH(32) CONSTRUCT, 20 STRUCTURES
1AGK	;		;	THE SOLUTION NMR STRUCTURE OF AN (R)-A-(N6-ADENYL)-STYRENE OXIDE-RAS61 OLIGODEOXYNUCLEOTIDE MODIFIED AT THE SECOND POSITION OF THE CODON 61 REGION, MINIMIZED AVERAGE STRUCTURE
1AGZ	;		;	THE SOLUTION NMR STRUCTURE OF AN (R)-A-(N6-ADENYL)-STYRENE OXIDE-RAS61 OLIGODEOXYNUCLEOTIDE MODIFIED AT THE THIRD POSITION OF THE CODON 61 REGION, MINIMIZED AVERAGE STRUCTURE
1AGO	;		;	THE SOLUTION NMR STRUCTURE OF AN (S)-A-(N6-ADENYL)-STYRENE OXIDE-RAS61 OLIGODEOXYNUCLEOTIDE MODIFIED AT THE THIRD POSITION OF THE CODON 61 REGION, MINIMIZED AVERAGE STRUCTURE
1AF1	;		;	THE SOLUTION NMR STRUCTURE OF AN R-STYRENE OXIDE ADDUCT AT THE N2 POSITION OF GUANINE OF AN 11 BASE-PAIR OLIGONUCLEOTIDE SEQUENCE CODING FOR AMINO ACIDS 11-13 OF THE PRODUCT OF THE N-RAS PROTOONCOGENE, MINIMIZED AVERAGE STRUCTURE
1AP1	;		;	THE SOLUTION NMR STRUCTURE OF AN S-STYRENE OXIDE ADDUCT AT THE N2 POSITION OF GUANINE OF AN 11 BASE-PAIR OLIGONUCLEOTIDE SEQUENCE CODING FOR AMINO ACIDS 11-13 OF THE PRODUCT OF THE N-RAS PROTOONCOGENE, MINIMIZED AVERAGE STRUCTURE
6G4I	;		;	The solution NMR structure of brevinin-1BYa in 33% trifluoroethanol
6G4U	;		;	The solution NMR structure of brevinin-1BYa in dodecylphosphocholine micelles
6G4K	;		;	The solution NMR structure of brevinin-1BYa in sodium dodecyl sulphate micelles
6R95	;		;	The solution NMR structure of cis-dicarba-brevinin-1BYa in 33% trifluoroethanol
6R96	;		;	The solution NMR structure of cis-dicarba-brevinin-1BYa in sodium dodecyl sulphate micelles
2M8C	;		;	The solution NMR structure of E. coli apo-HisJ
2MHW	;		;	The solution NMR structure of maximin-4 in SDS micelles
6ACV	;		;	the solution NMR structure of MBD domain
1A2S	;		;	THE SOLUTION NMR STRUCTURE OF OXIDIZED CYTOCHROME C6 FROM THE GREEN ALGA MONORAPHIDIUM BRAUNII, MINIMIZED AVERAGE STRUCTURE
1AW3	;		;	THE SOLUTION NMR STRUCTURE OF OXIDIZED RAT MICROSOMAL CYTOCHROME B5, MINIMIZED AVERAGE STRUCTURE
1BFX	;		;	THE SOLUTION NMR STRUCTURE OF THE B FORM OF OXIDIZED RAT MICROSOMAL CYTOCHROME B5, MINIMIZED AVERAGE STRUCTURE
2NAZ	;		;	The solution NMR structure of the C-terminal effector domain of BfmR from Acinetobacter baumannii
1AGU	;		;	THE SOLUTION NMR STRUCTURE OF THE C10R ADDUCT OF BENZO[A]PYRENE-DIOL-EPOXIDE AT THE N6 POSITION OF ADENINE OF AN 11 BASE-PAIR OLIGONUCLEOTIDE SEQUENCE CODING FOR AMINO ACIDS 60-62 OF THE PRODUCT OF THE N-RAS PROTOONCOGENE, MINIMIZED AVERAGE STRUCTURE
2K1R	;		;	The solution NMR structure of the complex between MNK1 and HAH1 mediated by Cu(I)
1BT7	;		;	THE SOLUTION NMR STRUCTURE OF THE N-TERMINAL PROTEASE DOMAIN OF THE HEPATITIS C VIRUS (HCV) NS3-PROTEIN, FROM BK STRAIN, 20 STRUCTURES
2MJM	;		;	The solution NMR structure of the NLRC5 caspase recruitment domain (CARD)
2JM4	;		;	The solution NMR structure of the relaxin (RXFP1) receptor LDLa module.
2LP1	;		;	The solution NMR structure of the transmembrane C-terminal domain of the amyloid precursor protein (C99)
7BX2	;		;	The solution NMR structure of VV14 peptide in the presence of Deuterated SDS micelle.
6G4V	;		;	The solution NMR structure of [C18S,C24S]brevinin-1BYa in 33% trifluoroethanol
6G4X	;		;	The solution NMR structure of [C18S,C24S]brevinin-1BYa in sodium dodecyl sulphate micelles
1CRP	;		;	THE SOLUTION STRUCTURE AND DYNAMICS OF RAS P21. GDP DETERMINED BY HETERONUCLEAR THREE AND FOUR DIMENSIONAL NMR SPECTROSCOPY
1CRQ	;		;	THE SOLUTION STRUCTURE AND DYNAMICS OF RAS P21. GDP DETERMINED BY HETERONUCLEAR THREE AND FOUR DIMENSIONAL NMR SPECTROSCOPY
1CRR	;		;	THE SOLUTION STRUCTURE AND DYNAMICS OF RAS P21. GDP DETERMINED BY HETERONUCLEAR THREE AND FOUR DIMENSIONAL NMR SPECTROSCOPY
1HMA	;		;	THE SOLUTION STRUCTURE AND DYNAMICS OF THE DNA BINDING DOMAIN OF HMG-D FROM DROSOPHILA MELANOGASTER
1XV6	;		;	The solution structure of 2',5'-linked 3'-O-(2-methoxyethyl)-RNA hairpin
2M39	;		;	The solution structure of 3',5'-LINKED 2'-O-(2-METHOXYETHYL)-RNA DUPLEX
1QGM	;		;	THE SOLUTION STRUCTURE OF A 30 RESIDUE AMINO-TERMINAL DOMAIN OF THE CARP GRANULIN-1 PROTEIN.
1FWO	;		;	THE SOLUTION STRUCTURE OF A 35-RESIDUE FRAGMENT FROM THE GRANULIN/EPITHELIN-LIKE SUBDOMAIN OF RICE ORYZAIN BETA (ROB 382-416 (C398S,C399S,C407S,C413S))
1I7V	;		;	THE SOLUTION STRUCTURE OF A BAY REGION 1R-BENZ[A]ANTHRACENE OXIDE ADDUCT AT THE N6 POSITION OF ADENINE OF AN OLIGODEOXYNUCLEOTIDE CONTAINING THE HUMAN N-RAS CODON 61 SEQUENCE
1QBY	;		;	THE SOLUTION STRUCTURE OF A BAY-REGION 1R-BENZ[A]ANTHRACENE OXIDE ADDUCT AT THE N6 POSITION OF ADENINE OF AN OLIGODEOXYNUCLEOTIDE CONTAINING THE HUMAN N-RAS CODON 61 SEQUENCE
1DL4	;		;	THE SOLUTION STRUCTURE OF A BAY-REGION 1S-BENZ[A]ANTHRACENE OXIDE ADDUCT AT THE N6 POSITION OF ADENINE OF AN OLIGODEOXYNUCLEOTIDE CONTAINING THE HUMAN N-RAS CODON 61 SEQUENCE
2MFD	;		;	The Solution Structure of a cGCUUAg RNA Pentaloop from Bovine Enterovirus Vir404/03
2K6U	;		;	The Solution Structure of a Conformationally Restricted Fully Active Derivative of the Human Relaxin-like Factor (RLF)
1BC4	;		;	THE SOLUTION STRUCTURE OF A CYTOTOXIC RIBONUCLEASE FROM THE OOCYTES OF RANA CATESBEIANA (BULLFROG), NMR, 15 STRUCTURES
108D	;		;	THE SOLUTION STRUCTURE OF A DNA COMPLEX WITH THE FLUORESCENT BIS INTERCALATOR TOTO DETERMINED BY NMR SPECTROSCOPY
214D	;		;	THE SOLUTION STRUCTURE OF A DNA DUPLEX CONTAINING A SINGLE 2'-O-METHYL-BETA-D-ARAT
2IVW	;		;	The solution structure of a domain from the Neisseria meningitidis PilP pilot protein.
1ZTA	;		;	THE SOLUTION STRUCTURE OF A LEUCINE-ZIPPER MOTIF PEPTIDE
1DSW	;		;	THE SOLUTION STRUCTURE OF A MONOMERIC, REDUCED FORM OF HUMAN COPPER, ZINC SUPEROXIDE DISMUTASE BEARING THE SAME CHARGE AS THE NATIVE PROTEIN
1DJD	;		;	THE SOLUTION STRUCTURE OF A NON-BAY REGION 11R-BENZ[A]ANTHRACENE OXIDE ADDUCT AT THE N6 POSITION OF ADENINE OF AN OLIGODEOXYNUCLEOTIDE CONTAINING THE HUMAN N-RAS CODON 61 SEQUENCE
2O4E	;		;	The solution structure of a protein-protein interaction module from a family 84 glycoside hydrolase of Clostridium perfringens
1YYX	;		;	The solution structure of a redesigned apocytochrome B562 (Rd-apocyt b562) at 2.8M urea
1YZC	;		;	The solution structure of a redesigned apocytochrome B562 (Rd-apocyt b562) with the N- and a part of the C-terminal helices unfolded
1YZA	;		;	The solution structure of a redesigned apocytochrome B562 (Rd-apocyt b562) with the N-terminal helix unfolded
1BM5	;		;	THE SOLUTION STRUCTURE OF A SITE-DIRECTED MUTANT (R111M) OF HUMAN CELLULAR RETIONIC ACID BINDING PROTEIN-TYPE II, NMR, 31 STRUCTURES
1U3K	;		;	The solution structure of a substrate of archaeal pre-tRNA splicing endonucleases
1MFD	;	2.1	;	THE SOLUTION STRUCTURE OF A TRISACCHARIDE-ANTIBODY COMPLEX: COMPARISON OF NMR MEASUREMENTS WITH A CRYSTAL STRUCTURE
1G26	;		;	THE SOLUTION STRUCTURE OF A WELL-FOLDED PEPTIDE BASED ON THE 31-RESIDUE AMINO-TERMINAL SUBDOMAIN OF HUMAN GRANULIN A
2XV9	;		;	The solution structure of ABA-1A saturated with oleic acid
8EPY	;		;	The solution structure of abxF in complex with its product (-)-ABX, an enzyme catalyzing the formation of the chiral spiroketal of an anthrabenzoxocinone antibiotic, (-)-ABX
8EO9	;		;	The solution structure of abxF, an enzyme catalyzing the formation of chiral spiroketal of an antibiotics, (-)-ABX
1KLP	;		;	The Solution Structure of Acyl Carrier Protein from Mycobacterium tuberculosis
5Y0U	;		;	The solution structure of AEBP2 C2H2 zinc fingers
1BA4	;		;	THE SOLUTION STRUCTURE OF AMYLOID BETA-PEPTIDE (1-40) IN A WATER-MICELLE ENVIRONMENT. IS THE MEMBRANE-SPANNING DOMAIN WHERE WE THINK IT IS? NMR, 10 STRUCTURES
1AGH	;		;	THE SOLUTION STRUCTURE OF AN 11 BASE-PAIR OLIGONUCLEOTIDE DUPLEX CODING FOR AMINO ACIDS 60-62 OF THE PRODUCT OF THE N-RAS PROTOONCOGENE, NMR, MINIMIZED AVERAGE STRUCTURE
1AG5	;		;	THE SOLUTION STRUCTURE OF AN AFLATOXIN B1 EPOXIDE ADDUCT AT THE N7 POSITION OF GUANINE OPPOSITE AN ADENINE IN THE COMPLEMENTARY STRAND OF AN OLIGODEOXYNUCLEOTIDE DUPLEX, NMR, MINIMIZED AVERAGE STRUCTURE
1P9Z	;		;	The Solution Structure of Antifungal Peptide Distinct With a Five-disulfide Motif from Eucommia ulmoides Oliver
2HHI	;		;	The solution structure of antigen MPT64 from Mycobacterium tuberculosis defines a novel class of beta-grasp proteins
1P8G	;		;	The solution structure of apo CopZ from Bacillus subtilis
2KEW	;		;	The solution structure of Bacillus subtilis SR211 START domain by NMR spectroscopy
2KTE	;		;	The solution structure of Bacillus subtilis, YndB, Northeast Structural Genomics Consoritum Target SR211
1OA5	;		;	The solution structure of bovine pancreatic trypsin inhibitor at high pressure
1OA6	;		;	The solution structure of bovine pancreatic trypsin inhibitor at high pressure
2LT9	;		;	The solution structure of Ca2+ binding domain 2B of the third isoform of the Na+/Ca2+ exchanger
2L4H	;		;	The Solution Structure of Calcium Bound CIB1
2JV9	;		;	The Solution Structure of Calponin Homology Domain from Smoothelin-like 1
1CVO	;		;	THE SOLUTION STRUCTURE OF CARDIOTOXIN V FROM NAJA NAJA ATRA
2KLQ	;		;	The solution structure of CBD of human MCM6
1HTH	;		;	The solution structure of cyclic human parathyroid hormone fragment 1-34, NMR, 10 structures
1C6S	;		;	THE SOLUTION STRUCTURE OF CYTOCHROME C6 FROM THE THERMOPHILIC CYANOBACTERIUM SYNECHOCOCCUS ELONGATUS, NMR, 20 STRUCTURES
1U64	;		;	The Solution Structure of d(G3T4G4)2
1LVS	;		;	THE SOLUTION STRUCTURE OF D(G4T4G3)2
2MXQ	;		;	The solution structure of DEFA1, a highly potent antimicrobial peptide from the horse
1EGL	;		;	THE SOLUTION STRUCTURE OF EGLIN C BASED ON MEASUREMENTS OF MANY NOES AND COUPLING CONSTANTS AND ITS COMPARISON WITH X-RAY STRUCTURES
2K4Q	;		;	The Solution Structure of gpV, the Major Tail Protein from Bacteriophage Lambda
2JXF	;		;	The solution structure of HCV NS4B(40-69)
2RQP	;		;	The Solution Structure of Heterochromatin Protein 1-Binding Protein 74 Histone H1 like domain
1NNV	;		;	The Solution structure of HI1450
1PFD	;		;	THE SOLUTION STRUCTURE OF HIGH PLANT PARSLEY [2FE-2S] FERREDOXIN, NMR, 18 STRUCTURES
2LP0	;		;	The solution structure of homeodomain-protein complex
2DCV	;		;	The solution structure of horseshoe crab antimicrobial peptide tachystatin b with the inhibitory cystine-knot motif
2DCW	;		;	The solution structure of horseshoe crab antimicrobial peptide tachystatin b with the inhibitory cystine-knot motif
7Q4L	;		;	The solution structure of hsDND1 RRM12 bound to CUUAUUUG RNA
2KDH	;		;	The Solution Structure of Human Cardiac Troponin C in complex with the Green Tea Polyphenol; (-)-epigallocatechin-3-gallate
2RQR	;		;	The solution structure of human DOCK2 SH3 domain - ELMO1 peptide chimera complex
2NBR	;		;	The Solution Structure of Human gammaC-crystallin
2K3J	;		;	The solution structure of human Mia40
6KVG	;		;	The solution structure of human Orc6
1HPY	;		;	THE SOLUTION STRUCTURE OF HUMAN PARATHYROID HORMONE FRAGMENT 1-34 IN 20% TRIFLUORETHANOL, NMR, 10 STRUCTURES
1BWX	;		;	THE SOLUTION STRUCTURE OF HUMAN PARATHYROID HORMONE FRAGMENT 1-39, NMR, 10 STRUCTURES
2L1X	;		;	The Solution Structure Of Human Parathyroid Hormone-Related Protein
1BZG	;		;	THE SOLUTION STRUCTURE OF HUMAN PARATHYROID HORMONE-RELATED PROTEIN (1-34) IN NEAR-PHYSIOLOGICAL SOLUTION, NMR, 30 STRUCTURES
2M0O	;		;	The solution structure of human PHF1 in complex with H3K36me3
2TGF	;		;	THE SOLUTION STRUCTURE OF HUMAN TRANSFORMING GROWTH FACTOR ALPHA
3TGF	;		;	THE SOLUTION STRUCTURE OF HUMAN TRANSFORMING GROWTH FACTOR ALPHA
2A2V	;		;	The solution structure of Jingzhaotoxin-XI
1YOP	;		;	The solution structure of Kti11p
2L4I	;		;	The Solution Structure of Magnesium bound CIB1
1MGS	;		;	THE SOLUTION STRUCTURE OF MELANOMA GROWTH STIMULATING ACTIVITY
2RPB	;		;	The solution structure of membrane protein
2D2P	;		;	The solution structure of micelle-bound peptide
1J0T	;		;	The solution structure of molt-inhibiting hormone from the kuruma prawn
1KMG	;		;	The Solution Structure Of Monomeric Copper-free Superoxide Dismutase
3ZD0	;		;	The Solution Structure of Monomeric Hepatitis C Virus p7 Yields Potent Inhibitors of Virion Release
2KX2	;		;	The solution structure of MTH1821
2RPA	;		;	The solution structure of N-terminal domain of microtubule severing enzyme
6LZP	;		;	The solution structure of N-terminal elongated hSNF5 RPT1 domain
2M08	;		;	The solution structure of NmPin, the parvuline of Nitrosopumilus maritimus
1AGG	;		;	THE SOLUTION STRUCTURE OF OMEGA-AGA-IVB, A P-TYPE CALCIUM CHANNEL ANTAGONIST FROM THE VENOM OF AGELENOPSIS APERTA
7JPM	;		;	The solution structure of omega-theraphotoxin-Pm1b isolated from King Baboon spider
1AXX	;		;	THE SOLUTION STRUCTURE OF OXIDIZED RAT MICROSOMAL CYTOCHROME B5, NMR, 19 STRUCTURES
2AXX	;		;	THE SOLUTION STRUCTURE OF OXIDIZED RAT MICROSOMAL CYTOCHROME B5, NMR, 21 STRUCTURES
2LTF	;		;	The solution structure of Phage P2 gpX
2RM8	;		;	The solution structure of phototactic transducer protein HtrII linker region from Natronomonas pharaonis
2GLW	;		;	The solution structure of PHS018 from pyrococcus horikoshii
1DIP	;		;	THE SOLUTION STRUCTURE OF PORCINE DELTA-SLEEP-INDUCING PEPTIDE IMMUNOREACTIVE PEPTIDE, NMR, 10 STRUCTURES
2L42	;		;	The solution structure of Rap1 BRCT domain from Saccharomyces cerevisiae
1NMJ	;		;	The Solution Structure of Rat Ab-(1-28) and its Interaction with Zinc: Insights into the Scarity of Amyloid Deposition in Aged Rat Brain
1L3N	;		;	The Solution Structure of Reduced Dimeric Copper Zinc SOD: the Structural Effects of Dimerization
1BA9	;		;	THE SOLUTION STRUCTURE OF REDUCED MONOMERIC SUPEROXIDE DISMUTASE, NMR, 36 STRUCTURES
7RZ3	;		;	The solution structure of remipede double-ICK toxin phi-Xibalbin3-Xt3a
2KI7	;		;	The solution structure of RPP29-RPP21 complex from Pyrococcus furiosus
1WIF	;		;	The solution structure of RSGI RUH-020, a PDZ domain of hypothetical protein from mouse
1WIX	;		;	The solution structure of RSGI RUH-026, conserved domain of HOOK1 protein from mouse
1SGG	;		;	THE SOLUTION STRUCTURE OF SAM DOMAIN FROM THE RECEPTOR TYROSINE KINASE EPHB2, NMR, 10 STRUCTURES
1FRY	;		;	THE SOLUTION STRUCTURE OF SHEEP MYELOID ANTIMICROBIAL PEPTIDE, RESIDUES 1-29 (SMAP29)
6LF5	;		;	The solution structure of ShSPI
2N4I	;		;	The solution structure of Skint-1, a critical determinant of dendritic epidermal gamma-delta T cell selection
2L1W	;		;	The solution structure of soybean calmodulin isoform 4 complexed with the vacuolar calcium ATPase BCA1 peptide
2LL3	;		;	The solution structure of TgMIC4 apple-5 domain
2CUM	;		;	The solution structure of the 33rd fibronectin type III domain of human Tenascin-X
1UYA	;		;	THE SOLUTION STRUCTURE OF THE A-FORM OF UROGUANYLIN-16 NMR, 10 STRUCTURES
1LYP	;		;	THE SOLUTION STRUCTURE OF THE ACTIVE DOMAIN OF CAP18: A LIPOPOLYSACCHARIDE BINDING PROTEIN FROM RABBIT LEUKOCYTES
2L3J	;		;	The solution structure of the ADAR2 dsRBM-RNA complex reveals a sequence-specific read out of the minor groove
2A00	;		;	The solution structure of the AMP-PNP bound nucleotide binding domain of KdpB
2A29	;		;	The solution structure of the AMP-PNP bound nucleotide binding domain of KdpB
1RZW	;		;	The Solution Structure of the Archaeglobus fulgidis protein AF2095. Northeast Structural Genomics Consortium target GR4
2K9A	;		;	The Solution Structure of the Arl2 Effector, BART
1UYB	;		;	THE SOLUTION STRUCTURE OF THE B-FORM OF UROGUANYLIN-16 NMR, 10 STRUCTURES
2HTF	;		;	The solution structure of the BRCT domain from human polymerase reveals homology with the TdT BRCT domain
1G84	;		;	THE SOLUTION STRUCTURE OF THE C EPSILON2 DOMAIN FROM IGE
7VU7	;		;	The Solution structure of the C-terminal domain from flagelliform spidroin
2EXD	;		;	The solution structure of the C-terminal domain of a nfeD homolog from Pyrococcus horikoshii
2MC4	;		;	The solution structure of the C-terminal domain of BldD from Streptomyces coelicolor
1X53	;		;	The solution structure of the C-terminal domain of human Activator of 90 kDa heat shock protein ATPase homolog 1
2L04	;		;	The Solution Structure of the C-terminal Ig-like Domain of the Bacteriophage Lambda Tail Tube Protein
2RRF	;		;	The solution structure of the C-terminal region of Zinc finger FYVE domain-containing protein 21
1K42	;		;	The Solution Structure of the CBM4-2 Carbohydrate Binding Module from a Thermostable Rhodothermus marinus Xylanase.
1K45	;		;	The Solution Structure of the CBM4-2 Carbohydrate Binding Module from a Thermostable Rhodothermus marinus Xylanase.
2BUD	;		;	The solution structure of the chromo barrel domain from the males- absent on the first (MOF) protein
2KJF	;		;	The solution structure of the circular bacteriocin carnocyclin A (CclA)
2I9S	;		;	The solution structure of the core of mesoderm development (MESD).
2LRE	;		;	The solution structure of the dimeric Acanthaporin
2LYD	;		;	The solution structure of the Dm DCP1 EVH1 domain in complex with the XRN1 DBM peptide
1QK9	;		;	The solution structure of the domain from MeCP2 that binds to methylated DNA
1OIG	;		;	The solution structure of the DPY module from the Dumpy protein
2KNH	;		;	The Solution structure of the eTAFH domain of AML1-ETO complexed with HEB peptide
1IRL	;		;	THE SOLUTION STRUCTURE OF THE F42A MUTANT OF HUMAN INTERLEUKIN 2
1W1N	;		;	The solution structure of the FATC Domain of the Protein Kinase TOR1 from yeast
1X5J	;		;	The solution structure of the fifth fibronectin type III domain of human Neogenin
1UDL	;		;	The solution structure of the fifth SH3 domain of intersectin 2 (KIAA1256)
1X5F	;		;	The solution structure of the first fibronectin type III domain of human Neogenin
2DJQ	;		;	The solution structure of the first SH3 domain of mouse SH3 domain containing ring finger 2
2DJ1	;		;	The solution structure of the first thioredoxin domain of mouse Protein disulfide-isomerase A4
2DML	;		;	The solution structure of the first thioredoxin domain of mouse Protein disulfide-isomerase A6
2DMK	;		;	The solution structure of the FN3 domain of human Midline 2 protein
1X5I	;		;	The solution structure of the fourth fibronectin type III domain of human Neogenin
2MUY	;		;	The solution structure of the FtsH periplasmic N-domain
2KQA	;		;	The solution structure of the fungal elicitor Cerato-Platanin
2L7H	;		;	The solution structure of the HAMP domain of the hypothetical transmembrane receptor Af1503
2L7I	;		;	The solution structure of the HAMP domain of the hypothetical transmembrane receptor Af1503 (A291F variant)
1QQ3	;		;	THE SOLUTION STRUCTURE OF THE HEME BINDING VARIANT ARG98CYS OF OXIDIZED ESCHERICHIA COLI CYTOCHROME B562
2DJN	;		;	The solution structure of the homeobox domain of human Homeobox protein DLX-5
2DMN	;		;	The solution structure of the homeobox domain of human homeobox protein TGIF2LX
1HRA	;		;	THE SOLUTION STRUCTURE OF THE HUMAN RETINOIC ACID RECEPTOR-BETA DNA-BINDING DOMAIN
2IXQ	;		;	The solution structure of the invasive tip complex from Afa-Dr fibrils
2M6Y	;		;	The solution structure of the J-domain of human DnaJA1
2RR9	;		;	The solution structure of the K63-Ub2:tUIMs complex
2N52	;		;	The solution structure of the kallikrein inhibitor SPINK6
2AFF	;		;	The solution structure of the Ki67FHA/hNIFK(226-269)3P complex
2LI8	;		;	The solution structure of the Lin28-ZnF domains bound to AGGAGAU of pre-let-7 miRNA
1MNX	;		;	The Solution Structure of the Loop E Region of the 5S rRNA from Spinach Chloroplasts.
6GD5	;		;	The solution structure of the LptA-Thanatin complex
2DJP	;		;	The solution structure of the LysM domain of human hypothetical protein SB145
2KSZ	;		;	The solution structure of the Magnesium bound soybean calmodulin isoform 4 N-domain
2MZK	;		;	The solution structure of the Magnesium-bound Conantokin RLB
2MZM	;		;	The Solution Structure of the Magnesium-bound Conantokin-G
2MZL	;		;	The Solution Structure of the Magnesium-bound Conantokin-G Mutant
2MYZ	;		;	The Solution Structure of the Magnesium-bound Conantokin-R1B Mutant
5TBG	;		;	The Solution Structure of the Magnesium-bound Conantokin-R1B Mutant
5TBQ	;		;	The Solution Structure of the Magnesium-bound Conantokin-R1B Mutant
5TBR	;		;	The Solution Structure of the Magnesium-bound Conantokin-R1B Mutant
1I4B	;		;	The solution structure of the major family of the mutant stem loop C 5'UUA3' triloop of brome mosaic virus (+) strand RNA
2MSX	;		;	The solution structure of the MANEC-type domain from Hepatocyte Growth Factor Inhibitor 1 reveals an unexpected PAN/apple domain-type fold
2ARW	;		;	The solution structure of the membrane proximal cytokine receptor domain of the human interleukin-6 receptor
6HKA	;		;	The solution structure of the micelle-associated FATC domain of the human protein kinase ataxia telangiectasia mutated (ATM)
1I4C	;		;	THE SOLUTION STRUCTURE OF THE MINOR FAMILY OF THE MUTANT STEM LOOP C 5'UUA3' TRILOOP OF BROME MOSAIC VIRUS (+) STRAND RNA
4BZT	;		;	The Solution Structure of the MLN 944-d(ATGCAT)2 Complex
4BZV	;		;	The Solution Structure of the MLN 944-d(TACGCGTA)2 complex
4BZU	;		;	The Solution Structure of the MLN 944-d(TATGCATA)2 Complex
2LRD	;		;	The solution structure of the monomeric Acanthaporin
2K4W	;		;	The Solution Structure of the Monomeric Copper, Zinc Superoxide Dismutase from Salmonella enterica
2JO0	;		;	The solution structure of the monomeric species of the C terminal domain of the CA protein of HIV-1
1JZC	;		;	THE SOLUTION STRUCTURE OF THE MUTANT 5'AUG3' TRILOOP IN THE RNA PROMOTER REGION OF THE BROME MOSAIC VIRUS GENOMIC (+)-RNA
2KX3	;		;	The solution structure of the mutant of UBL domain of UBLCP1, I5M
1I46	;		;	The solution structure of the mutant stem loop C 5'GUA3' triloop of brome mosaic virus (+) strand RNA
2DAN	;		;	The solution structure of the MYND domain (LEU384-CYS430) of human Zinc finger MYND domain containing protein 10
1YFB	;		;	The solution structure of the N-domain of the transcription factor abrB
1YSF	;		;	The solution structure of the N-domain of the transcription factor abrB
2L3L	;		;	The solution structure of the N-terminal domain of human Tubulin Binding Cofactor C reveals a platform for the interaction with ab-tubulin
2RQ2	;		;	The solution structure of the N-terminal fragment of big defensin
1WCO	;		;	The solution structure of the nisin-lipid II complex
1SVJ	;		;	The solution structure of the nucleotide binding domain of KdpB
1U7Q	;		;	THE SOLUTION STRUCTURE OF THE NUCLEOTIDE BINDING DOMAIN OF KDPB
1POU	;		;	THE SOLUTION STRUCTURE OF THE OCT-1 POU-SPECIFIC DOMAIN REVEALS A STRIKING SIMILARITY TO THE BACTERIOPHAGE LAMBDA REPRESSOR DNA-BINDING DOMAIN
2L49	;		;	The solution structure of the P2 C,the immunity repressor of the P2 bacteriophage
2RMN	;		;	The solution structure of the p63 DNA-binding domain
1RHW	;		;	The solution structure of the pH-induced monomer of dynein light chain LC8 from Drosophila
2KYU	;		;	The solution structure of the PHD3 finger of MLL
1SXE	;		;	The solution structure of the Pointed (PNT) domain from the transcrition factor Erg
169D	;		;	THE SOLUTION STRUCTURE OF THE R(GCG)D(TATACCC):D(GGGTATACGC) OKAZAKI FRAGMENT CONTAINS TWO DISTINCT DUPLEX MORPHOLOGIES CONNECTED BY A JUNCTION
2NPU	;		;	The solution structure of the rapamycin-binding domain of mTOR (FRB)
2BIC	;		;	The solution structure of the recombinant elicitor protein PcF from the oomycete pathogen P. cactorum
2KIT	;		;	The solution structure of the reduced yeast TOR1 FATC domain bound to DPC micelles at 298K
2F3J	;		;	The solution structure of the REF2-I mRNA export factor (residues 1-155).
2MDA	;		;	The Solution Structure of the Regulatory Domain of Tyrosine Hydroxylase
1X5G	;		;	The solution structure of the second fibronectin type III domain of human Neogenin
1X5A	;		;	The solution structure of the second fibronectin type III domain of mouse Ephrin type-A receptor 1
1ADZ	;		;	THE SOLUTION STRUCTURE OF THE SECOND KUNITZ DOMAIN OF TISSUE FACTOR PATHWAY INHIBITOR, NMR, 30 STRUCTURES
7FBV	;		;	The solution structure of the second RRM domain of Matrin-3
2DMM	;		;	The solution structure of the second thioredoxin domain of human Protein disulfide-isomerase A3
2DJ2	;		;	The solution structure of the second thioredoxin domain of mouse Protein disulfide-isomerase A4
1X5C	;		;	The solution structure of the second thioredoxin-like domain of human Protein disulfide-isomerase
1X5D	;		;	The solution structure of the second thioredoxin-like domain of human Protein disulfide-isomerase A6
2L3D	;		;	The solution structure of the short form SWIRM domain of LSD1
1X5K	;		;	The solution structure of the sixth fibronectin type III domain of human Neogenin
6K4V	;		;	The solution structure of the smart chimeric peptide G6
1NG7	;		;	The Solution Structure of the Soluble Domain of Poliovirus 3A Protein
2N0M	;		;	The solution structure of the soluble form of the Lipid-modified Azurin from Neisseria gonorrhoeae
2KXG	;		;	The solution structure of the squash aspartic acid proteinase inhibitor (SQAPI)
1ESH	;		;	THE SOLUTION STRUCTURE OF THE STEM LOOP C 5'AUA3' TRILOOP OF BROME MOSAIC VIRUS (+) STRAND RNA
2COM	;		;	The solution structure of the SWIRM domain of human LSD1
2DBA	;		;	The solution structure of the tetratrico peptide repeat of human Smooth muscle cell associated protein-1, isoform 2
1LY7	;		;	The solution structure of the the c-terminal domain of frataxin, the protein responsible for friedreich ataxia
2DIY	;		;	The solution structure of the thioredoxin domain of human Thioredoxin-like protein 2
2DJ0	;		;	The solution structure of the thioredoxin domain of human Thioredoxin-related transmembrane protein 2
1X5E	;		;	The solution structure of the thioredoxin-like domain of human Thioredoxin-related transmembrane protein
1X5H	;		;	The solution structure of the third fibronectin type III domain of human Neogenin
2ECB	;		;	The solution structure of the third homeobox domain of human zinc fingers and homeoboxes protein
1IRH	;		;	The Solution Structure of The Third Kunitz Domain of Tissue Factor Pathway Inhibitor
2DIZ	;		;	The solution structure of the third thioredoxin domain of human Thioredoxin domain-containing protein 5
2DJ3	;		;	The solution structure of the third thioredoxin domain of mouse Protein disulfide-isomerase A4
8AJR	;		;	The Solution Structure of the Triple Mutant Methyl-CpG-Binding Domain from MeCP2
8ALQ	;		;	The Solution Structure of the Triple Mutant Methyl-CpG-Binding Domain from MeCP2 that Binds to Asymmetrically Modified DNA
1X5B	;		;	The solution structure of the VHS domain of human Signal transducing adaptor molecule 2
2LN8	;		;	The solution structure of theromacin
1B69	;		;	THE SOLUTION STRUCTURE OF TN916 INTEGRASE N-TERMINAL DOMAIN/DNA COMPLEX
1TN9	;		;	THE SOLUTION STRUCTURE OF TN916 INTEGRASE N-TERMINAL DOMAIN/DNA COMPLEX
2AFP	;		;	THE SOLUTION STRUCTURE OF TYPE II ANTIFREEZE PROTEIN REVEALS A NEW MEMBER OF THE LECTIN FAMILY
2KX0	;		;	the solution structure of UBB+1, frameshift mutant of ubiquitin B
2K6L	;		;	The solution structure of XACb0070 from Xanthonomas axonopodis pv citri reveals this new protein is a member of the RHH family of transcriptional repressors
2LXW	;		;	The solution structure of XIAP(RING)-binding domain of human XAF1
1P9K	;		;	THE SOLUTION STRUCTURE OF YBCJ FROM E. COLI REVEALS A RECENTLY DISCOVERED ALFAL MOTIF INVOLVED IN RNA-BINDING
1YHD	;		;	The solution structure of YGGX from Escherichia Coli
1DXN	;		;	The Solution Structure of [d(CGC)r(aaa)d(TTTGCG)]2: Hybrid Junctions Flanked by DNA Duplexes
1L3M	;		;	The Solution Structure of [d(CGC)r(amamam)d(TTTGCG)]2
1WSO	;		;	The solution structures of human Orexin-A
1BOC	;		;	THE SOLUTION STRUCTURES OF MUTANT CALBINDIN D9K'S, AS DETERMINED BY NMR, SHOW THAT THE CALCIUM BINDING SITE CAN ADOPT DIFFERENT FOLDS
1BOD	;		;	THE SOLUTION STRUCTURES OF MUTANT CALBINDIN D9K'S, AS DETERMINED BY NMR, SHOW THAT THE CALCIUM BINDING SITE CAN ADOPT DIFFERENT FOLDS
203D	;		;	THE SOLUTION STRUCTURES OF PSORALEN MONOADDUCTED AND CROSSLINKED DNA OLIGOMERS BY NMR SPECTROSCOPY AND RESTRAINED MOLECULAR DYNAMICS
204D	;		;	THE SOLUTION STRUCTURES OF PSORALEN MONOADDUCTED AND CROSSLINKED DNA OLIGOMERS BY NMR SPECTROSCOPY AND RESTRAINED MOLECULAR DYNAMICS
1BTQ	;		;	THE SOLUTION STRUCTURES OF THE FIRST AND SECOND TRANSMEMBRANE-SPANNING SEGMENTS OF BAND 3
1BTR	;		;	THE SOLUTION STRUCTURES OF THE FIRST AND SECOND TRANSMEMBRANE-SPANNING SEGMENTS OF BAND 3
1BTS	;		;	THE SOLUTION STRUCTURES OF THE FIRST AND SECOND TRANSMEMBRANE-SPANNING SEGMENTS OF BAND 3
1BTT	;		;	THE SOLUTION STRUCTURES OF THE FIRST AND SECOND TRANSMEMBRANE-SPANNING SEGMENTS OF BAND 3
2OZ1	;	2.35	;	The SoxAX Complex of Rhodovulum Sulfidophilum
2OX5	;	1.98	;	The SoxYZ complex of Paracoccus pantotrophus
2OXG	;	1.4	;	The SoxYZ Complex of Paracoccus pantotrophus
2OXH	;	2.35	;	The SOXYZ Complex of Paracoccus Pantotrophus
7ZRO	;		;	The spatial structure of amyloidogenic SEM1(68-107) peptide
5BKH	;	2.43	;	The splicing activity and an alternative domain-swapped structure of the Pyrococcus horikoshii PolII mini-intein
2ROV	;		;	The split PH domain of ROCK II
5E4F	;	2.1	;	The spring alpha-helix coordinates multiple modes of HCV NS3 helicase action
7EGM	;	3.6	;	The SRM module of SWI/SNF-nucleosome complex
6QLC	;	2.2	;	The ssDNA-binding RNA polymerase cofactor Drc from Pseudomonas phage LUZ7
1PXV	;	1.8	;	The staphostatin-staphopain complex: a forward binding inhibitor in complex with its target cysteine protease
6KI2	;	2.197	;	The STAS domain of cyanobacteria bicarbonate transporter BicA
7WHJ	;	3.27	;	The state 1 complex structure of Omicron spike with Bn03 (1-up RBD, 3 nanobodies)
7WOQ	;	3.47	;	The state 1 of Omicron Spike with bispecific antibody FD01
7WHI	;	2.93	;	The state 2 complex structure of Omicron spike with Bn03 (2-up RBD, 4 nanobodies)
7WOR	;	3.7	;	The state 2 of Omicron Spike with bispecific antibody FD01
7WHK	;	3.01	;	The state 3 complex structure of Omicron spike with Bn03 (2-up RBD, 5 nanobodies)
7WOS	;	3.91	;	The state 3 of Omicron Spike with bispecific antibody FD01
7WOU	;	3.47	;	The state 4 of Omicron Spike with bispecific antibody FD01
7WOV	;	3.87	;	The state 5 of Omicron Spike with bispecific antibody FD01
7WOW	;	6.11	;	The state 6 of Omicron Spike with bispecific antibody FD01
1OSW	;		;	The Stem of SL1 RNA in HIV-1: Structure and Nucleocapsid Protein Binding for a 1X3 Internal Loop
1MBN	;	2.0	;	The stereochemistry of the protein myoglobin
7QUF	;	2.6	;	The STK17A (DRAK1) Kinase Domain Bound to CK156
7QUE	;	2.4	;	The STK17A (DRAK1) Kinase Domain Bound to CKJB68
2ZLG	;	2.52	;	The Structual Basis for Peptidomimetic Inhibition of Eukaryotic Ribonucleotide Reductase
7EBP	;	1.8	;	The structural analysis of A.Muciniphila sulfatase
7EBQ	;	2.4	;	The structural analysis of A.Muciniphila sulfatase
3QML	;	2.31	;	The structural analysis of Sil1-Bip complex reveals the mechanism for Sil1 to function as a novel nucleotide exchange factor
5EGL	;	2.1	;	The structural and biochemical characterization of acyl-coa hydrolase from Staphylococcus aureus in complex with Butyryl Coenzyme A, Coenzyme A, and Coenzyme A disulfide
5EGJ	;	2.4	;	The structural and biochemical characterization of acyl-coa hydrolase mutant Asn28Ala from Staphylococcus aureus in complex with COENZYME A
5HWF	;	2.5	;	The structural and biochemical characterization of acyl-coa hydrolase mutant Asn28Ala from Staphylococcus aureus.
5EGK	;	2.4	;	The structural and biochemical characterization of acyl-coa hydrolase mutant Asp43Ala from Staphylococcus aureus
5HZ4	;	2.5	;	The structural and biochemical characterization of acyl-coa hydrolase mutant Thr60Ala from Staphylococcus aureus.
2N79	;		;	The structural and functional effects of the Familial Hypertrophic Cardiomyopathy-linked cardiac troponin C mutation, L29Q
1T7I	;	1.35	;	The structural and thermodynamic basis for the binding of TMC114, a next-generation HIV-1 protease inhibitor.
1L54	;	1.9	;	THE STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF BURYING A CHARGED RESIDUE WITHIN THE HYDROPHOBIC CORE OF T4 LYSOZYME
5CJP	;	2.6	;	The Structural Basis for Cdc42-Induced Dimerization of IQGAPs
1F30	;	2.85	;	THE STRUCTURAL BASIS FOR DNA PROTECTION BY E. COLI DPS PROTEIN
1F33	;	2.6	;	THE STRUCTURAL BASIS FOR DNA PROTECTION BY E. COLI DPS PROTEIN
6LKQ	;	3.1	;	The Structural Basis for Inhibition of Ribosomal Translocation by Viomycin
4AF8	;	1.4	;	The structural basis for metacaspase substrate specificity and activation
3MMK	;	2.157	;	The structural basis for partial redundancy in a class of transcription factors, the lim-homeodomain proteins, in neural cell type specification
2ZLF	;	2.59	;	The Structural Basis for Peptidomimetic Inhibition of Eukaryotic Ribonucleotide Reductase
2XSE	;	1.9	;	The structural basis for recognition of J-base containing DNA by a novel DNA-binding domain in JBP1
3GCA	;	2.75	;	The structural basis for recognition of the preQ0 metabolite by an unusually small riboswitch aptamer domain
1UVN	;	3.0	;	The structural basis for RNA specificity and Ca2 inhibition of an RNA-dependent RNA polymerase phi6p2 ca2+ inhibition complex
1UVK	;	2.45	;	The structural basis for RNA specificity and Ca2 inhibition of an RNA-dependent RNA polymerase phi6p2 dead-end complex
1UVM	;	2.0	;	The structural basis for RNA specificity and Ca2 inhibition of an RNA-dependent RNA polymerase phi6p2 with 5NT RNA conformation A
1UVL	;	2.0	;	The structural basis for RNA specificity and Ca2 inhibition of an RNA-dependent RNA polymerase phi6p2 with 5nt RNA. Conformation B
1UVI	;	2.15	;	The structural basis for RNA specificity and Ca2 inhibition of an RNA-dependent RNA polymerase phi6p2 with 6nt RNA
1UVJ	;	1.9	;	The structural basis for RNA specificity and Ca2 inhibition of an RNA-dependent RNA polymerase phi6p2 with 7nt RNA
2H2D	;	1.7	;	The Structural Basis for Sirtuin Substrate Affinity
2H2F	;	2.2	;	The Structural basis for Sirtuin Substrate affinity
2RNW	;		;	The Structural Basis for Site-Specific Lysine-Acetylated Histone Recognition by the Bromodomains of the Human Transcriptional Co-Activators PCAf and CBP
2RNX	;		;	The Structural Basis for Site-Specific Lysine-Acetylated Histone Recognition by the Bromodomains of the HUman Transcriptional Co-Activators PCAF and CBP
3ZVL	;	1.65	;	The structural basis for substrate recognition by mammalian polynucleotide kinase 3' phosphatase
3ZVM	;	1.997	;	The structural basis for substrate recognition by mammalian polynucleotide kinase 3' phosphatase
3ZVN	;	2.15	;	The structural basis for substrate recognition by mammalian polynucleotide kinase 3' phosphatase
5CPP	;	2.08	;	THE STRUCTURAL BASIS FOR SUBSTRATE-INDUCED CHANGES IN REDOX POTENTIAL AND SPIN EQUILIBRIUM IN CYTOCHROME P-450(CAM)
7CPP	;	2.0	;	THE STRUCTURAL BASIS FOR SUBSTRATE-INDUCED CHANGES IN REDOX POTENTIAL AND SPIN EQUILIBRIUM IN CYTOCHROME P450(CAM)
1AAM	;	2.8	;	THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI
1AAW	;	2.4	;	THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI
4BA9	;	2.73	;	The structural basis for the coordination of Y-family Translesion DNA Polymerases by Rev1
6KM7	;	1.801	;	The structural basis for the internal interaction in RBBP5
1ASB	;	2.6	;	THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE
1ASC	;	2.4	;	THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE
1ASA	;	2.4	;	THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE
1ASF	;	2.8	;	THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE
1ASG	;	2.8	;	THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE
4AIA	;	1.8	;	The structural basis of 3-methyladenine recognition by 3- methyladenine DNA glycosylase I (TAG) from Staphylococcus aureus
3GKY	;	1.8	;	The Structural Basis of an ER Stress-Associated Bottleneck in a Protein Folding Landscape
1PTH	;	3.4	;	The Structural Basis of Aspirin Activity Inferred from the Crystal Structure of Inactivated Prostaglandin H2 Synthase
1YV3	;	2.0	;	The structural basis of blebbistatin inhibition and specificity for myosin II
1W98	;	2.15	;	The structural basis of CDK2 activation by cyclin E
1MG9	;	2.3	;	The structural basis of ClpS-mediated switch in ClpA substrate recognition
4PHM	;	2.03	;	The Structural Basis of Differential Inhibition of Human Calpain by Indole and Phenyl alpha-Mercaptoacrylic Acids
4PHN	;	1.79	;	The Structural Basis of Differential Inhibition of Human Calpain by Indole and Phenyl alpha-Mercaptoacrylic Acids
4PHK	;	2.05	;	The Structural Basis of Differential Inhibition of Human Calpain by Indole and Phenyl alpha-Mercaptoacrylic Acids. The complex with (Z)-3-(4-chlorophenyl)-2-mercaptoacrylic acid
4PHJ	;	1.6	;	The Structural Basis of Differential Inhibition of Human Calpain by Indole and Phenyl alpha-Mercaptoacrylic Acids: Human unliganded protein
2MNA	;		;	The structural basis of DNA binding by the single-stranded DNA-binding protein from Sulfolobus solfataricus
4C7O	;	2.6	;	The structural basis of FtsY recruitment and GTPase activation by SRP RNA
379D	;	3.1	;	THE STRUCTURAL BASIS OF HAMMERHEAD RIBOZYME SELF-CLEAVAGE
5YPS	;	2.097	;	The structural basis of histone chaperoneVps75
5ZB5	;	2.299	;	The structural basis of histone chaperoneVps75
2B7A	;	2.0	;	The structural basis of Janus Kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor
1OLA	;	2.1	;	THE STRUCTURAL BASIS OF MULTISPECIFICITY IN THE OLIGOPEPTIDE-BINDING PROTEIN OPPA
7JTX	;	3.23	;	the structural basis of PTEN regulation by multi-site phosphorylation
1DL7	;	2.35	;	THE STRUCTURAL BASIS OF REPERTOIRE SHIFT IN AN IMMUNE RESPONSE TO PHOSPHOCHOLINE
2H2G	;	1.63	;	The Structural Basis of Sirtuin substrate affinity
2H2I	;	1.8	;	The Structural basis of Sirtuin Substrate Affinity
2H2H	;	2.2	;	The Structural basis of sirtuin substrate specificity
1UDG	;	1.75	;	THE STRUCTURAL BASIS OF SPECIFIC BASE EXCISION REPAIR BY URACIL-DNA GLYCOSYLASE
1UDH	;	1.75	;	THE STRUCTURAL BASIS OF SPECIFIC BASE EXCISION REPAIR BY URACIL-DNA GLYCOSYLASE
6JQD	;	1.69	;	The structural basis of the beta-carbonic anhydrase CafC (L25G and L78G mutant) of the filamentous fungus Aspergillus fumigatus
6JQC	;	1.8	;	The structural basis of the beta-carbonic anhydrase CafC (wild type) of the filamentous fungus Aspergillus fumigatus
6LAC	;	1.3	;	The structural basis of the beta-carbonic anhydrase CafD (C39A mutant) of the filamentous fungus Aspergillus fumigatus
6LAI	;	1.6	;	The structural basis of the beta-carbonic anhydrase CafD (E54A mutant) of the filamentous fungus Aspergillus fumigatus
6JQE	;	1.9	;	The structural basis of the beta-carbonic anhydrases CafD (wild type) of the filamentous fungus Aspergillus fumigatus
1FZW	;	1.9	;	THE STRUCTURAL BASIS OF THE CATALYTIC MECHANISM AND REGULATION OF GLUCOSE-1-PHOSPHATE THYMIDYLYLTRANSFERASE (RMLA). APO ENZYME.
1G23	;	2.8	;	THE STRUCTURAL BASIS OF THE CATALYTIC MECHANISM AND REGULATION OF GLUCOSE-1-PHOSPHATE THYMIDYLYLTRANSFERASE (RMLA). GLUCOSE-1-PHOSPHATE COMPLEX.
1G1L	;	1.77	;	THE STRUCTURAL BASIS OF THE CATALYTIC MECHANISM AND REGULATION OF GLUCOSE-1-PHOSPHATE THYMIDYLYLTRANSFERASE (RMLA). TDP-GLUCOSE COMPLEX.
1G3L	;	2.7	;	THE STRUCTURAL BASIS OF THE CATALYTIC MECHANISM AND REGULATION OF GLUCOSE-1-PHOSPHATE THYMIDYLYLTRANSFERASE (RMLA). TDP-L-RHAMNOSE COMPLEX.
1G0R	;	1.87	;	THE STRUCTURAL BASIS OF THE CATALYTIC MECHANISM AND REGULATION OF GLUCOSE-1-PHOSPHATE THYMIDYLYLTRANSFERASE (RMLA). THYMIDINE/GLUCOSE-1-PHOSPHATE COMPLEX.
1FXO	;	1.66	;	THE STRUCTURAL BASIS OF THE CATALYTIC MECHANISM AND REGULATION OF GLUCOSE-1-PHOSPHATE THYMIDYLYLTRANSFERASE (RMLA). TMP COMPLEX.
1G2V	;	2.6	;	THE STRUCTURAL BASIS OF THE CATALYTIC MECHANISM AND REGULATION OF GLUCOSE-1-PHOSPHATE THYMIDYLYLTRANSFERASE (RMLA). TTP COMPLEX.
5OY3	;	2.136	;	The structural basis of the histone demethylase KDM6B histone 3 lysine 27 specificity
1UW4	;	1.95	;	The structural basis of the interaction between nonsense mediated decay factors UPF2 and UPF3
3ZS6	;	2.1	;	The Structural characterization of Burkholderia pseudomallei OppA.
1PZ4	;	1.35	;	The structural determination of an insect (mosquito) Sterol Carrier Protein-2 with a ligand bound C16 Fatty Acid at 1.35 A resolution
2VLJ	;	2.4	;	The Structural Dynamics and Energetics of an Immunodominant T-cell Receptor are Programmed by its Vbeta Domain
2VLK	;	2.5	;	The Structural Dynamics and Energetics of an Immunodominant T-cell Receptor are Programmed by its Vbeta Domain
2VLL	;	1.6	;	The Structural Dynamics and Energetics of an Immunodominant T-cell Receptor are Programmed by its Vbeta Domain
2VLM	;	1.98	;	The Structural Dynamics and Energetics of an Immunodominant T-cell Receptor are Programmed by its Vbeta Domain
2VLR	;	2.3	;	The Structural Dynamics and Energetics of an Immunodominant T-cell Receptor are Programmed by its Vbeta Domain
2NND	;	1.6	;	The Structural Identification of the Interaction Site and Functional State of RBP for its Membrane Receptor
2NNE	;	1.6	;	The Structural Identification of the Interaction Site and Functional State of RBP for its Membrane Receptor
4L5U	;	2.05	;	The structural implications of the secondary CO2 binding pocket in human carbonic anhydrase II
4L5V	;	1.63	;	The structural implications of the secondary CO2 binding pocket in human carbonic anhydrase II
4F3H	;	2.5	;	The structural of FimXEAL-c-di-GMP from Xanthomonas campestris
1DT3	;	2.6	;	THE STRUCTURAL ORIGINS OF INTERFACIAL ACTIVATION IN THERMOMYCES (HUMICOLA) LANUGINOSA LIPASE
1DT5	;	2.4	;	THE STRUCTURAL ORIGINS OF INTERFACIAL ACTIVATION IN THERMOMYCES (HUMICOLA) LANUGINOSA LIPASE
1DTE	;	2.35	;	THE STRUCTURAL ORIGINS OF INTERFACIAL ACTIVATION IN THERMOMYCES (HUMICOLA) LANUGINOSA LIPASE
1EIN	;	3.0	;	THE STRUCTURAL ORIGINS OF INTERFACIAL ACTIVATION IN THERMOMYCES (HUMICOLA) LANUGINOSA LIPASE
1DU4	;	2.5	;	THE STRUCTURAL ORIGINS OF INTERFACIAL ACTIVATION IN THERMOMYCES (HUMICOLA) LANUGINOSA LIPASE OTHER STRUCTURE DETAILS
6KP6	;	3.0	;	The structural study of mutation induced inactivation of Human muscarinic receptor M4
5OF1	;	1.56	;	The structural versatility of TasA in B. subtilis biofilm formation
5OF2	;	1.86	;	The structural versatility of TasA in B. subtilis biofilm formation
4RGD	;	1.2	;	The structure a AS-48 G13K/L40K mutant
4GSF	;	2.7	;	The structure analysis of cysteine free insulin degrading enzyme (ide) with (s)-2-{2-[carboxymethyl-(3-phenyl-propionyl)-amino]-acetylamino}-3-(3h-imidazol-4-yl)-propionic acid methyl ester
1FMD	;	3.5	;	THE STRUCTURE AND ANTIGENICITY OF A TYPE C FOOT-AND-MOUTH DISEASE VIRUS
2BVY	;	2.25	;	The structure and characterization of a modular endo-beta-1,4-mannanase from Cellulomonas fimi
3HM3	;	1.96	;	The Structure and conformation of Lys-63 linked tetra-ubiquitin
1P8K	;	2.6	;	The structure and DNA recognition of a bifunctional homing endonuclease and group I intron splicing factor
2HF5	;		;	The structure and function of a novel two-site calcium-binding fragment of calmodulin
3QED	;	2.99	;	The structure and function of an arabinan-specific alpha-1,2-arabinofuranosidase identified from screening the activities of bacterial GH43 glycoside hydrolases
3QEE	;	1.64	;	The structure and function of an arabinan-specific alpha-1,2-arabinofuranosidase identified from screening the activities of bacterial GH43 glycoside hydrolases
3QEF	;	1.789	;	The structure and function of an arabinan-specific alpha-1,2-arabinofuranosidase identified from screening the activities of bacterial GH43 glycoside hydrolases
1S99	;	1.65	;	The structure and function of B. subtilis YkoF gene product: ligand free protein
1SBR	;	2.3	;	The structure and function of B. subtilis YkoF gene product: the complex with thiamin
1RAP	;	2.25	;	THE STRUCTURE AND FUNCTION OF OMEGA LOOP A REPLACEMENTS IN CYTOCHROME C
1RAQ	;	1.9	;	THE STRUCTURE AND FUNCTION OF OMEGA LOOP A REPLACEMENTS IN CYTOCHROME C
1XE0	;	1.7	;	The structure and function of Xenopus NO38-core, a histone binding chaperone in the nucleolus
1XB9	;	1.9	;	The structure and function of Xenopus NO38-core, a histone chaperone in the nucleolus
7EZT	;	2.81	;	The structure and functional mechanism of nucleotide regulated acetylhexosaminidase Am2136 from Akkermansia muciniphila
1VT9	;	2.5	;	The structure and hydration of the A-DNA fragment D(GGGTACCC) at room temperature and low temperature
1VTA	;	2.5	;	THE STRUCTURE AND HYDRATION OF THE A-DNA FRAGMENT D(GGGTACCC) AT ROOM TEMPERATURE AND LOW TEMPERATURE
5J53	;	1.61	;	The Structure and Mechanism of NOV1, a Resveratrol-Cleaving Dioxygenase
5J54	;	1.89	;	The Structure and Mechanism of NOV1, a Resveratrol-Cleaving Dioxygenase
5J55	;	1.75	;	The Structure and Mechanism of NOV1, a Resveratrol-Cleaving Dioxygenase
1S2P	;	1.3	;	The structure and refinement of apocrustacyanin C2 to 1.3A resolution and the search for differences between this protein and the homologous apoproteins A1 and C1
1S44	;	1.6	;	The structure and refinement of apocrustacyanin C2 to 1.6A resolution and the search for differences between this protein and the homologous apoproteins A1 and C1.
4BOT	;	42.0	;	The structure and super-organization of acetylcholine receptor- rapsyn complexes class E
4BOG	;	50.0	;	The structure and super-organization of acetylcholine receptor-rapsyn complexes
4BOI	;	41.0	;	The structure and super-organization of acetylcholine receptor-rapsyn complexes class A
4BON	;	40.0	;	The structure and super-organization of acetylcholine receptor-rapsyn complexes class B
4BOO	;	42.0	;	The structure and super-organization of acetylcholine receptor-rapsyn complexes class C
4BOR	;	42.0	;	The structure and super-organization of acetylcholine receptor-rapsyn complexes class D
1BDM	;	1.8	;	THE STRUCTURE AT 1.8 ANGSTROMS RESOLUTION OF A SINGLE SITE MUTANT (T189I) OF MALATE DEHYDROGENASE FROM THERMUS FLAVUS WITH INCREASED ENZYMATIC ACTIVITY
1O5W	;	3.2	;	The structure basis of specific recognitions for substrates and inhibitors of rat monoamine oxidase A
4Y7N	;	3.3	;	The Structure Insight into 5-Carboxycytosine Recognition by RNA Polymerase II during Transcription Elongation.
3ZKO	;	13.7	;	The structure of ''breathing'' dengue virus.
1U1Z	;	2.5	;	The Structure of (3R)-hydroxyacyl-ACP dehydratase (FabZ)
2EFJ	;	2.0	;	The structure of 1,7 dimethylxanthine methyltransferase
5YQG	;	2.1	;	The structure of 14-3-3 and pNumb peptide
4K11	;	2.3	;	The structure of 1NA in complex with Src T338G
1H48	;	2.3	;	The structure of 2C-Methyl-D-erythritol 2,4-cyclodiphosphate synthase in complex with CMP and product
4INS	;	1.5	;	THE STRUCTURE OF 2ZN PIG INSULIN CRYSTALS AT 1.5 ANGSTROMS RESOLUTION
7DL3	;	1.84607	;	The structure of 3,5-DAHDHcca complex with NADPH
2B7O	;	2.3	;	The Structure of 3-Deoxy-D-Arabino-Heptulosonate 7-Phosphate Synthase from Mycobacterium tuberculosis
3RZI	;	1.95	;	The structure of 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase from mycobacterium tuberculosis cocrystallized and complexed with phenylalanine and tryptophan
3NUD	;	3.0	;	The structure of 3-deoxy-d-arabino-heptulosonate 7-phosphate synthase from mycobacterium tuberculosis complexed with phenylalanine
3KGF	;	2.0	;	The structure of 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase from Mycobacterium tuberculosis complexed with phenylalanine and tryptophan
3NUE	;	2.5	;	The structure of 3-deoxy-d-arabino-heptulosonate 7-phosphate synthase from mycobacterium tuberculosis complexed with tryptophan
3NV8	;	2.25	;	The structure of 3-deoxy-d-arabino-heptulosonate 7-phosphate synthase in complex with phosphoenol pyruvate and manganese (thesit-free)
6PBJ	;	1.9	;	The structure of 3-deoxy-d-arabino-heptulosonate 7-phosphate synthase with Gly190Pro mutation
6RLH	;	1.5	;	The structure of 3fPizza6-SH obtained via vapour diffusion
2PGD	;	2.0	;	THE STRUCTURE OF 6-PHOSPHOGLUCONATE DEHYDROGENASE REFINED AT 2 ANGSTROMS RESOLUTION
1D62	;	2.0	;	THE STRUCTURE OF A /B-DNA$ DECAMER WITH AN I(SLASH)*A MISMATCH AND COMPARISON WITH THE G(SLASH)*A MISMATCH
4V96	;	3.8	;	The structure of a 1.8 MDa viral genome injection device suggests alternative infection mechanisms
1TMR	;		;	THE STRUCTURE OF A 19 RESIDUE FRAGMENT FROM THE C-LOOP OF THE FOURTH EPIDERMAL GROWTH FACTOR-LIKE DOMAIN OF THROMBOMODULIN
8FN2	;	3.4	;	The structure of a 50S ribosomal subunit in the Lyme disease pathogen Borreliella burgdorferi
8HNQ	;	2.0	;	The structure of a alcohol dehydrogenase AKR13B2 with NADP
1D49	;	1.5	;	THE STRUCTURE OF A B-DNA DECAMER WITH A CENTRAL T-A STEP: C-G-A-T-T-A-A-T-C-G
3RPD	;	1.5	;	The structure of a B12-independent methionine synthase from Shewanella sp. W3-18-1 in complex with Selenomethionine.
2OST	;	3.1	;	The structure of a bacterial homing endonuclease : I-Ssp6803I
3SOV	;	1.27	;	The structure of a beta propeller domain in complex with peptide S
1JPP	;	3.1	;	The Structure of a beta-Catenin Binding Repeat from Adenomatous Polyposis Coli (APC) in Complex with beta-Catenin
6HPD	;	2.43	;	The structure of a beta-glucuronidase from glycoside hydrolase family 2
1LMK	;	2.6	;	THE STRUCTURE OF A BIVALENT DIABODY
3QP9	;	1.88	;	The Structure of a C2-type Ketoreductase from a Modular Polyketide Synthase
6G5O	;	2.25	;	The structure of a carbohydrate active P450
6G5Q	;	2.4	;	The structure of a carbohydrate active P450
4DHJ	;	2.35	;	The structure of a ceOTUB1 ubiquitin aldehyde UBC13~Ub complex
5YEY	;		;	The structure of a chair-type G-quadruplex of the human telomeric variant in K+ solution
4P48	;	1.35	;	The structure of a chicken anti-cardiac Troponin I scFv
4P49	;	1.4	;	The structure of a chicken anti-prostate specific antigen scFv
5Z34	;	2.399	;	The structure of a chitin deacetylase from Bombyx mori provide the first insight into insect chitin deacetylation mechanism
1TTE	;		;	The Structure of a Class II ubiquitin-conjugating enzyme, Ubc1.
1NQY	;	2.09	;	The structure of a CoA pyrophosphatase from D. Radiodurans
1NQZ	;	1.7	;	The structure of a CoA pyrophosphatase from D. Radiodurans complexed with a magnesium ion
5W8D	;	2.0	;	The structure of a COA-dependent acyl-homoserine lactone synthase, BjaI, with MTA
5W8C	;	1.85	;	The structure of a COA-dependent acyl-homoserine lactone synthase, BjaI, with MTA and isovaleryl-CoA
5W8G	;	2.0	;	The structure of a COA-dependent acyl-homoserine lactone synthase, BjaI, with SAH
5W8A	;	2.0	;	The structure of a COA-dependent acyl-homoserine lactone synthase, BjaI, with SAM and isopentyl-CoA
5W8E	;	1.8	;	The structure of a CoA-dependent acyl-homoserine lactone synthase, BjaI, with the adduct of SAH and IV-CoA
6WNS	;	1.93	;	The structure of a CoA-dependent acyl-homoserine lactone synthase, MesI
6WN0	;	1.85	;	The structure of a CoA-dependent acyl-homoserine lactone synthase, RpaI, with the adduct of SAH and p-coumaroyl CoA
1NMB	;	2.2	;	THE STRUCTURE OF A COMPLEX BETWEEN THE NC10 ANTIBODY AND INFLUENZA VIRUS NEURAMINIDASE AND COMPARISON WITH THE OVERLAPPING BINDING SITE OF THE NC41 ANTIBODY
1HRT	;	2.8	;	THE STRUCTURE OF A COMPLEX OF BOVINE ALPHA-THROMBIN AND RECOMBINANT HIRUDIN AT 2.8 ANGSTROMS RESOLUTION
1TYL	;	1.9	;	THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE
1TYM	;	1.9	;	THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE
3HTC	;	2.3	;	THE STRUCTURE OF A COMPLEX OF RECOMBINANT HIRUDIN AND HUMAN ALPHA-THROMBIN
4PKE	;	2.5	;	The structure of a conserved Piezo channel domain reveals a novel beta sandwich fold
4PKX	;	2.54	;	The structure of a conserved Piezo channel domain reveals a novel beta sandwich fold
3IKB	;	1.67	;	The structure of a conserved protein from Streptococcus mutans UA159.
3PEB	;	1.86	;	The Structure of a Creatine_N Superfamily domain of a dipeptidase from Streptococcus thermophilus.
8FO0	;	1.69	;	The structure of a crystallizable variant of E. coli pyruvate formate-lyase activating enzyme bound to a partially cleaved SAM molecule
8FSI	;	1.46	;	The structure of a crystallizable variant of E. coli pyruvate formate-lyase activating enzyme bound to SAM
8FOL	;	2.65	;	The structure of a crystallizable variant of E. coli pyruvate formate-lyase activating enzyme bound to SAM, alternate crystal form
6ZIF	;	2.2	;	The structure of a cytosolic copper storage protein from Methylocystis sp. Strain Rockwell (ATCC 49242)
1KM8	;	1.9	;	The Structure of a Cytotoxic Ribonuclease From the Oocyte of Rana Catesbeiana (Bullfrog)
1KM9	;	1.96	;	The Structure of a Cytotoxic Ribonuclease From the Oocyte of Rana Catesbeiana (Bullfrog)
2Y0O	;	1.229	;	The structure of a D-lyxose isomerase from the sigmaB regulon of Bacillus subtilis
467D	;	2.16	;	The structure of a decamer forming a four-way junction
3FDJ	;	1.8	;	The structure of a DegV family protein from Eubacterium eligens.
3WCV	;	2.6	;	The structure of a deoxygenated 400 kda hemoglobin provides a more accurate description of the cooperative mechanism of giant hemoglobins: CA bound form
3WCU	;	2.9	;	The structure of a deoxygenated 400 kda hemoglobin provides a more accurate description of the cooperative mechanism of giant hemoglobins: Deoxygenated form
3WCW	;	2.5	;	The structure of a deoxygenated 400 kda hemoglobin provides a more accurate description of the cooperative mechanism of giant hemoglobins: MG bound form
3WCT	;	2.4	;	The structure of a deoxygenated 400 kda hemoglobin provides a more accurate description of the cooperative mechanism of giant hemoglobins: Oxygenated form
6I7O	;	5.3	;	The structure of a di-ribosome (disome) as a unit for RQC and NGD quality control pathways recognition.
6BMC	;	2.7	;	The structure of a dimeric type II DAH7PS associated with pyocyanin biosynthesis in Pseudomonas aeruginosa
4A8E	;	2.99	;	The structure of a dimeric Xer recombinase from archaea
3BGW	;	3.91	;	The Structure Of A DnaB-Like Replicative Helicase And Its Interactions With Primase
2L7E	;		;	The structure of a domain from yeast
4ZR7	;	1.86	;	The structure of a domain of a functionally unknown protein from Bacillus subtilis subsp. subtilis str. 168
2R4Q	;	1.6	;	The structure of a domain of fruA from Bacillus subtilis
2WBT	;	2.7	;	The Structure of a Double C2H2 Zinc Finger Protein from a Hyperthermophilic Archaeal Virus in the Absence of DNA
3QUF	;	1.7	;	The structure of a family 1 extracellular solute-binding protein from Bifidobacterium longum subsp. infantis
2WAG	;	1.4	;	The Structure of a family 25 Glycosyl hydrolase from Bacillus anthracis.
2C79	;	1.5	;	The structure of a family 4 acetyl xylan esterase from Clostridium thermocellum in complex with a colbalt ion.
2C71	;	1.05	;	The structure of a family 4 acetyl xylan esterase from Clostridium thermocellum in complex with a magnesium ion.
2C8N	;	2.9	;	The Structure of a family 51 arabinofuranosidase, Araf51, from Clostridium thermocellum in complex with 1,3-linked arabinoside of xylobiose.
2C7F	;	2.7	;	The Structure of a family 51 arabinofuranosidase, Araf51, from Clostridium thermocellum in complex with 1,5-alpha-L-Arabinotriose.
2X8R	;	1.7	;	The structure of a family GH25 lysozyme from Aspergillus fumigatus
4OHS	;	2.19	;	The structure of a far-red fluorescent protein, AQ143
3IUS	;	1.66	;	The structure of a functionally unknown conserved protein from Silicibacter pomeroyi DSS
4AC1	;	1.3	;	The structure of a fungal endo-beta-N-acetylglucosaminidase from glycosyl hydrolase family 18, at 1.3A resolution
4H89	;	1.37	;	The Structure of a GCN5-Related N-Acetyltransferase from Kribbella flavida
4ZXO	;	1.5	;	The structure of a GH26 beta-mannanase from Bacteroides ovatus, BoMan26A.
5OES	;	2.48	;	The structure of a glutathione synthetase (StGSS1) from Solanum tuberosum in ADP and y-EC bound closed conformation.
5OEU	;	2.57	;	The structure of a glutathione synthetase like-effector (GSS22) from Globodera pallida in ADP-bound closed conformation.
5OEV	;	2.18	;	The structure of a glutathione synthetase like-effector (GSS22) from Globodera pallida in apoform.
5OET	;	2.57	;	The structure of a glutathione synthetase like-effector (GSS30) from Globodera pallida in apoform.
2VTC	;	1.6	;	The structure of a glycoside hydrolase family 61 member, Cel61B from the Hypocrea jecorina.
4K35	;	2.003	;	The structure of a glycoside hydrolase family 81 endo-[beta]-1,3-glucanase
4K3A	;	2.3	;	The structure of a glycoside hydrolase family 81 endo-[beta]-1,3-glucanase
2C3F	;	1.81	;	The structure of a group A streptococcal phage-encoded tail-fibre showing hyaluronan lyase activity.
1NRW	;	1.7	;	The structure of a HALOACID DEHALOGENASE-LIKE HYDROLASE FROM B. SUBTILIS
3R7C	;	2.4	;	The structure of a hexahestidine-tagged form of augmenter of liver regeneration reveals a novel Cd(2)Cl(4)O(6) cluster that aids in crystal packing
8FMW	;	2.86	;	The structure of a hibernating ribosome in the Lyme disease pathogen
3GL9	;	1.8	;	The structure of a histidine kinase-response regulator complex sheds light into two-component signaling and reveals a novel cis autophosphorylation mechanism
1Y58	;		;	The structure of a lactoferricinB derivative bound to micelles
1Y5C	;		;	The structure of a lactoferricinB derivative bound to micelles (LfcinB4-14)
5ZMP	;	2.19	;	The structure of a lysine deacylase
2RDP	;	2.3	;	The structure of a MarR family protein from Bacillus stearothermophilus
3IUV	;	2.554	;	The structure of a member of TetR family (SCO1917) from Streptomyces coelicolor A3
6R3Q	;	3.4	;	The structure of a membrane adenylyl cyclase bound to an activated stimulatory G protein
1ZFX	;	2.38	;	The Structure of a minimal all-RNA Hairpin Ribozyme with the mutant G8U at the cleavage site
165D	;	1.55	;	THE STRUCTURE OF A MISPAIRED RNA DOUBLE HELIX AT 1.6 ANGSTROMS RESOLUTION AND IMPLICATIONS FOR THE PREDICTION OF RNA SECONDARY STRUCTURE
2CMO	;	2.65	;	The structure of a mixed glur2 ligand-binding core dimer in complex with (s)-glutamate and the antagonist (s)-ns1209
2BVT	;	2.9	;	The structure of a modular endo-beta-1,4-mannanase from Cellulomonas fimi explains the product specificity of glycoside hydrolase family 26 mannanases.
3BXQ	;	1.3	;	The structure of a mutant insulin uncouples receptor binding from protein allostery. An electrostatic block to the TR transition
2LFU	;		;	The structure of a N. meningitides protein targeted for vaccine development
218D	;	2.25	;	THE STRUCTURE OF A NEW CRYSTAL FORM OF A DNA DODECAMER CONTAINING T.(O6ME)G BASE PAIRS
1HLT	;	3.0	;	THE STRUCTURE OF A NONADECAPEPTIDE OF THE FIFTH EGF DOMAIN OF THROMBOMODULIN COMPLEXED WITH THROMBIN
5AOB	;	1.79	;	The structure of a novel thermophilic esterase from the Planctomycetes species, Thermogutta terrifontis, Est2-butyrate bound
5AO9	;	1.58	;	The structure of a novel thermophilic esterase from the Planctomycetes species, Thermogutta terrifontis, Est2-native
5AOA	;	1.71	;	The structure of a novel thermophilic esterase from the Planctomycetes species, Thermogutta terrifontis, Est2-Propionate bound
5AOC	;	1.79	;	The structure of a novel thermophilic esterase from the Planctomycetes species, Thermogutta terrifontis, Est2-valerate bound
4QHQ	;	1.4	;	The structure of a nutrient binding protein from Burkholderia cenocepacia bound to methionine
3S6M	;	1.651	;	The structure of a Peptidyl-prolyl cis-trans isomerase from Burkholderia pseudomallei
1PTO	;	3.5	;	THE STRUCTURE OF A PERTUSSIS TOXIN-SUGAR COMPLEX AS A MODEL FOR RECEPTOR BINDING
4ZNP	;	2.94	;	The structure of A pfI Riboswitch Bound to ZMP
2W42	;	1.9	;	THE STRUCTURE OF A PIWI PROTEIN FROM ARCHAEOGLOBUS FULGIDUS COMPLEXED WITH A 16NT DNA DUPLEX.
2BGG	;	2.2	;	The structure of a Piwi protein from Archaeoglobus fulgidus complexed with a 16nt siRNA duplex.
1W9H	;	1.95	;	The Structure of a Piwi protein from Archaeoglobus fulgidus.
2O01	;	3.4	;	The Structure of a plant photosystem I supercomplex at 3.4 Angstrom resolution
3MJG	;	2.3	;	The structure of a platelet derived growth factor receptor complex
4WA0	;	1.7	;	The structure of a possible adhesin C-terminal domain from Caldicellulosiruptor kronotskyensis
3IVP	;	2.02	;	The structure of a possible transposon-related DNA-binding protein from Clostridium difficile 630.
6UFE	;	1.2	;	The structure of a potassium selective ion channel at atomic resolution
1U0K	;	1.5	;	The structure of a Predicted Epimerase PA4716 from Pseudomonas aeruginosa
2I6X	;	2.4	;	The structure of a predicted HAD-like family hydrolase from Porphyromonas gingivalis.
2OIW	;	2.0	;	The structure of a predicted thioesterase from Bacillus stearothermophilus
3F56	;	2.303	;	The structure of a previously undetected carboxysome shell protein: CsoS1D from Prochlorococcus marinus MED4
3FCH	;	2.201	;	The structure of a previously undetected carboxysome shell protein: CsoS1D from Prochlorococcus marinus MED4
2HJS	;	2.2	;	The structure of a probable aspartate-semialdehyde dehydrogenase from Pseudomonas aeruginosa
3ILK	;	2.01	;	The structure of a probable methylase family protein from Haemophilus influenzae Rd KW20
3OOO	;	1.57	;	The structure of a proline dipeptidase from Streptococcus agalactiae 2603V
1RH5	;	3.2	;	The structure of a protein conducting channel
1RHZ	;	3.5	;	The structure of a protein conducting channel
3TZT	;	2.1	;	The structure of a protein in glycosyl transferase family 8 from Anaerococcus prevotii.
3U1D	;	1.8	;	The structure of a protein with a GntR superfamily winged-helix-turn-helix domain from Halomicrobium mukohataei.
3ON1	;	1.65	;	The structure of a protein with unknown function from Bacillus halodurans C
3OOP	;	1.78	;	The structure of a protein with unknown function from Listeria innocua Clip11262
3OOU	;	1.57	;	The structure of a protein with unkown function from Listeria innocua
3TU6	;	2.0	;	The Structure of a Pseudoazurin From Sinorhizobium meliltoi
2OCZ	;	1.85	;	The Structure of a Putative 3-Dehydroquinate Dehydratase from Streptococcus pyogenes.
3EH7	;	2.05	;	The structure of a putative 4-hydroxybutyrate CoA-transferase from Porphyromonas gingivalis W83
2HI1	;	2.3	;	The structure of a putative 4-hydroxythreonine-4-phosphate dehydrogenase from Salmonella typhimurium.
3TX6	;	1.5	;	The Structure of a putative ABC-transporter periplasmic component from Rhodopseudomonas palustris
3DCI	;	2.0	;	The Structure of a putative arylesterase from Agrobacterium tumefaciens str. C58
3U7V	;	1.8	;	The structure of a putative Beta-galactosidase from Caulobacter crescentus CB15.
3RSI	;	2.0	;	The structure of a putative enoyl-CoA hydratase/isomerase from Mycobacterium abscessus ATCC 19977 / DSM 44196
3M1G	;	2.1	;	The structure of a putative glutathione S-transferase from Corynebacterium glutamicum
3DDH	;	2.0	;	The structure of a putative haloacid dehalogenase-like family hydrolase from Bacteroides thetaiotaomicron VPI-5482
3U24	;	2.25	;	The structure of a putative lipoprotein of unknown function from Shewanella oneidensis.
2G8Y	;	2.15	;	The structure of a putative malate/lactate dehydrogenase from E. coli.
1ZX5	;	2.3	;	The structure of a putative mannosephosphate isomerase from Archaeoglobus fulgidus
3JW4	;	2.1	;	The structure of a putative MarR family transcriptional regulator from Clostridium acetobutylicum
2IJL	;	2.3	;	The structure of a putative ModE from Agrobacterium tumefaciens.
2HSJ	;	1.5	;	The structure of a putative platelet activating factor from Streptococcus pneumonia.
2I6D	;	1.85	;	The structure of a putative RNA methyltransferase of the TrmH family from Porphyromonas gingivalis.
4FRY	;	2.1	;	The structure of a putative signal-transduction protein with CBS domains from Burkholderia ambifaria MC40-6
3IV3	;	1.8	;	The Structure of a putative tagatose 1,6-aldolase from Streptococcus mutans
3DEW	;	1.75	;	The structure of a putative TetR family transcriptional regulator from Geobacter sulfurreducens PCA.
3HE0	;	2.2	;	The Structure of a Putative Transcriptional Regulator TetR Family Protein from Vibrio parahaemolyticus.
4HG2	;	1.6	;	The Structure of a Putative Type II Methyltransferase from Anaeromyxobacter dehalogenans.
5G4T	;	2.751	;	The structure of a quasi-cyclic six k-turn duplex RNA species
6Y9C	;	1.8	;	The structure of a quaternary ammonium Rieske monooxygenase reveals insights into carnitine oxidation by gut microbiota and inter-subunit electron transfer
4K2P	;	1.98	;	The Structure of a Quintuple Mutant of the Tiam1 PH-CC-Ex Domain
6UZV	;	3.1	;	The structure of a red shifted photosystem I complex
3JV9	;	2.39	;	The structure of a reduced form of OxyR from N. meningitidis
3IJM	;	1.7	;	The structure of a restriction endonuclease-like fold superfamily protein from Spirosoma linguale.
1ZHO	;	2.6	;	The structure of a ribosomal protein L1 in complex with mRNA
1U63	;	3.4	;	THE STRUCTURE OF A RIBOSOMAL PROTEIN L1-mRNA COMPLEX
1S03	;	2.7	;	The Structure of a Ribosomal Protein S8/spc Operon mRNA Complex
1XJR	;	2.7	;	The Structure of a Rigorously Conserved RNA Element Within the SARS Virus Genome
7KB3	;	2.25	;	The structure of a sensor domain of a histidine kinase (VxrA) from Vibrio cholerae O1 biovar eltor str. N16961, 2nd form
7KB9	;	1.98	;	THE STRUCTURE OF A SENSOR DOMAIN OF A HISTIDINE KINASE (VxrA) FROM VIBRIO CHOLERAE O1 BIOVAR ELTOR STR. N16961, D238-T240 deletion mutant
7LA6	;	1.98	;	THE STRUCTURE OF A SENSOR DOMAIN OF A HISTIDINE KINASE (VxrA) FROM VIBRIO CHOLERAE O1 BIOVAR ELTOR STR. N16961, N239 deletion mutant
7KB7	;	2.2	;	THE STRUCTURE OF A SENSOR DOMAIN OF A HISTIDINE KINASE (VxrA) FROM VIBRIO CHOLERAE O1 BIOVAR ELTOR STR. N16961, N239-T240 deletion mutant
4R7Q	;	1.981	;	The structure of a sensor domain of a histidine kinase from Vibrio cholerae O1 biovar eltor str. N16961
3UCX	;	1.85	;	The structure of a Short chain dehydrogenase from Mycobacterium smegmatis
1TKK	;	2.1	;	The Structure of a Substrate-Liganded Complex of the L-Ala-D/L-Glu Epimerase from Bacillus subtilis
2ER6	;	2.0	;	The structure of a synthetic pepsin inhibitor complexed with endothiapepsin.
1GWC	;	2.25	;	The structure of a tau class glutathione S-transferase from wheat, active in herbicide detoxification
3UR1	;	4.5	;	The structure of a ternary complex between CheA domains P4 and P5 with CheW and with a truncated fragment of TM14, a chemoreceptor analog from Thermotoga maritima.
4JPB	;	3.186	;	The structure of a ternary complex between CheA domains P4 and P5 with CheW and with an unzipped fragment of TM14, a chemoreceptor analog from Thermotoga maritima.
6DFE	;	2.31	;	The structure of a ternary complex of E. coli WaaC
4UOV	;	1.85	;	The structure of a tetrameric alpha-carbonic anhydrase from Thermovibrio ammonificans reveals a core formed around intermolecular disulfides, which contribute to its thermostability.
3HH1	;	1.85	;	The Structure of a Tetrapyrrole methylase family protein domain from Chlorobium tepidum TLS
2ET0	;	1.7	;	The structure of a three-way DNA junction in complex with a metallo-supramolecular helicate reveals a new target for drugs
4K2O	;	2.15	;	The Structure of a Triple Mutant of the Tiam1 PH-CC-Ex Domain
2C10	;	2.5	;	The structure of a truncated, soluble version of semicarbazide- sensitive amine oxidase
7WZV	;	1.89931	;	The structure of a Twitch Radical SAM Dehydrogenase SpeY
7WZX	;	1.98001	;	The structure of a Twitch Radical SAM Dehydrogenase SpeY
7X0B	;	2.02028	;	The structure of a Twitch Radical SAM Dehydrogenase SpeY
2PO8	;		;	The structure of a two-disulfide intermediate of MCoTI-II
6R23	;	4.9	;	The structure of a Ty3 retrotransposon capsid C-terminal domain dimer
6R22	;	5.5	;	The structure of a Ty3 retrotransposon capsid N-terminal domain dimer
6R24	;	7.5	;	The structure of a Ty3 retrotransposon icosahedral capsid
1BCF	;	2.9	;	THE STRUCTURE OF A UNIQUE, TWO-FOLD SYMMETRIC, HAEM-BINDING SITE
1YG8	;	2.6	;	The structure of a V6A variant of ClpP.
3U0H	;	2.3	;	The Structure of a Xylose Isomerase domain protein from Alicyclobacillus acidocaldarius subsp. acidocaldarius.
4DS1	;	1.851	;	The Structure of a Yeast Dyn2-Nup159 Complex and the Molecular Basis for the Dynein Light Chain - Nuclear Pore Interaction
4HT6	;	1.9	;	The Structure of a Yeast Dynein Dyn2-Pac11 Complex and Effect on Single Molecule Dynein Motor Activity
4V35	;	2.3	;	The Structure of A-PGS from Pseudomonas aeruginosa
4V34	;	3.1	;	The Structure of A-PGS from Pseudomonas aeruginosa (SeMet derivative)
4IOV	;	3.5	;	The structure of AAVrh32.33, a Novel Gene Delivery Vector
6TQF	;	3.5	;	The structure of ABC transporter Rv1819c in AMP-PNP bound state
6TQE	;	4.3	;	The structure of ABC transporter Rv1819c without addition of substrate
7TBZ	;	4.3	;	The structure of ABCA1 Y482C
6F1G	;	1.672	;	The structure of AbnB-E201A, an intracellular 1,5-alpha-L-arabinanase from Geobacillus stearothermophilus, in complex with arabinopentaose
1W9Y	;	2.1	;	The structure of ACC oxidase
1WA6	;	2.55	;	The structure of ACC oxidase
4LGN	;	1.82	;	The structure of Acidothermus cellulolyticus family 74 glycoside hydrolase
1SEK	;	2.1	;	THE STRUCTURE OF ACTIVE SERPIN K FROM MANDUCA SEXTA AND A MODEL FOR SERPIN-PROTEASE COMPLEX FORMATION
1RKB	;	2.0	;	The structure of adrenal gland protein AD-004
5JM7	;	2.4	;	The structure of aerobactin synthetase IucA from a hypervirulent pathotype of Klebsiella pneumoniae
6CN7	;	2.45	;	The structure of aerobactin synthetase IucC from a hypervirulent pathotype of Klebsiella pneumoniae
7LOL	;	1.8	;	The structure of Agmatinase from E. Coli at 1.8 A displaying urea and agmatine
7LOX	;	3.2	;	The structure of Agmatinase from E. Coli at 3.2 A displaying guanidine in the active site
4YJX	;	2.547	;	The structure of Agrobacterium tumefaciens ClpS2 bound to L-phenylalaninamide
4YKA	;	2.801	;	The structure of Agrobacterium tumefaciens ClpS2 in complex with L-tyrosinamide
4X0X	;	1.9	;	The structure of AhpE from Mycobacterium tuberculosis revisited
4X1U	;	1.87	;	The structure of AhpE from Mycobacterium tuberculosis revisited
4QFM	;	2.3	;	The structure of aIF2gamma subunit D152A from archaeon Sulfolobus solfataricus complexed with GDPCP
3SJZ	;	2.8	;	The structure of aIF2gamma subunit delta 41-45 from archaeon Sulfolobus solfataricus complexed with GDP and GDPNP
2PLF	;	2.9	;	The structure of aIF2gamma subunit from the archaeon Sulfolobus solfataricus in the nucleotide-free form.
4NBS	;	2.305	;	The structure of aIF2gamma subunit H20F from archaeon Sulfolobus solfataricus complexed with GDPCP
4QHY	;	3.29	;	The structure of aIF2gamma subunit H20F/D152A from archaeon Sulfolobus solfataricus complexed with GDPCP
8HW0	;	1.5	;	the structure of AKR6D1
4QHR	;	1.9	;	The structure of alanine racemase from Acinetobacter baumannii
7ENN	;	2.8	;	The structure of ALC1 bound to the nucleosome
6YX8	;	1.831	;	The structure of allophycocyanin from cyanobacterium Nostoc sp. WR13, the C2221 crystal form.
2VJT	;	2.5	;	The Structure of Allophycocyanin from Gloeobacter Violaceus
1SZN	;	1.54	;	THE STRUCTURE OF ALPHA-GALACTOSIDASE
1T0O	;	1.96	;	The structure of alpha-galactosidase from Trichoderma reesei complexed with beta-D-galactose
1KTB	;	1.9	;	The Structure of alpha-N-Acetylgalactosaminidase
1KTC	;	2.4	;	The Structure of alpha-N-Acetylgalactosaminidase
1HUT	;	2.9	;	THE STRUCTURE OF ALPHA-THROMBIN INHIBITED BY A 15-MER SINGLE-STRANDED DNA APTAMER
4V3B	;	2.18	;	The structure of alpha2,3-sialyltransferase variant 1 from Pasteurella dagmatis in complex with the donor product CMP
4V3C	;	1.84	;	The structure of alpha2,3-sialyltransferase variant 2 from Pasteurella dagmatis in complex with the donor product CMP
6CZR	;	3.14	;	The structure of amicetin bound to the 70S ribosome
4AYS	;	3.15	;	The Structure of Amylosucrase from D. radiodurans
4FB4	;	1.85	;	The Structure of an ABC-Transporter Family Protein from Rhodopseudomonas palustris in Complex with Caffeic Acid
3HJZ	;	1.9	;	The structure of an aldolase from Prochlorococcus marinus
1ZFV	;	2.4	;	The structure of an all-RNA minimal Hairpin Ribozyme with Mutation G8A at the cleavage site
1U5U	;	2.0	;	The structure of an Allene Oxide Synthase reveals a novel use for a catalase fold
3OOS	;	1.65	;	The structure of an alpha/beta fold family hydrolase from Bacillus anthracis str. Sterne
3WMU	;	1.1	;	The structure of an anti-cancer lectin mytilec apo-form from the mussel Mytilus galloprovincialis
3WMV	;	1.05	;	The structure of an anti-cancer lectin mytilec with ligand from the mussel Mytilus galloprovincialis
3T6O	;	2.1	;	The Structure of an Anti-sigma-factor antagonist (STAS) domain protein from Planctomyces limnophilus.
1ZA6	;	2.8	;	The structure of an antitumor CH2-domain-deleted humanized antibody
2VUG	;	2.9	;	The structure of an archaeal homodimeric RNA ligase
4F8J	;	1.6	;	The structure of an aromatic compound transport protein from Rhodopseudomonas palustris in complex with p-coumarate
6CX6	;	2.84	;	The structure of an As(III) S-adenosylmethionine methyltransferase with As(III) and S-adenosyl-L-homocysteine (SAH)
4KW7	;	1.8	;	The structure of an As(III) S-adenosylmethionine methyltransferase with Phenylarsine oxide(PAO)
4FS8	;	1.78	;	The structure of an As(III) S-adenosylmethionine methyltransferase: insights into the mechanism of arsenic biotransformation
6ZM3	;	1.7	;	The structure of an E2 ubiquitin-conjugating complex (UBC2-UEV1) essential for Leishmania amastigote differentiation
7VWN	;	1.45	;	The structure of an engineered PET hydrolase
3CXC	;	3.0	;	The structure of an enhanced oxazolidinone inhibitor bound to the 50S ribosomal subunit of H. marismortui
1Z31	;		;	The structure of an enzyme-activating fragment of human telomerase RNA
1UZC	;		;	THE STRUCTURE OF AN FF DOMAIN FROM HUMAN HYPA/FBP11
1FAV	;	3.0	;	THE STRUCTURE OF AN HIV-1 SPECIFIC CELL ENTRY INHIBITOR IN COMPLEX WITH THE HIV-1 GP41 TRIMERIC CORE
7O5E	;		;	The structure of an i-motif/duplex junction at neutral pH
1HIB	;	2.4	;	THE STRUCTURE OF AN INTERLEUKIN-1 BETA MUTANT WITH REDUCED BIOACTIVITY SHOWS MULTIPLE SUBTLE CHANGES IN CONFORMATION THAT AFFECT PROTEIN-PROTEIN RECOGNITION
1A6A	;	2.75	;	THE STRUCTURE OF AN INTERMEDIATE IN CLASS II MHC MATURATION: CLIP BOUND TO HLA-DR3
3MCZ	;	1.9	;	The Structure of an O-methyltransferase family protein from Burkholderia thailandensis.
3QVQ	;	1.602	;	The structure of an Oleispira antarctica phosphodiesterase OLEI02445 in complex with the product sn-glycerol-3-phosphate
1D98	;	2.5	;	THE STRUCTURE OF AN OLIGO(DA).OLIGO(DT) TRACT AND ITS BIOLOGICAL IMPLICATIONS
7NTE	;	1.6	;	The structure of an open conformation of the SBP TarP_Csal
3OON	;	1.79	;	The structure of an outer membrance protein from Borrelia burgdorferi B31
280D	;	2.4	;	THE STRUCTURE OF AN RNA DODECAMER SHOWS HOW TANDEM U-U BASE PAIRS INCREASE THE RANGE OF STABLE RNA STRUCTURES AND THE DIVERSITY OF RECOGNITION SITES
1RNK	;		;	THE STRUCTURE OF AN RNA PSEUDOKNOT THAT CAUSES EFFICIENT FRAMESHIFTING IN MOUSE MAMMARY TUMOR VIRUS
1FIX	;	2.3	;	THE STRUCTURE OF AN RNA/DNA HYBRID: A SUBSTRATE OF THE RIBONUCLEASE ACTIVITY OF HIV-1 REVERSE TRANSCRIPTASE
3QJQ	;	2.9	;	The structure of and photolytic induced changes of carbon monoxide binding to the cytochrome ba3-oxidase from Thermus thermophilus
3QJR	;	3.2	;	The structure of and photolytic induced changes of carbon monoxide binding to the cytochrome ba3-oxidase from Thermus thermophilus
3QJS	;	2.8	;	The structure of and photolytic induced changes of carbon monoxide binding to the cytochrome ba3-oxidase from Thermus thermophilus
3QJT	;	2.95	;	The structure of and photolytic induced changes of carbon monoxide binding to the cytochrome ba3-oxidase from Thermus thermophilus
3QJU	;	2.9	;	The structure of and photolytic induced changes of carbon monoxide binding to the cytochrome ba3-oxidase from Thermus thermophilus
3QJV	;	2.8	;	The structure of and photolytic induced changes of carbon monoxide binding to the cytochrome ba3-oxidase from Thermus thermophilus
7KIX	;		;	The structure of anti-CRISPR AcrIE2
2KO8	;		;	The Structure of Anti-TRAP
1JOH	;	1.4	;	THE STRUCTURE OF ANTIAMOEBIN I, A MEMBRANE-ACTIVE PEPTIDE
1WUA	;	1.45	;	The structure of Aplyronine A-actin complex
4GGR	;	1.9	;	The structure of apo bradavidin2 (Form A)
1HL4	;	1.82	;	The Structure of Apo Type Human Cu, Zn Superoxide Dismutase
3SKP	;	1.7	;	The structure of apo-human transferrin C-lobe with bound sulfate ions
2HYG	;	2.8	;	The Structure of apo-MntR from Bacillus subtilis, Native Form
2HYF	;	2.8	;	The Structure of apo-MntR from Bacillus subtilis, selenomethionine derivative
8HIV	;	2.20003	;	The structure of apo-SoBcmB with Fe(II) and AKG
6IO9	;	1.9	;	The structure of apo-UdgX
4OJ2	;	3.05	;	The structure of aquaporin
4Y0B	;	2.4	;	The structure of Arabidopsis ClpT1
4Y0C	;	1.992	;	The structure of Arabidopsis ClpT2
5KWK	;	1.9	;	The structure of Arabidopsis thaliana FUT1 in complex with GDP
5KOE	;	1.79	;	The structure of Arabidopsis thaliana FUT1 in complex with XXLG
5KX6	;	2.2	;	The structure of Arabidopsis thaliana FUT1 Mutant R284K in complex with GDP
4HRY	;	1.5	;	The structure of Arabidopsis thaliana KAI2
6SW4	;	1.845	;	The structure of AraP, an arabinose binding protein from Geobacillus stearothermophilus
5UCQ	;	1.4	;	The structure of archaeal Inorganic Pyrophosphatase in complex with pyrophosphate
3Q4W	;	1.441	;	The structure of archaeal inorganic pyrophosphatase in complex with substrate
7YIK	;	2.191	;	The structure of archaeal nuclease RecJ2 from Methanocaldococcus jannaschii
7YKV	;	2.04	;	The structure of archaeal nuclease RecJ2 from Methanocaldococcus jannaschii
3A1Y	;	2.13	;	The structure of archaeal ribosomal stalk P1/P0 complex
2W82	;	2.8	;	The structure of ArdA
1YLE	;	1.7	;	The structure of arginine/ornithine succinyltransferase subunit AI from Pseudomonas aeruginosa.
7AFS	;	1.7	;	The structure of Artemis variant D37A
7AFU	;	1.56	;	The structure of Artemis variant H33A
7AGI	;	1.7	;	The structure of Artemis variant H35D
7AF1	;	1.7	;	The structure of Artemis/SNM1C/DCLRE1C with 2 Zinc ions
1ASH	;	2.15	;	THE STRUCTURE OF ASCARIS HEMOGLOBIN DOMAIN I AT 2.2 ANGSTROMS RESOLUTION: MOLECULAR FEATURES OF OXYGEN AVIDITY
2XI6	;	1.65	;	The structure of ascorbate peroxidase Compound I
2XIF	;	1.65	;	The structure of ascorbate peroxidase Compound II
5JQR	;	1.81	;	The Structure of Ascorbate Peroxidase Compound II formed by reaction with m-CPBA
2XIH	;	1.65	;	The structure of ascorbate peroxidase Compound III
8XB8	;	3.4	;	The structure of ASFV A137R
1KS4	;	2.5	;	The structure of Aspergillus niger endoglucanase-palladium complex
5C71	;	2.62	;	The structure of Aspergillus oryzae a-glucuronidase complexed with glycyrrhetinic acid monoglucuronide
5C70	;	3.1	;	The structure of Aspergillus oryzae beta-glucuronidase
7TBW	;	3.1	;	The structure of ATP-bound ABCA1
5JM8	;	2.2	;	The structure of ATP-bound aerobactin synthetase IucA from a hypervirulent pathotype of Klebsiella pneumoniae
6BJT	;	1.8	;	The structure of AtzH: a little known member of the atrazine breakdown pathway
6BJU	;	1.64	;	The structure of AtzH: a little known member of the atrazine breakdown pathway
6D63	;	2.3	;	The structure of AtzH: a little known member of the atrazine breakdown pathway
3AJ2	;	2.7	;	The structure of AxCeSD octamer (C-terminal HIS-tag) from Acetobacter xylinum
3AJ1	;	2.5	;	The structure of AxCeSD octamer (N-terminal HIS-tag) from Acetobacter xylinum
3A8E	;	3.0	;	The structure of AxCesD octamer complexed with cellopentaose
5Z85	;	1.85	;	The structure of azide-bound cytochrome c oxidase determined using the another batch crystals exposed to 20 mM azide solution for 2 days
5Z84	;	1.85	;	The structure of azide-bound cytochrome c oxidase determined using the crystals exposed to 20 mM azide solution for 4 days
8GVM	;	1.851	;	The structure of azide-bound cytochrome C oxidase determined using the crystals exposed to 20 mm azide solution for 4 days
1D23	;	1.5	;	THE STRUCTURE OF B-HELICAL C-G-A-T-C-G-A-T-C-G AND COMPARISON WITH C-C-A-A-C-G-T-T-G-G. THE EFFECT OF BASE PAIR REVERSALS
1S58	;	3.5	;	The structure of B19 parvovirus capsid
5BV9	;	1.93	;	The Structure of Bacillus pumilus GH48 in complex with cellobiose
5CVY	;	2.0	;	The Structure of Bacillus pumilus GH48 in complex with cellobiose and cellohexaose
7M33	;	3.55	;	The structure of Bacillus subtilis BmrCD in the inward-facing conformation bound to Hoechst-33342 and ATP
7BOV	;	2.293	;	The Structure of Bacillus subtilis glycosyltransferase,Bs-YjiC
1OGC	;	2.0	;	The Structure of Bacillus subtilis RbsD complexed with D-ribose
1OGD	;	1.95	;	The Structure of Bacillus subtilis RbsD complexed with D-ribose
1OGF	;	2.3	;	The Structure of Bacillus subtilis RbsD complexed with glycerol
1OGE	;	2.05	;	The Structure of Bacillus subtilis RbsD complexed with Ribose 5-phosphate
1ZP7	;	2.25	;	The structure of Bacillus subtilis RecU Holliday junction resolvase and its role in substrate selection and sequence specific cleavage.
8K38	;	3.2	;	The structure of bacteriophage lambda portal-adaptor
3QC7	;	1.52	;	The structure of bacteriophage phi29 head fibers has a supercoiled triple repeating helix-turn-helix motif
1NOH	;	2.8	;	The structure of bacteriophage phi29 scaffolding protein gp7 after prohead assembly
1LBA	;	2.2	;	THE STRUCTURE OF BACTERIOPHAGE T7 LYSOZYME, A ZINC AMIDASE AND AN INHIBITOR OF T7 RNA POLYMERASE
7LH6	;	2.85	;	The structure of Bacteroides plebeius L-galactose dehydrogenase
7RJ5	;	7.0	;	The structure of BAM in complex with EspP at 7 Angstrom resolution
7RI7	;	8.0	;	The structure of BAM in MSP1D1 nanodiscs
7RI9	;	6.9	;	The structure of BAM in MSP1E3D1 at 6.9 Angstrom resolution
7RI8	;	7.5	;	The structure of BAM in MSP2N2 nanodiscs
2YH3	;	2.6	;	The structure of BamB from E. coli
7JRK	;	1.71	;	The Structure of BamE from Pseudomonas aeruginosa
8GY8	;	1.94	;	The structure of Bax1 from Pyrococcus furiosus
1O0L	;		;	THE STRUCTURE OF BCL-W REVEALS A ROLE FOR THE C-TERMINAL RESIDUES IN MODULATING BIOLOGICAL ACTIVITY
4CP3	;	2.3	;	The structure of BCL6 BTB (POZ) domain in complex with the ansamycin antibiotic rifabutin.
6RX4	;	3.3	;	THE STRUCTURE OF BD OXIDASE FROM ESCHERICHIA COLI
5DOQ	;	3.05	;	The structure of bd oxidase from Geobacillus thermodenitrificans
5IR6	;	3.8	;	The structure of bd oxidase from Geobacillus thermodenitrificans
4PCV	;	2.05	;	The structure of BdcA (YjgI) from E. coli
4QAV	;	2.1	;	The structure of Beta-ketoacyl -(acyl carrier protein) synthase II (FabF) from Neisseria meningitidis
3U0F	;	1.25	;	The structure of Beta-ketoacyl synthase from Brucella melitensis bound to the fragment 7-hydroxycoumarin
1G5X	;	2.45	;	The Structure of Beta-Ketoacyl-[Acyl Carrier Protein] Synthase I
1FJ8	;	2.27	;	THE STRUCTURE OF BETA-KETOACYL-[ACYL CARRIER PROTEIN] SYNTHASE I IN COMPLEX WITH CERULENIN, IMPLICATIONS FOR DRUG DESIGN
1FJ4	;	2.35	;	THE STRUCTURE OF BETA-KETOACYL-[ACYL CARRIER PROTEIN] SYNTHASE I IN COMPLEX WITH THIOLACTOMYCIN, IMPLICATIONS FOR DRUG DESIGN
3ZI4	;	1.33	;	The structure of Beta-phosphoglucomutase Inhibited With Glucose-6-phosphate and Scandium Tetrafluoride
7VC6	;	2.54	;	The structure of beta-xylosidase from Phanerochaete chrysosporium(PcBxl3)
7VC7	;	3.08	;	The structure of beta-xylosidase from Phanerochaete chrysosporium(PcBxl3)
1Q7B	;	2.05	;	The structure of betaketoacyl-[ACP] reductase from E. coli in complex with NADP+
1Q7C	;	2.5	;	The structure of betaketoacyl-[ACP] reductase Y151F mutant in complex with NADPH fragment
4PFJ	;	2.3	;	The structure of bi-acetylated SAHH
1KVK	;	2.4	;	The Structure of Binary complex between a Mammalian Mevalonate Kinase and ATP: Insights into the Reaction Mechanism and Human Inherited Disease
1DV2	;	2.5	;	The structure of biotin carboxylase, mutant E288K, complexed with ATP
6KUE	;	1.992	;	The structure of BioZ from Agrobacterium tumefaciens
3HUH	;	1.5	;	The structure of biphenyl-2,3-diol 1,2-dioxygenase iii-related protein from salmonella typhimurium
2JH8	;	3.22	;	The structure of bluetongue virus VP4 reveals a multifunctional RNA- capping production-line
2JH9	;	3.0	;	The structure of bluetongue virus VP4 reveals a multifunctional RNA- capping production-line
2JHA	;	3.4	;	The structure of bluetongue virus VP4 reveals a multifunctional RNA- capping production-line
2JHC	;	3.0	;	The structure of bluetongue virus VP4 reveals a multifunctional RNA- capping production-line
2JHP	;	2.5	;	The structure of bluetongue virus VP4 reveals a multifunctional RNA- capping production-line
6HF2	;	1.69	;	The structure of BoMan26B, a GH26 beta-mannanase from Bacteroides ovatus
6HF4	;	1.781	;	The structure of BoMan26B, a GH26 beta-mannanase from Bacteroides ovatus, complexed with G1M4
1DAB	;	2.5	;	The Structure of Bordetella Pertussis Virulence Factor P.69 Pertactin
2AKQ	;	3.0	;	The structure of bovine B-lactoglobulin A in crystals grown at very low ionic strength
6NKQ	;	2.3	;	The structure of bovine beta-lactoglobulin in novel crystals grown at pH 3.8
1NBM	;	3.0	;	THE STRUCTURE OF BOVINE F1-ATPASE COVALENTLY INHIBITED WITH 4-CHLORO-7-NITROBENZOFURAZAN
1GMJ	;	2.2	;	The structure of bovine IF1, the regulatory subunit of mitochondrial F-ATPase
2BP2	;	3.0	;	THE STRUCTURE OF BOVINE PANCREATIC PROPHOSPHOLIPASE A2 AT 3.0 ANGSTROMS RESOLUTION
1BPI	;	1.09	;	THE STRUCTURE OF BOVINE PANCREATIC TRYPSIN INHIBITOR AT 125K: DEFINITION OF CARBOXYL-TERMINAL RESIDUES GLYCINE-57 AND ALANINE-58
7N4Y	;	2.61	;	The structure of bovine thyroglobulin with iodinated tyrosines
4GGZ	;	1.75	;	The structure of bradavidin2-biotin complex
5XBW	;	3.109	;	The structure of BrlR
5XBT	;	2.495	;	The structure of BrlR bound to c-di-GMP
5XBI	;	1.4	;	The structure of BrlR-C domain bound to 3-amino-2-phenazino(a pyocyanin analog)
4MIR	;	2.4	;	The structure of Brucella abortus PliC in the hexagonal crystal form
4MIS	;	2.0	;	The structure of Brucella abortus PliC in the orthorombic crystal form
6HC6	;	1.77	;	The structure of BSAP, a zinc aminopeptidase from Bacillus subtilis
2FCA	;	2.1	;	The structure of BsTrmB
6RCZ	;	1.74	;	The structure of Burkholderia pseudomallei trehalose-6-phosphatase
1VQ6	;	2.7	;	The structure of c-hpmn and CCA-PHE-CAP-BIO bound to the large ribosomal subunit of haloarcula marismortui
3L2Y	;	2.7	;	The structure of C-reactive protein bound to phosphoethanolamine
4ITK	;	1.18	;	The structure of C.reinhardtii Ferredoxin 2
6H0P	;	3.47	;	The structure of C100A mutant of Arabidopsis thaliana UDP-apiose/UDP-xylose synthase in complex with NADH and UDP-D-glucuronic acid
5LIQ	;	1.85	;	The structure of C160S,C508S,C578S mutant of Nt.BspD6I nicking endonuclease at 0.185 nm resolution .
4IMA	;	1.954	;	The structure of C436M-hLPYK in complex with Citrate/Mn/ATP/Fru-1,6-BP
3CME	;	2.95	;	The Structure of CA and CCA-PHE-CAP-BIO Bound to the Large Ribosomal Subunit of Haloarcula Marismortui
3O78	;	2.6	;	The structure of Ca2+ Sensor (Case-12)
3O77	;	2.35	;	The structure of Ca2+ Sensor (Case-16)
4DUQ	;	1.3	;	The Structure of Ca2+-loaded S100A2 at 1.3A resolution
3R5V	;	1.65	;	The structure of calcium bound Thermococcus thioreducens inorganic pyrophosphatase at 298K
1CNP	;		;	THE STRUCTURE OF CALCYCLIN REVEALS A NOVEL HOMODIMERIC FOLD FOR S100 CA2+-BINDING PROTEINS, NMR, 22 STRUCTURES
7PJC	;	2.11	;	The structure of Candida albicans phosphoglucomutase with isothiazolone modification on Cys359
5CB2	;	2.9	;	the structure of candida albicans Sey1p in complex with GMPPNP
1W92	;	1.7	;	The structure of carbomonoxy murine neuroglobin reveals a heme- sliding mechanism for affinity regulation
7EP9	;	2.604	;	The structure of carboxypeptidase from Fusobacterium nucleatum
1OPO	;	3.2	;	THE STRUCTURE OF CARNATION MOTTLE VIRUS
2OP3	;	1.6	;	The structure of cathepsin S with a novel 2-arylphenoxyacetaldehyde inhibitor derived by the Substrate Activity Screening (SAS) method
3MK7	;	3.2	;	The structure of CBB3 cytochrome oxidase
5DJQ	;	3.2	;	The structure of CBB3 cytochrome oxidase.
4DOD	;	1.7	;	The structure of Cbescii CelA GH9 module
4CCS	;	1.9	;	The structure of CbiX, the terminal Enzyme for Biosynthesis of Siroheme in Denitrifying Bacteria
7JND	;	2.0	;	The structure of CBM32-1 and CBM32-2 domains from Clostridium perfringens ZmpB
7JNB	;	2.0	;	The structure of CBM32-1 and CBM32-2 domains from Clostridium perfringens ZmpB in complex with GalNAc
7JNF	;	2.1	;	The structure of CBM32-1 and CBM32-2 domains from Clostridium perfringens ZmpB in complex with GalNAc
2VMH	;	1.5	;	The structure of CBM51 from Clostridium perfringens GH95
2VMG	;	1.9	;	The structure of CBM51 from Clostridium perfringens GH95 in complex with methyl-galactose
7JRM	;	2.0	;	The structure of CBM51-2 and INT domains from Clostridium perfringens ZmpB
7JRL	;	1.5	;	The structure of CBM51-2 in complex with GlcNAc and INT domains from Clostridium perfringens ZmpB
1VQN	;	2.4	;	The structure of CC-HPMN AND CCA-PHE-CAP-BIO bound to the large ribosomal subunit of haloarcula marismortui
4O9B	;	2.604	;	The Structure of CC1-IH in human STIM1.
3CMA	;	2.8	;	The structure of CCA and CCA-Phe-Cap-Bio bound to the large ribosomal subunit of Haloarcula marismortui
3H37	;	2.85	;	The structure of CCA-adding enzyme apo form I
3H38	;	2.37	;	The structure of CCA-adding enzyme apo form II
1VQ9	;	2.4	;	The structure of CCA-PHE-CAP-BIO and the antibiotic sparsomycin bound to the large ribosomal subunit of haloarcula marismortui
1VQ8	;	2.2	;	The structure of CCDA-PHE-CAP-BIO and the antibiotic sparsomycin bound to the large ribosomal subunit of haloarcula marismortui
1VQK	;	2.3	;	The structure of CCDA-PHE-CAP-BIO bound to the a site of the ribosomal subunit of haloarcula marismortui
7E5W	;	2.55	;	The structure of CcpA from Staphylococcus aureus
1VQO	;	2.2	;	The structure of CCPMN bound to the large ribosomal subunit haloarcula marismortui
1FVV	;	2.8	;	THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
1IUL	;	2.0	;	The structure of cell-free ID.343 from Thermus thermophilus
5ZIG	;	2.05	;	The Structure of cellobiose 2-epimerase from Spirochaeta thermophila DSM 6192
3QDE	;	2.4	;	The structure of Cellobiose phosphorylase from Clostridium thermocellum in complex with phosphate
6AGK	;	2.8	;	The structure of CH-II-77-tubulin complex
2OUL	;	2.2	;	The Structure of Chagasin in Complex with a Cysteine Protease Clarifies the Binding Mode and Evolution of a New Inhibitor Family
5JTQ	;		;	The structure of chaperone SecB in complex with unstructured MBP binding site d
5JTR	;		;	The structure of chaperone SecB in complex with unstructured MBP binding site e
5JTM	;		;	The structure of chaperone SecB in complex with unstructured PhoA binding site a
5JTL	;		;	The structure of chaperone SecB in complex with unstructured proPhoA
5JTN	;		;	The structure of chaperone SecB in complex with unstructured proPhoA binding site c
5JTO	;		;	The structure of chaperone SecB in complex with unstructured proPhoA binding site d
5JTP	;		;	The structure of chaperone SecB in complex with unstructured proPhoA binding site e
3OA5	;	1.74	;	The structure of chi1, a chitinase from Yersinia entomophaga
2QZY	;	1.9	;	The structure of chicken mitochondrial PEPCK in complex with PEP
2FAF	;	1.7	;	The structure of chicken mitochondrial PEPCK.
8HE1	;	1.61	;	The structure of chitin deacetylase Pst_13661 from Puccinia striiformis f. sp. tritici
8HE2	;	1.61	;	The structure of chitin deacetylase Pst_13661 from Puccinia striiformis f. sp. tritici
8HE4	;	1.93	;	The structure of chitin deacetylase Pst_13661 from Puccinia striiformis f. sp. tritici
8HF9	;	1.96	;	The structure of chitin deacetylase Pst_13661 from Puccinia striiformis f. sp. tritici
8HFA	;	2.64	;	The structure of chitin deacetylase VdPDA1 from Verticillium dahliae
7E76	;	2.65	;	The structure of chloroplastic TaPGI
7A03	;	1.39	;	The Structure of CHT
6FVF	;	1.47	;	The Structure of CK2alpha with CCh503 bound
6FVG	;	1.6	;	The Structure of CK2alpha with CCh507 bound
7C3Z	;	1.957	;	The structure of class II tumor suppressor protein H-REV107
7X3H	;	1.7	;	The structure of Clostridium botulinum ParM in the apo conformation
2VK5	;	0.97	;	THE STRUCTURE OF CLOSTRIDIUM PERFRINGENS NANI SIALIDASE AND ITS CATALYTIC INTERMEDIATES
2VK6	;	1.5	;	THE STRUCTURE OF CLOSTRIDIUM PERFRINGENS NANI SIALIDASE AND ITS CATALYTIC INTERMEDIATES
2VK7	;	1.2	;	THE STRUCTURE OF CLOSTRIDIUM PERFRINGENS NANI SIALIDASE AND ITS CATALYTIC INTERMEDIATES
1TYF	;	2.3	;	THE STRUCTURE OF CLPP AT 2.3 ANGSTROM RESOLUTION SUGGESTS A MODEL FOR ATP-DEPENDENT PROTEOLYSIS
1H7E	;	1.83	;	The structure of CMP:2-keto-3-deoxy-manno-octonic acid synthetase and of its complexes with substrates and substrate analogues, Apo-enzyme
1H7H	;	2.3	;	The structure of CMP:2-keto-3-deoxy-manno-octonic acid synthetase and of its complexes with substrates and substrate analogues, CDP complex
1H7F	;	2.12	;	The structure of CMP:2-keto-3-deoxy-manno-octonic acid synthetase and of its complexes with substrates and substrate analogues, CMP complex
1H7G	;	2.13	;	The structure of CMP:2-keto-3-deoxy-manno-octonic acid synthetase and of its complexes with substrates and substrate analogues, CTP MG2+ complex
1H7T	;	2.48	;	The structure of CMP:2-keto-3-deoxy-manno-octonic acid synthetase and of its complexes with substrates and substrate analogues, here complex with CMP-NeuAc
1GQC	;	2.6	;	THE STRUCTURE OF CMP:2-KETO-3-DEOXY-MANNO-OCTONIC ACID SYNTHETASE COMPLEXED WITH CMP-Kdo at 100K
1GQ9	;	2.6	;	THE STRUCTURE OF CMP:2-KETO-3-DEOXY-MANNO-OCTONIC ACID SYNTHETASE COMPLEXED WITH CTP at 100K
6JRJ	;	2.943	;	The structure of co-crystals of 8r-B-EGFR T790M/C797S complex
6JRK	;	2.796	;	The structure of co-crystals of 8r-B-EGFR WT complex
3NYK	;	1.86	;	The structure of cobalt-substituted pseudoazurin from Alcaligenes faecalis
3U4G	;	1.9	;	The Structure of CobT from Pyrococcus horikoshii
1RPR	;		;	THE STRUCTURE OF COLE1 ROP IN SOLUTION
5O32	;	4.20621	;	The structure of complement complex
6OYF	;	2.1	;	The structure of condensation and adenylation domains of teixobactin-producing nonribosomal peptide synthetase Txo1 serine module
6OZV	;	2.18	;	The structure of condensation and adenylation domains of teixobactin-producing nonribosomal peptide synthetase Txo1 serine module in complex with AMP
6P3I	;	2.15	;	The structure of condensation and adenylation domains of teixobactin-producing nonribosomal peptide synthetase Txo1 serine module in complex with Mg
6P4U	;	2.1	;	The structure of condensation and adenylation domains of teixobactin-producing nonribosomal peptide synthetase Txo1 serine module in complex with Mg and AMP
6P1J	;	2.95	;	The structure of condensation and adenylation domains of teixobactin-producing nonribosomal peptide synthetase Txo2 serine module
2HIY	;	1.4	;	The structure of conserved bacterial protein SP0830 from Streptococcus pneumoniae. (CASP Target)
4FFE	;	2.25	;	The structure of cowpox virus CPXV018 (OMCP)
7Y7M	;	3.05	;	The structure of coxsackievirus A16 mature virion in complex with Fab 8C4
3ZH7	;	2.102	;	The structure of crystal form II of Haemophilus influenzae protein E
2CHA	;	2.0	;	THE STRUCTURE OF CRYSTALLINE ALPHA-CHYMOTRYPSIN, $V.THE ATOMIC STRUCTURE OF TOSYL-ALPHA-CHYMOTRYPSIN AT 2 ANGSTROMS RESOLUTION
2BTF	;	2.55	;	THE STRUCTURE OF CRYSTALLINE PROFILIN-BETA-ACTIN
3ZC4	;	2.72	;	The structure of Csa5 from Sulfolobus solfataricus.
3DEL	;	1.92	;	The structure of CT381, the arginine binding protein from the periplasm Chlamydia trachomatis
5KAX	;	2.0	;	The structure of CTR107 protein bound to RHODAMINE 6G
4M4L	;	1.45	;	The structure of Cu T6 bovine insulin
1NIA	;	2.5	;	THE STRUCTURE OF CU-NITRITE REDUCTASE FROM ACHROMOBACTER CYCLOCLASTES AT FIVE PH VALUES, WITH NITRITE BOUND AND WITH TYPE II CU DEPLETED
1NIB	;	2.7	;	THE STRUCTURE OF CU-NITRITE REDUCTASE FROM ACHROMOBACTER CYCLOCLASTES AT FIVE PH VALUES, WITH NITRITE BOUND AND WITH TYPE II CU DEPLETED
1NIC	;	1.9	;	THE STRUCTURE OF CU-NITRITE REDUCTASE FROM ACHROMOBACTER CYCLOCLASTES AT FIVE PH VALUES, WITH NITRITE BOUND AND WITH TYPE II CU DEPLETED
1NID	;	2.2	;	THE STRUCTURE OF CU-NITRITE REDUCTASE FROM ACHROMOBACTER CYCLOCLASTES AT FIVE PH VALUES, WITH NITRITE BOUND AND WITH TYPE II CU DEPLETED
1NIE	;	1.9	;	THE STRUCTURE OF CU-NITRITE REDUCTASE FROM ACHROMOBACTER CYCLOCLASTES AT FIVE PH VALUES, WITH NITRITE BOUND AND WITH TYPE II CU DEPLETED
1NIF	;	1.7	;	THE STRUCTURE OF CU-NITRITE REDUCTASE FROM ACHROMOBACTER CYCLOCLASTES AT FIVE PH VALUES, WITH NITRITE BOUND AND WITH TYPE II CU DEPLETED
2NRD	;	2.1	;	THE STRUCTURE OF CU-NITRITE REDUCTASE FROM ACHROMOBACTER CYCLOCLASTES AT FIVE PH VALUES, WITH NITRITE BOUND AND WITH TYPE II CU DEPLETED
6AD0	;	3.9	;	The structure of CVA10 mature virion in complex with Fab 2G8
6AD1	;	4.2	;	The structure of CVA10 procapsid from its complex with Fab 2G8
6ACY	;	3.4	;	The structure of CVA10 virus A-particle
6ACZ	;	4.3	;	The structure of CVA10 virus A-particle from its complex with Fab 2G8
6ACU	;	3.4	;	The structure of CVA10 virus mature virion
6ACW	;	4.0	;	The structure of CVA10 virus procapsid particle
2XB3	;	2.8	;	The Structure of Cyanobacterial PsbP
3EN0	;	1.5	;	The Structure of Cyanophycinase
4JPD	;	1.9	;	The structure of CyaY from Burkholderia cenocepacia
3LE6	;	2.0	;	The structure of cyclin dependent kinase 2 (CKD2) with a pyrazolobenzodiazepine inhibitor
1P2A	;	2.5	;	The structure of cyclin dependent kinase 2 (CKD2) with a trisubstituted naphthostyril inhibitor
1JSV	;	1.96	;	The structure of cyclin-dependent kinase 2 (CDK2) in complex with 4-[(6-amino-4-pyrimidinyl)amino]benzenesulfonamide
1DI8	;	2.2	;	THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3-HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE
1FVT	;	2.2	;	THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITOR
7VDU	;	1.53	;	The structure of cyclin-dependent kinase 2 (CDK2) in complex with Compound 1
7VDP	;	2.09	;	The structure of cyclin-dependent kinase 5 (CDK5) in complex with p25 and Compound 1
7VDR	;	2.55	;	The structure of cyclin-dependent kinase 5 (CDK5) in complex with p25 and Compound 13
7VDS	;	3.05	;	The structure of cyclin-dependent kinase 5 (CDK5) in complex with p25 and Compound 24
7VDQ	;	2.91	;	The structure of cyclin-dependent kinase 5 (CDK5) in complex with p25 and Compound 7
8WY1	;	3.9	;	The structure of cyclization domain in cyclic beta-1,2-glucan synthase from Thermoanaerobacter italicus
2Y75	;	2.0	;	The Structure of CymR (YrzC) the Global Cysteine Regulator of B. subtilis
6TET	;	1.49987	;	The structure of CYP121 in complex with inhibitor L21
6TEV	;	1.70001	;	The structure of CYP121 in complex with inhibitor L44
6TE7	;	1.50002	;	The structure of CYP121 in complex with inhibitor S2
4I1Y	;	2.6	;	The structure of Cysteine synthase from Mycobacterium ulcerans Agy99
3QZ2	;	3.2	;	The structure of cysteine-free human insulin degrading enzyme
2XIL	;	1.68	;	The structure of cytochrome c peroxidase Compound I
2XJ5	;	1.69	;	The structure of cytochrome c peroxidase Compound II
1CED	;		;	THE STRUCTURE OF CYTOCHROME C6 FROM MONORAPHIDIUM BRAUNII, NMR, MINIMIZED AVERAGE STRUCTURE
7E77	;	2.04	;	The structure of cytosolic TaPGI
7E78	;	2.21	;	the structure of cytosolic TaPGI with substrate
1Z8V	;	1.75	;	The Structure of d(GGCCAATTGG) Complexed with Netropsin
362D	;	1.3	;	THE STRUCTURE OF D(TGCGCA)2 AND A COMPARISON TO OTHER Z-DNA HEXAMERS
1LJX	;	1.64	;	THE STRUCTURE OF D(TPGPCPGPCPA)2 AT 293K: COMPARISON OF THE EFFECT OF SEQUENCE AND TEMPERATURE
5LHC	;	2.4	;	The structure of D456A mutant of Nt.BspD6I nicking endonuclease at 0.24 nm resolution .
5JZV	;	2.07	;	The structure of D77G hCINAP-ADP
2VLE	;	2.4	;	The structure of daidzin, a naturally occurring anti alcohol- addiction agent, in complex with human mitochondrial aldehyde dehydrogenase
1D30	;	2.4	;	THE STRUCTURE OF DAPI BOUND TO DNA
7D79	;	2.10411	;	The structure of DcsB complex with its substrate analogue
4EXW	;	2.8	;	The structure of DdrB from Deinococcus: a new fold for single-stranded DNA binding proteins.
7W8D	;	2.75016	;	The structure of Deinococcus radiodurans RuvC
7W89	;	1.50006	;	The structure of Deinococcus radiodurans Yqgf
1TG8	;	2.61	;	The structure of Dengue virus E glycoprotein
1HMD	;	2.0	;	THE STRUCTURE OF DEOXY AND OXY HEMERYTHRIN AT 2.0 ANGSTROMS RESOLUTION
1HMO	;	2.0	;	THE STRUCTURE OF DEOXY AND OXY HEMERYTHRIN AT 2.0 ANGSTROMS RESOLUTION
2NOA	;	1.8	;	The structure of deoxycytidine kinase complexed with lamivudine and ADP.
2NO9	;	2.15	;	The structure of deoxycytidine kinase complexed with troxacitabine and ADP.
2INS	;	2.5	;	THE STRUCTURE OF DES-PHE B1 BOVINE INSULIN
5EL8	;	2.3	;	The structure of DHAR1 from Arabidopsis thaliana
5ELA	;	2.28	;	The structure of DHAR1 from Arabidopsis thaliana
5ELG	;	1.81	;	The structure of DHAR1 from Arabidopsis thaliana
5XGV	;	2.099	;	The structure of Diels-Alderase PyrE3 in the biosynthetic pathway of pyrroindomycins
5BTU	;	2.503	;	The structure of Diels-Alderase PyrI4 in the biosynthetic pathway of pyrroindomycins
4DPP	;	2.0	;	The structure of dihydrodipicolinate synthase 2 from Arabidopsis thaliana
4DPQ	;	2.202	;	The structure of dihydrodipicolinate synthase 2 from Arabidopsis thaliana in complex with (S)-lysine
3IC9	;	2.15	;	The structure of dihydrolipoamide dehydrogenase from Colwellia psychrerythraea 34H.
4HB7	;	1.95	;	The Structure of Dihydropteroate Synthase from Staphylococcus aureus subsp. aureus Mu50.
2HT9	;	1.9	;	The structure of dimeric human glutaredoxin 2
7VOR	;	2.74	;	The structure of dimeric photosynthetic RC-LH1 supercomplex in Class-1
7VOT	;	2.9	;	The structure of dimeric photosynthetic RC-LH1 supercomplex in Class-2
4ZPU	;	2.4	;	The structure of DLP12 endolysin exhibits likely active and inactive conformations.
3ZQ7	;	2.52	;	The Structure of DNA-binding domain of response regulator from Escherichia coli K-12
7EXX	;	2.5	;	The structure of DndG
5SUH	;	2.7	;	The structure of double ringed trimeric shell protein MSM0271 from the RMM microcompartment
3HAC	;	2.0	;	The structure of DPP-4 in complex with piperidine fused imidazopyridine 34
2HHA	;	2.35	;	The structure of DPP4 in complex with an oxadiazole inhibitor
3HAB	;	2.1	;	The structure of DPP4 in complex with piperidine fused benzimidazole 25
6B1E	;	1.77	;	The structure of DPP4 in complex with Vildagliptin
6B1O	;	1.91	;	The structure of DPP4 in complex with Vildagliptin Analog
6HVQ	;	1.9	;	The structure of Dps from Listeria innocua soaked before soaking experiments with Zn, Co and La
6HX2	;	1.597	;	The structure of Dps from Listeria innocua soaked with Cobalt
6HUI	;	2.995	;	The structure of Dps from Listeria innocua soaked with zinc
5YH0	;	3.45	;	The structure of DrFam20C1
5YH2	;	3.55	;	The structure of DrFam20C1 and hFam20A complex
5ZK4	;	2.03	;	The structure of DSZS acyltransferase with carrier protein
2KWF	;		;	The structure of E-protein activation domain 1 bound to the KIX domain of CBP/p300 elucidates leukemia induction by E2A-PBX1
1XJW	;	2.71	;	The Structure of E. coli Aspartate Transcarbamoylase Q137A Mutant in The R-State
7P8V	;	3.6	;	The structure of E. coli MutL bound to a 3' resected DNA end
1YKI	;	1.7	;	The structure of E. coli nitroreductase bound with the antibiotic nitrofurazone
1YLU	;	2.0	;	The structure of E. coli nitroreductase with bound acetate, crystal form 2
8RTZ	;	1.52	;	The structure of E. coli penicillin binding protein 3 (PBP3) in complex with a bicyclic peptide inhibitor
6CZF	;	1.949	;	The structure of E. coli PurF in complex with ppGpp-Mg
5F6C	;	3.002	;	The structure of E. coli RNase E catalytically inactive mutant with RNA bound
8I1Y	;	1.78	;	The structure of E. coli TrpRS bound with a chemical fragment
2V4Y	;	2.8	;	THE STRUCTURE OF E. COLI UMP KINASE IN COMPLEX WITH ITS ALLOSTERIC REGULATOR GTP
2BND	;	2.6	;	The structure of E. coli UMP kinase in complex with UDP
2BNE	;	2.3	;	The structure of E. coli UMP kinase in complex with UMP
2BNF	;	2.45	;	The structure of E. coli UMP kinase in complex with UTP
1YLR	;	1.7	;	The structure of E.coli nitroreductase with bound acetate, crystal form 1
3K6L	;	2.15	;	The structure of E.coli peptide deformylase (PDF) in complex with peptidomimetic ligand BB2827
4M80	;	1.858	;	The structure of E292S glycosynthase variant of exo-1,3-beta-glucanase from Candida albicans at 1.85A resolution
4M81	;	1.86	;	The structure of E292S glycosynthase variant of exo-1,3-beta-glucanase from Candida albicans complexed with 1-fluoro-alpha-D-glucopyranoside (donor) and p-nitrophenyl beta-D-glucopyranoside (acceptor) at 1.86A resolution
4M82	;	1.592	;	The structure of E292S glycosynthase variant of exo-1,3-beta-glucanase from Candida albicans complexed with p-nitrophenyl-gentiobioside (product) at 1.6A resolution
6KTV	;	2.2	;	The structure of EanB complex with hercynine and persulfided Cys412
6KVY	;	1.78	;	The structure of EanB/T414A complex with hercynine
6KVZ	;	2.18	;	The structure of EanB/T414V complex with hercynine
6KU1	;	2.25	;	The structure of EanB/Y353A complex with ergothioneine
6KU2	;	2.34	;	The structure of EanB/Y353A complex with ergothioneine covalent linked with persulfide Cys412
6KW0	;	2.8	;	The structure of EanB/Y353F-Cys412-persulfide in tetrahedral intermediate state with ergothioneine
7YER	;	3.0	;	The structure of EBOV L-VP35 complex
7YET	;	3.3	;	The structure of EBOV L-VP35 in complex with suramin
8JSL	;	2.95	;	The structure of EBOV L-VP35-RNA complex
8JSM	;	3.3	;	The structure of EBOV L-VP35-RNA complex (conformation 1)
8JSN	;	3.4	;	The structure of EBOV L-VP35-RNA complex (conformation 2)
7YES	;	3.4	;	The structure of EBOV L-VP35-RNA complex (state2)
6ZG3	;	2.8	;	the structure of ECF PanT transporter in a complex with a nanobody
4V5L	;	3.1	;	The structure of EF-Tu and aminoacyl-tRNA bound to the 70S ribosome with a GTP analog
6O6M	;	2.506	;	The Structure of EgtB (Cabther)
6O6L	;	2.25	;	The Structure of EgtB(Cabther) in complex with Hercynine
1R8L	;	2.6	;	The structure of endo-beta-1,4-galactanase from Bacillus licheniformis
1UR0	;	2.5	;	The structure of endo-beta-1,4-galactanase from Bacillus licheniformis in complex with two oligosaccharide products.
1UR4	;	2.2	;	The structure of endo-beta-1,4-galactanase from Bacillus licheniformis in complex with two oligosaccharide products.
1KS8	;	1.4	;	The structure of Endoglucanase from termite, Nasutitermes takasagoensis, at pH 2.5.
1KSC	;	1.55	;	The structure of Endoglucanase from termite, Nasutitermes takasagoensis, at pH 5.6.
1KSD	;	1.6	;	The structure of Endoglucanase from termite, Nasutitermes takasagoensis, at pH 6.5.
7XTT	;	1.82	;	The structure of engineered TfCut S130A in complex with MHET
4F47	;	1.75	;	The Structure of Enoyl-CoA hydratase EchA19 from Mycobacterium marinum
6IYK	;	2.45	;	The structure of EntE with 2-nitrobenzoyl adenylate analog
6IYL	;	2.56	;	The structure of EntE with 3-cyanobenzoyl adenylate analog
6AJ0	;	3.4	;	The structure of Enterovirus D68 mature virion
6AJ7	;	3.6	;	The structure of Enterovirus D68 mature virion in complex with Fab 15C5
6AJ9	;	3.5	;	The structure of Enterovirus D68 mature virion in complex with Fab 15C5 and 11G1
6AJ3	;	3.8	;	The structure of Enterovirus D68 procapsid
1MFG	;	1.25	;	The Structure of ERBIN PDZ domain bound to the Carboxy-terminal tail of the ErbB2 Receptor
1MFL	;	1.88	;	The Structure of ERBIN PDZ domain bound to the Carboxy-terminal tail of the ErbB2 Receptor
1TVO	;	2.5	;	The structure of ERK2 in complex with a small molecule inhibitor
7AUV	;	1.76	;	The structure of ERK2 in complex with dual inhibitor ASTX029
3W55	;	3.0	;	The structure of ERK2 in complex with FR148083
1K6W	;	1.75	;	The Structure of Escherichia coli Cytosine Deaminase
1K70	;	1.8	;	The Structure of Escherichia coli Cytosine Deaminase bound to 4-Hydroxy-3,4-Dihydro-1H-Pyrimidin-2-one
1EHS	;		;	THE STRUCTURE OF ESCHERICHIA COLI HEAT-STABLE ENTEROTOXIN B BY NUCLEAR MAGNETIC RESONANCE AND CIRCULAR DICHROISM
1ICR	;	1.7	;	THE STRUCTURE OF ESCHERICHIA COLI NITROREDUCTASE COMPLEXED WITH NICOTINIC ACID
1ICU	;	1.8	;	THE STRUCTURE OF ESCHERICHIA COLI NITROREDUCTASE COMPLEXED WITH NICOTINIC ACID
1ICV	;	2.4	;	THE STRUCTURE OF ESCHERICHIA COLI NITROREDUCTASE COMPLEXED WITH NICOTINIC ACID
4DAP	;	2.2	;	The structure of Escherichia coli SfsA
4P1M	;	1.95	;	The structure of Escherichia coli ZapA
5DKO	;	2.4	;	The structure of Escherichia coli ZapD
5HC3	;	2.4	;	The structure of esterase Est22
5HC5	;	2.43	;	The structure of esterase Est22 mutant-S188A
1UOM	;	2.28	;	The Structure of Estrogen Receptor in Complex with a Selective and Potent Tetrahydroisochiolin Ligand.
1FXX	;	2.4	;	THE STRUCTURE OF EXONUCLEASE I SUGGESTS HOW PROCESSIVITY IS ACHIEVED
3ZIA	;	2.5	;	The structure of F1-ATPase from Saccharomyces cerevisiae inhibited by its regulatory protein IF1
2V7Q	;	2.1	;	The structure of F1-ATPase inhibited by I1-60HIS, a monomeric form of the inhibitor protein, IF1.
2JJ1	;	2.7	;	The Structure of F1-ATPase inhibited by piceatannol.
2JJ2	;	2.4	;	The Structure of F1-ATPase inhibited by quercetin.
2JIZ	;	2.3	;	The Structure of F1-ATPase inhibited by resveratrol.
6W69	;	2.501	;	The structure of F64, S172A Keap1-BTB domain
1T66	;	2.3	;	The structure of FAB with intermediate affinity for fluorescein.
7DX4	;	3.6	;	The structure of FC08 Fab-hA.CE2-RBD complex
3EF0	;	2.1	;	The Structure of Fcp1, an essential RNA polymerase II CTD phosphatase
3EF1	;	2.15	;	The Structure of Fcp1, an essential RNA polymerase II CTD phosphatase
2G0B	;	3.0	;	The structure of FeeM, an N-acyl amino acid synthase from uncultured soil microbes
2XJ6	;	1.7	;	The structure of ferrous ascorbate peroxidase
2XJ8	;	1.69	;	The structure of ferrous cytochrome c peroxidase
2MTP	;		;	The structure of Filamin repeat 21 bound to integrin
7WVS	;	2.35	;	The structure of FinI complex with SAM
1FIP	;	1.9	;	THE STRUCTURE OF FIS MUTANT PRO61ALA ILLUSTRATES THAT THE KINK WITHIN THE LONG ALPHA-HELIX IS NOT DUE TO THE PRESENCE OF THE PROLINE RESIDUE
2HAH	;	1.7	;	The structure of FIV 12S protease in complex with TL-3
4I2O	;	1.77	;	The Structure of FixK2 from Bradyrhizobium japonicum
5MGX	;	2.18	;	The structure of FKBP38 in complex with the MEEVD tetratricopeptide binding-motif of Hsp90
7XQU	;	2.6	;	The structure of FLA-E*00301/EM-FECV-10
7XQS	;	2.69	;	The structure of FLA-K*00701/KP-CoV-9
7XQT	;	2.8	;	The structure of FLA-K*00701/KP-FECV-11
7F39	;	1.888	;	The structure of flavin transferase FmnB
1FCD	;	2.53	;	THE STRUCTURE OF FLAVOCYTOCHROME C SULFIDE DEHYDROGENASE FROM A PURPLE PHOTOTROPHIC BACTERIUM CHROMATIUM VINOSUM AT 2.5 ANGSTROMS RESOLUTION
8EW5	;	6.0	;	The structure of flightin within myosin thick filaments from Bombus ignitus flight muscle
8U8H	;	4.7	;	The structure of flightin within myosin thick filaments from Drosophila melanogaster flight muscle
5IKV	;	2.508	;	The Structure of Flufenamic Acid Bound to Human Cyclooxygenase-2
3H1O	;	2.0	;	The Structure of Fluorescent Protein FP480
8FIA	;	2.4	;	The structure of fly Teneurin self assembly
2WZR	;	3.0	;	The Structure of Foot and Mouth Disease Virus Serotype SAT1
7VFX	;	2.8	;	The structure of Formyl Peptide Receptor 1 in complex with Gi and peptide agonist fMIFL
7EUO	;	2.9	;	The structure of formyl peptide receptor 1 in complex with Gi and peptide agonist fMLF
6K1T	;	1.584	;	The structure of Francisella virulence factor BioJ
6GG2	;	2.598	;	The structure of FsqB from Aspergillus fumigatus, a flavoenzyme of the amine oxidase family
2VXY	;	1.7	;	The structure of FTsZ from Bacillus subtilis at 1.7A resolution
3HJL	;	2.4	;	The structure of full-length FliG from Aquifex aeolicus
6HYC	;	3.18	;	The structure of full-length human phenylalanine hydroxylase in complex with the cofactor and negative regulator tetrahydrobiopterin
6CI1	;	4.9	;	The Structure of Full-Length Kv Beta 2.1 Determined by Cryogenic Electron Microscopy
5KMP	;	3.2	;	The structure of G164E variant of type II NADH dehydrogenase from Caldalkalibacillus thermarum
1SZK	;	2.52	;	The structure of gamma-aminobutyrate aminotransferase mutant: E211S
1SZS	;	2.1	;	The structure of gamma-aminobutyrate aminotransferase mutant: I50Q
1SZU	;	2.52	;	The structure of gamma-aminobutyrate aminotransferase mutant: V241A
8B81	;	1.585	;	The structure of Gan1D W433A in complex with cellobiose-6-phosphate
8B80	;	1.78	;	The structure of Gan1D W433A in complex with galactose-6P
7VYO	;	2.25	;	The structure of GdmN
7VZY	;	2.81	;	The structure of GdmN complex with AMP and 20-O-methyl-19-chloroproansamitocin
7VX0	;	2.0	;	The structure of GdmN complex with ATP
7VYP	;	2.88	;	The structure of GdmN complex with the natural tetrahedral intermediate, carbamoylated derivative, and AMP
7VYJ	;	1.98	;	The structure of GdmN in complex with carbamoyl adenylate intermediate
7VZN	;	2.1	;	The structure of GdmN in complex with carbamoyl adenylate intermediate and 20-O-methyl-19-chloroproansamitocin
7VZZ	;	2.85	;	The structure of GdmN in complex with the natural tetrahedral intermediate, carbamoyl adenylate, and 20-O-methyl-19-chloroproansamitocin
7VZQ	;	2.1	;	The structure of GdmN V24Y/G157A/R158A/G188R mutant in complex with carbamoyl adenylate intermediate
7VZU	;	2.3	;	The structure of GdmN Y82F mutant
1W8I	;	2.1	;	The Structure of gene product af1683 from Archaeoglobus fulgidus.
1ZS7	;	1.85	;	The structure of gene product APE0525 from Aeropyrum pernix
7VEF	;	2.65	;	The structure of GfsA KSQ-AT didomain in complex with a malonate substrate analog
5A58	;	1.8	;	The structure of GH101 D764N mutant from Streptococcus pneumoniae TIGR4 in complex with serinyl T-antigen
5A5A	;	1.75	;	The structure of GH101 E796Q mutant from Streptococcus pneumoniae TIGR4 in complex with PNP-T-antigen
5A59	;	2.5	;	The structure of GH101 E796Q mutant from Streptococcus pneumoniae TIGR4 in complex with T-antigen
5A56	;	1.8	;	The structure of GH101 from Streptococcus pneumoniae TIGR4 in complex with 1-O-methyl-T-antigen
5A57	;	1.46	;	The structure of GH101 from Streptococcus pneumoniae TIGR4 in complex with PUGT
4CD6	;	1.64	;	The structure of GH113 beta-mannanase AaManA from Alicyclobacillus acidocaldarius in complex with ManIFG
4CD7	;	1.65	;	The structure of GH113 beta-mannanase AaManA from Alicyclobacillus acidocaldarius in complex with ManIFG and beta-1,4-mannobiose
4CD8	;	1.47	;	The structure of GH113 beta-mannanase AaManA from Alicyclobacillus acidocaldarius in complex with ManMIm
4CD4	;	1.2	;	The structure of GH26 beta-mannanase CjMan26C from Cellvibrio japonicus in complex with ManIFG
4CD5	;	1.1	;	The structure of GH26 beta-mannanase CjMan26C from Cellvibrio japonicus in complex with ManMIm
6Q75	;	1.75	;	The structure of GH26A from Muricauda sp. MAR_2010_75
6Q78	;	1.5	;	The structure of GH26C from Muricauda sp. MAR_2010_75
6NUM	;	1.9	;	The structure of GH32 from Bifidobacteium adolescentis
7YIL	;	2.17	;	The structure of GINS from Methanocaldococcus jannaschii
3MX1	;	2.3	;	The structure of GIY-YIG endonuclease R.Eco29kI
4EX4	;	2.1	;	The Structure of GlcB from Mycobacterium leprae
4EM6	;	1.9	;	The structure of Glucose-6-phosphate isomerase (GPI) from Brucella melitensis
6ZL4	;	3.0	;	the structure of glutamate transporter homologue GltTk in complex with the photo switchable compound (cis)
6ZLH	;	2.8	;	the structure of glutamate transporter homologue GltTk in complex with the photo switchable compound (trans)
4H3S	;	2.15	;	The Structure of Glutaminyl-tRNA Synthetase from Saccharomyces Cerevisiae
1GER	;	1.86	;	THE STRUCTURE OF GLUTATHIONE REDUCTASE FROM ESCHERICHIA COLI AT 1.86 ANGSTROMS RESOLUTION: COMPARISON WITH THE ENZYME FROM HUMAN ERYTHROCYTES
1YWG	;	2.6	;	The structure of glyceraldehyde-3-phosphate dehydrogenase from Plasmodium falciparum
7CKA	;	1.06	;	The structure of Glycine max (Soybean) Heme oxygenase 1
2AMV	;	2.3	;	THE STRUCTURE OF GLYCOGEN PHOSPHORYLASE B WITH AN ALKYL-DIHYDROPYRIDINE-DICARBOXYLIC ACID
1RHG	;	2.2	;	THE STRUCTURE OF GRANULOCYTE-COLONY-STIMULATING FACTOR AND ITS RELATIONSHIP TO THOSE OF OTHER GROWTH FACTORS
4RXO	;	2.6	;	The structure of GTP-bound SAMHD1
4RXP	;	2.1	;	The structure of GTP-dATP-bound SAMHD1
4RXR	;	2.117	;	The structure of GTP-dCTP-bound SAMHD1
4RXS	;	2.2	;	The structure of GTP-dTTP-bound SAMHD1
4RXQ	;	2.1	;	The structure of GTP-dUTP-bound SAMHD1
113D	;	2.5	;	THE STRUCTURE OF GUANOSINE-THYMIDINE MISMATCHES IN B-DNA AT 2.5 ANGSTROMS RESOLUTION
4DHZ	;	3.11	;	The structure of h/ceOTUB1-ubiquitin aldehyde-UBC13~Ub
4LDT	;	1.901	;	The structure of h/ceOTUB1-ubiquitin aldehyde-UBCH5B~Ub
8GHC	;	2.3	;	The structure of h12-LOX in dimeric form
8GHD	;	2.2	;	The structure of h12-LOX in hexameric form bound to inhibitor ML355 and arachidonic acid
8GHB	;	2.76	;	The structure of h12-LOX in monomeric form
8GHE	;	2.05	;	The structure of h12-LOX in tetrameric form bound to endogenous inhibitor oleoyl-CoA
3H09	;	1.75	;	The structure of Haemophilus influenzae IgA1 protease
3ZH5	;	1.801	;	The structure of Haemophilus influenzae protein E
7T2Z	;	2.2547	;	The structure of Haemophilus influenzae Rd KW20 nitroreductase complexed with 1-methyl-5-nitroimidazole
7T33	;	2.301	;	The structure of Haemophilus influenzae Rd KW20 nitroreductase complexed with nicotinic acid
3ZH6	;	2.292	;	The structure of Haemophilus influenzae Se_Met form of protein E
1SVD	;	1.8	;	The structure of Halothiobacillus neapolitanus RuBisCo
2M2K	;		;	The structure of HasB CTD
6JQ5	;	2.059	;	The structure of Hatchet Ribozyme
3IIJ	;	1.76	;	The structure of hCINAP-ADP complex at 1.76 angstroms resolution.
3IIM	;	2.0	;	The structure of hCINAP-dADP complex at 2.0 angstroms resolution
3IIL	;	2.0	;	The structure of hCINAP-MgADP-Pi complex at 2.0 angstroms resolution
3IIK	;	1.95	;	The structure of hCINAP-SO4 complex at 1.95 angstroms resolution
6DEJ	;	1.6279	;	The structure of HcRed7, a brighter and red-shifted HcRed variant
3RVB	;	2.2	;	The structure of HCV NS3 helicase (Heli-80) bound with inhibitor ITMN-3479
4BKX	;	3.0	;	The structure of HDAC1 in complex with the dimeric ELM2-SANT domain of MTA1 from the NuRD complex
2XUV	;	1.5	;	The structure of HdeB
4LKG	;	2.994	;	The structure of hemagglutinin from a avian-origin H7N9 influenza virus (A/Shanghai/1/2013) in complex with avian receptor analog 3'SLNLN
4LKH	;	3.099	;	The structure of hemagglutinin from a avian-origin H7N9 influenza virus (A/Shanghai/1/2013) in complex with human receptor analog 6'SLNLN
4YY0	;	2.59	;	The structure of hemagglutinin from a H6N1 influenza virus (A/chicken/Taiwan/A2837/2013)
4YY7	;	2.99	;	The structure of hemagglutinin from a H6N1 influenza virus (A/chicken/Taiwan/A2837/2013) in complex with avian receptor analog 3'SLNLN
4YY1	;	3.1	;	The structure of hemagglutinin from a H6N1 influenza virus (A/chicken/Taiwan/A2837/2013) in complex with human receptor analog 6'SLNLN
4YY9	;	2.601	;	The structure of hemagglutinin from a H6N1 influenza virus (A/Taiwan/2/2013)
4YYA	;	2.595	;	The structure of hemagglutinin from a H6N1 influenza virus (A/Taiwan/2/2013) in complex with avian receptor analog 3'SLNLN
4YYB	;	2.609	;	The structure of hemagglutinin from a H6N1 influenza virus (A/Taiwan/2/2013) in complex with human receptor analog 6'SLNLN
5XL1	;	2.3	;	The structure of hemagglutinin from an avian-origin H4N6 influenza virus
5XL4	;	2.102	;	The structure of hemagglutinin from an avian-origin H4N6 influenza virus in complex with human receptor analog Lstc
4KOL	;	2.799	;	The structure of hemagglutinin from avian-origin H7N9 influenza virus
4LCX	;	3.094	;	The structure of hemagglutinin from avian-origin H7N9 influenza virus (A/Shanghai/1/2013)
4KOM	;	2.604	;	The structure of hemagglutinin from avian-origin H7N9 influenza virus in complex with avian receptor analog 3'SLNLN (NeuAc&#945;2-3Gal&#946;1-4GlcNAc&#946;1-3Gal&#946;1-4Glc)
4KON	;	2.6	;	The structure of hemagglutinin from avian-origin H7N9 influenza virus in complex with human receptor analog 6'SLNLN (NeuAc&#945;2-6Gal&#946;1-4GlcNAc&#946;1-3Gal&#946;1-4Glc)
5XL8	;	2.001	;	The structure of hemagglutinin G228S mutant from a avian-origin H4N6 influenza virus (A/duck/Czech/1956)
5XL9	;	2.39	;	The structure of hemagglutinin G228S mutant from an avian-origin H4N6 influenza virus in complex with avian receptor analog LSTa
5XLA	;	2.1	;	The structure of hemagglutinin G228S mutant from an avian-origin H4N6 influenza virus in complex with human receptor analog LSTc
4LKJ	;	2.798	;	The structure of hemagglutinin L226Q mutant (H3 numbering) from a avian-origin H7N9 influenza virus (A/Anhui/1/2013) in complex with avian receptor analog 3'SLNLN
4LKK	;	2.491	;	The structure of hemagglutinin L226Q mutant (H3 numbering) from a avian-origin H7N9 influenza virus (A/Anhui/1/2013) in complex with human receptor analog 6'SLNLN
4LKI	;	2.7	;	The structure of hemagglutinin L226Q mutant from a avian-origin H7N9 influenza virus (A/Anhui/1/2013)
4FIU	;	1.999	;	The structure of hemagglutinin of H16 subtype influenza virus with V327G mutation
5XL6	;	2.41	;	The structure of hemagglutinin Q226L mutant from a avian-origin H4N6 influenza virus
5XL5	;	2.2	;	The structure of hemagglutinin Q226L mutant from an avian-origin H4N6 influenza virus
5XL7	;	2.1	;	The structure of hemagglutinin Q226L mutant from an avian-origin H4N6 influenza virus in complex with human receptor analog LSTc
5XLB	;	2.5	;	The structure of hemagglutinin Q226L-G228S mutant from an avian-origin H4N6 influenza virus
5XLC	;	2.4	;	The structure of hemagglutinin Q226L-G228S mutant from an avian-origin H4N6 influenza virus in complex with avian receptor analog LSTa
5XLD	;	2.3	;	The structure of hemagglutinin Q226L-G228S mutant from an avian-origin H4N6 influenza virus in complex with human receptor analog LSTc
5XL2	;	2.3	;	The structure of hemagglutininfrom a swine-origin H4N6 influenza virus
2C0K	;	2.6	;	The structure of hemoglobin from the botfly Gasterophilus intestinalis
1WTN	;	1.13	;	The structure of HEW Lysozyme Orthorhombic Crystal Growth under a High Magnetic Field
5YH3	;	3.3	;	The structure of hFam20C and hFam20A complex
2VD3	;	2.45	;	The structure of histidine inhibited HisG from Methanobacterium thermoautotrophicum
5ITJ	;	1.63	;	The structure of histone-like protein
6M01	;	2.0	;	The structure of HitB-HitD complex
1HH1	;	2.15	;	THE STRUCTURE OF HJC, A HOLLIDAY JUNCTION RESOLVING ENZYME FROM SULFOLOBUS SOLFATARICUS
6J1W	;	1.501	;	The structure of HLA-A*3001/RT313
6J29	;	1.6	;	The structure of HLA-A*3003/MTB
6J2A	;	1.4	;	The structure of HLA-A*3003/NP44
6J1V	;	2.0	;	The structure of HLA-A*3003/RT313
7XF3	;	1.91	;	The structure of HLA-B*1501/BM58-66AF9
4LNR	;	2.0	;	The structure of HLA-B*35:01 in complex with the peptide (RPQVPLRPMTY)
2Q6W	;	2.25	;	The structure of HLA-DRA, DRB3*0101 (DR52a) with bound platelet integrin peptide associated with fetal and neonatal alloimmune thrombocytopenia
3NOJ	;	1.82	;	The structure of HMG/CHA aldolase from the protocatechuate degradation pathway of Pseudomonas putida
1HL5	;	1.8	;	The Structure of Holo Type Human Cu, Zn Superoxide Dismutase
5ZE4	;	2.11	;	The structure of holo- structure of DHAD complex with [2Fe-2S] cluster
2MHB	;	2.0	;	THE STRUCTURE OF HORSE METHAEMOGLOBIN AT 2.0 ANGSTROMS RESOLUTION
7BQP	;	1.33	;	The structure of HpiI
7BQO	;	1.53	;	The structure of HpiI in complex with its substrate analogue
1NA1	;	3.3	;	The structure of HRV14 when complexed with Pleconaril
1NCQ	;	2.5	;	The structure of HRV14 when complexed with pleconaril, an antiviral compound
1ND3	;	2.8	;	The structure of HRV16, when complexed with pleconaril, an antiviral compound
5ME4	;	1.52	;	The structure of HtxB from Pseudomonas stutzeri in complex with hypophosphite to 1.52 A resolution
7XL9	;	2.58	;	The structure of HucR with urate
4NRE	;	2.63	;	The structure of human 15-lipoxygenase-2 with a substrate mimic
7TC0	;	3.1	;	The structure of human ABCA1 in digitonin
7TBY	;	4.0	;	The structure of human ABCA1 in nanodisc
7R8C	;	3.7	;	The structure of human ABCG1
7R8E	;	3.7	;	The structure of human ABCG1 E242Q complexed with ATP
7R8D	;	3.2	;	The structure of human ABCG1 E242Q with cholesterol
7R88	;	3.5	;	The structure of human ABCG5-I529W/ABCG8-WT
7R87	;	3.4	;	The structure of human ABCG5-WT/ABCG8-I419E
7R8A	;	2.9	;	The structure of human ABCG5/ABCG8 purified from mammalian cells
7R89	;	2.6	;	The structure of human ABCG5/ABCG8 purified from yeast
7R8B	;	3.1	;	The structure of human ABCG5/ABCG8 supplemented with cholesterol
1SOH	;		;	The structure of human apolipoprotein C-II in dodecyl phosphocholine
5W6V	;	2.828	;	The Structure of human Argonaute-1 in complex with the hook motif of human GW182
3HUD	;	3.2	;	THE STRUCTURE OF HUMAN BETA 1 BETA 1 ALCOHOL DEHYDROGENASE: CATALYTIC EFFECTS OF NON-ACTIVE-SITE SUBSTITUTIONS
3NFY	;	1.94	;	The Structure of Human Bisphosphoglycerate Mutase to 1.94A
5URF	;	2.9	;	The structure of human bocavirus 1
5XYZ	;	2.64	;	The structure of human BTK kinase domain in complex with a covalent inhibitor
5VLO	;	2.05	;	The structure of human CamKII with bound inhibitor
6AYW	;	2.05	;	The structure of human CamKII with bound inhibitor
6BAB	;	1.91	;	The structure of human CamKII with bound inhibitor
1RAY	;	1.8	;	THE STRUCTURE OF HUMAN CARBONIC ANHYDRASE II IN COMPLEX WITH BROMIDE AND AZIDE
1RAZ	;	1.9	;	THE STRUCTURE OF HUMAN CARBONIC ANHYDRASE II IN COMPLEX WITH BROMIDE AND AZIDE
1HCO	;	2.7	;	THE STRUCTURE OF HUMAN CARBONMONOXY HAEMOGLOBIN AT 2.7 ANGSTROMS RESOLUTION
2HCO	;	2.7	;	THE STRUCTURE OF HUMAN CARBONMONOXY HAEMOGLOBIN AT 2.7 ANGSTROMS RESOLUTION
3HXN	;	2.0	;	The structure of human carbonmonoxyhemoglobin complex to IHP at 2.0 angstrons resolution.
3FRT	;	4.0	;	The structure of human CHMP3 (residues 8 - 222).
3MPH	;	2.05	;	The structure of human diamine oxidase complexed with an inhibitor aminoguanidine
1UMK	;	1.75	;	The Structure of Human Erythrocyte NADH-cytochrome b5 Reductase
4YDH	;	3.8	;	The structure of human FMNL1 N-terminal domains bound to Cdc42
3QIC	;	2.2	;	The structure of human glucokinase E339K mutation
4EW3	;	1.702	;	The structure of human glycinamide ribonucleotide transformylase in complex with 10R-methylthio-DDATHF.
4EW2	;	1.602	;	The structure of human glycinamide ribonucleotide transformylase in complex with 10S-methylthio-DDATHF.
1ZLY	;	2.07	;	The structure of human glycinamide ribonucleotide transformylase in complex with alpha,beta-N-(hydroxyacetyl)-D-ribofuranosylamine and 10-formyl-5,8,dideazafolate
3CYN	;	2.0	;	The structure of human GPX8
7CUN	;	3.5	;	The structure of human Integrator-PP2A complex
6O4O	;	1.62	;	The structure of human interleukin 11
3K5E	;	1.97	;	The structure of human kinesin-like motor protein Kif11/KSP/Eg5 in complex with ADP and enastrol.
6NN4	;	2.15	;	The structure of human liver pyruvate kinase, hLPYK-D499N, in complex with Fru-1,6-BP
6NN7	;	2.32	;	The structure of human liver pyruvate kinase, hLPYK-GGG
6NN8	;	2.416	;	The structure of human liver pyruvate kinase, hLPYK-S531E
6NN5	;	2.256	;	The structure of human liver pyruvate kinase, hLPYK-W527H
4LCW	;	2.4	;	The structure of human MAIT TCR in complex with MR1-K43A-RL-6-Me-7OH
5A1G	;	1.83	;	The structure of Human MAT2A in complex with S-adenosylethionine and PPNP.
5A1I	;	1.09	;	The structure of Human MAT2A in complex with SAM, Adenosine, Methionine and PPNP.
1JY7	;	3.2	;	THE STRUCTURE OF HUMAN METHEMOGLOBIN. THE VARIATION OF A THEME
6FAJ	;	1.95	;	The structure of Human Methionine Adenosyltransferase II in apo state
1ZSY	;	1.75	;	The structure of human mitochondrial 2-enoyl thioester reductase (CGI-63)
8IPM	;	3.1	;	The structure of human mitochondrial methyltransferase METTL15 with h44_RNA, RBFA and SAM
8IPL	;	2.2	;	The structure of human mitochondrial methyltransferase METTL15 with RBFA and SAM
8IPK	;	1.9	;	The structure of human mitochondrial methyltransferase METTL15 with SAM
1N0J	;	2.2	;	The Structure of Human Mitochondrial MN3+ Superoxide Dismutase Reveals a Novel Tetrameric Interface of Two 4-Helix Bundles
7PGR	;	4.0	;	The structure of human neurofibromin isoform 2 in closed conformation
7PGT	;	4.8	;	The structure of human neurofibromin isoform 2 in opened conformation.
7CYZ	;	2.1	;	The structure of human ORP3 OSBP-related domain
5ZYQ	;	2.531	;	The Structure of Human PAF1/CTR9 complex
1HNY	;	1.8	;	The structure of human pancreatic alpha-amylase at 1.8 angstroms resolution and comparisons with related enzymes
4Z0V	;	1.78	;	The structure of human PDE12 residues 161-609
4Z2B	;	1.8	;	The structure of human PDE12 residues 161-609 in complex with GSK3036342A
3ZOZ	;	1.95	;	The structure of human phosphoglycerate kinase with bound bromide, a stimulating anion.
7YFK	;	2.1	;	The structure of human pregnane X receptor in complex with an SRC-1 coactivator peptide and a limonoid compound, nomilin
3N2Z	;	2.79	;	The Structure of Human Prolylcarboxypeptidase at 2.80 Angstroms Resolution
1QAB	;	3.2	;	The structure of human retinol binding protein with its carrier protein transthyretin reveals interaction with the carboxy terminus of RBP
3U0D	;	2.51	;	The structure of human Siderocalin bound to the bacterial siderophore 2,3-DHBA
4K19	;	2.74	;	The structure of Human Siderocalin bound to the bacterial siderophore fluvibactin
6SCJ	;	3.6	;	The structure of human thyroglobulin
3MOS	;	1.75	;	The structure of human Transketolase
5XOO	;	2.85	;	The structure of hydra Fam20 with sugar
2BNN	;	2.5	;	The structure of Hydroxypropylphosphonic acid epoxidase from S. wedmorenis in complex with fosfomycin
2BNM	;	1.7	;	The structure of Hydroxypropylphosphonic acid epoxidase from S. wedmorenis.
2BNO	;	1.9	;	The structure of Hydroxypropylphosphonic acid epoxidase from S. wedmorenis.
5A7M	;	1.8	;	The structure of Hypocrea jecorina beta-xylosidase Xyl3A (Bxl1)
5AE6	;	2.1	;	The structure of Hypocrea jecorina beta-xylosidase Xyl3A (Bxl1) in complex with 4-thioxylobiose
5KMQ	;	2.7	;	The structure of I379E variant of type II NADH dehydrogenase from Caldalkalibacillus thermarum
4PH9	;	1.81	;	The structure of Ibuprofen bound to cyclooxygenase-2
6AJ2	;	4.0	;	The structure of ICAM-5 triggered Enterovirus D68 virus A-particle
3LB6	;	3.05	;	The structure of IL-13 in complex with IL-13Ralpha2
1TGE	;	12.5	;	The structure of immature Dengue virus at 12.5 angstrom
1N6G	;	16.0	;	The structure of immature Dengue-2 prM particles
1NA4	;		;	The structure of immature Yellow Fever virus particle
2DOO	;	2.43	;	The structure of IMP-1 complexed with the detecting reagent (DansylC4SH) by a fluorescent probe
4D3Z	;	2.3	;	The structure of inactive prolegumain from chinese hamster, trigonal space group.
4D3Y	;	2.4	;	The structure of inactive prolegumain from chinese hamster.
2WRC	;	2.706	;	the structure of influenza H2 human singapore hemagglutinin
2WRB	;	3.1	;	the structure of influenza H2 human singapore hemagglutinin with avian receptor
2WR7	;	2.5	;	the structure of influenza H2 human singapore hemagglutinin with human receptor
4QLZ	;	2.326	;	The structure of inorganic pyrophosphatase from Schistosoma japonicum
4QMB	;	2.603	;	The structure of inorganic pyrophosphatase from Schistosoma japonicum
3Q5V	;	1.29	;	The structure of inorganic pyrophosphatase from Thermococcus Thioreducens in complex with magnesium and sulfate
7YCX	;	4.18	;	The structure of INTAC-PEC complex
3HOL	;	1.98	;	The Structure of Intact Ap-TbpB (N and C lobes)
8DPW	;	1.8	;	The structure of Interleukin-11 Mutein
8UZD	;	2.721	;	The structure of IpCS3, a theobromine methyltransferase from Yerba Mate
7XTW	;	1.91	;	The structure of IsPETase in complex with MHET
4QU2	;	2.7	;	The structure of JMJD7 with alpha-KG
1PMV	;	2.5	;	The structure of JNK3 in complex with a dihydroanthrapyrazole inhibitor
4Z9L	;	2.1	;	THE STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE-PYRIMIDINE INHIBITOR
1SUZ	;	1.8	;	The structure of K92A EcoRV bound to cognate DNA and Mg2+
7W4P	;	3.19	;	The structure of KATP H175K mutant in closed state
7W4O	;	2.96	;	The structure of KATP H175K mutant in pre-open state
7PVC	;		;	The structure of Kbp.K from E. coli with potassium bound.
7MDJ	;	2.75	;	The structure of KcsA in complex with a synthetic Fab
5FQ0	;	2.0	;	The structure of KdgF from Halomonas sp.
5FPZ	;	1.5	;	The structure of KdgF from Yersinia enterocolitica with malonate bound in the active site.
5FPX	;	1.5	;	The structure of KdgF from Yersinia enterocolitica.
5W3D	;	2.79	;	The structure of kinesin-14 wild-type Ncd-ADP dimer
2JB2	;	1.45	;	The structure of L-amino acid oxidase from Rhodococcus opacus in complex with L-phenylalanine.
2JB3	;	1.85	;	The structure of L-amino acid oxidase from Rhodococcus opacus in complex with o-aminobenzoate
2JAE	;	1.25	;	The structure of L-amino acid oxidase from Rhodococcus opacus in the unbound state
4V36	;	2.1	;	The structure of L-PGS from Bacillus licheniformis
7DT1	;	2.43002	;	The structure of Lactobacillus fermentum 4,6-alpha-Glucanotransferase
8HFS	;	2.98	;	The structure of LcnA, LciA, and the man-PTS of Lactococcus lactis
1PKL	;	2.35	;	THE STRUCTURE OF LEISHMANIA PYRUVATE KINASE
6IX7	;	1.835	;	The structure of LepI C52A in complex with SAH and substrate analogue
6IX8	;	1.659	;	The structure of LepI C52A in complex with SAM and its substrate analogue
6IX9	;	1.776	;	The structure of LepI C52A in complex with SAM and leporin C
6IX3	;	2.13	;	The structure of LepI complex with SAM
6IX5	;	1.7	;	The structure of LepI complex with SAM and its substrate analogue
6D6A	;	1.9	;	The structure of ligand binding domain of LasR in complex with TP-1 homolog, compound 10
6D6B	;	1.7	;	The structure of ligand binding domain of LasR in complex with TP-1 homolog, compound 11
6D6C	;	1.88	;	The structure of ligand binding domain of LasR in complex with TP-1 homolog, compound 12
6D6D	;	1.7	;	The structure of ligand binding domain of LasR in complex with TP-1 homolog, compound 13
6D6L	;	1.63	;	The structure of ligand binding domain of LasR in complex with TP-1 homolog, compound 14
6D6M	;	1.9	;	The structure of ligand binding domain of LasR in complex with TP-1 homolog, compound 15
6D6N	;	1.81	;	The structure of ligand binding domain of LasR in complex with TP-1 homolog, compound 16
6D6O	;	1.65	;	The structure of ligand binding domain of LasR in complex with TP-1 homolog, compound 17
6D6P	;	1.65	;	The structure of ligand binding domain of LasR in complex with TP-1 homolog, compound 19
5NNK	;	1.798	;	The structure of LL-37 crystallized in the presence LDAO
4GPD	;	2.8	;	THE STRUCTURE OF LOBSTER APO-D-GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE AT 3.0 ANGSTROMS RESOLUTION
3PMO	;	1.3	;	The structure of LpxD from Pseudomonas aeruginosa at 1.3 A resolution
8BYK	;	1.7	;	The structure of MadC from Clostridium maddingley reveals new insights into class I lanthipeptide cyclases
5JWA	;	2.162	;	the structure of malaria PfNDH2
4MB1	;	1.4	;	The Structure of MalL mutant enzyme G202P from Bacillus subtilus
7LV6	;	1.1	;	The structure of MalL mutant enzyme S536R from Bacillus subtilis
4M8U	;	1.45	;	The Structure of MalL mutant enzyme V200A from Bacillus subtilus
4MAZ	;	1.6	;	The Structure of MalL mutant enzyme V200S from Bacillus subtilus
6IWK	;	1.501	;	The Structure of Maltooligosaccharide-forming Amylase from Pseudomonas saccharophila STB07
6IYG	;	1.5	;	The Structure of Maltooligosaccharide-forming Amylase from Pseudomonas saccharophila STB07 with Maltotetraose
6J3X	;	1.62	;	The Structure of Maltooligosaccharide-forming Amylase from Pseudomonas saccharophila STB07 with Maltotriose
6JQB	;	1.101	;	The structure of maltooligosaccharide-forming amylase from Pseudomonas saccharophila STB07 with pseudo-maltoheptaose
3L6R	;	1.7	;	The structure of mammalian serine racemase: Evidence for conformational changes upon inhibitor binding
3R5U	;	1.92	;	The structure of manganese bound Thermococcus thioreducens Inorganic pyrophosphatase
2VVL	;	2.45	;	The structure of MAO-N-D3, a variant of monoamine oxidase from Aspergillus niger.
2VVM	;	1.85	;	The structure of MAO-N-D5, a variant of monoamine oxidase from Aspergillus niger.
3WZU	;	3.01	;	THE STRUCTURE OF MAP2K7 IN COMPLEX WITH 5Z-7-oxozeaenol
5A19	;	2.34	;	The structure of MAT2A in complex with PPNP.
4D3X	;	1.848	;	The structure of mature legumain from chinese hamster.
4WMW	;	1.9	;	The structure of MBP-MCL1 bound to ligand 5 at 1.9A
4WMX	;	2.0	;	The structure of MBP-MCL1 bound to ligand 6 at 2.0A
2G5F	;	1.8	;	The structure of MbtI from Mycobacterium Tuberculosis, the first enzyme in the synthesis of Mycobactin, reveals it to be a salicylate synthase
5IKQ	;	2.41	;	The Structure of Meclofenamic Acid Bound to Human Cyclooxygenase-2
5IKR	;	2.342	;	The Structure of Mefenamic Acid Bound to Human Cyclooxygenase-2
8RC7	;	0.98	;	The structure of membrane-active antibiotic cyclodecapeptide gramicidin S in complex with urea
4AFR	;	1.6	;	THE STRUCTURE OF METACASPASE 2 (C213A MUTANT) FROM T. BRUCEI
4AFV	;	1.5	;	THE STRUCTURE OF METACASPASE 2 FROM T. BRUCEI DETERMINED IN THE PRESENCE OF CALCIUM CHLORIDE
4AFP	;	2.1	;	The structure of metacaspase 2 from T. brucei determined in the presence of Samarium
2WNR	;	2.65	;	The structure of Methanothermobacter thermautotrophicus exosome core assembly
1T5E	;	3.0	;	The structure of MexA
2BM4	;	2.2	;	The Structure of MfpA (Rv3361c, C2 Crystal form). The Pentapeptide Repeat Protein from Mycobacterium tuberculosis Folds as A Right- handed Quadrilateral Beta-helix.
2BM6	;	2.2	;	The Structure of MfpA (Rv3361c, C2221 Crystal form). The Pentapeptide Repeat Protein from Mycobacterium tuberculosis Folds as A Right- handed Quadrilateral Beta-helix.
2BM5	;	2.0	;	The Structure of MfpA (Rv3361c, P21 Crystal form). The Pentapeptide Repeat Protein from Mycobacterium tuberculosis Folds as A Right- handed Quadrilateral Beta-helix.
2BM7	;	2.7	;	The Structure of MfpA (Rv3361c, P3221 Crystal form). The Pentapeptide Repeat Protein from Mycobacterium tuberculosis Folds as A Right- handed Quadrilateral Beta-helix.
7XTV	;	2.31	;	The structure of MHET-bound TfCut S130A
7MJZ	;	2.08	;	The structure of MiaB with pentasulfide bridge
6OM4	;	1.7	;	The structure of Microcin C7 biosynthetic enzyme MccB in complex with N-formylated MccA
1Q71	;		;	The structure of microcin J25 is a threaded sidechain-to-backbone ring structure and not a head-to-tail cyclized backbone
5I9K	;	3.5	;	The structure of microsomal glutathione transferase 1
5IA9	;	3.5	;	The structure of microsomal glutathione transferase 1 in complex with Meisenheimer complex
5GNU	;	4.113	;	the structure of mini-MFN1 apo
5GNR	;	2.65	;	the structure of mini-MFN1 K88A in complex with GDP
2FAH	;	2.09	;	The structure of mitochondrial PEPCK, Complex with Mn and GDP
6IB0	;	2.6	;	The structure of MKK7 in complex with the covalent 4-amino-pyrazolopyrimidine 3a
6IB2	;	2.1	;	The structure of MKK7 in complex with the covalent 4-amino-pyrazolopyrimidine 4a
4AS9	;	2.71	;	The structure of modified benzoquinone ansamycins bound to yeast N- terminal Hsp90
4ASA	;	2.25	;	The structure of modified benzoquinone ansamycins bound to yeast N- terminal Hsp90
4ASB	;	3.08	;	The structure of modified benzoquinone ansamycins bound to yeast N- terminal Hsp90
4ASF	;	2.6	;	The structure of modified benzoquinone ansamycins bound to yeast N- terminal Hsp90
4ASG	;	2.2	;	The structure of modified benzoquinone ansamycins bound to yeast N- terminal Hsp90
4PGF	;	2.59	;	The structure of mono-acetylated SAHH
3VFJ	;	2.05	;	The structure of monodechloro-teicoplanin in complex with its ligand, using MBP as a ligand carrier
3VFK	;	2.8	;	The structure of monodechloro-teicoplanin in complex with its ligand, using ubiquitin as a ligand carrier
5JZL	;	1.8	;	The Structure of Monomeric Ultra Stable Green Fluorescent Protein
5F5N	;	1.304	;	The structure of monooxygenase KstA11 in complex with NAD and its substrate
5F5L	;	1.68	;	The structure of monooxygenase KstA11 in the biosynthetic pathway of kosinostatin
426D	;	3.0	;	THE STRUCTURE OF MOST STUDIED DNA FRAGMENT CHANGES UNDER THE INFLUENCE OF IONS: A NEW PACKING OF D(CGCGAATTCGCG)
6GQF	;	2.9	;	The structure of mouse AsterA (GramD1a) with 25-hydroxy cholesterol
8AXW	;	1.6	;	The structure of mouse AsterC (GramD1c) with Ezetimibe
5BK7	;	2.196	;	The structure of MppP E15A mutant soaked with the substrate L-arginine
6C92	;	1.834	;	The structure of MppP soaked with the product 2-ketoarginine
6C9B	;	1.689	;	The structure of MppP soaked with the products 4HKA and 2KA
6C8T	;	2.2	;	The structure of MppP soaked with the substrate L-Arg
8HG1	;	2.8	;	The structure of MPXV polymerase holoenzyme in replicating state
5MWP	;	1.82	;	The structure of MR in complex with AZD9977.
5MWY	;	1.75	;	The structure of MR in complex with eplerenone.
1N1I	;	2.4	;	The structure of MSP-1(19) from Plasmodium knowlesi
5ZXH	;	2.8	;	The structure of MT189-tubulin complex
4QMG	;	2.701	;	The Structure of MTDH-SND1 Complex Reveals Novel Cancer-Promoting Interactions
4WIQ	;	1.59	;	The structure of Murine alpha-Dystroglycan T190M mutant N-terminal domain.
2MIB	;	2.84	;	THE STRUCTURE OF MURINE INTERLEUKIN-1 BETA AT 2.8 ANGSTROMS RESOLUTION
3N25	;	2.41	;	The structure of muscle pyruvate kinase in complex with proline, pyruvate, and Mn2+
1YG9	;	1.3	;	The structure of mutant (N93Q) of bla g 2
7OU4	;	3.3	;	The structure of MutS bound to one molecule of ATP and one molecule of ADP
7OU2	;	4.8	;	The structure of MutS bound to two molecules of ADP
7OU0	;	3.8	;	The structure of MutS bound to two molecules of ADP-Vanadate
7OTO	;	3.4	;	The structure of MutS bound to two molecules of AMPPNP
3BKN	;	2.72	;	The structure of Mycobacterial bacterioferritin
4QIH	;	2.299	;	The structure of mycobacterial glucosyl-3-phosphoglycerate phosphatase Rv2419c complexes with VO3
2VFB	;	2.0	;	The structure of Mycobacterium marinum arylamine N-acetyltransferase
4C5P	;	1.592	;	The structure of mycobacterium marinum arylamine n-acetyltransferase
2VFC	;	2.7	;	The structure of Mycobacterium marinum arylamine N-acetyltransferase in complex with CoA
3LTW	;	2.1	;	The structure of mycobacterium marinum arylamine n-acetyltransferase in complex with hydralazine
5UJY	;	2.7	;	The structure of Mycobacterium tuberculosis topoisomerase I from the 2nd crystal form
2C27	;	1.8	;	The Structure of Mycothiol Synthase in Complex with des- AcetylMycothiol and CoenzymeA.
8U95	;	4.7	;	The structure of myosin heavy chain from Drosophila melanogaster flight muscle thick filaments
6FV4	;	1.974	;	The structure of N-acetyl-D-glucosamine-6-phosphate deacetylase D267A mutant from Mycobacterium smegmatis in complex with N-acetyl-D-glucosamine-6-phosphate
2G17	;	2.3	;	The structure of N-acetyl-gamma-glutamyl-phosphate reductase from Salmonella typhimurium.
3MDW	;	1.8979	;	The structure of N-formimino-L-Glutamate Iminohydrolase from Pseudomonas aeruginosa complexed with N-formimino-L-Aspartate
4RDV	;	2.08	;	The structure of N-formimino-L-Glutamate Iminohydrolase from Pseudomonas aeruginosa complexed with N-formimino-L-Aspartate
4RZB	;	1.863	;	The structure of N-formimino-L-Glutamate Iminohydrolase from Pseudomonas aeruginosa complexed with N-formimino-L-Aspartate, SOAKED WITH MERCURY
3MDU	;	1.4003	;	The structure of N-formimino-L-Glutamate Iminohydrolase from Pseudomonas aeruginosa complexed with N-Guanidino-L-Glutamate
4RDW	;	1.591	;	The structure of N-formimino-L-Glutamate Iminohydrolase from Pseudomonas aeruginosa complexed with N-Guanidino-L-Glutaric acid
1XT0	;	2.16	;	The Structure of N-terminal Sec7 domain of RalF
1OC2	;	1.5	;	The structure of NADH in the dTDP-D-glucose dehydratase (RmlB) enzyme
5DAY	;	2.329	;	The structure of NAP1-Related Protein(NRP1) in Arabidopsis
1U6I	;	2.2	;	The Structure of native coenzyme F420-dependent methylenetetrahydromethanopterin dehydrogenase at 2.2A resolution
1U6J	;	2.4	;	The Structure of native coenzyme F420-dependent methylenetetrahydromethanopterin dehydrogenase at 2.4A resolution
3HBT	;	2.7	;	The structure of native G-actin
1IUK	;	1.7	;	The structure of native ID.343 from Thermus thermophilus
5K7D	;	2.68	;	The structure of native pistol ribozyme, bound to Iridium
1QNJ	;	1.1	;	THE STRUCTURE OF NATIVE PORCINE PANCREATIC ELASTASE AT ATOMIC RESOLUTION (1.1 A)
7QA1	;	2.2	;	The structure of natural crystals of the Lysinibacillus sphaericus Tpp49Aa1 pesticidal protein elucidated using serial femtosecond crystallography at an X-ray free electron laser
1NPC	;	2.0	;	THE STRUCTURE OF NEUTRAL PROTEASE FROM BACILLUS CEREUS AT 0.2-NM RESOLUTION
4M4M	;	1.5	;	The structure of Ni T6 bovine insulin
8DSV	;	2.5	;	The structure of NicA2 in complex with N-methylmyosmine
8DQ7	;	2.1	;	The structure of NicA2 variant F104L/A107T/S146I/G317D/H368R/L449V/N462S from Pseudomonas putida
8DQ8	;	1.9	;	The structure of NicA2 variant F104L/A107T/S146I/G317D/H368R/L449V/N462S in complex with N-methylmyosmine
3G3Z	;	2.1	;	The structure of NMB1585, a MarR family regulator from Neisseria meningitidis
4N8X	;	1.93	;	The structure of Nostoc sp. PCC 7120 CcmL
5LIZ	;	1.93	;	The structure of Nt.BspD6I nicking endonuclease with all cysteines mutated by serine residues at 0.19 nm resolution .
6PVA	;	1.84	;	The structure of NTMT1 in complex with compound 11
6PVB	;	1.5	;	The structure of NTMT1 in complex with compound 6
6WH8	;	1.729	;	The structure of NTMT1 in complex with compound BM-30
6WJ7	;	1.42	;	The structure of NTMT1 in complex with compound C2A
7K3D	;	2.34	;	The structure of NTMT1 in complex with compound DC1-13
6DTN	;	1.475	;	The structure of NTMT1 in complex with compound DC100-1
7SS1	;	2.4	;	The structure of NTMT1 in complex with compound GD433
4DUT	;	2.5	;	The structure of nucleoside diphosphate kinase (NDK) from Burkholderia thailandensis
4EK2	;	2.0	;	The structure of nucleoside diphosphate kinase (NDK) from Burkholderia thailandensis bound to deoxyadenosine monophosphate
7D8L	;	1.55	;	The structure of nucleoside phosphatase Sa1684 complex with GTP analogue from Staphylococcus aureus
2AYU	;	3.0	;	The structure of nucleosome assembly protein suggests a mechanism for histone binding and shuttling
7D8Q	;	1.5	;	The structure of nucleotide phosphatase Sa1684 complex with GDP analogue from Staphylococcus aureus
1HXQ	;	1.86	;	THE STRUCTURE OF NUCLEOTIDYLATED GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE FROM ESCHERICHIA COLI AT 1.86 ANGSTROMS RESOLUTION
6J2W	;		;	The structure of OBA3-OTA complex
7W9N	;		;	THE STRUCTURE OF OBA33-OTA COMPLEX
3QVM	;	1.998	;	The structure of olei00960, a hydrolase from Oleispira antarctica
1OPF	;	3.2	;	THE STRUCTURE OF OMPF PORIN IN A TETRAGONAL CRYSTAL FORM
3FYX	;	3.4	;	The Structure of OmpF porin with a synthetic dibenzo-18-crown-6 as modulator
4CSO	;	2.6	;	The structure of OrfY from Thermoproteus tenax
4BLC	;	2.3	;	THE STRUCTURE OF ORTHORHOMBIC CRYSTALS OF BEEF LIVER CATALASE
5XEG	;	1.8	;	The structure of OsALKBH1
5XOI	;	1.8	;	The structure of OsALKBH1
3ZUT	;	2.5	;	The structure of OST1 (D160A) kinase
3ZUU	;	2.7	;	The structure of OST1 (D160A, S175D) kinase in complex with gold
2CK1	;	1.8	;	The structure of oxidised cyclophilin A from s. mansoni
1AAZ	;	2.0	;	THE STRUCTURE OF OXIDIZED BACTERIOPHAGE T4 GLUTAREDOXIN (THIOREDOXIN)
1ABA	;	1.45	;	THE STRUCTURE OF OXIDIZED BACTERIOPHAGE T4 GLUTAREDOXIN (THIOREDOXIN). REFINEMENT OF NATIVE AND MUTANT PROTEINS
5C9M	;	1.362	;	The structure of oxidized rat cytochrome c (T28A) at 1.362 angstroms resolution.
5DF5	;	1.301	;	The structure of oxidized rat cytochrome c (T28E) at 1.30 angstroms resolution.
5C0Z	;	1.1236	;	The structure of oxidized rat cytochrome c at 1.13 angstroms resolution
4XEB	;	1.7	;	The structure of P. funicolosum Cel7A
1OUY	;	2.5	;	The structure of p38 alpha in complex with a dihydropyrido-pyrimidine inhibitor
1OVE	;	2.1	;	The structure of p38 alpha in complex with a dihydroquinolinone
1OUK	;	2.5	;	The structure of p38 alpha in complex with a pyridinylimidazole inhibitor
5XYX	;	2.61	;	The structure of p38 alpha in complex with a triazol inhibitor
5XYY	;	1.7	;	The structure of p38 alpha in complex with a triazol inhibitor
1DI9	;	2.6	;	THE STRUCTURE OF P38 MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH 4-[3-METHYLSULFANYLANILINO]-6,7-DIMETHOXYQUINAZOLINE
1R39	;	2.3	;	THE STRUCTURE OF P38ALPHA
1R3C	;	2.0	;	THE STRUCTURE OF P38ALPHA C162S MUTANT
3GC7	;	1.8	;	The structure of p38alpha in complex with a dihydroquinazolinone
2I0H	;	2.0	;	The structure of p38alpha in complex with an arylpyridazinone
3GC9	;	2.05	;	The structure of p38beta C119S, C162S in complex with a dihydroquinazolinone inhibitor
3GC8	;	2.4	;	The structure of p38beta C162S in complex with a dihydroquinazolinone
3UK2	;	2.25	;	The structure of Pantothenate synthetase from Burkholderia thailandensis
155C	;	2.5	;	THE STRUCTURE OF PARACOCCUS DENITRIFICANS CYTOCHROME C550
1F8V	;	3.0	;	THE STRUCTURE OF PARIACOTO VIRUS REVEALS A DODECAHEDRAL CAGE OF DUPLEX RNA
3TVX	;	2.84	;	The structure of PDE4A with pentoxifylline at 2.84A resolution
7BQJ	;	1.98	;	The structure of PdxI
7BQK	;	1.99	;	The structure of PdxI in complex with its substrate analogue
5HIZ	;	2.9	;	The structure of PEDV NSP9
1SAC	;	2.0	;	THE STRUCTURE OF PENTAMERIC HUMAN SERUM AMYLOID P COMPONENT
6WNM	;	2.58	;	The structure of Pf4r from a superinfective isolate of the filamentous phage Pf4 of Pseudomonas aeruginosa PA01
6WPZ	;	1.993	;	The structure of Pf4r from a superinfective isolate of the filamentous phage Pf4 of Pseudomonas aeruginosa PA01
6X6F	;	1.735	;	The structure of Pf6r from the filamentous phage Pf6 of Pseudomonas aeruginosa PA01
2BNK	;	2.9	;	The structure of phage phi29 replication organizer protein p16.7
2C5R	;	2.9	;	The structure of phage phi29 replication organizer protein p16.7 in complex with double stranded DNA
2PHL	;	2.2	;	THE STRUCTURE OF PHASEOLIN AT 2.2 ANGSTROMS RESOLUTION: IMPLICATIONS FOR A COMMON VICILIN(SLASH)LEGUMIN STRUCTURE AND THE GENETIC ENGINEERING OF SEED STORAGE PROTEINS
1N7J	;	2.7	;	The structure of Phenylethanolamine N-methyltransferase in complex with S-adenosylhomocysteine and an iodinated inhibitor
1N7I	;	2.8	;	The structure of Phenylethanolamine N-methyltransferase in complex with S-adenosylhomocysteine and the inhibitor LY134046
1P5E	;	2.22	;	The structure of phospho-CDK2/cyclin A in complex with the inhibitor 4,5,6,7-tetrabromobenzotriazole (TBS)
7PIZ	;	2.15	;	The structure of phosphoglucomutase from Candida albicans
7U34	;	1.56	;	The structure of phosphoglucose isomerase from Aspergillus fumigatus
4Y3U	;	3.51	;	The structure of phospholamban bound to the calcium pump SERCA1a
1LVH	;	2.3	;	The Structure of Phosphorylated beta-phosphoglucomutase from Lactoccocus lactis to 2.3 angstrom resolution
1BJO	;	2.8	;	THE STRUCTURE OF PHOSPHOSERINE AMINOTRANSFERASE FROM E. COLI IN COMPLEX WITH ALPHA-METHYL-L-GLUTAMATE
1Q6T	;	2.3	;	THE STRUCTURE OF PHOSPHOTYROSINE PHOSPHATASE 1B IN COMPLEX WITH COMPOUND 11
1Q6J	;	2.2	;	THE STRUCTURE OF PHOSPHOTYROSINE PHOSPHATASE 1B IN COMPLEX WITH COMPOUND 2
2FJM	;	2.1	;	The structure of phosphotyrosine phosphatase 1B in complex with compound 2
2FJN	;	2.2	;	The structure of phosphotyrosine phosphatase 1B in complex with compound 2
1Q6M	;	2.2	;	THE STRUCTURE OF PHOSPHOTYROSINE PHOSPHATASE 1B IN COMPLEX WITH COMPOUND 3
1Q6N	;	2.1	;	THE STRUCTURE OF PHOSPHOTYROSINE PHOSPHATASE 1B IN COMPLEX WITH COMPOUND 4
1Q6P	;	2.3	;	THE STRUCTURE OF PHOSPHOTYROSINE PHOSPHATASE 1B IN COMPLEX WITH COMPOUND 6
1Q6S	;	2.2	;	THE STRUCTURE OF PHOSPHOTYROSINE PHOSPHATASE 1B IN COMPLEX WITH COMPOUND 9
7QCO	;	3.7	;	The structure of Photosystem I tetramer from Chroococcidiopsis TS-821, a thermophilic, unicellular, non-heterocyst-forming cyanobacterium
2VJR	;	2.6	;	The structure of phycocyanin from Gloeobacter violaceus
2VJH	;	2.2	;	The structure of Phycoerythrin from Gloeobacter violaceus
2EIX	;	1.56	;	The Structure of Physarum polycephalum cytochrome b5 reductase
4IXJ	;	1.983	;	The structure of PilJ, a Type IV pilin from Clostridium difficile
6R47	;	3.1	;	The structure of pistol ribozyme bound to magnesium
5K7E	;	3.27	;	The structure of pistol ribozyme, soaked with Mn2+
1T27	;	2.2	;	THE STRUCTURE OF PITP COMPLEXED TO PHOSPHATIDYLCHOLINE
5DO0	;	2.6	;	The structure of PKMT1 from Rickettsia prowazekii
5DNK	;	1.9	;	The structure of PKMT1 from Rickettsia prowazekii in complex with AdoHcy
5DPD	;	3.0	;	The structure of PKMT1 from Rickettsia prowazekii in complex with AdoMet
5DOO	;	3.133	;	The structure of PKMT2 from Rickettsia typhi
5DPL	;	3.2	;	The structure of PKMT2 from Rickettsia typhi in complex with AdoHcy
5L8R	;	2.6	;	The structure of plant photosystem I super-complex at 2.6 angstrom resolution.
4Y28	;	2.8	;	The structure of plant photosystem I super-complex at 2.8 angstrom resolution.
3RIE	;	1.9	;	The structure of Plasmodium falciparum spermidine synthase in complex with 5'-methylthioadenosine and N-(3-aminopropyl)-trans-cyclohexane-1,4-diamine
2PT6	;	2.0	;	The structure of Plasmodium falciparum spermidine synthase in complex with decarboxylated S-adenosylmethionine
2PT9	;	2.2	;	The structure of Plasmodium falciparum spermidine synthase in complex with decarboxylated S-adenosylmethionine and the inhibitor cis-4-methylcyclohexylamine (4MCHA)
2PSS	;	2.2	;	The structure of Plasmodium falciparum spermidine synthase in its apo-form
6R2S	;	3.04	;	The structure of Plasmodium vivax Duffy binding protein (PvDBP) bound to human antibody DB9
7WDK	;	3.05	;	The structure of PldA-PA3488 complex
1DYR	;	1.86	;	THE STRUCTURE OF PNEUMOCYSTIS CARINII DIHYDROFOLATE REDUCTASE TO 1.9 ANGSTROMS RESOLUTION
5FR6	;	2.51	;	The structure of polycomb ULD complex
5GWZ	;	2.444	;	The structure of Porcine epidemic diarrhea virus main protease in complex with an inhibitor
1L0Z	;	1.5	;	THE STRUCTURE OF PORCINE PANCREATIC ELASTASE COMPLEXED WITH XENON AND BROMIDE, CRYOPROTECTED WITH DRY PARAFFIN OIL
1L1G	;	1.5	;	The Structure of Porcine Pancreatic Elastase Complexed with Xenon and Bromide, Cryoprotected with Glycerol
3KRV	;	2.55	;	The Structure Of Potential Metal-Dependent Hydrolase With Cyclase Activity
1R61	;	2.5	;	The structure of predicted metal-dependent hydrolase from Bacillus stearothermophilus
7PDS	;	3.14	;	The structure of PriRep1 with dsDNA
7C9M	;	2.7	;	The structure of product-bound CntL, an aminobutyrate transferase in staphylopine biosynthesis
2E8G	;	1.7	;	The structure of protein from P. horikoshii at 1.7 angstrom resolution
1DP5	;	2.2	;	THE STRUCTURE OF PROTEINASE A COMPLEXED WITH A IA3 MUTANT INHIBITOR
1G0V	;	2.0	;	THE STRUCTURE OF PROTEINASE A COMPLEXED WITH A IA3 MUTANT, MVV
1DPJ	;	1.8	;	THE STRUCTURE OF PROTEINASE A COMPLEXED WITH IA3 PEPTIDE INHIBITOR
3OSG	;	1.997	;	The structure of protozoan parasite Trichomonas vaginalis Myb2 in complex with MRE-1-12 DNA
3OSF	;	2.032	;	The structure of protozoan parasite Trichomonas vaginalis Myb2 in complex with MRE-2f-13 DNA
6LKX	;	2.998	;	The structure of PRRSV helicase
5WZE	;	1.783	;	The structure of Pseudomonas aeruginosa aminopeptidase PepP
6IGB	;	1.651	;	the structure of Pseudomonas aeruginosa Periplasmic gluconolactonase, PpgL
5MP4	;	2.79	;	The structure of Pst2p from Saccharomyces cerevisiae
4H7N	;	2.0	;	The Structure of Putative Aldehyde Dehydrogenase PutA from Anabaena variabilis.
2GWN	;	1.85	;	The structure of putative dihydroorotase from Porphyromonas gingivalis.
4HBZ	;	1.55	;	The Structure of Putative Phosphohistidine Phosphatase SixA from Nakamurella multipartitia.
2OJH	;	1.85	;	The structure of putative TolB from Agrobacterium tumefaciens
4DA2	;	1.8	;	The structure of Pyrococcus Furiosus SfsA in complex with Ca2+
4DAV	;	2.2	;	The structure of Pyrococcus Furiosus SfsA in complex with DNA
2Q7E	;	1.8	;	The structure of pyrrolysyl-tRNA synthetase bound to an ATP analogue
4E7V	;	1.8	;	The structure of R6 bovine insulin
5H53	;	5.2	;	The structure of rabbit skeletal muscle actomyosin rigor complex at 5.2 angstrom.
1XSZ	;	1.41	;	The structure of RalF
8HST	;	2.66	;	The structure of rat beta-arrestin1
8HSV	;	3.0	;	The structure of rat beta-arrestin1 in complex with a rat Mdm2 peptide
6P5O	;	1.49	;	The structure of rat cytosolic PEPCK in complex with 3-(carboxymethylthiol)-picolinic acid
2RKD	;	1.9	;	The Structure of rat cytosolic PEPCK in complex with 3-phosphonopropionate
3DT7	;	1.5	;	The structure of rat cytosolic PEPCK in complex with beta-sulfopyruvate and GTP
2RK7	;	1.9	;	The Structure of rat cytosolic PEPCK in complex with oxalate
3DT2	;	1.5	;	The structure of rat cytosolic PEPCK in complex with oxalate and GTP
3DT4	;	1.45	;	The structure of rat cytosolic PEPCK in complex with oxalate and GTP
2RKA	;	1.95	;	The Structure of rat cytosolic PEPCK in complex with phosphoglycolate
3DTB	;	1.3	;	The structure of rat cytosolic PEPCK in complex with phosphoglycolate and GDP
2RK8	;	2.0	;	The Structure of rat cytosolic PEPCK in complex with phosphonoformate
2RKE	;	1.8	;	The Structure of rat cytosolic PEPCK in complex with sulfoacetate.
3MOE	;	1.25	;	The structure of rat cytosolic PEPCK mutant A467G in complex with Beta-Sulfopyruvate and GTP
3MOF	;	1.75	;	The structure of rat cytosolic PEPCK mutant A467G in complex with oxalate and GTP
3MOH	;	2.1	;	The structure of rat cytosolic PEPCK mutant A467G in complex with phosphoglycolate and GDP
5FH0	;	1.6	;	The structure of rat cytosolic PEPCK variant E89A complex with GTP
5FH3	;	1.6	;	The structure of rat cytosolic PEPCK variant E89A in complex with oxalic acid and GTP
5FH4	;	1.49	;	The structure of rat cytosolic PEPCK variant E89D in complex with beta-sulfopyruvate and GTP
5FH1	;	1.55	;	The structure of rat cytosolic PEPCK variant E89D in complex with GTP
5FH2	;	1.49	;	The structure of rat cytosolic PEPCK variant E89Q in complex with GTP
5FH5	;	1.55	;	The structure of rat cytosolic PEPCK variant E89Q in complex with phosphoglycolate and GDP
4V60	;	3.5	;	The structure of rat liver vault at 3.5 angstrom resolution
3RP2	;	1.9	;	THE STRUCTURE OF RAT MAST CELL PROTEASE II AT 1.9-ANGSTROMS RESOLUTION
2P01	;		;	The structure of receptor-associated protein(RAP)
2P03	;		;	The structure of receptor-associated protein(RAP)
1PKR	;	2.48	;	THE STRUCTURE OF RECOMBINANT PLASMINOGEN KRINGLE 1 AND THE FIBRIN BINDING SITE
1RTC	;	2.3	;	THE STRUCTURE OF RECOMBINANT RICIN A CHAIN AT 2.3 ANGSTROMS
2CMT	;	1.5	;	The structure of reduced cyclophilin A from s. mansoni
1BBR	;	2.3	;	THE STRUCTURE OF RESIDUES 7-16 OF THE A ALPHA CHAIN OF HUMAN FIBRINOGEN BOUND TO BOVINE THROMBIN AT 2.3 ANGSTROMS RESOLUTION
5E27	;	2.6	;	The structure of Resuscitation Promoting Factor B from M. tuberculosis reveals unexpected ubiquitin-like domains
1ND2	;	2.5	;	The structure of Rhinovirus 16
1NCR	;	2.7	;	The structure of Rhinovirus 16 when complexed with pleconaril, an antiviral compound
1RBN	;	2.1	;	THE STRUCTURE OF RIBONUCLEASE A DERIVATIVE II AT 2.1 ANGSTROMS RESOLUTION
4EM8	;	1.95	;	The Structure of Ribose 5-phosphate Isomerase B from Anaplasma phagocytophilum
1PKP	;	2.8	;	THE STRUCTURE OF RIBOSOMAL PROTEIN S5 REVEALS SITES OF INTERACTION WITH 16S RRNA
7EOZ	;	3.4	;	The structure of rice Defective Pollen Wall (DPW) in the complex with its cofactor NADP
4PMH	;	1.79	;	The structure of rice weevil pectin methyl esterase
1NBK	;		;	The structure of RNA aptamer for HIV Tat complexed with two argininamide molecules
2KXZ	;		;	The Structure of RNA Internal Loops with Tandem AG Pairs: 5'AAGU/3'UGAA
2KY0	;		;	The Structure of RNA Internal Loops with Tandem AG Pairs: 5'GAGC/3'CGAG
2KY1	;		;	The Structure of RNA Internal Loops with Tandem AG Pairs: 5'UAGA/3'AGAU
2KY2	;		;	The Structure of RNA Internal Loops with Tandem AG Pairs: 5'UAGG/3'GGAU
5BY8	;	1.515	;	The structure of Rpf2-Rrs1 explains its role in ribosome biogenesis
7NTO	;	1.23	;	The structure of RRM domain of human TRMT2A at 1.23 A resolution
7NTN	;	2.016	;	The structure of RRM domain of human TRMT2A at 2 A resolution
6RXN	;	1.5	;	THE STRUCTURE OF RUBREDOXIN FROM DESULFOVIBRIO DESULFURICANS
4DI0	;	1.9	;	The structure of Rubrerythrin from Burkholderia pseudomallei
3E3A	;	2.35	;	The Structure of Rv0554 from Mycobacterium tuberculosis
8F8F	;	2.0	;	The structure of Rv2173 from M. tuberculosis (APO form)
8F8L	;	2.2	;	The structure of Rv2173 from M. tuberculosis with DMAP bound
8F8K	;	2.2	;	The structure of Rv2173 from M. tuberculosis with IPP bound
5Y0W	;	2.5	;	The structure of RVFV Gn head domain
7TIN	;	2.35	;	The Structure of S. aureus MenD
8DO6	;	3.1	;	The structure of S. epidermidis Cas10-Csm bound to target RNA
1GQM	;	2.7	;	The structure of S100A12 in a hexameric form and its proposed role in receptor signalling
6W67	;	2.2	;	The structure of S172A Keap1-BTB domain
5YEQ	;	1.75	;	The structure of Sac-KARI protein
3O26	;	1.91	;	The structure of salutaridine reductase from Papaver somniferum.
7C7M	;	1.81	;	The structure of SAM-bound CntL, an aminobutyrate transferase in staphylopine biosysnthesis
3FPB	;	2.55	;	The Structure of Sarcoplasmic Reticulum Ca2+-ATPase Bound To Cyclopiazonic acid with ATP
3FPS	;	3.2	;	The Structure of Sarcoplasmic Reticulum Ca2+-ATPase Bound To Cyclopiazonic and ADP
5KAV	;	2.0	;	The structure of SAV2435
5KCB	;	2.101	;	The structure of SAV2435 bound to ethidium bromide
5KAU	;	1.95	;	The structure of SAV2435 bound to RHODAMINE 6G
5KAT	;	2.101	;	The structure of SAV2435 bound to TETRAPHENYLPHOSPHONIUM
5KAW	;	1.86	;	The structure of SAV2435 bound to TETRAPHENYLPHOSPHONIUM and RHODAMINE 6G
6EG5	;	2.45	;	The structure of SB-1-202-tubulin complex
6N47	;	2.6	;	The structure of SB-2-204-tubulin complex
6QH1	;	2.9	;	The structure of Schizosaccharomyces pombe PCNA in complex with an Spd1 derived peptide
6L6W	;	2.17	;	The structure of ScoE with intermediate
6L6X	;	2.18	;	The structure of ScoE with substrate
7V3O	;	1.83005	;	The structure of Se-SoBcmB with Fe(II)and AKG
2VMI	;	1.7	;	The structure of seleno-methionine labelled CBM51 from Clostridium perfringens GH95
8K5K	;	1.81	;	The structure of SenA
8K5J	;	1.3	;	The structure of SenA in complex with N,N,N-trimethyl-histidine
8K5I	;	1.92	;	The structure of SenA in complex with N,N,N-trimethyl-histidine and thioglucose
2CKG	;	2.45	;	The structure of SENP1 SUMO-2 co-complex suggests a structural basis for discrimination between SUMO paralogues during processing
6SSV	;	3.22	;	The structure of serpin from Schistosoma mansoni
4A1R	;	1.92	;	The Structure of Serratia marcescens Lip, a membrane bound component of the Type VI Secretion System.
2W08	;	1.7	;	The structure of serum amyloid P component bound to 0-phospho- threonine
3KQR	;	1.5	;	The structure of serum amyloid p component bound to phosphoethanolamine
6L86	;	2.23	;	The structure of SfaA
4I4J	;	2.784	;	The structure of SgcE10, the ACP-polyene thioesterase involved in C-1027 biosynthesis
2KXD	;		;	The structure of SH3-F2
2DF3	;	1.9	;	The structure of Siglec-7 in complex with alpha(2,3)/alpha(2,6) disialyl lactotetraosyl 2-(trimethylsilyl)ethyl
4TWI	;	1.79	;	The structure of Sir2Af1 bound to a succinylated histone peptide
4TWJ	;	1.65	;	The structure of Sir2Af2 bound to a myristoylated histone peptide
6PDK	;	1.9	;	The Structure of Smlt3025, an immunity protein of the Stenotrophomonas maltophilia type IV secretion system
1FHF	;	2.8	;	THE STRUCTURE OF SOYBEAN PEROXIDASE
5LU3	;	1.5	;	The Structure of Spirochaeta thermophila CBM64
2JK9	;	1.79	;	The structure of splA-ryanodine receptor domain and SOCS box containing 1 in complex with a PAR-4 peptide
7E8L	;	2.3	;	The structure of Spodoptera litura chemosensory protein
3O6Q	;	2.5	;	The Structure of SpoIISA and SpoIISB, a Toxin - Antitoxin System
6NCF	;	2.871	;	The structure of Stable-5-Lipoxygenase bound to AKBA
6N2W	;	2.71	;	The structure of Stable-5-Lipoxygenase bound to NDGA
5U75	;	1.66	;	The structure of Staphylococcal Enterotoxin-like X (SElX), a Unique Superantigen
2FEY	;		;	The structure of stem loop IV of Tetrahymena telomerase RNA
1EE2	;	1.54	;	THE STRUCTURE OF STEROID-ACTIVE ALCOHOL DEHYDROGENASE AT 1.54 A RESOLUTION
4JGX	;	2.2	;	The Structure of Sterol Carrier Protein 2 from the Yeast Yarrowia Lipolytica
1Y7O	;	2.51	;	The structure of Streptococcus pneumoniae A153P ClpP
2LJJ	;		;	The structure of subdomain IV-B from the CVB-3 IRES
6W11	;	2.46	;	The structure of Sulfolobus solfataricus Csa3 in complex with cyclic tetraadenylate (cA4)
4KYT	;	2.833	;	The structure of superinhibitory phospholamban bound to the calcium pump SERCA1a
7EGP	;	6.9	;	The structure of SWI/SNF-nucleosome complex
7QXO	;	1.9	;	The structure of T. forsythia NanH
7QY8	;	2.06	;	The structure of T. forsythia NanH
7QYJ	;	2.11	;	The structure of T. forsythia NanH
7QYP	;	1.659	;	The structure of T. forsythia NanH
7QZ3	;	1.97	;	The structure of T. forsythia NanH
4JJJ	;	1.6	;	The structure of T. fusca GH48 D224N mutant
2O2S	;	2.6	;	The structure of T. gondii enoyl acyl carrier protein reductase in complex with NAD and triclosan
7QY9	;	1.92	;	The structure of T.forsythia NanH with oseltamivir
4E7U	;	1.3	;	The structure of T3R3 bovine insulin
7DWS	;	2.8	;	The structure of T4 Lysozyme I3C/C54T/R125C/E128C complex with Zinc ions
2A3G	;	2.25	;	The structure of T6 bovine insulin
4E7T	;	1.4	;	The structure of T6 bovine insulin
5VTG	;	1.859	;	The structure of TamB963-1138 from Escherichia coli reveals a novel hydrophobic Beta-taco fold
2O81	;		;	The Structure of Tandem GA RNA Pairs When Flanking Pairs are isoG-isoC Pairs
2O83	;		;	The Structure of Tandem GA RNA Pairs When Flanking Pairs are isoG-isoC Pairs
2V0P	;	1.8	;	The Structure of Tap42 Alpha4 Subunit
7XTU	;	2.43	;	The structure of TfCut S130A
5LQ4	;	2.65	;	The Structure of ThcOx, the First Oxidase Protein from the Cyanobactin Pathways
8DF2	;	2.35	;	The structure of the 'ALT' construct of the Amuc_1438 glycopeptidase
2XZ0	;	3.0	;	The Structure of the 2:1 (Partially Occupied) Complex Between Stearoyl Acyl Carrier Protein Desaturase from Ricinus Communis (Castor Bean) and Acyl Carrier Protein.
2XZ1	;	3.35	;	The Structure of the 2:2 (Fully Occupied) Complex Between Stearoyl Acyl Carrier Protein Desaturase from Ricinus Communis (Castor Bean) and Acyl Carrier Protein.
6XM2	;	1.91	;	The structure of the 4A11.v7 antibody in complex with human TGFb2
7EAL	;	2.5	;	The structure of the A20-Binding Inhibitor of NF-kB 1 in complex with di-ubiquitin
7EB9	;	3.2	;	The structure of the A20-binding inhibitor of NF-kB 1 in complex with tetra-ubiquitin
7EAO	;	2.9	;	The structure of the A20-binding inhibitor of NF-kB 1 in complex with tri-ubiquitin
7CCC	;	3.2	;	The structure of the actin filament uncapping complex mediated by twinfilin
6BIH	;	6.0	;	The Structure of the Actin-Smooth Muscle Myosin Motor Domain Complex in the Rigor State
2P6A	;	3.4	;	The structure of the Activin:Follistatin 315 complex
6IJP	;	1.85	;	The structure of the ADAL-IMP complex
2ORB	;	2.2	;	The structure of the anti-c-myc antibody 9E10 Fab fragment
2OR9	;	2.7	;	The structure of the anti-c-myc antibody 9E10 Fab fragment/epitope peptide complex reveals a novel binding mode dominated by the heavy chain hypervariable loops
3CPW	;	2.7	;	The structure of the antibiotic LINEZOLID bound to the large ribosomal subunit of HALOARCULA MARISMORTUI
1D6X	;		;	THE STRUCTURE OF THE ANTIMICROBIAL PEPTIDE TRITRPTICIN BOUND TO MICELLES-A DISTINCT MEMBRANE-BOUND PEPTIDE FOLD
7DBF	;	1.9	;	The structure of the Arabidopsis thaliana guanosine deaminase
7DCA	;	2.1	;	The structure of the Arabidopsis thaliana guanosine deaminase bound by xanthosine
7DCW	;	2.3	;	The structure of the Arabidopsis thaliana guanosine deaminase complexed with adenosine
7DM6	;	2.05	;	The structure of the Arabidopsis thaliana guanosine deaminase complexed with crotonoside
7DCB	;	2.0	;	The structure of the Arabidopsis thaliana guanosine deaminase complexed with inosine
7DOY	;	2.17	;	The structure of the Arabidopsis thaliana guanosine deaminase in complex with 6-O-methylguanosine
7DOX	;	1.9	;	The structure of the Arabidopsis thaliana guanosine deaminase in complex with m7G
7DGC	;	2.1	;	The structure of the Arabidopsis thaliana guanosine deaminase in reaction with 2'-O-Methylguanosine
7DOW	;	2.0	;	The structure of the Arabidopsis thaliana guanosine deaminase in reaction with 7-deazaguansoine
7DM5	;	2.2	;	The structure of the Arabidopsis thaliana guanosine deaminase in reaction with guanosine
7DLC	;	2.45	;	The structure of the Arabidopsis thaliana guanosine deaminase in reaction with N1-methylguanosine
7DH1	;	1.85	;	The structure of the Arabidopsis thaliana guanosine deaminase in reaction with N2-Methylguanosine
7DC9	;	1.7	;	The structure of the Arabidopsis thaliana guanosine deaminase mutant E82Q complex with guanosine
7W1Q	;	2.3	;	The structure of the Arabidopsis thaliana guanosine deaminase mutant E82Q complexed with 2'-O-methylguanosine
7DQN	;	2.6	;	The structure of the Arabidopsis thaliana guanosine deaminase mutant Y185F complexed with guanosine
5UAY	;	2.5	;	The structure of the Arabidopsis thaliana Toc75 POTRA domains
5UBC	;	2.862	;	The structure of the Arabidopsis thaliana Toc75 POTRA domains
6PNZ	;	2.27	;	The structure of the Aspartate Transcarbamoylase trimer from Staphylococcus aureus complexed with PALA at 2.27 Resolution.
4DNX	;	1.6	;	The structure of the ATP sulfurylase from Allochromatium vinosum in the open state
6YWV	;	3.03	;	The structure of the Atp25 bound assembly intermediate of the mitoribosome from Neurospora crassa
4APT	;	2.5	;	The structure of the AXH domain of ataxin-1.
4AQP	;	2.452	;	The structure of the AXH domain of ataxin-1.
1D61	;	1.3	;	THE STRUCTURE OF THE B-DNA DECAMER C-C-A-A-C-I-T-T-G-G: MONOCLINIC FORM
1D60	;	2.2	;	THE STRUCTURE OF THE B-DNA DECAMER C-C-A-A-C-I-T-T-G-G: TRIGONAL FORM
1K28	;	2.9	;	The Structure of the Bacteriophage T4 Cell-Puncturing Device
5EKQ	;	3.392	;	The structure of the BamACDE subcomplex from E. coli
2V6V	;	1.5	;	The structure of the Bem1p PX domain
5FA0	;	2.3	;	The structure of the beta-3-deoxy-D-manno-oct-2-ulosonic acid transferase domain from WbbB
5FA1	;	2.1	;	The structure of the beta-3-deoxy-D-manno-oct-2-ulosonic acid transferase domain of WbbB
5SWC	;	1.45	;	The structure of the beta-carbonic anhydrase CcaA
3MFD	;	1.75	;	The Structure of the Beta-lactamase superfamily domain of D-alanyl-D-alanine carboxypeptidase from Bacillus subtilis
4HZN	;	2.25	;	The Structure of the Bifunctional Acetyltransferase/Decarboxylase LnmK from the Leinamycin Biosynthetic Pathway Revealing Novel Activity for a Double Hot Dog Fold
4HZO	;	1.76	;	The Structure of the Bifunctional Acetyltransferase/Decarboxylase LnmK from the Leinamycin Biosynthetic Pathway Revealing Novel Activity for a Double Hot Dog Fold
4HZP	;	1.77	;	The Structure of the Bifunctional Acetyltransferase/Decarboxylase LnmK from the Leinamycin Biosynthetic Pathway Revealing Novel Activity for a Double Hot Dog Fold
2R9E	;	1.95	;	The structure of the binary complex of citryl dethia COA and citrate synthase from the thermophilic archaeonthermoplasma acidophilum
2IFC	;	1.7	;	The Structure of the Binary Complex of Oxalateacetate with Citrate Synthase from the Thermophilic Archaeon Thermolasma acidophilum
1XB1	;	2.7	;	The Structure of the BIR domain of IAP-like protein 2
7YDS	;	2.3	;	The structure of the bispecific antibody targeted PD-L1 and 4-1BB
7ABA	;	1.85002	;	The structure of the Bottromycin biosynthetic protein SalCYP
1O7D	;	2.7	;	The structure of the bovine lysosomal a-mannosidase suggests a novel mechanism for low pH activation
4BY9	;		;	The structure of the Box CD enzyme reveals regulation of rRNA methylation
2NAY	;		;	The structure of the Bt1.8 peptide synthesized by solid-phase method
2VXD	;		;	The structure of the C-terminal domain of Nucleophosmin
6Z4E	;	2.0	;	The structure of the C-terminal domain of RssB from E. coli
2EHB	;	2.1	;	The structure of the C-terminal domain of the protein kinase AtSOS2 bound to the calcium sensor AtSOS3
2O0A	;	1.6	;	The structure of the C-terminal domain of Vik1 has a motor domain fold but lacks a nucleotide-binding site.
6E3F	;	2.7	;	The structure of the C-terminal domains (C123) of Streptococcus intermedius antigen I/II (Pas)
3IA8	;	1.792	;	The structure of the C-terminal heme nitrobindin domain of THAP domain-containing protein 4 from Homo sapiens
5H3W	;	2.6	;	The structure of the C-terminal of the fibronectin/fibrinogen-binding protein from Streptococcus suis (FBPS)
4USX	;	1.8	;	The Structure of the C-terminal YadA-like domain of BPSL2063 from Burkholderia pseudomallei
5TP1	;	2.31	;	The structure of the C-terminus of virulence protein IncE from Chlamydia trachomatis bound to Mus musculus SNX5-PX domain
4YBA	;	1.7	;	The structure of the C.Kpn2I controller protein
3Q13	;	1.95	;	The Structure of the Ca2+-binding, Glycosylated F-spondin Domain of F-spondin, A C2-domain Variant from Extracellular Matrix
2L1R	;		;	The structure of the calcium-sensitizer, dfbp-o, in complex with the N-domain of troponin C and the switch region of troponin I
4I0C	;	1.95	;	The structure of the camelid antibody cAbHuL5 in complex with human lysozyme
2MWI	;		;	The structure of the carboxy-terminal domain of DNTTIP1
3A2A	;	2.0	;	The structure of the carboxyl-terminal domain of the human voltage-gated proton channel Hv1
3NDY	;	2.1	;	The structure of the catalytic and carbohydrate binding domain of endoglucanase D from Clostridium cellulovorans
3NDZ	;	2.08	;	The structure of the catalytic and carbohydrate binding domain of endoglucanase D from Clostridium cellulovorans bound to cellotriose
3K4S	;	2.05	;	The structure of the catalytic domain of human PDE4d with 4-(3-Butoxy-4-methoxyphenyl)methyl-2-imidazolidone
4D7U	;	1.56	;	The structure of the catalytic domain of NcLPMO9C from the filamentous fungus Neurospora crassa
4D7V	;	1.9	;	The structure of the catalytic domain of NcLPMO9C from the filamentous fungus Neurospora crassa
3UXU	;	2.706	;	The structure of the catalytic domain of the Sulfolobus Spindle-shaped viral integrase reveals an evolutionarily conserved catalytic core and supports a mechanism of DNA cleavage in trans
6XSX	;	2.1	;	The structure of the catalytic module of the metalloprotease ZmpA from Clostridium perfringens
2KFB	;		;	The structure of the cataract causing P23T mutant of human gamma-D crystallin
3GQ0	;	2.066	;	The structure of the Caulobacter crescentus clpS protease adaptor protein - apo structure with no peptide
3DNJ	;	1.15	;	The structure of the Caulobacter crescentus ClpS protease adaptor protein in complex with a N-end rule peptide
3GQ1	;	1.496	;	The structure of the caulobacter crescentus clpS protease adaptor protein in complex with a WLFVQRDSKE decapeptide
3GW1	;	2.36	;	The structure of the Caulobacter crescentus CLPs protease adaptor protein in complex with FGG tripeptide
3G19	;	1.849	;	The structure of the Caulobacter crescentus clpS protease adaptor protein in complex with LLL tripeptide
7JFS	;	4.6	;	The structure of the CBM32-1, CBM32-2, and M60 catalytic domains from Clostridium perfringens ZmpB
4B62	;	1.45	;	The structure of the cell wall anchor of the T6SS from Pseudomonas aeruginosa
3AN2	;	3.6	;	The structure of the centromeric nucleosome containing CENP-A
6CSU	;	2.5	;	The structure of the Cep63-Cep152 heterotetrameric complex
6CSV	;	2.5	;	The structure of the Cep63-Cep152 heterotetrameric complex
2I33	;	1.57	;	The structure of the Class C acid phosphatase from Bacillus anthracis
6ZLX	;	3.394	;	The structure of the ClpX-associated factor PDIP38
5N0L	;	1.68	;	The structure of the cofactor binding GAF domain of the nutrient sensor CodY from Clostridium difficile
6QPQ	;	2.1	;	The structure of the cohesin head module elucidates the mechanism of ring opening
1USU	;	2.15	;	The Structure of the complex between Aha1 and HSP90
1USV	;	2.7	;	The Structure of the complex between Aha1 and HSP90
3OED	;	3.16	;	The structure of the complex between complement receptor CR2 and its ligand complement fragment C3d
2BAT	;	2.0	;	THE STRUCTURE OF THE COMPLEX BETWEEN INFLUENZA VIRUS NEURAMINIDASE AND SIALIC ACID, THE VIRAL RECEPTOR
5YMY	;		;	The structure of the complex between Rpn13 and K48-diUb
2VPL	;	2.3	;	The structure of the complex between the first domain of L1 protein from Thermus thermophilus and mRNA from Methanococcus jannaschii
5N3U	;	1.89	;	The structure of the complex of CpcE and CpcF of phycocyanin lyase from Nostoc sp. PCC7120
2M56	;		;	The structure of the complex of cytochrome P450cam and its electron donor putidaredoxin determined by paramagnetic NMR spectroscopy
1MH5	;	2.1	;	The Structure Of The Complex Of The Fab Fragment Of The Esterolytic Antibody MS6-164 and A Transition-State Analog
3JQ4	;	3.52	;	The structure of the complex of the large ribosomal subunit from D. Radiodurans with the antibiotic lankacidin
5NZR	;	9.2	;	The structure of the COPI coat leaf
5NZS	;	10.1	;	The structure of the COPI coat leaf in complex with the ArfGAP2 uncoating factor
5A1V	;	21.0	;	The structure of the COPI coat linkage I
5NZT	;	17.0	;	The structure of the COPI coat linkage I
5A1W	;	18.0	;	The structure of the COPI coat linkage II
5NZU	;	15.0	;	The structure of the COPI coat linkage II
5A1X	;	23.0	;	The structure of the COPI coat linkage III
5A1Y	;	21.0	;	The structure of the COPI coat linkage IV
5NZV	;	17.3	;	The structure of the COPI coat linkage IV
5A1U	;	13.0	;	The structure of the COPI coat triad
4BZI	;	23.0	;	The structure of the COPII coat assembled on membranes
4BZJ	;	40.0	;	The structure of the COPII coat assembled on membranes
4BZK	;	40.0	;	The structure of the COPII coat assembled on membranes
3PS0	;	2.0	;	The structure of the CRISPR-associated protein, csa2, from Sulfolobus solfataricus
2WTE	;	1.8	;	The structure of the CRISPR-associated protein, Csa3, from Sulfolobus solfataricus at 1.8 angstrom resolution.
2GD7	;		;	The Structure of the Cyclin T-binding domain of Hexim1 reveals the molecular basis for regulation of transcription elongation
1H1Y	;	1.87	;	The structure of the cytosolic D-ribulose-5-phosphate 3-epimerase from rice complexed with sulfate
1H1Z	;	3.4	;	The structure of the cytosolic D-ribulose-5-phosphate 3-epimerase from rice complexed with sulfate and zinc
1BQG	;	2.3	;	THE STRUCTURE OF THE D-GLUCARATE DEHYDRATASE PROTEIN FROM PSEUDOMONAS PUTIDA
2P8D	;	1.9	;	The Structure of the Dickerson Sequence with an Incorporated CeNA Residue
3Q9L	;	2.343	;	The structure of the dimeric E.coli MinD-ATP complex
3ZRW	;	2.25	;	The structure of the dimeric Hamp-Dhp fusion A291V mutant
6Z2J	;	4.0	;	The structure of the dimeric HDAC1/MIDEAS/DNTTIP1 MiDAC deacetylase complex
6L94	;	3.10012	;	The structure of the dioxygenase ABH1 from mouse
1LU1	;	2.6	;	THE STRUCTURE OF THE DOLICHOS BIFLORUS SEED LECTIN IN COMPLEX WITH THE FORSSMAN DISACCHARIDE
2CLB	;	2.4	;	The structure of the DPS-like protein from Sulfolobus solfataricus reveals a bacterioferritin-like di-metal binding site within a Dps- like dodecameric assembly
8HVJ	;	4.05	;	The structure of the E. coli mRNA endoonuclease YiCC
2REB	;	2.3	;	THE STRUCTURE OF THE E. COLI RECA PROTEIN MONOMER AND POLYMER
5NDI	;	2.57	;	The structure of the E.coli guanidine II riboswitch P1 stem-loop
2KQ6	;		;	The structure of the EF-hand domain of polycystin-2 suggests a mechanism for Ca2+-dependent regulation of polycystin-2 channel activity
4RSW	;	1.9	;	The structure of the effector protein from Pseudomonas syringae pv. syringae strain 61
4RSX	;	2.303	;	The structure of the effector protein from Pseudomonas syringae pv. tomato strain DC3000
2W1B	;	3.85	;	The structure of the efflux pump AcrB in complex with bile acid
3O9P	;	2.07	;	The structure of the Escherichia coli murein tripeptide binding protein MppA
5I6C	;	3.7	;	The structure of the eukaryotic purine/H+ symporter, UapA, in complex with Xanthine
4V88	;	3.0	;	The structure of the eukaryotic ribosome at 3.0 A resolution.
7DPK	;	2.15	;	The structure of the exchange reaction of the Arabidopsis thaliana guanosine deaminase in complex with 7-deazaguaosine by guanosine
1Y6U	;		;	The Structure of the Excisionase (Xis) Protein from Conjugative Transposon Tn916 Provides Insights into the Regulation of Heterobivalent Tyrosine Recombinases
6W66	;	3.21	;	The structure of the F64A, S172A mutant Keap1-BTB domain in complex with SKP1-FBXL17
2C1F	;	2.1	;	The structure of the family 11 xylanase from Neocallimastix patriciarum
2V72	;	2.25	;	The structure of the family 32 CBM from C. perfringens NanJ in complex with galactose
2V73	;	2.2	;	The structure of the family 40 CBM from C. perfringens NanJ in complex with a sialic acid containing molecule
7ROY	;	2.9	;	The structure of the Fem1B:FNIP1 complex
6TXS	;	2.2	;	The structure of the FERM domain and helical linker of human moesin bound to a CD44 peptide
3SOQ	;	1.9	;	The structure of the first YWTD beta propeller domain of LRP6 in complex with a DKK1 peptide
3SOB	;	1.9	;	The structure of the first YWTD beta propeller domain of LRP6 in complex with a FAB
6H6K	;	2.0	;	The structure of the FKR mutant of the archaeal translation initiation factor 2 gamma subunit in complex with GDPCP, obtained in the absence of magnesium salts in the crystallization solution.
4UT1	;	1.8	;	The structure of the flagellar hook junction protein FlgK from Burkholderia pseudomallei
5XBJ	;	2.448	;	The structure of the flagellar hook junction protein HAP1 (FlgK) from Campylobacter jejuni
4BDX	;	1.62	;	The structure of the FnI-EGF tandem domain of coagulation factor XII
4BDW	;	2.501	;	The structure of the FnI-EGF tandem domain of coagulation factor XII in complex with Holmium
4YXP	;	1.92	;	The structure of the folded domain of the signature multifunctional protein ICP27 from herpes simplex virus-1 reveals an intertwined dimer.
2B0U	;	2.8	;	The Structure of the Follistatin:Activin Complex
2Y3I	;	2.9	;	The structure of the fully closed conformation of human PGK in complex with L-ADP, 3PG and the TSA aluminium tetrafluoride
2YBE	;	2.0	;	The structure of the fully closed conformation of human PGK in complex with L-ADP, 3PG and the TSA aluminium tetrafluoride at 2.0 A resolution
5L39	;	2.1	;	The structure of the fused permuted hexameric shell protein MSM0275 from the RMM microcompartment
2WZO	;	1.6	;	The structure of the FYR domain
5NEO	;	1.69	;	The structure of the G. violaceus guanidine II riboswitch P1 stem-loop
5NEX	;	1.72	;	The structure of the G. violaceus guanidine II riboswitch P1 stem-loop with agmatine
5NEQ	;	1.69	;	The structure of the G. violaceus guanidine II riboswitch P1 stem-loop with aminoguanidine
5NEF	;	1.91	;	The structure of the G. violaceus guanidine II riboswitch P1 stem-loop with guanidine
5NOM	;	1.93	;	The structure of the G. violaceus guanidine II riboswitch P1 stem-loop with guanidine
5NEP	;	1.6	;	The structure of the G. violaceus guanidine II riboswitch P1 stem-loop with methylguanidine
5NDH	;	1.81	;	The structure of the G. violaceus guanidine II riboswitch P2 stem-loop
6HBT	;	1.66	;	The structure of the G. violaceus guanidine II riboswitch P2 stem-loop with arcaine
6HC5	;	1.413	;	The structure of the G. violaceus guanidine II riboswitch P2 stem-loop with audouine
6HBX	;	1.54	;	The structure of the G. violaceus guanidine II riboswitch P2 stem-loop with ethylguanidine
2V5E	;	2.35	;	The structure of the GDNF:Coreceptor complex: Insights into RET signalling and heparin binding.
5GXH	;	1.8	;	The structure of the Gemin5 WD40 domain with AAUUUUUG
8IN9	;	3.4	;	The structure of the GfsA KSQ-AT didomain in complex with the GfsA ACP domain
4D1J	;	1.8	;	The structure of the GH35 beta-galactosidase Bgl35A from Cellvibrio japonicas in complex with 1-Deoxygalactonojirimycin
4D1I	;	1.8	;	The structure of the GH35 beta-galactosidase Bgl35A from Cellvibrio japonicus
8DEK	;	2.5	;	The structure of the glycopeptidase catalytic domain including the linker of Amuc_1438
6IOB	;	2.002	;	The structure of the H109A mutant of UdgX in complex with uracil
6IOC	;	1.624	;	The structure of the H109Q mutant of UdgX in complex with uracil
5GK2	;	2.201	;	The structure of the H302A mutant of StlD
2XIG	;	1.85	;	The structure of the Helicobacter pylori ferric uptake regulator Fur reveals three functional metal binding sites
4IOX	;	2.458	;	The structure of the herpes simplex virus DNA-packaging motor pUL15 C-terminal nuclease domain provides insights into cleavage of concatemeric viral genome precursors
5L38	;	2.2	;	The structure of the hexagonal shell protein MSM0272 from the RMM microcompartment
4V1X	;	2.2	;	The structure of the hexameric atrazine chlorohydrolase, AtzA
4V1Y	;	2.8	;	The structure of the hexameric atrazine chlorohydrolase, AtzA
1HSM	;		;	THE STRUCTURE OF THE HMG BOX AND ITS INTERACTION WITH DNA
1HSN	;		;	THE STRUCTURE OF THE HMG BOX AND ITS INTERACTION WITH DNA
1NHM	;		;	THE STRUCTURE OF THE HMG BOX AND ITS INTERACTION WITH DNA
1NHN	;		;	THE STRUCTURE OF THE HMG BOX AND ITS INTERACTION WITH DNA
7EZG	;	1.9	;	The structure of the human METTL6 enzyme in complex with SAH
1H9U	;	2.7	;	The structure of the human retinoid-X-receptor beta ligand binding domain in complex with the specific synthetic agonist LG100268
3P56	;	4.06	;	The structure of the human RNase H2 complex defines key interaction interfaces relevant to enzyme function and human disease
3P5J	;	2.9	;	The structure of the human RNase H2 complex defines key interaction interfaces relevant to enzyme function and human disease
7PDC	;	1.83	;	The structure of the human tetrameric LL-37 peptide in a channel conformation
7NC0	;	2.2	;	The structure of the humanised A33 Fab C226S variant, an immunotherapy candidate for colorectal cancer
7NFA	;	2.3	;	The structure of the humanised A33 Fab C226S variant, an immunotherapy candidate for colorectal cancer
1MWW	;	2.08	;	THE STRUCTURE OF THE HYPOTHETICAL PROTEIN HI1388.1 FROM HAEMOPHILUS INFLUENZAE REVEALS A TAUTOMERASE/MIF FOLD
3WXZ	;	2.303	;	The structure of the I375F mutant of CsyB
8DPT	;	4.0	;	The structure of the IL-11 signalling complex, with full-length extracellular gp130
4USN	;	8.8	;	The structure of the immature HIV-1 capsid in intact virus particles at sub-nm resolution
2FAP	;	2.2	;	THE STRUCTURE OF THE IMMUNOPHILIN-IMMUNOSUPPRESSANT FKBP12-(C16)-ETHOXY RAPAMYCIN COMPLEX INTERACTING WITH HUMA
1FAP	;	2.7	;	THE STRUCTURE OF THE IMMUNOPHILIN-IMMUNOSUPPRESSANT FKBP12-RAPAMYCIN COMPLEX INTERACTING WITH HUMAN FRAP
1NSG	;	2.2	;	THE STRUCTURE OF THE IMMUNOPHILIN-IMMUNOSUPPRESSANT FKBP12-RAPAMYCIN COMPLEX INTERACTING WITH HUMAN FRAP
4B54	;	2.8	;	The Structure of the inactive mutant G153R of LptC from E. coli
7LIC	;	3.3	;	The structure of the insect olfactory receptor OR5 from Machilis hrabei
7LIG	;	2.9	;	The structure of the insect olfactory receptor OR5 from Machilis hrabei in complex with DEET
7LID	;	2.9	;	The structure of the insect olfactory receptor OR5 from Machilis hrabei in complex with eugenol
8DPS	;	3.47	;	The structure of the interleukin 11 signalling complex, truncated gp130
3LAJ	;	2.306	;	The Structure of the Intermediate Complex of the Arginine Repressor from Mycobacterium tuberculosis Bound to its DNA Operator and L-arginine.
3LAP	;	2.15	;	The Structure of the Intermediate Complex of the Arginine Repressor from Mycobacterium tuberculosis Bound to its DNA Operator and L-canavanine.
1DTP	;	2.5	;	THE STRUCTURE OF THE ISOLATED CATALYTIC DOMAIN OF DIPHTHERIA TOXIN
1ATO	;		;	THE STRUCTURE OF THE ISOLATED, CENTRAL HAIRPIN OF THE HDV ANTIGENOMIC RIBOZYME, NMR, 10 STRUCTURES
5YBV	;	2.12	;	The structure of the KANK2 ankyrin domain with the KIF21A peptide
4HTA	;	1.901	;	The structure of the karrikin insensitive (KAI2) protein in Arabidopsis thaliana
5HNO	;	1.7	;	The structure of the kdo-capped saccharide binding subunit of the O-12 specific ABC transporter, Wzt
5HNP	;	2.2	;	The structure of the kdo-capped saccharide binding subunit of the O-12 specific ABC transporter, Wzt
2KMG	;		;	The structure of the KlcA and ArdB proteins show a novel fold and antirestriction activity against Type I DNA restriction systems in vivo but not in vitro
5G3T	;	1.8	;	The structure of the L-tryptophan oxidase VioA from Chromobacterium violaceum
5G3S	;	2.076	;	The structure of the L-tryptophan oxidase VioA from Chromobacterium violaceum - Samarium derivative
5G3U	;	2.377	;	The structure of the L-tryptophan oxidase VioA from Chromobacterium violaceum in complex with its inhibitor 2-(1H-indol-3-ylmethyl)prop-2- enoic acid
6YWS	;	2.74	;	The structure of the large subunit of the mitoribosome from Neurospora crassa
3P5B	;	3.3	;	The structure of the LDLR/PCSK9 complex reveals the receptor in an extended conformation
3P5C	;	4.2	;	The structure of the LDLR/PCSK9 complex reveals the receptor in an extended conformation
1C4R	;	2.6	;	THE STRUCTURE OF THE LIGAND-BINDING DOMAIN OF NEUREXIN 1BETA: REGULATION OF LNS DOMAIN FUNCTION BY ALTERNATIVE SPLICING
2W9Y	;	1.8	;	The structure of the lipid binding protein Ce-FAR-7 from Caenorhabditis elegans
6KYT	;	2.00101	;	The structure of the M. tb toxin MazEF-mt1 complex
6KYS	;	2.20041	;	The structure of the M. tb toxin MazF-mt1
7DU5	;	2.65	;	The structure of the M.tb MazF-mt1 toxin in complex with a fragment of cognate antitoxin
7DU4	;	2.18	;	The structure of the M.tb MazF-mt9 toxin in complex with a fragment of cognate antitoxin
3G1B	;	1.448	;	The structure of the M53A mutant of Caulobacter crescentus clpS protease adaptor protein in complex with WLFVQRDSKE peptide
3G3P	;	1.478	;	The structure of the M53A Mutant of the Caulobacter crescentus CLPS in complex with a peptide containing an amino-terminal norleucine residue
6XSZ	;	2.25	;	The structure of the M60 catalytic domain from Clostridium perfringens ZmpC
6XT1	;	2.49	;	The structure of the M60 catalytic domain from Clostridium perfringens ZmpC in complex the sialyl T antigen
7JS4	;	4.6	;	The structure of the M60 catalytic domain with the CBM51-1 and CBM51-2 domains from Clostridium perfringens ZmpB
1HFO	;	1.65	;	The Structure of the Macrophage Migration Inhibitory Factor from Trichinella Spiralis.
5TIP	;	2.0	;	The Structure of the Major Capsid protein of PBCV-1
5TIQ	;	2.537	;	The Structure of the Major Capsid protein of PBCV-1
3JC2	;	3.6	;	The structure of the mammalian Sec61 channel opened by a signal sequence
2FH5	;	2.45	;	The Structure of the Mammalian SRP Receptor
5UOJ	;	2.1	;	THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTROMS RESOLUTION
3ENM	;	2.35	;	The structure of the MAP2K MEK6 reveals an autoinhibitory dimer
5MCX	;	6.8	;	The structure of the mature HIV-1 CA hexamer in intact virus particles
5MCZ	;	8.2	;	The structure of the mature HIV-1 CA hexameric lattice with curvature parameters: tilt=-1, twist=0
5MD7	;	8.4	;	The structure of the mature HIV-1 CA hexameric lattice with curvature parameters: tilt=11, twist=-12
5MD6	;	8.1	;	The structure of the mature HIV-1 CA hexameric lattice with curvature parameters: tilt=11, twist=-6
5MD5	;	8.2	;	The structure of the mature HIV-1 CA hexameric lattice with curvature parameters: tilt=11, twist=0
5MD3	;	8.5	;	The structure of the mature HIV-1 CA hexameric lattice with curvature parameters: tilt=11, twist=12
5MD4	;	8.4	;	The structure of the mature HIV-1 CA hexameric lattice with curvature parameters: tilt=11, twist=6
5MDC	;	8.4	;	The structure of the mature HIV-1 CA hexameric lattice with curvature parameters: tilt=17, twist=-12
5MDB	;	8.4	;	The structure of the mature HIV-1 CA hexameric lattice with curvature parameters: tilt=17, twist=-6
5MDA	;	8.4	;	The structure of the mature HIV-1 CA hexameric lattice with curvature parameters: tilt=17, twist=0
5MD8	;	8.6	;	The structure of the mature HIV-1 CA hexameric lattice with curvature parameters: tilt=17, twist=12
5MD9	;	8.0	;	The structure of the mature HIV-1 CA hexameric lattice with curvature parameters: tilt=17, twist=6
5MDF	;	8.5	;	The structure of the mature HIV-1 CA hexameric lattice with curvature parameters: tilt=23, twist=-6
5MDE	;	8.4	;	The structure of the mature HIV-1 CA hexameric lattice with curvature parameters: tilt=23, twist=0
5MDD	;	8.5	;	The structure of the mature HIV-1 CA hexameric lattice with curvature parameters: tilt=23, twist=6
5MDG	;	8.7	;	The structure of the mature HIV-1 CA hexameric lattice with curvature parameters: tilt=29, twist=0
5MD2	;	8.6	;	The structure of the mature HIV-1 CA hexameric lattice with curvature parameters: tilt=5, twist=-6
5MD1	;	8.2	;	The structure of the mature HIV-1 CA hexameric lattice with curvature parameters: tilt=5, twist=0
5MD0	;	8.4	;	The structure of the mature HIV-1 CA hexameric lattice with curvature parameters: tilt=5, twist=6
5MCY	;	8.8	;	The structure of the mature HIV-1 CA pentamer in intact virus particles
6L29	;	2.30001	;	The structure of the MazF-mt1 mutant
2WSS	;	3.2	;	The structure of the membrane extrinsic region of bovine ATP synthase
6KW1	;	1.77521	;	The structure of the metallo-beta-lactamase VIM-2 in complex with a triazolylthioacetamide 1b
5LSC	;	1.497	;	The structure of the metallo-beta-lactamase VIM-2 in complex with a triazolylthioacetamide inhibitor
4GC0	;	2.6	;	The structure of the MFS (major facilitator superfamily) proton:xylose symporter XylE bound to 6-bromo-6-deoxy-D-glucose
4GBZ	;	2.894	;	The structure of the MFS (major facilitator superfamily) proton:xylose symporter XylE bound to D-glucose
4GBY	;	2.808	;	The structure of the MFS (major facilitator superfamily) proton:xylose symporter XylE bound to D-xylose
5Y91	;	1.901	;	The structure of the MHC class I molecule of bony fishes provides insights into the conserved nature of the antigen-presenting system
7XSJ	;	3.2	;	The structure of the Mint1/Munc18-1/syntaxin-1 complex
6YWE	;	2.99	;	The structure of the mitoribosome from Neurospora crassa in the P/E tRNA bound state
6YWY	;	3.05	;	The structure of the mitoribosome from Neurospora crassa with bound tRNA at the P-site
6YWX	;	3.1	;	The structure of the mitoribosome from Neurospora crassa with tRNA bound to the E-site
6Q32	;	1.39	;	The structure of the Mo-insertase domain Cnx1E (variant S269DD274S) from Arabidopsis thaliana in complex with Moco-AMP
6ETD	;	1.723	;	The Structure of the Mo-insertase domain Cnx1E from Arabidopsis thaliana in complex with AMP
6ETF	;	1.781	;	The Structure of the Mo-insertase domain Cnx1E from Arabidopsis thaliana in complex with AMP and molybdate
6ETH	;	1.64	;	The Structure of the Mo-insertase domain Cnx1E from Arabidopsis thaliana in complex with AMP and tungstate
6Y01	;	1.23	;	The structure of the molybdenum cofactor binding protein from the phototrophic bacterium Rippkaea orientalis
4TWG	;	1.85	;	The structure of the Molybdopterin biosynthesis Mog protein from Mycobacterium ulcerans
7KSQ	;	2.8	;	The Structure of the moss PSI-LHCI reveals the evolution of the LHCI antenna
7KU5	;	3.76	;	The Structure of the moss PSI-LHCI reveals the evolution of the LHCI antenna
7KUX	;	2.8	;	The Structure of the moss PSI-LHCI reveals the evolution of the LHCI antenna
1G2U	;	2.1	;	THE STRUCTURE OF THE MUTANT, A172V, OF 3-ISOPROPYLMALATE DEHYDROGENASE FROM THERMUS THERMOPHILUS HB8 : ITS THERMOSTABILITY AND STRUCTURE.
1V5B	;	2.95	;	The Structure Of The Mutant, S225A and E251L, Of 3-Isopropylmalate Dehydrogenase From Bacillus Coagulans
2WZL	;	2.1	;	The Structure of the N-RNA Binding Domain of the Mokola virus Phosphoprotein
7EEY	;	2.6	;	The structure of the N-terminal doamin of the Schizosaccharomyces pombe Tad2 adenosine deaminase
6E4L	;	1.6	;	The structure of the N-terminal domain of human clathrin heavy chain 1 (nTD) in complex with ES9
2BNL	;	2.0	;	The structure of the N-terminal domain of RsbR
6Z4C	;	2.0	;	The structure of the N-terminal domain of RssB from E. coli
1VZO	;	1.8	;	The structure of the N-terminal kinase domain of MSK1 reveals a novel autoinhibitory conformation for a dual kinase protein
1KDK	;	1.7	;	THE STRUCTURE OF THE N-TERMINAL LG DOMAIN OF SHBG IN CRYSTALS SOAKED WITH EDTA
5H3X	;	2.1	;	The structure of the N-terminal of the fibronectin/fibrinogen-binding protein from Streptococcus suis (FBPS)
3A8R	;	2.4	;	The structure of the N-terminal regulatory domain of a plant NADPH oxidase
8DD0	;	3.5	;	The structure of the native cardiac thin filament junction region
8V01	;	5.5	;	The structure of the native cardiac thin filament troponin core in Ca2+-bound fully activated state 1 from the lower strand
8V0I	;	5.8	;	The structure of the native cardiac thin filament troponin core in Ca2+-bound fully activated state 2 from the lower strand
8UZX	;	5.4	;	The structure of the native cardiac thin filament troponin core in Ca2+-bound fully activated state from the upper strand
8V0K	;	5.2	;	The structure of the native cardiac thin filament troponin core in Ca2+-bound partially activated state from the lower strand
8UZY	;	5.3	;	The structure of the native cardiac thin filament troponin core in Ca2+-bound partially activated state from the upper strand
8UZ5	;	5.9	;	The structure of the native cardiac thin filament troponin core in Ca2+-free rotated state from the lower strand
8UWY	;	5.5	;	The structure of the native cardiac thin filament troponin core in Ca2+-free rotated state from the upper strand
8UYD	;	5.3	;	The structure of the native cardiac thin filament troponin core in Ca2+-free state from the lower strand
8UWW	;	5.1	;	The structure of the native cardiac thin filament troponin core in Ca2+-free state from the upper strand
8V0Y	;	7.0	;	The structure of the native cardiac thin filament troponin core in Ca2+-free state from the upper strand activated by the C1-domain of cardiac myosin binding protein C
8UZ6	;	7.1	;	The structure of the native cardiac thin filament troponin core in Ca2+-free tilted state from the lower strand
8UWX	;	6.0	;	The structure of the native cardiac thin filament troponin core in Ca2+-free tilted state from the upper strand
7O4H	;	3.4	;	The structure of the native CNGA1/CNGB1 CNG channel from retinal rods
4RSO	;	3.5	;	The structure of the neurotropic AAVrh.8 viral vector
3T1E	;	3.301	;	The structure of the Newcastle disease virus hemagglutinin-neuraminidase (HN) ectodomain reveals a 4-helix bundle stalk
1A04	;	2.2	;	THE STRUCTURE OF THE NITRATE/NITRITE RESPONSE REGULATOR PROTEIN NARL IN THE MONOCLINIC C2 CRYSTAL FORM
5CS1	;	2.0	;	The structure of the NK1 fragment of HGF/SF
5CS3	;	2.5	;	The structure of the NK1 fragment of HGF/SF complexed with (H)EPPS
5CT3	;	2.0	;	The structure of the NK1 fragment of HGF/SF complexed with 2FA
5CT2	;	2.0	;	The structure of the NK1 fragment of HGF/SF complexed with CAPS
5CT1	;	2.0	;	The structure of the NK1 fragment of HGF/SF complexed with CHES
5COE	;	2.18	;	The structure of the NK1 fragment of HGF/SF complexed with HEPES
5CP9	;	1.9	;	The structure of the NK1 fragment of HGF/SF complexed with MB605
5CS9	;	2.0	;	The structure of the NK1 fragment of HGF/SF complexed with MES
5CSQ	;	1.95	;	The structure of the NK1 fragment of HGF/SF complexed with MOPS
5CS5	;	1.9	;	The structure of the NK1 fragment of HGF/SF complexed with PIPES
1CEB	;	2.07	;	THE STRUCTURE OF THE NON-COVALENT COMPLEX OF RECOMBINANT KRINGLE 1 DOMAIN OF HUMAN PLASMINOGEN WITH AMCHA (TRANS-4-AMINOMETHYLCYCLOHEXANE-1-CARBOXYLIC ACID)
1CEA	;	2.06	;	THE STRUCTURE OF THE NON-COVALENT COMPLEX OF RECOMBINANT KRINGLE 1 DOMAIN OF HUMAN PLASMINOGEN WITH EACA (EPSILON-AMINOCAPROIC ACID)
1XOC	;	1.55	;	The structure of the oligopeptide-binding protein, AppA, from Bacillus subtilis in complex with a nonapeptide.
4B98	;	1.65	;	The structure of the omega aminotransferase from Pseudomonas aeruginosa
4B9B	;	1.64	;	The structure of the omega aminotransferase from Pseudomonas aeruginosa
2H1L	;	3.16	;	The Structure of the Oncoprotein SV40 Large T Antigen and p53 Tumor Suppressor Complex
1QO8	;	2.15	;	The structure of the open conformation of a flavocytochrome c3 fumarate reductase
6PO0	;	1.75	;	The structure of the orthorhombic (P212121) crystal form of beef liver catalase at 1.85 A resolution
1AKI	;	1.5	;	THE STRUCTURE OF THE ORTHORHOMBIC FORM OF HEN EGG-WHITE LYSOZYME AT 1.5 ANGSTROMS RESOLUTION
2GV0	;	1.9	;	The structure of the orthorhombic form of soft-shelled turtle lysozyme at 1.9 angstroms resolution
6V7L	;	2.8	;	The structure of the P212121 crystal form of canavalin at 173 K
2BQP	;	1.9	;	THE STRUCTURE OF THE PEA LECTIN-D-GLUCOPYRANOSE COMPLEX
1BQP	;	2.1	;	THE STRUCTURE OF THE PEA LECTIN-D-MANNOPYRANOSE COMPLEX
5L37	;	1.6	;	The structure of the pentameric shell protein MSM0273 from the RMM microcompartment
4DT0	;	3.65	;	The structure of the peripheral stalk subunit E from Pyrococcus horikoshii
7CMG	;	3.7	;	The Structure of the periplasmic domain of PorM
4KZK	;	1.5	;	The structure of the periplasmic L-arabinose binding protein from Burkholderia thailandensis
6NWA	;	3.48	;	The structure of the photosystem I IsiA super-complex
1QY7	;	2.0	;	The structure of the PII protein from the cyanobacteria Synechococcus sp. PCC 7942
6MUX	;	3.9	;	The structure of the Plasmodium falciparum 20S proteasome in complex with one PA28 activator
6MUV	;	3.8	;	The structure of the Plasmodium falciparum 20S proteasome in complex with two PA28 activators
6MUW	;	3.6	;	The structure of the Plasmodium falciparum 20S proteasome.
4G7N	;	2.3	;	The Structure of the Plk4 Cryptic Polo Box Reveals Two Tandem Polo Boxes Required for Centriole Duplication
1Q4O	;	2.2	;	The structure of the polo box domain of human Plk1
5NMM	;	2.02	;	The structure of the polo-box domain (PBD) of Plk1 in complex with Alpha-Bromo-3-Iodotoluene.
5NN2	;	1.81	;	The structure of the polo-box domain (PBD) of Plk1 in complex with Z228588490
5NN1	;	1.785	;	The structure of the polo-box domain (PBD) of polo-like kinase 1 (Plk1)
4E9D	;	2.75	;	The structure of the polo-box domain (PBD) of polo-like kinase 1 (Plk1) in complex with 3-(1-benzothiophen-2-yl)propanoyl-derivatized DPPLHSpTA peptide
5NJE	;	1.978	;	The structure of the polo-box domain (PBD) of polo-like kinase 1 (Plk1) in complex with Alpha-Bromo-3-Iodotoluene.
4E67	;	2.1	;	The structure of the polo-box domain (PBD) of polo-like kinase 1 (Plk1) in complex with hydrocinnamoyl-derivatized PLHSpTA peptide
5NEI	;	2.68	;	The structure of the polo-box domain (PBD) of polo-like kinase 1 (Plk1) in complex with JES107
4E9C	;	1.7	;	The structure of the polo-box domain (PBD) of polo-like kinase 1 (Plk1) in complex with LDPPLHSpTA phosphopeptide
5NFU	;	1.809	;	The structure of the polo-box domain (PBD) of polo-like kinase 1 (Plk1) in complex with LHSpTA peptide
3K7B	;	2.1	;	The structure of the poxvirus A33 protein reveals a dimer of unique C-type lectin-like domains.
6VRO	;	2.45	;	The structure of the PP2A B56 subunit AIM1 complex
5K6S	;	2.794	;	The structure of the PP2A B56 subunit BubR1 complex
5SWF	;	2.818	;	The structure of the PP2A B56 subunit double phosphorylated BubR1 complex
6OYL	;	3.15	;	The structure of the PP2A B56 subunit KIF4A complex
5SW9	;	2.846	;	The structure of the PP2A B56 subunit RepoMan complex
8U1X	;	2.7	;	The structure of the PP2A-B56Delta holoenzyme mutant - E197K
8U89	;	3.3	;	The structure of the PP2A-B56Delta holoenzyme mutant - E197K
7SOY	;	3.4	;	The structure of the PP2A-B56gamma1 holoenzyme-PME-1 complex
3IAU	;	2.353	;	The structure of the processed form of threonine deaminase isoform 2 from Solanum lycopersicum
1E9K	;		;	The structure of the RACK1 interaction sites located within the unique N-terminal region of the cAMP-specific phosphodiesterase, PDE4D5.
1EVR	;	1.9	;	The structure of the resorcinol/insulin R6 hexamer
2OQR	;	2.03	;	The structure of the response regulator RegX3 from Mycobacterium tuberculosis
2VSW	;	2.2	;	The structure of the rhodanese domain of the human dual specificity phosphatase 16
3UZU	;	1.75	;	The structure of the Ribosomal RNA small subunit methyltransferase A from Burkholderia pseudomallei
4V5F	;	3.6	;	The structure of the ribosome with elongation factor G trapped in the post-translocational state
2KN4	;		;	The structure of the RRM domain of SC35
1QAM	;	2.2	;	THE STRUCTURE OF THE RRNA METHYLTRANSFERASE ERMC': IMPLICATIONS FOR THE REACTION MECHANISM
1QAN	;	2.4	;	THE STRUCTURE OF THE RRNA METHYLTRANSFERASE ERMC': IMPLICATIONS FOR THE REACTION MECHANISM
1QAO	;	2.7	;	THE STRUCTURE OF THE RRNA METHYLTRANSFERASE ERMC': IMPLICATIONS FOR THE REACTION MECHANISM
1QAQ	;	2.8	;	THE STRUCTURE OF THE RRNA METHYLTRANSFERASE ERMC': IMPLICATIONS FOR THE REACTION MECHANISM
4E2K	;	2.15	;	The structure of the S. aureus DnaG RNA Polymerase Domain
4EDG	;	2.003	;	The structure of the S. aureus DnaG RNA Polymerase Domain bound to ATP and Manganese
4EE1	;	2.02	;	The structure of the S. aureus DnaG RNA Polymerase Domain bound to CTP and Manganese
4EDK	;	2.0	;	The structure of the S. aureus DnaG RNA Polymerase Domain bound to GTP and Manganese
4EDT	;	2.005	;	The structure of the S. aureus DnaG RNA Polymerase Domain bound to ppGpp and Manganese
4EDV	;	2.01	;	The structure of the S. aureus DnaG RNA Polymerase Domain bound to pppGpp and Manganese
4EDR	;	2.01	;	The structure of the S. aureus DnaG RNA Polymerase Domain bound to UTP and Manganese
2F6F	;	2.0	;	The structure of the S295F mutant of human PTP1B
4ZOR	;	2.2	;	The structure of the S37P MS2 viral capsid assembly.
1Q97	;	2.3	;	The structure of the Saccharomyces cerevisiae SR protein kinase, Sky1p, with bound ATP
6HAG	;		;	The structure of the SAM/SAH-binding riboswitch.
7NRR	;	1.67	;	The structure of the SBP TarP_Csal in complex with caffeate
7NSW	;	1.67	;	The structure of the SBP TarP_Csal in complex with coumarate
7NTD	;	1.75	;	The structure of the SBP TarP_Csal in complex with ferulate
7NQG	;	1.1	;	The structure of the SBP TarP_Rhp in complex with 4-hydroxyphenylacetate
7NRA	;	1.91	;	The structure of the SBP TarP_Sse in complex with cinnamate
7NR2	;	2.13	;	The structure of the SBP TarP_Sse in complex with coumarate
6RLI	;	1.15	;	The structure of the self-assembled 3fPizza6-SH crystal
1PJT	;	2.8	;	The structure of the Ser128Ala point-mutant variant of CysG, the multifunctional methyltransferase/dehydrogenase/ferrochelatase for siroheme synthesis
4KQW	;	1.39	;	The structure of the Slackia exigua KARI in complex with NADP
3PYW	;	1.8	;	The structure of the SLH domain from B. anthracis surface array protein at 1.8A
6YW5	;	2.85	;	The structure of the small subunit of the mitoribosome from Neurospora crassa
5A17	;		;	The structure of the SOLE element of oskar mRNA
5A18	;		;	The structure of the SOLE element of oskar mRNA
4EGW	;	2.5	;	The structure of the soluble domain of CorA from Methanocaldococcus jannaschii
4BNQ	;	2.279	;	The structure of the Staphylococcus aureus Ham1 protein
4M54	;	2.36	;	The structure of the staphyloferrin B precursor biosynthetic enzyme SbnB bound to N-(1-amino-1-carboxyl-2-ethyl)-glutamic acid and NADH
6BAK	;	1.92	;	The structure of the Stigmatella aurantiaca phytochrome chromophore binding domain T289H mutant
6Q2K	;	2.0	;	The structure of the Streptococcus gordonii surface protein SspB in complex with TEV peptide provides clues to the adherence of oral streptococcal adherence to salivary agglutinin
6Q2L	;	1.8	;	The structure of the Streptococcus gordonii surface protein SspB in complex with TEV peptide provides clues to the adherence of oral streptococcal adherence to salivary agglutinin
6TZL	;	1.6	;	The structure of the Streptococcus gordonii surface protein SspB in complex with TEV peptide provides clues to the adherence of oral streptococcal adherence to salivary agglutinin
6UBV	;	2.7	;	The structure of the Streptococcus gordonii surface protein SspB in complex with TEV peptide provides clues to the adherence of oral streptococcal adherence to salivary agglutinin
2VRN	;	2.15	;	The structure of the stress response protein DR1199 from Deinococcus radiodurans: a member of the DJ-1 superfamily
3UOR	;	2.202	;	The structure of the sugar-binding protein MalE from the phytopathogen Xanthomonas citri
4AU7	;	2.07	;	The structure of the Suv4-20h2 ternary complex with histone H4
5E8O	;	1.98	;	The structure of the TEIPP associated altered peptide ligand Trh4-p2ABU in complex with H-2D(b)
5E8P	;	2.0	;	The structure of the TEIPP associated altered peptide ligand Trh4-p5NLE in complex with H-2D(b)
5E8N	;	2.25	;	The structure of the TEIPP associated Trh4 peptide in complex with H-2D(b)
2R26	;	2.5	;	The Structure of the Ternary Complex of Carboxymethyl Coenzyme A and Oxalateacetate with Citrate Synthase from the Thermophilic Archaeonthermoplasma Acidophilum
3SD3	;	1.95	;	The structure of the tetrahydrofolate riboswitch containing a U25C mutation
7MOQ	;	8.0	;	The structure of the Tetrahymena thermophila outer dynein arm on doublet microtubule
6Z2K	;	4.5	;	The structure of the tetrameric HDAC1/MIDEAS/DNTTIP1 MiDAC deacetylase complex
5NZD	;	2.007	;	The structure of the thermobifida fusca guanidine III riboswitch in space group P212121.
5O62	;	2.119	;	The structure of the thermobifida fusca guanidine III riboswitch with 1-Ethylguanidine.
5O69	;	2.319	;	The structure of the thermobifida fusca guanidine III riboswitch with agmatine.
5NY8	;	2.04	;	The structure of the thermobifida fusca guanidine III riboswitch with aminoguanidine
5NZ6	;	2.94	;	The structure of the thermobifida fusca guanidine III riboswitch with guanidine in space group P3212.
5NWQ	;	1.91	;	The structure of the thermobifida fusca guanidine III riboswitch with guanidine.
5NZ3	;	2.059	;	The structure of the thermobifida fusca guanidine III riboswitch with methylguanidine
3ZJB	;	1.84	;	The structure of the TRAF domain of human TRAF4
1VQ4	;	2.7	;	The structure of the transition state analogue ""DAA"" bound to the large ribosomal subunit of Haloarcula marismortui
1VQM	;	2.3	;	The structure of the transition state analogue ""DAN"" bound to the large ribosomal subunit of haloarcula marismortui
1VQ7	;	2.5	;	The structure of the transition state analogue ""DCA"" bound to the large ribosomal subunit of haloarcula marismortui
1VQL	;	2.3	;	The structure of the transition state analogue ""DCSN"" bound to the large ribosomal subunit of haloarcula marismortui
1VQ5	;	2.6	;	The structure of the transition state analogue ""RAA"" bound to the large ribosomal subunit of haloarcula marismortui
1VQP	;	2.25	;	The structure of the transition state analogue ""RAP"" bound to the large ribosomal subunit of haloarcula marismortui
1AH9	;		;	THE STRUCTURE OF THE TRANSLATIONAL INITIATION FACTOR IF1 FROM ESCHERICHIA COLI, NMR, 19 STRUCTURES
5AQ0	;	0.95	;	The structure of the Transthyretin-like domain of the first catalytic domain of the HUMAN Carboxypeptidase D
6PM7	;	1.85	;	The structure of the triclinic crystal form of beef liver catalase at 1.85 A resolution
5W9A	;	2.74	;	The structure of the Trim5alpha Bbox- coiled coil in complex LC3B
5NBQ	;	3.18	;	The structure of the tripartite complex between OspE, the C-terminal domains of factor H and C3dg
6L2L	;	2.40046	;	The structure of the tRNA-specific deaminase from M. capricolum
6L2M	;	2.30255	;	The structure of the tRNA-specific deaminase mutant from M. capricolum
1GTF	;	1.75	;	The structure of the trp RNA-binding attenuation protein (TRAP) bound to a 53-nucleotide RNA molecule containing GAGUU repeats
1UTD	;	2.1	;	The structure of the trp RNA-binding attenuation protein (TRAP) bound to a 63-nucleotide RNA molecule containing GAGUUU repeats
4V4F	;	1.9	;	The structure of the trp RNA-binding attenuation protein (TRAP) bound to a RNA molecule containing UAGAU repeats
4LL1	;	2.0	;	The structure of the TRX and TXNIP complex
4LL4	;	2.7	;	The structure of the TRX and TXNIP complex
4C18	;	1.49	;	The structure of the Tsi2 dimer with a disulfide bond
3ZD2	;	1.99	;	THE STRUCTURE OF THE TWO N-TERMINAL DOMAINS OF COMPLEMENT FACTOR H RELATED PROTEIN 1 SHOWS FORMATION OF A NOVEL DIMERISATION INTERFACE
2NUD	;	2.3	;	The structure of the type III effector AvrB complexed with a high-affinity RIN4 peptide
2NUN	;	2.4	;	The structure of the type III effector AvrB complexed with ADP
5T09	;	2.013	;	The structure of the type III effector HopBA1
5D88	;	1.66	;	The Structure of the U32 Peptidase Mk0906
6GF1	;	1.925	;	The structure of the ubiquitin-like modifier FAT10 reveals a novel targeting mechanism for degradation by the 26S proteasome
6GF2	;		;	The structure of the ubiquitin-like modifier FAT10 reveals a novel targeting mechanism for degradation by the 26S proteasome
6L5B	;	2.00005	;	The structure of the UdgX mutant H109E at a post-excision state
6L5A	;	1.80007	;	The structure of the UdgX mutant H109E at a pre-excision state
6L6S	;	2.06426	;	The structure of the UdgX mutant H109E crosslinked to single-stranded DNA
7K3P	;	2.04	;	The structure of the UDP-Glc/GlcNAc 4-epimerase from the human pathogen Campylobacter jejuni
4LLV	;	2.39	;	The structure of the unbound form of anti-HIV antibody 4E10 Fv
2ESZ	;		;	The structure of the V3 region within gp120 of JR-FL HIV-1 strain (ensemble)
2ESX	;		;	The structure of the V3 region within gp120 of JR-FL HIV-1 strain (minimized average structure)
6E36	;	1.7	;	The structure of the variable domain of Streptococcus intermedius antigen I/II (Pas)
2M8P	;		;	The structure of the W184AM185A mutant of the HIV-1 capsid protein
5M2R	;	1.5	;	The Structure of the Ycf54 A9G mutant protein from Synechocystis sp. PCC6803
5M2P	;	1.33	;	The Structure of the Ycf54 protein from Synechocystis sp. PCC6803
5M2U	;	2.2	;	The Structure of the Ycf54 protein from Synechocystis sp. PCC6803
1Q8Y	;	2.05	;	The structure of the yeast SR protein kinase, Sky1p, with bound ADP
1HRU	;	2.0	;	THE STRUCTURE OF THE YRDC GENE PRODUCT FROM E.COLI
2VRD	;		;	THE STRUCTURE OF THE ZINC FINGER FROM THE HUMAN SPLICEOSOMAL PROTEIN U1C
3R6E	;	1.18	;	The structure of Thermococcus thioreducens' inorganic pyrophosphatase bound to sulfate
4V8A	;	3.2	;	The structure of thermorubin in complex with the 70S ribosome from Thermus thermophilus.
2V8A	;	3.5	;	The structure of Thermosynechococcus elongatus allophycocyanin at 3.5 Angstroems.
1WS6	;	2.5	;	The Structure of Thermus thermphillus HB8 hypothetical protein TTHA0928
8Q9Y	;	1.1	;	The structure of thiocyanate dehydrogenase from Pelomicrobium methylotrophicum in complex with inhibitor thiourea at 1.10 A resolution
8Q9X	;	1.05	;	The structure of thiocyanate dehydrogenase from Pelomicrobium methylotrophicum with molecular oxygen at 1.05 A resolution
6G50	;	1.65	;	The structure of thiocyanate dehydrogenase from Thioalkalivibrio paradoxus as isolated.
6I3Q	;	1.45	;	The structure of thiocyanate dehydrogenase from Thioalkalivibrio paradoxus complex with acetate ions.
6G5M	;	2.31	;	The structure of thiocyanate dehydrogenase from Thioalkalivibrio paradoxus complex with CU(I) ions.
6SJI	;	1.8	;	The structure of thiocyanate dehydrogenase from Thioalkalivibrio paradoxus mutant with His 482 replaced by Gln
8P3M	;	2.07	;	The structure of thiocyanate dehydrogenase mutant form with Lys 281 replaced by Ala from Thioalkalivibrio paradoxus
8BPN	;	1.99	;	The structure of thiocyanate dehydrogenase mutant form with Phe 436 replaced by Gln from Thioalkalivibrio paradoxus
8P3L	;	1.8	;	The structure of thiocyanate dehydrogenase mutant form with Thr 169 replaced by Ala from Thioalkalivibrio paradoxus
7D78	;	1.96543	;	The structure of thioesterase DcsB
1T00	;	1.51	;	The structure of thioredoxin from S. coelicolor
3MI8	;	2.951	;	The structure of TL1A-DCR3 COMPLEX
1C5K	;	2.0	;	THE STRUCTURE OF TOLB, AN ESSENTIAL COMPONENT OF THE TOL-DEPENDENT TRANSLOCATION SYSTEM AND ITS INTERACTIONS WITH THE TRANSLOCATION DOMAIN OF COLICIN E9
5IKT	;	2.451	;	The Structure of Tolfenamic Acid Bound to Human Cyclooxygenase-2
1LAJ	;	3.4	;	The Structure of Tomato Aspermy Virus by X-Ray Crystallography
1S0Y	;	2.3	;	The structure of trans-3-chloroacrylic acid dehalogenase, covalently inactivated by the mechanism-based inhibitor 3-bromopropiolate at 2.3 Angstrom resolution
8HUZ	;	3.3	;	the structure of trans-editing factor ProX
5DDG	;	3.06	;	The structure of transcriptional factor AraR from Bacteroides thetaiotaomicron VPI in complex with target double strand DNA
2R8D	;	2.0	;	The structure of transporter associated domain CorC_HlyC from a Xylella fastidiosa Temecula1 hemolysin in complex with Mg++ and Mn++
2OAI	;	1.8	;	The structure of transporter associated domain CorC_HlyC from a Xylella fastidiosa Temecula1 hemolysin.
3ZO9	;	1.84	;	The structure of Trehalose Synthase (TreS) of Mycobacterium smegmatis
3ZOA	;	1.85	;	The structure of Trehalose Synthase (TreS) of Mycobacterium smegmatis in complex with acarbose
6QJ6	;	1.74	;	The structure of Trehalose-6-phosphatase from Burkholderia pseudomallei
7W5I	;	2.13	;	The structure of trichobrasilenol synthase TaTC6 in complex with FPP-1
7W5J	;	2.05	;	The structure of trichobrasilenol synthase TaTC6 in complex with FPP-2
7W5H	;	2.05	;	The structure of trichobrasilenol synthase TaTC6 in complex with FsPP
6IEU	;	1.787	;	The structure of TRIM66 PHD-Bromo domain with unmodified H3 N terminal peptide
1TRE	;	2.6	;	THE STRUCTURE OF TRIOSEPHOSPHATE ISOMERASE FROM ESCHERICHIA COLI DETERMINED AT 2.6 ANGSTROM RESOLUTION
4PMP	;	1.8	;	The structure of TrkA kinase bound to the inhibitor 1-cyclopropyl-1-[3-(1,3-thiazol-2-yl)benzyl]-3-[4-(trifluoromethoxy)phenyl]urea
4PMS	;	2.8	;	The structure of TrkA kinase bound to the inhibitor 4-naphthalen-1-yl-1-[(5-phenyl-1,2,4-oxadiazol-3-yl)methyl]-1H-pyrrolo[3,2-c]pyridine-2-carboxylic acid
4PMM	;	2.0	;	The structure of TrkA kinase bound to the inhibitor N-(3-cyclopropyl-1-phenyl-1H-pyrazol-5-yl)-2-{4-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1H-1,2,3-triazol-1-yl}acetamide
4PMT	;	2.1	;	The structure of TrkA kinase bound to the inhibitor N~4~-(4-morpholin-4-ylphenyl)-N~6~-(pyridin-3-ylmethyl)pyrido[3,2-d]pyrimidine-4,6-diamine
5KVT	;	2.45	;	THE STRUCTURE OF TRKA KINASE DOMAIN BOUND TO THE INHIBITOR ENTRECTINIB
1RLI	;	1.8	;	The Structure of Trp Repressor Binding Protein from Bacillus subtilis
5ITM	;	1.4	;	The structure of truncated histone-like protein
2CDM	;	2.7	;	The structure of TrwC complexed with a 27-mer DNA comprising the recognition hairpin and the cleavage site
1NDA	;	3.3	;	THE STRUCTURE OF TRYPANOSOMA CRUZI TRYPANOTHIONE REDUCTASE IN THE OXIDIZED AND NADPH REDUCED STATE
3S9F	;	1.8	;	The structure of Tryparedoxin I from Leishmania major
3TUE	;	3.0	;	The structure of tryparedoxin peroxidase I from Leishmania major
2AQJ	;	1.8	;	The structure of tryptophan 7-halogenase (PrnA) suggests a mechanism for regioselective chlorination
2ARD	;	2.6	;	The structure of tryptophan 7-halogenase (PrnA) suggests a mechanism for regioselective chlorination
2APG	;	1.9	;	The structure of tryptophan 7-halogenase (PrnA)suggests a mechanism for regioselective chlorination
2AR8	;	2.2	;	The structure of tryptophan 7-halogenase (PrnA)suggests a mechanism for regioselective chlorination
1IUJ	;	1.6	;	The structure of TT1380 protein from thermus thermophilus
1TNF	;	2.6	;	THE STRUCTURE OF TUMOR NECROSIS FACTOR-ALPHA AT 2.6 ANGSTROMS RESOLUTION. IMPLICATIONS FOR RECEPTOR BINDING
6GEL	;	2.51	;	The structure of TWITCH-2B
6GEZ	;	2.47	;	THE STRUCTURE OF TWITCH-2B N532F
1QFE	;	2.1	;	THE STRUCTURE OF TYPE I 3-DEHYDROQUINATE DEHYDRATASE FROM SALMONELLA TYPHI
5KMS	;	2.5	;	The structure of type II NADH dehydrogenase from Caldalkalibacillus thermarum complexed with NAD+ at 2.5 angstrom resolution.
5KMR	;	3.0	;	The structure of type II NADH dehydrogenase from Caldalkalibacillus thermarum complexed with NAD+ at 3.0 angstrom resolution.
1FFT	;	3.5	;	The structure of ubiquinol oxidase from Escherichia coli
3NIJ	;	2.1	;	The structure of UBR box (HIAA)
3NII	;	2.1	;	The structure of UBR box (KIAA)
3NIT	;	2.6	;	The structure of UBR box (native1)
3NIS	;	1.68	;	The structure of UBR box (native2)
3NIL	;	1.75	;	The structure of UBR box (RDAA)
3NIK	;	1.85	;	The structure of UBR box (REAA)
3NIH	;	2.1	;	The structure of UBR box (RIAAA)
3NIN	;	2.1	;	The structure of UBR box (RLGES)
3NIM	;	2.0	;	The structure of UBR box (RRAA)
6IOD	;	1.66	;	The structure of UdgX in complex with single-stranded DNA
6IOA	;	2.15	;	The structure of UdgX in complex with uracil
4NEQ	;	2.85	;	The structure of UDP-GlcNAc 2-epimerase from Methanocaldococcus jannaschii
7PPR	;	2.57	;	The structure of UDP-glucose pyrophosphorylase from Aspergillus fumigatus
1F6D	;	2.5	;	THE STRUCTURE OF UDP-N-ACETYLGLUCOSAMINE 2-EPIMERASE FROM E. COLI.
5JZK	;	1.9	;	The Structure of Ultra Stable Green Fluorescent Protein
3G5B	;	2.0	;	The structure of UNC5b cytoplasmic domain
3PF6	;	1.6	;	The structure of uncharacterized protein PP-LUZ7_gp033 from Pseudomonas phage LUZ7.
2NZC	;	1.95	;	The structure of uncharacterized protein TM1266 from Thermotoga maritima.
3F3K	;	1.75	;	The structure of uncharacterized protein YKR043C from Saccharomyces cerevisiae.
1HMV	;	3.2	;	THE STRUCTURE OF UNLIGANDED REVERSE TRANSCRIPTASE FROM THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
6L3F	;	1.975	;	The structure of UTP:RNA uridylyltransferase 1 (URT1) in in Arabidopsis
4HIQ	;	1.18	;	The Structure of V122I Mutant Transthyretin in Complex with AG10
4HIS	;	1.2	;	The Structure of V122I Mutant Transthyretin in Complex with Tafamidis
6W68	;	2.55	;	The structure of V98A S172A Keap1-BTB domain
4W5X	;	2.002	;	The structure of Vaccina virus H7 protein displays A Novel Phosphoinositide binding fold required for membrane biogenesis
4W60	;	2.7	;	The structure of Vaccina virus H7 protein displays A Novel Phosphoinositide binding fold required for membrane biogenesis
2VGA	;	1.9	;	The structure of Vaccinia virus A41
2UXE	;	2.9	;	The structure of Vaccinia virus N1
4BBB	;	3.09	;	THE STRUCTURE OF VACCINIA VIRUS N1 Q61Y MUTANT
4BBD	;	3.0	;	THE STRUCTURE OF VACCINIA VIRUS N1 R58Y MUTANT
4BBC	;	3.1	;	THE STRUCTURE OF VACCINIA VIRUS N1 R71Y MUTANT
4CYF	;	2.25	;	The structure of vanin-1: defining the link between metabolic disease, oxidative stress and inflammation
4CYG	;	2.3	;	The structure of vanin-1: defining the link between metabolic disease, oxidative stress and inflammation
4CYY	;	2.89	;	The structure of vanin-1: defining the link between metabolic disease, oxidative stress and inflammation
6RMS	;	1.74	;	The Structure of variant D274E of the Mo-insertase domain Cnx1E from Arabidopsis thaliana in complex with AMP
6GB0	;	1.814	;	The Structure of variant K294A of the Mo-insertase domain Cnx1E from Arabidopsis thaliana in complex with AMP
6GAX	;	1.77	;	The Structure of variant K294A of the Mo-insertase domain Cnx1E from Arabidopsis thaliana in complex with AMP and molybdate
6GBF	;	1.712	;	The Structure of variant R369A of the Mo-insertase domain Cnx1E from Arabidopsis thaliana in complex with AMP
6GBC	;	1.59	;	The Structure of variant R369A of the Mo-insertase domain Cnx1E from Arabidopsis thaliana in complex with AMP and molybdate
6GB9	;	1.67	;	The Structure of variant S328A of the Mo-insertase domain Cnx1E from Arabidopsis thaliana in complex with AMP
6GB4	;	1.648	;	The Structure of variant S328A of the Mo-insertase domain Cnx1E from Arabidopsis thaliana in complex with AMP and molybdate
4UHV	;	2.0	;	The structure of VgrG1, the needle tip of the bacterial Type VI Secretion System
5GLE	;	2.1	;	The structure of Vibrio anguillarum775 AngB-ICL
5CZC	;	1.8	;	The structure of VinK
5KIR	;	2.697	;	The Structure of Vioxx Bound to Human COX-2
2ZD7	;	1.85	;	The structure of VPS75 (Vacuolar protein sorting-associated protein 75)
1ASD	;	2.2	;	THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH N-MEPLP
1ASE	;	2.5	;	THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH PLP-N-OXIDE
6H0N	;	3.02	;	The structure of wild-type Arabidopsis thaliana UDP-apiose/UDP-xylose synthase in complex with NAD+ and UDP
2FZC	;	2.1	;	The Structure of Wild-Type E. Coli Aspartate Transcarbamoylase in Complex with Novel T State Inhibitors at 2.10 Resolution
2FZG	;	2.25	;	The Structure of Wild-Type E. Coli Aspartate Transcarbamoylase in Complex with Novel T State Inhibitors at 2.25 Resolution
2FZK	;	2.5	;	The Structure of Wild-Type E. Coli Aspartate Transcarbamoylase in Complex with Novel T State Inhibitors at 2.50 Resolution
2O23	;	1.2	;	The structure of wild-type human HADH2 (17beta-hydroxysteroid dehydrogenase type 10) bound to NAD+ at 1.2 A
4M56	;	2.3	;	The Structure of Wild-type MalL from Bacillus subtilis
4MU0	;	1.3	;	The structure of wt A. thaliana IGPD2 in complex with Mn2+ and 1,2,4-triazole at 1.3 A resolution
4QNJ	;	1.3	;	The structure of wt A. thaliana IGPD2 in complex with Mn2+ and formate at 1.3A resolution
4QNK	;	1.75	;	The structure of wt A. thaliana IGPD2 in complex with Mn2+ and phosphate
4MU1	;	1.5	;	The structure of wt A. thaliana IGPD2 in complex with Mn2+, imidazole, and sulfate at 1.5 A resolution
5GNY	;	2.105	;	The structure of WT Bgl6
2J58	;	2.25	;	The structure of Wza
2EG5	;	2.2	;	The structure of xanthosine methyltransferase
2C1W	;	2.2	;	The structure of XendoU: a splicing independent snoRNA processing endoribonuclease
1JEZ	;	2.2	;	THE STRUCTURE OF XYLOSE REDUCTASE, A DIMERIC ALDO-KETO REDUCTASE FROM CANDIDA TENUIS
6CI7	;	2.3	;	The structure of YcaO from Methanopyrus kandleri bound with AMPPCP and Mg2+
6CIB	;	2.05	;	The structure of YcaO from Methanopyrus kandleri bound with AMPPCP and Mg2+
3M92	;	2.05	;	The structure of yciN, an unchracterized protein from Shigella flexneri.
1K39	;	3.29	;	The structure of yeast delta3-delta2-enoyl-COA isomerase complexed with octanoyl-COA
3PGK	;	2.5	;	The structure of yeast phosphoglycerate kinase at 0.25 nm resolution
3PGM	;	2.8	;	THE STRUCTURE OF YEAST PHOSPHOGLYCERATE MUTASE AT 0.28 NM RESOLUTION
1R6F	;	2.17	;	The structure of Yersinia pestis V-antigen, an essential virulence factor and mediator of immunity against plague
7CUA	;	1.8	;	The structure of YoeB dimer from Staphylococcus aureus
7XH8	;	2.99	;	The structure of ZCB11 Fab against SARS-CoV-2 Omicron Spike
8H55	;	2.03	;	The structure of zebrafish angiotensinogen
6A5F	;	2.05	;	The structure of [4+2] and [6+4] cyclase in the biosynthetic pathway of nargenicin
6A5G	;	2.3	;	The structure of [4+2] and [6+4] cyclase in the biosynthetic pathway of streptoseomycin
6A5H	;	1.618	;	The structure of [4+2] and [6+4] cyclase in the biosynthetic pathway of unidentified natural product
1V1P	;	2.7	;	The structure SSL from Staphylococcus Aureus from an orthorhombic crystal form
8BFW	;	2.33	;	The structures of Ace2 in complex with bicyclic peptide inhibitor
8BN1	;	2.61	;	The structures of Ace2 in complex with bicyclic peptide inhibitor
8BYJ	;	2.07	;	The structures of Ace2 in complex with bicyclic peptide inhibitor
2PMD	;	2.65	;	The structures of aIF2gamma subunit from the archaeon Sulfolobus solfataricus in the GDP-bound form.
2PRH	;	2.4	;	The structures of apo- and inhibitor bound human dihydroorotate dehydrogenase reveal conformational flexibility within the inhibitor binding site
2PRL	;	2.1	;	The structures of apo- and inhibitor bound human dihydroorotate dehydrogenase reveal conformational flexibility within the inhibitor binding site
2PRM	;	3.0	;	The structures of apo- and inhibitor bound human dihydroorotate dehydrogenase reveal conformational flexibility within the inhibitor binding site
4V7M	;	3.45	;	The structures of Capreomycin bound to the 70S ribosome.
2B1E	;	2.0	;	The structures of exocyst subunit Exo70p and the Exo84p C-terminal domains reveal a common motif
1P5W	;	3.3	;	The structures of host range controlling regions of the capsids of canine and feline parvoviruses and mutants
1P5Y	;	3.2	;	The structures of host range controlling regions of the capsids of canine and feline parvoviruses and mutants
2HMQ	;	1.66	;	THE STRUCTURES OF MET AND AZIDOMET HEMERYTHRIN AT 1.66 ANGSTROMS RESOLUTION
2HMZ	;	1.66	;	THE STRUCTURES OF MET AND AZIDOMET HEMERYTHRIN AT 1.66 ANGSTROMS RESOLUTION
2IUF	;	1.71	;	The structures of Penicillium vitale catalase: resting state, oxidised state (compound I) and complex with aminotriazole
1RPF	;	2.2	;	THE STRUCTURES OF RNASE COMPLEXED WITH 3'-CMP AND D(CPA): ACTIVE SITE CONFORMATION AND CONSERVED WATER MOLECULES
2SIL	;	1.6	;	THE STRUCTURES OF SALMONELLA TYPHIMURIUM LT2 NEURAMINIDASE AND ITS COMPLEX WITH A TRANSITION STATE ANALOGUE AT 1.6 ANGSTROMS RESOLUTION
2SIM	;	1.6	;	THE STRUCTURES OF SALMONELLA TYPHIMURIUM LT2 NEURAMINIDASE AND ITS COMPLEX WITH A TRANSITION STATE ANALOGUE AT 1.6 ANGSTROMS RESOLUTION
1LZH	;	6.0	;	THE STRUCTURES OF THE MONOCLINIC AND ORTHORHOMBIC FORMS OF HEN EGG-WHITE LYSOZYME AT 6 ANGSTROMS RESOLUTION.
2LZH	;	6.0	;	THE STRUCTURES OF THE MONOCLINIC AND ORTHORHOMBIC FORMS OF HEN EGG-WHITE LYSOZYME AT 6 ANGSTROMS RESOLUTION.
2EVK	;	1.4	;	The Structures of Thiolate- and Carboxylate-Ligated Ferric H93G Myoglobin: Models for Cytochrome P450 and for Oxyanion-Bound Heme Proteins
2EVP	;	1.7	;	The Structures of Thiolate- and Carboxylate-Ligated Ferric H93G Myoglobin: Models for Cytochrome P450 and for Oxyanion-Bound Heme Proteins
1THU	;	2.6	;	THE STRUCTURES OF THREE CRYSTAL FORMS OF THE SWEET PROTEIN THAUMATIN
1THV	;	1.75	;	THE STRUCTURES OF THREE CRYSTAL FORMS OF THE SWEET PROTEIN THAUMATIN
1THW	;	1.75	;	THE STRUCTURES OF THREE CRYSTAL FORMS OF THE SWEET PROTEIN THAUMATIN
4V7L	;	3.0	;	The structures of viomycin bound to the 70S ribosome.
8AE7	;	1.28	;	The strucuture of Compound 15 bound to CK2alpha
1YMR	;	1.5	;	The study of reductive unfolding pathways of RNase A (Y92A mutant)
1YMW	;	1.5	;	The study of reductive unfolding pathways of RNase A (Y92G mutant)
1YMN	;	1.45	;	The study of reductive unfolding pathways of RNase A (Y92L mutant)
5MEW	;	1.35	;	The study of the X-ray induced enzymatic reduction of molecular oxygen to water for laccase from Steccherinum murashkinskyi. Second structure of the series with total exposition time 33 min.
5MI2	;	1.35	;	The study of the X-ray induced enzymatic reduction of molecular oxygen to water for laccase from Steccherinum murashkinskyi.The 10-th structure of the series with total exposition time 273 min.
5MIA	;	1.35	;	The study of the X-ray induced enzymatic reduction of molecular oxygen to water for laccase from Steccherinum murashkinskyi.The 11-th structure of the series with total exposition time 303 min.
5MIB	;	1.35	;	The study of the X-ray induced enzymatic reduction of molecular oxygen to water for laccase from Steccherinum murashkinskyi.The 12-th structure of the series with total exposition time 333 min.
5MIC	;	1.35	;	The study of the X-ray induced enzymatic reduction of molecular oxygen to water for laccase from Steccherinum murashkinskyi.The 13-th structure of the series with total exposition time 363 min.
5MID	;	1.35	;	The study of the X-ray induced enzymatic reduction of molecular oxygen to water for laccase from Steccherinum murashkinskyi.The 14-th structure of the series with total exposition time 393 min.
5MIE	;	1.35	;	The study of the X-ray induced enzymatic reduction of molecular oxygen to water for laccase from Steccherinum murashkinskyi.The 15-th structure of the series with total exposition time 423 min.
5MIG	;	1.35	;	The study of the X-ray induced enzymatic reduction of molecular oxygen to water for laccase from Steccherinum murashkinskyi.The 16-th structure of the series with total exposition time 453 min. The crystal was quick refreezing before this data collection.
5MHZ	;	1.35	;	The study of the X-ray induced enzymatic reduction of molecular oxygen to water for laccase from Steccherinum murashkinskyi.The 8-th structure of the series with total exposition time 213 min.
5MI1	;	1.35	;	The study of the X-ray induced enzymatic reduction of molecular oxygen to water for laccase from Steccherinum murashkinskyi.The 9-th structure of the series with total exposition time 243 min.
5MHW	;	1.35	;	The study of the X-ray induced enzymatic reduction of molecular oxygen to water for laccase from Steccherinum murashkinskyi.The fifth structure of the series with total exposition time 123 min.
5MHV	;	1.35	;	The study of the X-ray induced enzymatic reduction of molecular oxygen to water for laccase from Steccherinum murashkinskyi.The fourth structure of the series with total exposition time 93 min.
5MHY	;	1.35	;	The study of the X-ray induced enzymatic reduction of molecular oxygen to water for laccase from Steccherinum murashkinskyi.The seventh structure of the series with total exposition time 183 min.
5MHX	;	1.35	;	The study of the X-ray induced enzymatic reduction of molecular oxygen to water for laccase from Steccherinum murashkinskyi.The sixth structure of the series with total exposition time 153 min.
5MHU	;	1.35	;	The study of the X-ray induced enzymatic reduction of molecular oxygen to water for laccase from Steccherinum murashkinskyi.The third structure of the series with total exposition time 63 min.
8IPW	;	2.35	;	The sturecture of Legionella effector protein MavL with ADPR
1DKZ	;	2.0	;	THE SUBSTRATE BINDING DOMAIN OF DNAK IN COMPLEX WITH A SUBSTRATE PEPTIDE, DETERMINED FROM TYPE 1 NATIVE CRYSTALS
1DKX	;	2.0	;	THE SUBSTRATE BINDING DOMAIN OF DNAK IN COMPLEX WITH A SUBSTRATE PEPTIDE, DETERMINED FROM TYPE 1 SELENOMETHIONYL CRYSTALS
1DKY	;	2.8	;	THE SUBSTRATE BINDING DOMAIN OF DNAK IN COMPLEX WITH A SUBSTRATE PEPTIDE, DETERMINED FROM TYPE 2 NATIVE CRYSTALS
5HI0	;	2.602	;	The Substrate Binding Mode and Chemical Basis of a Reaction Specificity Switch in Oxalate Decarboxylase
2DE7	;	2.0	;	The substrate-bound complex between oxygenase and ferredoxin in carbazole 1,9a-dioxygenase
6D9R	;	1.64	;	The substrate-bound crystal structure of HPRT (hypoxanthine phosphoribosyltransferase)
4WO8	;	2.2	;	The substrate-free duplicated taurocyamine kinase from Schistosoma mansoni
6LPH	;	1.91	;	the Sufu-Fu complex crystal structure
6DDN	;	2.295	;	The sulfate-binding protein SubI from Mycobacterium tuberculosis H37Rv
6D9Q	;	2.056	;	The sulfate-bound crystal structure of HPRT (hypoxanthine phosphoribosyltransferase)
1NST	;	2.3	;	THE SULFOTRANSFERASE DOMAIN OF HUMAN HAPARIN SULFATE N-DEACETYLASE/N-SULFOTRANSFERASE
1W3B	;	2.85	;	The superhelical TPR domain of O-linked GlcNAc transferase reveals structural similarities to importin alpha.
5HSQ	;	1.85	;	The surface engineered photosensory module (PAS-GAF-PHY) of the bacterial phytochrome Agp1 (AtBphP1) in the Pr form, chromophore modelled with an endocyclic double bond in pyrrole ring A.
8CO5	;	2.42	;	The surface-engineered photosensory module (PAS-GAF-PHY) of the bacterial phytochrome Agp1 (AtBphP1) in the Pr form with parallel dimer formation
8BAI	;	1.69	;	The surface-exposed lipo-protein of BtuG2 in complex with cyanocobalamin.
8BAZ	;	2.0	;	The surface-exposed lipo-protein of BtuG2 in complex with cyanocobalamin.
8BB0	;	1.5	;	The surface-exposed lipo-protein of BtuG2 in complex with hydroxycobalamin.
6JFI	;	11.0	;	The symmetric-reconstructed cryo-EM structure of Zika virus-FabZK2B10 complex
7TNQ	;	8.4	;	The symmetry-released subpellicular microtubule map from detergent-extracted Toxoplasma cells
3ZO1	;	2.0	;	The Synthesis and Evaluation of Diazaspirocyclic Protein Kinase Inhibitors
3ZO2	;	1.98	;	The Synthesis and Evaluation of Diazaspirocyclic Protein Kinase Inhibitors
3ZO3	;	2.1	;	The Synthesis and Evaluation of Diazaspirocyclic Protein Kinase Inhibitors
3ZO4	;	1.65	;	The Synthesis and Evaluation of Diazaspirocyclic Protein Kinase Inhibitors
6C0M	;	1.83	;	The synthesis, biological evaluation and structural insights of unsaturated 3-N-substituted sialic acids as probes of human parainfluenza virus-3 haemagglutinin-neuraminidase
1FSA	;	2.3	;	THE T-STATE STRUCTURE OF LYS 42 TO ALA MUTANT OF THE PIG KIDNEY FRUCTOSE 1,6-BISPHOSPHATASE EXPRESSED IN E. COLI
1XXT	;	1.91	;	The T-to-T High Transitions in Human Hemoglobin: wild-type deoxy Hb A (low salt, one test set)
2J2F	;	2.65	;	The T199D Mutant of Stearoyl Acyl Carrier Protein Desaturase from Ricinus Communis (Castor Bean)
7QAC	;	2.29	;	The T2 structure of polycrystalline cubic human insulin
2EWK	;	1.0	;	The T24V mutant of tetraheme cytochrome c3 from Desulfovibrio Vulgaris Miyazaki F
4P0D	;	1.9	;	The T6 backbone pilin of serotype M6 Streptococcus pyogenes has a modular three-domain structure decorated with variable loops and extensions
7MWL	;	1.84	;	The TAM domain of BAZ2A in complex with a 12mer mCG DNA
7Q63	;	1.9	;	The tandem SH2 domains of SYK
7Q5U	;	2.4	;	The tandem SH2 domains of SYK with a bound CD3G diphospho-ITAM peptide
7Q5T	;	2.2	;	The tandem SH2 domains of SYK with a bound FCER1G diphospho-ITAM peptide
7Q5W	;	2.2	;	The tandem SH2 domains of SYK with a bound TYROBP diphospho-ITAM peptide
1MV2	;		;	The tandem, Face-to-Face AP Pairs in 5'(rGGCAPGCCU)2
1MV1	;		;	The Tandem, Sheared PA Pairs in 5'(rGGCPAGCCU)2
1MV6	;		;	The tandem, Sheared PP Pairs in 5'(rGGCPPGCCU)2
2J04	;	3.2	;	The tau60-tau91 subcomplex of yeast transcription factor IIIC
7D31	;	1.396	;	The TBA-Pb2+ complex in P41212 space group
7D32	;	1.707	;	The TBA-Pb2+ complex in P41212 space group
7N3R	;	2.25	;	The ternary complex of human Bisphosphoglycerate mutase with 3-phosphoglycerate and 2-phosphoglycolate
2X68	;	2.13	;	The ternary complex of PrnB (the second enzyme in pyrrolnitrin biosynthesis pathway), 7-Cl-L-tryptophan and cyanide
2X67	;	2.16	;	The ternary complex of PrnB (the second enzyme in pyrrolnitrin biosynthesis pathway), tryptophan and cyanide
1LLU	;	2.3	;	THE TERNARY COMPLEX OF PSEUDOMONAS AERUGINOSA ALCOHOL DEHYDROGENASE WITH ITS COENZYME AND WEAK SUBSTRATE
8U17	;	3.1	;	The ternary complex structure of DDB1-CRBN-SALL4(ZF1,2)-long bound to Pomalidomide
8U15	;	2.95	;	The ternary complex structure of DDB1-CRBN-SALL4(ZF1,2)-short bound to CC-220
8U16	;	2.9	;	The ternary complex structure of DDB1-CRBN-SALL4(ZF1,2)-short bound to Pomalidomide
7WSB	;	2.87	;	The ternary complex structure of FtmOx1 with a-ketoglutarate and 13-oxo-fumitremorgin B
3MOP	;	3.4	;	The ternary Death Domain complex of MyD88, IRAK4, and IRAK2
5Z21	;	2.3	;	The ternary structure of D-lactate dehydrogenase from Fusobacterium nucleatum with NADH and oxamate
5Z20	;	2.2	;	The ternary structure of D-lactate dehydrogenase from Pseudomonas aeruginosa with NADH and oxamate
5X20	;	2.4	;	The ternary structure of D-mandelate dehydrogenase with NADH and anilino(oxo)acetate
1U0N	;	2.95	;	The ternary von Willebrand Factor A1-glycoprotein Ibalpha-botrocetin complex
8I7N	;	2.98	;	The Tet-S1 state of G264A mutated Tetrahymena group I intron with 6nt 3'/5'-exon and 2-aminopurine nucleoside
7XD5	;	2.84	;	The Tet-S2 state of wild-type Tetrahymena group I intron with 30nt 3'/5'-exon
7XD6	;	2.84	;	The Tet-S2 state with a pseudoknotted 4-way junction of wild-type Tetrahymena group I intron with 30nt 3'/5'-exon
5G56	;	2.64	;	THE TETRA-MODULAR CELLULOSOMAL ARABINOXYLANASE CtXyl5A STRUCTURE AS REVEALED BY X-RAY CRYSTALLOGRAPHY
1WQ6	;	2.0	;	The tetramer structure of the nervy homolgy two (NHR2) domain of AML1-ETO is critical for AML1-ETO'S activity
8HZ4	;	3.2	;	The tetrameric structure of biotin carboxylase from Chloroflexus aurantiacus in complex with bicarbonate
7AVR	;	2.0	;	The tetrameric structure of haloalkane dehalogenase DpaA from Paraglaciecola agarilytica NO2
2KBY	;		;	The Tetramerization Domain of Human p73
6AVQ	;	35.0	;	The Therapeutic Antibody LM609 Selectively Inhibits Ligand Binding to Human alpha-V beta-3 Integrin via Steric Hindrance
3DF6	;	2.05	;	The thermo- and acido-stable ORF-99 from the archaeal virus AFV1
3DJW	;	3.1	;	The thermo- and acido-stable ORF-99 from the archaeal virus AFV1
8JPZ	;	2.08	;	The thermostability mutant Gox_M8 from Aspergillus niger
5OT0	;	2.18	;	The thermostable L-asparaginase from Thermococcus kodakarensis
1GTL	;	2.8	;	The thermostable serine-carboxyl type proteinase, kumamolisin (KSCP) - complex with Ac-Ile-Pro-Phe-cho
7WIE	;	2.9	;	The THF-II riboswitch bound to 7DG
7WIF	;	2.86	;	The THF-II riboswitch bound to H4B
7WII	;	2.75	;	The THF-II riboswitch bound to NPR
7WIB	;	2.83	;	The THF-II riboswitch bound to THF
7WI9	;	2.98	;	The THF-II riboswitch bound to THF and soaking with SeUrea
3ILS	;	1.7	;	The Thioesterase Domain from PksA
3KP8	;	1.66	;	The thioredoxin-like domain of a VKOR homolog from Synechococcus sp.
3ITE	;	2.0	;	The third adenylation domain of the fungal SidN non-ribosomal peptide synthetase
1WF6	;		;	The third BRCA1 C-terminus (BRCT) domain of Similar to S.pombe rad4+/cut5+ product
3P4K	;	2.304	;	The third conformation of p38a MAP kinase observed in phosphorylated p38a and in solution
2JRV	;		;	The third dimensional structure of mab198-bound pep.1 for autoimmune myasthenia gravis
1J7M	;		;	The Third Fibronectin Type II Module from Human Matrix Metalloproteinase 2
1IGD	;	1.1	;	THE THIRD IGG-BINDING DOMAIN FROM STREPTOCOCCAL PROTEIN G: AN ANALYSIS BY X-RAY CRYSTALLOGRAPHY OF THE STRUCTURE ALONE AND IN A COMPLEX WITH FAB
4B6V	;		;	The third member of the eIF4E family represses gene expression via a novel mode of recognition of the methyl-7 guanosine cap moiety
1BFE	;	2.3	;	THE THIRD PDZ DOMAIN FROM THE SYNAPTIC PROTEIN PSD-95
5HDY	;	1.801	;	The third PDZ domain from the synaptic protein PSD-95
5HET	;	2.001	;	The third PDZ domain from the synaptic protein PSD-95 (G330T mutant)
5HEY	;	1.5	;	The third PDZ domain from the synaptic protein PSD-95 (G330T mutant) in complex with a C-terminal peptide derived from CRIPT
5HF1	;	1.747	;	The third PDZ domain from the synaptic protein PSD-95 (G330T mutant) in complex with a mutant C-terminal peptide derived from CRIPT (T-2F)
5HFD	;	1.6	;	The third PDZ domain from the synaptic protein PSD-95 (G330T, H372A double mutant)
5HFE	;	1.8	;	The third PDZ domain from the synaptic protein PSD-95 (G330T, H372A double mutant) in complex with a C-terminal peptide derived from CRIPT
5HFF	;	1.749	;	The third PDZ domain from the synaptic protein PSD-95 (G330T, H372A double mutant) in complex with a mutant C-terminal peptide derived from CRIPT (T-2F)
5HF4	;	1.75	;	The third PDZ domain from the synaptic protein PSD-95 (H372A mutant)
5HFB	;	1.616	;	The third PDZ domain from the synaptic protein PSD-95 (H372A mutant) in complex with a C-terminal peptide derived from CRIPT
5HFC	;	1.851	;	The third PDZ domain from the synaptic protein PSD-95 (H372A mutant) in complex with a mutant C-terminal peptide derived from CRIPT (T-2F)
5HEB	;	1.65	;	The third PDZ domain from the synaptic protein PSD-95 in complex with a C-terminal peptide derived from CRIPT
1BE9	;	1.82	;	THE THIRD PDZ DOMAIN FROM THE SYNAPTIC PROTEIN PSD-95 IN COMPLEX WITH A C-TERMINAL PEPTIDE DERIVED FROM CRIPT.
5HED	;	1.7	;	The third PDZ domain from the synaptic protein PSD-95 in complex with a mutant C-terminal peptide derived from CRIPT (T-2F)
7PC5	;	1.7	;	The third PDZ domain of PDZD7 complexed with the PDZ-binding motif of EXOC4
3KCI	;	1.8	;	The third RLD domain of HERC2
2LJ0	;		;	The third SH3 domain of R85FL
2LJ1	;		;	The third SH3 domain of R85FL with ataxin-7 PRR
1C9K	;	2.2	;	THE THREE DIMENSIONAL STRUCTURE OF ADENOSYLCOBINAMIDE KINASE/ ADENOSYLCOBINAMIDE PHOSPHATE GUALYLYLTRANSFERASE (COBU) COMPLEXED WITH GMP: EVIDENCE FOR A SUBSTRATE INDUCED TRANSFERASE ACTIVE SITE
2O0T	;	2.33	;	The three dimensional structure of diaminopimelate decarboxylase from Mycobacterium tuberculosis reveals a tetrameric enzyme organisation
1RCK	;		;	THE THREE DIMENSIONAL STRUCTURE OF GUANINE-SPECIFIC RIBONUCLEASE F1 IN SOLUTION DETERMINED BY NMR SPECTROSCOPY AND DISTANCE GEOMETRY
1RCL	;		;	THE THREE DIMENSIONAL STRUCTURE OF GUANINE-SPECIFIC RIBONUCLEASE F1 IN SOLUTION DETERMINED BY NMR SPECTROSCOPY AND DISTANCE GEOMETRY
1QZ9	;	1.85	;	The Three Dimensional Structure of Kynureninase from Pseudomonas fluorescens
1HKF	;	2.2	;	The three dimensional structure of NK cell receptor Nkp44, a triggering partner in natural cytotoxicity
2RLU	;		;	The Three Dimensional Structure of the Moorella thermoacetica Selenocysteine Insertion Sequence RNA Hairpin and its Interaction with the Elongation factor SelB
1PIH	;		;	THE THREE DIMENSIONAL STRUCTURE OF THE PARAMAGNETIC PROTEIN HIPIP I FROM E.HALOPHILA THROUGH NUCLEAR MAGNETIC RESONANCE
1PIJ	;		;	THE THREE DIMENSIONAL STRUCTURE OF THE PARAMAGNETIC PROTEIN HIPIP I FROM E.HALOPHILA THROUGH NUCLEAR MAGNETIC RESONANCE
1HRR	;		;	THE THREE DIMENSIONAL STRUCTURE OF THE REDUCED HIGH POTENTIAL IRON-SULFUR PROTEIN FROM CHROMATIUM VINOSUM THROUGH NMR
2LZ2	;	2.2	;	THE THREE DIMENSIONAL STRUCTURE OF TURKEY EGG WHITE LYSOZYME AT 2.2 ANGSTROMS RESOLUTION
1CEL	;	1.8	;	THE THREE-DIMENSIONAL CRYSTAL STRUCTURE OF THE CATALYTIC CORE OF CELLOBIOHYDROLASE I FROM TRICHODERMA REESEI
1DMD	;		;	THE THREE-DIMENSIONAL SOLUTION STRUCTURE OF CALLINECTES SAPIDUS METALLOTHIONEIN-I DETERMINED BY HOMONUCLEAR AND HETERONUCLEAR MAGNETIC RESONANCE SPECTOSCOPY
1DME	;		;	THE THREE-DIMENSIONAL SOLUTION STRUCTURE OF CALLINECTES SAPIDUS METALLOTHIONEIN-I DETERMINED BY HOMONUCLEAR AND HETERONUCLEAR MAGNETIC RESONANCE SPECTOSCOPY
1DMF	;		;	THE THREE-DIMENSIONAL SOLUTION STRUCTURE OF CALLINECTES SAPIDUS METALLOTHIONEIN-I DETERMINED BY HOMONUCLEAR AND HETERONUCLEAR MAGNETIC RESONANCE SPECTOSCOPY
1DMC	;		;	THE THREE-DIMENSIONAL SOLUTION STRUCTURE OF CALLINECTES SAPIDUS METALLOTHIONEIN-I DETERMINED BY HOMONUCLEAR AND HETERONUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
1PSE	;		;	THE THREE-DIMENSIONAL SOLUTION STRUCTURE OF PSAE FROM THE CYANOBACTERIUM SYNECHOCOCCUS SP. STRAIN PCC 7002: A PHOTOSYSTEM I PROTEIN THAT SHOWS STRUCTURAL HOMOLOGY WITH SH3 DOMAINS
1PSF	;		;	THE THREE-DIMENSIONAL SOLUTION STRUCTURE OF PSAE FROM THE CYANOBACTERIUM SYNECHOCOCCUS SP. STRAIN PCC 7002: A PHOTOSYSTEM I PROTEIN THAT SHOWS STRUCTURAL HOMOLOGY WITH SH3 DOMAINS
1EWS	;		;	THE THREE-DIMENSIONAL SOLUTION STRUCTURE OF THE RABBIT KIDNEY DEFENSIN, RK-1
1HRQ	;		;	THE THREE-DIMENSIONAL SOLUTION STRUCTURE OF THE REDUCED HIGH-POTENTIAL IRON-SULFUR PROTEIN FROM CHROMATIUM VINOSUM THROUGH NMR
1FHS	;		;	THE THREE-DIMENSIONAL SOLUTION STRUCTURE OF THE SRC HOMOLOGY DOMAIN-2 OF THE GROWTH FACTOR RECEPTOR BOUND PROTEIN-2, NMR, 18 STRUCTURES
1SGL	;	2.2	;	The three-dimensional structure and X-ray sequence reveal that trichomaglin is a novel S-like ribonuclease
1PBG	;	2.3	;	THE THREE-DIMENSIONAL STRUCTURE OF 6-PHOSPHO-BETA GALACTOSIDASE FROM LACTOCOCCUS LACTIS
1TMC	;	2.3	;	THE THREE-DIMENSIONAL STRUCTURE OF A CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE MISSING THE ALPHA3 DOMAIN OF THE HEAVY CHAIN
1A57	;		;	THE THREE-DIMENSIONAL STRUCTURE OF A HELIX-LESS VARIANT OF INTESTINAL FATTY ACID BINDING PROTEIN, NMR, 20 STRUCTURES
2ABD	;		;	THE THREE-DIMENSIONAL STRUCTURE OF ACYL-COENZYME A BINDING PROTEIN FROM BOVINE LIVER. STRUCTURAL REFINEMENT USING HETERONUCLEAR MULTIDIMENSIONAL NMR SPECTROSCOPY
1LK9	;	1.53	;	The Three-dimensional Structure of Alliinase from Garlic
1ETZ	;	2.6	;	THE THREE-DIMENSIONAL STRUCTURE OF AN ANTI-SWEETENER FAB, NC10.14, SHOWS THE EXTENT OF STRUCTURAL DIVERSITY IN ANTIGEN RECOGNITION BY IMMUNOGLOBULINS
2SBL	;	2.6	;	THE THREE-DIMENSIONAL STRUCTURE OF AN ARACHIDONIC ACID 15-LIPOXYGENASE
1MOE	;	2.6	;	The three-dimensional structure of an engineered scFv T84.66 dimer or diabody in VL to VH linkage.
1LD9	;	2.4	;	THE THREE-DIMENSIONAL STRUCTURE OF AN H-2LD PEPTIDE COMPLEX EXPLAINS THE UNIQUE INTERACTION OF LD WITH BETA2M AND PEPTIDE
1TRM	;	2.3	;	THE THREE-DIMENSIONAL STRUCTURE OF ASN102 MUTANT OF TRYPSIN. ROLE OF ASP102 IN SERINE PROTEASE CATALYSIS
2TRM	;	2.8	;	THE THREE-DIMENSIONAL STRUCTURE OF ASN102 MUTANT OF TRYPSIN. ROLE OF ASP102 IN SERINE PROTEASE CATALYSIS
1G5R	;	2.1	;	THE THREE-DIMENSIONAL STRUCTURE OF ATP:CORRINOID ADENOSYLTRANSFERASE FROM SALMONELLA TYPHIMURIUM. APO FORM
1G5T	;	1.8	;	THE THREE-DIMENSIONAL STRUCTURE OF ATP:CORRINOID ADENOSYLTRANSFERASE FROM SALMONELLA TYPHIMURIUM. APO-ATP FORM
1G64	;	2.1	;	THE THREE-DIMENSIONAL STRUCTURE OF ATP:CORRINOID ADENOSYLTRANSFERASE FROM SALMONELLA TYPHIMURIUM. COBALAMIN/ATP TERNARY COMPLEX
1ST2	;	2.0	;	THE THREE-DIMENSIONAL STRUCTURE OF BACILLUS AMYLOLIQUEFACIENS SUBTILISIN AT 1.8 ANGSTROMS AND AN ANALYSIS OF THE STRUCTURAL CONSEQUENCES OF PEROXIDE INACTIVATION
2ST1	;	1.8	;	THE THREE-DIMENSIONAL STRUCTURE OF BACILLUS AMYLOLIQUEFACIENS SUBTILISIN AT 1.8 ANGSTROMS AND AN ANALYSIS OF THE STRUCTURAL CONSEQUENCES OF PEROXIDE INACTIVATION
1O4Y	;	1.48	;	THE THREE-DIMENSIONAL STRUCTURE OF BETA-AGARASE A FROM ZOBELLIA GALACTANIVORANS
1O4Z	;	2.3	;	THE THREE-DIMENSIONAL STRUCTURE OF BETA-AGARASE B FROM ZOBELLIA GALACTANIVORANS
1UYP	;	1.9	;	The three-dimensional structure of beta-fructosidase (invertase) from Thermotoga maritima
3DSL	;	2.7	;	The Three-dimensional Structure of Bothropasin, the Main Hemorrhagic Factor from Bothrops jararaca venom.
1PLF	;	2.2	;	THE THREE-DIMENSIONAL STRUCTURE OF BOVINE PLATELET FACTOR 4 AT 3.0 ANGSTROMS RESOLUTION
1A03	;		;	THE THREE-DIMENSIONAL STRUCTURE OF CA2+-BOUND CALCYCLIN: IMPLICATIONS FOR CA2+-SIGNAL TRANSDUCTION BY S100 PROTEINS, NMR, 20 STRUCTURES
1CAV	;	2.6	;	THE THREE-DIMENSIONAL STRUCTURE OF CANAVALIN FROM JACK BEAN (CANAVALIA ENSIFORMIS)
1H6J	;	2.32	;	The three-dimensional structure of capsule-specific CMP:2-keto-3-deoxy-manno-octonic acid synthetase from Escherichia coli
5EPO	;	2.0	;	The three-dimensional structure of Clostridium absonum 7alpha-hydroxysteroid dehydrogenase
1NG0	;	2.7	;	The three-dimensional structure of Cocksfoot mottle virus at 2.7A resolution
8GQQ	;	1.069	;	The three-dimensional structure of Cystatin A2, a cysteine protease inhibitor from Dictyostelium discoideum
1GNE	;	2.5	;	THE THREE-DIMENSIONAL STRUCTURE OF GLUTATHIONE S-TRANSFERASE OF SCHISTOSOMA JAPONICUM FUSED WITH A CONSERVED NEUTRALIZING EPITOPE ON GP41 OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
1HOC	;	2.4	;	THE THREE-DIMENSIONAL STRUCTURE OF H-2DB AT 2.4 ANGSTROMS RESOLUTION: IMPLICATIONS FOR ANTIGEN-DETERMINANT SELECTION
1HSA	;	2.1	;	THE THREE-DIMENSIONAL STRUCTURE OF HLA-B27 AT 2.1 ANGSTROMS RESOLUTION SUGGESTS A GENERAL MECHANISM FOR TIGHT PEPTIDE BINDING TO MHC
1E8A	;	1.95	;	The three-dimensional structure of human S100A12
1MHU	;		;	THE THREE-DIMENSIONAL STRUCTURE OF HUMAN [113CD7] METALLOTHIONEIN-2 IN SOLUTION DETERMINED BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
2MHU	;		;	THE THREE-DIMENSIONAL STRUCTURE OF HUMAN [113CD7] METALLOTHIONEIN-2 IN SOLUTION DETERMINED BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
1XVL	;	2.9	;	The three-dimensional structure of MntC from Synechocystis 6803
1NAL	;	2.2	;	THE THREE-DIMENSIONAL STRUCTURE OF N-ACETYLNEURAMINATE LYASE FROM ESCHERICHIA COLI
2O0R	;	2.0	;	The three-dimensional structure of N-Succinyldiaminopimelate aminotransferase from Mycobacterium tuberculosis
1GHL	;	2.1	;	THE THREE-DIMENSIONAL STRUCTURE OF PHEASANT AND GUINEA-FOWL EGG LYSOZYMES
1HHL	;	1.9	;	THE THREE-DIMENSIONAL STRUCTURE OF PHEASANT AND GUINEA-FOWL EGG LYSOZYMES
1PGS	;	1.8	;	THE THREE-DIMENSIONAL STRUCTURE OF PNGASE F, A GLYCOSYLASPARAGINASE FROM FLAVOBACTERIUM MENINGOSEPTICUM
1CMS	;	2.3	;	THE THREE-DIMENSIONAL STRUCTURE OF RECOMBINANT BOVINE CHYMOSIN AT 2.3 ANGSTROMS RESOLUTION
1SHK	;	1.9	;	THE THREE-DIMENSIONAL STRUCTURE OF SHIKIMATE KINASE FROM ERWINIA CHRYSANTHEMI
2SHK	;	2.6	;	THE THREE-DIMENSIONAL STRUCTURE OF SHIKIMATE KINASE FROM ERWINIA CHRYSANTHEMI COMPLEXED WITH ADP
2ASR	;	2.3	;	THE THREE-DIMENSIONAL STRUCTURE OF THE ASPARTATE RECEPTOR FROM ESCHERICHIA COLI
1HHP	;	2.7	;	THE THREE-DIMENSIONAL STRUCTURE OF THE ASPARTYL PROTEASE FROM THE HIV-1 ISOLATE BRU
1JJR	;		;	The Three-Dimensional Structure of the C-terminal DNA Binding Domain of Human Ku70
2AK3	;	1.85	;	THE THREE-DIMENSIONAL STRUCTURE OF THE COMPLEX BETWEEN MITOCHONDRIAL MATRIX ADENYLATE KINASE AND ITS SUBSTRATE AMP AT 1.85 ANGSTROMS RESOLUTION
1P90	;	1.8	;	The Three-dimensional Structure of the Core Domain of NafY from Azotobacter vinelandii determined at 1.8 resolution
2VMA	;	1.9	;	The three-dimensional structure of the cytoplasmic domains of EpsF from the Type 2 Secretion System of Vibrio cholerae
2VMB	;	1.95	;	The three-dimensional structure of the cytoplasmic domains of EpsF from the Type 2 Secretion System of Vibrio cholerae
3C1Q	;	1.7	;	The three-dimensional structure of the cytoplasmic domains of EpsF from the Type 2 Secretion System of Vibrio cholerae
1IXA	;		;	THE THREE-DIMENSIONAL STRUCTURE OF THE FIRST EGF-LIKE MODULE OF HUMAN FACTOR IX: COMPARISON WITH EGF AND TGF-A
1ISU	;	1.5	;	THE THREE-DIMENSIONAL STRUCTURE OF THE HIGH-POTENTIAL IRON-SULFUR PROTEIN ISOLATED FROM THE PURPLE PHOTOTROPHIC BACTERIUM RHODOCYCLUS TENUIS DETERMINED AND REFINED AT 1.5 ANGSTROMS RESOLUTION
1WAS	;	2.7	;	THE THREE-DIMENSIONAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF A WILD-TYPE BACTERIAL CHEMOTAXIS RECEPTOR
1WAT	;	3.0	;	THE THREE-DIMENSIONAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF A WILD-TYPE BACTERIAL CHEMOTAXIS RECEPTOR
2VHL	;	2.05	;	The Three-dimensional structure of the N-Acetylglucosamine-6- phosphate deacetylase from Bacillus subtilis
1PHS	;	3.0	;	THE THREE-DIMENSIONAL STRUCTURE OF THE SEED STORAGE PROTEIN PHASEOLIN AT 3 ANGSTROMS RESOLUTION
1TTF	;		;	THE THREE-DIMENSIONAL STRUCTURE OF THE TENTH TYPE III MODULE OF FIBRONECTIN: AN INSIGHT INTO RGD-MEDIATED INTERACTIONS
1TTG	;		;	THE THREE-DIMENSIONAL STRUCTURE OF THE TENTH TYPE III MODULE OF FIBRONECTIN: AN INSIGHT INTO RGD-MEDIATED INTERACTIONS
3QPH	;	2.992	;	The three-dimensional structure of TrmB, a global transcriptional regulator of the hyperthermophilic archaeon Pyrococcus furiosus in complex with sucrose
1TPL	;	2.3	;	THE THREE-DIMENSIONAL STRUCTURE OF TYROSINE PHENOL-LYASE
2H1P	;	2.4	;	THE THREE-DIMENSIONAL STRUCTURES OF A POLYSACCHARIDE BINDING ANTIBODY TO CRYPTOCOCCUS NEOFORMANS AND ITS COMPLEX WITH A PEPTIDE FROM A PHAGE DISPLAY LIBRARY: IMPLICATIONS FOR THE IDENTIFICATION OF PEPTIDE MIMOTOPES
1D31	;	2.6	;	THE THREE-DIMENSIONAL STRUCTURES OF BULGE-CONTAINING DNA FRAGMENTS
1GHR	;	2.2	;	THE THREE-DIMENSIONAL STRUCTURES OF TWO PLANT BETA-GLUCAN ENDOHYDROLASES WITH DISTINCT SUBSTRATE SPECIFICITIES
1GHS	;	2.3	;	THE THREE-DIMENSIONAL STRUCTURES OF TWO PLANT BETA-GLUCAN ENDOHYDROLASES WITH DISTINCT SUBSTRATE SPECIFICITIES
8FJF	;	1.6	;	The three-repeat design H10
2RHP	;	2.9	;	The Thrombospondin-1 Polymorphism Asn700Ser Associated with Cornoary Artery Disease Causes Local and Long-Ranging Changes in Protein Structure
5NF4	;	1.746	;	The tip fimbrial protein Mfa3 from Porphyromonas gingivalis with C-terminal truncation.
2J67	;	2.2	;	The TIR domain of human Toll-Like Receptor 10 (TLR10)
6SKI	;	2.6	;	The Tle hydrolase bound to the TTR domain of the VgrG spike of the Type 6 secretion system
8HIK	;	3.72	;	The TPP-bound BRIL-SLC19A1/Fab/Nb ternary complex
3CEQ	;	2.75	;	The TPR domain of Human Kinesin Light Chain 2 (hKLC2)
5LEJ	;	2.7	;	The Transcriptional Regulator PrfA from Listeria Monocytogenes in complex with a 30-bp operator PrfA-box motif
6EV0	;	2.3	;	The Transcriptional Regulator PrfA from Listeria Monocytogenes in complex with a ring-fused 2-pyridone (AC129)
5F1R	;	2.25	;	The Transcriptional Regulator PrfA from Listeria Monocytogenes in complex with a ring-fused 2-pyridone (C10)
6EUU	;	2.6	;	The Transcriptional Regulator PrfA from Listeria Monocytogenes in complex with a ring-fused 2-pyridone (KSK29)
6EUT	;	1.9	;	The Transcriptional Regulator PrfA from Listeria Monocytogenes in complex with a ring-fused 2-pyridone (KSK67)
6EXM	;	1.6	;	The Transcriptional Regulator PrfA from Listeria Monocytogenes in complex with a ring-fused 2-pyridone (MK202)
6EXL	;	1.9	;	The Transcriptional Regulator PrfA from Listeria Monocytogenes in complex with a ring-fused 2-pyridone (MK206) - folded HTH motif
6EXK	;	2.1	;	The Transcriptional Regulator PrfA from Listeria Monocytogenes in complex with a ring-fused 2-pyridone (MK206) - unfolded HTH motif
6EUZ	;	1.95	;	The Transcriptional Regulator PrfA from Listeria Monocytogenes in complex with a ring-fused 2-pyridone (MK37)
6HCK	;	2.7	;	The Transcriptional Regulator PrfA from Listeria Monocytogenes in complex with dipeptide Leu-Leu
5LRR	;	2.171	;	The Transcriptional Regulator PrfA from Listeria Monocytogenes in complex with glutathione
5LRS	;	2.9	;	The Transcriptional Regulator PrfA from Listeria Monocytogenes in complex with glutathione and a 30-bp operator PrfA-box motif
6T5I	;	2.0	;	The Transcriptional Regulator PrfA from Listeria Monocytogenes in complex with inhibitor of WNT production (IWP)-2
6QW2	;	2.6	;	The Transcriptional Regulator PrfA-A218G mutant from Listeria Monocytogenes
6QWM	;	2.9	;	The Transcriptional Regulator PrfA-A218G mutant from Listeria Monocytogenes in complex with a 30-bp operator PrfA-box motif
6QVY	;	1.686	;	The Transcriptional Regulator PrfA-A94V mutant from Listeria Monocytogenes
6QWF	;	2.7	;	The Transcriptional Regulator PrfA-A94V mutant from Listeria Monocytogenes in complex with a 30-bp operator PrfA-box motif
5LEK	;	2.8	;	The Transcriptional Regulator PrfA-G145S mutant from Listeria Monocytogenes in complex with a 30-bp operator PrfA-box motif
6QW1	;	1.844	;	The Transcriptional Regulator PrfA-L140F mutant from Listeria Monocytogenes
6QWK	;	2.9	;	The Transcriptional Regulator PrfA-L140F mutant from Listeria Monocytogenes in complex with a 30-bp operator PrfA-box motif
6QVZ	;	2.705	;	The Transcriptional Regulator PrfA-L140H mutant from Listeria Monocytogenes
6QWH	;	2.9	;	The Transcriptional Regulator PrfA-L140H mutant from Listeria Monocytogenes in complex with a 30-bp operator PrfA-box motif
1TKW	;		;	The transient complex of poplar plastocyanin with turnip cytochrome f determined with paramagnetic NMR
6KI1	;	2.809	;	The transmembrane domain of a cyanobacterium bicarbonate transporter BicA
1OLQ	;	1.7	;	The Trichoderma reesei cel12a P201C mutant, structure at 1.7 A resolution
1V6H	;	1.9	;	The Trimeric Structure Of Divalent Cation Tolerance Protein CutA1 From Thermus Thermophilus HB8
4IND	;	1.8	;	The Triple Jelly Roll Fold and Turret Assembly in an Archaeal Virus
5U9T	;	1.92	;	The Tris-thiolate Zn(II)S3Cl Binding Site Engineered by D-Cysteine Ligands in de Novo Three-stranded Coiled Coil Environment
3BBV	;	10.0	;	The tRNA(phe) fitted into the low resolution Cryo-EM map of the 50S.nc-tRNA.Hsp15 complex
2JOF	;		;	The Trp-cage: Optimizing the Stability of a Globular Miniprotein
4MUO	;	1.94	;	The TrpD2 enzyme from E.coli: YbiB
3HR9	;	1.7	;	The truncated Fibrobacter succinogenes 1,3-1,4-beta-D-glucanase F40I mutant
3AXD	;	1.53	;	The truncated Fibrobacter succinogenes 1,3-1,4-beta-D-glucanase V18Y/W203Y in apo-form
3AXE	;	1.53	;	The truncated Fibrobacter succinogenes 1,3-1,4-beta-D-glucanase V18Y/W203Y in complex with cellotetraose (cellobiose density was observed)
8J2M	;	3.4	;	The truncated rice Na+/H+ antiporter SOS1 (1-976) in a constitutively active state
7ABB	;	1.50004	;	The truncated structure of the Bottromycin biosynthetic protein SalCYP
3WSA	;	2.9	;	The Tuberculosis Drug SQ109 Inhibits Trypanosoma cruzi Cell Proliferation and acts Synergistically with Posaconazole
3WSB	;	2.4	;	The Tuberculosis Drug SQ109 Inhibits Trypanosoma cruzi Cell Proliferation and acts Synergistically with Posaconazole
7TNT	;	9.3	;	The tubulin-based conoid from detergent-extract Toxoplasma gondii cells
8G2M	;	1.8	;	The tumor activated anti-CTLA-4 monoclonal antibody XTX101 demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer
6X2K	;	2.88	;	The Tusavirus (TuV) capsid structure
2XCT	;	3.35	;	The twinned 3.35A structure of S. aureus Gyrase complex with Ciprofloxacin and DNA
8FJG	;	2.13	;	The two-repeat design H12
8GLK	;	2.8	;	The Type 9 Secretion System dGldL peak II, NucA substrate bound complex
8GL8	;	2.2	;	The Type 9 Secretion System Extended Translocon - SprA-PorV-PPI-RemZ-SkpA-SprE complex
8GLJ	;	3.2	;	The Type 9 Secretion System in vitro assembled, FspA-CTD substrate bound complex
8GL6	;	3.2	;	The Type 9 Secretion System in vitro assembled, RemA-CTD substrate bound complex
8GLM	;	2.2	;	The Type 9 Secretion System in vivo assembled, RemZ substrate bound complex - conformation 1
8GLN	;	2.2	;	The Type 9 Secretion System in vivo assembled, RemZ substrate bound complex - conformation 2
3TB7	;	2.45	;	The type I crystal structure of Streptococcus agalactiae sortase C1
5CD4	;	3.2	;	The Type IE CRISPR Cascade complex from E. coli, with two assemblies in the asymmetric unit arranged back-to-back
2B59	;	2.11	;	The type II cohesin dockerin complex
5K39	;	1.98	;	THE TYPE II COHESIN DOCKERIN COMPLEX FROM CLOSTRIDIUM THERMOCELLUM
3RBK	;	2.9	;	The Type II Crystal Structure of Streptococcus agalactiae Sortase C1
3RBI	;	3.0	;	The Type III Crystal Structure of Streptococcus agalactiae Sortase C1
5OT1	;	2.8	;	The type III pullulan hydrolase from Thermococcus kodakarensis
7OQC	;	4.1	;	The U1 part of Saccharomyces cerevisiae spliceosomal pre-A complex (delta BS-A ACT1)
7OQB	;	9.0	;	The U2 part of Saccharomyces cerevisiae spliceosomal pre-A complex (delta BS-A ACT1)
3JBA	;	12.0	;	The U4 antibody epitope on human papillomavirus 16 identified by cryo-EM
4AE4	;	1.65	;	The UBAP1 subunit of ESCRT-I interacts with ubiquitin via a novel SOUBA domain
7TDY	;	1.53	;	The ubiquitin-associated domain of human thirty-eight negative kinase 1, flexibly fused to the 1TEL crystallization chaperone via a 2-glycine linker and crystallized at low protein concentration
7TCY	;	1.54	;	The ubiquitin-associated domain of human thirty-eight negative kinase I
7U4W	;	2.1	;	The ubiquitin-associated domain of human thirty-eight negative kinase-1 flexibly fused to the 1TEL crystallization chaperone via a 2-glycine linker and crystallized at traditional protein concentration
7U4Z	;	2.03	;	The ubiquitin-associated domain of human thirty-eight negative kinase-1 flexibly fused to the 1TEL crystallization chaperone via a 2-glycine linker and crystallized at very low protein concentration
7T8J	;	1.89	;	The ubiquitin-associated domain of human thirty-eight negative kinase-1 flexibly fused to the 1TEL crystallization chaperone via a GSGG linker
2QGI	;	1.65	;	The UDP complex structure of the sixth gene product of the F1-ATPase operon of Rhodobacter blasticus
6TSZ	;	1.9	;	The ULK4 Pseudokinase Domain Bound To ATPgammaS
5A8C	;	0.97	;	The ultra high resolution structure of a novel alpha-L-arabinofuranosidase (CtGH43) from Clostridium thermocellum ATCC 27405 with bound trimethyl N-Oxide (TRS)
1SK5	;	0.89	;	The ultra-high resolution structure of d(CTTTTAAAAG)2: modulation of bending by T-A steps and its role in DNA recognition
4K74	;	2.5	;	The UmuC subunit of the E. coli DNA polymerase V shows a unique interaction with the beta-clamp processivity factor.
7VRT	;	5.1	;	The unexpanded head structure of phage T4
6SL4	;	1.8	;	The unique CBM-Cthe_0271 of Ruminiclostridium thermocellum
6XX1	;	1.61	;	The unique CBM3-Clocl_1192 of Hungateiclostridium clariflavum
3B1B	;	1.88	;	The unique structure of wild type carbonic anhydrase alpha-CA1 from Chlamydomonas reinhardtii
1FL5	;	2.1	;	THE UNLIGANDED GERMLINE PRECURSOR TO THE SULFIDE OXIDASE CATALYTIC ANTIBODY 28B4.
4EL8	;	2.45	;	The unliganded structure of C.bescii CelA GH48 module
5ECU	;	1.5	;	The unliganded structure of Caldicellulosiruptor saccharolyticus GH5
6T33	;		;	The unusual structure of Ruminococcin C1 antimicrobial peptide confers activity against clinical pathogens
103D	;		;	THE UNUSUAL STRUCTURE OF THE HUMAN CENTROMERE (GGA)2 MOTIF: UNPAIRED GUANOSINE RESIDUES STACKED BETWEEN SHEARED G(DOT)A PAIRS
4RHV	;	3.0	;	THE USE OF MOLECULAR-REPLACEMENT PHASES FOR THE REFINEMENT OF THE HUMAN RHINOVIRUS 14 STRUCTURE
2PGK	;	3.0	;	THE USE OF PHASE COMBINATION IN THE REFINEMENT OF PHOSPHOGLYCERATE KINASE AT 2.5 ANGSTROMS RESOLUTION
7UNE	;	3.73	;	The V1 region of bovine V-ATPase in complex with human mEAK7 (focused refinement)
6WLZ	;	2.9	;	The V1 region of human V-ATPase in state 1 (focused refinement)
2KWX	;		;	The V27A mutant of influenza A M2 proton channel
3O7N	;	1.72	;	The V59W mutation blocks the distal pocket of the hemoglobin - dehaloperoxidase from Amphitrite ornata
3K3U	;	1.63	;	The V59W mutation blocks the distal pocket of the hemoglobin dehaloperoxidase from Amphitrite ornata
5EJ0	;	1.9	;	The vaccinia virus H3 envelope protein, a major target of neutralizing antibodies, exhibits a glycosyltransferase fold and binds UDP-Glucose
4QOE	;	1.45	;	The value 'crystal structure of fad quinone reductase 2 at 1.45A
4QOD	;	1.35	;	The value crystal structure of apo quinone reductase 2 at 1.35A
1QSZ	;		;	THE VEGF-BINDING DOMAIN OF FLT-1 (MINIMIZED MEAN)
1QSV	;		;	THE VEGF-BINDING DOMAIN OF FLT-1, 20 NMR STRUCTURES
6SK0	;	2.3	;	The VgrG spike from the Type 6 secretion system
1VCB	;	2.7	;	THE VHL-ELONGINC-ELONGINB STRUCTURE
4IVN	;	1.9	;	The Vibrio vulnificus NanR protein complexed with ManNAc-6P
3RGC	;	2.3	;	The virulence factor PEB4 and the periplasmic protein Cj1289 are two structurally related SurA-like chaperones in the human pathogen Campylobacter jejuni
3RFW	;	2.2	;	The virulence factor PEB4 and the periplasmic protein Cj1289 are two structurally-related SurA-like chaperones in the human pathogen Campylobacter jejuni
5WPI	;	2.3	;	The virulence-associated protein HsvA from the fire blight pathogen Erwinia amylovora is a polyamine amidinotransferase
6WLW	;	3.0	;	The Vo region of human V-ATPase in state 1 (focused refinement)
6EBK	;	3.3	;	The voltage-activated Kv1.2-2.1 paddle chimera channel in lipid nanodiscs
6EBL	;	3.0	;	The voltage-activated Kv1.2-2.1 paddle chimera channel in lipid nanodiscs, cytosolic domain
6EBM	;	4.0	;	The voltage-activated Kv1.2-2.1 paddle chimera channel in lipid nanodiscs, transmembrane domain of subunit alpha
8FZ4	;	2.19	;	The von Willebrand factor A domain of Anthrax toxin receptor 2
7N1O	;	2.77	;	The von Willebrand factor A domain of human capillary morphogenesis gene II, flexibly fused to the 1TEL crystallization chaperone
8FZV	;	3.29	;	The von Willebrand factor A domain of human capillary morphogenesis gene II, flexibly fused to the 1TEL crystallization chaperone, Ala-Ala linker variant, expressed with SUMO tag
8FT6	;	2.62	;	The von Willebrand factor A domain of human capillary morphogenesis gene II, flexibly fused to the 1TEL crystallization chaperone, Ala-Ala linker variant, SUMO tag-free preparation.
8FZU	;	1.9	;	The von Willebrand factor A domain of human capillary morphogenesis gene II, flexibly fused to the 1TEL crystallization chaperone, Thr-Val linker variant, Expressed with SUMO tag
8FT8	;	1.6	;	The von Willebrand factor A domain of human capillary morphogenesis gene II, flexibly fused to the 1TEL crystallization chaperone, Thr-Val linker variant, SUMO tag-free preparation
4GYX	;	1.49	;	The von Willebrand Factor A3 domain binding region of type III collagen stabilized by the cysteine knot
1IJB	;	1.8	;	The von Willebrand Factor mutant (I546V) A1 domain
1IJK	;	2.6	;	The von Willebrand Factor mutant (I546V) A1 domain-botrocetin Complex
2PJW	;	3.01	;	The Vps27/Hse1 complex is a GAT domain-based scaffold for ubiquitin-dependent sorting
4E5A	;	1.87	;	The W197A mutant of p38a MAP kinase
2QEN	;	2.25	;	The walker-type atpase paby2304 of pyrococcus abyssi
4N78	;	2.43	;	The WAVE Regulatory Complex Links Diverse Receptors to the Actin Cytoskeleton
5KWN	;	1.42	;	The WD domain ofArabidopsis thaliana E3 Ubiquitin Ligase COP1 in complex with peptide from HY5
2Q7J	;	1.9	;	The Wild Type Androgen Receptor Ligand Binding Domain Bound with Testosterone and a TIF2 box 3 Coactivator Peptide 740-753
2Q7I	;	1.87	;	The Wild Type Androgen Receptor Ligand Binding Domain Bound with Testosterone and an AR 20-30 Peptide
3WUB	;	2.08	;	The wild type crystal structure of b-1,4-Xylanase (XynAS9) from Streptomyces sp. 9
3WUE	;	2.15	;	The wild type crystal structure of b-1,4-Xylanase (XynAS9) with xylobiose from Streptomyces sp. 9
6SYR	;	1.49	;	The wild type glucuronoyl esterase OtCE15A from Opitutus terrae in complex with D-glucuronate
6T0I	;	1.53	;	The wild type glucuronoyl esterase OtCE15A from Opitutus terrae in complex with the aldotetrauronic acid XUX
6SYU	;	1.33	;	The wild type glucuronoyl esterase OtCE15A from Opitutus terrae in complex with xylobiose
7QOV	;	1.4	;	The wild type nitrile hydratase from Geobacillus pallidus
4DGP	;	2.3	;	The wild-type Src homology 2 (SH2)-domain containing protein tyrosine phosphatase-2 (SHP2)
7DL7	;	2.30066	;	The wild-type structure of 3,5-DAHDHcca
6LAZ	;	2.76	;	the wildtype SAM-VI riboswitch bound to a N-mustard SAM analog M1
6LAU	;	3.109	;	the wildtype SAM-VI riboswitch bound to SAH
6LAS	;	2.708	;	the wildtype SAM-VI riboswitch bound to SAM
6KTX	;	2.189	;	The wildtype structure of EanB
5X3G	;	2.021	;	The WT UNG crystal structure from Nitratifractor salsuginis
5L2W	;	2.8	;	The X-ray co-crystal structure of human CDK2/CyclinE and Dinaciclib.
5L2S	;	2.27	;	The X-ray co-crystal structure of human CDK6 and Abemaciclib.
5L2I	;	2.75	;	The X-ray co-crystal structure of human CDK6 and Palbociclib.
5L2T	;	2.37	;	The X-ray co-crystal structure of human CDK6 and Ribociclib.
8UDU	;	1.737	;	The X-RAY co-crystal structure of human FGFR3 and Compound 17
8UDT	;	2.829	;	The X-RAY co-crystal structure of human FGFR3 and KIN-3248
8UDV	;	2.348	;	The X-RAY co-crystal structure of human FGFR3 V555M and Compound 17
4KXH	;	2.7	;	The X-ray crystal structure of a dimeric variant of human pancreatic ribonuclease
5K8H	;	1.069	;	The X-ray crystal structure of a parallel poly(rA) double helix generated by rA7 at acidic pH
1MTP	;	1.5	;	The X-ray crystal structure of a serpin from a thermophilic prokaryote
5X5I	;	2.554	;	The X-ray crystal structure of a TetR family transcription regulator RcdA involved in the regulation of biofilm formation in Escherichia coli
2O7I	;	1.5	;	The X-ray crystal structure of a thermophilic cellobiose binding protein bound with cellobiose
3I5O	;	1.5	;	The X-ray crystal structure of a thermophilic cellobiose binding protein bound with cellopentaose
4JSD	;	2.05	;	The X-ray crystal structure of a thermophilic cellobiose binding protein bound with laminaribiose
4JSO	;	2.07	;	The X-ray crystal structure of a thermophilic cellobiose binding protein bound with laminaripentaose
6N04	;	1.998	;	The X-ray crystal structure of AbsH3, an FAD dependent reductase from the Abyssomicin biosynthesis pathway in Streptomyces
1O9R	;	1.45	;	The X-ray crystal structure of Agrobacterium tumefaciens Dps, a member of the family that protect DNA without binding
7Q6Y	;	2.22	;	The X-ray crystal structure of CbTan2, a tannase enzyme from Clostridium butyricum
1K72	;	1.8	;	The X-ray Crystal Structure Of Cel9G Complexed With cellotriose
1KFG	;	1.9	;	The X-ray Crystal Structure of Cel9G from Clostridium cellulolyticum complexed with a Thio-Oligosaccharide Inhibitor
4EGP	;	3.0	;	The X-ray crystal structure of CYP199A4 in complex with 2-naphthoic acid
4EGM	;	2.91	;	The X-ray crystal structure of CYP199A4 in complex with 4-ethylbenzoic acid
4EGO	;	1.76	;	The X-ray crystal structure of CYP199A4 in complex with indole-6-carboxylic acid
4EGN	;	2.0	;	The X-ray crystal structure of CYP199A4 in complex with veratric acid
4C5C	;	1.4	;	The X-ray crystal structure of D-alanyl-D-alanine ligase in complex with ADP and D-ala-D-ala
4C5B	;	1.5	;	The X-ray crystal structure of D-alanyl-D-alanine ligase in complex with ATP and D-ala-D-ala
6ENK	;	1.96	;	The X-ray crystal structure of DesE bound to desferrioxamine B
1O9J	;	2.4	;	The X-ray crystal structure of eta-crystallin
2HZ2	;	2.0	;	The x-ray crystal structure of ferric Synechocystis hemoglobin H117A mutant with a covalent linkage
2HZ3	;	1.9	;	The x-ray crystal structure of ferrous Synechocystis hemoglobin H117A mutant with a covalent linkage
2HZ1	;	1.8	;	The x-ray crystal structure of ferrous Synechocystis hemoglobin with a covalent linkage
1DVO	;	2.0	;	THE X-RAY CRYSTAL STRUCTURE OF FINO, A REPRESSOR OF BACTERIAL CONJUGATION
4DUU	;	5.2	;	The X-ray Crystal Structure of Full-Length type I Human Plasminogen
4DUR	;	2.45	;	The X-ray Crystal Structure of Full-Length type II Human Plasminogen
4J1Y	;	2.6645	;	The X-ray crystal structure of human complement protease C1s zymogen
6DK5	;	1.85	;	The X-ray crystal structure of human endothelin-1, a polypeptide hormone regulator of blood pressure
2BJY	;	2.6	;	The X-ray crystal structure of Listeria innocua Dps H31G-H43G mutant.
3NSJ	;	2.75	;	The X-ray crystal structure of lymphocyte perforin
4KKD	;	2.5991	;	The X-ray crystal structure of Mannose-binding lectin-associated serine proteinase-3 reveals the structural basis for enzyme inactivity associated with the 3MC syndrome
1FI4	;	2.27	;	THE X-RAY CRYSTAL STRUCTURE OF MEVALONATE 5-DIPHOSPHATE DECARBOXYLASE AT 2.3 ANGSTROM RESOLUTION.
2Q5W	;	2.0	;	The X-ray Crystal Structure of Molybdopterin Synthase from Staphylococcus aureus
2HEW	;	1.45	;	The X-ray crystal structure of murine OX40L
3M0C	;	7.01	;	The X-ray Crystal Structure of PCSK9 in Complex with the LDL receptor
3SIG	;	1.28	;	The X-ray crystal structure of poly(ADP-ribose) glycohydrolase (PARG) bound to ADP-ribose from Thermomonospora curvata
3SIH	;	1.5	;	The X-ray crystal structure of poly(ADP-ribose) glycohydrolase (PARG) from Thermomonospora curvata
3SII	;	1.48	;	The X-ray crystal structure of poly(ADP-ribose) glycohydrolase bound to the inhibitor ADP-HPD from Thermomonospora curvata
3SIJ	;	1.9	;	The X-ray crystal structure of poly(ADP-ribose) glycohydrolase E115A mutant from Thermomonospora curvata
1A0H	;	3.2	;	THE X-RAY CRYSTAL STRUCTURE OF PPACK-MEIZOTHROMBIN DESF1: KRINGLE/THROMBIN AND CARBOHYDRATE/KRINGLE/THROMBIN INTERACTIONS AND LOCATION OF THE LINKER CHAIN
3KMG	;	2.1	;	The X-ray Crystal Structure of PPAR-gamma in Complex with an Indole Derivative Modulator, GSK538, and an SRC-1 Peptide
1IU8	;	1.6	;	The X-ray Crystal Structure of Pyrrolidone-Carboxylate Peptidase from Hyperthermophilic Archaeon Pyrococcus horikoshii
3HKZ	;	3.4	;	The X-ray crystal structure of RNA polymerase from Archaea
4QJV	;	1.601	;	The X-ray crystal structure of Rpo3/Rpo11 heterodimer of euryarchaeal RNA polymerase from Thermococcus kodakarensis
1HOW	;	2.1	;	THE X-RAY CRYSTAL STRUCTURE OF SKY1P, AN SR PROTEIN KINASE IN YEAST
7K7V	;	1.882	;	The X-ray crystal structure of SSR4, an S. pombe chromatin remodelling protein: iodide derivative
7K7W	;	1.77	;	The X-ray crystal structure of SSR4, an S. pombe chromatin remodelling protein: native
7K82	;	2.1	;	The X-ray crystal structure of SSR4, an S. pombe chromatin remodelling protein: sulfur SAD
6NYU	;	2.183	;	The X-ray crystal structure of Staphylococcus aureus Fatty Acid Kinase (Fak) B1 F263T mutant protein to 2.18 Angstrom resolution
7SCL	;	1.6	;	The X-ray crystal structure of Staphylococcus aureus Fatty Acid Kinase B1 (FakB1) mutant R173A in complex with Palmitate to 1.60 Angstrom resolution
6NOK	;	1.69	;	The X-ray crystal structure of Streptococcus pneumoniae Fatty Acid Kinase (Fak) B1 protein loaded with myristic acid (C14:0) to 1.69 Angstrom resolution
6DKE	;	1.76	;	The X-ray crystal structure of Streptococcus pneumoniae Fatty Acid Kinase (Fak) B1 protein loaded with palmitic acid (C16:0) to 1.76 Angstrom resolution
6NR1	;	2.1	;	The X-ray crystal structure of Streptococcus pneumoniae Fatty Acid Kinase (Fak) B2 protein loaded with Vaccenic acid (C18:1 delta11) to 2.1 Angstrom resolution
5X89	;	1.53	;	The X-ray crystal structure of subunit fusion RNA splicing endonuclease from Methanopyrus kandleri
2YGL	;	2.1	;	The X-ray crystal structure of tandem CBM51 modules of Sp3GH98, the family 98 glycoside hydrolase from Streptococcus pneumoniae SP3-BS71
2YGM	;	2.35	;	THE X-RAY CRYSTAL STRUCTURE OF TANDEM CBM51 MODULES OF SP3GH98, THE FAMILY 98 GLYCOSIDE HYDROLASE FROM STREPTOCOCCUS PNEUMONIAE SP3-BS71, IN COMPLEX WITH THE BLOOD GROUP B ANTIGEN
2OKK	;	2.3	;	The X-ray crystal structure of the 65kDa isoform of Glutamic Acid Decarboxylase (GAD65)
2OKJ	;	2.3	;	The X-ray crystal structure of the 67kDa isoform of Glutamic Acid Decarboxylase (GAD67)
6W6B	;	1.4	;	The X-ray crystal structure of the C-terminus domain of Staphylococcus aureus Fatty Acid Kinase A (FakA, residues 328-548) protein to 1.40 Angstrom resolution
1IJJ	;	2.85	;	THE X-RAY CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN RABBIT SKELETAL MUSCLE ACTIN AND LATRUNCULIN A AT 2.85 A RESOLUTION
3HI9	;	2.0	;	The x-ray crystal structure of the first RNA recognition motif (RRM1) of the AU-rich element (ARE) binding protein HuR at 2.0 angstrom resolution
4DKK	;	1.701	;	The X-ray Crystal Structure of the Human STAU1 SSM-'RBD'5 Domain-Swapped Dimer
2BK6	;	2.19	;	The X-ray crystal structure of the Listeria innocua H31G Dps mutant.
1PRH	;	3.5	;	THE X-RAY CRYSTAL STRUCTURE OF THE MEMBRANE PROTEIN PROSTAGLANDIN H2 SYNTHASE-1
7RM7	;	1.025	;	The X-ray crystal structure of the N-terminal domain of Staphylococcus aureus Fatty Acid Kinase A (FakA, residues 1-208) in complex with ADP to 1.025 Angstrom resolution
7UQ1	;	1.72	;	The X-ray crystal structure of the N-terminal domain of Staphylococcus aureus Fatty Acid Kinase A (FakA, residues 1-208) in complex with AMP and a single Mg ion at the dinuclear binding site
7SNB	;	1.11	;	The X-ray crystal structure of the N-terminal domain of Staphylococcus aureus Fatty Acid Kinase A (FakA, residues 1-208) in complex with AMP and ADP to 1.105 Angstrom resolution
2NV9	;	1.95	;	The X-ray Crystal Structure of the Paramecium bursaria Chlorella virus arginine decarboxylase
2NVA	;	1.8	;	The X-ray crystal structure of the Paramecium bursaria Chlorella virus arginine decarboxylase bound to agmatine
7SG3	;	2.35	;	The X-ray crystal structure of the Staphylococcus aureus Fatty Acid Kinase B1 mutant A121I-A158L to 2.35 Angstrom resolution (Open form chain A, Palmitate bound)
6DJ6	;	1.9	;	The X-ray crystal structure of the Streptococcus pneumoniae Fatty Acid Kinase (Fak) B2 protein loaded with cis-oleic acid to 1.9 Angstrom resolution
6CNG	;	1.47	;	The X-ray crystal structure of the Streptococcus pneumoniae Fatty Acid Kinase (Fak) B3 protein loaded with linoleic acid to 1.47 Angstrom resolution
1GMC	;	2.2	;	THE X-RAY CRYSTAL STRUCTURE OF THE TETRAHEDRAL INTERMEDIATE OF GAMMA-CHYMOTRYPSIN IN HEXANE
4H7M	;	2.068	;	The X-ray Crystal Structure of the Trichoderma harzianum Endoglucanase 3 from family GH12
1H8V	;	1.9	;	The X-ray Crystal Structure of the Trichoderma reesei Family 12 Endoglucanase 3, Cel12A, at 1.9 A Resolution
8ETN	;	3.16	;	The X-ray Crystal Structure of Tri-Ketone Dioxygenase from Rice
1ETA	;	1.7	;	THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL 30-->MET VARIANT TO 1.7 ANGSTROMS RESOLUTION
1ETB	;	1.7	;	THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL 30-->MET VARIANT TO 1.7 ANGSTROMS RESOLUTION
1TTA	;	1.7	;	THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL30MET VARIANT TO 1.7 ANGSTROMS RESOLUTION
1TTB	;	1.7	;	THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL30MET VARIANT TO 1.7 ANGSTROMS RESOLUTION
1TTC	;	1.7	;	THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL30MET VARIANT TO 1.7 ANGSTROMS RESOLUTION
4C5A	;	1.65	;	The X-ray crystal structures of D-alanyl-D-alanine ligase in complex ADP and D-cycloserine phosphate
7VMA	;	2.804	;	The X-ray crystallographic structure of amylo-alpha-1,6-glucosidase from Thermococcus gammatolerans STB12
1EKJ	;	1.93	;	THE X-RAY CRYSTALLOGRAPHIC STRUCTURE OF BETA CARBONIC ANHYDRASE FROM THE C3 DICOT PISUM SATIVUM
1M7X	;	2.3	;	The X-ray Crystallographic Structure of Branching Enzyme
6JOY	;	2.392	;	The X-ray Crystallographic Structure of Branching Enzyme from Rhodothermus obamensis STB05
7X7W	;	2.097	;	The X-ray Crystallographic Structure of D-Psicose 3-epimerase from Clostridia bacterium
7EAV	;	2.803	;	The X-ray crystallographic structure of glycogen debranching enzyme from Sulfolobus solfataricus STB09
6AG0	;	2.2	;	The X-ray Crystallographic Structure of Maltooligosaccharide-forming Amylase from Bacillus stearothermophilus STB04
1X7S	;	1.55	;	The X-ray crystallographic structure of the amyloidogenic variant TTR Tyr78Phe
2DOH	;	2.3	;	The X-ray crystallographic structure of the angiogenesis inhibitor, angiostatin, bound a to a peptide from the group A streptococcal surface protein PAM
2DOI	;	3.1	;	The X-ray crystallographic structure of the angiogenesis inhibitor, angiostatin, bound to a peptide from the group A streptococcus protein PAM
4F48	;	3.0	;	The X-ray structural of FimXEAL-c-di-GMP-PilZ complexes from Xanthomonas campestris
1FSX	;	2.1	;	THE X-RAY STRUCTURE DETERMINATION OF BOVINE CARBONMONOXY HB AT 2.1 A RESOLUTION AND ITS RELATIONSHIP TO THE QUATERNARY STRUCTURE OF OTHER HB CRYSTAL FORMS
1CWB	;	2.2	;	THE X-RAY STRUCTURE OF (MEBM2T)1-CYCLOSPORIN COMPLEXED WITH CYCLOPHILIN A PROVIDES AN EXPLANATION FOR ITS ANOMALOUSLY HIGH IMMUNOSUPPRESSIVE ACTIVITY
5GT9	;	1.7	;	The X-ray structure of 7beta-hydroxysteroid dehydrogenase
2IMS	;	1.48	;	The X-ray Structure of a Bak Homodimer Reveals an Inhibitory Zinc Binding Site
2IMT	;	1.49	;	The X-ray Structure of a Bak Homodimer Reveals an Inhibitory Zinc Binding Site
1CBF	;	2.4	;	THE X-RAY STRUCTURE OF A COBALAMIN BIOSYNTHETIC ENZYME, COBALT PRECORRIN-4 METHYLTRANSFERASE, CBIF
2CBF	;	3.1	;	THE X-RAY STRUCTURE OF A COBALAMIN BIOSYNTHETIC ENZYME, COBALT PRECORRIN-4 METHYLTRANSFERASE, CBIF, FROM BACILLUS MEGATERIUM, WITH THE HIS-TAG CLEAVED OFF
2QWD	;	2.0	;	THE X-RAY STRUCTURE OF A COMPLEX OF 4-AMINO-NEU5AC2EN AND A DRUG RESISTANT VARIANT R292K OF TERN N9 INFLUENZA VIRUS NEURAMINIDASE
2QWE	;	2.0	;	THE X-RAY STRUCTURE OF A COMPLEX OF 4-GUANIDINO-NEU5AC2EN AND A DRUG RESISTANT VARIANT R292K OF TERN N9 INFLUENZA VIRUS NEURAMINIDASE
2QWG	;	1.8	;	THE X-RAY STRUCTURE OF A COMPLEX OF 5-N-ACETYL-4-AMINO-6-DIETHYLCARBOXAMIDE-4,5-DIHYDRO-2H-PYRAN-2-CARBOXYLIC ACID AND A DRUG RESISTANT VARIANT R292K OF TERN N9 INFLUENZA VIRUS NEURAMINIDASE
2QWJ	;	2.0	;	THE X-RAY STRUCTURE OF A COMPLEX OF 5-N-ACETYL-4-AMINO-6-DIETHYLCARBOXAMIDE-4,5-DIHYDRO-2H-PYRAN-2-CARBOXYLIC ACID AND A DRUG RESISTANT VARIANT R292K OF TERN N9 INFLUENZA VIRUS NEURAMINIDASE
2QWH	;	1.8	;	THE X-RAY STRUCTURE OF A COMPLEX OF 5-N-ACETYL-5-AMINO-3-(1-ETHYLPROPOXY)-1-CYCLOHEXENE-1-CARBOXYLIC ACID (GS4071) AND A DRUG RESISTANT VARIANT R292K OF TERN N9 INFLUENZA VIRUS NEURAMINIDASE
2QWK	;	1.8	;	THE X-RAY STRUCTURE OF A COMPLEX OF 5-N-ACETYL-5-AMINO-3-(1-ETHYLPROPOXY)-1-CYCLOHEXENE-1-CARBOXYLIC ACID (GS4071) AND WILDTYPE TERN N9 INFLUENZA VIRUS NEURAMINIDASE
2QWF	;	1.9	;	THE X-RAY STRUCTURE OF A COMPLEX OF N-ACETYL-4-GUANIDINO-6-METHYL(PROPYL)CARBOXAMIDE-4,5-DIHYDRO-2H-PYRAN-2-CARBOXYLIC ACID AND A DRUG RESISTANT VARIANT R292K OF TERN N9 INFLUENZA VIRUS NEURAMINIDASE
2QWI	;	2.0	;	THE X-RAY STRUCTURE OF A COMPLEX OF N-ACETYL-4-GUANIDINO-6-METHYL(PROPYL)CARBOXAMIDE-4,5-DIHYDRO-2H-PYRAN-2-CARBOXYLIC ACID AND WILDTYPE TERN N9 INFLUENZA VIRUS NEURAMINIDASE
2QWC	;	1.6	;	THE X-RAY STRUCTURE OF A COMPLEX OF NEU5AC2EN AND A DRUG RESISTANT VARIANT R292K OF TERN N9 INFLUENZA VIRUS NEURAMINIDASE
2QWB	;	2.0	;	THE X-RAY STRUCTURE OF A COMPLEX OF SIALIC ACID AND A DRUG RESISTANT VARIANT R292K OF TERN N9 INFLUENZA VIRUS NEURAMINIDASE
1MWE	;	1.7	;	THE X-RAY STRUCTURE OF A COMPLEX OF TERN N9 INFLUENZA VIRUS NEURAMINIDASE COMPLEXED WITH SIALIC ACID AT 4 DEGREES C REVEALING A SECOND SIALIC ACID BINDING SITE
1BJI	;	2.0	;	THE X-RAY STRUCTURE OF A COMPLEX OF TERN N9 INFLUENZA VIRUS NEURAMINIDASE COMPLEXED WITH THE GLAXO 6-CARBOXAMIDE SIALIC ACID ANALOGUE GR217029
3F8G	;	2.6	;	The X-ray structure of a dimeric variant of human pancreatic ribonuclease with high cytotoxic and antitumor activities
2QWA	;	1.7	;	THE X-RAY STRUCTURE OF A DRUG RESISTANT VARIANT R292K OF TERN N9 INFLUENZA VIRUS NEURAMINIDASE
4WNL	;	2.8	;	The X-ray structure of a RNA-binding protein complex
3NYL	;	2.8	;	The X-ray structure of an antiparallel dimer of the human amyloid precursor protein E2 domain
1LFB	;	2.8	;	THE X-RAY STRUCTURE OF AN ATYPICAL HOMEODOMAIN PRESENT IN THE RAT LIVER TRANSCRIPTION FACTOR LFB1(SLASH)HNF1 AND IMPLICATIONS FOR DNA BINDING
1Y9L	;	1.5	;	The X-ray structure of an secretion system protein
5XZ3	;	1.86	;	The X-ray structure of Apis mellifera PGRP-SA
1EDO	;	2.3	;	THE X-RAY STRUCTURE OF BETA-KETO ACYL CARRIER PROTEIN REDUCTASE FROM BRASSICA NAPUS COMPLEXED WITH NADP+
6F60	;	1.14	;	The x-ray structure of bovine pancreatic ribonuclease in complex with a five-coordinate platinum(II) compound containing a sugar ligand
5NA9	;	2.07	;	The X-ray structure of bovine pancreatic ribonuclease incubated in the presence of an excess of carboplatin (1:10 ratio)
4RTE	;	1.95	;	The X-ray structure of bovine pancreatic ribonuclease incubated in the presence of an excess of cisplatin (1:10 ratio)
4USL	;	1.65	;	The X-ray structure of calcium bound human sorcin
5O8X	;	2.5	;	The X-ray Structure of Catenated Lytic Transglycosylase SltB1 from Pseudomonas aeruginosa
2C1H	;	2.6	;	The X-ray Structure of Chlorobium vibrioforme 5-Aminolaevulinic Acid Dehydratase Complexed with a Diacid Inhibitor
2FLZ	;	2.75	;	The X-ray structure of cis-3-chloroacrylic acid dehalogenase (cis-CaaD) with a sulfate ion bound in the active site
2XME	;	1.89	;	The X-ray structure of CTP:inositol-1-phosphate cytidylyltransferase from Archaeoglobus fulgidus
2XMH	;	2.4	;	The X-ray structure of CTP:inositol-1-phosphate cytidylyltransferase from Archaeoglobus fulgidus
2VY0	;	2.16	;	The X-ray structure of endo-beta-1,3-glucanase from Pyrococcus furiosus
1GVH	;	2.19	;	The X-ray structure of ferric Escherichia coli flavohemoglobin reveals an unespected geometry of the distal heme pocket
6FQF	;	2.1	;	THE X-RAY STRUCTURE OF FERRIC-BETA4 HUMAN HEMOGLOBIN
2X17	;	3.1	;	The X-ray structure of Ferritin from Pyrococcus furiosus loaded with Ag(I)
4FUS	;	1.75	;	The X-ray structure of Hahella chejuensis family 48 glycosyl hydrolase
7OON	;	2.8	;	The X-ray structure of heme-bound murine HEBP1
1KI0	;	1.75	;	The X-ray Structure of Human Angiostatin
5M6Z	;	1.67	;	The X-ray structure of human M189I PGK-1 mutant in partially closed conformation
5MXM	;	2.05	;	The X-ray structure of human M190I phosphoglycerate kinase 1 mutant
7VQG	;	1.35	;	The X-ray structure of human neuroglobin A15C mutant
3E0P	;	1.7	;	The X-ray structure of Human Prostasin in complex with a covalent benzoxazole inhibitor
3E0N	;	1.7	;	The X-ray structure of Human Prostasin in complex with DFFR-chloromethyl ketone inhibitor
5O7D	;	1.84	;	The X-ray structure of human R38M phosphoglycerate kinase 1 mutant
5M3U	;	1.81	;	The X-ray structure of human V216F phosphoglycerate kinase 1 mutant
5J47	;	1.99	;	The X-ray structure of Inhibitor Bound to JCV Helicase
3LJF	;	2.1	;	The X-ray structure of iron superoxide dismutase from Pseudoalteromonas haloplanktis (crystal form II)
5J40	;	2.17	;	The X-ray structure of JCV Helicase
7PJD	;	1.99	;	The X-ray structure of juvenile hormone diol kinase from the silk worm Bombyx mori.
7AJ9	;	2.35	;	The X-ray Structure of L,D-transpeptidase LdtA from Vibrio cholerae
7AJX	;	2.55	;	The X-ray Structure of L,D-transpeptidase LdtA from Vibrio cholerae in complex with meropenem
7AJZ	;	2.98	;	The X-ray Structure of L,D-transpeptidase LdtA from Vibrio cholerae in complex with NAG-NAM(tetrapeptide)
7AJO	;	1.85	;	The X-ray Structure of L,D-transpeptidase LdtA from Vibrio cholerae in complex with the cross-linking reaction intermediate
7OL1	;	2.6	;	The X-ray structure of L-threonine dehydrogenase from the common hospital pathogen Clostridium difficile.
5OHU	;	2.2	;	The X-ray Structure of Lytic Transglycosylase Slt from Pseudomonas aeruginosa
6FBT	;	2.5	;	The X-ray Structure of Lytic Transglycosylase Slt from Pseudomonas aeruginosa in complex with the reaction product NAG-anhNAMpentapeptide
6FC4	;	3.05	;	The X-ray Structure of Lytic Transglycosylase Slt inactive mutant E503Q from Pseudomonas aeruginosa
6FCU	;	3.2	;	The X-ray Structure of Lytic Transglycosylase Slt inactive mutant E503Q from Pseudomonas aeruginosa in complex with 4(NAG-NAMpentapeptide)
6FCQ	;	3.1	;	The X-ray Structure of Lytic Transglycosylase Slt inactive mutant E503Q from Pseudomonas aeruginosa in complex with Bulgecin A
6FCS	;	2.9	;	The X-ray Structure of Lytic Transglycosylase Slt inactive mutant E503Q from Pseudomonas aeruginosa in complex with NAG-NAMpentapeptide-NAG-NAMpentapeptide
6FCR	;	2.75	;	The X-ray Structure of Lytic Transglycosylase Slt inactive mutant E503Q from Pseudomonas aeruginosa in complex with NAG-NAMtetrapeptide-NAG-anhNAMtetrapeptide
1F8G	;	2.0	;	THE X-RAY STRUCTURE OF NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE FROM RHODOSPIRILLUM RUBRUM COMPLEXED WITH NAD+
2VNE	;	2.72	;	The X-ray structure of Norcoclaurine synthase from Thalictrum flavum
5HNR	;	2.83	;	The X-ray structure of octameric human native 5-aminolaevulinic acid dehydratase.
7VW4	;	1.8	;	The X-ray structure of sperm whale F46C/L61C myoglobin double mutant
5NJ7	;	2.15	;	The X-ray structure of the adduct formed in the reaction between bovine pancreatic ribonuclease and arsenoplatin-1
4S0Q	;	2.09	;	The X-ray structure of the adduct formed in the reaction between bovine pancreatic ribonuclease and carboplatin
6QE9	;	2.03	;	The X-ray structure of the adduct formed in the reaction between bovine pancreatic ribonuclease and complex I, a pentacoordinate Pt(II) compound containing 2,9-dimethyl-1,10-phenanthroline, dimethylfumarate, methyl and iodine as ligands
5JLG	;	1.79	;	The X-ray structure of the adduct formed in the reaction between bovine pancreatic ribonuclease and compound I, a piano-stool organometallic Ru(II) arene compound containing an O,S-chelating ligand
4S18	;	2.27	;	The X-ray structure of the adduct formed in the reaction between bovine pancreatic ribonuclease and oxaliplatin
5ILC	;	1.75	;	The X-ray structure of the adduct formed in the reaction between hen egg white lysozyme a compound 2, a platin(II) compound containing a O, S bidentate ligand
5IHG	;	1.75	;	The X-ray structure of the adduct formed in the reaction between hen egg white lysozyme a compound I, a platin(II) compound containing a O, S bidentate ligand
5NJ1	;	1.85	;	The X-ray structure of the adduct formed in the reaction between hen egg white lysozyme and arsenoplatin-1
6QEA	;	1.96	;	The X-ray structure of the adduct formed in the reaction between hen egg white lysozyme and complex I, a pentacoordinate Pt(II) compound containing 2,9-dimethyl-1,10-phenanthroline, dimethylfumarate, methyl and iodine as ligands
5II3	;	1.78	;	The X-ray structure of the adduct formed in the reaction between hen egg white lysozyme and compound 3, a platin(II) compound containing a O, S bidentate ligand
5ILF	;	1.85	;	The X-ray structure of the adduct formed in the reaction between hen egg white lysozyme and compound 4, a platin(II) compound containing a O, S bidentate ligand
6G5Y	;	1.49	;	The X-ray structure of the adduct formed in the reaction between lysozyme and a platinum(II) terpyridine compound (acid pH)
6G5V	;	1.96	;	The X-ray structure of the adduct formed in the reaction between lysozyme and a platinum(II) terpyridine compound (pH 7.0)
2FLT	;	2.1	;	The X-ray structure of the cis-3-chloroacrylic acid dehalogenase cis-CaaD inactivated with (R)-Oxirane-2-carboxylate
1S6A	;	1.69	;	The X-ray structure of the cyanobacteria Synechocystis hemoglobin ""cyanoglobin"" with azide ligand
1S69	;	1.68	;	The X-ray structure of the cyanobacteria Synechocystis hemoglobin ""cyanoglobin"" with cyanide ligand
1VM9	;	1.48	;	The X-ray Structure of the cys84ala cys85ala double mutant of the [2Fe-2S] Ferredoxin subunit of Toluene-4-Monooxygenase from Pseudomonas Mendocina KR1
5JK7	;	3.49	;	The X-ray structure of the DDB1-DCAF1-Vpr-UNG2 complex
1DNK	;	2.3	;	THE X-RAY STRUCTURE OF THE DNASE I-D(GGTATACC)2 COMPLEX AT 2.3 ANGSTROMS RESOLUTION
5MMH	;	2.2	;	The X-Ray Structure of the Effector Domain of the Transcriptional Regulator AmpR of Pseudomonas aeruginosa
2XGL	;	2.7	;	The X-ray structure of the Escherichia coli colicin M immunity protein demonstrates the presence of a disulphide bridge, which is functionally essential
6FX8	;	1.8	;	The X-ray structure of the ferritin nanocage containing Au and Pt, obtained upon encapsulation of a single heterobimetallic compound within the protein cage (rotating anode data)
6FX9	;	1.5	;	The X-ray structure of the ferritin nanocage containing Au and Pt, obtained upon encapsulation of a single heterobimetallic compound within the protein cage (synchrtron data)
1DGC	;	3.0	;	THE X-RAY STRUCTURE OF THE GCN4-BZIP BOUND TO ATF/CREB SITE DNA SHOWS THE COMPLEX DEPENDS ON DNA FLEXIBILITY
6RJV	;	3.21	;	The X-ray structure of the Gold/Serum Albumin adduct obtained upon reaction of the protein with AuL12, a gold(III) dithiocarbamate complex
3J2N	;	16.0	;	The X-ray structure of the gp15 hexamer and the model of the gp18 protein fitted into the cryo-EM reconstruction of the contracted T4 tail
3J2M	;	15.0	;	The X-ray structure of the gp15 hexamer and the model of the gp18 protein fitted into the cryo-EM reconstruction of the extended T4 tail
2BKC	;	2.3	;	The X-ray structure of the H43G Listeria innocua Dps mutant
6HJT	;	1.33	;	The X-ray structure of the horse spleen ferritin nanocage containing Pt, obtained upon encapsulation of a Pt(II) terpyridine compound within the protein cage
6HJU	;	1.58	;	The X-ray structure of the horse spleen ferritin nanocage containing Pt, obtained upon encapsulation of a Pt(II) terpyridine compound within the protein cage
1TUE	;	2.1	;	The X-ray Structure of the Papillomavirus Helicase in Complex with its Molecular Matchmaker E2
4RSZ	;	2.19	;	The X-ray structure of the Primary Adduct formed in the Reaction between Cisplatin and Cytochrome c
2YBO	;	2.0	;	The x-ray structure of the SAM-dependent uroporphyrinogen III methyltransferase NirE from Pseudomonas aeruginosa in complex with SAH
2YBQ	;	2.0	;	The x-ray structure of the SAM-dependent uroporphyrinogen III methyltransferase NirE from Pseudomonas aeruginosa in complex with SAH and uroporphyrinogen III
1GJY	;	2.2	;	The X-ray structure of the Sorcin Calcium Binding Domain (SCBD) provides insight into the phosphorylation and calcium dependent processess
2WDA	;	2.3	;	The X-ray structure of the Streptomyces coelicolor A3 Chondroitin AC Lyase in Complex with Chondroitin sulphate
2X03	;	2.3	;	The X-ray structure of the Streptomyces coelicolor A3 Chondroitin AC Lyase Y253A mutant
1QGH	;	2.35	;	THE X-RAY STRUCTURE OF THE UNUSUAL DODECAMERIC FERRITIN FROM LISTERIA INNOCUA, REVEALS A NOVEL INTERSUBUNIT IRON BINDING SITE.
2XQV	;	1.93	;	The X-ray structure of the Zn(II) bound ZnuA from Salmonella enterica
6JP6	;	2.699	;	The X-ray structure of yeast tRNA methyltransferase complex of Trm7 and Trm734 essential for 2'-O-methylation at the first position of anticodon in specific tRNAs
6JPL	;	2.32	;	The X-ray structure of yeast tRNA methyltransferase Trm7-Trm734 in complex with S-adenosyl-L-methionine
3LJD	;	1.38	;	The X-ray structure of zebrafish RNase1 from a new crystal form at pH 4.5
3LJE	;	1.8	;	The X-ray structure of zebrafish RNase5
3LN8	;	1.61	;	The X-ray structure of Zf-RNase-1 from a new crystal form at pH 7.3
4AYH	;	2.52	;	The X-ray structure of zinc bound ZinT
5XZ4	;	1.41	;	The X-tay structure of Bumblebee PGRP-SA
7B21	;	1.2	;	The X183 domain from Cellvibrio japonicus Cbp2D
1HQL	;	2.2	;	The xenograft antigen in complex with the B4 isolectin of Griffonia simplicifolia lectin-1
4QMH	;	1.652	;	The XMAP215 family drives microtubule polymerization using a structurally diverse TOG array
4QMI	;	1.9	;	The XMAP215 family drives microtubule polymerization using a structurally diverse TOG array
4QMJ	;	2.498	;	The XMAP215 family drives microtubule polymerization using a structurally diverse TOG array
5JQK	;	2.35	;	The Xray Crystal Structure of P. falciparum Aminopeptidase P
5JR6	;	2.3	;	The Xray Crystal Structure of P. falciparum Aminopeptidase P in Complex With Apstatin
1BP3	;	2.9	;	THE XRAY STRUCTURE OF A GROWTH HORMONE-PROLACTIN RECEPTOR COMPLEX
2BNJ	;	1.6	;	The xylanase TA from Thermoascus aurantiacus utilizes arabinose decorations of xylan as significant substrate specificity determinants.
2DVH	;		;	THE Y64A MUTANT OF CYTOCHROME C553 FROM DESULFOVIBRIO VULGARIS HILDENBOROUGH, NMR, 39 STRUCTURES
2YYX	;	1.0	;	The Y65A mutant of tetraheme cytochrome c3 from Desulfovibrio Vulgaris Miyazaki F
2Z47	;	1.6	;	The Y66L mutant of tetraheme cytochrome c3 from Desulfovibrio Vulgaris Miyazaki F
5X3H	;	2.5	;	The Y81G mutant of the UNG crystal structure from Nitratifractor salsuginis
5WYI	;	2.0	;	The Yaf9 YEATS domain Recognizing H3K122suc Peptide
1YVN	;	2.1	;	THE YEAST ACTIN VAL 159 ASN MUTANT COMPLEX WITH HUMAN GELSOLIN SEGMENT 1.
6WUC	;	3.23	;	The yeast Ctf3 complex with Cnn1-Wip1
2V3J	;	2.0	;	The yeast ribosome synthesis factor Emg1 alpha beta knot fold methyltransferase
2V3K	;	2.0	;	The yeast ribosome synthesis factor Emg1 alpha beta knot fold methyltransferase
4RIT	;	1.8	;	The yellow crystal structure of pyridoxal-dependent decarboxylase from sphaerobacter thermophilus dsm 20745
4ALZ	;	1.4	;	The Yersinia T3SS basal body component YscD reveals a different structural periplasmatic domain organization to known homologue PrgH
5CE3	;	2.93	;	The Yersinia YopO - actin complex with MgADP
5EB1	;	1.8	;	the YfiB-YfiR complex
1FL9	;	2.5	;	THE YJEE PROTEIN
6RT6	;	1.461	;	The YTH domain of YTHDC1 protein in complex with GGm6AC oligonucleotide
6RT5	;	2.303	;	The YTH domain of YTHDC1 protein in complex with Gm6AC oligonucleotide
6RT7	;	1.73	;	The YTH domain of YTHDC1 protein in complex with Gm6ACU oligonucleotide
6RT4	;	1.49	;	The YTH domain of YTHDC1 protein in complex with m6ACU oligonucleotide
2BAI	;		;	The Zinc finger domain of Mengovirus Leader polypeptide
4HCC	;	2.96	;	The zinc ion bound form of crystal structure of E.coli ExoI-ssDNA complex
7DGO	;	2.0	;	The Zn-bound dimeric structure of K79H/G80A/H81A myoglobin
2M13	;		;	The ZZ domain of cytoplasmic polyadenylation element binding protein 1 (CPEB1)
5O9W	;	1.85	;	Thebaine 6-O-demethylase (T6ODM) from Papaver somniferum in complex with 2-oxoglutarate
5O7Y	;	1.97	;	Thebaine 6-O-demethylase (T6ODM) from Papaver somniferum in complex with succinate
1EHT	;		;	THEOPHYLLINE-BINDING RNA IN COMPLEX WITH THEOPHYLLINE, NMR, 10 STRUCTURES
1O15	;		;	THEOPHYLLINE-BINDING RNA IN COMPLEX WITH THEOPHYLLINE, NMR, REGULARIZED MEAN STRUCTURE, REFINEMENT WITH TORSION ANGLE AND BASE-BASE POSITIONAL DATABASE POTENTIALS AND DIPOLAR COUPLINGS
6TUZ	;	1.24	;	Theophylline-Notum complex
6BP2	;	3.172	;	Therapeutic human monoclonal antibody MR191 bound to a marburgvirus glycoprotein
1LSM	;	1.7	;	THERMAL STABILITY DETERMINANTS OF CHICKEN EGG-WHITE LYSOZYME CORE MUTANTS: HYDROPHOBICITY, PACKING VOLUME AND CONSERVED BURIED WATER MOLECULES
1LSN	;	1.9	;	THERMAL STABILITY DETERMINANTS OF CHICKEN EGG-WHITE LYSOZYME CORE MUTANTS: HYDROPHOBICITY, PACKING VOLUME AND CONSERVED BURIED WATER MOLECULES
1NCL	;	2.2	;	THERMAL STABILITY OF HEXAMERIC AND TETRAMERIC NUCLEOSIDE, DIPHOSPHATE KINASES
2IV0	;	2.5	;	Thermal stability of isocitrate dehydrogenase from Archaeoglobus fulgidus studied by crystal structure analysis and engineering of chimers
2DCZ	;	1.9	;	Thermal Stabilization of Bacillus subtilis Family-11 Xylanase By Directed Evolution
7DQP	;	2.203	;	Thermal treated Marsupenaeus japonicus ferritin
6J4M	;	2.598	;	Thermal treated soybean seed H-2 ferritin
5EJT	;	1.55	;	Thermally annealed ferryl Cytochrome C Peroxidase crystal structure
1IZJ	;	2.2	;	Thermoactinomyces vulgaris R-47 alpha-amylase 1 mutant enzyme f313a
1IZK	;	2.2	;	Thermoactinomyces vulgaris R-47 alpha-amylase 1 mutant enzyme w398v
1UH4	;	1.8	;	Thermoactinomyces vulgaris R-47 alpha-amylase 1/malto-tridecaose complex
5Z0U	;	1.37	;	Thermoactinomyces vulgaris R-47 alpha-amylase I (TVA I) 11 residues (from A363 to N373) deletion mutant (Del11)
5Z0T	;	1.5	;	Thermoactinomyces vulgaris R-47 alpha-amylase I (TVA I) mutant A357V/Q359N/Y360E (AQY/VNE)
1WZK	;	2.3	;	Thermoactinomyces vulgaris R-47 alpha-amylase II (TVA II) mutatnt D465N
1WZM	;	3.2	;	Thermoactinomyces vulgaris R-47 alpha-amylase II (TVA II) mutatnt R469K
1WZL	;	2.0	;	Thermoactinomyces vulgaris R-47 alpha-amylase II (TVA II) mutatnt R469L
1UH3	;	2.6	;	Thermoactinomyces vulgaris R-47 alpha-amylase/acarbose complex
1UH2	;	2.0	;	Thermoactinomyces vulgaris R-47 alpha-amylase/malto-hexaose complex
4QK8	;	3.05	;	Thermoanaerobacter pseudethanolicus c-di-AMP riboswitch
8FXU	;	1.59	;	Thermoanaerobacter thermosaccharolyticum periplasmic Glucose-Binding Protein glucose complex: Badan conjugate attached at F17C
2YET	;	1.502	;	Thermoascus GH61 isozyme A
3ZUD	;	1.25	;	THERMOASCUS GH61 ISOZYME A
6WQW	;	2.102	;	Thermobacillus composti GH10 xylanase
5DIY	;	2.06	;	Thermobaculum terrenum O-GlcNAc hydrolase mutant - D120N
5DJS	;	2.8	;	Thermobaculum terrenum O-GlcNAc transferase mutant - K341M
4B4F	;	2.2	;	Thermobifida fusca Cel6B(E3) co-crystallized with cellobiose
4AVN	;	2.0	;	Thermobifida fusca cellobiohydrolase Cel6B catalytic mutant D226A- S232A cocrystallized with cellobiose
4AVO	;	1.8	;	Thermobifida fusca cellobiohydrolase Cel6B catalytic mutant D274A cocrystallized with cellobiose
4B4H	;	1.5	;	Thermobifida fusca cellobiohydrolase Cel6B(E3) catalytic domain
6EA3	;	1.65	;	Thermobifida fusca FscH adenylation domain complexed with MbtH-like protein FscK and Ser-AMP
7ZVM	;	1.58	;	Thermococcus barophilus phosphomannose isomerase protein structure at 1.6 A
1QYP	;		;	THERMOCOCCUS CELER RPB9, NMR, 25 STRUCTURES
7ZVY	;	2.16	;	Thermococcus kadokarensis phosphomannose isomerase
6GQI	;	2.0	;	Thermocrispum municipale cyclohexanone monooxygenase bound to hexanoic acid
3TEK	;	2.0	;	ThermoDBP: a non-canonical single-stranded DNA binding protein with a novel structure and mechanism
1PWT	;	1.77	;	THERMODYNAMIC ANALYSIS OF ALPHA-SPECTRIN SH3 AND TWO OF ITS CIRCULAR PERMUTANTS WITH DIFFERENT LOOP LENGTHS: DISCERNING THE REASONS FOR RAPID FOLDING IN PROTEINS
2DTM	;	2.25	;	Thermodynamic and structural analyses of hydrolytic mechanism by catalytic antibodies
2E4L	;	2.0	;	Thermodynamic and Structural Analysis of Thermolabile RNase HI from Shewanella oneidensis MR-1
195L	;	1.9	;	THERMODYNAMIC AND STRUCTURAL COMPENSATION IN ""SIZE-SWITCH"" CORE-REPACKING VARIANTS OF T4 LYSOZYME
196L	;	2.3	;	THERMODYNAMIC AND STRUCTURAL COMPENSATION IN ""SIZE-SWITCH"" CORE-REPACKING VARIANTS OF T4 LYSOZYME
197L	;	2.1	;	THERMODYNAMIC AND STRUCTURAL COMPENSATION IN ""SIZE-SWITCH"" CORE-REPACKING VARIANTS OF T4 LYSOZYME
198L	;	2.0	;	THERMODYNAMIC AND STRUCTURAL COMPENSATION IN ""SIZE-SWITCH"" CORE-REPACKING VARIANTS OF T4 LYSOZYME
199L	;	1.85	;	THERMODYNAMIC AND STRUCTURAL COMPENSATION IN ""SIZE-SWITCH"" CORE-REPACKING VARIANTS OF T4 LYSOZYME
200L	;	1.95	;	THERMODYNAMIC AND STRUCTURAL COMPENSATION IN ""SIZE-SWITCH"" CORE-REPACKING VARIANTS OF T4 LYSOZYME
2RLN	;	1.85	;	THERMODYNAMIC AND STRUCTURAL CONSEQUENCES OF CHANGING A SULPHUR ATOM TO A METHYLENE GROUP IN THE M13NLE MUTATION IN RIBONUCLEASE S
3CCT	;	2.12	;	Thermodynamic and structure guided design of statin hmg-coa reductase inhibitors
3CCW	;	2.1	;	Thermodynamic and structure guided design of statin hmg-coa reductase inhibitors
3CCZ	;	1.7	;	Thermodynamic and structure guided design of statin hmg-coa reductase inhibitors
3CD0	;	2.4	;	Thermodynamic and structure guided design of statin hmg-coa reductase inhibitors
3CD5	;	2.39	;	Thermodynamic and structure guided design of statin hmg-coa reductase inhibitors
3CD7	;	2.05	;	Thermodynamic and structure guided design of statin hmg-coa reductase inhibitors
3CDA	;	2.07	;	Thermodynamic and structure guided design of statin hmg-coa reductase inhibitors
3CDB	;	2.3	;	Thermodynamic and structure guided design of statin hmg-coa reductase inhibitors
1YTC	;	1.8	;	THERMODYNAMIC CYCLES AS PROBES OF STRUCTURE-FUNCTION RELATIONSHIPS IN UNFOLDED PROTEINS
4UOS	;	1.63	;	Thermodynamic hyperstability in parametrically designed helical bundles
4UOT	;	1.69	;	Thermodynamic hyperstability in parametrically designed helical bundles
2WEG	;	1.1	;	Thermodynamic Optimisation of Carbonic Anhydrase Fragment Inhibitors
2WEH	;	2.09	;	Thermodynamic Optimisation of Carbonic Anhydrase Fragment Inhibitors
2WEJ	;	1.45	;	Thermodynamic Optimisation of Carbonic Anhydrase Fragment Inhibitors
2WEO	;	1.4	;	Thermodynamic Optimisation of Carbonic Anhydrase Fragment Inhibitors
2DM5	;	1.7	;	Thermodynamic Penalty Arising From Burial of a Ligand Polar Group Within a Hydrophobic Pocket of a Protein Receptor
6GE7	;	2.3	;	Thermodynamic, Crystallographic and Computational Studies of Non Mammalian Fatty Acid Binding to Bovine b-Lactoglobulin
6GF9	;	2.1	;	Thermodynamic, Crystallographic and Computational Studies of Non Mammalian Fatty Acid Binding to Bovine b-Lactoglobulin
6GFS	;	2.0	;	Thermodynamic, Crystallographic and Computational Studies of Non Mammalian Fatty Acid Binding to Bovine b-Lactoglobulin
6GHH	;	1.9	;	Thermodynamic, Crystallographic and Computational Studies of Non Mammalian Fatty Acid Binding to Bovine b-Lactoglobulin
3MGW	;	1.75	;	Thermodynamics and structure of a salmon cold-active goose-type lysozyme
1QY0	;	1.8	;	Thermodynamics of Binding of 2-methoxy-3-isopropylpyrazine and 2-methoxy-3-isobutylpyrazine to the Major Urinary Protein
1QY1	;	1.7	;	Thermodynamics of Binding of 2-methoxy-3-isopropylpyrazine and 2-methoxy-3-isobutylpyrazine to the Major Urinary Protein
1QY2	;	1.75	;	Thermodynamics of Binding of 2-methoxy-3-isopropylpyrazine and 2-methoxy-3-isobutylpyrazine to the Major Urinary Protein
1IN5	;	2.0	;	THERMOGOTA MARITIMA RUVB A156S MUTANT
8AG9	;	1.56	;	Thermogutta terrifontis endoglucanase of glycoside hydrolase family 5 (TtEnd5A)
7BFV	;	1.84	;	Thermogutta terrifontis esterase 2 phosphonylated by cyclosarin
7BFU	;	1.65	;	Thermogutta terrifontis esterase 2 phosphonylated by sarin
7BFO	;	1.99	;	Thermogutta terrifontis esterase 2 phosphonylated by VX
7BFT	;	1.99	;	Thermogutta terrifontis esterase 2 phosphoramylated by tabun
7BFR	;	1.99	;	Thermogutta terrifontis esterase 2 phosphorylated by paraoxon
6LZN	;	1.5	;	Thermolysin
3TLI	;	1.95	;	THERMOLYSIN (10% ISOPROPANOL SOAKED CRYSTALS)
8TLI	;	2.2	;	THERMOLYSIN (100% ISOPROPANOL SOAKED CRYSTALS)
1TLI	;	2.05	;	THERMOLYSIN (2% ISOPROPANOL SOAKED CRYSTALS)
4TLI	;	1.95	;	THERMOLYSIN (25% ISOPROPANOL SOAKED CRYSTALS)
2TLI	;	1.95	;	THERMOLYSIN (5% ISOPROPANOL SOAKED CRYSTALS)
1FJW	;	1.9	;	THERMOLYSIN (50 MM PHENOL SOAKED)
1FJ3	;	2.0	;	THERMOLYSIN (50% ACETONE SOAKED)
1FJT	;	2.2	;	THERMOLYSIN (50% ACETONITRILE SOAKED CRYSTALS)
1FJO	;	2.0	;	THERMOLYSIN (60% ACETONE SOAKED CRYSTALS)
1FJV	;	2.0	;	THERMOLYSIN (60% ACETONITRILE SOAKED CRYSTALS)
5TLI	;	2.1	;	THERMOLYSIN (60% ISOPROPANOL SOAKED CRYSTALS)
6TLI	;	2.1	;	THERMOLYSIN (60% ISOPROPANOL SOAKED CRYSTALS)
1FJQ	;	1.7	;	THERMOLYSIN (70% ACETONE SOAKED CRYSTALS)
1FJU	;	2.0	;	THERMOLYSIN (80% ACETONITRILE SOAKED CRYSTALS)
7TLI	;	1.95	;	THERMOLYSIN (90% ISOPROPANOL SOAKED CRYSTALS)
1QF2	;	2.06	;	THERMOLYSIN (E.C.3.4.24.27) COMPLEXED WITH (2-SULPHANYL-3-PHENYLPROPANOYL)-GLY-(5-PHENYLPROLINE). PARAMETERS FOR ZN-MONODENTATION OF MERCAPTOACYLDIPEPTIDES IN METALLOENDOPEPTIDASE
1QF0	;	2.2	;	THERMOLYSIN (E.C.3.4.24.27) COMPLEXED WITH (2-SULPHANYL-3-PHENYLPROPANOYL)-PHE-TYR. PARAMETERS FOR ZN-BIDENTATION OF MERCAPTOACYLDIPEPTIDES IN METALLOENDOPEPTIDASE
1QF1	;	2.0	;	THERMOLYSIN (E.C.3.4.24.27) COMPLEXED WITH (2-SULPHANYLHEPTANOYL)-PHE-ALA. PARAMETERS FOR ZN-BIDENTATION OF MERCAPTOACYLDIPEPTIDES IN METALLOENDOPEPTIDASE
1TLX	;	2.1	;	THERMOLYSIN (NATIVE)
2TLX	;	1.65	;	THERMOLYSIN (NATIVE)
1KEI	;	1.6	;	Thermolysin (substrate-free)
3DO0	;	1.36	;	Thermolysin by classical hanging drop method after high X-Ray dose on esrf ID14-2 beamline
3DO1	;	1.33	;	Thermolysin by Classical hanging drop method before high X-Ray dose on ESRF ID14-2 beamline
3DO2	;	1.22	;	Thermolysin by LB nanotemplate method after high X-Ray dose on ESRF ID14-2 beamline
3DNZ	;	1.2	;	Thermolysin by LB nanotemplate method before high X-Ray dose on ESRF ID14-2 beamline
1THL	;	1.7	;	Thermolysin complexed with a novel glutaramide derivative, n-(1-(2(r,s)-carboxy-4-phenylbutyl) cyclopentylcarbonyl)-(s)-tryptophan
3FOR	;	1.93	;	Thermolysin Complexed with BNPA (2-Benzyl-3-Nitro Propanoic Acid Amide)
1KTO	;	1.9	;	Thermolysin complexed with Z-D-Alanine (benzyloxycarbonyl-D-Alanine)
1KS7	;	1.7	;	Thermolysin complexed with Z-D-Aspartic acid (benzyloxycarbonyl-D-Aspartic acid)
1KR6	;	1.8	;	Thermolysin complexed with Z-D-Glutamic acid (benzyloxycarbonyl-D-Glutamic acid)
1KRO	;	1.7	;	Thermolysin complexed with Z-D-Threonine (benzyloxycarbonyl-D-Threonine)
1KL6	;	1.8	;	Thermolysin complexed with Z-L-Alanine (benzyloxycarbonyl-L-Alanine)
1KKK	;	1.6	;	Thermolysin complexed with Z-L-Aspartic Acid (benzyloxycarbonyl-L-Aspartic Acid)
1KJP	;	1.6	;	Thermolysin complexed with Z-L-Glutamic acid (benzyloxycarbonyl-L-Glutamic acid)
1KJO	;	1.6	;	Thermolysin complexed with Z-L-Threonine (benzyloxycarbonyl-L-Threonine)
7AKN	;	2.46	;	Thermolysin from Bacillus thermoproteolyticus
4D91	;	1.9	;	Thermolysin In Complex With DMSO And Acetate
6SBK	;	1.48	;	THERMOLYSIN IN COMPLEX WITH FRAGMENT J13
6SC0	;	1.53	;	THERMOLYSIN IN COMPLEX WITH FRAGMENT J22
6SC3	;	1.82	;	THERMOLYSIN IN COMPLEX WITH FRAGMENT J62
6SCK	;	1.41	;	THERMOLYSIN IN COMPLEX WITH FRAGMENT J77
6SCU	;	1.42	;	THERMOLYSIN IN COMPLEX WITH FRAGMENT J88
6SC1	;	1.56	;	THERMOLYSIN IN COMPLEX WITH FRAGMENT J96
5LIF	;	1.31	;	Thermolysin in complex with inhibitor
5LVD	;	1.25	;	Thermolysin in complex with inhibitor (JC67)
5LWD	;	1.23	;	Thermolysin in complex with inhibitor (JC96)
5M5F	;	1.33	;	Thermolysin in complex with inhibitor and krypton
5M69	;	1.44	;	Thermolysin in complex with inhibitor and xenon
5MNR	;	1.249	;	Thermolysin in complex with inhibitor JC256
5N3Y	;	1.339	;	Thermolysin in complex with inhibitor JC267
5N2X	;	1.209	;	Thermolysin in complex with inhibitor JC272
5N34	;	1.22	;	Thermolysin in complex with inhibitor JC276
5N31	;	1.368	;	Thermolysin in complex with inhibitor JC277
5N2Z	;	1.37	;	Thermolysin in complex with inhibitor JC286
5N2T	;	1.379	;	Thermolysin in complex with inhibitor JC287
5N3V	;	1.12	;	Thermolysin in complex with inhibitor JC292
5DPE	;	1.34	;	Thermolysin in complex with inhibitor.
5DPF	;	1.47	;	Thermolysin in complex with inhibitor.
6SB9	;	1.3	;	Thermolysin in complex with J28
5JT9	;	1.26	;	Thermolysin in complex with JC106.
5L8P	;	1.29	;	Thermolysin in complex with JC114 (PEG400 cryo protectant)
5JS3	;	1.16	;	Thermolysin in complex with JC114.
5L41	;	1.25	;	Thermolysin in complex with JC148 (MPD cryo protectant)
5JVI	;	1.12	;	Thermolysin in complex with JC148.
5L3U	;	1.23	;	Thermolysin in complex with JC149 (MPD cryo protectant)
5JSS	;	1.19	;	Thermolysin in complex with JC149.
5JXN	;	1.38	;	Thermolysin in complex with JC240.
4N5P	;	1.25	;	Thermolysin in complex with UBTLN20
3T73	;	1.6	;	Thermolysin In Complex With UBTLN22
3T8G	;	1.5	;	Thermolysin In Complex With UBTLN26
3T74	;	1.28	;	Thermolysin In Complex With UBTLN27
3T87	;	1.28	;	Thermolysin In Complex With UBTLN28
3T8H	;	1.45	;	Thermolysin In Complex With UBTLN29
3T8C	;	1.66	;	Thermolysin In Complex With UBTLN30
3T8D	;	1.41	;	Thermolysin In Complex With UBTLN31
4D9W	;	1.381	;	Thermolysin In Complex With UBTLN32
3T8F	;	1.44	;	Thermolysin In Complex With UBTLN34
4MXJ	;	1.349	;	Thermolysin in complex with UBTLN35
4MTW	;	1.32	;	Thermolysin in complex with UBTLN36
4N66	;	1.44	;	Thermolysin in complex with UBTLN37
4MWP	;	1.23	;	Thermolysin in complex with UBTLN46
4N4E	;	1.13	;	Thermolysin in complex with UBTLN58
4MZN	;	1.172	;	Thermolysin in complex with UBTLN59
1L3F	;	2.3	;	Thermolysin in the Absence of Substrate has an Open Conformation
3F28	;	1.68	;	Thermolysin inhibition
3F2P	;	1.95	;	Thermolysin inhibition
3FCQ	;	1.75	;	Thermolysin inhibition
3FLF	;	1.97	;	Thermolysin inhibition
3FV4	;	1.56	;	Thermolysin inhibition
3FVP	;	1.41	;	Thermolysin inhibition
3FXP	;	2.05	;	Thermolysin inhibition
4H57	;	1.56	;	Thermolysin inhibition
4OW3	;	2.1	;	Thermolysin structure determined by free-electron laser
6LZO	;	1.8	;	Thermolysin with 1,10-phenanthroline
1OS0	;	2.1	;	Thermolysin with an alpha-amino phosphinic inhibitor
1PE7	;	1.82	;	Thermolysin with bicyclic inhibitor
1PE8	;	1.8	;	Thermolysin with monocyclic inhibitor
1PE5	;	1.7	;	Thermolysin with tricyclic inhibitor
5WR5	;	1.9	;	Thermolysin, liganded form with cryo condition 1
5WR6	;	2.3	;	Thermolysin, liganded form with cryo condition 2
5WR2	;	2.0	;	Thermolysin, SFX liganded form with oil-based carrier
5WR3	;	2.1	;	Thermolysin, SFX liganded form with water-based carrier
5WR4	;	2.1	;	Thermolysin, SFX unliganded form with oil-based carrier
6QAR	;	1.85	;	Thermolysine under 2 kbar of argon
7EXS	;	1.42	;	Thermomicrobium roseum sarcosine oxidase mutant - S320R
4N1A	;	3.24	;	Thermomonospora curvata EccC (ATPases 2 and 3) in complex with a signal sequence peptide
6I9E	;	3.74	;	Thermophage P23-45 empty expanded capsid
6QJT	;	3.74	;	Thermophage P23-45 in situ procapsid portal protein
6IBC	;	4.39	;	Thermophage P23-45 procapsid
5MR0	;	1.98	;	Thermophilic archaeal branched-chain amino acid transaminases from Geoglobus acetivorans and Archaeoglobus fulgidus: biochemical and structural characterisation
1M4W	;	2.1	;	Thermophilic b-1,4-xylanase from Nonomuraea flexuosa
1H1A	;	1.75	;	Thermophilic beta-1,4-xylanase from Chaetomium thermophilum
1IO7	;	1.5	;	THERMOPHILIC CYTOCHROME P450 (CYP119) FROM SULFOLOBUS SOLFATARICUS: HIGH RESOLUTION STRUCTURAL ORIGIN OF ITS THERMOSTABILITY AND FUNCTIONAL PROPERTIES
1IO8	;	2.0	;	Thermophilic cytochrome P450 (CYP119) from sulfolobus solfataricus: High resolution structural origin of its thermostability and functional properties
1IO9	;	2.05	;	THERMOPHILIC CYTOCHROME P450 (CYP119) FROM SULFOLOBUS SOLFATARICUS: HIGH RESOLUTION STRUCTURAL ORIGIN OF ITS THERMOSTABILITY AND FUNCTIONAL PROPERTIES
7OLC	;	2.9	;	Thermophilic eukaryotic 80S ribosome at idle POST state
7OLD	;	3.0	;	Thermophilic eukaryotic 80S ribosome at pe/E (TI)-POST state
1F4U	;	2.69	;	THERMOPHILIC P450: CYP119 FROM SULFOLOBUS SOLFACTARICUS
1F4T	;	1.93	;	THERMOPHILIC P450: CYP119 FROM SULFOLOBUS SOLFACTARICUS WITH 4-PHENYLIMIDAZOLE BOUND
8UCE	;	2.12	;	Thermophilic RNA Ligase from Palaeococcus pacificus + AMP
8UCF	;	1.9	;	Thermophilic RNA Ligase from Palaeococcus pacificus K238G
8UCI	;	2.14	;	Thermophilic RNA Ligase from Palaeococcus pacificus K238G + AMP
8UCG	;	1.86	;	Thermophilic RNA Ligase from Palaeococcus pacificus K92A
8UCH	;	2.14	;	Thermophilic RNA Ligase from Palaeococcus pacificus K92A + ATP
1C7I	;	2.0	;	THERMOPHYLIC PNB ESTERASE
3J9I	;	3.3	;	Thermoplasma acidophilum 20S proteasome
8F66	;	2.28	;	Thermoplasma acidophilum 20S proteasome - L81Y mutation in alpha subunit
8F6A	;	2.06	;	Thermoplasma acidophilum 20S proteasome - wild type
8F7K	;	1.94	;	Thermoplasma acidophilum 20S proteasome - wild type bound to ZYA
5VY4	;	3.3	;	Thermoplasma acidophilum 20S Proteasome using 200keV with image shift
5VY3	;	3.1	;	Thermoplasma acidophilum 20S Proteasome using 200keV with stage position
3C92	;	6.8	;	Thermoplasma acidophilum 20S proteasome with a closed gate
3C91	;	6.8	;	Thermoplasma acidophilum 20S proteasome with an open gate
5APZ	;	1.6	;	Thermosinus carboxydivorans Nor1 Tcar0761 residues 68-101 and 191-211 fused to GCN4 adaptors
7OMU	;	2.96	;	Thermosipho africanus DarTG in complex with ADP-ribose
1A6D	;	2.6	;	THERMOSOME FROM T. ACIDOPHILUM
1A6E	;	3.2	;	THERMOSOME-MG-ADP-ALF3 COMPLEX
7P2L	;	2.54	;	thermostabilised 7TM domain of human mGlu5 receptor bound to photoswitchable ligand alloswitch-1
3PWH	;	3.296	;	Thermostabilised Adenosine A2A Receptor
3UZC	;	3.341	;	Thermostabilised Adenosine A2A receptor in complex with 4-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-2-chlorophenol
3UZA	;	3.273	;	Thermostabilised Adenosine A2A receptor in complex with 6-(2,6-Dimethylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine
3RFM	;	3.598	;	Thermostabilised adenosine A2A receptor in complex with caffeine
3REY	;	3.309	;	Thermostabilised adenosine A2A receptor in complex with XAC
5A8E	;	2.4	;	thermostabilised beta1-adrenoceptor with rationally designed inverse agonist 7-methylcyanopindolol bound
7FD8	;	3.8	;	Thermostabilised full length human mGluR5-5M bound with L-quisqualic acid
7FD9	;	4.0	;	Thermostabilised full length human mGluR5-5M with orthosteric antagonist, LY341495
2YDO	;	3.0	;	Thermostabilised HUMAN A2a Receptor with adenosine bound
4UG2	;	2.6	;	Thermostabilised HUMAN A2a Receptor with CGS21680 bound
4UHR	;	2.6	;	Thermostabilised HUMAN A2a Receptor with CGS21680 bound
2YDV	;	2.6	;	Thermostabilised HUMAN A2a Receptor with NECA bound
3ZPQ	;	2.8	;	Thermostabilised turkey beta1 adrenergic receptor with 4-(piperazin-1- yl)-1H-indole bound (compound 19)
3ZPR	;	2.7	;	Thermostabilised turkey beta1 adrenergic receptor with 4-methyl-2-(piperazin-1-yl) quinoline bound
1XNC	;	1.6	;	THERMOSTABILIZATION OF THE BACILLUS CIRCULANS XYLANASE, BY THE INTRODUCTION OF DISULFIDE BONDS
7V73	;	3.52	;	Thermostabilized human prestin in complex with chloride
7V75	;	3.57	;	Thermostabilized human prestin in complex with salicylate
7V74	;	3.63	;	Thermostabilized human prestin in complex with sulfate
6B00	;	0.9	;	Thermostabilized mutant of human carbonic anhydrase II - A65T L100H K154N L224S L240P A248T
6D3S	;	6.6	;	Thermostabilized phosphorylated chicken CFTR
4LU6	;	3.05	;	Thermostabilized RebH
7SOG	;	1.74	;	Thermostable actophorin
5EK6	;	2.66	;	Thermostable aldehyde dehydrogenase from Pyrobaculum sp. 1860 complexed with NADP and isobutyraldehyde
5F2C	;	1.898	;	Thermostable aldehyde dehydrogenase from Pyrobaculum sp. 1860 crystallized in microgravity (complex with NADP+)
4H73	;	2.4	;	Thermostable aldehyde dehydrogenase from Pyrobaculum sp. complexed with NADP+
4NMJ	;	2.002	;	Thermostable aldehyde dehydrogenase from Pyrobaculum sp. complexed with NADP+ at 2 A resolution
4NMK	;	1.898	;	Thermostable aldehyde dehydrogenase from Pyrobaculum sp. crystallized in microgravity (complex with NADP+)
5EKC	;	1.895	;	Thermostable aldehyde dehydrogenase from Pyrobaculum sp.1860 complexed with NADP+
5EUY	;	2.06	;	Thermostable aldehyde dehydrogenase from Pyrobaculum sp.1860 complexed with NADP+
5EXF	;	2.19	;	Thermostable aldehyde dehydrogenase from Pyrobaculum sp.1860 complexed with NADP+
1TGO	;	2.5	;	THERMOSTABLE B TYPE DNA POLYMERASE FROM THERMOCOCCUS GORGONARIUS
6NJ2	;	1.5	;	thermostable carbonic anhydrase II variant with tetrazine 2.0 at site 186
1CIU	;	2.3	;	THERMOSTABLE CGTASE FROM THERMOANAEROBACTERIUM THERMOSULFURIGENES EM1 AT PH 8.0.
3IDA	;	1.6	;	Thermostable Cocaine Esterase with mutations L169K and G173Q, bound to DTT adduct
4YWS	;	2.45	;	Thermostable enolase from Chloroflexus aurantiacus
4Z17	;	2.65	;	Thermostable enolase from Chloroflexus aurantiacus
4Z1Y	;	2.53	;	Thermostable enolase from Chloroflexus aurantiacus with substrate 2-phosphoglycerate
7ZEI	;	1.7	;	Thermostable GH159 glycoside hydrolase from Caldicellulosiruptor at 1.7 A
2VUL	;	1.9	;	Thermostable mutant of ENVIRONMENTALLY ISOLATED GH11 XYLANASE
5KVC	;	1.501	;	Thermostable mutant of halohydrin dehalogenase (HheC)
5KWE	;	1.684	;	Thermostable mutant of halohydrin dehalogenase HheC - C153N
1N18	;	2.0	;	Thermostable mutant of Human Superoxide Dismutase, C6A, C111S
7B4I	;	1.7	;	Thermostable omega transaminase PjTA-R6 variant W58G engineered for asymmetric synthesis of enantiopure bulky amines
7B4J	;	1.9	;	Thermostable omega transaminase PjTA-R6 variant W58M/F86L/R417L engineered for asymmetric synthesis of enantiopure bulky amines
3K3W	;	3.31	;	Thermostable Penicillin G acylase from Alcaligenes faecalis in orthorhombic form
3ML0	;	3.5	;	Thermostable Penicillin G acylase from Alcaligenes faecalis in tetragonal form
4E5P	;	1.9	;	Thermostable phosphite dehydrogenase A176R variant in complex with NAD
4E5M	;	1.85	;	Thermostable phosphite dehydrogenase E175A/A176R in complex with NADP
4E5N	;	1.7	;	Thermostable phosphite dehydrogenase in complex with NAD
4E5K	;	1.95	;	Thermostable phosphite dehydrogenase in complex with NAD and sulfite
1POO	;	2.1	;	THERMOSTABLE PHYTASE FROM BACILLUS SP
2POO	;	2.05	;	THERMOSTABLE PHYTASE IN FULLY CALCIUM LOADED STATE
4AAI	;		;	THERMOSTABLE PROTEIN FROM HYPERTHERMOPHILIC VIRUS SSV-RH
1VII	;		;	THERMOSTABLE SUBDOMAIN FROM CHICKEN VILLIN HEADPIECE, NMR, MINIMIZED AVERAGE STRUCTURE
1BKO	;	2.75	;	THERMOSTABLE THYMIDYLATE SYNTHASE A FROM BACILLUS SUBTILIS
1BKP	;	1.7	;	THERMOSTABLE THYMIDYLATE SYNTHASE A FROM BACILLUS SUBTILIS
1BSF	;	2.2	;	THERMOSTABLE THYMIDYLATE SYNTHASE A FROM BACILLUS SUBTILIS
1BSP	;	2.5	;	THERMOSTABLE THYMIDYLATE SYNTHASE A FROM BACILLUS SUBTILIS
3WLV	;	1.747	;	Thermostable urate oxidase from Bacillus sp. TB-90
6NJ5	;	1.25	;	Thermostable variant of human carbonic anhydrase II with disordered tetrazine 2.0 at site 233
6NJ4	;	1.3	;	Thermostable variant of human carbonic anhydrase with disordered tetrazine 2.0 reacted with strained trans-cyclooctene at site 233
6NJ3	;	1.01	;	Thermostable variant of human carbonic anhydrase with ordered tetrazine 2.0 at site 233
6NJ6	;	1.6	;	Thermostable variant of human carbonic anhydrase with tetrazine 2.0 at site 186 reacted with sTCO in crystallo
1GOO	;	1.87	;	Thermostable xylanase I from Thermoascus aurantiacus - Cryocooled glycerol complex
1GOQ	;	1.8	;	Thermostable xylanase I from Thermoascus aurantiacus - Room temperature xylobiose complex
1GOR	;	1.7	;	THERMOSTABLE XYLANASE I FROM THERMOASCUS AURANTIACUS - XYLOBIOSE COMPLEX AT 100 K
1GOM	;	1.92	;	Thermostable xylanase I from Thermoascus aurantiacus- Crystal form I
1GOK	;	1.14	;	Thermostable xylanase I from Thermoascus aurantiacus- Crystal form II
6D3R	;	4.3	;	Thermostablilized dephosphorylated chicken CFTR
6MGB	;	1.8	;	Thermosulfurimonas dismutans KpsC, beta Kdo 2,4 transferase
6MGD	;	2.5	;	Thermosulfurimonas dismutans KpsC, beta Kdo 2,7 transferase
2WSP	;	2.65	;	Thermotoga maritima alpha-L-fucosynthase, TmD224G, in complex with alpha-L-Fuc-(1-2)-beta-L-Fuc-N3
5HC9	;	2.9	;	Thermotoga maritima CCA-adding enzyme complexed with tRNA_CCA
3PG9	;	2.35	;	Thermotoga maritima DAH7P synthase in complex with inhibitor
7LIJ	;	2.84	;	Thermotoga maritima Encapsulin Nanocompartment Pore Mutant S1K
7LIK	;	2.91	;	Thermotoga maritima Encapsulin Nanocompartment Pore Mutant S1R
7LIS	;	2.96	;	Thermotoga maritima Encapsulin Nanocompartment Pore Mutant S5D
7LIM	;	2.75	;	Thermotoga maritima Encapsulin Nanocompartment Pore Mutant S6E
7LII	;	3.55	;	Thermotoga maritima Encapsulin Nanocompartment Pore Mutant S7D
7LIT	;	2.53	;	Thermotoga maritima Encapsulin Nanocompartment Pore Mutant S7G
7LIL	;	2.84	;	Thermotoga maritima Encapsulin Nanocompartment Pore Mutant SE3
7MU1	;	3.3	;	Thermotoga maritima encapsulin shell
5N6T	;	2.1	;	Thermotoga maritima family 1 glycoside hydrolase complexed with a cyclophellitol analogue transition state mimic
5N6S	;	2.1	;	Thermotoga maritima family 1 Glycoside hydrolase complexed with Carba-Cyclophellitol transition state mimic
7DY8	;	2.103	;	Thermotoga maritima ferritin mutant-FLAL
7DY9	;	2.303	;	Thermotoga maritima ferritin mutant-FLAL
7DYB	;	1.779	;	Thermotoga maritima ferritin mutant-FLAL-L
7XA4	;	1.96	;	Thermotoga maritima ferritin variant-Tm-E (S111H) with Zn
7X9Z	;	2.29	;	Thermotoga maritima ferritin variant-Tm-E(G40E) with Co
7X9X	;	2.3	;	Thermotoga Maritima ferritin variant-Tm-E(G40E) with Zn
7XA0	;	2.03	;	Thermotoga maritima ferritin variant-Tm-E(S111F)
7XA2	;	1.84	;	Thermotoga maritima ferritin variant-Tm-E(S111H)
7XA1	;	2.2	;	Thermotoga maritima ferritin variant-Tm-E(S111Y)
4A2B	;	1.8	;	Thermotoga maritima FtsA with ATP gamma S
4A2A	;	1.8	;	Thermotoga maritima FtsA:FtsZ(336-351)
1B3B	;	3.1	;	THERMOTOGA MARITIMA GLUTAMATE DEHYDROGENASE MUTANT N97D, G376K
2TMG	;	2.9	;	THERMOTOGA MARITIMA GLUTAMATE DEHYDROGENASE MUTANT S128R, T158E, N117R, S160E
2P3N	;	2.2	;	Thermotoga maritima IMPase TM1415
2P3V	;	2.4	;	Thermotoga maritima IMPase TM1415
1GJW	;	2.1	;	Thermotoga maritima maltosyltransferase complex with maltose
2GHA	;	1.6	;	Thermotoga maritima maltotriose binding protein bound with maltotriose
2FNC	;	1.7	;	Thermotoga maritima maltotriose binding protein bound with maltotriose.
2GHB	;	2.1	;	Thermotoga maritima maltotriose binding protein, ligand free form
4DDW	;	3.9	;	Thermotoga maritima reverse gyrase, c-centered orthorhombic form
4DDU	;	3.0	;	Thermotoga maritima reverse gyrase, C2 FORM 1
4DDT	;	3.2	;	Thermotoga maritima reverse gyrase, C2 FORM 2
4DDX	;	4.17	;	Thermotoga maritima reverse gyrase, primitive monoclinic form
4DDV	;	3.46	;	Thermotoga maritima reverse gyrase, triclinic form
3O0N	;	1.95	;	Thermotoga maritima Ribonucleotide Reductase, NrdJ, in complex with dTTP and Adenosylcobalamin
3O0Q	;	1.8	;	Thermotoga maritima Ribonucleotide Reductase, NrdJ, in complex with dTTP, GDP and Adenosine
3O0O	;	1.9	;	Thermotoga maritima Ribonucleotide Reductase, NrdJ, in complex with dTTP, GDP and Adenosylcobalamin
2FN8	;	2.15	;	Thermotoga maritima Ribose Binding Protein Ribose Bound Form
2FN9	;	1.4	;	Thermotoga maritima Ribose Binding Protein Unliganded Form
1IN4	;	1.6	;	THERMOTOGA MARITIMA RUVB HOLLIDAY JUNCTION BRANCH MIGRATION MOTOR
1IN6	;	1.8	;	THERMOTOGA MARITIMA RUVB K64R MUTANT
1J7K	;	1.8	;	THERMOTOGA MARITIMA RUVB P216G MUTANT
1IN7	;	1.9	;	THERMOTOGA MARITIMA RUVB R170A
1IN8	;	1.9	;	THERMOTOGA MARITIMA RUVB T158V
2ORW	;	1.5	;	Thermotoga maritima thymidine kinase 1 like enzyme in complex with TP4A
2QPO	;	1.95	;	Thermotoga Maritima Thymidine Kinase in the apo form
4PY5	;	2.1	;	Thermovibrio ammonificans RNase H3 in complex with 19-mer RNA/DNA
4QK9	;	3.05	;	Thermovirga lienii c-di-AMP riboswitch
1I6V	;	3.3	;	THERMUS AQUATICUS CORE RNA POLYMERASE-RIFAMPICIN COMPLEX
5TJG	;	2.6	;	Thermus aquaticus delta1.1-sigmaA holoenzyme/downstream-fork promoter complex with an open clamp
1L9U	;	4.0	;	THERMUS AQUATICUS RNA POLYMERASE HOLOENZYME AT 4 A RESOLUTION
1L9Z	;	6.5	;	Thermus aquaticus RNA Polymerase Holoenzyme/Fork-Junction Promoter DNA Complex at 6.5 A Resolution
3UFX	;	2.35	;	Thermus aquaticus succinyl-CoA synthetase in complex with GDP-Mn2+
5VF4	;	2.81	;	Thermus aquaticus variable protein (TaqVP) from diversity-generating retroelements (DGR)
2J07	;	1.95	;	Thermus DNA photolyase with 8-HDF antenna chromophore
2J08	;	2.61	;	Thermus DNA photolyase with 8-Iod-riboflavin antenna chromophore
2J09	;	2.0	;	Thermus DNA photolyase with FMN antenna chromophore
1GVI	;	3.3	;	Thermus maltogenic amylase in complex with beta-CD
4ZNI	;	2.097	;	Thermus Phage P74-26 Large Terminase ATPase domain (I 2 3 space group)
4ZNL	;	2.068	;	Thermus Phage P74-26 Large Terminase ATPase domain bound to ADP Beryllium Fluoride
4ZNK	;	1.931	;	Thermus Phage P74-26 Large Terminase ATPase domain from (P 32 2 1 space group)
4ZNJ	;	2.532	;	Thermus Phage P74-26 Large Terminase ATPase domain mutant R139A (I 2 3 space group)
7KS4	;	1.887	;	Thermus Phage P74-26 Large Terminase ATPase domain with partially bound ADP
5TGE	;	2.6	;	Thermus Phage P74-26 Large Terminase Nuclease Domain
5NUX	;	2.3	;	Thermus scotoductus SA-01 Ene-reductase double mutant TsER_C25D_I67T
5OGT	;	2.3	;	Thermus scotoductus SA-01 Ene-reductase triple mutant TsER_C25D_I67T_A102H
7OMV	;	1.29	;	Thermus sp. 2.9 DarT
7ON0	;	1.46	;	Thermus sp. 2.9 DarT in complex with ADP-ribosylated ssDNA
7OMZ	;	1.66	;	Thermus sp. 2.9 DarT in complex with ADP-ribosylated ssDNA and nicotinamide
7OMX	;	1.52	;	Thermus sp. 2.9 DarT in complex with carba-NAD+
7OMY	;	1.6	;	Thermus sp. 2.9 DarT in complex with carba-NAD+ and ssDNA
7OMW	;	1.3	;	Thermus sp. 2.9 DarT in complex with NAD+
6CUU	;	2.994	;	Thermus thermophiles RNA polymerase in complex with promoter DNA and antibiotic Kanglemycin A
6BUW	;	3.5	;	Thermus thermophilus 70S complex containing 16S G299A ram mutation and empty A site.
6BZ6	;	3.18	;	Thermus thermophilus 70S complex containing 16S G347U ram mutation and empty A site
6BZ7	;	3.68	;	Thermus thermophilus 70S containing 16S G299A point mutation and near-cognate ASL Leucine in A site.
6BZ8	;	3.74	;	Thermus thermophilus 70S containing 16S G347U point mutation and near-cognate ASL Leucine in A site
5V8I	;	3.25	;	Thermus thermophilus 70S ribosome lacking ribosomal protein uS17
5J30	;	3.2	;	Thermus thermophilus 70S termination complex containing E. coli RF1
5J3C	;	3.04	;	Thermus thermophilus 70S termination complex containing E. coli RF1
2OWX	;	2.5	;	THERMUS THERMOPHILUS AMYLOMALTASE AT pH 5.6
1IQ0	;	2.3	;	THERMUS THERMOPHILUS ARGINYL-TRNA SYNTHETASE
1B5P	;	1.8	;	THERMUS THERMOPHILUS ASPARTATE AMINOTRANSFERASE DOUBLE MUTANT 1
1GCK	;	2.5	;	THERMUS THERMOPHILUS ASPARTATE AMINOTRANSFERASE DOUBLE MUTANT 1 COMPLEXED WITH ASPARTATE
1B5O	;	2.2	;	THERMUS THERMOPHILUS ASPARTATE AMINOTRANSFERASE SINGLE MUTANT 1
5BJ3	;	2.2	;	THERMUS THERMOPHILUS ASPARTATE AMINOTRANSFERASE TETRA MUTANT 1
5BJ4	;	2.0	;	THERMUS THERMOPHILUS ASPARTATE AMINOTRANSFERASE TETRA MUTANT 2
1GC4	;	3.3	;	THERMUS THERMOPHILUS ASPARTATE AMINOTRANSFERASE TETRA MUTANT 2 COMPLEXED WITH ASPARTATE
1GC3	;	3.3	;	THERMUS THERMOPHILUS ASPARTATE AMINOTRANSFERASE TETRA MUTANT 2 COMPLEXED WITH TRYPTOPHAN
7AP4	;	2.15	;	Thermus thermophilus Aspartyl-tRNA Synthetase in Complex with Compound AspS7HMDDA
4C98	;	2.001	;	Thermus thermophilus Cas6 (TTHB231)
1DT1	;	1.8	;	THERMUS THERMOPHILUS CYTOCHROME C552 SYNTHESIZED BY ESCHERICHIA COLI
1C52	;	1.28	;	THERMUS THERMOPHILUS CYTOCHROME-C552: A NEW HIGHLY THERMOSTABLE CYTOCHROME-C STRUCTURE OBTAINED BY MAD PHASING
6U1K	;	1.67	;	Thermus thermophilus D-alanine-D-alanine ligase in complex with ADP, carbonate, D-alanine-D-alanine, Mg2+ and K+
6U1J	;	2.2	;	Thermus thermophilus D-alanine-D-alanine ligase in complex with ADP, phosphate, D-ala-D-ala, Mg2+ and K+
6U1H	;	2.2	;	Thermus thermophilus D-alanine-D-alanine ligase in complex with ADP, phosphate, Mg2+ and K+
6U1I	;	2.3	;	Thermus thermophilus D-alanine-D-alanine ligase in complex with ADP, phosphorylated D-cycloserine, Mg2+ and K+
6U1F	;	2.3	;	Thermus thermophilus D-alanine-D-alanine ligase in complex with ATP, D-alanine-D-alanine, Mg2+ and Cs+
6U1G	;	2.4	;	Thermus thermophilus D-alanine-D-alanine ligase in complex with ATP, D-alanine-D-alanine, Mg2+ and Cs+
6U1D	;	1.9	;	Thermus thermophilus D-alanine-D-alanine ligase in complex with ATP, D-alanine-D-alanine, Mg2+ and Rb+
6U1E	;	2.1	;	Thermus thermophilus D-alanine-D-alanine ligase in complex with ATP, D-alanine-D-alanine, Mg2+ and Rb+
4J80	;	2.9	;	Thermus thermophilus DnaJ
4J7Z	;	1.64	;	Thermus thermophilus DNAJ J- and G/F-DOMAINS
3P0B	;	1.35	;	Thermus thermophilus family GH57 branching enzyme: crystal structure, mechanism of action and products formed
2B3F	;	1.56	;	Thermus thermophilus Glucose/Galactose Binding Protein Bound With Galactose
2B3B	;	1.95	;	Thermus thermophilus Glucose/Galactose Binding Protein With Bound Glucose
1SRV	;	1.7	;	THERMUS THERMOPHILUS GROEL (HSP60 CLASS) FRAGMENT (APICAL DOMAIN) COMPRISING RESIDUES 192-336
4KVB	;	4.198	;	Thermus thermophilus HB27 30S ribosomal subunit lacking ribosomal protein S17
6KQD	;	3.3	;	Thermus thermophilus initial transcription complex comprising sigma A and 5'-OH RNA of 3 nt
6KQE	;	3.3	;	Thermus thermophilus initial transcription complex comprising sigma A and 5'-OH RNA of 4 nt
6KQF	;	2.45	;	Thermus thermophilus initial transcription complex comprising sigma A and 5'-OH RNA of 5 nt
6KQG	;	2.783	;	Thermus thermophilus initial transcription complex comprising sigma A and 5'-OH RNA of 6 nt
6KQH	;	3.18	;	Thermus thermophilus initial transcription complex comprising sigma A and 5'-OH RNA of 7 nt
6L74	;	3.12	;	Thermus thermophilus initial transcription complex comprising sigma A and 5'-triphosphate RNA of 2 nt
6KQL	;	2.89	;	Thermus thermophilus initial transcription complex comprising sigma A and 5'-triphosphate RNA of 4 nt
6KQM	;	3.197	;	Thermus thermophilus initial transcription complex comprising sigma A and 5'-triphosphate RNA of 5 nt
6KQN	;	3.489	;	Thermus thermophilus initial transcription complex comprising sigma A and 5'-triphosphate RNA of 6 nt
2BYT	;	3.3	;	Thermus thermophilus Leucyl-tRNA synthetase complexed with a tRNAleu transcript in the post-editing conformation
2BTE	;	2.9	;	Thermus thermophilus Leucyl-tRNA synthetase complexed with a tRNAleu transcript in the post-editing conformation and a post- transfer editing substrate analogue
4DMG	;	1.7	;	Thermus thermophilus m5C1942 methyltransferase RlmO
2GH9	;	1.95	;	Thermus thermophilus maltotriose binding protein bound with maltotriose
7TH5	;	2.09	;	Thermus thermophilus methylenetetrahydrofolate reductase
8EAC	;	1.9	;	Thermus thermophilus methylenetetrahydrofolate reductase
5IT5	;	2.648	;	Thermus thermophilus PilB core ATPase region
6F8L	;	8.0	;	Thermus thermophilus PilF ATPase (AMPPNP-bound form)
6EJF	;	8.0	;	Thermus thermophilus PilF ATPase (apoprotein form)
8HSR	;	4.0	;	Thermus thermophilus Rho-engaged RNAP elongation complex
4V90	;	2.95	;	Thermus thermophilus Ribosome
4WQS	;	4.306	;	Thermus thermophilus RNA polymerase backtracked complex
8HSL	;	5.8	;	Thermus thermophilus RNA polymerase bound with an inverted Rho hexamer
4WQT	;	4.4	;	Thermus thermophilus RNA polymerase complexed with an RNA cleavage stimulating factor (a GreA/Gfh1 chimeric protein)
8HSH	;	3.4	;	Thermus thermophilus RNA polymerase coreenzyme
4Q4Z	;	2.9	;	Thermus thermophilus RNA polymerase de novo transcription initiation complex
8HSG	;	3.2	;	Thermus thermophilus RNA polymerase elongation complex
4Q5S	;	3.0	;	Thermus thermophilus RNA polymerase initially transcribing complex containing 6-mer RNA
6WOX	;	3.14	;	Thermus thermophilus RNA polymerase initially transcribing complex with 2'dCTP
6WOY	;	3.0	;	Thermus thermophilus RNA polymerase initially transcribing complex with 3'dCTP
7EH0	;	2.808	;	Thermus thermophilus RNA polymerase transcription initiation complex containing a template-strand purine at position TSS-2, UpA RNA primer and CMPcPP
4EP4	;	1.28	;	Thermus thermophilus RuvC structure
4EP5	;	2.08	;	Thermus thermophilus RuvC structure
7EH1	;	2.9	;	Thermus thermophilus transcription initiation complex containing a template-strand purine at position TSS-2, GpG RNA primer, and CMPcPP
7EH2	;	3.34	;	Thermus thermophilus transcription initiation complex containing a template-strand pyrimidine at position TSS-2 and GpG RNA primer
8HSJ	;	3.6	;	Thermus thermophilus transcription termination factor Rho bound with ADP-BeF3
3D8R	;	2.0	;	Thermus thermophilus Uroporphyrinogen III Synthase
3D8S	;	2.0	;	Thermus thermophilus Uroporphyrinogen III Synthase
3D8T	;	1.6	;	Thermus thermophilus Uroporphyrinogen III Synthase
5TSJ	;	8.7	;	Thermus thermophilus V/A-ATPase bound to VH dAbs
5GAR	;	6.4	;	Thermus thermophilus V/A-ATPase, conformation 1
5GAS	;	9.5	;	Thermus thermophilus V/A-ATPase, conformation 2
6QUM	;	3.25	;	Thermus thermophilus V/A-type ATPase/synthase, rotational state 1
6R0Z	;	3.8	;	Thermus thermophilus V/A-type ATPase/synthase, rotational state 1L
6R10	;	4.3	;	Thermus thermophilus V/A-type ATPase/synthase, rotational state 1R
6R0W	;	3.6	;	Thermus thermophilus V/A-type ATPase/synthase, rotational state 2
6R0Y	;	3.9	;	Thermus thermophilus V/A-type ATPase/synthase, rotational state 3
2DWQ	;	2.95	;	Thermus thermophilus YchF GTP-binding protein
1G4E	;	1.6	;	THIAMIN PHOSPHATE SYNTHASE
1G4P	;	2.5	;	THIAMIN PHOSPHATE SYNTHASE
1G4S	;	1.7	;	THIAMIN PHOSPHATE SYNTHASE
1G4T	;	1.55	;	THIAMIN PHOSPHATE SYNTHASE
1G67	;	1.4	;	THIAMIN PHOSPHATE SYNTHASE
1G69	;	1.5	;	THIAMIN PHOSPHATE SYNTHASE
1G6C	;	1.4	;	THIAMIN PHOSPHATE SYNTHASE
2TPS	;	1.25	;	THIAMIN PHOSPHATE SYNTHASE
2G9Z	;	1.96	;	Thiamin pyrophosphokinase from Candida albicans
2HH9	;	2.1	;	Thiamin pyrophosphokinase from Candida albicans
2THI	;	2.5	;	THIAMINASE I FROM BACILLUS THIAMINOLYTICUS
3THI	;	2.0	;	THIAMINASE I FROM BACILLUS THIAMINOLYTICUS
4THI	;	2.0	;	THIAMINASE I FROM BACILLUS THIAMINOLYTICUS WITH COVALENTLY BOUND 4-AMINO-2,5-DIMETHYLPYRIMIDINE
1XI3	;	1.7	;	Thiamine phosphate pyrophosphorylase from Pyrococcus furiosus Pfu-1255191-001
4C7X	;	2.29	;	Thiamine Pyrophosphate Bound Transketolase from Lactobacillus salivarius at 2.2A resolution
8XV2	;	3.7	;	Thiamine-bound human SLC19A3
3JSK	;	2.7	;	Thiazole synthase from Neurospora crassa
4Y4M	;	2.71	;	Thiazole synthase Thi4 from Methanocaldococcus jannaschii
4Y4N	;	2.1	;	Thiazole synthase Thi4 from Methanococcus igneus
2O5D	;	2.2	;	Thiazolone-acylsulfonamides as novel HCV NS5B polymerase allosteric inhibitors: Convergence of structure-based drug design and X-ray crystallographic study
2MNB	;		;	Thiazotropsin B DNA recognition sequence d(CGACGCGTCG)2
5LGT	;	3.0	;	Thieno[3,2-b]pyrrole-5-carboxamides as Novel Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1: Compound 15
5LGN	;	3.2	;	Thieno[3,2-b]pyrrole-5-carboxamides as Novel Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1: Compound 19
5LGU	;	3.2	;	Thieno[3,2-b]pyrrole-5-carboxamides as Novel Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1: Compound 34
3HUQ	;	1.45	;	Thieno[3,2-b]thiophene in complex with T4 lysozyme L99A/M102Q
7DU3	;	2.54	;	ThiL in complex with AMP-PNP
5MVY	;	28.4	;	Thin Filament at low calcium concentration
8Q4G	;	8.0	;	Thin filament from FIB milled relaxed left ventricular mouse myofibrils
3CMC	;	1.77	;	Thioacylenzyme intermediate of Bacillus stearothermophilus phosphorylating GAPDH
2QE0	;	2.19	;	Thioacylenzyme Intermediate of GAPN from S. Mutans, New Data Integration and Refinement.
5OVS	;	2.3	;	Thiobacillus denitrificans BPH
5OVT	;	2.95	;	Thiobacillus denitrificans BPH in complex with Epoxomicin
4VHB	;	1.8	;	THIOCYANATE ADDUCT OF THE BACTERIAL HEMOGLOBIN FROM VITREOSCILLA SP.
5F75	;	2.0	;	Thiocyanate dehydrogenase from Thioalkalivibrio paradoxus
2DD5	;	2.0	;	Thiocyanate hydrolase (SCNase) from Thiobacillus thioparus native holo-enzyme
2DD4	;	2.06	;	Thiocyanate hydrolase (SCNase) from Thiobacillus thioparus recombinant apo-enzyme
6NWR	;	3.5	;	Thioester acyl-intermediate of Apolipoprotein N-acyltransferase (Lnt)
6FWY	;	2.14	;	Thioester domain of the Enterococcus faecium TIE86 protein
6FX6	;	2.25	;	Thioester domain of the Staphylococcus aureus TIE protein
1MO2	;	3.0	;	Thioesterase Domain from 6-Deoxyerythronolide Synthase (DEBS TE), pH 8.5
3QIT	;	1.68	;	Thioesterase Domain From Curacin Biosynthetic Pathway
1MN6	;	2.2	;	Thioesterase Domain from Picromycin Polyketide Synthase, pH 7.6
7MHD	;	2.03	;	Thioesterase Domain of Human Fatty Acid Synthase (FASN-TE) binding a competitive inhibitor SBP-7635
7MHE	;	2.8	;	Thioesterase Domain of Human Fatty Acid Synthase (FASN-TE) binding a competitive inhibitor SBP-7957
1MNA	;	1.8	;	Thioesterase Domain of Picromycin Polyketide Synthase (PICS TE), pH 8.0
1MNQ	;	2.2	;	Thioesterase Domain of Picromycin Polyketide Synthase (PICS TE), pH 8.4
3LCR	;	2.0	;	Thioesterase from Tautomycetin Biosynthhetic Pathway
3KEB	;	1.8	;	Thiol peroxidase from Chromobacterium violaceum
2YJH	;	2.55	;	Thiol Peroxidase from Yersinia Psuedotuberculosis, inactive mutant C61S
3FKF	;	2.2	;	thiol-disulfide oxidoreductase from Bacteroides fragilis NCTC 9343
7UNN	;	1.45	;	Thiol-disulfide oxidoreductase TsdA from Corynebacterium diphtheriae
7UNO	;	1.1	;	Thiol-disulfide oxidoreductase TsdA, C129S mutant, from Corynebacterium diphtheriae
1H5V	;	1.1	;	Thiopentasaccharide complex of the endoglucanase Cel5A from Bacillus agaradharens at 1.1 A resolution in the tetragonal crystal form
2ZJP	;	3.7	;	Thiopeptide antibiotic Nosiheptide bound to the large ribosomal subunit of Deinococcus radiodurans
3CF5	;	3.3	;	Thiopeptide antibiotic Thiostrepton bound to the large ribosomal subunit of Deinococcus radiodurans
3MDM	;	1.6	;	Thioperamide complex of Cytochrome P450 46A1
7KSI	;	1.726	;	Thiophenyl-Pyrazolourea Derivatives as Potent, Brian Penetrant, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors
7KSJ	;	2.06	;	Thiophenyl-Pyrazolourea Derivatives as Potent, Brian Penetrant, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors
7KSK	;	1.84	;	Thiophenyl-Pyrazolourea Derivatives as Potent, Brian Penetrant, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors
6FD3	;	1.52	;	Thiophosphorylated PAK3 kinase domain
3BGD	;	2.0	;	Thiopurine S-Methyltransferase
3BGI	;	1.8	;	Thiopurine S-Methyltransferase
1XOA	;		;	THIOREDOXIN (OXIDIZED DISULFIDE FORM), NMR, 20 STRUCTURES
1XOB	;		;	THIOREDOXIN (REDUCED DITHIO FORM), NMR, 20 STRUCTURES
2VOC	;	1.5	;	THIOREDOXIN A ACTIVE SITE MUTANTS FORM MIXED DISULFIDE DIMERS THAT RESEMBLE ENZYME-SUBSTRATE REACTION INTERMEDIATE
4KND	;	1.9	;	Thioredoxin from Anaeromyxobacter dehalogenans.
6FMZ	;	1.8	;	Thioredoxin glutathione reductase from Schistosoma mansoni in complex with 1,4-Bis(2-hydroxyethyl)piperazine
6FP4	;	2.501	;	Thioredoxin glutathione reductase from Schistosoma mansoni in complex with 1,8-Naphthyridine-2-carboxylic acid
6RTJ	;	2.0	;	Thioredoxin glutathione reductase from Schistosoma mansoni in complex with 1-[(dimethylamino)methyl]-2-naphthol at 1 hour of soaking
6RTM	;	2.1	;	Thioredoxin glutathione reductase from Schistosoma mansoni in complex with 1-[(dimethylamino)methyl]-2-naphthol at 2 hour of soaking
6RTO	;	2.3	;	Thioredoxin glutathione reductase from Schistosoma mansoni in complex with 1-[(dimethylamino)methyl]-2-naphthol at 4 hours of soaking
6ZP3	;	1.8	;	Thioredoxin glutathione reductase from Schistosoma mansoni in complex with 2-Methylindole-3-acetic acid
6ZST	;	1.7	;	Thioredoxin glutathione reductase from Schistosoma mansoni in complex with 3-(3-methoxyquinoxalin-2-yl)propanoic acid
7NPX	;	2.7	;	Thioredoxin glutathione reductase from Schistosoma mansoni in complex with 3-(3-Methoxyquinoxalin-2-yl)propanoic acid at 24 hours of soaking
6ZLP	;	2.15	;	Thioredoxin glutathione reductase from Schistosoma mansoni in complex with 4-Aminopiazthiole
7B02	;	1.45	;	Thioredoxin glutathione reductase from Schistosoma mansoni in complex with 4-Hydroxy-7-methyl-1,8-naphthyridine-3-carboxylic acid
2X8H	;	1.9	;	Thioredoxin glutathione reductase from Schistosoma mansoni in complex with GSH
6FTC	;	1.8	;	Thioredoxin glutathione reductase from Schistosoma mansoni in complex with HEPES
6ZLB	;	1.9	;	Thioredoxin glutathione reductase from Schistosoma mansoni in complex with Indole-3-carbinol
2X99	;	2.3	;	Thioredoxin glutathione reductase from Schistosoma mansoni in complex with NADPH
2X8C	;	3.1	;	Thioredoxin glutathione reductase from Schistosoma mansoni with the reduced C-terminal end
6FMU	;	1.8	;	Thioredoxin glutathione reductase from Schistosome mansoni in complex with 2-[4-(4-amino-butyl)-piperazin-1-yl]-ethanol
8PDD	;	1.25	;	Thioredoxin glutathione reductase of Schistosoma mansoni at 1.25A resolution.
8PL0	;	1.7	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 1.
8PL9	;	1.98	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 10.
8PLA	;	1.66	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 11.
8PLB	;	2.0	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 12.
8PLC	;	2.34	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 13.
8PLD	;	1.85	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 14.
8PLE	;	1.94	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 15.
8PLF	;	1.95	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 16.
8PLG	;	1.75	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 17.
8PLH	;	1.62	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 18.
8PLI	;	2.33	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 19.
8PL1	;	2.46	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 2.
8PLJ	;	2.18	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 20.
8PLK	;	1.82	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 21.
8PLL	;	1.85	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 22.
8PLM	;	1.95	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 23.
8PLN	;	2.8	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 24.
8PLO	;	1.74	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 25.
8PLP	;	2.28	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 26.
8PLQ	;	2.29	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 27.
8PLR	;	2.72	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 28.
8PLS	;	1.8	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 29.
8PL2	;	1.88	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 3.
8PLT	;	2.33	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 30.
8PLU	;	2.04	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 31.
8PLV	;	2.46	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 32.
8PLW	;	1.78	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 33.
8PLX	;	1.77	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 34.
8PLY	;	2.43	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 35.
8PL3	;	1.65	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 4.
8PL4	;	1.97	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 5.
8PL5	;	2.15	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 6.
8PL6	;	1.81	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 7.
8PL7	;	1.77	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 8.
8PL8	;	2.35	;	Thioredoxin glutathione reductase of Schistosoma mansoni fragment screen hit 9.
1TOF	;		;	THIOREDOXIN H (OXIDIZED FORM), NMR, 23 STRUCTURES
2IWT	;	2.3	;	Thioredoxin h2 (HvTrxh2) in a mixed disulfide complex with the target protein BASI
1QMV	;	1.7	;	thioredoxin peroxidase B from red blood cells
1X0R	;	2.0	;	Thioredoxin Peroxidase from Aeropyrum pernix K1
7AAW	;	2.25	;	Thioredoxin Reductase from Bacillus cereus
5M5J	;	2.65	;	Thioredoxin reductase from Giardia duodenalis
1THX	;	1.6	;	THIOREDOXIN-2
3R9U	;	2.36	;	Thioredoxin-disulfide reductase from Campylobacter jejuni.
2L2W	;		;	Thiostrepton
2L2Y	;		;	Thiostrepton, epimer form of residue 9
2L2X	;		;	Thiostrepton, oxidized at CA-CB bond of residue 9
2L2Z	;		;	Thiostrepton, reduced at N-CA bond of residue 14
5I0S	;	1.3	;	Thiosulfate bound Cysteine Dioxygenase at pH 6.2
5I0T	;	1.37	;	Thiosulfate bound Cysteine Dioxygenase at pH 6.8
5EZW	;	1.65	;	Thiosulfate bound rat cysteine dioxygenase Y157H variant
4WQ7	;	1.98	;	Thiosulfate dehydrogenase (TsdA) from Allochromatium vinosum - ""as isolated"" form
4WQB	;	1.5013	;	Thiosulfate dehydrogenase (TsdA) from Allochromatium vinosum - bisulfite soak
4WQ9	;	1.47	;	Thiosulfate dehydrogenase (TsdA) from Allochromatium vinosum - dithionite soak
4WQD	;	1.22	;	Thiosulfate dehydrogenase (TsdA) from Allochromatium vinosum - K208G mutant
4WQE	;	1.4	;	Thiosulfate dehydrogenase (TsdA) from Allochromatium vinosum - K208G mutant
4WQC	;	1.56	;	Thiosulfate dehydrogenase (TsdA) from Allochromatium vinosum - K208N mutant
4WQA	;	1.64	;	Thiosulfate dehydrogenase (TsdA) from Allochromatium vinosum - tetrathionate co-crystallization
4WQ8	;	1.3989	;	Thiosulfate dehydrogenase (TsdA) from Allochromatium vinosum - tetrathionate soak
5LO9	;	2.75	;	Thiosulfate dehydrogenase (TsdBA) from Marichromatium purpuratum - ""as isolated"" form
7NED	;	1.9	;	Thiourocanate hydratase from Paenibacillus sp. Soil724D2 in complex with cofactor NAD+ and urocanate
2B96	;	1.7	;	Third Calcium ion found in an inhibitor bound phospholipase A2
1W8A	;	2.8	;	Third LRR domain of Drosophila Slit
2V70	;	3.01	;	Third LRR domain of human Slit2
4OOK	;	1.9	;	Third Metal bound M.tuberculosis methionine aminopeptidase
1BJ8	;		;	THIRD N-TERMINAL DOMAIN OF GP130, NMR, MINIMIZED AVERAGE STRUCTURE
5D13	;	2.151	;	Third PDZ domain (PDZ3) of PSD-95 complexed with CFMOC-KKETEV peptide
2JTE	;		;	Third SH3 domain of CD2AP
7RCE	;	2.42	;	Third stage reengineered variant of I-OnuI with specificity enhancing substitutions
5AHT	;		;	Third WW domain from the E3 ubiquitin-protein ligase NEDD4
2LAJ	;		;	Third WW domain of human Nedd4L in complex with doubly phosphorylated human smad3 derived peptide
4YKH	;	1.52	;	Thirty minutes iron loaded human H ferritin
4POV	;	2.2	;	ThiT with LMG135 bound
4POP	;	2.2	;	ThiT with LMG139 bound
5O34	;	2.45	;	ThnE from S.clavuligerus
7EZB	;	1.5	;	Thorarchaeota Rab bound to GDP
7EZD	;	1.76	;	Thorarchaeota Rab co-crystallized with GTP gamma-S
7EZE	;	1.95	;	Thorarchaeota Rab GTP-gamma-S/Mg2+ (soak)
7OM9	;	3.0	;	Thosea asigna virus RdRP domain
7OMA	;	3.1	;	Thosea asigna virus RdRP domain elongation complex
7OM2	;	2.07	;	Thosea asigna virus RdRP domain in complex with Mg+2
7OM6	;	2.18	;	Thosea asigna virus RdRP domain in complex with RNA
7OM7	;	2.4	;	Thosea asigna virus RdRP domain in complex with RNA and nucleotide UMPNPP
1C3Y	;		;	THP12-CARRIER PROTEIN FROM YELLOW MEAL WORM
1C3Z	;		;	THP12-CARRIER PROTEIN FROM YELLOW MEAL WORM
1E9H	;	2.5	;	Thr 160 phosphorylated CDK2 - Human cyclin A3 complex with the inhibitor indirubin-5-sulphonate bound
4EOJ	;	1.65	;	Thr 160 phosphorylated CDK2 H84S, Q85M, K89D - human cyclin A3 complex with ATP
4EOK	;	2.57	;	Thr 160 phosphorylated CDK2 H84S, Q85M, K89D - human cyclin A3 complex with the inhibitor NU6102
4EOL	;	2.4	;	Thr 160 phosphorylated CDK2 H84S, Q85M, K89D - human cyclin A3 complex with the inhibitor RO3306
4EOM	;	2.1	;	Thr 160 phosphorylated CDK2 H84S, Q85M, Q131E - human cyclin A3 complex with ATP
4EON	;	2.4	;	Thr 160 phosphorylated CDK2 H84S, Q85M, Q131E - human cyclin A3 complex with the inhibitor RO3306
4EOI	;	2.0	;	Thr 160 phosphorylated CDK2 K89D, Q131E - human cyclin A3 complex with the inhibitor RO3306
4EOO	;	2.1	;	Thr 160 phosphorylated CDK2 Q131E - human cyclin A3 complex with ATP
4EOP	;	1.99	;	Thr 160 phosphorylated CDK2 Q131E - human cyclin A3 complex with the inhibitor RO3306
4EOQ	;	2.15	;	Thr 160 phosphorylated CDK2 WT - human cyclin A3 complex with ATP
4EOR	;	2.2	;	Thr 160 phosphorylated CDK2 WT - human cyclin A3 complex with the inhibitor NU6102
4EOS	;	2.57	;	Thr 160 phosphorylated CDK2 WT - human cyclin A3 complex with the inhibitor RO3306
2Z29	;	1.9	;	Thr109Ala dihydroorotase from E. coli
2Z2A	;	1.87	;	Thr109Gly dihydroorotase from E. coli
2Z27	;	1.87	;	Thr109Ser dihydroorotase from E. coli
2Z28	;	1.87	;	Thr109Val dihydroorotase from E. coli
2Z26	;	1.29	;	Thr110Ala dihydroorotase from E. coli
2Z24	;	1.9	;	Thr110Ser dihydroorotase from E. coli
2Z25	;	1.87	;	Thr110Val dihydroorotase from E. coli
5NVG	;	1.07	;	Thr12 Phosphorylated Ubiquitin
1S54	;	2.2	;	Thr24Ala Bacteriorhodopsin
1S51	;	2.0	;	Thr24Ser Bacteriorhodopsin
1S52	;	2.3	;	Thr24Val Bacteriorhodopsin
1C8W	;	1.8	;	THR45GLY VARIANT OF RIBONUCLEASE A
1S53	;	2.0	;	Thr46Ser Bacteriorhodopsin
2JUM	;		;	ThrA3-DKP-insulin
6KKE	;	2.577	;	THRb mutation with a novel agonist
6KNU	;	2.7	;	THRb mutation with a novel agonist
6KNV	;	2.8	;	THRb mutation with a novel agonist
6KNW	;	2.67	;	THRb mutation with a novel agonist
4BIJ	;	16.0	;	Threading model of T7 large terminase
4BIL	;	29.0	;	Threading model of the T7 large terminase within the gp8gp19 complex
3KQH	;	2.4	;	Three Conformational Snapshots of the Hepatitis C Virus NS3 Helicase Reveal a Ratchet Translocation Mechanism
3KQK	;	2.8	;	Three Conformational Snapshots of the Hepatitis C Virus NS3 Helicase Reveal a Ratchet Translocation Mechanism
3KQL	;	2.5	;	Three Conformational Snapshots of the Hepatitis C Virus NS3 Helicase Reveal a Ratchet Translocation Mechanism
3KQN	;	2.05	;	Three Conformational Snapshots of the Hepatitis C Virus NS3 Helicase Reveal a Ratchet Translocation Mechanism
3KQU	;	2.4	;	Three Conformational Snapshots of the Hepatitis C Virus NS3 Helicase Reveal a Ratchet Translocation Mechanism
2DD1	;		;	Three consecutive sheared GA pairs in 5'GGUGGAGGCU/3'PCCAAAGCCG
1T2L	;	2.8	;	Three Crystal Structures of Human Coactosin-like Protein
1T3X	;	2.0	;	Three Crystal Structures of Human Coactosin-like Protein
1T3Y	;	1.15	;	Three Crystal Structures of Human Coactosin-like Protein
1CMC	;	1.8	;	THREE DIMENSIONAL CRYSTAL STRUCTURES OF E. COLI MET REPRESSOR WITH AND WITHOUT COREPRESSOR
1CMB	;	1.8	;	THREE DIMENSIONAL CRYSTAL STRUCTURES OF ESCHERICHIA COLI MET REPRESSOR WITH AND WITHOUT COREPRESSOR
2DHB	;	2.8	;	THREE DIMENSIONAL FOURIER SYNTHESIS OF HORSE DEOXYHAEMOGLOBIN AT 2.8 ANGSTROMS RESOLUTION
2PRF	;		;	THREE DIMENSIONAL SOLUTION STRUCTURE OF ACANTHAMOEBA PROFILIN I
1NIX	;		;	THREE DIMENSIONAL SOLUTION STRUCTURE OF HAINANTOXIN-I BY 2D 1H-NMR
2JTB	;		;	Three dimensional solution structure of hainantoxin-III by 2D 1H-NMR
1NIY	;		;	THREE DIMENSIONAL SOLUTION STRUCTURE OF HAINANTOXIN-IV BY 2D 1H-NMR
1I25	;		;	Three dimensional solution structure of huwentoxin-II by 2D 1H-NMR
1MB6	;		;	Three dimensional solution structure of huwentoxin-IV by 2D 1H-NMR
1Y29	;		;	Three dimensional solution structure of huwentoxin-x by 2D 1H-NMR
1X32	;		;	Three Dimensional Solution Structure of the Chromo1 domain of cpSRP43
1RYV	;		;	Three dimensional solution structure of the K27A MUTANT of sodium channels inhibitor HAINANTOXIN-IV BY 2D 1H-NMR
1RYG	;		;	Three dimensional solution structure of the R29A MUTANT of sodium channels inhibitor HAINANTOXIN-IV by 2D 1H-NMR
1OWC	;	2.2	;	Three Dimensional Structure Analysis Of The R109L Variant of the Type II Citrate Synthase From E. Coli
1KB3	;	2.1	;	Three Dimensional Structure Analysis of the R195A Variant of Human Pancreatic Alpha Amylase
1KGX	;	2.0	;	Three Dimensional Structure Analysis of the R195Q Variant of Human Pancreatic Alpha Amylase
1KGU	;	2.0	;	THREE DIMENSIONAL STRUCTURE ANALYSIS OF THE R337A VARIANT OF HUMAN PANCREATIC ALPHA-AMYLASE
1KGW	;	2.1	;	THREE DIMENSIONAL STRUCTURE ANALYSIS OF THE R337Q VARIANT OF HUMAN PANCREATIC ALPHA-MYLASE
4G6B	;	2.2	;	Three dimensional structure analysis of the type II citrate synthase from e.coli
1OWB	;	2.2	;	Three Dimensional Structure Analysis Of The Variant R109L NADH Complex of Type II Citrate Synthase From E. Coli
2J0E	;	2.1	;	Three dimensional structure and catalytic mechanism of 6- phosphogluconolactonase from Trypanosoma brucei
2DSZ	;	2.35	;	Three dimensional structure of a goat signalling protein secreted during involution
1T3F	;	2.0	;	THREE DIMENSIONAL STRUCTURE OF A HUMANIZED ANTI-IFN-GAMMA FAB (HuZAF) IN P21 21 21 SPACE GROUP
1T04	;	3.0	;	Three dimensional structure of a humanized anti-IFN-Gamma Fab in C2 space group
6GOL	;	1.7	;	Three dimensional structure of a novel influenza hemagglutinin tri-stalk protein
1W3A	;	2.65	;	Three dimensional structure of a novel pore-forming lectin from the mushroom Laetiporus sulphureus
2CLR	;	2.0	;	THREE DIMENSIONAL STRUCTURE OF A PEPTIDE EXTENDING OUT ONE END OF A CLASS I MHC BINDING SITE
1IGM	;	2.3	;	THREE DIMENSIONAL STRUCTURE OF AN FV FROM A HUMAN IGM IMMUNOGLOBULIN
1FIZ	;	2.9	;	THREE DIMENSIONAL STRUCTURE OF BETA-ACROSIN FROM BOAR SPERMATOZOA
2C2X	;	2.0	;	Three dimensional structure of bifunctional methylenetetrahydrofolate dehydrogenase-cyclohydrolase from Mycobacterium tuberculosis
2C2Y	;	2.3	;	Three Dimensional Structure of bifunctional methylenetetrahydrofolate dehydrogenase-cyclohydrolase from Mycobacterium tuberculosis
4JVP	;	1.76	;	Three dimensional structure of broadly neutralizing anti - Hepatitis C virus (HCV) glycoprotein E2 alpaca nanobody D03
3U6R	;	2.67	;	Three dimensional structure of broadly neutralizing anti - Hepatitis C virus (HCV) glycoprotein E2 single chain FV fragment 1:7
5FGB	;	1.65	;	Three dimensional structure of broadly neutralizing human anti - Hepatitis C virus (HCV) glycoprotein E2 Fab fragment HC33.4
5FGC	;	1.9	;	Three dimensional structure of broadly neutralizing human anti - Hepatitis C virus (HCV) glycoprotein E2 Fab fragment HC33.8
4JZN	;	2.05	;	Three dimensional structure of broadly neutralizing human anti - Hepatitis C virus (HCV) glycoprotein E2 Fab fragment HC84-1
4JZO	;	2.22	;	Three dimensional structure of broadly neutralizing human anti - Hepatitis C virus (HCV) glycoprotein E2 Fab fragment HC84-27
1CYE	;		;	THREE DIMENSIONAL STRUCTURE OF CHEMOTACTIC CHE Y PROTEIN IN AQUEOUS SOLUTION BY NUCLEAR MAGNETIC RESONANCE METHODS
4H18	;	1.755	;	Three dimensional structure of corynomycoloyl tranferase C
3U1O	;	2.494	;	THREE DIMENSIONAL STRUCTURE OF DE NOVO DESIGNED CYSTEINE ESTERASE ECH19, Northeast Structural Genomics Consortium Target OR49
4DRT	;	2.002	;	Three dimensional structure of de novo designed serine hydrolase OSH26, Northeast Structural Genomics Consortium (NESG) target OR89
2N0X	;		;	Three dimensional structure of EPI-X4, a human albumin-derived peptide that regulates innate immunity through the CXCR4/CXCL12 chemotactic axis and antagonizes HIV-1 entry
5AMD	;	1.5	;	Three dimensional structure of human carbonic anhydrase II in complex with 2-((2-Phenylethyl)sulfamoyl)-4-sulfamoylbenzoic acid
5AML	;	1.36	;	Three dimensional structure of human carbonic anhydrase II in complex with 2-(But-2-yn-1-ylsulfamoyl)-4-sulfamoylbenzoic acid
5AMG	;	1.55	;	Three dimensional structure of human carbonic anhydrase II in complex with 2-(Pentylsulfamoyl)-4-sulfamoylbenzoic acid
4BF6	;	1.82	;	Three dimensional structure of human carbonic anhydrase II in complex with 5-(1-(3-Cyanophenyl)-1H-1,2,3-triazol-4-yl)thiophene-2- sulfonamide
4BF1	;	1.35	;	Three dimensional structure of human carbonic anhydrase II in complex with 5-(1-naphthalen-1-yl-1,2,3-triazol-4-yl)thiophene-2-sulfonamide
5MJN	;	1.17	;	Three dimensional structure of human carbonic anhydrase II in complex with 5-[(4Chlorobenzyl)sulfanyl]thiophene-2-sulfonamide
6FE2	;	1.87	;	Three dimensional structure of human carbonic anhydrase IX
5FL5	;	2.05	;	Three dimensional structure of human carbonic anhydrase IX in complex with 5-(1-(4-Methoxyphenyl)-1H-1,2,3-triazol-4-yl)thiophene-2- sulfonamide
5FL6	;	1.95	;	Three dimensional structure of human carbonic anhydrase IX in complex with 5-(1-(4-Methylphenyl)-1H-1,2,3-triazol-4-yl)thiophene-2- sulfonamide
5FL4	;	1.82	;	Three dimensional structure of human carbonic anhydrase IX in complex with 5-(1-naphthalen-1-yl-1,2,3-triazol-4-yl)thiophene-2-sulfonamide
6QN2	;	1.95	;	Three dimensional structure of human carbonic anhydrase IX in complex with benzenesulfonamide
6QN5	;	1.96	;	Three dimensional structure of human carbonic anhydrase IX in complex with benzenesulfonamide
6QN6	;	2.25	;	Three dimensional structure of human carbonic anhydrase IX in complex with benzenesulfonamide
6QUT	;	1.96	;	Three dimensional structure of human carbonic anhydrase IX in complex with benzenesulfonamide
6FE0	;	1.91	;	Three dimensional structure of human carbonic anhydrase IX in complex with benzenesulfonamide.
6FE1	;	1.95	;	Three dimensional structure of human carbonic anhydrase IX in complex with benzenesulfonamide.
6G98	;	2.47	;	Three dimensional structure of human carbonic anhydrase IX in complex with sulfonamide
6G9U	;	1.75	;	Three dimensional structure of human carbonic anhydrase IX in complex with sulfonamide
6TL5	;	2.21	;	Three dimensional structure of human carbonic anhydrase IX in complex with sulfonamide
6TL6	;	2.15	;	Three dimensional structure of human carbonic anhydrase IX in complex with sulfonamide
7POM	;	1.98	;	Three dimensional structure of human carbonic anhydrase IX in complex with sulfonamide
8CO0	;	2.3	;	Three dimensional structure of human carbonic anhydrase IX in complex with sulfonamide
6QN0	;	1.89	;	Three dimensional structure of human carbonic anhydrase XII in complex with benzenesulfonamide
6QNG	;	1.67	;	Three dimensional structure of human carbonic anhydrase XII in complex with benzenesulfonamide
6QNL	;	1.53	;	Three dimensional structure of human carbonic anhydrase XII in complex with benzenesulfonamide
7PP9	;	2.34	;	Three dimensional structure of human carbonic anhydrase XII in complex with sulfonamide
8CO3	;	1.68	;	Three dimensional structure of human carbonic anhydrase XII in complex with sulfonamide
4BGK	;	2.18	;	Three dimensional structure of human gamma-butyrobetaine hydroxylase in complex with (3-(Trimethylammonio)propyl)phosphinate
4BG1	;	1.89	;	Three dimensional structure of human gamma-butyrobetaine hydroxylase in complex with 1-(3-Carboxypropyl)-1-methylpyrrolidin-1-ium chloride
4BHI	;	2.15	;	Three dimensional structure of human gamma-butyrobetaine hydroxylase in complex with 3-(1,1,1,2-Tetramethylhydrazin-1-ium-2-yl)propanoate
4BHG	;	1.85	;	Three dimensional structure of human gamma-butyrobetaine hydroxylase in complex with 3-(1-Ethyl-1,1-dimethylhydrazin-1-ium-2-yl)propanoate
4BGM	;	2.4	;	Three dimensional structure of human gamma-butyrobetaine hydroxylase in complex with 3-Carboxy-N-(2-fluoroethyl)-N,N-dimethylpropan-1- aminium chloride
4C5W	;	1.7	;	Three dimensional structure of human gamma-butyrobetaine hydroxylase in complex with 4-(Ethyldimethylammonio)butanoate
4BHF	;	2.05	;	Three dimensional structure of human gamma-butyrobetaine hydroxylase in complex with 4-(Trimethylammonio)pentanoate
2KUN	;		;	Three dimensional structure of HuPrP(90-231 M129 Q212P)
4L1J	;	1.824	;	Three dimensional structure of mutant D143A of human HD domain-containing protein 2, Northeast Structural Genomics Consortium (NESG) Target HR6723
4L7E	;	2.229	;	Three dimensional structure of mutant D78A of human HD domain-containing protein 2, Genomics Consortium (NESG) Target HR6723
1QJZ	;	3.8	;	Three Dimensional Structure of Physalis Mottle Virus : Implications for the Viral Assembly
2L4V	;		;	Three Dimensional Structure of Pineapple Cystatin
4CKU	;	1.85	;	Three dimensional structure of plasmepsin II in complex with hydroxyethylamine-based inhibitor
1PCA	;	2.0	;	THREE DIMENSIONAL STRUCTURE OF PORCINE PANCREATIC PROCARBOXYPEPTIDASE A. A COMPARISON OF THE A AND B ZYMOGENS AND THEIR DETERMINANTS FOR INHIBITION AND ACTIVATION
1EVE	;	2.5	;	THREE DIMENSIONAL STRUCTURE OF THE ANTI-ALZHEIMER DRUG, E2020 (ARICEPT), COMPLEXED WITH ITS TARGET ACETYLCHOLINESTERASE
4F67	;	1.79	;	Three dimensional structure of the double mutant of UPF0176 protein lpg2838 from Legionella pneumophila at the resolution 1.8A, Northeast Structural Genomics Consortium (NESG) Target LgR82
1WR5	;	1.4	;	Three dimensional Structure of the E41K mutant of Tetraheme Cytochrome c3 from Desulfovibrio vulgaris Miyazaki F
1BBD	;	2.8	;	THREE DIMENSIONAL STRUCTURE OF THE FAB FRAGMENT OF A NEUTRALIZING ANTIBODY TO HUMAN RHINOVIRUS SEROTYPE 2
6STM	;	1.7	;	Three dimensional structure of the giant reed (Arundodonax) lectin (ADL)
6STQ	;	1.5	;	Three dimensional structure of the giant reed (Arundodonax) lectin (ADL) complex with N,N'-Diacetylchitobiose; 30 seconds soaking
6STR	;	1.8	;	Three dimensional structure of the giant reed (Arundodonax) lectin (ADL) complex with N,N'-Diacetylchitobiose; 60 seconds soaking
6STN	;	1.75	;	Three dimensional structure of the giant reed (Arundodonax) lectin (ADL) complex with N-Acetyl glucosamine
6STO	;	1.5	;	Three dimensional structure of the giant reed (Arundodonax) lectin (ADL) complex with N-Acetyl lactosamine
6STP	;	1.6	;	Three dimensional structure of the giant reed (Arundodonax) lectin (ADL) complex with sialic acid
1BR0	;		;	THREE DIMENSIONAL STRUCTURE OF THE N-TERMINAL DOMAIN OF SYNTAXIN 1A
1OFW	;	1.5	;	Three dimensional structure of the oxidized form of nine heme cytochrome c at PH 7.5
2GUJ	;	3.0	;	Three dimensional structure of the protein P54332 from Bacillus Subtilis. Northeast Structural Genomics Consortium target sr353.
1OFY	;	2.0	;	three dimensional structure of the reduced form of nine-heme cytochrome c at ph 7.5
3F1X	;	2.0	;	Three dimensional structure of the serine acetyltransferase from Bacteroides vulgatus, NORTHEAST STRUCTURAL GENOMICS CONSORTIUM TARGET BVR62.
3U8V	;	1.9	;	Three dimensional structure of the Small Metal Binding Protein, SMBP
1F06	;	2.1	;	THREE DIMENSIONAL STRUCTURE OF THE TERNARY COMPLEX OF CORYNEBACTERIUM GLUTAMICUM DIAMINOPIMELATE DEHYDROGENASE NADPH-L-2-AMINO-6-METHYLENE-PIMELATE
1J0P	;	0.91	;	Three dimensional Structure of the Y43L mutant of Tetraheme Cytochrome c3 from Desulfovibrio vulgaris Miyazaki F
1Q9M	;	2.3	;	Three dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity
3SHS	;	1.951	;	Three N-terminal domains of the bacteriophage RB49 Highly Immunogenic Outer Capsid protein (Hoc)
1TTI	;	2.4	;	THREE NEW CRYSTAL STRUCTURES OF POINT MUTATION VARIANTS OF MONOTIM: CONFORMATIONAL FLEXIBILITY OF LOOP-1,LOOP-4 AND LOOP-8
1TTJ	;	2.4	;	THREE NEW CRYSTAL STRUCTURES OF POINT MUTATION VARIANTS OF MONOTIM: CONFORMATIONAL FLEXIBILITY OF LOOP-1,LOOP-4 AND LOOP-8
7UPW	;	2.7	;	Three RBD-down state of SARS-CoV-2 D614G spike in complex with the SP1-77 neutralizing antibody Fab fragment
7UPX	;	3.2	;	Three RBD-down state of SARS-CoV-2 D614G spike in complex with the SP1-77 neutralizing antibody Fab fragment (local refinement of the RBD and Fab variable domains)
5LP3	;	10.5	;	Three tetrameric rings of Isoaspartyl Dipeptidase fitted in an EM volume.
1UCR	;	1.2	;	Three-dimensional crystal structure of dissimilatory sulfite reductase D (DsrD)
1IFA	;	2.6	;	THREE-DIMENSIONAL CRYSTAL STRUCTURE OF RECOMBINANT MURINE INTERFERON-BETA
264D	;	2.44	;	THREE-DIMENSIONAL CRYSTAL STRUCTURE OF THE A-TRACT DNA DODECAMER D(CGCAAATTTGCG) COMPLEXED WITH THE MINOR-GROOVE-BINDING DRUG HOECHST 33258
6KBV	;		;	Three-dimensional cytoplasmic membrane-bound structure of VG16KRKP-KYE28
1COP	;		;	THREE-DIMENSIONAL DIMER STRUCTURE OF THE LAMBDA-CRO REPRESSOR IN SOLUTION AS DETERMINED BY HETERONUCLEAR MULTIDIMENSIONAL NMR
4F8G	;	1.93	;	Three-dimensional DNA lattices with non-canonical base pairs
4F8I	;	2.0	;	Three-dimensional DNA lattices with non-canonical base pairs
3IYD	;	19.8	;	Three-dimensional EM structure of an intact activator-dependent transcription initiation complex
6KBO	;		;	Three-dimensional LPS bound structure of VG16KRKP-KYE28.
2Y9J	;	6.4	;	THREE-DIMENSIONAL MODEL OF SALMONELLA'S NEEDLE COMPLEX AT SUBNANOMETER RESOLUTION
2Y9K	;	8.3	;	Three-dimensional model of Salmonella's needle complex at subnanometer resolution
2KJ7	;		;	Three-Dimensional NMR Structure of Rat Islet Amyloid Polypeptide in DPC micelles
1EPG	;		;	THREE-DIMENSIONAL NUCLEAR MAGNETIC RESONANCE STRUCTURES OF MOUSE EPIDERMAL GROWTH FACTOR IN ACIDIC AND PHYSIOLOGICAL PH SOLUTIONS
1EPH	;		;	THREE-DIMENSIONAL NUCLEAR MAGNETIC RESONANCE STRUCTURES OF MOUSE EPIDERMAL GROWTH FACTOR IN ACIDIC AND PHYSIOLOGICAL PH SOLUTIONS
1EPI	;		;	THREE-DIMENSIONAL NUCLEAR MAGNETIC RESONANCE STRUCTURES OF MOUSE EPIDERMAL GROWTH FACTOR IN ACIDIC AND PHYSIOLOGICAL PH SOLUTIONS
1EPJ	;		;	THREE-DIMENSIONAL NUCLEAR MAGNETIC RESONANCE STRUCTURES OF MOUSE EPIDERMAL GROWTH FACTOR IN ACIDIC AND PHYSIOLOGICAL PH SOLUTIONS
5GJE	;	21.0	;	Three-dimensional reconstruction of human LRP6 ectodomain complexed with Dkk1
4CAK	;	20.5	;	Three-dimensional reconstruction of intact human integrin alphaIIbbeta3 in a phospholipid bilayer nanodisc
6J12	;		;	Three-dimensional Solution NMR Structure of KYE28-PEG48 in Microgel
1BTA	;		;	THREE-DIMENSIONAL SOLUTION STRUCTURE AND 13C ASSIGNMENTS OF BARSTAR USING NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
1BTB	;		;	THREE-DIMENSIONAL SOLUTION STRUCTURE AND 13C ASSIGNMENTS OF BARSTAR USING NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
1NEA	;		;	THREE-DIMENSIONAL SOLUTION STRUCTURE OF A CURAREMIMETIC TOXIN FROM NAJA NIGRICOLLIS VENOM: A PROTON NMR AND MOLECULAR MODELING STUDY
1ZNF	;		;	THREE-DIMENSIONAL SOLUTION STRUCTURE OF A SINGLE ZINC FINGER DNA-BINDING DOMAIN
1MTQ	;		;	THREE-DIMENSIONAL SOLUTION STRUCTURE OF ALPHA-CONOTOXIN GID BY NMR SPECTROSCOPY
2PTL	;		;	THREE-DIMENSIONAL SOLUTION STRUCTURE OF AN IMMUNOGLOBULIN LIGHT CHAIN-BINDING DOMAIN OF PROTEIN L. COMPARISON WITH THE IGG-BINDING DOMAINS OF PROTEIN G
1MHI	;		;	THREE-DIMENSIONAL SOLUTION STRUCTURE OF AN INSULIN DIMER. A STUDY OF THE B9(ASP) MUTANT OF HUMAN INSULIN USING NUCLEAR MAGNETIC RESONANCE DISTANCE GEOMETRY AND RESTRAINED MOLECULAR DYNAMICS
1M31	;		;	Three-Dimensional Solution Structure of Apo-Mts1
1K2H	;		;	Three-dimensional Solution Structure of apo-S100A1.
1OZO	;		;	Three-dimensional solution structure of apo-S100P protein determined by NMR spectroscopy
1CB1	;		;	THREE-DIMENSIONAL SOLUTION STRUCTURE OF CA2+-LOADED PORCINE CALBINDIN D9K DETERMINED BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
1CLH	;		;	THREE-DIMENSIONAL SOLUTION STRUCTURE OF ESCHERICHIA COLI PERIPLASMIC CYCLOPHILIN
1BBN	;		;	THREE-DIMENSIONAL SOLUTION STRUCTURE OF HUMAN INTERLEUKIN-4 BY MULTI-DIMENSIONAL HETERONUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
1BCN	;		;	THREE-DIMENSIONAL SOLUTION STRUCTURE OF HUMAN INTERLEUKIN-4 BY MULTI-DIMENSIONAL HETERONUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
1F3K	;		;	THREE-DIMENSIONAL SOLUTION STRUCTURE OF OMEGA-CONOTOXIN TXVII, AN L-TYPE CALCIUM CHANNEL BLOCKER
1V4Q	;		;	Three-dimensional solution structure of the analogue peptide of omega-conotoxin MVIIC
1FHB	;		;	THREE-DIMENSIONAL SOLUTION STRUCTURE OF THE CYANIDE ADDUCT OF A MET80ALA VARIANT OF SACCHAROMYCES CEREVISIAE ISO-1-CYTOCHROME C. IDENTIFICATION OF LIGAND-RESIDUE INTERACTIONS IN THE DISTAL HEME CAVITY
1BAL	;		;	THREE-DIMENSIONAL SOLUTION STRUCTURE OF THE E3-BINDING DOMAIN OF THE DIHYDROLIPOAMIDE SUCCINYLTRANSFERASE CORE FROM THE 2-OXOGLUTARATE DEHYDROGENASE MULTIENZYME COMPLEX OF (ESCHERICHIA COLI)
1BBL	;		;	THREE-DIMENSIONAL SOLUTION STRUCTURE OF THE E3-BINDING DOMAIN OF THE DIHYDROLIPOAMIDE SUCCINYLTRANSFERASE CORE FROM THE 2-OXOGLUTARATE DEHYDROGENASE MULTIENZYME COMPLEX OF ESCHERICHIA COLI
1ERG	;		;	THREE-DIMENSIONAL SOLUTION STRUCTURE OF THE EXTRACELLULAR REGION OF THE COMPLEMENT REGULATORY PROTEIN, CD59, A NEW CELL SURFACE PROTEIN DOMAIN RELATED TO NEUROTOXINS
1ERH	;		;	THREE-DIMENSIONAL SOLUTION STRUCTURE OF THE EXTRACELLULAR REGION OF THE COMPLEMENT REGULATORY PROTEIN, CD59, A NEW CELL SURFACE PROTEIN DOMAIN RELATED TO NEUROTOXINS
1AB2	;		;	THREE-DIMENSIONAL SOLUTION STRUCTURE OF THE SRC HOMOLOGY 2 DOMAIN OF C-ABL
148D	;		;	THREE-DIMENSIONAL SOLUTION STRUCTURE OF THE THROMBIN BINDING DNA APTAMER D(GGTTGGTGTGGTTGG)
1WQB	;		;	Three-dimensional Solution Strucutre of Aptotoxin VII, from the venom of a Trap-door Spider
2MTS	;		;	Three-Dimensional Structure and Interaction Studies of Hepatitis C Virus p7 in 1,2-Dihexanoyl-sn-glycero-3-phosphocholine by Solution Nuclear Magnetic Resonance
386D	;	1.8	;	THREE-DIMENSIONAL STRUCTURE AND REACTIVITY OF A PHOTOCHEMICAL CLEAVAGE AGENT BOUND TO DNA
1OG7	;		;	Three-dimensional structure in lipid micelles of the pediocin-like antimicrobial peptide sakacin P.
1OHN	;		;	Three-dimensional structure in lipid micelles of the pediocin-like antimicrobial peptide sakacin P.
1BW3	;		;	THREE-DIMENSIONAL STRUCTURE IN SOLUTION OF BARWIN, A PROTEIN FROM BARLEY SEED
1BW4	;		;	THREE-DIMENSIONAL STRUCTURE IN SOLUTION OF BARWIN, A PROTEIN FROM BARLEY SEED
1TIN	;		;	THREE-DIMENSIONAL STRUCTURE IN SOLUTION OF CUCURBITA MAXIMA TRYPSIN INHIBITOR-V DETERMINED BY NMR SPECTROSCOPY
1ANS	;		;	THREE-DIMENSIONAL STRUCTURE IN SOLUTION OF NEUROTOXIN III FROM THE SEA ANEMONE ANEMONIA SULCATA
6OTA	;		;	THREE-DIMENSIONAL STRUCTURE IN SOLUTION OF THE RIBBON DISULFIDE ISOMER OF THE NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONIST ALPHA-CONOTOXIN TxIA
1FU3	;		;	THREE-DIMENSIONAL STRUCTURE IN SOLUTION OF THE SODIUM CHANNEL AGONIST/ANTAGONIST DELTA-CONOTOXIN TXVIA
1BHA	;		;	THREE-DIMENSIONAL STRUCTURE OF (1-71) BACTERIOOPSIN SOLUBILIZED IN METHANOL-CHLOROFORM AND SDS MICELLES DETERMINED BY 15N-1H HETERONUCLEAR NMR SPECTROSCOPY
1BHB	;		;	Three-dimensional structure of (1-71) bacterioopsin solubilized in methanol-chloroform and SDS micelles determined by 15N-1H heteronuclear NMR spectroscopy
1BVQ	;	2.0	;	THREE-DIMENSIONAL STRUCTURE OF 4-HYDROXYBENZOYL COA THIOESTERASE FROM PSEUDOMONAS SP. STRAIN CBS-3.
2WBL	;	2.9	;	Three-dimensional structure of a binary ROP-PRONE complex
1HCC	;		;	THREE-DIMENSIONAL STRUCTURE OF A COMPLEMENT CONTROL PROTEIN MODULE IN SOLUTION
1D2Z	;	2.0	;	THREE-DIMENSIONAL STRUCTURE OF A COMPLEX BETWEEN THE DEATH DOMAINS OF PELLE AND TUBE
1LDL	;		;	THREE-DIMENSIONAL STRUCTURE OF A CYSTEINE-RICH REPEAT FROM THE LOW-DENSITY LIPOPROTEIN RECEPTOR
4FAB	;	2.7	;	THREE-DIMENSIONAL STRUCTURE OF A FLUORESCEIN-FAB COMPLEX CRYSTALLIZED IN 2-METHYL-2,4-PENTANEDIOL
7MS2	;	2.04	;	Three-dimensional structure of a GH3 Beta-glucosidase from Clostridium thermocellum in complex with glycerol
1HMH	;	2.6	;	THREE-DIMENSIONAL STRUCTURE OF A HAMMERHEAD RIBOZYME
1JHL	;	2.4	;	THREE-DIMENSIONAL STRUCTURE OF A HETEROCLITIC ANTIGEN-ANTIBODY CROSS-REACTION COMPLEX
1IPD	;	2.2	;	THREE-DIMENSIONAL STRUCTURE OF A HIGHLY THERMOSTABLE ENZYME, 3-ISOPROPYLMALATE DEHYDROGENASE OF THERMUS THERMOPHILUS AT 2.2 ANGSTROMS RESOLUTION
1AQK	;	1.84	;	THREE-DIMENSIONAL STRUCTURE OF A HUMAN FAB WITH HIGH AFFINITY FOR TETANUS TOXOID
1MCO	;	3.2	;	THREE-DIMENSIONAL STRUCTURE OF A HUMAN IMMUNOGLOBULIN WITH A HINGE DELETION
1MCW	;	3.5	;	THREE-DIMENSIONAL STRUCTURE OF A HYBRID LIGHT CHAIN DIMER. PROTEIN ENGINEERING OF A BINDING CAVITY
1I3V	;	2.03	;	THREE-DIMENSIONAL STRUCTURE OF A LAMA VHH DOMAIN UNLIGANDED
2MCG	;	2.0	;	THREE-DIMENSIONAL STRUCTURE OF A LIGHT CHAIN DIMER CRYSTALLIZED IN WATER. CONFORMATIONAL FLEXIBILITY OF A MOLECULE IN TWO CRYSTAL FORMS
3MCG	;	2.0	;	THREE-DIMENSIONAL STRUCTURE OF A LIGHT CHAIN DIMER CRYSTALLIZED IN WATER. CONFORMATIONAL FLEXIBILITY OF A MOLECULE IN TWO CRYSTAL FORMS
1I3U	;	1.95	;	THREE-DIMENSIONAL STRUCTURE OF A LLAMA VHH DOMAIN COMPLEXED WITH THE DYE RR1
1SJX	;	2.2	;	Three-Dimensional Structure of a Llama VHH Domain OE7 binding the cell wall protein Malf1
1SJV	;	1.94	;	Three-Dimensional Structure of a Llama VHH Domain Swapping
1DQ7	;	2.2	;	THREE-DIMENSIONAL STRUCTURE OF A NEUROTOXIN FROM RED SCORPION (BUTHUS TAMULUS) AT 2.2A RESOLUTION.
1DPY	;	2.45	;	THREE-DIMENSIONAL STRUCTURE OF A NOVEL PHOSPHOLIPASE A2 FROM INDIAN COMMON KRAIT AT 2.45 A RESOLUTION
3GSH	;	1.8	;	Three-dimensional structure of a post translational modified barley LTP1
1HPT	;	2.3	;	THREE-DIMENSIONAL STRUCTURE OF A RECOMBINANT VARIANT OF HUMAN PANCREATIC SECRETORY TRYPSIN INHIBITOR (KAZAL TYPE)
1TA0	;	2.1	;	Three-dimensional structure of a RNA-polymerase II binding protein with associated ligand.
1T9Z	;	2.3	;	Three-dimensional structure of a RNA-polymerase II binding protein.
1P4B	;	2.35	;	Three-Dimensional Structure Of a Single Chain Fv Fragment Complexed With The peptide GCN4(7P-14P).
1SIV	;	2.5	;	THREE-DIMENSIONAL STRUCTURE OF A SIV PROTEASE(SLASH)INHIBITOR COMPLEX. IMPLICATIONS FOR THE DESIGN OF HIV-1 AND HIV-2 PROTEASE INHIBITORS
1GGT	;	2.65	;	THREE-DIMENSIONAL STRUCTURE OF A TRANSGLUTAMINASE: HUMAN BLOOD COAGULATION FACTOR XIII
2KZH	;		;	Three-dimensional structure of a truncated phosphoribosylanthranilate isomerase (residues 255-384) from Escherichia coli
4UZU	;	1.9	;	Three-dimensional structure of a variant `Termamyl-like' Geobacillus stearothermophilus alpha-amylase at 1.9 A resolution
1APS	;		;	THREE-DIMENSIONAL STRUCTURE OF ACYLPHOSPHATASE. REFINEMENT AND STRUCTURE ANALYSIS
6HY3	;	1.3	;	Three-dimensional structure of AgaC from Zobellia galactanivorans
7ZPF	;	2.54	;	Three-dimensional structure of AIP56, a short-trip single chain AB toxin from Photobacterium damselae subsp. piscicida.
1M2C	;		;	THREE-DIMENSIONAL STRUCTURE OF ALPHA-CONOTOXIN MII, NMR, 14 STRUCTURES
1DBA	;	2.8	;	THREE-DIMENSIONAL STRUCTURE OF AN ANTI-STEROID FAB' AND PROGESTERONE-FAB' COMPLEX
1DBB	;	2.7	;	THREE-DIMENSIONAL STRUCTURE OF AN ANTI-STEROID FAB' AND PROGESTERONE-FAB' COMPLEX
1JVK	;	1.94	;	THREE-DIMENSIONAL STRUCTURE OF AN IMMUNOGLOBULIN LIGHT CHAIN DIMER ACTING AS A LETHAL AMYLOID PRECURSOR
6Z2T	;	1.34	;	Three-dimensional structure of an influenza hemagglutinin LAH protein in its post-fusion conformation
1H8S	;	2.4	;	Three-dimensional structure of anti-ampicillin single chain Fv fragment complexed with the hapten.
1H8N	;	1.87	;	Three-dimensional structure of anti-ampicillin single chain Fv fragment from phage-displayed murine antibody libraries
1H8O	;	2.75	;	Three-dimensional structure of anti-ampicillin single chain Fv fragment.
1CIX	;		;	THREE-DIMENSIONAL STRUCTURE OF ANTIMICROBIAL PEPTIDE TACHYSTATIN A ISOLATED FROM HORSESHOE CRAB
2HVP	;	3.0	;	THREE-DIMENSIONAL STRUCTURE OF ASPARTYL PROTEASE FROM HUMAN IMMUNODEFICIENCY VIRUS HIV-1
2A8E	;	2.5	;	Three-dimensional structure of Bacillus subtilis Q45498 putative protein at resolution 2.5A. Northeast Structural Genomics Consortium target SR204.
1BRL	;	2.4	;	THREE-DIMENSIONAL STRUCTURE OF BACTERIAL LUCIFERASE FROM VIBRIO HARVEYI AT 2.4 ANGSTROMS RESOLUTION
1FIW	;	2.1	;	THREE-DIMENSIONAL STRUCTURE OF BETA-ACROSIN FROM RAM SPERMATOZOA
1BOM	;		;	THREE-DIMENSIONAL STRUCTURE OF BOMBYXIN-II, AN INSULIN-RELATED BRAIN-SECRETORY PEPTIDE OF THE SILKMOTH BOMBYX MORI: COMPARISON WITH INSULIN AND RELAXIN
1BON	;		;	THREE-DIMENSIONAL STRUCTURE OF BOMBYXIN-II, AN INSULIN-RELATED BRAIN-SECRETORY PEPTIDE OF THE SILKMOTH BOMBYX MORI: COMPARISON WITH INSULIN AND RELAXIN
1BUC	;	2.5	;	THREE-DIMENSIONAL STRUCTURE OF BUTYRYL-COA DEHYDROGENASE FROM MEGASPHAERA ELSDENII
2MPX	;		;	Three-dimensional structure of CAP-GLY DOMAIN ASSEMBLED ON MICROTUBULES DETERMINED BY MAS NMR SPECTROSCOPY
4CAT	;	3.0	;	THREE-DIMENSIONAL STRUCTURE OF CATALASE FROM PENICILLIUM VITALE AT 2.0 ANGSTROMS RESOLUTION
3CBH	;	2.0	;	THREE-DIMENSIONAL STRUCTURE OF CELLOBIOHYDROLASE FROM TRICHODERMA REESEI
2CHY	;	2.7	;	THREE-DIMENSIONAL STRUCTURE OF CHEY, THE RESPONSE REGULATOR OF BACTERIAL CHEMOTAXIS
2GMT	;	1.8	;	THREE-DIMENSIONAL STRUCTURE OF CHYMOTRYPSIN INACTIVATED WITH (2S) N-ACETYL-L-ALANYL-L-PHENYLALANYL-CHLOROETHYL KETONE: IMPLICATIONS FOR THE MECHANISM OF INACTIVATION OF SERINE PROTEASES BY CHLOROKETONES
1GSS	;	2.8	;	THREE-DIMENSIONAL STRUCTURE OF CLASS PI GLUTATHIONE S-TRANSFERASE FROM HUMAN PLACENTA IN COMPLEX WITH S-HEXYLGLUTATHIONE AT 2.8 ANGSTROMS RESOLUTION
1JHP	;	2.2	;	Three-dimensional Structure of CobT in Complex with 5-methoxybenzimidazole
1JHM	;	2.2	;	Three-dimensional Structure of CobT in Complex with 5-methylbenzimidazole
1JHU	;	2.0	;	Three-dimensional Structure of CobT in Complex with p-cresol
1JHV	;	2.0	;	Three-dimensional Structure of CobT in Complex with p-cresol and Nicotinate
1JHX	;	2.0	;	Three-dimensional Structure of CobT in Complex with Phenol
1JHY	;	2.0	;	Three-dimensional Structure of CobT in Complex with Phenol and Nicotinate
1JHR	;	2.0	;	Three-dimensional Structure of CobT in Complex with Reaction Products of 2-hydroxypurine and NaMN
1JHQ	;	2.0	;	Three-dimensional Structure of CobT in Complex with Reaction Products of 5-methoxybenzimidazole and NaMN
1JHO	;	2.0	;	Three-dimensional Structure of CobT in Complex with the Reaction Products of 5-methylbenzimidazole and NaMN
1SRD	;	2.0	;	Three-dimensional structure of CU,ZN-superoxide dismutase from spinach at 2.0 Angstroms resolution
1YMC	;	2.0	;	THREE-DIMENSIONAL STRUCTURE OF CYANOMET-SULFMYOGLOBIN C
2N8E	;		;	Three-dimensional structure of cyclic PVIIA
3ANA	;	2.5	;	THREE-DIMENSIONAL STRUCTURE OF D(GGGATCCC) IN THE CRYSTALLINE STATE
1CF2	;	2.1	;	THREE-DIMENSIONAL STRUCTURE OF D-GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE FROM THE HYPERTHERMOPHILIC ARCHAEON METHANOTHERMUS FERVIDUS
4CAU	;	7.0	;	THREE-DIMENSIONAL STRUCTURE OF DENGUE VIRUS SEROTYPE 1 COMPLEXED WITH 2 HMAB 14C10 FAB
3J05	;	7.0	;	Three-dimensional structure of Dengue virus serotype 1 complexed with HMAb 14c10 Fab
1HMC	;	2.5	;	THREE-DIMENSIONAL STRUCTURE OF DIMERIC HUMAN RECOMBINANT MACROPHAGE COLONY STIMULATING FACTOR
1YF2	;	2.4	;	Three-dimensional structure of DNA sequence specificity (S) subunit of a type I restriction-modification enzyme and its functional implications
1DIH	;	2.2	;	THREE-DIMENSIONAL STRUCTURE OF E. COLI DIHYDRODIPICOLINATE REDUCTASE
1CLC	;	1.9	;	THREE-DIMENSIONAL STRUCTURE OF ENDOGLUCANASE D AT 1.9 ANGSTROMS RESOLUTION
1SRX	;	2.8	;	THREE-DIMENSIONAL STRUCTURE OF ESCHERICHIA COLI THIOREDOXIN-S2 TO 2.8 ANGSTROMS RESOLUTION
1RN1	;	1.84	;	THREE-DIMENSIONAL STRUCTURE OF GLN 25-RIBONUCLEASE T1 AT 1.84 ANGSTROMS RESOLUTION: STRUCTURAL VARIATIONS AT THE BASE RECOGNITION AND CATALYTIC SITES
1AL8	;	2.2	;	THREE-DIMENSIONAL STRUCTURE OF GLYCOLATE OXIDASE WITH BOUND ACTIVE-SITE INHIBITORS
3RY5	;	2.3	;	Three-dimensional structure of glycosylated fcgammariia (high-responder polymorphism)
2FGF	;	1.77	;	THREE-DIMENSIONAL STRUCTURE OF HUMAN BASIC FIBROBLAST GROWTH FACTOR, A STRUCTURAL HOMOLOG OF INTERLEUKIN 1BETA
8OO8	;	1.4	;	Three-Dimensional Structure of Human Carbonic Anhydrase II in Complex with a Covalent Inhibitor
1EFV	;	2.1	;	THREE-DIMENSIONAL STRUCTURE OF HUMAN ELECTRON TRANSFER FLAVOPROTEIN TO 2.1 A RESOLUTION
2KG4	;		;	Three-dimensional structure of human Gadd45alpha in solution by NMR
1BQT	;		;	THREE-DIMENSIONAL STRUCTURE OF HUMAN INSULIN-LIKE GROWTH FACTOR-I (IGF-I) DETERMINED BY 1H-NMR AND DISTANCE GEOMETRY, 6 STRUCTURES
2M5V	;		;	Three-dimensional structure of human NLRP10/PYNOD pyrin domain
1NNA	;	2.5	;	THREE-DIMENSIONAL STRUCTURE OF INFLUENZA A N9 NEURAMINIDASE AND ITS COMPLEX WITH THE INHIBITOR 2-DEOXY 2,3-DEHYDRO-N-ACETYL NEURAMINIC ACID
1NNB	;	2.8	;	THREE-DIMENSIONAL STRUCTURE OF INFLUENZA A N9 NEURAMINIDASE AND ITS COMPLEX WITH THE INHIBITOR 2-DEOXY 2,3-DEHYDRO-N-ACETYL NEURAMINIC ACID
1IL8	;		;	THREE-DIMENSIONAL STRUCTURE OF INTERLEUKIN 8 IN SOLUTION
2IL8	;		;	THREE-DIMENSIONAL STRUCTURE OF INTERLEUKIN 8 IN SOLUTION
7ADH	;	3.2	;	THREE-DIMENSIONAL STRUCTURE OF ISONICOTINIMIDYLATED LIVER ALCOHOL DEHYDROGENASE
1RW2	;		;	Three-dimensional structure of Ku80 CTD
5K50	;	2.26	;	Three-dimensional structure of L-threonine 3-dehydrogenase from Trypanosoma brucei bound to NAD+ and L-allo-threonine refined to 2.23 angstroms
5K4V	;	2.2	;	Three-dimensional structure of L-threonine 3-dehydrogenase from Trypanosoma brucei bound to NAD+ refined to 2.2 angstroms
5K4Q	;	2.3	;	Three-dimensional structure of L-threonine 3-dehydrogenase from Trypanosoma brucei bound to NAD+ refined to 2.3 angstroms
5K4W	;	1.72	;	Three-dimensional structure of L-threonine 3-dehydrogenase from Trypanosoma brucei bound to NADH and L-threonine refined to 1.72 angstroms
5K4Y	;	1.77	;	Three-dimensional structure of L-threonine 3-dehydrogenase from Trypanosoma brucei refined to 1.77 angstroms
5K4T	;	2.1	;	Three-dimensional structure of L-threonine 3-dehydrogenase from Trypanosoma brucei refined to 2.1 angstroms
5K4U	;	1.9	;	Three-dimensional structure of L-threonine 3-dehydrogenase from Trypanosoma brucei showing different active site loop conformations between dimer subunits, refined to 1.9 angstroms
3AX4	;	2.613	;	Three-dimensional structure of lectin from Dioclea violacea and comparative vasorelaxant effects with Dioclea rostrata
1BOU	;	2.2	;	THREE-DIMENSIONAL STRUCTURE OF LIGAB
1LPF	;	2.8	;	THREE-DIMENSIONAL STRUCTURE OF LIPOAMIDE DEHYDROGENASE FROM PSEUDOMONAS FLUORESCENS AT 2.8 ANGSTROMS RESOLUTION. ANALYSIS OF REDOX AND THERMOSTABILITY PROPERTIES
6FAB	;	1.9	;	THREE-DIMENSIONAL STRUCTURE OF MURINE ANTI-P-AZOPHENYLARSONATE FAB 36-71. 1. X-RAY CRYSTALLOGRAPHY, SITE-DIRECTED MUTAGENESIS, AND MODELING OF THE COMPLEX WITH HAPTEN
3GXV	;	2.2	;	Three-dimensional structure of N-terminal domain of DnaB Helicase from Helicobacter pylori and its interactions with primase
1AMO	;	2.6	;	THREE-DIMENSIONAL STRUCTURE OF NADPH-CYTOCHROME P450 REDUCTASE: PROTOTYPE FOR FMN-AND FAD-CONTAINING ENZYMES
1H2R	;	1.4	;	THREE-DIMENSIONAL STRUCTURE OF NI-FE HYDROGENASE FROM DESULFIVIBRIO VULGARIS MIYAZAKI F IN THE REDUCED FORM AT 1.4 A RESOLUTION
4BWT	;	1.76	;	Three-dimensional structure of Paracoccus pantotrophus pseudoazurin at pH 6.5
1FIY	;	2.8	;	THREE-DIMENSIONAL STRUCTURE OF PHOSPHOENOLPYRUVATE CARBOXYLASE FROM ESCHERICHIA COLI AT 2.8 A RESOLUTION
1PTA	;	2.1	;	THREE-DIMENSIONAL STRUCTURE OF PHOSPHOTRIESTERASE: AN ENZYME CAPABLE OF DETOXIFYING ORGANOPHOSPHATE NERVE AGENTS
1C5A	;		;	THREE-DIMENSIONAL STRUCTURE OF PORCINE C5ADES*ARG FROM 1H NUCLEAR MAGNETIC RESONANCE DATA
1NSA	;	2.3	;	THREE-DIMENSIONAL STRUCTURE OF PORCINE PROCARBOXYPEPTIDASE B: A STRUCTURAL BASIS OF ITS INACTIVITY
1BZO	;	2.1	;	THREE-DIMENSIONAL STRUCTURE OF PROKARYOTIC CU,ZN SUPEROXIDE DISMUTASE FROM P.LEIOGNATHI, SOLVED BY X-RAY CRYSTALLOGRAPHY.
3PE5	;	2.381	;	Three-dimensional Structure of protein A7VV38_9CLOT from Clostridium leptum DSM 753, Northeast Structural Genomics Consortium Target QlR103
3P51	;	2.056	;	Three-dimensional structure of protein Q2Y8N9_NITMU from nitrosospira multiformis, Northeast structural genomics consortium target NMR118
1BCT	;		;	THREE-DIMENSIONAL STRUCTURE OF PROTEOLYTIC FRAGMENT 163-231 OF BACTERIOOPSIN DETERMINED FROM NUCLEAR MAGNETIC RESONANCE DATA IN SOLUTION
2MRB	;		;	THREE-DIMENSIONAL STRUCTURE OF RABBIT LIVER CD-7 METALLOTHIONEIN-2A IN AQUEOUS SOLUTION DETERMINED BY NUCLEAR MAGNETIC RESONANCE
1MRB	;		;	THREE-DIMENSIONAL STRUCTURE OF RABBIT LIVER CD7 METALLOTHIONEIN-2A IN AQUEOUS SOLUTION DETERMINED BY NUCLEAR MAGNETIC RESONANCE
1RPA	;	3.0	;	THREE-DIMENSIONAL STRUCTURE OF RAT ACID PHOSPHATASE IN COMPLEX WITH L(+) TARTRATE
1RAL	;	3.0	;	THREE-DIMENSIONAL STRUCTURE OF RAT LIVER 3ALPHA-HYDROXYSTEROID(SLASH)DIHYDRODIOL DEHYDROGENASE: A MEMBER OF THE ALDO-KETO REDUCTASE SUPERFAMILY
1RLA	;	2.1	;	THREE-DIMENSIONAL STRUCTURE OF RAT LIVER ARGINASE, THE BINUCLEAR MANGANESE METALLOENZYME OF THE UREA CYCLE
1CSG	;	2.7	;	Three-dimensional structure of recombinant human granulocyte-macrophage colony-stimulating factor
1HIG	;	3.5	;	THREE-DIMENSIONAL STRUCTURE OF RECOMBINANT HUMAN INTERFERON-GAMMA.
2HMB	;	2.1	;	THREE-DIMENSIONAL STRUCTURE OF RECOMBINANT HUMAN MUSCLE FATTY ACID-BINDING PROTEIN
1REC	;	1.9	;	THREE-DIMENSIONAL STRUCTURE OF RECOVERIN, A CALCIUM SENSOR IN VISION
2RNT	;	1.8	;	THREE-DIMENSIONAL STRUCTURE OF RIBONUCLEASE T1 COMPLEXED WITH GUANYLYL-2(PRIME),5(PRIME)-GUANOSINE AT 1.8 ANGSTROMS RESOLUTION
1B2M	;	2.0	;	THREE-DIMENSIONAL STRUCTURE OF RIBONULCEASE T1 COMPLEXED WITH AN ISOSTERIC PHOSPHONATE ANALOGUE OF GPU: ALTERNATE SUBSTRATE BINDING MODES AND CATALYSIS.
1SAX	;	2.8	;	Three-dimensional structure of s.aureus methicillin-resistance regulating transcriptional repressor meci in complex with 25-bp ds-DNA
1OKR	;	2.4	;	Three-dimensional structure of S.aureus methicillin-resistance regulating transcriptional repressor MecI.
1BTC	;	2.0	;	THREE-DIMENSIONAL STRUCTURE OF SOYBEAN BETA-AMYLASE DETERMINED AT 3.0 ANGSTROMS RESOLUTION: PRELIMINARY CHAIN TRACING OF THE COMPLEX WITH ALPHA-CYCLODEXTRIN
1BBI	;		;	THREE-DIMENSIONAL STRUCTURE OF SOYBEAN TRYPSIN(SLASH)CHYMOTRYPSIN BOWMAN-BIRK INHIBITOR IN SOLUTION
2BBI	;		;	THREE-DIMENSIONAL STRUCTURE OF SOYBEAN TRYPSIN(SLASH)CHYMOTRYPSIN BOWMAN-BIRK INHIBITOR IN SOLUTION
1TDT	;	2.2	;	THREE-DIMENSIONAL STRUCTURE OF TETRAHYDRODIPICOLINATE-N-SUCCINYLTRANSFERASE
1KAP	;	1.64	;	THREE-DIMENSIONAL STRUCTURE OF THE ALKALINE PROTEASE OF PSEUDOMONAS AERUGINOSA: A TWO-DOMAIN PROTEIN WITH A CALCIUM BINDING PARALLEL BETA ROLL MOTIF
1APO	;		;	THREE-DIMENSIONAL STRUCTURE OF THE APO FORM OF THE N-TERMINAL EGF-LIKE MODULE OF BLOOD COAGULATION FACTOR X AS DETERMINED BY NMR SPECTROSCOPY AND SIMULATED FOLDING
3HSC	;	1.93	;	THREE-DIMENSIONAL STRUCTURE OF THE ATPASE FRAGMENT OF A 70K HEAT-SHOCK COGNATE PROTEIN
2POL	;	2.5	;	THREE-DIMENSIONAL STRUCTURE OF THE BETA SUBUNIT OF ESCHERICHIA COLI DNA POLYMERASE III HOLOENZYME: A SLIDING DNA CLAMP
1PII	;	2.0	;	THREE-DIMENSIONAL STRUCTURE OF THE BIFUNCTIONAL ENZYME PHOSPHORIBOSYLANTHRANILATE ISOMERASE: INDOLEGLYCEROLPHOSPHATE SYNTHASE FROM ESCHERICHIA COLI REFINED AT 2.0 ANGSTROMS RESOLUTION
1BNC	;	2.4	;	THREE-DIMENSIONAL STRUCTURE OF THE BIOTIN CARBOXYLASE SUBUNIT OF ACETYL-COA CARBOXYLASE
2MLK	;		;	Three-dimensional structure of the C-terminal DNA-binding domain of RstA protein from Klebsiella pneumoniae
4ORS	;	1.4	;	Three-dimensional structure of the C65A mutant of Human lipocalin-type Prostaglandin D Synthase apo-form
4ORU	;	1.55	;	Three-dimensional structure of the C65A mutant of Human lipocalin-type Prostaglandin D Synthase holo-form second space group
4ORW	;	1.664	;	Three-dimensional structure of the C65A-K59A double mutant of Human lipocalin-type Prostaglandin D Synthase apo-form
4ORY	;	1.8	;	Three-dimensional structure of the C65A-K59A double mutant of Human lipocalin-type Prostaglandin D Synthase holo, second crystal form
4ORX	;	1.6	;	Three-dimensional structure of the C65A-K59A double mutant of Human lipocalin-type Prostaglandin D Synthase holo-form
4OS3	;	1.4	;	Three-dimensional structure of the C65A-W112F double mutant of Human lipocalin-type Prostaglandin D Synthase apo-form
4OS0	;	1.75	;	Three-dimensional structure of the C65A-W54F double mutant of Human lipocalin-type Prostaglandin D Synthase apo-form
4OS8	;	1.69	;	Three-dimensional structure of the C65A-W54F-W112F triple mutant of Human lipocalin-type Prostaglandin D Synthase apo-form
1RH8	;		;	Three-dimensional structure of the calcium-free Piccolo C2A-domain
1UBH	;	1.35	;	Three-dimensional Structure of The Carbon Monoxide Complex of [NiFe]hydrogenase From Desulufovibrio vulgaris Miyazaki F
1UBJ	;	1.35	;	Three-dimensional Structure of The Carbon Monoxide Complex of [NiFe]hydrogenase From Desulufovibrio vulgaris Miyazaki F
1UBK	;	1.18	;	Three-dimensional Structure of The Carbon Monoxide Complex of [NiFe]hydrogenase From Desulufovibrio vulgaris Miyazaki F
1UBL	;	1.2	;	Three-dimensional Structure of The Carbon Monoxide Complex of [NiFe]hydrogenase From Desulufovibrio vulgaris Miyazaki F
1UBM	;	1.4	;	Three-dimensional Structure of The Carbon Monoxide Complex of [NiFe]hydrogenase From Desulufovibrio vulgaris Miyazaki F
1UBO	;	1.35	;	Three-dimensional Structure of The Carbon Monoxide Complex of [NiFe]hydrogenase From Desulufovibrio vulgaris Miyazaki F
1UBR	;	1.34	;	Three-dimensional Structure of The Carbon Monoxide Complex of [NiFe]hydrogenase From Desulufovibrio vulgaris Miyazaki F
1UBT	;	1.34	;	Three-dimensional Structure of The Carbon Monoxide Complex of [NiFe]hydrogenase From Desulufovibrio vulgaris Miyazaki F
1UBU	;	1.35	;	Three-dimensional Structure of The Carbon Monoxide Complex of [NiFe]hydrogenase From Desulufovibrio vulgaris Miyazaki F
1ACA	;		;	THREE-DIMENSIONAL STRUCTURE OF THE COMPLEX BETWEEN ACYL-COENZYME A BINDING PROTEIN AND PALMITOYL-COENZYME A
1TGS	;	1.8	;	THREE-DIMENSIONAL STRUCTURE OF THE COMPLEX BETWEEN PANCREATIC SECRETORY INHIBITOR (KAZAL TYPE) AND TRYPSINOGEN AT 1.8 ANGSTROMS RESOLUTION. STRUCTURE SOLUTION, CRYSTALLOGRAPHIC REFINEMENT AND PRELIMINARY STRUCTURAL INTERPRETATION
1FPT	;	3.0	;	THREE-DIMENSIONAL STRUCTURE OF THE COMPLEX BETWEEN THE FAB FRAGMENT OF AN NEUTRALIZING ANTIBODY FOR TYPE 1 POLIOVIRUS AND ITS VIRAL EPITOPE
1CGI	;	2.3	;	THREE-DIMENSIONAL STRUCTURE OF THE COMPLEXES BETWEEN BOVINE CHYMOTRYPSINOGEN*A AND TWO RECOMBINANT VARIANTS OF HUMAN PANCREATIC SECRETORY TRYPSIN INHIBITOR (KAZAL-TYPE)
1CGJ	;	2.3	;	THREE-DIMENSIONAL STRUCTURE OF THE COMPLEXES BETWEEN BOVINE CHYMOTRYPSINOGEN*A AND TWO RECOMBINANT VARIANTS OF HUMAN PANCREATIC SECRETORY TRYPSIN INHIBITOR (KAZAL-TYPE)
1KIL	;	2.3	;	Three-dimensional structure of the complexin/SNARE complex
2LAM	;		;	Three-dimensional structure of the cyclotide Cter M
1AJA	;	2.5	;	THREE-DIMENSIONAL STRUCTURE OF THE D153G MUTANT OF E. COLI ALKALINE PHOSPHATASE: A MUTANT WITH WEAKER MAGNESIUM BINDING AND INCREASED CATALYTIC ACTIVITY
1AJB	;	2.5	;	THREE-DIMENSIONAL STRUCTURE OF THE D153G MUTANT OF E. COLI ALKALINE PHOSPHATASE: A MUTANT WITH WEAKER MAGNESIUM BINDING AND INCREASED CATALYTIC ACTIVITY
1AJC	;	2.5	;	THREE-DIMENSIONAL STRUCTURE OF THE D153G MUTANT OF E. COLI ALKALINE PHOSPHATASE: A MUTANT WITH WEAKER MAGNESIUM BINDING AND INCREASED CATALYTIC ACTIVITY
1AJD	;	2.5	;	THREE-DIMENSIONAL STRUCTURE OF THE D153G MUTANT OF E. COLI ALKALINE PHOSPHATASE: A MUTANT WITH WEAKER MAGNESIUM BINDING AND INCREASED CATALYTIC ACTIVITY
4GVW	;	2.113	;	Three-dimensional structure of the de novo designed serine hydrolase 2bfq_3, Northeast Structural Genomics Consortium (NESG) Target OR248
1EZM	;	1.5	;	THREE-DIMENSIONAL STRUCTURE OF THE ELASTASE OF PSEUDOMONAS AERUGINOSA AT 1.5 ANGSTROMS RESOLUTION
1F3G	;	2.1	;	THREE-DIMENSIONAL STRUCTURE OF THE ESCHERICHIA COLI PHOSPHOCARRIER PROTEIN III GLC
4N8C	;	1.6	;	Three-dimensional structure of the extracellular domain of Matrix protein 2 of influenza A virus
1GLV	;	2.7	;	THREE-DIMENSIONAL STRUCTURE OF THE GLUTATHIONE SYNTHETASE FROM ESCHERICHIA COLI B AT 2.0 ANGSTROMS RESOLUTION
2BW3	;	2.0	;	Three-dimensional structure of the Hermes DNA transposase
1L9M	;	2.1	;	Three-dimensional structure of the human transglutaminase 3 enzyme: binding of calcium ions change structure for activation
1L9N	;	2.1	;	Three-dimensional structure of the human transglutaminase 3 enzyme: binding of calcium ions change structure for activation
2HX0	;	1.55	;	Three-dimensional structure of the hypothetical protein from Salmonella cholerae-suis (aka Salmonella enterica) at the resolution 1.55 A. Northeast Structural Genomics target ScR59.
1LEP	;	3.5	;	THREE-DIMENSIONAL STRUCTURE OF THE IMMUNODOMINANT HEAT-SHOCK PROTEIN CHAPERONIN-10 OF MYCOBACTERIUM LEPRAE
5M85	;	2.1	;	Three-dimensional structure of the intermediate state of GAF3 from Slr1393 of Synechocystis sp. PCC6803
4BWU	;	1.76	;	Three-dimensional structure of the K109A mutant of Paracoccus pantotrophus pseudoazurin at pH 5.5
1LPE	;	2.25	;	THREE-DIMENSIONAL STRUCTURE OF THE LDL RECEPTOR-BINDING DOMAIN OF HUMAN APOLIPOPROTEIN E
1LAB	;		;	THREE-DIMENSIONAL STRUCTURE OF THE LIPOYL DOMAIN FROM BACILLUS STEAROTHERMOPHILUS PYRUVATE DEHYDROGENASE MULTIENZYME COMPLEX
1LAC	;		;	THREE-DIMENSIONAL STRUCTURE OF THE LIPOYL DOMAIN FROM BACILLUS STEAROTHERMOPHILUS PYRUVATE DEHYDROGENASE MULTIENZYME COMPLEX
1CEK	;		;	THREE-DIMENSIONAL STRUCTURE OF THE MEMBRANE-EMBEDDED M2 CHANNEL-LINING SEGMENT FROM THE NICOTINIC ACETYLCHOLINE RECEPTOR BY SOLID-STATE NMR SPECTROSCOPY
1FTP	;	2.2	;	THREE-DIMENSIONAL STRUCTURE OF THE MUSCLE FATTY-ACID-BINDING PROTEIN ISOLATED FROM THE DESERT LOCUST, SCHISTOCERCA GREGARIA
4BXV	;	1.76	;	Three-dimensional structure of the mutant K109A of Paracoccus pantotrophus pseudoazurin at pH 7.0
2L6A	;		;	Three-dimensional structure of the N-terminal effector PYRIN domain of NLRP12
1NN2	;	2.2	;	THREE-DIMENSIONAL STRUCTURE OF THE NEURAMINIDASE OF INFLUENZA VIRUS A(SLASH)TOKYO(SLASH)3(SLASH)67 AT 2.2 ANGSTROMS RESOLUTION
1ATX	;		;	THREE-DIMENSIONAL STRUCTURE OF THE NEUROTOXIN ATX IA FROM ANEMONIA SULCATA IN AQUEOUS SOLUTION DETERMINED BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
1WUH	;	1.24	;	Three-Dimensional Structure Of The Ni-A State Of [Nife]Hydrogenase From Desulufovibrio Vulgaris Miyazaki F
1WUJ	;	1.4	;	Three-Dimensional Structure Of The Ni-B State Of [Nife]Hydrogenase From Desulufovibrio Vulgaris Miyazaki F
2WC1	;	2.17	;	Three-dimensional Structure of the Nitrogen Fixation Flavodoxin (NifF) from Rhodobacter capsulatus at 2.2 A
4KY3	;	2.964	;	Three-dimensional Structure of the orthorhombic crystal of computationally designed insertion domain , Northeast Structural Genomics Consortium (NESG) Target OR327
1EQ8	;		;	THREE-DIMENSIONAL STRUCTURE OF THE PENTAMERIC HELICAL BUNDLE OF THE ACETYLCHOLINE RECEPTOR M2 TRANSMEMBRANE SEGMENT
7QAL	;		;	Three-dimensional structure of the PGAM5 C12L mutant TMD
7QAO	;		;	Three-dimensional structure of the PGAM5 C12S mutant TMD
7QAP	;		;	Three-dimensional structure of the PGAM5 G17L mutant TMD
7QAM	;		;	Three-dimensional structure of the PGAM5 WT TMD
2QGU	;	1.5	;	Three-dimensional structure of the phospholipid-binding protein from Ralstonia solanacearum Q8XV73_RALSQ in complex with a phospholipid at the resolution 1.53 A. Northeast Structural Genomics Consortium target RsR89
5M82	;	1.86	;	Three-dimensional structure of the photoproduct state of GAF3 from Slr1393 of Synechocystis sp. PCC6803
1LSG	;	2.4	;	THREE-DIMENSIONAL STRUCTURE OF THE PLATELET INTEGRIN RECOGNITION SEGMENT OF THE FIBRINOGEN GAMMA CHAIN OBTAINED BY CARRIER PROTEIN-DRIVEN CRYSTALLIZATION
4FDB	;	1.8	;	Three-dimensional structure of the protein prib from ralstonia solanacearum at the resolution 1.8a. northeast structural genomics consortium target rsr213c
3EN2	;	2.3	;	Three-dimensional structure of the protein priB from Ralstonia solanacearum at the resolution 2.3A. Northeast Structural Genomics Consortium target RsR213C.
3CNW	;	2.48	;	Three-dimensional structure of the protein XoxI (Q81AY6) from Bacillus cereus. Northeast Structural Genomics Consortium target BcR196.
1EVI	;	2.5	;	THREE-DIMENSIONAL STRUCTURE OF THE PURPLE INTERMEDIATE OF PORCINE KIDNEY D-AMINO ACID OXIDASE
3OTL	;	1.901	;	Three-dimensional Structure of the putative uncharacterized protein from Rhizobium leguminosarum at the resolution 1.9A, Northeast Structural Genomics Consortium Target RlR261
1H0M	;	3.0	;	Three-dimensional structure of the quorum sensing protein TraR bound to its autoinducer and to its target DNA
1DRS	;		;	THREE-DIMENSIONAL STRUCTURE OF THE RGD-CONTAINING NEUROTOXIN HOMOLOGUE, DENDROASPIN
1K5W	;		;	THREE-DIMENSIONAL STRUCTURE OF THE SYNAPTOTAGMIN 1 C2B-DOMAIN: SYNAPTOTAGMIN 1 AS A PHOSPHOLIPID BINDING MACHINE
1AVD	;	2.7	;	THREE-DIMENSIONAL STRUCTURE OF THE TETRAGONAL CRYSTAL FORM OF EGG-WHITE AVIDIN IN ITS FUNCTIONAL COMPLEX WITH BIOTIN AT 2.7 ANGSTROMS RESOLUTION
2GOF	;		;	Three-dimensional structure of the trans-membrane domain of Vpu from HIV-1 in aligned phospholipid bicelles
2GOH	;		;	Three-dimensional Structure of the Trans-membrane Domain of Vpu from HIV-1 in Aligned Phospholipid Bicelles
2JUI	;		;	Three-Dimensional Structure of the two Peptides that Constitute the Two-Peptide Bacteriocin Plantaracin EF
2RLW	;		;	Three-Dimensional Structure of the two Peptides that Constitute the Two-Peptide Bacteriocin Plantaracin EF
1DPM	;	2.1	;	THREE-DIMENSIONAL STRUCTURE OF THE ZINC-CONTAINING PHOSPHOTRIESTERASE WITH BOUND SUBSTRATE ANALOG DIETHYL 4-METHYLBENZYLPHOSPHONATE
1EZ2	;	1.9	;	THREE-DIMENSIONAL STRUCTURE OF THE ZINC-CONTAINING PHOSPHOTRIESTERASE WITH BOUND SUBSTRATE ANALOG DIISOPROPYLMETHYL PHOSPHONATE.
1EYW	;	1.9	;	THREE-DIMENSIONAL STRUCTURE OF THE ZINC-CONTAINING PHOSPHOTRIESTERASE WITH BOUND SUBSTRATE ANALOG TRIETHYLPHOSPHATE
1CTX	;	2.8	;	THREE-DIMENSIONAL STRUCTURE OF THE-LONG-NEUROTOXIN FROM COBRA VENOM
1TMF	;	3.5	;	THREE-DIMENSIONAL STRUCTURE OF THEILER MURINE ENCEPHALOMYELITIS VIRUS (BEAN STRAIN)
1TME	;	2.8	;	THREE-DIMENSIONAL STRUCTURE OF THEILER VIRUS
1TPT	;	2.8	;	THREE-DIMENSIONAL STRUCTURE OF THYMIDINE PHOSPHORYLASE FROM ESCHERICHIA COLI AT 2.8 ANGSTROMS RESOLUTION
4KYZ	;	2.492	;	Three-dimensional structure of triclinic form of de novo design insertion domain, Northeast Structural Genomics Consortium (NESG) Target OR327
1FAI	;	2.7	;	THREE-DIMENSIONAL STRUCTURE OF TWO CRYSTAL FORMS OF FAB R19.9, FROM A MONOCLONAL ANTI-ARSONATE ANTIBODY
2F19	;	2.8	;	THREE-DIMENSIONAL STRUCTURE OF TWO CRYSTAL FORMS OF FAB R19.9, FROM A MONOCLONAL ANTI-ARSONATE ANTIBODY
1XSO	;	1.49	;	THREE-DIMENSIONAL STRUCTURE OF XENOPUS LAEVIS CU,ZN SUPEROXIDE DISMUTASE B DETERMINED BY X-RAY CRYSTALLOGRAPHY AT 1.5 ANGSTROMS RESOLUTION
1R9G	;	2.5	;	Three-dimensional Structure of YaaE from Bacillus subtilis
1VTQ	;	3.0	;	THREE-DIMENSIONAL STRUCTURE OF YEAST T-RNA-ASP. I. STRUCTURE DETERMINATION
1GSQ	;	2.4	;	THREE-DIMENSIONAL STRUCTURE, CATALYTIC PROPERTIES AND EVOLUTION OF A SIGMA CLASS GLUTATHIONE TRANSFERASE FROM SQUID, A PROGENITOR OF THE LENS-CRYSTALLINS OF CEPHALOPODS
1AGP	;	2.3	;	THREE-DIMENSIONAL STRUCTURES AND PROPERTIES OF A TRANSFORMING AND A NONTRANSFORMING GLY-12 MUTANT OF P21-H-RAS
821P	;	1.5	;	THREE-DIMENSIONAL STRUCTURES AND PROPERTIES OF A TRANSFORMING AND A NONTRANSFORMING GLYCINE-12 MUTANT OF P21H-RAS
6DUL	;		;	Three-Dimensional Structures for mastoparano-L
6DUU	;		;	Three-Dimensional Structures for mastoparano-MO
1BAR	;	2.7	;	THREE-DIMENSIONAL STRUCTURES OF ACIDIC AND BASIC FIBROBLAST GROWTH FACTORS
1BAS	;	1.9	;	THREE-DIMENSIONAL STRUCTURES OF ACIDIC AND BASIC FIBROBLAST GROWTH FACTORS
2AVI	;	3.0	;	THREE-DIMENSIONAL STRUCTURES OF AVIDIN AND THE AVIDIN-BIOTIN COMPLEX
6CTG	;		;	Three-Dimensional Structures of Cm-p1
1LOA	;	2.2	;	THREE-DIMENSIONAL STRUCTURES OF COMPLEXES OF LATHYRUS OCHRUS ISOLECTIN I WITH GLUCOSE AND MANNOSE: FINE SPECIFICITY OF THE MONOSACCHARIDE-BINDING SITE
1LOB	;	2.0	;	THREE-DIMENSIONAL STRUCTURES OF COMPLEXES OF LATHYRUS OCHRUS ISOLECTIN I WITH GLUCOSE AND MANNOSE: FINE SPECIFICITY OF THE MONOSACCHARIDE-BINDING SITE
1RMU	;	3.0	;	THREE-DIMENSIONAL STRUCTURES OF DRUG-RESISTANT MUTANTS OF HUMAN RHINOVIRUS 14
2RMU	;	3.0	;	THREE-DIMENSIONAL STRUCTURES OF DRUG-RESISTANT MUTANTS OF HUMAN RHINOVIRUS 14
1AL7	;	2.6	;	THREE-DIMENSIONAL STRUCTURES OF GLYCOLATE OXIDASE WITH BOUND ACTIVE-SITE INHIBITORS
221P	;	2.3	;	THREE-DIMENSIONAL STRUCTURES OF H-RAS P21 MUTANTS: MOLECULAR BASIS FOR THEIR INABILITY TO FUNCTION AS SIGNAL SWITCH MOLECULES
421P	;	2.2	;	THREE-DIMENSIONAL STRUCTURES OF H-RAS P21 MUTANTS: MOLECULAR BASIS FOR THEIR INABILITY TO FUNCTION AS SIGNAL SWITCH MOLECULES
521P	;	2.6	;	THREE-DIMENSIONAL STRUCTURES OF H-RAS P21 MUTANTS: MOLECULAR BASIS FOR THEIR INABILITY TO FUNCTION AS SIGNAL SWITCH MOLECULES
621P	;	2.4	;	THREE-DIMENSIONAL STRUCTURES OF H-RAS P21 MUTANTS: MOLECULAR BASIS FOR THEIR INABILITY TO FUNCTION AS SIGNAL SWITCH MOLECULES
721P	;	2.0	;	THREE-DIMENSIONAL STRUCTURES OF H-RAS P21 MUTANTS: MOLECULAR BASIS FOR THEIR INABILITY TO FUNCTION AS SIGNAL SWITCH MOLECULES
1LIH	;	2.2	;	THREE-DIMENSIONAL STRUCTURES OF THE LIGAND-BINDING DOMAIN OF THE BACTERIAL ASPARTATE RECEPTOR WITH AND WITHOUT A LIGAND
2LIG	;	2.0	;	THREE-DIMENSIONAL STRUCTURES OF THE LIGAND-BINDING DOMAIN OF THE BACTERIAL ASPARTATE RECEPTOR WITH AND WITHOUT A LIGAND
1LST	;	1.8	;	THREE-DIMENSIONAL STRUCTURES OF THE PERIPLASMIC LYSINE-, ARGININE-, ORNITHINE-BINDING PROTEIN WITH AND WITHOUT A LIGAND
2LAO	;	1.9	;	THREE-DIMENSIONAL STRUCTURES OF THE PERIPLASMIC LYSINE-, ARGININE-, ORNITHINE-BINDING PROTEIN WITH AND WITHOUT A LIGAND
1AZH	;		;	THREE-DIMENSIONAL STRUCTURES OF THREE ENGINEERED CELLULOSE-BINDING DOMAINS OF CELLOBIOHYDROLASE I FROM TRICHODERMA REESEI, NMR, 14 STRUCTURES
1AZJ	;		;	THREE-DIMENSIONAL STRUCTURES OF THREE ENGINEERED CELLULOSE-BINDING DOMAINS OF CELLOBIOHYDROLASE I FROM TRICHODERMA REESEI, NMR, 18 STRUCTURES
1AZK	;		;	THREE-DIMENSIONAL STRUCTURES OF THREE ENGINEERED CELLULOSE-BINDING DOMAINS OF CELLOBIOHYDROLASE I FROM TRICHODERMA REESEI, NMR, 19 STRUCTURES
1AZ6	;		;	THREE-DIMENSIONAL STRUCTURES OF THREE ENGINEERED CELLULOSE-BINDING DOMAINS OF CELLOBIOHYDROLASE I FROM TRICHODERMA REESEI, NMR, 23 STRUCTURES
1HDX	;	2.5	;	THREE-DIMENSIONAL STRUCTURES OF THREE HUMAN ALCOHOL DEHYDROGENASE VARIANTS: CORRELATIONS WITH THEIR FUNCTIONAL DIFFERENCES
1HDY	;	2.5	;	THREE-DIMENSIONAL STRUCTURES OF THREE HUMAN ALCOHOL DEHYDROGENASE VARIANTS: CORRELATIONS WITH THEIR FUNCTIONAL DIFFERENCES
1HDZ	;	2.5	;	THREE-DIMENSIONAL STRUCTURES OF THREE HUMAN ALCOHOL DEHYDROGENASE VARIANTS: CORRELATIONS WITH THEIR FUNCTIONAL DIFFERENCES
5FJI	;	1.95	;	Three-dimensional structures of two heavily N-glycosylated Aspergillus sp. Family GH3 beta-D-glucosidases
5FJJ	;	1.95	;	Three-dimensional structures of two heavily N-glycosylated Aspergillus sp. Family GH3 beta-D-glucosidases
6D2H	;		;	Three-Dimensional Structures of [Phe3]Cm-p1 analogs
8PSC	;		;	Three-layered basket-type G-quadruplex from a G-rich sequence with five G-runs
8PSB	;		;	Three-layered parallel G-quadruplex with snapback loop from a G-rich sequence with five G-runs
6ZRR	;	4.0	;	three-protofilament amyloid structure of S20G variant of human amylin (IAPP - Islet Amyloid Polypeptide)
7NWD	;		;	Three-quartet c-kit2 G-quadruplex stabilized by a pyrene conjugate
2LUM	;		;	Three-State Ensemble obtained from eNOEs of the Third Immunoglobulin Binding Domain of Protein G (GB3)
4ORR	;	1.4	;	Threedimensional structure of the C65A mutant of Human lipocalin-type Prostaglandin D Synthase olo-form
1ATR	;	2.34	;	THREONINE 204 OF THE CHAPERONE PROTEIN HSC70 INFLUENCES THE STRUCTURE OF THE ACTIVE SITE BUT IS NOT ESSENTIAL FOR ATP HYDROLYSIS
1ATS	;	2.43	;	THREONINE 204 OF THE CHAPERONE PROTEIN HSC70 INFLUENCES THE STRUCTURE OF THE ACTIVE SITE BUT IS NOT ESSENTIAL FOR ATP HYDROLYSIS
1TDJ	;	2.8	;	THREONINE DEAMINASE (BIOSYNTHETIC) FROM E. COLI
6NMX	;	1.971	;	Threonine synthase from Bacillus subtilis ATCC 6633 with PLP and APPA
6CGQ	;	2.019	;	Threonine synthase from Bacillus subtilis ATCC 6633 with PLP and PLP-Ala
6RP2	;	1.35	;	Threonine to Cysteine (T225C) variant of E coli hydrogenase-1
6L2Q	;	2.3	;	Threonyl-tRNA synthetase from Salmonella enterica in complex with an inhibitor
7WM7	;	2.4	;	Threonyl-tRNA synthetase from Salmonella enterica in complex with an inhibitor
7WMF	;	2.1	;	Threonyl-tRNA synthetase from Salmonella enterica in complex with an inhibitor
7WMI	;	2.0	;	Threonyl-tRNA synthetase from Salmonella enterica in complex with an inhibitor
6L2P	;	2.3	;	Threonyl-tRNA synthetase from Salmonella enterica in the apo form
4LQV	;	1.54	;	Thrirty minutes iron loaded frog M ferritin
1Z71	;	1.8	;	thrombin and P2 pyridine N-oxide inhibitor complex structure
1A61	;	2.2	;	THROMBIN COMPLEXED WITH A BETA-MIMETIC THIAZOLE-CONTAINING INHIBITOR
1UCY	;	2.2	;	THROMBIN COMPLEXED WITH FIBRINOPEPTIDE A ALPHA (RESIDUES 7-19). THREE COMPLEXES, ONE WITH EPSILON-THROMBIN AND TWO WITH ALPHA-THROMBIN
1A46	;	2.12	;	THROMBIN COMPLEXED WITH HIRUGEN AND A BETA-STRAND MIMETIC INHIBITOR
5AHG	;	1.24	;	Thrombin in complex with ((4-chlorophenyl)sulfamoyl))diemethylamine
4UFG	;	1.65	;	Thrombin in complex with (2R)-2-(benzylsulfonylamino)-N-((1S)-2-((4- carbamimidoylphenyl)methylamino)-1-methyl-2-oxo-ethyl)-N-methyl-3- phenyl-propanamide ethane
4UFE	;	1.593	;	Thrombin in complex with (2R)-2-(benzylsulfonylamino)-N-(2-((4- carbamimidoylphenyl)methylamino)-2-oxo-butyl)-3-phenyl-propanamide
4UFF	;	1.55	;	Thrombin in complex with (2R)-2-(benzylsulfonylamino)-N-(2-((4- carbamimidoylphenyl)methylamino)-2-oxo-ethyl)-N-methyl-3-phenyl- propanamide
5AFZ	;	1.53	;	Thrombin in complex with (2R)-2-(benzylsulfonylamino)-N-(2-((4- carbamimidoylphenyl)methylamino)-2-oxo-propyl)-3-phenyl-propanamide
4YES	;	1.5	;	Thrombin in complex with (S)-(4-chloro-2-((1-(5-methyl-1H-pyrrole-2-carbonyl)pyrrolidine-2-carboxamido)methyl)phenyl)methanaminium
5LPD	;	1.5	;	Thrombin in complex with (S)-1-((R)-2-amino-3-cyclohexylpropanoyl)-N-(2-(aminomethyl)-5-chlorobenzyl) pyrrolidine-2-carboxamide
5JZY	;	1.27	;	Thrombin in complex with (S)-1-((R)-2-amino-3-cyclohexylpropanoyl)-N-(4-carbamimidoylbenzyl)pyrrolidine-2-carboxamide
5LCE	;	1.39	;	Thrombin in complex with (S)-1-((R)-2-amino-3-cyclohexylpropanoyl)-N-(5-chloro-2-(hydroxymethyl)benzy l)pyrrolidine-2-carboxamide
5JFD	;	1.46	;	Thrombin in complex with (S)-N-(2-(aminomethyl)-5-chlorobenzyl)-1-((benzylsulfonyl)-D-arginyl)pyrrolidine-2-carboxamide
6T89	;	2.0	;	Thrombin in complex with (S)-N-(tert-butyl)-4-(3-(3-carbamimidoylphenyl)-2-((2',4'-dimethoxy-[1,1'-biphenyl])-3-sulfonamido)propanoyl)piperazine-1-carboxamide (MI-498)
4UDW	;	1.16	;	Thrombin in complex with 1-(2R)-2-amino-3-phenyl-propanoyl-N-(2, 5dichlorophenyl)methylpyrrolidine-2-carboxamide
4UE7	;	1.129	;	Thrombin in complex with 1-amidinopiperidine
6Y02	;	1.48	;	Thrombin in complex with 13k
6YSJ	;	1.45	;	Thrombin in complex with 2-amino-1-(4-bromophenyl)ethan-1-one (j10)
6YMP	;	1.42	;	Thrombin in complex with 3-((5-(tert-butyl)isoxazol-3-yl)methyl)oxetan-3-amine (j54)
4E7R	;	2.25	;	Thrombin in complex with 3-amidinophenylalanine inhibitor
5AFY	;	1.12	;	Thrombin in complex with 3-chloro-benzamide
4UFD	;	1.429	;	Thrombin in complex with 4-(((1-((2S)-1-((2R)-2-(benzylsulfonylamino)- 3-phenyl-propanoyl)pyrrolidin-2-yl)-1-oxo-ethyl)amino)methyl) benzamidine
6YSX	;	1.48	;	Thrombin in complex with 4-amino-N-(5-methylisoxazol-3-yl)benzenesulfonamide (j80)
6YN3	;	1.49	;	Thrombin in complex with 4-hydroxybenzamide (j89)
5AF9	;	1.18	;	Thrombin in complex with 4-Methoxy-N-(2-pyridinyl)benzamide
4UD9	;	1.124	;	Thrombin in complex with 5-chlorothiophene-2-carboxamide
6YQV	;	1.45	;	Thrombin in complex with 5-chlorothiophene-2-sulfonamide (j94)
6TDT	;	1.53	;	Thrombin in Complex with a D-DiPhe-Pro-p-pyridine derivative
6T3Q	;	1.33	;	Thrombin in Complex with a D-Phe-Pro-2-aminopyridine derivative
6T54	;	1.57	;	Thrombin in Complex with a D-Phe-Pro-2-bromothiophene Derivative
6HSX	;	1.56	;	Thrombin in Complex with a D-Phe-Pro-diaminopyridine derivative
6T52	;	1.45	;	Thrombin in Complex with a D-Phe-Pro-imidazole derivative
6T57	;	1.57	;	Thrombin in Complex with a D-Phe-Pro-N-amidinopiperidine Derivative
6T4A	;	1.31	;	Thrombin in Complex with a D-Phe-Pro-p-aminopyridine derivative
6T53	;	1.35	;	Thrombin in Complex with a D-Phe-Pro-p-benzylamine derivative
6T3M	;	1.38	;	Thrombin in Complex with a D-Phe-Pro-p-phenol derivative
1ZRB	;	1.9	;	Thrombin in complex with an azafluorenyl inhibitor 23b
1ZGV	;	2.2	;	Thrombin in complex with an oxazolopyridine inhibitor 2
1ZGI	;	2.2	;	thrombin in complex with an oxazolopyridine inhibitor 21
4UEH	;	1.16	;	Thrombin in complex with benzamidine
3PO1	;	1.65	;	Thrombin in complex with Benzothiazole Guanidine
6T56	;	1.31	;	Thrombin in Complex with Benzylamine
7AC9	;	1.393	;	Thrombin in complex with D-arginine (j77)
6ZGO	;	1.79	;	Thrombin in complex with D-Phe-Pro-2-chlorofuran derivative (13l)
6YHJ	;	1.44	;	Thrombin in complex with D-Phe-Pro-2-chlorothiophen derivative (16e)
6YB6	;	1.33	;	Thrombin in complex with D-Phe-Pro-3-chloro-1,3-dihydroxybenzylamide derivative (13c)
6YHG	;	1.33	;	Thrombin in complex with D-Phe-Pro-m-methoxybenzylamide derivative (16a)
6Y9H	;	1.48	;	Thrombin in complex with D-Phe-Pro-m-Trifluoromethylbenzylamide derivative (phe2)
6T8A	;	1.62	;	Thrombin in complex with diphenyl ((4-carbamimidoylphenyl)((S)-1-((R)-3-cyclohexyl 2-((phenylmethyl)sulfonamido)propanoyl)pyrrolidine-2-carboxamido)methyl)phosphonate (MI-492)
6I51	;	1.4	;	Thrombin in complex with fragment J02
2BDY	;	1.61	;	thrombin in complex with inhibitor
2GDE	;	2.0	;	Thrombin in complex with inhibitor
2PKS	;	2.5	;	Thrombin in complex with inhibitor
2ZC9	;	1.58	;	Thrombin in complex with Inhibitor
4BAH	;	1.94	;	Thrombin in complex with inhibitor
4BAK	;	1.94	;	Thrombin in complex with inhibitor
4BAM	;	1.88	;	Thrombin in complex with inhibitor
4BAN	;	1.87	;	Thrombin in complex with inhibitor
4BAO	;	1.87	;	Thrombin in complex with inhibitor
4BAQ	;	1.89	;	Thrombin in complex with inhibitor
6T55	;	1.39	;	Thrombin in Complex with Methylbenzylamine
6GBW	;	1.45	;	Thrombin in complex with MI2100 ((S)-N-(2-(aminomethyl)-5-chlorobenzyl)-1-((benzylsulfonyl)-L-arginyl)pyrrolidine-2-carboxamide)
6ROT	;	1.339	;	Thrombin in complex with MI2105
1RIW	;	2.04	;	Thrombin in complex with natural product inhibitor Oscillarin
1NT1	;	2.0	;	thrombin in complex with selective macrocyclic inhibitor
1NM6	;	1.8	;	thrombin in complex with selective macrocyclic inhibitor at 1.8A
2ZGB	;	1.6	;	Thrombin Inhibition
2ZGX	;	1.8	;	Thrombin Inhibition
2ZHQ	;	1.96	;	Thrombin Inhibition
2ZI2	;	1.65	;	Thrombin Inhibition
2ZIQ	;	1.65	;	Thrombin Inhibition
2ZNK	;	1.8	;	Thrombin Inhibition
3D49	;	1.5	;	Thrombin Inhibition
3F68	;	1.75	;	Thrombin Inhibition
3P17	;	1.43	;	Thrombin Inhibition by Pyridin Derivatives
3QTO	;	1.52	;	Thrombin Inhibition by Pyridin Derivatives
3QTV	;	1.63	;	Thrombin Inhibition by Pyridin Derivatives
3QWC	;	1.75	;	Thrombin Inhibition by Pyridin Derivatives
3QX5	;	1.35	;	Thrombin Inhibition by Pyridin Derivatives
3EQ0	;	1.53	;	Thrombin Inhibitor
5A2M	;	1.4	;	Thrombin Inhibitor
1G30	;	2.0	;	THROMBIN INHIBITOR COMPLEX
1G32	;	1.9	;	THROMBIN INHIBITOR COMPLEX
1KTS	;	2.4	;	Thrombin Inhibitor Complex
1KTT	;	2.1	;	Thrombin inhibitor complex
1YPE	;	1.81	;	Thrombin Inhibitor Complex
1YPG	;	1.8	;	Thrombin Inhibitor Complex
1YPJ	;	1.78	;	Thrombin Inhibitor Complex
1YPK	;	1.78	;	Thrombin Inhibitor Complex
1AY6	;	1.8	;	THROMBIN INHIBITOR FROM THEONALLA, CYCLOTHEANAMIDE-BASED MACROCYCLIC TRIPEPTIDE MOTIF
1AVG	;	2.6	;	THROMBIN INHIBITOR FROM TRIATOMA PALLIDIPENNIS
1BA8	;	1.8	;	THROMBIN INHIBITOR WITH A RIGID TRIPEPTIDYL ALDEHYDES
2C8W	;	1.96	;	thrombin inhibitors
2C8X	;	2.17	;	thrombin inhibitors
2C8Y	;	2.2	;	thrombin inhibitors
2C8Z	;	2.14	;	thrombin inhibitors
2C90	;	2.25	;	thrombin inhibitors
2C93	;	2.2	;	thrombin inhibitors
1BB0	;	2.1	;	THROMBIN INHIBITORS WITH RIGID TRIPEPTIDYL ALDEHYDES
1CA8	;	2.1	;	Thrombin inhibitors with rigid tripeptidyl aldehydes
2ZFP	;	2.25	;	Thrombin Inibition
5MJT	;	1.4	;	Thrombin Mutant A190S in complex with (S) -1 - ((R) -2-amino-3,3-diphenylpropanoyl) -N- (3-chlorobenzyl) pyrrolidine-2-carboxamide
5MLS	;	1.62	;	Thrombin Mutant A190S in complex with (S)-1-(D-phenylalanyl)-N-(3-chlorobenzyl)pyrrolidine-2-carboxamide
5MM6	;	1.29	;	Thrombin Mutant A190S in complex with (S)-1-(D-phenylalanyl)-N-(4-carbamimidoylbenzyl)pyrrolidine-2-carboxamide
2V3H	;	1.79	;	Thrombin with 3-cycle no F
2V3O	;	1.79	;	Thrombin with 3-cycle with F
2ODY	;	2.35	;	Thrombin-bound boophilin displays a functional and accessible reactive-site loop
1EGT	;		;	THROMBIN-BOUND STRUCTURE OF AN EGF SUBDOMAIN FROM HUMAN THROMBOMODULIN DETERMINED BY TRANSFERRED NUCLEAR OVERHAUSER EFFECTS
2UUF	;	1.26	;	Thrombin-hirugen binary complex at 1.26A resolution
2UUK	;	1.39	;	Thrombin-hirugen-gw420128 ternary complex at 1.39A resolution
2UUJ	;	1.32	;	Thrombin-hirugen-gw473178 ternary complex at 1.32A resolution
1MUE	;	2.0	;	Thrombin-Hirugen-L405,426
1MU8	;	2.0	;	thrombin-hirugen_l-378,650
5DO4	;	1.859	;	Thrombin-RNA aptamer complex
1VIT	;	3.2	;	THROMBIN:HIRUDIN 51-65 COMPLEX
3BF6	;	2.5	;	Thrombin:suramin complex
7F9F	;	1.411	;	Thrombocorticin
7F9G	;	1.331	;	Thrombocorticin in complex with Ca2+ and fucose
7FBL	;	1.419	;	Thrombocorticin in complex with Ca2+ and mannose
7F9J	;	1.1	;	Thrombocorticin Q25K in complex with Ca2+
7Z0Y	;	2.95	;	THSC20.HVTR04 Fab bound to SARS-CoV-2 Receptor Binding Domain
7Z0X	;	1.8	;	THSC20.HVTR26 Fab bound to SARS-CoV-2 Receptor Binding Domain
7YNM	;	2.9	;	ThT-bound alpha-synuclein fibrils conformation 1
7YNN	;	2.9	;	ThT-bound alpha-synuclein fibrils conformation 2
7PP7	;	2.05	;	Thunberia alata 16:0-ACP desaturase
2LBZ	;		;	Thurincin H
7MSK	;	2.06	;	ThuS glycosin S-glycosyltransferase
7UID	;	2.0	;	Thyclotides peptide nucleic acid in complex with DNA
2J9R	;	2.7	;	Thymidine kinase from B. anthracis in complex with dT.
2JA1	;	2.8	;	Thymidine kinase from B. cereus with TTP bound as phosphate donor.
3VTK	;	3.0	;	THYMIDINE KINASE FROM HERPES SIMPLEX VIRUS TYPE 1 IN COMPLEX WITH ADP AND 5-IODO-DEOXYURIDINE-MONOPHOSPHATE
2VTK	;	2.8	;	THYMIDINE KINASE FROM HERPES SIMPLEX VIRUS TYPE 1 IN COMPLEX WITH ADP AND DEOXYTHYMIDINE
1VTK	;	2.75	;	THYMIDINE KINASE FROM HERPES SIMPLEX VIRUS TYPE 1 IN COMPLEX WITH ADP AND DEOXYTHYMIDINE-MONOPHOSPHATE
2QQE	;	1.9	;	Thymidine Kinase from Thermotoga Maritima in complex with Thymidine
2QQ0	;	1.5	;	Thymidine Kinase from Thermotoga Maritima in complex with thymidine + AppNHp
1E2P	;	2.5	;	Thymidine kinase, DHBT
4EAF	;	1.55	;	Thymidine phosphorylase from E.coli
4EAD	;	1.5	;	Thymidine phosphorylase from E.coli with 3'-azido-2'-fluoro-dideoxyuridine
4LHM	;	1.52	;	Thymidine phosphorylase from E.coli with 3'-azido-3'-deoxythymidine
4GFD	;	1.8	;	Thymidylate kinase (TMK) from S. Aureus in complex with TK-666
1NJB	;	2.74	;	THYMIDYLATE SYNTHASE
1TSD	;	1.95	;	THYMIDYLATE SYNTHASE COMPLEX WITH 2'-DEOXYURIDINE 5'-MONOPHOSPHATE (DUMP) AND FOLATE ANALOG 1843U89
1TLC	;	2.1	;	THYMIDYLATE SYNTHASE COMPLEXED WITH DGMP AND FOLATE ANALOG 1843U89
1VZA	;	2.5	;	THYMIDYLATE SYNTHASE E60D MUTANT BINARY COMPLEX WITH 2'-DEOXYURIDINE 5'-MONOPHOSPHATE (DUMP)
1RTS	;	3.3	;	THYMIDYLATE SYNTHASE FROM RAT IN TERNARY COMPLEX WITH DUMP AND TOMUDEX
2TSR	;	2.6	;	THYMIDYLATE SYNTHASE FROM RAT IN TERNARY COMPLEX WITH DUMP AND TOMUDEX
4DQ1	;	2.71	;	Thymidylate synthase from Staphylococcus aureus.
1BO8	;	2.4	;	THYMIDYLATE SYNTHASE R178T MUTANT
1BPJ	;	2.4	;	THYMIDYLATE SYNTHASE R178T, R179T DOUBLE MUTANT
1TSV	;	2.9	;	THYMIDYLATE SYNTHASE R179A MUTANT
1TSW	;	2.5	;	THYMIDYLATE SYNTHASE R179A MUTANT
1TSX	;	2.5	;	THYMIDYLATE SYNTHASE R179E MUTANT
1TSY	;	2.2	;	THYMIDYLATE SYNTHASE R179K MUTANT
1TSZ	;	2.75	;	THYMIDYLATE SYNTHASE R179K MUTANT
1BO7	;	2.4	;	THYMIDYLATE SYNTHASE R179T MUTANT
1BP0	;	2.4	;	THYMIDYLATE SYNTHASE R23I MUTANT
1BP6	;	2.4	;	THYMIDYLATE SYNTHASE R23I, R179T DOUBLE MUTANT
1TLS	;	2.6	;	THYMIDYLATE SYNTHASE TERNARY COMPLEX WITH FDUMP AND METHYLENETETRAHYDROFOLATE
1TSN	;	2.2	;	THYMIDYLATE SYNTHASE TERNARY COMPLEX WITH FDUMP AND METHYLENETETRAHYDROFOLATE
1NJE	;	2.3	;	THYMIDYLATE SYNTHASE WITH 2'-DEOXYCYTIDINE 5'-MONOPHOSPHATE (DCMP)
1NJA	;	2.5	;	THYMIDYLATE SYNTHASE, MUTATION, N229C WITH 2'-DEOXYCYTIDINE 5'-MONOPHOSPHATE (DCMP)
1NJC	;	2.5	;	THYMIDYLATE SYNTHASE, MUTATION, N229D WITH 2'-DEOXYCYTIDINE 5'-MONOPHOSPHATE (DCMP)
1NJD	;	2.2	;	THYMIDYLATE SYNTHASE, MUTATION, N229D WITH 2'-DEOXYURIDINE 5'-MONOPHOSPHATE (DUMP)
1H5R	;	1.9	;	Thymidylyltransferase complexed with Thimidine and Glucose-1-phospate
1H5T	;	1.9	;	Thymidylyltransferase complexed with Thymidylyldiphosphate-glucose
1H5S	;	2.3	;	Thymidylyltransferase complexed with TMP
1IIM	;	2.1	;	thymidylyltransferase complexed with TTP
1IIN	;	2.1	;	thymidylyltransferase complexed with UDP-glucose
1NJX	;	1.65	;	THYMINE-GUANINE MISMATCH AT THE POLYMERASE ACTIVE SITE
1NJY	;	2.0	;	THYMINE-THYMINE MISMATCH AT THE POLYMERASE ACTIVE SITE
1HJ0	;		;	Thymosin beta9
3M9E	;	2.406	;	Thyroid hormone beta DNA binding domain homodimer with inverted palindrome TRE
1NAV	;	2.5	;	Thyroid Receptor Alpha in complex with an agonist selective for Thyroid Receptor Beta1
2PIN	;	2.3	;	Thyroid receptor beta in complex with inhibitor
1NAX	;	2.7	;	Thyroid receptor beta1 in complex with a beta-selective ligand
1FTT	;		;	THYROID TRANSCRIPTION FACTOR 1 HOMEODOMAIN (RATTUS NORVEGICUS)
2CEO	;	2.8	;	thyroxine-binding globulin complex with thyroxine
1XZX	;	2.5	;	Thyroxine-Thyroid Hormone Receptor Interactions
1Y0X	;	3.1	;	Thyroxine-Thyroid Hormone Receptor Interactions
7NDZ	;	2.7	;	ThyX reconstituted with N5-carbinolamine flavin
7NDW	;	2.0	;	ThyX-FADH2 soaked with 20 mM Formaldehyde
6N4J	;	1.95	;	Ti(III)citrate-reduced, nucleotide-free form of the nitrogenase Fe-protein from A. vinelandii
5DYH	;	2.682	;	Ti(IV) bound human serum transferrin
5ITH	;	2.31	;	TIA-1 RRM2 recognition of target oligonucleotide
8CGV	;	1.66	;	Tiamulin bound to the 50S subunit
4E6Z	;	2.1501	;	Tic22 from Plasmodium falciparum
5ALC	;	1.7	;	Ticagrelor antidote candidate Fab 72 in complex with ticagrelor
5ALB	;	2.16	;	Ticagrelor antidote candidate MEDI2452 in complex with ticagrelor
2M1X	;		;	TICAM-1 TIR domain structure
2M1W	;		;	TICAM-2 TIR domain
7PK4	;	1.92	;	Tick salivary cystatin Ricistatin in complex with cathepsin V
7NE8	;		;	Tick salivary protein BSAP1
8ECH	;	2.05	;	Tick-borne encephalitis virus capsid protein NLS bound to host importin alpha 2
7Z51	;	3.3	;	Tick-borne encephalitis virus Kuutsalo-14
7X89	;		;	Tid1
1FVR	;	2.2	;	TIE2 KINASE DOMAIN
2GY5	;	2.9	;	Tie2 Ligand-Binding Domain Crystal Structure
5KHP	;	2.65	;	Tightening the Recognition of Tetravalent Zr and Th Complexes by the Siderophore-Binding Mammalian Protein Siderocalin for Theranostic Applications
5KID	;	2.15	;	Tightening the Recognition of Tetravalent Zr and Th Complexes by the Siderophore-Binding Mammalian Protein Siderocalin for Theranostic Applications
8PSQ	;	2.65	;	Tilapia Lake Virus polymerase in cRNA pre-initiation state mode A (core only)
8PT7	;	2.8	;	Tilapia Lake Virus polymerase in cRNA pre-initiation state mode A (core-endo only)
8PSS	;	2.83	;	Tilapia Lake Virus polymerase in cRNA pre-initiation state mode B (core-endo only)
8PSX	;	2.96	;	Tilapia Lake Virus polymerase in vRNA elongation state (transcriptase conformation)
8PSZ	;	2.42	;	Tilapia Lake Virus polymerase in vRNA elongation state with additional mode B promoter (transcriptase conformation)
8PSO	;	2.4	;	Tilapia Lake Virus polymerase in vRNA initiation state (core only)
8PT6	;	3.03	;	Tilapia Lake Virus polymerase in vRNA initiation state (replicase conformation)
8PSN	;	2.73	;	Tilapia Lake Virus polymerase in vRNA initiation state (transcriptase conformation)
8PSU	;	3.18	;	Tilapia Lake Virus polymerase in vRNA pre-initiation state mode A (core only)
8PTJ	;	2.86	;	Tilapia Lake Virus polymerase in vRNA pre-initiation state mode B (close core | partial replicase conformation)
8PTH	;	2.73	;	Tilapia Lake Virus polymerase in vRNA pre-initiation state mode B (open core | partial replicase conformation)
8PT2	;	2.59	;	Tilapia Lake Virus polymerase in vRNA pre-initiation state mode B (transcriptase conformation)
8QZ8	;	3.13	;	Tilapia Lake Virus polymerase in vRNA pre-termination state (transcriptase conformation)
8IXW	;	1.8	;	Tilapia lake virus S8 segment
3J8J	;	12.0	;	Tilted state of actin, T1
3J8K	;	12.0	;	Tilted state of actin, T2
2OR8	;	2.5	;	Tim-1
2OR7	;	1.5	;	Tim-2
3BI9	;	2.95	;	Tim-4
3BIB	;	2.5	;	Tim-4 in complex with phosphatidylserine
3BIA	;	2.2	;	Tim-4 in complex with sodium potassium tartrate
3CJH	;	2.6	;	Tim8-Tim13 complex
4WL9	;	1.6	;	Time Resolved Serial Femtosecond Crystallography Captures High Resolution Intermediates of PYP
4WLA	;	1.6	;	Time Resolved Serial Femtosecond Crystallography Captures High Resolution Intermediates of PYP
6QHU	;	1.73	;	Time resolved structural analysis of the full turnover of an enzyme - 100 ms
6QHV	;	1.715	;	Time resolved structural analysis of the full turnover of an enzyme - 100 ms
6QHY	;	1.698	;	Time resolved structural analysis of the full turnover of an enzyme - 100 ms
6QHQ	;	1.735	;	Time resolved structural analysis of the full turnover of an enzyme - 1128 ms
6QI1	;	1.9	;	Time resolved structural analysis of the full turnover of an enzyme - 12312 ms
6QI2	;	1.73	;	Time resolved structural analysis of the full turnover of an enzyme - 13536 ms
6QHP	;	1.8	;	Time resolved structural analysis of the full turnover of an enzyme - 2256 ms covalent intermediate 1
6QI3	;	1.739	;	Time resolved structural analysis of the full turnover of an enzyme - 27072 ms
6QHT	;	1.73	;	Time resolved structural analysis of the full turnover of an enzyme - 376 ms
6QHW	;	1.718	;	Time resolved structural analysis of the full turnover of an enzyme - 4512 ms
6QHS	;	1.733	;	Time resolved structural analysis of the full turnover of an enzyme - 564 ms
6QHX	;	1.85	;	Time resolved structural analysis of the full turnover of an enzyme - 6156 ms
6QHZ	;	1.799	;	Time resolved structural analysis of the full turnover of an enzyme - 6788 ms
6QI0	;	1.733	;	Time resolved structural analysis of the full turnover of an enzyme - 9024 ms
3P4Z	;	1.6	;	Time-dependent and Protein-directed In Situ Growth of Gold Nanoparticles in a Single Crystal of Lysozyme
3P64	;	1.3	;	Time-dependent and Protein-directed In Situ Growth of Gold Nanoparticles in a Single Crystal of Lysozyme
3P65	;	2.1	;	Time-dependent and Protein-directed In Situ Growth of Gold Nanoparticles in a Single Crystal of Lysozyme
3P66	;	1.36	;	Time-dependent and Protein-directed In Situ Growth of Gold Nanoparticles in a Single Crystal of Lysozyme
3P68	;	1.6	;	Time-dependent and Protein-directed In Situ Growth of Gold Nanoparticles in a Single Crystal of Lysozyme
2GVE	;	2.2	;	Time-of-Flight Neutron Diffraction Structure of D-Xylose Isomerase
8GBT	;	2.8	;	Time-resolve SFX structure of a photoproduct of carbon monoxide complex of bovine cytochrome c oxidase
1GTK	;	1.66	;	Time-resolved and static-ensemble structural chemistry of hydroxymethylbilane synthase
8G34	;	3.2	;	Time-resolved cryo-EM study of the 70S recycling by the HflX:1st intermediate
8G31	;	3.2	;	Time-resolved cryo-EM study of the 70S recycling by the HflX:2nd Intermediate
8G38	;	3.2	;	Time-resolved cryo-EM study of the 70S recycling by the HflX:3rd Intermediate
8G2U	;	3.0	;	Time-resolved cryo-EM study of the 70S recycling by the HflX:control-apo-70S at 900ms
3WVG	;	2.25	;	Time-Resolved Crystal Structure of HindIII with 0sec soaking
3WVK	;	2.0	;	Time-Resolved Crystal Structure of HindIII with 230sec soaking
3WVH	;	2.54	;	Time-Resolved Crystal Structure of HindIII with 25sec soaking
3WVI	;	2.55	;	Time-Resolved Crystal Structure of HindIII with 40 sec soaking
3WVP	;	2.3	;	Time-Resolved Crystal Structure of HindIII with 60sec soaking
7E6Y	;	2.5	;	Time-resolved serial femtosecond crystallography reveals early structural changes in channelrhodopsin: 1 microsecond structure
7E71	;	2.5	;	Time-resolved serial femtosecond crystallography reveals early structural changes in channelrhodopsin: 1 ms structure
7E70	;	2.5	;	Time-resolved serial femtosecond crystallography reveals early structural changes in channelrhodopsin: 250 microsecond structure
7E6X	;	2.5	;	Time-resolved serial femtosecond crystallography reveals early structural changes in channelrhodopsin: 4 ms structure
7E6Z	;	2.5	;	Time-resolved serial femtosecond crystallography reveals early structural changes in channelrhodopsin: 50 microsecond structure
7C86	;	2.3	;	Time-resolved serial femtosecond crystallography reveals early structural changes in channelrhodopsin: Dark state structure
7VGU	;	2.1	;	Time-resolved serial femtosecond crystallography structure of light-driven chloride ion-pumping rhodopsin, NM-R3 : structure obtained 1 msec after photoexcitation with bromide ion
7VGT	;	2.1	;	Time-resolved serial femtosecond crystallography structure of light-driven chloride ion-pumping rhodopsin, NM-R3: resting state structure with bromide ion
5Y5K	;	2.1	;	Time-resolved SFX structure of cytochrome P450nor : 20 ms after photo-irradiation of caged NO in the absence of NADH (NO-bound state), light data
5Y5I	;	2.1	;	Time-resolved SFX structure of cytochrome P450nor: 20 ms after photo-irradiation of caged NO in the presence of NADH (NO-bound state), light data
5Y5L	;	2.1	;	Time-resolved SFX structure of cytochrome P450nor: dark-2 data in the absence of NADH (resting state)
5Y5J	;	2.0	;	Time-resolved SFX structure of cytochrome P450nor: dark-2 data in the presence of NADH (resting state)
8OY9	;	2.24	;	Time-resolved SFX structure of the class II photolyase complexed with a thymine dimer (1 microsecond pump-probe delay)
8OY5	;	2.27	;	Time-resolved SFX structure of the class II photolyase complexed with a thymine dimer (1 nanosecond pump-probe delay)
8OYA	;	2.18	;	Time-resolved SFX structure of the class II photolyase complexed with a thymine dimer (10 microsecond pump probe delay)
8OY7	;	2.36	;	Time-resolved SFX structure of the class II photolyase complexed with a thymine dimer (10 nanosecond pump-probe delay)
8OYC	;	2.5	;	Time-resolved SFX structure of the class II photolyase complexed with a thymine dimer (100 microsecond timpeoint)
8OY6	;	2.35	;	Time-resolved SFX structure of the class II photolyase complexed with a thymine dimer (3 nanosecond pump-probe delay)
8OY3	;	2.16	;	Time-resolved SFX structure of the class II photolyase complexed with a thymine dimer (3 picosecond pump-probe delay)
8OYB	;	2.25	;	Time-resolved SFX structure of the class II photolyase complexed with a thymine dimer (30 microsecond pump-probe delay)
8OY8	;	2.39	;	Time-resolved SFX structure of the class II photolyase complexed with a thymine dimer (30 nanosecond timepoint)
8OY4	;	2.35	;	Time-resolved SFX structure of the class II photolyase complexed with a thymine dimer (300 ps pump-probe delay)
6NKN	;	2.5	;	Time-resolved SFX structure of the PR intermediate of cytochrome c oxidase at room temperature
8TDP	;	1.85	;	Time-resolved SFX-XFEL crystal structure of CYP121 bound with cYY reacted with peracetic acid for 200 milliseconds
6PJ4	;	2.3	;	Time-resolved structural snapshot of proteolysis by GlpG inside the membrane
6PJ5	;	2.4	;	Time-resolved structural snapshot of proteolysis by GlpG inside the membrane
6PJ7	;	2.3	;	Time-resolved structural snapshot of proteolysis by GlpG inside the membrane
6PJ8	;	2.4	;	Time-resolved structural snapshot of proteolysis by GlpG inside the membrane
6PJ9	;	2.5	;	Time-resolved structural snapshot of proteolysis by GlpG inside the membrane
6PJA	;	2.6	;	Time-resolved structural snapshot of proteolysis by GlpG inside the membrane
6PJP	;	2.45	;	Time-resolved structural snapshot of proteolysis by GlpG inside the membrane
6PJQ	;	2.5	;	Time-resolved structural snapshot of proteolysis by GlpG inside the membrane
6PJR	;	2.4	;	Time-resolved structural snapshot of proteolysis by GlpG inside the membrane
6PJU	;	2.5	;	Time-resolved structural snapshot of proteolysis by GlpG inside the membrane
8B21	;	2.59	;	Time-resolved structure of K+-dependent Na+-PPase from Thermotoga maritima 0-60-seconds post reaction initiation with Na+
8B22	;	3.98	;	Time-resolved structure of K+-dependent Na+-PPase from Thermotoga maritima 300-seconds post reaction initiation with Na+
8B24	;	4.53	;	Time-resolved structure of K+-dependent Na+-PPase from Thermotoga maritima 3600-seconds post reaction initiation with Na+
8B23	;	3.84	;	Time-resolved structure of K+-dependent Na+-PPase from Thermotoga maritima 600-seconds post reaction initiation with Na+
7UHR	;	2.2	;	Time-Resolved Structure of Metallo Beta-Lactamase L1 Before Reaction (Dark-Set)
7UHM	;	2.7	;	Time-Resolved Structure of Metallo Beta-Lactamase L1 in a Complex with Cleaved Moxalactam (150 ms Snapshot)
7UHP	;	2.6	;	Time-Resolved Structure of Metallo Beta-Lactamase L1 in a Complex with Cleaved Moxalactam (2000 ms Snapshot)
7UHN	;	2.2	;	Time-Resolved Structure of Metallo Beta-Lactamase L1 in a Complex with Cleaved Moxalactam (300 ms Snapshot)
7UHQ	;	2.2	;	Time-Resolved Structure of Metallo Beta-Lactamase L1 in a Complex with Cleaved Moxalactam (4000 ms Snapshot)
7UHO	;	2.2	;	Time-Resolved Structure of Metallo Beta-Lactamase L1 in a Complex with Cleaved Moxalactam (500 ms Snapshot)
7UHL	;	2.2	;	Time-Resolved Structure of Metallo Beta-Lactamase L1 in a Complex with Non-Hydrolyzed Moxalactam (100 ms Snapshot)
7UHH	;	2.2	;	Time-Resolved Structure of Metallo Beta-Lactamase L1 in a Complex with Non-Hydrolyzed Moxalactam (20 ms snapshot)
7UHI	;	2.2	;	Time-Resolved Structure of Metallo Beta-Lactamase L1 in a Complex with Non-Hydrolyzed Moxalactam (40 ms Snapshot)
7UHJ	;	2.2	;	Time-Resolved Structure of Metallo Beta-Lactamase L1 in a Complex with Non-Hydrolyzed Moxalactam (60 ms Snapshot)
7UHK	;	2.2	;	Time-Resolved Structure of Metallo Beta-Lactamase L1 in a Complex with Non-Hydrolyzed Moxalactam (80 ms Snapshot)
3AMO	;	2.1	;	Time-resolved X-ray Crystal Structure Analysis of Enzymatic Reaction of Copper Amine Oxidase from Arthrobacter globiformis
6TAZ	;		;	Timeless couples G quadruplex detection with processing by DDX11 during DNA replication
8PWR	;		;	TINA-conjugated antiparallel DNA triplex
3SPK	;	1.24	;	Tipranavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant
3UB2	;	2.4	;	TIR domain of Mal/TIRAP
7X5K	;	3.8	;	Tir-dsDNA complex, the initial binding state
7X5L	;	3.51	;	Tir-dsDNA complex, the initial binding state
7X5M	;	3.42	;	Tir-dsDNA complex, the initial binding state
7QQK	;	3.8	;	TIR-SAVED effector bound to cA3
2P1M	;	1.8	;	TIR1-ASK1 complex structure
5T7Q	;		;	TIRAP phosphoinositide-binding motif
1A21	;	2.35	;	TISSUE FACTOR (TF) FROM RABBIT
8BXR	;	2.7	;	Titin FnIII-domain I109-I111 (I/A4-A/A6) from the MIR region
8BW6	;	1.95	;	Titin FnIII-domain I110 (I/A6) from the MIR region
8BVO	;	2.55	;	Titin I110-I111 FnIII tandem from the MIR region (I/A5-I/A6)
3LCY	;	2.5	;	Titin Ig tandem domains A164-A165
6YGN	;	2.4	;	Titin kinase and its flanking domains
1BPV	;		;	TITIN MODULE A71 FROM HUMAN CARDIAC MUSCLE, NMR, 50 STRUCTURES
1NCT	;		;	TITIN MODULE M5, N-TERMINALLY EXTENDED, NMR
1NCU	;		;	Titin Module M5, N-terminally Extended, NMR
7NIP	;		;	titin N2A unique sequence (UN2A) core
1TIU	;		;	TITIN, IG REPEAT 27, NMR, 24 STRUCTURES
1TIT	;		;	TITIN, IG REPEAT 27, NMR, MINIMIZED AVERAGE STRUCTURE
7AHS	;	2.05	;	titin-N2A Ig81-Ig83
1TYX	;	1.8	;	TITLE OF TAILSPIKE-PROTEIN
8TA5	;	2.76	;	Title: Cryo-EM structure of the human CLC-2 chloride channel transmembrane domain with asymmetric C-terminal
1NPI	;	1.16	;	Tityus Serrulatus Neurotoxin (Ts1) at atomic resolution
5XER	;		;	TK9 NMR structure in DPC micelle
5XES	;		;	TK9 NMR structure in SDS micelle
7W6G	;	2.1	;	TKS-L190G mutant from Cannabis sativa in complex with lauroyl-CoA
4P6H	;	4.08	;	Tl+-bound inward-facing state (bound conformation) of the glutamate transporter homologue GltPh
4K4P	;	2.31	;	TL-3 inhibited Trp6Ala HIV Protease
4K4R	;	1.8	;	TL-3 inhibited Trp6Ala HIV Protease with 1-bromo-2-napthoic acid bound in exosite
4K4Q	;	1.8	;	TL-3 inhibited Trp6Ala HIV Protease with 3-bromo-2,6-dimethoxybenzoic acid bound in flap site
5GLV	;	1.8	;	Tl-gal
5GLZ	;	2.0	;	Tl-gal with Glucose
5GLW	;	2.0	;	Tl-gal with LacNAc
5GM0	;	1.7	;	Tl-gal with lactose
5GLT	;	2.0	;	Tl-gal with LNT
5GLU	;	2.1	;	Tl-gal with SiaLac
5O0Y	;	2.86	;	TLK2 kinase domain from human
7YTP	;	2.77	;	TLR7 in complex with an inhibitor
1U6K	;	1.55	;	TLS refinement of the structure of Se-methionine labelled Coenzyme f420-dependent methylenetetrahydromethanopterin dehydrogenase (MTD) from Methanopyrus kandleri
8CHE	;	1.49	;	TLT-1 binding Fab of the bispecific antibody HMB-001 in complex with the TLT-1 stalk peptide
3N0C	;	2.3	;	TM0449 mutant crystal grown by hanging drop method
3N0B	;	2.3	;	TM0449 mutant crystals grown in loops/micromounts
3IH4	;	2.3	;	TM1030 crystallized at 277K
3IH3	;	2.35	;	TM1030 crystallized at 310K
3IH2	;	2.3	;	TM1030 crystallized at 323K
4Q4H	;	2.527	;	TM287/288 in its apo state
1MV4	;		;	TM9A251-284: A Peptide Model of the C-Terminus of a Rat Striated Alpha Tropomyosin
3T2A	;	2.1	;	TMAO-grown cubic insulin (porcine)
3T25	;	1.7	;	TMAO-grown orthorhombic trypsin (bovine)
3T29	;	1.75	;	TMAO-grown trigonal trypsin (bovine)
3T28	;	2.8	;	TMAO-grown trypsin (bovine)-previously unreported tetragonal crystal form
5MMD	;	1.75	;	TMB-1. Structural insights into TMB-1 and the role of residue 119 and 228 in substrate and inhibitor binding
2GPL	;	2.81	;	TMC-95 based biphenyl-ether macrocycles: specific proteasome inhibitors
7XJA	;	3.5	;	TMD masked refine map of human ClC-2
8F9K	;	3.4	;	TMEM106B doublet filaments extracted from MSTD neurodegenerative human brain
7QVC	;	2.64	;	TMEM106B filaments with Fold I from Alzheimer's disease (case 1)
7QVF	;	3.64	;	TMEM106B filaments with Fold I-d from Multiple system atrophy (case 18)
7QWG	;	3.38	;	TMEM106B filaments with Fold IIa from Multiple system atrophy (case 19)
7QWL	;	3.47	;	TMEM106B filaments with Fold IIb from Multiple system atrophy (case 19)
7QWM	;	2.76	;	TMEM106B filaments with Fold III from Multiple system atrophy (case 17)
8OTE	;	3.6	;	TMEM106B Fold I-d filament from Guam ALS/PDC
8OTD	;	2.6	;	TMEM106B Fold1-s filament from Guam ALS/PDC
7TMC	;	3.25	;	TMEM106B singlet filament extracted from MSTD neurodegenerative human brain
7U16	;	2.7	;	TMEM106B(120-254) protofilament from frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP) type A (all cases combined).
7U11	;	3.2	;	TMEM106B(120-254) protofilament from frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP) type A (case 1)
7U10	;	3.0	;	TMEM106B(120-254) protofilament from progressive supranuclear palsy (PSP) case 2
7U12	;	3.5	;	TMEM106B(120-254) singlet amyloid fibril from frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP) type A (case 2)
7U13	;	2.9	;	TMEM106B(120-254) singlet amyloid fibril from frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP) type A (case 4)
7U15	;	3.0	;	TMEM106B(120-254) singlet amyloid fibril from frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP) type B case 2 (case 7).
7U14	;	4.5	;	TMEM106B(120-254) singlet amyloid fibril from frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP) type C (case 8)
7U18	;	2.7	;	TMEM106B(120-254) T185S protofilament from frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP) type A (all cases combined).
7U17	;	3.0	;	TMEM106B(120-254) T185S singlet amyloid fibril from frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP) type B case 2 (case 7).
4WIT	;	3.4	;	TMEM16 lipid scramblase in crystal form 2
8SUN	;	3.12	;	TMEM16F 1PBC
8SUR	;	3.1	;	TMEM16F bound with Niclosamide
8TAG	;	3.2	;	TMEM16F, with Calcium and PIP2, no inhibitor
8TAL	;	3.2	;	TMEM16F, with Calcium and PIP2, no inhibitor, Cl1
8TAI	;	3.1	;	TMEM16F, with Calcium and PIP2, no inhibitor, Cl2
8C6I	;	3.5	;	TMEM2 ectodomain
7P5H	;	2.3	;	TmHydABC- D2 map
7P91	;	2.8	;	TmHydABC- T. maritima bifurcating hydrogenase with bridge domain closed
7P92	;	2.7	;	TmHydABC- T. maritima bifurcating hydrogenase with bridge domain up
7P8N	;	2.8	;	TmHydABC- T. maritima hydrogenase with bridge closed
4XWA	;	1.89	;	TMK from S.aureus in complex with the Piperidinyl Thymine class inhibitor with a C5 ethyl-amine
4QGG	;	1.62	;	TMK in complex with compound 46, 2-(3-CHLOROPHENOXY)-3-FLUORO-4-{(1R)-3-METHYL-1-[(3S)-3-(5-METHYL-2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)PIPERIDIN-1-YL]BUTYL}BENZOIC ACID
5GSN	;	2.203	;	Tmm in complex with methimazole
6UI5	;	2.4	;	Tmn9 in complex with cofactor FAD
4XZ6	;	2.2	;	TmoX in complex with TMAO
8V1F	;	2.19	;	TMPRSS2 complexed with the noncovalent inhibitor 6-amidino-2-napthol
3IYQ	;	13.0	;	tmRNA-SmpB: a journey to the center of the bacterial ribosome
3IYR	;	13.0	;	tmRNA-SmpB: a journey to the center of the bacterial ribosome
1EI7	;	2.45	;	TMV COAT PROTEIN REFINED FROM THE 4-LAYER AGGREGATE
1TMZ	;		;	TMZIP: A CHIMERIC PEPTIDE MODEL OF THE N-TERMINUS OF ALPHA TROPOMYOSIN, NMR, 15 STRUCTURES
5CY1	;	3.4	;	Tn3 resolvase - site III complex crystal form I
5CY2	;	4.0	;	Tn3 resolvase - site III complex crystal form II
4DM0	;	2.5	;	TN5 transposase: 20MER OUTSIDE END 2 MN complex
7LNG	;	2.2	;	TNA modification at 3' end of RNA primer complex with guanosine dinucleotide ligand G(5')ppp(5')G
5VU6	;	3.0	;	TNA polymerase binary complex with primer/template duplex
5VU5	;	2.8	;	TNA polymerase, apo
5VU8	;	3.2	;	TNA polymerase, closed ternary complex
7RSU	;	2.1	;	TNA polymerase, n+2 product
5VU7	;	2.72	;	TNA polymerase, open ternary complex
5VU9	;	2.05	;	TNA polymerase, translocated product
6I0Y	;	3.2	;	TnaC-stalled ribosome complex with the titin I27 domain folding close to the ribosomal exit tunnel
2F14	;	1.71	;	Tne Crystal Structure of the Human Carbonic Anhydrase II in Complex with a Fluorescent Inhibitor
2E7A	;	1.8	;	TNF Receptor Subtype One-selective TNF Mutant with Antagonistic Activity
2ZPX	;	2.83	;	TNF Receptor Subtype One-selective TNF Mutant with Antagonistic Activity; R1antTNF-T8
5WUX	;	2.9	;	TNFalpha-certolizumab Fab
2ZJC	;	2.5	;	TNFR1 selectve TNF mutant; R1-6
5H07	;	2.586	;	TNIP2-Ub complex, C2 form
8BD4	;	3.44	;	TniQ-capped Tns-ATP-dsDNA complex
7POX	;	2.5	;	TNKS2 in complex with OM-1700, treated with H2O2
7MGK	;	3.1	;	TNNI3K complexed with 1-(3,5-dichloro-4-((6-(methylamino)pyrimidin-4-yl)oxy)phenyl)-3-(3-(trifluoromethyl)phenyl)urea
6B5J	;	2.97	;	TNNI3K complexed with a 4,6-diaminopyrimidine
4YFI	;	2.7	;	TNNI3K complexed with inhibitor 1
4YFF	;	3.07	;	TNNI3K complexed with inhibitor 2
7MGJ	;	2.95	;	TNNI3K complexed with N-methyl-4-(4-(3-(3-(trifluoromethyl) phenyl) ureido) phenoxy)picolinamide
4R22	;	2.6	;	TnrA-DNA complex
1F1Z	;	2.4	;	TNSA, a catalytic component of the TN7 transposition system
7SVV	;	3.54	;	TnsBctd-TnsC complex
7SVU	;	3.5	;	TnsBctd-TnsC-TniQ complex
5IKH	;	2.1	;	Tobacco 5-epi-aristolochene synthase M4 mutant with (-)-premnaspirodiene
5ILJ	;	2.05	;	Tobacco 5-epi-aristolochene synthase with BIS-TRIS buffer molecule
5ILY	;	2.45	;	Tobacco 5-epi-aristolochene synthase with BIS-TRIS buffer molecule and diphosphate (PPi)
5ILZ	;	1.92	;	Tobacco 5-epi-aristolochene synthase with BIS-TRIS propane (BTP) buffer molecule
5ILH	;	2.1	;	Tobacco 5-epi-aristolochene synthase with CAPSO buffer molecule and Ca2+ ions
5ILI	;	1.9	;	Tobacco 5-epi-aristolochene synthase with CAPSO buffer molecule and Mg2+ ions
5IK0	;	2.2	;	Tobacco 5-epi-aristolochene synthase with FPP
5IK6	;	2.3	;	Tobacco 5-epi-aristolochene synthase with germacrene A and PPi
5ILD	;	2.12	;	Tobacco 5-epi-aristolochene synthase with MES buffer molecule and Mg2+ ions
5IL8	;	2.3	;	Tobacco 5-epi-aristolochene synthase with MOPSO buffer molecule and Ca2+ ions
5IL3	;	1.85	;	Tobacco 5-epi-aristolochene synthase with MOPSO buffer molecule and Mg2+ ions
5ILK	;	2.35	;	Tobacco 5-epi-aristolochene synthase with partial density from MOPSO or BIS-TRIS buffer molecule in the active site
5IKA	;	2.45	;	Tobacco 5-epi-aristolochene synthase with PPi
5IM1	;	1.88	;	Tobacco 5-epi-aristolochene synthase without buffer molecule in the active site
5IK9	;	2.23	;	Tobacco 5-epi-aristolochene with farnesyl monophosphate
8QMG	;	2.3	;	Tobacco lectin Nictaba in apo state including I and Eu SAD datasets.
8AD2	;	2.0	;	Tobacco lectin Nictaba in complex with triacetylchitotriose
6I5A	;	2.3	;	Tobacco Mosaic Virus
6R7M	;	1.92	;	Tobacco Mosaic Virus (TMV)
1C8N	;	2.25	;	TOBACCO NECROSIS VIRUS
6Z38	;	2.9	;	TodX deltaS2S3 mutant monoaromatic hydrocarbon channel
6Z37	;	3.05	;	TodX monoaromatic hydrocarbon channel deltaS2 mutant
2OF3	;	1.9	;	TOG domain structure from C.elegans Zyg9
5VJC	;	2.0	;	TOG-tubulin binding specificity promotes microtubule dynamics and mitotic spindle formation
4U3J	;	2.81	;	TOG2:alpha/beta-tubulin complex
1IYQ	;	2.1	;	Toho-1 beta-Lactamase In Complex With Benzylpenicillin
1IYO	;	1.8	;	Toho-1 beta-Lactamase In Complex With Cefotaxime
1IYP	;	2.0	;	Toho-1 beta-Lactamase In Complex With Cephalothin
6U58	;	1.89	;	Toho1 Beta Lactamase Glu166Gln Mutant
6U58	;	1.9	;	Toho1 Beta Lactamase Glu166Gln Mutant
5KMW	;	1.1	;	TOHO1 Beta lactamase mutant E166A/R274N/R276N -benzyl penicillin complex
1L64	;	1.9	;	TOLERANCE OF T4 LYSOZYME TO MULTIPLE XAA (RIGHT ARROW) ALA SUBSTITUTIONS: A POLYALANINE ALPHA-HELIX CONTAINING TEN CONSECUTIVE ALANINES
1L65	;	1.7	;	TOLERANCE OF T4 LYSOZYME TO MULTIPLE XAA (RIGHT ARROW) ALA SUBSTITUTIONS: A POLYALANINE ALPHA-HELIX CONTAINING TEN CONSECUTIVE ALANINES
1L66	;	1.7	;	TOLERANCE OF T4 LYSOZYME TO MULTIPLE XAA (RIGHT ARROW) ALA SUBSTITUTIONS: A POLYALANINE ALPHA-HELIX CONTAINING TEN CONSECUTIVE ALANINES
1L67	;	1.9	;	TOLERANCE OF T4 LYSOZYME TO MULTIPLE XAA (RIGHT ARROW) ALA SUBSTITUTIONS: A POLYALANINE ALPHA-HELIX CONTAINING TEN CONSECUTIVE ALANINES
1L68	;	1.7	;	TOLERANCE OF T4 LYSOZYME TO MULTIPLE XAA (RIGHT ARROW) ALA SUBSTITUTIONS: A POLYALANINE ALPHA-HELIX CONTAINING TEN CONSECUTIVE ALANINES
1L76	;	1.9	;	TOLERANCE OF T4 LYSOZYME TO PROLINE SUBSTITUTIONS WITHIN THE LONG INTERDOMAIN ALPHA-HELIX ILLUSTRATES THE ADAPTABILITY OF PROTEINS TO POTENTIALLY DESTABILIZING LESIONS
7WV3	;	2.26	;	Toll-like receptor3 linear cluster
3RMK	;	1.95	;	Toluene 4 monooxygenase H with 4-bromophenol
3Q3M	;	1.748	;	Toluene 4 monooxygenase HD Complex with Inhibitor 4-Bromobenzoate
3Q2A	;	1.99	;	Toluene 4 monooxygenase HD complex with inhibitor p-aminobenzoate
3Q14	;	1.75	;	Toluene 4 monooxygenase HD Complex with p-cresol
3Q3N	;	1.84	;	Toluene 4 monooxygenase HD complex with p-nitrophenol
3Q3O	;	1.95	;	Toluene 4 monooxygenase HD complex with phenol
3RI7	;	2.1	;	Toluene 4 monooxygenase HD Mutant G103L
5TDU	;	1.742	;	Toluene 4-monooxygenase (T4moHD) bound to product after turnover in crystal
3GE8	;	2.19	;	Toluene 4-monooxygenase HD T201A diferric, resting state complex
5TDS	;	1.719	;	Toluene bound in the resting active site of toluene 4-monooxygenase (T4moH)
4EMI	;	1.806	;	Toluene dioxygenase reductase in reduced state in complex with NAD+
1G10	;		;	TOLUENE-4-MONOOXYGENASE CATALYTIC EFFECTOR PROTEIN NMR STRUCTURE
1G11	;		;	TOLUENE-4-MONOOXYGENASE CATALYTIC EFFECTOR PROTEIN NMR STRUCTURE
7VC4	;	3.74	;	Tom complex with Tom22 and Tom20 subunits
7VBY	;	2.54	;	Tom core complex with Tom20 and Tom22 subunits.
2N2N	;		;	Tom1 negatively modulates binding of Tollip to phosphatidylinositol 3-phosphate via a coupled folding and binding mechanism
2N31	;		;	Tom1 negatively modulates binding of Tollip to phosphatidylinositol 3-phosphate via a coupled folding and binding mechanism
7VC9	;	13.0	;	Tom20 subunits
5D8N	;	2.15	;	Tomato leucine aminopeptidase mutant - K354E
5IP1	;	2.703	;	Tomato spotted wilt tospovirus nucleocapsid protein
5IP3	;	3.0	;	Tomato spotted wilt tospovirus nucleocapsid protein-ssDNA complex
5IP2	;	3.3	;	Tomato spotted wilt tospovirus nucleocapsid protein-ssRNA complex
4CYL	;	22.2	;	Tomographic subvolume average of EFF-1 fusogen on extracellular vesicles
3L18	;	1.78	;	Ton1285, an Intracellular Protease from Thermococcus onnurineus NA1
1IMH	;	2.86	;	TonEBP/DNA COMPLEX
8PHQ	;	2.69	;	Top cap of the Borrelia bacteriophage BB1 procapsid, fivefold-symmetrized outer shell
7Z46	;	3.4	;	Top part (C5) of bacteriophage SU10 capsid
8IXL	;	3.5	;	top segment of the bacteriophage M13 mini variant
8JWW	;	3.5	;	top segment of the bacteriophage M13 mini variant
8F4X	;	3.01	;	Top-down design of protein architectures with reinforcement learning
8F53	;	2.93	;	Top-down design of protein architectures with reinforcement learning
8F54	;	2.5	;	Top-down design of protein architectures with reinforcement learning
7FAO	;	1.43	;	Top7 surface mutant K42A Q43A K46A K57S K58S, and I68R
1A36	;	2.8	;	TOPOISOMERASE I/DNA COMPLEX
1BJT	;	2.5	;	TOPOISOMERASE II RESIDUES 409-1201
3L4J	;	2.48	;	Topoisomerase II-DNA cleavage complex, apo
3L4K	;	2.98	;	Topoisomerase II-DNA cleavage complex, metal-bound
4GFH	;	4.408	;	Topoisomerase II-DNA-AMPPNP complex
2RGR	;	3.0	;	Topoisomerase IIA bound to G-segment DNA
4KQV	;	2.38	;	Topoisomerase iv atp binding domain of francisella tularensis in complex with a small molecule inhibitor
1BGW	;	2.7	;	TOPOISOMERASE RESIDUES 410-1202,
2HKJ	;	2.0	;	Topoisomerase VI-B bound to radicicol
1Z5B	;	2.0	;	Topoisomerase VI-B, ADP AlF4- bound dimer form
1Z5C	;	2.2	;	Topoisomerase VI-B, ADP Pi bound dimer form
1Z5A	;	2.2	;	Topoisomerase VI-B, ADP-bound dimer form
1Z59	;	2.1	;	Topoisomerase VI-B, ADP-bound monomer form
6ZIH	;	28.7	;	Topological model of p2 virion baseplate in activated conformation
6ZJJ	;	22.0	;	Topological model of p2 virion baseplate in resting conformation
6ZIG	;	42.2	;	Topological model of the p2 virion baseplate in activated conformation (closed Tal trimer)
6TG6	;	1.3	;	Toprim domain of RNase M5
6Z2B	;	2.138	;	Toprim domain of RNase M5 bound with two Mg2+ ions
1AVQ	;	2.4	;	TOROIDAL STRUCTURE OF LAMBDA EXONUCLEASE DETERMINED AT 2.4 ANGSTROMS
2J4F	;	2.8	;	Torpedo acetylcholinesterase - Hg heavy-atom derivative
2J3Q	;	2.8	;	Torpedo acetylcholinesterase complexed with fluorophore thioflavin T
6G4M	;	2.63	;	Torpedo californica acetylcholinesterase bound to uncharged hybrid reactivator 1
6G4N	;	2.9	;	Torpedo californica acetylcholinesterase bound to uncharged hybrid reactivator 2
2VQ6	;	2.71	;	Torpedo californica acetylcholinesterase complexed with 2-PAM
2CMF	;	2.5	;	Torpedo californica acetylcholinesterase complexed with alkylene- linked bis-tacrine dimer (5 carbon linker)
2CKM	;	2.15	;	Torpedo californica acetylcholinesterase complexed with alkylene- linked bis-tacrine dimer (7 carbon linker)
1E3Q	;	2.85	;	TORPEDO CALIFORNICA ACETYLCHOLINESTERASE COMPLEXED WITH BW284C51
7B8E	;	2.23	;	Torpedo californica acetylcholinesterase complexed with Ca+2
7B38	;	1.85	;	Torpedo californica acetylcholinesterase complexed with Mg+2
7B2W	;	2.65	;	Torpedo californica acetylcholinesterase complexed with UO2
2C58	;	2.3	;	Torpedo californica acetylcholinesterase in complex with 20mM acetylthiocholine
2C5G	;	1.95	;	Torpedo californica acetylcholinesterase in complex with 20mM thiocholine
2C4H	;	2.15	;	Torpedo californica acetylcholinesterase in complex with 500mM acetylthiocholine
4TVK	;	2.3	;	TORPEDO CALIFORNICA ACETYLCHOLINESTERASE IN COMPLEX WITH A CHLOROTACRINE-JUGLONE HYBRID INHIBITOR
5NUU	;	2.5	;	Torpedo californica acetylcholinesterase in complex with a chlorotacrine-tryptophan hybrid inhibitor
2VJA	;	2.3	;	Torpedo Californica Acetylcholinesterase In Complex With A Non Hydrolysable Substrate Analogue, 4-Oxo-N,N,N- Trimethylpentanaminium - Orthorhombic space group - Dataset A at 100K
2VJC	;	2.3	;	Torpedo Californica Acetylcholinesterase In Complex With A Non Hydrolysable Substrate Analogue, 4-Oxo-N,N,N- Trimethylpentanaminium - Orthorhombic space group - Dataset A at 150K
2VJD	;	2.3	;	Torpedo Californica Acetylcholinesterase In Complex With A Non Hydrolysable Substrate Analogue, 4-Oxo-N,N,N- Trimethylpentanaminium - Orthorhombic space group - Dataset C at 150K
2VJB	;	2.39	;	Torpedo Californica Acetylcholinesterase In Complex With A Non Hydrolysable Substrate Analogue, 4-Oxo-N,N,N- Trimethylpentanaminium - Orthorhombic space group - Dataset D at 100K
2C5F	;	2.6	;	Torpedo californica acetylcholinesterase in complex with a non hydrolysable substrate analogue, 4-oxo-N,N,N-trimethylpentanaminium
5NAU	;	2.25	;	Torpedo californica acetylcholinesterase in complex with a non-chiral donepezil-like compound 20
5NAP	;	2.17	;	Torpedo californica acetylcholinesterase in complex with a non-chiral donepezil-like inhibitor 17
4W63	;	2.8	;	TORPEDO CALIFORNICA ACETYLCHOLINESTERASE IN COMPLEX WITH A TACRINE-BENZOFURAN HYBRID INHIBITOR
4X3C	;	2.6	;	TORPEDO CALIFORNICA ACETYLCHOLINESTERASE IN COMPLEX WITH A TACRINE-NICOTINAMIDE HYBRID INHIBITOR
2XI4	;	2.3	;	Torpedo californica Acetylcholinesterase in Complex with Aflatoxin B1 (Orthorhombic Space Group)
1SOM	;	2.2	;	TORPEDO CALIFORNICA ACETYLCHOLINESTERASE INHIBITED BY NERVE AGENT GD (SOMAN).
3ZV7	;	2.26	;	Torpedo californica Acetylcholinesterase Inhibition by Bisnorcymserine
6EZG	;	2.2	;	Torpedo californica AChE in complex with indolic multi-target directed ligand
6EZH	;	2.6	;	Torpedo californica AChE in complex with indolic multi-target directed ligand
1TOS	;		;	TORPEDO CALIFORNICA ACHR RECEPTOR [ALA76] ANALOGUE COMPLEXED WITH THE ANTI-ACETYLCHOLINE MAB6 MONOCLONAL ANTIBODY
7QL6	;	3.23	;	Torpedo muscle-type nicotinic acetylcholine receptor - carbamylcholine-bound conformation
7QL5	;	2.5	;	Torpedo muscle-type nicotinic acetylcholine receptor - nicotine-bound conformation
7QKO	;	2.9	;	Torpedo muscle-type nicotinic acetylcholine receptor - Resting conformation
5J1S	;	1.399	;	TorsinA-LULL1 complex, H. sapiens, bound to VHH-BS2
5J1T	;	1.402	;	TorsinAdeltaE-LULL1 complex, H. sapiens, bound to VHH-BS2
5FVA	;	3.7	;	Toscana Virus Nucleocapsid Protein
1B3A	;	1.6	;	TOTAL CHEMICAL SYNTHESIS AND HIGH-RESOLUTION CRYSTAL STRUCTURE OF THE POTENT ANTI-HIV PROTEIN AOP-RANTES
5CY0	;	1.93	;	Total Chemical Synthesis, Covalent Structure Verification, and X-ray Structure of Bioactive Ts3 Toxin by Racemic Protein Crystallography
5HKG	;	1.5	;	Total chemical synthesis, refolding and crystallographic structure of a fully active immunophilin: calstabin 2 (FKBP12.6).
1L36	;	1.7	;	TOWARD A SIMPLIFICATION OF THE PROTEIN FOLDING PROBLEM: A STABILIZING POLYALANINE ALPHA-HELIX ENGINEERED IN T4 LYSOZYME
1SDE	;	1.15	;	Toward Better Antibiotics: Crystal Structure Of D-Ala-D-Ala Peptidase inhibited by a novel bicyclic phosphate inhibitor
1SCW	;	1.13	;	TOWARD BETTER ANTIBIOTICS: CRYSTAL STRUCTURE OF R61 DD-PEPTIDASE INHIBITED BY A NOVEL MONOCYCLIC PHOSPHATE INHIBITOR
1G7N	;	1.5	;	Toward changing specificity: adipocyte lipid binding protein mutant, apo form
1G74	;	1.7	;	Toward changing specificity: adipocyte lipid binding protein mutant, oleic acid bound form
1GAR	;	1.96	;	TOWARDS STRUCTURE-BASED DRUG DESIGN: CRYSTAL STRUCTURE OF A MULTISUBSTRATE ADDUCT COMPLEX OF GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE AT 1.96 ANGSTROMS RESOLUTION
1OX4	;	2.5	;	TOWARDS UNDERSTANDING THE MECHANISM OF THE COMPLEX CYCLIZATION REACTION CATALYZED BY IMIDAZOLE GLYCEROPHOSPHATE SYNTHASE
1OX5	;	2.5	;	TOWARDS UNDERSTANDING THE MECHANISM OF THE COMPLEX CYCLIZATION REACTION CATALYZED BY IMIDAZOLE GLYCEROPHOSPHATE SYNTHASE
1OX6	;	2.4	;	TOWARDS UNDERSTANDING THE MECHANISM OF THE COMPLEX CYCLIZATION REACTION CATALYZED BY IMIDAZOLE GLYCEROPHOSPHATE SYNTHASE
8HGJ	;	4.82	;	Toxascaris leonina galectin (Tl-gal) and Human T-cell immunoglobulin mucin-3 (Tim3) complex
2QIL	;	2.07	;	TOXIC SHOCK SYNDROME TOXIN-1 AT 2.07 A RESOLUTION
2TSS	;	2.05	;	TOXIC SHOCK SYNDROME TOXIN-1 FROM STAPHYLOCOCCUS AUREUS: ORTHORHOMBICC222(1) CRYSTAL FORM
3TSS	;	1.9	;	TOXIC SHOCK SYNDROME TOXIN-1 TETRAMUTANT, P2(1) CRYSTAL FORM
5TSS	;	2.9	;	TOXIC SHOCK SYNDROME TOXIN-1: ORTHORHOMBIC P222(1) CRYSTAL FORM
4TSS	;	2.75	;	TOXIC SHOCK SYNDROME TOXIN-1: TETRAGONAL P4(1)2(1)2 CRYSTAL FORM
1FGB	;	2.4	;	TOXIN
7VD7	;	1.43	;	Toxin - Antitoxin complex from Salmonella enterica serovar Typhimurium
6L7E	;	3.2	;	Toxin Complex TcdA1-TcdB1-TccC2
3GNU	;	1.9	;	Toxin fold as basis for microbial attack and plant defense
3GNZ	;	1.35	;	Toxin fold for microbial attack and plant defense
7NNA	;	1.901	;	Toxin Import Through the Antibiotic Efflux Channel TolC
7EWI	;	1.93	;	Toxin protein from Staphylococcus aureus
5IMT	;	2.7001	;	Toxin receptor complex
5SV2	;	1.31	;	Toxin VapC21 from Mycobacterium tuberculosis
7BY2	;	2.6	;	Toxin-antitoxin complex from Klebsiella pneumoniae
7BY3	;	2.0	;	Toxin-antitoxin complex from klebsiella pneumoniae
7BYE	;	2.3	;	Toxin-antitoxin complex from klebsiella pneumoniae
7EWJ	;	2.0	;	Toxin-antitoxin complex from Staphylococcus aureus
5YRZ	;	2.304	;	Toxin-Antitoxin complex from Streptococcus pneumoniae
6F8S	;	2.5	;	Toxin-Antitoxin complex GraTA
6AF3	;	2.803	;	Toxin-Antitoxin module from Streptococcus pneumoniae
6AF4	;	2.65	;	Toxin-Antitoxin module from Streptococcus pneumoniae
2QNW	;	1.9	;	Toxoplasma gondii apicoplast-targeted acyl carrier protein
1SOV	;	1.9	;	Toxoplasma gondii bradyzoite-specific LDH (LDH2) apo form
5W8R	;	2.2	;	Toxoplasma Gondii CDPK1 in complex with inhibitor 3CIB-PPI
5W9E	;	2.44	;	Toxoplasma Gondii CDPK1 in complex with inhibitor GXJ-186
5W80	;	2.0	;	Toxoplasma Gondii CDPK1 in complex with inhibitor GXJ-237
5W9R	;	2.7	;	Toxoplasma Gondii CDPK1 in complex with inhibitor LJQ138
5W91	;	2.4	;	Toxoplasma Gondii CDPK1 in complex with inhibitor LZH118
7FGX	;	2.05	;	Toxoplasma gondii dihydrofolate reductase thymidylate synthase (TgDHFR-TS) complexed with P39, NADPH and dUMP
7FGY	;	2.67	;	Toxoplasma gondii dihydrofolate reductase thymidylate synthase (TgDHFR-TS) complexed with P40, NADPH and dUMP
7FGW	;	2.15	;	Toxoplasma gondii dihydrofolate reductase thymidylate synthase (TgDHFR-TS) complexed with pyrimethamine, NADPH and dUMP
4XLL	;	2.08	;	Toxoplasma gondii DJ-1, oxidized
4O1M	;	2.0	;	Toxoplasma gondii Enoyl acyl carrier protein reductase
1FSG	;	1.05	;	TOXOPLASMA GONDII HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE COMPLEXED WITH 9-DEAZAGUANINE, ALPHA-D-5-PHOSPHORIBOSYL-1-PYROPHOSPHATE (PRPP) AND TWO MG2+ IONS
1QK3	;	1.65	;	TOXOPLASMA GONDII HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE GMP COMPLEX
1QK4	;	1.9	;	TOXOPLASMA GONDII HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE IMP COMPLEX
1QK5	;	1.6	;	TOXOPLASMA GONDII HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE WITH XMP, PYROPHOSPHATE AND TWO MG2+ IONS
6DUE	;	2.6	;	Toxoplasma gondii MyoA, a Class-XIV myosin, in the pre-powerstroke state
4KH6	;	2.4	;	Toxoplasma gondii NTPDase1 C258S/C268S E493G crystallized with Mg and AMPNP
4KH5	;	3.0	;	Toxoplasma gondii NTPDase1 C258S/C268S in complex with Mg and AMPNP
4KH4	;	3.0	;	Toxoplasma gondii NTPDase1 C258S/C268S in complex with Mg and AMPPNP
7F9P	;	1.57	;	Toxoplasma gondii Prolyl-tRNA Synthetase (TgPRS) in Complex with inhibitor L95 and azetidine
7VC1	;	1.892	;	Toxoplasma gondii Prolyl-tRNA Synthetase (TgPRS) in Complex with inhibitor L95 and L-proline in space group P21
7F9R	;	1.83	;	Toxoplasma gondii Prolyl-tRNA Synthetase (TgPRS) in Complex with inhibitor L95, L-Proline and Febrifugine
7VC2	;	2.096	;	Toxoplasma gondii Prolyl-tRNA Synthetase (TgPRS) in Complex with inhibitor L96 and L-proline in space group P21
7F9Q	;	2.796	;	Toxoplasma gondii Prolyl-tRNA Synthetase (TgPRS) in Complex with inhibitor L97 and Febrifugine
7F9T	;	1.489	;	Toxoplasma gondii Prolyl-tRNA Synthetase (TgPRS) in Complex with inhibitor L97 and Halofuginone
7VC3	;	1.973	;	Toxoplasma gondii Prolyl-tRNA Synthetase (TgPRS) in Complex with inhibitor L97 and L-proline at 1.97 A resolution
7F9S	;	1.861	;	Toxoplasma gondii Prolyl-tRNA Synthetase (TgPRS) in Complex with inhibitor T35 and Febrifugine (FF)
7VC5	;	1.612	;	Toxoplasma gondii Prolyl-tRNA Synthetase (TgPRS) in Complex with inhibitor T35 and Febrifugine (FF) at 1.61 A resolution
7F9U	;	2.8	;	Toxoplasma gondii Prolyl-tRNA Synthetase (TgPRS) in Complex with inhibitor T35 and Halofuginone
7F9V	;	1.816	;	Toxoplasma gondii Prolyl-tRNA Synthetase (TgPRS) in Complex with inhibitor T35 and Halofuginone
7V8K	;	2.47	;	Toxoplasma gondii Prolyl-tRNA Synthetase (TgPRS) in Complex with L-Proline
7V8J	;	2.519	;	Toxoplasma gondii Prolyl-tRNA Synthetase (TgPRS) in complex with the reaction intermediates proline-adenylate (Pro-AMP) and pyrophosphate
7Q4A	;	2.31	;	Toxoplasma gondii PRP4K kinase domain (L715F) bound to altiratinib
6N1S	;	3.0	;	Toxoplasma gondii TS-DHFR in complex with selective inhibitor 29
6N1T	;	3.5	;	Toxoplasma gondii TS-DHFR in complex with selective inhibitor 3
2F4Z	;	2.11	;	Toxoplasma gondii ubiquitin conjugating enzyme TgTwinScan_2721- E2 domain
8B4B	;	1.75	;	ToxR bacterial transcriptional regulator bound to 19 bp ompU promoter DNA
8B4C	;	2.07	;	ToxR bacterial transcriptional regulator bound to 20 bp toxT promoter DNA
8B4E	;	3.25	;	ToxR bacterial transcriptional regulator bound to 25 bp toxT promoter DNA
8B4D	;	2.64	;	ToxR bacterial transcriptional regulator bound to 40 bp toxT promoter DNA
1O75	;	1.95	;	Tp47, the 47-Kilodalton Lipoprotein of Treponema pallidum
5A7L	;	2.103	;	TP901-1 CI NTD (res 1-80)
8HKA	;	1.02	;	TPA bound-form of Periplasmic terephthalate binding protein (TBP) from Ideonella sakaiensis
8HKB	;	1.4	;	TPA bound-form of Periplasmic terephthalate binding protein (TBP) from Ideonella sakaiensis mutant K184D
8FZ7	;	2.88	;	TpeA bound closed MthK-A88F mutant in nanodisc
5BKJ	;	3.5	;	TPeA-bound closed MthK channel in nanodisc
8BAD	;	1.81	;	Tpp80Aa1
2C0L	;	2.3	;	TPR DOMAIN OF HUMAN PEX5P IN COMPLEX WITH HUMAN MSCP2
2E2E	;	2.05	;	TPR domain of NrfG mediates the complex formation between heme lyase and formate-dependent nitrite reductase in Escherichia Coli O157:H7
7NAZ	;	1.6	;	TPR-rich domain of EccA3 from M. smegmatis
3UQ3	;	2.6	;	TPR2AB-domain:pHSP90-complex of yeast Sti1
3UPV	;	1.6	;	TPR2B-domain:pHsp70-complex of yeast Sti1
4MAL	;	2.05	;	TPR3 of FimV from P. aeruginosa (PAO1)
4MBQ	;	2.006	;	TPR3 of FimV from P. aeruginosa (PAO1)
6JBR	;	2.03	;	Tps1/UDP/T6P complex
8CX6	;		;	TPX2 Minimal Active Domain on Microtubules
6VPJ	;	2.1	;	TPX2 residues 7-20 fused to Aurora A residues 116-389 C247V + C319V double mutant dephosphorylated, and in complex with AMP-PNP
6VPI	;	2.0	;	TPX2 residues 7-20 fused to Aurora A residues 116-389 C247V + D256N + C319V triple mutant disulfide homodimer in complex with AMP-PNP
6XKA	;	2.65	;	TPX2 residues 7-20 fused to Aurora A residues 116-389 dephosphorylated, and CoAlated on C290
6VPG	;	2.64	;	TPX2 residues 7-20 fused to Aurora A residues 116-389 in complex with AMP-PNP
6VPH	;	2.14	;	TPX2 residues 7-20 fused to Aurora A residues 116-389 modified with cacodylate and in complex with AMP-PNP
6VPL	;	1.86	;	TPX2 residues 7-20 fused to Aurora A residues 116-389 with C290 disulfide bonded to compound 7-80, and in complex with AMP-PNP
6VPM	;	1.58	;	TPX2 residues 7-20 fused to Aurora A residues 116-389 with C290 disulfide bonded to compound 8-34, and in complex with AMP-PNP
3KND	;	2.151	;	TPX2:importin-alpha complex
6BJC	;	3.3	;	TPX2_mini decorated GMPCPP-microtubule
1MA6	;		;	TPY4 Tachyplesin I tyrosine mutant in the presence of dodecylphosphocholine micelles (300 mM)
1NQ0	;	2.4	;	TR Receptor Mutations Conferring Hormone Resistance and Reduced Corepressor Release Exhibit Decreased Stability in the Nterminal LBD
1NQ1	;	2.9	;	TR Receptor Mutations Conferring Hormone Resistance and Reduced Corepressor Release Exhibit Decreased Stability in the Nterminal LBD
3D57	;	2.2	;	TR Variant D355R
7YD7	;	2.25	;	TR-SFX MmCPDII-DNA complex: 1 ns snapshot. Includes 1 ns, dark, and extrapolated structure factors
7YEE	;	2.15	;	TR-SFX MmCPDII-DNA complex: 10 ns snapshot. Includes 10 ns, dark, and extrapolated structure factors. Collected at SwissFEL
7YEI	;	2.7	;	TR-SFX MmCPDII-DNA complex: 10 ns time-point collected in SACLA. Includes 10 ns, dark, and extrapolated structure factors
7YEJ	;	2.55	;	TR-SFX MmCPDII-DNA complex: 100 ns time-point collected in SACLA. Includes 100 ns, dark, and extrapolated structure factors
7YCM	;	2.0	;	TR-SFX MmCPDII-DNA complex: 100 ps snapshot. Includes 100ps, dark, and extrapolated structure factors
7YD8	;	2.15	;	TR-SFX MmCPDII-DNA complex: 2 ns snapshot. Includes 2 ns, dark, and extrapolated structure factors
7YEM	;	2.6	;	TR-SFX MmCPDII-DNA complex: 200 us time-point collected in SACLA. Includes 200 us, dark, and extrapolated structure factors
7YEL	;	2.5	;	TR-SFX MmCPDII-DNA complex: 25 us time-point collected in SACLA. Includes 25 us, dark, and extrapolated structure factors
7YCP	;	2.08	;	TR-SFX MmCPDII-DNA complex: 250 ps snapshot. Includes 250 ps, dark, and extrapolated structure factors
7YEB	;	2.2	;	TR-SFX MmCPDII-DNA complex: 3.35 ns snapshot. Includes 3.35 ns, dark, and extrapolated structure factors
7YCR	;	2.15	;	TR-SFX MmCPDII-DNA complex: 450 ps snapshot. Includes 450ps, dark, and extrapolated structure factors
7YEK	;	2.4	;	TR-SFX MmCPDII-DNA complex: 500 ns time-point collected in SACLA. Includes 500 ns, dark, and extrapolated structure factors
7YEC	;	2.2	;	TR-SFX MmCPDII-DNA complex: 6 ns snapshot. Includes 6 ns, dark, and extrapolated structure factors
7YD6	;	2.15	;	TR-SFX MmCPDII-DNA complex: 650 ps snapshot. Includes 650ps, dark, and extrapolated structure factors
7YDZ	;	2.23	;	TR-SFX MmCPDII-DNA complex: dark state as collected in SACLA
6RNJ	;	2.6	;	TR-SMX closed state structure (0-5ms) of bacteriorhodopsin
6RPH	;	2.6	;	TR-SMX open state structure (10-15ms) of bacteriorhodopsin
1VGE	;	2.0	;	TR1.9 FAB FRAGMENT OF A HUMAN IGG1 KAPPA AUTOANTIBODY
7VVY	;	3.1	;	TRA module of NuA4
6IG9	;	4.6	;	Tra1 subunit from Saccharomyces cerevisiae SAGA complex
4ICY	;	2.4	;	Tracing the Evolution of Angucyclinone Monooxygenases: Structural Determinants for C-12b Hydroxylation and Substrate Inhibition in PgaE
3CUV	;	1.93	;	Tracking structure activity relationships of glycogen phosphorylase inhibitors: synthesis, kinetic and crystallographic evaluation of analogues of N-(-D-glucopyranosyl)-N'-oxamides
5WIP	;	2.62	;	TraE protein in complex with 2-(2-furyl)isonicotinic acid
5WII	;	2.79	;	TraE protein in complex with 2-Chloroisonicotinic Acid
5WIC	;	2.55	;	TraE protein in complex with 2-Furoic Acid (FOA)
5WIO	;	2.52	;	TraE protein in complex with 4-(1H-pyrrol-1-yl)pyridine-2-carboxylic acid
4M4E	;	2.6	;	TRAF domain of human TRAF4
5H10	;	3.205	;	TRAF1-TANk complex
5YC1	;	2.506	;	TRAF4_GPIb complex
1LB4	;	2.4	;	TRAF6 apo structure
1LB6	;	1.8	;	TRAF6-CD40 Complex
1LB5	;	2.4	;	TRAF6-RANK Complex
2L8B	;		;	TraI (381-569)
8A1B	;	1.7	;	TraI trans-esterase domain from pKM101 (apo)
8A1C	;	2.1	;	TraI trans-esterase domain from pKM101 (DNA bound)
3X3F	;	2.1	;	TRAIL-R2 Extracellular Region Complexed to a Fab fragment from Human Agonist Antibody KMTR2
3Q3U	;	1.85	;	Trametes cervina lignin peroxidase
6G1T	;	1.93	;	TraN, a repressor of an Enterococcus conjugative type IV secretion system
6NMB	;	2.3	;	Tranexamic Acid is an Active Site Inhibitor of Urokinase Plasminogen Activator
2M10	;		;	trans form of a photoswitchable PDZ domain crosslinked with an azobenzene derivative
6D53	;		;	Trans form of HemolysinII c-terminal domain
7QLJ	;	1.02	;	Trans structure of rsKiiro Illuminated at 290 K
2H3T	;		;	trans-(4-aminomethyl)phenylazobenzoic acid-aPP bound to DPC micelles
7E05	;	1.88	;	Trans-3/4-proline-hydroxylase H11 apo structure
8H7T	;	1.88	;	Trans-3/4-proline-hydroxylase H11 apo structure
7E01	;	1.72	;	Trans-3/4-proline-hydroxylase H11 in the sixth reaction state
7E09	;	2.38	;	Trans-3/4-proline-hydroxylase H11 with 3-hydroxyl-proline
8H85	;	2.38	;	Trans-3/4-proline-hydroxylase H11 with 3-hydroxyl-proline
7E08	;	1.84	;	Trans-3/4-proline-hydroxylase H11 with 4-Hydroxyl-proline
8H81	;	1.84	;	Trans-3/4-proline-hydroxylase H11 with 4-Hydroxyl-proline
7E06	;	1.97	;	Trans-3/4-proline-hydroxylase H11 with AKG
8H7V	;	1.97	;	Trans-3/4-proline-hydroxylase H11 with AKG
7E07	;	2.14	;	Trans-3/4-proline-hydroxylase H11 with AKG and L-proline
8H7Y	;	2.14	;	Trans-3/4-proline-hydroxylase H11 with AKG and L-proline
7DZZ	;	1.95	;	Trans-3/4-proline-hydroxylase H11-stateV
6LUF	;	3.45	;	Trans-acting mutant Y290A of the central AAA+ domain of the flagellar regulatory protein FlrC
3RGI	;	1.51	;	Trans-acting transferase from Disorazole synthase
6APF	;	1.63	;	Trans-acting transferase from Disorazole synthase complexed with Citrate.
3SBM	;	1.35	;	Trans-acting transferase from Disorazole synthase in complex with Acetate
6APK	;	2.5	;	Trans-acting transferase from Disorazole synthase solved by serial femtosecond XFEL crystallography
6APG	;	2.0	;	Trans-acting transferase from Disorazole synthase with malonate
1BE6	;	2.15	;	TRANS-CINNAMOYL-SUBTILISIN IN ANHYDROUS ACETONITRILE
1BE8	;	2.2	;	TRANS-CINNAMOYL-SUBTILISIN IN WATER
4BX6	;	1.595	;	trans-divalent streptavidin
4BX7	;	2.26	;	trans-divalent streptavidin bound to biotin-4-fluorescein
4CPH	;	1.64	;	trans-divalent streptavidin with love-hate ligand 4
7E00	;	1.92	;	Trans-proline-hydroxylase H11 with Succinic and L-proline in the fourth reaction state.
8WMQ	;	3.3	;	trans-Zeatin bound state of Arabidopsis AZG1 at pH5.5
8IRO	;	2.7	;	trans-Zeatin bound state of Arabidopsis AZG1 at pH7.4
7NMI	;	2.1	;	Transactivation domain of p53 in complex with S100P, using annexin A2 as crystallization chaperone
4RZ6	;	1.802	;	Transaldolase B E96Q F178Y from E.coli
4RZ5	;	1.8	;	Transaldolase B E96Q from E.coli
3R8R	;	1.9	;	Transaldolase from Bacillus subtilis
3R5E	;	2.1	;	TRANSALDOLASE from Corynebacterium glutamicum
3S1U	;	1.9	;	Transaldolase from Thermoplasma acidophilum in complex with D-erythrose 4-phosphate
3S1V	;	1.8	;	Transaldolase from Thermoplasma acidophilum in complex with D-fructose 6-phosphate Schiff-base intermediate
3S1X	;	1.65	;	Transaldolase from Thermoplasma acidophilum in complex with D-sedoheptulose 7-phosphate Schiff-base intermediate
6YS0	;	1.7	;	Transaldolase variant D211A from T. acidophilum in complex with D-fructose 6-phosphate Schiff-base intermediate
4XZ9	;	1.8	;	Transaldolase variant E60Q/F132Y from T. acidophilum in complex with DHA Schiff base and G3P
3S1W	;	1.8	;	Transaldolase variant Lys86Ala from Thermoplasma acidophilum in complex with glycerol and citrate
6YRM	;	1.7	;	Transaldolase variant T30A from T. acidophilum in complex with D-fructose 6-phosphate Schiff-base intermediate
6YRE	;	1.96	;	Transaldolase variant T30C/D211C from T. acidophilum
6YRH	;	1.8	;	Transaldolase variant T30C/D211C from T. acidophilum in complex with D-fructose 6-phosphate Schiff-base intermediate
6YRT	;	1.65	;	Transaldolase variant T30D from T. acidophilum in complex with D-fructose 6-phosphate Schiff-base intermediate
3S0C	;	1.78	;	Transaldolase wt of Thermoplasma acidophilum
6S54	;	2.21	;	Transaminase from Pseudomonas fluorescens
7P3T	;	1.6	;	Transaminase of gamma-proteobacterium
7QX0	;	3.5	;	Transaminase Structure of Plurienzyme (Tr2E2) in complex with PLP
5GHG	;	2.0	;	Transaminase W58L with SMBA
6SSG	;	1.47	;	Transaminase with DCS bound
5GHF	;	2.0	;	Transaminase with L-ala
6SSF	;	1.48	;	Transaminase with LCS bound
6SSD	;	1.18	;	Transaminase with PLP bound
6SSE	;	1.56	;	Transaminase with PMP bound
1ON9	;	2.0	;	Transcarboxylase 12S crystal structure: hexamer assembly and substrate binding to a multienzyme core (with hydrolyzed methylmalonyl-coenzyme a bound)
1ON3	;	1.9	;	Transcarboxylase 12S crystal structure: hexamer assembly and substrate binding to a multienzyme core (with methylmalonyl-coenzyme a and methylmalonic acid bound)
7KUF	;	2.6	;	Transcription activation subcomplex with WhiB7 bound to SigmaAr4-RNAP Beta flap tip chimera and DNA
2JEU	;	2.8	;	Transcription activator structure reveals redox control of a replication initiation reaction
2JEX	;	2.35	;	Transcription activator structure reveals redox control of a replication initiation reaction
7UBM	;	3.13	;	Transcription antitermination complex: ""pre-engaged"" Qlambda-loading complex
7UBN	;	3.36	;	Transcription antitermination complex: NusA-containing ""engaged"" Qlambda-loading complex
6P1B	;	1.942	;	Transcription antitermination factor Q21
6P1A	;	2.837	;	Transcription antitermination factor Q21 in complex with Q21-binding-element DNA
6P1C	;	2.005	;	Transcription antitermination factor Q21, SeMet-derivative
7UBL	;	2.177	;	Transcription antitermination factor Qlambda in complex with Q-lambda-binding-element DNA
7UBJ	;	1.46	;	Transcription antitermination factor Qlambda, type-I crystal
7UBK	;	1.97	;	Transcription antitermination factor Qlambda, type-II crystal
4Y5U	;	2.708	;	Transcription factor
1WTU	;		;	TRANSCRIPTION FACTOR 1, NMR, MINIMIZED AVERAGE STRUCTURE
1CI6	;	2.6	;	TRANSCRIPTION FACTOR ATF4-C/EBP BETA BZIP HETERODIMER
7Q4N	;	3.2	;	transcription factor CDX2 bound to hydroxymethylated DNA
6UCI	;	2.09	;	Transcription factor DeltaFosB bZIP domain self-assembly, oxidized form
6UCL	;	2.207	;	Transcription factor deltaFosB bZIP domain self-assembly, type-I crystal
6UCM	;	2.424	;	Transcription factor DeltaFosB bZIP domain self-assembly, type-II crystal
6GYR	;	3.1	;	Transcription factor dimerization activates the p300 acetyltransferase
6GYT	;	2.5	;	Transcription factor dimerization activates the p300 acetyltransferase
5VPA	;	2.83	;	Transcription factor FosB/JunD bZIP domain
7UCD	;	3.21	;	Transcription factor FosB/JunD bZIP domain covalently modified with the cysteine-targeting alpha-haloketone compound Z2159931480
5VPE	;	2.053	;	Transcription factor FosB/JunD bZIP domain in complex with cognate DNA, type-I crystal
5VPF	;	2.694	;	Transcription factor FosB/JunD bZIP domain in complex with cognate DNA, type-II crystal
5VPB	;	2.691	;	Transcription factor FosB/JunD bZIP domain in its oxidized form, type-I crystal
5VPC	;	2.498	;	Transcription factor FosB/JunD bZIP domain in its oxidized form, type-II crystal
5VPD	;	2.79	;	Transcription factor FosB/JunD bZIP domain in its oxidized form, type-III crystal
7UCC	;	1.94	;	Transcription factor FosB/JunD bZIP domain in the reduced form
5EMQ	;	2.3	;	Transcription factor GRDBD and GRE complex
5EMP	;	2.3	;	Transcription factor GRDBD and mmGRE complex
5EMC	;	2.3	;	Transcription factor GRDBD and smGRE complex
2HGH	;		;	Transcription Factor IIIA zinc fingers 4-6 bound to 5S rRNA 55mer (NMR structure)
8ILW	;	2.712	;	Transcription factor LMX1a homeobox domain in complex with Pitx3 promoter
8IK5	;	1.989	;	Transcription factor LMX1a homeobox domain in complex with Wnt1 promoter
7Z5K	;	2.28	;	Transcription factor MYF5 bound to non-symmetrical site
7Z5I	;	3.0	;	Transcription factor MYF5 bound to symmetrical site
1BOR	;		;	TRANSCRIPTION FACTOR PML, A PROTO-ONCOPROTEIN, NMR, 1 REPRESENTATIVE STRUCTURE AT PH 7.5, 30 C, IN THE PRESENCE OF ZINC
6LFF	;	1.79	;	transcription factor SATB1 CUTr1 domain in complex with a phosphorothioate DNA
1BG1	;	2.25	;	TRANSCRIPTION FACTOR STAT3B/DNA COMPLEX
5M4S	;	2.38	;	Transcription factor TFIIA as a single chain protein
2XDN	;	2.2	;	Transcription factor TtgR H67A mutant
4Y5W	;	3.104	;	Transcription factor-DNA complex
5D39	;	3.2	;	Transcription factor-DNA complex
8IKE	;	2.6	;	Transcription factors LMX1a mutant-R199A homeobox domain complex with Wnt1 promoter
5FZ5	;	8.8	;	Transcription initiation complex structures elucidate DNA opening (CC)
5FYW	;	4.35	;	Transcription initiation complex structures elucidate DNA opening (OC)
7ADE	;	4.2	;	Transcription termination complex IVa
6Z9P	;	3.9	;	Transcription termination intermediate complex 1
7ADB	;	4.4	;	Transcription termination intermediate complex 1 delta NusG
6Z9Q	;	5.7	;	Transcription termination intermediate complex 2
6Z9R	;	4.1	;	Transcription termination intermediate complex 3
7ADC	;	4.0	;	Transcription termination intermediate complex 3 delta NusG
6Z9S	;	4.4	;	Transcription termination intermediate complex 4
6Z9T	;	4.1	;	Transcription termination intermediate complex 5
7ADD	;	4.3	;	Transcription termination intermediate complex IIIa
8C7U	;	3.15	;	Transcriptional pleiotropic repressor CodY from Enterococcus faecalis in complex with Leu and a 30-bp DNA fragment encompassing two overlapping binding sites
8C7S	;	3.05	;	Transcriptional pleiotropic repressor CodY from Staphylococcus aureus in complex with Ile, GTP, and a 30-bp DNA fragment encompassing two overlapping binding sites
7Y19	;	2.39	;	Transcriptional regulator BrpR
5YSZ	;	1.631	;	transcriptional regulator CelR-cellobiose complex
7QZ7	;	2.3	;	Transcriptional regulator LmrR with bound daunomycin and with Trp-67 and Trp-96 replaced by 5,6,7-trifluoroTrp
7QZ6	;	2.15	;	Transcriptional regulator LmrR with bound daunomycin and with Trp-67 and Trp-96 replaced by 5-fluoroTrp
7QZ8	;	2.3	;	Transcriptional regulator LmrR with bound daunomycin and with Trp-67 and Trp-96 replaced by the unnatural amino acid 5,6-difluoroTrp
6FUU	;	1.75	;	Transcriptional regulator LmrR with bound heme
7QZ9	;	2.31	;	Transcriptional regulator LmrR with Trp-67 and Trp-96 replaced by the unnatural amino acid 5,6-difluoroTrp
7QZ5	;	1.8	;	Transcriptional regulator LmrR with Trp-67 and Trp-96 replaced by the unnatural amino acid 5-fluoroTrp
2IA0	;	2.37	;	Transcriptional Regulatory Protein PF0864 From Pyrococcus Furiosus a Member of the ASNC Family (PF0864)
5MQQ	;	2.093	;	Transcriptional repressor AmtR of corynebacterium glutamicum
2CPG	;	1.6	;	TRANSCRIPTIONAL REPRESSOR COPG
1EA4	;	2.95	;	TRANSCRIPTIONAL REPRESSOR COPG/22bp dsDNA COMPLEX
1B01	;	2.56	;	TRANSCRIPTIONAL REPRESSOR COPG/DNA COMPLEX
6HNX	;	1.7	;	TRANSCRIPTIONAL REPRESSOR ETHR FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH BDM35133
6HNZ	;	1.7	;	TRANSCRIPTIONAL REPRESSOR ETHR FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH BDM41231
6HO0	;	1.9	;	TRANSCRIPTIONAL REPRESSOR ETHR FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH BDM41325
6HO1	;	2.0	;	TRANSCRIPTIONAL REPRESSOR ETHR FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH BDM41974
6HO2	;	1.9	;	TRANSCRIPTIONAL REPRESSOR ETHR FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH BDM43138
6HO3	;	2.4	;	TRANSCRIPTIONAL REPRESSOR ETHR FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH BDM43265
6HO4	;	1.6	;	TRANSCRIPTIONAL REPRESSOR ETHR FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH BDM44693
6HO5	;	2.3	;	TRANSCRIPTIONAL REPRESSOR ETHR FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH BDM44719
6HO6	;	1.9	;	TRANSCRIPTIONAL REPRESSOR ETHR FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH BDM44725
6HO7	;	2.5	;	TRANSCRIPTIONAL REPRESSOR ETHR FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH BDM44814
6HO8	;	1.98	;	TRANSCRIPTIONAL REPRESSOR ETHR FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH BDM44815
6HO9	;	1.8	;	TRANSCRIPTIONAL REPRESSOR ETHR FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH BDM44825
6HOA	;	1.5	;	TRANSCRIPTIONAL REPRESSOR ETHR FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH BDM44830
6HOB	;	1.8	;	TRANSCRIPTIONAL REPRESSOR ETHR FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH BDM44831
6HOC	;	2.5	;	TRANSCRIPTIONAL REPRESSOR ETHR FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH BDM44847
6HOD	;	1.7	;	TRANSCRIPTIONAL REPRESSOR ETHR FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH BDM44848
6HOE	;	1.9	;	TRANSCRIPTIONAL REPRESSOR ETHR FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH BDM44850
6HOF	;	1.8	;	TRANSCRIPTIONAL REPRESSOR ETHR FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH BDM44852
6C9T	;	2.07	;	Transcriptional repressor, CouR
6C2S	;	2.85	;	Transcriptional repressor, CouR, bound to a 23-mer DNA duplex
6C28	;	2.09	;	Transcriptional repressor, CouR, bound to p-coumaroyl-CoA
1MF6	;		;	Transducin gamma subunit, C-terminal domain 60-71, rhodopsin-bound state: Ensemble of 15 models determined by TrNOE spectroscopy
1SYB	;	1.8	;	TRANSFER OF A BETA-TURN STRUCTURE TO A NEW PROTEIN CONTEXT
2Z9Q	;	11.7	;	Transfer RNA in the hybrid P/E state
7ED0	;	1.65	;	Transferase from Mycobacterium tuberculosis
7ED1	;	1.65	;	Transferase from Mycobacterium tuberculosis
7ED2	;	1.65	;	Transferase from Mycobacterium tuberculosis
5XHP	;	2.8	;	Transferase with ligands
2D4J	;	1.16	;	Transformed monoclinic crystal of hen egg-white lysozyme from a heavy water solution
1KS6	;		;	Transforming Growth Factor Beta type II receptor ligand binding domain
1PLO	;		;	TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR EXTRACELLULAR DOMAIN
1MIL	;	2.7	;	TRANSFORMING PROTEIN
3S3J	;	2.25	;	Transglutaminase 2 in complex with a novel inhibitor
3S3P	;	2.5	;	Transglutaminase 2 in complex with a novel inhibitor
3S3S	;	2.301	;	Transglutaminase 2 in complex with a novel inhibitor
6A8P	;	2.537	;	Transglutaminase 2 mutant G224V in complex with GTP
2Q3Z	;	2.0	;	Transglutaminase 2 undergoes large conformational change upon activation
8OXW	;	1.7	;	Transglutaminase 3 in complex with DH patient-derived Fab DH63-B02
8OXX	;	2.5	;	Transglutaminase 3 in complex with inhibitor Z-don and DH patient-derived Fab DH63-B02
8OXY	;	2.0	;	Transglutaminase 3 without calcium in complex with DH patient-derived Fab DH63-B02
8OXV	;	1.8	;	Transglutaminase 3 zymogen in complex with DH patient-derived Fab DH63-B02
7C9J	;	2.1	;	Transglutaminase from Geobacillus stearothermophilus (without C-terminal extension)
6KZB	;	3.55	;	Transglutaminase2 complexed with calcium
4PYG	;	2.8	;	Transglutaminase2 complexed with GTP
1U2G	;	2.2	;	transhydrogenase (dI.ADPr)2(dIII.NADPH)1 asymmetric complex
2MQS	;		;	Transient Collagen Triple Helix Binding to a Key Metalloproteinase in Invasion and Development: Spin Labels to Structure
7ZJD	;	2.94	;	Transient receptor potential cation channel subfamily V member 2,Enhanced green fluorescent protein
7ZJI	;	3.4	;	Transient receptor potential cation channel subfamily V member 2,Enhanced green fluorescent protein
6GTD	;	4.24	;	Transient state structure of CRISPR-Cpf1 (Cas12a) I2 conformation
6GTE	;	4.07	;	Transient state structure of CRISPR-Cpf1 (Cas12a) I3 conformation
6GTF	;	3.63	;	Transient state structure of CRISPR-Cpf1 (Cas12a) I5 conformation
6WYM	;	2.0	;	Transition metal inhibition and structural refinement of the M. tuberculosis esterase, Rv0045c
6WYN	;	1.81	;	Transition metal inhibition and structural refinement of the M. tuberculosis esterase, Rv0045c
1U6R	;	1.65	;	Transition state analog complex of muscle creatine kinase (R134K) mutant
1AMN	;	2.8	;	TRANSITION STATE ANALOG: ACETYLCHOLINESTERASE COMPLEXED WITH M-(N,N,N-TRIMETHYLAMMONIO)TRIFLUOROACETOPHENONE
8BOS	;	2.1	;	Transition state analogue complex of small G protein and its GAP effector
2HF7	;	1.6	;	Transition State Analogue of AphA class B Acid Phosphatase/Phosphotransferase (Aluminium Fluoride Complex)
1L7N	;	1.8	;	TRANSITION STATE ANALOGUE OF PHOSPHOSERINE PHOSPHATASE (ALUMINUM FLUORIDE COMPLEX)
7QTM	;	2.25	;	Transition state analogue of small G protein in complex with relevant GAP
1RLT	;	2.2	;	Transition State Analogue of ybiV from E. coli K12
5U99	;	2.4	;	Transition state analysis of adenosine triphosphate phosphoribosyltransferase
2NGR	;	1.9	;	TRANSITION STATE COMPLEX FOR GTP HYDROLYSIS BY CDC42: COMPARISONS OF THE HIGH RESOLUTION STRUCTURES FOR CDC42 BOUND TO THE ACTIVE AND CATALYTICALLY COMPROMISED FORMS OF THE CDC42-GAP.
4DZ6	;	2.2	;	Transition state mimic of nucleoside-diphosphate kinase from borrelia burgdorferi with bound vanadate and adp
7W94	;	3.4	;	Transition state of SARS-CoV-2 Delta variant spike protein
1M5O	;	2.2	;	Transition State Stabilization by a Catalytic RNA
1M5P	;	2.6	;	Transition State Stabilization by a Catalytic RNA
1M5V	;	2.4	;	Transition State Stabilization by a Catalytic RNA
1P50	;	2.8	;	Transition state structure of an Arginine Kinase mutant
1BG0	;	1.86	;	TRANSITION STATE STRUCTURE OF ARGININE KINASE
1M15	;	1.2	;	Transition state structure of arginine kinase
6GTC	;	3.91	;	Transition state structure of Cpf1(Cas12a) I1 conformation
6GTG	;	3.27	;	Transition state structure of Cpf1(Cas12a) I4 conformation
2VR4	;	1.8	;	Transition-state mimicry in mannoside hydrolysis: characterisation of twenty six inhibitors and insight into binding from linear free energy relationships and 3-D structure
3DWU	;	12.6	;	Transition-state model conformation of the switch I region fitted into the cryo-EM map of the eEF2.80S.AlF4.GDP complex
1CTT	;	2.2	;	TRANSITION-STATE SELECTIVITY FOR A SINGLE OH GROUP DURING CATALYSIS BY CYTIDINE DEAMINASE
1CTU	;	2.3	;	TRANSITION-STATE SELECTIVITY FOR A SINGLE OH GROUP DURING CATALYSIS BY CYTIDINE DEAMINASE
6VWT	;	3.03	;	Transitional unit cell 1 of adenine riboswitch aptamer crystal phase transition upon ligand binding
6VWV	;	3.0	;	Transitional unit cell 2 of adenine riboswitch aptamer crystal phase transition upon ligand binding
1GPU	;	1.86	;	Transketolase complex with reaction intermediate
2R8P	;	1.65	;	Transketolase from E. coli in complex with substrate D-fructose-6-phosphate
2R8O	;	1.47	;	Transketolase from E. coli in complex with substrate D-xylulose-5-phosphate
1QGD	;	1.9	;	TRANSKETOLASE FROM ESCHERICHIA COLI
1R9J	;	2.22	;	Transketolase from Leishmania mexicana
8QMF	;	2.1	;	Transketolase from Vibrio vulnificus in complex with thiamin pyrophosphate
8B0X	;	1.55	;	Translating 70S ribosome in the unrotated state (P and E, tRNAs)
1TIG	;	2.0	;	TRANSLATION INITIATION FACTOR 3 C-TERMINAL DOMAIN
1TIF	;	1.8	;	TRANSLATION INITIATION FACTOR 3 N-TERMINAL DOMAIN
5M80	;	2.12	;	Translation initiation factor 4E in complex with (RP)-iPr-m7GppSpG mRNA 5' cap analog
5M7X	;	1.68	;	Translation initiation factor 4E in complex with (RP)-m2(7,2'O)GppSepG mRNA 5' cap analog (beta-Se-ARCA D1)
5M83	;	1.86	;	Translation initiation factor 4E in complex with (RP)-m2(7,2'O)GppSpA mRNA 5' cap analog
5M7V	;	1.74	;	Translation initiation factor 4E in complex with (RP)-m2(7,2'O)GppSpG mRNA 5' cap analog (beta-S-ARCA D1)
5M81	;	1.9	;	Translation initiation factor 4E in complex with (SP)-iPr-m7GppSpG mRNA 5' cap analog
5M7Z	;	1.689	;	Translation initiation factor 4E in complex with (SP)-m2(7,2'O)GppSepG mRNA 5' cap analog (beta-Se-ARCA D2)
5M84	;	1.85	;	Translation initiation factor 4E in complex with (SP)-m2(7,2'O)GppSpA mRNA 5' cap analog
5M7W	;	1.97	;	Translation initiation factor 4E in complex with (SP)-m2(7,2'O)GppSpG mRNA 5' cap analog (beta-S-ARCA D2)
6YLT	;	2.67	;	Translation initiation factor 4E in complex with 3-MeBn7GpppG mRNA 5' cap analog
6YLV	;	2.66006	;	Translation initiation factor 4E in complex with 4-Cl-Bn7GpppG mRNA 5' cap analog
6GKK	;	1.858	;	Translation initiation factor 4E in complex with beta-phosphorothioate trinucleotide mRNA 5' cap diastereomer 1 (m7GppSpApG D1)
6GKL	;	2.2	;	Translation initiation factor 4E in complex with beta-phosphorothioate trinucleotide mRNA 5' cap diastereomer 2 (m7GppSpApG D2)
6YLR	;	2.19545	;	Translation initiation factor 4E in complex with bn7GpppG mRNA 5' cap analog
5J5Y	;	1.75	;	Translation initiation factor 4E in complex with m2(7,2'O)GppCCl2ppG mRNA 5' cap analog
5OSX	;	1.92	;	Translation initiation factor 4E in complex with m7G(5'S)ppp(5'S)G mRNA 5' cap analog
5J5O	;	1.867	;	Translation initiation factor 4E in complex with m7GppppG mRNA 5' cap analog
6GKJ	;	2.068	;	Translation initiation factor 4E in complex with trinucleotide mRNA 5' cap (m7GpppApG)
7N4D	;	2.45	;	Translation initiation factor eif-5a family protein from Naegleria fowleri ATCC 30863
1AP8	;		;	TRANSLATION INITIATION FACTOR EIF4E IN COMPLEX WITH M7GDP, NMR, 20 STRUCTURES
4TMW	;	1.55	;	Translation initiation factor eIF5B (517-858) from C. thermophilum, bound to GTP and Sodium
4TMZ	;	2.28	;	Translation initiation factor eIF5B (517-858) from C. thermophilum, bound to GTPgammaS and potassium
4TMV	;	1.53	;	Translation initiation factor eIF5B (517-858) from C. thermophilum, bound to GTPgammaS and Sodium
4TMT	;	1.58	;	Translation initiation factor eIF5B (517-858) mutant D533A from C. thermophilum, bound to GTPgammaS
4TMX	;	1.5	;	Translation initiation factor eIF5B (517-858) mutant D533N from C. thermophilum, bound to GTP and sodium
4TN1	;	2.75	;	Translation initiation factor eIF5B (517-858) mutant D533R from C. thermophilum, bound to GTPgammaS
2IFE	;		;	TRANSLATION INITIATION FACTOR IF3 FROM ESCHERICHIA COLI RIBOSOME BINDING DOMAIN (RESIDUES 84-180)
2EFG	;	2.6	;	TRANSLATIONAL ELONGATION FACTOR G COMPLEXED WITH GDP
1H6Q	;		;	Translationally Controlled Tumor-associated Protein p23fyp from Schizosaccharomyces pombe
1H7Y	;		;	Translationally Controlled Tumor-associated Protein p23fyp from Schizosaccharomyces pombe
8CF5	;	2.71	;	Translocation intermediate 1 (TI-1) of 80S S. cerevisiae ribosome with ligands and eEF2 in the presence of sordarin
8CKU	;	3.11	;	Translocation intermediate 1 (TI-1*) of 80S S. cerevisiae ribosome with ligands and eEF2 in the absence of sordarin
8CDR	;	2.04	;	Translocation intermediate 2 (TI-2) of 80S S. cerevisiae ribosome with ligands and eEF2 in the presence of sordarin
8CG8	;	2.57	;	Translocation intermediate 3 (TI-3) of 80S S. cerevisiae ribosome with ligands and eEF2 in the presence of sordarin
8CEH	;	2.05	;	Translocation intermediate 4 (TI-4) of 80S S. cerevisiae ribosome with ligands and eEF2 in the presence of sordarin
8CMJ	;	3.79	;	Translocation intermediate 4 (TI-4*) of 80S S. cerevisiae ribosome with eEF2 in the absence of sordarin
8CIV	;	2.47	;	Translocation intermediate 5 (TI-5) of 80S S. cerevisiae ribosome with ligands and eEF2 in the presence of sordarin
2GV3	;		;	Translocation of a tRNA with an extended anticodon through the ribosome
1UYN	;	2.6	;	Translocator domain of autotransporter NalP from Neisseria meningitidis
1UYO	;	3.2	;	Translocator domain of autotransporter NalP from Neisseria meningitidis
4UC3	;	2.5	;	Translocator protein 18 kDa (TSPO) from Rhodobacter sphaeroides wild type
8C2H	;	2.64	;	Transmembrane domain of active state homomeric GluA1 AMPA receptor in tandem with TARP gamma 3
2NA7	;		;	Transmembrane domain of human Fas/CD95 death receptor
2NA6	;		;	Transmembrane domain of mouse Fas/CD95 death receptor
8C2I	;	2.7	;	Transmembrane domain of resting state homomeric GluA1 AMPA receptor in complex with TARP gamma 3
8C1S	;	3.0	;	Transmembrane domain of resting state homomeric GluA2 F231A mutant AMPA receptor in complex with TARP gamma 2
7ASY	;		;	Transmembrane helix of tumor necrosis factor alpha in trifluorethanol
7ATB	;		;	Transmembrane helix of tumor necrosis factor alpha in trifluorethanol, AGALLL mutant
7AT7	;		;	Transmembrane helix of tumor necrosis factor alpha in trifluorethanol, S34P mutant
5TOD	;	2.96	;	Transmembrane protein 24 SMP domain
2NR1	;		;	TRANSMEMBRANE SEGMENT 2 OF NMDA RECEPTOR NR1, NMR, 10 STRUCTURES
2NA8	;		;	Transmembrane Structure of the Cytokine Receptor Common Subunit beta
2NA9	;		;	Transmembrane Structure of the P441A Mutant of the Cytokine Receptor Common Subunit beta
7K7A	;		;	Transmembrane structure of TNFR1
2MAE	;		;	Transmembrane-cytosolic part of Trop2 explored by NMR and Molecular Dynamics
6L95	;		;	transmembrane-domain of Bax
2Y26	;	2.7	;	Transmission defective mutant of Grapevine Fanleaf virus
4ZTK	;	2.104	;	Transpeptidase domain of FtsI4 D,D-transpeptidase from Legionella pneumophila.
4DX5	;	1.9	;	Transport of drugs by the multidrug transporter AcrB involves an access and a deep binding pocket that are separated by a switch-loop
4DX6	;	2.9	;	Transport of drugs by the multidrug transporter AcrB involves an access and a deep binding pocket that are separated by a switch-loop
4DX7	;	2.253	;	Transport of drugs by the multidrug transporter AcrB involves an access and a deep binding pocket that are separated by a switch-loop
2P13	;	1.65	;	Transporter associated domain CorC_HlyC from Nitrosomonas europaea
4C0O	;	2.557	;	Transportin 3 in complex with phosphorylated ASF/SF2
4C0Q	;	3.42	;	Transportin 3 in complex with Ran(Q69L)GTP
8CMK	;	2.945	;	Transportin-3 TNPO3 in complex with RSY region of CIRBP
3K9J	;	1.903	;	Transposase domain of Metnase
3K9K	;	2.55	;	Transposase domain of Metnase
1B7E	;	2.9	;	TRANSPOSASE INHIBITOR
1TC3	;	2.45	;	TRANSPOSASE TC3A1-65 FROM CAENORHABDITIS ELEGANS
2ROY	;	2.2	;	TRANSTHYRETIN (ALSO CALLED PREALBUMIN) COMPLEX WITH 3',5'-DINITRO-N-ACETYL-L-THYRONINE
2ROX	;	2.0	;	TRANSTHYRETIN (ALSO CALLED PREALBUMIN) COMPLEX WITH THYROXINE (T4)
1BZ8	;	2.0	;	TRANSTHYRETIN (DEL VAL122)
1TFP	;	2.9	;	TRANSTHYRETIN (FORMERLY KNOWN AS PREALBUMIN)
5AL8	;	1.5	;	Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites: daidzein-7-O- glucuronide
5AKV	;	1.52	;	Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites: genistein-7-O- glucuronide
5AKS	;	1.25	;	Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites: resveratrol-3-O- glucuronide
5AL0	;	1.388	;	Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites: resveratrol-3-O-sulfate
5AKT	;	1.35	;	Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites: resveratrol-4'-O- glucuronide
1TYR	;	1.8	;	TRANSTHYRETIN COMPLEX WITH RETINOIC ACID
7Q9L	;	1.45	;	Transthyretin complexed with (E)-4-(2-(naphthalen-1-yl)vinyl)benzene-1,2-diol
7Q9N	;	1.45	;	Transthyretin complexed with (E)-4-(2-(naphthalen-2-yl)vinyl)benzene-1,2-diol
8AWW	;	1.6	;	Transthyretin conjugated with a tafamidis derivative
3P3R	;	1.25	;	Transthyretin in complex with (3,4-dihydroxy-5-nitrophenyl)(2-fluorophenyl)methanone
3IMR	;	1.7	;	Transthyretin in complex with (E)-2,6-dibromo-4-(2,6-dichlorostyryl)phenol
3IMW	;	1.31	;	Transthyretin in complex with (E)-2,6-dibromo-4-(2,6-dimethoxystyryl)aniline
4L1T	;	1.16	;	Transthyretin in complex with (E)-3-(dimethylamino)-5-(4-hydroxy-3,5-dimethylstyryl)benzoic acid
3IMU	;	1.4	;	Transthyretin in complex with (E)-4-(3-aminostyryl)-2,6-dibromoaniline
3IMV	;	1.47	;	Transthyretin in complex with (E)-4-(4-aminostyryl)-2,6-dibromoaniline
3IMT	;	1.4	;	Transthyretin in complex with (E)-4-(4-aminostyryl)-2,6-dibromophenol
6U0Q	;	1.75	;	Transthyretin in complex with (E)-5,5'-(ethene-1,2-diyl)bis(1,1-dihydroxy-3-oxo-1,3-dihydrobenzo[c][1,2]oxaborol-1-uide)
4HJU	;	1.35	;	Transthyretin in complex with (E)-N-(3-(4-hydroxy-3,5-dimethylstyryl)phenyl)acrylamide
3IMS	;	1.4	;	Transthyretin in complex with 2,6-dibromo-4-(2,6-dichlorophenethyl)phenol
6EOY	;	1.38	;	Transthyretin in complex with 4-(1,3-Benzothiazol-2-yl)-2-methylaniline
6EP1	;	1.3	;	Transthyretin in complex with 5-(4-nitrophenylazo)-3-iodosalicylic acid
3HJ0	;	1.34	;	Transthyretin in complex with a covalent small molecule kinetic stabilizer
4KY2	;	1.13	;	Transthyretin in complex with the fluorescent folding sensor (E)-7-hydroxy-3-(4-hydroxy-3,5-dimethylstyryl)-4-methyl-2H-chromen-2-one
5DEJ	;	1.37	;	Transthyretin natural mutant A19D
3TFB	;	2.033	;	Transthyretin natural mutant A25T
1FH2	;	1.8	;	TRANSTHYRETIN STABILITY AS A KEY FACTOR IN AMYLOIDOGENESIS
1FHN	;	1.75	;	TRANSTHYRETIN STABILITY AS A KEY FACTOR IN AMYLOIDOGENESIS
1F86	;	1.1	;	TRANSTHYRETIN THR119MET PROTEIN STABILISATION
1U21	;	1.69	;	transthyretin with tethered inhibitor on one monomer.
2GPZ	;	2.5	;	Transthyretin-like protein from Salmonella dublin
1TTR	;	1.9	;	TRANSTHYRETIN-V/122/I CARDIOMYOPATHIC MUTANT
6SDZ	;	2.97	;	transthyritin derived amyloid fibril from patient with hereditary V30M ATTR amyloidosis
3MDR	;	2.0	;	Tranylcypromine complex of Cytochrome P450 46A1
2XFO	;	2.1	;	tranylcypromine-inhibited human monoamine oxidase B Ile199Ala mutant in complex with 2-(2-benzofuranyl)-2-imidazoline
2XCG	;	1.9	;	Tranylcypromine-inhibited human monoamine oxidase B in complex with 2- (2-benzofuranyl)-2-imidazoline
5F5R	;	1.85	;	TRAP1N-ADPNP
2EXS	;	2.0	;	TRAP3 (engineered TRAP)
2EXT	;	1.8	;	TRAP4 (engineered TRAP)
7B6Z	;	5.5	;	TRAPPC11 subunit (1-716)
7YH2	;	1.91	;	TRAPPC3 from Thorarchaeota AB25
7YH3	;	1.7	;	TRAPPC3 from Thorarchaeota SMTZ1-45
7B6X	;	3.6	;	TRAPPCore from the MiniTRAPPIII complex
7B70	;	4.0	;	TRAPPCore plus C8 (355-596) and C11 (1-718) from MiniTRAPPIII
1Y6W	;	2.4	;	Trapped intermediate of calmodulin
5IMW	;	2.89	;	Trapped Toxin
5IMY	;	2.4	;	Trapped Toxin
3KU4	;	2.099	;	Trapping of an oxocarbenium ion intermediate in UP crystals
3KUK	;	2.783	;	Trapping of an oxocarbenium ion intermediate in UP crystals
3KVR	;	2.6	;	Trapping of an oxocarbenium ion intermediate in UP crystals
3KVV	;	1.8	;	Trapping of an oxocarbenium ion intermediate in UP crystals
3KVY	;	2.3	;	Trapping of an oxocarbenium ion intermediate in UP crystals
2Y3E	;	1.449	;	Traptavidin, apo-form
2Y3F	;	1.493	;	Traptavidin, biotin bound form
4HKZ	;	2.08	;	Trastuzumab Fab complexed with Protein L and Protein A fragments
6BI2	;	1.801	;	Trastuzumab Fab D185A (Light Chain) Mutant Biotin Conjugation.
6BHZ	;	1.75	;	Trastuzumab Fab D185A (Light Chain) Mutant.
6BI0	;	2.057	;	Trastuzumab Fab N158A, D185A, K190A (Light Chain) Triple Mutant.
6B9Z	;	1.82	;	Trastuzumab Fab v3
6B9Y	;	2.14	;	Trastuzumab Fab v3 in complex with 5-phenyl meditope variant
6BAE	;	2.14	;	Trastuzumab Fab v3 in complex with CQFDLSTRRLKC
6BAH	;	1.9	;	Trastuzumab Fab v3 with 5-diphenyl meditope variant
7E9U	;	2.1	;	Trehalase of Arabidopsis thaliana
7E9X	;	1.88	;	Trehalase of Arabidopsis thaliana acid mutant -D380A
7EAW	;	1.8	;	Trehalase of Arabidopsis thaliana acid mutant -D380A trehalose complex
4XXH	;	2.4	;	TREHALOSE REPRESSOR FROM ESCHERICHIA COLI
8UQV	;	3.6	;	Trehalose Synthase (TreS) of Mycobacterium tuberculosis in complex with 6-TreAz compound
5X7U	;	2.501	;	Trehalose synthase from Thermobaculum terrenum
6ZJ7	;	2.15	;	Trehalose transferase (TreT) from Thermoproteus uzoniensis soaked with Mg
6ZN1	;	1.75	;	Trehalose transferase bound to alpha-D-glucopyranosyl-beta-galactopyranose from Thermoproteus uzoniensis
6ZJH	;	2.1	;	Trehalose transferase from Thermoproteus uzoniensis soaked with trehalose
1UQT	;	2.0	;	Trehalose-6-phosphate from E. coli bound with UDP-2-fluoro glucose.
1UQU	;	2.0	;	Trehalose-6-phosphate from E. coli bound with UDP-glucose.
5LQD	;	1.95	;	Trehalose-6-phosphate synthase, GDP-glucose-dependent OtsA
1GZ5	;	2.43	;	Trehalose-6-phosphate synthase. OtsA
6XA5	;	1.03	;	Trehalose-bound structure of Marinomonas primoryensis PA14 carbohydrate-binding domain
4H2C	;	1.7	;	Trehalulose synthase MutB R284C mutant
6YMQ	;	3.07	;	TREM2 extracellular domain (19-131) in complex with single-chain variable 4 (scFv-4)
6YYE	;	3.36	;	TREM2 extracellular domain (19-131) in complex with single-chain variable fragment (scFv-2)
6Y6C	;	2.26	;	TREM2 extracellular domain (19-174) in complex with single-chain variable fragment (scFv-4)
1H97	;	1.17	;	Trematode hemoglobin from Paramphistomum epiclitum
2Y3C	;	1.4	;	Treponema denticola variable protein 1
8DHV	;	1.6	;	Treponema lecithinolyticum beta-glucuronidase
8E72	;	1.95	;	Treponema lecithinolyticum beta-glucuronidase in complex with a ciprofloxacin-glucuronide conjugate
8DHW	;	1.75	;	Treponema lecithinolyticum beta-glucuronidase in complex with a UNC4917-glucuronide conjugate
8X7A	;	2.56	;	Treprostinil bound Prostacyclin Receptor G protein complex
3MXI	;	2.55	;	TREX1 3' Exonuclease D18N Familial Chilblain Lupus Mutant
3MXM	;	1.75	;	TREX1 3' Exonuclease V201D Aicardi-Goutieres Syndrome Mutant
7U8Y	;	2.22	;	TREX1 Structural Studies Capture Small Molecule Inhibition and Implicate Novel DNA Dynamics
4YNQ	;	2.8	;	TREX1-dsDNA complex
5UBP	;	2.3	;	TREX2 M-region
7WKD	;	3.01	;	TRH-TRHR G protein complex
6EQO	;	2.7	;	Tri-functional propionyl-CoA synthase of Erythrobacter sp. NAP1 with bound NADP+ and phosphomethylphosphonic acid adenylate ester
1GWG	;	2.01	;	Tri-iodide derivative of apoferritin
1GWD	;	1.77	;	Tri-iodide derivative of hen egg-white lysozyme
1GW9	;	1.55	;	Tri-iodide derivative of Xylose Isomerase from Streptomyces Rubiginosus
1R1N	;	1.74	;	Tri-nuclear oxo-iron clusters in the ferric binding protein from N. gonorrhoeae
2LHW	;		;	Tri-O-GalNAc glycosylated Mucin sequence based on MUC2 Mucin glycoprotein tandem repeat
6VEJ	;	4.5	;	TriABC transporter from Pseudomonas aeruginosa
1ETH	;	2.8	;	TRIACYLGLYCEROL LIPASE/COLIPASE COMPLEX
7JXO	;	2.81	;	Triangular trimer of beta-hairpins derived from Abeta17-36 with an F20Cha mutation
4M0R	;	1.96	;	Trianthranilate-like analogue bound to anthranilate phosphoribosyltransferase (AnPRT; TrpD).
4AXM	;	2.8	;	TRIAZINE CATHEPSIN INHIBITOR COMPLEX
4L9X	;	1.85	;	Triazine hydrolase from Arthobacter aurescens modified for maximum expression in E.coli
4LH8	;	1.8	;	Triazine hydrolase from Arthobacter aurescens modified for maximum expression in E.coli
6VXY	;	1.398	;	Triazole bridged SFTI1 inhibitor in complex with beta-trypsin
7M16	;	1.42	;	Triazole-based BET family bromodomain inhibitor bound to BRD4(D1)
4P7E	;	2.4	;	Triazolopyridine compounds as selective JAK1 inhibitors: from hit identification to GLPG0634
2YIX	;	2.3	;	Triazolopyridine Inhibitors of p38
2YIW	;	2.0	;	triazolopyridine inhibitors of p38 kinase
2YIS	;	2.0	;	triazolopyridine inhibitors of p38 kinase.
4AQC	;	1.9	;	Triazolopyridine-based Inhibitor of Janus Kinase 2
5NJH	;	2.394	;	Triazolopyrimidines stabilize microtubules by binding to the vinca inhibitor site of tubulin
2Y0J	;	2.43	;	Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors, part 2, Lead-optimisation.
6DC0	;	2.8	;	Tribbles (TRIB1) pseudokinase fused to CCAAT-enhancer binding protein (C/EBPalpha) degron
7UPM	;	2.7	;	Tribbles (TRIB2) pseudokinase bound to nanobody Nb4.103
7ZE1	;	3.2	;	Tribolium castaneum hexamerin 2
6KRE	;	4.45	;	TRiC at 0.05 mM ADP-AlFx, Conformation 2, 0.05-C2
6KRD	;	4.38	;	TRiC at 0.05 mM ADP-AlFx, Conformation 4, 0.05-C4
6KS7	;	4.62	;	TRiC at 0.1 mM ADP-AlFx, Conformation 1, 0.1-C1
6KS8	;	4.69	;	TRiC at 0.1 mM ADP-AlFx, Conformation 4, 0.1-C4
6KS6	;	2.99	;	TRiC at 0.2 mM ADP-AlFx, Conformation 1, 0.2-C1
2Q0M	;	1.7	;	Tricarbonylmanganese(I)-lysozyme complex : a structurally characterized organometallic protein
5JBK	;	2.593	;	Trichoderma harzianum GH1 beta-glucosidase ThBgl1
5JBO	;	1.97	;	Trichoderma harzianum GH1 beta-glucosidase ThBgl2
7NDE	;	1.45	;	Trichoderma parareesei PL7A beta-glucuronan lyase
7NYT	;	1.09	;	Trichoderma reesei Cel7A E212Q mutant in complex with lactose.
7OC8	;	1.6	;	Trichoderma reesei Cel7A E212Q mutant in complex with pNPL
4PSE	;	1.71	;	Trichoderma reesei cutinase in complex with a C11Y4 phosphonate inhibitor
7WAC	;	2.91	;	Trichodesmium erythraeum cyanophycin synthetase 1 (TeCphA1)
7WAD	;	2.96	;	Trichodesmium erythraeum cyanophycin synthetase 1 (TeCphA1) with ATPgammaS
7WAF	;	2.52	;	Trichodesmium erythraeum cyanophycin synthetase 1 (TeCphA1) with ATPgammaS and 4x(beta-Asp-Arg)
7WAE	;	2.64	;	Trichodesmium erythraeum cyanophycin synthetase 1 (TeCphA1) with ATPgammaS, 4x(beta-Asp-Arg), and aspartate
6G7Q	;	1.2	;	Trichodesmium Tery_3377 (IdiA) (FutA) in complex with iron and citrate ligands.
6G7N	;	1.1	;	Trichodesmium Tery_3377 (IdiA) (FutA) with iron and alanine ligand.
6G7P	;	1.5	;	Trichodesmium Tery_3377 (IdiA) (FutA) with iron and water ligands.
1JFA	;	2.5	;	Trichodiene Synthase from Fusarium Sporotrichioides
1JFG	;	2.5	;	TRICHODIENE SYNTHASE FROM FUSARIUM SPOROTRICHIOIDES COMPLEXED WITH DIPHOSPHATE
2Q9Z	;	2.95	;	Trichodiene synthase: Complex with inorganic pyrophosphate resulting from the reaction with 2-fluorofarnesyl diphosphate
2Q9Y	;	2.85	;	Trichodiene synthase: Complex with Mg, inorganic pyrophosphate, and benzyl triethyl ammonium cation
4U5Z	;	2.1	;	Trichodysplasia spinulosa-associated polyomavirus (TSPyV) VP1
4U62	;	1.55	;	Trichodysplasia spinulosa-associated polyomavirus (TSPyV) VP1 in complex with 3'-sialyllactose
4U61	;	1.65	;	Trichodysplasia spinulosa-associated polyomavirus (TSPyV) VP1 in complex with 6'-sialyllactose
4U60	;	1.5	;	Trichodysplasia spinulosa-associated polyomavirus (TSPyV) VP1 in complex with GM1 oligosaccharide
6HKU	;	1.98	;	Trichodysplasia spinulosa-associated polyomavirus (TSPyV) VP1 in complex with sialylated precision glycooligomers
6HKV	;	1.75	;	Trichodysplasia spinulosa-associated polyomavirus (TSPyV) VP1 in complex with sialylated precision glycooligomers
4UUN	;	1.78	;	Trichomonas vaginalis lactate dehydrogenase in complex with NADH
5A1T	;	1.97	;	Trichomonas vaginalis lactate dehydrogenase in complex with NADH and oxamate
8OI7	;	1.85	;	Trichomonas vaginalis riboside hydrolase
8OIC	;	2.8	;	Trichomonas vaginalis riboside hydrolase (His-tagged)
8OI9	;	1.95	;	Trichomonas vaginalis riboside hydrolase in complex with 5-methyluridine
8OIA	;	2.3	;	Trichomonas vaginalis riboside hydrolase in complex with D-ribose
8OIB	;	2.44	;	Trichomonas vaginalis riboside hydrolase in complex with glycerol
4RCX	;	1.75	;	Trichomonas vaginalis triosephosphate isomerase TVAG_497370 gene (Ile-45 variant) loop 3 deletion protein
5OI9	;	2.09	;	Trichoplax adhaerens STIL N-terminal domain
1M24	;	0.9	;	Trichotoxin_A50E, An Ion Channel-Forming Polypeptide
3SBN	;	0.9	;	trichovirin I-4A in polar environment at 0.9 Angstroem
6V4M	;	1.599	;	Trichuris suis BCL-2
2F4G	;	1.654	;	Triclinic cross-linked lysozyme soaked in bromoethanol 1M
2F30	;	1.65	;	Triclinic cross-linked Lysozyme soaked with 4.5M urea
2F4A	;	1.95	;	Triclinic cross-linked lysozyme soaked with thiourea 1.5M
6E6A	;	1.95	;	Triclinic crystal form of IncA G144A point mutant
1ZK3	;	2.2	;	Triclinic crystal structure of the apo-form of R-specific alcohol dehydrogenase (mutant G37D) from Lactobacillus brevis
7YZ8	;	2.5	;	Triclinic crystal structure of YTHDF1 YTH domain (544AVV546 mutant)
3PVN	;	1.98	;	Triclinic form of Human C-Reactive Protein in complex with Zinc
1MS4	;	2.21	;	Triclinic form of Trypanosoma cruzi trans-sialidase
1MS8	;	2.0	;	Triclinic form of Trypanosoma cruzi trans-sialidase, in complex with 3-deoxy-2,3-dehydro-N-acetylneuraminic acid (DANA)
1MS9	;	1.58	;	Triclinic form of Trypanosoma cruzi trans-sialidase, in complex with lactose
1MS5	;	2.0	;	Triclinic form of Trypanosoma cruzi trans-sialidase, soaked with N-acetylneuraminyl-a-2,3-thio-galactoside (NA-S-Gal)
2F2N	;	1.603	;	Triclinic hen egg lysozyme cross-linked by glutaraldehyde
1V7S	;	1.14	;	Triclinic hen lysozyme crystallized at 313K from a D2O solution
4YEO	;	0.98	;	Triclinic HEWL co-crystallised with cisplatin, studied at a data collection temperature of 150K - new refinement
7AVF	;	1.0	;	Triclinic hydrogenated hen egg-white lysozyme at 100 K (control)
6D6G	;	2.0	;	Triclinic lysozyme (295 K) in the presence of 47% MPD
6D6E	;	2.0	;	Triclinic lysozyme (295 K) in the presence of 47% xylose
6D6H	;	2.00006	;	Triclinic lysozyme cryocooled to 100 K with 47% MPD as cryoprotectant
6D6F	;	2.0	;	Triclinic lysozyme cryocooled to 100 K with 47% xylose as cryoprotectant
1V7T	;	1.13	;	Triclinic lysozyme with low solvent content obtained by phase transition
4OFM	;	2.64	;	Triclinic NaGST1
3BGY	;	1.65	;	Triclinic structure of Mimivirus Capping Enzyme Triphosphatase at 1.65 A
8G9Q	;	1.4	;	Tricomplex of Compound-1, KRAS G12C, and CypA
8G9P	;	1.5	;	Tricomplex of RMC-4998, KRAS G12C, and CypA
8TBG	;	1.2	;	Tricomplex of RMC-7977, HRAS WT, and CypA
8TBJ	;	1.45	;	Tricomplex of RMC-7977, KRAS G12A, and CypA
8TBK	;	1.26	;	Tricomplex of RMC-7977, KRAS G12C, and CypA
8TBL	;	1.88	;	Tricomplex of RMC-7977, KRAS G12D, and CypA
8TBH	;	1.5	;	Tricomplex of RMC-7977, KRAS G12R, and CypA
8TBN	;	1.46	;	Tricomplex of RMC-7977, KRAS G12S, and CypA
8TBM	;	1.57	;	Tricomplex of RMC-7977, KRAS G12V, and CypA
8TBF	;	1.5	;	Tricomplex of RMC-7977, KRAS WT, and CypA
8TBI	;	1.59	;	Tricomplex of RMC-7977, NRAS WT, and CypA
1N6E	;	2.6	;	tricorn protease in complex with a tridecapeptide chloromethyl ketone derivative
1N6D	;	2.8	;	Tricorn protease in complex with tetrapeptide chloromethyl ketone derivative
1N6F	;	2.7	;	tricorn protease in complex with Z-Phe-diketo-Arg-Glu-Phe
7ZWJ	;		;	Triculamin: an Unusual Lasso Peptide with Potent Anti-mycobacterial Activity
6IAR	;	1.84	;	Tricyclic indazoles a novel class of selective estrogen receptor degrader antagonists
2YJW	;	1.61	;	Tricyclic series of Hsp90 inhibitors
2YJX	;	1.83	;	Tricyclic series of Hsp90 inhibitors
2YK2	;	1.74	;	Tricyclic series of Hsp90 inhibitors
2YK9	;	1.32	;	Tricyclic series of Hsp90 inhibitors
2YKB	;	1.93	;	Tricyclic series of Hsp90 inhibitors
2YKC	;	1.67	;	Tricyclic series of Hsp90 inhibitors
2YKE	;	1.43	;	Tricyclic series of Hsp90 inhibitors
2YKI	;	1.67	;	Tricyclic series of Hsp90 inhibitors
2YKJ	;	1.46	;	Tricyclic series of Hsp90 inhibitors
1TVS	;		;	TRIFLUOROETHANOL STABILIZES A HELIX-TURN-HELIX MOTIF IN EQUINE INFECTIOUS-ANEMIA-VIRUS TRANS-ACTIVATOR PROTEIN
1T11	;	2.5	;	Trigger Factor
1W26	;	2.7	;	Trigger Factor in Complex with the Ribosome forms a Molecular Cradle for Nascent Proteins
1W2B	;	3.5	;	Trigger Factor ribosome binding domain in complex with 50S
5ELI	;	3.0977	;	Triggering receptor expressed on myeloid cells 2
1U27	;	2.3	;	Triglycine variant of the ARNO Pleckstrin Homology Domain in complex with Ins(1,3,4,5)P4
1U29	;	1.8	;	Triglycine variant of the ARNO Pleckstrin Homology Domain in complex with Ins(1,4,5)P3
1U2B	;	1.8	;	Triglycine variant of the Grp1 Pleckstrin Homology Domain unliganded
1DO2	;	4.0	;	TRIGONAL CRYSTAL FORM OF HEAT SHOCK LOCUS U (HSLU) FROM ESCHERICHIA COLI
5D7B	;	3.2	;	Trigonal Crystal Structure of an acetylester hydrolase from Corynebacterium glutamicum
6QI6	;	2.0	;	Trigonal form of WT recombinant bovine beta-lactoglobulin
5N8X	;	2.4	;	Trigonal structure of mutant V173I of 3D polymerase from Foot-and-Mouth Disease Virus
6MMV	;	4.71	;	Triheteromeric NMDA receptor GluN1/GluN2A/GluN2A* Extracellular Domain in the '2-Knuckle-Asymmetric' conformation, in complex with glycine and glutamate, in the presence of 1 micromolar zinc chloride, and at pH 7.4
6MMT	;	7.46	;	Triheteromeric NMDA receptor GluN1/GluN2A/GluN2A* in the '1-Knuckle' conformation, in complex with glycine and glutamate, in the presence of 1 micromolar zinc chloride, and at pH 7.4
6MMU	;	5.3	;	Triheteromeric NMDA receptor GluN1/GluN2A/GluN2A* in the '2-Knuckle-Asymmetric' conformation, in complex with glycine and glutamate, in the presence of 1 micromolar zinc chloride, and at pH 7.4
6MMW	;	6.2	;	Triheteromeric NMDA receptor GluN1/GluN2A/GluN2A* in the '2-Knuckle-Symmetric' conformation, in complex with glycine and glutamate, in the presence of 1 micromolar zinc chloride, and at pH 7.4
6MMS	;	5.38	;	Triheteromeric NMDA receptor GluN1/GluN2A/GluN2A* in the '2-Knuckle-Symmetric' conformation, in complex with glycine and glutamate, in the presence of 1 millimolar EDTA, and at pH 7.4
6MMX	;	6.99	;	Triheteromeric NMDA receptor GluN1/GluN2A/GluN2A* in the 'Extended' conformation, in complex with glycine and glutamate, in the presence of 1 micromolar zinc chloride, and at pH 7.4
5UOW	;	4.5	;	Triheteromeric NMDA receptor GluN1/GluN2A/GluN2B in complex with glycine, glutamate, MK-801 and a GluN2B-specific Fab, at pH 6.5
5UP2	;	6.0	;	Triheteromeric NMDA receptor GluN1/GluN2A/GluN2B in complex with glycine, glutamate, Ro 25-6981, MK-801 and a GluN2B-specific Fab, at pH 6.5
1GWA	;	1.85	;	Triiodide derivative of porcine pancreas elastase
7XV2	;	2.75	;	TRIM E3 ubiquitin ligase
7XYZ	;	4.62	;	TRIM E3 ubiquitin ligase
7XZ0	;	3.28	;	TRIM E3 ubiquitin ligase
7XZ1	;	5.2	;	TRIM E3 ubiquitin ligase
7XZ2	;	3.5	;	TRIM E3 ubiquitin ligase
7XYY	;	7.1	;	TRIM E3 ubiquitin ligase WT
5VA4	;	2.306	;	TRIM-Cyclophilin A B-box 2 and coiled-coil chimera
5OLM	;	1.95	;	TRIM21
5VZV	;	1.812	;	TRIM23 RING domain
5VZW	;	2.278	;	TRIM23 RING domain in complex with UbcH5-Ub
5EYA	;	2.4	;	TRIM25 RING domain in complex with Ubc13-Ub conjugate
7O0B	;	2.13	;	TRIM3 Filamin domain
5FEY	;	2.23	;	TRIM32 RING
5F7T	;	2.292	;	TRIM5 B-box2 and coiled-coil chimera
5IEA	;	3.258	;	TRIM5 B-box2 and coiled-coil chimera
7W0Q	;	1.1	;	TRIM7 in complex with C-terminal peptide of 2C
7W0S	;	1.4	;	TRIM7 in complex with C-terminal peptide of 2C
7W0T	;	1.57	;	TRIM7 in complex with C-terminal peptide of 2C
7X6Z	;	1.43	;	TRIM7 in complex with C-terminal peptide of NSP12
7X6Y	;	1.39	;	TRIM7 in complex with C-terminal peptide of NSP5
7X70	;	1.25	;	TRIM7 in complex with C-terminal peptide of NSP8
8A5L	;	1.622	;	TRIM7 PRYSPRY in complex with a 2BC peptide TIEALFQ
8A8X	;	2.37	;	TRIM7 PRYSPRY in complex with a MNV1-NS3 peptide HDDFGLQ
8A5M	;	2.918	;	TRIM7 PRYSPRY in complex with a MNV1-NS6 peptide LEALEFQ
4DGC	;	2.65	;	TRIMCyp cyclophilin domain from Macaca mulatta: cyclosporin A complex
4DGD	;	1.4	;	TRIMCyp cyclophilin domain from Macaca mulatta: H70C mutant
4DGE	;	2.2	;	TRIMCyp cyclophilin domain from Macaca mulatta: H70C mutant, HIV-1 CA(O-loop) complex
4DGA	;	1.9	;	TRIMCyp cyclophilin domain from Macaca mulatta: HIV-1 CA(O-loop) complex
4DGB	;	1.702	;	TRIMCyp cyclophilin domain from Macaca mulatta: HIV-2 CA cyclophilin-binding loop complex
8F3E	;	3.09	;	Trimer of aminoglycoside efflux pump AcrD
7XS0	;	2.59	;	Trimer structure of HtrA from Helicobacter pylori bound with a tripeptide
7TA3	;	2.5	;	Trimer-to-Monomer Disruption of Tumor Necrosis Factor-alpha (TNF-alpha) by alpha-peptide-3
7TA6	;	2.67	;	Trimer-to-Monomer Disruption of Tumor Necrosis Factor-alpha (TNF-alpha) by unnatural alpha/beta-peptide-1
5Z25	;	1.7	;	Trimeric Alpha-Helix-Inserted Circular Permutant of Cytochrome c555
8OSY	;	1.89	;	Trimeric catalytic domain of the E. coli Dihydrolipoamide Acetyltransferase (E2) of the pyruvate dehydrogenase complex
7DOU	;	3.0	;	Trimeric cement protein structure of Helicobacter pylori bacteriophage KHP40
2EI4	;	2.1	;	Trimeric complex of archaerhodopsin-2
4YPC	;	1.44	;	Trimeric crystal structure of vimentin coil1B fragment
4YV3	;	2.0	;	Trimeric crystal structure of vimentin coil1B fragment
1YVS	;	2.2	;	Trimeric domain swapped barnase
7NG9	;	3.3	;	Trimeric efflux pump Klebsiella TolC
7NG8	;	3.2	;	Trimeric efflux pump Klebsiella TolC in complex with KlebC
1RFO	;		;	Trimeric Foldon of the T4 phagehead fibritin
3F4Z	;	2.1	;	Trimeric helix bundle formed by an alpha/beta-peptide derivative of the HIV gp41 CHR domain
8DEL	;	2.56	;	Trimeric Heme-Free Cytochrome Variant ApoCyt-TriCyt3
1HIW	;	2.3	;	TRIMERIC HIV-1 MATRIX PROTEIN
7LEZ	;	4.15	;	Trimeric human Arginase 1 in complex with mAb1 - 2 hArg:2 mAb1 complex
7LEX	;	3.6	;	Trimeric human Arginase 1 in complex with mAb1 - 2 hArg:3 mAb1 complex
7LF0	;	3.68	;	Trimeric human Arginase 1 in complex with mAb2
7LF1	;	4.04	;	Trimeric human Arginase 1 in complex with mAb3
7LF2	;	3.72	;	Trimeric human Arginase 1 in complex with mAb4
7LEY	;	3.05	;	Trimeric human Arginase 1 in complex with mAb5
5ONU	;	2.22	;	Trimeric OmpU structure
6VPV	;	2.7	;	Trimeric Photosystem I from the High-Light Tolerant Cyanobacteria Cyanobacterium Aponinum
7NTC	;	3.6	;	Trimeric SARS-CoV-2 spike ectodomain bound to P008_056 Fab
7NT9	;	3.36	;	Trimeric SARS-CoV-2 spike ectodomain in complex with biliverdin (closed conformation)
7NTA	;	3.5	;	Trimeric SARS-CoV-2 spike ectodomain in complex with biliverdin (one RBD erect)
1RTM	;	1.8	;	TRIMERIC STRUCTURE OF A C-TYPE MANNOSE-BINDING PROTEIN
6AHG	;	2.83	;	Trimeric structure of concanavalin A from Canavalia ensiformis
6JJJ	;	2.792	;	Trimeric structure of Kupffer cell C-type lectin receptor Clec4f
3KQG	;	2.3	;	Trimeric Structure of Langerin
5NXR	;	2.7	;	Trimeric structure of Omp-Pst1, the major porin from Providencia stuartii
1WCR	;		;	Trimeric Structure of the Enzyme IIA from Escherichia coli Phosphotransferase System Specific for N,N'-Diacetylchitobiose
5Z81	;	2.334	;	Trimeric structure of Vibrio cholerae Heat Shock Protein 15 at 2.3 Angstrom resolution
1CE0	;	2.4	;	TRIMERIZATION SPECIFICITY IN HIV-1 GP41: ANALYSIS WITH A GCN4 LEUCINE ZIPPER MODEL
5H21	;	1.591	;	Trimethoxy-ring inhibitor in complex with the first bromodomain of BRD4
1TMO	;	2.5	;	TRIMETHYLAMINE N-OXIDE REDUCTASE FROM SHEWANELLA MASSILIA
7ZEZ	;		;	Trimolecular complex Cyp33-RRMdelta alpha : MLL1-PHD3 : H3K4me3
6M05	;		;	Trimolecular G-quadruplex
7V6V	;		;	trimolecular G-quadruplexes consists of a hairpin motif and two short chains
7PEU	;	7.2	;	Trinucleosome of the 4x177 nucleosome array containing H1
7PF0	;	11.0	;	Trinucleosome of the 4x177 nucleosome array containing H1
7PFA	;	9.7	;	Trinucleosome of the 4x197 nucleosome array containing H1
7PFT	;	9.8	;	Trinucleosome of the 4x207 nucleosome array containing H1
8TIM	;	2.5	;	TRIOSE PHOSPHATE ISOMERASE
1YDV	;	2.2	;	TRIOSEPHOSPHATE ISOMERASE (TIM)
1BTM	;	2.8	;	TRIOSEPHOSPHATE ISOMERASE (TIM) COMPLEXED WITH 2-PHOSPHOGLYCOLIC ACID
6UP1	;	1.83	;	Triosephosphate isomerase deficiency: Effect of F240L mutation on enzyme structure
6UP5	;	1.92	;	Triosephosphate isomerase deficiency: Effect of F240L mutation on enzyme structure
6UP8	;	2.0	;	Triosephosphate isomerase deficiency: Effect of F240L mutation on enzyme structure
6UPF	;	1.65	;	Triosephosphate isomerase deficiency: Effect of F240L mutation on enzyme structure
1TPW	;	1.9	;	TRIOSEPHOSPHATE ISOMERASE DRINKS WATER TO KEEP HEALTHY
1SW0	;	1.71	;	Triosephosphate isomerase from Gallus gallus, loop 6 hinge mutant K174L, T175W
1SW7	;	2.22	;	Triosephosphate isomerase from Gallus gallus, loop 6 mutant K174N, T175S, A176S
1SW3	;	2.03	;	Triosephosphate isomerase from Gallus gallus, loop 6 mutant T175V
6R8H	;	1.9	;	Triosephosphate isomerase from liver fluke (Fasciola hepatica).
1W0M	;	2.5	;	Triosephosphate isomerase from Thermoproteus tenax
1NEY	;	1.2	;	Triosephosphate Isomerase in Complex with DHAP
1NF0	;	1.6	;	Triosephosphate Isomerase in Complex with DHAP
6BVE	;	1.78	;	Triosephosphate isomerase of Synechocystis in complex with 2-Phosphoglycolic acid
1B9B	;	2.85	;	TRIOSEPHOSPHATE ISOMERASE OF THERMOTOGA MARITIMA
1AW2	;	2.65	;	TRIOSEPHOSPHATE ISOMERASE OF VIBRIO MARINUS
1AW1	;	2.7	;	TRIOSEPHOSPHATE ISOMERASE OF VIBRIO MARINUS COMPLEXED WITH 2-PHOSPHOGLYCOLATE
6JOX	;	1.803	;	triosephosphate isomerase-scylla paramamosain
5VWN	;	1.74	;	Triosephosphate isomerases deletion loop 3 from Trichomonas vaginalis
4HP7	;	1.09	;	Trioxacarcin D517 as a product of guanine robbery from d(AACCGGTT)
4EQF	;	3.0	;	Trip8b-1a#206-567 interacting with the carboxy-terminal seven residues of HCN2
7NS8	;	2.3	;	Triphosphate tunnel metalloenzyme from Sulfolobus acidocaldarius
7NSD	;	2.19	;	Triphosphate tunnel metalloenzyme from Sulfolobus acidocaldarius in complex with ATP and calcium
7OA2	;	2.7	;	Triphosphate tunnel metalloenzyme from Sulfolobus acidocaldarius in complex with pyrophosphate
7NSA	;	1.95	;	Triphosphate tunnel metalloenzyme from Sulfolobus acidocaldarius in complex with pyrophosphate and calcium
7NS9	;	1.75	;	Triphosphate tunnel metalloenzyme from Sulfolobus acidocaldarius in complex with triphosphate and calcium
7NSF	;	2.0	;	Triphosphate tunnel metalloenzyme from Sulfolobus acidocaldarius in complex with triphosphate and magnesium
4KHT	;	2.817	;	Triple helix bundle of GP41 complexed with fab 8066
3G5N	;	2.5	;	Triple ligand occupancy crystal structure of cytochrome P450 2B4 in complex with the inhibitor 1-biphenyl-4-methyl-1H-imidazole
7LWW	;	3.0	;	Triple mutant (K417N-E484K-N501Y) SARS-CoV-2 spike protein in the 1-RBD-up conformation (S-GSAS-D614G-K417N-E484K-N501Y)
8CSA	;	3.84	;	Triple mutant (K417N-E484K-N501Y) SARS-CoV-2 spike protein in the 3-RBD-Down conformation (S-GSAS-D614G-K417N-E484K-N501Y)
2ATB	;	1.6	;	Triple mutant 8D9D10V of scorpion toxin LQH-alpha-IT
3CFO	;	2.6	;	Triple Mutant APO structure
4J4Y	;	2.45	;	Triple mutant GraVN
4J4S	;	2.442	;	Triple mutant SFTAVN
4F59	;	1.71	;	Triple mutant Src SH2 domain
4F5A	;	1.8	;	Triple mutant Src SH2 domain bound to phosphate ion
4F5B	;	1.57	;	Triple mutant Src SH2 domain bound to phosphotyrosine
1TP0	;	2.2	;	Triple mutation in interleukin 1 beta cavity:replacement of phenylalanines with tryptophan.
3AI6	;	1.1	;	Triple-helical structure of (D-Pro-D-Pro-Gly)9 at 1.1 A resolution
1E40	;	2.2	;	Tris/maltotriose complex of chimaeric amylase from B. amyloliquefaciens and B. licheniformis at 2.2A
8H8I	;	2.03	;	Triterpenoid saponin acetyltransferase, AmAT7-3
6XIX	;	2.1	;	Triuret Hydrolase (TrtA) from Herbaspirillum sp. BH-1
6XJ4	;	1.78	;	Triuret Hydrolase (TrtA) from Herbaspirillum sp. BH-1 C162S bound with biuret
6XJE	;	1.45	;	Triuret Hydrolase (TrtA) from Herbaspirillum sp. BH-1 C162S bound with triuret
1NQB	;	2.0	;	TRIVALENT ANTIBODY FRAGMENT
2D39	;	1.9	;	Trivalent Recognition Unit of Innate Immunity System; Crystal Structure of human M-ficolin Fibrinogen-like Domain
6PMA	;	2.53	;	TRK-A IN COMPLEX WITH LIGAND
6PME	;	3.0	;	TRK-A IN COMPLEX WITH LIGAND
6NPT	;	2.19	;	TRK-A IN COMPLEX WITH LIGAND 1
6PL4	;	2.06	;	TRK-A IN COMPLEX WITH LIGAND 1
6PL2	;	2.59	;	TRK-A IN COMPLEX WITH LIGAND 1a
6PMB	;	2.81	;	TRK-A IN COMPLEX WITH LIGAND 1a
6PMC	;	2.19	;	TRK-A IN COMPLEX WITH LIGAND 1a
6PL1	;	2.03	;	TRK-A IN COMPLEX WITH LIGAND 1B
6PL3	;	3.0	;	TRK-A IN COMPLEX WITH LIGAND 2a
6NSS	;	1.97	;	TRK-A IN COMPLEX WITH LIGAND 6
6NSP	;	2.31	;	TRK-A IN COMPLEX WITH LIGAND 9
7N3T	;	1.84	;	TrkA ECD complex with designed miniprotein ligand
5KMM	;	2.12	;	TrkA JM-kinase with 1-(2-methyl-4-phenyl-pyrimidin-5-yl)-3-(1-naphthyl)urea
5KMO	;	2.67	;	TrkA JM-kinase with 1-(2-methyl-4-phenyl-pyrimidin-5-yl)-3-(2-pyridyl)urea
5KMN	;	2.14	;	TrkA JM-kinase with 1-(2-methyl-4-phenyl-pyrimidin-5-yl)-3-[[2-(trifluoromethyl)phenyl]methyl]urea
5KML	;	2.01	;	TrkA JM-kinase with 1-(5-methyl-3-phenyl-1,2-oxazol-4-yl)-3-[[2-(trifluoromethyl)phenyl]methyl]urea
5KMI	;	1.87	;	TrkA JM-kinase with 1-(9{H}-fluoren-9-yl)-3-(2-methyl-4-phenyl-pyrimidin-5-yl)urea
5KMK	;	2.24	;	TrkA JM-kinase with 2-fluoro-{N}-[2-(4-fluorophenyl)-6-methyl-3-pyridyl]-4-(trifluoromethyl)benzamide
5KMJ	;	2.04	;	TrkA JM-kinase with {N}-(2-pyridylmethyl)-2-[2-(2-thienyl)indol-1-yl]acetamide
2N90	;		;	TrkA transmembrane domain NMR structure in DPC micelles
5I8A	;	2.33	;	TrkA with (6~{R})-3-methylsulfanyl-6-phenyl-1-(1~{H}-pyrazol-3-yl)-6,7-dihydro-5~{H}-thieno[3,4-c]pyridin-4-one
7SSC	;	1.8	;	TRL345 lineage ancestor I8 Fab bound to an HCMV gB-derived peptide
7NZI	;	3.1	;	TrmB complex with SAH
7NYB	;	2.5	;	TrmB complex with SAM
1V2X	;	1.5	;	TrmH
2L9X	;		;	Trn- peptide of the two-component bacteriocin Thuricin CD
2LA0	;		;	Trn- peptide of the two-component bacteriocin Thuricin CD
8FCI	;	1.752	;	tRNA (N1G37) Methyltransferase (TrmD) of Mycobacterium avium complexed with S-Adenosyl homocysteine
6E3A	;	1.4	;	tRNA 2'-phosphotransferase
6EDE	;	1.553	;	tRNA 2'-phosphotransferase
8TG3	;	1.47	;	tRNA 2'-phosphotransferase (Tpt1) from Aeropyrum pernix in complex with ADP-ribose-1"" -phosphate
8TG4	;	1.37	;	tRNA 2'-phosphotransferase (Tpt1) from Aeropyrum pernix in complex with ADP-ribose-2""-phosphate and 2'-OH RNA
8TG6	;	1.6	;	tRNA 2'-phosphotransferase (Tpt1) from Aeropyrum pernix in complex with sulfate anions
8TFI	;	1.97	;	tRNA 2'-phosphotransferase (Tpt1) from Pyrococcus horikoshii
8TFX	;	1.7	;	tRNA 2'-phosphotransferase (Tpt1) from Pyrococcus horikoshii in complex with 2',5'-ADP
8TFZ	;	2.06	;	tRNA 2'-phosphotransferase (Tpt1) from Pyrococcus horikoshii in complex with NAD
8TFY	;	1.54	;	tRNA 2'-phosphotransferase (Tpt1) from Pyrococcus horikoshii in complex with NADP
2POT	;	1.8	;	tRNA guanine transglycosylase (TGT) E235Q mutant in complex with guanine
5LPS	;	1.27	;	tRNA guanine Transglycosylase (TGT) in co-crystallized complex (space group C2) with 6-amino-2-(methylamino)-4-(2-((2R,3R,4S,5R,6S)-3,4,5,6-tetramethoxytetrahydro-2H-pyran-2-yl)ethyl)-1H-imidazo[4,5-g]quinazolin-8(7H)-one
5LPP	;	1.99	;	tRNA guanine Transglycosylase (TGT) in co-crystallized complex (space group C2) with 6-amino-4-(2-((3aR,4R,6R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)ethyl)-2-(methylamino)-1H-imidazo[4,5-g]quinazolin-8(7H)-one
5LPT	;	2.36	;	tRNA guanine Transglycosylase (TGT) in co-crystallized complex (space group P21) with 6-amino-2-(methylamino)-4-(2-((2R,3R,4S,5R,6S)-3,4,5,6-tetramethoxytetrahydro-2H-pyran-2-yl)ethyl)-1H-imidazo[4,5-g]quinazolin-8(7H)-one
5LPQ	;	2.52	;	tRNA guanine Transglycosylase (TGT) in co-crystallized complex (space group P21) with 6-amino-4-(2-((3aR,4R,6R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)ethyl)-2-(methylamino)-1H-imidazo[4,5-g]quinazolin-8(7H)-one
5JT7	;	1.7	;	tRNA guanine Transglycosylase (TGT) in co-crystallized complex with 1-(2-((2-morpholinoethyl)amino)-1H-benzo[d]imidazol-6-yl)guanidine
5J9O	;	1.41	;	tRNA guanine Transglycosylase (TGT) in co-crystallized complex with 1-(2-(methylamino)-1H-benzo[d]imidazol-6-yl)guanidine
5JT6	;	1.54	;	tRNA guanine Transglycosylase (TGT) in co-crystallized complex with 2-((2-morpholinoethyl)amino)-1H-benzo[d]imidazole-5-carbohydrazide
5JT5	;	1.21	;	tRNA guanine Transglycosylase (TGT) in co-crystallized complex with 2-((2-morpholinoethyl)amino)-1H-benzo[d]imidazole-5-carboxamide
5J9N	;	1.64	;	tRNA guanine Transglycosylase (TGT) in co-crystallized complex with 2-(methylamino)-1H-benzo[d]imidazole-5-carbohydrazide
5J9M	;	1.33	;	tRNA guanine Transglycosylase (TGT) in co-crystallized complex with 2-(methylamino)-1H-benzo[d]imidazole-5-carboxamide
6FMN	;	1.36	;	tRNA guanine Transglycosylase (TGT) in co-crystallized complex with 6-amino-2-((((2R,3S,4R,5R)-3,4-dihydroxy-5-methoxytetrahydrofuran-2-yl)methyl)amino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
5JSW	;	1.22	;	tRNA guanine Transglycosylase (TGT) in co-crystallized complex with 6-amino-2-((((3a'R,6'R,6a'R)-2,2,2',2'-tetramethyldihydro-3a'H-spiro[[1,3]dioxolane-4,4'-furo[3,4-d][1,3]dioxol]-6'-yl)methyl)amino)-1H-imidazo[4,5-g]quinazolin-8(7H)-one
5JSV	;	1.17	;	tRNA guanine Transglycosylase (TGT) in co-crystallized complex with 6-amino-2-((((3aR,4R,6R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)amino)-1H-imidazo[4,5-g]quinazolin-8(7H)-one
6FPU	;	1.36	;	tRNA guanine Transglycosylase (TGT) in co-crystallized complex with 6-amino-2-((((3aS,5aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-3a-yl)methyl)amino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
5LPO	;	1.42	;	tRNA guanine Transglycosylase (TGT) in co-crystallized complex with 6-amino-2-(methylamino)-4-(2-((2R,3R,4R,5R)-3,4,5-trimethoxytetrahydrofuran-2-yl)ethyl)-1H-imidazo[4,5-g]quinazolin-8(7H)-one
5I07	;	1.89	;	tRNA guanine Transglycosylase (TGT) in co-crystallized complex with 6-Amino-4-(2-phenylethyl)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
5I02	;	1.25	;	tRNA guanine transglycosylase (TGT) in co-crystallized complex with 6-amino-4-{2-[(cyclohexylmethyl)amino]ethyl}-2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
5I00	;	1.49	;	tRNA guanine transglycosylase (TGT) in co-crystallized complex with 6-amino-4-{2-[(cyclopentylmethyl)amino]ethyl}-2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
5JGO	;	1.37	;	tRNA guanine Transglycosylase (TGT) in co-crystallized complex with allyl (2-(methylamino)-8-oxo-7,8-dihydro-1H-imidazo[4,5-g]quinazolin-6-yl)carbamate
5JGM	;	1.38	;	tRNA guanine Transglycosylase (TGT) in co-crystallized complex with ethyl (2-(methylamino)-8-oxo-7,8-dihydro-1H-imidazo[4,5-g]quinazolin-6-yl)carbamate
5EGR	;	1.55	;	tRNA guanine transglycosylase (TGT) in complex with an Immucillin derivative
4LEQ	;	1.405	;	tRNA guanine transglycosylase (TGT) in complex with Furanoside-Based lin-Benzoguanine 1
4LBU	;	1.17	;	tRNA guanine transglycosylase (TGT) in complex with Furanoside-Based lin-Benzoguanine 2
4KWO	;	1.32	;	tRNA guanine transglycosylase (TGT) in complex with Furanoside-Based lin-Benzoguanine 3
5I09	;	1.44	;	tRNA guanine transglycosylase (TGT) in soaked complex with Furanoside-Based lin-Benzoguanine 3
6YGZ	;	1.86	;	tRNA Guanine Transglycosylase (TGT) labelled with 5-fluoro-tryptophan in co-crystallized complex with 6-Amino-4-(2-phenylethyl)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
2Z1V	;	1.55	;	tRNA guanine transglycosylase E235Q mutant apo structure, pH 8.5
2PWV	;	1.7	;	tRNA guanine transglycosylase E235Q mutant in complex with preQ0
2Z1X	;	1.63	;	tRNA guanine transglycosylase E235Q mutant in complex with preQ1
6H7C	;	1.681	;	tRNA guanine transglycosylase H333A mutant apo structure
4L56	;	1.7	;	tRNA guanine transglycosylase H333D mutant apo structure
4GI4	;	1.97	;	tRNA Guanine Transglycosylase in complex with disubstituted lin-benzoguanine inhibitor
4GIY	;	1.75	;	tRNA Guanine Transglycosylase in complex with disubstituted lin-benzoguanine inhibitor
4GKT	;	1.53	;	tRNA Guanine Transglycosylase in complex with disubstituted lin-benzoguanine inhibitor
2PWU	;	1.77	;	tRNA guanine transglycosylase in complex with guanine
4GH1	;	1.45	;	tRNA Guanine Transglycosylase in complex with morpholine substituted lin-benzohypoxanthine inhibitor
4GH3	;	2.06	;	tRNA Guanine Transglycosylase in complex with phenethyl substituted lin-benzohypoxanthine inhibitor
4GG9	;	1.48	;	tRNA Guanine Transglycosylase in complex with thiophene-substituted lin-benzohypoxanthine inhibitor
2Z1W	;	1.63	;	tRNA guanine transglycosylase TGT E235Q mutant in complex with BDI (2-BUTYL-5,6-DIHYDRO-1H-IMIDAZO[4,5-D]PYRIDAZINE-4,7-DIONE)
3BL3	;	2.25	;	tRNA guanine transglycosylase V233G mutant apo structure
3BLD	;	1.19	;	tRNA guanine transglycosylase V233G mutant preQ1 complex structure
6N0T	;	2.511	;	tRNA ligase
6N0V	;	2.502	;	tRNA ligase
8AFJ	;	1.6	;	tRNA modifying enzyme MiaE soaked in Na-dithionite in a glovebox and flash-cooled using a miniature-airlock
1FCW	;	17.0	;	TRNA POSITIONS DURING THE ELONGATION CYCLE
3WFO	;	3.4	;	tRNA processing enzyme (apo form 1)
3WFP	;	4.005	;	tRNA processing enzyme (apo form 2)
3WFQ	;	3.619	;	tRNA processing enzyme complex 1
3WFR	;	3.501	;	tRNA processing enzyme complex 2
3WFS	;	3.311	;	tRNA processing enzyme complex 3
8Q70	;	1.85	;	tRNA pseudouridine synthase A homodimer
7UQ6	;	2.951	;	tRNA T-box antiterminator fusion, construct #4
4V5M	;	7.8	;	tRNA tranlocation on the 70S ribosome: the pre-translocational translocation intermediate TI(PRE)
6GZ3	;	3.6	;	tRNA translocation by the eukaryotic 80S ribosome and the impact of GTP hydrolysis, Translocation-intermediate-POST-1 (TI-POST-1)
6GZ4	;	3.6	;	tRNA translocation by the eukaryotic 80S ribosome and the impact of GTP hydrolysis, Translocation-intermediate-POST-2 (TI-POST-2)
6GZ5	;	3.5	;	tRNA translocation by the eukaryotic 80S ribosome and the impact of GTP hydrolysis, Translocation-intermediate-POST-3 (TI-POST-3)
4V5N	;	7.6	;	tRNA translocation on the 70S ribosome: the post- translocational translocation intermediate TI(POST)
3B0P	;	1.7	;	tRNA-dihydrouridine synthase from Thermus thermophilus
3B0V	;	3.51	;	tRNA-dihydrouridine synthase from Thermus thermophilus in complex with tRNA
3B0U	;	1.948	;	tRNA-dihydrouridine synthase from Thermus thermophilus in complex with tRNA fragment
1PUD	;	1.85	;	TRNA-GUANINE TRANSGLYCOSYLASE
1WKD	;	2.6	;	TRNA-GUANINE TRANSGLYCOSYLASE
1WKE	;	2.2	;	TRNA-GUANINE TRANSGLYCOSYLASE
1WKF	;	2.2	;	TRNA-GUANINE TRANSGLYCOSYLASE
4PUN	;	1.25	;	tRNA-Guanine Transglycosylase (TGT) Apo-Structure pH 7.8
6YRY	;	1.82	;	tRNA-Guanine Transglycosylase (TGT) H333A mutant crystallised at pH 5.5
6Z0D	;	1.65	;	tRNA-Guanine Transglycosylase (TGT) H333F mutant crystallised at pH 5.5
6YIQ	;	1.58	;	tRNA-Guanine Transglycosylase (TGT) in co-crystallized complex (P2) with 6-amino-2-(methylamino)-4-phenethyl-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
6YGV	;	1.63	;	tRNA-Guanine Transglycosylase (TGT) in co-crystallized complex with (E)-N-ethyl-4-oxo-4-phenylbut-2-enamide
6YGS	;	1.4	;	tRNA-guanine Transglycosylase (TGT) in co-crystallized complex with 6-amino-2-(methylamino)-4-(4-(trifluoromethyl)phenethyl)-3,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
6YH3	;	1.49	;	tRNA-Guanine Transglycosylase (TGT) in co-crystallized complex with 6-amino-2-(methylamino)-4-phenethyl-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
6YGR	;	1.7	;	tRNA-guanine Transglycosylase (TGT) in co-crystallized complex with 6-Amino-4-(2-phenylethyl)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
5I06	;	1.36	;	tRNA-guanine Transglycosylase (TGT) in co-crystallized complex with 6-Amino-4-[2-(4-methoxyphenyl)ethyl]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
5I03	;	1.73	;	tRNA-guanine Transglycosylase (TGT) in co-crystallized complex with 6-Amino-4-[2-(4-methylphenyl)ethyl]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
2Z7K	;	1.28	;	tRNA-Guanine transglycosylase (TGT) in complex with 2-Amino-lin-Benzoguanine
4Q4Q	;	1.41	;	tRNA-Guanine Transglycosylase (TGT) in Complex with 2-[(Thiophen-2-ylmethyl)amino]-1H,7H,8H-imidazo[4,5-g]quinazolin-8-one
4Q4R	;	1.448	;	tRNA-Guanine Transglycosylase (TGT) in Complex with 2-{[2-(Morpholin-4-yl)ethyl]amino}-1H,7H,8H-imidazo[4,5-g]quinazolin-8-one
4Q4P	;	1.539	;	tRNA-Guanine Transglycosylase (TGT) in Complex with 2-{[2-(PIPERIDIN-1-YL)ETHYL]AMINO}-3,5-DIHYDRO-8H-IMIDAZO[4,5-G]QUINAZOLIN-8-ONE
4Q8W	;	1.14	;	tRNA-Guanine Transglycosylase (TGT) in Complex with 4-[2-({6-Amino-8-oxo-1H,7H,8H-imidazo[4,5-g]quinazolin-2-yl}amino)ethyl]benzoic acid
4Q8V	;	1.396	;	tRNA-Guanine Transglycosylase (TGT) in Complex with 4-[2-({6-Amino-8-oxo-1H,7H,8H-imidazo[4,5-g]quinazolin-2-yl}amino)ethyl]benzonitrile
4PUK	;	1.49	;	tRNA-Guanine Transglycosylase (TGT) in Complex with 6-Amino-2-(methylamino)-1H,7H,8H-imidazo[4,5-g]quinazolin-8-one
3C2Y	;	1.78	;	tRNA-Guanine Transglycosylase (TGT) in complex with 6-Amino-2-methyl-1,7-dihydro-imidazo[4,5-g]quinazolin-8-one
4Q8T	;	1.4	;	tRNA-Guanine Transglycosylase (TGT) in Complex with 6-Amino-2-[(2-phenylethyl)amino]-1H,7H,8H-imidazo[4,5-g]quinazolin-8-one
4Q4S	;	1.249	;	tRNA-Guanine Transglycosylase (TGT) in Complex with 6-Amino-2-[(thiophen-2-ylmethyl)amino]-1H,7H,8H-imidazo[4,5-g]quinazolin-8-one
4PUJ	;	1.42	;	tRNA-Guanine Transglycosylase (TGT) in Complex with 6-Amino-2-{[2-(morpholin-4-yl)ethyl]amino}-1H,7H,8H-imidazo[4,5-g]quinazolin-8-one
4Q4O	;	1.35	;	tRNA-Guanine Transglycosylase (TGT) in Complex with 6-Amino-2-{[2-(piperidin-1-yl)ethyl]amino}-1H,7H,8H-imidazo[4,5-g]quinazolin-8-one
5JXQ	;	1.2	;	TRNA-GUANINE TRANSGLYCOSYLASE (TGT) IN COMPLEX WITH 6-AMINO-2-{[4-(2-HYDROXYETHYL)PHENETHYL]AMINO}-1,7-DIHYDRO-8H-IMIDAZO[4,5-g]QUINAZOLIN-8-ONE
1Y5V	;	1.58	;	tRNA-Guanine Transglycosylase (TGT) in complex with 6-Amino-4-(2-phenylethyl)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
4Q4M	;	1.621	;	tRNA-Guanine Transglycosylase (TGT) in Complex with 6-Amino-4-phenyl-1,2-dihydro-1,3,5-triazin-2-one
1Y5X	;	2.1	;	tRNA-guanine Transglycosylase (TGT) in complex with 6-Amino-4-[2-(4-methoxyphenyl)ethyl]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
1Y5W	;	1.58	;	tRNA-guanine Transglycosylase (TGT) in complex with 6-Amino-4-[2-(4-methylphenyl)ethyl]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
4Q8U	;	1.31	;	tRNA-Guanine Transglycosylase (TGT) in Complex with Methyl 4-[2-({6-amino-8-oxo-1H,7H,8H-imidazo[4,5-g]quinazolin-2-yl}amino)ethyl]benzoate
6YH2	;	1.19	;	tRNA-guanine Transglycosylase (TGT) labeled with 5-fluorotryptophan in co-crystallized complex with 2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
6YYZ	;	1.21	;	tRNA-Guanine Transglycosylase (TGT) labeled with 5-fluorotryptophan in co-crystallized complex with 6-amino-2-(methylamino)-4-(2-((2R,3R,4R,5R)-3,4,5-trimethoxytetrahydrofuran-2-yl)ethyl)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
6YGX	;	1.35	;	tRNA-guanine Transglycosylase (TGT) labeled with 5-fluorotryptophan in co-crystallized complex with 6-amino-2-(methylamino)-4-(2-((2R,3R,4S,5R,6S)-3,4,5,6-tetramethoxytetrahydro-2H-pyran-2-yl)ethyl)-1H-imidazo[4,5-g]quinazolin-8(7H)-one
6YH1	;	1.55	;	tRNA-guanine Transglycosylase (TGT) labeled with 5-fluorotryptophan in co-crystallized complex with 6-amino-2-(methylamino)-4-(4-(trifluoromethyl)phenethyl)-3,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
6YHD	;	1.25	;	tRNA-guanine Transglycosylase (TGT) labeled with 5-fluorotryptophan in co-crystallized complex with 6-amino-4-(2-((2R,3S,4R,5R)-3,4-dihydroxy-5-methoxytetrahydrofuran-2-yl)ethyl)-2-(methylamino)-3,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
6YHE	;	1.54	;	tRNA-Guanine Transglycosylase (TGT) labeled with 5-fluorotryptophan in co-crystallized complex with 6-amino-4-(2-((3aR,4R,6R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)ethyl)-2-(methylamino)-1H-imidazo[4,5-g]quinazolin-8(7H)-one
6YGY	;	1.52	;	tRNA-Guanine Transglycosylase (TGT) labeled with 5-fluorotryptophan in co-crystallized complex with 6-Amino-4-[2-(4-methylphenyl)ethyl]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
4PUL	;	1.654	;	tRNA-Guanine Transglycosylase (TGT) Mutant D102N in Complex with 6-Amino-2-(methylamino)-1H,7H,8H-imidazo[4,5-g]quinazolin-8-one
4PUM	;	1.93	;	tRNA-Guanine Transglycosylase (TGT) Mutant D156N in Complex with 6-Amino-2-(methylamino)-1H,7H,8H-imidazo[4,5-g]quinazolin-8-one
2NQZ	;	1.46	;	Trna-guanine transglycosylase (TGT) mutant in complex with 7-deaza-7-aminomethyl-guanine
4Q8N	;	1.449	;	tRNA-Guanine Transglycosylase (TGT) Mutant V262C Apo Structure
4Q8Q	;	1.721	;	tRNA-Guanine Transglycosylase (TGT) Mutant V262C in Complex with 6-Amino-2-{[2-(morpholin-4-yl)ethyl]amino}-1H,7H,8H-imidazo[4,5-g]quinazolin-8-one
4Q8P	;	1.45	;	tRNA-Guanine Transglycosylase (TGT) Mutant V262D in Complex with 6-Amino-2-{[2-(morpholin-4-yl)ethyl]amino}-1H,7H,8H-imidazo[4,5-g]quinazolin-8-one
4Q8M	;	1.241	;	tRNA-Guanine Transglycosylase (TGT) Mutant V262T Apo Structure
4Q8O	;	1.887	;	tRNA-Guanine Transglycosylase (TGT) Mutant V262T in Complex with 6-Amino-2-{[2-(morpholin-4-yl)ethyl]amino}-1H,7H,8H-imidazo[4,5-g]quinazolin-8-one
3UVI	;	1.55	;	tRNA-guanine transglycosylase C158S C281S W326E E339Q mutant
7A3V	;	1.7	;	tRNA-guanine transglycosylase C158S/C281S/Y330C/H333A mutant in complex with 3-hydroxysulfolane
7A4X	;	2.05	;	tRNA-guanine transglycosylase C158S/C281S/Y330C/H333A mutant in complex with dimethyl sulfoxide
7A9E	;	1.76	;	tRNA-guanine transglycosylase C158S/C281S/Y330C/H333A mutant in complex with ethyl methyl sulfone
7A0B	;	1.77	;	tRNA-guanine transglycosylase C158S/C281S/Y330C/H333A mutant in complex with rac-trans-3,4-dihydroxysulfolane
7A6D	;	1.59	;	tRNA-guanine transglycosylase C158S/C281S/Y330C/H333A mutant in complex with rac-trans-4,4-difluorocyclopentane-1,2-diol
7A3X	;	1.85	;	tRNA-guanine transglycosylase C158S/C281S/Y330C/H333A mutant in complex with sulfolane
7A4K	;	1.68	;	tRNA-guanine transglycosylase C158S/C281S/Y330C/H333A mutant in complex with tetramethylene sulfoxide
4FR1	;	1.74	;	tRNA-Guanine Transglycosylase cocrystallized with alkine-substituted lin-benzoguanine ligand
4FR6	;	1.59	;	tRNA-Guanine Transglycosylase cocrystallized with pyridyl-alkine-substituted lin-benzoguanine ligand
3UNT	;	1.801	;	tRNA-guanine transglycosylase E339Q mutant
4DY1	;	2.045	;	tRNA-guanine transglycosylase F92C C158S C281S mutant
7APL	;	1.99	;	tRNA-guanine transglycosylase G87C mutant spin-labeled with MTSL
7APM	;	1.66	;	tRNA-guanine transglycosylase H319C mutant spin-labeled with MTSL.
3GC5	;	1.4	;	tRNA-guanine transglycosylase in complex with 6-amino-4-(2-aminoethyl)-2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
3EOU	;	1.93	;	tRNA-guanine transglycosylase in complex with 6-amino-4-(2-hydroxyethyl)-2-(methylamino)-3,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
3EOS	;	1.78	;	tRNA-guanine transglycosylase in complex with 6-amino-4-{2-[(cyclohexylmethyl)amino]ethyl}-2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
3GE7	;	1.5	;	tRNA-guanine transglycosylase in complex with 6-amino-4-{2-[(cyclopentylmethyl)amino]ethyl}-2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
4FPS	;	1.45	;	tRNA-Guanine Transglycosylase in complex with adamantyl-substituted lin-benzoguanine ligand
3GC4	;	1.8	;	tRNA-guanine transglycosylase in complex with inhibitor
3S1G	;	1.82	;	tRNA-Guanine Transglycosylase in complex with lin-Benzohypoxanthine Inhibitor
3SM0	;	1.57	;	tRNA-Guanine Transglycosylase in complex with lin-Benzohypoxanthine Inhibitor
3TLL	;	1.37	;	tRNA-Guanine Transglycosylase in complex with N-Ethyl-lin-benzoguanine Inhibitor
3RR4	;	1.68	;	tRNA-Guanine Transglycosylase in complex with N-Methyl-lin-Benzoguanine Inhibitor
4FSA	;	1.62	;	tRNA-Guanine Transglycosylase soaked with pyridyl-alkine-substituted lin-benzoguanine ligand
4GD0	;	1.29	;	tRNA-guanine transglycosylase Y106F, C158V mutant
4H7Z	;	1.68	;	tRNA-guanine transglycosylase Y106F, C158V mutant in complex with guanine
4E2V	;	1.18	;	tRNA-guanine transglycosylase Y106F, C158V mutant in complex with preQ1
4HVX	;	1.82	;	tRNA-guanine transglycosylase Y106F, C158V mutant in complex with queuine
4H6E	;	1.42	;	tRNA-guanine transglycosylase Y106F, C158V, V233G mutant apo structure
4GCX	;	1.42	;	tRNA-guanine transglycosylase Y106F, C158V, V233G mutant in complex with preQ1
4HQV	;	1.66	;	tRNA-guanine transglycosylase Y106F, C158V, V233G mutant in complex with queuine
4HSH	;	1.56	;	tRNA-guanine transglycosylase Y106F, V233G mutant in complex with queuine
4JBR	;	2.92	;	tRNA-guanine transglycosylase Y330C mutant as covalently linked dimer in space group P6(5)22
4HTB	;	1.9	;	tRNA-guanine transglycosylase Y330C mutant in space group C2
2QZR	;	1.95	;	tRNA-Guanine Transglycosylase(TGT) in Complex with 6-amino-2-[(1-naphthylmethyl)amino]-3,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
4IPP	;	1.33	;	tRNA-guanine-transglycosylase (TGT) mutant V262D APO-Structure
2NSO	;	1.6	;	Trna-gunanine-transglycosylase (TGT) mutant Y106F, C158V, A232S, V233G- APO-Structure
7SAM	;	4.3	;	tRNA-like Structure from Brome Mosaic Virus
7SC6	;	5.51	;	tRNA-like Structure from Brome Mosaic Virus Bound to Tyrosyl-tRNA Synthetase from Phaseolus vulgaris. Conformation: Bound State 1.
7SCQ	;	6.0	;	tRNA-like Structure from Brome Mosaic Virus Bound to Tyrosyl-tRNA Synthetase from Phaseolus vulgaris. Conformation: Bound State 2.
4WBZ	;	3.3	;	tRNA-processing enzyme (apo form 2)
4WBY	;	1.5	;	tRNA-processing enzyme (apo form I)
4WC4	;	3.501	;	tRNA-processing enzyme complex 2
4WC0	;	3.1	;	tRNA-processing enzyme with ATP
2K4C	;		;	tRNAPhe-based homology model for tRNAVal refined against base N-H RDCs in two media and SAXS data
2V6W	;	1.8	;	tRNASer acceptor stem: Conformation and hydration of a microhelix in a crystal structure at 1.8 Angstrom resolution
2QM9	;	2.31	;	Troglitazone Bound to Fatty Acid Binding Protein 4
1AE1	;	2.4	;	TROPINONE REDUCTASE-I COMPLEX WITH NADP
2AE1	;	2.3	;	TROPINONE REDUCTASE-II
2AE2	;	1.9	;	TROPINONE REDUCTASE-II COMPLEXED WITH NADP+ AND PSEUDOTROPINE
1IPE	;	2.5	;	TROPINONE REDUCTASE-II COMPLEXED WITH NADPH
1IPF	;	2.5	;	TROPINONE REDUCTASE-II COMPLEXED WITH NADPH AND TROPINONE
2TMA	;	15.0	;	TROPOMYOSIN CRYSTAL STRUCTURE AND MUSCLE REGULATION. APPENDIX. CONSTRUCTION OF AN ATOMIC MODEL FOR TROPOMYOSIN AND IMPLICATIONS FOR INTERACTIONS WITH ACTIN
6KLQ	;	7.7	;	Tropomyosin of cardiac thin filament in high-calcium state
6KLP	;	6.6	;	Tropomyosin of cardiac thin filament in low-calcium state
8TEQ	;	2.84	;	Tropomyosin-receptor kinase fused gene protein (TRK-fused gene protein; TFG) Low Complexity Domain (residues 237-327) G269V mutant, amyloid fiber
8TER	;	2.59	;	Tropomyosin-receptor kinase fused gene protein (TRK-fused gene protein; TFG) Low Complexity Domain (residues 237-327) P285L mutant, amyloid fiber
1NCX	;	1.8	;	TROPONIN C
1NCZ	;	1.8	;	TROPONIN C
6KLU	;	12.0	;	Troponin of cardiac thin filament in high-calcium state
6KLT	;	12.0	;	Troponin of cardiac thin filament in low-calcium state
1NCY	;	2.1	;	TROPONIN-C, COMPLEX WITH MANGANESE
1OUT	;	2.3	;	TROUT HEMOGLOBIN I
1JHG	;	1.3	;	TRP REPRESSOR MUTANT V58I
1WAP	;	1.8	;	TRP RNA-BINDING ATTENUATION PROTEIN IN COMPLEX WITH L-TRYPTOPHAN
4B27	;	2.72	;	Trp RNA-binding attenuation protein: modifying symmetry and stability of a circular oligomer
1BEU	;	1.9	;	TRP SYNTHASE (D60N-IPP-SER) WITH K+
3ZJH	;	1.7	;	Trp(60)B9Ala mutation of M.acetivorans protoglobin in complex with cyanide
8TTI	;	1.98	;	Trp-6-Halogenase BorH complexed with FAD and Trp
5EB2	;	2.709	;	Trp-bound YfiR
2M7D	;		;	Trp-cage 16b P12W: a Hyperstable Miniprotein
3UC7	;	1.1	;	Trp-cage cyclo-TC1 - monoclinic crystal form
3UC8	;	1.33	;	Trp-cage cyclo-TC1 - tetragonal crystal form
6D37	;		;	Trp-cage tr16b R16Nva : Elimination of pH Dependent Interactions
5DW0	;	2.01	;	TrpB from Pyrococcus furiosus with L-serine bound as the external aldimine
4QYS	;	1.939	;	TrpB2 enzymes
1JCM	;	2.1	;	TRPC STABILITY MUTANT CONTAINING AN ENGINEERED DISULPHIDE BRIDGE AND IN COMPLEX WITH A CDRP-RELATED SUBSTRATE
7B1G	;	3.6	;	TRPC4 in complex with Calmodulin
7B0S	;	3.6	;	TRPC4 in complex with inhibitor GFB-8438
7B05	;	3.8	;	TRPC4 in complex with inhibitor GFB-8749
7B16	;	3.15	;	TRPC4 in complex with inhibitor GFB-9289
7B0J	;	2.85	;	TRPC4 in LMNG detergent
6AYF	;	3.62	;	TRPML3/ML-SA1 complex at pH 7.4
6BO5	;	3.6	;	TRPV2 ion channel in partially closed state
7ZJH	;	3.39	;	TRPV2-C16+Pro-2
6H7I	;		;	Trpzip2 structure in presence of exogenous haloprotectant molecule.
6H7Q	;		;	Trpzip2 structure in presence of exogenous haloprotectant molecule.
7A5L	;	2.1	;	tructure of DYRK1A in complex with compound 24
8OGH	;	1.6	;	Truncated 1-deoxy-D-xylulose 5-phosphate synthase (DXPS) from Mycobacterium tuberculosis with butylacetylphosphonate (BAP) bound
7A9H	;	1.849	;	Truncated 1-deoxy-D-xylulose 5-phosphate synthase (DXS) from Mycobacterium tuberculosis
7A9G	;	1.9	;	Truncated 1-deoxy-D-xylulose 5-phosphate synthase (DXS) from Mycobacterium tuberculosis with intermediate 2-acetyl-thiamine diphosphate
7T6G	;		;	Truncated Ac-AIP-2
2K32	;		;	Truncated AcrA from Campylobacter jejuni for glycosylation studies
5XNR	;	2.3	;	Truncated AlyQ with CBM32 and alginate lyase domains
5I14	;	1.745	;	Truncated and mutated T4 lysozyme
6QUC	;	2.3	;	Truncated beta-galactosidase III from Bifidobacterium bifidum
6QUB	;	1.95	;	Truncated beta-galactosidase III from Bifidobacterium bifidum in complex with galactose
6H8E	;	2.35	;	Truncated derivative of the C-terminal domain of the TssA component of the type VI secretion system from Burkholderia cenocepacia
2MG9	;		;	Truncated EGF-A
6QJB	;		;	Truncated Evasin-3 (tEv3 17-56)
6RGV	;	2.0	;	Truncated FljB phase 2 flagellin
3PG8	;	2.0	;	Truncated form of 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase from Thermotoga maritima
6XYC	;	1.85	;	Truncated form of carbohydrate esterase from gut microbiota
1QF8	;	1.74	;	TRUNCATED FORM OF CASEIN KINASE II BETA SUBUNIT (2-182) FROM HOMO SAPIENS
8FKL	;	1.48	;	Truncated form of the catalytic domain of Streptococcus mutans GtfB
4WW0	;	2.96	;	Truncated FtsH from A. aeolicus
4Z8X	;	3.25	;	Truncated FtsH from A. aeolicus
6GCO	;	3.323	;	Truncated FtsH from A. aeolicus in P312
6GCN	;	2.949	;	Truncated FtsH from A. aeolicus in R32
1MNE	;	2.7	;	TRUNCATED HEAD OF MYOSIN FROM DICTYOSTELIUM DISCOIDEUM COMPLEXED WITH MG-PYROPHOSPHATE
1MND	;	2.6	;	TRUNCATED HEAD OF MYOSIN FROM DICTYOSTELIUM DISCOIDEUM COMPLEXED WITH MGADP-ALF4
1MMD	;	2.0	;	TRUNCATED HEAD OF MYOSIN FROM DICTYOSTELIUM DISCOIDEUM COMPLEXED WITH MGADP-BEF3
5KDK	;	2.002	;	Truncated hemolysin A from P. mirabilis at 2.0 Angstroms resolution crystallized in a high salt condition
5KEH	;	1.551	;	Truncated hemolysin A from P. mirabilis at 2.0 Angstroms resolution crystallized in a high salt condition
5KF3	;	2.2	;	Truncated hemolysin A from P. mirabilis Y134A at 2.2 Angstroms resolution
5SZ8	;	1.83	;	Truncated hemolysin A Q125A/Y134A from P. mirabilis at 1.8 Angstroms resolution crystallized in a high salt condition
5KKD	;	2.13	;	Truncated hemolysin A Y134A from P. mirabilis at 2.1 Angstroms resolution crystallized in a high salt condition
5W4X	;	2.65	;	Truncated hUGDH
3PFF	;	2.3	;	Truncated human atp-citrate lyase with ADP and tartrate bound
3MWD	;	2.1	;	Truncated Human ATP-Citrate Lyase with Citrate Bound
3MWE	;	2.2	;	Truncated Human ATP-Citrate Lyase with Tartrate Bound
1QNK	;		;	TRUNCATED HUMAN GROB[5-73], NMR, 20 STRUCTURES
6QI8	;	3.75	;	Truncated human R2TP complex, structure 3 (ADP-filled)
6QI9	;	4.63	;	Truncated human R2TP complex, structure 4 (ADP-empty)
4YM4	;	3.12	;	Truncated Human TIFA in complex with its Thr9 phosphorylated N-terminal peptide 1-15
2MP3	;		;	Truncated L126Z-sod1 in DPC micelle
3U6W	;	2.21	;	Truncated M. tuberculosis LeuA (1-425) complexed with KIV
4NOA	;	1.25	;	Truncated minor pilin PilE from Pseudomonas aeruginosa
5GOE	;	1.801	;	Truncated mitofusin-1, GDP-bound
5GOF	;	1.604	;	Truncated mitofusin-1, GTP-bound
5GO4	;	2.202	;	Truncated mitofusin-1, nucleotide-free
5GOM	;	2.802	;	Truncated mitofusin-1, transition-like state
2QUY	;	1.7	;	Truncated mutant ASN175ALA of penicillin v acylase from bacillus sphaericus
5Z8B	;	2.91	;	Truncated N-acetylglucosaminyl transferase KfiA from E. coli K5 strain apo form
6RP3	;	1.81	;	Truncated Norcoclaurine synthase with reaction intermediate mimic
1DZO	;	1.63	;	Truncated PAK pilin from Pseudomonas aeruginosa
5CLL	;	2.45	;	Truncated Ran wild type in complex with GDP-BeF and RanBD1
1JMY	;	2.6	;	Truncated Recombinant Human Bile Salt Stimulated Lipase
2B44	;	1.83	;	Truncated S. aureus LytM, P 32 2 1 crystal form
2B0P	;	1.5	;	truncated S. aureus LytM, P212121 crystal form
2B13	;	1.55	;	Truncated S. aureus LytM, P41 crystal form
2YM0	;	3.0	;	Truncated SipD from Salmonella typhimurium
3RK2	;	2.2	;	Truncated SNARE complex
3RK3	;	3.5	;	Truncated SNARE complex with complexin
3RL0	;	3.8	;	Truncated SNARE complex with complexin (P1)
6B7T	;	1.91	;	Truncated strand 10-less green fluorescent protein
6B7R	;	1.73	;	Truncated strand 11-less green fluorescent protein
4CZ5	;	1.02	;	Truncated tetramerization domain of zebrafish p53 (crystal form I)
4CZ6	;	1.53	;	Truncated tetramerization domain of zebrafish p53 (crystal form II)
4CZ7	;	1.1	;	Truncated tetramerization domain of zebrafish p53 (crystal form III)
6TS2	;	5.74	;	Truncated version of Chaetomium thermophilum UDP-Glucose Glucosyl Transferase (UGGT) lacking domain TRXL2 (417-650).
4RNW	;	1.552	;	Truncated version of the G303 Circular Permutation of Old Yellow Enzyme
7X5P	;	3.4	;	Truncated VhChiP (1-19aa) in complex with doxycycline
5E3V	;	2.72	;	Truncated X-ray crystal structure of Adenylosuccinate Lyase from Salmonella typhimurium
5H8C	;	2.29	;	Truncated XPD
2WEV	;	2.3	;	Truncation and Optimisation of Peptide Inhibitors of CDK2, Cyclin A Through Structure Guided Design
2WFY	;	2.53	;	Truncation and Optimisation of Peptide Inhibitors of CDK2, Cyclin A Through Structure Guided Design
2WHB	;	2.9	;	Truncation and Optimisation of Peptide Inhibitors of CDK2, Cyclin A Through Structure Guided Design
2X1N	;	2.75	;	Truncation and Optimisation of Peptide Inhibitors of CDK2, Cyclin A Through Structure Guided Design
7O43	;	3.4	;	TrwK/VirB4unbound dimer complex from R388 type IV secretion system determined by cryo-EM.
7O42	;	4.1	;	TrwK/VirB4unbound trimer of dimers complex (with Hcp1) from the R388 type IV secretion system determined by cryo-EM.
6NEZ	;	2.2	;	Trypanosoma brucei - BDF5, Tb427tmp.01.5000 A, solved with PF-CBP1
5K29	;	2.1	;	Trypanosoma brucei bromodomain BDF5 (Tb427tmp.01.5000)
6Q2A	;	2.6	;	Trypanosoma brucei CLK1 kinase domain in complex with a covalent aminobenzimidazole inhibitor AB1
2W7T	;	2.1	;	Trypanosoma brucei CTPS - glutaminase domain with bound acivicin
6DFT	;	3.5	;	Trypanosoma brucei deoxyhypusine synthase
3RG9	;	2.0	;	Trypanosoma brucei dihydrofolate reductase (TbDHFR) in complex with WR99210
3QFX	;	2.2	;	Trypanosoma brucei dihydrofolate reductase pyrimethamine complex
6F5D	;	3.2	;	Trypanosoma brucei F1-ATPase
7ZGJ	;	3.58	;	Trypanosoma brucei gambiense ISG65 in complex with human complement component C3
7ZGK	;	3.59	;	Trypanosoma brucei gambiense ISG65 in complex with human complement component C3b
2WYO	;	3.15	;	Trypanosoma brucei glutathione synthetase
4X0J	;	1.85	;	Trypanosoma brucei haptoglobin-haemoglobin receptor
6APS	;	1.762	;	Trypanosoma brucei hypoxanthine guanine phosphoribosyltransferase in complex with [(2-((Guanine-9H-yl)methyl)propane-1,3 diyl)bis(oxy)]bis(methylene))diphosphonic acid
6APV	;	1.993	;	Trypanosoma brucei hypoxanthine guanine phosphoribosyltransferase in complex with [(2-{[2-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)ethyl][(E)-2-phosphonoethenyl]amino}ethoxy)methyl]phosphonic acid
6APT	;	1.795	;	Trypanosoma brucei hypoxanthine guanine phosphoribosyltransferase in complex with {[(2S)-3-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)propane-1,2-diyl]bis(oxyethane-2,1-diyl)}bis(phosphonic acid)
8C51	;	2.4	;	Trypanosoma brucei IMP dehydrogenase (cyto) crystallized in High Five cells revealing native ligands ATP, GDP and phosphate. Diffraction data collection at 100 K in cellulo
8C53	;	2.3	;	Trypanosoma brucei IMP dehydrogenase (ori) crystallized in High Five cells reveals native ligands ATP, GDP and phosphate. Diffraction data collection at 100 K in cellulo; CrystFEL processing
8CGY	;	3.0	;	Trypanosoma brucei IMP dehydrogenase (ori) crystallized in High Five cells reveals native ligands ATP, GDP and phosphate. Diffraction data collection at 100 K in cellulo; XDS processing
8RD2	;	2.69	;	Trypanosoma brucei Invariant Surface Glycoprotein 75 (ISG75)
7PI6	;	2.6	;	Trypanosoma brucei ISG65 bound to human complement C3d
5NFH	;	2.8	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with a quinazolinone inhibitor
4EG8	;	2.596	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with compound Chem 89
5TQU	;	2.6	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor
4ZT5	;	2.35	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor (2S)-N-(3,5-dichlorobenzyl)-N'-(1H-imidazo[4,5-b]pyridin-2-yl)-2-methylpropane-1,3-diamine (Chem 1655)
5J58	;	2.8	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor (Chem 1856)
5J59	;	2.4	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor (Chem 1893)
6MES	;	2.9	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor (Chem 1907)
5V49	;	2.3	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor (Chem 1917)
6CML	;	2.7	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor (Chem 2093)
5J5A	;	2.7	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor (Chem 70786556)
4MWB	;	2.313	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor 1-(3-{[(2,5-dichlorothiophen-3-yl)methyl]amino}propyl)-3-thiophen-3-ylurea (Chem 1509)
4MWC	;	2.649	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor 1-(3-{[(2-methyl-1-benzothiophen-3-yl)methyl]amino}propyl)-3-thiophen-3-ylurea (Chem 1540)
4MW6	;	2.558	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor 1-(3-{[2-(benzyloxy)-5-chloro-3-(prop-2-en-1-yl)benzyl]amino}propyl)-3-thiophen-3-ylurea (Chem 1476)
4MW2	;	2.3	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor 1-(3-{[5-chloro-2-hydroxy-3-(prop-2-en-1-yl)benzyl]amino}propyl)-3-thiophen-3-ylurea (Chem 1472)
4MWE	;	2.45	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor 1-(3-{[5-chloro-3-(prop-2-en-1-yl)-2-(prop-2-en-1-yloxy)benzyl]amino}propyl)-3-thiophen-3-ylurea (Chem 1475)
4MW0	;	2.201	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor 1-{3-[(3,5-dichlorobenzyl)amino]propyl}-3-(2-hydroxyphenyl)urea (Chem 1392)
4MVY	;	2.314	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor 1-{3-[(3,5-dichlorobenzyl)amino]propyl}-3-(3-hydroxyphenyl)urea (Chem 1387)
4MVX	;	2.55	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor 1-{3-[(3,5-dichlorobenzyl)amino]propyl}-3-phenylurea (Chem 1356)
4MVW	;	2.901	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor 1-{3-[(3,5-dichlorobenzyl)amino]propyl}-3-thiophen-3-ylurea (Chem 1433)
4MWD	;	2.253	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor 1-{3-[(3,5-dichlorobenzyl)amino]propyl}-3-thiophen-3-ylurea (Chem 1433) and ATP analog AMPPCP
4MW5	;	2.347	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor 1-{3-[(3-chloro-5-methoxybenzyl)amino]propyl}-3-phenylurea (Chem 1415)
4MW1	;	2.494	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor 1-{3-[(3-chloro-5-methoxybenzyl)amino]propyl}-3-thiophen-3-ylurea (Chem 1444)
4MW9	;	2.65	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor 1-{3-[(3-ethynylbenzyl)amino]propyl}-3-thiophen-3-ylurea (Chem 1478)
4MW7	;	2.75	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor 1-{3-[(5-chloro-2-ethoxy-3-iodobenzyl)amino]propyl}-3-thiophen-3-ylurea (Chem 1469)
4MW4	;	2.5	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor 1-{3-[(5-chloro-2-hydroxy-3-iodobenzyl)amino]propyl}-3-thiophen-3-ylurea (Chem 1473)
4EG4	;	3.151	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor Chem 1289
4EG5	;	3.1	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor Chem 1312
4EGA	;	2.698	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor Chem 1320
4EG6	;	2.901	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor Chem 1325
4EG7	;	2.747	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor Chem 1331
4ZT2	;	2.7	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor N-(3,5-dichlorobenzyl)-N'-(1H-imidazo[4,5-b]pyridin-2-yl)propane-1,3-diamine (Chem 1575)
4ZT3	;	2.8	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor N-(3,5-dichlorobenzyl)-N'-(5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl)propane-1,3-diamine (Chem 1614)
4ZT7	;	2.4	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor N-[(4R)-6,8-dichloro-1,2,3,4-tetrahydroquinolin-4-yl]-N'-(5-fluoro-3H-imidazo[4,5-b]pyridin-2-yl)propane-1,3-diamine (Chem 1717)
4ZT6	;	2.25	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitor N-[(4R)-6,8-dichloro-3,4-dihydro-2H-chromen-4-yl]-N'-(5-fluoro-1H-imidazo[4,5-b]pyridin-2-yl)propane-1,3-diamine (Chem 1709)
4ZT4	;	2.3	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with inhibitorN-(3,5-dichlorobenzyl)-2,2-difluoro-N'-(1H-imidazo[4,5-b]pyridin-2-yl)propane-1,3-diamine (Chem 1708)
4EG3	;	2.94	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with product methionyl-adenylate
4EG1	;	2.9	;	Trypanosoma brucei methionyl-tRNA synthetase in complex with substrate Methionine
8AP6	;	3.2	;	Trypanosoma brucei mitochondrial F1Fo ATP synthase dimer
7AOI	;	3.5	;	Trypanosoma brucei mitochondrial ribosome large subunit assembly intermediate
5MMC	;		;	Trypanosoma brucei Pex14 N-terminal domain
6DNZ	;	2.384	;	Trypanosoma brucei PRMT1 enzyme-prozyme heterotetrameric complex with AdoHcy
4HWY	;	2.1	;	Trypanosoma brucei procathepsin B solved from 40 fs free-electron laser pulse data by serial femtosecond X-ray crystallography
4N4Z	;	3.3	;	Trypanosoma brucei procathepsin B structure solved by Serial Microcrystallography using synchrotron radiation
5K6A	;	1.7	;	Trypanosoma brucei Pteridine reductase 1 (PTR1) in complex with compound 1
8OF2	;	1.48	;	Trypanosoma brucei pteridine reductase 1 (TbPTR1) in complex with 2,4,6 triamminopyrimidine (TAP)
6TBX	;	1.3	;	Trypanosoma brucei PTR1 (TbPTR1) in complex with a tricyclic-based inhibitor
6RX5	;	1.42	;	Trypanosoma brucei PTR1 (TbPTR1) in complex with inhibitor 1 (NMT-C0003)
6RX0	;	1.2	;	Trypanosoma brucei PTR1 (TbPTR1) in complex with inhibitor 3 (NMT-C0013)
6RX6	;	1.11	;	Trypanosoma brucei PTR1 (TbPTR1) in complex with inhibitor 4 (NMT-C0026)
7OPJ	;	1.34	;	Trypanosoma brucei PTR1 (TbPTR1) in complex with pyrimethamine
5JDI	;	1.38	;	Trypanosoma brucei PTR1 in complex with cofactor and inhibitor NMT-H024 (compound 2)
6HNC	;	1.5	;	Trypanosoma brucei PTR1 in complex with cycloguanil
4WCD	;	1.68	;	Trypanosoma brucei PTR1 in complex with inhibitor 10
6GCK	;	2.14	;	Trypanosoma brucei PTR1 in complex with inhibitor 1e (F206)
6GCQ	;	1.58	;	Trypanosoma brucei PTR1 in complex with inhibitor 2b (F192)
6GCP	;	1.52	;	Trypanosoma brucei PTR1 in complex with inhibitor 2d (F186)
6GDO	;	1.78	;	Trypanosoma brucei PTR1 in complex with inhibitor 2g (F240)
6GEX	;	1.78	;	Trypanosoma brucei PTR1 in complex with inhibitor 2h (F246)
6GCL	;	1.95	;	Trypanosoma brucei PTR1 in complex with inhibitor 3a (F020)
6GD4	;	1.42	;	Trypanosoma brucei PTR1 in complex with inhibitor 4c (F188)
6GEY	;	1.56	;	Trypanosoma brucei PTR1 in complex with inhibitor 4g (F125)
6GD0	;	1.74	;	Trypanosoma brucei PTR1 in complex with inhibitor 4g (F133)
6GDP	;	1.52	;	Trypanosoma brucei PTR1 in complex with inhibitor 4l (F162)
4WCF	;	1.93	;	Trypanosoma brucei PTR1 in complex with inhibitor 9
5IZC	;	1.92	;	Trypanosoma brucei PTR1 in complex with inhibitor F032
5JCJ	;	1.76	;	Trypanosoma brucei PTR1 in complex with inhibitor NMT-H037 (compound 7)
5JDC	;	1.78	;	Trypanosoma brucei PTR1 in complex with inhibitor NP-13 (Hesperetin)
5JCX	;	1.43	;	Trypanosoma brucei PTR1 in complex with inhibitor NP-29
2YHI	;	1.8	;	Trypanosoma brucei PTR1 in complex with inhibitor WH16
2YHU	;	2.01	;	Trypanosoma brucei PTR1 in complex with inhibitor WHF30
6HNR	;	1.58	;	Trypanosoma brucei PTR1 in complex with the triazine inhibitor 1 (F217)
6HOW	;	1.92	;	Trypanosoma brucei PTR1 in complex with the triazine inhibitor 2a (F219).
3LSQ	;	2.1	;	Trypanosoma brucei seryl-tRNA synthetase
6RLU	;	1.88	;	Trypanosoma brucei Seryl-tRNA Synthetase in Complex with 5'-O-(N-(L-seryl)-sulfamoyl)cytidine
6RLV	;	1.9	;	Trypanosoma brucei Seryl-tRNA Synthetase in Complex with 5'-O-(N-(L-seryl)-sulfamoyl)N3-methyluridine
6RLT	;	1.84	;	Trypanosoma brucei Seryl-tRNA Synthetase in Complex with 5'-O-(N-(L-seryl)-Sulfamoyl)uridine
3LSS	;	1.95	;	Trypanosoma brucei seryl-tRNA synthetase in complex with ATP
6SOY	;	2.75	;	Trypanosoma brucei transferrin receptor in complex with human transferrin
2WP5	;	2.8	;	Trypanosoma brucei trypanothione reductase in complex with 3,4- dihydroquinazoline inhibitor (DDD00065414)
2WP6	;	2.5	;	Trypanosoma brucei trypanothione reductase in complex with 3,4- dihydroquinazoline inhibitor (DDD00071494)
2WPC	;	2.1	;	Trypanosoma brucei trypanothione reductase in complex with 3,4- dihydroquinazoline inhibitor (DDD00073357)
2WPE	;	2.1	;	Trypanosoma brucei trypanothione reductase in complex with 3,4- dihydroquinazoline inhibitor (DDD00073359)
2WPF	;	1.9	;	Trypanosoma brucei trypanothione reductase in complex with 3,4- dihydroquinazoline inhibitor (DDD00085762)
2WOV	;	2.5	;	Trypanosoma brucei trypanothione reductase with bound NADP.
2WOW	;	2.2	;	Trypanosoma brucei trypanothione reductase with NADP and trypanothione bound
1GY8	;	2.0	;	Trypanosoma brucei UDP-galactose 4' epimerase
2CNB	;	2.7	;	Trypanosoma brucei UDP-galactose-4-epimerase in ternary complex with NAD and the substrate analogue UDP-4-deoxy-4-fluoro-alpha-D-galactose
6SU1	;	3.0	;	Trypanosoma congolense pyruvate kinase in complex with citrate and glycerol
6SU2	;	3.0	;	Trypanosoma congolense pyruvate kinase in complex with citrate and glycerol
6NIM	;	1.78	;	Trypanosoma cruzi - BDF2, TcCLB.506553.20, solved with bromosporine
3IRM	;	2.1	;	Trypanosoma cruzi Dihydrofolate Reductase-Thymidylate Synthase COMPLEXED WITH Cycloguanil
3IRN	;	2.6	;	Trypanosoma cruzi Dihydrofolate Reductase-Thymidylate Synthase COMPLEXED WITH NADPH AND Cycloguanil
3IRO	;	2.8	;	Trypanosoma cruzi Dihydrofolate Reductase-Thymidylate Synthase complexed with NADPH and Q-8 antifolate
3INV	;	2.37	;	Trypanosoma cruzi Dihydrofolate Reductase-Thymidylate Synthase COMPLEXED WITH NADPH, dUMP AND C-448 ANTIFOLATE
6O7Z	;	2.7	;	Trypanosoma cruzi EIF4E5 translation initiation factor in complex with cap-1
6O7Y	;	2.2	;	Trypanosoma cruzi EIF4E5 translation initiation factor in complex with cap-4
6O80	;	2.1	;	Trypanosoma cruzi EIF4E5 translation initiation factor in complex with m7GTP
1YHK	;	2.1	;	Trypanosoma cruzi farnesyl diphosphate synthase
6SFA	;	1.9	;	Trypanosoma cruzi farnesyl diphosphate synthase apo structure with Mn ions
6SE2	;	1.45	;	Trypanosoma cruzi farnesyl diphosphate synthase apo structure with zinc ions
3ICZ	;	2.15	;	Trypanosoma cruzi farnesyl diphosphate synthase homodimer in complex with 1-(2,2-Bis-phosphono-ethyl)-3-butyl-pyridinium and isopentenyl pyrophosphate
3ID0	;	2.81	;	Trypanosoma cruzi farnesyl diphosphate synthase homodimer in complex with 3-Fluoro-1-(2-hydroxy-2,2-bisphosphono-ethyl)pyridinium
3ICN	;	2.4	;	Trypanosoma cruzi farnesyl diphosphate synthase homodimer in complex with isopentenyl pyrophosphate and 3-Fluoro-1-(2-hydroxy-2,2-bis-phosphono-ethyl)-pyridinium
3ICM	;	2.2	;	Trypanosoma cruzi farnesyl diphosphate synthase homodimer in complex with isopentenyl pyrophosphate, Mg2+ and 1-(2-Hydroxy-2,2-bis-phosphono-ethyl)-3-phenyl-pyridinium
3ICK	;	2.4	;	Trypanosoma cruzi farnesyl diphosphate synthase homodimer in complex with minodronate and isopentenyl disphosphate
6SDO	;	1.68	;	Trypanosoma cruzi farnesyl diphosphate synthase in complex with 3np
6SDQ	;	1.68	;	Trypanosoma cruzi farnesyl diphosphate synthase in complex with fragment 2m5n
6SDP	;	1.45	;	Trypanosoma cruzi farnesyl diphosphate synthase in complex with fragment 4np
6SF8	;	1.62	;	Trypanosoma cruzi farnesyl diphosphate synthase in complex with fragment j51
6SF9	;	1.59	;	Trypanosoma cruzi farnesyl diphosphate synthase in complex with fragment j71
6SDN	;	1.51	;	Trypanosoma cruzi farnesyl diphosphate synthase in complex with fragment j82
6T7N	;	1.9	;	Trypanosoma cruzi farnesyl diphosphate synthase in complex with IPP and Mn
2Q2R	;	2.1	;	Trypanosoma cruzi glucokinase in complex with beta-D-glucose and ADP
6D24	;	3.35	;	Trypanosoma cruzi Glucose-6-P Dehydrogenase in complex with G6P
5AQ1	;	2.65	;	Trypanosoma cruzi Glucose-6-phosphate Dehydrogenase in complex with G6P and NADPH
1JVW	;	1.7	;	TRYPANOSOMA CRUZI MACROPHAGE INFECTIVITY POTENTIATOR (TCMIP)
6W2N	;	1.88	;	Trypanosoma cruzi Malic Enzyme in complex with inhibitor (MEC009)
6W49	;	1.7	;	Trypanosoma cruzi Malic Enzyme in complex with inhibitor (MEC010)
6W29	;	2.14	;	Trypanosoma cruzi Malic Enzyme in complex with inhibitor (MEC013)
6W56	;	1.9	;	Trypanosoma cruzi Malic Enzyme in complex with inhibitor (MEC062)
6W59	;	1.95	;	Trypanosoma cruzi Malic Enzyme in complex with inhibitor (MEC063)
6W57	;	1.78	;	Trypanosoma cruzi Malic Enzyme in complex with inhibitor (MEC069)
6W53	;	2.1	;	Trypanosoma cruzi Malic Enzyme in complex with inhibitor (MEC070)
3DWC	;	2.1	;	Trypanosoma Cruzi Metallocarboxypeptidase 1
7MK0	;	3.5	;	Trypanosoma cruzi Nucleoside Diphosphate Kinase 1 form a quinary multihexameric structure
6HJF	;	1.7	;	Trypanosoma cruzi proline racemase in complex with inhibitor BrOxoPA
6HJE	;	2.0	;	Trypanosoma cruzi proline racemase in complex with inhibitor NG-P27
6HJG	;	1.9	;	Trypanosoma cruzi proline racemase in complex with inhibitor OxoPA
2AH2	;	1.6	;	Trypanosoma cruzi trans-sialidase in complex with 2,3-difluorosialic acid (covalent intermediate)
1S0J	;	1.65	;	Trypanosoma cruzi trans-sialidase in complex with MuNANA (Michaelis complex)
1S0I	;	1.6	;	Trypanosoma cruzi trans-sialidase in complex with sialyl-lactose (Michaelis complex)
3PJQ	;	2.1	;	Trypanosoma cruzi trans-sialidase-like inactive isoform (including the natural mutation Tyr342His) in complex with lactose
1TCD	;	1.83	;	TRYPANOSOMA CRUZI TRIOSEPHOSPHATE ISOMERASE
1AOG	;	2.3	;	TRYPANOSOMA CRUZI TRYPANOTHIONE REDUCTASE (OXIDIZED FORM)
1MZ5	;	2.2	;	Trypanosoma rangeli sialidase
1N1S	;	1.64	;	Trypanosoma rangeli sialidase
2A75	;	1.95	;	Trypanosoma rangeli Sialidase In Complex With 2,3- Difluorosialic Acid (Covalent Intermediate)
2FHR	;	2.2	;	Trypanosoma Rangeli Sialidase In Complex With 2,3- Difluorosialic Acid (Covalent Intermediate)
2AGS	;	1.7	;	Trypanosoma rangeli Sialidase in Complex with 2-Keto-3-deoxy-D-glycero-D-galacto-2,3-difluoro-nononic acid (2,3-difluoro-KDN)
1N1V	;	2.1	;	Trypanosoma rangeli sialidase in complex with DANA
1N1T	;	1.6	;	Trypanosoma rangeli sialidase in complex with DANA at 1.6 A
1N1Y	;	2.8	;	Trypanosoma rangeli sialidase in complex with sialic acid
1MZ6	;	2.9	;	Trypanosoma rangeli sialidase in complex with the inhibitor DANA
5KAP	;	2.95	;	Trypanosome brucei Hypoxanthine-guanine phosphoribosyltranferase in complex with a 9-(4-(phosphonobutil)hypoxanthine
5K51	;	2.956	;	Trypanosome brucei Hypoxanthine-guanine phosphoribosyltranferase in complex with a 9-[5-(phosphonoheptyl]hypoxanthine
5JSQ	;	1.503	;	Trypanosome brucei Hypoxanthine-guanine phosphoribosyltranferase in complex with a 9-[7-(phosphonoheptyl]guanine
5JV5	;	2.73	;	Trypanosome brucei Hypoxanthine-guanine phosphoribosyltranferase in complex with Guanosine 5' monophosphate
5KAM	;	2.481	;	Trypanosome brucei Hypoxanthine-guanine phosphoribosyltranferase in complex with Inosine 5' monophosphate
5SMJ	;	1.65	;	Trypanothione reductase
6T98	;	3.0	;	Trypanothione Reductase from Leishmania infantum in complex with 9a
6T95	;	2.5	;	Trypanothione Reductase from Leismania infantum in complex with 4a
6I7N	;	3.3	;	Trypanothione Reductase from Leismania infantum in complex with TRL156
6T97	;	2.8	;	Trypanothione Reductase from Leismania infantum in complex with TRL190
2WOI	;	2.1	;	Trypanothione reductase from Trypanosoma brucei
7NVP	;	2.153	;	Trypanothione reductase from Trypanosoma brucei in complex with N-{4-methoxy-3-[(4-methoxyphenyl)sulfamoyl]phenyl}-5-nitrothiophene-2-carboxamide
6RB5	;	1.977	;	Trypanothione reductase in complex with 4-(((3-(8-(2-((1R,2S,5R)-6,6-dimethylbicyclo[3.1.1]heptan-2-yl)ethyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl)propyl)(methyl)amino)methyl)-4-hydroxypiperidine-1-carboximidamide
5EBK	;	3.51	;	Trypanothione reductase in complex with 6-(sec-butoxy)-2-((3-chlorophenyl)thio)pyrimidin-4-amine
2VOB	;	2.3	;	TRYPANOTHIONE SYNTHETASE
2VPM	;	2.8	;	Trypanothione synthetase
4B6M	;	1.59	;	Trypansoma brucei tubulin binding cofactor B CAP-Gly domain
1O73	;	2.28	;	Tryparedoxin from Trypanosoma brucei
6GXG	;	1.6	;	Tryparedoxin from Trypanosoma brucei in complex with CFT
6GXY	;	1.8	;	Tryparedoxin from Trypanosoma brucei in complex with CFT
1I5G	;	1.4	;	TRYPAREDOXIN II COMPLEXED WITH GLUTATHIONYLSPERMIDINE
1OC8	;	1.5	;	TRYPAREDOXIN II FROM C.FASCICULATA SOLVED BY MR
1OC9	;	2.35	;	TRYPAREDOXIN II FROM C.FASCICULATA solved by MR
1O6J	;	2.35	;	Tryparedoxin II from C.fasciculata solved by sulphur phasing
1O81	;	1.5	;	Tryparedoxin II from C.fasciculata solved by sulphur phasing
4LLR	;	2.8	;	Tryparedoxin peroxidase (TXNPX) from trypanosoma cruzi in the reduced state
1E2Y	;	3.2	;	Tryparedoxin peroxidase from Crithidia fasciculata
1QK8	;	1.4	;	TRYPAREDOXIN-I FROM CRITHIDIA FASCICULATA
7Z25	;	1.35	;	TRYPSIN (BOVINE) COMPLEXED WITH compound 12
7Z2I	;	1.09	;	TRYPSIN (BOVINE) COMPLEXED WITH compound 4
2BLW	;	1.2	;	Trypsin after a high dose X-ray ""Burn""
1PQ7	;	0.8	;	Trypsin at 0.8 A, pH5 / borax
1PQ8	;	1.0	;	Trypsin at pH 4 at atomic resolution
1PQ5	;	0.85	;	Trypsin at pH 5, 0.85 A
2BLV	;	1.2	;	Trypsin before a high dose x-ray ""burn""
5JYI	;	1.914	;	Trypsin bound with succinic acid at 1.9A
2PLX	;	1.56	;	Trypsin complexed to a synthetic peptide from Veronica hederifolia
6BVH	;	1.927	;	Trypsin complexed with a modified sunflower trypsin inhibitor, SFTI-TCTR(N12,N14)
1PPZ	;	1.23	;	Trypsin complexes at atomic and ultra-high resolution
6SWV	;	1.432	;	Trypsin fast data collection
1XVO	;	0.84	;	Trypsin from Fusarium oxysporum at pH 6
1XVM	;	1.1	;	Trypsin from Fusarium oxysporum- room temperature to atomic resolution
2A32	;	1.5	;	Trypsin in complex with benzene boronic acid
2A31	;	1.25	;	Trypsin in complex with borate
7PH1	;	1.18	;	Trypsin in complex with BPTI mutant (2S)-2-amino-4-monofluorobutanoic acid
3NKK	;	1.12	;	Trypsin in complex with fluorine containing fragment
3NK8	;	1.15	;	Trypsin in complex with fluorine-containing fragment
3M35	;	2.2	;	Trypsin in complex with the inhibitor 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)biphenyl-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423)
4Y0Y	;	1.25	;	Trypsin in complex with with BPTI
4Y11	;	1.3	;	Trypsin in complex with with BPTI mutant (2S)-2-amino-4,4,4-trifluorobutanoic acid
4Y10	;	1.37	;	Trypsin in complex with with BPTI mutant (2S)-2-amino-4,4-difluorobutanoic acid
4Y0Z	;	1.37	;	Trypsin in complex with with BPTI mutant AMINOBUTYRIC ACID
1TIH	;		;	TRYPSIN INHIBITOR (T1) FROM NICOTIANA ALATA
1G36	;	1.9	;	TRYPSIN INHIBITOR COMPLEX
1OYQ	;	1.9	;	TRYPSIN INHIBITOR COMPLEX
1Y3U	;	1.8	;	TRYPSIN INHIBITOR COMPLEX
1Y3V	;	1.6	;	Trypsin Inhibitor Complex
1Y3W	;	1.8	;	TRYPSIN INHIBITOR COMPLEX
1Y3X	;	1.7	;	TRYPSIN INHIBITOR COMPLEX
1Y3Y	;	1.75	;	TRYPSIN INHIBITOR COMPLEX
1YP9	;	2.1	;	Trypsin Inhibitor Complex
1EB2	;	2.0	;	Trypsin inhibitor complex (BPO)
1AVU	;	2.3	;	TRYPSIN INHIBITOR FROM SOYBEAN (STI)
6YIS	;	1.19	;	Trypsin inhibitor in complex with bovine trypsin
6YIT	;	1.25	;	Trypsin inhibitor in complex with bovine trypsin
6YIU	;	1.36	;	Trypsin inhibitor in complex with bovine trypsin
6YIV	;	0.95	;	Trypsin inhibitor in complex with bovine trypsin
6YIW	;	0.97	;	Trypsin inhibitor in complex with bovine trypsin
6YIX	;	1.31	;	Trypsin inhibitor in complex with bovine trypsin
6YIY	;	1.11	;	Trypsin inhibitor in complex with bovine trypsin
6YZA	;	1.3	;	Trypsin inhibitor in complex with bovine trypsin
6YZC	;	1.42	;	Trypsin inhibitor in complex with bovine trypsin
6ZFJ	;	1.0	;	Trypsin inhibitor in complex with bovine trypsin
6ZFK	;	1.1	;	Trypsin inhibitor in complex with bovine trypsin
1V2W	;	1.75	;	Trypsin inhibitor in complex with bovine trypsin variant X(SSAI)bT.B4
1V2T	;	1.9	;	Trypsin inhibitor in complex with bovine trypsin variant X(SSFI.Glu)bT.B4
1V2R	;	1.7	;	Trypsin inhibitor in complex with bovine trypsin variant X(SSRI)bT.B4
1V2Q	;	2.3	;	Trypsin inhibitor in complex with bovine trypsin variant X(SSWI)bT.B4
1V2P	;	1.92	;	Trypsin inhibitor in complex with bovine trypsin variant X(SSYI)bT.A4
1V2O	;	1.62	;	Trypsin inhibitor in complex with bovine trypsin variant X(SSYI)bT.B4
5LH4	;	1.37	;	Trypsin inhibitors for the treatment of pancreatitis - cpd 1
5LGO	;	1.12	;	Trypsin inhibitors for the treatment of pancreatitis - cpd 15
5LH8	;	1.54	;	Trypsin inhibitors for the treatment of pancreatitis - cpd 8
1YYY	;	2.1	;	Trypsin inhibitors with rigid tripeptidyl aldehydes
1ZZZ	;	1.9	;	Trypsin inhibitors with rigid tripeptidyl aldehydes
6DWR	;	1.319	;	Trypsin serine protease modified with the protease inhibitor cyanobenzylsulfonylfluoride
1UTJ	;	1.83	;	Trypsin specificity as elucidated by LIE calculations, X-ray structures and association constant measurements
1UTK	;	1.53	;	Trypsin specificity as elucidated by LIE calculations, X-ray structures and association constant measurements
1UTL	;	1.7	;	Trypsin specificity as elucidated by LIE calculations, X-ray structures and association constant measurements
1UTM	;	1.5	;	Trypsin specificity as elucidated by LIE calculations, X-ray structures and association constant measurements
1UTN	;	1.15	;	Trypsin specificity as elucidated by LIE calculations, X-ray structures and association constant measurements
1UTO	;	1.15	;	Trypsin specificity as elucidated by LIE calculations, X-ray structures and association constant measurements
1UTP	;	1.3	;	Trypsin specificity as elucidated by LIE calculations, X-ray structures and association constant measurements
1UTQ	;	1.15	;	Trypsin specificity as elucidated by LIE calculations, X-ray structures and association constant measurements
1AQ7	;	2.2	;	TRYPSIN WITH INHIBITOR AERUGINOSIN 98-B
1PQA	;	1.23	;	Trypsin with PMSF at atomic resolution
1XUK	;	1.8	;	TRYPSIN-BABIM-SULFATE, PH 5.9
1XUF	;	1.9	;	TRYPSIN-BABIM-ZN+2, PH 8.2
1XUG	;	1.5	;	TRYPSIN-BABIM-ZN+2, PH 8.2
6ACG	;	5.4	;	Trypsin-cleaved and low pH-treated SARS-CoV spike glycoprotein and ACE2 complex, ACE2-bound conformation 1
6ACJ	;	4.2	;	Trypsin-cleaved and low pH-treated SARS-CoV spike glycoprotein and ACE2 complex, ACE2-bound conformation 2
6ACK	;	4.5	;	Trypsin-cleaved and low pH-treated SARS-CoV spike glycoprotein and ACE2 complex, ACE2-bound conformation 3
6ACD	;	3.9	;	Trypsin-cleaved and low pH-treated SARS-CoV spike glycoprotein and ACE2 complex, ACE2-free conformation with one RBD in up conformation
6ACC	;	3.6	;	Trypsin-cleaved and low pH-treated SARS-CoV spike glycoprotein and ACE2 complex, ACE2-free conformation with three RBD in down conformation
7DX0	;	3.2	;	Trypsin-digested S protein of SARS-CoV-2
7DX7	;	3.4	;	Trypsin-digested S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 1 (1 up RBD and 1 PD bound)
7DX8	;	2.9	;	Trypsin-digested S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 2 (2 up RBD and 2 PD bound)
7DX9	;	3.6	;	Trypsin-digested S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 3 (3 up RBD and 2 PD bound)
7DX2	;	3.3	;	Trypsin-digested S protein of SARS-CoV-2 D614G mutant
1XUI	;	1.5	;	TRYPSIN-KETO-BABIM, ZN+2-FREE, PH 8.2
1XUH	;	2.2	;	TRYPSIN-KETO-BABIM-CO+2, PH 8.2
1XUJ	;	1.92	;	TRYPSIN-KETO-BABIM-ZN+2, PH 8.2
2HCJ	;	2.12	;	Trypsin-modified Elongation Factor Tu in complex with tetracycline
2HDN	;	2.8	;	Trypsin-modified Elongation Factor Tu in complex with tetracycline at 2.8 Angstrom resolution
1YKT	;	1.7	;	Trypsin/Bpti complex mutant
1YLC	;	1.7	;	Trypsin/BPTI complex mutant
1YLD	;	1.7	;	Trypsin/BPTI complex mutant
1TX6	;	2.2	;	trypsin:BBI complex
3TGK	;	1.7	;	TRYPSINOGEN MUTANT D194N AND DELETION OF ILE 16-VAL 17 COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI)
5F03	;	1.94	;	TRYPTASE B2 IN COMPLEX WITH 5-(3-Aminomethyl-phenoxymethyl)-3-[3-(2-chloro-pyridin-3-ylethynyl)-phenyl]-oxazolidin-2-one; compound with trifluoro-acetic acid
5L01	;	1.9	;	Tryptophan 5-hydroxylase in complex with inhibitor (3~{S})-8-[2-azanyl-6-[(1~{R})-1-(4-chloranyl-2-phenyl-phenyl)-2,2,2-tris(fluoranyl)ethoxy]pyrimidin-4-yl]-2,8-diazaspiro[4.5]decane-3-carboxylic acid
5W1B	;	2.0	;	Tryptophan indole-lyase
5W19	;	2.1	;	Tryptophan indole-lyase complex with oxindolyl-L-alanine
6HTO	;	1.45	;	Tryptophan lyase 'empty state'
6ELF	;	1.832	;	Tryptophan Repressor TrpR from E.coli variant M42F T44L T81I S88Y with Indole-3-acetic acid as ligand
6ELG	;	1.38	;	Tryptophan Repressor TrpR from E.coli variant M42F T44L T81I S88Y with Indole-3-acetonitrile
6ELB	;	1.437	;	Tryptophan Repressor TrpR from E.coli variant M42F T44L T81M N87G S88Y with Indole-3-acetic acid as ligand
6EJZ	;	1.9	;	Tryptophan Repressor TrpR from E.coli variant S88Y with Indole-3-acetic acid as ligand
6ENI	;	1.1	;	Tryptophan Repressor TrpR from E.coli variant T44L S88Y with Indole-3-acetic acid as ligand
6ENN	;	1.17	;	Tryptophan Repressor TrpR from E.coli variant T44L T81M N87G S88Y with Indole-3-acetic acid as ligand
6EKP	;	1.46	;	Tryptophan Repressor TrpR from E.coli variant T44L T81M S88Y with Indole-3-acetic acid as ligand
6EJW	;	1.99	;	Tryptophan Repressor TrpR from E.coli wildtype with Indole-3-acetic acid as ligand
6F7F	;	2.128	;	Tryptophan Repressor TrpR from E.coli with 3-Indolepropionic acid
6FAL	;	1.2	;	Tryptophan Repressor TrpR from E.coli with 3-Indolepropionic acid as ligand
6F9K	;	1.399	;	Tryptophan Repressor TrpR from E.coli with 5-methyl-L-tryptophan as ligand
6F7G	;	1.656	;	Tryptophan Repressor TrpR from E.coli with 5-Methyltryptamine
2XDI	;		;	Tryptophan repressor with L75F mutation in its apo form (no L- tryptophan bound)
1BKS	;	2.2	;	TRYPTOPHAN SYNTHASE (E.C.4.2.1.20) FROM SALMONELLA TYPHIMURIUM
1TTP	;	2.3	;	TRYPTOPHAN SYNTHASE (E.C.4.2.1.20) IN THE PRESENCE OF CESIUM, ROOM TEMPERATURE
1TTQ	;	2.0	;	TRYPTOPHAN SYNTHASE (E.C.4.2.1.20) IN THE PRESENCE OF POTASSIUM AT ROOM TEMPERATURE
1UBS	;	1.9	;	TRYPTOPHAN SYNTHASE (E.C.4.2.1.20) WITH A MUTATION OF LYS 87->THR IN THE B SUBUNIT AND IN THE PRESENCE OF LIGAND L-SERINE
2CLO	;	1.5	;	Tryptophan Synthase (external aldimine state) in complex with (naphthalene-2'-sulfonyl)-2-amino-1-ethylphosphate (F19)
2CLL	;	1.6	;	Tryptophan Synthase (external aldimine state) in complex with N-(4'- trifluoromethoxybenzenesulfonyl)-2-amino-1-ethylphosphate (F9)
2CLM	;	1.51	;	Tryptophan Synthase (external aldimine state) in complex with N-(4'- trifluoromethoxybenzoyl)-2-amino-1-ethylphosphate (F6F)
8B03	;	2.22	;	TRYPTOPHAN SYNTHASE - Cryo-trapping by the spitrobot crystal plunger after 0 sec
8B05	;	2.1	;	TRYPTOPHAN SYNTHASE - Cryo-trapping by the spitrobot crystal plunger after 20 sec
8B06	;	2.49	;	TRYPTOPHAN SYNTHASE - Cryo-trapping by the spitrobot crystal plunger after 25 sec
8B08	;	2.5	;	TRYPTOPHAN SYNTHASE - Cryo-trapping by the spitrobot crystal plunger after 30 sec
5IXJ	;	1.54	;	Tryptophan Synthase beta-subunit from Pyrococcus furiosus with L-threonine non-covalently bound in the active site
5DW3	;	1.74	;	Tryptophan Synthase beta-subunit from Pyrococcus furiosus with product L-tryptophan non-covalently bound in the active site
2RH9	;	1.7	;	Tryptophan synthase complexed with IGP, internal aldimine, pH 9.0
2RHG	;	2.0	;	Tryptophan synthase complexed with IGP, pH 7.0, internal aldimine
5BW6	;	1.82	;	Tryptophan Synthase from Salmonella typhimurium in complex with a single molecule of 2-({[4-(trifluoromethoxy)phenyl]carbonyl}amino)ethyl dihydrogen phosphate (F6) in the alpha-site.
4ZQC	;	1.54	;	Tryptophan Synthase from Salmonella typhimurium in complex with two molecules of N-(4'-trifluoromethoxybenzoyl)-2-amino-1-ethylphosphate (F6F) inhibitor in the alpha-site and a single F6F molecule in the beta-site at 1.54 Angstrom resolution.
2CLH	;	1.7	;	Tryptophan Synthase in complex with (naphthalene-2'-sulfonyl)-2-amino- 1-ethylphosphate (F19)
4HN4	;	1.64	;	Tryptophan synthase in complex with alpha aminoacrylate E(A-A) form and the F9 inhibitor in the alpha site
2CLK	;	1.5	;	Tryptophan Synthase in complex with D-glyceraldehyde 3-phosphate (G3P)
2J9X	;	1.9	;	Tryptophan Synthase in complex with GP, alpha-D,L-glycerol-phosphate, Cs, pH6.5 - alpha aminoacrylate form - (GP)E(A-A)
6VNT	;	1.25	;	Tryptophan synthase in complex with inhibitor N-(4'-trifluoromethoxybenzenesulfonyl)-2-amino-1-ethylphosphate (F9F) at the alpha-site, aminoacrylate at the beta site, and sodium ion at the metal coordination site at 1.25 Angstrom resolution
2CLI	;	1.7	;	Tryptophan Synthase in complex with N-(4'- trifluoromethoxybenzenesulfonyl)-2-amino-1-ethylphosphate (F9)
2CLF	;	1.7	;	Tryptophan Synthase in complex with N-(4'-trifluoromethoxybenzoyl)-2- amino-1-ethylphosphate (F6) - highF6 complex
2CLE	;	1.5	;	Tryptophan Synthase in complex with N-(4'-trifluoromethoxybenzoyl)-2- amino-1-ethylphosphate (F6) - lowF6 complex
3PR2	;	1.85	;	Tryptophan synthase indoline quinonoid structure with F9 inhibitor in alpha site
6X0C	;	1.45	;	Tryptophan Synthase mutant beta-Q114A in complex with Cesium ion at the metal coordination site and aminoacrylate and benzimidazole at the enzyme beta site
6VFD	;	1.7	;	Tryptophan synthase mutant Q114A in complex with cesium ion at the metal coordination site and 2-aminophenol quinonoid at the enzyme beta site
6C73	;	1.65	;	Tryptophan synthase Q114A mutant (internal aldimine state) in complex with N-(4'-trifluoromethoxybenzenesulfonyl)-2-amino-1-ethylphosphate (F9F) with cesium ion bound in the metal coordination site
6D0V	;	1.64	;	Tryptophan synthase Q114A mutant in complex with inhibitor N-(4'-trifluoromethoxybenzenesulfonyl)-2-amino-1-ethylphosphate (F9F) at the alpha-site, aminoacrylate at the beta site, and cesium ion at the metal coordination site
6O1H	;	1.64	;	Tryptophan synthase Q114A mutant in complex with N-(4'-trifluoromethoxybenzenesulfonyl)-2-amino-1-ethylphosphate (F9F) at the enzyme alpha-site, cesium ion at the metal coordination site, and 2-aminophenol quinonoid at the enzyme beta site
2J9Y	;	1.8	;	Tryptophan Synthase Q114N mutant in complex with Compound II
3THA	;	2.37	;	Tryptophan synthase subunit alpha from Campylobacter jejuni.
6QKY	;	2.54	;	Tryptophan synthase subunit alpha from Streptococcus pneumoniae with 3D domain swap in the core of TIM barrel
2J9Z	;	1.8	;	Tryptophan Synthase T110 mutant complex
6DFU	;	2.05	;	Tryptophan--tRNA ligase from Haemophilus influenzae.
8TTK	;	1.98	;	Tryptophan-6-halogenase BorH apo structure
8TTJ	;	1.98	;	Tryptophan-6-halogenase BorH complexed with 6-chlorotryptophan
1AX4	;	2.1	;	TRYPTOPHANASE FROM PROTEUS VULGARIS
3HV0	;	2.42	;	Tryptophanyl-tRNA synthetase from Cryptosporidium parvum
3FOC	;	2.09	;	Tryptophanyl-tRNA synthetase from Giardia lamblia
3I05	;	2.8	;	Tryptophanyl-tRNA synthetase from Trypanosoma brucei
3HZR	;	3.0	;	Tryptophanyl-tRNA synthetase homolog from Entamoeba histolytica
3PRH	;	2.8	;	tryptophanyl-tRNA synthetase Val144Pro mutant from B. subtilis
2LO7	;		;	Ts16 NMR solution structure
6Z81	;	2.31	;	TsaBD bound to the inhibitor
6S84	;	2.89	;	TsaBDE complex from Thermotoga maritima
3FZJ	;	7.1	;	TsaR low resolution crystal structure, tetragonal form
7A0M	;	2.32	;	TSC1 N-terminal domain
4M5E	;	1.49	;	Tse3 structure
7PHX	;	1.8	;	Tsetse thrombin inhibitor in complex with human alpha-thrombin - acid-stable sulfotyrosine analogue
6TKG	;	1.35	;	Tsetse thrombin inhibitor in complex with human alpha-thrombin - orthorhombic form at 12keV
6TKH	;	1.9	;	Tsetse thrombin inhibitor in complex with human alpha-thrombin - orthorhombic form at 7keV
6TKI	;	1.8	;	Tsetse thrombin inhibitor in complex with human alpha-thrombin - tetragonal form at 12.7keV
6TKJ	;	2.81	;	Tsetse thrombin inhibitor in complex with human alpha-thrombin - tetragonal form at 7keV
1S1Q	;	2.0	;	TSG101(UEV) domain in complex with Ubiquitin
6QTC	;		;	tSH2 domain of transcription elongation factor Spt6 complexed with tyrosine phosphorylated CTD
7XW6	;	2.78	;	TSHR-Gs-M22 antibody-ML109 complex
7XW7	;	5.5	;	TSHR-K1-70 complex
7XW5	;	2.96	;	TSHR-thyroid stimulating hormone-Gs-ML109 complex
8QFZ	;	1.65	;	TSLP-Bicycle complex
6NNW	;	1.7	;	Tsn15 in complex with substrate intermediate
6AEO	;	2.3	;	TssL periplasmic domain
8PZ3	;	3.15	;	TssM - A USP-like DUB from B. pseudomallei (193-430)
8Q00	;	1.62	;	TssM-Ub-PA complex - A USP-like DUB from B. pseudomallei (193-430) reacted with Ub-PA
1TLY	;	3.01	;	Tsx structure
1TLW	;	3.1	;	Tsx structure complexed with thymidine
1TLZ	;	3.1	;	Tsx structure complexed with uridine
3IQB	;	2.1	;	Tt I75F/L144F H-NOX
3QZ8	;	1.999	;	TT-4 ternary complex of Dpo4
1ZFH	;	2.51	;	TTA Duplex B-DNA
4BTJ	;	2.16	;	TTBK1 in complex with ATP
4BTK	;	2.0	;	TTBK1 in complex with inhibitor
4BTM	;	2.54	;	TTBK1 in complex with inhibitor
7QHW	;	2.8	;	TTBK1 kinase domain in complex with inhibitor 29
6U0K	;	1.744	;	TTBK2 kinase domain in complex with Compound 1
1ZFF	;	0.94	;	TTC Duplex B-DNA
3GX2	;	2.9	;	TteSAM-I riboswitch variant A94GU34C bound to sinefungin
6LCK	;	2.85	;	TtGalA, alpha-galactosidase from Thermus thermophilus in complex with p-nitrophenyl alpha-D-galactopyranoside (alpha-NPG)
6LCL	;	3.2	;	TtGalA, alpha-galactosidase from Thermus thermophilus in complex with stachyose
6LCJ	;	2.5	;	TtGalA, alpha-galactosidase from Thermus thermopilus in apo form
7KD8	;	1.71	;	TtgR C137I I141W M167L F168Y mutant in complex with resveratrol
2UXP	;	2.7	;	TtgR in complex Chloramphenicol
2UXU	;	2.3	;	TtgR in complex with Naringenin
2UXH	;	2.4	;	TtgR in complex with Quercetin
7K1C	;	1.9	;	TtgR in complex with resveratrol
2UXO	;	2.7	;	TtgR in complex with Tetracycline
7K1A	;	1.75	;	TtgR quadruple mutant (C137I I141W M167L F168Y)
7V4Y	;	2.4	;	TTHA1264/TTHA1265 complex
3AYT	;	1.95	;	TTHB071 protein from Thermus thermophilus HB8
3AYV	;	1.85	;	TTHB071 protein from Thermus thermophilus HB8 soaking with ZnCl2
7XDU	;	2.6	;	TtherAmDH-NAD+
6B4W	;	2.9	;	TTK in Complex with Inhibitor
5NA0	;	2.9	;	TTK kinase domain in complex with a PEG-linked pyrimido-indolizine
5N9S	;	2.3	;	TTK kinase domain in complex with BAY 1161909
5NAD	;	2.8	;	TTK kinase domain in complex with BAY 1217389
5N7V	;	2.52	;	TTK kinase domain in complex with MPI-0479605
5N84	;	2.3	;	TTK kinase domain in complex with Mps-BAY2b
5N87	;	2.29	;	TTK kinase domain in complex with NTRC 0066-0
5N93	;	2.1	;	TTK kinase domain in complex with TC-Mps1-12
6VZU	;	1.98	;	TTLL6 bound to alpha-elongation analog
6VZT	;	2.18	;	TTLL6 bound to ATP
6VZV	;	2.33	;	TTLL6 bound to gamma-elongation analog
6VZW	;	2.5	;	TTLL6 bound to the initiation analog
7OXG	;	2.0	;	ttSlyD FKBP domain with M8A pseudo-wild-type S2 peptide
7OXJ	;	1.85	;	ttSlyD with M8A pseudo-wild-type S2 peptide
7OXH	;	1.7	;	ttSlyD with pseudo-wild-type S2 peptide
7OXI	;	2.6	;	ttSlyD with W4A pseudo-wild-type S2 peptide
7OXK	;	2.8	;	ttSlyD with W4K pseudo-wild-type S2 peptide
5MKQ	;	2.79	;	TtuA enzyme containing a [4Fe-4S]
8Q29	;	1.5	;	TtX122A - A domain of unknown function from the Teredinibacter turnerae protein TERTU_3803
8Q2A	;	2.2	;	TtX122B - A domain of unknown function from the Teredinibacter turnerae protein TERTU_2913
8Q1V	;	1.4	;	TtX183A - A c-type cytochrome domain from the Teredinibacter turnerae protein TERTU_2913
8Q1W	;	1.8	;	TtX183B - A c-type cytochrome domain from the Teredinibacter turnerae protein TERTU_2913
6QVF	;	1.44	;	TT_C0855 competence pilin from Thermus thermophilus HB27
8AFQ	;	3.3	;	Tube assembly of Atg18-PR72AA
8AFW	;	3.8	;	Tube assembly of Atg18-WT
4AUP	;	1.9	;	Tuber borchii Phospholipase A2
4ASO	;	7.0	;	TubR bound to 24 bp of tubC from Bacillus thuringiensis serovar israelensis pBtoxis
4ASS	;	7.0	;	TubR bound to tubC - 26 bp - from Bacillus thuringiensis serovar israelensis pBtoxis
4ASN	;	3.5	;	TubR from Bacillus megaterium pBM400
8CLC	;	2.7	;	Tubulin (T2R-TTL) complex
8B7A	;	2.25	;	Tubulin - maytansinoid - 4 complex
8B7B	;	2.25	;	Tubulin - maytansinoid - 6 complex
5OV7	;	2.402	;	tubulin - rigosertib complex
4H6Z	;	2.701	;	Tubulin acetyltransferase
4PK2	;	1.35	;	tubulin acetyltransferase complex with bisubstrate analog
4PK3	;	1.347	;	tubulin acetyltransferase complex with bisubstrate analog
4H6U	;	2.4482	;	Tubulin acetyltransferase mutant
1TUB	;	3.7	;	TUBULIN ALPHA-BETA DIMER, ELECTRON DIFFRACTION
5AJ8	;	2.2	;	Tubulin Binding Cofactor C from Leishmania major
5NQU	;	1.8	;	Tubulin Darpin cryo structure
5NQT	;	2.15	;	Tubulin Darpin room-temperature structure determined by serial millisecond crystallography
5NM5	;	2.05	;	Tubulin Darpin room-temperature structure in complex with Colchicine determined by serial millisecond crystallography
6WVR	;	2.9	;	Tubulin dimers from a 13-protofilament, Taxol stabilized microtubule
4YLR	;	2.55	;	Tubulin Glutamylase
4YLS	;	2.6	;	Tubulin Glutamylase
7YSO	;	3.6	;	Tubulin heterodimer structure of GDP-1 state in solution
7YSP	;	3.9	;	Tubulin heterodimer structure of GDP-2 state in solution
7YSN	;	3.5	;	Tubulin heterodimer structure of GMPCPP state in solution
6U0H	;	4.3	;	Tubulin lattice of the ciliary doublet microtubule from Tetrahymena thermophila
5M8D	;	2.25	;	Tubulin MTD265-R1 complex
6LSM	;	2.751	;	Tubulin Polymerization Inhibitors
3TIG	;	2.5	;	Tubulin tyrosine ligase
3TII	;	2.5	;	Tubulin tyrosine ligase
3TIN	;	2.9	;	Tubulin tyrosine ligase
7Z2N	;	2.17	;	Tubulin-18-complex
6GJ4	;	2.4	;	Tubulin-6j complex
6Y6D	;	2.2	;	Tubulin-7-Aminonoscapine complex
5OSK	;	2.11	;	Tubulin-7j complex
3HKC	;	3.8	;	Tubulin-ABT751: RB3 stathmin-like domain complex
6SES	;	2.0	;	Tubulin-B2 complex
8BDE	;	1.902	;	Tubulin-baccatin III complex
4O2A	;	2.5	;	Tubulin-BAL27862 complex
5EYL	;	2.41	;	TUBULIN-BINDING DARPIN
5M7E	;	2.046	;	Tubulin-BKM120 complex
4O2B	;	2.3	;	Tubulin-Colchicine complex
3DU7	;	4.1	;	Tubulin-colchicine-phomopsin A: Stathmin-like domain complex
3E22	;	3.8	;	Tubulin-colchicine-soblidotin: Stathmin-like domain complex
3UT5	;	2.73	;	Tubulin-Colchicine-Ustiloxin: Stathmin-like domain complex
1Z2B	;	4.1	;	Tubulin-colchicine-vinblastine: stathmin-like domain complex
1SA0	;	3.58	;	TUBULIN-COLCHICINE: STATHMIN-LIKE DOMAIN COMPLEX
5LYJ	;	2.397	;	Tubulin-Combretastatin A4 complex
6F7C	;	2.002	;	TUBULIN-Compound 12 complex
6GX7	;	3.19	;	Tubulin-CopN-alphaRep complex
8A0L	;	1.9981	;	Tubulin-CW1-complex
6QTN	;	1.9	;	Tubulin-cyclostreptin complex
5EYP	;	1.9	;	TUBULIN-DARPIN COMPLEX
8CL9	;	2.5	;	Tubulin-DARPin D1 complex
5MF4	;	2.3	;	Tubulin-Dictyostatin complex
5LXT	;	1.9	;	Tubulin-Discodermolide complex
6FJM	;	2.1	;	tubulin-Disorazole Z complex
5JH7	;	2.25	;	Tubulin-Eribulin complex
6FJF	;	2.402	;	Tubulin-FcMaytansine complex
6S9E	;	2.25	;	Tubulin-GDP.AlF complex
6GZE	;	2.49	;	Tubulin-GDP.BeF complex
6TDE	;	2.286	;	Tubulin-inhibitor complex
6TH4	;	2.121	;	Tubulin-inhibitor complex
6GF3	;	2.4	;	Tubulin-Jerantinine B acetate complex
5LXS	;	2.2	;	Tubulin-KS-1-199-32 complex
4O4H	;	2.1	;	Tubulin-Laulimalide complex
4O4I	;	2.4	;	Tubulin-Laulimalide-Epothilone A complex
4TV8	;	2.103	;	Tubulin-Maytansine complex
8B7C	;	1.9	;	Tubulin-maytansinoid-12 complex
5SB8	;	2.3	;	Tubulin-maytansinoid-3-complex
5SB9	;	2.5	;	Tubulin-maytansinoid-4a-complex
5SBA	;	2.25	;	Tubulin-maytansinoid-4b-complex
5SBB	;	2.25	;	Tubulin-maytansinoid-4c-complex
5SBC	;	2.32	;	Tubulin-maytansinoid-5a-complex
5SBD	;	2.25	;	Tubulin-maytansinoid-5b-complex
5SBE	;	2.75	;	Tubulin-maytansinoid-5c-complex
5IYZ	;	1.8	;	Tubulin-MMAE complex
5J2U	;	2.5	;	Tubulin-MMAF complex
5NFZ	;	2.1	;	TUBULIN-MTC complex
5NG1	;	2.2	;	TUBULIN-MTC-zampanolide complex
5M7G	;	2.248	;	Tubulin-MTD147 complex
5M8G	;	2.147	;	Tubulin-MTD265 complex
7Z2P	;	2.0	;	Tubulin-nocodazole complex
7AU5	;	2.2	;	Tubulin-noscapine-analogue-14e complex
3N2K	;	4.0	;	TUBULIN-NSC 613862: RB3 Stathmin-like domain complex
3N2G	;	4.0	;	TUBULIN-NSC 613863: RB3 Stathmin-like domain complex
7ZX2	;	2.5	;	Tubulin-Pelophen B complex
4O4J	;	2.2	;	Tubulin-Peloruside A complex
4O4L	;	2.2	;	Tubulin-Peloruside A-Epothilone A complex
5LA6	;	2.1	;	Tubulin-pironetin complex
4TV9	;	2.0	;	Tubulin-PM060184 complex
1SA1	;	4.2	;	Tubulin-podophyllotoxin: stathmin-like domain complex
8C0F	;	2.1005	;	Tubulin-PTC596 complex
6XER	;	2.5	;	Tubulin-RB3_SLD in complex with colchicine
7TTD	;	2.27	;	Tubulin-RB3_SLD in complex with compound 12e
7TTE	;	2.7	;	Tubulin-RB3_SLD in complex with compound 12j
7TTF	;	2.1	;	Tubulin-RB3_SLD in complex with compound 12k
6XES	;	2.32	;	Tubulin-RB3_SLD in complex with compound 40a
6XET	;	2.6	;	Tubulin-RB3_SLD in complex with compound 60c
6O5N	;	3.003	;	Tubulin-RB3_SLD-TTL in complex with compound 10ab
6O5M	;	2.3	;	Tubulin-RB3_SLD-TTL in complex with compound 10bb
6D88	;	2.853	;	Tubulin-RB3_SLD-TTL in complex with compound 13f
6X1C	;	2.9	;	Tubulin-RB3_SLD-TTL in complex with compound 5j
7LZ7	;	2.8	;	Tubulin-RB3_SLD-TTL in complex with compound 5k
6X1E	;	2.9	;	Tubulin-RB3_SLD-TTL in complex with compound 5l
6X1F	;	2.7	;	Tubulin-RB3_SLD-TTL in complex with compound 5m
7LZ8	;	2.92	;	Tubulin-RB3_SLD-TTL in complex with compound 5t
6O61	;	2.599	;	Tubulin-RB3_SLD-TTL in complex with compound ABI-231
6PC4	;	2.602	;	Tubulin-RB3_SLD-TTL in complex with compound ABI-274
6NNG	;	2.397	;	Tubulin-RB3_SLD-TTL in complex with compound DJ95
6BR1	;	2.304	;	Tubulin-RB3_SLD-TTL in complex with heterocyclic pyrimidine compound 4a
6BRF	;	2.5	;	Tubulin-RB3_SLD-TTL in complex with heterocyclic pyrimidine compound 4b
6BRY	;	2.7	;	Tubulin-RB3_SLD-TTL in complex with heterocyclic pyrimidine compound 6a
6BS2	;	2.65	;	Tubulin-RB3_SLD-TTL in complex with heterocyclic pyrimidine compound 8b
8DIQ	;	2.395	;	Tubulin-RB3_SLD-TTL in complex with SB226
4TUY	;	2.1	;	Tubulin-Rhizoxin complex
6FII	;	2.405	;	Tubulin-Spongistatin complex
6HX8	;	2.402	;	Tubulin-STX3451 complex
3HKE	;	3.6	;	Tubulin-T138067: RB3 stathmin-like domain complex
8BDF	;	1.95	;	Tubulin-taxane-2a complex
8BDG	;	2.35	;	Tubulin-taxane-2b complex
6QQN	;	2.301	;	Tubulin-TH588 complex
3HKD	;	3.7	;	Tubulin-TN16 : RB3 stathmin-like domain complex
5SB6	;	2.3	;	Tubulin-todalam-10-complex
5SB7	;	2.1	;	Tubulin-todalam-18-complex
5SB3	;	2.2	;	Tubulin-todalam-4-complex
5SB4	;	2.5	;	Tubulin-todalam-8-complex
5SB5	;	2.31	;	Tubulin-todalam-9-complex
7Z7D	;	2.0	;	Tubulin-Todalam-Vinblastine-complex
6FKL	;	2.098	;	Tubulin-TUB015 complex
6FKJ	;	2.148	;	Tubulin-TUB075 complex
5JVD	;	2.393	;	Tubulin-TUB092 complex
5J2T	;	2.2	;	Tubulin-vinblastine complex
4EB6	;	3.47	;	Tubulin-Vinblastine: Stathmin-like complex
8JJC	;	2.76	;	Tubulin-Y62
5S62	;	2.75	;	Tubulin-Z100642432-complex
5S55	;	2.3	;	Tubulin-Z106307058-complex
5S5U	;	2.5	;	Tubulin-Z1124201124-complex
5S5G	;	2.69	;	Tubulin-Z1129283193-complex
5S5J	;	2.25	;	Tubulin-Z1148747945-complex
5S4R	;	2.35	;	Tubulin-Z117233350-complex
5S51	;	2.4	;	Tubulin-Z1251207602-complex
5S59	;	2.6	;	Tubulin-Z1324080698-complex
5S53	;	2.75	;	Tubulin-Z1349163663-complex
5S65	;	2.25	;	Tubulin-Z1354416068-complex
5S4W	;	2.8	;	Tubulin-Z1416571195-complex
5S5A	;	2.35	;	Tubulin-Z1449748885-complex
5S5L	;	2.25	;	Tubulin-Z1492796719-complex
5S5E	;	2.67	;	Tubulin-Z1515654336-complex
5S5N	;	2.9	;	Tubulin-Z165170770-complex
5S5S	;	2.36	;	Tubulin-Z166605480-complex
5S4L	;	2.3	;	Tubulin-Z1891773393-complex
5S67	;	2.1	;	Tubulin-Z1896597864-complex
5S5T	;	2.53	;	Tubulin-Z198194394-complex
5S5H	;	2.5	;	Tubulin-Z2074076908-complex
5S4M	;	2.15	;	Tubulin-Z2142244288-complex
5S63	;	2.6	;	Tubulin-Z2241115980-complex
5S4S	;	2.35	;	Tubulin-Z240297434-complex
5S5K	;	2.41	;	Tubulin-Z2472938267-complex
5S5Y	;	2.26	;	Tubulin-Z26781952-complex
5S4P	;	2.29	;	Tubulin-Z275165822-complex
5S5O	;	2.3	;	Tubulin-Z27682767-complex
5S60	;	2.3	;	Tubulin-Z27695365-complex
5S4Z	;	2.1	;	Tubulin-Z28290384-complex
5S56	;	2.25	;	Tubulin-Z2856434783-complex
5S54	;	2.4	;	Tubulin-Z2856434816-complex
5S58	;	2.3	;	Tubulin-Z2856434826-complex
5S4Y	;	2.3	;	Tubulin-Z2856434857-complex
5S57	;	2.45	;	Tubulin-Z2856434883-complex
5S4X	;	2.53	;	Tubulin-Z2856434917-complex
5S66	;	2.1	;	Tubulin-Z2856434929-complex
5S5Z	;	2.55	;	Tubulin-Z2856434944-complex
5S4N	;	2.53	;	Tubulin-Z285782452-complex
5S64	;	2.75	;	Tubulin-Z28870646-complex
5S5I	;	2.49	;	Tubulin-Z295848548-complex
5S4U	;	2.39	;	Tubulin-Z30620520-complex
5S5V	;	2.7	;	Tubulin-Z32386228-complex
5S5D	;	1.9	;	Tubulin-Z32400357-complex
5S4T	;	2.27	;	Tubulin-Z328695024-complex
5S5R	;	2.3	;	Tubulin-Z33452106-complex
5S5Q	;	2.05	;	Tubulin-Z396380540-complex
5S4Q	;	2.59	;	Tubulin-Z422344882-complex
5S5C	;	2.4	;	Tubulin-Z44592329-complex
5S5M	;	2.7	;	Tubulin-Z45527714-complex
5S5X	;	2.32	;	Tubulin-Z45705015-complex
5S4O	;	2.3	;	Tubulin-Z48847594-complex
5S52	;	2.83	;	Tubulin-Z50145861-complex
5S5P	;	2.79	;	Tubulin-Z53825177-complex
5S5W	;	2.35	;	Tubulin-Z53860899-complex
5S4V	;	2.3	;	Tubulin-Z57040482-complex
5S50	;	3.1	;	Tubulin-Z57299526-complex
5S61	;	1.95	;	Tubulin-Z57472297-complex
5S5F	;	2.24	;	Tubulin-Z87615031-complex
5S5B	;	2.3	;	Tubulin-Z906021418-complex
8A9T	;	2.304	;	Tubulin-[1,2]oxazoloisoindole-1 complex
8A9Z	;	2.294	;	Tubulin-[1,2]oxazoloisoindole-2e complex
3HKB	;	3.65	;	Tubulin: RB3 Stathmin-like domain complex
3RYC	;	2.1	;	Tubulin: RB3 stathmin-like domain complex
6GVM	;	3.5	;	Tubulin:F3II DARPin complex
6GWC	;	2.6	;	Tubulin:iE5 alphaRep complex
6GWD	;	3.2	;	Tubulin:iiH5 alphaRep complex
1FFX	;	3.95	;	TUBULIN:STATHMIN-LIKE DOMAIN COMPLEX
4F61	;	4.17	;	Tubulin:Stathmin-like domain complex
4F6R	;	2.64	;	Tubulin:Stathmin-like domain complex
6GVN	;	2.69	;	Tubulin:TM-3 DARPin complex
7W2P	;	1.15	;	Tudor domain of SMN in complex with a small molecule
7W30	;	1.8	;	Tudor domain of SMN in complex with a small molecule
6V9T	;	2.154	;	Tudor domain of TDRD3 in complex with a small molecule
8JTN	;	1.8	;	Tudor domain of TDRD3 in complex with a small molecule
6UPT	;	1.96	;	Tudor Domain of Tumor suppressor p53BP1 with MFP-2706
6VA5	;	1.28	;	Tudor Domain of Tumor suppressor p53BP1 with MFP-4184
8F0W	;	1.52	;	Tudor Domain of Tumor suppressor p53BP1 with MFP-5956
8EOM	;	1.7	;	TUDOR DOMAIN OF TUMOR SUPPRESSOR P53BP1 WITH MFP-5973
6VIP	;	1.36	;	TUDOR DOMAIN OF TUMOR SUPPRESSOR P53BP1 WITH MFP-6008
4RG2	;	1.5	;	Tudor Domain of Tumor suppressor p53BP1 with small molecule ligand
6B57	;	1.93	;	tudor in complex with ligand
8IYS	;	2.95	;	TUG891-bound FFAR4 in complex with Gq
1KYJ	;		;	Tumor Associated Mucin Motif from CD43 protein
1A8M	;	2.3	;	TUMOR NECROSIS FACTOR ALPHA, R31D MUTANT
8HZ2	;	2.6	;	Tumor Necrosis Factor Receptor Associated Factor 6 (TRAF6) N-terminal Domain
1D9S	;		;	TUMOR SUPPRESSOR P15(INK4B) STRUCTURE BY COMPARATIVE MODELING AND NMR DATA
1TUP	;	2.2	;	TUMOR SUPPRESSOR P53 COMPLEXED WITH DNA
8DS7	;	1.88	;	Tumor-activated antibody derivatives targeting CTLA4
5MY5	;	1.4	;	Tungstate binding protein - TupA - from Desulfovibrio alaskensis G20
1H9R	;	1.9	;	Tungstate bound complex Dimop domain of ModE from E.coli
1E3P	;	2.5	;	tungstate derivative of Streptomyces antibioticus PNPase/GPSI enzyme
1V0R	;	1.7	;	Tungstate-inhibited phospholipase D from Streptomyces sp. strain PMF
1H0H	;	1.8	;	Tungsten containing Formate Dehydrogenase from Desulfovibrio Gigas
5T5I	;	1.9	;	TUNGSTEN-CONTAINING FORMYLMETHANOFURAN DEHYDROGENASE FROM METHANOTHERMOBACTER WOLFEII, ORTHORHOMBIC FORM AT 1.9 A
5T61	;	2.55	;	TUNGSTEN-CONTAINING FORMYLMETHANOFURAN DEHYDROGENASE FROM METHANOTHERMOBACTER WOLFEII, TRICLINIC FORM AT 2.55 A
5T5M	;	2.5	;	TUNGSTEN-CONTAINING FORMYLMETHANOFURAN DEHYDROGENASE FROM METHANOTHERMOBACTER WOLFEII, TRIGONAL FORM AT 2.5 A.
1E18	;	2.0	;	TUNGSTEN-SUSBSTITUTED DMSO REDUCTASE FROM RHODOBACTER CAPSULATUS
7ERR	;	2.26	;	Tunnel-redesigned O2-tolerant CO dehydrogenase for removal of CO in real flue gas (Aerobic ChCODH2 A559W mutant)
7XDN	;	1.8	;	Tunnel-redesigned O2-tolerant CO dehydrogenase for removal of CO in real flue gas (ChCODH2 A559H mutant in anaerobic condition)
7XDP	;	1.84	;	Tunnel-redesigned O2-tolerant CO dehydrogenase for removal of CO in real flue gas (ChCODH2 A559S mutant in anaerobic condition)
2Y02	;	2.6	;	TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND AGONIST CARMOTEROL
2Y03	;	2.85	;	TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND AGONIST ISOPRENALINE
2YCW	;	3.0	;	TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND ANTAGONIST CARAZOLOL
2YCX	;	3.25	;	TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND ANTAGONIST CYANOPINDOLOL
2YCY	;	3.15	;	TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND ANTAGONIST CYANOPINDOLOL
2YCZ	;	3.65	;	TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND ANTAGONIST IODOCYANOPINDOLOL
4AMI	;	3.2	;	Turkey beta1 adrenergic receptor with stabilising mutations and bound biased agonist bucindolol
4AMJ	;	2.3	;	Turkey beta1 adrenergic receptor with stabilising mutations and bound biased agonist carvedilol
2VT4	;	2.7	;	TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND CYANOPINDOLOL
2Y01	;	2.6	;	TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND PARTIAL AGONIST DOBUTAMINE (CRYSTAL DOB102)
2Y00	;	2.5	;	TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND PARTIAL AGONIST DOBUTAMINE (CRYSTAL DOB92)
2Y04	;	3.05	;	TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND PARTIAL AGONIST SALBUTAMOL
1JEF	;	1.77	;	TURKEY LYSOZYME COMPLEX WITH (GLCNAC)3
1N0A	;		;	Turn stability in beta-hairpin peptides: 3:5 type I G1 bulge turns
6L4V	;	1.35	;	Turning an asparaginyl endopeptidase into a peptide ligase
6L4W	;	1.66	;	Turning an asparaginyl endopeptidase into a peptide ligase
6L4X	;	2.644	;	Turning an asparaginyl endopeptidase into a peptide ligase
6L4Y	;	1.5	;	Turning an asparaginyl endopeptidase into a peptide ligase
6LKO	;	2.0	;	Turning an asparaginyl endopeptidase into a peptide ligase
1AUY	;	3.0	;	TURNIP YELLOW MOSAIC VIRUS
5LW5	;	1.649	;	TURNIP YELLOW MOSAIC VIRUS PROTEASE/DEUBIQUITINASE DOMAIN, DELTAC5 MUTANT
5LWA	;	1.653	;	TURNIP YELLOW MOSAIC VIRUS PROTEASE/DEUBIQUITINASE DOMAIN, I847A MUTANT
4A5U	;	2.0	;	Turnip yellow mosaic virus proteinase and Escherichia coli 30S ribosomal S15
7ULN	;	1.53	;	Turnip yellows virus N-terminal readthrough domain
6LXO	;	1.89	;	TvCyP2 in apo form 1
6LXP	;	2.35	;	TvCyP2 in apo form 2
6LXQ	;	1.85	;	TvCyP2 in apo form 3
6LXR	;	2.56	;	TvCyP2 in apo form 4
4Q5B	;	1.8	;	TvNiR in complex with sulfite, high dose data set
4Q4U	;	1.62	;	TvNiR in complex with sulfite, low dose data set
4Q5C	;	1.62	;	TvNiR in complex with sulfite, middle dose data set
7LWY	;	4.0	;	TVV viral capsid protein
7M12	;	4.0	;	TVV2 capsid protein
6WKU	;	1.76	;	Twelve Chloride Ions Drive Assembly of Human alpha345 Collagen IV NC1 domain
6MPX	;	1.9	;	Twelve chloride ions induce formation and stabilize the NC1 hexamer of collagen IV assembled from transition state trimers
1XC0	;		;	Twenty Lowest Energy Structures of Pa4 by Solution NMR
6B8G	;	1.13	;	Twice-Contracted Human Heavy-Chain Ferritin Crystal-Hydrogel Hybrid
7SK0	;	3.33	;	TWIK1 in MSP1D1 lipid nanodisc at pH 7.4
7SK1	;	3.43	;	TWIK1 in MSP1E3D1 Lipid Nanodisc at pH 5.5
4YNG	;	2.28	;	Twinned pyruvate kinase from E. coli in the T-state
3GPD	;	3.5	;	TWINNING IN CRYSTALS OF HUMAN SKELETAL MUSCLE D-GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE
5NYZ	;	2.5	;	Twist and induce: Dissecting the link between the enzymatic activity and the SaPI inducing capacity of the phage 80 dUTPase. D95E mutant from dUTPase 80alpha phage.
5NZ2	;	2.85	;	Twist and induce: Dissecting the link between the enzymatic activity and the SaPI inducing capacity of the phage 80 dUTPase. D95E mutant from dUTPase 80alpha phage.
7QDU	;	5.14	;	Twist-corrected RNA origami 5-helix Tile A
7ARY	;	8.5	;	Twist-Tower_twist-corrected-variant
8OSB	;	2.9	;	TWIST1-TCF4-ALX4 complex on specific DNA
1KEO	;	2.2	;	TWISTS AND TURNS OF THE CD-MPR: LIGAND-BOUND VERSUS LIGAND-FREE RECEPTOR
7ARV	;	7.4	;	TwistTower_native-twist
1WIU	;		;	TWITCHIN IMMUNOGLOBULIN SUPERFAMILY DOMAIN (IGSF MODULE) (IG 18'), NMR, 30 STRUCTURES
1WIT	;		;	TWITCHIN IMMUNOGLOBULIN SUPERFAMILY DOMAIN (IGSF MODULE) (IG 18'), NMR, MINIMIZED AVERAGE STRUCTURE
1KOB	;	2.3	;	TWITCHIN KINASE FRAGMENT (APLYSIA), AUTOREGULATED PROTEIN KINASE DOMAIN
1KOA	;	3.3	;	TWITCHIN KINASE FRAGMENT (C.ELEGANS), AUTOREGULATED PROTEIN KINASE AND IMMUNOGLOBULIN DOMAINS
3UTO	;	2.4	;	Twitchin kinase region from C.elegans (Fn31-NL-kin-CRD-Ig26)
5EAO	;	2.988	;	Two active site divalent ion in the crystal structure of the hammerhead ribozyme bound to a transition state analog-Mg2+
5EAQ	;	3.201	;	Two active site divalent ion in the crystal structure of the hammerhead ribozyme bound to a transition state analog-Mn2+
5E54	;	2.3	;	Two apo structures of the adenine riboswitch aptamer domain determined using an X-ray free electron laser
1PRL	;		;	TWO BINDING ORIENTATIONS FOR PEPTIDES TO SRC SH3 DOMAIN: DEVELOPMENT OF A GENERAL MODEL FOR SH3-LIGAND INTERACTIONS
1PRM	;		;	TWO BINDING ORIENTATIONS FOR PEPTIDES TO SRC SH3 DOMAIN: DEVELOPMENT OF A GENERAL MODEL FOR SH3-LIGAND INTERACTIONS
1RLP	;		;	TWO BINDING ORIENTATIONS FOR PEPTIDES TO SRC SH3 DOMAIN: DEVELOPMENT OF A GENERAL MODEL FOR SH3-LIGAND INTERACTIONS
1RLQ	;		;	TWO BINDING ORIENTATIONS FOR PEPTIDES TO SRC SH3 DOMAIN: DEVELOPMENT OF A GENERAL MODEL FOR SH3-LIGAND INTERACTIONS
8AAD	;	2.04	;	Two carbons pendant pyridine derivative of the natural alkaloid Berberine as Human Telomeric G-quadruplex Binder
3FGR	;	1.8	;	Two chain form of the 66.3 kDa protein at 1.8 Angstroem
3FGT	;	2.4	;	Two chain form of the 66.3 kDa protein from mouse lacking the linker peptide
1ZZ2	;	2.0	;	Two Classes of p38alpha MAP Kinase Inhibitors Having a Common Diphenylether Core but Exhibiting Divergent Binding Modes
1TRH	;	2.1	;	TWO CONFORMATIONAL STATES OF CANDIDA RUGOSA LIPASE
7A54	;	2.7	;	Two copies of the catalytic domain of NanA sialidase from Streptococcus pneumoniae juxtaposed in the P212121 space group, in complex with DANA
7A5X	;	1.94	;	Two copies of the catalytic domain of NanA sialidase from Streptococcus pneumoniae juxtaposed in the P212121 space group, in complex with DANA derivatized with a PEG linker on the glycerol group.
1MOL	;	1.7	;	TWO CRYSTAL STRUCTURES OF A POTENTLY SWEET PROTEIN: NATURAL MONELLIN AT 2.75 ANGSTROMS RESOLUTION AND SINGLE-CHAIN MONELLIN AT 1.7 ANGSTROMS RESOLUTION
1PGB	;	1.92	;	TWO CRYSTAL STRUCTURES OF THE B1 IMMUNOGLOBULIN-BINDING DOMAIN OF STREPTOCCOCAL PROTEIN G AND COMPARISON WITH NMR
1PGA	;	2.07	;	TWO CRYSTAL STRUCTURES OF THE B1 IMMUNOGLOBULIN-BINDING DOMAIN OF STREPTOCOCCAL PROTEIN G AND COMPARISON WITH NMR
1H9M	;	1.65	;	Two crystal structures of the cytoplasmic molybdate-binding protein ModG suggest a novel cooperative binding mechanism and provide insights into ligand-binding specificity. PEG-grown form with molybdate bound
1H9J	;	1.8	;	Two crystal structures of the cytoplasmic molybdate-binding protein ModG suggest a novel cooperative binding mechanism and provide insights into ligand-binding specificity. Phosphate-grown form with molybdate and phosphate bound
1H9K	;	1.8	;	Two crystal structures of the cytoplasmic molybdate-binding protein ModG suggest a novel cooperative binding mechanism and provide insights into ligand-binding specificity. Phosphate-grown form with tungstate and phosphate bound
4KBF	;	1.9	;	two different open conformations of the helicase core of the RNA helicase Hera
4QEI	;	2.875	;	Two distinct conformational states of GlyRS captured in crystal lattice
1STG	;	1.7	;	TWO DISTINCTLY DIFFERENT METAL BINDING MODES ARE SEEN IN X-RAY CRYSTAL STRUCTURES OF STAPHYLOCOCCAL NUCLEASE-COBALT(II)-NUCLEOTIDE COMPLEXES
1STH	;	1.85	;	TWO DISTINCTLY DIFFERENT METAL BINDING MODES ARE SEEN IN X-RAY CRYSTAL STRUCTURES OF STAPHYLOCOCCAL NUCLEASE-COBALT(II)-NUCLEOTIDE COMPLEXES
5DH8	;	3.297	;	Two divalent metal ions and conformational changes play roles in the hammerhead ribozyme cleavage reaction- G12A mutant in Zn2+
5DH6	;	2.784	;	Two divalent metal ions and conformational changes play roles in the hammerhead ribozyme cleavage reaction-G12A mutant in Mg2+
5DH7	;	3.064	;	Two divalent metal ions and conformational changes play roles in the hammerhead ribozyme cleavage reaction-G12A mutant in Mn2+
5DQK	;	2.707	;	Two divalent metal ions and conformational changes play roles in the hammerhead ribozyme cleavage reaction-WT ribozyme in Mg2+
5DI2	;	2.989	;	Two divalent metal ions and conformational changes play roles in the hammerhead ribozyme cleavage reaction-WT ribozyme in Mn2+ at high pH
5DI4	;	2.948	;	Two divalent metal ions and conformational changes play roles in the hammerhead ribozyme cleavage reaction-WT ribozyme in Mn2+ at low pH
3F9K	;	3.2	;	Two domain fragment of HIV-2 integrase in complex with LEDGF IBD
2VY6	;	1.95	;	Two domains from the C-terminal region of influenza A virus polymerase PB2 subunit
1QR4	;	2.55	;	TWO FIBRONECTIN TYPE-III DOMAIN SEGMENT FROM CHICKEN TENASCIN
1IFM	;	3.3	;	TWO FORMS OF PF1 INOVIRUS: X-RAY DIFFRACTION STUDIES ON A STRUCTURAL PHASE TRANSITION AND A CALCULATED LIBRATION NORMAL MODE OF THE ASYMMETRIC UNIT
1IFN	;	4.0	;	TWO FORMS OF PF1 INOVIRUS: X-RAY DIFFRACTION STUDIES ON A STRUCTURAL PHASE TRANSITION AND A CALCULATED LIBRATION NORMAL MODE OF THE ASYMMETRIC UNIT
6ILA	;	2.69	;	Two Glycerol complexed Crystal structure of fructuronate-tagaturonate epimerase UxaE from Cohnella laeviribosi
3JBH	;	20.0	;	TWO HEAVY MEROMYOSIN INTERACTING-HEADS MOTIFS FLEXIBLE DOCKED INTO TARANTULA THICK FILAMENT 3D-MAP ALLOWS IN DEPTH STUDY OF INTRA- AND INTERMOLECULAR INTERACTIONS
2F55	;	3.3	;	Two hepatitis c virus ns3 helicase domains complexed with the same strand of dna
1MX7	;		;	Two homologous rat cellular retinol-binding proteins differ in local structure and flexibility
1MX8	;		;	Two homologous rat cellular retinol-binding proteins differ in local structure and flexibility
1FOS	;	3.05	;	TWO HUMAN C-FOS:C-JUN:DNA COMPLEXES
5XJV	;	1.69	;	Two intermediate states of conformation switch in dual specificity phosphatase 13a
2WZA	;	2.082	;	Two intramolecular isopeptide bonds are identified in the crystal structure of the Streptococcus gordonii SspB C-terminal domain
6A4E	;	2.45	;	Two linked uridine bound Oligoribonuclease (ORN) from Colwellia psychrerythraea strain 34H
5A2F	;	1.86	;	Two membrane distal IgSF domains of CD166
4LQJ	;	1.2	;	Two minutes iron loaded frog M ferritin
6I9T	;	1.2	;	Two minutes iron loaded Rana Catesbeiana H' ferritin variant H54N
7YLB	;	2.41	;	Two monobodies recognizing the conserved epitopes of SARS-CoV-2 N antigen applicable to the broad COVID-19 diagnosis
6XJD	;	6.8	;	Two mouse cGAS catalytic domain binding to human assembled nucleosome
6GK3	;	3.975	;	Two protofilament beta-2-microglobulin amyloid fibril
1NQ2	;	2.4	;	Two RTH Mutants with Impaired Hormone Binding
1NUO	;	3.1	;	Two RTH Mutants with Impaired Hormone Binding
1NR0	;	1.7	;	Two Seven-Bladed Beta-Propeller Domains Revealed By The Structure Of A C. elegans Homologue Of Yeast Actin Interacting Protein 1 (AIP1).
6ZT1	;	2.01	;	Two states of a de novo hexameric coiled coil assembly CC-Type2-(LaIdGe)4
1PHK	;	2.2	;	TWO STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHORYLASE, KINASE: AN ACTIVE PROTEIN KINASE COMPLEXED WITH NUCLEOTIDE, SUBSTRATE-ANALOGUE AND PRODUCT
3TO1	;	2.6	;	Two surfaces on Rtt106 mediate histone binding and chaperone activity
5KWQ	;	2.8	;	Two Tandem RRM Domains of FBP-Interacting Repressor (FIR), also Known as PUF60
5KW6	;	1.91	;	Two Tandem RRM Domains of PUF60 Bound to an AdML Pre-mRNA 3' Splice Site Analogue with a Modified Binding-Site Nucleic Acid Base
5FF1	;	1.97	;	Two way mode of binding of antithyroid drug methimazole to mammalian heme peroxidases: Structure of the complex of lactoperoxidase with methimazole at 1.97 Angstrom resolution
1HIP	;	2.0	;	TWO-ANGSTROM CRYSTAL STRUCTURE OF OXIDIZED CHROMATIUM HIGH POTENTIAL IRON PROTEIN
2UXZ	;	1.75	;	Two-Carbon-Elongated HIV-1 Protease Inhibitors with a Tertiary- Alcohol-Containing Transition-State Mimic
2UY0	;	1.76	;	Two-Carbon-Elongated HIV-1 Protease Inhibitors with a Tertiary- Alcohol-Containing Transition-State Mimic
8QOX	;	11.2	;	Two-component assembly of SlaA and SlaB S-layer proteins of Sulfolobus acidocaldarius
6X1I	;	4.32	;	Two-Component D3 Assembly Constructed by Fusing Symmetric Oligomers to Coiled Coils
1JE8	;	2.12	;	Two-Component response regulator NarL/DNA Complex: DNA Bending Found in a High Affinity Site
1E6K	;	2.0	;	Two-component signal transduction system D12A mutant of CheY
1E6L	;	1.9	;	Two-component signal transduction system D13A mutant of CheY
1E6M	;	1.7	;	TWO-COMPONENT SIGNAL TRANSDUCTION SYSTEM D57A MUTANT OF CHEY
6LKG	;	1.948	;	two-component system protein mediate signal transduction
6LKH	;	2.534	;	Two-component system protein mediate signal transduction
6LKI	;	1.781	;	Two-component system protein mediate signal transduction
6LKJ	;	2.004	;	Two-component system protein mediate signal transduction
6LKK	;	1.502	;	Two-component system protein mediate signal transduction
6LKL	;	2.213	;	Two-component system protein mediate signal transduction
1NOR	;		;	TWO-DIMENSIONAL 1H-NMR STUDY OF THE SPATIAL STRUCTURE OF NEUROTOXIN II FROM NAJA OXIANA
3KW8	;	2.29	;	Two-domain laccase from Streptomyces coelicolor at 2.3 A resolution
4GYB	;	2.4	;	Two-domain laccase from streptomyces lividans at 2.4 A resolution AC1709
4N8U	;	2.4	;	Two-Domain Laccase from Streptomyces viridochromogenes at 2.4 A resolution AC629
2N70	;		;	Two-fold symmetric structure of the 18-60 construct of S31N M2 from Influenza A in lipid bilayers
6HSY	;	2.53	;	Two-phospholipid-bound crystal structure of the substrate-binding protein Ttg2D from Pseudomonas aeruginosa
6V1Q	;	3.11	;	Two-pore channel 3
6ZRQ	;	3.9	;	two-protofilament amyloid structure of S20G variant of human amylin (IAPP - islet amyloid polypeptide)
6GH0	;		;	Two-quartet kit* G-quadruplex is formed via double-stranded pre-folded structure
3LB1	;	1.76	;	Two-site competitive inhibition in dehaloperoxidase-hemoglobin
3LB2	;	1.06	;	Two-site competitive inhibition in dehaloperoxidase-hemoglobin
3LB3	;	1.85	;	Two-site competitive inhibition in dehaloperoxidase-hemoglobin
3LB4	;	1.56	;	Two-site competitive inhibition in dehaloperoxidase-hemoglobin
6BY5	;		;	Two-State 14-mer UUCG Tetraloop calculated from Exact NOEs (State one: Conformers 1-5, State Two: Conformers 6-10)
7QCX	;		;	Two-state liquid NMR Structure of a PDZ2 Domain from hPTP1E, apo form
7QCY	;		;	Two-state liquid NMR Structure of a PDZ2 Domain from hPTP1E, complexed with RA-GEF2 peptide
7SA5	;		;	Two-state solution NMR structure of Apo Pin1
7SUQ	;		;	Two-state solution NMR structure of Pin1 bound to peptide FFpSPR
7SUR	;		;	Two-state solution NMR structure of Pin1 bound to peptide pCDC25c
6QS4	;	4.2	;	Two-Step Activation Mechanism of the ClpB Disaggregase for Sequential Substrate Threading by the Main ATPase Motor.
7XBJ	;	2.08	;	Txp40, an insecticidal toxin protein from Xenorhabdus nematophila
8UXR	;		;	TxVIIB,U-superfamily conotoxin
4OL8	;	3.1	;	Ty3 reverse transcriptase bound to DNA/RNA
4GJ3	;	2.5	;	Tyk2 (JH1) in complex with 2,6-dichloro-4-cyano-N-[2-({[(1R,2R)-2-fluorocyclopropyl]carbonyl}amino)pyridin-4-yl]benzamide
4GII	;	2.31	;	Tyk2 (JH1) in complex with 2,6-dichloro-4-cyano-N-{2-[(cyclopropylcarbonyl)amino]pyridin-4-yl}benzamide
4GJ2	;	2.4	;	Tyk2 (JH1) in complex with 2,6-dichloro-N-[2-({[(1R,2R)-2-fluorocyclopropyl]carbonyl}amino)pyridin-4-yl]benzamide
4GIH	;	2.0	;	Tyk2 (JH1) in complex with 2,6-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
4GVJ	;	2.03	;	Tyk2 (JH1) in complex with adenosine di-phosphate
8TB6	;	1.96	;	TYK2 JH2 bound to Compound14
8TB5	;	2.32	;	TYK2 JH2 bound to Compound7
4GFO	;	2.3	;	TYK2 kinase (JH1 domain) with 2,6-DICHLORO-N-(2-OXO-2,5-DIHYDROPYRIDIN-4-YL)BENZAMIDE
6DBM	;	2.368	;	Tyk2 with compound 23
6DBK	;	2.0	;	Tyk2 with compound 8
7VG8	;	2.04	;	TYLCV Rep-DNA
6B11	;	1.99	;	TylHI in complex with native substrate 23-deoxy-5-O-mycaminosyl-tylonolide (23-DMTL)
1I5R	;	1.6	;	TYPE 1 17-BETA HYDROXYSTEROID DEHYDROGENASE EM1745 COMPLEX
1EQU	;	3.0	;	TYPE 1 17-BETA HYDROXYSTEROID DEHYDROGENASE EQUILIN COMPLEXED WITH NADP+
2VMJ	;	2.5	;	Type 1 Copper-Binding Loop of Nitrite Reductase mutant: 130- CAPEGMVPWHVVSGM-144 to 130-CTPHPFM-136
1IGR	;	2.6	;	Type 1 Insulin-like growth factor receptor (DOMAINS 1-3)
6NT2	;	2.48	;	type 1 PRMT in complex with the inhibitor GSK3368715
1A41	;	2.3	;	TYPE 1-TOPOISOMERASE CATALYTIC FRAGMENT FROM VACCINIA VIRUS
7V47	;	2.8	;	Type 1A alpha-synuclein fibril seeded by cerebrospinal fluid from a preclinical Parkinson's disease patient
7NCA	;	3.47	;	Type 1A alpha-synuclein filament seeded in vitro by filaments purified from Multiple Systems Atrophy Case 2
7NCH	;	3.84	;	Type 1B alpha-synuclein filament seeded in vitro by filaments purified from Multiple Systems Atrophy Case 1
7XO3	;	2.6	;	Type 1C alpha-synuclein fibril seeded by cerebrospinal fluid from a mid-to-late stage (mid-PD-4) Parkinson's disease patient
7V48	;	3.0	;	Type 1D alpha-synuclein fibril seeded by cerebrospinal fluid from a postmortal Parkinson's disease patient
4N02	;	1.4	;	Type 2 IDI from S. pneumoniae
3I57	;	1.8	;	Type 2 repeat of the mucus binding protein MUB from Lactobacillus reuteri
1CQQ	;	1.85	;	TYPE 2 RHINOVIRUS 3C PROTEASE WITH AG7088 INHIBITOR
7NCG	;	3.43	;	Type 2A alpha-synuclein filament seeded in vitro by filaments purified from Multiple Systems Atrophy Case 2
7NCJ	;	4.23	;	Type 2AB alpha-synuclein filament seeded in vitro by filaments purified from Multiple Systems Atrophy Case 1
7NCI	;	3.55	;	Type 2B alpha-synuclein filament seeded in vitro by filaments purified from Multiple Systems Atrophy Case 1
7NCK	;	3.18	;	Type 3 alpha-synuclein filament seeded in vitro by filaments purified from Multiple Systems Atrophy Case 5
8AXK	;	4.05	;	Type 3 secretion system export apparatus core, inner rod and needle of Shigella flexneri
7V49	;	3.4	;	Type 4 alpha-synuclein fibril seeded by cerebrospinal fluid from a postmortal Parkinson's disease patient
6WIN	;	2.05	;	Type 6 secretion amidase effector 2 (Tae2)
1YUG	;		;	TYPE ALPHA TRANSFORMING GROWTH FACTOR, NMR, 15 MODELS AFTER ECEPP/3 ENERGY MINIMIZATION
1YUF	;		;	TYPE ALPHA TRANSFORMING GROWTH FACTOR, NMR, 16 MODELS WITHOUT ENERGY MINIMIZATION
8AZS	;	2.9	;	Type I amyloid-beta 42 filaments from high-spin supernatants of aqueous extracts from Alzheimer's disease brains | ABeta42
8SEJ	;	3.17	;	Type I beta-amyloid 42 Filaments from Down syndrome
7Q4B	;	2.5	;	Type I beta-amyloid 42 Filaments from Human Brain
6NXD	;	1.9	;	TYPE I L-ASPARAGINASE FROM ESCHERICHIA COLI IN COMPLEX WITH CITRATE AT PH 4
8G7W	;	3.4	;	Type I modPKS reducing region
2PNG	;		;	Type I rat fatty acid synthase acyl carrier protein (ACP) domain
8D3Q	;	3.9	;	Type I-C Cas4-Cas1-Cas2 complex bound to a PAM/NoPAM prespacer
8D3L	;	3.49	;	Type I-C Cas4-Cas1-Cas2 complex bound to a PAM/PAM prespacer
8D3M	;	3.41	;	Type I-C Cas4-Cas1-Cas2 complex bound to a PAM/Processed prespacer
8D3P	;	4.26	;	Type I-C Cas4-Cas1-Cas2 complex bound to half-site integration intermediate (HSI)
8DEX	;	2.7	;	type I-C Cascade
8DFO	;	3.1	;	type I-C Cascade bound to AcrIC4
8DFS	;	3.0	;	type I-C Cascade bound to AcrIF2
8DFA	;	2.8	;	type I-C Cascade bound to ssDNA target
7VEH	;	2.95	;	Type I-F Anti-CRISPR protein AcrIF13
6VQX	;	3.15	;	Type I-F CRISPR-Csy complex with its inhibitor AcrF6
6VQW	;	3.42	;	Type I-F CRISPR-Csy complex with its inhibitor AcrF8
6VQV	;	2.57	;	Type I-F CRISPR-Csy complex with its inhibitor AcrF9
1UQR	;	1.7	;	Type II 3-dehydroquinate dehydratase (DHQase) from Actinobacillus pleuropneumoniae
8AZT	;	3.7	;	Type II amyloid-beta 42 filaments from high-spin supernatants of aqueous extracts from Alzheimer's disease brains | ABeta42
4UWM	;	1.9	;	Type II Baeyer-Villiger monooxygenase.The oxygenating constituent of 3,6-diketocamphane monooxygenase from CAM plasmid of Pseudomonas putida in complex with FMN.
5AEC	;	1.93	;	Type II Baeyer-Villiger monooxygenase.The oxygenating constituent of 3,6-diketocamphane monooxygenase from CAM plasmid of Pseudomonas putida in complex with FMN.
7Q4M	;	2.8	;	Type II beta-amyloid 42 Filaments from Human Brain
4E6Y	;	2.5	;	Type II citrate synthase from Vibrio vulnificus.
2Y3N	;	1.9	;	Type II cohesin-dockerin domain from Bacteroides cellolosolvens
5UXO	;	2.35	;	Type II DAH7PS from Pseudomonas aeruginosa
5UXM	;	1.54	;	Type II DAH7PS from Pseudomonas aeruginosa with Trp bound
5UXN	;	2.2	;	Type II DAH7PS from Pseudomonas aeruginosa with Tyr bound
4YBJ	;	2.61	;	Type II Dasatinib Analog Crystallized with c-Src Kinase
1GQO	;	2.1	;	Type II Dehydroquinase from Bacillus subtilis
2C4W	;	1.55	;	Type II Dehydroquinase from H. pylori in complex with AH9095
1H0R	;	2.1	;	Type II Dehydroquinase from Mycobacterium tuberculosis complexed with 2,3-anhydro-quinic acid
3N59	;	2.52	;	Type II dehydroquinase from Mycobacterium Tuberculosis complexed with 3-dehydroshikimate
3N8K	;	2.25	;	Type II dehydroquinase from Mycobacterium tuberculosis complexed with citrazinic acid
2BT4	;	1.7	;	Type II Dehydroquinase inhibitor complex
2CJF	;	1.95	;	TYPE II DEHYDROQUINASE INHIBITOR COMPLEX
6LL8	;	1.3	;	Type II inorganic pyrophosphatase (PPase) from the psychrophilic bacterium Shewanella sp. AS-11, Mg-PNP form
6LL7	;	2.2	;	Type II inorganic pyrophosphatase (PPase) from the psychrophilic bacterium Shewanella sp. AS-11, Mn-activated form
5W68	;	3.3	;	Type II secretin from Enteropathogenic Escherichia coli - GspD
8CO1	;	2.56	;	Type II Secretion System
5HPZ	;	1.96	;	type II water soluble Chl binding proteins
2MSI	;	1.9	;	TYPE III ANTIFREEZE PROTEIN ISOFORM HPLC 12
3MSI	;	1.43	;	TYPE III ANTIFREEZE PROTEIN ISOFORM HPLC 12
4MSI	;	1.6	;	TYPE III ANTIFREEZE PROTEIN ISOFORM HPLC 12
5MSI	;	1.6	;	TYPE III ANTIFREEZE PROTEIN ISOFORM HPLC 12
6MSI	;	1.65	;	TYPE III ANTIFREEZE PROTEIN ISOFORM HPLC 12
7MSI	;	1.7	;	TYPE III ANTIFREEZE PROTEIN ISOFORM HPLC 12
1EKL	;	1.65	;	TYPE III ANTIFREEZE PROTEIN ISOFORM HPLC 12 E35K
2JIA	;	1.6	;	TYPE III ANTIFREEZE PROTEIN ISOFORM HPLC 12 K61I
1B7I	;	1.65	;	TYPE III ANTIFREEZE PROTEIN ISOFORM HPLC 12 K61R
6AME	;	2.1	;	TYPE III ANTIFREEZE PROTEIN ISOFORM HPLC 12 M21A
2AME	;	2.0	;	TYPE III ANTIFREEZE PROTEIN ISOFORM HPLC 12 N14Q
8AME	;	1.9	;	TYPE III ANTIFREEZE PROTEIN ISOFORM HPLC 12 N14SA16H
8MSI	;	2.6	;	TYPE III ANTIFREEZE PROTEIN ISOFORM HPLC 12 N14SQ44T
2MSJ	;	1.9	;	TYPE III ANTIFREEZE PROTEIN ISOFORM HPLC 12 N46S
3AME	;	2.3	;	TYPE III ANTIFREEZE PROTEIN ISOFORM HPLC 12 Q9TQ44T
1B7K	;	2.5	;	TYPE III ANTIFREEZE PROTEIN ISOFORM HPLC 12 R47H
9AME	;	1.8	;	TYPE III ANTIFREEZE PROTEIN ISOFORM HPLC 12 S42G
7AME	;	1.7	;	TYPE III ANTIFREEZE PROTEIN ISOFORM HPLC 12 T15A
2SPG	;	1.75	;	TYPE III ANTIFREEZE PROTEIN ISOFORM HPLC 12 T15S
1MSJ	;	2.3	;	TYPE III ANTIFREEZE PROTEIN ISOFORM HPLC 12 T15V
4AME	;	2.05	;	TYPE III ANTIFREEZE PROTEIN ISOFORM HPLC 12 T18A
9MSI	;	2.6	;	TYPE III ANTIFREEZE PROTEIN ISOFORM HPLC 12 T18N
1JAB	;	1.65	;	TYPE III ANTIFREEZE PROTEIN ISOFORM HPLC 12 T18S
1B7J	;	1.65	;	TYPE III ANTIFREEZE PROTEIN ISOFORM HPLC 12 V20A
1UCS	;	0.62	;	Type III Antifreeze Protein RD1 from an Antarctic Eel Pout
3BEX	;	1.51	;	Type III pantothenate kinase from Thermotoga maritima complexed with pantothenate
3BF1	;	2.3	;	Type III pantothenate kinase from Thermotoga maritima complexed with pantothenate and ADP
3BF3	;	1.63	;	Type III pantothenate kinase from Thermotoga maritima complexed with product phosphopantothenate
3WD7	;	2.35	;	Type III polyketide synthase
1K3E	;	2.8	;	Type III secretion chaperone CesT
1K3S	;	1.9	;	Type III Secretion Chaperone SigE
6IFY	;	3.8	;	Type III-A Csm complex, Cryo-EM structure of Csm-CTR1
6IG0	;	3.37	;	Type III-A Csm complex, Cryo-EM structure of Csm-CTR1, ATP bound
6IFZ	;	3.58	;	Type III-A Csm complex, Cryo-EM structure of Csm-CTR2-ssDNA complex
6IFR	;	3.4	;	Type III-A Csm complex, Cryo-EM structure of Csm-NTR, ATP bound
6S6B	;	2.75	;	Type III-B Cmr-beta Cryo-EM structure of the Apo state
8SEK	;	3.5	;	Type IIIa beta-amyloid 40 Filaments from Down syndrome
8SEL	;	3.8	;	Type IIIb beta-amyloid 40 Filaments from Down Syndrome
8EPX	;	3.15	;	Type IIS Restriction Endonuclease PaqCI, DNA bound
8EM1	;	2.5	;	Type IIS Restriction Endonuclease PaqCI, DNA Unbound
6SZ9	;	3.7	;	Type IV Coupling Complex (T4CC) from L. pneumophila.
6NJY	;	1.76	;	Type IV CRISPR associated RNA endonuclease Cas6 - apo form
3URJ	;	1.9	;	Type IV native endothiapepsin
8TUM	;	3.6	;	Type IV pilus from Pseudomonas PAO1 strain
8TUW	;	7.9	;	Type IV pilus from Pseudomonas PAO1 strain
2VY3	;	2.8	;	Type IV secretion system effector protein BepA
2VZA	;	3.05	;	Type IV secretion system effector protein BepA
2JK8	;	2.8	;	Type IV secretion system effector protein BepA complexed with a pyrophosphate moiety
7JHY	;	3.9	;	Type IV-B CRISPR Complex
5G2F	;	1.85	;	Type IV-like competence pilin TTHA1222 from Thermus thermophilus
5G25	;	2.3	;	Type IV-like pilin TTHA1218 from Thermus thermophilus
5G23	;	1.85	;	Type IV-like pilin TTHA1219 from Thermus thermophilus
5G24	;	2.3	;	Type IV-like pilin TTHA1219 from Thermus thermophilus
8CP6	;	2.45	;	Type six secretion system exported effector 5 (Tse5)
6HS7	;	4.6	;	Type VI membrane complex
8H8C	;	3.36	;	Type VI secretion system effector RhsP in its post-autoproteolysis and dimeric form
8H8A	;	3.25	;	Type VI secretion system effector RhsP in its post-autoproteolysis and monomeric form
8H8B	;	3.16	;	Type VI secretion system effector RhsP in its pre-autoproteolysis and monomeric form
6IXH	;	4.0	;	Type VI secretion system membrane core complex
1ITB	;	2.5	;	TYPE-1 INTERLEUKIN-1 RECEPTOR COMPLEXED WITH INTERLEUKIN-1 BETA
3PXL	;	1.2	;	Type-2 Cu-depleted fungus laccase from Trametes hirsuta
3V9C	;	2.0	;	Type-2 Cu-depleted fungus laccase from Trametes hirsuta at low dose of ionization radiation
1A65	;	2.23	;	TYPE-2 CU-DEPLETED LACCASE FROM COPRINUS CINEREUS
1HFU	;	1.68	;	TYPE-2 CU-DEPLETED LACCASE FROM COPRINUS CINEREUS at 1.68 A resolution
7X9U	;		;	Type-II KH motif of human mitochondrial RbfA
8CE7	;	2.7	;	Type1 alpha-synuclein filament assembled in vitro by wild-type and mutant (7 residues insertion) protein
8CEB	;	2.8	;	Type2 alpha-synuclein filament assembled in vitro by wild-type and mutant (7 residues insertion) protein
8OTH	;	3.4	;	TypeII tau filament from Kii ALS/PDC
3WD8	;	2.463	;	TypeIII polyketide synthases
1SGY	;	1.8	;	TYR 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 6.5
1UWB	;	3.2	;	TYR 181 CYS HIV-1 RT/8-CL TIBO
1BQN	;	3.3	;	TYR 188 LEU HIV-1 RT/HBY 097
3ZJI	;	1.5	;	Tyr(61)B10Ala mutation of M.acetivorans protoglobin in complex with cyanide
2CSM	;	2.8	;	TYR-BOUND T-STATE OF YEAST CHORISMATE MUTASE
1C72	;	2.8	;	TYR115, GLN165 AND TRP209 CONTRIBUTE TO THE 1,2-EPOXY-3-(P-NITROPHENOXY)PROPANE CONJUGATING ACTIVITIES OF GLUTATHIONE S-TRANSFERASE CGSTM1-1
3HZL	;	1.55	;	Tyr258Phe mutant of NikD, an unusual amino acid oxidase essential for nikkomycin biosynthesis: open form at 1.55A resolution
1AP5	;	2.2	;	TYR34->PHE MUTANT OF HUMAN MITOCHONDRIAL MANGANESE SUPEROXIDE DISMUTASE
1AP6	;	1.9	;	TYR34->PHE MUTANT OF HUMAN MITOCHONDRIAL MANGANESE SUPEROXIDE DISMUTASE
1L7R	;	1.64	;	Tyr44Phe Mutant of Bacterial Cocaine Esterase cocE
3ZS2	;	1.97	;	TyrB25,NMePheB26,LysB28,ProB29-insulin analogue crystal structure
5ZRE	;	2.5	;	Tyrosinase from Burkholderia thailandensis (BtTYR) at high pH condition
5ZRD	;	2.3	;	Tyrosinase from Burkholderia thailandensis (BtTYR) at low pH condition
8B74	;	1.965	;	Tyrosinase from halophilic bacterium Hahella sp. CCB MM4
3LKT	;	1.65	;	Tyrosine 447 of Protocatechuate 3,4-Dioxygenase Controls Efficient Progress Through Catalysis
3LXV	;	1.9	;	Tyrosine 447 of Protocatechuate 3,4-Dioxygenase Controls Efficient Progress Through Catalysis
3LMX	;	2.2	;	Tyrosine 447 of Protocatechuate 34,-Dioxygenase Controls Efficient Progress Through Catalysis
3TAT	;	3.5	;	TYROSINE AMINOTRANSFERASE FROM E. COLI
2O6Y	;	1.5	;	Tyrosine ammonia-lyase from Rhodobacter sphaeroides
2O78	;	1.9	;	Tyrosine ammonia-lyase from Rhodobacter sphaeroides (His89Phe variant) complexed with cinnamic acid
2O7E	;	1.75	;	Tyrosine ammonia-lyase from Rhodobacter sphaeroides (His89Phe variant), bound to 2-aminoindan-2-phosphonic acid
2O7F	;	2.0	;	Tyrosine ammonia-lyase from Rhodobacter sphaeroides (His89Phe variant), complexed with coumaric acid
2O7D	;	1.9	;	Tyrosine ammonia-lyase from Rhodobacter sphaeroides, complexed with caffeate
2O7B	;	1.6	;	Tyrosine ammonia-lyase from Rhodobacter sphaeroides, complexed with coumarate
1TOH	;	2.3	;	TYROSINE HYDROXYLASE CATALYTIC AND TETRAMERIZATION DOMAINS FROM RAT
2TOH	;	2.3	;	TYROSINE HYDROXYLASE CATALYTIC AND TETRAMERIZATION DOMAINS FROM RAT
4UEU	;	2.95	;	Tyrosine kinase AS - a common ancestor of Src and Abl
4CSV	;	2.05	;	Tyrosine kinase AS - a common ancestor of Src and Abl bound to Gleevec
1M14	;	2.6	;	Tyrosine Kinase Domain from Epidermal Growth Factor Receptor
2YCT	;	2.25	;	Tyrosine phenol-lyase from Citrobacter freundii in complex with pyridine N-oxide and the quinonoid intermediate formed with L-alanine
2TPL	;	2.5	;	TYROSINE PHENOL-LYASE FROM CITROBACTER INTERMEDIUS COMPLEX WITH 3-(4'-HYDROXYPHENYL)PROPIONIC ACID, PYRIDOXAL-5'-PHOSPHATE AND CS+ ION
1C7G	;	2.1	;	TYROSINE PHENOL-LYASE FROM ERWINIA HERBICOLA
7FJK	;	1.3	;	Tyrosine phenol-lyase from pantoea agglomerans
2SHP	;	2.0	;	TYROSINE PHOSPHATASE SHP-2
1BF5	;	2.9	;	TYROSINE PHOSPHORYLATED STAT-1/DNA COMPLEX
2ACU	;	1.76	;	TYROSINE-48 IS THE PROTON DONOR AND HISTIDINE-110 DIRECTS SUBSTRATE STEREOCHEMICAL SELECTIVITY IN THE REDUCTION REACTION OF HUMAN ALDOSE REDUCTASE: ENZYME KINETICS AND THE CRYSTAL STRUCTURE OF THE Y48H MUTANT ENZYME
6PDJ	;	1.81	;	Tyrosine-protein kinase LCK bound to Compound 11
1X8X	;	2.0	;	Tyrosyl t-RNA Synthetase from E.coli Complexed with Tyrosine
6WN2	;	1.78	;	Tyrosyl t-RNA Synthetase Mutant from E.coli Complexed with sulfotyrosine
2JAN	;	2.9	;	TYROSYL-TRNA SYNTHETASE FROM MYCOBACTERIUM TUBERCULOSIS IN UNLIGANDED STATE
1H3F	;	2.0	;	Tyrosyl-tRNA synthetase from Thermus thermophilus complexed with tyrosinol
1H3E	;	2.9	;	Tyrosyl-tRNA synthetase from Thermus thermophilus complexed with wild-type tRNAtyr(GUA) and with ATP and tyrosinol
6YS9	;	1.64	;	T_926 truncate of ChlH from Thermosynechococcus elongatus at 1.64 A resolution
6M4T	;	1.55	;	U shaped head to head four-way junction in d(TTCTGCTGCTGAA) sequence
6M5J	;	1.65	;	U shaped head to head four-way junction in d(TTCTGCTGCTGAA/TTCTGCAGCTGAA) sequence
6OQP	;		;	U-AITx-Ate1
2KR4	;		;	U-box domain of the E3 Ubiquitin Ligase E4B
4JAB	;	2.23	;	U/G Wobble Base Pair in a RNA Duplex
4PKD	;	2.5	;	U1-70k in complex with U1 snRNA stem-loops 1 and U1-A RRM in complex with stem-loop 2
2VY4	;		;	U11-48K CHHC ZN-FINGER DOMAIN
2VY5	;		;	U11-48K CHHC Zn-finger protein domain
1URN	;	1.92	;	U1A MUTANT/RNA COMPLEX + GLYCEROL
1NU4	;	1.8	;	U1A RNA binding domain at 1.8 angstrom resolution reveals a pre-organized C-terminal helix
1OIA	;	2.4	;	U1A rnp domain 1-95
1DRZ	;	2.3	;	U1A SPLICEOSOMAL PROTEIN/HEPATITIS DELTA VIRUS GENOMIC RIBOZYME COMPLEX
1AUD	;		;	U1A-UTRRNA, NMR, 31 STRUCTURES
7Q4P	;	2.15	;	U2 snRNP after ATP-dependent remodelling
2LK3	;		;	U2/U6 Helix I
7SN6	;	1.8	;	U2AF65 UHM BOUND TO SF3B155 ULM5
6SCY	;	2.81	;	U34-tRNA thiolase NcsA from Methanococcus maripaludis with its [4Fe-4S] cluster
1QOI	;	2.0	;	U4/U6 snRNP-specific cyclophilin SnuCyp-20
8XJO	;	3.11	;	U46619 bound Thromboxane A2 receptor-Gq Protein Complex
4HK2	;	1.4	;	U7Ub25.2540
4HJK	;	1.784	;	U7Ub7 Disulfide variant
1NC0	;		;	U80G U6 Intramolecular Stem-Loop RNA from Saccharomyces cerevisiae
6ZHS	;	2.35	;	Uba1 bound to two E2 (Ubc13) molecules
7ZH9	;	1.72	;	Uba1 in complex with ATP
5L6H	;	2.3	;	Uba1 in complex with Ub-ABPA3 covalent adduct
5L6I	;	2.76	;	Uba1 in complex with Ub-MLN4924 covalent adduct
5L6J	;	2.68	;	Uba1 in complex with Ub-MLN7243 covalent adduct
6ZHT	;	2.3	;	Uba1-Ubc13 disulfide mediated complex
4Y1L	;	2.7	;	Ubc9 Homodimer The Missing Link in Poly-SUMO Chain Formation
5TUT	;	2.604	;	UbcH5a-Ub isopeptide conjugate
3A33	;	2.2	;	UbcH5b~Ubiquitin Conjugate
3UGB	;	2.35	;	UbcH5c~Ubiquitin Conjugate
6N13	;		;	UbcH7-Ub Complex with R0RBR Parkin and phosphoubiquitin
8WWX	;		;	Ube1L acts akin to a mitt, that mediates UbcH8 binding and orchestrates ""E1-E2"" interaction
6D4P	;	2.11	;	Ube2D1 in complex with ubiquitin variant Ubv.D1.1
6D68	;	2.36	;	Ube2G1 in complex with ubiquitin variant Ubv.G1.1
5NGZ	;	2.4	;	Ube2T in complex with fragment EM04
6D6I	;	2.551	;	Ube2V1 in complex with ubiquitin variant Ubv.V1.1 and Ube2N/Ubc13
8EPT	;		;	UBE3A isoform 2 AZUL domain
8ENP	;		;	UBE3A isoform 3 AZUL
5O75	;	1.483	;	Ube4B U-box domain
6H6N	;	2.12	;	UbiJ-SCP2 Ubiquinone synthesis protein
6H6O	;	1.7	;	UbiJ-SCP2 Ubiquinone synthesis protein
6H6P	;	2.5	;	UbiJ-SCP2 Ubiquinone synthesis protein
7CUW	;	2.63	;	Ubiquinol Binding Site of Cytochrome bo3 from Escherichia coli
6NXK	;	2.2	;	Ubiquitin binding variants
6NXL	;	2.803	;	Ubiquitin binding variants
1QCQ	;	2.7	;	UBIQUITIN CONJUGATING ENZYME
4DS2	;	2.63	;	Ubiquitin conjugating enzyme (putative) from Trypanosoma cruzi
2UCZ	;	2.93	;	UBIQUITIN CONJUGATING ENZYME (UBC7) FROM SACCHAROMYCES CEREVISIAE
2AAK	;	2.4	;	UBIQUITIN CONJUGATING ENZYME FROM ARABIDOPSIS THALIANA
1JBB	;	2.0	;	Ubiquitin Conjugating Enzyme, Ubc13
2ZCC	;	1.4	;	Ubiquitin crystallized under high pressure
3KPA	;	2.2	;	Ubiquitin fold modifier conjugating enzyme from Leishmania major (probable)
6E2B	;	1.45	;	Ubiquitin in complex with Pt(2-phenilpyridine)(PPh3)
7B5S	;	3.6	;	Ubiquitin ligation to F-box protein substrates by SCF-RBR E3-E3 super-assembly: CUL1-RBX1-ARIH1 Ariadne. Transition State 1
7B5R	;	3.8	;	Ubiquitin ligation to F-box protein substrates by SCF-RBR E3-E3 super-assembly: CUL1-RBX1-SKP1-SKP2-CKSHS1-Cyclin A-CDK2-p27
7B5M	;	3.91	;	Ubiquitin ligation to F-box protein substrates by SCF-RBR E3-E3 super-assembly: CUL1-RBX1-SKP1-SKP2-CKSHS1-p27~Ub~ARIH1. Transition State 2
7B5L	;	3.8	;	Ubiquitin ligation to F-box protein substrates by SCF-RBR E3-E3 super-assembly: NEDD8-CUL1-RBX1-SKP1-SKP2-CKSHS1-Cyclin A-CDK2-p27-UBE2L3~Ub~ARIH1. Transition State 1
7B5N	;	3.6	;	Ubiquitin ligation to F-box protein substrates by SCF-RBR E3-E3 super-assembly: NEDD8-CUL1-RBX1-UBE2L3~Ub~ARIH1.
8R5H	;	3.44	;	Ubiquitin ligation to neosubstrate by a cullin-RING E3 ligase & Cdc34: NEDD8-CUL2-RBX1-ELOB/C-VHL-MZ1 with trapped UBE2R2~donor UB-BRD4 BD2
8Q7R	;	3.71	;	Ubiquitin ligation to substrate by a cullin-RING E3 ligase & Cdc34: NEDD8-CUL2-RBX1-ELOB/C-FEM1C with trapped UBE2R2~donor UB-Sil1 peptide
6TTU	;	3.7	;	Ubiquitin Ligation to substrate by a cullin-RING E3 ligase at 3.7A resolution: NEDD8-CUL1-RBX1 N98R-SKP1-monomeric b-TRCP1dD-IkBa-UB~UBE2D2
1D3Z	;		;	UBIQUITIN NMR STRUCTURE
1Q5W	;		;	Ubiquitin Recognition by Npl4 Zinc-Fingers
5OK6	;	1.3	;	Ubiquitin specific protease 11 USP11 - peptide F complex
6C16	;	3.27	;	Ubiquitin variant (UbV.Fbl10.1) bound to a human Skp1-Fbl11 fragment complex.
6BVA	;	2.66	;	Ubiquitin Variant (UbV.Fl10.1) bound to a human Skp1-Fbl10 fragment complex.
6BYH	;	2.61	;	Ubiquitin Variant (UbV.Fl11.1) bound to a human Skp1-Fbl11 fragment complex.
6DGF	;	2.34	;	Ubiquitin Variant bound to USP2
8SVG	;	1.21	;	Ubiquitin variant i53 in complex with 53BP1 Tudor domain
8SVH	;	1.16	;	Ubiquitin variant i53 mutant L67R bound to 53BP1 Tudor Domain
8SVJ	;	1.5	;	Ubiquitin variant i53: mutant VHH with 53BP1 Tudor domain
8SVI	;	1.15	;	Ubiquitin variant i53:Mutant L67H with 53BP1 Tudor domain
8T2D	;	1.751	;	Ubiquitin variant i53:Mutant T12Y.T14E.L67R with 53BP1 Tudor domain
6NJG	;	2.35	;	Ubiquitin Variant in Complex with Ubiquitin Interacting Motif
7MYF	;	3.0	;	Ubiquitin variant UbV.k.1 in complex with Ube2k
7MYH	;	2.394	;	Ubiquitin variant UbV.k.2 in complex with Ube2k
1YLA	;	2.4	;	Ubiquitin-conjugating enzyme E2-25 kDa (Huntington interacting protein 2)
2O25	;	2.6	;	Ubiquitin-Conjugating Enzyme E2-25 kDa Complexed With SUMO-1-Conjugating Enzyme UBC9
2QGX	;	2.56	;	Ubiquitin-conjugating enzyme E2Q
1ZDN	;	1.93	;	Ubiquitin-conjugating enzyme E2S
1YH2	;	2.0	;	Ubiquitin-Conjugating Enzyme HSPC150
7BOL	;	1.797	;	ubiquitin-conjugating enzyme, Ube2D2
3OQC	;	2.6	;	Ubiquitin-fold modifier 1 Specific Protease, UfSP2
2LGY	;		;	Ubiquitin-like domain from HOIL-1
2FAZ	;	2.0	;	Ubiquitin-Like Domain of Human Nuclear Zinc Finger Protein NP95
4ICV	;	1.45	;	Ubiquitin-like domain of human tubulin folding cofactor E - crystal form B
4ICU	;	2.4	;	Ubiquitin-like domain of human tubulin folding cofactor E - crystal from A
7Y39	;	1.88	;	Ubiquitin-like domain of human ZFAND1
4KV2	;	1.88	;	Ubiquitin-like domain of the mycobacterium tuberculosis type VII secretion system protein ECCD1
4KV3	;	2.2	;	Ubiquitin-like domain of the Mycobacterium tuberculosis type VII secretion system protein EccD1 as maltose-binding protein fusion
2M17	;		;	ubiquitin-like domain-containing C-terminal domain phosphatase (UBLCP1)
2BPS	;	2.7	;	Ubiquitin-like protein YukD of Bacillus subtilis
4ZAV	;	1.4	;	UbiX in complex with a covalent adduct between dimethylallyl monophosphate and reduced FMN
6XQC	;		;	UbKEKS
5DTC	;	1.7	;	UBL Structure
4ZBJ	;	2.248	;	UBN1 peptide bound to H3.3/H4/Asf1
7YRB	;	1.51	;	UBR box of human UBR6
5O6S	;	2.9	;	UbV.B4R, a dimeric ubiquitin variant binding to BIRC4 RING
1H8C	;		;	UBX domain from human faf1
8F36	;		;	Ubx Homeodomain NMR solution structure
2MX2	;		;	UBX-L domain of VCIP135
4QHK	;	3.487	;	UCA (unbound) from CH103 Lineage
5IBT	;	2.4	;	UCA Fab (unbound) from 6515 Lineage
5W6C	;	1.634	;	UCA Fab (unbound) from 6649 Lineage
4HK0	;	2.497	;	UCA Fab (unbound) from CH65-CH67 Lineage
8EK6	;	1.954	;	UCA Y35N (unbound) Fab from CH65-CH67 lineage
4UEM	;	2.82	;	UCH-L5 in complex with the RPN13 DEUBAD domain
4UF6	;	3.69	;	UCH-L5 in complex with ubiquitin-propargyl bound to an activating fragment of INO80G
4UEL	;	2.3	;	UCH-L5 in complex with ubiquitin-propargyl bound to the RPN13 DEUBAD domain
6QML	;	2.1	;	UCHL3 in complex with synthetic, K27-linked diubiquitin
1EN2	;	1.4	;	UDA TETRASACCHARIDE COMPLEX. CRYSTAL STRUCTURE OF URTICA DIOICA AGGLUTININ, A SUPERANTIGEN PRESENTED BY MHC MOLECULES OF CLASS I AND CLASS II
1ENM	;	1.9	;	UDA TRISACCHARIDE COMPLEX. CRYSTAL STRUCTURE OF URTICA DIOICA AGGLUTININ, A SUPERANTIGEN PRESENTED BY MHC MOLECULES OF CLASS I AND CLASS II
1EIS	;	1.66	;	UDA UNCOMPLEXED FORM. CRYSTAL STRUCTURE OF URTICA DIOICA AGGLUTININ, A SUPERANTIGEN PRESENTED BY MHC MOLECULES OF CLASS I AND CLASS II
5ZE7	;	1.99	;	UDP Glucose alpha tetrahydrobiopterin glycosyltransferase from Synechococcus species PCC 7942 - apo form
5ZER	;	2.39	;	UDP Glucose alpha tetrahydrobiopterin glycosyltransferase from Synechococcus species PCC 7942 - BH2 complex form
5ZES	;	2.03	;	UDP Glucose alpha tetrahydrobiopterin glycosyltransferase from Synechococcus species PCC 7942 - UDP complex
5ZFK	;	1.75	;	UDP Glucose alpha tetrahydrobiopterin glycosyltransferase from Synechococcus species PCC 7942 - UDP-BH2 complex
1LXA	;	2.6	;	UDP N-ACETYLGLUCOSAMINE ACYLTRANSFERASE
3UHM	;	1.26	;	UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase in complex with inhibitor
2BI7	;	2.0	;	udp-galactopyranose mutase from Klebsiella pneumoniae oxidised FAD
2BI8	;	2.35	;	udp-galactopyranose mutase from Klebsiella pneumoniae with reduced FAD
1V0J	;	2.25	;	Udp-galactopyranose mutase from Mycobacterium tuberculosis
1KVQ	;	2.15	;	UDP-GALACTOSE 4-EPIMERASE COMPLEXED WITH UDP-PHENOL
1KVR	;	1.9	;	UDP-GALACTOSE 4-EPIMERASE COMPLEXED WITH UDP-PHENOL
1KVS	;	2.15	;	UDP-GALACTOSE 4-EPIMERASE COMPLEXED WITH UDP-PHENOL
1KVT	;	2.15	;	UDP-GALACTOSE 4-EPIMERASE COMPLEXED WITH UDP-PHENOL
1KVU	;	1.9	;	UDP-GALACTOSE 4-EPIMERASE COMPLEXED WITH UDP-PHENOL
2UDP	;	1.8	;	UDP-GALACTOSE 4-EPIMERASE COMPLEXED WITH UDP-PHENOL
1XEL	;	1.8	;	UDP-GALACTOSE 4-EPIMERASE FROM ESCHERICHIA COLI
1NAI	;	2.0	;	UDP-GALACTOSE 4-EPIMERASE FROM ESCHERICHIA COLI, OXIDIZED
1NAH	;	1.8	;	UDP-GALACTOSE 4-EPIMERASE FROM ESCHERICHIA COLI, REDUCED
1A9Z	;	1.9	;	UDP-GALACTOSE 4-EPIMERASE MUTANT S124A/Y149F COMPLEXED WITH UDP-GALACTOSE
1A9Y	;	1.8	;	UDP-GALACTOSE 4-EPIMERASE MUTANT S124A/Y149F COMPLEXED WITH UDP-GLUCOSE
6MW8	;	1.756	;	UDP-galactose:glucoside-Skp1 alpha-D-galactosyltransferase with bound UDP and Manganese
6MW5	;	2.1	;	UDP-galactose:glucoside-Skp1 alpha-D-galactosyltransferase with bound UDP and Platinum
6WJB	;	2.1	;	UDP-GlcNAc C4-epimerase from Pseudomonas protegens in complex with NAD and UDP-GlcNAc
6WJA	;	2.094	;	UDP-GlcNAc C4-epimerase mutant S121A/Y146F from Pseudomonas protegens in complex with UDP-GalNAc
6WJ9	;	2.11	;	UDP-GlcNAc C4-epimerase mutant S121A/Y146F from Pseudomonas protegens in complex with UDP-GlcNAc
5N2J	;	4.4	;	UDP-Glucose Glycoprotein Glucosyltransferase from Chaetomium thermophilum (closed form)
5MZO	;	3.48	;	UDP-Glucose Glycoprotein Glucosyltransferase from Chaetomium thermophilum (open conformation)
5NV4	;	2.78	;	UDP-Glucose Glycoprotein Glucosyltransferase from Chaetomium thermophilum double mutant D611C:G1050C
5MU1	;	3.48	;	UDP-Glucose Glycoprotein Glucosyltransferase from Chaetomium thermophilum soaked with K2PtI6
6IKX	;	2.2	;	UDP-glucose pyrophosphorylase from acinetobacter baumanii
6IKZ	;	2.33	;	UDP-glucose pyrophosphorylase from acinetobacter baumanii
4M28	;	3.0	;	UDP-Glucose Pyrophosphorylase from Leishmania major in complex with UTP analog dUpCpp
6K8D	;	2.94	;	UDP-glucose pyrophosphorylase with UPG from Acinetobacter Baumanii
7CJX	;	1.98641	;	UDP-glucuronosyltransferase 2B15 C-terminal domain-L446S
7YAN	;	2.5	;	UDP-glucuronosyltransferase2B17 C-terminal domain
1QGS	;	2.0	;	UDP-MAGNESIUM COMPLEX OF SPSA FROM BACILLUS SUBTILIS
1QGQ	;	1.5	;	UDP-MANGANESE COMPLEX OF SPSA FROM BACILLUS SUBTILIS
7BVJ	;	2.15	;	UDP-N-acetylglucosamine 3-dehydrogenase GnnA from Acidithiobacillus ferrooxidans (P21)
7BVK	;	2.7	;	UDP-N-acetylglucosamine 3-dehydrogenase GnnA from Acidithiobacillus ferrooxidans (P212121)
3PVZ	;	2.1	;	UDP-N-acetylglucosamine 4,6-dehydratase from Vibrio fischeri
6DNT	;	1.66	;	UDP-N-acetylglucosamine 4-epimerase from Methanobrevibacter ruminantium M1 in complex with UDP-N-acetylmuramic acid
3R0S	;	2.3	;	UDP-N-acetylglucosamine acyltransferase from Campylobacter jejuni
6CAU	;	2.5	;	UDP-N-acetylmuramate--alanine ligase from Acinetobacter baumannii AB5075-UW with AMPPNP
1E0D	;	2.4	;	UDP-N-Acetylmuramoyl-L-Alanine:D-Glutamate Ligase
1EEH	;	1.9	;	UDP-N-ACETYLMURAMOYL-L-ALANINE:D-GLUTAMATE LIGASE
1UAG	;	1.95	;	UDP-N-ACETYLMURAMOYL-L-ALANINE:D-GLUTAMATE LIGASE
2UAG	;	1.7	;	UDP-N-ACETYLMURAMOYL-L-ALANINE:D-GLUTAMATE LIGASE
3UAG	;	1.77	;	UDP-N-ACETYLMURAMOYL-L-ALANINE:D-GLUTAMATE LIGASE
4UAG	;	1.66	;	UDP-N-ACETYLMURAMOYL-L-ALANINE:D-GLUTAMATE LIGASE
6ZMZ	;	1.9	;	UDPG-bound Trehalose transferase from Thermoproteus uzoniensis
8BZR	;	1.781	;	UFC1-UFM1 conjugate
1ZC1	;		;	Ufd1 exhibits the AAA-ATPase fold with two distinct ubiquitin interaction sites
8QFC	;	3.2	;	UFL1 E3 ligase bound 60S ribosome
8QFD	;	2.2	;	UFL1 E3 ligase bound 60S ribosome
8C0D	;	2.564	;	UFL1/DDRGK1 bound to UFC1
1AFX	;		;	UGAA EUKARYOTIC RIBOSOMAL RNA TETRALOOP, NMR, 13 STRUCTURES
8AIM	;	2.6	;	Ugi-2 SAUNG complex
2FUZ	;	1.8	;	UGL hexagonal crystal structure without glycine and DTT molecules
2FV0	;	1.91	;	UGL_D88N/dGlcA-Glc-Rha-Glc
2FV1	;	1.73	;	UGL_D88N/dGlcA-GlcNAc
7W10	;	2.15	;	UGT74AN2
7W09	;	1.95	;	UGT74AN2, Plant Steroid Glycosyltransferase
3ND3	;	1.37	;	Uhelix 16-mer dsRNA
8V59	;	1.12	;	UIC-1 mutant - UIC-1-B5I
8V56	;	0.98	;	UIC-1 mutant - UIC-1-B5W
8V5X	;	1.12	;	UIC-1 mutant - UIC-1-L6A
8V61	;	1.13	;	UIC-1 mutant - UIC-1-L6I
8V5Z	;	0.84	;	UIC-1 mutant - UIC-1-L6M
8V5W	;	1.07	;	UIC-1 mutant UIC-1-B5T
7LWS	;	3.22	;	UK (B.1.1.7) SARS-CoV-2 S-GSAS-D614G variant spike protein in the 3-RBD-down conformation
7LWT	;	3.19	;	UK (B.1.1.7) SARS-CoV-2 spike protein variant (S-GSAS-B.1.1.7) in the 1-RBD-up conformation
7LWU	;	3.22	;	UK (B.1.1.7) SARS-CoV-2 spike protein variant (S-GSAS-B.1.1.7) in the 1-RBD-up conformation
7LWV	;	3.12	;	UK (B.1.1.7) SARS-CoV-2 spike protein variant (S-GSAS-B.1.1.7) in the 1-RBD-up conformation
6FU8	;	3.2	;	uL23 beta hairpin loop deletion of E.coli ribosome
7NDT	;	2.999	;	UL40:01 TCR in complex with HLA-E with a non-natural amino acid
2NA1	;		;	ULD complex
8CD8	;	1.65	;	Ulilysin - C269A with AEBSF complex
2J83	;	2.0	;	Ulilysin metalloprotease in complex with batimastat.
6MNH	;	1.73	;	ULK1 Unc-51 like autophagy activating kinase in complex with inhibitor BTC
4WZX	;	1.3859	;	ULK3 regulates cytokinetic abscission by phosphorylating ESCRT-III proteins
8JLO	;	3.52	;	Ulotaront(SEP-363856)-bound hTAAR1-Gs protein complex
8JLK	;	3.22	;	Ulotaront(SEP-363856)-bound mTAAR1-Gs protein complex
8JSP	;	3.65	;	Ulotaront(SEP-363856)-bound Serotonin 1A (5-HT1A) receptor-Gi complex
2PLP	;		;	Ultra high resolution backbone conformation of protein GB1 from residual dipolar couplings alone
5U3A	;	0.95	;	Ultra High Resolution Crystal Structure of Human Pancreatic Alpha Amylase
1M40	;	0.85	;	ULTRA HIGH RESOLUTION CRYSTAL STRUCTURE OF TEM-1
5IBN	;	0.94	;	Ultra high resolution crystal structure of the apo- form of second bromodomain of BRD2.
4C64	;	1.32	;	ULTRA HIGH RESOLUTION DICKERSON-DREW DODECAMER B-DNA
4C63	;	1.32	;	ULTRA HIGH RESOLUTION DICKERSON-DREW DODECAMER B-DNA WITH 5- METHYLCYSTOSINE MODIFICATION
4C5X	;	1.3	;	Ultra High Resolution Dickerson-Drew dodecamer B-DNA with 5-Hydroxymethyl-cytosine Modification
1G6X	;	0.86	;	ULTRA HIGH RESOLUTION STRUCTURE OF BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI) MUTANT WITH ALTERED BINDING LOOP SEQUENCE
4U9H	;	0.89	;	Ultra High Resolution Structure Of The Ni-R State Of [Nife]Hydrogenase From Desulufovibrio Vulgaris Miyazaki F
7P4R	;	0.85	;	Ultra High Resolution X-ray Structure of Orthorhombic Bovine Pancreatic Ribonuclease at 100K
4TLJ	;	1.17	;	Ultra-high resolution crystal structure of caprine Beta-lactoglobulin
5IG6	;	0.91	;	Ultra-high resolution crystal structure of second bromodomain of BRD2 in complex with inhibitor 6B3
6SP6	;	1.1	;	Ultra-high Resolution Crystal Structure of the CTX-M-15 Extended-Spectrum beta-Lactamase in Complex with Taniborbactam (VNRX-5133)
4FC1	;	1.1	;	Ultra-high resolution neutron structure of crambin at room-temperature
3P4J	;	0.55	;	Ultra-high resolution structure of d(CGCGCG)2 Z-DNA
5D8V	;	0.48	;	Ultra-high resolution structure of high-potential iron-sulfur protein
1IUA	;	0.8	;	Ultra-high resolution structure of HiPIP from Thermochromatium tepidum
2B97	;	0.75	;	Ultra-high resolution structure of hydrophobin HFBII
3W5H	;	0.78	;	Ultra-high resolution structure of NADH-cytochrome b5 reductase
2PYA	;	0.86	;	Ultra-high resolution structure of P. abyssi rubredoxin W4L/R5S/A44S
1YK4	;	0.69	;	Ultra-high resolution structure of Pyrococcus abyssi rubredoxin W4L/R5S
1WUI	;	1.04	;	Ultra-High resolution Structure Of The Ni-A State Of [Nife]Hydrogenase From Desulufovibrio Vulgaris Miyazaki F
2HS1	;	0.84	;	Ultra-high resolution X-ray crystal structure of HIV-1 protease V32I mutant with TMC114 (darunavir) inhibitor
4BVN	;	2.1	;	Ultra-thermostable beta1-adrenoceptor with cyanopindolol bound
5CN4	;	1.8	;	Ultrafast dynamics in myoglobin: -0.1 ps time delay
5CN5	;	1.8	;	Ultrafast dynamics in myoglobin: 0 ps time delay
5CN6	;	1.8	;	Ultrafast dynamics in myoglobin: 0.1 ps time delay
5CN7	;	1.8	;	Ultrafast dynamics in myoglobin: 0.2 ps time delay
5CN8	;	1.8	;	Ultrafast dynamics in myoglobin: 0.3 ps time delay
5CN9	;	1.8	;	Ultrafast dynamics in myoglobin: 0.4 ps time delay
5CNB	;	1.8	;	Ultrafast dynamics in myoglobin: 0.5 ps time delay
5CNC	;	1.8	;	Ultrafast dynamics in myoglobin: 0.6 ps time delay
5CNE	;	1.8	;	Ultrafast dynamics in myoglobin: 10 ps time delay
5CNG	;	1.8	;	ultrafast dynamics in myoglobin: 150 ps time delay
5CND	;	1.8	;	Ultrafast dynamics in myoglobin: 3 ps time delay
5CNF	;	1.8	;	Ultrafast dynamics in myoglobin: 50 ps time delay
5CMV	;	1.8	;	Ultrafast dynamics in myoglobin: dark-state, CO-ligated structure
6ZHW	;	2.8	;	Ultrafast Structural Response to Charge Redistribution Within a Photosynthetic Reaction Centre - 1 ps structure
6ZI6	;	2.8	;	Ultrafast Structural Response to Charge Redistribution Within a Photosynthetic Reaction Centre - 20 ps structure
6ZI5	;	2.8	;	Ultrafast Structural Response to Charge Redistribution Within a Photosynthetic Reaction Centre - 300 ps (a) structure
6ZI9	;	2.8	;	Ultrafast Structural Response to Charge Redistribution Within a Photosynthetic Reaction Centre - 300 ps (b) structure
6ZI4	;	2.8	;	Ultrafast Structural Response to Charge Redistribution Within a Photosynthetic Reaction Centre - 5 ps (a) structure
6ZID	;	2.8	;	Ultrafast Structural Response to Charge Redistribution Within a Photosynthetic Reaction Centre - 5 ps (b) structure
6ZIA	;	2.8	;	Ultrafast Structural Response to Charge Redistribution Within a Photosynthetic Reaction Centre - 8 us structure
1D8G	;	0.74	;	ULTRAHIGH RESOLUTION CRYSTAL STRUCTURE OF B-DNA DECAMER D(CCAGTACTGG)
5WGI	;	1.05	;	Ultrahigh resolution crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 in complex with TSA
2OFZ	;	1.17	;	Ultrahigh Resolution Crystal Structure of RNA Binding Domain of SARS Nucleopcapsid (N Protein) at 1.1 Angstrom Resolution in Monoclinic Form.
1R6J	;	0.73	;	Ultrahigh resolution Crystal Structure of syntenin PDZ2
1N9B	;	0.9	;	Ultrahigh resolution structure of a class A beta-lactamase: On the mechanism and specificity of the extended-spectrum SHV-2 enzyme
5XSG	;	0.73	;	Ultrahigh resolution structure of FUS (37-42) SYSGYS determined by MicroED
5VLE	;	0.85	;	Ultrahigh Resolution X-Ray Crystal Structure of Ruthenocene Conjugated Penicilloate and Penilloate Products in Complex with CTX-M-14 E166A Beta-Lactamase
6LK1	;	0.9	;	Ultrahigh resolution X-ray structure of Ferredoxin I from C. reinhardtii
5JZQ	;	0.78	;	Ultrahigh-resolution centrosymmetric crystal structure of Z-DNA reveals massive presence of multiple conformations
4HIG	;	0.75	;	Ultrahigh-resolution crystal structure of Z-DNA in complex with Mn2+ ion.
4HIF	;	0.85	;	Ultrahigh-resolution crystal structure of Z-DNA in complex with Zn2+ ions
7E3K	;	3.9	;	Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants
7E3L	;	3.6	;	Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants
7WS4	;	3.7	;	Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants
1HG4	;	2.4	;	Ultraspiracle ligand binding domain from Drosophila melanogaster
1X9R	;	1.9	;	Umecyanin from Horse Raddish- Crystal Structure of the oxidised form
1X9U	;	1.8	;	Umecyanin from Horse Raddish- Crystal Structure of the reduced form
2BRI	;	3.0	;	UMP KINASE FROM PYROCOCCUS FURIOSUS COMPLEXED WITH ITS SUBSTRATE ANALOG AMPPNP
2BMU	;	2.55	;	UMP KINASE FROM PYROCOCCUS FURIOSUS COMPLEXED WITH ITS SUBSTRATE UMP AND ITS SUBSTRATE ANALOG AMPPNP
2BRX	;	2.4	;	UMP KINASE FROM PYROCOCCUS FURIOSUS WITHOUT LIGANDS
1UKE	;	2.2	;	UMP/CMP KINASE FROM SLIME MOLD
2UKD	;	2.2	;	UMP/CMP KINASE FROM SLIME MOLD COMPLEXED WITH ADP, CMP
3UKD	;	1.9	;	UMP/CMP KINASE FROM SLIME MOLD COMPLEXED WITH ADP, CMP, AND ALF3
4UKD	;	2.0	;	UMP/CMP KINASE FROM SLIME MOLD COMPLEXED WITH ADP, UDP, BERYLLIUM FLUORIDE
4A4R	;		;	UNAC Tetraloops: To What Extent Can They Mimic GNRA Tetraloops
4A4S	;		;	UNAC Tetraloops: To What Extent Can They Mimic GNRA Tetraloops
4A4T	;		;	UNAC Tetraloops: To What Extent Can They Mimic GNRA Tetraloops
4A4U	;		;	UNAC Tetraloops: To What Extent Can They Mimic GNRA Tetraloops
4F0M	;	2.25	;	UNACTIVATED RUBISCO with MAGNESIUM AND A WATER MOLECULE BOUND
4F0K	;	2.05	;	UNACTIVATED RUBISCO with MAGNESIUM AND CARBON DIOXIDE BOUND
4F0H	;	1.96	;	UNACTIVATED RUBISCO with OXYGEN BOUND
3S7V	;	2.55	;	Unassembled KI Polyomavirus VP1 Pentamer
1VPN	;	2.0	;	UNASSEMBLED POLYOMAVIRUS VP1 PENTAMER
1UNA	;	2.8	;	UNASSEMBLED VIRUS COAT PROTEIN DIMER, BACTERIOPHAGE RNA-BINDING DIMER
3S7X	;	2.9	;	Unassembled Washington University Polyomavirus VP1 Pentamer R198K Mutant
7NX2	;	1.47	;	Unbound antigen-binding fragment (FAb) 324
6UJ0	;	2.15	;	Unbound BACE2 mutant structure
8EEI	;	1.78	;	Unbound C. ammoniagenes monoamine oxidase (MAO)
1PJU	;	2.15	;	Unbound form of Tomato Inhibitor-II
2IWA	;	1.6	;	Unbound glutaminyl cyclotransferase from Carica papaya.
3E5Q	;	3.2	;	Unbound Oxidised CprK
7ZJ5	;	4.55	;	Unbound state of a brocolli-pepper aptamer FRET tile.
7S5B	;	1.5	;	Unbound State of a De novo designed Protein Binder to the Human Interleukin-7 Receptor
1O8P	;	2.0	;	Unbound structure of CsCBM6-3 from Clostridium stercorarium
3NOW	;	2.992	;	UNC-45 from Drosophila melanogaster
6FDY	;	1.7	;	Unc-51-Like Kinase 3 (ULK3) In Complex With Bosutinib
6FDZ	;	2.55	;	Unc-51-Like Kinase 3 (ULK3) In Complex With Momelotinib
4HCI	;	1.63	;	Uncharacterized Cupredoxin-like Domain Protein Cupredoxin_1 from Bacillus anthracis
4HCG	;	1.847	;	Uncharacterized Cupredoxin-like Domain Protein Cupredoxin_1 with Zinc bound from Bacillus anthracis
3KK4	;	1.95	;	uncharacterized protein BP1543 from Bordetella pertussis Tohama I
2O5H	;	1.9	;	Uncharacterized Protein Conserved in Bacteria, COG3792 from Neisseria meningitidis
3IJD	;	2.0	;	Uncharacterized protein Cthe_2304 from Clostridium thermocellum binds two copies of 5-methyl-5,6,7,8-tetrahydrofolic acid
3KFW	;	2.5	;	Uncharacterized protein Rv0674 from Mycobacterium tuberculosis
8P49	;	2.79	;	Uncharacterized Q8U0N8 protein from Pyrococcus furiosus
6ZGE	;	2.6	;	Uncleavable Spike Protein of SARS-CoV-2 in Closed Conformation
1ATU	;	2.7	;	UNCLEAVED ALPHA-1-ANTITRYPSIN
5JSA	;	6.308	;	Uncleaved prefusion optimized gp140 trimer with an engineered 10-residue HR1 turn bound to broadly neutralizing antibodies 8ANC195 and PGT128
5JS9	;	6.918	;	Uncleaved prefusion optimized gp140 trimer with an engineered 8-residue HR1 turn bound to broadly neutralizing antibodies 8ANC195 and PGT128
6M2J	;	2.2	;	Uncommon structural features of rabbit MHC class I (RLA-A1) complexed with rabbit haemorrhagic disease virus (RHDV) derived peptide, VP60-1
6M2K	;	2.59	;	Uncommon structural features of rabbit MHC class I (RLA-A1) complexed with rabbit haemorrhagic disease virus (RHDV) derived peptide, VP60-10
6M24	;	2.29	;	Uncommon structural features of rabbit MHC class I (RLA-A1) complexed with rabbit haemorrhagic disease virus (RHDV) derived peptide, VP60-2
1J6Z	;	1.54	;	UNCOMPLEXED ACTIN
2HMP	;	1.899	;	Uncomplexed actin cleaved with protease ECP32
1JK6	;	2.4	;	UNCOMPLEXED DES 1-6 BOVINE NEUROPHYSIN
1AMH	;	2.5	;	UNCOMPLEXED RAT TRYPSIN MUTANT WITH ASP 189 REPLACED WITH SER (D189S)
1R56	;	2.3	;	UNCOMPLEXED URATE OXIDASE FROM ASPERGILLUS FLAVUS
5O99	;	0.871	;	Unconventional SH3 domain from the postsynaptic density scaffold protein Shank3
1VLZ	;	2.05	;	UNCOUPLED PHOSPHORYLATION AND ACTIVATION IN BACTERIAL CHEMOTAXIS: THE 2.1 ANGSTROM STRUCTURE OF A THREONINE TO ISOLEUCINE MUTANT AT POSITION 87 OF CHEY
4IMK	;	2.202	;	Uncrossed Fab binding to human Angiopoietin 2
8T1J	;	2.7	;	Uncrosslinked nNOS-CaM oxygenase homodimer
6U7J	;	2.2	;	Uncultured Clostridium sp. Beta-glucuronidase
1YHH	;	1.5	;	Uncyclized precursor structure of S65A Y66S G67A GFP variant
1YHI	;	1.9	;	Uncyclized precursor structure of S65A Y66S R96A GFP variant
1YHG	;	2.5	;	Uncyclized precursor structure of S65G Y66S V68G GFP variant
8TNM	;	1.1	;	UNC_079 from Chroma generative model
8TNO	;	2.36	;	UNC_239 from Chroma generative model
4WWZ	;	1.8	;	UndA complexed with 2,3-dodecenoic acid
4WX0	;	1.7	;	UndA complexed with beta-hydroxydodecanoic acid
4WWJ	;	1.9	;	UndA, an oxygen-activating, non-heme iron dependent desaturase/decarboxylase
6QVM	;	2.5	;	Undecaheme cytochrome from S-layer of Carboxydothermus ferrireducens
7SJA	;	3.8	;	Undecorated 13pf E254N microtubule from recombinant human tubulin
7SJ7	;	3.8	;	Undecorated 13pf wildtype microtubule from recombinant human tubulin
6DPV	;	3.3	;	Undecorated GDP microtubule
6DPU	;	3.1	;	Undecorated GMPCPP microtubule
6DPW	;	3.5	;	Undecorated GTPgammaS microtubule
4D4G	;	2.25	;	Understanding bi-specificity of A-domains
4D4H	;	2.019	;	Understanding bi-specificity of A-domains
4D4I	;	2.0	;	Understanding bi-specificity of A-domains
4D56	;	2.1	;	Understanding bi-specificity of A-domains
4D57	;	2.0	;	Understanding bi-specificity of A-domains
4WZC	;	1.842	;	Understanding Extradiol Dioxygenase Mechanism in NAD+ Biosynthesis by Viewing Catalytic Intermediates - 2,3-cis-4,5-trans ACMS bound to I142A mutant HAO
4L2N	;	1.74	;	Understanding Extradiol Dioxygenase Mechanism in NAD+ Biosynthesis by Viewing Catalytic Intermediates - ligand-free structure
2WHJ	;	1.78	;	Understanding how diverse mannanases recognise heterogeneous substrates
2WHL	;	1.4	;	Understanding how diverse mannanases recognise heterogeneous substrates
7VEG	;	1.385	;	Understanding NH-pi interaction between Gln and Phe
1SPQ	;	2.16	;	Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase
1SQ7	;	2.85	;	Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase
1SSD	;	2.9	;	Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase
1SSG	;	2.9	;	Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase
1SU5	;	2.7	;	Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase
1U72	;	1.9	;	Understanding the Role of Leu22 Variants in Methotrexate Resistance: Comparison of Wild-type and Leu22Arg Variant Mouse and Human Dihydrfolate Reductase Ternary Crystal Complexes with Methotrexate and NADPH
1U70	;	2.5	;	Understanding the Role of Leu22 Variants in Methotrexate Resistance: Comparison of Wild-type and Leu22Arg Variant Mouse and Human Dihydrofolate Reductase
1U71	;	2.2	;	Understanding the Role of Leu22 Variants in Methotrexate Resistance: Comparison of Wild-type and Leu22Arg Variant Mouse and Human Dihydrofolate Reductase Ternary Crystal Complexes with Methotrexate and NADPH
5N7B	;	1.7	;	Understanding the singular conformational landscape of the Tn antigens: Sulfur-for- oxygen substitution in the glycosidic linkage provides new insights into molecular recognition by an antibody
6DM8	;	2.7	;	Understanding the Species Selectivity of Myeloid cell leukemia-1 (Mcl-1) inhibitors
3DT0	;	2.4	;	Understanding Thrombin Inhibition
3DUX	;	1.6	;	Understanding Thrombin Inhibition
6KFH	;	3.6	;	Undocked hemichannel of an N-terminal deletion mutant of INX-6 in a nanodisc
6KFF	;	3.8	;	Undocked INX-6 hemichannel in a nanodisc
6KFG	;	3.8	;	Undocked INX-6 hemichannel in detergent
8FAF	;	1.85	;	Unedited Octopus bimaculoides Synaptotagmin 1 C2A at room temperature
1JKX	;	1.6	;	Unexpected formation of an epoxide-derived multisubstrate adduct inhibitor on the active site of GAR transformylase
7QHR	;	1.4	;	Unexpected imidazole coordination to dirhodium tetraacetate complex in a protein environment: insights from X-ray crystallography and quantum chemistry
1QAU	;	1.25	;	UNEXPECTED MODES OF PDZ DOMAIN SCAFFOLDING REVEALED BY STRUCTURE OF NNOS-SYNTROPHIN COMPLEX
1QAV	;	1.9	;	Unexpected Modes of PDZ Domain Scaffolding Revealed by Structure of NNOS-Syntrophin Complex
1CA3	;	2.3	;	UNEXPECTED PH-DEPENDENT CONFORMATION OF HIS-64, THE PROTON SHUTTLE OF CARBONIC ANHYDRASE II.
1HCA	;	2.3	;	UNEXPECTED PH-DEPENDENT CONFORMATION OF HIS-64, THE PROTON SHUTTLE OF CARBONIC ANHYDRASE II.
4UOI	;	3.49	;	Unexpected structure for the N-terminal domain of Hepatitis C virus envelope glycoprotein E1
2Y4A	;	2.7	;	Unexpected tricovalent binding mode of boronic acids within the active site of a penicillin binding protein
2Y55	;	2.6	;	Unexpected tricovalent binding mode of boronic acids within the active site of a penicillin binding protein
2Y59	;	2.5	;	Unexpected tricovalent binding mode of boronic acids within the active site of a penicillin binding protein
3ZVT	;	3.1	;	Unexpected tricovalent binding mode of boronic acids within the active site of a penicillin binding protein
3ZVW	;	2.0	;	Unexpected tricovalent binding mode of boronic acids within the active site of a penicillin binding protein
3J63	;	3.8	;	Unified assembly mechanism of ASC-dependent inflammasomes
4IRG	;	1.7	;	Uninhibited DNA-binding domain of the Ets transcription factor ERG
5ILV	;	1.8	;	Uninhibited ETV5
2OXU	;	1.24	;	Uninhibited form of human MMP-12
1V0S	;	1.75	;	Uninhibited form of Phospholipase D from Streptomyces sp. strain PMF
2OY4	;	1.7	;	Uninhibited human MMP-8
5COX	;	3.0	;	UNINHIBITED MOUSE CYCLOOXYGENASE-2 (PROSTAGLANDIN SYNTHASE-2)
2DDC	;	1.55	;	Unique behavior of a histidine responsible for an engineered green-to-red photoconversion process
2DDD	;	1.55	;	Unique behavior of a histidine responsible for an engineered green-to-red photoconversion process
1BTP	;	2.2	;	UNIQUE BINDING OF A NOVEL SYNTHETIC INHIBITOR, N-[3-[4-[4-(AMIDINOPHENOXY)-CARBONYL]PHENYL]-2-METHYL-2-PROPENOYL]-N-ALLYLGLYCINE METHANESULFONATE TO BOVINE TRYPSIN, REVEALED BY THE CRYSTAL STRUCTURE OF THE COMPLEX
3SGJ	;	2.2	;	Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgIII and antibodies lacking core fucose
3SGK	;	2.4	;	Unique carbohydrate/carbohydrate interactions are required for high affinity binding of FcgIII and antibodies lacking core fucose
5X8Z	;	1.5	;	Unique Choloylglycine Hydrolase(CGH) member from Shewanella loihica PV-4
5X9I	;	1.5	;	Unique Choloylglycine Hydrolase(CGH) member Mutant (C1S) from Shewanella loihica PV-4
4R2X	;	0.93	;	Unique conformation of uridine and asymmetry of the hexameric molecule revealed in the high-resolution structures of Shewanella oneidensis uridine phosphorylase in the free form and in complex with uridine
6GAZ	;	3.1	;	Unique features of mammalian mitochondrial translation initiation revealed by cryo-EM. This file contains the 28S ribosomal subunit.
6GB2	;	3.2	;	Unique features of mammalian mitochondrial translation initiation revealed by cryo-EM. This file contains the 39S ribosomal subunit.
6GAW	;	3.2	;	Unique features of mammalian mitochondrial translation initiation revealed by cryo-EM. This file contains the complete 55S ribosome.
3EK5	;	2.56	;	Unique GTP-binding Pocket and Allostery of UMP Kinase from a Gram-Negative Phytopathogen Bacterium
3EK6	;	2.34	;	Unique GTP-binding Pocket and Allostery of UMP Kinase from a Gram-Negative Phytopathogen Bacterium
2W1Q	;	1.6	;	Unique ligand binding specificity for a family 32 Carbohydrate- Binding Module from the Mu toxin produced by Clostridium perfringens
2W1S	;	1.45	;	Unique ligand binding specificity of a family 32 Carbohydrate-Binding Module from the Mu toxin produced by Clostridium perfringens
7V4F	;	1.98	;	Unique non-heme hydroxylase in biosynthesis of nucleoside antibiotic pathway uncover mechanism of reaction
7V4M	;	1.9	;	Unique non-heme hydroxylase in biosynthesis of nucleoside antibiotic pathway uncover mechanism of reaction
7V4N	;	2.2	;	Unique non-heme hydroxylase in biosynthesis of nucleoside antibiotic pathway uncover mechanism of reaction
7V4O	;	1.65	;	Unique non-heme hydroxylase in biosynthesis of nucleoside antibiotic pathway uncover mechanism of reaction
7V4P	;	1.95	;	Unique non-heme hydroxylase in biosynthesis of nucleoside antibiotic pathway uncover mechanism of reaction
5YCQ	;	2.503	;	Unique Specificity-Enhancing Factor for the AAA+ Lon Protease
2LED	;		;	Unique structural features of interconverting monomeric and dimeric G-quadruplexes adopted by a sequence from intron of N-myc gene
2LEE	;		;	Unique structural features of interconverting monomeric and dimeric G-quadruplexes adopted by a sequence from intron of N-myc gene
1N7K	;	2.0	;	Unique tetrameric structure of deoxyribose phosphate aldolase from Aeropyrum pernix
7QOI	;	3.62	;	Unique vertex of the phicrAss001 virion
7QOH	;	3.32	;	Unique vertex of the phicrAss001 virion with C5 symmetry imposed
8PP5	;	2.0	;	Unitary crystal structure of positively supercharged ferritin variant Ftn(pos)-m1 (Mg Formate condition)
6H6U	;	2.0	;	Unitary crystal structure of the positively supercharged variant Ftn(pos) from human heavy chain ferritin (PEG 400 condition)
2N5P	;		;	Universal base control oligonucleotide structure
2N5O	;		;	Universal Base oligonucleotide structure
4TVA	;	2.597	;	Universal Pathway for Post-Transfer Editing Reactions: Insight from Crystal structure of TthPheRS with Puromycine
6JW2	;	3.03	;	Universal RVD R* accommodates 5hmC via water-mediated interactions
6JW1	;	2.49	;	Universal RVD R* accommodates 5mC via water-mediated interactions
6JW0	;	2.2	;	Universal RVD R* accommodates cytosine via water-mediated interactions
7JI4	;	2.3	;	Universal stress protein (USP) domain of KdpD histidine kinase in complex with second messenger c-di-AMP
2JAX	;	3.22	;	Universal Stress Protein Rv2623 from Mycobaterium Tuberculosis
3HGM	;	1.9	;	Universal Stress Protein TeaD from the TRAP transporter TeaABC of Halomonas elongata
3S3T	;	1.9	;	Universal stress protein UspA from Lactobacillus plantarum
1T3U	;	2.5	;	Unknown conserved bacterial protein from Pseudomonas aeruginosa PAO1
4M7Z	;	2.75	;	Unliganded 1 crystal structure of S25-26 Fab
4M93	;	2.09	;	Unliganded 2 crystal structure of S25-26 Fab
4MA1	;	2.32	;	Unliganded 3 crystal structure of S25-26 Fab
6O18	;	2.55	;	Unliganded alpha-L-fucosidase AlfC from Lactobacillus casei
3NEN	;	2.4	;	Unliganded aspartyl-tRNA synthetase from thermococcus kodakarensis
2RIT	;	1.43	;	Unliganded B-specific-1,3-galactosyltransferase (GTB)
2RIZ	;	1.45	;	Unliganded B-specific-1,3-galactosyltransferase G176R mutant (ABBB)
1MNU	;	2.5	;	UNLIGANDED BACTERICIDAL ANTIBODY AGAINST NEISSERIA MENINGITIDIS
1DLU	;	2.25	;	UNLIGANDED BIOSYNTHETIC THIOLASE FROM ZOOGLOEA RAMIGERA
4MJ1	;	2.0	;	unliganded BK Polyomavirus VP1 pentamer
1FEC	;	1.7	;	UNLIGANDED CRITHIDIA FASCICULATA TRYPANOTHIONE REDUCTASE AT 1.7 ANGSTROM RESOLUTION
1FEB	;	2.0	;	UNLIGANDED CRITHIDIA FASCICULATA TRYPANOTHIONE REDUCTASE AT 2.0 ANGSTROM RESOLUTION
1FEA	;	2.2	;	UNLIGANDED CRITHIDIA FASCICULATA TRYPANOTHIONE REDUCTASE AT 2.2 ANGSTROM RESOLUTION
4QV2	;	1.68	;	Unliganded crystal structure of Feline Norovirus P Domain co-crystallized with HBGA A-trisaccharide
4QVJ	;	2.26	;	Unliganded crystal structure of Feline Norovirus P Domain co-crystallized with N-acetylneuraminic acid
4QVA	;	2.18	;	Unliganded crystal structure of Feline Norovirus P Domain co-crystallized with N-glycolylneuraminic acid
4LEX	;	2.02	;	Unliganded crystal structure of mAb7
4OPV	;	1.85	;	Unliganded crystal structure of P domain from norovirus strain Farmington Hills 2004 co-crystallized with HBGA type Lea
6TN1	;	0.98	;	Unliganded Crystal Structure of Recombinant GBA
2IQ5	;	1.9	;	Unliganded Crystal Structure of the Uridine Phosphorylase from Salmonella Typhimurium at 1.90 A Resolution
4IEO	;	1.55	;	unliganded Cysteine Dioxygenase at pH 4.0 in the presence of Cys
4IEP	;	1.45	;	unliganded Cysteine Dioxygenase at pH 4.5 in the presence of Cys
4IEQ	;	1.396	;	unliganded Cysteine Dioxygenase at pH 5.0 in the presence of Cys
4IEZ	;	1.39	;	unliganded Cysteine Dioxygenase at pH 8.0
4PIX	;	1.35	;	Unliganded Cysteine Dioxygenase C93A variant at pH 6.2
3SPB	;	2.3	;	Unliganded E. Cloacae MurA
4EII	;	1.95	;	Unliganded E. cloacae R91K MurA
3V5V	;	2.7	;	UNLIGANDED E.CLOACAE C115D MURA
7L6U	;	3.3	;	Unliganded ELIC in POPC-only nanodiscs at 3.3-Angstrom resolution
6V0B	;	4.1	;	Unliganded ELIC in POPC-only nanodiscs.
7L6Q	;	2.5	;	Unliganded ELIC in styrene-maleic-acid nanodiscs at 2.5-Angstrom resolution
8SU0	;	1.99	;	Unliganded F96H epi-Isozizaene Synthase
4ODW	;	2.72	;	Unliganded Fab structure of lipid A-specific antibody A6
4ODU	;	2.29	;	Unliganded Fab structure of lipid A-specific antibody S1-15
4ODS	;	1.94	;	Unliganded Fab structure of lipid A-specific antibody S55-3
3T0V	;	1.451	;	Unliganded fluorogen activating protein M8VL
5IO5	;	2.85	;	Unliganded form of bovine beta-lactoglobulin, ambient pressure
7YLZ	;	2.72	;	Unliganded form of hydroxyamidotransferase TsnB9
5BUQ	;	1.98	;	Unliganded Form of O-succinylbenzoate Coenzyme A Synthetase (MenE) from Bacillus Subtilis, Solved at 1.98 Angstroms
3P2W	;	1.66	;	Unliganded form of Polo-like kinase I Polo-box domain
5N1I	;	2.4	;	unliganded form of the Mycobacterium tuberculosis repressor EthR2
1D5I	;	2.0	;	UNLIGANDED GERMLINE PRECURSOR OF AN OXY-COPE CATALYTIC ANTIBODY
1NYL	;	2.6	;	Unliganded glutaminyl-tRNA synthetase
2AUD	;	2.1	;	Unliganded HincII
6TVE	;	1.05	;	Unliganded human CD73 (5'-nucleotidase) in the open state
6E8Y	;	1.85	;	Unliganded Human Glycerol 3-Phosphate Dehydrogenase
5T2Q	;	1.9	;	Unliganded Human HVEM at 1.9A in P 1 21 1
5T2R	;	2.1	;	Unliganded Human HVEM at 2.1A in P 21 21 21
6PHH	;	2.4	;	Unliganded human transmission blocking antibody 2544
1D5B	;	2.8	;	UNLIGANDED MATURE OXY-COPE CATALYTIC ANTIBODY
3BY1	;	2.69	;	Unliganded Norvalk Virus P domain
4IEX	;	2.15	;	unliganded room-temp Cysteine Dioxygenase at pH 6.2
6C5I	;	1.89	;	Unliganded S25-5 Fab
1AZ5	;	2.0	;	UNLIGANDED SIV PROTEASE STRUCTURE IN AN ""OPEN"" CONFORMATION
1TOE	;	2.0	;	Unliganded structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase
5NSM	;	2.4	;	unliganded Structure of Leucyl aminopeptidase from Trypanosoma brucei
7C1X	;	2.38943	;	Unliganded structure of Pseudouridine kinase (PUKI) from Arabidopsis thaliana
7VTD	;	2.15055	;	Unliganded structure of Pseudouridine kinase (PUKI) from Escherichia coli strain B
3V93	;	2.0	;	unliganded structure of TcrPDEC1 catalytic domain
6QVS	;	1.6	;	Unliganded structure of the human wild type Beta-galactoside alpha-2,6-sialyltransferase 1 (ST6Gal1)
5EAV	;	1.6	;	Unliganded structure of the ornithine aminotransferase from Toxoplasma gondii
5QTC	;	1.645	;	Unliganded T. brucei FPPS
5QTD	;	1.642	;	Unliganded T. brucei FPPS
8C7T	;	2.21	;	Unliganded transcriptional pleiotropic repressor CodY from Enterococcus faecalis
8C7O	;	2.05	;	Unliganded transcriptional pleiotropic repressor CodY from Staphylococcus aureus
4C0P	;	2.95	;	Unliganded Transportin 3
3AQD	;	3.2	;	Unliganded TRAP
3U69	;	1.55	;	Unliganded wild-type human thrombin
5I33	;	2.2	;	Unligated adenylosuccinate synthetase from Cryptococcus neoformans
1HKH	;	1.73	;	unligated gamma lactamase from an Aureobacterium species
5H4I	;	2.004	;	Unlinked NS2B-NS3 Protease from Zika Virus in complex with a compound fragment
1DQ2	;	2.05	;	Unlocked metal-free concanavalin A
7L1W	;	1.71	;	Unlocking the structural features for the exo-xylobiosidase activity of an unusual GH11 member identified in a compost-derived consortium
7L1Z	;	2.05	;	Unlocking the structural features for the exo-xylobiosidase activity of an unusual GH11 member identified in a compost-derived consortium - NT-truncated form
7L1Y	;	1.2	;	Unlocking the structural features for the exo-xylobiosidase activity of an unusual GH11 member identified in a compost-derived consortium-xylobiose complex
1ON7	;	2.7	;	Unmethylated form of C-phycocyanin from Themosynechococcus vulcanus at 2.7A
7SFR	;	2.6	;	Unmethylated Mtb Ribosome 50S with SEQ-9
2LBL	;		;	Unmodified Glycyl-tRNA(UCC) anticodon stem-loop from Bacillus subtilis
2ATL	;	2.8	;	Unmodified Insertion Ternary Complex
2AU0	;	2.7	;	Unmodified preinsertion binary complex
6O3M	;	3.97	;	Unmodified tRNA(Pro) bound to Thermus thermophilus 70S (cognate)
6OSI	;	4.14	;	Unmodified tRNA(Pro) bound to Thermus thermophilus 70S (near cognate)
1JBA	;		;	UNMYRISTOYLATED GCAP-2 WITH THREE CALCIUM IONS BOUND
3TX0	;	2.26	;	Unphosphorylated Bacillus cereus phosphopentomutase in a P212121 crystal form
8TUC	;	1.5	;	Unphosphorylated CaMKK2 in complex with CC-8977
6TLC	;	2.9	;	Unphosphorylated human STAT3 in complex with MS3-6 monobody
2MMH	;		;	Unphosphorylated Mengovirus Leader Protein: NMR Studies of the Phosphorylation of the Mengovirus Leader Protein Reveal Stabilization of Intermolecular Domain Interactions
2Z7L	;	2.41	;	Unphosphorylated Mitogen Activated Protein Kinase ERK2 in Complex with (4-{[5-Carbamoyl-4-(3-Methylanilino)Pyrimidin 2-Yl]Amino}Phenyl)Acetic Acid
3CWG	;	3.05	;	Unphosphorylated mouse STAT3 core fragment
6IFH	;	1.8	;	Unphosphorylated Spo0F from Paenisporosarcina sp. TG-14
4E68	;	2.585	;	Unphosphorylated STAT3B core protein binding to dsDNA
2G0R	;	1.95	;	Unphotolyzed CO-bound L29F Myoglobin
2G0S	;	1.9	;	Unphotolyzed CO-bound L29F Myoglobin, crystal 2
2PUS	;	2.4	;	Unprecedented activation mechanism of a non-canonical RNA-dependent RNA polymerase
1TLF	;	2.6	;	UNPRECEDENTED QUATERNARY STRUCTURE OF E. COLI LAC REPRESSOR CORE TETRAMER: IMPLICATIONS FOR DNA LOOPING
4B21	;	1.45	;	Unprecedented sculpting of DNA at abasic sites by DNA glycosylase homolog Mag2
4B22	;	1.9	;	Unprecedented sculpting of DNA at abasic sites by DNA glycosylase homolog Mag2
4B23	;	2.0	;	Unprecedented sculpting of DNA at abasic sites by DNA glycosylase homolog Mag2
4B24	;	2.3	;	Unprecedented sculpting of DNA at abasic sites by DNA glycosylase homolog Mag2
1PYQ	;	1.9	;	Unprocessed Aspartate Decarboxylase Mutant, with Alanine inserted at position 24
1PT0	;	2.0	;	Unprocessed Pyruvoyl Dependent Aspartate Decarboxylase with an Alanine insertion at position 26
1PT1	;	1.9	;	Unprocessed Pyruvoyl Dependent Aspartate Decarboxylase with Histidine 11 Mutated to Alanine
4IJO	;	1.9	;	Unraveling hidden allosteric regulatory sites in structurally homologues metalloproteases
5FKQ	;	1.71	;	Unraveling the first step of xyloglucan degradation by the soil saprophyte Cellvibrio japonicus through the functional and structural characterization of a potent GH74 endo-xyloglucanase
5FKR	;	2.28	;	Unraveling the first step of xyloglucan degradation by the soil saprophyte Cellvibrio japonicus through the functional and structural characterization of a potent GH74 endo-xyloglucanase
5FKS	;	1.99	;	Unraveling the first step of xyloglucan degradation by the soil saprophyte Cellvibrio japonicus through the functional and structural characterization of a potent GH74 endo-xyloglucanase
5FKT	;	1.52	;	Unraveling the first step of xyloglucan degradation by the soil saprophyte Cellvibrio japonicus through the functional and structural characterization of a potent GH74 endo-xyloglucanase
6H9W	;	1.35	;	Unraveling the role of the secretor antigen in human rotavirus attachment to histo-blood group antigens
6H9Y	;	1.31	;	Unraveling the role of the secretor antigen in human rotavirus attachment to histo-blood group antigens
6HA0	;	1.85	;	Unraveling the role of the secretor antigen in human rotavirus attachment to histo-blood group antigens
3INK	;	2.5	;	UNRAVELING THE STRUCTURE OF INTERLEUKIN-2: REPLY
7WUO	;	3.19	;	Unravelling structure of riboflavin synthase for designing of potential anti-bacterial drug
4USK	;	1.76	;	Unravelling the B. pseudomallei heptokinase WcbL: from Structure to Drug Discovery.
4CU6	;	2.7	;	Unravelling the multiple functions of the architecturally intricate Streptococcus pneumoniae beta-galactosidase, BgaA
4CU7	;	2.2	;	Unravelling the multiple functions of the architecturally intricate Streptococcus pneumoniae beta-galactosidase, BgaA
4CU8	;	2.5	;	Unravelling the multiple functions of the architecturally intricate Streptococcus pneumoniae beta-galactosidase, BgaA
4CU9	;	1.83	;	Unravelling the multiple functions of the architecturally intricate Streptococcus pneumoniae beta-galactosidase, BgaA
4CUA	;	1.54	;	Unravelling the multiple functions of the architecturally intricate Streptococcus pneumoniae beta-galactosidase, BgaA
4CUB	;	2.1	;	Unravelling the multiple functions of the architecturally intricate Streptococcus pneumoniae beta-galactosidase, BgaA
4CUC	;	2.2	;	Unravelling the multiple functions of the architecturally intricate Streptococcus pneumoniae beta-galactosidase, BgaA.
3KSE	;	1.71	;	Unreduced cathepsin L in complex with stefin A
3KFQ	;	1.99	;	Unreduced cathepsin V in complex with stefin A
3K3R	;	3.2	;	Unrefined crystal structure of a LexA-DNA complex
2AHF	;	1.52	;	Unsaturated glucuronyl hydrolase mutant D88N
2AHG	;	1.9	;	Unsaturated glucuronyl hydrolase mutant D88N with dGlcA-GalNAc
2D5J	;	1.6	;	Unsaturated Glucuronyl Hydrolase Triggers Hydration of Vinyl Ether Group but not of Glycosidic Bond
8OT1	;	2.59	;	unseeded Abeta(1-40) amyloid fibril (morphology i)
8OT3	;	2.73	;	unseeded Abeta(1-40) amyloid fibril (morphology ii)
7ZCL	;	1.95	;	Unspecific peroxygenase from Collariella virescens
7O1X	;	1.6	;	Unspecific peroxygenase from Hypoxylon sp. EC38 in complex with 1-phenylimidazole
7O2D	;	2.68	;	Unspecific peroxygenase from Hypoxylon sp. EC38 in complex with 2-(N-morpholino) ethanesulfonic acid (MES)
7O1R	;	1.3	;	Unspecific peroxygenase from Hypoxylon sp. EC38 in complex with imidazole
7O1Z	;	1.8	;	Unspecific peroxygenase from Hypoxylon sp. EC38 in complex with S-1,2-propanediol
7O2G	;	2.1	;	Unspecific peroxygenase from Hypoxylon sp. EC38 in complex with styrene
7ZBP	;	1.45	;	Unspecific peroxygenase from Marasmius rotula
7PI0	;	2.43	;	Unstacked compact Dunaliella PSII
7PNK	;	3.61	;	Unstacked compact Dunaliella PSII
7PI5	;	2.78	;	Unstacked stretched Dunaliella PSII
5MM3	;	2.1	;	Unstructured MamC magnetite-binding protein located between two helices.
6MGF	;	2.982	;	untagged, wild-type LptB in complex with ADP
2MAB	;		;	Untangling the Solution Structure of C-Terminal Domain of Aciniform Spidroin
1L1V	;		;	UNUSUAL ACTD/DNA_TA COMPLEX STRUCTURE
1VTD	;	2.8	;	UNUSUAL HELICAL PACKING IN CRYSTALS OF DNA BEARING A MUTATION HOT SPOT
5OYA	;	1.8	;	Unusual posttranslational modifications revealed in crystal structures of diatom Rubisco.
7C28	;	2.4	;	Unusual quaternary structure of a homodimeric synergistic toxin from mamba snake venom
7BEB	;	1.32	;	Unusual structural features in the adduct of dirhodium tetraacetate with lysozyme (4)
7BEC	;	1.74	;	Unusual structural features in the adduct of dirhodium tetraacetate with lysozyme (5)
1PCL	;	2.2	;	UNUSUAL STRUCTURAL FEATURES IN THE PARALLEL BETA-HELIX IN PECTATE LYASES
2V7N	;	1.92	;	Unusual twinning in crystals of the CitS binding antibody Fab fragment f3p4
3ZQ4	;	3.0	;	Unusual, dual endo- and exo-nuclease activity in the degradosome explained by crystal structure analysis of RNase J1
5G26	;	2.42	;	Unveiling the Mechanism Behind the in-meso Crystallization of Membrane Proteins
2N5M	;		;	Unveiling the structural determinants of KIAA0323 binding preference for NEDD8
2N7K	;		;	Unveiling the structural determinants of KIAA0323 binding preference for NEDD8
4DJ2	;	2.75	;	Unwinding the Differences of the Mammalian PERIOD Clock Proteins from Crystal Structure to Cellular Function
4DJ3	;	2.5	;	Unwinding the Differences of the Mammalian PERIOD Clock Proteins from Crystal Structure to Cellular Function
1L3K	;	1.1	;	UP1, THE TWO RNA-RECOGNITION MOTIF DOMAIN OF HNRNP A1
1UP1	;	1.9	;	UP1, THE TWO RNA-RECOGNITION MOTIF DOMAIN OF HNRNP A1
5ZAJ	;	1.65	;	uPA-31F
5ZAE	;	1.73	;	uPA-6F-HMA
5ZA8	;	1.9	;	uPA-BB2-27F
5ZAF	;	1.65	;	uPA-BB2-28F
5ZAH	;	2.98	;	uPA-BB2-30F
5ZA9	;	1.62	;	uPA-BB2-50F
5ZAG	;	1.95	;	uPA-BB2-94F
5ZA7	;	1.7	;	uPA-HMA
6AG2	;	1.77	;	uPA-HMA
5ZC5	;	1.9	;	uPA-NU-09F
6XYU	;	2.51	;	Update of AChE from Drosophila Melanogaster complex with tacrine derivative 9-(3-iodobenzylamino)-1,2,3,4-tetrahydroacridine
6XYY	;	2.7	;	Update of ACHE FROM DROSOPHILA MELANOGASTER COMPLEX WITH TACRINE DERIVATIVE 9-(3-PHENYLMETHYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE
6XYS	;	2.46	;	Update of native acetylcholinesterase from Drosophila Melanogaster
2ZUP	;	3.7	;	Updated crystal structure of DsbB-DsbA complex from E. coli
7RVA	;	1.89	;	Updated Crystal Structure of Replication Initiator Protein REPE54.
2XZP	;	2.72	;	Upf1 helicase
2XZO	;	2.395	;	Upf1 helicase - RNA complex
2XZL	;	2.4	;	Upf1-RNA complex
8EGR	;	3.58	;	Upper tail structure of Staphylococcus phage Andhra
8B71	;	3.8	;	Upright KimA dimer with bound c-di-AMP from B. subtilis
1BD4	;	2.2	;	UPRT-URACIL COMPLEX
4LZB	;	2.03	;	Uracil binding pocket in Vaccinia virus uracil DNA glycosylase
1Q3F	;	1.9	;	Uracil DNA glycosylase bound to a cationic 1-aza-2'-deoxyribose-containing DNA
1FLZ	;	2.3	;	URACIL DNA GLYCOSYLASE WITH UAAP
2VWJ	;	2.78	;	Uracil Recognition in Archaeal DNA Polymerases Captured by X-ray Crystallography.
2VWK	;	2.6	;	Uracil Recognition in Archaeal DNA Polymerases Captured by X-ray Crystallography. V93Q polymerase variant
1LAU	;	1.8	;	URACIL-DNA GLYCOSYLASE
1EMJ	;	2.0	;	URACIL-DNA GLYCOSYLASE BOUND TO DNA CONTAINING A 4'-THIO-2'DEOXYURIDINE ANALOG PRODUCT
1UGI	;	1.55	;	URACIL-DNA GLYCOSYLASE INHIBITOR PROTEIN
4OP6	;	1.65	;	Urate OXIDASE + 8-AZAXANTHINE UNDER 40 BARS OXYGEN
3BK8	;	1.6	;	Urate oxidase aza-xanthine complex in cyanide
7Q09	;	2.19	;	URATE OXIDASE AZA-XANTHINE COMPLEX UNDER 1500 BAR OF ARGON
7PUF	;	1.86	;	urate oxidase azaxanthine complex under 600 bar (60 MPa) of argon
4PR8	;	1.16	;	URATE OXIDASE AZIDE URIC ACID TERNARY complex
4OQC	;	1.3	;	Urate OXIDASE CO-CRYSTALLIZED WITH AZIDE
4POE	;	1.07	;	Urate oxidase co-crystallized with uric acid and azide
3F2M	;	1.8	;	Urate oxidase complexed with 8-azaxanthine at 150 MPa
2ZKA	;	1.61	;	Urate oxidase complexed with 8-azaxanthine under 1.0 MPa oxygen pressure
2ZKB	;	1.61	;	Urate oxidase complexed with 8-azaxanthine under 2.5 MPa oxygen pressure
3CKS	;	1.7	;	Urate oxidase complexed with 8-azaxanthine under 4.0 MPa oxygen pressure
3LD4	;	1.35	;	Urate oxidase complexed with 8-nitro xanthine
3LBG	;	1.5	;	Urate oxidase complexed with 8-thio xanthine
3L9G	;	1.75	;	Urate oxidase complexed with uric acid and chloride
3BJP	;	1.8	;	Urate oxidase cyanide uric acid ternary complex
4PUV	;	1.3	;	URATE OXIDASE DI-AZIDE complex
1WS2	;	2.7	;	urate oxidase from aspergillus flavus complexed with 5,6-diaminouracil
1WRR	;	1.64	;	Urate oxidase from aspergillus flavus complexed with 5-amino 6-nitro uracil
1XXJ	;	2.8	;	Urate oxidase from aspergillus flavus complexed with 5-amino 6-nitro uracil
2FXL	;	1.76	;	Urate oxidase from aspergillus flavus complexed with allantoin
1XT4	;	2.01	;	Urate Oxidase From Aspergillus Flavus Complexed With Guanine
1XY3	;	3.2	;	Urate oxidase from aspergillus flavus complexed with guanine
1R51	;	1.75	;	URATE OXIDASE FROM ASPERGILLUS FLAVUS COMPLEXED WITH ITS INHIBITOR 8-AZAXANTHIN
3CKU	;	1.7	;	Urate oxidase from aspergillus flavus complexed with its inhibitor 8-azaxanthin and chloride
2IBA	;	1.5	;	Urate oxidase from Aspergillus flavus complexed with its inhibitor 8-azaxanthine
1R4S	;	1.8	;	URATE OXIDASE FROM ASPERGILLUS FLAVUS COMPLEXED WITH ITS INHIBITOR 9-METHYL URIC ACID
1R4U	;	1.65	;	URATE OXIDASE FROM ASPERGILLUS FLAVUS COMPLEXED WITH ITS INHIBITOR OXONIC ACID
1WS3	;	3.2	;	Urate oxidase from aspergillus flavus complexed with uracil
3L8W	;	1.0	;	Urate oxidase from aspergillus flavus complexed with xanthin
7F2V	;	1.6	;	Urate oxidase from Thermobispora bispora in apo form
4OP9	;	1.58	;	Urate OXIDASE IN COMPLEX WITH 8-AZAXANTHINE
2PES	;	1.6	;	Urate Oxidase in complex with tris-dipicolinate Lutetium
3PK5	;	1.75	;	Urate oxidase under 0.1 MPa / 1 bar pressure of xenon
3PKF	;	1.65	;	Urate oxidase under 0.2 MPa / 2 bars pressure of equimolar mixture of xenon and nitrous oxide
3PK6	;	1.8	;	Urate oxidase under 0.2 MPa / 2 bars pressure of xenon
3PLE	;	1.6	;	urate oxidase under 0.5 MPa / 5 bars pressure of equimolar mixture xenon : nitrous oxide
3PK8	;	1.65	;	Urate oxidase under 0.5 MPa / 5 bars pressure of nitrous oxide
3PKK	;	1.733	;	Urate oxidase under 0.5 MPa / 5 bars pressure of xenon
3PKL	;	1.749	;	Urate oxidase under 0.8 MPa / 8 bars pressure of xenon
3PKU	;	1.75	;	Urate oxidase under 1 MPa / 10 bars pressure of nitrous oxide
3PLG	;	1.601	;	urate oxidase under 1.0 MPa / 10 bars pressure of equimolar mixture xenon : nitrous oxide
3PJK	;	1.701	;	Urate oxidase under 1.0 MPa / 10 bars pressure of xenon
3PLH	;	1.8	;	urate oxidase under 1.5 MPa / 15 bars pressure of equimolar mixture xenon : nitrous oxide
3PKS	;	1.75	;	Urate oxidase under 1.5 MPa / 15 bars pressure of nitrous oxide
3PKH	;	1.71	;	Urate oxidase under 1.5 MPa / 15 bars pressure of xenon
3PLI	;	1.68	;	Urate oxidase under 1.8 MPa / 18 bars pressure of equimolar mixture xenon : nitrous oxide
6IA1	;	2.36	;	urate oxidase under 120 bar of argon
6RGM	;	1.5	;	urate oxidase under 130 bar of krypton
3PKT	;	1.75	;	Urate oxidase under 2 MPa / 20 bars pressure of nitrous oxide
3PKG	;	1.602	;	Urate oxidase under 2 MPa / 20 bars pressure of xenon
3PLM	;	1.621	;	Urate oxidase under 2.0 MPa / 20 bars pressure of equimolar mixture xenon : nitrous oxide
2ICQ	;	1.75	;	urate oxidase under 2.0 MPa pressure of nitrous oxide
2IC0	;	1.78	;	Urate oxidase under 2.0 MPa pressure of xenon
6IA9	;	1.8	;	urate oxidase under 2000 bar (220 MPa) of argon
6IA3	;	1.69	;	urate oxidase under 220 bar (22 MPa) of argon
3PLJ	;	1.732	;	Urate oxidase under 3.0 MPa / 30 bars pressure of equimolar mixture xenon : nitrous oxide
3PK3	;	1.65	;	urate oxidase under 3.0 MPa / 30 bars pressure of nitrous oxide
3PK4	;	1.85	;	Urate oxidase under 3.2 MPa / 32 bars pressure of xenon
6I9X	;	1.6	;	urate oxidase under 35 bar of argon
6I9Z	;	1.6	;	urate oxidase under 65 bar of argon
6IC1	;	1.1	;	urate oxidase under 90 bar of krypton
7P0C	;	2.15	;	URATE OXIDASE WITH 8-AZAXANTHINE UNDER 210 MPA PRESSURE
7P0D	;	2.4	;	URATE OXIDASE WITH 8-AZAXANTHINE UNDER 310 MPA PRESSURE
7P0G	;	1.9	;	URATE OXIDASE WITH 8-AZAXANTHINE UNDER AMBIENT PRESSURE
3P9F	;	1.7	;	Urate oxidase-azaxanthine-azide ternary complex
4FSK	;	1.98	;	Urate oxidase-azide complex in anaerobic conditions
7PWN	;	1.64	;	URATE OXYDASE AZA-XANTHINE COMPLEX AT 1000 BARS (100 MPa) OF ARGON
1JZR	;	2.9	;	Ure2p in complex with glutathione
1K0B	;	2.5	;	Ure2p in Complex with Glutathione
1K0D	;	2.2	;	Ure2p in Complex with Glutathione
1K0A	;	2.5	;	Ure2p in Complex with S-hexylglutathione
1K0C	;	2.5	;	Ure2p in complex with S-p-nitrobenzylglutathione
5O00	;	2.03	;	Ure2p5 from Phanerochaete chrysosporium cocrystallized with 1-(S-glutathionyl)-2,4-dinitrobenzene.
8CJ1	;	2.564	;	Urea-based foldamer inhibitor c3u_3 chimera in complex with ASF1 histone chaperone
8CJ2	;	2.127	;	Urea-based foldamer inhibitor c3u_5 chimera in complex with ASF1 histone chaperone
8CJ3	;	3.0	;	Urea-based foldamer inhibitor c3u_7 chimera in complex with ASF1 histone chaperone
6ZUF	;	1.798	;	Urea-based Foldamer Inhibitor chimera C2 in complex with ASF1 Histone chaperone
6KNL	;	2.32	;	Uridine and triphosphate-bound UGPase from acinetobacter baumannii
7VTE	;	2.15297	;	uridine bound structure of Pseudouridine kinase (PUKI) from Escherichia coli strain B
1K3F	;	2.5	;	Uridine Phosphorylase from E. coli, Refined in the Monoclinic Crystal Lattice
1RYZ	;	2.9	;	Uridine Phosphorylase from Salmonella typhimurium. Crystal Structure at 2.9 A Resolution
2JUC	;		;	URN1 FF domain yeast
6T85	;	1.1	;	Urocanate reductase in complex with ADP
6T86	;	2.56	;	Urocanate reductase in complex with FAD
6T88	;	1.4	;	Urocanate reductase in complex with imidazole propionate
6T87	;	1.56	;	Urocanate reductase in complex with urocanate
3GW0	;	2.0	;	UROD mutant G318R
3GVQ	;	2.1	;	UROD single-chain dimer
1F92	;	2.6	;	UROKINASE PLASMINOGEN ACTIVATOR B CHAIN-UKI-1D COMPLEX
1EJN	;	1.8	;	UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN INHIBITOR COMPLEX
1F5L	;	2.1	;	UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-AMILORIDE COMPLEX
1F5K	;	1.8	;	UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-BENZAMIDINE COMPLEX
2R2W	;	2.01	;	Urokinase plasminogen activator B-chain-GPPE complex
1SC8	;	2.4	;	Urokinase Plasminogen Activator B-Chain-J435 Complex
1VJA	;	2.0	;	Urokinase Plasminogen Activator B-Chain-JT463 Complex
1VJ9	;	2.4	;	Urokinase Plasminogen Activator B-Chain-JT464 Complex
1W0Z	;	1.9	;	Urokinase type plasminogen activator
1W10	;	2.0	;	Urokinase type plasminogen activator
1W11	;	2.0	;	UROKINASE TYPE PLASMINOGEN ACTIVATOR
1W12	;	2.4	;	UROKINASE TYPE PLASMINOGEN ACTIVATOR
1W13	;	2.0	;	UROKINASE TYPE PLASMINOGEN ACTIVATOR
1W14	;	2.2	;	UROKINASE TYPE PLASMINOGEN ACTIVATOR
2VNT	;	2.2	;	UROKINASE-TYPE PLASMINOGEN ACTIVATOR INHIBITOR COMPLEX WITH A 1-(7- SULPHOAMIDOISOQUINOLINYL)GUANIDINE
8I58	;	3.09	;	Uroporphyrin I (UPI)-bound CfbA
8I57	;	2.81	;	Uroporphyrin III (UPIII)-bound CfbA
1URO	;	1.8	;	UROPORPHYRINOGEN DECARBOXYLASE
2Q6Z	;	2.0	;	Uroporphyrinogen Decarboxylase G168R single mutant apo-enzyme
2Q71	;	1.9	;	Uroporphyrinogen Decarboxylase G168R single mutant enzyme in complex with coproporphyrinogen-III
1R3Q	;	1.7	;	Uroporphyrinogen Decarboxylase in complex with coproporphyrinogen-I
1R3Y	;	1.755	;	Uroporphyrinogen Decarboxylase in complex with coproporphyrinogen-III
1R3V	;	1.9	;	Uroporphyrinogen Decarboxylase single mutant D86E in complex with coproporphyrinogen-I
1R3S	;	1.65	;	Uroporphyrinogen Decarboxylase single mutant D86G in complex with coproporphyrinogen-I
1R3T	;	1.7	;	Uroporphyrinogen Decarboxylase single mutant D86G in complex with coproporphyrinogen-III
1R3R	;	1.85	;	Uroporphyrinogen Decarboxylase with mutation D86N
1R3W	;	1.7	;	Uroporphyrinogen Decarboxylase Y164F mutant in complex with coproporphyrinogen-III
3D8N	;	1.9	;	Uroporphyrinogen III Synthase-Uroporphyringen III Complex
5WB2	;	3.5	;	US28 bound to engineered chemokine CX3CL1.35 and nanobodies
3D8W	;	1.7	;	Use of a carbonic Anhydrase II, IX Active-site Mimic, for the Purpose of Screening Inhibitors for Possible Anti-Cancer Properties
1SWY	;	1.06	;	Use of a Halide Binding Site to Bypass the 1000-atom Limit to Ab initio Structure Determination
1SX2	;	1.06	;	Use of a Halide Binding Site to Bypass the 1000-atom Limit to Structure Determination by Direct Methods
1SWZ	;	1.06	;	Use of an ion-binding site to bypass the 1000-atom limit to ab initio structure determination by direct methods
1SX7	;	1.06	;	Use of an ion-binding site to bypass the 1000-atom limit to ab initio structure determination by direct methods
1D1U	;	2.3	;	USE OF AN N-TERMINAL FRAGMENT FROM MOLONEY MURINE LEUKEMIA VIRUS REVERSE TRANSCRIPTASE TO FACILITATE CRYSTALLIZATION AND ANALYSIS OF A PSEUDO-16-MER DNA MOLECULE CONTAINING G-A MISPAIRS
3D9Z	;	1.65	;	Use of Carbonic Anhydrase II, IX Active-Site Mimic, for the Purpose of Screening Inhibitors for Possible Anti-Cancer Properties
3DAZ	;	1.6	;	Use of Carbonic Anhydrase II, IX Active-Site Mimic, for the Purpose of Screening Inhibitors for Possible Anti-Cancer Properties
3DBU	;	1.7	;	Use of Carbonic Anhydrase II, IX Active-Site Mimic, for the Purpose of Screening Inhibitors for Possible Anti-Cancer Properties
3DC3	;	1.7	;	Use of Carbonic Anhydrase II, IX Active-Site Mimic, for the Purpose of Screening Inhibitors for Possible Anti-Cancer Properties
3DC9	;	1.6	;	Use of Carbonic Anhydrase II, IX Active-Site Mimic, for the Purpose of Screening Inhibitors for Possible Anti-Cancer Properties
3DCC	;	1.6	;	Use of Carbonic Anhydrase II, IX Active-Site Mimic, for the Purpose of Screening Inhibitors for Possible Anti-Cancer Properties
3DCS	;	1.8	;	Use of Carbonic Anhydrase II, IX Active-Site Mimic, for the Purpose of Screening Inhibitors for Possible Anti-Cancer Properties
3DCW	;	1.5	;	Use of Carbonic Anhydrase II, IX Active-Site Mimic, for the Purpose of Screening Inhibitors for Possible Anti-Cancer Properties
3DD0	;	1.48	;	Use of Carbonic Anhydrase II, IX Active-Site Mimic, for the Purpose of Screening Inhibitors for Possible Anti-Cancer Properties
4H1P	;	2.3	;	Use of Europium for SAD Phasing at the Cu K alpha wavelength
1BP4	;	2.2	;	USE OF PAPAIN AS A MODEL FOR THE STRUCTURE-BASED DESIGN OF CATHEPSIN K INHIBITORS. CRYSTAL STRUCTURES OF TWO PAPAIN INHIBITOR COMPLEXES DEMONSTRATE BINDING TO S'-SUBSITES.
1BQI	;	2.5	;	USE OF PAPAIN AS A MODEL FOR THE STRUCTURE-BASED DESIGN OF CATHEPSIN K INHIBITORS. CRYSTAL STRUCTURES OF TWO PAPAIN INHIBITOR COMPLEXES DEMONSTRATE BINDING TO S'-SUBSITES.
2ETI	;		;	USE OF RESTRAINED MOLECULAR DYNAMICS IN WATER TO DETERMINE THREE-DIMENSIONAL PROTEIN STRUCTURE: PREDICTION OF THE THREE-DIMENSIONAL STRUCTURE OF ECBALLIUM ELATERIUM TRYPSIN INHIBITOR II
1T8A	;	2.0	;	USE OF SEQUENCE DUPLICATION TO ENGINEER A LIGAND-TRIGGERED LONG-DISTANCE MOLECULAR SWITCH IN T4 Lysozyme
1T97	;	2.7	;	Use of sequence duplication to engineer a ligand-triggered long-distance molecular switch in T4 Lysozyme
3O7O	;	2.41	;	Use of synthetic symmetrization in the crystallization and structure determination of CelA from Thermotoga maritima
1NTP	;	1.8	;	USE OF THE NEUTRON DIFFRACTION H/D EXCHANGE TECHNIQUE TO DETERMINE THE CONFORMATIONAL DYNAMICS OF TRYPSIN
4ZN8	;	3.0	;	Using molecular dynamics simulations to predict domain swapping of computationally designed protein variants
3LJA	;	2.75	;	Using Soft X-Rays for a Detailed Picture of Divalent Metal Binding in the Nucleosome
5WHW	;	1.71	;	Using sound pulses to solve the crystal harvesting bottleneck
5WJG	;	1.5	;	Using sound pulses to solve the crystal harvesting bottleneck
5WJH	;	1.63	;	Using sound pulses to solve the crystal harvesting bottleneck
7ZH4	;	2.49	;	USP1 bound to ML323 and ubiquitin conjugated to FANCD2 (focused refinement)
7ZH3	;	2.5	;	USP1 bound to ubiquitin conjugated to FANCD2 (focused refinement)
6IIL	;	2.2	;	USP14 catalytic domain bind to IU1-47
6LVS	;	2.73	;	USP14 catalytic domain mutant C114S
6IIK	;	1.97	;	USP14 catalytic domain with IU1
6IIM	;	2.21	;	USP14 catalytic domain with IU1-206
6IIN	;	2.53	;	USP14 catalytic domain with IU1-248
6GH9	;	2.09	;	USP15 catalytic domain in complex with small molecule
6GHA	;	1.98	;	USP15 catalytic domain structure
7R2G	;	1.98	;	USP15 D1D2 in catalytically-competent state bound to mitoxantrone stack (isoform 2)
2HD5	;	1.85	;	USP2 in complex with ubiquitin
3MTN	;	2.7	;	Usp21 in complex with a ubiquitin-based, USP21-specific inhibitor
6H4J	;	3.07	;	Usp25 catalytic domain
6H4I	;	3.22	;	Usp28 catalytic domain apo
6H4H	;	3.5	;	Usp28 catalytic domain variant E593D in complex with UbPA
7W3R	;	1.92	;	USP34 catalytic domain
7W3U	;	3.13	;	USP34 catalytic domain in complex with UbPA
5CVM	;	1.9	;	USP46~ubiquitin BEA covalent complex
6M1K	;	2.255	;	USP7 in complex with a novel inhibitor
5WHC	;	2.548	;	USP7 in complex with Cpd2 (4-(3-(1-methylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl)phenol)
5UQV	;	2.84	;	USP7 in complex with GNE6640 (4-(2-amino-4-ethyl-5-(1H-indazol-5-yl)pyridin-3-yl)phenol)
5UQX	;	2.23	;	USP7 in complex with GNE6776 (6'-amino-4'-ethyl-5'-(4-hydroxyphenyl)-N-methyl-[3,3'-bipyridine]-6-carboxamide)
6VN4	;	2.69	;	USP7 IN COMPLEX WITH LIGAND COMPOUND 1
6VN6	;	2.99	;	USP7 IN COMPLEX WITH LIGAND COMPOUND 14
6VN2	;	2.93	;	USP7 IN COMPLEX WITH LIGAND COMPOUND 18
6VN3	;	2.73	;	USP7 IN COMPLEX WITH LIGAND COMPOUND 23
6VN5	;	2.9	;	USP7 IN COMPLEX WITH LIGAND COMPOUND 7
5JTJ	;	3.321	;	USP7CD-CTP in complex with Ubiquitin
5JTV	;	3.312	;	USP7CD-UBL45 in complex with Ubiquitin
1KP6	;	1.8	;	USTILAGO MAYDIS KILLER TOXIN KP6 ALPHA-SUBUNIT
5MM4	;	4.5	;	Ustilago maydis kinesin-5 motor domain in the AMPPNP state bound to microtubules
5MM7	;	5.1	;	Ustilago maydis kinesin-5 motor domain with N-terminal extension in the AMPPNP state bound to microtubules
3ZPX	;	1.99	;	USTILAGO MAYDIS LIPASE UM03410, SHORT FORM WITHOUT FLAP
1RTU	;	1.8	;	USTILAGO SPHAEROGENA RIBONUCLEASE U2
8B51	;	1.84	;	Usutu virus methyltransferase domain in complex with sinefungin
8B52	;	2.22	;	Usutu virus methyltransferase domain in complex with sinefungin
1UTR	;		;	UTEROGLOBIN-PCB COMPLEX (REDUCED FORM)
4FNJ	;	1.95	;	Utilizing the GAAA tetraloop/receptor to facilitate crystal packing and structure determination of a CUG RNA helix
7EJ3	;	1.6	;	UTP cyclohydrolase
6KNJ	;	3.2	;	UTP-bound UGPase from acinetobacter baumannii
7PF1	;	2.1	;	UVC treated Human apoferritin
3C0S	;	1.8	;	UVDE 3 metals
3C0Q	;	2.74	;	UVDE E175A
3BZJ	;	2.3	;	UVDE K229L
3C0L	;	3.15	;	UVDE K229R
3BZG	;	1.91	;	UVDE pH4.4
1D2M	;	1.9	;	UVRB PROTEIN OF THERMUS THERMOPHILUS HB8; A NUCLEOTIDE EXCISION REPAIR ENZYME
6YHZ	;		;	UvrD helicase RNA polymerase interactions are governed by UvrDs carboxy terminal Tudor domain.
6YI2	;		;	UvrD helicase RNA polymerase interactions are governed by UvrDs carboxy terminal Tudor domain.
3Q5T	;	2.005	;	V beta/V beta homodimerization-based pre-TCR model suggested by TCR beta crystal structures
3Q5Y	;	1.9	;	V beta/V beta homodimerization-based pre-TCR model suggested by TCR beta crystal structures
1AVZ	;	3.0	;	V-1 NEF PROTEIN IN COMPLEX WITH WILD TYPE FYN SH3 DOMAIN
1B88	;	2.5	;	V-ALPHA 2.6 MOUSE T CELL RECEPTOR (TCR) DOMAIN
7TMR	;	3.5	;	V-ATPase from Saccharomyces cerevisiae, State 1
7TMS	;	3.8	;	V-ATPase from Saccharomyces cerevisiae, State 2
7TMT	;	3.8	;	V-ATPase from Saccharomyces cerevisiae, State 3
8EA3	;	3.7	;	V-K CAST Transpososome from Scytonema hofmanni, major configuration
8EA4	;	3.0	;	V-K CAST Transpososome from Scytonema hofmanni, minor configuration
4BE5	;	2.46	;	V. cholera biofilm scaffolding protein RbmA
4BE6	;	2.05	;	V. cholera biofilm scaffolding protein RbmA
4BEI	;	2.6	;	V. cholera biofilm scaffolding protein RbmA in complex with 18-crown- 6
6WLU	;	5.7	;	V. cholerae glycine riboswitch with glycine models, 5.7 Angstrom resolution
8FUK	;	3.36	;	V. cholerae TniQ-Cascade complex with Type III-B crRNA
6PIG	;	3.5	;	V. cholerae TniQ-Cascade complex, closed conformation
6PIF	;	3.4	;	V. cholerae TniQ-Cascade complex, open conformation
6LY8	;	3.5	;	V/A-ATPase from Thermus thermophilus, the soluble domain, including V1, d, two EG stalks, and N-terminal domain of a-subunit.
5Y5Y	;	4.7	;	V/A-type ATPase/synthase from Thermus thermophilus, peripheral domain, rotational state 1
5Y5X	;	5.0	;	V/A-type ATPase/synthase from Thermus thermophilus, rotational state 1
5Y5Z	;	6.7	;	V/A-type ATPase/synthase from Thermus thermophilus, rotational state 2
5Y60	;	7.5	;	V/A-type ATPase/synthase from Thermus thermophilus, rotational state 3.
7TMO	;	3.3	;	V1 complex lacking subunit C from Saccharomyces cerevisiae, State 1
7TMP	;	3.3	;	V1 complex lacking subunit C from Saccharomyces cerevisiae, State 2
7TMQ	;	3.3	;	V1 complex lacking subunit C from Saccharomyces cerevisiae, State 3
8JFB	;	2.65	;	V1/S quadruple mutant Plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) complexed with compound 4 (B21588), NADPH and dUMP
8JFC	;	2.3	;	V1/S quadruple mutant Plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) complexed with compound 6 (B21591), NADPH and dUMP
8JFD	;	2.3	;	V1/S quadruple mutant Plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) complexed with compound 8 (B21594), NADPH and dUMP
4AHM	;	1.96	;	V113I - Angiogenin mutants and amyotrophic lateral sclerosis - a biochemical and biological analysis
5A6I	;	1.86	;	V122I Transthyretin structure in complex with Tolcalpone
5X8K	;	1.67	;	V158T mutant of thermus thermophilus HB8 thymidylate kinase
6CX4	;	3.081	;	V180A Mutant of Yeast PCNA
5KJ6	;	1.14	;	V197I Horse liver alcohol dehydrogenase complexed with NAD+ and pentafluorobenzyl alcohol
7VAR	;	2.9	;	V1EG domain of V/A-ATPase from Thermus thermophilus at low ATP concentration, state1-1
7VAS	;	3.0	;	V1EG domain of V/A-ATPase from Thermus thermophilus at low ATP concentration, state1-2
7VAW	;	2.7	;	V1EG domain of V/A-ATPase from Thermus thermophilus at saturated ATP-gamma-S condition, state1-1
7VAY	;	3.3	;	V1EG domain of V/A-ATPase from Thermus thermophilus at saturated ATP-gamma-S condition, state2
7VB0	;	3.6	;	V1EG domain of V/A-ATPase from Thermus thermophilus at saturated ATP-gamma-S condition, state3
7VAT	;	3.2	;	V1EG of V/A-ATPase from Thermus thermophilus at low ATP concentration, state2-1
7VAU	;	3.3	;	V1EG of V/A-ATPase from Thermus thermophilus at low ATP concentration, state2-2
7VAV	;	2.8	;	V1EG of V/A-ATPase from Thermus thermophilus at low ATP concentration, state3
7VAX	;	2.9	;	V1EG of V/A-ATPase from Thermus thermophilus at saturated ATP-gamma-S condition, state1-2
7VAL	;	3.1	;	V1EG of V/A-ATPase from Thermus thermophilus, high ATP, state1-1
7VAM	;	3.2	;	V1EG of V/A-ATPase from Thermus thermophilus, high ATP, state1-2
7VAN	;	3.0	;	V1EG of V/A-ATPase from Thermus thermophilus, high ATP, state2-1
7VAO	;	3.4	;	V1EG of V/A-ATPase from Thermus thermophilus, high ATP, state2-2
7VAP	;	3.0	;	V1EG of V/A-ATPase from Thermus thermophilus, high ATP, state2-2
7VAQ	;	3.6	;	V1EG of V/A-ATPase from Thermus thermophilus, high ATP, state3-2
7VAI	;	3.1	;	V1EG of V/A-ATPase from Thermus thermophilus, state1-1
4NFS	;	1.1	;	V203A horse liver alcohol dehydrogenase E complexed with NAD and 2,2,2-trifluoroethanol
4NG5	;	1.1	;	V203A horse liver alcohol dehydrogenase E complexed with NAD+ and 2,3,4,5,6-pentafluorobenzyl alcohol
4NFH	;	1.2	;	V207A Horse Liver Alcohol Dehydrogenase E complexed with NAD and 2,3,4,5,6-pentafluorobenzyl alcohol
5KJC	;	1.2	;	V222I horse liver alcohol dehydrogenase complexed with NAD+ and pentafluorobenzyl alcohol
5KJF	;	1.2	;	V222I horse liver alcohol dehydrogenase complexed with NAD+ and trifluoroethanol
2JJR	;	2.3	;	V232K, N236D-trichosanthin
6MG3	;	2.05	;	V285A Mutant of the C-terminal bZIP domain of human C/EBPbeta with 16bp Methylated Oligonucleotide Containing Consensus Recognition Sequence
8U8Q	;	2.7	;	V290N/S292F Streptomyces coelicolor Laccase
6CSD	;	2.391	;	V308E mutant of cytochrome P450 2D6 complexed with prinomastat
6CSB	;	2.394	;	V308E mutant of cytochrome P450 2D6 complexed with thioridazine
6TXW	;	1.153	;	V30G Transthyretin structure in complex with Tolcalpone
3KGS	;	1.8	;	V30M mutant human transthyretin (TTR) (apoV30M) pH 7.5
3NES	;	1.75	;	V30M mutant human transthyretin (TTR) complexed with GC-1 (V30M:GC-1)
3NEX	;	1.7	;	V30M mutant human transthyretin (TTR) complexed with GC-24 (V30M:GC-24)
3KGT	;	1.95	;	V30M mutant human transthyretin (TTR) complexed with genistein (V30M:GEN) pH 7.5
4LUU	;	1.95	;	V329A Epi-isozizaene synthase: Complex with Mg, inorganic pyrophosphate and benzyl triethyl ammonium cation
1ACD	;	2.7	;	V32D/F57H MUTANT OF MURINE ADIPOCYTE LIPID BINDING PROTEIN
3PNV	;	1.95	;	V369M mutant of Glutamyl-tRNA synthetase from Mycobacterium tuberculosis
7MNH	;	1.24	;	V59W mutant of Dehaloperoxidase A from Amphitrite ornata treated with Fluoride
5J57	;	1.7	;	V5E1-RTA complex
1M6M	;	1.8	;	V68N MET MYOGLOBIN
1MNO	;	1.95	;	V68N MYOGLOBIN OXY FORM
1M6C	;	1.9	;	V68N MYOGLOBIN WITH CO
3BQJ	;	2.7	;	VA387 polypeptide
5XDI	;		;	Vaccatide: Antifungal Glutamine-rich 8C-Hevein-like Peptide, vH1
8DTO	;	3.57	;	Vaccine elicited Antibody MU89 bound to CH848.D949.10.17_N133D_N138T.DS.SOSIP.664 HIV-1 Env trimer
8DY6	;	4.32	;	Vaccine elicited Antibody MU89+S27Y bound to CH848.D949.10.17_N133D_N138T.DS.SOSIP.664 HIV-1 Env trimer
6CDP	;	2.456	;	Vaccine-elicited HIV-1 neutralizing antibody vFP20.01 in complex with HIV-1 fusion peptide residue 512-519
8G4M	;	2.95	;	Vaccine-elicited human antibody 2C06 in complex with HIV-1 envelope trimer BG505 DS-SOSIP
8G4T	;	2.81	;	Vaccine-elicited human antibody 2C09 in complex with HIV-1 envelope trimer BG505 DS-SOSIP
6WX2	;	2.39	;	Vaccine-elicited mouse FP-targeting neutralizing antibody vFP16.02 with F60P mutation on light chain in complex with HIV fusion peptide (residue 512-519)
6WWC	;	2.563	;	Vaccine-elicited mouse FP-targeting neutralizing antibody vFP16.02 with S48K mutation in light chain in complex with HIV fusion peptide (residue 512-519)
6X78	;	2.359	;	Vaccine-elicited mouse FP-targeting neutralizing antibody vFP48.03 in complex with HIV fusion peptide (residue 512-519)
6X7W	;	1.7	;	Vaccine-elicited mouse FP-targeting neutralizing antibody vFP49.02 in complex with HIV fusion peptide (residue 512-519)
6PDR	;	1.555	;	Vaccine-elicited murine FP-targeting antibody vFP25.18 in complex with HIV fusion peptide (residue 512-519)
6P8D	;	2.102	;	Vaccine-elicited murine FP-targeting antibody vFP6.01 in complex with HIV fusion peptide (residue 512-519)
6PDS	;	1.893	;	Vaccine-elicited NHP FP-targeting antibody 0PV-a.04 in complex with HIV fusion peptide (residue 512-519)
6PDU	;	1.953	;	Vaccine-elicited NHP FP-targeting antibody 13N024-a.01 in complex with HIV fusion peptide (residue 512-519)
6PEF	;	2.004	;	Vaccine-elicited NHP FP-targeting antibody DF2F-a.01 in complex with HIV fusion peptide (residue 512-519)
6PEC	;	1.746	;	Vaccine-elicited NHP FP-targeting antibody DF2F-e.01 in complex with HIV fusion peptide (residue 512-519)
6MQS	;	2.997	;	Vaccine-elicited NHP FP-targeting HIV neutralizing antibody A12V163-a.01 in complex with HIV fusion peptide (residue 512-519)
6MQE	;	2.459	;	Vaccine-elicited NHP FP-targeting HIV neutralizing antibody DFPH-a.15 in complex with HIV fusion peptide (residue 512-519)
6MQR	;	2.45	;	Vaccine-elicited NHP FP-targeting neutralizing antibody 0PV-a.01 in complex with FP (residue 512-519)
6N16	;	2.302	;	Vaccine-elicited NHP FP-targeting neutralizing antibody 0PV-b.01 in complex with HIV fusion peptide (residue 512-519)
6MQC	;	1.99	;	Vaccine-elicited NHP FP-targeting neutralizing antibody 0PV-c.01 in complex with FP (residue 512-519)
6P60	;	2.498	;	Vaccine-elicited NHP FP-targeting neutralizing antibody A12V163-a.02 in complex with HIV fusion peptide (residue 512-519)
6MQM	;	3.484	;	Vaccine-elicited NHP FP-targeting neutralizing antibody DF1W-a.01 in complex with HIV fusion peptide (residue 512-519)
6P7H	;	1.782	;	Vaccine-elicited NHP FP-targeting neutralizing antibody DF2F-b.04 in complex with HIV fusion peptide (residue 512-519)
8AG3	;	3.47	;	Vaccinia C16 N-terminal domains
8AG4	;	2.46	;	Vaccinia C16 protein bound to Ku70/Ku80
8AG5	;	3.47	;	Vaccinia C16 protein bound to Ku70/Ku80
4E9O	;	1.42	;	Vaccinia D8L ectodomain structure
8INI	;	1.75	;	vaccinia H2 protein without the transmembrane region
4U6H	;	3.1	;	Vaccinia L1/M12B9-Fab complex
1B42	;	2.2	;	VACCINIA METHYLTRANSFERASE VP39 COMPLEXED WITH M1ADE AND S-ADENOSYLHOMOCYSTEINE
1BKY	;	2.0	;	VACCINIA METHYLTRANSFERASE VP39 COMPLEXED WITH M1CYT AND S-ADENOSYLHOMOCYSTEINE
3MAG	;	1.8	;	VACCINIA METHYLTRANSFERASE VP39 COMPLEXED WITH M3ADE AND S-ADENOSYLHOMOCYSTEINE
3MCT	;	2.0	;	VACCINIA METHYLTRANSFERASE VP39 COMPLEXED WITH M3CYT AND S-ADENOSYLHOMOCYSTEINE
1AV6	;	2.8	;	VACCINIA METHYLTRANSFERASE VP39 COMPLEXED WITH M7G CAPPED RNA HEXAMER AND S-ADENOSYLHOMOCYSTEINE
1EAM	;	2.0	;	VACCINIA METHYLTRANSFERASE VP39 MUTANT (EC: 2.7.7.19)
4DCG	;	1.8	;	VACCINIA METHYLTRANSFERASE VP39 MUTANT D182A COMPLEXED WITH M7G AND S-ADENOSYLHOMOCYSTEINE
1EQA	;	2.2	;	VACCINIA METHYLTRANSFERASE VP39 MUTANT E233Q COMPLEXED WITH M7G AND S-ADENOSYLHOMOCYSTEINE
2VTY	;	2.1	;	Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain swapped dimer
4CKB	;	2.8	;	Vaccinia virus capping enzyme complexed with GTP and SAH
4CKC	;	2.9	;	Vaccinia virus capping enzyme complexed with SAH (monoclinic form)
4CKE	;	2.9	;	Vaccinia virus capping enzyme complexed with SAH in P1 form
5JKT	;	2.49	;	vaccinia virus D4 P173G mutant /A20(1-50)
5JKS	;	2.79	;	vaccinia virus D4 R167A mutant /A20(1-50)
4YIG	;	2.7	;	vaccinia virus D4/A20(1-50) in complex with dsDNA containing an abasic site and free uracyl
5JKR	;	2.6	;	vaccinia virus D4/A20(1-50)w43a mutant
4ETQ	;	2.1	;	Vaccinia virus D8L IMV envelope protein in complex with Fab of murine IgG2a LA5
8APM	;	6.6	;	Vaccinia virus DNA helicase D5 residues 323-785 hexamer with bound DNA processed in C1
8APL	;	4.1	;	Vaccinia virus DNA helicase D5 residues 323-785 hexamer with bound DNA processed in C6
7PHY	;	2.3	;	Vaccinia virus E2
4D2L	;	2.903	;	Vaccinia Virus F1L bound to Bak BH3
4D2M	;	2.1	;	Vaccinia Virus F1L bound to Bim BH3
4YGM	;	1.85	;	Vaccinia virus his-D4/A20(1-50) in complex with uracil
8WT5	;		;	Vaccinia Virus J5 ectodomain
8P4K	;	3.8	;	Vaccinia Virus palisade layer A10 trimer
7NUF	;	2.0004	;	Vaccinia virus protein 018 in complex with STAT1
1VP3	;	1.9	;	VACCINIA VIRUS PROTEIN VP39 IN COMPLEX WITH S-ADENOSYLHOMOCYSTEINE
1VTP	;		;	VACUOLAR TARGETING PEPTIDE FROM NA-PROPI
8ADN	;	2.77	;	Vairimorpha necatrix 20S proteasome from spores
4P53	;	2.1	;	ValA (2-epi-5-epi-valiolone synthase) from Streptomyces hygroscopicus subsp. jinggangensis 5008 with NAD+ and Zn2+ bound
3J40	;	4.5	;	Validated Near-Atomic Resolution Structure of Bacteriophage Epsilon15 Derived from Cryo-EM and Modeling
2JW2	;		;	Validation of inter-helical orientation of the steril-alpha-motif of human deleted in liver cancer 2 by residual dipolar couplings
6W46	;	1.25	;	Valine-Containing Collagen Peptide
3T5T	;	1.7	;	Vall from streptomyces hygroscopicus in apo form
3T7D	;	1.7	;	Vall from streptomyces hygroscopicus in complex with trehalose
8SHI	;	2.90002	;	Valpha3S1 Vbeta13S1 HLA C 0602 VRSRRCLRL
1HS7	;		;	VAM3P N-TERMINAL DOMAIN SOLUTION STRUCTURE
2VX8	;	2.2	;	Vamp7 longin domain Hrb peptide complex
1YP6	;	1.8	;	Van der Waals Interactions Dominate Hydrophobic Association in a Protein Binding Site Occluded From Solvent Water
1YP7	;	2.0	;	Van der Waals Interactions Dominate Hydrophobic Association in a Protein Binding Site Occluded From Solvent Water
2P7E	;	2.05	;	Vanadate at the Active Site of a Small Ribozyme Suggests a Role for Water in Transition-State Stabilization
7QWI	;	2.15	;	Vanadate complex of the vanadium-dependent bromoperoxidase from Corallina pilulifera
6MHZ	;	4.1	;	Vanadate trapped Cryo-EM Structure of E.coli LptB2FG Transporter
7L0H	;	2.1	;	Vanadate-bound PTP1B T177G
7L0M	;	2.0	;	Vanadate-bound YopH G352T
8PMJ	;	2.81	;	Vanadate-trapped BSEP in nanodiscs
1QHB	;	2.3	;	VANADIUM BROMOPEROXIDASE FROM RED ALGA CORALLINA OFFICINALIS
7AIZ	;	1.05	;	Vanadium nitrogenase VFe protein, high CO state
4C3W	;	1.28	;	Vanadium(IV)-Picolinate Complexed with Lysozyme
7QYY	;	1.999	;	Vanadium-dependent bromoperoxidase from Corallina pilulifera in complex with chloride
6DYL	;	1.691	;	Vanadyl-bound structure of the engineered cyt b562 variant, CH3Y*
6DYH	;	1.83	;	Vanadyl-bound structure of the engineered cyt cb562 variant, CH3Y
1AA5	;	0.89	;	VANCOMYCIN
8G82	;	1.2	;	Vancomycin bound to D-Ala-D-Ser
2DLN	;	2.3	;	VANCOMYCIN RESISTANCE: STRUCTURE OF D-ALANINE:D-ALANINE LIGASE AT 2.3 ANGSTROMS RESOLUTION
5X1K	;	2.15	;	Vanillate/3-O-methylgallate O-demethylase, LigM, 3-O-methylgallate complex form
5X1M	;	1.9	;	Vanillate/3-O-methylgallate O-demethylase, LigM, protocatechuate-tetrahydrofolate complex form
5X1N	;	2.0	;	Vanillate/3-O-methylgallate O-demethylase, LigM, protocatechuate-tetrahydrofolate complex form
5X1I	;	1.9	;	Vanillate/3-O-methylgallate O-demethylase, LigM, substrate free form
5X1L	;	1.9	;	Vanillate/3-O-methylgallate O-demethylase, LigM, tetrahydrofolate complex form
5X1J	;	1.9	;	Vanillate/3-O-methylgallate O-demethylase, LigM, vanillate complex form
7SLX	;	2.35	;	Vanin-1 complexed with Compound 11
7SLY	;	2.17	;	Vanin-1 complexed with Compound 27
7SLV	;	2.13	;	Vanin-1 complexed with Compound 3
6LG2	;	1.6	;	VanR bound to Vanillate
8DX0	;	1.45	;	VanSC CA domain
6A6A	;	2.26	;	VanYB in complex with D-Alanine
5ZHW	;	2.18	;	VanYB in complex with D-Alanine-D-Alanine
5X3T	;	2.65	;	VapBC from Mycobacterium tuberculosis
8BRI	;	3.9	;	VaPomAB MSP1D1 nanodisc
7Z12	;	3.0	;	VAR2 complex with PAM1.4
7FAS	;	3.6	;	VAR2CSA 3D7 ectodomain core region
7Z1H	;	3.12	;	VAR2CSA APO
7B52	;	3.8	;	VAR2CSA full ectodomain
7B54	;	3.1	;	VAR2CSA full ectodomain in present of plCS, DBL1-DBL4
8BBY	;	2.9	;	VarB H/L (SLPL/SLPH) complex from C. difficile SlpA (R20291 strain)
5AIN	;	2.3	;	Varenicline Interactions at the 5HT3 Receptor Ligand Binding Site are Revealed by 5HTBP
109D	;	2.0	;	VARIABILITY IN DNA MINOR GROOVE WIDTH RECOGNISED BY LIGAND BINDING: THE CRYSTAL STRUCTURE OF A BIS-BENZIMIDAZOLE COMPOUND BOUND TO THE DNA DUPLEX D(CGCGAATTCGCG)2
1TVD	;	1.9	;	VARIABLE DOMAIN OF T CELL RECEPTOR DELTA CHAIN
3IY4	;	11.7	;	Variable domains of the computer generated model (WAM) of Fab 15 fitted into the cryoEM reconstruction of the virus-Fab 15 complex
3IY2	;	18.0	;	Variable domains of the computer generated model (WAM) of Fab 6 fitted into the cryoEM reconstruction of the virus-Fab 6 complex
3IY3	;	11.1	;	Variable domains of the computer generated model (WAM) of Fab 8 fitted into the cryoEM reconstruction of the virus-Fab 8 complex
3IY6	;	12.0	;	Variable domains of the computer generated model (WAM) of Fab E fitted into the cryoEM reconstruction of the virus-Fab E complex
3IY7	;	14.0	;	Variable domains of the computer generated model (WAM) of Fab F fitted into the cryoEM reconstruction of the virus-Fab F complex
3IY5	;	18.0	;	Variable domains of the mouse Fab (1AIF) fitted into the cryoEM reconstruction of the virus-Fab 16 complex
3IY1	;	18.0	;	Variable domains of the WAM of Fab B fitted into the cryoEM reconstruction of the virus-Fab B complex
3IY0	;	12.5	;	Variable domains of the x-ray structure of Fab 14 fitted into the cryoEM reconstruction of the virus-Fab 14 complex
6GHG	;	1.88	;	Variable heavy - variable light domain and Fab-arm CrossMabs with charged residue exchanges
4BLF	;	20.0	;	Variable internal flexibility characterizes the helical capsid formed by Agrobacterium VirE2 protein on single-stranded DNA.
1F6L	;	2.8	;	VARIABLE LIGHT CHAIN DIMER OF ANTI-FERRITIN ANTIBODY
3TWI	;	2.55	;	Variable Lymphocyte Receptor Recognition of the Immunodominant Glycoprotein of Bacillus anthracis Spores
1YJG	;	2.22	;	Variable Small Protein 1 of Borrelia turicatae (VspA or Vsp1)
2GA0	;	2.7	;	Variable Small Protein 1 of Borrelia turicatae (VspA or Vsp1)
2PXD	;	2.0	;	Variant 1 of Ribonucleoprotein Core of the E. Coli Signal Recognition Particle
2PXP	;	2.5	;	Variant 13 of Ribonucleoprotein Core of the E. Coli Signal Recognition Particle
2PXQ	;	2.5	;	Variant 14 of Ribonucleoprotein Core of the E. Coli Signal Recognition Particle
2PXT	;	2.5	;	Variant 15 of Ribonucleoprotein Core of the E. Coli Signal Recognition Particle
2PXU	;	2.5	;	Variant 16 of Ribonucleoprotein Core of the E. Coli Signal Recognition Particle
2PXB	;	2.5	;	Variant 2 of Ribonucleoprotein Core of the E. Coli Signal Recognition Particle
2PXE	;	2.0	;	Variant 4 of Ribonucleoprotein Core of the E. Coli Signal Recognition Particle
2PXF	;	2.0	;	Variant 5 of Ribonucleoprotein Core of the E. Coli Signal Recognition Particle
2PXV	;	2.0	;	Variant 6 of Ribonucleoprotein Core of the E. Coli Signal Recognition Particle
2PXK	;	2.5	;	Variant 8 of Ribonucleoprotein Core of the E. Coli Signal Recognition Particle
2PXL	;	2.5	;	Variant 9 of Ribonucleoprotein Core of the E. Coli Signal Recognition Particle
6E6U	;	1.55	;	Variant C89S of Dieckmann cyclase, NcmC
7Q1H	;	1.31	;	Variant D312N of Orotidine 5'-monophosphate decarboxylase-domain of human UMPS in complex with the substrate OMP at 1.31 Angstrom resolution
6HLM	;	1.8	;	Variant G129D of NuoEF from Aquifex aeolicus bound to NAD+
6HLJ	;	2.1	;	Variant G129S of NuoEF from Aquifex aeolicus - oxidized from
7P56	;	1.735	;	Variant Surface Glycoprotein 2 (VSG2, MiTat1.2, VSG221) Bound to Calcium
7P5D	;	1.42	;	Variant Surface Glycoprotein 3 (VSG3, MiTat1.3, VSG224) mutant (serine 317 and 319 to alanine)
7P5A	;	1.95	;	Variant Surface Glycoprotein 3 (VSG3, MiTat1.3, VSG224) mutant (serine 317 to alanine), single O-linked glycosylated at Ser319
7P5B	;	1.13	;	Variant Surface Glycoprotein 3 (VSG3, MiTat1.3, VSG224) mutant (serine 319 to alanine), single O-linked glycosylated at Ser317
7P59	;	1.27	;	Variant Surface Glycoprotein 3 (VSG3, MiTat1.3, VSG224) with two O-linked post-translational modifications
8OK5	;	1.27	;	Variant Surface Glycoprotein VSG11 monomer with iodine
8OK6	;	1.75	;	Variant Surface Glycoprotein VSG11 two monomers
8OK4	;	1.23	;	Variant Surface Glycoprotein VSG11wt-Oil
8ONH	;	2.59	;	Variant Surface Glycoprotein VSG11wt-Oil
8B3E	;	1.26	;	Variant Surface Glycoprotein VSG397
8OK7	;	1.74	;	Variant Surface Glycoprotein VSG558 NTD
8OK8	;	3.22	;	Variant Surface Glycoprotein VSG615
6Z7A	;	1.21	;	Variant Surface Glycoprotein VSGsur
6Z7B	;	1.86	;	Variant Surface Glycoprotein VSGsur bound to suramin
6Z7C	;	1.64	;	Variant Surface Glycoprotein VSGsur mutant H122A
6Z7D	;	1.75	;	Variant Surface Glycoprotein VSGsur mutant H122A soaked in 0.77 mM Suramin.
6Z7E	;	1.663	;	Variant Surface Glycoprotein VSGsur mutant H122A soaked in 7.7 mM suramin
6Z79	;	1.92	;	Variant Surface Glycoprotein VSGsur, I3C (""Magic Triangle"") derivative used for phasing of the structure and subsequently as a model for molecular replacement of native, mutants, and drug soaks.
6TXD	;	2.0	;	Variant W229D/F290W-12 of the last common ancestor of Gram-negative bacteria beta-lactamase class A (GNCA4)
6TWW	;	1.38	;	Variant W229D/F290W-19 of the last common ancestor of Gram-negative bacteria beta-lactamase class A (GNCA4)
6TY6	;	1.8	;	Variant W229D/F290W-2 of the last common ancestor of Gram-negative bacteria beta-lactamase class A (GNCA4) bound to 5(6)-nitrobenzotriazole (TS-analog)
1AET	;	2.1	;	VARIATION IN THE STRENGTH OF A CH TO O HYDROGEN BOND IN AN ARTIFICIAL PROTEIN CAVITY (1-METHYLIMIDAZOLE)
1AC4	;	2.1	;	VARIATION IN THE STRENGTH OF A CH TO O HYDROGEN BOND IN AN ARTIFICIAL PROTEIN CAVITY (2,3,4-TRIMETHYL-1,3-THIAZOLE)
1AEQ	;	2.1	;	VARIATION IN THE STRENGTH OF A CH TO O HYDROGEN BOND IN AN ARTIFICIAL PROTEIN CAVITY (2-ETHYLIMIDAZOLE)
1AC8	;	2.1	;	VARIATION IN THE STRENGTH OF A CH TO O HYDROGEN BOND IN AN ARTIFICIAL PROTEIN CAVITY (3,4,5-TRIMETHYLTHIAZOLE)
1XQM	;	2.1	;	Variations on the GFP chromophore scaffold: A fragmented 5-membered heterocycle revealed in the 2.1A crystal structure of a non-fluorescent chromoprotein
7PAB	;	2.1	;	Varicella zoster Orf24-Orf27 nuclear egress complex
7BW6	;	3.7	;	Varicella-zoster virus capsid
5BPK	;	1.49	;	Varying binding modes of inhibitors and structural differences in the binding pockets of different gamma-glutamyltranspeptidases
7VRV	;	4.2	;	VAS5 Spike (1 RBD up)
7VRW	;	3.6	;	VAS5 Spike (3 RBD down)
1BJ1	;	2.4	;	VASCULAR ENDOTHELIAL GROWTH FACTOR IN COMPLEX WITH A NEUTRALIZING ANTIBODY
4WPB	;	3.11	;	Vascular endothelial growth factor in complex with alpha/beta-VEGF-1
1CZ8	;	2.4	;	VASCULAR ENDOTHELIAL GROWTH FACTOR IN COMPLEX WITH AN AFFINITY MATURED ANTIBODY
1QTY	;	2.7	;	VASCULAR ENDOTHELIAL GROWTH FACTOR IN COMPLEX WITH DOMAIN 2 OF THE FLT-1 RECEPTOR
2VPF	;	1.93	;	VASCULAR ENDOTHELIAL GROWTH FACTOR REFINED TO 1.93 ANGSTROMS RESOLUTION
8JBN	;	1.99	;	Vascular endothelial protein tyrosine phosphatase in complex with Cpd-1
8JBY	;	1.99	;	Vascular endothelial protein tyrosine phosphatase in complex with Cpd-2
7MIT	;	3.4	;	Vascular KATP channel: Kir6.1 SUR2B propeller-like conformation 1
7MJP	;	4.2	;	Vascular KATP channel: Kir6.1 SUR2B propeller-like conformation 2
7MJO	;	4.0	;	Vascular KATP channel: Kir6.1 SUR2B quatrefoil-like conformation 1
7MJQ	;	4.2	;	Vascular KATP channel: Kir6.1 SUR2B quatrefoil-like conformation 2
7PKZ	;	9.8	;	Vault structure in committed conformation
7PKR	;	3.8	;	Vault structure in primmed conformation
6NF1	;	2.6	;	Vav1 inhibited by an allosteric inhibitor: Vav1 inhibitors block GEF activity
6NFA	;	2.7	;	Vav1 inhibited by an allosteric inhibitor: Vav1 inhibitors block GEF activity
5EB3	;	2.4	;	VB6-bound protein
3SHG	;	1.5	;	VBHT Fic protein from BARTONELLA SCHOENBUCHENSIS in complex with VBHA antitoxin
3ZC7	;	2.1	;	VbhT Fic protein from Bartonella schoenbuchensis in complex with VbhA antitoxin and ATP
3ZCB	;	1.94	;	VbhT Fic protein from Bartonella schoenbuchensis in complex with VbhA antitoxin mutant E24G and ATP
8BSA	;	1.9	;	Vc1313-LBD bound to D-arginine
8BSB	;	1.9	;	Vc1313-LBD bound to D-lysine
4JIV	;	1.903	;	VCA0105 PAAR-repeat protein from Vibrio cholerae in complex with a VgrG-like beta-helix that is based on a fragment of T4 gp5
1VSC	;	1.9	;	VCAM-1
6YJB	;	1.55	;	VcaM4I restriction endonuclease 5hmC-ssDNA complex
6YMG	;	3.14	;	VcaM4I restriction endonuclease in complex with 5mC-modified dsDNA
6YEX	;	1.5	;	VcaM4I restriction endonuclease in the absence of DNA
6YKF	;	1.48	;	VcaM4I restriction endonuclease in the presence of 5mC-modified ssDNA
8BDO	;	2.8	;	VCB in complex with compound 21
8BDN	;	2.76	;	VCB in complex with compound 23
8BDM	;	2.021	;	VCB in complex with compound 26
8BDL	;	2.295	;	VCB in complex with compound 27
8BDJ	;	2.02	;	VCB in complex with compound 30
8BDI	;	2.108	;	VCB in complex with compound 32
2XFD	;	1.19	;	vCBM60 in complex with cellobiose
2XFE	;	1.82	;	vCBM60 in complex with galactobiose
7UFI	;	3.4	;	VchTnsC AAA+ ATPase with DNA, single heptamer
7UFM	;	3.9	;	VchTnsC AAA+ with DNA (double heptamer)
7V5H	;	1.7	;	VcOrn native structure with N terminal tag
5VC7	;	3.9	;	VCP like ATPase from T. acidophilum (VAT) - conformation 1
5VCA	;	4.8	;	VCP like ATPase from T. acidophilum (VAT)-Substrate bound conformation
5KIU	;	2.2	;	VCP-interacting membrane protein (VIMP)
4K1C	;	2.3	;	VCX1 Calcium/Proton Exchanger
7TCV	;	2.604	;	VDAC K12E mutant
5OW7	;	2.1	;	VDR complex
7OXU	;	2.39	;	VDR complex - calcitroic acid
7OY4	;	2.0	;	VDR complex of a side-chain hydroxylated derivatives of lithocholic acid
7OXZ	;	2.2	;	VDR complex with a side-chain hydroxylated derivative of lithocholic acid
7ZFG	;	2.62	;	VDR complex with aromatic D-ring analog
7ZFX	;	2.6	;	VDR complex with Aromatic-D-Ring Analog
7BNS	;	2.7	;	VDR complex with BXL-62
7BNU	;	2.4	;	VDR complex with BXL-62
7BO6	;	2.86	;	VDR complex with LCA derivative
8CK5	;	2.1	;	VDR LBD complex with 25-nitro derivative of 1,25D3
3VRT	;	2.4	;	VDR ligand binding domain in complex with 2-Mehylidene-19,25,26,27-tetranor-1alpha,24-dihydroxyvitaminD3
3VRU	;	2.0	;	VDR ligand binding domain in complex with 2-Methylidene-19,24-dinor-1alpha,25-dihydroxy vitaminD3
3VRV	;	1.9	;	VDR ligand binding domain in complex with 2-Methylidene-26,27-dimethyl-19,24-dinor-1alpha,25-dihydroxyvitamin D3
3VRW	;	2.4	;	VDR ligand binding domain in complex with 22S-Butyl-2-methylidene-26,27-dimethyl-19,24-dinor-1alpha,25-dihydroxyvitamin D3
6T2M	;	3.0	;	VDR-ZK168281 complex
2OMQ	;	2.0	;	VEALYL peptide derived from human insulin chain B, residues 12-17
6SMS	;	1.47	;	Vegetative Insecticidal Protein 1 (Vip1Ac1) from Bacillus thuringiensis
1FLT	;	1.7	;	VEGF IN COMPLEX WITH DOMAIN 2 OF THE FLT-1 RECEPTOR
6ZCD	;	1.8	;	VEGF-A 13:107 crystallized with 1C bicyclic peptide
6Z3F	;	2.1	;	VEGF-A 13:107 crystallized with 2C bicyclic peptide
6Z13	;	1.8	;	VEGF-A 13:107 crystallized with 3C bicyclic peptide
6ZBR	;	1.6	;	VEGF-A 13:107 crystallized with 4C bicyclic peptide
3V2A	;	3.204	;	VEGFR-2/VEGF-A COMPLEX STRUCTURE
3V6B	;	3.205	;	VEGFR-2/VEGF-E complex structure
1YWN	;	1.71	;	Vegfr2 in complex with a novel 4-amino-furo[2,3-d]pyrimidine
2WKL	;	2.7	;	Velaglucerase alfa
7ZQA	;	3.6	;	VelcroVax tandem HBcAg with SUMO-Affimer inserted at MIR (T=3* VLP)
7ZQ8	;	2.9	;	VelcroVax tandem HBcAg with SUMO-Affimer inserted at MIR (T=4 VLP)
5EZQ	;	1.66	;	Venezuelan Equine Encephalitis Virus (VEEV) Nonstructural protein 2 (nsP2) Cysteine Protease
5EZS	;	2.16	;	Venezuelan Equine Encephalitis Virus (VEEV) Nonstructural Protein 2 (nsP2) Cysteine Protease Inhibited by E64d
8T8N	;	2.32	;	Venezuelan Equine Encephalitis Virus (VEEV) Nonstructural Protein 2 (nsP2) Cysteine Protease Inhibited with CA074
8EEV	;	3.6	;	Venezuelan equine encephalitis virus-like particle in complex with Fab SKT-20
8EEU	;	3.5	;	Venezuelan equine encephalitis virus-like particle in complex with Fab SKT05
6SM0	;	1.91	;	Venus 66 p-Azido-L-Phenylalanin (azF) variant, dark grown
4V25	;	2.6	;	VER-246608, a novel pan-isoform ATP competitive inhibitor of pyruvate dehydrogenase kinase, disrupts Warburg metabolism and induces context- dependent cytostasis in cancer cells
4V26	;	2.49	;	VER-246608, a novel pan-isoform ATP competitive inhibitor of pyruvate dehydrogenase kinase, disrupts Warburg metabolism and induces context- dependent cytostasis in cancer cells
1B7L	;	1.8	;	VERIFICATION OF SPMP USING MUTANT HUMAN LYSOZYMES
1B7M	;	2.2	;	VERIFICATION OF SPMP USING MUTANT HUMAN LYSOZYMES
1B7N	;	1.8	;	VERIFICATION OF SPMP USING MUTANT HUMAN LYSOZYMES
1B7O	;	1.8	;	VERIFICATION OF SPMP USING MUTANT HUMAN LYSOZYMES
1B7P	;	2.0	;	VERIFICATION OF SPMP USING MUTANT HUMAN LYSOZYMES
1B7Q	;	2.0	;	VERIFICATION OF SPMP USING MUTANT HUMAN LYSOZYMES
1B7R	;	1.8	;	VERIFICATION OF SPMP USING MUTANT HUMAN LYSOZYMES
1B7S	;	2.0	;	VERIFICATION OF SPMP USING MUTANT HUMAN LYSOZYMES
7PXG	;	2.73	;	Verruculogen-bound Drosophila Slo channel
7CC3	;	1.72	;	Versatile cis-prenyltransferase MM_0014 from Methanosarcina mazei (crystal type: co-FG)
7CAV	;	1.91	;	Versatile cis-prenyltransferase MM_0014 from Methanosarcina mazei (crystal type: co-FG+DMAPP)
7CAR	;	1.98	;	Versatile cis-prenyltransferase MM_0014 from Methanosarcina mazei (crystal type: free+IPP)
7CAS	;	2.28	;	Versatile cis-prenyltransferase MM_0014 from Methanosarcina mazei (crystal type: free+PPi)
7CAQ	;	1.69	;	Versatile cis-prenyltransferase MM_0014 from Methanosarcina mazei (crystal type: substrate-free)
1YFN	;	1.8	;	Versatile modes of peptide recognition by the AAA+ adaptor protein SspB- the crystal structure of a SspB-RseA complex
5XMZ	;	1.85	;	Verticillium effector PevD1
5AOT	;	1.02	;	Very high resolution structure of a novel carbohydrate binding module from Ruminococcus flavefaciens FD-1 endoglucanase Cel5A
1VSR	;	1.8	;	VERY SHORT PATCH REPAIR (VSR) ENDONUCLEASE FROM ESCHERICHIA COLI
1ODG	;	2.8	;	Very-short-patch DNA repair endonuclease bound to its reaction product site
1QNX	;	1.9	;	Ves v 5, an allergen from Vespula vulgaris venom
5UK4	;	3.204	;	VESICULAR STOMATITS VIRUS N PROTEIN IN COMPLEX WITH INHIBITORY NANOBODY 1307
4OWR	;	3.15	;	Vesiculoviral matrix (M) protein occupies nucleic acid binding site at nucleoporin pair Rae1-Nup98
6FI2	;	1.22	;	VexL: A periplasmic depolymerase provides new insight into ABC transporter-dependent secretion of bacterial capsular polysaccharides
7T5O	;	3.39	;	VFLIP Spike Trimer with GAR03
8GAS	;	4.04	;	vFP48.02 Fab in complex with BG505 DS-SOSIP Env trimer
8G85	;	3.99	;	vFP52.02 Fab in complex with BG505 DS-SOSIP Env trimer
5Z5W	;		;	VFR12 in complex with LPS micelles
5WRX	;		;	VG13P structure in LPS
2N9M	;		;	VG16KRKP solution structure in C.neoformans live cells (conformation 2)
7NHL	;	3.1	;	VgaA-LC, an antibiotic resistance ABCF, in complex with 70S ribosome from Staphylococcus aureus
7NHN	;	2.9	;	VgaL, an antibiotic resistance ABCF, in complex with 70S ribosome from Listeria monocytogenes
5Z2Q	;	2.74	;	Vgll1-TEAD4 core complex
5VOS	;	1.42	;	VGSNKGAIIGL from Amyloid Beta determined by MicroED
1VHP	;		;	VH-P8, NMR
5WKZ	;	1.85	;	VH1-69 germline antibody predicted from CR6261
5WL2	;	2.0	;	VH1-69 germline antibody with CDR H3 sequence of CR9114
7TJC	;	1.35	;	VHH Chl-B2 in complex with Chloramphenicol
6U12	;	1.56	;	VHH R303 C33A/C102A in complex withthe LRR domain of InlB
6U14	;	1.3	;	VHH R303 C33A/C102A in complex withthe LRR domain of InlB
7QCQ	;	1.7	;	VHH Z70 in interaction with PHF6 Tau peptide
8OPI	;	1.83	;	VHH Z70 mutant 1 in interaction with PHF6 Tau peptide
8OP0	;	1.54	;	VHH Z70 mutant 20 in interaction with PHF6 Tau peptide
8PII	;	2.35	;	VHH Z70 mutant 3 in interaction with PHF6 Tau peptide
4POU	;	1.75	;	VHH-metal in Complex with RNase A
7CJB	;	2.8	;	VHL recognizes hydroxyproline in RIPK1
8QJS	;	3.191	;	VHL/Elongin B/Elongin C complex with compound 155
3G2W	;	2.4	;	VHS Domain of human GGA1 complexed with a DXXLL hinge peptide
1UJJ	;	2.6	;	VHS domain of human GGA1 complexed with C-terminal peptide from BACE
1UJK	;	1.9	;	VHS domain of human GGA1 complexed with C-terminal phosphopeptide from BACE
1JWG	;	2.0	;	VHS Domain of human GGA1 complexed with cation-independent M6PR C-terminal Peptide
3G2S	;	1.7	;	VHS Domain of human GGA1 complexed with SorLA C-terminal Peptide
3G2T	;	2.0	;	VHS Domain of human GGA1 complexed with SorLA C-terminal Phosphopeptide
3G2U	;	2.301	;	VHS Domain of human GGA1 complexed with Sotilin C-terminal Peptide
3G2V	;	2.1	;	VHS Domain of human GGA1 complexed with Sotilin C-terminal Phosphopeptide
1ELK	;	1.5	;	VHS domain of TOM1 protein from H. sapiens
1MT7	;	1.9	;	Viability of a drug-resistant HIV-1 protease mutant: structural insights for better antiviral therapy
1MT8	;	2.15	;	Viability of a drug-resistant HIV-1 protease mutant: structural insights for better antiviral therapy
1MT9	;	2.0	;	Viability of a drug-resistant HIV-1 protease mutant: structural insights for better antiviral therapy
1MTB	;	2.5	;	Viability of a drug-resistant HIV-1 protease mutant: structural insights for better antiviral therapy
1N49	;	2.2	;	Viability of a Drug-Resistant HIV-1 Protease Variant: Structural Insights for Better Anti-Viral Therapy
7NPD	;	2.6	;	Vibiro cholerae ParA2
7DAG	;	4.37	;	Vibrio cholera aldehyde-alcohol dehrogenase
7R5A	;	2.95	;	Vibrio cholera ParD2:ParE2 antitoxin:toxin complex
2XWX	;	1.8	;	Vibrio cholerae colonization factor GbpA crystal structure
4GX7	;	2.85	;	Vibrio Cholerae Cytolysin Beta-Prism Domain With Methyl-Alpha-Mannose Bound
3GSM	;	2.4	;	Vibrio cholerae family 3 glycoside hydrolase (NagZ) bound to N-Valeryl-PUGNAc
2OXN	;	1.7	;	Vibrio cholerae family 3 glycoside hydrolase (NagZ) in complex with PUGNAc
8CC3	;	1.128	;	Vibrio cholerae GbpA (LPMO domain)
8CC5	;	1.62	;	Vibrio cholerae GbpA (LPMO domain)
2PBX	;	2.2	;	Vibrio cholerae HapR
6PWJ	;	2.7	;	Vibrio cholerae LapD S helix-GGDEF-EAL (apo)
6PWK	;	2.61	;	Vibrio cholerae LapD S helix-GGDEF-EAL (bound to c-di-GMP)
6KSG	;	1.9	;	Vibrio cholerae Methionine Aminopeptidase in holo form
1KIT	;	2.3	;	VIBRIO CHOLERAE NEURAMINIDASE
6EKS	;	1.87	;	Vibrio cholerae neuraminidase complexed with oseltamivir carboxylate
6EKU	;	1.75	;	Vibrio cholerae neuraminidase complexed with zanamivir
4XCK	;	2.37	;	Vibrio cholerae O395 Ribokinase complexed with ADP, Ribose and Cesium ion.
4XDA	;	1.75	;	Vibrio cholerae O395 Ribokinase complexed with Ribose, ADP and Sodium ion.
4X8F	;	3.4	;	Vibrio cholerae O395 Ribokinase in apo form
6N6C	;	1.619	;	Vibrio cholerae Oligoribonuclease bound to pAA
6N6D	;	1.534	;	Vibrio cholerae Oligoribonuclease bound to pAG
6N6G	;	2.018	;	Vibrio cholerae Oligoribonuclease bound to pCG
6N6H	;	1.757	;	Vibrio cholerae Oligoribonuclease bound to pCpU
6N6E	;	1.578	;	Vibrio cholerae Oligoribonuclease bound to pGA
6N6F	;	1.735	;	Vibrio cholerae Oligoribonuclease bound to pGC
6N6A	;	1.5	;	Vibrio cholerae Oligoribonuclease bound to pGG
7NPE	;	3.2	;	Vibrio cholerae ParA2-ADP
7NPF	;	4.5	;	Vibrio cholerae ParA2-ATPyS-DNA filament
7B22	;	3.08	;	Vibrio cholerae ParD2 Antitoxin
5G50	;	2.3	;	Vibrio cholerae scaffolding protein RbmA in complex with magnesium.
1W0O	;	1.9	;	Vibrio cholerae sialidase
1W0P	;	1.6	;	Vibrio cholerae sialidase with alpha-2,6-sialyllactose
3KLN	;	3.078	;	Vibrio cholerae VpsT
3KLO	;	2.802	;	Vibrio cholerae VpsT bound to c-di-GMP
3GS6	;	2.3	;	Vibrio Cholerea family 3 glycoside hydrolase (NagZ)in complex with N-butyryl-PUGNAc
8GM3	;	1.727	;	Vibrio harveyi Holo HphA
7Q6I	;	3.6	;	Vibrio maritimus FtsA 1-396 ATP and FtsN 1-29, bent tetramers in double filament arrangement
7Q6F	;	3.31	;	Vibrio maritimus FtsA 1-396 ATP, double filament
5KEV	;	2.7	;	Vibrio parahaemolyticus VtrA/VtrC complex
8DML	;	2.08	;	Vibrio parahaemolyticus VtrA/VtrC complex bound to the bile salt chenodeoxycholate
5KEW	;	2.103	;	Vibrio parahaemolyticus VtrA/VtrC complex bound to the bile salt taurodeoxycholate
4XNR	;	2.21	;	Vibrio Vulnificus Adenine Riboswitch Aptamer Domain, Synthesized by Position-selective Labeling of RNA (PLOR), in Complex with Adenine
4TZY	;	2.57	;	Vibrio vulnificus Adenine Riboswitch Variant, grown in both Sr2+ and Mg2+
4TZX	;	2.01	;	Vibrio Vulnificus Adenine Riboswitch variant, grown in Mg2+
6I1Y	;	3.4	;	Vibrio vulnificus EpsD
7O0I	;	8.3	;	Vibrio vulnificus stressosome
7DHD	;	1.71	;	Vibrio vulnificus Wzb
7DHE	;	2.79	;	Vibrio vulnificus Wzb in complex with benzylphosphonate
7DHF	;	1.211	;	Vibrio vulnificus Wzb in complex with benzylphosphonate
7PBK	;	2.8	;	Vibriophage phiVC8 family A DNA polymerase (DpoZ), two conformations: thumb-exo open and thumb-exo closed
7UV1	;		;	Vicilin Ana o 1.0101 leader sequence residues 20-75
7CG2	;	2.001	;	Vigna radiata Epoxide hydrolase mutant
7CG6	;	2.0	;	Vigna radiata Epoxide hydrolase mutant M263Q
6X89	;	3.9	;	Vigna radiata mitochondrial complex I*
8E73	;	3.2	;	Vigna radiata supercomplex I+III2 (full bridge)
2L3X	;		;	villin head piece domain of human ABLIM2
5I1O	;	1.348	;	Villin headpiece subdomain with a Gln26 to ACPC substitution
5I1N	;	1.3	;	Villin headpiece subdomain with a Gln26 to beta-3-homoglutamine substitution
5I1S	;	1.12	;	Villin headpiece subdomain with a Lys30 to APC substitution
5I1P	;	1.4	;	Villin headpiece subdomain with a Lys30 to beta-3-homolysine substitution
6Y6J	;	1.5	;	VIM-2 in Complex with Biapenem Imine and Enamine Hydrolysis Products
5K48	;	1.744	;	VIM-2 Metallo Beta Lactamase in complex with 3-(mercaptomethyl)-[1,1'-biphenyl]-4-carboxylic acid
5N4S	;	1.2	;	VIM-2 metallo-beta-lactamase in complex with ((S)-3-mercapto-2-methylpropanoyl)-D-tryptophan (Compound 3)
5N4T	;	1.16	;	VIM-2 metallo-beta-lactamase in complex with ((S)-3-mercapto-2-methylpropanoyl)-L-tryptophan (Compound 4)
5Y6D	;	2.1	;	VIM-2 metallo-beta-lactamase in complex with (R)-2-(4-fluorophenyl)-2-((S)-3-mercapto-2-methylpropanamido)acetic acid (compound 11)
5Y6E	;	1.8	;	VIM-2 metallo-beta-lactamase in complex with (R)-2-(4-hydroxyphenyl)-2-((S)-3-mercapto-2-methylpropanamido)acetic acid (compound 12)
5LCH	;	1.94	;	VIM-2 metallo-beta-lactamase in complex with (S)-1-allyl-2-(3-methoxyphenyl)-3-oxoisoindoline-4-carboxylic acid (compound 42)
5LE1	;	1.4	;	VIM-2 metallo-beta-lactamase in complex with 2-(2-chloro-6-fluorobenzyl)-3-oxoisoindoline-4-carboxylic acid (compound 16)
5LM6	;	1.17	;	VIM-2 metallo-beta-lactamase in complex with 2-(3-fluoro-4-hydroxyphenyl)-3-oxoisoindoline-4-carboxylic acid (compound 35)
5LCA	;	1.93	;	VIM-2 metallo-beta-lactamase in complex with 3-oxo-2-(3-(trifluoromethyl)phenyl)isoindoline-4-carboxylic acid (compound 17)
5LCF	;	1.86	;	VIM-2 metallo-beta-lactamase in complex with 3-oxo-2-phenylisoindoline-4-carboxylic acid (compound 30)
8R5U	;	1.56	;	VIM-2 metallo-beta-lactamase in complex with benzebisheterocycle compound 14
1KO2	;	2.2	;	VIM-2, a Zn-beta-lactamase from Pseudomonas aeruginosa with an oxidized Cys (cysteinesulfonic)
1KO3	;	1.91	;	VIM-2, a Zn-beta-lactamase from Pseudomonas aeruginosa with Cys221 reduced
5ACW	;	1.8	;	VIM-2-1, Discovery of novel inhibitor scaffolds against the metallo- beta-lactamase VIM-2 by SPR based fragment screening
5ACX	;	1.8	;	VIM-2-2, Discovery of novel inhibitor scaffolds against the metallo- beta-lactamase VIM-2 by SPR based fragment screening
5ACU	;	2.1	;	VIM-2-NAT, Discovery of novel inhibitor scaffolds against the metallo- beta-lactamase VIM-2 by SPR based fragment screening
5ACV	;	1.963	;	VIM-2-OX, Discovery of novel inhibitor scaffolds against the metallo- beta-lactamase VIM-2 by SPR based fragment screening
4UWS	;	1.66	;	VIM-26-PEG. Leu224 in VIM-26 from Klebsiella pneumoniae has implications for drug binding.
5NHZ	;	1.85	;	VIM-2_10b. Metallo-beta-Lactamase Inhibitors by Bioisosteric Replacement: Preparation, Activity and Binding
5NI0	;	1.673	;	VIM-2_10c. Metallo-beta-Lactamase Inhibitors by Bioisosteric Replacement: Preparation, Activity and Binding
6TM9	;	1.07	;	VIM-2_1cc-. Triazole inhibitors with promising inhibitor effects against antibiotic resistance metallo-beta-lactamases
6TMC	;	1.4	;	VIM-2_1dh-Triazole inhibitors with promising inhibitor effects against antibiotic resistance metallo-beta-lactamases
6TMB	;	1.5	;	VIM-2_1di-Triazole inhibitors with promising inhibitor effects against antibiotic resistance metallo-beta-lactamases
6TMA	;	1.5	;	VIM-2_1dj- Triazole inhibitors with promising inhibitor effects against antibiotic resistance metallo-beta-lactamases
5MM9	;	1.55	;	VIM-2_2b. Metallo-beta-Lactamase Inhibitors by Bioisosteric Replacement: Preparation, Activity and Binding
2Y8A	;	2.33	;	VIM-7 with Oxidised. Structural and computational investigations of VIM-7: Insights into the substrate specificity of VIM metallo-beta- lactamases
2Y8B	;	1.7	;	VIM-7 with Oxidised. Structural and computational investigations of VIM-7: Insights into the substrate specificity of VIM metallo-beta- lactamases
8RVE	;	7.2	;	Vimentin intermediate filament
8CLE	;	3.2	;	Vinblastine bound to tubulin (T2R-TTL) complex
1T01	;	2.06	;	Vinculin complexed with the VBS1 helix from talin
1ZVZ	;	1.8	;	Vinculin Head (0-258) in Complex with the Talin Rod Residue 820-844
1ZW3	;	3.3	;	Vinculin Head (0-258) in Complex with the Talin Rod residues 1630-1652
1ZW2	;	2.1	;	Vinculin Head (0-258) in Complex with the Talin Rod residues 2345-2369
1U6H	;	2.38	;	Vinculin head (0-258) in complex with the talin vinculin binding site 2 (849-879)
3ZDL	;	2.3	;	Vinculin head (1-258) in complex with a RIAM fragment
1XWJ	;	2.6	;	Vinculin head (1-258) in complex with the talin vinculin binding site 3 (1945-1969)
6BFI	;	2.3	;	Vinculin homolog in a sponge (phylum Porifera) reveals vertebrate-like cell adhesions involved in early multicellular evolution
7CNN	;	2.5	;	vinorelbine in complex with tubulin
3OZ3	;	1.57	;	Vinyl Carbocyclic LNA
6ALN	;	1.8	;	VioC L-arginine hydroxylase bound to Fe(II), 3S-hydroxy-L-arginine, and 2OG
6ALP	;	1.99	;	VioC L-arginine hydroxylase bound to Fe(II), 3S-hydroxy-L-arginine, and succinate
6ALM	;	1.6	;	VioC L-arginine hydroxylase bound to Fe(II), L-arginine, and 2-OXO-GLUTARIC ACID
6ALO	;	1.79	;	VioC L-arginine hydroxylase bound to Fe(II), L-arginine, and a peroxysuccinate intermediate
6ALQ	;	1.67	;	VioC L-arginine hydroxylase bound to Fe(II), L-arginine, and succinate
6ALR	;	1.55	;	VioC L-arginine hydroxylase bound to the vanadyl ion, L-arginine, and succinate
3BMZ	;	1.21	;	Violacein biosynthetic enzyme VioE
2FQA	;		;	Violacin A
6TFJ	;	2.9	;	Vip3Aa protoxin structure
6TFK	;	2.9	;	Vip3Aa toxin structure
6V1V	;	3.189	;	VIP3B (VIP3B_2160) adapted for crystallization
6YRF	;	3.9	;	Vip3Bc1 tetramer
6YRG	;	4.8	;	Vip3Bc1 tetramer in processed, activated state
7NTX	;	4.75	;	Vip3Bc1 tetramer in processed, activated state
7MJR	;	3.22	;	Vip4Da2 toxin structure
5MYU	;	4.0	;	VipA-N2/VipB contracted sheath of type VI secretion system
1AOK	;	2.0	;	VIPOXIN COMPLEX
1JLT	;	1.4	;	Vipoxin Complex
3EB8	;	2.4	;	VirA
4FMB	;	3.2	;	VirA-Rab1 complex structure
1OHR	;	2.1	;	VIRACEPT (R) (NELFINAVIR MESYLATE, AG1343): A POTENT ORALLY BIOAVAILABLE INHIBITOR OF HIV-1 PROTEASE
7TVL	;	0.89	;	Viral AMG chitosanase V-Csn, apo structure
7TVM	;	1.35	;	Viral AMG chitosanase V-Csn, apo structure, crystal form 2
7TVN	;	1.2	;	Viral AMG chitosanase V-Csn, D148N mutant
7TVO	;	1.15	;	Viral AMG chitosanase V-Csn, E157Q mutant
7TVP	;	1.3	;	Viral AMG chitosanase V-Csn, E157Q mutant, chitotriose complex
1TD0	;	1.95	;	Viral capsid protein SHP at pH 5.5
1MKF	;	2.1	;	VIRAL CHEMOKINE BINDING PROTEIN M3 FROM MURINE GAMMAHERPESVIRUS 68
2NYZ	;	2.6	;	Viral Chemokine Binding Protein M3 From Murine Gammaherpesvirus68 In Complex With The C- Chemokine XCL1
2NZ1	;	2.5	;	Viral Chemokine Binding Protein M3 From Murine Gammaherpesvirus68 In Complex With The CC-Chemokine CCL2/MCP-1
1ML0	;	2.8	;	VIRAL CHEMOKINE BINDING PROTEIN M3 FROM MURINE GAMMAHERPESVIRUS68 IN COMPLEX WITH THE P8A VARIANT OF CC-CHEMOKINE MCP-1
4ZKQ	;	1.898	;	Viral chemokine binding protein R17 encoded by rodent gammaherpesvirus Peru ( RHVP)
5ND1	;	3.7	;	Viral evolution results in multiple, surface-allocated enzymatic activities in a fungal double-stranded RNA virus
6JIM	;	2.0	;	Viral helicase protein
7E6K	;	1.6	;	Viral protease
8ADB	;	1.73	;	Viral tegument-like DUBs
8ADC	;	1.7	;	Viral tegument-like DUBs
8ADD	;	1.9	;	Viral tegument-like DUBs
6KNA	;		;	Viral Ubiquitin from Autographa californica Nucleo Polyhedrosis Virus
7AED	;	1.753	;	VirB8 domain of PrgL from Enterococcus faecalis pCF10
8AHQ	;	2.1	;	VirD/holo-ACP5b of Streptomyces virginiae complex
6TUI	;	10.47	;	Virion of empty GTA particle
7NS2	;	3.63	;	Virion of Leishmania RNA virus 1
6TBA	;	4.54	;	Virion of native gene transfer agent (GTA) particle
6VR4	;	3.5	;	Virion-packaged DNA-dependent RNA polymerase of crAss-like phage phi14:2
3VFE	;	1.88	;	Virtual Screening and X-Ray Crystallography for Human Kallikrein 6 Inhibitors with an Amidinothiophene P1 Group
7AJR	;	1.75	;	Virtual screening approach leading to the identification of a novel and tractable series of Pseudomonas aeruginosa elastase inhibitors
8DIB	;	2.17	;	Virtual screening for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors
8DIC	;	2.09	;	Virtual screening for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors
8DID	;	1.95	;	Virtual screening for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors
8DIE	;	1.9	;	Virtual screening for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors
8DIF	;	1.98	;	Virtual screening for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors
8DIG	;	2.45	;	Virtual screening for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors
8DIH	;	2.12	;	Virtual screening for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors
8DII	;	2.59	;	Virtual screening for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors
7B1Z	;	1.71	;	Virulence-associated protein VapB from the intracellular pathogen Rhodococcus equi
5AEO	;	1.8	;	Virulence-associated protein VapG from the intracellular pathogen Rhodococcus equi
8OKR	;	2.86	;	virus enhancing amyloid fibril formed by CKFKFQF
2XGK	;	4.2	;	Virus like particle of L172W mutant of Minute Virus of Mice - the immunosuppressive strain
3J7M	;	3.8	;	Virus model of brome mosaic virus (first half data set)
3J7N	;	3.8	;	Virus model of brome mosaic virus (second half data set)
8OPE	;	3.09	;	Virus-like Particle based on PVY coat protein with dC40 deletion with helical architecture encapsidating ssRNA
8OPD	;	3.5	;	Virus-like Particle based on PVY coat protein with dC40 deletion with stacked-ring architecture
8OPF	;	2.83	;	Virus-like Particle based on PVY coat protein with dC60 deletion with RNA-free helical architecture
8OPG	;	3.2	;	Virus-like Particle based on PVY coat protein with dC79 deletion with RNA-free helical architecture
8OPC	;	2.99	;	Virus-like Particle based on PVY coat protein with helical architecture encapsidating ssRNA
8OPB	;	3.58	;	Virus-like Particle based on PVY coat protein with RNA-free helical architecture
8OPA	;	3.34	;	Virus-like Particle based on PVY coat protein with stacked-ring architecture
8OPL	;	2.41	;	Virus-like Particle based on PVY coat protein with T43C and D136C mutation with helical architecture encapsidating ssRNA
6YF7	;	3.4	;	Virus-like particle of bacteriophage AC
6YF9	;	3.196	;	Virus-like particle of bacteriophage AVE002
6YFA	;	3.3	;	Virus-like particle of bacteriophage AVE015
6YFB	;	3.59	;	Virus-like particle of bacteriophage AVE016
6YFC	;	3.246	;	Virus-like particle of bacteriophage AVE019
6YFH	;	3.893	;	Virus-like particle of bacteriophage EMS014
6YFJ	;	3.233	;	Virus-like particle of bacteriophage ESE001
6YFK	;	3.7	;	Virus-like particle of bacteriophage ESE007
6YFL	;	3.3	;	Virus-like particle of bacteriophage ESE020
6YFM	;	2.762	;	Virus-like particle of bacteriophage ESE021
6YFN	;	3.189	;	Virus-like particle of bacteriophage ESE058
6YFP	;	3.1	;	Virus-like particle of bacteriophage GQ-112
6YFO	;	3.484	;	Virus-like particle of bacteriophage GQ-907
6YFQ	;	3.8	;	Virus-like particle of bacteriophage NT-214
6YFR	;	2.6	;	Virus-like particle of bacteriophage NT-391
6YFS	;	3.498	;	Virus-like particle of bacteriophage PQ-465
6YFD	;	3.3	;	Virus-like particle of Beihai levi-like virus 14
6YFE	;	3.794	;	Virus-like particle of Beihai levi-like virus 19
6YFF	;	3.089	;	Virus-like particle of Beihai levi-like virus 21
6YFG	;	3.897	;	Virus-like particle of Beihai levi-like virus 32
6YFT	;	3.5	;	Virus-like particle of Wenzhou levi-like virus 1
6YFU	;	4.018	;	Virus-like particle of Wenzhou levi-like virus 4
6HXZ	;	4.1	;	Virus-like Particles based on Potato Virus Y
6QGM	;	2.75	;	VirX1 apo structure
4Y1W	;	1.4	;	Vis toxin, an ADP-ribosyltransferase from Vibrio Splendidus
1OKH	;	1.75	;	Viscotoxin A3 from Viscum album L.
8HJE	;	2.85	;	Vismodegib binds to the catalytical domain of human Ubiquitin-Specific Protease 28
1JEK	;	1.5	;	Visna TM CORE STRUCTURE
3HPG	;	3.28	;	Visna virus integrase (residues 1-219) in complex with LEDGF IBD: examples of open integrase dimer-dimer interfaces
4ZRG	;	2.7	;	Visual arrestin mutant - R175E
2XMJ	;	1.08	;	Visualising the Metal-binding Versatility of Copper Trafficking Sites: Atx1 side-to-side (aerobic)
2XMK	;	1.35	;	Visualising the Metal-binding Versatility of Copper Trafficking Sites: Atx1 side-to-side (anaerobic)
2XMM	;	1.65	;	Visualising the Metal-binding Versatility of Copper Trafficking Sites: H61Y Atx1 side-to-side
5ABB	;	8.0	;	Visualization of a polytopic membrane protein during SecY-mediated membrane insertion
2TMV	;	2.9	;	VISUALIZATION OF PROTEIN-NUCLEIC ACID INTERACTIONS IN A VIRUS. REFINED STRUCTURE OF INTACT TOBACCO MOSAIC VIRUS AT 2.9 ANGSTROMS RESOLUTION BY X-RAY FIBER DIFFRACTION
4V7B	;	6.8	;	Visualization of two tRNAs trapped in transit during EF-G-mediated translocation
1NKN	;	2.5	;	VISUALIZING AN UNSTABLE COILED COIL: THE CRYSTAL STRUCTURE OF AN N-TERMINAL SEGMENT OF THE SCALLOP MYOSIN ROD
3O8B	;	1.95	;	Visualizing ATP-dependent RNA Translocation by the NS3 Helicase from HCV
3O8C	;	2.0	;	Visualizing ATP-dependent RNA Translocation by the NS3 Helicase from HCV
3O8D	;	2.05	;	Visualizing ATP-dependent RNA Translocation by the NS3 Helicase from HCV
3O8R	;	2.304	;	Visualizing ATP-dependent RNA Translocation by the NS3 Helicase from HCV
3ZPZ	;	8.9	;	Visualizing GroEL-ES in the Act of Encapsulating a Non-Native Substrate Protein
3ZQ0	;	9.2	;	Visualizing GroEL-ES in the Act of Encapsulating a Non-Native Substrate Protein
3ZQ1	;	15.9	;	Visualizing GroEL-ES in the Act of Encapsulating a Non-Native Substrate Protein
3PN7	;	2.25	;	Visualizing new hinges and a potential major source of compliance in the lever arm of myosin
8BLW	;	3.22	;	Vitamin B12 transporter BtuB1 with lipoprotein BtuG1 from B. theta
6FOD	;	2.5	;	Vitamin D nuclear receptor complex 1
6FO9	;	2.701	;	Vitamin D nuclear receptor complex 2
6FO7	;	2.59	;	Vitamin D nuclear receptor complex 3
6FO8	;	2.3	;	Vitamin D nuclear receptor complex 4
5OW9	;	2.403	;	Vitamin D receptor complex
5OWD	;	2.151	;	Vitamin D receptor complex
6FOB	;	2.75	;	Vitamin D receptor complex 5
8CKC	;	2.1	;	Vitamin D receptor complex with 25-amine derivative of 1,25D3
3VJS	;	1.93	;	Vitamin D receptor complex with a carborane compound
3VJT	;	2.0	;	Vitamin D receptor complex with a carborane compound
4Q0A	;	1.9	;	Vitamin D Receptor complex with lithocholic acid
7VQP	;	1.94	;	Vitamin D receptor complexed with a lithocholic acid derivative
5XZF	;	2.1	;	Vitamin D receptor with a synthetic ligand ADRO1
5XZH	;	2.0	;	Vitamin D receptor with a synthetic ligand ADRO2
7C7V	;	2.0	;	Vitamin D3 receptor/lithochoric acid derivative complex
7C7W	;	1.9	;	Vitamin D3 receptor/lithochoric acid derivative complex
6WVI	;	2.4	;	VKOR-like from Takifugu rubripes
2B2X	;	2.2	;	VLA1 RdeltaH I-domain complexed with a quadruple mutant of the AQC2 Fab
6ECB	;	1.7	;	Vlm2 thioesterase domain wild type structure 1
6ECC	;	1.8	;	Vlm2 thioesterase domain wild type structure 2
6ECE	;	2.0	;	Vlm2 thioesterase domain with genetically encoded 2,3-diaminopropionic acid bound with a dodecadepsipeptide, space group H3
6ECF	;	2.5	;	Vlm2 thioesterase domain with genetically encoded 2,3-diaminopropionic acid bound with a dodecadepsipeptide, space group P1
6ECD	;	1.9	;	Vlm2 thioesterase domain with genetically encoded 2,3-diaminopropionic acid bound with a tetradepsipeptide
8TGJ	;	3.5	;	VMAT1 dimer in unbound form and with reserpine
8TGH	;	3.5	;	VMAT1 dimer with amphetamine and reserpine
8TGI	;	3.4	;	VMAT1 dimer with dopamine and reserpine
8TGK	;	3.7	;	VMAT1 dimer with histamine and reserpine
8TGG	;	3.6	;	VMAT1 dimer with MPP+ and reserpine
8TGL	;	3.4	;	VMAT1 dimer with norepinephrine and reserpine
8TGM	;	3.5	;	VMAT1 dimer with reserpine
8TGN	;	3.3	;	VMAT1 dimer with serotonin and reserpine
5WHG	;	2.7	;	Vms1 mitochondrial localization core
1NK2	;		;	VND/NK-2 HOMEODOMAIN/DNA COMPLEX, NMR, 20 STRUCTURES
1NK3	;		;	VND/NK-2 HOMEODOMAIN/DNA COMPLEX, NMR, MINIMIZED AVERAGE STRUCTURE
1VND	;		;	VND/NK-2 PROTEIN (HOMEODOMAIN), NMR
5UZ7	;	4.1	;	Volta phase plate cryo-electron microscopy structure of a calcitonin receptor-heterotrimeric Gs protein complex
3EB4	;	2.0	;	Voltage-dependent K+ channel beta subunit (I211R) in complex with cortisone
3EB3	;	2.0	;	Voltage-dependent K+ channel beta subunit (W121A) in complex with cortisone
3EAU	;	1.82	;	Voltage-dependent K+ channel beta subunit in complex with cortisone
8F1D	;	2.94	;	Voltage-gated potassium channel Kv3.1 apo
8F1C	;	2.92	;	Voltage-gated potassium channel Kv3.1 with novel positive modulator (9M)-9-{5-chloro-6-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-4-yl)oxy]-4-methylpyridin-3-yl}-2-methyl-7,9-dihydro-8H-purin-8-one (compound 4)
3WKV	;	3.453	;	Voltage-gated proton channel: VSOP/Hv1 chimeric channel
4JPZ	;	3.02	;	Voltage-gated sodium channel 1.2 C-terminal domain in complex with FGF13U and Ca2+/calmodulin
4OVN	;	2.8	;	Voltage-gated Sodium Channel 1.5 (Nav1.5) C-terminal domain in complex with Calmodulin poised for activation
4JQ0	;	3.84	;	Voltage-gated sodium channel 1.5 C-terminal domain in complex with FGF12B and Ca2+/calmodulin
4L1D	;	2.5	;	Voltage-gated sodium channel beta3 subunit Ig domain
7DTD	;	3.3	;	Voltage-gated sodium channel Nav1.1 and beta4
6MUE	;	1.9	;	Voltage-gated sodium channel NaV1.4 IQ domain in complex with Ca2+/Calmodulin
6MUD	;	2.69	;	Voltage-gated sodium channel NaV1.5 C-terminal domain in complex with Ca2+/Calmodulin
6LQA	;	3.3	;	voltage-gated sodium channel Nav1.5 with quinidine
7DTC	;	3.3	;	voltage-gated sodium channel Nav1.5-E1784K
8XMN	;	3.37	;	Voltage-gated sodium channel Nav1.7 variant M2
8XMO	;	3.39	;	Voltage-gated sodium channel Nav1.7 variant M4
8XMM	;	2.89	;	Voltage-gated sodium channel Nav1.7 variant M9
1VGF	;	2.6	;	volvatoxin A2 (diamond crystal form)
1PP0	;	1.42	;	volvatoxin A2 in monoclinic crystal
4BKS	;	2.2	;	von Hippel Lindau protein:ElonginB:ElonginC complex, in complex with (2S,4R)-1-ethanoyl-N-[[4-(1,3-oxazol-5-yl)phenyl]methyl]-4-oxidanyl-pyrrolidine-2-carboxamide
4BKT	;	2.35	;	von Hippel Lindau protein:ElonginB:ElonginC complex, in complex with (2S,4R)-N-methyl-1-[2-(3-methyl-1,2-oxazol-5-yl)ethanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide
4AJY	;	1.73	;	von Hippel-Lindau protein-ElonginB-ElonginC complex, bound to Hif1- alpha peptide
7F49	;	2.09	;	von Willebrand factor (VWF) A1 domain with BT-100 aptamer RNA
3ZQK	;	1.7	;	Von Willebrand Factor A2 domain with calcium
4FX5	;	1.73	;	von Willebrand factor type A from Catenulispora acidiphila
3MDT	;	2.3	;	Voriconazole complex of Cytochrome P450 46A1
3ZMO	;	1.8	;	VP16, a capsid protein of bacteriophage P23-77 (VP16-type-1)
3ZN4	;	1.26	;	VP16, a capsid protein of bacteriophage P23-77 (VP16-type-2)
3ZN5	;	2.36	;	VP16, a capsid protein of bacteriophage P23-77 (VP16-virus-derived)
3ZN6	;	1.53	;	VP16-VP17 complex, a complex of the two major capsid proteins of bacteriophage P23-77
3ZMN	;	2.26	;	VP17, a capsid protein of bacteriophage P23-77
7Z5E	;	3.32	;	VP2-only capsid of MVM D263A mutant
7Z5F	;	3.22	;	VP2-only capsid of MVM D263A mutant
7Z5D	;	3.42	;	VP2-only capsid of wt MVM prototype strain p
3GZT	;	3.8	;	VP7 recoated rotavirus DLP
3GZU	;	3.8	;	VP7 recoated rotavirus DLP
5VX4	;	1.55	;	VP8* of a G2P[4] Human Rotavirus
5VX5	;	1.285	;	VP8* of a G2P[4] Human Rotavirus in complex with LNFP1
6PCU	;	2.4	;	VP8* of a G2P[4] human rotavirus in complex with scFv antibody 9
5VX8	;	2.0	;	VP8* of P[6] Human Rotavirus RV3
5VX9	;	1.822	;	VP8* of P[6] Human Rotavirus RV3 in complex with LNFP1
6DI7	;	2.3	;	Vps1 GTPase-BSE fusion complexed with GDP
6DJQ	;	3.1	;	Vps1 GTPase-BSE fusion complexed with GDP.AlF4-
6DEF	;	2.26	;	Vps1 GTPase-BSE fusion complexed with GMPPCP
7U8T	;	3.0	;	Vps13 adaptor binding domain in complex with Mcp1 PxP motif peptide
7BLO	;	9.5	;	VPS26 dimer region of metazoan membrane-assembled retromer:SNX3 complex modelled with human proteins
7BLQ	;	9.2	;	Vps26 dimer region of the fungal membrane-assembled retromer:Grd19 complex.
7BLP	;	9.5	;	Vps35/Vps29 arch of fungal membrane-assembled retromer:Grd19 complex
7BLR	;	9.3	;	Vps35/Vps29 arch of fungal membrane-assembled retromer:Vps5 (SNX-BAR) complex.
7BLN	;	8.9	;	VPS35/VPS29 arch of metazoan membrane-assembled retromer:SNX3 complex modelled with human proteins
2CAY	;	1.9	;	Vps36 N-terminal PH domain
8E22	;		;	VPS37A_21-148
6NDY	;	3.6	;	Vps4 with Cyclic Peptide Bound in the Central Pore
6OO2	;	4.4	;	Vps4 with Cyclic Peptide Bound in the Central Pore
5UIE	;	5.7	;	Vps4-Vta1 complex
2JQ9	;		;	VPS4A MIT-CHMP1A complex
2JQH	;		;	VPS4B MIT
2JQK	;		;	VPS4B MIT-CHMP2B Complex
6AP1	;	3.2	;	Vps4p-Vta1p complex with peptide binding to the central pore of Vps4p
6BMF	;	3.2	;	Vps4p-Vta1p complex with peptide binding to the central pore of Vps4p
3N1E	;	1.702	;	Vps54 C-terminal domain
5V5C	;	1.25	;	VQIINK, Structure of the amyloid-spine from microtubule associated protein tau Repeat 2
3Q9G	;	2.05	;	VQIVY segment from Alzheimer's tau displayed on 42-membered macrocycle scaffold
6UGL	;	2.03	;	VqmA bound to DPO
6V8X	;	3.0	;	VRC01 Bound BG505 F14 HIV-1 SOSIP Envelope Trimer Structure
6V8Z	;	2.9	;	VRC03 and 10-1074 Bound BG505 F14 HIV-1 SOSIP Envelope Trimer Structure
8F7Z	;	2.7	;	VRC34.01_mm28 bound to fusion peptide
4QBN	;	1.85	;	VRR_NUC domain
4QBO	;	1.3	;	VRR_NUC domain
4QBL	;	2.0	;	VRR_NUC domain protein
7UQ2	;	2.0	;	Vs.4 from T4 phage in complex with cGAMP
7P57	;	1.961	;	VSG2 mutant structure lacking the calcium binding pocket
5OYL	;	2.25	;	VSV G CR2
5OY9	;	3.6	;	VSV G CR3
6TIT	;	2.07	;	VSV G_440
5UKB	;	5.473	;	VSV N PROTEIN IN COMPLEX WITH INHIBITORY NANOBODY 1004
6BJY	;	3.46	;	VSV Nucleocapsid with Polyamide Bound
2V8S	;	2.22	;	VTI1B HABC DOMAIN - EPSINR ENTH DOMAIN COMPLEX
8JXW	;	3.01	;	VUF6884-bound H4R/Gi complex
1PP6	;	3.2	;	VVA2 (STRIP CRYSTAL FORM)
1VCY	;	2.6	;	VVA2 isoform
4R0W	;	1.5	;	Vvtgvta, an amyloid forming segment from alpha synuclein, residues 70-76
7WPR	;	4.39	;	VWF D'D3 dimer complexed with D1D2 at 4.39 angstron resolution(VWF tube)
8D3D	;	3.2	;	VWF tubule derived from dimeric D1-A1
8D3C	;	3.1	;	VWF tubule derived from monomeric D1-A1
7ZWH	;	3.2	;	VWF Tubules of D1D2 and D'D3A1 domains
7PMV	;	3.7	;	VWF Tubules of D1D2D'D3 domains
7PNF	;	4.35	;	VWF Tubules of D1D2D'D3 domains
4ZOG	;	2.3	;	VX-680/MK-0457 binds to human ABL1 also in inactive DFG conformations.
7R3C	;	2.4	;	VX-inhibited acetylcholinesterase in complex with 2-((hydroxyimino)methyl)-1-(5-(4-methyl-3-nitrobenzamido)pentyl)pyridinium
8CM5	;	2.15	;	W-formate dehydrogenase C872A from Desulfovibrio vulgaris
8CM4	;	2.3	;	W-formate dehydrogenase C872A from Desulfovibrio vulgaris - exposed to oxygen
8CM6	;	1.416	;	W-formate dehydrogenase C872A from Desulfovibrio vulgaris - with Formamide
8BQL	;	1.906	;	W-formate dehydrogenase from Desulfovibrio vulgaris - Co-crystallized with Formate and Reoxidized by exposure to air for 12 min
7Z5O	;	1.527	;	W-formate dehydrogenase from Desulfovibrio vulgaris - Dithionite reduced form
6SDV	;	1.9	;	W-formate dehydrogenase from Desulfovibrio vulgaris - Formate reduced form
6SDR	;	2.1	;	W-formate dehydrogenase from Desulfovibrio vulgaris - Oxidized form
8BQG	;	1.946	;	W-formate dehydrogenase from Desulfovibrio vulgaris - Soaking with Formate 1 min
8BQH	;	1.61	;	W-formate dehydrogenase from Desulfovibrio vulgaris - Soaking with Formate 1.5 min
8BQK	;	1.587	;	W-formate dehydrogenase from Desulfovibrio vulgaris - Soaking with Formate 22 min
8BQI	;	2.356	;	W-formate dehydrogenase from Desulfovibrio vulgaris - Soaking with Formate 3 min
8BQJ	;	2.107	;	W-formate dehydrogenase from Desulfovibrio vulgaris - Soaking with Formate 5 min
8CM7	;	2.117	;	W-formate dehydrogenase M405A from Desulfovibrio vulgaris
1Q55	;	30.0	;	W-shaped trans interactions of cadherins model based on fitting C-cadherin (1L3W) to 3D map of desmosomes obtained by electron tomography
3BNF	;	1.7	;	W. succinogenes NrfA Sulfite Complex
3BNG	;	1.5	;	W. succinogenes NrfA Y218F
3BNH	;	1.75	;	W. succinogenes NrfA Y218F Nitrite Complex
3BNJ	;	1.3	;	W. succinogenes NrfA Y218F Sulfite Complex
6VVW	;	2.1	;	W0 fused 4-OT wild type symmetric trimer
2H6G	;	1.85	;	W102T Protein Farnesyltransferase Mutant Complexed with a Geranylgeranylated DDPTASACVLS Peptide Product at 1.85A Resolution
2H6I	;	3.0	;	W102T/Y365F Protein Farnesyltransferase Double Mutant Complexed with a Geranylgeranylated DDPTASACVLS Peptide Product at 3.0A
4H6K	;	1.55	;	W116I mutant of OYE1
3RND	;	1.4	;	W116I-OYE1 complexed with 2-(Hydroxymethyl)-cyclopent-2-enone
4GWE	;	1.45	;	W116L-OYE1 complexed with (R)-carvone
3A6H	;	2.0	;	W154A mutant creatininase
3A6G	;	2.0	;	W154F mutant creatininase
3A6E	;	2.0	;	W174F mutant creatininase, type I
3A6F	;	1.78	;	W174F mutant creatininase, Type II
6AXU	;	1.822	;	W203Y Epi-isozizaene synthase
1MP4	;	2.2	;	W224H VARIANT OF S. ENTERICA RmlA
4DZ5	;	1.7	;	W227F active site mutant of AKR1C3
5ACQ	;	1.7	;	W228A-Investigation of the impact from residues W228 and Y233 in the metallo-beta-lactamase GIM-1
5ACP	;	1.98	;	W228R-Investigation of the impact from residues W228 and Y233 in the metallo-beta-lactamase GIM-1
5ACT	;	1.81	;	W228S-Investigation of the impact from residues W228 and Y233 in the metallo-beta-lactamase GIM-1
5ACR	;	1.9	;	W228Y-Investigation of the impact from residues W228 and Y233 in the metallo-beta-lactamase GIM-1
5FQI	;	1.4	;	W229D and F290W mutant of the last common ancestor of Gram-negative bacteria (GNCA4) beta-lactamase class A
5FQK	;	1.767	;	W229D and F290W mutant of the last common ancestor of Gram-negative bacteria (GNCA4) beta-lactamase class A bound to 5(6)-nitrobenzotriazole (TS-analog)
5FQJ	;	2.271	;	W229D mutant of the last common ancestor of Gram-negative bacteria (GNCA) beta-lactamase bound to 5(6)-nitrobenzotriazole (TS-analog)
4UHU	;	1.305	;	W229D mutant of the last common ancestor of Gram-negative bacteria (GNCA) beta-lactamase class A
5LQI	;	1.92	;	W288A mutant of GlxA from Streptomyces lividans: apo form
5LXZ	;	1.49	;	W288A mutant of GlxA from Streptomyces lividans: Cu-bound form
1PZY	;	2.3	;	W314A-BETA1,4-GALACTOSYLTRANSFERASE-I COMPLEXED WITH ALPHA-LACTALBUMIN IN THE PRESENCE OF N-ACETYLGLUCOSAMINE, UDP AND MANGANESE
7SG0	;	3.0	;	W316 TCR in complex with HLA-DQ2-omega1
4LZC	;	2.457	;	W325F Epi-isozizaene synthase: Complex with Mg, inorganic pyrophosphate
3VYA	;	2.4	;	W32Y mutant of FMN-binding protein from Desulfovibrio vulgaris (Miyazaki F)
3F99	;	1.65	;	W354F Yersinia enterocolitica PTPase apo form
3F9B	;	1.42	;	W354F Yersinia enterocolitica PTPase complexed with divanadate
3F9A	;	1.69	;	W354F Yersinia enterocolitica PTPase complexed with tungstate
7EBM	;	1.9	;	W363A mutant of Chitin-specific solute binding protein from Vibrio harveyi in complex with chitobiose.
6LZW	;	1.9	;	W513A mutant of chitin-specific solute binding protein from Vibrio harveyi co-crystalized with chitobiose.
1DX9	;	2.05	;	W57A Apoflavodoxin from Anabaena
2V5V	;	1.88	;	W57E Flavodoxin from Anabaena
1OBO	;	1.2	;	W57L flavodoxin from Anabaena
6TZP	;	1.72	;	W96F Oxalate Decarboxylase (B. subtilis)
6UFI	;	1.72	;	W96Y Oxalate Decarboxylase (Bacillus subtilis)
6DFL	;	2.396	;	WaaP in complex with acyl carrier protein
7RLK	;	2.69	;	Wallaby TTR
8SJ5	;	3.1	;	Walnut Tree Phytocystatin
6OFA	;		;	Wasabi Receptor Toxin
1RHA	;	1.8	;	WATER DEPENDENT DOMAIN MOTION AND FLEXIBILITY IN RIBONUCLEASE A AND THE INVARIANT FEATURES IN ITS HYDRATION SHELL. AN X-RAY STUDY OF TWO LOW HUMIDITY CRYSTAL FORMS OF THE ENZYME
1RHB	;	1.5	;	WATER DEPENDENT DOMAIN MOTION AND FLEXIBILITY IN RIBONUCLEASE A AND THE INVARIANT FEATURES IN ITS HYDRATION SHELL. AN X-RAY STUDY OF TWO LOW HUMIDITY CRYSTAL FORMS OF THE ENZYME
4V0I	;	2.54	;	Water Network Determines Selectivity for a Series of Pyrimidone Indoline Amide PI3KBeta Inhibitors over PI3K-Delta
2EYB	;		;	Water refined solution structure of crambin in ACETONE/WATER
2EYD	;		;	Water refined solution structure of crambin in dpc micelles
2L4K	;		;	Water refined solution structure of the human Grb7-SH2 domain in complex with the 10 amino acid peptide pY1139
1CRN	;	1.5	;	WATER STRUCTURE OF A HYDROPHOBIC PROTEIN AT ATOMIC RESOLUTION. PENTAGON RINGS OF WATER MOLECULES IN CRYSTALS OF CRAMBIN
2J45	;	1.14	;	Water structure of T. Aquaticus Ffh NG Domain At 1.1A Resolution
2J46	;	1.14	;	Water structure of T. Aquaticus Ffh NG Domain At 1.1A Resolution
5GW6	;	1.97	;	Water-Bridge Mediates Recognition of mRNA Cap in eIF4E
5ER0	;	2.406	;	Water-forming NADH oxidase from Lactobacillus brevis (LbNOX)
5VN0	;	2.001	;	Water-forming NADH oxidase from Lactobacillus brevis (LbNOX) bound to NADH.
1X1U	;	2.3	;	Water-mediate interaction at aprotein-protein interface
1X1W	;	2.1	;	Water-mediate interaction at aprotein-protein interface
1X1X	;	2.3	;	Water-mediate interaction at aprotein-protein interface
1X1Y	;	1.9	;	Water-mediate interaction at aprotein-protein interface
1TYS	;	1.8	;	WATER-MEDIATED SUBSTRATE(SLASH)PRODUCT DISCRIMINATION: THE PRODUCT COMPLEX OF THYMIDYLATE SYNTHASE AT 1.83 ANGSTROMS
6S2Z	;	2.5	;	Water-soluble Chlorophyll Protein (WSCP) from Brassica oleracea var. Botrytis with Chlorophyll-b
6GIW	;	2.8	;	Water-soluble Chlorophyll Protein (WSCP) from Lepidium virginicum (Mutation L91P) with Chlorophyll-a
6GIX	;	2.8	;	Water-soluble Chlorophyll Protein (WSCP) from Lepidium virginicum (Mutation L91P) with Chlorophyll-b
6S2Y	;	2.3	;	Water-soluble Chlorophyll Protein (WSCP) from Lepidium virginicum with Chlorophyll-b
3ND4	;	1.524	;	Watson-Crick 16-mer dsRNA
6CHJ	;	2.428	;	Wax ester synthase/diacylglycerol acyltransferase from Marinobacter aquaeolei VT8
7NXG	;	1.95	;	Wax synthase 1 from Acinetobacter baylyi (AbWSD1) co-crystallized with myristic acid
8CSD	;	1.95	;	WbbB D232C Kdo adduct
8CSF	;	2.4	;	WbbB D232C-Kdo adduct + alpha-Rha(1,3)GlcNAc ternary complex
8CSB	;	2.25	;	WbbB D232N in complex with CMP-beta-Kdo
8CSC	;	1.9	;	WbbB D232N-Kdo adduct
8CSE	;	2.3	;	WbbB in complex with alpha-Rha-(1-3)-beta-GlcNAc acceptor
6U4B	;	2.1	;	WbbM bifunctional glycosytransferase apo structure
3NUB	;	1.9	;	WbpE, an Aminotransferase from Pseudomonas aeruginosa Involved in O-antigen Assembly in Complex with Product as the External Aldimine
3NU7	;	1.95	;	WbpE, an Aminotransferase from Pseudomonas aeruginosa Involved in O-antigen Assembly in Complex with the Cofactor PMP
3NU8	;	1.5	;	WbpE, an Aminotransferase from Pseudomonas aeruginosa Involved in O-antigen Assembly in Complex with the Internal Aldimine
4USM	;	1.82	;	WcbL complex with glycerol bound to sugar site
8OK1	;	1.38	;	WD repeat containing protein 5 (WDR5)- N225A mutant
8OKF	;	1.85	;	WD repeat containing protein 5 (WDR5)- PER2 peptide
8E9F	;	1.55	;	WD repeat-containing protein 5 complexed with 4-(7-((1H-imidazol-1-yl)methyl)-5-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)-6-ethyl-N-methylquinoline-8-carboxamide (compound 10)
6UFX	;	2.015	;	WD repeat-containing protein 5 complexed with N-[(3,5-dimethoxyphenyl)methyl]-4'-fluoro-5-{[(2E)-2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl]methyl}-2'-methyl[1,1'-biphenyl]-3-carboxamide (compound 13)
6N31	;	2.6	;	WD repeats of human WDR12
5IGO	;	1.6	;	WD40 domain of Arabidopsis thaliana E3 Ubiquitin Ligase COP1 in complex with peptide from Trib1
5GVA	;	1.851	;	WD40 domain of human AND-1
5HQG	;	2.0	;	WD40 domain of Human E3 Ubiquitin Ligase COP1 (RFWD2)
5IGQ	;	3.9	;	WD40 domain of Human E3 Ubiquitin Ligase COP1 (RFWD2) bound to peptide from Trib1
1GXR	;	1.65	;	WD40 Region of Human Groucho/TLE1
5CVN	;	3.36	;	WDR48 (2-580):USP46~ubiquitin ternary complex
5CVL	;	3.0	;	WDR48 (UAF-1), residues 2-580
5CVO	;	3.885	;	WDR48:USP46~ubiquitin ternary complex
2CNX	;	2.1	;	WDR5 and Histone H3 Lysine 4 dimethyl complex at 2.1 angstrom
2CO0	;	2.25	;	WDR5 and unmodified Histone H3 complex at 2.25 Angstrom
7U9Y	;	1.9	;	WDR5 bound to 2-(3,5-dimethoxybenzyl)-7-((2-methyl-1H-imidazol-1-yl)methyl)-5-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-3,4-dihydroisoquinolin-1(2H)-one
5VFC	;	1.64	;	WDR5 bound to inhibitor MM-589
8F93	;	2.3	;	WDR5 covalently modified at Y228 by (R)-2-SF
6DY7	;	1.9	;	WDR5 in complex with a WIN site inhibitor
6DYA	;	2.56	;	WDR5 in complex with a WIN site inhibitor
2XL3	;	2.7	;	WDR5 IN COMPLEX WITH AN RBBP5 PEPTIDE AND HISTONE H3 PEPTIDE
2XL2	;	2.4	;	WDR5 IN COMPLEX WITH AN RBBP5 PEPTIDE RECRUITED TO NOVEL SITE
2O9K	;	1.9	;	WDR5 in Complex with Dimethylated H3K4 Peptide
8HMX	;	1.7	;	WDR5 in complex with histone H3Q5his peptide
4O45	;	1.87	;	WDR5 in complex with influenza NS1 C-terminal tail
5SXM	;	2.0	;	WDR5 in complex with MLL Win motif peptidomimetic
2H9N	;	2.0	;	WDR5 in complex with monomethylated H3K4 peptide
6UHY	;	1.26	;	WDR5 in complex with Myc site fragment inhibitor
6UHZ	;	1.258	;	WDR5 in complex with Myc site fragment inhibitor
2H9P	;	1.91	;	WDR5 in complex with trimethylated H3K4 peptide
2H9M	;	1.9	;	WDR5 in complex with unmodified H3K4 peptide
2H9L	;	1.75	;	WDR5delta23
6PG8	;	1.67	;	WDR5delta23 bound to (2-(3-phenylpropyl)-1H-imidazol-4-yl)methanol
6PG3	;	2.04	;	WDR5delta23 bound to (2-butyl-1H-imidazol-4-yl)methanol
6PG6	;	1.68	;	WDR5delta23 bound to N-(4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)acetamide
6PG9	;	1.75	;	WDR5delta23 bound to N-(4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)benzamide
6PG7	;	2.45	;	WDR5delta32 bound to (2-(3-methoxy-3-phenylpropyl)-1H-imidazol-4-yl)methanol
6PG4	;	1.6	;	WDR5delta32 bound to (2-methyl-1H-imidazol-4-yl)methanol
6PG5	;	1.99	;	WDR5delta32 bound to benzyl (4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)carbamate
6PGE	;	1.76	;	WDR5delta32 bound to ethyl 3-(4-(hydroxymethyl)-1H-imidazol-2-yl)propanoate
6PGA	;	2.45	;	WDR5delta32 bound to methyl (4-(4-(hydroxymethyl)-1H-imidazol-2-yl)butyl)carbamate
6PGC	;	1.81	;	WDR5delta32 bound to methyl benzyl(4-(4-(hydroxymethyl)-1H-imidazol-2-yl)butyl)carbamate
6PGF	;	1.54	;	WDR5delta32 bound to N-(4-(4-(hydroxymethyl)-1H-imidazol-2-yl)butyl)acrylamide
6PGB	;	1.73	;	WDR5delta32 bound to N-(4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)-2-phenylacetamide
6PGD	;	1.5	;	WDR5delta32 bound to peptidomimetic
8QD7	;	1.85	;	Wdyg1p from W. dermatitidis catalyzes polyketide shortening in the biosynthesis of DHN-melanin
8QD9	;	1.95	;	Wdyg1p in complex with 1,3,6,8-Tetrahydroxynaphthalene
8QD8	;	1.65	;	Wdyg1p in complex with 1,3-Dihydroxynaphthalene
8QDA	;	1.85	;	Wdyg1p Ser256DHA (PMSF)
8QDB	;	1.85	;	Wdyg1p Ser256DHA (PSF)
4WDI	;	2.313	;	Weak TCR binding to an unstable insulin epitope drives type 1 diabetes
4Z76	;	1.88	;	Weak TCR binding to an unstable insulin epitope drives type 1 diabetes
4Z77	;	1.85	;	Weak TCR binding to an unstable insulin epitope drives type 1 diabetes
4Z78	;	2.304	;	Weak TCR binding to an unstable insulin epitope drives type 1 diabetes
3CQE	;	2.5	;	Wee1 kinase complex with inhibitor PD074291
3CR0	;	2.3	;	Wee1 kinase complex with inhibitor PD259_809
2IN6	;	1.9	;	Wee1 kinase complex with inhibitor PD311839
3BIZ	;	2.2	;	Wee1 kinase complex with inhibitor PD331618
3BI6	;	2.2	;	Wee1 kinase complex with inhibitor PD352396
2IO6	;	2.2	;	Wee1 kinase complexed with inhibitor PD330961
4M9C	;	2.1	;	WeeI from Acinetobacter baumannii AYE
5IQT	;	2.4	;	WelO5 bound to Fe(II), Cl, 2-oxoglutarate, and 12-epifischerindole U
5IQS	;	2.0	;	WelO5 bound to Fe(II), Cl, and 2-oxoglutarate
5IQV	;	2.4	;	WelO5 bound to Fe, Cl, 2-oxoglutarate, 12-epifischerindole U, and nitric oxide
5IQU	;	2.51	;	WelO5 G166D variant bound to Fe(II), 2-oxoglutarate, and 12-epifischerindole U
5J4R	;	1.65	;	WELO5 SMALL MOLECULE HALOGENASE WITH NI(II) AND 2-OXOGLUTARATE
5T22	;	1.75	;	WELO5 SMALL MOLECULE HALOGENASE WITH NI(II) AND 2-OXOGLUTARATE P 21 CRYSTAL FORM
5TRQ	;	1.3	;	WELO5 SMALL MOLECULE HALOGENASE WITH NI(II) AND SUCCINATE
8ACV	;	2.26	;	WelO5* bound to Zn(II), Cl, and 2-oxoglutarate
8AUT	;	2.685	;	WelO5* L221A bound to Zn(II), Cl, 2-oxoglutarate, and 12-epi-hapalindole C
3ELD	;	1.9	;	Wesselsbron methyltransferase in complex with Sinefungin
3ELY	;	2.4	;	Wesselsbron virus Methyltransferase in complex with AdoHcy
3ELU	;	2.0	;	Wesselsbron virus Methyltransferase in complex with AdoMet
3EMB	;	2.3	;	Wesselsbron virus Methyltransferase in complex with AdoMet and 7MeGpppG
3ELW	;	1.9	;	Wesselsbron virus Methyltransferase in complex with AdoMet and GpppG
3EMD	;	2.0	;	Wesselsbron virus Methyltransferase in complex with Sinefungin and 7MeGpppA
3E90	;	2.45	;	West Nile vi rus NS2B-NS3protease in complexed with inhibitor Naph-KKR-H
1ZTX	;	2.5	;	West Nile Virus Envelope Protein DIII in complex with neutralizing E16 antibody Fab
3IYW	;	13.7	;	West Nile virus in complex with Fab fragments of MAb CR4354 (fitted coordinates of envelope proteins and Fab fragments of one icosahedral ASU)
4O6D	;	2.5936	;	West Nile Virus Non-structural protein 1 (NS1) Form 1 crystal
4TPL	;	2.9	;	West Nile Virus Non-structural protein 1 (NS1) Form 1 crystal
4O6C	;	2.7508	;	West Nile Virus Non-structural protein 1 (NS1) Form 2 crystal
4OIE	;	1.85	;	West Nile Virus Non-structural Protein NS1
4OII	;	3.0	;	West Nile Virus NS1 in complex with neutralizing 22NS1 antibody Fab
2YOL	;	3.2	;	West Nile Virus NS2B-NS3 protease in complex with 3,4- dichlorophenylacetyl-Lys-Lys-GCMA
2FP7	;	1.68	;	West Nile Virus NS2B/NS3protease in complex with Bz-Nle-Lys-Arg-Arg-H
6MAA	;	1.394	;	WFIKKN2 Follistatin Domain
6L0O	;	1.21	;	WH domain of human MCM8
5X1G	;	4.5	;	WHAMM's Microtubule binding motif
8IP9	;	3.0	;	Wheat 40S ribosome in complex with a tRNAi
8IPB	;	3.4	;	Wheat 80S ribosome pausing on AUG-Stop with cycloheximide
8IP8	;	2.9	;	Wheat 80S ribosome stalled on AUG-Stop boron dependently
8IPA	;	3.4	;	Wheat 80S ribosome stalled on AUG-Stop boron dependently with cycloheximide
6GER	;	2.00005	;	Wheat b-amylase, a clinically relevant food allergen
7KIK	;	1.73	;	Wheat dwarf virus Rep domain circular permutation complexed with a single-stranded DNA 10-mer comprising the cleavage site and Mn2+
6WE0	;	1.8	;	Wheat dwarf virus Rep domain complexed with a single-stranded DNA 10-mer comprising the cleavage site
6WE1	;	2.612	;	Wheat dwarf virus Rep domain complexed with a single-stranded DNA 8-mer comprising the cleavage site
8CYF	;	2.44	;	WhiB3 bound to SigmaAr4-RNAP Beta flap tip chimera and DNA
8D5V	;	1.8	;	WhiB6 bound to the SigmaAr4-RNAP Beta flap tip chimera
7Z05	;	2.33	;	White Bream virus N7-Methyltransferase
7Z2J	;	1.657	;	White Bream virus N7-Methyltransferase
1A75	;	1.9	;	WHITING PARVALBUMIN
2DHR	;	3.9	;	Whole cytosolic region of ATP-dependent metalloprotease FtsH (G399L)
4EIW	;	3.9	;	Whole cytosolic region of atp-dependent metalloprotease FtsH (G399L)
6IZR	;	4.7	;	Whole structure of a 15-stranded ParM filament from Clostridium botulinum
1DG1	;	2.5	;	WHOLE, UNMODIFIED, EF-TU(ELONGATION FACTOR TU).
8OO1	;	3.7	;	Wide inward-open liganded UraA in complex with a conformation-selective synthetic nanobody
8OMZ	;	3.5	;	Wide inward-open unliganded UraA in complex with a conformation-selective synthetic nanobody
1TW7	;	1.3	;	Wide Open 1.3A Structure of a Multi-drug Resistant HIV-1 Protease Represents a Novel Drug Target
2YGN	;	1.85	;	WIF domain of human Wnt inhibitory factor 1 in complex with 1,2- dipalmitoylphosphatidylcholine
2YGP	;	2.222	;	WIF domain-EGF-like domain 1 Met77Trp of human Wnt inhibitory factor 1 in complex with 1,2-dipalmitoylphosphatidylcholine
2YGO	;	1.85	;	WIF domain-EGF-like domain 1 of human Wnt inhibitory factor 1 in complex with 1,2-dipalmitoylphosphatidylcholine
2YGQ	;	3.951	;	WIF domain-epidermal growth factor (EGF)-like domains 1-3 of human Wnt inhibitory factor 1 in complex with 1,2- dipalmitoylphosphatidylcholine
7OUR	;	1.95	;	Wilavidin apo form (P1 form)
7OUQ	;	2.63	;	wilavidin biotin complex
6UN8	;	1.65	;	Wild type ANT bound to neomycin
8FII	;	2.94	;	Wild type APOBEC3A in complex with TT(FdZ)-hairpin inhibitor (crystal form 1)
8FIJ	;	2.799	;	Wild type APOBEC3A in complex with TT(FdZ)-hairpin inhibitor (crystal form 2)
8ADE	;	2.78	;	Wild type ATTR amyloid fibril from senile systemic amyloidosis
3WRT	;	2.9	;	Wild type beta-lactamase DERIVED FROM CHROMOHALOBACTER SP.560
7ONP	;	1.408	;	Wild type carbonic anhydrase II with bound IrCp* complex to generate an artificial transfer hydrogenase (ATHase)
3QR2	;	2.3	;	Wild type CD147 Ig0 domain
1QK2	;	2.0	;	WILD TYPE CEL6A WITH A NON-HYDROLYSABLE CELLOTETRAOSE
8SKM	;	2.2	;	Wild type chlorogenic acid esterase from Lactobacillus helveticus
2QKE	;	2.7	;	Wild Type Crystal Structure of Full Length Circadian Clock Protein KaiB from Thermosynechococcus elongatus BP-1
6U4S	;	2.49	;	wild type cysteine dioxygenase
5JX3	;	2.3	;	Wild type D4 in orthorhombic space group
1MWD	;	1.8	;	WILD TYPE DEOXY MYOGLOBIN
3M08	;	2.014	;	Wild Type Dihydrofolate Reductase from Staphylococcus aureus with inhibitor RAB1
4TS3	;	2.3	;	Wild type E. Coli purine nucleoside phosphorylase with 2 FMC molecules in active sites
7UKV	;	2.4	;	Wild type EGFR in complex with Lazertinib (YH25448)
6VHN	;	2.4	;	Wild type EGFR in complex with LN2057
6VH4	;	2.8	;	Wild type EGFR in complex with LN2380
6VHP	;	3.6	;	Wild type EGFR in complex with LN2899
1QKU	;	3.2	;	WILD TYPE ESTROGEN NUCLEAR RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH ESTRADIOL
4U0U	;	2.98	;	Wild type eukaryotic fic domain containing protein with ADP
4Q7D	;	2.35	;	Wild type Fc (wtFc)
4FM4	;	2.384	;	Wild Type Fe-type Nitrile Hydratase from Comamonas testosteroni Ni1
6OZX	;	1.851	;	Wild type GapR crystal structure 1 from C. crescentus
6OZY	;	2.014	;	Wild type GapR crystal structure 2 from C. crescentus
1BDT	;	2.5	;	WILD TYPE GENE-REGULATING PROTEIN ARC/DNA COMPLEX
7VFQ	;	1.55	;	Wild type GltA from Bifidobacterium infantis JCM 1222 complexed with lacto-N-tetraose
2GAW	;	2.2	;	WILD TYPE GLYCOSYLASPARAGINASE FROM FLAVOBACTERIUM MENINGOSEPTICUM
5EXB	;	1.81	;	Wild type green fluorescent protein DendFP (Dendronephthya sp.)
8ATD	;	3.1	;	Wild type hexamer oxalyl-CoA synthetase (OCS)
2FDE	;	2.7	;	Wild type HIV protease bound with GW0385
3NU3	;	1.02	;	Wild Type HIV-1 Protease with Antiviral Drug Amprenavir
3OXC	;	1.16	;	Wild Type HIV-1 Protease with Antiviral Drug Saquinavir
3DK1	;	1.07	;	Wild Type HIV-1 Protease with potent Antiviral inhibitor GRL-0105A
3DJK	;	1.0	;	Wild Type HIV-1 Protease with potent Antiviral inhibitor GRL-0255A
2Z4O	;	1.6	;	Wild Type HIV-1 Protease with potent Antiviral inhibitor GRL-98065
1IKW	;	3.0	;	Wild Type HIV-1 Reverse Transcriptase in Complex with Efavirenz
5FA6	;	2.3	;	wild type human CYPOR
2QD3	;	2.2	;	Wild type human ferrochelatase crystallized with ammonium sulfate
2QD4	;	2.0	;	Wild type human ferrochelatase crystallized with MnCl2
3MNG	;	1.45	;	wild type human PrxV with DTT bound as a competitive inhibitor
5N6O	;	2.59	;	Wild type human Rac1-GDP
6DZV	;	4.2	;	Wild type human serotonin transporter in complex with 15B8 Fab bound to ibogaine in occluded conformation
1E98	;	1.9	;	Wild type human thymidylate kinase complexed with AZTMP and ADP
3NEE	;	1.55	;	Wild type human transthyretin (TTR) complexed with GC-1 (TTRwt:GC-1)
3NEO	;	2.0	;	Wild type human transthyretin (TTR) complexed with GC-24 (TTRwt:GC-24)
3KGU	;	1.85	;	Wild type human transthyretin (TTR) complexed with genistein (TTRwt:GEN) pH 7.5
4MRB	;	1.27	;	Wild Type Human Transthyretin pH 7.5
5E5P	;	2.65	;	Wild type I-SmaMI in the space group of C121
6SM1	;	1.55	;	Wild type immunoglobulin light chain (WT-1)
1MDN	;	1.98	;	WILD TYPE MYOGLOBIN WITH CO
1MWC	;	1.7	;	WILD TYPE MYOGLOBIN WITH CO
7ENP	;	3.4	;	wild type of O type Foot-and-mouth disease virus
7XZF	;	1.3	;	Wild type of the N-terminal domain of fucoidan lyase FdlA
8AFF	;	2.87	;	Wild type oxalyl-CoA synthetase Pcs60p
8F2H	;	4.2	;	Wild type P53 dimer structure from human cancer cells
8QM1	;	1.91	;	wild type Pa.FabF in complex cerulenin
1OTB	;	1.1	;	WILD TYPE PHOTOACTIVE YELLOW PROTEIN, P63 AT 295K
2D01	;	1.34	;	Wild Type Photoactive Yellow Protein, P65 Form
1LJL	;	2.01	;	Wild Type pI258 S. aureus arsenate reductase
4DPD	;	2.5	;	WILD TYPE PLASMODIUM FALCIPARUM DIHYDROFOLATE REDUCTASE-THYMIDYLATE SYNTHASE (PfDHFR-TS), DHF COMPLEX, NADP+, dUMP
7CTY	;	2.8	;	Wild type plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS), fragment 263, NADP+, dUMP
8GU5	;	2.02	;	Wild type poly(ethylene terephthalate) hydrolase
5URD	;	1.9	;	wild type rat CYPOR bound with NADP+ - oxidized form
5URE	;	2.3	;	Wild type rat CYPOR bound with NADP+ - reduced form
2V2I	;	2.0	;	Wild type recombinant horse spleen apoferritin cocrystallized with haemin in acidic conditions
2V2J	;	2.22	;	Wild type recombinant horse spleen apoferritin cocrystallized with haemin in basic conditions
1NIK	;	4.1	;	Wild Type RNA Polymerase II
4MA9	;	1.82	;	Wild type Salmonella Alkyl Hydroperoxide Reductase C in its substrate-ready conformation
3ZXB	;	2.55	;	Wild type single insulin-like growth factor binding domain protein (SIBD-1) from Cupiennius salei
2B5G	;	1.7	;	Wild Type SSAT- 1.7A structure
1Y4H	;	1.93	;	Wild type staphopain-staphostatin complex
6C3M	;	1.5	;	Wild type structure of SiRHP
6C3X	;	1.542	;	Wild type structure of SiRHP
6C3Y	;	1.542	;	Wild type structure of SiRHP
4S0W	;	2.117	;	Wild type T4 lysozyme structure
5TC9	;	1.6	;	Wild type TrCel7A catalytic domain in a closed state
1W7S	;	1.85	;	Wild-Type Aequorea victoria Green Fluorescent Protein
2AYI	;	3.7	;	Wild-type AmpT from Thermus thermophilus
1CAY	;	2.1	;	WILD-TYPE AND E106Q MUTANT CARBONIC ANHYDRASE COMPLEXED WITH ACETATE
1CAZ	;	1.9	;	WILD-TYPE AND E106Q MUTANT CARBONIC ANHYDRASE COMPLEXED WITH ACETATE
6KJB	;	2.06	;	wild-type apo-form E. coli ATCase holoenzyme with an unusual open conformation of R167
5CRI	;	1.63	;	Wild-type Bacillus subtilis lipase A with 0% [BMIM][Cl]
5CT5	;	1.747	;	Wild-type Bacillus subtilis lipase A with 10% [BMIM][Cl]
5CT6	;	1.902	;	Wild-type Bacillus subtilis lipase A with 20% [BMIM][Cl]
5CT4	;	1.49	;	Wild-type Bacillus subtilis lipase A with 5% [BMIM][Cl]
8I55	;	1.99	;	Wild-type CfbA at 1.99 angstrom resolution
1CXI	;	2.2	;	WILD-TYPE CGTASE FROM BACILLUS CIRCULANS STRAIN 251 AT 120 K AND PH 7.55
6VUE	;	2.28	;	wild-type choline TMA lyase in complex with 1-methyl-1,2,3,6-tetrahydropyridin-3-ol
6ND3	;	2.364	;	wild-type choline TMA lyase in complex with betaine aldehyde
5FAU	;	1.9	;	wild-type choline TMA lyase in complex with choline
3ZO8	;	1.59	;	Wild-type chorismate mutase of Bacillus subtilis at 1.6 A resolution
3RY1	;	1.03	;	Wild-type core streptavidin at atomic resolution
3RY2	;	0.95	;	Wild-type core streptavidin-biotin complex at atomic resolution
6M7F	;	3.051	;	Wild-type Cucumene Synthase
4F5M	;	1.65	;	Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.
6NJ0	;	1.83	;	Wild-type E. coli MenE with bound m phenylether-linked analogue of OSB-AMS
5CCC	;	1.5	;	wild-type E.coli dihydrofolate reductase complexed with 5,10-dideazatetrahydrofolate and oxidized nicotinamide adenine dinucleotide phosphate
7KJF	;	1.4	;	Wild-type epi-isozizaene synthase: complex with 3 Mg2+ and neridronate
7KJ8	;	1.9	;	Wild-type epi-isozizaene synthase: complex with 3 Mg2+ and pamidronate
7KJ9	;	2.2	;	Wild-type epi-isozizaene synthase: complex with 3 Mg2+ and risedronate
7S1H	;	2.35	;	Wild-type Escherichia coli ribosome with antibiotic linezolid
7S1J	;	2.47	;	Wild-type Escherichia coli ribosome with antibiotic radezolid
7S1G	;	2.48	;	wild-type Escherichia coli stalled ribosome with antibiotic linezolid
7S1I	;	2.48	;	Wild-type Escherichia coli stalled ribosome with antibiotic radezolid
2LTB	;		;	Wild-type FAS1-4
7Z2X	;	1.5	;	Wild-type ferulic acid esterase from Lactobacillus buchneri
7Z2U	;	1.9	;	Wild-type ferulic acid esterase from Lactobacillus buchneri in complex with ferulate
2AII	;	1.54	;	wild-type Formylglycine generating enzyme reacted with iodoacetamide
4XYH	;	2.3	;	Wild-type full length Mis16 in Schizosaccharomyces japonicus
6NKE	;	1.72	;	Wild-type GGGPS from Thermoplasma volcanium
8B8E	;	1.55	;	Wild-type GH11 from Blastobotrys mokoenaii
5IZD	;	2.05	;	Wild-type glyceraldehyde dehydrogenase from Thermoplasma acidophilum in complex with NADP
1XZ2	;	1.9	;	wild-type hemoglobin deoxy no-salt
3TM3	;	1.75	;	Wild-type hemoglobin from Vitreoscilla stercoraria
7OG8	;	1.4	;	Wild-type Hfq protein from Neisseria meningitidis
6C8X	;	1.613	;	Wild-type HIV-1 protease in complex with a phenylboronic acid (P2') analog of darunavir
6O48	;	1.46	;	Wild-type HIV-1 protease in complex with a substrate analog CA-p2
6DJ1	;	1.26	;	Wild-type HIV-1 protease in complex with Lopinavir
2HB3	;	1.35	;	Wild-type HIV-1 Protease in complex with potent inhibitor GRL06579
6DIF	;	1.2	;	Wild-type HIV-1 protease in complex with tipranavir
3S45	;	1.51	;	wild-type HIV-2 protease with antiviral drug amprenavir
1G39	;	1.22	;	WILD-TYPE HNF-1ALPHA DIMERIZATION DOMAIN
4MPM	;	1.74	;	Wild-type human neuroglobin
4X9Y	;	1.07	;	Wild-Type Human Pancreatic Alpha-Amylase at True Atomic Resolution (1.07 A)
1D1S	;	2.5	;	WILD-TYPE HUMAN SIGMA (CLASS IV) ALCOHOL DEHYDROGENASE
5CRD	;	2.08	;	Wild-type human skeletal calsequestrin
4GD7	;	2.29	;	Wild-Type Human Thymidylate Synthase with bound Purpurogallin
7M1N	;	2.06	;	Wild-type Hydrogenobacter thermophilus ferredoxin 1
2VSS	;	2.22	;	Wild-type Hydroxycinnamoyl-CoA hydratase lyase in complex with acetyl- CoA and vanillin
6BCE	;	1.75	;	Wild-type I-LtrI bound to cognate substrate (pre-cleavage complex)
6BCI	;	2.28	;	Wild-type I-LtrI bound to non-cognate C4 substrate (pre-cleavage complex)
6BDA	;	1.88	;	Wild-type I-OnuI bound to A3G substrate (post-cleavage complex)
4H52	;	1.803	;	Wild-type influenza N2 neuraminidase covalent complex with 3-fluoro-Neu5Ac
5UK9	;	1.887	;	Wild-type K-Ras(GCP) pH 6.5
5UFE	;	2.302	;	Wild-type K-Ras(GNP)/R11.1.6 complex
6DVI	;	2.3	;	Wild-type Lactate Monooxygenase from Mycobacterium smegmatis
1ZRS	;	1.5	;	wild-type LD-carboxypeptidase
3ZXD	;	3.3	;	wild-type lysenin
4NSY	;	1.1	;	Wild-type lysobacter enzymogenes lysc endoproteinase covalently inhibited by TLCK
6U9Y	;	1.8	;	Wild-type MthK pore in 11 mM K+
6U9T	;	1.55	;	Wild-type MthK pore in 50 mM K+
6U9Z	;	1.954	;	Wild-type MthK pore in 6 mM K+
6U9P	;	1.65	;	Wild-type MthK pore in ~150 mM K+
8FRR	;	1.27	;	Wild-type myocilin olfactomedin domain
6P63	;	2.4	;	Wild-type NIS synthetase DesD bound to AMP and substrate analog cadaverine
5UHV	;	1.672	;	wild-type NRas bound to GppNHp
3VGS	;	2.3	;	Wild-type nucleoside diphosphate kinase derived from Halomonas sp. 593
3VGT	;	2.7	;	Wild-type nucleoside diphosphate kinase derived from Halomonas sp. 593
6HL2	;	1.95	;	wild-type NuoEF from Aquifex aeolicus - oxidized form
6HL3	;	2.04	;	wild-type NuoEF from Aquifex aeolicus - oxidized form bound to NAD+
6HL4	;	2.06	;	wild-type NuoEF from Aquifex aeolicus - reduced form
6HLI	;	2.38	;	wild-type NuoEF from Aquifex aeolicus - reduced form bound to NAD+
6HLA	;	1.9	;	wild-type NuoEF from Aquifex aeolicus - reduced form bound to NADH
6SAQ	;	2.02	;	wild-type NuoEF from Aquifex aeolicus bound to NADH-OH
3WJX	;	1.23	;	Wild-type orotidine 5'-monophosphate decarboxylase from M. thermoautotrophicus complexed with 6-amino-UMP
3WJW	;	1.59	;	Wild-type orotidine 5'-monophosphate decarboxylase from M. thermoautotrophicus complexed with 6-methyl-UMP
3WK1	;	1.6	;	Wild-type orotidine 5'-monophosphate decarboxylase from M. thermoautotrophicus complexed with orotidine 5'-monophosphate ethyl ester
3WK0	;	1.41	;	Wild-type orotidine 5'-monophosphate decarboxylase from M. thermoautotrophicus complexed with orotidine 5'-monophosphate methyl ester
5K5B	;	1.35	;	Wild-type PAS-GAF fragment from Deinococcus radiodurans BphP
5L8M	;	2.1	;	Wild-type PAS-GAF fragment from Deinococcus radiodurans Bphp collected at LCLS
5LBR	;	2.2	;	Wild-type PAS-GAF fragment from Deinococcus radiodurans Bphp collected at SACLA
1QG0	;	2.5	;	WILD-TYPE PEA FNR
1NZU	;	2.0	;	Wild-type penicillin-binding protein 5 from E. coli modified by beta-mercaptoethanol
3P62	;	1.4	;	Wild-type pentaerythritol tetranitrate reductase containing a C-terminal 8-histidine tag
4PVE	;	1.5	;	Wild-type Phl p 4.0202, a glucose dehydrogenase
3UM8	;	2.6	;	Wild-type Plasmodium falciparum DHFR-TS complexed with cycloguanil and NADPH
7CTZ	;	2.65	;	Wild-type plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) complexed with fragment 148, NADPH, and dUMP
7CTW	;	2.51	;	Wild-type Plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) complexed with fragment 820, NADPH, dUMP
7F3Y	;	2.252	;	Wild-type Plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) complexed with methotrexate (MTX), NADPH and dUMP
3DGA	;	2.7	;	Wild-type Plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) complexed with RJF01302, NADPH, and dUMP
1J3I	;	2.33	;	Wild-type Plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) complexed with WR99210, NADPH, and dUMP
1BYO	;	2.0	;	WILD-TYPE PLASTOCYANIN FROM SILENE
6IQC	;	1.49	;	Wild-type Programmed Cell Death 5 protein from Sulfolobus solfataricus
7LBH	;	1.15	;	Wild-type Pseudomonas fluorescens isocyanide hydratase (WT-1) at 274K, PHENIX-refined
7L9Q	;	1.149	;	Wild-type Pseudomonas fluorescens isocyanide hydratase (WT-1) at 274K, Refmac5-refined
7LBI	;	1.2	;	Wild-type Pseudomonas fluorescens isocyanide hydratase (WT-2) at 274K, PHENIX-refined
7L9S	;	1.2	;	Wild-type Pseudomonas fluorescens isocyanide hydratase (WT-2) at 274K, Refmac5-refined
7LCX	;	1.2	;	Wild-type Pseudomonas fluorescens isocyanide hydratase (WT-3) at 274K, Phenix-refined
7L9W	;	1.199	;	Wild-type Pseudomonas fluorescens isocyanide hydratase (WT-3) at 274K, Refmac5-refined
3TGI	;	1.8	;	WILD-TYPE RAT ANIONIC TRYPSIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI)
1DUK	;	2.13	;	WILD-TYPE RECOMBINANT SPERM WHALE METAQUOMYOGLOBIN
7WQK	;	2.15	;	wild-type SARS-CoV-2 main protease in complex with MG-132
6O9Q	;	1.9	;	Wild-type SaSQS1
6O9P	;	2.1	;	Wild-type SaSQS1 Complexed with Ibandronate
8FDJ	;	1.75	;	Wild-Type Sperm Whale Myoglobin in Complex with Nitrosobenzene
5IKS	;	1.87	;	Wild-type sperm whale myoglobin with a Fe-phenyl moiety
5VZN	;	1.7	;	Wild-type sperm whale myoglobin with nitric oxide
5UT7	;	1.85	;	Wild-type sperm whale myoglobin with nitrite
2W9G	;	1.95	;	Wild-type Staphylococcus aureus DHFR in complex with NADPH and trimethoprim
2W9H	;	1.48	;	Wild-type Staphylococcus aureus DHFR in complex with trimethoprim
6M9B	;	1.548	;	Wild-type streptavidin in complex with biotin solved by native SAD with data collected at 6 keV
4CPE	;	1.06	;	Wild-type streptavidin in complex with love-hate ligand 1 (LH1)
4CPF	;	1.14	;	Wild-type streptavidin in complex with love-hate ligand 3 (LH3)
2V8N	;	3.6	;	Wild-type Structure of Lactose Permease
5U4F	;	1.5	;	Wild-type Transthyretin in complex with 1,1'-(1E)-(1,2-Ethenediyl)bis[2-chloro-4-boronic acid]benzene
5U4G	;	1.8	;	Wild-type Transthyretin in complex with 2-Boronic Acid-1-[(1E)-2-(3-boronic acid)ethenyl]-4-chlorobenzene
5U4E	;	1.45	;	Wild-type Transthyretin in complex with 3-[(1E)-2-(2-Chloro-4-boronic acid)ethenyl]benzoic Acid
5U4D	;	1.55	;	Wild-type Transthyretin in complex with 3-[(1E)-2-(2-Chloro-4-hydroxyphenyl)ethenyl]benzoic Acid
5U4C	;	1.7	;	Wild-type Transthyretin in complex with 3-[(1E)-2-(4-Boronic acid)ethenyl]benzoic Acid
5U4B	;	1.448	;	Wild-type Transthyretin in complex with 3-[(1E)-2-(4-Hydroxyphenyl)ethenyl]benzoic Acid
5U4A	;	1.9	;	Wild-type Transthyretin in complex with 5-[(1E)-2-(2-Chloro-4-boronic acid)ethenyl]-1,3-benzenediol
5U49	;	2.22	;	Wild-type Transthyretin in complex with 5-[(1E)-2-(2-Chloro-4-hydroxyphenyl)ethenyl]-1,3-benzenediol
5U48	;	1.5	;	Wild-type Transthyretin in complex with 5-[(1E)-2-(4-Boronic acid)ethenyl]-1,3-benzenediol
1AY9	;	3.0	;	WILD-TYPE UMUD' FROM E. COLI
1SSP	;	1.9	;	WILD-TYPE URACIL-DNA GLYCOSYLASE BOUND TO URACIL-CONTAINING DNA
7R9F	;	2.89	;	Wild-type yeast Pseudouridine Synthase, PUS1, bound to 5-Fluorouracil RNA
6GH7	;	1.08	;	WILDTYPE CORE-STREPTAVIDIN WITH a conjugated BIOTINYLATED PYRROLIDINE
7NLV	;	1.29	;	WILDTYPE CORE-STREPTAVIDIN WITH a conjugated BIOTINYLATED PYRROLIDINE II
1MK5	;	1.4	;	Wildtype Core-Streptavidin with Biotin at 1.4A.
6KEU	;	1.99	;	Wildtype E53, a microbial HSL esterase
2DG3	;	1.7	;	Wildtype FK506-binding protein complexed with Rapamycin
6HN3	;	1.01	;	wildtype form (apo) of human GPX4 with Se-Cys46
6DTX	;	3.327	;	Wildtype HIV-1 Reverse Transcriptase in complex with JLJ 578
7PRX	;	2.2	;	wildtype ligand binding domain of the glucocorticoid receptor complexed with velsecorat and a PGC1a coactivator fragment
8G65	;	1.45	;	Wildtype PTP1b in complex with DES4799
8G67	;	1.53	;	Wildtype PTP1b in complex with DES4884
8G68	;	1.82	;	Wildtype PTP1b in complex with DES5742
8G69	;	1.53	;	Wildtype PTP1b in complex with DES5743
8G6A	;	1.62	;	Wildtype PTP1b in complex with DES6016
8FHI	;	3.25	;	Wildtype rabbit TRPV5 in nanodiscs in complex with oleoyl coenzyme A, Open stated
8FHH	;	3.09	;	Wildtype rabbit TRPV5 in nanodiscs in the presence of oleoyl coenzyme A, Closed stated
8TF2	;	2.57	;	Wildtype rabbit TRPV5 into nanodiscs in Apo state
8TF3	;	2.94	;	Wildtype rabbit TRPV5 into nanodiscs in complex with econazole
8TF4	;	2.86	;	Wildtype rabbit TRPV5 into nanodiscs in the presence of PI(4,5)P2 and econazole
8FFQ	;	2.65	;	Wildtype rabbit TRPV5 into nanodiscs in the presence of PI(4,5)P2 and ruthenium red
8FFL	;	3.47	;	Wildtype rat TRPV2 in nanodiscs bound to RR
8FFM	;	2.9	;	Wildtype rat TRPV2 in nanodiscs bound to RR and 2-APB
1M01	;	2.1	;	Wildtype Streptomyces plicatus beta-hexosaminidase in complex with product (GlcNAc)
1WBJ	;	1.5	;	wildtype tryptophan synthase complexed with glycerol phosphate
7QCC	;		;	Williams-Beuren syndrome related methyltransferase WBSCR27 in apo-form
7QCB	;		;	Williams-Beuren syndrome related methyltransferase WBSCR27 in complex with SAH
1WKT	;		;	WILLIOPSIS MRAKII KILLER TOXIN, NMR SOLUTION STRUCTURE
4R2S	;	2.489	;	Wilms Tumor Protein (WT1) Q369P zinc fingers in complex with methylated DNA
5KL6	;	1.641	;	Wilms Tumor Protein (WT1) Q369R ZnF2-4 in complex with DNA
4R2R	;	2.089	;	Wilms Tumor Protein (WT1) zinc fingers in complex with carboxylated DNA
4R2Q	;	1.54	;	Wilms Tumor Protein (WT1) zinc fingers in complex with formylated DNA
4R2P	;	1.788	;	Wilms Tumor Protein (WT1) zinc fingers in complex with hydroxymethylated DNA
4R2E	;	1.84	;	Wilms Tumor Protein (WT1) zinc fingers in complex with methylated DNA
5KL2	;	1.692	;	Wilms Tumor Protein (WT1) ZnF2-4 in complex with DNA
5KL5	;	2.289	;	Wilms Tumor Protein (WT1) ZnF2-4 Q369H in complex with carboxylated DNA
5KL3	;	1.449	;	Wilms Tumor Protein (WT1) ZnF2-4 Q369H in complex with DNA
5KL4	;	1.783	;	Wilms Tumor Protein (WT1) ZnF2-4 Q369H in complex with formylated DNA
5KL7	;	1.579	;	Wilms Tumor Protein (WT1) ZnF2-4Q369R in complex with carboxylated DNA
1F9K	;	3.0	;	WINGED BEAN ACIDIC LECTIN COMPLEXED WITH METHYL-ALPHA-D-GALACTOSE
1FAY	;	3.3	;	WINGED BEAN ACIDIC LECTIN COMPLEXED WITH METHYL-ALPHA-D-GALACTOSE (MONOCLINIC FORM)
1WBA	;	1.8	;	WINGED BEAN ALBUMIN 1
1WBL	;	2.5	;	WINGED BEAN LECTIN COMPLEXED WITH METHYL-ALPHA-D-GALACTOSE
1WBF	;	2.3	;	WINGED BEAN LECTIN, SACCHARIDE FREE FORM
6S2D	;		;	Winter flounder 1 in SDS micelles
6RYQ	;		;	Winter flounder 1a in SDS micelles
6RY9	;		;	Winter flounder 1a-1 in SDS micelles
6RZ1	;		;	Winter flounder 3 in SDS micelles
6RZC	;		;	Winter flounder 4 in SDS micelles
1WFA	;	1.7	;	WINTER FLOUNDER ANTIFREEZE PROTEIN ISOFORM HPLC6 AT 4 DEGREES C
1WFB	;	1.5	;	WINTER FLOUNDER ANTIFREEZE PROTEIN ISOFORM HPLC6 AT-180 DEGREES C
5KXB	;	2.33	;	Wisteria floribunda lectin in complex with GalNAc
5KXE	;	2.09	;	Wisteria floribunda lectin in complex with GalNAc(beta1-4)GlcNAc (LacdiNAc) at pH 4.2
5KXD	;	1.95	;	Wisteria floribunda lectin in complex with GalNAc(beta1-4)GlcNAc (LacdiNAc) at pH 6.5
5KXC	;	1.8	;	Wisteria floribunda lectin in complex with GalNAc(beta1-4)GlcNAc (LacdiNAc) at pH 8.5.
4Q2A	;	3.5	;	WNK1: A chloride sensor via autophosphorylation
6L8M	;		;	WNT DNA promoter mutant G-quadruplex
5FWS	;	1.9	;	Wnt modulator Kremen crystal form I at 1.90A
5FWT	;	2.1	;	Wnt modulator Kremen crystal form I at 2.10A
5FWU	;	2.8	;	Wnt modulator Kremen crystal form II at 2.8A
5FWV	;	3.2	;	Wnt modulator Kremen crystal form III at 3.2A
5FWW	;	3.5	;	Wnt modulator Kremen in complex with DKK1 (CRD2) and LRP6 (PE3PE4)
6AHY	;	2.8	;	Wnt signaling complex
6GBI	;	1.25	;	Wnt signalling
7E4K	;	2.69	;	WNV envelope protein
5NXT	;	1.379	;	Wobble base paired RNA double helix
8F0N	;	2.85	;	Wobble Beetroot (A16U-U38G) dimer bound to DFHO
6SYH	;	1.5	;	Wolinella succinogenes L-asparaginase mutant V23Q,K24T in P 22121
6RUE	;	1.65	;	Wolinella succinogenes L-asparaginase mutant V23Q,K24T with L-Asp
6RUF	;	2.0	;	Wolinella succinogenes L-asparaginase mutant V23Q,K24T with L-Glu
6RUD	;	1.7	;	WOLINELLA SUCCINOGENES L-ASPARAGINASE P1
5K45	;	1.63	;	Wolinella succinogenes L-asparaginase P121 + L-Glutamic acid
5K3O	;	1.696	;	Wolinella succinogenes L-asparaginase P121 and L-Aspartic acid
5K4G	;	1.6	;	Wolinella succinogenes L-asparaginase S121 + L-aspartic acid, open conformation
5K4H	;	2.0	;	Wolinella succinogenes L-asparaginase S121 + L-Glutamic acid
4RKM	;	2.2	;	Wolinella succinogenes octaheme sulfite reductase MccA, form I
4RKN	;	2.1	;	Wolinella succinogenes octaheme sulfite reductase MccA, form II
7TUL	;	6.5	;	Woodchuck hepatitis small surface protein without cytosolic and antigenic loops
6X1O	;	2.094	;	WOR5 from Pyrococcus furiosus, as crystallized
6X6U	;	1.944	;	WOR5 from Pyrococcus furiosus, taurine-bound
3B6K	;	1.99	;	WrbA from Escherichia coli, Benzoquinone complex
3B6J	;	2.05	;	WrbA from Escherichia coli, NADH complex
3B6I	;	1.66	;	WrbA from Escherichia coli, native structure
3B6M	;	1.85	;	WrbA from Escherichia coli, second crystal form
5F12	;	1.5	;	WrbA in complex with FMN under crystallization conditions of WrbA-FMN-BQ structure (4YQE)
2FBT	;	2.05	;	WRN exonuclease
2FBY	;	2.0	;	WRN exonuclease, Eu complex
2FBX	;	2.2	;	WRN exonuclease, Mg complex
2FBV	;	2.4	;	WRN exonuclease, Mn complex
2FC0	;	2.0	;	WRN exonuclease, Mn dGMP complex
2LKG	;		;	WSA major conformation
2LKH	;		;	WSA minor conformation
1F62	;		;	WSTF-PHD
7LKF	;	2.9	;	WT Chicken Scap L1-L7 / Fab 4G10 complex focused refinement
5UE9	;	2.72	;	WT DHODB with orotate bound
5F5Y	;	2.196	;	WT Drosophila Melanogaster Cycle PAS-B with Bound Ethylene Glycol
6NBS	;	1.9	;	WT ERK2 with compound 2507-8
7PZN	;	3.2	;	wt HBc capsid like particles in complex with inhibitory peptide SLLGRM and Triton X-100
6HTX	;	2.66	;	WT Hepatitis B core protein capsid
6W6T	;	1.84	;	WT HIV-1 Protease in Complex with Phosphonated UMass6 (PU6)
6W6Q	;	2.1	;	WT HTLV-1 Protease in Complex with Darunavir (DRV)
6W6S	;	2.29	;	WT HTLV-1 Protease in Complex with Phosphonated UMass6 (PU6)
6W6R	;	2.05	;	WT HTLV-1 Protease in Complex with UMass6 (UM6)
1YFH	;	3.01	;	wt Human O6-Alkylguanine-DNA Alkyltransferase Bound To DNA Containing an Alkylated Cytosine
6B8O	;	2.2	;	WT Ig-like V Domain with Phosphatidylserine
2W2N	;	2.3	;	WT PCSK9-deltaC bound to EGF-A H306Y mutant of LDLR
2W2M	;	2.4	;	WT PCSK9-DELTAC BOUND TO WT EGF-A OF LDLR
6X32	;	3.8	;	Wt pig RyR1 in complex with apoCaM, EGTA condition (class 1 and 2, closed)
6X33	;	4.2	;	Wt pig RyR1 in complex with apoCaM, EGTA condition (class 3, open)
4WB4	;	2.03	;	wt SA11 NSP4_CCD
7A90	;	3.185	;	WT STING in complex with 3',3'-c-di[2'FdAM(PS)]
6E02	;	1.76	;	WT swMb-MeNO
7E7S	;	3.3	;	WT transporter state1
8RF0	;	3.4	;	WT-CGS sample in nanodisc
5N2W	;	2.68	;	WT-Parkin and pUB complex
8TUS	;	2.6	;	WU Polyomavirus LTA NLS bound to importin alpha 2
6RYI	;	2.691	;	WUS-HD bound to G-Box DNA
6RYL	;	2.63	;	WUS-HD bound to TAAT DNA
6RYD	;	1.575	;	WUS-HD bound to TGAA DNA
2MPT	;		;	WW3 domain of Nedd4L in complex with its HECT domain PY motif
2OP7	;		;	WW4
6MIW	;	2.0	;	WWE domain of human HUWE1
6J1X	;	2.3	;	WWP1 close conformation
6J1Z	;	2.7	;	WWP2 semi-open conformation
7NHS	;	2.3	;	Wzc K540M C8
7NII	;	2.88	;	Wzc-K540M MgADP C1
7NIH	;	2.6	;	Wzc-K540M MgADP C8
7NIB	;	3.51	;	Wzc-K540M-4YE C1
7NI2	;	2.89	;	Wzc-K540M-4YE C8
2YNK	;	2.64	;	Wzi, an Outer Membrane Protein Involved in Group 1 Capsule Assembly in Escherichia coli, is a Carbohydrate Binding Beta-Barrel
5NBZ	;	9.0	;	Wzz dodecamer fitted by MDFF to the Wzz experimental map from cryo-EM
2RAO	;	2.0	;	X ray crystal structure of rabbit hemoglobin (oxy form) at 2.0 angstrom resolution
2W0H	;	3.0	;	X ray structure of Leishmania infantum Trypanothione reductase in complex with antimony and NADPH
2IT4	;	2.0	;	X ray structure of the complex between Carbonic Anhydrase I and the phosphonate antiviral drug foscarnet
3FFP	;	1.81	;	X ray structure of the complex between carbonic anhydrase II and LC inhibitors
5UXS	;	1.421	;	X ray structure of the periplasmic ligand binding protein YfeA from Yersinia pestis
4ARH	;	2.3	;	X ray structure of the periplasmic zinc binding protein ZinT from Salmonella enterica
2Y6J	;	1.7	;	X-2 engineered mutated CBM4-2 Carbohydrate Binding Module from a Thermostable Rhodothermus marinus Xylanase
2Y6H	;	1.08	;	X-2 L110F CBM4-2 Carbohydrate Binding Module from a Thermostable Rhodothermus marinus Xylanase
8G5A	;	3.3	;	X-31 hemagglutinin in complex with FL-1061 Fab
7ZJ7	;	3.95	;	X-31 Hemagglutinin Precursor HA0 at pH 4.8
7ZJ6	;	2.6	;	X-31 Hemagglutinin Precursor HA0 at pH 7.5
7ZJ8	;	3.1	;	X-31 Hemagglutinin Precursor HA0 at pH 7.5 after reneutralization
1IBH	;	2.0	;	X-RAY 3D STRUCTURE OF P.LEIOGNATHI CU,ZN SOD MUTANT M41I
1IBD	;	2.0	;	X-RAY 3D STRUCTURE OF P.LEIOGNATHI CU,ZN SOD MUTANT V29A
1IBF	;	2.2	;	X-RAY 3D STRUCTURE OF P.LEIOGNATHI CU,ZN SOD MUTANT V29G
1IBB	;	2.1	;	X-RAY 3D STRUCTURE OF P.LEIOGNATHI CU,ZN SOD MUTANT W83F
1IB5	;	2.45	;	X-RAY 3D STRUCTURE OF P.LEIOGNATHI CU,ZN SOD MUTANT W83Y
2YZ7	;	2.19	;	X-ray analyses of 3-hydroxybutyrate dehydrogenase from Alcaligenes faecalis
5PEP	;	2.34	;	X-RAY ANALYSES OF ASPARTIC PROTEASES. II. THREE-DIMENSIONAL STRUCTURE OF THE HEXAGONAL CRYSTAL FORM OF PORCINE PEPSIN AT 2.3 ANGSTROMS RESOLUTION
4CMS	;	2.2	;	X-RAY ANALYSES OF ASPARTIC PROTEINASES IV. STRUCTURE AND REFINEMENT AT 2.2 ANGSTROMS RESOLUTION OF BOVINE CHYMOSIN
1ENT	;	1.9	;	X-RAY ANALYSES OF ASPARTIC PROTEINASES. THE THREE-DIMENSIONAL STRUCTURE AT 2.1 ANGSTROMS RESOLUTION OF ENDOTHIAPEPSIN
1MPP	;	2.0	;	X-RAY ANALYSES OF ASPARTIC PROTEINASES. V. STRUCTURE AND REFINEMENT AT 2.0 ANGSTROMS RESOLUTION OF THE ASPARTIC PROTEINASE FROM MUCOR PUSILLUS
2ER7	;	1.6	;	X-RAY ANALYSES OF ASPARTIC PROTEINASES.III. THREE-DIMENSIONAL STRUCTURE OF ENDOTHIAPEPSIN COMPLEXED WITH A TRANSITION-STATE ISOSTERE INHIBITOR OF RENIN AT 1.6 ANGSTROMS RESOLUTION
1VE8	;	1.65	;	X-Ray analyses of oligonucleotides containing 5-formylcytosine, suggesting a structural reason for codon-anticodon recognition of mitochondrial tRNA-Met; Part 1, d(CGCGAATT(f5C)GCG)
1BBS	;	2.8	;	X-RAY ANALYSES OF PEPTIDE INHIBITOR COMPLEXES DEFINE THE STRUCTURAL BASIS OF SPECIFICITY FOR HUMAN AND MOUSE RENINS
1PPT	;	1.37	;	X-RAY ANALYSIS (1.4-ANGSTROMS RESOLUTION) OF AVIAN PANCREATIC POLYPEPTIDE. SMALL GLOBULAR PROTEIN HORMONE
1J8G	;	0.61	;	X-ray Analysis of a RNA Tetraplex r(uggggu)4 at Ultra-High Resolution
2BB2	;	2.1	;	X-RAY ANALYSIS OF BETA B2-CRYSTALLIN AND EVOLUTION OF OLIGOMERIC LENS PROTEINS
3AJ9	;	1.1	;	X-ray analysis of Crystal of Proteinase K Obtained from D2O Solution Using PEG 8000
3AJ8	;	1.1	;	X-ray analysis of Crystal of Proteinase K Obtained from H2O Solution Using PEG 8000
5RNT	;	3.2	;	X-RAY ANALYSIS OF CUBIC CRYSTALS OF THE COMPLEX FORMED BETWEEN RIBONUCLEASE T1 AND GUANOSINE-3',5'-BISPHOSPHATE
8XIA	;	1.9	;	X-RAY ANALYSIS OF D-XYLOSE ISOMERASE AT 1.9 ANGSTROMS: NATIVE ENZYME IN COMPLEX WITH SUBSTRATE AND WITH A MECHANISM-DESIGNED INACTIVATOR
9XIA	;	1.9	;	X-RAY ANALYSIS OF D-XYLOSE ISOMERASE AT 1.9 ANGSTROMS: NATIVE ENZYME IN COMPLEX WITH SUBSTRATE AND WITH A MECHANISM-DESIGNED INACTIVATOR
1GCN	;	3.0	;	X-RAY ANALYSIS OF GLUCAGON AND ITS RELATIONSHIP TO RECEPTOR BINDING
3PHV	;	2.7	;	X-RAY ANALYSIS OF HIV-1 PROTEINASE AT 2.7 ANGSTROMS RESOLUTION CONFIRMS STRUCTURAL HOMOLOGY AMONG RETROVIRAL ENZYMES
3AGG	;	1.6	;	X-ray analysis of lysozyme in the absence of Arg
3AGH	;	1.49	;	X-ray analysis of lysozyme in the presence of 200 mM Arg
1RZA	;	1.9	;	X-RAY ANALYSIS OF METAL SUBSTITUTED HUMAN CARBONIC ANHYDRASE II DERIVATIVES
1RZB	;	1.8	;	X-RAY ANALYSIS OF METAL SUBSTITUTED HUMAN CARBONIC ANHYDRASE II DERIVATIVES
1RZC	;	1.9	;	X-RAY ANALYSIS OF METAL SUBSTITUTED HUMAN CARBONIC ANHYDRASE II DERIVATIVES
1RZD	;	1.9	;	X-RAY ANALYSIS OF METAL SUBSTITUTED HUMAN CARBONIC ANHYDRASE II DERIVATIVES
1RZE	;	1.9	;	X-RAY ANALYSIS OF METAL SUBSTITUTED HUMAN CARBONIC ANHYDRASE II DERIVATIVES
6INS	;	2.0	;	X-RAY ANALYSIS OF THE SINGLE CHAIN B29-A1 PEPTIDE-LINKED INSULIN MOLECULE. A COMPLETELY INACTIVE ANALOGUE
285D	;	2.5	;	X-RAY AND SOLUTION STUDIES OF DNA OLIGOMERS AND IMPLICATIONS FOR THE STRUCTURAL BASIS OF A-TRACT-DEPENDENT CURVATURE
286D	;	2.5	;	X-RAY AND SOLUTION STUDIES OF DNA OLIGOMERS AND IMPLICATIONS FOR THE STRUCTURAL BASIS OF A-TRACT-DEPENDENT CURVATURE
287D	;	2.2	;	X-RAY AND SOLUTION STUDIES OF DNA OLIGOMERS AND IMPLICATIONS FOR THE STRUCTURAL BASIS OF A-TRACT-DEPENDENT CURVATURE
297D	;	2.5	;	X-RAY AND SOLUTION STUDIES OF DNA OLIGOMERS AND IMPLICATIONS FOR THE STRUCTURAL BASIS OF A-TRACT-DEPENDENT CURVATURE
5OVR	;	2.15	;	X-Ray Characterization of Striatal-Enriched Protein Tyrosine Phosphatase Inhibitors
5OVX	;	2.1	;	X-Ray Characterization of Striatal-Enriched Protein Tyrosine Phosphatase Inhibitors
5OW1	;	2.05	;	X-Ray Characterization of Striatal-Enriched Protein Tyrosine Phosphatase Inhibitors
3BYM	;	2.0	;	X-ray co-crystal structure aminobenzimidazole triazine 1 bound to Lck
3BYO	;	2.0	;	X-Ray co-crystal structure of 2-amino-6-phenylpyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-one 25 bound to Lck
6UDT	;	1.5	;	X-ray co-crystal structure of compound 10 bound to human Mcl-1
6UDI	;	1.94	;	X-ray co-crystal structure of compound 20 with Mcl-1
8G8X	;	1.97	;	X-ray co-crystal structure of compound 27 in with complex JAK2
6UDV	;	1.35	;	X-ray co-crystal structure of compound 3 bound to human Mcl-1
6UDY	;	1.7	;	X-ray co-crystal structure of compound 5 with Mcl-1
6UDX	;	1.7	;	X-ray co-crystal structure of compound 7 with Mcl-1
6UDU	;	1.75	;	X-ray co-crystal structure of compound 8 bound to human Mcl-1
3F7Z	;	2.4	;	X-ray Co-Crystal Structure of Glycogen Synthase Kinase 3beta in Complex with an Inhibitor
5BPA	;	1.79	;	X-RAY Co-structure of MMP-13 with 4-[({5-[2-(ethoxycarbonyl)-1H-indol-5-yl]-1-methyl-1H-pyrazol-3-yl}formamido)methyl]benzoate
5BOY	;	2.03	;	X-RAY Co-structure of MMP-13 with ethyl 5-(1-methyl-1H-imidazol-5-yl)-1H-indole-2-Carboxylate
5BOT	;	1.85	;	X-RAY Co-structure of MMP-13 with ethyl 5-carbamoyl-1H-indole-2-carboxylate
4YMQ	;	2.0	;	X-ray co-structure of nuclear receptor ROR-GAMMAT + SRC2 peptide with a benzothiadiazole dioxide inverse agonist
5VQK	;	3.1	;	X-ray co-structure of nuclear receptor ROR-gammat Ligand Binding Domain with a inverse agonist and SRC2 peptide
5VQL	;	2.7	;	X-ray co-structure of nuclear receptor ROR-gammat Ligand Binding Domain with a inverse agonist and SRC2 peptide
5VB7	;	2.335	;	X-ray co-structure of nuclear receptor ROR-gammat Ligand Binding Domain with an agonist and SRC2 peptide
5VB5	;	2.226	;	X-ray co-structure of nuclear receptor ROR-gammat Ligand Binding Domain with an inverse agonist and SRC2 peptide
5VB6	;	2.041	;	X-ray co-structure of nuclear receptor ROR-gammat Ligand Binding Domain with an inverse agonist and SRC2 peptide
5WNE	;	2.6	;	X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR
5WNF	;	2.45	;	X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR
5WNG	;	2.9	;	X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR
5WNH	;	3.1	;	X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR
3NCZ	;	3.0	;	X-Ray Co-structure of Rho-Associated Protein Kinase (ROCK1) with a potent 2H-isoquinolin-1-one inhibitor
7KKU	;	2.02	;	X-ray Counterpart to Neutron Structure of Oxidized Human MnSOD
7KLB	;	2.16	;	X-ray Counterpart to Neutron Structure of Reduced Human MnSOD
3ABG	;	2.3	;	X-ray Crystal Analysis of Bilirubin Oxidase from Myrothecium verrucaria at 2.3 angstrom Resolution using a Twin Crystal
6N1D	;	3.2	;	X-ray Crystal complex showing Spontaneous Ribosomal Translocation of mRNA and tRNAs into a Chimeric Hybrid State
7EHX	;	1.8	;	X-ray crystal strcture of F46C/L49C sperm whale myoglobin with an intramolecular disulfide bond
4YG2	;	3.7	;	X-ray crystal structur of Escherichia coli RNA polymerase sigma70 holoenzyme
3WXA	;	2.36	;	X-ray crystal structural analysis of the complex between ALG-2 and Sec31A peptide
2DC7	;	1.94	;	X-ray crystal structure analysis of bovine spleen cathepsin B-CA042 complex
2DC8	;	1.94	;	X-ray crystal structure analysis of bovine spleen cathepsin B-CA059 complex
2DC6	;	2.3	;	X-ray crystal structure analysis of bovine spleen cathepsin B-CA073 complex
2DC9	;	1.94	;	X-ray crystal structure analysis of bovine spleen cathepsin B-CA074Me complex
2DCA	;	2.11	;	X-ray crystal structure analysis of bovine spleen cathepsin B-CA075 complex
2DCB	;	1.94	;	X-ray crystal structure analysis of bovine spleen cathepsin B-CA076 complex
2DCC	;	1.93	;	X-ray crystal structure analysis of bovine spleen cathepsin B-CA077 complex
2DCD	;	2.5	;	X-ray crystal structure analysis of bovine spleen cathepsin B-CA078 complex
1QQY	;	1.85	;	X-RAY CRYSTAL STRUCTURE ANALYSIS OF CANINE MILK LYSOZYME (APO-TYPE)
1EL1	;	1.9	;	X-RAY CRYSTAL STRUCTURE ANALYSIS OF CANINE MILK LYSOZYME (HOLO-TYPE)
5E4P	;	1.792	;	X-ray Crystal Structure Analysis of Magnetically Oriented Microcrystals of Lysozyme at 1.8 angstrom Resolution
2CWI	;	1.941	;	X-ray crystal structure analysis of recombinant wild-type canine milk lysozyme (apo-type)
2QFK	;	1.62	;	X-ray Crystal Structure Analysis of the Binding Site in the Ferric and Oxyferrous Forms of the Recombinant Heme Dehaloperoxidase Cloned from Amphitrite ornata
2QFN	;	1.62	;	X-ray Crystal Structure Analysis of the Binding Site in the Ferric and Oxyferrous Forms of the Recombinant Heme Dehaloperoxidase Cloned from Amphitrite ornata
1GNP	;	2.7	;	X-RAY CRYSTAL STRUCTURE ANALYSIS OF THE CATALYTIC DOMAIN OF THE ONCOGENE PRODUCT P21H-RAS COMPLEXED WITH CAGED GTP AND MANT DGPPNHP
1GNQ	;	2.5	;	X-RAY CRYSTAL STRUCTURE ANALYSIS OF THE CATALYTIC DOMAIN OF THE ONCOGENE PRODUCT P21H-RAS COMPLEXED WITH CAGED GTP AND MANT DGPPNHP
1GNR	;	1.85	;	X-RAY CRYSTAL STRUCTURE ANALYSIS OF THE CATALYTIC DOMAIN OF THE ONCOGENE PRODUCT P21H-RAS COMPLEXED WITH CAGED GTP AND MANT DGPPNHP
1GEB	;	2.03	;	X-RAY CRYSTAL STRUCTURE AND CATALYTIC PROPERTIES OF THR252ILE MUTANT OF CYTOCHROME P450CAM
4EME	;	2.6	;	X-ray crystal structure and specificity of the Plasmodium falciparum malaria aminopeptidase
5CR5	;	1.61	;	X-RAY CRYSTAL STRUCTURE AT 1.61A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A BIPHENYL PYRROLIDINE ETHER COMPOUND AND AN INTERNAL ALDIMINE LINKED PLP COFACTOR.
5I5X	;	1.65	;	X-RAY CRYSTAL STRUCTURE AT 1.65A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A THIAZOLE COMPOUND AND PMP COFACTOR.
5BWX	;	1.703	;	X-RAY CRYSTAL STRUCTURE AT 1.70A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A 4-CHLORO-2-FLUORO SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUND AND AN INTERNAL ALDIMINE LINKED PLP COFACTOR.
5I5Y	;	1.81	;	X-RAY CRYSTAL STRUCTURE AT 1.81A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH AN ARYL ACETATE COMPOUND AND AN INTERNAL ALDIMINE LINKED PLP COFACTOR.
5BWW	;	1.82	;	X-RAY CRYSTAL STRUCTURE AT 1.82A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A PYRROLIDINE AMIDE COMPOUND AND AN INTERNAL ALDIMINE LINKED PLP COFACTOR.
5BWV	;	1.86	;	X-RAY CRYSTAL STRUCTURE AT 1.86A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A PYRAZOLOPYRIMIDINONE COMPOUND AND AN INTERNAL ALDIMINE LINKED PLP COFACTOR.
5I5V	;	1.94	;	X-RAY CRYSTAL STRUCTURE AT 1.94A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A THIENOPYRIMIDINE COMPOUND AND AN INTERNAL ALDIMINE LINKED PLP COFACTOR.
5I5S	;	2.06	;	X-RAY CRYSTAL STRUCTURE AT 2.06A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A BENZISOXAZOLE COMPOUND AND AN INTERNAL ALDIMINE LINKED PLP COFACTOR.
5I60	;	2.12	;	X-RAY CRYSTAL STRUCTURE AT 2.12A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A BIARL AMIDE COMPOUND AND AN INTERNAL ALDIMINE LINKED PLP COFACTOR.
5BWU	;	2.17	;	X-RAY CRYSTAL STRUCTURE AT 2.17A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A TRIAZOLOPYRIMIDINONE COMPOUND AND AN INTERNAL ALDIMINE LINKED PLP COFACTOR.
5BWR	;	2.2	;	X-RAY CRYSTAL STRUCTURE AT 2.20A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A PYRAZOLOPYRIMIDINONE FRAGMENT AND AN INTERNAL ALDIMINE LINKED PLP.
5BWT	;	2.2	;	X-RAY CRYSTAL STRUCTURE AT 2.20A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A PYRAZOLOPYRIMIDINONE FRAGMENT AND AN INTERNAL ALDIMINE LINKED PLP.
5I5T	;	2.31	;	X-RAY CRYSTAL STRUCTURE AT 2.31A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A TETRAHYDROQUINOLINE COMPOUND AND AN INTERNAL ALDIMINE LINKED PLP COFACTOR.
5I5W	;	2.4	;	X-RAY CRYSTAL STRUCTURE AT 2.40A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A BIARYL AMIDE COMPOUND AND AN INTERNAL ALDIMINE LINKED PLP COFACTOR.
5I5U	;	2.404	;	X-RAY CRYSTAL STRUCTURE AT 2.40A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A TETRAHYDRONAPHTHALENYL COMPOUND AND AN INTERNAL ALDIMINE LINKED PLP COFACTOR.
1EQB	;	2.7	;	X-RAY CRYSTAL STRUCTURE AT 2.7 ANGSTROMS RESOLUTION OF TERNARY COMPLEX BETWEEN THE Y65F MUTANT OF E-COLI SERINE HYDROXYMETHYLTRANSFERASE, GLYCINE AND 5-FORMYL TETRAHYDROFOLATE
1LOE	;	1.9	;	X-RAY CRYSTAL STRUCTURE DETERMINATION AND REFINEMENT AT 1.9 ANGSTROMS RESOLUTION OF ISOLECTIN I FROM THE SEEDS OF LATHYRUS OCHRUS
3KYU	;	1.1	;	X-ray crystal structure determination of fully perdeuterated rubredoxin at 100K
1EM1	;	2.13	;	X-RAY CRYSTAL STRUCTURE FOR HUMAN MANGANESE SUPEROXIDE DISMUTASE, Q143A
5U6V	;	1.775	;	X-ray crystal structure of 1,2,3-triazolobenzodiazepine in complex with BRD2(D2)
3MDL	;	2.2	;	X-ray crystal structure of 1-arachidonoyl glycerol bound to the cyclooxygenase channel of cyclooxygenase-2
3OLU	;	2.35	;	X-ray crystal structure of 1-arachidonoyl glycerol bound to the cyclooxygenase channel of R513H murine COX-2
4ZN6	;	2.05	;	X-ray Crystal Structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase (IspC) from Acinetobacter baumannii
8K14	;	1.28	;	X-ray crystal structure of 18a in BRD4(1)
4N71	;	2.984	;	X-Ray Crystal Structure of 2-amino-1-hydroxyethylphosphonate-bound PhnZ
4U3W	;	1.9501	;	X-ray crystal structure of 2-aminomuconate 6-semialdehyde dehydrogenase from Burkholderia cenocepacia
2OFU	;	2.0	;	x-ray crystal structure of 2-aminopyrimidine carbamate 43 bound to Lck
4DH0	;	2.1	;	X-ray Crystal Structure of 28-O-Methylrapamycin complexed with FKBP12: Is the Cyclohexyl Moiety Part of the Effector Domain of Rapamycin?
6IE0	;	2.976	;	X-ray crystal structure of 2R,3R-butanediol dehydrogenase from Bacillus subtilis
4JGA	;	2.1	;	X-ray crystal structure of 3-oxoacyl-[acyl-carrier-protein] synthase 2 from Rickettsia rickettsii
8EKF	;	1.9	;	X-ray crystal structure of 311R Fab in complex with the PfCSP peptide NPNA-3
1LO8	;	1.8	;	X-ray crystal structure of 4-hydroxybenzoyl CoA thioesterase complexed with 4-hydroxybenzyl CoA
1LO9	;	2.8	;	X-ray crystal structure of 4-hydroxybenzoyl CoA thioesterase mutant D17N complexed with 4-hydroxybenzoyl CoA
2C5B	;	2.5	;	X-ray crystal structure of 5'-fluorodeoxyadenosine synthase from Streptomyces cattleya complexed with 2'deoxy-5'deoxy-fluoroadenosine.
2C5H	;	2.7	;	X-ray crystal structure of 5'-fluorodeoxyadenosine synthase from Streptomyces cattleya complexed with 2'deoxy-adenosine
2V7V	;	1.94	;	X-ray crystal structure of 5'-fluorodeoxyadenosine synthase from streptomyces cattleya complexed with 5'-fluorodeoxyadenosine
2CC2	;	2.0	;	X-ray crystal structure of 5'-fluorodeoxyadenosine synthase from Streptomyces cattleya complexed with 5'deoxyadenosine
2C4T	;	2.3	;	X-ray crystal structure of 5'-fluorodeoxyadenosine synthase from Streptomyces cattleya complexed with an inhibitor, an analogue of S- adenosyl methionine
2CBX	;	2.0	;	X-ray crystal structure of 5'-fluorodeoxyadenosine synthase from Streptomyces cattleya complexed with beta-D-erythrofuranosyl- adenosine
2V7X	;	1.96	;	X-RAY CRYSTAL STRUCTURE OF 5'-FLUORODEOXYADENOSINE SYNTHASE S158A mutant FROM STREPTOMYCES CATTLEYA COMPLEXED WITH the PRODUCTS, FDA and Met
2V7W	;	1.9	;	X-ray crystal structure of 5'-fluorodeoxyadenosine synthase s158g mutant complexed with 5'-fluorodeoxyadenosin
2V7T	;	2.15	;	X-ray crystal structure of 5'-fluorodeoxyadenosine synthase s158g mutant complexed with s-adenosyl-l-homocysteine and chloride ion
2V7U	;	2.0	;	X-ray crystal structure of 5'-fluorodeoxyadenosine synthase s158g mutant complexed with s-adenosylmethionine and chloride ion
4PFZ	;	1.8	;	X-ray Crystal Structure of 5-carboxymethyl-2-hydroxymuconate delta-isomerase from Mycobacterium smegmatis
5B8F	;	1.45	;	X-ray Crystal Structure of a 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Pseudomonas aeruginosa
4O5O	;	1.4	;	X-ray Crystal Structure of a 3-hydroxyacyl-CoA dehydrogenase from Brucella suis
4JQP	;	1.65	;	X-ray crystal structure of a 4-hydroxythreonine-4-phosphate dehydrogenase from Burkholderia phymatum
5BNT	;	2.1	;	X-ray Crystal Structure of a Aspartate-semialdehyde dehydrogenase bound to NADP from Pseudomonas aeruginosa
6P71	;	2.92	;	X-ray crystal structure of a bacterial reiterative transcription complex of pyrBI promoter
5VO8	;	3.3	;	X-ray crystal structure of a bacterial reiterative transcription complex of pyrG promoter
6OY5	;	3.1	;	X-ray crystal structure of a bacterial reiterative transcription complex of pyrG promoter at 3 min
6OY6	;	3.096	;	X-ray crystal structure of a bacterial reiterative transcription complex of pyrG promoter at 5 min
6OY7	;	3.04	;	X-ray crystal structure of a bacterial reiterative transcription complex of pyrG promoter at 7 min
6OVY	;	2.999	;	X-ray crystal structure of a bacterial reiterative transcription complex of pyrG promoter variant -1C
6OVR	;	2.843	;	X-ray crystal structure of a bacterial reiterative transcription complex of pyrG promoter variant -1G
6OW3	;	2.766	;	X-ray crystal structure of a bacterial reiterative transcription complex of pyrG promoter variant -1T
1YIW	;	1.39	;	X-ray Crystal Structure of a Chemically Synthesized Ubiquitin
2FCQ	;	3.3	;	X-ray Crystal Structure of a Chemically Synthesized Ubiquitin with a Cubic Space Group
1YJ1	;	1.3	;	X-ray Crystal Structure of a Chemically Synthesized [D-Gln35]Ubiquitin
2FCM	;	2.2	;	X-ray Crystal Structure of a Chemically Synthesized [D-Gln35]Ubiquitin with a Cubic Space Group
2FCN	;	2.2	;	X-ray Crystal Structure of a Chemically Synthesized [D-Val35]Ubiquitin with a Cubic Space Group
2FCS	;	1.8	;	X-ray Crystal Structure of a Chemically Synthesized [L-Gln35]Ubiquitin with a Cubic Space Group
2JH2	;	2.5	;	X-ray crystal structure of a cohesin-like module from Clostridium perfringens
1S6B	;	1.6	;	X-ray Crystal Structure of a Complex Formed Between Two Homologous Isoforms of Phospholipase A2 from Naja naja sagittifera: Principle of Molecular Association and Inactivation
5BXW	;	2.15	;	X-ray crystal structure of a continuously hydrogen bonded 14mer DNA lattice.
5BZ7	;	2.03	;	X-ray crystal structure of a continuously hydrogen bonded 14mer DNA lattice.
5BZ9	;	2.1	;	X-ray crystal structure of a continuously hydrogen bonded 14mer DNA lattice.
5BZY	;	2.4	;	X-ray crystal structure of a continuously hydrogen bonded 14mer DNA lattice.
2ZOP	;	2.1	;	X-ray crystal structure of a CRISPR-associated Cmr5 family protein from Thermus thermophilus HB8
7LIB	;	1.1	;	X-ray crystal structure of a cyclic peptide containing beta-2-microglobulin (63-69) and a gamma-methylornithine turn unit
7JRH	;	1.32	;	X-ray crystal structure of a cyclic peptide containing medin(19-25) and medin(31-37)
4TM5	;	1.603	;	X-ray crystal structure of a D-amino acid aminotransferase from Burkholderia thailandensis E264 bound to the co-factor pyridoxal phosphate
3KEV	;	1.3	;	X-ray crystal structure of a DCUN1 domain-containing protein from Galdieria sulfuraria
8A3J	;	2.1	;	X-ray crystal structure of a de novo designed antiparallel coiled-coil heterotetramer with 3 heptad repeats, apCC-Tet*3-A2B2
8A3I	;	1.42	;	X-ray crystal structure of a de novo designed antiparallel coiled-coil homotetramer with 3 heptad repeats, apCC-Tet*3
8A3G	;	0.96	;	X-ray crystal structure of a de novo designed antiparallel coiled-coil homotetramer with 4 heptad repeats, apCC-Tet*
8BCS	;	2.1	;	X-ray crystal structure of a de novo designed helix-loop-helix homodimer in an anti arrangement, CC-HP1.0
8A3K	;	2.0	;	X-ray crystal structure of a de novo designed single-chain antiparallel 4-helix coiled-coil bundle, sc-apCC-4
8BCT	;	1.7	;	X-ray crystal structure of a de novo selected helix-loop-helix heterodimer in a syn arrangement, 26alpha/26beta
4HFJ	;	2.0	;	X-ray Crystal Structure of a Double Bond Reductase from Nicotiana tabacum
5DC2	;	2.182	;	X-RAY CRYSTAL STRUCTURE OF A ENZYMATICALLY DEGRADED BIAPENEM-ADDUCT OF L,D-TRANSPEPTIDASE 2 FROM MYCOBACTERIUM TUBERCULOSIS
5KVR	;	1.36	;	X-Ray Crystal Structure of a Fragment (1-75) of a Transcriptional Regulator PdhR from Escherichia coli CFT073
4K9D	;	2.1	;	X-ray crystal structure of a Glyceraldehyde 3-phosphate dehydrogenase from Brugia malayi bound to the co-factor NAD
4K0J	;	3.0	;	X-ray crystal structure of a heavy metal efflux pump, crystal form I
4K0E	;	3.713	;	X-ray crystal structure of a heavy metal efflux pump, crystal form II
3P4G	;	1.7	;	X-ray crystal structure of a hyperactive, Ca2+-dependent, beta-helical antifreeze protein from an Antarctic bacterium
4DZ4	;	1.7	;	X-ray crystal structure of a hypothetical Agmatinase from Burkholderia thailandensis
4GK6	;	1.65	;	X-ray crystal structure of a hypothetical deoxyuridine 5-triphosphate nucleotidohydrolase from Mycobacterium abscessus
3ZRS	;	3.05	;	X-ray crystal structure of a KirBac potassium channel highlights a mechanism of channel opening at the bundle-crossing gate.
5TJR	;	2.95	;	X-ray Crystal structure of a methylmalonate semialdehyde dehydrogenase from Pseudomonas sp. AAC
3CO3	;	2.16	;	X-Ray Crystal Structure of a Monofunctional Platinum-DNA Adduct, cis-{Pt(NH3)2(pyridine)}2+ Bound to Deoxyguanosine in a Dodecamer Duplex
3Q69	;	2.4	;	X-ray crystal structure of a MucBP domain of the protein LBA1460 from Lactobacillus acidophilus, Northeast structural genomics consortium target LaR80A
8JJM	;	1.8	;	X-ray crystal structure of a multifunctional enzyme (Amy63) from Vibrio alginolyticus 63
1Z3L	;	1.8	;	X-Ray Crystal Structure of a Mutant Ribonuclease S (F8Anb)
1Z3P	;	2.0	;	X-Ray crystal structure of a mutant Ribonuclease S (M13Nva)
4HFM	;	1.9	;	X-ray Crystal Structure of a NADP(H)-bound Double Bond Reductase from Nicotiana tabacum
4WSO	;	2.05	;	X-ray crystal structure of a nicotinate nucleotide adenylyltransferase from Burkholderia thailandensis bound to NAD
1UWW	;	1.4	;	X-ray crystal structure of a non-crystalline cellulose specific carbohydrate-binding module: CBM28.
5T79	;	1.86	;	X-Ray Crystal Structure of a Novel Aldo-keto Reductases for the Biocatalytic Conversion of 3-hydroxybutanal to 1,3-butanediol
3UE7	;	1.08	;	X-ray crystal structure of a novel topological analogue of crambin
5ONG	;	2.797	;	X-Ray crystal structure of a nucleosome core particle with its DNA site-specifically crosslinked to the histone octamer
5ONW	;	2.8	;	X-Ray crystal structure of a nucleosome core particle with its DNA site-specifically crosslinked to the histone octamer and the two H2A/H2B dimers crosslinked via H2A N38C
1RIN	;	2.6	;	X-RAY CRYSTAL STRUCTURE OF A PEA LECTIN-TRIMANNOSIDE COMPLEX AT 2.6 ANGSTROMS RESOLUTION
4GL8	;	2.2	;	X-ray crystal structure of a periplasmic oligopeptide-binding protein/Oligopeptide ABC transporter(OppAIV) from Borrelia burgdorferi
2NYV	;	2.103	;	X-ray crystal structure of a phosphoglycolate phosphatase from Aquifex aeolicus
3L0E	;	2.3	;	X-ray crystal structure of a Potent Liver X Receptor Modulator
4K6F	;	1.5	;	X-ray crystal structure of a putative Acetoacetyl-CoA reductase from Burkholderia cenocepacia bound to the co-factor NADP
4K6C	;	1.85	;	X-ray crystal structure of a putative Acetoacyl-CoA reductase from Burkholderia cenocepacia
4WJB	;	1.95	;	X-ray crystal structure of a putative amidohydrolase/peptidase from Burkholderia cenocepacia
4X00	;	1.38	;	X-ray crystal structure of a putative aryl esterase from Burkholderia cenocepacia
4IV5	;	2.1	;	X-ray crystal structure of a putative aspartate carbamoyltransferase from Trypanosoma cruzi
4PBC	;	1.8	;	X-ray crystal structure of a putative D-amino acid aminotransferase from Burkholderia cenocepacia
4Y0E	;	1.9	;	X-ray Crystal Structure of a putative dioxygenase from Mycobacterium abscessus
4OSE	;	2.4	;	X-ray Crystal Structure of a Putative Hydrolase from Rickettsia typhi
4JG9	;	2.425	;	X-ray Crystal Structure of a Putative Lipoprotein from Bacillus anthracis
4O5H	;	2.0	;	X-ray crystal structure of a putative phenylacetaldehyde dehydrogenase from Burkholderia cenocepacia
4GD5	;	1.7	;	X-ray Crystal Structure of a Putative Phosphate ABC Transporter Substrate-Binding Protein with Bound Phosphate from Clostridium perfringens
4F82	;	1.85	;	X-ray crystal structure of a putative thioredoxin reductase from Burkholderia cenocepacia
4LC3	;	1.6	;	X-ray crystal structure of a putative UDP-4-amino-4-deoxy-l-arabinose--oxoglutarate aminotransferase from Burkholderia cenocepacia
5DLC	;	2.65	;	X-ray Crystal Structure of a Pyridoxine 5-prime-phosphate synthase from Pseudomonas aeruginosa
4MSO	;	1.4	;	X-ray crystal structure of a serine hydroxymethyl transferase in apo form from Burkholderia cenocepacia
4N0W	;	1.65	;	X-ray crystal structure of a serine hydroxymethyltransferase from Burkholderia cenocepacia with covalently attached pyridoxal phosphate
4J5U	;	1.7	;	X-ray crystal structure of a serine hydroxymethyltransferase with covalently bound PLP from Rickettsia rickettsii str. Sheila Smith
3ND0	;	3.2	;	X-ray crystal structure of a slow cyanobacterial Cl-/H+ antiporter
5DCC	;	2.451	;	X-RAY CRYSTAL STRUCTURE OF a TEBIPENEM ADDUCT OF L,D TRANSPEPTIDASE 2 FROM MYCOBACTERIUM TUBERCULOSIS
4HFN	;	2.1	;	X-ray Crystal Structure of a Ternary Complex of Double Bond Reductase from Nicotiana tabacum
5F0V	;	1.8	;	X-ray crystal structure of a thiolase from Escherichia coli at 1.8 A resolution
5F38	;	1.9	;	X-ray crystal structure of a thiolase from Escherichia coli at 1.8 A resolution
3EUT	;	2.0	;	X-ray crystal structure of a type III pentaketide synthase from Neurospora crassa
3KDZ	;	2.2	;	X-ray crystal structure of a tyrosine aminomutase mutant construct with bound ligand
5LSV	;	1.1	;	X-ray crystal structure of AA13 LPMO
5T7J	;	1.65	;	X-ray crystal structure of AA13 LPMO
5T7K	;	1.3	;	X-ray crystal structure of AA13 LPMO
5T7N	;	1.6	;	X-ray crystal structure of AA13 LPMO
5J5I	;	2.326	;	X-Ray Crystal Structure of Acetylcholine Binding Protein (AChBP) in Complex with 4-(2-amino-6-{bis[(pyridin-2-yl)methyl]amino}pyrimidin-4-yl)phenol
5J5G	;	2.036	;	X-Ray Crystal Structure of Acetylcholine Binding Protein (AChBP) in Complex with 6-(4-methoxyphenyl)-N4,N4-bis[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine
5J5F	;	2.04	;	X-Ray Crystal Structure of Acetylcholine Binding Protein (AChBP) in Complex with N4,N4-bis[(pyridin-2-yl)methyl]-6-(thiophen-3-yl)pyrimidine-2,4-diamine
2RDD	;	3.5	;	X-ray crystal structure of AcrB in complex with a novel transmembrane helix.
8CUP	;	1.54	;	X-ray crystal structure of ADC-33 in complex with sulfonamidoboronic acid 6d
8CUQ	;	1.55	;	X-ray crystal structure of ADC-33 in complex with sulfonamidoboronic acid 6e
4NSL	;	3.0	;	X-ray Crystal structure of Adenylosuccinate Lyase from Salmonella typhimurium
8DTS	;	0.75	;	X-ray crystal structure of AFSSFN from chaperone DNAJB8.
8DQ3	;	1.67	;	X-ray crystal structure of Aggregatibacter actinomycetemcomitans dimanganese(II) class Id ribonucleotide reductase beta subunit
5FR3	;	1.935	;	X-ray crystal structure of aggregation-resistant protective antigen of Bacillus anthracis (mutant S559L T576E)
1T9K	;	2.6	;	X-ray crystal structure of aIF-2B alpha subunit-related translation initiation factor [Thermotoga maritima]
4X8Q	;	1.729	;	X-ray crystal structure of AlkD2 from Streptococcus mutans
5I5C	;	1.3	;	X-ray crystal structure of allo-Thr31-ShK
4F0U	;	2.5	;	X-Ray Crystal Structure of Allophycocyanin from Synechococcus elongatus PCC 7942
5XNE	;	1.501	;	X-ray Crystal Structure of alpha-acetolactate decarboxylase from Bacillus subtilis strain 168
1TZF	;	2.1	;	X-ray Crystal Structure of alpha-D-glucose-1-phosphate cytidylyltransferase from Salmonella typhi
4E1G	;	2.1	;	X-ray crystal structure of alpha-linolenic acid bound to the cyclooxygenase channel of cyclooxygenase-2
3F7L	;	0.99	;	X-ray Crystal Structure of Alvinella pompejana Cu,Zn Superoxide Dismutase
1SUJ	;	2.38	;	X-ray crystal structure of ambystoma tigrinum cone arrestin
1CLI	;	2.5	;	X-RAY CRYSTAL STRUCTURE OF AMINOIMIDAZOLE RIBONUCLEOTIDE SYNTHETASE (PURM), FROM THE E. COLI PURINE BIOSYNTHETIC PATHWAY, AT 2.5 A RESOLUTION
5EZV	;	2.99	;	X-ray crystal structure of AMP-activated protein kinase alpha-2/alpha-1 RIM chimaera (alpha-2(1-347)/alpha-1(349-401)/alpha-2(397-end) beta-1 gamma-1) co-crystallized with C2 (5-(5-hydroxyl-isoxazol-3-yl)-furan-2-phosphonic acid)
2ZJ9	;	1.7	;	X-ray crystal structure of AmpC beta-Lactamase (AmpC(D)) from an Escherichia coli with a Tripeptide Deletion (Gly286 Ser287 Asp288) on the H10 Helix
1KE4	;	1.72	;	X-ray crystal structure of AmpC beta-lactamase from E. coli
1L2S	;	1.94	;	X-ray crystal structure of AmpC beta-lactamase from E. coli in complex with a DOCK-predicted non-covalent inhibitor
4JXS	;	1.9	;	X-ray crystal structure of AmpC beta-lactamase from E. coli in complex with a non-covalent inhibitor 3-[(4-CARBOXYBENZYL)SULFAMOYL]THIOPHENE-2-CARBOXYLIC ACID (compound 4)
4JXV	;	1.76	;	X-ray crystal structure of AmpC beta-lactamase from E. coli in complex with a non-covalent inhibitor 3-{[2-(4-CARBOXYPHENYL)ETHYL]SULFAMOYL}THIOPHENE-2-CARBOXYLIC ACID (compound 5)
4JXW	;	2.3	;	X-ray crystal structure of AmpC beta-lactamase from E. coli in complex with a non-covalent inhibitor 3-{[3-(4-CARBOXYPHENYL)PROPYL]SULFAMOYL}THIOPHENE-2-CARBOXYLIC ACID (compound 6)
1KDS	;	2.15	;	X-ray crystal structure of AmpC beta-lactamase from E. coli in complex with the inhibitor 3-nitrophenylboronic acid
1KE3	;	2.15	;	X-ray crystal structure of AmpC beta-lactamase from E. coli in complex with the inhibitor 4,4'-biphenyldiboronic acid
1KE0	;	2.3	;	X-ray crystal structure of AmpC beta-lactamase from E. coli in complex with the inhibitor 4-(carboxyvin-2-yl)phenylboronic acid
1KDW	;	2.28	;	X-ray crystal structure of AmpC beta-lactamase from E. coli in complex with the inhibitor 4-carboxyphenylboronic acid
6DPX	;	1.9	;	X-ray crystal structure of AmpC beta-lactamase with inhibitor
6DPY	;	1.91	;	X-ray crystal structure of AmpC beta-lactamase with inhibitor
6DPZ	;	1.5	;	X-ray crystal structure of AmpC beta-lactamase with inhibitor
6DPT	;	1.79	;	X-ray crystal structure of AmpC beta-lactamase with nanomolar inhibitor
1L0E	;	1.9	;	X-ray Crystal Structure of AmpC K67Q Mutant beta-Lactamase
1L0F	;	1.66	;	X-ray Crystal Structure of AmpC N152H Mutant beta-Lactamase
1L0D	;	1.53	;	X-ray Crystal Structure of AmpC S64D Mutant beta-Lactamase
1L0G	;	1.5	;	X-ray Crystal Structure of AmpC S64G Mutant beta-Lactamase
1KVL	;	1.53	;	X-ray Crystal Structure of AmpC S64G Mutant beta-Lactamase in Complex with Substrate and Product Forms of Cephalothin
1KVM	;	2.06	;	X-ray Crystal Structure of AmpC WT beta-Lactamase in Complex with Covalently Bound Cephalothin
1LL5	;	1.8	;	X-ray crystal structure of AmpC WT beta-lactamase in complex with covalently bound imipenem
5NKW	;	1.48	;	X-ray crystal structure of an AA9 LPMO
3F7K	;	1.35	;	X-ray Crystal Structure of an Alvinella pompejana Cu,Zn Superoxide Dismutase- Hydrogen Peroxide Complex
4WHX	;	2.05	;	X-ray Crystal Structure of an Amino Acid Aminotransferase from Burkholderia pseudomallei Bound to the Co-factor Pyridoxal Phosphate
4TVI	;	2.1	;	X-ray crystal structure of an aminotransferase from Brucella abortus bound to the co-factor PLP
3NCY	;	3.2	;	X-ray crystal structure of an arginine agmatine antiporter (AdiC) in complex with a Fab fragment
2ZFC	;	1.5	;	X-ray crystal structure of an engineered N-terminal HIV-1 GP41 trimer with enhanced stability and potency
4IV6	;	2.0	;	X-ray crystal structure of an isovaleryl-CoA dehydrogenase from Mycobacterium smegmatis
4K73	;	1.65	;	X-ray crystal structure of an L,D-transpeptidase from Mycobacterium tuberculosis H37Rv
5N04	;	1.76	;	X-ray crystal structure of an LPMO
5N05	;	1.58	;	X-ray crystal structure of an LPMO
4XIN	;	1.5	;	X-ray Crystal Structure of an LpqH orthologue from Mycobacterium avium
4PCA	;	1.5	;	X-ray crystal structure of an O-methyltransferase from Anaplasma phagocytophilum bound to SAH and Manganese
4OA5	;	2.3	;	X-ray crystal structure of an O-methyltransferase from Anaplasma phagocytophilum bound to SAH solved by iodide SAD phasing
4PCL	;	1.85	;	X-ray crystal structure of an O-methyltransferase from Anaplasma phagocytophilum bound to SAM and a Manganese ion.
4U2Z	;	2.26	;	X-ray crystal structure of an Sco GlgEI-V279S/1,2,2-trifluromaltose complex
3GN8	;	2.5	;	X-ray Crystal Structure of AncGR2 in Complex with Dexamethasone
5BRX	;	2.05	;	X-ray crystal structure of Aplysia californica (Ac-AChBP) in complex with 2-pyridyl azatricyclo[3.3.1.13,7]decane; 2-pyridylazaadamantane; 2-Aza (TI-8480)
5BW2	;	2.27	;	X-ray crystal structure of Aplysia californica acetylcholine binding protein (Ac-AChBP) Y55W in complex with 2-Pyridin-3-yl-1-aza-bicyclo[2.2.2]octane; 2-(3-pyridyl)quinuclidine; 2-PQ (TI-4699)
5UY1	;	1.35	;	X-ray crystal structure of apo Halotag
4F40	;	1.6	;	X-ray crystal structure of Apo prostaglandin f synthase from Leishmania major Friedlin
1Z91	;	2.5	;	x-ray crystal structure of apo-OhrRC15S in reduced form: MarR family protein
3P76	;	1.93	;	X-ray crystal structure of Aquifex aeolicus LpxC complexed SCH1379777
2G5W	;	2.576	;	X-ray crystal structure of Arabidopsis thaliana 12-oxophytodienoate reductase isoform 3 (AtOPR3) in complex with 8-iso prostaglandin A1 and its cofactor, flavin mononucleotide.
3TZI	;	2.15	;	X-ray crystal structure of arachidonic acid bound in the cyclooxygenase channel of G533V murine COX-2
3KRK	;	2.4	;	X-ray crystal structure of arachidonic acid bound in the cyclooxygenase channel of L531F murine COX-2
3HS5	;	2.1	;	X-ray crystal structure of arachidonic acid bound to the cyclooxygenase channel of cyclooxygenase-2
3OLT	;	2.45	;	X-ray crystal structure of arachidonic acid bound to the cyclooxygenase channel of R513H murine COX-2
4JIN	;	2.095	;	X-ray crystal structure of Archaeoglobus fulgidus Rio1 bound to (2E)-N-benzyl-2-cyano-3-(pyridine-4-yl)acrylamide (WP1086)
3N2O	;	2.3	;	X-ray crystal structure of arginine decarboxylase complexed with Arginine from Vibrio vulnificus
2E4O	;	2.2	;	X-ray Crystal Structure of Aristolochene Synthase from Aspergillus terreus and the Evolution of Templates for the Cyclization of Farnesyl Diphosphate
7A8Y	;	1.75	;	X-ray crystal structure of Aspartate alpha-decarboxylase in complex with D-Serine
1Y4Y	;	2.0	;	X-ray crystal structure of Bacillus stearothermophilus Histidine phosphocarrier protein (Hpr)
1Y51	;	1.65	;	X-ray crystal structure of Bacillus stearothermophilus Histidine phosphocarrier protein (Hpr) F29W mutant
1Y50	;	2.0	;	X-ray crystal structure of Bacillus stearothermophilus Histidine phosphocarrier protein (Hpr) F29W mutant domain_swapped dimer
8DFK	;	3.2	;	X-ray crystal structure of Bacillus subtilis ComEA
6CGM	;	2.0	;	X-ray crystal structure of Bacillus subtilis ribonucleotide reductase NrdE alpha subunit (nucleotide free)
6CGN	;	2.26	;	X-ray crystal structure of Bacillus subtilis ribonucleotide reductase NrdE alpha subunit dAMP-bound (pH 7)
6CGL	;	3.2	;	X-ray crystal structure of Bacillus subtilis ribonucleotide reductase NrdE alpha subunit dAMP-bound as-isolated (pH 4)
6MV9	;	2.95	;	X-ray crystal structure of Bacillus subtilis ribonucleotide reductase NrdE alpha subunit with TTP and ADP
6MT9	;	2.5	;	X-ray crystal structure of Bacillus subtilis ribonucleotide reductase NrdE alpha subunit with TTP, ATP, and ADP
6PRH	;	2.08	;	X-ray Crystal Structure of Bacillus subtilis RicA
6PRK	;	3.2	;	X-ray Crystal Structure of Bacillus subtilis RicA in complex with RicF
6P70	;	3.052	;	X-ray crystal structure of bacterial RNA polymerase and pyrBI promoter complex
5VOI	;	2.8	;	X-ray crystal structure of bacterial RNA polymerase and pyrG promoter complex
1YLF	;	2.5	;	X-ray crystal structure of BC1842 protein from Bacillus cereus, a member of the Rrf2 family of putative transcription regulators.
1TXR	;	2.0	;	X-ray crystal structure of bestatin bound to AAP
2OHK	;	2.2	;	X-ray crystal structure of beta secretase complexed with 1-amino-isoquinoline
2OHL	;	2.65	;	X-ray crystal structure of beta secretase complexed with 2-aminoquinoline
2OHN	;	2.15	;	X-ray crystal structure of beta secretase complexed with 4-(4-fluorobenzyl)piperidine
2VA6	;	2.5	;	X-ray crystal structure of beta secretase complexed with compound 24
2VA7	;	2.2	;	X-ray crystal structure of beta secretase complexed with compound 27
2OHP	;	2.25	;	X-ray crystal structure of beta secretase complexed with compound 3
2OHQ	;	2.1	;	X-ray crystal structure of beta secretase complexed with compound 4
2OF0	;	2.25	;	X-ray crystal structure of beta secretase complexed with compound 5
2OHR	;	2.25	;	X-ray crystal structure of beta secretase complexed with compound 6a
2OHS	;	2.45	;	X-ray crystal structure of beta secretase complexed with compound 6b
2OHT	;	2.3	;	X-ray crystal structure of beta secretase complexed with compound 7
2OHU	;	2.35	;	X-ray crystal structure of beta secretase complexed with compound 8b
2VA5	;	2.75	;	X-ray crystal structure of beta secretase complexed with compound 8c
2OHM	;	2.7	;	X-ray crystal structure of beta secretase complexed with N~3~-benzylpyridine-2,3-diamine
1QDQ	;	2.18	;	X-RAY CRYSTAL STRUCTURE OF BOVINE CATHEPSIN B-CA074 COMPLEX
2Z2F	;	1.5	;	X-ray Crystal Structure of Bovine Stomach Lysozyme
6IXD	;	1.0	;	X-ray crystal structure of bPI-11 hiv-1 protease complex
4J1P	;	1.08	;	X-ray crystal structure of bromodomain 2 of human brd2 in complex with rvx208 to 1.08 A resolution
4J3I	;	1.24	;	X-ray crystal structure of bromodomain complex to 1.24 A resolution
5ERC	;	2.05	;	X-ray crystal structure of BRPF1 PZP domain
2P6P	;	1.88	;	X-ray crystal structure of C-C bond-forming dTDP-D-Olivose-transferase UrdGT2
6PW7	;	1.89	;	X-ray crystal structure of C. elegans STIM EF-SAM domain
4PL2	;	2.2	;	X-ray crystal structure of C118A RlmN from Escherichia coli
5HR7	;	2.4	;	X-ray crystal structure of C118A RlmN from Escherichia coli with cross-linked in vitro transcribed tRNA
4PL1	;	2.58	;	X-ray crystal structure of C118A RlmN from Escherichia coli with S-adenosylmethionine
5HR6	;	2.88	;	X-ray crystal structure of C118A RlmN with cross-linked tRNA purified from Escherichia coli
1W6N	;	1.65	;	X-RAY CRYSTAL STRUCTURE OF C2S HUMAN GALECTIN-1
1W6M	;	2.3	;	X-RAY CRYSTAL STRUCTURE OF C2S HUMAN GALECTIN-1 COMPLEXED WITH GALACTOSE
1W6O	;	1.9	;	X-RAY CRYSTAL STRUCTURE OF C2S HUMAN GALECTIN-1 COMPLEXED WITH LACTOSE
1W6P	;	1.8	;	X-RAY CRYSTAL STRUCTURE OF C2S HUMAN GALECTIN-1 COMPLEXED WITH N- Acetyl-LACTOSAMINE
1C3D	;	1.8	;	X-RAY CRYSTAL STRUCTURE OF C3D: A C3 FRAGMENT AND LIGAND FOR COMPLEMENT RECEPTOR 2
4X5U	;	2.3	;	X-ray crystal structure of CagL at pH 4.2
1MYP	;	3.0	;	X-RAY CRYSTAL STRUCTURE OF CANINE MYELOPEROXIDASE AT 3 ANGSTROMS RESOLUTION
6RPS	;	2.79	;	X-ray crystal structure of carbonic anhydrase XII complexed with a theranostic monoclonal antibody fragment
6SHR	;	1.745	;	X-RAY CRYSTAL STRUCTURE OF CELL-FREE PROTEIN SYNTHESIS (CFPS) PRODUCED SDF1-A
4WUM	;	1.77	;	X-ray crystal structure of Chalcone Synthase from Freesia hybrida
2FD7	;	1.75	;	X-ray Crystal Structure of Chemically Synthesized Crambin
2FD9	;	1.6	;	X-ray Crystal Structure of Chemically Synthesized Crambin-{alpha}carboxamide
6LFH	;	1.46	;	X-ray crystal structure of chemically synthesized human lysozyme
4ZXE	;	1.4	;	X-ray crystal structure of chitosan-binding module 1 derived from chitosanase/glucanase from Paenibacillus sp. IK-5.
4ZZ5	;	1.29	;	X-ray crystal structure of chitosan-binding module 2 derived from chitosanase/glucanase from Paenibacillus sp. IK-5
4ZZ8	;	1.65	;	X-ray crystal structure of chitosan-binding module 2 in complex with chitotriose derived from chitosanase/glucanase from Paenibacillus sp. IK-5
4M1H	;	1.695	;	X-ray crystal structure of Chlamydia trachomatis apo NrdB
4M1I	;	1.8	;	X-ray crystal structure of Chlamydia trachomatis Mn(II)Fe(II)-NrdB
6UXU	;	1.962	;	X-ray Crystal Structure of Chlorothalonil Dehalogenase: Analyzing the Catalytic Mechanism of Hydrolytic Dehalogenation
6UJ6	;	2.68	;	X-ray Crystal Structure of Chromium-transferrin with Synergistic Anion Malonate
4XGH	;	2.1	;	X-ray Crystal Structure of Citrate Synthase from Burkholderia thailandensis
4N6W	;	1.85	;	X-Ray Crystal Structure of Citrate-bound PhnZ
6VWQ	;	1.5	;	X-ray crystal structure of clavaminate synthase with vanadyl, succinate, and deoxyproclavaminic acid
4XWI	;	1.92	;	X-ray Crystal structure of CMP-KDO Synthase from Pseudomonas aeruginosa
1FQR	;	2.0	;	X-RAY CRYSTAL STRUCTURE OF COBALT-BOUND F93I/F95M/W97V CARBONIC ANHYDRASE (CAII) VARIANT
1FSQ	;	2.0	;	X-RAY CRYSTAL STRUCTURE OF COBALT-BOUND F93S/F95L/W97M CARBONIC ANHYDRASE (CAII) VARIANT
3G1E	;	1.83	;	X-ray crystal structure of coil 1A of human vimentin
1HBJ	;	2.5	;	X-ray Crystal structure of complex between Torpedo californica AChE and a reversible inhibitor, 4-Amino-5-fluoro-2-methyl-3-(3-trifluoroacetylbenzylthiomethyl)quinoline
3PA5	;	1.7	;	X-ray crystal structure of compound 1 bound to human CHK1 kinase domain
3U9N	;	1.85	;	X-ray crystal structure of compound 1 bound to human CHK1 kinase domain
3OT8	;	1.6455	;	X-ray crystal structure of compound 17r bound to human Chk1 kinase domain
4JIK	;	1.9	;	X-RAY Crystal structure of compound 22a (R)-2-(4-chlorophenyl)-8-(piperidin-3-ylamino)imidazo[1,2-c]pyrimidine-5-carboxamide bound to human chk1 kinase domain
3OT3	;	1.44	;	X-ray crystal structure of compound 22k bound to human Chk1 kinase domain
3PA4	;	1.59	;	X-ray crystal structure of compound 2a bound to human CHK1 kinase domain
4HYH	;	1.7	;	X-RAY Crystal structure of compound 39 bound to human chk1 kinase domain
4HYI	;	1.399	;	X-RAY Crystal structure of compound 40 bound to human chk1 kinase domain
3PA3	;	1.4	;	X-ray crystal structure of compound 70 bound to human CHK1 kinase domain
1XSV	;	1.7	;	X-ray crystal structure of conserved hypothetical UPF0122 protein SAV1236 from Staphylococcus aureus subsp. aureus Mu50
1FR4	;	1.6	;	X-RAY CRYSTAL STRUCTURE OF COPPER-BOUND F93I/F95M/W97V CARBONIC ANHYDRASE (CAII) VARIANT
1FSR	;	2.0	;	X-RAY CRYSTAL STRUCTURE OF COPPER-BOUND F93S/F95L/W97M CARBONIC ANHYDRASE (CAII) VARIANT
4FIW	;	1.5011	;	X-ray crystal structure of Corynebacterium glutamicum Nrdh-redoxin at 1.5A
6IQH	;	2.999	;	X-ray crystal structure of covalent-bonded complex of Fc and peptide
5EVJ	;	2.4	;	X-ray crystal structure of CrArsM, an arsenic (III) S-adenosylmethionine methyltransferase from Chlamydomonas reinhardtii
1SCD	;	2.3	;	X-RAY CRYSTAL STRUCTURE OF CROSS-LINKED SUBTILISM CARLSBERG IN WATER VS. ACETONITRILE
3AAI	;	2.1	;	X-ray crystal structure of CsoR from Thermus thermophilus HB8
6M5B	;	1.501	;	X-ray crystal structure of cyclic-PIP and DNA complex in a reverse binding orientation
1M9C	;	2.0	;	X-ray crystal structure of Cyclophilin A/HIV-1 CA N-terminal domain (1-146) M-type Complex.
1M9E	;	1.72	;	X-ray crystal structure of Cyclophilin A/HIV-1 CA N-terminal domain (1-146) M-type H87A Complex.
1M9F	;	1.73	;	X-ray crystal structure of Cyclophilin A/HIV-1 CA N-terminal domain (1-146) M-type H87A,A88M Complex.
1M9X	;	1.7	;	X-ray crystal structure of Cyclophilin A/HIV-1 CA N-terminal domain (1-146) M-type H87A,A88M,G89A Complex.
1M9Y	;	1.9	;	X-ray crystal structure of Cyclophilin A/HIV-1 CA N-terminal domain (1-146) M-type H87A,G89A Complex.
1M9D	;	1.9	;	X-ray crystal structure of Cyclophilin A/HIV-1 CA N-terminal domain (1-146) O-type chimera Complex.
4WPD	;	2.001	;	X-ray Crystal Structure of CYP119 complexed with 4-(4-flourophenyl)-1H-imidazole
4TUV	;	2.501	;	X-ray crystal structure of CYP119 from Sulfolobus acidocaldarius, complexed with 4-(4-chlorophenyl)imidazole
8FKB	;	1.42	;	X-ray crystal structure of CYP124A1 from Mycobacterium Marinum bound to Farnesol
8GDI	;	1.81	;	X-ray crystal structure of CYP124A1 from Mycobacterium Marinum in complex with 7-ketocholesterol
8FJO	;	1.69	;	X-ray crystal structure of CYP124A1 from Mycobacterium Marinum in complex with farnesyl acetate
4TRI	;	2.0	;	X-ray crystal structure of CYP142A2 from Mycobacterium smegmatis, complexed with cholesterol sulfate.
7SMZ	;	2.04	;	X-ray crystal structure of CYP142A3 from Mycobacterium Marinum in complex with 4-cholesten-3-one
1EUP	;	2.1	;	X-RAY CRYSTAL STRUCTURE OF CYTOCHROME P450ERYF WITH ANDROSTENDIONE BOUND
8IHW	;	1.7	;	X-ray crystal structure of D43R mutant of endo-1,4-beta glucanase from Eisenia fetida
6OGV	;	1.57	;	X-ray crystal structure of darunavir-resistant HIV-1 protease (P30) in apo state
6OGS	;	1.27	;	X-ray crystal structure of darunavir-resistant HIV-1 protease (P30) in complex with GRL-001
6OGQ	;	1.41	;	X-ray crystal structure of darunavir-resistant HIV-1 protease (P30) in complex with GRL-003
6OGR	;	1.28	;	X-ray crystal structure of darunavir-resistant HIV-1 protease (P30) in complex with GRL-142
6OGT	;	1.21	;	X-ray crystal structure of darunavir-resistant HIV-1 protease (P51) in complex with GRL-001
6OGL	;	1.21	;	X-ray crystal structure of darunavir-resistant HIV-1 protease (P51) in complex with GRL-003
6MK9	;	1.7	;	X-ray crystal structure of darunavir-resistant-P51 HIV-1 protease in complex with GRL-121
6MKL	;	1.7	;	X-ray crystal structure of darunavir-resistant-P51 HIV-1 protease in complex with GRL-142
2GQG	;	2.4	;	X-ray Crystal Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain
1S2Z	;	1.75	;	X-ray crystal structure of Desulfovibrio vulgaris Rubrerythrin with displacement of iron by zinc at the diiron Site
1S30	;	2.05	;	X-ray crystal structure of Desulfovibrio vulgaris Rubrerythrin with displacement of iron by zinc at the diiron Site
1QYB	;	1.75	;	X-ray crystal structure of Desulfovibrio vulgaris rubrerythrin with zinc substituted into the [Fe(SCys)4] site and alternative diiron site structures
4F3Y	;	2.1	;	X-Ray Crystal Structure of Dihydrodipicolinate reductase from Burkholderia thailandensis
2BDX	;	2.3	;	X-ray Crystal Structure of dihydromicrocystin-LA bound to Protein Phosphatase-1
3HS7	;	2.65	;	X-ray crystal structure of docosahexaenoic acid bound to the cyclooxygenase channel of cyclooxygenase-2
3Q6C	;	2.6	;	X-ray crystal structure of duf2500 (pf10694) from klebsiella pneumoniae, northeast structural genomics consortium target kpr96
3LPV	;	1.77	;	X-ray crystal structure of duplex DNA containing a cisplatin 1,2-d(GpG) intrastrand cross-link
4M1F	;	2.0	;	X-ray crystal structure of E. coli apo NrdF
1P3W	;	2.1	;	X-ray crystal structure of E. coli IscS
4K4D	;	2.17	;	X-ray crystal structure of E. coli YbdB complexed with 2,4-dihydroxyphenacyl-CoA
4K4C	;	1.85	;	X-ray crystal structure of E. coli YbdB complexed with phenacyl-CoA
4K49	;	1.89	;	X-ray crystal structure of E. coli YdiI complexed with 2,4-dihydroxyphenacyl CoA
4K4A	;	1.89	;	X-ray crystal structure of E. coli YdiI complexed with phenacyl-CoA
4K4B	;	1.9	;	X-ray crystal structure of E. coli YdiI complexed with undeca-2-one-CoA
7D3Z	;	1.65	;	X-ray crystal Structure of E.coli Dihydrofolate Reductase complexed with folate and NADP+ at pH4.5
7D49	;	1.651	;	X-ray crystal Structure of E.coli Dihydrofolate Reductase complexed with folate and NADP+ at pH4.5
7D4L	;	1.6	;	X-ray crystal Structure of E.coli Dihydrofolate Reductase complexed with folate and NADP+ at pH7.0
7D4X	;	1.599	;	X-ray crystal Structure of E.coli Dihydrofolate Reductase complexed with folate and NADP+ at pH7.0
1DYT	;	1.75	;	X-ray crystal structure of ECP (RNase 3) at 1.75 A
3HS6	;	2.4	;	X-ray crystal structure of eicosapentaenoic acid bound to the cyclooxygenase channel of cyclooxygenase-2
2V00	;	1.55	;	X-ray crystal structure of endothiapepsin complexed with compound 1
5FVN	;	1.45	;	X-ray crystal structure of Enterobacter cloacae OmpE36 porin.
1EIA	;	2.7	;	X-RAY CRYSTAL STRUCTURE OF EQUINE INFECTIOUS ANEMIA VIRUS (EIAV) CAPSID PROTEIN P26
2EIA	;	2.7	;	X-RAY CRYSTAL STRUCTURE OF EQUINE INFECTIOUS ANEMIA VIRUS (EIAV) CAPSID PROTEIN P26
6AQ5	;	2.194	;	X-ray crystal structure of Erythrina crista-galli lectin in complex with epilactose
6AQ6	;	1.903	;	X-ray crystal structure of Erythrina crista-galli lectin in complex with N-acetyllactosamine
6BYU	;	3.6	;	X-ray crystal structure of Escherichia coli RNA polymerase (RpoB-H526Y) and ppApp complex
5W1T	;	4.5	;	X-ray crystal structure of Escherichia coli RNA polymerase and DksA complex
5VSW	;	4.295	;	X-ray crystal structure of Escherichia coli RNA polymerase and DksA/ppGpp complex
5W1S	;	3.805	;	X-ray crystal structure of Escherichia coli RNA polymerase and TraR complex
4JK2	;	4.201	;	X-ray crystal structure of Escherichia coli sigma70 holoenzyme in complex with guanosine pentaphosphate (pppGpp)
4JK1	;	3.9	;	X-ray crystal structure of Escherichia coli sigma70 holoenzyme in complex with Guanosine tetraphosphate (ppGpp)
5FD7	;	2.4	;	X-ray Crystal Structure of ESCRT-III Snf7 core domain (conformation A)
5FD9	;	1.6	;	X-ray Crystal Structure of ESCRT-III Snf7 core domain (conformation B)
5U0L	;	2.285	;	X-ray crystal structure of fatty aldehyde dehydrogenase enzymes from Marinobacter aquaeolei VT8 complexed with a substrate
6IQG	;	2.998	;	X-ray crystal structure of Fc and peptide complex
4HVQ	;	2.81	;	X-ray crystal structure of FECU reconstituted 3-hydroxyanthranilate-3,4-dioxygenase from cupriavidus metallidurans
2FAL	;	1.8	;	X-RAY CRYSTAL STRUCTURE OF FERRIC APLYSIA LIMACINA MYOGLOBIN IN DIFFERENT LIGANDED STATES
2FAM	;	2.0	;	X-RAY CRYSTAL STRUCTURE OF FERRIC APLYSIA LIMACINA MYOGLOBIN IN DIFFERENT LIGANDED STATES
8DQ4	;	2.35	;	X-ray crystal structure of Flavobacterium johnsoniae dimanganese(II) class Id ribonucleotide reductase beta subunit K71R variant
8DQ5	;	2.1	;	X-ray crystal structure of Flavobacterium johnsoniae dimanganese(II) class Id ribonucleotide reductase T191I variant
6CWO	;	1.87	;	X-ray crystal structure of Flavobacterium johnsoniae dimanganese(II) ribonucleotide reductase beta subunit (aerobic)
6CWP	;	1.92	;	X-ray crystal structure of Flavobacterium johnsoniae dimanganese(II) ribonucleotide reductase beta subunit (anaerobic)
6CWQ	;	1.9	;	X-ray crystal structure of Flavobacterium johnsoniae dimanganese(II) ribonucleotide reductase beta subunit (as-isolated)
3BNK	;	2.05	;	X-ray crystal structure of Flavoredoxin from Methanosarcina acetivorans
8SNZ	;	2.17	;	X-ray Crystal Structure of FMN-bound long-chain flavodoxin from Rhodopseudomonas palustris
1GMD	;	2.2	;	X-ray crystal structure of gamma-chymotrypsin in hexane
4GHK	;	2.25	;	X-ray Crystal Structure of Gamma-glutamyl phosphate reductase from Burkholderia thailandensis
7US5	;	2.1	;	X-ray crystal structure of GDP-D-glycero-D-manno-heptose 4,6-Dehydratase from Campylobacter jejuni
8DSS	;	3.05	;	X-ray crystal structure of Geobacillus stearothermophilus ComEA
4LGV	;	2.3	;	X-ray crystal structure of Glucose-6-phosphate 1-dehydrogenase from Mycobacterium avium
3DLA	;	2.35	;	X-ray crystal structure of glutamine-dependent NAD+ synthetase from Mycobacterium tuberculosis bound to NaAD+ and DON
7TOL	;	2.03	;	X-ray crystal structure of glycerol dibiphytanyl glycerol tetraether - macrocyclic archaeol synthase (GDGT-MAS) from Methanocaldococcus jannaschii with archaeal lipid, 5'deoxyadenosine, and methionine bound
7TOM	;	1.85	;	X-ray crystal structure of glycerol dibiphytanyl glycerol tetraether - macrocyclic archaeol synthase (GDGT-MAS) from Methanocaldococcus jannaschii with bacterial lipid substrate analog, 5'deoxyadenosine, and methionine bound
5HLP	;	2.45	;	X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
5HLN	;	3.1	;	X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
6RQU	;	1.393	;	X-ray crystal structure of H/D exchanged (H/D) small monoclinic unit cell CA IX SV.
5VNP	;	2.23	;	X-ray crystal structure of Halotag bound to the P1 benzoxadiazole fluorogenic ligand
5UXZ	;	1.92	;	X-ray crystal structure of Halotag bound to the P9 benzothiadiazole fluorogenic ligand
8FNR	;	1.4	;	X-ray crystal structure of Hansschlegelia quercus lanmodulin (LanM) with dysprosium (III) bound at pH 7
8DQ2	;	1.8	;	X-ray crystal structure of Hansschlegelia quercus lanmodulin (LanM) with lanthanum (III) bound at pH 7
1DLY	;	1.8	;	X-RAY CRYSTAL STRUCTURE OF HEMOGLOBIN FROM THE GREEN UNICELLULAR ALGA CHLAMYDOMONAS EUGAMETOS
2D3U	;	2.0	;	X-ray crystal structure of hepatitis C virus RNA dependent RNA polymerase in complex with non-nucleoside analogue inhibitor
2D3Z	;	1.8	;	X-ray crystal structure of hepatitis C virus RNA-dependent RNA polymerase in complex with non-nucleoside analogue inhibitor
2D41	;	2.1	;	X-ray crystal structure of hepatitis C virus RNA-dependent RNA polymerase in complex with non-nucleoside inhibitor
4A7D	;	1.497	;	X-ray crystal structure of HEWL flash-cooled at high pressure
6OXH	;	1.92	;	X-ray crystal structure of His-tagged Y140F FtmOx1 bound to Fe(II) and 2-oxoglutarate
2FXE	;	1.8	;	X-ray crystal structure of HIV-1 protease CRM mutant complexed with atazanavir (BMS-232632)
2FXD	;	1.6	;	X-ray crystal structure of HIV-1 protease IRM mutant complexed with atazanavir (BMS-232632)
2FGV	;	1.5	;	X-ray crystal structure of HIV-1 Protease T80N variant in complex with the inhibitor saquinavir used to explore the role of invariant Thr80 in HIV-1 protease structure, function, and viral infectivity.
2FGU	;	2.0	;	X-ray crystal structure of HIV-1 Protease T80S variant in complex with the inhibitor saquinavir used to explore the role of invariant Thr80 in HIV-1 protease structure, function, and viral infectivity.
4QGI	;	1.896	;	X-ray crystal structure of HIV-1 protease variant G48T/L89M in complex with Saquinavir
7TV2	;	1.98	;	X-ray crystal structure of HIV-2 CA protein CTD
2SEB	;	2.5	;	X-RAY CRYSTAL STRUCTURE OF HLA-DR4 COMPLEXED WITH A PEPTIDE FROM HUMAN COLLAGEN II
1D5X	;	2.45	;	X-RAY CRYSTAL STRUCTURE OF HLA-DR4 COMPLEXED WITH DIPEPTIDE MIMETIC AND SEB
1D5M	;	2.0	;	X-RAY CRYSTAL STRUCTURE OF HLA-DR4 COMPLEXED WITH PEPTIDE AND SEB
1D5Z	;	2.0	;	X-RAY CRYSTAL STRUCTURE OF HLA-DR4 COMPLEXED WITH PEPTIDOMIMETIC AND SEB
1H15	;	3.1	;	X-ray crystal structure of HLA-DRA1*0101/DRB5*0101 complexed with a peptide from Epstein Barr Virus DNA polymerase
3I1I	;	2.44	;	X-ray crystal structure of homoserine O-acetyltransferase from Bacillus anthracis
2VF2	;	2.35	;	X-ray crystal structure of HsaD from Mycobacterium tuberculosis
1H8I	;	1.75	;	X-ray crystal structure of human alpha-thrombin with a tripeptide phosphonate inhibitor.
3AOX	;	1.75	;	X-ray crystal structure of human anaplastic lymphoma kinase in complex with CH5424802
5DW1	;	1.55	;	X-ray crystal structure of human BRD2(BD2) in complex with RVX297 to 1.55 A resolution
5DW2	;	1.12	;	X-ray crystal structure of human BRD4(BD1) in complex with RVX297 to 1.12 A resolution
7MLS	;	1.26	;	X-ray crystal structure of human BRD4(D1) in complex with 2-(2,5-dibromophenoxy)-6-[4-methyl-1-(piperidin-4-yl)-1H-1,2,3-triazol-5-yl]pyridine (compound 23)
7MLQ	;	1.32	;	X-ray crystal structure of human BRD4(D1) in complex with 2-(4-{5-[6-(2,5-dibromophenoxy)pyridin-2-yl]-4-methyl-1H-1,2,3-triazol-1-yl}piperidin-1-yl)-N,N-dimethylethan-1-amine (compound 26)
7MLR	;	1.2	;	X-ray crystal structure of human BRD4(D1) in complex with 2-(4-{5-[6-(3,5-dimethylphenoxy)pyridin-2-yl]-4-methyl-1H-1,2,3-triazol-1- yl}piperidin-1-yl)-N,N-dimethylethan-1-amine (DW34)
6Y74	;	1.53	;	X-ray crystal structure of human carbonic anhydrase IX catalytic domain.
1KCW	;	3.0	;	X-RAY CRYSTAL STRUCTURE OF HUMAN CERULOPLASMIN AT 3.0 ANGSTROMS
4KM5	;	2.499	;	X-ray crystal structure of human cyclic GMP-AMP synthase (cGAS)
3K9X	;	1.9	;	X-ray crystal structure of human fxa in complex with (S)-N-((2-METHYLBENZOFURAN-5-YLAMINO)(2-OXO-1-(2-OXO-2- (PYRROLIDIN-1-YL)ETHYL)AZEPAN-3- YLAMINO)METHYLENE)NICOTINAMIDE
3SW2	;	2.42	;	X-ray crystal structure of human FXA in complex with 6-chloro-N-((3S)-2-oxo-1-(2-oxo-2-((5S)-8-oxo-5,6-dihydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocin-3(2H,4H,8H)-yl)ethyl)piperidin-3-yl)naphthalene-2-sulfonamide
1GZW	;	1.7	;	X-RAY CRYSTAL STRUCTURE OF HUMAN GALECTIN-1
1N45	;	1.5	;	X-RAY CRYSTAL STRUCTURE OF HUMAN HEME OXYGENASE-1 (HO-1) IN COMPLEX WITH ITS SUBSTRATE HEME
3TGM	;	2.85	;	X-Ray Crystal Structure of Human Heme Oxygenase-1 in Complex with 1-(1H-imidazol-1-yl)-4,4-diphenyl-2 butanone
3K4F	;	2.17	;	X-Ray Crystal Structure of Human Heme Oxygenase-1 in Complex with 4-Phenyl-1-(1H-1,2,4-triazol-1-yl)-2-butanone
3HOK	;	2.19	;	X-ray Crystal Structure of Human Heme Oxygenase-1 with (2R, 4S)-2-[2-(4-Chlorophenyl)ethyl]-2-[(1H-imidazol-1-yl)methyl]-4[((5-trifluoromethylpyridin-2-yl)thio)methyl]-1,3-dioxolane: A Novel, Inducible Binding Mode
4E3C	;	3.98	;	X-ray crystal structure of human IKK2 in an active conformation
3DRX	;	3.11	;	X-ray crystal structure of human KCTD5 protein crystallized in high-salt buffer
3DRY	;	3.3	;	X-ray crystal structure of human KCTD5 protein crystallized in low-salt buffer
2PQK	;	2.0	;	X-ray crystal structure of human Mcl-1 in complex with Bim BH3
5HNE	;	2.04	;	X-RAY CRYSTAL STRUCTURE OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A 2-ARYL BENZIMIDAZOLE COMPOUND AND AN INTERNAL ALDIMINE LINKED PLP COFACTOR
2A1H	;	1.8	;	X-ray crystal structure of human mitochondrial branched chain aminotransferase (BCATm) complexed with gabapentin
4IFP	;	1.9948	;	X-ray Crystal Structure of Human NLRP1 CARD Domain
3BC5	;	2.27	;	X-ray crystal structure of human ppar gamma with 2-(5-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-2-phenyl-2h-1,2,3-triazol-4-yl)acetic acid
2RNF	;	2.4	;	X-RAY CRYSTAL STRUCTURE OF HUMAN RIBONUCLEASE 4 IN COMPLEX WITH D(UP)
3L6B	;	1.5	;	X-ray crystal structure of human serine racemase in complex with malonate a potent inhibitor
3QYB	;	3.5	;	X-ray Crystal Structure of Human TBC1D4 (AS160) RabGAP domain
4U6A	;	2.37	;	X-ray crystal structure of human TNKS in complex with a small molecule inhibitor
4UUH	;	2.52	;	X-ray crystal structure of human TNKS in complex with a small molecule inhibitor
4UW1	;	3.37	;	X-ray crystal structure of human TNKS in complex with a small molecule inhibitor
3U2I	;	1.7	;	X-ray crystal structure of human Transthyretin at room temperature
1YRC	;	1.4	;	X-ray Crystal Structure of hydrogenated Cytochrome P450cam
4ECP	;	1.8	;	X-ray crystal structure of Inorganic Pyrophosphate PPA from Mycobacterium leprae
1J2F	;	2.3	;	X-ray crystal structure of IRF-3 and its functional implications
6MDH	;	1.37	;	X-ray crystal structure of ISG15 from Myotis davidii
4O5M	;	2.2	;	X-ray Crystal Structure of Isovaleryl-CoA Dehydrogenase from Brucella suis
3MJ2	;	1.9	;	X-ray crystal structure of ITK complexed with inhibitor BMS-509744
3MJ1	;	1.72	;	X-ray crystal structure of ITK complexed with inhibitor RO5191614
3MIY	;	1.67	;	X-ray crystal structure of ITK complexed with sunitinib
8TXY	;	2.1	;	X-ray crystal structure of JRD-SIK1/2i-3 bound to a MARK2-SIK2 chimera
1Y71	;	1.95	;	X-ray crystal structure of kinase-associated protein B from Bacillus cereus
5D7H	;	2.49	;	X-RAY CRYSTAL STRUCTURE OF L,D TRANSPEPTIDASE 2 FROM MYCOBACTERIUM TUBERCULOSIS
3SMV	;	1.38	;	X-ray Crystal Structure of L-Azetidine-2-Carboxylate Hydrolase
3E7U	;	1.35	;	X-ray Crystal Structure of L-Plectasin
2FON	;	2.74	;	X-ray crystal structure of LeACX1, an acyl-CoA oxidase from Lycopersicon esculentum (tomato)
4UAX	;	1.78	;	X-ray crystal structure of ligand free CYP142A2 from Mycobacterium smegmatis
3TX1	;	2.69	;	X-ray crystal structure of Listeria monocytogenes EGD-e UDP-N-acetylenolpyruvylglucosamine reductase (MurB)
2O3Z	;	2.25	;	X-ray crystal structure of LpxC complexed with 3-heptyloxybenzoate
7NIM	;	1.45	;	X-ray crystal structure of LsAA9A - cinnamon extract soak
7NIN	;	1.4	;	X-ray crystal structure of LsAA9A - CinnamtanninB1 soak
6RS6	;	1.6	;	X-ray crystal structure of LsAA9B
6RS7	;	1.6	;	X-ray crystal structure of LsAA9B (deglycosylated form)
6RS8	;	1.58	;	X-ray crystal structure of LsAA9B (transition metals soak)
6RS9	;	1.4	;	X-ray crystal structure of LsAA9B (xylotetraose soak)
1P8D	;	2.8	;	X-Ray Crystal Structure of LXR Ligand Binding Domain with 24(S),25-epoxycholesterol
4ZRU	;	1.9	;	X-ray crystal structure of Lymnaea stagnalis acetylcholine binding protein (Ls-AChBP) in complex with 3-[2-[(2S)-pyrrolidin-2-yl]ethynyl]pyridine (TI-5180)
5BP0	;	2.4	;	X-ray crystal structure of Lymnaea stagnalis acetylcholine binding protein (Ls-AChBP) in complex with 5-Fluoronicotine (TI-4650)
4ZJT	;	1.85	;	X-ray crystal structure of Lymnaea stagnalis acetylcholine binding protein (LsAChBP) in complex with 2-Thiophenylmethylene Anabaseine (2TAB)
2I04	;	2.15	;	X-ray crystal structure of MAGI-1 PDZ1 bound to the C-terminal peptide of HPV18 E6
5I4A	;	1.949	;	X-ray crystal structure of Marinitoga piezophila Argonaute in complex with 5' OH guide RNA
5UX0	;	3.197	;	X-ray crystal structure of Marinitoga piezophila Argonaute in complex with 5' OH guide RNA and target DNA
3LA5	;	1.7	;	X-ray crystal structure of mc6 RNA Riboswitch bound to azacytosine
5HLQ	;	1.5	;	X-ray crystal structure of met F43H/H64A sperm whale myoglobin
5HLU	;	1.5	;	X-ray crystal structure of met F43H/H64A sperm whale myoglobin in complex with nitric oxide
5HLX	;	1.5	;	X-ray crystal structure of met F43H/H64A sperm whale myoglobin in complex with nitrite
5B84	;	1.61	;	X-ray crystal structure of met I107Y sperm whale myoglobin
5YZF	;	1.77	;	X-ray crystal structure of met K42C sperm whale myoglobin
6O5C	;	3.1	;	X-ray crystal structure of metal-dependent transcriptional regulator MtsR
1FQN	;	2.0	;	X-RAY CRYSTAL STRUCTURE OF METAL-FREE F93I/F95M/W97V CARBONIC ANHYDRASE (CAII) VARIANT
1FSN	;	2.0	;	X-RAY CRYSTAL STRUCTURE OF METAL-FREE F93S/F95L/W97M CARBONIC ANHYDRASE (CAII) VARIANT
8FNS	;	1.01	;	X-ray crystal structure of Methylorubrum extorquens AM1 lanmodulin (LanM) with neodymium (III) bound at pH 7
1XJC	;	2.1	;	X-ray crystal structure of MobB protein homolog from Bacillus stearothermophilus
4OVE	;	2.64	;	X-ray Crystal Structure of Mouse Netrin-1
6XIG	;	1.59	;	X-ray crystal structure of MqnE from Pedobacter heparinus
6XI9	;	2.14	;	X-ray crystal structure of MqnE from Pedobacter heparinus in complex with aminofutalosine and methionine
2GAK	;	2.0	;	X-ray crystal structure of murine leukocyte-type Core 2 b1,6-N-acetylglucosaminyltransferase (C2GnT-L)
2GAM	;	2.7	;	X-ray crystal structure of murine leukocyte-type Core 2 b1,6-N-acetylglucosaminyltransferase (C2GnT-L) in complex with Galb1,3GalNAc
3DVD	;	1.6	;	X-ray crystal structure of mutant N62D of human Carbonic Anhydrase II
3DVC	;	1.6	;	X-ray crystal structure of mutant N62T of human Carbonic Anhydrase II
3DVB	;	1.7	;	X-ray crystal structure of mutant N62V human Carbonic Anhydrase II
2GP6	;	2.4	;	X-ray crystal structure of Mycobacterium tuberculosis beta-ketoacyl acyl carrier protein synthase II (mtKasB)
1M1M	;	2.7	;	X-RAY CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS BETA-KETOACYL-ACYL CARRIER PROTEIN SYNTHASE III (MTFABH)
1XXO	;	1.8	;	X-ray crystal structure of mycobacterium tuberculosis pyridoxine 5'-phosphate oxidase at 1.8 a resolution
1Y30	;	2.2	;	X-ray crystal structure of mycobacterium tuberculosis pyridoxine 5'-phosphate oxidase complexed with flavin mononucleotide at 2.2 a resolution
2AQ6	;	1.7	;	X-ray crystal structure of mycobacterium tuberculosis pyridoxine 5'-phosphate oxidase complexed with pyridoxal 5'-phosphate at 1.7 a resolution
5LKY	;	1.7	;	X-ray crystal structure of N-acetylneuraminic acid lyase in complex with pyruvate, with the phenylalanine at position 190 replaced with the non-canonical amino acid dihydroxypropylcysteine.
8IHX	;	1.6	;	X-ray crystal structure of N372D mutant of endo-1,4-beta glucanase from Eisenia fetida
3JSX	;	2.45	;	X-ray Crystal structure of NAD(P)H: Quinone Oxidoreductase-1 (NQO1) bound to the coumarin-based inhibitor AS1
6DAW	;	2.1	;	X-ray crystal structure of NapI L-arginine desaturase bound to Fe(II), L-arginine, and acetate
6BXI	;	2.2	;	X-ray crystal structure of NDR1 kinase domain
1EPU	;	2.4	;	X-RAY crystal structure of neuronal SEC1 from squid
2GK1	;	3.25	;	X-ray crystal structure of NGT-bound HexA
4AB0	;	1.636	;	X-ray crystal structure of Nicotiana alata defensin NaD1
4XBM	;	3.2	;	X-ray crystal structure of Notch ligand Delta-like 1
3QMO	;	3.0	;	X-ray crystal structure of NS-398 bound to the cyclooxygenase channel of cyclooxygenase-2
4WXP	;	2.08	;	X-ray crystal structure of NS3 Helicase from HCV with a bound fragment inhibitor at 2.08 A resolution
4WXR	;	2.42	;	X-ray crystal structure of NS3 Helicase from HCV with a bound inhibitor at 2.42 A resolution
8CWP	;	1.8	;	X-ray crystal structure of NTHi Protein D bound to a putative glycerol moiety
4KAM	;	2.0	;	X-ray crystal structure of O-acetylhomoserine sulfhydrylase MetC from Mycobacterium marinum ATCC BAA-535 / M
4OA8	;	2.15	;	X-ray crystal structure of O-methyltransferase from Anaplasma phagocytophilum in apo form
4K0W	;	1.2	;	X-ray crystal structure of OXA-23 A220 duplication clinical variant
4K0X	;	1.61	;	X-ray Crystal Structure of OXA-23 from Acinetobacter baumannii
7RPF	;	1.9	;	X-ray crystal structure of OXA-24/40 in complex with doripenem
7RPE	;	1.53	;	X-ray crystal structure of OXA-24/40 in complex with ertapenem
8CUM	;	1.49	;	X-ray crystal structure of OXA-24/40 in complex with sulfonamidoboronic acid 6d
8CUO	;	1.47	;	X-ray crystal structure of OXA-24/40 in complex with sulfonamidoboronic acid 6e
7RPG	;	1.62	;	X-ray crystal structure of OXA-24/40 K84D in complex with cefotaxime
7RPC	;	2.58	;	X-ray crystal structure of OXA-24/40 K84D in complex with ertapenem
7RP8	;	2.28	;	X-ray crystal structure of OXA-24/40 K84D in complex with imipenem
7RPA	;	2.27	;	X-ray crystal structure of OXA-24/40 K84D in complex with meropenem
7RPD	;	1.95	;	X-ray crystal structure of OXA-24/40 V130D in complex with ertapenem
7RP9	;	1.94	;	X-ray crystal structure of OXA-24/40 V130D in complex with imipenem
7RPB	;	1.97	;	X-ray crystal structure of OXA-24/40 V130D in complex with meropenem
2HHF	;	1.8	;	X-ray crystal structure of oxidized human mitochondrial branched chain aminotransferase (hBCATm)
1FHH	;	1.5	;	X-RAY CRYSTAL STRUCTURE OF OXIDIZED RUBREDOXIN
3LQC	;	2.349	;	X-ray crystal structure of oxidized XRCC1 bound to DNA pol beta Palm thumb domain
4P9A	;	2.1999	;	X-ray Crystal Structure of PA protein from Influenza strain H7N9
3QH0	;	2.1	;	X-ray crystal structure of palmitic acid bound to the cyclooxygenase channel of cyclooxygenase-2
3VOL	;	2.399	;	X-ray Crystal Structure of PAS-HAMP Aer2 in the CN-bound Form
4BG2	;	2.13	;	X-ray Crystal Structure of PatF from Prochloron didemni
1Y1O	;	2.2	;	X-ray crystal Structure of Penicillin-binding protein-related factor A from Bacillus stearothermophilus
4EA7	;	1.0	;	X-ray crystal structure of PerB from Caulobacter crescentus in complex with CoA and GDP-perosamine at 1.0 Angstrom resolution
4EA8	;	1.0	;	X-ray crystal structure of PerB from Caulobacter crescentus in complex with coenzyme A and GDP-N-acetylperosamine at 1 Angstrom resolution
6RQW	;	1.488	;	X-ray crystal structure of perdeuterated (D) small monoclinic unit cell CA IX SV.
1YRD	;	1.7	;	X-ray crystal structure of PERDEUTERATED Cytochrome P450cam
7PSY	;	0.9	;	X-ray crystal structure of perdeuterated LecB lectin in complex with perdeuterated fucose
5GGY	;	2.5	;	X-ray crystal structure of Periplasmic Desferal binding protein FhuD from Vibrio cholerae
2WL8	;	2.05	;	X-ray crystal structure of Pex19p
6EA1	;	1.815	;	X-ray crystal structure of Pf-M1 in complex with inhibitor (6da) and catalytic zinc ion
6EA2	;	1.35	;	X-ray crystal structure of Pf-M1 in complex with inhibitor (6h) and catalytic zinc ion
6EAA	;	1.65	;	X-ray crystal structure of Pf-M1 in complex with inhibitor (6i) and catalytic zinc ion
6EAB	;	1.85	;	X-ray crystal structure of Pf-M1 in complex with inhibitor (6j) and catalytic zinc ion
6EE3	;	1.82	;	X-ray crystal structure of Pf-M1 in complex with inhibitor (6k) and catalytic zinc ion
6EE4	;	1.58	;	X-ray crystal structure of Pf-M1 in complex with inhibitor (6m) and catalytic zinc ion
6EE6	;	1.5	;	X-ray crystal structure of Pf-M1 in complex with inhibitor (6o) and catalytic zinc ion
6EED	;	1.5	;	X-ray crystal structure of Pf-M1 in complex with inhibitor (6p) and catalytic zinc ion
6EEE	;	2.3	;	X-ray crystal structure of Pf-M17 in complex with inhibitor (6k) and regulatory zinc ion
6EE2	;	2.1	;	X-ray crystal structure of Pf-M17 in complex with inhibitor 6i and regulatory zinc ion
3Q43	;	1.8	;	X-ray crystal structure of PfA-M1 bound to bestatin derivative 15
3Q44	;	1.8	;	X-ray crystal structure of PfA-M1 bound to Bestatin derivative 16
4ZX3	;	2.0	;	X-ray crystal structure of PfA-M1 in complex with hydroxamic acid-based inhibitor 10b
4ZX4	;	1.9	;	X-ray crystal structure of PfA-M1 in complex with hydroxamic acid-based inhibitor 10o
4ZX5	;	1.95	;	X-ray crystal structure of PfA-M1 in complex with hydroxamic acid-based inhibitor 10q
4ZX6	;	2.05	;	X-ray crystal structure of PfA-M1 in complex with hydroxamic acid-based inhibitor 10s
4ZW3	;	1.8	;	X-ray crystal structure of PfA-M1 in complex with hydroxamic acid-based inhibitor 9b
4ZW5	;	1.8	;	X-ray crystal structure of PfA-M1 in complex with hydroxamic acid-based inhibitor 9f
4ZW7	;	1.95	;	X-ray crystal structure of PfA-M1 in complex with hydroxamic acid-based inhibitor 9m
4ZW6	;	1.9	;	X-ray crystal structure of PfA-M1 in complex with hydroxamic acid-based inhibitor 9q
4ZW8	;	2.0	;	X-ray crystal structure of PfA-M1 in complex with hydroxamic acid-based inhibitor 9r
4ZX9	;	2.6	;	X-ray crystal structure of PfA-M17 in complex with hydroxamic acid-based inhibitor 10b
4ZY2	;	2.1	;	X-ray crystal structure of PfA-M17 in complex with hydroxamic acid-based inhibitor 10o
4ZY0	;	2.2	;	X-ray crystal structure of PfA-M17 in complex with hydroxamic acid-based inhibitor 10q
4ZY1	;	2.5	;	X-ray crystal structure of PfA-M17 in complex with hydroxamic acid-based inhibitor 10r
4ZYQ	;	2.6	;	X-ray crystal structure of PfA-M17 in complex with hydroxamic acid-based inhibitor 10s
4ZX8	;	2.7	;	X-ray crystal structure of PfA-M17 in complex with hydroxamic acid-based inhibitor 9b
6D0Y	;	2.676	;	X-ray Crystal Structure of PGC-1beta C-terminus bound to the CBP80-CBP20 Cap Binding Complex
2BDV	;	2.2	;	X-Ray Crystal Structure of Phage-related Protein BB2244 from Bordetella bronchiseptica. Northeast Structural Genomics Consortium Target BoR24.
5J1D	;	1.9	;	X-ray crystal structure of Phosphate binding protein (PBP) from Stenotrophomonas maltophilia
3UW2	;	1.95	;	X-ray Crystal Structure of Phosphoglucomutase/phosphomannomutase family protein (BTH_I1489)from Burkholderia thailandensis
5BT8	;	2.3	;	X-ray Crystal Structure of phosphoglycerate kinase from Acinetobacter baumannii
2ZOH	;	1.25	;	X-ray Crystal Structure of Photoactive Yellow Protein, Wild type, at 295K
4H0M	;	2.2	;	X-Ray Crystal Structure of Phycocyanin from Synechococcus elongatus sp. PCC 7942
4F0T	;	2.25	;	X-Ray Crystal Structure of Phycocyanin from Synechocystis sp. PCC 6803
1T9M	;	1.9	;	X-ray crystal structure of phzG from pseudomonas aeruginosa
1TY9	;	1.8	;	X-RAY CRYSTAL STRUCTURE OF PHZG FROM PSEUDOMONAS FLUORESCENS
2BL9	;	1.9	;	X-ray crystal structure of Plasmodium vivax dihydrofolate reductase in complex with pyrimethamine and its derivative
2BLB	;	3.0	;	X-ray crystal structure of Plasmodium vivax dihydrofolate reductase in complex with pyrimethamine and its derivative
4F4F	;	1.9	;	X-Ray crystal structure of PLP bound Threonine synthase from Brucella melitensis
4F88	;	3.3	;	X-ray Crystal Structure of PlyC
4F87	;	1.4	;	X-ray Crystal Structure of PlyCB
7KWW	;	1.8	;	X-ray Crystal Structure of PlyCB Mutant K59H
7KWY	;	1.7	;	X-ray Crystal Structure of PlyCB Mutant R66K
7KWT	;	1.79	;	X-ray Crystal Structure of PlyCB Mutant Y28H
3FT9	;	2.05	;	X-ray Crystal structure of pollen allergen - Phl p 3
2PO4	;	2.0	;	X-ray crystal structure of polymerase domain of the bacteriophage N4 virion RNA polymerase
4A7E	;	1.856	;	X-ray crystal structure of porcine insulin flash-cooled at high pressure
8ADF	;	2.13	;	X-ray crystal structure of PPAR gamma ligand binding domain in complex with CZ39
8C0C	;	2.2	;	X-ray crystal structure of PPAR gamma ligand binding domain in complex with CZ46
5TTO	;	2.246	;	X-ray crystal structure of PPARgamma in complex with SR1643
5F9B	;	2.25	;	X-ray crystal structure of PPARgamma in the complex with caulophyllogenin
7E2O	;	3.2	;	X-ray Crystal structure of PPARgamma R288H mutant.
4G5D	;	1.8	;	X-ray crystal structure of Prostaglandin f synthase from Leishmania major Friedlin bound to NADPH
1ZBM	;	2.3	;	X-Ray Crystal Structure of Protein AF1704 from Archaeoglobus fulgidus. Northeast Structural Genomics Consortium Target GR62A.
2NYS	;	2.7	;	X-ray Crystal Structure of Protein AGR_C_3712 from Agrobacterium tumefaciens. Northeast Structural Genomics Consortium Target AtR88.
2HQV	;	2.0	;	X-ray Crystal Structure of Protein AGR_C_4470 from Agrobacterium tumefaciens. Northeast Structural Genomics Consortium Target AtR92.
2AXO	;	1.8	;	X-Ray Crystal Structure of Protein AGR_C_4864 from Agrobacterium tumefaciens. Northeast Structural Genomics Consortium Target AtR35.
2O8S	;	2.4	;	X-ray Crystal Structure of Protein AGR_C_984 from Agrobacterium tumefaciens. Northeast Structural Genomics Consortium Target AtR120.
1ZCE	;	1.3	;	X-Ray Crystal Structure of Protein Atu2648 from Agrobacterium tumefaciens. Northeast Structural Genomics Consortium Target AtR33.
2AP6	;	2.5	;	X-Ray Crystal Structure of Protein Atu4242 from Agrobacterium tumefaciens. Northeast Strucutral Genomics Consortium Target AtR43.
2AEG	;	2.3	;	X-Ray Crystal Structure of Protein Atu5096 from Agrobacterium tumefaciens. Northeast Structural Genomics Consortium Target AtR63.
2HZB	;	2.8	;	X-Ray Crystal Structure of Protein BH3568 from Bacillus halodurans. Northeast Structural Genomics Consortium BhR60.
1ZBO	;	2.6	;	X-Ray Crystal Structure of Protein BPP1347 from Bordetella parapertussis. Northeast Structural Genomics Consortium Target BoR27.
2AXP	;	2.5	;	X-Ray Crystal Structure of Protein BSU20280 from Bacillus subtilis. Northeast Structural Genomics Consortium Target SR256.
2F20	;	2.1	;	X-ray Crystal Structure of Protein BT_1218 from Bacteroides thetaiotaomicron. Northeast Structural Genomics Consortium Target BtR8.
2O0P	;	1.9	;	X-ray Crystal Structure of Protein CC0527 (V27M / L66M double mutant) from Caulobacter crescentus. Northeast Structural Genomics Consortium Target CcR55.
2O0Q	;	1.8	;	X-ray Crystal Structure of Protein CC0527 from Caulobacter crescentus. Northeast Structural Genomics Consortium Target CcR55
2NVP	;	2.2	;	X-Ray Crystal Structure of Protein CPF_0428 from Clostridium perfringens. Northeast Structural Genomics Consortium Target CpR63.
2ID1	;	3.0	;	X-Ray Crystal Structure of Protein CV0518 from Chromobacterium violaceum, Northeast Structural Genomics Consortium Target CvR5.
1Z94	;	2.1	;	X-Ray Crystal Structure of Protein CV1439 from Chromobacterium violaceum. Northeast Structural Genomics Consortium Target CvR12.
2O3I	;	2.3	;	X-ray Crystal Structure of Protein CV_3147 from Chromobacterium violaceum. Northeast Structural Genomics Consortium Target CvR68.
2HRX	;	1.9	;	X-Ray Crystal Structure of Protein DIP2367 from Corynebacterium diphtheriae. Northeast Structural Genomics Consortium Target CdR13.
2GSL	;	2.6	;	X-Ray Crystal Structure of Protein FN1578 from Fusobacterium nucleatum. Northeast Structural Genomics Consortium Target NR1.
2B6E	;	1.9	;	X-Ray Crystal Structure of Protein HI1161 from Haemophilus influenzae. Northeast Structural Genomics Consortium Target IR63.
3Q63	;	2.0	;	X-ray crystal structure of protein MLL2253 from Mesorhizobium loti, Northeast Structural Genomics Consortium Target MlR404.
3Q64	;	1.5	;	X-ray crystal structure of protein mll3774 from Mesorhizobium loti, Northeast Structural Genomics Consortium Target MlR405.
1XUV	;	2.1	;	X-Ray Crystal Structure of Protein MM0500 from Methanosarcina mazei. Northeast Structural Genomics Consortium Target MaR10.
1XFS	;	1.7	;	X-Ray Crystal Structure of Protein NE0264 from Nitrosomonas europaea. Northeast Structural Genomics Consortium Target NeR5.
2IMJ	;	1.5	;	X-ray Crystal Structure of Protein PFL_3262 from Pseudomonas fluorescens. Northeast Structural Genomics Consortium Target PlR14.
2BCD	;	2.1	;	X-ray crystal structure of Protein Phosphatase-1 with the marine toxin motuporin bound
2EVE	;	1.6	;	X-Ray Crystal Structure of Protein PSPTO5229 from Pseudomonas syringae. Northeast Structural Genomics Consortium Target PsR62
2EW0	;	1.4	;	X-ray Crystal Structure of Protein Q6FF54 from Acinetobacter sp. ADP1. Northeast Structural Genomics Consortium Target AsR1.
1ZN6	;	1.8	;	X-ray Crystal Structure of Protein Q7WLM8 from Bordetella bronchiseptica. Northeast Structural Genomics Consortium Target BoR19.
1ZXO	;	3.2	;	X-ray Crystal Structure of Protein Q8A1P1 from Bacteroides thetaiotaomicron. Northeast Structural Genomics Consortium Target BtR25.
2AFC	;	2.5	;	X-Ray Crystal Structure of Protein Q8A8B0 from Bacteroides thetaiotaomicron. Northeast Structural Genomics Consortium Target BtR9.
1ZQ7	;	2.11	;	X-Ray Crystal Structure of Protein Q8PZK8 from Methanosarcina mazei. Northeast Structural Genomics Consortium Target MaR9.
1ZNP	;	2.5	;	X-Ray Crystal Structure of Protein Q8U9W0 from Agrobacterium tumefaciens. Northeast Structural Genomics Consortium Target AtR55.
2FFM	;	2.51	;	X-Ray Crystal Structure of Protein SAV1430 from Staphylococcus aureus. Northeast Structural Genomics Consortium Target ZR18.
1YUD	;	2.7	;	X-ray Crystal Structure of Protein SO0799 from Shewanella oneidensis. Northeast Structural Genomics Consortium Target SoR12.
1ZEE	;	2.31	;	X-Ray Crystal Structure of Protein SO4414 from Shewanella oneidensis. Northeast Structural Genomics Consortium Target SoR52.
2IBO	;	2.8	;	X-ray Crystal Structure of Protein SP2199 from Streptococcus pneumoniae. Northeast Structural Genomics Consortium Target SpR31
1PG6	;	1.7	;	X-Ray Crystal Structure of Protein SPYM3_0169 from Streptococcus pyogenes. Northeast Structural Genomics Consortium Target DR2.
3OBH	;	1.891	;	X-ray crystal structure of protein SP_0782 (7-79) from Streptococcus pneumoniae. Northeast Structural Genomics Consortium Target SpR104
2AJ2	;	3.21	;	X-Ray Crystal Structure of Protein VC0467 from Vibrio cholerae. Northeast Structural Genomics Consortium Target VcR8.
1ZBP	;	2.4	;	X-Ray Crystal Structure of Protein VPA1032 from Vibrio parahaemolyticus. Northeast Structural Genomics Consortium Target VpR44
1NXZ	;	2.0	;	X-Ray Crystal Structure of Protein yggj_haein of Haemophilus influenzae. Northeast Structural Genomics Consortium Target IR73.
2H4O	;	2.8	;	X-ray Crystal Structure of Protein yonK from Bacillus subtilis. Northeast Structural Genomics Consortium Target SR415
2DLB	;	1.2	;	X-ray Crystal Structure of Protein yopT from Bacillus subtilis. Northeast Structural Genomics Consortium Target SR412
2I2L	;	2.8	;	X-ray Crystal Structure of Protein yopX from Bacillus subtilis. Northeast Structural Genomics Consortium Target SR411.
2IM8	;	2.0	;	X-Ray Crystal Structure of Protein yppE from Bacillus subtilis. Northeast Structural Genomics Consortium Target SR213.
2NWA	;	2.7	;	X-ray Crystal Structure of Protein ytmB from Bacillus subtilis. Northeast Structural Genomics Consortium Target SR466
2GSV	;	1.9	;	X-Ray Crystal Structure of Protein YvfG from Bacillus subtilis. Northeast Structural Genomics Consortium Target SR478.
2O14	;	2.1	;	X-Ray Crystal Structure of Protein YXIM_BACsu from Bacillus subtilis. Northeast Structural Genomics Consortium Target SR595
2GXF	;	3.1	;	X-Ray Crystal Structure of Protein YybH from Bacillus subtilis. Northeast Structural Genomics Consortium Target SR506.
6RQQ	;	1.276	;	X-ray crystal structure of protiated (H) large monoclinic unit cell CA IX SV.
6RQN	;	1.777	;	X-ray crystal structure of protiated (H) small monoclinic unit cell CA IX SV.
5WV4	;	1.8	;	X-ray Crystal Structure of Pseudoazurin Met16Gly variant
5YSG	;	2.0	;	X-ray Crystal Structure of Pseudoazurin Met16Gly Variant, Reduced Form.
8HM9	;	1.36	;	X-ray Crystal Structure of Pseudoazurin Met16His Variant at pH 4.0
6IFP	;	1.0	;	X-ray Crystal Structure of Pseudoazurin Met16Ile Variant
6AKN	;	1.19	;	X-ray Crystal Structure of Pseudoazurin Met16Leu Variant
5Y23	;	1.4	;	X-ray crystal structure of Pseudoazurin Met16Phe variant
5XMO	;	1.19	;	X-ray crystal structure of Pseudoazurin Met16Phe/Thr36Lys variant
5Z0X	;	1.46	;	X-ray Crystal Structure of Pseudoazurin Met16Tyr Variant
5ZTD	;	1.05	;	X-ray Crystal Structure of Pseudoazurin Met16Val Variant
5YW3	;	1.19	;	X-ray Crystal Structure of Pseudoazurin Thr36Lys Variant
7BK8	;	1.74	;	X-ray crystal structure of Pseudomonas aeruginosa MagC
1XHD	;	1.9	;	X-ray crystal structure of putative acetyltransferase, product of BC4754 gene [Bacillus cereus]
1XR4	;	2.37	;	X-ray crystal structure of putative citrate lyase alpha chain/citrate-ACP transferase [Salmonella typhimurium]
1SFX	;	1.55	;	X-ray crystal structure of putative HTH transcription regulator from Archaeoglobus fulgidus
2Q3F	;	2.1	;	X-ray crystal structure of putative human Ras-related GTP binding D in complex with GMPPNP
1Q77	;	2.7	;	X-ray crystal structure of putative Universal Stress Protein from Aquifex aeolicus
6PLN	;	2.6	;	X-ray crystal structure of Pyrococcus furiosus general transcription factor TFE-alpha
6XJF	;	3.2	;	X-ray crystal structure of Pyrococcus furiosus general transcription factor TFE-alpha (SeMet labeled protein)
3P8B	;	1.8	;	X-ray crystal structure of Pyrococcus furiosus transcription elongation factor Spt4/5
8IHY	;	1.6	;	X-ray crystal structure of Q387E mutant of endo-1,4-beta glucanase from Eisenia fetida
1W6Q	;	2.1	;	X-RAY CRYSTAL STRUCTURE OF R111H HUMAN GALECTIN-1
1ES9	;	1.3	;	X-RAY CRYSTAL STRUCTURE OF R22K MUTANT OF THE MAMMALIAN BRAIN PLATELET-ACTIVATING FACTOR ACETYLHYDROLASES (PAF-AH)
2AHB	;	2.0	;	X-ray crystal structure of R46A,R161A mutant of Mycobacterium tuberculosis FabH
4OIJ	;	2.0	;	X-ray crystal structure of racemic non-glycosylated chemokine Ser-CCL1
3E7R	;	1.0	;	X-ray Crystal Structure of Racemic Plectasin
5O5O	;	3.404	;	X-ray crystal structure of RapZ from Escherichia coli (P32 space group)
5O5Q	;	3.25	;	X-ray crystal structure of RapZ from Escherichia coli (P3221 space group)
3L6C	;	2.2	;	X-ray crystal structure of rat serine racemase in complex with malonate a potent inhibitor
1MUQ	;	2.3	;	X-ray Crystal Structure of Rattlesnake Venom Complexed With Thiodigalactoside
3C1D	;	1.8	;	X-ray crystal structure of RecX
1FHM	;	1.5	;	X-RAY CRYSTAL STRUCTURE OF REDUCED RUBREDOXIN
3K75	;	2.95	;	X-ray crystal structure of reduced XRCC1 bound to DNA pol beta catalytic domain
1PVO	;	3.0	;	X-ray crystal structure of Rho transcription termination factor in complex with ssRNA substrate and ANPPNP
5D6U	;	1.52	;	X-ray crystal structure of ribonuclease A determined for the real space D/H contrast method
5TOY	;	1.3	;	X-Ray Crystal Structure of Ruthenocene Conjugated Penicilloate and Penilloate Products in Complex with CTX-M-14 E166A Beta-Lactamase
6VNU	;	1.47	;	X-ray Crystal Structure of Ruthenocenyl-7-Aminocephalosporanic Acid Covalent Acyl-Enzyme Complex with CTX-M-14 E166A Beta-Lactamase
5UJO	;	1.35	;	X-Ray Crystal Structure of Ruthenocenyl-7-Aminodesacetoxycephalosporanic Acid Covalent Acyl-Enyzme Complex with CTX-M-14 E166A Beta-Lactamase
2A15	;	1.68	;	X-ray Crystal Structure of RV0760 from Mycobacterium Tuberculosis at 1.68 Angstrom Resolution
2Z76	;	1.82	;	X-ray crystal structure of RV0760c from Mycobacterium tuberculosis at 1.82 Angstrom resolution
2Z7A	;	2.1	;	X-ray crystal structure of RV0760c from Mycobacterium tuberculosis at 2.10 Angstrom resolution
2Z77	;	2.03	;	X-ray crystal structure of RV0760c from Mycobacterium tuberculosis in complex with estradiol-17beta-hemisuccinate
5AF3	;	1.78	;	X-RAY CRYSTAL STRUCTURE OF RV2018 FROM MYCOBACTERIUM TUBERCULOSIS
4XAH	;	2.5	;	X-ray crystal structure of S. cerevisiae Cgi121
2OGA	;	2.05	;	X-ray crystal structure of S. venezuelae DesV in complex with ketimine intermediate
4HVR	;	2.7	;	X-ray crystal structure of salicylic acid bound 3-hydroxyanthranilate-3,4-dioxygenase from cupriavidus metallidurans
8EZC	;	1.6	;	X-ray crystal structure of salmonella typhimurium Tryptophan synthase internal aldimine
8EYS	;	2.2	;	X-ray crystal structure of salmonella typhimurium Tryptophan synthase internal aldimine at pH 5.0
2I0L	;	2.31	;	X-ray crystal structure of Sap97 PDZ2 bound to the C-terminal peptide of HPV18 E6.
2I0I	;	2.8	;	X-ray crystal structure of Sap97 PDZ3 bound to the C-terminal peptide of HPV18 E6
4ZY9	;	1.2	;	X-ray crystal structure of selenomethionine-labelled V110M mutant of chitosan-binding module 1 derived from chitosanase/glucanase from Paenibacillus sp. IK-5
5CUF	;	3.5	;	X-ray crystal structure of SeMet human Sestrin2
4OTL	;	2.0	;	X-ray Crystal Structure of Serine Hydroxymethyl Transferase from Burkholderia cenocepacia bound to PLP and Glycine
4OT8	;	2.0	;	X-ray Crystal Structure of Serine Hydroxymethyl Transferase from Burkholderia cenocepacia bound to PLP and Serine
7Z1P	;	1.82	;	X-ray crystal structure of SLPYL1-E151D mutant
7Z1R	;	1.601	;	X-ray crystal structure of SLPYL1-E151D mutant ABA complex
7Z1Q	;	1.683	;	X-ray crystal structure of SLPYL1-E151D mutant with NIO molecules
7Z1S	;	1.65	;	X-ray crystal structure of SLPYL1-NIO complex
6NTT	;	2.4	;	X-ray Crystal Structure of Soybean Trypsin Inhibitor (Kunitz) Complexed with 1,5-Disulfonyl Naphthalene
7XC9	;	1.9	;	X-ray crystal structure of sperm whale myoglobin F46C mutant
7XCQ	;	1.6	;	X-ray crystal structure of sperm whale myoglobin H64D mutant
7XCF	;	1.7	;	X-ray crystal structure of sperm whale myoglobin T67C mutant
5CNP	;	2.38	;	X-ray crystal structure of Spermidine n1-acetyltransferase from Vibrio cholerae.
7B5A	;	1.97	;	X-ray crystal structure of Sporosarcina pasteurii urease inhibited by Ag(PEt3)2NO3 determined at 1.97 Angstroms
7B59	;	1.63	;	X-ray crystal structure of Sporosarcina pasteurii urease inhibited by Ag(PEt3)Br determined at 1.63 Angstroms
7B58	;	1.72	;	X-ray crystal structure of Sporosarcina pasteurii urease inhibited by Ag(PEt3)Cl determined at 1.72 Angstroms
7P7O	;	1.87	;	X-RAY CRYSTAL STRUCTURE OF SPOROSARCINA PASTEURII UREASE INHIBITED BY THE GOLD(I)-DIPHOSPHINE COMPOUND Au(PEt3)2Cl DETERMINED AT 1.87 ANGSTROMS
7P7N	;	1.8	;	X-RAY CRYSTAL STRUCTURE OF SPOROSARCINA PASTEURII UREASE INHIBITED BY THE GOLD(I)-PHOSPHINE COMPOUND Au(PEt3)I DETERMINED AT 1.80 ANGSTROMS
1LRZ	;	2.1	;	x-ray crystal structure of staphylococcus aureus femA
4C13	;	1.9	;	x-ray crystal structure of Staphylococcus aureus MurE with UDP-MurNAc- Ala-Glu-Lys
4C12	;	1.8	;	X-ray Crystal Structure of Staphylococcus aureus MurE with UDP-MurNAc- Ala-Glu-Lys and ADP
4YV6	;	2.053	;	X-ray crystal structure of Streptococcus dysgalactiae SHP pheromone receptor Rgg2
4YV9	;	1.95	;	X-ray crystal structure of Streptococcus dysgalactiae SHP pheromone receptor Rgg2
4N83	;	2.65	;	X-ray crystal structure of Streptococcus sanguinis dimanganese(II)-NrdF
4N82	;	1.88	;	X-ray crystal structure of Streptococcus sanguinis NrdIox
8FLO	;	1.71	;	X-ray crystal structure of substrate free CYP124A1 from Mycobacterium Marinum
7TLO	;	1.55	;	X-ray crystal structure of substrate free cytochrome P450 CYP142A3 from Mycobacterium Marinum
4WWM	;	2.2	;	X-ray crystal structure of Sulfolobus solfataricus Urm1
4YET	;	1.75	;	X-ray crystal structure of superoxide dismutase from Babesia bovis solved by Sulfur SAD
3QMX	;	1.822	;	X-ray crystal structure of Synechocystis sp. PCC 6803 Glutaredoxin A
6M3D	;	1.6	;	X-ray crystal structure of tandemly connected engrailed homeodomains (EHD) with R53A mutations and DNA complex
1VPD	;	1.65	;	X-Ray Crystal Structure of Tartronate Semialdehyde Reductase [Salmonella Typhimurium LT2]
1RRV	;	2.0	;	X-ray crystal structure of TDP-vancosaminyltransferase GtfD as a complex with TDP and the natural substrate, desvancosaminyl vancomycin.
8U8M	;	2.7	;	X-ray crystal structure of TEBP-1 MCD2 homodimer
8U8L	;	2.2	;	X-ray crystal structure of TEBP-2 MCD3 with ds DNA
1ERQ	;	1.9	;	X-RAY CRYSTAL STRUCTURE OF TEM-1 BETA LACTAMASE IN COMPLEX WITH A DESIGNED BORONIC ACID INHIBITOR (1R)-1-ACETAMIDO-2-(3-CARBOXY-2-HYDROXYPHENYL)ETHYL BORONIC ACID
1ERM	;	1.7	;	X-RAY CRYSTAL STRUCTURE OF TEM-1 BETA LACTAMASE IN COMPLEX WITH A DESIGNED BORONIC ACID INHIBITOR (1R)-1-ACETAMIDO-2-(3-CARBOXYPHENYL)ETHANE BORONIC ACID
1ERO	;	2.1	;	X-RAY CRYSTAL STRUCTURE OF TEM-1 BETA LACTAMASE IN COMPLEX WITH A DESIGNED BORONIC ACID INHIBITOR (1R)-2-PHENYLACETAMIDO-2-(3-CARBOXYPHENYL)ETHYL BORONIC ACID
8ER1	;	1.9	;	X-ray crystal structure of Tet(X6)
8ER0	;	2.2	;	X-ray crystal structure of Tet(X6) bound to anhydrotetracycline
5TKV	;	2.7	;	X-RAY CRYSTAL STRUCTURE OF THE ""CLOSED"" CONFORMATION OF CTP-INHIBITED E. COLI CYTIDINE TRIPHOSPHATE (CTP) SYNTHETASE
4FNE	;	2.78	;	X-ray Crystal structure of the Ancestral 3-keto steroid receptor - DOC complex
4FN9	;	3.0	;	X-ray Crystal structure of the Ancestral 3-keto steroid receptor - Progesterone complex
4E2J	;	2.5	;	X-Ray Crystal Structure of the Ancestral Glucocorticoid Receptor 2 ligand binding domain in complex with mometasone furoate and TIF-2 coactivator fragment
5UFS	;	2.118	;	X-Ray Crystal Structure of the Ancestral Glucocorticoid Receptor 2 ligand binding domain in complex with triamcinolone acetonide and SHP coregulator fragment
1ZXV	;	2.67	;	X-Ray Crystal Structure of the Anthrax Lethal Factor Bound to a Small Molecule Inhibitor, BI-MFM3, 3-{5-[5-(4-Chloro-phenyl)-furan-2-ylmethylene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid.
2ANL	;	3.3	;	X-ray crystal structure of the aspartic protease plasmepsin 4 from the malarial parasite plasmodium malariae bound to an allophenylnorstatine based inhibitor
5TUP	;	2.602	;	X-ray Crystal Structure of the Aspergillus fumigatus Sliding Clamp
3NCT	;	2.2	;	X-ray crystal structure of the bacterial conjugation factor PsiB, a negative regulator of reca
8VCW	;	1.35	;	X-Ray Crystal Structure of the biotin synthase from B. obeum
8VDW	;	1.807	;	X-Ray Crystal Structure of the biotin synthase from V. parvula
6PRY	;	1.55	;	X-ray crystal structure of the blue-light absorbing state of PixJ from Thermosynechococcus elongatus by serial femtosecond crystallographic analysis
6VSX	;	2.0	;	X-ray crystal structure of the C-terminal domain of Bacillus subtilis RNA polymerase binding helicase HelD
1UU6	;	1.4	;	X-RAY CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMICOLA GRISEA CEL12A IN COMPLEX WITH A SOAKED CELLOPENTAOSE
1W2U	;	1.52	;	X-RAY CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMICOLA GRISEA CEL12A IN COMPLEX WITH A SOAKED THIO CELLOTETRAOSE
1UU4	;	1.49	;	X-RAY CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMICOLA GRISEA CEL12A IN COMPLEX WITH CELLOBIOSE
1UU5	;	1.67	;	X-RAY CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMICOLA GRISEA CEL12A SOAKED WITH CELLOTETRAOSE
2CKS	;	1.6	;	X-RAY CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THERMOBIFIDA FUSCA ENDOGLUCANASE CEL5A (E5)
2CKR	;	1.77	;	X-RAY CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THERMOBIFIDA FUSCA ENDOGLUCANASE CEL5A (E5) E355Q IN COMPLEX WITH CELLOTETRAOSE
3C7I	;	1.7	;	X-RAY crystal structure of the complex between the grb2-sh2 domain and a flexible ligand, FPTVN.
1PPF	;	1.8	;	X-RAY CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN LEUKOCYTE ELASTASE (PMN ELASTASE) AND THE THIRD DOMAIN OF THE TURKEY OVOMUCOID INHIBITOR
1L4Z	;	2.8	;	X-RAY CRYSTAL STRUCTURE OF THE COMPLEX OF MICROPLASMINOGEN WITH ALPHA DOMAIN OF STREPTOKINASE IN THE PRESENCE CADMIUM IONS
8AY9	;	2.281	;	X-RAY CRYSTAL STRUCTURE OF THE CsPYL1(V112L, T135L,F137I, T153I, V168A)-ABA-HAB1 TERNARY COMPLEX
8AY7	;	2.131	;	X-RAY CRYSTAL STRUCTURE OF THE CsPYL1(V112L, T135L,F137I, T153I, V168A)-iSB7-HAB1 TERNARY COMPLEX
8AY8	;	1.78	;	X-RAY CRYSTAL STRUCTURE OF THE CsPYL1(V112L, T135L,F137I, T153I, V168A)-iSB9-HAB1 TERNARY COMPLEX
8AY6	;	1.84	;	X-RAY CRYSTAL STRUCTURE OF THE CsPYL1(V112L, T135L,F137I, T153I, V168A)-SB-HAB1 TERNARY COMPLEX
8AYA	;	1.742	;	X-RAY CRYSTAL STRUCTURE OF THE CsPYL1-A10-HAB1 TERNARY COMPLEX
7AVW	;	2.1	;	X-RAY CRYSTAL STRUCTURE OF THE CsPYL1-iSB07-HAB1 TERNARY COMPLEX
8AY3	;	1.9	;	X-RAY CRYSTAL STRUCTURE OF THE CsPYL1-iSB9-HAB1 TERNARY COMPLEX
6ZUC	;	2.37	;	X-RAY CRYSTAL STRUCTURE OF THE CsPYL1-Lig1-HAB1 TERNARY COMPLEX
2PA8	;	1.76	;	X-Ray Crystal Structure of the D/L Subcomplex of the Sulfolobus Solfataricus RNA polymerase
1BU5	;	1.83	;	X-RAY CRYSTAL STRUCTURE OF THE DESULFOVIBRIO VULGARIS (HILDENBOROUGH) APOFLAVODOXIN-RIBOFLAVIN COMPLEX
4X1J	;	2.5	;	X-ray crystal structure of the dimeric BMP antagonist NBL1
3PC7	;	1.65	;	X-ray crystal structure of the DNA ligase III-alpha BRCT domain.
1IL0	;	2.2	;	X-RAY CRYSTAL STRUCTURE OF THE E170Q MUTANT OF HUMAN L-3-HYDROXYACYL-COA DEHYDROGENASE
3K6B	;	2.8	;	X-ray crystal structure of the E2 domain of APL-1 from C. elegans, in complex with sucrose octasulfate (SOS)
3K66	;	2.7	;	X-ray crystal structure of the E2 domain of C. elegans APL-1
6M4M	;	1.7	;	X-ray crystal structure of the E249Q mutan of alpha-amylase I and maltohexaose complex from Eisenia fetida
6M4L	;	1.6	;	X-ray crystal structure of the E249Q mutant of alpha-amylase I from Eisenia fetida
6OIU	;	2.2	;	X-ray crystal structure of the ectodomain of the Toxoplasma gondii ME49 Aminopeptidase N (TGME49_224350)
2VTF	;	1.79	;	X-ray crystal structure of the Endo-beta-N-acetylglucosaminidase from Arthrobacter protophormiae E173Q mutant reveals a TIM barrel catalytic domain and two ancillary domains
3N75	;	2.0	;	X-ray Crystal Structure of the Escherichia coli Inducible Lysine Decarboxylase LdcI
4KN4	;	3.965	;	X-ray crystal structure of the Escherichia coli RNA polymerase in complex with Benzoxazinorifamycin-2b
4KN7	;	3.686	;	X-ray crystal structure of the Escherichia coli RNA polymerase in complex with Benzoxazinorifamycin-2c
4KMU	;	3.85	;	X-ray crystal structure of the Escherichia coli RNA polymerase in complex with Rifampin
3IWQ	;	1.84	;	X-ray crystal structure of the extended-spectrum AmpC E219K mutant beta-lactamase at 1.84 Angstrom resolution
3IXB	;	1.63	;	X-ray crystal structure of the extended-spectrum AmpC E219K mutant beta-lactamase complexed with benzo(b)thiophene-2-boronic acid (BZB) at 1.63 Angstrom resolution
3IWI	;	1.64	;	X-ray crystal structure of the extended-spectrum AmpC omega loop insertion (H210AAA) mutant beta-lactamase at 1.64 Angstrom resolution
3IXG	;	2.14	;	X-ray crystal structure of the extended-spectrum AmpC T70I mutant beta-lactamase with and without benzo(b)thiophene-2-boronic acid bound at 2.14 Angstrom resolution
3IXD	;	2.64	;	X-ray crystal structure of the extended-spectrum AmpC V298E mutant beta-lactamase at 2.64 Angstrom resolution
3IWO	;	1.9	;	X-ray crystal structure of the extended-spectrum AmpC Y221G mutant beta-lactamase at 1.90 Angstrom resolution
3IXH	;	2.3	;	X-ray crystal structure of the extended-spectrum AmpC Y221G mutant beta-lactamase in complex with cefotaxime at 2.3 Angstrom resolution
3L3H	;	2.7	;	X-ray crystal structure of the F6A mutant of influenza A acid polymerase epitope PA224 bound to murine H2-Db MHC
3GK8	;	2.0	;	X-ray crystal structure of the Fab from MAb 14, mouse antibody against Canine Parvovirus
1MBI	;	2.0	;	X-RAY CRYSTAL STRUCTURE OF THE FERRIC SPERM WHALE MYOGLOBIN: IMIDAZOLE COMPLEX AT 2.0 ANGSTROMS RESOLUTION
1SWM	;	1.8	;	X-RAY CRYSTAL STRUCTURE OF THE FERRIC SPERM WHALE MYOGLOBIN: IMIDAZOLE COMPLEX AT 2.0 ANGSTROMS RESOLUTION
6S6Y	;	3.1	;	X-ray crystal structure of the formyltransferase/hydrolase complex (FhcABCD) from Methylorubrum extorquens in complex with methylofuran
2HUW	;	1.9	;	X-ray crystal structure of the Grb2 SH2 domain complexed to a constrained and cyclopropane-derived ligand
4EAB	;	1.35	;	X-ray crystal structure of the H141A mutant of GDP-perosamine N-acetyl transferase from Caulobacter crescentus in complex with CoA and GDP-perosamine
4EAA	;	1.45	;	X-ray crystal structure of the H141N mutant of perosamine N-acetyltransferase from Caulobacter crescentus in complex with CoA and GDP-perosamine
3PC8	;	2.31	;	X-ray crystal structure of the heterodimeric complex of XRCC1 and DNA ligase III-alpha BRCT domains.
3E9W	;	2.05	;	X-Ray Crystal Structure of the hexamer DCACACG:Crystal grown in the presence of cobalt(III)hexammine Chloride.
4PHV	;	2.1	;	X-RAY CRYSTAL STRUCTURE OF THE HIV PROTEASE COMPLEX WITH L-700,417, AN INHIBITOR WITH PSEUDO C2 SYMMETRY
1F3H	;	2.58	;	X-RAY CRYSTAL STRUCTURE OF THE HUMAN ANTI-APOPTOTIC PROTEIN SURVIVIN
6EQU	;	1.65	;	X-Ray crystal structure of the human carbonic anhydrase II adduct with a membrane-impermeant inhibitor
1HLC	;	2.9	;	X-RAY CRYSTAL STRUCTURE OF THE HUMAN DIMERIC S-LAC LECTIN, L-14-II, IN COMPLEX WITH LACTOSE AT 2.9 ANGSTROMS RESOLUTION
1A3K	;	2.1	;	X-RAY CRYSTAL STRUCTURE OF THE HUMAN GALECTIN-3 CARBOHYDRATE RECOGNITION DOMAIN (CRD) AT 2.1 ANGSTROM RESOLUTION
3KDF	;	1.975	;	X-ray Crystal Structure of the Human Replication Protein A Complex from Wheat Germ Cell Free Expression
1U7P	;	1.9	;	X-ray Crystal Structure of the Hypothetical Phosphotyrosine Phosphatase MDP-1 of the Haloacid Dehalogenase Superfamily
1K3Z	;	2.5	;	X-ray crystal structure of the IkBb/NF-kB p65 homodimer complex
2VKL	;	1.65	;	X-ray crystal structure of the intracellular Chorismate mutase from Mycobactrerium Tuberculosis in complex with malate
4PIJ	;	1.5	;	X-ray crystal structure of the K11S/K63S double mutant of ubiquitin
4PIH	;	1.5	;	X-ray crystal structure of the K33S mutant of ubiquitin
1P1Z	;	3.26	;	X-RAY CRYSTAL STRUCTURE OF THE LECTIN-LIKE NATURAL KILLER CELL RECEPTOR LY-49C BOUND TO ITS MHC CLASS I LIGAND H-2Kb
4LX5	;	2.13	;	X-ray crystal structure of the M6"" riboswitch aptamer bound to pyrimido[4,5-d]pyrimidine-2,4-diamine (PPDA)
4LX6	;	2.15	;	X-ray crystal structure of the M6C"" riboswitch aptamer bound to 2-aminopyrimido[4,5-d]pyrimidin-4(3H)-one (PPAO)
2H6L	;	2.0	;	X-Ray Crystal Structure of the Metal-containing Protein AF0104 from Archaeoglobus fulgidus. Northeast Structural Genomics Consortium Target GR103.
1LVK	;	1.9	;	X-RAY CRYSTAL STRUCTURE OF THE MG (DOT) 2'(3')-O-(N-METHYLANTHRANILOYL) NUCLEOTIDE BOUND TO DICTYOSTELIUM DISCOIDEUM MYOSIN MOTOR DOMAIN
3JR2	;	1.8	;	X-ray crystal structure of the Mg-bound 3-keto-L-gulonate-6-phosphate decarboxylase from Vibrio cholerae O1 biovar El Tor str. N16961
6XBO	;	1.8	;	X-ray crystal structure of the mouse CMP-Sialic acid transporter in complex with 5-methyl CMP
6OH4	;	3.38	;	X-ray crystal structure of the mouse CMP-sialic acid transporter in complex with CMP, by hanging drop vapor diffusion
6OH2	;	2.58	;	X-ray crystal structure of the mouse CMP-sialic acid transporter in complex with CMP, by lipidic cubic phase
6OH3	;	2.75	;	X-ray crystal structure of the mouse CMP-sialic acid transporter in complex with CMP-sialic acid, by lipidic cubic phase
6H24	;	1.53	;	X-Ray Crystal Structure of the MSBI1.176 WH1 Domain, a Replication Protein Isolated from a Multiple Sclerosis Patient
6RO1	;	3.07	;	X-ray crystal structure of the MTR4 NVL complex
6L27	;	0.77	;	X-ray crystal structure of the mutant green fluorescent protein
3DRZ	;	1.9	;	X-ray crystal structure of the N-terminal BTB domain of human KCTD5 protein
8FRT	;	1.8	;	X-ray crystal structure of the N-terminal region from HCMV US11 binding to HLA-A*02:01
3Q23	;	1.8	;	X-ray crystal structure of the N4 mini-VRNAP and P2_7a promoter transcription initiation complex with GMPCPP and Manganese: sustrate complex II
3Q22	;	2.11	;	X-ray crystal structure of the N4 mini-VRNAP and P2_7a promoter transcription initiation complex with GTP and Magnesium: substrate complex I
3Q24	;	1.81	;	X-ray crystal structure of the N4 mini-VRNAP and P2_7a promoter transcription initiation complex with pppGpG and pyrophosphate: product complex
3C2P	;	2.0	;	X-ray crystal structure of the N4 mini-vRNAP P1 promoter complex
3C3L	;	2.4	;	X-ray crystal structure of the N4 mini-vRNAP P2 promoter complex
3C46	;	2.0	;	X-ray crystal structure of the N4 mini-vRNAP P2_7a promoter complex soaked with MgCl2
1MIO	;	3.0	;	X-RAY CRYSTAL STRUCTURE OF THE NITROGENASE MOLYBDENUM-IRON PROTEIN FROM CLOSTRIDIUM PASTEURIANUM AT 3.0 ANGSTROMS RESOLUTION
3R8A	;	2.41	;	X-ray crystal structure of the nuclear hormone receptor PPAR-gamma in a complex with a compound with dual PPAR gamma agonism and Angiotensin II Type I receptor antagonism activity
2Q8S	;	2.3	;	X-ray Crystal structure of the nuclear hormone receptor PPAR-gamma in a complex with a PPAR gamma/alpha dual agonist
3IA6	;	2.31	;	X-ray Crystal structure of the nuclear hormone receptor PPAR-gamma in a complex with a PPAR gamma/alpha dual agonist
4X2U	;	1.5	;	X-ray crystal structure of the orally available aminopeptidase inhibitor, Tosedostat, bound to the M1 Alanyl Aminopeptidase from P. falciparum
4X2T	;	2.729	;	X-ray crystal structure of the orally available aminopeptidase inhibitor, Tosedostat, bound to the M17 Leucyl Aminopeptidase from P. falciparum
4OM9	;	2.3	;	X-Ray Crystal Structure of the passenger domain of Plasmid encoded toxin, an Autrotansporter Enterotoxin from enteroaggregative Escherichia coli (EAEC)
1CVJ	;	2.6	;	X-RAY CRYSTAL STRUCTURE OF THE POLY(A)-BINDING PROTEIN IN COMPLEX WITH POLYADENYLATE RNA
5U5L	;	2.55	;	X-ray Crystal Structure of the PPARgamma Ligand Binding Domain in Complex with Rivoglitazone
1AAP	;	1.5	;	X-RAY CRYSTAL STRUCTURE OF THE PROTEASE INHIBITOR DOMAIN OF ALZHEIMER'S AMYLOID BETA-PROTEIN PRECURSOR
3Q6A	;	1.8	;	X-ray crystal structure of the protein SSP2350 from Staphylococcus saprophyticus, Northeast structural genomics consortium target SyR116
3RK0	;	2.4	;	X-ray crystal Structure of the putative N-type ATP pyrophosphatase (PF0828) in complex with AMP from Pyrococcus furiosus, Northeast Structural Genomics Consortium Target PfR23
3RJZ	;	2.3	;	X-ray crystal structure of the putative n-type atp pyrophosphatase from pyrococcus furiosus, the northeast structural genomics target pfr23
3OJI	;	1.84	;	X-ray crystal structure of the Py13 -pyrabactin complex
3NJ1	;	1.948	;	X-ray crystal structure of the PYL2(V114I)-pyrabactin A complex
3NJ0	;	1.89	;	X-ray crystal structure of the PYL2-pyrabactin A complex
4LA7	;	1.98	;	X-ray crystal structure of the PYL2-quinabactin-Hab1 ternary complex
3NJO	;	2.473	;	X-ray crystal structure of the Pyr1-pyrabactin A complex
6QSQ	;	2.0	;	X-ray crystal structure of the R336L Vibrio alkaline phosphatase variant.
5O5S	;	1.17	;	X-ray crystal structure of the RapZ C-terminal domain from Escherichia coli
3C0C	;	1.7	;	X-ray Crystal Structure of the Rat Endophilin A2 SH3 Domain
1PV4	;	3.0	;	X-ray crystal structure of the Rho transcription termination factor in complex with single stranded DNA
1IU5	;	1.5	;	X-ray Crystal Structure of the rubredoxin mutant from Pyrococcus Furiosus
4LY2	;	2.1	;	X-ray crystal structure of the ruthenium complex [Ru(phen)2(dppz)]2+ bound to d(TCGGTACCGA)
3QF8	;	1.73	;	X-ray crystal structure of the ruthenium complex [Ru(tap)2(dppz)]2+ bound to d(TCGGCGCCGA) at medium resolution
3QRN	;	1.1	;	X-ray crystal structure of the ruthenium complex [Ru(tap)2(dppz)]2+ bound to d(TCGGCGCCGA)at high resolution
3UYB	;	1.5	;	X-ray crystal structure of the ruthenium complex [Ru(tap)2(dppz)]2+ bound to d(TCGGTACCGA)
4M3I	;	2.1	;	X-ray crystal structure of the ruthenium complex [Ru(TAP)2(dppz-{Me2})]2+ bound to d(CCGGTACCGG)
4M3V	;	2.05	;	X-ray crystal structure of the ruthenium complex [Ru(Tap)2(dppz-{Me2})]2+ bound to d(TCGGTACCGA)
4OXP	;	2.1	;	X-ray crystal structure of the S1 and 5'-sensor domains of RNase E from Caulobacter crescentus
1Q2W	;	1.86	;	X-Ray Crystal Structure of the SARS Coronavirus Main Protease
3BGF	;	3.0	;	X-ray crystal structure of the SARS coronavirus spike receptor binding domain in complex with F26G19 Fab
7LKE	;	2.69	;	X-ray crystal structure of the SARS-CoV-2 main protease in space group C2
7LKD	;	2.01	;	X-ray crystal structure of the SARS-CoV-2 main protease in space group P21.
7LBN	;	1.76	;	X-ray crystal structure of the SARS-CoV-2 main protease with Calpain I Inhibitor
3PC6	;	1.9	;	X-ray crystal structure of the second XRCC1 BRCT domain.
6Q57	;	2.72	;	X-ray crystal structure of the tetrahydrofolate riboswitch aptamer bound to 5-deazatetrahydropterin
3Q0A	;	2.69	;	X-ray crystal structure of the transcription initiation complex of the N4 mini-vRNAP with P2 promoter: Mismatch complex
4E1S	;	1.855	;	X-ray crystal structure of the transmembrane beta-domain from intimin from EHEC strain O157:H7
4E1T	;	2.263	;	X-ray crystal structure of the transmembrane beta-domain from invasin from Yersinia pseudotuberculosis
1V8Z	;	2.21	;	X-ray crystal structure of the Tryptophan Synthase b2 Subunit from Hyperthermophile, Pyrococcus furiosus
2AZU	;	1.9	;	X-RAY CRYSTAL STRUCTURE OF THE TWO SITE-SPECIFIC MUTANTS HIS35*GLN AND HIS35*LEU OF AZURIN FROM PSEUDOMONAS AERUGINOSA
3AZU	;	2.1	;	X-RAY CRYSTAL STRUCTURE OF THE TWO SITE-SPECIFIC MUTANTS HIS35GLN AND HIS35LEU OF AZURIN FROM PSEUDOMONAS AERUGINOSA
3RRU	;	3.0	;	X-ray crystal structure of the VHS domain of human TOM1-like protein, Northeast Structural Genomics Consortium Target HR3050E
3NYU	;	1.501	;	X-ray crystal structure of the Wbpe (WlbE) aminotransferase from pseudomonas aeruginosa as the PLP internal aldimine adduct with lysine 185
3NYT	;	1.301	;	X-ray crystal structure of the WlbE (WpbE) aminotransferase from pseudomonas aeruginosa, mutation K185A, in complex with the PLP external aldimine adduct with UDP-3-amino-2-N-acetyl-glucuronic acid, at 1.3 angstrom resolution
6OFU	;	1.75	;	X-ray crystal structure of the YdjI aldolase from Escherichia coli K12
4QJF	;	2.312	;	X-ray crystal structure of Thermocuccus kodakarensis RNA polymerase Rpp4/Rpo7 (RpoF/RpoE) complex
8EMB	;	3.06	;	X-ray crystal structure of Thermosynechococcus elongatus Si3 domain of RNA polymerase RpoC2 subunit
4HYN	;	2.5	;	X-ray crystal structure of Thermotoga maritima FliY
4WXT	;	1.2	;	X-ray crystal structure of thioredoxin from Mycobacterium avium
1YPL	;	1.85	;	X-ray crystal structure of thrombin inhibited by synthetic cyanopeptide analogue RA-1008
1YPM	;	1.85	;	X-ray crystal structure of thrombin inhibited by synthetic cyanopeptide analogue RA-1014
8VPO	;	1.66	;	X-Ray Crystal Structure of TigE from Paramaledivibacter caminithermalis
1NF2	;	2.2	;	X-ray crystal structure of TM0651 from Thermotoga maritima
6NPB	;	1.73	;	X-ray crystal structure of TmpA, 2-trimethylaminoethylphosphonate hydroxylase, with Fe and 2OG
6NPD	;	1.78	;	X-ray crystal structure of TmpA, 2-trimethylaminoethylphosphonate hydroxylase, with Fe, 2OG, and (R)-1-hydroxy-2-trimethylaminoethylphosphonate
6NPC	;	1.7	;	X-ray crystal structure of TmpA, 2-trimethylaminoethylphosphonate hydroxylase, with Fe, 2OG, and 2-trimethylaminoethylphosphonate
6NPA	;	1.73	;	X-ray crystal structure of TmpB, (R)-1-hydroxy-2-trimethylaminoethylphosphonate oxygenase, with (R)-1-hydroxy-2-trimethylaminoethylphosphonate
2RDB	;	2.1	;	X-ray Crystal Structure of Toluene/o-Xylene Monooxygenase Hydroxylase I100W Mutant
3N1X	;	2.4	;	X-ray Crystal Structure of Toluene/o-Xylene Monooxygenase Hydroxylase T201C Mutant
3N1Y	;	2.1	;	X-ray Crystal Structure of Toluene/o-Xylene Monooxygenase Hydroxylase T201G Mutant
3N1Z	;	2.9	;	X-ray Crystal Structure of Toluene/o-Xylene Monooxygenase Hydroxylase T201S Mutant
3N20	;	1.9	;	X-ray Crystal Structure of Toluene/o-Xylene Monooxygenase Hydroxylase T201V Mutant
3QFI	;	2.71	;	X-ray crystal structure of transcriptional regulator (EF0465) from Enterococcus faecalis, Northeast Structural Genomics Consortium Target EfR190
3FM5	;	2.0	;	X-ray crystal structure of transcriptional regulator (MarR family) from Rhodococcus sp. RHA1
3L82	;	2.4	;	X-ray Crystal structure of TRF1 and Fbx4 complex
6V3T	;	2.84	;	X-Ray Crystal Structure of Tribolium castaneum Arylalkylamine N-acyltransferase in Complex with Acetyl-CoA
1DLW	;	1.54	;	X-RAY CRYSTAL STRUCTURE OF TRUNCATED HEMOGLOBIN FROM P.CAUDATUM.
7STA	;	2.5	;	X-ray Crystal Structure of Truncated Human Chemokine CCL19 (7-70)
5E0K	;	2.76	;	X-ray crystal structure of tryptophan synthase complex from Pyrococcus furiosus at 2.76 A
2OHY	;	2.5	;	X-ray Crystal Structure of Tyrosine Aminomutase from streptomyces globisporus
3KDY	;	2.2	;	X-ray crystal structure of tyrosine aminomutase mutant construct
8SXY	;	1.8	;	X-ray crystal structure of UDP- 2,3-diacetamido-2,3-dideoxy-glucuronic acid-2-epimerase from Thermus thermophilus strain HB27 in complex with its product UDP-2,3-diacetamido-2,3-dideoxy-d-mannuronic acid at pH 5
8SY0	;	2.1	;	X-ray crystal structure of UDP- 2,3-diacetamido-2,3-dideoxy-glucuronic acid-2-epimerase from Thermus thermophilus strain HB27 in complex with its product UDP-2,3-diacetamido-2,3-dideoxy-d-mannuronic acid at pH 9
8SXV	;	2.3	;	X-ray crystal structure of UDP- 2,3-diacetamido-2,3-dideoxy-glucuronic acid-2-epimerase from Thermus thermophilus strain HB27, apo form, pH 9
8SXW	;	1.8	;	X-ray crystal structure of UDP- 2,3-diacetamido-2,3-dideoxy-glucuronic acid-2-epimerase from Thermus thermophilus strain HB27, D98N mutation, apo structure at pH 6
8SYE	;	1.9	;	X-ray crystal structure of UDP-2,3-diacetamido-2,3-dideoxy-glucuronic acid-2-epimerase from Thermus thermophilus strain HB27, D98N variant in the presence of UDP-2,3-diacetamido-2,3-dideoxy-glucuronic acid and UDP at pH 6
8SYH	;	2.0	;	X-ray crystal structure of UDP-2,3-diacetamido-2,3-dideoxy-glucuronic acid-2-epimerase from Thermus thermophilus strain HB27, D98N variant in the presence of UDP-2,3-diacetamido-2,3-dideoxy-glucuronic acid and UDP at pH 8
8SYA	;	2.3	;	X-ray crystal structure of UDP-2,3-diacetamido-2,3-dideoxy-glucuronic acid-2-epimerase from Thermus thermophilus strain HB27, D98N variant in the presence of UDP-2,3-diacetamido-2,3-dideoxy-glucuronic acid and UDP at pH 9
8SYD	;	2.2	;	X-ray crystal structure of UDP-2,3-diacetamido-2,3-dideoxy-glucuronic acid-2-epimerase from Thermus thermophilus strain HB27, D98N variant in the presence of UDP-2,3-diacetamido-2,3-dideoxy-glucuronic acid and UDP-N-acetylglucosamine at pH 6
8SYB	;	2.2	;	X-ray crystal structure of UDP-2,3-diacetamido-2,3-dideoxy-glucuronic acid-2-epimerase from Thermus thermophilus strain HB27, D98N variant in the presence of UDP-2,3-diacetamido-2,3-dideoxy-glucuronic acid and UDP-N-acetylglucosamine at pH 9
8SY9	;	2.2	;	X-ray crystal structure of UDP-2,3-diacetamido-2,3-dideoxy-glucuronic acid-2-epimerase from Thermus thermophilus strain HB27, D98N variant in the presence of UDP-2,3-diacetamido-2,3-dideoxy-glucuronic acid, UDP-N-acetylglucosamine and UDP at pH 7
1RNF	;	2.1	;	X-RAY CRYSTAL STRUCTURE OF UNLIGANDED HUMAN RIBONUCLEASE 4
8W47	;	1.4	;	X-ray crystal structure of V30M-TTR in complex with isorhapontigenin
8W44	;	1.399	;	X-ray crystal structure of V30M-TTR in complex with oxyresveratrol
8W43	;	1.302	;	X-ray crystal structure of V30M-TTR in complex with piceatannol
8W45	;	1.1	;	X-ray crystal structure of V30M-TTR in complex with pinostilbene
8W46	;	1.35	;	X-ray crystal structure of V30M-TTR in complex with pterostilbene
8W42	;	1.45	;	X-ray crystal structure of V30M-TTR in complex with resveratrol
8GRZ	;	2.0	;	X-ray crystal structure of V71C human neuroglobin mutant
7E4J	;	1.63	;	X-ray crystal structure of VapB12 antitoxin from mycobacterium tuberculosis in space group P41.
6T26	;	2.265	;	X-ray crystal structure of Vibrio alkaline phosphatase with the non-competitive inhibitor cyclohexylamine
6MP9	;	1.89	;	X-ray crystal structure of VioC bound to Fe(II), 2-oxo-5-guanidinopentanoic acid, and succinate
6DAZ	;	1.94	;	X-ray crystal structure of VioC bound to Fe(II), 3S-hydroxy-L-homoarginine, and succinate
6MP8	;	1.89	;	X-ray crystal structure of VioC bound to Fe(II), D-arginine, and 2-oxoglutarate
6DAX	;	1.7	;	X-ray crystal structure of VioC bound to Fe(II), L-homoarginine, and 2-oxoglutarate
6DB2	;	1.7	;	X-ray crystal structure of VioC bound to vanadyl ion, L-homoarginine, and succinate
7N7H	;	1.42	;	X-ray crystal structure of Viperin-like enzyme from Nematostella vectensis
7N7I	;	3.19	;	X-ray crystal structure of Viperin-like enzyme from Trichoderma virens
7F1X	;	3.0	;	X-ray crystal structure of visual arrestin complexed with inositol 1,4,5-triphosphate
7F1W	;	3.097	;	X-ray crystal structure of visual arrestin complexed with inositol hexaphosphate
2AJ9	;	2.5	;	X-ray crystal structure of W42A,R161A double mutant of Mycobacterium tuberculosis beta-ketoacyl-ACP synthase III
6M4K	;	1.3	;	X-ray crystal structure of wild type alpha-amylase I from Eisenia fetida
6MCR	;	1.48	;	X-ray crystal structure of wild type HIV-1 protease in complex with GRL-001
6OYR	;	1.54	;	X-ray crystal structure of wild type HIV-1 protease in complex with GRL-002
6MCS	;	1.52	;	X-ray crystal structure of wild type HIV-1 protease in complex with GRL-003
6OYD	;	1.46	;	X-ray crystal structure of wild type HIV-1 protease in complex with GRL-004
5CON	;	1.8	;	X-ray crystal structure of wild type HIV-1 protease in complex with GRL-015
5COK	;	1.801	;	X-ray crystal structure of wild type HIV-1 protease in complex with GRL-0476
6OGP	;	1.53	;	X-ray crystal structure of wild type HIV-1 protease in complex with GRL-063
6D0E	;	1.95	;	X-ray crystal structure of wild type HIV-1 protease in complex with GRL-084-13
5COO	;	1.8	;	X-ray crystal structure of wild type HIV-1 protease in complex with GRL-085
6UWB	;	1.95	;	X-ray crystal structure of wild type HIV-1 protease in complex with GRL-08513
6UWC	;	1.95	;	X-ray crystal structure of wild type HIV-1 protease in complex with GRL-08613
6D0D	;	1.85	;	X-ray crystal structure of wild type HIV-1 protease in complex with GRL-087-13
5V4Y	;	1.9	;	X-ray crystal structure of wild type HIV-1 protease in complex with GRL-09510
5COP	;	2.0	;	X-ray crystal structure of wild type HIV-1 protease in complex with GRL-097
5TYR	;	1.8	;	X-ray crystal structure of wild type HIV-1 protease in complex with GRL-121
5TYS	;	2.007	;	X-ray crystal structure of wild type HIV-1 protease in complex with GRL-142
3VOX	;	3.1	;	X-ray Crystal Structure of Wild Type HrtR in the Apo Form
3VOK	;	2.0	;	X-ray Crystal Structure of Wild Type HrtR in the Apo Form with the Target DNA.
3VP5	;	1.9	;	X-ray Crystal Structure of Wild Type HrtR in the Holo Form
3FE0	;	1.5	;	X-ray crystal structure of wild type human lysozyme in D2O
1XI0	;	2.0	;	X-ray crystal structure of wild-type Xerocomus chrysenteron lectin XCL
3U52	;	1.95	;	X-ray Crystal Structure of Xenon-Pressurized Phenol Hydroxylase from Pseudomonas sp. OX1
3WUD	;	1.68	;	X-ray crystal structure of Xenopus laevis galectin-Ib
3WUC	;	1.6	;	X-ray crystal structure of Xenopus laevis galectin-Va
1X99	;	1.4	;	X-ray crystal structure of Xerocomus chrysenteron lectin XCL at 1.4 Angstroms resolution, mutated at Q46M, V54M, L58M
3K77	;	2.597	;	X-ray crystal structure of XRCC1
6OXJ	;	1.55	;	X-ray crystal structure of Y140F FtmOx1 bound to Fe(II)
7F4Z	;	1.8	;	X-ray crystal structure of Y149A mutated Hsp72-NBD in complex with ADP
7F50	;	1.703	;	X-ray crystal structure of Y149A mutated Hsp72-NBD in complex with AMPPnP
1D8I	;	2.05	;	X-RAY CRYSTAL STRUCTURE OF YEAST RNA TRIPHOSPHATASE IN COMPLEX WITH A SULFATE ION.
1D8H	;	2.0	;	X-RAY CRYSTAL STRUCTURE OF YEAST RNA TRIPHOSPHATASE IN COMPLEX WITH SULFATE AND MANGANESE IONS.
1S3J	;	2.25	;	X-ray crystal structure of YusO protein from Bacillus subtilis
1FQM	;	2.0	;	X-RAY CRYSTAL STRUCTURE OF ZINC-BOUND F93I/F95M/W97V CARBONIC ANHYDRASE (CAII) VARIANT
1FR7	;	1.5	;	X-RAY CRYSTAL STRUCTURE OF ZINC-BOUND F93S/F95L/W97M CARBONIC ANHYDRASE (CAII) VARIANT
1FQL	;	2.0	;	X-RAY CRYSTAL STRUCTURE OF ZINC-BOUND F95M/W97V CARBONIC ANHYDRASE (CAII) VARIANT
1ZHV	;	1.5	;	X-ray Crystal Structure Protein Atu0741 from Agobacterium tumefaciens. Northeast Structural Genomics Consortium Target AtR8.
2G2X	;	2.3	;	X-Ray Crystal Structure Protein Q88CH6 from Pseudomonas putida. Northeast Structural Genomics Consortium Target PpR72.
1SQS	;	1.5	;	X-Ray Crystal Structure Protein SP1951 of Streptococcus pneumoniae. Northeast Structural Genomics Consortium Target SpR27.
3PFH	;	1.792	;	X-Ray crystal structure the N,N-dimethyltransferase TylM1 from Streptomyces fradiae in complex with SAH and dTDP-Quip3N
3PFG	;	1.349	;	X-Ray crystal structure the N,N-dimethyltransferase TylM1 from Streptomyces fradiae in complex with SAM and dTDP-phenol
1ILS	;	2.2	;	X-RAY CRYSTAL STRUCTURE THE TWO SITE-SPECIFIC MUTANTS ILE7SER AND PHE110SER OF AZURIN FROM PSEUDOMONAS AERUGINOSA
1ILU	;	2.3	;	X-RAY CRYSTAL STRUCTURE THE TWO SITE-SPECIFIC MUTANTS ILE7SER AND PHE110SER OF AZURIN FROM PSEUDOMONAS AERUGINOSA
486D	;	7.5	;	X-RAY CRYSTAL STRUCTURES OF 70S RIBOSOME FUNCTIONAL COMPLEXES
3AYI	;	1.25	;	X-ray crystal structures of L-phenylalanine oxidase (deaminating and decaboxylating) from Pseudomonas sp. P501. Structures of the enzyme-ligand complex and catalytic mechanism
3AYJ	;	1.1	;	X-ray crystal structures of L-phenylalanine oxidase (deaminating and decaboxylating) from Pseudomonas sp. P501. Structures of the enzyme-ligand complex and catalytic mechanism
3AYL	;	1.25	;	X-ray crystal structures of L-phenylalanine oxidase (deaminating and decaboxylating) from Pseudomonas sp. P501. Structures of the enzyme-ligand complex and catalytic mechanism
1YCH	;	2.8	;	X-ray Crystal Structures of Moorella thermoacetica FprA. Novel Diiron Site Structure and Mechanistic Insights into a Scavenging Nitric Oxide Reductase
349D	;	1.9	;	X-RAY CRYSTAL STRUCTURES OF THE DECAMER DGACCGCGGTC: HIGH SALT CONCENTRATION
348D	;	1.7	;	X-RAY CRYSTAL STRUCTURES OF THE DECAMER DGACCGCGGTC: LOW SALT CONCENTRATION
351D	;	1.64	;	X-RAY CRYSTAL STRUCTURES OF THE HEXAMER DCACGCG: CRYSTALS GROWN IN THE PRESENCE OF RUTHENIUM (II) HEXAMMINE CHLORIDE
1CAA	;	1.8	;	X-RAY CRYSTAL STRUCTURES OF THE OXIDIZED AND REDUCED FORMS OF THE RUBREDOXIN FROM THE MARINE HYPERTHERMOPHILIC ARCHAEBACTERIUM PYROCOCCUS FURIOSUS
1CAD	;	1.8	;	X-RAY CRYSTAL STRUCTURES OF THE OXIDIZED AND REDUCED FORMS OF THE RUBREDOXIN FROM THE MARINE HYPERTHERMOPHILIC ARCHAEBACTERIUM PYROCOCCUS FURIOSUS
1IOF	;	2.2	;	X-RAY CRYSTALLINE STRUCTURES OF PYRROLIDONE CARBOXYL PEPTIDASE FROM A HYPERTHERMOPHILE, PYROCOCCUS FURIOSUS, AND ITS CYS-FREE MUTANT
1IOI	;	2.7	;	x-ray crystalline structures of pyrrolidone carboxyl peptidase from a hyperthermophile, pyrococcus furiosus, and its cys-free mutant
1K0Y	;	1.87	;	X-ray Crystallographic Analyses of Symmetrical Allosteric Effectors of Hemoglobin. Compounds Designed to Link Primary and Secondary Binding Sites
1Q7R	;	1.9	;	X-ray crystallographic analysis of a predicted amidotransferase from B. stearothermophilus at 1.9 A resolution
3U3H	;	0.97	;	X-Ray Crystallographic Analysis of D-Xylose Isomerase-Catalyzed Isomerization of (R)-Glyceraldehyde
1EED	;	2.0	;	X-ray crystallographic analysis of inhibition of endothiapepsin by cyclohexyl renin inhibitors
3L2M	;	1.97	;	X-ray Crystallographic Analysis of Pig Pancreatic Alpha-Amylase with Alpha-cyclodextrin
3L2L	;	2.11	;	X-ray Crystallographic Analysis of Pig Pancreatic Alpha-Amylase with Limit Dextrin and Oligosaccharide
1TRP	;	2.4	;	X-RAY CRYSTALLOGRAPHIC AND CALORIMERIC STUDIES OF THE EFFECTS OF THE MUTATION TRP 59 TYR IN RIBONUCLEASE T1
1TRQ	;	2.3	;	X-RAY CRYSTALLOGRAPHIC AND CALORIMERIC STUDIES OF THE EFFECTS OF THE MUTATION TRP 59 TYR IN RIBONUCLEASE T1
2PRQ	;	2.15	;	X-ray crystallographic characterization of the Co(II)-substituted Tris-bound form of the aminopeptidase from Aeromonas proteolytica
1A3I	;	1.97	;	X-RAY CRYSTALLOGRAPHIC DETERMINATION OF A COLLAGEN-LIKE PEPTIDE WITH THE REPEATING SEQUENCE (PRO-PRO-GLY)
1A3J	;	1.6	;	X-RAY CRYSTALLOGRAPHIC DETERMINATION OF A COLLAGEN-LIKE PEPTIDE WITH THE REPEATING SEQUENCE (PRO-PRO-GLY)
1BLL	;	2.4	;	X-RAY CRYSTALLOGRAPHIC DETERMINATION OF THE STRUCTURE OF BOVINE LENS LEUCINE AMINOPEPTIDASE COMPLEXED WITH AMASTATIN: FORMULATION OF A CATALYTIC MECHANISM FEATURING A GEM-DIOLATE TRANSITION STATE
3CPA	;	2.0	;	X-RAY CRYSTALLOGRAPHIC INVESTIGATION OF SUBSTRATE BINDING TO CARBOXYPEPTIDASE A AT SUBZERO TEMPERATURE
5CXP	;	1.77	;	X-ray crystallographic protein structure of the glycoside hydrolase family 30 subfamily 8 xylanase, Xyn30A, from Clostridium acetobutylicum
3ZHW	;	2.22	;	X-ray Crystallographic Structural Characteristics of Arabidopsis Hemoglobin I and their Functional Implications
3NHF	;	2.0	;	X-ray Crystallographic Structure Activity Relationship (SAR) of Casimiroin and its Analogs Bound to Human Quinone Reductase 2
3NHJ	;	2.33	;	X-ray Crystallographic Structure Activity Relationship (SAR) of Casimiroin and its Analogs Bound to Human Quinone Reductase 2
3NHK	;	1.96	;	X-ray Crystallographic Structure Activity Relationship (SAR) of Casimiroin and its Analogs Bound to Human Quinone Reductase 2
3NHL	;	1.57	;	X-ray Crystallographic Structure Activity Relationship (SAR) of Casimiroin and its Analogs Bound to Human Quinone Reductase 2
3NHP	;	1.7	;	X-ray Crystallographic Structure Activity Relationship (SAR) of Casimiroin and its Analogs Bound to Human Quinone Reductase 2
3NHR	;	1.8	;	X-ray Crystallographic Structure Activity Relationship (SAR) of Casimiroin and its Analogs Bound to Human Quinone Reductase 2
3NHS	;	1.78	;	X-ray Crystallographic Structure Activity Relationship (SAR) of Casimiroin and its Analogs Bound to Human Quinone Reductase 2
3NHU	;	1.9	;	X-ray Crystallographic Structure Activity Relationship (SAR) of Casimiroin and its Analogs Bound to Human Quinone Reductase 2
3NHW	;	1.65	;	X-ray Crystallographic Structure Activity Relationship (SAR) of Casimiroin and its Analogs Bound to Human Quinone Reductase 2
3NHY	;	1.9	;	X-ray Crystallographic Structure Activity Relationship (SAR) of Casimiroin and its Analogs Bound to Human Quinone Reductase 2
3O2N	;	1.6	;	X-ray Crystallographic Structure Activity Relationship (SAR) of Casimiroin and its Analogs Bound to Human Quinone Reductase 2
7N02	;	2.35	;	X-ray crystallographic structure model of Lactococcus lactis prolidase mutant D36S
6XMR	;	1.7	;	X-ray crystallographic structure model of Lactococcus lactis prolidase mutant H38S
7K3U	;	2.7	;	X-ray crystallographic structure model of Lactococcus lactis prolidase mutant R293S
7AYV	;	1.79	;	X-ray crystallographic structure of (6-4)photolyase from Drosophila melanogaster at cryogenic temperature
7AZT	;	2.27	;	X-ray crystallographic structure of (6-4)photolyase from Drosophila melanogaster at room temperature
8GJC	;	1.431	;	X-ray crystallographic structure of a beta-hairpin peptide derived from Abeta 17-35. (ORN)LVFFAED(ORN)GAI(N-Me-Ile)GLM
8GJD	;	2.03	;	X-ray crystallographic structure of a beta-hairpin peptide derived from Abeta 17-36. (ORN)LVFFAED(ORN)AII(N-Me-Gly)LMV
7RTZ	;	2.1	;	X-ray crystallographic structure of a beta-hairpin peptide derived from amyloid beta 14-40
6WXM	;	2.3	;	X-ray crystallographic structure of a beta-hairpin peptide derived from amyloid beta 16-36
5W4I	;	2.026	;	X-ray crystallographic structure of a beta-hairpin peptide mimic derived from Abeta 16-36. Rigaku data set. (ORN)KLV(MEA)FAE(ORN)AIIGLMV.
5W4H	;	1.718	;	X-ray crystallographic structure of a beta-hairpin peptide mimic derived from Abeta 16-36. Synchrotron data set. (ORN)KLV(MEA)FAE(ORN)AIIGLMV.
5W4J	;	2.08	;	X-ray crystallographic structure of a beta-hairpin peptide mimic. (ORN)KLV(MEA)FAE(ORN)AIIGLMV.
1W5R	;	1.45	;	X-ray crystallographic structure of a C70Q Mycobacterium smegmatis N- arylamine Acetyltransferase
7HVP	;	2.4	;	X-RAY CRYSTALLOGRAPHIC STRUCTURE OF A COMPLEX BETWEEN A SYNTHETIC PROTEASE OF HUMAN IMMUNODEFICIENCY VIRUS 1 AND A SUBSTRATE-BASED HYDROXYETHYLAMINE INHIBITOR
1BCD	;	1.9	;	X-RAY CRYSTALLOGRAPHIC STRUCTURE OF A COMPLEX BETWEEN HUMAN CARBONIC ANHYDRASE II AND A NEW TOPICAL INHIBITOR, TRIFLUOROMETHANE SULPHONAMIDE
5SUU	;	2.032	;	X-ray crystallographic structure of a covalent trimer derived from A-beta 17-36. X-ray diffractometer data set. (ORN)CVFFCED(ORN)AII(SAR)L(ORN)V.
6DR6	;	2.608	;	X-ray crystallographic structure of a covalent trimer derived from A-beta 17_36 containing the F20Cha point mutation
6DR5	;	2.079	;	X-ray crystallographic structure of a covalent trimer derived from A-beta 17_36 containing the I31Chg point mutation
6DR4	;	2.105	;	X-ray crystallographic structure of a covalent trimer derived from A-beta 17_36 containing the I31V point mutation
5SUR	;	1.801	;	X-ray crystallographic structure of a covalent trimer derived from A-beta 17_36. Synchrotron data set. (ORN)CVF(MEA)CED(ORN)AIIGL(ORN)V.
5SUT	;	1.902	;	X-ray crystallographic structure of a covalent trimer derived from A-beta 17_36. Synchrotron data set. (ORN)CVFFCED(ORN)AII(SAR)L(ORN)V.
5SUS	;	2.349	;	X-ray crystallographic structure of a covalent trimer derived from A-beta 17_36. X-ray diffractometer data set. (ORN)CVF(MEA)CED(ORN)AIIGL(ORN)V.
5VF1	;	2.1	;	X-ray Crystallographic Structure of a Giant Double-Walled Peptide Nanotube Formed by a Macrocyclic Beta-Sheet Containing ABeta16-22
5IEI	;	2.8	;	X-ray crystallographic structure of a high affinity IGF2 antagonist (Domain11 AB5 RHH) based on human IGF2R domain 11
1POP	;	2.1	;	X-RAY CRYSTALLOGRAPHIC STRUCTURE OF A PAPAIN-LEUPEPTIN COMPLEX
3LT5	;	2.3	;	X-ray Crystallographic structure of a Pseudomonas Aeruginosa Azoreductase in complex with balsalazide
2V9C	;	2.18	;	X-ray Crystallographic Structure of a Pseudomonas aeruginosa Azoreductase in Complex with Methyl Red.
3KEG	;	2.1	;	X-ray Crystallographic Structure of a Y131F mutant of Pseudomonas Aeruginosa Azoreductase in complex with Methyl RED
5HOX	;	1.9	;	X-ray crystallographic structure of an A-beta 17_36 beta-hairpin. Synchrotron data set. (LVFFAEDCGSNKCAII(SAR)LMV).
5HOY	;	2.295	;	X-ray crystallographic structure of an A-beta 17_36 beta-hairpin. X-ray diffractometer data set. (LVFFAEDCGSNKCAII(SAR)LMV).
5HOW	;	2.295	;	X-ray crystallographic structure of an Abeta 17-36 beta-hairpin. LV(PHI)FAEDCGSNKCAII(SAR)L(ORN)V
4AQF	;	3.1	;	X-ray crystallographic structure of Crimean-congo haemorrhagic fever virus nucleoprotein
4AQG	;	2.8	;	X-ray crystallographic structure of Crimean-congo haemorrhagic fever virus nucleoprotein
1YLZ	;	1.35	;	X-ray crystallographic structure of CTX-M-14 beta-lactamase complexed with ceftazidime-like boronic acid
1YM1	;	1.12	;	X-ray crystallographic structure of CTX-M-9 beta-lactamase complexed with a boronic acid inhibitor (SM2)
1YLY	;	1.25	;	X-ray crystallographic structure of CTX-M-9 beta-lactamase complexed with ceftazidime-like boronic acid
1YMS	;	1.6	;	X-ray crystallographic structure of CTX-M-9 beta-lactamase complexed with nafcinin-like boronic acid inhibitor
1YMX	;	1.7	;	X-ray crystallographic structure of CTX-M-9 beta-lactamase covalently linked to cefoxitin
3HRE	;	1.45	;	X-ray crystallographic structure of CTX-M-9 S70G
3HUO	;	1.5	;	X-ray crystallographic structure of CTX-M-9 S70G in complex with benzylpenicillin
3HVF	;	1.5	;	X-ray crystallographic structure of CTX-M-9 S70G in complex with hydrolyzed benzylpenicillin
2Y4D	;	2.0	;	X-ray crystallographic structure of E. coli apo-EfeB
2Y4F	;	2.7	;	X-ray crystallographic structure of E. coli heme-EfeB
7QCF	;	3.0	;	X-ray crystallographic structure of E. coli K-12 glycyl-tRNA synthetase alpha subunit (glyQ)
2Y4E	;	2.3	;	X-ray crystallographic structure of E. coli ppix-EfeB
4A02	;	0.95	;	X-ray crystallographic structure of EfCBM33A
6NWD	;	2.0	;	X-ray Crystallographic structure of Gloeobacter rhodopsin
5F3K	;	1.82	;	X-Ray Crystallographic Structure of hTrap1 N-terminal Domain-apo
3I98	;	1.85	;	X-ray crystallographic structure of Inorganic Pyrophosphatase at 298K from archaeon Thermococcus thioreducens
6Z4U	;	1.95	;	X-ray Crystallographic Structure of Orf9b from SARS-CoV-2
1F38	;	2.4	;	X-RAY CRYSTALLOGRAPHIC STRUCTURE OF PRECORRIN 8W DECARBOXYLASE, THE PRODUCT OF GENE MT0146 IN THE METHANOBACTERIUM THERMOAUTOTROPHICUM GENOME
1W4T	;	1.95	;	X-ray crystallographic structure of Pseudomonas aeruginosa arylamine N-acetyltransferase
7JNO	;	1.95	;	X-ray crystallographic structure of the NS3 helicase domain from Tick-borne encephalitis virus
4AR5	;	1.0	;	X-ray crystallographic structure of the oxidised form perdeuterated Pyrococcus furiosus rubredoxin in D2O at 295K (in quartz capillary) to 1.00 Angstrom resolution.
2VF1	;	3.4	;	X-ray crystallographic structure of the picobirnavirus capsid
4AR6	;	0.92	;	X-ray crystallographic structure of the reduced form perdeuterated Pyrococcus furiosus rubredoxin at 295 K (in quartz capillary) to 0.92 Angstroms resolution.
1LIE	;	1.6	;	X-RAY CRYSTALLOGRAPHIC STRUCTURES OF ADIPOCYTE LIPID BINDING PROTEIN COMPLEXED WITH PALMITATE AND HEXADECANESULFONIC ACID. PROPERTIES OF CAVITY BINDING SITES
1LIC	;	1.6	;	X-RAY CRYSTALLOGRAPHIC STRUCTURES OF ADIPOCYTE LIPID BINDING PROTEIN COMPLEXED WITH PALMITATE AND HEXADECANESULFONIC ACID. PROPERTIES OF CAVITY BINDING SITES.
1XYA	;	1.81	;	X-RAY CRYSTALLOGRAPHIC STRUCTURES OF D-XYLOSE ISOMERASE-SUBSTRATE COMPLEXES POSITION THE SUBSTRATE AND PROVIDE EVIDENCE FOR METAL MOVEMENT DURING CATALYSIS
1XYB	;	1.96	;	X-RAY CRYSTALLOGRAPHIC STRUCTURES OF D-XYLOSE ISOMERASE-SUBSTRATE COMPLEXES POSITION THE SUBSTRATE AND PROVIDE EVIDENCE FOR METAL MOVEMENT DURING CATALYSIS
1XYC	;	2.19	;	X-RAY CRYSTALLOGRAPHIC STRUCTURES OF D-XYLOSE ISOMERASE-SUBSTRATE COMPLEXES POSITION THE SUBSTRATE AND PROVIDE EVIDENCE FOR METAL MOVEMENT DURING CATALYSIS
2RAR	;	1.52	;	X-ray Crystallographic Structures Show Conservation of a Trigonal-Bipyramidal Intermediate in a Phosphoryl-transfer Superfamily.
2RAV	;	1.07	;	X-ray Crystallographic Structures Show Conservation of a Trigonal-Bipyramidal Intermediate in a Phosphoryl-transfer Superfamily.
2RB5	;	1.03	;	X-ray Crystallographic Structures Show Conservation of a Trigonal-Bipyramidal Intermediate in a Phosphoryl-transfer Superfamily.
2RBK	;	1.0	;	X-ray Crystallographic Structures Show Conservation of a Trigonal-Bipyramidal Intermediate in a Phosphoryl-transfer Superfamily.
1HTE	;	2.8	;	X-RAY CRYSTALLOGRAPHIC STUDIES OF A SERIES OF PENICILLIN-DERIVED ASYMMETRIC INHIBITORS OF HIV-1 PROTEASE
1HTF	;	2.2	;	X-RAY CRYSTALLOGRAPHIC STUDIES OF A SERIES OF PENICILLIN-DERIVED ASYMMETRIC INHIBITORS OF HIV-1 PROTEASE
1HTG	;	2.0	;	X-RAY CRYSTALLOGRAPHIC STUDIES OF A SERIES OF PENICILLIN-DERIVED ASYMMETRIC INHIBITORS OF HIV-1 PROTEASE
1CJR	;	2.3	;	X-RAY CRYSTALLOGRAPHIC STUDIES OF DENATURATION IN RIBONUCLEASE S
1CNG	;	1.9	;	X-RAY CRYSTALLOGRAPHIC STUDIES OF ENGINEERED HYDROGEN BOND NETWORKS IN A PROTEIN-ZINC BINDING SITE
1CNH	;	2.05	;	X-RAY CRYSTALLOGRAPHIC STUDIES OF ENGINEERED HYDROGEN BOND NETWORKS IN A PROTEIN-ZINC BINDING SITE
1CNI	;	1.8	;	X-RAY CRYSTALLOGRAPHIC STUDIES OF ENGINEERED HYDROGEN BOND NETWORKS IN A PROTEIN-ZINC BINDING SITE
1CNJ	;	1.8	;	X-RAY CRYSTALLOGRAPHIC STUDIES OF ENGINEERED HYDROGEN BOND NETWORKS IN A PROTEIN-ZINC BINDING SITE
1CNK	;	2.15	;	X-RAY CRYSTALLOGRAPHIC STUDIES OF ENGINEERED HYDROGEN BOND NETWORKS IN A PROTEIN-ZINC BINDING SITE
1IGP	;	2.2	;	X-RAY CRYSTALLOGRAPHIC STUDIES OF RECOMBINANT INORGANIC PYROPHOSPHATASE FROM ESCHERICHIA COLI
1MBS	;	2.5	;	X-RAY CRYSTALLOGRAPHIC STUDIES OF SEAL MYOGLOBIN. THE MOLECULE AT 2.5 ANGSTROMS RESOLUTION
1KUV	;	2.0	;	X-ray Crystallographic Studies of Serotonin N-acetyltransferase Catalysis and Inhibition
1KUX	;	1.8	;	X-ray Crystallographic Studies of Serotonin N-acetyltransferase Catalysis and Inhibition
1KUY	;	2.4	;	X-ray Crystallographic Studies of Serotonin N-acetyltransferase Catalysis and Inhibition
1CJQ	;	3.0	;	X-RAY CRYSTALLOGRAPHIC STUDIES OF THE DENATURATION OF THE DENATURATION OF RIBONUCLEASE S.
1MPJ	;	2.3	;	X-RAY CRYSTALLOGRAPHIC STUDIES ON HEXAMERIC INSULINS IN THE PRESENCE OF HELIX-STABILIZING AGENTS, THIOCYANATE, METHYLPARABEN AND PHENOL
2TCI	;	1.8	;	X-RAY CRYSTALLOGRAPHIC STUDIES ON HEXAMERIC INSULINS IN THE PRESENCE OF HELIX-STABILIZING AGENTS, THIOCYANATE, METHYLPARABEN AND PHENOL
3MTH	;	1.9	;	X-RAY CRYSTALLOGRAPHIC STUDIES ON HEXAMERIC INSULINS IN THE PRESENCE OF HELIX-STABILIZING AGENTS, THIOCYANATE, METHYLPARABEN AND PHENOL
3FX6	;	1.851	;	X-RAY crystallographic studies on the complex of carboxypeptidase A with the inhibitor using alpha-nitro ketone as the zinc-binding group
1AVS	;	1.75	;	X-RAY CRYSTALLOGRAPHIC STUDY OF CALCIUM-SATURATED N-TERMINAL DOMAIN OF TROPONIN C
7NW3	;	3.20001	;	X-ray crystallographic study of PIYDIN, which contains the truncation determinants of binding PI and N, bound to RoAb13, a CCR5 antibody
1ARS	;	1.8	;	X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM
1ART	;	1.8	;	X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM
1AMQ	;	2.2	;	X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS
1AMR	;	2.1	;	X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS
1AMS	;	2.7	;	X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS
4ZNG	;	2.25	;	X-ray crystallography of recombinant Lactococcus lactis prolidase
9LYZ	;	2.5	;	X-RAY CRYSTALLOGRAPHY OF THE BINDING OF THE BACTERIAL CELL WALL TRISACCHARIDE NAM-NAG-NAM TO LYSOZYME
1SLA	;	2.45	;	X-RAY CRYSTALLOGRAPHY REVEALS CROSSLINKING OF MAMMALIAN LECTIN (GALECTIN-1) BY BIANTENNARY COMPLEX TYPE SACCHARIDES
1SLB	;	2.3	;	X-RAY CRYSTALLOGRAPHY REVEALS CROSSLINKING OF MAMMALIAN LECTIN (GALECTIN-1) BY BIANTENNARY COMPLEX TYPE SACCHARIDES
1SLC	;	2.15	;	X-RAY CRYSTALLOGRAPHY REVEALS CROSSLINKING OF MAMMALIAN LECTIN (GALECTIN-1) BY BIANTENNARY COMPLEX TYPE SACCHARIDES
5VXQ	;	1.002	;	X-Ray crystallography structure of the parallel stranded duplex formed by 5-rA5-dA-rA5
7NJZ	;	3.2	;	X-ray crystallography study of RoAb13 which binds to PIYDIN, a part of the CCR5 N terminal domain
2MC2	;		;	X-ray crystallography-solution NMR hybrid structure of mouse RyR2 domain A
1ZET	;	2.3	;	X-ray data do not support hoogsteen base-pairing during replication by human polymerase iota
5ZC1	;	2.30271	;	X-ray diffraction analysis of the CsStefin-1
5NGB	;	2.9	;	X-Ray Diffraction Crystal Structure of the murine PI3K p110delta in complex with a pan inhibitor
5VTP	;	2.8	;	X-ray diffraction data of DNA Polymerase Eta (RAD30) of Saccharomyces cerevisiae with a single magnesium bound in absence of DNA and incoming dNTP
4R6C	;	1.7	;	X-ray diffraction in temporally and spatially resolved biomolecular science: the X-ray crystal structure of hen egg white lysozyme cocrystallized with Ta6Br12 and then a crystal soaked in K2PtBr6
6ZI8	;	2.3	;	X-ray diffraction structure of bovine insulin at 2.3 A resolution
2I6Z	;	1.9	;	X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme
3UM4	;	2.82	;	X-ray Diffraction Studies of Ring Crystals obtained for d(CACGCG).d(CGCGTG): Stage (i) Hexagonal plates
3ULM	;	3.01	;	X-ray Diffraction Studies of Ring Crystals obtained for d(CACGCG).d(CGCGTG): Stage (ii) Hexagonal plates with spots
3ULN	;	2.72	;	X-ray Diffraction Studies of Ring Crystals obtained for d(CACGCG).d(CGCGTG): Stage (iii) Hexagonal plates with intense spots and a depression
3ULO	;	3.24	;	X-ray Diffraction Studies of Ring Crystals obtained for d(CACGCG).d(CGCGTG): Stage (iv) Hexagonal rings
1PYP	;	3.0	;	X-RAY DIFFRACTION STUDY OF INORGANIC PYROPHOSPHATASE FROM BAKER,S YEAST AT THE 3 ANGSTROMS RESOLUTION (RUSSIAN)
5EJX	;	1.5	;	X-ray Free Electron Laser Structure of Cytochrome C Peroxidase
5MAP	;	1.49	;	X-ray generated oxyferrous complex of DtpA from Streptomyces lividans
5MJH	;	1.45	;	X-ray generated oxyferrous/water mixed complex of DtpA from Streptomyces lividans
2UXK	;	2.31	;	X-ray high resolution structure of the photosynthetic reaction center from Rb. sphaeroides at pH 10 in the charge-separated state
2UXM	;	2.7	;	X-ray high resolution structure of the photosynthetic reaction center from Rb. sphaeroides at pH 10 in the charge-separated state, 2nd dataset
2UXJ	;	2.25	;	X-ray high resolution structure of the photosynthetic reaction center from Rb. sphaeroides at pH 10 in the neutral state
2UXL	;	2.88	;	X-ray high resolution structure of the photosynthetic reaction center from Rb. sphaeroides at pH 10 in the neutral state, 2nd dataset
2UWS	;	2.9	;	X-ray high resolution structure of the photosynthetic reaction center from Rb. sphaeroides at pH 6.5 in the charge-separated state
2UWT	;	2.5	;	X-ray high resolution structure of the photosynthetic reaction center from Rb. sphaeroides at pH 6.5 in the charge-separated state 2nd dataset
2UWV	;	2.13	;	X-ray high resolution structure of the photosynthetic reaction center from Rb. sphaeroides at pH 6.5 in the charge-separated state, 3rd dataset
2UWW	;	2.05	;	X-ray high resolution structure of the photosynthetic reaction center from Rb. sphaeroides at pH 6.5 in the neutral state
2UWU	;	2.04	;	X-ray high resolution structure of the photosynthetic reaction center from Rb. sphaeroides at pH 6.5 in the neutral state, 2nd dataset
2J8D	;	2.07	;	X-ray high resolution structure of the photosynthetic reaction center from Rb. sphaeroides at pH 8 in the charge-separated state
2J8C	;	1.87	;	X-ray high resolution structure of the photosynthetic reaction center from Rb. sphaeroides at pH 8 in the neutral state
2UX5	;	2.21	;	X-ray high resolution structure of the photosynthetic reaction center from Rb. sphaeroides at pH 9 in the charge-separated state
2UX4	;	2.51	;	X-ray high resolution structure of the photosynthetic reaction center from Rb. sphaeroides at pH 9 in the charge-separated state, 2nd dataset
2UX3	;	2.5	;	X-ray high resolution structure of the photosynthetic reaction center from Rb. sphaeroides at pH 9 in the neutral state
3RDH	;	2.39	;	X-ray induced covalent inhibition of 14-3-3
1H5M	;	1.6	;	X-ray induced reduction of horseradish peroxidase C1A Compound III (0-100% dose)
1H5D	;	1.6	;	X-ray induced reduction of horseradish peroxidase C1A Compound III (0-11% dose)
1H5C	;	1.62	;	X-ray induced reduction of horseradish peroxidase C1A Compound III (100-200% dose)
1H5E	;	1.6	;	X-ray induced reduction of horseradish peroxidase C1A Compound III (11-22% dose)
1H5F	;	1.6	;	X-ray induced reduction of horseradish peroxidase C1A Compound III (22-33% dose)
1H5G	;	1.6	;	X-ray induced reduction of horseradish peroxidase C1A Compound III (33-44% dose)
1H5H	;	1.6	;	X-ray induced reduction of horseradish peroxidase C1A Compound III (44-56% dose)
1H5I	;	1.6	;	X-ray induced reduction of horseradish peroxidase C1A Compound III (56-67% dose)
1H5J	;	1.6	;	X-ray induced reduction of horseradish peroxidase C1A Compound III (67-78% dose)
1H5K	;	1.6	;	X-ray induced reduction of horseradish peroxidase C1A Compound III (78-89% dose)
1H5L	;	1.6	;	X-ray induced reduction of horseradish peroxidase C1A Compound III (89-100% dose)
2YAF	;	1.8	;	X-ray induced reduction of laccase from Thermus thermophilus HB27 (12. 5-25.0 percent dose)
2YAH	;	1.8	;	X-ray induced reduction of laccase from Thermus thermophilus HB27 (25. 0-37.5 percent dose)
2YAM	;	1.8	;	X-ray induced reduction of laccase from Thermus thermophilus HB27 (37. 5-50.0 percent dose)
2YAO	;	1.8	;	X-ray induced reduction of laccase from Thermus thermophilus HB27 (50. 0-62.5 percent dose)
2YAP	;	1.8	;	X-ray induced reduction of laccase from Thermus thermophilus HB27 (62. 5-75.0 percent dose)
2YAQ	;	1.8	;	X-ray induced reduction of laccase from Thermus thermophilus HB27 (75. 0-87.5 percent dose)
2YAR	;	1.8	;	X-ray induced reduction of laccase from Thermus thermophilus HB27 (87. 5-100.0 percent dose)
2YAE	;	1.8	;	X-ray induced reduction of laccase from Thermus thermophilus HB27(0.0- 12.5 percent dose)
3LR9	;	1.55	;	X-ray photogenerated ferrous horse heart myoglobin, nitrite adduct
4ALC	;	1.49	;	X-Ray photoreduction of Polysaccharide monooxigenase CBM33
4ALQ	;	1.48	;	X-Ray photoreduction of Polysaccharide monooxygenase CBM33
4ALR	;	1.49	;	X-Ray photoreduction of Polysaccharide monooxygenase CBM33
4ALS	;	1.47	;	X-Ray photoreduction of Polysaccharide monooxygenase CBM33
4ALT	;	1.49	;	X-Ray photoreduction of Polysaccharide monooxygenase CBM33
6SR5	;	2.3	;	X-ray pump X-ray probe on lysozyme.Gd nanocrystals: 102 fs time delay
6SR4	;	2.3	;	X-ray pump X-ray probe on lysozyme.Gd nanocrystals: 112 fs time delay
6SR1	;	2.3	;	X-ray pump X-ray probe on lysozyme.Gd nanocrystals: 35 fs time delay
6SR2	;	2.3	;	X-ray pump X-ray probe on lysozyme.Gd nanocrystals: 37 fs time delay
6SR3	;	2.3	;	X-ray pump X-ray probe on lysozyme.Gd nanocrystals: 62 fs time delay
6SR0	;	2.3	;	X-ray pump X-ray probe on lysozyme.Gd nanocrystals: single colour reference data
6SRP	;	2.3	;	X-ray pump X-ray probe on thaumatin nanocrystals: 100 fs time delay
6SRQ	;	2.3	;	X-ray pump X-ray probe on thaumatin nanocrystals: 18 fs time delay
6SRK	;	2.3	;	X-ray pump X-ray probe on thaumatin nanocrystals: 35 fs time delay
6SRL	;	2.3	;	X-ray pump X-ray probe on thaumatin nanocrystals: 54 fs time delay
6SRO	;	2.3	;	X-ray pump X-ray probe on thaumatin nanocrystals: 76 fs time delay
6SRJ	;	2.3	;	X-ray pump X-ray probe on thaumatin nanocrystals: single pulse reference data
7LLP	;	1.13	;	X-ray radiation damage series on Lysozyme at 277K, crystal structure, dataset 1
7LN8	;	1.52	;	X-ray radiation damage series on Lysozyme at 277K, crystal structure, dataset 3
7LPM	;	1.1	;	X-ray radiation damage series on Lysozyme at 277K, multi-conformer model, crystal 2
7LN9	;	1.13	;	X-ray radiation damage series on Lysozyme at 277K, multi-conformer model, dataset 1
7LOQ	;	1.3	;	X-ray radiation damage series on Lysozyme at 277K, multi-conformer model, dataset 2
7LP6	;	1.13	;	X-ray radiation damage series on Lysozyme at 277K, multi-conformer model, dataset 2 (merged)
7LOR	;	1.52	;	X-ray radiation damage series on Lysozyme at 277K, multi-conformer model, dataset 3
7LPL	;	1.14	;	X-ray radiation damage series on Lysozyme at 277K, multi-conformer model, dataset 3 (merged)
7LTD	;	0.9	;	X-ray radiation damage series on Proteinase K at 100K, crystal structure, dataset 1
7LTI	;	0.91	;	X-ray radiation damage series on Proteinase K at 100K, crystal structure, dataset 2
7LTV	;	0.95	;	X-ray radiation damage series on Proteinase K at 100K, crystal structure, dataset 3
7LU0	;	1.01	;	X-ray radiation damage series on Proteinase K at 100K, crystal structure, dataset 4
7LU1	;	1.06	;	X-ray radiation damage series on Proteinase K at 100K, crystal structure, dataset 5
7LU2	;	1.11	;	X-ray radiation damage series on Proteinase K at 100K, crystal structure, dataset 6
7LU3	;	1.16	;	X-ray radiation damage series on Proteinase K at 100K, crystal structure, dataset 7
7LN7	;	1.02	;	X-ray radiation damage series on Proteinase K at 277K, crystal structure, dataset 1
7LPT	;	1.43	;	X-ray radiation damage series on Proteinase K at 277K, crystal structure, dataset 4
7LPU	;	1.02	;	X-ray radiation damage series on Proteinase K at 277K, multi-conformer model, dataset 1
7LPV	;	1.1	;	X-ray radiation damage series on Proteinase K at 277K, multi-conformer model, dataset 2
7LQA	;	1.02	;	X-ray radiation damage series on Proteinase K at 277K, multi-conformer model, dataset 2 (merged)
7LQ8	;	1.3	;	X-ray radiation damage series on Proteinase K at 277K, multi-conformer model, dataset 3
7LQB	;	1.02	;	X-ray radiation damage series on Proteinase K at 277K, multi-conformer model, dataset 3 (merged)
7LQ9	;	1.43	;	X-ray radiation damage series on Proteinase K at 277K, multi-conformer model, dataset 4
7LQC	;	1.02	;	X-ray radiation damage series on Proteinase K at 277K, multi-conformer model, dataset 4 (merged)
7LFG	;	1.22	;	X-ray radiation damage series on Thaumatin at 277K, crystal structure, dataset 1
7LJV	;	1.48	;	X-ray radiation damage series on Thaumatin at 277K, crystal structure, dataset 4
7LJW	;	1.22	;	X-ray radiation damage series on Thaumatin at 277K, multi-conformer model, dataset 1
7LJZ	;	1.29	;	X-ray radiation damage series on Thaumatin at 277K, multi-conformer model, dataset 2
7LNB	;	1.22	;	X-ray radiation damage series on Thaumatin at 277K, multi-conformer model, dataset 2 (merged)
7LK5	;	1.38	;	X-ray radiation damage series on Thaumatin at 277K, multi-conformer model, dataset 3
7LNC	;	1.22	;	X-ray radiation damage series on Thaumatin at 277K, multi-conformer model, dataset 3 (merged)
7LK6	;	1.48	;	X-ray radiation damage series on Thaumatin at 277K, multi-conformer model, dataset 4
7LND	;	1.22	;	X-ray radiation damage series on Thaumatin at 277K, multi-conformer model, dataset 4 (merged)
3TMV	;	1.9	;	X-Ray Radiation Damage to HEWL Crystals soaked in 100mM Sodium Nitrate (Dose=0.12MGy)
3TMX	;	1.9	;	X-Ray Radiation Damage to HEWL Crystals soaked in 100mM Sodium Nitrate (Dose=1.9MGy)
3TMU	;	1.9	;	X-Ray Radiation Damage to HEWL Crystals soaked in 100mM Sodium Nitrate (Undosed)
3TMW	;	1.9	;	X-Ray Radiation Damage to HEWL Crystals soaked in 100mM Sodium Nitrate (Undosed)
6QRR	;	1.096	;	X-ray radiation dose series on xylose isomerase - 0.13 MGy
6QRS	;	1.17	;	X-ray radiation dose series on xylose isomerase - 0.13 MGy
6QRT	;	1.17	;	X-ray radiation dose series on xylose isomerase - 1.38 MGy
6QRU	;	1.17	;	X-ray radiation dose series on xylose isomerase - 2.01 MGy
6QRV	;	1.17	;	X-ray radiation dose series on xylose isomerase - 2.63 MGy
6QRW	;	1.17	;	X-ray radiation dose series on xylose isomerase - 3.25 MGy
6QRX	;	1.17	;	X-ray radiation dose series on xylose isomerase - 3.88 MGy
6QRY	;	1.17	;	X-ray radiation dose series on xylose isomerase - merged data
6NSZ	;	2.2	;	X-ray reduced Catalase 3 from N.Crassa (0.526 MGy)
6NSW	;	2.099	;	X-ray reduced Catalase 3 From N.Crassa in Cpd I state (0.135 MGy)
6NSY	;	2.2	;	X-ray reduced Catalase 3 From N.Crassa in Cpd I state (0.263 MGy)
2J57	;	2.25	;	X-ray reduced Paraccocus denitrificans methylamine dehydrogenase N- quinol in complex with amicyanin.
2J56	;	2.1	;	X-ray reduced Paraccocus denitrificans methylamine dehydrogenase N- semiquinone in complex with amicyanin.
2J55	;	2.15	;	X-ray reduced Paraccocus denitrificans methylamine dehydrogenase O- quinone in complex with amicyanin.
1QNY	;	1.8	;	X-ray refinement of D2O soaked crystal of concanavalin A
2OQA	;	1.4	;	X-ray Sequence and Crystal Structure of Luffaculin 1, a Novel Type 1 Ribosome-inactivating Protein
6IYH	;	1.7	;	X-ray sequence and high resolution crystal structure of Persian sturgeon methemoglobin
6IYI	;	2.2	;	X-ray sequence and high resolution crystal structure of Starry sturgeon methemoglobin
1QI9	;	2.05	;	X-RAY SIRAS STRUCTURE DETERMINATION OF A VANADIUM-DEPENDENT HALOPEROXIDASE FROM ASCOPHYLLUM NODOSUM AT 2.0 A RESOLUTION
5YRS	;	1.76	;	X-ray Snapshot of HIV-1 Protease in Action: Observation of Tetrahedral Intermediate and Its SIHB with Catalytic Aspartate
4JXC	;	1.5	;	X-ray snapshots of possible intermediates in the time course of synthesis and degradation of protein-bound Fe4S4 clusters
4JY8	;	2.901	;	X-ray snapshots of possible intermediates in the time course of synthesis and degradation of protein-bound Fe4S4 clusters
4JY9	;	1.6	;	X-ray snapshots of possible intermediates in the time course of synthesis and degradation of protein-bound Fe4S4 clusters
4JYD	;	1.71	;	X-ray snapshots of possible intermediates in the time course of synthesis and degradation of protein-bound Fe4S4 clusters.
4JYE	;	1.65	;	X-ray snapshots of possible intermediates in the time course of synthesis and degradation of protein-bound Fe4S4 clusters.
4JYF	;	1.45	;	X-ray snapshots of possible intermediates in the time course of synthesis and degradation of protein-bound Fe4S4 clusters.
3MEZ	;	1.94	;	X-ray structural analysis of a mannose specific lectin from dutch crocus (crocus vernus)
1WQY	;	2.0	;	X-RAY structural analysis of B-DNA decamer D(CCATTAATGG)2 crystal grown in D2O solution
2ALV	;	1.9	;	X-ray structural analysis of SARS coronavirus 3CL proteinase in complex with designed anti-viral inhibitors
4OVZ	;	2.5	;	X-Ray Structural and Biological Evaluation of a Series of Potent and Highly Selective Inhibitors of Human Coronavirus Papain-Like Proteases
4OW0	;	2.1	;	X-Ray Structural and Biological Evaluation of a Series of Potent and Highly Selective Inhibitors of Human Coronavirus Papain-Like Proteases
1LH1	;	2.0	;	X-RAY STRUCTURAL INVESTIGATION OF LEGHEMOGLOBIN. VI. STRUCTURE OF ACETATE-FERRILEGHEMOGLOBIN AT A RESOLUTION OF 2.0 ANGSTROMS (RUSSIAN)
1LH2	;	2.0	;	X-RAY STRUCTURAL INVESTIGATION OF LEGHEMOGLOBIN. VI. STRUCTURE OF ACETATE-FERRILEGHEMOGLOBIN AT A RESOLUTION OF 2.0 ANGSTROMS (RUSSIAN)
1LH3	;	2.0	;	X-RAY STRUCTURAL INVESTIGATION OF LEGHEMOGLOBIN. VI. STRUCTURE OF ACETATE-FERRILEGHEMOGLOBIN AT A RESOLUTION OF 2.0 ANGSTROMS (RUSSIAN)
1LH5	;	2.0	;	X-RAY STRUCTURAL INVESTIGATION OF LEGHEMOGLOBIN. VI. STRUCTURE OF ACETATE-FERRILEGHEMOGLOBIN AT A RESOLUTION OF 2.0 ANGSTROMS (RUSSIAN)
1LH6	;	2.0	;	X-RAY STRUCTURAL INVESTIGATION OF LEGHEMOGLOBIN. VI. STRUCTURE OF ACETATE-FERRILEGHEMOGLOBIN AT A RESOLUTION OF 2.0 ANGSTROMS (RUSSIAN)
1LH7	;	2.0	;	X-RAY STRUCTURAL INVESTIGATION OF LEGHEMOGLOBIN. VI. STRUCTURE OF ACETATE-FERRILEGHEMOGLOBIN AT A RESOLUTION OF 2.0 ANGSTROMS (RUSSIAN)
2LH1	;	2.0	;	X-RAY STRUCTURAL INVESTIGATION OF LEGHEMOGLOBIN. VI. STRUCTURE OF ACETATE-FERRILEGHEMOGLOBIN AT A RESOLUTION OF 2.0 ANGSTROMS (RUSSIAN)
2LH2	;	2.0	;	X-RAY STRUCTURAL INVESTIGATION OF LEGHEMOGLOBIN. VI. STRUCTURE OF ACETATE-FERRILEGHEMOGLOBIN AT A RESOLUTION OF 2.0 ANGSTROMS (RUSSIAN)
2LH3	;	2.0	;	X-RAY STRUCTURAL INVESTIGATION OF LEGHEMOGLOBIN. VI. STRUCTURE OF ACETATE-FERRILEGHEMOGLOBIN AT A RESOLUTION OF 2.0 ANGSTROMS (RUSSIAN)
2LH5	;	2.0	;	X-RAY STRUCTURAL INVESTIGATION OF LEGHEMOGLOBIN. VI. STRUCTURE OF ACETATE-FERRILEGHEMOGLOBIN AT A RESOLUTION OF 2.0 ANGSTROMS (RUSSIAN)
2LH6	;	2.0	;	X-RAY STRUCTURAL INVESTIGATION OF LEGHEMOGLOBIN. VI. STRUCTURE OF ACETATE-FERRILEGHEMOGLOBIN AT A RESOLUTION OF 2.0 ANGSTROMS (RUSSIAN)
2LH7	;	2.0	;	X-RAY STRUCTURAL INVESTIGATION OF LEGHEMOGLOBIN. VI. STRUCTURE OF ACETATE-FERRILEGHEMOGLOBIN AT A RESOLUTION OF 2.0 ANGSTROMS (RUSSIAN)
3EUQ	;	2.1	;	X-ray structural of a type III pentaketide synthase from Neurospora crassa
4YPT	;	2.6009	;	X-ray structural of three tandemly linked domains of nsp3 from murine hepatitis virus at 2.60 Angstroms resolution
3PY9	;	2.2	;	X-ray structural studies of the entire extra-cellular region of the Ser/Thr kinase PrkC from Staphylococcus aureus
3OVM	;	2.09	;	X-ray Structural study of quinone reductase II inhibition by compounds with micromolar to nanomolar range IC50 values
3OWH	;	2.28	;	X-ray Structural study of quinone reductase II inhibition by compounds with micromolar to nanomolar range IC50 values
3OWX	;	1.85	;	X-ray Structural study of quinone reductase II inhibition by compounds with micromolar to nanomolar range IC50 values
3OX1	;	2.0	;	X-ray Structural study of quinone reductase II inhibition by compounds with micromolar to nanomolar range IC50 values
3OX2	;	2.41	;	X-ray Structural study of quinone reductase II inhibition by compounds with micromolar to nanomolar range IC50 values
3OX3	;	1.8	;	X-ray Structural study of quinone reductase II inhibition by compounds with micromolar to nanomolar range IC50 values
3L77	;	1.55	;	X-ray structure alcohol dehydrogenase from archaeon Thermococcus sibiricus complexed with 5-hydroxy-NADP
2BE4	;	2.1	;	X-RAY STRUCTURE AN EF-HAND PROTEIN FROM DANIO RERIO Dr.36843
7EO3	;	1.141	;	X-ray structure analysis of beita-1,3-glucanase
1AR4	;	1.9	;	X-RAY STRUCTURE ANALYSIS OF THE CAMBIALISTIC SUPEROXIDE DISMUTASE FROM PROPIONIBACTERIUM SHERMANII ACTIVE WITH FE OR MN
1IDS	;	2.0	;	X-RAY STRUCTURE ANALYSIS OF THE IRON-DEPENDENT SUPEROXIDE DISMUTASE FROM MYCOBACTERIUM TUBERCULOSIS AT 2.0 ANGSTROMS RESOLUTIONS REVEALS NOVEL DIMER-DIMER INTERACTIONS
1JRQ	;	2.15	;	X-ray Structure Analysis of the Role of the Conserved Tyrosine-369 in Active Site of E. coli Amine Oxidase
7EO6	;	1.9	;	X-ray structure analysis of xylanase
4XQ4	;	1.25	;	X-ray structure analysis of xylanase - N44D
4XQW	;	1.5	;	X-ray structure analysis of xylanase-N44E with MES at pH6.0
4XQD	;	1.5	;	X-ray structure analysis of xylanase-WT at pH4.0
4UCI	;	2.21	;	X-ray structure and activities of an essential Mononegavirales L- protein domain
4UCJ	;	3.26	;	X-ray structure and activities of an essential Mononegavirales L- protein domain
4UCK	;	2.66	;	X-ray structure and activities of an essential Mononegavirales L- protein domain
4UCL	;	2.8	;	X-ray structure and activities of an essential Mononegavirales L- protein domain
4UCY	;	2.83	;	X-ray structure and activities of an essential Mononegavirales L- protein domain
4UCZ	;	2.99	;	X-ray structure and activities of an essential Mononegavirales L- protein domain
4UD0	;	3.2	;	X-ray structure and activities of an essential Mononegavirales L- protein domain
1PDY	;	2.4	;	X-RAY STRUCTURE AND CATALYTIC MECHANISM OF LOBSTER ENOLASE
1PDZ	;	2.2	;	X-RAY STRUCTURE AND CATALYTIC MECHANISM OF LOBSTER ENOLASE
5AKQ	;	2.6	;	X-ray structure and mutagenesis studies of the N-isopropylammelide isopropylaminohydrolase, AtzC
1MBC	;	1.5	;	X-RAY STRUCTURE AND REFINEMENT OF CARBON-MONOXY (FE II)-MYOGLOBIN AT 1.5 ANGSTROMS RESOLUTION
1TGX	;	1.55	;	X-RAY STRUCTURE AT 1.55 A OF TOXIN GAMMA, A CARDIOTOXIN FROM NAJA NIGRICOLLIS VENOM. CRYSTAL PACKING REVEALS A MODEL FOR INSERTION INTO MEMBRANES
2IPH	;	1.75	;	X-ray Structure at 1.75 A Resolution of a Norovirus Protease Linked to an Active Site Directed Peptide Inhibitor
3CGR	;	2.1	;	X-ray structure containing the pseudouridylated U2 snRNA and intron branch site consensus sequences
3CGS	;	1.65	;	X-ray structure containing the pseudouridylated U2 snRNA and mammalian intron branch site consensus sequences
1TLK	;	2.8	;	X-RAY STRUCTURE DETERMINATION OF TELOKIN, THE C-TERMINAL DOMAIN OF MYOSIN LIGHT CHAIN KINASE, AT 2.8 ANGSTROMS RESOLUTION
6GKQ	;	2.3	;	X-ray structure determined from ex vivo Charcot-Leyden crystal
6GKS	;	1.38	;	X-ray structure determined from recombinant Charcot-Leyden crystal
3I3R	;	2.35	;	X-ray structure dihydrofolate reductase/thymidylate synthase from babesia bovis at 2.35A resolution
4A25	;	2.0	;	X-ray structure Dps from Kineococcus radiotolerans in complex with Mn (II) ions.
4ZU7	;	2.3	;	X-ray structure if the QdtA 3,4-ketoisomerase from Thermoanaerobacterium thermosaccharolyticum, double mutant Y17R/R97H, in complex with TDP
1XBF	;	2.0	;	X-RAY STRUCTURE NORTHEAST STRUCTURAL GENOMICS CONSORTIUM TARGET CAR10 FROM C. ACETOBUTYLICUM
6XVX	;	1.4	;	X-ray structure obtained upon reaction of dirhodium tetraacetate with RNase A (high resolution)
6XW0	;	1.8	;	X-ray structure obtained upon reaction of dirhodium tetraacetate with RNase A (low resolution)
1YV7	;	1.9	;	X-ray structure of (C87S,des103-104) onconase
2C82	;	1.9	;	X-Ray Structure Of 1-Deoxy-D-xylulose 5-phosphate Reductoisomerase, DXR, Rv2870c, From Mycobacterium tuberculosis
2Y1D	;	2.05	;	X-ray structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase, DXR, Rv2870c, from Mycobacterium tuberculosis, in complex with a 3,4- dichlorophenyl-substituted fosmidomycin analogue and manganese.
2Y1F	;	1.96	;	X-ray structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase, DXR, Rv2870c, from Mycobacterium tuberculosis, in complex with a 3,4- dichlorophenyl-substituted fosmidomycin analogue, manganese and NADPH.
2Y1G	;	1.95	;	X-ray structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase, DXR, Rv2870c, from Mycobacterium tuberculosis, in complex with a 3,4- dichlorophenyl-substituted FR900098 analogue and manganese.
2JCV	;	2.2	;	X-ray structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase, DXR, Rv2870c, from Mycobacterium tuberculosis, in complex with fosmidomycin and NADPH
4AIC	;	2.05	;	X-ray structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase, DXR, Rv2870c, from Mycobacterium tuberculosis, in complex with fosmidomycin, manganese and NADPH
2JD2	;	2.15	;	X-ray structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase, DXR, Rv2870c, from Mycobacterium tuberculosis, in complex with manganese
2JD1	;	2.0	;	X-ray structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase, DXR, Rv2870c, from Mycobacterium tuberculosis, in complex with manganese and NADPH
2Y1C	;	1.9	;	X-ray structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase, DXR, Rv2870c, from Mycobacterium tuberculosis, in complex with manganese.
2Y1E	;	1.65	;	X-ray structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase, DXR, Rv2870c, from Mycobacterium tuberculosis, in complex with manganese.
5AI3	;	1.02	;	X-ray structure of 113Cd-substituted Perdeuterated Pyrococcus furiosus rubredoxin to 1.02A resolution at 295K in a quartz capillary
2XH8	;	2.08	;	X-ray structure of 119-141 ZnuA deletion mutant from Salmonella enterica.
2AZN	;	2.7	;	X-RAY Structure of 2,5-diamino-6-ribosylamino-4(3h)-pyrimidinone 5-phosphate reductase
5SXU	;	3.1	;	X-ray structure of 2-bromoethanol bound to a pentameric ligand gated ion channel (ELIC) in a desensitized state
5SXV	;	3.4	;	X-ray structure of 2-bromoethanol bound to a pentameric ligand gated ion channel (ELIC) in a resting state
5L1W	;	2.06	;	X-ray Structure of 2-Mercaptoethanol modified M81C mutant of Cytochrome P450 PntM with pentalenolactone F
8KC6	;	1.2	;	X-ray structure of 3-alpha-(Or 20-beta)-hydroxysteroid dehydrogenase
1LO7	;	1.5	;	X-ray structure of 4-Hydroxybenzoyl CoA Thioesterase complexed with 4-hydroxyphenacyl CoA
1B4E	;	2.0	;	X-ray structure of 5-aminolevulinic acid dehydratase complexed with the inhibitor levulinic acid
1PGJ	;	2.82	;	X-RAY STRUCTURE OF 6-PHOSPHOGLUCONATE DEHYDROGENASE FROM THE PROTOZOAN PARASITE T. BRUCEI
2QEF	;	1.6	;	X-ray structure of 7-deaza-dG and Z3dU modified duplex CGCGAATXCZCG
3MVW	;	1.79	;	X-ray structure of a ""NikA+Iron complex"" hybrid, NikA/1
1LOG	;	2.1	;	X-RAY STRUCTURE OF A (ALPHA-MAN(1-3)BETA-MAN(1-4)GLCNAC)-LECTIN COMPLEX AT 2.1 ANGSTROMS RESOLUTION
5O5K	;	3.4	;	X-ray structure of a bacterial adenylyl cyclase soluble domain
5O5L	;	2.7	;	X-ray structure of a bacterial adenylyl cyclase soluble domain, solved at cryogenic temperature
1YAI	;	1.9	;	X-RAY STRUCTURE OF A BACTERIAL COPPER,ZINC SUPEROXIDE DISMUTASE
1DDZ	;	2.2	;	X-RAY STRUCTURE OF A BETA-CARBONIC ANHYDRASE FROM THE RED ALGA, PORPHYRIDIUM PURPUREUM R-1
1LOF	;	2.3	;	X-RAY STRUCTURE OF A BIANTENNARY OCTASACCHARIDE-LECTIN COMPLEX AT 2.3 ANGSTROMS RESOLUTION
1HAU	;	1.9	;	X-RAY STRUCTURE OF A BLUE COPPER NITRITE REDUCTASE AT HIGH PH AND IN COPPER FREE FORM AT 1.9 A RESOLUTION
1HAW	;	1.9	;	X-RAY STRUCTURE OF A BLUE COPPER NITRITE REDUCTASE AT HIGH PH AND IN COPPER FREE FORM AT 1.9 A RESOLUTION
3RAR	;	2.19	;	X-ray structure of a bound phosphonate transition state analog and enantioselectivity of Candida rugosa lipase toward chiral carboxylic acids
3NDJ	;	1.5	;	X-ray Structure of a C-3'-Methyltransferase in Complex with S-Adenosyl-L-Homocysteine and Sugar Product
3NDI	;	1.5	;	X-ray Structure of a C-3'-Methyltransferase in Complex with S-adenosylmethionine and dTMP
2P4A	;	1.9	;	X-ray structure of a camelid affinity matured single-domain vhh antibody fragment in complex with RNASE A
6X0A	;	2.9	;	X-ray structure of a chimeric ParDE toxin-antitoxin complex from Mesorhizobium opportunistum
3RH1	;	2.1	;	X-ray Structure of a cis-proline (P114) to alanine variant of Ribonuclease A
1QUF	;	2.25	;	X-RAY STRUCTURE OF A COMPLEX NADP+-FERREDOXIN:NADP+ REDUCTASE FROM THE CYANOBACTERIUM ANABAENA PCC 7119 AT 2.25 ANGSTROMS
6E0D	;	2.24	;	X-ray structure of a complex of thaumatin with xylene cyanol
2VT0	;	2.15	;	X-ray structure of a conjugate with conduritol-beta-epoxide of acid-beta-glucosidase overexpressed in cultured plant cells
1JMT	;	2.2	;	X-ray Structure of a Core U2AF65/U2AF35 Heterodimer
7L33	;	1.45	;	X-ray Structure of a Cu-Bound De Novo Designed Peptide Trimer
1Z9P	;	1.5	;	X-Ray structure of a Cu-Zn superoxide dismutase from Haemophilus ducreyi
1Z9N	;	1.5	;	X-Ray structure of a Cu-Zn superoxide dismutase from Haemophilus ducreyi with haem bound at the dimer interface
1FQ5	;	2.4	;	X-ray structure of a cyclic statine inhibitor PD-129,541 bound to yeast proteinase A
5HSV	;	1.5	;	X-Ray structure of a CypA-Alisporivir complex at 1.5 angstrom resolution
2BDU	;	2.35	;	X-Ray Structure of a Cytosolic 5'-Nucleotidase III from Mus Musculus MM.158936
2W4J	;	1.3	;	X-ray structure of a DAP-Kinase 2-277
2W4K	;	1.9	;	X-ray structure of a DAP-Kinase 2-302
2X0G	;	2.2	;	X-RAY STRUCTURE OF A DAP-KINASE CALMODULIN COMPLEX
2BH9	;	2.5	;	X-RAY STRUCTURE OF A DELETION VARIANT OF HUMAN GLUCOSE 6-PHOSPHATE DEHYDROGENASE COMPLEXED WITH STRUCTURAL AND COENZYME NADP
4OXW	;	1.73	;	X-ray structure of a designed CISK-PX domain
7T2Y	;	1.34	;	X-ray structure of a designed cold unfolding four helix bundle
183D	;	1.6	;	X-RAY STRUCTURE OF A DNA DECAMER CONTAINING 7, 8-DIHYDRO-8-OXOGUANINE
2OKS	;	1.65	;	X-ray Structure of a DNA Repair Substrate Containing an Alkyl Interstrand Crosslink at 1.65 Resolution
7D75	;	2.5	;	X-ray structure of a domain-swapped dimer of Monellin with YEDKG loop-1 mutant
7VWW	;	2.7	;	X-ray structure of a domain-swapped poly-glutamine Monellin mutant
4NDD	;	2.9	;	X-ray structure of a double mutant of calexcitin - a neuronal calcium-signalling protein
6M3Z	;	3.11	;	X-ray structure of a Drosophila dopamine transporter with NET-like mutations (D121G/S426M/F471L) in milnacipran bound form
6M47	;	3.252	;	X-ray structure of a Drosophila dopamine transporter with NET-like mutations (D121G/S426M/F471L) in tramadol bound form
6M38	;	3.001	;	X-ray structure of a Drosophila dopamine transporter with subsiteB mutations (D121G/S426M) in S-duloxetine bound form
8J4H	;	2.01	;	X-ray structure of a ferric ion-binding protein A (FbpA) from Vibrio metschnikovii in complex with Danshensu (DSS)
8J4J	;	2.15	;	X-ray structure of a ferric ion-binding protein A (FbpA) from Vibrio metschnikovii in complex with ferric ion
6M2R	;	2.802	;	X-ray structure of a functional Drosophila dopamine transporter in L-norepinephrine bound form
3VKH	;	3.8	;	X-ray structure of a functional full-length dynein motor domain
7DA8	;	2.4	;	X-ray structure of a GB1:T2Q/D46K mutant
5KGP	;	1.8	;	X-ray structure of a glucosamine N-Acetyltransferase from Clostridium acetobutylicum in complex with chitosan
5KGJ	;	1.9	;	X-ray structure of a glucosamine N-Acetyltransferase from Clostridium acetobutylicum in complex with galactosamine
5KF8	;	1.9	;	X-ray structure of a glucosamine N-Acetyltransferase from Clostridium acetobutylicum in complex with glucosamine
5KF9	;	1.49	;	X-ray structure of a glucosamine N-Acetyltransferase from Clostridium acetobutylicum in complex with N-acetylglucosamine
5KF1	;	2.0	;	X-ray structure of a glucosamine N-Acetyltransferase from Clostridium acetobutylicum, apo form, pH 5
5KF2	;	1.9	;	X-ray structure of a glucosamine N-Acetyltransferase from Clostridium acetobutylicum, apo form, pH 8
5KGA	;	1.9	;	X-ray structure of a glucosamine N-Acetyltransferase from Clostridium acetobutylicum, mutant D287N, in complex with N-acetylglucosamine
5KGH	;	1.8	;	X-ray structure of a glucosamine N-Acetyltransferase from Clostridium acetobutylicum, mutant Y297F
5AOO	;	2.1	;	X-ray structure of a human Kobuvirus: Aichi virus A (AiV)
2GNX	;	2.45	;	X-ray structure of a hypothetical protein from Mouse Mm.209172
1ZLA	;	2.9	;	X-ray Structure of a Kaposi's sarcoma herpesvirus LANA peptide bound to the nucleosomal core
3M9V	;	2.05	;	X-ray Structure of a KijD3 in Complex with dTDP
4KCF	;	2.098	;	X-ray Structure of a KijD3 in Complex with FMN and dTDP-3-amino-2,3,6-trideoxy-4-keto-3-methyl-D-glucose
8I4D	;	1.06	;	X-ray structure of a L-rhamnose-alpha-1,4-D-glucuronate lyase from Fusarium oxysporum 12S, L-Rha complex at 100K
5HCH	;	2.9	;	X-ray structure of a lectin-bound DNA duplex containing an unnatural phenanthrenyl pair
2A33	;	1.95	;	X-Ray Structure of a Lysine Decarboxylase-Like Protein from Arabidopsis Thaliana Gene AT2G37210
1YDH	;	2.152	;	X-ray structure of a lysine decarboxylase-like protein from arabidopsis thaliana gene at5g11950
1KU9	;	2.8	;	X-ray Structure of a Methanococcus jannaschii DNA-Binding Protein: Implications for Antibiotic Resistance in Staphylococcus aureus
7QJJ	;	4.6	;	X-Ray Structure of a Mn2+ soak of EleNRMT in complex with two Nanobodies at 4.6A
6XSJ	;	1.4	;	X-ray structure of a monoclinic form of alpha amylase from Aspergillus at 1.4 A resolution
1LYS	;	1.72	;	X-RAY STRUCTURE OF A MONOCLINIC FORM OF HEN EGG-WHITE LYSOZYME CRYSTALLIZED AT 313K. COMPARISON OF TWO INDEPENDENT MOLECULES
1CWA	;	2.1	;	X-RAY STRUCTURE OF A MONOMERIC CYCLOPHILIN A-CYCLOSPORIN A CRYSTAL COMPLEX AT 2.1 ANGSTROMS RESOLUTION
7NIT	;	2.89	;	X-ray structure of a multidomain BbgIII from Bifidobacterium bifidum
4NDC	;	2.0	;	X-ray structure of a mutant (T188D) of calexcitin - a neuronal calcium-signalling protein
4NDB	;	2.0	;	X-ray structure of a mutant (T61D) of calexcitin - a neuronal calcium-signalling protein
5YFK	;	1.8	;	X-ray structure of a mutant form C232S of Clostridium perfringens sortase B
2GH8	;	3.2	;	X-ray structure of a native calicivirus
1PVB	;	1.75	;	X-RAY STRUCTURE OF A NEW CRYSTAL FORM OF PIKE 4.10 PARVALBUMIN
5LFG	;	1.94	;	X-ray structure of a new fully ligated carbomonoxy form of Trematomus newnesi hemoglobin (Hb1TnCO).
2V2T	;	3.05	;	X-ray structure of a NF-kB p50-RelB-DNA complex
3DO7	;	3.05	;	X-ray structure of a NF-kB p52/RelB/DNA complex
6GKT	;	2.1	;	X-ray structure of a non-autocrystallizing galectin-10 variant, Gal10-Tyr69Glu
3LTD	;	2.8	;	X-ray structure of a non-biological ATP binding protein determined at 2.8 A by multi-wavelength anomalous dispersion
3LTC	;	2.0	;	X-ray structure of a non-biological ATP binding protein determined in the presence of 10 mM ATP at 2.0 A by multi-wavelength anomalous dispersion
3LTB	;	2.6	;	X-ray structure of a non-biological ATP binding protein determined in the presence of 10 mM ATP at 2.6 A after 3 weeks of incubation
1G4K	;	2.0	;	X-ray Structure of a Novel Matrix Metalloproteinase Inhibitor Complexed to Stromelysin
2BMM	;	2.48	;	X-ray structure of a novel thermostable hemoglobin from the actinobacterium Thermobifida fusca
7EUA	;	2.43	;	X-ray structure of a P93A Monellin mutant
2VL0	;	3.3	;	X-ray structure of a pentameric ligand gated ion channel from Erwinia chrysanthemi (ELIC)
6HJX	;	2.5	;	X-ray structure of a pentameric ligand gated ion channel from Erwinia chrysanthemi (ELIC) 7'C pore mutant (L238C) in complex with nanobody 72
6HJY	;	2.78	;	X-ray structure of a pentameric ligand gated ion channel from Erwinia chrysanthemi (ELIC) Delta8 truncation mutant in complex with nanobody 72
6HK0	;	3.45	;	X-ray structure of a pentameric ligand gated ion channel from Erwinia chrysanthemi (ELIC) F16'S pore mutant (F247S) with alternate M4 conformation.
4A98	;	3.61	;	X-ray structure of a pentameric ligand gated ion channel from Erwinia chrysanthemi (ELIC) in complex with bromoflurazepam
3ZKR	;	3.649	;	X-ray structure of a pentameric ligand gated ion channel from Erwinia chrysanthemi (ELIC) in complex with bromoform
4TWF	;	3.901	;	X-ray structure of a pentameric ligand gated ion channel from Erwinia chrysanthemi (ELIC) in complex with bromomemantine
5LID	;	4.5	;	X-ray structure of a pentameric ligand gated ion channel from Erwinia chrysanthemi (ELIC) in complex with bromopromazine
5LG3	;	3.567	;	X-ray structure of a pentameric ligand gated ion channel from Erwinia chrysanthemi (ELIC) in complex with chlorpromazine
2YOE	;	3.9	;	X-ray structure of a pentameric ligand gated ion channel from Erwinia chrysanthemi (ELIC) in complex with GABA and flurazepam
4TWD	;	3.2	;	X-ray structure of a pentameric ligand gated ion channel from Erwinia chrysanthemi (ELIC) in complex with memantine
4A97	;	3.343	;	X-ray structure of a pentameric ligand gated ion channel from Erwinia chrysanthemi (ELIC) in complex with zopiclone
4TWH	;	3.6	;	X-ray structure of a pentameric ligand gated ion channel from Erwinia chrysanthemi (ELIC) mutant F16'S
3UQ4	;	3.5	;	X-ray structure of a pentameric ligand gated ion channel from Erwinia chrysanthemi (ELIC) mutant F247L (F16L)
3UQ5	;	4.2	;	X-ray structure of a pentameric ligand gated ion channel from Erwinia chrysanthemi (ELIC) mutant L240A F247L (L9A F16L) in the presence of 10 mM cysteamine
3UQ7	;	3.8	;	X-ray structure of a pentameric ligand gated ion channel from Erwinia chrysanthemi (ELIC) mutant L240S F247L (L9S F16L) in presence of 10 mM cysteamine
4BD0	;	1.207	;	X-ray structure of a perdeuterated Toho-1 R274N R276N double mutant Beta-lactamase in complex with a fully deuterated boronic acid (BZB)
4D73	;	1.8	;	X-ray structure of a peroxiredoxin
4BWC	;	1.89	;	X-ray structure of a phospholiapse B like protein 1 from bovine kidneys
1APA	;	2.3	;	X-RAY STRUCTURE OF A POKEWEED ANTIVIRAL PROTEIN, CODED BY A NEW GENOMIC CLONE, AT 0.23 NM RESOLUTION. A MODEL STRUCTURE PROVIDES A SUITABLE ELECTROSTATIC FIELD FOR SUBSTRATE BINDING.
2Q98	;	2.7	;	X-ray structure of a prolactin antagonist
3CGQ	;	2.55	;	X-ray structure of a pseudouridine-containing yeast spliceosomal U2 snRNA-intron branch site duplex
3CGP	;	1.57	;	X-ray structure of a pseudouridine-containing yeast spliceosomal U2 snRNA-intron branch site duplex bound to iodide ions
2ACA	;	2.25	;	X-ray structure of a putative adenylate cyclase Q87NV8 from Vibrio parahaemolyticus at the 2.25 A resolution. Northeast Structural Genomics Target VpR19.
1XRI	;	3.3	;	X-ray structure of a putative phosphoprotein phosphatase from Arabidopsis thaliana gene AT1G05000
4Q9D	;	2.2	;	X-ray structure of a putative thiamin diphosphate-dependent enzyme isolated from Mycobacterium smegmatis
5UPR	;	2.0	;	X-ray structure of a putative triosephosphate isomerase from Toxoplasma gondii ME49
1XCB	;	2.9	;	X-ray Structure of a Rex-Family Repressor/NADH Complex from Thermus Aquaticus
6NAG	;	2.683	;	X-ray structure of a secreted C11 cysteine protease from Bacteroides thetaiotaomicron ""iotapain
6N9J	;	2.17	;	X-ray structure of a secreted C11 cysteine protease from Bacteroides thetaiotaomicron in complex with an irreversible peptide inhibitor
7N2H	;	1.102	;	X-Ray structure of a sequence variant of a repeat segment of the yeast prion New1p
6V33	;	2.03	;	X-ray structure of a sugar N-formyltransferase from Pseudomonas congelans
6V2T	;	1.9	;	X-ray structure of a sugar N-formyltransferase from Shewanella sp FDAARGOS_354
6XSV	;	1.65	;	X-ray structure of a tetragonal crystal form of alpha amylase from Aspergillus oryzae (Tala-Amylase) at 1.65 A resolution
1QM7	;	2.1	;	X-ray structure of a three-fingered chimeric protein, stability of a structural scaffold
6HK5	;	2.042	;	X-ray structure of a truncated mutant of the metallochaperone CooJ with a high-affinity nickel-binding site
1BU2	;	3.0	;	X-RAY STRUCTURE OF A VIRAL CYCLIN FROM HERPESVIRUS SAIMIRI
1ORQ	;	3.2	;	X-ray structure of a voltage-dependent potassium channel in complex with an Fab
1WOE	;	1.5	;	X-ray structure of a Z-DNA hexamer d(CGCGCG)
5O94	;	1.9	;	X-ray structure of a zinc binding GB1 mutant
5OFS	;	1.1	;	X-ray structure of a zinc binding GB1 mutant
4ZQ9	;	2.6	;	X-ray structure of AAV-2 OBD bound to AAVS1 site 3:1
4ZO0	;	2.3	;	X-ray Structure of AAV-2 Origin Binding Domain
5BYG	;	2.5	;	X-ray structure of AAV2 OBD-AAVS1 complex 2:1
3ELH	;	2.4	;	X-ray structure of Acanthamoeba ployphaga mimivirus nucleoside diphosphate kinase complexed with dUDP
2B8Q	;	2.5	;	X-ray structure of Acanthamoeba ployphaga mimivirus nucleoside diphosphate kinase complexed with TDP
3EIC	;	2.3	;	X-ray structure of Acanthamoeba ployphaga mimivirus nucleoside diphosphate kinase complexed with UDP
1ESW	;	1.9	;	X-RAY STRUCTURE OF ACARBOSE BOUND TO AMYLOMALTASE FROM THERMUS AQUATICUS. IMPLICATIONS FOR THE SYNTHESIS OF LARGE CYCLIC GLUCANS
1I9B	;	2.7	;	X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP)
1UX2	;	2.2	;	X-ray structure of acetylcholine binding protein (AChBP)
5Y2Q	;	2.363	;	X-ray structure of acetylcholine binding protein (AChBP) complexed with a small molecule
4QAC	;	2.1	;	X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(4-methylpiperidin-1-yl)-6-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine
4QAB	;	2.984	;	X-RAY STRUCTURE of ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(MORPHOLIN-4-YL)-6-[4-(TRIFLUOROMETHYL)PHENYL]PYRIMIDIN-2-AMINE
5J5H	;	2.7	;	X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 6-(2-methoxyphenyl)-N4,N4-bis[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine
4QAA	;	2.7	;	X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 6-(4-Methoxyphenyl)-N4-octylpyrimidine-2,4-diamine
1UV6	;	2.5	;	X-ray structure of acetylcholine binding protein (AChBP) in complex with carbamylcholine
1UW6	;	2.2	;	X-ray structure of acetylcholine binding protein (AChBP) in complex with nicotine
4FRR	;	2.2	;	X-ray structure of Acetylcholine binding protein from Aplysia californica in presence of 3-((S)-azetidin-2-ylmethoxy)-5-((1S,2R)-2-(2-methoxyethyl)cyclopropyl)pyridine
7NDP	;	2.0	;	X-ray structure of acetylcholine-binding protein (AChBP) in complex with FL001856.
7NDV	;	1.7	;	X-ray structure of acetylcholine-binding protein (AChBP) in complex with FL001888.
2XWD	;	2.66	;	X-RAY STRUCTURE OF ACID-BETA-GLUCOSIDASE WITH 5N,6O-(N'-(N-OCTYL)IMINO)NOJIRIMYCIN IN THE ACTIVE SITE
2XWE	;	2.31	;	X-RAY STRUCTURE OF ACID-BETA-GLUCOSIDASE WITH 5N,6S-(N'-(N-OCTYL)IMINO)-6-THIONOJIRIMYCIN IN THE ACTIVE SITE
2WCG	;	2.3	;	X-ray structure of acid-beta-glucosidase with N-octyl(cyclic guanidine)-nojirimycin in the active site
1OZ6	;	2.6	;	X-ray structure of acidic phospholipase A2 from Indian saw-scaled viper (Echis carinatus) with a potent platelet aggregation inhibitory activity
3B4V	;	2.48	;	X-Ray structure of Activin in complex with FSTL3
2EIS	;	2.1	;	X-ray structure of acyl-CoA hydrolase-like protein, TT1379, from Thermus thermophilus HB8
5TID	;	1.2	;	X-ray structure of acyl-CoA thioesterase I, TesA, mutant M141L/Y145K/L146K at pH 5 in complex with octanoic acid
5TIE	;	1.15	;	x-ray structure of acyl-CoA thioesterase I, TesA, mutant M141L/Y145K/L146K at pH 7.5 in complex with octanoic acid
5TIF	;	0.97	;	x-ray structure of acyl-CoA thioesterase I, TesA, triple mutant M141L/Y145K/L146K in complex with octanoic acid
2A3L	;	3.34	;	X-Ray Structure of Adenosine 5'-Monophosphate Deaminase from Arabidopsis Thaliana in Complex with Coformycin 5'-Phosphate
2DFP	;	2.3	;	X-RAY STRUCTURE OF AGED DI-ISOPROPYL-PHOSPHORO-FLUORIDATE (DFP) BOUND TO ACETYLCHOLINESTERASE
1Y1P	;	1.6	;	X-ray structure of aldehyde reductase with NADPH
4XNK	;	2.8	;	X-ray structure of AlgE1
4XNL	;	2.9	;	X-ray structure of AlgE2
1ZEB	;	1.9	;	X-ray structure of alkaline phosphatase from human placenta in complex with 5'-AMP
3BI3	;	1.9	;	X-ray structure of AlkB protein bound to dsDNA containing 1meA/A with cofactors
6VWU	;	3.4	;	X-ray structure of ALKS 4230, a fusion of circularly permuted human Interleukin-2 and Interleukin-2 Receptor alpha
3JSR	;	1.8	;	X-Ray structure of All0216 protein from Nostoc sp. PCC 7120 at the resolution 1.8A. Northeast Structural Genomics Consortium target NsR236
1ZVC	;	1.79	;	X-ray structure of allene oxide cyclase from arabidopsis thaliana AT3G25760
1Z8K	;	1.712	;	X-ray structure of allene oxide cyclase from Arabidopsis thaliana at3g25770
3IFN	;	1.5	;	X-ray structure of amyloid beta peptide:antibody (Abeta1-40:12A11) complex
3IFO	;	2.15	;	X-ray structure of amyloid beta peptide:antibody (Abeta1-7:10D5) complex
3IFL	;	1.5	;	X-ray structure of amyloid beta peptide:antibody (Abeta1-7:12A11) complex
3IFP	;	2.95	;	X-ray structure of amyloid beta peptide:antibody (Abeta1-7:12B4) complex
4L0A	;	1.7	;	X-ray structure of an all LNA quadruplex
2AJA	;	2.8	;	X-Ray structure of an ankyrin repeat family protein Q5ZSV0 from Legionella pneumophila. Northeast Structural Genomics Consortium target LgR21.
1KG8	;	2.0	;	X-ray structure of an early-M intermediate of bacteriorhodopsin
1XVK	;	1.26	;	X-ray structure of an Echinomycin-(GCGTACGC)2 complex
4CTD	;	3.2	;	X-ray structure of an engineered OmpG loop6-deletion
7K1R	;	2.4	;	X-ray Structure of an Enterobacter GH43 Beta-Xylosidase: EcXyl43 F507A mutant
6MZO	;	1.653	;	X-ray Structure of an Inactive Zymogen C11 Protease from Parabacteroides distasonis
3GKV	;	1.4	;	X-ray structure of an intermediate along the oxidation pathway of Trematomus bernacchii hemoglobin
3VKG	;	2.81	;	X-ray structure of an MTBD truncation mutant of dynein motor domain
5ZM0	;	1.6	;	X-ray structure of animal-like Cryptochrome from Chlamydomonas reinhardtii
6FN2	;	2.3	;	X-ray structure of animal-like Cryptochrome from Chlamydomonas reinhardtii
6FN3	;	1.9	;	X-ray structure of animal-like Cryptochrome from Chlamydomonas reinhardtii
5W7I	;	2.105	;	X-ray structure of ankyrin repeat domain of DHHC17 in complex with Snap25b peptide
1YCN	;	2.51	;	X-RAY STRUCTURE OF ANNEXIN FROM ARABIDOPSIS THALIANA GENE AT1G35720
6I5E	;	2.6	;	X-ray structure of apo human soluble Epoxide Hydrolase C-terminal Domain (hsEH CTD)
5L8X	;	1.85	;	X-RAY STRUCTURE OF APO METHANOCALDOCOCCUS JANNASCHII METHYLTRANSFERASE SUBUNIT A AT 1.85 ANGSTROM
7QJI	;	4.1	;	X-Ray Structure of apo-EleNRMT in complex with two Nanobodies at 4.1A
2BGK	;	1.6	;	X-Ray structure of apo-Secoisolariciresinol Dehydrogenase
3WAF	;	1.8	;	X-ray structure of apo-TtFbpA, a ferric ion-binding protein from thermus thermophilus HB8
7W3W	;	1.858	;	X-ray structure of apo-VmFbpA, a ferric ion-binding protein from Vibrio metschnikovii
2XRY	;	1.5	;	X-ray structure of archaeal class II CPD photolyase from Methanosarcina mazei
2XRZ	;	2.2	;	X-ray structure of archaeal class II CPD photolyase from Methanosarcina mazei in complex with intact CPD-lesion
7BD7	;	1.5	;	X-ray structure of Arsenoplatin-1-encapsulated horse spleen ferritin
2BEB	;	2.81	;	X-ray structure of Asn to Thr mutant of Winged Bean Chymotrypsin inhibitor
6ENV	;	1.82	;	X-ray structure of Au2phen-encapsulated horse spleen apoferritin
5IX6	;	1.85	;	X-ray structure of Auoxo3-encapsulated horse spleen apoferritin
6ENW	;	2.6	;	X-ray structure of Auoxo4-encapsulated horse spleen apoferritin
8B7L	;	1.24	;	X-ray structure of Auranofin-horse spleen ferritin
8B7O	;	1.17	;	X-ray structure of Auranofin-human H-chain ferritin
7CFL	;	1.56	;	X-ray structure of autolysin Acd24020 catalytic domain from Clostridium difficile
2ZDZ	;	2.0	;	X-ray structure of Bace-1 in complex with compound 3.b.10
2ZE1	;	2.2	;	X-ray structure of Bace-1 in complex with compound 6g
6DHC	;	2.85	;	X-ray structure of BACE1 in complex with a bicyclic isoxazoline carboxamide as the P3 ligand
3A9S	;	1.6	;	X-ray Structure of Bacillus pallidus D-Arabinose Isomerase Complex with Glycerol
3A9T	;	2.61	;	X-ray Structure of Bacillus pallidus D-Arabinose Isomerase Complex with L-Fucitol
1O82	;	1.46	;	X-RAY STRUCTURE OF BACTERIOCIN AS-48 AT PH 4.5. SULPHATE BOUND FORM
5VGT	;	1.776	;	X-ray structure of bacteriophage Sf6 tail adaptor protein gp7
3NS0	;	1.78	;	X-ray structure of bacteriorhodopsin
1AP9	;	2.35	;	X-RAY STRUCTURE OF BACTERIORHODOPSIN FROM MICROCRYSTALS GROWN IN LIPIDIC CUBIC PHASES
1QHJ	;	1.9	;	X-RAY STRUCTURE OF BACTERIORHODOPSIN GROWN IN LIPIDIC CUBIC PHASES
1MAZ	;	2.2	;	X-RAY STRUCTURE OF BCL-XL, AN INHIBITOR OF PROGRAMMED CELL DEATH
3IPS	;	2.26	;	X-ray structure of benzisoxazole synthetic agonist bound to the LXR-alpha
3IPU	;	2.4	;	X-ray structure of benzisoxazole urea synthetic agonist bound to the LXR-alpha
1KRH	;	1.5	;	X-ray Structure of Benzoate Dioxygenase Reductase
3SL9	;	2.2	;	X-ray structure of Beta catenin in complex with Bcl9
2C0H	;	1.6	;	X-ray structure of beta-mannanase from blue mussel Mytilus edulis
4XL5	;	2.0	;	X-ray structure of bGFP-A / EGFP complex
4XVP	;	3.4	;	X-ray structure of bGFP-C / EGFP complex
1BIK	;	2.5	;	X-RAY STRUCTURE OF BIKUNIN FROM THE HUMAN INTER-ALPHA-INHIBITOR COMPLEX
2BGL	;	2.8	;	X-Ray structure of binary-Secoisolariciresinol Dehydrogenase
2C1Q	;	2.1	;	X-ray structure of biotin binding protein from chicken
2C1S	;	1.75	;	X-ray structure of biotin binding protein from chicken
2FXU	;	1.35	;	X-ray Structure of Bistramide A- Actin Complex at 1.35 A resolution.
1WBE	;	1.36	;	X-ray structure of bovine GLTP
6FF5	;	1.74	;	X-ray structure of bovine heart cytochrome c at high ionic strength
3CR4	;	2.15	;	X-ray structure of bovine Pnt,Ca(2+)-S100B
3CR5	;	1.85	;	X-ray structure of bovine Pnt-Zn(2+),Ca(2+)-S100B
3GK1	;	2.1	;	X-ray structure of bovine SBi132,Ca(2+)-S100B
3GK2	;	1.984	;	X-ray structure of bovine SBi279,Ca(2+)-S100B
3GK4	;	1.9	;	X-ray structure of bovine SBi523,Ca(2+)-S100B
3LK0	;	2.04	;	X-ray structure of bovine SC0067,Ca(2+)-S100B
3LK1	;	1.79	;	X-ray structure of bovine SC0322,Ca(2+)-S100B
3LLE	;	1.85	;	X-ray structure of bovine SC0322,Ca(2+)-S100B
1R5D	;	2.5	;	X-ray structure of bovine seminal ribonuclease swapping dimer from a new crystal form
3IQQ	;	2.01	;	X-ray structure of bovine TRTK12-Ca(2+)-S100B
3CR2	;	1.88	;	X-ray structure of bovine Zn(2+),Ca(2+)-S100B
6M9X	;	1.81	;	X-ray Structure of Branchiostoma floridae fluorescent protein lanFP10A
6MAS	;	1.3	;	X-ray Structure of Branchiostoma floridae fluorescent protein lanFP10G
6M9Y	;	1.35	;	X-ray Structure of Branchiostoma floridae fluorescent protein lanFP6A
6M9Z	;	1.2	;	X-ray Structure of Branchiostoma floridae fluorescent protein lanFP6G
4N27	;	2.73	;	X-ray structure of Brucella abortus RicA
5W71	;	2.1	;	X-ray structure of BtrR from Bacillus circulans in the presence of the 2-DOS external aldimine
3ZCL	;	1.4	;	X-ray Structure of c-Met kinase in complex with inhibitor (S)-3-(1-(1H-pyrrolo(2,3-b)pyridin-3-yl)ethyl)-N-isopropyl-(1,2,4)triazolo(4,3- b)pyridazin-6-amine
3ZC5	;	2.2	;	X-ray Structure of c-Met kinase in complex with inhibitor (S)-6-(1-(6- (1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)ethyl) quinoline.
3ZBX	;	2.2	;	X-ray Structure of c-Met kinase in complex with inhibitor 6-((6-(4- fluorophenyl)-(1,2,4)triazolo(4,3-b)(1,2,4)triazin-3-yl)methyl) quinoline.
2RFN	;	2.5	;	x-ray structure of c-Met with inhibitor.
3CCN	;	1.9	;	X-ray structure of c-Met with triazolopyridazine inhibitor.
3CD8	;	2.0	;	X-ray Structure of c-Met with triazolopyridazine Inhibitor.
6TJU	;	1.8	;	X-ray structure of C-terminal domain of human T-cell lymphotropic virus type 1 (HTLV-1)
6UHJ	;	1.5	;	X-ray Structure of C148 mGFP
1LJU	;	1.4	;	X-RAY STRUCTURE OF C15A ARSENATE REDUCTASE FROM PI258 COMPLEXED WITH ARSENITE
4XYN	;	2.55	;	X-ray structure of Ca(2+)-S100B with human RAGE-derived W61 peptide
5D7F	;	1.3	;	X-ray structure of Ca(2+)-S100B with human RAGE-derived W72 peptide
4UPG	;	2.1	;	X-ray structure of calcium-free human sorcin
1QX2	;	1.44	;	X-ray Structure of Calcium-loaded Calbindomodulin (A Calbindin D9k Re-engineered to Undergo a Conformational Opening) at 1.44 A Resolution
2CCM	;	1.8	;	X-ray structure of Calexcitin from Loligo pealeii at 1.8A
4IAI	;	1.55	;	X-ray Structure of cAMP dependent protein kinase A in complex with high Ca2+ concentration, ADP and phosphorylated peptide pSP20
4IAC	;	2.15	;	X-RAY structure of cAMP dependent protein kinase A in complex with HIGH MG2+ concentration, AMP-PCP AND pseudo-substrate peptide SP20
4IB0	;	1.87	;	X-ray Structure of cAMP dependent protein kinase A in complex with high Na+ concentration, ADP and phosphorylated peptide pSP20
3GUU	;	2.1	;	X-ray structure of Candida Antarctica lipase A
2VEO	;	2.2	;	X-ray structure of Candida antarctica lipase A in its closed state.
8AEH	;	3.0	;	X-ray structure of Canis familiaris Odorant Binding Protein 1
8AEI	;	1.74	;	X-ray structure of Canis familiaris Odorant Binding Protein 2 bound to citronellal
8AEJ	;	1.84	;	X-ray structure of Canis familiaris Odorant Binding Protein 3 bound to menthone
8EGI	;	2.3	;	X-ray structure of carbonmonoxy hemoglobin in complex with VZHE039-NO
4ESA	;	1.45	;	X-ray structure of carbonmonoxy hemoglobin of Eleginops maclovinus
5GMO	;	2.304	;	X-ray structure of carbonyl reductase SsCR
5MIJ	;	1.49	;	X-ray structure of carboplatin-encapsulated horse spleen apoferritin
5MIK	;	1.96	;	X-ray structure of carboplatin-encapsulated horse spleen apoferritin (rotating anode data)
4IKM	;	2.4606	;	X-ray structure of CARD8 CARD domain
8P89	;	3.187	;	X-ray structure of cardiotoxic light chain H3 in complex to neutralizing nanobody B5
8P88	;	2.022	;	X-ray structure of cardiotoxic light chain H3 in complex to neutralizing nanobody C4
5WQW	;	1.76	;	X-ray structure of catalytic domain of autolysin from Clostridium perfringens
4KRU	;	1.37	;	X-ray structure of catalytic domain of endolysin from clostridium perfringens phage phiSM101
3KW9	;	1.8	;	X-ray structure of Cathepsin K covalently bound to a triazine ligand
3WW1	;	1.95	;	X-ray structure of Cellulomonas parahominis L-ribose isomerase with L-ribose
2Q57	;	2.0	;	X-ray structure of Cerulean GFP: A tryptophan-based chromophore useful for fluorescence lifetime imaging
2YJ0	;	2.4	;	X-ray structure of chemically engineered Mycobacterium tuberculosis Dodecin
2F6L	;	1.7	;	X-ray structure of Chorismate Mutase from Mycobacterium Tuberculosis
5ERJ	;	1.45	;	X-ray structure of cisplatin-encapsulated horse spleen apoferritin
7M14	;	2.1	;	x-ray structure of cj1430 in the presence of GDP, a GDP-D-glycero-4-keto-D-lyxo-heptose-3,5-epimerase from campylobacter jejuni
6VWR	;	1.5	;	X-ray structure of clavaminate synthase with vanadyl, succinate, and deoxyguanidinoproclavaminic acid
6FYO	;	2.32	;	X-RAY STRUCTURE OF CLK1-KD(148-484)/Cpd-2 AT 2.32A
6FYI	;	2.6	;	X-ray Structure of CLK2-KD(130-496)/TG003 at 2.6A
6FYL	;	1.95	;	X-ray structure of CLK2-KD(136-496)/CX-4945 at 1.95A
6FYK	;	2.39	;	X-Ray structure of CLK2-KD(136-496)/Indazole1 at 2.39A
6FYR	;	1.42	;	X-RAY STRUCTURE OF CLK3-KD(GP-[275-632], NON-PHOS.)/Cpd-2 AT 1.42A
6FYP	;	2.29	;	X-RAY STRUCTURE OF CLK3-KD(GP-[275-632], NON-PHOS.)/CX-4945 AT 2.29A
6FYV	;	2.46	;	X-RAY STRUCTURE OF CLK4-KD(146-480)/CX-4945 AT 2.46A
7T31	;	2.3	;	X-ray Structure of Clostridiodies difficile PilW
1XX6	;	2.0	;	X-ray structure of Clostridium acetobutylicum thymidine kinase with ADP. Northeast Structural Genomics Target CAR26.
8GSX	;	2.86	;	X-ray structure of Clostridium perfringens pili protein B collagen-binding domains
8GSY	;	1.55	;	X-ray structure of Clostridium perfringens pili protein B N-terminal domain
5XCC	;	2.48	;	X-ray structure of Clostridium perfringens pili protein CppA
5B23	;	2.2	;	X-ray Structure of Clostridium Perfringens Sortase B
7D6T	;	1.68	;	X-ray structure of Clostridium perfringens sortase C with the C-terminal cell wall sorting motif.
7F5I	;	1.65	;	X-ray structure of Clostridium perfringens-specific amidase endolysin
5JOM	;	1.9	;	X-ray structure of CO-bound sperm whale myoglobin using a fixed target crystallography chip
4ML3	;	3.15	;	X-ray structure of ComE D58A REC domain from Streptococcus pneumoniae
4MLD	;	2.88	;	X-ray structure of ComE D58E REC domain from Streptococcus pneumoniae
2OJU	;	2.4	;	X-ray structure of complex of human cyclophilin J with cyclosporin A
6Q9W	;	1.55	;	X-ray structure of compound 15 bound to HdmX: Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes
8SLB	;	2.04	;	X-ray structure of CorA N-terminal domain in complex with conformation-specific synthetic antibody C12
2BFU	;	4.0	;	X-ray structure of CPMV top component
4GV5	;	1.7	;	X-ray structure of crotamine, a cell-penetrating peptide from the Brazilian snake Crotalus durissus terrificus
1YLW	;	1.74	;	X-ray structure of CTX-M-16 beta-lactamase
2WNO	;	2.3	;	X-ray Structure of CUB_C domain from TSG-6
1RTE	;	2.0	;	X-ray Structure of Cyanide Derivative of Truncated Hemoglobin N (trHbN) from Mycobacterium Tuberculosis
3X2Q	;	2.0	;	X-ray structure of cyanide-bound bovine heart cytochrome c oxidase in the fully oxidized state at 2.0 angstrom resolution
6A37	;	2.204	;	X-ray structure of cyclohexanone monooxygenase from Acinetobacter calcoaceticus
2WV2	;	2.7	;	X-ray structure of CYP51 from the human pathogen Trypanosoma brucei in complex with fluconazole
2WX2	;	2.27	;	X-RAY STRUCTURE OF CYP51 FROM THE HUMAN PATHOGEN TRYPANOSOMA CRUZI IN COMPLEX WITH FLUCONAZOLE
2X2N	;	2.6	;	X-ray structure of cyp51 from trypanosoma brucei in complex with posaconazole in two different conformations
2WUZ	;	2.35	;	X-ray structure of CYP51 from Trypanosoma cruzi in complex with fluconazole in alternative conformation
7PCJ	;	1.91	;	X-ray structure of CypA-C52AK125C/CsA/aromatic foldamer complex
2ATF	;	1.75	;	X-RAY STRUCTURE OF cysteine dioxygenase type I FROM MUS MUSCULUS MM.241056
3ETQ	;	1.9	;	X-ray structure of cysteine-free fragment of mHCN2 C-terminal region from amino acids 443-630 including C508N, C584S, and C601S mutations
5L1Q	;	2.03	;	X-ray Structure of Cytochrome P450 PntM with Dihydropentalenolactone F
5L1P	;	2.28	;	X-ray Structure of Cytochrome P450 PntM with Pentalenolactone
5L1O	;	2.03	;	X-ray Structure of Cytochrome P450 PntM with Pentalenolactone F
2EXR	;	1.702	;	X-Ray Structure of Cytokinin Oxidase/Dehydrogenase (CKX) From Arabidopsis Thaliana AT5G21482
4Z0H	;	2.3	;	X-ray structure of cytoplasmic glyceraldehyde-3-phosphate dehydrogenase (GapC1) complexed with NAD
3DCK	;	1.8	;	X-ray structure of D25N chemical analogue of HIV-1 protease complexed with ketomethylene isostere inhibitor
7FCU	;	1.42	;	X-ray structure of D2O-solvent lysozyme
6R0K	;	1.15	;	X-ray structure of Danio rerio histone deacetylase 6 (HDAC6) CD2 in complex with a inhibitor SS208
6TCY	;	1.6	;	X-ray structure of Danio rerio histone deacetylase 6 (HDAC6) CD2 in complex with a inhibitor SS555
8BJK	;	1.35	;	X-ray structure of Danio rerio histone deacetylase 6 (HDAC6) CD2 in complex with an inhibitor CPD11352
6ZW1	;	1.13	;	X-ray structure of Danio rerio histone deacetylase 6 (HDAC6) CD2 in complex with an inhibitor SW101
3U1V	;	2.797	;	X-ray Structure of De Novo design cysteine esterase FR29, Northeast Structural Genomics Consortium Target OR52
1T3H	;	2.5	;	X-ray Structure of Dephospho-CoA Kinase from E. coli Norteast Structural Genomics Consortium Target ER57
1KTJ	;	2.15	;	X-ray Structure Of Der P 2, The Major House Dust Mite Allergen
4FM5	;	2.81	;	X-ray structure of des-methylflurbiprofen bound to murine COX-2
1NFV	;	1.95	;	X-ray structure of Desulfovibrio desulfuricans bacterioferritin: the diiron centre in different catalytic states (as-isolated structure)
1XLU	;	2.198	;	X-Ray Structure Of Di-Isopropyl-Phosphoro-Fluoridate (Dfp) Inhibited Butyrylcholinesterase after Aging
1FQ8	;	2.8	;	X-RAY STRUCTURE OF DIFLUOROSTATINE INHIBITOR CP81,198 BOUND TO SACCHAROPEPSIN
3MTK	;	2.24	;	X-Ray Structure of Diguanylate cyclase/phosphodiesterase from Caldicellulosiruptor saccharolyticus, Northeast Structural Genomics Consortium Target ClR27C
7PVK	;	2.4	;	X-ray structure of dimeric PorX (T272A mutant), in complex with pGpG.
6GXJ	;	1.43	;	X-ray structure of DiRu-1-encapsulated Apoferritin
3UQZ	;	2.7	;	X-ray structure of DNA processing protein A (DprA) from Streptococcus pneumoniae
5XCB	;	2.14	;	X-ray structure of domains D1 and D2 of Clostridium perfringens pili protein CppA
4M48	;	2.955	;	X-ray structure of dopamine transporter elucidates antidepressant mechanism
2IY4	;	2.31	;	X-ray structure of Dps from Listeria monocytogenes
1UVH	;	2.8	;	X-ray structure of Dps from Mycobacterium smegmatis
2C41	;	1.81	;	X-ray structure of Dps from Thermosynechococcus elongatus
2VXX	;	2.4	;	X-ray structure of DpsA from Thermosynechococcus elongatus
5B16	;	3.2	;	X-ray structure of DROSHA in complex with the C-terminal tail of DGCR8.
4XPA	;	2.95	;	X-ray structure of Drosophila dopamine transporter bound to 3,4dichlorophenethylamine
4XP5	;	3.3	;	X-ray structure of Drosophila dopamine transporter bound to cocaine analogue-RTI55
4XP1	;	2.89	;	X-ray structure of Drosophila dopamine transporter bound to neurotransmitter dopamine
4XP9	;	2.8	;	X-ray structure of Drosophila dopamine transporter bound to psychostimulant D-amphetamine
4XP6	;	3.1	;	X-ray structure of Drosophila dopamine transporter bound to psychostimulant methamphetamine
4XP4	;	2.8	;	X-ray structure of Drosophila dopamine transporter in complex with cocaine
4XNU	;	2.98	;	X-ray structure of Drosophila dopamine transporter in complex with nisoxetine
4XNX	;	3.0	;	X-ray structure of Drosophila dopamine transporter in complex with reboxetine
6M0Z	;	2.88	;	X-ray structure of Drosophila dopamine transporter with NET-like mutations (D121G/S426M/F471L) in L-norepinephrine bound form
4XPH	;	2.9	;	X-ray structure of Drosophila dopamine transporter with subsiteB mutations (D121G/S426M) bound to 3,4dichlorophenethylamine
4XPG	;	3.21	;	X-ray structure of Drosophila dopamine transporter with subsiteB mutations (D121G/S426M) bound to beta-CFT or Win35428
4XPB	;	3.05	;	X-ray structure of Drosophila dopamine transporter with subsiteB mutations (D121G/S426M) bound to cocaine
4XPF	;	3.273	;	X-ray structure of Drosophila dopamine transporter with subsiteB mutations (D121G/S426M) bound to RTI-55
6M0F	;	3.3	;	X-ray structure of Drosophila dopamine transporter with subsiteB mutations (D121G/S426M) in substrate-free form
4XPT	;	3.36	;	X-ray structure of Drosophila dopamine transporter with subsiteB mutations D121G/S426M and EL2 deletion of 162-201 in complex with substrate analogue 3,4 dichlorophen ethylamine
1SQH	;	2.0	;	X-RAY STRUCTURE OF DROSOPHILA MALONOGASTER PROTEIN Q9VR51 NORTHEAST STRUCTURAL GENOMICS CONSORTIUM TARGET FR87.
1T3B	;	2.5	;	X-ray Structure of DsbC from Haemophilus influenzae
3BIE	;	1.68	;	X-ray structure of E coli AlkB bound to dsDNA containing 1meA/T with Mn and 2KG
3BKZ	;	1.65	;	X-ray structure of E coli AlkB crosslinked to dsDNA in the active site
4CCL	;	2.596	;	X-Ray structure of E. coli ycfD
3ZHO	;	1.2	;	X-ray structure of E.coli Wrba in complex with FMN at 1.2 A resolution
2JI2	;	1.7	;	X-ray structure of E114A mutant of superoxide reductase from Desulfoarculus baarsii in the native, reduced form
3BEL	;	2.3	;	X-ray structure of EGFR in complex with oxime inhibitor
1OY1	;	2.95	;	X-Ray Structure Of ElbB From E. Coli. Northeast Structural Genomics Research Consortium (Nesg) Target Er105
4KRT	;	1.92	;	X-ray structure of endolysin from clostridium perfringens phage phiSM101
2Y0G	;	1.5	;	X-ray structure of Enhanced Green Fluorescent Protein (EGFP)
5YCV	;	1.851	;	X-Ray Structure of Enoyl-Acyl Carrier Protein Reductase from Bacillus Anthracis (Apo form)
5YCX	;	1.701	;	X-Ray Structure of Enoyl-Acyl Carrier Protein Reductase from Bacillus Anthracis with c-terminal His tag (Apo form)
5YCR	;	1.96	;	X-Ray Structure of Enoyl-Acyl Carrier Protein Reductase from Bacillus Anthracis with NAD+
2QIO	;	2.44	;	X-Ray Structure of Enoyl-Acyl Carrier Protein Reductase from Bacillus Anthracis with Triclosan
5YCS	;	1.95	;	X-Ray Structure of Enoyl-Acyl Carrier Protein Reductase from Bacillus Anthracis with triclosan
8WL7	;	1.74	;	X-ray structure of Enterobacter cloacae allose-binding protein in complex with D-allose
8WLB	;	1.71	;	X-ray structure of Enterobacter cloacae allose-binding protein in complex with D-psicose
8WL9	;	1.93	;	X-ray structure of Enterobacter cloacae allose-binding protein in complex with D-ribose
8WL5	;	1.87	;	X-ray structure of Enterobacter cloacae allose-binding protein in free form
6PNW	;	2.0	;	X-RAY STRUCTURE OF ERABUTOXIN C, A DIMERIC NEUROTOXIN
1XQC	;	2.05	;	X-ray structure of ERalpha LBD bound to a tetrahydroisoquinoline SERM ligand at 2.05A resolution
1XB7	;	2.5	;	X-ray structure of ERRalpha LBD in complex with a PGC-1alpha peptide at 2.5A resolution
6XG5	;	1.9	;	X-ray structure of Escherichia coli dihydrofolate reductase in complex with trimethoprim
6XG4	;	2.1	;	X-ray structure of Escherichia coli dihydrofolate reductase L28R mutant in complex with trimethoprim
1DFI	;	2.09	;	X-RAY STRUCTURE OF ESCHERICHIA COLI ENOYL REDUCTASE WITH BOUND NAD
1DFG	;	2.5	;	X-RAY STRUCTURE OF ESCHERICHIA COLI ENOYL REDUCTASE WITH BOUND NAD AND BENZO-DIAZABORINE
1DFH	;	2.2	;	X-RAY STRUCTURE OF ESCHERICHIA COLI ENOYL REDUCTASE WITH BOUND NAD AND THIENO-DIAZABORINE
1DNL	;	1.8	;	X-RAY STRUCTURE OF ESCHERICHIA COLI PYRIDOXINE 5'-PHOSPHATE OXIDASE COMPLEXED WITH FMN AT 1.8 ANGSTROM RESOLUTION
1G76	;	2.2	;	X-RAY STRUCTURE OF ESCHERICHIA COLI PYRIDOXINE 5'-PHOSPHATE OXIDASE COMPLEXED WITH PYRIDOXAL 5'-PHOSPHATE AT 2.0 A RESOLUTION
1G78	;	2.2	;	X-RAY STRUCTURE OF ESCHERICHIA COLI PYRIDOXINE 5'-PHOSPHATE OXIDASE COMPLEXED WITH PYRIDOXAL 5'-PHOSPHATE AT 2.0 A RESOLUTION
1G79	;	2.0	;	X-RAY STRUCTURE OF ESCHERICHIA COLI PYRIDOXINE 5'-PHOSPHATE OXIDASE COMPLEXED WITH PYRIDOXAL 5'-PHOSPHATE AT 2.0 A RESOLUTION
1WV4	;	2.6	;	X-ray Structure of Escherichia coli pyridoxine 5'-phosphate oxidase in tetragonal crystal form
1G77	;	2.1	;	X-RAY STRUCTURE OF ESCHERICHIA COLI PYRIDOXINE 5`-PHOSPHATE OXIDASE COMPLEXED WITH PYRIDOXAL 5'-PHOSPHATE AT 2.0 A RESOLUTION
3NXN	;	1.8	;	X-ray structure of ester chemical analogue 'covalent dimer' [Ile50,O-Ile50']HIV-1 protease complexed with KVS-1 inhibitor
3NXE	;	1.61	;	X-ray structure of ester chemical analogue 'covalent dimer' [Ile50,O-Ile50']HIV-1 protease complexed with MVT-101 inhibitor
3NYG	;	1.45	;	X-ray structure of ester chemical analogue [O-Gly51,O-Gly51']HIV-1 protease complexed with MVT-101 inhibitor
3NWX	;	1.9	;	X-ray structure of ester chemical analogue [O-Ile50,O-Ile50']HIV-1 protease complexed with KVS-1 inhibitor
3NWQ	;	1.5	;	X-ray structure of ester chemical analogue [O-Ile50,O-Ile50']HIV-1 protease complexed with MVT-101
2P7G	;	2.1	;	X-ray Structure of Estrogen Related Receptor g in complex with Bisphenol A.
5YBD	;	2.769	;	X-ray structure of ETS domain of Ergp55 in complex with E74DNA
5L1S	;	2.08	;	X-ray Structure of F232L mutant of Cytochrome P450 PntM with pentalenolactone F
5ZZF	;	1.6	;	X-ray structure of F43Y/H64D sperm whale myoglobin
5ZZG	;	1.8	;	X-ray structure of F43Y/H64D sperm whale myoglobin in complex with TCP
7QTY	;	1.69	;	X-ray structure of FAD domain of NqrF of Klebsiella pneumoniae
7QU0	;	1.62	;	X-ray structure of FAD domain of NqrF of Klebsiella pneumoniae
7QU3	;	1.6	;	X-ray structure of FAD domain of NqrF of Pseudomonas aeruginosa
7QU5	;	1.25	;	X-ray structure of FAD domain of NqrF of Pseudomonas aeruginosa
1ZW5	;	2.3	;	X-ray structure of Farnesyl diphosphate synthase protein
2VIM	;	1.38	;	X-ray structure of Fasciola hepatica thioredoxin
6P5Q	;	1.86	;	X-ray structure of Fe(II)-soaked UndA bound to lauric acid
4MXK	;	1.52	;	X-ray structure of Fe(II)-ZnPIXFeBMb1
3WAE	;	1.7	;	X-ray structure of Fe(III)-bicarbonates-ttfbpa, a ferric ion-binding protein from thermus thermophilus HB8
2BGV	;	1.9	;	X-ray structure of ferric cytochrome c-550 from Paracoccus versutus
5B85	;	1.85	;	X-ray structure of ferric F138Y sperm whale myoglobin
6DCE	;	1.56	;	X-ray structure of FIP200 claw domain
3SLA	;	2.5	;	X-ray structure of first four repeats of human beta-catenin
6YHH	;	1.7	;	X-ray Structure of Flavobacterium johnsoniae chitobiase (FjGH20)
6PNY	;	1.65	;	X-ray Structure of Flpp3
4P5P	;	1.54	;	X-ray structure of Francisella tularensis Rapid Encystment Protein 24 KDa (REP24), gene product of FTN_0841
3MMH	;	1.25	;	X-ray structure of free methionine-R-sulfoxide reductase from neisseria meningitidis in complex with its substrate
1HM6	;	1.8	;	X-RAY STRUCTURE OF FULL-LENGTH ANNEXIN 1
4CBV	;	3.39	;	X-ray structure of full-length ComE from Streptococcus pneumoniae.
4OPH	;	3.158	;	X-ray structure of full-length H6N6 NS1
3SNG	;	2.16	;	X-ray structure of fully glycosylated bifunctional nuclease TBN1 from Solanum lycopersicum (Tomato)
8B4W	;	1.6	;	X-ray structure of furin (PCSK3) in complex with 1H-isoindol-3-amine
8B4V	;	1.6	;	X-ray structure of furin (PCSK3) in complex with benzamidine
8OYH	;	1.8	;	X-ray structure of furin (PCSK3) in complex with Guanidinomethyl-Phac-Can-Tle-Can-6-(aminomethyl)-3-amino-isoindol
8B4X	;	1.6	;	X-ray structure of furin (PCSK3) in complex with Guanidinomethyl-Phac-R-Tle-K-6-(aminomethyl)-3-amino-isoindol
7LCU	;	1.24	;	X-ray structure of Furin bound to BOS-318, a small molecule inhibitor
6YD3	;	2.0	;	X-ray structure of furin in complex with the canavanine derived inhibitor 4-guanidinomethyl-phenylacetyl-Canavanine-Tle-Arg-Amba
6YD2	;	1.8	;	X-ray structure of furin in complex with the canavanine-based inhibitor 4-aminomethyl-phenylacetyl-canavanine-Tle-Arg-Amba
6YD7	;	1.8	;	X-ray structure of furin in complex with the canavanine-based inhibitor 4-guanidinomethyl-phenylacetyl-Arg-Tle-Canavanine-Amba
6YD4	;	1.7	;	X-ray structure of furin in complex with the canavanine-based inhibitor 4-guanidinomethyl-phenylacetyl-Canavanine-Tle-Canavanine-Amba
6HZD	;	1.9	;	X-ray structure of furin in complex with the cyclic inhibitor c[glutaryl-Arg-Arg-Arg-Lys]-Arg-4-Amba
6HZB	;	1.9	;	X-ray structure of furin in complex with the cyclic inhibitor c[glutaryl-Arg-Arg-Lys]-Lys-4-Amba
6HZC	;	1.9	;	X-ray structure of furin in complex with the cyclic inhibitor c[glutaryl-BVK-Lys-Arg-Arg-Tle-Lys]-4-Amba
6HZA	;	1.9	;	X-ray structure of furin in complex with the cyclic peptide c[glutaryl-Arg-Arg-Lys]-Arg-4-Amba
6HLD	;	2.1	;	X-ray structure of furin in complex with the cyclic peptide c[succinyl-Phe-2-Nal-(Arg)3-Lys]-Lys-4-Amba
6HLB	;	2.0	;	X-ray structure of furin in complex with the cyclic peptide c[succinyl-Phe-2-Nal-(Arg)4-Lys]-Arg-4-Amba
7QY0	;	1.54	;	X-ray structure of furin in complex with the dichlorophenylpyridine-based inhibitor 1
7QY2	;	1.55	;	X-ray structure of furin in complex with the dichlorophenylpyridine-based inhibitor 2
7QXY	;	1.478	;	X-ray structure of furin in complex with the dichlorophenylpyridine-based inhibitor 3
7QY1	;	1.45	;	X-ray structure of furin in complex with the dichlorophenylpyridine-based inhibitor 4
7QXZ	;	1.8	;	X-ray structure of furin in complex with the dichlorophenylpyridine-based inhibitor 5
7O1U	;	1.7	;	X-ray structure of furin in complex with the guanylhydrazone-based inhibitor 1 (BEV241)
7O1Y	;	1.7	;	X-ray structure of furin in complex with the guanylhydrazone-based inhibitor 2 (mi307) soaked at 0.25 M NaCl
7O1W	;	1.8	;	X-ray structure of furin in complex with the guanylhydrazone-based inhibitor 2 (mi307) soaked at 1 M NaCl
7O20	;	1.8	;	X-ray structure of furin in complex with the guanylhydrazone-based inhibitor 3 (mi300)
7O22	;	1.8	;	X-ray structure of furin in complex with the guanylhydrazone-based inhibitor 4 (mi359)
5JMO	;	1.998	;	X-ray structure of furin in complex with the inhibitory antibody Nb14
6HLE	;	1.994	;	X-ray structure of furin in complex with the P6-P2-cyclized peptide H-Lys-Arg-Arg-Tle-Lys-4-Amba
2RA0	;	2.3	;	X-ray Structure of FXa in complex with 7-fluoroindazole
1L7J	;	1.9	;	X-ray structure of galactose mutarotase from Lactococcus lactis (apo)
1L7K	;	1.95	;	x-ray structure of galactose mutarotase from Lactococcus lactis complexed with galactose
1Z84	;	1.83	;	X-ray structure of galt-like protein from arabidopsis thaliana at5g18200
1ZWJ	;	2.3	;	X-ray structure of galt-like protein from arabidopsis thaliana AT5G18200
4EA9	;	0.9	;	X-ray structure of GDP-perosamine N-acetyltransferase in complex with transition state analog at 0.9 Angstrom resolution
6CBO	;	1.6	;	X-ray structure of GenB1 from micromonospora echinospora in complex with neamine and PLP (as the external aldimine)
2GCU	;	1.477	;	X-Ray Structure of Gene Product from Arabidopsis Thaliana At1g53580
1XMT	;	1.15	;	X-ray structure of gene product from arabidopsis thaliana at1g77540
1XFI	;	1.7	;	X-ray structure of gene product from Arabidopsis thaliana At2g17340
1XYG	;	2.19	;	X-RAY STRUCTURE OF GENE PRODUCT FROM ARABIDOPSIS THALIANA AT2G19940
1VM0	;	1.8	;	X-RAY STRUCTURE OF GENE PRODUCT FROM ARABIDOPSIS THALIANA AT2G34160
1Z90	;	1.86	;	X-ray structure of gene product from arabidopsis thaliana at3g03250, a putative UDP-glucose pyrophosphorylase
2F2G	;	2.1	;	X-Ray Structure of Gene Product From Arabidopsis Thaliana AT3G16990
1Y0Z	;	2.4	;	X-ray structure of gene product from Arabidopsis thaliana At3g21360
1VK5	;	1.604	;	X-ray Structure of Gene Product from Arabidopsis Thaliana At3g22680
1YDW	;	2.488	;	X-RAY STRUCTURE OF GENE PRODUCT FROM ARABIDOPSIS THALIANA AT4G09670
1XQ6	;	1.8	;	X-ray Structure of Gene Product from Arabidopsis Thaliana At5g02240
1VK0	;	2.1	;	X-ray Structure of Gene Product from Arabidopsis Thaliana At5g06450
1VKP	;	1.53	;	X-RAY STRUCTURE OF GENE PRODUCT FROM ARABIDOPSIS THALIANA AT5G08170, AGMATINE IMINOHYDROLASE
1XY7	;	1.8	;	X-RAY STRUCTURE OF GENE PRODUCT FROM ARABIDOPSIS THALIANA AT5G48480
1ZTP	;	2.5	;	X-ray structure of gene product from homo sapiens Hs.433573
2AB1	;	2.59	;	X-Ray Structure of Gene Product from Homo Sapiens HS.95870
3GB3	;	1.75	;	X-ray structure of genetically encoded photosensitizer KillerRed in native form
1IHC	;	1.9	;	X-ray Structure of Gephyrin N-terminal Domain
4UAP	;	2.0	;	X-ray structure of GH31 CBM32-2 bound to GalNAc
6HPP	;	3.2	;	X-ray structure of GLIC in complex with propionate
1LAA	;	1.77	;	X-RAY STRUCTURE OF GLU 53 HUMAN LYSOZYME
3GA5	;	1.87	;	X-ray structure of glucose/galactose receptor from Salmonella typhimurium in complex with (2R)-glyceryl-beta-D-galactopyranoside
4CKQ	;	1.4	;	X-ray structure of glucuronoxylan-xylanohydrolase (Xyn30A) from Clostridium thermocellum
4UQA	;	1.52	;	X-ray structure of glucuronoxylan-xylanohydrolase (Xyn30A) from Clostridium thermocellum
4UQD	;	1.25	;	X-ray structure of glucuronoxylan-xylanohydrolase (Xyn30A) from Clostridium thermocellum at 1.25 A resolution
4UQE	;	1.28	;	X-ray structure of glucuronoxylan-xylanohydrolase (Xyn30A) from Clostridium thermocellum at 1.28 A resolution
4UQC	;	1.3	;	X-ray structure of glucuronoxylan-xylanohydrolase (Xyn30A) from Clostridium thermocellum at 1.30 A resolution
4UQB	;	1.68	;	X-ray structure of glucuronoxylan-xylanohydrolase (Xyn30A) from Clostridium thermocellum at 1.68 A resolution
4UQ9	;	1.77	;	X-ray structure of glucuronoxylan-xylanohydrolase (Xyn30A) from Clostridium thermocellum at 1.77 A resolution
1OKT	;	1.9	;	X-ray Structure of Glutathione S-Transferase from the Malarial Parasite Plasmodium falciparum
1FQ6	;	2.7	;	X-RAY STRUCTURE OF GLYCOL INHIBITOR PD-133,450 BOUND TO SACCHAROPEPSIN
1XM8	;	1.74	;	X-RAY STRUCTURE OF GLYOXALASE II FROM ARABIDOPSIS THALIANA GENE AT2G31350
1TIY	;	2.5	;	X-RAY STRUCTURE OF GUANINE DEAMINASE FROM BACILLUS SUBTILIS NORTHEAST STRUCTURAL GENOMICS CONSORTIUM TARGET SR160
3IPQ	;	2.0	;	X-ray structure of GW3965 synthetic agonist bound to the LXR-alpha
5GY7	;	1.43	;	X-Ray structure of H243I mutant of UDP-Galactose 4-epimerase from E.coli:evidence for existence of open and closed active site during catalysis.
7FCW	;	1.43	;	X-ray structure of H2O-solvent lysozyme
3F5T	;	2.7	;	X-ray Structure of H5N1 NS1
6O01	;	3.0	;	X-ray structure of H5N1-NS1 R38A K41A G71E mutant
4OPA	;	2.7	;	X-ray structure of H6N6-NS1 delta(80-84) mutant
6NRL	;	3.2	;	X-ray structure of H6N6-NS1 delta(80-84) R38A K41A E71G mutant
6OQE	;	3.899	;	X-ray structure of H6N6-NS1 delta(80-84) R38A K41A mutant
7N63	;	1.4	;	X-ray structure of HCAN_0200, an aminotransferase from Helicobacter canadensis in complex with its external aldimine
7NUS	;	1.45	;	X-RAY STRUCTURE OF HDM2/CMR19 AT 1.45A: Discovery, X-ray structure and CPP-conjugation enabled uptake of p53/MDM2 macrocyclic peptide inhibitors
4YVM	;	2.791	;	X-ray structure of Helicobacter pylori CagL-K74
7BDZ	;	1.94	;	X-ray structure of Hen Egg White Lysozyme with dirhodium tetraacetate (1)
7BE0	;	1.62	;	X-ray structure of Hen Egg White Lysozyme with dirhodium tetraacetate (2)
7BE1	;	1.4	;	X-ray structure of Hen Egg White Lysozyme with dirhodium tetraacetate (3)
7BE2	;	1.65	;	X-ray structure of Hen Egg White Lysozyme with dirhodium tetraacetate (6)
2ZYP	;	1.18	;	X-ray structure of hen egg-white lysozyme with poly(allyl amine)
1WTM	;	1.33	;	X-ray structure of HEW Lysozyme Orthorhombic Crystal formed in the Earth's magnetic field
8C39	;	1.2	;	X-ray structure of HEWL upon reaction with a Ruthenium(II)-arene Complexed with Glycosylated Carbene Ligands (5)
3GV2	;	7.0	;	X-ray Structure of Hexameric HIV-1 CA
3H47	;	1.9	;	X-ray Structure of Hexameric HIV-1 CA
3H4E	;	2.704	;	X-ray Structure of Hexameric HIV-1 CA
3MGE	;	1.9	;	X-ray Structure of Hexameric HIV-1 CA
7FBN	;	1.44	;	X-ray structure of high-strength hydrogel-grown FABP3 crystal soaked in 50% DMF solution containing dibutylhydroxytoluene (BHT)
7EUW	;	1.55	;	X-ray structure of high-strength hydrogel-grown FABP3 crystal soaked in 50% DMSO solution containing 4-[2-[1-(4-bromophenyl)-5-phenyl-1H-pyrazol-3-yl]phenoxy] (HA174)
7FBM	;	1.0	;	X-ray structure of high-strength hydrogel-grown FABP3 crystal soaked in 50% DMSO solution containing dibutylhydroxytoluene (BHT)
7EUV	;	1.28	;	X-ray structure of high-strength hydrogel-grown FABP3 crystal soaked in 50% DMSO solution containing Flurbiprofen
7FCG	;	1.19	;	X-ray structure of high-strength hydrogel-grown FABP3 crystal soaked in 50% DMSO solution containing Indometacin
3DCR	;	1.4	;	X-ray structure of HIV-1 protease and hydrated form of ketomethylene isostere inhibitor
3DOX	;	2.0	;	X-ray structure of HIV-1 protease in situ product complex
7WFC	;	2.6	;	X-ray structure of HKU1-PLP2(Cys109Ser) catalytic mutant in complex with free ubiquitin
6FOH	;	1.56	;	X-ray structure of homo sapiens Fumarylacetoacetate hydrolase domain containing protein 1 (FAHD1) at 1.56A resolution.
6FOG	;	1.94	;	X-ray structure of homo sapiens Fumarylacetoacetate hydrolase domain containing protein 1 (FAHD1) in complex with inhibitor oxalate at 1.94A resolution.
1SAW	;	2.2	;	X-ray structure of homo sapiens protein FLJ36880
5ERK	;	2.0	;	X-ray structure of horse spleen apoferritin (control)
5IFO	;	3.2	;	X-ray structure of HSA-Myr-KP1019
7Q1Y	;	4.4	;	X-ray structure of human A2ML1
3BTX	;	2.0	;	X-ray structure of human ABH2 bound to dsDNA through active site cross-linking
3BUC	;	2.59	;	X-ray structure of human ABH2 bound to dsDNA with Mn(II) and 2KG
8DT7	;	2.207	;	X-ray structure of human acetylcholinesterase in complex with oxime MMB4 (hAChE-MMB4)
8DT2	;	2.803	;	X-ray structure of human acetylcholinesterase inhibited by paraoxon (POX-hAChE)
8DT4	;	2.8	;	X-ray structure of human acetylcholinesterase ternary complex with paraoxon and oxime MMB4 (POX-hAChE-MMB4)
8DT5	;	2.6	;	X-ray structure of human acetylcholinesterase ternary complex with paraoxon and oxime RS170B (POX-hAChE-RS170B)
1Y7V	;	2.4	;	X-ray structure of human acid-beta-glucosidase covalently bound to conduritol B epoxide
2GLQ	;	1.6	;	X-ray structure of human alkaline phosphatase in complex with strontium
4NEF	;	2.75	;	X-ray structure of human Aquaporin 2
6QF5	;	3.7	;	X-Ray structure of human Aquaporin 2 crystallized on a silicon chip
3E6V	;	1.72	;	X-ray structure of human arginase I-D183N mutant: the complex with ABH
3E6K	;	2.1	;	X-ray structure of Human Arginase I: the mutant D183A in complex with ABH
4XII	;	2.7	;	X-ray structure of human butyrylcholinesterase in complex with N-((1-(2,3-dihydro-1H-inden-2-yl)piperidin-3-yl)methyl)-8-hydroxy-N-(2-methoxyethyl)-5-nitroquinoline-7-carboxamide
2XQJ	;	2.4	;	X-ray Structure of human butyrylcholinesterase inhibited by pure enantiomer VX-(R)
2XQK	;	2.4	;	X-ray Structure of human butyrylcholinesterase inhibited by pure enantiomer VX-(S)
2XQI	;	2.6	;	X-ray Structure of human butyrylcholinesterase inhibited by racemic CVX
2XQG	;	2.3	;	X-ray Structure of human butyrylcholinesterase inhibited by racemic VR
2XQF	;	2.1	;	X-ray Structure of human butyrylcholinesterase inhibited by racemic VX
2H61	;	1.9	;	X-ray structure of human Ca2+-loaded S100B
3DA2	;	2.05	;	X-ray structure of human carbonic anhydrase 13 in complex with inhibitor
6VUA	;	1.5	;	X-ray structure of human CD38 catalytic domain with 2'-Cl-araNAD+
2EUF	;	3.0	;	X-ray structure of human CDK6-Vcyclin in complex with the inhibitor PD0332991
2F2C	;	2.8	;	X-ray structure of human CDK6-Vcyclinwith the inhibitor aminopurvalanol
3N7O	;	1.8	;	X-ray structure of human chymase in complex with small molecule inhibitor.
1IW2	;	1.9	;	X-ray structure of Human Complement Protein C8gamma at pH=7.O
2OVA	;	1.5	;	X-ray structure of Human Complement Protein C8gamma Y83W Mutant
2OK3	;	2.0	;	X-ray structure of human cyclophilin J at 2.0 angstrom
3IPX	;	2.0	;	X-Ray structure of Human Deoxycytidine Kinase in complex with ADP and an inhibitor
3IPY	;	2.54	;	X-Ray structure of Human Deoxycytidine Kinase in complex with an inhibitor
6ZR7	;	1.85	;	X-ray structure of human Dscam Ig7-Ig9
4OMC	;	2.3	;	X-ray structure of human furin in complex with the competitive inhibitor meta-guanidinomethyl-Phac-RVR-Amba
4RYD	;	2.15	;	X-ray structure of human furin in complex with the competitive inhibitor para-guanidinomethyl-Phac-R-Tle-R-Amba
4OMD	;	2.7	;	X-ray structure of human furin in complex with the competitive inhibitor Phac-RVR-Amba
5M1R	;	1.64	;	X-ray structure of human G166D PGK-1 mutant
6L68	;	1.92	;	X-ray structure of human galectin-10 in complex with D-allose
6L6C	;	1.77	;	X-ray structure of human galectin-10 in complex with D-arabinose
6L67	;	1.97	;	X-ray structure of human galectin-10 in complex with D-galactose
6L64	;	2.08	;	X-ray structure of human galectin-10 in complex with D-glucose
6L6A	;	1.81	;	X-ray structure of human galectin-10 in complex with D-mannose
6L6D	;	1.93	;	X-ray structure of human galectin-10 in complex with D-N-acetylgalactosamine
6L6B	;	1.802	;	X-ray structure of human galectin-10 in complex with L-fucose
1QYM	;	2.8	;	X-ray structure of human gankyrin
1QKI	;	3.0	;	X-RAY STRUCTURE OF HUMAN GLUCOSE 6-PHOSPHATE DEHYDROGENASE (VARIANT CANTON R459L) COMPLEXED WITH STRUCTURAL NADP+
2BHL	;	2.9	;	X-RAY STRUCTURE OF HUMAN GLUCOSE-6-PHOSPHATE DEHYDROGENASE (DELETION VARIANT) COMPLEXED WITH GLUCOSE-6-PHOSPHATE
6FE5	;	1.52	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) - the E424M inactive mutant, in complex with a inhibitor JHU 2249
6EZ9	;	1.61	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) - the E424M inactive mutant, in complex with a inhibitor JHU3372
6SKH	;	1.58	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) - the E424M inactive mutant, in complex with a inhibitor sulfamide inhibitor GluAsp
6SGP	;	1.58	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) - the E424M inactive mutant, in complex with a sulfamide inhibitor GluGlu
4W9Y	;	1.64	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a glutamyl sulfamide inhibitor CJC47
5D29	;	1.8	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a hydroxamate inhibitor JHU241
5ELY	;	1.81	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a hydroxamate inhibitor JHU242
6F5L	;	1.63	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a inhibitor JHU2379
6ETY	;	1.68	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a inhibitor JHU3371
6RBC	;	1.77	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a inhibitor KB1157
6H7Y	;	1.81	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a inhibitor RNA 1-79-1
6HKJ	;	2.09	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a inhibitor RNA 2-19-1
6HKZ	;	2.09	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a inhibitor RNA 2-49-1
6H7Z	;	2.0	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a inhibitor RNA 2-65-1
4LQG	;	1.77	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a phosphoramidate inhibitor CTT1056
4P4B	;	1.93	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a phosphoramidate inhibitor CTT54
4P45	;	1.87	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a phosphoramidate inhibitor JRB-4-73
4P44	;	1.75	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a phosphoramidate inhibitor JRB-4-81
4P4D	;	1.65	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a phosphoramidate inhibitor MP1C
4P4E	;	1.67	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a phosphoramidate inhibitor MP1D
4P4F	;	1.86	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a phosphoramidate inhibitor NC-2-40
4P4I	;	1.87	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a phosphoramidate inhibitor T33
4P4J	;	1.66	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a phosphoramidate inhibitor T33D
3BHX	;	1.6	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a transition state analog of Asp-Glu
3BI0	;	1.67	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a transition state analog of Glu-Glu
3BI1	;	1.5	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a transition state analog of methotrexate-Glu
5O5T	;	1.43	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a urea based inhibitor PSMA 1007
5O5R	;	1.65	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a urea based inhibitor PSMA 1023
5O5U	;	1.53	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a urea based inhibitor PSMA 1027
8BOW	;	1.58	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with an inhibitor 617
8BO8	;	1.55	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with an inhibitor P17
8BOL	;	1.55	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with an inhibitor P18
6RTI	;	2.2	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with aptamer A9g
4JZ0	;	1.83	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with CTT1055
4JYW	;	1.73	;	X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with CTT1057
5OF0	;	1.48	;	X-ray structure of human glutamate carboxypeptidase II (GCPII), the E424M inactive mutant, in complex with a inhibitor CFBzOG
6S1X	;	1.76	;	X-ray structure of human glutamate carboxypeptidase II (GCPII)-E424M inactive mutant, in complex with a inhibitor KB1160
3SJE	;	1.7	;	X-ray structure of human glutamate carboxypeptidase II (the E424A inactive mutant) in complex with N-acetyl-aspartyl-aminononanoic acid
3SJX	;	1.66	;	X-ray structure of human glutamate carboxypeptidase II (the E424A inactive mutant) in complex with N-acetyl-aspartyl-methionine
3SJF	;	1.65	;	X-ray structure of human glutamate carboxypeptidase II in complex with a urea-based inhibitor (A25)
4OME	;	1.79	;	X-ray structure of human glutamate carboxypeptidase II in complex with DCCBL, a urea based inhibitor with distal carborane moiety
8A5N	;	1.52	;	X-ray structure of human H-chain ferritin treated with SDS
5N27	;	1.74	;	X-ray structure of human heavy chain ferritin (apo form)
5N26	;	2.05	;	X-ray structure of human heavy chain ferritin in complex with cisplatin
6FTV	;	1.58	;	X-ray structure of human heavy chain ferritin in complex with NAMI A
4DMB	;	1.9	;	X-ray structure of human hepatitus C virus NS5A-transactivated protein 2 at the resolution 1.9A, Northeast Structural Genomics Consortium (NESG) Target HR6723
6TAN	;	1.16	;	X-RAY STRUCTURE OF HUMAN K-RAS G12C IN COMPLEX WITH COVALENT ISOQUINOLINONE INHIBITOR (COMPOUND 17)
6TAM	;	1.64	;	X-RAY STRUCTURE OF HUMAN K-RAS G12C IN COMPLEX WITH COVALENT ISOQUINOLINONE INHIBITOR (COMPOUND 3)
6SBV	;	2.6	;	X-ray Structure of Human LDH-A with an Allosteric Inhibitor (Compound 7)
6SBU	;	2.91	;	X-ray Structure of Human LDHA with an Allosteric Inhibitor (Compound 3)
2A2C	;	1.65	;	x-ray structure of human N-acetyl galactosamine kinase complexed with Mg-ADP and N-acetyl galactosamine 1-phosphate
2A2D	;	2.2	;	X-ray structure of human n-acetyl galactosamine kinase complexed with Mn-AMPPNP and n-acetyl glactosamine
8AHY	;	1.7	;	X-ray structure of human NCS-1 bound to Ric-8A
8ALH	;	1.86	;	X-ray structure of human NCS-1 bound to Ric-8A
8ALM	;	1.85402	;	X-ray structure of human NCS-1 bound to Ric-8A
1UCN	;	2.0	;	X-ray structure of human nucleoside diphosphate kinase A complexed with ADP at 2 A resolution
1QNT	;	1.9	;	X-ray structure of human O6alkylguanine-DNA alkyltransferase
3MK4	;	2.42	;	X-Ray structure of human PEX3 in complex with a PEX19 derived peptide
2AMY	;	2.09	;	X-Ray Structure of Human Phosphomannomutase 2 (PMM2)
1TVG	;	1.6	;	X-ray structure of human PP25 gene product, HSPC034. Northeast Structural Genomics Target HR1958.
8HUQ	;	1.65	;	X-ray structure of human PPAR alpha ligand binding domain-elafibranor-SRC1 coactivator peptide co-crystals obtained by soaking
8HUK	;	2.981	;	X-ray structure of human PPAR alpha ligand binding domain-lanifibranor-SRC1 coactivator peptide co-crystals obtained by soaking
8HUN	;	2.01	;	X-ray structure of human PPAR alpha ligand binding domain-seladelpar co-crystals obtained by cross-seeding
7WGL	;	2.091	;	X-ray structure of human PPAR delta ligand binding domain-bezafibrate co-crystals obtained by co-crystallization
8HUL	;	2.461	;	X-ray structure of human PPAR delta ligand binding domain-lanifibranor co-crystals obtained by co-crystallization
7WGN	;	1.813	;	X-ray structure of human PPAR delta ligand binding domain-pemafibrate co-crystals obtained by co-crystallization
8HUO	;	2.671	;	X-ray structure of human PPAR delta ligand binding domain-seladelpar co-crystals obtained by co-crystallization
7WGO	;	2.36	;	X-ray structure of human PPAR gamma ligand binding domain-bezafibrate co-rystals obtained by co-crystallization
7WGP	;	2.53	;	X-ray structure of human PPAR gamma ligand binding domain-fenofibric acid co-crystals obtained by co-crystallization
8HUM	;	2.29	;	X-ray structure of human PPAR gamma ligand binding domain-lanifibranor-SRC1 coactivator peptide co-crystals obtained by co-crystallization
7WGQ	;	2.43	;	X-ray structure of human PPAR gamma ligand binding domain-pemafibrate co-crystals obtained by co-crystallization
8HUP	;	2.36	;	X-ray structure of human PPAR gamma ligand binding domain-seladelpar-SRC1 coactivator peptide co-crystals obtained by co-crystallization
6KB5	;	1.95	;	X-ray structure of human PPARalpha ligand binding domain-5,8,11,14-eicosatetraynoic Acid (ETYA) co-crystals obtained by delipidation and cross-seeding
6KB0	;	1.35	;	X-ray structure of human PPARalpha ligand binding domain-5,8,11,14-eicosatetraynoic acid (ETYA) co-crystals obtained by soaking
6LX9	;	1.4	;	X-ray structure of human PPARalpha ligand binding domain-arachidonic acid co-crystals obtained by delipidation and cross-seeding
7BPZ	;	2.43	;	X-ray structure of human PPARalpha ligand binding domain-bezafibrate-SRC1 coactivator peptide co-crystals obtained by soaking
6LX5	;	1.87	;	X-ray structure of human PPARalpha ligand binding domain-ciprofibrate co-crystals obtained by delipidation and co-crystallization
7BPY	;	2.09	;	X-ray structure of human PPARalpha ligand binding domain-clofibric acid-SRC1 coactivator peptide co-crystals obtained by delipidation and co-crystallization
6LXA	;	1.23	;	X-ray structure of human PPARalpha ligand binding domain-eicosapentaenoic acid (EPA) co-crystals obtained by delipidation and cross-seeding
7BQ4	;	1.62	;	X-ray structure of human PPARalpha ligand binding domain-eicosapentaenoic acid (EPA)-SRC1 coactivator peptide co-crystals obtained by delipidation and co-crystallization
6LX4	;	2.13	;	X-ray structure of human PPARalpha ligand binding domain-fenofibric acid co-crystals obtained by delipidation and co-crystallization
7BQ0	;	1.771	;	X-ray structure of human PPARalpha ligand binding domain-fenofibric acid-SRC1 coactivator peptide co-crystals obtained by delipidation and co-crystallization
6KB8	;	1.47	;	X-ray structure of human PPARalpha ligand binding domain-GW7647 co-crystals obtained by cross-seeding
6KB3	;	1.45	;	X-ray structure of human PPARalpha ligand binding domain-GW7647 co-crystals obtained by delipidation and cross-seeding
6KAY	;	1.735	;	X-ray structure of human PPARalpha ligand binding domain-GW7647 co-crystals obtained by soaking
7BQ3	;	1.98	;	X-ray structure of human PPARalpha ligand binding domain-GW7647-SRC1 coactivator peptide co-crystals obtained by delipidation and co-crystallization
6L37	;	2.91	;	X-ray structure of human PPARalpha ligand binding domain-GW9662-ciprofibrate co-crystals obtained by delipidation and co-crystallization
6KYP	;	2.86	;	X-ray structure of human PPARalpha ligand binding domain-GW9662-clofibric acid co-crystals obtained by delipidation and co-crystallization
6L36	;	3.301	;	X-ray structure of human PPARalpha ligand binding domain-GW9662-fenofibric acid co-crystals obtained by delipidation and co-crystallization
6L38	;	2.761	;	X-ray structure of human PPARalpha ligand binding domain-GW9662-gemfibrozil co-crystals obtained by delipidation and co-crystallization
6KAX	;	1.23	;	X-ray structure of human PPARalpha ligand binding domain-intrinsic fatty acid (E. coli origin) co-crystals obtained by cross-seeding
7BQ1	;	1.521	;	X-ray structure of human PPARalpha ligand binding domain-intrinsic fatty acid (E. coli origin)-SRC1 coactivator peptide co-crystals obtained by co-crystallization
6LX8	;	1.54	;	X-ray structure of human PPARalpha ligand binding domain-oleic acid co-crystals obtained by delipidation and cross-seeding
6LX6	;	1.3	;	X-ray structure of human PPARalpha ligand binding domain-palmitic acid co-crystals obtained by delipidation and cross-seeding
6KB9	;	1.55	;	X-ray structure of human PPARalpha ligand binding domain-pemafibrate co-crystals obtained by cross-seeding
6KB4	;	1.42	;	X-ray structure of human PPARalpha ligand binding domain-pemafibrate co-crystals obtained by delipidation and cross-seeding
6KAZ	;	1.48	;	X-ray structure of human PPARalpha ligand binding domain-pemafibrate co-crystals obtained by soaking
7BQ2	;	1.52	;	X-ray structure of human PPARalpha ligand binding domain-pemafibrate-SRC1 coactivator peptide co-crystals obtained by soaking
6LXC	;	2.03	;	X-ray structure of human PPARalpha ligand binding domain-saroglitazar co-crystals obtained by delipidation and cross-seeding
6LXB	;	2.36	;	X-ray structure of human PPARalpha ligand binding domain-saroglitazar co-crystals obtained by soaking
6LX7	;	1.41	;	X-ray structure of human PPARalpha ligand binding domain-stearic acid co-crystals obtained by delipidation and cross-seeding
6KB6	;	1.431	;	X-ray structure of human PPARalpha ligand binding domain-tetradecylthioacetic acid (TTA) co-crystals obtained by delipidation and cross-seeding
6KB1	;	1.25	;	X-ray structure of human PPARalpha ligand binding domain-tetradecylthioacetic acid (TTA) co-crystals obtained by soaking
6KBA	;	1.82	;	X-ray structure of human PPARalpha ligand binding domain-Wy14643 co-crystals obtained by co-crystallization
6KB7	;	2.14	;	X-ray structure of human PPARalpha ligand binding domain-Wy14643 co-crystals obtained by delipidation and cross-seeding
6KB2	;	1.95	;	X-ray structure of human PPARalpha ligand binding domain-Wy14643 co-crystals obtained by soaking
7E0A	;	1.771	;	X-ray structure of human PPARgamma ligand binding domain-saroglitazar co-crystals obtained by co-crystallization
1SU3	;	2.2	;	X-ray structure of human proMMP-1: New insights into collagenase action
3E16	;	1.6	;	X-ray structure of human prostasin in complex with Benzoxazole warhead peptidomimic, lysine in P3
7BFZ	;	1.73	;	X-ray structure of human prostate-specific membrane antigen(PSMA) in complex with a inhibitor Glu-490
5CYJ	;	1.79	;	X-ray structure of human RBPMS
5DET	;	1.95	;	X-ray structure of human RBPMS in complex with the RNA
5E7W	;	0.9519	;	X-ray Structure of Human Recombinant 2Zn insulin at 0.92 Angstrom
5HMS	;	2.8	;	X-ray structure of human recombinant 5-aminolaevulinic acid dehydratase (hrALAD).
6RLX	;	1.5	;	X-RAY STRUCTURE OF HUMAN RELAXIN AT 1.5 ANGSTROMS. COMPARISON TO INSULIN AND IMPLICATIONS FOR RECEPTOR BINDING DETERMINANTS
6VE5	;	2.0	;	X-ray structure of human REV7 in complex with Shieldin3 (residues 41-74)
1Z7X	;	1.95	;	X-ray structure of human ribonuclease inhibitor complexed with ribonuclease I
6QF4	;	2.495	;	X-Ray structure of human Serine/Threonine Kinase 17B (STK17B) aka DRAK2 in complex with ADP obtained by on-chip soaking
4S1Y	;	3.16	;	X-ray structure of human serum albumin complexed with cisplatin
1AGN	;	3.0	;	X-RAY STRUCTURE OF HUMAN SIGMA ALCOHOL DEHYDROGENASE
6I5G	;	2.0	;	X-ray structure of human soluble Epoxide Hydrolase C-terminal Domain (hsEH CTD)in complex with 15d-PGJ2
4AYZ	;	3.5	;	X-ray Structure of human SOUL
1B8Y	;	2.0	;	X-RAY STRUCTURE OF HUMAN STROMELYSIN CATALYTIC DOMAIN COMPLEXED WITH NON-PEPTIDE INHIBITORS: IMPLICATIONS FOR INHIBITOR SELECTIVITY
1CAQ	;	1.8	;	X-RAY STRUCTURE OF HUMAN STROMELYSIN CATALYTIC DOMAIN COMPLEXES WITH NON-PEPTIDE INHIBITORS: IMPLICATION FOR INHIBITOR SELECTIVITY
1CIZ	;	1.64	;	X-RAY STRUCTURE OF HUMAN STROMELYSIN CATALYTIC DOMAIN COMPLEXES WITH NON-PEPTIDE INHIBITORS: IMPLICATION FOR INHIBITOR SELECTIVITY
2J3N	;	2.8	;	X-ray structure of human thioredoxin reductase 1
3BS9	;	1.95	;	X-ray structure of human TIA-1 RRM2
2BJN	;	1.7	;	X-ray Structure of human TPC6
4PVL	;	1.851	;	X-ray structure of human transthyretin (TTR) at room temperature to 1.9A resolution
3EEC	;	3.0	;	X-ray structure of human ubiquitin Cd(II) adduct
3EHV	;	1.81	;	X-ray structure of human ubiquitin Zn(II) adduct
3EFU	;	1.84	;	X-ray structure of human ubiquitin-Hg(II) adduct
1FGJ	;	2.8	;	X-RAY STRUCTURE OF HYDROXYLAMINE OXIDOREDUCTASE
2ECE	;	2.0	;	X-ray structure of hypothetical selenium-binding protein from Sulfolobus tokodaii, ST0059
1XMB	;	2.0	;	X-ray structure of IAA-aminoacid hydrolase from Arabidopsis thaliana gene AT5G56660
3AKM	;	1.9	;	X-ray structure of iFABP from human and rat with bound fluorescent fatty acid analogue
3AKN	;	1.6	;	X-ray structure of iFABP from human and rat with bound fluorescent fatty acid analogue
3FAT	;	1.9	;	X-ray structure of iGluR4 flip ligand-binding core (S1S2) in complex with (S)-AMPA at 1.90A resolution
3FAS	;	1.4	;	X-ray structure of iGluR4 flip ligand-binding core (S1S2) in complex with (S)-glutamate at 1.40A resolution
3GBA	;	1.35	;	X-ray structure of iGluR5 ligand-binding core (S1S2) in complex with dysiherbaine at 1.35A resolution
3GBB	;	2.1	;	X-ray structure of iGluR5 ligand-binding core (S1S2) in complex with MSVIII-19 at 2.10A resolution
2F1D	;	3.0	;	X-Ray Structure of imidazoleglycerol-phosphate dehydratase
2GX9	;	2.1	;	X-ray structure of influenza virus NS1 effector domain
1FQ7	;	2.8	;	X-RAY STRUCTURE OF INHIBITOR CP-72,647 BOUND TO SACCHAROPEPSIN
7RKD	;	1.25	;	X-Ray structure of Insulin Analog GLULISINE
5VIZ	;	1.7	;	X-Ray structure of Insulin Glargine
7OGS	;	2.37	;	X-ray Structure of Interferon Regulatory Factor 4 DNA binding domain bound to an interferon-stimulated response element
7OOT	;	2.25	;	X-ray Structure of Interferon Regulatory Factor 4 DNA binding domain bound to an interferon-stimulated response element
7O56	;	2.6	;	X-ray Structure of Interferon Regulatory Factor 4 DNA binding domain bound to an interferon-stimulated response element solved by Phosphorus and Sulphur SAD methods
5BVI	;	2.6	;	X-ray Structure of Interferon Regulatory Factor 4 IAD Domain
1ILT	;	2.0	;	X-RAY STRUCTURE OF INTERLEUKIN-1 RECEPTOR ANTAGONIST AT 2.0 ANGSTROMS RESOLUTION
4FFK	;	1.76	;	X-ray structure of iron superoxide dismutase from Acidilobus saccharovorans
3ODV	;	0.95	;	X-ray structure of kaliotoxin by racemic protein crystallography
5K8B	;	2.15	;	X-ray structure of KdnA, 8-amino-3,8-dideoxy-alpha-D-manno-octulosonate transaminase, from Shewanella oneidensis in the presence of the external aldimine with PLP and glutamate
5K8C	;	1.85	;	X-ray structure of KdnB, 3-deoxy-alpha-D-manno-octulosonate 8-oxidase, from Shewanella oneidensis
3NC9	;	2.4	;	X-ray structure of ketohexokinase complexed with an indazole compound
3NBW	;	2.341	;	X-ray structure of ketohexokinase in complex with a pyrazole compound
3Q92	;	2.8	;	X-ray Structure of ketohexokinase in complex with a pyrimidopyrimidine analog 1
3QA2	;	2.519	;	X-ray Structure of ketohexokinase in complex with a pyrimidopyrimidine analog 2
3QAI	;	2.7	;	X-ray Structure of ketohexokinase in complex with a pyrimidopyrimidine analog 3
3NCA	;	2.602	;	X-ray structure of ketohexokinase in complex with a thieno pyridinol compound
3NBV	;	2.3	;	X-ray Structure of Ketohexokinase in complex with AMP-PNP and fructose
3RO4	;	2.6	;	X-ray Structure of Ketohexokinase in complex with an indazole compound derivative
3NC2	;	2.5	;	X-ray structure of ketohexokinase with a quinazoline
6GQE	;	2.15	;	X-ray structure of KH1-2 domain of IMP3
1LW5	;	2.05	;	X-ray structure of L-Threonine Aldolase (low-specificity) in complex with glycine
1LW4	;	1.9	;	X-ray structure of L-Threonine Aldolase (low-specificity) in complex with L-allo-threonine
6H07	;	1.482	;	X-ray structure of Lactobacillus brevis alcohol dehydrogenase
6HLF	;	1.55	;	X-ray structure of Lactobacillus brevis alcohol dehydrogenase mutant - K32A
6Y1C	;	1.41	;	X-ray structure of Lactobacillus brevis alcohol dehydrogenase mutant D54F
6Y1B	;	1.4	;	X-ray structure of Lactobacillus brevis alcohol dehydrogenase mutant K32A_Q126K
6Y10	;	1.22	;	X-ray structure of Lactobacillus brevis alcohol dehydrogenase mutant Q126H
6Y0Z	;	1.21	;	X-ray structure of Lactobacillus brevis alcohol dehydrogenase mutant Q126K
7A2B	;	1.399	;	X-ray structure of Lactobacillus brevis alcohol dehydrogenase mutant Q207D
6Y0S	;	1.44	;	X-ray structure of Lactobacillus brevis alcohol dehydrogenase mutant T102E
6Y15	;	1.8	;	X-ray structure of Lactobacillus brevis alcohol dehydrogenase mutant T102E_Q126K
7P36	;	1.14	;	X-ray structure of Lactobacillus kefir alcohol dehydrogenase (wild type)
7P7Y	;	1.25	;	X-ray structure of Lactobacillus kefir alcohol dehydrogenase mutant Q126K
1IF2	;	2.0	;	X-RAY STRUCTURE OF LEISHMANIA MEXICANA TRIOSEPHOSPHATE ISOMERASE COMPLEXED WITH IPP
2B6P	;	2.4	;	X-ray structure of lens Aquaporin-0 (AQP0) (lens MIP) in an open pore state
6NLE	;	2.615	;	X-ray structure of LeuT with V269 deletion
7KC3	;	1.8	;	X-ray structure of Lfa-1 I domain collected at 273 K
7KC5	;	1.86	;	X-ray structure of Lfa-1 I domain in complex with BMS-68852 collected at 273 K
7KC6	;	1.85	;	X-ray structure of Lfa-1 I domain in complex with Lovastatin collected at 273 K
1XUO	;	1.8	;	X-ray structure of LFA-1 I-domain bound to a 1,4-diazepane-2,5-dione inhibitor at 1.8A resolution
4IXD	;	1.8	;	X-ray structure of lfa-1 i-domain in complex with ibe-667 at 1.8a resolution
1XDD	;	2.2	;	X-ray structure of LFA-1 I-domain in complex with LFA703 at 2.2A resolution
1XDG	;	2.1	;	X-ray structure of LFA-1 I-domain in complex with LFA878 at 2.1A resolution
3OWQ	;	2.606	;	X-Ray Structure of Lin1025 protein from Listeria innocua, Northeast Structural Genomics Consortium Target LkR164
6A12	;	2.145	;	X-ray structure of lipase from Geobacillus thermoleovorans
5ACF	;	1.8	;	X-ray Structure of LPMO
5ACG	;	1.91	;	X-ray Structure of LPMO
5ACH	;	1.28	;	X-ray Structure of LPMO
5ACI	;	1.75	;	X-ray Structure of LPMO
5ACJ	;	1.7	;	X-ray Structure of LPMO
6YDC	;	2.0	;	X-ray structure of LPMO
6YDE	;	2.2	;	X-ray structure of LPMO
6YDG	;	1.9	;	X-ray structure of LPMO
7PXK	;	1.4	;	X-ray structure of LPMO at 1.39x10^5 Gy
7PXM	;	1.3	;	X-ray structure of LPMO at 1.45x10^6 Gy
7PXL	;	1.35	;	X-ray structure of LPMO at 3.6x10^5 Gy
7PXJ	;	1.75	;	X-ray structure of LPMO at 5.99x10^4 Gy
7PXN	;	1.65	;	X-ray structure of LPMO at 6.65x10^6 Gy
7PXI	;	1.63	;	X-ray structure of LPMO at 7.88x10^3 Gy
6YDD	;	2.8	;	X-ray structure of LPMO.
6YDF	;	2.12	;	X-ray structure of LPMO.
4XJF	;	1.8	;	X-ray structure of Lysozyme B1
4XJG	;	1.8	;	X-ray structure of Lysozyme B2
8OM8	;	1.08	;	X-ray structure of lysozyme obtained upon reaction with [VIVO(empp)2] (Structure A)
8OMS	;	1.1	;	X-ray structure of lysozyme obtained upon reaction with [VIVO(empp)2] (Structure B)
8OMT	;	1.097	;	X-ray structure of lysozyme obtained upon reaction with [VIVO(empp)2] (Structure C)
8AJ4	;	1.22	;	X-ray structure of lysozyme obtained upon reaction with [VIVO(malt)2] (Structure A')
8AJ3	;	1.13	;	X-ray structure of lysozyme obtained upon reaction with [VIVO(malt)2] (Structure A)
8AJ5	;	1.31	;	X-ray structure of lysozyme obtained upon reaction with [VIVO(malt)2] (Structure B)
4XJB	;	1.8	;	X-ray structure of Lysozyme1
4XJD	;	1.801	;	X-ray structure of Lysozyme2
4XJH	;	2.0	;	X-ray structure of LysozymeS1
4XJI	;	2.0	;	X-ray structure of LysozymeS2
6G0Y	;	2.42	;	X-ray structure of M-21 protein complex
1YV4	;	1.51	;	X-ray structure of M23L onconase at 100K
1YV6	;	1.78	;	X-ray structure of M23L onconase at 298K
5L1T	;	2.082	;	X-ray Structure of M77S mutant of Cytochrome P450 PntM with pentalenolactone F
5L1U	;	2.074	;	X-ray Structure of M81A mutant of Cytochrome P450 PntM with pentalenolactone F
5L1V	;	2.12	;	X-ray Structure of M81C mutant of Cytochrome P450 PntM with pentalenolactone F
5COR	;	2.548	;	X-RAY STRUCTURE OF MACROPHAGE INFLAMMATORY PROTEIN-1 ALPHA (CCL3) N-TERMINAL-SWITCH POLYMER
5D65	;	3.1	;	X-RAY STRUCTURE OF MACROPHAGE INFLAMMATORY PROTEIN-1 ALPHA (CCL3) WITH HEPARIN COMPLEX
2X6G	;	2.18	;	X-ray Structure of Macrophage Inflammatory Protein-1 alpha (D27A)
2X69	;	2.65	;	X-ray Structure of Macrophage Inflammatory Protein-1 alpha polymer
2X6L	;	2.602	;	X-ray Structure of Macrophage Inflammatory Protein-1 beta
6IXY	;	2.72	;	X-ray structure of major pilin from C. perfringens SM101
1D2F	;	2.5	;	X-RAY STRUCTURE OF MALY FROM ESCHERICHIA COLI: A PYRIDOXAL-5'-PHOSPHATE-DEPENDENT ENZYME ACTING AS A MODULATOR IN MAL GENE EXPRESSION
6TD9	;	1.96	;	X-ray structure of mature PA1624 from Pseudomonas aeruginosa PAO1
2YFA	;	1.8	;	X-ray structure of McpS ligand binding domain in complex with malate
2YFB	;	1.9	;	X-ray structure of McpS ligand binding domain in complex with succinate
7AD0	;	2.07	;	X-ray structure of Mdm2 with modified p53 peptide
2ZAH	;	2.81	;	X-ray structure of Melon necrotic spot virus
8BK2	;	2.41	;	X-ray structure of meningococcal factor H binding protein variant 2 in complex with a specific and bactericidal human monoclonal antibody 1B1
6BI8	;	2.291	;	X-ray structure of MERS coronavirus papain-like protease in complex with human ISG15
4RSP	;	1.62	;	X-ray structure of MERS-CoV nsp5 protease bound with a designed inhibitor
4YLU	;	2.1	;	X-ray structure of MERS-CoV nsp5 protease bound with a non-covalent inhibitor
1IK4	;	2.0	;	X-ray Structure of Methylglyoxal Synthase from E. coli Complexed with Phosphoglycolohydroxamic Acid
4U8D	;	2.3	;	X-ray structure of Mg-bound human sorcin
5WFI	;	1.851	;	X-ray structure of MHV PLP2 (Cys1716Ser) catalytic mutant in complex with free ubiquitin
3L9H	;	2.0	;	X-ray structure of mitotic kinesin-5 (KSP, KIF11, Eg5)in complex with the hexahydro-2H-pyrano[3,2-c]quinoline EMD 534085
7JU8	;	2.0	;	X-ray structure of MMP-13 in Complex with 4-(1,2,3-thiadiazol-4-yl)pyridine
8Q0R	;	1.55	;	X-ray structure of MNEI mutant Mut9 (E23A, C41A, Y65R, S76Y)
1Q6W	;	2.81	;	X-Ray structure of Monoamine oxidase regulatory protein from Archaeoglobus fulgius
135L	;	1.3	;	X-RAY STRUCTURE OF MONOCLINIC TURKEY EGG LYSOZYME AT 1.3 ANGSTROMS RESOLUTION
6MGH	;	1.95	;	X-ray structure of monomeric near-infrared fluorescent protein miRFP670nano
3HJD	;	1.65	;	X-ray structure of monomeric variant of HNP1
4X51	;	2.05	;	X-ray structure of mouse interleukin-10 mutant - S1_E8del, C149Y
2G0A	;	2.35	;	X-ray structure of mouse pyrimidine 5'-nucleotidase type 1 with lead(II) bound in active site
2G07	;	2.3	;	X-ray structure of mouse pyrimidine 5'-nucleotidase type 1, phospho-enzyme intermediate analog with Beryllium fluoride
2G09	;	2.1	;	X-ray structure of mouse pyrimidine 5'-nucleotidase type 1, product complex
2G08	;	2.35	;	X-ray structure of mouse pyrimidine 5'-nucleotidase type 1, product-transition complex analog with Aluminum fluoride
2G06	;	2.25	;	X-ray structure of mouse pyrimidine 5'-nucleotidase type 1, with bound magnesium(II)
3TSR	;	2.1999	;	X-ray structure of mouse ribonuclease inhibitor complexed with mouse ribonuclease 1
6TN9	;	2.6	;	X-RAY STRUCTURE OF MPS1 IN COMPLEX WITH COMPOUND 16
6TNB	;	2.65	;	X-RAY STRUCTURE OF MPS1 IN COMPLEX WITH COMPOUND 41
6TNC	;	2.3	;	X-RAY STRUCTURE OF MPS1 IN COMPLEX WITH COMPOUND 46
6TND	;	2.58	;	X-RAY STRUCTURE OF MPS1 IN COMPLEX WITH COMPOUND 79
1LXN	;	2.3	;	X-RAY STRUCTURE OF MTH1187 NORTHEAST STRUCTURAL GENOMICS CONSORTIUM TARGET TT272
6SBI	;	2.7	;	X-ray structure of murine Fumarylacetoacetate hydrolase domain containing protein 1 (FAHD1) in complex with inhibitor oxalate
6SBJ	;	2.22	;	X-ray structure of mus musculus Fumarylacetoacetate hydrolase domain containing protein 1 (FAHD1) apo-form uuncomplexed
1FF4	;	1.5	;	X-RAY STRUCTURE OF MUSCARINIC TOXIN 2 AT 1.5 ANGSTROM RESOLUTION
2JCY	;	2.35	;	X-ray structure of mutant 1-deoxy-D-xylulose 5-phosphate reductoisomerase, DXR, Rv2870c, from Mycobacterium tuberculosis
2JCX	;	2.1	;	X-ray structure of mutant 1-deoxy-D-xylulose 5-phosphate reductoisomerase, DXR, Rv2870c, from Mycobacterium tuberculosis, in complex with fosmidomycin and NADPH
2JD0	;	2.3	;	X-ray structure of mutant 1-deoxy-D-xylulose 5-phosphate reductoisomerase, DXR, Rv2870c, from Mycobacterium tuberculosis, in complex with NADPH
2ZKN	;	1.86	;	X-ray structure of mutant galectin-1/lactose complex
4DJ4	;	2.35	;	X-ray structure of mutant N211D of bifunctional nuclease TBN1 from Solanum lycopersicum (Tomato)
6ZT6	;	2.3	;	X-ray structure of mutated arabinofuranosidase
6ZT7	;	1.85	;	X-ray structure of mutated arabinofuranosidase
6ZT8	;	2.8	;	X-ray structure of mutated arabinofuranosidase
6ZT9	;	2.0	;	X-ray structure of mutated arabinofuranosidase
6ZTA	;	3.1	;	X-ray structure of mutated arabinofuranosidase
2XC3	;	1.5	;	X-ray structure of Mycobacterium tuberculosis cyp125 bound to the reverse type I inhibitor
2WM4	;	2.11	;	X-ray structure of Mycobacterium tuberculosis cytochrome P450 CYP124 in complex with phytanic acid
2X5W	;	1.58	;	X-ray structure of Mycobacterium tuberculosis cytochrome P450 CYP125 in complex with substrate cholest-4-en-3-one
2YIZ	;	1.7	;	X-ray structure of Mycobacterium tuberculosis Dodecin
2UZZ	;	3.2	;	X-ray structure of N-methyl-L-tryptophan oxidase (MTOX)
8ACW	;	3.4	;	X-ray structure of Na+-NQR from Vibrio cholerae at 3.4 A resolution
8ACY	;	3.5	;	X-ray structure of Na+-NQR from Vibrio cholerae at 3.5 A resolution
8AD0	;	3.11	;	X-ray structure of Na+-NQR from Vibrio cholerae in different conformation at 3.1 A
1ZZE	;	1.8	;	X-ray Structure of NADPH-dependent Carbonyl Reductase from Sporobolomyces salmonicolor
5YBC	;	2.5	;	X-ray structure of native ETS-domain domain of Ergp55
1M22	;	1.4	;	X-ray structure of native peptide amidase from Stenotrophomonas maltophilia at 1.4 A
2E3W	;	1.05	;	X-ray structure of native RNase A
4J8X	;	2.87	;	X-ray structure of NCP145 with bound chlorido(eta-6-p-cymene)(N-fluorophenyl-2-pyridinecarbothioamide)ruthenium(II)
4J8V	;	2.58	;	X-ray structure of NCP145 with bound chlorido(eta-6-p-cymene)(N-phenyl-2-pyridinecarbothioamide)ruthenium(II)
4J8W	;	2.41	;	X-ray structure of NCP145 with chlorido(eta-6-p-cymene)(N-fluorophenyl-2-pyridinecarbothioamide)osmium(II)
4J8U	;	2.38	;	X-ray structure of NCP145 with chlorido(eta-6-p-cymene)(N-phenyl-2-pyridinecarbothioamide)osmium(II)
6A7K	;	1.9	;	X-ray structure of NdhS from T. elongatus
6CBL	;	1.6	;	x-ray structure of NeoB from Streptomyces fradiae in complex with neamine as an external aldimine
6CBN	;	1.35	;	x-ray structure of NeoB from streptomyces fradiae in complex with PLP and neomycin (as the external aldimine) at pH 7.5
6CBM	;	1.65	;	x-ray structure of NeoB from streptomyces fradiae in complex with PLP and neomycin (as the external aldimine) at pH 9
6CBK	;	1.75	;	X-ray structure of NeoB from Streptomyces fradiae in complex with PMP
5IJR	;	1.52	;	X-ray structure of neuropilin-1 b1 domain complexed with Arg-1 ligand.
5IYY	;	1.6	;	X-ray structure of neuropilin-1 b1 domain complexed with Arg-4 ligand.
5J1X	;	2.1	;	X-ray structure of neuropilin-1 b1 domain complexed with Arg-5 ligand.
5JHK	;	1.8	;	X-ray structure of neuropilin-1 b1 domain complexed with Arg-6 ligand.
5JGQ	;	1.6	;	X-ray structure of neuropilin-1 b1 domain complexed with Arg-7 ligand.
5JGI	;	1.38	;	X-ray structure of neuropilin-1 b1 domain complexed with M45 compound
7T5C	;	1.5	;	X-ray structure of Neurospora crassa Polysaccharide Monooxygenase 9D (NcLPMO9D) at low pH
2UU8	;	0.94	;	X-ray structure of Ni, Ca concanavalin A at Ultra-high resolution (0. 94A)
4AAZ	;	1.4	;	X-ray structure of Nicotiana alata Defensin 1 NaD1
4IXO	;	2.2	;	X-ray structure of NifS-like protein from Rickettsia africae ESF-5
7A0C	;	1.9	;	X-ray structure of NikA from Escherichia coli in complex with Fe-6-Me2-BPMCN
5L8D	;	1.8	;	X-ray structure of NikA from Escherichia coli in complex with Ru(bis(pyrzol-1-yl)acetate scorpionate)(CO)2Cl
4DCX	;	2.0	;	X-ray structure of NikA in complex with Fe(1R,2R)-N,N'-Bis(2-pyridylmethyl)-N,N'-dicarboxymethyl-1,2-cyclohexanediamine
4DCY	;	2.0	;	X-ray structure of NikA in complex with Fe(1S,2S)-N,N-kappa-Bis(2-pyridylmethyl)-N-carboxymethyl-N-kappa-methyl-1,2-cyclohexanediamine
4I9D	;	1.7	;	X-ray structure of NikA in complex with Fe-N,N'-Bis(2-pyridylmethyl)-N-carboxymethyl-N'-methyl
3MZ9	;	1.8	;	X-ray structure of NikA in complex with HBED
4I8C	;	2.503	;	X-ray structure of NikA in complex with Ni-(L-His)2
3MZB	;	1.7	;	X-ray structure of NikA in complex with the doubly hydroxylated iron complex, 1-O2
1JFB	;	1.0	;	X-ray structure of nitric oxide reductase (cytochrome P450nor) in the ferric resting state at atomic resolution
1JFC	;	1.05	;	X-ray structure of nitric oxide reductase (cytochrome P450nor) in the ferrous CO state at atomic resolution
1NUE	;	2.0	;	X-RAY STRUCTURE OF NM23 HUMAN NUCLEOSIDE DIPHOSPHATE KINASE B COMPLEXED WITH GDP AT 2 ANGSTROMS RESOLUTION
2VQ5	;	2.09	;	X-ray structure of Norcoclaurine synthase from Thalictrum flavum in complex with dopamine and hydroxybenzaldehyde
1XSR	;	2.8	;	X-Ray structure of Northeast Structural Genomics Consortium target SfR7
1TZA	;	2.4	;	X-ray structure of Northeast Structural Genomics Consortium target SoR45
1TO0	;	2.5	;	X-ray structure of Northeast Structural Genomics target protein sr145 from Bacillus subtilis
1TTZ	;	2.11	;	X-ray structure of Northeast Structural Genomics target protein XcR50 from X. campestris
1YDM	;	2.5	;	X-Ray structure of Northeast Structural Genomics target SR44
2AJL	;	2.5	;	X-ray Structure of Novel Biaryl-Based Dipeptidyl peptidase IV inhibitor
8AD4	;	1.5	;	X-ray structure of NqrF(129-408)of Vibrio cholerae in complex with NADH
8AD3	;	1.55	;	X-ray structure of NqrF(129-408)of Vibrio cholerae variant F406A
8AD5	;	1.65	;	X-ray structure of NqrF(129-408)of Vibrio cholerae variant F406A
3KWG	;	2.21	;	X-ray structure of NS1 effector domain W187A mutant
3KWI	;	2.21	;	X-ray structure of NS1 effector domain W187Y mutant
6G3T	;	2.53	;	X-ray structure of NSD3-PWWP1
6G2E	;	1.85	;	X-ray structure of NSD3-PWWP1 in complex with compound 13
6G2F	;	1.74	;	X-ray structure of NSD3-PWWP1 in complex with compound 16
6G24	;	2.1	;	X-ray structure of NSD3-PWWP1 in complex with compound 3
6G25	;	1.432	;	X-ray structure of NSD3-PWWP1 in complex with compound 4
6G27	;	1.65	;	X-ray structure of NSD3-PWWP1 in complex with compound 5
6G29	;	1.7	;	X-ray structure of NSD3-PWWP1 in complex with compound 6
6G2B	;	1.61	;	X-ray structure of NSD3-PWWP1 in complex with compound 8
6G2C	;	1.76	;	X-ray structure of NSD3-PWWP1 in complex with compound 9
6G2O	;	1.81	;	X-ray structure of NSD3-PWWP1 in complex with compound BI-9321
5VB3	;	1.95	;	X-ray structure of nuclear receptor ROR-gammat Ligand Binding Domain + SRC2 peptide
1NDK	;	2.2	;	X-RAY STRUCTURE OF NUCLEOSIDE DIPHOSPHATE KINASE
1NDC	;	2.0	;	X-RAY STRUCTURE OF NUCLEOSIDE DIPHOSPHATE KINASE COMPLEXED WITH DTDP AND MG2+ AT 2 A RESOLUTION
1KCX	;	2.12	;	X-ray structure of NYSGRC target T-45
1SJA	;	2.3	;	X-ray structure of o-Succinylbenzoate Synthase complexed with N-acetylmethionine
1SJC	;	2.1	;	x-ray structure of o-succinylbenzoate synthase complexed with N-succinyl methionine
1SJD	;	1.87	;	x-ray structure of o-succinylbenzoate synthase complexed with n-succinyl phenylglycine
1SJB	;	2.2	;	X-ray structure of o-succinylbenzoate synthase complexed with o-succinylbenzoic acid
4OC0	;	1.85	;	X-ray structure of of human glutamate carboxypeptidase II (GCPII) in a complex with CCIBzL, a urea-based inhibitor N~2~-[(1-carboxycyclopropyl)carbamoyl]-N~6~-(4-iodobenzoyl)-L-lysine
4OC2	;	1.65	;	X-ray structure of of human glutamate carboxypeptidase II (GCPII) in a complex with CEIBzL, a urea-based inhibitor N~2~-{[(1S)-1-carboxybut-3-yn-1-yl]carbamoyl}-N~6~-(4-iodobenzoyl)-L-lysine
4OC3	;	1.79	;	X-ray structure of of human glutamate carboxypeptidase II (GCPII) in a complex with CFIBzL, a urea-based inhibitor N~2~-{[(1S)-1-carboxy-2-(furan-2-yl)ethyl]carbamoyl}-N~6~-(4-iodobenzoyl)-L-lysine
4OC5	;	1.7	;	X-ray structure of of human glutamate carboxypeptidase II (GCPII) in a complex with CHIBzL, a urea-based inhibitor N~2~-{[(S)-carboxy(4-hydroxyphenyl)methyl]carbamoyl}-N~6~-(4-iodobenzoyl)-L-lysine
4OC1	;	1.75	;	X-ray structure of of human glutamate carboxypeptidase II (GCPII) in a complex with COIBzL, a urea-based inhibitor (2S)-2-[({(1S)-1-carboxy-2-[(2S)-oxiran-2-yl]ethyl}carbamoyl)amino]-6-[(4-iodobenzoyl)amino]hexanoic acid
4OC4	;	1.66	;	X-ray structure of of human glutamate carboxypeptidase II (GCPII) in a complex with CPIBzL, a urea-based inhibitor N~2~-{[(1S)-1-carboxy-2-(pyridin-4-yl)ethyl]carbamoyl}-N~6~-(4-iodobenzoyl)-L-lysine
3NGG	;	1.33	;	X-ray Structure of Omwaprin
3GRF	;	2.0	;	X-ray Structure of Ornithine Transcarbamoylase from Giardia lamblia
2JI9	;	2.2	;	X-ray structure of Oxalyl-CoA decarboxylase in complex with 3-deaza- ThDP
2JI6	;	2.06	;	X-ray structure of Oxalyl-CoA decarboxylase in complex with 3-deaza- ThDP and oxalyl-CoA
2JIB	;	2.2	;	X-ray structure of Oxalyl-CoA decarboxylase in complex with coenzyme- A
2JI8	;	2.15	;	X-ray structure of Oxalyl-CoA decarboxylase in complex with Formyl- CoA
2JI7	;	1.82	;	X-ray structure of Oxalyl-CoA decarboxylase with covalent reaction intermediate
1JFV	;	2.0	;	X-Ray Structure of oxidised C10S, C15A arsenate reductase from pI258
3K20	;	2.5	;	X-ray structure of oxidoreductase from corynebacterium diphtheriae,hexagonal crystal form. northeast structural genomics consortium target cdr100d
3K1Y	;	2.5	;	X-ray structure of oxidoreductase from corynebacterium diphtheriae. orthorombic crystal form, northeast structural genomics consortium target cdr100d
3KKJ	;	2.5	;	X-ray structure of P. syringae q888a4 Oxidoreductase at resolution 2.5A, Northeast Structural Genomics Consortium target PsR10
3ZSH	;	2.05	;	X-ray structure of p38alpha bound to SCIO-469
3ZSG	;	1.89	;	X-ray structure of p38alpha bound to TAK-715
3ZSI	;	2.4	;	X-ray structure of p38alpha bound to VX-745
4ETR	;	2.25	;	X-ray structure of PA2169 from Pseudomonas aeruginosa
5H20	;	2.5	;	X-ray structure of PadR-like Transcription factor from bacteroid fragilis
6BWL	;	1.45	;	X-ray structure of Pal from Bacillus thuringiensis
3X2L	;	0.83	;	X-ray structure of PcCel45A apo form at 95K.
3X2J	;	1.301	;	X-ray structure of PcCel45A D114N apo form at 95K.
3X2K	;	1.182	;	X-ray structure of PcCel45A D114N with cellopentaose at 95K.
5KJO	;	1.47	;	X-ray structure of PcCel45A expressed in Aspergillus nidullans
5KJQ	;	1.704	;	X-ray structure of PcCel45A in complex with cellobiose expressed in Aspergillus nidullans
3X2G	;	1.0	;	X-ray structure of PcCel45A N92D apo form at 100K
3X2I	;	1.6	;	X-ray structure of PcCel45A N92D apo form at 298K.
3X2H	;	0.99	;	X-ray structure of PcCel45A N92D with cellopentaose at 95K.
3X2M	;	0.64	;	X-ray structure of PcCel45A with cellopentaose at 0.64 angstrom resolution.
3IBJ	;	3.02	;	X-ray structure of PDE2A
8BPY	;	3.3	;	X-RAY STRUCTURE OF PDE9A IN COMPLEX WITH Inhibitor 13A
1X8M	;	2.6	;	X-ray structure of pectin degrading enzyme 5-keto 4-deoxyuronate isomerase from Escherichia coli
6NOZ	;	1.95	;	X-ray structure of PEDV papain-like protease 2
7MC9	;	3.099	;	X-RAY STRUCTURE OF PEDV PAPAIN-LIKE PROTEASE 2 bound to UB-PA
6BWC	;	2.7	;	X-ray structure of Pen from Bacillus thuringiensis
3P05	;	2.5	;	X-ray structure of pentameric HIV-1 CA
3P0A	;	5.954	;	X-ray structure of pentameric HIV-1 CA
1ZY1	;	3.0	;	X-ray structure of peptide deformylase from Arabidopsis thaliana (AtPDF1A) in complex with Met-Ala-Ser
1ZXZ	;	2.8	;	X-ray structure of peptide deformylase from Arabidopsis thaliana (AtPDF1A); crystals grown in PEG-5000 MME as precipitant
1ZY0	;	2.9	;	X-ray structure of peptide deformylase from Arabidopsis thaliana (AtPDF1A); crystals grown in PEG-6000
1W74	;	2.6	;	X-ray structure of peptidyl-prolyl cis-trans isomerase A, PpiA, Rv0009, from Mycobacterium tuberculosis.
4XNI	;	2.8	;	X-ray structure of PepTst1
4XNJ	;	2.3	;	X-ray structure of PepTst2
4XWR	;	1.1	;	X-ray structure of perdeuterated Cholesterol Oxidase from Streptomyces SA-COO
3KGG	;	2.1	;	X-ray structure of perdeuterated diisopropyl fluorophosphatase (DFPase): Perdeuteration of proteins for neutron diffraction
5VNR	;	1.631	;	X-ray structure of perdeuterated T4 lysozyme cysteine-free pseudo-wild type at cryogenic temperature
5CLX	;	1.28	;	X-ray structure of perdeuterated TTR mutant - S52P at 1.28A resolution
5CM1	;	1.22	;	X-ray structure of perdeuterated TTR mutant - T119M at 1.22A
5CNH	;	1.42	;	X-ray structure of perdeuterated wild-type TTR at 1.42A resolution
2WGJ	;	2.0	;	X-ray Structure of PF-02341066 bound to the kinase domain of c-Met
3ZXZ	;	1.8	;	X-ray Structure of PF-04217903 bound to the kinase domain of c-Met
1RTW	;	2.35	;	X-ray Structure of PF1337, a TenA Homologue from Pyrococcus furiosus. Northeast Structural Genomics Research Consortium (Nesg) Target PFR34
2WKM	;	2.2	;	X-ray Structure of PHA-00665752 bound to the kinase domain of c-Met
2Q5L	;	1.85	;	X-ray structure of phenylpyruvate decarboxylase in complex with 2-(1-hydroxyethyl)-3-deaza-ThDP
2Q5J	;	3.2	;	X-ray structure of phenylpyruvate decarboxylase in complex with 3-deaza-ThDP
2Q5Q	;	1.9	;	X-ray structure of phenylpyruvate decarboxylase in complex with 3-deaza-ThDP and 5-phenyl-2-oxo-valeric acid
2Q5O	;	2.15	;	X-ray structure of phenylpyruvate decarboxylase in complex with 3-deaza-ThDP and phenylpyruvate
5Y2U	;	1.98	;	X-ray structure of Phosphoglycerate Mutase 1(PGAM1) complexed with a small molecule
5P2P	;	2.4	;	X-RAY STRUCTURE OF PHOSPHOLIPASE A2 COMPLEXED WITH A SUBSTRATE-DERIVED INHIBITOR
7ABM	;	3.004	;	X-ray structure of phosphorylated Barrier-to-autointegration factor (BAF)
1P6B	;	1.9	;	X-ray structure of phosphotriesterase, triple mutant H254G/H257W/L303T
3GL4	;	2.15	;	X-ray structure of photobleached killerred
8H2U	;	3.4	;	X-ray Structure of photosystem I-LHCI super complex from Chlamydomonas reinhardtii.
3OSJ	;	2.3	;	X-Ray Structure of Phycobilisome LCM core-membrane linker polypeptide (fragment 254-400) from Synechocystis sp. PCC 6803, Northeast Structural Genomics Consortium Target SgR209C
3OHW	;	2.7	;	X-Ray Structure of Phycobilisome LCM core-membrane linker polypeptide (fragment 721-860) from Synechocystis sp. PCC 6803, Northeast Structural Genomics Consortium Target SgR209E
8B4N	;	1.6	;	X-ray structure of phycoerythrin from Porphyridium cruentum
4G11	;	3.4	;	X-ray structure of PI3K-gamma bound to a 4-(morpholin-4-yl)- (6-oxo-1,6-dihydropyrimidin-2-yl)amide inhibitor
5G2N	;	2.68	;	X-ray structure of PI3Kinase Gamma in complex with Copanlisib
4XW6	;	1.9	;	X-ray structure of PKAc with ADP, free phosphate ion, CP20, magnesium ions
4XW4	;	1.82	;	X-ray structure of PKAc with AMPPNP, SP20, calcium ions
4XW5	;	1.95	;	X-ray structure of PKAc with ATP, CP20, calcium ions
2CW3	;	2.5	;	X-ray structure of PmSOD2, superoxide dismutase from Perkinsus marinus
6OW2	;	1.7	;	X-ray Structure of Polypeptide Deformylase
4EOX	;	1.783	;	X-ray Structure of Polypeptide Deformylase Bound to a Acylprolinamide inhibitor
6OW7	;	1.45	;	X-ray Structure of Polypeptide Deformylase with a Piperazic Acid
6QJ5	;	2.0	;	X-ray structure of PPARgamma LBD with the ligand NV1380
6C8V	;	3.2	;	X-ray structure of PqqE from Methylobacterium extorquens
4LUB	;	2.1	;	X-ray structure of prephenate dehydratase from Streptococcus mutans
7NR4	;	2.03	;	X-RAY STRUCTURE OF PRMT6 IN COMPLEX WITH indazole type inhibitor
3ICL	;	2.0	;	X-Ray Structure of Protein (EAL/GGDEF domain protein) from M.capsulatus, Northeast Structural Genomics Consortium Target McR174C
2A13	;	1.32	;	X-ray structure of protein from Arabidopsis thaliana AT1G79260
3EMM	;	1.358	;	X-ray structure of protein from Arabidopsis thaliana AT1G79260 with Bound Heme
2APJ	;	1.6	;	X-Ray Structure of Protein from Arabidopsis Thaliana AT4G34215 at 1.6 Angstrom Resolution
1ZXU	;	1.7	;	X-ray structure of protein from arabidopsis thaliana AT5G01750
2A3Q	;	2.32	;	X-Ray Structure of Protein from Mus Musculus MM.29898
5ZN2	;	1.2	;	X-ray structure of protein kinase ck2 alpha subunit H148A mutant
5ZN5	;	1.7	;	X-ray structure of protein kinase ck2 alpha subunit H148A mutant
5ZN4	;	1.651	;	X-ray structure of protein kinase ck2 alpha subunit H148N mutant
5ZN3	;	1.5	;	X-ray structure of protein kinase ck2 alpha subunit H148S mutant
5ZN1	;	1.05	;	X-ray structure of protein kinase ck2 alpha subunit in D2O
3H5C	;	3.26	;	X-Ray Structure of Protein Z-Protein Z Inhibitor Complex
6QF1	;	1.737	;	X-Ray structure of Proteinase K crystallized on a silicon chip
4F8P	;	2.05	;	X-ray structure of PsaA from Yersinia pestis, in complex with galactose
4F8L	;	1.5	;	X-ray structure of PsaA from Yersinia pestis, in complex with galactose and AEBSF
4F8N	;	2.501	;	X-ray structure of PsaA from Yersinia pestis, in complex with galactose and phosphate choline
4F8O	;	1.9	;	X-ray structure of PsaA from Yersinia pestis, in complex with lactose and AEBSF
1ZA0	;	2.0	;	X-ray structure of putative acyl-ACP desaturase DesA2 from Mycobacterium tuberculosis H37Rv
2EWO	;	2.9	;	X-ray structure of putative agmatine deiminase Q8DW17, Northeast Structural Genomics target SmR6.
1YVI	;	2.0	;	X-RAY STRUCTURE OF PUTATIVE HISTIDINE-CONTAINING PHOSPHOTRANSFER PROTEIN FROM RICE, AK104879
1XW8	;	2.0	;	X-ray structure of putative lactam utilization protein YBGL. Northeast Structural Genomics Consortium target ET90.
1XQ1	;	2.1	;	X-RAY STRUCTURE OF PUTATIVE TROPINONE REDUCATSE FROM ARABIDOPSIS THALIANA GENE AT1G07440
4TMD	;	2.0	;	X-ray structure of Putative uncharacterized protein (Rv0999 ortholog) from Mycobacterium smegmatis
1QYI	;	2.5	;	X-RAY STRUCTURE OF Q8NW41 NORTHEAST STRUCTURAL GENOMICS CONSORTIUM TARGET ZR25.
3FRK	;	2.15	;	X-ray structure of QdtB from T. thermosaccharolyticum in complex with a PLP:TDP-3-aminoquinovose aldimine
4CBS	;	2.3	;	X-ray structure of quintuple mutant of human alanine glyoxylate aminotransferase, AGXT_RHEAM
4Z7P	;	1.2	;	X-ray structure of racemic ShK Q16K toxin
3E8Z	;	2.0	;	X-ray structure of rat arginase I-N130A mutant: the unliganded complex
3E9B	;	2.15	;	X-ray structure of rat arginase I-T135A mutant: the complex with BEC
3E8Q	;	2.9	;	X-ray structure of rat arginase I-T135A: the unliganded complex
5W70	;	2.1	;	X-ray Structure of RbmB from Streptomyces ribosidificus
7RTI	;	2.05	;	X-ray structure of RBPJ-L3MBTL3(dT62)-DNA complex
5EYB	;	2.7	;	X-ray Structure of Reb1-Ter Complex
4NEU	;	2.57	;	X-ray structure of Receptor Interacting Protein 1 (RIP1)kinase domain with a 1-aminoisoquinoline inhibitor
1JF8	;	1.12	;	X-ray structure of reduced C10S, C15A arsenate reductase from pI258
6AA2	;	2.3	;	X-ray structure of ReQy1 (oxidized form)
6AA6	;	2.39	;	X-ray structure of ReQy1 (reduced form)
3RF9	;	2.2	;	X-ray structure of RlmN from Escherichia coli
3RFA	;	2.05	;	X-ray structure of RlmN from Escherichia coli in complex with S-adenosylmethionine
4RBZ	;	1.18	;	X-ray structure of RNA containing adenosine phosphorodithioate
4RC0	;	1.13	;	X-ray structure of RNA containing guanosine phosphorodithioate
2CKZ	;	3.2	;	X-ray structure of RNA polymerase III subcomplex C17-C25.
8C3B	;	1.24	;	X-ray structure of RNase A upon reaction with a Ruthenium(II)-arene Complexed with Glycosylated Carbene Ligands (5)
5F5F	;	3.0	;	X-ray structure of Roquin ROQ domain in complex with a Selex-derived hexa-loop RNA motif
6TQB	;	1.6	;	X-ray structure of Roquin ROQ domain in complex with a UCP3 CDE1 SL RNA motif
6TQA	;	2.4	;	X-ray structure of Roquin ROQ domain in complex with a UCP3 CDE2 SL RNA motif
5F5H	;	2.23	;	X-ray structure of Roquin ROQ domain in complex with Ox40 hexa-loop RNA motif
5AJC	;	1.7	;	X-ray structure of RSL lectin in complex with sialyl lewis X tetrasaccharide
8A2M	;	1.57	;	X-ray structure of Ru(bpy)3]2+ complex (Ru1)-encapsulated human heavy chain ferritin
3JXQ	;	1.45	;	X-Ray structure of r[CGCG(5-fluoro)CG]2
3JXR	;	1.25	;	X-Ray structure of r[CGCG(5-fluoro)CG]2
2OGE	;	2.05	;	x-ray structure of S. venezuelae DesV in its internal aldimine form
4FGR	;	2.597	;	X-Ray Structure of SAICAR Synthetase (PurC) from Streptococcus pneumoniae complexed with ADP and Mg2+
4FE2	;	2.288	;	X-Ray Structure of SAICAR Synthetase (PurC) from Streptococcus pneumoniae complexed with AIR, ADP, Asp and Mg2+
7RC1	;	1.63	;	X-ray Structure of SARS-CoV main protease covalently modified by compound GRL-0686
6WNP	;	1.443	;	X-ray Structure of SARS-CoV-2 main protease bound to Boceprevir at 1.45 A
6XR3	;	1.45	;	X-ray Structure of SARS-CoV-2 main protease bound to GRL-024-20 at 1.45 A
7RBZ	;	1.65	;	X-ray Structure of SARS-CoV-2 main protease covalently modified by compound GRL-017-20
7RC0	;	1.65	;	X-ray Structure of SARS-CoV-2 main protease covalently modified by compound GRL-091-20
7NT4	;	2.68	;	X-ray structure of SCoV2-PLpro in complex with small molecule inhibitor
6G3P	;	2.8	;	X-ray structure of seleno-methionine labelled NSD3-PWWP1
1YBM	;	2.096	;	X-ray structure of selenomethionyl gene product from Arabidopsis thaliana at5g02240 in space group P21212
1NPD	;	2.3	;	X-RAY STRUCTURE OF SHIKIMATE DEHYDROGENASE COMPLEXED WITH NAD+ FROM E.COLI (YDIB) NORTHEAST STRUCTURAL GENOMICS RESEARCH CONSORTIUM (NESG) TARGET ER24
7O2B	;	2.03	;	X-RAY STRUCTURE OF SMYD3 in complex with benzodiazepine-type inhibitor 6
7O2A	;	1.57	;	X-RAY STRUCTURE OF SMYD3 IN COMPLEX WITH benzodiazepine-type inhibitor compound 15
7O2C	;	1.52	;	X-RAY STRUCTURE OF SMYD3 IN COMPLEX WITH the benzodiazepine-based probe BAY-6035
7OKT	;	1.95	;	X-ray structure of soluble EPCR in C2221 space group
7OKS	;	1.95	;	X-ray structure of soluble EPCR in P212121 space group
7OKU	;	1.95	;	X-ray structure of soluble EPCR in P3121 space group
6IXZ	;	1.98	;	X-ray structure of sortase C from Clostridium perfringens SM101
1MBD	;	1.4	;	X-ray structure of sperm whale deoxymoglobin refined at 1.4A resolution
5ZEO	;	1.77	;	X-ray structure of sperm whale V21C/V66C/F46S myoglobin mutant with an intramolecular disulfide bond
1XJ5	;	2.7	;	X-RAY STRUCTURE OF SPERMIDINE SYNTHASE FROM ARABIDOPSIS THALIANA GENE AT1G23820
2F5I	;	2.3	;	X-ray structure of spermidine/spermine N1-acetyltransferase (SAT) from Homo sapiens
7LIP	;	1.48	;	X-ray structure of SPOP MATH domain (D140G)
7LIN	;	1.44	;	X-ray structure of SPOP MATH domain (D140G) in complex with a 53BP1 peptide
7LIQ	;	1.98	;	X-ray structure of SPOP MATH domain (S119A)
7LIO	;	3.01	;	X-ray structure of SPOP MATH domain (S119D) in complex with a 53BP1 peptide
1WAK	;	1.73	;	X-ray structure of SRPK1
6H0R	;	1.73	;	X-ray structure of SRS2 fragment of Rgs4 3' UTR
7BFK	;	1.89	;	X-ray structure of SS-RNase-2
7BFL	;	2.88	;	X-ray structure of SS-RNase-2 des116-120
7Y5Y	;	1.85	;	X-ray Structure of Stay-Green (SGR) from Anaerolineae bacterium.
2RFS	;	2.2	;	X-ray structure of SU11274 bound to c-Met
2BCO	;	2.33	;	X-ray structure of succinylglutamate desuccinalase from Vibrio Parahaemolyticus (RIMD 2210633) at the resolution 2.3 A, Northeast Structural Genomics Target Vpr14
1MZG	;	2.0	;	X-Ray Structure of SufE from E.coli Northeast Structural Genomics (NESG) Consortium Target ER30
6L9B	;	1.95	;	X-ray structure of synthetic GB1 domain with mutations K10(DVA), T11A
6L9D	;	1.73	;	X-ray structure of synthetic GB1 domain with mutations K10(DVA), T11S
6LJI	;	1.843	;	X-ray structure of synthetic GB1 domain with mutations K10(DVA), T11V
6L91	;	1.842	;	X-ray structure of synthetic GB1 domain with the mutation K10(DVA).
2NUI	;	1.1	;	X-ray Structure of synthetic [D83A]RNase A
2BBH	;	1.85	;	X-ray structure of T.maritima CorA soluble domain
6HIL	;	2.3	;	X-ray structure of TEAD1(Y421H mutant) complexed with YAP(wildtype): Molecular and structural characterization of a TEAD mutation at the origin of Sveinsson's chorioretinal atrophy
6GE3	;	1.85	;	X-ray structure of TEAD4 (wildtype) complexed with YAP (wildtype): The role of residual flexibility and water molecules in the adaptation of a bound intrinsically disordered protein to mutations at a binding interface
6GE6	;	1.8	;	X-ray structure of TEAD4(E263A+Y429F mutant) complexed with YAP(wildtype): The role of residual flexibility and water molecules in the adaptation of a bound intrinsically disordered protein to mutations at a binding interface
6HIK	;	1.65	;	X-ray structure of TEAD4(Y429H) mutant) complexed with YAP (wildtype): Molecular and structural characterization of a TEAD mutation at the origin of Sveinsson's chorioretinal atrophy
2BGM	;	2.0	;	X-Ray structure of ternary-Secoisolariciresinol Dehydrogenase
3MVZ	;	1.7	;	X-ray structure of the (hydro)peroxo intermediate NikA/1-Int"", after monohydroxylation of the iron complex
5L4H	;	3.3	;	X-ray structure of the 2-22' locally-closed mutant of GLIC in complex with 5-(2-BROMO-ETHYL)-5-ETHYL-PYRIMIDINE-2,4,6-TRIONE (brominated barbiturate)
5L47	;	3.3	;	X-ray structure of the 2-22' locally-closed mutant of GLIC in complex with cyanoselenobarbital (seleniated barbiturate)
5MUO	;	3.19	;	X-ray structure of the 2-22' locally-closed mutant of GLIC in complex with propofol
5L4E	;	3.5	;	X-ray structure of the 2-22' locally-closed mutant of GLIC in complex with thiopental
4ZU4	;	1.7	;	X-ray structure of the 3,4-ketoisomerase domain of FdtD from Shewanella denitrificans
4YFV	;	1.89	;	X-ray structure of the 4-N-formyltransferase VioF from Providencia alcalifaciens O30
1WV5	;	2.3	;	X-ray structure of the A-decamer GCGTATACGC with a single 2'-o-butyl thymine in place of T6, Mg-form
1WV6	;	2.55	;	X-ray structure of the A-decamer GCGTATACGC with a single 2'-O-butyl thymine in place of T6, Sr-form
4MXF	;	2.25	;	X-ray structure of the adduct between bovine pancreatic ribonuclease and Auoxo6, a dinuclear gold(III) complex with -dioxo bridges linking the two metal centers
4L55	;	1.65	;	X-ray structure of the adduct between bovine pancreatic ribonuclease and AziRu
4LFP	;	1.72	;	X-ray structure of the adduct between hen egg white lysozyme and a homoleptic gold(I) complex with the saccharynate ligand
4LGK	;	1.96	;	X-ray structure of the adduct between hen egg white lysozyme and Au2Phen, a dinuclear gold(III) complex with -dioxo bridges linking the two metal centers
4QY9	;	2.05	;	X-ray structure of the adduct between hen egg white lysozyme and Auoxo3, a cytotoxic gold(III) compound
4LFX	;	2.1	;	X-ray structure of the adduct between hen egg white lysozyme and Auoxo6, a dinuclear gold(III) complex with -dioxo bridges linking the two metal centers
4J1B	;	1.66	;	X-ray structure of the adduct between hen egg white lysozyme and AziRu (black crystal)
4J1A	;	1.79	;	X-ray structure of the adduct between hen egg white lysozyme and AziRu (green crystal)
4MR1	;	1.99	;	X-ray structure of the adduct between hen egg white lysozyme and cis-diamminediiodoplatinum(II)
5FCP	;	1.55	;	X-RAY STRUCTURE OF THE ADDUCT BETWEEN HEN EGG WHITE LYSOZYME AND CISPLATIN AT LONG INCUBATION TIMES
5F9U	;	1.85	;	X-RAY STRUCTURE OF THE ADDUCT BETWEEN HEN EGG WHITE LYSOZYME AND CISPLATIN UPON 24 HOURS OF INCUBATION AT 20 DEGREES
5F9X	;	1.94	;	X-RAY STRUCTURE OF THE ADDUCT BETWEEN HEN EGG WHITE LYSOZYME AND CISPLATIN UPON 24 HOURS OF INCUBATION AT 55 DEGREES
5L4R	;	1.45	;	X-ray structure of the adduct between thaumatin and cisplatin
4QH3	;	2.0	;	X-ray structure of the adduct formed between bovine pancreatic ribonuclease and trans-dimethylamine methylamine dichlorido platinum(II)
4OT4	;	1.85	;	X-ray Structure of the Adduct formed between cisplatin and Ribonuclease A
4NY5	;	1.85	;	X-ray structure of the adduct formed between hen egg white lysozyme and NAMI-A
4QGZ	;	2.51	;	X-ray structure of the adduct formed between hen egg white lysozyme and trans-dimethylamine methylamine dichlorido platinum(II)
4Z3M	;	2.15	;	X-ray structure of the adduct formed in the reaction between lysozyme and a platinum(II) Complex with S,O Bidentate Ligands (9b)
4Z41	;	1.89	;	X-ray structure of the adduct formed in the reaction between lysozyme and a platinum(II) Compound with a S,O Bidentate Ligand (9a=Chloro-(1-(3'-hydroxy)-3-(methylthio)-3-thioxo-prop-1-en-1-olate-O,S)-(dimethylsulfoxide-S)-platinum(II))
5E5E	;	1.98	;	X-ray structure of the adduct formed in the reaction between RNase A and a neutral organometallic derivative [Pt(pbi)(Me)(DMSO)], pbi=2-(2'-pyridil)benzimidazole (compound 3)
5JVX	;	1.7	;	X-ray structure of the adduct formed in the reaction between thaumatin and a gold carbene compound
8CE2	;	1.24	;	X-ray structure of the adduct formed upon reaction of a B-DNA double helical dodecamer with dirhodium tetraacetate
7QWH	;	1.573	;	X-ray structure of the adduct formed upon reaction of a vanadium hydroxyquinoline complex with RNase A
6GOK	;	2.65	;	X-ray structure of the adduct formed upon reaction of bovine pancreatic ribonuclease with a Pd(II) complex bearing N,N-pyridylbenzimidazole derivative with an alkylated sulphonate side chain
8OO4	;	1.99	;	X-ray structure of the adduct formed upon reaction of cisplatin with human angiogenin after 1 month soaking
8OO3	;	1.76	;	X-ray structure of the adduct formed upon reaction of cisplatin with human angiogenin after 5 days soaking
5OLE	;	1.78	;	X-ray structure of the adduct formed upon reaction of hen egg white lysozyme with a tetranuclear Pt-thiosemicarbazone compound
6GOB	;	1.96	;	X-ray structure of the adduct formed upon reaction of lysozyme with a Pd(II) complex bearing N,N-pyridylbenzimidazole derivative with an alkylated sulphonate side chain
6GOI	;	1.99	;	X-ray structure of the adduct formed upon reaction of lysozyme with a Pd(II) complex bearing N,N-pyridylbenzimidazole derivative with an alkylated triphenylphosphonium cation
6GOH	;	2.43	;	X-ray structure of the adduct formed upon reaction of lysozyme with a Pt(II) complex bearing N,N-pyridylbenzimidazole derivative with an alkylated sulphonate side chain
6GOJ	;	2.25	;	X-ray structure of the adduct formed upon reaction of lysozyme with a Pt(II) complex bearing N,N-pyridylbenzimidazole derivative with an alkylated triphenylphosphonium cation
8PFT	;	1.304	;	X-ray structure of the adduct formed upon reaction of Lysozyme with K2[Ru2(D-p-FPhF)(CO3)3] in condition A
8PFX	;	1.03	;	X-ray structure of the adduct formed upon reaction of Lysozyme with K2[Ru2(D-p-FPhF)(CO3)3] in condition B
8PFW	;	1.12	;	X-ray structure of the adduct formed upon reaction of Lysozyme with K2[Ru2(DAniF)(CO3)3] in condition A
8PFY	;	1.19	;	X-ray structure of the adduct formed upon reaction of Lysozyme with K2[Ru2(DAniF)(CO3)3] in condition B
8PH6	;	1.07	;	X-ray structure of the adduct formed upon reaction of Lysozyme with K2[Ru2(DPhF)(CO3)3] in condition B
8PFU	;	1.18	;	X-ray structure of the adduct formed upon reaction of Lysozyme with K3[Ru2(CO3)4] in condition A
5OB6	;	1.88	;	X-ray structure of the adduct formed upon reaction of lysozyme with the compound fac-[RuII(CO)3Cl2(N3-IM), IM=imidazole
5OB7	;	2.1	;	X-ray structure of the adduct formed upon reaction of lysozyme with the compound fac-[RuII(CO)3Cl2(N3-IM), IM=imidazole (crystal 2)
5OB9	;	2.38	;	X-ray structure of the adduct formed upon reaction of lysozyme with the compound fac-[RuII(CO)3Cl2(N3-MIM), MIM=methyl-imidazole (crystals grown using ethylene glycol
5OB8	;	1.85	;	X-ray structure of the adduct formed upon reaction of lysozyme with the compound fac-[RuII(CO)3Cl2(N3-MIM), MIM=methyl-imidazole (crystals grown using NaCl)
8BPJ	;	1.38	;	X-ray structure of the adduct formed upon reaction of Lysozyme with [Ru2Cl(D-p-FPhF)(O2CCH3)3] (Structure 1)
8BPU	;	1.81	;	X-ray structure of the adduct formed upon reaction of Lysozyme with [Ru2Cl(D-p-FPhF)(O2CCH3)3] (Structure 2)
8BPH	;	1.07	;	X-ray structure of the adduct formed upon reaction of Lysozyme with [Ru2Cl(D-p-FPhF)(O2CCH3)3] (Structure 3)
8BQM	;	1.17	;	X-ray structure of the adduct formed upon reaction of Lysozyme with [Ru2Cl(D-p-FPhF)(O2CCH3)3] (Structure 4)
8PFV	;	1.46	;	X-ray structure of the adduct formed upon reaction of Lysozyme with [Ru2Cl(DAniF)(O2CCH3)3] in condition A
8PH7	;	1.406	;	X-ray structure of the adduct formed upon reaction of Lysozyme with [Ru2Cl(DPhF)(O2CCH3)3] in condition A
8PH8	;	1.29	;	X-ray structure of the adduct formed upon reaction of Lysozyme with [Ru2Cl(DPhF)2(O2CCH3)2] in condition A
8PH5	;	1.29	;	X-ray structure of the adduct formed upon reaction of Lysozyme with [Ru2Cl(DPhF)2(O2CCH3)2] in condition B
7NPM	;	1.86	;	X-ray structure of the adduct formed upon reaction of oxaliplatin with human angiogenin
7PNH	;	1.22	;	X-ray structure of the adduct formed upon reaction of Pt(II) complex 2c with lysozyme
7PNI	;	2.13	;	X-ray structure of the adduct formed upon reaction of Pt(II) complex 2c with ribonuclease A
5OLD	;	1.78	;	X-ray structure of the adduct formed upon reaction of ribonuclease A with a tetranuclear Pt-thiosemicarbazone compound
5OBC	;	2.07	;	X-ray structure of the adduct formed upon reaction of ribonuclease A with the compound fac-[RuII(CO)3Cl2(N3-IM), IM=imidazole
5OBE	;	1.82	;	X-ray structure of the adduct formed upon reaction of ribonuclease A with the compound fac-[RuII(CO)3Cl2(N3-MBI), MBI=methyl-benzimidazole
5OBD	;	1.98	;	X-ray structure of the adduct formed upon reaction of ribonuclease A with the compound fac-[RuII(CO)3Cl2(N3-MIM), MIM=methyl-imidazole
8BOY	;	1.33	;	X-ray structure of the adduct formed upon reaction of the five-coordinate Pt(II) complex, 1-Me,Me, with HEWL at pH 4.0
8BOV	;	1.25	;	X-ray structure of the adduct formed upon reaction of the five-coordinate Pt(II) complex, 1-Me,Me, with HEWL at pH 7.5
7R1P	;	1.42	;	X-ray structure of the adduct formed upon reaction of the gold(I) N-heterocyclic carbene complex Au1 with RNase A
7R1Q	;	1.1	;	X-ray structure of the adduct formed upon reaction of the gold(I) N-heterocyclic carbene complex Au2 with lysozyme
6ZS8	;	2.153	;	X-ray structure of the adduct formed upon treating lysozyme with an aged solution of arsenoplatin-1
7QQ1	;	1.48	;	X-ray structure of the adduct obtained upon reaction of [cis-Rh2(OCOCH3)2(OCOCF3)2] with HEWL
7QPW	;	1.15	;	X-ray structure of the adduct obtained upon reaction of [cis-Rh2(OCOCH3)2(OCOCF3)2] with RNase A (1)
7QQ0	;	1.32	;	X-ray structure of the adduct obtained upon reaction of [cis-Rh2(OCOCH3)2(OCOCF3)2] with RNase A (2)
7QPY	;	1.42	;	X-ray structure of the adduct obtained upon reaction of [cis-Rh2(OCOCH3)2(OCOCF3)2] with RNase A (3)
7QPZ	;	1.45	;	X-ray structure of the adduct obtained upon reaction of [cis-Rh2(OCOCH3)2(OCOCF3)2] with RNase A (4)
7Z6J	;	1.53	;	X-ray structure of the adduct obtained upon reaction of [Rh2(OCOCH3)(OCOCF3)3] with HEWL
7Z6D	;	1.45	;	X-ray structure of the adduct obtained upon reaction of [Rh2(OCOCH3)(OCOCF3)3] with RNase A (1)
7Z6G	;	1.71	;	X-ray structure of the adduct obtained upon reaction of [Rh2(OCOCH3)(OCOCF3)3] with RNase A (2)
7P8R	;	1.27	;	X-ray structure of the adduct of a vanadium picolinate complex with RNase A at pH 5.1
2BRJ	;	1.5	;	X-ray structure of the Allene Oxide Cyclase from Arabidopsis thaliana
4RDA	;	2.497	;	X-RAY STRUCTURE OF THE AMYLOID PRECURSOR PROTEIN-LIKE PROTEIN 1 (APLP1) E2 DOMAIN IN COMPLEX WITH A HEPARIN DODECASACCHARIDE
4F8H	;	2.99	;	X-ray Structure of the Anesthetic Ketamine Bound to the GLIC Pentameric Ligand-gated Ion Channel
3NXA	;	2.1	;	X-ray structure of the apo form of human S100A16
4RD9	;	2.6	;	X-RAY STRUCTURE OF THE APO FORM OF THE AMYLOID PRECURSOR PROTEIN-LIKE PROTEIN 1 (APLP1) E2 DOMAIN
6GYG	;	1.98	;	X-ray structure of the apo form of the establishement gene regulator Reg576 of the G+ plasmid p576
3C02	;	2.05	;	X-ray structure of the aquaglyceroporin from Plasmodium falciparum
2HU9	;	1.78	;	X-ray structure of the Archaeoglobus fulgidus CopZ N-terminal Domain
4GVR	;	1.52	;	X-ray structure of the Archaeoglobus fulgidus methenyl-tetrahydromethanopterin cyclohydrolase
4GVS	;	1.75	;	X-ray structure of the Archaeoglobus fulgidus methenyl-tetrahydromethanopterin cyclohydrolase in complex with N5-formyl-tetrahydromethanopterin
4GVQ	;	1.3	;	X-ray structure of the Archaeoglobus fulgidus methenyl-tetrahydromethanopterin cyclohydrolase in complex with tetrahydromethanpterin
4G1U	;	3.008	;	X-ray structure of the bacterial heme transporter HmuUV from Yersinia pestis
3BKV	;	2.6	;	X-ray structure of the bacteriophage phiKZ lytic transglycosylase, gp144, in complex with chitotetraose, (NAG)4
1BRR	;	2.9	;	X-RAY STRUCTURE OF THE BACTERIORHODOPSIN TRIMER/LIPID COMPLEX
2BMB	;	2.3	;	X-ray structure of the bifunctional 6-hydroxymethyl-7,8- dihydroxypterin pyrophosphokinase dihydropteroate synthase from Saccharomyces cerevisiae
3ZED	;	2.2	;	X-ray structure of the birnavirus VP1-VP3 complex
4Z46	;	1.85	;	X-ray structure of the bis-platinum lysozyme adduct formed in the reaction between the protein and the two drugs Cisplatin and Oxaliplatin
4ZEE	;	1.95	;	X-ray structure of the bis-platinum lysozyme adduct formed in the reaction between the protein and the two drugs Cisplatin and Oxaliplatin (preparation 2)
2ING	;	3.6	;	X-ray Structure of the BRCA1 BRCT mutant M1775K
4E32	;	1.5	;	X-ray Structure of the C-3'-Methyltransferase TcaB9 in Complex with S-Adenosyl-L-Homocysteine and dTDP-Sugar Substrate
4E33	;	1.6	;	X-ray Structure of the C-3'-Methyltransferase TcaB9 in Complex with S-Adenosyl-L-Homocysteine and Reduced dTDP-Sugar Substrate
3GGL	;	3.0	;	X-Ray Structure of the C-terminal domain (277-440) of Putative chitobiase from Bacteroides thetaiotaomicron. Northeast Structural Genomics Consortium Target BtR324A.
6OE2	;	3.0	;	X-Ray Structure of the C-terminal domain (277-440) of Putative chitobiase from Bacteroides thetaiotaomicron. Northeast Structural Genomics Consortium Target BtR324A. Re-refinement of 3GGL with correct metal Mn replacing Zn. New metal confirmed with PIXE analysis of original sample.
5IP4	;	1.81	;	X-RAY STRUCTURE OF THE C-TERMINAL DOMAIN OF HUMAN DOUBLECORTIN
6T7O	;	1.60004	;	X-ray structure of the C-terminal domain of S. aureus Hibernating Promoting Factor (CTD-SaHPF)
3RID	;	2.18	;	X-ray structure of the C-terminal swapped dimer of P114A variant of Ribonuclease A
1EUV	;	1.6	;	X-RAY STRUCTURE OF THE C-TERMINAL ULP1 PROTEASE DOMAIN IN COMPLEX WITH SMT3, THE YEAST ORTHOLOG OF SUMO.
5T64	;	1.7	;	X-ray structure of the C3-methyltransferase KijD1 from Actinomadura kijaniata in complex with TDP and SAH
4L2C	;	1.66	;	X-ray structure of the C57R mutant of the iron superoxide dismutase from Pseudoalteromonas haloplanktis (crystal form I)
4L2A	;	2.06	;	X-ray structure of the C57R mutant of the iron superoxide dismutase from Pseudoalteromonas haloplanktis (crystal form II)
4L2B	;	1.97	;	X-ray structure of the C57S mutant of the iron superoxide dismutase from Pseudoalteromonas haloplanktis
1P5V	;	1.7	;	X-ray structure of the Caf1M:Caf1 chaperone:subunit preassembly complex
1AR5	;	1.6	;	X-RAY STRUCTURE OF THE CAMBIALISTIC SUPEROXIDE DISMUTASE FROM PROPIONIBACTERIUM SHERMANII ACTIVE WITH FE OR MN
4IHB	;	2.044	;	X-RAY STRUCTURE OF THE canonical C2A DOMAIN FROM HUMAN DYSFERLIN
4IRL	;	1.47	;	X-ray structure of the CARD domain of zebrafish GBP-NLRP1 like protein
4QKZ	;	1.2	;	X-ray structure of the catalytic domain of MMP-8 with the inhibitor ML115
4USO	;	1.95	;	X-ray structure of the CCL2 lectin in complex with sialyl lewis X
8BAW	;	1.471	;	X-ray structure of the CeuE Homologue from Geobacillus stearothermophilus - 5-LICAM siderophore analogue complex.
8B7X	;	1.42	;	X-ray structure of the CeuE Homologue from Geobacillus stearothermophilus - apo form.
8BAX	;	1.38	;	X-ray structure of the CeuE Homologue from Geobacillus stearothermophilus - azotochelin complex.
8BJ9	;	2.069	;	X-ray structure of the CeuE Homologue from Parageobacillus thermoglucosidasius - 5LICAM complex.
8BNW	;	2.133	;	X-ray structure of the CeuE Homologue from Parageobacillus thermoglucosidasius - apo form
8BF6	;	1.969	;	X-ray structure of the CeuE Homologue from Parageobacillus thermoglucosidasius - azotochelin complex
2J2Z	;	2.3	;	X-Ray Structure of the Chaperone PapD in complex with the Pilus terminator subunit PapH at 2.3 Angstrom resolution
6VO8	;	2.4	;	X-ray structure of the Cj1427 in the presence of NADH and GDP-D-glycero-D-mannoheptose, an essential NAD-dependent dehydrogenase from Campylobacter jejuni
1KD8	;	1.9	;	X-RAY STRUCTURE OF THE COILED COIL GCN4 ACID BASE HETERODIMER ACID-d12Ia16V BASE-d12La16L
1KDD	;	2.14	;	X-ray structure of the coiled coil GCN4 ACID BASE HETERODIMER ACID-d12La16I BASE-d12La16L
1KD9	;	2.1	;	X-RAY STRUCTURE OF THE COILED COIL GCN4 ACID BASE HETERODIMER ACID-d12La16L BASE-d12La16L
5JMG	;	1.85	;	X-ray structure of the complex between bovine pancreatic ribonuclease and pentachlorocarbonyliridate(III) (4 days of soaking)
5JML	;	2.29	;	X-ray structure of the complex between bovine pancreatic ribonuclease and penthachlorocarbonyliridate(III) (2 months of soaking)
1HG1	;	1.8	;	X-ray structure of the complex between Erwinia chrysanthemi L-asparaginase and D-aspartate
1HFW	;	1.8	;	X-ray structure of the complex between Erwinia chrysanthemi L-asparaginase and L-Glutamate
1HG0	;	1.9	;	X-ray structure of the complex between Erwinia chrysanthemi L-asparaginase and succinic acid
4NIJ	;	1.86	;	X-ray structure of the complex between hen egg white lysozyme and pentachlorocarbonyliridate(III) (30 days)
4NHQ	;	1.92	;	X-ray structure of the complex between hen egg white lysozyme and pentachlorocarbonyliridate(III) (5 days)
4NHT	;	1.65	;	X-ray structure of the complex between hen egg white lysozyme and pentachlorocarbonyliridate(III) (6 days)
4NHS	;	1.99	;	X-ray structure of the complex between hen egg white lysozyme and pentachlorocarbonyliridate(III) (9 days)
4N9R	;	1.55	;	X-ray structure of the complex between hen egg white lysozyme and pentacholrocarbonyliridate(III) (1 day)
5CMX	;	2.98	;	X-ray structure of the complex between human alpha thrombin and a duplex/quadruplex 31-mer DNA aptamer
3QLP	;	2.14	;	X-ray structure of the complex between human alpha thrombin and a modified thrombin binding aptamer (mTBA)
7ZKL	;	3.18	;	X-ray structure of the complex between human alpha thrombin and a pseudo-cyclic thrombin binding aptamer (TBA-NNp/DDp) - Crystal form alpha
7ZKM	;	2.0	;	X-ray structure of the complex between human alpha thrombin and a pseudo-cyclic thrombin binding aptamer (TBA-NNp/DDp) - Crystal form beta
7ZKO	;	2.5	;	X-ray structure of the complex between human alpha thrombin and a pseudo-cyclic thrombin binding aptamer (TBA-NNp/DDp) - Crystal form delta
7ZKN	;	3.03	;	X-ray structure of the complex between human alpha thrombin and a pseudo-cyclic thrombin binding aptamer (TBA-NNp/DDp) - Crystal form gamma
6Z8W	;	1.73	;	X-ray structure of the complex between human alpha thrombin and a thrombin binding aptamer variant (TBA-3G), which contains 1-beta-D-glucopyranosyl residue in the side chain of Thy3 at N3.
6Z8V	;	1.58	;	X-ray structure of the complex between human alpha thrombin and a thrombin binding aptamer variant (TBA-3L), which contains 1-beta-D-lactopyranosyl residue in the side chain of Thy3 at N3.
6Z8X	;	2.53	;	X-ray structure of the complex between human alpha thrombin and a thrombin binding aptamer variant (TBA-3Leu), which contains leucyl amide in the side chain of Thy3 at N3.
6EVV	;	2.5	;	X-ray structure of the complex between human alpha thrombin and NU172, a duplex/quadruplex 26-mer DNA aptamer, in the presence of potassium ions.
6GN7	;	2.8	;	X-ray structure of the complex between human alpha thrombin and NU172, a duplex/quadruplex 26-mer DNA aptamer, in the presence of sodium ions.
8BW5	;	2.8	;	X-ray structure of the complex between human alpha thrombin and the duplex/quadruplex aptamer M08s-1_41mer
4DII	;	2.05	;	X-ray structure of the complex between human alpha thrombin and thrombin binding aptamer in the presence of potassium ions
4DIH	;	1.8	;	X-ray structure of the complex between human alpha thrombin and thrombin binding aptamer in the presence of sodium ions
7NTU	;	3.1	;	X-ray structure of the complex between human alpha thrombin and two duplex/quadruplex aptamers: NU172 and HD22_27mer
6EO6	;	1.69	;	X-ray structure of the complex between human alpha-thrombin and modified 15-mer DNA aptamer containing 5-(3-(2-(1H-indol-3-yl)acetamide-N-yl)-1-propen-1-yl)-2'-deoxyuridine residue
6EO7	;	2.24	;	X-ray structure of the complex between human alpha-thrombin and modified 15-mer DNA aptamer containing 5-(3-(acetamide-N-yl)-1-propen-1-yl)-2'-deoxyuridine residue
4LZ1	;	1.65	;	X-ray structure of the complex between human thrombin and the TBA deletion mutant lacking thymine 12 nucleobase
4LZ4	;	2.56	;	X-ray structure of the complex between human thrombin and the TBA deletion mutant lacking thymine 3 nucleobase
5E9R	;	2.25	;	X-ray structure of the complex between lysozyme and the compound fac, cis-[RuII(CO)3Cl2(N3-MBI), MBI=N-methyl-benzimidazole
5E5F	;	1.68	;	X-ray structure of the complex between RNase A and compound 4-PF6 ([(PPh3)Au(mi-pbi)Pt(Me)(DMSO)][PF6]), the heterobimetallic derivative obtained in the reaction between the organometallic compound [Pt(pbi)(Me)(DMSO)], pbi=2-(2'-pyridil)benzimidazole (compound 3) and the gold(I) compound [Au(Ph3P)][PF6]
4C56	;	2.9	;	X-ray structure of the complex between staphylococcal enterotoxin B, T cell receptor and major histocompatibility complex class II
4NHP	;	1.42	;	X-ray structure of the complex between the hen egg white lysozyme and pentachlorocarbonyliridate (III) (4 days)
4KAC	;	2.223	;	X-Ray Structure of the complex HaloTag2 with HALTS. Northeast Structural Genomics Consortium (NESG) Target OR150.
1R5C	;	2.1	;	X-ray structure of the complex of Bovine seminal ribonuclease swapping dimer with d(CpA)
4KAJ	;	1.948	;	X-Ray Structure of the complex of Haloalkane dehalogenase HaloTag7 with HALTS, Northeast Structural Genomics Consortium (NESG) Target OR151
1BHX	;	2.3	;	X-RAY STRUCTURE OF THE COMPLEX OF HUMAN ALPHA THROMBIN WITH THE INHIBITOR SDZ 229-357
3E0J	;	3.0	;	X-ray structure of the complex of regulatory subunits of human DNA polymerase delta
5OLN	;	1.88	;	X-Ray Structure of the Complex Pyrimidine-nucleoside phosphorylase from Bacillus subtilis at 1.88 A
5EP8	;	2.66	;	X-Ray Structure of the Complex Pyrimidine-nucleoside phosphorylase from Bacillus subtilis with Sulfate Ion
4IP0	;	1.294	;	X-Ray Structure of the Complex Uridine Phosphorylase from Vibrio cholerae with Phosphate Ion at 1.29 A Resolution
4H1T	;	1.924	;	X-RAY Structure of the Complex VchUPh with Phosphate ion at 1.92A Resolution.
8CKP	;	3.31	;	X-ray structure of the crystallization-prone form of subfamily III haloalkane dehalogenase DhmeA from Haloferax mediterranei
4AS8	;	1.02	;	X-ray structure of the cyan fluorescent protein Cerulean cryoprotected with ethylene glycol
4AR7	;	1.23	;	X-ray structure of the cyan fluorescent protein mTurquoise
2YE0	;	1.47	;	X-ray structure of the cyan fluorescent protein mTurquoise (K206A mutant)
4B5Y	;	1.45	;	X-ray structure of the cyan fluorescent protein mTurquoise-GL (K206A mutant) in space group C222(1)
3ZTF	;	1.31	;	X-ray Structure of the Cyan Fluorescent Protein mTurquoise2 (K206A mutant)
2YDZ	;	1.59	;	X-ray structure of the cyan fluorescent protein SCFP3A (K206A mutant)
2YE1	;	1.63	;	X-ray structure of the cyan fluorescent proteinmTurquoise-GL (K206A mutant)
4J20	;	1.3	;	X-ray structure of the cytochrome c-554 from chlorobaculum tepidum
1COT	;	1.7	;	X-RAY STRUCTURE OF THE CYTOCHROME C2 ISOLATED FROM PARACOCCUS DENITRIFICANS REFINED TO 1.7 ANGSTROMS RESOLUTION
1L9J	;	3.25	;	X-Ray Structure of the Cytochrome-c(2)-Photosynthetic Reaction Center Electron Transfer Complex from Rhodobacter sphaeroides in Type I Co-Crystals
1L9B	;	2.4	;	X-Ray Structure of the Cytochrome-c(2)-Photosynthetic Reaction Center Electron Transfer Complex from Rhodobacter sphaeroides in Type II Co-Crystals
4R5F	;	1.9	;	X-ray structure of the D199K mutant of the cysteine desulfurase IscS from A. fulgidus
6THV	;	1.1	;	X-ray structure of the Danio rerio histone deacetylase 6 (HDAC6; catalytic domain 2) in complex with Tubastatin A
4LOA	;	1.819	;	X-ray structure of the de-novo design amidase at the resolution 1.8A, Northeast Structural Genomics Consortium (NESG) Target OR398
7ZIZ	;	1.5	;	X-ray structure of the dead variant haloalkane dehalogenase HaloTag7-D106A bound to a pentanol tetramethylrhodamine ligand (TMR-Hy5)
2G7R	;	2.7	;	X-ray structure of the death domain of the human mucosa associated lymphoid tissue lymphoma translocation protein 1
8AEZ	;	2.574	;	X-ray structure of the deglycosylated receptor binding domain of Env glycoprotein of Simian Foamy virus
8E6H	;	2.39	;	X-ray structure of the Deinococcus radiodurans Nramp/MntH divalent transition metal transporter A47W mutant in an occluded, manganese-bound state
8E6L	;	3.12	;	X-ray structure of the Deinococcus radiodurans Nramp/MntH divalent transition metal transporter D296A mutant in an inward-open, manganese-bound state
8E6N	;	2.4	;	X-ray structure of the Deinococcus radiodurans Nramp/MntH divalent transition metal transporter G223W mutant in an outward-open, manganese-bound state
8E6I	;	2.52	;	X-ray structure of the Deinococcus radiodurans Nramp/MntH divalent transition metal transporter M230A mutant in an inward-open, manganese-bound state
8E6M	;	2.48	;	X-ray structure of the Deinococcus radiodurans Nramp/MntH divalent transition metal transporter WT in an inward-open, cadmium-bound state
8E5S	;	2.38	;	X-ray structure of the Deinococcus radiodurans Nramp/MntH divalent transition metal transporter WT in an occluded state
8E60	;	2.38	;	X-ray structure of the Deinococcus radiodurans Nramp/MntH divalent transition metal transporter WT in an occluded, manganese-bound state
8E5V	;	2.36	;	X-ray structure of the Deinococcus radiodurans Nramp/MntH divalent transition metal transporter WTsoak in an occluded state
1NF6	;	2.35	;	X-ray structure of the Desulfovibrio desulfuricans bacterioferritin: the diiron site in different catalytic states (""cycled"" structure: reduced in solution and allowed to reoxidise before crystallisation)
1NF4	;	2.05	;	X-Ray Structure of the Desulfovibrio desulfuricans bacterioferritin: the diiron site in different states (reduced structure)
3MVY	;	2.5	;	X-ray structure of the diatomic oxo-intermediate NikA/1-Int', prior hydroxylation
1OI2	;	1.75	;	X-ray structure of the dihydroxyacetone kinase from Escherichia coli
1OI3	;	2.0	;	X-ray structure of the dihydroxyacetone kinase from Escherichia coli
4USP	;	2.25	;	X-ray structure of the dimeric CCL2 lectin in native form
2YIU	;	2.7	;	X-ray structure of the dimeric cytochrome BC1 complex from the soil bacterium paracoccus denitrificans at 2.7 angstrom resolution
2W6A	;	1.4	;	X-ray Structure of the Dimeric GIT1 Coiled-Coil Domain
1QRI	;	2.6	;	X-RAY STRUCTURE OF THE DNA-ECO RI ENDONUCLEASE COMPLEXES WITH AN E144D MUTATION AT 2.7 A
1QRH	;	2.5	;	X-RAY STRUCTURE OF THE DNA-ECO RI ENDONUCLEASE COMPLEXES WITH AN R145K MUTATION AT 2.7 A
1ERI	;	2.5	;	X-RAY STRUCTURE OF THE DNA-ECO RI ENDONUCLEASE-DNA RECOGNITION COMPLEX: THE RECOGNITION NETWORK AND THE INTEGRATION OF RECOGNITION AND CLEAVAGE
3MW0	;	2.3	;	X-ray structure of the doubly hydroxylated iron complex-NikA species, NikA1/O2
3UMH	;	2.0	;	X-ray structure of the E2 domain of the human amyloid precursor protein (APP) in complex with cadmium
3UMK	;	2.6	;	X-ray structure of the E2 domain of the human amyloid precursor protein (APP) in complex with copper
3UMI	;	2.4	;	X-ray structure of the E2 domain of the human amyloid precursor protein (APP) in complex with zinc
4E2Y	;	1.8	;	X-ray Structure of the E224Q mutant of TcaB9, a C-3'-Methyltransferase, in Complex with S-Adenosyl-L-Homocysteine and Sugar Product
1LOV	;	1.55	;	X-ray structure of the E58A mutant of Ribonuclease T1 complexed with 3'-guanosine monophosphate
5W7J	;	2.202	;	X-ray structure of the E89A variant of ankyrin repeat domain of DHHC17 in complex with Snap25b peptide
5ZF0	;	4.2	;	X-ray Structure of the Electron Transfer Complex between Ferredoxin and Photosystem I
6RJI	;	1.48	;	X-ray structure of the elongation factor P of S. aureus
6TN6	;	1.45	;	X-ray structure of the endo-beta-1,4-mannanase from Thermotoga petrophila
2W0C	;	7.0	;	X-ray structure of the entire lipid-containing bacteriophage PM2
1EHY	;	2.1	;	X-ray structure of the epoxide hydrolase from agrobacterium radiobacter ad1
5MVM	;	3.1	;	X-ray structure of the F14'A -N15'A double mutant of GLIC in complex with propofol
5MUR	;	3.1	;	X-ray structure of the F14'A mutant of GLIC in complex with propofol
6D9G	;	2.3	;	X-ray Structure of the FAB Fragment of 15B8, a Murine Monoclonal Antibody Specific for the Human Serotonin Transporter
5I66	;	1.624	;	X-ray structure of the Fab fragment of 8B6, a murine monoclonal antibody specific for the human serotonin transporter
5DMG	;	2.5	;	X-RAY STRUCTURE OF THE FAB FRAGMENT OF THE ANTI TAU ANTIBODY RB86 IN COMPLEX WITH THE PHOSPHORYLATED TAU PEPTIDE (416-430)
5UIK	;	2.2	;	X-ray structure of the FdtF formyltransferase from salmonella enteric O60 in complex with TDP-Fuc3N and folinic acid
5UIM	;	2.2	;	X-ray structure of the FdtF N-formyltransferase from salmonella enteric O60 in complex with folinic acid and TDP-Qui3N
5UIJ	;	1.9	;	X-ray structure of The FdtF N-formyltransferase from Salmonella enteric O60 in complex with TDP
5UIL	;	2.2	;	X-ray structure of the FdtF N-formyltransferase from Salmonella enterica O60 in complex with TDP-Fuc3N and tetrahydrofolate
4L2D	;	2.07	;	X-ray structure of the Fe(II) form of the iron superoxide dismutase from Pseudoalteromonas haloplanktis
3IIX	;	1.25	;	X-ray structure of the FeFe-hydrogenase maturase HydE from T. maritima in complex with methionine and 5'deoxyadenosine
3IIZ	;	1.62	;	X-ray structure of the FeFe-hydrogenase maturase HydE from T. maritima in complex with S-adenosyl-L-methionine
4RTB	;	2.79	;	X-ray structure of the FeFe-hydrogenase maturase HydG from Carboxydothermus hydrogenoformans
6MEZ	;	1.74	;	X-ray structure of the Fenna-Matthews-Olsen antenna complex from Prosthecochloris aestuarii
6RRA	;	1.4	;	X-RAY STRUCTURE OF THE FERREDOXIN-NADP REDUCTASE FROM BRUCELLA OVIS IN COMPLEX WITH NADP
2BGJ	;	2.1	;	X-Ray Structure of the Ferredoxin-NADP(H) Reductase from Rhodobacter capsulatus at 2.1 Angstroms
2BGI	;	1.68	;	X-Ray Structure of the Ferredoxin-NADP(H) Reductase from Rhodobacter capsulatus complexed with three molecules of the detergent n-heptyl- beta-D-thioglucoside at 1.7 Angstroms
2VNI	;	2.24	;	X-RAY STRUCTURE OF THE FERREDOXIN-NADP(H) REDUCTASE FROM RHODOBACTER CAPSULATUS IN COMPLEX WITH 2P-AMP AT 2.37 ANGSTROMS RESOLUTION
2VNJ	;	2.13	;	X-RAY STRUCTURE OF THE FERREDOXIN-NADP(H) REDUCTASE FROM RHODOBACTER CAPSULATUS IN COMPLEX WITH NADP. FORM I AT 2.13 ANGSTROMS RESOLUTION
2VNH	;	2.27	;	X-RAY STRUCTURE OF THE FERREDOXIN-NADP(H) REDUCTASE FROM RHODOBACTER CAPSULATUS IN COMPLEX WITH NADP. FORM II AT 2.27 ANGSTROMS RESOLUTION
2VNK	;	1.93	;	X-RAY STRUCTURE OF THE FERREDOXIN-NADP(H) REDUCTASE FROM RHODOBACTER CAPSULATUS IN COMPLEX WITH NADP. FORM III AT 1.93 ANGSTROMS RESOLUTION
1QUE	;	1.8	;	X-RAY STRUCTURE OF THE FERREDOXIN:NADP+ REDUCTASE FROM THE CYANOBACTERIUM ANABAENA PCC 7119 AT 1.8 ANGSTROMS
1QUN	;	2.8	;	X-RAY STRUCTURE OF THE FIMC-FIMH CHAPERONE ADHESIN COMPLEX FROM UROPATHOGENIC E.COLI
3ZHH	;	2.85	;	X-ray structure of the full-length beta-lactamase from M.tuberculosis
5JMR	;	2.27	;	X-ray structure of the furin inhibitory antibody Nb14
3DCD	;	1.9	;	X-ray structure of the galactose mutarotase related enzyme Q5FKD7 from Lactobacillus acidophilus at the resolution 1.9A. Northeast Structural Genomics consortium target LaR33.
2ZTA	;	1.8	;	X-RAY STRUCTURE OF THE GCN4 LEUCINE ZIPPER, A TWO-STRANDED, PARALLEL COILED COIL
8EWU	;	1.45	;	X-ray structure of the GDP-6-deoxy-4-keto-D-lyxo-heptose-4-reductase from Campylobacter jejuni HS:15
2BH1	;	2.4	;	X-ray structure of the general secretion pathway complex of the N- terminal domain of EpsE and the cytosolic domain of EpsL of Vibrio cholerae
2P2A	;	2.26	;	X-ray structure of the GluR2 ligand binding core (S1S2J) in complex with 2-Bn-tet-AMPA at 2.26A resolution
1M5B	;	1.85	;	X-RAY STRUCTURE OF THE GLUR2 LIGAND BINDING CORE (S1S2J) IN COMPLEX WITH 2-Me-Tet-AMPA AT 1.85 A RESOLUTION.
1M5E	;	1.46	;	X-RAY STRUCTURE OF THE GLUR2 LIGAND BINDING CORE (S1S2J) IN COMPLEX WITH ACPA AT 1.46 A RESOLUTION
1M5C	;	1.65	;	X-RAY STRUCTURE OF THE GLUR2 LIGAND BINDING CORE (S1S2J) IN COMPLEX WITH Br-HIBO AT 1.65 A RESOLUTION
1M5F	;	1.95	;	X-RAY STRUCTURE OF THE GLUR2 LIGAND BINDING CORE (S1S2J-Y702F) IN COMPLEX WITH ACPA AT 1.95 A RESOLUTION
1M5D	;	1.73	;	X-RAY STRUCTURE OF THE GLUR2 LIGAND BINDING CORE (S1S2J-Y702F) IN COMPLEX WITH Br-HIBO AT 1.73 A RESOLUTION
1NNK	;	1.85	;	X-ray structure of the GluR2 ligand-binding core (S1S2J) in complex with (S)-ATPA at 1.85 A resolution. Crystallization with zinc ions.
1NNP	;	1.9	;	X-ray structure of the GluR2 ligand-binding core (S1S2J) in complex with (S)-ATPA at 1.9 A resolution. Crystallization without zinc ions.
1SYH	;	1.8	;	X-RAY STRUCTURE OF THE GLUR2 LIGAND-BINDING CORE (S1S2J) IN COMPLEX WITH (S)-CPW399 AT 1.85 A RESOLUTION.
1MQD	;	1.46	;	X-ray structure of the GluR2 ligand-binding core (S1S2J) in complex with (S)-Des-Me-AMPA at 1.46 A resolution. Crystallization in the presence of lithium sulfate.
1MS7	;	1.97	;	X-ray structure of the GluR2 ligand-binding core (S1S2J) in complex with (S)-Des-Me-AMPA at 1.97 A resolution, Crystallization in the presence of zinc acetate
2AIX	;	2.17	;	X-ray structure of the GLUR2 ligand-binding core (S1S2J) in complex with (s)-thio-atpa at 2.2 a resolution.
1N0T	;	2.1	;	X-ray structure of the GluR2 ligand-binding core (S1S2J) in complex with the antagonist (S)-ATPO at 2.1 A resolution.
1S50	;	1.65	;	X-ray structure of the GluR6 ligand binding core (S1S2A) in complex with glutamate at 1.65 A resolution
3DA1	;	2.7	;	X-Ray structure of the glycerol-3-phosphate dehydrogenase from Bacillus halodurans complexed with FAD. Northeast Structural Genomics Consortium target BhR167.
6SEX	;	1.78	;	X-ray structure of the gold/lysozyme adduct formed upon 21h exposure of protein crystals to compound 1
6SEU	;	1.95	;	X-ray structure of the gold/lysozyme adduct formed upon 21h exposure of protein crystals to compound 2
6SEZ	;	2.22	;	X-ray structure of the gold/lysozyme adduct formed upon 24h exposure of protein crystals to compound 1
6SEW	;	2.12	;	X-ray structure of the gold/lysozyme adduct formed upon 24h exposure of protein crystals to compound 2
6SET	;	1.9	;	X-ray structure of the gold/lysozyme adduct formed upon 3 days exposure of protein crystals to compound 1
4V5T	;	3.0	;	X-ray structure of the Grapevine Fanleaf virus
4E2W	;	1.5	;	X-ray Structure of the H181N mutant of TcaB9, a C-3'-Methyltransferase, in Complex with S-Adenosyl-L-Homocysteine and Sugar Product
4E30	;	1.5	;	X-ray Structure of the H181N/E224Q double mutant of TcaB9, a C-3'-Methyltransferase, in Complex with S-Adenosyl-L-Homocysteine and dTDP
4E2Z	;	1.41	;	X-ray Structure of the H225N mutant of TcaB9, a C-3'-Methyltransferase, in Complex with S-Adenosyl-L-Homocysteine and Sugar Product
5NJY	;	2.95	;	X-ray structure of the H235Q mutant of GLIC
5MZT	;	2.65	;	X-ray structure of the H235Q mutant of GLIC in complex with bromoform
5MZR	;	2.65	;	X-ray structure of the H235Q mutant of GLIC in complex with propofol
5OMX	;	2.32	;	X-ray Structure of the H2A-N38C Nucleosome Core Particle
1LOW	;	1.9	;	X-ray structure of the H40A mutant of Ribonuclease T1 complexed with 3'-guanosine monophosphate
1LOY	;	1.55	;	X-ray structure of the H40A/E58A mutant of Ribonuclease T1 complexed with 3'-guanosine monophosphate
1FLC	;	3.2	;	X-RAY STRUCTURE OF THE HAEMAGGLUTININ-ESTERASE-FUSION GLYCOPROTEIN OF INFLUENZA C VIRUS
1ZO8	;	1.9	;	X-ray Structure of the haloalcohol dehalogenase HheC of Agrobacterium radiobacter AD1 in complex with (S)-para-nitrostyrene oxide, with a water molecule in the halide-binding site
7ZIV	;	1.4	;	X-ray structure of the haloalkane dehalogenase dead variant HaloTag7-D106A bound to a chloroalkane tetramethylrhodamine fluorophore ligand (CA-TMR)
7ZIX	;	2.39	;	X-ray structure of the haloalkane dehalogenase HaloTag7 bound to a butylmethanesulfonamide tetramethylrhodamine ligand (TMR-S4)
7ZIW	;	1.99	;	X-ray structure of the haloalkane dehalogenase HaloTag7 bound to a butyltrifluoromethanesulfonamide tetramethylrhodamine ligand (TMR-T4)
7ZJ0	;	1.5	;	X-ray structure of the haloalkane dehalogenase HaloTag7 bound to a pentylmethanesulfonamide tetramethylrhodamine ligand (TMR-S5)
7ZIY	;	1.7	;	X-ray structure of the haloalkane dehalogenase HaloTag7 bound to a pentyltrifluoromethanesulfonamide tetramethylrhodamine ligand (TMR-T5)
8B6N	;	2.3	;	X-ray structure of the haloalkane dehalogenase HaloTag7 circular permutated at positions 141-156 (cpHaloTagDelta)
8B6O	;	2.0	;	X-ray structure of the haloalkane dehalogenase HaloTag7 circular permutated at positions 141-156 (cpHaloTagDelta) fused to M13
8B6P	;	1.1	;	X-ray structure of the haloalkane dehalogenase HaloTag7 circular permutated at positions 154-156 (cpHaloTag7_154-156)
8B6S	;	1.8	;	X-ray structure of the haloalkane dehalogenase HaloTag7 fusion to the green fluorescent protein GFP (ChemoG1) labeled with a chloroalkane tetramethylrhodamine fluorophore substrate
8B6R	;	1.5	;	X-ray structure of the haloalkane dehalogenase HaloTag7 labeled with a chloroalkane Cyanine3 fluorophore substrate
6Y7B	;	3.1	;	X-ray structure of the Haloalkane dehalogenase HaloTag7 labeled with a chloroalkane-carbopyronine fluorophore substrate
6Y7A	;	1.4	;	X-ray structure of the Haloalkane dehalogenase HaloTag7 labeled with a chloroalkane-tetramethylrhodamine fluorophore substrate
8B6Q	;	2.6	;	X-ray structure of the haloalkane dehalogenase HaloTag7 with an insertion of Calmodulin-M13 fusion at position 154-156 that mimic the structure of CaProLa, an calcium gated protein labeling technology
7PCW	;	2.3	;	X-RAY STRUCTURE OF THE HALOALKANE DEHALOGENASE HALOTAG7-M175W LABELED WITH A CHLOROALKANE-TETRAMETHYLRHODAMINE FLUOROPHORE SUBSTRATE
6ZVU	;	1.4	;	X-RAY STRUCTURE OF THE HALOALKANE DEHALOGENASE HALOTAG7-P174L LABELED WITH A CHLOROALKANE-TETRAMETHYLRHODAMINE FLUOROPHORE SUBSTRATE
6ZVV	;	1.4	;	X-RAY STRUCTURE OF THE HALOALKANE DEHALOGENASE HALOTAG7-P174W LABELED WITH A CHLOROALKANE-TETRAMETHYLRHODAMINE FLUOROPHORE SUBSTRATE
6ZVW	;	1.6	;	X-RAY STRUCTURE OF THE HALOALKANE DEHALOGENASE HALOTAG7-Q165H LABELED WITH A CHLOROALKANE-TETRAMETHYLRHODAMINE FLUOROPHORE SUBSTRATE
6ZVX	;	1.4	;	X-RAY STRUCTURE OF THE HALOALKANE DEHALOGENASE HALOTAG7-Q165H-P174L LABELED WITH A CHLOROALKANE-TETRAMETHYLRHODAMINE FLUOROPHORE SUBSTRATE
6ZVY	;	1.4	;	X-RAY STRUCTURE OF THE HALOALKANE DEHALOGENASE HALOTAG7-Q165H-P174R LABELED WITH A CHLOROALKANE-TETRAMETHYLRHODAMINE FLUOROPHORE SUBSTRATE
7PCX	;	1.4	;	X-RAY STRUCTURE OF THE HALOALKANE DEHALOGENASE HALOTAG7-Q165W LABELED WITH A CHLOROALKANE-TETRAMETHYLRHODAMINE FLUOROPHORE SUBSTRATE
6ZCC	;	1.52	;	X-ray structure of the Haloalkane dehalogenase HOB (HaloTag7-based Oligonucleotide Binder) labeled with a chloroalkane-tetramethylrhodamine fluorophore substrate
6GW5	;	2.52	;	X-ray structure of the Helicobacter pylori SabA adhesin domain
2VZW	;	2.3	;	X-ray structure of the heme-bound GAF domain of sensory histidine kinase DosT of Mycobacterium tuberculosis
7TBP	;	2.151	;	X-ray structure of the HIV-1 myristoylated matrix protein
1KO7	;	1.95	;	X-ray structure of the HPr kinase/phosphatase from Staphylococcus xylosus at 1.95 A resolution
4L3B	;	6.5	;	X-ray structure of the HRV2 A particle uncoating intermediate
3TN9	;	3.0	;	X-ray structure of the HRV2 empty capsid (B-particle)
7WC3	;	1.5	;	X-ray structure of the human adipocyte fatty acid-binding protein complexed with the fluorescent probe HA728
1TJT	;	2.19	;	X-ray structure of the human alpha-actinin isoform 3 at 2.2A resolution
1H8D	;	1.4	;	X-ray structure of the human alpha-thrombin complex with a tripeptide phosphonate inhibitor.
5KXI	;	3.941	;	X-ray structure of the human Alpha4Beta2 nicotinic receptor
7FC4	;	1.5	;	X-ray structure of the human heart fatty acid-binding protein complexed with S-Ibuprofen
7FDX	;	0.95	;	X-ray structure of the human heart fatty acid-binding protein complexed with the fluorescent probe 8-Anilino-1-naphthalenesulfonic acid (ANS)
7EGO	;	1.21	;	X-ray structure of the human heart fatty acid-binding protein complexed with the fluorescent probe HA527
1I2T	;	1.04	;	X-RAY STRUCTURE OF THE HUMAN HYPERPLASTIC DISCS PROTEIN: AN ORTHOLOG OF THE C-TERMINAL DOMAIN OF POLY(A)-BINDING PROTEIN
6I3V	;	1.98	;	x-ray structure of the human mitochondrial PRELID1 in complex with TRIAP1
6I4Y	;	2.91	;	X-ray structure of the human mitochondrial PRELID3b-TRIAP1 complex
3E8N	;	2.5	;	X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) complexed with a potent inhibitor RDEA119 and MgATP
3EQI	;	1.9	;	X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a binary complex with ADP and MG2P
3EQD	;	2.1	;	X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a binary complex with ATP-GS and MG2P
3EQF	;	2.7	;	X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a binary complex with K252A and MG2P
1S9J	;	2.4	;	X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a complex with ligand and MgATP
2P55	;	2.8	;	X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a complex with ligand and MgATP
3DY7	;	2.7	;	X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a complex with ligand and MgATP
3EQB	;	2.62	;	X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a complex with ligand and MgATP
3EQC	;	1.8	;	X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a ternary complex with compound 1, ATP-GS AND MG2P
3EQG	;	2.5	;	X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a ternary complex with PD, ADP AND MG2P
3EQH	;	2.0	;	X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a ternary complex with U0126, ADP and MG2P
3VVH	;	2.0	;	X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in complex with an inhibitor and MgATP
1S9I	;	3.2	;	X-ray structure of the human mitogen-activated protein kinase kinase 2 (MEK2)in a complex with ligand and MgATP
4UT2	;	1.96	;	X-ray structure of the human PP1 gamma catalytic subunit treated with ascorbate
4UT3	;	2.19	;	X-ray structure of the human PP1 gamma catalytic subunit treated with hydrogen peroxide
6QD5	;	2.398	;	X-ray Structure of the Human Urea Channel SLC14A1/UT1
8OVP	;	1.7	;	X-ray structure of the iAspSnFR in complex with L-aspartate
8B6T	;	2.0	;	X-ray structure of the interface optimized haloalkane dehalogenase HaloTag7 fusion to the green fluorescent protein GFP (ChemoG5-TMR) labeled with a chloroalkane tetramethylrhodamine fluorophore substrate
7D6P	;	2.38	;	X-ray structure of the intermolecular complex of Clostridium perfringens sortase C with the C-terminal cell wall sorting signal motif.
3LIO	;	1.5	;	X-ray structure of the iron superoxide dismutase from pseudoalteromonas haloplanktis (crystal form I)
3LJ9	;	2.1	;	X-ray structure of the iron superoxide dismutase from pseudoalteromonas haloplanktis in complex with sodium azide
2JI3	;	1.95	;	X-ray structure of the iron-peroxide intermediate of superoxide reductase (E114A mutant) from Desulfoarculus baarsii
4YIP	;	2.15	;	X-ray structure of the iron/manganese cambialistic superoxide dismutase from Streptococcus mutans
4YIO	;	1.6	;	X-ray structure of the iron/manganese cambialistic superoxide dismutase from Streptococcus thermophilus
3NYS	;	1.45	;	X-ray structure of the K185A mutant of WbpE (WlbE) from pseudomonas aeruginosa in complex with PLP at 1.45 angstrom resolution
6YMH	;	2.417	;	X-ray structure of the K72I, Y129F, R133L, H199A quadruple mutant of PNP-oxidase from E. coli in complex with PLP
6YLZ	;	1.558	;	X-ray structure of the K72I,Y129F,R133L, H199A quadruple mutant of PNP-oxidase from E. coli
5T6B	;	2.0	;	X-ray structure of the KijD1 C3-methyltransfeerase, converted to monomeric form
5T67	;	1.6	;	x-ray structure of the KijD1 C3-methyltransferase from Actinomadura kijaniata in complex with SAH and dTDP-sugar product
1ORS	;	1.9	;	X-ray structure of the KvAP potassium channel voltage sensor in complex with an Fab
7MFO	;	1.7	;	X-ray structure of the L136 Aminotransferase from Acanthamoeba polyphaga mimivirus in the presence of TDP and PMP
3ILN	;	1.95	;	X-ray structure of the laminarinase from Rhodothermus marinus
6GEB	;	3.19	;	X-ray structure of the Legionella pneumophila ATPase DotB
2YAU	;	3.5	;	X-ray structure of the Leishmania infantum tryopanothione reductase in complex with auranofin
4D47	;	2.77	;	X-ray structure of the levansucrase from Erwinia amylovora
6FRW	;	1.52	;	X-ray structure of the levansucrase from Erwinia tasmaniensis
6RV5	;	1.58	;	X-ray structure of the levansucrase from Erwinia tasmaniensis in complex with levanbiose
3FL3	;	1.6	;	X-ray structure of the ligand free non covalent swapped form of the A19P/Q28L/K31C/S32C mutant of bovine pancreatic ribonuclease
3PD9	;	2.1	;	X-ray structure of the ligand-binding core of GluA2 in complex with (R)-5-HPCA at 2.1 A resolution
3PD8	;	2.476	;	X-ray structure of the ligand-binding core of GluA2 in complex with (S)-7-HPCA at 2.5 A resolution
6L93	;	4.47	;	X-ray structure of the ligand-free human TRPV1 ankyrin repeat domain
3T50	;	1.64	;	X-ray structure of the LOV domain from the LOV-HK sensory protein from Brucella abortus (dark state).
4OOO	;	2.15	;	X-ray structure of the lysozyme derivative of tetrakis(acetato)chlorido diruthenium(II,III) complex
7QVD	;	1.7	;	X-ray structure of the lytic transglycosylase SltB2 from Pseudomonas aeruginosa
2BH4	;	1.55	;	X-ray structure of the M100K variant of ferric cyt c-550 from Paracoccus versutus determined at 100 K.
2BH5	;	1.95	;	X-ray structure of the M100K variant of ferric cyt c-550 from Paracoccus versutus determined at 295 K.
5MZQ	;	2.8	;	X-ray structure of the M205W mutant of GLIC in complex with bromoform
5MVN	;	3.49	;	X-ray structure of the M205W mutant of GLIC in complex with propofol
5M4V	;	1.06	;	X-ray structure of the mambaquaretin-1, a selective antagonist of the vasopressin type 2 receptor
5A08	;	2.21	;	X-ray structure of the mannosyltransferase Ktr4p from S. cerevisiae
5A07	;	1.9	;	X-ray structure of the mannosyltransferase Ktr4p from S. cerevisiae in complex with GDP
3EPV	;	1.742	;	X-ray Structure of the Metal-sensor CnrX in both the Apo- and Copper-bound Forms
8SJJ	;	1.781	;	X-ray structure of the metastable SEPT14-SEPT7 heterodimeric coiled coil
3KUN	;	1.26	;	X-ray structure of the metcyano form of dehaloperoxidase from amphitrite ornata: evidence for photoreductive lysis of iron-cyanide bond
3KUO	;	1.26	;	X-ray structure of the metcyano form of dehaloperoxidase from amphitrite ornata: evidence for photoreductive lysis of iron-cyanide bond
5LAA	;	3.0	;	X-RAY STRUCTURE OF THE METHYLTRANSFERASE SUBUNIT A FROM METHANOTHERMUS FERVIDUS IN COMPLEX WITH COBALAMIN
8DS5	;	1.926	;	X-ray structure of the MK5890 Fab - CD27 antibody-antigen complex
5F99	;	2.63	;	X-ray Structure of the MMTV-A Nucleosome Core Particle
6XRV	;	1.43	;	X-ray structure of the monoclinic crystal form at 1.43 A resolution of lipase from Thermomyces (Humicola) lanuginosa at 173 K
6XS3	;	2.48	;	X-ray structure of the monoclinic crystal form at 2.48 A resolution of lipase from Thermomyces (Humicola) lanuginosa at 298 K
4CBR	;	2.3	;	X-ray structure of the more stable human AGXT triple mutant (AGXT_HEM)
4PIR	;	3.5	;	X-ray structure of the mouse serotonin 5-HT3 receptor
6KCR	;	3.5	;	X-ray structure of the MtlR-HPr complex from Escherichia coli
3LQE	;	2.0	;	X-Ray Structure of the Murine Norovirus (MNV)-1 Capsid Protein Protruding (P) Domain
3KPF	;	2.9	;	X-ray structure of the mutant Lys300Met of polyamine oxidase from Zea mays
3L1R	;	3.2	;	X-ray structure of the mutant lys300met of polyamine oxidase from zea mays in complex with spermidine
3KU9	;	3.2	;	X-ray structure of the mutant lys300met of polyamine oxidase from zea mays in complex with spermine
4YPJ	;	2.5	;	X-ray Structure of The Mutant of Glycoside Hydrolase
2C86	;	3.0	;	x-ray structure of the N and C-terminal domain of coronavirus nucleocapsid protein.
7L7Z	;	1.55	;	x-ray structure of the N-acetyltransferase Pcryo_0637 from psychrobacter cryohalolentis in the presence of coenzyme A and UDP-di-N-acetyl-bacillosamine
7L7Y	;	1.3	;	x-ray structure of the N-acetyltransferase Pcryo_0637 from psychrobacter cryohalolentis in the presence of UDP and acetyl-conezyme A
4XD0	;	1.8	;	X-ray structure of the N-formyltransferase QdtF from Providencia alcalifaciens
4XCZ	;	1.5	;	X-ray structure of the N-formyltransferase QdtF from Providencia alcalifaciens in complex with TDP-Qui3n and N5-THF
4XD1	;	1.5	;	X-ray structure of the N-formyltransferase QdtF from Providencia alcalifaciens, W305A mutant, in the presence of TDP-Qui3N and N5-THF
2BQQ	;	2.2	;	X-ray Structure of the N-terminal Domain of Human Doublecortin
5IN7	;	2.48	;	X-RAY STRUCTURE OF THE N-TERMINAL DOMAIN OF HUMAN DOUBLECORTIN
5IO9	;	1.3	;	X-RAY STRUCTURE OF THE N-TERMINAL DOMAIN OF HUMAN DOUBLECORTIN
5IOI	;	2.4	;	X-RAY STRUCTURE OF THE N-TERMINAL DOMAIN OF HUMAN DOUBLECORTIN
5IKC	;	2.06	;	X-RAY STRUCTURE OF THE N-TERMINAL DOMAIN OF HUMAN DOUBLECORTIN in complex with FAB
4UYR	;	0.89	;	X-ray structure of the N-terminal domain of the flocculin Flo11 from Saccharomyces cerevisiae
4UYS	;	1.05	;	X-ray structure of the N-terminal domain of the flocculin Flo11 from Saccharomyces cerevisiae
4UYT	;	1.03	;	X-ray structure of the N-terminal domain of the flocculin Flo11 from Saccharomyces cerevisiae
2XJQ	;	1.35	;	X-ray structure of the N-terminal domain of the flocculin Flo5 from Saccharomyces cerevisiae
2XJS	;	1.3	;	X-ray structure of the N-terminal domain of the flocculin Flo5 from Saccharomyces cerevisiae in complex with calcium and a1,2-mannobiose
2XJT	;	1.2	;	X-ray structure of the N-terminal domain of the flocculin Flo5 from Saccharomyces cerevisiae in complex with calcium and Man5(D1)
2XJR	;	1.25	;	X-ray structure of the N-terminal domain of the flocculin Flo5 from Saccharomyces cerevisiae in complex with calcium and Man5(D2-D3)
2XJP	;	0.95	;	X-ray structure of the N-terminal domain of the flocculin Flo5 from Saccharomyces cerevisiae in complex with calcium and mannose
2XJV	;	1.74	;	X-ray structure of the N-terminal domain of the flocculin Flo5 from Saccharomyces cerevisiae with mutation D201T in complex with calcium and glucose
2XJU	;	1.7	;	X-ray structure of the N-terminal domain of the flocculin Flo5 from Saccharomyces cerevisiae with mutation S227A in complex with calcium and a1,2-mannobiose
1G6G	;	1.6	;	X-RAY STRUCTURE OF THE N-TERMINAL FHA DOMAIN FROM S. CEREVISIAE RAD53P IN COMPLEX WITH A PHOSPHOTHREONINE PEPTIDE AT 1.6 A RESOLUTION
1U2H	;	0.96	;	X-ray Structure of the N-terminally truncated human APEP-1
2J8A	;	3.0	;	X-ray structure of the N-terminus RRM domain of Set1
6EMX	;	3.2	;	X-ray structure of the N15'C mutant of GLIC in complex with bromoform
5NKJ	;	3.74	;	X-ray structure of the N239C mutant of GLIC
8V4G	;	2.0	;	X-ray structure of the NADP-dependent reductase from Campylobacter jejuni responsible for the synthesis of CDP-glucitol in the presence of CDP and NADP
8V4H	;	2.2	;	X-ray structure of the NADP-dependent reductase from Campylobacter jejuni responsible for the synthesis of CDP-glucitol in the presence of CDP-glucitol
8SKP	;	1.3	;	X-ray structure of the NDM-4 beta-lactamase from Klebsiella pneumonia in complex with 1-hydroxypyridine-2(1H)-thione-6-carboxylic acid
8SKO	;	1.3	;	X-ray structure of the NDM-4 beta-lactamase from Klebsiella pneumonia with L-Captopril bound
8SK2	;	1.3	;	X-ray structure of the NDM-4 beta-lactamase from Klebsiella pneumonia, apo form
1L4A	;	2.95	;	X-RAY STRUCTURE OF THE NEURONAL COMPLEXIN/SNARE COMPLEX FROM THE SQUID LOLIGO PEALEI
3FL1	;	1.9	;	X-ray structure of the non covalent swapped form of the A19P/Q28L/K31C/S32C mutant of bovine pancreatic ribonuclease in complex with 2'-DEOXYCYTIDINE-2'-DEOXYGUANOSINE-3',5'-MONOPHOSPHATE
3FL0	;	1.94	;	X-ray structure of the non covalent swapped form of the Q28L/K31C/S32C mutant of bovine pancreatic ribonuclease in complex with 2'-DEOXYCYTIDINE-2'-DEOXYGUANOSINE-3',5'-MONOPHOSPHATE
3FKZ	;	1.99	;	X-ray structure of the non covalent swapped form of the S16G/T17N/A19P/A20S/K31C/S32C mutant of bovine pancreatic ribonuclease
3PTF	;	2.7	;	X-ray structure of the non-covalent complex between UbcH5A and Ubiquitin
1EQZ	;	2.5	;	X-RAY STRUCTURE OF THE NUCLEOSOME CORE PARTICLE AT 2.5 A RESOLUTION
1KX3	;	2.0	;	X-Ray Structure of the Nucleosome Core Particle, NCP146, at 2.0 A Resolution
1KX4	;	2.6	;	X-Ray Structure of the Nucleosome Core Particle, NCP146b, at 2.6 A Resolution
1KX5	;	1.94	;	X-Ray Structure of the Nucleosome Core Particle, NCP147, at 1.9 A Resolution
4OKI	;	1.5	;	X-ray structure of the nucleotide-binding subdomain of the enoylreductase domain of PpsC from Mycobacterium tuberculosis
2G1Z	;	3.11	;	X-ray structure of the oligonucleotide sequence d(AAATTT)
1KV6	;	2.7	;	X-ray structure of the orphan nuclear receptor ERR3 ligand-binding domain in the constitutively active conformation
1K4W	;	1.9	;	X-ray structure of the orphan nuclear receptor ROR beta ligand-binding domain in the active conformation
6I29	;	2.1	;	X-ray structure of the p53-MDM2 inhibitor NMI801 bound to HDM2 at 2.1A resolution
7L7X	;	1.3	;	X-ray structure of the Pcryo_0638 aminotransferase from Psychrobacter cryohalolentis
3EHZ	;	3.1	;	X-ray structure of the pentameric ligand gated ion channel of Gloebacter violaceus (GLIC) in a presumptive open conformation
7ZJR	;	2.50312	;	X-ray structure of the periplasmic region of PilJ from P. aeruginosa
3K63	;	2.494	;	X-ray structure of the PF04200 domain from Q9PRA0_UREPA protein of Ureaplasma parvum. NESG target UuR17a.
5BJY	;	1.6	;	x-ray structure of the PglF 4,5-dehydratase from campylobacter jejuni, variant M405Y, in complex with UDP
5BJW	;	1.6	;	X-ray structure of the PglF 4,6-dehydratase from campylobacter jejuni, T595S variant, in complex with UDP
5BJX	;	1.6	;	X-ray structure of the PglF 4,6-dehydratase from campylobacter jejuni, variant T395V, in complex with UDP
5BJU	;	2.0	;	X-ray structure of the PglF dehydratase from Campylobacter jejuni in complex with UDP and NAD(H)
5BJV	;	1.8	;	X-ray structure of the PglF UDP-N-acetylglucosamine 4,6-dehydratase from Campylobacterjejuni, D396N/K397A variant in complex with UDP-N-acrtylglucosamine
7S00	;	3.3	;	X-ray structure of the phage AR9 non-virion RNA polymerase core
7S01	;	3.4	;	X-ray structure of the phage AR9 non-virion RNA polymerase holoenzyme in complex with a forked oligonucleotide containing the P077 promoter
7OBE	;	3.0	;	X-ray structure of the phosphatase PAPP5 from Arabidopsis thaliana
6AE9	;	1.47	;	X-ray structure of the photosystem II phosphatase PBCP
6EQW	;	1.994	;	X-ray structure of the proprotein convertase furin bound with the competitive inhibitor 4-aminomethyl-phenylacetyl-Arg-Val-Arg-Amba
6EQX	;	1.994	;	X-ray structure of the proprotein convertase furin bound with the competitive inhibitor Arg-Arg-Arg-Val-Arg-Amba
6EQV	;	1.895	;	X-ray structure of the proprotein convertase furin bound with the competitive inhibitor Phac-Cit-Val-Arg-Amba
2QGG	;	2.4	;	X-Ray structure of the protein Q6F7I0 from Acinetobacter calcoaceticus AmMS 248. Northeast Structural Genomics Consortium target AsR73.
2RD1	;	2.3	;	X-Ray structure of the protein Q7CQI7. Northeast Structural Genomics Consortium target StR87A
3E29	;	2.4	;	X-Ray structure of the protein Q7WE92_BORBR from thioesterase superfamily. Northeast Structural Genomics Consortium Target BoR214A.
2RB6	;	2.5	;	X-Ray structure of the protein Q8EI81. Northeast Structural Genomics Consortium target SoR78A
2P6Y	;	1.63	;	X-ray structure of the protein Q9KM02_VIBCH from Vibrio cholerae at the resolution 1.63 A. Northeast Structural Genomics Consortium target VcR80.
4OOT	;	1.8	;	X-ray structure of the protein-gold adduct formed upon reaction of Aubipic with hen egg white lysozyme
6KOB	;	3.6	;	X-ray Structure of the proton-pumping cytochrome aa3-600 menaquinol oxidase from Bacillus subtilis
6KOE	;	3.75	;	X-ray Structure of the proton-pumping cytochrome aa3-600 menaquinol oxidase from Bacillus subtilis
6KOC	;	3.8	;	X-ray Structure of the proton-pumping cytochrome aa3-600 menaquinol oxidase from Bacillus subtilis complexed with 3-iodo-N-oxo-2-heptyl-4-hydroxyquinoline
7L81	;	1.3	;	x-ray structure of the psychrobacter cryohalolentis N-acetyltransferase Pcryo_0637 in the presence of coenzyme A and
7L82	;	1.4	;	x-ray structure of the psychrobacter cryohalolentis Pcryo_0637 N-acetyltransferase in the presene of its reaction tetrahedral intermediate
3E5Z	;	2.01	;	X-Ray structure of the putative gluconolactonase in protein family PF08450. Northeast Structural Genomics Consortium target DrR130.
1WYZ	;	2.5	;	X-Ray structure of the putative methyltransferase from Bacteroides thetaiotaomicron VPI-5482 at the resolution 2.5 A. Norteast Structural Genomics Consortium target Btr28
1ZKD	;	2.1	;	X-Ray structure of the putative protein Q6N1P6 from Rhodopseudomonas palustris at the resolution 2.1 A , Northeast Structural Genomics Consortium target RpR58
2OBK	;	2.7	;	X-Ray structure of the putative Se binding protein from Pseudomonas fluorescens. Northeast Structural Genomics Consortium target PlR6.
3C37	;	1.7	;	X-ray structure of the putative Zn-dependent peptidase Q74D82 at the resolution 1.7 A. Northeast Structural Genomics Consortium target GsR143A
2RA2	;	1.9	;	X-Ray structure of the Q7CPV8 protein from Salmonella typhimurium at the resolution 1.9 A. Northeast Structural Genomics Consortium target StR88A
6VLO	;	2.05	;	X-ray Structure of the R141 Sugar 4,6-dehydratase from Acanthamoeba polyphaga Minivirus
1T6M	;	2.107	;	X-ray Structure of the R70D PI-PLC enzyme: Insight into the role of calcium and surrounding amino acids on active site geometry and catalysis.
6Y1X	;	1.95	;	X-ray structure of the radical SAM protein NifB, a key nitrogenase maturating enzyme
8AIC	;	2.8	;	X-ray structure of the receptor binding domain of Env glycoprotein of Simian Foamy virus
3MVX	;	1.7	;	X-ray structure of the reduced NikA/1 hybrid, NikA/1-Red
3K9R	;	1.96	;	X-ray structure of the Rhodanese-like domain of the Alr3790 protein from Anabaena sp. Northeast Structural Genomics Consortium Target NsR437c.
6XOK	;	1.3	;	X-ray structure of the rhombohedral form of the lipase from Thermomyces lanuginosa at 1.3 A resolution
1XLY	;	1.95	;	X-RAY STRUCTURE OF THE RNA-BINDING PROTEIN SHE2p
1UOC	;	2.3	;	X-ray structure of the RNase domain of the yeast Pop2 protein
4QI0	;	1.94	;	X-ray structure of the ROQ domain from murine Roquin-1
4QI2	;	3.0	;	X-ray structure of the ROQ domain from murine Roquin-1 in complex with a 23-mer Tnf-CDE RNA
5AJB	;	1.8	;	X-ray structure of the RSL lectin in complex with Lewis X tetrasaccahride
6CU1	;	3.0	;	X-ray structure of the S. typhimurium YrlA effector-binding module
6AWN	;	3.62	;	X-ray structure of the S439T human serotonin transporter complexed with paroxetine at the central site
2RKN	;	1.6	;	X-ray structure of the self-defense and signaling protein DIR1 from Arabidopsis taliana
4E3Y	;	0.95	;	X-ray structure of the Serratia marcescens endonuclease at 0.95 A resolution
8OVN	;	2.6	;	X-ray structure of the SF-iGluSnFR-S72A
8OVO	;	1.7	;	X-ray structure of the SF-iGluSnFR-S72A in complex with L-aspartate
8Q0S	;	1.19	;	X-ray structure of the single chain monellin derivative MNEI
1OIV	;	1.98	;	X-ray structure of the small G protein Rab11a in complex with GDP
1OIX	;	1.7	;	X-ray structure of the small G protein Rab11a in complex with GDP and Pi
1OIW	;	2.05	;	X-ray structure of the small G protein Rab11a in complex with GTPgammaS
6ZFW	;	1.58	;	X-ray structure of the soluble N-terminal domain of T. cruzi PEX-14
2XBK	;	1.95	;	X-ray structure of the substrate-bound cytochrome P450 PimD - a polyene macrolide antibiotic pimaricin epoxidase
2X9P	;	2.1	;	X-ray structure of the substrate-free cytochrome P450 PimD - a polyene macrolide antibiotic pimaricin epoxidase
5L1R	;	2.0	;	X-ray Structure of the Substrate-free Cytochrome P450 PntM
2WM5	;	1.5	;	X-ray structure of the substrate-free Mycobacterium tuberculosis cytochrome P450 CYP124
2XN8	;	1.64	;	X-RAY STRUCTURE OF THE SUBSTRATE-FREE MYCOBACTERIUM TUBERCULOSIS CYTOCHROME P450 CYP125
2X5L	;	1.48	;	X-RAY STRUCTURE OF THE SUBSTRATE-FREE MYCOBACTERIUM TUBERCULOSIS CYTOCHROME P450 CYP125, ALTERNATIVE CRYSTAL FORM
1S2O	;	1.4	;	X-Ray structure of the sucrose-phosphatase (SPP) from Synechocystis sp. PCC6803 at 1.40 A resolution
1TJ3	;	2.8	;	X-Ray structure of the Sucrose-Phosphatase (SPP) from Synechocystis sp. PCC6803 in a closed conformation
1U2S	;	2.5	;	X-Ray structure of the sucrose-phosphatase (SPP) from Synechocystis sp. PCC6803 in complex with glucose
1TJ4	;	2.7	;	X-Ray structure of the Sucrose-Phosphatase (SPP) from Synechocystis sp. PCC6803 in complex with sucrose
1TJ5	;	2.2	;	X-Ray structure of the Sucrose-Phosphatase (SPP) from Synechocystis sp. PCC6803 in complex with sucrose and phosphate
1U2T	;	2.9	;	X-Ray structure of the sucrose-phosphatase (SPP) from Synechocystis sp. PCC6803 in complex with sucrose6P
2B1R	;	2.2	;	X-ray structure of the sucrose-phosphatase (SPP) from Synechocystis sp.PCC6803 in complex with cellobiose
2D2V	;	2.5	;	X-ray structure of the sucrose-phosphatase (SPP) from Synechocystis sp.PCC6803 in complex with maltose
2B1Q	;	2.2	;	X-ray structure of the sucrose-phosphatase (SPP) from Synechocystis sp.PCC6803 in complex with trehalose
5BSZ	;	2.0	;	X-ray structure of the sugar N-methyltransferase KedS8 from Streptoalloteichus sp ATCC 53650
1P5U	;	1.99	;	X-ray structure of the ternary Caf1M:Caf1:Caf1 chaperone:subunit:subunit complex
1MVK	;	2.5	;	X-ray structure of the tetrameric mutant of the B1 domain of streptococcal protein G
5EY3	;	1.905	;	X-ray structure of the thymidine phosphorylase from Salmonella typhimurium in complex with cytidine and sulphate
4YEK	;	2.55	;	X-ray structure of the thymidine phosphorylase from Salmonella typhimurium in complex with thymidine
4YYY	;	2.43	;	X-ray structure of the thymidine phosphorylase from Salmonella typhimurium in complex with uridine
6HTK	;	2.0	;	X-ray structure of the tryptophan lyase NosL in complex with (R)-(+)-indoline-2-carboxylate
6HTM	;	1.7	;	X-ray structure of the tryptophan lyase NosL in complex with bound tryptamin
4R33	;	1.78	;	X-ray structure of the tryptophan lyase NosL with Tryptophan and S-adenosyl-L-homocysteine bound
4R34	;	1.8	;	X-ray structure of the tryptophan lyase NosL with Tryptophan, 5'-deoxyadenosine and methionine bound
5I6Z	;	4.53	;	X-ray structure of the ts2 human serotonin transporter
5I74	;	3.395	;	X-ray structure of the ts3 human serotonin transporter complexed with Br-citalopram at the central site
6AWP	;	3.8	;	X-ray structure of the ts3 human serotonin transporter complexed with fluvoxamine at the central site
5I6X	;	3.14	;	X-ray structure of the ts3 human serotonin transporter complexed with paroxetine at the central site
5I73	;	3.24	;	X-ray structure of the ts3 human serotonin transporter complexed with s-citalopram at the central and allosteric sites
5I71	;	3.15	;	X-ray structure of the ts3 human serotonin transporter complexed with s-citalopram at the central site
5I75	;	3.49	;	X-ray structure of the ts3 human serotonin transporter complexed with s-citalopram at the central site and Br-citalopram at the allosteric site
6AWO	;	3.534	;	X-ray structure of the ts3 human serotonin transporter complexed with sertraline at the central site
4XR5	;	2.05	;	X-ray structure of the unliganded thymidine phosphorylase from Salmonella typhimurium at 2.05 A resolution
2QDK	;	1.62	;	X-ray structure of the unliganded uridine phosphorylase from Salmonella typhimurium at 1.62A resolution
2OXF	;	1.76	;	X-ray structure of the unliganded uridine phosphorylase from Salmonella typhimurium in homodimeric form at 1.76A resolution
3DPS	;	1.8	;	X-ray structure of the unliganded uridine phosphorylase from salmonella typhimurium in homodimeric form at 1.8A
6EYP	;	1.22	;	X-ray structure of the unliganded uridine phosphorylase from Vibrio cholerae at 1.22A
4NY1	;	1.7	;	X-ray structure of the unliganded uridine phosphorylase from Yersinia pseudotuberculosis at 1.7 A resolution
4I2V	;	2.121	;	X-ray structure of the unliganded uridine phosphorylase from Yersinia pseudotuberculosis at 2.12A resolution
3C74	;	2.38	;	X-ray structure of the uridine phosphorylase from salmonella typhimurium in complex with 2,2'-anhydrouridine at 2.38a resolution
4E1V	;	2.15	;	X-RAY Structure of the Uridine Phosphorylase from Salmonella Typhimurium in Complex with 5-Fluorouracil at 2.15 A Resolution
3DDO	;	1.5	;	X-RAY Structure of the Uridine Phosphorylase from Salmonella Typhimurium in Complex with by Phosphate Ion at 1.5A Resolution
2PGA	;	1.74	;	X-ray Structure of the Uridine Phosphorylase From SALMONELLA TYPHIMURIUM in Complex with Inhibitor and Phosphate and Potassium Ion at 1.74 A Resolution
4OGK	;	2.4	;	X-ray structure of the uridine phosphorylase from Salmonella typhimurium in complex with thymidine at 2.40 A resolution
7TXP	;	1.45	;	X-ray structure of the VioB N-acetyltransferase from Acinetobacter baumannii in complex with TDP-4-amino-4,6-dideoxy-D-glucose
7TXQ	;	1.65	;	x-ray structure of the VioB N-acetyltransferase from Acinetobacter baumannii in the present of TDP and Acetyl-CoenzymeA
7TXS	;	1.25	;	X-ray structure of the VioB N-aetyltransferase from Acinetobacter baumannii in the presence of a reaction intermediate
4YFY	;	1.9	;	X-ray structure of the Viof N-formyltransferase from Providencia alcalifaciens O30 in complex with THF and TDP-Qui4N
5UIN	;	2.2	;	X-ray structure of the W305A variant of the FdtF N-formyltransferase from salmonella enteric O60
8CUK	;	2.22	;	X-ray Structure of the WD40 domain of HOPS subunit Vps11 from Yeast
5TPU	;	2.0	;	x-ray structure of the WlaRB TDP-quinovose 3,4-ketoisomerase from campylobacter jejuni
5U21	;	1.6	;	X-ray structure of the WlaRF aminotransferase from Campylobacter jejuni, K184A mutant in complex with TDP-Qui3N
5U23	;	1.45	;	X-ray structure of the WlaRG aminotransferase from Campylobacter jejuni in complex with TDP-Qui3N
5U20	;	1.5	;	X-ray structure of the WlaRG aminotransferase from Campylobacter jejuni, internal PLP-aldimine
5U24	;	1.7	;	X-ray structure of the WlaRG aminotransferase from campylobacter jejuni, K184A mutant in complex with TDP-Fuc3N
5U1Z	;	1.6	;	X-ray structure of the WlarG aminotransferase, apo form, from Campylobacter jejune
2GIN	;	1.8	;	X-ray structure of the wt allene oxide cyclase 2 from arabidopsis thaliana
4E2X	;	1.4	;	X-ray Structure of the Y222F mutant of TcaB9, a C-3'-Methyltransferase, in Complex with S-Adenosyl-L-Homocysteine and dTDP
1SYI	;	2.1	;	X-RAY STRUCTURE OF THE Y702F MUTANT OF THE GLUR2 LIGAND-BINDING CORE (S1S2J) IN COMPLEX WITH (S)-CPW399 AT 2.1 A RESOLUTION.
1XHY	;	1.85	;	X-ray structure of the Y702F mutant of the GluR2 ligand-binding core (S1S2J) in complex with kainate at 1.85 A resolution
4E31	;	1.75	;	X-ray Structure of the Y76F mutant of TcaB9, a C-3'-Methyltransferase, in Complex with S-Adenosyl-L-Homocysteine and Sugar Product
6GEF	;	2.75	;	X-ray structure of the Yersinia pseudotuberculosis ATPase DotB
2YMA	;	2.545	;	X-ray structure of the Yos9 dimerization domain
6Y4E	;	1.02	;	X-ray structure of the Zn-dependent receptor-binding domain of Proteus mirabilis MR/P fimbrial adhesin MrpH
6Y4F	;	1.75	;	X-ray structure of the Zn-dependent receptor-binding domain of Proteus mirabilis MR/P fimbrial adhesin MrpH
3CIW	;	1.35	;	X-RAY structure of the [FeFe]-hydrogenase maturase HydE from thermotoga maritima
3CIX	;	1.7	;	X-RAY structure of the [FeFe]-hydrogenase maturase HydE from thermotoga maritima in complex with thiocyanate
8P84	;	1.5	;	X-ray structure of Thermoanaerobacterales bacterium monoamine oxidase
6UT3	;	2.95	;	X-ray structure of Thermococcus gammatolerans McrB AAA+ domain hexamer in P21 symmetry
6QF2	;	1.733	;	X-Ray structure of Thermolysin crystallized on a silicon chip
6QF3	;	1.521	;	X-Ray structure of Thermolysin soaked with sodium aspartate on a silicon chip
6Y3D	;	1.8	;	X-ray structure of thermophilic C-phycocyanin from Galdiera phlegrea
7WGT	;	2.75	;	X-ray structure of thermostabilized Drosophila dopamine transporter with GABA transporter1-like substitutions in the binding site, in complex with NO711.
7WLW	;	2.9	;	X-ray structure of thermostabilized Drosophila dopamine transporter with GABA transporter1-like substitutions in the binding site, in complex with SKF89976a
7WGD	;	3.2	;	X-ray structure of thermostabilized Drosophila dopamine transporter with GABA transporter1-like substitutions in the binding site, in substrate-free form.
1XKR	;	1.75	;	X-ray Structure of Thermotoga maritima CheC
7WRR	;	2.01	;	X-ray structure of Thermus thermophilus HB8 transketorase in complex with TPP and MES
2E6K	;	2.09	;	X-ray structure of Thermus thermopilus HB8 TT0505
2BEI	;	1.842	;	X-ray structure of thialysine n-acetyltransferase (SSAT2) from homo sapiens
8GQL	;	2.3	;	X-ray structure of Thiolase from Pseudomonas aeruginosa PAO1
8GQN	;	2.7	;	X-ray structure of thiolase with CoA
1RCU	;	2.5	;	X-RAY STRUCTURE OF TM1055 NORTHEAST STRUCTURAL GENOMICS CONSORTIUM TARGET VT76
5CEG	;	1.59	;	X-ray structure of toxin/anti-toxin complex from Mesorhizobium opportunistum
1G7R	;	2.2	;	X-RAY STRUCTURE OF TRANSLATION INITIATION FACTOR IF2/EIF5B
1G7S	;	2.0	;	X-RAY STRUCTURE OF TRANSLATION INITIATION FACTOR IF2/EIF5B COMPLEXED WITH GDP
1G7T	;	2.0	;	X-RAY STRUCTURE OF TRANSLATION INITIATION FACTOR IF2/EIF5B COMPLEXED WITH GDPNP
5L7O	;	3.6	;	X-ray structure of Triatoma virus empty capsid
8A2L	;	2.301	;	X-ray structure of TRIL-encapsulated human heavy chain ferritin
8A58	;	2.25	;	X-ray structure of TRIM21 RING E3 ligase in complex with E2 enzyme Ube2W
1UX8	;	2.15	;	X-ray structure of truncated oxygen-avid haemoglobin from Bacillus subtilis
7QRC	;	2.18	;	X-ray structure of Trypanosoma cruzi PEX14 in complex with a PEX5-PEX14 PPI inhibitor
2TPR	;	2.4	;	X-RAY STRUCTURE OF TRYPANOTHIONE REDUCTASE FROM CRITHIDIA FASCICULATA AT 2.4 ANGSTROMS RESOLUTION
6ER5	;	3.37	;	X-ray structure of Trypanothione Reductase from Leishmania infantum in complex with 2-(diethylamino)ethyl 4-((3-(4-nitrophenyl)-3-oxopropyl)amino)benzoate
2E6X	;	2.0	;	X-ray structure of TT1592 from Thermus thermophilus HB8
5CLY	;	1.23	;	X-ray structure of TTR mutant - S52P at 1.23A resolution
5CLZ	;	1.22	;	X-ray structure of TTR mutant - T119M at 1.22A resolution
1LZY	;	1.55	;	X-RAY STRUCTURE OF TURKEY EGG LYSOZYME COMPLEX WITH DI-N-ACETYLCHITOBIOSE. RECOGNITION AND BINDING OF ALPHA-ANOMERIC FORM
6YPT	;	3.663	;	X-ray structure of Turnip Yellow Mosaic Virus PRO/DUB in complex with Ubiquitin
1LCO	;	2.9	;	X-RAY STRUCTURE OF TWO COMPLEXES OF THE Y143F FLAVOCYTOCHROME B2 MUTANT CRYSTALLIZED IN THE PRESENCE OF LACTATE OR PHENYL-LACTATE
1LDC	;	2.9	;	X-RAY STRUCTURE OF TWO COMPLEXES OF THE Y143F FLAVOCYTOCHROME B2 MUTANT CRYSTALLIZED IN THE PRESENCE OF LACTATE OR PHENYL-LACTATE
5HYO	;	2.104	;	X-Ray Structure of Unbound Porcine Epidemic Diarrhea Virus 3CLpro
4OF4	;	1.4	;	X-ray structure of unliganded uridine phosphorylase from Yersinia pseudotuberculosis at 1.4 A resolution
3FWP	;	1.86	;	X-ray structure of uridine nucleoside phosphorylease from Salmonella typhimurium complexed with phosphate and its inhibitor 2,2'-anhydrouridine at 1.86 A resolution
4R2W	;	1.6	;	X-ray structure of uridine phosphorylase from Shewanella oneidensis MR-1 in complex with uridine at 1.6 A resolution
4OEH	;	1.91	;	X-ray Structure of Uridine Phosphorylase from Vibrio cholerae Complexed with Uracil at 1.91 A Resolution
5LOK	;	1.109	;	X-ray structure of uridine phosphorylase from Vibrio cholerae in complex with cytidine and cytosine at 1.11 A resolution
5LHV	;	1.288	;	X-ray structure of uridine phosphorylase from Vibrio cholerae in complex with uridine and sulfate ion at 1.29 A resolution
5M2T	;	1.03	;	X-ray structure of uridine phosphorylase from Vibrio cholerae in complex with uridine at 1.03 A resolution
4JP5	;	2.27	;	X-ray structure of uridine phosphorylase from Yersinia pseudotuberculosis in unliganded state at 2.27 A resolution
4G8J	;	2.119	;	X-ray Structure of Uridine Phosphorylease from Vibrio cholerae Complexed with Thymidine at 2.12 A Resolution
3C8P	;	1.25	;	X-ray structure of Viscotoxin A1 from Viscum album L.
2V9B	;	1.05	;	X-ray structure of viscotoxin B2 from Viscum album
5BUV	;	1.75	;	X-ray structure of WbcA from Yersinia enterocolitica
7BED	;	1.26	;	X-ray structure of WDR5 bound to the WDR5 win motif peptide
4ESG	;	1.7	;	X-ray structure of WDR5-MLL1 Win motif peptide binary complex
4ERQ	;	1.906	;	X-ray structure of WDR5-MLL2 Win motif peptide binary complex
4ERY	;	1.3	;	X-ray structure of WDR5-MLL3 Win motif peptide binary complex
4ERZ	;	1.75	;	X-ray structure of WDR5-MLL4 Win motif peptide binary complex
4EWR	;	1.503	;	X-ray structure of WDR5-SETd1a Win motif peptide binary complex
4ES0	;	1.817	;	X-ray structure of WDR5-SETd1b Win motif peptide binary complex
7BCY	;	1.5	;	X-ray structure of WDR5delta24 bound to the Kaposi's sarcoma herpesvirus LANA win motif peptide
1WGT	;	1.9	;	X-RAY STRUCTURE OF WHEAT GERM AGGLUTININ ISOLECTIN 3
7RTE	;	2.06	;	X-ray structure of wild type RBPJ-L3MBTL3-DNA complex
5TIC	;	1.65	;	X-ray structure of wild-type E. coli Acyl-CoA thioesterase I at pH 5
2JI1	;	1.7	;	X-ray structure of wild-type superoxide reductase from Desulfoarculus baarsii
5CN3	;	1.3	;	X-ray structure of wild-type TTR at 1.30A resolution
5TPV	;	2.14	;	X-ray structure of WlaRA (TDP-fucose-3,4-ketoisomerase) from Campylobacter jejuni
3CAK	;	1.83	;	X-ray structure of WT PTE with ethyl phosphate
1MW7	;	2.0	;	X-RAY STRUCTURE OF Y162_HELPY NORTHEAST STRUCTURAL GENOMICS CONSORTIUM TARGET PR6
1XQB	;	2.85	;	X-Ray Structure Of YaeB from Haemophilus influenzae. Northeast Structural Genomics Research Consortium (NESGC)target IR47.
1SC0	;	1.7	;	X-ray Structure of YB61_HAEIN Northeast Structural Genomics Consortium Target IR63
1NS5	;	1.68	;	X-RAY STRUCTURE OF YBEA FROM E.COLI. NORTHEAST STRUCTURAL GENOMICS RESEARCH CONSORTIUM (NESG) TARGET ER45
1LXJ	;	1.8	;	X-RAY STRUCTURE OF YBL001c NORTHEAST STRUCTURAL GENOMICS (NESG) CONSORTIUM TARGET YTYst72
1SDJ	;	2.3	;	X-RAY STRUCTURE OF YDDE_ECOLI NORTHEAST STRUCTURAL GENOMICS CONSORTIUM TARGET ET25.
1SBK	;	2.0	;	X-RAY STRUCTURE OF YDII_ECOLI NORTHEAST STRUCTURAL GENOMICS CONSORTIUM TARGET ER29.
7MI1	;	4.5	;	X-ray structure of yeast dynein motor domain in the presence of a pyrazolo-pyrimidinone-based compound (compound 20)
4G1V	;	2.098	;	X-ray structure of yeast flavohemoglobin
4G1B	;	3.0	;	X-ray structure of yeast flavohemoglobin in complex with econazole
1QGX	;	1.6	;	X-RAY STRUCTURE OF YEAST HAL2P
1OYZ	;	2.1	;	X-RAY STRUCTURE OF YIBA_ECOLI NORTHEAST STRUCTURAL GENOMICS CONSORTIUM TARGET ET31.
1NKV	;	2.9	;	X-RAY STRUCTURE OF YJHP FROM E.COLI NORTHEAST STRUCTURAL GENOMICS RESEARCH CONSORTIUM (NESG) TARGET ER13
4BBP	;	2.15	;	X-ray structure of zinc bound ZnuA in complex with RDS51
4AW8	;	2.0	;	X-ray structure of ZinT from Salmonella enterica in complex with zinc ion and PEG
4MXL	;	1.5	;	X-ray structure of ZnPFeBMb1
2XY4	;	1.71	;	X-RAY STRUCTURE OF ZNUA-WT FROM SALMONELLA ENTERICA
1T7H	;	1.13	;	X-ray structure of [Lys(-2)-Arg(-1)-des(17-21)]-endothelin-1 peptide
7WRT	;	2.25	;	X-ray structure ofThermus thermophilus HB8 transketorase demonstrate in complex with TPP and D-erythrose-4-phosphate
7AAT	;	1.9	;	X-RAY STRUCTURE REFINEMENT AND COMPARISON OF THREE FORMS OF MITOCHONDRIAL ASPARTATE AMINOTRANSFERASE
8AAT	;	2.3	;	X-RAY STRUCTURE REFINEMENT AND COMPARISON OF THREE FORMS OF MITOCHONDRIAL ASPARTATE AMINOTRANSFERASE
9AAT	;	2.2	;	X-RAY STRUCTURE REFINEMENT AND COMPARISON OF THREE FORMS OF MITOCHONDRIAL ASPARTATE AMINOTRANSFERASE
4X46	;	2.2	;	X-RAY structure thymidine phosphorylase from Salmonella typhimurium complex with SO4 at 2.19 A
6RCA	;	1.345	;	X-ray structure uridine phosphorylase from Vibrio cholerae in complex with 2.2'-anhydrouridine at 1.34 A
4K6O	;	1.17	;	X-ray structure uridine phosphorylase from Vibrio cholerae in complex with 6-methyluracil at 1.17 A resolution
4U2K	;	2.13	;	X-ray structure uridine phosphorylase from Vibrio cholerae in complex with anticancer compound at 2.13 A resolution
5EFO	;	1.63	;	X-ray structure uridine phosphorylase from Vibrio cholerae in complex with cytidine and cytosine at 1.63A.
5EPU	;	1.06	;	X-ray structure uridine phosphorylase from Vibrio cholerae in complex with cytosine at 1.06A.
4LZW	;	1.29	;	X-ray structure uridine phosphorylase from Vibrio cholerae in complex with thymidine at 1.29 A resolution
4OGL	;	1.249	;	X-ray structure uridine phosphorylase from Vibrio cholerae in complex with thymine at 1.25 A resolution
5MIW	;	1.28	;	X-ray structure uridine phosphorylase from Vibrio cholerae in complex with uracil at 1.28 A.
5C80	;	2.243	;	X-ray structure uridine phosphorylase from Vibrio cholerae in complex with uridine at 2.24 A resolution
1NXH	;	2.8	;	X-RAY STRUCTURE: NORTHEAST STRUCTURAL GENOMICS CONSORTIUM TARGET TT87
1ASO	;	2.2	;	X-RAY STRUCTURES AND MECHANISTIC IMPLICATIONS OF THREE FUNCTIONAL DERIVATIVES OF ASCORBATE OXIDASE FROM ZUCCHINI: REDUCED-, PEROXIDE-, AND AZIDE-FORMS
1ASP	;	2.59	;	X-RAY STRUCTURES AND MECHANISTIC IMPLICATIONS OF THREE FUNCTIONAL DERIVATIVES OF ASCORBATE OXIDASE FROM ZUCCHINI: REDUCED-, PEROXIDE-, AND AZIDE-FORMS
1ASQ	;	2.32	;	X-RAY STRUCTURES AND MECHANISTIC IMPLICATIONS OF THREE FUNCTIONAL DERIVATIVES OF ASCORBATE OXIDASE FROM ZUCCHINI: REDUCED-, PEROXIDE-, AND AZIDE-FORMS
1URG	;	1.8	;	X-ray structures from the maltose-maltodextrin binding protein of the thermoacidophilic bacterium Alicyclobacillus acidocaldarius
3A9R	;	1.77	;	X-ray Structures of Bacillus pallidus D-Arabinose IsomeraseComplex with (4R)-2-METHYLPENTANE-2,4-DIOL
3WW4	;	1.95	;	X-ray structures of Cellulomonas parahominis L-ribose isomerase with L-allose
3WW2	;	2.0	;	X-ray structures of Cellulomonas parahominis L-ribose isomerase with L-psicose
3WW3	;	1.9	;	X-ray structures of Cellulomonas parahominis L-ribose isomerase with no ligand
1FGV	;	1.9	;	X-RAY STRUCTURES OF FRAGMENTS FROM BINDING AND NONBINDING VERSIONS OF A HUMANIZED ANTI-CD18 ANTIBODY: STRUCTURAL INDICATIONS OF THE KEY ROLE OF VH RESIDUES 59 TO 65
2FGW	;	3.0	;	X-RAY STRUCTURES OF FRAGMENTS FROM BINDING AND NONBINDING VERSIONS OF A HUMANIZED ANTI-CD18 ANTIBODY: STRUCTURAL INDICATIONS OF THE KEY ROLE OF VH RESIDUES 59 TO 65
3LL9	;	2.148	;	X-ray structures of isopentenyl phosphate kinase
1YCG	;	2.8	;	X-ray Structures of Moorella thermoacetica FprA. Novel Diiron Site Structure and Mechanistic Insights into a Scavenging Nitric Oxide Reductase
4A6V	;	1.46	;	X-ray structures of oxazole hydroxamate EcMetAp-Mn complexes
4A6W	;	1.46	;	X-ray structures of oxazole hydroxamate EcMetAp-Mn complexes
1CCP	;	2.2	;	X-RAY STRUCTURES OF RECOMBINANT YEAST CYTOCHROME C PEROXIDASE AND THREE HEME-CLEFT MUTANTS PREPARED BY SITE-DIRECTED MUTAGENESIS
2CCP	;	2.2	;	X-RAY STRUCTURES OF RECOMBINANT YEAST CYTOCHROME C PEROXIDASE AND THREE HEME-CLEFT MUTANTS PREPARED BY SITE-DIRECTED MUTAGENESIS
3CCP	;	2.2	;	X-RAY STRUCTURES OF RECOMBINANT YEAST CYTOCHROME C PEROXIDASE AND THREE HEME-CLEFT MUTANTS PREPARED BY SITE-DIRECTED MUTAGENESIS
4CCP	;	2.2	;	X-RAY STRUCTURES OF RECOMBINANT YEAST CYTOCHROME C PEROXIDASE AND THREE HEME-CLEFT MUTANTS PREPARED BY SITE-DIRECTED MUTAGENESIS
3CZW	;	1.4	;	X-ray structures of the (GUGGUCUGAUGAGGCC) RNA duplex
3D0M	;	2.0	;	X-ray structures of the (GUGGUCUGAUGAGGCC) RNA duplex
1FVC	;	2.2	;	X-RAY STRUCTURES OF THE ANTIGEN-BINDING DOMAINS FROM THREE VARIANTS OF HUMANIZED ANTI-P185-HER2 ANTIBODY 4D5 AND COMPARISON WITH MOLECULAR MODELING
1FVD	;	2.5	;	X-RAY STRUCTURES OF THE ANTIGEN-BINDING DOMAINS FROM THREE VARIANTS OF HUMANIZED ANTI-P185-HER2 ANTIBODY 4D5 AND COMPARISON WITH MOLECULAR MODELING
1FVE	;	2.7	;	X-RAY STRUCTURES OF THE ANTIGEN-BINDING DOMAINS FROM THREE VARIANTS OF HUMANIZED ANTI-P185-HER2 ANTIBODY 4D5 AND COMPARISON WITH MOLECULAR MODELING
194D	;	2.3	;	X-RAY STRUCTURES OF THE B-DNA DODECAMER D(CGCGTTAACGCG) WITH AN INVERTED CENTRAL TETRANUCLEOTIDE AND ITS NETROPSIN COMPLEX
195D	;	2.3	;	X-RAY STRUCTURES OF THE B-DNA DODECAMER D(CGCGTTAACGCG) WITH AN INVERTED CENTRAL TETRANUCLEOTIDE AND ITS NETROPSIN COMPLEX
1URS	;	1.45	;	X-ray structures of the maltose-maltodextrin binding protein of the thermoacidophilic bacterium Alicyclobacillus acidocaldarius
1URD	;	1.53	;	X-ray structures of the maltose-maltodextrin binding protein of the thermoacidophilic bacterium Alicyclobacillus acidocaldarius provide insight into acid stability of proteins
1MMA	;	2.1	;	X-RAY STRUCTURES OF THE MGADP, MGATPGAMMAS, AND MGAMPPNP COMPLEXES OF THE DICTYOSTELIUM DISCOIDEUM MYOSIN MOTOR DOMAIN
1MMG	;	2.1	;	X-RAY STRUCTURES OF THE MGADP, MGATPGAMMAS, AND MGAMPPNP COMPLEXES OF THE DICTYOSTELIUM DISCOIDEUM MYOSIN MOTOR DOMAIN
1MMN	;	2.1	;	X-RAY STRUCTURES OF THE MGADP, MGATPGAMMAS, AND MGAMPPNP COMPLEXES OF THE DICTYOSTELIUM DISCOIDEUM MYOSIN MOTOR DOMAIN
2ER0	;	3.0	;	X-RAY STUDIES OF ASPARTIC PROTEINASE-STATINE INHIBITOR COMPLEXES
2ER9	;	2.2	;	X-RAY STUDIES OF ASPARTIC PROTEINASE-STATINE INHIBITOR COMPLEXES.
7Z6O	;	3.7	;	X-Ray studies of Ku70/80 reveal the binding site for IP6
2AZD	;	2.16	;	X-Ray studies on Maltodextrin Phosphorylase (MalP) Complexes: recognition of substrates and CATALYTIC mechanism of phosphorylase family
2AV6	;	2.01	;	X-Ray studies on maltodextrin phosphorylase complexes: recognition of substrates and cathalitic mechanism of phosphorylase family
2AW3	;	2.2	;	X-Ray studies on maltodextrin phosphorylase complexes: recognition of substrates and cathalitic mechanism of phosphorylase family
2ASV	;	1.95	;	X-Ray studies on protein complexes: Enzymatic catalysis in Crystals of E. coli Maltodextrin Phosphorylase (MalP)
4L8U	;	2.01	;	X-ray study of human serum albumin complexed with 9 amino camptothecin
4LA0	;	2.4	;	X-ray study of human serum albumin complexed with bicalutamide
4L9K	;	2.4	;	X-ray study of human serum albumin complexed with camptothecin
4LB9	;	2.7	;	X-ray study of human serum albumin complexed with etoposide
1N5U	;	1.9	;	X-RAY STUDY OF HUMAN SERUM ALBUMIN COMPLEXED WITH HEME
4LB2	;	2.8	;	X-ray study of human serum albumin complexed with idarubicin
4L9Q	;	2.7	;	X-ray study of human serum albumin complexed with teniposide
1UOR	;	2.8	;	X-RAY STUDY OF RECOMBINANT HUMAN SERUM ALBUMIN. PHASES DETERMINED BY MOLECULAR REPLACEMENT METHOD, USING LOW RESOLUTION STRUCTURE MODEL OF TETRAGONAL FORM OF HUMAN SERUM ALBUMIN
1RSB	;	2.17	;	X-ray study of the DNA oligomer d(ATATAT) in P65 space group
3WHO	;	1.85	;	X-ray-Crystallographic Structure of an RNase Po1 Exhibiting Anti-tumor Activity
4OT7	;	1.8	;	X-structure of a variant of NCR from zymomonas mobilis
4A3U	;	1.7	;	X-structure of the old yellow enzyme homologue from zymomonas mobilis (NCR)
1G9J	;	1.9	;	X-TAL STRUCTURE OF THE MUTANT E44Q OF THE CELLULASE CEL48F IN COMPLEX WITH A THIOOLIGOSACCHARIDE
8Q6P	;	3.53	;	X. laevis CMG dimer bound to dimeric DONSON - MCM ATPase
8Q6O	;	3.14	;	X. laevis CMG dimer bound to dimeric DONSON - without ATPase
7NQB	;	2.01	;	X.ray structure of the oxaliplatin/beta-lactoglobulin adduct
4GPG	;	1.979	;	X/N joint refinement of Achromobacter Lyticus Protease I free form at pD8.0
4GPG	;	1.895	;	X/N joint refinement of Achromobacter Lyticus Protease I free form at pD8.0
3VXF	;	2.752	;	X/N Joint refinement of Human alpha-thrombin-Bivalirudin complex PD5
3VXF	;	1.602	;	X/N Joint refinement of Human alpha-thrombin-Bivalirudin complex PD5
1X11	;	2.5	;	X11 PTB DOMAIN
1AQC	;	2.3	;	X11 PTB DOMAIN-10MER PEPTIDE COMPLEX
7RPY	;	1.67	;	X25-2 domain of Sca5 from Ruminococcus bromii
3Q6D	;	1.97	;	Xaa-Pro dipeptidase from Bacillus anthracis.
5GIQ	;	1.8	;	Xaa-Pro peptidase from Deinococcus radiodurans, Zinc bound
5UB7	;	2.48	;	XAC2383 from Xanthomonas citri bound to ATP
5UB3	;	1.9	;	XAC2383 from Xanthomonas citri bound to chloride ion
5UB4	;	2.09	;	XAC2383 from Xanthomonas citri bound to phosphate
5UB6	;	2.2	;	XAC2383 from Xanthomonas citri bound to pyrophosphate
2MWZ	;		;	Xanthine and 8-oxoguanine in G-quadruplexes: formation of a G G X O tetrad
1N5X	;	2.8	;	Xanthine Dehydrogenase from Bovine Milk with Inhibitor TEI-6720 Bound
6Q62	;	1.5	;	Xanthomonas albilineans Dihydropteroate synthase in complex with (indole-2-carboxylic acid) and (6-chloroguanine)
6DAY	;	1.65	;	Xanthomonas albilineans Dihydropteroate synthase with 4-aminobenzoic acid at 1.65 A
5IO2	;	1.2	;	Xanthomonas campestris Peroxiredoxin Q - C48S mutant
5IPH	;	1.3	;	Xanthomonas campestris Peroxiredoxin Q - C84S mutant
5IIZ	;	1.05	;	Xanthomonas campestris Peroxiredoxin Q - Structure F0
5IM9	;	1.1	;	Xanthomonas campestris Peroxiredoxin Q - Structure F1
5IMA	;	1.04	;	Xanthomonas campestris Peroxiredoxin Q - Structure F2
5IMC	;	1.05	;	Xanthomonas campestris Peroxiredoxin Q - Structure F3
5IMD	;	1.16	;	Xanthomonas campestris Peroxiredoxin Q - Structure F4
5IMF	;	1.04	;	Xanthomonas campestris Peroxiredoxin Q - Structure F5
5IMV	;	1.05	;	Xanthomonas campestris Peroxiredoxin Q - Structure F6
5IMZ	;	1.1	;	Xanthomonas campestris Peroxiredoxin Q - Structure F7
5INY	;	1.04	;	Xanthomonas campestris Peroxiredoxin Q - Structure F8
5IO0	;	1.3	;	Xanthomonas campestris Peroxiredoxin Q - Structure F9
5IOW	;	1.35	;	Xanthomonas campestris Peroxiredoxin Q - Structure FFcumene (Hyperoxidized by cumene hydroperoxide)
5IPG	;	1.35	;	Xanthomonas campestris Peroxiredoxin Q - Structure FFT-butyl (Hyperoxodized by t-butyl hydroperoxide)
5IOX	;	1.3	;	Xanthomonas campestris Peroxiredoxin Q - Structure LUss
2VSY	;	2.1	;	Xanthomonas campestris putative OGT (XCC0866), apostructure
2JLB	;	2.5	;	Xanthomonas campestris putative OGT (XCC0866), complex with UDP- GlcNAc phosphonate analogue
6NNT	;	1.45	;	Xanthomonas citri Dephospho-PGM in complex with glucose-1,6-bisphosphate
6NNN	;	1.35	;	Xanthomonas citri Dephospho-PGM in complex with glucose-1-phosphate
6NNP	;	1.5	;	Xanthomonas citri Dephospho-PGM in complex with glucose-6-phosphate
6NOL	;	1.73	;	Xanthomonas citri Dephospho-PGM in complex with mannose-1-phosphate
6NPX	;	1.42	;	Xanthomonas citri Dephospho-PGM in complex with mannose-6-phosphate
6NQH	;	1.45	;	Xanthomonas citri Dephospho-PGM in complex with xylose-1-phosphate
6WQI	;	2.0	;	Xanthomonas citri Methionyl-tRNA synthetase (apo)
6WQ6	;	1.7	;	Xanthomonas citri Methionyl-tRNA synthetase in complex with methionine
6WQT	;	1.65	;	Xanthomonas citri Methionyl-tRNA synthetase in complex with REP3123
6WQS	;	2.0	;	Xanthomonas citri Methionyl-tRNA synthetase in complex with REP8839
6NN1	;	1.5	;	Xanthomonas citri PGM Apo-Dephospho
6NQE	;	1.85	;	Xanthomonas citri PGM Apo-Dephospho at room temperature
6NN2	;	1.44	;	Xanthomonas citri PGM Apo-Phospho
6NQF	;	1.9	;	Xanthomonas citri PGM Apo-Phospho at room temperature
6NQG	;	2.05	;	Xanthomonas citri Phospho-PGM in complex with glucopyranosyl-1-methyl-phosphonic acid at room temperature
6NNU	;	1.46	;	Xanthomonas citri Phospho-PGM in complex with glucose-1,6-phosphate
6NNO	;	1.57	;	Xanthomonas citri Phospho-PGM in complex with glucose-1-phosphate
6NNS	;	1.45	;	Xanthomonas citri Phospho-PGM in complex with glucose-6-phosphate
6NOQ	;	1.61	;	Xanthomonas citri Phospho-PGM in complex with mannose-1-phosphate
6NP8	;	1.41	;	Xanthomonas citri Phospho-PGM in complex with mannose-6-phosphate
2OIX	;	1.8	;	Xanthomonas XopD C470A Mutant
4NAG	;	0.81	;	Xanthomonins I III are a New Class of Lasso Peptides Featuringa Seven-Membered Macrolactam Ring
6GY6	;	4.0	;	XaxAB pore complex from Xenorhabdus nematophila
8PQ2	;	3.85	;	XBB 1.0 RBD bound to P4J15 (Local)
8WRL	;	3.36	;	XBB.1.5 RBD in complex with ACE2
8XE9	;	3.3	;	XBB.1.5 RBD in complex with BD55-1205
8WRM	;	4.34	;	XBB.1.5 spike protein in complex with ACE2
8WTD	;	3.06	;	XBB.1.5.10 RBD in complex with ACE2
8WRO	;	3.9	;	XBB.1.5.10 spike protein in complex with ACE2
8WTJ	;	4.64	;	XBB.1.5.70 spike protein in complex with ACE2
1K8L	;		;	XBY6: An analog of CK14 containing 6 dithiophosphate groups
3DSG	;	2.09	;	XC1028 from Xanthomonas campestris Adopts a PilZ Domain-like Structure Yet with Trivial c-di-GMP Binding Activity
8IGZ	;	3.11	;	Xcc NAMPT Quadruple mutant
7YQO	;	1.79	;	Xcc Nicotinamide Phosphoribosyltransferase
7YQP	;	2.088	;	Xcc Nicotinamide Phosphoribosyltransferase
6Y1W	;	1.6	;	Xcc4156, a flavin-dependent halogenase from Xanthomonas campestris
5R4X	;	1.4	;	XChem fragment screen -- CRYSTAL STRUCTURE OF THE BROMODOMAIN OF THE HUMAN ATAD2 in complex with N13413a
5R4V	;	1.29	;	XChem fragment screen -- CRYSTAL STRUCTURE OF THE BROMODOMAIN OF THE HUMAN ATAD2 in complex with N13475a
5R4W	;	1.47	;	XChem fragment screen -- CRYSTAL STRUCTURE OF THE BROMODOMAIN OF THE HUMAN ATAD2 in complex with N13501a
5R4Z	;	1.46	;	XChem fragment screen -- CRYSTAL STRUCTURE OF THE BROMODOMAIN OF THE HUMAN ATAD2 in complex with N13605a
5R4Y	;	1.84	;	XChem fragment screen -- CRYSTAL STRUCTURE OF THE BROMODOMAIN OF THE HUMAN ATAD2 in complex with N13612a
5S7C	;	1.31	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM000274c
5S7M	;	1.32	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM000275d
5S7B	;	1.32	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM000329d
5S7X	;	1.3	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM000376d
5S85	;	1.33	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM000884c
5S7J	;	1.31	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM000893d
5S7O	;	1.43	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM007391c
5S79	;	1.5	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010910a
5S75	;	1.3	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010913a
5S7H	;	1.3	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010914a
5S76	;	1.31	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010916a
5S7R	;	1.46	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010918a
5S7N	;	1.3	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010920a
5S7S	;	1.3	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010921a
5S7D	;	1.31	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010923a
5S7T	;	1.3	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010926a
5S7I	;	1.3	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010928a
5S7E	;	1.32	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010930a
5S7Y	;	1.37	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010933a
5S78	;	1.3	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010934a
5S7F	;	1.31	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010935a
5S7K	;	1.31	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010936a
5S7P	;	1.31	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010937a
5S7U	;	1.59	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010938a
5S7V	;	1.31	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010942a
5S7L	;	1.36	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010943a
5S7Q	;	1.53	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010944a
5S80	;	1.67	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010946a
5S81	;	1.43	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010947a
5S83	;	1.33	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010948a
5S84	;	1.35	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010949a
5S86	;	1.31	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010952a
5S87	;	1.3	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010953a
5S88	;	1.31	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010954a
5S9K	;	1.35	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010955a
5S89	;	1.3	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010957a
5S8B	;	1.64	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010960a
5S7W	;	1.33	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with HM000007h
5S8A	;	1.3	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with NU074484b
5S7Z	;	1.3	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with NU074488b
5S7A	;	1.3	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with PK012456b
5S82	;	1.71	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with XS035128c
5S77	;	1.31	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with XS035133b
5S7G	;	1.78	;	XChem group deposition -- Crystal Structure of human ACVR1 in complex with XS035844b
5R68	;	1.64	;	XChem group deposition -- Crystal Structure of human YEATS4 in complex with FM000199e
5R69	;	1.83	;	XChem group deposition -- Crystal Structure of human YEATS4 in complex with XS038644e
5S8N	;	1.23	;	XChem group deposition -- Crystal Structure of the second bromodomain of pleckstrin homology domain interacting protein (PHIP) in complex with E07179c (space group C2)
5S8P	;	1.41	;	XChem group deposition -- Crystal Structure of the second bromodomain of pleckstrin homology domain interacting protein (PHIP) in complex with E07179c (space group P212121)
5S8L	;	1.23	;	XChem group deposition -- Crystal Structure of the second bromodomain of pleckstrin homology domain interacting protein (PHIP) in complex with E11289c (space group C2)
5S8Q	;	1.5	;	XChem group deposition -- Crystal Structure of the second bromodomain of pleckstrin homology domain interacting protein (PHIP) in complex with FMO3D000185a (space group P212121)
5S8C	;	1.25	;	XChem group deposition -- Crystal Structure of the second bromodomain of pleckstrin homology domain interacting protein (PHIP) in complex with N00322e (space group C2)
5S8E	;	1.24	;	XChem group deposition -- Crystal Structure of the second bromodomain of pleckstrin homology domain interacting protein (PHIP) in complex with N00531b (space group C2)
5S8D	;	1.26	;	XChem group deposition -- Crystal Structure of the second bromodomain of pleckstrin homology domain interacting protein (PHIP) in complex with N00539e (space group C2)
5S8F	;	1.18	;	XChem group deposition -- Crystal Structure of the second bromodomain of pleckstrin homology domain interacting protein (PHIP) in complex with N00572d (space group C2)
5S8G	;	1.19	;	XChem group deposition -- Crystal Structure of the second bromodomain of pleckstrin homology domain interacting protein (PHIP) in complex with N00804d (space group C2)
5S8H	;	1.29	;	XChem group deposition -- Crystal Structure of the second bromodomain of pleckstrin homology domain interacting protein (PHIP) in complex with N00964e (space group C2)
5S8I	;	1.3	;	XChem group deposition -- Crystal Structure of the second bromodomain of pleckstrin homology domain interacting protein (PHIP) in complex with N01186d (space group C2)
5S8J	;	1.21	;	XChem group deposition -- Crystal Structure of the second bromodomain of pleckstrin homology domain interacting protein (PHIP) in complex with N01207d (space group C2)
5S8K	;	1.24	;	XChem group deposition -- Crystal Structure of the second bromodomain of pleckstrin homology domain interacting protein (PHIP) in complex with N01225c (space group C2)
5S8O	;	1.67	;	XChem group deposition -- Crystal Structure of the second bromodomain of pleckstrin homology domain interacting protein (PHIP) in complex with N01460c (space group P212121)
5S8M	;	1.2	;	XChem group deposition -- Crystal Structure of the second bromodomain of pleckstrin homology domain interacting protein (PHIP) in complex with N11511a (space group C2)
2XGS	;	2.39	;	XcOGT in complex with C-UDP
2XGO	;	2.6	;	XcOGT in complex with UDP-S-GlcNAc
5MP2	;	2.9	;	XcpQN012 in complex with VHH04
2XKH	;	2.31	;	Xe derivative of C.lacteus mini-Hb Leu86Ala mutant
4UTH	;	1.25	;	XenA - oxidized - Y183F variant
5LNI	;	1.133	;	XenA - oxidized - Y183F variant in complex with 7-hydroxycoumarin
4UTJ	;	1.07	;	XenA - oxidized - Y183F variant in complex with 8-hydroxycoumarin
4UTI	;	1.099	;	XenA - oxidized - Y183F variant in complex with coumarin
3N19	;	1.75	;	XenA - reduced
4UTK	;	1.44	;	XenA - reduced - Y183F variant
5LNJ	;	1.16	;	XenA - reduced - Y183F variant in complex with 7-hydroxycoumarin
4UTM	;	1.09	;	XenA - Reduced - Y183F variant in complex with 8-hydroxycoumarin
4UTL	;	1.229	;	XenA - reduced - Y183F variant in complex with coumarin
3N14	;	1.9	;	XenA - W358A
5CPM	;	1.5	;	XenA from Pseudomonas putida in complex with NADPH4.
8AUG	;	1.35	;	XenA Y183F variant in complex with ethyl (Z)-2-(hydroxyimino)-3-oxobutanoate
8AUF	;	1.35	;	XenA Y183F variant in complex with ethyl (Z)-2-(hydroxyimino)-3-oxopentanoate
5N6Q	;	2.2	;	Xenobiotic reductase A (XenA) from Pseudomonas putida in complex with 2-phenylacrylic acid
3L65	;	1.2	;	Xenobiotic Reductase A - C25A Mutant
3L66	;	1.28	;	Xenobiotic Reductase A - C25A Variant with Coumarin
3L67	;	1.8	;	Xenobiotic reductase A - C25S variant
3L68	;	1.75	;	Xenobiotic Reductase A - C25S variant with coumarin
3L5M	;	1.1	;	Xenobiotic reductase A - coumarin bound
3L5L	;	1.03	;	Xenobiotic Reductase A - oxidized
8AU8	;	1.58	;	Xenobiotic reductase A from P. putida in complex with ethyl (Z)-2-(hydroxyimino)-3-oxopentanoate
8AU9	;	1.5	;	Xenobiotic reductase A from Pseudomonas putida in complex with 2-methoxyethyl (Z)-2-(hydroxyimino)-3-oxobutanoate
8A8I	;	1.88	;	Xenobiotic reductase A from Pseudomonas putida in complex with ethyl (Z)-2-(hydroxyimino)-3-oxobutanoate
2H8Z	;	1.42	;	Xenobiotic Reductase A in complex with 8-Hydroxycoumarin
2H90	;	1.42	;	Xenobiotic reductase A in complex with coumarin
8AUI	;	1.54	;	Xenobiotic reductase A Y27F variant in complex with 2-methoxyethyl (Z)-2-(hydroxyimino)-3-oxobutanoate
8AUH	;	1.35	;	Xenobiotic reductase A Y27F variant in complex with ethyl (Z)-2-(hydroxyimino)-3-oxobutanoate
2H8X	;	1.5	;	Xenobiotic Reductase A-oxidized
1E9V	;	1.79	;	XENON BOUND IN HYDROPHOBIC CHANNEL OF HYBRID CLUSTER PROTEIN FROM DESULFOVIBRIO VULGARIS
1UYU	;	2.0	;	Xenon COMPLEX OF wildtype P450CAM FROM PSEUDOMONAS PUTIDA
1VAU	;	1.5	;	Xenon derivative of hen egg-white lysozyme
6QII	;	2.28	;	Xenon derivatization of the F420-reducing [NiFe] hydrogenase complex from Methanosarcina barkeri
5NSW	;	2.5	;	Xenon for tunnelling analysis of the efflux pump component OprN.
4L78	;	2.18	;	Xenon Trapping and Statistical Coupling Analysis Uncover Regions Important for Structure and Function of Multidomain Protein StPurL
2Z8Y	;	2.51	;	Xenon-bound structure of bifunctional carbon monoxide dehydrogenase/acetyl-CoA synthase(CODH/ACS) from Moorella thermoacetica
7TSJ	;	2.1	;	Xenon-bound structure of carbon monoxide dehydrogenase (CODH) from Desulfovibrio vulgaris
6L9X	;	2.9	;	Xenons in frog EPDR1
1L6O	;	2.2	;	XENOPUS DISHEVELLED PDZ DOMAIN
4WN0	;	2.2	;	Xenopus laevis embryonic epidermal lectin in complex with glycerol phosphate
2KR2	;		;	Xenopus laevis malectin complexed with maltose (Glcalpha1-4Glc)
2K46	;		;	Xenopus laevis malectin complexed with nigerose (Glcalpha1-3Glc)
1YCQ	;	2.3	;	XENOPUS LAEVIS MDM2 BOUND TO THE TRANSACTIVATION DOMAIN OF HUMAN P53
6U11	;	2.7	;	Xenopus laevis N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase (NAGPA) (C46S C219S C453S C480S C486S) with CTD mostly flexible
6VG1	;	2.0	;	xenopus protocadherin 8.1 EC1-6
4C9V	;	2.7	;	Xenopus RNF43 ectodomain in complex with Xenopus RSPO2 Fu1-Fu2
4C8V	;	2.2	;	Xenopus RSPO2 Fu1-Fu2 crystal form I
4C8W	;	3.1	;	Xenopus RSPO2 Fu1-Fu2 crystal form II
1OE4	;	2.0	;	Xenopus SMUG1, an anti-mutator uracil-DNA Glycosylase
1OE5	;	2.3	;	Xenopus SMUG1, an anti-mutator uracil-DNA Glycosylase
1OE6	;	2.65	;	Xenopus SMUG1, an anti-mutator uracil-DNA Glycosylase
6BBJ	;	3.8	;	Xenopus Tropicalis TRPV4
4C8T	;	2.4	;	Xenopus ZNRF3 ectodomain crystal form I
4C8U	;	3.01	;	Xenopus ZNRF3 ectodomain crystal form II
4C9R	;	2.1	;	Xenopus ZNRF3 ectodomain in complex with Xenopus RSPO2 Fu1-Fu2 crystal form I
4C9U	;	3.0	;	Xenopus ZNRF3 ectodomain in complex with Xenopus RSPO2 Fu1-Fu2 crystal form II
1LP9	;	2.0	;	Xenoreactive complex AHIII 12.2 TCR bound to p1049/HLA-A2.1
6YEY	;	3.7	;	Xenorhabdus nematophila XptA1 in complex with porcine mucosa heparin
7Q6G	;	2.8	;	Xenorhabdus poinarii FtsA 1-396 ADP
6PS7	;	1.85	;	XFEL A2aR structure by ligand exchange from LUF5843 to ZM241385.
6PRZ	;	2.8	;	XFEL beta2 AR structure by ligand exchange from Alprenolol to Alprenolol.
6PS0	;	3.4	;	XFEL beta2 AR structure by ligand exchange from Alprenolol to Carazolol.
6PS1	;	3.2	;	XFEL beta2 AR structure by ligand exchange from Alprenolol to Timolol.
6PS2	;	2.4	;	XFEL beta2 AR structure by ligand exchange from Timolol to Alprenolol.
6PS3	;	2.5	;	XFEL beta2 AR structure by ligand exchange from Timolol to Carvedilol.
6PS4	;	2.6	;	XFEL beta2 AR structure by ligand exchange from Timolol to ICI-118551.
6PS5	;	2.9	;	XFEL beta2 AR structure by ligand exchange from Timolol to Propranolol.
6PS6	;	2.7	;	XFEL beta2 AR structure by ligand exchange from Timolol to Timolol.
6CH7	;	3.8	;	XFEL crystal structure of a natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and 35O22
7BIU	;	1.06	;	XFEL crystal structure of cytochrome c peroxidase compound II
6ME4	;	3.2	;	XFEL crystal structure of human melatonin receptor MT1 in complex with 2-iodomelatonin
6ME3	;	2.9	;	XFEL crystal structure of human melatonin receptor MT1 in complex with 2-phenylmelatonin
6ME5	;	3.2	;	XFEL crystal structure of human melatonin receptor MT1 in complex with agomelatine
6ME2	;	2.8	;	XFEL crystal structure of human melatonin receptor MT1 in complex with ramelteon
6ME7	;	3.2	;	XFEL crystal structure of human melatonin receptor MT2 (H208A) in complex with 2-phenylmelatonin
6ME8	;	3.1	;	XFEL crystal structure of human melatonin receptor MT2 (N86D) in complex with 2-phenylmelatonin
6ME6	;	2.8	;	XFEL crystal structure of human melatonin receptor MT2 in complex with 2-phenylmelatonin
6ME9	;	3.3	;	XFEL crystal structure of human melatonin receptor MT2 in complex with ramelteon
7BI1	;	1.5	;	XFEL crystal structure of soybean ascorbate peroxidase compound II
6RZ5	;	2.53	;	XFEL crystal structure of the human cysteinyl leukotriene receptor 1 in complex with zafirlukast
7YXA	;	2.2	;	XFEL crystal structure of the human sphingosine 1 phosphate receptor 5 in complex with ONO-5430608
7M8W	;	2.61	;	XFEL crystal structure of the prostaglandin D2 receptor CRTH2 in complex with 15R-methyl-PGD2
6PS8	;	3.3	;	XFEL MT1R structure by ligand exchange from agomelatine to 2-phenylmelatonin.
7SUC	;	1.9	;	XFEL Serial Crystallography Reveals the Room Temperature Structure of Methyl-Coenzyme M Reductase
7BH4	;	1.55	;	XFEL structure of apo CTX-M-15 after mixing for 0.7 sec with ertapenem using a piezoelectric injector (PolyPico)
8EBI	;	2.7	;	XFEL structure of beta lactamase microcrystals mixed with sulbactam solution for 15ms
7Z3E	;	2.0	;	XFEL structure of Class Ib ribonucleotide reductase dimanganese(II) NrdF in complex with hydroquinone NrdI from Bacillus cereus
7Z3D	;	2.0	;	XFEL structure of Class Ib ribonucleotide reductase dimanganese(II) NrdF in complex with oxidized NrdI from Bacillus cereus
7BH3	;	1.6	;	XFEL structure of CTX-M-15 resting state
6JLK	;	2.15	;	XFEL structure of cyanobacterial photosystem II (1F state, dataset1)
6JLN	;	2.4	;	XFEL structure of cyanobacterial photosystem II (1F state, dataset2)
6JLL	;	2.15	;	XFEL structure of cyanobacterial photosystem II (2F state, dataset1)
6JLO	;	2.4	;	XFEL structure of cyanobacterial photosystem II (2F state, dataset2)
6JLP	;	2.5	;	XFEL structure of cyanobacterial photosystem II (3F state, dataset2)
6JLJ	;	2.15	;	XFEL structure of cyanobacterial photosystem II (dark state, dataset1)
6JLM	;	2.35	;	XFEL structure of cyanobacterial photosystem II (dark state, dataset2)
8IR8	;	2.25	;	XFEL structure of cyanobacterial photosystem II following one flash (1F) with a 1-microsecond delay
8IR6	;	2.2	;	XFEL structure of cyanobacterial photosystem II following one flash (1F) with a 20-nanosecond delay
8IRA	;	2.2	;	XFEL structure of cyanobacterial photosystem II following one flash (1F) with a 200-microsecond delay
8IR7	;	2.25	;	XFEL structure of cyanobacterial photosystem II following one flash (1F) with a 200-nanosecond delay
8IR9	;	2.2	;	XFEL structure of cyanobacterial photosystem II following one flash (1F) with a 30-microsecond delay
8IRB	;	2.3	;	XFEL structure of cyanobacterial photosystem II following one flash (1F) with a 5-millisecond delay
8IRC	;	2.25	;	XFEL structure of cyanobacterial photosystem II following one flash (1F) with a 5-millisecond delay (Single conformation)
8IRF	;	2.25	;	XFEL structure of cyanobacterial photosystem II following two flashes (2F) with a 1-microsecond delay
8IRD	;	2.3	;	XFEL structure of cyanobacterial photosystem II following two flashes (2F) with a 20-nanosecond delay
8IRH	;	2.25	;	XFEL structure of cyanobacterial photosystem II following two flashes (2F) with a 200-microsecond delay
8IRE	;	2.25	;	XFEL structure of cyanobacterial photosystem II following two flashes (2F) with a 200-nanosecond delay
8IRG	;	2.3	;	XFEL structure of cyanobacterial photosystem II following two flashes (2F) with a 30-microsecond delay
8IRI	;	2.25	;	XFEL structure of cyanobacterial photosystem II following two flashes (2F) with a 5-millisecond delay
8IR5	;	2.15	;	XFEL structure of cyanobacterial photosystem II under dark conditions
6OIV	;	3.06	;	XFEL structure of Escherichia coli dGTPase
5DM9	;	2.3	;	XFEL structure of hen egg-white lysozyme solved using a droplet injector at SACLA
5UNF	;	2.8	;	XFEL structure of human angiotensin II type 2 receptor (Monoclinic form) in complex with compound 1 (N-benzyl-N-(2-ethyl-4-oxo-3-{[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl])
5UNG	;	2.8	;	XFEL structure of human angiotensin II type 2 receptor (Orthorhombic form) in complex with compound 1 (N-benzyl-N-(2-ethyl-4-oxo-3-{[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl] methyl}-3,4-dihydroquinazolin-6-yl)thiophene-2-carboxamide)
4YAY	;	2.9	;	XFEL structure of human Angiotensin Receptor
5TTC	;	1.4	;	XFEL structure of influenza A M2 wild type TM domain at high pH in the lipidic cubic phase at room temperature
5UM1	;	1.451	;	XFEL structure of influenza A M2 wild type TM domain at intermediate pH in the lipidic cubic phase at room temperature
5JOO	;	1.413	;	XFEL structure of influenza A M2 wild type TM domain at low pH in the lipidic cubic phase at room temperature
8GCV	;	2.2	;	XFEL structure of Mycobacterium tuberculosis beta lactamase microcrystals
8EC4	;	2.35	;	XFEL structure of Mycobacterium tuberculosis beta lactamase microcrystals mixed with sulbactam for 240ms
8GCS	;	2.62	;	XFEL structure of Mycobacterium tuberculosis beta lactamase microcrystals mixed with sulbactam for 3 ms
8EBR	;	2.8	;	XFEL structure of Mycobacterium tuberculosis beta lactamase microcrystals mixed with sulbactam for 30ms
8GCT	;	2.75	;	XFEL structure of Mycobacterium tuberculosis beta lactamase microcrystals mixed with sulbactam for 6 ms
8GCX	;	3.2	;	XFEL structure of Mycobacterium tuberculosis beta lactamase microcrystals mixed with sulbactam for 700 ms
6L18	;	1.9	;	XFEL structure of T4dCH D179N mutant complex with natively expressed dTMP
7BH5	;	1.55	;	XFEL structure of the ertapenem-derived CTX-M-15 acylenzyme after mixing for 2 sec using a piezoelectric injector (PolyPico)
4RWD	;	2.7	;	XFEL structure of the human delta opioid receptor in complex with a bifunctional peptide
5OQ9	;	1.51	;	XFEL structure of the off state of a reversibly photoswitching fluorescent protein determined using the droplet on demand injection method
5OQA	;	1.53	;	XFEL structure of the off state of a reversibly photoswitching fluorescent protein determined using the GDVN injection method
5OQE	;	1.91	;	XFEL structure of the on state of a reversibly photoswitching fluorescent protein determined using the droplet injection method
5OOZ	;	1.92	;	XFEL structure of the on state of a reversibly photoswitching fluorescent protein determined using the grease injection method
6YD0	;	1.95	;	XFEL structure of the Soluble methane monooxygenase hydroxylase and regulatory subunit complex, from Methylosinus trichosporium OB3b, diferric state
6YDI	;	1.95	;	XFEL structure of the Soluble methane monooxygenase hydroxylase and regulatory subunit complex, from Methylosinus trichosporium OB3b, diferrous state
6YDU	;	1.95	;	XFEL structure of the Soluble methane monooxygenase hydroxylase and regulatory subunit complex, from Methylosinus trichosporium OB3b, reoxidized diferric state, 10s O2 exposure.
6YY3	;	2.0	;	XFEL structure of the Soluble methane monooxygenase hydroxylase and regulatory subunit complex, from Methylosinus trichosporium OB3b, t=0 diferrous state prior to oxygen activation
7V26	;	3.85	;	XG005-bound SARS-CoV-2 S
6GZF	;	2.614	;	Xi Class GST from Natrialba magadii
5LVU	;	2.6	;	XiaF (apo) from Streptomyces sp.
5LVW	;	2.9	;	XiaF (FADH2) from Streptomyces sp.
5MR6	;	2.4	;	XiaF from Streptomyces sp. in complex with FADH2 and Glycerol
2JK7	;	2.82	;	XIAP BIR3 bound to a Smac Mimetic
5OQW	;	2.31	;	XIAP in complex with small molecule
4EC4	;	3.3	;	XIAP-BIR3 in complex with a potent divalent Smac mimetic
7PO6	;	1.77	;	Xist (m6A)UCG tetraloop RNA bound to the YTH domain of YTHDC1
3W03	;	8.492	;	XLF-XRCC4 complex
4HKQ	;	3.04	;	XMRV reverse transcriptase in complex with RNA/DNA hybrid
6KK8	;	2.349	;	XN joint refinement of manganese catalase from Thermus Thermophilus HB27
6KK8	;	1.37	;	XN joint refinement of manganese catalase from Thermus Thermophilus HB27
1FRE	;		;	XNF7 BBOX, DEVELOPMENTAL PROTEIN, PH 7.5, 30 C, WITH ZINC, NMR, 1 STRUCTURE
8EBX	;	3.6	;	XPA repositioning Core7 of TFIIH relative to XPC-DNA lesion (AP)
8EBT	;	3.9	;	XPA repositioning Core7 of TFIIH relative to XPC-DNA lesion (Cy5)
7SG1	;	3.1	;	XPA5 TCR in complex with HLA-DQ2-alpha1
7SG2	;	3.1	;	XPA5 TCR in complex with HLA-DQ2-omega1
6P4W	;	2.956	;	XPB helicase in a complex with truncated Bax1 from Sulfurisphaera tokodaii at 2.96 Angstrom resolution
7NVV	;	2.9	;	XPB-containing part of TFIIH in a post-translocated state (with ADP-BeF3)
8EBY	;	3.6	;	XPC release from Core7-XPA-DNA (AP)
8EBU	;	3.3	;	XPC release from Core7-XPA-DNA (Cy5)
5H8W	;	2.2	;	XPD mechanism
3CRW	;	4.0	;	XPD_APO
3CRV	;	2.0	;	XPD_Helicase
2BHN	;	3.2	;	XPF from Aeropyrum pernix
2BGW	;	2.8	;	XPF from Aeropyrum pernix, complex with DNA
6SXA	;	3.6	;	XPF-ERCC1 Cryo-EM Structure, Apo-form
6SXB	;	7.9	;	XPF-ERCC1 Cryo-EM Structure, DNA-Bound form
1NUL	;	1.8	;	XPRTASE FROM E. COLI
1A97	;	2.6	;	XPRTASE FROM E. COLI COMPLEXED WITH GMP
1A98	;	2.25	;	XPRTASE FROM E. COLI COMPLEXED WITH GMP
1A95	;	2.0	;	XPRTASE FROM E. COLI COMPLEXED WITH MG:CPRPP AND GUANINE
1A96	;	2.0	;	XPRTASE FROM E. COLI WITH BOUND CPRPP AND XANTHINE
2XO0	;	1.7	;	xpt-pbuX C74U Riboswitch from B. subtilis bound to 24-diamino-1,3,5- triazine identified by virtual screening
2XNW	;	1.5	;	XPT-PBUX C74U RIBOSWITCH FROM B. SUBTILIS BOUND TO A TRIAZOLO- TRIAZOLE-DIAMINE LIGAND IDENTIFIED BY VIRTUAL SCREENING
2XNZ	;	1.59	;	xpt-pbuX C74U Riboswitch from B. subtilis bound to acetoguanamine identified by virtual screening
2XO1	;	1.6	;	xpt-pbuX C74U Riboswitch from B. subtilis bound to N6-methyladenine
8TQE	;	3.1	;	XptA2 wild type
8TV0	;	3.1	;	XptA2 wild type
3KYW	;	1.1	;	Xray crystal structure determination of H-labeled perdeuterated rubredoxin at 295K
5ENA	;	1.35	;	Xray crystal structure of isotope-labeled human insulin
2F32	;	1.8	;	Xray crystal structure of lysozyme mutant L20/R63A liganded to ethylguanidinium
2F47	;	1.7	;	Xray crystal structure of T4 lysozyme mutant L20/R63A liganded to methylguanidinium
8CUL	;	2.01	;	Xray ray crystal structure of OXA-24/40 in complex with CR167
2DRJ	;	2.25	;	Xray structure of alpha-2,3/8-sialyltransferase CstII F91Y mutant
2ACO	;	1.8	;	Xray structure of Blc dimer in complex with vaccenic acid
6FK0	;	2.9	;	Xray structure of domain-swapped cystatin E dimer
2JEE	;	2.8	;	Xray structure of E. coli YiiU
2VE8	;	1.4	;	Xray structure of FtsK gamma domain (P. aeruginosa)
2GON	;	1.9	;	Xray Structure of Gag133-278
2GOL	;	2.2	;	Xray Structure of Gag278
6HJI	;	2.8	;	Xray structure of GLIC in complex with crotonate
6HJ3	;	2.7	;	Xray structure of GLIC in complex with fumarate
6HJA	;	2.7	;	Xray structure of GLIC in complex with glutarate
6HJB	;	3.0	;	Xray structure of GLIC in complex with malonate
6HJZ	;	2.5	;	Xray structure of GLIC in complex with succinate
1JYU	;	2.75	;	Xray Structure of Grb2 SH2 Domain
1JYQ	;	2.0	;	Xray Structure of Grb2 SH2 Domain Complexed with a Highly Affine Phospho Peptide
1JYR	;	1.55	;	Xray Structure of Grb2 SH2 Domain Complexed with a Phosphorylated Peptide
5LC2	;	1.8	;	Xray structure of human FAM3C ILEI monomer
5MIM	;	1.9	;	Xray structure of human furin bound with the 2,5-dideoxystreptamine derived small molecule inhibitor 1n
2VE9	;	1.9	;	Xray structure of KOPS bound gamma domain of FtsK (P. aeruginosa)
5LC4	;	1.84	;	Xray structure of mouse FAM3C ILEI dimer
5LC3	;	2.0	;	Xray structure of mouse FAM3C ILEI monomer
7CXD	;	1.71	;	Xray structure of rat Galectin-3 CRD in complex with TD-139 belonging to P121 space group
3E8Y	;	1.1	;	Xray structure of scorpion toxin BmBKTx1
3QVG	;	2.26	;	XRCC1 bound to DNA ligase
7M3P	;	2.00002	;	Xrcc4-Spc110p(164-207) fusion
3F6W	;	1.85	;	XRE-family like protein from Pseudomonas syringae pv. tomato str. DC3000
6U7V	;	1.42	;	xRRM structure of spPof8
4NOV	;	1.33	;	Xsa43E, a GH43 family enzyme from Butyrivibrio proteoclasticus
1G9G	;	1.9	;	XTAL-STRUCTURE OF THE FREE NATIVE CELLULASE CEL48F
2W87	;	1.6	;	Xyl-CBM35 in complex with glucuronic acid containing disaccharide.
1DYO	;	2.1	;	Xylan-Binding Domain from CBM 22, formally x6b domain
1GNY	;	1.63	;	xylan-binding module CBM15
1E0V	;	1.7	;	Xylanase 10A from Sreptomyces lividans. cellobiosyl-enzyme intermediate at 1.7 A
1E0W	;	1.2	;	Xylanase 10A from Sreptomyces lividans. native structure at 1.2 angstrom resolution
1E0X	;	1.65	;	XYLANASE 10A FROM SREPTOMYCES LIVIDANS. XYLOBIOSYL-ENZYME INTERMEDIATE AT 1.65 A
3WP3	;	1.98	;	Xylanase 11C from Talaromyces cellulolyticus (formerly known as Acremonium cellulolyticus)
3RI8	;	2.0	;	Xylanase C from Aspergillus kawachii D37N mutant
3RI9	;	2.0	;	Xylanase C from Aspergillus kawachii F131W mutant
1BG4	;	1.75	;	XYLANASE FROM PENICILLIUM SIMPLICISSIMUM
1B30	;	2.25	;	XYLANASE FROM PENICILLIUM SIMPLICISSIMUM, COMPLEX WITH 1,2-(4-DEOXY-BETA-L-THREO-HEX-4-ENOPYRANOSYLURONIC ACID)-BETA-1,4-XYLOTRIOSE)
1B3W	;	2.6	;	XYLANASE FROM PENICILLIUM SIMPLICISSIMUM, COMPLEX WITH XYLOBIOSE
1B3Z	;	2.3	;	XYLANASE FROM PENICILLIUM SIMPLICISSIMUM, COMPLEX WITH XYLOPENTAOSE
1B3V	;	2.4	;	XYLANASE FROM PENICILLIUM SIMPLICISSIMUM, COMPLEX WITH XYLOSE
1B3Y	;	2.45	;	XYLANASE FROM PENICILLIUM SIMPLICISSIMUM, COMPLEX WITH XYLOTETRAOSE
1B3X	;	2.2	;	XYLANASE FROM PENICILLIUM SIMPLICISSIMUM, COMPLEX WITH XYLOTRIOSE
1B31	;	1.75	;	XYLANASE FROM PENICILLIUM SIMPLICISSIMUM, NATIVE WITH PEG200 AS CRYOPROTECTANT
3LGR	;	1.64	;	Xylanase II from Trichoderma reesei cocrystallized with tris-dipicolinate europium
2DFB	;	1.11	;	Xylanase II from Tricoderma reesei at 100K
2DFC	;	1.19	;	Xylanase II from Tricoderma reesei at 293K
6KJL	;	2.45	;	Xylanase J from Bacillus sp. strain 41M-1
6KKA	;	2.36	;	Xylanase J mutant from Bacillus sp. 41M-1
7CPK	;	1.6	;	Xylanase R from Bacillus sp. TAR-1
7CPL	;	1.52	;	Xylanase R from Bacillus sp. TAR-1
1HIZ	;	2.4	;	Xylanase T6 (Xt6) from Bacillus Stearothermophilus
4PRW	;	1.8	;	Xylanase T6 (XT6) from Geobacillus Stearothermophilus in complex with xylohexaose
1V0K	;	1.03	;	Xylanase Xyn10A from Streptomyces lividans in complex with xylobio-deoxynojirimycin at pH 5.8
1V0M	;	1.07	;	Xylanase Xyn10a from Streptomyces lividans in complex with xylobio-deoxynojirimycin at pH 7.5
1V0L	;	0.98	;	Xylanase Xyn10A from Streptomyces lividans in complex with xylobio-isofagomine at pH 5.8
1V0N	;	1.1	;	Xylanase Xyn10a from Streptomyces lividans in complex with xylobio-isofagomine at pH 7.5
1OD8	;	1.05	;	Xylanase Xyn10A from Streptomyces lividans in complex with xylobio-isofagomine lactam
1UQZ	;	1.55	;	Xylanase Xyn10B mutant (E262S) from Cellvibrio mixtus in complex with 4-O-methyl glucuronic acid
1UR2	;	1.6	;	Xylanase Xyn10B mutant (E262S) from Cellvibrio mixtus in complex with arabinofuranose alpha 1,3 linked to xylotriose
1UR1	;	1.43	;	Xylanase Xyn10B mutant (E262S) from Cellvibrio mixtus in complex with arabinofuranose alpha-1,3 linked to xylobiose
1UQY	;	1.72	;	Xylanase Xyn10B mutant (E262S) from Cellvibrio mixtus in complex with xylopentaose
1US2	;	1.85	;	Xylanase10C (mutant E385A) from Cellvibrio japonicus in complex with xylopentaose
5XSS	;	2.093	;	XylFII molecule
5XSJ	;	2.202	;	XylFII-LytSN complex
5XSD	;	2.5	;	XylFII-LytSN complex mutant - D103A
7Y9P	;	2.8	;	Xylitol dehydrogenase S96C/S99C/Y102C mutant(thermostabilized form) from Pichia stipitis
4BJ0	;	1.0	;	Xyloglucan binding module (CBM4-2 X2-L110F) in complex with branched xyloses
1UMZ	;	1.8	;	Xyloglucan endotransglycosylase in complex with the xyloglucan nonasaccharide XLLG.
1UN1	;	2.1	;	Xyloglucan endotransglycosylase native structure.
6SDU	;	2.2	;	Xyloglucanase domain of NopAA, a type three effector from Sinorhizobium fredii in complex with cellobiose
5K8E	;	1.93	;	Xylooligosaccharide oxidase from Myceliophthora thermophila C1
5L6F	;	1.8	;	Xylooligosaccharide oxidase from Myceliophthora thermophila C1 in complex with Xylobiose
5L6G	;	1.79	;	Xylooligosaccharide oxidase from Myceliophthora thermophila C1 in complex with Xylose
2Y64	;	1.4	;	Xylopentaose binding mutated (X-2 L110F) CBM4-2 Carbohydrate Binding Module from a Thermostable Rhodothermus marinus Xylanase
2Y6L	;	1.28	;	Xylopentaose binding X-2 engineered mutated CBM4-2 Carbohydrate Binding Module from a Thermostable Rhodothermus marinus Xylanase
6N98	;	1.55	;	Xylose isomerase 1F1 variant from Streptomyces sp. F-1
6N99	;	2.8	;	Xylose isomerase 2F1 variant from Streptomyces sp. F-1
1A0D	;	3.0	;	XYLOSE ISOMERASE FROM BACILLUS STEAROTHERMOPHILUS
6INT	;	1.942	;	xylose isomerase from Paenibacillus sp. R4
1A0C	;	2.5	;	XYLOSE ISOMERASE FROM THERMOANAEROBACTERIUM THERMOSULFURIGENES
1A0E	;	2.7	;	XYLOSE ISOMERASE FROM THERMOTOGA NEAPOLITANA
1BXC	;	2.3	;	XYLOSE ISOMERASE FROM THERMUS CALDOPHILUS
1BXB	;	2.2	;	XYLOSE ISOMERASE FROM THERMUS THERMOPHILUS
7NJG	;	1.9	;	Xylose isomerase grown inside HARE serial crystallography chip
8AW8	;	1.63	;	Xylose Isomerase in 70% relative humidity environment
8AW9	;	1.62	;	Xylose Isomerase in 75% relative humidity environment
8AWF	;	1.61	;	Xylose Isomerase in 80% relative humidity environment
8AWC	;	1.75	;	Xylose Isomerase in 85% relative humidity environment
8AWB	;	2.3	;	Xylose Isomerase in 90% relative humidity environment
8AWD	;	1.85	;	Xylose Isomerase in 95% relative humidity environment
8AWE	;	1.7	;	Xylose Isomerase in 99% relative humidity environment
1S5M	;	0.98	;	Xylose Isomerase in Substrate and Inhibitor Michaelis States: Atomic Resolution Studies of a Metal-Mediated Hydride Shift
1S5N	;	0.95	;	Xylose Isomerase in Substrate and Inhibitor Michaelis States: Atomic Resolution Studies of a Metal-Mediated Hydride Shift
5HMQ	;	2.371	;	xylose isomerase-like TIM barrel/4-hydroxyphenylpyruvate dioxygenase fusion protein
6DRU	;	2.7	;	Xylosidase from Aspergillus niger
2Y6K	;	1.36	;	Xylotetraose bound to X-2 engineered mutated CBM4-2 Carbohydrate Binding Module from a Thermostable Rhodothermus marinus Xylanase
6GUA	;	1.95	;	Xylulose 5-phosphate phosphoketolase from Lactococcus lactis
4YCZ	;	4.1	;	Y-COMPLEX HUB (NUP85-NUP120-NUP145C-SEC13 COMPLEX) FROM M. THERMOPHILA (A.K.A. T. HETEROTHALLICA)
4F50	;	2.215	;	Y-family DNA polymerase chimera Dbh-Dbh-Dpo4
4NLG	;	2.4	;	Y-family DNA polymerase chimera Dbh-Dpo4(243-245)-Dbh
4F4Y	;	2.338	;	Y-family DNA polymerase chimera Dbh-Dpo4-Dbh
4F4W	;	1.898	;	Y-family DNA polymerase chimera Dbh-Dpo4-Dpo4 #1
4F4X	;	2.049	;	Y-family DNA polymerase chimera Dbh-Dpo4-Dpo4 #2
4F4Z	;	2.305	;	Y-family DNA polymerase chimera Dpo4-Dpo4-Dbh
2W8L	;	3.0	;	Y-family DNA polymerase Dpo4 bypassing N2-naphthyl-guanine adduct in anti orientation
2W8K	;	3.1	;	Y-family DNA polymerase Dpo4 bypassing N2-naphthyl-guanine adduct in syn orientation
1N48	;	2.2	;	Y-family DNA polymerase Dpo4 in complex with DNA containing abasic lesion
1N56	;	2.4	;	Y-family DNA polymerase Dpo4 in complex with DNA containing abasic lesion
4DCB	;	2.033	;	Y. pestis Plasminogen Activator Pla in Complex with Human Plasminogen Activation Loop Peptide ALP11
6QNE	;	1.8	;	Y102G mutated sulfur oxygenase reductase from Acidianus ambivalens
1R67	;	1.77	;	Y104A MUTANT OF E.COLI IPP ISOMERASE
1X83	;	1.8	;	Y104F IPP isomerase reacted with (S)-bromohydrine of IPP
2G74	;	1.96	;	Y104F mutant of type 1 isopentenylpyrophosphate-dimethylallylpyrophosphate isomerase
2G73	;	1.97	;	Y104F mutant type 1 IPP isomerase complex with EIPP
1OZM	;	1.95	;	Y106F mutant of Z. mobilis TGT
6XTK	;	1.7	;	Y114C Transthyretin structure in complex with Tolcalpone
4RRJ	;	1.86	;	Y115A mutant of N-terminal editing domain of threonyl-tRNA synthetase from Aeropyrum pernix with L-Ser3AA
4RRK	;	1.86	;	Y115A mutant of N-terminal editing domain of threonyl-tRNA synthetase from Aeropyrum pernix with L-Thr3AA
2AV8	;	2.46	;	Y122F MUTANT OF RIBONUCLEOTIDE REDUCTASE FROM ESCHERICHIA COLI
1FTC	;	2.35	;	Y13C MUTANT OF AZOTOBACTER VINELANDII FDI
3LGU	;	2.46	;	Y162A mutant of the DegS-deltaPDZ protease
3LGT	;	2.68	;	Y162A/H198P double mutant of DegS-deltaPDZ protease
5X98	;	1.76	;	Y162F mutant of thermus thermophilus HB8 thymidylate kinase
1MP5	;	2.75	;	Y177F VARIANT OF S. ENTERICA RmlA
6T6O	;	1.4	;	Y201W mutant of the orange carotenoid protein from Synechocystis at pH 4.6
6T6M	;	1.49	;	Y201W mutant of the orange carotenoid protein from Synechocystis at pH 5.5
6T6K	;	1.37	;	Y201W mutant of the orange carotenoid protein from Synechocystis at pH 6.5
5FAY	;	1.901	;	Y208F mutant of choline TMA-lyase
4JEX	;	1.43	;	Y21K mutant of N-acetylornithine aminotransferase complexed with L-canaline
8U8S	;	2.63	;	Y229F/S292F Streptomyces coelicolor Laccase
8U8T	;	2.9	;	Y229F/V290N Streptomyces coelicolor Laccase
8U8R	;	2.86	;	Y229F/V290N/S292F Streptomyces coelicolor Laccase
5ACS	;	1.459	;	Y233A-Investigation of the impact from residues W228 and Y233 in the metallo-beta-lactamase GIM-1
3NJF	;	2.47	;	Y26F mutant of SO1698 protein, an aspartic peptidase from Shewanella oneidensis
6UOL	;	1.936	;	Y271G DNA polymerase beta substrate complex with a templating cytosine and incoming rGTP
6UOK	;	2.55	;	Y271G DNA polymerase beta substrate complex with templating cytosine and incoming r8-oxo-GTP
6UOM	;	2.05	;	Y271G DNA polymerase beta ternary complex with templating adenine and incoming r8-oxo-GTP
4WR3	;	1.9	;	Y274F alanine racemase from E. coli
4XBJ	;	2.25	;	Y274F alanine racemase from E. coli inhibited by l-ala-p
2PS7	;	2.35	;	Y295F trichodiene synthase
2PS8	;	2.67	;	Y295F Trichodiene Synthase: Complex With Mg and Pyrophosphate
3TM9	;	1.72	;	Y29A mutant of Vitreoscilla stercoraria hemoglobin
1YJ4	;	2.3	;	Y305F Trichodiene Synthase
1YYQ	;	2.1	;	Y305F Trichodiene Synthase complexed with pyrophosphate
1YYR	;	2.5	;	Y305F Trichodiene Synthase: Complex With Mg, Pyrophosphate, and (4R)-7-azabisabolene
1YYS	;	2.75	;	Y305F Trichodiene Synthase: Complex With Mg, Pyrophosphate, and (4S)-7-azabisabolene
5VWA	;	1.8	;	Y316F mutant of corn root ferredoxin:NADP+ reductase
5VWB	;	1.8	;	Y316F mutant of corn root ferredoxin:NADP+ reductase in alternate space group
1U0C	;	2.5	;	Y33C Mutant of Homing endonuclease I-CreI
1U0D	;	2.9	;	Y33H Mutant of Homing endonuclease I-CreI
8OLH	;	1.23	;	Y345F Variant of Dye Type Peroxidase Aa (DtpAa) from Streptomyces lividans
8OLP	;	1.27	;	Y345F/F347Y Variant of Dye Type Peroxidase Aa (DtpAa) from Streptomyces lividans
8OMC	;	1.5	;	Y345F/F347Y/Y389F Variant of Dye Type Peroxidase Aa (DtpAa) from Streptomyces lividans
3P84	;	1.1	;	Y351A mutant of pentaerythritol tetranitrate reductase containing a bound acetate molecule
3P8I	;	1.19	;	Y351F mutant of pentaerythritol tetranitrate reductase containing a bound acetate molecule
3P8J	;	1.0	;	Y351S mutant of pentaerythritol tetranitrate reductase containing a bound acetate molecule
2H6H	;	1.8	;	Y365F Protein Farnesyltransferase Mutant Complexed with a Farnesylated DDPTASACVLS Peptide Product at 1.8A
2BER	;	1.8	;	Y370G Active Site Mutant of the Sialidase from Micromonospora viridifaciens in complex with beta-Neu5Ac (sialic acid).
2MMK	;		;	Y41 and T47 phosphorylation of the Mengovirus Leader Protein: NMR Studies of the Phosphorylation of the Mengovirus Leader Protein Reveal Stabilization of Intermolecular Domain Interactions
8D2Y	;	1.22	;	Y430F mutant of D-ornithine/D-lysine decarboxylase
5O10	;	1.36	;	Y48H mutant of human cytochrome c
3T6L	;	1.3	;	Y54F mutant of core streptavidin
5I21	;	1.55	;	Y55W Hfq from Pseudomonas aeruginosa
3VHO	;	1.93	;	Y61-gg insertion mutant of Tm-Cellulase 12A
3VHN	;	2.5	;	Y61G mutant of Cellulase 12A from thermotoga maritima
1Z1Q	;	1.5	;	Y66L Variant of Enhanced Green Fluorescent Protein with 374-nm Absorbing Chromophore
1Z1P	;	2.0	;	Y66L variant of Enhanced Green Fluorescent Protein with 412-nm Absorbing Chromophore
5DY9	;	1.6	;	Y68T Hfq from Methanococcus jannaschii in complex with AMP
2YCN	;	2.04	;	Y71F mutant of tyrosine phenol-lyase from Citrobacter freundii in complex with quinonoid intermediate formed with 3-fluoro-L-tyrosine
5GV4	;	2.09	;	Y74COX MUTANT OF PLASMODIUM FALCIPARUM TRIOSEPHOSPHATE ISOMERASE
5GZP	;	2.03	;	Y74COX MUTANT OF PLASMODIUM FALCIPARUM TRIOSEPHOSPHATE ISOMERASE
4MSW	;	2.06	;	Y78 ester mutant of KcsA in high K+
1T2H	;	1.0	;	Y81W mutant of RNase Sa from Streptomyces aureofaciens
6SE5	;	2.21	;	Y830A mutant from Mycoplasma genitalium P110 adhesin
3KKK	;	2.08	;	Y92C catalytic residue mutant of Phosphoglycerate Mutase from Plasmodium falciparum
5X8V	;	1.66	;	Y92H mutant of thermus thermophilus HB8 thymidylate kinase
1OBV	;	2.1	;	Y94F flavodoxin from Anabaena
2FTO	;	2.0	;	Y94F mutant of thymidylate synthase bound to thymidine-5'-phosphate and 10-propargyl-5,8-dideazafolid acid
3GU2	;	2.0	;	Y97L/G100-/E101- mutant in organophosphorus hydrolase
3GU1	;	2.0	;	Y97W mutant in organophosphorus hydrolase from Deinococcus radiodurans
1F4P	;	1.3	;	Y98W FLAVODOXIN MUTANT 1.5A (D. VULGARIS)
5XAL	;	1.84	;	Y99F mutant of Thermus thermophilus HB8 thymidylate kinase
6JIE	;	1.75	;	YaeO bound to Magnesium from Vibrio cholerae O395
1IN0	;	2.14	;	YAJQ PROTEIN (HI1034)
2LTW	;		;	YAP WW1 in complex with a Smad7 derived peptide
2L4J	;		;	Yap ww2
2LTV	;		;	YAP WW2 in complex with a Smad7 derived peptide
6IM5	;	1.701	;	YAP-binding domain of human TEAD1
1JMQ	;		;	YAP65 (L30K mutant) WW domain in Complex with GTPPPPYTVG peptide
1K9R	;		;	YAP65 WW domain complexed to Acetyl-PLPPY
1K9Q	;		;	YAP65 WW domain complexed to N-(n-octyl)-GPPPY-NH2
1K5R	;		;	YAP65 WW domain S24-Amino-Ethylsulfanyl-Acetic Acid mutant
8EAV	;	5.7	;	YAR027W and YAR028W in complex with c subunits from yeast VO complex
6EK7	;	1.8	;	YaxA from Yersinia enterocolitica
6EL1	;	6.1	;	YaxAB pore complex
6EK8	;	4.0	;	YaxB from Yersinia enterocolitica
1YTT	;	1.8	;	YB SUBSTITUTED SUBTILISIN FRAGMENT OF MANNOSE BINDING PROTEIN-A (SUB-MBP-A), MAD STRUCTURE AT 110K
2PZH	;	1.7	;	YbgC thioesterase (Hp0496) from Helicobacter pylori
6BA8	;	1.9	;	YbtT - Type II thioesterase from Yersiniabactin NRPS/PKS biosynthetic pathway
6BA9	;	1.4	;	YbtT - Type II thioesterase from Yersiniabactin NRPS/PKS biosynthetic pathway- S89A mutant
4WGF	;	2.34021	;	YcaC from Pseudomonas aeruginosa with hexane-2,5-diol and covalent acrylamide
4WH0	;	2.563	;	YcaC from Pseudomonas aeruginosa with S-mercaptocysteine active site cysteine
4Q86	;	2.25	;	YcaO with AMP Bound
4Q85	;	3.29	;	YcaO with Non-hydrolyzable ATP (AMPCPP) Bound
7U58	;	3.1	;	YcaO-mediated ATP-dependent peptidase activity in ribosomal peptide biosynthesis
7CPJ	;	3.3	;	ycbZ-stalled 70S ribosome
1M65	;	1.57	;	YCDX PROTEIN
1PB0	;	1.95	;	YCDX PROTEIN IN AUTOINHIBITED STATE
1M68	;	2.3	;	YCDX PROTEIN, TRINUCLEAR ZINC SITE
5OJ5	;	1.08	;	YCF48 bound to D1 peptide
5OJP	;	1.86	;	YCF48 bound to D1 peptide
5OJR	;	1.96	;	YCF48 bound to D1 peptide
5OJ3	;	2.982	;	YCF48 from Cyanidioschyzon merolae
2GYQ	;	1.4	;	YcfI, a putative structural protein from Rhodopseudomonas palustris.
1JAL	;	2.4	;	YCHF PROTEIN (HI0393)
6NZ4	;	1.92	;	YcjX-GDP (type I)
6NZ6	;	1.95	;	YcjX-GDP (type II)
6NZ5	;	2.233	;	YcjX-GDPCP
4QZ4	;	3.0	;	yCP beta5-A49S mutant in complex with the epoxyketone inhibitor ONX 0914
4QUY	;	2.8	;	yCP beta5-A49S-mutant
4QVW	;	3.0	;	yCP beta5-A49S-mutant in complex with bortezomib
4QWI	;	2.6	;	yCP beta5-A49S-mutant in complex with carfilzomib
4QZ6	;	2.9	;	yCP beta5-A49T-A50V double mutant in complex with the epoxyketone inhibitor ONX 0914
4QV0	;	3.1	;	yCP beta5-A49T-A50V-double mutant
4QW0	;	2.9	;	yCP beta5-A49T-A50V-double mutant in complex with bortezomib
4QWK	;	2.8	;	yCP beta5-A49T-A50V-double mutant in complex with carfilzomib
4QUX	;	3.0	;	yCP beta5-A49T-mutant
4QVY	;	2.51	;	yCP beta5-A49T-mutant in complex with bortezomib
4QWJ	;	2.9	;	yCP beta5-A49T-mutant in complex with carfilzomib
4QZ5	;	2.8	;	yCP beta5-A49T-mutant in complex with ONX 0914
4QV6	;	2.8	;	yCP beta5-A49V mutant
4QVV	;	2.8	;	yCP beta5-A49V mutant in complex with bortezomib
4QWG	;	2.6	;	yCP beta5-A49V mutant in complex with carfilzomib
4QZ3	;	2.8	;	yCP beta5-A49V mutant in complex with the epoxyketone inhibitor ONX 0914
4QV7	;	2.6	;	yCP beta5-A50V mutant
4QW1	;	2.9	;	yCP beta5-A50V mutant in complex with bortezomib
4QWL	;	2.6	;	yCP beta5-A50V mutant in complex with carfilzomib
4QZ7	;	2.8	;	yCP beta5-A50V mutant in complex with the epoxyketone inhibitor ONX 0914
4QV8	;	2.9	;	yCP beta5-C52F mutant
4QWU	;	3.0	;	yCP beta5-C52F mutant in complex with bortezomib
4QWR	;	2.9	;	yCP beta5-C52F mutant in complex with carfilzomib
4R00	;	2.8	;	yCP beta5-C52F mutant in complex with Omuralide
4QZW	;	3.0	;	yCP beta5-C52F mutant in complex with the epoxyketone inhibitor ONX 0914
4QV9	;	2.6	;	yCP beta5-C63F mutant
4QW3	;	2.9	;	yCP beta5-C63F mutant in complex with bortezomib
4QWS	;	3.0	;	yCP beta5-C63F mutant in complex with carfilzomib
4QZX	;	2.6	;	yCP beta5-C63F mutant in complex with the epoxyketone inhibitor ONX 0914
4QV1	;	2.5	;	yCP beta5-M45A mutant
4QVM	;	2.8	;	yCP beta5-M45A mutant in complex with bortezomib
4QW5	;	3.0	;	yCP beta5-M45A mutant in complex with carfilzomib
4QXJ	;	2.8	;	yCP beta5-M45A mutant in complex with the epoxyketone inhibitor ONX 0914
4QV5	;	2.7	;	yCP beta5-M45I mutant
4QVQ	;	2.6	;	yCP beta5-M45I mutant in complex with bortezomib
4QWF	;	3.0	;	yCP beta5-M45I mutant in complex with carfilzomib
4QZ2	;	2.7	;	yCP beta5-M45I mutant in complex with the epoxyketone inhibitor ONX 0914
4QV4	;	2.7	;	yCP beta5-M45T mutant
4QVP	;	2.3	;	yCP beta5-M45T mutant in complex with bortezomib
4QW7	;	2.7	;	yCP beta5-M45T mutant in complex with carfilzomib
4QZ1	;	3.0	;	yCP beta5-M45T mutant in complex with the epoxyketone inhibitor ONX 0914
4QV3	;	3.0	;	yCP beta5-M45V mutant
4QVN	;	2.9	;	yCP beta5-M45V mutant in complex with bortezomib
4QW6	;	2.9	;	yCP beta5-M45V mutant in complex with carfilzomib
4QZ0	;	3.0	;	yCP beta5-M45V mutant in complex with the epoxyketone inhibitor ONX 0914
4QBY	;	3.0	;	yCP in complex with BOC-ALA-ALA-ALA-CHO
4QVL	;	2.8	;	yCP in complex with bortezomib
4R02	;	2.5	;	yCP in complex with BSc4999 (alpha-Keto Phenylamide)
4QW4	;	2.8	;	yCP in complex with carfilzomib
4NNN	;	2.5	;	yCP in complex with MG132
4QZZ	;	2.9	;	yCP in complex with Omuralide
4QWX	;	2.9	;	yCP in complex with the epoxyketone inhibitor ONX 0914
4QLS	;	2.8	;	yCP in complex with tripeptidic epoxyketone inhibitor 11
4QLV	;	2.9	;	yCP in complex with tripeptidic epoxyketone inhibitor 17
4QLT	;	2.8	;	yCP in complex with tripeptidic epoxyketone inhibitor 2 (PR924)
4QLQ	;	2.4	;	yCP in complex with tripeptidic epoxyketone inhibitor 8
4QLU	;	2.8	;	yCP in complex with tripeptidic epoxyketone inhibitor 9
4NO1	;	2.5	;	yCP in complex with Z-Leu-Leu-Leu-B(OH)2
4NO9	;	2.9	;	yCP in complex with Z-Leu-Leu-Leu-epoxyketone
4NNW	;	2.6	;	yCP in complex with Z-Leu-Leu-Leu-ketoaldehyde
4NO8	;	2.7	;	yCP in complex with Z-Leu-Leu-Leu-ketoamide
4NO6	;	3.0	;	yCP in complex with Z-Leu-Leu-Leu-vinylsulfone
4QLM	;	2.721	;	ydao riboswitch binding to c-di-AMP
8C7K	;		;	YdaS from E. coli O157:H7 cryptic prophage CP-933P
8CO2	;	1.63881	;	YdaS N-terminal domain from prophage CP-933P in E. coli O157:H7
8BT1	;	2.39788	;	YdaT transcription regulator (CII functional analog)
1NE8	;	2.1	;	YDCE protein from Bacillus subtilis
1OG6	;	2.8	;	ydhF, an aldo-keto reductase from E.coli complexed with NADPH
6LNA	;	1.701	;	YdiU complex with AMPNPP and Mn2+
7CNM	;	2.44	;	YDX in complex with tubulin
1CK2	;		;	YEAST (SACCHAROMYCES CEREVISIAE) RIBOSOMAL PROTEIN L30
5CZ4	;	2.3	;	Yeast 20S proteasome at 2.3 A resolution
5FGI	;	2.9	;	Yeast 20S proteasome beta1-T1A beta2-T1A double mutant in complex with Carfilzomib
5CZ5	;	2.8	;	Yeast 20S proteasome beta1-T1A mutant in complex with Carfilzomib
5BXL	;	2.8	;	Yeast 20S proteasome beta2-G170A mutant
5BXN	;	2.8	;	Yeast 20S proteasome beta2-G170A mutant in complex with Bortezomib
6HWC	;	2.8	;	Yeast 20S proteasome beta2-G45A mutant
6HWD	;	2.8	;	Yeast 20S proteasome beta2-G45A mutant in complex with bortezomib
6HWE	;	2.3	;	Yeast 20S proteasome beta2-G45A mutant in complex with carfilzomib
6HWF	;	2.5	;	Yeast 20S proteasome beta2-G45A mutant in complex with ONX 0914
4YA4	;	2.9	;	Yeast 20S proteasome beta2-H114D mutant
4YA9	;	2.7	;	Yeast 20S proteasome beta2-H114D mutant in complex with Ac-LAD-ep
4YA7	;	2.7	;	Yeast 20S proteasome beta2-H114D mutant in complex with Ac-LAE-ep
4Y6A	;	2.6	;	Yeast 20S proteasome beta2-H114D mutant in complex with Ac-PAD-ep
4YA5	;	2.5	;	Yeast 20S proteasome beta2-H114D mutant in complex with Ac-PAE-ep
4Y8R	;	2.7	;	Yeast 20S proteasome beta2-H116D mutant
4Y8S	;	2.7	;	Yeast 20S proteasome beta2-H116D mutant in complex with Ac-LAE-ep
4Y8U	;	2.9	;	Yeast 20S proteasome beta2-H116D mutant in complex with Ac-PAD-ep
4Y8T	;	2.7	;	Yeast 20S proteasome beta2-H116D mutant in complex with Ac-PAE-ep
4Y9Y	;	2.8	;	Yeast 20S proteasome beta2-H116E mutant
4Y9Z	;	2.8	;	Yeast 20S proteasome beta2-H116E mutant in complex with Ac-LAE-ep
4YA0	;	2.8	;	Yeast 20S proteasome beta2-H116E mutant in complex with Ac-PAE-ep
4YA1	;	2.9	;	Yeast 20S proteasome beta2-H116N mutant
4YA2	;	2.7	;	Yeast 20S proteasome beta2-H116N mutant in complex with Ac-LAE-ep
4YA3	;	2.7	;	Yeast 20S proteasome beta2-H116N mutant in complex with Ac-PAE-ep
5FG9	;	2.6	;	Yeast 20S proteasome beta2-T(-2)V mutant
5FG7	;	2.7	;	Yeast 20S proteasome beta2-T1A mutant
5CZA	;	2.5	;	Yeast 20S proteasome beta5-D166N mutant
5D0S	;	2.5	;	Yeast 20S proteasome beta5-D166N mutant in complex with Carfilzomib
5D0T	;	2.6	;	Yeast 20S proteasome beta5-D166N mutant in complex with MG132
5CZ9	;	2.9	;	Yeast 20S proteasome beta5-D17N mutant in complex with Carfilzomib; Propeptide expressed in trans
5CGF	;	2.8	;	Yeast 20S proteasome beta5-G48C mutant
5CGG	;	2.9	;	Yeast 20S proteasome beta5-G48C mutant in complex with alpha-chloroacetamide 1
5CGH	;	2.5	;	Yeast 20S proteasome beta5-G48C mutant in complex with alpha-chloroacetamide 5
5CGI	;	2.8	;	Yeast 20S proteasome beta5-G48C mutant in complex with ONX 0914
5FGF	;	2.6	;	Yeast 20S proteasome beta5-H(-2)A-T1A-K81R triple mutant in complex with Carfilzomib
5FGD	;	2.8	;	Yeast 20S proteasome beta5-H(-2)L-T1A double mutant in complex with Carfilzomib
5FGE	;	2.6	;	Yeast 20S proteasome beta5-H(-2)T-T1A double mutant in complex with Carfilzomib
5FGA	;	2.7	;	Yeast 20S proteasome beta5-K33A mutant (propeptide expressed in trans)
5FHS	;	2.7	;	Yeast 20S proteasome beta5-K33A mutant (propeptide expressed in trans) in complex with Carfilzomib
5FGH	;	2.8	;	Yeast 20S proteasome beta5-K33A mutant (propeptide expressed in trans) in complex with MG132
5CZ8	;	2.8	;	Yeast 20S proteasome beta5-L(-49)S-K33A mutant in complex with Carfilzomib
5FGG	;	2.7	;	Yeast 20S proteasome beta5-L(-49S)_D17N double mutant in complex with Carfilzomib
5CZ7	;	2.5	;	Yeast 20S proteasome beta5-T1A beta5-K81R double mutant in complex with Bortezomib, propeptide expressed in cis
5CZ6	;	2.7	;	Yeast 20S proteasome beta5-T1A mutant in complex with Syringolin A, propeptide expressed in trans
5D0V	;	2.9	;	Yeast 20S proteasome beta5-T1C mutant in complex with Carfilzomib
5D0W	;	2.8	;	Yeast 20S proteasome beta5-T1S mutant
5D0X	;	2.6	;	Yeast 20S proteasome beta5-T1S mutant in complex with Bortezomib
5D0Z	;	2.9	;	Yeast 20S proteasome beta5-T1S mutant in complex with Carfilzomib
4Y8M	;	2.8	;	Yeast 20S proteasome beta7-delta7_Cter mutant
4Y8N	;	2.6	;	Yeast 20S proteasome beta7-delta7_Cter mutant in complex with Ac-PAE-ep
4Y8O	;	2.7	;	Yeast 20S proteasome beta7-delta7_Cter mutant in complex with Ac-PAF-ep
4Y8P	;	2.8	;	Yeast 20S proteasome beta7-delta7_Cter mutant in complex with Ac-PAL-ep
4Y8Q	;	2.6	;	Yeast 20S proteasome beta7-delta7_Cter mutant in complex with Ac-PAY-ep
6HW3	;	2.6	;	Yeast 20S proteasome in complex with 13
6HW4	;	2.9	;	Yeast 20S proteasome in complex with 16
6HW5	;	2.9	;	Yeast 20S proteasome in complex with 18
6HW6	;	2.7	;	Yeast 20S proteasome in complex with 20
6HW7	;	2.7	;	Yeast 20S proteasome in complex with 29
6HW8	;	2.8	;	Yeast 20S proteasome in complex with 39
6HVX	;	2.8	;	Yeast 20S proteasome in complex with 4
6HW9	;	2.8	;	Yeast 20S proteasome in complex with 41b
6HWA	;	2.8	;	Yeast 20S proteasome in complex with 43
6HWB	;	2.6	;	Yeast 20S proteasome in complex with 44b
6HVY	;	2.7	;	Yeast 20S proteasome in complex with 5 (7- and 6-membered ring)
6HW0	;	2.8	;	Yeast 20S proteasome in complex with 7
5BOU	;	2.6	;	Yeast 20S proteasome in complex with a beta1 / beta2 specific non-peptidic sulfonamide Ligand
8OHZ	;	2.65	;	Yeast 20S proteasome in complex with a photoswitchable cepafungin derivative (transCep1)
8OI1	;	2.95	;	Yeast 20S proteasome in complex with a photoswitchable cepafungin derivative (transCep4)
4Y8L	;	2.4	;	Yeast 20S proteasome in complex with Ac-APLL-ep
4Y7Y	;	2.4	;	Yeast 20S proteasome in complex with Ac-LAA-ep
4Y78	;	2.8	;	Yeast 20S proteasome in complex with Ac-LAD-ep
4Y7W	;	2.5	;	Yeast 20S proteasome in complex with Ac-LAE-ep
4Y77	;	2.5	;	Yeast 20S proteasome in complex with Ac-LAF-ep
4Y80	;	2.5	;	Yeast 20S proteasome in complex with Ac-LAI-ep
4Y74	;	2.7	;	Yeast 20S proteasome in complex with Ac-LAL-ep
4Y70	;	2.4	;	Yeast 20S proteasome in complex with Ac-LAV-ep
4Y82	;	2.8	;	Yeast 20S proteasome in complex with Ac-LAY-ep
4Y8J	;	2.7	;	Yeast 20S proteasome in complex with Ac-LLL-ep
4Y7X	;	2.6	;	Yeast 20S proteasome in complex with Ac-PAA-ep
4Y69	;	2.9	;	Yeast 20S proteasome in complex with Ac-PAD-ep
4Y6V	;	2.8	;	Yeast 20S proteasome in complex with Ac-PAE-ep
4Y75	;	2.8	;	Yeast 20S proteasome in complex with Ac-PAF-ep
4Y6Z	;	2.7	;	Yeast 20S proteasome in complex with Ac-PAL-ep
4Y81	;	2.8	;	Yeast 20S proteasome in complex with Ac-PAY-ep
4Y8I	;	2.6	;	Yeast 20S proteasome in complex with Ac-PLL-ep
5DKI	;	2.8	;	Yeast 20S proteasome in complex with alkyne-PI
8BW1	;	3.25	;	Yeast 20S proteasome in complex with an engineered fellutamide derivative (C14QAL)
4Z1L	;	3.0	;	Yeast 20S proteasome in complex with belactosin C derivative 3
5NIF	;	3.0	;	Yeast 20S proteasome in complex with Blm-pep activator
6G7F	;	2.7	;	Yeast 20S proteasome in complex with Cystargolide B
6G8M	;	2.7	;	Yeast 20S proteasome in complex with Cystargolide B Derivative 1
6G8N	;	3.0	;	Yeast 20S proteasome in complex with Cystargolide B Derivative 2
5L52	;	2.7	;	Yeast 20S proteasome in complex with epoxyketone inhibitor 14
5L54	;	2.8	;	Yeast 20S proteasome in complex with epoxyketone inhibitor 16
5L55	;	2.9	;	Yeast 20S proteasome in complex with epoxyketone inhibitor 18
6ZOU	;	2.9	;	Yeast 20S proteasome in complex with glidobactin-like natural product HB333
6ZP6	;	2.8	;	Yeast 20S proteasome in complex with glidobactin-like natural product HB334
6ZP8	;	3.0	;	Yeast 20S proteasome in complex with glidobactin-like natural product HB335
4Y8K	;	2.6	;	Yeast 20S proteasome in complex with H-APLL-ep
6GOP	;	2.9	;	Yeast 20S Proteasome in complex with Homosalinosporamide A
4Q1S	;	2.6	;	Yeast 20S proteasome in Complex with Kendomycin
5AHJ	;	2.8	;	Yeast 20S proteasome in complex with Macyranone A
4Y84	;	2.7	;	Yeast 20S proteasome in complex with N3-A(4,4-F2P)nLL-ep
4Y8H	;	2.5	;	Yeast 20S proteasome in complex with N3-APAL-ep
4Y8G	;	2.6	;	Yeast 20S proteasome in complex with N3-APnLL-ep
5DKJ	;	2.8	;	Yeast 20S proteasome in complex with octreotide-PI
3UN8	;	2.7	;	Yeast 20S proteasome in complex with PR-957 (epoxide)
3UN4	;	3.4	;	Yeast 20S proteasome in complex with PR-957 (morpholine)
4X6Z	;	2.7	;	Yeast 20S proteasome in complex with PR-VI modulator
4RUR	;	2.5	;	Yeast 20S proteasome in complex with the alkaloid indolo-phakellin (4)
4J70	;	2.8	;	Yeast 20S proteasome in complex with the belactosin derivative 3e
7O2L	;	3.0	;	Yeast 20S proteasome in complex with the covalently bound inhibitor b-lactone (2R,3S)-3-isopropyl-4-oxo-2-oxetane-carboxylate (IOC)
4JSU	;	2.9	;	Yeast 20S proteasome in complex with the dimerized linear mimetic of TMC-95A - yCP:3a
4JT0	;	3.1	;	Yeast 20S proteasome in complex with the dimerized linear mimetic of TMC-95A - yCP:4a
4JSQ	;	2.8	;	Yeast 20S proteasome in complex with the dimerized linear mimetic of TMC-95A - yCP:4e
5JHS	;	3.0	;	Yeast 20S proteasome in complex with the peptidic epoxyketone inhibitor 15
5JHR	;	2.9	;	Yeast 20S proteasome in complex with the peptidic epoxyketone inhibitor 27
6H39	;	2.5	;	Yeast 20S proteasome in complex with the peptidic non-covalent binding inhibitor RTS-V5
4GK7	;	2.8	;	yeast 20S proteasome in complex with the Syringolin-Glidobactin chimera
4INR	;	2.7	;	Yeast 20S proteasome in complex with the vinyl sulfone LU102
4INU	;	3.1	;	Yeast 20S proteasome in complex with the vinyl sulfone LU112
4INT	;	2.9	;	Yeast 20S proteasome in complex with the vinyl sulfone LU122
4LQI	;	2.7	;	Yeast 20S Proteasome in complex with Vibralactone
3WXR	;	3.15	;	Yeast 20S proteasome with a mutation of alpha7 subunit
6HTB	;	2.7	;	Yeast 20S proteasome with human beta2c (S171G)
6HTR	;	2.6	;	Yeast 20S proteasome with human beta2c (S171G) in complex with 13
6HUB	;	2.9	;	Yeast 20S proteasome with human beta2c (S171G) in complex with 16
6HUC	;	3.0	;	Yeast 20S proteasome with human beta2c (S171G) in complex with 18
6HUQ	;	3.0	;	Yeast 20S proteasome with human beta2c (S171G) in complex with 20
6HUU	;	2.8	;	Yeast 20S proteasome with human beta2c (S171G) in complex with 29
6HUV	;	3.1	;	Yeast 20S proteasome with human beta2c (S171G) in complex with 39
6HTD	;	3.0	;	Yeast 20S proteasome with human beta2c (S171G) in complex with 4
6HTP	;	3.0	;	Yeast 20S proteasome with human beta2c (S171G) in complex with 7
6HTC	;	2.8	;	Yeast 20S proteasome with human beta2c (S171G) in complex with ONX 0914
6HV3	;	2.7	;	Yeast 20S proteasome with human beta2i (1-53)
6HVA	;	2.9	;	Yeast 20S proteasome with human beta2i (1-53) in complex with 13
6HVR	;	2.7	;	Yeast 20S proteasome with human beta2i (1-53) in complex with 16
6HVS	;	3.1	;	Yeast 20S proteasome with human beta2i (1-53) in complex with 18
6HVT	;	2.9	;	Yeast 20S proteasome with human beta2i (1-53) in complex with 20
6HVU	;	2.9	;	Yeast 20S proteasome with human beta2i (1-53) in complex with 29
6HVV	;	2.7	;	Yeast 20S proteasome with human beta2i (1-53) in complex with 39
6HV5	;	3.0	;	Yeast 20S proteasome with human beta2i (1-53) in complex with 4
6HVW	;	3.0	;	Yeast 20S proteasome with human beta2i (1-53) in complex with 43
6HV7	;	3.4	;	Yeast 20S proteasome with human beta2i (1-53) in complex with 7
6HV4	;	3.0	;	Yeast 20S proteasome with human beta2i (1-53) in complex with ONX 0914
5L5W	;	2.8	;	Yeast 20S proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133)
5L5Z	;	2.7	;	Yeast 20S proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with bortezomib
5L5Y	;	2.7	;	Yeast 20S proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with carfilzomib
5L62	;	2.8	;	Yeast 20S proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 16
5L63	;	2.7	;	Yeast 20S proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 17
5L64	;	2.7	;	Yeast 20S proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 18
5L5X	;	2.9	;	Yeast 20S proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with ONX 0914
5L60	;	2.7	;	Yeast 20S proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with PR-924
5L61	;	2.8	;	Yeast 20S proteasome with human beta5c (1-138) and human beta6 (99-132) in complex with epoxyketone inhibitor 14
5L5B	;	2.8	;	Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133)
5L5F	;	2.5	;	Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with bortezomib
5L5E	;	2.9	;	Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with carfilzomib
5L5Q	;	2.8	;	Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone 18
5L5J	;	2.9	;	Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 14
5L5O	;	2.6	;	Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 16
5L5P	;	2.8	;	Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 17
5L5I	;	2.9	;	Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 9
5L5D	;	2.8	;	Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with ONX 0914
5L5H	;	2.6	;	Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with PR-924
5M2B	;	2.7	;	Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with thiazole based inhibitor Ro19
5L5A	;	2.4	;	Yeast 20S proteasome with human beta5i (1-138; R57T)
5LTT	;	2.7	;	Yeast 20S proteasome with human beta5i (1-138; R57T)in complex with PR-924
5L5T	;	2.9	;	Yeast 20S proteasome with human beta5i (1-138; V31M) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 16
5L5U	;	2.6	;	Yeast 20S proteasome with human beta5i (1-138; V31M) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 17
5L5S	;	2.6	;	Yeast 20S proteasome with human beta5i (1-138; V31M) and human beta6 (97-111; 118-133) in complex with PR-924
5L5R	;	2.9	;	Yeast 20S proteasome with human beta5i (1-138;V31M) and human beta6 (97-111; 118-133)
5L66	;	2.8	;	Yeast 20S proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with bortezomib
5L65	;	2.9	;	Yeast 20S proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with carfilzomib
5L68	;	2.8	;	Yeast 20S proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 14
5L69	;	2.7	;	Yeast 20S proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 16
5L6A	;	2.8	;	Yeast 20S proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 17
5L6C	;	2.6	;	Yeast 20S proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 18
5L6B	;	2.6	;	Yeast 20S proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with ONX 0914
5L67	;	2.6	;	Yeast 20S proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with PR-924
3BDM	;	2.7	;	yeast 20S proteasome:glidobactin A-complex
2ZCY	;	2.9	;	yeast 20S proteasome:syringolin A-complex
6EF0	;	4.43	;	Yeast 26S proteasome bound to ubiquitinated substrate (1D* motor state)
6EF3	;	4.17	;	Yeast 26S proteasome bound to ubiquitinated substrate (4D motor state)
6EF1	;	4.73	;	Yeast 26S proteasome bound to ubiquitinated substrate (5D motor state)
6EF2	;	4.27	;	Yeast 26S proteasome bound to ubiquitinated substrate (5T motor state)
8I7J	;	4.6	;	Yeast 40S-eIF4B - partially open conformation of the 40S head
1EB3	;	1.75	;	YEAST 5-AMINOLAEVULINIC ACID DEHYDRATASE 4,7-DIOXOSEBACIC ACID COMPLEX
1W31	;	1.9	;	YEAST 5-AMINOLAEVULINIC ACID DEHYDRATASE 5-HYDROXYLAEVULINIC ACID COMPLEX
1QNV	;	2.5	;	yeast 5-aminolaevulinic acid dehydratase Lead (Pb) complex
1OHL	;	1.6	;	YEAST 5-AMINOLAEVULINIC ACID DEHYDRATASE PUTATIVE CYCLIC REACTION INTERMEDIATE COMPLEX
5GAK	;	3.88	;	Yeast 60S ribosomal subunit with A-site tRNA, P-site tRNA and eIF-5A
7B7D	;	3.3	;	Yeast 80S ribosome bound to eEF3 and A/A- and P/P-tRNAs
7TOO	;	2.7	;	Yeast 80S ribosome bound with the ALS/FTD-associated dipeptide repeat protein GR20
7TOP	;	2.4	;	Yeast 80S ribosome bound with the ALS/FTD-associated dipeptide repeat protein PR20
6TNU	;	3.1	;	Yeast 80S ribosome in complex with eIF5A and decoding A-site and P-site tRNAs.
8BQD	;	3.9	;	Yeast 80S ribosome in complex with Map1 (conformation 1)
8BQX	;	3.8	;	Yeast 80S ribosome in complex with Map1 (conformation 2)
6TB3	;	2.8	;	yeast 80S ribosome in complex with the Not5 subunit of the CCR4-NOT complex
6SNT	;	2.8	;	Yeast 80S ribosome stalled on SDD1 mRNA.
4V7R	;	4.0	;	Yeast 80S ribosome.
8BN3	;	2.4	;	Yeast 80S, ES7s delta, eIF5A, Stm1 containing
1PI6	;	2.5	;	YEAST ACTIN INTERACTING PROTEIN 1 (Aip1), ORTHORHOMBIC CRYSTAL FORM
1PGU	;	2.3	;	YEAST ACTIN INTERACTING PROTEIN 1 (AIP1), Se-Met PROTEIN, MONOCLINIC CRYSTAL FORM
5LQW	;	5.8	;	yeast activated spliceosome
2BKW	;	2.57	;	Yeast alanine:glyoxylate aminotransferase YFL030w
4W6Z	;	2.4	;	YEAST ALCOHOL DEHYDROGENASE I, SACCHAROMYCES CEREVISIAE FERMENTATIVE ENZYME
5ENV	;	3.0	;	YEAST ALCOHOL DEHYDROGENASE WITH BOUND COENZYME
6HLS	;	3.21	;	Yeast apo RNA polymerase I*
1BS2	;	2.75	;	YEAST ARGINYL-TRNA SYNTHETASE
4EO5	;	2.35	;	Yeast Asf1 bound to H3/H4G94P mutant
7TJU	;	3.3	;	Yeast ATP synthase F1 region State 1-3binding beta_tight open without exogenous ATP
7TJS	;	3.2	;	Yeast ATP synthase F1 region State 1-3catalytic beta_tight closed without exogenous ATP
7TJT	;	3.2	;	Yeast ATP synthase F1 region State 1-3catalytic beta_tight open without exogenous ATP
7TJX	;	4.0	;	Yeast ATP synthase F1 region State 1binding(a-d) with 10 mM ATP
7TJV	;	3.6	;	Yeast ATP synthase F1 region State 1catalytic(a) with 10 mM ATP
7TJW	;	4.0	;	Yeast ATP synthase F1 region State 1catalytic(e-h) with 10 mM ATP
8F29	;	4.0	;	Yeast ATP synthase in conformation-1 at pH 6
8F39	;	3.5	;	Yeast ATP synthase in conformation-2, at pH 6
8FKJ	;	4.2	;	Yeast ATP Synthase in conformation-3, at pH 6
7TK2	;	6.5	;	Yeast ATP synthase State 1binding(a) with 10 mM ATP backbone model
7TK3	;	6.3	;	Yeast ATP synthase State 1binding(b) with 10 mM ATP backbone model
7TK4	;	7.0	;	Yeast ATP synthase State 1binding(c) with 10 mM ATP backbone model
7TK5	;	7.8	;	Yeast ATP synthase State 1binding(d) with 10 mM ATP backbone model
7TK6	;	6.5	;	Yeast ATP synthase State 1catalytic(a) with 10 mM ATP backbone model
7TJY	;	3.8	;	Yeast ATP synthase State 1catalytic(a) without exogenous ATP backbone model
7TK7	;	6.7	;	Yeast ATP synthase State 1catalytic(b) with 10 mM ATP backbone model
7TJZ	;	4.4	;	Yeast ATP synthase State 1catalytic(b) without exogenous ATP backbone model
7TK8	;	4.7	;	Yeast ATP synthase State 1catalytic(c) with 10 mM ATP backbone model
7TK0	;	4.4	;	Yeast ATP synthase State 1catalytic(c) without exogenous ATP backbone model
7TK9	;	6.0	;	Yeast ATP synthase State 1catalytic(d) with 10 mM ATP backbone model
7TK1	;	7.1	;	Yeast ATP synthase State 1catalytic(d) without exogenous ATP backbone model
7TKA	;	7.1	;	Yeast ATP synthase State 1catalytic(e) with 10 mM ATP backbone model
7TKB	;	6.3	;	Yeast ATP synthase State 1catalytic(f) with 10 mM ATP backbone model
7TKC	;	5.8	;	Yeast ATP synthase State 1catalytic(g) with 10 mM ATP backbone model
7TKD	;	7.7	;	Yeast ATP synthase State 1catalytic(h) with 10 mM ATP backbone model
7TKE	;	7.1	;	Yeast ATP synthase State 2binding(a) with 10 mM ATP backbone model
7TKF	;	7.1	;	Yeast ATP synthase State 2binding(b) with 10 mM ATP backbone model
7TKG	;	4.5	;	Yeast ATP synthase State 2catalytic(a) with 10 mM ATP backbone model
7TKH	;	4.4	;	Yeast ATP synthase State 2catalytic(b) with 10 mM ATP backbone model
7TKI	;	7.1	;	Yeast ATP synthase State 2catalytic(c) with 10 mM ATP backbone model
7TKJ	;	7.5	;	Yeast ATP synthase State 2catalytic(d) with 10 mM ATP backbone model
7TKK	;	7.3	;	Yeast ATP synthase State 2catalytic(e) with 10 mM ATP backbone model
7TKL	;	6.4	;	Yeast ATP synthase State 3binding(a) with 10 mM ATP backbone model
7TKM	;	4.5	;	Yeast ATP synthase State 3binding(b) with 10 mM ATP backbone model
7TKN	;	7.1	;	Yeast ATP synthase State 3binding(c) with 10 mM ATP backbone model
7TKO	;	4.8	;	Yeast ATP synthase State 3catalytic(a) with 10 mM ATP backbone model
7TKP	;	4.6	;	Yeast ATP synthase State 3catalytic(b) with 10 mM ATP backbone model
7TKQ	;	4.5	;	Yeast ATP synthase State 3catalytic(c) with 10 mM ATP backbone model
7TKR	;	6.5	;	Yeast ATP synthase State 3catalytic(d) with 10 mM ATP backbone model
7TKS	;	7.5	;	Yeast ATP synthase State 3catalytic(e) with 10 mM ATP backbone model
8FL8	;	4.2	;	Yeast ATP Synthase structure in presence of MgATP
1ZUK	;	1.9	;	Yeast BBC1 Sh3 domain complexed with a peptide from Las17
1WDX	;	2.5	;	Yeast BBC1 SH3 domain, triclinic crystal form
2YNN	;	1.782	;	yeast betaprime COP 1-304 with KTKTN motif
2YNO	;	1.8	;	yeast betaprime COP 1-304H6
2YNP	;	2.962	;	yeast betaprime COP 1-604 with KTKTN motif
7B9V	;	2.8	;	Yeast C complex spliceosome at 2.8 Angstrom resolution with Prp18/Slu7 bound
4CSM	;	2.8	;	YEAST CHORISMATE MUTASE + TYR + ENDOOXABICYCLIC INHIBITOR
5CSM	;	2.0	;	YEAST CHORISMATE MUTASE, T226S MUTANT, COMPLEX WITH TRP
8E5T	;	4.0	;	Yeast co-transcriptional Noc1-Noc2 RNP assembly checkpoint intermediate
1QPV	;	3.0	;	YEAST COFILIN
1CFY	;	2.3	;	YEAST COFILIN, MONOCLINIC CRYSTAL FORM
1COF	;	2.3	;	YEAST COFILIN, ORTHORHOMBIC CRYSTAL FORM
6VEN	;	3.37	;	Yeast COMPASS in complex with a ubiquitinated nucleosome
1TLB	;	2.4	;	Yeast coproporphyrinogen oxidase
7DBG	;	2.06	;	Yeast CRM1e (apo) in complex with Ran-RanBP1
6NUW	;	4.25	;	Yeast Ctf19 complex
7RMO	;	7.0	;	Yeast CTP Synthase (Ura7) Bundle bound to Products at low pH
7RMK	;	6.6	;	Yeast CTP Synthase (Ura7) Bundle bound to substrates at low pH
7RMC	;	3.5	;	Yeast CTP Synthase (Ura7) filament bound to CTP at low pH
7RMV	;	6.7	;	Yeast CTP Synthase (Ura7) H360R Filament bound to Substrates
7RNL	;	3.7	;	Yeast CTP Synthase (Ura7) H360R Filament bound to Substrates
7RNR	;	3.3	;	Yeast CTP Synthase (Ura8) Bundle Bound to Substrates at Low pH
7RL0	;	2.8	;	Yeast CTP Synthase (URA8) Filament bound to ATP/UTP at low pH
7RL5	;	3.8	;	Yeast CTP Synthase (URA8) filament bound to CTP at low pH
7RKH	;	2.8	;	Yeast CTP Synthase (URA8) tetramer bound to ATP/UTP at neutral pH
1YSO	;	1.73	;	YEAST CU, ZN SUPEROXIDE DISMUTASE WITH THE REDUCED BRIDGE BROKEN
3TDI	;	2.3	;	yeast Cul1WHB-Dcn1P acetylated Ubc12N complex
1KB9	;	2.3	;	YEAST CYTOCHROME BC1 COMPLEX
1KYO	;	2.97	;	YEAST CYTOCHROME BC1 COMPLEX WITH BOUND SUBSTRATE CYTOCHROME C
2IBZ	;	2.3	;	Yeast Cytochrome BC1 Complex with Stigmatellin
6SUY	;	1.75	;	Yeast cytochrome c in complex with an octa-anionic calix[4]arene
6P41	;	2.9	;	Yeast cytochrome c peroxidase (W191Y:L232E) in complex with iso-1 cytochrome c
6P42	;	2.905	;	Yeast cytochrome c peroxidase (W191Y:L232H) in complex with iso-1 cytochrome c
6P43	;	1.913	;	Yeast cytochrome c peroxidase in complex with iso-1 cytochrome c (Y48K)
8QCF	;	2.55	;	yeast cytoplasmic exosome-Ski2 complex degrading a RNA substrate
1RB7	;	2.1	;	Yeast cytosine deaminase crystal form p212121 with sodium acetate.
2O3K	;	2.3	;	Yeast Cytosine Deaminase D92E Triple Mutant bound to transition state analogue HPY
1YSD	;	1.9	;	Yeast Cytosine Deaminase Double Mutant
1YSB	;	1.7	;	Yeast Cytosine Deaminase Triple Mutant
6DK9	;	2.6	;	Yeast Ddi2 Cyanamide Hydratase
6DKA	;	2.901	;	Yeast Ddi2 Cyanamide Hydratase
6DKD	;	3.0	;	Yeast Ddi2 Cyanamide Hydratase
6DKC	;	2.9	;	Yeast Ddi2 Cyanamide Hydratase, T157V mutant, apo structure
6JCN	;	1.998	;	Yeast dehydrodolichyl diphosphate synthase complex subunit NUS1
5FK0	;	3.0	;	Yeast delta-COP-I mu-homology domain
5FJW	;	2.8	;	Yeast delta-COP-I mu-homology domain complexed with Dsl1 WxWx(MSE) peptide
5FJZ	;	1.9	;	Yeast delta-COP-I mu-homology domain complexed with Dsl1 WxWxV peptide
5FJX	;	2.45	;	Yeast delta-COP-I mu-homology domain complexed with Gcs1 WxxF peptide
2QIY	;	1.69	;	yeast Deubiquitinase Ubp3 and Bre5 cofactor complex
7AUK	;	2.0	;	Yeast Diphosphoinositol Polyphosphate Phosphohydrolase DDP1 in complex with 5-InsP7
7AUL	;	1.85	;	Yeast Diphosphoinositol Polyphosphate Phosphohydrolase DDP1 in complex with 5-InsP7 in presence of Mg
7AUM	;	2.07	;	Yeast Diphosphoinositol Polyphosphate Phosphohydrolase DDP1 in complex with 5-PCF2Am-InsP5
7AUR	;	1.65	;	Yeast Diphosphoinositol Polyphosphate Phosphohydrolase DDP1 in complex with AMP-PNP
7AUQ	;	2.25	;	Yeast Diphosphoinositol Polyphosphate Phosphohydrolase DDP1 in complex with Ap5A and Ca2+
7AUI	;	1.98	;	Yeast Diphosphoinositol Polyphosphate Phosphohydrolase DDP1 in complex with InsP6
7AUS	;	1.75	;	Yeast Diphosphoinositol Polyphosphate Phosphohydrolase DDP1 in complex with P15
7AUO	;	2.65	;	Yeast Diphosphoinositol Polyphosphate Phosphohydrolase DDP1 in complex with PA-InsP8
7AUP	;	1.85	;	Yeast Diphosphoinositol Polyphosphate Phosphohydrolase DDP1 in complex with PCP-InsP7
7AUN	;	1.95	;	Yeast Diphosphoinositol Polyphosphate Phosphohydrolase DDP1 in complex with PCP-InsP8
7AUJ	;	2.1	;	Yeast Diphosphoinositol Polyphosphate Phosphohydrolase DDP1 mutation E80Q in complex with 1-InsP7
7AUT	;	1.6	;	Yeast Diphosphoinositol Polyphosphate Phosphohydrolase DDP1 mutation K63A
7AUU	;	2.45	;	Yeast Diphosphoinositol Polyphosphate Phosphohydrolase DDP1-nose mutant in complex with InsP6
7EJ7	;	3.41	;	Yeast Dmc1 post-synaptic complex
7EJ6	;	3.21	;	Yeast Dmc1 presynaptic complex
4B08	;	2.67	;	Yeast DNA polymerase alpha, Selenomethionine protein
1JIH	;	2.25	;	Yeast DNA Polymerase ETA
3OHB	;	2.0	;	Yeast DNA polymerase eta extending from an 8-oxoG lesion
2XGP	;	2.7	;	Yeast DNA polymerase eta in complex with C8-2-acetylaminofluorene containing DNA
3OHA	;	2.0	;	Yeast DNA polymerase eta inserting dCTP opposite an 8oxoG lesion
1OIS	;	1.9	;	YEAST DNA TOPOISOMERASE I, N-TERMINAL FRAGMENT
7MI6	;	3.9	;	Yeast dynein motor domain in the presence of a pyrazolo-pyrimidinone-based compound, Model 1
1G7C	;	2.05	;	YEAST EEF1A:EEF1BA IN COMPLEX WITH GDPNP
1ONE	;	1.8	;	YEAST ENOLASE COMPLEXED WITH AN EQUILIBRIUM MIXTURE OF 2'-PHOSPHOGLYCEATE AND PHOSPHOENOLPYRUVATE
4ZDB	;	2.14	;	Yeast enoyl-CoA isomerase (ScECI2) complexed with acetoacetyl-CoA
4ZDC	;	2.13	;	Yeast enoyl-CoA isomerase complexed with octanoyl-CoA
3ONK	;	2.09	;	yeast Ent3_ENTH domain
3ONL	;	2.2	;	yeast Ent3_ENTH-Vti1p_Habc complex structure
3FKS	;	3.587	;	Yeast F1 ATPase in the absence of bound nucleotides
2GA5	;		;	yeast frataxin
7Q51	;	2.22	;	yeast Gid10 bound to a Phe/N-peptide
7QQY	;	1.26	;	yeast Gid10 bound to Art2 Pro/N-degron
7VGW	;	2.8	;	Yeast gid10 with Pro-peptide
7JTZ	;	2.07	;	Yeast Glo3 GAP domain
1M0T	;	2.3	;	Yeast Glutathione Synthase
1M0W	;	1.8	;	Yeast Glutathione Synthase Bound to gamma-glutamyl-cysteine, AMP-PNP and 2 Magnesium Ions
3NCH	;	2.88	;	Yeast Glycogen Synthase (Gsy2p) Basal State Conformation
6OH9	;	1.75	;	Yeast Guanine Deaminase
6OHA	;	2.21	;	Yeast Guanine Deaminase
2B7C	;	1.8	;	Yeast guanine nucleotide exchange factor eEF1Balpha K205A mutant in complex with eEF1A
2B7B	;	2.6	;	Yeast guanine nucleotide exchange factor eEF1Balpha K205A mutant in complex with eEF1A and GDP
1UST	;		;	YEAST HISTONE H1 GLOBULAR DOMAIN I, HHO1P GI, SOLUTION NMR STRUCTURES
1USS	;		;	YEAST HISTONE H1 GLOBULAR DOMAIN II, HHO1P GII, SOLUTION NMR STRUCTURES
6NSX	;	2.0	;	Yeast Hsh155 Ligand bound to Human Tat-SF1 Motif
5WBW	;	2.6	;	Yeast Hsp104 fragment 1-360
1ZW9	;	1.9	;	Yeast HSP82 in complex with the Novel HSP90 Inhibitor 8-(6-Bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-(3-isopropylamino-propyl)-adenine
2FXS	;	2.0	;	Yeast HSP82 in complex with the novel HSP90 Inhibitor Radamide
1ZWH	;	1.65	;	Yeast Hsp82 in complex with the novel Hsp90 inhibitor Radester amine
3C11	;	1.6	;	Yeast Hsp82 N-terminal domain-Geldanamycin complex: effects of mutants 98-99 KS-AA
3C0E	;	1.9	;	Yeast Hsp82 N-terminal domain: effects of mutants 98-99 KS-AA
2WEP	;	2.0	;	Yeast Hsp90 N-terminal domain LI-IV mutant with ADP
2WEQ	;	2.2	;	Yeast Hsp90 N-terminal domain LI-IV mutant with Geldanamycin
2WER	;	1.6	;	Yeast Hsp90 N-terminal domain LI-IV mutant with Radicicol
1FUU	;	2.5	;	YEAST INITIATION FACTOR 4A
1QVA	;	2.5	;	YEAST INITIATION FACTOR 4A N-TERMINAL DOMAIN
1YFG	;	3.0	;	YEAST INITIATOR TRNA
2IK2	;	1.8	;	Yeast inorganic pyrophosphatase variant D115E with magnesium and phosphate
2IK4	;	1.8	;	Yeast inorganic pyrophosphatase variant D117E with magnesium and phosphate
2IK6	;	1.8	;	Yeast inorganic pyrophosphatase variant D120E with magnesium and phosphate
2IK7	;	1.9	;	Yeast inorganic pyrophosphatase variant D120N with magnesium and phosphate
2IK9	;	1.5	;	Yeast inorganic pyrophosphatase variant D152E with magnesium and phosphate
2IK0	;	1.7	;	Yeast inorganic pyrophosphatase variant E48D with magnesium and phosphate
2IK1	;	1.7	;	Yeast inorganic pyrophosphatase variant Y93F with magnesium and phosphate
2IHP	;	1.5	;	Yeast inorganic pyrophosphatase with magnesium and phosphate
3BLX	;	2.7	;	Yeast Isocitrate Dehydrogenase (Apo Form)
3BLW	;	4.3	;	Yeast Isocitrate Dehydrogenase with Citrate and AMP Bound in the Regulatory Subunits
3BLV	;	3.2	;	Yeast Isocitrate Dehydrogenase with Citrate Bound in the Regulatory Subunits
1EE5	;	2.4	;	YEAST KARYOPHERIN (IMPORTIN) ALPHA IN A COMPLEX WITH A NUCLEOPLASMIN NLS PEPTIDE
7SXO	;	3.3	;	Yeast Lon (PIM1) with endogenous substrate
1MNM	;	2.25	;	YEAST MATALPHA2/MCM1/DNA TERNARY TRANSCRIPTION COMPLEX CRYSTAL STRUCTURE
5W3H	;	4.0	;	Yeast microtubule stabilized with epothilone
5W3J	;	4.0	;	Yeast microtubule stabilized with Taxol assembled from mutated tubulin
1HR6	;	2.5	;	Yeast Mitochondrial Processing Peptidase
1HR7	;	2.55	;	Yeast Mitochondrial Processing Peptidase beta-E73Q Mutant
1HR8	;	2.7	;	Yeast Mitochondrial Processing Peptidase beta-E73Q Mutant Complexed with Cytochrome C Oxidase IV Signal Peptide
1HR9	;	3.01	;	Yeast Mitochondrial Processing Peptidase beta-E73Q Mutant Complexed with Malate Dehydrogenase Signal Peptide
6F4A	;	3.55	;	Yeast mitochondrial RNA degradosome complex mtEXO
8D8J	;	3.8	;	Yeast mitochondrial small subunit assembly intermediate (State 1)
8D8K	;	3.13	;	Yeast mitochondrial small subunit assembly intermediate (State 2)
8D8L	;	2.6	;	Yeast mitochondrial small subunit assembly intermediate (State 3)
1VA7	;	2.9	;	Yeast Myo3 SH3 domain, triclinic crystal form
1YP5	;	1.68	;	Yeast Myo5 SH3 domain, tetragonal crystal form
3W6X	;	2.299	;	Yeast N-acetyltransferase Mpr1 in complex with CHOP
3W6S	;	1.9	;	yeast N-acetyltransferase Mpr1 involved in oxidative stress tolerance via proline metabolism
2LCS	;		;	Yeast Nbp2p SH3 domain in complex with a peptide from Ste20p
4CV5	;	3.807	;	yeast NOT1 CN9BD-CAF40 complex
4BY6	;	2.797	;	Yeast Not1-Not2-Not5 complex
6JWI	;	2.55	;	Yeast Npl4 in complex with Lys48-linked diubiquitin
6JWH	;	1.72	;	Yeast Npl4 zinc finger, MPN and CTD domains
6C0F	;	3.7	;	Yeast nucleolar pre-60S ribosomal subunit (state 2)
6CB1	;	4.6	;	Yeast nucleolar pre-60S ribosomal subunit (state 3)
1TK1	;	1.9	;	YEAST OXYGEN-DEPENDENT COPROPORPHYRINOGEN OXIDASE
1TKL	;	2.0	;	Yeast Oxygen-Dependent Coproporphyrinogen Oxidase
2V1R	;	2.1	;	Yeast Pex13 SH3 domain complexed with a peptide from Pex14 at 2.1 A resolution
8U0X	;	1.86	;	Yeast Pex6 N1(1-184) Domain
1QHF	;	1.7	;	YEAST PHOSPHOGLYCERATE MUTASE-3PG COMPLEX STRUCTURE TO 1.7 A
3C66	;	2.6	;	Yeast poly(A) polymerase in complex with Fip1 residues 80-105
4ECH	;	2.4	;	Yeast Polyamine Oxidase FMS1, H67Q Mutant
4GDP	;	1.9998	;	Yeast polyamine oxidase FMS1, N195A mutant
1K0K	;	2.35	;	Yeast Profilin, Cubic Crystal Form
6J2X	;	3.8	;	Yeast proteasome in resting state (C1-a)
6J2N	;	7.5	;	yeast proteasome in substrate-processing state (C3-b)
6J2C	;	7.0	;	Yeast proteasome in translocation competent state (C3-a)
6J2Q	;	3.8	;	Yeast proteasome in Ub-accepted state (C1-b)
6J30	;	4.5	;	yeast proteasome in Ub-engaged state (C2)
5WVK	;	4.2	;	Yeast proteasome-ADP-AlFx
4YHW	;	3.25	;	Yeast Prp3 (296-469) in complex with fragment of U4/U6 di-snRNA
4YHU	;	2.7	;	Yeast Prp3 C-terminal fragment 296-469
4YHV	;	2.0	;	Yeast Prp3 C-terminal fragment 325-469
5AX7	;	2.46	;	yeast pyruvyltransferase Pvg1p
3LDA	;	2.5	;	Yeast Rad51 H352Y Filament Interface Mutant
4A3T	;	2.1	;	yeast regulatory particle proteasome assembly chaperone Hsm3
4A3V	;	3.8	;	yeast regulatory particle proteasome assembly chaperone Hsm3 in complex with Rpt1 C-terminal fragment
8KG6	;	3.07	;	Yeast replisome in state I
8KG8	;	4.23	;	Yeast replisome in state II
8KG9	;	4.52	;	Yeast replisome in state III
8W7S	;	7.39	;	Yeast replisome in state IV
8W7M	;	4.12	;	Yeast replisome in state V
1CN7	;		;	Yeast ribosomal protein L30
5M3F	;	3.8	;	Yeast RNA polymerase I elongation complex at 3.8A
6HKO	;	3.42	;	Yeast RNA polymerase I elongation complex bound to nucleotide analog GMPCPP
6HLR	;	3.18	;	Yeast RNA polymerase I elongation complex bound to nucleotide analog GMPCPP (core focused)
6H67	;	3.6	;	Yeast RNA polymerase I elongation complex stalled by cyclobutane pyrimidine dimer (CPD)
6H68	;	4.6	;	Yeast RNA polymerase I elongation complex stalled by cyclobutane pyrimidine dimer (CPD) with fully-ordered A49
6HLQ	;	3.18	;	Yeast RNA polymerase I* elongation complex bound to nucleotide analog GMPCPP
7O4J	;	2.9	;	Yeast RNA polymerase II transcription pre-initiation complex (consensus)
7O73	;	3.4	;	Yeast RNA polymerase II transcription pre-initiation complex with closed distorted promoter DNA
7O72	;	3.4	;	Yeast RNA polymerase II transcription pre-initiation complex with closed promoter DNA
8CEN	;	3.0	;	Yeast RNA polymerase II transcription pre-initiation complex with core Mediator
8CEO	;	3.6	;	Yeast RNA polymerase II transcription pre-initiation complex with core Mediator and the +1 nucleosome
7O4I	;	3.2	;	Yeast RNA polymerase II transcription pre-initiation complex with initial transcription bubble
7O75	;	3.2	;	Yeast RNA polymerase II transcription pre-initiation complex with open promoter DNA
7ZS9	;	3.1	;	Yeast RNA polymerase II transcription pre-initiation complex with the +1 nucleosome (complex A)
7ZSA	;	4.0	;	Yeast RNA polymerase II transcription pre-initiation complex with the +1 nucleosome and NTP (complex B)
7ZSB	;	6.6	;	Yeast RNA polymerase II transcription pre-initiation complex with the +1 nucleosome and NTP, complex C
6CNF	;	4.5	;	Yeast RNA polymerase III elongation complex
6CNB	;	4.1	;	Yeast RNA polymerase III initial transcribing complex
6CND	;	4.8	;	Yeast RNA polymerase III natural open complex (nOC)
6CNC	;	4.1	;	Yeast RNA polymerase III open complex
1A1D	;		;	YEAST RNA POLYMERASE SUBUNIT RPB8, NMR, MINIMIZED AVERAGE STRUCTURE, ALPHA CARBONS ONLY
3H3V	;	4.0	;	Yeast RNAP II containing poly(A)-signal sequence in the active site
6I52	;	4.7	;	Yeast RPA bound to ssDNA
8AGW	;	2.6	;	Yeast RQC complex in state D
8AGU	;	2.7	;	Yeast RQC complex in state E
8AGT	;	2.6	;	Yeast RQC complex in state F
8AAF	;	2.5	;	Yeast RQC complex in state G
8AGV	;	2.6	;	Yeast RQC complex in state H
8AGX	;	2.4	;	Yeast RQC complex in state with the RING domain of Ltn1 in the IN position
8AGZ	;	2.6	;	Yeast RQC complex in state with the RING domain of Ltn1 in the OUT position
2WP8	;	3.0	;	yeast rrp44 nuclease
5BV3	;	2.25	;	Yeast Scavenger Decapping Enzyme in complex with m7GDP
7EA5	;	3.3	;	Yeast Set2 bound to a nucleosome containing oncohistone mutations
2VKN	;	2.05	;	YEAST SHO1 SH3 DOMAIN COMPLEXED WITH A PEPTIDE FROM PBS2
4RSI	;	2.9	;	Yeast Smc2-Smc4 hinge domain with extended coiled coils
6OD2	;	2.435	;	Yeast Spc42 C-terminal Antiparallel Coiled-Coil
6OEI	;	2.58	;	Yeast Spc42 N-terminal coiled-coil fused to PDB: 3K2N
6OEC	;	2.514	;	Yeast Spc42 Trimeric Coiled-Coil Amino Acids 181-211 fused to PDB: 3H5I
5VKY	;	2.3	;	Yeast Tda2 (YER071C) - a dynein light chain family member that works independently of the dynein motor complex and microtubules.
1YTF	;	2.5	;	YEAST TFIIA/TBP/DNA COMPLEX
7O4K	;	3.6	;	Yeast TFIIH in the contracted state within the pre-initiation complex
7O4L	;	3.4	;	Yeast TFIIH in the expanded state within the pre-initiation complex
6XI8	;	3.64	;	Yeast TFIIK (Kin28/Ccl1/Tfb3) Complex
6UTL	;	2.6	;	Yeast Thiol Specific antoxidant 2 with C171S mutation and catalytic cysteine alkylated with iodoacetamide
7APX	;	3.4	;	yeast THO-Sub2 complex
7AQO	;	4.5	;	yeast THO-Sub2 complex dimer
2TMK	;	2.4	;	YEAST THYMIDYLATE KINASE COMPLEXED WITH 3'-AZIDO-3'-DEOXYTHYMIDINE MONOPHOSPHATE (AZT-MP)
1TMK	;	2.1	;	YEAST THYMIDYLATE KINASE COMPLEXED WITH THYMIDINE MONOPHOSPHATE (DTMP)
3QK9	;	3.1	;	Yeast Tim44 C-terminal domain complexed with Cymal-3
7YLY	;	3.05	;	yeast TRiC-plp2 complex at S5 closed TRiC state
7YLX	;	3.2	;	yeast TRiC-plp2-actin complex at S4 closed TRiC state
7YLU	;	4.55	;	yeast TRiC-plp2-substrate complex at S1 TRiC-NPP state
7YLV	;	3.91	;	yeast TRiC-plp2-substrate complex at S2 ATP binding state
7YLW	;	3.39	;	yeast TRiC-plp2-tubulin complex at S3 closed TRiC state
1I45	;	1.8	;	YEAST TRIOSEPHOSPHATE ISOMERASE (MUTANT)
5W3F	;	3.7	;	Yeast tubulin polymerized with GTP in vitro
2LKR	;		;	Yeast U2/U6 complex
6ZHU	;	3.18	;	Yeast Uba1 in complex with Ubc3 and ATP
6ZQH	;	2.032	;	Yeast Uba1 in complex with ubiquitin
5I1M	;	7.0	;	Yeast V-ATPase average of densities, a subunit segment
5VOX	;	6.8	;	Yeast V-ATPase in complex with Legionella pneumophila effector SidK (rotational state 1)
5VOY	;	7.9	;	Yeast V-ATPase in complex with Legionella pneumophila effector SidK (rotational state 2)
5VOZ	;	7.6	;	Yeast V-ATPase in complex with Legionella pneumophila effector SidK (rotational state 3)
3J9T	;	6.9	;	Yeast V-ATPase state 1
3J9U	;	7.6	;	Yeast V-ATPase state 2
3J9V	;	8.3	;	Yeast V-ATPase state 3
6HH0	;		;	Yeast V-ATPase transmembrane helix 7 NMR structure in DPC micelles
6C6L	;	3.5	;	Yeast Vacuolar ATPase Vo in lipid nanodisc
6R84	;	3.6	;	Yeast Vms1 (Q295L)-60S ribosomal subunit complex (pre-state with Arb1)
6R87	;	3.4	;	Yeast Vms1 (Q295L)-60S ribosomal subunit complex (pre-state without Arb1)
6R86	;	3.4	;	Yeast Vms1-60S ribosomal subunit complex (post-state)
8EAS	;	2.6	;	Yeast VO in complex with Vma12-22p
8EAU	;	3.1	;	Yeast VO in complex with Vma21p
8EAT	;	3.1	;	Yeast VO missing subunits a, e, and f in complex with Vma12-22p
6PE4	;	3.1	;	Yeast Vo motor in complex with 1 VopQ molecule
6PE5	;	3.2	;	Yeast Vo motor in complex with 2 VopQ molecules
5JPE	;	2.611	;	Yeast-specific serine/threonine protein phosphatase (PPZ1) of Candida albicans
5VNB	;	2.4	;	YEATS in complex with histone H3
4Y0W	;	2.5	;	YeaZ from Pseudomonas aeruginosa
2LQV	;		;	YebF
6KZ4	;	3.0	;	YebT domain 5-7
6KZ3	;	3.1	;	YebT domain1-4
8J4C	;	3.34	;	YeeE(TsuA)-YeeD(TsuB) complex for thiosulfate uptake
8K1R	;	2.6	;	YeeE(TsuA)-YeeD(TsuB) complex for thiosulfate uptake
2JQM	;		;	Yellow Fever Envelope Protein Domain III NMR Structure (S288-K398)
5FFM	;	2.6	;	Yellow fever virus helicase
2JAD	;	2.7	;	Yellow fluorescent protein - glutaredoxin fusion protein
5G36	;	2.6	;	Yellow form of Halorhodopsin from Halobacterium salinarum in a new rhombohedral crystal form
1CLV	;	2.0	;	YELLOW MEAL WORM ALPHA-AMYLASE IN COMPLEX WITH THE AMARANTH ALPHA-AMYLASE INHIBITOR
5KIS	;	2.4	;	YenB/RHS2 complex
4ARV	;	1.67	;	Yersinia kristensenii phytase apo form
5JQ9	;	2.101	;	Yersinia pestis DHPS with pterine-sulfa conjugate Compound 16
5G2O	;	1.9	;	Yersinia pestis FabV variant T276A
5JAQ	;	1.9	;	Yersinia pestis FabV variant T276C
5JAI	;	1.9	;	Yersinia pestis FabV variant T276G
5JAM	;	2.0	;	Yersinia pestis FabV variant T276V
2X4M	;	2.55	;	Yersinia Pestis Plasminogen Activator Pla
2X55	;	1.85	;	Yersinia Pestis Plasminogen Activator Pla (Native)
2X56	;	2.3	;	Yersinia Pestis Plasminogen Activator Pla (Native)
1PA9	;	2.0	;	Yersinia Protein-Tyrosine Phosphatase complexed with pNCS (Yop51,Pasteurella X,Ptpase,Yop51delta162) (Catalytic Domain, Residues 163-468) Mutant With Cys 235 Replaced By Arg (C235r)
2WWO	;	2.4	;	Yersinia pseudotuberculosis Superoxide Dismutase C
2WWN	;	2.6	;	Yersinia pseudotuberculosis Superoxide Dismutase C with bound Azide
1YTW	;	2.4	;	YERSINIA PTPASE COMPLEXED WITH TUNGSTATE
1XXV	;	2.5	;	Yersinia YopH (residues 163-468) binds phosphonodifluoromethyl-Phe containing hexapeptide at two sites
1XXP	;	3.0	;	Yersinia YopH (residues 163-468) C403S binds phosphotyrosyl peptide at two sites
6EJP	;	2.48	;	Yersinia YscU C-terminal fragment in complex with a synthetic compound
6C4L	;	2.0	;	Yersinopine dehydrogenase (YpODH) - Apo
6C4M	;	1.94	;	Yersinopine dehydrogenase (YpODH) - NADP+ bound
8G01	;	3.4	;	YES Complex - E. coli MraY, Protein E ID21, E. coli SlyD
8G02	;	3.5	;	YES Complex - E. coli MraY, Protein E PhiX174, E. coli SlyD
2HDA	;	1.9	;	Yes SH3 domain
5MTJ	;	1.949	;	Yes1-SH2 in complex with monobody Mb(Yes_1)
2JV6	;		;	YF ED3 Protein NMR Structure
4HL6	;	2.12	;	YfdE from Escherichia coli
5UYW	;	1.954	;	YfeA ancillary sites that co-load with site 2
5UYV	;	1.691	;	YfeA ancillary sites that do not co-load with site 2
5UY4	;	1.915	;	YfeA from M9 minimal media supplemented with iron - Fe wavelength
5UY5	;	2.144	;	YfeA from M9 minimal media supplemented with iron - Mn wavelength
5UY0	;	1.709	;	YfeA from M9 minimal media supplemented with iron - Zn wavelength
5UYB	;	1.95	;	YfeA from M9 minimal media supplemented with manganese - Fe wavelength
5UYC	;	1.959	;	YfeA from M9 minimal media supplemented with manganese - Mn wavelength
5UYA	;	1.719	;	YfeA from M9 minimal media supplemented with manganese - Zn wavelength
5UYE	;	2.088	;	YfeA from M9 minimal media supplemented with zinc - Fe wavelength
5UYF	;	2.057	;	YfeA from M9 minimal media supplemented with zinc - Mn wavelength
5UYD	;	1.927	;	YfeA from M9 minimal media supplemented with zinc - Zn wavelength
5UXU	;	1.839	;	YfeA from Yersinia pestis treated with EDTA during purification and crystallization
7ME1	;	2.05	;	YfeA oligomer crystal 1, form 1
7ME2	;	1.85	;	YfeA oligomer crystal 2, form 2
7ME3	;	2.25	;	YfeA oligomer crystal 3, form 2
5UYH	;	1.99	;	YfeA with metal bound to site 2 - Mn wavelength
5UYG	;	1.859	;	YfeA with metal bound to site 2 - Zn wavelength
1RW1	;	1.02	;	YFFB (PA3664) PROTEIN
5Y61	;	2.99	;	YfiB-YfiR complexed with GMP
5Y62	;	3.0	;	YfiR complexed with GMP
4YN9	;	2.45	;	YfiR mutant-C110S
1RXQ	;	1.7	;	YfiT from Bacillus subtilis is a probable metal-dependent hydrolase with an unusual four-helix bundle topology
8GPU	;	2.79	;	YFV_E_YD6Fab_prefusion
8GPT	;	3.07	;	YFV_E_YD6scFv_postfusion
8GPX	;	3.8	;	YFV_E_YD73Fab_postfusion
1NRK	;	2.8	;	YGFZ PROTEIN
7UKA	;	2.2	;	YgiC from Escherichia coli K-12 in complex with ADP
4WQ5	;	2.33	;	YgjD(V85E)-YeaZ heterodimer in complex with ATP
6K6L	;	1.77	;	YGL082W-catalytic domain
6U77	;	2.85	;	yGsy2p in complex with small molecule
1JOP	;	2.6	;	YHCH protein (HI0227)
1S4C	;	2.2	;	YHCH PROTEIN (HI0227) COPPER COMPLEX
4P0E	;	2.3	;	YhdE E33A (p212121 space group)
4P0U	;	2.36	;	YhdE E33A p4 space group
2OEE	;	1.96	;	yheA from Bacillus subtilis
8UIW	;	2.77	;	yjdF riboswitch from R. gauvreauii in complex with chelerythrine bound to Fab BL3-6 S97N
8UTA	;	3.05	;	yjdF riboswitch from R. gauvreauii in complex with proflavine bound to Fab BL3-6 S97N
7UK7	;	1.95	;	YjfC from Escherichia coli K-12 in complex with ADP, Mg2+ and SO4
1NIJ	;	2.0	;	YJIA PROTEIN
1E0N	;		;	YJQ8WW domain from Saccharomyces cerevisae
4A1I	;	1.76	;	ykud from B.subtilis
4A1K	;	1.75	;	Ykud L,D-transpeptidase
4A1J	;	2.2	;	Ykud L,D-transpeptidase from B.subtilis
7RTR	;	2.6	;	YLQ-SG3 TCR in complex with SARS-CoV-2 Spike-derived peptide S269-277 (YLQPRTFLL) presented by HLA-A*02:01
1T0I	;	2.0	;	YLR011wp, a Saccharomyces cerevisiae NA(D)PH-dependent FMN reductase
2K5S	;		;	YmoA
6ZYD	;	3.0	;	YnaI
6ZYE	;	4.1	;	YnaI in an open-like conformation
5ONJ	;	1.7	;	YnDL in Complex with 5 amino acid (PGA) complex
5ONL	;	1.7	;	YNDL-apo (Zinc-free)
1OEE	;	2.1	;	YodA from Escherichia coli crystallised with cadmium ions
1OEJ	;	1.81	;	YodA from Escherichia coli crystallised with no added ions
1OEK	;	2.4	;	YodA from Escherichia coli crystallised with zinc ions
7BWF	;	1.7	;	YoeB-YefM complex from Staphylococcus aureus
6N90	;	1.755	;	YoeB/ParE toxin from Agrobacterium tumefaciens
3GCZ	;	1.7	;	Yokose virus Methyltransferase in complex with AdoMet
6DR1	;	2.5	;	YopH PTP1B Chimera 2 PTPase
6DR7	;	1.849	;	YopH PTP1B WPD loop Chimera 2 PTPase bound to vanadate
4ZI4	;	1.121	;	YopH W354H Yersinia enterocolitica PTPase bond with Divanadate glycerol ester in the active site
4Z6B	;	1.2	;	YopH W354H Yersinia enterocolitica PTPase in the apo form
4YAA	;	1.05	;	YopH W354Y Yersinia enterocolitica PTPase apo form
4ZN5	;	1.12	;	YopH W354Y Yersinia enterocolitica PTPase bond with Divanadate glycerol ester in the active site
4OW2	;	3.2	;	YopM from Yersinia enterocolitica WA-314
4CIL	;	1.5	;	YopM-InlB: Hybrid leucine-rich repeat protein
8BRF	;	2.74	;	YopQ apo from Yersinia enterocolitica
7PTK	;	5.18	;	Young conformer of a 6-helix bundle of RNA with clasp
2GU3	;	1.74	;	YpmB protein from Bacillus subtilis
2L1S	;		;	Yp_001336205.1
6A8Y	;		;	YR26_SDS
6XGQ	;	3.8	;	YSD1 bacteriophage capsid
6XGR	;	3.5	;	YSD1 major tail protein
6XGP	;	2.6	;	YSD1_17 major capsid protein
7QIU	;	1.877	;	YsgA 23s RNA methyltransferase from Bacillus subtilis
2GH4	;	1.9	;	YteR/D143N/dGalA-Rha
6DIY	;	0.9	;	YTFGQ segment from Human Immunoglobulin Light-Chain Variable Domain, Residues 96-100, assembled as an amyloid fibril
6WE8	;	1.18	;	YTH domain of human YTHDC1
6WE9	;	1.59	;	YTH domain of human YTHDC1 with 11mer ssDNA Containing N6mA
6WEA	;	1.8	;	YTH domain of human YTHDC1 with a 10mer Oligo Containing N6mA
7L4Y	;	1.79	;	YTH Domain of Human YTHDC1 with dsDNA Comprising Single N6mA joined by Two Six-bp DNA Duplexes in P212121 Crystal
7L4X	;	1.79	;	YTH Domain of Human YTHDC1 with dsDNA Comprising Single N6mA joined by two six-bp DNA duplexes in P3221 Crystal
5EIM	;	1.54	;	YTH domain-containing protein mmi1 and RNA complex
8EV3	;	3.0	;	Ytm1 associated 60S nascent ribosome (-Fkbp39) State 1B
8EUP	;	3.1	;	Ytm1 associated 60S nascent ribosome State 1A
8ETH	;	3.8	;	Ytm1 associated 60S nascent ribosome State 1B
8EUY	;	3.0	;	Ytm1 associated nascent 60S ribosome (-fkbp39) State 1A
8ESR	;	3.2	;	Ytm1 associated nascent 60S ribosome (-fkbp39) State 2
8EUI	;	3.1	;	Ytm1 associated nascent 60S ribosome (-fkbp39) State 3
8ESQ	;	2.8	;	Ytm1 associated nascent 60S ribosome State 2
8EUG	;	2.8	;	Ytm1 associated nascent 60S ribosome State 3
6SBS	;	2.801	;	YtrA from Sulfolobus acidocaldarius, a GntR-family transcription factor
4X1D	;	2.8	;	Ytterbium-bound human serum transferrin
2OPA	;	2.4	;	YwhB binary complex with 2-Fluoro-p-hydroxycinnamate
4KK4	;	1.8	;	YwlE arginine phosphatase - C7S mutant with phosphorylated active site serine
4KK3	;	1.7	;	YwlE arginine phosphatase - wildtype
4PIC	;	1.4	;	YwlE arginine phosphatase from Geobacillus stearothermophilus
7ZCC	;	1.848	;	yxBC from Bacillus subtilis in complex with Mn and N-oxalylglycine (NOG)
6CQG	;	1.932	;	YycF Effector Domain Structure without DNA bound
6EB7	;	1.58	;	YycF homologue (SP1227) Receiver Domain Activated by BeF3
4OCB	;	0.75	;	Z-DNA dodecamer d(CGCGCGCGCGCG)2 at 0.75 A resolution solved by P-SAD
313D	;	1.68	;	Z-DNA HEXAMER WITH 5' OVERHANGS THAT FORM A REVERSE HOOGSTEEN BASE PAIR
312D	;	1.8	;	Z-DNA HEXAMER WITH 5' OVERHANGS THAT FORM A REVERSE WATSON-CRICK BASE PAIR
314D	;	1.9	;	Z-DNA HEXAMER WITH 5' OVERHANGS THAT FORM A REVERSE WOBBLE BASE PAIR
7JY2	;	1.5	;	Z-DNA joint X-ray/Neutron
7JY2	;	1.0	;	Z-DNA joint X-ray/Neutron
6XPN	;	2.26	;	Z-loop Deletion Mutant of AztC from Paracoccus denitrificans
6ZWC	;	2.04	;	Z-SBTub2 photoswitch bound to tubulin-DARPin D1 complex
7Z02	;	2.36	;	Z-SBTub2M photoswitch bound to tubulin-DARPin D1 complex
6ZWB	;	1.747	;	Z-SBTub3 photoswitch bound to tubulin-DARPin D1 complex
7Z01	;	1.82	;	Z-SBTubA4 photoswitch bound to tubulin-DARPin D1 complex
8CLA	;	2.0	;	Z-SBTubA4 photoswitch bound to tubulin-DARPin D1 complex
8CLF	;	2.7	;	Z-SolQ2Br bound to tubulin (T2R-TTL) complex
5TS8	;	1.45	;	Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 5,6-DIBROMOBENZOTRIAZOLE
2OKO	;	1.5	;	Z. mobilis tRNA guanine transglycosylase E235Q mutant apo-structure at pH 5.5
1NL7	;	1.903	;	Z. ramigera biosynthetic thiolase, acetylated enzyme complexed with CoA at pH 9.5
3MPB	;	1.91	;	Z5688 from E. coli O157:H7 bound to fructose
7YPZ	;	2.15	;	Zafirlukast in complex with CRM1-Ran-RanBP1
4XZ0	;	2.0	;	ZAP-70-tSH2:compound-A complex
4XZ1	;	2.8	;	ZAP-70-tSH2:Compound-B adduct
2MMV	;		;	ZapA mutant dimer from Geobacillus stearothermophilus
5FO3	;	2.9	;	ZapC cell division regulator from E. coli
6ML2	;	1.874	;	ZBTB24 Zinc Fingers 4-8 with 19+1mer DNA Oligonucleotide (Sequence 1)
6ML3	;	1.683	;	ZBTB24 Zinc Fingers 4-8 with 19+1mer DNA Oligonucleotide (Sequence 2)
6ML6	;	1.54	;	ZBTB24 Zinc Fingers 4-8 with 19+1mer DNA Oligonucleotide (Sequence 4 with a CpA 5mC Modification)
6ML7	;	1.75	;	ZBTB24 Zinc Fingers 4-8 with 19+1mer DNA Oligonucleotide (Sequence 4 with a CpG 5mC Modification)
6ML5	;	1.65	;	ZBTB24 Zinc Fingers 4-8 with 19+1mer DNA Oligonucleotide (Sequence 4)
7N5T	;	2.9	;	ZBTB7A Zinc Finger Domain Bound to -200 Site of Fetal Globin Promoter (Oligo 5)
7N5S	;	2.86	;	ZBTB7A Zinc Finger Domain Bound to -200 Site of Fetal Globin Promoter (Oligo 6)
8E3E	;	2.99	;	ZBTB7A Zinc Finger Domain Bound to DNA Duplex Containing CAST sequence (#10)
8E3D	;	2.62	;	ZBTB7A Zinc Finger Domain Bound to DNA Duplex Containing CAST sequence (#11)
7N5V	;	3.08	;	ZBTB7A Zinc Finger Domain Bound to DNA Duplex Containing GGACCC (Oligo 20)
7N5U	;	2.86	;	ZBTB7A Zinc Finger Domain Bound to DNA Duplex Containing GGACCC (Oligo 21)
7N5W	;	2.24	;	ZBTB7A Zinc Finger Domain Bound to DNA Duplex Containing GGACCC (Oligo 23)
6SJD	;	3.29	;	ZC3H12B-ribonuclease domain bound to RNA
8CLU	;	1.8	;	Zearalenone lactonase from Rhodococcus erythropolis in complex with zearalactamenone
8CLO	;	1.4	;	Zearalenone lactonase from Streptomyces coelicoflavus
8CLP	;	1.92	;	Zearalenone lactonase from Streptomyces coelicoflavus mutant H286Y
8CLN	;	2.5	;	Zearalenone lactonase from Streptomyces coelicoflavus, SeMet derivative for SAD phasing
8CLT	;	1.46	;	Zearalenone lactonase of Rhodococcus erythropolis
8CLV	;	2.54	;	Zearalenone lactonase of Rhodococcus erythropolis in complex with hydrolyzed zearalenone
8CLQ	;	1.53	;	Zearalenone lactonase of Streptomyces coelicoflavus mutant H286Y in complex with hydrolyzed zearalenone
4BJ8	;	2.4	;	Zebavidin
5JFT	;	2.28	;	Zebra Fish Caspase-3
6B82	;	3.03	;	Zebra Fish CYP-450 17A1 Mutant Abiraterone Complex
4R1Z	;	3.3	;	Zebra fish cytochrome P450 17A1 with Abiraterone
4R20	;	2.86	;	Zebra fish cytochrome P450 17A2 with Abiraterone
4R21	;	2.7	;	Zebra fish cytochrome P450 17A2 with Progesterone
3N3E	;	1.75	;	Zebrafish AlphaA crystallin
6MZP	;	2.1	;	Zebrafish betaglycan orphan domain structure from orthorhombic crystal form
6MZN	;	2.38	;	Zebrafish betaglycan orphan domain structure from tetragonal crystal form
7JL7	;	2.05	;	Zebrafish Caspase N213T
4HED	;	1.62	;	Zebrafish chemokine CXL1
7MQY	;	2.46	;	Zebrafish CNTN4 APLP2 complex
7MRS	;	2.93	;	Zebrafish CNTN4 APPb complex
7MRO	;	1.87	;	Zebrafish CNTN4 FN1-FN3 domains
3UIW	;	2.601	;	Zebrafish Grx2 (APO)
3PIV	;	2.086	;	Zebrafish interferon 1
3PIW	;	1.492	;	Zebrafish interferon 2
8D2U	;	3.3	;	Zebrafish MFSD2A isoform B in inward open ligand 1A conformation
8D2V	;	4.1	;	Zebrafish MFSD2A isoform B in inward open ligand 1B conformation
8D2W	;	3.4	;	Zebrafish MFSD2A isoform B in inward open ligand 2B conformation
8D2X	;	3.4	;	Zebrafish MFSD2A isoform B in inward open ligand 3C conformation
8D2S	;	2.9	;	Zebrafish MFSD2A isoform B in inward open ligand bound conformation
8D2T	;	3.4	;	Zebrafish MFSD2A isoform B in inward open ligand-free conformation
6PKI	;	2.293	;	Zebrafish N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase (NAGPA) catalytic domain (C56S C230S) in complex with N-acetyl-alpha-D-glucosamine (alpha-GlcNAc) and mannose 6-phosphate (M6P)
6PKG	;	2.8	;	Zebrafish N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase (NAGPA) catalytic domain auto-inhibited by pro-peptide
6PKH	;	1.6	;	Zebrafish N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase (NAGPA) catalytic domain auto-inhibited by pro-peptide
7AMK	;	2.2	;	Zebrafish RET Cadherin Like Domains 1 to 4.
7FCL	;	3.04	;	Zebrafish SIGIRR TIR domain
7FCJ	;	1.88	;	Zebrafish SIGIRR TIR domain mutant - C299S
6ENX	;	1.95	;	Zebrafish Sirt5 in complex with stalled bicyclic intermediate of inhibitory compound 10
6EO0	;	2.4	;	Zebrafish Sirt5 in complex with stalled peptidylimidate and bicyclic intermediate of inhibitory compound 29
6C08	;	3.17	;	Zebrafish SLC38A9 with arginine bound in the cytosol open state
8GYN	;	1.38	;	zebrafish TIPE1 strucutre in complex with PE
6D14	;	2.5	;	Zebrafish TRAP1 bound to AMPPNP and calcium in the asymmetric closed state
5GVI	;	1.87	;	Zebrafish USP30 in complex with Lys6-linked diubiquitin
4C84	;	1.6	;	zebrafish ZNRF3 ectodomain crystal form I
4C85	;	2.5	;	zebrafish ZNRF3 ectodomain crystal form II
1M0E	;	2.5	;	ZEBULARINE: A NOVEL DNA METHYLATION INHIBITOR THAT FORMS A COVALENT COMPLEX WITH DNA METHYLTRANSFERASE
3WZL	;	2.6	;	ZEN lactonase
3WZM	;	2.48	;	ZEN lactonase mutant complex
2UZG	;		;	Zf-UBP domain of VDU1
4M9V	;	0.969	;	Zfp57 mutant (E182Q) in complex with 5-carboxylcytosine DNA
4U6B	;	2.3	;	Zg3597, a family 117 glycoside hydrolase, produced by the marine bacterium Zobellia galactanivorans
4U6D	;	1.7	;	Zg3615, a family 117 glycoside hydrolase in complex with beta-3,6-anhydro-L-galactose
6JRC	;	1.65	;	ZHD complex with hydrolyzed alpha-ZOL
6JRD	;	1.65	;	ZHD complex with hydrolyzed beta-ZOL
5C81	;	1.8	;	ZHD-Intermediate complex after ZHD crystal soaking in ZEN for 12min
5C8X	;	1.8	;	ZHD-Intermediate complex after ZHD crystal soaking in ZEN for 20min
5C7Y	;	1.75	;	ZHD-Intermediate complex after ZHD crystal soaking in ZEN for 9min
5C8Z	;	1.6	;	ZHD-ZGR complex after ZHD crystal soaking in ZEN for 30min
6JR2	;	1.65	;	ZHD/H242A complex with aZOL
6JR5	;	2.08	;	ZHD/H242A complex with bZOL
6JQZ	;	2.09	;	ZHD/H242A complex with ZEN
6JRB	;	1.8	;	ZHD/W183F complex with bZOL
6JRA	;	1.8	;	ZHD/W183F complex with hydrolyzed aZOL
6JR9	;	1.72	;	ZHD/W183F complex with ZEN
1JK2	;	1.65	;	Zif268 D20A mutant bound to the GCT DNA site
1JK1	;	1.9	;	Zif268 D20A Mutant Bound to WT DNA Site
1AAY	;	1.6	;	ZIF268 ZINC FINGER-DNA COMPLEX
1A1L	;	2.3	;	ZIF268 ZINC FINGER-DNA COMPLEX (GCAC SITE)
5W41	;	2.2	;	Zika MR766 NLS in complex with Importin alpha subunit-1
5MFX	;	1.598	;	Zika NS3 helicase:RNA complex
6LD1	;	1.4	;	Zika NS5 polymerase domain
6LD2	;	1.4	;	Zika NS5 polymerase domain
6LD3	;	2.3	;	Zika NS5 polymerase domain
6LD4	;	1.5	;	Zika NS5 polymerase domain
6LD5	;	1.94	;	Zika NS5 polymerase domain
5KVD	;	1.65	;	Zika specific antibody, ZV-2, bound to ZIKA envelope DIII
5KVE	;	1.7	;	Zika specific antibody, ZV-48, bound to ZIKA envelope DIII
5KVF	;	1.4	;	Zika specific antibody, ZV-64, bound to ZIKA envelope DIII
5KVG	;	1.4	;	Zika specific antibody, ZV-67, bound to ZIKA envelope DIII
7T17	;	5.26	;	Zika Virus asymmetric unit bound with IgM antibody DH1017 Fab fragment
6C44	;		;	Zika virus capsid protein
5GZR	;	9.4	;	Zika virus E protein complexed with a neutralizing antibody Z23-Fab
7BPK	;	3.1	;	Zika virus envelope protein mutant bound to mAb
8DV6	;	3.38	;	Zika virus envelope protein structure in complex with a potent Human mAb
5Y6N	;	1.571	;	Zika virus helicase in complex with ADP
5Y6M	;	2.002	;	Zika virus helicase in complex with ADP-AlF3
5K6K	;	1.89	;	Zika virus non-structural protein 1 (NS1)
5IY3	;	2.2	;	Zika Virus Non-structural Protein NS1
5GXJ	;	2.6	;	Zika Virus NS2B-NS3 protease
7VXX	;	1.9	;	Zika virus NS2B/NS3 protease bZipro(C143S) in complex with 4-amino benzamidine
7VXY	;	1.901	;	Zika virus NS2B/NS3 protease bZipro(C143S) in complex with D-RKOR
5GJC	;	2.204	;	Zika virus NS3 helicase in complex with ATP
5GJB	;	1.702	;	Zika virus NS3 helicase in complex with ssRNA
7LYG	;	3.804	;	Zika virus RNA promoter stem-loop A with tRNA-scaffold
8Y9V	;	1.9	;	ZIKV NS2B/NS3 protease
7V2Z	;	2.10102	;	ZIKV NS3helicase in complex with ssRNA and ATP-Mn2+
7BQ5	;	2.99	;	ZIKV sE bound to mAb Z6
7YAR	;	5.9	;	ZIKV_Fab_G9E
5TRE	;	15.6	;	Zinc and the Iron Donor Frataxin Regulate Oligomerization of the Scaffold Protein to Form New Fe-S Cluster Assembly Centers
5LFY	;		;	Zinc bound dimer of the fragment of human amyloid-beta peptide with Alzheimer's disease pathogenic Taiwanese mutation D7H
7BEZ	;	1.981	;	Zinc bound domain 3 of carbonic anhydrase from marine diatom Thalassiosira weissflogii
4AO7	;	1.85	;	Zinc bound structure of a novel cold-adapted esterase from an Arctic intertidal metagenomic library
3TA7	;	1.48	;	Zinc bound structure of an archaeal member of the LigD 3'-phosphoesterase DNA repair enzyme family
1BSK	;	3.0	;	ZINC DEFORMYLASE INHIBITOR COMPLEX FROM E.COLI
5YLN	;	2.189	;	Zinc dependent alcohol dehydrogenase 2 from Streptococcus pneumonia - apo form
1BNL	;	2.9	;	ZINC DEPENDENT DIMERS OBSERVED IN CRYSTALS OF HUMAN ENDOSTATIN
6UCP	;		;	Zinc finger 2 from the transcription factor Sp1 DNA binding domain
7KZH	;	2.49	;	Zinc finger antiviral protein (ZAP) central domain
7TGQ	;	2.0	;	Zinc finger antiviral protein (ZAP) central domain bound to ADP-ribose
6A3Z	;		;	Zinc finger domain from the HRD1 Protein
5YZ9	;		;	zinc finger domain of METTL3-METTL14 N6-methyladenosine methyltransferase
6IR0	;		;	Zinc finger domain of the human DTX protein
6BLW	;	1.835	;	Zinc finger Domain of WT1(+KTS form) with M342R Mutation and 17+1mer Oligonucleotide with Triplet GGT
6B0P	;	2.077	;	Zinc finger Domain of WT1(-KTS form) with 12+1mer Oligonucleotide with 3' Triplet GGT
6B0O	;	1.552	;	Zinc finger Domain of WT1(-KTS form) with 12+1mer Oligonucleotide with 3' Triplet TGT
6B0Q	;	2.794	;	Zinc finger Domain of WT1(-KTS form) with 13+1mer Oligonucleotide with 3' Triplet TGT
6B0R	;	1.818	;	Zinc finger Domain of WT1(-KTS form) with M342R Mutation and 14+1mer Oligonucleotide with 3' Triplet TGG
5VC9	;	2.1	;	Zinc finger of human CXXC4 in complex with CpG DNA
5W9S	;	2.1	;	Zinc finger of human CXXC5 in complex with CpG DNA
6L99	;		;	Zinc finger of RING finger protein 144A
6ASD	;	1.85	;	Zinc finger region of human TET1 in complex with CpG DNA
4Z3C	;	1.57	;	Zinc finger region of human TET3 in complex with CpG DNA
5W9Q	;	1.8	;	Zinc finger region of MBD1 in complex with CpG DNA
4PZI	;	2.15	;	Zinc finger region of MLL2 in complex with CpG DNA
1ZAA	;	2.1	;	ZINC FINGER-DNA RECOGNITION: CRYSTAL STRUCTURE OF A ZIF268-DNA COMPLEX AT 2.1 ANGSTROMS
1Y0J	;		;	Zinc fingers as protein recognition motifs: structural basis for the GATA-1/Friend of GATA interaction
4O64	;	2.13	;	Zinc fingers of KDM2B
6S34	;	1.35	;	Zinc free, dimeric human insulin determined to 1.35 Angstrom resolution
2MGT	;		;	Zinc induced dimer of the metal binding domain 1-16 of human amyloid beta-peptide with Alzheimer's disease pathogenic English mutation H6R
2EIN	;	2.7	;	Zinc ion binding structure of bovine heart cytochrome C oxidase in the fully oxidized state
2EIM	;	2.6	;	Zinc ion binding structure of bovine heart cytochrome C oxidase in the fully reduced state
2L9Z	;		;	Zinc knuckle in PRDM4
6YA1	;	1.48	;	Zinc metalloprotease ProA
6YZE	;	2.18	;	Zinc metalloprotease ProA from native source
1G12	;	1.6	;	ZINC PEPTIDASE FROM GRIFOLA FRONDOSA
1GE5	;	2.0	;	ZINC PEPTIDASE FROM GRIFOLA FRONDOSA
1GE6	;	2.2	;	ZINC PEPTIDASE FROM GRIFOLA FRONDOSA
1GE7	;	2.0	;	ZINC PEPTIDASE FROM GRIFOLA FRONDOSA
1KUH	;	1.6	;	ZINC PROTEASE FROM STREPTOMYCES CAESPITOSUS
2WGQ	;	2.5	;	Zinc substituted E Coli Copper Amine Oxidase, a model for the precursor for 2,4,5-trihydroxyphenylalaninequinone formation
4N7L	;	2.85	;	Zinc Substituted Reaction Center M(L214H) Variant of Rhodobacter sphaeroides
4N7K	;	2.85	;	Zinc Substituted Reaction Center of the Rhodobacter sphaeroides
2L1O	;		;	Zinc to cadmium replacement in the A. thaliana SUPERMAN Cys2His2 zinc finger induces structural rearrangements of typical DNA base determinant positions
4MTD	;	2.5	;	Zinc Uptake Regulator Complexed With Zinc AND DNA
4MTE	;	2.5	;	Zinc Uptake Regulator Complexed with Zinc and DNA
6R2U	;	2.49	;	Zinc-alpha2-Glycoprotein with a Fluorescent Dansyl C 11 Fatty Acid
1HVN	;		;	ZINC-AND SEQUENCE-DEPENDENT BINDING TO NUCLEIC ACIDS BY THE N-TERMINAL ZINC FINGER DOMAIN OF THE HIV-1 NUCLEOCAPSID PROTEIN: NMR STRUCTURE OF THE COMPLEX WITH THE PSI-SITE ANALOG, D/ACGCC
1HVO	;		;	ZINC-AND SEQUENCE-DEPENDENT BINDING TO NUCLEIC ACIDS BY THE N-TERMINAL ZINC FINGER DOMAIN OF THE HIV-1 NUCLEOCAPSID PROTEIN: NMR STRUCTURE OF THE COMPLEX WITH THE PSI-SITE ANALOG, D/ACGCC
2FU6	;	2.05	;	Zinc-beta-lactamase l1 from stenotrophomonas maltophilia (apo form)
2FU7	;	1.85	;	Zinc-beta-lactamase L1 from stenotrophomonas maltophilia (Cu-substituted form)
2FU8	;	1.8	;	Zinc-beta-lactamase L1 from stenotrophomonas maltophilia (d-captopril complex)
2FU9	;	1.8	;	Zinc-beta-lactamase L1 from stenotrophomonas maltophilia (mp2 inhibitor complex)
2FM6	;	1.75	;	Zinc-beta-lactamase L1 from stenotrophomonas maltophilia (native form)
1ZE9	;		;	Zinc-binding domain of Alzheimer's disease amyloid beta-peptide complexed with a zinc (II) cation
2BP4	;		;	Zinc-binding domain of Alzheimer's disease amyloid beta-peptide in TFE-water (80-20) solution
1ZE7	;		;	Zinc-binding domain of Alzheimer's disease amyloid beta-peptide in water solution at pH 6.5
5UGK	;		;	Zinc-Binding Structure of a Catalytic Amyloid from Solid-State NMR Spectroscopy
3BKF	;	1.9	;	Zinc-bound C-terminal Domain of NikR
2XGW	;	2.1	;	ZINC-BOUND CRYSTAL STRUCTURE OF STREPTOCOCCUS PYOGENES DPR
3EII	;	2.25	;	Zinc-bound glycoside hydrolase 61 E from Thielavia terrestris
5FD6	;	2.48	;	zinc-bound manganese uptake regulator
4O8X	;	1.991	;	Zinc-bound Rpn11 in complex with Rpn8
3ENR	;	2.4	;	ZINC-CALCIUM CONCANAVALIN A AT PH 6.15
3W52	;	1.76	;	Zinc-dependent bifunctional nuclease
1D8E	;	3.0	;	Zinc-depleted FTase complexed with K-RAS4B peptide substrate and FPP analog.
2K0C	;		;	Zinc-finger 2 of Nup153
6L1W	;	2.194	;	Zinc-finger Antiviral Protein (ZAP) bound to RNA
8FIL	;	2.01	;	Zinc-free APOBEC3A (inactive E72A mutant) in complex with TTC-hairpin DNA substrate
5HX4	;	1.92	;	Zinc-Free APOBEC3F Catalytic Domain Crystal Structure
1ZKB	;	2.2	;	Zinc-free Engineered maltose binding protein
4O8Y	;	1.95	;	Zinc-free Rpn11 in complex with Rpn8
4FXO	;	2.85	;	Zinc-mediated allosteric inhibiton of caspase-6
6QWO	;	2.0	;	Zinc-reconstituted ODP from T. maritima
3KM1	;	2.0	;	ZINC-Reconstituted TOMATO CHLOROPLAST SUPEROXIDE DISMUTASE
4RH4	;	1.6	;	Zinc-substituted pseudoazurin solved by S/Zn-SAD phasing
2QL0	;		;	Zinc-substituted Rubredoxin from Desulfovibrio Vulgaris
6PBE	;	3.78	;	ZINC17988990-bound TRPV5 in nanodiscs
6PBF	;	4.2	;	ZINC9155420-bound TRPV5 in nanodiscs
3HT2	;	2.0	;	Zink containing polyketide cyclase RemF from Streptomyces resistomycificus
2N8M	;		;	Zipcode-binding-protein-1 KH3(DD)KH4 domains in complex with the KH4 RNA target
2N8L	;		;	Zipcode-binding-protein-1 KH3KH4(DD) domains in complex with the KH3 RNA target
2LV4	;		;	ZirS C-terminal Domain
8H92	;	2.6	;	Ziziphus jujuba adenylyl cyclase
8INH	;	2.5	;	ZjOGT3, flavonoid 7,4'-di-O-glycosyltransferase
7QAJ	;	2.1	;	ZK002 with Anti-angiogenic and Anti-inflamamtory Properties
5KDJ	;	2.15	;	ZmpB metallopeptidase from Clostridium perfringens
5KDN	;	1.66	;	ZmpB metallopeptidase from Clostridium perfringens
5KDU	;	2.0	;	ZmpB metallopeptidase in complex with a2,6-Sialyl T-antigen
5KDS	;	1.6	;	ZmpB metallopeptidase in complex with an O-glycopeptide (a2,6-sialylated core-3 pentapeptide).
3KJI	;	2.13	;	Zn and ADP bound state of CooC1
1OEZ	;	2.15	;	Zn His46Arg mutant of Human Cu, Zn Superoxide Dismutase
2YAV	;	1.701	;	ZN INHIBITED SULFUR OXYGENASE REDUCTASE
2BHB	;	2.41	;	Zn substituted E. coli Aminopeptidase P
2BH3	;	2.4	;	Zn substituted E. coli Aminopeptidase P in complex with product
1XB8	;	2.0	;	Zn substituted form of D62C/K74C double mutant of Pseudomonas Aeruginosa Azurin
6GW8	;		;	Zn(II) form of shortened metallothionein from Pseudomonas fluorescens Q2-87 (residues 1-52)
8DRF	;	1.7	;	Zn(II)-bound B2 dimer (H60/H100/H104)
8DRL	;	1.65	;	Zn(II)-bound B2 dimer (H60/H100/H104) formed in Cu(II)//Zn(II) (M1 // M2) condition
8DRM	;	1.55	;	Zn(II)-bound B2 dimer (H60/H100/H104) formed in Zn(II)//Cu(II) (M1 // M2) condition
6LUY	;	1.2	;	Zn- Carbonic Anhydrase II pH 11.0 0 atm CO2
6LUZ	;	1.2	;	Zn- Carbonic Anhydrase II pH 11.0 20 atm CO2
6LUW	;	1.2	;	Zn- Carbonic Anhydrase II pH 7.8 0 atm CO2
6LUX	;	1.2	;	Zn- Carbonic Anhydrase II pH 7.8 20 atm CO2
1T7Z	;	3.0	;	Zn-alpha-2-glycoprotein; baculo-ZAG no PEG, no glycerol
1T7V	;	1.95	;	Zn-alpha-2-glycoprotein; baculo-ZAG PEG 200
1T7Y	;	2.8	;	Zn-alpha-2-glycoprotein; baculo-ZAG PEG 200, no glycerol
1T80	;	2.1	;	Zn-alpha-2-glycoprotein; CHO-ZAG PEG 200
1T7W	;	2.7	;	Zn-alpha-2-glycoprotein; CHO-ZAG PEG 400
1T7X	;	3.1	;	Zn-alpha-2-glycoprotein; refolded CHO-ZAG PEG 400
1E67	;	2.14	;	Zn-Azurin from Pseudomonas aeruginosa
2MJC	;		;	Zn-binding domain of eukaryotic translation initiation factor 3, subunit G
1Q7L	;	1.4	;	Zn-binding domain of the T347G mutant of human aminoacylase-I
7BF0	;	1.6	;	Zn-bound domain 3 of CDCA1 in complex with carbon dioxide
2Y3D	;	2.3	;	Zn-bound form of Cupriavidus metallidurans CH34 CnrXs
4MTR	;	1.83	;	Zn-bound GloA2
3KJH	;	1.9	;	Zn-bound state of CooC1
5WPN	;	1.57	;	Zn-bound Structure of Chaetopterus variopedatus Ferritin
8SJG	;	2.39	;	Zn-Bound Structure of Computationally Designed Homotrimer Tet4
8SJH	;	1.6	;	Zn-Bound Structure of Computationally Designed Homotrimer TP1
7Y2E	;	1.2	;	Zn-Carbonic Anhydrase II complexed with 3NPA after UV at 120 K
7Y2F	;	1.2	;	Zn-Carbonic Anhydrase II complexed with 3NPA after UV at 140 K
7Y2G	;	1.2	;	Zn-Carbonic Anhydrase II complexed with 3NPA after UV at 160 K
7Y2H	;	1.2	;	Zn-Carbonic Anhydrase II complexed with 3NPA after UV at 180 K
7Y2I	;	1.4	;	Zn-Carbonic Anhydrase II complexed with 3NPA after UV at 200 K
7Y2C	;	1.2	;	Zn-Carbonic Anhydrase II complexed with 3NPA after UV at 90 K
7Y2A	;	1.2	;	Zn-Carbonic Anhydrase II complexed with 3NPA before UV at 90 K
6DJA	;	2.48	;	ZN-DEPENDENT 5/B/6 METALLO-BETA-LACTAMASE FROM BACILLUS CEREUS
1HI9	;	2.4	;	Zn-dependent D-aminopeptidase DppA from Bacillus subtilis, a self-compartmentalizing protease.
1BC2	;	1.9	;	ZN-DEPENDENT METALLO-BETA-LACTAMASE FROM BACILLUS CEREUS
7Q02	;	1.45	;	Zn-free structure of lipocalin-like Milk protein, inspired from Diploptera punctata, expressed in Saccharomyces cerevisiae
3SBA	;	2.75	;	Zn-mediated Hexamer of T4 Lysozyme R76H/R80H by Synthetic Symmetrization
3SEW	;	1.55	;	Zn-mediated Polymer of Maltose-binding Protein A216H/K220H by Synthetic Symmetrization (Form I)
3SEY	;	1.85	;	Zn-mediated Polymer of Maltose-binding Protein A216H/K220H by Synthetic Symmetrization (Form II)
3SEU	;	1.85	;	Zn-mediated Polymer of Maltose-binding Protein A216H/K220H by Synthetic Symmetrization (Form III)
3SER	;	2.35	;	Zn-mediated Polymer of Maltose-binding Protein K26H/K30H by Synthetic Symmetrization
6OWJ	;	1.94	;	Zn-mediated polymerization of human SFPQ
3SEV	;	3.05	;	Zn-mediated Trimer of Maltose-binding Protein E310H/K314H by Synthetic Symmetrization
3SB5	;	2.46	;	Zn-mediated Trimer of T4 Lysozyme R125C/E128C by Synthetic Symmetrization
6RUW	;	1.35	;	Zn-substituted alpha-Keggin bound to Proteinase K solved by MR
3SXK	;	1.63	;	Zn2+-bound FCD domain of TM0439, a putative transcriptional regulator
3IUI	;	2.3	;	Zn2+-bound form of Pseudomonas stutzeri L-rhamnose isomerase
5K8P	;	2.2	;	Zn2+/Tetrahedral intermediate-bound R289A 5-nitroanthranilate aminohydrolase
6WMI	;	2.75	;	ZNF410 zinc fingers 1-5 with 17 mer blunt DNA Oligonucleotide
8SSS	;	2.3	;	ZnFs 1-7 of CCCTC-binding factor (CTCF) Complexed with 23mer
8SST	;	2.19	;	ZnFs 1-7 of CCCTC-binding factor (CTCF) K365T Mutant Complexed with 23mer
8SSU	;	2.89	;	ZnFs 3-11 of CCCTC-binding factor (CTCF) Complexed with 19mer DNA
8SSR	;	3.14	;	ZnFs 3-11 of CCCTC-binding factor (CTCF) Complexed with 35mer DNA 35-20
8SSQ	;	3.12	;	ZnFs 3-11 of CCCTC-binding factor (CTCF) Complexed with 35mer DNA 35-4
1W7V	;	2.0	;	ZnMg substituted aminopeptidase P from E. coli
1WBQ	;	2.3	;	ZnMg substituted aminopeptidase P from E. coli
4Q2Q	;	1.45	;	ZO1 PDZ3 in Complex with a Phage-Derived Peptide
2KXS	;		;	ZO1 ZU5 domain in complex with GRINL1A peptide
2KXR	;		;	ZO1 ZU5 domain MC/AA mutation
7LCL	;	2.295	;	Zoogloea ramigera biosynthetic thiolase Q183Y mutant
7LD2	;	2.8	;	Zoogloea ramigera biosynthetic thiolase Q183Y mutant, RbCl soak
7LDC	;	2.5	;	Zoogloea ramigera biosynthetic thiolase Q183Y/Y218E mutant
7LDT	;	2.6	;	Zoogloea ramigera biosynthetic thiolase Q183Y/Y218E mutant, RbCl soak
7LDU	;	2.85	;	Zoogloea ramigera biosynthetic thiolase Q183Y/Y218E/delH221 mutant
7LDV	;	2.9	;	Zoogloea ramigera biosynthetic thiolase Q183Y/Y218E/delH221/S227K mutant
7LDW	;	2.5	;	Zoogloea ramigera biosynthetic thiolase Q183Y/Y218E/delH221/S227K/G248T mutant
7LBZ	;	2.6	;	Zoogloea ramigera biosynthetic thiolase Y218E mutant
7LCA	;	2.0	;	Zoogloea ramigera biosynthetic thiolase Y218E/delH221 mutant
8T9X	;	2.0	;	Zophobas morio black wasting virus strain NJ2-molitor virion structure
8TA7	;	2.7	;	Zophobas morio black wasting virus strain OR-molitor empty capsid structure
8TJE	;	3.4	;	Zophobas morio black wasting virus strain OR-molitor virion structure
8T9E	;	2.9	;	Zophobas morio black wasting virus strain UT-morio empty capsid structure
8T9C	;	2.7	;	Zophobas morio black wasting virus strain UT-morio virion structure
6FN1	;	3.58	;	Zosuquidar and UIC2 Fab complex of human-mouse chimeric ABCB1 (ABCB1HM)
3D4C	;	2.9	;	ZP-N domain of mammalian sperm receptor ZP3 (crystal form I)
3D4G	;	2.3	;	ZP-N domain of mammalian sperm receptor ZP3 (crystal form II)
5OSQ	;	2.05	;	ZP-N domain of mammalian sperm receptor ZP3 (crystal form II, processed in P21221)
3EF7	;	3.1	;	ZP-N domain of mammalian sperm receptor ZP3 (crystal form III)
6GNL	;	1.23	;	Zr(IV)-substituted Keggin directly binding to the side chain of Hen Egg-White Lysozyme (HEWL)
6HYB	;	1.964	;	Zr(IV)-substituted Wells-Dawson binding to Hen Egg-White Lysozyme (HEWL)
5Y8R	;	2.3	;	ZsYellow at pH 3.5
5Y8Q	;	2.9	;	ZsYellow at pH 8.0
6QPK	;	1.36	;	Zt-KP6-1: an effector from Zymoseptoria tritici
3H11	;	1.9	;	Zymogen caspase-8:c-FLIPL protease domain complex
4O3T	;	2.99	;	Zymogen HGF-beta/MET with Zymogen Activator Peptide ZAP.14
4O3U	;	3.04	;	Zymogen HGF-beta/MET with Zymogen Activator Peptide ZAP2.3
3LQ0	;	1.45	;	Zymogen structure of crayfish astacin metallopeptidase
2LT5	;		;	Zymogen-FLG of the onconase
5TMA	;	1.67	;	Zymomonas mobilis pyruvate decarboxylase mutant PDC-2.3
1TOT	;		;	ZZ Domain of CBP- a Novel Fold for a Protein Interaction Module
8CS2	;	6.0	;	[(1AP)G/TC] Self-Assembled 3D DNA Hexagonal Tensegrity Triangle
6ZND	;	2.35	;	[1,2,4]Triazolo[1,5-a]pyrimidine Phosphodiesterase 2 Inhibitors
6ZQZ	;	1.88	;	[1,2,4]Triazolo[1,5-a]pyrimidine Phosphodiesterase 2 Inhibitors
6QES	;		;	[1-40]Gga-AvBD11
8DAH	;	5.47	;	[20 bp edge] Self-Assembled 3D DNA Hexagonal Tensegrity Triangle
5MKO	;	2.65	;	[2Fe-2S] cluster containing TtuA in complex with AMP.
1JQ4	;		;	[2Fe-2S] Domain of Methane Monooxygenase Reductase from Methylococcus capsulatus (Bath)
1E0Z	;		;	[2Fe-2S]-Ferredoxin from Halobacterium salinarum
1E10	;		;	[2Fe-2S]-Ferredoxin from Halobacterium salinarum
5FFI	;	2.17	;	[2Fe:2S] ferredoxin FeSII from Azotobacter vinelandii
7SPL	;	6.09	;	[2T3] Self-assembling 3D DNA triangle with three inter-junction base pairs containing the L1 junction and a zero-linked center strand
7U3R	;	6.27	;	[2T7+10] Self-assembling tensegrity triangle with two turns of DNA and the sticky end attachment of a one-turn linker per axis, with R3 symmetry
8CYN	;	9.45	;	[2T7+20bp Linker] Self-Assembled 3D DNA Hexagonal Tensegrity Triangle with 20 bp Sticky-End Linker
7U3S	;	9.5	;	[2T7+21] Self-assembling tensegrity triangle with two turns of DNA and the sticky end addition of a two-turn linker per axis with R3 symmetry
8CYM	;	7.76	;	[2T7+9bp Linker] Self-Assembled 3D DNA Hexagonal Tensegrity Triangle with 9 bp Sticky-End Linker
8D93	;	2.96	;	[2T7] Self-assembling tensegrity triangle with R3 symmetry at 2.96 A resolution, update and junction cut for entry 3GBI
7LL7	;		;	[2]Catenane From MccJ25 Variant G12C G21C
1OCI	;		;	[3.2.0]bcANA:DNA
7U3P	;	6.06	;	[3T7] Self-assembling tensegrity triangle with three turns of DNA per axis with R3 symmetry
5T56	;		;	[3]catenane from MccJ25 G12R/I13C/G21C lasso peptide
8EJY	;	2.47	;	[4+2] Aza-Cyclase F293A variant
8EJZ	;	1.7	;	[4+2] Aza-Cyclase Y293F variant
6QET	;		;	[41-82]Gga-AvBD11
8CP4	;	3.19	;	[4Fe-4S] cluster containing LarE in complex with AMP
6Z93	;	1.505	;	[4Fe-4S]-dependent thiouracil desulfidase TudS (DUF523Vcz)
6Z96	;	1.327	;	[4Fe-4S]-dependent thiouracil desulfidase TudS (DUF523Vcz) soaked with 4-thiouracil (12.65 keV, 7.125 keV (Fe-SAD) and 6.5 keV (S-SAD) data)
6ZW9	;	1.759	;	[4Fe-4S]-dependent thiouracil desulfidase TudS (DUF523Vcz) soaked with 4-thiouracil (S-SAD data)
6Z92	;	2.067	;	[4Fe-4S]-dependent thiouracil desulfidase TudS (DUF523Vcz) solved by Fe-SAD phasing
6Z94	;	1.759	;	[4Fe-4S]-dependent thiouracil desulfidase TudS (DUF523Vcz)(S-SAD data)
7B0C	;	3.0	;	[4Fe-4S]-NsrR complexed to 23-bp HmpA1 operator fragment
7U3Q	;	9.32	;	[4T7] Self-assembling tensegrity triangle with four turns of DNA per axis with R3 symmetry
8DAG	;	6.16	;	[8 bp center] Self-Assembled 3D DNA Hexagonal Tensegrity Triangle
7U3O	;	3.31	;	[a2T7] Self-assembling asymmetric tensegrity triangle with P1 symmetry
8DCJ	;	3.33	;	[A:T] Self-Assembled 3D DNA Rhombohedral Tensegrity Triangle
2M1P	;		;	[Aba5,14]BTD-2
8D31	;	7.45	;	[AG/TC] Self-Assembled 3D DNA Cubic Tensegrity Triangle with 24 bp Arm Length
8CS4	;	6.03	;	[AGC/GTC] Self-Assembled 3D DNA Hexagonal Tensegrity Triangle
8CS6	;	6.76	;	[AGG/CTC] Self-Assembled 3D DNA Hexagonal Tensegrity Triangle
1FVN	;		;	[ALA31, AIB32]-NEUROPEPTIDE Y
1ICY	;		;	[ALA31,PRO32]-PNPY BOUND TO DPC MICELLES
2M78	;		;	[Asp11]RTD-1
2M79	;		;	[Asp2,11]RTD-1
2M77	;		;	[Asp2]RTD-1
7SGB	;	5.2	;	[C-C] DNA mismatch in a self-assembling rhombohedral lattice at pH 5.5
7SGA	;	3.15	;	[C-S] DNA mismatch in a self-assembling rhombohedral lattice
7SDG	;	3.63	;	[C:Ag+:C] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
7SE2	;	4.03	;	[C:Ag+:mC] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
7SDF	;	3.46	;	[C:Ag+:S] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
7SDS	;	3.7	;	[C:Ag+:T] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
7SDN	;	4.32	;	[C:Ag+:U] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
8DX6	;	5.34	;	[C:Hg2+/Ag+:C--pH 5.5] Metal-mediated DNA base pair in tensegrity triangle in Ag+ and Hg2+ solution
8DX5	;	5.9	;	[C:Hg2+/Ag+:C--pH 5] Metal-mediated DNA base pair in tensegrity triangle in Ag+ and Hg2+ solution
8DX9	;	4.55	;	[C:Hg2+/Ag+:C--pH 6.5] Metal-mediated DNA base pair in tensegrity triangle in Ag+ and Hg2+ solution
8DX7	;	4.92	;	[C:Hg2+/Ag+:C--pH 6] Metal-mediated DNA base pair in tensegrity triangle in Ag+ and Hg2+ solution
8DX1	;	4.79	;	[C:Hg2+/Ag+:C--pH 7 MOPS] Metal-mediated DNA base pair in tensegrity triangle in Ag+ and Hg2+ solution in MOPS
8DXC	;	5.04	;	[C:Hg2+/Ag+:C--pH 7.5] Metal-mediated DNA base pair in tensegrity triangle in Ag+ and Hg2+ solution
8DXA	;	4.21	;	[C:Hg2+/Ag+:C--pH 7] Metal-mediated DNA base pair in tensegrity triangle in Ag+ and Hg2+ solution
8DXD	;	4.28	;	[C:Hg2+/Ag+:C--pH 8] Metal-mediated DNA base pair in tensegrity triangle in Ag+ and Hg2+ solution
8DXF	;	4.29	;	[C:Hg2+/Ag+:C--pH 9] Metal-mediated DNA base pair in tensegrity triangle in Ag+ and Hg2+ solution
7SD7	;	3.68	;	[C:Hg2+:T] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
7SDY	;	4.45	;	[C:Hg2+:U] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
8CS3	;	5.14	;	[CAG/TCG] Self-Assembled 3D DNA Hexagonal Tensegrity Triangle
8CS7	;	6.67	;	[CCG/CCG] Self-Assembled 3D DNA Hexagonal Tensegrity Triangle
1BZV	;		;	[D-ALAB26]-DES(B27-B30)-INSULIN-B26-AMIDE A SUPERPOTENT SINGLE-REPLACEMENT INSULIN ANALOGUE, NMR, MINIMIZED AVERAGE STRUCTURE
8HR3	;		;	[D-Cys5,Asp7,Val8,D-Lys16]-STp(5-17)
8HR4	;		;	[D-Cys5,D-Lys16]-STp(5-17)
3B7T	;	2.3	;	[E296Q]LTA4H in complex with Arg-Ala-Arg substrate
3B7S	;	1.465	;	[E296Q]LTA4H in complex with RSR substrate
7U3T	;	4.69	;	[F223] Self-assembling tensegrity triangle with two turns, two turns and three turns of DNA per axis by extension with P1 symmetry
7U3V	;	5.14	;	[F224] Self-assembling tensegrity triangle with two turns, two turns and four turns of DNA per axis by extension with P1 symmetry
7U3X	;	5.68	;	[F233] Self-assembling tensegrity triangle with two turns, three turns and three turns of DNA per axis by extension with P1 symmetry
7U41	;	7.24	;	[F234] Self-assembling tensegrity triangle with two turns, three turns and four turns of DNA per axis by extension with P1 symmetry
7U3Z	;	7.55	;	[F244] Self-assembling tensegrity triangle with two turns, four turns and four turns of DNA per axis by extension with P1 symmetry
7U42	;	7.71	;	[F334] Self-assembling tensegrity triangle with three turns, three turns and four turns of DNA per axis by extension with P1 symmetry
7U44	;	8.46	;	[F344] Self-assembling tensegrity triangle with three turns, four turns and four turns of DNA per axis by extension with P1 symmetry
6GLY	;	2.09	;	[FeFe]-hydrogenase CpI from Clostridium pasteurianum, variant C299A
6GLZ	;	2.02	;	[FeFe]-hydrogenase CpI from Clostridium pasteurianum, variant C299D
5LA3	;	2.29	;	[FeFe]-hydrogenase CpI from Clostridium pasteurianum, variant E279A
6GM0	;	2.11	;	[FeFe]-hydrogenase CpI from Clostridium pasteurianum, variant E279Q
6GM1	;	2.05	;	[FeFe]-hydrogenase CpI from Clostridium pasteurianum, variant E282A
6GM2	;	2.76	;	[FeFe]-hydrogenase CpI from Clostridium pasteurianum, variant E282D
6GM8	;	1.96	;	[FeFe]-hydrogenase CpI from Clostridium pasteurianum, variant E282Q
6GM3	;	2.22	;	[FeFe]-hydrogenase CpI from Clostridium pasteurianum, variant R286A
6GM4	;	1.97	;	[FeFe]-hydrogenase CpI from Clostridium pasteurianum, variant S319A
8CJY	;	1.6	;	[FeFe]-hydrogenase CpI from Clostridium pasteurianum, variant S357T
6GM5	;	1.45	;	[FeFe]-hydrogenase HydA1 from Chlamydomonas reinhardtii,variant E141A
6GM6	;	1.61	;	[FeFe]-hydrogenase HydA1 from Chlamydomonas reinhardtii,variant E141Q
6GM7	;	2.14	;	[FeFe]-hydrogenase HydA1 from Chlamydomonas reinhardtii,variant E144A
6YF4	;	1.77	;	[FeFe]-hydrogenase I from Clostridium pasteurianum (CpI), variant E279D
7QHF	;	1.63	;	[FeFe]-hydrogenase I from Clostridium pasteurianum (CpI), variant G302S
7O1P	;	2.58	;	[FeFe]-hydrogenase maturase HydE from T. Maritima (C-ter stretch absent)
8QMN	;	1.48	;	[FeFe]-hydrogenase maturase HydE from T. maritima - dialysis experiment - empty structure
4R0V	;	2.29	;	[FeFe]-hydrogenase Oxygen Inactivation is Initiated by the Modification and Degradation of the H cluster 2Fe Subcluster
6YKB	;	1.55	;	[Fe]-hydrogenase from Methanolacinia paynteri in complex with GMP at 1.55-A resolution
6YK9	;	1.7	;	[Fe]-hydrogenase from Methanolacinia paynteri with bound guanylylpyridinol at 1.7-A resolution
1FY3	;	1.89	;	[G175Q]HBP, A mutant of human heparin binding protein (CAP37)
8CS1	;	4.56	;	[GA/CT] Self-Assembled 3D DNA Hexagonal Tensegrity Triangle
8DAP	;	6.47	;	[GA/TC] Self-Assembled 3D DNA Tensegrity Triangle with 24 bp Arm Length forming a Trigonal Hexagon
8CS5	;	6.52	;	[GGA/CTC] Self-Assembled 3D DNA Hexagonal Tensegrity Triangle
8CS8	;	6.0	;	[High G:C, High Vapor Diffusion] Self-Assembled 3D DNA Hexagonal Tensegrity Triangle
1TZ4	;		;	[hPP19-23]-pNPY bound to DPC Micelles
7RIJ	;	1.3	;	[I11G]hyen D
7RII	;	1.22	;	[I11L]hyen D crystal structure
7SDO	;	3.62	;	[iU:Ag+:C] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
8EG4	;	4.18	;	[iU:Ag+:iU] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
7SDU	;	4.33	;	[iU:Ag+:mC] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
7SDT	;	4.0	;	[iU:Ag+:S] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
7SE4	;	4.65	;	[iU:Hg2+:C] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
7SE5	;	4.05	;	[iU:Hg2+:iU] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
7SE1	;	4.19	;	[iU:Hg2+:mC] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
7SDZ	;	4.51	;	[iU:Hg2+:S] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
7SE0	;	3.93	;	[iU:Hg2+:T] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
7SE3	;	3.76	;	[iU:Hg2+:U] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
7U3U	;	4.46	;	[L223] Self-assembling tensegrity triangle with two turns, two turns and three turns of DNA per axis by linker addition with P1 symmetry
7U3W	;	6.33	;	[L224] Self-assembling tensegrity triangle with two turns, two turns and four turns of DNA per axis by linker addition with P1 symmetry
7U3Y	;	6.06	;	[L233] Self-assembling tensegrity triangle with two turns, three turns and three turns of DNA per axis by linker addition with P1 symmetry
7U40	;	7.55	;	[L244] Self-assembling tensegrity triangle with two turns, four turns and four turns of DNA per axis by linker addition with P1 symmetry
7U43	;	7.55	;	[L334] Self-assembling tensegrity triangle with three turns, three turns and four turns of DNA per axis by extension and linker addition with P1 symmetry
7U45	;	8.05	;	[L344] Self-assembling tensegrity triangle with three turns, four turns and four turns of DNA per axis by extension and linker addition with P1 symmetry
4ONK	;	1.9	;	[Leu-5]-Enkephalin mutant - YVVFL
4OLR	;	1.1	;	[Leu-5]-Enkephalin mutant - YVVFV
7SG9	;	3.81	;	[mC-mC] DNA mismatch in a self-assembling rhombohedral lattice at pH 5.5
7SDJ	;	4.0	;	[mC:Ag+:mC] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
7SDK	;	3.86	;	[mC:Ag+:S] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
7SDQ	;	4.3	;	[mC:Ag+:U] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
1E3D	;	1.8	;	[NiFe] Hydrogenase from Desulfovibrio desulfuricans ATCC 27774
5IJA	;	1.82	;	[NiFe] hydrogenase maturation protease HybD from Thermococcus kodakarensis
5XVC	;	2.05	;	[NiFe]-hydrogenase (Hyb-type) from Citrobacter sp. S-77 in a ferricyanide-oxidized condition
5XVD	;	1.57	;	[NiFe]-hydrogenase (Hyb-type) from Citrobacter sp. S-77 in an air-oxidized condition
5XVB	;	1.84	;	[NiFe]-hydrogenase (Hyb-type) from Citrobacter sp. S-77 in an H2-reduced condition
1TZ5	;		;	[pNPY19-23]-hPP bound to DPC Micelles
1P1P	;		;	[PRO7,13] AA-CONOTOXIN PIVA, NMR, 12 STRUCTURES
1FY1	;	2.5	;	[R23S,F25E]HBP, A MUTANT OF HUMAN HEPARIN BINDING PROTEIN (CAP37)
4E1U	;	0.92	;	[Ru(bpy)2 dppz]2+ bound to DNA
6HWG	;	1.74	;	[Ru(phen)2(dppz-11-CN)]2+ bound to d(TCGGCGCCGA)2
6G8S	;	1.66	;	[Ru(TAP)2(11,12-CN2-dppz)]2+ bound to d(CCGGACCCGG/CCGGGTCCGG)2
6R6D	;	1.838	;	[Ru(TAP)2(11,12-CN2-dppz)]2+ bound to d(TCGGCGCCGA)2
5NBE	;	1.51	;	[Ru(TAP)2(dppz-11-CN)]2+ bound to d(TCGGCGCCGA)2
4X18	;	1.05	;	[Ru(TAP)2(dppz-11-Me)]2+ bound to d(TCGGCGCCGA)
7SDH	;	4.05	;	[S:Ag+:S] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
7SDL	;	4.37	;	[S:Ag+:T] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
2BC8	;		;	[Sec2,3,8,12]-ImI
7SG8	;	3.71	;	[T-T] DNA mismatch in a self-assembling rhombohedral lattice
7SM5	;	4.84	;	[T:Ag+/Ag+:T--pH 11] Metal-mediated DNA base pair in tensegrity triangle in Ag+ and Hg2+ solution
7TFX	;	4.99	;	[T:Ag+/Hg2+:T--(pH11-pH7; 120s)] Metal-mediated DNA base pair in tensegrity triangle grown at pH 11 and soaked in pH 7 for 120s
7TG9	;	4.69	;	[T:Ag+/Hg2+:T--(pH11-pH7; 300s in metals)] Metal-mediated DNA base pair in tensegrity triangle grown at pH 11 and soaked in pH 7 with Ag+ and Hg2+ for 300s
7TFY	;	4.71	;	[T:Ag+/Hg2+:T--(pH11-pH7; 300s)] Metal-mediated DNA base pair in tensegrity triangle grown at pH 11 and soaked in pH 7 for 300s
7TG6	;	4.82	;	[T:Ag+/Hg2+:T--(pH11-pH7; 30s in metals)] Metal-mediated DNA base pair in tensegrity triangle grown at pH 11 and soaked in pH 7 with Ag+ and Hg2+ for 30s
7TFU	;	4.55	;	[T:Ag+/Hg2+:T--(pH11-pH7; 30s)] Metal-mediated DNA base pair in tensegrity triangle grown at pH 11 and soaked in pH 7 for 30s
7TG4	;	5.21	;	[T:Ag+/Hg2+:T--(pH11-pH7; 5s in metals)] Metal-mediated DNA base pair in tensegrity triangle grown at pH 11 and soaked in pH 7 with Ag+ and Hg2+ for 5s
7TFT	;	4.42	;	[T:Ag+/Hg2+:T--(pH11-pH7; 5s)] Metal-mediated DNA base pair in tensegrity triangle grown at pH 11 and soaked in pH 7 for 5s
7TG7	;	3.94	;	[T:Ag+/Hg2+:T--(pH11-pH7; 60s in metals)] Metal-mediated DNA base pair in tensegrity triangle grown at pH 11 and soaked in pH 7 with Ag+ and Hg2+ for 60s
7TFV	;	4.23	;	[T:Ag+/Hg2+:T--(pH11-pH7; 60s)] Metal-mediated DNA base pair in tensegrity triangle grown at pH 11 and soaked in pH 7 for 60s
7TFW	;	3.92	;	[T:Ag+/Hg2+:T--(pH11-pH7; 60s)] Metal-mediated DNA base pair in tensegrity triangle grown at pH 11 and soaked in pH 7 for 60s
7TG8	;	5.46	;	[T:Ag+/Hg2+:T--(pH11-pH7; 90s in metals)] Metal-mediated DNA base pair in tensegrity triangle grown at pH 11 and soaked in pH 7 with Ag+ and Hg2+ for 90s
7TGD	;	5.25	;	[T:Ag+/Hg2+:T--(pH8.5-pH11; 300s in metals)] Metal-mediated DNA base pair in tensegrity triangle grown at pH 8.5 and soaked in pH 11 with Ag+ and Hg2+ for 300s
7TG3	;	4.59	;	[T:Ag+/Hg2+:T--(pH8.5-pH11; 300s)] Metal-mediated DNA base pair in tensegrity triangle grown at pH 8.5 and soaked in pH 11 for 300s
7TGA	;	6.61	;	[T:Ag+/Hg2+:T--(pH8.5-pH11; 30s in metals)] Metal-mediated DNA base pair in tensegrity triangle grown at pH 8.5 and soaked in pH 11 with Ag+ and Hg2+ for 30s
7TG0	;	6.05	;	[T:Ag+/Hg2+:T--(pH8.5-pH11; 30s)] Metal-mediated DNA base pair in tensegrity triangle grown at pH 8.5 and soaked in pH 11 for 30s
7TFZ	;	6.13	;	[T:Ag+/Hg2+:T--(pH8.5-pH11; 5s)] Metal-mediated DNA base pair in tensegrity triangle grown at pH 8.5 and soaked in pH 11 for 5s
7TGB	;	5.36	;	[T:Ag+/Hg2+:T--(pH8.5-pH11; 60s in metals)] Metal-mediated DNA base pair in tensegrity triangle grown at pH 8.5 and soaked in pH 11 with Ag+ and Hg2+ for 60s
7TG1	;	4.85	;	[T:Ag+/Hg2+:T--(pH8.5-pH11; 60s)] Metal-mediated DNA base pair in tensegrity triangle grown at pH 8.5 and soaked in pH 11 for 60s
7TGC	;	5.19	;	[T:Ag+/Hg2+:T--(pH8.5-pH11; 90s in metals)] Metal-mediated DNA base pair in tensegrity triangle grown at pH 8.5 and soaked in pH 11 with Ag+ and Hg2+ for 90s
7TG2	;	4.37	;	[T:Ag+/Hg2+:T--(pH8.5-pH11; 90s)] Metal-mediated DNA base pair in tensegrity triangle grown at pH 8.5 and soaked in pH 11 for 90s
7SDV	;	4.19	;	[T:Ag+:mC] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
7SLF	;	4.83	;	[T:Ag+:T--pH 10.5] Metal-mediated DNA base pair in tensegrity triangle
7SLE	;	4.39	;	[T:Ag+:T--pH 10] Metal-mediated DNA base pair in tensegrity triangle
7SLG	;	5.1	;	[T:Ag+:T--pH 11] Metal-mediated DNA base pair in tensegrity triangle
7SLB	;	4.31	;	[T:Ag+:T--pH 8.5] Metal-mediated DNA base pair in tensegrity triangle
7SLD	;	4.13	;	[T:Ag+:T--pH 9.5] Metal-mediated DNA base pair in tensegrity triangle
7SLC	;	4.02	;	[T:Ag+:T--pH 9] Metal-mediated DNA base pair in tensegrity triangle
8E4E	;	4.19	;	[T:Ag+:T] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
8DXW	;	4.52	;	[T:Au+:T--(pH11-pH7; 15s)] Metal-mediated DNA base pair in tensegrity triangle grown at pH 11 and soaked in pH 7 for 15s
8DXY	;	4.87	;	[T:Au+:T--(pH11-pH7; 180s)] Metal-mediated DNA base pair in tensegrity triangle grown at pH 11 and soaked in pH 7 for 180s
8DXZ	;	4.71	;	[T:Au+:T--(pH11-pH7; 420s)] Metal-mediated DNA base pair in tensegrity triangle grown at pH 11 and soaked in pH 7 for 420s
8DXX	;	4.07	;	[T:Au+:T--(pH11-pH7; 45s)] Metal-mediated DNA base pair in tensegrity triangle grown at pH 11 and soaked in pH 7 for 45s
8DXV	;	4.59	;	[T:Au+:T--(pH11-pH7; 5s)] Metal-mediated DNA base pair in tensegrity triangle grown at pH 11 and soaked in pH 7 for 5s
7UK0	;	4.36	;	[T:Au+:T--pH 11 w/ HgCl2] Metal-mediated DNA base pair in tensegrity triangle
7UL8	;	4.22	;	[T:Au+:T--pH 11] Metal-mediated DNA base pair in tensegrity triangle
7UJZ	;	3.94	;	[T:Cd2+/Hg2+:T--pH 11] Metal-mediated DNA base pair in tensegrity triangle
7SM4	;	4.01	;	[T:Hg2+/Ag+:T--pH 10.5] Metal-mediated DNA base pair in tensegrity triangle in Ag+ and Hg2+ solution
7SM3	;	3.74	;	[T:Hg2+/Ag+:T--pH 10] Metal-mediated DNA base pair in tensegrity triangle in Ag+ and Hg2+ solution
7SM2	;	3.92	;	[T:Hg2+/Ag+:T--pH 9.5] Metal-mediated DNA base pair in tensegrity triangle in Ag+ and Hg2+ solution
7SM0	;	4.18	;	[T:Hg2+/Hg2+:T--pH 8.5] Metal-mediated DNA base pair in tensegrity triangle in Ag+ and Hg2+ solution
7SM1	;	3.81	;	[T:Hg2+/Hg2+:T--pH 9] Metal-mediated DNA base pair in tensegrity triangle in Ag+ and Hg2+ solution
7SDW	;	4.2	;	[T:Hg2+:mC] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
7TI3	;	4.79	;	[T:Hg2+:T--pH 11] Metal-mediated DNA base pair in tensegrity triangle
7SD6	;	3.53	;	[T:Hg2+:T] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
7SDI	;	3.58	;	[T:Hg2+:U] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
7SMB	;	4.63	;	[U:Ag+/Ag+:U--pH 11] Metal-mediated DNA base pair in tensegrity triangle in Ag+ and Hg2+ solution
7SDM	;	4.01	;	[U:Ag+:S] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
7SLN	;	4.02	;	[U:Ag+:U--pH 10.5] Metal-mediated DNA base pair in tensegrity triangle
7SLM	;	4.3	;	[U:Ag+:U--pH 10] Metal-mediated DNA base pair in tensegrity triangle
7SLO	;	4.12	;	[U:Ag+:U--pH 11] Metal-mediated DNA base pair in tensegrity triangle
7SLJ	;	4.16	;	[U:Ag+:U--pH 8.5] Metal-mediated DNA base pair in tensegrity triangle
7SLL	;	3.73	;	[U:Ag+:U--pH 9.5] Metal-mediated DNA base pair in tensegrity triangle
7SLK	;	4.01	;	[U:Ag+:U--pH 9] Metal-mediated DNA base pair in tensegrity triangle
8E4D	;	4.19	;	[U:Ag+:U] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
7SMA	;	3.64	;	[U:Hg2+/Ag+:U--pH 10.5] Metal-mediated DNA base pair in tensegrity triangle in Ag+ and Hg2+ solution
7SM9	;	3.24	;	[U:Hg2+/Ag+:U--pH 10] Metal-mediated DNA base pair in tensegrity triangle in Ag+ and Hg2+ solution
7SM8	;	3.62	;	[U:Hg2+/Ag+:U--pH 9.5] Metal-mediated DNA base pair in tensegrity triangle in Ag+ and Hg2+ solution
7SM7	;	3.9	;	[U:Hg2+/Ag+:U--pH 9] Metal-mediated DNA base pair in tensegrity triangle in Ag+ and Hg2+ solution
7SM6	;	3.8	;	[U:Hg2+/Hg2+:U--pH 8.5] Metal-mediated DNA base pair in tensegrity triangle in Ag+ and Hg2+ solution
7SDX	;	3.89	;	[U:Hg2+:mC] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
7SD8	;	2.94	;	[U:Hg2+:U] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice